From fc664104a92be156fca3a6af7b9a445845fc6da4 Mon Sep 17 00:00:00 2001 From: dvs23 Date: Thu, 21 Dec 2023 15:52:40 +0100 Subject: [PATCH] Initial commit --- .gitignore | 243 +++ README.md | 93 ++ data/dataset_splits/dm2_test_ids.txt | 20 + data/dataset_splits/dm2_train_ids.txt | 68 + data/dataset_splits/dm2_validation_ids.txt | 16 + data/dataset_splits/glaucoma_test_ids.txt | 21 + data/dataset_splits/glaucoma_train_ids.txt | 69 + .../glaucoma_validation_ids.txt | 17 + data/dm2 11315821_admin.annodb | 95 ++ data/dm2 11315821_admin.n-triples | 169 ++ data/dm2 11315821_akramersunderbrink.annodb | 96 ++ .../dm2 11315821_akramersunderbrink.n-triples | 10 + data/dm2 11315821_export.csv | 504 ++++++ data/dm2 11315821_kwoodley.annodb | 81 + data/dm2 11315821_kwoodley.n-triples | 10 + data/dm2 12734781_admin.annodb | 86 ++ data/dm2 12734781_admin.n-triples | 173 +++ data/dm2 12734781_akramersunderbrink.annodb | 84 + .../dm2 12734781_akramersunderbrink.n-triples | 10 + data/dm2 12734781_export.csv | 494 ++++++ data/dm2 12734781_kwoodley.annodb | 84 + data/dm2 12734781_kwoodley.n-triples | 10 + data/dm2 14578243_admin.annodb | 99 ++ data/dm2 14578243_admin.n-triples | 149 ++ data/dm2 14578243_akramersunderbrink.annodb | 85 ++ .../dm2 14578243_akramersunderbrink.n-triples | 10 + data/dm2 14578243_export.csv | 500 ++++++ data/dm2 14578243_kwoodley.annodb | 89 ++ data/dm2 14578243_kwoodley.n-triples | 10 + data/dm2 14706058_admin.annodb | 85 ++ data/dm2 14706058_admin.n-triples | 182 +++ data/dm2 14706058_akramersunderbrink.annodb | 76 + .../dm2 14706058_akramersunderbrink.n-triples | 10 + data/dm2 14706058_export.csv | 410 +++++ data/dm2 14706058_kwoodley.annodb | 82 + data/dm2 14706058_kwoodley.n-triples | 10 + data/dm2 15205563_admin.annodb | 99 ++ data/dm2 15205563_admin.n-triples | 156 ++ data/dm2 15205563_akramersunderbrink.annodb | 91 ++ .../dm2 15205563_akramersunderbrink.n-triples | 10 + data/dm2 15205563_export.csv | 546 +++++++ data/dm2 15205563_kwoodley.annodb | 92 ++ data/dm2 15205563_kwoodley.n-triples | 10 + data/dm2 15562200_admin.annodb | 118 ++ data/dm2 15562200_admin.n-triples | 142 ++ data/dm2 15562200_akramersunderbrink.annodb | 115 ++ .../dm2 15562200_akramersunderbrink.n-triples | 10 + data/dm2 15562200_export.csv | 594 +++++++ data/dm2 15562200_kwoodley.annodb | 114 ++ data/dm2 15562200_kwoodley.n-triples | 10 + data/dm2 15677775_admin.annodb | 116 ++ data/dm2 15677775_admin.n-triples | 207 +++ data/dm2 15677775_akramersunderbrink.annodb | 106 ++ .../dm2 15677775_akramersunderbrink.n-triples | 10 + data/dm2 15677775_export.csv | 583 +++++++ data/dm2 15677775_kwoodley.annodb | 113 ++ data/dm2 15677775_kwoodley.n-triples | 10 + data/dm2 15677776_admin.annodb | 141 ++ data/dm2 15677776_admin.n-triples | 249 +++ data/dm2 15677776_akramersunderbrink.annodb | 131 ++ .../dm2 15677776_akramersunderbrink.n-triples | 10 + data/dm2 15677776_export.csv | 730 +++++++++ data/dm2 15677776_kwoodley.annodb | 132 ++ data/dm2 15677776_kwoodley.n-triples | 10 + data/dm2 15715892_admin.annodb | 88 ++ data/dm2 15715892_admin.n-triples | 175 +++ data/dm2 15715892_akramersunderbrink.annodb | 81 + .../dm2 15715892_akramersunderbrink.n-triples | 10 + data/dm2 15715892_export.csv | 479 ++++++ data/dm2 15715892_kwoodley.annodb | 87 ++ data/dm2 15715892_kwoodley.n-triples | 10 + data/dm2 15842521_admin.annodb | 94 ++ data/dm2 15842521_admin.n-triples | 216 +++ data/dm2 15842521_akramersunderbrink.annodb | 89 ++ .../dm2 15842521_akramersunderbrink.n-triples | 10 + data/dm2 15842521_export.csv | 444 ++++++ data/dm2 15842521_kwoodley.annodb | 87 ++ data/dm2 15842521_kwoodley.n-triples | 10 + data/dm2 16456680_admin.annodb | 153 ++ data/dm2 16456680_admin.n-triples | 195 +++ data/dm2 16456680_akramersunderbrink.annodb | 141 ++ .../dm2 16456680_akramersunderbrink.n-triples | 10 + data/dm2 16456680_export.csv | 778 ++++++++++ data/dm2 16456680_kwoodley.annodb | 144 ++ data/dm2 16456680_kwoodley.n-triples | 10 + data/dm2 16505498_admin.annodb | 101 ++ data/dm2 16505498_admin.n-triples | 168 ++ data/dm2 16505498_akramersunderbrink.annodb | 99 ++ .../dm2 16505498_akramersunderbrink.n-triples | 10 + data/dm2 16505498_export.csv | 547 +++++++ data/dm2 16505498_kwoodley.annodb | 89 ++ data/dm2 16505498_kwoodley.n-triples | 10 + data/dm2 16715577_admin.annodb | 90 ++ data/dm2 16715577_admin.n-triples | 202 +++ data/dm2 16715577_akramersunderbrink.annodb | 78 + .../dm2 16715577_akramersunderbrink.n-triples | 10 + data/dm2 16715577_export.csv | 476 ++++++ data/dm2 16715577_kwoodley.annodb | 88 ++ data/dm2 16715577_kwoodley.n-triples | 10 + data/dm2 17115351_admin.annodb | 133 ++ data/dm2 17115351_admin.n-triples | 238 +++ data/dm2 17115351_akramersunderbrink.annodb | 129 ++ .../dm2 17115351_akramersunderbrink.n-triples | 15 + data/dm2 17115351_export.csv | 632 ++++++++ data/dm2 17115351_kwoodley.annodb | 128 ++ data/dm2 17115351_kwoodley.n-triples | 10 + data/dm2 17130197_admin.annodb | 102 ++ data/dm2 17130197_admin.n-triples | 254 +++ data/dm2 17130197_akramersunderbrink.annodb | 85 ++ .../dm2 17130197_akramersunderbrink.n-triples | 10 + data/dm2 17130197_export.csv | 510 +++++++ data/dm2 17130197_kwoodley.annodb | 90 ++ data/dm2 17130197_kwoodley.n-triples | 10 + data/dm2 17157112_admin.annodb | 151 ++ data/dm2 17157112_admin.n-triples | 195 +++ data/dm2 17157112_akramersunderbrink.annodb | 141 ++ .../dm2 17157112_akramersunderbrink.n-triples | 10 + data/dm2 17157112_export.csv | 824 ++++++++++ data/dm2 17157112_kwoodley.annodb | 130 ++ data/dm2 17157112_kwoodley.n-triples | 10 + data/dm2 17363756_admin.annodb | 90 ++ data/dm2 17363756_admin.n-triples | 161 ++ data/dm2 17363756_akramersunderbrink.annodb | 83 + .../dm2 17363756_akramersunderbrink.n-triples | 10 + data/dm2 17363756_export.csv | 463 ++++++ data/dm2 17363756_kwoodley.annodb | 88 ++ data/dm2 17363756_kwoodley.n-triples | 10 + data/dm2 17379048_admin.annodb | 158 ++ data/dm2 17379048_admin.n-triples | 313 ++++ data/dm2 17379048_akramersunderbrink.annodb | 163 ++ .../dm2 17379048_akramersunderbrink.n-triples | 10 + data/dm2 17379048_export.csv | 855 +++++++++++ data/dm2 17379048_kwoodley.annodb | 145 ++ data/dm2 17379048_kwoodley.n-triples | 146 ++ data/dm2 17404349_admin.annodb | 133 ++ data/dm2 17404349_admin.n-triples | 208 +++ data/dm2 17404349_akramersunderbrink.annodb | 140 ++ .../dm2 17404349_akramersunderbrink.n-triples | 10 + data/dm2 17404349_export.csv | 704 +++++++++ data/dm2 17404349_kwoodley.annodb | 122 ++ data/dm2 17404349_kwoodley.n-triples | 10 + data/dm2 17593236_admin.annodb | 152 ++ data/dm2 17593236_admin.n-triples | 162 ++ data/dm2 17593236_akramersunderbrink.annodb | 149 ++ .../dm2 17593236_akramersunderbrink.n-triples | 10 + data/dm2 17593236_export.csv | 751 +++++++++ data/dm2 17593236_kwoodley.annodb | 150 ++ data/dm2 17593236_kwoodley.n-triples | 10 + data/dm2 17929538_admin.annodb | 96 ++ data/dm2 17929538_admin.n-triples | 128 ++ data/dm2 17929538_akramersunderbrink.annodb | 65 + .../dm2 17929538_akramersunderbrink.n-triples | 10 + data/dm2 17929538_export.csv | 546 +++++++ data/dm2 17929538_kwoodley.annodb | 97 ++ data/dm2 17929538_kwoodley.n-triples | 10 + data/dm2 17934150 copy_admin.annodb | 95 ++ data/dm2 17934150 copy_admin.n-triples | 175 +++ data/dm2 17934150 copy_export.csv | 550 +++++++ data/dm2 17934150_admin.annodb | 95 ++ data/dm2 17934150_admin.n-triples | 191 +++ data/dm2 17934150_akramersunderbrink.annodb | 85 ++ .../dm2 17934150_akramersunderbrink.n-triples | 10 + data/dm2 17934150_export.csv | 550 +++++++ data/dm2 17934150_kwoodley.annodb | 110 ++ data/dm2 17934150_kwoodley.n-triples | 10 + data/dm2 17992639 copy_admin.annodb | 79 + data/dm2 17992639 copy_admin.n-triples | 148 ++ data/dm2 17992639 copy_export.csv | 496 ++++++ data/dm2 17992639_admin.annodb | 79 + data/dm2 17992639_admin.n-triples | 140 ++ data/dm2 17992639_akramersunderbrink.annodb | 69 + .../dm2 17992639_akramersunderbrink.n-triples | 10 + data/dm2 17992639_export.csv | 496 ++++++ data/dm2 17992639_kwoodley.annodb | 73 + data/dm2 17992639_kwoodley.n-triples | 39 + data/dm2 18158076 copy_admin.annodb | 291 ++++ data/dm2 18158076 copy_admin.n-triples | 422 +++++ data/dm2 18158076 copy_export.csv | 1358 +++++++++++++++++ data/dm2 18158076_admin.annodb | 291 ++++ data/dm2 18158076_admin.n-triples | 431 ++++++ data/dm2 18158076_akramersunderbrink.annodb | 246 +++ .../dm2 18158076_akramersunderbrink.n-triples | 10 + data/dm2 18158076_export.csv | 1358 +++++++++++++++++ data/dm2 18158076_kwoodley.annodb | 259 ++++ data/dm2 18158076_kwoodley.n-triples | 10 + data/dm2 18194595 copy_admin.annodb | 94 ++ data/dm2 18194595 copy_admin.n-triples | 211 +++ data/dm2 18194595 copy_export.csv | 498 ++++++ data/dm2 18194595_admin.annodb | 94 ++ data/dm2 18194595_admin.n-triples | 195 +++ data/dm2 18194595_akramersunderbrink.annodb | 91 ++ .../dm2 18194595_akramersunderbrink.n-triples | 13 + data/dm2 18194595_export.csv | 498 ++++++ data/dm2 18194595_kwoodley.annodb | 89 ++ data/dm2 18194595_kwoodley.n-triples | 10 + data/dm2 18204830 copy_admin.annodb | 136 ++ data/dm2 18204830 copy_admin.n-triples | 221 +++ data/dm2 18204830 copy_export.csv | 678 ++++++++ data/dm2 18204830_admin.annodb | 136 ++ data/dm2 18204830_admin.n-triples | 219 +++ data/dm2 18204830_akramersunderbrink.annodb | 132 ++ .../dm2 18204830_akramersunderbrink.n-triples | 10 + data/dm2 18204830_export.csv | 678 ++++++++ data/dm2 18204830_kwoodley.annodb | 131 ++ data/dm2 18204830_kwoodley.n-triples | 51 + data/dm2 18761646 copy_admin.annodb | 81 + data/dm2 18761646 copy_admin.n-triples | 183 +++ data/dm2 18761646 copy_export.csv | 524 +++++++ data/dm2 18761646_admin.annodb | 81 + data/dm2 18761646_admin.n-triples | 178 +++ data/dm2 18761646_akramersunderbrink.annodb | 76 + .../dm2 18761646_akramersunderbrink.n-triples | 10 + data/dm2 18761646_export.csv | 524 +++++++ data/dm2 18761646_kwoodley.annodb | 77 + data/dm2 18761646_kwoodley.n-triples | 10 + data/dm2 18936501 copy_admin.annodb | 124 ++ data/dm2 18936501 copy_admin.n-triples | 205 +++ data/dm2 18936501 copy_export.csv | 790 ++++++++++ data/dm2 18936501_admin.annodb | 124 ++ data/dm2 18936501_admin.n-triples | 184 +++ data/dm2 18936501_akramersunderbrink.annodb | 129 ++ .../dm2 18936501_akramersunderbrink.n-triples | 10 + data/dm2 18936501_export.csv | 790 ++++++++++ data/dm2 18936501_kwoodley.annodb | 119 ++ data/dm2 18936501_kwoodley.n-triples | 10 + data/dm2 19108786 copy_admin.annodb | 178 +++ data/dm2 19108786 copy_admin.n-triples | 220 +++ data/dm2 19108786 copy_export.csv | 1009 ++++++++++++ data/dm2 19108786_admin.annodb | 178 +++ data/dm2 19108786_admin.n-triples | 203 +++ data/dm2 19108786_akramersunderbrink.annodb | 166 ++ .../dm2 19108786_akramersunderbrink.n-triples | 10 + data/dm2 19108786_export.csv | 1009 ++++++++++++ data/dm2 19108786_kwoodley.annodb | 171 +++ data/dm2 19108786_kwoodley.n-triples | 10 + data/dm2 19307526 copy_admin.annodb | 87 ++ data/dm2 19307526 copy_admin.n-triples | 147 ++ data/dm2 19307526 copy_export.csv | 637 ++++++++ data/dm2 19307526_admin.annodb | 87 ++ data/dm2 19307526_admin.n-triples | 134 ++ data/dm2 19307526_akramersunderbrink.annodb | 86 ++ .../dm2 19307526_akramersunderbrink.n-triples | 10 + data/dm2 19307526_export.csv | 637 ++++++++ data/dm2 19307526_kwoodley.annodb | 79 + data/dm2 19307526_kwoodley.n-triples | 10 + data/dm2 19336625 copy_admin.annodb | 128 ++ data/dm2 19336625 copy_admin.n-triples | 273 ++++ data/dm2 19336625 copy_export.csv | 718 +++++++++ data/dm2 19336625_admin.annodb | 128 ++ data/dm2 19336625_admin.n-triples | 270 ++++ data/dm2 19336625_akramersunderbrink.annodb | 107 ++ .../dm2 19336625_akramersunderbrink.n-triples | 10 + data/dm2 19336625_export.csv | 718 +++++++++ data/dm2 19336625_kwoodley.annodb | 118 ++ data/dm2 19336625_kwoodley.n-triples | 10 + data/dm2 19565569_admin.annodb | 124 ++ data/dm2 19565569_admin.n-triples | 182 +++ data/dm2 19565569_akramersunderbrink.annodb | 121 ++ .../dm2 19565569_akramersunderbrink.n-triples | 10 + data/dm2 19565569_export.csv | 612 ++++++++ data/dm2 19565569_kwoodley.annodb | 125 ++ data/dm2 19565569_kwoodley.n-triples | 10 + data/dm2 19821654_admin.annodb | 109 ++ data/dm2 19821654_admin.n-triples | 212 +++ data/dm2 19821654_akramersunderbrink.annodb | 113 ++ .../dm2 19821654_akramersunderbrink.n-triples | 10 + data/dm2 19821654_export.csv | 595 ++++++++ data/dm2 19821654_kwoodley.annodb | 106 ++ data/dm2 19821654_kwoodley.n-triples | 10 + data/dm2 20092584_admin.annodb | 136 ++ data/dm2 20092584_admin.n-triples | 266 ++++ data/dm2 20092584_akramersunderbrink.annodb | 140 ++ .../dm2 20092584_akramersunderbrink.n-triples | 10 + data/dm2 20092584_export.csv | 772 ++++++++++ data/dm2 20092584_kwoodley.annodb | 115 ++ data/dm2 20092584_kwoodley.n-triples | 10 + data/dm2 20092585_admin.annodb | 130 ++ data/dm2 20092585_admin.n-triples | 262 ++++ data/dm2 20092585_akramersunderbrink.annodb | 129 ++ .../dm2 20092585_akramersunderbrink.n-triples | 10 + data/dm2 20092585_export.csv | 677 ++++++++ data/dm2 20092585_kwoodley.annodb | 120 ++ data/dm2 20092585_kwoodley.n-triples | 10 + data/dm2 20200301_admin.annodb | 92 ++ data/dm2 20200301_admin.n-triples | 202 +++ data/dm2 20200301_akramersunderbrink.annodb | 83 + .../dm2 20200301_akramersunderbrink.n-triples | 10 + data/dm2 20200301_export.csv | 443 ++++++ data/dm2 20200301_kwoodley.annodb | 89 ++ data/dm2 20200301_kwoodley.n-triples | 10 + data/dm2 20415692_admin.annodb | 112 ++ data/dm2 20415692_admin.n-triples | 191 +++ data/dm2 20415692_akramersunderbrink.annodb | 89 ++ .../dm2 20415692_akramersunderbrink.n-triples | 206 +++ data/dm2 20415692_export.csv | 565 +++++++ data/dm2 20415692_kwoodley.annodb | 101 ++ data/dm2 20415692_kwoodley.n-triples | 10 + data/dm2 20880343_admin.annodb | 117 ++ data/dm2 20880343_admin.n-triples | 213 +++ data/dm2 20880343_akramersunderbrink.annodb | 107 ++ .../dm2 20880343_akramersunderbrink.n-triples | 214 +++ data/dm2 20880343_export.csv | 597 ++++++++ data/dm2 20880343_kwoodley.annodb | 123 ++ data/dm2 20880343_kwoodley.n-triples | 10 + data/dm2 20920045_admin.annodb | 120 ++ data/dm2 20920045_admin.n-triples | 247 +++ data/dm2 20920045_akramersunderbrink.annodb | 121 ++ .../dm2 20920045_akramersunderbrink.n-triples | 258 ++++ data/dm2 20920045_export.csv | 588 +++++++ data/dm2 20920045_kwoodley.annodb | 113 ++ data/dm2 20920045_kwoodley.n-triples | 10 + data/dm2 21114605_admin.annodb | 105 ++ data/dm2 21114605_admin.n-triples | 178 +++ data/dm2 21114605_akramersunderbrink.annodb | 103 ++ .../dm2 21114605_akramersunderbrink.n-triples | 193 +++ data/dm2 21114605_export.csv | 534 +++++++ data/dm2 21114605_kwoodley.annodb | 99 ++ data/dm2 21114605_kwoodley.n-triples | 10 + data/dm2 21138825_admin.annodb | 149 ++ data/dm2 21138825_admin.n-triples | 248 +++ data/dm2 21138825_akramersunderbrink.annodb | 142 ++ .../dm2 21138825_akramersunderbrink.n-triples | 281 ++++ data/dm2 21138825_export.csv | 787 ++++++++++ data/dm2 21138825_kwoodley.annodb | 139 ++ data/dm2 21138825_kwoodley.n-triples | 10 + data/dm2 21781152_admin.annodb | 109 ++ data/dm2 21781152_admin.n-triples | 201 +++ data/dm2 21781152_akramersunderbrink.annodb | 115 ++ .../dm2 21781152_akramersunderbrink.n-triples | 210 +++ data/dm2 21781152_export.csv | 602 ++++++++ data/dm2 21781152_kwoodley.annodb | 101 ++ data/dm2 21781152_kwoodley.n-triples | 10 + data/dm2 21802161_admin.annodb | 69 + data/dm2 21802161_admin.n-triples | 171 +++ data/dm2 21802161_akramersunderbrink.annodb | 75 + .../dm2 21802161_akramersunderbrink.n-triples | 10 + data/dm2 21802161_export.csv | 437 ++++++ data/dm2 21802161_kwoodley.annodb | 69 + data/dm2 21802161_kwoodley.n-triples | 10 + data/dm2 21819517_admin.annodb | 107 ++ data/dm2 21819517_admin.n-triples | 219 +++ data/dm2 21819517_akramersunderbrink.annodb | 100 ++ .../dm2 21819517_akramersunderbrink.n-triples | 10 + data/dm2 21819517_export.csv | 542 +++++++ data/dm2 21819517_kwoodley.annodb | 94 ++ data/dm2 21819517_kwoodley.n-triples | 10 + data/dm2 22134839_admin.annodb | 120 ++ data/dm2 22134839_admin.n-triples | 199 +++ data/dm2 22134839_akramersunderbrink.annodb | 107 ++ .../dm2 22134839_akramersunderbrink.n-triples | 10 + data/dm2 22134839_export.csv | 658 ++++++++ data/dm2 22134839_kwoodley.annodb | 115 ++ data/dm2 22134839_kwoodley.n-triples | 10 + data/dm2 22313154_admin.annodb | 124 ++ data/dm2 22313154_admin.n-triples | 277 ++++ data/dm2 22313154_akramersunderbrink.annodb | 133 ++ .../dm2 22313154_akramersunderbrink.n-triples | 10 + data/dm2 22313154_export.csv | 631 ++++++++ data/dm2 22313154_kwoodley.annodb | 123 ++ data/dm2 22313154_kwoodley.n-triples | 10 + data/dm2 22672081_admin.annodb | 87 ++ data/dm2 22672081_admin.n-triples | 116 ++ data/dm2 22672081_akramersunderbrink.annodb | 71 + .../dm2 22672081_akramersunderbrink.n-triples | 10 + data/dm2 22672081_export.csv | 556 +++++++ data/dm2 22672081_kwoodley.annodb | 79 + data/dm2 22672081_kwoodley.n-triples | 10 + data/dm2 22672586_admin.annodb | 92 ++ data/dm2 22672586_admin.n-triples | 149 ++ data/dm2 22672586_akramersunderbrink.annodb | 83 + .../dm2 22672586_akramersunderbrink.n-triples | 10 + data/dm2 22672586_export.csv | 427 ++++++ data/dm2 22672586_kwoodley.annodb | 83 + data/dm2 22672586_kwoodley.n-triples | 10 + data/dm2 22742523_admin.annodb | 115 ++ data/dm2 22742523_admin.n-triples | 195 +++ data/dm2 22742523_akramersunderbrink.annodb | 112 ++ .../dm2 22742523_akramersunderbrink.n-triples | 10 + data/dm2 22742523_export.csv | 541 +++++++ data/dm2 22742523_kwoodley.annodb | 108 ++ data/dm2 22742523_kwoodley.n-triples | 10 + data/dm2 23039321_admin.annodb | 93 ++ data/dm2 23039321_admin.n-triples | 180 +++ data/dm2 23039321_akramersunderbrink.annodb | 93 ++ .../dm2 23039321_akramersunderbrink.n-triples | 10 + data/dm2 23039321_export.csv | 441 ++++++ data/dm2 23039321_kwoodley.annodb | 93 ++ data/dm2 23039321_kwoodley.n-triples | 10 + data/dm2 23082447_admin.annodb | 83 + data/dm2 23082447_admin.n-triples | 132 ++ data/dm2 23082447_akramersunderbrink.annodb | 73 + .../dm2 23082447_akramersunderbrink.n-triples | 10 + data/dm2 23082447_export.csv | 393 +++++ data/dm2 23082447_kwoodley.annodb | 79 + data/dm2 23082447_kwoodley.n-triples | 10 + data/dm2 23116881_admin.annodb | 105 ++ data/dm2 23116881_admin.n-triples | 194 +++ data/dm2 23116881_akramersunderbrink.annodb | 102 ++ .../dm2 23116881_akramersunderbrink.n-triples | 10 + data/dm2 23116881_export.csv | 483 ++++++ data/dm2 23116881_kwoodley.annodb | 96 ++ data/dm2 23116881_kwoodley.n-triples | 10 + data/dm2 23160726_admin.annodb | 70 + data/dm2 23160726_admin.n-triples | 121 ++ data/dm2 23160726_akramersunderbrink.annodb | 66 + .../dm2 23160726_akramersunderbrink.n-triples | 10 + data/dm2 23160726_export.csv | 351 +++++ data/dm2 23160726_kwoodley.annodb | 68 + data/dm2 23160726_kwoodley.n-triples | 10 + data/dm2 23230096_admin.annodb | 89 ++ data/dm2 23230096_admin.n-triples | 127 ++ data/dm2 23230096_akramersunderbrink.annodb | 75 + .../dm2 23230096_akramersunderbrink.n-triples | 10 + data/dm2 23230096_export.csv | 727 +++++++++ data/dm2 23230096_kwoodley.annodb | 87 ++ data/dm2 23230096_kwoodley.n-triples | 10 + data/dm2 23250357_admin.annodb | 79 + data/dm2 23250357_admin.n-triples | 125 ++ data/dm2 23250357_akramersunderbrink.annodb | 55 + .../dm2 23250357_akramersunderbrink.n-triples | 10 + data/dm2 23250357_export.csv | 429 ++++++ data/dm2 23250357_kwoodley.annodb | 83 + data/dm2 23250357_kwoodley.n-triples | 10 + data/dm2 23404788_admin.annodb | 117 ++ data/dm2 23404788_admin.n-triples | 203 +++ data/dm2 23404788_akramersunderbrink.annodb | 111 ++ .../dm2 23404788_akramersunderbrink.n-triples | 10 + data/dm2 23404788_export.csv | 505 ++++++ data/dm2 23404788_kwoodley.annodb | 108 ++ data/dm2 23404788_kwoodley.n-triples | 10 + data/dm2 23627775_admin.annodb | 103 ++ data/dm2 23627775_admin.n-triples | 209 +++ data/dm2 23627775_akramersunderbrink.annodb | 105 ++ .../dm2 23627775_akramersunderbrink.n-triples | 10 + data/dm2 23627775_export.csv | 488 ++++++ data/dm2 23627775_kwoodley.annodb | 99 ++ data/dm2 23627775_kwoodley.n-triples | 10 + data/dm2 23628617_admin.annodb | 121 ++ data/dm2 23628617_admin.n-triples | 197 +++ data/dm2 23628617_akramersunderbrink.annodb | 124 ++ .../dm2 23628617_akramersunderbrink.n-triples | 10 + data/dm2 23628617_export.csv | 557 +++++++ data/dm2 23628617_kwoodley.annodb | 116 ++ data/dm2 23628617_kwoodley.n-triples | 10 + data/dm2 23706759_admin.annodb | 87 ++ data/dm2 23706759_admin.n-triples | 127 ++ data/dm2 23706759_akramersunderbrink.annodb | 89 ++ .../dm2 23706759_akramersunderbrink.n-triples | 10 + data/dm2 23706759_export.csv | 674 ++++++++ data/dm2 23706759_kwoodley.annodb | 81 + data/dm2 23706759_kwoodley.n-triples | 10 + data/dm2 23906445_admin.annodb | 114 ++ data/dm2 23906445_admin.n-triples | 160 ++ data/dm2 23906445_akramersunderbrink.annodb | 102 ++ .../dm2 23906445_akramersunderbrink.n-triples | 10 + data/dm2 23906445_export.csv | 525 +++++++ data/dm2 23906445_kwoodley.annodb | 109 ++ data/dm2 23906445_kwoodley.n-triples | 10 + data/dm2 23948125_admin.annodb | 109 ++ data/dm2 23948125_admin.n-triples | 164 ++ data/dm2 23948125_akramersunderbrink.annodb | 111 ++ .../dm2 23948125_akramersunderbrink.n-triples | 10 + data/dm2 23948125_export.csv | 745 +++++++++ data/dm2 23948125_kwoodley.annodb | 105 ++ data/dm2 23948125_kwoodley.n-triples | 10 + data/dm2 23949898_admin.annodb | 161 ++ data/dm2 23949898_admin.n-triples | 256 ++++ data/dm2 23949898_akramersunderbrink.annodb | 162 ++ .../dm2 23949898_akramersunderbrink.n-triples | 10 + data/dm2 23949898_export.csv | 877 +++++++++++ data/dm2 23949898_kwoodley.annodb | 151 ++ data/dm2 23949898_kwoodley.n-triples | 10 + data/dm2 24062327_admin.annodb | 120 ++ data/dm2 24062327_admin.n-triples | 194 +++ data/dm2 24062327_akramersunderbrink.annodb | 124 ++ .../dm2 24062327_akramersunderbrink.n-triples | 10 + data/dm2 24062327_export.csv | 545 +++++++ data/dm2 24062327_kwoodley.annodb | 115 ++ data/dm2 24062327_kwoodley.n-triples | 10 + data/dm2 24144654_admin.annodb | 132 ++ data/dm2 24144654_admin.n-triples | 154 ++ data/dm2 24144654_akramersunderbrink.annodb | 130 ++ .../dm2 24144654_akramersunderbrink.n-triples | 10 + data/dm2 24144654_export.csv | 1026 +++++++++++++ data/dm2 24144654_kwoodley.annodb | 127 ++ data/dm2 24144654_kwoodley.n-triples | 10 + data/dm2 24199686_admin.annodb | 111 ++ data/dm2 24199686_admin.n-triples | 195 +++ data/dm2 24199686_akramersunderbrink.annodb | 114 ++ .../dm2 24199686_akramersunderbrink.n-triples | 10 + data/dm2 24199686_export.csv | 516 +++++++ data/dm2 24199686_kwoodley.annodb | 102 ++ data/dm2 24199686_kwoodley.n-triples | 10 + data/dm2 24205943_admin.annodb | 103 ++ data/dm2 24205943_admin.n-triples | 176 +++ data/dm2 24205943_akramersunderbrink.annodb | 109 ++ .../dm2 24205943_akramersunderbrink.n-triples | 10 + data/dm2 24205943_export.csv | 526 +++++++ data/dm2 24205943_kwoodley.annodb | 103 ++ data/dm2 24205943_kwoodley.n-triples | 10 + data/dm2 24237386_admin.annodb | 92 ++ data/dm2 24237386_admin.n-triples | 184 +++ data/dm2 24237386_akramersunderbrink.annodb | 92 ++ .../dm2 24237386_akramersunderbrink.n-triples | 10 + data/dm2 24237386_export.csv | 517 +++++++ data/dm2 24237386_kwoodley.annodb | 94 ++ data/dm2 24237386_kwoodley.n-triples | 10 + data/dm2 24356792_admin.annodb | 87 ++ data/dm2 24356792_admin.n-triples | 198 +++ data/dm2 24356792_akramersunderbrink.annodb | 90 ++ .../dm2 24356792_akramersunderbrink.n-triples | 10 + data/dm2 24356792_export.csv | 553 +++++++ data/dm2 24356792_kwoodley.annodb | 91 ++ data/dm2 24356792_kwoodley.n-triples | 10 + data/dm2 24639432_admin.annodb | 117 ++ data/dm2 24639432_admin.n-triples | 293 ++++ data/dm2 24639432_akramersunderbrink.annodb | 120 ++ .../dm2 24639432_akramersunderbrink.n-triples | 10 + data/dm2 24639432_export.csv | 574 +++++++ data/dm2 24639432_kwoodley.annodb | 119 ++ data/dm2 24639432_kwoodley.n-triples | 10 + data/dm2 24650952_admin.annodb | 127 ++ data/dm2 24650952_admin.n-triples | 237 +++ data/dm2 24650952_akramersunderbrink.annodb | 123 ++ .../dm2 24650952_akramersunderbrink.n-triples | 10 + data/dm2 24650952_export.csv | 684 +++++++++ data/dm2 24650952_kwoodley.annodb | 120 ++ data/dm2 24650952_kwoodley.n-triples | 10 + data/dm2 24824197_admin.annodb | 103 ++ data/dm2 24824197_admin.n-triples | 178 +++ data/dm2 24824197_akramersunderbrink.annodb | 104 ++ .../dm2 24824197_akramersunderbrink.n-triples | 10 + data/dm2 24824197_export.csv | 522 +++++++ data/dm2 24824197_kwoodley.annodb | 102 ++ data/dm2 24824197_kwoodley.n-triples | 10 + data/dm2 24939043_admin.annodb | 91 ++ data/dm2 24939043_admin.n-triples | 266 ++++ data/dm2 24939043_akramersunderbrink.annodb | 78 + .../dm2 24939043_akramersunderbrink.n-triples | 10 + data/dm2 24939043_export.csv | 443 ++++++ data/dm2 24939043_kwoodley.annodb | 94 ++ data/dm2 24939043_kwoodley.n-triples | 10 + data/dm2 25036533_admin.annodb | 108 ++ data/dm2 25036533_admin.n-triples | 196 +++ data/dm2 25036533_akramersunderbrink.annodb | 99 ++ .../dm2 25036533_akramersunderbrink.n-triples | 10 + data/dm2 25036533_export.csv | 593 +++++++ data/dm2 25036533_kwoodley.annodb | 87 ++ data/dm2 25036533_kwoodley.n-triples | 10 + data/dm2 25054436_admin.annodb | 112 ++ data/dm2 25054436_admin.n-triples | 336 ++++ data/dm2 25054436_akramersunderbrink.annodb | 112 ++ .../dm2 25054436_akramersunderbrink.n-triples | 10 + data/dm2 25054436_export.csv | 616 ++++++++ data/dm2 25054436_kwoodley.annodb | 104 ++ data/dm2 25054436_kwoodley.n-triples | 10 + data/dm2 25125506_admin.annodb | 95 ++ data/dm2 25125506_admin.n-triples | 149 ++ data/dm2 25125506_akramersunderbrink.annodb | 96 ++ .../dm2 25125506_akramersunderbrink.n-triples | 10 + data/dm2 25125506_export.csv | 613 ++++++++ data/dm2 25125506_kwoodley.annodb | 90 ++ data/dm2 25125506_kwoodley.n-triples | 10 + data/dm2 25138574_admin.annodb | 82 + data/dm2 25138574_admin.n-triples | 196 +++ data/dm2 25138574_akramersunderbrink.annodb | 78 + .../dm2 25138574_akramersunderbrink.n-triples | 10 + data/dm2 25138574_export.csv | 561 +++++++ data/dm2 25138574_kwoodley.annodb | 83 + data/dm2 25138574_kwoodley.n-triples | 10 + data/dm2 25208756_admin.annodb | 139 ++ data/dm2 25208756_admin.n-triples | 169 ++ data/dm2 25208756_akramersunderbrink.annodb | 134 ++ .../dm2 25208756_akramersunderbrink.n-triples | 10 + data/dm2 25208756_export.csv | 728 +++++++++ data/dm2 25208756_kwoodley.annodb | 130 ++ data/dm2 25208756_kwoodley.n-triples | 10 + data/dm2 25753488_admin.annodb | 115 ++ data/dm2 25753488_admin.n-triples | 185 +++ data/dm2 25753488_akramersunderbrink.annodb | 122 ++ .../dm2 25753488_akramersunderbrink.n-triples | 10 + data/dm2 25753488_export.csv | 633 ++++++++ data/dm2 25753488_kwoodley.annodb | 110 ++ data/dm2 25753488_kwoodley.n-triples | 10 + data/dm2 26067186_admin.annodb | 102 ++ data/dm2 26067186_admin.n-triples | 133 ++ data/dm2 26067186_akramersunderbrink.annodb | 102 ++ .../dm2 26067186_akramersunderbrink.n-triples | 10 + data/dm2 26067186_export.csv | 570 +++++++ data/dm2 26067186_kwoodley.annodb | 98 ++ data/dm2 26067186_kwoodley.n-triples | 10 + data/dm2 26598090_admin.annodb | 117 ++ data/dm2 26598090_admin.n-triples | 228 +++ data/dm2 26598090_akramersunderbrink.annodb | 107 ++ .../dm2 26598090_akramersunderbrink.n-triples | 10 + data/dm2 26598090_export.csv | 762 +++++++++ data/dm2 26598090_kwoodley.annodb | 118 ++ data/dm2 26598090_kwoodley.n-triples | 10 + data/dm2 26950829_admin.annodb | 118 ++ data/dm2 26950829_admin.n-triples | 143 ++ data/dm2 26950829_akramersunderbrink.annodb | 119 ++ .../dm2 26950829_akramersunderbrink.n-triples | 10 + data/dm2 26950829_export.csv | 610 ++++++++ data/dm2 26950829_kwoodley.annodb | 113 ++ data/dm2 26950829_kwoodley.n-triples | 10 + data/dm2 27321385_admin.annodb | 93 ++ data/dm2 27321385_admin.n-triples | 115 ++ data/dm2 27321385_akramersunderbrink.annodb | 89 ++ .../dm2 27321385_akramersunderbrink.n-triples | 10 + data/dm2 27321385_export.csv | 431 ++++++ data/dm2 27321385_kwoodley.annodb | 92 ++ data/dm2 27321385_kwoodley.n-triples | 10 + data/dm2 27589252_admin.annodb | 124 ++ data/dm2 27589252_admin.n-triples | 217 +++ data/dm2 27589252_akramersunderbrink.annodb | 112 ++ .../dm2 27589252_akramersunderbrink.n-triples | 10 + data/dm2 27589252_export.csv | 726 +++++++++ data/dm2 27589252_kwoodley.annodb | 118 ++ data/dm2 27589252_kwoodley.n-triples | 10 + data/dm2 27650977_admin.annodb | 139 ++ data/dm2 27650977_admin.n-triples | 174 +++ data/dm2 27650977_akramersunderbrink.annodb | 126 ++ .../dm2 27650977_akramersunderbrink.n-triples | 10 + data/dm2 27650977_export.csv | 776 ++++++++++ data/dm2 27650977_kwoodley.annodb | 132 ++ data/dm2 27650977_kwoodley.n-triples | 10 + data/dm2 27711199_admin.annodb | 91 ++ data/dm2 27711199_admin.n-triples | 210 +++ data/dm2 27711199_akramersunderbrink.annodb | 85 ++ .../dm2 27711199_akramersunderbrink.n-triples | 10 + data/dm2 27711199_export.csv | 847 ++++++++++ data/dm2 27711199_kwoodley.annodb | 79 + data/dm2 27711199_kwoodley.n-triples | 10 + data/dm2 27740719_admin.annodb | 106 ++ data/dm2 27740719_admin.n-triples | 191 +++ data/dm2 27740719_akramersunderbrink.annodb | 102 ++ .../dm2 27740719_akramersunderbrink.n-triples | 10 + data/dm2 27740719_export.csv | 639 ++++++++ data/dm2 27740719_kwoodley.annodb | 104 ++ data/dm2 27740719_kwoodley.n-triples | 10 + data/dm2 28026912_admin.annodb | 146 ++ data/dm2 28026912_admin.n-triples | 229 +++ data/dm2 28026912_akramersunderbrink.annodb | 153 ++ .../dm2 28026912_akramersunderbrink.n-triples | 10 + data/dm2 28026912_export.csv | 1047 +++++++++++++ data/dm2 28026912_kwoodley.annodb | 144 ++ data/dm2 28026912_kwoodley.n-triples | 10 + data/dm2 28035868_admin.annodb | 109 ++ data/dm2 28035868_admin.n-triples | 226 +++ data/dm2 28035868_akramersunderbrink.annodb | 105 ++ .../dm2 28035868_akramersunderbrink.n-triples | 10 + data/dm2 28035868_export.csv | 657 ++++++++ data/dm2 28035868_kwoodley.annodb | 109 ++ data/dm2 28035868_kwoodley.n-triples | 10 + data/dm2 28093853_admin.annodb | 103 ++ data/dm2 28093853_admin.n-triples | 156 ++ data/dm2 28093853_akramersunderbrink.annodb | 102 ++ .../dm2 28093853_akramersunderbrink.n-triples | 10 + data/dm2 28093853_export.csv | 584 +++++++ data/dm2 28093853_kwoodley.annodb | 102 ++ data/dm2 28093853_kwoodley.n-triples | 10 + data/dm2 28345162_admin.annodb | 110 ++ data/dm2 28345162_admin.n-triples | 166 ++ data/dm2 28345162_akramersunderbrink.annodb | 106 ++ .../dm2 28345162_akramersunderbrink.n-triples | 10 + data/dm2 28345162_export.csv | 680 +++++++++ data/dm2 28345162_kwoodley.annodb | 108 ++ data/dm2 28345162_kwoodley.n-triples | 10 + data/dm2 28345792_admin.annodb | 115 ++ data/dm2 28345792_admin.n-triples | 211 +++ data/dm2 28345792_akramersunderbrink.annodb | 107 ++ .../dm2 28345792_akramersunderbrink.n-triples | 10 + data/dm2 28345792_export.csv | 697 +++++++++ data/dm2 28345792_kwoodley.annodb | 119 ++ data/dm2 28345792_kwoodley.n-triples | 10 + data/dm2 28449402_admin.annodb | 121 ++ data/dm2 28449402_admin.n-triples | 280 ++++ data/dm2 28449402_akramersunderbrink.annodb | 114 ++ .../dm2 28449402_akramersunderbrink.n-triples | 10 + data/dm2 28449402_export.csv | 748 +++++++++ data/dm2 28449402_kwoodley.annodb | 122 ++ data/dm2 28449402_kwoodley.n-triples | 10 + data/dm2 28483786_admin.annodb | 118 ++ data/dm2 28483786_admin.n-triples | 231 +++ data/dm2 28483786_akramersunderbrink.annodb | 106 ++ .../dm2 28483786_akramersunderbrink.n-triples | 10 + data/dm2 28483786_export.csv | 755 +++++++++ data/dm2 28483786_kwoodley.annodb | 114 ++ data/dm2 28483786_kwoodley.n-triples | 10 + data/dm2 28547998_admin.annodb | 114 ++ data/dm2 28547998_admin.n-triples | 188 +++ data/dm2 28547998_akramersunderbrink.annodb | 110 ++ .../dm2 28547998_akramersunderbrink.n-triples | 10 + data/dm2 28547998_export.csv | 608 ++++++++ data/dm2 28547998_kwoodley.annodb | 117 ++ data/dm2 28547998_kwoodley.n-triples | 10 + data/dm2 28548024_admin.annodb | 112 ++ data/dm2 28548024_admin.n-triples | 164 ++ data/dm2 28548024_akramersunderbrink.annodb | 107 ++ .../dm2 28548024_akramersunderbrink.n-triples | 10 + data/dm2 28548024_export.csv | 583 +++++++ data/dm2 28548024_kwoodley.annodb | 108 ++ data/dm2 28548024_kwoodley.n-triples | 10 + data/dm2 28742225_admin.annodb | 136 ++ data/dm2 28742225_admin.n-triples | 216 +++ data/dm2 28742225_akramersunderbrink.annodb | 131 ++ .../dm2 28742225_akramersunderbrink.n-triples | 10 + data/dm2 28742225_export.csv | 757 +++++++++ data/dm2 28742225_kwoodley.annodb | 124 ++ data/dm2 28742225_kwoodley.n-triples | 10 + data/dm2 28923291_admin.annodb | 114 ++ data/dm2 28923291_admin.n-triples | 138 ++ data/dm2 28923291_akramersunderbrink.annodb | 115 ++ .../dm2 28923291_akramersunderbrink.n-triples | 10 + data/dm2 28923291_export.csv | 848 ++++++++++ data/dm2 28923291_kwoodley.annodb | 102 ++ data/dm2 28923291_kwoodley.n-triples | 10 + data/dm2 29017497_admin.annodb | 150 ++ data/dm2 29017497_admin.n-triples | 201 +++ data/dm2 29017497_akramersunderbrink.annodb | 109 ++ .../dm2 29017497_akramersunderbrink.n-triples | 10 + data/dm2 29017497_export.csv | 962 ++++++++++++ data/dm2 29017497_kwoodley.annodb | 142 ++ data/dm2 29017497_kwoodley.n-triples | 10 + data/dm2 29110647_admin.annodb | 136 ++ data/dm2 29110647_admin.n-triples | 188 +++ data/dm2 29110647_akramersunderbrink.annodb | 126 ++ .../dm2 29110647_akramersunderbrink.n-triples | 10 + data/dm2 29110647_export.csv | 762 +++++++++ data/dm2 29110647_kwoodley.annodb | 132 ++ data/dm2 29110647_kwoodley.n-triples | 10 + data/dm2 29144061_admin.annodb | 110 ++ data/dm2 29144061_admin.n-triples | 150 ++ data/dm2 29144061_akramersunderbrink.annodb | 108 ++ .../dm2 29144061_akramersunderbrink.n-triples | 10 + data/dm2 29144061_export.csv | 645 ++++++++ data/dm2 29144061_kwoodley.annodb | 108 ++ data/dm2 29144061_kwoodley.n-triples | 10 + data/dm2 29246950_admin.annodb | 130 ++ data/dm2 29246950_admin.n-triples | 181 +++ data/dm2 29246950_akramersunderbrink.annodb | 133 ++ .../dm2 29246950_akramersunderbrink.n-triples | 10 + data/dm2 29246950_export.csv | 749 +++++++++ data/dm2 29246950_kwoodley.annodb | 127 ++ data/dm2 29246950_kwoodley.n-triples | 10 + data/dm2 29362626_admin.annodb | 89 ++ data/dm2 29362626_admin.n-triples | 167 ++ data/dm2 29362626_akramersunderbrink.annodb | 86 ++ .../dm2 29362626_akramersunderbrink.n-triples | 10 + data/dm2 29362626_export.csv | 458 ++++++ data/dm2 29362626_kwoodley.annodb | 88 ++ data/dm2 29362626_kwoodley.n-triples | 10 + data/dm2 29862619_admin.annodb | 141 ++ data/dm2 29862619_admin.n-triples | 283 ++++ data/dm2 29862619_akramersunderbrink.annodb | 146 ++ .../dm2 29862619_akramersunderbrink.n-triples | 10 + data/dm2 29862619_export.csv | 890 +++++++++++ data/dm2 29862619_kwoodley.annodb | 137 ++ data/dm2 29862619_kwoodley.n-triples | 10 + data/dm2 30019498_admin.annodb | 109 ++ data/dm2 30019498_admin.n-triples | 172 +++ data/dm2 30019498_akramersunderbrink.annodb | 100 ++ .../dm2 30019498_akramersunderbrink.n-triples | 10 + data/dm2 30019498_export.csv | 627 ++++++++ data/dm2 30019498_kwoodley.annodb | 103 ++ data/dm2 30019498_kwoodley.n-triples | 10 + data/gl 10080213_admin.annodb | 133 ++ data/gl 10080213_admin.n-triples | 202 +++ data/gl 10080213_export.csv | 696 +++++++++ data/gl 10080213_jshahinitiran.annodb | Bin 0 -> 13115 bytes data/gl 10080213_jshahinitiran.n-triples | 130 ++ data/gl 10080213_tstrakeljahn.annodb | 137 ++ data/gl 10080213_tstrakeljahn.n-triples | 165 ++ data/gl 10664047_admin.annodb | 80 + data/gl 10664047_admin.n-triples | 121 ++ data/gl 10664047_export.csv | 356 +++++ data/gl 10664047_jshahinitiran.annodb | 73 + data/gl 10664047_jshahinitiran.n-triples | 10 + data/gl 10664047_tstrakeljahn.annodb | 81 + data/gl 10664047_tstrakeljahn.n-triples | 10 + data/gl 10837379_admin.annodb | 88 ++ data/gl 10837379_admin.n-triples | 159 ++ data/gl 10837379_export.csv | 425 ++++++ data/gl 10837379_jshahinitiran.annodb | 87 ++ data/gl 10837379_jshahinitiran.n-triples | 10 + data/gl 10837379_tstrakeljahn.annodb | 90 ++ data/gl 10837379_tstrakeljahn.n-triples | 41 + data/gl 10877373_admin.annodb | 99 ++ data/gl 10877373_admin.n-triples | 171 +++ data/gl 10877373_export.csv | 446 ++++++ data/gl 10877373_jshahinitiran.annodb | 77 + data/gl 10877373_jshahinitiran.n-triples | 10 + data/gl 10877373_tstrakeljahn.annodb | 80 + data/gl 10877373_tstrakeljahn.n-triples | 10 + data/gl 10901475_admin.annodb | 144 ++ data/gl 10901475_admin.n-triples | 151 ++ data/gl 10901475_export.csv | 556 +++++++ data/gl 10901475_jshahinitiran.annodb | 131 ++ data/gl 10901475_jshahinitiran.n-triples | 10 + data/gl 10901475_tstrakeljahn.annodb | 127 ++ data/gl 10901475_tstrakeljahn.n-triples | 10 + data/gl 11039742_admin.annodb | 74 + data/gl 11039742_admin.n-triples | 147 ++ data/gl 11039742_export.csv | 439 ++++++ data/gl 11039742_jshahinitiran.annodb | 69 + data/gl 11039742_jshahinitiran.n-triples | 10 + data/gl 11039742_tstrakeljahn.annodb | 63 + data/gl 11039742_tstrakeljahn.n-triples | 13 + data/gl 11158796_admin.annodb | 88 ++ data/gl 11158796_admin.n-triples | 146 ++ data/gl 11158796_export.csv | 426 ++++++ data/gl 11158796_jshahinitiran.annodb | 87 ++ data/gl 11158796_jshahinitiran.n-triples | 10 + data/gl 11158796_tstrakeljahn.annodb | 78 + data/gl 11158796_tstrakeljahn.n-triples | 10 + data/gl 11167277_admin.annodb | 63 + data/gl 11167277_admin.n-triples | 136 ++ data/gl 11167277_export.csv | 278 ++++ data/gl 11167277_jshahinitiran.annodb | 62 + data/gl 11167277_jshahinitiran.n-triples | 10 + data/gl 11167277_tstrakeljahn.annodb | 59 + data/gl 11167277_tstrakeljahn.n-triples | 10 + data/gl 11336940_admin.annodb | 108 ++ data/gl 11336940_admin.n-triples | 153 ++ data/gl 11336940_export.csv | 537 +++++++ data/gl 11336940_jshahinitiran.annodb | 99 ++ data/gl 11336940_jshahinitiran.n-triples | 10 + data/gl 11336940_tstrakeljahn.annodb | 103 ++ data/gl 11336940_tstrakeljahn.n-triples | 10 + data/gl 11558817_admin.annodb | 87 ++ data/gl 11558817_admin.n-triples | 111 ++ data/gl 11558817_export.csv | 441 ++++++ data/gl 11558817_jshahinitiran.annodb | 86 ++ data/gl 11558817_jshahinitiran.n-triples | 10 + data/gl 11558817_tstrakeljahn.annodb | 78 + data/gl 11558817_tstrakeljahn.n-triples | 10 + data/gl 11813932 copy_admin.annodb | 119 ++ data/gl 11813932 copy_admin.n-triples | 165 ++ data/gl 11813932 copy_export.csv | 664 ++++++++ data/gl 11813932_admin.annodb | 119 ++ data/gl 11813932_admin.n-triples | 175 +++ data/gl 11813932_export.csv | 664 ++++++++ data/gl 11813932_jshahinitiran.annodb | 121 ++ data/gl 11813932_jshahinitiran.n-triples | 10 + data/gl 11813932_tstrakeljahn.annodb | 107 ++ data/gl 11813932_tstrakeljahn.n-triples | 10 + data/gl 11825814_admin.annodb | 128 ++ data/gl 11825814_admin.n-triples | 221 +++ data/gl 11825814_export.csv | 676 ++++++++ data/gl 11825814_jshahinitiran.annodb | 123 ++ data/gl 11825814_jshahinitiran.n-triples | 10 + data/gl 11825814_tstrakeljahn.annodb | 129 ++ data/gl 11825814_tstrakeljahn.n-triples | 10 + data/gl 11912355_admin.annodb | 97 ++ data/gl 11912355_admin.n-triples | 138 ++ data/gl 11912355_export.csv | 440 ++++++ data/gl 11912355_jshahinitiran.annodb | 91 ++ data/gl 11912355_jshahinitiran.n-triples | 10 + data/gl 11912355_tstrakeljahn.annodb | 87 ++ data/gl 11912355_tstrakeljahn.n-triples | 10 + data/gl 11952485_admin.annodb | 53 + data/gl 11952485_admin.n-triples | 131 ++ data/gl 11952485_export.csv | 377 +++++ data/gl 11952485_jshahinitiran.annodb | 43 + data/gl 11952485_jshahinitiran.n-triples | 10 + data/gl 11952485_tstrakeljahn.annodb | 42 + data/gl 11952485_tstrakeljahn.n-triples | 10 + data/gl 12383812_admin.annodb | 132 ++ data/gl 12383812_admin.n-triples | 176 +++ data/gl 12383812_export.csv | 674 ++++++++ data/gl 12383812_jshahinitiran.annodb | 108 ++ data/gl 12383812_jshahinitiran.n-triples | 10 + data/gl 12383812_tstrakeljahn.annodb | 123 ++ data/gl 12383812_tstrakeljahn.n-triples | 10 + data/gl 12466165_admin.annodb | 142 ++ data/gl 12466165_admin.n-triples | 208 +++ data/gl 12466165_export.csv | 619 ++++++++ data/gl 12466165_jshahinitiran.annodb | 135 ++ data/gl 12466165_jshahinitiran.n-triples | 10 + data/gl 12466165_tstrakeljahn.annodb | 124 ++ data/gl 12466165_tstrakeljahn.n-triples | 10 + data/gl 12470755 copy_admin.annodb | 98 ++ data/gl 12470755 copy_admin.n-triples | 132 ++ data/gl 12470755 copy_export.csv | 478 ++++++ data/gl 12470755_admin.annodb | 98 ++ data/gl 12470755_admin.n-triples | 128 ++ data/gl 12470755_export.csv | 478 ++++++ data/gl 12470755_jshahinitiran.annodb | 95 ++ data/gl 12470755_jshahinitiran.n-triples | 10 + data/gl 12470755_tstrakeljahn.annodb | 92 ++ data/gl 12470755_tstrakeljahn.n-triples | 10 + data/gl 12483094_admin.annodb | 108 ++ data/gl 12483094_admin.n-triples | 165 ++ data/gl 12483094_export.csv | 507 ++++++ data/gl 12483094_jshahinitiran.annodb | 103 ++ data/gl 12483094_jshahinitiran.n-triples | 10 + data/gl 12483094_tstrakeljahn.annodb | 106 ++ data/gl 12483094_tstrakeljahn.n-triples | 10 + data/gl 12485286_admin.annodb | 84 + data/gl 12485286_admin.n-triples | 103 ++ data/gl 12485286_export.csv | 361 +++++ data/gl 12485286_jshahinitiran.annodb | 74 + data/gl 12485286_jshahinitiran.n-triples | 10 + data/gl 12485286_tstrakeljahn.annodb | 79 + data/gl 12485286_tstrakeljahn.n-triples | 10 + data/gl 12486510_admin.annodb | 87 ++ data/gl 12486510_admin.n-triples | 146 ++ data/gl 12486510_export.csv | 447 ++++++ data/gl 12486510_jshahinitiran.annodb | 81 + data/gl 12486510_jshahinitiran.n-triples | 10 + data/gl 12486510_tstrakeljahn.annodb | 76 + data/gl 12486510_tstrakeljahn.n-triples | 10 + data/gl 12586182_admin.annodb | 99 ++ data/gl 12586182_admin.n-triples | 121 ++ data/gl 12586182_export.csv | 415 +++++ data/gl 12586182_jshahinitiran.annodb | 96 ++ data/gl 12586182_jshahinitiran.n-triples | 10 + data/gl 12586182_tstrakeljahn.annodb | 82 + data/gl 12586182_tstrakeljahn.n-triples | 10 + data/gl 12660585_admin.annodb | 169 ++ data/gl 12660585_admin.n-triples | 182 +++ data/gl 12660585_export.csv | 958 ++++++++++++ data/gl 12660585_jshahinitiran.annodb | 125 ++ data/gl 12660585_jshahinitiran.n-triples | 10 + data/gl 12660585_tstrakeljahn.annodb | 134 ++ data/gl 12660585_tstrakeljahn.n-triples | 10 + data/gl 12780402_admin.annodb | 71 + data/gl 12780402_admin.n-triples | 104 ++ data/gl 12780402_export.csv | 409 +++++ data/gl 12780402_jshahinitiran.annodb | 72 + data/gl 12780402_jshahinitiran.n-triples | 10 + data/gl 12780402_tstrakeljahn.annodb | 67 + data/gl 12780402_tstrakeljahn.n-triples | 10 + data/gl 12859261_admin.annodb | 112 ++ data/gl 12859261_admin.n-triples | 206 +++ data/gl 12859261_export.csv | 457 ++++++ data/gl 12859261_jshahinitiran.annodb | 104 ++ data/gl 12859261_jshahinitiran.n-triples | 10 + data/gl 12859261_tstrakeljahn.annodb | 103 ++ data/gl 12859261_tstrakeljahn.n-triples | 10 + data/gl 12867391_admin.annodb | 103 ++ data/gl 12867391_admin.n-triples | 145 ++ data/gl 12867391_export.csv | 514 +++++++ data/gl 12867391_jshahinitiran.annodb | 82 + data/gl 12867391_jshahinitiran.n-triples | 10 + data/gl 12867391_tstrakeljahn.annodb | 97 ++ data/gl 12867391_tstrakeljahn.n-triples | 10 + data/gl 14736774_admin.annodb | 83 + data/gl 14736774_admin.n-triples | 119 ++ data/gl 14736774_export.csv | 485 ++++++ data/gl 14736774_jshahinitiran.annodb | 78 + data/gl 14736774_jshahinitiran.n-triples | 10 + data/gl 14736774_tstrakeljahn.annodb | 75 + data/gl 14736774_tstrakeljahn.n-triples | 10 + data/gl 14746165_admin.annodb | 85 ++ data/gl 14746165_admin.n-triples | 121 ++ data/gl 14746165_export.csv | 380 +++++ data/gl 14746165_jshahinitiran.annodb | 86 ++ data/gl 14746165_jshahinitiran.n-triples | 10 + data/gl 14746165_tstrakeljahn.annodb | 78 + data/gl 14746165_tstrakeljahn.n-triples | 10 + data/gl 15019375_admin.annodb | 110 ++ data/gl 15019375_admin.n-triples | 103 ++ data/gl 15019375_export.csv | 480 ++++++ data/gl 15019375_jshahinitiran.annodb | 100 ++ data/gl 15019375_jshahinitiran.n-triples | 10 + data/gl 15019375_tstrakeljahn.annodb | 105 ++ data/gl 15019375_tstrakeljahn.n-triples | 10 + data/gl 15037890_admin.annodb | 84 + data/gl 15037890_admin.n-triples | 161 ++ data/gl 15037890_export.csv | 423 +++++ data/gl 15037890_jshahinitiran.annodb | 74 + data/gl 15037890_jshahinitiran.n-triples | 10 + data/gl 15037890_tstrakeljahn.annodb | 83 + data/gl 15037890_tstrakeljahn.n-triples | 10 + data/gl 15094733_admin.annodb | 100 ++ data/gl 15094733_admin.n-triples | 164 ++ data/gl 15094733_export.csv | 463 ++++++ data/gl 15094733_jshahinitiran.annodb | 91 ++ data/gl 15094733_jshahinitiran.n-triples | 10 + data/gl 15094733_tstrakeljahn.annodb | 91 ++ data/gl 15094733_tstrakeljahn.n-triples | 10 + data/gl 15097262_admin.annodb | 88 ++ data/gl 15097262_admin.n-triples | 110 ++ data/gl 15097262_export.csv | 434 ++++++ data/gl 15097262_jshahinitiran.annodb | 80 + data/gl 15097262_jshahinitiran.n-triples | 10 + data/gl 15097262_tstrakeljahn.annodb | 76 + data/gl 15097262_tstrakeljahn.n-triples | 10 + data/gl 15205229_admin.annodb | 116 ++ data/gl 15205229_admin.n-triples | 160 ++ data/gl 15205229_export.csv | 493 ++++++ data/gl 15205229_jshahinitiran.annodb | 109 ++ data/gl 15205229_jshahinitiran.n-triples | 10 + data/gl 15205229_tstrakeljahn.annodb | 112 ++ data/gl 15205229_tstrakeljahn.n-triples | 10 + data/gl 15220019_admin.annodb | 139 ++ data/gl 15220019_admin.n-triples | 160 ++ data/gl 15220019_export.csv | 668 ++++++++ data/gl 15220019_jshahinitiran.annodb | 110 ++ data/gl 15220019_jshahinitiran.n-triples | 10 + data/gl 15220019_tstrakeljahn.annodb | 131 ++ data/gl 15220019_tstrakeljahn.n-triples | 10 + data/gl 1524115_admin.annodb | 83 + data/gl 1524115_admin.n-triples | 160 ++ data/gl 1524115_export.csv | 437 ++++++ data/gl 1524115_jshahinitiran.annodb | 71 + data/gl 1524115_jshahinitiran.n-triples | 10 + data/gl 1524115_tstrakeljahn.annodb | 72 + data/gl 1524115_tstrakeljahn.n-triples | 10 + data/gl 15598478_admin.annodb | 129 ++ data/gl 15598478_admin.n-triples | 180 +++ data/gl 15598478_export.csv | 748 +++++++++ data/gl 15598478_jshahinitiran.annodb | 125 ++ data/gl 15598478_jshahinitiran.n-triples | 10 + data/gl 15598478_tstrakeljahn.annodb | 100 ++ data/gl 15598478_tstrakeljahn.n-triples | 10 + data/gl 15741820_admin.annodb | 87 ++ data/gl 15741820_admin.n-triples | 107 ++ data/gl 15741820_export.csv | 454 ++++++ data/gl 15741820_jshahinitiran.annodb | 84 + data/gl 15741820_jshahinitiran.n-triples | 10 + data/gl 15741820_tstrakeljahn.annodb | 72 + data/gl 15741820_tstrakeljahn.n-triples | 10 + data/gl 15857284_admin.annodb | 92 ++ data/gl 15857284_admin.n-triples | 150 ++ data/gl 15857284_export.csv | 429 ++++++ data/gl 15857284_jshahinitiran.annodb | 84 + data/gl 15857284_jshahinitiran.n-triples | 10 + data/gl 15857284_tstrakeljahn.annodb | 84 + data/gl 15857284_tstrakeljahn.n-triples | 10 + data/gl 15945001_admin.annodb | 87 ++ data/gl 15945001_admin.n-triples | 151 ++ data/gl 15945001_export.csv | 427 ++++++ data/gl 15945001_jshahinitiran.annodb | 76 + data/gl 15945001_jshahinitiran.n-triples | 10 + data/gl 15945001_tstrakeljahn.annodb | 88 ++ data/gl 15945001_tstrakeljahn.n-triples | 10 + data/gl 15969642_admin.annodb | 103 ++ data/gl 15969642_admin.n-triples | 116 ++ data/gl 15969642_export.csv | 496 ++++++ data/gl 15969642_jshahinitiran.annodb | 95 ++ data/gl 15969642_jshahinitiran.n-triples | 10 + data/gl 15969642_tstrakeljahn.annodb | 85 ++ data/gl 15969642_tstrakeljahn.n-triples | 10 + data/gl 16009829_admin.annodb | 82 + data/gl 16009829_admin.n-triples | 197 +++ data/gl 16009829_export.csv | 434 ++++++ data/gl 16009829_jshahinitiran.annodb | 73 + data/gl 16009829_jshahinitiran.n-triples | 10 + data/gl 16009829_tstrakeljahn.annodb | 73 + data/gl 16009829_tstrakeljahn.n-triples | 10 + data/gl 16263174_admin.annodb | 98 ++ data/gl 16263174_admin.n-triples | 127 ++ data/gl 16263174_export.csv | 524 +++++++ data/gl 16263174_jshahinitiran.annodb | 91 ++ data/gl 16263174_jshahinitiran.n-triples | 10 + data/gl 16263174_tstrakeljahn.annodb | 97 ++ data/gl 16263174_tstrakeljahn.n-triples | 10 + data/gl 16458964_admin.annodb | 105 ++ data/gl 16458964_admin.n-triples | 103 ++ data/gl 16458964_export.csv | 543 +++++++ data/gl 16458964_jshahinitiran.annodb | 96 ++ data/gl 16458964_jshahinitiran.n-triples | 10 + data/gl 16458964_tstrakeljahn.annodb | 111 ++ data/gl 16458964_tstrakeljahn.n-triples | 10 + data/gl 16750448_admin.annodb | 169 ++ data/gl 16750448_admin.n-triples | 333 ++++ data/gl 16750448_export.csv | 754 +++++++++ data/gl 16750448_jshahinitiran.annodb | 120 ++ data/gl 16750448_jshahinitiran.n-triples | 10 + data/gl 16750448_tstrakeljahn.annodb | 150 ++ data/gl 16750448_tstrakeljahn.n-triples | 10 + data/gl 16825272_admin.annodb | 108 ++ data/gl 16825272_admin.n-triples | 161 ++ data/gl 16825272_export.csv | 497 ++++++ data/gl 16825272_jshahinitiran.annodb | 80 + data/gl 16825272_jshahinitiran.n-triples | 10 + data/gl 16825272_tstrakeljahn.annodb | 103 ++ data/gl 16825272_tstrakeljahn.n-triples | 10 + data/gl 16968583_admin.annodb | 99 ++ data/gl 16968583_admin.n-triples | 137 ++ data/gl 16968583_export.csv | 443 ++++++ data/gl 16968583_jshahinitiran.annodb | 84 + data/gl 16968583_jshahinitiran.n-triples | 10 + data/gl 16968583_tstrakeljahn.annodb | 98 ++ data/gl 16968583_tstrakeljahn.n-triples | 10 + data/gl 17197028_admin.annodb | 79 + data/gl 17197028_admin.n-triples | 146 ++ data/gl 17197028_export.csv | 395 +++++ data/gl 17197028_jshahinitiran.annodb | 67 + data/gl 17197028_jshahinitiran.n-triples | 10 + data/gl 17197028_tstrakeljahn.annodb | 79 + data/gl 17197028_tstrakeljahn.n-triples | 10 + data/gl 17244215_admin.annodb | 82 + data/gl 17244215_admin.n-triples | 101 ++ data/gl 17244215_export.csv | 411 +++++ data/gl 17244215_jshahinitiran.annodb | 70 + data/gl 17244215_jshahinitiran.n-triples | 10 + data/gl 17244215_tstrakeljahn.annodb | 69 + data/gl 17244215_tstrakeljahn.n-triples | 10 + data/gl 17407624_admin.annodb | 119 ++ data/gl 17407624_admin.n-triples | 169 ++ data/gl 17407624_export.csv | 542 +++++++ data/gl 17407624_jshahinitiran.annodb | 108 ++ data/gl 17407624_jshahinitiran.n-triples | 10 + data/gl 17407624_tstrakeljahn.annodb | 105 ++ data/gl 17407624_tstrakeljahn.n-triples | 10 + data/gl 17519068_admin.annodb | 89 ++ data/gl 17519068_admin.n-triples | 120 ++ data/gl 17519068_export.csv | 437 ++++++ data/gl 17519068_jshahinitiran.annodb | 80 + data/gl 17519068_jshahinitiran.n-triples | 10 + data/gl 17519068_tstrakeljahn.annodb | 90 ++ data/gl 17519068_tstrakeljahn.n-triples | 10 + data/gl 17571086_admin.annodb | 76 + data/gl 17571086_admin.n-triples | 133 ++ data/gl 17571086_export.csv | 465 ++++++ data/gl 17571086_jshahinitiran.annodb | 70 + data/gl 17571086_jshahinitiran.n-triples | 10 + data/gl 17571086_tstrakeljahn.annodb | 75 + data/gl 17571086_tstrakeljahn.n-triples | 10 + data/gl 18327364 copy_admin.annodb | 84 + data/gl 18327364 copy_admin.n-triples | 139 ++ data/gl 18327364 copy_export.csv | 368 +++++ data/gl 18327364_admin.annodb | 84 + data/gl 18327364_admin.n-triples | 139 ++ data/gl 18327364_export.csv | 368 +++++ data/gl 18327364_jshahinitiran.annodb | 83 + data/gl 18327364_jshahinitiran.n-triples | 10 + data/gl 18327364_tstrakeljahn.annodb | 82 + data/gl 18327364_tstrakeljahn.n-triples | 10 + data/gl 18402717 copy_admin.annodb | 111 ++ data/gl 18402717 copy_admin.n-triples | 206 +++ data/gl 18402717 copy_export.csv | 493 ++++++ data/gl 18402717_admin.annodb | 111 ++ data/gl 18402717_admin.n-triples | 140 ++ data/gl 18402717_export.csv | 493 ++++++ data/gl 18402717_jshahinitiran.annodb | 100 ++ data/gl 18402717_jshahinitiran.n-triples | 10 + data/gl 18402717_tstrakeljahn.annodb | 103 ++ data/gl 18402717_tstrakeljahn.n-triples | 10 + data/gl 18535605_admin.annodb | 96 ++ data/gl 18535605_admin.n-triples | 111 ++ data/gl 18535605_export.csv | 474 ++++++ data/gl 18535605_jshahinitiran.annodb | 79 + data/gl 18535605_jshahinitiran.n-triples | 10 + data/gl 18535605_tstrakeljahn.annodb | 89 ++ data/gl 18535605_tstrakeljahn.n-triples | 10 + data/gl 18721251 copy_admin.annodb | 97 ++ data/gl 18721251 copy_admin.n-triples | 237 +++ data/gl 18721251 copy_export.csv | 510 +++++++ data/gl 18721251_admin.annodb | 97 ++ data/gl 18721251_admin.n-triples | 154 ++ data/gl 18721251_export.csv | 510 +++++++ data/gl 18721251_jshahinitiran.annodb | 88 ++ data/gl 18721251_jshahinitiran.n-triples | 10 + data/gl 18721251_tstrakeljahn.annodb | 82 + data/gl 18721251_tstrakeljahn.n-triples | 10 + data/gl 1882923_admin.annodb | 78 + data/gl 1882923_admin.n-triples | 130 ++ data/gl 1882923_export.csv | 309 ++++ data/gl 1882923_jshahinitiran.annodb | 64 + data/gl 1882923_jshahinitiran.n-triples | 10 + data/gl 1882923_tstrakeljahn.annodb | 80 + data/gl 1882923_tstrakeljahn.n-triples | 10 + data/gl 19092465 copy_admin.annodb | 147 ++ data/gl 19092465 copy_admin.n-triples | 143 ++ data/gl 19092465 copy_export.csv | 665 ++++++++ data/gl 19092465_admin.annodb | 147 ++ data/gl 19092465_admin.n-triples | 141 ++ data/gl 19092465_export.csv | 665 ++++++++ data/gl 19092465_jshahinitiran.annodb | 132 ++ data/gl 19092465_jshahinitiran.n-triples | 10 + data/gl 19092465_tstrakeljahn.annodb | 130 ++ data/gl 19092465_tstrakeljahn.n-triples | 10 + data/gl 19123151 copy_admin.annodb | 102 ++ data/gl 19123151 copy_admin.n-triples | 155 ++ data/gl 19123151 copy_export.csv | 478 ++++++ data/gl 19123151_admin.annodb | 102 ++ data/gl 19123151_admin.n-triples | 147 ++ data/gl 19123151_export.csv | 478 ++++++ data/gl 19123151_jshahinitiran.annodb | 90 ++ data/gl 19123151_jshahinitiran.n-triples | 10 + data/gl 19123151_tstrakeljahn.annodb | 94 ++ data/gl 19123151_tstrakeljahn.n-triples | 10 + data/gl 19336424 copy_admin.annodb | 88 ++ data/gl 19336424 copy_admin.n-triples | 157 ++ data/gl 19336424 copy_export.csv | 423 +++++ data/gl 19336424_admin.annodb | 88 ++ data/gl 19336424_admin.n-triples | 158 ++ data/gl 19336424_export.csv | 423 +++++ data/gl 19336424_jshahinitiran.annodb | 80 + data/gl 19336424_jshahinitiran.n-triples | 10 + data/gl 19336424_tstrakeljahn.annodb | 81 + data/gl 19336424_tstrakeljahn.n-triples | 10 + data/gl 19476406_admin.annodb | 159 ++ data/gl 19476406_admin.n-triples | 196 +++ data/gl 19476406_export.csv | 634 ++++++++ data/gl 19476406_jshahinitiran.annodb | 123 ++ data/gl 19476406_jshahinitiran.n-triples | 10 + data/gl 19476406_tstrakeljahn.annodb | 149 ++ data/gl 19476406_tstrakeljahn.n-triples | 10 + data/gl 19726422 copy_admin.annodb | 115 ++ data/gl 19726422 copy_admin.n-triples | 234 +++ data/gl 19726422 copy_export.csv | 526 +++++++ data/gl 19726422_admin.annodb | 115 ++ data/gl 19726422_admin.n-triples | 179 +++ data/gl 19726422_export.csv | 526 +++++++ data/gl 19726422_jshahinitiran.annodb | 107 ++ data/gl 19726422_jshahinitiran.n-triples | 10 + data/gl 19726422_tstrakeljahn.annodb | 106 ++ data/gl 19726422_tstrakeljahn.n-triples | 10 + data/gl 19787599_admin.annodb | 99 ++ data/gl 19787599_admin.n-triples | 189 +++ data/gl 19787599_export.csv | 440 ++++++ data/gl 19787599_jshahinitiran.annodb | 93 ++ data/gl 19787599_jshahinitiran.n-triples | 10 + data/gl 19787599_tstrakeljahn.annodb | 73 + data/gl 19787599_tstrakeljahn.n-triples | 10 + data/gl 19860553_admin.annodb | 107 ++ data/gl 19860553_admin.n-triples | 166 ++ data/gl 19860553_export.csv | 547 +++++++ data/gl 19860553_jshahinitiran.annodb | 94 ++ data/gl 19860553_jshahinitiran.n-triples | 10 + data/gl 19860553_tstrakeljahn.annodb | 97 ++ data/gl 19860553_tstrakeljahn.n-triples | 10 + data/gl 20019759 copy_admin.annodb | 128 ++ data/gl 20019759 copy_admin.n-triples | 122 ++ data/gl 20019759 copy_export.csv | 570 +++++++ data/gl 20019759_admin.annodb | 128 ++ data/gl 20019759_admin.n-triples | 140 ++ data/gl 20019759_export.csv | 570 +++++++ data/gl 20019759_jshahinitiran.annodb | 91 ++ data/gl 20019759_jshahinitiran.n-triples | 10 + data/gl 20019759_tstrakeljahn.annodb | 126 ++ data/gl 20019759_tstrakeljahn.n-triples | 10 + data/gl 20420586_admin.annodb | 65 + data/gl 20420586_admin.n-triples | 100 ++ data/gl 20420586_export.csv | 415 +++++ data/gl 20420586_jshahinitiran.annodb | 68 + data/gl 20420586_jshahinitiran.n-triples | 10 + data/gl 20420586_tstrakeljahn.annodb | 63 + data/gl 20420586_tstrakeljahn.n-triples | 10 + data/gl 20429818_admin.annodb | 116 ++ data/gl 20429818_admin.n-triples | 163 ++ data/gl 20429818_export.csv | 623 ++++++++ data/gl 20429818_jshahinitiran.annodb | 106 ++ data/gl 20429818_jshahinitiran.n-triples | 10 + data/gl 20429818_tstrakeljahn.annodb | 110 ++ data/gl 20429818_tstrakeljahn.n-triples | 10 + data/gl 20545217_admin.annodb | 67 + data/gl 20545217_admin.n-triples | 113 ++ data/gl 20545217_export.csv | 308 ++++ data/gl 20545217_jshahinitiran.annodb | 64 + data/gl 20545217_jshahinitiran.n-triples | 10 + data/gl 20545217_tstrakeljahn.annodb | 63 + data/gl 20545217_tstrakeljahn.n-triples | 10 + data/gl 21034177_admin.annodb | 118 ++ data/gl 21034177_admin.n-triples | 227 +++ data/gl 21034177_export.csv | 514 +++++++ data/gl 21034177_jshahinitiran.annodb | 112 ++ data/gl 21034177_jshahinitiran.n-triples | 15 + data/gl 21034177_tstrakeljahn.annodb | 109 ++ data/gl 21034177_tstrakeljahn.n-triples | 10 + data/gl 21048504_admin.annodb | 89 ++ data/gl 21048504_admin.n-triples | 126 ++ data/gl 21048504_export.csv | 492 ++++++ data/gl 21048504_jshahinitiran.annodb | 82 + data/gl 21048504_jshahinitiran.n-triples | 10 + data/gl 21048504_tstrakeljahn.annodb | 83 + data/gl 21048504_tstrakeljahn.n-triples | 10 + data/gl 21257146_admin.annodb | 72 + data/gl 21257146_admin.n-triples | 129 ++ data/gl 21257146_export.csv | 685 +++++++++ data/gl 21257146_jshahinitiran.annodb | 66 + data/gl 21257146_jshahinitiran.n-triples | 10 + data/gl 21257146_tstrakeljahn.annodb | 72 + data/gl 21257146_tstrakeljahn.n-triples | 10 + data/gl 21499770_admin.annodb | 83 + data/gl 21499770_admin.n-triples | 134 ++ data/gl 21499770_export.csv | 627 ++++++++ data/gl 21499770_jshahinitiran.annodb | 82 + data/gl 21499770_jshahinitiran.n-triples | 10 + data/gl 21499770_tstrakeljahn.annodb | 79 + data/gl 21499770_tstrakeljahn.n-triples | 10 + data/gl 21680022_admin.annodb | 131 ++ data/gl 21680022_admin.n-triples | 180 +++ data/gl 21680022_export.csv | 703 +++++++++ data/gl 21680022_jshahinitiran.annodb | 120 ++ data/gl 21680022_jshahinitiran.n-triples | 14 + data/gl 21680022_tstrakeljahn.annodb | 104 ++ data/gl 21680022_tstrakeljahn.n-triples | 10 + data/gl 21792284_admin.annodb | 123 ++ data/gl 21792284_admin.n-triples | 189 +++ data/gl 21792284_export.csv | 541 +++++++ data/gl 21792284_jshahinitiran.annodb | 117 ++ data/gl 21792284_jshahinitiran.n-triples | 10 + data/gl 21792284_tstrakeljahn.annodb | 115 ++ data/gl 21792284_tstrakeljahn.n-triples | 10 + data/gl 21851642_admin.annodb | 113 ++ data/gl 21851642_admin.n-triples | 122 ++ data/gl 21851642_export.csv | 606 ++++++++ data/gl 21851642_jshahinitiran.annodb | 95 ++ data/gl 21851642_jshahinitiran.n-triples | 10 + data/gl 21851642_tstrakeljahn.annodb | 110 ++ data/gl 21851642_tstrakeljahn.n-triples | 10 + data/gl 21960068_admin.annodb | 89 ++ data/gl 21960068_admin.n-triples | 145 ++ data/gl 21960068_export.csv | 488 ++++++ data/gl 21960068_jshahinitiran.annodb | 62 + data/gl 21960068_jshahinitiran.n-triples | 10 + data/gl 21960068_tstrakeljahn.annodb | 83 + data/gl 21960068_tstrakeljahn.n-triples | 10 + data/gl 22207522_admin.annodb | 86 ++ data/gl 22207522_admin.n-triples | 157 ++ data/gl 22207522_export.csv | 471 ++++++ data/gl 22207522_jshahinitiran.annodb | 71 + data/gl 22207522_jshahinitiran.n-triples | 10 + data/gl 22207522_tstrakeljahn.annodb | 81 + data/gl 22207522_tstrakeljahn.n-triples | 10 + data/gl 22320418_admin.annodb | 95 ++ data/gl 22320418_admin.n-triples | 139 ++ data/gl 22320418_export.csv | 414 +++++ data/gl 22320418_jshahinitiran.annodb | 79 + data/gl 22320418_jshahinitiran.n-triples | 10 + data/gl 22320418_tstrakeljahn.annodb | 87 ++ data/gl 22320418_tstrakeljahn.n-triples | 10 + data/gl 22458918_admin.annodb | 113 ++ data/gl 22458918_admin.n-triples | 131 ++ data/gl 22458918_export.csv | 567 +++++++ data/gl 22458918_jshahinitiran.annodb | 104 ++ data/gl 22458918_jshahinitiran.n-triples | 10 + data/gl 22458918_tstrakeljahn.annodb | 95 ++ data/gl 22458918_tstrakeljahn.n-triples | 10 + data/gl 22775229_admin.annodb | 95 ++ data/gl 22775229_admin.n-triples | 137 ++ data/gl 22775229_export.csv | 520 +++++++ data/gl 22775229_jshahinitiran.annodb | 88 ++ data/gl 22775229_jshahinitiran.n-triples | 10 + data/gl 22775229_tstrakeljahn.annodb | 73 + data/gl 22775229_tstrakeljahn.n-triples | 10 + data/gl 23203707_admin.annodb | 91 ++ data/gl 23203707_admin.n-triples | 161 ++ data/gl 23203707_export.csv | 490 ++++++ data/gl 23203707_jshahinitiran.annodb | 96 ++ data/gl 23203707_jshahinitiran.n-triples | 10 + data/gl 23203707_tstrakeljahn.annodb | 82 + data/gl 23203707_tstrakeljahn.n-triples | 10 + data/gl 23429621_admin.annodb | 110 ++ data/gl 23429621_admin.n-triples | 193 +++ data/gl 23429621_export.csv | 485 ++++++ data/gl 23429621_jshahinitiran.annodb | 107 ++ data/gl 23429621_jshahinitiran.n-triples | 15 + data/gl 23429621_tstrakeljahn.annodb | 99 ++ data/gl 23429621_tstrakeljahn.n-triples | 28 + data/gl 23550916_admin.annodb | 103 ++ data/gl 23550916_admin.n-triples | 109 ++ data/gl 23550916_export.csv | 527 +++++++ data/gl 23550916_jshahinitiran.annodb | 93 ++ data/gl 23550916_jshahinitiran.n-triples | 10 + data/gl 23550916_tstrakeljahn.annodb | 95 ++ data/gl 23550916_tstrakeljahn.n-triples | 10 + data/gl 23686322_admin.annodb | 85 ++ data/gl 23686322_admin.n-triples | 111 ++ data/gl 23686322_export.csv | 438 ++++++ data/gl 23686322_jshahinitiran.annodb | 81 + data/gl 23686322_jshahinitiran.n-triples | 10 + data/gl 23686322_tstrakeljahn.annodb | 76 + data/gl 23686322_tstrakeljahn.n-triples | 10 + data/gl 23807349_admin.annodb | 121 ++ data/gl 23807349_admin.n-triples | 143 ++ data/gl 23807349_export.csv | 577 +++++++ data/gl 23807349_jshahinitiran.annodb | 120 ++ data/gl 23807349_jshahinitiran.n-triples | 10 + data/gl 23807349_tstrakeljahn.annodb | 107 ++ data/gl 23807349_tstrakeljahn.n-triples | 10 + data/gl 23950156_admin.annodb | 87 ++ data/gl 23950156_admin.n-triples | 111 ++ data/gl 23950156_export.csv | 475 ++++++ data/gl 23950156_jshahinitiran.annodb | 83 + data/gl 23950156_jshahinitiran.n-triples | 10 + data/gl 23950156_tstrakeljahn.annodb | 81 + data/gl 23950156_tstrakeljahn.n-triples | 10 + data/gl 24073548_admin.annodb | 127 ++ data/gl 24073548_admin.n-triples | 157 ++ data/gl 24073548_export.csv | 502 ++++++ data/gl 24073548_jshahinitiran.annodb | 108 ++ data/gl 24073548_jshahinitiran.n-triples | 10 + data/gl 24073548_tstrakeljahn.annodb | 126 ++ data/gl 24073548_tstrakeljahn.n-triples | 10 + data/gl 24672097_admin.annodb | 126 ++ data/gl 24672097_admin.n-triples | 118 ++ data/gl 24672097_export.csv | 796 ++++++++++ data/gl 24672097_jshahinitiran.annodb | 106 ++ data/gl 24672097_jshahinitiran.n-triples | 10 + data/gl 24672097_tstrakeljahn.annodb | 91 ++ data/gl 24672097_tstrakeljahn.n-triples | 10 + data/gl 24919410_admin.annodb | 132 ++ data/gl 24919410_admin.n-triples | 215 +++ data/gl 24919410_export.csv | 645 ++++++++ data/gl 24919410_jshahinitiran.annodb | 120 ++ data/gl 24919410_jshahinitiran.n-triples | 10 + data/gl 24919410_tstrakeljahn.annodb | 118 ++ data/gl 24919410_tstrakeljahn.n-triples | 10 + data/gl 25264990_admin.annodb | 87 ++ data/gl 25264990_admin.n-triples | 134 ++ data/gl 25264990_export.csv | 460 ++++++ data/gl 25264990_jshahinitiran.annodb | 76 + data/gl 25264990_jshahinitiran.n-triples | 10 + data/gl 25264990_tstrakeljahn.annodb | 89 ++ data/gl 25264990_tstrakeljahn.n-triples | 10 + data/gl 25430900_admin.annodb | 114 ++ data/gl 25430900_admin.n-triples | 208 +++ data/gl 25430900_export.csv | 601 ++++++++ data/gl 25430900_jshahinitiran.annodb | 102 ++ data/gl 25430900_jshahinitiran.n-triples | 10 + data/gl 25430900_tstrakeljahn.annodb | 77 + data/gl 25430900_tstrakeljahn.n-triples | 10 + data/gl 25432143_admin.annodb | 121 ++ data/gl 25432143_admin.n-triples | 140 ++ data/gl 25432143_export.csv | 623 ++++++++ data/gl 25432143_jshahinitiran.annodb | 101 ++ data/gl 25432143_jshahinitiran.n-triples | 10 + data/gl 25432143_tstrakeljahn.annodb | 113 ++ data/gl 25432143_tstrakeljahn.n-triples | 10 + data/gl 25533656_admin.annodb | 125 ++ data/gl 25533656_admin.n-triples | 151 ++ data/gl 25533656_export.csv | 1079 +++++++++++++ data/gl 25533656_jshahinitiran.annodb | 120 ++ data/gl 25533656_jshahinitiran.n-triples | 10 + data/gl 25533656_tstrakeljahn.annodb | 114 ++ data/gl 25533656_tstrakeljahn.n-triples | 10 + data/gl 26578422_admin.annodb | 90 ++ data/gl 26578422_admin.n-triples | 143 ++ data/gl 26578422_export.csv | 641 ++++++++ data/gl 26578422_jshahinitiran.annodb | 91 ++ data/gl 26578422_jshahinitiran.n-triples | 15 + data/gl 26578422_tstrakeljahn.annodb | 75 + data/gl 26578422_tstrakeljahn.n-triples | 10 + data/gl 26940161_admin.annodb | 115 ++ data/gl 26940161_admin.n-triples | 131 ++ data/gl 26940161_export.csv | 620 ++++++++ data/gl 26940161_jshahinitiran.annodb | 102 ++ data/gl 26940161_jshahinitiran.n-triples | 10 + data/gl 26940161_tstrakeljahn.annodb | 108 ++ data/gl 26940161_tstrakeljahn.n-triples | 10 + data/gl 27050347_admin.annodb | 91 ++ data/gl 27050347_admin.n-triples | 145 ++ data/gl 27050347_export.csv | 459 ++++++ data/gl 27050347_jshahinitiran.annodb | 82 + data/gl 27050347_jshahinitiran.n-triples | 10 + data/gl 27050347_tstrakeljahn.annodb | 74 + data/gl 27050347_tstrakeljahn.n-triples | 10 + data/gl 27367743_admin.annodb | 116 ++ data/gl 27367743_admin.n-triples | 142 ++ data/gl 27367743_export.csv | 667 ++++++++ data/gl 27367743_jshahinitiran.annodb | 87 ++ data/gl 27367743_jshahinitiran.n-triples | 10 + data/gl 27367743_tstrakeljahn.annodb | 113 ++ data/gl 27367743_tstrakeljahn.n-triples | 10 + data/gl 27445072_admin.annodb | 69 + data/gl 27445072_admin.n-triples | 131 ++ data/gl 27445072_export.csv | 415 +++++ data/gl 27445072_jshahinitiran.annodb | 57 + data/gl 27445072_jshahinitiran.n-triples | 10 + data/gl 27445072_tstrakeljahn.annodb | 53 + data/gl 27445072_tstrakeljahn.n-triples | 10 + data/gl 28129020_admin.annodb | 94 ++ data/gl 28129020_admin.n-triples | 162 ++ data/gl 28129020_export.csv | 510 +++++++ data/gl 28129020_jshahinitiran.annodb | 87 ++ data/gl 28129020_jshahinitiran.n-triples | 10 + data/gl 28129020_tstrakeljahn.annodb | 81 + data/gl 28129020_tstrakeljahn.n-triples | 10 + data/gl 7880782_admin.annodb | 84 + data/gl 7880782_admin.n-triples | 144 ++ data/gl 7880782_export.csv | 405 +++++ data/gl 7880782_jshahinitiran.annodb | 75 + data/gl 7880782_jshahinitiran.n-triples | 10 + data/gl 7880782_tstrakeljahn.annodb | 80 + data/gl 7880782_tstrakeljahn.n-triples | 10 + data/gl 8123096_admin.annodb | 60 + data/gl 8123096_admin.n-triples | 95 ++ data/gl 8123096_export.csv | 310 ++++ data/gl 8123096_jshahinitiran.annodb | 59 + data/gl 8123096_jshahinitiran.n-triples | 10 + data/gl 8123096_tstrakeljahn.annodb | 55 + data/gl 8123096_tstrakeljahn.n-triples | 10 + data/gl 8145982_admin.annodb | 63 + data/gl 8145982_admin.n-triples | 123 ++ data/gl 8145982_export.csv | 294 ++++ data/gl 8145982_jshahinitiran.annodb | 57 + data/gl 8145982_jshahinitiran.n-triples | 10 + data/gl 8145982_tstrakeljahn.annodb | 64 + data/gl 8145982_tstrakeljahn.n-triples | 10 + data/gl 8628543_admin.annodb | 90 ++ data/gl 8628543_admin.n-triples | 134 ++ data/gl 8628543_export.csv | 417 +++++ data/gl 8628543_jshahinitiran.annodb | 82 + data/gl 8628543_jshahinitiran.n-triples | 10 + data/gl 8628543_tstrakeljahn.annodb | 82 + data/gl 8628543_tstrakeljahn.n-triples | 10 + data/gl 8628544_admin.annodb | 85 ++ data/gl 8628544_admin.n-triples | 179 +++ data/gl 8628544_export.csv | 413 +++++ data/gl 8628544_jshahinitiran.annodb | 71 + data/gl 8628544_jshahinitiran.n-triples | 10 + data/gl 8628544_tstrakeljahn.annodb | 70 + data/gl 8628544_tstrakeljahn.n-triples | 10 + data/gl 8694726_admin.annodb | 85 ++ data/gl 8694726_admin.n-triples | 140 ++ data/gl 8694726_export.csv | 399 +++++ data/gl 8694726_jshahinitiran.annodb | 72 + data/gl 8694726_jshahinitiran.n-triples | 10 + data/gl 8694726_tstrakeljahn.annodb | 81 + data/gl 8694726_tstrakeljahn.n-triples | 10 + data/gl 8970248_admin.annodb | 89 ++ data/gl 8970248_admin.n-triples | 140 ++ data/gl 8970248_export.csv | 450 ++++++ data/gl 8970248_jshahinitiran.annodb | 82 + data/gl 8970248_jshahinitiran.n-triples | 10 + data/gl 8970248_tstrakeljahn.annodb | 81 + data/gl 8970248_tstrakeljahn.n-triples | 10 + data/gl 9230823_admin.annodb | 113 ++ data/gl 9230823_admin.n-triples | 225 +++ data/gl 9230823_export.csv | 510 +++++++ data/gl 9230823_jshahinitiran.annodb | 93 ++ data/gl 9230823_jshahinitiran.n-triples | 10 + data/gl 9230823_tstrakeljahn.annodb | 86 ++ data/gl 9230823_tstrakeljahn.n-triples | 10 + data/gl 9331215_admin.annodb | 88 ++ data/gl 9331215_admin.n-triples | 136 ++ data/gl 9331215_export.csv | 499 ++++++ data/gl 9331215_jshahinitiran.annodb | 88 ++ data/gl 9331215_jshahinitiran.n-triples | 10 + data/gl 9331215_tstrakeljahn.annodb | 94 ++ data/gl 9331215_tstrakeljahn.n-triples | 10 + data/gl 9663361_admin.annodb | 107 ++ data/gl 9663361_admin.n-triples | 205 +++ data/gl 9663361_export.csv | 508 ++++++ data/gl 9663361_jshahinitiran.annodb | 73 + data/gl 9663361_jshahinitiran.n-triples | 10 + data/gl 9663361_tstrakeljahn.annodb | 93 ++ data/gl 9663361_tstrakeljahn.n-triples | 10 + requirements.txt | 13 + scripts-extractive/all_runs.txt | 11 + scripts-extractive/eval-extr.sh | 11 + scripts-extractive/extractive-best.sh | 6 + scripts-extractive/extractive-dm2.sh | 10 + scripts-extractive/extractive-gl.sh | 10 + scripts-generative/allRuns.txt | 7 + scripts-generative/eval-gen.sh | 11 + scripts-generative/generative-best.sh | 6 + scripts-generative/generative-dm2.sh | 10 + scripts-generative/generative-gl.sh | 10 + sort_results.sh | 25 + src/eval_summary.py | 556 +++++++ src/eval_summary_best.py | 274 ++++ src/extractive_approach/__init__.py | 0 .../clustering_approaches.py | 446 ++++++ .../create_task_config_file.py | 157 ++ src/extractive_approach/data_handling.py | 218 +++ src/extractive_approach/entity_clustering.py | 139 ++ src/extractive_approach/entity_extraction.py | 114 ++ src/extractive_approach/evaluation.py | 304 ++++ src/extractive_approach/modules.py | 132 ++ src/extractive_approach/param_search.py | 97 ++ src/extractive_approach/training.py | 478 ++++++ src/extractive_approach/utils.py | 58 + src/full_eval.py | 181 +++ src/generative_approach/.gitignore | 2 + src/generative_approach/__init__.py | 0 .../create_task_config_file.py | 168 ++ src/generative_approach/data_handling.py | 141 ++ src/generative_approach/decoding.py | 577 +++++++ src/generative_approach/evaluation.py | 308 ++++ src/generative_approach/generation.py | 111 ++ src/generative_approach/grammar.py | 194 +++ .../max_cardinalities_estimator.py | 25 + src/generative_approach/models/__init__.py | 0 src/generative_approach/models/ed_model.py | 39 + src/generative_approach/models/flan_t5.py | 40 + src/generative_approach/models/longformer.py | 38 + src/generative_approach/modules.py | 5 + src/generative_approach/parsing.py | 290 ++++ .../resources/grammar_dm2.txt | 80 + .../resources/grammar_gl.txt | 78 + src/generative_approach/template_coding.py | 309 ++++ src/generative_approach/training.py | 393 +++++ src/generative_approach/utils.py | 245 +++ src/main.py | 60 + src/template_lib/CharTokenizer.py | 3 + src/template_lib/DocumentChunking.py | 157 ++ src/template_lib/DocumentEncoder.py | 180 +++ src/template_lib/EntityDecoder.py | 91 ++ src/template_lib/SlotFillingEvaluation.py | 158 ++ src/template_lib/TempCollectionVisualizer.py | 32 + src/template_lib/TemplateAlignment.py | 126 ++ src/template_lib/__init__.py | 0 src/template_lib/consts.py | 5 + src/template_lib/ctro.py | 1178 ++++++++++++++ .../data_classes/AnnotatedSentence.py | 53 + src/template_lib/data_classes/Chunk.py | 69 + src/template_lib/data_classes/Document.py | 146 ++ src/template_lib/data_classes/Entity.py | 159 ++ src/template_lib/data_classes/Sentence.py | 118 ++ src/template_lib/data_classes/Template.py | 192 +++ .../data_classes/TemplateCollection.py | 155 ++ .../data_classes/TokenSequence.py | 21 + src/template_lib/data_classes/__init__.py | 0 src/template_lib/data_handling.py | 56 + src/template_lib/evaluation_utils.py | 69 + .../max_cardinalities_estimator.py | 14 + src/template_lib/rdf_strings.py | 25 + src/template_lib/resources/classes.csv | 341 +++++ .../resources/most_general_superclasses.csv | 292 ++++ src/template_lib/resources/properties.csv | 88 ++ src/template_lib/resources/subclasses.csv | 293 ++++ src/template_lib/santo/SantoAnnotation.py | 96 ++ src/template_lib/santo/SantoAnnotationFile.py | 126 ++ src/template_lib/santo/SantoDataset.py | 132 ++ src/template_lib/santo/SantoToken.py | 9 + .../santo/SantoTokenizationFile.py | 132 ++ src/template_lib/santo/SantoTriplesFile.py | 84 + src/template_lib/santo/__init__.py | 0 1626 files changed, 257165 insertions(+) create mode 100644 .gitignore create mode 100644 README.md create mode 100644 data/dataset_splits/dm2_test_ids.txt create mode 100644 data/dataset_splits/dm2_train_ids.txt create mode 100644 data/dataset_splits/dm2_validation_ids.txt create mode 100644 data/dataset_splits/glaucoma_test_ids.txt create mode 100644 data/dataset_splits/glaucoma_train_ids.txt create mode 100644 data/dataset_splits/glaucoma_validation_ids.txt create mode 100644 data/dm2 11315821_admin.annodb create mode 100644 data/dm2 11315821_admin.n-triples create mode 100644 data/dm2 11315821_akramersunderbrink.annodb create mode 100644 data/dm2 11315821_akramersunderbrink.n-triples create mode 100644 data/dm2 11315821_export.csv create mode 100644 data/dm2 11315821_kwoodley.annodb create mode 100644 data/dm2 11315821_kwoodley.n-triples create mode 100644 data/dm2 12734781_admin.annodb create mode 100644 data/dm2 12734781_admin.n-triples create mode 100644 data/dm2 12734781_akramersunderbrink.annodb create mode 100644 data/dm2 12734781_akramersunderbrink.n-triples create mode 100644 data/dm2 12734781_export.csv create mode 100644 data/dm2 12734781_kwoodley.annodb create mode 100644 data/dm2 12734781_kwoodley.n-triples create mode 100644 data/dm2 14578243_admin.annodb create mode 100644 data/dm2 14578243_admin.n-triples create mode 100644 data/dm2 14578243_akramersunderbrink.annodb create mode 100644 data/dm2 14578243_akramersunderbrink.n-triples create mode 100644 data/dm2 14578243_export.csv create mode 100644 data/dm2 14578243_kwoodley.annodb create mode 100644 data/dm2 14578243_kwoodley.n-triples create mode 100644 data/dm2 14706058_admin.annodb create mode 100644 data/dm2 14706058_admin.n-triples create mode 100644 data/dm2 14706058_akramersunderbrink.annodb create mode 100644 data/dm2 14706058_akramersunderbrink.n-triples create mode 100644 data/dm2 14706058_export.csv create mode 100644 data/dm2 14706058_kwoodley.annodb create mode 100644 data/dm2 14706058_kwoodley.n-triples create mode 100644 data/dm2 15205563_admin.annodb create mode 100644 data/dm2 15205563_admin.n-triples create mode 100644 data/dm2 15205563_akramersunderbrink.annodb create mode 100644 data/dm2 15205563_akramersunderbrink.n-triples create mode 100644 data/dm2 15205563_export.csv create mode 100644 data/dm2 15205563_kwoodley.annodb create mode 100644 data/dm2 15205563_kwoodley.n-triples create mode 100644 data/dm2 15562200_admin.annodb create mode 100644 data/dm2 15562200_admin.n-triples create mode 100644 data/dm2 15562200_akramersunderbrink.annodb create mode 100644 data/dm2 15562200_akramersunderbrink.n-triples create mode 100644 data/dm2 15562200_export.csv create mode 100644 data/dm2 15562200_kwoodley.annodb create mode 100644 data/dm2 15562200_kwoodley.n-triples create mode 100644 data/dm2 15677775_admin.annodb create mode 100644 data/dm2 15677775_admin.n-triples create mode 100644 data/dm2 15677775_akramersunderbrink.annodb create mode 100644 data/dm2 15677775_akramersunderbrink.n-triples create mode 100644 data/dm2 15677775_export.csv create mode 100644 data/dm2 15677775_kwoodley.annodb create mode 100644 data/dm2 15677775_kwoodley.n-triples create mode 100644 data/dm2 15677776_admin.annodb create mode 100644 data/dm2 15677776_admin.n-triples create mode 100644 data/dm2 15677776_akramersunderbrink.annodb create mode 100644 data/dm2 15677776_akramersunderbrink.n-triples create mode 100644 data/dm2 15677776_export.csv create mode 100644 data/dm2 15677776_kwoodley.annodb create mode 100644 data/dm2 15677776_kwoodley.n-triples create mode 100644 data/dm2 15715892_admin.annodb create mode 100644 data/dm2 15715892_admin.n-triples create mode 100644 data/dm2 15715892_akramersunderbrink.annodb create mode 100644 data/dm2 15715892_akramersunderbrink.n-triples create mode 100644 data/dm2 15715892_export.csv create mode 100644 data/dm2 15715892_kwoodley.annodb create mode 100644 data/dm2 15715892_kwoodley.n-triples create mode 100644 data/dm2 15842521_admin.annodb create mode 100644 data/dm2 15842521_admin.n-triples create mode 100644 data/dm2 15842521_akramersunderbrink.annodb create mode 100644 data/dm2 15842521_akramersunderbrink.n-triples create mode 100644 data/dm2 15842521_export.csv create mode 100644 data/dm2 15842521_kwoodley.annodb create mode 100644 data/dm2 15842521_kwoodley.n-triples create mode 100644 data/dm2 16456680_admin.annodb create mode 100644 data/dm2 16456680_admin.n-triples create mode 100644 data/dm2 16456680_akramersunderbrink.annodb create mode 100644 data/dm2 16456680_akramersunderbrink.n-triples create mode 100644 data/dm2 16456680_export.csv create mode 100644 data/dm2 16456680_kwoodley.annodb create mode 100644 data/dm2 16456680_kwoodley.n-triples create mode 100644 data/dm2 16505498_admin.annodb create mode 100644 data/dm2 16505498_admin.n-triples create mode 100644 data/dm2 16505498_akramersunderbrink.annodb create mode 100644 data/dm2 16505498_akramersunderbrink.n-triples create mode 100644 data/dm2 16505498_export.csv create mode 100644 data/dm2 16505498_kwoodley.annodb create mode 100644 data/dm2 16505498_kwoodley.n-triples create mode 100644 data/dm2 16715577_admin.annodb create mode 100644 data/dm2 16715577_admin.n-triples create mode 100644 data/dm2 16715577_akramersunderbrink.annodb create mode 100644 data/dm2 16715577_akramersunderbrink.n-triples create mode 100644 data/dm2 16715577_export.csv create mode 100644 data/dm2 16715577_kwoodley.annodb create mode 100644 data/dm2 16715577_kwoodley.n-triples create mode 100644 data/dm2 17115351_admin.annodb create mode 100644 data/dm2 17115351_admin.n-triples create mode 100644 data/dm2 17115351_akramersunderbrink.annodb create mode 100644 data/dm2 17115351_akramersunderbrink.n-triples create mode 100644 data/dm2 17115351_export.csv create mode 100644 data/dm2 17115351_kwoodley.annodb create mode 100644 data/dm2 17115351_kwoodley.n-triples create mode 100644 data/dm2 17130197_admin.annodb create mode 100644 data/dm2 17130197_admin.n-triples create mode 100644 data/dm2 17130197_akramersunderbrink.annodb create mode 100644 data/dm2 17130197_akramersunderbrink.n-triples create mode 100644 data/dm2 17130197_export.csv create mode 100644 data/dm2 17130197_kwoodley.annodb create mode 100644 data/dm2 17130197_kwoodley.n-triples create mode 100644 data/dm2 17157112_admin.annodb create mode 100644 data/dm2 17157112_admin.n-triples create mode 100644 data/dm2 17157112_akramersunderbrink.annodb create mode 100644 data/dm2 17157112_akramersunderbrink.n-triples create mode 100644 data/dm2 17157112_export.csv create mode 100644 data/dm2 17157112_kwoodley.annodb create mode 100644 data/dm2 17157112_kwoodley.n-triples create mode 100644 data/dm2 17363756_admin.annodb create mode 100644 data/dm2 17363756_admin.n-triples create mode 100644 data/dm2 17363756_akramersunderbrink.annodb create mode 100644 data/dm2 17363756_akramersunderbrink.n-triples create mode 100644 data/dm2 17363756_export.csv create mode 100644 data/dm2 17363756_kwoodley.annodb create mode 100644 data/dm2 17363756_kwoodley.n-triples create mode 100644 data/dm2 17379048_admin.annodb create mode 100644 data/dm2 17379048_admin.n-triples create mode 100644 data/dm2 17379048_akramersunderbrink.annodb create mode 100644 data/dm2 17379048_akramersunderbrink.n-triples create mode 100644 data/dm2 17379048_export.csv create mode 100644 data/dm2 17379048_kwoodley.annodb create mode 100644 data/dm2 17379048_kwoodley.n-triples create mode 100644 data/dm2 17404349_admin.annodb create mode 100644 data/dm2 17404349_admin.n-triples create mode 100644 data/dm2 17404349_akramersunderbrink.annodb create mode 100644 data/dm2 17404349_akramersunderbrink.n-triples create mode 100644 data/dm2 17404349_export.csv create mode 100644 data/dm2 17404349_kwoodley.annodb create mode 100644 data/dm2 17404349_kwoodley.n-triples create mode 100644 data/dm2 17593236_admin.annodb create mode 100644 data/dm2 17593236_admin.n-triples create mode 100644 data/dm2 17593236_akramersunderbrink.annodb create mode 100644 data/dm2 17593236_akramersunderbrink.n-triples create mode 100644 data/dm2 17593236_export.csv create mode 100644 data/dm2 17593236_kwoodley.annodb create mode 100644 data/dm2 17593236_kwoodley.n-triples create mode 100644 data/dm2 17929538_admin.annodb create mode 100644 data/dm2 17929538_admin.n-triples create mode 100644 data/dm2 17929538_akramersunderbrink.annodb create mode 100644 data/dm2 17929538_akramersunderbrink.n-triples create mode 100644 data/dm2 17929538_export.csv create mode 100644 data/dm2 17929538_kwoodley.annodb create mode 100644 data/dm2 17929538_kwoodley.n-triples create mode 100644 data/dm2 17934150 copy_admin.annodb create mode 100644 data/dm2 17934150 copy_admin.n-triples create mode 100644 data/dm2 17934150 copy_export.csv create mode 100644 data/dm2 17934150_admin.annodb create mode 100644 data/dm2 17934150_admin.n-triples create mode 100644 data/dm2 17934150_akramersunderbrink.annodb create mode 100644 data/dm2 17934150_akramersunderbrink.n-triples create mode 100644 data/dm2 17934150_export.csv create mode 100644 data/dm2 17934150_kwoodley.annodb create mode 100644 data/dm2 17934150_kwoodley.n-triples create mode 100644 data/dm2 17992639 copy_admin.annodb create mode 100644 data/dm2 17992639 copy_admin.n-triples create mode 100644 data/dm2 17992639 copy_export.csv create mode 100644 data/dm2 17992639_admin.annodb create mode 100644 data/dm2 17992639_admin.n-triples create mode 100644 data/dm2 17992639_akramersunderbrink.annodb create mode 100644 data/dm2 17992639_akramersunderbrink.n-triples create mode 100644 data/dm2 17992639_export.csv create mode 100644 data/dm2 17992639_kwoodley.annodb create mode 100644 data/dm2 17992639_kwoodley.n-triples create mode 100644 data/dm2 18158076 copy_admin.annodb create mode 100644 data/dm2 18158076 copy_admin.n-triples create mode 100644 data/dm2 18158076 copy_export.csv create mode 100644 data/dm2 18158076_admin.annodb create mode 100644 data/dm2 18158076_admin.n-triples create mode 100644 data/dm2 18158076_akramersunderbrink.annodb create mode 100644 data/dm2 18158076_akramersunderbrink.n-triples create mode 100644 data/dm2 18158076_export.csv create mode 100644 data/dm2 18158076_kwoodley.annodb create mode 100644 data/dm2 18158076_kwoodley.n-triples create mode 100644 data/dm2 18194595 copy_admin.annodb create mode 100644 data/dm2 18194595 copy_admin.n-triples create mode 100644 data/dm2 18194595 copy_export.csv create mode 100644 data/dm2 18194595_admin.annodb create mode 100644 data/dm2 18194595_admin.n-triples create mode 100644 data/dm2 18194595_akramersunderbrink.annodb create mode 100644 data/dm2 18194595_akramersunderbrink.n-triples create mode 100644 data/dm2 18194595_export.csv create mode 100644 data/dm2 18194595_kwoodley.annodb create mode 100644 data/dm2 18194595_kwoodley.n-triples create mode 100644 data/dm2 18204830 copy_admin.annodb create mode 100644 data/dm2 18204830 copy_admin.n-triples create mode 100644 data/dm2 18204830 copy_export.csv create mode 100644 data/dm2 18204830_admin.annodb create mode 100644 data/dm2 18204830_admin.n-triples create mode 100644 data/dm2 18204830_akramersunderbrink.annodb create mode 100644 data/dm2 18204830_akramersunderbrink.n-triples create mode 100644 data/dm2 18204830_export.csv create mode 100644 data/dm2 18204830_kwoodley.annodb create mode 100644 data/dm2 18204830_kwoodley.n-triples create mode 100644 data/dm2 18761646 copy_admin.annodb create mode 100644 data/dm2 18761646 copy_admin.n-triples create mode 100644 data/dm2 18761646 copy_export.csv create mode 100644 data/dm2 18761646_admin.annodb create mode 100644 data/dm2 18761646_admin.n-triples create mode 100644 data/dm2 18761646_akramersunderbrink.annodb create mode 100644 data/dm2 18761646_akramersunderbrink.n-triples create mode 100644 data/dm2 18761646_export.csv create mode 100644 data/dm2 18761646_kwoodley.annodb create mode 100644 data/dm2 18761646_kwoodley.n-triples create mode 100644 data/dm2 18936501 copy_admin.annodb create mode 100644 data/dm2 18936501 copy_admin.n-triples create mode 100644 data/dm2 18936501 copy_export.csv create mode 100644 data/dm2 18936501_admin.annodb create mode 100644 data/dm2 18936501_admin.n-triples create mode 100644 data/dm2 18936501_akramersunderbrink.annodb create mode 100644 data/dm2 18936501_akramersunderbrink.n-triples create mode 100644 data/dm2 18936501_export.csv create mode 100644 data/dm2 18936501_kwoodley.annodb create mode 100644 data/dm2 18936501_kwoodley.n-triples create mode 100644 data/dm2 19108786 copy_admin.annodb create mode 100644 data/dm2 19108786 copy_admin.n-triples create mode 100644 data/dm2 19108786 copy_export.csv create mode 100644 data/dm2 19108786_admin.annodb create mode 100644 data/dm2 19108786_admin.n-triples create mode 100644 data/dm2 19108786_akramersunderbrink.annodb create mode 100644 data/dm2 19108786_akramersunderbrink.n-triples create mode 100644 data/dm2 19108786_export.csv create mode 100644 data/dm2 19108786_kwoodley.annodb create mode 100644 data/dm2 19108786_kwoodley.n-triples create mode 100644 data/dm2 19307526 copy_admin.annodb create mode 100644 data/dm2 19307526 copy_admin.n-triples create mode 100644 data/dm2 19307526 copy_export.csv create mode 100644 data/dm2 19307526_admin.annodb create mode 100644 data/dm2 19307526_admin.n-triples create mode 100644 data/dm2 19307526_akramersunderbrink.annodb create mode 100644 data/dm2 19307526_akramersunderbrink.n-triples create mode 100644 data/dm2 19307526_export.csv create mode 100644 data/dm2 19307526_kwoodley.annodb create mode 100644 data/dm2 19307526_kwoodley.n-triples create mode 100644 data/dm2 19336625 copy_admin.annodb create mode 100644 data/dm2 19336625 copy_admin.n-triples create mode 100644 data/dm2 19336625 copy_export.csv create mode 100644 data/dm2 19336625_admin.annodb create mode 100644 data/dm2 19336625_admin.n-triples create mode 100644 data/dm2 19336625_akramersunderbrink.annodb create mode 100644 data/dm2 19336625_akramersunderbrink.n-triples create mode 100644 data/dm2 19336625_export.csv create mode 100644 data/dm2 19336625_kwoodley.annodb create mode 100644 data/dm2 19336625_kwoodley.n-triples create mode 100644 data/dm2 19565569_admin.annodb create mode 100644 data/dm2 19565569_admin.n-triples create mode 100644 data/dm2 19565569_akramersunderbrink.annodb create mode 100644 data/dm2 19565569_akramersunderbrink.n-triples create mode 100644 data/dm2 19565569_export.csv create mode 100644 data/dm2 19565569_kwoodley.annodb create mode 100644 data/dm2 19565569_kwoodley.n-triples create mode 100644 data/dm2 19821654_admin.annodb create mode 100644 data/dm2 19821654_admin.n-triples create mode 100644 data/dm2 19821654_akramersunderbrink.annodb create mode 100644 data/dm2 19821654_akramersunderbrink.n-triples create mode 100644 data/dm2 19821654_export.csv create mode 100644 data/dm2 19821654_kwoodley.annodb create mode 100644 data/dm2 19821654_kwoodley.n-triples create mode 100644 data/dm2 20092584_admin.annodb create mode 100644 data/dm2 20092584_admin.n-triples create mode 100644 data/dm2 20092584_akramersunderbrink.annodb create mode 100644 data/dm2 20092584_akramersunderbrink.n-triples create mode 100644 data/dm2 20092584_export.csv create mode 100644 data/dm2 20092584_kwoodley.annodb create mode 100644 data/dm2 20092584_kwoodley.n-triples create mode 100644 data/dm2 20092585_admin.annodb create mode 100644 data/dm2 20092585_admin.n-triples create mode 100644 data/dm2 20092585_akramersunderbrink.annodb create mode 100644 data/dm2 20092585_akramersunderbrink.n-triples create mode 100644 data/dm2 20092585_export.csv create mode 100644 data/dm2 20092585_kwoodley.annodb create mode 100644 data/dm2 20092585_kwoodley.n-triples create mode 100644 data/dm2 20200301_admin.annodb create mode 100644 data/dm2 20200301_admin.n-triples create mode 100644 data/dm2 20200301_akramersunderbrink.annodb create mode 100644 data/dm2 20200301_akramersunderbrink.n-triples create mode 100644 data/dm2 20200301_export.csv create mode 100644 data/dm2 20200301_kwoodley.annodb create mode 100644 data/dm2 20200301_kwoodley.n-triples create mode 100644 data/dm2 20415692_admin.annodb create mode 100644 data/dm2 20415692_admin.n-triples create mode 100644 data/dm2 20415692_akramersunderbrink.annodb create mode 100644 data/dm2 20415692_akramersunderbrink.n-triples create mode 100644 data/dm2 20415692_export.csv create mode 100644 data/dm2 20415692_kwoodley.annodb create mode 100644 data/dm2 20415692_kwoodley.n-triples create mode 100644 data/dm2 20880343_admin.annodb create mode 100644 data/dm2 20880343_admin.n-triples create mode 100644 data/dm2 20880343_akramersunderbrink.annodb create mode 100644 data/dm2 20880343_akramersunderbrink.n-triples create mode 100644 data/dm2 20880343_export.csv create mode 100644 data/dm2 20880343_kwoodley.annodb create mode 100644 data/dm2 20880343_kwoodley.n-triples create mode 100644 data/dm2 20920045_admin.annodb create mode 100644 data/dm2 20920045_admin.n-triples create mode 100644 data/dm2 20920045_akramersunderbrink.annodb create mode 100644 data/dm2 20920045_akramersunderbrink.n-triples create mode 100644 data/dm2 20920045_export.csv create mode 100644 data/dm2 20920045_kwoodley.annodb create mode 100644 data/dm2 20920045_kwoodley.n-triples create mode 100644 data/dm2 21114605_admin.annodb create mode 100644 data/dm2 21114605_admin.n-triples create mode 100644 data/dm2 21114605_akramersunderbrink.annodb create mode 100644 data/dm2 21114605_akramersunderbrink.n-triples create mode 100644 data/dm2 21114605_export.csv create mode 100644 data/dm2 21114605_kwoodley.annodb create mode 100644 data/dm2 21114605_kwoodley.n-triples create mode 100644 data/dm2 21138825_admin.annodb create mode 100644 data/dm2 21138825_admin.n-triples create mode 100644 data/dm2 21138825_akramersunderbrink.annodb create mode 100644 data/dm2 21138825_akramersunderbrink.n-triples create mode 100644 data/dm2 21138825_export.csv create mode 100644 data/dm2 21138825_kwoodley.annodb create mode 100644 data/dm2 21138825_kwoodley.n-triples create mode 100644 data/dm2 21781152_admin.annodb create mode 100644 data/dm2 21781152_admin.n-triples create mode 100644 data/dm2 21781152_akramersunderbrink.annodb create mode 100644 data/dm2 21781152_akramersunderbrink.n-triples create mode 100644 data/dm2 21781152_export.csv create mode 100644 data/dm2 21781152_kwoodley.annodb create mode 100644 data/dm2 21781152_kwoodley.n-triples create mode 100644 data/dm2 21802161_admin.annodb create mode 100644 data/dm2 21802161_admin.n-triples create mode 100644 data/dm2 21802161_akramersunderbrink.annodb create mode 100644 data/dm2 21802161_akramersunderbrink.n-triples create mode 100644 data/dm2 21802161_export.csv create mode 100644 data/dm2 21802161_kwoodley.annodb create mode 100644 data/dm2 21802161_kwoodley.n-triples create mode 100644 data/dm2 21819517_admin.annodb create mode 100644 data/dm2 21819517_admin.n-triples create mode 100644 data/dm2 21819517_akramersunderbrink.annodb create mode 100644 data/dm2 21819517_akramersunderbrink.n-triples create mode 100644 data/dm2 21819517_export.csv create mode 100644 data/dm2 21819517_kwoodley.annodb create mode 100644 data/dm2 21819517_kwoodley.n-triples create mode 100644 data/dm2 22134839_admin.annodb create mode 100644 data/dm2 22134839_admin.n-triples create mode 100644 data/dm2 22134839_akramersunderbrink.annodb create mode 100644 data/dm2 22134839_akramersunderbrink.n-triples create mode 100644 data/dm2 22134839_export.csv create mode 100644 data/dm2 22134839_kwoodley.annodb create mode 100644 data/dm2 22134839_kwoodley.n-triples create mode 100644 data/dm2 22313154_admin.annodb create mode 100644 data/dm2 22313154_admin.n-triples create mode 100644 data/dm2 22313154_akramersunderbrink.annodb create mode 100644 data/dm2 22313154_akramersunderbrink.n-triples create mode 100644 data/dm2 22313154_export.csv create mode 100644 data/dm2 22313154_kwoodley.annodb create mode 100644 data/dm2 22313154_kwoodley.n-triples create mode 100644 data/dm2 22672081_admin.annodb create mode 100644 data/dm2 22672081_admin.n-triples create mode 100644 data/dm2 22672081_akramersunderbrink.annodb create mode 100644 data/dm2 22672081_akramersunderbrink.n-triples create mode 100644 data/dm2 22672081_export.csv create mode 100644 data/dm2 22672081_kwoodley.annodb create mode 100644 data/dm2 22672081_kwoodley.n-triples create mode 100644 data/dm2 22672586_admin.annodb create mode 100644 data/dm2 22672586_admin.n-triples create mode 100644 data/dm2 22672586_akramersunderbrink.annodb create mode 100644 data/dm2 22672586_akramersunderbrink.n-triples create mode 100644 data/dm2 22672586_export.csv create mode 100644 data/dm2 22672586_kwoodley.annodb create mode 100644 data/dm2 22672586_kwoodley.n-triples create mode 100644 data/dm2 22742523_admin.annodb create mode 100644 data/dm2 22742523_admin.n-triples create mode 100644 data/dm2 22742523_akramersunderbrink.annodb create mode 100644 data/dm2 22742523_akramersunderbrink.n-triples create mode 100644 data/dm2 22742523_export.csv create mode 100644 data/dm2 22742523_kwoodley.annodb create mode 100644 data/dm2 22742523_kwoodley.n-triples create mode 100644 data/dm2 23039321_admin.annodb create mode 100644 data/dm2 23039321_admin.n-triples create mode 100644 data/dm2 23039321_akramersunderbrink.annodb create mode 100644 data/dm2 23039321_akramersunderbrink.n-triples create mode 100644 data/dm2 23039321_export.csv create mode 100644 data/dm2 23039321_kwoodley.annodb create mode 100644 data/dm2 23039321_kwoodley.n-triples create mode 100644 data/dm2 23082447_admin.annodb create mode 100644 data/dm2 23082447_admin.n-triples create mode 100644 data/dm2 23082447_akramersunderbrink.annodb create mode 100644 data/dm2 23082447_akramersunderbrink.n-triples create mode 100644 data/dm2 23082447_export.csv create mode 100644 data/dm2 23082447_kwoodley.annodb create mode 100644 data/dm2 23082447_kwoodley.n-triples create mode 100644 data/dm2 23116881_admin.annodb create mode 100644 data/dm2 23116881_admin.n-triples create mode 100644 data/dm2 23116881_akramersunderbrink.annodb create mode 100644 data/dm2 23116881_akramersunderbrink.n-triples create mode 100644 data/dm2 23116881_export.csv create mode 100644 data/dm2 23116881_kwoodley.annodb create mode 100644 data/dm2 23116881_kwoodley.n-triples create mode 100644 data/dm2 23160726_admin.annodb create mode 100644 data/dm2 23160726_admin.n-triples create mode 100644 data/dm2 23160726_akramersunderbrink.annodb create mode 100644 data/dm2 23160726_akramersunderbrink.n-triples create mode 100644 data/dm2 23160726_export.csv create mode 100644 data/dm2 23160726_kwoodley.annodb create mode 100644 data/dm2 23160726_kwoodley.n-triples create mode 100644 data/dm2 23230096_admin.annodb create mode 100644 data/dm2 23230096_admin.n-triples create mode 100644 data/dm2 23230096_akramersunderbrink.annodb create mode 100644 data/dm2 23230096_akramersunderbrink.n-triples create mode 100644 data/dm2 23230096_export.csv create mode 100644 data/dm2 23230096_kwoodley.annodb create mode 100644 data/dm2 23230096_kwoodley.n-triples create mode 100644 data/dm2 23250357_admin.annodb create mode 100644 data/dm2 23250357_admin.n-triples create mode 100644 data/dm2 23250357_akramersunderbrink.annodb create mode 100644 data/dm2 23250357_akramersunderbrink.n-triples create mode 100644 data/dm2 23250357_export.csv create mode 100644 data/dm2 23250357_kwoodley.annodb create mode 100644 data/dm2 23250357_kwoodley.n-triples create mode 100644 data/dm2 23404788_admin.annodb create mode 100644 data/dm2 23404788_admin.n-triples create mode 100644 data/dm2 23404788_akramersunderbrink.annodb create mode 100644 data/dm2 23404788_akramersunderbrink.n-triples create mode 100644 data/dm2 23404788_export.csv create mode 100644 data/dm2 23404788_kwoodley.annodb create mode 100644 data/dm2 23404788_kwoodley.n-triples create mode 100644 data/dm2 23627775_admin.annodb create mode 100644 data/dm2 23627775_admin.n-triples create mode 100644 data/dm2 23627775_akramersunderbrink.annodb create mode 100644 data/dm2 23627775_akramersunderbrink.n-triples create mode 100644 data/dm2 23627775_export.csv create mode 100644 data/dm2 23627775_kwoodley.annodb create mode 100644 data/dm2 23627775_kwoodley.n-triples create mode 100644 data/dm2 23628617_admin.annodb create mode 100644 data/dm2 23628617_admin.n-triples create mode 100644 data/dm2 23628617_akramersunderbrink.annodb create mode 100644 data/dm2 23628617_akramersunderbrink.n-triples create mode 100644 data/dm2 23628617_export.csv create mode 100644 data/dm2 23628617_kwoodley.annodb create mode 100644 data/dm2 23628617_kwoodley.n-triples create mode 100644 data/dm2 23706759_admin.annodb create mode 100644 data/dm2 23706759_admin.n-triples create mode 100644 data/dm2 23706759_akramersunderbrink.annodb create mode 100644 data/dm2 23706759_akramersunderbrink.n-triples create mode 100644 data/dm2 23706759_export.csv create mode 100644 data/dm2 23706759_kwoodley.annodb create mode 100644 data/dm2 23706759_kwoodley.n-triples create mode 100644 data/dm2 23906445_admin.annodb create mode 100644 data/dm2 23906445_admin.n-triples create mode 100644 data/dm2 23906445_akramersunderbrink.annodb create mode 100644 data/dm2 23906445_akramersunderbrink.n-triples create mode 100644 data/dm2 23906445_export.csv create mode 100644 data/dm2 23906445_kwoodley.annodb create mode 100644 data/dm2 23906445_kwoodley.n-triples create mode 100644 data/dm2 23948125_admin.annodb create mode 100644 data/dm2 23948125_admin.n-triples create mode 100644 data/dm2 23948125_akramersunderbrink.annodb create mode 100644 data/dm2 23948125_akramersunderbrink.n-triples create mode 100644 data/dm2 23948125_export.csv create mode 100644 data/dm2 23948125_kwoodley.annodb create mode 100644 data/dm2 23948125_kwoodley.n-triples create mode 100644 data/dm2 23949898_admin.annodb create mode 100644 data/dm2 23949898_admin.n-triples create mode 100644 data/dm2 23949898_akramersunderbrink.annodb create mode 100644 data/dm2 23949898_akramersunderbrink.n-triples create mode 100644 data/dm2 23949898_export.csv create mode 100644 data/dm2 23949898_kwoodley.annodb create mode 100644 data/dm2 23949898_kwoodley.n-triples create mode 100644 data/dm2 24062327_admin.annodb create mode 100644 data/dm2 24062327_admin.n-triples create mode 100644 data/dm2 24062327_akramersunderbrink.annodb create mode 100644 data/dm2 24062327_akramersunderbrink.n-triples create mode 100644 data/dm2 24062327_export.csv create mode 100644 data/dm2 24062327_kwoodley.annodb create mode 100644 data/dm2 24062327_kwoodley.n-triples create mode 100644 data/dm2 24144654_admin.annodb create mode 100644 data/dm2 24144654_admin.n-triples create mode 100644 data/dm2 24144654_akramersunderbrink.annodb create mode 100644 data/dm2 24144654_akramersunderbrink.n-triples create mode 100644 data/dm2 24144654_export.csv create mode 100644 data/dm2 24144654_kwoodley.annodb create mode 100644 data/dm2 24144654_kwoodley.n-triples create mode 100644 data/dm2 24199686_admin.annodb create mode 100644 data/dm2 24199686_admin.n-triples create mode 100644 data/dm2 24199686_akramersunderbrink.annodb create mode 100644 data/dm2 24199686_akramersunderbrink.n-triples create mode 100644 data/dm2 24199686_export.csv create mode 100644 data/dm2 24199686_kwoodley.annodb create mode 100644 data/dm2 24199686_kwoodley.n-triples create mode 100644 data/dm2 24205943_admin.annodb create mode 100644 data/dm2 24205943_admin.n-triples create mode 100644 data/dm2 24205943_akramersunderbrink.annodb create mode 100644 data/dm2 24205943_akramersunderbrink.n-triples create mode 100644 data/dm2 24205943_export.csv create mode 100644 data/dm2 24205943_kwoodley.annodb create mode 100644 data/dm2 24205943_kwoodley.n-triples create mode 100644 data/dm2 24237386_admin.annodb create mode 100644 data/dm2 24237386_admin.n-triples create mode 100644 data/dm2 24237386_akramersunderbrink.annodb create mode 100644 data/dm2 24237386_akramersunderbrink.n-triples create mode 100644 data/dm2 24237386_export.csv create mode 100644 data/dm2 24237386_kwoodley.annodb create mode 100644 data/dm2 24237386_kwoodley.n-triples create mode 100644 data/dm2 24356792_admin.annodb create mode 100644 data/dm2 24356792_admin.n-triples create mode 100644 data/dm2 24356792_akramersunderbrink.annodb create mode 100644 data/dm2 24356792_akramersunderbrink.n-triples create mode 100644 data/dm2 24356792_export.csv create mode 100644 data/dm2 24356792_kwoodley.annodb create mode 100644 data/dm2 24356792_kwoodley.n-triples create mode 100644 data/dm2 24639432_admin.annodb create mode 100644 data/dm2 24639432_admin.n-triples create mode 100644 data/dm2 24639432_akramersunderbrink.annodb create mode 100644 data/dm2 24639432_akramersunderbrink.n-triples create mode 100644 data/dm2 24639432_export.csv create mode 100644 data/dm2 24639432_kwoodley.annodb create mode 100644 data/dm2 24639432_kwoodley.n-triples create mode 100644 data/dm2 24650952_admin.annodb create mode 100644 data/dm2 24650952_admin.n-triples create mode 100644 data/dm2 24650952_akramersunderbrink.annodb create mode 100644 data/dm2 24650952_akramersunderbrink.n-triples create mode 100644 data/dm2 24650952_export.csv create mode 100644 data/dm2 24650952_kwoodley.annodb create mode 100644 data/dm2 24650952_kwoodley.n-triples create mode 100644 data/dm2 24824197_admin.annodb create mode 100644 data/dm2 24824197_admin.n-triples create mode 100644 data/dm2 24824197_akramersunderbrink.annodb create mode 100644 data/dm2 24824197_akramersunderbrink.n-triples create mode 100644 data/dm2 24824197_export.csv create mode 100644 data/dm2 24824197_kwoodley.annodb create mode 100644 data/dm2 24824197_kwoodley.n-triples create mode 100644 data/dm2 24939043_admin.annodb create mode 100644 data/dm2 24939043_admin.n-triples create mode 100644 data/dm2 24939043_akramersunderbrink.annodb create mode 100644 data/dm2 24939043_akramersunderbrink.n-triples create mode 100644 data/dm2 24939043_export.csv create mode 100644 data/dm2 24939043_kwoodley.annodb create mode 100644 data/dm2 24939043_kwoodley.n-triples create mode 100644 data/dm2 25036533_admin.annodb create mode 100644 data/dm2 25036533_admin.n-triples create mode 100644 data/dm2 25036533_akramersunderbrink.annodb create mode 100644 data/dm2 25036533_akramersunderbrink.n-triples create mode 100644 data/dm2 25036533_export.csv create mode 100644 data/dm2 25036533_kwoodley.annodb create mode 100644 data/dm2 25036533_kwoodley.n-triples create mode 100644 data/dm2 25054436_admin.annodb create mode 100644 data/dm2 25054436_admin.n-triples create mode 100644 data/dm2 25054436_akramersunderbrink.annodb create mode 100644 data/dm2 25054436_akramersunderbrink.n-triples create mode 100644 data/dm2 25054436_export.csv create mode 100644 data/dm2 25054436_kwoodley.annodb create mode 100644 data/dm2 25054436_kwoodley.n-triples create mode 100644 data/dm2 25125506_admin.annodb create mode 100644 data/dm2 25125506_admin.n-triples create mode 100644 data/dm2 25125506_akramersunderbrink.annodb create mode 100644 data/dm2 25125506_akramersunderbrink.n-triples create mode 100644 data/dm2 25125506_export.csv create mode 100644 data/dm2 25125506_kwoodley.annodb create mode 100644 data/dm2 25125506_kwoodley.n-triples create mode 100644 data/dm2 25138574_admin.annodb create mode 100644 data/dm2 25138574_admin.n-triples create mode 100644 data/dm2 25138574_akramersunderbrink.annodb create mode 100644 data/dm2 25138574_akramersunderbrink.n-triples create mode 100644 data/dm2 25138574_export.csv create mode 100644 data/dm2 25138574_kwoodley.annodb create mode 100644 data/dm2 25138574_kwoodley.n-triples create mode 100644 data/dm2 25208756_admin.annodb create mode 100644 data/dm2 25208756_admin.n-triples create mode 100644 data/dm2 25208756_akramersunderbrink.annodb create mode 100644 data/dm2 25208756_akramersunderbrink.n-triples create mode 100644 data/dm2 25208756_export.csv create mode 100644 data/dm2 25208756_kwoodley.annodb create mode 100644 data/dm2 25208756_kwoodley.n-triples create mode 100644 data/dm2 25753488_admin.annodb create mode 100644 data/dm2 25753488_admin.n-triples create mode 100644 data/dm2 25753488_akramersunderbrink.annodb create mode 100644 data/dm2 25753488_akramersunderbrink.n-triples create mode 100644 data/dm2 25753488_export.csv create mode 100644 data/dm2 25753488_kwoodley.annodb create mode 100644 data/dm2 25753488_kwoodley.n-triples create mode 100644 data/dm2 26067186_admin.annodb create mode 100644 data/dm2 26067186_admin.n-triples create mode 100644 data/dm2 26067186_akramersunderbrink.annodb create mode 100644 data/dm2 26067186_akramersunderbrink.n-triples create mode 100644 data/dm2 26067186_export.csv create mode 100644 data/dm2 26067186_kwoodley.annodb create mode 100644 data/dm2 26067186_kwoodley.n-triples create mode 100644 data/dm2 26598090_admin.annodb create mode 100644 data/dm2 26598090_admin.n-triples create mode 100644 data/dm2 26598090_akramersunderbrink.annodb create mode 100644 data/dm2 26598090_akramersunderbrink.n-triples create mode 100644 data/dm2 26598090_export.csv create mode 100644 data/dm2 26598090_kwoodley.annodb create mode 100644 data/dm2 26598090_kwoodley.n-triples create mode 100644 data/dm2 26950829_admin.annodb create mode 100644 data/dm2 26950829_admin.n-triples create mode 100644 data/dm2 26950829_akramersunderbrink.annodb create mode 100644 data/dm2 26950829_akramersunderbrink.n-triples create mode 100644 data/dm2 26950829_export.csv create mode 100644 data/dm2 26950829_kwoodley.annodb create mode 100644 data/dm2 26950829_kwoodley.n-triples create mode 100644 data/dm2 27321385_admin.annodb create mode 100644 data/dm2 27321385_admin.n-triples create mode 100644 data/dm2 27321385_akramersunderbrink.annodb create mode 100644 data/dm2 27321385_akramersunderbrink.n-triples create mode 100644 data/dm2 27321385_export.csv create mode 100644 data/dm2 27321385_kwoodley.annodb create mode 100644 data/dm2 27321385_kwoodley.n-triples create mode 100644 data/dm2 27589252_admin.annodb create mode 100644 data/dm2 27589252_admin.n-triples create mode 100644 data/dm2 27589252_akramersunderbrink.annodb create mode 100644 data/dm2 27589252_akramersunderbrink.n-triples create mode 100644 data/dm2 27589252_export.csv create mode 100644 data/dm2 27589252_kwoodley.annodb create mode 100644 data/dm2 27589252_kwoodley.n-triples create mode 100644 data/dm2 27650977_admin.annodb create mode 100644 data/dm2 27650977_admin.n-triples create mode 100644 data/dm2 27650977_akramersunderbrink.annodb create mode 100644 data/dm2 27650977_akramersunderbrink.n-triples create mode 100644 data/dm2 27650977_export.csv create mode 100644 data/dm2 27650977_kwoodley.annodb create mode 100644 data/dm2 27650977_kwoodley.n-triples create mode 100644 data/dm2 27711199_admin.annodb create mode 100644 data/dm2 27711199_admin.n-triples create mode 100644 data/dm2 27711199_akramersunderbrink.annodb create mode 100644 data/dm2 27711199_akramersunderbrink.n-triples create mode 100644 data/dm2 27711199_export.csv create mode 100644 data/dm2 27711199_kwoodley.annodb create mode 100644 data/dm2 27711199_kwoodley.n-triples create mode 100644 data/dm2 27740719_admin.annodb create mode 100644 data/dm2 27740719_admin.n-triples create mode 100644 data/dm2 27740719_akramersunderbrink.annodb create mode 100644 data/dm2 27740719_akramersunderbrink.n-triples create mode 100644 data/dm2 27740719_export.csv create mode 100644 data/dm2 27740719_kwoodley.annodb create mode 100644 data/dm2 27740719_kwoodley.n-triples create mode 100644 data/dm2 28026912_admin.annodb create mode 100644 data/dm2 28026912_admin.n-triples create mode 100644 data/dm2 28026912_akramersunderbrink.annodb create mode 100644 data/dm2 28026912_akramersunderbrink.n-triples create mode 100644 data/dm2 28026912_export.csv create mode 100644 data/dm2 28026912_kwoodley.annodb create mode 100644 data/dm2 28026912_kwoodley.n-triples create mode 100644 data/dm2 28035868_admin.annodb create mode 100644 data/dm2 28035868_admin.n-triples create mode 100644 data/dm2 28035868_akramersunderbrink.annodb create mode 100644 data/dm2 28035868_akramersunderbrink.n-triples create mode 100644 data/dm2 28035868_export.csv create mode 100644 data/dm2 28035868_kwoodley.annodb create mode 100644 data/dm2 28035868_kwoodley.n-triples create mode 100644 data/dm2 28093853_admin.annodb create mode 100644 data/dm2 28093853_admin.n-triples create mode 100644 data/dm2 28093853_akramersunderbrink.annodb create mode 100644 data/dm2 28093853_akramersunderbrink.n-triples create mode 100644 data/dm2 28093853_export.csv create mode 100644 data/dm2 28093853_kwoodley.annodb create mode 100644 data/dm2 28093853_kwoodley.n-triples create mode 100644 data/dm2 28345162_admin.annodb create mode 100644 data/dm2 28345162_admin.n-triples create mode 100644 data/dm2 28345162_akramersunderbrink.annodb create mode 100644 data/dm2 28345162_akramersunderbrink.n-triples create mode 100644 data/dm2 28345162_export.csv create mode 100644 data/dm2 28345162_kwoodley.annodb create mode 100644 data/dm2 28345162_kwoodley.n-triples create mode 100644 data/dm2 28345792_admin.annodb create mode 100644 data/dm2 28345792_admin.n-triples create mode 100644 data/dm2 28345792_akramersunderbrink.annodb create mode 100644 data/dm2 28345792_akramersunderbrink.n-triples create mode 100644 data/dm2 28345792_export.csv create mode 100644 data/dm2 28345792_kwoodley.annodb create mode 100644 data/dm2 28345792_kwoodley.n-triples create mode 100644 data/dm2 28449402_admin.annodb create mode 100644 data/dm2 28449402_admin.n-triples create mode 100644 data/dm2 28449402_akramersunderbrink.annodb create mode 100644 data/dm2 28449402_akramersunderbrink.n-triples create mode 100644 data/dm2 28449402_export.csv create mode 100644 data/dm2 28449402_kwoodley.annodb create mode 100644 data/dm2 28449402_kwoodley.n-triples create mode 100644 data/dm2 28483786_admin.annodb create mode 100644 data/dm2 28483786_admin.n-triples create mode 100644 data/dm2 28483786_akramersunderbrink.annodb create mode 100644 data/dm2 28483786_akramersunderbrink.n-triples create mode 100644 data/dm2 28483786_export.csv create mode 100644 data/dm2 28483786_kwoodley.annodb create mode 100644 data/dm2 28483786_kwoodley.n-triples create mode 100644 data/dm2 28547998_admin.annodb create mode 100644 data/dm2 28547998_admin.n-triples create mode 100644 data/dm2 28547998_akramersunderbrink.annodb create mode 100644 data/dm2 28547998_akramersunderbrink.n-triples create mode 100644 data/dm2 28547998_export.csv create mode 100644 data/dm2 28547998_kwoodley.annodb create mode 100644 data/dm2 28547998_kwoodley.n-triples create mode 100644 data/dm2 28548024_admin.annodb create mode 100644 data/dm2 28548024_admin.n-triples create mode 100644 data/dm2 28548024_akramersunderbrink.annodb create mode 100644 data/dm2 28548024_akramersunderbrink.n-triples create mode 100644 data/dm2 28548024_export.csv create mode 100644 data/dm2 28548024_kwoodley.annodb create mode 100644 data/dm2 28548024_kwoodley.n-triples create mode 100644 data/dm2 28742225_admin.annodb create mode 100644 data/dm2 28742225_admin.n-triples create mode 100644 data/dm2 28742225_akramersunderbrink.annodb create mode 100644 data/dm2 28742225_akramersunderbrink.n-triples create mode 100644 data/dm2 28742225_export.csv create mode 100644 data/dm2 28742225_kwoodley.annodb create mode 100644 data/dm2 28742225_kwoodley.n-triples create mode 100644 data/dm2 28923291_admin.annodb create mode 100644 data/dm2 28923291_admin.n-triples create mode 100644 data/dm2 28923291_akramersunderbrink.annodb create mode 100644 data/dm2 28923291_akramersunderbrink.n-triples create mode 100644 data/dm2 28923291_export.csv create mode 100644 data/dm2 28923291_kwoodley.annodb create mode 100644 data/dm2 28923291_kwoodley.n-triples create mode 100644 data/dm2 29017497_admin.annodb create mode 100644 data/dm2 29017497_admin.n-triples create mode 100644 data/dm2 29017497_akramersunderbrink.annodb create mode 100644 data/dm2 29017497_akramersunderbrink.n-triples create mode 100644 data/dm2 29017497_export.csv create mode 100644 data/dm2 29017497_kwoodley.annodb create mode 100644 data/dm2 29017497_kwoodley.n-triples create mode 100644 data/dm2 29110647_admin.annodb create mode 100644 data/dm2 29110647_admin.n-triples create mode 100644 data/dm2 29110647_akramersunderbrink.annodb create mode 100644 data/dm2 29110647_akramersunderbrink.n-triples create mode 100644 data/dm2 29110647_export.csv create mode 100644 data/dm2 29110647_kwoodley.annodb create mode 100644 data/dm2 29110647_kwoodley.n-triples create mode 100644 data/dm2 29144061_admin.annodb create mode 100644 data/dm2 29144061_admin.n-triples create mode 100644 data/dm2 29144061_akramersunderbrink.annodb create mode 100644 data/dm2 29144061_akramersunderbrink.n-triples create mode 100644 data/dm2 29144061_export.csv create mode 100644 data/dm2 29144061_kwoodley.annodb create mode 100644 data/dm2 29144061_kwoodley.n-triples create mode 100644 data/dm2 29246950_admin.annodb create mode 100644 data/dm2 29246950_admin.n-triples create mode 100644 data/dm2 29246950_akramersunderbrink.annodb create mode 100644 data/dm2 29246950_akramersunderbrink.n-triples create mode 100644 data/dm2 29246950_export.csv create mode 100644 data/dm2 29246950_kwoodley.annodb create mode 100644 data/dm2 29246950_kwoodley.n-triples create mode 100644 data/dm2 29362626_admin.annodb create mode 100644 data/dm2 29362626_admin.n-triples create mode 100644 data/dm2 29362626_akramersunderbrink.annodb create mode 100644 data/dm2 29362626_akramersunderbrink.n-triples create mode 100644 data/dm2 29362626_export.csv create mode 100644 data/dm2 29362626_kwoodley.annodb create mode 100644 data/dm2 29362626_kwoodley.n-triples create mode 100644 data/dm2 29862619_admin.annodb create mode 100644 data/dm2 29862619_admin.n-triples create mode 100644 data/dm2 29862619_akramersunderbrink.annodb create mode 100644 data/dm2 29862619_akramersunderbrink.n-triples create mode 100644 data/dm2 29862619_export.csv create mode 100644 data/dm2 29862619_kwoodley.annodb create mode 100644 data/dm2 29862619_kwoodley.n-triples create mode 100644 data/dm2 30019498_admin.annodb create mode 100644 data/dm2 30019498_admin.n-triples create mode 100644 data/dm2 30019498_akramersunderbrink.annodb create mode 100644 data/dm2 30019498_akramersunderbrink.n-triples create mode 100644 data/dm2 30019498_export.csv create mode 100644 data/dm2 30019498_kwoodley.annodb create mode 100644 data/dm2 30019498_kwoodley.n-triples create mode 100644 data/gl 10080213_admin.annodb create mode 100644 data/gl 10080213_admin.n-triples create mode 100644 data/gl 10080213_export.csv create mode 100644 data/gl 10080213_jshahinitiran.annodb create mode 100644 data/gl 10080213_jshahinitiran.n-triples create mode 100644 data/gl 10080213_tstrakeljahn.annodb create mode 100644 data/gl 10080213_tstrakeljahn.n-triples create mode 100644 data/gl 10664047_admin.annodb create mode 100644 data/gl 10664047_admin.n-triples create mode 100644 data/gl 10664047_export.csv create mode 100644 data/gl 10664047_jshahinitiran.annodb create mode 100644 data/gl 10664047_jshahinitiran.n-triples create mode 100644 data/gl 10664047_tstrakeljahn.annodb create mode 100644 data/gl 10664047_tstrakeljahn.n-triples create mode 100644 data/gl 10837379_admin.annodb create mode 100644 data/gl 10837379_admin.n-triples create mode 100644 data/gl 10837379_export.csv create mode 100644 data/gl 10837379_jshahinitiran.annodb create mode 100644 data/gl 10837379_jshahinitiran.n-triples create mode 100644 data/gl 10837379_tstrakeljahn.annodb create mode 100644 data/gl 10837379_tstrakeljahn.n-triples create mode 100644 data/gl 10877373_admin.annodb create mode 100644 data/gl 10877373_admin.n-triples create mode 100644 data/gl 10877373_export.csv create mode 100644 data/gl 10877373_jshahinitiran.annodb create mode 100644 data/gl 10877373_jshahinitiran.n-triples create mode 100644 data/gl 10877373_tstrakeljahn.annodb create mode 100644 data/gl 10877373_tstrakeljahn.n-triples create mode 100644 data/gl 10901475_admin.annodb create mode 100644 data/gl 10901475_admin.n-triples create mode 100644 data/gl 10901475_export.csv create mode 100644 data/gl 10901475_jshahinitiran.annodb create mode 100644 data/gl 10901475_jshahinitiran.n-triples create mode 100644 data/gl 10901475_tstrakeljahn.annodb create mode 100644 data/gl 10901475_tstrakeljahn.n-triples create mode 100644 data/gl 11039742_admin.annodb create mode 100644 data/gl 11039742_admin.n-triples create mode 100644 data/gl 11039742_export.csv create mode 100644 data/gl 11039742_jshahinitiran.annodb create mode 100644 data/gl 11039742_jshahinitiran.n-triples create mode 100644 data/gl 11039742_tstrakeljahn.annodb create mode 100644 data/gl 11039742_tstrakeljahn.n-triples create mode 100644 data/gl 11158796_admin.annodb create mode 100644 data/gl 11158796_admin.n-triples create mode 100644 data/gl 11158796_export.csv create mode 100644 data/gl 11158796_jshahinitiran.annodb create mode 100644 data/gl 11158796_jshahinitiran.n-triples create mode 100644 data/gl 11158796_tstrakeljahn.annodb create mode 100644 data/gl 11158796_tstrakeljahn.n-triples create mode 100644 data/gl 11167277_admin.annodb create mode 100644 data/gl 11167277_admin.n-triples create mode 100644 data/gl 11167277_export.csv create mode 100644 data/gl 11167277_jshahinitiran.annodb create mode 100644 data/gl 11167277_jshahinitiran.n-triples create mode 100644 data/gl 11167277_tstrakeljahn.annodb create mode 100644 data/gl 11167277_tstrakeljahn.n-triples create mode 100644 data/gl 11336940_admin.annodb create mode 100644 data/gl 11336940_admin.n-triples create mode 100644 data/gl 11336940_export.csv create mode 100644 data/gl 11336940_jshahinitiran.annodb create mode 100644 data/gl 11336940_jshahinitiran.n-triples create mode 100644 data/gl 11336940_tstrakeljahn.annodb create mode 100644 data/gl 11336940_tstrakeljahn.n-triples create mode 100644 data/gl 11558817_admin.annodb create mode 100644 data/gl 11558817_admin.n-triples create mode 100644 data/gl 11558817_export.csv create mode 100644 data/gl 11558817_jshahinitiran.annodb create mode 100644 data/gl 11558817_jshahinitiran.n-triples create mode 100644 data/gl 11558817_tstrakeljahn.annodb create mode 100644 data/gl 11558817_tstrakeljahn.n-triples create mode 100644 data/gl 11813932 copy_admin.annodb create mode 100644 data/gl 11813932 copy_admin.n-triples create mode 100644 data/gl 11813932 copy_export.csv create mode 100644 data/gl 11813932_admin.annodb create mode 100644 data/gl 11813932_admin.n-triples create mode 100644 data/gl 11813932_export.csv create mode 100644 data/gl 11813932_jshahinitiran.annodb create mode 100644 data/gl 11813932_jshahinitiran.n-triples create mode 100644 data/gl 11813932_tstrakeljahn.annodb create mode 100644 data/gl 11813932_tstrakeljahn.n-triples create mode 100644 data/gl 11825814_admin.annodb create mode 100644 data/gl 11825814_admin.n-triples create mode 100644 data/gl 11825814_export.csv create mode 100644 data/gl 11825814_jshahinitiran.annodb create mode 100644 data/gl 11825814_jshahinitiran.n-triples create mode 100644 data/gl 11825814_tstrakeljahn.annodb create mode 100644 data/gl 11825814_tstrakeljahn.n-triples create mode 100644 data/gl 11912355_admin.annodb create mode 100644 data/gl 11912355_admin.n-triples create mode 100644 data/gl 11912355_export.csv create mode 100644 data/gl 11912355_jshahinitiran.annodb create mode 100644 data/gl 11912355_jshahinitiran.n-triples create mode 100644 data/gl 11912355_tstrakeljahn.annodb create mode 100644 data/gl 11912355_tstrakeljahn.n-triples create mode 100644 data/gl 11952485_admin.annodb create mode 100644 data/gl 11952485_admin.n-triples create mode 100644 data/gl 11952485_export.csv create mode 100644 data/gl 11952485_jshahinitiran.annodb create mode 100644 data/gl 11952485_jshahinitiran.n-triples create mode 100644 data/gl 11952485_tstrakeljahn.annodb create mode 100644 data/gl 11952485_tstrakeljahn.n-triples create mode 100644 data/gl 12383812_admin.annodb create mode 100644 data/gl 12383812_admin.n-triples create mode 100644 data/gl 12383812_export.csv create mode 100644 data/gl 12383812_jshahinitiran.annodb create mode 100644 data/gl 12383812_jshahinitiran.n-triples create mode 100644 data/gl 12383812_tstrakeljahn.annodb create mode 100644 data/gl 12383812_tstrakeljahn.n-triples create mode 100644 data/gl 12466165_admin.annodb create mode 100644 data/gl 12466165_admin.n-triples create mode 100644 data/gl 12466165_export.csv create mode 100644 data/gl 12466165_jshahinitiran.annodb create mode 100644 data/gl 12466165_jshahinitiran.n-triples create mode 100644 data/gl 12466165_tstrakeljahn.annodb create mode 100644 data/gl 12466165_tstrakeljahn.n-triples create mode 100644 data/gl 12470755 copy_admin.annodb create mode 100644 data/gl 12470755 copy_admin.n-triples create mode 100644 data/gl 12470755 copy_export.csv create mode 100644 data/gl 12470755_admin.annodb create mode 100644 data/gl 12470755_admin.n-triples create mode 100644 data/gl 12470755_export.csv create mode 100644 data/gl 12470755_jshahinitiran.annodb create mode 100644 data/gl 12470755_jshahinitiran.n-triples create mode 100644 data/gl 12470755_tstrakeljahn.annodb create mode 100644 data/gl 12470755_tstrakeljahn.n-triples create mode 100644 data/gl 12483094_admin.annodb create mode 100644 data/gl 12483094_admin.n-triples create mode 100644 data/gl 12483094_export.csv create mode 100644 data/gl 12483094_jshahinitiran.annodb create mode 100644 data/gl 12483094_jshahinitiran.n-triples create mode 100644 data/gl 12483094_tstrakeljahn.annodb create mode 100644 data/gl 12483094_tstrakeljahn.n-triples create mode 100644 data/gl 12485286_admin.annodb create mode 100644 data/gl 12485286_admin.n-triples create mode 100644 data/gl 12485286_export.csv create mode 100644 data/gl 12485286_jshahinitiran.annodb create mode 100644 data/gl 12485286_jshahinitiran.n-triples create mode 100644 data/gl 12485286_tstrakeljahn.annodb create mode 100644 data/gl 12485286_tstrakeljahn.n-triples create mode 100644 data/gl 12486510_admin.annodb create mode 100644 data/gl 12486510_admin.n-triples create mode 100644 data/gl 12486510_export.csv create mode 100644 data/gl 12486510_jshahinitiran.annodb create mode 100644 data/gl 12486510_jshahinitiran.n-triples create mode 100644 data/gl 12486510_tstrakeljahn.annodb create mode 100644 data/gl 12486510_tstrakeljahn.n-triples create mode 100644 data/gl 12586182_admin.annodb create mode 100644 data/gl 12586182_admin.n-triples create mode 100644 data/gl 12586182_export.csv create mode 100644 data/gl 12586182_jshahinitiran.annodb create mode 100644 data/gl 12586182_jshahinitiran.n-triples create mode 100644 data/gl 12586182_tstrakeljahn.annodb create mode 100644 data/gl 12586182_tstrakeljahn.n-triples create mode 100644 data/gl 12660585_admin.annodb create mode 100644 data/gl 12660585_admin.n-triples create mode 100644 data/gl 12660585_export.csv create mode 100644 data/gl 12660585_jshahinitiran.annodb create mode 100644 data/gl 12660585_jshahinitiran.n-triples create mode 100644 data/gl 12660585_tstrakeljahn.annodb create mode 100644 data/gl 12660585_tstrakeljahn.n-triples create mode 100644 data/gl 12780402_admin.annodb create mode 100644 data/gl 12780402_admin.n-triples create mode 100644 data/gl 12780402_export.csv create mode 100644 data/gl 12780402_jshahinitiran.annodb create mode 100644 data/gl 12780402_jshahinitiran.n-triples create mode 100644 data/gl 12780402_tstrakeljahn.annodb create mode 100644 data/gl 12780402_tstrakeljahn.n-triples create mode 100644 data/gl 12859261_admin.annodb create mode 100644 data/gl 12859261_admin.n-triples create mode 100644 data/gl 12859261_export.csv create mode 100644 data/gl 12859261_jshahinitiran.annodb create mode 100644 data/gl 12859261_jshahinitiran.n-triples create mode 100644 data/gl 12859261_tstrakeljahn.annodb create mode 100644 data/gl 12859261_tstrakeljahn.n-triples create mode 100644 data/gl 12867391_admin.annodb create mode 100644 data/gl 12867391_admin.n-triples create mode 100644 data/gl 12867391_export.csv create mode 100644 data/gl 12867391_jshahinitiran.annodb create mode 100644 data/gl 12867391_jshahinitiran.n-triples create mode 100644 data/gl 12867391_tstrakeljahn.annodb create mode 100644 data/gl 12867391_tstrakeljahn.n-triples create mode 100644 data/gl 14736774_admin.annodb create mode 100644 data/gl 14736774_admin.n-triples create mode 100644 data/gl 14736774_export.csv create mode 100644 data/gl 14736774_jshahinitiran.annodb create mode 100644 data/gl 14736774_jshahinitiran.n-triples create mode 100644 data/gl 14736774_tstrakeljahn.annodb create mode 100644 data/gl 14736774_tstrakeljahn.n-triples create mode 100644 data/gl 14746165_admin.annodb create mode 100644 data/gl 14746165_admin.n-triples create mode 100644 data/gl 14746165_export.csv create mode 100644 data/gl 14746165_jshahinitiran.annodb create mode 100644 data/gl 14746165_jshahinitiran.n-triples create mode 100644 data/gl 14746165_tstrakeljahn.annodb create mode 100644 data/gl 14746165_tstrakeljahn.n-triples create mode 100644 data/gl 15019375_admin.annodb create mode 100644 data/gl 15019375_admin.n-triples create mode 100644 data/gl 15019375_export.csv create mode 100644 data/gl 15019375_jshahinitiran.annodb create mode 100644 data/gl 15019375_jshahinitiran.n-triples create mode 100644 data/gl 15019375_tstrakeljahn.annodb create mode 100644 data/gl 15019375_tstrakeljahn.n-triples create mode 100644 data/gl 15037890_admin.annodb create mode 100644 data/gl 15037890_admin.n-triples create mode 100644 data/gl 15037890_export.csv create mode 100644 data/gl 15037890_jshahinitiran.annodb create mode 100644 data/gl 15037890_jshahinitiran.n-triples create mode 100644 data/gl 15037890_tstrakeljahn.annodb create mode 100644 data/gl 15037890_tstrakeljahn.n-triples create mode 100644 data/gl 15094733_admin.annodb create mode 100644 data/gl 15094733_admin.n-triples create mode 100644 data/gl 15094733_export.csv create mode 100644 data/gl 15094733_jshahinitiran.annodb create mode 100644 data/gl 15094733_jshahinitiran.n-triples create mode 100644 data/gl 15094733_tstrakeljahn.annodb create mode 100644 data/gl 15094733_tstrakeljahn.n-triples create mode 100644 data/gl 15097262_admin.annodb create mode 100644 data/gl 15097262_admin.n-triples create mode 100644 data/gl 15097262_export.csv create mode 100644 data/gl 15097262_jshahinitiran.annodb create mode 100644 data/gl 15097262_jshahinitiran.n-triples create mode 100644 data/gl 15097262_tstrakeljahn.annodb create mode 100644 data/gl 15097262_tstrakeljahn.n-triples create mode 100644 data/gl 15205229_admin.annodb create mode 100644 data/gl 15205229_admin.n-triples create mode 100644 data/gl 15205229_export.csv create mode 100644 data/gl 15205229_jshahinitiran.annodb create mode 100644 data/gl 15205229_jshahinitiran.n-triples create mode 100644 data/gl 15205229_tstrakeljahn.annodb create mode 100644 data/gl 15205229_tstrakeljahn.n-triples create mode 100644 data/gl 15220019_admin.annodb create mode 100644 data/gl 15220019_admin.n-triples create mode 100644 data/gl 15220019_export.csv create mode 100644 data/gl 15220019_jshahinitiran.annodb create mode 100644 data/gl 15220019_jshahinitiran.n-triples create mode 100644 data/gl 15220019_tstrakeljahn.annodb create mode 100644 data/gl 15220019_tstrakeljahn.n-triples create mode 100644 data/gl 1524115_admin.annodb create mode 100644 data/gl 1524115_admin.n-triples create mode 100644 data/gl 1524115_export.csv create mode 100644 data/gl 1524115_jshahinitiran.annodb create mode 100644 data/gl 1524115_jshahinitiran.n-triples create mode 100644 data/gl 1524115_tstrakeljahn.annodb create mode 100644 data/gl 1524115_tstrakeljahn.n-triples create mode 100644 data/gl 15598478_admin.annodb create mode 100644 data/gl 15598478_admin.n-triples create mode 100644 data/gl 15598478_export.csv create mode 100644 data/gl 15598478_jshahinitiran.annodb create mode 100644 data/gl 15598478_jshahinitiran.n-triples create mode 100644 data/gl 15598478_tstrakeljahn.annodb create mode 100644 data/gl 15598478_tstrakeljahn.n-triples create mode 100644 data/gl 15741820_admin.annodb create mode 100644 data/gl 15741820_admin.n-triples create mode 100644 data/gl 15741820_export.csv create mode 100644 data/gl 15741820_jshahinitiran.annodb create mode 100644 data/gl 15741820_jshahinitiran.n-triples create mode 100644 data/gl 15741820_tstrakeljahn.annodb create mode 100644 data/gl 15741820_tstrakeljahn.n-triples create mode 100644 data/gl 15857284_admin.annodb create mode 100644 data/gl 15857284_admin.n-triples create mode 100644 data/gl 15857284_export.csv create mode 100644 data/gl 15857284_jshahinitiran.annodb create mode 100644 data/gl 15857284_jshahinitiran.n-triples create mode 100644 data/gl 15857284_tstrakeljahn.annodb create mode 100644 data/gl 15857284_tstrakeljahn.n-triples create mode 100644 data/gl 15945001_admin.annodb create mode 100644 data/gl 15945001_admin.n-triples create mode 100644 data/gl 15945001_export.csv create mode 100644 data/gl 15945001_jshahinitiran.annodb create mode 100644 data/gl 15945001_jshahinitiran.n-triples create mode 100644 data/gl 15945001_tstrakeljahn.annodb create mode 100644 data/gl 15945001_tstrakeljahn.n-triples create mode 100644 data/gl 15969642_admin.annodb create mode 100644 data/gl 15969642_admin.n-triples create mode 100644 data/gl 15969642_export.csv create mode 100644 data/gl 15969642_jshahinitiran.annodb create mode 100644 data/gl 15969642_jshahinitiran.n-triples create mode 100644 data/gl 15969642_tstrakeljahn.annodb create mode 100644 data/gl 15969642_tstrakeljahn.n-triples create mode 100644 data/gl 16009829_admin.annodb create mode 100644 data/gl 16009829_admin.n-triples create mode 100644 data/gl 16009829_export.csv create mode 100644 data/gl 16009829_jshahinitiran.annodb create mode 100644 data/gl 16009829_jshahinitiran.n-triples create mode 100644 data/gl 16009829_tstrakeljahn.annodb create mode 100644 data/gl 16009829_tstrakeljahn.n-triples create mode 100644 data/gl 16263174_admin.annodb create mode 100644 data/gl 16263174_admin.n-triples create mode 100644 data/gl 16263174_export.csv create mode 100644 data/gl 16263174_jshahinitiran.annodb create mode 100644 data/gl 16263174_jshahinitiran.n-triples create mode 100644 data/gl 16263174_tstrakeljahn.annodb create mode 100644 data/gl 16263174_tstrakeljahn.n-triples create mode 100644 data/gl 16458964_admin.annodb create mode 100644 data/gl 16458964_admin.n-triples create mode 100644 data/gl 16458964_export.csv create mode 100644 data/gl 16458964_jshahinitiran.annodb create mode 100644 data/gl 16458964_jshahinitiran.n-triples create mode 100644 data/gl 16458964_tstrakeljahn.annodb create mode 100644 data/gl 16458964_tstrakeljahn.n-triples create mode 100644 data/gl 16750448_admin.annodb create mode 100644 data/gl 16750448_admin.n-triples create mode 100644 data/gl 16750448_export.csv create mode 100644 data/gl 16750448_jshahinitiran.annodb create mode 100644 data/gl 16750448_jshahinitiran.n-triples create mode 100644 data/gl 16750448_tstrakeljahn.annodb create mode 100644 data/gl 16750448_tstrakeljahn.n-triples create mode 100644 data/gl 16825272_admin.annodb create mode 100644 data/gl 16825272_admin.n-triples create mode 100644 data/gl 16825272_export.csv create mode 100644 data/gl 16825272_jshahinitiran.annodb create mode 100644 data/gl 16825272_jshahinitiran.n-triples create mode 100644 data/gl 16825272_tstrakeljahn.annodb create mode 100644 data/gl 16825272_tstrakeljahn.n-triples create mode 100644 data/gl 16968583_admin.annodb create mode 100644 data/gl 16968583_admin.n-triples create mode 100644 data/gl 16968583_export.csv create mode 100644 data/gl 16968583_jshahinitiran.annodb create mode 100644 data/gl 16968583_jshahinitiran.n-triples create mode 100644 data/gl 16968583_tstrakeljahn.annodb create mode 100644 data/gl 16968583_tstrakeljahn.n-triples create mode 100644 data/gl 17197028_admin.annodb create mode 100644 data/gl 17197028_admin.n-triples create mode 100644 data/gl 17197028_export.csv create mode 100644 data/gl 17197028_jshahinitiran.annodb create mode 100644 data/gl 17197028_jshahinitiran.n-triples create mode 100644 data/gl 17197028_tstrakeljahn.annodb create mode 100644 data/gl 17197028_tstrakeljahn.n-triples create mode 100644 data/gl 17244215_admin.annodb create mode 100644 data/gl 17244215_admin.n-triples create mode 100644 data/gl 17244215_export.csv create mode 100644 data/gl 17244215_jshahinitiran.annodb create mode 100644 data/gl 17244215_jshahinitiran.n-triples create mode 100644 data/gl 17244215_tstrakeljahn.annodb create mode 100644 data/gl 17244215_tstrakeljahn.n-triples create mode 100644 data/gl 17407624_admin.annodb create mode 100644 data/gl 17407624_admin.n-triples create mode 100644 data/gl 17407624_export.csv create mode 100644 data/gl 17407624_jshahinitiran.annodb create mode 100644 data/gl 17407624_jshahinitiran.n-triples create mode 100644 data/gl 17407624_tstrakeljahn.annodb create mode 100644 data/gl 17407624_tstrakeljahn.n-triples create mode 100644 data/gl 17519068_admin.annodb create mode 100644 data/gl 17519068_admin.n-triples create mode 100644 data/gl 17519068_export.csv create mode 100644 data/gl 17519068_jshahinitiran.annodb create mode 100644 data/gl 17519068_jshahinitiran.n-triples create mode 100644 data/gl 17519068_tstrakeljahn.annodb create mode 100644 data/gl 17519068_tstrakeljahn.n-triples create mode 100644 data/gl 17571086_admin.annodb create mode 100644 data/gl 17571086_admin.n-triples create mode 100644 data/gl 17571086_export.csv create mode 100644 data/gl 17571086_jshahinitiran.annodb create mode 100644 data/gl 17571086_jshahinitiran.n-triples create mode 100644 data/gl 17571086_tstrakeljahn.annodb create mode 100644 data/gl 17571086_tstrakeljahn.n-triples create mode 100644 data/gl 18327364 copy_admin.annodb create mode 100644 data/gl 18327364 copy_admin.n-triples create mode 100644 data/gl 18327364 copy_export.csv create mode 100644 data/gl 18327364_admin.annodb create mode 100644 data/gl 18327364_admin.n-triples create mode 100644 data/gl 18327364_export.csv create mode 100644 data/gl 18327364_jshahinitiran.annodb create mode 100644 data/gl 18327364_jshahinitiran.n-triples create mode 100644 data/gl 18327364_tstrakeljahn.annodb create mode 100644 data/gl 18327364_tstrakeljahn.n-triples create mode 100644 data/gl 18402717 copy_admin.annodb create mode 100644 data/gl 18402717 copy_admin.n-triples create mode 100644 data/gl 18402717 copy_export.csv create mode 100644 data/gl 18402717_admin.annodb create mode 100644 data/gl 18402717_admin.n-triples create mode 100644 data/gl 18402717_export.csv create mode 100644 data/gl 18402717_jshahinitiran.annodb create mode 100644 data/gl 18402717_jshahinitiran.n-triples create mode 100644 data/gl 18402717_tstrakeljahn.annodb create mode 100644 data/gl 18402717_tstrakeljahn.n-triples create mode 100644 data/gl 18535605_admin.annodb create mode 100644 data/gl 18535605_admin.n-triples create mode 100644 data/gl 18535605_export.csv create mode 100644 data/gl 18535605_jshahinitiran.annodb create mode 100644 data/gl 18535605_jshahinitiran.n-triples create mode 100644 data/gl 18535605_tstrakeljahn.annodb create mode 100644 data/gl 18535605_tstrakeljahn.n-triples create mode 100644 data/gl 18721251 copy_admin.annodb create mode 100644 data/gl 18721251 copy_admin.n-triples create mode 100644 data/gl 18721251 copy_export.csv create mode 100644 data/gl 18721251_admin.annodb create mode 100644 data/gl 18721251_admin.n-triples create mode 100644 data/gl 18721251_export.csv create mode 100644 data/gl 18721251_jshahinitiran.annodb create mode 100644 data/gl 18721251_jshahinitiran.n-triples create mode 100644 data/gl 18721251_tstrakeljahn.annodb create mode 100644 data/gl 18721251_tstrakeljahn.n-triples create mode 100644 data/gl 1882923_admin.annodb create mode 100644 data/gl 1882923_admin.n-triples create mode 100644 data/gl 1882923_export.csv create mode 100644 data/gl 1882923_jshahinitiran.annodb create mode 100644 data/gl 1882923_jshahinitiran.n-triples create mode 100644 data/gl 1882923_tstrakeljahn.annodb create mode 100644 data/gl 1882923_tstrakeljahn.n-triples create mode 100644 data/gl 19092465 copy_admin.annodb create mode 100644 data/gl 19092465 copy_admin.n-triples create mode 100644 data/gl 19092465 copy_export.csv create mode 100644 data/gl 19092465_admin.annodb create mode 100644 data/gl 19092465_admin.n-triples create mode 100644 data/gl 19092465_export.csv create mode 100644 data/gl 19092465_jshahinitiran.annodb create mode 100644 data/gl 19092465_jshahinitiran.n-triples create mode 100644 data/gl 19092465_tstrakeljahn.annodb create mode 100644 data/gl 19092465_tstrakeljahn.n-triples create mode 100644 data/gl 19123151 copy_admin.annodb create mode 100644 data/gl 19123151 copy_admin.n-triples create mode 100644 data/gl 19123151 copy_export.csv create mode 100644 data/gl 19123151_admin.annodb create mode 100644 data/gl 19123151_admin.n-triples create mode 100644 data/gl 19123151_export.csv create mode 100644 data/gl 19123151_jshahinitiran.annodb create mode 100644 data/gl 19123151_jshahinitiran.n-triples create mode 100644 data/gl 19123151_tstrakeljahn.annodb create mode 100644 data/gl 19123151_tstrakeljahn.n-triples create mode 100644 data/gl 19336424 copy_admin.annodb create mode 100644 data/gl 19336424 copy_admin.n-triples create mode 100644 data/gl 19336424 copy_export.csv create mode 100644 data/gl 19336424_admin.annodb create mode 100644 data/gl 19336424_admin.n-triples create mode 100644 data/gl 19336424_export.csv create mode 100644 data/gl 19336424_jshahinitiran.annodb create mode 100644 data/gl 19336424_jshahinitiran.n-triples create mode 100644 data/gl 19336424_tstrakeljahn.annodb create mode 100644 data/gl 19336424_tstrakeljahn.n-triples create mode 100644 data/gl 19476406_admin.annodb create mode 100644 data/gl 19476406_admin.n-triples create mode 100644 data/gl 19476406_export.csv create mode 100644 data/gl 19476406_jshahinitiran.annodb create mode 100644 data/gl 19476406_jshahinitiran.n-triples create mode 100644 data/gl 19476406_tstrakeljahn.annodb create mode 100644 data/gl 19476406_tstrakeljahn.n-triples create mode 100644 data/gl 19726422 copy_admin.annodb create mode 100644 data/gl 19726422 copy_admin.n-triples create mode 100644 data/gl 19726422 copy_export.csv create mode 100644 data/gl 19726422_admin.annodb create mode 100644 data/gl 19726422_admin.n-triples create mode 100644 data/gl 19726422_export.csv create mode 100644 data/gl 19726422_jshahinitiran.annodb create mode 100644 data/gl 19726422_jshahinitiran.n-triples create mode 100644 data/gl 19726422_tstrakeljahn.annodb create mode 100644 data/gl 19726422_tstrakeljahn.n-triples create mode 100644 data/gl 19787599_admin.annodb create mode 100644 data/gl 19787599_admin.n-triples create mode 100644 data/gl 19787599_export.csv create mode 100644 data/gl 19787599_jshahinitiran.annodb create mode 100644 data/gl 19787599_jshahinitiran.n-triples create mode 100644 data/gl 19787599_tstrakeljahn.annodb create mode 100644 data/gl 19787599_tstrakeljahn.n-triples create mode 100644 data/gl 19860553_admin.annodb create mode 100644 data/gl 19860553_admin.n-triples create mode 100644 data/gl 19860553_export.csv create mode 100644 data/gl 19860553_jshahinitiran.annodb create mode 100644 data/gl 19860553_jshahinitiran.n-triples create mode 100644 data/gl 19860553_tstrakeljahn.annodb create mode 100644 data/gl 19860553_tstrakeljahn.n-triples create mode 100644 data/gl 20019759 copy_admin.annodb create mode 100644 data/gl 20019759 copy_admin.n-triples create mode 100644 data/gl 20019759 copy_export.csv create mode 100644 data/gl 20019759_admin.annodb create mode 100644 data/gl 20019759_admin.n-triples create mode 100644 data/gl 20019759_export.csv create mode 100644 data/gl 20019759_jshahinitiran.annodb create mode 100644 data/gl 20019759_jshahinitiran.n-triples create mode 100644 data/gl 20019759_tstrakeljahn.annodb create mode 100644 data/gl 20019759_tstrakeljahn.n-triples create mode 100644 data/gl 20420586_admin.annodb create mode 100644 data/gl 20420586_admin.n-triples create mode 100644 data/gl 20420586_export.csv create mode 100644 data/gl 20420586_jshahinitiran.annodb create mode 100644 data/gl 20420586_jshahinitiran.n-triples create mode 100644 data/gl 20420586_tstrakeljahn.annodb create mode 100644 data/gl 20420586_tstrakeljahn.n-triples create mode 100644 data/gl 20429818_admin.annodb create mode 100644 data/gl 20429818_admin.n-triples create mode 100644 data/gl 20429818_export.csv create mode 100644 data/gl 20429818_jshahinitiran.annodb create mode 100644 data/gl 20429818_jshahinitiran.n-triples create mode 100644 data/gl 20429818_tstrakeljahn.annodb create mode 100644 data/gl 20429818_tstrakeljahn.n-triples create mode 100644 data/gl 20545217_admin.annodb create mode 100644 data/gl 20545217_admin.n-triples create mode 100644 data/gl 20545217_export.csv create mode 100644 data/gl 20545217_jshahinitiran.annodb create mode 100644 data/gl 20545217_jshahinitiran.n-triples create mode 100644 data/gl 20545217_tstrakeljahn.annodb create mode 100644 data/gl 20545217_tstrakeljahn.n-triples create mode 100644 data/gl 21034177_admin.annodb create mode 100644 data/gl 21034177_admin.n-triples create mode 100644 data/gl 21034177_export.csv create mode 100644 data/gl 21034177_jshahinitiran.annodb create mode 100644 data/gl 21034177_jshahinitiran.n-triples create mode 100644 data/gl 21034177_tstrakeljahn.annodb create mode 100644 data/gl 21034177_tstrakeljahn.n-triples create mode 100644 data/gl 21048504_admin.annodb create mode 100644 data/gl 21048504_admin.n-triples create mode 100644 data/gl 21048504_export.csv create mode 100644 data/gl 21048504_jshahinitiran.annodb create mode 100644 data/gl 21048504_jshahinitiran.n-triples create mode 100644 data/gl 21048504_tstrakeljahn.annodb create mode 100644 data/gl 21048504_tstrakeljahn.n-triples create mode 100644 data/gl 21257146_admin.annodb create mode 100644 data/gl 21257146_admin.n-triples create mode 100644 data/gl 21257146_export.csv create mode 100644 data/gl 21257146_jshahinitiran.annodb create mode 100644 data/gl 21257146_jshahinitiran.n-triples create mode 100644 data/gl 21257146_tstrakeljahn.annodb create mode 100644 data/gl 21257146_tstrakeljahn.n-triples create mode 100644 data/gl 21499770_admin.annodb create mode 100644 data/gl 21499770_admin.n-triples create mode 100644 data/gl 21499770_export.csv create mode 100644 data/gl 21499770_jshahinitiran.annodb create mode 100644 data/gl 21499770_jshahinitiran.n-triples create mode 100644 data/gl 21499770_tstrakeljahn.annodb create mode 100644 data/gl 21499770_tstrakeljahn.n-triples create mode 100644 data/gl 21680022_admin.annodb create mode 100644 data/gl 21680022_admin.n-triples create mode 100644 data/gl 21680022_export.csv create mode 100644 data/gl 21680022_jshahinitiran.annodb create mode 100644 data/gl 21680022_jshahinitiran.n-triples create mode 100644 data/gl 21680022_tstrakeljahn.annodb create mode 100644 data/gl 21680022_tstrakeljahn.n-triples create mode 100644 data/gl 21792284_admin.annodb create mode 100644 data/gl 21792284_admin.n-triples create mode 100644 data/gl 21792284_export.csv create mode 100644 data/gl 21792284_jshahinitiran.annodb create mode 100644 data/gl 21792284_jshahinitiran.n-triples create mode 100644 data/gl 21792284_tstrakeljahn.annodb create mode 100644 data/gl 21792284_tstrakeljahn.n-triples create mode 100644 data/gl 21851642_admin.annodb create mode 100644 data/gl 21851642_admin.n-triples create mode 100644 data/gl 21851642_export.csv create mode 100644 data/gl 21851642_jshahinitiran.annodb create mode 100644 data/gl 21851642_jshahinitiran.n-triples create mode 100644 data/gl 21851642_tstrakeljahn.annodb create mode 100644 data/gl 21851642_tstrakeljahn.n-triples create mode 100644 data/gl 21960068_admin.annodb create mode 100644 data/gl 21960068_admin.n-triples create mode 100644 data/gl 21960068_export.csv create mode 100644 data/gl 21960068_jshahinitiran.annodb create mode 100644 data/gl 21960068_jshahinitiran.n-triples create mode 100644 data/gl 21960068_tstrakeljahn.annodb create mode 100644 data/gl 21960068_tstrakeljahn.n-triples create mode 100644 data/gl 22207522_admin.annodb create mode 100644 data/gl 22207522_admin.n-triples create mode 100644 data/gl 22207522_export.csv create mode 100644 data/gl 22207522_jshahinitiran.annodb create mode 100644 data/gl 22207522_jshahinitiran.n-triples create mode 100644 data/gl 22207522_tstrakeljahn.annodb create mode 100644 data/gl 22207522_tstrakeljahn.n-triples create mode 100644 data/gl 22320418_admin.annodb create mode 100644 data/gl 22320418_admin.n-triples create mode 100644 data/gl 22320418_export.csv create mode 100644 data/gl 22320418_jshahinitiran.annodb create mode 100644 data/gl 22320418_jshahinitiran.n-triples create mode 100644 data/gl 22320418_tstrakeljahn.annodb create mode 100644 data/gl 22320418_tstrakeljahn.n-triples create mode 100644 data/gl 22458918_admin.annodb create mode 100644 data/gl 22458918_admin.n-triples create mode 100644 data/gl 22458918_export.csv create mode 100644 data/gl 22458918_jshahinitiran.annodb create mode 100644 data/gl 22458918_jshahinitiran.n-triples create mode 100644 data/gl 22458918_tstrakeljahn.annodb create mode 100644 data/gl 22458918_tstrakeljahn.n-triples create mode 100644 data/gl 22775229_admin.annodb create mode 100644 data/gl 22775229_admin.n-triples create mode 100644 data/gl 22775229_export.csv create mode 100644 data/gl 22775229_jshahinitiran.annodb create mode 100644 data/gl 22775229_jshahinitiran.n-triples create mode 100644 data/gl 22775229_tstrakeljahn.annodb create mode 100644 data/gl 22775229_tstrakeljahn.n-triples create mode 100644 data/gl 23203707_admin.annodb create mode 100644 data/gl 23203707_admin.n-triples create mode 100644 data/gl 23203707_export.csv create mode 100644 data/gl 23203707_jshahinitiran.annodb create mode 100644 data/gl 23203707_jshahinitiran.n-triples create mode 100644 data/gl 23203707_tstrakeljahn.annodb create mode 100644 data/gl 23203707_tstrakeljahn.n-triples create mode 100644 data/gl 23429621_admin.annodb create mode 100644 data/gl 23429621_admin.n-triples create mode 100644 data/gl 23429621_export.csv create mode 100644 data/gl 23429621_jshahinitiran.annodb create mode 100644 data/gl 23429621_jshahinitiran.n-triples create mode 100644 data/gl 23429621_tstrakeljahn.annodb create mode 100644 data/gl 23429621_tstrakeljahn.n-triples create mode 100644 data/gl 23550916_admin.annodb create mode 100644 data/gl 23550916_admin.n-triples create mode 100644 data/gl 23550916_export.csv create mode 100644 data/gl 23550916_jshahinitiran.annodb create mode 100644 data/gl 23550916_jshahinitiran.n-triples create mode 100644 data/gl 23550916_tstrakeljahn.annodb create mode 100644 data/gl 23550916_tstrakeljahn.n-triples create mode 100644 data/gl 23686322_admin.annodb create mode 100644 data/gl 23686322_admin.n-triples create mode 100644 data/gl 23686322_export.csv create mode 100644 data/gl 23686322_jshahinitiran.annodb create mode 100644 data/gl 23686322_jshahinitiran.n-triples create mode 100644 data/gl 23686322_tstrakeljahn.annodb create mode 100644 data/gl 23686322_tstrakeljahn.n-triples create mode 100644 data/gl 23807349_admin.annodb create mode 100644 data/gl 23807349_admin.n-triples create mode 100644 data/gl 23807349_export.csv create mode 100644 data/gl 23807349_jshahinitiran.annodb create mode 100644 data/gl 23807349_jshahinitiran.n-triples create mode 100644 data/gl 23807349_tstrakeljahn.annodb create mode 100644 data/gl 23807349_tstrakeljahn.n-triples create mode 100644 data/gl 23950156_admin.annodb create mode 100644 data/gl 23950156_admin.n-triples create mode 100644 data/gl 23950156_export.csv create mode 100644 data/gl 23950156_jshahinitiran.annodb create mode 100644 data/gl 23950156_jshahinitiran.n-triples create mode 100644 data/gl 23950156_tstrakeljahn.annodb create mode 100644 data/gl 23950156_tstrakeljahn.n-triples create mode 100644 data/gl 24073548_admin.annodb create mode 100644 data/gl 24073548_admin.n-triples create mode 100644 data/gl 24073548_export.csv create mode 100644 data/gl 24073548_jshahinitiran.annodb create mode 100644 data/gl 24073548_jshahinitiran.n-triples create mode 100644 data/gl 24073548_tstrakeljahn.annodb create mode 100644 data/gl 24073548_tstrakeljahn.n-triples create mode 100644 data/gl 24672097_admin.annodb create mode 100644 data/gl 24672097_admin.n-triples create mode 100644 data/gl 24672097_export.csv create mode 100644 data/gl 24672097_jshahinitiran.annodb create mode 100644 data/gl 24672097_jshahinitiran.n-triples create mode 100644 data/gl 24672097_tstrakeljahn.annodb create mode 100644 data/gl 24672097_tstrakeljahn.n-triples create mode 100644 data/gl 24919410_admin.annodb create mode 100644 data/gl 24919410_admin.n-triples create mode 100644 data/gl 24919410_export.csv create mode 100644 data/gl 24919410_jshahinitiran.annodb create mode 100644 data/gl 24919410_jshahinitiran.n-triples create mode 100644 data/gl 24919410_tstrakeljahn.annodb create mode 100644 data/gl 24919410_tstrakeljahn.n-triples create mode 100644 data/gl 25264990_admin.annodb create mode 100644 data/gl 25264990_admin.n-triples create mode 100644 data/gl 25264990_export.csv create mode 100644 data/gl 25264990_jshahinitiran.annodb create mode 100644 data/gl 25264990_jshahinitiran.n-triples create mode 100644 data/gl 25264990_tstrakeljahn.annodb create mode 100644 data/gl 25264990_tstrakeljahn.n-triples create mode 100644 data/gl 25430900_admin.annodb create mode 100644 data/gl 25430900_admin.n-triples create mode 100644 data/gl 25430900_export.csv create mode 100644 data/gl 25430900_jshahinitiran.annodb create mode 100644 data/gl 25430900_jshahinitiran.n-triples create mode 100644 data/gl 25430900_tstrakeljahn.annodb create mode 100644 data/gl 25430900_tstrakeljahn.n-triples create mode 100644 data/gl 25432143_admin.annodb create mode 100644 data/gl 25432143_admin.n-triples create mode 100644 data/gl 25432143_export.csv create mode 100644 data/gl 25432143_jshahinitiran.annodb create mode 100644 data/gl 25432143_jshahinitiran.n-triples create mode 100644 data/gl 25432143_tstrakeljahn.annodb create mode 100644 data/gl 25432143_tstrakeljahn.n-triples create mode 100644 data/gl 25533656_admin.annodb create mode 100644 data/gl 25533656_admin.n-triples create mode 100644 data/gl 25533656_export.csv create mode 100644 data/gl 25533656_jshahinitiran.annodb create mode 100644 data/gl 25533656_jshahinitiran.n-triples create mode 100644 data/gl 25533656_tstrakeljahn.annodb create mode 100644 data/gl 25533656_tstrakeljahn.n-triples create mode 100644 data/gl 26578422_admin.annodb create mode 100644 data/gl 26578422_admin.n-triples create mode 100644 data/gl 26578422_export.csv create mode 100644 data/gl 26578422_jshahinitiran.annodb create mode 100644 data/gl 26578422_jshahinitiran.n-triples create mode 100644 data/gl 26578422_tstrakeljahn.annodb create mode 100644 data/gl 26578422_tstrakeljahn.n-triples create mode 100644 data/gl 26940161_admin.annodb create mode 100644 data/gl 26940161_admin.n-triples create mode 100644 data/gl 26940161_export.csv create mode 100644 data/gl 26940161_jshahinitiran.annodb create mode 100644 data/gl 26940161_jshahinitiran.n-triples create mode 100644 data/gl 26940161_tstrakeljahn.annodb create mode 100644 data/gl 26940161_tstrakeljahn.n-triples create mode 100644 data/gl 27050347_admin.annodb create mode 100644 data/gl 27050347_admin.n-triples create mode 100644 data/gl 27050347_export.csv create mode 100644 data/gl 27050347_jshahinitiran.annodb create mode 100644 data/gl 27050347_jshahinitiran.n-triples create mode 100644 data/gl 27050347_tstrakeljahn.annodb create mode 100644 data/gl 27050347_tstrakeljahn.n-triples create mode 100644 data/gl 27367743_admin.annodb create mode 100644 data/gl 27367743_admin.n-triples create mode 100644 data/gl 27367743_export.csv create mode 100644 data/gl 27367743_jshahinitiran.annodb create mode 100644 data/gl 27367743_jshahinitiran.n-triples create mode 100644 data/gl 27367743_tstrakeljahn.annodb create mode 100644 data/gl 27367743_tstrakeljahn.n-triples create mode 100644 data/gl 27445072_admin.annodb create mode 100644 data/gl 27445072_admin.n-triples create mode 100644 data/gl 27445072_export.csv create mode 100644 data/gl 27445072_jshahinitiran.annodb create mode 100644 data/gl 27445072_jshahinitiran.n-triples create mode 100644 data/gl 27445072_tstrakeljahn.annodb create mode 100644 data/gl 27445072_tstrakeljahn.n-triples create mode 100644 data/gl 28129020_admin.annodb create mode 100644 data/gl 28129020_admin.n-triples create mode 100644 data/gl 28129020_export.csv create mode 100644 data/gl 28129020_jshahinitiran.annodb create mode 100644 data/gl 28129020_jshahinitiran.n-triples create mode 100644 data/gl 28129020_tstrakeljahn.annodb create mode 100644 data/gl 28129020_tstrakeljahn.n-triples create mode 100644 data/gl 7880782_admin.annodb create mode 100644 data/gl 7880782_admin.n-triples create mode 100644 data/gl 7880782_export.csv create mode 100644 data/gl 7880782_jshahinitiran.annodb create mode 100644 data/gl 7880782_jshahinitiran.n-triples create mode 100644 data/gl 7880782_tstrakeljahn.annodb create mode 100644 data/gl 7880782_tstrakeljahn.n-triples create mode 100644 data/gl 8123096_admin.annodb create mode 100644 data/gl 8123096_admin.n-triples create mode 100644 data/gl 8123096_export.csv create mode 100644 data/gl 8123096_jshahinitiran.annodb create mode 100644 data/gl 8123096_jshahinitiran.n-triples create mode 100644 data/gl 8123096_tstrakeljahn.annodb create mode 100644 data/gl 8123096_tstrakeljahn.n-triples create mode 100644 data/gl 8145982_admin.annodb create mode 100644 data/gl 8145982_admin.n-triples create mode 100644 data/gl 8145982_export.csv create mode 100644 data/gl 8145982_jshahinitiran.annodb create mode 100644 data/gl 8145982_jshahinitiran.n-triples create mode 100644 data/gl 8145982_tstrakeljahn.annodb create mode 100644 data/gl 8145982_tstrakeljahn.n-triples create mode 100644 data/gl 8628543_admin.annodb create mode 100644 data/gl 8628543_admin.n-triples create mode 100644 data/gl 8628543_export.csv create mode 100644 data/gl 8628543_jshahinitiran.annodb create mode 100644 data/gl 8628543_jshahinitiran.n-triples create mode 100644 data/gl 8628543_tstrakeljahn.annodb create mode 100644 data/gl 8628543_tstrakeljahn.n-triples create mode 100644 data/gl 8628544_admin.annodb create mode 100644 data/gl 8628544_admin.n-triples create mode 100644 data/gl 8628544_export.csv create mode 100644 data/gl 8628544_jshahinitiran.annodb create mode 100644 data/gl 8628544_jshahinitiran.n-triples create mode 100644 data/gl 8628544_tstrakeljahn.annodb create mode 100644 data/gl 8628544_tstrakeljahn.n-triples create mode 100644 data/gl 8694726_admin.annodb create mode 100644 data/gl 8694726_admin.n-triples create mode 100644 data/gl 8694726_export.csv create mode 100644 data/gl 8694726_jshahinitiran.annodb create mode 100644 data/gl 8694726_jshahinitiran.n-triples create mode 100644 data/gl 8694726_tstrakeljahn.annodb create mode 100644 data/gl 8694726_tstrakeljahn.n-triples create mode 100644 data/gl 8970248_admin.annodb create mode 100644 data/gl 8970248_admin.n-triples create mode 100644 data/gl 8970248_export.csv create mode 100644 data/gl 8970248_jshahinitiran.annodb create mode 100644 data/gl 8970248_jshahinitiran.n-triples create mode 100644 data/gl 8970248_tstrakeljahn.annodb create mode 100644 data/gl 8970248_tstrakeljahn.n-triples create mode 100644 data/gl 9230823_admin.annodb create mode 100644 data/gl 9230823_admin.n-triples create mode 100644 data/gl 9230823_export.csv create mode 100644 data/gl 9230823_jshahinitiran.annodb create mode 100644 data/gl 9230823_jshahinitiran.n-triples create mode 100644 data/gl 9230823_tstrakeljahn.annodb create mode 100644 data/gl 9230823_tstrakeljahn.n-triples create mode 100644 data/gl 9331215_admin.annodb create mode 100644 data/gl 9331215_admin.n-triples create mode 100644 data/gl 9331215_export.csv create mode 100644 data/gl 9331215_jshahinitiran.annodb create mode 100644 data/gl 9331215_jshahinitiran.n-triples create mode 100644 data/gl 9331215_tstrakeljahn.annodb create mode 100644 data/gl 9331215_tstrakeljahn.n-triples create mode 100644 data/gl 9663361_admin.annodb create mode 100644 data/gl 9663361_admin.n-triples create mode 100644 data/gl 9663361_export.csv create mode 100644 data/gl 9663361_jshahinitiran.annodb create mode 100644 data/gl 9663361_jshahinitiran.n-triples create mode 100644 data/gl 9663361_tstrakeljahn.annodb create mode 100644 data/gl 9663361_tstrakeljahn.n-triples create mode 100644 requirements.txt create mode 100644 scripts-extractive/all_runs.txt create mode 100644 scripts-extractive/eval-extr.sh create mode 100755 scripts-extractive/extractive-best.sh create mode 100755 scripts-extractive/extractive-dm2.sh create mode 100755 scripts-extractive/extractive-gl.sh create mode 100644 scripts-generative/allRuns.txt create mode 100644 scripts-generative/eval-gen.sh create mode 100755 scripts-generative/generative-best.sh create mode 100755 scripts-generative/generative-dm2.sh create mode 100755 scripts-generative/generative-gl.sh create mode 100644 sort_results.sh create mode 100644 src/eval_summary.py create mode 100644 src/eval_summary_best.py create mode 100644 src/extractive_approach/__init__.py create mode 100644 src/extractive_approach/clustering_approaches.py create mode 100644 src/extractive_approach/create_task_config_file.py create mode 100644 src/extractive_approach/data_handling.py create mode 100644 src/extractive_approach/entity_clustering.py create mode 100644 src/extractive_approach/entity_extraction.py create mode 100644 src/extractive_approach/evaluation.py create mode 100644 src/extractive_approach/modules.py create mode 100644 src/extractive_approach/param_search.py create mode 100644 src/extractive_approach/training.py create mode 100644 src/extractive_approach/utils.py create mode 100644 src/full_eval.py create mode 100644 src/generative_approach/.gitignore create mode 100644 src/generative_approach/__init__.py create mode 100644 src/generative_approach/create_task_config_file.py create mode 100644 src/generative_approach/data_handling.py create mode 100644 src/generative_approach/decoding.py create mode 100644 src/generative_approach/evaluation.py create mode 100644 src/generative_approach/generation.py create mode 100644 src/generative_approach/grammar.py create mode 100644 src/generative_approach/max_cardinalities_estimator.py create mode 100644 src/generative_approach/models/__init__.py create mode 100644 src/generative_approach/models/ed_model.py create mode 100644 src/generative_approach/models/flan_t5.py create mode 100644 src/generative_approach/models/longformer.py create mode 100644 src/generative_approach/modules.py create mode 100644 src/generative_approach/parsing.py create mode 100644 src/generative_approach/resources/grammar_dm2.txt create mode 100644 src/generative_approach/resources/grammar_gl.txt create mode 100644 src/generative_approach/template_coding.py create mode 100644 src/generative_approach/training.py create mode 100644 src/generative_approach/utils.py create mode 100644 src/main.py create mode 100644 src/template_lib/CharTokenizer.py create mode 100644 src/template_lib/DocumentChunking.py create mode 100644 src/template_lib/DocumentEncoder.py create mode 100644 src/template_lib/EntityDecoder.py create mode 100644 src/template_lib/SlotFillingEvaluation.py create mode 100644 src/template_lib/TempCollectionVisualizer.py create mode 100644 src/template_lib/TemplateAlignment.py create mode 100644 src/template_lib/__init__.py create mode 100644 src/template_lib/consts.py create mode 100644 src/template_lib/ctro.py create mode 100644 src/template_lib/data_classes/AnnotatedSentence.py create mode 100644 src/template_lib/data_classes/Chunk.py create mode 100644 src/template_lib/data_classes/Document.py create mode 100644 src/template_lib/data_classes/Entity.py create mode 100644 src/template_lib/data_classes/Sentence.py create mode 100644 src/template_lib/data_classes/Template.py create mode 100644 src/template_lib/data_classes/TemplateCollection.py create mode 100644 src/template_lib/data_classes/TokenSequence.py create mode 100644 src/template_lib/data_classes/__init__.py create mode 100644 src/template_lib/data_handling.py create mode 100644 src/template_lib/evaluation_utils.py create mode 100644 src/template_lib/max_cardinalities_estimator.py create mode 100644 src/template_lib/rdf_strings.py create mode 100644 src/template_lib/resources/classes.csv create mode 100644 src/template_lib/resources/most_general_superclasses.csv create mode 100644 src/template_lib/resources/properties.csv create mode 100644 src/template_lib/resources/subclasses.csv create mode 100644 src/template_lib/santo/SantoAnnotation.py create mode 100644 src/template_lib/santo/SantoAnnotationFile.py create mode 100644 src/template_lib/santo/SantoDataset.py create mode 100644 src/template_lib/santo/SantoToken.py create mode 100644 src/template_lib/santo/SantoTokenizationFile.py create mode 100644 src/template_lib/santo/SantoTriplesFile.py create mode 100644 src/template_lib/santo/__init__.py diff --git a/.gitignore b/.gitignore new file mode 100644 index 0000000..a75deb0 --- /dev/null +++ b/.gitignore @@ -0,0 +1,243 @@ +# Byte-compiled / optimized / DLL files +__pycache__/ +*.py[cod] +*$py.class + +# C extensions +*.so + +# Distribution / packaging +.Python +build/ +develop-eggs/ +dist/ +downloads/ +eggs/ +.eggs/ +lib/ +lib64/ +parts/ +sdist/ +var/ +wheels/ +share/python-wheels/ +*.egg-info/ +.installed.cfg +*.egg +MANIFEST + +# PyInstaller +# Usually these files are written by a python script from a template +# before PyInstaller builds the exe, so as to inject date/other infos into it. +*.manifest +*.spec + +# Installer logs +pip-log.txt +pip-delete-this-directory.txt + +# Unit test / coverage reports +htmlcov/ +.tox/ +.nox/ +.coverage +.coverage.* +.cache +nosetests.xml +coverage.xml +*.cover +*.py,cover +.hypothesis/ +.pytest_cache/ +cover/ + +# Translations +*.mo +*.pot + +# Django stuff: +*.log +local_settings.py +db.sqlite3 +db.sqlite3-journal + +# Flask stuff: +instance/ +.webassets-cache + +# Scrapy stuff: +.scrapy + +# Sphinx documentation +docs/build/ + +# PyBuilder +.pybuilder/ +target/ + +# Jupyter Notebook +.ipynb_checkpoints + +# IPython +profile_default/ +ipython_config.py + +# pyenv +# For a library or package, you might want to ignore these files since the code is +# intended to run in multiple environments; otherwise, check them in: +# .python-version + +# pipenv +# According to pypa/pipenv#598, it is recommended to include Pipfile.lock in version control. +# However, in case of collaboration, if having platform-specific dependencies or dependencies +# having no cross-platform support, pipenv may install dependencies that don't work, or not +# install all needed dependencies. +#Pipfile.lock + +# poetry +# Similar to Pipfile.lock, it is generally recommended to include poetry.lock in version control. +# This is especially recommended for binary packages to ensure reproducibility, and is more +# commonly ignored for libraries. +# https://python-poetry.org/docs/basic-usage/#commit-your-poetrylock-file-to-version-control +#poetry.lock + +# pdm +# Similar to Pipfile.lock, it is generally recommended to include pdm.lock in version control. +#pdm.lock +# pdm stores project-wide configurations in .pdm.toml, but it is recommended to not include it +# in version control. +# https://pdm.fming.dev/#use-with-ide +.pdm.toml + +# PEP 582; used by e.g. github.com/David-OConnor/pyflow and github.com/pdm-project/pdm +__pypackages__/ + +# Celery stuff +celerybeat-schedule +celerybeat.pid + +# SageMath parsed files +*.sage.py + +# Environments +.env +.venv +env/ +venv/ +ENV/ +env.bak/ +venv.bak/ + +# Spyder project settings +.spyderproject +.spyproject + +# Rope project settings +.ropeproject + +# mkdocs documentation +/site + +# mypy +.mypy_cache/ +.dmypy.json +dmypy.json + +# Pyre type checker +.pyre/ + +# pytype static type analyzer +.pytype/ + +# Cython debug symbols +cython_debug/ + +# PyCharm +# JetBrains specific template is maintained in a separate JetBrains.gitignore that can +# be found at https://github.com/github/gitignore/blob/main/Global/JetBrains.gitignore +# and can be added to the global gitignore or merged into this file. For a more nuclear +# option (not recommended) you can uncomment the following to ignore the entire idea folder. +#.idea/ +# Covers JetBrains IDEs: IntelliJ, RubyMine, PhpStorm, AppCode, PyCharm, CLion, Android Studio, WebStorm and Rider +# Reference: https://intellij-support.jetbrains.com/hc/en-us/articles/206544839 + +# User-specific stuff +.idea/**/workspace.xml +.idea/**/tasks.xml +.idea/**/usage.statistics.xml +.idea/**/dictionaries +.idea/**/shelf + +# AWS User-specific +.idea/**/aws.xml + +# Generated files +.idea/**/contentModel.xml + +# Sensitive or high-churn files +.idea/**/dataSources/ +.idea/**/dataSources.ids +.idea/**/dataSources.local.xml +.idea/**/sqlDataSources.xml +.idea/**/dynamic.xml +.idea/**/uiDesigner.xml +.idea/**/dbnavigator.xml + +# Gradle +.idea/**/gradle.xml +.idea/**/libraries + +# Gradle and Maven with auto-import +# When using Gradle or Maven with auto-import, you should exclude module files, +# since they will be recreated, and may cause churn. Uncomment if using +# auto-import. +# .idea/artifacts +# .idea/compiler.xml +# .idea/jarRepositories.xml +# .idea/modules.xml +# .idea/*.iml +# .idea/modules +# *.iml +# *.ipr + +# CMake +cmake-build-*/ + +# Mongo Explorer plugin +.idea/**/mongoSettings.xml + +# File-based project format +*.iws + +# IntelliJ +out/ + +# mpeltonen/sbt-idea plugin +.idea_modules/ + +# JIRA plugin +atlassian-ide-plugin.xml + +# Cursive Clojure plugin +.idea/replstate.xml + +# SonarLint plugin +.idea/sonarlint/ + +# Crashlytics plugin (for Android Studio and IntelliJ) +com_crashlytics_export_strings.xml +crashlytics.properties +crashlytics-build.properties +fabric.properties + +# Editor-based Rest Client +.idea/httpRequests + +# Android studio 3.1+ serialized cache file +.idea/caches/build_file_checksums.ser + +*.json +*.out +*epochs/ +results/ +old/ diff --git a/README.md b/README.md new file mode 100644 index 0000000..715d7d1 --- /dev/null +++ b/README.md @@ -0,0 +1,93 @@ +# Artifact "Comparing Generative and Extractive Approaches to Information Extraction from Abstracts Describing Randomized Clinical Trials" + +## Setup + +We suggest using Python 3.10.12 or newer to run this artifact, older versions have not been tested. The following instructions should work for most mayor Linux distributions. + +Start by setting up a virtual environment and installing the required packages. For this, run the following at the top level of a cloned version of this repository: + +```bash +python -m venv venv +source venv/bin/activate +pip install -r requirements.txt +``` + +All scripts in this artifact automatically activate the virtual environment assuming it is named and located as shown above and set the `PYTHONPATH` accordingly. If you want to execute a single Python file manually, you have to activate the virtual environment and add the `src/` subdirectory as `PYTHONPATH`: + +```bash +source venv/bin/activate +export PYTHONPATH=./src/ +python some/python/file.py +``` + +## Artifact Structure + +* data/ - annotated datasets for type 2 diabetes and glaucoma RCT abstracts used in the paper +* scripts-extractive/ - scripts to execute training and evaluation of the extractive approach + * all_runs.txt - list of commands necessary to start full hyperparameter search training run + * extractive-dm2.sh - given a model name, executes an extractive hyperparameter optimization training run with 30 trials for type 2 diabetes dataset + * extractive-gl.sh - given a model name, executes an extractive hyperparameter optimization training run with 30 trials for glaucoma dataset + * extractive-best.sh - given path to a `best_params.pkl` file generated by `src/eval_summary.py`, executes 10 training runs with the best parameters found during hyperparameter optimization + * eval-extr.sh - executes evaluation for extractive part of directory of trained models, CHANGE PATH IN FILE TO ACTUAL LOCATION OF RESULTS! +* scripts-generative/ - scripts to execute training and evaluation of the generative approach + * same as extractive, but for the generative approach +* src/ - source code of both approaches used in the paper + * extractive_approach - source code of the extractive approach (training file is `training.py`) + * generative_approach - source code of the generative approach (training file is `training.py`) + * template_lib - source code of general classes and functions to load and use the dataset + * full_eval.py - runs evaluation for whole given training results directory + * eval_summary.py - generates summary of evaluated training results of hyperparameter search + * eval_summary_best.py - generates summary of evaluated training results of the 10 training runs executed separately with the best hyperparameters + * main.py - can be used to play around with loaded datasets, contains code to list and count slot fillers of "Journal" +* requirements.txt - Python requirements of this project +* sort_results.sh - expecting training to have been executed in top directory of project, sorts models etc. into folders grouped by approach, disease and model, CHANGE PATH IN FILE TO ACTUAL LOCATION OF RESULTS! + +## Replication Steps + +1. Go to the top directory of this project + +2. Execute all hyperparameter optimization trainings, i.e.: +```bash +scripts-extractive/extractive-dm2.sh 'allenai/longformer-base-4096' | tee train-longformer-dm2.txt +scripts-extractive/extractive-dm2.sh "allenai/led-base-16384" | tee train-led-dm2.txt +scripts-extractive/extractive-dm2.sh "google/flan-t5-base" | tee train-t5-dm2.txt +scripts-extractive/extractive-gl.sh 'allenai/longformer-base-4096' | tee train-longformer-gl.txt +scripts-extractive/extractive-gl.sh "allenai/led-base-16384" | tee train-led-gl.txt +scripts-extractive/extractive-gl.sh "google/flan-t5-base" | tee train-t5-gl.txt +scripts-generative/generative-dm2.sh 'allenai/led-base-16384' | tee train-led-dm2-gen.txt +scripts-generative/generative-dm2.sh 'google/flan-t5-base' | tee train-t5-dm2-gen.txt +scripts-generative/generative-gl.sh 'allenai/led-base-16384' | tee train-led-gl-gen.txt +scripts-generative/generative-gl.sh 'google/flan-t5-base' | tee train-t5-gl-gen.txt +``` + +3. Sort results into folders: `sort_results.sh` (change paths in file!) + +4. Run evaluation for extractive and generative models (change paths in file!): +```bash +scripts-extractive/eval-extr.sh +scripts-generative/eval-gen.sh +``` + +5. Generate evaluation summary for hyperparameter optimization (first activate virtual environment and set `PYTHONPATH` as shown above!). To generate case study data, append `--casestudy`. Some tables are only printed and generated if you run the command a second time because they are first only saved to pickle files. +```bash +python src/eval_summary.py --results /path/to/results/folder/ +``` + +6. Run training again for best found parameters: +```bash +scripts-extractive/extractive-best.sh /path/to/best_params.pkl +scripts-generative/generative-best.sh /path/to/best_params.pkl +``` + +7. Sort new results into folders: `sort_results.sh` and make sure the files are sorted into a different directory such that you can differentiate the hyperparameter optimization from the training with best parameters. Do not forget to also copy the `config_*.json` files from the original results to the directories of the new results (e.g. using `cp --parents`) as they are necessary for running the evaluation. + +8. Run evaluation for new extractive and generative models (change paths in file accordingly!): +```bash +scripts-extractive/eval-extr.sh +scripts-generative/eval-gen.sh +``` + +9. Generate evaluation summary with mean and standard deviations for training with best parameters (first activate virtual environment and set `PYTHONPATH` as shown above!). Some tables are only printed and generated if you run the command a second time because they are first only saved to pickle files. +```bash +python src/eval_summary_best.py --results /path/to/results/folder/ +``` diff --git a/data/dataset_splits/dm2_test_ids.txt b/data/dataset_splits/dm2_test_ids.txt new file mode 100644 index 0000000..24df183 --- /dev/null +++ b/data/dataset_splits/dm2_test_ids.txt @@ -0,0 +1,20 @@ +27740719 +17992639 +30019498 +19821654 +29246950 +25125506 +22672586 +23250357 +24939043 +21781152 +24199686 +15677776 +17130197 +23116881 +29110647 +20092584 +25208756 +25036533 +24356792 +24824197 diff --git a/data/dataset_splits/dm2_train_ids.txt b/data/dataset_splits/dm2_train_ids.txt new file mode 100644 index 0000000..f655876 --- /dev/null +++ b/data/dataset_splits/dm2_train_ids.txt @@ -0,0 +1,68 @@ +16715577 +28345162 +19108786 +27650977 +14706058 +27321385 +24650952 +15842521 +28035868 +18204830 +18761646 +21114605 +22313154 +25753488 +23706759 +21819517 +21802161 +23906445 +17929538 +23404788 +18194595 +17115351 +20920045 +22672081 +22742523 +23949898 +28923291 +29862619 +17404349 +12734781 +28547998 +23039321 +17157112 +28483786 +16505498 +19565569 +20092585 +24205943 +17593236 +24639432 +23082447 +28345792 +19307526 +29017497 +23230096 +24237386 +15205563 +29362626 +11315821 +23628617 +18158076 +23627775 +20415692 +19336625 +14578243 +15715892 +21138825 +26598090 +23948125 +28026912 +28548024 +27711199 +23160726 +20200301 +22134839 +27589252 +26950829 +20880343 diff --git a/data/dataset_splits/dm2_validation_ids.txt b/data/dataset_splits/dm2_validation_ids.txt new file mode 100644 index 0000000..f760b95 --- /dev/null +++ b/data/dataset_splits/dm2_validation_ids.txt @@ -0,0 +1,16 @@ +17379048 +16456680 +26067186 +15562200 +25138574 +17363756 +25054436 +24144654 +18936501 +17934150 +29144061 +24062327 +28449402 +28093853 +15677775 +28742225 diff --git a/data/dataset_splits/glaucoma_test_ids.txt b/data/dataset_splits/glaucoma_test_ids.txt new file mode 100644 index 0000000..e08ddb2 --- /dev/null +++ b/data/dataset_splits/glaucoma_test_ids.txt @@ -0,0 +1,21 @@ +8970248 +20420586 +22207522 +21960068 +15741820 +15969642 +23807349 +19336424 +20019759 +19092465 +24919410 +14746165 +25264990 +15945001 +11912355 +9663361 +12780402 +11039742 +11813932 +27367743 +22458918 diff --git a/data/dataset_splits/glaucoma_train_ids.txt b/data/dataset_splits/glaucoma_train_ids.txt new file mode 100644 index 0000000..536ef13 --- /dev/null +++ b/data/dataset_splits/glaucoma_train_ids.txt @@ -0,0 +1,69 @@ +11336940 +12586182 +12867391 +21499770 +19123151 +19860553 +10837379 +15097262 +17519068 +25430900 +24672097 +16458964 +12485286 +11167277 +18327364 +15598478 +10901475 +21792284 +12470755 +9230823 +23550916 +27445072 +10664047 +21851642 +15857284 +22775229 +12383812 +12466165 +20545217 +25533656 +20429818 +12483094 +12660585 +1524115 +25432143 +8694726 +17571086 +17407624 +21257146 +17197028 +1882923 +16750448 +10877373 +8123096 +16825272 +22320418 +11825814 +17244215 +16009829 +26578422 +11558817 +15094733 +21034177 +11952485 +15037890 +26940161 +9331215 +23203707 +10080213 +14736774 +18402717 +18535605 +18721251 +19726422 +8628544 +12486510 +15220019 +19476406 +23950156 diff --git a/data/dataset_splits/glaucoma_validation_ids.txt b/data/dataset_splits/glaucoma_validation_ids.txt new file mode 100644 index 0000000..dc01494 --- /dev/null +++ b/data/dataset_splits/glaucoma_validation_ids.txt @@ -0,0 +1,17 @@ +21680022 +23686322 +11158796 +23429621 +24073548 +7880782 +28129020 +8628543 +8145982 +16263174 +12859261 +16968583 +19787599 +15205229 +27050347 +21048504 +15019375 diff --git a/data/dm2 11315821_admin.annodb b/data/dm2 11315821_admin.annodb new file mode 100644 index 0000000..4324638 --- /dev/null +++ b/data/dm2 11315821_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +92943, Journal, 0, 15, "Diabetes Care .", "", " \"Diabetes Care .\"." +92929, PublicationYear, 16, 20, "2001", "", " \"2001\"." +92916, Title, 48, 161, "Basal insulin therapy in type 2 diabetes : 28 - week comparison of insulin glargine ( HOE 901 ) and NPH insulin .", "", " \"Basal insulin therapy in type 2 diabetes : 28 - week comparison of insulin glargine ( HOE 901 ) and NPH insulin .\"." +92459, Type2Diabetes, 73, 88, "type 2 diabetes", "", " ." +16, Duration, 91, 100, "28 - week", "", " \"28 - week\"." +92952, InsulinGlargine, 115, 131, "insulin glargine", "", " ." +92949, IsophaneInsulin_NPH, 148, 159, "NPH insulin", "", +92931, Author, 183, 194, "Schwartz SL", "", " \"Schwartz SL\"." +92937, Author, 197, 208, "Clark CM Jr", "", " \"Clark CM Jr\"." +92930, Author, 211, 218, "Park GD", "", " \"Park GD\"." +92932, Author, 221, 230, "Donley DW", "", " \"Donley DW\"." +92938, Author, 233, 243, "Edwards MB", "", " \"Edwards MB\"." +92928, Country, 326, 329, "USA", "", " . ." +167, ObjectiveDescription, 383, 572, "To determine the safety and efficacy of the long - acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone .", "", " \"To determine the safety and efficacy of the long - acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone .\"." +92954, InsulinGlargine, 448, 464, "insulin glargine", "", +312, IsophaneInsulin_NPH, 479, 490, "NPH insulin", "", +62, Precondition, 494, 570, "patients with type 2 diabetes who were previously treated with insulin alone", "", +92953, Type2Diabetes, 508, 523, "type 2 diabetes", "", +109, Insulin, 557, 564, "insulin", "", +92466, Precondition, 618, 735, "subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control", "", " \"subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control\"." +316, Type2Diabetes, 632, 647, "type 2 diabetes", "", +92460, IsophaneInsulin_NPH, 667, 678, "NPH insulin", "", +110, Insulin, 703, 710, "insulin", "", +92463, Randomized, 741, 751, "randomized", "", " ." +92955, InsulinGlargine, 763, 779, "insulin glargine", "", +24, InsulinGlargine, 782, 789, "HOE 901", "", +106179, Frequency, 792, 802, "once daily", "", " \"once daily\"." +111, NumberPatientsArm, 809, 812, "259", "", " \"259\"." +92461, IsophaneInsulin_NPH, 818, 829, "NPH insulin", "", " ." +106180, Frequency, 830, 849, "once or twice daily", "", " \"once or twice daily\"." +112, NumberPatientsArm, 855, 858, "259", "", " \"259\"." +92959, Duration, 865, 873, "28 weeks", "", +106178, OpenLabel, 880, 892, "open - label", "", " ." +106181, Multicenter, 895, 906, "multicenter", "", " ." +106182, DoseDescription, 915, 986, "Doses were adjusted to obtain target fasting glucose < 6 . 7 mmol / l .", "", " \"Doses were adjusted to obtain target fasting glucose < 6 . 7 mmol / l .\". \"Doses were adjusted to obtain target fasting glucose < 6 . 7 mmol / l .\"." +153, FastingPlasmaGlucose_target, 952, 984, "fasting glucose < 6 . 7 mmol / l", "", +121, Millimoles_per_litre, 976, 984, "mmol / l", "", +164, TimePoint, 990, 1005, "study end point", "", +159, Insulin, 1031, 1038, "insulin", "", +63, DoseValue, 1073, 1079, "0 . 75", "", +117, IntUnit_per_Kg, 1080, 1087, "IU / kg", "", +39, HbA1c, 1152, 1157, "HbA1c", "", " ." +181, TimePoint, 1163, 1171, "baseline", "", +182, TimePoint, 1175, 1184, "end point", "", +92948, IntentionToTreat, 1188, 1207, "intent - to - treat", "", " ." +162, Mean, 1223, 1227, "mean", "", +46, Mean, 1237, 1236, "", "", +40, HbA1c, 1257, 1262, "HbA1c", "", +183, TimePoint, 1268, 1276, "baseline", "", +184, TimePoint, 1280, 1289, "end point", "", +92960, InsulinGlargine, 1309, 1325, "insulin glargine", "", +92897, Reduction, 1336, 1342, "0 . 41", "", +92946, SdDevChangeValue, 1349, 1354, "0 . 1", "", +147, Percentage, 1355, 1356, "%", "", +34, IsophaneInsulin_NPH, 1367, 1370, "NPH", "", +50, Reduction, 1381, 1387, "0 . 59", "", " \"0 . 59\"." +92945, SdDevChangeValue, 1394, 1399, "0 . 1", "", +148, Percentage, 1400, 1401, "%", "", +41, HbA1c, 1450, 1455, "HbA1c", "", +92944, BaseLineValue, 1473, 1478, "8 . 5", "", " \"8 . 5\". \"8 . 5\"." +128, Percentage, 1479, 1480, "%", "", " ." +52, ObservedResult, 1483, 1565, "The treatments were associated with similar reductions in fasting glucose levels .", "", +42, FastingPlasmaGlucose, 1541, 1563, "fasting glucose levels", "", " ." +92950, SymptomaticHypoglycemia, 1581, 1605, "symptomatic hypoglycemia", "", " ." +92962, InsulinGlargine, 1621, 1637, "insulin glargine", "", +92911, PercentageAffected, 1649, 1655, "61 . 4", "", " \"61 . 4\"." +35, IsophaneInsulin_NPH, 1664, 1675, "NPH insulin", "", +92972, PercentageAffected, 1687, 1689, "66", "", " \"66\"." +44, NocturnalHypoglycemia, 1706, 1728, "nocturnal hypoglycemia", "", " ." +92958, InsulinGlargine, 1736, 1752, "insulin glargine", "", +55, RelativeReduction, 1774, 1776, "25", "", " \"25\"." +133, PercentageAffected, 1842, 1848, "26 . 5", "", " \"26 . 5\"." +134, PercentageAffected, 1854, 1860, "35 . 5", "", " \"35 . 5\"." +135, PvalueDiff, 1865, 1877, "P = 0 . 0136", "", " \"P = 0 . 0136\"." +28, InsulinGlargine, 1898, 1914, "insulin glargine", "", +136, WeightGain, 1938, 1949, "weight gain", "", " ." +92951, IsophaneInsulin_NPH, 1968, 1971, "NPH", "", +56, Increment, 1980, 1985, "0 . 4", "", " \"HbA1c\". \"0 . 4\"." +57, Increment, 1991, 1996, "1 . 4", "", " \"HbA1c\". \"1 . 4\"." +58, Kg, 1997, 1999, "kg", "", " ." +139, PvalueDiff, 2002, 2014, "P < 0 . 0007", "", " \"P < 0 . 0007\"." +108, ConclusionComment, 2033, 2200, "In patients with type 2 diabetes , once - daily bedtime insulin glargine is as effective as once - or twice - daily NPH in improving and maintaining glycemic control .", "", " \"In patients with type 2 diabetes , once - daily bedtime insulin glargine is as effective as once - or twice - daily NPH in improving and maintaining glycemic control .\"." +92956, Type2Diabetes, 2050, 2065, "type 2 diabetes", "", +65, Frequency, 2068, 2080, "once - daily", "", +92961, Bedtime, 2081, 2088, "bedtime", "", +29, InsulinGlargine, 2089, 2105, "insulin glargine", "", +68, Frequency, 2125, 2148, "once - or twice - daily", "", +36, IsophaneInsulin_NPH, 2149, 2152, "NPH", "", +314, ConclusionComment, 2201, 2331, "In addition , insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin .", "", " \"In addition , insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin .\"." +30, InsulinGlargine, 2215, 2231, "insulin glargine", "", +66, NocturnalHypoglycemia, 2260, 2282, "nocturnal hypoglycemia", "", +143, WeightGain, 2292, 2303, "weight gain", "", +92971, IsophaneInsulin_NPH, 2318, 2329, "NPH insulin", "", +92917, PMID, 2380, 2388, "11315821", "", " \"11315821\"." diff --git a/data/dm2 11315821_admin.n-triples b/data/dm2 11315821_admin.n-triples new file mode 100644 index 0000000..cbc1858 --- /dev/null +++ b/data/dm2 11315821_admin.n-triples @@ -0,0 +1,169 @@ +# RDF export of group: Publication + . + "Publication " . + . + "2001" . + "11315821" . + "Basal insulin therapy in type 2 diabetes : 28 - week comparison of insulin glargine ( HOE 901 ) and NPH insulin ." . + "Schwartz SL" . + "Park GD" . + "Donley DW" . + "Clark CM Jr" . + "Edwards MB" . + "Diabetes Care ." . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To determine the safety and efficacy of the long - acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone ." . + "28 - week" . + . + . + "In patients with type 2 diabetes , once - daily bedtime insulin glargine is as effective as once - or twice - daily NPH in improving and maintaining glycemic control ." . + . + . + . + . + . + . + "In addition , insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint FPG" . + . + . + . + . + . + "Endpoint SH" . + . + . + . + . + . + "Endpoint NH" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig" . + "259" . + . + . + . + . + . + . + . + "Arm nph" . + "259" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig" . + . + . + "once daily" . + . + "Intervention nph" . + . + . + "once or twice daily" . +# RDF export of group: Medication + . + "Medication ig" . + . + . + "Doses were adjusted to obtain target fasting glucose < 6 . 7 mmol / l ." . + . + . + "Medication nph" . + . + . + . + "Doses were adjusted to obtain target fasting glucose < 6 . 7 mmol / l ." . +# RDF export of group: Outcome + . + "Outcome hba1c ig" . + . + "8 . 5" . + "NPH insulin" . + . + "Outcome hba1c nph" . + . + "8 . 5" . + "0 . 59" . + . + "Outcome fpg both drugs" . + . + "bedtime" . + "The treatments were associated with similar reductions in fasting glucose levels ." . + . + "Outcome sh ig " . + . + "61 . 4" . + . + "Outcome sh nph" . + . + "66" . + . + "Outcome nh ig" . + . + "25" . + "26 . 5" . + . + "Outcome nh nph" . + . + "35 . 5" . + . + "Outcome weight ig" . + . + "HbA1c" . + "0 . 4" . + . + "Outcome weight nph" . + . + "HbA1c" . + "1 . 4" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups nh" . + "P = 0 . 0136" . + . + . + . + "DiffBetweenGroups weight" . + "P < 0 . 0007" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 11315821_akramersunderbrink.annodb b/data/dm2 11315821_akramersunderbrink.annodb new file mode 100644 index 0000000..0ff7d69 --- /dev/null +++ b/data/dm2 11315821_akramersunderbrink.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +92942, Journal, 0, 15, "Diabetes Care .", "", +571, PublicationYear, 16, 20, "2001", "", +572, Title, 48, 159, "Basal insulin therapy in type 2 diabetes : 28 - week comparison of insulin glargine ( HOE 901 ) and NPH insulin", "", +581, Type2Diabetes, 73, 88, "type 2 diabetes", "", +31689, Duration, 91, 100, "28 - week", "", +590, InsulinGlargine, 115, 131, "insulin glargine", "", +591, IsophaneInsulin_NPH, 148, 159, "NPH insulin", "", +573, Author, 162, 174, "Rosenstock J", "", +574, Author, 183, 194, "Schwartz SL", "", +575, Author, 197, 208, "Clark CM Jr", "", +576, Author, 211, 218, "Park GD", "", +577, Author, 221, 230, "Donley DW", "", +578, Author, 233, 243, "Edwards MB", "", +31690, USA, 326, 329, "USA", "", +579, ObjectiveDescription, 383, 570, "To determine the safety and efficacy of the long - acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone", "", +592, InsulinGlargine, 448, 464, "insulin glargine", "", +593, IsophaneInsulin_NPH, 479, 490, "NPH insulin", "", +587, Type2Diabetes, 508, 523, "type 2 diabetes", "", +588, Precondition, 533, 570, "previously treated with insulin alone", "", +610, Insulin, 557, 564, "insulin", "", +580, NumberPatientsCT, 614, 617, "518", "", +582, Type2Diabetes, 632, 647, "type 2 diabetes", "", +589, Precondition, 657, 735, "receiving NPH insulin with or without regular insulin for postprandial control", "", +594, IsophaneInsulin_NPH, 667, 678, "NPH insulin", "", +611, Insulin, 703, 710, "insulin", "", +584, Randomized, 741, 751, "randomized", "", +595, InsulinGlargine, 763, 779, "insulin glargine", "", +615, Frequency, 792, 802, "once daily", "", +612, NumberPatientsArm, 809, 812, "259", "", +596, IsophaneInsulin_NPH, 818, 829, "NPH insulin", "", +616, Frequency, 830, 849, "once or twice daily", "", +613, NumberPatientsArm, 855, 858, "259", "", +614, Duration, 865, 873, "28 weeks", "", +585, OpenLabel, 880, 892, "open - label", "", +586, Multicenter, 895, 906, "multicenter", "", +622, FastingPlasmaGlucose_target, 945, 984, "target fasting glucose < 6 . 7 mmol / l", "", +623, Millimoles_per_litre, 976, 984, "mmol / l", "", +39085, TimePoint, 990, 1005, "study end point", "", +617, DoseValue, 1073, 1079, "0 . 75", "", +618, IntUnit_per_Kg, 1080, 1087, "IU / kg", "", +621, HbA1c, 1152, 1157, "HbA1c", "", +31714, TimePoint, 1163, 1171, "baseline", "", +31715, TimePoint, 1175, 1184, "end point", "", +620, IntentionToTreat, 1188, 1207, "intent - to - treat", "", +9789, Mean, 1223, 1227, "mean", "", +625, Mean, 1237, 1242, "means", "", +624, HbA1c, 1257, 1262, "HbA1c", "", +31716, TimePoint, 1268, 1276, "baseline", "", +31717, TimePoint, 1280, 1289, "end point", "", +597, InsulinGlargine, 1317, 1325, "glargine", "", +31687, ChangeValue, 1334, 1342, "- 0 . 41", "", +627, SdDevChangeValue, 1349, 1354, "0 . 1", "", +31684, Percentage, 1355, 1356, "%", "", +598, IsophaneInsulin_NPH, 1367, 1370, "NPH", "", +31688, ChangeValue, 1379, 1387, "- 0 . 59", "", +629, SdDevChangeValue, 1394, 1399, "0 . 1", "", +31686, Percentage, 1400, 1401, "%", "", +632, HbA1c, 1450, 1455, "HbA1c", "", +631, BaseLineValue, 1473, 1478, "8 . 5", "", +634, Percentage, 1479, 1480, "%", "", +650, FastingPlasmaGlucose, 1541, 1563, "fasting glucose levels", "", +635, SymptomaticHypoglycemia, 1576, 1605, "mild symptomatic hypoglycemia", "", +599, InsulinGlargine, 1621, 1637, "insulin glargine", "", +636, PercentageAffected, 1649, 1655, "61 . 4", "", +31691, Percentage, 1656, 1657, "%", "", +600, IsophaneInsulin_NPH, 1664, 1675, "NPH insulin", "", +637, PercentageAffected, 1687, 1689, "66", "", +31692, Percentage, 1692, 1693, "%", "", +638, NocturnalHypoglycemia, 1706, 1728, "nocturnal hypoglycemia", "", +601, InsulinGlargine, 1736, 1752, "insulin glargine", "", +651, RelativeReduction, 1774, 1776, "25", "", +31693, Percentage, 1777, 1778, "%", "", +639, PercentageAffected, 1842, 1848, "26 . 5", "", +640, PercentageAffected, 1854, 1860, "35 . 5", "", +31694, Percentage, 1861, 1862, "%", "", +641, PvalueDiff, 1865, 1877, "P = 0 . 0136", "", +602, InsulinGlargine, 1898, 1914, "insulin glargine", "", +642, WeightGain, 1938, 1949, "weight gain", "", +603, IsophaneInsulin_NPH, 1968, 1971, "NPH", "", +643, Increment, 1980, 1985, "0 . 4", "", +644, Increment, 1991, 1996, "1 . 4", "", +652, Kg, 1997, 1999, "kg", "", +645, PvalueDiff, 2002, 2014, "P < 0 . 0007", "", +609, ConclusionComment, 2033, 2200, "In patients with type 2 diabetes , once - daily bedtime insulin glargine is as effective as once - or twice - daily NPH in improving and maintaining glycemic control .", "", +604, Type2Diabetes, 2050, 2065, "type 2 diabetes", "", +646, Frequency, 2068, 2080, "once - daily", "", +605, InsulinGlargine, 2089, 2105, "insulin glargine", "", +647, Frequency, 2125, 2148, "once - or twice - daily", "", +606, IsophaneInsulin_NPH, 2149, 2152, "NPH", "", +31695, ConclusionComment, 2201, 2331, "In addition , insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin .", "", +607, InsulinGlargine, 2215, 2231, "insulin glargine", "", +648, NocturnalHypoglycemia, 2260, 2282, "nocturnal hypoglycemia", "", +649, WeightGain, 2292, 2303, "weight gain", "", +608, IsophaneInsulin_NPH, 2318, 2329, "NPH insulin", "", +583, PMID, 2380, 2388, "11315821", "", diff --git a/data/dm2 11315821_akramersunderbrink.n-triples b/data/dm2 11315821_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 11315821_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 11315821_export.csv b/data/dm2 11315821_export.csv new file mode 100644 index 0000000..c496d5e --- /dev/null +++ b/data/dm2 11315821_export.csv @@ -0,0 +1,504 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +378, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +378, 1, 2, 2, 9, 13, 9, 13, "Care" +378, 1, 3, 3, 14, 15, 14, 15, "." +378, 2, 1, 4, 0, 4, 16, 20, "2001" +378, 2, 2, 5, 5, 8, 21, 24, "Apr" +378, 2, 3, 6, 9, 10, 25, 26, ";" +378, 2, 4, 7, 11, 13, 27, 29, "24" +378, 2, 5, 8, 14, 15, 30, 31, "(" +378, 2, 6, 9, 16, 17, 32, 33, "4" +378, 2, 7, 10, 18, 19, 34, 35, ")" +378, 2, 8, 11, 20, 21, 36, 37, ":" +378, 2, 9, 12, 22, 25, 38, 41, "631" +378, 2, 10, 13, 26, 27, 42, 43, "-" +378, 2, 11, 14, 28, 29, 44, 45, "6" +378, 2, 12, 15, 30, 31, 46, 47, "." +378, 3, 1, 16, 0, 5, 48, 53, "Basal" +378, 3, 2, 17, 6, 13, 54, 61, "insulin" +378, 3, 3, 18, 14, 21, 62, 69, "therapy" +378, 3, 4, 19, 22, 24, 70, 72, "in" +378, 3, 5, 20, 25, 29, 73, 77, "type" +378, 3, 6, 21, 30, 31, 78, 79, "2" +378, 3, 7, 22, 32, 40, 80, 88, "diabetes" +378, 3, 8, 23, 41, 42, 89, 90, ":" +378, 3, 9, 24, 43, 45, 91, 93, "28" +378, 3, 10, 25, 46, 47, 94, 95, "-" +378, 3, 11, 26, 48, 52, 96, 100, "week" +378, 3, 12, 27, 53, 63, 101, 111, "comparison" +378, 3, 13, 28, 64, 66, 112, 114, "of" +378, 3, 14, 29, 67, 74, 115, 122, "insulin" +378, 3, 15, 30, 75, 83, 123, 131, "glargine" +378, 3, 16, 31, 84, 85, 132, 133, "(" +378, 3, 17, 32, 86, 89, 134, 137, "HOE" +378, 3, 18, 33, 90, 93, 138, 141, "901" +378, 3, 19, 34, 94, 95, 142, 143, ")" +378, 3, 20, 35, 96, 99, 144, 147, "and" +378, 3, 21, 36, 100, 103, 148, 151, "NPH" +378, 3, 22, 37, 104, 111, 152, 159, "insulin" +378, 3, 23, 38, 112, 113, 160, 161, "." +378, 4, 1, 39, 0, 10, 162, 172, "Rosenstock" +378, 4, 2, 40, 11, 12, 173, 174, "J" +378, 4, 3, 41, 13, 14, 175, 176, "(" +378, 4, 4, 42, 15, 16, 177, 178, "1" +378, 4, 5, 43, 17, 18, 179, 180, ")" +378, 4, 6, 44, 19, 20, 181, 182, "," +378, 4, 7, 45, 21, 29, 183, 191, "Schwartz" +378, 4, 8, 46, 30, 32, 192, 194, "SL" +378, 4, 9, 47, 33, 34, 195, 196, "," +378, 4, 10, 48, 35, 40, 197, 202, "Clark" +378, 4, 11, 49, 41, 43, 203, 205, "CM" +378, 4, 12, 50, 44, 46, 206, 208, "Jr" +378, 4, 13, 51, 47, 48, 209, 210, "," +378, 4, 14, 52, 49, 53, 211, 215, "Park" +378, 4, 15, 53, 54, 56, 216, 218, "GD" +378, 4, 16, 54, 57, 58, 219, 220, "," +378, 4, 17, 55, 59, 65, 221, 227, "Donley" +378, 4, 18, 56, 66, 68, 228, 230, "DW" +378, 4, 19, 57, 69, 70, 231, 232, "," +378, 4, 20, 58, 71, 78, 233, 240, "Edwards" +378, 4, 21, 59, 79, 81, 241, 243, "MB" +378, 4, 22, 60, 82, 83, 244, 245, "." +378, 5, 1, 61, 0, 6, 246, 252, "Author" +378, 5, 2, 62, 7, 18, 253, 264, "information" +378, 5, 3, 63, 19, 20, 265, 266, ":" +378, 5, 4, 64, 21, 22, 267, 268, "(" +378, 5, 5, 65, 23, 24, 269, 270, "1" +378, 5, 6, 66, 25, 26, 271, 272, ")" +378, 5, 7, 67, 27, 33, 273, 279, "Dallas" +378, 5, 8, 68, 34, 42, 280, 288, "Diabetes" +378, 5, 9, 69, 43, 46, 289, 292, "and" +378, 5, 10, 70, 47, 56, 293, 302, "Endocrine" +378, 5, 11, 71, 57, 63, 303, 309, "Center" +378, 5, 12, 72, 64, 65, 310, 311, "," +378, 5, 13, 73, 66, 71, 312, 317, "Texas" +378, 5, 14, 74, 72, 77, 318, 323, "75230" +378, 5, 15, 75, 78, 79, 324, 325, "," +378, 5, 16, 76, 80, 83, 326, 329, "USA" +378, 5, 17, 77, 84, 85, 330, 331, "." +378, 6, 1, 78, 0, 15, 332, 347, "juliorosenstock" +378, 6, 2, 79, 16, 17, 348, 349, "@" +378, 6, 3, 80, 18, 32, 350, 364, "dallasdiabetes" +378, 6, 4, 81, 33, 34, 365, 366, "." +378, 6, 5, 82, 35, 38, 367, 370, "com" +378, 6, 6, 83, 39, 48, 371, 380, "OBJECTIVE" +378, 6, 7, 84, 49, 50, 381, 382, ":" +378, 6, 8, 85, 51, 53, 383, 385, "To" +378, 6, 9, 86, 54, 63, 386, 395, "determine" +378, 6, 10, 87, 64, 67, 396, 399, "the" +378, 6, 11, 88, 68, 74, 400, 406, "safety" +378, 6, 12, 89, 75, 78, 407, 410, "and" +378, 6, 13, 90, 79, 87, 411, 419, "efficacy" +378, 6, 14, 91, 88, 90, 420, 422, "of" +378, 6, 15, 92, 91, 94, 423, 426, "the" +378, 6, 16, 93, 95, 99, 427, 431, "long" +378, 6, 17, 94, 100, 101, 432, 433, "-" +378, 6, 18, 95, 102, 108, 434, 440, "acting" +378, 6, 19, 96, 109, 115, 441, 447, "analog" +378, 6, 20, 97, 116, 123, 448, 455, "insulin" +378, 6, 21, 98, 124, 132, 456, 464, "glargine" +378, 6, 22, 99, 133, 141, 465, 473, "compared" +378, 6, 23, 100, 142, 146, 474, 478, "with" +378, 6, 24, 101, 147, 150, 479, 482, "NPH" +378, 6, 25, 102, 151, 158, 483, 490, "insulin" +378, 6, 26, 103, 159, 161, 491, 493, "in" +378, 6, 27, 104, 162, 170, 494, 502, "patients" +378, 6, 28, 105, 171, 175, 503, 507, "with" +378, 6, 29, 106, 176, 180, 508, 512, "type" +378, 6, 30, 107, 181, 182, 513, 514, "2" +378, 6, 31, 108, 183, 191, 515, 523, "diabetes" +378, 6, 32, 109, 192, 195, 524, 527, "who" +378, 6, 33, 110, 196, 200, 528, 532, "were" +378, 6, 34, 111, 201, 211, 533, 543, "previously" +378, 6, 35, 112, 212, 219, 544, 551, "treated" +378, 6, 36, 113, 220, 224, 552, 556, "with" +378, 6, 37, 114, 225, 232, 557, 564, "insulin" +378, 6, 38, 115, 233, 238, 565, 570, "alone" +378, 6, 39, 116, 239, 240, 571, 572, "." +378, 7, 1, 117, 0, 8, 573, 581, "RESEARCH" +378, 7, 2, 118, 9, 15, 582, 588, "DESIGN" +378, 7, 3, 119, 16, 19, 589, 592, "AND" +378, 7, 4, 120, 20, 27, 593, 600, "METHODS" +378, 7, 5, 121, 28, 29, 601, 602, ":" +378, 7, 6, 122, 30, 31, 603, 604, "A" +378, 7, 7, 123, 32, 37, 605, 610, "total" +378, 7, 8, 124, 38, 40, 611, 613, "of" +378, 7, 9, 125, 41, 44, 614, 617, "518" +378, 7, 10, 126, 45, 53, 618, 626, "subjects" +378, 7, 11, 127, 54, 58, 627, 631, "with" +378, 7, 12, 128, 59, 63, 632, 636, "type" +378, 7, 13, 129, 64, 65, 637, 638, "2" +378, 7, 14, 130, 66, 74, 639, 647, "diabetes" +378, 7, 15, 131, 75, 78, 648, 651, "who" +378, 7, 16, 132, 79, 83, 652, 656, "were" +378, 7, 17, 133, 84, 93, 657, 666, "receiving" +378, 7, 18, 134, 94, 97, 667, 670, "NPH" +378, 7, 19, 135, 98, 105, 671, 678, "insulin" +378, 7, 20, 136, 106, 110, 679, 683, "with" +378, 7, 21, 137, 111, 113, 684, 686, "or" +378, 7, 22, 138, 114, 121, 687, 694, "without" +378, 7, 23, 139, 122, 129, 695, 702, "regular" +378, 7, 24, 140, 130, 137, 703, 710, "insulin" +378, 7, 25, 141, 138, 141, 711, 714, "for" +378, 7, 26, 142, 142, 154, 715, 727, "postprandial" +378, 7, 27, 143, 155, 162, 728, 735, "control" +378, 7, 28, 144, 163, 167, 736, 740, "were" +378, 7, 29, 145, 168, 178, 741, 751, "randomized" +378, 7, 30, 146, 179, 181, 752, 754, "to" +378, 7, 31, 147, 182, 189, 755, 762, "receive" +378, 7, 32, 148, 190, 197, 763, 770, "insulin" +378, 7, 33, 149, 198, 206, 771, 779, "glargine" +378, 7, 34, 150, 207, 208, 780, 781, "(" +378, 7, 35, 151, 209, 212, 782, 785, "HOE" +378, 7, 36, 152, 213, 216, 786, 789, "901" +378, 7, 37, 153, 217, 218, 790, 791, ")" +378, 7, 38, 154, 219, 223, 792, 796, "once" +378, 7, 39, 155, 224, 229, 797, 802, "daily" +378, 7, 40, 156, 230, 231, 803, 804, "(" +378, 7, 41, 157, 232, 233, 805, 806, "n" +378, 7, 42, 158, 234, 235, 807, 808, "=" +378, 7, 43, 159, 236, 239, 809, 812, "259" +378, 7, 44, 160, 240, 241, 813, 814, ")" +378, 7, 45, 161, 242, 244, 815, 817, "or" +378, 7, 46, 162, 245, 248, 818, 821, "NPH" +378, 7, 47, 163, 249, 256, 822, 829, "insulin" +378, 7, 48, 164, 257, 261, 830, 834, "once" +378, 7, 49, 165, 262, 264, 835, 837, "or" +378, 7, 50, 166, 265, 270, 838, 843, "twice" +378, 7, 51, 167, 271, 276, 844, 849, "daily" +378, 7, 52, 168, 277, 279, 850, 852, "in" +378, 7, 53, 169, 280, 281, 853, 854, "=" +378, 7, 54, 170, 282, 285, 855, 858, "259" +378, 7, 55, 171, 286, 287, 859, 860, ")" +378, 7, 56, 172, 288, 291, 861, 864, "for" +378, 7, 57, 173, 292, 294, 865, 867, "28" +378, 7, 58, 174, 295, 300, 868, 873, "weeks" +378, 7, 59, 175, 301, 303, 874, 876, "in" +378, 7, 60, 176, 304, 306, 877, 879, "an" +378, 7, 61, 177, 307, 311, 880, 884, "open" +378, 7, 62, 178, 312, 313, 885, 886, "-" +378, 7, 63, 179, 314, 319, 887, 892, "label" +378, 7, 64, 180, 320, 321, 893, 894, "," +378, 7, 65, 181, 322, 333, 895, 906, "multicenter" +378, 7, 66, 182, 334, 339, 907, 912, "trial" +378, 7, 67, 183, 340, 341, 913, 914, "." +378, 8, 1, 184, 0, 5, 915, 920, "Doses" +378, 8, 2, 185, 6, 10, 921, 925, "were" +378, 8, 3, 186, 11, 19, 926, 934, "adjusted" +378, 8, 4, 187, 20, 22, 935, 937, "to" +378, 8, 5, 188, 23, 29, 938, 944, "obtain" +378, 8, 6, 189, 30, 36, 945, 951, "target" +378, 8, 7, 190, 37, 44, 952, 959, "fasting" +378, 8, 8, 191, 45, 52, 960, 967, "glucose" +378, 8, 9, 192, 53, 54, 968, 969, "<" +378, 8, 10, 193, 55, 56, 970, 971, "6" +378, 8, 11, 194, 57, 58, 972, 973, "." +378, 8, 12, 195, 59, 60, 974, 975, "7" +378, 8, 13, 196, 61, 65, 976, 980, "mmol" +378, 8, 14, 197, 66, 67, 981, 982, "/" +378, 8, 15, 198, 68, 69, 983, 984, "l" +378, 8, 16, 199, 70, 71, 985, 986, "." +378, 9, 1, 200, 0, 2, 987, 989, "At" +378, 9, 2, 201, 3, 8, 990, 995, "study" +378, 9, 3, 202, 9, 12, 996, 999, "end" +378, 9, 4, 203, 13, 18, 1000, 1005, "point" +378, 9, 5, 204, 19, 20, 1006, 1007, "," +378, 9, 6, 205, 21, 24, 1008, 1011, "the" +378, 9, 7, 206, 25, 31, 1012, 1018, "median" +378, 9, 8, 207, 32, 37, 1019, 1024, "total" +378, 9, 9, 208, 38, 43, 1025, 1030, "daily" +378, 9, 10, 209, 44, 51, 1031, 1038, "insulin" +378, 9, 11, 210, 52, 56, 1039, 1043, "dose" +378, 9, 12, 211, 57, 59, 1044, 1046, "in" +378, 9, 13, 212, 60, 64, 1047, 1051, "both" +378, 9, 14, 213, 65, 74, 1052, 1061, "treatment" +378, 9, 15, 214, 75, 81, 1062, 1068, "groups" +378, 9, 16, 215, 82, 85, 1069, 1072, "was" +378, 9, 17, 216, 86, 87, 1073, 1074, "0" +378, 9, 18, 217, 88, 89, 1075, 1076, "." +378, 9, 19, 218, 90, 92, 1077, 1079, "75" +378, 9, 20, 219, 93, 95, 1080, 1082, "IU" +378, 9, 21, 220, 96, 97, 1083, 1084, "/" +378, 9, 22, 221, 98, 100, 1085, 1087, "kg" +378, 9, 23, 222, 101, 102, 1088, 1089, "." +378, 10, 1, 223, 0, 7, 1090, 1097, "RESULTS" +378, 10, 2, 224, 8, 9, 1098, 1099, ":" +378, 10, 3, 225, 10, 13, 1100, 1103, "The" +378, 10, 4, 226, 14, 23, 1104, 1113, "treatment" +378, 10, 5, 227, 24, 30, 1114, 1120, "groups" +378, 10, 6, 228, 31, 37, 1121, 1127, "showed" +378, 10, 7, 229, 38, 45, 1128, 1135, "similar" +378, 10, 8, 230, 46, 58, 1136, 1148, "improvements" +378, 10, 9, 231, 59, 61, 1149, 1151, "in" +378, 10, 10, 232, 62, 67, 1152, 1157, "HbA1c" +378, 10, 11, 233, 68, 72, 1158, 1162, "from" +378, 10, 12, 234, 73, 81, 1163, 1171, "baseline" +378, 10, 13, 235, 82, 84, 1172, 1174, "to" +378, 10, 14, 236, 85, 88, 1175, 1178, "end" +378, 10, 15, 237, 89, 94, 1179, 1184, "point" +378, 10, 16, 238, 95, 97, 1185, 1187, "on" +378, 10, 17, 239, 98, 104, 1188, 1194, "intent" +378, 10, 18, 240, 105, 106, 1195, 1196, "-" +378, 10, 19, 241, 107, 109, 1197, 1199, "to" +378, 10, 20, 242, 110, 111, 1200, 1201, "-" +378, 10, 21, 243, 112, 117, 1202, 1207, "treat" +378, 10, 22, 244, 118, 126, 1208, 1216, "analysis" +378, 10, 23, 245, 127, 128, 1217, 1218, "." +378, 11, 1, 246, 0, 3, 1219, 1222, "The" +378, 11, 2, 247, 4, 8, 1223, 1227, "mean" +378, 11, 3, 248, 9, 15, 1228, 1234, "change" +378, 11, 4, 249, 16, 17, 1235, 1236, "(" +378, 11, 5, 250, 18, 23, 1237, 1242, "means" +378, 11, 6, 251, 24, 25, 1243, 1244, "+" +378, 11, 7, 252, 26, 27, 1245, 1246, "/" +378, 11, 8, 253, 28, 29, 1247, 1248, "-" +378, 11, 9, 254, 30, 32, 1249, 1251, "SD" +378, 11, 10, 255, 33, 34, 1252, 1253, ")" +378, 11, 11, 256, 35, 37, 1254, 1256, "in" +378, 11, 12, 257, 38, 43, 1257, 1262, "HbA1c" +378, 11, 13, 258, 44, 48, 1263, 1267, "from" +378, 11, 14, 259, 49, 57, 1268, 1276, "baseline" +378, 11, 15, 260, 58, 60, 1277, 1279, "to" +378, 11, 16, 261, 61, 64, 1280, 1283, "end" +378, 11, 17, 262, 65, 70, 1284, 1289, "point" +378, 11, 18, 263, 71, 74, 1290, 1293, "was" +378, 11, 19, 264, 75, 82, 1294, 1301, "similar" +378, 11, 20, 265, 83, 85, 1302, 1304, "in" +378, 11, 21, 266, 86, 89, 1305, 1308, "the" +378, 11, 22, 267, 90, 97, 1309, 1316, "insulin" +378, 11, 23, 268, 98, 106, 1317, 1325, "glargine" +378, 11, 24, 269, 107, 112, 1326, 1331, "group" +378, 11, 25, 270, 113, 114, 1332, 1333, "(" +378, 11, 26, 271, 115, 116, 1334, 1335, "-" +378, 11, 27, 272, 117, 118, 1336, 1337, "0" +378, 11, 28, 273, 119, 120, 1338, 1339, "." +378, 11, 29, 274, 121, 123, 1340, 1342, "41" +378, 11, 30, 275, 124, 125, 1343, 1344, "+" +378, 11, 31, 276, 126, 127, 1345, 1346, "/" +378, 11, 32, 277, 128, 129, 1347, 1348, "-" +378, 11, 33, 278, 130, 131, 1349, 1350, "0" +378, 11, 34, 279, 132, 133, 1351, 1352, "." +378, 11, 35, 280, 134, 135, 1353, 1354, "1" +378, 11, 36, 281, 136, 137, 1355, 1356, "%" +378, 11, 37, 282, 138, 139, 1357, 1358, ")" +378, 11, 38, 283, 140, 143, 1359, 1362, "and" +378, 11, 39, 284, 144, 147, 1363, 1366, "the" +378, 11, 40, 285, 148, 151, 1367, 1370, "NPH" +378, 11, 41, 286, 152, 157, 1371, 1376, "group" +378, 11, 42, 287, 158, 159, 1377, 1378, "(" +378, 11, 43, 288, 160, 161, 1379, 1380, "-" +378, 11, 44, 289, 162, 163, 1381, 1382, "0" +378, 11, 45, 290, 164, 165, 1383, 1384, "." +378, 11, 46, 291, 166, 168, 1385, 1387, "59" +378, 11, 47, 292, 169, 170, 1388, 1389, "+" +378, 11, 48, 293, 171, 172, 1390, 1391, "/" +378, 11, 49, 294, 173, 174, 1392, 1393, "-" +378, 11, 50, 295, 175, 176, 1394, 1395, "0" +378, 11, 51, 296, 177, 178, 1396, 1397, "." +378, 11, 52, 297, 179, 180, 1398, 1399, "1" +378, 11, 53, 298, 181, 182, 1400, 1401, "%" +378, 11, 54, 299, 183, 184, 1402, 1403, ")" +378, 11, 55, 300, 185, 190, 1404, 1409, "after" +378, 11, 56, 301, 191, 199, 1410, 1418, "patients" +378, 11, 57, 302, 200, 205, 1419, 1424, "began" +378, 11, 58, 303, 206, 210, 1425, 1429, "with" +378, 11, 59, 304, 211, 213, 1430, 1432, "an" +378, 11, 60, 305, 214, 221, 1433, 1440, "average" +378, 11, 61, 306, 222, 230, 1441, 1449, "baseline" +378, 11, 62, 307, 231, 236, 1450, 1455, "HbA1c" +378, 11, 63, 308, 237, 239, 1456, 1458, "of" +378, 11, 64, 309, 240, 253, 1459, 1472, "approximately" +378, 11, 65, 310, 254, 255, 1473, 1474, "8" +378, 11, 66, 311, 256, 257, 1475, 1476, "." +378, 11, 67, 312, 258, 259, 1477, 1478, "5" +378, 11, 68, 313, 260, 261, 1479, 1480, "%" +378, 11, 69, 314, 262, 263, 1481, 1482, "." +378, 12, 1, 315, 0, 3, 1483, 1486, "The" +378, 12, 2, 316, 4, 14, 1487, 1497, "treatments" +378, 12, 3, 317, 15, 19, 1498, 1502, "were" +378, 12, 4, 318, 20, 30, 1503, 1513, "associated" +378, 12, 5, 319, 31, 35, 1514, 1518, "with" +378, 12, 6, 320, 36, 43, 1519, 1526, "similar" +378, 12, 7, 321, 44, 54, 1527, 1537, "reductions" +378, 12, 8, 322, 55, 57, 1538, 1540, "in" +378, 12, 9, 323, 58, 65, 1541, 1548, "fasting" +378, 12, 10, 324, 66, 73, 1549, 1556, "glucose" +378, 12, 11, 325, 74, 80, 1557, 1563, "levels" +378, 12, 12, 326, 81, 82, 1564, 1565, "." +378, 13, 1, 327, 0, 7, 1566, 1573, "Overall" +378, 13, 2, 328, 8, 9, 1574, 1575, "," +378, 13, 3, 329, 10, 14, 1576, 1580, "mild" +378, 13, 4, 330, 15, 26, 1581, 1592, "symptomatic" +378, 13, 5, 331, 27, 39, 1593, 1605, "hypoglycemia" +378, 13, 6, 332, 40, 43, 1606, 1609, "was" +378, 13, 7, 333, 44, 51, 1610, 1617, "similar" +378, 13, 8, 334, 52, 54, 1618, 1620, "in" +378, 13, 9, 335, 55, 62, 1621, 1628, "insulin" +378, 13, 10, 336, 63, 71, 1629, 1637, "glargine" +378, 13, 11, 337, 72, 80, 1638, 1646, "subjects" +378, 13, 12, 338, 81, 82, 1647, 1648, "(" +378, 13, 13, 339, 83, 85, 1649, 1651, "61" +378, 13, 14, 340, 86, 87, 1652, 1653, "." +378, 13, 15, 341, 88, 89, 1654, 1655, "4" +378, 13, 16, 342, 90, 91, 1656, 1657, "%" +378, 13, 17, 343, 92, 93, 1658, 1659, ")" +378, 13, 18, 344, 94, 97, 1660, 1663, "and" +378, 13, 19, 345, 98, 101, 1664, 1667, "NPH" +378, 13, 20, 346, 102, 109, 1668, 1675, "insulin" +378, 13, 21, 347, 110, 118, 1676, 1684, "subjects" +378, 13, 22, 348, 119, 120, 1685, 1686, "(" +378, 13, 23, 349, 121, 123, 1687, 1689, "66" +378, 13, 24, 350, 124, 125, 1690, 1691, "." +378, 13, 25, 351, 126, 127, 1692, 1693, "%" +378, 13, 26, 352, 128, 129, 1694, 1695, ")" +378, 13, 27, 353, 130, 137, 1696, 1703, "However" +378, 13, 28, 354, 138, 139, 1704, 1705, "," +378, 13, 29, 355, 140, 149, 1706, 1715, "nocturnal" +378, 13, 30, 356, 150, 162, 1716, 1728, "hypoglycemia" +378, 13, 31, 357, 163, 165, 1729, 1731, "in" +378, 13, 32, 358, 166, 169, 1732, 1735, "the" +378, 13, 33, 359, 170, 177, 1736, 1743, "insulin" +378, 13, 34, 360, 178, 186, 1744, 1752, "glargine" +378, 13, 35, 361, 187, 192, 1753, 1758, "group" +378, 13, 36, 362, 193, 196, 1759, 1762, "was" +378, 13, 37, 363, 197, 204, 1763, 1770, "reduced" +378, 13, 38, 364, 205, 207, 1771, 1773, "by" +378, 13, 39, 365, 208, 210, 1774, 1776, "25" +378, 13, 40, 366, 211, 212, 1777, 1778, "%" +378, 13, 41, 367, 213, 219, 1779, 1785, "during" +378, 13, 42, 368, 220, 223, 1786, 1789, "the" +378, 13, 43, 369, 224, 233, 1790, 1799, "treatment" +378, 13, 44, 370, 234, 240, 1800, 1806, "period" +378, 13, 45, 371, 241, 246, 1807, 1812, "after" +378, 13, 46, 372, 247, 250, 1813, 1816, "the" +378, 13, 47, 373, 251, 255, 1817, 1821, "dose" +378, 13, 48, 374, 256, 257, 1822, 1823, "-" +378, 13, 49, 375, 258, 267, 1824, 1833, "titration" +378, 13, 50, 376, 268, 273, 1834, 1839, "phase" +378, 13, 51, 377, 274, 275, 1840, 1841, "(" +378, 13, 52, 378, 276, 278, 1842, 1844, "26" +378, 13, 53, 379, 279, 280, 1845, 1846, "." +378, 13, 54, 380, 281, 282, 1847, 1848, "5" +378, 13, 55, 381, 283, 285, 1849, 1851, "vs" +378, 13, 56, 382, 286, 287, 1852, 1853, "." +378, 13, 57, 383, 288, 290, 1854, 1856, "35" +378, 13, 58, 384, 291, 292, 1857, 1858, "." +378, 13, 59, 385, 293, 294, 1859, 1860, "5" +378, 13, 60, 386, 295, 296, 1861, 1862, "%" +378, 13, 61, 387, 297, 298, 1863, 1864, "," +378, 13, 62, 388, 299, 300, 1865, 1866, "P" +378, 13, 63, 389, 301, 302, 1867, 1868, "=" +378, 13, 64, 390, 303, 304, 1869, 1870, "0" +378, 13, 65, 391, 305, 306, 1871, 1872, "." +378, 13, 66, 392, 307, 311, 1873, 1877, "0136" +378, 13, 67, 393, 312, 313, 1878, 1879, ")" +378, 13, 68, 394, 314, 315, 1880, 1881, "." +378, 14, 1, 395, 0, 8, 1882, 1890, "Subjects" +378, 14, 2, 396, 9, 11, 1891, 1893, "in" +378, 14, 3, 397, 12, 15, 1894, 1897, "the" +378, 14, 4, 398, 16, 23, 1898, 1905, "insulin" +378, 14, 5, 399, 24, 32, 1906, 1914, "glargine" +378, 14, 6, 400, 33, 38, 1915, 1920, "group" +378, 14, 7, 401, 39, 50, 1921, 1932, "experienced" +378, 14, 8, 402, 51, 55, 1933, 1937, "less" +378, 14, 9, 403, 56, 62, 1938, 1944, "weight" +378, 14, 10, 404, 63, 67, 1945, 1949, "gain" +378, 14, 11, 405, 68, 72, 1950, 1954, "than" +378, 14, 12, 406, 73, 78, 1955, 1960, "those" +378, 14, 13, 407, 79, 81, 1961, 1963, "in" +378, 14, 14, 408, 82, 85, 1964, 1967, "the" +378, 14, 15, 409, 86, 89, 1968, 1971, "NPH" +378, 14, 16, 410, 90, 95, 1972, 1977, "group" +378, 14, 17, 411, 96, 97, 1978, 1979, "(" +378, 14, 18, 412, 98, 99, 1980, 1981, "0" +378, 14, 19, 413, 100, 101, 1982, 1983, "." +378, 14, 20, 414, 102, 103, 1984, 1985, "4" +378, 14, 21, 415, 104, 106, 1986, 1988, "vs" +378, 14, 22, 416, 107, 108, 1989, 1990, "." +378, 14, 23, 417, 109, 110, 1991, 1992, "1" +378, 14, 24, 418, 111, 112, 1993, 1994, "." +378, 14, 25, 419, 113, 114, 1995, 1996, "4" +378, 14, 26, 420, 115, 117, 1997, 1999, "kg" +378, 14, 27, 421, 118, 119, 2000, 2001, "," +378, 14, 28, 422, 120, 121, 2002, 2003, "P" +378, 14, 29, 423, 122, 123, 2004, 2005, "<" +378, 14, 30, 424, 124, 125, 2006, 2007, "0" +378, 14, 31, 425, 126, 127, 2008, 2009, "." +378, 14, 32, 426, 128, 132, 2010, 2014, "0007" +378, 14, 33, 427, 133, 134, 2015, 2016, ")" +378, 14, 34, 428, 135, 136, 2017, 2018, "." +378, 15, 1, 429, 0, 11, 2019, 2030, "CONCLUSIONS" +378, 15, 2, 430, 12, 13, 2031, 2032, ":" +378, 15, 3, 431, 14, 16, 2033, 2035, "In" +378, 15, 4, 432, 17, 25, 2036, 2044, "patients" +378, 15, 5, 433, 26, 30, 2045, 2049, "with" +378, 15, 6, 434, 31, 35, 2050, 2054, "type" +378, 15, 7, 435, 36, 37, 2055, 2056, "2" +378, 15, 8, 436, 38, 46, 2057, 2065, "diabetes" +378, 15, 9, 437, 47, 48, 2066, 2067, "," +378, 15, 10, 438, 49, 53, 2068, 2072, "once" +378, 15, 11, 439, 54, 55, 2073, 2074, "-" +378, 15, 12, 440, 56, 61, 2075, 2080, "daily" +378, 15, 13, 441, 62, 69, 2081, 2088, "bedtime" +378, 15, 14, 442, 70, 77, 2089, 2096, "insulin" +378, 15, 15, 443, 78, 86, 2097, 2105, "glargine" +378, 15, 16, 444, 87, 89, 2106, 2108, "is" +378, 15, 17, 445, 90, 92, 2109, 2111, "as" +378, 15, 18, 446, 93, 102, 2112, 2121, "effective" +378, 15, 19, 447, 103, 105, 2122, 2124, "as" +378, 15, 20, 448, 106, 110, 2125, 2129, "once" +378, 15, 21, 449, 111, 112, 2130, 2131, "-" +378, 15, 22, 450, 113, 115, 2132, 2134, "or" +378, 15, 23, 451, 116, 121, 2135, 2140, "twice" +378, 15, 24, 452, 122, 123, 2141, 2142, "-" +378, 15, 25, 453, 124, 129, 2143, 2148, "daily" +378, 15, 26, 454, 130, 133, 2149, 2152, "NPH" +378, 15, 27, 455, 134, 136, 2153, 2155, "in" +378, 15, 28, 456, 137, 146, 2156, 2165, "improving" +378, 15, 29, 457, 147, 150, 2166, 2169, "and" +378, 15, 30, 458, 151, 162, 2170, 2181, "maintaining" +378, 15, 31, 459, 163, 171, 2182, 2190, "glycemic" +378, 15, 32, 460, 172, 179, 2191, 2198, "control" +378, 15, 33, 461, 180, 181, 2199, 2200, "." +378, 16, 1, 462, 0, 2, 2201, 2203, "In" +378, 16, 2, 463, 3, 11, 2204, 2212, "addition" +378, 16, 3, 464, 12, 13, 2213, 2214, "," +378, 16, 4, 465, 14, 21, 2215, 2222, "insulin" +378, 16, 5, 466, 22, 30, 2223, 2231, "glargine" +378, 16, 6, 467, 31, 42, 2232, 2243, "deonstrates" +378, 16, 7, 468, 43, 44, 2244, 2245, "a" +378, 16, 8, 469, 45, 50, 2246, 2251, "lower" +378, 16, 9, 470, 51, 55, 2252, 2256, "risk" +378, 16, 10, 471, 56, 58, 2257, 2259, "of" +378, 16, 11, 472, 59, 68, 2260, 2269, "nocturnal" +378, 16, 12, 473, 69, 81, 2270, 2282, "hypoglycemia" +378, 16, 13, 474, 82, 85, 2283, 2286, "and" +378, 16, 14, 475, 86, 90, 2287, 2291, "less" +378, 16, 15, 476, 91, 97, 2292, 2298, "weight" +378, 16, 16, 477, 98, 102, 2299, 2303, "gain" +378, 16, 17, 478, 103, 111, 2304, 2312, "compared" +378, 16, 18, 479, 112, 116, 2313, 2317, "with" +378, 16, 19, 480, 117, 120, 2318, 2321, "NPH" +378, 16, 20, 481, 121, 128, 2322, 2329, "insulin" +378, 16, 21, 482, 129, 130, 2330, 2331, "." +378, 17, 1, 483, 0, 3, 2332, 2335, "DOI" +378, 17, 2, 484, 4, 5, 2336, 2337, ":" +378, 17, 3, 485, 6, 8, 2338, 2340, "10" +378, 17, 4, 486, 9, 10, 2341, 2342, "." +378, 17, 5, 487, 11, 15, 2343, 2347, "2337" +378, 17, 6, 488, 16, 17, 2348, 2349, "/" +378, 17, 7, 489, 18, 25, 2350, 2357, "diacare" +378, 17, 8, 490, 26, 27, 2358, 2359, "." +378, 17, 9, 491, 28, 30, 2360, 2362, "24" +378, 17, 10, 492, 31, 32, 2363, 2364, "." +378, 17, 11, 493, 33, 34, 2365, 2366, "4" +378, 17, 12, 494, 35, 36, 2367, 2368, "." +378, 17, 13, 495, 37, 40, 2369, 2372, "631" +378, 17, 14, 496, 41, 45, 2373, 2377, "PMID" +378, 17, 15, 497, 46, 47, 2378, 2379, ":" +378, 17, 16, 498, 48, 56, 2380, 2388, "11315821" +378, 17, 17, 499, 57, 58, 2389, 2390, "[" +378, 17, 18, 500, 59, 66, 2391, 2398, "Indexed" +378, 17, 19, 501, 67, 70, 2399, 2402, "for" +378, 17, 20, 502, 71, 78, 2403, 2410, "MEDLINE" +378, 17, 21, 503, 79, 80, 2411, 2412, "]" diff --git a/data/dm2 11315821_kwoodley.annodb b/data/dm2 11315821_kwoodley.annodb new file mode 100644 index 0000000..48ffddd --- /dev/null +++ b/data/dm2 11315821_kwoodley.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31451, Journal, 0, 15, "Diabetes Care .", "", +92936, PublicationYear, 16, 20, "2001", "", +92926, Title, 48, 161, "Basal insulin therapy in type 2 diabetes : 28 - week comparison of insulin glargine ( HOE 901 ) and NPH insulin .", "", +24, Duration, 91, 100, "28 - week", "", +32, InsulinGlargine, 115, 131, "insulin glargine", "", +33, InsulinGlargine, 134, 141, "HOE 901", "", +43, IsophaneInsulin_NPH, 148, 159, "NPH insulin", "", +3, Author, 162, 174, "Rosenstock J", "", +4, Author, 183, 194, "Schwartz SL", "", +5, Author, 197, 208, "Clark CM Jr", "", +91711, Author, 211, 218, "Park GD", "", +91712, Author, 221, 230, "Donley DW", "", +91713, Author, 233, 243, "Edwards MB", "", +92918, Country, 326, 329, "USA", "", +31452, ObjectiveDescription, 383, 572, "To determine the safety and efficacy of the long - acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone .", "", +34, InsulinGlargine, 448, 464, "insulin glargine", "", +44, IsophaneInsulin_NPH, 479, 490, "NPH insulin", "", +317, Precondition, 494, 570, "patients with type 2 diabetes who were previously treated with insulin alone", "", +3490, Insulin, 557, 564, "insulin", "", +92934, NumberPatientsCT, 614, 617, "518", "", +92462, Precondition, 618, 735, "subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control", "", +31424, Type2Diabetes, 632, 647, "type 2 diabetes", "", +3491, IsophaneInsulin_NPH, 667, 678, "NPH insulin", "", +3492, Insulin, 703, 710, "insulin", "", +35, InsulinGlargine, 763, 779, "insulin glargine", "", +36, InsulinGlargine, 782, 789, "HOE 901", "", +28, Frequency, 792, 802, "once daily", "", +3493, NumberPatientsArm, 809, 812, "259", "", +29, Frequency, 830, 849, "once or twice daily", "", +3495, NumberPatientsArm, 855, 858, "259", "", +25, Duration, 865, 873, "28 weeks", "", +2096, FastingPlasmaGlucose_target, 952, 984, "fasting glucose < 6 . 7 mmol / l", "", +31427, TimePoint, 990, 1005, "study end point", "", +3497, Insulin, 1031, 1038, "insulin", "", +318, DoseValue, 1073, 1079, "0 . 75", "", +3498, IntUnit_per_Kg, 1080, 1087, "IU / kg", "", +56, HbA1c, 1152, 1157, "HbA1c", "", +320, IntentionToTreat, 1188, 1207, "intent - to - treat", "", +63, Mean, 1237, 1251, "means + / - SD", "", +57, HbA1c, 1257, 1262, "HbA1c", "", +92939, Reduction, 1336, 1342, "0 . 41", "", +2089, Percentage, 1355, 1356, "%", "", +46, IsophaneInsulin_NPH, 1367, 1370, "NPH", "", +68, Reduction, 1381, 1387, "0 . 59", "", +66, SdDevChangeValue, 1394, 1399, "0 . 1", "", +2090, Percentage, 1400, 1401, "%", "", +58, HbA1c, 1450, 1455, "HbA1c", "", +69, BaseLineValue, 1473, 1478, "8 . 5", "", +2091, Percentage, 1479, 1480, "%", "", +70, ObservedResult, 1483, 1563, "The treatments were associated with similar reductions in fasting glucose levels", "", +59, FastingPlasmaGlucose, 1541, 1563, "fasting glucose levels", "", +92967, InsulinGlargine, 1621, 1637, "insulin glargine", "", +92927, PercentageAffected, 1649, 1655, "61 . 4", "", +47, IsophaneInsulin_NPH, 1664, 1675, "NPH insulin", "", +92968, PercentageAffected, 1687, 1689, "66", "", +61, NocturnalHypoglycemia, 1706, 1728, "nocturnal hypoglycemia", "", +39, InsulinGlargine, 1736, 1752, "insulin glargine", "", +73, RelativeReduction, 1774, 1776, "25", "", +2092, PercentageAffected, 1842, 1848, "26 . 5", "", +2093, PercentageAffected, 1854, 1860, "35 . 5", "", +2094, PvalueDiff, 1865, 1877, "P = 0 . 0136", "", +40, InsulinGlargine, 1898, 1914, "insulin glargine", "", +62, BodyWeight, 1938, 1944, "weight", "", +121, IsophaneInsulin_NPH, 1968, 1971, "NPH", "", +74, Increment, 1980, 1985, "0 . 4", "", +75, Increment, 1991, 1996, "1 . 4", "", +76, Kg, 1997, 1999, "kg", "", +3499, PvalueDiff, 2002, 2014, "P < 0 . 0007", "", +31453, ConclusionComment, 2033, 2200, "In patients with type 2 diabetes , once - daily bedtime insulin glargine is as effective as once - or twice - daily NPH in improving and maintaining glycemic control .", "", +321, Frequency, 2068, 2080, "once - daily", "", +52, Bedtime, 2081, 2088, "bedtime", "", +41, InsulinGlargine, 2089, 2105, "insulin glargine", "", +326, Frequency, 2125, 2148, "once - or twice - daily", "", +49, IsophaneInsulin_NPH, 2149, 2152, "NPH", "", +31454, ConclusionComment, 2201, 2331, "In addition , insulin glargine deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin .", "", +42, InsulinGlargine, 2215, 2231, "insulin glargine", "", +324, NocturnalHypoglycemia, 2260, 2282, "nocturnal hypoglycemia", "", +325, BodyWeight, 2292, 2298, "weight", "", +92969, IsophaneInsulin_NPH, 2318, 2329, "NPH insulin", "", +92933, PMID, 2380, 2388, "11315821", "", diff --git a/data/dm2 11315821_kwoodley.n-triples b/data/dm2 11315821_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 11315821_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 12734781_admin.annodb b/data/dm2 12734781_admin.annodb new file mode 100644 index 0000000..452f5da --- /dev/null +++ b/data/dm2 12734781_admin.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +143, Journal, 0, 16, "Horm Metab Res .", "", " \"Horm Metab Res .\"." +0, PublicationYear, 17, 21, "2003", "", " \"2003\"." +144, Title, 50, 206, "A one - year , randomised , multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes .", "", " \"A one - year , randomised , multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes .\"." +60, Duration, 52, 62, "one - year", "", +20, Randomized, 65, 75, "randomised", "", +21, Multicenter, 78, 89, "multicentre", "", +22, InsulinGlargine, 106, 122, "insulin glargine", "", +30, IsophaneInsulin_NPH, 128, 139, "NPH insulin", "", +137, OralAntidiabeticAgent, 160, 171, "oral agents", "", +10, Type2Diabetes, 189, 204, "type 2 diabetes", "", +1, Author, 207, 224, "Massi Benedetti M", "", +2, Author, 233, 242, "Humburg E", "", " \"Humburg E\"." +3, Author, 245, 255, "Dressler A", "", " \"Dressler A\"." +4, Author, 258, 266, "Ziemen M", "", " \"Ziemen M\"." +5, Italy, 330, 335, "Italy", "", " ." +145, ObjectiveDescription, 364, 527, "The aim of the trial was to compare the efficacy and safety of the new , long - acting basal insulin , insulin glargine ( LANTUS ( R ) ) , with NPH human insulin ,", "", " \"The aim of the trial was to compare the efficacy and safety of the new , long - acting basal insulin , insulin glargine ( LANTUS ( R ) ) , with NPH human insulin ,\"." +142, Insulin, 457, 464, "insulin", "", +24, InsulinGlargine, 467, 483, "insulin glargine", "", +31, IsophaneInsulin_NPH, 508, 525, "NPH human insulin", "", +146, ObjectiveDescription, 528, 634, "each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes .", "", " \"each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes .\"." +136, OralAntidiabeticAgent, 576, 599, "oral antidiabetic drugs", "", +11, Type2Diabetes, 617, 632, "Type 2 diabetes", "", " ." +14, Multicenter, 650, 661, "multicentre", "", " ." +15, OpenLabel, 664, 668, "open", "", +16, Randomized, 671, 681, "randomised", "", " ." +9, NumberPatientsCT, 690, 693, "570", "", " \"570\"." +12, Type2Diabetes, 708, 723, "Type 2 diabetes", "", +7, MinAge, 731, 733, "34", "", " \"34\"." +8, MaxAge, 736, 738, "80", "", " \"80\"." +17, Duration, 764, 772, "52 weeks", "", " \"52 weeks\"." +25, InsulinGlargine, 778, 794, "insulin glargine", "", " ." +32, IsophaneInsulin_NPH, 798, 809, "NPH insulin", "", " ." +18, Frequency, 816, 826, "once daily", "", +19, Bedtime, 830, 837, "bedtime", "", +87, Precondition, 840, 911, "Previous oral antidiabetic therapy was continued throughout the study .", "", " \"Italy\". \"Previous oral antidiabetic therapy was continued throughout the study .\"." +51, HbA1c, 966, 990, "glycosylated haemoglobin", "", " ." +52, HbA1c, 993, 996, "GHb", "", +149, TimePoint, 1011, 1019, "baseline", "", +150, TimePoint, 1023, 1031, "endpoint", "", +26, InsulinGlargine, 1050, 1066, "insulin glargine", "", +39, Reduction, 1071, 1077, "0 . 46", "", " \"0 . 46\"." +138, Percentage, 1078, 1079, "%", "", " ." +33, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", +40, Reduction, 1098, 1104, "0 . 38", "", " \"0 . 38\"." +139, Percentage, 1105, 1106, "%", "", +90, PvalueDiff, 1109, 1120, "p = 0 . 415", "", " \"34\". \"p = 0 . 415\"." +91, SubGroupDescription, 1197, 1239, "overweight patients with BMI > 28 kg / m 2", "", " \"80\". \"overweight patients with BMI > 28 kg / m 2\". \"80\". \"overweight patients with BMI > 28 kg / m 2\". \"80\". \"overweight patients with BMI > 28 kg / m 2\"." +133, BMI, 1222, 1225, "BMI", "", +41, Kg_per_squareMeter, 1231, 1239, "kg / m 2", "", +35, InsulinGlargine, 1242, 1258, "insulin glargine", "", +42, Reduction, 1263, 1269, "0 . 42", "", " \"0 . 42\"." +140, Percentage, 1270, 1271, "%", "", +34, IsophaneInsulin_NPH, 1274, 1285, "NPH insulin", "", +43, Reduction, 1290, 1296, "0 . 11", "", " \"0 . 11\"." +141, Percentage, 1297, 1298, "%", "", +94, PvalueDiff, 1301, 1313, "p = 0 . 0237", "", " \"570\". \"p = 0 . 0237\"." +36, IsophaneInsulin_NPH, 1353, 1364, "NPH insulin", "", +44, PercentageAffected, 1386, 1388, "41", "", " \"41\"." +27, InsulinGlargine, 1397, 1413, "insulin glargine", "", +45, PercentageAffected, 1435, 1437, "35", "", " \"35\"." +46, SymptomaticHypoglycemia, 1473, 1498, "symptomatic hypoglycaemia", "", " ." +37, IsophaneInsulin_NPH, 1592, 1603, "NPH insulin", "", +120, EndPointDescription, 1617, 1664, "at least one episode of nocturnal hypoglycaemia", "", " . ." +131, NocturnalHypoglycemia, 1641, 1664, "nocturnal hypoglycaemia", "", +28, InsulinGlargine, 1698, 1714, "insulin glargine", "", +118, SubGroupDescription, 1752, 1762, "overweight", "", +47, PercentageAffected, 1784, 1786, "24", "", " \"24\"." +48, PercentageAffected, 1794, 1796, "12", "", " \"12\"." +104, PvalueDiff, 1801, 1812, "p = 0 . 002", "", " \"p = 0 . 002\"." +119, SubGroupDescription, 1815, 1825, "overweight", "", " \"overweight\"." +49, PercentageAffected, 1828, 1834, "22 . 2", "", " \"22 . 2\"." +50, PercentageAffected, 1842, 1847, "9 . 5", "", " \"9 . 5\"." +107, PvalueDiff, 1852, 1864, "p = 0 . 0006", "", " \"p = 0 . 0006\"." +53, MeasurementDevice, 1879, 1911, "Cochran - Mantel - Haenszel test", "", " . ." +115, SubGroupDescription, 1956, 1973, "insulin - na ï ve", "", +116, SubGroupDescription, 1978, 2010, "overweight ( BMI > 28 kg / m 2 )", "", +132, BMI, 1991, 1994, "BMI", "", +54, Kg_per_squareMeter, 2000, 2008, "kg / m 2", "", +108, ConclusionComment, 2109, 2354, "This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes , and is associated with fewer episodes of symptomatic hypoglycaemia , particularly nocturnal episodes .", "", " \"This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes , and is associated with fewer episodes of symptomatic hypoglycaemia , particularly nocturnal episodes .\"." +29, InsulinGlargine, 2138, 2154, "insulin glargine", "", +38, IsophaneInsulin_NPH, 2174, 2185, "NPH insulin", "", +13, Type2Diabetes, 2234, 2249, "Type 2 diabetes", "", +55, SymptomaticHypoglycemia, 2293, 2318, "symptomatic hypoglycaemia", "", +56, NocturnalHypoglycemia, 2334, 2352, "nocturnal episodes", "", +6, PMID, 2397, 2405, "12734781", "", " \"12734781\"." diff --git a/data/dm2 12734781_admin.n-triples b/data/dm2 12734781_admin.n-triples new file mode 100644 index 0000000..17705fc --- /dev/null +++ b/data/dm2 12734781_admin.n-triples @@ -0,0 +1,173 @@ +# RDF export of group: Publication + . + "Publication " . + "A one - year , randomised , multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes ." . + "2003" . + "Horm Metab Res ." . + "12734781" . + . + "Humburg E" . + "Dressler A" . + "Ziemen M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The aim of the trial was to compare the efficacy and safety of the new , long - acting basal insulin , insulin glargine ( LANTUS ( R ) ) , with NPH human insulin ," . + "570" . + "52 weeks" . + . + . + . + "This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes , and is associated with fewer episodes of symptomatic hypoglycaemia , particularly nocturnal episodes ." . + . + . + . + . + . + "each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes ." . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "Italy" . + "Previous oral antidiabetic therapy was continued throughout the study ." . + . + . + "34" . + "80" . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig" . + . + . + . + . + . + . + . + "Arm nph" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig" . + . + . + . + "Intervention nph" . + . + . +# RDF export of group: Medication + . + "Medication ig" . + . + . + . + . + "Medication nph" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c ig" . + . + "0 . 46" . + . + "Outcome hba1c nph" . + . + "0 . 38" . + . + "Outcome hba1c sg ig " . + . + "0 . 42" . + "80" . + "overweight patients with BMI > 28 kg / m 2" . + . + "Outcome hba1c sg nph" . + . + "0 . 11" . + "80" . + "overweight patients with BMI > 28 kg / m 2" . + . + "Outcome sh ig" . + . + "35" . + . + "Outcome sh nph" . + . + "41" . + . + "Outcome nh ig" . + . + "12" . + . + "Outcome nh nph" . + . + "24" . + . + "Outcome nh sg ig" . + . + "9 . 5" . + "overweight" . + . + "Outcome nh sg nph" . + . + "22 . 2" . + "80" . + "overweight patients with BMI > 28 kg / m 2" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "34" . + "p = 0 . 415" . + . + . + . + "DiffBetweenGroups hba1c sg" . + "570" . + "p = 0 . 0237" . + . + . + . + "DiffBetweenGroups nh" . + "p = 0 . 002" . + . + . + . + "DiffBetweenGroups nh sg" . + "p = 0 . 0006" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 12734781_akramersunderbrink.annodb b/data/dm2 12734781_akramersunderbrink.annodb new file mode 100644 index 0000000..a8bdd7f --- /dev/null +++ b/data/dm2 12734781_akramersunderbrink.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +653, Journal, 0, 14, "Horm Metab Res", "", +654, PublicationYear, 17, 21, "2003", "", +655, Title, 50, 204, "A one - year , randomised , multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes", "", +656, Duration, 52, 62, "one - year", "", +658, Randomized, 65, 75, "randomised", "", +659, Multicenter, 78, 89, "multicentre", "", +660, InsulinGlargine, 106, 122, "insulin glargine", "", +661, IsophaneInsulin_NPH, 128, 139, "NPH insulin", "", +662, Type2Diabetes, 189, 204, "type 2 diabetes", "", +663, Author, 207, 224, "Massi Benedetti M", "", +664, Author, 233, 242, "Humburg E", "", +665, Author, 245, 255, "Dressler A", "", +666, Author, 258, 266, "Ziemen M", "", +31696, Italy, 330, 335, "Italy", "", +667, ObjectiveDescription, 364, 525, "The aim of the trial was to compare the efficacy and safety of the new , long - acting basal insulin , insulin glargine ( LANTUS ( R ) ) , with NPH human insulin", "", +671, InsulinGlargine, 467, 483, "insulin glargine", "", +672, IsophaneInsulin_NPH, 508, 525, "NPH human insulin", "", +670, ObjectiveDescription, 526, 634, ", each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes .", "", +673, Type2Diabetes, 617, 632, "Type 2 diabetes", "", +674, Multicenter, 650, 661, "multicentre", "", +675, OpenLabel, 664, 668, "open", "", +676, Randomized, 671, 681, "randomised", "", +677, NumberPatientsCT, 690, 693, "570", "", +678, Type2Diabetes, 708, 723, "Type 2 diabetes", "", +679, MinAge, 731, 733, "34", "", +680, MaxAge, 736, 738, "80", "", +681, Duration, 764, 772, "52 weeks", "", +682, InsulinGlargine, 778, 794, "insulin glargine", "", +683, IsophaneInsulin_NPH, 798, 809, "NPH insulin", "", +684, Frequency, 816, 826, "once daily", "", +685, Bedtime, 830, 837, "bedtime", "", +686, Precondition, 840, 909, "Previous oral antidiabetic therapy was continued throughout the study", "", +1856, HbA1c, 966, 998, "glycosylated haemoglobin ( GHb )", "", +31697, TimePoint, 1011, 1019, "baseline", "", +31698, TimePoint, 1023, 1031, "endpoint", "", +688, InsulinGlargine, 1050, 1066, "insulin glargine", "", +31701, ChangeValue, 1069, 1077, "- 0 . 46", "", +31699, Percentage, 1078, 1079, "%", "", +689, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", +31702, ChangeValue, 1096, 1104, "- 0 . 38", "", +31705, Percentage, 1105, 1106, "%", "", +692, PvalueDiff, 1109, 1120, "p = 0 . 415", "", +693, SubGroupDescription, 1197, 1239, "overweight patients with BMI > 28 kg / m 2", "", +694, InsulinGlargine, 1242, 1258, "insulin glargine", "", +31703, ChangeValue, 1261, 1269, "- 0 . 42", "", +31700, Percentage, 1270, 1271, "%", "", +695, IsophaneInsulin_NPH, 1274, 1285, "NPH insulin", "", +31704, ChangeValue, 1288, 1296, "- 0 . 11", "", +31706, Percentage, 1297, 1298, "%", "", +698, PvalueDiff, 1301, 1313, "p = 0 . 0237", "", +700, IsophaneInsulin_NPH, 1353, 1364, "NPH insulin", "", +701, PercentageAffected, 1386, 1388, "41", "", +31708, Percentage, 1389, 1390, "%", "", +702, InsulinGlargine, 1397, 1413, "insulin glargine", "", +703, PercentageAffected, 1435, 1437, "35", "", +31707, Percentage, 1438, 1439, "%", "", +699, SymptomaticHypoglycemia, 1473, 1498, "symptomatic hypoglycaemia", "", +704, IsophaneInsulin_NPH, 1592, 1603, "NPH insulin", "", +771, EndPointDescription, 1617, 1664, "at least one episode of nocturnal hypoglycaemia", "", +705, InsulinGlargine, 1698, 1714, "insulin glargine", "", +766, SubGroupDescription, 1752, 1762, "overweight", "", +707, PercentageAffected, 1784, 1786, "24", "", +31709, Percentage, 1787, 1788, "%", "", +708, PercentageAffected, 1794, 1796, "12", "", +31710, Percentage, 1797, 1798, "%", "", +709, PvalueDiff, 1801, 1812, "p = 0 . 002", "", +767, SubGroupDescription, 1815, 1825, "overweight", "", +710, PercentageAffected, 1828, 1834, "22 . 2", "", +31711, Percentage, 1835, 1836, "%", "", +711, PercentageAffected, 1842, 1847, "9 . 5", "", +31712, Percentage, 1848, 1849, "%", "", +712, PvalueDiff, 1852, 1864, "p = 0 . 0006", "", +763, SubGroupDescription, 1956, 1973, "insulin - na ï ve", "", +764, SubGroupDescription, 1978, 2010, "overweight ( BMI > 28 kg / m 2 )", "", +31713, BMI, 1991, 1994, "BMI", "", +765, Kg_per_squareMeter, 2000, 2008, "kg / m 2", "", +713, ConclusionComment, 2109, 2354, "This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes , and is associated with fewer episodes of symptomatic hypoglycaemia , particularly nocturnal episodes .", "", +714, InsulinGlargine, 2138, 2154, "insulin glargine", "", +715, IsophaneInsulin_NPH, 2174, 2185, "NPH insulin", "", +716, Type2Diabetes, 2234, 2249, "Type 2 diabetes", "", +717, SymptomaticHypoglycemia, 2293, 2318, "symptomatic hypoglycaemia", "", +718, NocturnalHypoglycemia, 2334, 2352, "nocturnal episodes", "", +719, PMID, 2397, 2405, "12734781", "", diff --git a/data/dm2 12734781_akramersunderbrink.n-triples b/data/dm2 12734781_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 12734781_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 12734781_export.csv b/data/dm2 12734781_export.csv new file mode 100644 index 0000000..5bef82c --- /dev/null +++ b/data/dm2 12734781_export.csv @@ -0,0 +1,494 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +377, 1, 1, 1, 0, 4, 0, 4, "Horm" +377, 1, 2, 2, 5, 10, 5, 10, "Metab" +377, 1, 3, 3, 11, 14, 11, 14, "Res" +377, 1, 4, 4, 15, 16, 15, 16, "." +377, 2, 1, 5, 0, 4, 17, 21, "2003" +377, 2, 2, 6, 5, 8, 22, 25, "Mar" +377, 2, 3, 7, 9, 10, 26, 27, ";" +377, 2, 4, 8, 11, 13, 28, 30, "35" +377, 2, 5, 9, 14, 15, 31, 32, "(" +377, 2, 6, 10, 16, 17, 33, 34, "3" +377, 2, 7, 11, 18, 19, 35, 36, ")" +377, 2, 8, 12, 20, 21, 37, 38, ":" +377, 2, 9, 13, 22, 25, 39, 42, "189" +377, 2, 10, 14, 26, 27, 43, 44, "-" +377, 2, 11, 15, 28, 30, 45, 47, "96" +377, 2, 12, 16, 31, 32, 48, 49, "." +377, 3, 1, 17, 0, 1, 50, 51, "A" +377, 3, 2, 18, 2, 5, 52, 55, "one" +377, 3, 3, 19, 6, 7, 56, 57, "-" +377, 3, 4, 20, 8, 12, 58, 62, "year" +377, 3, 5, 21, 13, 14, 63, 64, "," +377, 3, 6, 22, 15, 25, 65, 75, "randomised" +377, 3, 7, 23, 26, 27, 76, 77, "," +377, 3, 8, 24, 28, 39, 78, 89, "multicentre" +377, 3, 9, 25, 40, 45, 90, 95, "trial" +377, 3, 10, 26, 46, 55, 96, 105, "comparing" +377, 3, 11, 27, 56, 63, 106, 113, "insulin" +377, 3, 12, 28, 64, 72, 114, 122, "glargine" +377, 3, 13, 29, 73, 77, 123, 127, "with" +377, 3, 14, 30, 78, 81, 128, 131, "NPH" +377, 3, 15, 31, 82, 89, 132, 139, "insulin" +377, 3, 16, 32, 90, 92, 140, 142, "in" +377, 3, 17, 33, 93, 104, 143, 154, "combination" +377, 3, 18, 34, 105, 109, 155, 159, "with" +377, 3, 19, 35, 110, 114, 160, 164, "oral" +377, 3, 20, 36, 115, 121, 165, 171, "agents" +377, 3, 21, 37, 122, 124, 172, 174, "in" +377, 3, 22, 38, 125, 133, 175, 183, "patients" +377, 3, 23, 39, 134, 138, 184, 188, "with" +377, 3, 24, 40, 139, 143, 189, 193, "type" +377, 3, 25, 41, 144, 145, 194, 195, "2" +377, 3, 26, 42, 146, 154, 196, 204, "diabetes" +377, 3, 27, 43, 155, 156, 205, 206, "." +377, 4, 1, 44, 0, 5, 207, 212, "Massi" +377, 4, 2, 45, 6, 15, 213, 222, "Benedetti" +377, 4, 3, 46, 16, 17, 223, 224, "M" +377, 4, 4, 47, 18, 19, 225, 226, "(" +377, 4, 5, 48, 20, 21, 227, 228, "1" +377, 4, 6, 49, 22, 23, 229, 230, ")" +377, 4, 7, 50, 24, 25, 231, 232, "," +377, 4, 8, 51, 26, 33, 233, 240, "Humburg" +377, 4, 9, 52, 34, 35, 241, 242, "E" +377, 4, 10, 53, 36, 37, 243, 244, "," +377, 4, 11, 54, 38, 46, 245, 253, "Dressler" +377, 4, 12, 55, 47, 48, 254, 255, "A" +377, 4, 13, 56, 49, 50, 256, 257, "," +377, 4, 14, 57, 51, 57, 258, 264, "Ziemen" +377, 4, 15, 58, 58, 59, 265, 266, "M" +377, 4, 16, 59, 60, 61, 267, 268, "." +377, 4, 17, 60, 62, 68, 269, 275, "Author" +377, 4, 18, 61, 69, 80, 276, 287, "information" +377, 4, 19, 62, 81, 82, 288, 289, ":" +377, 4, 20, 63, 83, 84, 290, 291, "(" +377, 4, 21, 64, 85, 86, 292, 293, "1" +377, 4, 22, 65, 87, 88, 294, 295, ")" +377, 4, 23, 66, 89, 99, 296, 306, "University" +377, 4, 24, 67, 100, 102, 307, 309, "of" +377, 4, 25, 68, 103, 110, 310, 317, "Perugia" +377, 4, 26, 69, 111, 112, 318, 319, "," +377, 4, 27, 70, 113, 120, 320, 327, "Perugia" +377, 4, 28, 71, 121, 122, 328, 329, "," +377, 4, 29, 72, 123, 128, 330, 335, "Italy" +377, 4, 30, 73, 129, 130, 336, 337, "." +377, 5, 1, 74, 0, 5, 338, 343, "massi" +377, 5, 2, 75, 6, 7, 344, 345, "@" +377, 5, 3, 76, 8, 13, 346, 351, "unipg" +377, 5, 4, 77, 14, 15, 352, 353, "." +377, 5, 5, 78, 16, 18, 354, 356, "it" +377, 5, 6, 79, 19, 23, 357, 361, "AIMS" +377, 5, 7, 80, 24, 25, 362, 363, ":" +377, 5, 8, 81, 26, 29, 364, 367, "The" +377, 5, 9, 82, 30, 33, 368, 371, "aim" +377, 5, 10, 83, 34, 36, 372, 374, "of" +377, 5, 11, 84, 37, 40, 375, 378, "the" +377, 5, 12, 85, 41, 46, 379, 384, "trial" +377, 5, 13, 86, 47, 50, 385, 388, "was" +377, 5, 14, 87, 51, 53, 389, 391, "to" +377, 5, 15, 88, 54, 61, 392, 399, "compare" +377, 5, 16, 89, 62, 65, 400, 403, "the" +377, 5, 17, 90, 66, 74, 404, 412, "efficacy" +377, 5, 18, 91, 75, 78, 413, 416, "and" +377, 5, 19, 92, 79, 85, 417, 423, "safety" +377, 5, 20, 93, 86, 88, 424, 426, "of" +377, 5, 21, 94, 89, 92, 427, 430, "the" +377, 5, 22, 95, 93, 96, 431, 434, "new" +377, 5, 23, 96, 97, 98, 435, 436, "," +377, 5, 24, 97, 99, 103, 437, 441, "long" +377, 5, 25, 98, 104, 105, 442, 443, "-" +377, 5, 26, 99, 106, 112, 444, 450, "acting" +377, 5, 27, 100, 113, 118, 451, 456, "basal" +377, 5, 28, 101, 119, 126, 457, 464, "insulin" +377, 5, 29, 102, 127, 128, 465, 466, "," +377, 5, 30, 103, 129, 136, 467, 474, "insulin" +377, 5, 31, 104, 137, 145, 475, 483, "glargine" +377, 5, 32, 105, 146, 147, 484, 485, "(" +377, 5, 33, 106, 148, 154, 486, 492, "LANTUS" +377, 5, 34, 107, 155, 156, 493, 494, "(" +377, 5, 35, 108, 157, 158, 495, 496, "R" +377, 5, 36, 109, 159, 160, 497, 498, ")" +377, 5, 37, 110, 161, 162, 499, 500, ")" +377, 5, 38, 111, 163, 164, 501, 502, "," +377, 5, 39, 112, 165, 169, 503, 507, "with" +377, 5, 40, 113, 170, 173, 508, 511, "NPH" +377, 5, 41, 114, 174, 179, 512, 517, "human" +377, 5, 42, 115, 180, 187, 518, 525, "insulin" +377, 5, 43, 116, 188, 189, 526, 527, "," +377, 5, 44, 117, 190, 194, 528, 532, "each" +377, 5, 45, 118, 195, 207, 533, 545, "administered" +377, 5, 46, 119, 208, 210, 546, 548, "in" +377, 5, 47, 120, 211, 212, 549, 550, "a" +377, 5, 48, 121, 213, 224, 551, 562, "combination" +377, 5, 49, 122, 225, 232, 563, 570, "regimen" +377, 5, 50, 123, 233, 237, 571, 575, "with" +377, 5, 51, 124, 238, 242, 576, 580, "oral" +377, 5, 52, 125, 243, 255, 581, 593, "antidiabetic" +377, 5, 53, 126, 256, 261, 594, 599, "drugs" +377, 5, 54, 127, 262, 264, 600, 602, "in" +377, 5, 55, 128, 265, 273, 603, 611, "patients" +377, 5, 56, 129, 274, 278, 612, 616, "with" +377, 5, 57, 130, 279, 283, 617, 621, "Type" +377, 5, 58, 131, 284, 285, 622, 623, "2" +377, 5, 59, 132, 286, 294, 624, 632, "diabetes" +377, 5, 60, 133, 295, 296, 633, 634, "." +377, 6, 1, 134, 0, 7, 635, 642, "METHODS" +377, 6, 2, 135, 8, 9, 643, 644, ":" +377, 6, 3, 136, 10, 12, 645, 647, "In" +377, 6, 4, 137, 13, 14, 648, 649, "a" +377, 6, 5, 138, 15, 26, 650, 661, "multicentre" +377, 6, 6, 139, 27, 28, 662, 663, "," +377, 6, 7, 140, 29, 33, 664, 668, "open" +377, 6, 8, 141, 34, 35, 669, 670, "," +377, 6, 9, 142, 36, 46, 671, 681, "randomised" +377, 6, 10, 143, 47, 52, 682, 687, "study" +377, 6, 11, 144, 53, 54, 688, 689, "," +377, 6, 12, 145, 55, 58, 690, 693, "570" +377, 6, 13, 146, 59, 67, 694, 702, "patients" +377, 6, 14, 147, 68, 72, 703, 707, "with" +377, 6, 15, 148, 73, 77, 708, 712, "Type" +377, 6, 16, 149, 78, 79, 713, 714, "2" +377, 6, 17, 150, 80, 88, 715, 723, "diabetes" +377, 6, 18, 151, 89, 90, 724, 725, "," +377, 6, 19, 152, 91, 95, 726, 730, "aged" +377, 6, 20, 153, 96, 98, 731, 733, "34" +377, 6, 21, 154, 99, 100, 734, 735, "-" +377, 6, 22, 155, 101, 103, 736, 738, "80" +377, 6, 23, 156, 104, 109, 739, 744, "years" +377, 6, 24, 157, 110, 111, 745, 746, "," +377, 6, 25, 158, 112, 116, 747, 751, "were" +377, 6, 26, 159, 117, 124, 752, 759, "treated" +377, 6, 27, 160, 125, 128, 760, 763, "for" +377, 6, 28, 161, 129, 131, 764, 766, "52" +377, 6, 29, 162, 132, 137, 767, 772, "weeks" +377, 6, 30, 163, 138, 142, 773, 777, "with" +377, 6, 31, 164, 143, 150, 778, 785, "insulin" +377, 6, 32, 165, 151, 159, 786, 794, "glargine" +377, 6, 33, 166, 160, 162, 795, 797, "or" +377, 6, 34, 167, 163, 166, 798, 801, "NPH" +377, 6, 35, 168, 167, 174, 802, 809, "insulin" +377, 6, 36, 169, 175, 180, 810, 815, "given" +377, 6, 37, 170, 181, 185, 816, 820, "once" +377, 6, 38, 171, 186, 191, 821, 826, "daily" +377, 6, 39, 172, 192, 194, 827, 829, "at" +377, 6, 40, 173, 195, 202, 830, 837, "bedtime" +377, 6, 41, 174, 203, 204, 838, 839, "." +377, 7, 1, 175, 0, 8, 840, 848, "Previous" +377, 7, 2, 176, 9, 13, 849, 853, "oral" +377, 7, 3, 177, 14, 26, 854, 866, "antidiabetic" +377, 7, 4, 178, 27, 34, 867, 874, "therapy" +377, 7, 5, 179, 35, 38, 875, 878, "was" +377, 7, 6, 180, 39, 48, 879, 888, "continued" +377, 7, 7, 181, 49, 59, 889, 899, "throughout" +377, 7, 8, 182, 60, 63, 900, 903, "the" +377, 7, 9, 183, 64, 69, 904, 909, "study" +377, 7, 10, 184, 70, 71, 910, 911, "." +377, 8, 1, 185, 0, 7, 912, 919, "RESULTS" +377, 8, 2, 186, 8, 9, 920, 921, ":" +377, 8, 3, 187, 10, 15, 922, 927, "There" +377, 8, 4, 188, 16, 19, 928, 931, "was" +377, 8, 5, 189, 20, 21, 932, 933, "a" +377, 8, 6, 190, 22, 32, 934, 944, "clinically" +377, 8, 7, 191, 33, 41, 945, 953, "relevant" +377, 8, 8, 192, 42, 50, 954, 962, "decrease" +377, 8, 9, 193, 51, 53, 963, 965, "in" +377, 8, 10, 194, 54, 66, 966, 978, "glycosylated" +377, 8, 11, 195, 67, 78, 979, 990, "haemoglobin" +377, 8, 12, 196, 79, 80, 991, 992, "(" +377, 8, 13, 197, 81, 84, 993, 996, "GHb" +377, 8, 14, 198, 85, 86, 997, 998, ")" +377, 8, 15, 199, 87, 93, 999, 1005, "values" +377, 8, 16, 200, 94, 98, 1006, 1010, "from" +377, 8, 17, 201, 99, 107, 1011, 1019, "baseline" +377, 8, 18, 202, 108, 110, 1020, 1022, "to" +377, 8, 19, 203, 111, 119, 1023, 1031, "endpoint" +377, 8, 20, 204, 120, 124, 1032, 1036, "with" +377, 8, 21, 205, 125, 129, 1037, 1041, "both" +377, 8, 22, 206, 130, 135, 1042, 1047, "drugs" +377, 8, 23, 207, 136, 137, 1048, 1049, "(" +377, 8, 24, 208, 138, 145, 1050, 1057, "insulin" +377, 8, 25, 209, 146, 154, 1058, 1066, "glargine" +377, 8, 26, 210, 155, 156, 1067, 1068, ":" +377, 8, 27, 211, 157, 158, 1069, 1070, "-" +377, 8, 28, 212, 159, 160, 1071, 1072, "0" +377, 8, 29, 213, 161, 162, 1073, 1074, "." +377, 8, 30, 214, 163, 165, 1075, 1077, "46" +377, 8, 31, 215, 166, 167, 1078, 1079, "%" +377, 8, 32, 216, 168, 169, 1080, 1081, ";" +377, 8, 33, 217, 170, 173, 1082, 1085, "NPH" +377, 8, 34, 218, 174, 181, 1086, 1093, "insulin" +377, 8, 35, 219, 182, 183, 1094, 1095, ":" +377, 8, 36, 220, 184, 185, 1096, 1097, "-" +377, 8, 37, 221, 186, 187, 1098, 1099, "0" +377, 8, 38, 222, 188, 189, 1100, 1101, "." +377, 8, 39, 223, 190, 192, 1102, 1104, "38" +377, 8, 40, 224, 193, 194, 1105, 1106, "%" +377, 8, 41, 225, 195, 196, 1107, 1108, ";" +377, 8, 42, 226, 197, 198, 1109, 1110, "p" +377, 8, 43, 227, 199, 200, 1111, 1112, "=" +377, 8, 44, 228, 201, 202, 1113, 1114, "0" +377, 8, 45, 229, 203, 204, 1115, 1116, "." +377, 8, 46, 230, 205, 208, 1117, 1120, "415" +377, 8, 47, 231, 209, 210, 1121, 1122, ")" +377, 8, 48, 232, 211, 212, 1123, 1124, ";" +377, 8, 49, 233, 213, 217, 1125, 1129, "also" +377, 8, 50, 234, 218, 219, 1130, 1131, "," +377, 8, 51, 235, 220, 224, 1132, 1136, "this" +377, 8, 52, 236, 225, 235, 1137, 1147, "difference" +377, 8, 53, 237, 236, 239, 1148, 1151, "was" +377, 8, 54, 238, 240, 253, 1152, 1165, "statistically" +377, 8, 55, 239, 254, 265, 1166, 1177, "significant" +377, 8, 56, 240, 266, 268, 1178, 1180, "in" +377, 8, 57, 241, 269, 272, 1181, 1184, "the" +377, 8, 58, 242, 273, 281, 1185, 1193, "subgroup" +377, 8, 59, 243, 282, 284, 1194, 1196, "of" +377, 8, 60, 244, 285, 295, 1197, 1207, "overweight" +377, 8, 61, 245, 296, 304, 1208, 1216, "patients" +377, 8, 62, 246, 305, 309, 1217, 1221, "with" +377, 8, 63, 247, 310, 313, 1222, 1225, "BMI" +377, 8, 64, 248, 314, 315, 1226, 1227, ">" +377, 8, 65, 249, 316, 318, 1228, 1230, "28" +377, 8, 66, 250, 319, 321, 1231, 1233, "kg" +377, 8, 67, 251, 322, 323, 1234, 1235, "/" +377, 8, 68, 252, 324, 325, 1236, 1237, "m" +377, 8, 69, 253, 326, 327, 1238, 1239, "2" +377, 8, 70, 254, 328, 329, 1240, 1241, "(" +377, 8, 71, 255, 330, 337, 1242, 1249, "insulin" +377, 8, 72, 256, 338, 346, 1250, 1258, "glargine" +377, 8, 73, 257, 347, 348, 1259, 1260, ":" +377, 8, 74, 258, 349, 350, 1261, 1262, "-" +377, 8, 75, 259, 351, 352, 1263, 1264, "0" +377, 8, 76, 260, 353, 354, 1265, 1266, "." +377, 8, 77, 261, 355, 357, 1267, 1269, "42" +377, 8, 78, 262, 358, 359, 1270, 1271, "%" +377, 8, 79, 263, 360, 361, 1272, 1273, "," +377, 8, 80, 264, 362, 365, 1274, 1277, "NPH" +377, 8, 81, 265, 366, 373, 1278, 1285, "insulin" +377, 8, 82, 266, 374, 375, 1286, 1287, ":" +377, 8, 83, 267, 376, 377, 1288, 1289, "-" +377, 8, 84, 268, 378, 379, 1290, 1291, "0" +377, 8, 85, 269, 380, 381, 1292, 1293, "." +377, 8, 86, 270, 382, 384, 1294, 1296, "11" +377, 8, 87, 271, 385, 386, 1297, 1298, "%" +377, 8, 88, 272, 387, 388, 1299, 1300, ";" +377, 8, 89, 273, 389, 390, 1301, 1302, "p" +377, 8, 90, 274, 391, 392, 1303, 1304, "=" +377, 8, 91, 275, 393, 394, 1305, 1306, "0" +377, 8, 92, 276, 395, 396, 1307, 1308, "." +377, 8, 93, 277, 397, 401, 1309, 1313, "0237" +377, 8, 94, 278, 402, 403, 1314, 1315, ")" +377, 8, 95, 279, 404, 405, 1316, 1317, "." +377, 9, 1, 280, 0, 4, 1318, 1322, "Over" +377, 9, 2, 281, 5, 8, 1323, 1326, "the" +377, 9, 3, 282, 9, 15, 1327, 1333, "entire" +377, 9, 4, 283, 16, 25, 1334, 1343, "treatment" +377, 9, 5, 284, 26, 32, 1344, 1350, "period" +377, 9, 6, 285, 33, 34, 1351, 1352, "," +377, 9, 7, 286, 35, 38, 1353, 1356, "NPH" +377, 9, 8, 287, 39, 46, 1357, 1364, "insulin" +377, 9, 9, 288, 47, 48, 1365, 1366, "-" +377, 9, 10, 289, 49, 56, 1367, 1374, "treated" +377, 9, 11, 290, 57, 65, 1375, 1383, "patients" +377, 9, 12, 291, 66, 67, 1384, 1385, "(" +377, 9, 13, 292, 68, 70, 1386, 1388, "41" +377, 9, 14, 293, 71, 72, 1389, 1390, "%" +377, 9, 15, 294, 73, 74, 1391, 1392, ")" +377, 9, 16, 295, 75, 78, 1393, 1396, "and" +377, 9, 17, 296, 79, 86, 1397, 1404, "insulin" +377, 9, 18, 297, 87, 95, 1405, 1413, "glargine" +377, 9, 19, 298, 96, 97, 1414, 1415, "-" +377, 9, 20, 299, 98, 105, 1416, 1423, "treated" +377, 9, 21, 300, 106, 114, 1424, 1432, "patients" +377, 9, 22, 301, 115, 116, 1433, 1434, "(" +377, 9, 23, 302, 117, 119, 1435, 1437, "35" +377, 9, 24, 303, 120, 121, 1438, 1439, "%" +377, 9, 25, 304, 122, 123, 1440, 1441, ")" +377, 9, 26, 305, 124, 135, 1442, 1453, "experienced" +377, 9, 27, 306, 136, 137, 1454, 1455, "a" +377, 9, 28, 307, 138, 145, 1456, 1463, "similar" +377, 9, 29, 308, 146, 151, 1464, 1469, "level" +377, 9, 30, 309, 152, 154, 1470, 1472, "of" +377, 9, 31, 310, 155, 166, 1473, 1484, "symptomatic" +377, 9, 32, 311, 167, 180, 1485, 1498, "hypoglycaemia" +377, 9, 33, 312, 181, 182, 1499, 1500, "." +377, 10, 1, 313, 0, 1, 1501, 1502, "A" +377, 10, 2, 314, 2, 15, 1503, 1516, "statistically" +377, 10, 3, 315, 16, 27, 1517, 1528, "significant" +377, 10, 4, 316, 28, 38, 1529, 1539, "difference" +377, 10, 5, 317, 39, 42, 1540, 1543, "was" +377, 10, 6, 318, 43, 51, 1544, 1552, "observed" +377, 10, 7, 319, 52, 54, 1553, 1555, "in" +377, 10, 8, 320, 55, 58, 1556, 1559, "the" +377, 10, 9, 321, 59, 65, 1560, 1566, "number" +377, 10, 10, 322, 66, 68, 1567, 1569, "of" +377, 10, 11, 323, 69, 77, 1570, 1578, "patients" +377, 10, 12, 324, 78, 85, 1579, 1586, "treated" +377, 10, 13, 325, 86, 90, 1587, 1591, "with" +377, 10, 14, 326, 91, 94, 1592, 1595, "NPH" +377, 10, 15, 327, 95, 102, 1596, 1603, "insulin" +377, 10, 16, 328, 103, 106, 1604, 1607, "who" +377, 10, 17, 329, 107, 115, 1608, 1616, "reported" +377, 10, 18, 330, 116, 118, 1617, 1619, "at" +377, 10, 19, 331, 119, 124, 1620, 1625, "least" +377, 10, 20, 332, 125, 128, 1626, 1629, "one" +377, 10, 21, 333, 129, 136, 1630, 1637, "episode" +377, 10, 22, 334, 137, 139, 1638, 1640, "of" +377, 10, 23, 335, 140, 149, 1641, 1650, "nocturnal" +377, 10, 24, 336, 150, 163, 1651, 1664, "hypoglycaemia" +377, 10, 25, 337, 164, 172, 1665, 1673, "compared" +377, 10, 26, 338, 173, 177, 1674, 1678, "with" +377, 10, 27, 339, 178, 183, 1679, 1684, "those" +377, 10, 28, 340, 184, 191, 1685, 1692, "treated" +377, 10, 29, 341, 192, 196, 1693, 1697, "with" +377, 10, 30, 342, 197, 204, 1698, 1705, "insulin" +377, 10, 31, 343, 205, 213, 1706, 1714, "glargine" +377, 10, 32, 344, 214, 216, 1715, 1717, "in" +377, 10, 33, 345, 217, 220, 1718, 1721, "the" +377, 10, 34, 346, 221, 228, 1722, 1729, "overall" +377, 10, 35, 347, 229, 239, 1730, 1740, "population" +377, 10, 36, 348, 240, 243, 1741, 1744, "and" +377, 10, 37, 349, 244, 246, 1745, 1747, "in" +377, 10, 38, 350, 247, 250, 1748, 1751, "the" +377, 10, 39, 351, 251, 261, 1752, 1762, "overweight" +377, 10, 40, 352, 262, 270, 1763, 1771, "subgroup" +377, 10, 41, 353, 271, 272, 1772, 1773, "(" +377, 10, 42, 354, 273, 280, 1774, 1781, "overall" +377, 10, 43, 355, 281, 282, 1782, 1783, ":" +377, 10, 44, 356, 283, 285, 1784, 1786, "24" +377, 10, 45, 357, 286, 287, 1787, 1788, "%" +377, 10, 46, 358, 288, 290, 1789, 1791, "vs" +377, 10, 47, 359, 291, 292, 1792, 1793, "." +377, 10, 48, 360, 293, 295, 1794, 1796, "12" +377, 10, 49, 361, 296, 297, 1797, 1798, "%" +377, 10, 50, 362, 298, 299, 1799, 1800, "," +377, 10, 51, 363, 300, 301, 1801, 1802, "p" +377, 10, 52, 364, 302, 303, 1803, 1804, "=" +377, 10, 53, 365, 304, 305, 1805, 1806, "0" +377, 10, 54, 366, 306, 307, 1807, 1808, "." +377, 10, 55, 367, 308, 311, 1809, 1812, "002" +377, 10, 56, 368, 312, 313, 1813, 1814, ";" +377, 10, 57, 369, 314, 324, 1815, 1825, "overweight" +377, 10, 58, 370, 325, 326, 1826, 1827, ":" +377, 10, 59, 371, 327, 329, 1828, 1830, "22" +377, 10, 60, 372, 330, 331, 1831, 1832, "." +377, 10, 61, 373, 332, 333, 1833, 1834, "2" +377, 10, 62, 374, 334, 335, 1835, 1836, "%" +377, 10, 63, 375, 336, 338, 1837, 1839, "vs" +377, 10, 64, 376, 339, 340, 1840, 1841, "." +377, 10, 65, 377, 341, 342, 1842, 1843, "9" +377, 10, 66, 378, 343, 344, 1844, 1845, "." +377, 10, 67, 379, 345, 346, 1846, 1847, "5" +377, 10, 68, 380, 347, 348, 1848, 1849, "%" +377, 10, 69, 381, 349, 350, 1850, 1851, "," +377, 10, 70, 382, 351, 352, 1852, 1853, "p" +377, 10, 71, 383, 353, 354, 1854, 1855, "=" +377, 10, 72, 384, 355, 356, 1856, 1857, "0" +377, 10, 73, 385, 357, 358, 1858, 1859, "." +377, 10, 74, 386, 359, 363, 1860, 1864, "0006" +377, 10, 75, 387, 364, 365, 1865, 1866, ")" +377, 10, 76, 388, 366, 367, 1867, 1868, "," +377, 10, 77, 389, 368, 373, 1869, 1874, "using" +377, 10, 78, 390, 374, 377, 1875, 1878, "the" +377, 10, 79, 391, 378, 385, 1879, 1886, "Cochran" +377, 10, 80, 392, 386, 387, 1887, 1888, "-" +377, 10, 81, 393, 388, 394, 1889, 1895, "Mantel" +377, 10, 82, 394, 395, 396, 1896, 1897, "-" +377, 10, 83, 395, 397, 405, 1898, 1906, "Haenszel" +377, 10, 84, 396, 406, 410, 1907, 1911, "test" +377, 10, 85, 397, 411, 412, 1912, 1913, "." +377, 11, 1, 398, 0, 5, 1914, 1919, "These" +377, 11, 2, 399, 6, 17, 1920, 1931, "differences" +377, 11, 3, 400, 18, 22, 1932, 1936, "were" +377, 11, 4, 401, 23, 27, 1937, 1941, "most" +377, 11, 5, 402, 28, 38, 1942, 1952, "pronounced" +377, 11, 6, 403, 39, 41, 1953, 1955, "in" +377, 11, 7, 404, 42, 49, 1956, 1963, "insulin" +377, 11, 8, 405, 50, 51, 1964, 1965, "-" +377, 11, 9, 406, 52, 54, 1966, 1968, "na" +377, 11, 10, 407, 55, 56, 1969, 1970, "ï" +377, 11, 11, 408, 57, 59, 1971, 1973, "ve" +377, 11, 12, 409, 60, 63, 1974, 1977, "and" +377, 11, 13, 410, 64, 74, 1978, 1988, "overweight" +377, 11, 14, 411, 75, 76, 1989, 1990, "(" +377, 11, 15, 412, 77, 80, 1991, 1994, "BMI" +377, 11, 16, 413, 81, 82, 1995, 1996, ">" +377, 11, 17, 414, 83, 85, 1997, 1999, "28" +377, 11, 18, 415, 86, 88, 2000, 2002, "kg" +377, 11, 19, 416, 89, 90, 2003, 2004, "/" +377, 11, 20, 417, 91, 92, 2005, 2006, "m" +377, 11, 21, 418, 93, 94, 2007, 2008, "2" +377, 11, 22, 419, 95, 96, 2009, 2010, ")" +377, 11, 23, 420, 97, 100, 2011, 2014, "sub" +377, 11, 24, 421, 101, 102, 2015, 2016, "-" +377, 11, 25, 422, 103, 109, 2017, 2023, "groups" +377, 11, 26, 423, 110, 111, 2024, 2025, "." +377, 12, 1, 424, 0, 3, 2026, 2029, "The" +377, 12, 2, 425, 4, 13, 2030, 2039, "incidence" +377, 12, 3, 426, 14, 16, 2040, 2042, "of" +377, 12, 4, 427, 17, 24, 2043, 2050, "adverse" +377, 12, 5, 428, 25, 31, 2051, 2057, "events" +377, 12, 6, 429, 32, 35, 2058, 2061, "was" +377, 12, 7, 430, 36, 43, 2062, 2069, "similar" +377, 12, 8, 431, 44, 47, 2070, 2073, "for" +377, 12, 9, 432, 48, 51, 2074, 2077, "the" +377, 12, 10, 433, 52, 55, 2078, 2081, "two" +377, 12, 11, 434, 56, 66, 2082, 2092, "treatments" +377, 12, 12, 435, 67, 68, 2093, 2094, "." +377, 13, 1, 436, 0, 11, 2095, 2106, "CONCLUSIONS" +377, 13, 2, 437, 12, 13, 2107, 2108, ":" +377, 13, 3, 438, 14, 18, 2109, 2113, "This" +377, 13, 4, 439, 19, 24, 2114, 2119, "study" +377, 13, 5, 440, 25, 37, 2120, 2132, "demonstrated" +377, 13, 6, 441, 38, 42, 2133, 2137, "that" +377, 13, 7, 442, 43, 50, 2138, 2145, "insulin" +377, 13, 8, 443, 51, 59, 2146, 2154, "glargine" +377, 13, 9, 444, 60, 62, 2155, 2157, "is" +377, 13, 10, 445, 63, 65, 2158, 2160, "as" +377, 13, 11, 446, 66, 75, 2161, 2170, "effective" +377, 13, 12, 447, 76, 78, 2171, 2173, "as" +377, 13, 13, 448, 79, 82, 2174, 2177, "NPH" +377, 13, 14, 449, 83, 90, 2178, 2185, "insulin" +377, 13, 15, 450, 91, 93, 2186, 2188, "in" +377, 13, 16, 451, 94, 103, 2189, 2198, "achieving" +377, 13, 17, 452, 104, 113, 2199, 2208, "glycaemic" +377, 13, 18, 453, 114, 121, 2209, 2216, "control" +377, 13, 19, 454, 122, 124, 2217, 2219, "in" +377, 13, 20, 455, 125, 133, 2220, 2228, "patients" +377, 13, 21, 456, 134, 138, 2229, 2233, "with" +377, 13, 22, 457, 139, 143, 2234, 2238, "Type" +377, 13, 23, 458, 144, 145, 2239, 2240, "2" +377, 13, 24, 459, 146, 154, 2241, 2249, "diabetes" +377, 13, 25, 460, 155, 156, 2250, 2251, "," +377, 13, 26, 461, 157, 160, 2252, 2255, "and" +377, 13, 27, 462, 161, 163, 2256, 2258, "is" +377, 13, 28, 463, 164, 174, 2259, 2269, "associated" +377, 13, 29, 464, 175, 179, 2270, 2274, "with" +377, 13, 30, 465, 180, 185, 2275, 2280, "fewer" +377, 13, 31, 466, 186, 194, 2281, 2289, "episodes" +377, 13, 32, 467, 195, 197, 2290, 2292, "of" +377, 13, 33, 468, 198, 209, 2293, 2304, "symptomatic" +377, 13, 34, 469, 210, 223, 2305, 2318, "hypoglycaemia" +377, 13, 35, 470, 224, 225, 2319, 2320, "," +377, 13, 36, 471, 226, 238, 2321, 2333, "particularly" +377, 13, 37, 472, 239, 248, 2334, 2343, "nocturnal" +377, 13, 38, 473, 249, 257, 2344, 2352, "episodes" +377, 13, 39, 474, 258, 259, 2353, 2354, "." +377, 14, 1, 475, 0, 3, 2355, 2358, "DOI" +377, 14, 2, 476, 4, 5, 2359, 2360, ":" +377, 14, 3, 477, 6, 8, 2361, 2363, "10" +377, 14, 4, 478, 9, 10, 2364, 2365, "." +377, 14, 5, 479, 11, 15, 2366, 2370, "1055" +377, 14, 6, 480, 16, 17, 2371, 2372, "/" +377, 14, 7, 481, 18, 19, 2373, 2374, "s" +377, 14, 8, 482, 20, 21, 2375, 2376, "-" +377, 14, 9, 483, 22, 26, 2377, 2381, "2003" +377, 14, 10, 484, 27, 28, 2382, 2383, "-" +377, 14, 11, 485, 29, 34, 2384, 2389, "39080" +377, 14, 12, 486, 35, 39, 2390, 2394, "PMID" +377, 14, 13, 487, 40, 41, 2395, 2396, ":" +377, 14, 14, 488, 42, 50, 2397, 2405, "12734781" +377, 14, 15, 489, 51, 52, 2406, 2407, "[" +377, 14, 16, 490, 53, 60, 2408, 2415, "Indexed" +377, 14, 17, 491, 61, 64, 2416, 2419, "for" +377, 14, 18, 492, 65, 72, 2420, 2427, "MEDLINE" +377, 14, 19, 493, 73, 74, 2428, 2429, "]" diff --git a/data/dm2 12734781_kwoodley.annodb b/data/dm2 12734781_kwoodley.annodb new file mode 100644 index 0000000..f385301 --- /dev/null +++ b/data/dm2 12734781_kwoodley.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31455, Journal, 0, 16, "Horm Metab Res .", "", +81, PublicationYear, 17, 21, "2003", "", +31456, Title, 50, 206, "A one - year , randomised , multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes .", "", +3500, Duration, 52, 62, "one - year", "", +331, Randomized, 65, 75, "randomised", "", +332, Multicenter, 78, 89, "multicentre", "", +333, InsulinGlargine, 106, 122, "insulin glargine", "", +342, IsophaneInsulin_NPH, 128, 139, "NPH insulin", "", +3502, OralAntidiabeticAgent, 160, 171, "oral agents", "", +96, Type2Diabetes, 189, 204, "type 2 diabetes", "", +83, Author, 207, 224, "Massi Benedetti M", "", +84, Author, 233, 242, "Humburg E", "", +85, Author, 245, 255, "Dressler A", "", +86, Author, 258, 266, "Ziemen M", "", +87, Italy, 330, 335, "Italy", "", +31457, ObjectiveDescription, 364, 527, "The aim of the trial was to compare the efficacy and safety of the new , long - acting basal insulin , insulin glargine ( LANTUS ( R ) ) , with NPH human insulin ,", "", +31428, Insulin, 457, 464, "insulin", "", +335, InsulinGlargine, 467, 483, "insulin glargine", "", +334, InsulinGlargine, 486, 498, "LANTUS ( R )", "", +343, IsophaneInsulin_NPH, 508, 525, "NPH human insulin", "", +31458, ObjectiveDescription, 528, 634, "each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes .", "", +3501, OralAntidiabeticAgent, 576, 599, "oral antidiabetic drugs", "", +97, Type2Diabetes, 617, 632, "Type 2 diabetes", "", +100, Multicenter, 650, 661, "multicentre", "", +101, OpenLabel, 664, 668, "open", "", +102, Randomized, 671, 681, "randomised", "", +94, NumberPatientsCT, 690, 693, "570", "", +98, Type2Diabetes, 708, 723, "Type 2 diabetes", "", +90, MinAge, 731, 733, "34", "", +91, MaxAge, 736, 738, "80", "", +103, Duration, 764, 772, "52 weeks", "", +337, InsulinGlargine, 778, 794, "insulin glargine", "", +344, IsophaneInsulin_NPH, 798, 809, "NPH insulin", "", +329, Frequency, 816, 826, "once daily", "for both drugs", +330, Bedtime, 830, 837, "bedtime", "for both drugs", +373, HbA1c, 966, 990, "glycosylated haemoglobin", "", +374, HbA1c, 993, 996, "GHb", "", +338, InsulinGlargine, 1050, 1066, "insulin glargine", "", +353, Reduction, 1071, 1077, "0 . 46", "", +3503, Percentage, 1078, 1079, "%", "", +345, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", +354, Reduction, 1098, 1104, "0 . 38", "", +3504, Percentage, 1105, 1106, "%", "", +772, PvalueDiff, 1109, 1120, "p = 0 . 415", "", +773, SubGroupDescription, 1197, 1239, "overweight patients with BMI > 28 kg / m 2", "", +879, BMI, 1222, 1225, "BMI", "", +358, Kg_per_squareMeter, 1231, 1239, "kg / m 2", "", +347, InsulinGlargine, 1242, 1258, "insulin glargine", "", +360, Reduction, 1263, 1269, "0 . 42", "", +3505, Percentage, 1270, 1271, "%", "", +346, IsophaneInsulin_NPH, 1274, 1285, "NPH insulin", "", +361, Reduction, 1290, 1296, "0 . 11", "", +3506, Percentage, 1297, 1298, "%", "", +775, PvalueDiff, 1301, 1313, "p = 0 . 0237", "", +348, IsophaneInsulin_NPH, 1353, 1364, "NPH insulin", "", +363, PercentageAffected, 1386, 1388, "41", "", +339, InsulinGlargine, 1397, 1413, "insulin glargine", "", +364, PercentageAffected, 1435, 1437, "35", "", +365, SymptomaticHypoglycemia, 1473, 1498, "symptomatic hypoglycaemia", "", +349, IsophaneInsulin_NPH, 1592, 1603, "NPH insulin", "", +776, EndPointDescription, 1617, 1664, "at least one episode of nocturnal hypoglycaemia", "", +877, NocturnalHypoglycemia, 1641, 1664, "nocturnal hypoglycaemia", "", +340, InsulinGlargine, 1698, 1714, "insulin glargine", "", +777, SubGroupDescription, 1752, 1762, "overweight", "", +369, PercentageAffected, 1784, 1786, "24", "", +370, PercentageAffected, 1794, 1796, "12", "", +779, PvalueDiff, 1801, 1812, "p = 0 . 002", "", +778, SubGroupDescription, 1815, 1825, "overweight", "", +371, PercentageAffected, 1828, 1834, "22 . 2", "", +372, PercentageAffected, 1842, 1847, "9 . 5", "", +780, PvalueDiff, 1852, 1864, "p = 0 . 0006", "", +379, MeasurementDevice, 1879, 1911, "Cochran - Mantel - Haenszel test", "", +781, SubGroupDescription, 1956, 1973, "insulin - na ï ve", "", +782, SubGroupDescription, 1978, 2010, "overweight ( BMI > 28 kg / m 2 )", "", +878, BMI, 1991, 1994, "BMI", "", +383, Kg_per_squareMeter, 2000, 2008, "kg / m 2", "", +31459, ConclusionComment, 2109, 2354, "This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes , and is associated with fewer episodes of symptomatic hypoglycaemia , particularly nocturnal episodes .", "", +341, InsulinGlargine, 2138, 2154, "insulin glargine", "", +350, IsophaneInsulin_NPH, 2174, 2185, "NPH insulin", "", +99, Type2Diabetes, 2234, 2249, "Type 2 diabetes", "", +384, SymptomaticHypoglycemia, 2293, 2318, "symptomatic hypoglycaemia", "", +385, NocturnalHypoglycemia, 2334, 2352, "nocturnal episodes", "", +88, PMID, 2397, 2405, "12734781", "", diff --git a/data/dm2 12734781_kwoodley.n-triples b/data/dm2 12734781_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 12734781_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14578243_admin.annodb b/data/dm2 14578243_admin.annodb new file mode 100644 index 0000000..58a0eb5 --- /dev/null +++ b/data/dm2 14578243_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +160, Journal, 0, 15, "Diabetes Care .", "", " \"Diabetes Care .\"." +1, PublicationYear, 16, 20, "2003", "", +61, Title, 50, 180, "The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "", " \"The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .\"." +62, Randomized, 82, 92, "randomized", "", +18, InsulinGlargine, 105, 113, "glargine", "", +57, IsophaneInsulin_NPH, 117, 134, "human NPH insulin", "", +138, OralAntidiabeticAgent, 138, 150, "oral therapy", "", +10, Type2Diabetes, 154, 169, "type 2 diabetic", "", +2, Author, 181, 190, "Riddle MC", "", " \"Riddle MC\"." +3, Author, 199, 211, "Rosenstock J", "", " \"Rosenstock J\"." +4, Author, 214, 222, "Gerich J", "", " \"Gerich J\"." +5, USA, 361, 364, "USA", "", " ." +162, ObjectiveDescription, 400, 569, "To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 % HbA ( 1c ) .", "", " \"To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 % HbA ( 1c ) .\"." +32, Hypoglycemia, 440, 452, "hypoglycemia", "", +19, InsulinGlargine, 462, 478, "insulin glargine", "", +28, IsophaneInsulin_NPH, 483, 500, "human NPH insulin", "", " ." +139, OralAntidiabeticAgent, 510, 522, "oral therapy", "", +11, Type2Diabetes, 526, 541, "type 2 diabetes", "", " ." +150, HbA1c_target, 553, 567, "7 % HbA ( 1c )", "", +167, Percentage, 555, 556, "%", "", +86, HbA1c, 557, 567, "HbA ( 1c )", "", +13, Randomized, 605, 615, "randomized", "", " ." +14, OpenLabel, 618, 630, "open - label", "", " ." +15, Parallel, 633, 641, "parallel", "", +17, Duration, 644, 653, "24 - week", "", " \"24 - week\"." +16, Multicenter, 654, 665, "multicenter", "", " ." +9, NumberPatientsCT, 674, 677, "756", "", +8, Precondition, 678, 786, "overweight men and women with inadequate glycemic control ( HbA ( 1c ) > 7 . 5 % ) on one or two oral agents", "", +6, Male, 689, 692, "men", "", " ." +7, Female, 697, 702, "women", "", " ." +151, HbA1c, 738, 748, "HbA ( 1c )", "", +152, Percentage, 757, 758, "%", "", +140, OralAntidiabeticAgent, 775, 786, "oral agents", "", +141, OralAntidiabeticAgent, 806, 817, "oral agents", "", +51222, Bedtime, 831, 838, "bedtime", "", " ." +20, InsulinGlargine, 839, 847, "glargine", "", +29, IsophaneInsulin_NPH, 851, 854, "NPH", "", +34, Frequency, 855, 865, "once daily", "", " \"once daily\". \"once daily\"." +60991, DoseDescription, 868, 989, "titrated using a simple algorithm seeking a target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l ) .", "", " \"titrated using a simple algorithm seeking a target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l ) .\". \"titrated using a simple algorithm seeking a target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l ) .\"." +142, FastingPlasmaGlucose_target, 919, 987, "fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l )", "", +85, Mg_per_deciliter, 961, 968, "mg / dl", "", +87, Millimoles_per_litre, 977, 985, "mmol / l", "", +35, FastingPlasmaGlucose, 1012, 1015, "FPG", "", +36, HbA1c, 1018, 1028, "HbA ( 1c )", "", +37, Hypoglycemia, 1031, 1043, "hypoglycemia", "", +153, HbA1c_target, 1082, 1147, "HbA ( 1c ) < or = 7 % without documented nocturnal hypoglycemia .", "", +38, NocturnalHypoglycemia, 1123, 1145, "nocturnal hypoglycemia", "", +149, Mean, 1158, 1162, "Mean", "", +39, FastingPlasmaGlucose, 1163, 1166, "FPG", "", " ." +154, TimePoint, 1170, 1179, "end point", "", +21, InsulinGlargine, 1197, 1205, "glargine", "", +30, IsophaneInsulin_NPH, 1210, 1213, "NPH", "", +41, ResultMeasuredValue, 1216, 1219, "117", "", " \"117\"." +42, ResultMeasuredValue, 1225, 1228, "120", "", " \"120\"." +96, Mg_per_deciliter, 1229, 1236, "mg / dl", "", " ." +43, ResultMeasuredValue, 1239, 1244, "6 . 5", "", +44, ResultMeasuredValue, 1250, 1255, "6 . 7", "", +45, Millimoles_per_litre, 1256, 1264, "mmol / l", "", +40, HbA1c, 1278, 1288, "HbA ( 1c )", "", " ." +46, ResultMeasuredValue, 1291, 1297, "6 . 96", "", " \"6 . 96\"." +47, ResultMeasuredValue, 1303, 1309, "6 . 97", "", " \"6 . 97\"." +103, Percentage, 1310, 1311, "%", "", " ." +48, PercentageAffected, 1355, 1357, "60", "", " \"60\"." +155, HbA1c_target, 1371, 1392, "HbA ( 1c ) < or = 7 %", "", " ." +27, Insulin, 1403, 1410, "insulin", "", +106, DiffGroupRelValue, 1435, 1437, "25", "", " \"25\"." +117, Percentage, 1438, 1439, "%", "", +107, NocturnalHypoglycemia, 1487, 1550, "nocturnal hypoglycemia ( < or = 72 mg / dl [ 4 . 0 mmol / l ] )", "", " ." +156, Mg_per_deciliter, 1522, 1529, "mg / dl", "", +157, Millimoles_per_litre, 1538, 1546, "mmol / l", "", +22, InsulinGlargine, 1556, 1564, "glargine", "", +50, PercentageAffected, 1567, 1573, "33 . 2", "", " \"33 . 2\"." +51, PercentageAffected, 1579, 1585, "26 . 7", "", " \"26 . 7\"." +52, PvalueDiff, 1590, 1600, "P < 0 . 05", "", " \"P < 0 . 05\"." +92973, ObservedResult, 1616, 1704, "rates of other categories of symptomatic hypoglycemia were 21 - 48 % lower with glargine", "", +53, SymptomaticHypoglycemia, 1645, 1669, "symptomatic hypoglycemia", "", " \"P < 0 . 05\"." +118, Percentage, 1683, 1684, "%", "", +23, InsulinGlargine, 1696, 1704, "glargine", "", +163, ConclusionComment, 1721, 1947, "Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7 % HbA ( 1c ) in a majority of overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone .", "", " \"Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7 % HbA ( 1c ) in a majority of overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone .\"." +51223, Bedtime, 1746, 1753, "bedtime", "", +121, Insulin, 1754, 1767, "basal insulin", "", +146, OralAntidiabeticAgent, 1777, 1789, "oral therapy", "", +58, HbA1c_target, 1809, 1823, "7 % HbA ( 1c )", "", +123, Percentage, 1811, 1812, "%", "", +122, HbA1c, 1813, 1823, "HbA ( 1c )", "", +148, Precondition, 1841, 1945, "overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone", "", " \"overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone\"." +12, Type2Diabetes, 1866, 1881, "type 2 diabetes", "", +55, HbA1c, 1887, 1897, "HbA ( 1c )", "", +159, Percentage, 1923, 1924, "%", "", +147, OralAntidiabeticAgent, 1928, 1939, "oral agents", "", +164, ConclusionComment, 1948, 2088, "In doing this , glargine causes significantly less nocturnal hypoglycemia than NPH , thus reducing a leading barrier to initiating insulin .", "", " \"In doing this , glargine causes significantly less nocturnal hypoglycemia than NPH , thus reducing a leading barrier to initiating insulin .\"." +24, InsulinGlargine, 1964, 1972, "glargine", "", +56, NocturnalHypoglycemia, 1999, 2021, "nocturnal hypoglycemia", "", +31, IsophaneInsulin_NPH, 2027, 2030, "NPH", "", +26, Insulin, 2079, 2086, "insulin", "", +165, ConclusionComment, 2089, 2253, "This simple regimen may facilitate earlier and effective insulin use in routine medical practice , improving achievement of recommended standards of diabetes care .", "", " \"This simple regimen may facilitate earlier and effective insulin use in routine medical practice , improving achievement of recommended standards of diabetes care .\"." +25, Insulin, 2146, 2153, "insulin", "", +92974, PMID, 2304, 2312, "14578243", "", " \"14578243\"." diff --git a/data/dm2 14578243_admin.n-triples b/data/dm2 14578243_admin.n-triples new file mode 100644 index 0000000..5ef1134 --- /dev/null +++ b/data/dm2 14578243_admin.n-triples @@ -0,0 +1,149 @@ +# RDF export of group: Publication + . + "Publication " . + "The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients ." . + "Riddle MC" . + "Diabetes Care ." . + "14578243" . + . + "Rosenstock J" . + "Gerich J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 % HbA ( 1c ) ." . + "24 - week" . + . + . + . + "Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7 % HbA ( 1c ) in a majority of overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone ." . + . + . + . + . + . + . + . + . + "In doing this , glargine causes significantly less nocturnal hypoglycemia than NPH , thus reducing a leading barrier to initiating insulin ." . + "This simple regimen may facilitate earlier and effective insulin use in routine medical practice , improving achievement of recommended standards of diabetes care ." . + . +# RDF export of group: Population + . + "Population " . + "overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig" . + . + . + . + . + . + . + . + "Arm nph" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig" . + "once daily" . + . + . + . + "Intervention nph" . + "once daily" . + . + . +# RDF export of group: Medication + . + "Medication ig" . + . + . + . + "titrated using a simple algorithm seeking a target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l ) ." . + . + "Medication nph" . + . + . + . + "titrated using a simple algorithm seeking a target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l ) ." . +# RDF export of group: Outcome + . + "Outcome fpg ig" . + . + "117" . + . + "Outcome fpg nph" . + . + "120" . + . + "Outcome hba1c ig" . + . + "6 . 96" . + . + "Outcome hba1c nph" . + . + "6 . 97" . + . + "Outcome nh ig " . + . + "33 . 2" . + . + "Outcome nh nph" . + . + "26 . 7" . + . + "Outcome sh ig" . + . + . + "Outcome hba1c target both drugs" . + . + "60" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups nh" . + "25" . + "P < 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14578243_akramersunderbrink.annodb b/data/dm2 14578243_akramersunderbrink.annodb new file mode 100644 index 0000000..7e3f440 --- /dev/null +++ b/data/dm2 14578243_akramersunderbrink.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +1932, Journal, 0, 13, "Diabetes Care", "", +1933, PublicationYear, 16, 20, "2003", "", +1934, Title, 50, 180, "The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "", +1935, Randomized, 82, 92, "randomized", "", +1936, InsulinGlargine, 105, 113, "glargine", "", +1937, IsophaneInsulin_NPH, 117, 134, "human NPH insulin", "", +1938, Type2Diabetes, 154, 169, "type 2 diabetic", "", +1939, Author, 181, 190, "Riddle MC", "", +1940, Author, 199, 211, "Rosenstock J", "", +1941, Author, 214, 222, "Gerich J", "", +31731, USA, 361, 364, "USA", "", +1942, ObjectiveDescription, 400, 567, "To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 % HbA ( 1c )", "", +1943, Hypoglycemia, 440, 452, "hypoglycemia", "", +1944, InsulinGlargine, 462, 478, "insulin glargine", "", +1945, IsophaneInsulin_NPH, 483, 500, "human NPH insulin", "", +1946, Type2Diabetes, 526, 541, "type 2 diabetes", "", +31732, Percentage, 555, 556, "%", "", +1962, HbA1c, 557, 567, "HbA ( 1c )", "", +1948, Randomized, 605, 615, "randomized", "", +1949, OpenLabel, 618, 630, "open - label", "", +1950, Parallel, 633, 641, "parallel", "", +1951, Duration, 644, 653, "24 - week", "", +1952, Multicenter, 654, 665, "multicenter", "", +1953, NumberPatientsCT, 674, 677, "756", "", +1954, Precondition, 708, 786, "inadequate glycemic control ( HbA ( 1c ) > 7 . 5 % ) on one or two oral agents", "", +31733, Percentage, 757, 758, "%", "", +1955, Bedtime, 831, 838, "bedtime", "", +1956, InsulinGlargine, 839, 847, "glargine", "", +1957, IsophaneInsulin_NPH, 851, 854, "NPH", "", +1958, Frequency, 855, 865, "once daily", "", +31734, FastingPlasmaGlucose_target, 912, 987, "target fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l )", "", +1960, Mg_per_deciliter, 961, 968, "mg / dl", "", +1963, Millimoles_per_litre, 977, 985, "mmol / l", "", +1964, FastingPlasmaGlucose, 1012, 1015, "FPG", "", +1965, HbA1c, 1018, 1028, "HbA ( 1c )", "", +1966, Hypoglycemia, 1031, 1043, "hypoglycemia", "", +1993, NocturnalHypoglycemia, 1073, 1145, "reaching HbA ( 1c ) < or = 7 % without documented nocturnal hypoglycemia", "", +9788, Mean, 1158, 1162, "Mean", "", +1968, FastingPlasmaGlucose, 1163, 1166, "FPG", "", +31735, TimePoint, 1170, 1179, "end point", "", +1969, InsulinGlargine, 1197, 1205, "glargine", "", +1970, IsophaneInsulin_NPH, 1210, 1213, "NPH", "", +1971, ResultMeasuredValue, 1216, 1219, "117", "", +1972, ResultMeasuredValue, 1225, 1228, "120", "", +1973, Mg_per_deciliter, 1229, 1236, "mg / dl", "", +1974, ResultMeasuredValue, 1239, 1244, "6 . 5", "", +1975, ResultMeasuredValue, 1250, 1255, "6 . 7", "", +1976, Millimoles_per_litre, 1256, 1264, "mmol / l", "", +1977, HbA1c, 1278, 1288, "HbA ( 1c )", "", +1978, ResultMeasuredValue, 1291, 1297, "6 . 96", "", +1979, ResultMeasuredValue, 1303, 1309, "6 . 97", "", +1980, Percentage, 1310, 1311, "%", "", +1981, PercentageAffected, 1355, 1357, "60", "", +1991, Percentage, 1358, 1359, "%", "", +1982, EndPointDescription, 1371, 1392, "HbA ( 1c ) < or = 7 %", "", +1983, DiffGroupRelValue, 1435, 1437, "25", "", +1996, Percentage, 1438, 1439, "%", "", +1986, NocturnalHypoglycemia, 1487, 1550, "nocturnal hypoglycemia ( < or = 72 mg / dl [ 4 . 0 mmol / l ] )", "", +1988, InsulinGlargine, 1556, 1564, "glargine", "", +1987, PercentageAffected, 1567, 1573, "33 . 2", "", +1989, PercentageAffected, 1579, 1585, "26 . 7", "", +1990, Percentage, 1586, 1587, "%", "", +1992, PvalueDiff, 1590, 1600, "P < 0 . 05", "", +1994, SymptomaticHypoglycemia, 1645, 1669, "symptomatic hypoglycemia", "", +1995, DiffGroupRelValue, 1675, 1682, "21 - 48", "", +1997, Percentage, 1683, 1684, "%", "", +1998, InsulinGlargine, 1696, 1704, "glargine", "", +2012, ConclusionComment, 1721, 1945, "Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7 % HbA ( 1c ) in a majority of overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone", "", +1999, Bedtime, 1746, 1753, "bedtime", "", +2000, Insulin, 1754, 1767, "basal insulin", "", +2002, Percentage, 1811, 1812, "%", "", +2001, HbA1c, 1813, 1823, "HbA ( 1c )", "", +2003, Type2Diabetes, 1866, 1881, "type 2 diabetes", "", +2004, Precondition, 1887, 1945, "HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone", "", +2005, HbA1c, 1887, 1905, "HbA ( 1c ) between", "", +31736, Percentage, 1923, 1924, "%", "", +2013, ConclusionComment, 1948, 2086, "In doing this , glargine causes significantly less nocturnal hypoglycemia than NPH , thus reducing a leading barrier to initiating insulin", "", +2006, InsulinGlargine, 1964, 1972, "glargine", "", +2007, NocturnalHypoglycemia, 1999, 2021, "nocturnal hypoglycemia", "", +2008, IsophaneInsulin_NPH, 2027, 2030, "NPH", "", +2009, Insulin, 2079, 2086, "insulin", "", +2014, ConclusionComment, 2089, 2251, "This simple regimen may facilitate earlier and effective insulin use in routine medical practice , improving achievement of recommended standards of diabetes care", "", +2010, Insulin, 2146, 2153, "insulin", "", +2011, PMID, 2304, 2312, "14578243", "", diff --git a/data/dm2 14578243_akramersunderbrink.n-triples b/data/dm2 14578243_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 14578243_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14578243_export.csv b/data/dm2 14578243_export.csv new file mode 100644 index 0000000..6307a54 --- /dev/null +++ b/data/dm2 14578243_export.csv @@ -0,0 +1,500 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +375, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +375, 1, 2, 2, 9, 13, 9, 13, "Care" +375, 1, 3, 3, 14, 15, 14, 15, "." +375, 2, 1, 4, 0, 4, 16, 20, "2003" +375, 2, 2, 5, 5, 8, 21, 24, "Nov" +375, 2, 3, 6, 9, 10, 25, 26, ";" +375, 2, 4, 7, 11, 13, 27, 29, "26" +375, 2, 5, 8, 14, 15, 30, 31, "(" +375, 2, 6, 9, 16, 18, 32, 34, "11" +375, 2, 7, 10, 19, 20, 35, 36, ")" +375, 2, 8, 11, 21, 22, 37, 38, ":" +375, 2, 9, 12, 23, 27, 39, 43, "3080" +375, 2, 10, 13, 28, 29, 44, 45, "-" +375, 2, 11, 14, 30, 31, 46, 47, "6" +375, 2, 12, 15, 32, 33, 48, 49, "." +375, 3, 1, 16, 0, 3, 50, 53, "The" +375, 3, 2, 17, 4, 9, 54, 59, "treat" +375, 3, 3, 18, 10, 11, 60, 61, "-" +375, 3, 4, 19, 12, 14, 62, 64, "to" +375, 3, 5, 20, 15, 16, 65, 66, "-" +375, 3, 6, 21, 17, 23, 67, 73, "target" +375, 3, 7, 22, 24, 29, 74, 79, "trial" +375, 3, 8, 23, 30, 31, 80, 81, ":" +375, 3, 9, 24, 32, 42, 82, 92, "randomized" +375, 3, 10, 25, 43, 51, 93, 101, "addition" +375, 3, 11, 26, 52, 54, 102, 104, "of" +375, 3, 12, 27, 55, 63, 105, 113, "glargine" +375, 3, 13, 28, 64, 66, 114, 116, "or" +375, 3, 14, 29, 67, 72, 117, 122, "human" +375, 3, 15, 30, 73, 76, 123, 126, "NPH" +375, 3, 16, 31, 77, 84, 127, 134, "insulin" +375, 3, 17, 32, 85, 87, 135, 137, "to" +375, 3, 18, 33, 88, 92, 138, 142, "oral" +375, 3, 19, 34, 93, 100, 143, 150, "therapy" +375, 3, 20, 35, 101, 103, 151, 153, "of" +375, 3, 21, 36, 104, 108, 154, 158, "type" +375, 3, 22, 37, 109, 110, 159, 160, "2" +375, 3, 23, 38, 111, 119, 161, 169, "diabetic" +375, 3, 24, 39, 120, 128, 170, 178, "patients" +375, 3, 25, 40, 129, 130, 179, 180, "." +375, 4, 1, 41, 0, 6, 181, 187, "Riddle" +375, 4, 2, 42, 7, 9, 188, 190, "MC" +375, 4, 3, 43, 10, 11, 191, 192, "(" +375, 4, 4, 44, 12, 13, 193, 194, "1" +375, 4, 5, 45, 14, 15, 195, 196, ")" +375, 4, 6, 46, 16, 17, 197, 198, "," +375, 4, 7, 47, 18, 28, 199, 209, "Rosenstock" +375, 4, 8, 48, 29, 30, 210, 211, "J" +375, 4, 9, 49, 31, 32, 212, 213, "," +375, 4, 10, 50, 33, 39, 214, 220, "Gerich" +375, 4, 11, 51, 40, 41, 221, 222, "J" +375, 4, 12, 52, 42, 43, 223, 224, ";" +375, 4, 13, 53, 44, 51, 225, 232, "Insulin" +375, 4, 14, 54, 52, 60, 233, 241, "Glargine" +375, 4, 15, 55, 61, 65, 242, 246, "4002" +375, 4, 16, 56, 66, 71, 247, 252, "Study" +375, 4, 17, 57, 72, 85, 253, 266, "Investigators" +375, 4, 18, 58, 86, 87, 267, 268, "." +375, 5, 1, 59, 0, 6, 269, 275, "Author" +375, 5, 2, 60, 7, 18, 276, 287, "information" +375, 5, 3, 61, 19, 20, 288, 289, ":" +375, 5, 4, 62, 21, 22, 290, 291, "(" +375, 5, 5, 63, 23, 24, 292, 293, "1" +375, 5, 6, 64, 25, 26, 294, 295, ")" +375, 5, 7, 65, 27, 33, 296, 302, "Oregon" +375, 5, 8, 66, 34, 40, 303, 309, "Health" +375, 5, 9, 67, 41, 44, 310, 313, "and" +375, 5, 10, 68, 45, 52, 314, 321, "Science" +375, 5, 11, 69, 53, 63, 322, 332, "University" +375, 5, 12, 70, 64, 65, 333, 334, "," +375, 5, 13, 71, 66, 74, 335, 343, "Portland" +375, 5, 14, 72, 75, 76, 344, 345, "," +375, 5, 15, 73, 77, 83, 346, 352, "Oregon" +375, 5, 16, 74, 84, 89, 353, 358, "97201" +375, 5, 17, 75, 90, 91, 359, 360, "," +375, 5, 18, 76, 92, 95, 361, 364, "USA" +375, 5, 19, 77, 96, 97, 365, 366, "." +375, 6, 1, 78, 0, 7, 367, 374, "riddlem" +375, 6, 2, 79, 8, 9, 375, 376, "@" +375, 6, 3, 80, 10, 14, 377, 381, "ohsu" +375, 6, 4, 81, 15, 16, 382, 383, "." +375, 6, 5, 82, 17, 20, 384, 387, "edu" +375, 6, 6, 83, 21, 30, 388, 397, "OBJECTIVE" +375, 6, 7, 84, 31, 32, 398, 399, ":" +375, 6, 8, 85, 33, 35, 400, 402, "To" +375, 6, 9, 86, 36, 43, 403, 410, "compare" +375, 6, 10, 87, 44, 47, 411, 414, "the" +375, 6, 11, 88, 48, 57, 415, 424, "abilities" +375, 6, 12, 89, 58, 61, 425, 428, "and" +375, 6, 13, 90, 62, 72, 429, 439, "associated" +375, 6, 14, 91, 73, 85, 440, 452, "hypoglycemia" +375, 6, 15, 92, 86, 91, 453, 458, "risks" +375, 6, 16, 93, 92, 94, 459, 461, "of" +375, 6, 17, 94, 95, 102, 462, 469, "insulin" +375, 6, 18, 95, 103, 111, 470, 478, "glargine" +375, 6, 19, 96, 112, 115, 479, 482, "and" +375, 6, 20, 97, 116, 121, 483, 488, "human" +375, 6, 21, 98, 122, 125, 489, 492, "NPH" +375, 6, 22, 99, 126, 133, 493, 500, "insulin" +375, 6, 23, 100, 134, 139, 501, 506, "added" +375, 6, 24, 101, 140, 142, 507, 509, "to" +375, 6, 25, 102, 143, 147, 510, 514, "oral" +375, 6, 26, 103, 148, 155, 515, 522, "therapy" +375, 6, 27, 104, 156, 158, 523, 525, "of" +375, 6, 28, 105, 159, 163, 526, 530, "type" +375, 6, 29, 106, 164, 165, 531, 532, "2" +375, 6, 30, 107, 166, 174, 533, 541, "diabetes" +375, 6, 31, 108, 175, 177, 542, 544, "to" +375, 6, 32, 109, 178, 185, 545, 552, "achieve" +375, 6, 33, 110, 186, 187, 553, 554, "7" +375, 6, 34, 111, 188, 189, 555, 556, "%" +375, 6, 35, 112, 190, 193, 557, 560, "HbA" +375, 6, 36, 113, 194, 195, 561, 562, "(" +375, 6, 37, 114, 196, 198, 563, 565, "1c" +375, 6, 38, 115, 199, 200, 566, 567, ")" +375, 6, 39, 116, 201, 202, 568, 569, "." +375, 7, 1, 117, 0, 8, 570, 578, "RESEARCH" +375, 7, 2, 118, 9, 15, 579, 585, "DESIGN" +375, 7, 3, 119, 16, 19, 586, 589, "AND" +375, 7, 4, 120, 20, 27, 590, 597, "METHODS" +375, 7, 5, 121, 28, 29, 598, 599, ":" +375, 7, 6, 122, 30, 32, 600, 602, "In" +375, 7, 7, 123, 33, 34, 603, 604, "a" +375, 7, 8, 124, 35, 45, 605, 615, "randomized" +375, 7, 9, 125, 46, 47, 616, 617, "," +375, 7, 10, 126, 48, 52, 618, 622, "open" +375, 7, 11, 127, 53, 54, 623, 624, "-" +375, 7, 12, 128, 55, 60, 625, 630, "label" +375, 7, 13, 129, 61, 62, 631, 632, "," +375, 7, 14, 130, 63, 71, 633, 641, "parallel" +375, 7, 15, 131, 72, 73, 642, 643, "," +375, 7, 16, 132, 74, 76, 644, 646, "24" +375, 7, 17, 133, 77, 78, 647, 648, "-" +375, 7, 18, 134, 79, 83, 649, 653, "week" +375, 7, 19, 135, 84, 95, 654, 665, "multicenter" +375, 7, 20, 136, 96, 101, 666, 671, "trial" +375, 7, 21, 137, 102, 103, 672, 673, "," +375, 7, 22, 138, 104, 107, 674, 677, "756" +375, 7, 23, 139, 108, 118, 678, 688, "overweight" +375, 7, 24, 140, 119, 122, 689, 692, "men" +375, 7, 25, 141, 123, 126, 693, 696, "and" +375, 7, 26, 142, 127, 132, 697, 702, "women" +375, 7, 27, 143, 133, 137, 703, 707, "with" +375, 7, 28, 144, 138, 148, 708, 718, "inadequate" +375, 7, 29, 145, 149, 157, 719, 727, "glycemic" +375, 7, 30, 146, 158, 165, 728, 735, "control" +375, 7, 31, 147, 166, 167, 736, 737, "(" +375, 7, 32, 148, 168, 171, 738, 741, "HbA" +375, 7, 33, 149, 172, 173, 742, 743, "(" +375, 7, 34, 150, 174, 176, 744, 746, "1c" +375, 7, 35, 151, 177, 178, 747, 748, ")" +375, 7, 36, 152, 179, 180, 749, 750, ">" +375, 7, 37, 153, 181, 182, 751, 752, "7" +375, 7, 38, 154, 183, 184, 753, 754, "." +375, 7, 39, 155, 185, 186, 755, 756, "5" +375, 7, 40, 156, 187, 188, 757, 758, "%" +375, 7, 41, 157, 189, 190, 759, 760, ")" +375, 7, 42, 158, 191, 193, 761, 763, "on" +375, 7, 43, 159, 194, 197, 764, 767, "one" +375, 7, 44, 160, 198, 200, 768, 770, "or" +375, 7, 45, 161, 201, 204, 771, 774, "two" +375, 7, 46, 162, 205, 209, 775, 779, "oral" +375, 7, 47, 163, 210, 216, 780, 786, "agents" +375, 7, 48, 164, 217, 226, 787, 796, "continued" +375, 7, 49, 165, 227, 235, 797, 805, "prestudy" +375, 7, 50, 166, 236, 240, 806, 810, "oral" +375, 7, 51, 167, 241, 247, 811, 817, "agents" +375, 7, 52, 168, 248, 251, 818, 821, "and" +375, 7, 53, 169, 252, 260, 822, 830, "received" +375, 7, 54, 170, 261, 268, 831, 838, "bedtime" +375, 7, 55, 171, 269, 277, 839, 847, "glargine" +375, 7, 56, 172, 278, 280, 848, 850, "or" +375, 7, 57, 173, 281, 284, 851, 854, "NPH" +375, 7, 58, 174, 285, 289, 855, 859, "once" +375, 7, 59, 175, 290, 295, 860, 865, "daily" +375, 7, 60, 176, 296, 297, 866, 867, "," +375, 7, 61, 177, 298, 306, 868, 876, "titrated" +375, 7, 62, 178, 307, 312, 877, 882, "using" +375, 7, 63, 179, 313, 314, 883, 884, "a" +375, 7, 64, 180, 315, 321, 885, 891, "simple" +375, 7, 65, 181, 322, 331, 892, 901, "algorithm" +375, 7, 66, 182, 332, 339, 902, 909, "seeking" +375, 7, 67, 183, 340, 341, 910, 911, "a" +375, 7, 68, 184, 342, 348, 912, 918, "target" +375, 7, 69, 185, 349, 356, 919, 926, "fasting" +375, 7, 70, 186, 357, 363, 927, 933, "plasma" +375, 7, 71, 187, 364, 371, 934, 941, "glucose" +375, 7, 72, 188, 372, 373, 942, 943, "(" +375, 7, 73, 189, 374, 377, 944, 947, "FPG" +375, 7, 74, 190, 378, 379, 948, 949, ")" +375, 7, 75, 191, 380, 381, 950, 951, "<" +375, 7, 76, 192, 382, 384, 952, 954, "or" +375, 7, 77, 193, 385, 386, 955, 956, "=" +375, 7, 78, 194, 387, 390, 957, 960, "100" +375, 7, 79, 195, 391, 393, 961, 963, "mg" +375, 7, 80, 196, 394, 395, 964, 965, "/" +375, 7, 81, 197, 396, 398, 966, 968, "dl" +375, 7, 82, 198, 399, 400, 969, 970, "(" +375, 7, 83, 199, 401, 402, 971, 972, "5" +375, 7, 84, 200, 403, 404, 973, 974, "." +375, 7, 85, 201, 405, 406, 975, 976, "5" +375, 7, 86, 202, 407, 411, 977, 981, "mmol" +375, 7, 87, 203, 412, 413, 982, 983, "/" +375, 7, 88, 204, 414, 415, 984, 985, "l" +375, 7, 89, 205, 416, 417, 986, 987, ")" +375, 7, 90, 206, 418, 419, 988, 989, "." +375, 8, 1, 207, 0, 7, 990, 997, "Outcome" +375, 8, 2, 208, 8, 16, 998, 1006, "measures" +375, 8, 3, 209, 17, 21, 1007, 1011, "were" +375, 8, 4, 210, 22, 25, 1012, 1015, "FPG" +375, 8, 5, 211, 26, 27, 1016, 1017, "," +375, 8, 6, 212, 28, 31, 1018, 1021, "HbA" +375, 8, 7, 213, 32, 33, 1022, 1023, "(" +375, 8, 8, 214, 34, 36, 1024, 1026, "1c" +375, 8, 9, 215, 37, 38, 1027, 1028, ")" +375, 8, 10, 216, 39, 40, 1029, 1030, "," +375, 8, 11, 217, 41, 53, 1031, 1043, "hypoglycemia" +375, 8, 12, 218, 54, 55, 1044, 1045, "," +375, 8, 13, 219, 56, 59, 1046, 1049, "and" +375, 8, 14, 220, 60, 70, 1050, 1060, "percentage" +375, 8, 15, 221, 71, 73, 1061, 1063, "of" +375, 8, 16, 222, 74, 82, 1064, 1072, "patients" +375, 8, 17, 223, 83, 91, 1073, 1081, "reaching" +375, 8, 18, 224, 92, 95, 1082, 1085, "HbA" +375, 8, 19, 225, 96, 97, 1086, 1087, "(" +375, 8, 20, 226, 98, 100, 1088, 1090, "1c" +375, 8, 21, 227, 101, 102, 1091, 1092, ")" +375, 8, 22, 228, 103, 104, 1093, 1094, "<" +375, 8, 23, 229, 105, 107, 1095, 1097, "or" +375, 8, 24, 230, 108, 109, 1098, 1099, "=" +375, 8, 25, 231, 110, 111, 1100, 1101, "7" +375, 8, 26, 232, 112, 113, 1102, 1103, "%" +375, 8, 27, 233, 114, 121, 1104, 1111, "without" +375, 8, 28, 234, 122, 132, 1112, 1122, "documented" +375, 8, 29, 235, 133, 142, 1123, 1132, "nocturnal" +375, 8, 30, 236, 143, 155, 1133, 1145, "hypoglycemia" +375, 8, 31, 237, 156, 157, 1146, 1147, "." +375, 9, 1, 238, 0, 7, 1148, 1155, "RESULTS" +375, 9, 2, 239, 8, 9, 1156, 1157, ":" +375, 9, 3, 240, 10, 14, 1158, 1162, "Mean" +375, 9, 4, 241, 15, 18, 1163, 1166, "FPG" +375, 9, 5, 242, 19, 21, 1167, 1169, "at" +375, 9, 6, 243, 22, 25, 1170, 1173, "end" +375, 9, 7, 244, 26, 31, 1174, 1179, "point" +375, 9, 8, 245, 32, 35, 1180, 1183, "was" +375, 9, 9, 246, 36, 43, 1184, 1191, "similar" +375, 9, 10, 247, 44, 48, 1192, 1196, "with" +375, 9, 11, 248, 49, 57, 1197, 1205, "glargine" +375, 9, 12, 249, 58, 61, 1206, 1209, "and" +375, 9, 13, 250, 62, 65, 1210, 1213, "NPH" +375, 9, 14, 251, 66, 67, 1214, 1215, "(" +375, 9, 15, 252, 68, 71, 1216, 1219, "117" +375, 9, 16, 253, 72, 74, 1220, 1222, "vs" +375, 9, 17, 254, 75, 76, 1223, 1224, "." +375, 9, 18, 255, 77, 80, 1225, 1228, "120" +375, 9, 19, 256, 81, 83, 1229, 1231, "mg" +375, 9, 20, 257, 84, 85, 1232, 1233, "/" +375, 9, 21, 258, 86, 88, 1234, 1236, "dl" +375, 9, 22, 259, 89, 90, 1237, 1238, "[" +375, 9, 23, 260, 91, 92, 1239, 1240, "6" +375, 9, 24, 261, 93, 94, 1241, 1242, "." +375, 9, 25, 262, 95, 96, 1243, 1244, "5" +375, 9, 26, 263, 97, 99, 1245, 1247, "vs" +375, 9, 27, 264, 100, 101, 1248, 1249, "." +375, 9, 28, 265, 102, 103, 1250, 1251, "6" +375, 9, 29, 266, 104, 105, 1252, 1253, "." +375, 9, 30, 267, 106, 107, 1254, 1255, "7" +375, 9, 31, 268, 108, 112, 1256, 1260, "mmol" +375, 9, 32, 269, 113, 114, 1261, 1262, "/" +375, 9, 33, 270, 115, 116, 1263, 1264, "l" +375, 9, 34, 271, 117, 118, 1265, 1266, "]" +375, 9, 35, 272, 119, 120, 1267, 1268, ")" +375, 9, 36, 273, 121, 122, 1269, 1270, "," +375, 9, 37, 274, 123, 125, 1271, 1273, "as" +375, 9, 38, 275, 126, 129, 1274, 1277, "was" +375, 9, 39, 276, 130, 133, 1278, 1281, "HbA" +375, 9, 40, 277, 134, 135, 1282, 1283, "(" +375, 9, 41, 278, 136, 138, 1284, 1286, "1c" +375, 9, 42, 279, 139, 140, 1287, 1288, ")" +375, 9, 43, 280, 141, 142, 1289, 1290, "(" +375, 9, 44, 281, 143, 144, 1291, 1292, "6" +375, 9, 45, 282, 145, 146, 1293, 1294, "." +375, 9, 46, 283, 147, 149, 1295, 1297, "96" +375, 9, 47, 284, 150, 152, 1298, 1300, "vs" +375, 9, 48, 285, 153, 154, 1301, 1302, "." +375, 9, 49, 286, 155, 156, 1303, 1304, "6" +375, 9, 50, 287, 157, 158, 1305, 1306, "." +375, 9, 51, 288, 159, 161, 1307, 1309, "97" +375, 9, 52, 289, 162, 163, 1310, 1311, "%" +375, 9, 53, 290, 164, 165, 1312, 1313, ")" +375, 9, 54, 291, 166, 167, 1314, 1315, "." +375, 10, 1, 292, 0, 1, 1316, 1317, "A" +375, 10, 2, 293, 2, 10, 1318, 1326, "majority" +375, 10, 3, 294, 11, 13, 1327, 1329, "of" +375, 10, 4, 295, 14, 22, 1330, 1338, "patients" +375, 10, 5, 296, 23, 24, 1339, 1340, "(" +375, 10, 6, 297, 25, 38, 1341, 1354, "approximately" +375, 10, 7, 298, 39, 41, 1355, 1357, "60" +375, 10, 8, 299, 42, 43, 1358, 1359, "%" +375, 10, 9, 300, 44, 45, 1360, 1361, ")" +375, 10, 10, 301, 46, 54, 1362, 1370, "attained" +375, 10, 11, 302, 55, 58, 1371, 1374, "HbA" +375, 10, 12, 303, 59, 60, 1375, 1376, "(" +375, 10, 13, 304, 61, 63, 1377, 1379, "1c" +375, 10, 14, 305, 64, 65, 1380, 1381, ")" +375, 10, 15, 306, 66, 67, 1382, 1383, "<" +375, 10, 16, 307, 68, 70, 1384, 1386, "or" +375, 10, 17, 308, 71, 72, 1387, 1388, "=" +375, 10, 18, 309, 73, 74, 1389, 1390, "7" +375, 10, 19, 310, 75, 76, 1391, 1392, "%" +375, 10, 20, 311, 77, 81, 1393, 1397, "with" +375, 10, 21, 312, 82, 86, 1398, 1402, "each" +375, 10, 22, 313, 87, 94, 1403, 1410, "insulin" +375, 10, 23, 314, 95, 99, 1411, 1415, "type" +375, 10, 24, 315, 100, 101, 1416, 1417, "." +375, 11, 1, 316, 0, 7, 1418, 1425, "However" +375, 11, 2, 317, 8, 9, 1426, 1427, "," +375, 11, 3, 318, 10, 16, 1428, 1434, "nearly" +375, 11, 4, 319, 17, 19, 1435, 1437, "25" +375, 11, 5, 320, 20, 21, 1438, 1439, "%" +375, 11, 6, 321, 22, 26, 1440, 1444, "more" +375, 11, 7, 322, 27, 35, 1445, 1453, "patients" +375, 11, 8, 323, 36, 44, 1454, 1462, "attained" +375, 11, 9, 324, 45, 49, 1463, 1467, "this" +375, 11, 10, 325, 50, 57, 1468, 1475, "without" +375, 11, 11, 326, 58, 68, 1476, 1486, "documented" +375, 11, 12, 327, 69, 78, 1487, 1496, "nocturnal" +375, 11, 13, 328, 79, 91, 1497, 1509, "hypoglycemia" +375, 11, 14, 329, 92, 93, 1510, 1511, "(" +375, 11, 15, 330, 94, 95, 1512, 1513, "<" +375, 11, 16, 331, 96, 98, 1514, 1516, "or" +375, 11, 17, 332, 99, 100, 1517, 1518, "=" +375, 11, 18, 333, 101, 103, 1519, 1521, "72" +375, 11, 19, 334, 104, 106, 1522, 1524, "mg" +375, 11, 20, 335, 107, 108, 1525, 1526, "/" +375, 11, 21, 336, 109, 111, 1527, 1529, "dl" +375, 11, 22, 337, 112, 113, 1530, 1531, "[" +375, 11, 23, 338, 114, 115, 1532, 1533, "4" +375, 11, 24, 339, 116, 117, 1534, 1535, "." +375, 11, 25, 340, 118, 119, 1536, 1537, "0" +375, 11, 26, 341, 120, 124, 1538, 1542, "mmol" +375, 11, 27, 342, 125, 126, 1543, 1544, "/" +375, 11, 28, 343, 127, 128, 1545, 1546, "l" +375, 11, 29, 344, 129, 130, 1547, 1548, "]" +375, 11, 30, 345, 131, 132, 1549, 1550, ")" +375, 11, 31, 346, 133, 137, 1551, 1555, "with" +375, 11, 32, 347, 138, 146, 1556, 1564, "glargine" +375, 11, 33, 348, 147, 148, 1565, 1566, "(" +375, 11, 34, 349, 149, 151, 1567, 1569, "33" +375, 11, 35, 350, 152, 153, 1570, 1571, "." +375, 11, 36, 351, 154, 155, 1572, 1573, "2" +375, 11, 37, 352, 156, 158, 1574, 1576, "vs" +375, 11, 38, 353, 159, 160, 1577, 1578, "." +375, 11, 39, 354, 161, 163, 1579, 1581, "26" +375, 11, 40, 355, 164, 165, 1582, 1583, "." +375, 11, 41, 356, 166, 167, 1584, 1585, "7" +375, 11, 42, 357, 168, 169, 1586, 1587, "%" +375, 11, 43, 358, 170, 171, 1588, 1589, "," +375, 11, 44, 359, 172, 173, 1590, 1591, "P" +375, 11, 45, 360, 174, 175, 1592, 1593, "<" +375, 11, 46, 361, 176, 177, 1594, 1595, "0" +375, 11, 47, 362, 178, 179, 1596, 1597, "." +375, 11, 48, 363, 180, 182, 1598, 1600, "05" +375, 11, 49, 364, 183, 184, 1601, 1602, ")" +375, 11, 50, 365, 185, 186, 1603, 1604, "." +375, 12, 1, 366, 0, 8, 1605, 1613, "Moreover" +375, 12, 2, 367, 9, 10, 1614, 1615, "," +375, 12, 3, 368, 11, 16, 1616, 1621, "rates" +375, 12, 4, 369, 17, 19, 1622, 1624, "of" +375, 12, 5, 370, 20, 25, 1625, 1630, "other" +375, 12, 6, 371, 26, 36, 1631, 1641, "categories" +375, 12, 7, 372, 37, 39, 1642, 1644, "of" +375, 12, 8, 373, 40, 51, 1645, 1656, "symptomatic" +375, 12, 9, 374, 52, 64, 1657, 1669, "hypoglycemia" +375, 12, 10, 375, 65, 69, 1670, 1674, "were" +375, 12, 11, 376, 70, 72, 1675, 1677, "21" +375, 12, 12, 377, 73, 74, 1678, 1679, "-" +375, 12, 13, 378, 75, 77, 1680, 1682, "48" +375, 12, 14, 379, 78, 79, 1683, 1684, "%" +375, 12, 15, 380, 80, 85, 1685, 1690, "lower" +375, 12, 16, 381, 86, 90, 1691, 1695, "with" +375, 12, 17, 382, 91, 99, 1696, 1704, "glargine" +375, 12, 18, 383, 100, 101, 1705, 1706, "." +375, 13, 1, 384, 0, 11, 1707, 1718, "CONCLUSIONS" +375, 13, 2, 385, 12, 13, 1719, 1720, ":" +375, 13, 3, 386, 14, 28, 1721, 1735, "Systematically" +375, 13, 4, 387, 29, 38, 1736, 1745, "titrating" +375, 13, 5, 388, 39, 46, 1746, 1753, "bedtime" +375, 13, 6, 389, 47, 52, 1754, 1759, "basal" +375, 13, 7, 390, 53, 60, 1760, 1767, "insulin" +375, 13, 8, 391, 61, 66, 1768, 1773, "added" +375, 13, 9, 392, 67, 69, 1774, 1776, "to" +375, 13, 10, 393, 70, 74, 1777, 1781, "oral" +375, 13, 11, 394, 75, 82, 1782, 1789, "therapy" +375, 13, 12, 395, 83, 86, 1790, 1793, "can" +375, 13, 13, 396, 87, 93, 1794, 1800, "safely" +375, 13, 14, 397, 94, 101, 1801, 1808, "achieve" +375, 13, 15, 398, 102, 103, 1809, 1810, "7" +375, 13, 16, 399, 104, 105, 1811, 1812, "%" +375, 13, 17, 400, 106, 109, 1813, 1816, "HbA" +375, 13, 18, 401, 110, 111, 1817, 1818, "(" +375, 13, 19, 402, 112, 114, 1819, 1821, "1c" +375, 13, 20, 403, 115, 116, 1822, 1823, ")" +375, 13, 21, 404, 117, 119, 1824, 1826, "in" +375, 13, 22, 405, 120, 121, 1827, 1828, "a" +375, 13, 23, 406, 122, 130, 1829, 1837, "majority" +375, 13, 24, 407, 131, 133, 1838, 1840, "of" +375, 13, 25, 408, 134, 144, 1841, 1851, "overweight" +375, 13, 26, 409, 145, 153, 1852, 1860, "patients" +375, 13, 27, 410, 154, 158, 1861, 1865, "with" +375, 13, 28, 411, 159, 163, 1866, 1870, "type" +375, 13, 29, 412, 164, 165, 1871, 1872, "2" +375, 13, 30, 413, 166, 174, 1873, 1881, "diabetes" +375, 13, 31, 414, 175, 179, 1882, 1886, "with" +375, 13, 32, 415, 180, 183, 1887, 1890, "HbA" +375, 13, 33, 416, 184, 185, 1891, 1892, "(" +375, 13, 34, 417, 186, 188, 1893, 1895, "1c" +375, 13, 35, 418, 189, 190, 1896, 1897, ")" +375, 13, 36, 419, 191, 198, 1898, 1905, "between" +375, 13, 37, 420, 199, 200, 1906, 1907, "7" +375, 13, 38, 421, 201, 202, 1908, 1909, "." +375, 13, 39, 422, 203, 204, 1910, 1911, "5" +375, 13, 40, 423, 205, 208, 1912, 1915, "and" +375, 13, 41, 424, 209, 211, 1916, 1918, "10" +375, 13, 42, 425, 212, 213, 1919, 1920, "." +375, 13, 43, 426, 214, 215, 1921, 1922, "0" +375, 13, 44, 427, 216, 217, 1923, 1924, "%" +375, 13, 45, 428, 218, 220, 1925, 1927, "on" +375, 13, 46, 429, 221, 225, 1928, 1932, "oral" +375, 13, 47, 430, 226, 232, 1933, 1939, "agents" +375, 13, 48, 431, 233, 238, 1940, 1945, "alone" +375, 13, 49, 432, 239, 240, 1946, 1947, "." +375, 14, 1, 433, 0, 2, 1948, 1950, "In" +375, 14, 2, 434, 3, 8, 1951, 1956, "doing" +375, 14, 3, 435, 9, 13, 1957, 1961, "this" +375, 14, 4, 436, 14, 15, 1962, 1963, "," +375, 14, 5, 437, 16, 24, 1964, 1972, "glargine" +375, 14, 6, 438, 25, 31, 1973, 1979, "causes" +375, 14, 7, 439, 32, 45, 1980, 1993, "significantly" +375, 14, 8, 440, 46, 50, 1994, 1998, "less" +375, 14, 9, 441, 51, 60, 1999, 2008, "nocturnal" +375, 14, 10, 442, 61, 73, 2009, 2021, "hypoglycemia" +375, 14, 11, 443, 74, 78, 2022, 2026, "than" +375, 14, 12, 444, 79, 82, 2027, 2030, "NPH" +375, 14, 13, 445, 83, 84, 2031, 2032, "," +375, 14, 14, 446, 85, 89, 2033, 2037, "thus" +375, 14, 15, 447, 90, 98, 2038, 2046, "reducing" +375, 14, 16, 448, 99, 100, 2047, 2048, "a" +375, 14, 17, 449, 101, 108, 2049, 2056, "leading" +375, 14, 18, 450, 109, 116, 2057, 2064, "barrier" +375, 14, 19, 451, 117, 119, 2065, 2067, "to" +375, 14, 20, 452, 120, 130, 2068, 2078, "initiating" +375, 14, 21, 453, 131, 138, 2079, 2086, "insulin" +375, 14, 22, 454, 139, 140, 2087, 2088, "." +375, 15, 1, 455, 0, 4, 2089, 2093, "This" +375, 15, 2, 456, 5, 11, 2094, 2100, "simple" +375, 15, 3, 457, 12, 19, 2101, 2108, "regimen" +375, 15, 4, 458, 20, 23, 2109, 2112, "may" +375, 15, 5, 459, 24, 34, 2113, 2123, "facilitate" +375, 15, 6, 460, 35, 42, 2124, 2131, "earlier" +375, 15, 7, 461, 43, 46, 2132, 2135, "and" +375, 15, 8, 462, 47, 56, 2136, 2145, "effective" +375, 15, 9, 463, 57, 64, 2146, 2153, "insulin" +375, 15, 10, 464, 65, 68, 2154, 2157, "use" +375, 15, 11, 465, 69, 71, 2158, 2160, "in" +375, 15, 12, 466, 72, 79, 2161, 2168, "routine" +375, 15, 13, 467, 80, 87, 2169, 2176, "medical" +375, 15, 14, 468, 88, 96, 2177, 2185, "practice" +375, 15, 15, 469, 97, 98, 2186, 2187, "," +375, 15, 16, 470, 99, 108, 2188, 2197, "improving" +375, 15, 17, 471, 109, 120, 2198, 2209, "achievement" +375, 15, 18, 472, 121, 123, 2210, 2212, "of" +375, 15, 19, 473, 124, 135, 2213, 2224, "recommended" +375, 15, 20, 474, 136, 145, 2225, 2234, "standards" +375, 15, 21, 475, 146, 148, 2235, 2237, "of" +375, 15, 22, 476, 149, 157, 2238, 2246, "diabetes" +375, 15, 23, 477, 158, 162, 2247, 2251, "care" +375, 15, 24, 478, 163, 164, 2252, 2253, "." +375, 16, 1, 479, 0, 3, 2254, 2257, "DOI" +375, 16, 2, 480, 4, 5, 2258, 2259, ":" +375, 16, 3, 481, 6, 8, 2260, 2262, "10" +375, 16, 4, 482, 9, 10, 2263, 2264, "." +375, 16, 5, 483, 11, 15, 2265, 2269, "2337" +375, 16, 6, 484, 16, 17, 2270, 2271, "/" +375, 16, 7, 485, 18, 25, 2272, 2279, "diacare" +375, 16, 8, 486, 26, 27, 2280, 2281, "." +375, 16, 9, 487, 28, 30, 2282, 2284, "26" +375, 16, 10, 488, 31, 32, 2285, 2286, "." +375, 16, 11, 489, 33, 35, 2287, 2289, "11" +375, 16, 12, 490, 36, 37, 2290, 2291, "." +375, 16, 13, 491, 38, 42, 2292, 2296, "3080" +375, 16, 14, 492, 43, 47, 2297, 2301, "PMID" +375, 16, 15, 493, 48, 49, 2302, 2303, ":" +375, 16, 16, 494, 50, 58, 2304, 2312, "14578243" +375, 16, 17, 495, 59, 60, 2313, 2314, "[" +375, 16, 18, 496, 61, 68, 2315, 2322, "Indexed" +375, 16, 19, 497, 69, 72, 2323, 2326, "for" +375, 16, 20, 498, 73, 80, 2327, 2334, "MEDLINE" +375, 16, 21, 499, 81, 82, 2335, 2336, "]" diff --git a/data/dm2 14578243_kwoodley.annodb b/data/dm2 14578243_kwoodley.annodb new file mode 100644 index 0000000..70e071f --- /dev/null +++ b/data/dm2 14578243_kwoodley.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31466, Journal, 0, 15, "Diabetes Care .", "", +115, PublicationYear, 16, 20, "2003", "", +31467, Title, 50, 180, "The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "", +3527, Randomized, 82, 92, "randomized", "", +915, InsulinGlargine, 105, 113, "glargine", "", +967, IsophaneInsulin_NPH, 117, 134, "human NPH insulin", "", +3528, OralAntidiabeticAgent, 138, 150, "oral therapy", "", +906, Type2Diabetes, 154, 169, "type 2 diabetic", "", +117, Author, 181, 190, "Riddle MC", "", +118, Author, 199, 211, "Rosenstock J", "", +119, Author, 214, 222, "Gerich J", "", +897, USA, 361, 364, "USA", "", +31468, ObjectiveDescription, 400, 569, "To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 % HbA ( 1c ) .", "", +931, Hypoglycemia, 440, 452, "hypoglycemia", "", +916, InsulinGlargine, 462, 478, "insulin glargine", "", +927, IsophaneInsulin_NPH, 483, 500, "human NPH insulin", "", +3529, OralAntidiabeticAgent, 510, 522, "oral therapy", "", +907, Type2Diabetes, 526, 541, "type 2 diabetes", "", +31433, HbA1c_target, 553, 567, "7 % HbA ( 1c )", "", +910, Randomized, 605, 615, "randomized", "", +911, OpenLabel, 618, 630, "open - label", "", +912, Parallel, 633, 641, "parallel", "", +914, Duration, 644, 653, "24 - week", "", +913, Multicenter, 654, 665, "multicenter", "", +902, NumberPatientsCT, 674, 677, "756", "", +900, Precondition, 678, 760, "overweight men and women with inadequate glycemic control ( HbA ( 1c ) > 7 . 5 % )", "", +898, Male, 689, 692, "men", "", +899, Female, 697, 702, "women", "", +31434, HbA1c, 738, 748, "HbA ( 1c )", "", +31435, Percentage, 757, 758, "%", "", +3530, OralAntidiabeticAgent, 775, 786, "oral agents", "", +3534, OralAntidiabeticAgent, 806, 817, "oral agents", "", +934, Bedtime, 831, 838, "bedtime", "", +917, InsulinGlargine, 839, 847, "glargine", "", +928, IsophaneInsulin_NPH, 851, 854, "NPH", "", +935, Frequency, 855, 865, "once daily", "", +3535, FastingPlasmaGlucose_target, 919, 987, "fasting plasma glucose ( FPG ) < or = 100 mg / dl ( 5 . 5 mmol / l )", "", +942, FastingPlasmaGlucose, 1012, 1015, "FPG", "", +943, HbA1c, 1018, 1028, "HbA ( 1c )", "", +944, Hypoglycemia, 1031, 1043, "hypoglycemia", "", +31436, HbA1c_target, 1082, 1103, "HbA ( 1c ) < or = 7 %", "", +945, NocturnalHypoglycemia, 1123, 1145, "nocturnal hypoglycemia", "", +947, FastingPlasmaGlucose, 1163, 1166, "FPG", "", +31437, TimePoint, 1170, 1179, "end point", "", +918, InsulinGlargine, 1197, 1205, "glargine", "", +929, IsophaneInsulin_NPH, 1210, 1213, "NPH", "", +949, ResultMeasuredValue, 1216, 1219, "117", "", +950, ResultMeasuredValue, 1225, 1228, "120", "", +3536, Mg_per_deciliter, 1229, 1236, "mg / dl", "", +951, ResultMeasuredValue, 1239, 1244, "6 . 5", "", +952, ResultMeasuredValue, 1250, 1255, "6 . 7", "", +953, Millimoles_per_litre, 1256, 1264, "mmol / l", "", +948, HbA1c, 1278, 1288, "HbA ( 1c )", "", +955, ResultMeasuredValue, 1291, 1297, "6 . 96", "", +956, ResultMeasuredValue, 1303, 1309, "6 . 97", "", +2097, Percentage, 1310, 1311, "%", "", +957, PercentageAffected, 1355, 1357, "60", "", +31438, HbA1c_target, 1371, 1392, "HbA ( 1c ) < or = 7 %", "", +925, Insulin, 1403, 1410, "insulin", "", +959, NocturnalHypoglycemia, 1487, 1509, "nocturnal hypoglycemia", "", +31440, Mg_per_deciliter, 1522, 1529, "mg / dl", "", +31443, Millimoles_per_litre, 1538, 1546, "mmol / l", "", +919, InsulinGlargine, 1556, 1564, "glargine", "", +960, PercentageAffected, 1567, 1573, "33 . 2", "", +961, PercentageAffected, 1579, 1585, "26 . 7", "", +3539, Percentage, 1586, 1587, "%", "", +962, PvalueDiff, 1590, 1600, "P < 0 . 05", "", +3540, ObservedResult, 1616, 1704, "rates of other categories of symptomatic hypoglycemia were 21 - 48 % lower with glargine", "", +963, SymptomaticHypoglycemia, 1645, 1669, "symptomatic hypoglycemia", "", +920, InsulinGlargine, 1696, 1704, "glargine", "", +31469, ConclusionComment, 1721, 1947, "Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7 % HbA ( 1c ) in a majority of overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone .", "", +964, Bedtime, 1746, 1753, "bedtime", "", +31444, InsulinGlargine, 1754, 1767, "basal insulin", "", +3541, OralAntidiabeticAgent, 1777, 1789, "oral therapy", "", +971, HbA1c_target, 1809, 1823, "7 % HbA ( 1c )", "", +3544, Precondition, 1841, 1945, "overweight patients with type 2 diabetes with HbA ( 1c ) between 7 . 5 and 10 . 0 % on oral agents alone", "", +909, Type2Diabetes, 1866, 1881, "type 2 diabetes", "", +965, HbA1c, 1887, 1897, "HbA ( 1c )", "", +31445, Percentage, 1923, 1924, "%", "", +3543, OralAntidiabeticAgent, 1928, 1939, "oral agents", "", +31470, ConclusionComment, 1948, 2088, "In doing this , glargine causes significantly less nocturnal hypoglycemia than NPH , thus reducing a leading barrier to initiating insulin .", "", +922, InsulinGlargine, 1964, 1972, "glargine", "", +966, NocturnalHypoglycemia, 1999, 2021, "nocturnal hypoglycemia", "", +930, IsophaneInsulin_NPH, 2027, 2030, "NPH", "", +924, Insulin, 2079, 2086, "insulin", "", +31471, ConclusionComment, 2089, 2253, "This simple regimen may facilitate earlier and effective insulin use in routine medical practice , improving achievement of recommended standards of diabetes care .", "", +923, Insulin, 2146, 2153, "insulin", "", +113, PMID, 2304, 2312, "14578243", "", diff --git a/data/dm2 14578243_kwoodley.n-triples b/data/dm2 14578243_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 14578243_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14706058_admin.annodb b/data/dm2 14706058_admin.annodb new file mode 100644 index 0000000..54710c2 --- /dev/null +++ b/data/dm2 14706058_admin.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +152, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +106298, PublicationYear, 13, 17, "2004", "", " \"2004\"." +105, Title, 44, 162, "Nine weeks of bedtime diazoxide is well tolerated and improves beta - cell function in subjects with Type 2 diabetes .", "", " \"Nine weeks of bedtime diazoxide is well tolerated and improves beta - cell function in subjects with Type 2 diabetes .\"." +13, Duration, 44, 54, "Nine weeks", "", +33, Bedtime, 58, 65, "bedtime", "", +106336, Diazoxide, 66, 75, "diazoxide", "", +7, Type2Diabetes, 145, 160, "Type 2 diabetes", "", +2, Author, 163, 173, "Qvigstad E", "", " \"Qvigstad E\"." +3, Author, 182, 191, "Kollind M", "", " \"Kollind M\"." +4, Author, 194, 201, "Grill V", "", " \"Grill V\"." +15, Country, 307, 313, "Norway", "", " . ." +154, ObjectiveDescription, 410, 538, "To test whether a bedtime dose of diazoxide can improve daytime beta - cell function without side - effects in Type 2 diabetes .", "", " \"To test whether a bedtime dose of diazoxide can improve daytime beta - cell function without side - effects in Type 2 diabetes .\"." +34, Bedtime, 428, 435, "bedtime", "", +106331, Diazoxide, 444, 453, "diazoxide", "", +8, Type2Diabetes, 521, 536, "Type 2 diabetes", "", " ." +11, DoubleBlind, 551, 565, "double - blind", "", " ." +12, Randomized, 566, 576, "randomized", "", " ." +5, NumberPatientsCT, 600, 602, "27", "", " \"27\"." +9, Type2Diabetes, 603, 618, "Type 2 diabetic", "", +20, Precondition, 603, 703, "Type 2 diabetic subjects ( 17 male , 10 female ) who were treated with bedtime insulin and metformin", "", +16, Male, 630, 637, "17 male", "", " ." +17, Female, 640, 649, "10 female", "", " ." +55, Bedtime, 674, 681, "bedtime", "", +56, Insulin, 682, 689, "insulin", "", +57, Metformin, 694, 703, "metformin", "", +35, Bedtime, 731, 738, "bedtime", "", " ." +106337, Diazoxide, 739, 748, "diazoxide", "", +36, DoseValue, 751, 754, "100", "", " \"100\"." +37, mg, 755, 757, "mg", "", +28, Placebo, 763, 770, "placebo", "", " ." +14, Duration, 775, 782, "9 weeks", "", " \"9 weeks\"." +149, ObservedResult, 893, 939, "No side - effects of diazoxide were detected .", "", " \"No side - effects of diazoxide were detected .\"." +92900, EndPointDescription, 896, 910, "side - effects", "", " . ." +106332, Diazoxide, 914, 923, "diazoxide", "", +106333, Diazoxide, 955, 964, "diazoxide", "", +65, Bedtime, 995, 1002, "bedtime", "", +66, Insulin, 1003, 1010, "insulin", "", +67, EndPointDescription, 1013, 1046, "C - peptide responses to glucagon", "", " . ." +106359, Increment, 1068, 1074, "0 . 15", "", " \"0 . 15\"." +110, SdDevChangeValue, 1081, 1087, "0 . 06", "", " \"0 . 06\"." +70, Nanomol_per_litre, 1088, 1096, "nmol / l", "", " ." +112, Reduction, 1104, 1110, "0 . 01", "", " \"0 . 01\"." +113, SdDevChangeValue, 1117, 1123, "0 . 04", "", " \"0 . 04\"." +71, Nanomol_per_litre, 1124, 1132, "nmol / l", "", +29, Placebo, 1137, 1144, "placebo", "", +73, PvalueDiff, 1147, 1157, "P < 0 . 06", "", " \"P < 0 . 06\"." +137, EndPointDescription, 1189, 1207, "effects on insulin", "", " . ." +116, Increment, 1213, 1219, "66 . 2", "", " \"66 . 2\"." +117, SdDevChangeValue, 1226, 1232, "41 . 7", "", " \"41 . 7\"." +76, Picomole_per_liter, 1233, 1241, "pmol / l", "", " ." +106334, Diazoxide, 1246, 1255, "diazoxide", "", +119, Reduction, 1263, 1269, "84 . 2", "", " \"84 . 2\"." +120, SdDevChangeValue, 1276, 1282, "51 . 5", "", " \"51 . 5\"." +30, Placebo, 1287, 1294, "placebo", "", +80, PvalueDiff, 1297, 1307, "P < 0 . 03", "", " \"P < 0 . 03\"." +106338, Diazoxide, 1325, 1334, "diazoxide", "", +124, FastingPlasmaGlucose, 1345, 1361, "fasting glucagon", "", " ." +122, RelativeReduction, 1372, 1374, "41", "", " \"41\"." +31, Placebo, 1382, 1389, "placebo", "", +85, PvalueDiff, 1392, 1402, "P < 0 . 03", "", " \"P < 0 . 03\"." +126, HbA1c, 1405, 1425, "Glycated haemoglobin", "", " ." +127, HbA1c, 1428, 1433, "HbA1c", "", +151, ObservedResult, 1443, 1460, "were not affected", "", " \"were not affected\". \"were not affected\"." +37993, PostprandialBloodGlucose, 1481, 1509, "blood glucose post breakfast", "", " ." +26, Drug, 1529, 1538, "diazoxide", "", +129, ResultMeasuredValue, 1541, 1547, "1 . 34", "", " \"1 . 34\"." +130, SdDevResValue, 1554, 1560, "0 . 43", "", " \"0 . 43\"." +90, Millimoles_per_litre, 1561, 1569, "mmol / l", "", " ." +132, PValueResValue, 1572, 1582, "P < 0 . 01", "", " \"P < 0 . 01\"." +32, Placebo, 1588, 1595, "placebo", "", +93, Bedtime, 1614, 1621, "Bedtime", "", +6, ConclusionComment, 1614, 1795, "Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side - effects , does not increase bedtime insulin supplementation ,", "", " \"Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side - effects , does not increase bedtime insulin supplementation ,\"." +106335, Diazoxide, 1637, 1646, "diazoxide", "", +133, Precondition, 1650, 1707, "Type 2 diabetic subjects on bedtime insulin and metformin", "", +10, Type2Diabetes, 1650, 1665, "Type 2 diabetic", "", +96, Bedtime, 1678, 1685, "bedtime", "", +97, Insulin, 1686, 1693, "insulin", "", +98, Metformin, 1698, 1707, "metformin", "", +100, Bedtime, 1762, 1769, "bedtime", "", +99, Insulin, 1770, 1777, "insulin", "", +155, ConclusionComment, 1796, 1877, "tends to ameliorate beta - cell function but fails to improve metabolic control .", "", " \"tends to ameliorate beta - cell function but fails to improve metabolic control .\"." +101, EndPointDescription, 1816, 1836, "beta - cell function", "", +102, EndPointDescription, 1850, 1875, "improve metabolic control", "", +1, PMID, 1885, 1893, "14706058", "", " \"14706058\"." diff --git a/data/dm2 14706058_admin.n-triples b/data/dm2 14706058_admin.n-triples new file mode 100644 index 0000000..3ee8670 --- /dev/null +++ b/data/dm2 14706058_admin.n-triples @@ -0,0 +1,182 @@ +# RDF export of group: Publication + . + "Publication " . + "Nine weeks of bedtime diazoxide is well tolerated and improves beta - cell function in subjects with Type 2 diabetes ." . + "Qvigstad E" . + "2004" . + "Diabet Med ." . + "14706058" . + . + "Kollind M" . + "Grill V" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To test whether a bedtime dose of diazoxide can improve daytime beta - cell function without side - effects in Type 2 diabetes ." . + "27" . + "9 weeks" . + . + . + . + "Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side - effects , does not increase bedtime insulin supplementation ," . + . + . + . + . + . + . + "tends to ameliorate beta - cell function but fails to improve metabolic control ." . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint c peptide" . + . + . + . + . + . + . + "Endpoint insulin" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint pbg" . + . + . + . + . + . + "Endpoint side-effects" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm d" . + . + . + . + . + . + . + . + . + "Arm p" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention d" . + . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication d" . + . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome c peptide d" . + . + "0 . 06" . + "0 . 15" . + . + "Outcome c peptide p " . + . + "0 . 01" . + "0 . 04" . + . + "Outcome insulin d " . + . + "66 . 2" . + "41 . 7" . + . + "Outcome insulin p " . + . + "84 . 2" . + "51 . 5" . + . + "Outcome fpg d" . + . + "41" . + . + "Outcome fpg p " . + . + . + "Outcome hba1c d" . + . + "were not affected" . + . + "Outcome pbg d" . + . + "1 . 34" . + "P < 0 . 01" . + "0 . 43" . + . + "Outcome side-effects d" . + . + "No side - effects of diazoxide were detected ." . + . + "Outcome hba1c p" . + . + "were not affected" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups c peptide" . + "P < 0 . 06" . + . + . + . + "DiffBetweenGroups insulin" . + "P < 0 . 03" . + . + . + . + "DiffBetweenGroups fpg" . + "P < 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14706058_akramersunderbrink.annodb b/data/dm2 14706058_akramersunderbrink.annodb new file mode 100644 index 0000000..4d88b16 --- /dev/null +++ b/data/dm2 14706058_akramersunderbrink.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2015, Journal, 0, 10, "Diabet Med", "", +2016, PublicationYear, 13, 17, "2004", "", +2087, Title, 44, 160, "Nine weeks of bedtime diazoxide is well tolerated and improves beta - cell function in subjects with Type 2 diabetes", "", +2017, Duration, 44, 54, "Nine weeks", "", +2018, Bedtime, 58, 65, "bedtime", "", +2019, Drug, 66, 75, "diazoxide", "", +2020, Type2Diabetes, 145, 160, "Type 2 diabetes", "", +2021, Author, 163, 173, "Qvigstad E", "", +2022, Author, 182, 191, "Kollind M", "", +2023, Author, 194, 201, "Grill V", "", +31738, Country, 307, 313, "Norway", "", +2027, ObjectiveDescription, 410, 536, "To test whether a bedtime dose of diazoxide can improve daytime beta - cell function without side - effects in Type 2 diabetes", "", +2024, Bedtime, 428, 435, "bedtime", "", +2025, Drug, 444, 453, "diazoxide", "", +2026, Type2Diabetes, 521, 536, "Type 2 diabetes", "", +2028, DoubleBlind, 551, 565, "double - blind", "", +2029, Randomized, 566, 576, "randomized", "", +2030, NumberPatientsCT, 600, 602, "27", "", +2031, Type2Diabetes, 603, 618, "Type 2 diabetic", "", +2032, Bedtime, 674, 681, "bedtime", "", +2033, Insulin, 682, 689, "insulin", "", +2034, Metformin, 694, 703, "metformin", "", +2035, Bedtime, 731, 738, "bedtime", "", +2036, Drug, 739, 748, "diazoxide", "", +2037, DoseValue, 751, 754, "100", "", +2038, mg, 755, 757, "mg", "", +2039, Placebo, 763, 770, "placebo", "", +2040, Duration, 775, 782, "9 weeks", "", +2041, ObservedResult, 965, 1010, "did not incur any increase in bedtime insulin", "", +2042, Bedtime, 995, 1002, "bedtime", "", +2043, Insulin, 1003, 1010, "insulin", "", +2044, EndPointDescription, 1013, 1046, "C - peptide responses to glucagon", "", +2045, ChangeValue, 1068, 1074, "0 . 15", "", +11062, SdErrorChangeValue, 1081, 1087, "0 . 06", "", +2049, Nanomol_per_litre, 1088, 1096, "nmol / l", "", +2046, ChangeValue, 1102, 1110, "- 0 . 01", "", +11063, SdErrorChangeValue, 1117, 1123, "0 . 04", "", +2050, Nanomol_per_litre, 1124, 1132, "nmol / l", "", +2051, Placebo, 1137, 1144, "placebo", "", +2052, PvalueDiff, 1147, 1157, "P < 0 . 06", "", +2053, EndPointDescription, 1175, 1207, "Corresponding effects on insulin", "", +2054, ChangeValue, 1213, 1219, "66 . 2", "", +11064, SdErrorChangeValue, 1226, 1232, "41 . 7", "", +2056, Picomole_per_liter, 1233, 1241, "pmol / l", "", +2057, Drug, 1246, 1255, "diazoxide", "", +2058, ChangeValue, 1261, 1269, "- 84 . 2", "", +11065, SdErrorChangeValue, 1276, 1282, "51 . 5", "", +2060, Placebo, 1287, 1294, "placebo", "", +2061, PvalueDiff, 1297, 1307, "P < 0 . 03", "", +2062, Drug, 1325, 1334, "diazoxide", "", +2063, EndPointDescription, 1345, 1368, "fasting glucagon levels", "", +2064, DiffGroupRelValue, 1372, 1374, "41", "", +2088, Percentage, 1375, 1376, "%", "", +2065, Placebo, 1382, 1389, "placebo", "", +2066, PvalueDiff, 1392, 1402, "P < 0 . 03", "", +2069, HbA1c, 1405, 1442, "Glycated haemoglobin ( HbA1c ) levels", "", +2067, EndPointDescription, 1471, 1509, "levels of blood glucose post breakfast", "", +2068, Drug, 1529, 1538, "diazoxide", "", +2070, DiffGroupAbsValue, 1541, 1547, "1 . 34", "", +11066, SdErrorDiff, 1554, 1560, "0 . 43", "", +2072, Millimoles_per_litre, 1561, 1569, "mmol / l", "", +2073, PvalueDiff, 1572, 1582, "P < 0 . 01", "", +2074, Placebo, 1588, 1595, "placebo", "", +2075, Bedtime, 1614, 1621, "Bedtime", "", +2085, ConclusionComment, 1614, 1857, "Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side - effects , does not increase bedtime insulin supplementation , tends to ameliorate beta - cell function but fails to improve", "", +2076, Drug, 1637, 1646, "diazoxide", "", +2077, Type2Diabetes, 1650, 1665, "Type 2 diabetic", "", +2078, Bedtime, 1678, 1685, "bedtime", "", +2079, Insulin, 1686, 1693, "insulin", "", +2080, Metformin, 1698, 1707, "metformin", "", +2082, Bedtime, 1762, 1769, "bedtime", "", +2081, Insulin, 1770, 1777, "insulin", "", +2083, EndPointDescription, 1816, 1836, "beta - cell function", "", +2084, EndPointDescription, 1850, 1875, "improve metabolic control", "", +2086, PMID, 1885, 1893, "14706058", "", diff --git a/data/dm2 14706058_akramersunderbrink.n-triples b/data/dm2 14706058_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 14706058_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 14706058_export.csv b/data/dm2 14706058_export.csv new file mode 100644 index 0000000..f30213e --- /dev/null +++ b/data/dm2 14706058_export.csv @@ -0,0 +1,410 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +374, 1, 1, 1, 0, 6, 0, 6, "Diabet" +374, 1, 2, 2, 7, 10, 7, 10, "Med" +374, 1, 3, 3, 11, 12, 11, 12, "." +374, 2, 1, 4, 0, 4, 13, 17, "2004" +374, 2, 2, 5, 5, 8, 18, 21, "Jan" +374, 2, 3, 6, 9, 10, 22, 23, ";" +374, 2, 4, 7, 11, 13, 24, 26, "21" +374, 2, 5, 8, 14, 15, 27, 28, "(" +374, 2, 6, 9, 16, 17, 29, 30, "1" +374, 2, 7, 10, 18, 19, 31, 32, ")" +374, 2, 8, 11, 20, 21, 33, 34, ":" +374, 2, 9, 12, 22, 24, 35, 37, "73" +374, 2, 10, 13, 25, 26, 38, 39, "-" +374, 2, 11, 14, 27, 28, 40, 41, "6" +374, 2, 12, 15, 29, 30, 42, 43, "." +374, 3, 1, 16, 0, 4, 44, 48, "Nine" +374, 3, 2, 17, 5, 10, 49, 54, "weeks" +374, 3, 3, 18, 11, 13, 55, 57, "of" +374, 3, 4, 19, 14, 21, 58, 65, "bedtime" +374, 3, 5, 20, 22, 31, 66, 75, "diazoxide" +374, 3, 6, 21, 32, 34, 76, 78, "is" +374, 3, 7, 22, 35, 39, 79, 83, "well" +374, 3, 8, 23, 40, 49, 84, 93, "tolerated" +374, 3, 9, 24, 50, 53, 94, 97, "and" +374, 3, 10, 25, 54, 62, 98, 106, "improves" +374, 3, 11, 26, 63, 67, 107, 111, "beta" +374, 3, 12, 27, 68, 69, 112, 113, "-" +374, 3, 13, 28, 70, 74, 114, 118, "cell" +374, 3, 14, 29, 75, 83, 119, 127, "function" +374, 3, 15, 30, 84, 86, 128, 130, "in" +374, 3, 16, 31, 87, 95, 131, 139, "subjects" +374, 3, 17, 32, 96, 100, 140, 144, "with" +374, 3, 18, 33, 101, 105, 145, 149, "Type" +374, 3, 19, 34, 106, 107, 150, 151, "2" +374, 3, 20, 35, 108, 116, 152, 160, "diabetes" +374, 3, 21, 36, 117, 118, 161, 162, "." +374, 4, 1, 37, 0, 8, 163, 171, "Qvigstad" +374, 4, 2, 38, 9, 10, 172, 173, "E" +374, 4, 3, 39, 11, 12, 174, 175, "(" +374, 4, 4, 40, 13, 14, 176, 177, "1" +374, 4, 5, 41, 15, 16, 178, 179, ")" +374, 4, 6, 42, 17, 18, 180, 181, "," +374, 4, 7, 43, 19, 26, 182, 189, "Kollind" +374, 4, 8, 44, 27, 28, 190, 191, "M" +374, 4, 9, 45, 29, 30, 192, 193, "," +374, 4, 10, 46, 31, 36, 194, 199, "Grill" +374, 4, 11, 47, 37, 38, 200, 201, "V" +374, 4, 12, 48, 39, 40, 202, 203, "." +374, 4, 13, 49, 41, 47, 204, 210, "Author" +374, 4, 14, 50, 48, 59, 211, 222, "information" +374, 4, 15, 51, 60, 61, 223, 224, ":" +374, 4, 16, 52, 62, 63, 225, 226, "(" +374, 4, 17, 53, 64, 65, 227, 228, "1" +374, 4, 18, 54, 66, 67, 229, 230, ")" +374, 4, 19, 55, 68, 78, 231, 241, "Department" +374, 4, 20, 56, 79, 81, 242, 244, "of" +374, 4, 21, 57, 82, 95, 245, 258, "Endocrinology" +374, 4, 22, 58, 96, 97, 259, 260, "," +374, 4, 23, 59, 98, 100, 261, 263, "St" +374, 4, 24, 60, 101, 105, 264, 268, "Olav" +374, 4, 25, 61, 106, 107, 269, 270, "'" +374, 4, 26, 62, 108, 109, 271, 272, "s" +374, 4, 27, 63, 110, 120, 273, 283, "University" +374, 4, 28, 64, 121, 129, 284, 292, "Hospital" +374, 4, 29, 65, 130, 131, 293, 294, "," +374, 4, 30, 66, 132, 141, 295, 304, "Trondheim" +374, 4, 31, 67, 142, 143, 305, 306, "," +374, 4, 32, 68, 144, 150, 307, 313, "Norway" +374, 4, 33, 69, 151, 152, 314, 315, "." +374, 5, 1, 70, 0, 9, 316, 325, "elisabeth" +374, 5, 2, 71, 10, 11, 326, 327, "." +374, 5, 3, 72, 12, 20, 328, 336, "qvigstad" +374, 5, 4, 73, 21, 22, 337, 338, "@" +374, 5, 5, 74, 23, 29, 339, 345, "stolav" +374, 5, 6, 75, 30, 31, 346, 347, "." +374, 5, 7, 76, 32, 34, 348, 350, "no" +374, 5, 8, 77, 35, 42, 351, 358, "Erratum" +374, 5, 9, 78, 43, 45, 359, 361, "in" +374, 5, 10, 79, 46, 52, 362, 368, "Diabet" +374, 5, 11, 80, 53, 56, 369, 372, "Med" +374, 5, 12, 81, 57, 58, 373, 374, "." +374, 6, 1, 82, 0, 4, 375, 379, "2008" +374, 6, 2, 83, 5, 8, 380, 383, "Feb" +374, 6, 3, 84, 9, 10, 384, 385, ";" +374, 6, 4, 85, 11, 13, 386, 388, "25" +374, 6, 5, 86, 14, 15, 389, 390, "(" +374, 6, 6, 87, 16, 17, 391, 392, "2" +374, 6, 7, 88, 18, 19, 393, 394, ")" +374, 6, 8, 89, 20, 21, 395, 396, ":" +374, 6, 9, 90, 22, 25, 397, 400, "243" +374, 6, 10, 91, 26, 27, 401, 402, "." +374, 7, 1, 92, 0, 4, 403, 407, "AIMS" +374, 7, 2, 93, 5, 6, 408, 409, ":" +374, 7, 3, 94, 7, 9, 410, 412, "To" +374, 7, 4, 95, 10, 14, 413, 417, "test" +374, 7, 5, 96, 15, 22, 418, 425, "whether" +374, 7, 6, 97, 23, 24, 426, 427, "a" +374, 7, 7, 98, 25, 32, 428, 435, "bedtime" +374, 7, 8, 99, 33, 37, 436, 440, "dose" +374, 7, 9, 100, 38, 40, 441, 443, "of" +374, 7, 10, 101, 41, 50, 444, 453, "diazoxide" +374, 7, 11, 102, 51, 54, 454, 457, "can" +374, 7, 12, 103, 55, 62, 458, 465, "improve" +374, 7, 13, 104, 63, 70, 466, 473, "daytime" +374, 7, 14, 105, 71, 75, 474, 478, "beta" +374, 7, 15, 106, 76, 77, 479, 480, "-" +374, 7, 16, 107, 78, 82, 481, 485, "cell" +374, 7, 17, 108, 83, 91, 486, 494, "function" +374, 7, 18, 109, 92, 99, 495, 502, "without" +374, 7, 19, 110, 100, 104, 503, 507, "side" +374, 7, 20, 111, 105, 106, 508, 509, "-" +374, 7, 21, 112, 107, 114, 510, 517, "effects" +374, 7, 22, 113, 115, 117, 518, 520, "in" +374, 7, 23, 114, 118, 122, 521, 525, "Type" +374, 7, 24, 115, 123, 124, 526, 527, "2" +374, 7, 25, 116, 125, 133, 528, 536, "diabetes" +374, 7, 26, 117, 134, 135, 537, 538, "." +374, 8, 1, 118, 0, 7, 539, 546, "METHODS" +374, 8, 2, 119, 8, 9, 547, 548, ":" +374, 8, 3, 120, 10, 11, 549, 550, "A" +374, 8, 4, 121, 12, 18, 551, 557, "double" +374, 8, 5, 122, 19, 20, 558, 559, "-" +374, 8, 6, 123, 21, 26, 560, 565, "blind" +374, 8, 7, 124, 27, 37, 566, 576, "randomized" +374, 8, 8, 125, 38, 43, 577, 582, "study" +374, 8, 9, 126, 44, 47, 583, 586, "was" +374, 8, 10, 127, 48, 57, 587, 596, "performed" +374, 8, 11, 128, 58, 60, 597, 599, "in" +374, 8, 12, 129, 61, 63, 600, 602, "27" +374, 8, 13, 130, 64, 68, 603, 607, "Type" +374, 8, 14, 131, 69, 70, 608, 609, "2" +374, 8, 15, 132, 71, 79, 610, 618, "diabetic" +374, 8, 16, 133, 80, 88, 619, 627, "subjects" +374, 8, 17, 134, 89, 90, 628, 629, "(" +374, 8, 18, 135, 91, 93, 630, 632, "17" +374, 8, 19, 136, 94, 98, 633, 637, "male" +374, 8, 20, 137, 99, 100, 638, 639, "," +374, 8, 21, 138, 101, 103, 640, 642, "10" +374, 8, 22, 139, 104, 110, 643, 649, "female" +374, 8, 23, 140, 111, 112, 650, 651, ")" +374, 8, 24, 141, 113, 116, 652, 655, "who" +374, 8, 25, 142, 117, 121, 656, 660, "were" +374, 8, 26, 143, 122, 129, 661, 668, "treated" +374, 8, 27, 144, 130, 134, 669, 673, "with" +374, 8, 28, 145, 135, 142, 674, 681, "bedtime" +374, 8, 29, 146, 143, 150, 682, 689, "insulin" +374, 8, 30, 147, 151, 154, 690, 693, "and" +374, 8, 31, 148, 155, 164, 694, 703, "metformin" +374, 8, 32, 149, 165, 166, 704, 705, "." +374, 9, 1, 150, 0, 8, 706, 714, "Subjects" +374, 9, 2, 151, 9, 17, 715, 723, "received" +374, 9, 3, 152, 18, 24, 724, 730, "either" +374, 9, 4, 153, 25, 32, 731, 738, "bedtime" +374, 9, 5, 154, 33, 42, 739, 748, "diazoxide" +374, 9, 6, 155, 43, 44, 749, 750, "," +374, 9, 7, 156, 45, 48, 751, 754, "100" +374, 9, 8, 157, 49, 51, 755, 757, "mg" +374, 9, 9, 158, 52, 53, 758, 759, "," +374, 9, 10, 159, 54, 56, 760, 762, "or" +374, 9, 11, 160, 57, 64, 763, 770, "placebo" +374, 9, 12, 161, 65, 68, 771, 774, "for" +374, 9, 13, 162, 69, 70, 775, 776, "9" +374, 9, 14, 163, 71, 76, 777, 782, "weeks" +374, 9, 15, 164, 77, 78, 783, 784, "." +374, 10, 1, 165, 0, 9, 785, 794, "Duplicate" +374, 10, 2, 166, 10, 11, 795, 796, "C" +374, 10, 3, 167, 12, 13, 797, 798, "-" +374, 10, 4, 168, 14, 21, 799, 806, "peptide" +374, 10, 5, 169, 22, 30, 807, 815, "glucagon" +374, 10, 6, 170, 31, 36, 816, 821, "tests" +374, 10, 7, 171, 37, 41, 822, 826, "were" +374, 10, 8, 172, 42, 51, 827, 836, "performed" +374, 10, 9, 173, 52, 58, 837, 843, "before" +374, 10, 10, 174, 59, 62, 844, 847, "and" +374, 10, 11, 175, 63, 65, 848, 850, "in" +374, 10, 12, 176, 66, 69, 851, 854, "the" +374, 10, 13, 177, 70, 74, 855, 859, "last" +374, 10, 14, 178, 75, 79, 860, 864, "days" +374, 10, 15, 179, 80, 82, 865, 867, "of" +374, 10, 16, 180, 83, 95, 868, 880, "intervention" +374, 10, 17, 181, 96, 97, 881, 882, "." +374, 11, 1, 182, 0, 7, 883, 890, "RESULTS" +374, 11, 2, 183, 8, 9, 891, 892, ":" +374, 11, 3, 184, 10, 12, 893, 895, "No" +374, 11, 4, 185, 13, 17, 896, 900, "side" +374, 11, 5, 186, 18, 19, 901, 902, "-" +374, 11, 6, 187, 20, 27, 903, 910, "effects" +374, 11, 7, 188, 28, 30, 911, 913, "of" +374, 11, 8, 189, 31, 40, 914, 923, "diazoxide" +374, 11, 9, 190, 41, 45, 924, 928, "were" +374, 11, 10, 191, 46, 54, 929, 937, "detected" +374, 11, 11, 192, 55, 56, 938, 939, "." +374, 12, 1, 193, 0, 9, 940, 949, "Treatment" +374, 12, 2, 194, 10, 14, 950, 954, "with" +374, 12, 3, 195, 15, 24, 955, 964, "diazoxide" +374, 12, 4, 196, 25, 28, 965, 968, "did" +374, 12, 5, 197, 29, 32, 969, 972, "not" +374, 12, 6, 198, 33, 38, 973, 978, "incur" +374, 12, 7, 199, 39, 42, 979, 982, "any" +374, 12, 8, 200, 43, 51, 983, 991, "increase" +374, 12, 9, 201, 52, 54, 992, 994, "in" +374, 12, 10, 202, 55, 62, 995, 1002, "bedtime" +374, 12, 11, 203, 63, 70, 1003, 1010, "insulin" +374, 12, 12, 204, 71, 72, 1011, 1012, "." +374, 13, 1, 205, 0, 1, 1013, 1014, "C" +374, 13, 2, 206, 2, 3, 1015, 1016, "-" +374, 13, 3, 207, 4, 11, 1017, 1024, "peptide" +374, 13, 4, 208, 12, 21, 1025, 1034, "responses" +374, 13, 5, 209, 22, 24, 1035, 1037, "to" +374, 13, 6, 210, 25, 33, 1038, 1046, "glucagon" +374, 13, 7, 211, 34, 40, 1047, 1053, "tended" +374, 13, 8, 212, 41, 43, 1054, 1056, "to" +374, 13, 9, 213, 44, 52, 1057, 1065, "increase" +374, 13, 10, 214, 53, 54, 1066, 1067, ":" +374, 13, 11, 215, 55, 56, 1068, 1069, "0" +374, 13, 12, 216, 57, 58, 1070, 1071, "." +374, 13, 13, 217, 59, 61, 1072, 1074, "15" +374, 13, 14, 218, 62, 63, 1075, 1076, "+" +374, 13, 15, 219, 64, 65, 1077, 1078, "/" +374, 13, 16, 220, 66, 67, 1079, 1080, "-" +374, 13, 17, 221, 68, 69, 1081, 1082, "0" +374, 13, 18, 222, 70, 71, 1083, 1084, "." +374, 13, 19, 223, 72, 74, 1085, 1087, "06" +374, 13, 20, 224, 75, 79, 1088, 1092, "nmol" +374, 13, 21, 225, 80, 81, 1093, 1094, "/" +374, 13, 22, 226, 82, 83, 1095, 1096, "l" +374, 13, 23, 227, 84, 86, 1097, 1099, "vs" +374, 13, 24, 228, 87, 88, 1100, 1101, "." +374, 13, 25, 229, 89, 90, 1102, 1103, "-" +374, 13, 26, 230, 91, 92, 1104, 1105, "0" +374, 13, 27, 231, 93, 94, 1106, 1107, "." +374, 13, 28, 232, 95, 97, 1108, 1110, "01" +374, 13, 29, 233, 98, 99, 1111, 1112, "+" +374, 13, 30, 234, 100, 101, 1113, 1114, "/" +374, 13, 31, 235, 102, 103, 1115, 1116, "-" +374, 13, 32, 236, 104, 105, 1117, 1118, "0" +374, 13, 33, 237, 106, 107, 1119, 1120, "." +374, 13, 34, 238, 108, 110, 1121, 1123, "04" +374, 13, 35, 239, 111, 115, 1124, 1128, "nmol" +374, 13, 36, 240, 116, 117, 1129, 1130, "/" +374, 13, 37, 241, 118, 119, 1131, 1132, "l" +374, 13, 38, 242, 120, 123, 1133, 1136, "for" +374, 13, 39, 243, 124, 131, 1137, 1144, "placebo" +374, 13, 40, 244, 132, 133, 1145, 1146, "," +374, 13, 41, 245, 134, 135, 1147, 1148, "P" +374, 13, 42, 246, 136, 137, 1149, 1150, "<" +374, 13, 43, 247, 138, 139, 1151, 1152, "0" +374, 13, 44, 248, 140, 141, 1153, 1154, "." +374, 13, 45, 249, 142, 144, 1155, 1157, "06" +374, 13, 46, 250, 145, 148, 1158, 1161, "for" +374, 13, 47, 251, 149, 159, 1162, 1172, "difference" +374, 13, 48, 252, 160, 161, 1173, 1174, "." +374, 14, 1, 253, 0, 13, 1175, 1188, "Corresponding" +374, 14, 2, 254, 14, 21, 1189, 1196, "effects" +374, 14, 3, 255, 22, 24, 1197, 1199, "on" +374, 14, 4, 256, 25, 32, 1200, 1207, "insulin" +374, 14, 5, 257, 33, 37, 1208, 1212, "were" +374, 14, 6, 258, 38, 40, 1213, 1215, "66" +374, 14, 7, 259, 41, 42, 1216, 1217, "." +374, 14, 8, 260, 43, 44, 1218, 1219, "2" +374, 14, 9, 261, 45, 46, 1220, 1221, "+" +374, 14, 10, 262, 47, 48, 1222, 1223, "/" +374, 14, 11, 263, 49, 50, 1224, 1225, "-" +374, 14, 12, 264, 51, 53, 1226, 1228, "41" +374, 14, 13, 265, 54, 55, 1229, 1230, "." +374, 14, 14, 266, 56, 57, 1231, 1232, "7" +374, 14, 15, 267, 58, 62, 1233, 1237, "pmol" +374, 14, 16, 268, 63, 64, 1238, 1239, "/" +374, 14, 17, 269, 65, 66, 1240, 1241, "l" +374, 14, 18, 270, 67, 70, 1242, 1245, "for" +374, 14, 19, 271, 71, 80, 1246, 1255, "diazoxide" +374, 14, 20, 272, 81, 83, 1256, 1258, "vs" +374, 14, 21, 273, 84, 85, 1259, 1260, "." +374, 14, 22, 274, 86, 87, 1261, 1262, "-" +374, 14, 23, 275, 88, 90, 1263, 1265, "84" +374, 14, 24, 276, 91, 92, 1266, 1267, "." +374, 14, 25, 277, 93, 94, 1268, 1269, "2" +374, 14, 26, 278, 95, 96, 1270, 1271, "+" +374, 14, 27, 279, 97, 98, 1272, 1273, "/" +374, 14, 28, 280, 99, 100, 1274, 1275, "-" +374, 14, 29, 281, 101, 103, 1276, 1278, "51" +374, 14, 30, 282, 104, 105, 1279, 1280, "." +374, 14, 31, 283, 106, 107, 1281, 1282, "5" +374, 14, 32, 284, 108, 111, 1283, 1286, "for" +374, 14, 33, 285, 112, 119, 1287, 1294, "placebo" +374, 14, 34, 286, 120, 121, 1295, 1296, "," +374, 14, 35, 287, 122, 123, 1297, 1298, "P" +374, 14, 36, 288, 124, 125, 1299, 1300, "<" +374, 14, 37, 289, 126, 127, 1301, 1302, "0" +374, 14, 38, 290, 128, 129, 1303, 1304, "." +374, 14, 39, 291, 130, 132, 1305, 1307, "03" +374, 14, 40, 292, 133, 134, 1308, 1309, "." +374, 15, 1, 293, 0, 9, 1310, 1319, "Treatment" +374, 15, 2, 294, 10, 14, 1320, 1324, "with" +374, 15, 3, 295, 15, 24, 1325, 1334, "diazoxide" +374, 15, 4, 296, 25, 34, 1335, 1344, "decreased" +374, 15, 5, 297, 35, 42, 1345, 1352, "fasting" +374, 15, 6, 298, 43, 51, 1353, 1361, "glucagon" +374, 15, 7, 299, 52, 58, 1362, 1368, "levels" +374, 15, 8, 300, 59, 61, 1369, 1371, "by" +374, 15, 9, 301, 62, 64, 1372, 1374, "41" +374, 15, 10, 302, 65, 66, 1375, 1376, "%" +374, 15, 11, 303, 67, 69, 1377, 1379, "vs" +374, 15, 12, 304, 70, 71, 1380, 1381, "." +374, 15, 13, 305, 72, 79, 1382, 1389, "placebo" +374, 15, 14, 306, 80, 81, 1390, 1391, "," +374, 15, 15, 307, 82, 83, 1392, 1393, "P" +374, 15, 16, 308, 84, 85, 1394, 1395, "<" +374, 15, 17, 309, 86, 87, 1396, 1397, "0" +374, 15, 18, 310, 88, 89, 1398, 1399, "." +374, 15, 19, 311, 90, 92, 1400, 1402, "03" +374, 15, 20, 312, 93, 94, 1403, 1404, "." +374, 16, 1, 313, 0, 8, 1405, 1413, "Glycated" +374, 16, 2, 314, 9, 20, 1414, 1425, "haemoglobin" +374, 16, 3, 315, 21, 22, 1426, 1427, "(" +374, 16, 4, 316, 23, 28, 1428, 1433, "HbA1c" +374, 16, 5, 317, 29, 30, 1434, 1435, ")" +374, 16, 6, 318, 31, 37, 1436, 1442, "levels" +374, 16, 7, 319, 38, 42, 1443, 1447, "were" +374, 16, 8, 320, 43, 46, 1448, 1451, "not" +374, 16, 9, 321, 47, 55, 1452, 1460, "affected" +374, 16, 10, 322, 56, 57, 1461, 1462, "," +374, 16, 11, 323, 58, 65, 1463, 1470, "whereas" +374, 16, 12, 324, 66, 72, 1471, 1477, "levels" +374, 16, 13, 325, 73, 75, 1478, 1480, "of" +374, 16, 14, 326, 76, 81, 1481, 1486, "blood" +374, 16, 15, 327, 82, 89, 1487, 1494, "glucose" +374, 16, 16, 328, 90, 94, 1495, 1499, "post" +374, 16, 17, 329, 95, 104, 1500, 1509, "breakfast" +374, 16, 18, 330, 105, 109, 1510, 1514, "were" +374, 16, 19, 331, 110, 116, 1515, 1521, "higher" +374, 16, 20, 332, 117, 123, 1522, 1528, "during" +374, 16, 21, 333, 124, 133, 1529, 1538, "diazoxide" +374, 16, 22, 334, 134, 135, 1539, 1540, "(" +374, 16, 23, 335, 136, 137, 1541, 1542, "1" +374, 16, 24, 336, 138, 139, 1543, 1544, "." +374, 16, 25, 337, 140, 142, 1545, 1547, "34" +374, 16, 26, 338, 143, 144, 1548, 1549, "+" +374, 16, 27, 339, 145, 146, 1550, 1551, "/" +374, 16, 28, 340, 147, 148, 1552, 1553, "-" +374, 16, 29, 341, 149, 150, 1554, 1555, "0" +374, 16, 30, 342, 151, 152, 1556, 1557, "." +374, 16, 31, 343, 153, 155, 1558, 1560, "43" +374, 16, 32, 344, 156, 160, 1561, 1565, "mmol" +374, 16, 33, 345, 161, 162, 1566, 1567, "/" +374, 16, 34, 346, 163, 164, 1568, 1569, "l" +374, 16, 35, 347, 165, 166, 1570, 1571, "," +374, 16, 36, 348, 167, 168, 1572, 1573, "P" +374, 16, 37, 349, 169, 170, 1574, 1575, "<" +374, 16, 38, 350, 171, 172, 1576, 1577, "0" +374, 16, 39, 351, 173, 174, 1578, 1579, "." +374, 16, 40, 352, 175, 177, 1580, 1582, "01" +374, 16, 41, 353, 178, 180, 1583, 1585, "vs" +374, 16, 42, 354, 181, 182, 1586, 1587, "." +374, 16, 43, 355, 183, 190, 1588, 1595, "placebo" +374, 16, 44, 356, 191, 192, 1596, 1597, ")" +374, 16, 45, 357, 193, 194, 1598, 1599, "." +374, 17, 1, 358, 0, 11, 1600, 1611, "CONCLUSIONS" +374, 17, 2, 359, 12, 13, 1612, 1613, ":" +374, 17, 3, 360, 14, 21, 1614, 1621, "Bedtime" +374, 17, 4, 361, 22, 31, 1622, 1631, "treatment" +374, 17, 5, 362, 32, 36, 1632, 1636, "with" +374, 17, 6, 363, 37, 46, 1637, 1646, "diazoxide" +374, 17, 7, 364, 47, 49, 1647, 1649, "in" +374, 17, 8, 365, 50, 54, 1650, 1654, "Type" +374, 17, 9, 366, 55, 56, 1655, 1656, "2" +374, 17, 10, 367, 57, 65, 1657, 1665, "diabetic" +374, 17, 11, 368, 66, 74, 1666, 1674, "subjects" +374, 17, 12, 369, 75, 77, 1675, 1677, "on" +374, 17, 13, 370, 78, 85, 1678, 1685, "bedtime" +374, 17, 14, 371, 86, 93, 1686, 1693, "insulin" +374, 17, 15, 372, 94, 97, 1694, 1697, "and" +374, 17, 16, 373, 98, 107, 1698, 1707, "metformin" +374, 17, 17, 374, 108, 111, 1708, 1711, "has" +374, 17, 18, 375, 112, 114, 1712, 1714, "no" +374, 17, 19, 376, 115, 126, 1715, 1726, "significant" +374, 17, 20, 377, 127, 131, 1727, 1731, "side" +374, 17, 21, 378, 132, 133, 1732, 1733, "-" +374, 17, 22, 379, 134, 141, 1734, 1741, "effects" +374, 17, 23, 380, 142, 143, 1742, 1743, "," +374, 17, 24, 381, 144, 148, 1744, 1748, "does" +374, 17, 25, 382, 149, 152, 1749, 1752, "not" +374, 17, 26, 383, 153, 161, 1753, 1761, "increase" +374, 17, 27, 384, 162, 169, 1762, 1769, "bedtime" +374, 17, 28, 385, 170, 177, 1770, 1777, "insulin" +374, 17, 29, 386, 178, 193, 1778, 1793, "supplementation" +374, 17, 30, 387, 194, 195, 1794, 1795, "," +374, 17, 31, 388, 196, 201, 1796, 1801, "tends" +374, 17, 32, 389, 202, 204, 1802, 1804, "to" +374, 17, 33, 390, 205, 215, 1805, 1815, "ameliorate" +374, 17, 34, 391, 216, 220, 1816, 1820, "beta" +374, 17, 35, 392, 221, 222, 1821, 1822, "-" +374, 17, 36, 393, 223, 227, 1823, 1827, "cell" +374, 17, 37, 394, 228, 236, 1828, 1836, "function" +374, 17, 38, 395, 237, 240, 1837, 1840, "but" +374, 17, 39, 396, 241, 246, 1841, 1846, "fails" +374, 17, 40, 397, 247, 249, 1847, 1849, "to" +374, 17, 41, 398, 250, 257, 1850, 1857, "improve" +374, 17, 42, 399, 258, 267, 1858, 1867, "metabolic" +374, 17, 43, 400, 268, 275, 1868, 1875, "control" +374, 17, 44, 401, 276, 277, 1876, 1877, "." +374, 18, 1, 402, 0, 4, 1878, 1882, "PMID" +374, 18, 2, 403, 5, 6, 1883, 1884, ":" +374, 18, 3, 404, 7, 15, 1885, 1893, "14706058" +374, 18, 4, 405, 16, 17, 1894, 1895, "[" +374, 18, 5, 406, 18, 25, 1896, 1903, "Indexed" +374, 18, 6, 407, 26, 29, 1904, 1907, "for" +374, 18, 7, 408, 30, 37, 1908, 1915, "MEDLINE" +374, 18, 8, 409, 38, 39, 1916, 1917, "]" diff --git a/data/dm2 14706058_kwoodley.annodb b/data/dm2 14706058_kwoodley.annodb new file mode 100644 index 0000000..702b957 --- /dev/null +++ b/data/dm2 14706058_kwoodley.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31472, Journal, 0, 12, "Diabet Med .", "", +973, PublicationYear, 13, 17, "2004", "", +989, Duration, 44, 54, "Nine weeks", "", +31473, Title, 44, 162, "Nine weeks of bedtime diazoxide is well tolerated and improves beta - cell function in subjects with Type 2 diabetes .", "", +1009, Bedtime, 58, 65, "bedtime", "", +994, Drug, 66, 75, "diazoxide", "", +983, Type2Diabetes, 145, 160, "Type 2 diabetes", "", +975, Author, 163, 173, "Qvigstad E", "", +976, Author, 182, 191, "Kollind M", "", +977, Author, 194, 201, "Grill V", "", +991, Country, 307, 313, "Norway", "", +31474, ObjectiveDescription, 410, 538, "To test whether a bedtime dose of diazoxide can improve daytime beta - cell function without side - effects in Type 2 diabetes .", "", +1010, Bedtime, 428, 435, "bedtime", "", +995, Drug, 444, 453, "diazoxide", "", +984, Type2Diabetes, 521, 536, "Type 2 diabetes", "", +987, DoubleBlind, 551, 565, "double - blind", "", +988, Randomized, 566, 576, "randomized", "", +980, NumberPatientsCT, 600, 602, "27", "", +985, Type2Diabetes, 603, 618, "Type 2 diabetic", "", +996, Precondition, 603, 703, "Type 2 diabetic subjects ( 17 male , 10 female ) who were treated with bedtime insulin and metformin", "", +992, Male, 630, 637, "17 male", "", +993, Female, 640, 649, "10 female", "", +3642, Bedtime, 674, 681, "bedtime", "", +3643, Insulin, 682, 689, "insulin", "", +3644, Metformin, 694, 703, "metformin", "", +1011, Bedtime, 731, 738, "bedtime", "", +997, Drug, 739, 748, "diazoxide", "", +1012, DoseValue, 751, 754, "100", "", +1013, mg, 755, 757, "mg", "", +1004, Placebo, 763, 770, "placebo", "", +990, Duration, 775, 782, "9 weeks", "", +31447, ObservedResult, 893, 939, "No side - effects of diazoxide were detected .", "", +998, Drug, 914, 923, "diazoxide", "", +31448, ObservedResult, 940, 1012, "Treatment with diazoxide did not incur any increase in bedtime insulin .", "", +999, Drug, 955, 964, "diazoxide", "", +2100, Bedtime, 995, 1002, "bedtime", "", +2098, Insulin, 1003, 1010, "insulin", "", +3648, EndPointDescription, 1013, 1046, "C - peptide responses to glucagon", "", +2102, Increment, 1068, 1074, "0 . 15", "", +2103, SdDevChangeValue, 1081, 1087, "0 . 06", "", +2104, Millimoles_per_litre, 1088, 1096, "nmol / l", "", +2105, Reduction, 1104, 1110, "0 . 01", "", +2106, SdDevChangeValue, 1117, 1123, "0 . 04", "", +2107, Millimoles_per_litre, 1124, 1132, "nmol / l", "", +1005, Placebo, 1137, 1144, "placebo", "", +2108, PvalueDiff, 1147, 1157, "P < 0 . 06", "", +3646, EndPointDescription, 1189, 1207, "effects on insulin", "", +2110, Increment, 1213, 1219, "66 . 2", "", +2111, SdDevChangeValue, 1226, 1232, "41 . 7", "", +2112, Picomole_per_liter, 1233, 1241, "pmol / l", "", +1000, Drug, 1246, 1255, "diazoxide", "", +2113, Reduction, 1263, 1269, "84 . 2", "", +2114, SdDevChangeValue, 1276, 1282, "51 . 5", "", +1006, Placebo, 1287, 1294, "placebo", "", +2115, PvalueDiff, 1297, 1307, "P < 0 . 03", "", +1001, Drug, 1325, 1334, "diazoxide", "", +2118, FastingPlasmaGlucose, 1345, 1361, "fasting glucagon", "", +2116, RelativeReduction, 1372, 1374, "41", "", +1007, Placebo, 1382, 1389, "placebo", "", +2117, PValueChangeValue, 1392, 1402, "P < 0 . 03", "", +2120, HbA1c, 1405, 1425, "Glycated haemoglobin", "", +2121, HbA1c, 1428, 1433, "HbA1c", "", +31449, ObservedResult, 1443, 1460, "were not affected", "", +92238, FastingBloodGlucose, 1481, 1494, "blood glucose", "", +2122, TimePoint, 1495, 1509, "post breakfast", "", +1002, Drug, 1529, 1538, "diazoxide", "", +2123, ResultMeasuredValue, 1541, 1547, "1 . 34", "", +2124, SdDevResValue, 1554, 1560, "0 . 43", "", +2125, Millimoles_per_litre, 1561, 1569, "mmol / l", "", +2126, PValueResValue, 1572, 1582, "P < 0 . 01", "", +1008, Placebo, 1588, 1595, "placebo", "", +3653, Bedtime, 1614, 1621, "Bedtime", "", +981, ConclusionComment, 1614, 1795, "Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side - effects , does not increase bedtime insulin supplementation ,", "", +1003, Drug, 1637, 1646, "diazoxide", "", +2127, Precondition, 1650, 1707, "Type 2 diabetic subjects on bedtime insulin and metformin", "", +986, Type2Diabetes, 1650, 1665, "Type 2 diabetic", "", +3655, Bedtime, 1678, 1685, "bedtime", "", +3656, Insulin, 1686, 1693, "insulin", "", +3657, Metformin, 1698, 1707, "metformin", "", +31475, ConclusionComment, 1796, 1877, "tends to ameliorate beta - cell function but fails to improve metabolic control .", "", +974, PMID, 1885, 1893, "14706058", "", diff --git a/data/dm2 14706058_kwoodley.n-triples b/data/dm2 14706058_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 14706058_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15205563_admin.annodb b/data/dm2 15205563_admin.annodb new file mode 100644 index 0000000..106215f --- /dev/null +++ b/data/dm2 15205563_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +171, Journal, 0, 10, "Horm Res .", "", " \"Horm Res .\"." +0, PublicationYear, 11, 15, "2004", "", " \"2004\"." +84, Title, 57, 130, "Does bromocriptine improve glycemic control of obese type - 2 diabetics ?", "", " \"Does bromocriptine improve glycemic control of obese type - 2 diabetics ?\"." +73, Bromocriptine, 62, 75, "bromocriptine", "", +75, Precondition, 104, 128, "obese type - 2 diabetics", "", +74, Type2Diabetes, 110, 128, "type - 2 diabetics", "", +23, Author, 131, 144, "Aminorroaya A", "", " \"Aminorroaya A\"." +24, Author, 153, 166, "Janghorbani M", "", " \"Janghorbani M\"." +25, Author, 169, 179, "Ramezani M", "", " \"Ramezani M\"." +26, Author, 182, 192, "Haghighi S", "", " \"Haghighi S\"." +27, Author, 195, 202, "Amini M", "", " \"Amini M\"." +2, Iran, 358, 362, "Iran", "", " ." +76, OralAntidiabeticAgent, 420, 444, "oral hypoglycemic agents", "", +40, Type2Diabetes, 479, 496, "type - 2 diabetic", "", +173, PlasmaGlucose, 525, 539, "plasma glucose", "", +41, Bromocriptine, 628, 641, "bromocriptine", "", +167, ObjectiveDescription, 705, 802, "the effect of bromocriptine on glycemic control was evaluated in obese type - 2 diabetic patients", "", " \"32\". \"the effect of bromocriptine on glycemic control was evaluated in obese type - 2 diabetic patients\"." +42, Bromocriptine, 719, 732, "bromocriptine", "", +3, Precondition, 770, 802, "obese type - 2 diabetic patients", "", +43, Type2Diabetes, 776, 793, "type - 2 diabetic", "", +7, DoubleBlind, 820, 834, "double - blind", "", " ." +100, Placebo, 835, 842, "placebo", "", +6, NumberPatientsCT, 873, 875, "40", "", " \"40\"." +77, Precondition, 876, 913, "obese patients with type - 2 diabetes", "", " \"obese patients with type - 2 diabetes\"." +44, Type2Diabetes, 896, 913, "type - 2 diabetes", "", " ." +4, MinAge, 921, 923, "32", "", " \"32\"." +5, MaxAge, 926, 928, "70", "", " \"70\"." +92889, Randomized, 942, 950, "randomly", "", " ." +45, Bromocriptine, 1016, 1029, "bromocriptine", "", " ." +10, DoseValue, 1032, 1037, "2 . 5", "", " \"2 . 5\"." +11, mg, 1038, 1040, "mg", "", " ." +78, Frequency, 1041, 1046, "daily", "", " \"daily\"." +9, Duration, 1064, 1072, "3 months", "", +46, Placebo, 1101, 1108, "placebo", "", " ." +113, Precondition, 1125, 1249, "uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study", "", " \"uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study\"." +115, Drug, 1156, 1169, "glibenclamide", "", +114, Metformin, 1194, 1203, "metformin", "", +38176, Duration, 1211, 1219, "3 months", "", +47, FastingPlasmaGlucose, 1256, 1278, "fasting plasma glucose", "", +48, FastingPlasmaGlucose, 1281, 1284, "FPG", "", +49, HbA1c, 1297, 1320, "glycosylated hemoglobin", "", +50, HbA1c, 1323, 1327, "HbA1", "", +51, BMI, 1348, 1363, "body mass index", "", +52, BMI, 1366, 1369, "BMI", "", +38177, TimePoint, 1398, 1416, "1 , 2 and 3 months", "", +38178, TimePoint, 1402, 1416, "2 and 3 months", "", +38179, TimePoint, 1408, 1416, "3 months", "", +12, FastingPlasmaGlucose, 1449, 1452, "FPG", "", " ." +53, Bromocriptine, 1476, 1489, "bromocriptine", "", +28, BaseLineValue, 1511, 1518, "10 . 59", "", " \"10 . 59\"." +33, SdErrorBL, 1525, 1531, "0 . 42", "", " \"0 . 42\"." +124, ResultMeasuredValue, 1535, 1541, "9 . 06", "", " \"9 . 06\"." +125, SdErrorResValue, 1548, 1554, "0 . 41", "", " \"0 . 41\"." +54, Millimoles_per_litre, 1555, 1563, "mmol / l", "", +170, Mean, 1566, 1570, "mean", "", +38180, PValueChangeValue, 1583, 1593, "p < 0 . 01", "", " \"p < 0 . 01\"." +55, Placebo, 1613, 1620, "placebo", "", +29, BaseLineValue, 1648, 1655, "10 . 69", "", " \"10 . 69\"." +34, SdErrorBL, 1662, 1668, "0 . 52", "", " \"0 . 52\"." +130, ResultMeasuredValue, 1673, 1679, "10 . 6", "", " \"10 . 6\"." +131, SdErrorResValue, 1686, 1692, "0 . 57", "", " \"0 . 57\"." +56, Millimoles_per_litre, 1693, 1701, "mmol / l", "", +57, HbA1c, 1723, 1727, "HbA1", "", " ." +58, Bromocriptine, 1761, 1774, "bromocriptine", "", +30, BaseLineValue, 1796, 1801, "9 . 9", "", " \"9 . 9\"." +35, SdErrorBL, 1808, 1813, "0 . 3", "", " \"0 . 3\"." +137, ResultMeasuredValue, 1817, 1822, "9 . 5", "", " \"9 . 5\"." +138, SdErrorResValue, 1829, 1834, "0 . 2", "", " \"0 . 2\"." +80, Percentage, 1835, 1836, "%", "", " ." +63, PValueChangeValue, 1839, 1849, "p = 0 . 06", "", " \"p = 0 . 06\"." +61, Placebo, 1882, 1889, "placebo", "", +31, BaseLineValue, 1911, 1917, "10 . 2", "", " \"10 . 2\"." +36, SdErrorBL, 1924, 1929, "0 . 3", "", " \"0 . 3\"." +144, ResultMeasuredValue, 1933, 1939, "11 . 3", "", " \"11 . 3\"." +62, SdErrorChangeValue, 1946, 1951, "0 . 6", "", " \"0 . 6\"." +81, Percentage, 1952, 1953, "%", "", +17, PValueChangeValue, 1956, 1966, "p < 0 . 05", "", " \"p < 0 . 05\"." +64, HbA1c, 1990, 1994, "HbA1", "", +154, DiffGroupAbsValue, 1997, 2002, "1 . 8", "", " \"1 . 8\"." +155, Percentage, 2003, 2004, "%", "", +19, PvalueDiff, 2007, 2017, "p < 0 . 01", "", +65, FastingPlasmaGlucose, 2024, 2027, "FPG", "", +20, DiffGroupAbsValue, 2030, 2036, "1 . 55", "", +22, Millimoles_per_litre, 2037, 2045, "mmol / l", "", +21, PvalueDiff, 2048, 2058, "p < 0 . 05", "", +66, Bromocriptine, 2080, 2093, "bromocriptine", "", +67, Placebo, 2098, 2105, "placebo", "", +158, TimePoint, 2116, 2124, "3 months", "", +179, ObservedResult, 2144, 2257, "No changes in body weight or BMI occurred during the study in either placebo - or bromocriptine - treated group .", "", " \"double - blind\". \"No changes in body weight or BMI occurred during the study in either placebo - or bromocriptine - treated group .\". \"double - blind\". \"No changes in body weight or BMI occurred during the study in either placebo - or bromocriptine - treated group .\"." +13, BodyWeight, 2158, 2169, "body weight", "", " ." +68, BMI, 2173, 2176, "BMI", "", " ." +69, Placebo, 2213, 2220, "placebo", "", +70, Bromocriptine, 2226, 2239, "bromocriptine", "", +168, ConclusionComment, 2271, 2451, "The data further support the contention that bromocriptine improves glycemic control in obese type - 2 diabetic patients , although the mechanism of action remains to be determined", "", " \"The data further support the contention that bromocriptine improves glycemic control in obese type - 2 diabetic patients , although the mechanism of action remains to be determined\". \"70\"." +71, Bromocriptine, 2316, 2329, "bromocriptine", "", +79, Precondition, 2359, 2391, "obese type - 2 diabetic patients", "", +72, Type2Diabetes, 2365, 2382, "type - 2 diabetic", "", +1, PMID, 2489, 2497, "15205563", "", diff --git a/data/dm2 15205563_admin.n-triples b/data/dm2 15205563_admin.n-triples new file mode 100644 index 0000000..c8e39b9 --- /dev/null +++ b/data/dm2 15205563_admin.n-triples @@ -0,0 +1,156 @@ +# RDF export of group: Publication + . + "Publication " . + "Does bromocriptine improve glycemic control of obese type - 2 diabetics ?" . + "Aminorroaya A" . + "2004" . + "Horm Res ." . + . + "Janghorbani M" . + "Ramezani M" . + "Haghighi S" . + "Amini M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "32" . + "the effect of bromocriptine on glycemic control was evaluated in obese type - 2 diabetic patients" . + "40" . + . + . + . + "The data further support the contention that bromocriptine improves glycemic control in obese type - 2 diabetic patients , although the mechanism of action remains to be determined" . + "70" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study" . + . + . + "32" . + "70" . + . + "obese patients with type - 2 diabetes" . +# RDF export of group: Endpoint + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint bmi" . + . + . + . + . +# RDF export of group: Arm + . + "Arm b" . + . + . + . + . + . + . + "Arm p" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention b" . + . + "daily" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication b" . + . + "2 . 5" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome fpg b " . + . + "10 . 59" . + "0 . 42" . + "9 . 06" . + "0 . 41" . + "p < 0 . 01" . + . + "Outcome fpg p " . + . + "10 . 69" . + "0 . 52" . + "10 . 6" . + "0 . 57" . + . + "Outcome hba1c b" . + . + "9 . 9" . + "0 . 3" . + "9 . 5" . + "0 . 2" . + "p = 0 . 06" . + . + "Outcome hba1c p " . + . + "10 . 2" . + "0 . 3" . + "11 . 3" . + "p < 0 . 05" . + "0 . 6" . + . + "Outcome weight both drugs" . + . + "double - blind" . + "No changes in body weight or BMI occurred during the study in either placebo - or bromocriptine - treated group ." . + . + "Outcome bmi both drugs" . + . + "double - blind" . + "No changes in body weight or BMI occurred during the study in either placebo - or bromocriptine - treated group ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "1 . 8" . + . + . + . + "DiffBetweenGroups fpg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15205563_akramersunderbrink.annodb b/data/dm2 15205563_akramersunderbrink.annodb new file mode 100644 index 0000000..4d3da10 --- /dev/null +++ b/data/dm2 15205563_akramersunderbrink.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6218, Journal, 0, 8, "Horm Res", "", +6219, PublicationYear, 11, 15, "2004", "", +6220, Title, 57, 130, "Does bromocriptine improve glycemic control of obese type - 2 diabetics ?", "", +6221, Bromocriptine, 62, 75, "bromocriptine", "", +6222, Precondition, 104, 109, "obese", "", +6223, Type2Diabetes, 110, 128, "type - 2 diabetics", "", +6224, Author, 131, 144, "Aminorroaya A", "", +6225, Author, 153, 166, "Janghorbani M", "", +6226, Author, 169, 179, "Ramezani M", "", +6227, Author, 182, 192, "Haghighi S", "", +6228, Author, 195, 202, "Amini M", "", +39088, Iran, 358, 362, "Iran", "", +6229, Type2Diabetes, 479, 496, "type - 2 diabetic", "", +6230, FastingPlasmaGlucose, 525, 554, "plasma glucose concentrations", "", +6231, Bromocriptine, 628, 641, "bromocriptine", "", +6307, ObjectiveDescription, 705, 802, "the effect of bromocriptine on glycemic control was evaluated in obese type - 2 diabetic patients", "", +6232, Bromocriptine, 719, 732, "bromocriptine", "", +6233, Precondition, 770, 775, "obese", "", +6234, Type2Diabetes, 776, 793, "type - 2 diabetic", "", +6235, DoubleBlind, 820, 834, "double - blind", "", +6236, Placebo, 835, 842, "placebo", "", +6237, NumberPatientsCT, 873, 875, "40", "", +6239, Precondition, 876, 881, "obese", "", +6238, Type2Diabetes, 896, 913, "type - 2 diabetes", "", +6240, MinAge, 921, 923, "32", "", +6241, MaxAge, 926, 928, "70", "", +6242, Randomized, 942, 950, "randomly", "", +6243, Bromocriptine, 1016, 1029, "bromocriptine", "", +6246, DoseValue, 1032, 1037, "2 . 5", "", +6247, mg, 1038, 1040, "mg", "", +6248, Frequency, 1041, 1046, "daily", "", +6244, Duration, 1064, 1072, "3 months", "", +6245, Placebo, 1101, 1108, "placebo", "", +6249, Precondition, 1125, 1249, "uncontrolled on fixed doses of glibenclamide or its combination with metformin in the 3 months before enrolling in the study", "", +6251, Drug, 1156, 1169, "glibenclamide", "", +6250, Metformin, 1194, 1203, "metformin", "", +6252, FastingPlasmaGlucose, 1256, 1292, "fasting plasma glucose ( FPG ) level", "", +6253, HbA1c, 1297, 1329, "glycosylated hemoglobin ( HbA1 )", "", +6254, BMI, 1348, 1371, "body mass index ( BMI )", "", +6255, FastingPlasmaGlucose, 1449, 1458, "FPG level", "", +6258, Bromocriptine, 1476, 1489, "bromocriptine", "", +6260, BaseLineValue, 1511, 1518, "10 . 59", "", +6261, SdErrorBL, 1519, 1531, "+ / - 0 . 42", "", +6262, ResultMeasuredValue, 1535, 1541, "9 . 06", "", +6263, SdErrorResValue, 1542, 1554, "+ / - 0 . 41", "", +6264, Millimoles_per_litre, 1555, 1563, "mmol / l", "", +9787, Mean, 1566, 1570, "mean", "", +6265, PValueChangeValue, 1583, 1593, "p < 0 . 01", "", +6259, Placebo, 1613, 1620, "placebo", "", +6267, BaseLineValue, 1648, 1655, "10 . 69", "", +6268, SdErrorBL, 1656, 1668, "+ / - 0 . 52", "", +6269, ResultMeasuredValue, 1673, 1679, "10 . 6", "", +6270, SdErrorResValue, 1680, 1692, "+ / - 0 . 57", "", +6271, Millimoles_per_litre, 1693, 1701, "mmol / l", "", +6272, HbA1c, 1723, 1741, "HbA1 concentration", "", +6273, Bromocriptine, 1761, 1774, "bromocriptine", "", +6274, BaseLineValue, 1796, 1801, "9 . 9", "", +6275, SdErrorBL, 1802, 1813, "+ / - 0 . 3", "", +6276, ResultMeasuredValue, 1817, 1822, "9 . 5", "", +6277, SdErrorResValue, 1823, 1834, "+ / - 0 . 2", "", +6278, Percentage, 1835, 1836, "%", "", +6279, PValueChangeValue, 1839, 1849, "p = 0 . 06", "", +6280, Placebo, 1882, 1889, "placebo", "", +6281, BaseLineValue, 1911, 1917, "10 . 2", "", +6282, SdErrorBL, 1918, 1929, "+ / - 0 . 3", "", +6283, ResultMeasuredValue, 1933, 1939, "11 . 3", "", +6284, SdErrorChangeValue, 1940, 1951, "+ / - 0 . 6", "", +6285, Percentage, 1952, 1953, "%", "", +6286, PValueChangeValue, 1956, 1966, "p < 0 . 05", "", +6287, HbA1c, 1990, 1994, "HbA1", "", +6294, DiffGroupAbsValue, 1997, 2002, "1 . 8", "", +6295, Percentage, 2003, 2004, "%", "", +6289, PvalueDiff, 2007, 2017, "p < 0 . 01", "", +6290, FastingPlasmaGlucose, 2024, 2027, "FPG", "", +6291, DiffGroupAbsValue, 2030, 2036, "1 . 55", "", +6292, Millimoles_per_litre, 2037, 2045, "mmol / l", "", +6293, PvalueDiff, 2048, 2058, "p < 0 . 05", "", +6296, Bromocriptine, 2080, 2093, "bromocriptine", "", +6297, Placebo, 2098, 2105, "placebo", "", +6298, TimePoint, 2116, 2124, "3 months", "", +6309, ObservedResult, 2144, 2154, "No changes", "", +6299, BodyWeight, 2158, 2169, "body weight", "", +6300, BMI, 2173, 2176, "BMI", "", +6301, Placebo, 2213, 2220, "placebo", "", +6302, Bromocriptine, 2226, 2239, "bromocriptine", "", +6308, ConclusionComment, 2271, 2451, "The data further support the contention that bromocriptine improves glycemic control in obese type - 2 diabetic patients , although the mechanism of action remains to be determined", "", +6303, Bromocriptine, 2316, 2329, "bromocriptine", "", +6304, Precondition, 2359, 2364, "obese", "", +6305, Type2Diabetes, 2365, 2382, "type - 2 diabetic", "", +6306, PMID, 2489, 2497, "15205563", "", diff --git a/data/dm2 15205563_akramersunderbrink.n-triples b/data/dm2 15205563_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15205563_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15205563_export.csv b/data/dm2 15205563_export.csv new file mode 100644 index 0000000..622365b --- /dev/null +++ b/data/dm2 15205563_export.csv @@ -0,0 +1,546 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +373, 1, 1, 1, 0, 4, 0, 4, "Horm" +373, 1, 2, 2, 5, 8, 5, 8, "Res" +373, 1, 3, 3, 9, 10, 9, 10, "." +373, 2, 1, 4, 0, 4, 11, 15, "2004" +373, 2, 2, 5, 5, 6, 16, 17, ";" +373, 2, 3, 6, 7, 9, 18, 20, "62" +373, 2, 4, 7, 10, 11, 21, 22, "(" +373, 2, 5, 8, 12, 13, 23, 24, "2" +373, 2, 6, 9, 14, 15, 25, 26, ")" +373, 2, 7, 10, 16, 17, 27, 28, ":" +373, 2, 8, 11, 18, 20, 29, 31, "55" +373, 2, 9, 12, 21, 22, 32, 33, "-" +373, 2, 10, 13, 23, 24, 34, 35, "9" +373, 2, 11, 14, 25, 26, 36, 37, "." +373, 3, 1, 15, 0, 4, 38, 42, "Epub" +373, 3, 2, 16, 5, 9, 43, 47, "2004" +373, 3, 3, 17, 10, 13, 48, 51, "Jun" +373, 3, 4, 18, 14, 16, 52, 54, "11" +373, 3, 5, 19, 17, 18, 55, 56, "." +373, 4, 1, 20, 0, 4, 57, 61, "Does" +373, 4, 2, 21, 5, 18, 62, 75, "bromocriptine" +373, 4, 3, 22, 19, 26, 76, 83, "improve" +373, 4, 4, 23, 27, 35, 84, 92, "glycemic" +373, 4, 5, 24, 36, 43, 93, 100, "control" +373, 4, 6, 25, 44, 46, 101, 103, "of" +373, 4, 7, 26, 47, 52, 104, 109, "obese" +373, 4, 8, 27, 53, 57, 110, 114, "type" +373, 4, 9, 28, 58, 59, 115, 116, "-" +373, 4, 10, 29, 60, 61, 117, 118, "2" +373, 4, 11, 30, 62, 71, 119, 128, "diabetics" +373, 4, 12, 31, 72, 73, 129, 130, "?" +373, 5, 1, 32, 0, 11, 131, 142, "Aminorroaya" +373, 5, 2, 33, 12, 13, 143, 144, "A" +373, 5, 3, 34, 14, 15, 145, 146, "(" +373, 5, 4, 35, 16, 17, 147, 148, "1" +373, 5, 5, 36, 18, 19, 149, 150, ")" +373, 5, 6, 37, 20, 21, 151, 152, "," +373, 5, 7, 38, 22, 33, 153, 164, "Janghorbani" +373, 5, 8, 39, 34, 35, 165, 166, "M" +373, 5, 9, 40, 36, 37, 167, 168, "," +373, 5, 10, 41, 38, 46, 169, 177, "Ramezani" +373, 5, 11, 42, 47, 48, 178, 179, "M" +373, 5, 12, 43, 49, 50, 180, 181, "," +373, 5, 13, 44, 51, 59, 182, 190, "Haghighi" +373, 5, 14, 45, 60, 61, 191, 192, "S" +373, 5, 15, 46, 62, 63, 193, 194, "," +373, 5, 16, 47, 64, 69, 195, 200, "Amini" +373, 5, 17, 48, 70, 71, 201, 202, "M" +373, 5, 18, 49, 72, 73, 203, 204, "." +373, 5, 19, 50, 74, 80, 205, 211, "Author" +373, 5, 20, 51, 81, 92, 212, 223, "information" +373, 5, 21, 52, 93, 94, 224, 225, ":" +373, 5, 22, 53, 95, 96, 226, 227, "(" +373, 5, 23, 54, 97, 98, 228, 229, "1" +373, 5, 24, 55, 99, 100, 230, 231, ")" +373, 5, 25, 56, 101, 108, 232, 239, "Isfahan" +373, 5, 26, 57, 109, 122, 240, 253, "Endocrinology" +373, 5, 27, 58, 123, 126, 254, 257, "and" +373, 5, 28, 59, 127, 137, 258, 268, "Metabolism" +373, 5, 29, 60, 138, 146, 269, 277, "Research" +373, 5, 30, 61, 147, 153, 278, 284, "Center" +373, 5, 31, 62, 154, 155, 285, 286, "," +373, 5, 32, 63, 156, 163, 287, 294, "Isfahan" +373, 5, 33, 64, 164, 174, 295, 305, "University" +373, 5, 34, 65, 175, 177, 306, 308, "of" +373, 5, 35, 66, 178, 185, 309, 316, "Medical" +373, 5, 36, 67, 186, 194, 317, 325, "Sciences" +373, 5, 37, 68, 195, 198, 326, 329, "and" +373, 5, 38, 69, 199, 205, 330, 336, "Health" +373, 5, 39, 70, 206, 214, 337, 345, "Services" +373, 5, 40, 71, 215, 216, 346, 347, "," +373, 5, 41, 72, 217, 224, 348, 355, "Isfahan" +373, 5, 42, 73, 225, 226, 356, 357, "," +373, 5, 43, 74, 227, 231, 358, 362, "Iran" +373, 5, 44, 75, 232, 233, 363, 364, "." +373, 6, 1, 76, 0, 11, 365, 376, "aminorroaya" +373, 6, 2, 77, 12, 13, 377, 378, "@" +373, 6, 3, 78, 14, 17, 379, 382, "med" +373, 6, 4, 79, 18, 19, 383, 384, "." +373, 6, 5, 80, 20, 23, 385, 388, "mui" +373, 6, 6, 81, 24, 25, 389, 390, "." +373, 6, 7, 82, 26, 28, 391, 393, "ac" +373, 6, 8, 83, 29, 30, 394, 395, "." +373, 6, 9, 84, 31, 33, 396, 398, "ir" +373, 6, 10, 85, 34, 44, 399, 409, "BACKGROUND" +373, 6, 11, 86, 45, 46, 410, 411, ":" +373, 6, 12, 87, 47, 54, 412, 419, "Various" +373, 6, 13, 88, 55, 59, 420, 424, "oral" +373, 6, 14, 89, 60, 72, 425, 437, "hypoglycemic" +373, 6, 15, 90, 73, 79, 438, 444, "agents" +373, 6, 16, 91, 80, 84, 445, 449, "have" +373, 6, 17, 92, 85, 92, 450, 457, "already" +373, 6, 18, 93, 93, 97, 458, 462, "been" +373, 6, 19, 94, 98, 110, 463, 475, "administered" +373, 6, 20, 95, 111, 113, 476, 478, "to" +373, 6, 21, 96, 114, 118, 479, 483, "type" +373, 6, 22, 97, 119, 120, 484, 485, "-" +373, 6, 23, 98, 121, 122, 486, 487, "2" +373, 6, 24, 99, 123, 131, 488, 496, "diabetic" +373, 6, 25, 100, 132, 140, 497, 505, "patients" +373, 6, 26, 101, 141, 143, 506, 508, "to" +373, 6, 27, 102, 144, 153, 509, 518, "normalize" +373, 6, 28, 103, 154, 159, 519, 524, "their" +373, 6, 29, 104, 160, 166, 525, 531, "plasma" +373, 6, 30, 105, 167, 174, 532, 539, "glucose" +373, 6, 31, 106, 175, 189, 540, 554, "concentrations" +373, 6, 32, 107, 190, 193, 555, 558, "but" +373, 6, 33, 108, 194, 198, 559, 563, "they" +373, 6, 34, 109, 199, 203, 564, 568, "have" +373, 6, 35, 110, 204, 207, 569, 572, "not" +373, 6, 36, 111, 208, 211, 573, 576, "had" +373, 6, 37, 112, 212, 220, 577, 585, "complete" +373, 6, 38, 113, 221, 224, 586, 589, "and" +373, 6, 39, 114, 225, 234, 590, 599, "sustained" +373, 6, 40, 115, 235, 242, 600, 607, "success" +373, 6, 41, 116, 243, 244, 608, 609, "." +373, 7, 1, 117, 0, 2, 610, 612, "In" +373, 7, 2, 118, 3, 9, 613, 619, "recent" +373, 7, 3, 119, 10, 15, 620, 625, "years" +373, 7, 4, 120, 16, 17, 626, 627, "," +373, 7, 5, 121, 18, 31, 628, 641, "bromocriptine" +373, 7, 6, 122, 32, 35, 642, 645, "has" +373, 7, 7, 123, 36, 40, 646, 650, "been" +373, 7, 8, 124, 41, 46, 651, 656, "tried" +373, 7, 9, 125, 47, 51, 657, 661, "with" +373, 7, 10, 126, 52, 65, 662, 675, "controversial" +373, 7, 11, 127, 66, 73, 676, 683, "results" +373, 7, 12, 128, 74, 75, 684, 685, "." +373, 8, 1, 129, 0, 2, 686, 688, "In" +373, 8, 2, 130, 3, 10, 689, 696, "present" +373, 8, 3, 131, 11, 16, 697, 702, "study" +373, 8, 4, 132, 17, 18, 703, 704, "," +373, 8, 5, 133, 19, 22, 705, 708, "the" +373, 8, 6, 134, 23, 29, 709, 715, "effect" +373, 8, 7, 135, 30, 32, 716, 718, "of" +373, 8, 8, 136, 33, 46, 719, 732, "bromocriptine" +373, 8, 9, 137, 47, 49, 733, 735, "on" +373, 8, 10, 138, 50, 58, 736, 744, "glycemic" +373, 8, 11, 139, 59, 66, 745, 752, "control" +373, 8, 12, 140, 67, 70, 753, 756, "was" +373, 8, 13, 141, 71, 80, 757, 766, "evaluated" +373, 8, 14, 142, 81, 83, 767, 769, "in" +373, 8, 15, 143, 84, 89, 770, 775, "obese" +373, 8, 16, 144, 90, 94, 776, 780, "type" +373, 8, 17, 145, 95, 96, 781, 782, "-" +373, 8, 18, 146, 97, 98, 783, 784, "2" +373, 8, 19, 147, 99, 107, 785, 793, "diabetic" +373, 8, 20, 148, 108, 116, 794, 802, "patients" +373, 8, 21, 149, 117, 118, 803, 804, "." +373, 9, 1, 150, 0, 7, 805, 812, "METHODS" +373, 9, 2, 151, 8, 9, 813, 814, ":" +373, 9, 3, 152, 10, 12, 815, 817, "In" +373, 9, 4, 153, 13, 14, 818, 819, "a" +373, 9, 5, 154, 15, 21, 820, 826, "double" +373, 9, 6, 155, 22, 23, 827, 828, "-" +373, 9, 7, 156, 24, 29, 829, 834, "blind" +373, 9, 8, 157, 30, 37, 835, 842, "placebo" +373, 9, 9, 158, 38, 39, 843, 844, "-" +373, 9, 10, 159, 40, 50, 845, 855, "controlled" +373, 9, 11, 160, 51, 59, 856, 864, "clinical" +373, 9, 12, 161, 60, 65, 865, 870, "trial" +373, 9, 13, 162, 66, 67, 871, 872, "," +373, 9, 14, 163, 68, 70, 873, 875, "40" +373, 9, 15, 164, 71, 76, 876, 881, "obese" +373, 9, 16, 165, 77, 85, 882, 890, "patients" +373, 9, 17, 166, 86, 90, 891, 895, "with" +373, 9, 18, 167, 91, 95, 896, 900, "type" +373, 9, 19, 168, 96, 97, 901, 902, "-" +373, 9, 20, 169, 98, 99, 903, 904, "2" +373, 9, 21, 170, 100, 108, 905, 913, "diabetes" +373, 9, 22, 171, 109, 110, 914, 915, "(" +373, 9, 23, 172, 111, 115, 916, 920, "aged" +373, 9, 24, 173, 116, 118, 921, 923, "32" +373, 9, 25, 174, 119, 120, 924, 925, "-" +373, 9, 26, 175, 121, 123, 926, 928, "70" +373, 9, 27, 176, 124, 129, 929, 934, "years" +373, 9, 28, 177, 130, 131, 935, 936, ")" +373, 9, 29, 178, 132, 136, 937, 941, "were" +373, 9, 30, 179, 137, 145, 942, 950, "randomly" +373, 9, 31, 180, 146, 155, 951, 960, "allocated" +373, 9, 32, 181, 156, 158, 961, 963, "to" +373, 9, 33, 182, 159, 162, 964, 967, "the" +373, 9, 34, 183, 163, 166, 968, 971, "two" +373, 9, 35, 184, 167, 176, 972, 981, "treatment" +373, 9, 36, 185, 177, 183, 982, 988, "groups" +373, 9, 37, 186, 184, 185, 989, 990, "." +373, 10, 1, 187, 0, 3, 991, 994, "The" +373, 10, 2, 188, 4, 9, 995, 1000, "first" +373, 10, 3, 189, 10, 15, 1001, 1006, "group" +373, 10, 4, 190, 16, 24, 1007, 1015, "received" +373, 10, 5, 191, 25, 38, 1016, 1029, "bromocriptine" +373, 10, 6, 192, 39, 40, 1030, 1031, "(" +373, 10, 7, 193, 41, 42, 1032, 1033, "2" +373, 10, 8, 194, 43, 44, 1034, 1035, "." +373, 10, 9, 195, 45, 46, 1036, 1037, "5" +373, 10, 10, 196, 47, 49, 1038, 1040, "mg" +373, 10, 11, 197, 50, 55, 1041, 1046, "daily" +373, 10, 12, 198, 56, 57, 1047, 1048, ")" +373, 10, 13, 199, 58, 61, 1049, 1052, "for" +373, 10, 14, 200, 62, 63, 1053, 1054, "a" +373, 10, 15, 201, 64, 69, 1055, 1060, "total" +373, 10, 16, 202, 70, 72, 1061, 1063, "of" +373, 10, 17, 203, 73, 74, 1064, 1065, "3" +373, 10, 18, 204, 75, 81, 1066, 1072, "months" +373, 10, 19, 205, 82, 83, 1073, 1074, "." +373, 11, 1, 206, 0, 3, 1075, 1078, "The" +373, 11, 2, 207, 4, 10, 1079, 1085, "second" +373, 11, 3, 208, 11, 16, 1086, 1091, "group" +373, 11, 4, 209, 17, 25, 1092, 1100, "received" +373, 11, 5, 210, 26, 33, 1101, 1108, "placebo" +373, 11, 6, 211, 34, 35, 1109, 1110, "." +373, 12, 1, 212, 0, 4, 1111, 1115, "They" +373, 12, 2, 213, 5, 8, 1116, 1119, "had" +373, 12, 3, 214, 9, 13, 1120, 1124, "been" +373, 12, 4, 215, 14, 26, 1125, 1137, "uncontrolled" +373, 12, 5, 216, 27, 29, 1138, 1140, "on" +373, 12, 6, 217, 30, 35, 1141, 1146, "fixed" +373, 12, 7, 218, 36, 41, 1147, 1152, "doses" +373, 12, 8, 219, 42, 44, 1153, 1155, "of" +373, 12, 9, 220, 45, 58, 1156, 1169, "glibenclamide" +373, 12, 10, 221, 59, 61, 1170, 1172, "or" +373, 12, 11, 222, 62, 65, 1173, 1176, "its" +373, 12, 12, 223, 66, 77, 1177, 1188, "combination" +373, 12, 13, 224, 78, 82, 1189, 1193, "with" +373, 12, 14, 225, 83, 92, 1194, 1203, "metformin" +373, 12, 15, 226, 93, 95, 1204, 1206, "in" +373, 12, 16, 227, 96, 99, 1207, 1210, "the" +373, 12, 17, 228, 100, 101, 1211, 1212, "3" +373, 12, 18, 229, 102, 108, 1213, 1219, "months" +373, 12, 19, 230, 109, 115, 1220, 1226, "before" +373, 12, 20, 231, 116, 125, 1227, 1236, "enrolling" +373, 12, 21, 232, 126, 128, 1237, 1239, "in" +373, 12, 22, 233, 129, 132, 1240, 1243, "the" +373, 12, 23, 234, 133, 138, 1244, 1249, "study" +373, 12, 24, 235, 139, 140, 1250, 1251, "." +373, 13, 1, 236, 0, 3, 1252, 1255, "The" +373, 13, 2, 237, 4, 11, 1256, 1263, "fasting" +373, 13, 3, 238, 12, 18, 1264, 1270, "plasma" +373, 13, 4, 239, 19, 26, 1271, 1278, "glucose" +373, 13, 5, 240, 27, 28, 1279, 1280, "(" +373, 13, 6, 241, 29, 32, 1281, 1284, "FPG" +373, 13, 7, 242, 33, 34, 1285, 1286, ")" +373, 13, 8, 243, 35, 40, 1287, 1292, "level" +373, 13, 9, 244, 41, 44, 1293, 1296, "and" +373, 13, 10, 245, 45, 57, 1297, 1309, "glycosylated" +373, 13, 11, 246, 58, 68, 1310, 1320, "hemoglobin" +373, 13, 12, 247, 69, 70, 1321, 1322, "(" +373, 13, 13, 248, 71, 75, 1323, 1327, "HbA1" +373, 13, 14, 249, 76, 77, 1328, 1329, ")" +373, 13, 15, 250, 78, 82, 1330, 1334, "were" +373, 13, 16, 251, 83, 91, 1335, 1343, "measured" +373, 13, 17, 252, 92, 95, 1344, 1347, "and" +373, 13, 18, 253, 96, 100, 1348, 1352, "body" +373, 13, 19, 254, 101, 105, 1353, 1357, "mass" +373, 13, 20, 255, 106, 111, 1358, 1363, "index" +373, 13, 21, 256, 112, 113, 1364, 1365, "(" +373, 13, 22, 257, 114, 117, 1366, 1369, "BMI" +373, 13, 23, 258, 118, 119, 1370, 1371, ")" +373, 13, 24, 259, 120, 123, 1372, 1375, "was" +373, 13, 25, 260, 124, 134, 1376, 1386, "calculated" +373, 13, 26, 261, 135, 141, 1387, 1393, "before" +373, 13, 27, 262, 142, 145, 1394, 1397, "and" +373, 13, 28, 263, 146, 147, 1398, 1399, "1" +373, 13, 29, 264, 148, 149, 1400, 1401, "," +373, 13, 30, 265, 150, 151, 1402, 1403, "2" +373, 13, 31, 266, 152, 155, 1404, 1407, "and" +373, 13, 32, 267, 156, 157, 1408, 1409, "3" +373, 13, 33, 268, 158, 164, 1410, 1416, "months" +373, 13, 34, 269, 165, 170, 1417, 1422, "after" +373, 13, 35, 270, 171, 180, 1423, 1432, "treatment" +373, 13, 36, 271, 181, 182, 1433, 1434, "." +373, 14, 1, 272, 0, 7, 1435, 1442, "RESULTS" +373, 14, 2, 273, 8, 9, 1443, 1444, ":" +373, 14, 3, 274, 10, 13, 1445, 1448, "The" +373, 14, 4, 275, 14, 17, 1449, 1452, "FPG" +373, 14, 5, 276, 18, 23, 1453, 1458, "level" +373, 14, 6, 277, 24, 33, 1459, 1468, "decreased" +373, 14, 7, 278, 34, 36, 1469, 1471, "in" +373, 14, 8, 279, 37, 40, 1472, 1475, "the" +373, 14, 9, 280, 41, 54, 1476, 1489, "bromocriptine" +373, 14, 10, 281, 55, 56, 1490, 1491, "-" +373, 14, 11, 282, 57, 64, 1492, 1499, "treated" +373, 14, 12, 283, 65, 70, 1500, 1505, "group" +373, 14, 13, 284, 71, 75, 1506, 1510, "from" +373, 14, 14, 285, 76, 78, 1511, 1513, "10" +373, 14, 15, 286, 79, 80, 1514, 1515, "." +373, 14, 16, 287, 81, 83, 1516, 1518, "59" +373, 14, 17, 288, 84, 85, 1519, 1520, "+" +373, 14, 18, 289, 86, 87, 1521, 1522, "/" +373, 14, 19, 290, 88, 89, 1523, 1524, "-" +373, 14, 20, 291, 90, 91, 1525, 1526, "0" +373, 14, 21, 292, 92, 93, 1527, 1528, "." +373, 14, 22, 293, 94, 96, 1529, 1531, "42" +373, 14, 23, 294, 97, 99, 1532, 1534, "to" +373, 14, 24, 295, 100, 101, 1535, 1536, "9" +373, 14, 25, 296, 102, 103, 1537, 1538, "." +373, 14, 26, 297, 104, 106, 1539, 1541, "06" +373, 14, 27, 298, 107, 108, 1542, 1543, "+" +373, 14, 28, 299, 109, 110, 1544, 1545, "/" +373, 14, 29, 300, 111, 112, 1546, 1547, "-" +373, 14, 30, 301, 113, 114, 1548, 1549, "0" +373, 14, 31, 302, 115, 116, 1550, 1551, "." +373, 14, 32, 303, 117, 119, 1552, 1554, "41" +373, 14, 33, 304, 120, 124, 1555, 1559, "mmol" +373, 14, 34, 305, 125, 126, 1560, 1561, "/" +373, 14, 35, 306, 127, 128, 1562, 1563, "l" +373, 14, 36, 307, 129, 130, 1564, 1565, "(" +373, 14, 37, 308, 131, 135, 1566, 1570, "mean" +373, 14, 38, 309, 136, 137, 1571, 1572, "+" +373, 14, 39, 310, 138, 139, 1573, 1574, "/" +373, 14, 40, 311, 140, 141, 1575, 1576, "-" +373, 14, 41, 312, 142, 145, 1577, 1580, "SEM" +373, 14, 42, 313, 146, 147, 1581, 1582, ";" +373, 14, 43, 314, 148, 149, 1583, 1584, "p" +373, 14, 44, 315, 150, 151, 1585, 1586, "<" +373, 14, 45, 316, 152, 153, 1587, 1588, "0" +373, 14, 46, 317, 154, 155, 1589, 1590, "." +373, 14, 47, 318, 156, 158, 1591, 1593, "01" +373, 14, 48, 319, 159, 160, 1594, 1595, ")" +373, 14, 49, 320, 161, 162, 1596, 1597, "," +373, 14, 50, 321, 163, 170, 1598, 1605, "whereas" +373, 14, 51, 322, 171, 173, 1606, 1608, "in" +373, 14, 52, 323, 174, 177, 1609, 1612, "the" +373, 14, 53, 324, 178, 185, 1613, 1620, "placebo" +373, 14, 54, 325, 186, 191, 1621, 1626, "group" +373, 14, 55, 326, 192, 194, 1627, 1629, "it" +373, 14, 56, 327, 195, 198, 1630, 1633, "was" +373, 14, 57, 328, 199, 202, 1634, 1637, "not" +373, 14, 58, 329, 203, 210, 1638, 1645, "changed" +373, 14, 59, 330, 211, 212, 1646, 1647, "," +373, 14, 60, 331, 213, 215, 1648, 1650, "10" +373, 14, 61, 332, 216, 217, 1651, 1652, "." +373, 14, 62, 333, 218, 220, 1653, 1655, "69" +373, 14, 63, 334, 221, 222, 1656, 1657, "+" +373, 14, 64, 335, 223, 224, 1658, 1659, "/" +373, 14, 65, 336, 225, 226, 1660, 1661, "-" +373, 14, 66, 337, 227, 228, 1662, 1663, "0" +373, 14, 67, 338, 229, 230, 1664, 1665, "." +373, 14, 68, 339, 231, 233, 1666, 1668, "52" +373, 14, 69, 340, 234, 237, 1669, 1672, "and" +373, 14, 70, 341, 238, 240, 1673, 1675, "10" +373, 14, 71, 342, 241, 242, 1676, 1677, "." +373, 14, 72, 343, 243, 244, 1678, 1679, "6" +373, 14, 73, 344, 245, 246, 1680, 1681, "+" +373, 14, 74, 345, 247, 248, 1682, 1683, "/" +373, 14, 75, 346, 249, 250, 1684, 1685, "-" +373, 14, 76, 347, 251, 252, 1686, 1687, "0" +373, 14, 77, 348, 253, 254, 1688, 1689, "." +373, 14, 78, 349, 255, 257, 1690, 1692, "57" +373, 14, 79, 350, 258, 262, 1693, 1697, "mmol" +373, 14, 80, 351, 263, 264, 1698, 1699, "/" +373, 14, 81, 352, 265, 266, 1700, 1701, "l" +373, 14, 82, 353, 267, 268, 1702, 1703, "," +373, 14, 83, 354, 269, 281, 1704, 1716, "respectively" +373, 14, 84, 355, 282, 283, 1717, 1718, "." +373, 15, 1, 356, 0, 3, 1719, 1722, "The" +373, 15, 2, 357, 4, 8, 1723, 1727, "HbA1" +373, 15, 3, 358, 9, 22, 1728, 1741, "concentration" +373, 15, 4, 359, 23, 26, 1742, 1745, "was" +373, 15, 5, 360, 27, 34, 1746, 1753, "reduced" +373, 15, 6, 361, 35, 37, 1754, 1756, "in" +373, 15, 7, 362, 38, 41, 1757, 1760, "the" +373, 15, 8, 363, 42, 55, 1761, 1774, "bromocriptine" +373, 15, 9, 364, 56, 57, 1775, 1776, "-" +373, 15, 10, 365, 58, 65, 1777, 1784, "treated" +373, 15, 11, 366, 66, 71, 1785, 1790, "group" +373, 15, 12, 367, 72, 76, 1791, 1795, "from" +373, 15, 13, 368, 77, 78, 1796, 1797, "9" +373, 15, 14, 369, 79, 80, 1798, 1799, "." +373, 15, 15, 370, 81, 82, 1800, 1801, "9" +373, 15, 16, 371, 83, 84, 1802, 1803, "+" +373, 15, 17, 372, 85, 86, 1804, 1805, "/" +373, 15, 18, 373, 87, 88, 1806, 1807, "-" +373, 15, 19, 374, 89, 90, 1808, 1809, "0" +373, 15, 20, 375, 91, 92, 1810, 1811, "." +373, 15, 21, 376, 93, 94, 1812, 1813, "3" +373, 15, 22, 377, 95, 97, 1814, 1816, "to" +373, 15, 23, 378, 98, 99, 1817, 1818, "9" +373, 15, 24, 379, 100, 101, 1819, 1820, "." +373, 15, 25, 380, 102, 103, 1821, 1822, "5" +373, 15, 26, 381, 104, 105, 1823, 1824, "+" +373, 15, 27, 382, 106, 107, 1825, 1826, "/" +373, 15, 28, 383, 108, 109, 1827, 1828, "-" +373, 15, 29, 384, 110, 111, 1829, 1830, "0" +373, 15, 30, 385, 112, 113, 1831, 1832, "." +373, 15, 31, 386, 114, 115, 1833, 1834, "2" +373, 15, 32, 387, 116, 117, 1835, 1836, "%" +373, 15, 33, 388, 118, 119, 1837, 1838, "(" +373, 15, 34, 389, 120, 121, 1839, 1840, "p" +373, 15, 35, 390, 122, 123, 1841, 1842, "=" +373, 15, 36, 391, 124, 125, 1843, 1844, "0" +373, 15, 37, 392, 126, 127, 1845, 1846, "." +373, 15, 38, 393, 128, 130, 1847, 1849, "06" +373, 15, 39, 394, 131, 132, 1850, 1851, ")" +373, 15, 40, 395, 133, 134, 1852, 1853, "," +373, 15, 41, 396, 135, 142, 1854, 1861, "whereas" +373, 15, 42, 397, 143, 145, 1862, 1864, "it" +373, 15, 43, 398, 146, 155, 1865, 1874, "increased" +373, 15, 44, 399, 156, 158, 1875, 1877, "in" +373, 15, 45, 400, 159, 162, 1878, 1881, "the" +373, 15, 46, 401, 163, 170, 1882, 1889, "placebo" +373, 15, 47, 402, 171, 172, 1890, 1891, "-" +373, 15, 48, 403, 173, 180, 1892, 1899, "treated" +373, 15, 49, 404, 181, 186, 1900, 1905, "group" +373, 15, 50, 405, 187, 191, 1906, 1910, "from" +373, 15, 51, 406, 192, 194, 1911, 1913, "10" +373, 15, 52, 407, 195, 196, 1914, 1915, "." +373, 15, 53, 408, 197, 198, 1916, 1917, "2" +373, 15, 54, 409, 199, 200, 1918, 1919, "+" +373, 15, 55, 410, 201, 202, 1920, 1921, "/" +373, 15, 56, 411, 203, 204, 1922, 1923, "-" +373, 15, 57, 412, 205, 206, 1924, 1925, "0" +373, 15, 58, 413, 207, 208, 1926, 1927, "." +373, 15, 59, 414, 209, 210, 1928, 1929, "3" +373, 15, 60, 415, 211, 213, 1930, 1932, "to" +373, 15, 61, 416, 214, 216, 1933, 1935, "11" +373, 15, 62, 417, 217, 218, 1936, 1937, "." +373, 15, 63, 418, 219, 220, 1938, 1939, "3" +373, 15, 64, 419, 221, 222, 1940, 1941, "+" +373, 15, 65, 420, 223, 224, 1942, 1943, "/" +373, 15, 66, 421, 225, 226, 1944, 1945, "-" +373, 15, 67, 422, 227, 228, 1946, 1947, "0" +373, 15, 68, 423, 229, 230, 1948, 1949, "." +373, 15, 69, 424, 231, 232, 1950, 1951, "6" +373, 15, 70, 425, 233, 234, 1952, 1953, "%" +373, 15, 71, 426, 235, 236, 1954, 1955, "(" +373, 15, 72, 427, 237, 238, 1956, 1957, "p" +373, 15, 73, 428, 239, 240, 1958, 1959, "<" +373, 15, 74, 429, 241, 242, 1960, 1961, "0" +373, 15, 75, 430, 243, 244, 1962, 1963, "." +373, 15, 76, 431, 245, 247, 1964, 1966, "05" +373, 15, 77, 432, 248, 249, 1967, 1968, ")" +373, 15, 78, 433, 250, 251, 1969, 1970, "." +373, 16, 1, 434, 0, 3, 1971, 1974, "The" +373, 16, 2, 435, 4, 15, 1975, 1986, "differences" +373, 16, 3, 436, 16, 18, 1987, 1989, "in" +373, 16, 4, 437, 19, 23, 1990, 1994, "HbA1" +373, 16, 5, 438, 24, 25, 1995, 1996, "(" +373, 16, 6, 439, 26, 27, 1997, 1998, "1" +373, 16, 7, 440, 28, 29, 1999, 2000, "." +373, 16, 8, 441, 30, 31, 2001, 2002, "8" +373, 16, 9, 442, 32, 33, 2003, 2004, "%" +373, 16, 10, 443, 34, 35, 2005, 2006, "," +373, 16, 11, 444, 36, 37, 2007, 2008, "p" +373, 16, 12, 445, 38, 39, 2009, 2010, "<" +373, 16, 13, 446, 40, 41, 2011, 2012, "0" +373, 16, 14, 447, 42, 43, 2013, 2014, "." +373, 16, 15, 448, 44, 46, 2015, 2017, "01" +373, 16, 16, 449, 47, 48, 2018, 2019, ")" +373, 16, 17, 450, 49, 52, 2020, 2023, "and" +373, 16, 18, 451, 53, 56, 2024, 2027, "FPG" +373, 16, 19, 452, 57, 58, 2028, 2029, "(" +373, 16, 20, 453, 59, 60, 2030, 2031, "1" +373, 16, 21, 454, 61, 62, 2032, 2033, "." +373, 16, 22, 455, 63, 65, 2034, 2036, "55" +373, 16, 23, 456, 66, 70, 2037, 2041, "mmol" +373, 16, 24, 457, 71, 72, 2042, 2043, "/" +373, 16, 25, 458, 73, 74, 2044, 2045, "l" +373, 16, 26, 459, 75, 76, 2046, 2047, "," +373, 16, 27, 460, 77, 78, 2048, 2049, "p" +373, 16, 28, 461, 79, 80, 2050, 2051, "<" +373, 16, 29, 462, 81, 82, 2052, 2053, "0" +373, 16, 30, 463, 83, 84, 2054, 2055, "." +373, 16, 31, 464, 85, 87, 2056, 2058, "05" +373, 16, 32, 465, 88, 89, 2059, 2060, ")" +373, 16, 33, 466, 90, 96, 2061, 2067, "levels" +373, 16, 34, 467, 97, 104, 2068, 2075, "between" +373, 16, 35, 468, 105, 108, 2076, 2079, "the" +373, 16, 36, 469, 109, 122, 2080, 2093, "bromocriptine" +373, 16, 37, 470, 123, 126, 2094, 2097, "and" +373, 16, 38, 471, 127, 134, 2098, 2105, "placebo" +373, 16, 39, 472, 135, 141, 2106, 2112, "groups" +373, 16, 40, 473, 142, 144, 2113, 2115, "at" +373, 16, 41, 474, 145, 146, 2116, 2117, "3" +373, 16, 42, 475, 147, 153, 2118, 2124, "months" +373, 16, 43, 476, 154, 158, 2125, 2129, "were" +373, 16, 44, 477, 159, 170, 2130, 2141, "significant" +373, 16, 45, 478, 171, 172, 2142, 2143, "." +373, 17, 1, 479, 0, 2, 2144, 2146, "No" +373, 17, 2, 480, 3, 10, 2147, 2154, "changes" +373, 17, 3, 481, 11, 13, 2155, 2157, "in" +373, 17, 4, 482, 14, 18, 2158, 2162, "body" +373, 17, 5, 483, 19, 25, 2163, 2169, "weight" +373, 17, 6, 484, 26, 28, 2170, 2172, "or" +373, 17, 7, 485, 29, 32, 2173, 2176, "BMI" +373, 17, 8, 486, 33, 41, 2177, 2185, "occurred" +373, 17, 9, 487, 42, 48, 2186, 2192, "during" +373, 17, 10, 488, 49, 52, 2193, 2196, "the" +373, 17, 11, 489, 53, 58, 2197, 2202, "study" +373, 17, 12, 490, 59, 61, 2203, 2205, "in" +373, 17, 13, 491, 62, 68, 2206, 2212, "either" +373, 17, 14, 492, 69, 76, 2213, 2220, "placebo" +373, 17, 15, 493, 77, 78, 2221, 2222, "-" +373, 17, 16, 494, 79, 81, 2223, 2225, "or" +373, 17, 17, 495, 82, 95, 2226, 2239, "bromocriptine" +373, 17, 18, 496, 96, 97, 2240, 2241, "-" +373, 17, 19, 497, 98, 105, 2242, 2249, "treated" +373, 17, 20, 498, 106, 111, 2250, 2255, "group" +373, 17, 21, 499, 112, 113, 2256, 2257, "." +373, 18, 1, 500, 0, 10, 2258, 2268, "CONCLUSION" +373, 18, 2, 501, 11, 12, 2269, 2270, ":" +373, 18, 3, 502, 13, 16, 2271, 2274, "The" +373, 18, 4, 503, 17, 21, 2275, 2279, "data" +373, 18, 5, 504, 22, 29, 2280, 2287, "further" +373, 18, 6, 505, 30, 37, 2288, 2295, "support" +373, 18, 7, 506, 38, 41, 2296, 2299, "the" +373, 18, 8, 507, 42, 52, 2300, 2310, "contention" +373, 18, 9, 508, 53, 57, 2311, 2315, "that" +373, 18, 10, 509, 58, 71, 2316, 2329, "bromocriptine" +373, 18, 11, 510, 72, 80, 2330, 2338, "improves" +373, 18, 12, 511, 81, 89, 2339, 2347, "glycemic" +373, 18, 13, 512, 90, 97, 2348, 2355, "control" +373, 18, 14, 513, 98, 100, 2356, 2358, "in" +373, 18, 15, 514, 101, 106, 2359, 2364, "obese" +373, 18, 16, 515, 107, 111, 2365, 2369, "type" +373, 18, 17, 516, 112, 113, 2370, 2371, "-" +373, 18, 18, 517, 114, 115, 2372, 2373, "2" +373, 18, 19, 518, 116, 124, 2374, 2382, "diabetic" +373, 18, 20, 519, 125, 133, 2383, 2391, "patients" +373, 18, 21, 520, 134, 135, 2392, 2393, "," +373, 18, 22, 521, 136, 144, 2394, 2402, "although" +373, 18, 23, 522, 145, 148, 2403, 2406, "the" +373, 18, 24, 523, 149, 158, 2407, 2416, "mechanism" +373, 18, 25, 524, 159, 161, 2417, 2419, "of" +373, 18, 26, 525, 162, 168, 2420, 2426, "action" +373, 18, 27, 526, 169, 176, 2427, 2434, "remains" +373, 18, 28, 527, 177, 179, 2435, 2437, "to" +373, 18, 29, 528, 180, 182, 2438, 2440, "be" +373, 18, 30, 529, 183, 193, 2441, 2451, "determined" +373, 18, 31, 530, 194, 195, 2452, 2453, "." +373, 19, 1, 531, 0, 3, 2454, 2457, "DOI" +373, 19, 2, 532, 4, 5, 2458, 2459, ":" +373, 19, 3, 533, 6, 8, 2460, 2462, "10" +373, 19, 4, 534, 9, 10, 2463, 2464, "." +373, 19, 5, 535, 11, 15, 2465, 2469, "1159" +373, 19, 6, 536, 16, 17, 2470, 2471, "/" +373, 19, 7, 537, 18, 27, 2472, 2481, "000078932" +373, 19, 8, 538, 28, 32, 2482, 2486, "PMID" +373, 19, 9, 539, 33, 34, 2487, 2488, ":" +373, 19, 10, 540, 35, 43, 2489, 2497, "15205563" +373, 19, 11, 541, 44, 45, 2498, 2499, "[" +373, 19, 12, 542, 46, 53, 2500, 2507, "Indexed" +373, 19, 13, 543, 54, 57, 2508, 2511, "for" +373, 19, 14, 544, 58, 65, 2512, 2519, "MEDLINE" +373, 19, 15, 545, 66, 67, 2520, 2521, "]" diff --git a/data/dm2 15205563_kwoodley.annodb b/data/dm2 15205563_kwoodley.annodb new file mode 100644 index 0000000..5fa3f7f --- /dev/null +++ b/data/dm2 15205563_kwoodley.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31476, Journal, 0, 10, "Horm Res .", "", +157, PublicationYear, 11, 15, "2004", "", +31477, Title, 57, 130, "Does bromocriptine improve glycemic control of obese type - 2 diabetics ?", "", +3658, Bromocriptine, 62, 75, "bromocriptine", "", +3661, Precondition, 104, 128, "obese type - 2 diabetics", "", +3660, Type2Diabetes, 110, 128, "type - 2 diabetics", "", +294, Author, 131, 144, "Aminorroaya A", "", +295, Author, 153, 166, "Janghorbani M", "", +296, Author, 169, 179, "Ramezani M", "", +297, Author, 182, 192, "Haghighi S", "", +298, Author, 195, 202, "Amini M", "", +165, Iran, 358, 362, "Iran", "", +3662, OralAntidiabeticAgent, 420, 444, "oral hypoglycemic agents", "", +1026, Type2Diabetes, 479, 496, "type - 2 diabetic", "", +31478, PlasmaGlucose, 525, 539, "plasma glucose", "", +1027, Bromocriptine, 628, 641, "bromocriptine", "", +31479, ObjectiveDescription, 686, 804, "In present study , the effect of bromocriptine on glycemic control was evaluated in obese type - 2 diabetic patients .", "", +1028, Bromocriptine, 719, 732, "bromocriptine", "", +166, Precondition, 770, 802, "obese type - 2 diabetic patients", "", +1029, Type2Diabetes, 776, 793, "type - 2 diabetic", "", +179, DoubleBlind, 820, 834, "double - blind", "", +31480, Placebo, 835, 842, "placebo", "", +172, NumberPatientsCT, 873, 875, "40", "", +3664, Precondition, 876, 913, "obese patients with type - 2 diabetes", "", +1031, Type2Diabetes, 896, 913, "type - 2 diabetes", "", +167, MinAge, 921, 923, "32", "", +168, MaxAge, 926, 928, "70", "", +1032, Bromocriptine, 1016, 1029, "bromocriptine", "", +185, DoseValue, 1032, 1037, "2 . 5", "", +186, mg, 1038, 1040, "mg", "", +3665, Frequency, 1041, 1046, "daily", "", +181, Duration, 1064, 1072, "3 months", "", +1033, Placebo, 1101, 1108, "placebo", "", +31481, Drug, 1156, 1169, "glibenclamide", "", +31482, Metformin, 1194, 1203, "metformin", "", +1034, FastingPlasmaGlucose, 1256, 1278, "fasting plasma glucose", "", +1035, FastingPlasmaGlucose, 1281, 1284, "FPG", "", +1036, HbA1c, 1297, 1320, "glycosylated hemoglobin", "", +1037, HbA1c, 1323, 1327, "HbA1", "", +1038, BMI, 1348, 1363, "body mass index", "", +1039, BMI, 1366, 1369, "BMI", "", +204, FastingPlasmaGlucose, 1449, 1452, "FPG", "", +1040, Bromocriptine, 1476, 1489, "bromocriptine", "", +300, BaseLineValue, 1511, 1518, "10 . 59", "", +306, SdErrorBL, 1525, 1531, "0 . 42", "", +1025, Reduction, 1535, 1541, "9 . 06", "", +305, SdErrorChangeValue, 1548, 1554, "0 . 41", "", +1041, Millimoles_per_litre, 1555, 1563, "mmol / l", "", +220, Mean, 1571, 1580, "+ / - SEM", "", +1021, PValueChangeValue, 1583, 1593, "p < 0 . 01", "", +1042, Placebo, 1613, 1620, "placebo", "", +301, BaseLineValue, 1648, 1655, "10 . 69", "", +307, SdErrorBL, 1662, 1668, "0 . 52", "", +223, NoChange, 1673, 1679, "10 . 6", "", +1023, SdErrorChangeValue, 1686, 1692, "0 . 57", "", +1043, Millimoles_per_litre, 1693, 1701, "mmol / l", "", +1044, HbA1c, 1723, 1727, "HbA1", "", +1045, Bromocriptine, 1761, 1774, "bromocriptine", "", +302, BaseLineValue, 1796, 1801, "9 . 9", "", +308, SdErrorBL, 1808, 1813, "0 . 3", "", +1046, Reduction, 1817, 1822, "9 . 5", "", +1047, SdErrorChangeValue, 1829, 1834, "0 . 2", "", +3678, Percentage, 1835, 1836, "%", "", +1050, PValueChangeValue, 1839, 1849, "p = 0 . 06", "", +1048, Placebo, 1882, 1889, "placebo", "", +303, BaseLineValue, 1911, 1917, "10 . 2", "", +309, SdErrorBL, 1924, 1929, "0 . 3", "", +278, Increment, 1933, 1939, "11 . 3", "", +1049, SdErrorChangeValue, 1946, 1951, "0 . 6", "", +3679, Percentage, 1952, 1953, "%", "", +280, PValueChangeValue, 1956, 1966, "p < 0 . 05", "", +1051, HbA1c, 1990, 1994, "HbA1", "", +281, DiffGroupRelValue, 1997, 2002, "1 . 8", "", +286, PvalueDiff, 2007, 2017, "p < 0 . 01", "", +1052, FastingPlasmaGlucose, 2024, 2027, "FPG", "", +287, DiffGroupAbsValue, 2030, 2036, "1 . 55", "", +289, Millimoles_per_litre, 2037, 2045, "mmol / l", "", +288, PvalueDiff, 2048, 2058, "p < 0 . 05", "", +1053, Bromocriptine, 2080, 2093, "bromocriptine", "", +1054, Placebo, 2098, 2105, "placebo", "", +31483, TimePoint, 2116, 2124, "3 months", "", +31484, ObservedResult, 2144, 2202, "No changes in body weight or BMI occurred during the study", "", +210, BodyWeight, 2158, 2169, "body weight", "", +1055, BMI, 2173, 2176, "BMI", "", +1056, Placebo, 2213, 2220, "placebo", "", +1057, Bromocriptine, 2226, 2239, "bromocriptine", "", +31485, ObservedResult, 2271, 2453, "The data further support the contention that bromocriptine improves glycemic control in obese type - 2 diabetic patients , although the mechanism of action remains to be determined .", "", +1058, Bromocriptine, 2316, 2329, "bromocriptine", "", +3672, Precondition, 2359, 2391, "obese type - 2 diabetic patients", "", +1059, Type2Diabetes, 2365, 2382, "type - 2 diabetic", "", +158, PMID, 2489, 2497, "15205563", "", diff --git a/data/dm2 15205563_kwoodley.n-triples b/data/dm2 15205563_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15205563_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15562200_admin.annodb b/data/dm2 15562200_admin.annodb new file mode 100644 index 0000000..e3b9055 --- /dev/null +++ b/data/dm2 15562200_admin.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +0, PublicationYear, 16, 20, "2004", "", " \"2004\"." +119, Duration, 51, 73, "Twelve - and 52 - week", "", +212, Title, 51, 185, "Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes .", "", " \"Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes .\"." +38502, Vildagliptin, 124, 130, "LAF237", "", +8, Precondition, 134, 183, "metformin - treated patients with type 2 diabetes", "", " \"metformin - treated patients with type 2 diabetes\"." +12, Metformin, 134, 143, "metformin", "", +13, Type2Diabetes, 168, 183, "type 2 diabetes", "", " ." +1, Author, 186, 195, "Ahr é n B", "", +2, Author, 204, 211, "Gomis R", "", " \"Gomis R\"." +3, Author, 214, 222, "Standl E", "", " \"Standl E\"." +4, Author, 225, 232, "Mills D", "", " \"Mills D\"." +5, Author, 235, 246, "Schweizer A", "", " \"Schweizer A\"." +7, Sweden, 346, 352, "Sweden", "", " ." +213, ObjectiveDescription, 394, 564, "To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment .", "", " \"To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment .\"." +120, Duration, 408, 426, "12 - and 52 - week", "", " \"12 - and 52 - week\"." +38402, Duration, 417, 426, "52 - week", "", +38503, Vildagliptin, 477, 483, "LAF237", "", +71, Placebo, 491, 498, "placebo", "", +72, Type2Diabetes, 516, 531, "type 2 diabetes", "", +73, Metformin, 543, 552, "metformin", "", +19, Duration, 610, 619, "12 - week", "", +20, Randomized, 622, 632, "randomized", "", " ." +21, DoubleBlind, 635, 649, "double - blind", "", " ." +22, Placebo, 652, 659, "placebo", "", +23, NumberPatientsCT, 682, 685, "107", "", " \"107\"." +24, Type2Diabetes, 700, 715, "type 2 diabetes", "", +216, Duration, 723, 732, "40 - week", "", +66, Duration, 849, 855, "1 year", "", +25, Placebo, 858, 865, "Placebo", "", " ." +88, NumberPatientsArm, 872, 874, "51", "", " \"51\"." +38501, Vildagliptin, 880, 886, "LAF237", "", " ." +28, DoseValue, 889, 891, "50", "", " \"50\"." +29, mg, 892, 894, "mg", "", " ." +30, Frequency, 895, 905, "once daily", "", " \"once daily\"." +89, NumberPatientsArm, 912, 914, "56", "", " \"56\"." +31, Metformin, 938, 947, "metformin", "", +32, DoseValue, 960, 977, "1 , 500 - 3 , 000", "", +33, mg, 978, 980, "mg", "", +38403, Interval, 983, 986, "day", "", +35, HbA1c, 991, 996, "HbA1c", "", +142, FastingPlasmaGlucose, 1001, 1023, "fasting plasma glucose", "", +143, FastingPlasmaGlucose, 1026, 1029, "FPG", "", +144, TimePoint, 1107, 1115, "baseline", "", +67, TimePoint, 1118, 1125, "week 12", "", +68, TimePoint, 1132, 1139, "week 52", "", +147, Randomized, 1164, 1174, "randomized", "", +38506, Vildagliptin, 1178, 1184, "LAF237", "", +38, HbA1c, 1196, 1201, "HbA1c", "", +39, BaseLineValue, 1211, 1216, "7 . 7", "", " \"7 . 7\"." +151, SdDevBL, 1223, 1228, "0 . 1", "", " \"0 . 1\"." +101, Percentage, 1229, 1230, "%", "", " ." +110, TimePoint, 1248, 1255, "week 12", "", " \"week 12\". \"week 12\"." +154, Reduction, 1268, 1273, "0 . 6", "", " \"0 . 6\"." +155, SdDevChangeValue, 1280, 1285, "0 . 1", "", " \"0 . 1\"." +102, Percentage, 1286, 1287, "%", "", +43, HbA1c, 1300, 1305, "HbA1c", "", +93000, ObservedResult, 1306, 1336, "did not change from a baseline", "", " \"did not change from a baseline\"." +44, BaseLineValue, 1340, 1345, "7 . 9", "", " \"7 . 9\"." +159, SdDevBL, 1352, 1357, "0 . 1", "", " \"0 . 1\"." +103, Percentage, 1358, 1359, "%", "", +46, Placebo, 1378, 1385, "placebo", "", +47, DiffGroupAbsValue, 1431, 1438, "- 0 . 7", "", " \"- 0 . 7\"." +162, SdDevDiff, 1445, 1450, "0 . 1", "", " \"0 . 1\"." +104, Percentage, 1451, 1452, "%", "", +49, PvalueDiff, 1455, 1467, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +114, Mean, 1472, 1476, "Mean", "", +219, PostprandialBloodGlucose, 1477, 1493, "prandial glucose", "", " ." +50, FastingPlasmaGlucose, 1498, 1501, "FPG", "", " ." +38507, Vildagliptin, 1551, 1557, "LAF237", "", +53, Placebo, 1565, 1572, "placebo", "", +168, Reduction, 1576, 1581, "2 . 2", "", " \"2 . 2\"." +170, SdDevChangeValue, 1588, 1593, "0 . 4", "", " \"0 . 4\"." +56, Millimoles_per_litre, 1594, 1602, "mmol / l", "", " ." +38508, PValueChangeValue, 1605, 1617, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +172, Reduction, 1624, 1629, "1 . 2", "", " \"1 . 2\"." +174, SdDevChangeValue, 1636, 1641, "0 . 4", "", " \"0 . 4\"." +60, Millimoles_per_litre, 1642, 1650, "mmol / l", "", +38509, PValueChangeValue, 1653, 1665, "P = 0 . 0057", "", " \"P = 0 . 0057\"." +93001, Insulin, 1689, 1703, "plasma insulin", "", +62, ObservedResult, 1704, 1728, "levels were not affected", "", " \"levels were not affected\"." +113, TimePoint, 1734, 1760, "end point of the extension", "", +115, Mean, 1808, 1812, "mean", "", +179, EndPointDescription, 1813, 1829, "prandial glucose", "", +93002, Insulin, 1832, 1839, "insulin", "", +65, FastingPlasmaGlucose, 1846, 1849, "FPG", "", +74, DiffGroupAbsValue, 1855, 1862, "- 2 . 4", "", +184, SdDevDiff, 1869, 1874, "0 . 6", "", +76, Millimoles_per_litre, 1875, 1883, "mmol / l", "", +77, PvalueDiff, 1886, 1898, "P = 0 . 0001", "", +78, DiffGroupAbsValue, 1903, 1905, "40", "", +192, SdDevDiff, 1912, 1914, "16", "", +80, Picomole_per_liter, 1915, 1923, "pmol / l", "", +81, PvalueDiff, 1926, 1938, "P = 0 . 0153", "", +82, DiffGroupAbsValue, 1947, 1954, "- 1 . 1", "", +185, SdDevDiff, 1961, 1966, "0 . 5", "", +84, Millimoles_per_litre, 1967, 1975, "mmol / l", "", +85, PvalueDiff, 1978, 1990, "P = 0 . 0312", "", +93003, ObservedResult, 2010, 2054, "HbA1c did not change from week 12 to week 52", "", " \"HbA1c did not change from week 12 to week 52\"." +86, HbA1c, 2010, 2015, "HbA1c", "", +93, TimePoint, 2036, 2043, "week 12", "", +92, TimePoint, 2047, 2054, "week 52", "", +38505, Vildagliptin, 2058, 2064, "LAF237", "", +93005, NumberPatientsArm, 2090, 2092, "42", "", +93004, ObservedResult, 2099, 2138, "increased in participants given placebo", "", +94, Placebo, 2131, 2138, "placebo", "", +93006, NumberPatientsArm, 2145, 2147, "29", "", +203, TimePoint, 2203, 2209, "1 year", "", +97, DiffGroupAbsValue, 2214, 2221, "- 1 . 1", "", +205, SdDevDiff, 2228, 2233, "0 . 2", "", +99, Percentage, 2234, 2235, "%", "", +100, PvalueDiff, 2238, 2250, "P < 0 . 0001", "", +218, ConclusionComment, 2269, 2425, "Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes .", "", " \"Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes .\"." +38504, Vildagliptin, 2307, 2313, "LAF237", "", +107, Metformin, 2383, 2392, "metformin", "", +108, Type2Diabetes, 2408, 2423, "type 2 diabetes", "", +6, PMID, 2476, 2484, "15562200", "", " \"15562200\"." diff --git a/data/dm2 15562200_admin.n-triples b/data/dm2 15562200_admin.n-triples new file mode 100644 index 0000000..6fca437 --- /dev/null +++ b/data/dm2 15562200_admin.n-triples @@ -0,0 +1,142 @@ +# RDF export of group: Publication + . + "Publication " . + "Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes ." . + "2004" . + "Diabetes Care" . + "15562200" . + . + "Gomis R" . + "Standl E" . + "Mills D" . + "Schweizer A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment ." . + "107" . + "12 - and 52 - week" . + . + . + . + "Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "metformin - treated patients with type 2 diabetes" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint plasma insulin" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm v" . + "56" . + . + . + . + . + . + . + . + "Arm p" . + "51" . + . + . + . +# RDF export of group: Intervention + . + "Intervention v" . + . + "once daily" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication v" . + . + "50" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome ppg v" . + . + "2 . 2" . + "P < 0 . 0001" . + "0 . 4" . + . + "Outcome fpg v" . + . + "1 . 2" . + "P = 0 . 0057" . + "0 . 4" . + . + "Outcome plasma insulin v" . + . + "levels were not affected" . + . + "Outcome hba1c v" . + . + "7 . 7" . + "0 . 1" . + "0 . 6" . + "0 . 1" . + "HbA1c did not change from week 12 to week 52" . + "week 12" . + . + "Outcome hba1c p" . + . + "7 . 9" . + "0 . 1" . + "did not change from a baseline" . + "week 12" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 7" . + "P < 0 . 0001" . + "0 . 1" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15562200_akramersunderbrink.annodb b/data/dm2 15562200_akramersunderbrink.annodb new file mode 100644 index 0000000..66269ed --- /dev/null +++ b/data/dm2 15562200_akramersunderbrink.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6310, Journal, 0, 13, "Diabetes Care", "", +6311, PublicationYear, 16, 20, "2004", "", +6312, Title, 51, 183, "Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes", "", +6327, Drug, 124, 130, "LAF237", "", +6313, Metformin, 134, 143, "metformin", "", +6314, Type2Diabetes, 168, 183, "type 2 diabetes", "", +6315, Author, 186, 195, "Ahr é n B", "", +6316, Author, 204, 211, "Gomis R", "", +6317, Author, 214, 222, "Standl E", "", +6318, Author, 225, 232, "Mills D", "", +6319, Author, 235, 246, "Schweizer A", "", +39089, Sweden, 346, 352, "Sweden", "", +6371, ObjectiveDescription, 394, 562, "To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment", "", +6372, Drug, 477, 483, "LAF237", "", +6373, Placebo, 491, 498, "placebo", "", +6374, Type2Diabetes, 516, 531, "type 2 diabetes", "", +6375, Metformin, 543, 552, "metformin", "", +6320, Duration, 610, 619, "12 - week", "", +6321, Randomized, 622, 632, "randomized", "", +6322, DoubleBlind, 635, 649, "double - blind", "", +6323, Placebo, 652, 659, "placebo", "", +6324, NumberPatientsCT, 682, 685, "107", "", +6325, Type2Diabetes, 700, 715, "type 2 diabetes", "", +39090, Duration, 723, 732, "40 - week", "", +6368, Duration, 849, 855, "1 year", "", +6326, Placebo, 858, 865, "Placebo", "", +6390, NumberPatientsArm, 872, 874, "51", "", +6328, Drug, 880, 886, "LAF237", "", +6329, DoseValue, 889, 891, "50", "", +6330, mg, 892, 894, "mg", "", +6331, Frequency, 895, 905, "once daily", "", +6391, NumberPatientsArm, 912, 914, "56", "", +6332, Metformin, 938, 947, "metformin", "", +6333, DoseValue, 960, 977, "1 , 500 - 3 , 000", "", +6334, mg, 978, 980, "mg", "", +6335, Frequency, 981, 986, "/ day", "", +6336, HbA1c, 991, 996, "HbA1c", "", +6337, FastingPlasmaGlucose, 1001, 1031, "fasting plasma glucose ( FPG )", "", +39095, TimePoint, 1107, 1115, "baseline", "", +6369, TimePoint, 1118, 1125, "week 12", "", +6370, TimePoint, 1132, 1139, "week 52", "", +6338, Drug, 1178, 1184, "LAF237", "", +39091, TimePoint, 1187, 1195, "baseline", "", +6339, HbA1c, 1196, 1201, "HbA1c", "", +6340, BaseLineValue, 1211, 1216, "7 . 7", "", +6341, SdErrorBL, 1217, 1228, "+ / - 0 . 1", "", +6404, Percentage, 1229, 1230, "%", "", +6413, TimePoint, 1248, 1255, "week 12", "", +6342, ChangeValue, 1266, 1273, "- 0 . 6", "", +6343, SdErrorChangeValue, 1274, 1285, "+ / - 0 . 1", "", +6405, Percentage, 1286, 1287, "%", "", +6344, HbA1c, 1300, 1305, "HbA1c", "", +6414, ObservedResult, 1306, 1320, "did not change", "", +6345, BaseLineValue, 1340, 1345, "7 . 9", "", +6346, SdErrorBL, 1346, 1357, "+ / - 0 . 1", "", +6406, Percentage, 1358, 1359, "%", "", +6347, Placebo, 1378, 1385, "placebo", "", +39092, HbA1c, 1418, 1428, "DeltaHbA1c", "", +6348, DiffGroupAbsValue, 1431, 1438, "- 0 . 7", "", +6349, SdErrorDiff, 1439, 1450, "+ / - 0 . 1", "", +6407, Percentage, 1451, 1452, "%", "", +6350, PvalueDiff, 1455, 1467, "P < 0 . 0001", "", +9785, Mean, 1472, 1476, "Mean", "", +6352, InsulinDose, 1477, 1493, "prandial glucose", "", +6351, FastingPlasmaGlucose, 1498, 1501, "FPG", "", +6353, Drug, 1551, 1557, "LAF237", "", +6354, Placebo, 1565, 1572, "placebo", "", +6355, DiffGroupAbsValue, 1576, 1581, "2 . 2", "", +6356, SdErrorDiff, 1582, 1593, "+ / - 0 . 4", "", +6357, Millimoles_per_litre, 1594, 1602, "mmol / l", "", +6358, PvalueDiff, 1605, 1617, "P < 0 . 0001", "", +6359, DiffGroupAbsValue, 1624, 1629, "1 . 2", "", +6360, SdErrorDiff, 1630, 1641, "+ / - 0 . 4", "", +6361, Millimoles_per_litre, 1642, 1650, "mmol / l", "", +6362, PvalueDiff, 1653, 1665, "P = 0 . 0057", "", +6415, EndPointDescription, 1689, 1710, "plasma insulin levels", "", +6364, ObservedResult, 1716, 1728, "not affected", "", +6416, TimePoint, 1734, 1760, "end point of the extension", "", +9786, Mean, 1808, 1812, "mean", "", +6365, InsulinDose, 1813, 1829, "prandial glucose", "", +6366, Insulin, 1832, 1839, "insulin", "", +6367, FastingPlasmaGlucose, 1846, 1849, "FPG", "", +6376, DiffGroupAbsValue, 1855, 1862, "- 2 . 4", "", +6377, SdErrorDiff, 1863, 1874, "+ / - 0 . 6", "", +6378, Millimoles_per_litre, 1875, 1883, "mmol / l", "", +6379, PvalueDiff, 1886, 1898, "P = 0 . 0001", "", +6380, DiffGroupAbsValue, 1903, 1905, "40", "", +6381, SdErrorDiff, 1906, 1914, "+ / - 16", "", +6382, Picomole_per_liter, 1915, 1923, "pmol / l", "", +6383, PvalueDiff, 1926, 1938, "P = 0 . 0153", "", +6384, DiffGroupAbsValue, 1947, 1954, "- 1 . 1", "", +6385, SdErrorDiff, 1955, 1966, "+ / - 0 . 5", "", +6386, Millimoles_per_litre, 1967, 1975, "mmol / l", "", +6387, PvalueDiff, 1978, 1990, "P = 0 . 0312", "", +6388, HbA1c, 2010, 2015, "HbA1c", "", +6398, ObservedResult, 2020, 2030, "not change", "", +6396, TimePoint, 2036, 2043, "week 12", "", +6395, TimePoint, 2047, 2054, "week 52", "", +6389, Drug, 2058, 2064, "LAF237", "", +6393, FinalNumPatientsArm, 2090, 2092, "42", "", +6399, ObservedResult, 2099, 2108, "increased", "", +6397, Placebo, 2131, 2138, "placebo", "", +6394, FinalNumPatientsArm, 2145, 2147, "29", "", +39093, HbA1c, 2186, 2196, "DeltaHbA1c", "", +39094, Duration, 2203, 2209, "1 year", "", +6400, DiffGroupAbsValue, 2214, 2221, "- 1 . 1", "", +6401, SdErrorDiff, 2222, 2233, "+ / - 0 . 2", "", +6402, Percentage, 2234, 2235, "%", "", +6403, PvalueDiff, 2238, 2250, "P < 0 . 0001", "", +6408, ConclusionComment, 2269, 2423, "Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes", "", +6409, Drug, 2307, 2313, "LAF237", "", +6410, Metformin, 2383, 2392, "metformin", "", +6411, Type2Diabetes, 2408, 2423, "type 2 diabetes", "", +6412, PMID, 2476, 2484, "15562200", "", diff --git a/data/dm2 15562200_akramersunderbrink.n-triples b/data/dm2 15562200_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15562200_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15562200_export.csv b/data/dm2 15562200_export.csv new file mode 100644 index 0000000..b6231a5 --- /dev/null +++ b/data/dm2 15562200_export.csv @@ -0,0 +1,594 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +372, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +372, 1, 2, 2, 9, 13, 9, 13, "Care" +372, 1, 3, 3, 14, 15, 14, 15, "." +372, 2, 1, 4, 0, 4, 16, 20, "2004" +372, 2, 2, 5, 5, 8, 21, 24, "Dec" +372, 2, 3, 6, 9, 10, 25, 26, ";" +372, 2, 4, 7, 11, 13, 27, 29, "27" +372, 2, 5, 8, 14, 15, 30, 31, "(" +372, 2, 6, 9, 16, 18, 32, 34, "12" +372, 2, 7, 10, 19, 20, 35, 36, ")" +372, 2, 8, 11, 21, 22, 37, 38, ":" +372, 2, 9, 12, 23, 27, 39, 43, "2874" +372, 2, 10, 13, 28, 29, 44, 45, "-" +372, 2, 11, 14, 30, 32, 46, 48, "80" +372, 2, 12, 15, 33, 34, 49, 50, "." +372, 3, 1, 16, 0, 6, 51, 57, "Twelve" +372, 3, 2, 17, 7, 8, 58, 59, "-" +372, 3, 3, 18, 9, 12, 60, 63, "and" +372, 3, 4, 19, 13, 15, 64, 66, "52" +372, 3, 5, 20, 16, 17, 67, 68, "-" +372, 3, 6, 21, 18, 22, 69, 73, "week" +372, 3, 7, 22, 23, 31, 74, 82, "efficacy" +372, 3, 8, 23, 32, 34, 83, 85, "of" +372, 3, 9, 24, 35, 38, 86, 89, "the" +372, 3, 10, 25, 39, 49, 90, 100, "dipeptidyl" +372, 3, 11, 26, 50, 59, 101, 110, "peptidase" +372, 3, 12, 27, 60, 62, 111, 113, "IV" +372, 3, 13, 28, 63, 72, 114, 123, "inhibitor" +372, 3, 14, 29, 73, 79, 124, 130, "LAF237" +372, 3, 15, 30, 80, 82, 131, 133, "in" +372, 3, 16, 31, 83, 92, 134, 143, "metformin" +372, 3, 17, 32, 93, 94, 144, 145, "-" +372, 3, 18, 33, 95, 102, 146, 153, "treated" +372, 3, 19, 34, 103, 111, 154, 162, "patients" +372, 3, 20, 35, 112, 116, 163, 167, "with" +372, 3, 21, 36, 117, 121, 168, 172, "type" +372, 3, 22, 37, 122, 123, 173, 174, "2" +372, 3, 23, 38, 124, 132, 175, 183, "diabetes" +372, 3, 24, 39, 133, 134, 184, 185, "." +372, 4, 1, 40, 0, 3, 186, 189, "Ahr" +372, 4, 2, 41, 4, 5, 190, 191, "é" +372, 4, 3, 42, 6, 7, 192, 193, "n" +372, 4, 4, 43, 8, 9, 194, 195, "B" +372, 4, 5, 44, 10, 11, 196, 197, "(" +372, 4, 6, 45, 12, 13, 198, 199, "1" +372, 4, 7, 46, 14, 15, 200, 201, ")" +372, 4, 8, 47, 16, 17, 202, 203, "," +372, 4, 9, 48, 18, 23, 204, 209, "Gomis" +372, 4, 10, 49, 24, 25, 210, 211, "R" +372, 4, 11, 50, 26, 27, 212, 213, "," +372, 4, 12, 51, 28, 34, 214, 220, "Standl" +372, 4, 13, 52, 35, 36, 221, 222, "E" +372, 4, 14, 53, 37, 38, 223, 224, "," +372, 4, 15, 54, 39, 44, 225, 230, "Mills" +372, 4, 16, 55, 45, 46, 231, 232, "D" +372, 4, 17, 56, 47, 48, 233, 234, "," +372, 4, 18, 57, 49, 58, 235, 244, "Schweizer" +372, 4, 19, 58, 59, 60, 245, 246, "A" +372, 4, 20, 59, 61, 62, 247, 248, "." +372, 5, 1, 60, 0, 6, 249, 255, "Author" +372, 5, 2, 61, 7, 18, 256, 267, "information" +372, 5, 3, 62, 19, 20, 268, 269, ":" +372, 5, 4, 63, 21, 22, 270, 271, "(" +372, 5, 5, 64, 23, 24, 272, 273, "1" +372, 5, 6, 65, 25, 26, 274, 275, ")" +372, 5, 7, 66, 27, 37, 276, 286, "Department" +372, 5, 8, 67, 38, 40, 287, 289, "of" +372, 5, 9, 68, 41, 49, 290, 298, "Medicine" +372, 5, 10, 69, 50, 51, 299, 300, "," +372, 5, 11, 70, 52, 56, 301, 305, "Lund" +372, 5, 12, 71, 57, 67, 306, 316, "University" +372, 5, 13, 72, 68, 71, 317, 320, "B11" +372, 5, 14, 73, 72, 75, 321, 324, "BMC" +372, 5, 15, 74, 76, 77, 325, 326, "," +372, 5, 16, 75, 78, 80, 327, 329, "SE" +372, 5, 17, 76, 81, 82, 330, 331, "-" +372, 5, 18, 77, 83, 86, 332, 335, "221" +372, 5, 19, 78, 87, 89, 336, 338, "84" +372, 5, 20, 79, 90, 94, 339, 343, "Lund" +372, 5, 21, 80, 95, 96, 344, 345, "," +372, 5, 22, 81, 97, 103, 346, 352, "Sweden" +372, 5, 23, 82, 104, 105, 353, 354, "." +372, 6, 1, 83, 0, 2, 355, 357, "bo" +372, 6, 2, 84, 3, 4, 358, 359, "." +372, 6, 3, 85, 5, 10, 360, 365, "ahren" +372, 6, 4, 86, 11, 12, 366, 367, "@" +372, 6, 5, 87, 13, 16, 368, 371, "med" +372, 6, 6, 88, 17, 18, 372, 373, "." +372, 6, 7, 89, 19, 21, 374, 376, "lu" +372, 6, 8, 90, 22, 23, 377, 378, "." +372, 6, 9, 91, 24, 26, 379, 381, "se" +372, 6, 10, 92, 27, 36, 382, 391, "OBJECTIVE" +372, 6, 11, 93, 37, 38, 392, 393, ":" +372, 6, 12, 94, 39, 41, 394, 396, "To" +372, 6, 13, 95, 42, 48, 397, 403, "assess" +372, 6, 14, 96, 49, 52, 404, 407, "the" +372, 6, 15, 97, 53, 55, 408, 410, "12" +372, 6, 16, 98, 56, 57, 411, 412, "-" +372, 6, 17, 99, 58, 61, 413, 416, "and" +372, 6, 18, 100, 62, 64, 417, 419, "52" +372, 6, 19, 101, 65, 66, 420, 421, "-" +372, 6, 20, 102, 67, 71, 422, 426, "week" +372, 6, 21, 103, 72, 80, 427, 435, "efficacy" +372, 6, 22, 104, 81, 83, 436, 438, "of" +372, 6, 23, 105, 84, 87, 439, 442, "the" +372, 6, 24, 106, 88, 98, 443, 453, "dipeptidyl" +372, 6, 25, 107, 99, 108, 454, 463, "peptidase" +372, 6, 26, 108, 109, 111, 464, 466, "IV" +372, 6, 27, 109, 112, 121, 467, 476, "inhibitor" +372, 6, 28, 110, 122, 128, 477, 483, "LAF237" +372, 6, 29, 111, 129, 135, 484, 490, "versus" +372, 6, 30, 112, 136, 143, 491, 498, "placebo" +372, 6, 31, 113, 144, 146, 499, 501, "in" +372, 6, 32, 114, 147, 155, 502, 510, "patients" +372, 6, 33, 115, 156, 160, 511, 515, "with" +372, 6, 34, 116, 161, 165, 516, 520, "type" +372, 6, 35, 117, 166, 167, 521, 522, "2" +372, 6, 36, 118, 168, 176, 523, 531, "diabetes" +372, 6, 37, 119, 177, 187, 532, 542, "continuing" +372, 6, 38, 120, 188, 197, 543, 552, "metformin" +372, 6, 39, 121, 198, 207, 553, 562, "treatment" +372, 6, 40, 122, 208, 209, 563, 564, "." +372, 7, 1, 123, 0, 8, 565, 573, "RESEARCH" +372, 7, 2, 124, 9, 15, 574, 580, "DESIGN" +372, 7, 3, 125, 16, 19, 581, 584, "AND" +372, 7, 4, 126, 20, 27, 585, 592, "METHODS" +372, 7, 5, 127, 28, 29, 593, 594, ":" +372, 7, 6, 128, 30, 32, 595, 597, "We" +372, 7, 7, 129, 33, 42, 598, 607, "conducted" +372, 7, 8, 130, 43, 44, 608, 609, "a" +372, 7, 9, 131, 45, 47, 610, 612, "12" +372, 7, 10, 132, 48, 49, 613, 614, "-" +372, 7, 11, 133, 50, 54, 615, 619, "week" +372, 7, 12, 134, 55, 56, 620, 621, "," +372, 7, 13, 135, 57, 67, 622, 632, "randomized" +372, 7, 14, 136, 68, 69, 633, 634, "," +372, 7, 15, 137, 70, 76, 635, 641, "double" +372, 7, 16, 138, 77, 78, 642, 643, "-" +372, 7, 17, 139, 79, 84, 644, 649, "blind" +372, 7, 18, 140, 85, 86, 650, 651, "," +372, 7, 19, 141, 87, 94, 652, 659, "placebo" +372, 7, 20, 142, 95, 96, 660, 661, "-" +372, 7, 21, 143, 97, 107, 662, 672, "controlled" +372, 7, 22, 144, 108, 113, 673, 678, "trial" +372, 7, 23, 145, 114, 116, 679, 681, "in" +372, 7, 24, 146, 117, 120, 682, 685, "107" +372, 7, 25, 147, 121, 129, 686, 694, "patients" +372, 7, 26, 148, 130, 134, 695, 699, "with" +372, 7, 27, 149, 135, 139, 700, 704, "type" +372, 7, 28, 150, 140, 141, 705, 706, "2" +372, 7, 29, 151, 142, 150, 707, 715, "diabetes" +372, 7, 30, 152, 151, 155, 716, 720, "with" +372, 7, 31, 153, 156, 157, 721, 722, "a" +372, 7, 32, 154, 158, 160, 723, 725, "40" +372, 7, 33, 155, 161, 162, 726, 727, "-" +372, 7, 34, 156, 163, 167, 728, 732, "week" +372, 7, 35, 157, 168, 177, 733, 742, "extension" +372, 7, 36, 158, 178, 180, 743, 745, "in" +372, 7, 37, 159, 181, 186, 746, 751, "those" +372, 7, 38, 160, 187, 197, 752, 762, "completing" +372, 7, 39, 161, 198, 201, 763, 766, "the" +372, 7, 40, 162, 202, 206, 767, 771, "core" +372, 7, 41, 163, 207, 212, 772, 777, "study" +372, 7, 42, 164, 213, 216, 778, 781, "and" +372, 7, 43, 165, 217, 225, 782, 790, "agreeing" +372, 7, 44, 166, 226, 227, 791, 792, "," +372, 7, 45, 167, 228, 236, 793, 801, "together" +372, 7, 46, 168, 237, 241, 802, 806, "with" +372, 7, 47, 169, 242, 245, 807, 810, "the" +372, 7, 48, 170, 246, 258, 811, 823, "investigator" +372, 7, 49, 171, 259, 260, 824, 825, "," +372, 7, 50, 172, 261, 263, 826, 828, "to" +372, 7, 51, 173, 264, 270, 829, 835, "extend" +372, 7, 52, 174, 271, 280, 836, 845, "treatment" +372, 7, 53, 175, 281, 283, 846, 848, "to" +372, 7, 54, 176, 284, 285, 849, 850, "1" +372, 7, 55, 177, 286, 290, 851, 855, "year" +372, 7, 56, 178, 291, 292, 856, 857, "." +372, 8, 1, 179, 0, 7, 858, 865, "Placebo" +372, 8, 2, 180, 8, 9, 866, 867, "(" +372, 8, 3, 181, 10, 11, 868, 869, "n" +372, 8, 4, 182, 12, 13, 870, 871, "=" +372, 8, 5, 183, 14, 16, 872, 874, "51" +372, 8, 6, 184, 17, 18, 875, 876, ")" +372, 8, 7, 185, 19, 21, 877, 879, "or" +372, 8, 8, 186, 22, 28, 880, 886, "LAF237" +372, 8, 9, 187, 29, 30, 887, 888, "(" +372, 8, 10, 188, 31, 33, 889, 891, "50" +372, 8, 11, 189, 34, 36, 892, 894, "mg" +372, 8, 12, 190, 37, 41, 895, 899, "once" +372, 8, 13, 191, 42, 47, 900, 905, "daily" +372, 8, 14, 192, 48, 49, 906, 907, "," +372, 8, 15, 193, 50, 51, 908, 909, "n" +372, 8, 16, 194, 52, 53, 910, 911, "=" +372, 8, 17, 195, 54, 56, 912, 914, "56" +372, 8, 18, 196, 57, 58, 915, 916, ")" +372, 8, 19, 197, 59, 62, 917, 920, "was" +372, 8, 20, 198, 63, 68, 921, 926, "added" +372, 8, 21, 199, 69, 71, 927, 929, "to" +372, 8, 22, 200, 72, 79, 930, 937, "ongoing" +372, 8, 23, 201, 80, 89, 938, 947, "metformin" +372, 8, 24, 202, 90, 99, 948, 957, "treatment" +372, 8, 25, 203, 100, 101, 958, 959, "(" +372, 8, 26, 204, 102, 103, 960, 961, "1" +372, 8, 27, 205, 104, 105, 962, 963, "," +372, 8, 28, 206, 106, 109, 964, 967, "500" +372, 8, 29, 207, 110, 111, 968, 969, "-" +372, 8, 30, 208, 112, 113, 970, 971, "3" +372, 8, 31, 209, 114, 115, 972, 973, "," +372, 8, 32, 210, 116, 119, 974, 977, "000" +372, 8, 33, 211, 120, 122, 978, 980, "mg" +372, 8, 34, 212, 123, 124, 981, 982, "/" +372, 8, 35, 213, 125, 128, 983, 986, "day" +372, 8, 36, 214, 129, 130, 987, 988, ")" +372, 8, 37, 215, 131, 132, 989, 990, "." +372, 9, 1, 216, 0, 5, 991, 996, "HbA1c" +372, 9, 2, 217, 6, 9, 997, 1000, "and" +372, 9, 3, 218, 10, 17, 1001, 1008, "fasting" +372, 9, 4, 219, 18, 24, 1009, 1015, "plasma" +372, 9, 5, 220, 25, 32, 1016, 1023, "glucose" +372, 9, 6, 221, 33, 34, 1024, 1025, "(" +372, 9, 7, 222, 35, 38, 1026, 1029, "FPG" +372, 9, 8, 223, 39, 40, 1030, 1031, ")" +372, 9, 9, 224, 41, 45, 1032, 1036, "were" +372, 9, 10, 225, 46, 54, 1037, 1045, "measured" +372, 9, 11, 226, 55, 67, 1046, 1058, "periodically" +372, 9, 12, 227, 68, 69, 1059, 1060, "," +372, 9, 13, 228, 70, 73, 1061, 1064, "and" +372, 9, 14, 229, 74, 86, 1065, 1077, "standardized" +372, 9, 15, 230, 87, 91, 1078, 1082, "meal" +372, 9, 16, 231, 92, 97, 1083, 1088, "tests" +372, 9, 17, 232, 98, 102, 1089, 1093, "were" +372, 9, 18, 233, 103, 112, 1094, 1103, "performed" +372, 9, 19, 234, 113, 115, 1104, 1106, "at" +372, 9, 20, 235, 116, 124, 1107, 1115, "baseline" +372, 9, 21, 236, 125, 126, 1116, 1117, "," +372, 9, 22, 237, 127, 131, 1118, 1122, "week" +372, 9, 23, 238, 132, 134, 1123, 1125, "12" +372, 9, 24, 239, 135, 136, 1126, 1127, "," +372, 9, 25, 240, 137, 140, 1128, 1131, "and" +372, 9, 26, 241, 141, 145, 1132, 1136, "week" +372, 9, 27, 242, 146, 148, 1137, 1139, "52" +372, 9, 28, 243, 149, 150, 1140, 1141, "." +372, 10, 1, 244, 0, 7, 1142, 1149, "RESULTS" +372, 10, 2, 245, 8, 9, 1150, 1151, ":" +372, 10, 3, 246, 10, 12, 1152, 1154, "In" +372, 10, 4, 247, 13, 21, 1155, 1163, "patients" +372, 10, 5, 248, 22, 32, 1164, 1174, "randomized" +372, 10, 6, 249, 33, 35, 1175, 1177, "to" +372, 10, 7, 250, 36, 42, 1178, 1184, "LAF237" +372, 10, 8, 251, 43, 44, 1185, 1186, "," +372, 10, 9, 252, 45, 53, 1187, 1195, "baseline" +372, 10, 10, 253, 54, 59, 1196, 1201, "HbA1c" +372, 10, 11, 254, 60, 68, 1202, 1210, "averaged" +372, 10, 12, 255, 69, 70, 1211, 1212, "7" +372, 10, 13, 256, 71, 72, 1213, 1214, "." +372, 10, 14, 257, 73, 74, 1215, 1216, "7" +372, 10, 15, 258, 75, 76, 1217, 1218, "+" +372, 10, 16, 259, 77, 78, 1219, 1220, "/" +372, 10, 17, 260, 79, 80, 1221, 1222, "-" +372, 10, 18, 261, 81, 82, 1223, 1224, "0" +372, 10, 19, 262, 83, 84, 1225, 1226, "." +372, 10, 20, 263, 85, 86, 1227, 1228, "1" +372, 10, 21, 264, 87, 88, 1229, 1230, "%" +372, 10, 22, 265, 89, 92, 1231, 1234, "and" +372, 10, 23, 266, 93, 102, 1235, 1244, "decreased" +372, 10, 24, 267, 103, 105, 1245, 1247, "at" +372, 10, 25, 268, 106, 110, 1248, 1252, "week" +372, 10, 26, 269, 111, 113, 1253, 1255, "12" +372, 10, 27, 270, 114, 115, 1256, 1257, "(" +372, 10, 28, 271, 116, 121, 1258, 1263, "Delta" +372, 10, 29, 272, 122, 123, 1264, 1265, "=" +372, 10, 30, 273, 124, 125, 1266, 1267, "-" +372, 10, 31, 274, 126, 127, 1268, 1269, "0" +372, 10, 32, 275, 128, 129, 1270, 1271, "." +372, 10, 33, 276, 130, 131, 1272, 1273, "6" +372, 10, 34, 277, 132, 133, 1274, 1275, "+" +372, 10, 35, 278, 134, 135, 1276, 1277, "/" +372, 10, 36, 279, 136, 137, 1278, 1279, "-" +372, 10, 37, 280, 138, 139, 1280, 1281, "0" +372, 10, 38, 281, 140, 141, 1282, 1283, "." +372, 10, 39, 282, 142, 143, 1284, 1285, "1" +372, 10, 40, 283, 144, 145, 1286, 1287, "%" +372, 10, 41, 284, 146, 147, 1288, 1289, ")" +372, 10, 42, 285, 148, 149, 1290, 1291, "," +372, 10, 43, 286, 150, 157, 1292, 1299, "whereas" +372, 10, 44, 287, 158, 163, 1300, 1305, "HbA1c" +372, 10, 45, 288, 164, 167, 1306, 1309, "did" +372, 10, 46, 289, 168, 171, 1310, 1313, "not" +372, 10, 47, 290, 172, 178, 1314, 1320, "change" +372, 10, 48, 291, 179, 183, 1321, 1325, "from" +372, 10, 49, 292, 184, 185, 1326, 1327, "a" +372, 10, 50, 293, 186, 194, 1328, 1336, "baseline" +372, 10, 51, 294, 195, 197, 1337, 1339, "of" +372, 10, 52, 295, 198, 199, 1340, 1341, "7" +372, 10, 53, 296, 200, 201, 1342, 1343, "." +372, 10, 54, 297, 202, 203, 1344, 1345, "9" +372, 10, 55, 298, 204, 205, 1346, 1347, "+" +372, 10, 56, 299, 206, 207, 1348, 1349, "/" +372, 10, 57, 300, 208, 209, 1350, 1351, "-" +372, 10, 58, 301, 210, 211, 1352, 1353, "0" +372, 10, 59, 302, 212, 213, 1354, 1355, "." +372, 10, 60, 303, 214, 215, 1356, 1357, "1" +372, 10, 61, 304, 216, 217, 1358, 1359, "%" +372, 10, 62, 305, 218, 220, 1360, 1362, "in" +372, 10, 63, 306, 221, 229, 1363, 1371, "patients" +372, 10, 64, 307, 230, 235, 1372, 1377, "given" +372, 10, 65, 308, 236, 243, 1378, 1385, "placebo" +372, 10, 66, 309, 244, 245, 1386, 1387, "(" +372, 10, 67, 310, 246, 253, 1388, 1395, "between" +372, 10, 68, 311, 254, 255, 1396, 1397, "-" +372, 10, 69, 312, 256, 261, 1398, 1403, "group" +372, 10, 70, 313, 262, 272, 1404, 1414, "difference" +372, 10, 71, 314, 273, 275, 1415, 1417, "in" +372, 10, 72, 315, 276, 286, 1418, 1428, "DeltaHbA1c" +372, 10, 73, 316, 287, 288, 1429, 1430, "=" +372, 10, 74, 317, 289, 290, 1431, 1432, "-" +372, 10, 75, 318, 291, 292, 1433, 1434, "0" +372, 10, 76, 319, 293, 294, 1435, 1436, "." +372, 10, 77, 320, 295, 296, 1437, 1438, "7" +372, 10, 78, 321, 297, 298, 1439, 1440, "+" +372, 10, 79, 322, 299, 300, 1441, 1442, "/" +372, 10, 80, 323, 301, 302, 1443, 1444, "-" +372, 10, 81, 324, 303, 304, 1445, 1446, "0" +372, 10, 82, 325, 305, 306, 1447, 1448, "." +372, 10, 83, 326, 307, 308, 1449, 1450, "1" +372, 10, 84, 327, 309, 310, 1451, 1452, "%" +372, 10, 85, 328, 311, 312, 1453, 1454, "," +372, 10, 86, 329, 313, 314, 1455, 1456, "P" +372, 10, 87, 330, 315, 316, 1457, 1458, "<" +372, 10, 88, 331, 317, 318, 1459, 1460, "0" +372, 10, 89, 332, 319, 320, 1461, 1462, "." +372, 10, 90, 333, 321, 325, 1463, 1467, "0001" +372, 10, 91, 334, 326, 327, 1468, 1469, ")" +372, 10, 92, 335, 328, 329, 1470, 1471, "." +372, 11, 1, 336, 0, 4, 1472, 1476, "Mean" +372, 11, 2, 337, 5, 13, 1477, 1485, "prandial" +372, 11, 3, 338, 14, 21, 1486, 1493, "glucose" +372, 11, 4, 339, 22, 25, 1494, 1497, "and" +372, 11, 5, 340, 26, 29, 1498, 1501, "FPG" +372, 11, 6, 341, 30, 34, 1502, 1506, "were" +372, 11, 7, 342, 35, 48, 1507, 1520, "significantly" +372, 11, 8, 343, 49, 56, 1521, 1528, "reduced" +372, 11, 9, 344, 57, 59, 1529, 1531, "in" +372, 11, 10, 345, 60, 68, 1532, 1540, "patients" +372, 11, 11, 346, 69, 78, 1541, 1550, "receiving" +372, 11, 12, 347, 79, 85, 1551, 1557, "LAF237" +372, 11, 13, 348, 86, 92, 1558, 1564, "versus" +372, 11, 14, 349, 93, 100, 1565, 1572, "placebo" +372, 11, 15, 350, 101, 103, 1573, 1575, "by" +372, 11, 16, 351, 104, 105, 1576, 1577, "2" +372, 11, 17, 352, 106, 107, 1578, 1579, "." +372, 11, 18, 353, 108, 109, 1580, 1581, "2" +372, 11, 19, 354, 110, 111, 1582, 1583, "+" +372, 11, 20, 355, 112, 113, 1584, 1585, "/" +372, 11, 21, 356, 114, 115, 1586, 1587, "-" +372, 11, 22, 357, 116, 117, 1588, 1589, "0" +372, 11, 23, 358, 118, 119, 1590, 1591, "." +372, 11, 24, 359, 120, 121, 1592, 1593, "4" +372, 11, 25, 360, 122, 126, 1594, 1598, "mmol" +372, 11, 26, 361, 127, 128, 1599, 1600, "/" +372, 11, 27, 362, 129, 130, 1601, 1602, "l" +372, 11, 28, 363, 131, 132, 1603, 1604, "(" +372, 11, 29, 364, 133, 134, 1605, 1606, "P" +372, 11, 30, 365, 135, 136, 1607, 1608, "<" +372, 11, 31, 366, 137, 138, 1609, 1610, "0" +372, 11, 32, 367, 139, 140, 1611, 1612, "." +372, 11, 33, 368, 141, 145, 1613, 1617, "0001" +372, 11, 34, 369, 146, 147, 1618, 1619, ")" +372, 11, 35, 370, 148, 151, 1620, 1623, "and" +372, 11, 36, 371, 152, 153, 1624, 1625, "1" +372, 11, 37, 372, 154, 155, 1626, 1627, "." +372, 11, 38, 373, 156, 157, 1628, 1629, "2" +372, 11, 39, 374, 158, 159, 1630, 1631, "+" +372, 11, 40, 375, 160, 161, 1632, 1633, "/" +372, 11, 41, 376, 162, 163, 1634, 1635, "-" +372, 11, 42, 377, 164, 165, 1636, 1637, "0" +372, 11, 43, 378, 166, 167, 1638, 1639, "." +372, 11, 44, 379, 168, 169, 1640, 1641, "4" +372, 11, 45, 380, 170, 174, 1642, 1646, "mmol" +372, 11, 46, 381, 175, 176, 1647, 1648, "/" +372, 11, 47, 382, 177, 178, 1649, 1650, "l" +372, 11, 48, 383, 179, 180, 1651, 1652, "(" +372, 11, 49, 384, 181, 182, 1653, 1654, "P" +372, 11, 50, 385, 183, 184, 1655, 1656, "=" +372, 11, 51, 386, 185, 186, 1657, 1658, "0" +372, 11, 52, 387, 187, 188, 1659, 1660, "." +372, 11, 53, 388, 189, 193, 1661, 1665, "0057" +372, 11, 54, 389, 194, 195, 1666, 1667, ")" +372, 11, 55, 390, 196, 197, 1668, 1669, "," +372, 11, 56, 391, 198, 210, 1670, 1682, "respectively" +372, 11, 57, 392, 211, 212, 1683, 1684, "," +372, 11, 58, 393, 213, 216, 1685, 1688, "but" +372, 11, 59, 394, 217, 223, 1689, 1695, "plasma" +372, 11, 60, 395, 224, 231, 1696, 1703, "insulin" +372, 11, 61, 396, 232, 238, 1704, 1710, "levels" +372, 11, 62, 397, 239, 243, 1711, 1715, "were" +372, 11, 63, 398, 244, 247, 1716, 1719, "not" +372, 11, 64, 399, 248, 256, 1720, 1728, "affected" +372, 11, 65, 400, 257, 258, 1729, 1730, "." +372, 12, 1, 401, 0, 2, 1731, 1733, "At" +372, 12, 2, 402, 3, 6, 1734, 1737, "end" +372, 12, 3, 403, 7, 12, 1738, 1743, "point" +372, 12, 4, 404, 13, 15, 1744, 1746, "of" +372, 12, 5, 405, 16, 19, 1747, 1750, "the" +372, 12, 6, 406, 20, 29, 1751, 1760, "extension" +372, 12, 7, 407, 30, 31, 1761, 1762, "," +372, 12, 8, 408, 32, 35, 1763, 1766, "the" +372, 12, 9, 409, 36, 43, 1767, 1774, "between" +372, 12, 10, 410, 44, 45, 1775, 1776, "-" +372, 12, 11, 411, 46, 51, 1777, 1782, "group" +372, 12, 12, 412, 52, 63, 1783, 1794, "differences" +372, 12, 13, 413, 64, 66, 1795, 1797, "in" +372, 12, 14, 414, 67, 73, 1798, 1804, "change" +372, 12, 15, 415, 74, 76, 1805, 1807, "in" +372, 12, 16, 416, 77, 81, 1808, 1812, "mean" +372, 12, 17, 417, 82, 90, 1813, 1821, "prandial" +372, 12, 18, 418, 91, 98, 1822, 1829, "glucose" +372, 12, 19, 419, 99, 100, 1830, 1831, "," +372, 12, 20, 420, 101, 108, 1832, 1839, "insulin" +372, 12, 21, 421, 109, 110, 1840, 1841, "," +372, 12, 22, 422, 111, 114, 1842, 1845, "and" +372, 12, 23, 423, 115, 118, 1846, 1849, "FPG" +372, 12, 24, 424, 119, 123, 1850, 1854, "were" +372, 12, 25, 425, 124, 125, 1855, 1856, "-" +372, 12, 26, 426, 126, 127, 1857, 1858, "2" +372, 12, 27, 427, 128, 129, 1859, 1860, "." +372, 12, 28, 428, 130, 131, 1861, 1862, "4" +372, 12, 29, 429, 132, 133, 1863, 1864, "+" +372, 12, 30, 430, 134, 135, 1865, 1866, "/" +372, 12, 31, 431, 136, 137, 1867, 1868, "-" +372, 12, 32, 432, 138, 139, 1869, 1870, "0" +372, 12, 33, 433, 140, 141, 1871, 1872, "." +372, 12, 34, 434, 142, 143, 1873, 1874, "6" +372, 12, 35, 435, 144, 148, 1875, 1879, "mmol" +372, 12, 36, 436, 149, 150, 1880, 1881, "/" +372, 12, 37, 437, 151, 152, 1882, 1883, "l" +372, 12, 38, 438, 153, 154, 1884, 1885, "(" +372, 12, 39, 439, 155, 156, 1886, 1887, "P" +372, 12, 40, 440, 157, 158, 1888, 1889, "=" +372, 12, 41, 441, 159, 160, 1890, 1891, "0" +372, 12, 42, 442, 161, 162, 1892, 1893, "." +372, 12, 43, 443, 163, 167, 1894, 1898, "0001" +372, 12, 44, 444, 168, 169, 1899, 1900, ")" +372, 12, 45, 445, 170, 171, 1901, 1902, "," +372, 12, 46, 446, 172, 174, 1903, 1905, "40" +372, 12, 47, 447, 175, 176, 1906, 1907, "+" +372, 12, 48, 448, 177, 178, 1908, 1909, "/" +372, 12, 49, 449, 179, 180, 1910, 1911, "-" +372, 12, 50, 450, 181, 183, 1912, 1914, "16" +372, 12, 51, 451, 184, 188, 1915, 1919, "pmol" +372, 12, 52, 452, 189, 190, 1920, 1921, "/" +372, 12, 53, 453, 191, 192, 1922, 1923, "l" +372, 12, 54, 454, 193, 194, 1924, 1925, "(" +372, 12, 55, 455, 195, 196, 1926, 1927, "P" +372, 12, 56, 456, 197, 198, 1928, 1929, "=" +372, 12, 57, 457, 199, 200, 1930, 1931, "0" +372, 12, 58, 458, 201, 202, 1932, 1933, "." +372, 12, 59, 459, 203, 207, 1934, 1938, "0153" +372, 12, 60, 460, 208, 209, 1939, 1940, ")" +372, 12, 61, 461, 210, 211, 1941, 1942, "," +372, 12, 62, 462, 212, 215, 1943, 1946, "and" +372, 12, 63, 463, 216, 217, 1947, 1948, "-" +372, 12, 64, 464, 218, 219, 1949, 1950, "1" +372, 12, 65, 465, 220, 221, 1951, 1952, "." +372, 12, 66, 466, 222, 223, 1953, 1954, "1" +372, 12, 67, 467, 224, 225, 1955, 1956, "+" +372, 12, 68, 468, 226, 227, 1957, 1958, "/" +372, 12, 69, 469, 228, 229, 1959, 1960, "-" +372, 12, 70, 470, 230, 231, 1961, 1962, "0" +372, 12, 71, 471, 232, 233, 1963, 1964, "." +372, 12, 72, 472, 234, 235, 1965, 1966, "5" +372, 12, 73, 473, 236, 240, 1967, 1971, "mmol" +372, 12, 74, 474, 241, 242, 1972, 1973, "/" +372, 12, 75, 475, 243, 244, 1974, 1975, "l" +372, 12, 76, 476, 245, 246, 1976, 1977, "(" +372, 12, 77, 477, 247, 248, 1978, 1979, "P" +372, 12, 78, 478, 249, 250, 1980, 1981, "=" +372, 12, 79, 479, 251, 252, 1982, 1983, "0" +372, 12, 80, 480, 253, 254, 1984, 1985, "." +372, 12, 81, 481, 255, 259, 1986, 1990, "0312" +372, 12, 82, 482, 260, 261, 1991, 1992, ")" +372, 12, 83, 483, 262, 263, 1993, 1994, "," +372, 12, 84, 484, 264, 276, 1995, 2007, "respectively" +372, 12, 85, 485, 277, 278, 2008, 2009, "." +372, 13, 1, 486, 0, 5, 2010, 2015, "HbA1c" +372, 13, 2, 487, 6, 9, 2016, 2019, "did" +372, 13, 3, 488, 10, 13, 2020, 2023, "not" +372, 13, 4, 489, 14, 20, 2024, 2030, "change" +372, 13, 5, 490, 21, 25, 2031, 2035, "from" +372, 13, 6, 491, 26, 30, 2036, 2040, "week" +372, 13, 7, 492, 31, 33, 2041, 2043, "12" +372, 13, 8, 493, 34, 36, 2044, 2046, "to" +372, 13, 9, 494, 37, 41, 2047, 2051, "week" +372, 13, 10, 495, 42, 44, 2052, 2054, "52" +372, 13, 11, 496, 45, 47, 2055, 2057, "in" +372, 13, 12, 497, 48, 54, 2058, 2064, "LAF237" +372, 13, 13, 498, 55, 56, 2065, 2066, "-" +372, 13, 14, 499, 57, 64, 2067, 2074, "treated" +372, 13, 15, 500, 65, 73, 2075, 2083, "patients" +372, 13, 16, 501, 74, 75, 2084, 2085, "(" +372, 13, 17, 502, 76, 77, 2086, 2087, "n" +372, 13, 18, 503, 78, 79, 2088, 2089, "=" +372, 13, 19, 504, 80, 82, 2090, 2092, "42" +372, 13, 20, 505, 83, 84, 2093, 2094, ")" +372, 13, 21, 506, 85, 88, 2095, 2098, "but" +372, 13, 22, 507, 89, 98, 2099, 2108, "increased" +372, 13, 23, 508, 99, 101, 2109, 2111, "in" +372, 13, 24, 509, 102, 114, 2112, 2124, "participants" +372, 13, 25, 510, 115, 120, 2125, 2130, "given" +372, 13, 26, 511, 121, 128, 2131, 2138, "placebo" +372, 13, 27, 512, 129, 130, 2139, 2140, "(" +372, 13, 28, 513, 131, 132, 2141, 2142, "n" +372, 13, 29, 514, 133, 134, 2143, 2144, "=" +372, 13, 30, 515, 135, 137, 2145, 2147, "29" +372, 13, 31, 516, 138, 139, 2148, 2149, ")" +372, 13, 32, 517, 140, 141, 2150, 2151, "." +372, 14, 1, 518, 0, 3, 2152, 2155, "The" +372, 14, 2, 519, 4, 11, 2156, 2163, "between" +372, 14, 3, 520, 12, 13, 2164, 2165, "-" +372, 14, 4, 521, 14, 19, 2166, 2171, "group" +372, 14, 5, 522, 20, 30, 2172, 2182, "difference" +372, 14, 6, 523, 31, 33, 2183, 2185, "in" +372, 14, 7, 524, 34, 44, 2186, 2196, "DeltaHbA1c" +372, 14, 8, 525, 45, 50, 2197, 2202, "after" +372, 14, 9, 526, 51, 52, 2203, 2204, "1" +372, 14, 10, 527, 53, 57, 2205, 2209, "year" +372, 14, 11, 528, 58, 61, 2210, 2213, "was" +372, 14, 12, 529, 62, 63, 2214, 2215, "-" +372, 14, 13, 530, 64, 65, 2216, 2217, "1" +372, 14, 14, 531, 66, 67, 2218, 2219, "." +372, 14, 15, 532, 68, 69, 2220, 2221, "1" +372, 14, 16, 533, 70, 71, 2222, 2223, "+" +372, 14, 17, 534, 72, 73, 2224, 2225, "/" +372, 14, 18, 535, 74, 75, 2226, 2227, "-" +372, 14, 19, 536, 76, 77, 2228, 2229, "0" +372, 14, 20, 537, 78, 79, 2230, 2231, "." +372, 14, 21, 538, 80, 81, 2232, 2233, "2" +372, 14, 22, 539, 82, 83, 2234, 2235, "%" +372, 14, 23, 540, 84, 85, 2236, 2237, "(" +372, 14, 24, 541, 86, 87, 2238, 2239, "P" +372, 14, 25, 542, 88, 89, 2240, 2241, "<" +372, 14, 26, 543, 90, 91, 2242, 2243, "0" +372, 14, 27, 544, 92, 93, 2244, 2245, "." +372, 14, 28, 545, 94, 98, 2246, 2250, "0001" +372, 14, 29, 546, 99, 100, 2251, 2252, ")" +372, 14, 30, 547, 101, 102, 2253, 2254, "." +372, 15, 1, 548, 0, 11, 2255, 2266, "CONCLUSIONS" +372, 15, 2, 549, 12, 13, 2267, 2268, ":" +372, 15, 3, 550, 14, 18, 2269, 2273, "Data" +372, 15, 4, 551, 19, 23, 2274, 2278, "from" +372, 15, 5, 552, 24, 28, 2279, 2283, "this" +372, 15, 6, 553, 29, 34, 2284, 2289, "study" +372, 15, 7, 554, 35, 46, 2290, 2301, "demonstrate" +372, 15, 8, 555, 47, 51, 2302, 2306, "that" +372, 15, 9, 556, 52, 58, 2307, 2313, "LAF237" +372, 15, 10, 557, 59, 70, 2314, 2325, "effectively" +372, 15, 11, 558, 71, 79, 2326, 2334, "prevents" +372, 15, 12, 559, 80, 93, 2335, 2348, "deterioration" +372, 15, 13, 560, 94, 96, 2349, 2351, "of" +372, 15, 14, 561, 97, 105, 2352, 2360, "glycemic" +372, 15, 15, 562, 106, 113, 2361, 2368, "control" +372, 15, 16, 563, 114, 118, 2369, 2373, "when" +372, 15, 17, 564, 119, 124, 2374, 2379, "added" +372, 15, 18, 565, 125, 127, 2380, 2382, "to" +372, 15, 19, 566, 128, 137, 2383, 2392, "metformin" +372, 15, 20, 567, 138, 149, 2393, 2404, "monotherapy" +372, 15, 21, 568, 150, 152, 2405, 2407, "in" +372, 15, 22, 569, 153, 157, 2408, 2412, "type" +372, 15, 23, 570, 158, 159, 2413, 2414, "2" +372, 15, 24, 571, 160, 168, 2415, 2423, "diabetes" +372, 15, 25, 572, 169, 170, 2424, 2425, "." +372, 16, 1, 573, 0, 3, 2426, 2429, "DOI" +372, 16, 2, 574, 4, 5, 2430, 2431, ":" +372, 16, 3, 575, 6, 8, 2432, 2434, "10" +372, 16, 4, 576, 9, 10, 2435, 2436, "." +372, 16, 5, 577, 11, 15, 2437, 2441, "2337" +372, 16, 6, 578, 16, 17, 2442, 2443, "/" +372, 16, 7, 579, 18, 25, 2444, 2451, "diacare" +372, 16, 8, 580, 26, 27, 2452, 2453, "." +372, 16, 9, 581, 28, 30, 2454, 2456, "27" +372, 16, 10, 582, 31, 32, 2457, 2458, "." +372, 16, 11, 583, 33, 35, 2459, 2461, "12" +372, 16, 12, 584, 36, 37, 2462, 2463, "." +372, 16, 13, 585, 38, 42, 2464, 2468, "2874" +372, 16, 14, 586, 43, 47, 2469, 2473, "PMID" +372, 16, 15, 587, 48, 49, 2474, 2475, ":" +372, 16, 16, 588, 50, 58, 2476, 2484, "15562200" +372, 16, 17, 589, 59, 60, 2485, 2486, "[" +372, 16, 18, 590, 61, 68, 2487, 2494, "Indexed" +372, 16, 19, 591, 69, 72, 2495, 2498, "for" +372, 16, 20, 592, 73, 80, 2499, 2506, "MEDLINE" +372, 16, 21, 593, 81, 82, 2507, 2508, "]" diff --git a/data/dm2 15562200_kwoodley.annodb b/data/dm2 15562200_kwoodley.annodb new file mode 100644 index 0000000..df60599 --- /dev/null +++ b/data/dm2 15562200_kwoodley.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31486, Journal, 0, 15, "Diabetes Care .", "", +1182, PublicationYear, 16, 20, "2004", "", +10175, Duration, 51, 73, "Twelve - and 52 - week", "", +31487, Title, 51, 185, "Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes .", "", +10174, Drug, 124, 130, "LAF237", "", +1191, Precondition, 134, 183, "metformin - treated patients with type 2 diabetes", "", +10172, Metformin, 134, 143, "metformin", "", +10173, Type2Diabetes, 168, 183, "type 2 diabetes", "", +1184, Author, 186, 195, "Ahr é n B", "", +1185, Author, 204, 211, "Gomis R", "", +1186, Author, 214, 222, "Standl E", "", +1187, Author, 225, 232, "Mills D", "", +1188, Author, 235, 246, "Schweizer A", "", +1190, Sweden, 346, 352, "Sweden", "", +31488, ObjectiveDescription, 394, 564, "To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment .", "", +10176, Duration, 408, 426, "12 - and 52 - week", "", +10177, Drug, 477, 483, "LAF237", "", +10178, Placebo, 491, 498, "placebo", "", +10179, Type2Diabetes, 516, 531, "type 2 diabetes", "", +10180, Metformin, 543, 552, "metformin", "", +10182, Duration, 610, 619, "12 - week", "", +10183, Randomized, 622, 632, "randomized", "", +10184, DoubleBlind, 635, 649, "double - blind", "", +31489, Placebo, 652, 659, "placebo", "", +10186, NumberPatientsCT, 682, 685, "107", "", +10187, Type2Diabetes, 700, 715, "type 2 diabetes", "", +31491, Duration, 723, 732, "40 - week", "extension", +31492, Duration, 849, 855, "1 year", "extension", +10190, Placebo, 858, 865, "Placebo", "", +10191, NumberPatientsArm, 872, 874, "51", "", +10192, Drug, 880, 886, "LAF237", "", +10193, DoseValue, 889, 891, "50", "", +10194, mg, 892, 894, "mg", "", +10195, Frequency, 895, 905, "once daily", "", +10196, NumberPatientsArm, 912, 914, "56", "", +10197, Metformin, 938, 947, "metformin", "", +10198, DoseValue, 960, 977, "1 , 500 - 3 , 000", "", +10199, mg, 978, 980, "mg", "", +10200, Frequency, 983, 986, "day", "", +10201, HbA1c, 991, 996, "HbA1c", "", +10202, FastingPlasmaGlucose, 1001, 1023, "fasting plasma glucose", "", +10203, FastingPlasmaGlucose, 1026, 1029, "FPG", "", +10204, TimePoint, 1107, 1115, "baseline", "", +10205, TimePoint, 1118, 1125, "week 12", "", +10206, TimePoint, 1132, 1139, "week 52", "", +10207, Randomized, 1164, 1174, "randomized", "", +10208, Drug, 1178, 1184, "LAF237", "", +10209, HbA1c, 1196, 1201, "HbA1c", "", +10210, BaseLineValue, 1211, 1216, "7 . 7", "", +10211, SdDevBL, 1223, 1228, "0 . 1", "", +10212, Percentage, 1229, 1230, "%", "", +10213, TimePoint, 1248, 1255, "week 12", "", +10214, Reduction, 1268, 1273, "0 . 6", "", +10215, SdDevChangeValue, 1280, 1285, "0 . 1", "", +10216, Percentage, 1286, 1287, "%", "", +10217, HbA1c, 1300, 1305, "HbA1c", "", +10218, BaseLineValue, 1340, 1345, "7 . 9", "", +10219, SdDevBL, 1352, 1357, "0 . 1", "", +10220, Percentage, 1358, 1359, "%", "", +10221, Placebo, 1378, 1385, "placebo", "", +10268, SubGroupDescription, 1418, 1428, "DeltaHbA1c", "", +10231, DiffGroupAbsValue, 1431, 1438, "- 0 . 7", "", +10223, SdDevDiff, 1445, 1450, "0 . 1", "", +10224, Percentage, 1451, 1452, "%", "", +10225, PvalueDiff, 1455, 1467, "P < 0 . 0001", "", +31683, PostprandialBloodGlucose, 1472, 1493, "Mean prandial glucose", "", +10227, FastingPlasmaGlucose, 1498, 1501, "FPG", "", +10228, Drug, 1551, 1557, "LAF237", "", +10229, Placebo, 1565, 1572, "placebo", "", +10230, Reduction, 1576, 1581, "2 . 2", "", +10233, SdDevChangeValue, 1588, 1593, "0 . 4", "", +10234, Millimoles_per_litre, 1594, 1602, "mmol / l", "", +10237, PValueChangeValue, 1605, 1617, "P < 0 . 0001", "", +10236, Reduction, 1624, 1629, "1 . 2", "", +10238, SdDevChangeValue, 1636, 1641, "0 . 4", "", +10239, Millimoles_per_litre, 1642, 1650, "mmol / l", "", +10240, PValueChangeValue, 1653, 1665, "P = 0 . 0057", "", +10241, EndPointDescription, 1689, 1710, "plasma insulin levels", "", +10242, ObservedResult, 1711, 1728, "were not affected", "", +31490, TimePoint, 1734, 1743, "end point", "extension", +10243, EndPointDescription, 1808, 1829, "mean prandial glucose", "", +10245, EndPointDescription, 1832, 1839, "insulin", "", +10246, FastingPlasmaGlucose, 1846, 1849, "FPG", "", +10248, DiffGroupAbsValue, 1855, 1862, "- 2 . 4", "", +10250, SdDevDiff, 1869, 1874, "0 . 6", "", +10252, Millimoles_per_litre, 1875, 1883, "mmol / l", "", +10254, PvalueDiff, 1886, 1898, "P = 0 . 0001", "", +10257, DiffGroupAbsValue, 1903, 1905, "40", "", +10258, SdDevDiff, 1912, 1914, "16", "", +10259, Picomole_per_liter, 1915, 1923, "pmol / l", "", +10255, PvalueDiff, 1926, 1938, "P = 0 . 0153", "", +10249, DiffGroupAbsValue, 1947, 1954, "- 1 . 1", "", +10251, SdDevDiff, 1961, 1966, "0 . 5", "", +10253, Millimoles_per_litre, 1967, 1975, "mmol / l", "", +10256, PvalueDiff, 1978, 1990, "P = 0 . 0312", "", +10260, HbA1c, 2010, 2015, "HbA1c", "", +10261, TimePoint, 2036, 2043, "week 12", "", +10262, TimePoint, 2047, 2054, "week 52", "", +10263, Drug, 2058, 2064, "LAF237", "", +10264, FinalNumPatientsArm, 2090, 2092, "42", "", +10265, Placebo, 2131, 2138, "placebo", "", +10266, FinalNumPatientsArm, 2145, 2147, "29", "", +10269, SubGroupDescription, 2186, 2196, "DeltaHbA1c", "", +10270, TimePoint, 2203, 2209, "1 year", "", +10271, DiffGroupAbsValue, 2214, 2221, "- 1 . 1", "", +10272, SdDevDiff, 2228, 2233, "0 . 2", "", +10273, Percentage, 2234, 2235, "%", "", +10274, PvalueDiff, 2238, 2250, "P < 0 . 0001", "", +31493, ConclusionComment, 2269, 2425, "Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes .", "extension", +10275, Drug, 2307, 2313, "LAF237", "", +10276, Metformin, 2383, 2392, "metformin", "", +10277, Type2Diabetes, 2408, 2423, "type 2 diabetes", "", +1189, PMID, 2476, 2484, "15562200", "", diff --git a/data/dm2 15562200_kwoodley.n-triples b/data/dm2 15562200_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15562200_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677775_admin.annodb b/data/dm2 15677775_admin.annodb new file mode 100644 index 0000000..e4492bb --- /dev/null +++ b/data/dm2 15677775_admin.annodb @@ -0,0 +1,116 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +100, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +0, PublicationYear, 16, 20, "2005", "", " \"2005\"." +199, Title, 48, 183, "Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes .", "", " \"Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes .\"." +127, Insulin, 68, 75, "insulin", "", +85, OralAntidiabeticAgent, 82, 96, "to oral agents", "", +19, Frequency, 104, 117, "twice - daily", "", +39003, PremixedInsulin, 118, 134, "premixed insulin", "", +86, Insulin, 146, 153, "insulin", "", +12, Type2Diabetes, 166, 181, "type 2 diabetes", "", +1, Author, 184, 192, "Janka HU", "", +2, Author, 201, 208, "Plewe G", "", " \"Plewe G\"." +3, Author, 211, 220, "Riddle MC", "", " \"Riddle MC\"." +4, Author, 223, 240, "Kliebe - Frisch C", "", " \"Kliebe - Frisch C\"." +5, Author, 243, 256, "Schweitzer MA", "", " \"Schweitzer MA\"." +6, Author, 259, 277, "Yki - J ä rvinen H", "", " \"Yki - J ä rvinen H\"." +8, Germany, 413, 420, "Germany", "", " ." +200, ObjectiveDescription, 608, 823, "To compare the efficacy and safety of adding once - daily basal insulin versus switching to twice - daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs ) .", "", " \"To compare the efficacy and safety of adding once - daily basal insulin versus switching to twice - daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs ) .\"." +20, Frequency, 653, 665, "once - daily", "", +131, Insulin, 672, 679, "insulin", "", +21, Frequency, 700, 713, "twice - daily", "", +39004, PremixedInsulin, 714, 730, "premixed insulin", "", +9, Precondition, 734, 821, "type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs )", "", " \"type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs )\"." +13, Type2Diabetes, 734, 749, "type 2 diabetic", "", " ." +87, OralAntidiabeticAgent, 788, 812, "oral antidiabetic agents", "", +88, OralAntidiabeticAgent, 815, 819, "OADs", "", +18, Duration, 859, 868, "24 - week", "", " \"24 - week\"." +155, CTDesign, 871, 884, "multinational", "", " . ." +15, Multicenter, 887, 898, "multicenter", "", +16, OpenLabel, 901, 905, "open", "", " ." +17, Parallel, 908, 916, "parallel", "", " ." +10, NumberPatientsCT, 940, 943, "371", "", " \"371\"." +117, Precondition, 944, 1117, "insulin - naive patients with poor glycemic control ( fasting blood glucose [ FBG ] > / = 120 mg / dl , HbA ( 1c ) 7 . 5 - 10 . 5 % ) on OADs ( sulfonylurea plus metformin )", "", " \"insulin - naive patients with poor glycemic control ( fasting blood glucose [ FBG ] > / = 120 mg / dl , HbA ( 1c ) 7 . 5 - 10 . 5 % ) on OADs ( sulfonylurea plus metformin )\"." +202, FastingBloodGlucose, 998, 1019, "fasting blood glucose", "", +203, FastingBloodGlucose, 1022, 1025, "FBG", "", +22, Mg_per_deciliter, 1038, 1045, "mg / dl", "", +23, HbA1c, 1048, 1058, "HbA ( 1c )", "", +24, Percentage, 1074, 1075, "%", "", +89, OralAntidiabeticAgent, 1081, 1085, "OADs", "", +80, Sulfonylureas, 1088, 1100, "sulfonylurea", "", +81, Metformin, 1106, 1115, "metformin", "", +25, Randomized, 1123, 1133, "randomized", "", " ." +26, Frequency, 1137, 1149, "once - daily", "", " \"once - daily\"." +27, Morning, 1150, 1157, "morning", "", " ." +28, InsulinGlargine, 1158, 1174, "insulin glargine", "", " ." +29, Glimepiride, 1180, 1191, "glimepiride", "", " ." +30, Metformin, 1196, 1205, "metformin", "", " ." +31, InsulinGlargine, 1208, 1216, "glargine", "", +90, OralAntidiabeticAgent, 1222, 1225, "OAD", "", +39005, NPH/regular70/30, 1234, 1271, "30 % regular / 70 % human NPH insulin", "", " ." +39006, NPH/regular70/30, 1274, 1281, "70 / 30", "", +33, Frequency, 1284, 1295, "twice daily", "", " \"twice daily\"." +91, OralAntidiabeticAgent, 1304, 1308, "OADs", "", +51227, DoseDescription, 1330, 1451, "titrated to target FBG < / = 100 mg / dl ( both insulins ) and predinner blood glucose < / = 100 mg / dl ( 70 / 30 only )", "", " \"titrated to target FBG < / = 100 mg / dl ( both insulins ) and predinner blood glucose < / = 100 mg / dl ( 70 / 30 only )\". \"titrated to target FBG < / = 100 mg / dl ( both insulins ) and predinner blood glucose < / = 100 mg / dl ( 70 / 30 only )\"." +134, FastingPlasmaGlucose_target, 1349, 1370, "FBG < / = 100 mg / dl", "", +34, Mg_per_deciliter, 1363, 1370, "mg / dl", "", +83, Insulin, 1378, 1386, "insulins", "", +51226, RelativeTime, 1393, 1402, "predinner", "", +135, FastingPlasmaGlucose_target, 1393, 1434, "predinner blood glucose < / = 100 mg / dl", "", +36, Mg_per_deciliter, 1427, 1434, "mg / dl", "", +39007, NPH/regular70/30, 1437, 1444, "70 / 30", "", +35, MeasurementDevice, 1460, 1495, "weekly forced - titration algorithm", "", +195, Mean, 1508, 1512, "Mean", "", " . ." +37, HbA1c, 1513, 1523, "HbA ( 1c )", "", +38, Reduction, 1585, 1591, "1 . 64", "", " \"1 . 64\"." +39, Reduction, 1599, 1605, "1 . 31", "", " \"1 . 31\"." +40, Percentage, 1606, 1607, "%", "", " ." +41, PvalueDiff, 1610, 1622, "P = 0 . 0003", "", " \"P = 0 . 0003\"." +42, HbA1c_target, 1653, 1677, "HbA ( 1c ) < / = 7 . 0 %", "", " ." +43, Percentage, 1676, 1677, "%", "", +44, NocturnalHypoglycemia, 1696, 1718, "nocturnal hypoglycemia", "", " ." +60, PercentageAffected, 1721, 1727, "45 . 5", "", +61, PercentageAffected, 1733, 1739, "28 . 6", "", " \"28 . 6\"." +45, PvalueDiff, 1744, 1756, "P = 0 . 0013", "", " \"P = 0 . 0013\"." +46, InsulinGlargine, 1764, 1772, "glargine", "", +94, OralAntidiabeticAgent, 1778, 1781, "OAD", "", +39008, NPH/regular70/30, 1792, 1799, "70 / 30", "", +205, FastingBloodGlucose, 1814, 1817, "FBG", "", " ." +48, InsulinGlargine, 1844, 1852, "glargine", "", +95, OralAntidiabeticAgent, 1858, 1861, "OAD", "", +196, Mean, 1873, 1877, "mean", "", " . ." +162, DiffGroupAbsValue, 1889, 1893, "- 17", "", " \"- 17\"." +50, Mg_per_deciliter, 1894, 1901, "mg / dl", "", " ." +164, DiffGroupAbsValue, 1904, 1911, "- 0 . 9", "", +53, Millimoles_per_litre, 1912, 1920, "mmol / l", "", +166, PvalueDiff, 1925, 1937, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +209, FastingBloodGlucose_target, 1968, 1996, "target FBG < / = 100 mg / dl", "", " ." +54, Mg_per_deciliter, 1989, 1996, "mg / dl", "", +55, InsulinGlargine, 2002, 2010, "glargine", "", +96, OralAntidiabeticAgent, 2016, 2019, "OAD", "", +39009, NPH/regular70/30, 2030, 2037, "70 / 30", "", +57, PercentageAffected, 2040, 2046, "31 . 6", "", " \"31 . 6\"." +58, PercentageAffected, 2052, 2058, "15 . 0", "", " \"15 . 0\"." +59, PvalueDiff, 2063, 2075, "P = 0 . 0001", "", " \"P = 0 . 0001\". \"P = 0 . 0001\"." +62, InsulinGlargine, 2080, 2088, "Glargine", "", +97, OralAntidiabeticAgent, 2094, 2097, "OAD", "", +63, Hypoglycemia, 2127, 2148, "hypoglycemic episodes", "", " ." +39010, NPH/regular70/30, 2154, 2161, "70 / 30", "", +197, Mean, 2173, 2177, "mean", "", " . ." +65, NumberAffected, 2178, 2184, "4 . 07", "", " \"4 . 07\"." +66, NumberAffected, 2190, 2196, "9 . 87", "", " \"9 . 87\"." +177, BioAndMedicalUnit, 2197, 2213, "/ patient - year", "", " . ." +67, PvalueDiff, 2216, 2228, "P < 0 . 0001", "", +190, ConclusionComment, 2247, 2490, "Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice - daily injections of 70 / 30 and discontinuing OADs in type 2 diabetic patients", "", " \"Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice - daily injections of 70 / 30 and discontinuing OADs in type 2 diabetic patients\"." +68, Insulin, 2258, 2265, "insulin", "", +69, InsulinGlargine, 2292, 2308, "insulin glargine", "", +70, Frequency, 2309, 2319, "once daily", "", +71, Glimepiride, 2323, 2334, "glimepiride", "", +72, Metformin, 2340, 2349, "metformin", "", +73, Frequency, 2404, 2417, "twice - daily", "", +39011, NPH/regular70/30, 2432, 2439, "70 / 30", "", +98, OralAntidiabeticAgent, 2458, 2462, "OADs", "", +14, Type2Diabetes, 2466, 2481, "type 2 diabetic", "", +191, ConclusionComment, 2491, 2526, "inadequately controlled with OADs .", "", " \"inadequately controlled with OADs .\"." +99, OralAntidiabeticAgent, 2520, 2524, "OADs", "", +7, PMID, 2575, 2583, "15677775", "", " \"15677775\"." diff --git a/data/dm2 15677775_admin.n-triples b/data/dm2 15677775_admin.n-triples new file mode 100644 index 0000000..867a0c9 --- /dev/null +++ b/data/dm2 15677775_admin.n-triples @@ -0,0 +1,207 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes ." . + "2005" . + "Diabetes Care" . + "15677775" . + . + "Plewe G" . + "Riddle MC" . + "Kliebe - Frisch C" . + "Schweitzer MA" . + "Yki - J ä rvinen H" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy and safety of adding once - daily basal insulin versus switching to twice - daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs ) ." . + "371" . + "24 - week" . + . + . + . + . + "Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice - daily injections of 70 / 30 and discontinuing OADs in type 2 diabetic patients" . + . + . + . + . + . + . + . + . + . + "inadequately controlled with OADs ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive patients with poor glycemic control ( fasting blood glucose [ FBG ] > / = 120 mg / dl , HbA ( 1c ) 7 . 5 - 10 . 5 % ) on OADs ( sulfonylurea plus metformin )" . + . + . + . + "type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs )" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + "Endpoint fbg" . + . + . + . + . + . + . + "Endpoint fbg target" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig + g + m " . + . + . + . + . + . + . + . + "Arm nph" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig + g + m " . + . + "once - daily" . + . + . + . + . + "Intervention nph " . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication ig" . + . + . + . + "titrated to target FBG < / = 100 mg / dl ( both insulins ) and predinner blood glucose < / = 100 mg / dl ( 70 / 30 only )" . + . + "Medication nph" . + . + . + . + "titrated to target FBG < / = 100 mg / dl ( both insulins ) and predinner blood glucose < / = 100 mg / dl ( 70 / 30 only )" . + . + "Medication g" . + . + . + . + . + "Medication m" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c ig" . + . + "1 . 64" . + . + "Outcome hba1c nph" . + . + "1 . 31" . + . + "Outcome hba1c target ig " . + . + . + "Outcome hba1c target nph" . + . + "28 . 6" . + . + "Outcome fbg ig" . + . + . + "Outcome fbg nph" . + . + . + "Outcome fbg target ig" . + . + "31 . 6" . + . + "Outcome fbg target nph" . + . + "15 . 0" . + . + "Outcome h ig" . + . + "4 . 07" . + . + "Outcome h nph" . + . + "9 . 87" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "P = 0 . 0003" . + . + . + . + "DiffBetweenGroups hba1c target" . + "P = 0 . 0013" . + . + . + . + "DiffBetweenGroups fbg" . + "- 17" . + "P < 0 . 0001" . + . + . + . + "DiffBetweenGroups fbg target" . + "P = 0 . 0001" . + . + . + . + "DiffBetweenGroups h" . + "P = 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677775_akramersunderbrink.annodb b/data/dm2 15677775_akramersunderbrink.annodb new file mode 100644 index 0000000..04c8ba5 --- /dev/null +++ b/data/dm2 15677775_akramersunderbrink.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6417, Journal, 0, 13, "Diabetes Care", "", +6418, PublicationYear, 16, 20, "2005", "", +6419, Title, 48, 181, "Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes", "", +6444, Insulin, 62, 75, "basal insulin", "", +6445, Frequency, 104, 117, "twice - daily", "", +6446, Insulin, 127, 134, "insulin", "", +6465, Insulin, 146, 153, "insulin", "", +6420, Type2Diabetes, 166, 181, "type 2 diabetes", "", +6421, Author, 184, 192, "Janka HU", "", +6422, Author, 201, 208, "Plewe G", "", +6423, Author, 211, 220, "Riddle MC", "", +6424, Author, 223, 240, "Kliebe - Frisch C", "", +6425, Author, 243, 256, "Schweitzer MA", "", +6426, Author, 259, 277, "Yki - J ä rvinen H", "", +39096, Germany, 413, 420, "Germany", "", +6427, ObjectiveDescription, 608, 821, "To compare the efficacy and safety of adding once - daily basal insulin versus switching to twice - daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs )", "", +6447, Frequency, 653, 665, "once - daily", "", +6448, Insulin, 666, 679, "basal insulin", "", +6449, Frequency, 700, 713, "twice - daily", "", +6464, Insulin, 714, 730, "premixed insulin", "", +6428, Type2Diabetes, 734, 749, "type 2 diabetic", "", +6450, Precondition, 759, 821, "insufficiently controlled by oral antidiabetic agents ( OADs )", "", +6466, Drug, 788, 821, "oral antidiabetic agents ( OADs )", "", +6429, Duration, 859, 868, "24 - week", "", +6472, CTDesign, 871, 884, "multinational", "", +6430, Multicenter, 887, 898, "multicenter", "", +6431, OpenLabel, 901, 905, "open", "", +6432, Parallel, 908, 916, "parallel", "", +6433, NumberPatientsCT, 940, 943, "371", "", +6434, Precondition, 944, 1117, "insulin - naive patients with poor glycemic control ( fasting blood glucose [ FBG ] > / = 120 mg / dl , HbA ( 1c ) 7 . 5 - 10 . 5 % ) on OADs ( sulfonylurea plus metformin )", "", +6467, Drug, 1081, 1085, "OADs", "", +6468, Sulfonylureas, 1088, 1100, "sulfonylurea", "", +6469, Metformin, 1106, 1115, "metformin", "", +6435, Randomized, 1123, 1133, "randomized", "", +6436, Frequency, 1137, 1149, "once - daily", "", +6438, Morning, 1150, 1157, "morning", "", +6437, InsulinGlargine, 1158, 1174, "insulin glargine", "", +6439, Glimepiride, 1180, 1191, "glimepiride", "", +6440, Metformin, 1196, 1205, "metformin", "", +6441, InsulinGlargine, 1208, 1216, "glargine", "", +6470, Drug, 1222, 1225, "OAD", "", +39097, NPH/regular70/30, 1234, 1271, "30 % regular / 70 % human NPH insulin", "", +39098, NPH/regular70/30, 1274, 1281, "70 / 30", "", +6443, Frequency, 1284, 1295, "twice daily", "", +6471, Drug, 1304, 1308, "OADs", "", +6451, FastingPlasmaGlucose_target, 1349, 1370, "FBG < / = 100 mg / dl", "", +6473, Mg_per_deciliter, 1363, 1370, "mg / dl", "", +6452, FastingPlasmaGlucose_target, 1393, 1434, "predinner blood glucose < / = 100 mg / dl", "", +6474, Mg_per_deciliter, 1427, 1434, "mg / dl", "", +39099, NPH/regular70/30, 1437, 1444, "70 / 30", "", +9782, Mean, 1508, 1512, "Mean", "", +6453, HbA1c, 1513, 1523, "HbA ( 1c )", "", +6454, ChangeValue, 1583, 1591, "- 1 . 64", "", +6455, ChangeValue, 1597, 1605, "- 1 . 31", "", +6456, Percentage, 1606, 1607, "%", "", +6457, PvalueDiff, 1610, 1622, "P = 0 . 0003", "", +6458, EndPointDescription, 1653, 1718, "HbA ( 1c ) < / = 7 . 0 % without confirmed nocturnal hypoglycemia", "", +6459, PercentageAffected, 1721, 1727, "45 . 5", "", +6460, PercentageAffected, 1733, 1739, "28 . 6", "", +6461, Percentage, 1740, 1741, "%", "", +6462, PvalueDiff, 1744, 1756, "P = 0 . 0013", "", +6463, InsulinGlargine, 1764, 1772, "glargine", "", +6475, Drug, 1778, 1781, "OAD", "", +39100, NPH/regular70/30, 1792, 1799, "70 / 30", "", +6476, FastingPlasmaGlucose, 1814, 1817, "FBG", "", +6477, InsulinGlargine, 1844, 1852, "glargine", "", +6478, Drug, 1858, 1861, "OAD", "", +9783, Mean, 1873, 1877, "mean", "", +6480, DiffGroupAbsValue, 1889, 1893, "- 17", "", +6481, Mg_per_deciliter, 1894, 1901, "mg / dl", "", +6482, DiffGroupAbsValue, 1904, 1911, "- 0 . 9", "", +6483, Millimoles_per_litre, 1912, 1920, "mmol / l", "", +6484, PvalueDiff, 1925, 1937, "P < 0 . 0001", "", +6512, EndPointDescription, 1960, 1996, "reached target FBG < / = 100 mg / dl", "", +6485, Mg_per_deciliter, 1989, 1996, "mg / dl", "", +6486, InsulinGlargine, 2002, 2010, "glargine", "", +6487, Drug, 2016, 2019, "OAD", "", +39101, NPH/regular70/30, 2030, 2037, "70 / 30", "", +6488, PercentageAffected, 2040, 2046, "31 . 6", "", +6489, PercentageAffected, 2052, 2058, "15 . 0", "", +6490, Percentage, 2059, 2060, "%", "", +6491, PvalueDiff, 2063, 2075, "P = 0 . 0001", "", +6492, InsulinGlargine, 2080, 2088, "Glargine", "", +6493, Drug, 2094, 2097, "OAD", "", +6494, EndPointDescription, 2117, 2148, "confirmed hypoglycemic episodes", "", +39102, NPH/regular70/30, 2154, 2161, "70 / 30", "", +9784, Mean, 2173, 2177, "mean", "", +6513, ResultMeasuredValue, 2178, 2184, "4 . 07", "", +6514, ResultMeasuredValue, 2190, 2196, "9 . 87", "", +6497, BioAndMedicalUnit, 2197, 2213, "/ patient - year", "", +6498, PvalueDiff, 2216, 2228, "P < 0 . 0001", "", +6510, ConclusionComment, 2247, 2490, "Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice - daily injections of 70 / 30 and discontinuing OADs in type 2 diabetic patients", "", +6499, Insulin, 2258, 2265, "insulin", "", +6500, InsulinGlargine, 2286, 2308, "basal insulin glargine", "", +6501, Frequency, 2309, 2319, "once daily", "", +6502, Glimepiride, 2323, 2334, "glimepiride", "", +6503, Metformin, 2340, 2349, "metformin", "", +6504, Frequency, 2404, 2417, "twice - daily", "", +39103, NPH/regular70/30, 2432, 2439, "70 / 30", "", +6505, Drug, 2458, 2462, "OADs", "", +6506, Type2Diabetes, 2466, 2481, "type 2 diabetic", "", +6507, Precondition, 2491, 2524, "inadequately controlled with OADs", "", +6511, ConclusionComment, 2491, 2524, "inadequately controlled with OADs", "", +6508, Drug, 2520, 2524, "OADs", "", +6509, PMID, 2575, 2583, "15677775", "", diff --git a/data/dm2 15677775_akramersunderbrink.n-triples b/data/dm2 15677775_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15677775_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677775_export.csv b/data/dm2 15677775_export.csv new file mode 100644 index 0000000..feab4bd --- /dev/null +++ b/data/dm2 15677775_export.csv @@ -0,0 +1,583 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +371, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +371, 1, 2, 2, 9, 13, 9, 13, "Care" +371, 1, 3, 3, 14, 15, 14, 15, "." +371, 2, 1, 4, 0, 4, 16, 20, "2005" +371, 2, 2, 5, 5, 8, 21, 24, "Feb" +371, 2, 3, 6, 9, 10, 25, 26, ";" +371, 2, 4, 7, 11, 13, 27, 29, "28" +371, 2, 5, 8, 14, 15, 30, 31, "(" +371, 2, 6, 9, 16, 17, 32, 33, "2" +371, 2, 7, 10, 18, 19, 34, 35, ")" +371, 2, 8, 11, 20, 21, 36, 37, ":" +371, 2, 9, 12, 22, 25, 38, 41, "254" +371, 2, 10, 13, 26, 27, 42, 43, "-" +371, 2, 11, 14, 28, 29, 44, 45, "9" +371, 2, 12, 15, 30, 31, 46, 47, "." +371, 3, 1, 16, 0, 10, 48, 58, "Comparison" +371, 3, 2, 17, 11, 13, 59, 61, "of" +371, 3, 3, 18, 14, 19, 62, 67, "basal" +371, 3, 4, 19, 20, 27, 68, 75, "insulin" +371, 3, 5, 20, 28, 33, 76, 81, "added" +371, 3, 6, 21, 34, 36, 82, 84, "to" +371, 3, 7, 22, 37, 41, 85, 89, "oral" +371, 3, 8, 23, 42, 48, 90, 96, "agents" +371, 3, 9, 24, 49, 55, 97, 103, "versus" +371, 3, 10, 25, 56, 61, 104, 109, "twice" +371, 3, 11, 26, 62, 63, 110, 111, "-" +371, 3, 12, 27, 64, 69, 112, 117, "daily" +371, 3, 13, 28, 70, 78, 118, 126, "premixed" +371, 3, 14, 29, 79, 86, 127, 134, "insulin" +371, 3, 15, 30, 87, 89, 135, 137, "as" +371, 3, 16, 31, 90, 97, 138, 145, "initial" +371, 3, 17, 32, 98, 105, 146, 153, "insulin" +371, 3, 18, 33, 106, 113, 154, 161, "therapy" +371, 3, 19, 34, 114, 117, 162, 165, "for" +371, 3, 20, 35, 118, 122, 166, 170, "type" +371, 3, 21, 36, 123, 124, 171, 172, "2" +371, 3, 22, 37, 125, 133, 173, 181, "diabetes" +371, 3, 23, 38, 134, 135, 182, 183, "." +371, 4, 1, 39, 0, 5, 184, 189, "Janka" +371, 4, 2, 40, 6, 8, 190, 192, "HU" +371, 4, 3, 41, 9, 10, 193, 194, "(" +371, 4, 4, 42, 11, 12, 195, 196, "1" +371, 4, 5, 43, 13, 14, 197, 198, ")" +371, 4, 6, 44, 15, 16, 199, 200, "," +371, 4, 7, 45, 17, 22, 201, 206, "Plewe" +371, 4, 8, 46, 23, 24, 207, 208, "G" +371, 4, 9, 47, 25, 26, 209, 210, "," +371, 4, 10, 48, 27, 33, 211, 217, "Riddle" +371, 4, 11, 49, 34, 36, 218, 220, "MC" +371, 4, 12, 50, 37, 38, 221, 222, "," +371, 4, 13, 51, 39, 45, 223, 229, "Kliebe" +371, 4, 14, 52, 46, 47, 230, 231, "-" +371, 4, 15, 53, 48, 54, 232, 238, "Frisch" +371, 4, 16, 54, 55, 56, 239, 240, "C" +371, 4, 17, 55, 57, 58, 241, 242, "," +371, 4, 18, 56, 59, 69, 243, 253, "Schweitzer" +371, 4, 19, 57, 70, 72, 254, 256, "MA" +371, 4, 20, 58, 73, 74, 257, 258, "," +371, 4, 21, 59, 75, 78, 259, 262, "Yki" +371, 4, 22, 60, 79, 80, 263, 264, "-" +371, 4, 23, 61, 81, 82, 265, 266, "J" +371, 4, 24, 62, 83, 84, 267, 268, "ä" +371, 4, 25, 63, 85, 91, 269, 275, "rvinen" +371, 4, 26, 64, 92, 93, 276, 277, "H" +371, 4, 27, 65, 94, 95, 278, 279, "." +371, 4, 28, 66, 96, 102, 280, 286, "Author" +371, 4, 29, 67, 103, 114, 287, 298, "information" +371, 4, 30, 68, 115, 116, 299, 300, ":" +371, 4, 31, 69, 117, 118, 301, 302, "(" +371, 4, 32, 70, 119, 120, 303, 304, "1" +371, 4, 33, 71, 121, 122, 305, 306, ")" +371, 4, 34, 72, 123, 141, 307, 325, "Zentralkrankenhaus" +371, 4, 35, 73, 142, 143, 326, 327, "," +371, 4, 36, 74, 144, 150, 328, 334, "Bremen" +371, 4, 37, 75, 151, 152, 335, 336, "-" +371, 4, 38, 76, 153, 157, 337, 341, "Nord" +371, 4, 39, 77, 158, 159, 342, 343, "," +371, 4, 40, 78, 160, 162, 344, 346, "II" +371, 4, 41, 79, 163, 175, 347, 359, "Medizinische" +371, 4, 42, 80, 176, 185, 360, 369, "Abteilung" +371, 4, 43, 81, 186, 187, 370, 371, "," +371, 4, 44, 82, 188, 201, 372, 385, "Hammersbecker" +371, 4, 45, 83, 202, 205, 386, 389, "Str" +371, 4, 46, 84, 206, 207, 390, 391, "." +371, 5, 1, 85, 0, 3, 392, 395, "228" +371, 5, 2, 86, 4, 5, 396, 397, "," +371, 5, 3, 87, 6, 11, 398, 403, "28755" +371, 5, 4, 88, 12, 18, 404, 410, "Bremen" +371, 5, 5, 89, 19, 20, 411, 412, "," +371, 5, 6, 90, 21, 28, 413, 420, "Germany" +371, 5, 7, 91, 29, 30, 421, 422, "." +371, 6, 1, 92, 0, 4, 423, 427, "hans" +371, 6, 2, 93, 5, 6, 428, 429, "." +371, 6, 3, 94, 7, 12, 430, 435, "janka" +371, 6, 4, 95, 13, 14, 436, 437, "@" +371, 6, 5, 96, 15, 23, 438, 446, "klinikum" +371, 6, 6, 97, 24, 25, 447, 448, "-" +371, 6, 7, 98, 26, 32, 449, 455, "bremen" +371, 6, 8, 99, 33, 34, 456, 457, "-" +371, 6, 9, 100, 35, 39, 458, 462, "nord" +371, 6, 10, 101, 40, 41, 463, 464, "." +371, 6, 11, 102, 42, 44, 465, 467, "de" +371, 6, 12, 103, 45, 52, 468, 475, "Comment" +371, 6, 13, 104, 53, 55, 476, 478, "in" +371, 6, 14, 105, 56, 64, 479, 487, "Diabetes" +371, 6, 15, 106, 65, 69, 488, 492, "Care" +371, 6, 16, 107, 70, 71, 493, 494, "." +371, 7, 1, 108, 0, 4, 495, 499, "2005" +371, 7, 2, 109, 5, 8, 500, 503, "Feb" +371, 7, 3, 110, 9, 10, 504, 505, ";" +371, 7, 4, 111, 11, 13, 506, 508, "28" +371, 7, 5, 112, 14, 15, 509, 510, "(" +371, 7, 6, 113, 16, 17, 511, 512, "2" +371, 7, 7, 114, 18, 19, 513, 514, ")" +371, 7, 8, 115, 20, 21, 515, 516, ":" +371, 7, 9, 116, 22, 25, 517, 520, "494" +371, 7, 10, 117, 26, 27, 521, 522, "-" +371, 7, 11, 118, 28, 29, 523, 524, "5" +371, 7, 12, 119, 30, 31, 525, 526, "." +371, 8, 1, 120, 0, 8, 527, 535, "Diabetes" +371, 8, 2, 121, 9, 13, 536, 540, "Care" +371, 8, 3, 122, 14, 15, 541, 542, "." +371, 9, 1, 123, 0, 4, 543, 547, "2005" +371, 9, 2, 124, 5, 8, 548, 551, "Jun" +371, 9, 3, 125, 9, 10, 552, 553, ";" +371, 9, 4, 126, 11, 13, 554, 556, "28" +371, 9, 5, 127, 14, 15, 557, 558, "(" +371, 9, 6, 128, 16, 17, 559, 560, "6" +371, 9, 7, 129, 18, 19, 561, 562, ")" +371, 9, 8, 130, 20, 21, 563, 564, ":" +371, 9, 9, 131, 22, 26, 565, 569, "1537" +371, 9, 10, 132, 27, 28, 570, 571, "-" +371, 9, 11, 133, 29, 30, 572, 573, "8" +371, 9, 12, 134, 31, 32, 574, 575, ";" +371, 9, 13, 135, 33, 39, 576, 582, "author" +371, 9, 14, 136, 40, 45, 583, 588, "reply" +371, 9, 15, 137, 46, 50, 589, 593, "1538" +371, 9, 16, 138, 51, 52, 594, 595, "." +371, 10, 1, 139, 0, 9, 596, 605, "OBJECTIVE" +371, 10, 2, 140, 10, 11, 606, 607, ":" +371, 10, 3, 141, 12, 14, 608, 610, "To" +371, 10, 4, 142, 15, 22, 611, 618, "compare" +371, 10, 5, 143, 23, 26, 619, 622, "the" +371, 10, 6, 144, 27, 35, 623, 631, "efficacy" +371, 10, 7, 145, 36, 39, 632, 635, "and" +371, 10, 8, 146, 40, 46, 636, 642, "safety" +371, 10, 9, 147, 47, 49, 643, 645, "of" +371, 10, 10, 148, 50, 56, 646, 652, "adding" +371, 10, 11, 149, 57, 61, 653, 657, "once" +371, 10, 12, 150, 62, 63, 658, 659, "-" +371, 10, 13, 151, 64, 69, 660, 665, "daily" +371, 10, 14, 152, 70, 75, 666, 671, "basal" +371, 10, 15, 153, 76, 83, 672, 679, "insulin" +371, 10, 16, 154, 84, 90, 680, 686, "versus" +371, 10, 17, 155, 91, 100, 687, 696, "switching" +371, 10, 18, 156, 101, 103, 697, 699, "to" +371, 10, 19, 157, 104, 109, 700, 705, "twice" +371, 10, 20, 158, 110, 111, 706, 707, "-" +371, 10, 21, 159, 112, 117, 708, 713, "daily" +371, 10, 22, 160, 118, 126, 714, 722, "premixed" +371, 10, 23, 161, 127, 134, 723, 730, "insulin" +371, 10, 24, 162, 135, 137, 731, 733, "in" +371, 10, 25, 163, 138, 142, 734, 738, "type" +371, 10, 26, 164, 143, 144, 739, 740, "2" +371, 10, 27, 165, 145, 153, 741, 749, "diabetic" +371, 10, 28, 166, 154, 162, 750, 758, "patients" +371, 10, 29, 167, 163, 177, 759, 773, "insufficiently" +371, 10, 30, 168, 178, 188, 774, 784, "controlled" +371, 10, 31, 169, 189, 191, 785, 787, "by" +371, 10, 32, 170, 192, 196, 788, 792, "oral" +371, 10, 33, 171, 197, 209, 793, 805, "antidiabetic" +371, 10, 34, 172, 210, 216, 806, 812, "agents" +371, 10, 35, 173, 217, 218, 813, 814, "(" +371, 10, 36, 174, 219, 223, 815, 819, "OADs" +371, 10, 37, 175, 224, 225, 820, 821, ")" +371, 10, 38, 176, 226, 227, 822, 823, "." +371, 11, 1, 177, 0, 8, 824, 832, "RESEARCH" +371, 11, 2, 178, 9, 15, 833, 839, "DESIGN" +371, 11, 3, 179, 16, 19, 840, 843, "AND" +371, 11, 4, 180, 20, 27, 844, 851, "METHODS" +371, 11, 5, 181, 28, 29, 852, 853, ":" +371, 11, 6, 182, 30, 32, 854, 856, "In" +371, 11, 7, 183, 33, 34, 857, 858, "a" +371, 11, 8, 184, 35, 37, 859, 861, "24" +371, 11, 9, 185, 38, 39, 862, 863, "-" +371, 11, 10, 186, 40, 44, 864, 868, "week" +371, 11, 11, 187, 45, 46, 869, 870, "," +371, 11, 12, 188, 47, 60, 871, 884, "multinational" +371, 11, 13, 189, 61, 62, 885, 886, "," +371, 11, 14, 190, 63, 74, 887, 898, "multicenter" +371, 11, 15, 191, 75, 76, 899, 900, "," +371, 11, 16, 192, 77, 81, 901, 905, "open" +371, 11, 17, 193, 82, 83, 906, 907, "," +371, 11, 18, 194, 84, 92, 908, 916, "parallel" +371, 11, 19, 195, 93, 98, 917, 922, "group" +371, 11, 20, 196, 99, 107, 923, 931, "clinical" +371, 11, 21, 197, 108, 113, 932, 937, "trial" +371, 11, 22, 198, 114, 115, 938, 939, "," +371, 11, 23, 199, 116, 119, 940, 943, "371" +371, 11, 24, 200, 120, 127, 944, 951, "insulin" +371, 11, 25, 201, 128, 129, 952, 953, "-" +371, 11, 26, 202, 130, 135, 954, 959, "naive" +371, 11, 27, 203, 136, 144, 960, 968, "patients" +371, 11, 28, 204, 145, 149, 969, 973, "with" +371, 11, 29, 205, 150, 154, 974, 978, "poor" +371, 11, 30, 206, 155, 163, 979, 987, "glycemic" +371, 11, 31, 207, 164, 171, 988, 995, "control" +371, 11, 32, 208, 172, 173, 996, 997, "(" +371, 11, 33, 209, 174, 181, 998, 1005, "fasting" +371, 11, 34, 210, 182, 187, 1006, 1011, "blood" +371, 11, 35, 211, 188, 195, 1012, 1019, "glucose" +371, 11, 36, 212, 196, 197, 1020, 1021, "[" +371, 11, 37, 213, 198, 201, 1022, 1025, "FBG" +371, 11, 38, 214, 202, 203, 1026, 1027, "]" +371, 11, 39, 215, 204, 205, 1028, 1029, ">" +371, 11, 40, 216, 206, 207, 1030, 1031, "/" +371, 11, 41, 217, 208, 209, 1032, 1033, "=" +371, 11, 42, 218, 210, 213, 1034, 1037, "120" +371, 11, 43, 219, 214, 216, 1038, 1040, "mg" +371, 11, 44, 220, 217, 218, 1041, 1042, "/" +371, 11, 45, 221, 219, 221, 1043, 1045, "dl" +371, 11, 46, 222, 222, 223, 1046, 1047, "," +371, 11, 47, 223, 224, 227, 1048, 1051, "HbA" +371, 11, 48, 224, 228, 229, 1052, 1053, "(" +371, 11, 49, 225, 230, 232, 1054, 1056, "1c" +371, 11, 50, 226, 233, 234, 1057, 1058, ")" +371, 11, 51, 227, 235, 236, 1059, 1060, "7" +371, 11, 52, 228, 237, 238, 1061, 1062, "." +371, 11, 53, 229, 239, 240, 1063, 1064, "5" +371, 11, 54, 230, 241, 242, 1065, 1066, "-" +371, 11, 55, 231, 243, 245, 1067, 1069, "10" +371, 11, 56, 232, 246, 247, 1070, 1071, "." +371, 11, 57, 233, 248, 249, 1072, 1073, "5" +371, 11, 58, 234, 250, 251, 1074, 1075, "%" +371, 11, 59, 235, 252, 253, 1076, 1077, ")" +371, 11, 60, 236, 254, 256, 1078, 1080, "on" +371, 11, 61, 237, 257, 261, 1081, 1085, "OADs" +371, 11, 62, 238, 262, 263, 1086, 1087, "(" +371, 11, 63, 239, 264, 276, 1088, 1100, "sulfonylurea" +371, 11, 64, 240, 277, 281, 1101, 1105, "plus" +371, 11, 65, 241, 282, 291, 1106, 1115, "metformin" +371, 11, 66, 242, 292, 293, 1116, 1117, ")" +371, 11, 67, 243, 294, 298, 1118, 1122, "were" +371, 11, 68, 244, 299, 309, 1123, 1133, "randomized" +371, 11, 69, 245, 310, 312, 1134, 1136, "to" +371, 11, 70, 246, 313, 317, 1137, 1141, "once" +371, 11, 71, 247, 318, 319, 1142, 1143, "-" +371, 11, 72, 248, 320, 325, 1144, 1149, "daily" +371, 11, 73, 249, 326, 333, 1150, 1157, "morning" +371, 11, 74, 250, 334, 341, 1158, 1165, "insulin" +371, 11, 75, 251, 342, 350, 1166, 1174, "glargine" +371, 11, 76, 252, 351, 355, 1175, 1179, "plus" +371, 11, 77, 253, 356, 367, 1180, 1191, "glimepiride" +371, 11, 78, 254, 368, 371, 1192, 1195, "and" +371, 11, 79, 255, 372, 381, 1196, 1205, "metformin" +371, 11, 80, 256, 382, 383, 1206, 1207, "(" +371, 11, 81, 257, 384, 392, 1208, 1216, "glargine" +371, 11, 82, 258, 393, 397, 1217, 1221, "plus" +371, 11, 83, 259, 398, 401, 1222, 1225, "OAD" +371, 11, 84, 260, 402, 403, 1226, 1227, ")" +371, 11, 85, 261, 404, 406, 1228, 1230, "or" +371, 11, 86, 262, 407, 409, 1231, 1233, "to" +371, 11, 87, 263, 410, 412, 1234, 1236, "30" +371, 11, 88, 264, 413, 414, 1237, 1238, "%" +371, 11, 89, 265, 415, 422, 1239, 1246, "regular" +371, 11, 90, 266, 423, 424, 1247, 1248, "/" +371, 11, 91, 267, 425, 427, 1249, 1251, "70" +371, 11, 92, 268, 428, 429, 1252, 1253, "%" +371, 11, 93, 269, 430, 435, 1254, 1259, "human" +371, 11, 94, 270, 436, 439, 1260, 1263, "NPH" +371, 11, 95, 271, 440, 447, 1264, 1271, "insulin" +371, 11, 96, 272, 448, 449, 1272, 1273, "(" +371, 11, 97, 273, 450, 452, 1274, 1276, "70" +371, 11, 98, 274, 453, 454, 1277, 1278, "/" +371, 11, 99, 275, 455, 457, 1279, 1281, "30" +371, 11, 100, 276, 458, 459, 1282, 1283, ")" +371, 11, 101, 277, 460, 465, 1284, 1289, "twice" +371, 11, 102, 278, 466, 471, 1290, 1295, "daily" +371, 11, 103, 279, 472, 479, 1296, 1303, "without" +371, 11, 104, 280, 480, 484, 1304, 1308, "OADs" +371, 11, 105, 281, 485, 486, 1309, 1310, "." +371, 12, 1, 282, 0, 7, 1311, 1318, "Insulin" +371, 12, 2, 283, 8, 14, 1319, 1325, "dosage" +371, 12, 3, 284, 15, 18, 1326, 1329, "was" +371, 12, 4, 285, 19, 27, 1330, 1338, "titrated" +371, 12, 5, 286, 28, 30, 1339, 1341, "to" +371, 12, 6, 287, 31, 37, 1342, 1348, "target" +371, 12, 7, 288, 38, 41, 1349, 1352, "FBG" +371, 12, 8, 289, 42, 43, 1353, 1354, "<" +371, 12, 9, 290, 44, 45, 1355, 1356, "/" +371, 12, 10, 291, 46, 47, 1357, 1358, "=" +371, 12, 11, 292, 48, 51, 1359, 1362, "100" +371, 12, 12, 293, 52, 54, 1363, 1365, "mg" +371, 12, 13, 294, 55, 56, 1366, 1367, "/" +371, 12, 14, 295, 57, 59, 1368, 1370, "dl" +371, 12, 15, 296, 60, 61, 1371, 1372, "(" +371, 12, 16, 297, 62, 66, 1373, 1377, "both" +371, 12, 17, 298, 67, 75, 1378, 1386, "insulins" +371, 12, 18, 299, 76, 77, 1387, 1388, ")" +371, 12, 19, 300, 78, 81, 1389, 1392, "and" +371, 12, 20, 301, 82, 91, 1393, 1402, "predinner" +371, 12, 21, 302, 92, 97, 1403, 1408, "blood" +371, 12, 22, 303, 98, 105, 1409, 1416, "glucose" +371, 12, 23, 304, 106, 107, 1417, 1418, "<" +371, 12, 24, 305, 108, 109, 1419, 1420, "/" +371, 12, 25, 306, 110, 111, 1421, 1422, "=" +371, 12, 26, 307, 112, 115, 1423, 1426, "100" +371, 12, 27, 308, 116, 118, 1427, 1429, "mg" +371, 12, 28, 309, 119, 120, 1430, 1431, "/" +371, 12, 29, 310, 121, 123, 1432, 1434, "dl" +371, 12, 30, 311, 124, 125, 1435, 1436, "(" +371, 12, 31, 312, 126, 128, 1437, 1439, "70" +371, 12, 32, 313, 129, 130, 1440, 1441, "/" +371, 12, 33, 314, 131, 133, 1442, 1444, "30" +371, 12, 34, 315, 134, 138, 1445, 1449, "only" +371, 12, 35, 316, 139, 140, 1450, 1451, ")" +371, 12, 36, 317, 141, 146, 1452, 1457, "using" +371, 12, 37, 318, 147, 148, 1458, 1459, "a" +371, 12, 38, 319, 149, 155, 1460, 1466, "weekly" +371, 12, 39, 320, 156, 162, 1467, 1473, "forced" +371, 12, 40, 321, 163, 164, 1474, 1475, "-" +371, 12, 41, 322, 165, 174, 1476, 1485, "titration" +371, 12, 42, 323, 175, 184, 1486, 1495, "algorithm" +371, 12, 43, 324, 185, 186, 1496, 1497, "." +371, 13, 1, 325, 0, 7, 1498, 1505, "RESULTS" +371, 13, 2, 326, 8, 9, 1506, 1507, ":" +371, 13, 3, 327, 10, 14, 1508, 1512, "Mean" +371, 13, 4, 328, 15, 18, 1513, 1516, "HbA" +371, 13, 5, 329, 19, 20, 1517, 1518, "(" +371, 13, 6, 330, 21, 23, 1519, 1521, "1c" +371, 13, 7, 331, 24, 25, 1522, 1523, ")" +371, 13, 8, 332, 26, 34, 1524, 1532, "decrease" +371, 13, 9, 333, 35, 39, 1533, 1537, "from" +371, 13, 10, 334, 40, 48, 1538, 1546, "baseline" +371, 13, 11, 335, 49, 52, 1547, 1550, "was" +371, 13, 12, 336, 53, 66, 1551, 1564, "significantly" +371, 13, 13, 337, 67, 71, 1565, 1569, "more" +371, 13, 14, 338, 72, 82, 1570, 1580, "pronounced" +371, 13, 15, 339, 83, 84, 1581, 1582, "(" +371, 13, 16, 340, 85, 86, 1583, 1584, "-" +371, 13, 17, 341, 87, 88, 1585, 1586, "1" +371, 13, 18, 342, 89, 90, 1587, 1588, "." +371, 13, 19, 343, 91, 93, 1589, 1591, "64" +371, 13, 20, 344, 94, 96, 1592, 1594, "vs" +371, 13, 21, 345, 97, 98, 1595, 1596, "." +371, 13, 22, 346, 99, 100, 1597, 1598, "-" +371, 13, 23, 347, 101, 102, 1599, 1600, "1" +371, 13, 24, 348, 103, 104, 1601, 1602, "." +371, 13, 25, 349, 105, 107, 1603, 1605, "31" +371, 13, 26, 350, 108, 109, 1606, 1607, "%" +371, 13, 27, 351, 110, 111, 1608, 1609, "," +371, 13, 28, 352, 112, 113, 1610, 1611, "P" +371, 13, 29, 353, 114, 115, 1612, 1613, "=" +371, 13, 30, 354, 116, 117, 1614, 1615, "0" +371, 13, 31, 355, 118, 119, 1616, 1617, "." +371, 13, 32, 356, 120, 124, 1618, 1622, "0003" +371, 13, 33, 357, 125, 126, 1623, 1624, ")" +371, 13, 34, 358, 127, 128, 1625, 1626, "," +371, 13, 35, 359, 129, 132, 1627, 1630, "and" +371, 13, 36, 360, 133, 137, 1631, 1635, "more" +371, 13, 37, 361, 138, 146, 1636, 1644, "patients" +371, 13, 38, 362, 147, 154, 1645, 1652, "reached" +371, 13, 39, 363, 155, 158, 1653, 1656, "HbA" +371, 13, 40, 364, 159, 160, 1657, 1658, "(" +371, 13, 41, 365, 161, 163, 1659, 1661, "1c" +371, 13, 42, 366, 164, 165, 1662, 1663, ")" +371, 13, 43, 367, 166, 167, 1664, 1665, "<" +371, 13, 44, 368, 168, 169, 1666, 1667, "/" +371, 13, 45, 369, 170, 171, 1668, 1669, "=" +371, 13, 46, 370, 172, 173, 1670, 1671, "7" +371, 13, 47, 371, 174, 175, 1672, 1673, "." +371, 13, 48, 372, 176, 177, 1674, 1675, "0" +371, 13, 49, 373, 178, 179, 1676, 1677, "%" +371, 13, 50, 374, 180, 187, 1678, 1685, "without" +371, 13, 51, 375, 188, 197, 1686, 1695, "confirmed" +371, 13, 52, 376, 198, 207, 1696, 1705, "nocturnal" +371, 13, 53, 377, 208, 220, 1706, 1718, "hypoglycemia" +371, 13, 54, 378, 221, 222, 1719, 1720, "(" +371, 13, 55, 379, 223, 225, 1721, 1723, "45" +371, 13, 56, 380, 226, 227, 1724, 1725, "." +371, 13, 57, 381, 228, 229, 1726, 1727, "5" +371, 13, 58, 382, 230, 232, 1728, 1730, "vs" +371, 13, 59, 383, 233, 234, 1731, 1732, "." +371, 13, 60, 384, 235, 237, 1733, 1735, "28" +371, 13, 61, 385, 238, 239, 1736, 1737, "." +371, 13, 62, 386, 240, 241, 1738, 1739, "6" +371, 13, 63, 387, 242, 243, 1740, 1741, "%" +371, 13, 64, 388, 244, 245, 1742, 1743, "," +371, 13, 65, 389, 246, 247, 1744, 1745, "P" +371, 13, 66, 390, 248, 249, 1746, 1747, "=" +371, 13, 67, 391, 250, 251, 1748, 1749, "0" +371, 13, 68, 392, 252, 253, 1750, 1751, "." +371, 13, 69, 393, 254, 258, 1752, 1756, "0013" +371, 13, 70, 394, 259, 260, 1757, 1758, ")" +371, 13, 71, 395, 261, 265, 1759, 1763, "with" +371, 13, 72, 396, 266, 274, 1764, 1772, "glargine" +371, 13, 73, 397, 275, 279, 1773, 1777, "plus" +371, 13, 74, 398, 280, 283, 1778, 1781, "OAD" +371, 13, 75, 399, 284, 288, 1782, 1786, "than" +371, 13, 76, 400, 289, 293, 1787, 1791, "with" +371, 13, 77, 401, 294, 296, 1792, 1794, "70" +371, 13, 78, 402, 297, 298, 1795, 1796, "/" +371, 13, 79, 403, 299, 301, 1797, 1799, "30" +371, 13, 80, 404, 302, 303, 1800, 1801, "." +371, 14, 1, 405, 0, 9, 1802, 1811, "Similarly" +371, 14, 2, 406, 10, 11, 1812, 1813, "," +371, 14, 3, 407, 12, 15, 1814, 1817, "FBG" +371, 14, 4, 408, 16, 24, 1818, 1826, "decrease" +371, 14, 5, 409, 25, 28, 1827, 1830, "was" +371, 14, 6, 410, 29, 36, 1831, 1838, "greater" +371, 14, 7, 411, 37, 41, 1839, 1843, "with" +371, 14, 8, 412, 42, 50, 1844, 1852, "glargine" +371, 14, 9, 413, 51, 55, 1853, 1857, "plus" +371, 14, 10, 414, 56, 59, 1858, 1861, "OAD" +371, 14, 11, 415, 60, 61, 1862, 1863, "(" +371, 14, 12, 416, 62, 70, 1864, 1872, "adjusted" +371, 14, 13, 417, 71, 75, 1873, 1877, "mean" +371, 14, 14, 418, 76, 86, 1878, 1888, "difference" +371, 14, 15, 419, 87, 88, 1889, 1890, "-" +371, 14, 16, 420, 89, 91, 1891, 1893, "17" +371, 14, 17, 421, 92, 94, 1894, 1896, "mg" +371, 14, 18, 422, 95, 96, 1897, 1898, "/" +371, 14, 19, 423, 97, 99, 1899, 1901, "dl" +371, 14, 20, 424, 100, 101, 1902, 1903, "[" +371, 14, 21, 425, 102, 103, 1904, 1905, "-" +371, 14, 22, 426, 104, 105, 1906, 1907, "0" +371, 14, 23, 427, 106, 107, 1908, 1909, "." +371, 14, 24, 428, 108, 109, 1910, 1911, "9" +371, 14, 25, 429, 110, 114, 1912, 1916, "mmol" +371, 14, 26, 430, 115, 116, 1917, 1918, "/" +371, 14, 27, 431, 117, 118, 1919, 1920, "l" +371, 14, 28, 432, 119, 120, 1921, 1922, "]" +371, 14, 29, 433, 121, 122, 1923, 1924, "," +371, 14, 30, 434, 123, 124, 1925, 1926, "P" +371, 14, 31, 435, 125, 126, 1927, 1928, "<" +371, 14, 32, 436, 127, 128, 1929, 1930, "0" +371, 14, 33, 437, 129, 130, 1931, 1932, "." +371, 14, 34, 438, 131, 135, 1933, 1937, "0001" +371, 14, 35, 439, 136, 137, 1938, 1939, ")" +371, 14, 36, 440, 138, 139, 1940, 1941, "," +371, 14, 37, 441, 140, 143, 1942, 1945, "and" +371, 14, 38, 442, 144, 148, 1946, 1950, "more" +371, 14, 39, 443, 149, 157, 1951, 1959, "patients" +371, 14, 40, 444, 158, 165, 1960, 1967, "reached" +371, 14, 41, 445, 166, 172, 1968, 1974, "target" +371, 14, 42, 446, 173, 176, 1975, 1978, "FBG" +371, 14, 43, 447, 177, 178, 1979, 1980, "<" +371, 14, 44, 448, 179, 180, 1981, 1982, "/" +371, 14, 45, 449, 181, 182, 1983, 1984, "=" +371, 14, 46, 450, 183, 186, 1985, 1988, "100" +371, 14, 47, 451, 187, 189, 1989, 1991, "mg" +371, 14, 48, 452, 190, 191, 1992, 1993, "/" +371, 14, 49, 453, 192, 194, 1994, 1996, "dl" +371, 14, 50, 454, 195, 199, 1997, 2001, "with" +371, 14, 51, 455, 200, 208, 2002, 2010, "glargine" +371, 14, 52, 456, 209, 213, 2011, 2015, "plus" +371, 14, 53, 457, 214, 217, 2016, 2019, "OAD" +371, 14, 54, 458, 218, 222, 2020, 2024, "than" +371, 14, 55, 459, 223, 227, 2025, 2029, "with" +371, 14, 56, 460, 228, 230, 2030, 2032, "70" +371, 14, 57, 461, 231, 232, 2033, 2034, "/" +371, 14, 58, 462, 233, 235, 2035, 2037, "30" +371, 14, 59, 463, 236, 237, 2038, 2039, "(" +371, 14, 60, 464, 238, 240, 2040, 2042, "31" +371, 14, 61, 465, 241, 242, 2043, 2044, "." +371, 14, 62, 466, 243, 244, 2045, 2046, "6" +371, 14, 63, 467, 245, 247, 2047, 2049, "vs" +371, 14, 64, 468, 248, 249, 2050, 2051, "." +371, 14, 65, 469, 250, 252, 2052, 2054, "15" +371, 14, 66, 470, 253, 254, 2055, 2056, "." +371, 14, 67, 471, 255, 256, 2057, 2058, "0" +371, 14, 68, 472, 257, 258, 2059, 2060, "%" +371, 14, 69, 473, 259, 260, 2061, 2062, "," +371, 14, 70, 474, 261, 262, 2063, 2064, "P" +371, 14, 71, 475, 263, 264, 2065, 2066, "=" +371, 14, 72, 476, 265, 266, 2067, 2068, "0" +371, 14, 73, 477, 267, 268, 2069, 2070, "." +371, 14, 74, 478, 269, 273, 2071, 2075, "0001" +371, 14, 75, 479, 274, 275, 2076, 2077, ")" +371, 14, 76, 480, 276, 277, 2078, 2079, "." +371, 15, 1, 481, 0, 8, 2080, 2088, "Glargine" +371, 15, 2, 482, 9, 13, 2089, 2093, "plus" +371, 15, 3, 483, 14, 17, 2094, 2097, "OAD" +371, 15, 4, 484, 18, 26, 2098, 2106, "patients" +371, 15, 5, 485, 27, 30, 2107, 2110, "had" +371, 15, 6, 486, 31, 36, 2111, 2116, "fewer" +371, 15, 7, 487, 37, 46, 2117, 2126, "confirmed" +371, 15, 8, 488, 47, 59, 2127, 2139, "hypoglycemic" +371, 15, 9, 489, 60, 68, 2140, 2148, "episodes" +371, 15, 10, 490, 69, 73, 2149, 2153, "than" +371, 15, 11, 491, 74, 76, 2154, 2156, "70" +371, 15, 12, 492, 77, 78, 2157, 2158, "/" +371, 15, 13, 493, 79, 81, 2159, 2161, "30" +371, 15, 14, 494, 82, 90, 2162, 2170, "patients" +371, 15, 15, 495, 91, 92, 2171, 2172, "(" +371, 15, 16, 496, 93, 97, 2173, 2177, "mean" +371, 15, 17, 497, 98, 99, 2178, 2179, "4" +371, 15, 18, 498, 100, 101, 2180, 2181, "." +371, 15, 19, 499, 102, 104, 2182, 2184, "07" +371, 15, 20, 500, 105, 107, 2185, 2187, "vs" +371, 15, 21, 501, 108, 109, 2188, 2189, "." +371, 15, 22, 502, 110, 111, 2190, 2191, "9" +371, 15, 23, 503, 112, 113, 2192, 2193, "." +371, 15, 24, 504, 114, 116, 2194, 2196, "87" +371, 15, 25, 505, 117, 118, 2197, 2198, "/" +371, 15, 26, 506, 119, 126, 2199, 2206, "patient" +371, 15, 27, 507, 127, 128, 2207, 2208, "-" +371, 15, 28, 508, 129, 133, 2209, 2213, "year" +371, 15, 29, 509, 134, 135, 2214, 2215, "," +371, 15, 30, 510, 136, 137, 2216, 2217, "P" +371, 15, 31, 511, 138, 139, 2218, 2219, "<" +371, 15, 32, 512, 140, 141, 2220, 2221, "0" +371, 15, 33, 513, 142, 143, 2222, 2223, "." +371, 15, 34, 514, 144, 148, 2224, 2228, "0001" +371, 15, 35, 515, 149, 150, 2229, 2230, ")" +371, 15, 36, 516, 151, 152, 2231, 2232, "." +371, 16, 1, 517, 0, 11, 2233, 2244, "CONCLUSIONS" +371, 16, 2, 518, 12, 13, 2245, 2246, ":" +371, 16, 3, 519, 14, 24, 2247, 2257, "Initiating" +371, 16, 4, 520, 25, 32, 2258, 2265, "insulin" +371, 16, 5, 521, 33, 42, 2266, 2275, "treatment" +371, 16, 6, 522, 43, 45, 2276, 2278, "by" +371, 16, 7, 523, 46, 52, 2279, 2285, "adding" +371, 16, 8, 524, 53, 58, 2286, 2291, "basal" +371, 16, 9, 525, 59, 66, 2292, 2299, "insulin" +371, 16, 10, 526, 67, 75, 2300, 2308, "glargine" +371, 16, 11, 527, 76, 80, 2309, 2313, "once" +371, 16, 12, 528, 81, 86, 2314, 2319, "daily" +371, 16, 13, 529, 87, 89, 2320, 2322, "to" +371, 16, 14, 530, 90, 101, 2323, 2334, "glimepiride" +371, 16, 15, 531, 102, 106, 2335, 2339, "plus" +371, 16, 16, 532, 107, 116, 2340, 2349, "metformin" +371, 16, 17, 533, 117, 126, 2350, 2359, "treatment" +371, 16, 18, 534, 127, 130, 2360, 2363, "was" +371, 16, 19, 535, 131, 136, 2364, 2369, "safer" +371, 16, 20, 536, 137, 140, 2370, 2373, "and" +371, 16, 21, 537, 141, 145, 2374, 2378, "more" +371, 16, 22, 538, 146, 155, 2379, 2388, "effective" +371, 16, 23, 539, 156, 160, 2389, 2393, "than" +371, 16, 24, 540, 161, 170, 2394, 2403, "beginning" +371, 16, 25, 541, 171, 176, 2404, 2409, "twice" +371, 16, 26, 542, 177, 178, 2410, 2411, "-" +371, 16, 27, 543, 179, 184, 2412, 2417, "daily" +371, 16, 28, 544, 185, 195, 2418, 2428, "injections" +371, 16, 29, 545, 196, 198, 2429, 2431, "of" +371, 16, 30, 546, 199, 201, 2432, 2434, "70" +371, 16, 31, 547, 202, 203, 2435, 2436, "/" +371, 16, 32, 548, 204, 206, 2437, 2439, "30" +371, 16, 33, 549, 207, 210, 2440, 2443, "and" +371, 16, 34, 550, 211, 224, 2444, 2457, "discontinuing" +371, 16, 35, 551, 225, 229, 2458, 2462, "OADs" +371, 16, 36, 552, 230, 232, 2463, 2465, "in" +371, 16, 37, 553, 233, 237, 2466, 2470, "type" +371, 16, 38, 554, 238, 239, 2471, 2472, "2" +371, 16, 39, 555, 240, 248, 2473, 2481, "diabetic" +371, 16, 40, 556, 249, 257, 2482, 2490, "patients" +371, 16, 41, 557, 258, 270, 2491, 2503, "inadequately" +371, 16, 42, 558, 271, 281, 2504, 2514, "controlled" +371, 16, 43, 559, 282, 286, 2515, 2519, "with" +371, 16, 44, 560, 287, 291, 2520, 2524, "OADs" +371, 16, 45, 561, 292, 293, 2525, 2526, "." +371, 17, 1, 562, 0, 3, 2527, 2530, "DOI" +371, 17, 2, 563, 4, 5, 2531, 2532, ":" +371, 17, 3, 564, 6, 8, 2533, 2535, "10" +371, 17, 4, 565, 9, 10, 2536, 2537, "." +371, 17, 5, 566, 11, 15, 2538, 2542, "2337" +371, 17, 6, 567, 16, 17, 2543, 2544, "/" +371, 17, 7, 568, 18, 25, 2545, 2552, "diacare" +371, 17, 8, 569, 26, 27, 2553, 2554, "." +371, 17, 9, 570, 28, 30, 2555, 2557, "28" +371, 17, 10, 571, 31, 32, 2558, 2559, "." +371, 17, 11, 572, 33, 34, 2560, 2561, "2" +371, 17, 12, 573, 35, 36, 2562, 2563, "." +371, 17, 13, 574, 37, 40, 2564, 2567, "254" +371, 17, 14, 575, 41, 45, 2568, 2572, "PMID" +371, 17, 15, 576, 46, 47, 2573, 2574, ":" +371, 17, 16, 577, 48, 56, 2575, 2583, "15677775" +371, 17, 17, 578, 57, 58, 2584, 2585, "[" +371, 17, 18, 579, 59, 66, 2586, 2593, "Indexed" +371, 17, 19, 580, 67, 70, 2594, 2597, "for" +371, 17, 20, 581, 71, 78, 2598, 2605, "MEDLINE" +371, 17, 21, 582, 79, 80, 2606, 2607, "]" diff --git a/data/dm2 15677775_kwoodley.annodb b/data/dm2 15677775_kwoodley.annodb new file mode 100644 index 0000000..1f8c3de --- /dev/null +++ b/data/dm2 15677775_kwoodley.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31494, Journal, 0, 15, "Diabetes Care .", "", +1193, PublicationYear, 16, 20, "2005", "", +31495, Title, 48, 183, "Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes .", "", +2277, InsulinGlargine, 62, 75, "basal insulin", "basal", +3697, OralAntidiabeticAgent, 82, 96, "to oral agents", "", +2193, Frequency, 104, 117, "twice - daily", "", +2278, IsophaneInsulin_NPH, 118, 134, "premixed insulin", "premixed", +3698, Insulin, 146, 153, "insulin", "", +1209, Type2Diabetes, 166, 181, "type 2 diabetes", "", +1195, Author, 184, 192, "Janka HU", "", +1196, Author, 201, 208, "Plewe G", "", +1197, Author, 211, 220, "Riddle MC", "", +1198, Author, 223, 240, "Kliebe - Frisch C", "", +1199, Author, 243, 256, "Schweitzer MA", "", +1200, Author, 259, 277, "Yki - J ä rvinen H", "", +1202, Germany, 413, 420, "Germany", "", +31496, ObjectiveDescription, 608, 823, "To compare the efficacy and safety of adding once - daily basal insulin versus switching to twice - daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs ) .", "", +2197, Frequency, 653, 665, "once - daily", "basal", +2279, InsulinGlargine, 666, 679, "basal insulin", "basal", +2198, Frequency, 700, 713, "twice - daily", "basal", +2280, IsophaneInsulin_NPH, 714, 730, "premixed insulin", "premixed", +1203, Precondition, 734, 821, "type 2 diabetic patients insufficiently controlled by oral antidiabetic agents ( OADs )", "", +1210, Type2Diabetes, 734, 749, "type 2 diabetic", "", +3699, OralAntidiabeticAgent, 788, 812, "oral antidiabetic agents", "", +3700, OralAntidiabeticAgent, 815, 819, "OADs", "", +1216, Duration, 859, 868, "24 - week", "", +31497, Multicenter, 871, 884, "multinational", "", +1213, Multicenter, 887, 898, "multicenter", "", +1214, OpenLabel, 901, 905, "open", "", +1215, Parallel, 908, 916, "parallel", "", +1205, NumberPatientsCT, 940, 943, "371", "", +31502, Precondition, 944, 1117, "insulin - naive patients with poor glycemic control ( fasting blood glucose [ FBG ] > / = 120 mg / dl , HbA ( 1c ) 7 . 5 - 10 . 5 % ) on OADs ( sulfonylurea plus metformin )", "", +31498, FastingBloodGlucose, 998, 1019, "fasting blood glucose", "", +31500, FastingBloodGlucose, 1022, 1025, "FBG", "", +2202, Mg_per_deciliter, 1038, 1045, "mg / dl", "", +2204, HbA1c, 1048, 1058, "HbA ( 1c )", "", +2207, Percentage, 1074, 1075, "%", "", +3701, OralAntidiabeticAgent, 1081, 1085, "OADs", "", +2281, Sulfonylureas, 1088, 1100, "sulfonylurea", "", +2282, Metformin, 1106, 1115, "metformin", "", +2208, Randomized, 1123, 1133, "randomized", "", +2209, Frequency, 1137, 1149, "once - daily", "", +2210, Morning, 1150, 1157, "morning", "", +2211, InsulinGlargine, 1158, 1174, "insulin glargine", "basal", +2212, Glimepiride, 1180, 1191, "glimepiride", "basal", +2213, Metformin, 1196, 1205, "metformin", "basal", +2214, InsulinGlargine, 1208, 1216, "glargine", "basal", +3702, OralAntidiabeticAgent, 1222, 1225, "OAD", "", +2215, IsophaneInsulin_NPH, 1234, 1271, "30 % regular / 70 % human NPH insulin", "premixed", +2285, IsophaneInsulin_NPH, 1274, 1281, "70 / 30", "premixed", +2216, Frequency, 1284, 1295, "twice daily", "", +3703, OralAntidiabeticAgent, 1304, 1308, "OADs", "", +32334, FastingBloodGlucose_target, 1342, 1370, "target FBG < / = 100 mg / dl", "", +2219, Mg_per_deciliter, 1363, 1370, "mg / dl", "", +2286, Insulin, 1378, 1386, "insulins", "", +3706, TimePoint, 1393, 1402, "predinner", "", +32335, FastingBloodGlucose_target, 1403, 1434, "blood glucose < / = 100 mg / dl", "", +2223, Mg_per_deciliter, 1427, 1434, "mg / dl", "", +3707, IsophaneInsulin_NPH, 1437, 1444, "70 / 30", "", +2221, MeasurementDevice, 1460, 1495, "weekly forced - titration algorithm", "", +2225, HbA1c, 1513, 1523, "HbA ( 1c )", "", +2226, Reduction, 1585, 1591, "1 . 64", "", +2227, Reduction, 1599, 1605, "1 . 31", "", +2228, Percentage, 1606, 1607, "%", "", +2229, PvalueDiff, 1610, 1622, "P = 0 . 0003", "", +2287, SubGroupDescription, 1631, 1718, "more patients reached HbA ( 1c ) < / = 7 . 0 % without confirmed nocturnal hypoglycemia", "", +2231, HbA1c_target, 1653, 1677, "HbA ( 1c ) < / = 7 . 0 %", "", +2232, Percentage, 1676, 1677, "%", "", +2233, NocturnalHypoglycemia, 1696, 1718, "nocturnal hypoglycemia", "", +2257, PercentageAffected, 1721, 1727, "45 . 5", "", +2258, PercentageAffected, 1733, 1739, "28 . 6", "", +2236, PvalueDiff, 1744, 1756, "P = 0 . 0013", "", +2239, InsulinGlargine, 1764, 1772, "glargine", "basal", +3709, OralAntidiabeticAgent, 1778, 1781, "OAD", "", +2240, IsophaneInsulin_NPH, 1792, 1799, "70 / 30", "premixed", +31504, FastingBloodGlucose, 1814, 1817, "FBG", "", +2242, InsulinGlargine, 1844, 1852, "glargine", "basal", +3710, OralAntidiabeticAgent, 1858, 1861, "OAD", "", +2244, Reduction, 1891, 1893, "17", "", +2245, Mg_per_deciliter, 1894, 1901, "mg / dl", "", +2247, Reduction, 1906, 1911, "0 . 9", "", +2248, Millimoles_per_litre, 1912, 1920, "mmol / l", "", +2246, PValueChangeValue, 1925, 1937, "P < 0 . 0001", "", +32336, FastingBloodGlucose_target, 1968, 1996, "target FBG < / = 100 mg / dl", "", +2251, Mg_per_deciliter, 1989, 1996, "mg / dl", "", +2252, InsulinGlargine, 2002, 2010, "glargine", "", +3712, OralAntidiabeticAgent, 2016, 2019, "OAD", "", +2253, IsophaneInsulin_NPH, 2030, 2037, "70 / 30", "", +2254, PercentageAffected, 2040, 2046, "31 . 6", "", +2255, PercentageAffected, 2052, 2058, "15 . 0", "", +2256, PvalueDiff, 2063, 2075, "P = 0 . 0001", "", +2259, InsulinGlargine, 2080, 2088, "Glargine", "basal", +3713, OralAntidiabeticAgent, 2094, 2097, "OAD", "", +2260, Hypoglycemia, 2127, 2148, "hypoglycemic episodes", "", +2263, IsophaneInsulin_NPH, 2154, 2161, "70 / 30", "premixed", +2264, NumberAffected, 2178, 2184, "4 . 07", "", +2267, NumberAffected, 2190, 2196, "9 . 87", "", +2268, PvalueDiff, 2216, 2228, "P < 0 . 0001", "", +1207, ConclusionComment, 2247, 2439, "Initiating insulin treatment by adding basal insulin glargine once daily to glimepiride plus metformin treatment was safer and more effective than beginning twice - daily injections of 70 / 30", "", +2269, Insulin, 2258, 2265, "insulin", "", +2270, InsulinGlargine, 2286, 2308, "basal insulin glargine", "basal", +2271, Frequency, 2309, 2319, "once daily", "", +2272, Glimepiride, 2323, 2334, "glimepiride", "", +2273, Metformin, 2340, 2349, "metformin", "", +2274, Frequency, 2404, 2417, "twice - daily", "", +2275, IsophaneInsulin_NPH, 2432, 2439, "70 / 30", "premixed", +31506, ObjectiveDescription, 2440, 2526, "and discontinuing OADs in type 2 diabetic patients inadequately controlled with OADs .", "", +3715, OralAntidiabeticAgent, 2458, 2462, "OADs", "", +1211, Type2Diabetes, 2466, 2481, "type 2 diabetic", "", +2276, Precondition, 2466, 2524, "type 2 diabetic patients inadequately controlled with OADs", "", +3716, OralAntidiabeticAgent, 2520, 2524, "OADs", "", +1201, PMID, 2575, 2583, "15677775", "", diff --git a/data/dm2 15677775_kwoodley.n-triples b/data/dm2 15677775_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15677775_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677776_admin.annodb b/data/dm2 15677776_admin.annodb new file mode 100644 index 0000000..3afad7a --- /dev/null +++ b/data/dm2 15677776_admin.annodb @@ -0,0 +1,141 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +112, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +0, PublicationYear, 16, 20, "2005", "", " \"2005\"." +240, Title, 48, 148, "Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs .", "", " \"Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs .\"." +101, Insulin, 59, 66, "insulin", "", +10, Type2Diabetes, 78, 93, "type 2 Diabetes", "", +117, Insulin, 131, 138, "insulin", "", +1, Author, 149, 157, "Raskin P", "", +2, Author, 166, 173, "Allen E", "", " \"Allen E\"." +3, Author, 176, 187, "Hollander P", "", " \"Hollander P\"." +4, Author, 190, 197, "Lewin A", "", " \"Lewin A\"." +5, Author, 200, 209, "Gabbay RA", "", " \"Gabbay RA\"." +6, Author, 212, 216, "Hu P", "", " \"Hu P\"." +7, Author, 219, 225, "Bode B", "", " \"Bode B\"." +8, Author, 228, 236, "Garber A", "", " \"Garber A\"." +13, USA, 390, 393, "USA", "", " ." +241, ObjectiveDescription, 575, 815, "Safety and efficacy of biphasic insulin aspart 70 / 30 ( BIAsp 70 / 30 , prebreakfast and presupper ) were compared with once - daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs ( OADs ) .", "", " \"Safety and efficacy of biphasic insulin aspart 70 / 30 ( BIAsp 70 / 30 , prebreakfast and presupper ) were compared with once - daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs ( OADs ) .\"." +38997, Aspart70/30, 598, 629, "biphasic insulin aspart 70 / 30", "", +38994, Aspart70/30, 632, 645, "BIAsp 70 / 30", "", +60992, RelativeTime, 648, 660, "prebreakfast", "", " . ." +60993, RelativeTime, 665, 674, "presupper", "", " . ." +42, Frequency, 696, 708, "once - daily", "", " \"once - daily\"." +22, InsulinGlargine, 709, 725, "insulin glargine", "", +11, Type2Diabetes, 729, 744, "type 2 diabetic", "", " ." +14, Precondition, 745, 804, "subjects inadequately controlled on oral antidiabetic drugs", "", +102, OralAntidiabeticAgent, 781, 804, "oral antidiabetic drugs", "", +103, OralAntidiabeticAgent, 807, 811, "OADs", "", +20, Duration, 851, 860, "28 - week", "", " \"28 - week\"." +18, Parallel, 861, 877, "parallel - group", "", " ." +19, Randomized, 884, 894, "randomized", "", " ." +17, NumberPatientsCT, 895, 898, "233", "", " \"233\"." +15, Precondition, 899, 1032, "insulin - naive patients with HbA ( 1c ) values > / = 8 . 0 % on > 1 , 000 mg / day metformin alone or in combination with other OADs", "", " \"insulin - naive patients with HbA ( 1c ) values > / = 8 . 0 % on > 1 , 000 mg / day metformin alone or in combination with other OADs\"." +141, Insulin, 899, 906, "insulin", "", +43, HbA1c, 929, 939, "HbA ( 1c )", "", +44, Percentage, 959, 960, "%", "", +229, DoseValue, 966, 973, "1 , 000", "", +242, mg, 974, 976, "mg", "", +243, Frequency, 979, 982, "day", "", +104, Metformin, 983, 992, "metformin", "", +105, OralAntidiabeticAgent, 1028, 1032, "OADs", "", +106, Metformin, 1035, 1044, "Metformin", "", " ." +107, DoseValue, 1064, 1071, "2 , 550", "", " \"2 , 550\"." +108, mg, 1072, 1074, "mg", "", " ." +245, Frequency, 1077, 1080, "day", "", +149, Insulin, 1088, 1095, "insulin", "", +155, DoseValue, 1123, 1128, "5 - 6", "", " \"5 - 6\"." +156, BioAndMedicalUnit, 1129, 1134, "units", "", " . ." +38995, Aspart70/30, 1135, 1148, "BIAsp 70 / 30", "", " ." +45, Frequency, 1149, 1160, "twice daily", "", " \"twice daily\"." +157, DoseValue, 1164, 1171, "10 - 12", "", " \"10 - 12\"." +158, BioAndMedicalUnit, 1172, 1177, "units", "", " . ." +23, InsulinGlargine, 1178, 1186, "glargine", "", +46, Bedtime, 1190, 1197, "bedtime", "", " ." +51228, DoseDescription, 1202, 1289, "titrated to target blood glucose ( 80 - 110 mg / dl ) by algorithm - directed titration", "", " \"titrated to target blood glucose ( 80 - 110 mg / dl ) by algorithm - directed titration\"." +154, FastingPlasmaGlucose_target, 1221, 1255, "blood glucose ( 80 - 110 mg / dl )", "", +159, Mg_per_deciliter, 1246, 1253, "mg / dl", "", +109, FinalNumPatientsCT, 1313, 1316, "209", "", " \"209\"." +38989, TimePoint, 1351, 1360, "study end", "", +232, Mean, 1367, 1371, "mean", "", +47, HbA1c, 1372, 1382, "HbA ( 1c )", "", +38996, Aspart70/30, 1406, 1419, "BIAsp 70 / 30", "", +24, InsulinGlargine, 1438, 1446, "glargine", "", +48, ResultMeasuredValue, 1455, 1461, "6 . 91", "", " \"6 . 91\"." +50, SdErrorResValue, 1468, 1474, "1 . 17", "", " \"1 . 17\"." +49, ResultMeasuredValue, 1480, 1486, "7 . 41", "", " \"7 . 41\"." +51, SdErrorResValue, 1493, 1499, "1 . 24", "", " \"1 . 24\"." +52, Percentage, 1500, 1501, "%", "", " ." +53, PvalueDiff, 1504, 1514, "P < 0 . 01", "", " ." +54, HbA1c, 1523, 1533, "HbA ( 1c )", "", +38998, Aspart70/30, 1563, 1576, "BIAsp 70 / 30", "", +25, InsulinGlargine, 1595, 1603, "glargine", "", +55, Reduction, 1614, 1620, "2 . 79", "", " \"2 . 79\"." +60995, SdErrorChangeValue, 1627, 1633, "0 . 11", "", " \"0 . 11\"." +56, Reduction, 1641, 1647, "2 . 36", "", " \"2 . 36\"." +60996, SdErrorChangeValue, 1654, 1660, "0 . 11", "", " \"0 . 11\"." +99, Percentage, 1661, 1662, "%", "", +59, PvalueDiff, 1680, 1690, "P < 0 . 01", "", " \"P < 0 . 01\"." +60, SubGroupDescription, 1710, 1753, "subjects with baseline HbA ( 1c ) > 8 . 5 %", "", " \"subjects with baseline HbA ( 1c ) > 8 . 5 %\". \"subjects with baseline HbA ( 1c ) > 8 . 5 %\"." +61, HbA1c, 1733, 1743, "HbA ( 1c )", "", +62, BaseLineValue, 1744, 1751, "> 8 . 5", "", +63, Percentage, 1752, 1753, "%", "", +64, Reduction, 1758, 1764, "3 . 13", "", " \"3 . 13\"." +60997, SdErrorChangeValue, 1771, 1777, "1 . 63", "", " \"1 . 63\"." +65, Reduction, 1785, 1791, "2 . 60", "", " \"2 . 60\"." +60998, SdErrorChangeValue, 1798, 1804, "1 . 50", "", " \"1 . 50\"." +68, Percentage, 1805, 1806, "%", "", +69, PvalueDiff, 1824, 1834, "P < 0 . 05", "", " \"P < 0 . 05\"." +39002, Aspart70/30, 1844, 1857, "BIAsp 70 / 30", "", +70, HbA1c, 1892, 1902, "HbA ( 1c )", "", " ." +26, InsulinGlargine, 1915, 1923, "glargine", "", +185, HbA1c_target, 1945, 1969, "HbA ( 1c ) < / = 6 . 5 %", "", " ." +186, Percentage, 1968, 1969, "%", "", +73, PercentageAffected, 1972, 1974, "42", "", " \"42\"." +74, PercentageAffected, 1980, 1982, "28", "", " \"28\"." +71, PvalueDiff, 1987, 1997, "P < 0 . 05", "", " \"P < 0 . 05\"." +187, HbA1c_target, 2000, 2020, "HbA ( 1c ) < 7 . 0 %", "", " ." +188, Percentage, 2019, 2020, "%", "", +75, PercentageAffected, 2023, 2025, "66", "", " \"66\"." +76, PercentageAffected, 2031, 2033, "40", "", " \"40\"." +72, PvalueDiff, 2038, 2049, "P < 0 . 001", "", " \"P < 0 . 001\"." +77, Hypoglycemia, 2060, 2072, "hypoglycemia", "", " ." +38984, BioAndMedicalUnit, 2075, 2090, "episodes / year", "", " . ." +38999, Aspart70/30, 2112, 2125, "BIAsp 70 / 30", "", +27, InsulinGlargine, 2144, 2152, "glargine", "", +78, ResultMeasuredValue, 2161, 2166, "3 . 4", "", " \"3 . 4\"." +80, SdErrorResValue, 2173, 2178, "6 . 6", "", " \"6 . 6\"." +79, ResultMeasuredValue, 2183, 2188, "0 . 7", "", " \"0 . 7\"." +81, SdErrorResValue, 2195, 2200, "2 . 0", "", " \"2 . 0\"." +82, PvalueDiff, 2218, 2228, "P < 0 . 05", "", " \"P < 0 . 05\"." +38990, BodyWeight, 2233, 2239, "Weight", "", " ." +253, InsulinDose, 2255, 2267, "insulin dose", "", " . ." +206, TimePoint, 2271, 2280, "study end", "", +39000, Aspart70/30, 2298, 2311, "BIAsp 70 / 30", "", +28, InsulinGlargine, 2340, 2348, "glargine", "", +60994, BodyWeight, 2370, 2376, "weight", "", +85, Increment, 2384, 2389, "5 . 4", "", " \"5 . 4\"." +38991, SdErrorChangeValue, 2396, 2401, "4 . 8", "", " \"4 . 8\"." +86, Increment, 2407, 2412, "3 . 5", "", " \"3 . 5\"." +38992, SdErrorChangeValue, 2419, 2424, "4 . 5", "", " \"4 . 5\"." +89, Kg, 2425, 2427, "kg", "", " ." +90, PvalueDiff, 2430, 2440, "P < 0 . 01", "", " \"P < 0 . 01\"." +254, InsulinDose, 2443, 2455, "insulin dose", "", +91, ResultMeasuredValue, 2458, 2464, "78 . 5", "", " \"78 . 5\"." +93, SdErrorResValue, 2471, 2477, "39 . 5", "", " \"39 . 5\"." +92, ResultMeasuredValue, 2482, 2488, "51 . 3", "", " \"51 . 3\"." +94, SdErrorResValue, 2495, 2501, "26 . 7", "", " \"26 . 7\"." +217, BioAndMedicalUnit, 2502, 2513, "units / day", "", " . ." +218, ConclusionComment, 2547, 2798, "In subjects with type 2 diabetes poorly controlled on OADs , initiating insulin therapy with twice - daily BIAsp 70 / 30 was more effective in achieving HbA ( 1c ) targets than once - daily glargine , especially in subjects with HbA ( 1c ) > 8 . 5 % .", "", " \"In subjects with type 2 diabetes poorly controlled on OADs , initiating insulin therapy with twice - daily BIAsp 70 / 30 was more effective in achieving HbA ( 1c ) targets than once - daily glargine , especially in subjects with HbA ( 1c ) > 8 . 5 % .\"." +16, Precondition, 2550, 2605, "subjects with type 2 diabetes poorly controlled on OADs", "", +12, Type2Diabetes, 2564, 2579, "type 2 diabetes", "", +110, OralAntidiabeticAgent, 2601, 2605, "OADs", "", +111, Insulin, 2619, 2626, "insulin", "", +95, Frequency, 2640, 2653, "twice - daily", "", +39001, Aspart70/30, 2654, 2667, "BIAsp 70 / 30", "", +228, HbA1c, 2700, 2710, "HbA ( 1c )", "", +100, Frequency, 2724, 2736, "once - daily", "", +29, InsulinGlargine, 2737, 2745, "glargine", "", +226, SubGroupDescription, 2762, 2796, "subjects with HbA ( 1c ) > 8 . 5 %", "", +97, HbA1c, 2776, 2786, "HbA ( 1c )", "", +98, Percentage, 2795, 2796, "%", "", +9, PMID, 2847, 2855, "15677776", "", " \"15677776\"." diff --git a/data/dm2 15677776_admin.n-triples b/data/dm2 15677776_admin.n-triples new file mode 100644 index 0000000..8b294a5 --- /dev/null +++ b/data/dm2 15677776_admin.n-triples @@ -0,0 +1,249 @@ +# RDF export of group: Publication + . + "Publication " . + "Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs ." . + "2005" . + "Diabetes Care" . + "15677776" . + . + "Allen E" . + "Hollander P" . + "Lewin A" . + "Gabbay RA" . + "Hu P" . + "Bode B" . + "Garber A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "Safety and efficacy of biphasic insulin aspart 70 / 30 ( BIAsp 70 / 30 , prebreakfast and presupper ) were compared with once - daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs ( OADs ) ." . + "233" . + "28 - week" . + . + . + . + "In subjects with type 2 diabetes poorly controlled on OADs , initiating insulin therapy with twice - daily BIAsp 70 / 30 was more effective in achieving HbA ( 1c ) targets than once - daily glargine , especially in subjects with HbA ( 1c ) > 8 . 5 % ." . + . + . + . + . + . + "209" . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive patients with HbA ( 1c ) values > / = 8 . 0 % on > 1 , 000 mg / day metformin alone or in combination with other OADs" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target 1" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint hba1c target 2" . + . + . + . + . +# RDF export of group: Arm + . + "Arm a" . + . + . + . + . + . + . + . + . + . + "Arm ig" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention a" . + . + "twice daily" . + . + . + . + . + . + . + "Intervention ig" . + . + "once - daily" . + . + . +# RDF export of group: Medication + . + "Medication a" . + . + "5 - 6" . + . + . + . + . + "Medication ig" . + . + "10 - 12" . + . + . + . + . + "Medication m" . + . + "2 , 550" . + . + . + "titrated to target blood glucose ( 80 - 110 mg / dl ) by algorithm - directed titration" . +# RDF export of group: Outcome + . + "Outcome hba1c a" . + . + "6 . 91" . + "1 . 17" . + "2 . 79" . + "0 . 11" . + . + "Outcome hba1c ig" . + . + "7 . 41" . + "1 . 24" . + "2 . 36" . + "0 . 11" . + . + "Outcome hba1c sg a" . + . + "3 . 13" . + "1 . 63" . + "subjects with baseline HbA ( 1c ) > 8 . 5 %" . + . + "Outcome hba1c sg ig" . + . + "2 . 60" . + "1 . 50" . + "subjects with baseline HbA ( 1c ) > 8 . 5 %" . + . + "Outcome hba1c target 1 a" . + . + "42" . + . + "Outcome hba1c target 1 ig" . + . + "28" . + . + "Outcome hba1c target 2 a" . + . + "66" . + . + "Outcome hba1c target 2 ig" . + . + "40" . + . + "Outcome h a" . + . + "3 . 4" . + "6 . 6" . + . + "Outcome h ig" . + . + "0 . 7" . + "2 . 0" . + . + "Outcome weight a" . + . + "5 . 4" . + "4 . 8" . + . + "Outcome weight ig " . + . + "3 . 5" . + "4 . 5" . + . + "Outcome id a" . + . + "78 . 5" . + "39 . 5" . + . + "Outcome id ig " . + . + "51 . 3" . + "26 . 7" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "P < 0 . 01" . + . + . + . + "DiffBetweenGroups hba1c sg " . + "P < 0 . 05" . + . + . + . + "DiffBetweenGroups hba1c target 1" . + "P < 0 . 05" . + . + . + . + "DiffBetweenGroups hba1c target 2" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups h" . + "P < 0 . 05" . + . + . + . + "DiffBetweenGroups weight" . + "P < 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677776_akramersunderbrink.annodb b/data/dm2 15677776_akramersunderbrink.annodb new file mode 100644 index 0000000..0a2ab4a --- /dev/null +++ b/data/dm2 15677776_akramersunderbrink.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6515, Journal, 0, 13, "Diabetes Care", "", +6516, PublicationYear, 16, 20, "2005", "", +6517, Title, 48, 146, "Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs", "", +6518, Insulin, 59, 66, "insulin", "", +6519, Type2Diabetes, 78, 93, "type 2 Diabetes", "", +6520, Insulin, 131, 138, "insulin", "", +6523, Author, 149, 157, "Raskin P", "", +6524, Author, 166, 173, "Allen E", "", +6525, Author, 176, 187, "Hollander P", "", +6526, Author, 190, 197, "Lewin A", "", +6527, Author, 200, 209, "Gabbay RA", "", +6528, Author, 212, 216, "Hu P", "", +6529, Author, 219, 225, "Bode B", "", +6530, Author, 228, 236, "Garber A", "", +39104, USA, 390, 393, "USA", "", +6531, ObjectiveDescription, 575, 813, "Safety and efficacy of biphasic insulin aspart 70 / 30 ( BIAsp 70 / 30 , prebreakfast and presupper ) were compared with once - daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs ( OADs )", "", +6532, InsulinAspart, 598, 629, "biphasic insulin aspart 70 / 30", "", +6533, InsulinAspart, 632, 645, "BIAsp 70 / 30", "", +6534, Morning, 648, 660, "prebreakfast", "", +6535, Bedtime, 665, 674, "presupper", "", +6537, Frequency, 696, 708, "once - daily", "", +6538, InsulinGlargine, 709, 725, "insulin glargine", "", +6539, Type2Diabetes, 729, 744, "type 2 diabetic", "", +6540, Precondition, 754, 813, "inadequately controlled on oral antidiabetic drugs ( OADs )", "", +6541, Drug, 781, 813, "oral antidiabetic drugs ( OADs )", "", +6542, Duration, 851, 860, "28 - week", "", +6543, Parallel, 861, 877, "parallel - group", "", +6544, Randomized, 884, 894, "randomized", "", +6545, NumberPatientsCT, 895, 898, "233", "", +6546, Precondition, 899, 1032, "insulin - naive patients with HbA ( 1c ) values > / = 8 . 0 % on > 1 , 000 mg / day metformin alone or in combination with other OADs", "", +6547, Insulin, 899, 906, "insulin", "", +6549, Percentage, 959, 960, "%", "", +6645, DoseValue, 966, 973, "1 , 000", "", +6548, BioAndMedicalUnit, 974, 982, "mg / day", "", +6550, Metformin, 983, 992, "metformin", "", +6551, Drug, 1028, 1032, "OADs", "", +6552, Metformin, 1035, 1044, "Metformin", "", +6553, DoseValue, 1064, 1071, "2 , 550", "", +6554, BioAndMedicalUnit, 1072, 1080, "mg / day", "", +6555, Insulin, 1088, 1095, "insulin", "", +6562, DoseValue, 1123, 1128, "5 - 6", "", +6563, BioAndMedicalUnit, 1129, 1134, "units", "", +6556, InsulinAspart, 1135, 1148, "BIAsp 70 / 30", "", +6558, Frequency, 1149, 1160, "twice daily", "", +6564, DoseValue, 1164, 1171, "10 - 12", "", +6565, BioAndMedicalUnit, 1172, 1177, "units", "", +6559, InsulinGlargine, 1178, 1186, "glargine", "", +6560, Bedtime, 1190, 1197, "bedtime", "", +6561, FastingPlasmaGlucose_target, 1221, 1255, "blood glucose ( 80 - 110 mg / dl )", "", +6566, Mg_per_deciliter, 1246, 1253, "mg / dl", "", +6567, FinalNumPatientsCT, 1313, 1316, "209", "", +39105, TimePoint, 1351, 1360, "study end", "", +9790, Mean, 1367, 1371, "mean", "", +6568, HbA1c, 1372, 1382, "HbA ( 1c )", "", +6569, InsulinAspart, 1406, 1419, "BIAsp 70 / 30", "", +6570, InsulinGlargine, 1438, 1446, "glargine", "", +6571, ResultMeasuredValue, 1455, 1461, "6 . 91", "", +6573, SdErrorResValue, 1462, 1474, "+ / - 1 . 17", "", +6572, ResultMeasuredValue, 1480, 1486, "7 . 41", "", +6646, SdErrorResValue, 1487, 1499, "+ / - 1 . 24", "", +6575, Percentage, 1500, 1501, "%", "", +6576, PvalueDiff, 1504, 1514, "P < 0 . 01", "", +39106, HbA1c, 1523, 1533, "HbA ( 1c )", "", +6577, InsulinAspart, 1563, 1576, "BIAsp 70 / 30", "", +6578, InsulinGlargine, 1595, 1603, "glargine", "", +6579, ChangeValue, 1612, 1620, "- 2 . 79", "", +6580, SdErrorChangeValue, 1621, 1633, "+ / - 0 . 11", "", +6583, ChangeValue, 1639, 1647, "- 2 . 36", "", +6582, SdErrorChangeValue, 1648, 1660, "+ / - 0 . 11", "", +6584, Percentage, 1661, 1662, "%", "", +6585, PvalueDiff, 1680, 1690, "P < 0 . 01", "", +6586, SubGroupDescription, 1710, 1753, "subjects with baseline HbA ( 1c ) > 8 . 5 %", "", +6587, ChangeValue, 1756, 1764, "- 3 . 13", "", +6588, SdErrorChangeValue, 1765, 1777, "+ / - 1 . 63", "", +6589, ChangeValue, 1783, 1791, "- 2 . 60", "", +6590, SdErrorChangeValue, 1792, 1804, "+ / - 1 . 50", "", +6591, Percentage, 1805, 1806, "%", "", +6592, PvalueDiff, 1824, 1834, "P < 0 . 05", "", +6593, InsulinAspart, 1844, 1857, "BIAsp 70 / 30", "", +7328, HbA1c_target, 1885, 1909, "target HbA ( 1c ) values", "", +6606, InsulinGlargine, 1915, 1923, "glargine", "", +6595, HbA1c_target, 1945, 1969, "HbA ( 1c ) < / = 6 . 5 %", "", +6596, Percentage, 1968, 1969, "%", "", +6599, PercentageAffected, 1972, 1974, "42", "", +6600, PercentageAffected, 1980, 1982, "28", "", +6601, PvalueDiff, 1987, 1997, "P < 0 . 05", "", +6597, HbA1c_target, 2000, 2020, "HbA ( 1c ) < 7 . 0 %", "", +6598, Percentage, 2019, 2020, "%", "", +6602, PercentageAffected, 2023, 2025, "66", "", +6603, PercentageAffected, 2031, 2033, "40", "", +6604, Percentage, 2034, 2035, "%", "", +6605, PvalueDiff, 2038, 2049, "P < 0 . 001", "", +6607, EndPointDescription, 2054, 2072, "Minor hypoglycemia", "", +6608, BioAndMedicalUnit, 2075, 2090, "episodes / year", "", +6609, InsulinAspart, 2112, 2125, "BIAsp 70 / 30", "", +6610, InsulinGlargine, 2144, 2152, "glargine", "", +6611, ResultMeasuredValue, 2161, 2166, "3 . 4", "", +11067, SdDevResValue, 2167, 2178, "+ / - 6 . 6", "", +6613, ResultMeasuredValue, 2183, 2188, "0 . 7", "", +11068, SdDevResValue, 2189, 2200, "+ / - 2 . 0", "", +6615, PvalueDiff, 2218, 2228, "P < 0 . 05", "", +6616, WeightGain, 2233, 2244, "Weight gain", "", +6617, EndPointDescription, 2249, 2267, "daily insulin dose", "", +6618, TimePoint, 2271, 2280, "study end", "", +6619, InsulinAspart, 2298, 2311, "BIAsp 70 / 30", "", +6620, InsulinGlargine, 2340, 2348, "glargine", "", +6621, WeightGain, 2370, 2381, "weight gain", "", +6622, ResultMeasuredValue, 2384, 2389, "5 . 4", "", +11069, SdDevResValue, 2390, 2401, "+ / - 4 . 8", "", +6624, ResultMeasuredValue, 2407, 2412, "3 . 5", "", +11070, SdDevResValue, 2413, 2424, "+ / - 4 . 5", "", +6626, Kg, 2425, 2427, "kg", "", +6627, PvalueDiff, 2430, 2440, "P < 0 . 01", "", +6628, EndPointDescription, 2443, 2455, "insulin dose", "", +6629, ResultMeasuredValue, 2458, 2464, "78 . 5", "", +11071, SdDevResValue, 2465, 2477, "+ / - 39 . 5", "", +6631, ResultMeasuredValue, 2482, 2488, "51 . 3", "", +11072, SdDevResValue, 2489, 2501, "+ / - 26 . 7", "", +6633, BioAndMedicalUnit, 2502, 2513, "units / day", "", +6634, ConclusionComment, 2547, 2798, "In subjects with type 2 diabetes poorly controlled on OADs , initiating insulin therapy with twice - daily BIAsp 70 / 30 was more effective in achieving HbA ( 1c ) targets than once - daily glargine , especially in subjects with HbA ( 1c ) > 8 . 5 % .", "", +6635, Type2Diabetes, 2564, 2579, "type 2 diabetes", "", +6636, Precondition, 2580, 2605, "poorly controlled on OADs", "", +6637, Insulin, 2619, 2626, "insulin", "", +6638, Frequency, 2640, 2653, "twice - daily", "", +6639, InsulinAspart, 2654, 2667, "BIAsp 70 / 30", "", +6644, HbA1c, 2700, 2710, "HbA ( 1c )", "", +6640, Frequency, 2724, 2736, "once - daily", "", +6641, InsulinGlargine, 2737, 2745, "glargine", "", +6642, SubGroupDescription, 2762, 2796, "subjects with HbA ( 1c ) > 8 . 5 %", "", +6643, PMID, 2847, 2855, "15677776", "", diff --git a/data/dm2 15677776_akramersunderbrink.n-triples b/data/dm2 15677776_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15677776_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15677776_export.csv b/data/dm2 15677776_export.csv new file mode 100644 index 0000000..9788be4 --- /dev/null +++ b/data/dm2 15677776_export.csv @@ -0,0 +1,730 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +370, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +370, 1, 2, 2, 9, 13, 9, 13, "Care" +370, 1, 3, 3, 14, 15, 14, 15, "." +370, 2, 1, 4, 0, 4, 16, 20, "2005" +370, 2, 2, 5, 5, 8, 21, 24, "Feb" +370, 2, 3, 6, 9, 10, 25, 26, ";" +370, 2, 4, 7, 11, 13, 27, 29, "28" +370, 2, 5, 8, 14, 15, 30, 31, "(" +370, 2, 6, 9, 16, 17, 32, 33, "2" +370, 2, 7, 10, 18, 19, 34, 35, ")" +370, 2, 8, 11, 20, 21, 36, 37, ":" +370, 2, 9, 12, 22, 25, 38, 41, "260" +370, 2, 10, 13, 26, 27, 42, 43, "-" +370, 2, 11, 14, 28, 29, 44, 45, "5" +370, 2, 12, 15, 30, 31, 46, 47, "." +370, 3, 1, 16, 0, 10, 48, 58, "Initiating" +370, 3, 2, 17, 11, 18, 59, 66, "insulin" +370, 3, 3, 18, 19, 26, 67, 74, "therapy" +370, 3, 4, 19, 27, 29, 75, 77, "in" +370, 3, 5, 20, 30, 34, 78, 82, "type" +370, 3, 6, 21, 35, 36, 83, 84, "2" +370, 3, 7, 22, 37, 45, 85, 93, "Diabetes" +370, 3, 8, 23, 46, 47, 94, 95, ":" +370, 3, 9, 24, 48, 49, 96, 97, "a" +370, 3, 10, 25, 50, 60, 98, 108, "comparison" +370, 3, 11, 26, 61, 63, 109, 111, "of" +370, 3, 12, 27, 64, 72, 112, 120, "biphasic" +370, 3, 13, 28, 73, 76, 121, 124, "and" +370, 3, 14, 29, 77, 82, 125, 130, "basal" +370, 3, 15, 30, 83, 90, 131, 138, "insulin" +370, 3, 16, 31, 91, 98, 139, 146, "analogs" +370, 3, 17, 32, 99, 100, 147, 148, "." +370, 4, 1, 33, 0, 6, 149, 155, "Raskin" +370, 4, 2, 34, 7, 8, 156, 157, "P" +370, 4, 3, 35, 9, 10, 158, 159, "(" +370, 4, 4, 36, 11, 12, 160, 161, "1" +370, 4, 5, 37, 13, 14, 162, 163, ")" +370, 4, 6, 38, 15, 16, 164, 165, "," +370, 4, 7, 39, 17, 22, 166, 171, "Allen" +370, 4, 8, 40, 23, 24, 172, 173, "E" +370, 4, 9, 41, 25, 26, 174, 175, "," +370, 4, 10, 42, 27, 36, 176, 185, "Hollander" +370, 4, 11, 43, 37, 38, 186, 187, "P" +370, 4, 12, 44, 39, 40, 188, 189, "," +370, 4, 13, 45, 41, 46, 190, 195, "Lewin" +370, 4, 14, 46, 47, 48, 196, 197, "A" +370, 4, 15, 47, 49, 50, 198, 199, "," +370, 4, 16, 48, 51, 57, 200, 206, "Gabbay" +370, 4, 17, 49, 58, 60, 207, 209, "RA" +370, 4, 18, 50, 61, 62, 210, 211, "," +370, 4, 19, 51, 63, 65, 212, 214, "Hu" +370, 4, 20, 52, 66, 67, 215, 216, "P" +370, 4, 21, 53, 68, 69, 217, 218, "," +370, 4, 22, 54, 70, 74, 219, 223, "Bode" +370, 4, 23, 55, 75, 76, 224, 225, "B" +370, 4, 24, 56, 77, 78, 226, 227, "," +370, 4, 25, 57, 79, 85, 228, 234, "Garber" +370, 4, 26, 58, 86, 87, 235, 236, "A" +370, 4, 27, 59, 88, 89, 237, 238, ";" +370, 4, 28, 60, 90, 98, 239, 247, "INITIATE" +370, 4, 29, 61, 99, 104, 248, 253, "Study" +370, 4, 30, 62, 105, 110, 254, 259, "Group" +370, 4, 31, 63, 111, 112, 260, 261, "." +370, 5, 1, 64, 0, 6, 262, 268, "Author" +370, 5, 2, 65, 7, 18, 269, 280, "information" +370, 5, 3, 66, 19, 20, 281, 282, ":" +370, 5, 4, 67, 21, 22, 283, 284, "(" +370, 5, 5, 68, 23, 24, 285, 286, "1" +370, 5, 6, 69, 25, 26, 287, 288, ")" +370, 5, 7, 70, 27, 37, 289, 299, "Department" +370, 5, 8, 71, 38, 40, 300, 302, "of" +370, 5, 9, 72, 41, 49, 303, 311, "Internal" +370, 5, 10, 73, 50, 58, 312, 320, "Medicine" +370, 5, 11, 74, 59, 60, 321, 322, "," +370, 5, 12, 75, 61, 73, 323, 335, "Southwestern" +370, 5, 13, 76, 74, 81, 336, 343, "Medical" +370, 5, 14, 77, 82, 88, 344, 350, "Center" +370, 5, 15, 78, 89, 91, 351, 353, "at" +370, 5, 16, 79, 92, 98, 354, 360, "Dallas" +370, 5, 17, 80, 99, 100, 361, 362, "," +370, 5, 18, 81, 101, 107, 363, 369, "Dallas" +370, 5, 19, 82, 108, 109, 370, 371, "," +370, 5, 20, 83, 110, 112, 372, 374, "TX" +370, 5, 21, 84, 113, 118, 375, 380, "75390" +370, 5, 22, 85, 119, 120, 381, 382, "-" +370, 5, 23, 86, 121, 125, 383, 387, "8858" +370, 5, 24, 87, 126, 127, 388, 389, "," +370, 5, 25, 88, 128, 131, 390, 393, "USA" +370, 5, 26, 89, 132, 133, 394, 395, "." +370, 6, 1, 90, 0, 6, 396, 402, "philip" +370, 6, 2, 91, 7, 8, 403, 404, "." +370, 6, 3, 92, 9, 15, 405, 411, "raskin" +370, 6, 4, 93, 16, 17, 412, 413, "@" +370, 6, 5, 94, 18, 32, 414, 428, "utsouthwestern" +370, 6, 6, 95, 33, 34, 429, 430, "." +370, 6, 7, 96, 35, 38, 431, 434, "edu" +370, 6, 8, 97, 39, 46, 435, 442, "Comment" +370, 6, 9, 98, 47, 49, 443, 445, "in" +370, 6, 10, 99, 50, 58, 446, 454, "Diabetes" +370, 6, 11, 100, 59, 63, 455, 459, "Care" +370, 6, 12, 101, 64, 65, 460, 461, "." +370, 7, 1, 102, 0, 4, 462, 466, "2005" +370, 7, 2, 103, 5, 8, 467, 470, "Feb" +370, 7, 3, 104, 9, 10, 471, 472, ";" +370, 7, 4, 105, 11, 13, 473, 475, "28" +370, 7, 5, 106, 14, 15, 476, 477, "(" +370, 7, 6, 107, 16, 17, 478, 479, "2" +370, 7, 7, 108, 18, 19, 480, 481, ")" +370, 7, 8, 109, 20, 21, 482, 483, ":" +370, 7, 9, 110, 22, 25, 484, 487, "494" +370, 7, 10, 111, 26, 27, 488, 489, "-" +370, 7, 11, 112, 28, 29, 490, 491, "5" +370, 7, 12, 113, 30, 31, 492, 493, "." +370, 8, 1, 114, 0, 8, 494, 502, "Diabetes" +370, 8, 2, 115, 9, 13, 503, 507, "Care" +370, 8, 3, 116, 14, 15, 508, 509, "." +370, 9, 1, 117, 0, 4, 510, 514, "2005" +370, 9, 2, 118, 5, 8, 515, 518, "Jun" +370, 9, 3, 119, 9, 10, 519, 520, ";" +370, 9, 4, 120, 11, 13, 521, 523, "28" +370, 9, 5, 121, 14, 15, 524, 525, "(" +370, 9, 6, 122, 16, 17, 526, 527, "6" +370, 9, 7, 123, 18, 19, 528, 529, ")" +370, 9, 8, 124, 20, 21, 530, 531, ":" +370, 9, 9, 125, 22, 26, 532, 536, "1537" +370, 9, 10, 126, 27, 28, 537, 538, "-" +370, 9, 11, 127, 29, 30, 539, 540, "8" +370, 9, 12, 128, 31, 32, 541, 542, ";" +370, 9, 13, 129, 33, 39, 543, 549, "author" +370, 9, 14, 130, 40, 45, 550, 555, "reply" +370, 9, 15, 131, 46, 50, 556, 560, "1538" +370, 9, 16, 132, 51, 52, 561, 562, "." +370, 10, 1, 133, 0, 9, 563, 572, "OBJECTIVE" +370, 10, 2, 134, 10, 11, 573, 574, ":" +370, 10, 3, 135, 12, 18, 575, 581, "Safety" +370, 10, 4, 136, 19, 22, 582, 585, "and" +370, 10, 5, 137, 23, 31, 586, 594, "efficacy" +370, 10, 6, 138, 32, 34, 595, 597, "of" +370, 10, 7, 139, 35, 43, 598, 606, "biphasic" +370, 10, 8, 140, 44, 51, 607, 614, "insulin" +370, 10, 9, 141, 52, 58, 615, 621, "aspart" +370, 10, 10, 142, 59, 61, 622, 624, "70" +370, 10, 11, 143, 62, 63, 625, 626, "/" +370, 10, 12, 144, 64, 66, 627, 629, "30" +370, 10, 13, 145, 67, 68, 630, 631, "(" +370, 10, 14, 146, 69, 74, 632, 637, "BIAsp" +370, 10, 15, 147, 75, 77, 638, 640, "70" +370, 10, 16, 148, 78, 79, 641, 642, "/" +370, 10, 17, 149, 80, 82, 643, 645, "30" +370, 10, 18, 150, 83, 84, 646, 647, "," +370, 10, 19, 151, 85, 97, 648, 660, "prebreakfast" +370, 10, 20, 152, 98, 101, 661, 664, "and" +370, 10, 21, 153, 102, 111, 665, 674, "presupper" +370, 10, 22, 154, 112, 113, 675, 676, ")" +370, 10, 23, 155, 114, 118, 677, 681, "were" +370, 10, 24, 156, 119, 127, 682, 690, "compared" +370, 10, 25, 157, 128, 132, 691, 695, "with" +370, 10, 26, 158, 133, 137, 696, 700, "once" +370, 10, 27, 159, 138, 139, 701, 702, "-" +370, 10, 28, 160, 140, 145, 703, 708, "daily" +370, 10, 29, 161, 146, 153, 709, 716, "insulin" +370, 10, 30, 162, 154, 162, 717, 725, "glargine" +370, 10, 31, 163, 163, 165, 726, 728, "in" +370, 10, 32, 164, 166, 170, 729, 733, "type" +370, 10, 33, 165, 171, 172, 734, 735, "2" +370, 10, 34, 166, 173, 181, 736, 744, "diabetic" +370, 10, 35, 167, 182, 190, 745, 753, "subjects" +370, 10, 36, 168, 191, 203, 754, 766, "inadequately" +370, 10, 37, 169, 204, 214, 767, 777, "controlled" +370, 10, 38, 170, 215, 217, 778, 780, "on" +370, 10, 39, 171, 218, 222, 781, 785, "oral" +370, 10, 40, 172, 223, 235, 786, 798, "antidiabetic" +370, 10, 41, 173, 236, 241, 799, 804, "drugs" +370, 10, 42, 174, 242, 243, 805, 806, "(" +370, 10, 43, 175, 244, 248, 807, 811, "OADs" +370, 10, 44, 176, 249, 250, 812, 813, ")" +370, 10, 45, 177, 251, 252, 814, 815, "." +370, 11, 1, 178, 0, 8, 816, 824, "RESEARCH" +370, 11, 2, 179, 9, 15, 825, 831, "DESIGN" +370, 11, 3, 180, 16, 19, 832, 835, "AND" +370, 11, 4, 181, 20, 27, 836, 843, "METHODS" +370, 11, 5, 182, 28, 29, 844, 845, ":" +370, 11, 6, 183, 30, 34, 846, 850, "This" +370, 11, 7, 184, 35, 37, 851, 853, "28" +370, 11, 8, 185, 38, 39, 854, 855, "-" +370, 11, 9, 186, 40, 44, 856, 860, "week" +370, 11, 10, 187, 45, 53, 861, 869, "parallel" +370, 11, 11, 188, 54, 55, 870, 871, "-" +370, 11, 12, 189, 56, 61, 872, 877, "group" +370, 11, 13, 190, 62, 67, 878, 883, "study" +370, 11, 14, 191, 68, 78, 884, 894, "randomized" +370, 11, 15, 192, 79, 82, 895, 898, "233" +370, 11, 16, 193, 83, 90, 899, 906, "insulin" +370, 11, 17, 194, 91, 92, 907, 908, "-" +370, 11, 18, 195, 93, 98, 909, 914, "naive" +370, 11, 19, 196, 99, 107, 915, 923, "patients" +370, 11, 20, 197, 108, 112, 924, 928, "with" +370, 11, 21, 198, 113, 116, 929, 932, "HbA" +370, 11, 22, 199, 117, 118, 933, 934, "(" +370, 11, 23, 200, 119, 121, 935, 937, "1c" +370, 11, 24, 201, 122, 123, 938, 939, ")" +370, 11, 25, 202, 124, 130, 940, 946, "values" +370, 11, 26, 203, 131, 132, 947, 948, ">" +370, 11, 27, 204, 133, 134, 949, 950, "/" +370, 11, 28, 205, 135, 136, 951, 952, "=" +370, 11, 29, 206, 137, 138, 953, 954, "8" +370, 11, 30, 207, 139, 140, 955, 956, "." +370, 11, 31, 208, 141, 142, 957, 958, "0" +370, 11, 32, 209, 143, 144, 959, 960, "%" +370, 11, 33, 210, 145, 147, 961, 963, "on" +370, 11, 34, 211, 148, 149, 964, 965, ">" +370, 11, 35, 212, 150, 151, 966, 967, "1" +370, 11, 36, 213, 152, 153, 968, 969, "," +370, 11, 37, 214, 154, 157, 970, 973, "000" +370, 11, 38, 215, 158, 160, 974, 976, "mg" +370, 11, 39, 216, 161, 162, 977, 978, "/" +370, 11, 40, 217, 163, 166, 979, 982, "day" +370, 11, 41, 218, 167, 176, 983, 992, "metformin" +370, 11, 42, 219, 177, 182, 993, 998, "alone" +370, 11, 43, 220, 183, 185, 999, 1001, "or" +370, 11, 44, 221, 186, 188, 1002, 1004, "in" +370, 11, 45, 222, 189, 200, 1005, 1016, "combination" +370, 11, 46, 223, 201, 205, 1017, 1021, "with" +370, 11, 47, 224, 206, 211, 1022, 1027, "other" +370, 11, 48, 225, 212, 216, 1028, 1032, "OADs" +370, 11, 49, 226, 217, 218, 1033, 1034, "." +370, 12, 1, 227, 0, 9, 1035, 1044, "Metformin" +370, 12, 2, 228, 10, 13, 1045, 1048, "was" +370, 12, 3, 229, 14, 22, 1049, 1057, "adjusted" +370, 12, 4, 230, 23, 25, 1058, 1060, "up" +370, 12, 5, 231, 26, 28, 1061, 1063, "to" +370, 12, 6, 232, 29, 30, 1064, 1065, "2" +370, 12, 7, 233, 31, 32, 1066, 1067, "," +370, 12, 8, 234, 33, 36, 1068, 1071, "550" +370, 12, 9, 235, 37, 39, 1072, 1074, "mg" +370, 12, 10, 236, 40, 41, 1075, 1076, "/" +370, 12, 11, 237, 42, 45, 1077, 1080, "day" +370, 12, 12, 238, 46, 52, 1081, 1087, "before" +370, 12, 13, 239, 53, 60, 1088, 1095, "insulin" +370, 12, 14, 240, 61, 68, 1096, 1103, "therapy" +370, 12, 15, 241, 69, 72, 1104, 1107, "was" +370, 12, 16, 242, 73, 82, 1108, 1117, "initiated" +370, 12, 17, 243, 83, 87, 1118, 1122, "with" +370, 12, 18, 244, 88, 89, 1123, 1124, "5" +370, 12, 19, 245, 90, 91, 1125, 1126, "-" +370, 12, 20, 246, 92, 93, 1127, 1128, "6" +370, 12, 21, 247, 94, 99, 1129, 1134, "units" +370, 12, 22, 248, 100, 105, 1135, 1140, "BIAsp" +370, 12, 23, 249, 106, 108, 1141, 1143, "70" +370, 12, 24, 250, 109, 110, 1144, 1145, "/" +370, 12, 25, 251, 111, 113, 1146, 1148, "30" +370, 12, 26, 252, 114, 119, 1149, 1154, "twice" +370, 12, 27, 253, 120, 125, 1155, 1160, "daily" +370, 12, 28, 254, 126, 128, 1161, 1163, "or" +370, 12, 29, 255, 129, 131, 1164, 1166, "10" +370, 12, 30, 256, 132, 133, 1167, 1168, "-" +370, 12, 31, 257, 134, 136, 1169, 1171, "12" +370, 12, 32, 258, 137, 142, 1172, 1177, "units" +370, 12, 33, 259, 143, 151, 1178, 1186, "glargine" +370, 12, 34, 260, 152, 154, 1187, 1189, "at" +370, 12, 35, 261, 155, 162, 1190, 1197, "bedtime" +370, 12, 36, 262, 163, 166, 1198, 1201, "and" +370, 12, 37, 263, 167, 175, 1202, 1210, "titrated" +370, 12, 38, 264, 176, 178, 1211, 1213, "to" +370, 12, 39, 265, 179, 185, 1214, 1220, "target" +370, 12, 40, 266, 186, 191, 1221, 1226, "blood" +370, 12, 41, 267, 192, 199, 1227, 1234, "glucose" +370, 12, 42, 268, 200, 201, 1235, 1236, "(" +370, 12, 43, 269, 202, 204, 1237, 1239, "80" +370, 12, 44, 270, 205, 206, 1240, 1241, "-" +370, 12, 45, 271, 207, 210, 1242, 1245, "110" +370, 12, 46, 272, 211, 213, 1246, 1248, "mg" +370, 12, 47, 273, 214, 215, 1249, 1250, "/" +370, 12, 48, 274, 216, 218, 1251, 1253, "dl" +370, 12, 49, 275, 219, 220, 1254, 1255, ")" +370, 12, 50, 276, 221, 223, 1256, 1258, "by" +370, 12, 51, 277, 224, 233, 1259, 1268, "algorithm" +370, 12, 52, 278, 234, 235, 1269, 1270, "-" +370, 12, 53, 279, 236, 244, 1271, 1279, "directed" +370, 12, 54, 280, 245, 254, 1280, 1289, "titration" +370, 12, 55, 281, 255, 256, 1290, 1291, "." +370, 13, 1, 282, 0, 7, 1292, 1299, "RESULTS" +370, 13, 2, 283, 8, 9, 1300, 1301, ":" +370, 13, 3, 284, 10, 11, 1302, 1303, "A" +370, 13, 4, 285, 12, 17, 1304, 1309, "total" +370, 13, 5, 286, 18, 20, 1310, 1312, "of" +370, 13, 6, 287, 21, 24, 1313, 1316, "209" +370, 13, 7, 288, 25, 33, 1317, 1325, "subjects" +370, 13, 8, 289, 34, 43, 1326, 1335, "completed" +370, 13, 9, 290, 44, 47, 1336, 1339, "the" +370, 13, 10, 291, 48, 53, 1340, 1345, "study" +370, 13, 11, 292, 54, 55, 1346, 1347, "." +370, 14, 1, 293, 0, 2, 1348, 1350, "At" +370, 14, 2, 294, 3, 8, 1351, 1356, "study" +370, 14, 3, 295, 9, 12, 1357, 1360, "end" +370, 14, 4, 296, 13, 14, 1361, 1362, "," +370, 14, 5, 297, 15, 18, 1363, 1366, "the" +370, 14, 6, 298, 19, 23, 1367, 1371, "mean" +370, 14, 7, 299, 24, 27, 1372, 1375, "HbA" +370, 14, 8, 300, 28, 29, 1376, 1377, "(" +370, 14, 9, 301, 30, 32, 1378, 1380, "1c" +370, 14, 10, 302, 33, 34, 1381, 1382, ")" +370, 14, 11, 303, 35, 40, 1383, 1388, "value" +370, 14, 12, 304, 41, 44, 1389, 1392, "was" +370, 14, 13, 305, 45, 50, 1393, 1398, "lower" +370, 14, 14, 306, 51, 53, 1399, 1401, "in" +370, 14, 15, 307, 54, 57, 1402, 1405, "the" +370, 14, 16, 308, 58, 63, 1406, 1411, "BIAsp" +370, 14, 17, 309, 64, 66, 1412, 1414, "70" +370, 14, 18, 310, 67, 68, 1415, 1416, "/" +370, 14, 19, 311, 69, 71, 1417, 1419, "30" +370, 14, 20, 312, 72, 77, 1420, 1425, "group" +370, 14, 21, 313, 78, 82, 1426, 1430, "than" +370, 14, 22, 314, 83, 85, 1431, 1433, "in" +370, 14, 23, 315, 86, 89, 1434, 1437, "the" +370, 14, 24, 316, 90, 98, 1438, 1446, "glargine" +370, 14, 25, 317, 99, 104, 1447, 1452, "group" +370, 14, 26, 318, 105, 106, 1453, 1454, "(" +370, 14, 27, 319, 107, 108, 1455, 1456, "6" +370, 14, 28, 320, 109, 110, 1457, 1458, "." +370, 14, 29, 321, 111, 113, 1459, 1461, "91" +370, 14, 30, 322, 114, 115, 1462, 1463, "+" +370, 14, 31, 323, 116, 117, 1464, 1465, "/" +370, 14, 32, 324, 118, 119, 1466, 1467, "-" +370, 14, 33, 325, 120, 121, 1468, 1469, "1" +370, 14, 34, 326, 122, 123, 1470, 1471, "." +370, 14, 35, 327, 124, 126, 1472, 1474, "17" +370, 14, 36, 328, 127, 129, 1475, 1477, "vs" +370, 14, 37, 329, 130, 131, 1478, 1479, "." +370, 14, 38, 330, 132, 133, 1480, 1481, "7" +370, 14, 39, 331, 134, 135, 1482, 1483, "." +370, 14, 40, 332, 136, 138, 1484, 1486, "41" +370, 14, 41, 333, 139, 140, 1487, 1488, "+" +370, 14, 42, 334, 141, 142, 1489, 1490, "/" +370, 14, 43, 335, 143, 144, 1491, 1492, "-" +370, 14, 44, 336, 145, 146, 1493, 1494, "1" +370, 14, 45, 337, 147, 148, 1495, 1496, "." +370, 14, 46, 338, 149, 151, 1497, 1499, "24" +370, 14, 47, 339, 152, 153, 1500, 1501, "%" +370, 14, 48, 340, 154, 155, 1502, 1503, "," +370, 14, 49, 341, 156, 157, 1504, 1505, "P" +370, 14, 50, 342, 158, 159, 1506, 1507, "<" +370, 14, 51, 343, 160, 161, 1508, 1509, "0" +370, 14, 52, 344, 162, 163, 1510, 1511, "." +370, 14, 53, 345, 164, 166, 1512, 1514, "01" +370, 14, 54, 346, 167, 168, 1515, 1516, ")" +370, 14, 55, 347, 169, 170, 1517, 1518, "." +370, 15, 1, 348, 0, 3, 1519, 1522, "The" +370, 15, 2, 349, 4, 7, 1523, 1526, "HbA" +370, 15, 3, 350, 8, 9, 1527, 1528, "(" +370, 15, 4, 351, 10, 12, 1529, 1531, "1c" +370, 15, 5, 352, 13, 14, 1532, 1533, ")" +370, 15, 6, 353, 15, 24, 1534, 1543, "reduction" +370, 15, 7, 354, 25, 28, 1544, 1547, "was" +370, 15, 8, 355, 29, 36, 1548, 1555, "greater" +370, 15, 9, 356, 37, 39, 1556, 1558, "in" +370, 15, 10, 357, 40, 43, 1559, 1562, "the" +370, 15, 11, 358, 44, 49, 1563, 1568, "BIAsp" +370, 15, 12, 359, 50, 52, 1569, 1571, "70" +370, 15, 13, 360, 53, 54, 1572, 1573, "/" +370, 15, 14, 361, 55, 57, 1574, 1576, "30" +370, 15, 15, 362, 58, 63, 1577, 1582, "group" +370, 15, 16, 363, 64, 68, 1583, 1587, "than" +370, 15, 17, 364, 69, 71, 1588, 1590, "in" +370, 15, 18, 365, 72, 75, 1591, 1594, "the" +370, 15, 19, 366, 76, 84, 1595, 1603, "glargine" +370, 15, 20, 367, 85, 90, 1604, 1609, "group" +370, 15, 21, 368, 91, 92, 1610, 1611, "(" +370, 15, 22, 369, 93, 94, 1612, 1613, "-" +370, 15, 23, 370, 95, 96, 1614, 1615, "2" +370, 15, 24, 371, 97, 98, 1616, 1617, "." +370, 15, 25, 372, 99, 101, 1618, 1620, "79" +370, 15, 26, 373, 102, 103, 1621, 1622, "+" +370, 15, 27, 374, 104, 105, 1623, 1624, "/" +370, 15, 28, 375, 106, 107, 1625, 1626, "-" +370, 15, 29, 376, 108, 109, 1627, 1628, "0" +370, 15, 30, 377, 110, 111, 1629, 1630, "." +370, 15, 31, 378, 112, 114, 1631, 1633, "11" +370, 15, 32, 379, 115, 117, 1634, 1636, "vs" +370, 15, 33, 380, 118, 119, 1637, 1638, "." +370, 15, 34, 381, 120, 121, 1639, 1640, "-" +370, 15, 35, 382, 122, 123, 1641, 1642, "2" +370, 15, 36, 383, 124, 125, 1643, 1644, "." +370, 15, 37, 384, 126, 128, 1645, 1647, "36" +370, 15, 38, 385, 129, 130, 1648, 1649, "+" +370, 15, 39, 386, 131, 132, 1650, 1651, "/" +370, 15, 40, 387, 133, 134, 1652, 1653, "-" +370, 15, 41, 388, 135, 136, 1654, 1655, "0" +370, 15, 42, 389, 137, 138, 1656, 1657, "." +370, 15, 43, 390, 139, 141, 1658, 1660, "11" +370, 15, 44, 391, 142, 143, 1661, 1662, "%" +370, 15, 45, 392, 144, 145, 1663, 1664, "," +370, 15, 46, 393, 146, 158, 1665, 1677, "respectively" +370, 15, 47, 394, 159, 160, 1678, 1679, ";" +370, 15, 48, 395, 161, 162, 1680, 1681, "P" +370, 15, 49, 396, 163, 164, 1682, 1683, "<" +370, 15, 50, 397, 165, 166, 1684, 1685, "0" +370, 15, 51, 398, 167, 168, 1686, 1687, "." +370, 15, 52, 399, 169, 171, 1688, 1690, "01" +370, 15, 53, 400, 172, 173, 1691, 1692, ")" +370, 15, 54, 401, 174, 175, 1693, 1694, "," +370, 15, 55, 402, 176, 186, 1695, 1705, "especially" +370, 15, 56, 403, 187, 190, 1706, 1709, "for" +370, 15, 57, 404, 191, 199, 1710, 1718, "subjects" +370, 15, 58, 405, 200, 204, 1719, 1723, "with" +370, 15, 59, 406, 205, 213, 1724, 1732, "baseline" +370, 15, 60, 407, 214, 217, 1733, 1736, "HbA" +370, 15, 61, 408, 218, 219, 1737, 1738, "(" +370, 15, 62, 409, 220, 222, 1739, 1741, "1c" +370, 15, 63, 410, 223, 224, 1742, 1743, ")" +370, 15, 64, 411, 225, 226, 1744, 1745, ">" +370, 15, 65, 412, 227, 228, 1746, 1747, "8" +370, 15, 66, 413, 229, 230, 1748, 1749, "." +370, 15, 67, 414, 231, 232, 1750, 1751, "5" +370, 15, 68, 415, 233, 234, 1752, 1753, "%" +370, 15, 69, 416, 235, 236, 1754, 1755, "(" +370, 15, 70, 417, 237, 238, 1756, 1757, "-" +370, 15, 71, 418, 239, 240, 1758, 1759, "3" +370, 15, 72, 419, 241, 242, 1760, 1761, "." +370, 15, 73, 420, 243, 245, 1762, 1764, "13" +370, 15, 74, 421, 246, 247, 1765, 1766, "+" +370, 15, 75, 422, 248, 249, 1767, 1768, "/" +370, 15, 76, 423, 250, 251, 1769, 1770, "-" +370, 15, 77, 424, 252, 253, 1771, 1772, "1" +370, 15, 78, 425, 254, 255, 1773, 1774, "." +370, 15, 79, 426, 256, 258, 1775, 1777, "63" +370, 15, 80, 427, 259, 261, 1778, 1780, "vs" +370, 15, 81, 428, 262, 263, 1781, 1782, "." +370, 15, 82, 429, 264, 265, 1783, 1784, "-" +370, 15, 83, 430, 266, 267, 1785, 1786, "2" +370, 15, 84, 431, 268, 269, 1787, 1788, "." +370, 15, 85, 432, 270, 272, 1789, 1791, "60" +370, 15, 86, 433, 273, 274, 1792, 1793, "+" +370, 15, 87, 434, 275, 276, 1794, 1795, "/" +370, 15, 88, 435, 277, 278, 1796, 1797, "-" +370, 15, 89, 436, 279, 280, 1798, 1799, "1" +370, 15, 90, 437, 281, 282, 1800, 1801, "." +370, 15, 91, 438, 283, 285, 1802, 1804, "50" +370, 15, 92, 439, 286, 287, 1805, 1806, "%" +370, 15, 93, 440, 288, 289, 1807, 1808, "," +370, 15, 94, 441, 290, 302, 1809, 1821, "respectively" +370, 15, 95, 442, 303, 304, 1822, 1823, ";" +370, 15, 96, 443, 305, 306, 1824, 1825, "P" +370, 15, 97, 444, 307, 308, 1826, 1827, "<" +370, 15, 98, 445, 309, 310, 1828, 1829, "0" +370, 15, 99, 446, 311, 312, 1830, 1831, "." +370, 15, 100, 447, 313, 315, 1832, 1834, "05" +370, 15, 101, 448, 316, 317, 1835, 1836, ")" +370, 15, 102, 449, 318, 319, 1837, 1838, "." +370, 16, 1, 450, 0, 4, 1839, 1843, "More" +370, 16, 2, 451, 5, 10, 1844, 1849, "BIAsp" +370, 16, 3, 452, 11, 13, 1850, 1852, "70" +370, 16, 4, 453, 14, 15, 1853, 1854, "/" +370, 16, 5, 454, 16, 18, 1855, 1857, "30" +370, 16, 6, 455, 19, 20, 1858, 1859, "-" +370, 16, 7, 456, 21, 28, 1860, 1867, "treated" +370, 16, 8, 457, 29, 37, 1868, 1876, "subjects" +370, 16, 9, 458, 38, 45, 1877, 1884, "reached" +370, 16, 10, 459, 46, 52, 1885, 1891, "target" +370, 16, 11, 460, 53, 56, 1892, 1895, "HbA" +370, 16, 12, 461, 57, 58, 1896, 1897, "(" +370, 16, 13, 462, 59, 61, 1898, 1900, "1c" +370, 16, 14, 463, 62, 63, 1901, 1902, ")" +370, 16, 15, 464, 64, 70, 1903, 1909, "values" +370, 16, 16, 465, 71, 75, 1910, 1914, "than" +370, 16, 17, 466, 76, 84, 1915, 1923, "glargine" +370, 16, 18, 467, 85, 86, 1924, 1925, "-" +370, 16, 19, 468, 87, 94, 1926, 1933, "treated" +370, 16, 20, 469, 95, 103, 1934, 1942, "subjects" +370, 16, 21, 470, 104, 105, 1943, 1944, "(" +370, 16, 22, 471, 106, 109, 1945, 1948, "HbA" +370, 16, 23, 472, 110, 111, 1949, 1950, "(" +370, 16, 24, 473, 112, 114, 1951, 1953, "1c" +370, 16, 25, 474, 115, 116, 1954, 1955, ")" +370, 16, 26, 475, 117, 118, 1956, 1957, "<" +370, 16, 27, 476, 119, 120, 1958, 1959, "/" +370, 16, 28, 477, 121, 122, 1960, 1961, "=" +370, 16, 29, 478, 123, 124, 1962, 1963, "6" +370, 16, 30, 479, 125, 126, 1964, 1965, "." +370, 16, 31, 480, 127, 128, 1966, 1967, "5" +370, 16, 32, 481, 129, 130, 1968, 1969, "%" +370, 16, 33, 482, 131, 132, 1970, 1971, ":" +370, 16, 34, 483, 133, 135, 1972, 1974, "42" +370, 16, 35, 484, 136, 138, 1975, 1977, "vs" +370, 16, 36, 485, 139, 140, 1978, 1979, "." +370, 16, 37, 486, 141, 143, 1980, 1982, "28" +370, 16, 38, 487, 144, 145, 1983, 1984, "%" +370, 16, 39, 488, 146, 147, 1985, 1986, "," +370, 16, 40, 489, 148, 149, 1987, 1988, "P" +370, 16, 41, 490, 150, 151, 1989, 1990, "<" +370, 16, 42, 491, 152, 153, 1991, 1992, "0" +370, 16, 43, 492, 154, 155, 1993, 1994, "." +370, 16, 44, 493, 156, 158, 1995, 1997, "05" +370, 16, 45, 494, 159, 160, 1998, 1999, ";" +370, 16, 46, 495, 161, 164, 2000, 2003, "HbA" +370, 16, 47, 496, 165, 166, 2004, 2005, "(" +370, 16, 48, 497, 167, 169, 2006, 2008, "1c" +370, 16, 49, 498, 170, 171, 2009, 2010, ")" +370, 16, 50, 499, 172, 173, 2011, 2012, "<" +370, 16, 51, 500, 174, 175, 2013, 2014, "7" +370, 16, 52, 501, 176, 177, 2015, 2016, "." +370, 16, 53, 502, 178, 179, 2017, 2018, "0" +370, 16, 54, 503, 180, 181, 2019, 2020, "%" +370, 16, 55, 504, 182, 183, 2021, 2022, ":" +370, 16, 56, 505, 184, 186, 2023, 2025, "66" +370, 16, 57, 506, 187, 189, 2026, 2028, "vs" +370, 16, 58, 507, 190, 191, 2029, 2030, "." +370, 16, 59, 508, 192, 194, 2031, 2033, "40" +370, 16, 60, 509, 195, 196, 2034, 2035, "%" +370, 16, 61, 510, 197, 198, 2036, 2037, "," +370, 16, 62, 511, 199, 200, 2038, 2039, "P" +370, 16, 63, 512, 201, 202, 2040, 2041, "<" +370, 16, 64, 513, 203, 204, 2042, 2043, "0" +370, 16, 65, 514, 205, 206, 2044, 2045, "." +370, 16, 66, 515, 207, 210, 2046, 2049, "001" +370, 16, 67, 516, 211, 212, 2050, 2051, ")" +370, 16, 68, 517, 213, 214, 2052, 2053, "." +370, 17, 1, 518, 0, 5, 2054, 2059, "Minor" +370, 17, 2, 519, 6, 18, 2060, 2072, "hypoglycemia" +370, 17, 3, 520, 19, 20, 2073, 2074, "(" +370, 17, 4, 521, 21, 29, 2075, 2083, "episodes" +370, 17, 5, 522, 30, 31, 2084, 2085, "/" +370, 17, 6, 523, 32, 36, 2086, 2090, "year" +370, 17, 7, 524, 37, 38, 2091, 2092, ")" +370, 17, 8, 525, 39, 42, 2093, 2096, "was" +370, 17, 9, 526, 43, 50, 2097, 2104, "greater" +370, 17, 10, 527, 51, 53, 2105, 2107, "in" +370, 17, 11, 528, 54, 57, 2108, 2111, "the" +370, 17, 12, 529, 58, 63, 2112, 2117, "BIAsp" +370, 17, 13, 530, 64, 66, 2118, 2120, "70" +370, 17, 14, 531, 67, 68, 2121, 2122, "/" +370, 17, 15, 532, 69, 71, 2123, 2125, "30" +370, 17, 16, 533, 72, 77, 2126, 2131, "group" +370, 17, 17, 534, 78, 82, 2132, 2136, "than" +370, 17, 18, 535, 83, 85, 2137, 2139, "in" +370, 17, 19, 536, 86, 89, 2140, 2143, "the" +370, 17, 20, 537, 90, 98, 2144, 2152, "glargine" +370, 17, 21, 538, 99, 104, 2153, 2158, "group" +370, 17, 22, 539, 105, 106, 2159, 2160, "(" +370, 17, 23, 540, 107, 108, 2161, 2162, "3" +370, 17, 24, 541, 109, 110, 2163, 2164, "." +370, 17, 25, 542, 111, 112, 2165, 2166, "4" +370, 17, 26, 543, 113, 114, 2167, 2168, "+" +370, 17, 27, 544, 115, 116, 2169, 2170, "/" +370, 17, 28, 545, 117, 118, 2171, 2172, "-" +370, 17, 29, 546, 119, 120, 2173, 2174, "6" +370, 17, 30, 547, 121, 122, 2175, 2176, "." +370, 17, 31, 548, 123, 124, 2177, 2178, "6" +370, 17, 32, 549, 125, 128, 2179, 2182, "and" +370, 17, 33, 550, 129, 130, 2183, 2184, "0" +370, 17, 34, 551, 131, 132, 2185, 2186, "." +370, 17, 35, 552, 133, 134, 2187, 2188, "7" +370, 17, 36, 553, 135, 136, 2189, 2190, "+" +370, 17, 37, 554, 137, 138, 2191, 2192, "/" +370, 17, 38, 555, 139, 140, 2193, 2194, "-" +370, 17, 39, 556, 141, 142, 2195, 2196, "2" +370, 17, 40, 557, 143, 144, 2197, 2198, "." +370, 17, 41, 558, 145, 146, 2199, 2200, "0" +370, 17, 42, 559, 147, 148, 2201, 2202, "," +370, 17, 43, 560, 149, 161, 2203, 2215, "respectively" +370, 17, 44, 561, 162, 163, 2216, 2217, ";" +370, 17, 45, 562, 164, 165, 2218, 2219, "P" +370, 17, 46, 563, 166, 167, 2220, 2221, "<" +370, 17, 47, 564, 168, 169, 2222, 2223, "0" +370, 17, 48, 565, 170, 171, 2224, 2225, "." +370, 17, 49, 566, 172, 174, 2226, 2228, "05" +370, 17, 50, 567, 175, 176, 2229, 2230, ")" +370, 17, 51, 568, 177, 178, 2231, 2232, "." +370, 18, 1, 569, 0, 6, 2233, 2239, "Weight" +370, 18, 2, 570, 7, 11, 2240, 2244, "gain" +370, 18, 3, 571, 12, 15, 2245, 2248, "and" +370, 18, 4, 572, 16, 21, 2249, 2254, "daily" +370, 18, 5, 573, 22, 29, 2255, 2262, "insulin" +370, 18, 6, 574, 30, 34, 2263, 2267, "dose" +370, 18, 7, 575, 35, 37, 2268, 2270, "at" +370, 18, 8, 576, 38, 43, 2271, 2276, "study" +370, 18, 9, 577, 44, 47, 2277, 2280, "end" +370, 18, 10, 578, 48, 52, 2281, 2285, "were" +370, 18, 11, 579, 53, 60, 2286, 2293, "greater" +370, 18, 12, 580, 61, 64, 2294, 2297, "for" +370, 18, 13, 581, 65, 70, 2298, 2303, "BIAsp" +370, 18, 14, 582, 71, 73, 2304, 2306, "70" +370, 18, 15, 583, 74, 75, 2307, 2308, "/" +370, 18, 16, 584, 76, 78, 2309, 2311, "30" +370, 18, 17, 585, 79, 80, 2312, 2313, "-" +370, 18, 18, 586, 81, 88, 2314, 2321, "treated" +370, 18, 19, 587, 89, 97, 2322, 2330, "subjects" +370, 18, 20, 588, 98, 102, 2331, 2335, "than" +370, 18, 21, 589, 103, 106, 2336, 2339, "for" +370, 18, 22, 590, 107, 115, 2340, 2348, "glargine" +370, 18, 23, 591, 116, 117, 2349, 2350, "-" +370, 18, 24, 592, 118, 125, 2351, 2358, "treated" +370, 18, 25, 593, 126, 134, 2359, 2367, "subjects" +370, 18, 26, 594, 135, 136, 2368, 2369, "(" +370, 18, 27, 595, 137, 143, 2370, 2376, "weight" +370, 18, 28, 596, 144, 148, 2377, 2381, "gain" +370, 18, 29, 597, 149, 150, 2382, 2383, ":" +370, 18, 30, 598, 151, 152, 2384, 2385, "5" +370, 18, 31, 599, 153, 154, 2386, 2387, "." +370, 18, 32, 600, 155, 156, 2388, 2389, "4" +370, 18, 33, 601, 157, 158, 2390, 2391, "+" +370, 18, 34, 602, 159, 160, 2392, 2393, "/" +370, 18, 35, 603, 161, 162, 2394, 2395, "-" +370, 18, 36, 604, 163, 164, 2396, 2397, "4" +370, 18, 37, 605, 165, 166, 2398, 2399, "." +370, 18, 38, 606, 167, 168, 2400, 2401, "8" +370, 18, 39, 607, 169, 171, 2402, 2404, "vs" +370, 18, 40, 608, 172, 173, 2405, 2406, "." +370, 18, 41, 609, 174, 175, 2407, 2408, "3" +370, 18, 42, 610, 176, 177, 2409, 2410, "." +370, 18, 43, 611, 178, 179, 2411, 2412, "5" +370, 18, 44, 612, 180, 181, 2413, 2414, "+" +370, 18, 45, 613, 182, 183, 2415, 2416, "/" +370, 18, 46, 614, 184, 185, 2417, 2418, "-" +370, 18, 47, 615, 186, 187, 2419, 2420, "4" +370, 18, 48, 616, 188, 189, 2421, 2422, "." +370, 18, 49, 617, 190, 191, 2423, 2424, "5" +370, 18, 50, 618, 192, 194, 2425, 2427, "kg" +370, 18, 51, 619, 195, 196, 2428, 2429, "," +370, 18, 52, 620, 197, 198, 2430, 2431, "P" +370, 18, 53, 621, 199, 200, 2432, 2433, "<" +370, 18, 54, 622, 201, 202, 2434, 2435, "0" +370, 18, 55, 623, 203, 204, 2436, 2437, "." +370, 18, 56, 624, 205, 207, 2438, 2440, "01" +370, 18, 57, 625, 208, 209, 2441, 2442, ";" +370, 18, 58, 626, 210, 217, 2443, 2450, "insulin" +370, 18, 59, 627, 218, 222, 2451, 2455, "dose" +370, 18, 60, 628, 223, 224, 2456, 2457, ":" +370, 18, 61, 629, 225, 227, 2458, 2460, "78" +370, 18, 62, 630, 228, 229, 2461, 2462, "." +370, 18, 63, 631, 230, 231, 2463, 2464, "5" +370, 18, 64, 632, 232, 233, 2465, 2466, "+" +370, 18, 65, 633, 234, 235, 2467, 2468, "/" +370, 18, 66, 634, 236, 237, 2469, 2470, "-" +370, 18, 67, 635, 238, 240, 2471, 2473, "39" +370, 18, 68, 636, 241, 242, 2474, 2475, "." +370, 18, 69, 637, 243, 244, 2476, 2477, "5" +370, 18, 70, 638, 245, 248, 2478, 2481, "and" +370, 18, 71, 639, 249, 251, 2482, 2484, "51" +370, 18, 72, 640, 252, 253, 2485, 2486, "." +370, 18, 73, 641, 254, 255, 2487, 2488, "3" +370, 18, 74, 642, 256, 257, 2489, 2490, "+" +370, 18, 75, 643, 258, 259, 2491, 2492, "/" +370, 18, 76, 644, 260, 261, 2493, 2494, "-" +370, 18, 77, 645, 262, 264, 2495, 2497, "26" +370, 18, 78, 646, 265, 266, 2498, 2499, "." +370, 18, 79, 647, 267, 268, 2500, 2501, "7" +370, 18, 80, 648, 269, 274, 2502, 2507, "units" +370, 18, 81, 649, 275, 276, 2508, 2509, "/" +370, 18, 82, 650, 277, 280, 2510, 2513, "day" +370, 18, 83, 651, 281, 282, 2514, 2515, "," +370, 18, 84, 652, 283, 295, 2516, 2528, "respectively" +370, 18, 85, 653, 296, 297, 2529, 2530, ")" +370, 18, 86, 654, 298, 299, 2531, 2532, "." +370, 19, 1, 655, 0, 11, 2533, 2544, "CONCLUSIONS" +370, 19, 2, 656, 12, 13, 2545, 2546, ":" +370, 19, 3, 657, 14, 16, 2547, 2549, "In" +370, 19, 4, 658, 17, 25, 2550, 2558, "subjects" +370, 19, 5, 659, 26, 30, 2559, 2563, "with" +370, 19, 6, 660, 31, 35, 2564, 2568, "type" +370, 19, 7, 661, 36, 37, 2569, 2570, "2" +370, 19, 8, 662, 38, 46, 2571, 2579, "diabetes" +370, 19, 9, 663, 47, 53, 2580, 2586, "poorly" +370, 19, 10, 664, 54, 64, 2587, 2597, "controlled" +370, 19, 11, 665, 65, 67, 2598, 2600, "on" +370, 19, 12, 666, 68, 72, 2601, 2605, "OADs" +370, 19, 13, 667, 73, 74, 2606, 2607, "," +370, 19, 14, 668, 75, 85, 2608, 2618, "initiating" +370, 19, 15, 669, 86, 93, 2619, 2626, "insulin" +370, 19, 16, 670, 94, 101, 2627, 2634, "therapy" +370, 19, 17, 671, 102, 106, 2635, 2639, "with" +370, 19, 18, 672, 107, 112, 2640, 2645, "twice" +370, 19, 19, 673, 113, 114, 2646, 2647, "-" +370, 19, 20, 674, 115, 120, 2648, 2653, "daily" +370, 19, 21, 675, 121, 126, 2654, 2659, "BIAsp" +370, 19, 22, 676, 127, 129, 2660, 2662, "70" +370, 19, 23, 677, 130, 131, 2663, 2664, "/" +370, 19, 24, 678, 132, 134, 2665, 2667, "30" +370, 19, 25, 679, 135, 138, 2668, 2671, "was" +370, 19, 26, 680, 139, 143, 2672, 2676, "more" +370, 19, 27, 681, 144, 153, 2677, 2686, "effective" +370, 19, 28, 682, 154, 156, 2687, 2689, "in" +370, 19, 29, 683, 157, 166, 2690, 2699, "achieving" +370, 19, 30, 684, 167, 170, 2700, 2703, "HbA" +370, 19, 31, 685, 171, 172, 2704, 2705, "(" +370, 19, 32, 686, 173, 175, 2706, 2708, "1c" +370, 19, 33, 687, 176, 177, 2709, 2710, ")" +370, 19, 34, 688, 178, 185, 2711, 2718, "targets" +370, 19, 35, 689, 186, 190, 2719, 2723, "than" +370, 19, 36, 690, 191, 195, 2724, 2728, "once" +370, 19, 37, 691, 196, 197, 2729, 2730, "-" +370, 19, 38, 692, 198, 203, 2731, 2736, "daily" +370, 19, 39, 693, 204, 212, 2737, 2745, "glargine" +370, 19, 40, 694, 213, 214, 2746, 2747, "," +370, 19, 41, 695, 215, 225, 2748, 2758, "especially" +370, 19, 42, 696, 226, 228, 2759, 2761, "in" +370, 19, 43, 697, 229, 237, 2762, 2770, "subjects" +370, 19, 44, 698, 238, 242, 2771, 2775, "with" +370, 19, 45, 699, 243, 246, 2776, 2779, "HbA" +370, 19, 46, 700, 247, 248, 2780, 2781, "(" +370, 19, 47, 701, 249, 251, 2782, 2784, "1c" +370, 19, 48, 702, 252, 253, 2785, 2786, ")" +370, 19, 49, 703, 254, 255, 2787, 2788, ">" +370, 19, 50, 704, 256, 257, 2789, 2790, "8" +370, 19, 51, 705, 258, 259, 2791, 2792, "." +370, 19, 52, 706, 260, 261, 2793, 2794, "5" +370, 19, 53, 707, 262, 263, 2795, 2796, "%" +370, 19, 54, 708, 264, 265, 2797, 2798, "." +370, 20, 1, 709, 0, 3, 2799, 2802, "DOI" +370, 20, 2, 710, 4, 5, 2803, 2804, ":" +370, 20, 3, 711, 6, 8, 2805, 2807, "10" +370, 20, 4, 712, 9, 10, 2808, 2809, "." +370, 20, 5, 713, 11, 15, 2810, 2814, "2337" +370, 20, 6, 714, 16, 17, 2815, 2816, "/" +370, 20, 7, 715, 18, 25, 2817, 2824, "diacare" +370, 20, 8, 716, 26, 27, 2825, 2826, "." +370, 20, 9, 717, 28, 30, 2827, 2829, "28" +370, 20, 10, 718, 31, 32, 2830, 2831, "." +370, 20, 11, 719, 33, 34, 2832, 2833, "2" +370, 20, 12, 720, 35, 36, 2834, 2835, "." +370, 20, 13, 721, 37, 40, 2836, 2839, "260" +370, 20, 14, 722, 41, 45, 2840, 2844, "PMID" +370, 20, 15, 723, 46, 47, 2845, 2846, ":" +370, 20, 16, 724, 48, 56, 2847, 2855, "15677776" +370, 20, 17, 725, 57, 58, 2856, 2857, "[" +370, 20, 18, 726, 59, 66, 2858, 2865, "Indexed" +370, 20, 19, 727, 67, 70, 2866, 2869, "for" +370, 20, 20, 728, 71, 78, 2870, 2877, "MEDLINE" +370, 20, 21, 729, 79, 80, 2878, 2879, "]" diff --git a/data/dm2 15677776_kwoodley.annodb b/data/dm2 15677776_kwoodley.annodb new file mode 100644 index 0000000..849fadb --- /dev/null +++ b/data/dm2 15677776_kwoodley.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31507, Journal, 0, 15, "Diabetes Care .", "", +2429, PublicationYear, 16, 20, "2005", "", +31508, Title, 48, 148, "Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs .", "", +3718, Insulin, 59, 66, "insulin", "", +2448, Type2Diabetes, 78, 93, "type 2 Diabetes", "", +2479, IsophaneInsulin_NPH, 112, 120, "biphasic", "", +2468, InsulinGlargine, 125, 138, "basal insulin", "", +2433, Author, 149, 157, "Raskin P", "", +2435, Author, 166, 173, "Allen E", "", +2436, Author, 176, 187, "Hollander P", "", +2437, Author, 190, 197, "Lewin A", "", +2439, Author, 200, 209, "Gabbay RA", "", +2441, Author, 212, 216, "Hu P", "", +2443, Author, 219, 225, "Bode B", "", +2445, Author, 228, 236, "Garber A", "", +2458, USA, 390, 393, "USA", "", +31509, ObjectiveDescription, 575, 815, "Safety and efficacy of biphasic insulin aspart 70 / 30 ( BIAsp 70 / 30 , prebreakfast and presupper ) were compared with once - daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs ( OADs ) .", "", +2480, IsophaneInsulin_NPH, 598, 629, "biphasic insulin aspart 70 / 30", "", +2482, IsophaneInsulin_NPH, 632, 645, "BIAsp 70 / 30", "", +2502, Morning, 648, 660, "prebreakfast", "", +2505, Bedtime, 665, 674, "presupper", "", +2506, Frequency, 696, 708, "once - daily", "", +2469, InsulinGlargine, 709, 725, "insulin glargine", "", +2451, Type2Diabetes, 729, 744, "type 2 diabetic", "", +2459, Precondition, 745, 813, "subjects inadequately controlled on oral antidiabetic drugs ( OADs )", "", +3719, OralAntidiabeticAgent, 781, 804, "oral antidiabetic drugs", "", +3720, OralAntidiabeticAgent, 807, 811, "OADs", "", +2467, Duration, 851, 860, "28 - week", "", +2465, Parallel, 861, 869, "parallel", "", +2466, Randomized, 884, 894, "randomized", "", +2463, NumberPatientsCT, 895, 898, "233", "", +2460, Precondition, 899, 1032, "insulin - naive patients with HbA ( 1c ) values > / = 8 . 0 % on > 1 , 000 mg / day metformin alone or in combination with other OADs", "", +2507, HbA1c, 929, 939, "HbA ( 1c )", "", +2509, Percentage, 959, 960, "%", "", +31512, DoseValue, 961, 973, "on > 1 , 000", "could not annotate without "on"", +31510, mg, 974, 976, "mg", "", +31511, Frequency, 979, 982, "day", "", +3721, Metformin, 983, 992, "metformin", "", +3722, OralAntidiabeticAgent, 1028, 1032, "OADs", "", +3723, Metformin, 1035, 1044, "Metformin", "", +3724, DoseValue, 1064, 1071, "2 , 550", "", +3725, mg, 1072, 1074, "mg", "", +31513, Frequency, 1077, 1080, "day", "", +31514, Insulin, 1088, 1095, "insulin", "", +31515, DoseValue, 1123, 1128, "5 - 6", "", +31516, BioAndMedicalUnit, 1129, 1134, "units", "", +2485, IsophaneInsulin_NPH, 1135, 1148, "BIAsp 70 / 30", "", +2514, Frequency, 1149, 1160, "twice daily", "", +31517, DoseValue, 1164, 1171, "10 - 12", "", +31518, BioAndMedicalUnit, 1172, 1177, "units", "", +2470, InsulinGlargine, 1178, 1186, "glargine", "", +2517, Bedtime, 1190, 1197, "bedtime", "", +32337, FastingBloodGlucose_target, 1214, 1255, "target blood glucose ( 80 - 110 mg / dl )", "", +3726, FinalNumPatientsCT, 1313, 1316, "209", "", +2522, HbA1c, 1372, 1382, "HbA ( 1c )", "", +2486, IsophaneInsulin_NPH, 1406, 1419, "BIAsp 70 / 30", "", +2471, InsulinGlargine, 1438, 1446, "glargine", "", +2524, ResultMeasuredValue, 1455, 1461, "6 . 91", "", +2527, SdErrorResValue, 1468, 1474, "1 . 17", "", +2526, ResultMeasuredValue, 1480, 1486, "7 . 41", "", +2529, SdErrorResValue, 1493, 1499, "1 . 24", "", +2531, Percentage, 1500, 1501, "%", "", +2533, PvalueDiff, 1504, 1514, "P < 0 . 01", "", +2535, HbA1c, 1523, 1533, "HbA ( 1c )", "", +2488, IsophaneInsulin_NPH, 1563, 1576, "BIAsp 70 / 30", "", +2472, InsulinGlargine, 1595, 1603, "glargine", "", +2537, Reduction, 1614, 1620, "2 . 79", "", +2541, SdDevChangeValue, 1627, 1633, "0 . 11", "", +2538, Reduction, 1641, 1647, "2 . 36", "", +2542, SdDevChangeValue, 1654, 1660, "0 . 11", "", +2609, Percentage, 1661, 1662, "%", "", +2544, PvalueDiff, 1680, 1690, "P < 0 . 01", "", +2546, SubGroupDescription, 1710, 1753, "subjects with baseline HbA ( 1c ) > 8 . 5 %", "", +2548, HbA1c, 1733, 1743, "HbA ( 1c )", "", +2549, BaseLineValue, 1744, 1751, "> 8 . 5", "", +2550, Percentage, 1752, 1753, "%", "", +2551, Reduction, 1758, 1764, "3 . 13", "", +2553, SdDevChangeValue, 1771, 1777, "1 . 63", "", +2552, Reduction, 1785, 1791, "2 . 60", "", +2554, SdDevChangeValue, 1798, 1804, "1 . 50", "", +2555, Percentage, 1805, 1806, "%", "", +2556, PvalueDiff, 1824, 1834, "P < 0 . 05", "", +2490, IsophaneInsulin_NPH, 1844, 1857, "BIAsp 70 / 30", "", +2557, HbA1c, 1892, 1902, "HbA ( 1c )", "", +2473, InsulinGlargine, 1915, 1923, "glargine", "", +31519, HbA1c_target, 1945, 1969, "HbA ( 1c ) < / = 6 . 5 %", "", +2563, PercentageAffected, 1972, 1974, "42", "", +2565, PercentageAffected, 1980, 1982, "28", "", +2560, PvalueDiff, 1987, 1997, "P < 0 . 05", "", +31520, HbA1c_target, 2000, 2020, "HbA ( 1c ) < 7 . 0 %", "", +2566, PercentageAffected, 2023, 2025, "66", "", +2567, PercentageAffected, 2031, 2033, "40", "", +2561, PvalueDiff, 2038, 2049, "P < 0 . 001", "", +2569, Hypoglycemia, 2060, 2072, "hypoglycemia", "", +2491, IsophaneInsulin_NPH, 2112, 2125, "BIAsp 70 / 30", "", +2474, InsulinGlargine, 2144, 2152, "glargine", "", +2571, ResultMeasuredValue, 2161, 2166, "3 . 4", "", +2574, SdErrorResValue, 2173, 2178, "6 . 6", "", +2573, ResultMeasuredValue, 2183, 2188, "0 . 7", "", +2575, SdErrorResValue, 2195, 2200, "2 . 0", "", +2576, PvalueDiff, 2218, 2228, "P < 0 . 05", "", +2577, BodyWeight, 2233, 2239, "Weight", "", +31521, InsulinDose, 2255, 2267, "insulin dose", "", +2493, IsophaneInsulin_NPH, 2298, 2311, "BIAsp 70 / 30", "", +2475, InsulinGlargine, 2340, 2348, "glargine", "", +2580, BodyWeight, 2370, 2376, "weight", "", +2581, Increment, 2384, 2389, "5 . 4", "", +2583, SdErrorResValue, 2396, 2401, "4 . 8", "", +2582, Increment, 2407, 2412, "3 . 5", "", +2584, SdErrorResValue, 2419, 2424, "4 . 5", "", +2585, Kg, 2425, 2427, "kg", "", +2586, PvalueDiff, 2430, 2440, "P < 0 . 01", "", +31522, InsulinDose, 2443, 2455, "insulin dose", "", +2593, ResultMeasuredValue, 2458, 2464, "78 . 5", "", +2597, SdErrorResValue, 2471, 2477, "39 . 5", "", +2595, ResultMeasuredValue, 2482, 2488, "51 . 3", "", +2599, SdErrorResValue, 2495, 2501, "26 . 7", "", +31523, BioAndMedicalUnit, 2502, 2513, "units / day", "", +31524, ConclusionComment, 2547, 2798, "In subjects with type 2 diabetes poorly controlled on OADs , initiating insulin therapy with twice - daily BIAsp 70 / 30 was more effective in achieving HbA ( 1c ) targets than once - daily glargine , especially in subjects with HbA ( 1c ) > 8 . 5 % .", "", +2461, Precondition, 2550, 2605, "subjects with type 2 diabetes poorly controlled on OADs", "", +2455, Type2Diabetes, 2564, 2579, "type 2 diabetes", "", +3727, OralAntidiabeticAgent, 2601, 2605, "OADs", "", +3728, Insulin, 2619, 2626, "insulin", "", +2602, Frequency, 2640, 2653, "twice - daily", "", +2495, IsophaneInsulin_NPH, 2654, 2667, "BIAsp 70 / 30", "", +2604, HbA1c_target, 2700, 2718, "HbA ( 1c ) targets", "", +2612, Frequency, 2724, 2736, "once - daily", "", +2478, InsulinGlargine, 2737, 2745, "glargine", "", +2605, HbA1c, 2776, 2786, "HbA ( 1c )", "", +2606, Percentage, 2795, 2796, "%", "", +2447, PMID, 2847, 2855, "15677776", "", diff --git a/data/dm2 15677776_kwoodley.n-triples b/data/dm2 15677776_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15677776_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15715892_admin.annodb b/data/dm2 15715892_admin.annodb new file mode 100644 index 0000000..7a69687 --- /dev/null +++ b/data/dm2 15715892_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +153, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +0, PublicationYear, 22, 26, "2005", "", " \"2005\"." +154, Title, 54, 150, "Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes .", "", " \"Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes .\"." +18, Metformin, 65, 74, "metformin", "", +25, Precondition, 102, 148, "subjects with risk factors for type 2 diabetes", "", +11, Type2Diabetes, 133, 148, "type 2 diabetes", "", +1, Author, 151, 177, "Rodr í guez - Moctezuma JR", "", +2, Author, 186, 204, "Robles - L ó pez G", "", " \"Robles - L ó pez G\"." +3, Author, 207, 227, "L ó pez - Carmona JM", "", " \"L ó pez - Carmona JM\"." +4, Author, 230, 252, "Guti é rrez - Rosas MJ", "", " \"Guti é rrez - Rosas MJ\"." +6, Mexico, 352, 358, "Mexico", "", " ." +155, ObjectiveDescription, 402, 572, "To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM ) .", "", " \"To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM ) .\"." +8, Metformin, 427, 436, "metformin", "", +40591, EndPointDescription, 463, 481, "insulin resistance", "", +72, Insulin, 463, 470, "insulin", "", +7, Precondition, 501, 570, "subjects with risk factors for type 2 diabetes mellitus ( type 2 DM )", "", " \"subjects with risk factors for type 2 diabetes mellitus ( type 2 DM )\"." +12, Type2Diabetes, 532, 556, "type 2 diabetes mellitus", "", " ." +13, Type2Diabetes, 559, 568, "type 2 DM", "", +87, Placebo, 582, 589, "Placebo", "", +10, NumberPatientsCT, 643, 657, "Twenty - three", "", " \"Twenty - three\"." +9, Precondition, 658, 698, "subjects with risk factors for type 2 DM", "", +14, Type2Diabetes, 689, 698, "type 2 DM", "", +16, Randomized, 704, 712, "randomly", "", " ." +26, DoseValue, 733, 736, "850", "", " \"850\"." +27, mg, 737, 739, "mg", "", " ." +19, Metformin, 743, 752, "metformin", "", +28, Placebo, 758, 765, "placebo", "", " ." +29, Frequency, 766, 777, "twice a day", "", " \"twice a day\". \"twice a day\"." +17, Duration, 782, 790, "2 months", "", " \"2 months\"." +32, BMI, 830, 845, "body mass index", "", +40537, MeasurementDevice, 928, 949, "bioelectric impedance", "", +157, FastingBloodGlucose, 958, 989, "fasting levels of blood glucose", "", +33, Insulin, 992, 999, "insulin", "", +142, EndPointDescription, 1002, 1031, "triglycerides and cholesterol", "", +63, EndPointDescription, 1061, 1079, "insulin resistance", "", +34, MeasurementDevice, 1102, 1119, "homeostatic model", "", +35, MeasurementDevice, 1156, 1207, "quantitative insulin sensitivity check index method", "", +36, MeasurementDevice, 1214, 1232, "Wilcoxon rank test", "", +73, FinalNumPatientsCT, 1254, 1266, "Twenty - one", "", " \"Twenty - one\"." +30, FinalNumPatientsArm, 1298, 1300, "12", "", " \"12\"." +20, Metformin, 1308, 1317, "metformin", "", +31, FinalNumPatientsArm, 1328, 1332, "nine", "", " \"nine\"." +37, Placebo, 1340, 1347, "placebo", "", +21, Metformin, 1363, 1372, "metformin", "", +40590, EndPointDescription, 1405, 1415, "fat weight", "", " . ." +38, BaseLineValue, 1421, 1427, "25 . 9", "", " \"25 . 9\"." +39, SdDevBL, 1434, 1439, "9 . 4", "", " \"9 . 4\"." +41, ResultMeasuredValue, 1443, 1449, "20 . 8", "", " \"20 . 8\"." +40, SdDevResValue, 1456, 1461, "9 . 2", "", " \"9 . 2\"." +42, Kg, 1462, 1464, "kg", "", " ." +110, PValueChangeValue, 1467, 1477, "p < 0 . 01", "", " \"p < 0 . 01\"." +111, EndPointDescription, 1495, 1506, "lean weight", "", " . ." +46, BaseLineValue, 1512, 1519, "57 . 05", "", " \"57 . 05\"." +52, SdDevBL, 1526, 1532, "13 . 6", "", " \"13 . 6\"." +47, ResultMeasuredValue, 1536, 1542, "61 . 9", "", " \"61 . 9\"." +48, SdDevResValue, 1549, 1555, "16 . 5", "", " \"16 . 5\"." +49, Kg, 1556, 1558, "kg", "", " ." +115, PValueChangeValue, 1561, 1571, "p < 0 . 01", "", " \"p < 0 . 01\"." +51, EndPointDescription, 1589, 1605, "basal metabolism", "", " . ." +53, BaseLineValue, 1611, 1615, "1735", "", " \"13 . 6\"." +54, SdDevBL, 1622, 1625, "413", "", " \"413\"." +55, ResultMeasuredValue, 1629, 1633, "1878", "", " \"1878\"." +57, SdDevResValue, 1640, 1643, "505", "", " \"505\"." +58, BioAndMedicalUnit, 1644, 1658, "calories / day", "", " . ." +120, PValueChangeValue, 1661, 1671, "p < 0 . 05", "", " \"p < 0 . 05\"." +122, ObservedResult, 1679, 1687, "increase", "", " \"increase\"." +59, EndPointDescription, 1691, 1701, "body water", "", " . ." +123, PValueChangeValue, 1704, 1714, "p < 0 . 05", "", " \"p < 0 . 05\"." +160, ObservedResult, 1717, 1750, "There was no significant decrease", "", " \"There was no significant decrease\"." +62, EndPointDescription, 1754, 1772, "insulin resistance", "", " . ." +64, Placebo, 1782, 1789, "placebo", "", +161, BloodGlucose, 1802, 1815, "blood glucose", "", " ." +65, BaseLineValue, 1831, 1837, "84 . 7", "", " \"84 . 7\"." +66, SdDevBL, 1844, 1846, "13", "", " \"13\"." +67, ResultMeasuredValue, 1850, 1856, "96 . 7", "", " \"96 . 7\"." +68, SdDevResValue, 1863, 1865, "16", "", " \"16\"." +69, Mg_per_deciliter, 1866, 1873, "mg / dl", "", " ." +144, PValueChangeValue, 1876, 1886, "p < 0 . 05", "", " \"p < 0 . 05\"." +163, ObservedResult, 1889, 1928, "There were no significant modifications", "", " \"There were no significant modifications\"." +137, EndPointDescription, 1932, 1938, "lipids", "", " . ." +164, ConclusionComment, 1955, 2110, "The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM .", "", " \"The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM .\"." +22, Metformin, 1977, 1986, "metformin", "", +23, Duration, 1991, 1999, "2 months", "", +71, Insulin, 2048, 2055, "insulin", "", +24, Precondition, 2068, 2108, "subjects with risk factors for type 2 DM", "", +15, Type2Diabetes, 2099, 2108, "type 2 DM", "", +5, PMID, 2171, 2179, "15715892", "", " \"15715892\"." diff --git a/data/dm2 15715892_admin.n-triples b/data/dm2 15715892_admin.n-triples new file mode 100644 index 0000000..e0ae5d7 --- /dev/null +++ b/data/dm2 15715892_admin.n-triples @@ -0,0 +1,175 @@ +# RDF export of group: Publication + . + "Publication_1" . + "Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes ." . + "2005" . + "Diabetes Obes Metab ." . + "15715892" . + . + "Robles - L ó pez G" . + "L ó pez - Carmona JM" . + "Guti é rrez - Rosas MJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM ) ." . + "Twenty - three" . + "2 months" . + . + . + . + "The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM ." . + . + . + . + . + . + "Twenty - one" . + . +# RDF export of group: Population + . + "Population " . + "subjects with risk factors for type 2 diabetes mellitus ( type 2 DM )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint fw" . + . + . + . + . + . + . + "Endpoint lw" . + . + . + . + . + . + . + "Endpoint bm" . + . + . + . + . + . + . + . + "Endpoint body water" . + . + . + . + . + . + . + "Endpoint insulin resistance" . + . + . + . + . + . + . + "Endpoint blood glucose" . + . + . + . + . + . + "Endpoint lipids" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm m" . + "12" . + . + . + . + . + . + . + . + . + "Arm p" . + "nine" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention m" . + . + "twice a day" . + . + . + "Intervention p" . + . + "twice a day" . + . +# RDF export of group: Medication + . + "Medication m" . + . + "850" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome fw m" . + . + "25 . 9" . + "9 . 4" . + "20 . 8" . + "9 . 2" . + "p < 0 . 01" . + . + "Outcome lw m" . + . + "57 . 05" . + "13 . 6" . + "61 . 9" . + "16 . 5" . + "p < 0 . 01" . + . + "Outcome bm m" . + . + "1735" . + "413" . + "1878" . + "505" . + "p < 0 . 05" . + . + "Outcome body water m" . + . + "p < 0 . 05" . + "increase" . + . + "Outcome insulin resistance both drugs" . + . + "There was no significant decrease" . + . + "Outcome blood glucose p " . + . + "84 . 7" . + "13" . + "96 . 7" . + "16" . + "p < 0 . 05" . + . + "Outcome lipids both drugs" . + . + "There were no significant modifications" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15715892_akramersunderbrink.annodb b/data/dm2 15715892_akramersunderbrink.annodb new file mode 100644 index 0000000..bc02c1d --- /dev/null +++ b/data/dm2 15715892_akramersunderbrink.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7338, Journal, 0, 19, "Diabetes Obes Metab", "", +7339, PublicationYear, 22, 26, "2005", "", +7340, Title, 54, 148, "Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes", "", +7341, Metformin, 65, 74, "metformin", "", +7342, Type2Diabetes, 133, 148, "type 2 diabetes", "", +7343, Author, 151, 177, "Rodr í guez - Moctezuma JR", "", +7344, Author, 186, 204, "Robles - L ó pez G", "", +7345, Author, 207, 227, "L ó pez - Carmona JM", "", +7346, Author, 230, 252, "Guti é rrez - Rosas MJ", "", +39107, Mexico, 352, 358, "Mexico", "", +7347, ObjectiveDescription, 402, 570, "To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM )", "", +7348, Metformin, 427, 436, "metformin", "", +7349, Insulin, 463, 470, "insulin", "", +7350, Type2Diabetes, 532, 570, "type 2 diabetes mellitus ( type 2 DM )", "", +7351, Placebo, 582, 589, "Placebo", "", +7352, NumberPatientsCT, 643, 657, "Twenty - three", "", +7353, Type2Diabetes, 689, 698, "type 2 DM", "", +7354, Randomized, 704, 712, "randomly", "", +7357, DoseValue, 733, 736, "850", "", +7358, mg, 737, 739, "mg", "", +7355, Metformin, 743, 752, "metformin", "", +7356, Placebo, 758, 765, "placebo", "", +7359, Frequency, 766, 777, "twice a day", "", +7360, Duration, 782, 790, "2 months", "", +7361, BMI, 830, 845, "body mass index", "", +7427, EndPointDescription, 850, 867, "waist / hip ratio", "", +7430, EndPointDescription, 928, 949, "bioelectric impedance", "", +7362, FastingPlasmaGlucose, 958, 989, "fasting levels of blood glucose", "", +7363, Insulin, 992, 999, "insulin", "", +7432, EndPointDescription, 1002, 1015, "triglycerides", "", +7435, EndPointDescription, 1020, 1031, "cholesterol", "", +7423, EndPointDescription, 1061, 1079, "insulin resistance", "", +7364, FinalNumPatientsCT, 1254, 1266, "Twenty - one", "", +7365, NumberPatientsArm, 1298, 1300, "12", "", +7366, Metformin, 1308, 1317, "metformin", "", +7367, NumberPatientsArm, 1328, 1332, "nine", "", +7368, Placebo, 1340, 1347, "placebo", "", +7369, Metformin, 1363, 1372, "metformin", "", +7370, EndPointDescription, 1405, 1415, "fat weight", "", +7376, BaseLineValue, 1421, 1427, "25 . 9", "", +11074, SdDevBL, 1428, 1439, "+ / - 9 . 4", "", +7378, ResultMeasuredValue, 1443, 1449, "20 . 8", "", +11075, SdDevResValue, 1450, 1461, "+ / - 9 . 2", "", +7375, Kg, 1462, 1464, "kg", "", +7379, PValueChangeValue, 1467, 1477, "p < 0 . 01", "", +7380, EndPointDescription, 1495, 1506, "lean weight", "", +7381, BaseLineValue, 1512, 1519, "57 . 05", "", +11073, SdDevBL, 1520, 1532, "+ / - 13 . 6", "", +7383, ResultMeasuredValue, 1536, 1542, "61 . 9", "", +11076, SdDevResValue, 1543, 1555, "+ / - 16 . 5", "", +7385, Kg, 1556, 1558, "kg", "", +7386, PValueChangeValue, 1561, 1571, "p < 0 . 01", "", +7387, EndPointDescription, 1589, 1605, "basal metabolism", "", +7388, BaseLineValue, 1611, 1615, "1735", "", +11077, SdDevBL, 1616, 1625, "+ / - 413", "", +7390, ResultMeasuredValue, 1629, 1633, "1878", "", +11078, SdDevResValue, 1634, 1643, "+ / - 505", "", +7392, BioAndMedicalUnit, 1644, 1658, "calories / day", "", +7393, PValueChangeValue, 1661, 1671, "p < 0 . 05", "", +7395, ObservedResult, 1679, 1687, "increase", "", +7394, EndPointDescription, 1691, 1701, "body water", "", +7396, PValueChangeValue, 1704, 1714, "p < 0 . 05", "", +7397, ObservedResult, 1727, 1750, "no significant decrease", "", +7398, EndPointDescription, 1754, 1772, "insulin resistance", "", +7399, Placebo, 1782, 1789, "placebo", "", +7400, FastingPlasmaGlucose, 1802, 1815, "blood glucose", "", +7401, BaseLineValue, 1831, 1837, "84 . 7", "", +11079, SdDevBL, 1838, 1846, "+ / - 13", "", +7403, ResultMeasuredValue, 1850, 1856, "96 . 7", "", +11080, SdDevResValue, 1857, 1865, "+ / - 16", "", +7405, Mg_per_deciliter, 1866, 1873, "mg / dl", "", +7802, PValueChangeValue, 1876, 1886, "p < 0 . 05", "", +7420, ObservedResult, 1900, 1928, "no significant modifications", "", +7417, EndPointDescription, 1932, 1938, "lipids", "", +7407, ConclusionComment, 1955, 2108, "The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM", "", +7409, Metformin, 1977, 1986, "metformin", "", +7411, Duration, 1991, 1999, "2 months", "", +7412, Insulin, 2048, 2055, "insulin", "", +7413, Type2Diabetes, 2099, 2108, "type 2 DM", "", +7414, PMID, 2171, 2179, "15715892", "", diff --git a/data/dm2 15715892_akramersunderbrink.n-triples b/data/dm2 15715892_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15715892_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15715892_export.csv b/data/dm2 15715892_export.csv new file mode 100644 index 0000000..ff6559c --- /dev/null +++ b/data/dm2 15715892_export.csv @@ -0,0 +1,479 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +369, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +369, 1, 2, 2, 9, 13, 9, 13, "Obes" +369, 1, 3, 3, 14, 19, 14, 19, "Metab" +369, 1, 4, 4, 20, 21, 20, 21, "." +369, 2, 1, 5, 0, 4, 22, 26, "2005" +369, 2, 2, 6, 5, 8, 27, 30, "Mar" +369, 2, 3, 7, 9, 10, 31, 32, ";" +369, 2, 4, 8, 11, 12, 33, 34, "7" +369, 2, 5, 9, 13, 14, 35, 36, "(" +369, 2, 6, 10, 15, 16, 37, 38, "2" +369, 2, 7, 11, 17, 18, 39, 40, ")" +369, 2, 8, 12, 19, 20, 41, 42, ":" +369, 2, 9, 13, 21, 24, 43, 46, "189" +369, 2, 10, 14, 25, 26, 47, 48, "-" +369, 2, 11, 15, 27, 29, 49, 51, "92" +369, 2, 12, 16, 30, 31, 52, 53, "." +369, 3, 1, 17, 0, 7, 54, 61, "Effects" +369, 3, 2, 18, 8, 10, 62, 64, "of" +369, 3, 3, 19, 11, 20, 65, 74, "metformin" +369, 3, 4, 20, 21, 23, 75, 77, "on" +369, 3, 5, 21, 24, 27, 78, 81, "the" +369, 3, 6, 22, 28, 32, 82, 86, "body" +369, 3, 7, 23, 33, 44, 87, 98, "composition" +369, 3, 8, 24, 45, 47, 99, 101, "in" +369, 3, 9, 25, 48, 56, 102, 110, "subjects" +369, 3, 10, 26, 57, 61, 111, 115, "with" +369, 3, 11, 27, 62, 66, 116, 120, "risk" +369, 3, 12, 28, 67, 74, 121, 128, "factors" +369, 3, 13, 29, 75, 78, 129, 132, "for" +369, 3, 14, 30, 79, 83, 133, 137, "type" +369, 3, 15, 31, 84, 85, 138, 139, "2" +369, 3, 16, 32, 86, 94, 140, 148, "diabetes" +369, 3, 17, 33, 95, 96, 149, 150, "." +369, 4, 1, 34, 0, 4, 151, 155, "Rodr" +369, 4, 2, 35, 5, 6, 156, 157, "í" +369, 4, 3, 36, 7, 11, 158, 162, "guez" +369, 4, 4, 37, 12, 13, 163, 164, "-" +369, 4, 5, 38, 14, 23, 165, 174, "Moctezuma" +369, 4, 6, 39, 24, 26, 175, 177, "JR" +369, 4, 7, 40, 27, 28, 178, 179, "(" +369, 4, 8, 41, 29, 30, 180, 181, "1" +369, 4, 9, 42, 31, 32, 182, 183, ")" +369, 4, 10, 43, 33, 34, 184, 185, "," +369, 4, 11, 44, 35, 41, 186, 192, "Robles" +369, 4, 12, 45, 42, 43, 193, 194, "-" +369, 4, 13, 46, 44, 45, 195, 196, "L" +369, 4, 14, 47, 46, 47, 197, 198, "ó" +369, 4, 15, 48, 48, 51, 199, 202, "pez" +369, 4, 16, 49, 52, 53, 203, 204, "G" +369, 4, 17, 50, 54, 55, 205, 206, "," +369, 4, 18, 51, 56, 57, 207, 208, "L" +369, 4, 19, 52, 58, 59, 209, 210, "ó" +369, 4, 20, 53, 60, 63, 211, 214, "pez" +369, 4, 21, 54, 64, 65, 215, 216, "-" +369, 4, 22, 55, 66, 73, 217, 224, "Carmona" +369, 4, 23, 56, 74, 76, 225, 227, "JM" +369, 4, 24, 57, 77, 78, 228, 229, "," +369, 4, 25, 58, 79, 83, 230, 234, "Guti" +369, 4, 26, 59, 84, 85, 235, 236, "é" +369, 4, 27, 60, 86, 90, 237, 241, "rrez" +369, 4, 28, 61, 91, 92, 242, 243, "-" +369, 4, 29, 62, 93, 98, 244, 249, "Rosas" +369, 4, 30, 63, 99, 101, 250, 252, "MJ" +369, 4, 31, 64, 102, 103, 253, 254, "." +369, 5, 1, 65, 0, 6, 255, 261, "Author" +369, 5, 2, 66, 7, 18, 262, 273, "information" +369, 5, 3, 67, 19, 20, 274, 275, ":" +369, 5, 4, 68, 21, 22, 276, 277, "(" +369, 5, 5, 69, 23, 24, 278, 279, "1" +369, 5, 6, 70, 25, 26, 280, 281, ")" +369, 5, 7, 71, 27, 35, 282, 290, "Hospital" +369, 5, 8, 72, 36, 43, 291, 298, "General" +369, 5, 9, 73, 44, 52, 299, 307, "Regional" +369, 5, 10, 74, 53, 55, 308, 310, "72" +369, 5, 11, 75, 56, 57, 311, 312, "," +369, 5, 12, 76, 58, 67, 313, 322, "Instituto" +369, 5, 13, 77, 68, 76, 323, 331, "Mexicano" +369, 5, 14, 78, 77, 80, 332, 335, "del" +369, 5, 15, 79, 81, 87, 336, 342, "Seguro" +369, 5, 16, 80, 88, 94, 343, 349, "Social" +369, 5, 17, 81, 95, 96, 350, 351, "," +369, 5, 18, 82, 97, 103, 352, 358, "Mexico" +369, 5, 19, 83, 104, 105, 359, 360, "." +369, 6, 1, 84, 0, 6, 361, 367, "rodmoc" +369, 6, 2, 85, 7, 8, 368, 369, "@" +369, 6, 3, 86, 9, 16, 370, 377, "prodigy" +369, 6, 4, 87, 17, 18, 378, 379, "." +369, 6, 5, 88, 19, 22, 380, 383, "net" +369, 6, 6, 89, 23, 24, 384, 385, "." +369, 6, 7, 90, 25, 27, 386, 388, "mx" +369, 6, 8, 91, 28, 38, 389, 399, "OBJECTIVES" +369, 6, 9, 92, 39, 40, 400, 401, ":" +369, 6, 10, 93, 41, 43, 402, 404, "To" +369, 6, 11, 94, 44, 51, 405, 412, "measure" +369, 6, 12, 95, 52, 55, 413, 416, "the" +369, 6, 13, 96, 56, 62, 417, 423, "effect" +369, 6, 14, 97, 63, 65, 424, 426, "of" +369, 6, 15, 98, 66, 75, 427, 436, "metformin" +369, 6, 16, 99, 76, 78, 437, 439, "on" +369, 6, 17, 100, 79, 82, 440, 443, "the" +369, 6, 18, 101, 83, 87, 444, 448, "body" +369, 6, 19, 102, 88, 99, 449, 460, "composition" +369, 6, 20, 103, 100, 101, 461, 462, "," +369, 6, 21, 104, 102, 109, 463, 470, "insulin" +369, 6, 22, 105, 110, 120, 471, 481, "resistance" +369, 6, 23, 106, 121, 124, 482, 485, "and" +369, 6, 24, 107, 125, 136, 486, 497, "sensitivity" +369, 6, 25, 108, 137, 139, 498, 500, "in" +369, 6, 26, 109, 140, 148, 501, 509, "subjects" +369, 6, 27, 110, 149, 153, 510, 514, "with" +369, 6, 28, 111, 154, 158, 515, 519, "risk" +369, 6, 29, 112, 159, 166, 520, 527, "factors" +369, 6, 30, 113, 167, 170, 528, 531, "for" +369, 6, 31, 114, 171, 175, 532, 536, "type" +369, 6, 32, 115, 176, 177, 537, 538, "2" +369, 6, 33, 116, 178, 186, 539, 547, "diabetes" +369, 6, 34, 117, 187, 195, 548, 556, "mellitus" +369, 6, 35, 118, 196, 197, 557, 558, "(" +369, 6, 36, 119, 198, 202, 559, 563, "type" +369, 6, 37, 120, 203, 204, 564, 565, "2" +369, 6, 38, 121, 205, 207, 566, 568, "DM" +369, 6, 39, 122, 208, 209, 569, 570, ")" +369, 6, 40, 123, 210, 211, 571, 572, "." +369, 7, 1, 124, 0, 6, 573, 579, "DESIGN" +369, 7, 2, 125, 7, 8, 580, 581, ":" +369, 7, 3, 126, 9, 16, 582, 589, "Placebo" +369, 7, 4, 127, 17, 18, 590, 591, "-" +369, 7, 5, 128, 19, 29, 592, 602, "controlled" +369, 7, 6, 129, 30, 38, 603, 611, "clinical" +369, 7, 7, 130, 39, 44, 612, 617, "trial" +369, 7, 8, 131, 45, 46, 618, 619, "." +369, 8, 1, 132, 0, 8, 620, 628, "MATERIAL" +369, 8, 2, 133, 9, 12, 629, 632, "AND" +369, 8, 3, 134, 13, 20, 633, 640, "METHODS" +369, 8, 4, 135, 21, 22, 641, 642, ":" +369, 8, 5, 136, 23, 29, 643, 649, "Twenty" +369, 8, 6, 137, 30, 31, 650, 651, "-" +369, 8, 7, 138, 32, 37, 652, 657, "three" +369, 8, 8, 139, 38, 46, 658, 666, "subjects" +369, 8, 9, 140, 47, 51, 667, 671, "with" +369, 8, 10, 141, 52, 56, 672, 676, "risk" +369, 8, 11, 142, 57, 64, 677, 684, "factors" +369, 8, 12, 143, 65, 68, 685, 688, "for" +369, 8, 13, 144, 69, 73, 689, 693, "type" +369, 8, 14, 145, 74, 75, 694, 695, "2" +369, 8, 15, 146, 76, 78, 696, 698, "DM" +369, 8, 16, 147, 79, 83, 699, 703, "were" +369, 8, 17, 148, 84, 92, 704, 712, "randomly" +369, 8, 18, 149, 93, 101, 713, 721, "assigned" +369, 8, 19, 150, 102, 104, 722, 724, "to" +369, 8, 20, 151, 105, 112, 725, 732, "receive" +369, 8, 21, 152, 113, 116, 733, 736, "850" +369, 8, 22, 153, 117, 119, 737, 739, "mg" +369, 8, 23, 154, 120, 122, 740, 742, "of" +369, 8, 24, 155, 123, 132, 743, 752, "metformin" +369, 8, 25, 156, 133, 135, 753, 755, "or" +369, 8, 26, 157, 136, 137, 756, 757, "a" +369, 8, 27, 158, 138, 145, 758, 765, "placebo" +369, 8, 28, 159, 146, 151, 766, 771, "twice" +369, 8, 29, 160, 152, 153, 772, 773, "a" +369, 8, 30, 161, 154, 157, 774, 777, "day" +369, 8, 31, 162, 158, 161, 778, 781, "for" +369, 8, 32, 163, 162, 163, 782, 783, "2" +369, 8, 33, 164, 164, 170, 784, 790, "months" +369, 8, 34, 165, 171, 172, 791, 792, "." +369, 9, 1, 166, 0, 6, 793, 799, "Before" +369, 9, 2, 167, 7, 10, 800, 803, "and" +369, 9, 3, 168, 11, 16, 804, 809, "after" +369, 9, 4, 169, 17, 20, 810, 813, "the" +369, 9, 5, 170, 21, 30, 814, 823, "treatment" +369, 9, 6, 171, 31, 32, 824, 825, "," +369, 9, 7, 172, 33, 36, 826, 829, "the" +369, 9, 8, 173, 37, 41, 830, 834, "body" +369, 9, 9, 174, 42, 46, 835, 839, "mass" +369, 9, 10, 175, 47, 52, 840, 845, "index" +369, 9, 11, 176, 53, 56, 846, 849, "and" +369, 9, 12, 177, 57, 62, 850, 855, "waist" +369, 9, 13, 178, 63, 64, 856, 857, "/" +369, 9, 14, 179, 65, 68, 858, 861, "hip" +369, 9, 15, 180, 69, 74, 862, 867, "ratio" +369, 9, 16, 181, 75, 79, 868, 872, "were" +369, 9, 17, 182, 80, 90, 873, 883, "calculated" +369, 9, 18, 183, 91, 92, 884, 885, "," +369, 9, 19, 184, 93, 96, 886, 889, "the" +369, 9, 20, 185, 97, 101, 890, 894, "body" +369, 9, 21, 186, 102, 113, 895, 906, "composition" +369, 9, 22, 187, 114, 117, 907, 910, "was" +369, 9, 23, 188, 118, 126, 911, 919, "measured" +369, 9, 24, 189, 127, 134, 920, 927, "through" +369, 9, 25, 190, 135, 146, 928, 939, "bioelectric" +369, 9, 26, 191, 147, 156, 940, 949, "impedance" +369, 9, 27, 192, 157, 160, 950, 953, "and" +369, 9, 28, 193, 161, 164, 954, 957, "the" +369, 9, 29, 194, 165, 172, 958, 965, "fasting" +369, 9, 30, 195, 173, 179, 966, 972, "levels" +369, 9, 31, 196, 180, 182, 973, 975, "of" +369, 9, 32, 197, 183, 188, 976, 981, "blood" +369, 9, 33, 198, 189, 196, 982, 989, "glucose" +369, 9, 34, 199, 197, 198, 990, 991, "," +369, 9, 35, 200, 199, 206, 992, 999, "insulin" +369, 9, 36, 201, 207, 208, 1000, 1001, "," +369, 9, 37, 202, 209, 222, 1002, 1015, "triglycerides" +369, 9, 38, 203, 223, 226, 1016, 1019, "and" +369, 9, 39, 204, 227, 238, 1020, 1031, "cholesterol" +369, 9, 40, 205, 239, 243, 1032, 1036, "were" +369, 9, 41, 206, 244, 252, 1037, 1045, "measured" +369, 9, 42, 207, 253, 254, 1046, 1047, "." +369, 10, 1, 208, 0, 3, 1048, 1051, "The" +369, 10, 2, 209, 4, 9, 1052, 1057, "level" +369, 10, 3, 210, 10, 12, 1058, 1060, "of" +369, 10, 4, 211, 13, 20, 1061, 1068, "insulin" +369, 10, 5, 212, 21, 31, 1069, 1079, "resistance" +369, 10, 6, 213, 32, 35, 1080, 1083, "was" +369, 10, 7, 214, 36, 46, 1084, 1094, "calculated" +369, 10, 8, 215, 47, 49, 1095, 1097, "by" +369, 10, 9, 216, 50, 53, 1098, 1101, "the" +369, 10, 10, 217, 54, 65, 1102, 1113, "homeostatic" +369, 10, 11, 218, 66, 71, 1114, 1119, "model" +369, 10, 12, 219, 72, 75, 1120, 1123, "and" +369, 10, 13, 220, 76, 79, 1124, 1127, "the" +369, 10, 14, 221, 80, 85, 1128, 1133, "level" +369, 10, 15, 222, 86, 88, 1134, 1136, "of" +369, 10, 16, 223, 89, 100, 1137, 1148, "sensitivity" +369, 10, 17, 224, 101, 103, 1149, 1151, "by" +369, 10, 18, 225, 104, 107, 1152, 1155, "the" +369, 10, 19, 226, 108, 120, 1156, 1168, "quantitative" +369, 10, 20, 227, 121, 128, 1169, 1176, "insulin" +369, 10, 21, 228, 129, 140, 1177, 1188, "sensitivity" +369, 10, 22, 229, 141, 146, 1189, 1194, "check" +369, 10, 23, 230, 147, 152, 1195, 1200, "index" +369, 10, 24, 231, 153, 159, 1201, 1207, "method" +369, 10, 25, 232, 160, 161, 1208, 1209, "." +369, 11, 1, 233, 0, 3, 1210, 1213, "The" +369, 11, 2, 234, 4, 12, 1214, 1222, "Wilcoxon" +369, 11, 3, 235, 13, 17, 1223, 1227, "rank" +369, 11, 4, 236, 18, 22, 1228, 1232, "test" +369, 11, 5, 237, 23, 26, 1233, 1236, "was" +369, 11, 6, 238, 27, 31, 1237, 1241, "used" +369, 11, 7, 239, 32, 33, 1242, 1243, "." +369, 12, 1, 240, 0, 7, 1244, 1251, "RESULTS" +369, 12, 2, 241, 8, 9, 1252, 1253, ":" +369, 12, 3, 242, 10, 16, 1254, 1260, "Twenty" +369, 12, 4, 243, 17, 18, 1261, 1262, "-" +369, 12, 5, 244, 19, 22, 1263, 1266, "one" +369, 12, 6, 245, 23, 31, 1267, 1275, "subjects" +369, 12, 7, 246, 32, 41, 1276, 1285, "completed" +369, 12, 8, 247, 42, 45, 1286, 1289, "the" +369, 12, 9, 248, 46, 51, 1290, 1295, "study" +369, 12, 10, 249, 52, 53, 1296, 1297, "," +369, 12, 11, 250, 54, 56, 1298, 1300, "12" +369, 12, 12, 251, 57, 59, 1301, 1303, "of" +369, 12, 13, 252, 60, 63, 1304, 1307, "the" +369, 12, 14, 253, 64, 73, 1308, 1317, "metformin" +369, 12, 15, 254, 74, 79, 1318, 1323, "group" +369, 12, 16, 255, 80, 83, 1324, 1327, "and" +369, 12, 17, 256, 84, 88, 1328, 1332, "nine" +369, 12, 18, 257, 89, 91, 1333, 1335, "of" +369, 12, 19, 258, 92, 95, 1336, 1339, "the" +369, 12, 20, 259, 96, 103, 1340, 1347, "placebo" +369, 12, 21, 260, 104, 109, 1348, 1353, "group" +369, 12, 22, 261, 110, 111, 1354, 1355, "." +369, 13, 1, 262, 0, 2, 1356, 1358, "In" +369, 13, 2, 263, 3, 6, 1359, 1362, "the" +369, 13, 3, 264, 7, 16, 1363, 1372, "metformin" +369, 13, 4, 265, 17, 22, 1373, 1378, "group" +369, 13, 5, 266, 23, 24, 1379, 1380, "," +369, 13, 6, 267, 25, 30, 1381, 1386, "there" +369, 13, 7, 268, 31, 34, 1387, 1390, "was" +369, 13, 8, 269, 35, 36, 1391, 1392, "a" +369, 13, 9, 270, 37, 45, 1393, 1401, "decrease" +369, 13, 10, 271, 46, 48, 1402, 1404, "in" +369, 13, 11, 272, 49, 52, 1405, 1408, "fat" +369, 13, 12, 273, 53, 59, 1409, 1415, "weight" +369, 13, 13, 274, 60, 64, 1416, 1420, "from" +369, 13, 14, 275, 65, 67, 1421, 1423, "25" +369, 13, 15, 276, 68, 69, 1424, 1425, "." +369, 13, 16, 277, 70, 71, 1426, 1427, "9" +369, 13, 17, 278, 72, 73, 1428, 1429, "+" +369, 13, 18, 279, 74, 75, 1430, 1431, "/" +369, 13, 19, 280, 76, 77, 1432, 1433, "-" +369, 13, 20, 281, 78, 79, 1434, 1435, "9" +369, 13, 21, 282, 80, 81, 1436, 1437, "." +369, 13, 22, 283, 82, 83, 1438, 1439, "4" +369, 13, 23, 284, 84, 86, 1440, 1442, "to" +369, 13, 24, 285, 87, 89, 1443, 1445, "20" +369, 13, 25, 286, 90, 91, 1446, 1447, "." +369, 13, 26, 287, 92, 93, 1448, 1449, "8" +369, 13, 27, 288, 94, 95, 1450, 1451, "+" +369, 13, 28, 289, 96, 97, 1452, 1453, "/" +369, 13, 29, 290, 98, 99, 1454, 1455, "-" +369, 13, 30, 291, 100, 101, 1456, 1457, "9" +369, 13, 31, 292, 102, 103, 1458, 1459, "." +369, 13, 32, 293, 104, 105, 1460, 1461, "2" +369, 13, 33, 294, 106, 108, 1462, 1464, "kg" +369, 13, 34, 295, 109, 110, 1465, 1466, "," +369, 13, 35, 296, 111, 112, 1467, 1468, "p" +369, 13, 36, 297, 113, 114, 1469, 1470, "<" +369, 13, 37, 298, 115, 116, 1471, 1472, "0" +369, 13, 38, 299, 117, 118, 1473, 1474, "." +369, 13, 39, 300, 119, 121, 1475, 1477, "01" +369, 13, 40, 301, 122, 123, 1478, 1479, "," +369, 13, 41, 302, 124, 126, 1480, 1482, "an" +369, 13, 42, 303, 127, 135, 1483, 1491, "increase" +369, 13, 43, 304, 136, 138, 1492, 1494, "in" +369, 13, 44, 305, 139, 143, 1495, 1499, "lean" +369, 13, 45, 306, 144, 150, 1500, 1506, "weight" +369, 13, 46, 307, 151, 155, 1507, 1511, "from" +369, 13, 47, 308, 156, 158, 1512, 1514, "57" +369, 13, 48, 309, 159, 160, 1515, 1516, "." +369, 13, 49, 310, 161, 163, 1517, 1519, "05" +369, 13, 50, 311, 164, 165, 1520, 1521, "+" +369, 13, 51, 312, 166, 167, 1522, 1523, "/" +369, 13, 52, 313, 168, 169, 1524, 1525, "-" +369, 13, 53, 314, 170, 172, 1526, 1528, "13" +369, 13, 54, 315, 173, 174, 1529, 1530, "." +369, 13, 55, 316, 175, 176, 1531, 1532, "6" +369, 13, 56, 317, 177, 179, 1533, 1535, "to" +369, 13, 57, 318, 180, 182, 1536, 1538, "61" +369, 13, 58, 319, 183, 184, 1539, 1540, "." +369, 13, 59, 320, 185, 186, 1541, 1542, "9" +369, 13, 60, 321, 187, 188, 1543, 1544, "+" +369, 13, 61, 322, 189, 190, 1545, 1546, "/" +369, 13, 62, 323, 191, 192, 1547, 1548, "-" +369, 13, 63, 324, 193, 195, 1549, 1551, "16" +369, 13, 64, 325, 196, 197, 1552, 1553, "." +369, 13, 65, 326, 198, 199, 1554, 1555, "5" +369, 13, 66, 327, 200, 202, 1556, 1558, "kg" +369, 13, 67, 328, 203, 204, 1559, 1560, "," +369, 13, 68, 329, 205, 206, 1561, 1562, "p" +369, 13, 69, 330, 207, 208, 1563, 1564, "<" +369, 13, 70, 331, 209, 210, 1565, 1566, "0" +369, 13, 71, 332, 211, 212, 1567, 1568, "." +369, 13, 72, 333, 213, 215, 1569, 1571, "01" +369, 13, 73, 334, 216, 217, 1572, 1573, "," +369, 13, 74, 335, 218, 220, 1574, 1576, "an" +369, 13, 75, 336, 221, 229, 1577, 1585, "increase" +369, 13, 76, 337, 230, 232, 1586, 1588, "in" +369, 13, 77, 338, 233, 238, 1589, 1594, "basal" +369, 13, 78, 339, 239, 249, 1595, 1605, "metabolism" +369, 13, 79, 340, 250, 254, 1606, 1610, "from" +369, 13, 80, 341, 255, 259, 1611, 1615, "1735" +369, 13, 81, 342, 260, 261, 1616, 1617, "+" +369, 13, 82, 343, 262, 263, 1618, 1619, "/" +369, 13, 83, 344, 264, 265, 1620, 1621, "-" +369, 13, 84, 345, 266, 269, 1622, 1625, "413" +369, 13, 85, 346, 270, 272, 1626, 1628, "to" +369, 13, 86, 347, 273, 277, 1629, 1633, "1878" +369, 13, 87, 348, 278, 279, 1634, 1635, "+" +369, 13, 88, 349, 280, 281, 1636, 1637, "/" +369, 13, 89, 350, 282, 283, 1638, 1639, "-" +369, 13, 90, 351, 284, 287, 1640, 1643, "505" +369, 13, 91, 352, 288, 296, 1644, 1652, "calories" +369, 13, 92, 353, 297, 298, 1653, 1654, "/" +369, 13, 93, 354, 299, 302, 1655, 1658, "day" +369, 13, 94, 355, 303, 304, 1659, 1660, "," +369, 13, 95, 356, 305, 306, 1661, 1662, "p" +369, 13, 96, 357, 307, 308, 1663, 1664, "<" +369, 13, 97, 358, 309, 310, 1665, 1666, "0" +369, 13, 98, 359, 311, 312, 1667, 1668, "." +369, 13, 99, 360, 313, 315, 1669, 1671, "05" +369, 13, 100, 361, 316, 319, 1672, 1675, "and" +369, 13, 101, 362, 320, 322, 1676, 1678, "an" +369, 13, 102, 363, 323, 331, 1679, 1687, "increase" +369, 13, 103, 364, 332, 334, 1688, 1690, "in" +369, 13, 104, 365, 335, 339, 1691, 1695, "body" +369, 13, 105, 366, 340, 345, 1696, 1701, "water" +369, 13, 106, 367, 346, 347, 1702, 1703, "," +369, 13, 107, 368, 348, 349, 1704, 1705, "p" +369, 13, 108, 369, 350, 351, 1706, 1707, "<" +369, 13, 109, 370, 352, 353, 1708, 1709, "0" +369, 13, 110, 371, 354, 355, 1710, 1711, "." +369, 13, 111, 372, 356, 358, 1712, 1714, "05" +369, 13, 112, 373, 359, 360, 1715, 1716, "." +369, 14, 1, 374, 0, 5, 1717, 1722, "There" +369, 14, 2, 375, 6, 9, 1723, 1726, "was" +369, 14, 3, 376, 10, 12, 1727, 1729, "no" +369, 14, 4, 377, 13, 24, 1730, 1741, "significant" +369, 14, 5, 378, 25, 33, 1742, 1750, "decrease" +369, 14, 6, 379, 34, 36, 1751, 1753, "in" +369, 14, 7, 380, 37, 44, 1754, 1761, "insulin" +369, 14, 8, 381, 45, 55, 1762, 1772, "resistance" +369, 14, 9, 382, 56, 57, 1773, 1774, "." +369, 15, 1, 383, 0, 2, 1775, 1777, "In" +369, 15, 2, 384, 3, 6, 1778, 1781, "the" +369, 15, 3, 385, 7, 14, 1782, 1789, "placebo" +369, 15, 4, 386, 15, 20, 1790, 1795, "group" +369, 15, 5, 387, 21, 22, 1796, 1797, "," +369, 15, 6, 388, 23, 26, 1798, 1801, "the" +369, 15, 7, 389, 27, 32, 1802, 1807, "blood" +369, 15, 8, 390, 33, 40, 1808, 1815, "glucose" +369, 15, 9, 391, 41, 50, 1816, 1825, "increased" +369, 15, 10, 392, 51, 55, 1826, 1830, "from" +369, 15, 11, 393, 56, 58, 1831, 1833, "84" +369, 15, 12, 394, 59, 60, 1834, 1835, "." +369, 15, 13, 395, 61, 62, 1836, 1837, "7" +369, 15, 14, 396, 63, 64, 1838, 1839, "+" +369, 15, 15, 397, 65, 66, 1840, 1841, "/" +369, 15, 16, 398, 67, 68, 1842, 1843, "-" +369, 15, 17, 399, 69, 71, 1844, 1846, "13" +369, 15, 18, 400, 72, 74, 1847, 1849, "to" +369, 15, 19, 401, 75, 77, 1850, 1852, "96" +369, 15, 20, 402, 78, 79, 1853, 1854, "." +369, 15, 21, 403, 80, 81, 1855, 1856, "7" +369, 15, 22, 404, 82, 83, 1857, 1858, "+" +369, 15, 23, 405, 84, 85, 1859, 1860, "/" +369, 15, 24, 406, 86, 87, 1861, 1862, "-" +369, 15, 25, 407, 88, 90, 1863, 1865, "16" +369, 15, 26, 408, 91, 93, 1866, 1868, "mg" +369, 15, 27, 409, 94, 95, 1869, 1870, "/" +369, 15, 28, 410, 96, 98, 1871, 1873, "dl" +369, 15, 29, 411, 99, 100, 1874, 1875, "," +369, 15, 30, 412, 101, 102, 1876, 1877, "p" +369, 15, 31, 413, 103, 104, 1878, 1879, "<" +369, 15, 32, 414, 105, 106, 1880, 1881, "0" +369, 15, 33, 415, 107, 108, 1882, 1883, "." +369, 15, 34, 416, 109, 111, 1884, 1886, "05" +369, 15, 35, 417, 112, 113, 1887, 1888, "." +369, 16, 1, 418, 0, 5, 1889, 1894, "There" +369, 16, 2, 419, 6, 10, 1895, 1899, "were" +369, 16, 3, 420, 11, 13, 1900, 1902, "no" +369, 16, 4, 421, 14, 25, 1903, 1914, "significant" +369, 16, 5, 422, 26, 39, 1915, 1928, "modifications" +369, 16, 6, 423, 40, 42, 1929, 1931, "in" +369, 16, 7, 424, 43, 49, 1932, 1938, "lipids" +369, 16, 8, 425, 50, 51, 1939, 1940, "." +369, 17, 1, 426, 0, 11, 1941, 1952, "CONCLUSIONS" +369, 17, 2, 427, 12, 13, 1953, 1954, ":" +369, 17, 3, 428, 14, 17, 1955, 1958, "The" +369, 17, 4, 429, 18, 32, 1959, 1973, "administration" +369, 17, 5, 430, 33, 35, 1974, 1976, "of" +369, 17, 6, 431, 36, 45, 1977, 1986, "metformin" +369, 17, 7, 432, 46, 49, 1987, 1990, "for" +369, 17, 8, 433, 50, 51, 1991, 1992, "2" +369, 17, 9, 434, 52, 58, 1993, 1999, "months" +369, 17, 10, 435, 59, 67, 2000, 2008, "improves" +369, 17, 11, 436, 68, 71, 2009, 2012, "the" +369, 17, 12, 437, 72, 82, 2013, 2023, "parameters" +369, 17, 13, 438, 83, 85, 2024, 2026, "of" +369, 17, 14, 439, 86, 90, 2027, 2031, "body" +369, 17, 15, 440, 91, 102, 2032, 2043, "composition" +369, 17, 16, 441, 103, 106, 2044, 2047, "and" +369, 17, 17, 442, 107, 114, 2048, 2055, "insulin" +369, 17, 18, 443, 115, 123, 2056, 2064, "dynamics" +369, 17, 19, 444, 124, 126, 2065, 2067, "in" +369, 17, 20, 445, 127, 135, 2068, 2076, "subjects" +369, 17, 21, 446, 136, 140, 2077, 2081, "with" +369, 17, 22, 447, 141, 145, 2082, 2086, "risk" +369, 17, 23, 448, 146, 153, 2087, 2094, "factors" +369, 17, 24, 449, 154, 157, 2095, 2098, "for" +369, 17, 25, 450, 158, 162, 2099, 2103, "type" +369, 17, 26, 451, 163, 164, 2104, 2105, "2" +369, 17, 27, 452, 165, 167, 2106, 2108, "DM" +369, 17, 28, 453, 168, 169, 2109, 2110, "." +369, 18, 1, 454, 0, 3, 2111, 2114, "DOI" +369, 18, 2, 455, 4, 5, 2115, 2116, ":" +369, 18, 3, 456, 6, 8, 2117, 2119, "10" +369, 18, 4, 457, 9, 10, 2120, 2121, "." +369, 18, 5, 458, 11, 15, 2122, 2126, "1111" +369, 18, 6, 459, 16, 17, 2127, 2128, "/" +369, 18, 7, 460, 18, 19, 2129, 2130, "j" +369, 18, 8, 461, 20, 21, 2131, 2132, "." +369, 18, 9, 462, 22, 26, 2133, 2137, "1463" +369, 18, 10, 463, 27, 28, 2138, 2139, "-" +369, 18, 11, 464, 29, 33, 2140, 2144, "1326" +369, 18, 12, 465, 34, 35, 2145, 2146, "." +369, 18, 13, 466, 36, 40, 2147, 2151, "2004" +369, 18, 14, 467, 41, 42, 2152, 2153, "." +369, 18, 15, 468, 43, 48, 2154, 2159, "00385" +369, 18, 16, 469, 49, 50, 2160, 2161, "." +369, 18, 17, 470, 51, 52, 2162, 2163, "x" +369, 18, 18, 471, 53, 57, 2164, 2168, "PMID" +369, 18, 19, 472, 58, 59, 2169, 2170, ":" +369, 18, 20, 473, 60, 68, 2171, 2179, "15715892" +369, 18, 21, 474, 69, 70, 2180, 2181, "[" +369, 18, 22, 475, 71, 78, 2182, 2189, "Indexed" +369, 18, 23, 476, 79, 82, 2190, 2193, "for" +369, 18, 24, 477, 83, 90, 2194, 2201, "MEDLINE" +369, 18, 25, 478, 91, 92, 2202, 2203, "]" diff --git a/data/dm2 15715892_kwoodley.annodb b/data/dm2 15715892_kwoodley.annodb new file mode 100644 index 0000000..88b42f7 --- /dev/null +++ b/data/dm2 15715892_kwoodley.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31525, Journal, 0, 21, "Diabetes Obes Metab .", "", +1219, PublicationYear, 22, 26, "2005", "", +31526, Title, 54, 150, "Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes .", "", +1241, Metformin, 65, 74, "metformin", "", +1248, Precondition, 102, 148, "subjects with risk factors for type 2 diabetes", "", +1233, Type2Diabetes, 133, 148, "type 2 diabetes", "", +1221, Author, 151, 177, "Rodr í guez - Moctezuma JR", "", +1222, Author, 186, 204, "Robles - L ó pez G", "", +1223, Author, 207, 227, "L ó pez - Carmona JM", "", +1224, Author, 230, 252, "Guti é rrez - Rosas MJ", "", +1226, Mexico, 352, 358, "Mexico", "", +31527, ObjectiveDescription, 402, 572, "To measure the effect of metformin on the body composition , insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus ( type 2 DM ) .", "", +1229, Metformin, 427, 436, "metformin", "", +3729, Insulin, 463, 470, "insulin", "", +1228, Precondition, 501, 570, "subjects with risk factors for type 2 diabetes mellitus ( type 2 DM )", "", +1234, Type2Diabetes, 532, 556, "type 2 diabetes mellitus", "", +1235, Type2Diabetes, 559, 568, "type 2 DM", "", +31528, Placebo, 582, 589, "Placebo", "", +1231, NumberPatientsCT, 643, 657, "Twenty - three", "", +1230, Precondition, 658, 698, "subjects with risk factors for type 2 DM", "", +1236, Type2Diabetes, 689, 698, "type 2 DM", "", +1238, Randomized, 704, 712, "randomly", "", +1249, DoseValue, 733, 736, "850", "", +1250, mg, 737, 739, "mg", "", +1242, Metformin, 743, 752, "metformin", "", +1251, Placebo, 758, 765, "placebo", "", +1252, Frequency, 766, 777, "twice a day", "", +1240, Duration, 782, 790, "2 months", "", +1255, BMI, 830, 845, "body mass index", "", +31529, FastingBloodGlucose, 958, 989, "fasting levels of blood glucose", "", +1257, Insulin, 992, 999, "insulin", "", +31530, EndPointDescription, 1002, 1015, "triglycerides", "", +31531, EndPointDescription, 1020, 1031, "cholesterol", "", +2843, EndPointDescription, 1061, 1079, "insulin resistance", "insulin resistence", +1259, MeasurementDevice, 1102, 1119, "homeostatic model", "", +1260, MeasurementDevice, 1156, 1207, "quantitative insulin sensitivity check index method", "", +1261, MeasurementDevice, 1214, 1232, "Wilcoxon rank test", "", +3730, FinalNumPatientsCT, 1254, 1266, "Twenty - one", "", +1253, FinalNumPatientsArm, 1298, 1300, "12", "", +1243, Metformin, 1308, 1317, "metformin", "", +1254, FinalNumPatientsArm, 1328, 1332, "nine", "", +1262, Placebo, 1340, 1347, "placebo", "", +1244, Metformin, 1363, 1372, "metformin", "", +2818, BodyWeight, 1405, 1415, "fat weight", "fat weight", +2811, BaseLineValue, 1421, 1427, "25 . 9", "", +2812, SdDevBL, 1434, 1439, "9 . 4", "", +2815, ResultMeasuredValue, 1443, 1449, "20 . 8", "", +2814, SdDevResValue, 1456, 1461, "9 . 2", "", +2816, Kg, 1462, 1464, "kg", "", +2817, PValueResValue, 1467, 1477, "p < 0 . 01", "", +2819, BodyWeight, 1495, 1506, "lean weight", "lean weight", +2820, BaseLineValue, 1512, 1519, "57 . 05", "lean weight", +2827, SdDevBL, 1526, 1532, "13 . 6", "basal metabolism", +2822, ResultMeasuredValue, 1536, 1542, "61 . 9", "lean weight", +2823, SdDevResValue, 1549, 1555, "16 . 5", "lean weight", +2824, Kg, 1556, 1558, "kg", "lean weight", +2825, PValueResValue, 1561, 1571, "p < 0 . 01", "lean weight", +2826, EndPointDescription, 1589, 1605, "basal metabolism", "basal metabolism", +2828, BaseLineValue, 1611, 1615, "1735", "", +2830, SdDevBL, 1622, 1625, "413", "", +2831, ResultMeasuredValue, 1629, 1633, "1878", "", +2834, SdDevResValue, 1640, 1643, "505", "", +2836, BioAndMedicalUnit, 1644, 1658, "calories / day", "", +2833, PValueResValue, 1661, 1671, "p < 0 . 05", "", +2839, Increment, 1679, 1687, "increase", "body water", +2837, EndPointDescription, 1691, 1701, "body water", "body water", +2838, PValueResValue, 1704, 1714, "p < 0 . 05", "body water", +31532, ObservedResult, 1717, 1750, "There was no significant decrease", "", +2840, EndPointDescription, 1754, 1772, "insulin resistance", "insulin resistence", +2844, Placebo, 1782, 1789, "placebo", "", +31533, BloodGlucose, 1802, 1815, "blood glucose", "", +2846, BaseLineValue, 1831, 1837, "84 . 7", "", +2847, SdDevBL, 1844, 1846, "13", "", +2848, ResultMeasuredValue, 1850, 1856, "96 . 7", "", +2849, SdDevResValue, 1863, 1865, "16", "", +2850, Mg_per_deciliter, 1866, 1873, "mg / dl", "", +2851, PValueResValue, 1876, 1886, "p < 0 . 05", "", +31535, ObservedResult, 1889, 1928, "There were no significant modifications", "", +31534, EndPointDescription, 1932, 1938, "lipids", "", +31536, ConclusionComment, 1955, 2110, "The administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM .", "", +1245, Metformin, 1977, 1986, "metformin", "", +1246, Duration, 1991, 1999, "2 months", "", +2852, Insulin, 2048, 2055, "insulin", "", +1247, Precondition, 2068, 2108, "subjects with risk factors for type 2 DM", "", +1237, Type2Diabetes, 2099, 2108, "type 2 DM", "", +1225, PMID, 2171, 2179, "15715892", "", diff --git a/data/dm2 15715892_kwoodley.n-triples b/data/dm2 15715892_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15715892_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15842521_admin.annodb b/data/dm2 15842521_admin.annodb new file mode 100644 index 0000000..145cb1e --- /dev/null +++ b/data/dm2 15842521_admin.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +161, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +0, PublicationYear, 13, 17, "2005", "", " \"2005\"." +162, Title, 46, 180, "Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial .", "", " \"Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial .\"." +16, Metformin, 57, 66, "metformin", "", +17, Insulin, 81, 88, "insulin", "", +9, Type2Diabetes, 106, 121, "Type 2 diabetes", "", +13, DoubleBlind, 126, 140, "double - blind", "", +14, Randomized, 141, 151, "randomized", "", +82, Placebo, 152, 159, "placebo", "", +1, Author, 181, 189, "Douek IF", "", +2, Author, 198, 206, "Allen SE", "", " \"Allen SE\"." +3, Author, 209, 217, "Ewings P", "", " \"Ewings P\"." +4, Author, 220, 227, "Gale EA", "", " \"Gale EA\"." +5, Author, 230, 240, "Bingley PJ", "", " \"Bingley PJ\"." +88, Metformin, 243, 252, "Metformin", "", +6, UK, 377, 379, "UK", "", " ." +164, ObjectiveDescription, 389, 547, "To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin .", "", " \"To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin .\"." +15, Metformin, 422, 431, "metformin", "", +46, BodyWeight, 435, 441, "weight", "", +18, Precondition, 472, 545, "patients with poorly controlled Type 2 diabetes who need to start insulin", "", +10, Type2Diabetes, 504, 519, "Type 2 diabetes", "", " ." +19, Insulin, 538, 545, "insulin", "", +11, Type2Diabetes, 572, 587, "Type 2 diabetes", "", +96, Precondition, 588, 652, "on maximum tolerated oral agents referred for insulin conversion", "", " \"on maximum tolerated oral agents referred for insulin conversion\"." +71, OralAntidiabeticAgent, 609, 620, "oral agents", "", +72, Insulin, 634, 641, "insulin", "", +22, DoubleBlind, 706, 720, "double - blind", "", " ." +21, Randomized, 721, 731, "randomized", "", " ." +99, Placebo, 732, 739, "placebo", "", +7, NumberPatientsCT, 765, 768, "183", "", " \"183\"." +23, Metformin, 791, 800, "metformin", "", " ." +24, Placebo, 804, 811, "placebo", "", " ." +93007, DoseDescription, 814, 864, "titrated up to 2 g a day or maximum tolerated dose", "", " \"titrated up to 2 g a day or maximum tolerated dose\". \"titrated up to 2 g a day or maximum tolerated dose\"." +25, DoseValue, 829, 830, "2", "", " \"2\". \"2\"." +26, Gram, 831, 832, "g", "", " . ." +27, Frequency, 833, 838, "a day", "", " \"a day\". \"a day\"." +28, Insulin, 872, 879, "insulin", "", +29, BodyWeight, 949, 955, "weight", "", +30, Duration, 968, 977, "12 months", "", " \"12 months\"." +31, HbA1c, 980, 985, "HbA1c", "", +166, InsulinDose, 988, 1000, "insulin dose", "", +32, Hypoglycemia, 1016, 1029, "hypoglycaemia", "", +110, EndPointDescription, 1032, 1054, "treatment satisfaction", "", +111, EndPointDescription, 1061, 1073, "well - being", "", +33, Duration, 1091, 1100, "12 months", "", +34, Metformin, 1103, 1112, "metformin", "", +35, BodyWeight, 1138, 1144, "weight", "", " ." +36, Placebo, 1155, 1162, "placebo", "", +118, Mean, 1165, 1169, "mean", "", " . ." +65, Increment, 1170, 1175, "6 . 1", "", " \"6 . 1\"." +62, Kg, 1176, 1178, "kg", "", " ." +66, Increment, 1184, 1189, "7 . 6", "", " \"7 . 6\"." +63, Kg, 1190, 1192, "kg", "", +67, DiffGroupAbsValue, 1215, 1220, "1 . 5", "", " \"1 . 5\"." +64, Kg, 1221, 1223, "kg", "", +123, ConfIntervalDiff, 1226, 1264, "95 % confidence interval 0 . 2 - 2 . 9", "", " \"95 % confidence interval 0 . 2 - 2 . 9\"." +49, PvalueDiff, 1269, 1279, "P = 0 . 02", "", " \"P = 0 . 02\"." +47, HbA1c, 1307, 1312, "HbA1c", "", " ." +50, Reduction, 1315, 1320, "1 . 5", "", " \"1 . 5\"." +52, Percentage, 1321, 1322, "%", "", " ." +51, Reduction, 1328, 1333, "1 . 3", "", " \"1 . 3\"." +53, Percentage, 1334, 1335, "%", "", " ." +68, DiffGroupAbsValue, 1358, 1363, "0 . 5", "", " \"0 . 5\"." +54, Percentage, 1364, 1365, "%", "", +69, ConfIntervalDiff, 1368, 1381, "0 . 1 - 0 . 9", "", " \"0 . 1 - 0 . 9\"." +55, PvalueDiff, 1386, 1396, "P = 0 . 02", "", " \"P = 0 . 02\"." +168, InsulinDose, 1411, 1430, "insulin requirement", "", " . ." +135, ResultMeasuredValue, 1433, 1435, "62", "", " \"62\"." +137, BioAndMedicalUnit, 1436, 1441, "units", "", " . ." +136, ResultMeasuredValue, 1447, 1449, "86", "", " \"86\"." +138, DiffGroupAbsValue, 1472, 1474, "25", "", " \"25\"." +139, BioAndMedicalUnit, 1475, 1480, "units", "", +140, ConfIntervalDiff, 1483, 1490, "15 - 34", "", " \"15 - 34\"." +56, PvalueDiff, 1495, 1506, "P < 0 . 001", "", " \"P < 0 . 001\"." +48, Hypoglycemia, 1525, 1538, "hypoglycaemia", "", " ." +146, BioAndMedicalUnit, 1541, 1569, "relative risk of any episode", "", " . ." +143, DiffGroupRelValue, 1570, 1576, "1 . 24", "", " \"1 . 24\"." +144, ConfIntervalDiff, 1579, 1593, "1 . 02 - 1 . 1", "", " \"1 . 02 - 1 . 1\"." +145, PvalueDiff, 1598, 1608, "P = 0 . 03", "", " \"P = 0 . 03\"." +40, EndPointDescription, 1613, 1635, "Treatment satisfaction", "", " . ." +70, ObservedResult, 1636, 1690, "improved more in patients on metformin than on placebo", "", " \"improved more in patients on metformin than on placebo\". \"improved more in patients on metformin than on placebo\". \"improved more in patients on metformin than on placebo\". \"improved more in patients on metformin than on placebo\"." +37, Metformin, 1665, 1674, "metformin", "", +38, Placebo, 1683, 1690, "placebo", "", +39, PvalueDiff, 1693, 1704, "P < 0 . 001", "", " \"P < 0 . 001\"." +152, EndPointDescription, 1720, 1747, "positive well - being score", "", " . ." +42, PvalueDiff, 1750, 1760, "P = 0 . 02", "", " \"P = 0 . 02\"." +43, Metformin, 1779, 1788, "Metformin", "", +171, ConclusionComment, 1779, 1957, "Metformin decreases weight gain , lowers insulin requirement , and improves glycaemic control , and should be continued in patients with Type 2 diabetes who transfer to insulin .", "", " \"Metformin decreases weight gain , lowers insulin requirement , and improves glycaemic control , and should be continued in patients with Type 2 diabetes who transfer to insulin .\"." +44, BodyWeight, 1799, 1805, "weight", "", +172, InsulinDose, 1820, 1839, "insulin requirement", "", +12, Type2Diabetes, 1916, 1931, "Type 2 diabetes", "", +73, Insulin, 1948, 1955, "insulin", "", +8, PMID, 2018, 2026, "15842521", "", " \"15842521\"." diff --git a/data/dm2 15842521_admin.n-triples b/data/dm2 15842521_admin.n-triples new file mode 100644 index 0000000..8616245 --- /dev/null +++ b/data/dm2 15842521_admin.n-triples @@ -0,0 +1,216 @@ +# RDF export of group: Publication + . + "Publication " . + "Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial ." . + "2005" . + "Diabet Med ." . + "15842521" . + . + "Allen SE" . + "Ewings P" . + "Gale EA" . + "Bingley PJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin ." . + "183" . + "12 months" . + . + . + . + "Metformin decreases weight gain , lowers insulin requirement , and improves glycaemic control , and should be continued in patients with Type 2 diabetes who transfer to insulin ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . + "on maximum tolerated oral agents referred for insulin conversion" . +# RDF export of group: Endpoint + . + "Endpoint weight" . + . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . + "Endpoint ts" . + . + . + . + . + . + . + "Endpoint well being" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm m" . + . + . + . + . + . + . + . + . + "Arm p" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention m" . + . + "a day" . + . + . + "Intervention p" . + . + "a day" . + . +# RDF export of group: Medication + . + "Medication m" . + . + "2" . + . + . + "titrated up to 2 g a day or maximum tolerated dose" . + . + "Medication p" . + . + "2" . + . + . + "titrated up to 2 g a day or maximum tolerated dose" . +# RDF export of group: Outcome + . + "Outcome weight m" . + . + "6 . 1" . + . + "Outcome weight p" . + . + "7 . 6" . + . + "Outcome hba1c m" . + . + "1 . 5" . + . + "Outcome hba1c p" . + . + "1 . 3" . + . + "Outcome id m" . + . + "62" . + . + "Outcome id p " . + . + "86" . + . + "Outcome h m " . + . + . + "Outcome h p " . + . + . + "Outcome ts m" . + . + "improved more in patients on metformin than on placebo" . + . + "Outcome ts p " . + . + "improved more in patients on metformin than on placebo" . + . + "Outcome well being m " . + . + "improved more in patients on metformin than on placebo" . + . + "Outcome weel being p " . + . + "improved more in patients on metformin than on placebo" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups weight" . + "1 . 5" . + "P = 0 . 02" . + "95 % confidence interval 0 . 2 - 2 . 9" . + . + . + . + "DiffBetweenGroups hba1c" . + "0 . 5" . + "P = 0 . 02" . + "0 . 1 - 0 . 9" . + . + . + . + "DiffBetweenGroups id" . + "25" . + "P < 0 . 001" . + "15 - 34" . + . + . + . + "DiffBetweenGroups h " . + "1 . 24" . + "P = 0 . 03" . + "1 . 02 - 1 . 1" . + . + . + . + "DiffBetweenGroups ts " . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups well being " . + "P = 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15842521_akramersunderbrink.annodb b/data/dm2 15842521_akramersunderbrink.annodb new file mode 100644 index 0000000..c73c1cf --- /dev/null +++ b/data/dm2 15842521_akramersunderbrink.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7817, Journal, 0, 10, "Diabet Med", "", +7818, PublicationYear, 13, 17, "2005", "", +7819, Title, 46, 178, "Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial", "", +7820, Metformin, 57, 66, "metformin", "", +7821, Insulin, 81, 88, "insulin", "", +7822, Type2Diabetes, 106, 121, "Type 2 diabetes", "", +7823, DoubleBlind, 126, 140, "double - blind", "", +7824, Randomized, 141, 151, "randomized", "", +7825, Placebo, 152, 159, "placebo", "", +7826, Author, 181, 189, "Douek IF", "", +7827, Author, 198, 206, "Allen SE", "", +7828, Author, 209, 217, "Ewings P", "", +7829, Author, 220, 227, "Gale EA", "", +7830, Author, 230, 240, "Bingley PJ", "", +7831, Metformin, 243, 252, "Metformin", "", +39108, UK, 377, 379, "UK", "", +7832, ObjectiveDescription, 389, 545, "To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin", "", +7834, Metformin, 422, 431, "metformin", "", +7835, WeightGain, 435, 446, "weight gain", "", +7838, Precondition, 486, 545, "poorly controlled Type 2 diabetes who need to start insulin", "", +7836, Type2Diabetes, 504, 519, "Type 2 diabetes", "", +7837, Insulin, 538, 545, "insulin", "", +7839, Type2Diabetes, 572, 587, "Type 2 diabetes", "", +7842, Precondition, 588, 652, "on maximum tolerated oral agents referred for insulin conversion", "", +7844, DoubleBlind, 706, 720, "double - blind", "", +7846, Randomized, 721, 731, "randomized", "", +7848, Placebo, 732, 739, "placebo", "", +7851, NumberPatientsCT, 765, 768, "183", "", +7853, Metformin, 791, 800, "metformin", "", +7856, Placebo, 804, 811, "placebo", "", +7858, DoseValue, 829, 830, "2", "", +7860, Gram, 831, 832, "g", "", +7978, Frequency, 833, 838, "a day", "", +7862, BodyWeight, 949, 962, "weight change", "", +7864, Duration, 968, 977, "12 months", "", +7866, HbA1c, 980, 985, "HbA1c", "", +7871, EndPointDescription, 988, 1000, "insulin dose", "", +7873, Hypoglycemia, 1003, 1029, "frequency of hypoglycaemia", "", +7874, EndPointDescription, 1032, 1054, "treatment satisfaction", "", +7877, EndPointDescription, 1061, 1073, "well - being", "", +7879, Duration, 1091, 1100, "12 months", "", +7881, Metformin, 1103, 1112, "metformin", "", +7882, WeightGain, 1138, 1149, "weight gain", "", +7883, Placebo, 1155, 1162, "placebo", "", +7890, Mean, 1165, 1169, "mean", "", +7887, ResultMeasuredValue, 1170, 1175, "6 . 1", "", +7891, Kg, 1176, 1178, "kg", "", +7889, ResultMeasuredValue, 1184, 1189, "7 . 6", "", +7892, Kg, 1190, 1192, "kg", "", +7894, DiffGroupAbsValue, 1215, 1220, "1 . 5", "", +7895, Kg, 1221, 1223, "kg", "", +7898, ConfIntervalDiff, 1226, 1264, "95 % confidence interval 0 . 2 - 2 . 9", "", +7900, PvalueDiff, 1269, 1279, "P = 0 . 02", "", +7902, HbA1c, 1307, 1312, "HbA1c", "", +7903, ResultMeasuredValue, 1315, 1320, "1 . 5", "", +7904, Percentage, 1321, 1322, "%", "", +7906, ResultMeasuredValue, 1328, 1333, "1 . 3", "", +7908, Percentage, 1334, 1335, "%", "", +7910, DiffGroupAbsValue, 1358, 1363, "0 . 5", "", +7913, Percentage, 1364, 1365, "%", "", +7915, ConfIntervalDiff, 1368, 1381, "0 . 1 - 0 . 9", "", +7917, PvalueDiff, 1386, 1396, "P = 0 . 02", "", +7921, EndPointDescription, 1411, 1430, "insulin requirement", "", +7923, ResultMeasuredValue, 1433, 1435, "62", "", +7927, BioAndMedicalUnit, 1436, 1441, "units", "", +7925, ResultMeasuredValue, 1447, 1449, "86", "", +7929, DiffGroupAbsValue, 1472, 1474, "25", "", +7932, BioAndMedicalUnit, 1475, 1480, "units", "", +7934, ConfIntervalDiff, 1483, 1490, "15 - 34", "", +7936, PvalueDiff, 1495, 1506, "P < 0 . 001", "", +7942, Hypoglycemia, 1525, 1538, "hypoglycaemia", "", +7951, BioAndMedicalUnit, 1541, 1569, "relative risk of any episode", "", +7947, DiffGroupRelValue, 1570, 1576, "1 . 24", "", +7948, ConfIntervalDiff, 1579, 1593, "1 . 02 - 1 . 1", "", +7949, PvalueDiff, 1598, 1608, "P = 0 . 03", "", +7954, EndPointDescription, 1613, 1635, "Treatment satisfaction", "", +7957, ObservedResult, 1636, 1649, "improved more", "", +7959, Metformin, 1665, 1674, "metformin", "", +7960, Placebo, 1683, 1690, "placebo", "", +7962, PvalueDiff, 1693, 1704, "P < 0 . 001", "", +7963, EndPointDescription, 1720, 1747, "positive well - being score", "", +7965, PvalueDiff, 1750, 1760, "P = 0 . 02", "", +7967, ConclusionComment, 1779, 1955, "Metformin decreases weight gain , lowers insulin requirement , and improves glycaemic control , and should be continued in patients with Type 2 diabetes who transfer to insulin", "", +7968, Metformin, 1779, 1788, "Metformin", "", +7969, WeightGain, 1799, 1810, "weight gain", "", +7970, EndPointDescription, 1820, 1839, "insulin requirement", "", +7971, Type2Diabetes, 1916, 1931, "Type 2 diabetes", "", +7972, PMID, 2018, 2026, "15842521", "", diff --git a/data/dm2 15842521_akramersunderbrink.n-triples b/data/dm2 15842521_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15842521_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 15842521_export.csv b/data/dm2 15842521_export.csv new file mode 100644 index 0000000..6a21433 --- /dev/null +++ b/data/dm2 15842521_export.csv @@ -0,0 +1,444 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +368, 1, 1, 1, 0, 6, 0, 6, "Diabet" +368, 1, 2, 2, 7, 10, 7, 10, "Med" +368, 1, 3, 3, 11, 12, 11, 12, "." +368, 2, 1, 4, 0, 4, 13, 17, "2005" +368, 2, 2, 5, 5, 8, 18, 21, "May" +368, 2, 3, 6, 9, 10, 22, 23, ";" +368, 2, 4, 7, 11, 13, 24, 26, "22" +368, 2, 5, 8, 14, 15, 27, 28, "(" +368, 2, 6, 9, 16, 17, 29, 30, "5" +368, 2, 7, 10, 18, 19, 31, 32, ")" +368, 2, 8, 11, 20, 21, 33, 34, ":" +368, 2, 9, 12, 22, 25, 35, 38, "634" +368, 2, 10, 13, 26, 27, 39, 40, "-" +368, 2, 11, 14, 28, 30, 41, 43, "40" +368, 2, 12, 15, 31, 32, 44, 45, "." +368, 3, 1, 16, 0, 10, 46, 56, "Continuing" +368, 3, 2, 17, 11, 20, 57, 66, "metformin" +368, 3, 3, 18, 21, 25, 67, 71, "when" +368, 3, 4, 19, 26, 34, 72, 80, "starting" +368, 3, 5, 20, 35, 42, 81, 88, "insulin" +368, 3, 6, 21, 43, 45, 89, 91, "in" +368, 3, 7, 22, 46, 54, 92, 100, "patients" +368, 3, 8, 23, 55, 59, 101, 105, "with" +368, 3, 9, 24, 60, 64, 106, 110, "Type" +368, 3, 10, 25, 65, 66, 111, 112, "2" +368, 3, 11, 26, 67, 75, 113, 121, "diabetes" +368, 3, 12, 27, 76, 77, 122, 123, ":" +368, 3, 13, 28, 78, 79, 124, 125, "a" +368, 3, 14, 29, 80, 86, 126, 132, "double" +368, 3, 15, 30, 87, 88, 133, 134, "-" +368, 3, 16, 31, 89, 94, 135, 140, "blind" +368, 3, 17, 32, 95, 105, 141, 151, "randomized" +368, 3, 18, 33, 106, 113, 152, 159, "placebo" +368, 3, 19, 34, 114, 115, 160, 161, "-" +368, 3, 20, 35, 116, 126, 162, 172, "controlled" +368, 3, 21, 36, 127, 132, 173, 178, "trial" +368, 3, 22, 37, 133, 134, 179, 180, "." +368, 4, 1, 38, 0, 5, 181, 186, "Douek" +368, 4, 2, 39, 6, 8, 187, 189, "IF" +368, 4, 3, 40, 9, 10, 190, 191, "(" +368, 4, 4, 41, 11, 12, 192, 193, "1" +368, 4, 5, 42, 13, 14, 194, 195, ")" +368, 4, 6, 43, 15, 16, 196, 197, "," +368, 4, 7, 44, 17, 22, 198, 203, "Allen" +368, 4, 8, 45, 23, 25, 204, 206, "SE" +368, 4, 9, 46, 26, 27, 207, 208, "," +368, 4, 10, 47, 28, 34, 209, 215, "Ewings" +368, 4, 11, 48, 35, 36, 216, 217, "P" +368, 4, 12, 49, 37, 38, 218, 219, "," +368, 4, 13, 50, 39, 43, 220, 224, "Gale" +368, 4, 14, 51, 44, 46, 225, 227, "EA" +368, 4, 15, 52, 47, 48, 228, 229, "," +368, 4, 16, 53, 49, 56, 230, 237, "Bingley" +368, 4, 17, 54, 57, 59, 238, 240, "PJ" +368, 4, 18, 55, 60, 61, 241, 242, ";" +368, 4, 19, 56, 62, 71, 243, 252, "Metformin" +368, 4, 20, 57, 72, 77, 253, 258, "Trial" +368, 4, 21, 58, 78, 83, 259, 264, "Group" +368, 4, 22, 59, 84, 85, 265, 266, "." +368, 5, 1, 60, 0, 6, 267, 273, "Author" +368, 5, 2, 61, 7, 18, 274, 285, "information" +368, 5, 3, 62, 19, 20, 286, 287, ":" +368, 5, 4, 63, 21, 22, 288, 289, "(" +368, 5, 5, 64, 23, 24, 290, 291, "1" +368, 5, 6, 65, 25, 26, 292, 293, ")" +368, 5, 7, 66, 27, 35, 294, 302, "Diabetes" +368, 5, 8, 67, 36, 39, 303, 306, "and" +368, 5, 9, 68, 40, 50, 307, 317, "Metabolism" +368, 5, 10, 69, 51, 52, 318, 319, "," +368, 5, 11, 70, 53, 61, 320, 328, "Division" +368, 5, 12, 71, 62, 64, 329, 331, "of" +368, 5, 13, 72, 65, 73, 332, 340, "Medicine" +368, 5, 14, 73, 74, 75, 341, 342, "," +368, 5, 15, 74, 76, 86, 343, 353, "University" +368, 5, 16, 75, 87, 89, 354, 356, "of" +368, 5, 17, 76, 90, 97, 357, 364, "Bristol" +368, 5, 18, 77, 98, 99, 365, 366, "," +368, 5, 19, 78, 100, 107, 367, 374, "Bristol" +368, 5, 20, 79, 108, 109, 375, 376, "," +368, 5, 21, 80, 110, 112, 377, 379, "UK" +368, 5, 22, 81, 113, 114, 380, 381, "." +368, 6, 1, 82, 0, 4, 382, 386, "AIMS" +368, 6, 2, 83, 5, 6, 387, 388, ":" +368, 6, 3, 84, 7, 9, 389, 391, "To" +368, 6, 4, 85, 10, 14, 392, 396, "test" +368, 6, 5, 86, 15, 18, 397, 400, "the" +368, 6, 6, 87, 19, 25, 401, 407, "effect" +368, 6, 7, 88, 26, 28, 408, 410, "of" +368, 6, 8, 89, 29, 39, 411, 421, "continuing" +368, 6, 9, 90, 40, 49, 422, 431, "metformin" +368, 6, 10, 91, 50, 52, 432, 434, "on" +368, 6, 11, 92, 53, 59, 435, 441, "weight" +368, 6, 12, 93, 60, 64, 442, 446, "gain" +368, 6, 13, 94, 65, 68, 447, 450, "and" +368, 6, 14, 95, 69, 78, 451, 460, "glycaemic" +368, 6, 15, 96, 79, 86, 461, 468, "control" +368, 6, 16, 97, 87, 89, 469, 471, "in" +368, 6, 17, 98, 90, 98, 472, 480, "patients" +368, 6, 18, 99, 99, 103, 481, 485, "with" +368, 6, 19, 100, 104, 110, 486, 492, "poorly" +368, 6, 20, 101, 111, 121, 493, 503, "controlled" +368, 6, 21, 102, 122, 126, 504, 508, "Type" +368, 6, 22, 103, 127, 128, 509, 510, "2" +368, 6, 23, 104, 129, 137, 511, 519, "diabetes" +368, 6, 24, 105, 138, 141, 520, 523, "who" +368, 6, 25, 106, 142, 146, 524, 528, "need" +368, 6, 26, 107, 147, 149, 529, 531, "to" +368, 6, 27, 108, 150, 155, 532, 537, "start" +368, 6, 28, 109, 156, 163, 538, 545, "insulin" +368, 6, 29, 110, 164, 165, 546, 547, "." +368, 7, 1, 111, 0, 7, 548, 555, "METHODS" +368, 7, 2, 112, 8, 9, 556, 557, ":" +368, 7, 3, 113, 10, 18, 558, 566, "Patients" +368, 7, 4, 114, 19, 23, 567, 571, "with" +368, 7, 5, 115, 24, 28, 572, 576, "Type" +368, 7, 6, 116, 29, 30, 577, 578, "2" +368, 7, 7, 117, 31, 39, 579, 587, "diabetes" +368, 7, 8, 118, 40, 42, 588, 590, "on" +368, 7, 9, 119, 43, 50, 591, 598, "maximum" +368, 7, 10, 120, 51, 60, 599, 608, "tolerated" +368, 7, 11, 121, 61, 65, 609, 613, "oral" +368, 7, 12, 122, 66, 72, 614, 620, "agents" +368, 7, 13, 123, 73, 81, 621, 629, "referred" +368, 7, 14, 124, 82, 85, 630, 633, "for" +368, 7, 15, 125, 86, 93, 634, 641, "insulin" +368, 7, 16, 126, 94, 104, 642, 652, "conversion" +368, 7, 17, 127, 105, 109, 653, 657, "were" +368, 7, 18, 128, 110, 119, 658, 667, "recruited" +368, 7, 19, 129, 120, 124, 668, 672, "from" +368, 7, 20, 130, 125, 133, 673, 681, "hospital" +368, 7, 21, 131, 134, 142, 682, 690, "diabetes" +368, 7, 22, 132, 143, 150, 691, 698, "clinics" +368, 7, 23, 133, 151, 155, 699, 703, "into" +368, 7, 24, 134, 156, 157, 704, 705, "a" +368, 7, 25, 135, 158, 164, 706, 712, "double" +368, 7, 26, 136, 165, 166, 713, 714, "-" +368, 7, 27, 137, 167, 172, 715, 720, "blind" +368, 7, 28, 138, 173, 183, 721, 731, "randomized" +368, 7, 29, 139, 184, 191, 732, 739, "placebo" +368, 7, 30, 140, 192, 193, 740, 741, "-" +368, 7, 31, 141, 194, 204, 742, 752, "controlled" +368, 7, 32, 142, 205, 210, 753, 758, "trial" +368, 7, 33, 143, 211, 212, 759, 760, "." +368, 8, 1, 144, 0, 3, 761, 764, "The" +368, 8, 2, 145, 4, 7, 765, 768, "183" +368, 8, 3, 146, 8, 20, 769, 781, "participants" +368, 8, 4, 147, 21, 29, 782, 790, "received" +368, 8, 5, 148, 30, 39, 791, 800, "metformin" +368, 8, 6, 149, 40, 42, 801, 803, "or" +368, 8, 7, 150, 43, 50, 804, 811, "placebo" +368, 8, 8, 151, 51, 52, 812, 813, "," +368, 8, 9, 152, 53, 61, 814, 822, "titrated" +368, 8, 10, 153, 62, 64, 823, 825, "up" +368, 8, 11, 154, 65, 67, 826, 828, "to" +368, 8, 12, 155, 68, 69, 829, 830, "2" +368, 8, 13, 156, 70, 71, 831, 832, "g" +368, 8, 14, 157, 72, 73, 833, 834, "a" +368, 8, 15, 158, 74, 77, 835, 838, "day" +368, 8, 16, 159, 78, 80, 839, 841, "or" +368, 8, 17, 160, 81, 88, 842, 849, "maximum" +368, 8, 18, 161, 89, 98, 850, 859, "tolerated" +368, 8, 19, 162, 99, 103, 860, 864, "dose" +368, 8, 20, 163, 104, 105, 865, 866, "," +368, 8, 21, 164, 106, 110, 867, 871, "with" +368, 8, 22, 165, 111, 118, 872, 879, "insulin" +368, 8, 23, 166, 119, 126, 880, 887, "started" +368, 8, 24, 167, 127, 136, 888, 897, "according" +368, 8, 25, 168, 137, 139, 898, 900, "to" +368, 8, 26, 169, 140, 145, 901, 906, "local" +368, 8, 27, 170, 146, 154, 907, 915, "practice" +368, 8, 28, 171, 155, 156, 916, 917, "." +368, 9, 1, 172, 0, 3, 918, 921, "The" +368, 9, 2, 173, 4, 8, 922, 926, "main" +368, 9, 3, 174, 9, 16, 927, 934, "outcome" +368, 9, 4, 175, 17, 25, 935, 943, "measures" +368, 9, 5, 176, 26, 30, 944, 948, "were" +368, 9, 6, 177, 31, 37, 949, 955, "weight" +368, 9, 7, 178, 38, 44, 956, 962, "change" +368, 9, 8, 179, 45, 49, 963, 967, "over" +368, 9, 9, 180, 50, 52, 968, 970, "12" +368, 9, 10, 181, 53, 59, 971, 977, "months" +368, 9, 11, 182, 60, 61, 978, 979, "," +368, 9, 12, 183, 62, 67, 980, 985, "HbA1c" +368, 9, 13, 184, 68, 69, 986, 987, "," +368, 9, 14, 185, 70, 77, 988, 995, "insulin" +368, 9, 15, 186, 78, 82, 996, 1000, "dose" +368, 9, 16, 187, 83, 84, 1001, 1002, "," +368, 9, 17, 188, 85, 94, 1003, 1012, "frequency" +368, 9, 18, 189, 95, 97, 1013, 1015, "of" +368, 9, 19, 190, 98, 111, 1016, 1029, "hypoglycaemia" +368, 9, 20, 191, 112, 113, 1030, 1031, "," +368, 9, 21, 192, 114, 123, 1032, 1041, "treatment" +368, 9, 22, 193, 124, 136, 1042, 1054, "satisfaction" +368, 9, 23, 194, 137, 138, 1055, 1056, "," +368, 9, 24, 195, 139, 142, 1057, 1060, "and" +368, 9, 25, 196, 143, 147, 1061, 1065, "well" +368, 9, 26, 197, 148, 149, 1066, 1067, "-" +368, 9, 27, 198, 150, 155, 1068, 1073, "being" +368, 9, 28, 199, 156, 157, 1074, 1075, "." +368, 10, 1, 200, 0, 7, 1076, 1083, "RESULTS" +368, 10, 2, 201, 8, 9, 1084, 1085, ":" +368, 10, 3, 202, 10, 14, 1086, 1090, "Over" +368, 10, 4, 203, 15, 17, 1091, 1093, "12" +368, 10, 5, 204, 18, 24, 1094, 1100, "months" +368, 10, 6, 205, 25, 26, 1101, 1102, "," +368, 10, 7, 206, 27, 36, 1103, 1112, "metformin" +368, 10, 8, 207, 37, 40, 1113, 1116, "was" +368, 10, 9, 208, 41, 51, 1117, 1127, "associated" +368, 10, 10, 209, 52, 56, 1128, 1132, "with" +368, 10, 11, 210, 57, 61, 1133, 1137, "less" +368, 10, 12, 211, 62, 68, 1138, 1144, "weight" +368, 10, 13, 212, 69, 73, 1145, 1149, "gain" +368, 10, 14, 213, 74, 78, 1150, 1154, "than" +368, 10, 15, 214, 79, 86, 1155, 1162, "placebo" +368, 10, 16, 215, 87, 88, 1163, 1164, "[" +368, 10, 17, 216, 89, 93, 1165, 1169, "mean" +368, 10, 18, 217, 94, 95, 1170, 1171, "6" +368, 10, 19, 218, 96, 97, 1172, 1173, "." +368, 10, 20, 219, 98, 99, 1174, 1175, "1" +368, 10, 21, 220, 100, 102, 1176, 1178, "kg" +368, 10, 22, 221, 103, 105, 1179, 1181, "vs" +368, 10, 23, 222, 106, 107, 1182, 1183, "." +368, 10, 24, 223, 108, 109, 1184, 1185, "7" +368, 10, 25, 224, 110, 111, 1186, 1187, "." +368, 10, 26, 225, 112, 113, 1188, 1189, "6" +368, 10, 27, 226, 114, 116, 1190, 1192, "kg" +368, 10, 28, 227, 117, 118, 1193, 1194, ";" +368, 10, 29, 228, 119, 127, 1195, 1203, "adjusted" +368, 10, 30, 229, 128, 138, 1204, 1214, "difference" +368, 10, 31, 230, 139, 140, 1215, 1216, "1" +368, 10, 32, 231, 141, 142, 1217, 1218, "." +368, 10, 33, 232, 143, 144, 1219, 1220, "5" +368, 10, 34, 233, 145, 147, 1221, 1223, "kg" +368, 10, 35, 234, 148, 149, 1224, 1225, "(" +368, 10, 36, 235, 150, 152, 1226, 1228, "95" +368, 10, 37, 236, 153, 154, 1229, 1230, "%" +368, 10, 38, 237, 155, 165, 1231, 1241, "confidence" +368, 10, 39, 238, 166, 174, 1242, 1250, "interval" +368, 10, 40, 239, 175, 176, 1251, 1252, "0" +368, 10, 41, 240, 177, 178, 1253, 1254, "." +368, 10, 42, 241, 179, 180, 1255, 1256, "2" +368, 10, 43, 242, 181, 182, 1257, 1258, "-" +368, 10, 44, 243, 183, 184, 1259, 1260, "2" +368, 10, 45, 244, 185, 186, 1261, 1262, "." +368, 10, 46, 245, 187, 188, 1263, 1264, "9" +368, 10, 47, 246, 189, 190, 1265, 1266, ")" +368, 10, 48, 247, 191, 192, 1267, 1268, ";" +368, 10, 49, 248, 193, 194, 1269, 1270, "P" +368, 10, 50, 249, 195, 196, 1271, 1272, "=" +368, 10, 51, 250, 197, 198, 1273, 1274, "0" +368, 10, 52, 251, 199, 200, 1275, 1276, "." +368, 10, 53, 252, 201, 203, 1277, 1279, "02" +368, 10, 54, 253, 204, 205, 1280, 1281, "]" +368, 10, 55, 254, 206, 207, 1282, 1283, "," +368, 10, 56, 255, 208, 209, 1284, 1285, "a" +368, 10, 57, 256, 210, 217, 1286, 1293, "greater" +368, 10, 58, 257, 218, 227, 1294, 1303, "reduction" +368, 10, 59, 258, 228, 230, 1304, 1306, "in" +368, 10, 60, 259, 231, 236, 1307, 1312, "HbA1c" +368, 10, 61, 260, 237, 238, 1313, 1314, "[" +368, 10, 62, 261, 239, 240, 1315, 1316, "1" +368, 10, 63, 262, 241, 242, 1317, 1318, "." +368, 10, 64, 263, 243, 244, 1319, 1320, "5" +368, 10, 65, 264, 245, 246, 1321, 1322, "%" +368, 10, 66, 265, 247, 249, 1323, 1325, "vs" +368, 10, 67, 266, 250, 251, 1326, 1327, "." +368, 10, 68, 267, 252, 253, 1328, 1329, "1" +368, 10, 69, 268, 254, 255, 1330, 1331, "." +368, 10, 70, 269, 256, 257, 1332, 1333, "3" +368, 10, 71, 270, 258, 259, 1334, 1335, "%" +368, 10, 72, 271, 260, 261, 1336, 1337, ";" +368, 10, 73, 272, 262, 270, 1338, 1346, "adjusted" +368, 10, 74, 273, 271, 281, 1347, 1357, "difference" +368, 10, 75, 274, 282, 283, 1358, 1359, "0" +368, 10, 76, 275, 284, 285, 1360, 1361, "." +368, 10, 77, 276, 286, 287, 1362, 1363, "5" +368, 10, 78, 277, 288, 289, 1364, 1365, "%" +368, 10, 79, 278, 290, 291, 1366, 1367, "(" +368, 10, 80, 279, 292, 293, 1368, 1369, "0" +368, 10, 81, 280, 294, 295, 1370, 1371, "." +368, 10, 82, 281, 296, 297, 1372, 1373, "1" +368, 10, 83, 282, 298, 299, 1374, 1375, "-" +368, 10, 84, 283, 300, 301, 1376, 1377, "0" +368, 10, 85, 284, 302, 303, 1378, 1379, "." +368, 10, 86, 285, 304, 305, 1380, 1381, "9" +368, 10, 87, 286, 306, 307, 1382, 1383, ")" +368, 10, 88, 287, 308, 309, 1384, 1385, ";" +368, 10, 89, 288, 310, 311, 1386, 1387, "P" +368, 10, 90, 289, 312, 313, 1388, 1389, "=" +368, 10, 91, 290, 314, 315, 1390, 1391, "0" +368, 10, 92, 291, 316, 317, 1392, 1393, "." +368, 10, 93, 292, 318, 320, 1394, 1396, "02" +368, 10, 94, 293, 321, 322, 1397, 1398, "]" +368, 10, 95, 294, 323, 326, 1399, 1402, "and" +368, 10, 96, 295, 327, 328, 1403, 1404, "a" +368, 10, 97, 296, 329, 334, 1405, 1410, "lower" +368, 10, 98, 297, 335, 342, 1411, 1418, "insulin" +368, 10, 99, 298, 343, 354, 1419, 1430, "requirement" +368, 10, 100, 299, 355, 356, 1431, 1432, "[" +368, 10, 101, 300, 357, 359, 1433, 1435, "62" +368, 10, 102, 301, 360, 365, 1436, 1441, "units" +368, 10, 103, 302, 366, 368, 1442, 1444, "vs" +368, 10, 104, 303, 369, 370, 1445, 1446, "." +368, 10, 105, 304, 371, 373, 1447, 1449, "86" +368, 10, 106, 305, 374, 375, 1450, 1451, ";" +368, 10, 107, 306, 376, 384, 1452, 1460, "adjusted" +368, 10, 108, 307, 385, 395, 1461, 1471, "difference" +368, 10, 109, 308, 396, 398, 1472, 1474, "25" +368, 10, 110, 309, 399, 404, 1475, 1480, "units" +368, 10, 111, 310, 405, 406, 1481, 1482, "(" +368, 10, 112, 311, 407, 409, 1483, 1485, "15" +368, 10, 113, 312, 410, 411, 1486, 1487, "-" +368, 10, 114, 313, 412, 414, 1488, 1490, "34" +368, 10, 115, 314, 415, 416, 1491, 1492, ")" +368, 10, 116, 315, 417, 418, 1493, 1494, ";" +368, 10, 117, 316, 419, 420, 1495, 1496, "P" +368, 10, 118, 317, 421, 422, 1497, 1498, "<" +368, 10, 119, 318, 423, 424, 1499, 1500, "0" +368, 10, 120, 319, 425, 426, 1501, 1502, "." +368, 10, 121, 320, 427, 430, 1503, 1506, "001" +368, 10, 122, 321, 431, 432, 1507, 1508, "]" +368, 10, 123, 322, 433, 434, 1509, 1510, "," +368, 10, 124, 323, 435, 438, 1511, 1514, "but" +368, 10, 125, 324, 439, 443, 1515, 1519, "also" +368, 10, 126, 325, 444, 448, 1520, 1524, "more" +368, 10, 127, 326, 449, 462, 1525, 1538, "hypoglycaemia" +368, 10, 128, 327, 463, 464, 1539, 1540, "[" +368, 10, 129, 328, 465, 473, 1541, 1549, "relative" +368, 10, 130, 329, 474, 478, 1550, 1554, "risk" +368, 10, 131, 330, 479, 481, 1555, 1557, "of" +368, 10, 132, 331, 482, 485, 1558, 1561, "any" +368, 10, 133, 332, 486, 493, 1562, 1569, "episode" +368, 10, 134, 333, 494, 495, 1570, 1571, "1" +368, 10, 135, 334, 496, 497, 1572, 1573, "." +368, 10, 136, 335, 498, 500, 1574, 1576, "24" +368, 10, 137, 336, 501, 502, 1577, 1578, "(" +368, 10, 138, 337, 503, 504, 1579, 1580, "1" +368, 10, 139, 338, 505, 506, 1581, 1582, "." +368, 10, 140, 339, 507, 509, 1583, 1585, "02" +368, 10, 141, 340, 510, 511, 1586, 1587, "-" +368, 10, 142, 341, 512, 513, 1588, 1589, "1" +368, 10, 143, 342, 514, 515, 1590, 1591, "." +368, 10, 144, 343, 516, 517, 1592, 1593, "1" +368, 10, 145, 344, 518, 519, 1594, 1595, ")" +368, 10, 146, 345, 520, 521, 1596, 1597, ";" +368, 10, 147, 346, 522, 523, 1598, 1599, "P" +368, 10, 148, 347, 524, 525, 1600, 1601, "=" +368, 10, 149, 348, 526, 527, 1602, 1603, "0" +368, 10, 150, 349, 528, 529, 1604, 1605, "." +368, 10, 151, 350, 530, 532, 1606, 1608, "03" +368, 10, 152, 351, 533, 534, 1609, 1610, "]" +368, 10, 153, 352, 535, 536, 1611, 1612, "." +368, 11, 1, 353, 0, 9, 1613, 1622, "Treatment" +368, 11, 2, 354, 10, 22, 1623, 1635, "satisfaction" +368, 11, 3, 355, 23, 31, 1636, 1644, "improved" +368, 11, 4, 356, 32, 36, 1645, 1649, "more" +368, 11, 5, 357, 37, 39, 1650, 1652, "in" +368, 11, 6, 358, 40, 48, 1653, 1661, "patients" +368, 11, 7, 359, 49, 51, 1662, 1664, "on" +368, 11, 8, 360, 52, 61, 1665, 1674, "metformin" +368, 11, 9, 361, 62, 66, 1675, 1679, "than" +368, 11, 10, 362, 67, 69, 1680, 1682, "on" +368, 11, 11, 363, 70, 77, 1683, 1690, "placebo" +368, 11, 12, 364, 78, 79, 1691, 1692, "(" +368, 11, 13, 365, 80, 81, 1693, 1694, "P" +368, 11, 14, 366, 82, 83, 1695, 1696, "<" +368, 11, 15, 367, 84, 85, 1697, 1698, "0" +368, 11, 16, 368, 86, 87, 1699, 1700, "." +368, 11, 17, 369, 88, 91, 1701, 1704, "001" +368, 11, 18, 370, 92, 93, 1705, 1706, ")" +368, 11, 19, 371, 94, 95, 1707, 1708, "," +368, 11, 20, 372, 96, 98, 1709, 1711, "as" +368, 11, 21, 373, 99, 102, 1712, 1715, "did" +368, 11, 22, 374, 103, 106, 1716, 1719, "the" +368, 11, 23, 375, 107, 115, 1720, 1728, "positive" +368, 11, 24, 376, 116, 120, 1729, 1733, "well" +368, 11, 25, 377, 121, 122, 1734, 1735, "-" +368, 11, 26, 378, 123, 128, 1736, 1741, "being" +368, 11, 27, 379, 129, 134, 1742, 1747, "score" +368, 11, 28, 380, 135, 136, 1748, 1749, "(" +368, 11, 29, 381, 137, 138, 1750, 1751, "P" +368, 11, 30, 382, 139, 140, 1752, 1753, "=" +368, 11, 31, 383, 141, 142, 1754, 1755, "0" +368, 11, 32, 384, 143, 144, 1756, 1757, "." +368, 11, 33, 385, 145, 147, 1758, 1760, "02" +368, 11, 34, 386, 148, 149, 1761, 1762, ")" +368, 11, 35, 387, 150, 151, 1763, 1764, "." +368, 12, 1, 388, 0, 11, 1765, 1776, "CONCLUSIONS" +368, 12, 2, 389, 12, 13, 1777, 1778, ":" +368, 12, 3, 390, 14, 23, 1779, 1788, "Metformin" +368, 12, 4, 391, 24, 33, 1789, 1798, "decreases" +368, 12, 5, 392, 34, 40, 1799, 1805, "weight" +368, 12, 6, 393, 41, 45, 1806, 1810, "gain" +368, 12, 7, 394, 46, 47, 1811, 1812, "," +368, 12, 8, 395, 48, 54, 1813, 1819, "lowers" +368, 12, 9, 396, 55, 62, 1820, 1827, "insulin" +368, 12, 10, 397, 63, 74, 1828, 1839, "requirement" +368, 12, 11, 398, 75, 76, 1840, 1841, "," +368, 12, 12, 399, 77, 80, 1842, 1845, "and" +368, 12, 13, 400, 81, 89, 1846, 1854, "improves" +368, 12, 14, 401, 90, 99, 1855, 1864, "glycaemic" +368, 12, 15, 402, 100, 107, 1865, 1872, "control" +368, 12, 16, 403, 108, 109, 1873, 1874, "," +368, 12, 17, 404, 110, 113, 1875, 1878, "and" +368, 12, 18, 405, 114, 120, 1879, 1885, "should" +368, 12, 19, 406, 121, 123, 1886, 1888, "be" +368, 12, 20, 407, 124, 133, 1889, 1898, "continued" +368, 12, 21, 408, 134, 136, 1899, 1901, "in" +368, 12, 22, 409, 137, 145, 1902, 1910, "patients" +368, 12, 23, 410, 146, 150, 1911, 1915, "with" +368, 12, 24, 411, 151, 155, 1916, 1920, "Type" +368, 12, 25, 412, 156, 157, 1921, 1922, "2" +368, 12, 26, 413, 158, 166, 1923, 1931, "diabetes" +368, 12, 27, 414, 167, 170, 1932, 1935, "who" +368, 12, 28, 415, 171, 179, 1936, 1944, "transfer" +368, 12, 29, 416, 180, 182, 1945, 1947, "to" +368, 12, 30, 417, 183, 190, 1948, 1955, "insulin" +368, 12, 31, 418, 191, 192, 1956, 1957, "." +368, 13, 1, 419, 0, 3, 1958, 1961, "DOI" +368, 13, 2, 420, 4, 5, 1962, 1963, ":" +368, 13, 3, 421, 6, 8, 1964, 1966, "10" +368, 13, 4, 422, 9, 10, 1967, 1968, "." +368, 13, 5, 423, 11, 15, 1969, 1973, "1111" +368, 13, 6, 424, 16, 17, 1974, 1975, "/" +368, 13, 7, 425, 18, 19, 1976, 1977, "j" +368, 13, 8, 426, 20, 21, 1978, 1979, "." +368, 13, 9, 427, 22, 26, 1980, 1984, "1464" +368, 13, 10, 428, 27, 28, 1985, 1986, "-" +368, 13, 11, 429, 29, 33, 1987, 1991, "5491" +368, 13, 12, 430, 34, 35, 1992, 1993, "." +368, 13, 13, 431, 36, 40, 1994, 1998, "2005" +368, 13, 14, 432, 41, 42, 1999, 2000, "." +368, 13, 15, 433, 43, 48, 2001, 2006, "01475" +368, 13, 16, 434, 49, 50, 2007, 2008, "." +368, 13, 17, 435, 51, 52, 2009, 2010, "x" +368, 13, 18, 436, 53, 57, 2011, 2015, "PMID" +368, 13, 19, 437, 58, 59, 2016, 2017, ":" +368, 13, 20, 438, 60, 68, 2018, 2026, "15842521" +368, 13, 21, 439, 69, 70, 2027, 2028, "[" +368, 13, 22, 440, 71, 78, 2029, 2036, "Indexed" +368, 13, 23, 441, 79, 82, 2037, 2040, "for" +368, 13, 24, 442, 83, 90, 2041, 2048, "MEDLINE" +368, 13, 25, 443, 91, 92, 2049, 2050, "]" diff --git a/data/dm2 15842521_kwoodley.annodb b/data/dm2 15842521_kwoodley.annodb new file mode 100644 index 0000000..a8c5caf --- /dev/null +++ b/data/dm2 15842521_kwoodley.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31537, Journal, 0, 12, "Diabet Med .", "", +2870, PublicationYear, 13, 17, "2005", "", +31538, Title, 46, 180, "Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial .", "", +2914, Metformin, 57, 66, "metformin", "", +2915, Insulin, 81, 88, "insulin", "", +2890, Type2Diabetes, 106, 121, "Type 2 diabetes", "", +2904, DoubleBlind, 126, 140, "double - blind", "", +2906, Randomized, 141, 151, "randomized", "", +31539, Placebo, 152, 159, "placebo", "", +2873, Author, 181, 189, "Douek IF", "", +2874, Author, 198, 206, "Allen SE", "", +2875, Author, 209, 217, "Ewings P", "", +2876, Author, 220, 227, "Gale EA", "", +2877, Author, 230, 240, "Bingley PJ", "", +2880, UK, 377, 379, "UK", "", +31540, ObjectiveDescription, 389, 547, "To test the effect of continuing metformin on weight gain and glycaemic control in patients with poorly controlled Type 2 diabetes who need to start insulin .", "", +2912, Metformin, 422, 431, "metformin", "", +2962, BodyWeight, 435, 441, "weight", "", +2928, Precondition, 472, 545, "patients with poorly controlled Type 2 diabetes who need to start insulin", "", +2895, Type2Diabetes, 504, 519, "Type 2 diabetes", "", +2929, Insulin, 538, 545, "insulin", "", +2930, Precondition, 558, 652, "Patients with Type 2 diabetes on maximum tolerated oral agents referred for insulin conversion", "", +2899, Type2Diabetes, 572, 587, "Type 2 diabetes", "", +3731, OralAntidiabeticAgent, 609, 620, "oral agents", "", +3732, Insulin, 634, 641, "insulin", "", +2933, DoubleBlind, 706, 720, "double - blind", "", +2932, Randomized, 721, 731, "randomized", "", +31541, Placebo, 732, 739, "placebo", "", +2885, NumberPatientsCT, 765, 768, "183", "", +2934, Metformin, 791, 800, "metformin", "", +2935, Placebo, 804, 811, "placebo", "", +2936, DoseValue, 829, 830, "2", "", +2937, Gram, 831, 832, "g", "", +2938, Frequency, 833, 838, "a day", "", +2939, Insulin, 872, 879, "insulin", "", +2940, BodyWeight, 949, 955, "weight", "", +2941, Duration, 968, 977, "12 months", "", +2942, HbA1c, 980, 985, "HbA1c", "", +31542, InsulinDose, 988, 1000, "insulin dose", "", +2944, Hypoglycemia, 1016, 1029, "hypoglycaemia", "", +31545, EndPointDescription, 1032, 1054, "treatment satisfaction", "", +31546, EndPointDescription, 1061, 1073, "well - being", "", +2945, Duration, 1091, 1100, "12 months", "", +2946, Metformin, 1103, 1112, "metformin", "", +2947, BodyWeight, 1138, 1144, "weight", "", +2948, Placebo, 1155, 1162, "placebo", "", +2993, Increment, 1170, 1175, "6 . 1", "", +2989, Kg, 1176, 1178, "kg", "", +2994, Increment, 1184, 1189, "7 . 6", "", +2991, Kg, 1190, 1192, "kg", "", +2995, DiffGroupAbsValue, 1215, 1220, "1 . 5", "", +2992, Kg, 1221, 1223, "kg", "", +31543, ConfIntervalDiff, 1226, 1264, "95 % confidence interval 0 . 2 - 2 . 9", "", +2968, PvalueDiff, 1269, 1279, "P = 0 . 02", "", +2964, HbA1c, 1307, 1312, "HbA1c", "", +2969, Reduction, 1315, 1320, "1 . 5", "", +2971, Percentage, 1321, 1322, "%", "", +2970, Reduction, 1328, 1333, "1 . 3", "", +2972, Percentage, 1334, 1335, "%", "", +2996, DiffGroupAbsValue, 1358, 1363, "0 . 5", "", +2973, Percentage, 1364, 1365, "%", "", +2997, ConfIntervalDiff, 1368, 1381, "0 . 1 - 0 . 9", "", +2976, PvalueDiff, 1386, 1396, "P = 0 . 02", "", +31544, InsulinDose, 1411, 1430, "insulin requirement", "", +2980, ObservedResult, 1433, 1492, "62 units vs . 86 ; adjusted difference 25 units ( 15 - 34 )", "", +2978, PvalueDiff, 1495, 1506, "P < 0 . 001", "", +2966, Hypoglycemia, 1525, 1538, "hypoglycaemia", "", +2981, EndPointDescription, 1525, 1569, "hypoglycaemia [ relative risk of any episode", "Hypoglycemia", +2984, RelativeIncrement, 1570, 1576, "1 . 24", "only metformin", +2983, ConfIntervalChangeValue, 1579, 1593, "1 . 02 - 1 . 1", "only metformin", +2987, PValueChangeValue, 1598, 1608, "P = 0 . 03", "only metformin", +2952, EndPointDescription, 1613, 1635, "Treatment satisfaction", "treatment satisfaction", +2999, ObservedResult, 1636, 1690, "improved more in patients on metformin than on placebo", "", +2949, Metformin, 1665, 1674, "metformin", "", +2950, Placebo, 1683, 1690, "placebo", "", +2951, PvalueDiff, 1693, 1704, "P < 0 . 001", "", +2954, EndPointDescription, 1729, 1741, "well - being", "well-being", +2956, PvalueDiff, 1750, 1760, "P = 0 . 02", "", +31547, ConclusionComment, 1779, 1957, "Metformin decreases weight gain , lowers insulin requirement , and improves glycaemic control , and should be continued in patients with Type 2 diabetes who transfer to insulin .", "", +2957, Metformin, 1779, 1788, "Metformin", "", +2958, BodyWeight, 1799, 1805, "weight", "", +31548, InsulinDose, 1820, 1839, "insulin requirement", "", +2960, Precondition, 1902, 1955, "patients with Type 2 diabetes who transfer to insulin", "", +2900, Type2Diabetes, 1916, 1931, "Type 2 diabetes", "", +3733, Insulin, 1948, 1955, "insulin", "", +2888, PMID, 2018, 2026, "15842521", "", diff --git a/data/dm2 15842521_kwoodley.n-triples b/data/dm2 15842521_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 15842521_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16456680_admin.annodb b/data/dm2 16456680_admin.annodb new file mode 100644 index 0000000..6910268 --- /dev/null +++ b/data/dm2 16456680_admin.annodb @@ -0,0 +1,153 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +127, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +106431, PublicationYear, 15, 19, "2006", "", +106430, PublicationYear, 53, 57, "2006", "", " \"2006\"." +130, InsulinGlargine, 66, 82, "Insulin glargine", "", +268, Title, 66, 153, "Insulin glargine or NPH combined with metformin in type 2 diabetes : the LANMET study .", "", " \"Insulin glargine or NPH combined with metformin in type 2 diabetes : the LANMET study .\"." +131, IsophaneInsulin_NPH, 86, 89, "NPH", "", +132, Metformin, 104, 113, "metformin", "", +133, Type2Diabetes, 117, 132, "type 2 diabetes", "", +119895, Author, 154, 172, "Yki - J ä rvinen H", "", " \"Yki - J ä rvinen H\"." +2, Author, 181, 204, "Kauppinen - M ä kelin R", "", " \"Kauppinen - M ä kelin R\"." +3, Author, 207, 219, "Tiikkainen M", "", " \"Tiikkainen M\"." +4, Author, 222, 236, "V ä h ä talo M", "", " \"V ä h ä talo M\"." +5, Author, 239, 248, "Virtamo H", "", " \"Virtamo H\"." +6, Author, 251, 261, "Nikkil ä K", "", " \"Nikkil ä K\"." +7, Author, 264, 273, "Tulokas T", "", " \"Tulokas T\"." +8, Author, 276, 283, "Hulme S", "", " \"Hulme S\"." +9, Author, 286, 293, "Hardy K", "", " \"Hardy K\"." +10, Author, 296, 305, "McNulty S", "", " \"McNulty S\"." +11, Author, 308, 320, "H ä nninen J", "", " \"H ä nninen J\"." +12, Author, 323, 334, "Lev ä nen H", "", " \"Lev ä nen H\"." +13, Author, 337, 350, "Lahdenper ä S", "", " \"Lahdenper ä S\"." +14, Author, 353, 363, "Lehtonen R", "", " \"Lehtonen R\"." +15, Author, 366, 373, "Ryysy L", "", " \"Ryysy L\"." +16, Finland, 501, 508, "Finland", "", " ." +273, ObjectiveDescription, 561, 723, "In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin .", "", " \"In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin .\"." +17, Type2Diabetes, 564, 579, "type 2 diabetic", "", " ." +18, Duration, 601, 609, "9 months", "", +106429, InsulinGlargine, 633, 654, "with insulin glargine", "", +119893, Metformin, 659, 668, "metformin", "", +119894, Duration, 674, 682, "9 months", "", +22, IsophaneInsulin_NPH, 686, 697, "NPH insulin", "", +23, Metformin, 712, 721, "metformin", "", +24, HbA1c, 757, 767, "HbA ( 1c )", "", +274, Glucose, 790, 805, "diurnal glucose", "", +117, SymptomaticHypoglycemia, 819, 844, "symptomatic hypoglycaemia", "", +26, OpenLabel, 890, 894, "open", "", " ." +25, Parallel, 897, 913, "parallel - group", "", " ." +161, Multicenter, 939, 952, "seven centres", "", " ." +27, NumberPatientsCT, 955, 958, "110", "", " \"110\"." +28, Precondition, 959, 1129, "insulin - naive type 2 diabetic patients with poor glycaemic control ( HbA ( 1c ) > or = 8 . 0 % ) on oral hypoglycaemic agents ( 90 % using sulfonylurea plus metformin )", "", " \"insulin - naive type 2 diabetic patients with poor glycaemic control ( HbA ( 1c ) > or = 8 . 0 % ) on oral hypoglycaemic agents ( 90 % using sulfonylurea plus metformin )\"." +29, Type2Diabetes, 975, 990, "type 2 diabetic", "", +122, HbA1c, 1030, 1040, "HbA ( 1c )", "", +121, Percentage, 1054, 1055, "%", "", +123, OralAntidiabeticAgent, 1061, 1086, "oral hypoglycaemic agents", "", +124, Sulfonylureas, 1100, 1112, "sulfonylurea", "", +125, Metformin, 1118, 1127, "metformin", "", +30, Randomized, 1135, 1145, "randomised", "", " ." +31, Bedtime, 1157, 1164, "bedtime", "", " ." +32, InsulinGlargine, 1165, 1181, "insulin glargine", "", " ." +33, Metformin, 1187, 1196, "metformin", "", " ." +34, InsulinGlargine, 1199, 1200, "G", "", +35, Metformin, 1203, 1206, "MET", "", +38, Bedtime, 1212, 1219, "bedtime", "", " ." +39, IsophaneInsulin_NPH, 1220, 1223, "NPH", "", " ." +36, Metformin, 1229, 1238, "metformin", "", +40, IsophaneInsulin_NPH, 1241, 1244, "NPH", "", +37, Metformin, 1247, 1250, "MET", "", +41, Duration, 1257, 1265, "36 weeks", "", " \"36 weeks\". \"36 weeks\". \"36 weeks\"." +51229, DoseDescription, 1272, 1332, "patients were taught how to self - adjust their insulin dose", "", " \"patients were taught how to self - adjust their insulin dose\". \"patients were taught how to self - adjust their insulin dose\". \"patients were taught how to self - adjust their insulin dose\"." +276, InsulinDose, 1320, 1332, "insulin dose", "", +45514, FastingPlasmaGlucose, 1445, 1467, "fasting plasma glucose", "", +42, FastingPlasmaGlucose_target, 1445, 1502, "fasting plasma glucose ( FPG ) of 4 . 0 to 5 . 5 mmol / l", "", +45512, FastingPlasmaGlucose, 1470, 1473, "FPG", "", +178, Millimoles_per_litre, 1494, 1502, "mmol / l", "", +179, TimePoint, 1541, 1554, "last 12 weeks", "", +44, FastingPlasmaGlucose, 1557, 1561, "FPGs", "", " ." +45, ResultMeasuredValue, 1571, 1577, "5 . 75", "", " \"5 . 75\"." +51, SdDevResValue, 1584, 1590, "0 . 02", "", " \"0 . 02\"." +46, ResultMeasuredValue, 1595, 1601, "5 . 96", "", " \"5 . 96\"." +52, SdDevResValue, 1608, 1614, "0 . 03", "", " \"0 . 03\"." +57, Millimoles_per_litre, 1615, 1623, "mmol / l", "", " ." +58, PvalueDiff, 1626, 1637, "p < 0 . 001", "", " \"p < 0 . 001\"." +60999, InsulinDose, 1644, 1657, "insulin doses", "", " . ." +61000, ResultMeasuredValue, 1663, 1665, "68", "", " \"68\"." +61005, SdDevResValue, 1672, 1673, "5", "", " \"5\"." +61001, ResultMeasuredValue, 1678, 1680, "70", "", " \"70\"." +61004, SdDevResValue, 1687, 1688, "6", "", " \"6\"." +61008, BioAndMedicalUnit, 1689, 1697, "IU / day", "", " . ." +61002, ResultMeasuredValue, 1700, 1706, "0 . 69", "", +61006, SdDevResValue, 1713, 1719, "0 . 05", "", +61003, ResultMeasuredValue, 1724, 1730, "0 . 66", "", +61007, SdDevResValue, 1737, 1743, "0 . 04", "", +57595, IntUnit_per_Kg, 1744, 1749, "IU kg", "", +57597, Interval, 1758, 1761, "day", "", +62, InsulinGlargine, 1784, 1785, "G", "", +61, Metformin, 1788, 1791, "MET", "", +118, IsophaneInsulin_NPH, 1796, 1799, "NPH", "", +60, Metformin, 1802, 1805, "MET", "", +206, TimePoint, 1833, 1841, "36 weeks", "", +266, Mean, 1844, 1848, "mean", "", " . ." +64, HbA1c, 1849, 1859, "HbA ( 1c )", "", " ." +65, ResultMeasuredValue, 1864, 1870, "7 . 14", "", " \"7 . 14\"." +67, SdDevResValue, 1877, 1883, "0 . 12", "", " \"0 . 12\"." +66, ResultMeasuredValue, 1888, 1894, "7 . 16", "", " \"7 . 16\"." +68, SdDevResValue, 1901, 1907, "0 . 14", "", " \"0 . 14\"." +69, Percentage, 1908, 1909, "%", "", " ." +70, SymptomaticHypoglycemia, 1934, 1993, "Symptomatic , but not confirmed symptomatic , hypoglycaemia", "", " ." +71, TimePoint, 2029, 2043, "first 12 weeks", "", " \"first 12 weeks\". \"first 12 weeks\"." +72, InsulinGlargine, 2051, 2052, "G", "", +73, Metformin, 2055, 2058, "MET", "", +217, ResultMeasuredValue, 2067, 2072, "4 . 1", "", " \"4 . 1\"." +45515, SdDevResValue, 2079, 2084, "0 . 8", "", " \"0 . 8\"." +219, BioAndMedicalUnit, 2085, 2110, "episodes / patient - year", "", " . ." +77, IsophaneInsulin_NPH, 2125, 2128, "NPH", "", +74, Metformin, 2131, 2134, "MET", "", +222, ResultMeasuredValue, 2143, 2148, "9 . 0", "", " \"9 . 0\"." +45517, SdDevResValue, 2155, 2160, "2 . 3", "", " \"2 . 3\"." +224, BioAndMedicalUnit, 2161, 2186, "episodes / patient - year", "", +80, PvalueDiff, 2189, 2199, "p < 0 . 05", "", " \"p < 0 . 05\"." +45518, Glucose, 2249, 2277, "Glucose levels before dinner", "", " . ." +227, RelativeTime, 2264, 2277, "before dinner", "", +82, IsophaneInsulin_NPH, 2297, 2300, "NPH", "", +83, Metformin, 2303, 2306, "MET", "", +85, ResultMeasuredValue, 2315, 2321, "10 . 1", "", +87, SdDevResValue, 2328, 2333, "0 . 3", "", +90, Millimoles_per_litre, 2334, 2342, "mmol / l", "", " ." +89, InsulinGlargine, 2357, 2358, "G", "", +84, Metformin, 2361, 2364, "MET", "", +86, ResultMeasuredValue, 2373, 2378, "8 . 6", "", +88, SdDevResValue, 2385, 2390, "0 . 3", "", +91, Millimoles_per_litre, 2391, 2399, "mmol / l", "", +92, PvalueDiff, 2402, 2413, "p = 0 . 002", "", +93, Duration, 2431, 2440, "36 - week", "", +279, HbA1c_target, 2611, 2631, "HbA ( 1c ) < 7 . 0 %", "", " ." +96, BodyWeight, 2723, 2729, "weight", "", +97, Insulin, 2766, 2773, "insulin", "", +94, FastingPlasmaGlucose, 2788, 2791, "FPG", "", +243, TimePoint, 2803, 2816, "last 12 weeks", "", +100, ResultMeasuredValue, 2819, 2824, "5 . 7", "", +102, SdDevResValue, 2831, 2836, "0 . 2", "", +101, ResultMeasuredValue, 2840, 2845, "6 . 7", "", +103, SdDevResValue, 2852, 2857, "0 . 3", "", +98, Millimoles_per_litre, 2858, 2866, "mmol / l", "", +244, SubGroupDescription, 2871, 2888, "patients reaching", "", +245, SubGroupDescription, 2892, 2917, "those not reaching target", "", +99, PvalueDiff, 2920, 2930, "p < 0 . 01", "", +281, ConclusionComment, 2966, 3038, "Good glycaemic control can be achieved with both G + MET and NPH + MET .", "", " \"Good glycaemic control can be achieved with both G + MET and NPH + MET .\"." +104, InsulinGlargine, 3015, 3016, "G", "", +105, Metformin, 3019, 3022, "MET", "", +107, IsophaneInsulin_NPH, 3027, 3030, "NPH", "", +106, Metformin, 3033, 3036, "MET", "", +282, ConclusionComment, 3039, 3170, "Use of G + MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH + MET .", "", " \"Use of G + MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH + MET .\"." +108, InsulinGlargine, 3046, 3047, "G", "", +109, Metformin, 3050, 3053, "MET", "", +112, SymptomaticHypoglycemia, 3062, 3087, "symptomatic hypoglycaemia", "", +260, TimePoint, 3099, 3113, "first 12 weeks", "", +261, Hypoglycemia, 3118, 3144, "dinner time hyperglycaemia", "", +45511, RelativeTime, 3118, 3129, "dinner time", "", +115, Hypoglycemia, 3130, 3144, "hyperglycaemia", "", +111, IsophaneInsulin_NPH, 3159, 3162, "NPH", "", +110, Metformin, 3165, 3168, "MET", "", +116, PMID, 3220, 3228, "16456680", "", " \"16456680\"." diff --git a/data/dm2 16456680_admin.n-triples b/data/dm2 16456680_admin.n-triples new file mode 100644 index 0000000..f5ed591 --- /dev/null +++ b/data/dm2 16456680_admin.n-triples @@ -0,0 +1,195 @@ +# RDF export of group: Publication + . + "Publication " . + "Insulin glargine or NPH combined with metformin in type 2 diabetes : the LANMET study ." . + "Diabetologia" . + "16456680" . + . + "Kauppinen - M ä kelin R" . + "Tiikkainen M" . + "V ä h ä talo M" . + "Virtamo H" . + "Nikkil ä K" . + "Tulokas T" . + "Hulme S" . + "Hardy K" . + "McNulty S" . + "H ä nninen J" . + "Lev ä nen H" . + "Lahdenper ä S" . + "Lehtonen R" . + "Ryysy L" . + "2006" . + "Yki - J ä rvinen H" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin ." . + "110" . + "36 weeks" . + . + . + . + "Good glycaemic control can be achieved with both G + MET and NPH + MET ." . + . + . + . + . + . + . + . + . + "Use of G + MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH + MET ." . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive type 2 diabetic patients with poor glycaemic control ( HbA ( 1c ) > or = 8 . 0 % ) on oral hypoglycaemic agents ( 90 % using sulfonylurea plus metformin )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint id " . + . + . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + . + "Endpoint glucose" . + . + . + . + . + . + . + "Endpoint hba1c target " . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig + m " . + . + . + . + . + . + . + "Arm nph + m " . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig + m " . + . + "36 weeks" . + . + . + . + "Intervention nph + m " . + . + "36 weeks" . + . + . +# RDF export of group: Medication + . + "Medication ig " . + . + . + . + "patients were taught how to self - adjust their insulin dose" . + . + "Medication nph" . + . + . + . + "patients were taught how to self - adjust their insulin dose" . + . + "Medication m" . + . + . + . + "patients were taught how to self - adjust their insulin dose" . +# RDF export of group: Outcome + . + "Outcome fpg ig " . + . + "5 . 75" . + "0 . 02" . + . + "Outcome fpg nph" . + . + "5 . 96" . + "0 . 03" . + . + "Outcome id ig" . + . + "68" . + "5" . + . + "Outcome id nph" . + . + "70" . + "6" . + . + "Outcome hba1c ig" . + . + "7 . 14" . + "0 . 12" . + . + "Outcome hba1c nph" . + . + "7 . 16" . + "0 . 14" . + . + "Outcome sh ig" . + . + "4 . 1" . + "0 . 8" . + "first 12 weeks" . + . + "Outcome sh nph" . + . + "9 . 0" . + "2 . 3" . + "first 12 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups fpg" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups sh" . + "p < 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16456680_akramersunderbrink.annodb b/data/dm2 16456680_akramersunderbrink.annodb new file mode 100644 index 0000000..b9b0b56 --- /dev/null +++ b/data/dm2 16456680_akramersunderbrink.annodb @@ -0,0 +1,141 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9332, Journal, 0, 12, "Diabetologia", "", +9333, PublicationYear, 15, 19, "2006", "", +9334, Title, 66, 151, "Insulin glargine or NPH combined with metformin in type 2 diabetes : the LANMET study", "", +9335, InsulinGlargine, 66, 82, "Insulin glargine", "", +9336, IsophaneInsulin_NPH, 86, 89, "NPH", "", +9337, Metformin, 104, 113, "metformin", "", +9338, Type2Diabetes, 117, 132, "type 2 diabetes", "", +9339, Author, 154, 172, "Yki - J ä rvinen H", "", +9340, Author, 181, 204, "Kauppinen - M ä kelin R", "", +9341, Author, 207, 219, "Tiikkainen M", "", +9342, Author, 222, 236, "V ä h ä talo M", "", +9343, Author, 239, 248, "Virtamo H", "", +9344, Author, 251, 261, "Nikkil ä K", "", +9345, Author, 264, 273, "Tulokas T", "", +9346, Author, 276, 283, "Hulme S", "", +9347, Author, 286, 293, "Hardy K", "", +9348, Author, 296, 305, "McNulty S", "", +9349, Author, 308, 320, "H ä nninen J", "", +9350, Author, 323, 334, "Lev ä nen H", "", +9351, Author, 337, 350, "Lahdenper ä S", "", +9352, Author, 353, 363, "Lehtonen R", "", +9353, Author, 366, 373, "Ryysy L", "", +9354, Finland, 501, 508, "Finland", "", +9363, ObjectiveDescription, 561, 721, "In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin", "", +9355, Type2Diabetes, 564, 579, "type 2 diabetic", "", +9356, Duration, 601, 609, "9 months", "", +9357, InsulinGlargine, 638, 654, "insulin glargine", "", +9358, Metformin, 659, 668, "metformin", "", +9359, Duration, 674, 682, "9 months", "", +9360, IsophaneInsulin_NPH, 686, 697, "NPH insulin", "", +9361, Metformin, 712, 721, "metformin", "", +9362, HbA1c, 757, 767, "HbA ( 1c )", "", +9364, OpenLabel, 890, 894, "open", "", +9365, Parallel, 897, 913, "parallel - group", "", +9366, Multicenter, 939, 952, "seven centres", "", +9367, NumberPatientsCT, 955, 958, "110", "", +9368, Precondition, 959, 974, "insulin - naive", "", +9369, Type2Diabetes, 975, 990, "type 2 diabetic", "", +9370, Precondition, 1005, 1057, "poor glycaemic control ( HbA ( 1c ) > or = 8 . 0 % )", "", +9371, Precondition, 1058, 1129, "on oral hypoglycaemic agents ( 90 % using sulfonylurea plus metformin )", "", +9372, Sulfonylureas, 1100, 1112, "sulfonylurea", "", +9373, Metformin, 1118, 1127, "metformin", "", +9374, Randomized, 1135, 1145, "randomised", "", +9375, Bedtime, 1157, 1164, "bedtime", "", +9376, InsulinGlargine, 1165, 1181, "insulin glargine", "", +9377, Metformin, 1187, 1196, "metformin", "", +9407, InsulinGlargine, 1199, 1200, "G", "", +9408, Metformin, 1203, 1206, "MET", "", +9378, Bedtime, 1212, 1219, "bedtime", "", +9379, IsophaneInsulin_NPH, 1220, 1223, "NPH", "", +9380, Metformin, 1229, 1238, "metformin", "", +9409, IsophaneInsulin_NPH, 1241, 1244, "NPH", "", +9410, Metformin, 1247, 1250, "MET", "", +9381, Duration, 1257, 1265, "36 weeks", "", +9382, FastingPlasmaGlucose_target, 1445, 1502, "fasting plasma glucose ( FPG ) of 4 . 0 to 5 . 5 mmol / l", "", +9383, Millimoles_per_litre, 1494, 1502, "mmol / l", "", +9384, TimePoint, 1546, 1554, "12 weeks", "", +9385, FastingPlasmaGlucose, 1557, 1561, "FPGs", "", +9386, ResultMeasuredValue, 1571, 1577, "5 . 75", "", +9395, SdErrorResValue, 1578, 1590, "+ / - 0 . 02", "", +9388, ResultMeasuredValue, 1595, 1601, "5 . 96", "", +9396, SdErrorResValue, 1602, 1614, "+ / - 0 . 03", "", +9390, Millimoles_per_litre, 1615, 1623, "mmol / l", "", +9391, PvalueDiff, 1626, 1637, "p < 0 . 001", "", +9392, EndPointDescription, 1644, 1657, "insulin doses", "", +9393, ResultMeasuredValue, 1663, 1665, "68", "", +9397, SdErrorResValue, 1666, 1673, "+ / - 5", "", +9399, ResultMeasuredValue, 1678, 1680, "70", "", +9400, SdErrorResValue, 1681, 1688, "+ / - 6", "", +9401, BioAndMedicalUnit, 1689, 1697, "IU / day", "", +9402, ResultMeasuredValue, 1700, 1706, "0 . 69", "", +9403, SdErrorResValue, 1707, 1719, "+ / - 0 . 05", "", +9404, ResultMeasuredValue, 1724, 1730, "0 . 66", "", +9405, SdErrorResValue, 1731, 1743, "+ / - 0 . 04", "", +9406, BioAndMedicalUnit, 1744, 1769, "IU kg ( - 1 ) day ( - 1 )", "", +9411, InsulinGlargine, 1784, 1785, "G", "", +9412, Metformin, 1788, 1791, "MET", "", +9413, IsophaneInsulin_NPH, 1796, 1799, "NPH", "", +9414, Metformin, 1802, 1805, "MET", "", +9415, TimePoint, 1833, 1841, "36 weeks", "", +9793, Mean, 1844, 1848, "mean", "", +9416, HbA1c, 1849, 1859, "HbA ( 1c )", "", +9417, ResultMeasuredValue, 1864, 1870, "7 . 14", "", +9418, SdErrorResValue, 1871, 1883, "+ / - 0 . 12", "", +9419, ResultMeasuredValue, 1888, 1894, "7 . 16", "", +9420, SdErrorResValue, 1895, 1907, "+ / - 0 . 14", "", +9421, Percentage, 1908, 1909, "%", "", +9422, SymptomaticHypoglycemia, 1934, 1993, "Symptomatic , but not confirmed symptomatic , hypoglycaemia", "", +9423, TimePoint, 2035, 2043, "12 weeks", "", +9424, InsulinGlargine, 2051, 2052, "G", "", +9425, Metformin, 2055, 2058, "MET", "", +9426, ResultMeasuredValue, 2067, 2072, "4 . 1", "", +9427, SdErrorResValue, 2073, 2084, "+ / - 0 . 8", "", +9428, BioAndMedicalUnit, 2085, 2110, "episodes / patient - year", "", +9429, IsophaneInsulin_NPH, 2125, 2128, "NPH", "", +9430, Metformin, 2131, 2134, "MET", "", +9431, ResultMeasuredValue, 2143, 2148, "9 . 0", "", +9432, SdErrorResValue, 2149, 2160, "+ / - 2 . 3", "", +9433, BioAndMedicalUnit, 2161, 2186, "episodes / patient - year", "", +9434, PvalueDiff, 2189, 2199, "p < 0 . 05", "", +9435, FastingPlasmaGlucose, 2249, 2263, "Glucose levels", "", +9436, RelativeTime, 2264, 2277, "before dinner", "", +9437, IsophaneInsulin_NPH, 2297, 2300, "NPH", "", +9438, Metformin, 2303, 2306, "MET", "", +9439, ResultMeasuredValue, 2315, 2321, "10 . 1", "", +9440, SdErrorResValue, 2322, 2333, "+ / - 0 . 3", "", +9441, Millimoles_per_litre, 2334, 2342, "mmol / l", "", +9442, InsulinGlargine, 2357, 2358, "G", "", +9443, Metformin, 2361, 2364, "MET", "", +9444, ResultMeasuredValue, 2373, 2378, "8 . 6", "", +9445, SdErrorResValue, 2379, 2390, "+ / - 0 . 3", "", +9446, Millimoles_per_litre, 2391, 2399, "mmol / l", "", +9447, PvalueDiff, 2402, 2413, "p = 0 . 002", "", +9448, TimePoint, 2416, 2446, "throughout the 36 - week study", "", +9449, HbA1c, 2611, 2621, "HbA ( 1c )", "", +9450, Percentage, 2630, 2631, "%", "", +9451, FastingPlasmaGlucose, 2788, 2791, "FPG", "", +9452, TimePoint, 2803, 2816, "last 12 weeks", "", +9456, ResultMeasuredValue, 2819, 2824, "5 . 7", "", +9457, SdErrorResValue, 2825, 2836, "+ / - 0 . 2", "", +9458, ResultMeasuredValue, 2840, 2845, "6 . 7", "", +9459, SdErrorResValue, 2846, 2857, "+ / - 0 . 3", "", +9460, Millimoles_per_litre, 2858, 2866, "mmol / l", "", +9453, SubGroupDescription, 2871, 2888, "patients reaching", "", +9454, SubGroupDescription, 2898, 2917, "not reaching target", "", +9455, PvalueDiff, 2920, 2930, "p < 0 . 01", "", +9465, ConclusionComment, 2966, 3036, "Good glycaemic control can be achieved with both G + MET and NPH + MET", "", +9461, InsulinGlargine, 3015, 3016, "G", "", +9462, Metformin, 3019, 3022, "MET", "", +9463, IsophaneInsulin_NPH, 3027, 3030, "NPH", "", +9464, Metformin, 3033, 3036, "MET", "", +9474, ConclusionComment, 3039, 3168, "Use of G + MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH + MET", "", +9466, InsulinGlargine, 3046, 3047, "G", "", +9467, Metformin, 3050, 3053, "MET", "", +9468, SymptomaticHypoglycemia, 3062, 3087, "symptomatic hypoglycaemia", "", +9470, TimePoint, 3099, 3113, "first 12 weeks", "", +9471, Hypoglycemia, 3118, 3144, "dinner time hyperglycaemia", "", +9472, IsophaneInsulin_NPH, 3159, 3162, "NPH", "", +9473, Metformin, 3165, 3168, "MET", "", +9475, PMID, 3220, 3228, "16456680", "", diff --git a/data/dm2 16456680_akramersunderbrink.n-triples b/data/dm2 16456680_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16456680_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16456680_export.csv b/data/dm2 16456680_export.csv new file mode 100644 index 0000000..cdabab2 --- /dev/null +++ b/data/dm2 16456680_export.csv @@ -0,0 +1,778 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +365, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +365, 1, 2, 2, 13, 14, 13, 14, "." +365, 2, 1, 3, 0, 4, 15, 19, "2006" +365, 2, 2, 4, 5, 8, 20, 23, "Mar" +365, 2, 3, 5, 9, 10, 24, 25, ";" +365, 2, 4, 6, 11, 13, 26, 28, "49" +365, 2, 5, 7, 14, 15, 29, 30, "(" +365, 2, 6, 8, 16, 17, 31, 32, "3" +365, 2, 7, 9, 18, 19, 33, 34, ")" +365, 2, 8, 10, 20, 21, 35, 36, ":" +365, 2, 9, 11, 22, 25, 37, 40, "442" +365, 2, 10, 12, 26, 27, 41, 42, "-" +365, 2, 11, 13, 28, 30, 43, 45, "51" +365, 2, 12, 14, 31, 32, 46, 47, "." +365, 3, 1, 15, 0, 4, 48, 52, "Epub" +365, 3, 2, 16, 5, 9, 53, 57, "2006" +365, 3, 3, 17, 10, 13, 58, 61, "Feb" +365, 3, 4, 18, 14, 15, 62, 63, "3" +365, 3, 5, 19, 16, 17, 64, 65, "." +365, 4, 1, 20, 0, 7, 66, 73, "Insulin" +365, 4, 2, 21, 8, 16, 74, 82, "glargine" +365, 4, 3, 22, 17, 19, 83, 85, "or" +365, 4, 4, 23, 20, 23, 86, 89, "NPH" +365, 4, 5, 24, 24, 32, 90, 98, "combined" +365, 4, 6, 25, 33, 37, 99, 103, "with" +365, 4, 7, 26, 38, 47, 104, 113, "metformin" +365, 4, 8, 27, 48, 50, 114, 116, "in" +365, 4, 9, 28, 51, 55, 117, 121, "type" +365, 4, 10, 29, 56, 57, 122, 123, "2" +365, 4, 11, 30, 58, 66, 124, 132, "diabetes" +365, 4, 12, 31, 67, 68, 133, 134, ":" +365, 4, 13, 32, 69, 72, 135, 138, "the" +365, 4, 14, 33, 73, 79, 139, 145, "LANMET" +365, 4, 15, 34, 80, 85, 146, 151, "study" +365, 4, 16, 35, 86, 87, 152, 153, "." +365, 5, 1, 36, 0, 3, 154, 157, "Yki" +365, 5, 2, 37, 4, 5, 158, 159, "-" +365, 5, 3, 38, 6, 7, 160, 161, "J" +365, 5, 4, 39, 8, 9, 162, 163, "ä" +365, 5, 5, 40, 10, 16, 164, 170, "rvinen" +365, 5, 6, 41, 17, 18, 171, 172, "H" +365, 5, 7, 42, 19, 20, 173, 174, "(" +365, 5, 8, 43, 21, 22, 175, 176, "1" +365, 5, 9, 44, 23, 24, 177, 178, ")" +365, 5, 10, 45, 25, 26, 179, 180, "," +365, 5, 11, 46, 27, 36, 181, 190, "Kauppinen" +365, 5, 12, 47, 37, 38, 191, 192, "-" +365, 5, 13, 48, 39, 40, 193, 194, "M" +365, 5, 14, 49, 41, 42, 195, 196, "ä" +365, 5, 15, 50, 43, 48, 197, 202, "kelin" +365, 5, 16, 51, 49, 50, 203, 204, "R" +365, 5, 17, 52, 51, 52, 205, 206, "," +365, 5, 18, 53, 53, 63, 207, 217, "Tiikkainen" +365, 5, 19, 54, 64, 65, 218, 219, "M" +365, 5, 20, 55, 66, 67, 220, 221, "," +365, 5, 21, 56, 68, 69, 222, 223, "V" +365, 5, 22, 57, 70, 71, 224, 225, "ä" +365, 5, 23, 58, 72, 73, 226, 227, "h" +365, 5, 24, 59, 74, 75, 228, 229, "ä" +365, 5, 25, 60, 76, 80, 230, 234, "talo" +365, 5, 26, 61, 81, 82, 235, 236, "M" +365, 5, 27, 62, 83, 84, 237, 238, "," +365, 5, 28, 63, 85, 92, 239, 246, "Virtamo" +365, 5, 29, 64, 93, 94, 247, 248, "H" +365, 5, 30, 65, 95, 96, 249, 250, "," +365, 5, 31, 66, 97, 103, 251, 257, "Nikkil" +365, 5, 32, 67, 104, 105, 258, 259, "ä" +365, 5, 33, 68, 106, 107, 260, 261, "K" +365, 5, 34, 69, 108, 109, 262, 263, "," +365, 5, 35, 70, 110, 117, 264, 271, "Tulokas" +365, 5, 36, 71, 118, 119, 272, 273, "T" +365, 5, 37, 72, 120, 121, 274, 275, "," +365, 5, 38, 73, 122, 127, 276, 281, "Hulme" +365, 5, 39, 74, 128, 129, 282, 283, "S" +365, 5, 40, 75, 130, 131, 284, 285, "," +365, 5, 41, 76, 132, 137, 286, 291, "Hardy" +365, 5, 42, 77, 138, 139, 292, 293, "K" +365, 5, 43, 78, 140, 141, 294, 295, "," +365, 5, 44, 79, 142, 149, 296, 303, "McNulty" +365, 5, 45, 80, 150, 151, 304, 305, "S" +365, 5, 46, 81, 152, 153, 306, 307, "," +365, 5, 47, 82, 154, 155, 308, 309, "H" +365, 5, 48, 83, 156, 157, 310, 311, "ä" +365, 5, 49, 84, 158, 164, 312, 318, "nninen" +365, 5, 50, 85, 165, 166, 319, 320, "J" +365, 5, 51, 86, 167, 168, 321, 322, "," +365, 5, 52, 87, 169, 172, 323, 326, "Lev" +365, 5, 53, 88, 173, 174, 327, 328, "ä" +365, 5, 54, 89, 175, 178, 329, 332, "nen" +365, 5, 55, 90, 179, 180, 333, 334, "H" +365, 5, 56, 91, 181, 182, 335, 336, "," +365, 5, 57, 92, 183, 192, 337, 346, "Lahdenper" +365, 5, 58, 93, 193, 194, 347, 348, "ä" +365, 5, 59, 94, 195, 196, 349, 350, "S" +365, 5, 60, 95, 197, 198, 351, 352, "," +365, 5, 61, 96, 199, 207, 353, 361, "Lehtonen" +365, 5, 62, 97, 208, 209, 362, 363, "R" +365, 5, 63, 98, 210, 211, 364, 365, "," +365, 5, 64, 99, 212, 217, 366, 371, "Ryysy" +365, 5, 65, 100, 218, 219, 372, 373, "L" +365, 5, 66, 101, 220, 221, 374, 375, "." +365, 5, 67, 102, 222, 228, 376, 382, "Author" +365, 5, 68, 103, 229, 240, 383, 394, "information" +365, 5, 69, 104, 241, 242, 395, 396, ":" +365, 5, 70, 105, 243, 244, 397, 398, "(" +365, 5, 71, 106, 245, 246, 399, 400, "1" +365, 5, 72, 107, 247, 248, 401, 402, ")" +365, 5, 73, 108, 249, 259, 403, 413, "Department" +365, 5, 74, 109, 260, 262, 414, 416, "of" +365, 5, 75, 110, 263, 271, 417, 425, "Medicine" +365, 5, 76, 111, 272, 273, 426, 427, "," +365, 5, 77, 112, 274, 284, 428, 438, "University" +365, 5, 78, 113, 285, 287, 439, 441, "of" +365, 5, 79, 114, 288, 296, 442, 450, "Helsinki" +365, 5, 80, 115, 297, 298, 451, 452, "," +365, 5, 81, 116, 299, 300, 453, 454, "P" +365, 5, 82, 117, 301, 302, 455, 456, "." +365, 5, 83, 118, 303, 304, 457, 458, "O" +365, 5, 84, 119, 305, 306, 459, 460, "." +365, 6, 1, 120, 0, 3, 461, 464, "Box" +365, 6, 2, 121, 4, 7, 465, 468, "340" +365, 6, 3, 122, 8, 9, 469, 470, "," +365, 6, 4, 123, 10, 13, 471, 474, "FIN" +365, 6, 5, 124, 14, 15, 475, 476, "-" +365, 6, 6, 125, 16, 21, 477, 482, "00029" +365, 6, 7, 126, 22, 26, 483, 487, "HUCH" +365, 6, 8, 127, 27, 28, 488, 489, "," +365, 6, 9, 128, 29, 37, 490, 498, "Helsinki" +365, 6, 10, 129, 38, 39, 499, 500, "," +365, 6, 11, 130, 40, 47, 501, 508, "Finland" +365, 6, 12, 131, 48, 49, 509, 510, "." +365, 7, 1, 132, 0, 8, 511, 519, "ykijarvi" +365, 7, 2, 133, 9, 10, 520, 521, "@" +365, 7, 3, 134, 11, 13, 522, 524, "cc" +365, 7, 4, 135, 14, 15, 525, 526, "." +365, 7, 5, 136, 16, 24, 527, 535, "helsinki" +365, 7, 6, 137, 25, 26, 536, 537, "." +365, 7, 7, 138, 27, 29, 538, 540, "fi" +365, 7, 8, 139, 30, 34, 541, 545, "AIMS" +365, 7, 9, 140, 35, 36, 546, 547, "/" +365, 7, 10, 141, 37, 47, 548, 558, "HYPOTHESIS" +365, 7, 11, 142, 48, 49, 559, 560, ":" +365, 7, 12, 143, 50, 52, 561, 563, "In" +365, 7, 13, 144, 53, 57, 564, 568, "type" +365, 7, 14, 145, 58, 59, 569, 570, "2" +365, 7, 15, 146, 60, 68, 571, 579, "diabetic" +365, 7, 16, 147, 69, 77, 580, 588, "patients" +365, 7, 17, 148, 78, 80, 589, 591, "we" +365, 7, 18, 149, 81, 89, 592, 600, "compared" +365, 7, 19, 150, 90, 91, 601, 602, "9" +365, 7, 20, 151, 92, 98, 603, 609, "months" +365, 7, 21, 152, 99, 101, 610, 612, "of" +365, 7, 22, 153, 102, 113, 613, 624, "combination" +365, 7, 23, 154, 114, 121, 625, 632, "therapy" +365, 7, 24, 155, 122, 126, 633, 637, "with" +365, 7, 25, 156, 127, 134, 638, 645, "insulin" +365, 7, 26, 157, 135, 143, 646, 654, "glargine" +365, 7, 27, 158, 144, 147, 655, 658, "and" +365, 7, 28, 159, 148, 157, 659, 668, "metformin" +365, 7, 29, 160, 158, 162, 669, 673, "with" +365, 7, 30, 161, 163, 164, 674, 675, "9" +365, 7, 31, 162, 165, 171, 676, 682, "months" +365, 7, 32, 163, 172, 174, 683, 685, "of" +365, 7, 33, 164, 175, 178, 686, 689, "NPH" +365, 7, 34, 165, 179, 186, 690, 697, "insulin" +365, 7, 35, 166, 187, 195, 698, 706, "combined" +365, 7, 36, 167, 196, 200, 707, 711, "with" +365, 7, 37, 168, 201, 210, 712, 721, "metformin" +365, 7, 38, 169, 211, 212, 722, 723, "." +365, 8, 1, 170, 0, 3, 724, 727, "The" +365, 8, 2, 171, 4, 11, 728, 735, "primary" +365, 8, 3, 172, 12, 17, 736, 741, "focus" +365, 8, 4, 173, 18, 21, 742, 745, "was" +365, 8, 5, 174, 22, 29, 746, 753, "changes" +365, 8, 6, 175, 30, 32, 754, 756, "in" +365, 8, 7, 176, 33, 36, 757, 760, "HbA" +365, 8, 8, 177, 37, 38, 761, 762, "(" +365, 8, 9, 178, 39, 41, 763, 765, "1c" +365, 8, 10, 179, 42, 43, 766, 767, ")" +365, 8, 11, 180, 44, 45, 768, 769, ";" +365, 8, 12, 181, 46, 55, 770, 779, "secondary" +365, 8, 13, 182, 56, 61, 780, 785, "focus" +365, 8, 14, 183, 62, 65, 786, 789, "was" +365, 8, 15, 184, 66, 73, 790, 797, "diurnal" +365, 8, 16, 185, 74, 81, 798, 805, "glucose" +365, 8, 17, 186, 82, 90, 806, 814, "profiles" +365, 8, 18, 187, 91, 94, 815, 818, "and" +365, 8, 19, 188, 95, 106, 819, 830, "symptomatic" +365, 8, 20, 189, 107, 120, 831, 844, "hypoglycaemia" +365, 8, 21, 190, 121, 122, 845, 846, "." +365, 9, 1, 191, 0, 7, 847, 854, "METHODS" +365, 9, 2, 192, 8, 9, 855, 856, ":" +365, 9, 3, 193, 10, 12, 857, 859, "In" +365, 9, 4, 194, 13, 17, 860, 864, "this" +365, 9, 5, 195, 18, 30, 865, 877, "investigator" +365, 9, 6, 196, 31, 32, 878, 879, "-" +365, 9, 7, 197, 33, 42, 880, 889, "initiated" +365, 9, 8, 198, 43, 47, 890, 894, "open" +365, 9, 9, 199, 48, 49, 895, 896, "," +365, 9, 10, 200, 50, 58, 897, 905, "parallel" +365, 9, 11, 201, 59, 60, 906, 907, "-" +365, 9, 12, 202, 61, 66, 908, 913, "group" +365, 9, 13, 203, 67, 75, 914, 922, "clinical" +365, 9, 14, 204, 76, 81, 923, 928, "trial" +365, 9, 15, 205, 82, 91, 929, 938, "involving" +365, 9, 16, 206, 92, 97, 939, 944, "seven" +365, 9, 17, 207, 98, 105, 945, 952, "centres" +365, 9, 18, 208, 106, 107, 953, 954, "," +365, 9, 19, 209, 108, 111, 955, 958, "110" +365, 9, 20, 210, 112, 119, 959, 966, "insulin" +365, 9, 21, 211, 120, 121, 967, 968, "-" +365, 9, 22, 212, 122, 127, 969, 974, "naive" +365, 9, 23, 213, 128, 132, 975, 979, "type" +365, 9, 24, 214, 133, 134, 980, 981, "2" +365, 9, 25, 215, 135, 143, 982, 990, "diabetic" +365, 9, 26, 216, 144, 152, 991, 999, "patients" +365, 9, 27, 217, 153, 157, 1000, 1004, "with" +365, 9, 28, 218, 158, 162, 1005, 1009, "poor" +365, 9, 29, 219, 163, 172, 1010, 1019, "glycaemic" +365, 9, 30, 220, 173, 180, 1020, 1027, "control" +365, 9, 31, 221, 181, 182, 1028, 1029, "(" +365, 9, 32, 222, 183, 186, 1030, 1033, "HbA" +365, 9, 33, 223, 187, 188, 1034, 1035, "(" +365, 9, 34, 224, 189, 191, 1036, 1038, "1c" +365, 9, 35, 225, 192, 193, 1039, 1040, ")" +365, 9, 36, 226, 194, 195, 1041, 1042, ">" +365, 9, 37, 227, 196, 198, 1043, 1045, "or" +365, 9, 38, 228, 199, 200, 1046, 1047, "=" +365, 9, 39, 229, 201, 202, 1048, 1049, "8" +365, 9, 40, 230, 203, 204, 1050, 1051, "." +365, 9, 41, 231, 205, 206, 1052, 1053, "0" +365, 9, 42, 232, 207, 208, 1054, 1055, "%" +365, 9, 43, 233, 209, 210, 1056, 1057, ")" +365, 9, 44, 234, 211, 213, 1058, 1060, "on" +365, 9, 45, 235, 214, 218, 1061, 1065, "oral" +365, 9, 46, 236, 219, 232, 1066, 1079, "hypoglycaemic" +365, 9, 47, 237, 233, 239, 1080, 1086, "agents" +365, 9, 48, 238, 240, 241, 1087, 1088, "(" +365, 9, 49, 239, 242, 244, 1089, 1091, "90" +365, 9, 50, 240, 245, 246, 1092, 1093, "%" +365, 9, 51, 241, 247, 252, 1094, 1099, "using" +365, 9, 52, 242, 253, 265, 1100, 1112, "sulfonylurea" +365, 9, 53, 243, 266, 270, 1113, 1117, "plus" +365, 9, 54, 244, 271, 280, 1118, 1127, "metformin" +365, 9, 55, 245, 281, 282, 1128, 1129, ")" +365, 9, 56, 246, 283, 287, 1130, 1134, "were" +365, 9, 57, 247, 288, 298, 1135, 1145, "randomised" +365, 9, 58, 248, 299, 301, 1146, 1148, "to" +365, 9, 59, 249, 302, 309, 1149, 1156, "receive" +365, 9, 60, 250, 310, 317, 1157, 1164, "bedtime" +365, 9, 61, 251, 318, 325, 1165, 1172, "insulin" +365, 9, 62, 252, 326, 334, 1173, 1181, "glargine" +365, 9, 63, 253, 335, 339, 1182, 1186, "with" +365, 9, 64, 254, 340, 349, 1187, 1196, "metformin" +365, 9, 65, 255, 350, 351, 1197, 1198, "(" +365, 9, 66, 256, 352, 353, 1199, 1200, "G" +365, 9, 67, 257, 354, 355, 1201, 1202, "+" +365, 9, 68, 258, 356, 359, 1203, 1206, "MET" +365, 9, 69, 259, 360, 361, 1207, 1208, ")" +365, 9, 70, 260, 362, 364, 1209, 1211, "or" +365, 9, 71, 261, 365, 372, 1212, 1219, "bedtime" +365, 9, 72, 262, 373, 376, 1220, 1223, "NPH" +365, 9, 73, 263, 377, 381, 1224, 1228, "with" +365, 9, 74, 264, 382, 391, 1229, 1238, "metformin" +365, 9, 75, 265, 392, 393, 1239, 1240, "(" +365, 9, 76, 266, 394, 397, 1241, 1244, "NPH" +365, 9, 77, 267, 398, 399, 1245, 1246, "+" +365, 9, 78, 268, 400, 403, 1247, 1250, "MET" +365, 9, 79, 269, 404, 405, 1251, 1252, ")" +365, 9, 80, 270, 406, 409, 1253, 1256, "for" +365, 9, 81, 271, 410, 412, 1257, 1259, "36" +365, 9, 82, 272, 413, 418, 1260, 1265, "weeks" +365, 9, 83, 273, 419, 420, 1266, 1267, "." +365, 10, 1, 274, 0, 3, 1268, 1271, "The" +365, 10, 2, 275, 4, 12, 1272, 1280, "patients" +365, 10, 3, 276, 13, 17, 1281, 1285, "were" +365, 10, 4, 277, 18, 24, 1286, 1292, "taught" +365, 10, 5, 278, 25, 28, 1293, 1296, "how" +365, 10, 6, 279, 29, 31, 1297, 1299, "to" +365, 10, 7, 280, 32, 36, 1300, 1304, "self" +365, 10, 8, 281, 37, 38, 1305, 1306, "-" +365, 10, 9, 282, 39, 45, 1307, 1313, "adjust" +365, 10, 10, 283, 46, 51, 1314, 1319, "their" +365, 10, 11, 284, 52, 59, 1320, 1327, "insulin" +365, 10, 12, 285, 60, 64, 1328, 1332, "dose" +365, 10, 13, 286, 65, 68, 1333, 1336, "and" +365, 10, 14, 287, 69, 72, 1337, 1340, "use" +365, 10, 15, 288, 73, 74, 1341, 1342, "a" +365, 10, 16, 289, 75, 80, 1343, 1348, "modem" +365, 10, 17, 290, 81, 83, 1349, 1351, "to" +365, 10, 18, 291, 84, 88, 1352, 1356, "send" +365, 10, 19, 292, 89, 92, 1357, 1360, "the" +365, 10, 20, 293, 93, 100, 1361, 1368, "results" +365, 10, 21, 294, 101, 103, 1369, 1371, "of" +365, 10, 22, 295, 104, 108, 1372, 1376, "home" +365, 10, 23, 296, 109, 116, 1377, 1384, "glucose" +365, 10, 24, 297, 117, 127, 1385, 1395, "monitoring" +365, 10, 25, 298, 128, 130, 1396, 1398, "to" +365, 10, 26, 299, 131, 140, 1399, 1408, "treatment" +365, 10, 27, 300, 141, 148, 1409, 1416, "centres" +365, 10, 28, 301, 149, 150, 1417, 1418, "." +365, 11, 1, 302, 0, 3, 1419, 1422, "The" +365, 11, 2, 303, 4, 8, 1423, 1427, "goal" +365, 11, 3, 304, 9, 12, 1428, 1431, "was" +365, 11, 4, 305, 13, 15, 1432, 1434, "to" +365, 11, 5, 306, 16, 23, 1435, 1442, "achieve" +365, 11, 6, 307, 24, 25, 1443, 1444, "a" +365, 11, 7, 308, 26, 33, 1445, 1452, "fasting" +365, 11, 8, 309, 34, 40, 1453, 1459, "plasma" +365, 11, 9, 310, 41, 48, 1460, 1467, "glucose" +365, 11, 10, 311, 49, 50, 1468, 1469, "(" +365, 11, 11, 312, 51, 54, 1470, 1473, "FPG" +365, 11, 12, 313, 55, 56, 1474, 1475, ")" +365, 11, 13, 314, 57, 59, 1476, 1478, "of" +365, 11, 14, 315, 60, 61, 1479, 1480, "4" +365, 11, 15, 316, 62, 63, 1481, 1482, "." +365, 11, 16, 317, 64, 65, 1483, 1484, "0" +365, 11, 17, 318, 66, 68, 1485, 1487, "to" +365, 11, 18, 319, 69, 70, 1488, 1489, "5" +365, 11, 19, 320, 71, 72, 1490, 1491, "." +365, 11, 20, 321, 73, 74, 1492, 1493, "5" +365, 11, 21, 322, 75, 79, 1494, 1498, "mmol" +365, 11, 22, 323, 80, 81, 1499, 1500, "/" +365, 11, 23, 324, 82, 83, 1501, 1502, "l" +365, 11, 24, 325, 84, 86, 1503, 1505, "in" +365, 11, 25, 326, 87, 91, 1506, 1510, "both" +365, 11, 26, 327, 92, 98, 1511, 1517, "groups" +365, 11, 27, 328, 99, 100, 1518, 1519, "." +365, 12, 1, 329, 0, 7, 1520, 1527, "RESULTS" +365, 12, 2, 330, 8, 9, 1528, 1529, ":" +365, 12, 3, 331, 10, 16, 1530, 1536, "During" +365, 12, 4, 332, 17, 20, 1537, 1540, "the" +365, 12, 5, 333, 21, 25, 1541, 1545, "last" +365, 12, 6, 334, 26, 28, 1546, 1548, "12" +365, 12, 7, 335, 29, 34, 1549, 1554, "weeks" +365, 12, 8, 336, 35, 36, 1555, 1556, "," +365, 12, 9, 337, 37, 41, 1557, 1561, "FPGs" +365, 12, 10, 338, 42, 50, 1562, 1570, "averaged" +365, 12, 11, 339, 51, 52, 1571, 1572, "5" +365, 12, 12, 340, 53, 54, 1573, 1574, "." +365, 12, 13, 341, 55, 57, 1575, 1577, "75" +365, 12, 14, 342, 58, 59, 1578, 1579, "+" +365, 12, 15, 343, 60, 61, 1580, 1581, "/" +365, 12, 16, 344, 62, 63, 1582, 1583, "-" +365, 12, 17, 345, 64, 65, 1584, 1585, "0" +365, 12, 18, 346, 66, 67, 1586, 1587, "." +365, 12, 19, 347, 68, 70, 1588, 1590, "02" +365, 12, 20, 348, 71, 74, 1591, 1594, "and" +365, 12, 21, 349, 75, 76, 1595, 1596, "5" +365, 12, 22, 350, 77, 78, 1597, 1598, "." +365, 12, 23, 351, 79, 81, 1599, 1601, "96" +365, 12, 24, 352, 82, 83, 1602, 1603, "+" +365, 12, 25, 353, 84, 85, 1604, 1605, "/" +365, 12, 26, 354, 86, 87, 1606, 1607, "-" +365, 12, 27, 355, 88, 89, 1608, 1609, "0" +365, 12, 28, 356, 90, 91, 1610, 1611, "." +365, 12, 29, 357, 92, 94, 1612, 1614, "03" +365, 12, 30, 358, 95, 99, 1615, 1619, "mmol" +365, 12, 31, 359, 100, 101, 1620, 1621, "/" +365, 12, 32, 360, 102, 103, 1622, 1623, "l" +365, 12, 33, 361, 104, 105, 1624, 1625, "(" +365, 12, 34, 362, 106, 107, 1626, 1627, "p" +365, 12, 35, 363, 108, 109, 1628, 1629, "<" +365, 12, 36, 364, 110, 111, 1630, 1631, "0" +365, 12, 37, 365, 112, 113, 1632, 1633, "." +365, 12, 38, 366, 114, 117, 1634, 1637, "001" +365, 12, 39, 367, 118, 119, 1638, 1639, ")" +365, 12, 40, 368, 120, 123, 1640, 1643, "and" +365, 12, 41, 369, 124, 131, 1644, 1651, "insulin" +365, 12, 42, 370, 132, 137, 1652, 1657, "doses" +365, 12, 43, 371, 138, 142, 1658, 1662, "were" +365, 12, 44, 372, 143, 145, 1663, 1665, "68" +365, 12, 45, 373, 146, 147, 1666, 1667, "+" +365, 12, 46, 374, 148, 149, 1668, 1669, "/" +365, 12, 47, 375, 150, 151, 1670, 1671, "-" +365, 12, 48, 376, 152, 153, 1672, 1673, "5" +365, 12, 49, 377, 154, 157, 1674, 1677, "and" +365, 12, 50, 378, 158, 160, 1678, 1680, "70" +365, 12, 51, 379, 161, 162, 1681, 1682, "+" +365, 12, 52, 380, 163, 164, 1683, 1684, "/" +365, 12, 53, 381, 165, 166, 1685, 1686, "-" +365, 12, 54, 382, 167, 168, 1687, 1688, "6" +365, 12, 55, 383, 169, 171, 1689, 1691, "IU" +365, 12, 56, 384, 172, 173, 1692, 1693, "/" +365, 12, 57, 385, 174, 177, 1694, 1697, "day" +365, 12, 58, 386, 178, 179, 1698, 1699, "(" +365, 12, 59, 387, 180, 181, 1700, 1701, "0" +365, 12, 60, 388, 182, 183, 1702, 1703, "." +365, 12, 61, 389, 184, 186, 1704, 1706, "69" +365, 12, 62, 390, 187, 188, 1707, 1708, "+" +365, 12, 63, 391, 189, 190, 1709, 1710, "/" +365, 12, 64, 392, 191, 192, 1711, 1712, "-" +365, 12, 65, 393, 193, 194, 1713, 1714, "0" +365, 12, 66, 394, 195, 196, 1715, 1716, "." +365, 12, 67, 395, 197, 199, 1717, 1719, "05" +365, 12, 68, 396, 200, 203, 1720, 1723, "and" +365, 12, 69, 397, 204, 205, 1724, 1725, "0" +365, 12, 70, 398, 206, 207, 1726, 1727, "." +365, 12, 71, 399, 208, 210, 1728, 1730, "66" +365, 12, 72, 400, 211, 212, 1731, 1732, "+" +365, 12, 73, 401, 213, 214, 1733, 1734, "/" +365, 12, 74, 402, 215, 216, 1735, 1736, "-" +365, 12, 75, 403, 217, 218, 1737, 1738, "0" +365, 12, 76, 404, 219, 220, 1739, 1740, "." +365, 12, 77, 405, 221, 223, 1741, 1743, "04" +365, 12, 78, 406, 224, 226, 1744, 1746, "IU" +365, 12, 79, 407, 227, 229, 1747, 1749, "kg" +365, 12, 80, 408, 230, 231, 1750, 1751, "(" +365, 12, 81, 409, 232, 233, 1752, 1753, "-" +365, 12, 82, 410, 234, 235, 1754, 1755, "1" +365, 12, 83, 411, 236, 237, 1756, 1757, ")" +365, 12, 84, 412, 238, 241, 1758, 1761, "day" +365, 12, 85, 413, 242, 243, 1762, 1763, "(" +365, 12, 86, 414, 244, 245, 1764, 1765, "-" +365, 12, 87, 415, 246, 247, 1766, 1767, "1" +365, 12, 88, 416, 248, 249, 1768, 1769, ")" +365, 12, 89, 417, 250, 251, 1770, 1771, "," +365, 12, 90, 418, 252, 254, 1772, 1774, "NS" +365, 12, 91, 419, 255, 256, 1775, 1776, ")" +365, 12, 92, 420, 257, 259, 1777, 1779, "in" +365, 12, 93, 421, 260, 263, 1780, 1783, "the" +365, 12, 94, 422, 264, 265, 1784, 1785, "G" +365, 12, 95, 423, 266, 267, 1786, 1787, "+" +365, 12, 96, 424, 268, 271, 1788, 1791, "MET" +365, 12, 97, 425, 272, 275, 1792, 1795, "and" +365, 12, 98, 426, 276, 279, 1796, 1799, "NPH" +365, 12, 99, 427, 280, 281, 1800, 1801, "+" +365, 12, 100, 428, 282, 285, 1802, 1805, "MET" +365, 12, 101, 429, 286, 292, 1806, 1812, "groups" +365, 12, 102, 430, 293, 294, 1813, 1814, "," +365, 12, 103, 431, 295, 307, 1815, 1827, "respectively" +365, 12, 104, 432, 308, 309, 1828, 1829, "." +365, 13, 1, 433, 0, 2, 1830, 1832, "At" +365, 13, 2, 434, 3, 5, 1833, 1835, "36" +365, 13, 3, 435, 6, 11, 1836, 1841, "weeks" +365, 13, 4, 436, 12, 13, 1842, 1843, "," +365, 13, 5, 437, 14, 18, 1844, 1848, "mean" +365, 13, 6, 438, 19, 22, 1849, 1852, "HbA" +365, 13, 7, 439, 23, 24, 1853, 1854, "(" +365, 13, 8, 440, 25, 27, 1855, 1857, "1c" +365, 13, 9, 441, 28, 29, 1858, 1859, ")" +365, 13, 10, 442, 30, 33, 1860, 1863, "was" +365, 13, 11, 443, 34, 35, 1864, 1865, "7" +365, 13, 12, 444, 36, 37, 1866, 1867, "." +365, 13, 13, 445, 38, 40, 1868, 1870, "14" +365, 13, 14, 446, 41, 42, 1871, 1872, "+" +365, 13, 15, 447, 43, 44, 1873, 1874, "/" +365, 13, 16, 448, 45, 46, 1875, 1876, "-" +365, 13, 17, 449, 47, 48, 1877, 1878, "0" +365, 13, 18, 450, 49, 50, 1879, 1880, "." +365, 13, 19, 451, 51, 53, 1881, 1883, "12" +365, 13, 20, 452, 54, 57, 1884, 1887, "and" +365, 13, 21, 453, 58, 59, 1888, 1889, "7" +365, 13, 22, 454, 60, 61, 1890, 1891, "." +365, 13, 23, 455, 62, 64, 1892, 1894, "16" +365, 13, 24, 456, 65, 66, 1895, 1896, "+" +365, 13, 25, 457, 67, 68, 1897, 1898, "/" +365, 13, 26, 458, 69, 70, 1899, 1900, "-" +365, 13, 27, 459, 71, 72, 1901, 1902, "0" +365, 13, 28, 460, 73, 74, 1903, 1904, "." +365, 13, 29, 461, 75, 77, 1905, 1907, "14" +365, 13, 30, 462, 78, 79, 1908, 1909, "%" +365, 13, 31, 463, 80, 81, 1910, 1911, "," +365, 13, 32, 464, 82, 94, 1912, 1924, "respectively" +365, 13, 33, 465, 95, 96, 1925, 1926, "(" +365, 13, 34, 466, 97, 99, 1927, 1929, "NS" +365, 13, 35, 467, 100, 101, 1930, 1931, ")" +365, 13, 36, 468, 102, 103, 1932, 1933, "." +365, 14, 1, 469, 0, 11, 1934, 1945, "Symptomatic" +365, 14, 2, 470, 12, 13, 1946, 1947, "," +365, 14, 3, 471, 14, 17, 1948, 1951, "but" +365, 14, 4, 472, 18, 21, 1952, 1955, "not" +365, 14, 5, 473, 22, 31, 1956, 1965, "confirmed" +365, 14, 6, 474, 32, 43, 1966, 1977, "symptomatic" +365, 14, 7, 475, 44, 45, 1978, 1979, "," +365, 14, 8, 476, 46, 59, 1980, 1993, "hypoglycaemia" +365, 14, 9, 477, 60, 63, 1994, 1997, "was" +365, 14, 10, 478, 64, 77, 1998, 2011, "significantly" +365, 14, 11, 479, 78, 83, 2012, 2017, "lower" +365, 14, 12, 480, 84, 90, 2018, 2024, "during" +365, 14, 13, 481, 91, 94, 2025, 2028, "the" +365, 14, 14, 482, 95, 100, 2029, 2034, "first" +365, 14, 15, 483, 101, 103, 2035, 2037, "12" +365, 14, 16, 484, 104, 109, 2038, 2043, "weeks" +365, 14, 17, 485, 110, 112, 2044, 2046, "in" +365, 14, 18, 486, 113, 116, 2047, 2050, "the" +365, 14, 19, 487, 117, 118, 2051, 2052, "G" +365, 14, 20, 488, 119, 120, 2053, 2054, "+" +365, 14, 21, 489, 121, 124, 2055, 2058, "MET" +365, 14, 22, 490, 125, 130, 2059, 2064, "group" +365, 14, 23, 491, 131, 132, 2065, 2066, "(" +365, 14, 24, 492, 133, 134, 2067, 2068, "4" +365, 14, 25, 493, 135, 136, 2069, 2070, "." +365, 14, 26, 494, 137, 138, 2071, 2072, "1" +365, 14, 27, 495, 139, 140, 2073, 2074, "+" +365, 14, 28, 496, 141, 142, 2075, 2076, "/" +365, 14, 29, 497, 143, 144, 2077, 2078, "-" +365, 14, 30, 498, 145, 146, 2079, 2080, "0" +365, 14, 31, 499, 147, 148, 2081, 2082, "." +365, 14, 32, 500, 149, 150, 2083, 2084, "8" +365, 14, 33, 501, 151, 159, 2085, 2093, "episodes" +365, 14, 34, 502, 160, 161, 2094, 2095, "/" +365, 14, 35, 503, 162, 169, 2096, 2103, "patient" +365, 14, 36, 504, 170, 171, 2104, 2105, "-" +365, 14, 37, 505, 172, 176, 2106, 2110, "year" +365, 14, 38, 506, 177, 178, 2111, 2112, ")" +365, 14, 39, 507, 179, 183, 2113, 2117, "than" +365, 14, 40, 508, 184, 186, 2118, 2120, "in" +365, 14, 41, 509, 187, 190, 2121, 2124, "the" +365, 14, 42, 510, 191, 194, 2125, 2128, "NPH" +365, 14, 43, 511, 195, 196, 2129, 2130, "+" +365, 14, 44, 512, 197, 200, 2131, 2134, "MET" +365, 14, 45, 513, 201, 206, 2135, 2140, "group" +365, 14, 46, 514, 207, 208, 2141, 2142, "(" +365, 14, 47, 515, 209, 210, 2143, 2144, "9" +365, 14, 48, 516, 211, 212, 2145, 2146, "." +365, 14, 49, 517, 213, 214, 2147, 2148, "0" +365, 14, 50, 518, 215, 216, 2149, 2150, "+" +365, 14, 51, 519, 217, 218, 2151, 2152, "/" +365, 14, 52, 520, 219, 220, 2153, 2154, "-" +365, 14, 53, 521, 221, 222, 2155, 2156, "2" +365, 14, 54, 522, 223, 224, 2157, 2158, "." +365, 14, 55, 523, 225, 226, 2159, 2160, "3" +365, 14, 56, 524, 227, 235, 2161, 2169, "episodes" +365, 14, 57, 525, 236, 237, 2170, 2171, "/" +365, 14, 58, 526, 238, 245, 2172, 2179, "patient" +365, 14, 59, 527, 246, 247, 2180, 2181, "-" +365, 14, 60, 528, 248, 252, 2182, 2186, "year" +365, 14, 61, 529, 253, 254, 2187, 2188, "," +365, 14, 62, 530, 255, 256, 2189, 2190, "p" +365, 14, 63, 531, 257, 258, 2191, 2192, "<" +365, 14, 64, 532, 259, 260, 2193, 2194, "0" +365, 14, 65, 533, 261, 262, 2195, 2196, "." +365, 14, 66, 534, 263, 265, 2197, 2199, "05" +365, 14, 67, 535, 266, 267, 2200, 2201, ")" +365, 14, 68, 536, 268, 269, 2202, 2203, "," +365, 14, 69, 537, 270, 273, 2204, 2207, "but" +365, 14, 70, 538, 274, 277, 2208, 2211, "not" +365, 14, 71, 539, 278, 291, 2212, 2225, "significantly" +365, 14, 72, 540, 292, 301, 2226, 2235, "different" +365, 14, 73, 541, 302, 312, 2236, 2246, "thereafter" +365, 14, 74, 542, 313, 314, 2247, 2248, "." +365, 15, 1, 543, 0, 7, 2249, 2256, "Glucose" +365, 15, 2, 544, 8, 14, 2257, 2263, "levels" +365, 15, 3, 545, 15, 21, 2264, 2270, "before" +365, 15, 4, 546, 22, 28, 2271, 2277, "dinner" +365, 15, 5, 547, 29, 33, 2278, 2282, "were" +365, 15, 6, 548, 34, 40, 2283, 2289, "higher" +365, 15, 7, 549, 41, 43, 2290, 2292, "in" +365, 15, 8, 550, 44, 47, 2293, 2296, "the" +365, 15, 9, 551, 48, 51, 2297, 2300, "NPH" +365, 15, 10, 552, 52, 53, 2301, 2302, "+" +365, 15, 11, 553, 54, 57, 2303, 2306, "MET" +365, 15, 12, 554, 58, 63, 2307, 2312, "group" +365, 15, 13, 555, 64, 65, 2313, 2314, "(" +365, 15, 14, 556, 66, 68, 2315, 2317, "10" +365, 15, 15, 557, 69, 70, 2318, 2319, "." +365, 15, 16, 558, 71, 72, 2320, 2321, "1" +365, 15, 17, 559, 73, 74, 2322, 2323, "+" +365, 15, 18, 560, 75, 76, 2324, 2325, "/" +365, 15, 19, 561, 77, 78, 2326, 2327, "-" +365, 15, 20, 562, 79, 80, 2328, 2329, "0" +365, 15, 21, 563, 81, 82, 2330, 2331, "." +365, 15, 22, 564, 83, 84, 2332, 2333, "3" +365, 15, 23, 565, 85, 89, 2334, 2338, "mmol" +365, 15, 24, 566, 90, 91, 2339, 2340, "/" +365, 15, 25, 567, 92, 93, 2341, 2342, "l" +365, 15, 26, 568, 94, 95, 2343, 2344, ")" +365, 15, 27, 569, 96, 100, 2345, 2349, "than" +365, 15, 28, 570, 101, 103, 2350, 2352, "in" +365, 15, 29, 571, 104, 107, 2353, 2356, "the" +365, 15, 30, 572, 108, 109, 2357, 2358, "G" +365, 15, 31, 573, 110, 111, 2359, 2360, "+" +365, 15, 32, 574, 112, 115, 2361, 2364, "MET" +365, 15, 33, 575, 116, 121, 2365, 2370, "group" +365, 15, 34, 576, 122, 123, 2371, 2372, "(" +365, 15, 35, 577, 124, 125, 2373, 2374, "8" +365, 15, 36, 578, 126, 127, 2375, 2376, "." +365, 15, 37, 579, 128, 129, 2377, 2378, "6" +365, 15, 38, 580, 130, 131, 2379, 2380, "+" +365, 15, 39, 581, 132, 133, 2381, 2382, "/" +365, 15, 40, 582, 134, 135, 2383, 2384, "-" +365, 15, 41, 583, 136, 137, 2385, 2386, "0" +365, 15, 42, 584, 138, 139, 2387, 2388, "." +365, 15, 43, 585, 140, 141, 2389, 2390, "3" +365, 15, 44, 586, 142, 146, 2391, 2395, "mmol" +365, 15, 45, 587, 147, 148, 2396, 2397, "/" +365, 15, 46, 588, 149, 150, 2398, 2399, "l" +365, 15, 47, 589, 151, 152, 2400, 2401, "," +365, 15, 48, 590, 153, 154, 2402, 2403, "p" +365, 15, 49, 591, 155, 156, 2404, 2405, "=" +365, 15, 50, 592, 157, 158, 2406, 2407, "0" +365, 15, 51, 593, 159, 160, 2408, 2409, "." +365, 15, 52, 594, 161, 164, 2410, 2413, "002" +365, 15, 53, 595, 165, 166, 2414, 2415, ")" +365, 15, 54, 596, 167, 177, 2416, 2426, "throughout" +365, 15, 55, 597, 178, 181, 2427, 2430, "the" +365, 15, 56, 598, 182, 184, 2431, 2433, "36" +365, 15, 57, 599, 185, 186, 2434, 2435, "-" +365, 15, 58, 600, 187, 191, 2436, 2440, "week" +365, 15, 59, 601, 192, 197, 2441, 2446, "study" +365, 15, 60, 602, 198, 199, 2447, 2448, "." +365, 16, 1, 603, 0, 4, 2449, 2453, "With" +365, 16, 2, 604, 5, 11, 2454, 2460, "regard" +365, 16, 3, 605, 12, 14, 2461, 2463, "to" +365, 16, 4, 606, 15, 23, 2464, 2472, "baseline" +365, 16, 5, 607, 24, 39, 2473, 2488, "characteristics" +365, 16, 6, 608, 40, 44, 2489, 2493, "such" +365, 16, 7, 609, 45, 47, 2494, 2496, "as" +365, 16, 8, 610, 48, 55, 2497, 2504, "initial" +365, 16, 9, 611, 56, 65, 2505, 2514, "glycaemia" +365, 16, 10, 612, 66, 68, 2515, 2517, "or" +365, 16, 11, 613, 69, 70, 2518, 2519, "C" +365, 16, 12, 614, 71, 72, 2520, 2521, "-" +365, 16, 13, 615, 73, 80, 2522, 2529, "peptide" +365, 16, 14, 616, 81, 82, 2530, 2531, "," +365, 16, 15, 617, 83, 88, 2532, 2537, "there" +365, 16, 16, 618, 89, 92, 2538, 2541, "was" +365, 16, 17, 619, 93, 95, 2542, 2544, "no" +365, 16, 18, 620, 96, 106, 2545, 2555, "difference" +365, 16, 19, 621, 107, 114, 2556, 2563, "between" +365, 16, 20, 622, 115, 123, 2564, 2572, "patients" +365, 16, 21, 623, 124, 127, 2573, 2576, "who" +365, 16, 22, 624, 128, 136, 2577, 2585, "achieved" +365, 16, 23, 625, 137, 141, 2586, 2590, "good" +365, 16, 24, 626, 142, 151, 2591, 2600, "glycaemic" +365, 16, 25, 627, 152, 159, 2601, 2608, "control" +365, 16, 26, 628, 160, 161, 2609, 2610, "(" +365, 16, 27, 629, 162, 165, 2611, 2614, "HbA" +365, 16, 28, 630, 166, 167, 2615, 2616, "(" +365, 16, 29, 631, 168, 170, 2617, 2619, "1c" +365, 16, 30, 632, 171, 172, 2620, 2621, ")" +365, 16, 31, 633, 173, 174, 2622, 2623, "<" +365, 16, 32, 634, 175, 176, 2624, 2625, "7" +365, 16, 33, 635, 177, 178, 2626, 2627, "." +365, 16, 34, 636, 179, 180, 2628, 2629, "0" +365, 16, 35, 637, 181, 182, 2630, 2631, "%" +365, 16, 36, 638, 183, 184, 2632, 2633, ")" +365, 16, 37, 639, 185, 188, 2634, 2637, "and" +365, 16, 38, 640, 189, 194, 2638, 2643, "those" +365, 16, 39, 641, 195, 198, 2644, 2647, "who" +365, 16, 40, 642, 199, 202, 2648, 2651, "did" +365, 16, 41, 643, 203, 206, 2652, 2655, "not" +365, 16, 42, 644, 207, 208, 2656, 2657, "." +365, 17, 1, 645, 0, 11, 2658, 2669, "Differences" +365, 17, 2, 646, 12, 16, 2670, 2674, "were" +365, 17, 3, 647, 17, 21, 2675, 2679, "seen" +365, 17, 4, 648, 22, 24, 2680, 2682, "in" +365, 17, 5, 649, 25, 28, 2683, 2686, "the" +365, 17, 6, 650, 29, 38, 2687, 2696, "following" +365, 17, 7, 651, 39, 40, 2697, 2698, ":" +365, 17, 8, 652, 41, 48, 2699, 2706, "between" +365, 17, 9, 653, 49, 54, 2707, 2712, "study" +365, 17, 10, 654, 55, 62, 2713, 2720, "centres" +365, 17, 11, 655, 63, 64, 2721, 2722, "," +365, 17, 12, 656, 65, 71, 2723, 2729, "weight" +365, 17, 13, 657, 72, 76, 2730, 2734, "gain" +365, 17, 14, 658, 77, 83, 2735, 2741, "during" +365, 17, 15, 659, 84, 87, 2742, 2745, "the" +365, 17, 16, 660, 88, 91, 2746, 2749, "run" +365, 17, 17, 661, 92, 93, 2750, 2751, "-" +365, 17, 18, 662, 94, 96, 2752, 2754, "in" +365, 17, 19, 663, 97, 103, 2755, 2761, "period" +365, 17, 20, 664, 104, 107, 2762, 2765, "and" +365, 17, 21, 665, 108, 115, 2766, 2773, "insulin" +365, 17, 22, 666, 116, 123, 2774, 2781, "therapy" +365, 17, 23, 667, 124, 125, 2782, 2783, "," +365, 17, 24, 668, 126, 129, 2784, 2787, "and" +365, 17, 25, 669, 130, 133, 2788, 2791, "FPG" +365, 17, 26, 670, 134, 140, 2792, 2798, "during" +365, 17, 27, 671, 141, 144, 2799, 2802, "the" +365, 17, 28, 672, 145, 149, 2803, 2807, "last" +365, 17, 29, 673, 150, 152, 2808, 2810, "12" +365, 17, 30, 674, 153, 158, 2811, 2816, "weeks" +365, 17, 31, 675, 159, 160, 2817, 2818, "(" +365, 17, 32, 676, 161, 162, 2819, 2820, "5" +365, 17, 33, 677, 163, 164, 2821, 2822, "." +365, 17, 34, 678, 165, 166, 2823, 2824, "7" +365, 17, 35, 679, 167, 168, 2825, 2826, "+" +365, 17, 36, 680, 169, 170, 2827, 2828, "/" +365, 17, 37, 681, 171, 172, 2829, 2830, "-" +365, 17, 38, 682, 173, 174, 2831, 2832, "0" +365, 17, 39, 683, 175, 176, 2833, 2834, "." +365, 17, 40, 684, 177, 178, 2835, 2836, "2" +365, 17, 41, 685, 179, 181, 2837, 2839, "vs" +365, 17, 42, 686, 182, 183, 2840, 2841, "6" +365, 17, 43, 687, 184, 185, 2842, 2843, "." +365, 17, 44, 688, 186, 187, 2844, 2845, "7" +365, 17, 45, 689, 188, 189, 2846, 2847, "+" +365, 17, 46, 690, 190, 191, 2848, 2849, "/" +365, 17, 47, 691, 192, 193, 2850, 2851, "-" +365, 17, 48, 692, 194, 195, 2852, 2853, "0" +365, 17, 49, 693, 196, 197, 2854, 2855, "." +365, 17, 50, 694, 198, 199, 2856, 2857, "3" +365, 17, 51, 695, 200, 204, 2858, 2862, "mmol" +365, 17, 52, 696, 205, 206, 2863, 2864, "/" +365, 17, 53, 697, 207, 208, 2865, 2866, "l" +365, 17, 54, 698, 209, 212, 2867, 2870, "for" +365, 17, 55, 699, 213, 221, 2871, 2879, "patients" +365, 17, 56, 700, 222, 230, 2880, 2888, "reaching" +365, 17, 57, 701, 231, 233, 2889, 2891, "vs" +365, 17, 58, 702, 234, 239, 2892, 2897, "those" +365, 17, 59, 703, 240, 243, 2898, 2901, "not" +365, 17, 60, 704, 244, 252, 2902, 2910, "reaching" +365, 17, 61, 705, 253, 259, 2911, 2917, "target" +365, 17, 62, 706, 260, 261, 2918, 2919, "," +365, 17, 63, 707, 262, 263, 2920, 2921, "p" +365, 17, 64, 708, 264, 265, 2922, 2923, "<" +365, 17, 65, 709, 266, 267, 2924, 2925, "0" +365, 17, 66, 710, 268, 269, 2926, 2927, "." +365, 17, 67, 711, 270, 272, 2928, 2930, "01" +365, 17, 68, 712, 273, 274, 2931, 2932, ")" +365, 17, 69, 713, 275, 276, 2933, 2934, "." +365, 18, 1, 714, 0, 11, 2935, 2946, "CONCLUSIONS" +365, 18, 2, 715, 12, 13, 2947, 2948, "/" +365, 18, 3, 716, 14, 28, 2949, 2963, "INTERPRETATION" +365, 18, 4, 717, 29, 30, 2964, 2965, ":" +365, 18, 5, 718, 31, 35, 2966, 2970, "Good" +365, 18, 6, 719, 36, 45, 2971, 2980, "glycaemic" +365, 18, 7, 720, 46, 53, 2981, 2988, "control" +365, 18, 8, 721, 54, 57, 2989, 2992, "can" +365, 18, 9, 722, 58, 60, 2993, 2995, "be" +365, 18, 10, 723, 61, 69, 2996, 3004, "achieved" +365, 18, 11, 724, 70, 74, 3005, 3009, "with" +365, 18, 12, 725, 75, 79, 3010, 3014, "both" +365, 18, 13, 726, 80, 81, 3015, 3016, "G" +365, 18, 14, 727, 82, 83, 3017, 3018, "+" +365, 18, 15, 728, 84, 87, 3019, 3022, "MET" +365, 18, 16, 729, 88, 91, 3023, 3026, "and" +365, 18, 17, 730, 92, 95, 3027, 3030, "NPH" +365, 18, 18, 731, 96, 97, 3031, 3032, "+" +365, 18, 19, 732, 98, 101, 3033, 3036, "MET" +365, 18, 20, 733, 102, 103, 3037, 3038, "." +365, 19, 1, 734, 0, 3, 3039, 3042, "Use" +365, 19, 2, 735, 4, 6, 3043, 3045, "of" +365, 19, 3, 736, 7, 8, 3046, 3047, "G" +365, 19, 4, 737, 9, 10, 3048, 3049, "+" +365, 19, 5, 738, 11, 14, 3050, 3053, "MET" +365, 19, 6, 739, 15, 22, 3054, 3061, "reduces" +365, 19, 7, 740, 23, 34, 3062, 3073, "symptomatic" +365, 19, 8, 741, 35, 48, 3074, 3087, "hypoglycaemia" +365, 19, 9, 742, 49, 55, 3088, 3094, "during" +365, 19, 10, 743, 56, 59, 3095, 3098, "the" +365, 19, 11, 744, 60, 65, 3099, 3104, "first" +365, 19, 12, 745, 66, 68, 3105, 3107, "12" +365, 19, 13, 746, 69, 74, 3108, 3113, "weeks" +365, 19, 14, 747, 75, 78, 3114, 3117, "and" +365, 19, 15, 748, 79, 85, 3118, 3124, "dinner" +365, 19, 16, 749, 86, 90, 3125, 3129, "time" +365, 19, 17, 750, 91, 105, 3130, 3144, "hyperglycaemia" +365, 19, 18, 751, 106, 114, 3145, 3153, "compared" +365, 19, 19, 752, 115, 119, 3154, 3158, "with" +365, 19, 20, 753, 120, 123, 3159, 3162, "NPH" +365, 19, 21, 754, 124, 125, 3163, 3164, "+" +365, 19, 22, 755, 126, 129, 3165, 3168, "MET" +365, 19, 23, 756, 130, 131, 3169, 3170, "." +365, 20, 1, 757, 0, 3, 3171, 3174, "DOI" +365, 20, 2, 758, 4, 5, 3175, 3176, ":" +365, 20, 3, 759, 6, 8, 3177, 3179, "10" +365, 20, 4, 760, 9, 10, 3180, 3181, "." +365, 20, 5, 761, 11, 15, 3182, 3186, "1007" +365, 20, 6, 762, 16, 17, 3187, 3188, "/" +365, 20, 7, 763, 18, 24, 3189, 3195, "s00125" +365, 20, 8, 764, 25, 26, 3196, 3197, "-" +365, 20, 9, 765, 27, 30, 3198, 3201, "005" +365, 20, 10, 766, 31, 32, 3202, 3203, "-" +365, 20, 11, 767, 33, 37, 3204, 3208, "0132" +365, 20, 12, 768, 38, 39, 3209, 3210, "-" +365, 20, 13, 769, 40, 41, 3211, 3212, "0" +365, 20, 14, 770, 42, 46, 3213, 3217, "PMID" +365, 20, 15, 771, 47, 48, 3218, 3219, ":" +365, 20, 16, 772, 49, 57, 3220, 3228, "16456680" +365, 20, 17, 773, 58, 59, 3229, 3230, "[" +365, 20, 18, 774, 60, 67, 3231, 3238, "Indexed" +365, 20, 19, 775, 68, 71, 3239, 3242, "for" +365, 20, 20, 776, 72, 79, 3243, 3250, "MEDLINE" +365, 20, 21, 777, 80, 81, 3251, 3252, "]" diff --git a/data/dm2 16456680_kwoodley.annodb b/data/dm2 16456680_kwoodley.annodb new file mode 100644 index 0000000..7c2fa44 --- /dev/null +++ b/data/dm2 16456680_kwoodley.annodb @@ -0,0 +1,144 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31607, Journal, 0, 14, "Diabetologia .", "", +3125, PublicationYear, 15, 19, "2006", "", +31608, Title, 66, 153, "Insulin glargine or NPH combined with metformin in type 2 diabetes : the LANMET study .", "", +31609, InsulinGlargine, 66, 82, "Insulin glargine", "", +31610, IsophaneInsulin_NPH, 86, 89, "NPH", "", +31611, Metformin, 104, 113, "metformin", "", +31612, Type2Diabetes, 117, 132, "type 2 diabetes", "", +3127, Author, 154, 172, "Yki - J ä rvinen H", "", +3128, Author, 181, 204, "Kauppinen - M ä kelin R", "", +3129, Author, 207, 219, "Tiikkainen M", "", +3130, Author, 222, 236, "V ä h ä talo M", "", +3131, Author, 239, 248, "Virtamo H", "", +3132, Author, 251, 261, "Nikkil ä K", "", +3133, Author, 264, 273, "Tulokas T", "", +3134, Author, 276, 283, "Hulme S", "", +3135, Author, 286, 293, "Hardy K", "", +3136, Author, 296, 305, "McNulty S", "", +3137, Author, 308, 320, "H ä nninen J", "", +3138, Author, 323, 334, "Lev ä nen H", "", +3139, Author, 337, 350, "Lahdenper ä S", "", +3140, Author, 353, 363, "Lehtonen R", "", +3141, Author, 366, 373, "Ryysy L", "", +3142, Finland, 501, 508, "Finland", "", +31613, ObjectiveDescription, 561, 723, "In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin .", "", +3143, Type2Diabetes, 564, 579, "type 2 diabetic", "", +3144, Duration, 601, 609, "9 months", "", +3145, InsulinGlargine, 638, 654, "insulin glargine", "", +3146, Metformin, 659, 668, "metformin", "", +3147, Duration, 674, 682, "9 months", "", +3148, IsophaneInsulin_NPH, 686, 697, "NPH insulin", "", +3149, Metformin, 712, 721, "metformin", "", +3151, HbA1c, 757, 767, "HbA ( 1c )", "", +31614, Glucose, 790, 805, "diurnal glucose", "", +3485, SymptomaticHypoglycemia, 819, 844, "symptomatic hypoglycaemia", "", +3745, CTDesign, 865, 889, "investigator - initiated", "", +3158, OpenLabel, 890, 894, "open", "", +3157, Parallel, 897, 913, "parallel - group", "", +31615, Multicenter, 939, 952, "seven centres", "", +3159, NumberPatientsCT, 955, 958, "110", "", +3160, Precondition, 959, 1129, "insulin - naive type 2 diabetic patients with poor glycaemic control ( HbA ( 1c ) > or = 8 . 0 % ) on oral hypoglycaemic agents ( 90 % using sulfonylurea plus metformin )", "", +3161, Type2Diabetes, 975, 990, "type 2 diabetic", "", +3747, HbA1c, 1030, 1040, "HbA ( 1c )", "", +3746, Percentage, 1054, 1055, "%", "", +3748, OralAntidiabeticAgent, 1061, 1086, "oral hypoglycaemic agents", "", +3749, Sulfonylureas, 1100, 1112, "sulfonylurea", "", +3750, Metformin, 1118, 1127, "metformin", "", +3165, Randomized, 1135, 1145, "randomised", "", +3166, Bedtime, 1157, 1164, "bedtime", "", +3167, InsulinGlargine, 1165, 1181, "insulin glargine", "", +3168, Metformin, 1187, 1196, "metformin", "", +3169, InsulinGlargine, 1199, 1200, "G", "", +3170, Metformin, 1203, 1206, "MET", "", +3173, Bedtime, 1212, 1219, "bedtime", "", +3174, IsophaneInsulin_NPH, 1220, 1223, "NPH", "", +3171, Metformin, 1229, 1238, "metformin", "", +3175, IsophaneInsulin_NPH, 1241, 1244, "NPH", "", +3172, Metformin, 1247, 1250, "MET", "", +3176, Duration, 1257, 1265, "36 weeks", "", +31616, InsulinDose, 1320, 1332, "insulin dose", "", +3177, FastingPlasmaGlucose_target, 1445, 1502, "fasting plasma glucose ( FPG ) of 4 . 0 to 5 . 5 mmol / l", "", +3181, TimePoint, 1530, 1554, "During the last 12 weeks", "", +3182, FastingPlasmaGlucose, 1557, 1561, "FPGs", "", +3183, ResultMeasuredValue, 1571, 1577, "5 . 75", "", +3189, SdDevResValue, 1584, 1590, "0 . 02", "", +3184, ResultMeasuredValue, 1595, 1601, "5 . 96", "", +3190, SdDevResValue, 1608, 1614, "0 . 03", "", +3195, Millimoles_per_litre, 1615, 1623, "mmol / l", "", +3196, PvalueDiff, 1626, 1637, "p < 0 . 001", "", +31617, InsulinDose, 1644, 1657, "insulin doses", "", +3185, ResultMeasuredValue, 1663, 1665, "68", "", +3191, SdDevResValue, 1672, 1673, "5", "", +3186, ResultMeasuredValue, 1678, 1680, "70", "", +3192, SdDevResValue, 1687, 1688, "6", "", +3198, BioAndMedicalUnit, 1689, 1697, "IU / day", "insulin dose", +3187, ResultMeasuredValue, 1700, 1706, "0 . 69", "", +3193, SdDevResValue, 1713, 1719, "0 . 05", "", +3188, ResultMeasuredValue, 1724, 1730, "0 . 66", "", +3194, SdDevResValue, 1737, 1743, "0 . 04", "", +3488, IntUnit_per_Kg, 1744, 1769, "IU kg ( - 1 ) day ( - 1 )", "", +3205, InsulinGlargine, 1784, 1785, "G", "", +3204, Metformin, 1788, 1791, "MET", "", +3486, IsophaneInsulin_NPH, 1796, 1799, "NPH", "", +3203, Metformin, 1802, 1805, "MET", "", +3206, TimePoint, 1830, 1841, "At 36 weeks", "", +3207, HbA1c, 1849, 1859, "HbA ( 1c )", "", +3208, ResultMeasuredValue, 1864, 1870, "7 . 14", "", +3210, SdDevResValue, 1877, 1883, "0 . 12", "", +3209, ResultMeasuredValue, 1888, 1894, "7 . 16", "", +3211, SdDevResValue, 1901, 1907, "0 . 14", "", +3212, Percentage, 1908, 1909, "%", "", +3213, SymptomaticHypoglycemia, 1934, 1993, "Symptomatic , but not confirmed symptomatic , hypoglycaemia", "", +3214, TimePoint, 2029, 2043, "first 12 weeks", "", +3215, InsulinGlargine, 2051, 2052, "G", "", +3216, Metformin, 2055, 2058, "MET", "", +3218, NumberAffected, 2067, 2072, "4 . 1", "", +3219, SdDevNumAffected, 2079, 2084, "0 . 8", "", +3220, IsophaneInsulin_NPH, 2125, 2128, "NPH", "", +3217, Metformin, 2131, 2134, "MET", "", +3221, NumberAffected, 2143, 2148, "9 . 0", "", +3222, SdDevNumAffected, 2155, 2160, "2 . 3", "", +3224, PvalueDiff, 2189, 2199, "p < 0 . 05", "", +31618, Glucose, 2249, 2263, "Glucose levels", "", +3226, TimePoint, 2264, 2277, "before dinner", "", +3227, IsophaneInsulin_NPH, 2297, 2300, "NPH", "", +3228, Metformin, 2303, 2306, "MET", "", +3230, ResultMeasuredValue, 2315, 2321, "10 . 1", "", +3232, SdDevResValue, 2328, 2333, "0 . 3", "", +3235, Millimoles_per_litre, 2334, 2342, "mmol / l", "", +3234, InsulinGlargine, 2357, 2358, "G", "", +3229, Metformin, 2361, 2364, "MET", "", +3231, ResultMeasuredValue, 2373, 2378, "8 . 6", "", +3233, SdDevResValue, 2385, 2390, "0 . 3", "", +3236, Millimoles_per_litre, 2391, 2399, "mmol / l", "", +3237, PvalueDiff, 2402, 2413, "p = 0 . 002", "", +3238, Duration, 2431, 2440, "36 - week", "", +31621, ObservedResult, 2449, 2657, "With regard to baseline characteristics such as initial glycaemia or C - peptide , there was no difference between patients who achieved good glycaemic control ( HbA ( 1c ) < 7 . 0 % ) and those who did not .", "", +31619, HbA1c_target, 2611, 2631, "HbA ( 1c ) < 7 . 0 %", "", +3246, BodyWeight, 2723, 2729, "weight", "", +3247, Insulin, 2766, 2773, "insulin", "", +3244, FastingPlasmaGlucose, 2788, 2791, "FPG", "", +3245, TimePoint, 2792, 2816, "during the last 12 weeks", "", +3250, ResultMeasuredValue, 2819, 2824, "5 . 7", "", +3252, SdDevResValue, 2831, 2836, "0 . 2", "", +3251, ResultMeasuredValue, 2840, 2845, "6 . 7", "", +3253, SdDevResValue, 2852, 2857, "0 . 3", "", +3248, Millimoles_per_litre, 2858, 2866, "mmol / l", "", +3752, SubGroupDescription, 2867, 2917, "for patients reaching vs those not reaching target", "", +3249, PvalueDiff, 2920, 2930, "p < 0 . 01", "", +31622, ConclusionComment, 2966, 3038, "Good glycaemic control can be achieved with both G + MET and NPH + MET .", "", +3254, InsulinGlargine, 3015, 3016, "G", "", +3255, Metformin, 3019, 3022, "MET", "", +3257, IsophaneInsulin_NPH, 3027, 3030, "NPH", "", +3256, Metformin, 3033, 3036, "MET", "", +31623, ConclusionComment, 3039, 3170, "Use of G + MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH + MET .", "", +3259, InsulinGlargine, 3046, 3047, "G", "", +3260, Metformin, 3050, 3053, "MET", "", +3263, SymptomaticHypoglycemia, 3062, 3087, "symptomatic hypoglycaemia", "", +3264, TimePoint, 3088, 3113, "during the first 12 weeks", "", +3265, TimePoint, 3118, 3129, "dinner time", "", +3266, Hypoglycemia, 3130, 3144, "hyperglycaemia", "", +3262, IsophaneInsulin_NPH, 3159, 3162, "NPH", "", +3261, Metformin, 3165, 3168, "MET", "", +3268, PMID, 3220, 3228, "16456680", "", diff --git a/data/dm2 16456680_kwoodley.n-triples b/data/dm2 16456680_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16456680_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16505498_admin.annodb b/data/dm2 16505498_admin.annodb new file mode 100644 index 0000000..700e3ee --- /dev/null +++ b/data/dm2 16505498_admin.annodb @@ -0,0 +1,101 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +79, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +0, PublicationYear, 16, 20, "2006", "", " \"2006\"." +175, Title, 49, 185, "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients : an 18 - week , randomized , double - blind study .", "", " \"Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients : an 18 - week , randomized , double - blind study .\"." +81, Drug, 61, 71, "benfluorex", "", +82, Sulfonylureas, 92, 104, "sulfonylurea", "", +83, Type2Diabetes, 108, 123, "type 2 diabetic", "", +84, Duration, 138, 147, "18 - week", "", +85, Randomized, 150, 160, "randomized", "", +86, DoubleBlind, 163, 177, "double - blind", "", +1, Author, 186, 194, "Moulin P", "", " \"Moulin P\"." +2, Author, 203, 210, "Andre M", "", " \"Andre M\"." +3, Author, 213, 220, "Alawi H", "", " \"Alawi H\"." +4, Author, 223, 236, "dos Santos LC", "", " \"dos Santos LC\"." +5, Author, 239, 248, "Khalid AK", "", " \"Khalid AK\"." +6, Author, 251, 257, "Koev D", "", " \"Koev D\"." +7, Author, 260, 267, "Moore R", "", " \"Moore R\"." +8, Author, 270, 278, "Serban V", "", " \"Serban V\"." +9, Author, 281, 291, "Picandet B", "", " \"Picandet B\"." +10, Author, 294, 307, "Francillard M", "", " \"Francillard M\"." +11, France, 425, 431, "France", "", " ." +45705, ObjectiveDescription, 482, 633, "The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add - on therapy in type 2 diabetic patients in whom diabetes", "", " \"The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add - on therapy in type 2 diabetic patients in whom diabetes\"." +14, Drug, 542, 552, "benfluorex", "", +15, Placebo, 558, 565, "placebo", "", +12, Precondition, 592, 741, "type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin", "", +18, Type2Diabetes, 592, 607, "type 2 diabetic", "", +102, Type2Diabetes, 625, 633, "diabetes", "", +45706, ObjectiveDescription, 625, 743, "diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin .", "", " \"diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin .\"." +16, Sulfonylureas, 666, 678, "sulfonylurea", "", +17, Metformin, 732, 741, "metformin", "", +19, Type2Diabetes, 774, 789, "Type 2 diabetic", "", +20, Precondition, 774, 955, "Type 2 diabetic patients with HbA ( 1c ) ( A1C ) ( 7 - 10 % ) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin", "", " \"Type 2 diabetic patients with HbA ( 1c ) ( A1C ) ( 7 - 10 % ) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin\"." +21, HbA1c, 804, 814, "HbA ( 1c )", "", " ." +178, HbA1c, 817, 820, "A1C", "", +177, Percentage, 832, 833, "%", "", +22, Sulfonylureas, 877, 889, "sulfonylurea", "", +23, Metformin, 946, 955, "metformin", "", +24, Randomized, 961, 969, "randomly", "", " ." +25, DoubleBlind, 981, 993, "double blind", "", " ." +26, Drug, 1007, 1017, "benfluorex", "", " . ." +27, DoseValue, 1018, 1021, "450", "", " \"450\"." +28, mg, 1022, 1024, "mg", "", " ." +78, Interval, 1027, 1030, "day", "", " \"day\"." +29, NumberPatientsArm, 1037, 1040, "165", "", " \"165\"." +30, Placebo, 1046, 1053, "placebo", "", " ." +31, NumberPatientsArm, 1060, 1063, "160", "", " \"160\"." +32, Duration, 1070, 1078, "18 weeks", "", " \"18 weeks\"." +33, HbA1c, 1113, 1116, "A1C", "", +183, TimePoint, 1147, 1155, "baseline", "", +184, TimePoint, 1163, 1179, "end of treatment", "", +34, MeasurementDevice, 1186, 1192, "ANCOVA", "", " . ." +35, FastingPlasmaGlucose, 1259, 1281, "fasting plasma glucose", "", +36, FastingPlasmaGlucose, 1284, 1287, "FPG", "", +37, EndPointDescription, 1292, 1310, "insulin resistance", "", +38, EndPointDescription, 1317, 1335, "plasma lipid level", "", +185, TimePoint, 1376, 1384, "baseline", "", +128, IntentionToTreat, 1392, 1414, "intention - to - treat", "", " ." +39, HbA1c, 1428, 1431, "A1C", "", +40, Drug, 1461, 1471, "benfluorex", "", +41, BaseLineValue, 1477, 1483, "8 . 34", "", " \"8 . 34\"." +42, SdDevBL, 1490, 1496, "0 . 83", "", " \"0 . 83\"." +43, ResultMeasuredValue, 1500, 1506, "7 . 52", "", " \"7 . 52\"." +44, SdDevResValue, 1513, 1519, "1 . 04", "", " \"1 . 04\"." +45, Percentage, 1520, 1521, "%", "", " ." +136, PValueChangeValue, 1524, 1535, "P < 0 . 001", "", " \"P < 0 . 001\"." +47, Placebo, 1566, 1573, "placebo", "", +48, BaseLineValue, 1579, 1585, "8 . 33", "", " \"8 . 33\"." +49, SdDevBL, 1592, 1598, "0 . 87", "", " \"0 . 87\"." +50, ResultMeasuredValue, 1602, 1608, "8 . 52", "", " \"8 . 52\"." +51, SdDevResValue, 1615, 1621, "1 . 36", "", " \"1 . 36\"." +52, Percentage, 1622, 1623, "%", "", +172, Mean, 1648, 1652, "mean", "", " . ." +143, DiffGroupAbsValue, 1691, 1699, "- 1 . 01", "", " \"- 1 . 01\"." +54, Percentage, 1700, 1701, "%", "", +55, ConfIntervalDiff, 1704, 1732, "95 % CI - 1 . 26 to - 0 . 76", "", " \"95 % CI - 1 . 26 to - 0 . 76\"." +56, PvalueDiff, 1735, 1746, "P < 0 . 001", "", " \"P < 0 . 001\"." +57, HbA1c_target, 1755, 1780, "target A1C ( < or = 7 % )", "", " ." +58, PercentageAffected, 1797, 1799, "34", "", " \"34\"." +59, Drug, 1824, 1834, "benfluorex", "", +60, PercentageAffected, 1842, 1844, "12", "", " \"12\"." +61, Placebo, 1869, 1876, "placebo", "", +62, Drug, 1931, 1941, "benfluorex", "", +173, Mean, 1960, 1964, "mean", "", +63, FastingPlasmaGlucose, 1965, 1968, "FPG", "", " ." +156, DiffGroupAbsValue, 1971, 1979, "- 1 . 65", "", " \"- 1 . 65\"." +64, Millimoles_per_litre, 1980, 1988, "mmol / l", "", +158, PvalueDiff, 1993, 2004, "P < 0 . 001", "", " \"P < 0 . 001\"." +67, EndPointDescription, 2047, 2065, "insulin resistance", "", " . ." +180, ObservedResult, 2115, 2180, "Serious adverse events were more frequent in the benfluorex group", "", " \"Serious adverse events were more frequent in the benfluorex group\"." +179, EndPointDescription, 2123, 2137, "adverse events", "", " . ." +68, Drug, 2164, 2174, "benfluorex", "", +69, ConclusionComment, 2242, 2446, "Benfluorex as an add - on therapy was superior to placebo in lowering A1C with a between - group difference of 1 % in type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea", "", " \"Benfluorex as an add - on therapy was superior to placebo in lowering A1C with a between - group difference of 1 % in type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea\"." +70, Drug, 2242, 2252, "Benfluorex", "", +71, Placebo, 2292, 2299, "placebo", "", +72, HbA1c, 2312, 2315, "A1C", "", +45707, DiffGroupRelValue, 2353, 2354, "1", "", +164, Type2Diabetes, 2360, 2375, "type 2 diabetic", "", +74, Sulfonylureas, 2434, 2446, "sulfonylurea", "", +181, ConclusionComment, 2447, 2513, "alone and in whom metformin was contraindicated or not tolerated .", "", " \"alone and in whom metformin was contraindicated or not tolerated .\"." +75, Metformin, 2465, 2474, "metformin", "", +77, PMID, 2576, 2584, "16505498", "", " \"16505498\"." diff --git a/data/dm2 16505498_admin.n-triples b/data/dm2 16505498_admin.n-triples new file mode 100644 index 0000000..6ce65e1 --- /dev/null +++ b/data/dm2 16505498_admin.n-triples @@ -0,0 +1,168 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients : an 18 - week , randomized , double - blind study ." . + "Moulin P" . + "2006" . + "Diabetes Care" . + "16505498" . + . + "Andre M" . + "Alawi H" . + "dos Santos LC" . + "Khalid AK" . + "Koev D" . + "Moore R" . + "Serban V" . + "Picandet B" . + "Francillard M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add - on therapy in type 2 diabetic patients in whom diabetes" . + "18 weeks" . + . + . + . + "Benfluorex as an add - on therapy was superior to placebo in lowering A1C with a between - group difference of 1 % in type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea" . + . + . + . + . + . + "diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin ." . + . + "alone and in whom metformin was contraindicated or not tolerated ." . + . + . +# RDF export of group: Population + . + "Population " . + "Type 2 diabetic patients with HbA ( 1c ) ( A1C ) ( 7 - 10 % ) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint insulin resistance" . + . + . + . + . + . + . + "Endpoint ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm b" . + "165" . + . + . + . + . + . + . + "Arm p" . + "160" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention b" . + . + "day" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication b" . + . + . + "450" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c b" . + . + "8 . 34" . + "0 . 83" . + "7 . 52" . + "1 . 04" . + "P < 0 . 001" . + . + "Outcome hba1c p" . + . + "8 . 33" . + "0 . 87" . + "8 . 52" . + "1 . 36" . + . + "Outcome hba1c target b" . + . + "34" . + . + "Outcome hba1c target p " . + . + "12" . + . + "Outcome fpg b" . + . + . + "Outcome fpg p " . + . + . + "Outcome ae b" . + . + "Serious adverse events were more frequent in the benfluorex group" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 1 . 01" . + "P < 0 . 001" . + "95 % CI - 1 . 26 to - 0 . 76" . + . + . + . + "DiffBetweenGroups fpg" . + "- 1 . 65" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16505498_akramersunderbrink.annodb b/data/dm2 16505498_akramersunderbrink.annodb new file mode 100644 index 0000000..dd24df5 --- /dev/null +++ b/data/dm2 16505498_akramersunderbrink.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9479, Journal, 0, 13, "Diabetes Care", "", +9480, PublicationYear, 16, 20, "2006", "", +9487, Title, 49, 183, "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients : an 18 - week , randomized , double - blind study", "", +9481, Drug, 61, 71, "benfluorex", "", +9482, Sulfonylureas, 92, 104, "sulfonylurea", "", +9483, Type2Diabetes, 108, 123, "type 2 diabetic", "", +9484, Duration, 138, 147, "18 - week", "", +9485, Randomized, 150, 160, "randomized", "", +9486, DoubleBlind, 163, 177, "double - blind", "", +9488, Author, 186, 194, "Moulin P", "", +9489, Author, 203, 210, "Andre M", "", +9490, Author, 213, 220, "Alawi H", "", +9491, Author, 223, 236, "dos Santos LC", "", +9492, Author, 239, 248, "Khalid AK", "", +9493, Author, 251, 257, "Koev D", "", +9494, Author, 260, 267, "Moore R", "", +9495, Author, 270, 278, "Serban V", "", +9496, Author, 281, 291, "Picandet B", "", +9497, Author, 294, 307, "Francillard M", "", +9498, France, 425, 431, "France", "", +9508, ObjectiveDescription, 482, 731, "The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add - on therapy in type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of", "", +9499, Drug, 542, 552, "benfluorex", "", +9500, Placebo, 558, 565, "placebo", "", +9501, Type2Diabetes, 592, 607, "type 2 diabetic", "", +9502, Type2Diabetes, 625, 633, "diabetes", "", +9503, Precondition, 625, 690, "diabetes is insufficiently controlled by sulfonylurea monotherapy", "", +9504, Sulfonylureas, 666, 678, "sulfonylurea", "", +9505, Precondition, 695, 741, "who have a limitation for the use of metformin", "", +9506, Metformin, 732, 741, "metformin", "", +9511, ObjectiveDescription, 732, 741, "metformin", "", +9507, Type2Diabetes, 774, 789, "Type 2 diabetic", "", +9512, Precondition, 804, 835, "HbA ( 1c ) ( A1C ) ( 7 - 10 % )", "", +9513, Precondition, 840, 894, "were receiving the maximum tolerated sulfonylurea dose", "", +9514, Sulfonylureas, 877, 889, "sulfonylurea", "", +9515, Precondition, 899, 955, "had a contraindication to or poor tolerance of metformin", "", +9516, Metformin, 946, 955, "metformin", "", +9517, Randomized, 961, 969, "randomly", "", +9518, DoubleBlind, 981, 993, "double blind", "", +9519, Drug, 1007, 1017, "benfluorex", "", +9520, DoseValue, 1018, 1021, "450", "", +9521, BioAndMedicalUnit, 1022, 1030, "mg / day", "", +9522, NumberPatientsArm, 1037, 1040, "165", "", +9523, Placebo, 1046, 1053, "placebo", "", +9524, NumberPatientsArm, 1060, 1063, "160", "", +9525, Duration, 1070, 1078, "18 weeks", "", +9526, HbA1c, 1113, 1116, "A1C", "", +39126, TimePoint, 1147, 1155, "baseline", "", +39127, TimePoint, 1163, 1179, "end of treatment", "", +9527, FastingPlasmaGlucose, 1259, 1289, "fasting plasma glucose ( FPG )", "", +9530, EndPointDescription, 1292, 1310, "insulin resistance", "", +9531, EndPointDescription, 1317, 1335, "plasma lipid level", "", +39128, TimePoint, 1376, 1384, "baseline", "", +9532, IntentionToTreat, 1392, 1414, "intention - to - treat", "", +9533, HbA1c, 1428, 1431, "A1C", "", +9534, Drug, 1461, 1471, "benfluorex", "", +9535, BaseLineValue, 1477, 1483, "8 . 34", "", +9536, SdErrorBL, 1484, 1496, "+ / - 0 . 83", "", +9537, ResultMeasuredValue, 1500, 1506, "7 . 52", "", +9538, SdErrorResValue, 1507, 1519, "+ / - 1 . 04", "", +9539, Percentage, 1520, 1521, "%", "", +9540, PValueChangeValue, 1524, 1535, "P < 0 . 001", "", +9541, Placebo, 1566, 1573, "placebo", "", +9542, BaseLineValue, 1579, 1585, "8 . 33", "", +9543, SdErrorBL, 1586, 1598, "+ / - 0 . 87", "", +9544, ResultMeasuredValue, 1602, 1608, "8 . 52", "", +9545, SdErrorResValue, 1609, 1621, "+ / - 1 . 36", "", +9546, Percentage, 1622, 1623, "%", "", +9780, Mean, 1648, 1652, "mean", "", +9547, DiffGroupAbsValue, 1691, 1699, "- 1 . 01", "", +9548, Percentage, 1700, 1701, "%", "", +9549, ConfIntervalDiff, 1704, 1732, "95 % CI - 1 . 26 to - 0 . 76", "", +9550, PvalueDiff, 1735, 1746, "P < 0 . 001", "", +9551, EndPointDescription, 1755, 1793, "target A1C ( < or = 7 % ) was achieved", "", +9552, PercentageAffected, 1797, 1799, "34", "", +9556, Percentage, 1800, 1801, "%", "", +9554, Drug, 1824, 1834, "benfluorex", "", +9553, PercentageAffected, 1842, 1844, "12", "", +9557, Percentage, 1845, 1846, "%", "", +9555, Placebo, 1869, 1876, "placebo", "", +9558, Drug, 1931, 1941, "benfluorex", "", +9781, Mean, 1960, 1964, "mean", "", +9559, FastingPlasmaGlucose, 1965, 1968, "FPG", "", +9560, DiffGroupAbsValue, 1971, 1979, "- 1 . 65", "", +9561, Millimoles_per_litre, 1980, 1988, "mmol / l", "", +9562, PvalueDiff, 1993, 2004, "P < 0 . 001", "", +9563, EndPointDescription, 2015, 2065, "homeostasis model assessment of insulin resistance", "", +9564, Drug, 2164, 2174, "benfluorex", "", +9565, Drug, 2242, 2252, "Benfluorex", "", +9566, Placebo, 2292, 2299, "placebo", "", +9567, HbA1c, 2312, 2315, "A1C", "", +9569, DiffGroupAbsValue, 2353, 2354, "1", "", +9570, Percentage, 2355, 2356, "%", "", +9568, Type2Diabetes, 2360, 2375, "type 2 diabetic", "", +9571, Precondition, 2385, 2446, "whose disease was insufficiently controlled with sulfonylurea", "", +9572, Sulfonylureas, 2434, 2446, "sulfonylurea", "", +9574, Precondition, 2457, 2511, "in whom metformin was contraindicated or not tolerated", "", +9573, Metformin, 2465, 2474, "metformin", "", +9575, PMID, 2576, 2584, "16505498", "", diff --git a/data/dm2 16505498_akramersunderbrink.n-triples b/data/dm2 16505498_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16505498_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16505498_export.csv b/data/dm2 16505498_export.csv new file mode 100644 index 0000000..bc3993c --- /dev/null +++ b/data/dm2 16505498_export.csv @@ -0,0 +1,547 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +364, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +364, 1, 2, 2, 9, 13, 9, 13, "Care" +364, 1, 3, 3, 14, 15, 14, 15, "." +364, 2, 1, 4, 0, 4, 16, 20, "2006" +364, 2, 2, 5, 5, 8, 21, 24, "Mar" +364, 2, 3, 6, 9, 10, 25, 26, ";" +364, 2, 4, 7, 11, 13, 27, 29, "29" +364, 2, 5, 8, 14, 15, 30, 31, "(" +364, 2, 6, 9, 16, 17, 32, 33, "3" +364, 2, 7, 10, 18, 19, 34, 35, ")" +364, 2, 8, 11, 20, 21, 36, 37, ":" +364, 2, 9, 12, 22, 25, 38, 41, "515" +364, 2, 10, 13, 26, 27, 42, 43, "-" +364, 2, 11, 14, 28, 30, 44, 46, "20" +364, 2, 12, 15, 31, 32, 47, 48, "." +364, 3, 1, 16, 0, 8, 49, 57, "Efficacy" +364, 3, 2, 17, 9, 11, 58, 60, "of" +364, 3, 3, 18, 12, 22, 61, 71, "benfluorex" +364, 3, 4, 19, 23, 25, 72, 74, "in" +364, 3, 5, 20, 26, 37, 75, 86, "combination" +364, 3, 6, 21, 38, 42, 87, 91, "with" +364, 3, 7, 22, 43, 55, 92, 104, "sulfonylurea" +364, 3, 8, 23, 56, 58, 105, 107, "in" +364, 3, 9, 24, 59, 63, 108, 112, "type" +364, 3, 10, 25, 64, 65, 113, 114, "2" +364, 3, 11, 26, 66, 74, 115, 123, "diabetic" +364, 3, 12, 27, 75, 83, 124, 132, "patients" +364, 3, 13, 28, 84, 85, 133, 134, ":" +364, 3, 14, 29, 86, 88, 135, 137, "an" +364, 3, 15, 30, 89, 91, 138, 140, "18" +364, 3, 16, 31, 92, 93, 141, 142, "-" +364, 3, 17, 32, 94, 98, 143, 147, "week" +364, 3, 18, 33, 99, 100, 148, 149, "," +364, 3, 19, 34, 101, 111, 150, 160, "randomized" +364, 3, 20, 35, 112, 113, 161, 162, "," +364, 3, 21, 36, 114, 120, 163, 169, "double" +364, 3, 22, 37, 121, 122, 170, 171, "-" +364, 3, 23, 38, 123, 128, 172, 177, "blind" +364, 3, 24, 39, 129, 134, 178, 183, "study" +364, 3, 25, 40, 135, 136, 184, 185, "." +364, 4, 1, 41, 0, 6, 186, 192, "Moulin" +364, 4, 2, 42, 7, 8, 193, 194, "P" +364, 4, 3, 43, 9, 10, 195, 196, "(" +364, 4, 4, 44, 11, 12, 197, 198, "1" +364, 4, 5, 45, 13, 14, 199, 200, ")" +364, 4, 6, 46, 15, 16, 201, 202, "," +364, 4, 7, 47, 17, 22, 203, 208, "Andre" +364, 4, 8, 48, 23, 24, 209, 210, "M" +364, 4, 9, 49, 25, 26, 211, 212, "," +364, 4, 10, 50, 27, 32, 213, 218, "Alawi" +364, 4, 11, 51, 33, 34, 219, 220, "H" +364, 4, 12, 52, 35, 36, 221, 222, "," +364, 4, 13, 53, 37, 40, 223, 226, "dos" +364, 4, 14, 54, 41, 47, 227, 233, "Santos" +364, 4, 15, 55, 48, 50, 234, 236, "LC" +364, 4, 16, 56, 51, 52, 237, 238, "," +364, 4, 17, 57, 53, 59, 239, 245, "Khalid" +364, 4, 18, 58, 60, 62, 246, 248, "AK" +364, 4, 19, 59, 63, 64, 249, 250, "," +364, 4, 20, 60, 65, 69, 251, 255, "Koev" +364, 4, 21, 61, 70, 71, 256, 257, "D" +364, 4, 22, 62, 72, 73, 258, 259, "," +364, 4, 23, 63, 74, 79, 260, 265, "Moore" +364, 4, 24, 64, 80, 81, 266, 267, "R" +364, 4, 25, 65, 82, 83, 268, 269, "," +364, 4, 26, 66, 84, 90, 270, 276, "Serban" +364, 4, 27, 67, 91, 92, 277, 278, "V" +364, 4, 28, 68, 93, 94, 279, 280, "," +364, 4, 29, 69, 95, 103, 281, 289, "Picandet" +364, 4, 30, 70, 104, 105, 290, 291, "B" +364, 4, 31, 71, 106, 107, 292, 293, "," +364, 4, 32, 72, 108, 119, 294, 305, "Francillard" +364, 4, 33, 73, 120, 121, 306, 307, "M" +364, 4, 34, 74, 122, 123, 308, 309, "." +364, 4, 35, 75, 124, 130, 310, 316, "Author" +364, 4, 36, 76, 131, 142, 317, 328, "information" +364, 4, 37, 77, 143, 144, 329, 330, ":" +364, 4, 38, 78, 145, 146, 331, 332, "(" +364, 4, 39, 79, 147, 148, 333, 334, "1" +364, 4, 40, 80, 149, 150, 335, 336, ")" +364, 4, 41, 81, 151, 164, 337, 350, "Endocrinology" +364, 4, 42, 82, 165, 175, 351, 361, "Department" +364, 4, 43, 83, 176, 177, 362, 363, "," +364, 4, 44, 84, 178, 192, 364, 378, "Cardiovascular" +364, 4, 45, 85, 193, 201, 379, 387, "Hospital" +364, 4, 46, 86, 202, 203, 388, 389, "," +364, 4, 47, 87, 204, 214, 390, 400, "University" +364, 4, 48, 88, 215, 221, 401, 407, "Claude" +364, 4, 49, 89, 222, 229, 408, 415, "Bernard" +364, 4, 50, 90, 230, 231, 416, 417, "," +364, 4, 51, 91, 232, 236, 418, 422, "Lyon" +364, 4, 52, 92, 237, 238, 423, 424, "," +364, 4, 53, 93, 239, 245, 425, 431, "France" +364, 4, 54, 94, 246, 247, 432, 433, "." +364, 5, 1, 95, 0, 8, 434, 442, "philippe" +364, 5, 2, 96, 9, 10, 443, 444, "." +364, 5, 3, 97, 11, 17, 445, 451, "moulin" +364, 5, 4, 98, 18, 19, 452, 453, "@" +364, 5, 5, 99, 20, 23, 454, 457, "chu" +364, 5, 6, 100, 24, 25, 458, 459, "-" +364, 5, 7, 101, 26, 30, 460, 464, "lyon" +364, 5, 8, 102, 31, 32, 465, 466, "." +364, 5, 9, 103, 33, 35, 467, 469, "fr" +364, 5, 10, 104, 36, 45, 470, 479, "OBJECTIVE" +364, 5, 11, 105, 46, 47, 480, 481, ":" +364, 5, 12, 106, 48, 51, 482, 485, "The" +364, 5, 13, 107, 52, 55, 486, 489, "aim" +364, 5, 14, 108, 56, 58, 490, 492, "of" +364, 5, 15, 109, 59, 63, 493, 497, "this" +364, 5, 16, 110, 64, 69, 498, 503, "study" +364, 5, 17, 111, 70, 73, 504, 507, "was" +364, 5, 18, 112, 74, 76, 508, 510, "to" +364, 5, 19, 113, 77, 88, 511, 522, "demonstrate" +364, 5, 20, 114, 89, 92, 523, 526, "the" +364, 5, 21, 115, 93, 104, 527, 538, "superiority" +364, 5, 22, 116, 105, 107, 539, 541, "of" +364, 5, 23, 117, 108, 118, 542, 552, "benfluorex" +364, 5, 24, 118, 119, 123, 553, 557, "over" +364, 5, 25, 119, 124, 131, 558, 565, "placebo" +364, 5, 26, 120, 132, 134, 566, 568, "as" +364, 5, 27, 121, 135, 137, 569, 571, "an" +364, 5, 28, 122, 138, 141, 572, 575, "add" +364, 5, 29, 123, 142, 143, 576, 577, "-" +364, 5, 30, 124, 144, 146, 578, 580, "on" +364, 5, 31, 125, 147, 154, 581, 588, "therapy" +364, 5, 32, 126, 155, 157, 589, 591, "in" +364, 5, 33, 127, 158, 162, 592, 596, "type" +364, 5, 34, 128, 163, 164, 597, 598, "2" +364, 5, 35, 129, 165, 173, 599, 607, "diabetic" +364, 5, 36, 130, 174, 182, 608, 616, "patients" +364, 5, 37, 131, 183, 185, 617, 619, "in" +364, 5, 38, 132, 186, 190, 620, 624, "whom" +364, 5, 39, 133, 191, 199, 625, 633, "diabetes" +364, 5, 40, 134, 200, 202, 634, 636, "is" +364, 5, 41, 135, 203, 217, 637, 651, "insufficiently" +364, 5, 42, 136, 218, 228, 652, 662, "controlled" +364, 5, 43, 137, 229, 231, 663, 665, "by" +364, 5, 44, 138, 232, 244, 666, 678, "sulfonylurea" +364, 5, 45, 139, 245, 256, 679, 690, "monotherapy" +364, 5, 46, 140, 257, 260, 691, 694, "and" +364, 5, 47, 141, 261, 264, 695, 698, "who" +364, 5, 48, 142, 265, 269, 699, 703, "have" +364, 5, 49, 143, 270, 271, 704, 705, "a" +364, 5, 50, 144, 272, 282, 706, 716, "limitation" +364, 5, 51, 145, 283, 286, 717, 720, "for" +364, 5, 52, 146, 287, 290, 721, 724, "the" +364, 5, 53, 147, 291, 294, 725, 728, "use" +364, 5, 54, 148, 295, 297, 729, 731, "of" +364, 5, 55, 149, 298, 307, 732, 741, "metformin" +364, 5, 56, 150, 308, 309, 742, 743, "." +364, 6, 1, 151, 0, 8, 744, 752, "RESEARCH" +364, 6, 2, 152, 9, 15, 753, 759, "DESIGN" +364, 6, 3, 153, 16, 19, 760, 763, "AND" +364, 6, 4, 154, 20, 27, 764, 771, "METHODS" +364, 6, 5, 155, 28, 29, 772, 773, ":" +364, 6, 6, 156, 30, 34, 774, 778, "Type" +364, 6, 7, 157, 35, 36, 779, 780, "2" +364, 6, 8, 158, 37, 45, 781, 789, "diabetic" +364, 6, 9, 159, 46, 54, 790, 798, "patients" +364, 6, 10, 160, 55, 59, 799, 803, "with" +364, 6, 11, 161, 60, 63, 804, 807, "HbA" +364, 6, 12, 162, 64, 65, 808, 809, "(" +364, 6, 13, 163, 66, 68, 810, 812, "1c" +364, 6, 14, 164, 69, 70, 813, 814, ")" +364, 6, 15, 165, 71, 72, 815, 816, "(" +364, 6, 16, 166, 73, 76, 817, 820, "A1C" +364, 6, 17, 167, 77, 78, 821, 822, ")" +364, 6, 18, 168, 79, 80, 823, 824, "(" +364, 6, 19, 169, 81, 82, 825, 826, "7" +364, 6, 20, 170, 83, 84, 827, 828, "-" +364, 6, 21, 171, 85, 87, 829, 831, "10" +364, 6, 22, 172, 88, 89, 832, 833, "%" +364, 6, 23, 173, 90, 91, 834, 835, ")" +364, 6, 24, 174, 92, 95, 836, 839, "who" +364, 6, 25, 175, 96, 100, 840, 844, "were" +364, 6, 26, 176, 101, 110, 845, 854, "receiving" +364, 6, 27, 177, 111, 114, 855, 858, "the" +364, 6, 28, 178, 115, 122, 859, 866, "maximum" +364, 6, 29, 179, 123, 132, 867, 876, "tolerated" +364, 6, 30, 180, 133, 145, 877, 889, "sulfonylurea" +364, 6, 31, 181, 146, 150, 890, 894, "dose" +364, 6, 32, 182, 151, 154, 895, 898, "and" +364, 6, 33, 183, 155, 158, 899, 902, "had" +364, 6, 34, 184, 159, 160, 903, 904, "a" +364, 6, 35, 185, 161, 177, 905, 921, "contraindication" +364, 6, 36, 186, 178, 180, 922, 924, "to" +364, 6, 37, 187, 181, 183, 925, 927, "or" +364, 6, 38, 188, 184, 188, 928, 932, "poor" +364, 6, 39, 189, 189, 198, 933, 942, "tolerance" +364, 6, 40, 190, 199, 201, 943, 945, "of" +364, 6, 41, 191, 202, 211, 946, 955, "metformin" +364, 6, 42, 192, 212, 216, 956, 960, "were" +364, 6, 43, 193, 217, 225, 961, 969, "randomly" +364, 6, 44, 194, 226, 234, 970, 978, "assigned" +364, 6, 45, 195, 235, 236, 979, 980, "(" +364, 6, 46, 196, 237, 243, 981, 987, "double" +364, 6, 47, 197, 244, 249, 988, 993, "blind" +364, 6, 48, 198, 250, 251, 994, 995, ")" +364, 6, 49, 199, 252, 254, 996, 998, "to" +364, 6, 50, 200, 255, 262, 999, 1006, "receive" +364, 6, 51, 201, 263, 273, 1007, 1017, "benfluorex" +364, 6, 52, 202, 274, 277, 1018, 1021, "450" +364, 6, 53, 203, 278, 280, 1022, 1024, "mg" +364, 6, 54, 204, 281, 282, 1025, 1026, "/" +364, 6, 55, 205, 283, 286, 1027, 1030, "day" +364, 6, 56, 206, 287, 288, 1031, 1032, "(" +364, 6, 57, 207, 289, 290, 1033, 1034, "n" +364, 6, 58, 208, 291, 292, 1035, 1036, "=" +364, 6, 59, 209, 293, 296, 1037, 1040, "165" +364, 6, 60, 210, 297, 298, 1041, 1042, ")" +364, 6, 61, 211, 299, 301, 1043, 1045, "or" +364, 6, 62, 212, 302, 309, 1046, 1053, "placebo" +364, 6, 63, 213, 310, 311, 1054, 1055, "(" +364, 6, 64, 214, 312, 313, 1056, 1057, "n" +364, 6, 65, 215, 314, 315, 1058, 1059, "=" +364, 6, 66, 216, 316, 319, 1060, 1063, "160" +364, 6, 67, 217, 320, 321, 1064, 1065, ")" +364, 6, 68, 218, 322, 325, 1066, 1069, "for" +364, 6, 69, 219, 326, 328, 1070, 1072, "18" +364, 6, 70, 220, 329, 334, 1073, 1078, "weeks" +364, 6, 71, 221, 335, 336, 1079, 1080, "." +364, 7, 1, 222, 0, 3, 1081, 1084, "The" +364, 7, 2, 223, 4, 8, 1085, 1089, "main" +364, 7, 3, 224, 9, 17, 1090, 1098, "efficacy" +364, 7, 4, 225, 18, 27, 1099, 1108, "criterion" +364, 7, 5, 226, 28, 31, 1109, 1112, "was" +364, 7, 6, 227, 32, 35, 1113, 1116, "A1C" +364, 7, 7, 228, 36, 37, 1117, 1118, "," +364, 7, 8, 229, 38, 46, 1119, 1127, "analyzed" +364, 7, 9, 230, 47, 49, 1128, 1130, "as" +364, 7, 10, 231, 50, 53, 1131, 1134, "the" +364, 7, 11, 232, 54, 60, 1135, 1141, "change" +364, 7, 12, 233, 61, 65, 1142, 1146, "from" +364, 7, 13, 234, 66, 74, 1147, 1155, "baseline" +364, 7, 14, 235, 75, 77, 1156, 1158, "to" +364, 7, 15, 236, 78, 81, 1159, 1162, "the" +364, 7, 16, 237, 82, 85, 1163, 1166, "end" +364, 7, 17, 238, 86, 88, 1167, 1169, "of" +364, 7, 18, 239, 89, 98, 1170, 1179, "treatment" +364, 7, 19, 240, 99, 104, 1180, 1185, "using" +364, 7, 20, 241, 105, 111, 1186, 1192, "ANCOVA" +364, 7, 21, 242, 112, 116, 1193, 1197, "with" +364, 7, 22, 243, 117, 125, 1198, 1206, "baseline" +364, 7, 23, 244, 126, 129, 1207, 1210, "and" +364, 7, 24, 245, 130, 137, 1211, 1218, "country" +364, 7, 25, 246, 138, 140, 1219, 1221, "as" +364, 7, 26, 247, 141, 151, 1222, 1232, "covariates" +364, 7, 27, 248, 152, 153, 1233, 1234, "." +364, 8, 1, 249, 0, 9, 1235, 1244, "Secondary" +364, 8, 2, 250, 10, 18, 1245, 1253, "criteria" +364, 8, 3, 251, 19, 23, 1254, 1258, "were" +364, 8, 4, 252, 24, 31, 1259, 1266, "fasting" +364, 8, 5, 253, 32, 38, 1267, 1273, "plasma" +364, 8, 6, 254, 39, 46, 1274, 1281, "glucose" +364, 8, 7, 255, 47, 48, 1282, 1283, "(" +364, 8, 8, 256, 49, 52, 1284, 1287, "FPG" +364, 8, 9, 257, 53, 54, 1288, 1289, ")" +364, 8, 10, 258, 55, 56, 1290, 1291, "," +364, 8, 11, 259, 57, 64, 1292, 1299, "insulin" +364, 8, 12, 260, 65, 75, 1300, 1310, "resistance" +364, 8, 13, 261, 76, 77, 1311, 1312, "," +364, 8, 14, 262, 78, 81, 1313, 1316, "and" +364, 8, 15, 263, 82, 88, 1317, 1323, "plasma" +364, 8, 16, 264, 89, 94, 1324, 1329, "lipid" +364, 8, 17, 265, 95, 100, 1330, 1335, "level" +364, 8, 18, 266, 101, 102, 1336, 1337, "." +364, 9, 1, 267, 0, 7, 1338, 1345, "RESULTS" +364, 9, 2, 268, 8, 9, 1346, 1347, ":" +364, 9, 3, 269, 10, 14, 1348, 1352, "Both" +364, 9, 4, 270, 15, 21, 1353, 1359, "groups" +364, 9, 5, 271, 22, 26, 1360, 1364, "were" +364, 9, 6, 272, 27, 34, 1365, 1372, "similar" +364, 9, 7, 273, 35, 37, 1373, 1375, "at" +364, 9, 8, 274, 38, 46, 1376, 1384, "baseline" +364, 9, 9, 275, 47, 49, 1385, 1387, "in" +364, 9, 10, 276, 50, 53, 1388, 1391, "the" +364, 9, 11, 277, 54, 63, 1392, 1401, "intention" +364, 9, 12, 278, 64, 65, 1402, 1403, "-" +364, 9, 13, 279, 66, 68, 1404, 1406, "to" +364, 9, 14, 280, 69, 70, 1407, 1408, "-" +364, 9, 15, 281, 71, 76, 1409, 1414, "treat" +364, 9, 16, 282, 77, 87, 1415, 1425, "population" +364, 9, 17, 283, 88, 89, 1426, 1427, "." +364, 10, 1, 284, 0, 3, 1428, 1431, "A1C" +364, 10, 2, 285, 4, 17, 1432, 1445, "significantly" +364, 10, 3, 286, 18, 27, 1446, 1455, "decreased" +364, 10, 4, 287, 28, 32, 1456, 1460, "with" +364, 10, 5, 288, 33, 43, 1461, 1471, "benfluorex" +364, 10, 6, 289, 44, 48, 1472, 1476, "from" +364, 10, 7, 290, 49, 50, 1477, 1478, "8" +364, 10, 8, 291, 51, 52, 1479, 1480, "." +364, 10, 9, 292, 53, 55, 1481, 1483, "34" +364, 10, 10, 293, 56, 57, 1484, 1485, "+" +364, 10, 11, 294, 58, 59, 1486, 1487, "/" +364, 10, 12, 295, 60, 61, 1488, 1489, "-" +364, 10, 13, 296, 62, 63, 1490, 1491, "0" +364, 10, 14, 297, 64, 65, 1492, 1493, "." +364, 10, 15, 298, 66, 68, 1494, 1496, "83" +364, 10, 16, 299, 69, 71, 1497, 1499, "to" +364, 10, 17, 300, 72, 73, 1500, 1501, "7" +364, 10, 18, 301, 74, 75, 1502, 1503, "." +364, 10, 19, 302, 76, 78, 1504, 1506, "52" +364, 10, 20, 303, 79, 80, 1507, 1508, "+" +364, 10, 21, 304, 81, 82, 1509, 1510, "/" +364, 10, 22, 305, 83, 84, 1511, 1512, "-" +364, 10, 23, 306, 85, 86, 1513, 1514, "1" +364, 10, 24, 307, 87, 88, 1515, 1516, "." +364, 10, 25, 308, 89, 91, 1517, 1519, "04" +364, 10, 26, 309, 92, 93, 1520, 1521, "%" +364, 10, 27, 310, 94, 95, 1522, 1523, "(" +364, 10, 28, 311, 96, 97, 1524, 1525, "P" +364, 10, 29, 312, 98, 99, 1526, 1527, "<" +364, 10, 30, 313, 100, 101, 1528, 1529, "0" +364, 10, 31, 314, 102, 103, 1530, 1531, "." +364, 10, 32, 315, 104, 107, 1532, 1535, "001" +364, 10, 33, 316, 108, 109, 1536, 1537, ")" +364, 10, 34, 317, 110, 113, 1538, 1541, "and" +364, 10, 35, 318, 114, 120, 1542, 1548, "tended" +364, 10, 36, 319, 121, 123, 1549, 1551, "to" +364, 10, 37, 320, 124, 132, 1552, 1560, "increase" +364, 10, 38, 321, 133, 137, 1561, 1565, "with" +364, 10, 39, 322, 138, 145, 1566, 1573, "placebo" +364, 10, 40, 323, 146, 150, 1574, 1578, "from" +364, 10, 41, 324, 151, 152, 1579, 1580, "8" +364, 10, 42, 325, 153, 154, 1581, 1582, "." +364, 10, 43, 326, 155, 157, 1583, 1585, "33" +364, 10, 44, 327, 158, 159, 1586, 1587, "+" +364, 10, 45, 328, 160, 161, 1588, 1589, "/" +364, 10, 46, 329, 162, 163, 1590, 1591, "-" +364, 10, 47, 330, 164, 165, 1592, 1593, "0" +364, 10, 48, 331, 166, 167, 1594, 1595, "." +364, 10, 49, 332, 168, 170, 1596, 1598, "87" +364, 10, 50, 333, 171, 173, 1599, 1601, "to" +364, 10, 51, 334, 174, 175, 1602, 1603, "8" +364, 10, 52, 335, 176, 177, 1604, 1605, "." +364, 10, 53, 336, 178, 180, 1606, 1608, "52" +364, 10, 54, 337, 181, 182, 1609, 1610, "+" +364, 10, 55, 338, 183, 184, 1611, 1612, "/" +364, 10, 56, 339, 185, 186, 1613, 1614, "-" +364, 10, 57, 340, 187, 188, 1615, 1616, "1" +364, 10, 58, 341, 189, 190, 1617, 1618, "." +364, 10, 59, 342, 191, 193, 1619, 1621, "36" +364, 10, 60, 343, 194, 195, 1622, 1623, "%" +364, 10, 61, 344, 196, 197, 1624, 1625, "(" +364, 10, 62, 345, 198, 200, 1626, 1628, "NS" +364, 10, 63, 346, 201, 202, 1629, 1630, ")" +364, 10, 64, 347, 203, 204, 1631, 1632, "," +364, 10, 65, 348, 205, 214, 1633, 1642, "resulting" +364, 10, 66, 349, 215, 217, 1643, 1645, "in" +364, 10, 67, 350, 218, 219, 1646, 1647, "a" +364, 10, 68, 351, 220, 224, 1648, 1652, "mean" +364, 10, 69, 352, 225, 233, 1653, 1661, "adjusted" +364, 10, 70, 353, 234, 244, 1662, 1672, "difference" +364, 10, 71, 354, 245, 252, 1673, 1680, "between" +364, 10, 72, 355, 253, 259, 1681, 1687, "groups" +364, 10, 73, 356, 260, 262, 1688, 1690, "of" +364, 10, 74, 357, 263, 264, 1691, 1692, "-" +364, 10, 75, 358, 265, 266, 1693, 1694, "1" +364, 10, 76, 359, 267, 268, 1695, 1696, "." +364, 10, 77, 360, 269, 271, 1697, 1699, "01" +364, 10, 78, 361, 272, 273, 1700, 1701, "%" +364, 10, 79, 362, 274, 275, 1702, 1703, "(" +364, 10, 80, 363, 276, 278, 1704, 1706, "95" +364, 10, 81, 364, 279, 280, 1707, 1708, "%" +364, 10, 82, 365, 281, 283, 1709, 1711, "CI" +364, 10, 83, 366, 284, 285, 1712, 1713, "-" +364, 10, 84, 367, 286, 287, 1714, 1715, "1" +364, 10, 85, 368, 288, 289, 1716, 1717, "." +364, 10, 86, 369, 290, 292, 1718, 1720, "26" +364, 10, 87, 370, 293, 295, 1721, 1723, "to" +364, 10, 88, 371, 296, 297, 1724, 1725, "-" +364, 10, 89, 372, 298, 299, 1726, 1727, "0" +364, 10, 90, 373, 300, 301, 1728, 1729, "." +364, 10, 91, 374, 302, 304, 1730, 1732, "76" +364, 10, 92, 375, 305, 306, 1733, 1734, ";" +364, 10, 93, 376, 307, 308, 1735, 1736, "P" +364, 10, 94, 377, 309, 310, 1737, 1738, "<" +364, 10, 95, 378, 311, 312, 1739, 1740, "0" +364, 10, 96, 379, 313, 314, 1741, 1742, "." +364, 10, 97, 380, 315, 318, 1743, 1746, "001" +364, 10, 98, 381, 319, 320, 1747, 1748, ")" +364, 10, 99, 382, 321, 322, 1749, 1750, "." +364, 11, 1, 383, 0, 3, 1751, 1754, "The" +364, 11, 2, 384, 4, 10, 1755, 1761, "target" +364, 11, 3, 385, 11, 14, 1762, 1765, "A1C" +364, 11, 4, 386, 15, 16, 1766, 1767, "(" +364, 11, 5, 387, 17, 18, 1768, 1769, "<" +364, 11, 6, 388, 19, 21, 1770, 1772, "or" +364, 11, 7, 389, 22, 23, 1773, 1774, "=" +364, 11, 8, 390, 24, 25, 1775, 1776, "7" +364, 11, 9, 391, 26, 27, 1777, 1778, "%" +364, 11, 10, 392, 28, 29, 1779, 1780, ")" +364, 11, 11, 393, 30, 33, 1781, 1784, "was" +364, 11, 12, 394, 34, 42, 1785, 1793, "achieved" +364, 11, 13, 395, 43, 45, 1794, 1796, "in" +364, 11, 14, 396, 46, 48, 1797, 1799, "34" +364, 11, 15, 397, 49, 50, 1800, 1801, "%" +364, 11, 16, 398, 51, 53, 1802, 1804, "of" +364, 11, 17, 399, 54, 62, 1805, 1813, "patients" +364, 11, 18, 400, 63, 72, 1814, 1823, "receiving" +364, 11, 19, 401, 73, 83, 1824, 1834, "benfluorex" +364, 11, 20, 402, 84, 90, 1835, 1841, "versus" +364, 11, 21, 403, 91, 93, 1842, 1844, "12" +364, 11, 22, 404, 94, 95, 1845, 1846, "%" +364, 11, 23, 405, 96, 98, 1847, 1849, "of" +364, 11, 24, 406, 99, 107, 1850, 1858, "patients" +364, 11, 25, 407, 108, 117, 1859, 1868, "receiving" +364, 11, 26, 408, 118, 125, 1869, 1876, "placebo" +364, 11, 27, 409, 126, 127, 1877, 1878, "." +364, 12, 1, 410, 0, 11, 1879, 1890, "Significant" +364, 12, 2, 411, 12, 19, 1891, 1898, "between" +364, 12, 3, 412, 20, 21, 1899, 1900, "-" +364, 12, 4, 413, 22, 27, 1901, 1906, "group" +364, 12, 5, 414, 28, 39, 1907, 1918, "differences" +364, 12, 6, 415, 40, 42, 1919, 1921, "in" +364, 12, 7, 416, 43, 48, 1922, 1927, "favor" +364, 12, 8, 417, 49, 51, 1928, 1930, "of" +364, 12, 9, 418, 52, 62, 1931, 1941, "benfluorex" +364, 12, 10, 419, 63, 67, 1942, 1946, "were" +364, 12, 11, 420, 68, 76, 1947, 1955, "observed" +364, 12, 12, 421, 77, 80, 1956, 1959, "for" +364, 12, 13, 422, 81, 85, 1960, 1964, "mean" +364, 12, 14, 423, 86, 89, 1965, 1968, "FPG" +364, 12, 15, 424, 90, 91, 1969, 1970, "(" +364, 12, 16, 425, 92, 93, 1971, 1972, "-" +364, 12, 17, 426, 94, 95, 1973, 1974, "1" +364, 12, 18, 427, 96, 97, 1975, 1976, "." +364, 12, 19, 428, 98, 100, 1977, 1979, "65" +364, 12, 20, 429, 101, 105, 1980, 1984, "mmol" +364, 12, 21, 430, 106, 107, 1985, 1986, "/" +364, 12, 22, 431, 108, 109, 1987, 1988, "l" +364, 12, 23, 432, 110, 111, 1989, 1990, ")" +364, 12, 24, 433, 112, 113, 1991, 1992, "(" +364, 12, 25, 434, 114, 115, 1993, 1994, "P" +364, 12, 26, 435, 116, 117, 1995, 1996, "<" +364, 12, 27, 436, 118, 119, 1997, 1998, "0" +364, 12, 28, 437, 120, 121, 1999, 2000, "." +364, 12, 29, 438, 122, 125, 2001, 2004, "001" +364, 12, 30, 439, 126, 127, 2005, 2006, ")" +364, 12, 31, 440, 128, 131, 2007, 2010, "and" +364, 12, 32, 441, 132, 135, 2011, 2014, "for" +364, 12, 33, 442, 136, 147, 2015, 2026, "homeostasis" +364, 12, 34, 443, 148, 153, 2027, 2032, "model" +364, 12, 35, 444, 154, 164, 2033, 2043, "assessment" +364, 12, 36, 445, 165, 167, 2044, 2046, "of" +364, 12, 37, 446, 168, 175, 2047, 2054, "insulin" +364, 12, 38, 447, 176, 186, 2055, 2065, "resistance" +364, 12, 39, 448, 187, 188, 2066, 2067, "." +364, 13, 1, 449, 0, 7, 2068, 2075, "Overall" +364, 13, 2, 450, 8, 17, 2076, 2085, "tolerance" +364, 13, 3, 451, 18, 21, 2086, 2089, "was" +364, 13, 4, 452, 22, 29, 2090, 2097, "similar" +364, 13, 5, 453, 30, 32, 2098, 2100, "in" +364, 13, 6, 454, 33, 37, 2101, 2105, "both" +364, 13, 7, 455, 38, 44, 2106, 2112, "groups" +364, 13, 8, 456, 45, 46, 2113, 2114, "." +364, 14, 1, 457, 0, 7, 2115, 2122, "Serious" +364, 14, 2, 458, 8, 15, 2123, 2130, "adverse" +364, 14, 3, 459, 16, 22, 2131, 2137, "events" +364, 14, 4, 460, 23, 27, 2138, 2142, "were" +364, 14, 5, 461, 28, 32, 2143, 2147, "more" +364, 14, 6, 462, 33, 41, 2148, 2156, "frequent" +364, 14, 7, 463, 42, 44, 2157, 2159, "in" +364, 14, 8, 464, 45, 48, 2160, 2163, "the" +364, 14, 9, 465, 49, 59, 2164, 2174, "benfluorex" +364, 14, 10, 466, 60, 65, 2175, 2180, "group" +364, 14, 11, 467, 66, 67, 2181, 2182, "," +364, 14, 12, 468, 68, 75, 2183, 2190, "without" +364, 14, 13, 469, 76, 84, 2191, 2199, "evidence" +364, 14, 14, 470, 85, 87, 2200, 2202, "of" +364, 14, 15, 471, 88, 97, 2203, 2212, "causality" +364, 14, 16, 472, 98, 110, 2213, 2225, "relationship" +364, 14, 17, 473, 111, 112, 2226, 2227, "." +364, 15, 1, 474, 0, 11, 2228, 2239, "CONCLUSIONS" +364, 15, 2, 475, 12, 13, 2240, 2241, ":" +364, 15, 3, 476, 14, 24, 2242, 2252, "Benfluorex" +364, 15, 4, 477, 25, 27, 2253, 2255, "as" +364, 15, 5, 478, 28, 30, 2256, 2258, "an" +364, 15, 6, 479, 31, 34, 2259, 2262, "add" +364, 15, 7, 480, 35, 36, 2263, 2264, "-" +364, 15, 8, 481, 37, 39, 2265, 2267, "on" +364, 15, 9, 482, 40, 47, 2268, 2275, "therapy" +364, 15, 10, 483, 48, 51, 2276, 2279, "was" +364, 15, 11, 484, 52, 60, 2280, 2288, "superior" +364, 15, 12, 485, 61, 63, 2289, 2291, "to" +364, 15, 13, 486, 64, 71, 2292, 2299, "placebo" +364, 15, 14, 487, 72, 74, 2300, 2302, "in" +364, 15, 15, 488, 75, 83, 2303, 2311, "lowering" +364, 15, 16, 489, 84, 87, 2312, 2315, "A1C" +364, 15, 17, 490, 88, 92, 2316, 2320, "with" +364, 15, 18, 491, 93, 94, 2321, 2322, "a" +364, 15, 19, 492, 95, 102, 2323, 2330, "between" +364, 15, 20, 493, 103, 104, 2331, 2332, "-" +364, 15, 21, 494, 105, 110, 2333, 2338, "group" +364, 15, 22, 495, 111, 121, 2339, 2349, "difference" +364, 15, 23, 496, 122, 124, 2350, 2352, "of" +364, 15, 24, 497, 125, 126, 2353, 2354, "1" +364, 15, 25, 498, 127, 128, 2355, 2356, "%" +364, 15, 26, 499, 129, 131, 2357, 2359, "in" +364, 15, 27, 500, 132, 136, 2360, 2364, "type" +364, 15, 28, 501, 137, 138, 2365, 2366, "2" +364, 15, 29, 502, 139, 147, 2367, 2375, "diabetic" +364, 15, 30, 503, 148, 156, 2376, 2384, "patients" +364, 15, 31, 504, 157, 162, 2385, 2390, "whose" +364, 15, 32, 505, 163, 170, 2391, 2398, "disease" +364, 15, 33, 506, 171, 174, 2399, 2402, "was" +364, 15, 34, 507, 175, 189, 2403, 2417, "insufficiently" +364, 15, 35, 508, 190, 200, 2418, 2428, "controlled" +364, 15, 36, 509, 201, 205, 2429, 2433, "with" +364, 15, 37, 510, 206, 218, 2434, 2446, "sulfonylurea" +364, 15, 38, 511, 219, 224, 2447, 2452, "alone" +364, 15, 39, 512, 225, 228, 2453, 2456, "and" +364, 15, 40, 513, 229, 231, 2457, 2459, "in" +364, 15, 41, 514, 232, 236, 2460, 2464, "whom" +364, 15, 42, 515, 237, 246, 2465, 2474, "metformin" +364, 15, 43, 516, 247, 250, 2475, 2478, "was" +364, 15, 44, 517, 251, 266, 2479, 2494, "contraindicated" +364, 15, 45, 518, 267, 269, 2495, 2497, "or" +364, 15, 46, 519, 270, 273, 2498, 2501, "not" +364, 15, 47, 520, 274, 283, 2502, 2511, "tolerated" +364, 15, 48, 521, 284, 285, 2512, 2513, "." +364, 16, 1, 522, 0, 3, 2514, 2517, "DOI" +364, 16, 2, 523, 4, 5, 2518, 2519, ":" +364, 16, 3, 524, 6, 8, 2520, 2522, "10" +364, 16, 4, 525, 9, 10, 2523, 2524, "." +364, 16, 5, 526, 11, 15, 2525, 2529, "2337" +364, 16, 6, 527, 16, 17, 2530, 2531, "/" +364, 16, 7, 528, 18, 25, 2532, 2539, "diacare" +364, 16, 8, 529, 26, 27, 2540, 2541, "." +364, 16, 9, 530, 28, 30, 2542, 2544, "29" +364, 16, 10, 531, 31, 32, 2545, 2546, "." +364, 16, 11, 532, 33, 35, 2547, 2549, "03" +364, 16, 12, 533, 36, 37, 2550, 2551, "." +364, 16, 13, 534, 38, 40, 2552, 2554, "06" +364, 16, 14, 535, 41, 42, 2555, 2556, "." +364, 16, 15, 536, 43, 47, 2557, 2561, "dc05" +364, 16, 16, 537, 48, 49, 2562, 2563, "-" +364, 16, 17, 538, 50, 54, 2564, 2568, "1439" +364, 16, 18, 539, 55, 59, 2569, 2573, "PMID" +364, 16, 19, 540, 60, 61, 2574, 2575, ":" +364, 16, 20, 541, 62, 70, 2576, 2584, "16505498" +364, 16, 21, 542, 71, 72, 2585, 2586, "[" +364, 16, 22, 543, 73, 80, 2587, 2594, "Indexed" +364, 16, 23, 544, 81, 84, 2595, 2598, "for" +364, 16, 24, 545, 85, 92, 2599, 2606, "MEDLINE" +364, 16, 25, 546, 93, 94, 2607, 2608, "]" diff --git a/data/dm2 16505498_kwoodley.annodb b/data/dm2 16505498_kwoodley.annodb new file mode 100644 index 0000000..038d209 --- /dev/null +++ b/data/dm2 16505498_kwoodley.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31627, Journal, 0, 15, "Diabetes Care .", "", +3754, PublicationYear, 16, 20, "2006", "", +31628, Title, 49, 185, "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients : an 18 - week , randomized , double - blind study .", "", +3756, Author, 186, 194, "Moulin P", "", +3757, Author, 203, 210, "Andre M", "", +3758, Author, 213, 220, "Alawi H", "", +3759, Author, 223, 236, "dos Santos LC", "", +3760, Author, 239, 248, "Khalid AK", "", +3761, Author, 251, 257, "Koev D", "", +3762, Author, 260, 267, "Moore R", "", +3763, Author, 270, 278, "Serban V", "", +3764, Author, 281, 291, "Picandet B", "", +3765, Author, 294, 307, "Francillard M", "", +3766, France, 425, 431, "France", "", +3768, ObjectiveDescription, 482, 616, "The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add - on therapy in type 2 diabetic patients", "", +3771, Drug, 542, 552, "benfluorex", "", +3772, Placebo, 558, 565, "placebo", "", +3767, Precondition, 592, 741, "type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin", "", +3775, Type2Diabetes, 592, 607, "type 2 diabetic", "", +31629, ObjectiveDescription, 617, 743, "in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin .", "", +3773, Sulfonylureas, 666, 678, "sulfonylurea", "", +3774, Metformin, 732, 741, "metformin", "", +3776, Type2Diabetes, 774, 789, "Type 2 diabetic", "", +3777, Precondition, 774, 955, "Type 2 diabetic patients with HbA ( 1c ) ( A1C ) ( 7 - 10 % ) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin", "", +3778, HbA1c, 804, 814, "HbA ( 1c )", "", +31631, HbA1c, 817, 820, "A1C", "", +31630, Percentage, 832, 833, "%", "", +3779, Sulfonylureas, 877, 889, "sulfonylurea", "", +3780, Metformin, 946, 955, "metformin", "", +3781, Randomized, 961, 969, "randomly", "", +3782, DoubleBlind, 981, 993, "double blind", "", +3783, Drug, 1007, 1017, "benfluorex", "", +3784, DoseValue, 1018, 1021, "450", "", +3785, mg, 1022, 1024, "mg", "", +3848, Interval, 1027, 1030, "day", "", +3786, NumberPatientsArm, 1037, 1040, "165", "", +3787, Placebo, 1046, 1053, "placebo", "", +3788, NumberPatientsArm, 1060, 1063, "160", "", +3789, Duration, 1070, 1078, "18 weeks", "", +3790, HbA1c, 1113, 1116, "A1C", "", +3791, MeasurementDevice, 1186, 1192, "ANCOVA", "", +3792, FastingPlasmaGlucose, 1259, 1281, "fasting plasma glucose", "", +3793, FastingPlasmaGlucose, 1284, 1287, "FPG", "", +3794, EndPointDescription, 1292, 1310, "insulin resistance", "insulin resistance", +3795, EndPointDescription, 1317, 1335, "plasma lipid level", "plasma lipid level", +3808, HbA1c, 1428, 1431, "A1C", "", +3809, Drug, 1461, 1471, "benfluorex", "", +3810, BaseLineValue, 1477, 1483, "8 . 34", "", +3811, SdDevBL, 1490, 1496, "0 . 83", "", +3812, ResultMeasuredValue, 1500, 1506, "7 . 52", "", +3813, SdDevResValue, 1513, 1519, "1 . 04", "", +3814, Percentage, 1520, 1521, "%", "", +3815, PValueResValue, 1524, 1535, "P < 0 . 001", "", +3816, Placebo, 1566, 1573, "placebo", "", +3817, BaseLineValue, 1579, 1585, "8 . 33", "", +3818, SdDevBL, 1592, 1598, "0 . 87", "", +3819, ResultMeasuredValue, 1602, 1608, "8 . 52", "", +3820, SdDevResValue, 1615, 1621, "1 . 36", "", +3821, Percentage, 1622, 1623, "%", "", +3822, DiffGroupAbsValue, 1693, 1699, "1 . 01", "", +3823, Percentage, 1700, 1701, "%", "", +3824, ConfIntervalDiff, 1704, 1732, "95 % CI - 1 . 26 to - 0 . 76", "", +3825, PvalueDiff, 1735, 1746, "P < 0 . 001", "", +3826, HbA1c_target, 1755, 1780, "target A1C ( < or = 7 % )", "", +3827, PercentageAffected, 1797, 1799, "34", "", +3828, Drug, 1824, 1834, "benfluorex", "", +3829, PercentageAffected, 1842, 1844, "12", "", +3830, Placebo, 1869, 1876, "placebo", "", +3831, Drug, 1931, 1941, "benfluorex", "", +3832, FastingPlasmaGlucose, 1965, 1968, "FPG", "", +3834, Reduction, 1973, 1979, "1 . 65", "", +3833, Millimoles_per_litre, 1980, 1988, "mmol / l", "", +3835, PValueChangeValue, 1993, 2004, "P < 0 . 001", "", +3836, EndPointDescription, 2047, 2065, "insulin resistance", "insulin resistance", +31633, ObservedResult, 2115, 2227, "Serious adverse events were more frequent in the benfluorex group , without evidence of causality relationship .", "", +31632, EndPointDescription, 2123, 2137, "adverse events", "", +3837, Drug, 2164, 2174, "benfluorex", "", +3840, Drug, 2242, 2252, "Benfluorex", "", +3838, ConclusionComment, 2242, 2452, "Benfluorex as an add - on therapy was superior to placebo in lowering A1C with a between - group difference of 1 % in type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea alone", "", +3841, Placebo, 2292, 2299, "placebo", "", +3842, HbA1c, 2312, 2315, "A1C", "", +31635, Percentage, 2355, 2356, "%", "", +3843, Type2Diabetes, 2357, 2375, "in type 2 diabetic", "", +3846, Precondition, 2360, 2511, "type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea alone and in whom metformin was contraindicated or not tolerated", "", +3844, Sulfonylureas, 2434, 2446, "sulfonylurea", "", +31634, ConclusionComment, 2447, 2513, "alone and in whom metformin was contraindicated or not tolerated .", "", +3845, Metformin, 2465, 2474, "metformin", "", +3847, PMID, 2576, 2584, "16505498", "", diff --git a/data/dm2 16505498_kwoodley.n-triples b/data/dm2 16505498_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16505498_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16715577_admin.annodb b/data/dm2 16715577_admin.annodb new file mode 100644 index 0000000..7f27fde --- /dev/null +++ b/data/dm2 16715577_admin.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +160, Journal, 0, 14, "Arch Med Res .", "", " \"Arch Med Res .\"." +0, PublicationYear, 15, 19, "2006", "", " \"2006\"." +161, Title, 49, 150, "Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride .", "", " \"Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride .\"." +1, Type2Diabetes, 60, 75, "type 2 diabetes", "", +2, InsulinGlargine, 78, 94, "insulin glargine", "", +3, IsophaneInsulin_NPH, 100, 111, "NPH insulin", "", +4, Glimepiride, 137, 148, "glimepiride", "", +5, Author, 151, 166, "Eliaschewitz FG", "", " \"Eliaschewitz FG\"." +6, Author, 175, 182, "Calvo C", "", " \"Calvo C\"." +7, Author, 185, 195, "Valbuena H", "", " \"Valbuena H\"." +8, Author, 198, 204, "Ruiz M", "", " \"Ruiz M\"." +9, Author, 207, 216, "Aschner P", "", " \"Aschner P\"." +10, Author, 219, 228, "Villena J", "", " \"Villena J\"." +11, Author, 231, 241, "Ramirez LA", "", " \"Ramirez LA\"." +12, Author, 244, 253, "Jimenez J", "", " \"Jimenez J\"." +13, Brazil, 353, 359, "Brazil", "", " ." +14, Type2Diabetes, 403, 418, "Type 2 diabetes", "", +15, Type2Diabetes, 421, 425, "T2DM", "", +16, OralAntidiabeticAgent, 490, 513, "oral antidiabetic drugs", "", +17, OralAntidiabeticAgent, 516, 520, "OADs", "", +18, Insulin, 525, 532, "Insulin", "", +19, Hypoglycemia, 621, 633, "hypoglycemia", "", +162, ObjectiveDescription, 636, 846, "This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia .", "", " \"This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia .\"." +20, InsulinGlargine, 683, 699, "insulin glargine", "", +21, IsophaneInsulin_NPH, 704, 715, "NPH insulin", "", +104, Frequency, 745, 757, "once - daily", "", " \"once - daily\". \"once - daily\"." +23, Glimepiride, 772, 783, "glimepiride", "", +24, Hypoglycemia, 832, 844, "hypoglycemia", "", +25, OpenLabel, 865, 877, "open - label", "", " ." +27, Duration, 880, 889, "24 - week", "", " \"24 - week\"." +26, Randomized, 890, 900, "randomized", "", " ." +28, Multicenter, 910, 938, "ten Latin American countries", "", " ." +29, Type2Diabetes, 941, 945, "T2DM", "", +33, Precondition, 941, 1023, "T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )", "", " \"T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )\"." +30, OralAntidiabeticAgent, 976, 980, "OADs", "", +31, HbA1c, 983, 988, "HbA1c", "", +32, Percentage, 1020, 1021, "%", "", +34, Glimepiride, 1033, 1044, "glimepiride", "", " ." +35, InsulinGlargine, 1050, 1066, "insulin glargine", "", " ." +36, NumberPatientsArm, 1073, 1076, "231", "", " \"231\"." +37, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", " ." +38, NumberPatientsArm, 1100, 1103, "250", "", " \"250\"." +51230, DoseDescription, 1106, 1140, "using a forced titration algorithm", "", " \"using a forced titration algorithm\". \"using a forced titration algorithm\". \"using a forced titration algorithm\"." +39, Duration, 1187, 1196, "24 - week", "", +158, Mean, 1197, 1201, "mean", "", +40, HbA1c, 1213, 1218, "HbA1c", "", +41, InsulinGlargine, 1231, 1247, "Insulin glargine", "", +42, IsophaneInsulin_NPH, 1252, 1263, "NPH insulin", "", +43, HbA1c, 1281, 1286, "HbA1c", "", " ." +159, Mean, 1309, 1313, "mean", "", " . ." +124, DiffGroupAbsValue, 1325, 1334, "- 0 . 047", "", " \"- 0 . 047\"." +125, ConfIntervalDiff, 1337, 1364, "90 % CI - 0 . 232 , 0 . 138", "", " \"90 % CI - 0 . 232 , 0 . 138\"." +45874, SubGroupDescription, 1367, 1390, "per - protocol analysis", "", " \"per - protocol analysis\". \"per - protocol analysis\"." +80, PerProtocol, 1367, 1381, "per - protocol", "", " ." +46, NocturnalHypoglycemia, 1405, 1427, "nocturnal hypoglycemia", "", " ." +47, InsulinGlargine, 1457, 1473, "insulin glargine", "", +48, IsophaneInsulin_NPH, 1479, 1490, "NPH insulin", "", +49, PercentageAffected, 1493, 1499, "16 . 9", "", " \"16 . 9\"." +50, PercentageAffected, 1505, 1511, "30 . 0", "", " \"30 . 0\"." +51, PvalueDiff, 1516, 1526, "p < 0 . 01", "", " \"p < 0 . 01\"." +52, InsulinGlargine, 1568, 1584, "insulin glargine", "", +53, HbA1c_target, 1627, 1649, "HbA1c levels < 7 . 0 %", "", " ." +54, Percentage, 1648, 1649, "%", "", +55, Hypoglycemia, 1658, 1670, "hypoglycemia", "", " ." +57, PercentageAffected, 1673, 1675, "27", "", " \"27\"." +58, PercentageAffected, 1681, 1683, "17", "", " \"17\"." +59, PvalueDiff, 1688, 1699, "p = 0 . 014", "", " \"p = 0 . 014\"." +45873, SubGroupDescription, 1702, 1725, "per - protocol analysis", "", " \"per - protocol analysis\". \"per - protocol analysis\"." +78, PerProtocol, 1702, 1716, "per - protocol", "", +62, EndPointDescription, 1758, 1780, "treatment satisfaction", "", " . ." +60, InsulinGlargine, 1798, 1814, "insulin glargine", "", +61, IsophaneInsulin_NPH, 1820, 1831, "NPH insulin", "", +63, PvalueDiff, 1834, 1844, "p < 0 . 02", "", " \"p < 0 . 02\"." +45875, SubGroupDescription, 1847, 1860, "full analysis", "", " \"full analysis\". \"full analysis\"." +68, EndPointDescription, 1883, 1952, "patients who lost time from work or normal activities due to diabetes", "", " . ." +64, InsulinGlargine, 1968, 1984, "insulin glargine", "", +65, IsophaneInsulin_NPH, 1990, 1993, "NPH", "", +66, PercentageAffected, 1996, 2001, "1 . 8", "", " \"1 . 8\"." +67, PercentageAffected, 2007, 2012, "3 . 3", "", " \"3 . 3\"." +45872, SubGroupDescription, 2017, 2030, "full analysis", "", " \"full analysis\". \"full analysis\"." +163, ConclusionComment, 2049, 2276, "In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin .", "", " \"In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin .\"." +69, Type2Diabetes, 2066, 2070, "T2DM", "", +70, OralAntidiabeticAgent, 2100, 2104, "OADs", "", +72, Frequency, 2107, 2119, "once - daily", "", +73, InsulinGlargine, 2120, 2136, "insulin glargine", "", +74, Glimepiride, 2142, 2153, "glimepiride", "", +75, NocturnalHypoglycemia, 2226, 2248, "nocturnal hypoglycemia", "", +76, IsophaneInsulin_NPH, 2263, 2274, "NPH insulin", "", +77, PMID, 2284, 2292, "16715577", "", " \"16715577\"." diff --git a/data/dm2 16715577_admin.n-triples b/data/dm2 16715577_admin.n-triples new file mode 100644 index 0000000..1358c93 --- /dev/null +++ b/data/dm2 16715577_admin.n-triples @@ -0,0 +1,202 @@ +# RDF export of group: Publication + . + "Publication " . + "Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride ." . + "Eliaschewitz FG" . + "2006" . + "Arch Med Res ." . + "16715577" . + . + "Calvo C" . + "Valbuena H" . + "Ruiz M" . + "Aschner P" . + "Villena J" . + "Ramirez LA" . + "Jimenez J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia ." . + "24 - week" . + . + . + "In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint ts" . + . + . + . + . + . + . + "Endpoint ae in life" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm g + ig" . + "231" . + . + . + . + . + . + . + . + "Arm g + nph" . + "250" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention g + ig" . + . + "once - daily" . + . + . + . + "Intervention g + nph" . + . + "once - daily" . + . + . +# RDF export of group: Medication + . + "Medication g" . + . + . + . + "using a forced titration algorithm" . + . + "Medication ig" . + . + . + . + "using a forced titration algorithm" . + . + "Medication nph" . + . + . + . + "using a forced titration algorithm" . +# RDF export of group: Outcome + . + "Outcome hba1c ig" . + . + "per - protocol analysis" . + . + "Outcome hba1c nph" . + . + "per - protocol analysis" . + . + "Outcome nh ig" . + . + "16 . 9" . + . + "Outcome nh nph" . + . + "30 . 0" . + . + "Outcome hba1c target ig" . + . + "27" . + "per - protocol analysis" . + . + "Outcome hba1c target nph" . + . + "17" . + "per - protocol analysis" . + . + "Outcome ts ig " . + . + "full analysis" . + . + "Outcome ts nph" . + . + "full analysis" . + . + "Outcome ae in life ig " . + . + "1 . 8" . + "full analysis" . + . + "Outcome ae in life nph " . + . + "3 . 3" . + "full analysis" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 047" . + "90 % CI - 0 . 232 , 0 . 138" . + . + . + . + "DiffBetweenGroups nh" . + "p < 0 . 01" . + . + . + . + "DiffBetweenGroups hba1c target" . + "p = 0 . 014" . + . + . + . + "DiffBetweenGroups ts " . + "p < 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16715577_akramersunderbrink.annodb b/data/dm2 16715577_akramersunderbrink.annodb new file mode 100644 index 0000000..709c168 --- /dev/null +++ b/data/dm2 16715577_akramersunderbrink.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9576, Journal, 0, 12, "Arch Med Res", "", +9577, PublicationYear, 15, 19, "2006", "", +9582, Title, 49, 148, "Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride", "", +9578, Type2Diabetes, 60, 75, "type 2 diabetes", "", +9579, InsulinGlargine, 78, 94, "insulin glargine", "", +9580, IsophaneInsulin_NPH, 100, 111, "NPH insulin", "", +9581, Glimepiride, 137, 148, "glimepiride", "", +9583, Author, 151, 166, "Eliaschewitz FG", "", +9584, Author, 175, 182, "Calvo C", "", +9585, Author, 185, 195, "Valbuena H", "", +9586, Author, 198, 204, "Ruiz M", "", +9587, Author, 207, 216, "Aschner P", "", +9588, Author, 219, 228, "Villena J", "", +9589, Author, 231, 241, "Ramirez LA", "", +9590, Author, 244, 253, "Jimenez J", "", +9591, Brazil, 353, 359, "Brazil", "", +9592, Type2Diabetes, 403, 427, "Type 2 diabetes ( T2DM )", "", +9593, Insulin, 525, 532, "Insulin", "", +9594, Hypoglycemia, 621, 633, "hypoglycemia", "", +9602, ObjectiveDescription, 636, 844, "This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia", "", +9595, InsulinGlargine, 683, 699, "insulin glargine", "", +9596, IsophaneInsulin_NPH, 704, 715, "NPH insulin", "", +9597, Frequency, 745, 757, "once - daily", "", +9598, Glimepiride, 772, 783, "glimepiride", "", +9599, Hypoglycemia, 832, 844, "hypoglycemia", "", +9601, OpenLabel, 865, 877, "open - label", "", +9600, Duration, 880, 889, "24 - week", "", +9603, Randomized, 890, 900, "randomized", "", +9604, Multicenter, 907, 938, "in ten Latin American countries", "", +9605, Type2Diabetes, 941, 945, "T2DM", "", +9606, Precondition, 955, 1023, "poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )", "", +9607, Glimepiride, 1033, 1044, "glimepiride", "", +9608, InsulinGlargine, 1050, 1066, "insulin glargine", "", +9609, NumberPatientsArm, 1073, 1076, "231", "", +9610, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", +9611, NumberPatientsArm, 1100, 1103, "250", "", +9612, Duration, 1187, 1196, "24 - week", "", +9778, Mean, 1197, 1201, "mean", "", +9613, HbA1c, 1213, 1218, "HbA1c", "", +9614, InsulinGlargine, 1231, 1247, "Insulin glargine", "", +9615, IsophaneInsulin_NPH, 1252, 1263, "NPH insulin", "", +9616, HbA1c, 1281, 1286, "HbA1c", "", +9779, Mean, 1309, 1313, "mean", "", +9617, DiffGroupAbsValue, 1325, 1334, "- 0 . 047", "", +9618, ConfIntervalDiff, 1337, 1364, "90 % CI - 0 . 232 , 0 . 138", "", +9619, NocturnalHypoglycemia, 1395, 1427, "Confirmed nocturnal hypoglycemia", "", +9620, InsulinGlargine, 1457, 1473, "insulin glargine", "", +9621, IsophaneInsulin_NPH, 1479, 1490, "NPH insulin", "", +9622, ResultMeasuredValue, 1493, 1499, "16 . 9", "", +9623, ResultMeasuredValue, 1505, 1511, "30 . 0", "", +9624, Percentage, 1512, 1513, "%", "", +9625, PvalueDiff, 1516, 1526, "p < 0 . 01", "", +9626, InsulinGlargine, 1568, 1584, "insulin glargine", "", +9627, EndPointDescription, 1619, 1670, "achieve HbA1c levels < 7 . 0 % without hypoglycemia", "", +9628, PercentageAffected, 1673, 1675, "27", "", +9629, PercentageAffected, 1681, 1683, "17", "", +9630, Percentage, 1684, 1685, "%", "", +9631, PvalueDiff, 1688, 1699, "p = 0 . 014", "", +9632, EndPointDescription, 1758, 1792, "treatment satisfaction improvement", "", +9633, InsulinGlargine, 1798, 1814, "insulin glargine", "", +9634, IsophaneInsulin_NPH, 1820, 1831, "NPH insulin", "", +9635, PvalueDiff, 1834, 1844, "p < 0 . 02", "", +9636, EndPointDescription, 1883, 1952, "patients who lost time from work or normal activities due to diabetes", "", +9637, InsulinGlargine, 1968, 1984, "insulin glargine", "", +9638, IsophaneInsulin_NPH, 1990, 1993, "NPH", "", +9639, PercentageAffected, 1996, 2001, "1 . 8", "", +9640, PercentageAffected, 2007, 2012, "3 . 3", "", +9641, Percentage, 2013, 2014, "%", "", +9650, ConclusionComment, 2049, 2274, "In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin", "", +9642, Type2Diabetes, 2066, 2070, "T2DM", "", +9643, Precondition, 2073, 2104, "inadequately controlled on OADs", "", +9644, Frequency, 2107, 2119, "once - daily", "", +9645, InsulinGlargine, 2120, 2136, "insulin glargine", "", +9646, Glimepiride, 2142, 2153, "glimepiride", "", +9647, NocturnalHypoglycemia, 2226, 2248, "nocturnal hypoglycemia", "", +9648, IsophaneInsulin_NPH, 2263, 2274, "NPH insulin", "", +9649, PMID, 2284, 2292, "16715577", "", diff --git a/data/dm2 16715577_akramersunderbrink.n-triples b/data/dm2 16715577_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16715577_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 16715577_export.csv b/data/dm2 16715577_export.csv new file mode 100644 index 0000000..6ff987a --- /dev/null +++ b/data/dm2 16715577_export.csv @@ -0,0 +1,476 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +362, 1, 1, 1, 0, 4, 0, 4, "Arch" +362, 1, 2, 2, 5, 8, 5, 8, "Med" +362, 1, 3, 3, 9, 12, 9, 12, "Res" +362, 1, 4, 4, 13, 14, 13, 14, "." +362, 2, 1, 5, 0, 4, 15, 19, "2006" +362, 2, 2, 6, 5, 8, 20, 23, "May" +362, 2, 3, 7, 9, 10, 24, 25, ";" +362, 2, 4, 8, 11, 13, 26, 28, "37" +362, 2, 5, 9, 14, 15, 29, 30, "(" +362, 2, 6, 10, 16, 17, 31, 32, "4" +362, 2, 7, 11, 18, 19, 33, 34, ")" +362, 2, 8, 12, 20, 21, 35, 36, ":" +362, 2, 9, 13, 22, 25, 37, 40, "495" +362, 2, 10, 14, 26, 27, 41, 42, "-" +362, 2, 11, 15, 28, 31, 43, 46, "501" +362, 2, 12, 16, 32, 33, 47, 48, "." +362, 3, 1, 17, 0, 7, 49, 56, "Therapy" +362, 3, 2, 18, 8, 10, 57, 59, "in" +362, 3, 3, 19, 11, 15, 60, 64, "type" +362, 3, 4, 20, 16, 17, 65, 66, "2" +362, 3, 5, 21, 18, 26, 67, 75, "diabetes" +362, 3, 6, 22, 27, 28, 76, 77, ":" +362, 3, 7, 23, 29, 36, 78, 85, "insulin" +362, 3, 8, 24, 37, 45, 86, 94, "glargine" +362, 3, 9, 25, 46, 48, 95, 97, "vs" +362, 3, 10, 26, 49, 50, 98, 99, "." +362, 3, 11, 27, 51, 54, 100, 103, "NPH" +362, 3, 12, 28, 55, 62, 104, 111, "insulin" +362, 3, 13, 29, 63, 67, 112, 116, "both" +362, 3, 14, 30, 68, 70, 117, 119, "in" +362, 3, 15, 31, 71, 82, 120, 131, "combination" +362, 3, 16, 32, 83, 87, 132, 136, "with" +362, 3, 17, 33, 88, 99, 137, 148, "glimepiride" +362, 3, 18, 34, 100, 101, 149, 150, "." +362, 4, 1, 35, 0, 12, 151, 163, "Eliaschewitz" +362, 4, 2, 36, 13, 15, 164, 166, "FG" +362, 4, 3, 37, 16, 17, 167, 168, "(" +362, 4, 4, 38, 18, 19, 169, 170, "1" +362, 4, 5, 39, 20, 21, 171, 172, ")" +362, 4, 6, 40, 22, 23, 173, 174, "," +362, 4, 7, 41, 24, 29, 175, 180, "Calvo" +362, 4, 8, 42, 30, 31, 181, 182, "C" +362, 4, 9, 43, 32, 33, 183, 184, "," +362, 4, 10, 44, 34, 42, 185, 193, "Valbuena" +362, 4, 11, 45, 43, 44, 194, 195, "H" +362, 4, 12, 46, 45, 46, 196, 197, "," +362, 4, 13, 47, 47, 51, 198, 202, "Ruiz" +362, 4, 14, 48, 52, 53, 203, 204, "M" +362, 4, 15, 49, 54, 55, 205, 206, "," +362, 4, 16, 50, 56, 63, 207, 214, "Aschner" +362, 4, 17, 51, 64, 65, 215, 216, "P" +362, 4, 18, 52, 66, 67, 217, 218, "," +362, 4, 19, 53, 68, 75, 219, 226, "Villena" +362, 4, 20, 54, 76, 77, 227, 228, "J" +362, 4, 21, 55, 78, 79, 229, 230, "," +362, 4, 22, 56, 80, 87, 231, 238, "Ramirez" +362, 4, 23, 57, 88, 90, 239, 241, "LA" +362, 4, 24, 58, 91, 92, 242, 243, "," +362, 4, 25, 59, 93, 100, 244, 251, "Jimenez" +362, 4, 26, 60, 101, 102, 252, 253, "J" +362, 4, 27, 61, 103, 104, 254, 255, ";" +362, 4, 28, 62, 105, 108, 256, 259, "HOE" +362, 4, 29, 63, 109, 112, 260, 263, "901" +362, 4, 30, 64, 113, 114, 264, 265, "/" +362, 4, 31, 65, 115, 119, 266, 270, "4013" +362, 4, 32, 66, 120, 122, 271, 273, "LA" +362, 4, 33, 67, 123, 128, 274, 279, "Study" +362, 4, 34, 68, 129, 134, 280, 285, "Group" +362, 4, 35, 69, 135, 136, 286, 287, "." +362, 5, 1, 70, 0, 6, 288, 294, "Author" +362, 5, 2, 71, 7, 18, 295, 306, "information" +362, 5, 3, 72, 19, 20, 307, 308, ":" +362, 5, 4, 73, 21, 22, 309, 310, "(" +362, 5, 5, 74, 23, 24, 311, 312, "1" +362, 5, 6, 75, 25, 26, 313, 314, ")" +362, 5, 7, 76, 27, 35, 315, 323, "Hospital" +362, 5, 8, 77, 36, 40, 324, 328, "Heli" +362, 5, 9, 78, 41, 42, 329, 330, "ó" +362, 5, 10, 79, 43, 48, 331, 336, "polis" +362, 5, 11, 80, 49, 50, 337, 338, "," +362, 5, 12, 81, 51, 52, 339, 340, "S" +362, 5, 13, 82, 53, 54, 341, 342, "ã" +362, 5, 14, 83, 55, 56, 343, 344, "o" +362, 5, 15, 84, 57, 62, 345, 350, "Paulo" +362, 5, 16, 85, 63, 64, 351, 352, "," +362, 5, 17, 86, 65, 71, 353, 359, "Brazil" +362, 5, 18, 87, 72, 73, 360, 361, "." +362, 6, 1, 88, 0, 6, 362, 368, "freddy" +362, 6, 2, 89, 7, 8, 369, 370, "." +362, 6, 3, 90, 9, 10, 371, 372, "g" +362, 6, 4, 91, 11, 12, 373, 374, "@" +362, 6, 5, 92, 13, 16, 375, 378, "uol" +362, 6, 6, 93, 17, 18, 379, 380, "." +362, 6, 7, 94, 19, 22, 381, 384, "com" +362, 6, 8, 95, 23, 24, 385, 386, "." +362, 6, 9, 96, 25, 27, 387, 389, "br" +362, 6, 10, 97, 28, 38, 390, 400, "BACKGROUND" +362, 6, 11, 98, 39, 40, 401, 402, ":" +362, 6, 12, 99, 41, 45, 403, 407, "Type" +362, 6, 13, 100, 46, 47, 408, 409, "2" +362, 6, 14, 101, 48, 56, 410, 418, "diabetes" +362, 6, 15, 102, 57, 58, 419, 420, "(" +362, 6, 16, 103, 59, 63, 421, 425, "T2DM" +362, 6, 17, 104, 64, 65, 426, 427, ")" +362, 6, 18, 105, 66, 74, 428, 436, "patients" +362, 6, 19, 106, 75, 80, 437, 442, "often" +362, 6, 20, 107, 81, 85, 443, 447, "fail" +362, 6, 21, 108, 86, 88, 448, 450, "to" +362, 6, 22, 109, 89, 96, 451, 458, "achieve" +362, 6, 23, 110, 97, 105, 459, 467, "adequate" +362, 6, 24, 111, 106, 114, 468, 476, "glycemic" +362, 6, 25, 112, 115, 122, 477, 484, "control" +362, 6, 26, 113, 123, 127, 485, 489, "with" +362, 6, 27, 114, 128, 132, 490, 494, "oral" +362, 6, 28, 115, 133, 145, 495, 507, "antidiabetic" +362, 6, 29, 116, 146, 151, 508, 513, "drugs" +362, 6, 30, 117, 152, 153, 514, 515, "(" +362, 6, 31, 118, 154, 158, 516, 520, "OADs" +362, 6, 32, 119, 159, 160, 521, 522, ")" +362, 6, 33, 120, 161, 162, 523, 524, "." +362, 7, 1, 121, 0, 7, 525, 532, "Insulin" +362, 7, 2, 122, 8, 11, 533, 536, "has" +362, 7, 3, 123, 12, 16, 537, 541, "been" +362, 7, 4, 124, 17, 22, 542, 547, "shown" +362, 7, 5, 125, 23, 25, 548, 550, "to" +362, 7, 6, 126, 26, 33, 551, 558, "improve" +362, 7, 7, 127, 34, 42, 559, 567, "glycemic" +362, 7, 8, 128, 43, 50, 568, 575, "control" +362, 7, 9, 129, 51, 53, 576, 578, "in" +362, 7, 10, 130, 54, 59, 579, 584, "these" +362, 7, 11, 131, 60, 68, 585, 593, "patients" +362, 7, 12, 132, 69, 72, 594, 597, "but" +362, 7, 13, 133, 73, 77, 598, 602, "with" +362, 7, 14, 134, 78, 87, 603, 612, "increased" +362, 7, 15, 135, 88, 92, 613, 617, "risk" +362, 7, 16, 136, 93, 95, 618, 620, "of" +362, 7, 17, 137, 96, 108, 621, 633, "hypoglycemia" +362, 7, 18, 138, 109, 110, 634, 635, "." +362, 8, 1, 139, 0, 4, 636, 640, "This" +362, 8, 2, 140, 5, 10, 641, 646, "study" +362, 8, 3, 141, 11, 19, 647, 655, "compared" +362, 8, 4, 142, 20, 23, 656, 659, "the" +362, 8, 5, 143, 24, 32, 660, 668, "efficacy" +362, 8, 6, 144, 33, 36, 669, 672, "and" +362, 8, 7, 145, 37, 43, 673, 679, "safety" +362, 8, 8, 146, 44, 46, 680, 682, "of" +362, 8, 9, 147, 47, 54, 683, 690, "insulin" +362, 8, 10, 148, 55, 63, 691, 699, "glargine" +362, 8, 11, 149, 64, 67, 700, 703, "and" +362, 8, 12, 150, 68, 71, 704, 707, "NPH" +362, 8, 13, 151, 72, 79, 708, 715, "insulin" +362, 8, 14, 152, 80, 81, 716, 717, "," +362, 8, 15, 153, 82, 86, 718, 722, "both" +362, 8, 16, 154, 87, 89, 723, 725, "in" +362, 8, 17, 155, 90, 101, 726, 737, "combination" +362, 8, 18, 156, 102, 106, 738, 742, "with" +362, 8, 19, 157, 107, 108, 743, 744, "a" +362, 8, 20, 158, 109, 113, 745, 749, "once" +362, 8, 21, 159, 114, 115, 750, 751, "-" +362, 8, 22, 160, 116, 121, 752, 757, "daily" +362, 8, 23, 161, 122, 127, 758, 763, "fixed" +362, 8, 24, 162, 128, 132, 764, 768, "dose" +362, 8, 25, 163, 133, 135, 769, 771, "of" +362, 8, 26, 164, 136, 147, 772, 783, "glimepiride" +362, 8, 27, 165, 148, 149, 784, 785, "," +362, 8, 28, 166, 150, 152, 786, 788, "in" +362, 8, 29, 167, 153, 158, 789, 794, "terms" +362, 8, 30, 168, 159, 161, 795, 797, "of" +362, 8, 31, 169, 162, 170, 798, 806, "glycemic" +362, 8, 32, 170, 171, 178, 807, 814, "control" +362, 8, 33, 171, 179, 182, 815, 818, "and" +362, 8, 34, 172, 183, 192, 819, 828, "incidence" +362, 8, 35, 173, 193, 195, 829, 831, "of" +362, 8, 36, 174, 196, 208, 832, 844, "hypoglycemia" +362, 8, 37, 175, 209, 210, 845, 846, "." +362, 9, 1, 176, 0, 7, 847, 854, "METHODS" +362, 9, 2, 177, 8, 9, 855, 856, ":" +362, 9, 3, 178, 10, 12, 857, 859, "In" +362, 9, 4, 179, 13, 17, 860, 864, "this" +362, 9, 5, 180, 18, 22, 865, 869, "open" +362, 9, 6, 181, 23, 24, 870, 871, "-" +362, 9, 7, 182, 25, 30, 872, 877, "label" +362, 9, 8, 183, 31, 32, 878, 879, "," +362, 9, 9, 184, 33, 35, 880, 882, "24" +362, 9, 10, 185, 36, 37, 883, 884, "-" +362, 9, 11, 186, 38, 42, 885, 889, "week" +362, 9, 12, 187, 43, 53, 890, 900, "randomized" +362, 9, 13, 188, 54, 59, 901, 906, "trial" +362, 9, 14, 189, 60, 62, 907, 909, "in" +362, 9, 15, 190, 63, 66, 910, 913, "ten" +362, 9, 16, 191, 67, 72, 914, 919, "Latin" +362, 9, 17, 192, 73, 81, 920, 928, "American" +362, 9, 18, 193, 82, 91, 929, 938, "countries" +362, 9, 19, 194, 92, 93, 939, 940, "," +362, 9, 20, 195, 94, 98, 941, 945, "T2DM" +362, 9, 21, 196, 99, 107, 946, 954, "patients" +362, 9, 22, 197, 108, 114, 955, 961, "poorly" +362, 9, 23, 198, 115, 125, 962, 972, "controlled" +362, 9, 24, 199, 126, 128, 973, 975, "on" +362, 9, 25, 200, 129, 133, 976, 980, "OADs" +362, 9, 26, 201, 134, 135, 981, 982, "(" +362, 9, 27, 202, 136, 141, 983, 988, "HbA1c" +362, 9, 28, 203, 142, 143, 989, 990, ">" +362, 9, 29, 204, 144, 146, 991, 993, "or" +362, 9, 30, 205, 147, 148, 994, 995, "=" +362, 9, 31, 206, 149, 150, 996, 997, "7" +362, 9, 32, 207, 151, 152, 998, 999, "." +362, 9, 33, 208, 153, 154, 1000, 1001, "5" +362, 9, 34, 209, 155, 158, 1002, 1005, "and" +362, 9, 35, 210, 159, 160, 1006, 1007, "<" +362, 9, 36, 211, 161, 163, 1008, 1010, "or" +362, 9, 37, 212, 164, 165, 1011, 1012, "=" +362, 9, 38, 213, 166, 168, 1013, 1015, "10" +362, 9, 39, 214, 169, 170, 1016, 1017, "." +362, 9, 40, 215, 171, 172, 1018, 1019, "5" +362, 9, 41, 216, 173, 174, 1020, 1021, "%" +362, 9, 42, 217, 175, 176, 1022, 1023, ")" +362, 9, 43, 218, 177, 185, 1024, 1032, "received" +362, 9, 44, 219, 186, 197, 1033, 1044, "glimepiride" +362, 9, 45, 220, 198, 202, 1045, 1049, "plus" +362, 9, 46, 221, 203, 210, 1050, 1057, "insulin" +362, 9, 47, 222, 211, 219, 1058, 1066, "glargine" +362, 9, 48, 223, 220, 221, 1067, 1068, "(" +362, 9, 49, 224, 222, 223, 1069, 1070, "n" +362, 9, 50, 225, 224, 225, 1071, 1072, "=" +362, 9, 51, 226, 226, 229, 1073, 1076, "231" +362, 9, 52, 227, 230, 231, 1077, 1078, ")" +362, 9, 53, 228, 232, 234, 1079, 1081, "or" +362, 9, 54, 229, 235, 238, 1082, 1085, "NPH" +362, 9, 55, 230, 239, 246, 1086, 1093, "insulin" +362, 9, 56, 231, 247, 248, 1094, 1095, "(" +362, 9, 57, 232, 249, 250, 1096, 1097, "n" +362, 9, 58, 233, 251, 252, 1098, 1099, "=" +362, 9, 59, 234, 253, 256, 1100, 1103, "250" +362, 9, 60, 235, 257, 258, 1104, 1105, ")" +362, 9, 61, 236, 259, 264, 1106, 1111, "using" +362, 9, 62, 237, 265, 266, 1112, 1113, "a" +362, 9, 63, 238, 267, 273, 1114, 1120, "forced" +362, 9, 64, 239, 274, 283, 1121, 1130, "titration" +362, 9, 65, 240, 284, 293, 1131, 1140, "algorithm" +362, 9, 66, 241, 294, 295, 1141, 1142, "." +362, 10, 1, 242, 0, 3, 1143, 1146, "The" +362, 10, 2, 243, 4, 11, 1147, 1154, "primary" +362, 10, 3, 244, 12, 20, 1155, 1163, "endpoint" +362, 10, 4, 245, 21, 24, 1164, 1167, "was" +362, 10, 5, 246, 25, 28, 1168, 1171, "the" +362, 10, 6, 247, 29, 40, 1172, 1183, "equivalence" +362, 10, 7, 248, 41, 43, 1184, 1186, "of" +362, 10, 8, 249, 44, 46, 1187, 1189, "24" +362, 10, 9, 250, 47, 48, 1190, 1191, "-" +362, 10, 10, 251, 49, 53, 1192, 1196, "week" +362, 10, 11, 252, 54, 58, 1197, 1201, "mean" +362, 10, 12, 253, 59, 66, 1202, 1209, "changes" +362, 10, 13, 254, 67, 69, 1210, 1212, "in" +362, 10, 14, 255, 70, 75, 1213, 1218, "HbA1c" +362, 10, 15, 256, 76, 77, 1219, 1220, "." +362, 11, 1, 257, 0, 7, 1221, 1228, "RESULTS" +362, 11, 2, 258, 8, 9, 1229, 1230, ":" +362, 11, 3, 259, 10, 17, 1231, 1238, "Insulin" +362, 11, 4, 260, 18, 26, 1239, 1247, "glargine" +362, 11, 5, 261, 27, 30, 1248, 1251, "and" +362, 11, 6, 262, 31, 34, 1252, 1255, "NPH" +362, 11, 7, 263, 35, 42, 1256, 1263, "insulin" +362, 11, 8, 264, 43, 51, 1264, 1272, "achieved" +362, 11, 9, 265, 52, 59, 1273, 1280, "similar" +362, 11, 10, 266, 60, 65, 1281, 1286, "HbA1c" +362, 11, 11, 267, 66, 76, 1287, 1297, "reductions" +362, 11, 12, 268, 77, 78, 1298, 1299, "(" +362, 11, 13, 269, 79, 87, 1300, 1308, "adjusted" +362, 11, 14, 270, 88, 92, 1309, 1313, "mean" +362, 11, 15, 271, 93, 103, 1314, 1324, "difference" +362, 11, 16, 272, 104, 105, 1325, 1326, "-" +362, 11, 17, 273, 106, 107, 1327, 1328, "0" +362, 11, 18, 274, 108, 109, 1329, 1330, "." +362, 11, 19, 275, 110, 113, 1331, 1334, "047" +362, 11, 20, 276, 114, 115, 1335, 1336, ";" +362, 11, 21, 277, 116, 118, 1337, 1339, "90" +362, 11, 22, 278, 119, 120, 1340, 1341, "%" +362, 11, 23, 279, 121, 123, 1342, 1344, "CI" +362, 11, 24, 280, 124, 125, 1345, 1346, "-" +362, 11, 25, 281, 126, 127, 1347, 1348, "0" +362, 11, 26, 282, 128, 129, 1349, 1350, "." +362, 11, 27, 283, 130, 133, 1351, 1354, "232" +362, 11, 28, 284, 134, 135, 1355, 1356, "," +362, 11, 29, 285, 136, 137, 1357, 1358, "0" +362, 11, 30, 286, 138, 139, 1359, 1360, "." +362, 11, 31, 287, 140, 143, 1361, 1364, "138" +362, 11, 32, 288, 144, 145, 1365, 1366, ";" +362, 11, 33, 289, 146, 149, 1367, 1370, "per" +362, 11, 34, 290, 150, 151, 1371, 1372, "-" +362, 11, 35, 291, 152, 160, 1373, 1381, "protocol" +362, 11, 36, 292, 161, 169, 1382, 1390, "analysis" +362, 11, 37, 293, 170, 171, 1391, 1392, ")" +362, 11, 38, 294, 172, 173, 1393, 1394, "." +362, 12, 1, 295, 0, 9, 1395, 1404, "Confirmed" +362, 12, 2, 296, 10, 19, 1405, 1414, "nocturnal" +362, 12, 3, 297, 20, 32, 1415, 1427, "hypoglycemia" +362, 12, 4, 298, 33, 36, 1428, 1431, "was" +362, 12, 5, 299, 37, 50, 1432, 1445, "significantly" +362, 12, 6, 300, 51, 56, 1446, 1451, "lower" +362, 12, 7, 301, 57, 61, 1452, 1456, "with" +362, 12, 8, 302, 62, 69, 1457, 1464, "insulin" +362, 12, 9, 303, 70, 78, 1465, 1473, "glargine" +362, 12, 10, 304, 79, 81, 1474, 1476, "vs" +362, 12, 11, 305, 82, 83, 1477, 1478, "." +362, 12, 12, 306, 84, 87, 1479, 1482, "NPH" +362, 12, 13, 307, 88, 95, 1483, 1490, "insulin" +362, 12, 14, 308, 96, 97, 1491, 1492, "(" +362, 12, 15, 309, 98, 100, 1493, 1495, "16" +362, 12, 16, 310, 101, 102, 1496, 1497, "." +362, 12, 17, 311, 103, 104, 1498, 1499, "9" +362, 12, 18, 312, 105, 107, 1500, 1502, "vs" +362, 12, 19, 313, 108, 109, 1503, 1504, "." +362, 12, 20, 314, 110, 112, 1505, 1507, "30" +362, 12, 21, 315, 113, 114, 1508, 1509, "." +362, 12, 22, 316, 115, 116, 1510, 1511, "0" +362, 12, 23, 317, 117, 118, 1512, 1513, "%" +362, 12, 24, 318, 119, 120, 1514, 1515, ";" +362, 12, 25, 319, 121, 122, 1516, 1517, "p" +362, 12, 26, 320, 123, 124, 1518, 1519, "<" +362, 12, 27, 321, 125, 126, 1520, 1521, "0" +362, 12, 28, 322, 127, 128, 1522, 1523, "." +362, 12, 29, 323, 129, 131, 1524, 1526, "01" +362, 12, 30, 324, 132, 133, 1527, 1528, ";" +362, 12, 31, 325, 134, 140, 1529, 1535, "safety" +362, 12, 32, 326, 141, 149, 1536, 1544, "analysis" +362, 12, 33, 327, 150, 151, 1545, 1546, ")" +362, 12, 34, 328, 152, 153, 1547, 1548, "." +362, 13, 1, 329, 0, 8, 1549, 1557, "Patients" +362, 13, 2, 330, 9, 18, 1558, 1567, "receiving" +362, 13, 3, 331, 19, 26, 1568, 1575, "insulin" +362, 13, 4, 332, 27, 35, 1576, 1584, "glargine" +362, 13, 5, 333, 36, 40, 1585, 1589, "were" +362, 13, 6, 334, 41, 54, 1590, 1603, "significantly" +362, 13, 7, 335, 55, 59, 1604, 1608, "more" +362, 13, 8, 336, 60, 66, 1609, 1615, "likely" +362, 13, 9, 337, 67, 69, 1616, 1618, "to" +362, 13, 10, 338, 70, 77, 1619, 1626, "achieve" +362, 13, 11, 339, 78, 83, 1627, 1632, "HbA1c" +362, 13, 12, 340, 84, 90, 1633, 1639, "levels" +362, 13, 13, 341, 91, 92, 1640, 1641, "<" +362, 13, 14, 342, 93, 94, 1642, 1643, "7" +362, 13, 15, 343, 95, 96, 1644, 1645, "." +362, 13, 16, 344, 97, 98, 1646, 1647, "0" +362, 13, 17, 345, 99, 100, 1648, 1649, "%" +362, 13, 18, 346, 101, 108, 1650, 1657, "without" +362, 13, 19, 347, 109, 121, 1658, 1670, "hypoglycemia" +362, 13, 20, 348, 122, 123, 1671, 1672, "(" +362, 13, 21, 349, 124, 126, 1673, 1675, "27" +362, 13, 22, 350, 127, 129, 1676, 1678, "vs" +362, 13, 23, 351, 130, 131, 1679, 1680, "." +362, 13, 24, 352, 132, 134, 1681, 1683, "17" +362, 13, 25, 353, 135, 136, 1684, 1685, "%" +362, 13, 26, 354, 137, 138, 1686, 1687, ";" +362, 13, 27, 355, 139, 140, 1688, 1689, "p" +362, 13, 28, 356, 141, 142, 1690, 1691, "=" +362, 13, 29, 357, 143, 144, 1692, 1693, "0" +362, 13, 30, 358, 145, 146, 1694, 1695, "." +362, 13, 31, 359, 147, 150, 1696, 1699, "014" +362, 13, 32, 360, 151, 152, 1700, 1701, ";" +362, 13, 33, 361, 153, 156, 1702, 1705, "per" +362, 13, 34, 362, 157, 158, 1706, 1707, "-" +362, 13, 35, 363, 159, 167, 1708, 1716, "protocol" +362, 13, 36, 364, 168, 176, 1717, 1725, "analysis" +362, 13, 37, 365, 177, 178, 1726, 1727, ")" +362, 13, 38, 366, 179, 180, 1728, 1729, "." +362, 14, 1, 367, 0, 5, 1730, 1735, "There" +362, 14, 2, 368, 6, 9, 1736, 1739, "was" +362, 14, 3, 369, 10, 11, 1740, 1741, "a" +362, 14, 4, 370, 12, 16, 1742, 1746, "more" +362, 14, 5, 371, 17, 27, 1747, 1757, "pronounced" +362, 14, 6, 372, 28, 37, 1758, 1767, "treatment" +362, 14, 7, 373, 38, 50, 1768, 1780, "satisfaction" +362, 14, 8, 374, 51, 62, 1781, 1792, "improvement" +362, 14, 9, 375, 63, 67, 1793, 1797, "with" +362, 14, 10, 376, 68, 75, 1798, 1805, "insulin" +362, 14, 11, 377, 76, 84, 1806, 1814, "glargine" +362, 14, 12, 378, 85, 87, 1815, 1817, "vs" +362, 14, 13, 379, 88, 89, 1818, 1819, "." +362, 14, 14, 380, 90, 93, 1820, 1823, "NPH" +362, 14, 15, 381, 94, 101, 1824, 1831, "insulin" +362, 14, 16, 382, 102, 103, 1832, 1833, "(" +362, 14, 17, 383, 104, 105, 1834, 1835, "p" +362, 14, 18, 384, 106, 107, 1836, 1837, "<" +362, 14, 19, 385, 108, 109, 1838, 1839, "0" +362, 14, 20, 386, 110, 111, 1840, 1841, "." +362, 14, 21, 387, 112, 114, 1842, 1844, "02" +362, 14, 22, 388, 115, 116, 1845, 1846, ";" +362, 14, 23, 389, 117, 121, 1847, 1851, "full" +362, 14, 24, 390, 122, 130, 1852, 1860, "analysis" +362, 14, 25, 391, 131, 132, 1861, 1862, ")" +362, 14, 26, 392, 133, 134, 1863, 1864, "." +362, 15, 1, 393, 0, 3, 1865, 1868, "The" +362, 15, 2, 394, 4, 14, 1869, 1879, "proportion" +362, 15, 3, 395, 15, 17, 1880, 1882, "of" +362, 15, 4, 396, 18, 26, 1883, 1891, "patients" +362, 15, 5, 397, 27, 30, 1892, 1895, "who" +362, 15, 6, 398, 31, 35, 1896, 1900, "lost" +362, 15, 7, 399, 36, 40, 1901, 1905, "time" +362, 15, 8, 400, 41, 45, 1906, 1910, "from" +362, 15, 9, 401, 46, 50, 1911, 1915, "work" +362, 15, 10, 402, 51, 53, 1916, 1918, "or" +362, 15, 11, 403, 54, 60, 1919, 1925, "normal" +362, 15, 12, 404, 61, 71, 1926, 1936, "activities" +362, 15, 13, 405, 72, 75, 1937, 1940, "due" +362, 15, 14, 406, 76, 78, 1941, 1943, "to" +362, 15, 15, 407, 79, 87, 1944, 1952, "diabetes" +362, 15, 16, 408, 88, 91, 1953, 1956, "was" +362, 15, 17, 409, 92, 97, 1957, 1962, "lower" +362, 15, 18, 410, 98, 102, 1963, 1967, "with" +362, 15, 19, 411, 103, 110, 1968, 1975, "insulin" +362, 15, 20, 412, 111, 119, 1976, 1984, "glargine" +362, 15, 21, 413, 120, 122, 1985, 1987, "vs" +362, 15, 22, 414, 123, 124, 1988, 1989, "." +362, 15, 23, 415, 125, 128, 1990, 1993, "NPH" +362, 15, 24, 416, 129, 130, 1994, 1995, "(" +362, 15, 25, 417, 131, 132, 1996, 1997, "1" +362, 15, 26, 418, 133, 134, 1998, 1999, "." +362, 15, 27, 419, 135, 136, 2000, 2001, "8" +362, 15, 28, 420, 137, 139, 2002, 2004, "vs" +362, 15, 29, 421, 140, 141, 2005, 2006, "." +362, 15, 30, 422, 142, 143, 2007, 2008, "3" +362, 15, 31, 423, 144, 145, 2009, 2010, "." +362, 15, 32, 424, 146, 147, 2011, 2012, "3" +362, 15, 33, 425, 148, 149, 2013, 2014, "%" +362, 15, 34, 426, 150, 151, 2015, 2016, ";" +362, 15, 35, 427, 152, 156, 2017, 2021, "full" +362, 15, 36, 428, 157, 165, 2022, 2030, "analysis" +362, 15, 37, 429, 166, 167, 2031, 2032, ")" +362, 15, 38, 430, 168, 169, 2033, 2034, "." +362, 16, 1, 431, 0, 11, 2035, 2046, "CONCLUSIONS" +362, 16, 2, 432, 12, 13, 2047, 2048, ":" +362, 16, 3, 433, 14, 16, 2049, 2051, "In" +362, 16, 4, 434, 17, 25, 2052, 2060, "patients" +362, 16, 5, 435, 26, 30, 2061, 2065, "with" +362, 16, 6, 436, 31, 35, 2066, 2070, "T2DM" +362, 16, 7, 437, 36, 37, 2071, 2072, "," +362, 16, 8, 438, 38, 50, 2073, 2085, "inadequately" +362, 16, 9, 439, 51, 61, 2086, 2096, "controlled" +362, 16, 10, 440, 62, 64, 2097, 2099, "on" +362, 16, 11, 441, 65, 69, 2100, 2104, "OADs" +362, 16, 12, 442, 70, 71, 2105, 2106, "," +362, 16, 13, 443, 72, 76, 2107, 2111, "once" +362, 16, 14, 444, 77, 78, 2112, 2113, "-" +362, 16, 15, 445, 79, 84, 2114, 2119, "daily" +362, 16, 16, 446, 85, 92, 2120, 2127, "insulin" +362, 16, 17, 447, 93, 101, 2128, 2136, "glargine" +362, 16, 18, 448, 102, 106, 2137, 2141, "plus" +362, 16, 19, 449, 107, 118, 2142, 2153, "glimepiride" +362, 16, 20, 450, 119, 121, 2154, 2156, "is" +362, 16, 21, 451, 122, 131, 2157, 2166, "effective" +362, 16, 22, 452, 132, 134, 2167, 2169, "in" +362, 16, 23, 453, 135, 144, 2170, 2179, "improving" +362, 16, 24, 454, 145, 154, 2180, 2189, "metabolic" +362, 16, 25, 455, 155, 162, 2190, 2197, "control" +362, 16, 26, 456, 163, 167, 2198, 2202, "with" +362, 16, 27, 457, 168, 169, 2203, 2204, "a" +362, 16, 28, 458, 170, 177, 2205, 2212, "reduced" +362, 16, 29, 459, 178, 187, 2213, 2222, "incidence" +362, 16, 30, 460, 188, 190, 2223, 2225, "of" +362, 16, 31, 461, 191, 200, 2226, 2235, "nocturnal" +362, 16, 32, 462, 201, 213, 2236, 2248, "hypoglycemia" +362, 16, 33, 463, 214, 222, 2249, 2257, "compared" +362, 16, 34, 464, 223, 227, 2258, 2262, "with" +362, 16, 35, 465, 228, 231, 2263, 2266, "NPH" +362, 16, 36, 466, 232, 239, 2267, 2274, "insulin" +362, 16, 37, 467, 240, 241, 2275, 2276, "." +362, 17, 1, 468, 0, 4, 2277, 2281, "PMID" +362, 17, 2, 469, 5, 6, 2282, 2283, ":" +362, 17, 3, 470, 7, 15, 2284, 2292, "16715577" +362, 17, 4, 471, 16, 17, 2293, 2294, "[" +362, 17, 5, 472, 18, 25, 2295, 2302, "Indexed" +362, 17, 6, 473, 26, 29, 2303, 2306, "for" +362, 17, 7, 474, 30, 37, 2307, 2314, "MEDLINE" +362, 17, 8, 475, 38, 39, 2315, 2316, "]" diff --git a/data/dm2 16715577_kwoodley.annodb b/data/dm2 16715577_kwoodley.annodb new file mode 100644 index 0000000..9072245 --- /dev/null +++ b/data/dm2 16715577_kwoodley.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31636, Journal, 0, 14, "Arch Med Res .", "", +3850, PublicationYear, 15, 19, "2006", "", +31637, Title, 49, 150, "Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride .", "", +3852, Type2Diabetes, 60, 75, "type 2 diabetes", "", +3853, InsulinGlargine, 78, 94, "insulin glargine", "", +3854, IsophaneInsulin_NPH, 100, 111, "NPH insulin", "", +3855, Glimepiride, 137, 148, "glimepiride", "", +3856, Author, 151, 166, "Eliaschewitz FG", "", +3857, Author, 175, 182, "Calvo C", "", +3858, Author, 185, 195, "Valbuena H", "", +3859, Author, 198, 204, "Ruiz M", "", +3860, Author, 207, 216, "Aschner P", "", +3861, Author, 219, 228, "Villena J", "", +3862, Author, 231, 241, "Ramirez LA", "", +3863, Author, 244, 253, "Jimenez J", "", +3864, Brazil, 353, 359, "Brazil", "", +3865, Type2Diabetes, 403, 418, "Type 2 diabetes", "", +3866, Type2Diabetes, 421, 425, "T2DM", "", +3867, OralAntidiabeticAgent, 490, 513, "oral antidiabetic drugs", "", +3868, OralAntidiabeticAgent, 516, 520, "OADs", "", +3870, Insulin, 525, 532, "Insulin", "", +3871, Hypoglycemia, 621, 633, "hypoglycemia", "", +31638, ObjectiveDescription, 636, 846, "This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia .", "", +3874, InsulinGlargine, 683, 699, "insulin glargine", "", +3875, IsophaneInsulin_NPH, 704, 715, "NPH insulin", "", +3876, Frequency, 743, 757, "a once - daily", "", +3877, Glimepiride, 772, 783, "glimepiride", "", +3878, Hypoglycemia, 832, 844, "hypoglycemia", "", +3880, OpenLabel, 865, 877, "open - label", "", +3882, Duration, 880, 889, "24 - week", "", +3881, Randomized, 890, 900, "randomized", "", +3883, Multicenter, 910, 938, "ten Latin American countries", "", +3884, Type2Diabetes, 941, 945, "T2DM", "", +3888, Precondition, 941, 1023, "T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )", "", +3885, OralAntidiabeticAgent, 976, 980, "OADs", "", +3886, HbA1c, 983, 988, "HbA1c", "", +3887, Percentage, 1020, 1021, "%", "", +3889, Glimepiride, 1033, 1044, "glimepiride", "", +3890, InsulinGlargine, 1050, 1066, "insulin glargine", "", +3891, NumberPatientsArm, 1073, 1076, "231", "", +3892, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", +3893, NumberPatientsArm, 1100, 1103, "250", "", +3894, Duration, 1187, 1196, "24 - week", "", +3895, HbA1c, 1213, 1218, "HbA1c", "", +3896, InsulinGlargine, 1231, 1247, "Insulin glargine", "", +3897, IsophaneInsulin_NPH, 1252, 1263, "NPH insulin", "", +3898, HbA1c, 1281, 1286, "HbA1c", "", +3900, Reduction, 1327, 1334, "0 . 047", "", +3899, ConfIntervalChangeValue, 1337, 1364, "90 % CI - 0 . 232 , 0 . 138", "", +3941, PerProtocol, 1367, 1390, "per - protocol analysis", "", +3902, NocturnalHypoglycemia, 1405, 1427, "nocturnal hypoglycemia", "", +3903, InsulinGlargine, 1457, 1473, "insulin glargine", "", +3904, IsophaneInsulin_NPH, 1479, 1490, "NPH insulin", "", +3905, PercentageAffected, 1493, 1499, "16 . 9", "", +3906, PercentageAffected, 1505, 1511, "30 . 0", "", +3907, PvalueDiff, 1516, 1526, "p < 0 . 01", "", +3940, PerProtocol, 1529, 1544, "safety analysis", "", +3909, InsulinGlargine, 1568, 1584, "insulin glargine", "", +3910, HbA1c_target, 1627, 1649, "HbA1c levels < 7 . 0 %", "", +3911, Percentage, 1648, 1649, "%", "", +3913, SubGroupDescription, 1650, 1670, "without hypoglycemia", "", +3912, Hypoglycemia, 1658, 1670, "hypoglycemia", "", +3914, PercentageAffected, 1673, 1675, "27", "", +3915, PercentageAffected, 1681, 1683, "17", "", +3916, PvalueDiff, 1688, 1699, "p = 0 . 014", "", +3939, PerProtocol, 1702, 1725, "per - protocol analysis", "", +3920, EndPointDescription, 1758, 1780, "treatment satisfaction", "treatment satisfaction", +3918, InsulinGlargine, 1798, 1814, "insulin glargine", "", +3919, IsophaneInsulin_NPH, 1820, 1831, "NPH insulin", "", +3921, PvalueDiff, 1834, 1844, "p < 0 . 02", "treatment satisfaction", +3943, PerProtocol, 1847, 1860, "full analysis", "", +3928, EndPointDescription, 1883, 1952, "patients who lost time from work or normal activities due to diabetes", "", +3923, InsulinGlargine, 1968, 1984, "insulin glargine", "", +3924, IsophaneInsulin_NPH, 1990, 1993, "NPH", "", +3925, PercentageAffected, 1996, 2001, "1 . 8", "", +3926, PercentageAffected, 2007, 2012, "3 . 3", "", +3942, PerProtocol, 2017, 2030, "full analysis", "", +31640, ConclusionComment, 2049, 2276, "In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin .", "", +3931, Precondition, 2052, 2104, "patients with T2DM , inadequately controlled on OADs", "", +3929, Type2Diabetes, 2066, 2070, "T2DM", "", +3930, OralAntidiabeticAgent, 2100, 2104, "OADs", "", +3932, Frequency, 2107, 2119, "once - daily", "", +3933, InsulinGlargine, 2120, 2136, "insulin glargine", "", +3934, Glimepiride, 2142, 2153, "glimepiride", "", +3935, NocturnalHypoglycemia, 2226, 2248, "nocturnal hypoglycemia", "", +3936, IsophaneInsulin_NPH, 2263, 2274, "NPH insulin", "", +3938, PMID, 2284, 2292, "16715577", "", diff --git a/data/dm2 16715577_kwoodley.n-triples b/data/dm2 16715577_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 16715577_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17115351_admin.annodb b/data/dm2 17115351_admin.annodb new file mode 100644 index 0000000..e5e7b40 --- /dev/null +++ b/data/dm2 17115351_admin.annodb @@ -0,0 +1,133 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +118, Journal, 0, 28, "Exp Clin Endocrinol Diabetes", "", " \"Exp Clin Endocrinol Diabetes\"." +0, PublicationYear, 31, 35, "2006", "", " \"2006\"." +245, Title, 65, 222, "Starting insulin therapy in type 2 diabetes : twice - daily biphasic insulin Aspart 30 plus metformin versus once - daily insulin glargine plus glimepiride .", "", " \"Starting insulin therapy in type 2 diabetes : twice - daily biphasic insulin Aspart 30 plus metformin versus once - daily insulin glargine plus glimepiride .\"." +1, Insulin, 74, 81, "insulin", "", +2, Type2Diabetes, 93, 108, "type 2 diabetes", "", +3, Frequency, 111, 124, "twice - daily", "", +51237, Aspart70/30, 142, 151, "Aspart 30", "", +4, Metformin, 157, 166, "metformin", "", +5, Frequency, 174, 186, "once - daily", "", +6, InsulinGlargine, 187, 203, "insulin glargine", "", +7, Glimepiride, 209, 220, "glimepiride", "", +8, Author, 223, 230, "Kann PH", "", " \"Kann PH\"." +9, Author, 239, 248, "Wascher T", "", " \"Wascher T\"." +10, Author, 251, 260, "Zackova V", "", " \"Zackova V\"." +11, Author, 263, 272, "Moeller J", "", " \"Moeller J\"." +12, Author, 275, 284, "Medding J", "", " \"Medding J\"." +13, Author, 287, 294, "Szocs A", "", " \"Szocs A\"." +14, Author, 297, 304, "Mokan M", "", " \"Mokan M\"." +15, Author, 307, 316, "Mrevlje F", "", " \"Mrevlje F\"." +16, Author, 319, 329, "Regulski M", "", " \"Regulski M\"." +17, Germany, 477, 484, "Germany", "", " ." +246, ObjectiveDescription, 526, 652, "To compare the efficacy and safety of two analog insulins as starting regimens in insulin - na ï ve Type 2 diabetes patients .", "", " \"To compare the efficacy and safety of two analog insulins as starting regimens in insulin - na ï ve Type 2 diabetes patients .\"." +18, Insulin, 575, 583, "insulins", "", +20, Precondition, 608, 650, "insulin - na ï ve Type 2 diabetes patients", "", " \"insulin - na ï ve Type 2 diabetes patients\"." +19, Type2Diabetes, 626, 641, "Type 2 diabetes", "", +21, Randomized, 671, 681, "randomized", "", " ." +22, OpenLabel, 684, 696, "open - label", "", " ." +23, Parallel, 697, 705, "parallel", "", " ." +24, Frequency, 714, 727, "twice - daily", "", " \"twice - daily\"." +51231, Aspart70/30, 737, 754, "insulin aspart 30", "", +147, InsulinAspart, 792, 806, "insulin aspart", "", " ." +51232, Aspart70/30, 809, 817, "BIAsp 30", "", +25, Metformin, 825, 834, "metformin", "", " ." +26, Metformin, 837, 840, "met", "", +27, Frequency, 861, 873, "once - daily", "", " \"once - daily\"." +28, InsulinGlargine, 874, 890, "insulin glargine", "", " ." +29, InsulinGlargine, 893, 898, "glarg", "", +30, Glimepiride, 906, 917, "glimepiride", "", " ." +31, Glimepiride, 920, 924, "glim", "", +32, NumberPatientsCT, 930, 933, "255", "", " \"255\"." +33, Precondition, 934, 960, "insulin - na ï ve patients", "", +115, Male, 963, 971, "131 male", "", " ." +242, Mean, 974, 978, "mean", "", +154, AvgAge, 994, 1000, "61 . 2", "", " \"61 . 2\"." +243, Mean, 1023, 1027, "Mean", "", " . ." +254, TimePoint, 1028, 1036, "baseline", "", " \"baseline\". \"baseline\"." +34, HbA1c, 1037, 1047, "HbA ( 1c )", "", " ." +36, BaseLineValue, 1065, 1070, "9 . 2", "", " \"9 . 2\". \"9 . 2\"." +38, SdDevBL, 1077, 1082, "1 . 4", "", " \"1 . 4\". \"1 . 4\"." +40, Percentage, 1083, 1084, "%", "", " ." +37, BaseLineValue, 1089, 1094, "8 . 9", "", " \"8 . 9\". \"8 . 9\"." +39, SdDevBL, 1101, 1106, "1 . 3", "", " \"1 . 3\". \"1 . 3\"." +41, Percentage, 1107, 1108, "%", "", +51233, Aspart70/30, 1113, 1121, "BIAsp 30", "", +42, Metformin, 1127, 1130, "met", "", +43, NumberPatientsArm, 1137, 1140, "128", "", +44, InsulinGlargine, 1147, 1152, "glarg", "", +45, Glimepiride, 1158, 1162, "glim", "", +46, NumberPatientsArm, 1169, 1172, "127", "", " \"127\". \"127\"." +47, PvalueDiff, 1192, 1204, "P = 0 . 0747", "", " \"P = 0 . 0747\"." +48, HbA1c, 1267, 1277, "HbA ( 1c )", "", +49, Duration, 1299, 1307, "26 weeks", "", " \"26 weeks\"." +50, HbA1c, 1333, 1343, "HbA ( 1c )", "", +51234, Aspart70/30, 1384, 1392, "BIAsp 30", "", +51, Metformin, 1398, 1401, "met", "", +52, InsulinGlargine, 1417, 1422, "glarg", "", +53, Glimepiride, 1428, 1432, "glim", "", +176, DiffGroupAbsValue, 1470, 1477, "- 0 . 5", "", " \"- 0 . 5\"." +55, Percentage, 1478, 1479, "%", "", +56, ConfIntervalDiff, 1482, 1509, "95 % CI : - 0 . 8 ; - 0 . 2", "", " \"95 % CI : - 0 . 8 ; - 0 . 2\"." +57, PvalueDiff, 1514, 1526, "P = 0 . 0002", "", " \"P = 0 . 0002\"." +181, Mean, 1531, 1535, "Mean", "", " . ." +247, PostprandialPlasmaGlucose, 1536, 1559, "prandial plasma glucose", "", " ." +51236, Aspart70/30, 1598, 1606, "BIAsp 30", "", +58, Metformin, 1612, 1615, "met", "", +59, InsulinGlargine, 1630, 1635, "glarg", "", +60, Glimepiride, 1641, 1645, "glim", "", +62, Increment, 1648, 1653, "1 . 4", "", " \"1 . 4\"." +187, SdDevChangeValue, 1660, 1665, "1 . 4", "", " \"1 . 4\"." +64, Millimoles_per_litre, 1666, 1674, "mmol / l", "", " ." +63, Increment, 1680, 1685, "2 . 2", "", " \"2 . 2\"." +190, SdDevChangeValue, 1692, 1697, "1 . 8", "", " \"1 . 8\"." +65, Millimoles_per_litre, 1698, 1706, "mmol / l", "", +67, PvalueDiff, 1709, 1721, "P = 0 . 0002", "", " \"P = 0 . 0002\"." +68, TimePoint, 1753, 1769, "( weeks 6 - 26 )", "", " \"( weeks 6 - 26 )\". \"( weeks 6 - 26 )\". \"( weeks 6 - 26 )\"." +193, NumberAffected, 1772, 1775, "one", "", " \"one\"." +196, SevereHypoglycemia, 1776, 1802, "major hypoglycemic episode", "", " ." +71, PercentageAffected, 1828, 1834, "20 . 3", "", " \"20 . 3\"." +72, PercentageAffected, 1841, 1842, "9", "", " \"9\"." +195, Hypoglycemia, 1869, 1896, "minor hypoglycemic episodes", "", " ." +51238, Aspart70/30, 1904, 1912, "BIAsp 30", "", +74, Metformin, 1918, 1921, "met", "", +75, InsulinGlargine, 1926, 1931, "glarg", "", +76, Glimepiride, 1937, 1941, "glim", "", +77, PvalueDiff, 1966, 1978, "P = 0 . 0124", "", " \"P = 0 . 0124\"." +207, TimePoint, 1986, 2002, "end - of - trial", "", " \"end - of - trial\". \"end - of - trial\"." +208, Mean, 2005, 2009, "mean", "", " . ." +47814, Frequency, 2010, 2015, "daily", "", +47815, InsulinDose, 2016, 2029, "insulin doses", "", " . ." +116, ResultMeasuredValue, 2035, 2041, "0 . 40", "", " \"0 . 40\"." +78, IntUnit_per_Kg, 2042, 2048, "U / kg", "", " ." +51235, Aspart70/30, 2049, 2057, "BIAsp 30", "", +117, ResultMeasuredValue, 2062, 2068, "0 . 39", "", " \"0 . 39\"." +80, IntUnit_per_Kg, 2069, 2075, "U / kg", "", +81, InsulinGlargine, 2076, 2081, "glarg", "", +82, InsulinGlargine, 2084, 2089, "Glarg", "", +83, Glimepiride, 2095, 2099, "glim", "", +84, BodyWeight, 2143, 2149, "weight", "", " ." +85, Increment, 2158, 2163, "1 . 5", "", " \"1 . 5\"." +86, Kg, 2164, 2166, "kg", "", " ." +221, ConfIntervalChangeValue, 2169, 2194, "95 % CI : 0 . 84 ; 2 . 19", "", " \"95 % CI : 0 . 84 ; 2 . 19\"." +222, PValueChangeValue, 2197, 2209, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +89, BodyWeight, 2214, 2220, "Weight", "", +51239, Aspart70/30, 2233, 2241, "BIAsp 30", "", +90, Metformin, 2247, 2250, "met", "", +91, Increment, 2256, 2261, "0 . 7", "", " \"0 . 7\"." +92, Kg, 2262, 2264, "kg", "", +228, ConfIntervalChangeValue, 2301, 2328, "95 % CI : - 0 . 07 ; 1 . 42", "", " \"95 % CI : - 0 . 07 ; 1 . 42\"." +229, PValueChangeValue, 2331, 2343, "P = 0 . 0762", "", " \"P = 0 . 0762\"." +251, ConclusionComment, 2362, 2564, "Starting insulin in Type 2 diabetes patients with twice - daily BIAsp 30 plus met can reduce HbA ( 1c ) and mean prandial plasma glucose increment to a greater extent than once - daily glarg plus glim .", "", " \"Starting insulin in Type 2 diabetes patients with twice - daily BIAsp 30 plus met can reduce HbA ( 1c ) and mean prandial plasma glucose increment to a greater extent than once - daily glarg plus glim .\"." +95, Insulin, 2371, 2378, "insulin", "", +96, Type2Diabetes, 2382, 2397, "Type 2 diabetes", "", +97, Frequency, 2412, 2425, "twice - daily", "", +51240, Aspart70/30, 2426, 2434, "BIAsp 30", "", +108, Metformin, 2440, 2443, "met", "", +109, HbA1c, 2455, 2465, "HbA ( 1c )", "", +236, Mean, 2470, 2474, "mean", "", +252, PostprandialPlasmaGlucose, 2475, 2498, "prandial plasma glucose", "", +110, Frequency, 2534, 2546, "once - daily", "", +111, InsulinGlargine, 2547, 2552, "glarg", "", +112, Glimepiride, 2558, 2562, "glim", "", +113, PMID, 2608, 2616, "17115351", "", " \"17115351\"." diff --git a/data/dm2 17115351_admin.n-triples b/data/dm2 17115351_admin.n-triples new file mode 100644 index 0000000..829a185 --- /dev/null +++ b/data/dm2 17115351_admin.n-triples @@ -0,0 +1,238 @@ +# RDF export of group: Publication + . + "Publication " . + "Starting insulin therapy in type 2 diabetes : twice - daily biphasic insulin Aspart 30 plus metformin versus once - daily insulin glargine plus glimepiride ." . + "Kann PH" . + "2006" . + "Exp Clin Endocrinol Diabetes" . + "17115351" . + . + "Wascher T" . + "Zackova V" . + "Moeller J" . + "Medding J" . + "Szocs A" . + "Mokan M" . + "Mrevlje F" . + "Regulski M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy and safety of two analog insulins as starting regimens in insulin - na ï ve Type 2 diabetes patients ." . + "255" . + "26 weeks" . + . + . + . + "Starting insulin in Type 2 diabetes patients with twice - daily BIAsp 30 plus met can reduce HbA ( 1c ) and mean prandial plasma glucose increment to a greater extent than once - daily glarg plus glim ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - na ï ve Type 2 diabetes patients" . + . + . + "61 . 2" . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint ppg " . + . + . + . + . + . + . + "Endpoint severeh" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm a + m" . + "127" . + . + . + . + . + . + . + . + . + . + "Arm ig + g" . + "127" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention a + m " . + . + "twice - daily" . + . + . + . + "Intervention ig + g" . + . + "once - daily" . + . + . +# RDF export of group: Medication + . + "Medication a" . + . + . + . + . + "Medication m" . + . + . + . + . + "Medication ig" . + . + . + . + . + "Medication g" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c a baseline" . + . + "9 . 2" . + "1 . 4" . + "baseline" . + . + "Outcome hba1c ig baseline" . + . + "8 . 9" . + "1 . 3" . + "baseline" . + . + "Outcome hba1c a without timepoint “baseline“" . + . + "9 . 2" . + "1 . 4" . + . + "Outcome hba1c ig without timepoint “baseline“" . + . + "8 . 9" . + "1 . 3" . + . + "Outcome ppg a" . + . + "1 . 4" . + "1 . 4" . + . + "Outcome ppg ig" . + . + "2 . 2" . + "1 . 8" . + . + "Outcome severeh both drugs" . + . + "one" . + "( weeks 6 - 26 )" . + . + "Outcome h a" . + . + "20 . 3" . + "( weeks 6 - 26 )" . + . + "Outcome h ig" . + . + "9" . + "( weeks 6 - 26 )" . + . + "Outcome id a" . + . + "0 . 40" . + "end - of - trial" . + . + "Outcome id ig " . + . + "0 . 39" . + "end - of - trial" . + . + "Outcome weight a" . + . + "0 . 7" . + "P = 0 . 0762" . + "95 % CI : - 0 . 07 ; 1 . 42" . + . + "Outcome weight ig" . + . + "1 . 5" . + "P < 0 . 0001" . + "95 % CI : 0 . 84 ; 2 . 19" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c baseline" . + "P = 0 . 0747" . + . + . + . + "DiffBetweenGroups hba1c" . + "- 0 . 5" . + "P = 0 . 0002" . + "95 % CI : - 0 . 8 ; - 0 . 2" . + . + . + . + "DiffBetweenGroups ppg" . + "P = 0 . 0002" . + . + . + . + "DiffBetweenGroups h " . + "P = 0 . 0124" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17115351_akramersunderbrink.annodb b/data/dm2 17115351_akramersunderbrink.annodb new file mode 100644 index 0000000..c97f2bc --- /dev/null +++ b/data/dm2 17115351_akramersunderbrink.annodb @@ -0,0 +1,129 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9651, Journal, 0, 28, "Exp Clin Endocrinol Diabetes", "", +9652, PublicationYear, 31, 35, "2006", "", +9673, Title, 65, 220, "Starting insulin therapy in type 2 diabetes : twice - daily biphasic insulin Aspart 30 plus metformin versus once - daily insulin glargine plus glimepiride", "", +9653, Insulin, 74, 81, "insulin", "", +9654, Type2Diabetes, 93, 108, "type 2 diabetes", "", +9655, Frequency, 111, 124, "twice - daily", "", +9656, InsulinAspart, 134, 151, "insulin Aspart 30", "", +9657, Metformin, 157, 166, "metformin", "", +9658, Frequency, 174, 186, "once - daily", "", +9659, InsulinGlargine, 187, 203, "insulin glargine", "", +9660, Glimepiride, 209, 220, "glimepiride", "", +9661, Author, 223, 230, "Kann PH", "", +9662, Author, 239, 248, "Wascher T", "", +9663, Author, 251, 260, "Zackova V", "", +9664, Author, 263, 272, "Moeller J", "", +9665, Author, 275, 284, "Medding J", "", +9666, Author, 287, 294, "Szocs A", "", +9667, Author, 297, 304, "Mokan M", "", +9668, Author, 307, 316, "Mrevlje F", "", +9669, Author, 319, 329, "Regulski M", "", +9741, Germany, 477, 484, "Germany", "", +9674, ObjectiveDescription, 526, 650, "To compare the efficacy and safety of two analog insulins as starting regimens in insulin - na ï ve Type 2 diabetes patients", "", +9670, Insulin, 575, 583, "insulins", "", +9671, Precondition, 608, 625, "insulin - na ï ve", "", +9672, Type2Diabetes, 626, 641, "Type 2 diabetes", "", +9675, Randomized, 671, 681, "randomized", "", +9676, OpenLabel, 684, 696, "open - label", "", +9677, Parallel, 697, 705, "parallel", "", +9678, Frequency, 714, 727, "twice - daily", "", +9679, InsulinAspart, 728, 754, "biphasic insulin aspart 30", "", +9680, InsulinAspart, 792, 806, "insulin aspart", "", +39129, InsulinAspart, 809, 817, "BIAsp 30", "", +9681, Metformin, 825, 842, "metformin ( met )", "", +9682, Frequency, 861, 873, "once - daily", "", +9683, InsulinGlargine, 882, 900, "glargine ( glarg )", "", +9684, Glimepiride, 906, 926, "glimepiride ( glim )", "", +9685, NumberPatientsCT, 930, 933, "255", "", +9686, Precondition, 934, 951, "insulin - na ï ve", "", +9794, Mean, 974, 978, "mean", "", +9687, AvgAge, 994, 1000, "61 . 2", "", +9795, Mean, 1023, 1027, "Mean", "", +39130, TimePoint, 1028, 1036, "baseline", "", +9688, HbA1c, 1037, 1047, "HbA ( 1c )", "", +9689, BaseLineValue, 1065, 1070, "9 . 2", "", +9690, SdDevBL, 1071, 1082, "+ / - 1 . 4", "", +9691, Percentage, 1083, 1084, "%", "", +9692, BaseLineValue, 1089, 1094, "8 . 9", "", +9693, SdDevBL, 1095, 1106, "+ / - 1 . 3", "", +9694, Percentage, 1107, 1108, "%", "", +9695, InsulinAspart, 1113, 1121, "BIAsp 30", "", +9696, Metformin, 1127, 1130, "met", "", +9697, NumberPatientsArm, 1137, 1140, "128", "", +9698, InsulinGlargine, 1147, 1152, "glarg", "", +9699, Glimepiride, 1158, 1162, "glim", "", +9700, NumberPatientsArm, 1169, 1172, "127", "", +9701, PvalueDiff, 1192, 1204, "P = 0 . 0747", "", +9702, HbA1c, 1267, 1277, "HbA ( 1c )", "", +9703, Duration, 1299, 1307, "26 weeks", "", +9704, HbA1c, 1333, 1343, "HbA ( 1c )", "", +9705, InsulinAspart, 1384, 1392, "BIAsp 30", "", +9706, Metformin, 1398, 1401, "met", "", +9707, InsulinGlargine, 1417, 1422, "glarg", "", +9708, Glimepiride, 1428, 1432, "glim", "", +9709, DiffGroupAbsValue, 1470, 1477, "- 0 . 5", "", +9710, Percentage, 1478, 1479, "%", "", +9711, ConfIntervalDiff, 1482, 1509, "95 % CI : - 0 . 8 ; - 0 . 2", "", +9712, PvalueDiff, 1514, 1526, "P = 0 . 0002", "", +9715, Mean, 1531, 1535, "Mean", "", +9713, InsulinDose, 1536, 1559, "prandial plasma glucose", "", +9716, InsulinAspart, 1598, 1606, "BIAsp 30", "", +9717, Metformin, 1612, 1615, "met", "", +9718, InsulinGlargine, 1630, 1635, "glarg", "", +9719, Glimepiride, 1641, 1645, "glim", "", +9720, ChangeValue, 1648, 1653, "1 . 4", "", +9722, SdDevChangeValue, 1654, 1665, "+ / - 1 . 4", "", +9723, Millimoles_per_litre, 1666, 1674, "mmol / l", "", +9724, ChangeValue, 1680, 1685, "2 . 2", "", +9725, SdDevChangeValue, 1686, 1697, "+ / - 1 . 8", "", +9726, Millimoles_per_litre, 1698, 1706, "mmol / l", "", +9727, PvalueDiff, 1709, 1721, "P = 0 . 0002", "", +9730, TimePoint, 1735, 1769, "maintenance phase ( weeks 6 - 26 )", "", +9729, NumberAffected, 1772, 1775, "one", "", +9732, SevereHypoglycemia, 1776, 1802, "major hypoglycemic episode", "", +9733, PercentageAffected, 1828, 1834, "20 . 3", "", +9735, Percentage, 1835, 1836, "%", "", +9734, PercentageAffected, 1841, 1842, "9", "", +9736, Percentage, 1843, 1844, "%", "", +9731, Hypoglycemia, 1869, 1896, "minor hypoglycemic episodes", "", +9737, InsulinAspart, 1904, 1912, "BIAsp 30", "", +9738, Metformin, 1918, 1921, "met", "", +9739, InsulinGlargine, 1926, 1931, "glarg", "", +9740, Glimepiride, 1937, 1941, "glim", "", +9742, PvalueDiff, 1966, 1978, "P = 0 . 0124", "", +9743, TimePoint, 1986, 2002, "end - of - trial", "", +9744, Mean, 2005, 2009, "mean", "", +9745, EndPointDescription, 2010, 2029, "daily insulin doses", "", +9746, ResultMeasuredValue, 2035, 2041, "0 . 40", "", +9747, BioAndMedicalUnit, 2042, 2048, "U / kg", "", +9748, InsulinAspart, 2049, 2057, "BIAsp 30", "", +9749, ResultMeasuredValue, 2062, 2068, "0 . 39", "", +9750, BioAndMedicalUnit, 2069, 2075, "U / kg", "", +9751, InsulinGlargine, 2076, 2081, "glarg", "", +9752, InsulinGlargine, 2084, 2089, "Glarg", "", +9753, Glimepiride, 2095, 2099, "glim", "", +9754, BodyWeight, 2143, 2149, "weight", "", +9755, ChangeValue, 2158, 2163, "1 . 5", "", +9756, Kg, 2164, 2166, "kg", "", +9757, ConfIntervalChangeValue, 2169, 2194, "95 % CI : 0 . 84 ; 2 . 19", "", +9758, PValueChangeValue, 2197, 2209, "P < 0 . 0001", "", +9759, BodyWeight, 2214, 2220, "Weight", "", +9760, InsulinAspart, 2233, 2241, "BIAsp 30", "", +9761, Metformin, 2247, 2250, "met", "", +9762, ChangeValue, 2254, 2261, "+ 0 . 7", "", +9763, Kg, 2262, 2264, "kg", "", +9764, ConfIntervalChangeValue, 2301, 2328, "95 % CI : - 0 . 07 ; 1 . 42", "", +9765, PValueChangeValue, 2331, 2343, "P = 0 . 0762", "", +9766, Insulin, 2371, 2378, "insulin", "", +9767, Type2Diabetes, 2382, 2397, "Type 2 diabetes", "", +9768, Frequency, 2412, 2425, "twice - daily", "", +9769, InsulinAspart, 2426, 2434, "BIAsp 30", "", +9770, Metformin, 2440, 2443, "met", "", +9771, HbA1c, 2455, 2465, "HbA ( 1c )", "", +9772, Mean, 2470, 2474, "mean", "", +9773, InsulinDose, 2475, 2498, "prandial plasma glucose", "", +9774, Frequency, 2534, 2546, "once - daily", "", +9775, InsulinGlargine, 2547, 2552, "glarg", "", +9776, Glimepiride, 2558, 2562, "glim", "", +9777, PMID, 2608, 2616, "17115351", "", diff --git a/data/dm2 17115351_akramersunderbrink.n-triples b/data/dm2 17115351_akramersunderbrink.n-triples new file mode 100644 index 0000000..c5ded7e --- /dev/null +++ b/data/dm2 17115351_akramersunderbrink.n-triples @@ -0,0 +1,15 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population + . + "Population 19090" . + . + . + . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17115351_export.csv b/data/dm2 17115351_export.csv new file mode 100644 index 0000000..8078317 --- /dev/null +++ b/data/dm2 17115351_export.csv @@ -0,0 +1,632 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +360, 1, 1, 1, 0, 3, 0, 3, "Exp" +360, 1, 2, 2, 4, 8, 4, 8, "Clin" +360, 1, 3, 3, 9, 19, 9, 19, "Endocrinol" +360, 1, 4, 4, 20, 28, 20, 28, "Diabetes" +360, 1, 5, 5, 29, 30, 29, 30, "." +360, 2, 1, 6, 0, 4, 31, 35, "2006" +360, 2, 2, 7, 5, 8, 36, 39, "Oct" +360, 2, 3, 8, 9, 10, 40, 41, ";" +360, 2, 4, 9, 11, 14, 42, 45, "114" +360, 2, 5, 10, 15, 16, 46, 47, "(" +360, 2, 6, 11, 17, 18, 48, 49, "9" +360, 2, 7, 12, 19, 20, 50, 51, ")" +360, 2, 8, 13, 21, 22, 52, 53, ":" +360, 2, 9, 14, 23, 26, 54, 57, "527" +360, 2, 10, 15, 27, 28, 58, 59, "-" +360, 2, 11, 16, 29, 31, 60, 62, "32" +360, 2, 12, 17, 32, 33, 63, 64, "." +360, 3, 1, 18, 0, 8, 65, 73, "Starting" +360, 3, 2, 19, 9, 16, 74, 81, "insulin" +360, 3, 3, 20, 17, 24, 82, 89, "therapy" +360, 3, 4, 21, 25, 27, 90, 92, "in" +360, 3, 5, 22, 28, 32, 93, 97, "type" +360, 3, 6, 23, 33, 34, 98, 99, "2" +360, 3, 7, 24, 35, 43, 100, 108, "diabetes" +360, 3, 8, 25, 44, 45, 109, 110, ":" +360, 3, 9, 26, 46, 51, 111, 116, "twice" +360, 3, 10, 27, 52, 53, 117, 118, "-" +360, 3, 11, 28, 54, 59, 119, 124, "daily" +360, 3, 12, 29, 60, 68, 125, 133, "biphasic" +360, 3, 13, 30, 69, 76, 134, 141, "insulin" +360, 3, 14, 31, 77, 83, 142, 148, "Aspart" +360, 3, 15, 32, 84, 86, 149, 151, "30" +360, 3, 16, 33, 87, 91, 152, 156, "plus" +360, 3, 17, 34, 92, 101, 157, 166, "metformin" +360, 3, 18, 35, 102, 108, 167, 173, "versus" +360, 3, 19, 36, 109, 113, 174, 178, "once" +360, 3, 20, 37, 114, 115, 179, 180, "-" +360, 3, 21, 38, 116, 121, 181, 186, "daily" +360, 3, 22, 39, 122, 129, 187, 194, "insulin" +360, 3, 23, 40, 130, 138, 195, 203, "glargine" +360, 3, 24, 41, 139, 143, 204, 208, "plus" +360, 3, 25, 42, 144, 155, 209, 220, "glimepiride" +360, 3, 26, 43, 156, 157, 221, 222, "." +360, 4, 1, 44, 0, 4, 223, 227, "Kann" +360, 4, 2, 45, 5, 7, 228, 230, "PH" +360, 4, 3, 46, 8, 9, 231, 232, "(" +360, 4, 4, 47, 10, 11, 233, 234, "1" +360, 4, 5, 48, 12, 13, 235, 236, ")" +360, 4, 6, 49, 14, 15, 237, 238, "," +360, 4, 7, 50, 16, 23, 239, 246, "Wascher" +360, 4, 8, 51, 24, 25, 247, 248, "T" +360, 4, 9, 52, 26, 27, 249, 250, "," +360, 4, 10, 53, 28, 35, 251, 258, "Zackova" +360, 4, 11, 54, 36, 37, 259, 260, "V" +360, 4, 12, 55, 38, 39, 261, 262, "," +360, 4, 13, 56, 40, 47, 263, 270, "Moeller" +360, 4, 14, 57, 48, 49, 271, 272, "J" +360, 4, 15, 58, 50, 51, 273, 274, "," +360, 4, 16, 59, 52, 59, 275, 282, "Medding" +360, 4, 17, 60, 60, 61, 283, 284, "J" +360, 4, 18, 61, 62, 63, 285, 286, "," +360, 4, 19, 62, 64, 69, 287, 292, "Szocs" +360, 4, 20, 63, 70, 71, 293, 294, "A" +360, 4, 21, 64, 72, 73, 295, 296, "," +360, 4, 22, 65, 74, 79, 297, 302, "Mokan" +360, 4, 23, 66, 80, 81, 303, 304, "M" +360, 4, 24, 67, 82, 83, 305, 306, "," +360, 4, 25, 68, 84, 91, 307, 314, "Mrevlje" +360, 4, 26, 69, 92, 93, 315, 316, "F" +360, 4, 27, 70, 94, 95, 317, 318, "," +360, 4, 28, 71, 96, 104, 319, 327, "Regulski" +360, 4, 29, 72, 105, 106, 328, 329, "M" +360, 4, 30, 73, 107, 108, 330, 331, "." +360, 4, 31, 74, 109, 115, 332, 338, "Author" +360, 4, 32, 75, 116, 127, 339, 350, "information" +360, 4, 33, 76, 128, 129, 351, 352, ":" +360, 4, 34, 77, 130, 131, 353, 354, "(" +360, 4, 35, 78, 132, 133, 355, 356, "1" +360, 4, 36, 79, 134, 135, 357, 358, ")" +360, 4, 37, 80, 136, 144, 359, 367, "Philipps" +360, 4, 38, 81, 145, 146, 368, 369, "-" +360, 4, 39, 82, 147, 156, 370, 379, "Universit" +360, 4, 40, 83, 157, 158, 380, 381, "ä" +360, 4, 41, 84, 159, 160, 382, 383, "t" +360, 4, 42, 85, 161, 168, 384, 391, "Marburg" +360, 4, 43, 86, 169, 170, 392, 393, "," +360, 4, 44, 87, 171, 178, 394, 401, "Zentrum" +360, 4, 45, 88, 179, 180, 402, 403, "f" +360, 4, 46, 89, 181, 182, 404, 405, "ü" +360, 4, 47, 90, 183, 184, 406, 407, "r" +360, 4, 48, 91, 185, 191, 408, 414, "Innere" +360, 4, 49, 92, 192, 199, 415, 422, "Medizin" +360, 4, 50, 93, 200, 201, 423, 424, "," +360, 4, 51, 94, 202, 209, 425, 432, "Bereich" +360, 4, 52, 95, 210, 224, 433, 447, "Endokrinologie" +360, 4, 53, 96, 225, 228, 448, 451, "and" +360, 4, 54, 97, 229, 241, 452, 464, "Diabetologie" +360, 4, 55, 98, 242, 243, 465, 466, "," +360, 4, 56, 99, 244, 251, 467, 474, "Marburg" +360, 4, 57, 100, 252, 253, 475, 476, "," +360, 4, 58, 101, 254, 261, 477, 484, "Germany" +360, 4, 59, 102, 262, 263, 485, 486, "." +360, 5, 1, 103, 0, 5, 487, 492, "kannp" +360, 5, 2, 104, 6, 7, 493, 494, "@" +360, 5, 3, 105, 8, 11, 495, 498, "med" +360, 5, 4, 106, 12, 13, 499, 500, "." +360, 5, 5, 107, 14, 17, 501, 504, "uni" +360, 5, 6, 108, 18, 19, 505, 506, "-" +360, 5, 7, 109, 20, 27, 507, 514, "marburg" +360, 5, 8, 110, 28, 29, 515, 516, "." +360, 5, 9, 111, 30, 32, 517, 519, "de" +360, 5, 10, 112, 33, 36, 520, 523, "AIM" +360, 5, 11, 113, 37, 38, 524, 525, ":" +360, 5, 12, 114, 39, 41, 526, 528, "To" +360, 5, 13, 115, 42, 49, 529, 536, "compare" +360, 5, 14, 116, 50, 53, 537, 540, "the" +360, 5, 15, 117, 54, 62, 541, 549, "efficacy" +360, 5, 16, 118, 63, 66, 550, 553, "and" +360, 5, 17, 119, 67, 73, 554, 560, "safety" +360, 5, 18, 120, 74, 76, 561, 563, "of" +360, 5, 19, 121, 77, 80, 564, 567, "two" +360, 5, 20, 122, 81, 87, 568, 574, "analog" +360, 5, 21, 123, 88, 96, 575, 583, "insulins" +360, 5, 22, 124, 97, 99, 584, 586, "as" +360, 5, 23, 125, 100, 108, 587, 595, "starting" +360, 5, 24, 126, 109, 117, 596, 604, "regimens" +360, 5, 25, 127, 118, 120, 605, 607, "in" +360, 5, 26, 128, 121, 128, 608, 615, "insulin" +360, 5, 27, 129, 129, 130, 616, 617, "-" +360, 5, 28, 130, 131, 133, 618, 620, "na" +360, 5, 29, 131, 134, 135, 621, 622, "ï" +360, 5, 30, 132, 136, 138, 623, 625, "ve" +360, 5, 31, 133, 139, 143, 626, 630, "Type" +360, 5, 32, 134, 144, 145, 631, 632, "2" +360, 5, 33, 135, 146, 154, 633, 641, "diabetes" +360, 5, 34, 136, 155, 163, 642, 650, "patients" +360, 5, 35, 137, 164, 165, 651, 652, "." +360, 6, 1, 138, 0, 7, 653, 660, "METHODS" +360, 6, 2, 139, 8, 9, 661, 662, ":" +360, 6, 3, 140, 10, 12, 663, 665, "In" +360, 6, 4, 141, 13, 17, 666, 670, "this" +360, 6, 5, 142, 18, 28, 671, 681, "randomized" +360, 6, 6, 143, 29, 30, 682, 683, "," +360, 6, 7, 144, 31, 35, 684, 688, "open" +360, 6, 8, 145, 36, 37, 689, 690, "-" +360, 6, 9, 146, 38, 43, 691, 696, "label" +360, 6, 10, 147, 44, 52, 697, 705, "parallel" +360, 6, 11, 148, 53, 58, 706, 711, "study" +360, 6, 12, 149, 59, 60, 712, 713, "," +360, 6, 13, 150, 61, 66, 714, 719, "twice" +360, 6, 14, 151, 67, 68, 720, 721, "-" +360, 6, 15, 152, 69, 74, 722, 727, "daily" +360, 6, 16, 153, 75, 83, 728, 736, "biphasic" +360, 6, 17, 154, 84, 91, 737, 744, "insulin" +360, 6, 18, 155, 92, 98, 745, 751, "aspart" +360, 6, 19, 156, 99, 101, 752, 754, "30" +360, 6, 20, 157, 102, 103, 755, 756, "(" +360, 6, 21, 158, 104, 106, 757, 759, "30" +360, 6, 22, 159, 107, 108, 760, 761, "%" +360, 6, 23, 160, 109, 116, 762, 769, "soluble" +360, 6, 24, 161, 117, 120, 770, 773, "and" +360, 6, 25, 162, 121, 123, 774, 776, "70" +360, 6, 26, 163, 124, 125, 777, 778, "%" +360, 6, 27, 164, 126, 138, 779, 791, "protaminated" +360, 6, 28, 165, 139, 146, 792, 799, "insulin" +360, 6, 29, 166, 147, 153, 800, 806, "aspart" +360, 6, 30, 167, 154, 155, 807, 808, ";" +360, 6, 31, 168, 156, 161, 809, 814, "BIAsp" +360, 6, 32, 169, 162, 164, 815, 817, "30" +360, 6, 33, 170, 165, 166, 818, 819, ")" +360, 6, 34, 171, 167, 171, 820, 824, "plus" +360, 6, 35, 172, 172, 181, 825, 834, "metformin" +360, 6, 36, 173, 182, 183, 835, 836, "(" +360, 6, 37, 174, 184, 187, 837, 840, "met" +360, 6, 38, 175, 188, 189, 841, 842, ")" +360, 6, 39, 176, 190, 193, 843, 846, "was" +360, 6, 40, 177, 194, 202, 847, 855, "compared" +360, 6, 41, 178, 203, 207, 856, 860, "with" +360, 6, 42, 179, 208, 212, 861, 865, "once" +360, 6, 43, 180, 213, 214, 866, 867, "-" +360, 6, 44, 181, 215, 220, 868, 873, "daily" +360, 6, 45, 182, 221, 228, 874, 881, "insulin" +360, 6, 46, 183, 229, 237, 882, 890, "glargine" +360, 6, 47, 184, 238, 239, 891, 892, "(" +360, 6, 48, 185, 240, 245, 893, 898, "glarg" +360, 6, 49, 186, 246, 247, 899, 900, ")" +360, 6, 50, 187, 248, 252, 901, 905, "plus" +360, 6, 51, 188, 253, 264, 906, 917, "glimepiride" +360, 6, 52, 189, 265, 266, 918, 919, "(" +360, 6, 53, 190, 267, 271, 920, 924, "glim" +360, 6, 54, 191, 272, 273, 925, 926, ")" +360, 6, 55, 192, 274, 276, 927, 929, "in" +360, 6, 56, 193, 277, 280, 930, 933, "255" +360, 6, 57, 194, 281, 288, 934, 941, "insulin" +360, 6, 58, 195, 289, 290, 942, 943, "-" +360, 6, 59, 196, 291, 293, 944, 946, "na" +360, 6, 60, 197, 294, 295, 947, 948, "ï" +360, 6, 61, 198, 296, 298, 949, 951, "ve" +360, 6, 62, 199, 299, 307, 952, 960, "patients" +360, 6, 63, 200, 308, 309, 961, 962, "(" +360, 6, 64, 201, 310, 313, 963, 966, "131" +360, 6, 65, 202, 314, 318, 967, 971, "male" +360, 6, 66, 203, 319, 320, 972, 973, ";" +360, 6, 67, 204, 321, 325, 974, 978, "mean" +360, 6, 68, 205, 326, 327, 979, 980, "+" +360, 6, 69, 206, 328, 329, 981, 982, "/" +360, 6, 70, 207, 330, 331, 983, 984, "-" +360, 6, 71, 208, 332, 334, 985, 987, "SD" +360, 6, 72, 209, 335, 338, 988, 991, "age" +360, 6, 73, 210, 339, 340, 992, 993, "," +360, 6, 74, 211, 341, 343, 994, 996, "61" +360, 6, 75, 212, 344, 345, 997, 998, "." +360, 6, 76, 213, 346, 347, 999, 1000, "2" +360, 6, 77, 214, 348, 349, 1001, 1002, "+" +360, 6, 78, 215, 350, 351, 1003, 1004, "/" +360, 6, 79, 216, 352, 353, 1005, 1006, "-" +360, 6, 80, 217, 354, 355, 1007, 1008, "9" +360, 6, 81, 218, 356, 357, 1009, 1010, "." +360, 6, 82, 219, 358, 359, 1011, 1012, "1" +360, 6, 83, 220, 360, 365, 1013, 1018, "years" +360, 6, 84, 221, 366, 367, 1019, 1020, ")" +360, 6, 85, 222, 368, 369, 1021, 1022, "." +360, 7, 1, 223, 0, 4, 1023, 1027, "Mean" +360, 7, 2, 224, 5, 13, 1028, 1036, "baseline" +360, 7, 3, 225, 14, 17, 1037, 1040, "HbA" +360, 7, 4, 226, 18, 19, 1041, 1042, "(" +360, 7, 5, 227, 20, 22, 1043, 1045, "1c" +360, 7, 6, 228, 23, 24, 1046, 1047, ")" +360, 7, 7, 229, 25, 26, 1048, 1049, "(" +360, 7, 8, 230, 27, 28, 1050, 1051, "+" +360, 7, 9, 231, 29, 30, 1052, 1053, "/" +360, 7, 10, 232, 31, 32, 1054, 1055, "-" +360, 7, 11, 233, 33, 35, 1056, 1058, "SD" +360, 7, 12, 234, 36, 37, 1059, 1060, ")" +360, 7, 13, 235, 38, 41, 1061, 1064, "was" +360, 7, 14, 236, 42, 43, 1065, 1066, "9" +360, 7, 15, 237, 44, 45, 1067, 1068, "." +360, 7, 16, 238, 46, 47, 1069, 1070, "2" +360, 7, 17, 239, 48, 49, 1071, 1072, "+" +360, 7, 18, 240, 50, 51, 1073, 1074, "/" +360, 7, 19, 241, 52, 53, 1075, 1076, "-" +360, 7, 20, 242, 54, 55, 1077, 1078, "1" +360, 7, 21, 243, 56, 57, 1079, 1080, "." +360, 7, 22, 244, 58, 59, 1081, 1082, "4" +360, 7, 23, 245, 60, 61, 1083, 1084, "%" +360, 7, 24, 246, 62, 65, 1085, 1088, "and" +360, 7, 25, 247, 66, 67, 1089, 1090, "8" +360, 7, 26, 248, 68, 69, 1091, 1092, "." +360, 7, 27, 249, 70, 71, 1093, 1094, "9" +360, 7, 28, 250, 72, 73, 1095, 1096, "+" +360, 7, 29, 251, 74, 75, 1097, 1098, "/" +360, 7, 30, 252, 76, 77, 1099, 1100, "-" +360, 7, 31, 253, 78, 79, 1101, 1102, "1" +360, 7, 32, 254, 80, 81, 1103, 1104, "." +360, 7, 33, 255, 82, 83, 1105, 1106, "3" +360, 7, 34, 256, 84, 85, 1107, 1108, "%" +360, 7, 35, 257, 86, 89, 1109, 1112, "for" +360, 7, 36, 258, 90, 95, 1113, 1118, "BIAsp" +360, 7, 37, 259, 96, 98, 1119, 1121, "30" +360, 7, 38, 260, 99, 103, 1122, 1126, "plus" +360, 7, 39, 261, 104, 107, 1127, 1130, "met" +360, 7, 40, 262, 108, 109, 1131, 1132, "(" +360, 7, 41, 263, 110, 111, 1133, 1134, "N" +360, 7, 42, 264, 112, 113, 1135, 1136, "=" +360, 7, 43, 265, 114, 117, 1137, 1140, "128" +360, 7, 44, 266, 118, 119, 1141, 1142, ")" +360, 7, 45, 267, 120, 123, 1143, 1146, "and" +360, 7, 46, 268, 124, 129, 1147, 1152, "glarg" +360, 7, 47, 269, 130, 134, 1153, 1157, "plus" +360, 7, 48, 270, 135, 139, 1158, 1162, "glim" +360, 7, 49, 271, 140, 141, 1163, 1164, "(" +360, 7, 50, 272, 142, 143, 1165, 1166, "N" +360, 7, 51, 273, 144, 145, 1167, 1168, "=" +360, 7, 52, 274, 146, 149, 1169, 1172, "127" +360, 7, 53, 275, 150, 151, 1173, 1174, ")" +360, 7, 54, 276, 152, 153, 1175, 1176, "," +360, 7, 55, 277, 154, 166, 1177, 1189, "respectively" +360, 7, 56, 278, 167, 168, 1190, 1191, "(" +360, 7, 57, 279, 169, 170, 1192, 1193, "P" +360, 7, 58, 280, 171, 172, 1194, 1195, "=" +360, 7, 59, 281, 173, 174, 1196, 1197, "0" +360, 7, 60, 282, 175, 176, 1198, 1199, "." +360, 7, 61, 283, 177, 181, 1200, 1204, "0747" +360, 7, 62, 284, 182, 183, 1205, 1206, ")" +360, 7, 63, 285, 184, 185, 1207, 1208, "." +360, 8, 1, 286, 0, 7, 1209, 1216, "Primary" +360, 8, 2, 287, 8, 16, 1217, 1225, "endpoint" +360, 8, 3, 288, 17, 20, 1226, 1229, "was" +360, 8, 4, 289, 21, 24, 1230, 1233, "the" +360, 8, 5, 290, 25, 35, 1234, 1244, "difference" +360, 8, 6, 291, 36, 38, 1245, 1247, "in" +360, 8, 7, 292, 39, 47, 1248, 1256, "absolute" +360, 8, 8, 293, 48, 54, 1257, 1263, "change" +360, 8, 9, 294, 55, 57, 1264, 1266, "in" +360, 8, 10, 295, 58, 61, 1267, 1270, "HbA" +360, 8, 11, 296, 62, 63, 1271, 1272, "(" +360, 8, 12, 297, 64, 66, 1273, 1275, "1c" +360, 8, 13, 298, 67, 68, 1276, 1277, ")" +360, 8, 14, 299, 69, 76, 1278, 1285, "between" +360, 8, 15, 300, 77, 83, 1286, 1292, "groups" +360, 8, 16, 301, 84, 89, 1293, 1298, "after" +360, 8, 17, 302, 90, 92, 1299, 1301, "26" +360, 8, 18, 303, 93, 98, 1302, 1307, "weeks" +360, 8, 19, 304, 99, 101, 1308, 1310, "of" +360, 8, 20, 305, 102, 111, 1311, 1320, "treatment" +360, 8, 21, 306, 112, 113, 1321, 1322, "." +360, 9, 1, 307, 0, 7, 1323, 1330, "RESULTS" +360, 9, 2, 308, 8, 9, 1331, 1332, ":" +360, 9, 3, 309, 10, 13, 1333, 1336, "HbA" +360, 9, 4, 310, 14, 15, 1337, 1338, "(" +360, 9, 5, 311, 16, 18, 1339, 1341, "1c" +360, 9, 6, 312, 19, 20, 1342, 1343, ")" +360, 9, 7, 313, 21, 27, 1344, 1350, "change" +360, 9, 8, 314, 28, 31, 1351, 1354, "was" +360, 9, 9, 315, 32, 45, 1355, 1368, "significantly" +360, 9, 10, 316, 46, 53, 1369, 1376, "greater" +360, 9, 11, 317, 54, 56, 1377, 1379, "in" +360, 9, 12, 318, 57, 60, 1380, 1383, "the" +360, 9, 13, 319, 61, 66, 1384, 1389, "BIAsp" +360, 9, 14, 320, 67, 69, 1390, 1392, "30" +360, 9, 15, 321, 70, 74, 1393, 1397, "plus" +360, 9, 16, 322, 75, 78, 1398, 1401, "met" +360, 9, 17, 323, 79, 84, 1402, 1407, "group" +360, 9, 18, 324, 85, 89, 1408, 1412, "than" +360, 9, 19, 325, 90, 93, 1413, 1416, "the" +360, 9, 20, 326, 94, 99, 1417, 1422, "glarg" +360, 9, 21, 327, 100, 104, 1423, 1427, "plus" +360, 9, 22, 328, 105, 109, 1428, 1432, "glim" +360, 9, 23, 329, 110, 115, 1433, 1438, "group" +360, 9, 24, 330, 116, 117, 1439, 1440, "(" +360, 9, 25, 331, 118, 125, 1441, 1448, "between" +360, 9, 26, 332, 126, 127, 1449, 1450, "-" +360, 9, 27, 333, 128, 133, 1451, 1456, "group" +360, 9, 28, 334, 134, 144, 1457, 1467, "difference" +360, 9, 29, 335, 145, 146, 1468, 1469, ":" +360, 9, 30, 336, 147, 148, 1470, 1471, "-" +360, 9, 31, 337, 149, 150, 1472, 1473, "0" +360, 9, 32, 338, 151, 152, 1474, 1475, "." +360, 9, 33, 339, 153, 154, 1476, 1477, "5" +360, 9, 34, 340, 155, 156, 1478, 1479, "%" +360, 9, 35, 341, 157, 158, 1480, 1481, "(" +360, 9, 36, 342, 159, 161, 1482, 1484, "95" +360, 9, 37, 343, 162, 163, 1485, 1486, "%" +360, 9, 38, 344, 164, 166, 1487, 1489, "CI" +360, 9, 39, 345, 167, 168, 1490, 1491, ":" +360, 9, 40, 346, 169, 170, 1492, 1493, "-" +360, 9, 41, 347, 171, 172, 1494, 1495, "0" +360, 9, 42, 348, 173, 174, 1496, 1497, "." +360, 9, 43, 349, 175, 176, 1498, 1499, "8" +360, 9, 44, 350, 177, 178, 1500, 1501, ";" +360, 9, 45, 351, 179, 180, 1502, 1503, "-" +360, 9, 46, 352, 181, 182, 1504, 1505, "0" +360, 9, 47, 353, 183, 184, 1506, 1507, "." +360, 9, 48, 354, 185, 186, 1508, 1509, "2" +360, 9, 49, 355, 187, 188, 1510, 1511, ")" +360, 9, 50, 356, 189, 190, 1512, 1513, ";" +360, 9, 51, 357, 191, 192, 1514, 1515, "P" +360, 9, 52, 358, 193, 194, 1516, 1517, "=" +360, 9, 53, 359, 195, 196, 1518, 1519, "0" +360, 9, 54, 360, 197, 198, 1520, 1521, "." +360, 9, 55, 361, 199, 203, 1522, 1526, "0002" +360, 9, 56, 362, 204, 205, 1527, 1528, ")" +360, 9, 57, 363, 206, 207, 1529, 1530, "." +360, 10, 1, 364, 0, 4, 1531, 1535, "Mean" +360, 10, 2, 365, 5, 13, 1536, 1544, "prandial" +360, 10, 3, 366, 14, 20, 1545, 1551, "plasma" +360, 10, 4, 367, 21, 28, 1552, 1559, "glucose" +360, 10, 5, 368, 29, 38, 1560, 1569, "increment" +360, 10, 6, 369, 39, 42, 1570, 1573, "was" +360, 10, 7, 370, 43, 56, 1574, 1587, "significantly" +360, 10, 8, 371, 57, 62, 1588, 1593, "lower" +360, 10, 9, 372, 63, 66, 1594, 1597, "for" +360, 10, 10, 373, 67, 72, 1598, 1603, "BIAsp" +360, 10, 11, 374, 73, 75, 1604, 1606, "30" +360, 10, 12, 375, 76, 80, 1607, 1611, "plus" +360, 10, 13, 376, 81, 84, 1612, 1615, "met" +360, 10, 14, 377, 85, 93, 1616, 1624, "compared" +360, 10, 15, 378, 94, 98, 1625, 1629, "with" +360, 10, 16, 379, 99, 104, 1630, 1635, "glarg" +360, 10, 17, 380, 105, 109, 1636, 1640, "plus" +360, 10, 18, 381, 110, 114, 1641, 1645, "glim" +360, 10, 19, 382, 115, 116, 1646, 1647, ":" +360, 10, 20, 383, 117, 118, 1648, 1649, "1" +360, 10, 21, 384, 119, 120, 1650, 1651, "." +360, 10, 22, 385, 121, 122, 1652, 1653, "4" +360, 10, 23, 386, 123, 124, 1654, 1655, "+" +360, 10, 24, 387, 125, 126, 1656, 1657, "/" +360, 10, 25, 388, 127, 128, 1658, 1659, "-" +360, 10, 26, 389, 129, 130, 1660, 1661, "1" +360, 10, 27, 390, 131, 132, 1662, 1663, "." +360, 10, 28, 391, 133, 134, 1664, 1665, "4" +360, 10, 29, 392, 135, 139, 1666, 1670, "mmol" +360, 10, 30, 393, 140, 141, 1671, 1672, "/" +360, 10, 31, 394, 142, 143, 1673, 1674, "l" +360, 10, 32, 395, 144, 146, 1675, 1677, "vs" +360, 10, 33, 396, 147, 148, 1678, 1679, "." +360, 10, 34, 397, 149, 150, 1680, 1681, "2" +360, 10, 35, 398, 151, 152, 1682, 1683, "." +360, 10, 36, 399, 153, 154, 1684, 1685, "2" +360, 10, 37, 400, 155, 156, 1686, 1687, "+" +360, 10, 38, 401, 157, 158, 1688, 1689, "/" +360, 10, 39, 402, 159, 160, 1690, 1691, "-" +360, 10, 40, 403, 161, 162, 1692, 1693, "1" +360, 10, 41, 404, 163, 164, 1694, 1695, "." +360, 10, 42, 405, 165, 166, 1696, 1697, "8" +360, 10, 43, 406, 167, 171, 1698, 1702, "mmol" +360, 10, 44, 407, 172, 173, 1703, 1704, "/" +360, 10, 45, 408, 174, 175, 1705, 1706, "l" +360, 10, 46, 409, 176, 177, 1707, 1708, ";" +360, 10, 47, 410, 178, 179, 1709, 1710, "P" +360, 10, 48, 411, 180, 181, 1711, 1712, "=" +360, 10, 49, 412, 182, 183, 1713, 1714, "0" +360, 10, 50, 413, 184, 185, 1715, 1716, "." +360, 10, 51, 414, 186, 190, 1717, 1721, "0002" +360, 10, 52, 415, 191, 192, 1722, 1723, "." +360, 11, 1, 416, 0, 6, 1724, 1730, "During" +360, 11, 2, 417, 7, 10, 1731, 1734, "the" +360, 11, 3, 418, 11, 22, 1735, 1746, "maintenance" +360, 11, 4, 419, 23, 28, 1747, 1752, "phase" +360, 11, 5, 420, 29, 30, 1753, 1754, "(" +360, 11, 6, 421, 31, 36, 1755, 1760, "weeks" +360, 11, 7, 422, 37, 38, 1761, 1762, "6" +360, 11, 8, 423, 39, 40, 1763, 1764, "-" +360, 11, 9, 424, 41, 43, 1765, 1767, "26" +360, 11, 10, 425, 44, 45, 1768, 1769, ")" +360, 11, 11, 426, 46, 47, 1770, 1771, "," +360, 11, 12, 427, 48, 51, 1772, 1775, "one" +360, 11, 13, 428, 52, 57, 1776, 1781, "major" +360, 11, 14, 429, 58, 70, 1782, 1794, "hypoglycemic" +360, 11, 15, 430, 71, 78, 1795, 1802, "episode" +360, 11, 16, 431, 79, 87, 1803, 1811, "occurred" +360, 11, 17, 432, 88, 90, 1812, 1814, "in" +360, 11, 18, 433, 91, 95, 1815, 1819, "each" +360, 11, 19, 434, 96, 101, 1820, 1825, "group" +360, 11, 20, 435, 102, 103, 1826, 1827, ";" +360, 11, 21, 436, 104, 106, 1828, 1830, "20" +360, 11, 22, 437, 107, 108, 1831, 1832, "." +360, 11, 23, 438, 109, 110, 1833, 1834, "3" +360, 11, 24, 439, 111, 112, 1835, 1836, "%" +360, 11, 25, 440, 113, 116, 1837, 1840, "and" +360, 11, 26, 441, 117, 118, 1841, 1842, "9" +360, 11, 27, 442, 119, 120, 1843, 1844, "%" +360, 11, 28, 443, 121, 123, 1845, 1847, "of" +360, 11, 29, 444, 124, 132, 1848, 1856, "patients" +360, 11, 30, 445, 133, 144, 1857, 1868, "experienced" +360, 11, 31, 446, 145, 150, 1869, 1874, "minor" +360, 11, 32, 447, 151, 163, 1875, 1887, "hypoglycemic" +360, 11, 33, 448, 164, 172, 1888, 1896, "episodes" +360, 11, 34, 449, 173, 175, 1897, 1899, "in" +360, 11, 35, 450, 176, 179, 1900, 1903, "the" +360, 11, 36, 451, 180, 185, 1904, 1909, "BIAsp" +360, 11, 37, 452, 186, 188, 1910, 1912, "30" +360, 11, 38, 453, 189, 193, 1913, 1917, "plus" +360, 11, 39, 454, 194, 197, 1918, 1921, "met" +360, 11, 40, 455, 198, 201, 1922, 1925, "and" +360, 11, 41, 456, 202, 207, 1926, 1931, "glarg" +360, 11, 42, 457, 208, 212, 1932, 1936, "plus" +360, 11, 43, 458, 213, 217, 1937, 1941, "glim" +360, 11, 44, 459, 218, 224, 1942, 1948, "groups" +360, 11, 45, 460, 225, 226, 1949, 1950, "," +360, 11, 46, 461, 227, 239, 1951, 1963, "respectively" +360, 11, 47, 462, 240, 241, 1964, 1965, "(" +360, 11, 48, 463, 242, 243, 1966, 1967, "P" +360, 11, 49, 464, 244, 245, 1968, 1969, "=" +360, 11, 50, 465, 246, 247, 1970, 1971, "0" +360, 11, 51, 466, 248, 249, 1972, 1973, "." +360, 11, 52, 467, 250, 254, 1974, 1978, "0124" +360, 11, 53, 468, 255, 256, 1979, 1980, ")" +360, 11, 54, 469, 257, 258, 1981, 1982, "." +360, 12, 1, 470, 0, 2, 1983, 1985, "At" +360, 12, 2, 471, 3, 6, 1986, 1989, "end" +360, 12, 3, 472, 7, 8, 1990, 1991, "-" +360, 12, 4, 473, 9, 11, 1992, 1994, "of" +360, 12, 5, 474, 12, 13, 1995, 1996, "-" +360, 12, 6, 475, 14, 19, 1997, 2002, "trial" +360, 12, 7, 476, 20, 21, 2003, 2004, "," +360, 12, 8, 477, 22, 26, 2005, 2009, "mean" +360, 12, 9, 478, 27, 32, 2010, 2015, "daily" +360, 12, 10, 479, 33, 40, 2016, 2023, "insulin" +360, 12, 11, 480, 41, 46, 2024, 2029, "doses" +360, 12, 12, 481, 47, 51, 2030, 2034, "were" +360, 12, 13, 482, 52, 53, 2035, 2036, "0" +360, 12, 14, 483, 54, 55, 2037, 2038, "." +360, 12, 15, 484, 56, 58, 2039, 2041, "40" +360, 12, 16, 485, 59, 60, 2042, 2043, "U" +360, 12, 17, 486, 61, 62, 2044, 2045, "/" +360, 12, 18, 487, 63, 65, 2046, 2048, "kg" +360, 12, 19, 488, 66, 71, 2049, 2054, "BIAsp" +360, 12, 20, 489, 72, 74, 2055, 2057, "30" +360, 12, 21, 490, 75, 78, 2058, 2061, "and" +360, 12, 22, 491, 79, 80, 2062, 2063, "0" +360, 12, 23, 492, 81, 82, 2064, 2065, "." +360, 12, 24, 493, 83, 85, 2066, 2068, "39" +360, 12, 25, 494, 86, 87, 2069, 2070, "U" +360, 12, 26, 495, 88, 89, 2071, 2072, "/" +360, 12, 27, 496, 90, 92, 2073, 2075, "kg" +360, 12, 28, 497, 93, 98, 2076, 2081, "glarg" +360, 12, 29, 498, 99, 100, 2082, 2083, "." +360, 13, 1, 499, 0, 5, 2084, 2089, "Glarg" +360, 13, 2, 500, 6, 10, 2090, 2094, "plus" +360, 13, 3, 501, 11, 15, 2095, 2099, "glim" +360, 13, 4, 502, 16, 17, 2100, 2101, "-" +360, 13, 5, 503, 18, 25, 2102, 2109, "treated" +360, 13, 6, 504, 26, 34, 2110, 2118, "patients" +360, 13, 7, 505, 35, 46, 2119, 2130, "experienced" +360, 13, 8, 506, 47, 58, 2131, 2142, "significant" +360, 13, 9, 507, 59, 65, 2143, 2149, "weight" +360, 13, 10, 508, 66, 70, 2150, 2154, "gain" +360, 13, 11, 509, 71, 73, 2155, 2157, "of" +360, 13, 12, 510, 74, 75, 2158, 2159, "1" +360, 13, 13, 511, 76, 77, 2160, 2161, "." +360, 13, 14, 512, 78, 79, 2162, 2163, "5" +360, 13, 15, 513, 80, 82, 2164, 2166, "kg" +360, 13, 16, 514, 83, 84, 2167, 2168, "(" +360, 13, 17, 515, 85, 87, 2169, 2171, "95" +360, 13, 18, 516, 88, 89, 2172, 2173, "%" +360, 13, 19, 517, 90, 92, 2174, 2176, "CI" +360, 13, 20, 518, 93, 94, 2177, 2178, ":" +360, 13, 21, 519, 95, 96, 2179, 2180, "0" +360, 13, 22, 520, 97, 98, 2181, 2182, "." +360, 13, 23, 521, 99, 101, 2183, 2185, "84" +360, 13, 24, 522, 102, 103, 2186, 2187, ";" +360, 13, 25, 523, 104, 105, 2188, 2189, "2" +360, 13, 26, 524, 106, 107, 2190, 2191, "." +360, 13, 27, 525, 108, 110, 2192, 2194, "19" +360, 13, 28, 526, 111, 112, 2195, 2196, ";" +360, 13, 29, 527, 113, 114, 2197, 2198, "P" +360, 13, 30, 528, 115, 116, 2199, 2200, "<" +360, 13, 31, 529, 117, 118, 2201, 2202, "0" +360, 13, 32, 530, 119, 120, 2203, 2204, "." +360, 13, 33, 531, 121, 125, 2205, 2209, "0001" +360, 13, 34, 532, 126, 127, 2210, 2211, ")" +360, 13, 35, 533, 128, 129, 2212, 2213, "." +360, 14, 1, 534, 0, 6, 2214, 2220, "Weight" +360, 14, 2, 535, 7, 13, 2221, 2227, "change" +360, 14, 3, 536, 14, 18, 2228, 2232, "with" +360, 14, 4, 537, 19, 24, 2233, 2238, "BIAsp" +360, 14, 5, 538, 25, 27, 2239, 2241, "30" +360, 14, 6, 539, 28, 32, 2242, 2246, "plus" +360, 14, 7, 540, 33, 36, 2247, 2250, "met" +360, 14, 8, 541, 37, 39, 2251, 2253, "of" +360, 14, 9, 542, 40, 41, 2254, 2255, "+" +360, 14, 10, 543, 42, 43, 2256, 2257, "0" +360, 14, 11, 544, 44, 45, 2258, 2259, "." +360, 14, 12, 545, 46, 47, 2260, 2261, "7" +360, 14, 13, 546, 48, 50, 2262, 2264, "kg" +360, 14, 14, 547, 51, 54, 2265, 2268, "was" +360, 14, 15, 548, 55, 58, 2269, 2272, "not" +360, 14, 16, 549, 59, 72, 2273, 2286, "statistically" +360, 14, 17, 550, 73, 84, 2287, 2298, "significant" +360, 14, 18, 551, 85, 86, 2299, 2300, "(" +360, 14, 19, 552, 87, 89, 2301, 2303, "95" +360, 14, 20, 553, 90, 91, 2304, 2305, "%" +360, 14, 21, 554, 92, 94, 2306, 2308, "CI" +360, 14, 22, 555, 95, 96, 2309, 2310, ":" +360, 14, 23, 556, 97, 98, 2311, 2312, "-" +360, 14, 24, 557, 99, 100, 2313, 2314, "0" +360, 14, 25, 558, 101, 102, 2315, 2316, "." +360, 14, 26, 559, 103, 105, 2317, 2319, "07" +360, 14, 27, 560, 106, 107, 2320, 2321, ";" +360, 14, 28, 561, 108, 109, 2322, 2323, "1" +360, 14, 29, 562, 110, 111, 2324, 2325, "." +360, 14, 30, 563, 112, 114, 2326, 2328, "42" +360, 14, 31, 564, 115, 116, 2329, 2330, ";" +360, 14, 32, 565, 117, 118, 2331, 2332, "P" +360, 14, 33, 566, 119, 120, 2333, 2334, "=" +360, 14, 34, 567, 121, 122, 2335, 2336, "0" +360, 14, 35, 568, 123, 124, 2337, 2338, "." +360, 14, 36, 569, 125, 129, 2339, 2343, "0762" +360, 14, 37, 570, 130, 131, 2344, 2345, ")" +360, 14, 38, 571, 132, 133, 2346, 2347, "." +360, 15, 1, 572, 0, 11, 2348, 2359, "CONCLUSIONS" +360, 15, 2, 573, 12, 13, 2360, 2361, ":" +360, 15, 3, 574, 14, 22, 2362, 2370, "Starting" +360, 15, 4, 575, 23, 30, 2371, 2378, "insulin" +360, 15, 5, 576, 31, 33, 2379, 2381, "in" +360, 15, 6, 577, 34, 38, 2382, 2386, "Type" +360, 15, 7, 578, 39, 40, 2387, 2388, "2" +360, 15, 8, 579, 41, 49, 2389, 2397, "diabetes" +360, 15, 9, 580, 50, 58, 2398, 2406, "patients" +360, 15, 10, 581, 59, 63, 2407, 2411, "with" +360, 15, 11, 582, 64, 69, 2412, 2417, "twice" +360, 15, 12, 583, 70, 71, 2418, 2419, "-" +360, 15, 13, 584, 72, 77, 2420, 2425, "daily" +360, 15, 14, 585, 78, 83, 2426, 2431, "BIAsp" +360, 15, 15, 586, 84, 86, 2432, 2434, "30" +360, 15, 16, 587, 87, 91, 2435, 2439, "plus" +360, 15, 17, 588, 92, 95, 2440, 2443, "met" +360, 15, 18, 589, 96, 99, 2444, 2447, "can" +360, 15, 19, 590, 100, 106, 2448, 2454, "reduce" +360, 15, 20, 591, 107, 110, 2455, 2458, "HbA" +360, 15, 21, 592, 111, 112, 2459, 2460, "(" +360, 15, 22, 593, 113, 115, 2461, 2463, "1c" +360, 15, 23, 594, 116, 117, 2464, 2465, ")" +360, 15, 24, 595, 118, 121, 2466, 2469, "and" +360, 15, 25, 596, 122, 126, 2470, 2474, "mean" +360, 15, 26, 597, 127, 135, 2475, 2483, "prandial" +360, 15, 27, 598, 136, 142, 2484, 2490, "plasma" +360, 15, 28, 599, 143, 150, 2491, 2498, "glucose" +360, 15, 29, 600, 151, 160, 2499, 2508, "increment" +360, 15, 30, 601, 161, 163, 2509, 2511, "to" +360, 15, 31, 602, 164, 165, 2512, 2513, "a" +360, 15, 32, 603, 166, 173, 2514, 2521, "greater" +360, 15, 33, 604, 174, 180, 2522, 2528, "extent" +360, 15, 34, 605, 181, 185, 2529, 2533, "than" +360, 15, 35, 606, 186, 190, 2534, 2538, "once" +360, 15, 36, 607, 191, 192, 2539, 2540, "-" +360, 15, 37, 608, 193, 198, 2541, 2546, "daily" +360, 15, 38, 609, 199, 204, 2547, 2552, "glarg" +360, 15, 39, 610, 205, 209, 2553, 2557, "plus" +360, 15, 40, 611, 210, 214, 2558, 2562, "glim" +360, 15, 41, 612, 215, 216, 2563, 2564, "." +360, 16, 1, 613, 0, 3, 2565, 2568, "DOI" +360, 16, 2, 614, 4, 5, 2569, 2570, ":" +360, 16, 3, 615, 6, 8, 2571, 2573, "10" +360, 16, 4, 616, 9, 10, 2574, 2575, "." +360, 16, 5, 617, 11, 15, 2576, 2580, "1055" +360, 16, 6, 618, 16, 17, 2581, 2582, "/" +360, 16, 7, 619, 18, 19, 2583, 2584, "s" +360, 16, 8, 620, 20, 21, 2585, 2586, "-" +360, 16, 9, 621, 22, 26, 2587, 2591, "2006" +360, 16, 10, 622, 27, 28, 2592, 2593, "-" +360, 16, 11, 623, 29, 35, 2594, 2600, "949655" +360, 16, 12, 624, 36, 40, 2601, 2605, "PMID" +360, 16, 13, 625, 41, 42, 2606, 2607, ":" +360, 16, 14, 626, 43, 51, 2608, 2616, "17115351" +360, 16, 15, 627, 52, 53, 2617, 2618, "[" +360, 16, 16, 628, 54, 61, 2619, 2626, "Indexed" +360, 16, 17, 629, 62, 65, 2627, 2630, "for" +360, 16, 18, 630, 66, 73, 2631, 2638, "MEDLINE" +360, 16, 19, 631, 74, 75, 2639, 2640, "]" diff --git a/data/dm2 17115351_kwoodley.annodb b/data/dm2 17115351_kwoodley.annodb new file mode 100644 index 0000000..786d846 --- /dev/null +++ b/data/dm2 17115351_kwoodley.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31641, Journal, 0, 30, "Exp Clin Endocrinol Diabetes .", "", +3945, PublicationYear, 31, 35, "2006", "", +31642, Title, 65, 222, "Starting insulin therapy in type 2 diabetes : twice - daily biphasic insulin Aspart 30 plus metformin versus once - daily insulin glargine plus glimepiride .", "", +3946, Insulin, 74, 81, "insulin", "", +3947, Type2Diabetes, 93, 108, "type 2 diabetes", "", +3948, Frequency, 111, 124, "twice - daily", "", +4105, InsulinAspart, 125, 151, "biphasic insulin Aspart 30", "", +3950, Metformin, 157, 166, "metformin", "", +3951, Frequency, 174, 186, "once - daily", "", +3952, InsulinGlargine, 187, 203, "insulin glargine", "", +3953, Glimepiride, 209, 220, "glimepiride", "", +3955, Author, 223, 230, "Kann PH", "", +3956, Author, 239, 248, "Wascher T", "", +3957, Author, 251, 260, "Zackova V", "", +3958, Author, 263, 272, "Moeller J", "", +3959, Author, 275, 284, "Medding J", "", +3960, Author, 287, 294, "Szocs A", "", +3961, Author, 297, 304, "Mokan M", "", +3962, Author, 307, 316, "Mrevlje F", "", +3963, Author, 319, 329, "Regulski M", "", +3964, Germany, 477, 484, "Germany", "", +31643, ObjectiveDescription, 526, 652, "To compare the efficacy and safety of two analog insulins as starting regimens in insulin - na ï ve Type 2 diabetes patients .", "", +3965, Insulin, 575, 583, "insulins", "", +3967, Precondition, 608, 650, "insulin - na ï ve Type 2 diabetes patients", "", +3966, Type2Diabetes, 626, 641, "Type 2 diabetes", "", +3969, Randomized, 671, 681, "randomized", "", +3970, OpenLabel, 684, 696, "open - label", "", +3971, Parallel, 697, 705, "parallel", "", +3972, Frequency, 714, 727, "twice - daily", "", +4106, InsulinAspart, 728, 754, "biphasic insulin aspart 30", "", +4107, InsulinAspart, 757, 806, "30 % soluble and 70 % protaminated insulin aspart", "", +4108, InsulinAspart, 809, 817, "BIAsp 30", "", +3976, Metformin, 825, 834, "metformin", "", +3977, Metformin, 837, 840, "met", "", +3978, Frequency, 861, 873, "once - daily", "", +3979, InsulinGlargine, 874, 890, "insulin glargine", "", +3980, InsulinGlargine, 893, 898, "glarg", "", +3981, Glimepiride, 906, 917, "glimepiride", "", +3982, Glimepiride, 920, 924, "glim", "", +3983, NumberPatientsCT, 930, 933, "255", "", +3984, Precondition, 934, 960, "insulin - na ï ve patients", "", +4151, Male, 963, 971, "131 male", "", +4147, AvgAge, 994, 1018, "61 . 2 + / - 9 . 1 years", "", +3985, HbA1c, 1037, 1047, "HbA ( 1c )", "", +3987, Mean, 1050, 1058, "+ / - SD", "", +3988, BaseLineValue, 1065, 1070, "9 . 2", "", +3992, SdDevBL, 1077, 1082, "1 . 4", "", +3994, Percentage, 1083, 1084, "%", "", +3990, BaseLineValue, 1089, 1094, "8 . 9", "", +3993, SdDevBL, 1101, 1106, "1 . 3", "", +3995, Percentage, 1107, 1108, "%", "", +4109, InsulinAspart, 1113, 1121, "BIAsp 30", "", +3998, Metformin, 1127, 1130, "met", "", +3999, NumberPatientsArm, 1137, 1140, "128", "", +4000, InsulinGlargine, 1147, 1152, "glarg", "", +4001, Glimepiride, 1158, 1162, "glim", "", +4004, NumberPatientsArm, 1169, 1172, "127", "", +4008, PvalueDiff, 1192, 1204, "P = 0 . 0747", "", +4010, HbA1c, 1267, 1277, "HbA ( 1c )", "", +4012, Duration, 1299, 1307, "26 weeks", "", +4016, HbA1c, 1333, 1343, "HbA ( 1c )", "", +4112, InsulinAspart, 1384, 1392, "BIAsp 30", "", +4019, Metformin, 1398, 1401, "met", "", +4020, InsulinGlargine, 1417, 1422, "glarg", "", +4021, Glimepiride, 1428, 1432, "glim", "", +4023, DiffGroupAbsValue, 1472, 1477, "0 . 5", "", +4024, Percentage, 1478, 1479, "%", "", +4025, ConfIntervalDiff, 1482, 1509, "95 % CI : - 0 . 8 ; - 0 . 2", "", +4026, PvalueDiff, 1514, 1526, "P = 0 . 0002", "", +31644, PostprandialPlasmaGlucose, 1536, 1559, "prandial plasma glucose", "", +4113, InsulinAspart, 1598, 1606, "BIAsp 30", "", +4029, Metformin, 1612, 1615, "met", "", +4030, InsulinGlargine, 1630, 1635, "glarg", "", +4031, Glimepiride, 1641, 1645, "glim", "", +4034, Increment, 1648, 1653, "1 . 4", "", +4033, SdDevResValue, 1660, 1665, "1 . 4", "", +4036, Millimoles_per_litre, 1666, 1674, "mmol / l", "", +4035, Increment, 1680, 1685, "2 . 2", "", +4038, SdDevResValue, 1692, 1697, "1 . 8", "", +4037, Millimoles_per_litre, 1698, 1706, "mmol / l", "", +4039, PvalueDiff, 1709, 1721, "P = 0 . 0002", "", +4054, ObservedResult, 1724, 1825, "During the maintenance phase ( weeks 6 - 26 ) , one major hypoglycemic episode occurred in each group", "", +4040, TimePoint, 1735, 1769, "maintenance phase ( weeks 6 - 26 )", "", +4041, Hypoglycemia, 1782, 1802, "hypoglycemic episode", "", +4050, PercentageAffected, 1828, 1834, "20 . 3", "", +4051, PercentageAffected, 1841, 1842, "9", "", +31645, ObservedResult, 1857, 1896, "experienced minor hypoglycemic episodes", "", +4045, Hypoglycemia, 1875, 1896, "hypoglycemic episodes", "", +4114, InsulinAspart, 1904, 1912, "BIAsp 30", "", +4056, Metformin, 1918, 1921, "met", "", +4057, InsulinGlargine, 1926, 1931, "glarg", "", +4070, Glimepiride, 1937, 1941, "glim", "", +4071, PvalueDiff, 1966, 1978, "P = 0 . 0124", "", +31646, TimePoint, 1986, 2002, "end - of - trial", "", +31647, InsulinDose, 2005, 2029, "mean daily insulin doses", "", +4153, ResultMeasuredValue, 2035, 2041, "0 . 40", "", +4077, IntUnit_per_Kg, 2042, 2048, "U / kg", "", +4080, IsophaneInsulin_NPH, 2049, 2057, "BIAsp 30", "", +4154, ResultMeasuredValue, 2062, 2068, "0 . 39", "", +4082, IntUnit_per_Kg, 2069, 2075, "U / kg", "", +4083, InsulinGlargine, 2076, 2081, "glarg", "", +4087, InsulinGlargine, 2084, 2089, "Glarg", "", +4088, Glimepiride, 2095, 2099, "glim", "", +4089, BodyWeight, 2143, 2149, "weight", "", +4090, Increment, 2158, 2163, "1 . 5", "", +4091, Kg, 2164, 2166, "kg", "", +4092, ConfIntervalResValue, 2169, 2194, "95 % CI : 0 . 84 ; 2 . 19", "", +4093, PValueResValue, 2197, 2209, "P < 0 . 0001", "", +4094, BodyWeight, 2214, 2220, "Weight", "", +4115, InsulinAspart, 2233, 2241, "BIAsp 30", "", +4096, Metformin, 2247, 2250, "met", "", +4097, Increment, 2256, 2261, "0 . 7", "", +4098, Kg, 2262, 2264, "kg", "", +4099, ConfIntervalResValue, 2301, 2328, "95 % CI : - 0 . 07 ; 1 . 42", "", +4100, PValueResValue, 2331, 2343, "P = 0 . 0762", "", +31648, ConclusionComment, 2362, 2564, "Starting insulin in Type 2 diabetes patients with twice - daily BIAsp 30 plus met can reduce HbA ( 1c ) and mean prandial plasma glucose increment to a greater extent than once - daily glarg plus glim .", "", +4101, Insulin, 2371, 2378, "insulin", "", +4102, Type2Diabetes, 2382, 2397, "Type 2 diabetes", "", +4103, Frequency, 2412, 2425, "twice - daily", "", +4104, InsulinAspart, 2426, 2434, "BIAsp 30", "", +4116, Metformin, 2440, 2443, "met", "", +4117, HbA1c, 2455, 2465, "HbA ( 1c )", "", +31649, PostprandialPlasmaGlucose, 2475, 2498, "prandial plasma glucose", "", +4119, Frequency, 2534, 2546, "once - daily", "", +4120, InsulinGlargine, 2547, 2552, "glarg", "", +4121, Glimepiride, 2558, 2562, "glim", "", +4124, PMID, 2608, 2616, "17115351", "", diff --git a/data/dm2 17115351_kwoodley.n-triples b/data/dm2 17115351_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17115351_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17130197_admin.annodb b/data/dm2 17130197_admin.annodb new file mode 100644 index 0000000..4e22f02 --- /dev/null +++ b/data/dm2 17130197_admin.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2006", "", " \"2006\"." +166, Title, 51, 239, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone .", "", " \"Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone .\"." +4, Sitagliptin, 113, 124, "sitagliptin", "", +5, Metformin, 142, 151, "metformin", "", +89, Precondition, 163, 237, "patients with type 2 diabetes inadequately controlled with metformin alone", "", +6, Type2Diabetes, 177, 192, "type 2 diabetes", "", +8, Precondition, 193, 237, "inadequately controlled with metformin alone", "", +7, Metformin, 222, 231, "metformin", "", +10, Author, 240, 252, "Charbonnel B", "", " \"Charbonnel B\"." +11, Author, 261, 270, "Karasik A", "", " \"Karasik A\"." +12, Author, 273, 278, "Liu J", "", " \"Liu J\"." +13, Author, 281, 285, "Wu M", "", " \"Wu M\"." +14, Author, 288, 299, "Meininger G", "", " \"Meininger G\"." +15, France, 404, 410, "France", "", " ." +104, ObjectiveDescription, 501, 619, "The efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , added to ongoing metformin therapy ,", "", " \"The efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , added to ongoing metformin therapy ,\"." +16, Sitagliptin, 569, 580, "sitagliptin", "", +17, Metformin, 600, 609, "metformin", "", +167, ObjectiveDescription, 620, 773, "were assessed in patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone .", "", " \"were assessed in patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone .\"." +103, Precondition, 637, 771, "patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone", "", " \"patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone\"." +18, Type2Diabetes, 651, 666, "type 2 diabetes", "", +19, Precondition, 675, 771, "inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone", "", +99, HbA1c, 705, 715, "HbA ( 1c )", "", +100, HbA1c, 718, 721, "A1C", "", +101, Percentage, 747, 748, "%", "", +20, Metformin, 756, 765, "metformin", "", +21, Metformin, 858, 867, "metformin", "", +24, Duration, 914, 922, "2 - week", "", +22, Blind, 925, 939, "single - blind", "", " ." +23, Placebo, 942, 949, "placebo", "", +27, NumberPatientsCT, 968, 971, "701", "", " \"701\"." +28, MinAge, 988, 990, "19", "", " \"19\"." +29, MaxAge, 993, 995, "78", "", " \"78\"." +124, Precondition, 1004, 1116, "with mild to moderate hyperglycemia ( mean A1C 8 . 0 % ) receiving ongoing metformin ( > or = 1 , 500 mg / day )", "", " \"with mild to moderate hyperglycemia ( mean A1C 8 . 0 % ) receiving ongoing metformin ( > or = 1 , 500 mg / day )\"." +109, Hypoglycemia, 1026, 1039, "hyperglycemia", "", +110, HbA1c, 1047, 1050, "A1C", "", +168, BaseLineValue, 1051, 1056, "8 . 0", "", " \"8 . 0\". \"8 . 0\"." +111, Percentage, 1057, 1058, "%", "", " ." +31, Metformin, 1079, 1088, "metformin", "", +113, DoseValue, 1091, 1105, "> or = 1 , 500", "", +114, mg, 1106, 1108, "mg", "", +51301, Interval, 1111, 1114, "day", "", +33, Randomized, 1122, 1130, "randomly", "", " ." +34, Placebo, 1167, 1174, "placebo", "", " ." +35, Sitagliptin, 1178, 1189, "sitagliptin", "", " ." +36, DoseValue, 1190, 1193, "100", "", " \"100\"." +37, mg, 1194, 1196, "mg", "", " ." +38, Frequency, 1197, 1209, "once - daily", "", " \"once - daily\"." +122, AllocationRatio, 1215, 1220, "1 : 2", "", " . ." +39, Duration, 1231, 1239, "24 weeks", "", " \"24 weeks\"." +40, Pioglitazone, 1317, 1329, "pioglitazone", "", +172, TimePoint, 1342, 1358, "end of the study", "", +41, TimePoint, 1516, 1523, "week 24", "", +42, Sitagliptin, 1526, 1537, "sitagliptin", "", +43, Placebo, 1592, 1599, "placebo", "", +44, HbA1c, 1603, 1606, "A1C", "", " ." +45, DiffGroupAbsValue, 1609, 1617, "- 0 . 65", "", " \"- 0 . 65\"." +46, Percentage, 1618, 1619, "%", "", +47, FastingPlasmaGlucose, 1624, 1646, "fasting plasma glucose", "", " ." +170, PostprandialBloodGlucose, 1653, 1675, "2 - h postmeal glucose", "", " ." +47992, RelativeTime, 1678, 1685, "Fasting", "", +49, EndPointDescription, 1678, 1693, "Fasting insulin", "", " . ." +47993, Insulin, 1686, 1693, "insulin", "", +47994, RelativeTime, 1696, 1703, "fasting", "", +50, EndPointDescription, 1696, 1715, "fasting C - peptide", "", " . ." +47995, RelativeTime, 1718, 1725, "fasting", "", +51, EndPointDescription, 1718, 1757, "fasting proinsulin - to - insulin ratio", "", " . ." +47989, RelativeTime, 1760, 1768, "postmeal", "", +47996, EndPointDescription, 1760, 1776, "postmeal insulin", "", " . ." +47991, Insulin, 1769, 1776, "insulin", "", +135, EndPointDescription, 1781, 1814, "C - peptide areas under the curve", "", " . ." +136, EndPointDescription, 1817, 1821, "AUCs", "", +54, EndPointDescription, 1826, 1871, "postmeal insulin AUC - to - glucose AUC ratio", "", " . ." +55, EndPointDescription, 1874, 1926, "homeostasis model assessment of beta - cell function", "", " . ." +56, EndPointDescription, 1933, 1977, "quantitative insulin sensitivity check index", "", " . ." +140, ObservedResult, 1978, 2005, "were significantly improved", "", " \"were significantly improved\". \"were significantly improved\". \"were significantly improved\". \"were significantly improved\". \"were significantly improved\". \"were significantly improved\". \"were significantly improved\". \"were significantly improved\"." +58, Sitagliptin, 2011, 2022, "sitagliptin", "", +59, Placebo, 2035, 2042, "placebo", "", +143, HbA1c_target, 2104, 2113, "A1C < 7 %", "", " ." +61, Sitagliptin, 2119, 2130, "sitagliptin", "", +62, PercentageAffected, 2133, 2139, "47 . 0", "", " \"47 . 0\"." +64, Placebo, 2154, 2161, "placebo", "", +65, PercentageAffected, 2164, 2170, "18 . 3", "", " \"18 . 3\"." +83, ObservedResult, 2177, 2204, "There was no increased risk", "", " \"There was no increased risk\". \"There was no increased risk\"." +148, Hypoglycemia, 2208, 2220, "hypoglycemia", "", " ." +149, GastrointestinalProblem, 2224, 2260, "gastrointestinal adverse experiences", "", " ." +69, Sitagliptin, 2266, 2277, "sitagliptin", "", +70, Placebo, 2292, 2299, "placebo", "", +71, BodyWeight, 2302, 2313, "Body weight", "", " ." +84, ObservedResult, 2314, 2362, "decreased similarly with sitagliptin and placebo", "", " \"decreased similarly with sitagliptin and placebo\"." +72, Sitagliptin, 2339, 2350, "sitagliptin", "", +73, Placebo, 2355, 2362, "placebo", "", +74, Sitagliptin, 2379, 2390, "Sitagliptin", "", +171, ConclusionComment, 2379, 2572, "Sitagliptin 100 mg once - daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone .", "", " \"Sitagliptin 100 mg once - daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone .\"." +75, DoseValue, 2391, 2394, "100", "", +76, mg, 2395, 2397, "mg", "", +77, Frequency, 2398, 2410, "once - daily", "", +78, Metformin, 2428, 2437, "metformin", "", +79, Type2Diabetes, 2498, 2513, "type 2 diabetes", "", +80, Metformin, 2555, 2564, "metformin", "", +81, PMID, 2610, 2618, "17130197", "", " \"17130197\"." diff --git a/data/dm2 17130197_admin.n-triples b/data/dm2 17130197_admin.n-triples new file mode 100644 index 0000000..5bd8a2f --- /dev/null +++ b/data/dm2 17130197_admin.n-triples @@ -0,0 +1,254 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone ." . + "Charbonnel B" . + "2006" . + "Diabetes Care" . + "17130197" . + . + "Karasik A" . + "Liu J" . + "Wu M" . + "Meininger G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , added to ongoing metformin therapy ," . + "701" . + "24 weeks" . + . + . + . + . + "Sitagliptin 100 mg once - daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone ." . + . + . + . + . + . + "were assessed in patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone ." . + . + . +# RDF export of group: Population + . + "Population " . + "patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone" . + . + . + "19" . + "78" . + . + "with mild to moderate hyperglycemia ( mean A1C 8 . 0 % ) receiving ongoing metformin ( > or = 1 , 500 mg / day )" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint pbg" . + . + . + . + . + . + "Endpoint fi " . + . + . + . + . + . + . + "Endpoint fcpeptide" . + . + . + . + . + . + . + "Endpoint fptir" . + . + . + . + . + . + . + "Endpoint pi" . + . + . + . + . + . + . + "Endpoint cpeptide" . + . + . + . + . + . + . + "Endpoint piAUC..." . + . + . + . + . + . + . + "Endpoint hmao b cell f" . + . + . + . + . + . + . + "Endpoint qisci" . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint g aes" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm p" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s + m" . + . + "once - daily" . + . + . + "Intervention p + m" . + . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s" . + . + "8 . 0" . + . + "Outcome hba1c p " . + . + "8 . 0" . + . + "Outcome fi s" . + . + "were significantly improved" . + . + "Outcome fcpeptide s" . + . + "were significantly improved" . + . + "Outcome fptir s" . + . + "were significantly improved" . + . + "Outcome pi s" . + . + "were significantly improved" . + . + "Outcome cpeptide s" . + . + "were significantly improved" . + . + "Outcome piAUC s" . + . + "were significantly improved" . + . + "Outcome hmao beta cell s" . + . + "were significantly improved" . + . + "Outcome qisci s" . + . + "were significantly improved" . + . + "Outcome hba1c target s" . + . + "47 . 0" . + . + "Outcome hba1c target p" . + . + "18 . 3" . + . + "Outcome h s " . + . + "There was no increased risk" . + . + "Outcome g aes s" . + . + "There was no increased risk" . + . + "Outcome weight both drugs" . + . + "decreased similarly with sitagliptin and placebo" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 65" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17130197_akramersunderbrink.annodb b/data/dm2 17130197_akramersunderbrink.annodb new file mode 100644 index 0000000..b73dded --- /dev/null +++ b/data/dm2 17130197_akramersunderbrink.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9796, Journal, 0, 13, "Diabetes Care", "", +9797, PublicationYear, 16, 20, "2006", "", +9803, Title, 51, 237, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone", "", +9798, Sitagliptin, 113, 124, "sitagliptin", "", +9799, Metformin, 142, 151, "metformin", "", +9800, Type2Diabetes, 177, 192, "type 2 diabetes", "", +9802, Precondition, 193, 237, "inadequately controlled with metformin alone", "", +9801, Metformin, 222, 231, "metformin", "", +9804, Author, 240, 252, "Charbonnel B", "", +9805, Author, 261, 270, "Karasik A", "", +9806, Author, 273, 278, "Liu J", "", +9807, Author, 281, 285, "Wu M", "", +9808, Author, 288, 299, "Meininger G", "", +9809, France, 404, 410, "France", "", +9819, ObjectiveDescription, 501, 755, "The efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , added to ongoing metformin therapy , were assessed in patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with", "", +9810, Sitagliptin, 569, 580, "sitagliptin", "", +9811, Metformin, 600, 609, "metformin", "", +9812, Type2Diabetes, 651, 666, "type 2 diabetes", "", +9813, Precondition, 667, 771, "who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone", "", +9814, Metformin, 756, 765, "metformin", "", +9820, ObjectiveDescription, 756, 771, "metformin alone", "", +9815, Metformin, 858, 867, "metformin", "", +9818, Duration, 914, 922, "2 - week", "", +9816, Blind, 925, 939, "single - blind", "", +9817, Placebo, 942, 949, "placebo", "", +9821, NumberPatientsCT, 968, 971, "701", "", +9822, MinAge, 988, 990, "19", "", +9823, MaxAge, 993, 995, "78", "", +9824, Precondition, 1004, 1060, "with mild to moderate hyperglycemia ( mean A1C 8 . 0 % )", "", +9826, Precondition, 1061, 1116, "receiving ongoing metformin ( > or = 1 , 500 mg / day )", "", +9825, Metformin, 1079, 1088, "metformin", "", +9827, Randomized, 1122, 1130, "randomly", "", +9828, Placebo, 1167, 1174, "placebo", "", +9829, Sitagliptin, 1178, 1189, "sitagliptin", "", +9830, DoseValue, 1190, 1193, "100", "", +9831, mg, 1194, 1196, "mg", "", +9832, Frequency, 1197, 1209, "once - daily", "", +9833, Duration, 1231, 1239, "24 weeks", "", +9834, Pioglitazone, 1317, 1329, "pioglitazone", "", +39131, TimePoint, 1342, 1358, "end of the study", "", +9835, TimePoint, 1516, 1523, "week 24", "", +9836, Sitagliptin, 1526, 1537, "sitagliptin", "", +9837, Placebo, 1592, 1599, "placebo", "", +9838, HbA1c, 1603, 1606, "A1C", "", +9839, DiffGroupAbsValue, 1609, 1617, "- 0 . 65", "", +9840, Percentage, 1618, 1619, "%", "", +9841, FastingPlasmaGlucose, 1624, 1646, "fasting plasma glucose", "", +9842, InsulinDose, 1653, 1675, "2 - h postmeal glucose", "", +9843, EndPointDescription, 1678, 1693, "Fasting insulin", "", +9844, EndPointDescription, 1696, 1715, "fasting C - peptide", "", +9845, EndPointDescription, 1718, 1757, "fasting proinsulin - to - insulin ratio", "", +9846, EndPointDescription, 1760, 1776, "postmeal insulin", "", +9847, EndPointDescription, 1781, 1823, "C - peptide areas under the curve ( AUCs )", "", +9848, EndPointDescription, 1826, 1871, "postmeal insulin AUC - to - glucose AUC ratio", "", +9849, EndPointDescription, 1874, 1926, "homeostasis model assessment of beta - cell function", "", +9850, EndPointDescription, 1933, 1977, "quantitative insulin sensitivity check index", "", +9851, ObservedResult, 1983, 2005, "significantly improved", "", +9852, Sitagliptin, 2011, 2022, "sitagliptin", "", +9853, Placebo, 2035, 2042, "placebo", "", +9854, EndPointDescription, 2104, 2113, "A1C < 7 %", "", +9855, Sitagliptin, 2119, 2130, "sitagliptin", "", +9856, PercentageAffected, 2133, 2139, "47 . 0", "", +9857, Percentage, 2140, 2141, "%", "", +9858, Placebo, 2154, 2161, "placebo", "", +9859, PercentageAffected, 2164, 2170, "18 . 3", "", +9860, Percentage, 2171, 2172, "%", "", +9877, ObservedResult, 2177, 2299, "There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo", "", +9861, Hypoglycemia, 2200, 2220, "risk of hypoglycemia", "", +9862, EndPointDescription, 2224, 2260, "gastrointestinal adverse experiences", "", +9863, Sitagliptin, 2266, 2277, "sitagliptin", "", +9864, Placebo, 2292, 2299, "placebo", "", +9865, BodyWeight, 2302, 2313, "Body weight", "", +9878, ObservedResult, 2302, 2362, "Body weight decreased similarly with sitagliptin and placebo", "", +9866, Sitagliptin, 2339, 2350, "sitagliptin", "", +9867, Placebo, 2355, 2362, "placebo", "", +9868, Sitagliptin, 2379, 2390, "Sitagliptin", "", +9876, ConclusionComment, 2379, 2570, "Sitagliptin 100 mg once - daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone", "", +9869, DoseValue, 2391, 2394, "100", "", +9870, mg, 2395, 2397, "mg", "", +9871, Frequency, 2398, 2410, "once - daily", "", +9872, Metformin, 2428, 2437, "metformin", "", +9873, Type2Diabetes, 2498, 2513, "type 2 diabetes", "", +9874, Metformin, 2555, 2564, "metformin", "", +9875, PMID, 2610, 2618, "17130197", "", diff --git a/data/dm2 17130197_akramersunderbrink.n-triples b/data/dm2 17130197_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17130197_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17130197_export.csv b/data/dm2 17130197_export.csv new file mode 100644 index 0000000..242eb97 --- /dev/null +++ b/data/dm2 17130197_export.csv @@ -0,0 +1,510 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +359, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +359, 1, 2, 2, 9, 13, 9, 13, "Care" +359, 1, 3, 3, 14, 15, 14, 15, "." +359, 2, 1, 4, 0, 4, 16, 20, "2006" +359, 2, 2, 5, 5, 8, 21, 24, "Dec" +359, 2, 3, 6, 9, 10, 25, 26, ";" +359, 2, 4, 7, 11, 13, 27, 29, "29" +359, 2, 5, 8, 14, 15, 30, 31, "(" +359, 2, 6, 9, 16, 18, 32, 34, "12" +359, 2, 7, 10, 19, 20, 35, 36, ")" +359, 2, 8, 11, 21, 22, 37, 38, ":" +359, 2, 9, 12, 23, 27, 39, 43, "2638" +359, 2, 10, 13, 28, 29, 44, 45, "-" +359, 2, 11, 14, 30, 32, 46, 48, "43" +359, 2, 12, 15, 33, 34, 49, 50, "." +359, 3, 1, 16, 0, 8, 51, 59, "Efficacy" +359, 3, 2, 17, 9, 12, 60, 63, "and" +359, 3, 3, 18, 13, 19, 64, 70, "safety" +359, 3, 4, 19, 20, 22, 71, 73, "of" +359, 3, 5, 20, 23, 26, 74, 77, "the" +359, 3, 6, 21, 27, 37, 78, 88, "dipeptidyl" +359, 3, 7, 22, 38, 47, 89, 98, "peptidase" +359, 3, 8, 23, 48, 49, 99, 100, "-" +359, 3, 9, 24, 50, 51, 101, 102, "4" +359, 3, 10, 25, 52, 61, 103, 112, "inhibitor" +359, 3, 11, 26, 62, 73, 113, 124, "sitagliptin" +359, 3, 12, 27, 74, 79, 125, 130, "added" +359, 3, 13, 28, 80, 82, 131, 133, "to" +359, 3, 14, 29, 83, 90, 134, 141, "ongoing" +359, 3, 15, 30, 91, 100, 142, 151, "metformin" +359, 3, 16, 31, 101, 108, 152, 159, "therapy" +359, 3, 17, 32, 109, 111, 160, 162, "in" +359, 3, 18, 33, 112, 120, 163, 171, "patients" +359, 3, 19, 34, 121, 125, 172, 176, "with" +359, 3, 20, 35, 126, 130, 177, 181, "type" +359, 3, 21, 36, 131, 132, 182, 183, "2" +359, 3, 22, 37, 133, 141, 184, 192, "diabetes" +359, 3, 23, 38, 142, 154, 193, 205, "inadequately" +359, 3, 24, 39, 155, 165, 206, 216, "controlled" +359, 3, 25, 40, 166, 170, 217, 221, "with" +359, 3, 26, 41, 171, 180, 222, 231, "metformin" +359, 3, 27, 42, 181, 186, 232, 237, "alone" +359, 3, 28, 43, 187, 188, 238, 239, "." +359, 4, 1, 44, 0, 10, 240, 250, "Charbonnel" +359, 4, 2, 45, 11, 12, 251, 252, "B" +359, 4, 3, 46, 13, 14, 253, 254, "(" +359, 4, 4, 47, 15, 16, 255, 256, "1" +359, 4, 5, 48, 17, 18, 257, 258, ")" +359, 4, 6, 49, 19, 20, 259, 260, "," +359, 4, 7, 50, 21, 28, 261, 268, "Karasik" +359, 4, 8, 51, 29, 30, 269, 270, "A" +359, 4, 9, 52, 31, 32, 271, 272, "," +359, 4, 10, 53, 33, 36, 273, 276, "Liu" +359, 4, 11, 54, 37, 38, 277, 278, "J" +359, 4, 12, 55, 39, 40, 279, 280, "," +359, 4, 13, 56, 41, 43, 281, 283, "Wu" +359, 4, 14, 57, 44, 45, 284, 285, "M" +359, 4, 15, 58, 46, 47, 286, 287, "," +359, 4, 16, 59, 48, 57, 288, 297, "Meininger" +359, 4, 17, 60, 58, 59, 298, 299, "G" +359, 4, 18, 61, 60, 61, 300, 301, ";" +359, 4, 19, 62, 62, 73, 302, 313, "Sitagliptin" +359, 4, 20, 63, 74, 79, 314, 319, "Study" +359, 4, 21, 64, 80, 83, 320, 323, "020" +359, 4, 22, 65, 84, 89, 324, 329, "Group" +359, 4, 23, 66, 90, 91, 330, 331, "." +359, 5, 1, 67, 0, 6, 332, 338, "Author" +359, 5, 2, 68, 7, 18, 339, 350, "information" +359, 5, 3, 69, 19, 20, 351, 352, ":" +359, 5, 4, 70, 21, 22, 353, 354, "(" +359, 5, 5, 71, 23, 24, 355, 356, "1" +359, 5, 6, 72, 25, 26, 357, 358, ")" +359, 5, 7, 73, 27, 33, 359, 365, "Center" +359, 5, 8, 74, 34, 45, 366, 377, "Hospitalier" +359, 5, 9, 75, 46, 59, 378, 391, "Universitaire" +359, 5, 10, 76, 60, 62, 392, 394, "de" +359, 5, 11, 77, 63, 69, 395, 401, "Nantes" +359, 5, 12, 78, 70, 71, 402, 403, "," +359, 5, 13, 79, 72, 78, 404, 410, "France" +359, 5, 14, 80, 79, 80, 411, 412, "." +359, 6, 1, 81, 0, 7, 413, 420, "Comment" +359, 6, 2, 82, 8, 10, 421, 423, "in" +359, 6, 3, 83, 11, 14, 424, 427, "Nat" +359, 6, 4, 84, 15, 19, 428, 432, "Clin" +359, 6, 5, 85, 20, 25, 433, 438, "Pract" +359, 6, 6, 86, 26, 36, 439, 449, "Endocrinol" +359, 6, 7, 87, 37, 42, 450, 455, "Metab" +359, 6, 8, 88, 43, 44, 456, 457, "." +359, 7, 1, 89, 0, 4, 458, 462, "2007" +359, 7, 2, 90, 5, 8, 463, 466, "Jun" +359, 7, 3, 91, 9, 10, 467, 468, ";" +359, 7, 4, 92, 11, 12, 469, 470, "3" +359, 7, 5, 93, 13, 14, 471, 472, "(" +359, 7, 6, 94, 15, 16, 473, 474, "6" +359, 7, 7, 95, 17, 18, 475, 476, ")" +359, 7, 8, 96, 19, 20, 477, 478, ":" +359, 7, 9, 97, 21, 24, 479, 482, "450" +359, 7, 10, 98, 25, 26, 483, 484, "-" +359, 7, 11, 99, 27, 28, 485, 486, "1" +359, 7, 12, 100, 29, 30, 487, 488, "." +359, 8, 1, 101, 0, 9, 489, 498, "OBJECTIVE" +359, 8, 2, 102, 10, 11, 499, 500, ":" +359, 8, 3, 103, 12, 15, 501, 504, "The" +359, 8, 4, 104, 16, 24, 505, 513, "efficacy" +359, 8, 5, 105, 25, 28, 514, 517, "and" +359, 8, 6, 106, 29, 35, 518, 524, "safety" +359, 8, 7, 107, 36, 38, 525, 527, "of" +359, 8, 8, 108, 39, 42, 528, 531, "the" +359, 8, 9, 109, 43, 53, 532, 542, "dipeptidyl" +359, 8, 10, 110, 54, 63, 543, 552, "peptidase" +359, 8, 11, 111, 64, 65, 553, 554, "-" +359, 8, 12, 112, 66, 67, 555, 556, "4" +359, 8, 13, 113, 68, 77, 557, 566, "inhibitor" +359, 8, 14, 114, 78, 79, 567, 568, "," +359, 8, 15, 115, 80, 91, 569, 580, "sitagliptin" +359, 8, 16, 116, 92, 93, 581, 582, "," +359, 8, 17, 117, 94, 99, 583, 588, "added" +359, 8, 18, 118, 100, 102, 589, 591, "to" +359, 8, 19, 119, 103, 110, 592, 599, "ongoing" +359, 8, 20, 120, 111, 120, 600, 609, "metformin" +359, 8, 21, 121, 121, 128, 610, 617, "therapy" +359, 8, 22, 122, 129, 130, 618, 619, "," +359, 8, 23, 123, 131, 135, 620, 624, "were" +359, 8, 24, 124, 136, 144, 625, 633, "assessed" +359, 8, 25, 125, 145, 147, 634, 636, "in" +359, 8, 26, 126, 148, 156, 637, 645, "patients" +359, 8, 27, 127, 157, 161, 646, 650, "with" +359, 8, 28, 128, 162, 166, 651, 655, "type" +359, 8, 29, 129, 167, 168, 656, 657, "2" +359, 8, 30, 130, 169, 177, 658, 666, "diabetes" +359, 8, 31, 131, 178, 181, 667, 670, "who" +359, 8, 32, 132, 182, 185, 671, 674, "had" +359, 8, 33, 133, 186, 196, 675, 685, "inadequate" +359, 8, 34, 134, 197, 205, 686, 694, "glycemic" +359, 8, 35, 135, 206, 213, 695, 702, "control" +359, 8, 36, 136, 214, 215, 703, 704, "(" +359, 8, 37, 137, 216, 219, 705, 708, "HbA" +359, 8, 38, 138, 220, 221, 709, 710, "(" +359, 8, 39, 139, 222, 224, 711, 713, "1c" +359, 8, 40, 140, 225, 226, 714, 715, ")" +359, 8, 41, 141, 227, 228, 716, 717, "[" +359, 8, 42, 142, 229, 232, 718, 721, "A1C" +359, 8, 43, 143, 233, 234, 722, 723, "]" +359, 8, 44, 144, 235, 236, 724, 725, ">" +359, 8, 45, 145, 237, 239, 726, 728, "or" +359, 8, 46, 146, 240, 241, 729, 730, "=" +359, 8, 47, 147, 242, 243, 731, 732, "7" +359, 8, 48, 148, 244, 247, 733, 736, "and" +359, 8, 49, 149, 248, 249, 737, 738, "<" +359, 8, 50, 150, 250, 252, 739, 741, "or" +359, 8, 51, 151, 253, 254, 742, 743, "=" +359, 8, 52, 152, 255, 257, 744, 746, "10" +359, 8, 53, 153, 258, 259, 747, 748, "%" +359, 8, 54, 154, 260, 261, 749, 750, ")" +359, 8, 55, 155, 262, 266, 751, 755, "with" +359, 8, 56, 156, 267, 276, 756, 765, "metformin" +359, 8, 57, 157, 277, 282, 766, 771, "alone" +359, 8, 58, 158, 283, 284, 772, 773, "." +359, 9, 1, 159, 0, 8, 774, 782, "RESEARCH" +359, 9, 2, 160, 9, 15, 783, 789, "DESIGN" +359, 9, 3, 161, 16, 19, 790, 793, "AND" +359, 9, 4, 162, 20, 27, 794, 801, "METHODS" +359, 9, 5, 163, 28, 29, 802, 803, ":" +359, 9, 6, 164, 30, 35, 804, 809, "After" +359, 9, 7, 165, 36, 37, 810, 811, "a" +359, 9, 8, 166, 38, 47, 812, 821, "screening" +359, 9, 9, 167, 48, 52, 822, 826, "diet" +359, 9, 10, 168, 53, 54, 827, 828, "/" +359, 9, 11, 169, 55, 63, 829, 837, "exercise" +359, 9, 12, 170, 64, 67, 838, 841, "run" +359, 9, 13, 171, 68, 69, 842, 843, "-" +359, 9, 14, 172, 70, 72, 844, 846, "in" +359, 9, 15, 173, 73, 79, 847, 853, "period" +359, 9, 16, 174, 80, 81, 854, 855, "," +359, 9, 17, 175, 82, 83, 856, 857, "a" +359, 9, 18, 176, 84, 93, 858, 867, "metformin" +359, 9, 19, 177, 94, 98, 868, 872, "dose" +359, 9, 20, 178, 99, 108, 873, 882, "titration" +359, 9, 21, 179, 109, 110, 883, 884, "/" +359, 9, 22, 180, 111, 124, 885, 898, "stabilization" +359, 9, 23, 181, 125, 131, 899, 905, "period" +359, 9, 24, 182, 132, 133, 906, 907, "," +359, 9, 25, 183, 134, 137, 908, 911, "and" +359, 9, 26, 184, 138, 139, 912, 913, "a" +359, 9, 27, 185, 140, 141, 914, 915, "2" +359, 9, 28, 186, 142, 143, 916, 917, "-" +359, 9, 29, 187, 144, 148, 918, 922, "week" +359, 9, 30, 188, 149, 150, 923, 924, "," +359, 9, 31, 189, 151, 157, 925, 931, "single" +359, 9, 32, 190, 158, 159, 932, 933, "-" +359, 9, 33, 191, 160, 165, 934, 939, "blind" +359, 9, 34, 192, 166, 167, 940, 941, "," +359, 9, 35, 193, 168, 175, 942, 949, "placebo" +359, 9, 36, 194, 176, 179, 950, 953, "run" +359, 9, 37, 195, 180, 181, 954, 955, "-" +359, 9, 38, 196, 182, 184, 956, 958, "in" +359, 9, 39, 197, 185, 191, 959, 965, "period" +359, 9, 40, 198, 192, 193, 966, 967, "," +359, 9, 41, 199, 194, 197, 968, 971, "701" +359, 9, 42, 200, 198, 206, 972, 980, "patients" +359, 9, 43, 201, 207, 208, 981, 982, "," +359, 9, 44, 202, 209, 213, 983, 987, "aged" +359, 9, 45, 203, 214, 216, 988, 990, "19" +359, 9, 46, 204, 217, 218, 991, 992, "-" +359, 9, 47, 205, 219, 221, 993, 995, "78" +359, 9, 48, 206, 222, 227, 996, 1001, "years" +359, 9, 49, 207, 228, 229, 1002, 1003, "," +359, 9, 50, 208, 230, 234, 1004, 1008, "with" +359, 9, 51, 209, 235, 239, 1009, 1013, "mild" +359, 9, 52, 210, 240, 242, 1014, 1016, "to" +359, 9, 53, 211, 243, 251, 1017, 1025, "moderate" +359, 9, 54, 212, 252, 265, 1026, 1039, "hyperglycemia" +359, 9, 55, 213, 266, 267, 1040, 1041, "(" +359, 9, 56, 214, 268, 272, 1042, 1046, "mean" +359, 9, 57, 215, 273, 276, 1047, 1050, "A1C" +359, 9, 58, 216, 277, 278, 1051, 1052, "8" +359, 9, 59, 217, 279, 280, 1053, 1054, "." +359, 9, 60, 218, 281, 282, 1055, 1056, "0" +359, 9, 61, 219, 283, 284, 1057, 1058, "%" +359, 9, 62, 220, 285, 286, 1059, 1060, ")" +359, 9, 63, 221, 287, 296, 1061, 1070, "receiving" +359, 9, 64, 222, 297, 304, 1071, 1078, "ongoing" +359, 9, 65, 223, 305, 314, 1079, 1088, "metformin" +359, 9, 66, 224, 315, 316, 1089, 1090, "(" +359, 9, 67, 225, 317, 318, 1091, 1092, ">" +359, 9, 68, 226, 319, 321, 1093, 1095, "or" +359, 9, 69, 227, 322, 323, 1096, 1097, "=" +359, 9, 70, 228, 324, 325, 1098, 1099, "1" +359, 9, 71, 229, 326, 327, 1100, 1101, "," +359, 9, 72, 230, 328, 331, 1102, 1105, "500" +359, 9, 73, 231, 332, 334, 1106, 1108, "mg" +359, 9, 74, 232, 335, 336, 1109, 1110, "/" +359, 9, 75, 233, 337, 340, 1111, 1114, "day" +359, 9, 76, 234, 341, 342, 1115, 1116, ")" +359, 9, 77, 235, 343, 347, 1117, 1121, "were" +359, 9, 78, 236, 348, 356, 1122, 1130, "randomly" +359, 9, 79, 237, 357, 365, 1131, 1139, "assigned" +359, 9, 80, 238, 366, 368, 1140, 1142, "to" +359, 9, 81, 239, 369, 376, 1143, 1150, "receive" +359, 9, 82, 240, 377, 380, 1151, 1154, "the" +359, 9, 83, 241, 381, 389, 1155, 1163, "addition" +359, 9, 84, 242, 390, 392, 1164, 1166, "of" +359, 9, 85, 243, 393, 400, 1167, 1174, "placebo" +359, 9, 86, 244, 401, 403, 1175, 1177, "or" +359, 9, 87, 245, 404, 415, 1178, 1189, "sitagliptin" +359, 9, 88, 246, 416, 419, 1190, 1193, "100" +359, 9, 89, 247, 420, 422, 1194, 1196, "mg" +359, 9, 90, 248, 423, 427, 1197, 1201, "once" +359, 9, 91, 249, 428, 429, 1202, 1203, "-" +359, 9, 92, 250, 430, 435, 1204, 1209, "daily" +359, 9, 93, 251, 436, 438, 1210, 1212, "in" +359, 9, 94, 252, 439, 440, 1213, 1214, "a" +359, 9, 95, 253, 441, 442, 1215, 1216, "1" +359, 9, 96, 254, 443, 444, 1217, 1218, ":" +359, 9, 97, 255, 445, 446, 1219, 1220, "2" +359, 9, 98, 256, 447, 452, 1221, 1226, "ratio" +359, 9, 99, 257, 453, 456, 1227, 1230, "for" +359, 9, 100, 258, 457, 459, 1231, 1233, "24" +359, 9, 101, 259, 460, 465, 1234, 1239, "weeks" +359, 9, 102, 260, 466, 467, 1240, 1241, "." +359, 10, 1, 261, 0, 8, 1242, 1250, "Patients" +359, 10, 2, 262, 9, 18, 1251, 1260, "exceeding" +359, 10, 3, 263, 19, 27, 1261, 1269, "specific" +359, 10, 4, 264, 28, 36, 1270, 1278, "glycemic" +359, 10, 5, 265, 37, 43, 1279, 1285, "limits" +359, 10, 6, 266, 44, 48, 1286, 1290, "were" +359, 10, 7, 267, 49, 57, 1291, 1299, "provided" +359, 10, 8, 268, 58, 64, 1300, 1306, "rescue" +359, 10, 9, 269, 65, 72, 1307, 1314, "therapy" +359, 10, 10, 270, 73, 74, 1315, 1316, "(" +359, 10, 11, 271, 75, 87, 1317, 1329, "pioglitazone" +359, 10, 12, 272, 88, 89, 1330, 1331, ")" +359, 10, 13, 273, 90, 95, 1332, 1337, "until" +359, 10, 14, 274, 96, 99, 1338, 1341, "the" +359, 10, 15, 275, 100, 103, 1342, 1345, "end" +359, 10, 16, 276, 104, 106, 1346, 1348, "of" +359, 10, 17, 277, 107, 110, 1349, 1352, "the" +359, 10, 18, 278, 111, 116, 1353, 1358, "study" +359, 10, 19, 279, 117, 118, 1359, 1360, "." +359, 11, 1, 280, 0, 3, 1361, 1364, "The" +359, 11, 2, 281, 4, 12, 1365, 1373, "efficacy" +359, 11, 3, 282, 13, 21, 1374, 1382, "analyses" +359, 11, 4, 283, 22, 26, 1383, 1387, "were" +359, 11, 5, 284, 27, 32, 1388, 1393, "based" +359, 11, 6, 285, 33, 35, 1394, 1396, "on" +359, 11, 7, 286, 36, 38, 1397, 1399, "an" +359, 11, 8, 287, 39, 42, 1400, 1403, "all" +359, 11, 9, 288, 43, 44, 1404, 1405, "-" +359, 11, 10, 289, 45, 53, 1406, 1414, "patients" +359, 11, 11, 290, 54, 55, 1415, 1416, "-" +359, 11, 12, 291, 56, 63, 1417, 1424, "treated" +359, 11, 13, 292, 64, 74, 1425, 1435, "population" +359, 11, 14, 293, 75, 80, 1436, 1441, "using" +359, 11, 15, 294, 81, 83, 1442, 1444, "an" +359, 11, 16, 295, 84, 90, 1445, 1451, "ANCOVA" +359, 11, 17, 296, 91, 94, 1452, 1455, "and" +359, 11, 18, 297, 95, 103, 1456, 1464, "excluded" +359, 11, 19, 298, 104, 108, 1465, 1469, "data" +359, 11, 20, 299, 109, 117, 1470, 1478, "obtained" +359, 11, 21, 300, 118, 123, 1479, 1484, "after" +359, 11, 22, 301, 124, 132, 1485, 1493, "glycemic" +359, 11, 23, 302, 133, 139, 1494, 1500, "rescue" +359, 11, 24, 303, 140, 141, 1501, 1502, "." +359, 12, 1, 304, 0, 7, 1503, 1510, "RESULTS" +359, 12, 2, 305, 8, 9, 1511, 1512, ":" +359, 12, 3, 306, 10, 12, 1513, 1515, "At" +359, 12, 4, 307, 13, 17, 1516, 1520, "week" +359, 12, 5, 308, 18, 20, 1521, 1523, "24" +359, 12, 6, 309, 21, 22, 1524, 1525, "," +359, 12, 7, 310, 23, 34, 1526, 1537, "sitagliptin" +359, 12, 8, 311, 35, 44, 1538, 1547, "treatment" +359, 12, 9, 312, 45, 48, 1548, 1551, "led" +359, 12, 10, 313, 49, 51, 1552, 1554, "to" +359, 12, 11, 314, 52, 63, 1555, 1566, "significant" +359, 12, 12, 315, 64, 74, 1567, 1577, "reductions" +359, 12, 13, 316, 75, 83, 1578, 1586, "compared" +359, 12, 14, 317, 84, 88, 1587, 1591, "with" +359, 12, 15, 318, 89, 96, 1592, 1599, "placebo" +359, 12, 16, 319, 97, 99, 1600, 1602, "in" +359, 12, 17, 320, 100, 103, 1603, 1606, "A1C" +359, 12, 18, 321, 104, 105, 1607, 1608, "(" +359, 12, 19, 322, 106, 107, 1609, 1610, "-" +359, 12, 20, 323, 108, 109, 1611, 1612, "0" +359, 12, 21, 324, 110, 111, 1613, 1614, "." +359, 12, 22, 325, 112, 114, 1615, 1617, "65" +359, 12, 23, 326, 115, 116, 1618, 1619, "%" +359, 12, 24, 327, 117, 118, 1620, 1621, ")" +359, 12, 25, 328, 119, 120, 1622, 1623, "," +359, 12, 26, 329, 121, 128, 1624, 1631, "fasting" +359, 12, 27, 330, 129, 135, 1632, 1638, "plasma" +359, 12, 28, 331, 136, 143, 1639, 1646, "glucose" +359, 12, 29, 332, 144, 145, 1647, 1648, "," +359, 12, 30, 333, 146, 149, 1649, 1652, "and" +359, 12, 31, 334, 150, 151, 1653, 1654, "2" +359, 12, 32, 335, 152, 153, 1655, 1656, "-" +359, 12, 33, 336, 154, 155, 1657, 1658, "h" +359, 12, 34, 337, 156, 164, 1659, 1667, "postmeal" +359, 12, 35, 338, 165, 172, 1668, 1675, "glucose" +359, 12, 36, 339, 173, 174, 1676, 1677, "." +359, 13, 1, 340, 0, 7, 1678, 1685, "Fasting" +359, 13, 2, 341, 8, 15, 1686, 1693, "insulin" +359, 13, 3, 342, 16, 17, 1694, 1695, "," +359, 13, 4, 343, 18, 25, 1696, 1703, "fasting" +359, 13, 5, 344, 26, 27, 1704, 1705, "C" +359, 13, 6, 345, 28, 29, 1706, 1707, "-" +359, 13, 7, 346, 30, 37, 1708, 1715, "peptide" +359, 13, 8, 347, 38, 39, 1716, 1717, "," +359, 13, 9, 348, 40, 47, 1718, 1725, "fasting" +359, 13, 10, 349, 48, 58, 1726, 1736, "proinsulin" +359, 13, 11, 350, 59, 60, 1737, 1738, "-" +359, 13, 12, 351, 61, 63, 1739, 1741, "to" +359, 13, 13, 352, 64, 65, 1742, 1743, "-" +359, 13, 14, 353, 66, 73, 1744, 1751, "insulin" +359, 13, 15, 354, 74, 79, 1752, 1757, "ratio" +359, 13, 16, 355, 80, 81, 1758, 1759, "," +359, 13, 17, 356, 82, 90, 1760, 1768, "postmeal" +359, 13, 18, 357, 91, 98, 1769, 1776, "insulin" +359, 13, 19, 358, 99, 102, 1777, 1780, "and" +359, 13, 20, 359, 103, 104, 1781, 1782, "C" +359, 13, 21, 360, 105, 106, 1783, 1784, "-" +359, 13, 22, 361, 107, 114, 1785, 1792, "peptide" +359, 13, 23, 362, 115, 120, 1793, 1798, "areas" +359, 13, 24, 363, 121, 126, 1799, 1804, "under" +359, 13, 25, 364, 127, 130, 1805, 1808, "the" +359, 13, 26, 365, 131, 136, 1809, 1814, "curve" +359, 13, 27, 366, 137, 138, 1815, 1816, "(" +359, 13, 28, 367, 139, 143, 1817, 1821, "AUCs" +359, 13, 29, 368, 144, 145, 1822, 1823, ")" +359, 13, 30, 369, 146, 147, 1824, 1825, "," +359, 13, 31, 370, 148, 156, 1826, 1834, "postmeal" +359, 13, 32, 371, 157, 164, 1835, 1842, "insulin" +359, 13, 33, 372, 165, 168, 1843, 1846, "AUC" +359, 13, 34, 373, 169, 170, 1847, 1848, "-" +359, 13, 35, 374, 171, 173, 1849, 1851, "to" +359, 13, 36, 375, 174, 175, 1852, 1853, "-" +359, 13, 37, 376, 176, 183, 1854, 1861, "glucose" +359, 13, 38, 377, 184, 187, 1862, 1865, "AUC" +359, 13, 39, 378, 188, 193, 1866, 1871, "ratio" +359, 13, 40, 379, 194, 195, 1872, 1873, "," +359, 13, 41, 380, 196, 207, 1874, 1885, "homeostasis" +359, 13, 42, 381, 208, 213, 1886, 1891, "model" +359, 13, 43, 382, 214, 224, 1892, 1902, "assessment" +359, 13, 44, 383, 225, 227, 1903, 1905, "of" +359, 13, 45, 384, 228, 232, 1906, 1910, "beta" +359, 13, 46, 385, 233, 234, 1911, 1912, "-" +359, 13, 47, 386, 235, 239, 1913, 1917, "cell" +359, 13, 48, 387, 240, 248, 1918, 1926, "function" +359, 13, 49, 388, 249, 250, 1927, 1928, "," +359, 13, 50, 389, 251, 254, 1929, 1932, "and" +359, 13, 51, 390, 255, 267, 1933, 1945, "quantitative" +359, 13, 52, 391, 268, 275, 1946, 1953, "insulin" +359, 13, 53, 392, 276, 287, 1954, 1965, "sensitivity" +359, 13, 54, 393, 288, 293, 1966, 1971, "check" +359, 13, 55, 394, 294, 299, 1972, 1977, "index" +359, 13, 56, 395, 300, 304, 1978, 1982, "were" +359, 13, 57, 396, 305, 318, 1983, 1996, "significantly" +359, 13, 58, 397, 319, 327, 1997, 2005, "improved" +359, 13, 59, 398, 328, 332, 2006, 2010, "with" +359, 13, 60, 399, 333, 344, 2011, 2022, "sitagliptin" +359, 13, 61, 400, 345, 353, 2023, 2031, "relative" +359, 13, 62, 401, 354, 356, 2032, 2034, "to" +359, 13, 63, 402, 357, 364, 2035, 2042, "placebo" +359, 13, 64, 403, 365, 366, 2043, 2044, "." +359, 14, 1, 404, 0, 1, 2045, 2046, "A" +359, 14, 2, 405, 2, 15, 2047, 2060, "significantly" +359, 14, 3, 406, 16, 23, 2061, 2068, "greater" +359, 14, 4, 407, 24, 34, 2069, 2079, "proportion" +359, 14, 5, 408, 35, 37, 2080, 2082, "of" +359, 14, 6, 409, 38, 46, 2083, 2091, "patients" +359, 14, 7, 410, 47, 55, 2092, 2100, "achieved" +359, 14, 8, 411, 56, 58, 2101, 2103, "an" +359, 14, 9, 412, 59, 62, 2104, 2107, "A1C" +359, 14, 10, 413, 63, 64, 2108, 2109, "<" +359, 14, 11, 414, 65, 66, 2110, 2111, "7" +359, 14, 12, 415, 67, 68, 2112, 2113, "%" +359, 14, 13, 416, 69, 73, 2114, 2118, "with" +359, 14, 14, 417, 74, 85, 2119, 2130, "sitagliptin" +359, 14, 15, 418, 86, 87, 2131, 2132, "(" +359, 14, 16, 419, 88, 90, 2133, 2135, "47" +359, 14, 17, 420, 91, 92, 2136, 2137, "." +359, 14, 18, 421, 93, 94, 2138, 2139, "0" +359, 14, 19, 422, 95, 96, 2140, 2141, "%" +359, 14, 20, 423, 97, 98, 2142, 2143, ")" +359, 14, 21, 424, 99, 103, 2144, 2148, "than" +359, 14, 22, 425, 104, 108, 2149, 2153, "with" +359, 14, 23, 426, 109, 116, 2154, 2161, "placebo" +359, 14, 24, 427, 117, 118, 2162, 2163, "(" +359, 14, 25, 428, 119, 121, 2164, 2166, "18" +359, 14, 26, 429, 122, 123, 2167, 2168, "." +359, 14, 27, 430, 124, 125, 2169, 2170, "3" +359, 14, 28, 431, 126, 127, 2171, 2172, "%" +359, 14, 29, 432, 128, 129, 2173, 2174, ")" +359, 14, 30, 433, 130, 131, 2175, 2176, "." +359, 15, 1, 434, 0, 5, 2177, 2182, "There" +359, 15, 2, 435, 6, 9, 2183, 2186, "was" +359, 15, 3, 436, 10, 12, 2187, 2189, "no" +359, 15, 4, 437, 13, 22, 2190, 2199, "increased" +359, 15, 5, 438, 23, 27, 2200, 2204, "risk" +359, 15, 6, 439, 28, 30, 2205, 2207, "of" +359, 15, 7, 440, 31, 43, 2208, 2220, "hypoglycemia" +359, 15, 8, 441, 44, 46, 2221, 2223, "or" +359, 15, 9, 442, 47, 63, 2224, 2240, "gastrointestinal" +359, 15, 10, 443, 64, 71, 2241, 2248, "adverse" +359, 15, 11, 444, 72, 83, 2249, 2260, "experiences" +359, 15, 12, 445, 84, 88, 2261, 2265, "with" +359, 15, 13, 446, 89, 100, 2266, 2277, "sitagliptin" +359, 15, 14, 447, 101, 109, 2278, 2286, "compared" +359, 15, 15, 448, 110, 114, 2287, 2291, "with" +359, 15, 16, 449, 115, 122, 2292, 2299, "placebo" +359, 15, 17, 450, 123, 124, 2300, 2301, "." +359, 16, 1, 451, 0, 4, 2302, 2306, "Body" +359, 16, 2, 452, 5, 11, 2307, 2313, "weight" +359, 16, 3, 453, 12, 21, 2314, 2323, "decreased" +359, 16, 4, 454, 22, 31, 2324, 2333, "similarly" +359, 16, 5, 455, 32, 36, 2334, 2338, "with" +359, 16, 6, 456, 37, 48, 2339, 2350, "sitagliptin" +359, 16, 7, 457, 49, 52, 2351, 2354, "and" +359, 16, 8, 458, 53, 60, 2355, 2362, "placebo" +359, 16, 9, 459, 61, 62, 2363, 2364, "." +359, 17, 1, 460, 0, 11, 2365, 2376, "CONCLUSIONS" +359, 17, 2, 461, 12, 13, 2377, 2378, ":" +359, 17, 3, 462, 14, 25, 2379, 2390, "Sitagliptin" +359, 17, 4, 463, 26, 29, 2391, 2394, "100" +359, 17, 5, 464, 30, 32, 2395, 2397, "mg" +359, 17, 6, 465, 33, 37, 2398, 2402, "once" +359, 17, 7, 466, 38, 39, 2403, 2404, "-" +359, 17, 8, 467, 40, 45, 2405, 2410, "daily" +359, 17, 9, 468, 46, 51, 2411, 2416, "added" +359, 17, 10, 469, 52, 54, 2417, 2419, "to" +359, 17, 11, 470, 55, 62, 2420, 2427, "ongoing" +359, 17, 12, 471, 63, 72, 2428, 2437, "metformin" +359, 17, 13, 472, 73, 80, 2438, 2445, "therapy" +359, 17, 14, 473, 81, 84, 2446, 2449, "was" +359, 17, 15, 474, 85, 96, 2450, 2461, "efficacious" +359, 17, 16, 475, 97, 100, 2462, 2465, "and" +359, 17, 17, 476, 101, 105, 2466, 2470, "well" +359, 17, 18, 477, 106, 115, 2471, 2480, "tolerated" +359, 17, 19, 478, 116, 118, 2481, 2483, "in" +359, 17, 20, 479, 119, 127, 2484, 2492, "patients" +359, 17, 21, 480, 128, 132, 2493, 2497, "with" +359, 17, 22, 481, 133, 137, 2498, 2502, "type" +359, 17, 23, 482, 138, 139, 2503, 2504, "2" +359, 17, 24, 483, 140, 148, 2505, 2513, "diabetes" +359, 17, 25, 484, 149, 152, 2514, 2517, "who" +359, 17, 26, 485, 153, 156, 2518, 2521, "had" +359, 17, 27, 486, 157, 167, 2522, 2532, "inadequate" +359, 17, 28, 487, 168, 176, 2533, 2541, "glycemic" +359, 17, 29, 488, 177, 184, 2542, 2549, "control" +359, 17, 30, 489, 185, 189, 2550, 2554, "with" +359, 17, 31, 490, 190, 199, 2555, 2564, "metformin" +359, 17, 32, 491, 200, 205, 2565, 2570, "alone" +359, 17, 33, 492, 206, 207, 2571, 2572, "." +359, 18, 1, 493, 0, 3, 2573, 2576, "DOI" +359, 18, 2, 494, 4, 5, 2577, 2578, ":" +359, 18, 3, 495, 6, 8, 2579, 2581, "10" +359, 18, 4, 496, 9, 10, 2582, 2583, "." +359, 18, 5, 497, 11, 15, 2584, 2588, "2337" +359, 18, 6, 498, 16, 17, 2589, 2590, "/" +359, 18, 7, 499, 18, 22, 2591, 2595, "dc06" +359, 18, 8, 500, 23, 24, 2596, 2597, "-" +359, 18, 9, 501, 25, 29, 2598, 2602, "0706" +359, 18, 10, 502, 30, 34, 2603, 2607, "PMID" +359, 18, 11, 503, 35, 36, 2608, 2609, ":" +359, 18, 12, 504, 37, 45, 2610, 2618, "17130197" +359, 18, 13, 505, 46, 47, 2619, 2620, "[" +359, 18, 14, 506, 48, 55, 2621, 2628, "Indexed" +359, 18, 15, 507, 56, 59, 2629, 2632, "for" +359, 18, 16, 508, 60, 67, 2633, 2640, "MEDLINE" +359, 18, 17, 509, 68, 69, 2641, 2642, "]" diff --git a/data/dm2 17130197_kwoodley.annodb b/data/dm2 17130197_kwoodley.annodb new file mode 100644 index 0000000..bcfc857 --- /dev/null +++ b/data/dm2 17130197_kwoodley.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4155, Journal, 0, 13, "Diabetes Care", "", +4156, PublicationYear, 16, 20, "2006", "", +36860, Title, 51, 239, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone .", "", +10418, Sitagliptin, 113, 124, "sitagliptin", "", +10419, Metformin, 142, 151, "metformin", "", +10422, Precondition, 163, 237, "patients with type 2 diabetes inadequately controlled with metformin alone", "", +10420, Type2Diabetes, 177, 192, "type 2 diabetes", "", +10421, Metformin, 222, 231, "metformin", "", +10424, Author, 240, 252, "Charbonnel B", "", +10425, Author, 261, 270, "Karasik A", "", +10426, Author, 273, 278, "Liu J", "", +10427, Author, 281, 285, "Wu M", "", +10428, Author, 288, 299, "Meininger G", "", +10429, France, 404, 410, "France", "", +10438, ObjectiveDescription, 501, 619, "The efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , added to ongoing metformin therapy ,", "", +10430, Sitagliptin, 569, 580, "sitagliptin", "", +10431, Metformin, 600, 609, "metformin", "", +36861, ObjectiveDescription, 620, 773, "were assessed in patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone .", "", +10437, Precondition, 637, 771, "patients with type 2 diabetes who had inadequate glycemic control ( HbA ( 1c ) [ A1C ] > or = 7 and < or = 10 % ) with metformin alone", "", +10432, Type2Diabetes, 651, 666, "type 2 diabetes", "", +10433, HbA1c, 705, 715, "HbA ( 1c )", "", +10434, HbA1c, 718, 721, "A1C", "", +10435, Percentage, 747, 748, "%", "", +10436, Metformin, 756, 765, "metformin", "", +10442, Metformin, 858, 867, "metformin", "", +10443, NumberPatientsCT, 968, 971, "701", "", +10444, MinAge, 988, 990, "19", "", +10445, MaxAge, 993, 995, "78", "", +10462, Precondition, 1004, 1116, "with mild to moderate hyperglycemia ( mean A1C 8 . 0 % ) receiving ongoing metformin ( > or = 1 , 500 mg / day )", "", +10446, Hypoglycemia, 1026, 1039, "hyperglycemia", "", +10447, HbA1c, 1047, 1050, "A1C", "", +36862, BaseLineValue, 1051, 1056, "8 . 0", "", +10449, Percentage, 1057, 1058, "%", "", +10450, Metformin, 1079, 1088, "metformin", "", +10451, DoseValue, 1091, 1105, "> or = 1 , 500", "", +10452, mg, 1106, 1108, "mg", "", +10453, Frequency, 1111, 1114, "day", "", +10454, Randomized, 1122, 1130, "randomly", "", +10455, Placebo, 1167, 1174, "placebo", "", +10456, Sitagliptin, 1178, 1189, "sitagliptin", "", +10457, DoseValue, 1190, 1193, "100", "", +10458, mg, 1194, 1196, "mg", "", +10459, Frequency, 1197, 1209, "once - daily", "", +10460, AllocationRatio, 1215, 1220, "1 : 2", "", +10461, Duration, 1231, 1239, "24 weeks", "", +36863, TimePoint, 1516, 1523, "week 24", "", +10464, Sitagliptin, 1526, 1537, "sitagliptin", "", +10465, Placebo, 1592, 1599, "placebo", "", +10466, HbA1c, 1603, 1606, "A1C", "", +10468, DiffGroupAbsValue, 1609, 1617, "- 0 . 65", "", +10467, Percentage, 1618, 1619, "%", "", +10469, FastingPlasmaGlucose, 1624, 1646, "fasting plasma glucose", "", +36864, PostprandialBloodGlucose, 1653, 1675, "2 - h postmeal glucose", "", +10473, EndPointDescription, 1678, 1693, "Fasting insulin", "", +10474, EndPointDescription, 1696, 1715, "fasting C - peptide", "", +10475, EndPointDescription, 1718, 1757, "fasting proinsulin - to - insulin ratio", "", +10476, EndPointDescription, 1760, 1776, "postmeal insulin", "", +10477, EndPointDescription, 1781, 1814, "C - peptide areas under the curve", "", +10478, EndPointDescription, 1817, 1821, "AUCs", "", +10479, EndPointDescription, 1826, 1871, "postmeal insulin AUC - to - glucose AUC ratio", "", +10480, EndPointDescription, 1874, 1926, "homeostasis model assessment of beta - cell function", "", +10481, EndPointDescription, 1933, 1977, "quantitative insulin sensitivity check index", "", +10482, ObservedResult, 1978, 2005, "were significantly improved", "", +10483, Sitagliptin, 2011, 2022, "sitagliptin", "", +10485, Placebo, 2035, 2042, "placebo", "", +10487, HbA1c_target, 2104, 2113, "A1C < 7 %", "", +10488, Sitagliptin, 2119, 2130, "sitagliptin", "", +10489, PercentageAffected, 2133, 2139, "47 . 0", "", +10491, Placebo, 2154, 2161, "placebo", "", +10490, PercentageAffected, 2164, 2170, "18 . 3", "", +10496, ObservedResult, 2177, 2204, "There was no increased risk", "", +10492, Hypoglycemia, 2208, 2220, "hypoglycemia", "", +10493, GastrointestinalProblem, 2224, 2260, "gastrointestinal adverse experiences", "", +10494, Sitagliptin, 2266, 2277, "sitagliptin", "", +10495, Placebo, 2292, 2299, "placebo", "", +10497, BodyWeight, 2302, 2313, "Body weight", "", +10498, ObservedResult, 2314, 2323, "decreased", "", +10499, Sitagliptin, 2339, 2350, "sitagliptin", "", +10500, Placebo, 2355, 2362, "placebo", "", +36865, ConclusionComment, 2379, 2572, "Sitagliptin 100 mg once - daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone .", "", +10501, Sitagliptin, 2379, 2390, "Sitagliptin", "", +10502, DoseValue, 2391, 2394, "100", "", +10503, mg, 2395, 2397, "mg", "", +10504, Frequency, 2398, 2410, "once - daily", "", +10505, Metformin, 2428, 2437, "metformin", "", +10508, Precondition, 2484, 2570, "patients with type 2 diabetes who had inadequate glycemic control with metformin alone", "", +10506, Type2Diabetes, 2498, 2513, "type 2 diabetes", "", +10507, Metformin, 2555, 2564, "metformin", "", +10510, PMID, 2610, 2618, "17130197", "", diff --git a/data/dm2 17130197_kwoodley.n-triples b/data/dm2 17130197_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17130197_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17157112_admin.annodb b/data/dm2 17157112_admin.annodb new file mode 100644 index 0000000..571316c --- /dev/null +++ b/data/dm2 17157112_admin.annodb @@ -0,0 +1,151 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +2, PublicationYear, 12, 16, "2006", "", " \"2006\"." +253, Title, 47, 299, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study .", "", " \"Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study .\"." +3, Sitagliptin, 109, 120, "sitagliptin", "", +4, Pioglitazone, 138, 150, "pioglitazone", "", +5, Type2Diabetes, 176, 191, "type 2 diabetes", "", +6, Duration, 196, 205, "24 - week", "", +7, Multicenter, 208, 219, "multicenter", "", +8, Randomized, 222, 232, "randomized", "", +9, DoubleBlind, 235, 249, "double - blind", "", +10, Placebo, 252, 259, "placebo", "", +11, Parallel, 275, 291, "parallel - group", "", +13, Author, 300, 312, "Rosenstock J", "", " \"Rosenstock J\"." +14, Author, 321, 328, "Brazg R", "", " \"Brazg R\"." +15, Author, 331, 341, "Andryuk PJ", "", " \"Andryuk PJ\"." +16, Author, 344, 348, "Lu K", "", " \"Lu K\"." +17, Author, 351, 358, "Stein P", "", " \"Stein P\"." +18, USA, 474, 477, "USA", "", +159, ObjectiveDescription, 492, 613, "The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy", "", " \"The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy\"." +19, Sitagliptin, 564, 575, "sitagliptin", "", +20, Pioglitazone, 593, 605, "pioglitazone", "", +255, ObjectiveDescription, 614, 810, "were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone .", "", " \"were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone .\"." +158, Precondition, 645, 808, "type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone", "", " \"type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone\"." +21, Type2Diabetes, 645, 660, "type 2 diabetes", "", " ." +153, HbA1c, 695, 718, "glycosylated hemoglobin", "", +154, HbA1c, 721, 731, "HbA ( 1c )", "", +155, Percentage, 743, 744, "%", "", +156, Percentage, 759, 760, "%", "", +23, Pioglitazone, 796, 808, "pioglitazone", "", +26, Duration, 832, 841, "24 - week", "", " \"24 - week\"." +27, Multicenter, 844, 855, "multicenter", "", " ." +28, Randomized, 858, 868, "randomized", "", " ." +29, DoubleBlind, 871, 885, "double - blind", "", " ." +30, Placebo, 888, 895, "placebo", "", +31, Parallel, 911, 925, "parallel group", "", " ." +32, MinAge, 956, 958, "18", "", " \"18\"." +33, Pioglitazone, 1162, 1174, "pioglitazone", "", +35, Duration, 1226, 1242, "8 - to 14 - week", "", +36, OpenLabel, 1243, 1255, "open - label", "", " ." +37, Pioglitazone, 1256, 1268, "pioglitazone", "", +167, HbA1c, 1328, 1338, "HbA ( 1c )", "", +168, Percentage, 1348, 1349, "%", "", +169, Percentage, 1364, 1365, "%", "", +268, TimePoint, 1369, 1391, "the end of this period", "", +38, Duration, 1402, 1410, "2 - week", "", +39, Blind, 1413, 1427, "single - blind", "", " ." +40, Placebo, 1430, 1437, "placebo", "", +41, Duration, 1498, 1506, "21 weeks", "", +43, Pioglitazone, 1543, 1555, "pioglitazone", "", +44, DoseValue, 1570, 1572, "30", "", +45, DoseValue, 1576, 1578, "45", "", +48501, mg, 1579, 1581, "mg", "", +48502, Interval, 1584, 1585, "d", "", +174, HbA1c, 1599, 1609, "HbA ( 1c )", "", +175, Percentage, 1619, 1620, "%", "", +176, Percentage, 1635, 1636, "%", "", +47, Duration, 1649, 1657, "2 - week", "", +48, Blind, 1660, 1674, "single - blind", "", +49, Placebo, 1677, 1684, "placebo", "", +51, Randomized, 1734, 1747, "randomization", "", +52, Pioglitazone, 1786, 1798, "pioglitazone", "", +53, DoseValue, 1801, 1803, "30", "", +54, DoseValue, 1807, 1809, "45", "", +180, mg, 1810, 1812, "mg", "", +48505, Interval, 1815, 1816, "d", "", +56, Randomized, 1835, 1845, "randomized", "", +183, AllocationRatio, 1851, 1856, "1 : 1", "", " . ." +57, Sitagliptin, 1874, 1885, "sitagliptin", "", " ." +58, DoseValue, 1886, 1889, "100", "", " \"100\"." +59, mg, 1890, 1892, "mg", "", " ." +60, Frequency, 1893, 1903, "once daily", "", " \"once daily\"." +61, Placebo, 1907, 1914, "placebo", "", " ." +62, Duration, 1919, 1927, "24 weeks", "", +257, TimePoint, 1981, 1989, "baseline", "", +63, HbA1c, 1993, 2003, "HbA ( 1c )", "", +258, TimePoint, 2007, 2014, "week 24", "", +259, TimePoint, 2072, 2080, "baseline", "", +191, FastingPlasmaGlucose, 2084, 2106, "fasting plasma glucose", "", +192, FastingPlasmaGlucose, 2109, 2112, "FPG", "", +260, InsulinDose, 2117, 2124, "insulin", "", +67, EndPointDescription, 2131, 2141, "proinsulin", "", +194, EndPointDescription, 2148, 2197, "Homeostasis Model Assessment beta - cell function", "", +69, EndPointDescription, 2202, 2230, "insulin - resistance indexes", "", +70, EndPointDescription, 2237, 2263, "proinsulin / insulin ratio", "", +71, EndPointDescription, 2270, 2314, "Quantitative Insulin Sensitivity Check Index", "", +261, TimePoint, 2342, 2350, "baseline", "", +72, EndPointDescription, 2354, 2379, "selected lipid parameters", "", +198, HbA1c_target, 2451, 2481, "HbA ( 1c ) , goal of < 7 . 0 %", "", +75, EndPointDescription, 2488, 2545, "proportion of patients requiring metformin rescue therapy", "", +74, Metformin, 2521, 2530, "metformin", "", +76, EndPointDescription, 2556, 2596, "time to the initiation of rescue therapy", "", +201, NumberPatientsArm, 2609, 2635, "One hundred seventy - five", "", " \"One hundred seventy - five\"." +77, Randomized, 2650, 2660, "randomized", "", +78, Sitagliptin, 2672, 2683, "sitagliptin", "", +79, NumberPatientsArm, 2690, 2693, "178", "", " \"178\"." +81, Randomized, 2699, 2709, "randomized", "", +82, Placebo, 2721, 2728, "placebo", "", +83, Mean, 2735, 2739, "mean", "", " . ." +266, TimePoint, 2747, 2755, "baseline", "", +84, HbA1c, 2756, 2761, "HbAlc", "", " ." +85, BaseLineValue, 2772, 2777, "8 . 1", "", " \"8 . 1\"." +87, Percentage, 2778, 2779, "%", "", " ." +86, SdDevBL, 2782, 2787, "0 . 8", "", " \"0 . 8\"." +88, Sitagliptin, 2797, 2808, "sitagliptin", "", +89, BaseLineValue, 2819, 2824, "8 . 0", "", " \"8 . 0\"." +90, Percentage, 2825, 2826, "%", "", +91, SdDevBL, 2829, 2834, "0 . 8", "", " \"0 . 8\"." +92, Placebo, 2844, 2851, "placebo", "", +94, TimePoint, 2860, 2874, "After 24 weeks", "", " \"After 24 weeks\". \"After 24 weeks\"." +93, Sitagliptin, 2877, 2888, "sitagliptin", "", +95, Pioglitazone, 2898, 2910, "pioglitazone", "", +96, Placebo, 2976, 2983, "placebo", "", +97, HbA1c, 2987, 2997, "HbA ( 1c )", "", +98, LeastSquaresMean, 3034, 3059, "least squares [ LS ] mean", "", +267, TimePoint, 3072, 3080, "baseline", "", +99, DiffGroupAbsValue, 3083, 3091, "- 0 . 70", "", " \"- 0 . 70\"." +100, Percentage, 3092, 3093, "%", "", +101, ConfIntervalDiff, 3096, 3126, "95 % CI , - 0 . 85 to - 0 . 54", "", " \"95 % CI , - 0 . 85 to - 0 . 54\"." +102, PvalueDiff, 3129, 3140, "P < 0 . 001", "", " \"P < 0 . 001\"." +103, FastingPlasmaGlucose, 3147, 3150, "FPG", "", " ." +104, DiffGroupAbsValue, 3153, 3161, "- 17 . 7", "", " \"- 17 . 7\"." +105, Mg_per_deciliter, 3162, 3169, "mg / dL", "", " ." +106, ConfIntervalDiff, 3172, 3202, "95 % CI , - 24 . 3 to - 11 . 0", "", " \"95 % CI , - 24 . 3 to - 11 . 0\"." +107, PvalueDiff, 3205, 3216, "P < 0 . 001", "", " \"P < 0 . 001\"." +108, Mean, 3221, 3225, "Mean", "", +109, HbA1c, 3226, 3236, "HbA ( 1c )", "", +110, TimePoint, 3247, 3256, "end point", "", +111, ResultMeasuredValue, 3262, 3267, "7 . 2", "", " \"7 . 2\"." +112, Percentage, 3268, 3269, "%", "", +113, SdDevResValue, 3272, 3277, "0 . 9", "", " \"0 . 9\"." +114, ResultMeasuredValue, 3284, 3289, "7 . 8", "", " \"7 . 8\"." +115, Percentage, 3290, 3291, "%", "", +116, SdDevResValue, 3294, 3299, "1 . 1", "", " \"1 . 1\"." +237, HbA1c_target, 3382, 3412, "target HbA ( 1c ) of < 7 . 0 %", "", " ." +118, PercentageAffected, 3418, 3424, "45 . 4", "", " \"45 . 4\"." +121, PercentageAffected, 3431, 3437, "23 . 0", "", " \"23 . 0\"." +122, PvalueDiff, 3442, 3453, "P < 0 . 001", "", " \"23 . 0\"." +127, ObservedResult, 3458, 3480, "Significant reductions", "", " \"Significant reductions\". \"Significant reductions\"." +123, EndPointDescription, 3484, 3515, "fasting serum proinsulin levels", "", " . ." +124, EndPointDescription, 3524, 3550, "proinsulin / insulin ratio", "", " . ." +125, Sitagliptin, 3566, 3577, "sitagliptin", "", +126, Placebo, 3602, 3609, "placebo", "", +244, PValueChangeValue, 3619, 3629, "P < 0 . 01", "", " \"P < 0 . 01\". \"P < 0 . 01\"." +129, Sitagliptin, 3634, 3645, "Sitagliptin", "", +251, ObservedResult, 3682, 3699, "no increased risk", "", " \"no increased risk\"." +247, Hypoglycemia, 3703, 3715, "hypoglycemia", "", " ." +131, Placebo, 3730, 3737, "placebo", "", +132, NumberAffected, 3740, 3741, "2", "", " \"2\"." +133, NumberAffected, 3745, 3746, "0", "", +134, PMID, 3832, 3840, "17157112", "", " \"17157112\"." diff --git a/data/dm2 17157112_admin.n-triples b/data/dm2 17157112_admin.n-triples new file mode 100644 index 0000000..307bddb --- /dev/null +++ b/data/dm2 17157112_admin.n-triples @@ -0,0 +1,195 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study ." . + "Rosenstock J" . + "2006" . + "Clin Ther ." . + "17157112" . + . + "Brazg R" . + "Andryuk PJ" . + "Lu K" . + "Stein P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy" . + "24 - week" . + . + . + . + . + . + . + . + . + . + "were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone" . + . + . + "18" . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint fspl" . + . + . + . + . + . + . + "Endpoint p/ir" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s + p " . + "One hundred seventy - five" . + . + . + . + . + . + . + . + . + "Arm pl + p " . + "178" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s + p" . + "once daily" . + . + . + . + "Intervention pl + p " . + . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication pl" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s " . + . + "8 . 1" . + "0 . 8" . + "7 . 2" . + "0 . 9" . + "After 24 weeks" . + . + "Outcome hba1c pl" . + . + "8 . 0" . + "0 . 8" . + "7 . 8" . + "1 . 1" . + "After 24 weeks" . + . + "Outcome fpg s" . + . + . + "Outcome fpg pl" . + . + . + "Outcome hba1c target s" . + . + "45 . 4" . + . + "Outcome hba1c target pl " . + . + "23 . 0" . + . + "Outcome fspl s" . + . + "P < 0 . 01" . + "Significant reductions" . + . + "Outcome p/ir s" . + . + "P < 0 . 01" . + "Significant reductions" . + . + "Outcome h s" . + . + "2" . + "no increased risk" . + . + "Outcome h pl" . + . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 70" . + "P < 0 . 001" . + "95 % CI , - 0 . 85 to - 0 . 54" . + . + . + . + "DiffBetweenGroups fpg " . + "- 17 . 7" . + "P < 0 . 001" . + "95 % CI , - 24 . 3 to - 11 . 0" . + . + . + . + "DiffBetweenGroups hba1c target " . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17157112_akramersunderbrink.annodb b/data/dm2 17157112_akramersunderbrink.annodb new file mode 100644 index 0000000..9b9a8e6 --- /dev/null +++ b/data/dm2 17157112_akramersunderbrink.annodb @@ -0,0 +1,141 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9879, Journal, 0, 9, "Clin Ther", "", +9880, PublicationYear, 12, 16, "2006", "", +9890, Title, 47, 297, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study", "", +9881, Sitagliptin, 109, 120, "sitagliptin", "", +9882, Pioglitazone, 138, 150, "pioglitazone", "", +9883, Type2Diabetes, 176, 191, "type 2 diabetes", "", +9884, Duration, 196, 205, "24 - week", "", +9885, Multicenter, 208, 219, "multicenter", "", +9886, Randomized, 222, 232, "randomized", "", +9887, DoubleBlind, 235, 249, "double - blind", "", +9888, Placebo, 252, 259, "placebo", "", +9889, Parallel, 275, 291, "parallel - group", "", +9891, Author, 300, 312, "Rosenstock J", "", +9892, Author, 321, 328, "Brazg R", "", +9893, Author, 331, 341, "Andryuk PJ", "", +9894, Author, 344, 348, "Lu K", "", +9895, Author, 351, 358, "Stein P", "", +9896, USA, 474, 477, "USA", "", +9902, ObjectiveDescription, 492, 744, "The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 %", "", +9897, Sitagliptin, 564, 575, "sitagliptin", "", +9898, Pioglitazone, 593, 605, "pioglitazone", "", +9899, Type2Diabetes, 645, 660, "type 2 diabetes", "", +9900, Precondition, 665, 762, "inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % )", "", +9903, ObjectiveDescription, 745, 808, "and < or = 10 % ) while receiving a stable dose of pioglitazone", "", +9901, Pioglitazone, 796, 808, "pioglitazone", "", +9904, Duration, 832, 841, "24 - week", "", +9905, Multicenter, 844, 855, "multicenter", "", +9906, Randomized, 858, 868, "randomized", "", +9907, DoubleBlind, 871, 885, "double - blind", "", +9908, Placebo, 888, 895, "placebo", "", +9909, Parallel, 911, 925, "parallel group", "", +9910, MinAge, 956, 958, "18", "", +9912, Precondition, 1109, 1308, "Patients taking antihyperglycemic therapy other than pioglitazone underwent a washout of this therapy and entered an 8 - to 14 - week open - label pioglitazone dose - titration / stabilization period", "", +9911, Pioglitazone, 1162, 1174, "pioglitazone", "", +9913, Duration, 1226, 1242, "8 - to 14 - week", "", +9914, OpenLabel, 1243, 1255, "open - label", "", +9915, Pioglitazone, 1256, 1268, "pioglitazone", "", +9920, Precondition, 1311, 1508, "Patients with an HbA ( 1c ) > or = 7 % and < or = 10 % at the end of this period entered a 2 - week , single - blind , placebo run - in period ( total duration of run - in period , up to 21 weeks )", "", +39137, TimePoint, 1369, 1391, "the end of this period", "", +9916, Duration, 1402, 1410, "2 - week", "", +9917, Blind, 1413, 1427, "single - blind", "", +9918, Placebo, 1430, 1437, "placebo", "", +9919, Duration, 1498, 1506, "21 weeks", "", +9928, Precondition, 1511, 1709, "Patients who had been receiving pioglitazone monotherapy ( 30 or 45 mg / d ) and had an HbA ( 1c ) > or = 7 % and < or = 10 % entered the 2 - week , single - blind , placebo run - in period directly", "", +9921, Pioglitazone, 1543, 1555, "pioglitazone", "", +9922, DoseValue, 1570, 1572, "30", "", +9923, DoseValue, 1576, 1578, "45", "", +9924, Mg_per_deciliter, 1579, 1585, "mg / d", "", +9925, Duration, 1649, 1657, "2 - week", "", +9926, Blind, 1660, 1674, "single - blind", "", +9927, Placebo, 1677, 1684, "placebo", "", +9929, Randomized, 1734, 1747, "randomization", "", +9930, Pioglitazone, 1786, 1798, "pioglitazone", "", +9931, DoseValue, 1801, 1803, "30", "", +9932, DoseValue, 1807, 1809, "45", "", +9933, Mg_per_deciliter, 1810, 1816, "mg / d", "", +9934, Randomized, 1835, 1845, "randomized", "", +9935, Sitagliptin, 1874, 1885, "sitagliptin", "", +9936, DoseValue, 1886, 1889, "100", "", +9937, mg, 1890, 1892, "mg", "", +9938, Frequency, 1893, 1903, "once daily", "", +9939, Placebo, 1907, 1914, "placebo", "", +9940, Duration, 1919, 1927, "24 weeks", "", +39132, TimePoint, 1981, 1989, "baseline", "", +9941, HbA1c, 1993, 2003, "HbA ( 1c )", "", +9942, Duration, 2007, 2014, "week 24", "", +39133, TimePoint, 2072, 2080, "baseline", "", +9943, FastingPlasmaGlucose, 2084, 2114, "fasting plasma glucose ( FPG )", "", +9944, EndPointDescription, 2117, 2124, "insulin", "", +9945, EndPointDescription, 2131, 2141, "proinsulin", "", +9946, EndPointDescription, 2148, 2197, "Homeostasis Model Assessment beta - cell function", "", +9947, EndPointDescription, 2202, 2230, "insulin - resistance indexes", "", +9948, EndPointDescription, 2237, 2263, "proinsulin / insulin ratio", "", +9949, EndPointDescription, 2270, 2314, "Quantitative Insulin Sensitivity Check Index", "", +39134, TimePoint, 2342, 2350, "baseline", "", +9950, EndPointDescription, 2354, 2379, "selected lipid parameters", "", +9951, EndPointDescription, 2386, 2481, "proportion of patients meeting the American Diabetes Association HbA ( 1c ) , goal of < 7 . 0 %", "", +9953, EndPointDescription, 2488, 2545, "proportion of patients requiring metformin rescue therapy", "", +9952, Metformin, 2521, 2530, "metformin", "", +9954, EndPointDescription, 2556, 2596, "time to the initiation of rescue therapy", "", +9959, NumberPatientsArm, 2613, 2635, "hundred seventy - five", "", +9956, Randomized, 2650, 2660, "randomized", "", +9957, Sitagliptin, 2672, 2683, "sitagliptin", "", +9958, NumberPatientsArm, 2690, 2693, "178", "", +9960, Randomized, 2699, 2709, "randomized", "", +9961, Placebo, 2721, 2728, "placebo", "", +9962, Mean, 2735, 2739, "mean", "", +39135, TimePoint, 2747, 2755, "baseline", "", +9963, HbA1c, 2756, 2761, "HbAlc", "", +9964, BaseLineValue, 2772, 2777, "8 . 1", "", +9966, Percentage, 2778, 2779, "%", "", +9965, SdDevBL, 2782, 2787, "0 . 8", "", +9967, Sitagliptin, 2797, 2808, "sitagliptin", "", +9968, BaseLineValue, 2819, 2824, "8 . 0", "", +9969, Percentage, 2825, 2826, "%", "", +9970, SdDevBL, 2829, 2834, "0 . 8", "", +9971, Placebo, 2844, 2851, "placebo", "", +9974, TimePoint, 2860, 2874, "After 24 weeks", "", +9973, Sitagliptin, 2877, 2888, "sitagliptin", "", +9975, Pioglitazone, 2898, 2910, "pioglitazone", "", +9976, Placebo, 2976, 2983, "placebo", "", +9977, HbA1c, 2987, 2997, "HbA ( 1c )", "", +9978, LeastSquaresMean, 3034, 3059, "least squares [ LS ] mean", "", +39136, TimePoint, 3072, 3080, "baseline", "", +9979, DiffGroupAbsValue, 3083, 3091, "- 0 . 70", "", +9980, Percentage, 3092, 3093, "%", "", +9981, ConfIntervalDiff, 3096, 3126, "95 % CI , - 0 . 85 to - 0 . 54", "", +9982, PvalueDiff, 3129, 3140, "P < 0 . 001", "", +9983, FastingPlasmaGlucose, 3147, 3150, "FPG", "", +9984, DiffGroupAbsValue, 3153, 3161, "- 17 . 7", "", +9985, Mg_per_deciliter, 3162, 3169, "mg / dL", "", +9986, ConfIntervalDiff, 3172, 3202, "95 % CI , - 24 . 3 to - 11 . 0", "", +9987, PvalueDiff, 3205, 3216, "P < 0 . 001", "", +9988, Mean, 3221, 3225, "Mean", "", +9989, HbA1c, 3226, 3236, "HbA ( 1c )", "", +9990, TimePoint, 3247, 3256, "end point", "", +9991, ResultMeasuredValue, 3262, 3267, "7 . 2", "", +9992, Percentage, 3268, 3269, "%", "", +9993, SdDevResValue, 3272, 3277, "0 . 9", "", +9994, ResultMeasuredValue, 3284, 3289, "7 . 8", "", +9995, Percentage, 3290, 3291, "%", "", +9996, SdDevResValue, 3294, 3299, "1 . 1", "", +9997, EndPointDescription, 3362, 3412, "patients reaching a target HbA ( 1c ) of < 7 . 0 %", "", +9998, PercentageAffected, 3418, 3424, "45 . 4", "", +9999, Percentage, 3425, 3426, "%", "", +10001, PercentageAffected, 3431, 3437, "23 . 0", "", +10000, Percentage, 3438, 3439, "%", "", +10002, PvalueDiff, 3442, 3453, "P < 0 . 001", "", +10007, ObservedResult, 3458, 3480, "Significant reductions", "", +10003, EndPointDescription, 3484, 3515, "fasting serum proinsulin levels", "", +10004, EndPointDescription, 3524, 3550, "proinsulin / insulin ratio", "", +10005, Sitagliptin, 3566, 3577, "sitagliptin", "", +10006, Placebo, 3602, 3609, "placebo", "", +10008, PvalueDiff, 3619, 3629, "P < 0 . 01", "", +10009, Sitagliptin, 3634, 3645, "Sitagliptin", "", +10010, EndPointDescription, 3695, 3715, "risk of hypoglycemia", "", +10011, Placebo, 3730, 3737, "placebo", "", +10012, NumberAffected, 3740, 3741, "2", "", +10013, NumberAffected, 3745, 3746, "0", "", +10014, PMID, 3832, 3840, "17157112", "", diff --git a/data/dm2 17157112_akramersunderbrink.n-triples b/data/dm2 17157112_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17157112_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17157112_export.csv b/data/dm2 17157112_export.csv new file mode 100644 index 0000000..562fffd --- /dev/null +++ b/data/dm2 17157112_export.csv @@ -0,0 +1,824 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +358, 1, 1, 1, 0, 4, 0, 4, "Clin" +358, 1, 2, 2, 5, 9, 5, 9, "Ther" +358, 1, 3, 3, 10, 11, 10, 11, "." +358, 2, 1, 4, 0, 4, 12, 16, "2006" +358, 2, 2, 5, 5, 8, 17, 20, "Oct" +358, 2, 3, 6, 9, 10, 21, 22, ";" +358, 2, 4, 7, 11, 13, 23, 25, "28" +358, 2, 5, 8, 14, 15, 26, 27, "(" +358, 2, 6, 9, 16, 18, 28, 30, "10" +358, 2, 7, 10, 19, 20, 31, 32, ")" +358, 2, 8, 11, 21, 22, 33, 34, ":" +358, 2, 9, 12, 23, 27, 35, 39, "1556" +358, 2, 10, 13, 28, 29, 40, 41, "-" +358, 2, 11, 14, 30, 32, 42, 44, "68" +358, 2, 12, 15, 33, 34, 45, 46, "." +358, 3, 1, 16, 0, 8, 47, 55, "Efficacy" +358, 3, 2, 17, 9, 12, 56, 59, "and" +358, 3, 3, 18, 13, 19, 60, 66, "safety" +358, 3, 4, 19, 20, 22, 67, 69, "of" +358, 3, 5, 20, 23, 26, 70, 73, "the" +358, 3, 6, 21, 27, 37, 74, 84, "dipeptidyl" +358, 3, 7, 22, 38, 47, 85, 94, "peptidase" +358, 3, 8, 23, 48, 49, 95, 96, "-" +358, 3, 9, 24, 50, 51, 97, 98, "4" +358, 3, 10, 25, 52, 61, 99, 108, "inhibitor" +358, 3, 11, 26, 62, 73, 109, 120, "sitagliptin" +358, 3, 12, 27, 74, 79, 121, 126, "added" +358, 3, 13, 28, 80, 82, 127, 129, "to" +358, 3, 14, 29, 83, 90, 130, 137, "ongoing" +358, 3, 15, 30, 91, 103, 138, 150, "pioglitazone" +358, 3, 16, 31, 104, 111, 151, 158, "therapy" +358, 3, 17, 32, 112, 114, 159, 161, "in" +358, 3, 18, 33, 115, 123, 162, 170, "patients" +358, 3, 19, 34, 124, 128, 171, 175, "with" +358, 3, 20, 35, 129, 133, 176, 180, "type" +358, 3, 21, 36, 134, 135, 181, 182, "2" +358, 3, 22, 37, 136, 144, 183, 191, "diabetes" +358, 3, 23, 38, 145, 146, 192, 193, ":" +358, 3, 24, 39, 147, 148, 194, 195, "a" +358, 3, 25, 40, 149, 151, 196, 198, "24" +358, 3, 26, 41, 152, 153, 199, 200, "-" +358, 3, 27, 42, 154, 158, 201, 205, "week" +358, 3, 28, 43, 159, 160, 206, 207, "," +358, 3, 29, 44, 161, 172, 208, 219, "multicenter" +358, 3, 30, 45, 173, 174, 220, 221, "," +358, 3, 31, 46, 175, 185, 222, 232, "randomized" +358, 3, 32, 47, 186, 187, 233, 234, "," +358, 3, 33, 48, 188, 194, 235, 241, "double" +358, 3, 34, 49, 195, 196, 242, 243, "-" +358, 3, 35, 50, 197, 202, 244, 249, "blind" +358, 3, 36, 51, 203, 204, 250, 251, "," +358, 3, 37, 52, 205, 212, 252, 259, "placebo" +358, 3, 38, 53, 213, 214, 260, 261, "-" +358, 3, 39, 54, 215, 225, 262, 272, "controlled" +358, 3, 40, 55, 226, 227, 273, 274, "," +358, 3, 41, 56, 228, 236, 275, 283, "parallel" +358, 3, 42, 57, 237, 238, 284, 285, "-" +358, 3, 43, 58, 239, 244, 286, 291, "group" +358, 3, 44, 59, 245, 250, 292, 297, "study" +358, 3, 45, 60, 251, 252, 298, 299, "." +358, 4, 1, 61, 0, 10, 300, 310, "Rosenstock" +358, 4, 2, 62, 11, 12, 311, 312, "J" +358, 4, 3, 63, 13, 14, 313, 314, "(" +358, 4, 4, 64, 15, 16, 315, 316, "1" +358, 4, 5, 65, 17, 18, 317, 318, ")" +358, 4, 6, 66, 19, 20, 319, 320, "," +358, 4, 7, 67, 21, 26, 321, 326, "Brazg" +358, 4, 8, 68, 27, 28, 327, 328, "R" +358, 4, 9, 69, 29, 30, 329, 330, "," +358, 4, 10, 70, 31, 38, 331, 338, "Andryuk" +358, 4, 11, 71, 39, 41, 339, 341, "PJ" +358, 4, 12, 72, 42, 43, 342, 343, "," +358, 4, 13, 73, 44, 46, 344, 346, "Lu" +358, 4, 14, 74, 47, 48, 347, 348, "K" +358, 4, 15, 75, 49, 50, 349, 350, "," +358, 4, 16, 76, 51, 56, 351, 356, "Stein" +358, 4, 17, 77, 57, 58, 357, 358, "P" +358, 4, 18, 78, 59, 60, 359, 360, ";" +358, 4, 19, 79, 61, 72, 361, 372, "Sitagliptin" +358, 4, 20, 80, 73, 78, 373, 378, "Study" +358, 4, 21, 81, 79, 82, 379, 382, "019" +358, 4, 22, 82, 83, 88, 383, 388, "Group" +358, 4, 23, 83, 89, 90, 389, 390, "." +358, 5, 1, 84, 0, 6, 391, 397, "Author" +358, 5, 2, 85, 7, 18, 398, 409, "information" +358, 5, 3, 86, 19, 20, 410, 411, ":" +358, 5, 4, 87, 21, 22, 412, 413, "(" +358, 5, 5, 88, 23, 24, 414, 415, "1" +358, 5, 6, 89, 25, 26, 416, 417, ")" +358, 5, 7, 90, 27, 33, 418, 424, "Dallas" +358, 5, 8, 91, 34, 42, 425, 433, "Diabetes" +358, 5, 9, 92, 43, 46, 434, 437, "and" +358, 5, 10, 93, 47, 56, 438, 447, "Endocrine" +358, 5, 11, 94, 57, 63, 448, 454, "Center" +358, 5, 12, 95, 64, 65, 455, 456, "," +358, 5, 13, 96, 66, 72, 457, 463, "Dallas" +358, 5, 14, 97, 73, 74, 464, 465, "," +358, 5, 15, 98, 75, 80, 466, 471, "Texas" +358, 5, 16, 99, 81, 82, 472, 473, "," +358, 5, 17, 100, 83, 86, 474, 477, "USA" +358, 5, 18, 101, 87, 88, 478, 479, "." +358, 6, 1, 102, 0, 9, 480, 489, "OBJECTIVE" +358, 6, 2, 103, 10, 11, 490, 491, ":" +358, 6, 3, 104, 12, 15, 492, 495, "The" +358, 6, 4, 105, 16, 24, 496, 504, "efficacy" +358, 6, 5, 106, 25, 28, 505, 508, "and" +358, 6, 6, 107, 29, 41, 509, 521, "tolerability" +358, 6, 7, 108, 42, 44, 522, 524, "of" +358, 6, 8, 109, 45, 48, 525, 528, "the" +358, 6, 9, 110, 49, 59, 529, 539, "dipeptidyl" +358, 6, 10, 111, 60, 69, 540, 549, "peptidase" +358, 6, 11, 112, 70, 71, 550, 551, "-" +358, 6, 12, 113, 72, 73, 552, 553, "4" +358, 6, 13, 114, 74, 83, 554, 563, "inhibitor" +358, 6, 14, 115, 84, 95, 564, 575, "sitagliptin" +358, 6, 15, 116, 96, 101, 576, 581, "added" +358, 6, 16, 117, 102, 104, 582, 584, "to" +358, 6, 17, 118, 105, 112, 585, 592, "ongoing" +358, 6, 18, 119, 113, 125, 593, 605, "pioglitazone" +358, 6, 19, 120, 126, 133, 606, 613, "therapy" +358, 6, 20, 121, 134, 138, 614, 618, "were" +358, 6, 21, 122, 139, 147, 619, 627, "assessed" +358, 6, 22, 123, 148, 150, 628, 630, "in" +358, 6, 23, 124, 151, 159, 631, 639, "patients" +358, 6, 24, 125, 160, 164, 640, 644, "with" +358, 6, 25, 126, 165, 169, 645, 649, "type" +358, 6, 26, 127, 170, 171, 650, 651, "2" +358, 6, 27, 128, 172, 180, 652, 660, "diabetes" +358, 6, 28, 129, 181, 184, 661, 664, "and" +358, 6, 29, 130, 185, 195, 665, 675, "inadequate" +358, 6, 30, 131, 196, 204, 676, 684, "glycemic" +358, 6, 31, 132, 205, 212, 685, 692, "control" +358, 6, 32, 133, 213, 214, 693, 694, "(" +358, 6, 33, 134, 215, 227, 695, 707, "glycosylated" +358, 6, 34, 135, 228, 238, 708, 718, "hemoglobin" +358, 6, 35, 136, 239, 240, 719, 720, "[" +358, 6, 36, 137, 241, 244, 721, 724, "HbA" +358, 6, 37, 138, 245, 246, 725, 726, "(" +358, 6, 38, 139, 247, 249, 727, 729, "1c" +358, 6, 39, 140, 250, 251, 730, 731, ")" +358, 6, 40, 141, 252, 253, 732, 733, "]" +358, 6, 41, 142, 254, 255, 734, 735, ">" +358, 6, 42, 143, 256, 258, 736, 738, "or" +358, 6, 43, 144, 259, 260, 739, 740, "=" +358, 6, 44, 145, 261, 262, 741, 742, "7" +358, 6, 45, 146, 263, 264, 743, 744, "%" +358, 6, 46, 147, 265, 268, 745, 748, "and" +358, 6, 47, 148, 269, 270, 749, 750, "<" +358, 6, 48, 149, 271, 273, 751, 753, "or" +358, 6, 49, 150, 274, 275, 754, 755, "=" +358, 6, 50, 151, 276, 278, 756, 758, "10" +358, 6, 51, 152, 279, 280, 759, 760, "%" +358, 6, 52, 153, 281, 282, 761, 762, ")" +358, 6, 53, 154, 283, 288, 763, 768, "while" +358, 6, 54, 155, 289, 298, 769, 778, "receiving" +358, 6, 55, 156, 299, 300, 779, 780, "a" +358, 6, 56, 157, 301, 307, 781, 787, "stable" +358, 6, 57, 158, 308, 312, 788, 792, "dose" +358, 6, 58, 159, 313, 315, 793, 795, "of" +358, 6, 59, 160, 316, 328, 796, 808, "pioglitazone" +358, 6, 60, 161, 329, 330, 809, 810, "." +358, 7, 1, 162, 0, 7, 811, 818, "METHODS" +358, 7, 2, 163, 8, 9, 819, 820, ":" +358, 7, 3, 164, 10, 14, 821, 825, "This" +358, 7, 4, 165, 15, 18, 826, 829, "was" +358, 7, 5, 166, 19, 20, 830, 831, "a" +358, 7, 6, 167, 21, 23, 832, 834, "24" +358, 7, 7, 168, 24, 25, 835, 836, "-" +358, 7, 8, 169, 26, 30, 837, 841, "week" +358, 7, 9, 170, 31, 32, 842, 843, "," +358, 7, 10, 171, 33, 44, 844, 855, "multicenter" +358, 7, 11, 172, 45, 46, 856, 857, "," +358, 7, 12, 173, 47, 57, 858, 868, "randomized" +358, 7, 13, 174, 58, 59, 869, 870, "," +358, 7, 14, 175, 60, 66, 871, 877, "double" +358, 7, 15, 176, 67, 68, 878, 879, "-" +358, 7, 16, 177, 69, 74, 880, 885, "blind" +358, 7, 17, 178, 75, 76, 886, 887, "," +358, 7, 18, 179, 77, 84, 888, 895, "placebo" +358, 7, 19, 180, 85, 86, 896, 897, "-" +358, 7, 20, 181, 87, 97, 898, 908, "controlled" +358, 7, 21, 182, 98, 99, 909, 910, "," +358, 7, 22, 183, 100, 108, 911, 919, "parallel" +358, 7, 23, 184, 109, 114, 920, 925, "group" +358, 7, 24, 185, 115, 120, 926, 931, "study" +358, 7, 25, 186, 121, 123, 932, 934, "in" +358, 7, 26, 187, 124, 132, 935, 943, "patients" +358, 7, 27, 188, 133, 137, 944, 948, "aged" +358, 7, 28, 189, 138, 139, 949, 950, ">" +358, 7, 29, 190, 140, 142, 951, 953, "or" +358, 7, 30, 191, 143, 144, 954, 955, "=" +358, 7, 31, 192, 145, 147, 956, 958, "18" +358, 7, 32, 193, 148, 153, 959, 964, "years" +358, 7, 33, 194, 154, 155, 965, 966, "(" +358, 7, 34, 195, 156, 170, 967, 981, "ClinicalTrials" +358, 7, 35, 196, 171, 172, 982, 983, "." +358, 8, 1, 197, 0, 3, 984, 987, "gov" +358, 8, 2, 198, 4, 15, 988, 999, "NCT00086502" +358, 8, 3, 199, 16, 17, 1000, 1001, ")" +358, 8, 4, 200, 18, 19, 1002, 1003, "." +358, 9, 1, 201, 0, 2, 1004, 1006, "At" +358, 9, 2, 202, 3, 12, 1007, 1016, "screening" +358, 9, 3, 203, 13, 14, 1017, 1018, "," +358, 9, 4, 204, 15, 18, 1019, 1022, "all" +358, 9, 5, 205, 19, 27, 1023, 1031, "patients" +358, 9, 6, 206, 28, 33, 1032, 1037, "began" +358, 9, 7, 207, 34, 35, 1038, 1039, "a" +358, 9, 8, 208, 36, 40, 1040, 1044, "diet" +358, 9, 9, 209, 41, 42, 1045, 1046, "/" +358, 9, 10, 210, 43, 51, 1047, 1055, "exercise" +358, 9, 11, 211, 52, 59, 1056, 1063, "program" +358, 9, 12, 212, 60, 64, 1064, 1068, "that" +358, 9, 13, 213, 65, 74, 1069, 1078, "continued" +358, 9, 14, 214, 75, 85, 1079, 1089, "throughout" +358, 9, 15, 215, 86, 89, 1090, 1093, "the" +358, 9, 16, 216, 90, 95, 1094, 1099, "study" +358, 9, 17, 217, 96, 102, 1100, 1106, "period" +358, 9, 18, 218, 103, 104, 1107, 1108, "." +358, 10, 1, 219, 0, 8, 1109, 1117, "Patients" +358, 10, 2, 220, 9, 15, 1118, 1124, "taking" +358, 10, 3, 221, 16, 33, 1125, 1142, "antihyperglycemic" +358, 10, 4, 222, 34, 41, 1143, 1150, "therapy" +358, 10, 5, 223, 42, 47, 1151, 1156, "other" +358, 10, 6, 224, 48, 52, 1157, 1161, "than" +358, 10, 7, 225, 53, 65, 1162, 1174, "pioglitazone" +358, 10, 8, 226, 66, 75, 1175, 1184, "underwent" +358, 10, 9, 227, 76, 77, 1185, 1186, "a" +358, 10, 10, 228, 78, 85, 1187, 1194, "washout" +358, 10, 11, 229, 86, 88, 1195, 1197, "of" +358, 10, 12, 230, 89, 93, 1198, 1202, "this" +358, 10, 13, 231, 94, 101, 1203, 1210, "therapy" +358, 10, 14, 232, 102, 105, 1211, 1214, "and" +358, 10, 15, 233, 106, 113, 1215, 1222, "entered" +358, 10, 16, 234, 114, 116, 1223, 1225, "an" +358, 10, 17, 235, 117, 118, 1226, 1227, "8" +358, 10, 18, 236, 119, 120, 1228, 1229, "-" +358, 10, 19, 237, 121, 123, 1230, 1232, "to" +358, 10, 20, 238, 124, 126, 1233, 1235, "14" +358, 10, 21, 239, 127, 128, 1236, 1237, "-" +358, 10, 22, 240, 129, 133, 1238, 1242, "week" +358, 10, 23, 241, 134, 138, 1243, 1247, "open" +358, 10, 24, 242, 139, 140, 1248, 1249, "-" +358, 10, 25, 243, 141, 146, 1250, 1255, "label" +358, 10, 26, 244, 147, 159, 1256, 1268, "pioglitazone" +358, 10, 27, 245, 160, 164, 1269, 1273, "dose" +358, 10, 28, 246, 165, 166, 1274, 1275, "-" +358, 10, 29, 247, 167, 176, 1276, 1285, "titration" +358, 10, 30, 248, 177, 178, 1286, 1287, "/" +358, 10, 31, 249, 179, 192, 1288, 1301, "stabilization" +358, 10, 32, 250, 193, 199, 1302, 1308, "period" +358, 10, 33, 251, 200, 201, 1309, 1310, "." +358, 11, 1, 252, 0, 8, 1311, 1319, "Patients" +358, 11, 2, 253, 9, 13, 1320, 1324, "with" +358, 11, 3, 254, 14, 16, 1325, 1327, "an" +358, 11, 4, 255, 17, 20, 1328, 1331, "HbA" +358, 11, 5, 256, 21, 22, 1332, 1333, "(" +358, 11, 6, 257, 23, 25, 1334, 1336, "1c" +358, 11, 7, 258, 26, 27, 1337, 1338, ")" +358, 11, 8, 259, 28, 29, 1339, 1340, ">" +358, 11, 9, 260, 30, 32, 1341, 1343, "or" +358, 11, 10, 261, 33, 34, 1344, 1345, "=" +358, 11, 11, 262, 35, 36, 1346, 1347, "7" +358, 11, 12, 263, 37, 38, 1348, 1349, "%" +358, 11, 13, 264, 39, 42, 1350, 1353, "and" +358, 11, 14, 265, 43, 44, 1354, 1355, "<" +358, 11, 15, 266, 45, 47, 1356, 1358, "or" +358, 11, 16, 267, 48, 49, 1359, 1360, "=" +358, 11, 17, 268, 50, 52, 1361, 1363, "10" +358, 11, 18, 269, 53, 54, 1364, 1365, "%" +358, 11, 19, 270, 55, 57, 1366, 1368, "at" +358, 11, 20, 271, 58, 61, 1369, 1372, "the" +358, 11, 21, 272, 62, 65, 1373, 1376, "end" +358, 11, 22, 273, 66, 68, 1377, 1379, "of" +358, 11, 23, 274, 69, 73, 1380, 1384, "this" +358, 11, 24, 275, 74, 80, 1385, 1391, "period" +358, 11, 25, 276, 81, 88, 1392, 1399, "entered" +358, 11, 26, 277, 89, 90, 1400, 1401, "a" +358, 11, 27, 278, 91, 92, 1402, 1403, "2" +358, 11, 28, 279, 93, 94, 1404, 1405, "-" +358, 11, 29, 280, 95, 99, 1406, 1410, "week" +358, 11, 30, 281, 100, 101, 1411, 1412, "," +358, 11, 31, 282, 102, 108, 1413, 1419, "single" +358, 11, 32, 283, 109, 110, 1420, 1421, "-" +358, 11, 33, 284, 111, 116, 1422, 1427, "blind" +358, 11, 34, 285, 117, 118, 1428, 1429, "," +358, 11, 35, 286, 119, 126, 1430, 1437, "placebo" +358, 11, 36, 287, 127, 130, 1438, 1441, "run" +358, 11, 37, 288, 131, 132, 1442, 1443, "-" +358, 11, 38, 289, 133, 135, 1444, 1446, "in" +358, 11, 39, 290, 136, 142, 1447, 1453, "period" +358, 11, 40, 291, 143, 144, 1454, 1455, "(" +358, 11, 41, 292, 145, 150, 1456, 1461, "total" +358, 11, 42, 293, 151, 159, 1462, 1470, "duration" +358, 11, 43, 294, 160, 162, 1471, 1473, "of" +358, 11, 44, 295, 163, 166, 1474, 1477, "run" +358, 11, 45, 296, 167, 168, 1478, 1479, "-" +358, 11, 46, 297, 169, 171, 1480, 1482, "in" +358, 11, 47, 298, 172, 178, 1483, 1489, "period" +358, 11, 48, 299, 179, 180, 1490, 1491, "," +358, 11, 49, 300, 181, 183, 1492, 1494, "up" +358, 11, 50, 301, 184, 186, 1495, 1497, "to" +358, 11, 51, 302, 187, 189, 1498, 1500, "21" +358, 11, 52, 303, 190, 195, 1501, 1506, "weeks" +358, 11, 53, 304, 196, 197, 1507, 1508, ")" +358, 11, 54, 305, 198, 199, 1509, 1510, "." +358, 12, 1, 306, 0, 8, 1511, 1519, "Patients" +358, 12, 2, 307, 9, 12, 1520, 1523, "who" +358, 12, 3, 308, 13, 16, 1524, 1527, "had" +358, 12, 4, 309, 17, 21, 1528, 1532, "been" +358, 12, 5, 310, 22, 31, 1533, 1542, "receiving" +358, 12, 6, 311, 32, 44, 1543, 1555, "pioglitazone" +358, 12, 7, 312, 45, 56, 1556, 1567, "monotherapy" +358, 12, 8, 313, 57, 58, 1568, 1569, "(" +358, 12, 9, 314, 59, 61, 1570, 1572, "30" +358, 12, 10, 315, 62, 64, 1573, 1575, "or" +358, 12, 11, 316, 65, 67, 1576, 1578, "45" +358, 12, 12, 317, 68, 70, 1579, 1581, "mg" +358, 12, 13, 318, 71, 72, 1582, 1583, "/" +358, 12, 14, 319, 73, 74, 1584, 1585, "d" +358, 12, 15, 320, 75, 76, 1586, 1587, ")" +358, 12, 16, 321, 77, 80, 1588, 1591, "and" +358, 12, 17, 322, 81, 84, 1592, 1595, "had" +358, 12, 18, 323, 85, 87, 1596, 1598, "an" +358, 12, 19, 324, 88, 91, 1599, 1602, "HbA" +358, 12, 20, 325, 92, 93, 1603, 1604, "(" +358, 12, 21, 326, 94, 96, 1605, 1607, "1c" +358, 12, 22, 327, 97, 98, 1608, 1609, ")" +358, 12, 23, 328, 99, 100, 1610, 1611, ">" +358, 12, 24, 329, 101, 103, 1612, 1614, "or" +358, 12, 25, 330, 104, 105, 1615, 1616, "=" +358, 12, 26, 331, 106, 107, 1617, 1618, "7" +358, 12, 27, 332, 108, 109, 1619, 1620, "%" +358, 12, 28, 333, 110, 113, 1621, 1624, "and" +358, 12, 29, 334, 114, 115, 1625, 1626, "<" +358, 12, 30, 335, 116, 118, 1627, 1629, "or" +358, 12, 31, 336, 119, 120, 1630, 1631, "=" +358, 12, 32, 337, 121, 123, 1632, 1634, "10" +358, 12, 33, 338, 124, 125, 1635, 1636, "%" +358, 12, 34, 339, 126, 133, 1637, 1644, "entered" +358, 12, 35, 340, 134, 137, 1645, 1648, "the" +358, 12, 36, 341, 138, 139, 1649, 1650, "2" +358, 12, 37, 342, 140, 141, 1651, 1652, "-" +358, 12, 38, 343, 142, 146, 1653, 1657, "week" +358, 12, 39, 344, 147, 148, 1658, 1659, "," +358, 12, 40, 345, 149, 155, 1660, 1666, "single" +358, 12, 41, 346, 156, 157, 1667, 1668, "-" +358, 12, 42, 347, 158, 163, 1669, 1674, "blind" +358, 12, 43, 348, 164, 165, 1675, 1676, "," +358, 12, 44, 349, 166, 173, 1677, 1684, "placebo" +358, 12, 45, 350, 174, 177, 1685, 1688, "run" +358, 12, 46, 351, 178, 179, 1689, 1690, "-" +358, 12, 47, 352, 180, 182, 1691, 1693, "in" +358, 12, 48, 353, 183, 189, 1694, 1700, "period" +358, 12, 49, 354, 190, 198, 1701, 1709, "directly" +358, 12, 50, 355, 199, 200, 1710, 1711, "." +358, 13, 1, 356, 0, 4, 1712, 1716, "Thus" +358, 13, 2, 357, 5, 6, 1717, 1718, "," +358, 13, 3, 358, 7, 9, 1719, 1721, "at" +358, 13, 4, 359, 10, 13, 1722, 1725, "the" +358, 13, 5, 360, 14, 18, 1726, 1730, "time" +358, 13, 6, 361, 19, 21, 1731, 1733, "of" +358, 13, 7, 362, 22, 35, 1734, 1747, "randomization" +358, 13, 8, 363, 36, 37, 1748, 1749, "," +358, 13, 9, 364, 38, 41, 1750, 1753, "all" +358, 13, 10, 365, 42, 50, 1754, 1762, "patients" +358, 13, 11, 366, 51, 55, 1763, 1767, "were" +358, 13, 12, 367, 56, 65, 1768, 1777, "receiving" +358, 13, 13, 368, 66, 73, 1778, 1785, "ongoing" +358, 13, 14, 369, 74, 86, 1786, 1798, "pioglitazone" +358, 13, 15, 370, 87, 88, 1799, 1800, "(" +358, 13, 16, 371, 89, 91, 1801, 1803, "30" +358, 13, 17, 372, 92, 94, 1804, 1806, "or" +358, 13, 18, 373, 95, 97, 1807, 1809, "45" +358, 13, 19, 374, 98, 100, 1810, 1812, "mg" +358, 13, 20, 375, 101, 102, 1813, 1814, "/" +358, 13, 21, 376, 103, 104, 1815, 1816, "d" +358, 13, 22, 377, 105, 106, 1817, 1818, ")" +358, 13, 23, 378, 107, 108, 1819, 1820, "." +358, 14, 1, 379, 0, 8, 1821, 1829, "Patients" +358, 14, 2, 380, 9, 13, 1830, 1834, "were" +358, 14, 3, 381, 14, 24, 1835, 1845, "randomized" +358, 14, 4, 382, 25, 27, 1846, 1848, "in" +358, 14, 5, 383, 28, 29, 1849, 1850, "a" +358, 14, 6, 384, 30, 31, 1851, 1852, "1" +358, 14, 7, 385, 32, 33, 1853, 1854, ":" +358, 14, 8, 386, 34, 35, 1855, 1856, "1" +358, 14, 9, 387, 36, 41, 1857, 1862, "ratio" +358, 14, 10, 388, 42, 44, 1863, 1865, "to" +358, 14, 11, 389, 45, 52, 1866, 1873, "receive" +358, 14, 12, 390, 53, 64, 1874, 1885, "sitagliptin" +358, 14, 13, 391, 65, 68, 1886, 1889, "100" +358, 14, 14, 392, 69, 71, 1890, 1892, "mg" +358, 14, 15, 393, 72, 76, 1893, 1897, "once" +358, 14, 16, 394, 77, 82, 1898, 1903, "daily" +358, 14, 17, 395, 83, 85, 1904, 1906, "or" +358, 14, 18, 396, 86, 93, 1907, 1914, "placebo" +358, 14, 19, 397, 94, 97, 1915, 1918, "for" +358, 14, 20, 398, 98, 100, 1919, 1921, "24" +358, 14, 21, 399, 101, 106, 1922, 1927, "weeks" +358, 14, 22, 400, 107, 108, 1928, 1929, "." +358, 15, 1, 401, 0, 3, 1930, 1933, "The" +358, 15, 2, 402, 4, 11, 1934, 1941, "primary" +358, 15, 3, 403, 12, 20, 1942, 1950, "efficacy" +358, 15, 4, 404, 21, 24, 1951, 1954, "end" +358, 15, 5, 405, 25, 30, 1955, 1960, "point" +358, 15, 6, 406, 31, 34, 1961, 1964, "was" +358, 15, 7, 407, 35, 38, 1965, 1968, "the" +358, 15, 8, 408, 39, 45, 1969, 1975, "change" +358, 15, 9, 409, 46, 50, 1976, 1980, "from" +358, 15, 10, 410, 51, 59, 1981, 1989, "baseline" +358, 15, 11, 411, 60, 62, 1990, 1992, "in" +358, 15, 12, 412, 63, 66, 1993, 1996, "HbA" +358, 15, 13, 413, 67, 68, 1997, 1998, "(" +358, 15, 14, 414, 69, 71, 1999, 2001, "1c" +358, 15, 15, 415, 72, 73, 2002, 2003, ")" +358, 15, 16, 416, 74, 76, 2004, 2006, "at" +358, 15, 17, 417, 77, 81, 2007, 2011, "week" +358, 15, 18, 418, 82, 84, 2012, 2014, "24" +358, 15, 19, 419, 85, 86, 2015, 2016, "." +358, 16, 1, 420, 0, 9, 2017, 2026, "Secondary" +358, 16, 2, 421, 10, 18, 2027, 2035, "efficacy" +358, 16, 3, 422, 19, 22, 2036, 2039, "end" +358, 16, 4, 423, 23, 29, 2040, 2046, "points" +358, 16, 5, 424, 30, 38, 2047, 2055, "included" +358, 16, 6, 425, 39, 42, 2056, 2059, "the" +358, 16, 7, 426, 43, 49, 2060, 2066, "change" +358, 16, 8, 427, 50, 54, 2067, 2071, "from" +358, 16, 9, 428, 55, 63, 2072, 2080, "baseline" +358, 16, 10, 429, 64, 66, 2081, 2083, "in" +358, 16, 11, 430, 67, 74, 2084, 2091, "fasting" +358, 16, 12, 431, 75, 81, 2092, 2098, "plasma" +358, 16, 13, 432, 82, 89, 2099, 2106, "glucose" +358, 16, 14, 433, 90, 91, 2107, 2108, "(" +358, 16, 15, 434, 92, 95, 2109, 2112, "FPG" +358, 16, 16, 435, 96, 97, 2113, 2114, ")" +358, 16, 17, 436, 98, 99, 2115, 2116, "," +358, 16, 18, 437, 100, 107, 2117, 2124, "insulin" +358, 16, 19, 438, 108, 109, 2125, 2126, "," +358, 16, 20, 439, 110, 113, 2127, 2130, "and" +358, 16, 21, 440, 114, 124, 2131, 2141, "proinsulin" +358, 16, 22, 441, 125, 126, 2142, 2143, ";" +358, 16, 23, 442, 127, 130, 2144, 2147, "the" +358, 16, 24, 443, 131, 142, 2148, 2159, "Homeostasis" +358, 16, 25, 444, 143, 148, 2160, 2165, "Model" +358, 16, 26, 445, 149, 159, 2166, 2176, "Assessment" +358, 16, 27, 446, 160, 164, 2177, 2181, "beta" +358, 16, 28, 447, 165, 166, 2182, 2183, "-" +358, 16, 29, 448, 167, 171, 2184, 2188, "cell" +358, 16, 30, 449, 172, 180, 2189, 2197, "function" +358, 16, 31, 450, 181, 184, 2198, 2201, "and" +358, 16, 32, 451, 185, 192, 2202, 2209, "insulin" +358, 16, 33, 452, 193, 194, 2210, 2211, "-" +358, 16, 34, 453, 195, 205, 2212, 2222, "resistance" +358, 16, 35, 454, 206, 213, 2223, 2230, "indexes" +358, 16, 36, 455, 214, 215, 2231, 2232, ";" +358, 16, 37, 456, 216, 219, 2233, 2236, "the" +358, 16, 38, 457, 220, 230, 2237, 2247, "proinsulin" +358, 16, 39, 458, 231, 232, 2248, 2249, "/" +358, 16, 40, 459, 233, 240, 2250, 2257, "insulin" +358, 16, 41, 460, 241, 246, 2258, 2263, "ratio" +358, 16, 42, 461, 247, 248, 2264, 2265, ";" +358, 16, 43, 462, 249, 252, 2266, 2269, "the" +358, 16, 44, 463, 253, 265, 2270, 2282, "Quantitative" +358, 16, 45, 464, 266, 273, 2283, 2290, "Insulin" +358, 16, 46, 465, 274, 285, 2291, 2302, "Sensitivity" +358, 16, 47, 466, 286, 291, 2303, 2308, "Check" +358, 16, 48, 467, 292, 297, 2309, 2314, "Index" +358, 16, 49, 468, 298, 299, 2315, 2316, ";" +358, 16, 50, 469, 300, 303, 2317, 2320, "the" +358, 16, 51, 470, 304, 311, 2321, 2328, "percent" +358, 16, 52, 471, 312, 319, 2329, 2336, "changes" +358, 16, 53, 472, 320, 324, 2337, 2341, "from" +358, 16, 54, 473, 325, 333, 2342, 2350, "baseline" +358, 16, 55, 474, 334, 336, 2351, 2353, "in" +358, 16, 56, 475, 337, 345, 2354, 2362, "selected" +358, 16, 57, 476, 346, 351, 2363, 2368, "lipid" +358, 16, 58, 477, 352, 362, 2369, 2379, "parameters" +358, 16, 59, 478, 363, 364, 2380, 2381, ";" +358, 16, 60, 479, 365, 368, 2382, 2385, "the" +358, 16, 61, 480, 369, 379, 2386, 2396, "proportion" +358, 16, 62, 481, 380, 382, 2397, 2399, "of" +358, 16, 63, 482, 383, 391, 2400, 2408, "patients" +358, 16, 64, 483, 392, 399, 2409, 2416, "meeting" +358, 16, 65, 484, 400, 403, 2417, 2420, "the" +358, 16, 66, 485, 404, 412, 2421, 2429, "American" +358, 16, 67, 486, 413, 421, 2430, 2438, "Diabetes" +358, 16, 68, 487, 422, 433, 2439, 2450, "Association" +358, 16, 69, 488, 434, 437, 2451, 2454, "HbA" +358, 16, 70, 489, 438, 439, 2455, 2456, "(" +358, 16, 71, 490, 440, 442, 2457, 2459, "1c" +358, 16, 72, 491, 443, 444, 2460, 2461, ")" +358, 16, 73, 492, 445, 446, 2462, 2463, "," +358, 16, 74, 493, 447, 451, 2464, 2468, "goal" +358, 16, 75, 494, 452, 454, 2469, 2471, "of" +358, 16, 76, 495, 455, 456, 2472, 2473, "<" +358, 16, 77, 496, 457, 458, 2474, 2475, "7" +358, 16, 78, 497, 459, 460, 2476, 2477, "." +358, 16, 79, 498, 461, 462, 2478, 2479, "0" +358, 16, 80, 499, 463, 464, 2480, 2481, "%" +358, 16, 81, 500, 465, 466, 2482, 2483, ";" +358, 16, 82, 501, 467, 470, 2484, 2487, "the" +358, 16, 83, 502, 471, 481, 2488, 2498, "proportion" +358, 16, 84, 503, 482, 484, 2499, 2501, "of" +358, 16, 85, 504, 485, 493, 2502, 2510, "patients" +358, 16, 86, 505, 494, 503, 2511, 2520, "requiring" +358, 16, 87, 506, 504, 513, 2521, 2530, "metformin" +358, 16, 88, 507, 514, 520, 2531, 2537, "rescue" +358, 16, 89, 508, 521, 528, 2538, 2545, "therapy" +358, 16, 90, 509, 529, 530, 2546, 2547, ";" +358, 16, 91, 510, 531, 534, 2548, 2551, "and" +358, 16, 92, 511, 535, 538, 2552, 2555, "the" +358, 16, 93, 512, 539, 543, 2556, 2560, "time" +358, 16, 94, 513, 544, 546, 2561, 2563, "to" +358, 16, 95, 514, 547, 550, 2564, 2567, "the" +358, 16, 96, 515, 551, 561, 2568, 2578, "initiation" +358, 16, 97, 516, 562, 564, 2579, 2581, "of" +358, 16, 98, 517, 565, 571, 2582, 2588, "rescue" +358, 16, 99, 518, 572, 579, 2589, 2596, "therapy" +358, 16, 100, 519, 580, 581, 2597, 2598, "." +358, 17, 1, 520, 0, 7, 2599, 2606, "RESULTS" +358, 17, 2, 521, 8, 9, 2607, 2608, ":" +358, 17, 3, 522, 10, 13, 2609, 2612, "One" +358, 17, 4, 523, 14, 21, 2613, 2620, "hundred" +358, 17, 5, 524, 22, 29, 2621, 2628, "seventy" +358, 17, 6, 525, 30, 31, 2629, 2630, "-" +358, 17, 7, 526, 32, 36, 2631, 2635, "five" +358, 17, 8, 527, 37, 45, 2636, 2644, "patients" +358, 17, 9, 528, 46, 50, 2645, 2649, "were" +358, 17, 10, 529, 51, 61, 2650, 2660, "randomized" +358, 17, 11, 530, 62, 64, 2661, 2663, "to" +358, 17, 12, 531, 65, 72, 2664, 2671, "receive" +358, 17, 13, 532, 73, 84, 2672, 2683, "sitagliptin" +358, 17, 14, 533, 85, 86, 2684, 2685, "," +358, 17, 15, 534, 87, 90, 2686, 2689, "and" +358, 17, 16, 535, 91, 94, 2690, 2693, "178" +358, 17, 17, 536, 95, 99, 2694, 2698, "were" +358, 17, 18, 537, 100, 110, 2699, 2709, "randomized" +358, 17, 19, 538, 111, 113, 2710, 2712, "to" +358, 17, 20, 539, 114, 121, 2713, 2720, "receive" +358, 17, 21, 540, 122, 129, 2721, 2728, "placebo" +358, 17, 22, 541, 130, 131, 2729, 2730, "." +358, 18, 1, 542, 0, 3, 2731, 2734, "The" +358, 18, 2, 543, 4, 8, 2735, 2739, "mean" +358, 18, 3, 544, 9, 10, 2740, 2741, "(" +358, 18, 4, 545, 11, 13, 2742, 2744, "SD" +358, 18, 5, 546, 14, 15, 2745, 2746, ")" +358, 18, 6, 547, 16, 24, 2747, 2755, "baseline" +358, 18, 7, 548, 25, 30, 2756, 2761, "HbAlc" +358, 18, 8, 549, 31, 36, 2762, 2767, "value" +358, 18, 9, 550, 37, 40, 2768, 2771, "was" +358, 18, 10, 551, 41, 42, 2772, 2773, "8" +358, 18, 11, 552, 43, 44, 2774, 2775, "." +358, 18, 12, 553, 45, 46, 2776, 2777, "1" +358, 18, 13, 554, 47, 48, 2778, 2779, "%" +358, 18, 14, 555, 49, 50, 2780, 2781, "(" +358, 18, 15, 556, 51, 52, 2782, 2783, "0" +358, 18, 16, 557, 53, 54, 2784, 2785, "." +358, 18, 17, 558, 55, 56, 2786, 2787, "8" +358, 18, 18, 559, 57, 58, 2788, 2789, ")" +358, 18, 19, 560, 59, 61, 2790, 2792, "in" +358, 18, 20, 561, 62, 65, 2793, 2796, "the" +358, 18, 21, 562, 66, 77, 2797, 2808, "sitagliptin" +358, 18, 22, 563, 78, 83, 2809, 2814, "group" +358, 18, 23, 564, 84, 87, 2815, 2818, "and" +358, 18, 24, 565, 88, 89, 2819, 2820, "8" +358, 18, 25, 566, 90, 91, 2821, 2822, "." +358, 18, 26, 567, 92, 93, 2823, 2824, "0" +358, 18, 27, 568, 94, 95, 2825, 2826, "%" +358, 18, 28, 569, 96, 97, 2827, 2828, "(" +358, 18, 29, 570, 98, 99, 2829, 2830, "0" +358, 18, 30, 571, 100, 101, 2831, 2832, "." +358, 18, 31, 572, 102, 103, 2833, 2834, "8" +358, 18, 32, 573, 104, 105, 2835, 2836, ")" +358, 18, 33, 574, 106, 108, 2837, 2839, "in" +358, 18, 34, 575, 109, 112, 2840, 2843, "the" +358, 18, 35, 576, 113, 120, 2844, 2851, "placebo" +358, 18, 36, 577, 121, 126, 2852, 2857, "group" +358, 18, 37, 578, 127, 128, 2858, 2859, "." +358, 19, 1, 579, 0, 5, 2860, 2865, "After" +358, 19, 2, 580, 6, 8, 2866, 2868, "24" +358, 19, 3, 581, 9, 14, 2869, 2874, "weeks" +358, 19, 4, 582, 15, 16, 2875, 2876, "," +358, 19, 5, 583, 17, 28, 2877, 2888, "sitagliptin" +358, 19, 6, 584, 29, 34, 2889, 2894, "added" +358, 19, 7, 585, 35, 37, 2895, 2897, "to" +358, 19, 8, 586, 38, 50, 2898, 2910, "pioglitazone" +358, 19, 9, 587, 51, 58, 2911, 2918, "therapy" +358, 19, 10, 588, 59, 62, 2919, 2922, "was" +358, 19, 11, 589, 63, 73, 2923, 2933, "associated" +358, 19, 12, 590, 74, 78, 2934, 2938, "with" +358, 19, 13, 591, 79, 90, 2939, 2950, "significant" +358, 19, 14, 592, 91, 101, 2951, 2961, "reductions" +358, 19, 15, 593, 102, 110, 2962, 2970, "compared" +358, 19, 16, 594, 111, 115, 2971, 2975, "with" +358, 19, 17, 595, 116, 123, 2976, 2983, "placebo" +358, 19, 18, 596, 124, 126, 2984, 2986, "in" +358, 19, 19, 597, 127, 130, 2987, 2990, "HbA" +358, 19, 20, 598, 131, 132, 2991, 2992, "(" +358, 19, 21, 599, 133, 135, 2993, 2995, "1c" +358, 19, 22, 600, 136, 137, 2996, 2997, ")" +358, 19, 23, 601, 138, 139, 2998, 2999, "(" +358, 19, 24, 602, 140, 147, 3000, 3007, "between" +358, 19, 25, 603, 148, 149, 3008, 3009, "-" +358, 19, 26, 604, 150, 159, 3010, 3019, "treatment" +358, 19, 27, 605, 160, 170, 3020, 3030, "difference" +358, 19, 28, 606, 171, 173, 3031, 3033, "in" +358, 19, 29, 607, 174, 179, 3034, 3039, "least" +358, 19, 30, 608, 180, 187, 3040, 3047, "squares" +358, 19, 31, 609, 188, 189, 3048, 3049, "[" +358, 19, 32, 610, 190, 192, 3050, 3052, "LS" +358, 19, 33, 611, 193, 194, 3053, 3054, "]" +358, 19, 34, 612, 195, 199, 3055, 3059, "mean" +358, 19, 35, 613, 200, 206, 3060, 3066, "change" +358, 19, 36, 614, 207, 211, 3067, 3071, "from" +358, 19, 37, 615, 212, 220, 3072, 3080, "baseline" +358, 19, 38, 616, 221, 222, 3081, 3082, "." +358, 20, 1, 617, 0, 1, 3083, 3084, "-" +358, 20, 2, 618, 2, 3, 3085, 3086, "0" +358, 20, 3, 619, 4, 5, 3087, 3088, "." +358, 20, 4, 620, 6, 8, 3089, 3091, "70" +358, 20, 5, 621, 9, 10, 3092, 3093, "%" +358, 20, 6, 622, 11, 12, 3094, 3095, ";" +358, 20, 7, 623, 13, 15, 3096, 3098, "95" +358, 20, 8, 624, 16, 17, 3099, 3100, "%" +358, 20, 9, 625, 18, 20, 3101, 3103, "CI" +358, 20, 10, 626, 21, 22, 3104, 3105, "," +358, 20, 11, 627, 23, 24, 3106, 3107, "-" +358, 20, 12, 628, 25, 26, 3108, 3109, "0" +358, 20, 13, 629, 27, 28, 3110, 3111, "." +358, 20, 14, 630, 29, 31, 3112, 3114, "85" +358, 20, 15, 631, 32, 34, 3115, 3117, "to" +358, 20, 16, 632, 35, 36, 3118, 3119, "-" +358, 20, 17, 633, 37, 38, 3120, 3121, "0" +358, 20, 18, 634, 39, 40, 3122, 3123, "." +358, 20, 19, 635, 41, 43, 3124, 3126, "54" +358, 20, 20, 636, 44, 45, 3127, 3128, ";" +358, 20, 21, 637, 46, 47, 3129, 3130, "P" +358, 20, 22, 638, 48, 49, 3131, 3132, "<" +358, 20, 23, 639, 50, 51, 3133, 3134, "0" +358, 20, 24, 640, 52, 53, 3135, 3136, "." +358, 20, 25, 641, 54, 57, 3137, 3140, "001" +358, 20, 26, 642, 58, 59, 3141, 3142, ")" +358, 20, 27, 643, 60, 63, 3143, 3146, "and" +358, 20, 28, 644, 64, 67, 3147, 3150, "FPG" +358, 20, 29, 645, 68, 69, 3151, 3152, "(" +358, 20, 30, 646, 70, 71, 3153, 3154, "-" +358, 20, 31, 647, 72, 74, 3155, 3157, "17" +358, 20, 32, 648, 75, 76, 3158, 3159, "." +358, 20, 33, 649, 77, 78, 3160, 3161, "7" +358, 20, 34, 650, 79, 81, 3162, 3164, "mg" +358, 20, 35, 651, 82, 83, 3165, 3166, "/" +358, 20, 36, 652, 84, 86, 3167, 3169, "dL" +358, 20, 37, 653, 87, 88, 3170, 3171, ";" +358, 20, 38, 654, 89, 91, 3172, 3174, "95" +358, 20, 39, 655, 92, 93, 3175, 3176, "%" +358, 20, 40, 656, 94, 96, 3177, 3179, "CI" +358, 20, 41, 657, 97, 98, 3180, 3181, "," +358, 20, 42, 658, 99, 100, 3182, 3183, "-" +358, 20, 43, 659, 101, 103, 3184, 3186, "24" +358, 20, 44, 660, 104, 105, 3187, 3188, "." +358, 20, 45, 661, 106, 107, 3189, 3190, "3" +358, 20, 46, 662, 108, 110, 3191, 3193, "to" +358, 20, 47, 663, 111, 112, 3194, 3195, "-" +358, 20, 48, 664, 113, 115, 3196, 3198, "11" +358, 20, 49, 665, 116, 117, 3199, 3200, "." +358, 20, 50, 666, 118, 119, 3201, 3202, "0" +358, 20, 51, 667, 120, 121, 3203, 3204, ";" +358, 20, 52, 668, 122, 123, 3205, 3206, "P" +358, 20, 53, 669, 124, 125, 3207, 3208, "<" +358, 20, 54, 670, 126, 127, 3209, 3210, "0" +358, 20, 55, 671, 128, 129, 3211, 3212, "." +358, 20, 56, 672, 130, 133, 3213, 3216, "001" +358, 20, 57, 673, 134, 135, 3217, 3218, ")" +358, 20, 58, 674, 136, 137, 3219, 3220, "." +358, 21, 1, 675, 0, 4, 3221, 3225, "Mean" +358, 21, 2, 676, 5, 8, 3226, 3229, "HbA" +358, 21, 3, 677, 9, 10, 3230, 3231, "(" +358, 21, 4, 678, 11, 13, 3232, 3234, "1c" +358, 21, 5, 679, 14, 15, 3235, 3236, ")" +358, 21, 6, 680, 16, 22, 3237, 3243, "values" +358, 21, 7, 681, 23, 25, 3244, 3246, "at" +358, 21, 8, 682, 26, 29, 3247, 3250, "end" +358, 21, 9, 683, 30, 35, 3251, 3256, "point" +358, 21, 10, 684, 36, 40, 3257, 3261, "were" +358, 21, 11, 685, 41, 42, 3262, 3263, "7" +358, 21, 12, 686, 43, 44, 3264, 3265, "." +358, 21, 13, 687, 45, 46, 3266, 3267, "2" +358, 21, 14, 688, 47, 48, 3268, 3269, "%" +358, 21, 15, 689, 49, 50, 3270, 3271, "(" +358, 21, 16, 690, 51, 52, 3272, 3273, "0" +358, 21, 17, 691, 53, 54, 3274, 3275, "." +358, 21, 18, 692, 55, 56, 3276, 3277, "9" +358, 21, 19, 693, 57, 58, 3278, 3279, ")" +358, 21, 20, 694, 59, 62, 3280, 3283, "and" +358, 21, 21, 695, 63, 64, 3284, 3285, "7" +358, 21, 22, 696, 65, 66, 3286, 3287, "." +358, 21, 23, 697, 67, 68, 3288, 3289, "8" +358, 21, 24, 698, 69, 70, 3290, 3291, "%" +358, 21, 25, 699, 71, 72, 3292, 3293, "(" +358, 21, 26, 700, 73, 74, 3294, 3295, "1" +358, 21, 27, 701, 75, 76, 3296, 3297, "." +358, 21, 28, 702, 77, 78, 3298, 3299, "1" +358, 21, 29, 703, 79, 80, 3300, 3301, ")" +358, 21, 30, 704, 81, 83, 3302, 3304, "in" +358, 21, 31, 705, 84, 87, 3305, 3308, "the" +358, 21, 32, 706, 88, 98, 3309, 3319, "respective" +358, 21, 33, 707, 99, 108, 3320, 3329, "treatment" +358, 21, 34, 708, 109, 115, 3330, 3336, "groups" +358, 21, 35, 709, 116, 117, 3337, 3338, "," +358, 21, 36, 710, 118, 121, 3339, 3342, "and" +358, 21, 37, 711, 122, 125, 3343, 3346, "the" +358, 21, 38, 712, 126, 137, 3347, 3358, "proportions" +358, 21, 39, 713, 138, 140, 3359, 3361, "of" +358, 21, 40, 714, 141, 149, 3362, 3370, "patients" +358, 21, 41, 715, 150, 158, 3371, 3379, "reaching" +358, 21, 42, 716, 159, 160, 3380, 3381, "a" +358, 21, 43, 717, 161, 167, 3382, 3388, "target" +358, 21, 44, 718, 168, 171, 3389, 3392, "HbA" +358, 21, 45, 719, 172, 173, 3393, 3394, "(" +358, 21, 46, 720, 174, 176, 3395, 3397, "1c" +358, 21, 47, 721, 177, 178, 3398, 3399, ")" +358, 21, 48, 722, 179, 181, 3400, 3402, "of" +358, 21, 49, 723, 182, 183, 3403, 3404, "<" +358, 21, 50, 724, 184, 185, 3405, 3406, "7" +358, 21, 51, 725, 186, 187, 3407, 3408, "." +358, 21, 52, 726, 188, 189, 3409, 3410, "0" +358, 21, 53, 727, 190, 191, 3411, 3412, "%" +358, 21, 54, 728, 192, 196, 3413, 3417, "were" +358, 21, 55, 729, 197, 199, 3418, 3420, "45" +358, 21, 56, 730, 200, 201, 3421, 3422, "." +358, 21, 57, 731, 202, 203, 3423, 3424, "4" +358, 21, 58, 732, 204, 205, 3425, 3426, "%" +358, 21, 59, 733, 206, 209, 3427, 3430, "and" +358, 21, 60, 734, 210, 212, 3431, 3433, "23" +358, 21, 61, 735, 213, 214, 3434, 3435, "." +358, 21, 62, 736, 215, 216, 3436, 3437, "0" +358, 21, 63, 737, 217, 218, 3438, 3439, "%" +358, 21, 64, 738, 219, 220, 3440, 3441, "(" +358, 21, 65, 739, 221, 222, 3442, 3443, "P" +358, 21, 66, 740, 223, 224, 3444, 3445, "<" +358, 21, 67, 741, 225, 226, 3446, 3447, "0" +358, 21, 68, 742, 227, 228, 3448, 3449, "." +358, 21, 69, 743, 229, 232, 3450, 3453, "001" +358, 21, 70, 744, 233, 234, 3454, 3455, ")" +358, 21, 71, 745, 235, 236, 3456, 3457, "." +358, 22, 1, 746, 0, 11, 3458, 3469, "Significant" +358, 22, 2, 747, 12, 22, 3470, 3480, "reductions" +358, 22, 3, 748, 23, 25, 3481, 3483, "in" +358, 22, 4, 749, 26, 33, 3484, 3491, "fasting" +358, 22, 5, 750, 34, 39, 3492, 3497, "serum" +358, 22, 6, 751, 40, 50, 3498, 3508, "proinsulin" +358, 22, 7, 752, 51, 57, 3509, 3515, "levels" +358, 22, 8, 753, 58, 61, 3516, 3519, "and" +358, 22, 9, 754, 62, 65, 3520, 3523, "the" +358, 22, 10, 755, 66, 76, 3524, 3534, "proinsulin" +358, 22, 11, 756, 77, 78, 3535, 3536, "/" +358, 22, 12, 757, 79, 86, 3537, 3544, "insulin" +358, 22, 13, 758, 87, 92, 3545, 3550, "ratio" +358, 22, 14, 759, 93, 97, 3551, 3555, "were" +358, 22, 15, 760, 98, 102, 3556, 3560, "seen" +358, 22, 16, 761, 103, 107, 3561, 3565, "with" +358, 22, 17, 762, 108, 119, 3566, 3577, "sitagliptin" +358, 22, 18, 763, 120, 129, 3578, 3587, "treatment" +358, 22, 19, 764, 130, 138, 3588, 3596, "compared" +358, 22, 20, 765, 139, 143, 3597, 3601, "with" +358, 22, 21, 766, 144, 151, 3602, 3609, "placebo" +358, 22, 22, 767, 152, 153, 3610, 3611, "(" +358, 22, 23, 768, 154, 158, 3612, 3616, "both" +358, 22, 24, 769, 159, 160, 3617, 3618, "," +358, 22, 25, 770, 161, 162, 3619, 3620, "P" +358, 22, 26, 771, 163, 164, 3621, 3622, "<" +358, 22, 27, 772, 165, 166, 3623, 3624, "0" +358, 22, 28, 773, 167, 168, 3625, 3626, "." +358, 22, 29, 774, 169, 171, 3627, 3629, "01" +358, 22, 30, 775, 172, 173, 3630, 3631, ")" +358, 22, 31, 776, 174, 175, 3632, 3633, "." +358, 23, 1, 777, 0, 11, 3634, 3645, "Sitagliptin" +358, 23, 2, 778, 12, 15, 3646, 3649, "was" +358, 23, 3, 779, 16, 25, 3650, 3659, "generally" +358, 23, 4, 780, 26, 30, 3660, 3664, "well" +358, 23, 5, 781, 31, 40, 3665, 3674, "tolerated" +358, 23, 6, 782, 41, 42, 3675, 3676, "," +358, 23, 7, 783, 43, 47, 3677, 3681, "with" +358, 23, 8, 784, 48, 50, 3682, 3684, "no" +358, 23, 9, 785, 51, 60, 3685, 3694, "increased" +358, 23, 10, 786, 61, 65, 3695, 3699, "risk" +358, 23, 11, 787, 66, 68, 3700, 3702, "of" +358, 23, 12, 788, 69, 81, 3703, 3715, "hypoglycemia" +358, 23, 13, 789, 82, 90, 3716, 3724, "compared" +358, 23, 14, 790, 91, 95, 3725, 3729, "with" +358, 23, 15, 791, 96, 103, 3730, 3737, "placebo" +358, 23, 16, 792, 104, 105, 3738, 3739, "(" +358, 23, 17, 793, 106, 107, 3740, 3741, "2" +358, 23, 18, 794, 108, 110, 3742, 3744, "vs" +358, 23, 19, 795, 111, 112, 3745, 3746, "0" +358, 23, 20, 796, 113, 121, 3747, 3755, "patients" +358, 23, 21, 797, 122, 123, 3756, 3757, "," +358, 23, 22, 798, 124, 136, 3758, 3770, "respectively" +358, 23, 23, 799, 137, 138, 3771, 3772, ")" +358, 23, 24, 800, 139, 140, 3773, 3774, "." +358, 24, 1, 801, 0, 3, 3775, 3778, "DOI" +358, 24, 2, 802, 4, 5, 3779, 3780, ":" +358, 24, 3, 803, 6, 8, 3781, 3783, "10" +358, 24, 4, 804, 9, 10, 3784, 3785, "." +358, 24, 5, 805, 11, 15, 3786, 3790, "1016" +358, 24, 6, 806, 16, 17, 3791, 3792, "/" +358, 24, 7, 807, 18, 19, 3793, 3794, "j" +358, 24, 8, 808, 20, 21, 3795, 3796, "." +358, 24, 9, 809, 22, 31, 3797, 3806, "clinthera" +358, 24, 10, 810, 32, 33, 3807, 3808, "." +358, 24, 11, 811, 34, 38, 3809, 3813, "2006" +358, 24, 12, 812, 39, 40, 3814, 3815, "." +358, 24, 13, 813, 41, 43, 3816, 3818, "10" +358, 24, 14, 814, 44, 45, 3819, 3820, "." +358, 24, 15, 815, 46, 49, 3821, 3824, "007" +358, 24, 16, 816, 50, 54, 3825, 3829, "PMID" +358, 24, 17, 817, 55, 56, 3830, 3831, ":" +358, 24, 18, 818, 57, 65, 3832, 3840, "17157112" +358, 24, 19, 819, 66, 67, 3841, 3842, "[" +358, 24, 20, 820, 68, 75, 3843, 3850, "Indexed" +358, 24, 21, 821, 76, 79, 3851, 3854, "for" +358, 24, 22, 822, 80, 87, 3855, 3862, "MEDLINE" +358, 24, 23, 823, 88, 89, 3863, 3864, "]" diff --git a/data/dm2 17157112_kwoodley.annodb b/data/dm2 17157112_kwoodley.annodb new file mode 100644 index 0000000..9da7f86 --- /dev/null +++ b/data/dm2 17157112_kwoodley.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4157, Journal, 0, 9, "Clin Ther", "", +10511, PublicationYear, 12, 16, "2006", "", +36850, Title, 47, 299, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study .", "", +10512, Sitagliptin, 109, 120, "sitagliptin", "", +10513, Pioglitazone, 138, 150, "pioglitazone", "", +10514, Type2Diabetes, 176, 191, "type 2 diabetes", "", +10515, Duration, 196, 205, "24 - week", "", +10516, Multicenter, 208, 219, "multicenter", "", +10517, Randomized, 222, 232, "randomized", "", +10518, DoubleBlind, 235, 249, "double - blind", "", +36851, Placebo, 252, 259, "placebo", "", +10520, Parallel, 275, 291, "parallel - group", "", +10522, Author, 300, 312, "Rosenstock J", "", +10523, Author, 321, 328, "Brazg R", "", +10524, Author, 331, 341, "Andryuk PJ", "", +10525, Author, 344, 348, "Lu K", "", +10526, Author, 351, 358, "Stein P", "", +10527, USA, 474, 477, "USA", "", +10537, ObjectiveDescription, 492, 613, "The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy", "", +10528, Sitagliptin, 564, 575, "sitagliptin", "", +10529, Pioglitazone, 593, 605, "pioglitazone", "", +36852, ObjectiveDescription, 614, 810, "were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone .", "", +10536, Precondition, 631, 808, "patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone", "", +10530, Type2Diabetes, 645, 660, "type 2 diabetes", "", +10531, HbA1c, 695, 718, "glycosylated hemoglobin", "", +10532, HbA1c, 721, 731, "HbA ( 1c )", "", +10533, Percentage, 743, 744, "%", "", +10534, Percentage, 759, 760, "%", "", +10535, Pioglitazone, 796, 808, "pioglitazone", "", +10539, Duration, 832, 841, "24 - week", "", +10540, Multicenter, 844, 855, "multicenter", "", +10541, Randomized, 858, 868, "randomized", "", +10542, DoubleBlind, 871, 885, "double - blind", "", +36853, Placebo, 888, 895, "placebo", "", +10544, Parallel, 911, 925, "parallel group", "", +10545, AvgAge, 949, 958, "> or = 18", "", +10546, Pioglitazone, 1162, 1174, "pioglitazone", "", +10547, HbA1c, 1328, 1338, "HbA ( 1c )", "", +10548, Percentage, 1348, 1349, "%", "", +10549, Percentage, 1364, 1365, "%", "", +10550, Pioglitazone, 1543, 1555, "pioglitazone", "", +10551, DoseValue, 1570, 1578, "30 or 45", "", +10552, mg, 1579, 1581, "mg", "", +10553, Frequency, 1584, 1585, "d", "", +10554, HbA1c, 1599, 1609, "HbA ( 1c )", "", +10555, Percentage, 1619, 1620, "%", "", +10556, Percentage, 1635, 1636, "%", "", +10557, Randomized, 1734, 1747, "randomization", "", +10558, Pioglitazone, 1786, 1798, "pioglitazone", "", +10559, DoseValue, 1801, 1809, "30 or 45", "", +10561, mg, 1810, 1812, "mg", "", +10563, Frequency, 1815, 1816, "d", "", +10565, Randomized, 1835, 1845, "randomized", "", +10568, AllocationRatio, 1851, 1856, "1 : 1", "", +10569, Sitagliptin, 1874, 1885, "sitagliptin", "", +10570, DoseValue, 1886, 1889, "100", "", +10571, mg, 1890, 1892, "mg", "", +10572, Frequency, 1893, 1903, "once daily", "", +10573, Placebo, 1907, 1914, "placebo", "", +10575, Duration, 1919, 1927, "24 weeks", "", +36854, TimePoint, 1981, 1989, "baseline", "", +10577, HbA1c, 1993, 2003, "HbA ( 1c )", "", +36855, TimePoint, 2007, 2014, "week 24", "", +36856, TimePoint, 2072, 2080, "baseline", "", +10583, FastingPlasmaGlucose, 2084, 2106, "fasting plasma glucose", "", +10584, FastingPlasmaGlucose, 2109, 2112, "FPG", "", +36857, InsulinDose, 2117, 2124, "insulin", "", +10588, EndPointDescription, 2131, 2141, "proinsulin", "", +10595, EndPointDescription, 2148, 2230, "Homeostasis Model Assessment beta - cell function and insulin - resistance indexes", "", +10597, EndPointDescription, 2237, 2263, "proinsulin / insulin ratio", "", +10598, EndPointDescription, 2270, 2314, "Quantitative Insulin Sensitivity Check Index", "", +36858, TimePoint, 2342, 2350, "baseline", "", +10602, EndPointDescription, 2363, 2379, "lipid parameters", "", +10606, HbA1c_target, 2451, 2481, "HbA ( 1c ) , goal of < 7 . 0 %", "", +10608, Metformin, 2521, 2530, "metformin", "", +10615, NumberPatientsArm, 2609, 2635, "One hundred seventy - five", "", +10614, Randomized, 2650, 2660, "randomized", "", +10617, Sitagliptin, 2672, 2683, "sitagliptin", "", +10618, NumberPatientsArm, 2690, 2693, "178", "", +10620, Randomized, 2699, 2709, "randomized", "", +10622, Placebo, 2721, 2728, "placebo", "", +10624, Mean, 2742, 2744, "SD", "", +10623, HbA1c, 2756, 2761, "HbAlc", "", +10626, BaseLineValue, 2772, 2777, "8 . 1", "", +10627, Percentage, 2778, 2779, "%", "", +10629, SdDevBL, 2782, 2787, "0 . 8", "", +10631, Sitagliptin, 2797, 2808, "sitagliptin", "", +10632, BaseLineValue, 2819, 2824, "8 . 0", "", +10634, Percentage, 2825, 2826, "%", "", +10636, SdDevBL, 2829, 2834, "0 . 8", "", +10637, Placebo, 2844, 2851, "placebo", "", +10639, Duration, 2866, 2874, "24 weeks", "", +10640, Sitagliptin, 2877, 2888, "sitagliptin", "", +10642, Pioglitazone, 2898, 2910, "pioglitazone", "", +10643, Placebo, 2976, 2983, "placebo", "", +10645, HbA1c, 2987, 2997, "HbA ( 1c )", "", +10653, DiffGroupAbsValue, 3083, 3091, "- 0 . 70", "", +10654, Percentage, 3092, 3093, "%", "", +10657, ConfIntervalDiff, 3096, 3126, "95 % CI , - 0 . 85 to - 0 . 54", "", +10658, PvalueDiff, 3129, 3140, "P < 0 . 001", "", +10661, FastingPlasmaGlucose, 3147, 3150, "FPG", "", +10663, DiffGroupAbsValue, 3153, 3161, "- 17 . 7", "", +10664, Mg_per_deciliter, 3162, 3169, "mg / dL", "", +10666, ConfIntervalDiff, 3172, 3202, "95 % CI , - 24 . 3 to - 11 . 0", "", +10669, PvalueDiff, 3205, 3216, "P < 0 . 001", "", +10671, HbA1c, 3226, 3236, "HbA ( 1c )", "", +10674, ResultMeasuredValue, 3262, 3267, "7 . 2", "", +10678, Percentage, 3268, 3269, "%", "", +10682, SdDevResValue, 3272, 3277, "0 . 9", "", +10677, ResultMeasuredValue, 3284, 3289, "7 . 8", "", +10679, Percentage, 3290, 3291, "%", "", +10683, SdDevResValue, 3294, 3299, "1 . 1", "", +10685, HbA1c_target, 3382, 3412, "target HbA ( 1c ) of < 7 . 0 %", "", +10686, PercentageAffected, 3418, 3424, "45 . 4", "", +10687, PercentageAffected, 3431, 3437, "23 . 0", "", +10689, PvalueDiff, 3442, 3453, "P < 0 . 001", "", +10703, ObservedResult, 3458, 3480, "Significant reductions", "", +10691, EndPointDescription, 3484, 3515, "fasting serum proinsulin levels", "", +10692, EndPointDescription, 3524, 3550, "proinsulin / insulin ratio", "", +10694, Sitagliptin, 3566, 3577, "sitagliptin", "", +36859, Placebo, 3602, 3609, "placebo", "", +10699, PValueChangeValue, 3619, 3629, "P < 0 . 01", "", +10705, Sitagliptin, 3634, 3645, "Sitagliptin", "", +10715, ObservedResult, 3682, 3699, "no increased risk", "", +10709, Hypoglycemia, 3703, 3715, "hypoglycemia", "", +10712, Placebo, 3730, 3737, "placebo", "", +10713, NumberAffected, 3740, 3741, "2", "", +10714, NumberAffected, 3745, 3746, "0", "", +10716, PMID, 3832, 3840, "17157112", "", diff --git a/data/dm2 17157112_kwoodley.n-triples b/data/dm2 17157112_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17157112_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17363756_admin.annodb b/data/dm2 17363756_admin.annodb new file mode 100644 index 0000000..d0f5f41 --- /dev/null +++ b/data/dm2 17363756_admin.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +75, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +0, PublicationYear, 16, 20, "2007", "", " \"2007\"." +1, PublicationYear, 54, 58, "2007", "", +153, Title, 68, 260, "A randomized , double - blind , placebo - controlled , multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients .", "", " \"A randomized , double - blind , placebo - controlled , multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients .\"." +2, Randomized, 70, 80, "randomized", "", " ." +3, DoubleBlind, 83, 97, "double - blind", "", " ." +79, Placebo, 100, 107, "placebo", "", +4, Multicenter, 123, 134, "multicenter", "", " ." +5, Drug, 178, 188, "topiramate", "", +7, Precondition, 228, 258, "obese type 2 diabetic patients", "", +6, Type2Diabetes, 234, 249, "type 2 diabetic", "", +8, Author, 261, 273, "Rosenstock J", "", " \"Rosenstock J\"." +9, Author, 282, 293, "Hollander P", "", " \"Hollander P\"." +10, Author, 296, 304, "Gadde KM", "", " \"Gadde KM\"." +11, Author, 307, 312, "Sun X", "", " \"Sun X\"." +12, Author, 315, 324, "Strauss R", "", " \"Strauss R\"." +13, Author, 327, 334, "Leung A", "", " \"Leung A\"." +14, USA, 450, 453, "USA", "", " ." +20, ObjectiveDescription, 507, 642, "This is a randomized , placebo - controlled study of the weight - loss efficacy and safety of a controlled - release ( CR ) formulation", "", " \"This is a randomized , placebo - controlled study of the weight - loss efficacy and safety of a controlled - release ( CR ) formulation\"." +15, Randomized, 517, 527, "randomized", "", +92, Placebo, 530, 537, "placebo", "", +21, BodyWeight, 564, 570, "weight", "", +155, ObjectiveDescription, 643, 782, "of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin .", "", " \"of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin .\"." +16, Drug, 646, 656, "topiramate", "", +19, Precondition, 660, 780, "overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin", "", +17, Type2Diabetes, 695, 710, "type 2 diabetes", "", " ." +18, Metformin, 771, 780, "metformin", "", +28, Precondition, 813, 979, "Patients with type 2 diabetes , BMI > or = 27 kg / m2 , A1C > 6 . 5 and < 11 . 0 % , treated with diet and exercise alone or in combination with metformin monotherapy", "", " \"Patients with type 2 diabetes , BMI > or = 27 kg / m2 , A1C > 6 . 5 and < 11 . 0 % , treated with diet and exercise alone or in combination with metformin monotherapy\"." +22, Type2Diabetes, 827, 842, "type 2 diabetes", "", +23, BMI, 845, 848, "BMI", "", +25, Kg_per_squareMeter, 859, 866, "kg / m2", "", +24, HbA1c, 869, 872, "A1C", "", +26, Percentage, 894, 895, "%", "", +27, Metformin, 958, 967, "metformin", "", +29, Randomized, 1010, 1020, "randomized", "", +30, Placebo, 1024, 1031, "placebo", "", " ." +31, Drug, 1035, 1045, "topiramate", "", " . ." +51213, DoseDescription, 1049, 1076, "titrated up to 175 mg / day", "", " \"titrated up to 175 mg / day\"." +32, DoseValue, 1064, 1067, "175", "", " \"175\"." +33, mg, 1068, 1070, "mg", "", " ." +34, Interval, 1073, 1076, "day", "", " \"day\"." +35, Duration, 1104, 1112, "7 - week", "", " \"7 - week\"." +36, Duration, 1143, 1151, "9 - week", "", +37, NumberPatientsCT, 1193, 1196, "111", "", " \"111\"." +38, Randomized, 1211, 1221, "randomized", "", +39, TimePoint, 1251, 1258, "week 16", "", +40, Placebo, 1277, 1284, "placebo", "", +41, Drug, 1289, 1299, "topiramate", "", +42, Reduction, 1312, 1317, "2 . 5", "", " \"2 . 5\"." +43, Reduction, 1322, 1327, "6 . 0", "", " \"6 . 0\"." +44, Kg, 1328, 1330, "kg", "", " ." +45, RelativeReduction, 1351, 1356, "2 . 3", "", " \"2 . 3\"." +46, RelativeReduction, 1361, 1366, "5 . 8", "", " \"5 . 8\"." +72, BodyWeight, 1404, 1415, "body weight", "", " ." +47, PvalueDiff, 1418, 1429, "P < 0 . 001", "", " \"P < 0 . 001\"." +73, Placebo, 1435, 1442, "placebo", "", +48, HbA1c, 1447, 1450, "A1C", "", " ." +166, TimePoint, 1467, 1475, "baseline", "", +49, BaseLineValue, 1479, 1484, "7 . 4", "", " \"7 . 4\"." +50, Percentage, 1485, 1486, "%", "", " ." +51, Placebo, 1494, 1501, "placebo", "", +52, BaseLineValue, 1506, 1511, "7 . 6", "", " \"7 . 6\"." +53, Percentage, 1512, 1513, "%", "", " \"7 . 6\"." +54, Drug, 1521, 1531, "topiramate", "", +55, ResultMeasuredValue, 1542, 1547, "7 . 1", "", " \"7 . 1\"." +56, ResultMeasuredValue, 1552, 1557, "6 . 7", "", " \"6 . 7\"." +57, Percentage, 1558, 1559, "%", "", +58, RelativeReduction, 1592, 1597, "0 . 4", "", " \"0 . 4\"." +59, RelativeReduction, 1602, 1607, "0 . 9", "", " \"0 . 9\"." +165, TimePoint, 1625, 1633, "baseline", "", +60, PvalueDiff, 1651, 1662, "P < 0 . 001", "", " \"P < 0 . 001\"." +74, Placebo, 1668, 1675, "placebo", "", +61, Drug, 1680, 1690, "Topiramate", "", +140, ObservedResult, 1696, 1717, "significantly reduced", "", " \"significantly reduced\". \"significantly reduced\"." +157, BloodPressure, 1718, 1732, "blood pressure", "", " . ." +62, EndPointDescription, 1737, 1762, "urinary albumin excretion", "", " . ." +159, EndPointDescription, 1765, 1779, "Adverse events", "", " . ." +160, ObservedResult, 1780, 1864, "were predominantly neuropsychiatric or central and peripheral nervous system related", "", " \"were predominantly neuropsychiatric or central and peripheral nervous system related\"." +63, Drug, 1881, 1891, "Topiramate", "", +161, ConclusionComment, 1881, 2096, "Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin .", "", " \"Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin .\"." +142, BodyWeight, 1926, 1937, "weight loss", "", +65, HbA1c, 1969, 1972, "A1C", "", +163, BloodPressure, 1977, 1991, "blood pressure", "", +66, Type2Diabetes, 2015, 2030, "type 2 diabetes", "", +67, Metformin, 2085, 2094, "metformin", "", +162, ConclusionComment, 2097, 2252, "However , the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes .", "", " \"However , the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes .\"." +69, Drug, 2175, 2185, "topiramate", "", +70, Type2Diabetes, 2242, 2250, "diabetes", "", +71, PMID, 2290, 2298, "17363756", "", " \"17363756\"." diff --git a/data/dm2 17363756_admin.n-triples b/data/dm2 17363756_admin.n-triples new file mode 100644 index 0000000..b2fbc79 --- /dev/null +++ b/data/dm2 17363756_admin.n-triples @@ -0,0 +1,161 @@ +# RDF export of group: Publication + . + "Publication " . + "A randomized , double - blind , placebo - controlled , multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients ." . + "Rosenstock J" . + "2007" . + "Diabetes Care" . + "17363756" . + . + "Hollander P" . + "Gadde KM" . + "Sun X" . + "Strauss R" . + "Leung A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This is a randomized , placebo - controlled study of the weight - loss efficacy and safety of a controlled - release ( CR ) formulation" . + "111" . + "7 - week" . + . + . + . + "Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin ." . + . + . + . + . + . + "of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin ." . + . + . + "However , the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes ." . + . + . +# RDF export of group: Population + . + "Population " . + "Patients with type 2 diabetes , BMI > or = 27 kg / m2 , A1C > 6 . 5 and < 11 . 0 % , treated with diet and exercise alone or in combination with metformin monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint bp" . + . + . + . + . + . + . + "Endpoint uae" . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm t" . + . + . + . + . + . + . + . + "Arm p" . + . + . + . +# RDF export of group: Intervention + . + "Intervention t" . + . + "day" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication t" . + . + . + "175" . + . + . + "titrated up to 175 mg / day" . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome weight t " . + . + "6 . 0" . + "5 . 8" . + . + "Outcome weight p " . + . + "2 . 5" . + "2 . 3" . + . + "Outcome hba1c t" . + . + "7 . 6" . + "6 . 7" . + "0 . 9" . + . + "Outcome hba1c p " . + . + "7 . 4" . + "7 . 1" . + "0 . 4" . + . + "Outcome bp t" . + . + "significantly reduced" . + . + "Outcome uae t" . + . + "significantly reduced" . + . + "Outcome aes t" . + . + "were predominantly neuropsychiatric or central and peripheral nervous system related" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups weight" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups hba1c" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17363756_akramersunderbrink.annodb b/data/dm2 17363756_akramersunderbrink.annodb new file mode 100644 index 0000000..a3d6d08 --- /dev/null +++ b/data/dm2 17363756_akramersunderbrink.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +10087, Journal, 0, 13, "Diabetes Care", "", +10088, PublicationYear, 16, 20, "2007", "", +10113, Title, 68, 258, "A randomized , double - blind , placebo - controlled , multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients", "", +10089, Randomized, 70, 80, "randomized", "", +10090, DoubleBlind, 83, 97, "double - blind", "", +10091, Placebo, 100, 107, "placebo", "", +10092, Multicenter, 123, 134, "multicenter", "", +10094, Drug, 178, 188, "topiramate", "", +10095, Precondition, 228, 240, "obese type 2", "", +10093, Type2Diabetes, 234, 249, "type 2 diabetic", "", +10096, Author, 261, 273, "Rosenstock J", "", +10097, Author, 282, 293, "Hollander P", "", +10098, Author, 296, 304, "Gadde KM", "", +10099, Author, 307, 312, "Sun X", "", +10100, Author, 315, 324, "Strauss R", "", +10101, Author, 327, 334, "Leung A", "", +10102, USA, 450, 453, "USA", "", +10114, ObjectiveDescription, 507, 753, "This is a randomized , placebo - controlled study of the weight - loss efficacy and safety of a controlled - release ( CR ) formulation of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in", "", +10103, Randomized, 517, 527, "randomized", "", +10104, Placebo, 530, 537, "placebo", "", +10112, Drug, 646, 656, "topiramate", "", +10105, Precondition, 660, 680, "overweight and obese", "", +10106, Type2Diabetes, 695, 710, "type 2 diabetes", "", +10115, ObjectiveDescription, 754, 780, "combination with metformin", "", +10107, Metformin, 771, 780, "metformin", "", +10108, Type2Diabetes, 827, 842, "type 2 diabetes", "", +10109, Precondition, 845, 866, "BMI > or = 27 kg / m2", "", +10110, Precondition, 869, 895, "A1C > 6 . 5 and < 11 . 0 %", "", +10111, Metformin, 958, 967, "metformin", "", +10122, Randomized, 1010, 1020, "randomized", "", +10123, Placebo, 1024, 1031, "placebo", "", +10124, Drug, 1035, 1045, "topiramate", "", +10125, DoseValue, 1064, 1067, "175", "", +10126, BioAndMedicalUnit, 1068, 1076, "mg / day", "", +10127, Duration, 1104, 1112, "7 - week", "", +10128, Duration, 1143, 1151, "9 - week", "", +10129, NumberPatientsCT, 1193, 1196, "111", "", +10130, Randomized, 1211, 1221, "randomized", "", +10131, TimePoint, 1240, 1258, "the end of week 16", "", +10132, Placebo, 1277, 1284, "placebo", "", +10133, Drug, 1289, 1299, "topiramate", "", +10134, Reduction, 1312, 1317, "2 . 5", "", +10135, Reduction, 1322, 1327, "6 . 0", "", +10136, Kg, 1328, 1330, "kg", "", +10137, RelativeReduction, 1351, 1356, "2 . 3", "", +10138, RelativeReduction, 1361, 1366, "5 . 8", "", +10139, Percentage, 1367, 1368, "%", "", +39139, TimePoint, 1395, 1408, "baseline body", "", +10140, BodyWeight, 1404, 1415, "body weight", "", +10141, PvalueDiff, 1418, 1429, "P < 0 . 001", "", +39142, Placebo, 1435, 1442, "placebo", "", +10142, HbA1c, 1447, 1450, "A1C", "", +39141, TimePoint, 1467, 1475, "baseline", "", +10143, BaseLineValue, 1479, 1484, "7 . 4", "", +10144, Percentage, 1485, 1486, "%", "", +10145, Placebo, 1494, 1501, "placebo", "", +10146, BaseLineValue, 1506, 1511, "7 . 6", "", +10147, Percentage, 1512, 1513, "%", "", +10148, Drug, 1521, 1531, "topiramate", "", +10149, ResultMeasuredValue, 1542, 1547, "7 . 1", "", +10150, ResultMeasuredValue, 1552, 1557, "6 . 7", "", +10151, Percentage, 1558, 1559, "%", "", +10152, Reduction, 1592, 1597, "0 . 4", "", +10153, Reduction, 1602, 1607, "0 . 9", "", +10155, Percentage, 1608, 1609, "%", "", +39140, TimePoint, 1625, 1633, "baseline", "", +10154, PvalueDiff, 1651, 1662, "P < 0 . 001", "", +39143, Placebo, 1668, 1675, "placebo", "", +10156, Drug, 1680, 1690, "Topiramate", "", +10159, ObservedResult, 1696, 1717, "significantly reduced", "", +10158, EndPointDescription, 1737, 1762, "urinary albumin excretion", "", +10160, Drug, 1881, 1891, "Topiramate", "", +10170, ConclusionComment, 1881, 2094, "Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin", "", +10161, BodyWeight, 1926, 1937, "weight loss", "", +10162, HbA1c, 1969, 1972, "A1C", "", +10164, Precondition, 1995, 2000, "obese", "", +10165, Type2Diabetes, 2015, 2030, "type 2 diabetes", "", +10166, Metformin, 2085, 2094, "metformin", "", +10171, ConclusionComment, 2097, 2250, "However , the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes", "", +10167, Drug, 2175, 2185, "topiramate", "", +10168, Type2Diabetes, 2242, 2250, "diabetes", "", +10169, PMID, 2290, 2298, "17363756", "", diff --git a/data/dm2 17363756_akramersunderbrink.n-triples b/data/dm2 17363756_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17363756_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17363756_export.csv b/data/dm2 17363756_export.csv new file mode 100644 index 0000000..e004195 --- /dev/null +++ b/data/dm2 17363756_export.csv @@ -0,0 +1,463 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +356, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +356, 1, 2, 2, 9, 13, 9, 13, "Care" +356, 1, 3, 3, 14, 15, 14, 15, "." +356, 2, 1, 4, 0, 4, 16, 20, "2007" +356, 2, 2, 5, 5, 8, 21, 24, "Jun" +356, 2, 3, 6, 9, 10, 25, 26, ";" +356, 2, 4, 7, 11, 13, 27, 29, "30" +356, 2, 5, 8, 14, 15, 30, 31, "(" +356, 2, 6, 9, 16, 17, 32, 33, "6" +356, 2, 7, 10, 18, 19, 34, 35, ")" +356, 2, 8, 11, 20, 21, 36, 37, ":" +356, 2, 9, 12, 22, 26, 38, 42, "1480" +356, 2, 10, 13, 27, 28, 43, 44, "-" +356, 2, 11, 14, 29, 30, 45, 46, "6" +356, 2, 12, 15, 31, 32, 47, 48, "." +356, 3, 1, 16, 0, 4, 49, 53, "Epub" +356, 3, 2, 17, 5, 9, 54, 58, "2007" +356, 3, 3, 18, 10, 13, 59, 62, "Mar" +356, 3, 4, 19, 14, 16, 63, 65, "15" +356, 3, 5, 20, 17, 18, 66, 67, "." +356, 4, 1, 21, 0, 1, 68, 69, "A" +356, 4, 2, 22, 2, 12, 70, 80, "randomized" +356, 4, 3, 23, 13, 14, 81, 82, "," +356, 4, 4, 24, 15, 21, 83, 89, "double" +356, 4, 5, 25, 22, 23, 90, 91, "-" +356, 4, 6, 26, 24, 29, 92, 97, "blind" +356, 4, 7, 27, 30, 31, 98, 99, "," +356, 4, 8, 28, 32, 39, 100, 107, "placebo" +356, 4, 9, 29, 40, 41, 108, 109, "-" +356, 4, 10, 30, 42, 52, 110, 120, "controlled" +356, 4, 11, 31, 53, 54, 121, 122, "," +356, 4, 12, 32, 55, 66, 123, 134, "multicenter" +356, 4, 13, 33, 67, 72, 135, 140, "study" +356, 4, 14, 34, 73, 75, 141, 143, "to" +356, 4, 15, 35, 76, 82, 144, 150, "assess" +356, 4, 16, 36, 83, 86, 151, 154, "the" +356, 4, 17, 37, 87, 95, 155, 163, "efficacy" +356, 4, 18, 38, 96, 99, 164, 167, "and" +356, 4, 19, 39, 100, 106, 168, 174, "safety" +356, 4, 20, 40, 107, 109, 175, 177, "of" +356, 4, 21, 41, 110, 120, 178, 188, "topiramate" +356, 4, 22, 42, 121, 131, 189, 199, "controlled" +356, 4, 23, 43, 132, 139, 200, 207, "release" +356, 4, 24, 44, 140, 142, 208, 210, "in" +356, 4, 25, 45, 143, 146, 211, 214, "the" +356, 4, 26, 46, 147, 156, 215, 224, "treatment" +356, 4, 27, 47, 157, 159, 225, 227, "of" +356, 4, 28, 48, 160, 165, 228, 233, "obese" +356, 4, 29, 49, 166, 170, 234, 238, "type" +356, 4, 30, 50, 171, 172, 239, 240, "2" +356, 4, 31, 51, 173, 181, 241, 249, "diabetic" +356, 4, 32, 52, 182, 190, 250, 258, "patients" +356, 4, 33, 53, 191, 192, 259, 260, "." +356, 5, 1, 54, 0, 10, 261, 271, "Rosenstock" +356, 5, 2, 55, 11, 12, 272, 273, "J" +356, 5, 3, 56, 13, 14, 274, 275, "(" +356, 5, 4, 57, 15, 16, 276, 277, "1" +356, 5, 5, 58, 17, 18, 278, 279, ")" +356, 5, 6, 59, 19, 20, 280, 281, "," +356, 5, 7, 60, 21, 30, 282, 291, "Hollander" +356, 5, 8, 61, 31, 32, 292, 293, "P" +356, 5, 9, 62, 33, 34, 294, 295, "," +356, 5, 10, 63, 35, 40, 296, 301, "Gadde" +356, 5, 11, 64, 41, 43, 302, 304, "KM" +356, 5, 12, 65, 44, 45, 305, 306, "," +356, 5, 13, 66, 46, 49, 307, 310, "Sun" +356, 5, 14, 67, 50, 51, 311, 312, "X" +356, 5, 15, 68, 52, 53, 313, 314, "," +356, 5, 16, 69, 54, 61, 315, 322, "Strauss" +356, 5, 17, 70, 62, 63, 323, 324, "R" +356, 5, 18, 71, 64, 65, 325, 326, "," +356, 5, 19, 72, 66, 71, 327, 332, "Leung" +356, 5, 20, 73, 72, 73, 333, 334, "A" +356, 5, 21, 74, 74, 75, 335, 336, ";" +356, 5, 22, 75, 76, 79, 337, 340, "OBD" +356, 5, 23, 76, 80, 81, 341, 342, "-" +356, 5, 24, 77, 82, 85, 343, 346, "202" +356, 5, 25, 78, 86, 91, 347, 352, "Study" +356, 5, 26, 79, 92, 97, 353, 358, "Group" +356, 5, 27, 80, 98, 99, 359, 360, "." +356, 6, 1, 81, 0, 6, 361, 367, "Author" +356, 6, 2, 82, 7, 18, 368, 379, "information" +356, 6, 3, 83, 19, 20, 380, 381, ":" +356, 6, 4, 84, 21, 22, 382, 383, "(" +356, 6, 5, 85, 23, 24, 384, 385, "1" +356, 6, 6, 86, 25, 26, 386, 387, ")" +356, 6, 7, 87, 27, 33, 388, 394, "Dallas" +356, 6, 8, 88, 34, 42, 395, 403, "Diabetes" +356, 6, 9, 89, 43, 46, 404, 407, "and" +356, 6, 10, 90, 47, 56, 408, 417, "Endocrine" +356, 6, 11, 91, 57, 63, 418, 424, "Center" +356, 6, 12, 92, 64, 65, 425, 426, "," +356, 6, 13, 93, 66, 72, 427, 433, "Dallas" +356, 6, 14, 94, 73, 74, 434, 435, "," +356, 6, 15, 95, 75, 80, 436, 441, "Texas" +356, 6, 16, 96, 81, 86, 442, 447, "75230" +356, 6, 17, 97, 87, 88, 448, 449, "," +356, 6, 18, 98, 89, 92, 450, 453, "USA" +356, 6, 19, 99, 93, 94, 454, 455, "." +356, 7, 1, 100, 0, 15, 456, 471, "juliorosenstock" +356, 7, 2, 101, 16, 17, 472, 473, "@" +356, 7, 3, 102, 18, 32, 474, 488, "dallasdiabetes" +356, 7, 4, 103, 33, 34, 489, 490, "." +356, 7, 5, 104, 35, 38, 491, 494, "com" +356, 7, 6, 105, 39, 48, 495, 504, "OBJECTIVE" +356, 7, 7, 106, 49, 50, 505, 506, ":" +356, 7, 8, 107, 51, 55, 507, 511, "This" +356, 7, 9, 108, 56, 58, 512, 514, "is" +356, 7, 10, 109, 59, 60, 515, 516, "a" +356, 7, 11, 110, 61, 71, 517, 527, "randomized" +356, 7, 12, 111, 72, 73, 528, 529, "," +356, 7, 13, 112, 74, 81, 530, 537, "placebo" +356, 7, 14, 113, 82, 83, 538, 539, "-" +356, 7, 15, 114, 84, 94, 540, 550, "controlled" +356, 7, 16, 115, 95, 100, 551, 556, "study" +356, 7, 17, 116, 101, 103, 557, 559, "of" +356, 7, 18, 117, 104, 107, 560, 563, "the" +356, 7, 19, 118, 108, 114, 564, 570, "weight" +356, 7, 20, 119, 115, 116, 571, 572, "-" +356, 7, 21, 120, 117, 121, 573, 577, "loss" +356, 7, 22, 121, 122, 130, 578, 586, "efficacy" +356, 7, 23, 122, 131, 134, 587, 590, "and" +356, 7, 24, 123, 135, 141, 591, 597, "safety" +356, 7, 25, 124, 142, 144, 598, 600, "of" +356, 7, 26, 125, 145, 146, 601, 602, "a" +356, 7, 27, 126, 147, 157, 603, 613, "controlled" +356, 7, 28, 127, 158, 159, 614, 615, "-" +356, 7, 29, 128, 160, 167, 616, 623, "release" +356, 7, 30, 129, 168, 169, 624, 625, "(" +356, 7, 31, 130, 170, 172, 626, 628, "CR" +356, 7, 32, 131, 173, 174, 629, 630, ")" +356, 7, 33, 132, 175, 186, 631, 642, "formulation" +356, 7, 34, 133, 187, 189, 643, 645, "of" +356, 7, 35, 134, 190, 200, 646, 656, "topiramate" +356, 7, 36, 135, 201, 203, 657, 659, "in" +356, 7, 37, 136, 204, 214, 660, 670, "overweight" +356, 7, 38, 137, 215, 218, 671, 674, "and" +356, 7, 39, 138, 219, 224, 675, 680, "obese" +356, 7, 40, 139, 225, 233, 681, 689, "patients" +356, 7, 41, 140, 234, 238, 690, 694, "with" +356, 7, 42, 141, 239, 243, 695, 699, "type" +356, 7, 43, 142, 244, 245, 700, 701, "2" +356, 7, 44, 143, 246, 254, 702, 710, "diabetes" +356, 7, 45, 144, 255, 262, 711, 718, "treated" +356, 7, 46, 145, 263, 267, 719, 723, "with" +356, 7, 47, 146, 268, 272, 724, 728, "diet" +356, 7, 48, 147, 273, 276, 729, 732, "and" +356, 7, 49, 148, 277, 285, 733, 741, "exercise" +356, 7, 50, 149, 286, 291, 742, 747, "alone" +356, 7, 51, 150, 292, 294, 748, 750, "or" +356, 7, 52, 151, 295, 297, 751, 753, "in" +356, 7, 53, 152, 298, 309, 754, 765, "combination" +356, 7, 54, 153, 310, 314, 766, 770, "with" +356, 7, 55, 154, 315, 324, 771, 780, "metformin" +356, 7, 56, 155, 325, 326, 781, 782, "." +356, 8, 1, 156, 0, 8, 783, 791, "RESEARCH" +356, 8, 2, 157, 9, 15, 792, 798, "DESIGN" +356, 8, 3, 158, 16, 19, 799, 802, "AND" +356, 8, 4, 159, 20, 27, 803, 810, "METHODS" +356, 8, 5, 160, 28, 29, 811, 812, ":" +356, 8, 6, 161, 30, 38, 813, 821, "Patients" +356, 8, 7, 162, 39, 43, 822, 826, "with" +356, 8, 8, 163, 44, 48, 827, 831, "type" +356, 8, 9, 164, 49, 50, 832, 833, "2" +356, 8, 10, 165, 51, 59, 834, 842, "diabetes" +356, 8, 11, 166, 60, 61, 843, 844, "," +356, 8, 12, 167, 62, 65, 845, 848, "BMI" +356, 8, 13, 168, 66, 67, 849, 850, ">" +356, 8, 14, 169, 68, 70, 851, 853, "or" +356, 8, 15, 170, 71, 72, 854, 855, "=" +356, 8, 16, 171, 73, 75, 856, 858, "27" +356, 8, 17, 172, 76, 78, 859, 861, "kg" +356, 8, 18, 173, 79, 80, 862, 863, "/" +356, 8, 19, 174, 81, 83, 864, 866, "m2" +356, 8, 20, 175, 84, 85, 867, 868, "," +356, 8, 21, 176, 86, 89, 869, 872, "A1C" +356, 8, 22, 177, 90, 91, 873, 874, ">" +356, 8, 23, 178, 92, 93, 875, 876, "6" +356, 8, 24, 179, 94, 95, 877, 878, "." +356, 8, 25, 180, 96, 97, 879, 880, "5" +356, 8, 26, 181, 98, 101, 881, 884, "and" +356, 8, 27, 182, 102, 103, 885, 886, "<" +356, 8, 28, 183, 104, 106, 887, 889, "11" +356, 8, 29, 184, 107, 108, 890, 891, "." +356, 8, 30, 185, 109, 110, 892, 893, "0" +356, 8, 31, 186, 111, 112, 894, 895, "%" +356, 8, 32, 187, 113, 114, 896, 897, "," +356, 8, 33, 188, 115, 122, 898, 905, "treated" +356, 8, 34, 189, 123, 127, 906, 910, "with" +356, 8, 35, 190, 128, 132, 911, 915, "diet" +356, 8, 36, 191, 133, 136, 916, 919, "and" +356, 8, 37, 192, 137, 145, 920, 928, "exercise" +356, 8, 38, 193, 146, 151, 929, 934, "alone" +356, 8, 39, 194, 152, 154, 935, 937, "or" +356, 8, 40, 195, 155, 157, 938, 940, "in" +356, 8, 41, 196, 158, 169, 941, 952, "combination" +356, 8, 42, 197, 170, 174, 953, 957, "with" +356, 8, 43, 198, 175, 184, 958, 967, "metformin" +356, 8, 44, 199, 185, 196, 968, 979, "monotherapy" +356, 8, 45, 200, 197, 201, 980, 984, "were" +356, 8, 46, 201, 202, 210, 985, 993, "enrolled" +356, 8, 47, 202, 211, 212, 994, 995, "." +356, 9, 1, 203, 0, 8, 996, 1004, "Patients" +356, 9, 2, 204, 9, 13, 1005, 1009, "were" +356, 9, 3, 205, 14, 24, 1010, 1020, "randomized" +356, 9, 4, 206, 25, 27, 1021, 1023, "to" +356, 9, 5, 207, 28, 35, 1024, 1031, "placebo" +356, 9, 6, 208, 36, 38, 1032, 1034, "or" +356, 9, 7, 209, 39, 49, 1035, 1045, "topiramate" +356, 9, 8, 210, 50, 52, 1046, 1048, "CR" +356, 9, 9, 211, 53, 61, 1049, 1057, "titrated" +356, 9, 10, 212, 62, 64, 1058, 1060, "up" +356, 9, 11, 213, 65, 67, 1061, 1063, "to" +356, 9, 12, 214, 68, 71, 1064, 1067, "175" +356, 9, 13, 215, 72, 74, 1068, 1070, "mg" +356, 9, 14, 216, 75, 76, 1071, 1072, "/" +356, 9, 15, 217, 77, 80, 1073, 1076, "day" +356, 9, 16, 218, 81, 82, 1077, 1078, "." +356, 10, 1, 219, 0, 9, 1079, 1088, "Treatment" +356, 10, 2, 220, 10, 19, 1089, 1098, "consisted" +356, 10, 3, 221, 20, 22, 1099, 1101, "of" +356, 10, 4, 222, 23, 24, 1102, 1103, "a" +356, 10, 5, 223, 25, 26, 1104, 1105, "7" +356, 10, 6, 224, 27, 28, 1106, 1107, "-" +356, 10, 7, 225, 29, 33, 1108, 1112, "week" +356, 10, 8, 226, 34, 43, 1113, 1122, "titration" +356, 10, 9, 227, 44, 49, 1123, 1128, "phase" +356, 10, 10, 228, 50, 58, 1129, 1137, "followed" +356, 10, 11, 229, 59, 61, 1138, 1140, "by" +356, 10, 12, 230, 62, 63, 1141, 1142, "a" +356, 10, 13, 231, 64, 65, 1143, 1144, "9" +356, 10, 14, 232, 66, 67, 1145, 1146, "-" +356, 10, 15, 233, 68, 72, 1147, 1151, "week" +356, 10, 16, 234, 73, 84, 1152, 1163, "maintenance" +356, 10, 17, 235, 85, 90, 1164, 1169, "phase" +356, 10, 18, 236, 91, 92, 1170, 1171, "." +356, 11, 1, 237, 0, 7, 1172, 1179, "RESULTS" +356, 11, 2, 238, 8, 9, 1180, 1181, ":" +356, 11, 3, 239, 10, 11, 1182, 1183, "A" +356, 11, 4, 240, 12, 17, 1184, 1189, "total" +356, 11, 5, 241, 18, 20, 1190, 1192, "of" +356, 11, 6, 242, 21, 24, 1193, 1196, "111" +356, 11, 7, 243, 25, 33, 1197, 1205, "subjects" +356, 11, 8, 244, 34, 38, 1206, 1210, "were" +356, 11, 9, 245, 39, 49, 1211, 1221, "randomized" +356, 11, 10, 246, 50, 53, 1222, 1225, "and" +356, 11, 11, 247, 54, 62, 1226, 1234, "analyzed" +356, 11, 12, 248, 63, 64, 1235, 1236, "." +356, 12, 1, 249, 0, 2, 1237, 1239, "By" +356, 12, 2, 250, 3, 6, 1240, 1243, "the" +356, 12, 3, 251, 7, 10, 1244, 1247, "end" +356, 12, 4, 252, 11, 13, 1248, 1250, "of" +356, 12, 5, 253, 14, 18, 1251, 1255, "week" +356, 12, 6, 254, 19, 21, 1256, 1258, "16" +356, 12, 7, 255, 22, 23, 1259, 1260, "," +356, 12, 8, 256, 24, 32, 1261, 1269, "patients" +356, 12, 9, 257, 33, 35, 1270, 1272, "in" +356, 12, 10, 258, 36, 39, 1273, 1276, "the" +356, 12, 11, 259, 40, 47, 1277, 1284, "placebo" +356, 12, 12, 260, 48, 51, 1285, 1288, "and" +356, 12, 13, 261, 52, 62, 1289, 1299, "topiramate" +356, 12, 14, 262, 63, 69, 1300, 1306, "groups" +356, 12, 15, 263, 70, 74, 1307, 1311, "lost" +356, 12, 16, 264, 75, 76, 1312, 1313, "2" +356, 12, 17, 265, 77, 78, 1314, 1315, "." +356, 12, 18, 266, 79, 80, 1316, 1317, "5" +356, 12, 19, 267, 81, 84, 1318, 1321, "and" +356, 12, 20, 268, 85, 86, 1322, 1323, "6" +356, 12, 21, 269, 87, 88, 1324, 1325, "." +356, 12, 22, 270, 89, 90, 1326, 1327, "0" +356, 12, 23, 271, 91, 93, 1328, 1330, "kg" +356, 12, 24, 272, 94, 95, 1331, 1332, "," +356, 12, 25, 273, 96, 101, 1333, 1338, "which" +356, 12, 26, 274, 102, 113, 1339, 1350, "represented" +356, 12, 27, 275, 114, 115, 1351, 1352, "2" +356, 12, 28, 276, 116, 117, 1353, 1354, "." +356, 12, 29, 277, 118, 119, 1355, 1356, "3" +356, 12, 30, 278, 120, 123, 1357, 1360, "and" +356, 12, 31, 279, 124, 125, 1361, 1362, "5" +356, 12, 32, 280, 126, 127, 1363, 1364, "." +356, 12, 33, 281, 128, 129, 1365, 1366, "8" +356, 12, 34, 282, 130, 131, 1367, 1368, "%" +356, 12, 35, 283, 132, 133, 1369, 1370, "," +356, 12, 36, 284, 134, 146, 1371, 1383, "respectively" +356, 12, 37, 285, 147, 148, 1384, 1385, "," +356, 12, 38, 286, 149, 151, 1386, 1388, "of" +356, 12, 39, 287, 152, 157, 1389, 1394, "their" +356, 12, 40, 288, 158, 166, 1395, 1403, "baseline" +356, 12, 41, 289, 167, 171, 1404, 1408, "body" +356, 12, 42, 290, 172, 178, 1409, 1415, "weight" +356, 12, 43, 291, 179, 180, 1416, 1417, "(" +356, 12, 44, 292, 181, 182, 1418, 1419, "P" +356, 12, 45, 293, 183, 184, 1420, 1421, "<" +356, 12, 46, 294, 185, 186, 1422, 1423, "0" +356, 12, 47, 295, 187, 188, 1424, 1425, "." +356, 12, 48, 296, 189, 192, 1426, 1429, "001" +356, 12, 49, 297, 193, 195, 1430, 1432, "vs" +356, 12, 50, 298, 196, 197, 1433, 1434, "." +356, 12, 51, 299, 198, 205, 1435, 1442, "placebo" +356, 12, 52, 300, 206, 207, 1443, 1444, ")" +356, 12, 53, 301, 208, 209, 1445, 1446, "." +356, 13, 1, 302, 0, 3, 1447, 1450, "A1C" +356, 13, 2, 303, 4, 12, 1451, 1459, "improved" +356, 13, 3, 304, 13, 17, 1460, 1464, "from" +356, 13, 4, 305, 18, 19, 1465, 1466, "a" +356, 13, 5, 306, 20, 28, 1467, 1475, "baseline" +356, 13, 6, 307, 29, 31, 1476, 1478, "of" +356, 13, 7, 308, 32, 33, 1479, 1480, "7" +356, 13, 8, 309, 34, 35, 1481, 1482, "." +356, 13, 9, 310, 36, 37, 1483, 1484, "4" +356, 13, 10, 311, 38, 39, 1485, 1486, "%" +356, 13, 11, 312, 40, 42, 1487, 1489, "in" +356, 13, 12, 313, 43, 46, 1490, 1493, "the" +356, 13, 13, 314, 47, 54, 1494, 1501, "placebo" +356, 13, 14, 315, 55, 58, 1502, 1505, "and" +356, 13, 15, 316, 59, 60, 1506, 1507, "7" +356, 13, 16, 317, 61, 62, 1508, 1509, "." +356, 13, 17, 318, 63, 64, 1510, 1511, "6" +356, 13, 18, 319, 65, 66, 1512, 1513, "%" +356, 13, 19, 320, 67, 69, 1514, 1516, "in" +356, 13, 20, 321, 70, 73, 1517, 1520, "the" +356, 13, 21, 322, 74, 84, 1521, 1531, "topiramate" +356, 13, 22, 323, 85, 91, 1532, 1538, "groups" +356, 13, 23, 324, 92, 94, 1539, 1541, "to" +356, 13, 24, 325, 95, 96, 1542, 1543, "7" +356, 13, 25, 326, 97, 98, 1544, 1545, "." +356, 13, 26, 327, 99, 100, 1546, 1547, "1" +356, 13, 27, 328, 101, 104, 1548, 1551, "and" +356, 13, 28, 329, 105, 106, 1552, 1553, "6" +356, 13, 29, 330, 107, 108, 1554, 1555, "." +356, 13, 30, 331, 109, 110, 1556, 1557, "7" +356, 13, 31, 332, 111, 112, 1558, 1559, "%" +356, 13, 32, 333, 113, 114, 1560, 1561, "," +356, 13, 33, 334, 115, 127, 1562, 1574, "respectively" +356, 13, 34, 335, 128, 129, 1575, 1576, "," +356, 13, 35, 336, 130, 142, 1577, 1589, "representing" +356, 13, 36, 337, 143, 144, 1590, 1591, "a" +356, 13, 37, 338, 145, 146, 1592, 1593, "0" +356, 13, 38, 339, 147, 148, 1594, 1595, "." +356, 13, 39, 340, 149, 150, 1596, 1597, "4" +356, 13, 40, 341, 151, 154, 1598, 1601, "and" +356, 13, 41, 342, 155, 156, 1602, 1603, "0" +356, 13, 42, 343, 157, 158, 1604, 1605, "." +356, 13, 43, 344, 159, 160, 1606, 1607, "9" +356, 13, 44, 345, 161, 162, 1608, 1609, "%" +356, 13, 45, 346, 163, 172, 1610, 1619, "reduction" +356, 13, 46, 347, 173, 177, 1620, 1624, "from" +356, 13, 47, 348, 178, 186, 1625, 1633, "baseline" +356, 13, 48, 349, 187, 188, 1634, 1635, "," +356, 13, 49, 350, 189, 201, 1636, 1648, "respectively" +356, 13, 50, 351, 202, 203, 1649, 1650, "(" +356, 13, 51, 352, 204, 205, 1651, 1652, "P" +356, 13, 52, 353, 206, 207, 1653, 1654, "<" +356, 13, 53, 354, 208, 209, 1655, 1656, "0" +356, 13, 54, 355, 210, 211, 1657, 1658, "." +356, 13, 55, 356, 212, 215, 1659, 1662, "001" +356, 13, 56, 357, 216, 218, 1663, 1665, "vs" +356, 13, 57, 358, 219, 220, 1666, 1667, "." +356, 13, 58, 359, 221, 228, 1668, 1675, "placebo" +356, 13, 59, 360, 229, 230, 1676, 1677, ")" +356, 13, 60, 361, 231, 232, 1678, 1679, "." +356, 14, 1, 362, 0, 10, 1680, 1690, "Topiramate" +356, 14, 2, 363, 11, 15, 1691, 1695, "also" +356, 14, 3, 364, 16, 29, 1696, 1709, "significantly" +356, 14, 4, 365, 30, 37, 1710, 1717, "reduced" +356, 14, 5, 366, 38, 43, 1718, 1723, "blood" +356, 14, 6, 367, 44, 52, 1724, 1732, "pressure" +356, 14, 7, 368, 53, 56, 1733, 1736, "and" +356, 14, 8, 369, 57, 64, 1737, 1744, "urinary" +356, 14, 9, 370, 65, 72, 1745, 1752, "albumin" +356, 14, 10, 371, 73, 82, 1753, 1762, "excretion" +356, 14, 11, 372, 83, 84, 1763, 1764, "." +356, 15, 1, 373, 0, 7, 1765, 1772, "Adverse" +356, 15, 2, 374, 8, 14, 1773, 1779, "events" +356, 15, 3, 375, 15, 19, 1780, 1784, "were" +356, 15, 4, 376, 20, 33, 1785, 1798, "predominantly" +356, 15, 5, 377, 34, 50, 1799, 1815, "neuropsychiatric" +356, 15, 6, 378, 51, 53, 1816, 1818, "or" +356, 15, 7, 379, 54, 61, 1819, 1826, "central" +356, 15, 8, 380, 62, 65, 1827, 1830, "and" +356, 15, 9, 381, 66, 76, 1831, 1841, "peripheral" +356, 15, 10, 382, 77, 84, 1842, 1849, "nervous" +356, 15, 11, 383, 85, 91, 1850, 1856, "system" +356, 15, 12, 384, 92, 99, 1857, 1864, "related" +356, 15, 13, 385, 100, 101, 1865, 1866, "." +356, 16, 1, 386, 0, 11, 1867, 1878, "CONCLUSIONS" +356, 16, 2, 387, 12, 13, 1879, 1880, ":" +356, 16, 3, 388, 14, 24, 1881, 1891, "Topiramate" +356, 16, 4, 389, 25, 27, 1892, 1894, "CR" +356, 16, 5, 390, 28, 37, 1895, 1904, "treatment" +356, 16, 6, 391, 38, 46, 1905, 1913, "produced" +356, 16, 7, 392, 47, 58, 1914, 1925, "significant" +356, 16, 8, 393, 59, 65, 1926, 1932, "weight" +356, 16, 9, 394, 66, 70, 1933, 1937, "loss" +356, 16, 10, 395, 71, 74, 1938, 1941, "and" +356, 16, 11, 396, 75, 85, 1942, 1952, "meaningful" +356, 16, 12, 397, 86, 98, 1953, 1965, "improvements" +356, 16, 13, 398, 99, 101, 1966, 1968, "in" +356, 16, 14, 399, 102, 105, 1969, 1972, "A1C" +356, 16, 15, 400, 106, 109, 1973, 1976, "and" +356, 16, 16, 401, 110, 115, 1977, 1982, "blood" +356, 16, 17, 402, 116, 124, 1983, 1991, "pressure" +356, 16, 18, 403, 125, 127, 1992, 1994, "in" +356, 16, 19, 404, 128, 133, 1995, 2000, "obese" +356, 16, 20, 405, 134, 142, 2001, 2009, "patients" +356, 16, 21, 406, 143, 147, 2010, 2014, "with" +356, 16, 22, 407, 148, 152, 2015, 2019, "type" +356, 16, 23, 408, 153, 154, 2020, 2021, "2" +356, 16, 24, 409, 155, 163, 2022, 2030, "diabetes" +356, 16, 25, 410, 164, 171, 2031, 2038, "treated" +356, 16, 26, 411, 172, 176, 2039, 2043, "with" +356, 16, 27, 412, 177, 181, 2044, 2048, "diet" +356, 16, 28, 413, 182, 185, 2049, 2052, "and" +356, 16, 29, 414, 186, 194, 2053, 2061, "exercise" +356, 16, 30, 415, 195, 197, 2062, 2064, "or" +356, 16, 31, 416, 198, 200, 2065, 2067, "in" +356, 16, 32, 417, 201, 212, 2068, 2079, "combination" +356, 16, 33, 418, 213, 217, 2080, 2084, "with" +356, 16, 34, 419, 218, 227, 2085, 2094, "metformin" +356, 16, 35, 420, 228, 229, 2095, 2096, "." +356, 17, 1, 421, 0, 7, 2097, 2104, "However" +356, 17, 2, 422, 8, 9, 2105, 2106, "," +356, 17, 3, 423, 10, 13, 2107, 2110, "the" +356, 17, 4, 424, 14, 21, 2111, 2118, "central" +356, 17, 5, 425, 22, 29, 2119, 2126, "nervous" +356, 17, 6, 426, 30, 36, 2127, 2133, "system" +356, 17, 7, 427, 37, 40, 2134, 2137, "and" +356, 17, 8, 428, 41, 52, 2138, 2149, "psychiatric" +356, 17, 9, 429, 53, 60, 2150, 2157, "adverse" +356, 17, 10, 430, 61, 66, 2158, 2163, "event" +356, 17, 11, 431, 67, 74, 2164, 2171, "profile" +356, 17, 12, 432, 75, 77, 2172, 2174, "of" +356, 17, 13, 433, 78, 88, 2175, 2185, "topiramate" +356, 17, 14, 434, 89, 91, 2186, 2188, "CR" +356, 17, 15, 435, 92, 97, 2189, 2194, "makes" +356, 17, 16, 436, 98, 100, 2195, 2197, "it" +356, 17, 17, 437, 101, 111, 2198, 2208, "unsuitable" +356, 17, 18, 438, 112, 115, 2209, 2212, "for" +356, 17, 19, 439, 116, 119, 2213, 2216, "the" +356, 17, 20, 440, 120, 129, 2217, 2226, "treatment" +356, 17, 21, 441, 130, 132, 2227, 2229, "of" +356, 17, 22, 442, 133, 140, 2230, 2237, "obesity" +356, 17, 23, 443, 141, 144, 2238, 2241, "and" +356, 17, 24, 444, 145, 153, 2242, 2250, "diabetes" +356, 17, 25, 445, 154, 155, 2251, 2252, "." +356, 18, 1, 446, 0, 3, 2253, 2256, "DOI" +356, 18, 2, 447, 4, 5, 2257, 2258, ":" +356, 18, 3, 448, 6, 8, 2259, 2261, "10" +356, 18, 4, 449, 9, 10, 2262, 2263, "." +356, 18, 5, 450, 11, 15, 2264, 2268, "2337" +356, 18, 6, 451, 16, 17, 2269, 2270, "/" +356, 18, 7, 452, 18, 22, 2271, 2275, "dc06" +356, 18, 8, 453, 23, 24, 2276, 2277, "-" +356, 18, 9, 454, 25, 29, 2278, 2282, "2001" +356, 18, 10, 455, 30, 34, 2283, 2287, "PMID" +356, 18, 11, 456, 35, 36, 2288, 2289, ":" +356, 18, 12, 457, 37, 45, 2290, 2298, "17363756" +356, 18, 13, 458, 46, 47, 2299, 2300, "[" +356, 18, 14, 459, 48, 55, 2301, 2308, "Indexed" +356, 18, 15, 460, 56, 59, 2309, 2312, "for" +356, 18, 16, 461, 60, 67, 2313, 2320, "MEDLINE" +356, 18, 17, 462, 68, 69, 2321, 2322, "]" diff --git a/data/dm2 17363756_kwoodley.annodb b/data/dm2 17363756_kwoodley.annodb new file mode 100644 index 0000000..e2d4853 --- /dev/null +++ b/data/dm2 17363756_kwoodley.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31650, Journal, 0, 15, "Diabetes Care .", "", +4163, PublicationYear, 16, 20, "2007", "", +4164, PublicationYear, 54, 58, "2007", "", +31651, Title, 68, 260, "A randomized , double - blind , placebo - controlled , multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients .", "", +4165, Randomized, 70, 80, "randomized", "", +4166, DoubleBlind, 83, 97, "double - blind", "", +31652, Placebo, 100, 107, "placebo", "", +4168, Multicenter, 123, 134, "multicenter", "", +4169, Drug, 178, 188, "topiramate", "", +4171, Precondition, 228, 258, "obese type 2 diabetic patients", "", +4170, Type2Diabetes, 234, 249, "type 2 diabetic", "", +4173, Author, 261, 273, "Rosenstock J", "", +4174, Author, 282, 293, "Hollander P", "", +4175, Author, 296, 304, "Gadde KM", "", +4176, Author, 307, 312, "Sun X", "", +4177, Author, 315, 324, "Strauss R", "", +4178, Author, 327, 334, "Leung A", "", +4179, USA, 450, 453, "USA", "", +4186, ObjectiveDescription, 507, 642, "This is a randomized , placebo - controlled study of the weight - loss efficacy and safety of a controlled - release ( CR ) formulation", "", +4180, Randomized, 517, 527, "randomized", "", +31654, Placebo, 530, 537, "placebo", "", +4188, BodyWeight, 564, 570, "weight", "", +31653, ObjectiveDescription, 643, 782, "of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin .", "", +4182, Drug, 646, 656, "topiramate", "", +4185, Precondition, 660, 780, "overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin", "", +4183, Type2Diabetes, 695, 710, "type 2 diabetes", "", +4184, Metformin, 771, 780, "metformin", "", +4197, Precondition, 813, 979, "Patients with type 2 diabetes , BMI > or = 27 kg / m2 , A1C > 6 . 5 and < 11 . 0 % , treated with diet and exercise alone or in combination with metformin monotherapy", "", +4190, Type2Diabetes, 827, 842, "type 2 diabetes", "", +4191, BMI, 845, 848, "BMI", "", +4194, Kg_per_squareMeter, 859, 866, "kg / m2", "", +4193, HbA1c, 869, 872, "A1C", "", +4195, Percentage, 894, 895, "%", "", +4196, Metformin, 958, 967, "metformin", "", +4198, Randomized, 1010, 1020, "randomized", "", +4199, Placebo, 1024, 1031, "placebo", "", +4200, Drug, 1035, 1045, "topiramate", "", +4201, DoseValue, 1064, 1067, "175", "", +4202, mg, 1068, 1070, "mg", "", +4203, Interval, 1073, 1076, "day", "", +4204, Duration, 1104, 1112, "7 - week", "", +4205, Duration, 1143, 1151, "9 - week", "", +4206, NumberPatientsCT, 1193, 1196, "111", "", +4207, Randomized, 1211, 1221, "randomized", "", +4208, TimePoint, 1251, 1258, "week 16", "", +4209, Placebo, 1277, 1284, "placebo", "", +4210, Drug, 1289, 1299, "topiramate", "", +4211, Reduction, 1312, 1317, "2 . 5", "", +4212, Reduction, 1322, 1327, "6 . 0", "", +4213, Kg, 1328, 1330, "kg", "", +4214, RelativeReduction, 1351, 1356, "2 . 3", "", +4215, RelativeReduction, 1361, 1366, "5 . 8", "", +4248, BodyWeight, 1404, 1415, "body weight", "", +4217, PvalueDiff, 1418, 1429, "P < 0 . 001", "", +4249, Placebo, 1435, 1442, "placebo", "", +4218, HbA1c, 1447, 1450, "A1C", "", +4219, BaseLineValue, 1479, 1484, "7 . 4", "", +4220, Percentage, 1485, 1486, "%", "", +4221, Placebo, 1494, 1501, "placebo", "", +4222, BaseLineValue, 1506, 1511, "7 . 6", "", +4223, Percentage, 1512, 1513, "%", "", +4224, Drug, 1521, 1531, "topiramate", "", +4225, ResultMeasuredValue, 1542, 1547, "7 . 1", "", +4226, ResultMeasuredValue, 1552, 1557, "6 . 7", "", +4227, Percentage, 1558, 1559, "%", "", +4228, RelativeReduction, 1592, 1597, "0 . 4", "", +4229, RelativeReduction, 1602, 1607, "0 . 9", "", +4230, PvalueDiff, 1651, 1662, "P < 0 . 001", "", +4250, Placebo, 1668, 1675, "placebo", "", +4231, Drug, 1680, 1690, "Topiramate", "", +31656, ObservedResult, 1696, 1717, "significantly reduced", "", +31655, BloodPressure, 1718, 1732, "blood pressure", "", +4234, EndPointDescription, 1737, 1762, "urinary albumin excretion", "", +31657, EndPointDescription, 1765, 1779, "Adverse events", "", +31658, ObservedResult, 1780, 1864, "were predominantly neuropsychiatric or central and peripheral nervous system related", "", +4236, Drug, 1881, 1891, "Topiramate", "", +31659, ConclusionComment, 1881, 2096, "Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin .", "", +4237, BodyWeight, 1926, 1932, "weight", "", +4238, HbA1c, 1969, 1972, "A1C", "", +31661, BloodPressure, 1977, 1991, "blood pressure", "", +4242, Precondition, 1995, 2094, "obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin", "", +4240, Type2Diabetes, 2015, 2030, "type 2 diabetes", "", +4241, Metformin, 2085, 2094, "metformin", "", +31660, ConclusionComment, 2097, 2252, "However , the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes .", "", +4244, Drug, 2175, 2185, "topiramate", "", +4245, Type2Diabetes, 2242, 2250, "diabetes", "", +4247, PMID, 2290, 2298, "17363756", "", diff --git a/data/dm2 17363756_kwoodley.n-triples b/data/dm2 17363756_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17363756_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17379048_admin.annodb b/data/dm2 17379048_admin.annodb new file mode 100644 index 0000000..2e44071 --- /dev/null +++ b/data/dm2 17379048_admin.annodb @@ -0,0 +1,158 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +278, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +0, PublicationYear, 12, 16, "2007", "", " \"2007\"." +132, Title, 44, 284, "Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .", "", " \"Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .\"." +1, Randomized, 116, 126, "randomized", "", " ." +2, DoubleBlind, 129, 143, "double - blind", "", " ." +129, Placebo, 146, 153, "placebo", "", +79868, Colesevelam, 204, 229, "colesevelam hydrochloride", "", +4, Type2Diabetes, 267, 282, "type 2 diabetes", "", +5, Author, 285, 293, "Zieve FJ", "", " \"Zieve FJ\"." +6, Author, 302, 310, "Kalin MF", "", " \"Kalin MF\"." +7, Author, 313, 324, "Schwartz SL", "", " \"Schwartz SL\"." +8, Author, 327, 335, "Jones MR", "", " \"Jones MR\"." +9, Author, 338, 347, "Bailey WL", "", " \"Bailey WL\"." +10, USA, 451, 454, "USA", "", " ." +281, ObjectiveDescription, 494, 736, "This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .", "", " \"This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .\"." +11, HbA1c, 519, 542, "glycosylated hemoglobin", "", +12, HbA1c, 545, 555, "HbA ( 1c )", "", +79869, Colesevelam, 577, 602, "colesevelam hydrochloride", "", +15, Precondition, 634, 734, "subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy", "", " \"subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy\"." +14, Type2Diabetes, 648, 663, "type 2 diabetes", "", " ." +151, Duration, 755, 763, "4 - week", "", +16, Placebo, 764, 771, "placebo", "", +21, Precondition, 790, 866, "subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %", "", " \"subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %\"." +17, Type2Diabetes, 804, 819, "type 2 diabetes", "", +18, HbA1c, 827, 837, "HbA ( 1c )", "", +19, Percentage, 853, 854, "%", "", +20, Percentage, 865, 866, "%", "", +22, Randomized, 872, 882, "randomized", "", +79870, Colesevelam, 894, 905, "colesevelam", "", " ." +24, DoseValue, 906, 912, "3 . 75", "", " \"3 . 75\"." +25, Gram, 913, 914, "g", "", " ." +49128, Interval, 917, 918, "d", "", " \"d\"." +26, Placebo, 931, 938, "placebo", "", " ." +27, Duration, 943, 951, "12 weeks", "", " \"12 weeks\"." +28, OralAntidiabeticAgent, 974, 1008, "oral anti hyperglycemic medication", "", +29, Sulfonylureas, 1011, 1023, "sulfonylurea", "", +30, Metformin, 1033, 1042, "metformin", "", +31, FastingPlasmaGlucose, 1082, 1095, "Fasting blood", "", +299, TimePoint, 1121, 1130, "weeks - 5", "", +300, TimePoint, 1121, 1136, "weeks - 5 , - 1", "", +301, TimePoint, 1121, 1140, "weeks - 5 , - 1 , 0", "", +302, TimePoint, 1121, 1144, "weeks - 5 , - 1 , 0 , 1", "", +303, TimePoint, 1121, 1148, "weeks - 5 , - 1 , 0 , 1 , 4", "", +304, TimePoint, 1121, 1152, "weeks - 5 , - 1 , 0 , 1 , 4 , 8", "", +305, TimePoint, 1121, 1161, "weeks - 5 , - 1 , 0 , 1 , 4 , 8 , and 12", "", +32, HbA1c, 1213, 1223, "HbA ( 1c )", "", +283, TimePoint, 1229, 1237, "baseline", "", +162, TimePoint, 1241, 1248, "week 12", "", +33, Fructosamine, 1292, 1304, "fructosamine", "", +34, FastingPlasmaGlucose, 1314, 1336, "fasting plasma glucose", "", +285, PostprandialBloodGlucose, 1346, 1366, "postprandial glucose", "", " \"This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .\"." +35, MealGlucoseResponse, 1379, 1400, "meal glucose response", "", +36, EndPointDescription, 1490, 1506, "lipid parameters", "", +168, TimePoint, 1512, 1520, "baseline", "", +169, TimePoint, 1524, 1531, "week 12", "", +37, NumberPatientsCT, 1548, 1550, "65", "", " \"65\"." +38, Randomized, 1551, 1561, "randomized", "", +39, NumberPatientsArm, 1573, 1575, "31", "", " \"31\"." +79871, Colesevelam, 1576, 1587, "colesevelam", "", +40, NumberPatientsArm, 1590, 1592, "34", "", " \"34\"." +42, Placebo, 1593, 1600, "placebo", "", +306, Mean, 1609, 1613, "mean", "", +43, AvgAge, 1621, 1627, "56 . 2", "", " \"56 . 2\"." +44, BMI, 1645, 1660, "body mass index", "", +178, Kg_per_squareMeter, 1671, 1683, "kg / m ( 2 )", "", +46, Male, 1686, 1704, "55 . 4 % were male", "", " ." +47, Ethnicity, 1709, 1728, "53 . 8 % were white", "", " . ." +189, LeastSquaresMean, 1749, 1774, "least squares ( LS ) mean", "", " ." +48, HbA1c, 1792, 1802, "HbA ( 1c )", "", " ." +79872, Colesevelam, 1815, 1826, "colesevelam", "", +50, Placebo, 1841, 1848, "placebo", "", +118, DiffGroupAbsValue, 1859, 1866, "- 0 . 5", "", " \"- 0 . 5\"." +119, Percentage, 1867, 1868, "%", "", " ." +120, SdErrorDiff, 1871, 1877, "0 . 18", "", " \"0 . 18\"." +51, PvalueDiff, 1882, 1893, "P = 0 . 007", "", " \"P = 0 . 007\"." +52, SubGroupDescription, 1901, 1946, "subjects with a baseline HbAIc > or = 8 . 0 %", "", " \"subjects with a baseline HbAIc > or = 8 . 0 %\". \"subjects with a baseline HbAIc > or = 8 . 0 %\"." +53, HbA1c, 1926, 1931, "HbAIc", "", " \"subjects with a baseline HbAIc > or = 8 . 0 %\". \"subjects with a baseline HbAIc > or = 8 . 0 %\"." +54, Percentage, 1945, 1946, "%", "", +193, LeastSquaresMean, 1967, 1974, "LS mean", "", +55, HbA1c, 1985, 1995, "HbA ( 1c )", "", +121, DiffGroupAbsValue, 2000, 2007, "- 1 . 0", "", " \"- 1 . 0\"." +122, Percentage, 2008, 2009, "%", "", " \"- 1 . 0\"." +196, SdErrorDiff, 2012, 2018, "0 . 27", "", " \"0 . 27\"." +56, PvalueDiff, 2023, 2034, "P = 0 . 002", "", " \"P = 0 . 002\"." +57, Placebo, 2051, 2058, "placebo", "", +79877, Colesevelam, 2061, 2072, "colesevelam", "", +59, Fructosamine, 2127, 2139, "fructosamine", "", " ." +60, Reduction, 2144, 2150, "29 . 0", "", " \"29 . 0\"." +124, ResultMeasuredValue, 2153, 2159, "10 . 9", "", " \"10 . 9\"." +61, Picomole_per_liter, 2162, 2170, "pmol / L", "", " ." +62, PValueChangeValue, 2173, 2184, "P = 0 . 011", "", " \"P = 0 . 011\"." +290, PostprandialBloodGlucose, 2191, 2211, "postprandial glucose", "", " ." +63, Reduction, 2216, 2222, "31 . 5", "", " \"31 . 5\"." +64, ResultMeasuredValue, 2225, 2231, "13 . 6", "", " \"13 . 6\"." +65, Mg_per_deciliter, 2234, 2241, "mg / dL", "", " ." +66, PValueChangeValue, 2244, 2255, "P = 0 . 026", "", " \"P = 0 . 026\"." +215, Mean, 2264, 2268, "mean", "", " . ." +67, EndPointDescription, 2287, 2324, "low - density lipoprotein cholesterol", "", " . ." +68, RelativeReduction, 2331, 2336, "9 . 6", "", " \"9 . 6\"." +79873, Colesevelam, 2346, 2357, "colesevelam", "", +291, RelativeIncrement, 2380, 2385, "2 . 1", "", " \"2 . 1\"." +70, Placebo, 2395, 2402, "placebo", "", +49225, DiffGroupRelValue, 2434, 2442, "- 11 . 7", "", " \"- 11 . 7\"." +72, DiffGroupAbsValue, 2447, 2452, "4 . 2", "", " \"4 . 2\"." +73, PvalueDiff, 2457, 2468, "P = 0 . 007", "", " \"P = 0 . 007\"." +224, Mean, 2488, 2492, "mean", "", " . ." +74, EndPointDescription, 2512, 2529, "total cholesterol", "", " . ." +75, RelativeReduction, 2537, 2542, "4 . 0", "", " \"4 . 0\"." +49226, RelativeIncrement, 2549, 2554, "3 . 4", "", " \"3 . 4\"." +49227, DiffGroupRelValue, 2582, 2589, "- 7 . 3", "", " \"- 7 . 3\"." +78, DiffGroupAbsValue, 2594, 2599, "3 . 0", "", " \"3 . 0\"." +79, PvalueDiff, 2604, 2615, "P = 0 . 019", "", " \"P = 0 . 019\"." +79874, Colesevelam, 2620, 2631, "Colesevelam", "", +238, ObservedResult, 2657, 2678, "significant decreases", "", " \"significant decreases\"." +81, EndPointDescription, 2704, 2720, "apolipoprotein B", "", " . ." +82, PValueChangeValue, 2723, 2734, "P = 0 . 003", "", " \"P = 0 . 003\"." +83, EndPointDescription, 2741, 2789, "low - density lipoprotein particle concentration", "", " . ." +84, PValueChangeValue, 2792, 2803, "P = 0 . 037", "", " \"P = 0 . 037\"." +116, EndPointDescription, 2812, 2860, "incidence of treatment - emergent adverse events", "", " . ." +117, EndPointDescription, 2863, 2868, "TEAEs", "", +87, ObservedResult, 2871, 2897, "was similar in both groups", "", " \"was similar in both groups\"." +242, EndPointDescription, 2929, 2943, "adverse events", "", " . ." +49224, ObservedResult, 2944, 2987, "were more frequent in the colesevelam group", "", " \"were more frequent in the colesevelam group\"." +79875, Colesevelam, 2970, 2981, "colesevelam", "", +86, Placebo, 3000, 3007, "placebo", "", +89, PercentageAffected, 3016, 3022, "29 . 0", "", " \"29 . 0\"." +90, PercentageAffected, 3028, 3033, "8 . 8", "", " \"8 . 8\"." +79876, Colesevelam, 3086, 3097, "colesevelam", "", +91, GastrointestinalProblem, 3109, 3135, "gastrointestinal disorders", "", " ." +93, PercentageAffected, 3138, 3144, "22 . 6", "", " \"22 . 6\"." +257, EndPointDescription, 3151, 3173, "primarily constipation", "", " . ." +94, PercentageAffected, 3176, 3182, "19 . 4", "", " \"19 . 4\"." +96, PercentageAffected, 3206, 3211, "8 . 8", "", " \"8 . 8\"." +97, GastrointestinalProblem, 3227, 3253, "gastrointestinal disorders", "", +99, PercentageAffected, 3256, 3257, "0", "", +258, EndPointDescription, 3260, 3272, "constipation", "", " . ." +98, Placebo, 3282, 3289, "placebo", "", +292, ObservedResult, 3298, 3407, "There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .", "", " \"There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .\". \"There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .\"." +101, BodyWeight, 3335, 3346, "body weight", "", " ." +102, Hypoglycemia, 3368, 3380, "hypoglycemia", "", " ." +270, ConclusionComment, 3422, 3630, "In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .", "", " \"In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .\"." +103, Type2Diabetes, 3445, 3460, "type 2 diabetes", "", +104, Duration, 3463, 3471, "12 weeks", "", +79878, Colesevelam, 3475, 3486, "colesevelam", "", +106, HbA1c, 3544, 3554, "HbA ( 1c )", "", +107, Fructosamine, 3562, 3574, "fructosamine", "", +298, PostprandialBloodGlucose, 3579, 3599, "postprandial glucose", "", +108, Placebo, 3621, 3628, "placebo", "", +272, ConclusionComment, 3631, 3771, "The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .", "", " \"The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .\"." +49223, EndPointDescription, 3658, 3681, "adverse - event profile", "", +109, Constipation, 3732, 3744, "constipation", "", +79880, Colesevelam, 3752, 3763, "colesevelam", "", +276, ConclusionComment, 3772, 3942, "These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .", "", " \"These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .\"." +79879, Colesevelam, 3799, 3810, "colesevelam", "", +114, Type2Diabetes, 3880, 3895, "type 2 diabetes", "", +297, OralAntidiabeticAgent, 3906, 3940, "oral antihyperglycemic medications", "", +115, PMID, 4000, 4008, "17379048", "", " \"17379048\"." diff --git a/data/dm2 17379048_admin.n-triples b/data/dm2 17379048_admin.n-triples new file mode 100644 index 0000000..0e411fb --- /dev/null +++ b/data/dm2 17379048_admin.n-triples @@ -0,0 +1,313 @@ +# RDF export of group: Publication + . + "Publication " . + "Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes ." . + "Zieve FJ" . + "2007" . + "Clin Ther ." . + "17379048" . + . + "Kalin MF" . + "Schwartz SL" . + "Jones MR" . + "Bailey WL" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy ." . + "65" . + "12 weeks" . + . + . + . + "In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo ." . + . + . + . + . + . + . + "The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group ." . + "These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy" . + . + . + . + "56 . 2" . + . + "subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint fructosamine" . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint ld l cholesterol" . + . + . + . + . + . + . + . + "Endpoint cholesterol" . + . + . + . + . + . + . + . + "Endpoint aB" . + . + . + . + . + . + . + "Endpoint ld l p c" . + . + . + . + . + . + . + "Endpoint TEAEs" . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint gd" . + . + . + . + . + . + "Endpoint pc" . + . + . + . + . + . + . + "Endpoint constipation" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . +# RDF export of group: Arm + . + "Arm c" . + "31" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm p " . + "34" . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention c" . + . + "d" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication c" . + . + "3 . 75" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c c" . + . + . + "Outcome hba1c p " . + . + . + "Outcome hba1c sg c" . + . + "subjects with a baseline HbAIc > or = 8 . 0 %" . + . + "Outcome hba1c sg p " . + . + "subjects with a baseline HbAIc > or = 8 . 0 %" . + . + "Outcome fructosamine c" . + . + "10 . 9" . + "29 . 0" . + "P = 0 . 011" . + . + "Outcome ppg c" . + . + "13 . 6" . + "31 . 5" . + "P = 0 . 026" . + . + "Outcome ld l cholesterol c" . + . + "9 . 6" . + . + "Outcome ld l cholesterol p " . + . + "2 . 1" . + . + "Outcome cholesterol c" . + . + "4 . 0" . + . + "Outcome cholesterol p " . + . + "3 . 4" . + . + "Outcome aB c" . + . + "P = 0 . 003" . + "significant decreases" . + . + "Outcome ld l p c c" . + . + "P = 0 . 037" . + . + "Outcome TEAEs c both drugs" . + . + "was similar in both groups" . + . + "Outcome aes c" . + . + "29 . 0" . + "were more frequent in the colesevelam group" . + . + "Outcome aes p " . + . + "8 . 8" . + . + "Outcome g aes c" . + . + "22 . 6" . + . + "Outcome pc c" . + . + "19 . 4" . + . + "Outcome g aes p " . + . + "8 . 8" . + . + "Outcome constipation p " . + . + . + "Outcome weight both drugs " . + . + "There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups ." . + . + "Outcome h both drugs" . + . + "There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 5" . + "P = 0 . 007" . + "0 . 18" . + . + . + . + "DiffBetweenGroups hba1c sg" . + "- 1 . 0" . + "P = 0 . 002" . + "0 . 27" . + . + . + . + "DiffBetweenGroups ld l cholesterol " . + "4 . 2" . + "- 11 . 7" . + "P = 0 . 007" . + . + . + . + "DiffBetweenGroups cholesterol " . + "3 . 0" . + "- 7 . 3" . + "P = 0 . 019" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17379048_akramersunderbrink.annodb b/data/dm2 17379048_akramersunderbrink.annodb new file mode 100644 index 0000000..f0ec135 --- /dev/null +++ b/data/dm2 17379048_akramersunderbrink.annodb @@ -0,0 +1,163 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +21660, Journal, 0, 9, "Clin Ther", "", +21661, PublicationYear, 12, 16, "2007", "", +21667, Title, 44, 284, "Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .", "", +21662, Randomized, 116, 126, "randomized", "", +21663, DoubleBlind, 129, 143, "double - blind", "", +21664, Placebo, 146, 153, "placebo", "", +21666, Drug, 204, 229, "colesevelam hydrochloride", "", +21665, Type2Diabetes, 267, 282, "type 2 diabetes", "", +21668, Author, 285, 293, "Zieve FJ", "", +21669, Author, 302, 310, "Kalin MF", "", +21670, Author, 313, 324, "Schwartz SL", "", +21671, Author, 327, 335, "Jones MR", "", +21672, Author, 338, 347, "Bailey WL", "", +21673, USA, 451, 454, "USA", "", +21679, ObjectiveDescription, 494, 734, "This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy", "", +21675, HbA1c, 519, 542, "glycosylated hemoglobin", "", +21674, HbA1c, 545, 555, "HbA ( 1c )", "", +21676, Drug, 577, 602, "colesevelam hydrochloride", "", +21677, Type2Diabetes, 648, 663, "type 2 diabetes", "", +21678, Precondition, 673, 734, "inadequately controlled by existing antihyperglycemic therapy", "", +21693, Precondition, 747, 787, "After a 4 - week placebo run - in period", "", +21686, Duration, 755, 763, "4 - week", "", +21687, Placebo, 764, 771, "placebo", "", +21680, Type2Diabetes, 804, 819, "type 2 diabetes", "", +21681, HbA1c, 827, 837, "HbA ( 1c )", "", +21688, Precondition, 827, 866, "HbA ( 1c ) value of 7 . 0 % to 10 . 0 %", "", +21689, Percentage, 853, 854, "%", "", +21690, Percentage, 865, 866, "%", "", +21682, Randomized, 872, 882, "randomized", "", +21683, Drug, 894, 905, "colesevelam", "", +21692, DoseValue, 906, 912, "3 . 75", "", +21691, ConcentrationUnit, 913, 918, "g / d", "", +21684, Placebo, 931, 938, "placebo", "", +21685, Duration, 943, 951, "12 weeks", "", +21701, Precondition, 954, 1081, "Subjects ' previous oral anti hyperglycemic medication ( sulfonylurea and / or metformin ) was continued throughout the study .", "", +21694, Sulfonylureas, 1011, 1023, "sulfonylurea", "", +21698, Metformin, 1033, 1042, "metformin", "", +39144, TimePoint, 1121, 1130, "weeks - 5", "", +39145, TimePoint, 1121, 1136, "weeks - 5 , - 1", "", +39146, TimePoint, 1121, 1140, "weeks - 5 , - 1 , 0", "", +39147, TimePoint, 1121, 1144, "weeks - 5 , - 1 , 0 , 1", "", +39148, TimePoint, 1121, 1148, "weeks - 5 , - 1 , 0 , 1 , 4", "", +39149, TimePoint, 1121, 1152, "weeks - 5 , - 1 , 0 , 1 , 4 , 8", "", +39150, TimePoint, 1121, 1161, "weeks - 5 , - 1 , 0 , 1 , 4 , 8 , and 12", "", +21699, HbA1c, 1213, 1223, "HbA ( 1c )", "", +39152, TimePoint, 1229, 1237, "baseline", "", +21700, TimePoint, 1241, 1248, "week 12", "", +21702, Fructosamine, 1292, 1311, "fructosamine levels", "", +21703, FastingPlasmaGlucose, 1314, 1343, "fasting plasma glucose levels", "", +21704, InsulinDose, 1346, 1372, "postprandial glucose level", "", +21705, MealGlucoseResponse, 1379, 1466, "meal glucose response ( ie , difference between preprandial and postprandial levels ) ,", "", +21706, TimePoint, 1512, 1520, "baseline", "", +21707, TimePoint, 1524, 1531, "week 12", "", +21708, NumberPatientsCT, 1548, 1550, "65", "", +21713, Randomized, 1551, 1561, "randomized", "", +21709, NumberPatientsArm, 1573, 1575, "31", "", +21711, Drug, 1576, 1587, "colesevelam", "", +21710, NumberPatientsArm, 1590, 1592, "34", "", +21712, Placebo, 1593, 1600, "placebo", "", +39151, Mean, 1609, 1613, "mean", "", +21714, AvgAge, 1621, 1627, "56 . 2", "", +21715, Precondition, 1640, 1683, "mean body mass index of 32 . 4 kg / m ( 2 )", "", +21716, Kg_per_squareMeter, 1671, 1683, "kg / m ( 2 )", "", +21719, Gender, 1686, 1704, "55 . 4 % were male", "", +21720, Percentage, 1693, 1694, "%", "", +21718, Ethnicity, 1709, 1728, "53 . 8 % were white", "", +21721, Percentage, 1716, 1717, "%", "", +21730, LeastSquaresMean, 1749, 1774, "least squares ( LS ) mean", "", +21722, HbA1c, 1792, 1802, "HbA ( 1c )", "", +21723, Drug, 1815, 1826, "colesevelam", "", +21724, Placebo, 1841, 1848, "placebo", "", +21749, DiffGroupAbsValue, 1859, 1866, "- 0 . 5", "", +21728, Percentage, 1867, 1868, "%", "", +21725, SdErrorDiff, 1871, 1877, "0 . 18", "", +21727, PvalueDiff, 1882, 1893, "P = 0 . 007", "", +21733, SubGroupDescription, 1901, 1946, "subjects with a baseline HbAIc > or = 8 . 0 %", "", +21735, HbA1c, 1926, 1931, "HbAIc", "", +21734, Percentage, 1945, 1946, "%", "", +21736, LeastSquaresMean, 1967, 1974, "LS mean", "", +21737, HbA1c, 1985, 1995, "HbA ( 1c )", "", +21750, DiffGroupAbsValue, 2000, 2007, "- 1 . 0", "", +21739, Percentage, 2008, 2009, "%", "", +21740, SdErrorDiff, 2012, 2018, "0 . 27", "", +21741, PvalueDiff, 2023, 2034, "P = 0 . 002", "", +21742, Placebo, 2051, 2058, "placebo", "", +21743, Drug, 2061, 2072, "colesevelam", "", +21744, Fructosamine, 2127, 2139, "fructosamine", "", +21747, DiffGroupAbsValue, 2142, 2150, "- 29 . 0", "", +21748, SdErrorDiff, 2153, 2159, "10 . 9", "", +21746, Picomole_per_liter, 2162, 2170, "pmol / L", "", +21745, PvalueDiff, 2173, 2184, "P = 0 . 011", "", +21751, InsulinDose, 2191, 2211, "postprandial glucose", "", +21752, DiffGroupAbsValue, 2214, 2222, "- 31 . 5", "", +21753, SdErrorDiff, 2225, 2231, "13 . 6", "", +21754, Mg_per_deciliter, 2234, 2241, "mg / dL", "", +21755, PvalueDiff, 2244, 2255, "P = 0 . 026", "", +21759, Mean, 2264, 2268, "mean", "", +21758, EndPointDescription, 2277, 2324, "change in low - density lipoprotein cholesterol", "", +21760, RelativeChangeValue, 2329, 2336, "- 9 . 6", "", +21762, Percentage, 2337, 2338, "%", "", +21756, Drug, 2346, 2357, "colesevelam", "", +21763, RelativeChangeValue, 2380, 2385, "2 . 1", "", +21764, Percentage, 2386, 2387, "%", "", +21757, Placebo, 2395, 2402, "placebo", "", +21765, DiffGroupAbsValue, 2434, 2442, "- 11 . 7", "", +21766, Percentage, 2443, 2444, "%", "", +21767, SdErrorDiff, 2447, 2452, "4 . 2", "", +21768, PvalueDiff, 2457, 2468, "P = 0 . 007", "", +21769, Mean, 2488, 2492, "mean", "", +21770, EndPointDescription, 2501, 2529, "changes in total cholesterol", "", +21771, RelativeChangeValue, 2535, 2542, "- 4 . 0", "", +21772, Percentage, 2543, 2544, "%", "", +21775, RelativeChangeValue, 2549, 2554, "3 . 4", "", +21773, Percentage, 2555, 2556, "%", "", +21776, DiffGroupAbsValue, 2582, 2589, "- 7 . 3", "", +21774, Percentage, 2590, 2591, "%", "", +21777, SdErrorDiff, 2594, 2599, "3 . 0", "", +21778, PvalueDiff, 2604, 2615, "P = 0 . 019", "", +21780, Drug, 2620, 2631, "Colesevelam", "", +21785, ObservedResult, 2657, 2678, "significant decreases", "", +21784, EndPointDescription, 2694, 2718, "change in apolipoprotein", "", +21781, PValueChangeValue, 2723, 2734, "P = 0 . 003", "", +21786, EndPointDescription, 2741, 2789, "low - density lipoprotein particle concentration", "", +21782, PValueChangeValue, 2792, 2803, "P = 0 . 037", "", +21789, EndPointDescription, 2909, 2943, "treatment - related adverse events", "", +21787, Drug, 2970, 2981, "colesevelam", "", +21788, Placebo, 3000, 3007, "placebo", "", +21790, PercentageAffected, 3016, 3022, "29 . 0", "", +21791, Percentage, 3023, 3024, "%", "", +21792, PercentageAffected, 3028, 3033, "8 . 8", "", +21793, Percentage, 3034, 3035, "%", "", +21795, Drug, 3086, 3097, "colesevelam", "", +21794, EndPointDescription, 3109, 3135, "gastrointestinal disorders", "", +21796, PercentageAffected, 3138, 3144, "22 . 6", "", +21800, Percentage, 3145, 3146, "%", "", +21804, EndPointDescription, 3151, 3173, "primarily constipation", "", +21797, PercentageAffected, 3176, 3182, "19 . 4", "", +21801, Percentage, 3183, 3184, "%", "", +21798, PercentageAffected, 3206, 3211, "8 . 8", "", +21802, Percentage, 3212, 3213, "%", "", +21806, EndPointDescription, 3227, 3253, "gastrointestinal disorders", "", +21799, PercentageAffected, 3256, 3257, "0", "", +21803, Percentage, 3258, 3259, "%", "", +21805, EndPointDescription, 3260, 3272, "constipation", "", +21807, Placebo, 3282, 3289, "placebo", "", +21808, BodyWeight, 3335, 3346, "body weight", "", +21809, Hypoglycemia, 3354, 3380, "occurrence of hypoglycemia", "", +21817, ConclusionComment, 3422, 3630, "In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .", "", +21810, Type2Diabetes, 3445, 3460, "type 2 diabetes", "", +21811, Duration, 3463, 3471, "12 weeks", "", +21812, Drug, 3475, 3486, "colesevelam", "", +21813, HbA1c, 3544, 3554, "HbA ( 1c )", "", +21814, Fructosamine, 3562, 3574, "fructosamine", "", +21815, InsulinDose, 3579, 3606, "postprandial glucose levels", "", +21816, Placebo, 3621, 3628, "placebo", "", +21819, ConclusionComment, 3631, 3771, "The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .", "", +21818, Drug, 3752, 3763, "colesevelam", "", +21824, ConclusionComment, 3772, 3942, "These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .", "", +21820, Drug, 3799, 3810, "colesevelam", "", +21821, Type2Diabetes, 3880, 3895, "type 2 diabetes", "", +21823, Precondition, 3896, 3940, "receiving oral antihyperglycemic medications", "", +21825, PMID, 4000, 4008, "17379048", "", diff --git a/data/dm2 17379048_akramersunderbrink.n-triples b/data/dm2 17379048_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17379048_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17379048_export.csv b/data/dm2 17379048_export.csv new file mode 100644 index 0000000..a0de039 --- /dev/null +++ b/data/dm2 17379048_export.csv @@ -0,0 +1,855 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +355, 1, 1, 1, 0, 4, 0, 4, "Clin" +355, 1, 2, 2, 5, 9, 5, 9, "Ther" +355, 1, 3, 3, 10, 11, 10, 11, "." +355, 2, 1, 4, 0, 4, 12, 16, "2007" +355, 2, 2, 5, 5, 8, 17, 20, "Jan" +355, 2, 3, 6, 9, 10, 21, 22, ";" +355, 2, 4, 7, 11, 13, 23, 25, "29" +355, 2, 5, 8, 14, 15, 26, 27, "(" +355, 2, 6, 9, 16, 17, 28, 29, "1" +355, 2, 7, 10, 18, 19, 30, 31, ")" +355, 2, 8, 11, 20, 21, 32, 33, ":" +355, 2, 9, 12, 22, 24, 34, 36, "74" +355, 2, 10, 13, 25, 26, 37, 38, "-" +355, 2, 11, 14, 27, 29, 39, 41, "83" +355, 2, 12, 15, 30, 31, 42, 43, "." +355, 3, 1, 16, 0, 7, 44, 51, "Results" +355, 3, 2, 17, 8, 10, 52, 54, "of" +355, 3, 3, 18, 11, 14, 55, 58, "the" +355, 3, 4, 19, 15, 22, 59, 66, "glucose" +355, 3, 5, 20, 23, 24, 67, 68, "-" +355, 3, 6, 21, 25, 33, 69, 77, "lowering" +355, 3, 7, 22, 34, 40, 78, 84, "effect" +355, 3, 8, 23, 41, 43, 85, 87, "of" +355, 3, 9, 24, 44, 51, 88, 95, "WelChol" +355, 3, 10, 25, 52, 57, 96, 101, "study" +355, 3, 11, 26, 58, 59, 102, 103, "(" +355, 3, 12, 27, 60, 65, 104, 109, "GLOWS" +355, 3, 13, 28, 66, 67, 110, 111, ")" +355, 3, 14, 29, 68, 69, 112, 113, ":" +355, 3, 15, 30, 70, 71, 114, 115, "a" +355, 3, 16, 31, 72, 82, 116, 126, "randomized" +355, 3, 17, 32, 83, 84, 127, 128, "," +355, 3, 18, 33, 85, 91, 129, 135, "double" +355, 3, 19, 34, 92, 93, 136, 137, "-" +355, 3, 20, 35, 94, 99, 138, 143, "blind" +355, 3, 21, 36, 100, 101, 144, 145, "," +355, 3, 22, 37, 102, 109, 146, 153, "placebo" +355, 3, 23, 38, 110, 111, 154, 155, "-" +355, 3, 24, 39, 112, 122, 156, 166, "controlled" +355, 3, 25, 40, 123, 128, 167, 172, "pilot" +355, 3, 26, 41, 129, 134, 173, 178, "study" +355, 3, 27, 42, 135, 145, 179, 189, "evaluating" +355, 3, 28, 43, 146, 149, 190, 193, "the" +355, 3, 29, 44, 150, 156, 194, 200, "effect" +355, 3, 30, 45, 157, 159, 201, 203, "of" +355, 3, 31, 46, 160, 171, 204, 215, "colesevelam" +355, 3, 32, 47, 172, 185, 216, 229, "hydrochloride" +355, 3, 33, 48, 186, 188, 230, 232, "on" +355, 3, 34, 49, 189, 197, 233, 241, "glycemic" +355, 3, 35, 50, 198, 205, 242, 249, "control" +355, 3, 36, 51, 206, 208, 250, 252, "in" +355, 3, 37, 52, 209, 217, 253, 261, "subjects" +355, 3, 38, 53, 218, 222, 262, 266, "with" +355, 3, 39, 54, 223, 227, 267, 271, "type" +355, 3, 40, 55, 228, 229, 272, 273, "2" +355, 3, 41, 56, 230, 238, 274, 282, "diabetes" +355, 3, 42, 57, 239, 240, 283, 284, "." +355, 4, 1, 58, 0, 5, 285, 290, "Zieve" +355, 4, 2, 59, 6, 8, 291, 293, "FJ" +355, 4, 3, 60, 9, 10, 294, 295, "(" +355, 4, 4, 61, 11, 12, 296, 297, "1" +355, 4, 5, 62, 13, 14, 298, 299, ")" +355, 4, 6, 63, 15, 16, 300, 301, "," +355, 4, 7, 64, 17, 22, 302, 307, "Kalin" +355, 4, 8, 65, 23, 25, 308, 310, "MF" +355, 4, 9, 66, 26, 27, 311, 312, "," +355, 4, 10, 67, 28, 36, 313, 321, "Schwartz" +355, 4, 11, 68, 37, 39, 322, 324, "SL" +355, 4, 12, 69, 40, 41, 325, 326, "," +355, 4, 13, 70, 42, 47, 327, 332, "Jones" +355, 4, 14, 71, 48, 50, 333, 335, "MR" +355, 4, 15, 72, 51, 52, 336, 337, "," +355, 4, 16, 73, 53, 59, 338, 344, "Bailey" +355, 4, 17, 74, 60, 62, 345, 347, "WL" +355, 4, 18, 75, 63, 64, 348, 349, "." +355, 5, 1, 76, 0, 6, 350, 356, "Author" +355, 5, 2, 77, 7, 18, 357, 368, "information" +355, 5, 3, 78, 19, 20, 369, 370, ":" +355, 5, 4, 79, 21, 22, 371, 372, "(" +355, 5, 5, 80, 23, 24, 373, 374, "1" +355, 5, 6, 81, 25, 26, 375, 376, ")" +355, 5, 7, 82, 27, 30, 377, 380, "The" +355, 5, 8, 83, 31, 37, 381, 387, "Hunter" +355, 5, 9, 84, 38, 44, 388, 394, "Holmes" +355, 5, 10, 85, 45, 52, 395, 402, "McGuire" +355, 5, 11, 86, 53, 55, 403, 405, "VA" +355, 5, 12, 87, 56, 63, 406, 413, "Medical" +355, 5, 13, 88, 64, 70, 414, 420, "Center" +355, 5, 14, 89, 71, 72, 421, 422, "," +355, 5, 15, 90, 73, 81, 423, 431, "Richmond" +355, 5, 16, 91, 82, 83, 432, 433, "," +355, 5, 17, 92, 84, 92, 434, 442, "Virginia" +355, 5, 18, 93, 93, 98, 443, 448, "23249" +355, 5, 19, 94, 99, 100, 449, 450, "," +355, 5, 20, 95, 101, 104, 451, 454, "USA" +355, 5, 21, 96, 105, 106, 455, 456, "." +355, 6, 1, 97, 0, 5, 457, 462, "frank" +355, 6, 2, 98, 6, 7, 463, 464, "@" +355, 6, 3, 99, 8, 18, 465, 475, "vadiabetes" +355, 6, 4, 100, 19, 20, 476, 477, "." +355, 6, 5, 101, 21, 24, 478, 481, "org" +355, 6, 6, 102, 25, 34, 482, 491, "OBJECTIVE" +355, 6, 7, 103, 35, 36, 492, 493, ":" +355, 6, 8, 104, 37, 41, 494, 498, "This" +355, 6, 9, 105, 42, 47, 499, 504, "study" +355, 6, 10, 106, 48, 57, 505, 514, "evaluated" +355, 6, 11, 107, 58, 61, 515, 518, "the" +355, 6, 12, 108, 62, 74, 519, 531, "glycosylated" +355, 6, 13, 109, 75, 85, 532, 542, "hemoglobin" +355, 6, 14, 110, 86, 87, 543, 544, "(" +355, 6, 15, 111, 88, 91, 545, 548, "HbA" +355, 6, 16, 112, 92, 93, 549, 550, "(" +355, 6, 17, 113, 94, 96, 551, 553, "1c" +355, 6, 18, 114, 97, 98, 554, 555, ")" +355, 6, 19, 115, 99, 100, 556, 557, "-" +355, 6, 20, 116, 101, 109, 558, 566, "lowering" +355, 6, 21, 117, 110, 116, 567, 573, "effect" +355, 6, 22, 118, 117, 119, 574, 576, "of" +355, 6, 23, 119, 120, 131, 577, 588, "colesevelam" +355, 6, 24, 120, 132, 145, 589, 602, "hydrochloride" +355, 6, 25, 121, 146, 147, 603, 604, "," +355, 6, 26, 122, 148, 149, 605, 606, "a" +355, 6, 27, 123, 150, 154, 607, 611, "bile" +355, 6, 28, 124, 155, 159, 612, 616, "acid" +355, 6, 29, 125, 160, 171, 617, 628, "sequestrant" +355, 6, 30, 126, 172, 173, 629, 630, "," +355, 6, 31, 127, 174, 176, 631, 633, "in" +355, 6, 32, 128, 177, 185, 634, 642, "subjects" +355, 6, 33, 129, 186, 190, 643, 647, "with" +355, 6, 34, 130, 191, 195, 648, 652, "type" +355, 6, 35, 131, 196, 197, 653, 654, "2" +355, 6, 36, 132, 198, 206, 655, 663, "diabetes" +355, 6, 37, 133, 207, 211, 664, 668, "that" +355, 6, 38, 134, 212, 215, 669, 672, "was" +355, 6, 39, 135, 216, 228, 673, 685, "inadequately" +355, 6, 40, 136, 229, 239, 686, 696, "controlled" +355, 6, 41, 137, 240, 242, 697, 699, "by" +355, 6, 42, 138, 243, 251, 700, 708, "existing" +355, 6, 43, 139, 252, 269, 709, 726, "antihyperglycemic" +355, 6, 44, 140, 270, 277, 727, 734, "therapy" +355, 6, 45, 141, 278, 279, 735, 736, "." +355, 7, 1, 142, 0, 7, 737, 744, "METHODS" +355, 7, 2, 143, 8, 9, 745, 746, ":" +355, 7, 3, 144, 10, 15, 747, 752, "After" +355, 7, 4, 145, 16, 17, 753, 754, "a" +355, 7, 5, 146, 18, 19, 755, 756, "4" +355, 7, 6, 147, 20, 21, 757, 758, "-" +355, 7, 7, 148, 22, 26, 759, 763, "week" +355, 7, 8, 149, 27, 34, 764, 771, "placebo" +355, 7, 9, 150, 35, 38, 772, 775, "run" +355, 7, 10, 151, 39, 40, 776, 777, "-" +355, 7, 11, 152, 41, 43, 778, 780, "in" +355, 7, 12, 153, 44, 50, 781, 787, "period" +355, 7, 13, 154, 51, 52, 788, 789, "," +355, 7, 14, 155, 53, 61, 790, 798, "subjects" +355, 7, 15, 156, 62, 66, 799, 803, "with" +355, 7, 16, 157, 67, 71, 804, 808, "type" +355, 7, 17, 158, 72, 73, 809, 810, "2" +355, 7, 18, 159, 74, 82, 811, 819, "diabetes" +355, 7, 19, 160, 83, 86, 820, 823, "and" +355, 7, 20, 161, 87, 89, 824, 826, "an" +355, 7, 21, 162, 90, 93, 827, 830, "HbA" +355, 7, 22, 163, 94, 95, 831, 832, "(" +355, 7, 23, 164, 96, 98, 833, 835, "1c" +355, 7, 24, 165, 99, 100, 836, 837, ")" +355, 7, 25, 166, 101, 106, 838, 843, "value" +355, 7, 26, 167, 107, 109, 844, 846, "of" +355, 7, 27, 168, 110, 111, 847, 848, "7" +355, 7, 28, 169, 112, 113, 849, 850, "." +355, 7, 29, 170, 114, 115, 851, 852, "0" +355, 7, 30, 171, 116, 117, 853, 854, "%" +355, 7, 31, 172, 118, 120, 855, 857, "to" +355, 7, 32, 173, 121, 123, 858, 860, "10" +355, 7, 33, 174, 124, 125, 861, 862, "." +355, 7, 34, 175, 126, 127, 863, 864, "0" +355, 7, 35, 176, 128, 129, 865, 866, "%" +355, 7, 36, 177, 130, 134, 867, 871, "were" +355, 7, 37, 178, 135, 145, 872, 882, "randomized" +355, 7, 38, 179, 146, 148, 883, 885, "to" +355, 7, 39, 180, 149, 156, 886, 893, "receive" +355, 7, 40, 181, 157, 168, 894, 905, "colesevelam" +355, 7, 41, 182, 169, 170, 906, 907, "3" +355, 7, 42, 183, 171, 172, 908, 909, "." +355, 7, 43, 184, 173, 175, 910, 912, "75" +355, 7, 44, 185, 176, 177, 913, 914, "g" +355, 7, 45, 186, 178, 179, 915, 916, "/" +355, 7, 46, 187, 180, 181, 917, 918, "d" +355, 7, 47, 188, 182, 184, 919, 921, "or" +355, 7, 48, 189, 185, 193, 922, 930, "matching" +355, 7, 49, 190, 194, 201, 931, 938, "placebo" +355, 7, 50, 191, 202, 205, 939, 942, "for" +355, 7, 51, 192, 206, 208, 943, 945, "12" +355, 7, 52, 193, 209, 214, 946, 951, "weeks" +355, 7, 53, 194, 215, 216, 952, 953, "." +355, 8, 1, 195, 0, 8, 954, 962, "Subjects" +355, 8, 2, 196, 9, 10, 963, 964, "'" +355, 8, 3, 197, 11, 19, 965, 973, "previous" +355, 8, 4, 198, 20, 24, 974, 978, "oral" +355, 8, 5, 199, 25, 29, 979, 983, "anti" +355, 8, 6, 200, 30, 43, 984, 997, "hyperglycemic" +355, 8, 7, 201, 44, 54, 998, 1008, "medication" +355, 8, 8, 202, 55, 56, 1009, 1010, "(" +355, 8, 9, 203, 57, 69, 1011, 1023, "sulfonylurea" +355, 8, 10, 204, 70, 73, 1024, 1027, "and" +355, 8, 11, 205, 74, 75, 1028, 1029, "/" +355, 8, 12, 206, 76, 78, 1030, 1032, "or" +355, 8, 13, 207, 79, 88, 1033, 1042, "metformin" +355, 8, 14, 208, 89, 90, 1043, 1044, ")" +355, 8, 15, 209, 91, 94, 1045, 1048, "was" +355, 8, 16, 210, 95, 104, 1049, 1058, "continued" +355, 8, 17, 211, 105, 115, 1059, 1069, "throughout" +355, 8, 18, 212, 116, 119, 1070, 1073, "the" +355, 8, 19, 213, 120, 125, 1074, 1079, "study" +355, 8, 20, 214, 126, 127, 1080, 1081, "." +355, 9, 1, 215, 0, 7, 1082, 1089, "Fasting" +355, 9, 2, 216, 8, 13, 1090, 1095, "blood" +355, 9, 3, 217, 14, 21, 1096, 1103, "samples" +355, 9, 4, 218, 22, 26, 1104, 1108, "were" +355, 9, 5, 219, 27, 35, 1109, 1117, "obtained" +355, 9, 6, 220, 36, 38, 1118, 1120, "at" +355, 9, 7, 221, 39, 44, 1121, 1126, "weeks" +355, 9, 8, 222, 45, 46, 1127, 1128, "-" +355, 9, 9, 223, 47, 48, 1129, 1130, "5" +355, 9, 10, 224, 49, 50, 1131, 1132, "," +355, 9, 11, 225, 51, 52, 1133, 1134, "-" +355, 9, 12, 226, 53, 54, 1135, 1136, "1" +355, 9, 13, 227, 55, 56, 1137, 1138, "," +355, 9, 14, 228, 57, 58, 1139, 1140, "0" +355, 9, 15, 229, 59, 60, 1141, 1142, "," +355, 9, 16, 230, 61, 62, 1143, 1144, "1" +355, 9, 17, 231, 63, 64, 1145, 1146, "," +355, 9, 18, 232, 65, 66, 1147, 1148, "4" +355, 9, 19, 233, 67, 68, 1149, 1150, "," +355, 9, 20, 234, 69, 70, 1151, 1152, "8" +355, 9, 21, 235, 71, 72, 1153, 1154, "," +355, 9, 22, 236, 73, 76, 1155, 1158, "and" +355, 9, 23, 237, 77, 79, 1159, 1161, "12" +355, 9, 24, 238, 80, 81, 1162, 1163, "." +355, 10, 1, 239, 0, 3, 1164, 1167, "The" +355, 10, 2, 240, 4, 11, 1168, 1175, "primary" +355, 10, 3, 241, 12, 20, 1176, 1184, "efficacy" +355, 10, 4, 242, 21, 24, 1185, 1188, "end" +355, 10, 5, 243, 25, 30, 1189, 1194, "point" +355, 10, 6, 244, 31, 34, 1195, 1198, "was" +355, 10, 7, 245, 35, 38, 1199, 1202, "the" +355, 10, 8, 246, 39, 45, 1203, 1209, "change" +355, 10, 9, 247, 46, 48, 1210, 1212, "in" +355, 10, 10, 248, 49, 52, 1213, 1216, "HbA" +355, 10, 11, 249, 53, 54, 1217, 1218, "(" +355, 10, 12, 250, 55, 57, 1219, 1221, "1c" +355, 10, 13, 251, 58, 59, 1222, 1223, ")" +355, 10, 14, 252, 60, 64, 1224, 1228, "from" +355, 10, 15, 253, 65, 73, 1229, 1237, "baseline" +355, 10, 16, 254, 74, 76, 1238, 1240, "to" +355, 10, 17, 255, 77, 81, 1241, 1245, "week" +355, 10, 18, 256, 82, 84, 1246, 1248, "12" +355, 10, 19, 257, 85, 86, 1249, 1250, "." +355, 11, 1, 258, 0, 9, 1251, 1260, "Secondary" +355, 11, 2, 259, 10, 13, 1261, 1264, "end" +355, 11, 3, 260, 14, 20, 1265, 1271, "points" +355, 11, 4, 261, 21, 29, 1272, 1280, "included" +355, 11, 5, 262, 30, 37, 1281, 1288, "changes" +355, 11, 6, 263, 38, 40, 1289, 1291, "in" +355, 11, 7, 264, 41, 53, 1292, 1304, "fructosamine" +355, 11, 8, 265, 54, 60, 1305, 1311, "levels" +355, 11, 9, 266, 61, 62, 1312, 1313, "," +355, 11, 10, 267, 63, 70, 1314, 1321, "fasting" +355, 11, 11, 268, 71, 77, 1322, 1328, "plasma" +355, 11, 12, 269, 78, 85, 1329, 1336, "glucose" +355, 11, 13, 270, 86, 92, 1337, 1343, "levels" +355, 11, 14, 271, 93, 94, 1344, 1345, "," +355, 11, 15, 272, 95, 107, 1346, 1358, "postprandial" +355, 11, 16, 273, 108, 115, 1359, 1366, "glucose" +355, 11, 17, 274, 116, 121, 1367, 1372, "level" +355, 11, 18, 275, 122, 123, 1373, 1374, "," +355, 11, 19, 276, 124, 127, 1375, 1378, "and" +355, 11, 20, 277, 128, 132, 1379, 1383, "meal" +355, 11, 21, 278, 133, 140, 1384, 1391, "glucose" +355, 11, 22, 279, 141, 149, 1392, 1400, "response" +355, 11, 23, 280, 150, 151, 1401, 1402, "(" +355, 11, 24, 281, 152, 154, 1403, 1405, "ie" +355, 11, 25, 282, 155, 156, 1406, 1407, "," +355, 11, 26, 283, 157, 167, 1408, 1418, "difference" +355, 11, 27, 284, 168, 175, 1419, 1426, "between" +355, 11, 28, 285, 176, 187, 1427, 1438, "preprandial" +355, 11, 29, 286, 188, 191, 1439, 1442, "and" +355, 11, 30, 287, 192, 204, 1443, 1455, "postprandial" +355, 11, 31, 288, 205, 211, 1456, 1462, "levels" +355, 11, 32, 289, 212, 213, 1463, 1464, ")" +355, 11, 33, 290, 214, 215, 1465, 1466, "," +355, 11, 34, 291, 216, 219, 1467, 1470, "and" +355, 11, 35, 292, 220, 227, 1471, 1478, "percent" +355, 11, 36, 293, 228, 235, 1479, 1486, "changes" +355, 11, 37, 294, 236, 238, 1487, 1489, "in" +355, 11, 38, 295, 239, 244, 1490, 1495, "lipid" +355, 11, 39, 296, 245, 255, 1496, 1506, "parameters" +355, 11, 40, 297, 256, 260, 1507, 1511, "from" +355, 11, 41, 298, 261, 269, 1512, 1520, "baseline" +355, 11, 42, 299, 270, 272, 1521, 1523, "to" +355, 11, 43, 300, 273, 277, 1524, 1528, "week" +355, 11, 44, 301, 278, 280, 1529, 1531, "12" +355, 11, 45, 302, 281, 282, 1532, 1533, "." +355, 12, 1, 303, 0, 7, 1534, 1541, "RESULTS" +355, 12, 2, 304, 8, 9, 1542, 1543, ":" +355, 12, 3, 305, 10, 13, 1544, 1547, "The" +355, 12, 4, 306, 14, 16, 1548, 1550, "65" +355, 12, 5, 307, 17, 27, 1551, 1561, "randomized" +355, 12, 6, 308, 28, 36, 1562, 1570, "subjects" +355, 12, 7, 309, 37, 38, 1571, 1572, "(" +355, 12, 8, 310, 39, 41, 1573, 1575, "31" +355, 12, 9, 311, 42, 53, 1576, 1587, "colesevelam" +355, 12, 10, 312, 54, 55, 1588, 1589, "," +355, 12, 11, 313, 56, 58, 1590, 1592, "34" +355, 12, 12, 314, 59, 66, 1593, 1600, "placebo" +355, 12, 13, 315, 67, 68, 1601, 1602, ")" +355, 12, 14, 316, 69, 72, 1603, 1606, "had" +355, 12, 15, 317, 73, 74, 1607, 1608, "a" +355, 12, 16, 318, 75, 79, 1609, 1613, "mean" +355, 12, 17, 319, 80, 83, 1614, 1617, "age" +355, 12, 18, 320, 84, 86, 1618, 1620, "of" +355, 12, 19, 321, 87, 89, 1621, 1623, "56" +355, 12, 20, 322, 90, 91, 1624, 1625, "." +355, 12, 21, 323, 92, 93, 1626, 1627, "2" +355, 12, 22, 324, 94, 99, 1628, 1633, "years" +355, 12, 23, 325, 100, 103, 1634, 1637, "and" +355, 12, 24, 326, 104, 105, 1638, 1639, "a" +355, 12, 25, 327, 106, 110, 1640, 1644, "mean" +355, 12, 26, 328, 111, 115, 1645, 1649, "body" +355, 12, 27, 329, 116, 120, 1650, 1654, "mass" +355, 12, 28, 330, 121, 126, 1655, 1660, "index" +355, 12, 29, 331, 127, 129, 1661, 1663, "of" +355, 12, 30, 332, 130, 132, 1664, 1666, "32" +355, 12, 31, 333, 133, 134, 1667, 1668, "." +355, 12, 32, 334, 135, 136, 1669, 1670, "4" +355, 12, 33, 335, 137, 139, 1671, 1673, "kg" +355, 12, 34, 336, 140, 141, 1674, 1675, "/" +355, 12, 35, 337, 142, 143, 1676, 1677, "m" +355, 12, 36, 338, 144, 145, 1678, 1679, "(" +355, 12, 37, 339, 146, 147, 1680, 1681, "2" +355, 12, 38, 340, 148, 149, 1682, 1683, ")" +355, 12, 39, 341, 150, 151, 1684, 1685, ";" +355, 12, 40, 342, 152, 154, 1686, 1688, "55" +355, 12, 41, 343, 155, 156, 1689, 1690, "." +355, 12, 42, 344, 157, 158, 1691, 1692, "4" +355, 12, 43, 345, 159, 160, 1693, 1694, "%" +355, 12, 44, 346, 161, 165, 1695, 1699, "were" +355, 12, 45, 347, 166, 170, 1700, 1704, "male" +355, 12, 46, 348, 171, 174, 1705, 1708, "and" +355, 12, 47, 349, 175, 177, 1709, 1711, "53" +355, 12, 48, 350, 178, 179, 1712, 1713, "." +355, 12, 49, 351, 180, 181, 1714, 1715, "8" +355, 12, 50, 352, 182, 183, 1716, 1717, "%" +355, 12, 51, 353, 184, 188, 1718, 1722, "were" +355, 12, 52, 354, 189, 194, 1723, 1728, "white" +355, 12, 53, 355, 195, 196, 1729, 1730, "." +355, 13, 1, 356, 0, 3, 1731, 1734, "The" +355, 13, 2, 357, 4, 14, 1735, 1745, "difference" +355, 13, 3, 358, 15, 17, 1746, 1748, "in" +355, 13, 4, 359, 18, 23, 1749, 1754, "least" +355, 13, 5, 360, 24, 31, 1755, 1762, "squares" +355, 13, 6, 361, 32, 33, 1763, 1764, "(" +355, 13, 7, 362, 34, 36, 1765, 1767, "LS" +355, 13, 8, 363, 37, 38, 1768, 1769, ")" +355, 13, 9, 364, 39, 43, 1770, 1774, "mean" +355, 13, 10, 365, 44, 45, 1775, 1776, "(" +355, 13, 11, 366, 46, 48, 1777, 1779, "SE" +355, 13, 12, 367, 49, 50, 1780, 1781, ")" +355, 13, 13, 368, 51, 57, 1782, 1788, "change" +355, 13, 14, 369, 58, 60, 1789, 1791, "in" +355, 13, 15, 370, 61, 64, 1792, 1795, "HbA" +355, 13, 16, 371, 65, 66, 1796, 1797, "(" +355, 13, 17, 372, 67, 69, 1798, 1800, "1c" +355, 13, 18, 373, 70, 71, 1801, 1802, ")" +355, 13, 19, 374, 72, 79, 1803, 1810, "between" +355, 13, 20, 375, 80, 83, 1811, 1814, "the" +355, 13, 21, 376, 84, 95, 1815, 1826, "colesevelam" +355, 13, 22, 377, 96, 101, 1827, 1832, "group" +355, 13, 23, 378, 102, 105, 1833, 1836, "and" +355, 13, 24, 379, 106, 109, 1837, 1840, "the" +355, 13, 25, 380, 110, 117, 1841, 1848, "placebo" +355, 13, 26, 381, 118, 123, 1849, 1854, "group" +355, 13, 27, 382, 124, 127, 1855, 1858, "was" +355, 13, 28, 383, 128, 129, 1859, 1860, "-" +355, 13, 29, 384, 130, 131, 1861, 1862, "0" +355, 13, 30, 385, 132, 133, 1863, 1864, "." +355, 13, 31, 386, 134, 135, 1865, 1866, "5" +355, 13, 32, 387, 136, 137, 1867, 1868, "%" +355, 13, 33, 388, 138, 139, 1869, 1870, "(" +355, 13, 34, 389, 140, 141, 1871, 1872, "0" +355, 13, 35, 390, 142, 143, 1873, 1874, "." +355, 13, 36, 391, 144, 146, 1875, 1877, "18" +355, 13, 37, 392, 147, 148, 1878, 1879, ")" +355, 13, 38, 393, 149, 150, 1880, 1881, "(" +355, 13, 39, 394, 151, 152, 1882, 1883, "P" +355, 13, 40, 395, 153, 154, 1884, 1885, "=" +355, 13, 41, 396, 155, 156, 1886, 1887, "0" +355, 13, 42, 397, 157, 158, 1888, 1889, "." +355, 13, 43, 398, 159, 162, 1890, 1893, "007" +355, 13, 44, 399, 163, 164, 1894, 1895, ")" +355, 13, 45, 400, 165, 166, 1896, 1897, "." +355, 14, 1, 401, 0, 2, 1898, 1900, "In" +355, 14, 2, 402, 3, 11, 1901, 1909, "subjects" +355, 14, 3, 403, 12, 16, 1910, 1914, "with" +355, 14, 4, 404, 17, 18, 1915, 1916, "a" +355, 14, 5, 405, 19, 27, 1917, 1925, "baseline" +355, 14, 6, 406, 28, 33, 1926, 1931, "HbAIc" +355, 14, 7, 407, 34, 35, 1932, 1933, ">" +355, 14, 8, 408, 36, 38, 1934, 1936, "or" +355, 14, 9, 409, 39, 40, 1937, 1938, "=" +355, 14, 10, 410, 41, 42, 1939, 1940, "8" +355, 14, 11, 411, 43, 44, 1941, 1942, "." +355, 14, 12, 412, 45, 46, 1943, 1944, "0" +355, 14, 13, 413, 47, 48, 1945, 1946, "%" +355, 14, 14, 414, 49, 50, 1947, 1948, "," +355, 14, 15, 415, 51, 54, 1949, 1952, "the" +355, 14, 16, 416, 55, 65, 1953, 1963, "difference" +355, 14, 17, 417, 66, 68, 1964, 1966, "in" +355, 14, 18, 418, 69, 71, 1967, 1969, "LS" +355, 14, 19, 419, 72, 76, 1970, 1974, "mean" +355, 14, 20, 420, 77, 83, 1975, 1981, "change" +355, 14, 21, 421, 84, 86, 1982, 1984, "in" +355, 14, 22, 422, 87, 90, 1985, 1988, "HbA" +355, 14, 23, 423, 91, 92, 1989, 1990, "(" +355, 14, 24, 424, 93, 95, 1991, 1993, "1c" +355, 14, 25, 425, 96, 97, 1994, 1995, ")" +355, 14, 26, 426, 98, 101, 1996, 1999, "was" +355, 14, 27, 427, 102, 103, 2000, 2001, "-" +355, 14, 28, 428, 104, 105, 2002, 2003, "1" +355, 14, 29, 429, 106, 107, 2004, 2005, "." +355, 14, 30, 430, 108, 109, 2006, 2007, "0" +355, 14, 31, 431, 110, 111, 2008, 2009, "%" +355, 14, 32, 432, 112, 113, 2010, 2011, "(" +355, 14, 33, 433, 114, 115, 2012, 2013, "0" +355, 14, 34, 434, 116, 117, 2014, 2015, "." +355, 14, 35, 435, 118, 120, 2016, 2018, "27" +355, 14, 36, 436, 121, 122, 2019, 2020, ")" +355, 14, 37, 437, 123, 124, 2021, 2022, "(" +355, 14, 38, 438, 125, 126, 2023, 2024, "P" +355, 14, 39, 439, 127, 128, 2025, 2026, "=" +355, 14, 40, 440, 129, 130, 2027, 2028, "0" +355, 14, 41, 441, 131, 132, 2029, 2030, "." +355, 14, 42, 442, 133, 136, 2031, 2034, "002" +355, 14, 43, 443, 137, 138, 2035, 2036, ")" +355, 14, 44, 444, 139, 140, 2037, 2038, "." +355, 15, 1, 445, 0, 8, 2039, 2047, "Relative" +355, 15, 2, 446, 9, 11, 2048, 2050, "to" +355, 15, 3, 447, 12, 19, 2051, 2058, "placebo" +355, 15, 4, 448, 20, 21, 2059, 2060, "," +355, 15, 5, 449, 22, 33, 2061, 2072, "colesevelam" +355, 15, 6, 450, 34, 43, 2073, 2082, "treatment" +355, 15, 7, 451, 44, 47, 2083, 2086, "was" +355, 15, 8, 452, 48, 58, 2087, 2097, "associated" +355, 15, 9, 453, 59, 63, 2098, 2102, "with" +355, 15, 10, 454, 64, 74, 2103, 2113, "reductions" +355, 15, 11, 455, 75, 77, 2114, 2116, "in" +355, 15, 12, 456, 78, 84, 2117, 2123, "levels" +355, 15, 13, 457, 85, 87, 2124, 2126, "of" +355, 15, 14, 458, 88, 100, 2127, 2139, "fructosamine" +355, 15, 15, 459, 101, 102, 2140, 2141, "(" +355, 15, 16, 460, 103, 104, 2142, 2143, "-" +355, 15, 17, 461, 105, 107, 2144, 2146, "29" +355, 15, 18, 462, 108, 109, 2147, 2148, "." +355, 15, 19, 463, 110, 111, 2149, 2150, "0" +355, 15, 20, 464, 112, 113, 2151, 2152, "[" +355, 15, 21, 465, 114, 116, 2153, 2155, "10" +355, 15, 22, 466, 117, 118, 2156, 2157, "." +355, 15, 23, 467, 119, 120, 2158, 2159, "9" +355, 15, 24, 468, 121, 122, 2160, 2161, "]" +355, 15, 25, 469, 123, 127, 2162, 2166, "pmol" +355, 15, 26, 470, 128, 129, 2167, 2168, "/" +355, 15, 27, 471, 130, 131, 2169, 2170, "L" +355, 15, 28, 472, 132, 133, 2171, 2172, ";" +355, 15, 29, 473, 134, 135, 2173, 2174, "P" +355, 15, 30, 474, 136, 137, 2175, 2176, "=" +355, 15, 31, 475, 138, 139, 2177, 2178, "0" +355, 15, 32, 476, 140, 141, 2179, 2180, "." +355, 15, 33, 477, 142, 145, 2181, 2184, "011" +355, 15, 34, 478, 146, 147, 2185, 2186, ")" +355, 15, 35, 479, 148, 151, 2187, 2190, "and" +355, 15, 36, 480, 152, 164, 2191, 2203, "postprandial" +355, 15, 37, 481, 165, 172, 2204, 2211, "glucose" +355, 15, 38, 482, 173, 174, 2212, 2213, "(" +355, 15, 39, 483, 175, 176, 2214, 2215, "-" +355, 15, 40, 484, 177, 179, 2216, 2218, "31" +355, 15, 41, 485, 180, 181, 2219, 2220, "." +355, 15, 42, 486, 182, 183, 2221, 2222, "5" +355, 15, 43, 487, 184, 185, 2223, 2224, "[" +355, 15, 44, 488, 186, 188, 2225, 2227, "13" +355, 15, 45, 489, 189, 190, 2228, 2229, "." +355, 15, 46, 490, 191, 192, 2230, 2231, "6" +355, 15, 47, 491, 193, 194, 2232, 2233, "]" +355, 15, 48, 492, 195, 197, 2234, 2236, "mg" +355, 15, 49, 493, 198, 199, 2237, 2238, "/" +355, 15, 50, 494, 200, 202, 2239, 2241, "dL" +355, 15, 51, 495, 203, 204, 2242, 2243, ";" +355, 15, 52, 496, 205, 206, 2244, 2245, "P" +355, 15, 53, 497, 207, 208, 2246, 2247, "=" +355, 15, 54, 498, 209, 210, 2248, 2249, "0" +355, 15, 55, 499, 211, 212, 2250, 2251, "." +355, 15, 56, 500, 213, 216, 2252, 2255, "026" +355, 15, 57, 501, 217, 218, 2256, 2257, ")" +355, 15, 58, 502, 219, 220, 2258, 2259, "." +355, 16, 1, 503, 0, 3, 2260, 2263, "The" +355, 16, 2, 504, 4, 8, 2264, 2268, "mean" +355, 16, 3, 505, 9, 16, 2269, 2276, "percent" +355, 16, 4, 506, 17, 23, 2277, 2283, "change" +355, 16, 5, 507, 24, 26, 2284, 2286, "in" +355, 16, 6, 508, 27, 30, 2287, 2290, "low" +355, 16, 7, 509, 31, 32, 2291, 2292, "-" +355, 16, 8, 510, 33, 40, 2293, 2300, "density" +355, 16, 9, 511, 41, 52, 2301, 2312, "lipoprotein" +355, 16, 10, 512, 53, 64, 2313, 2324, "cholesterol" +355, 16, 11, 513, 65, 68, 2325, 2328, "was" +355, 16, 12, 514, 69, 70, 2329, 2330, "-" +355, 16, 13, 515, 71, 72, 2331, 2332, "9" +355, 16, 14, 516, 73, 74, 2333, 2334, "." +355, 16, 15, 517, 75, 76, 2335, 2336, "6" +355, 16, 16, 518, 77, 78, 2337, 2338, "%" +355, 16, 17, 519, 79, 81, 2339, 2341, "in" +355, 16, 18, 520, 82, 85, 2342, 2345, "the" +355, 16, 19, 521, 86, 97, 2346, 2357, "colesevelam" +355, 16, 20, 522, 98, 103, 2358, 2363, "group" +355, 16, 21, 523, 104, 105, 2364, 2365, "," +355, 16, 22, 524, 106, 114, 2366, 2374, "compared" +355, 16, 23, 525, 115, 119, 2375, 2379, "with" +355, 16, 24, 526, 120, 121, 2380, 2381, "2" +355, 16, 25, 527, 122, 123, 2382, 2383, "." +355, 16, 26, 528, 124, 125, 2384, 2385, "1" +355, 16, 27, 529, 126, 127, 2386, 2387, "%" +355, 16, 28, 530, 128, 130, 2388, 2390, "in" +355, 16, 29, 531, 131, 134, 2391, 2394, "the" +355, 16, 30, 532, 135, 142, 2395, 2402, "placebo" +355, 16, 31, 533, 143, 148, 2403, 2408, "group" +355, 16, 32, 534, 149, 150, 2409, 2410, "(" +355, 16, 33, 535, 151, 160, 2411, 2420, "treatment" +355, 16, 34, 536, 161, 171, 2421, 2431, "difference" +355, 16, 35, 537, 172, 173, 2432, 2433, "," +355, 16, 36, 538, 174, 175, 2434, 2435, "-" +355, 16, 37, 539, 176, 178, 2436, 2438, "11" +355, 16, 38, 540, 179, 180, 2439, 2440, "." +355, 16, 39, 541, 181, 182, 2441, 2442, "7" +355, 16, 40, 542, 183, 184, 2443, 2444, "%" +355, 16, 41, 543, 185, 186, 2445, 2446, "[" +355, 16, 42, 544, 187, 188, 2447, 2448, "4" +355, 16, 43, 545, 189, 190, 2449, 2450, "." +355, 16, 44, 546, 191, 192, 2451, 2452, "2" +355, 16, 45, 547, 193, 194, 2453, 2454, "]" +355, 16, 46, 548, 195, 196, 2455, 2456, ";" +355, 16, 47, 549, 197, 198, 2457, 2458, "P" +355, 16, 48, 550, 199, 200, 2459, 2460, "=" +355, 16, 49, 551, 201, 202, 2461, 2462, "0" +355, 16, 50, 552, 203, 204, 2463, 2464, "." +355, 16, 51, 553, 205, 208, 2465, 2468, "007" +355, 16, 52, 554, 209, 210, 2469, 2470, ")" +355, 16, 53, 555, 211, 212, 2471, 2472, ";" +355, 16, 54, 556, 213, 216, 2473, 2476, "the" +355, 16, 55, 557, 217, 227, 2477, 2487, "respective" +355, 16, 56, 558, 228, 232, 2488, 2492, "mean" +355, 16, 57, 559, 233, 240, 2493, 2500, "percent" +355, 16, 58, 560, 241, 248, 2501, 2508, "changes" +355, 16, 59, 561, 249, 251, 2509, 2511, "in" +355, 16, 60, 562, 252, 257, 2512, 2517, "total" +355, 16, 61, 563, 258, 269, 2518, 2529, "cholesterol" +355, 16, 62, 564, 270, 274, 2530, 2534, "were" +355, 16, 63, 565, 275, 276, 2535, 2536, "-" +355, 16, 64, 566, 277, 278, 2537, 2538, "4" +355, 16, 65, 567, 279, 280, 2539, 2540, "." +355, 16, 66, 568, 281, 282, 2541, 2542, "0" +355, 16, 67, 569, 283, 284, 2543, 2544, "%" +355, 16, 68, 570, 285, 288, 2545, 2548, "and" +355, 16, 69, 571, 289, 290, 2549, 2550, "3" +355, 16, 70, 572, 291, 292, 2551, 2552, "." +355, 16, 71, 573, 293, 294, 2553, 2554, "4" +355, 16, 72, 574, 295, 296, 2555, 2556, "%" +355, 16, 73, 575, 297, 298, 2557, 2558, "(" +355, 16, 74, 576, 299, 308, 2559, 2568, "treatment" +355, 16, 75, 577, 309, 319, 2569, 2579, "difference" +355, 16, 76, 578, 320, 321, 2580, 2581, "," +355, 16, 77, 579, 322, 323, 2582, 2583, "-" +355, 16, 78, 580, 324, 325, 2584, 2585, "7" +355, 16, 79, 581, 326, 327, 2586, 2587, "." +355, 16, 80, 582, 328, 329, 2588, 2589, "3" +355, 16, 81, 583, 330, 331, 2590, 2591, "%" +355, 16, 82, 584, 332, 333, 2592, 2593, "[" +355, 16, 83, 585, 334, 335, 2594, 2595, "3" +355, 16, 84, 586, 336, 337, 2596, 2597, "." +355, 16, 85, 587, 338, 339, 2598, 2599, "0" +355, 16, 86, 588, 340, 341, 2600, 2601, "]" +355, 16, 87, 589, 342, 343, 2602, 2603, ";" +355, 16, 88, 590, 344, 345, 2604, 2605, "P" +355, 16, 89, 591, 346, 347, 2606, 2607, "=" +355, 16, 90, 592, 348, 349, 2608, 2609, "0" +355, 16, 91, 593, 350, 351, 2610, 2611, "." +355, 16, 92, 594, 352, 355, 2612, 2615, "019" +355, 16, 93, 595, 356, 357, 2616, 2617, ")" +355, 16, 94, 596, 358, 359, 2618, 2619, "." +355, 17, 1, 597, 0, 11, 2620, 2631, "Colesevelam" +355, 17, 2, 598, 12, 16, 2632, 2636, "also" +355, 17, 3, 599, 17, 20, 2637, 2640, "was" +355, 17, 4, 600, 21, 31, 2641, 2651, "associated" +355, 17, 5, 601, 32, 36, 2652, 2656, "with" +355, 17, 6, 602, 37, 48, 2657, 2668, "significant" +355, 17, 7, 603, 49, 58, 2669, 2678, "decreases" +355, 17, 8, 604, 59, 61, 2679, 2681, "in" +355, 17, 9, 605, 62, 65, 2682, 2685, "the" +355, 17, 10, 606, 66, 73, 2686, 2693, "percent" +355, 17, 11, 607, 74, 80, 2694, 2700, "change" +355, 17, 12, 608, 81, 83, 2701, 2703, "in" +355, 17, 13, 609, 84, 98, 2704, 2718, "apolipoprotein" +355, 17, 14, 610, 99, 100, 2719, 2720, "B" +355, 17, 15, 611, 101, 102, 2721, 2722, "(" +355, 17, 16, 612, 103, 104, 2723, 2724, "P" +355, 17, 17, 613, 105, 106, 2725, 2726, "=" +355, 17, 18, 614, 107, 108, 2727, 2728, "0" +355, 17, 19, 615, 109, 110, 2729, 2730, "." +355, 17, 20, 616, 111, 114, 2731, 2734, "003" +355, 17, 21, 617, 115, 116, 2735, 2736, ")" +355, 17, 22, 618, 117, 120, 2737, 2740, "and" +355, 17, 23, 619, 121, 124, 2741, 2744, "low" +355, 17, 24, 620, 125, 126, 2745, 2746, "-" +355, 17, 25, 621, 127, 134, 2747, 2754, "density" +355, 17, 26, 622, 135, 146, 2755, 2766, "lipoprotein" +355, 17, 27, 623, 147, 155, 2767, 2775, "particle" +355, 17, 28, 624, 156, 169, 2776, 2789, "concentration" +355, 17, 29, 625, 170, 171, 2790, 2791, "(" +355, 17, 30, 626, 172, 173, 2792, 2793, "P" +355, 17, 31, 627, 174, 175, 2794, 2795, "=" +355, 17, 32, 628, 176, 177, 2796, 2797, "0" +355, 17, 33, 629, 178, 179, 2798, 2799, "." +355, 17, 34, 630, 180, 183, 2800, 2803, "037" +355, 17, 35, 631, 184, 185, 2804, 2805, ")" +355, 17, 36, 632, 186, 187, 2806, 2807, "." +355, 18, 1, 633, 0, 3, 2808, 2811, "The" +355, 18, 2, 634, 4, 13, 2812, 2821, "incidence" +355, 18, 3, 635, 14, 16, 2822, 2824, "of" +355, 18, 4, 636, 17, 26, 2825, 2834, "treatment" +355, 18, 5, 637, 27, 28, 2835, 2836, "-" +355, 18, 6, 638, 29, 37, 2837, 2845, "emergent" +355, 18, 7, 639, 38, 45, 2846, 2853, "adverse" +355, 18, 8, 640, 46, 52, 2854, 2860, "events" +355, 18, 9, 641, 53, 54, 2861, 2862, "(" +355, 18, 10, 642, 55, 60, 2863, 2868, "TEAEs" +355, 18, 11, 643, 61, 62, 2869, 2870, ")" +355, 18, 12, 644, 63, 66, 2871, 2874, "was" +355, 18, 13, 645, 67, 74, 2875, 2882, "similar" +355, 18, 14, 646, 75, 77, 2883, 2885, "in" +355, 18, 15, 647, 78, 82, 2886, 2890, "both" +355, 18, 16, 648, 83, 89, 2891, 2897, "groups" +355, 18, 17, 649, 90, 91, 2898, 2899, "," +355, 18, 18, 650, 92, 100, 2900, 2908, "although" +355, 18, 19, 651, 101, 110, 2909, 2918, "treatment" +355, 18, 20, 652, 111, 112, 2919, 2920, "-" +355, 18, 21, 653, 113, 120, 2921, 2928, "related" +355, 18, 22, 654, 121, 128, 2929, 2936, "adverse" +355, 18, 23, 655, 129, 135, 2937, 2943, "events" +355, 18, 24, 656, 136, 140, 2944, 2948, "were" +355, 18, 25, 657, 141, 145, 2949, 2953, "more" +355, 18, 26, 658, 146, 154, 2954, 2962, "frequent" +355, 18, 27, 659, 155, 157, 2963, 2965, "in" +355, 18, 28, 660, 158, 161, 2966, 2969, "the" +355, 18, 29, 661, 162, 173, 2970, 2981, "colesevelam" +355, 18, 30, 662, 174, 179, 2982, 2987, "group" +355, 18, 31, 663, 180, 184, 2988, 2992, "than" +355, 18, 32, 664, 185, 187, 2993, 2995, "in" +355, 18, 33, 665, 188, 191, 2996, 2999, "the" +355, 18, 34, 666, 192, 199, 3000, 3007, "placebo" +355, 18, 35, 667, 200, 205, 3008, 3013, "group" +355, 18, 36, 668, 206, 207, 3014, 3015, "(" +355, 18, 37, 669, 208, 210, 3016, 3018, "29" +355, 18, 38, 670, 211, 212, 3019, 3020, "." +355, 18, 39, 671, 213, 214, 3021, 3022, "0" +355, 18, 40, 672, 215, 216, 3023, 3024, "%" +355, 18, 41, 673, 217, 219, 3025, 3027, "vs" +355, 18, 42, 674, 220, 221, 3028, 3029, "8" +355, 18, 43, 675, 222, 223, 3030, 3031, "." +355, 18, 44, 676, 224, 225, 3032, 3033, "8" +355, 18, 45, 677, 226, 227, 3034, 3035, "%" +355, 18, 46, 678, 228, 229, 3036, 3037, "," +355, 18, 47, 679, 230, 242, 3038, 3050, "respectively" +355, 18, 48, 680, 243, 244, 3051, 3052, ")" +355, 18, 49, 681, 245, 246, 3053, 3054, "." +355, 19, 1, 682, 0, 3, 3055, 3058, "The" +355, 19, 2, 683, 4, 8, 3059, 3063, "most" +355, 19, 3, 684, 9, 17, 3064, 3072, "frequent" +355, 19, 4, 685, 18, 23, 3073, 3078, "TEAEs" +355, 19, 5, 686, 24, 26, 3079, 3081, "in" +355, 19, 6, 687, 27, 30, 3082, 3085, "the" +355, 19, 7, 688, 31, 42, 3086, 3097, "colesevelam" +355, 19, 8, 689, 43, 48, 3098, 3103, "group" +355, 19, 9, 690, 49, 53, 3104, 3108, "were" +355, 19, 10, 691, 54, 70, 3109, 3125, "gastrointestinal" +355, 19, 11, 692, 71, 80, 3126, 3135, "disorders" +355, 19, 12, 693, 81, 82, 3136, 3137, "(" +355, 19, 13, 694, 83, 85, 3138, 3140, "22" +355, 19, 14, 695, 86, 87, 3141, 3142, "." +355, 19, 15, 696, 88, 89, 3143, 3144, "6" +355, 19, 16, 697, 90, 91, 3145, 3146, "%" +355, 19, 17, 698, 92, 93, 3147, 3148, ")" +355, 19, 18, 699, 94, 95, 3149, 3150, "," +355, 19, 19, 700, 96, 105, 3151, 3160, "primarily" +355, 19, 20, 701, 106, 118, 3161, 3173, "constipation" +355, 19, 21, 702, 119, 120, 3174, 3175, "(" +355, 19, 22, 703, 121, 123, 3176, 3178, "19" +355, 19, 23, 704, 124, 125, 3179, 3180, "." +355, 19, 24, 705, 126, 127, 3181, 3182, "4" +355, 19, 25, 706, 128, 129, 3183, 3184, "%" +355, 19, 26, 707, 130, 131, 3185, 3186, ")" +355, 19, 27, 708, 132, 133, 3187, 3188, "," +355, 19, 28, 709, 134, 142, 3189, 3197, "compared" +355, 19, 29, 710, 143, 147, 3198, 3202, "with" +355, 19, 30, 711, 148, 150, 3203, 3205, "an" +355, 19, 31, 712, 151, 152, 3206, 3207, "8" +355, 19, 32, 713, 153, 154, 3208, 3209, "." +355, 19, 33, 714, 155, 156, 3210, 3211, "8" +355, 19, 34, 715, 157, 158, 3212, 3213, "%" +355, 19, 35, 716, 159, 168, 3214, 3223, "incidence" +355, 19, 36, 717, 169, 171, 3224, 3226, "of" +355, 19, 37, 718, 172, 188, 3227, 3243, "gastrointestinal" +355, 19, 38, 719, 189, 198, 3244, 3253, "disorders" +355, 19, 39, 720, 199, 200, 3254, 3255, "(" +355, 19, 40, 721, 201, 202, 3256, 3257, "0" +355, 19, 41, 722, 203, 204, 3258, 3259, "%" +355, 19, 42, 723, 205, 217, 3260, 3272, "constipation" +355, 19, 43, 724, 218, 219, 3273, 3274, ")" +355, 19, 44, 725, 220, 222, 3275, 3277, "in" +355, 19, 45, 726, 223, 226, 3278, 3281, "the" +355, 19, 46, 727, 227, 234, 3282, 3289, "placebo" +355, 19, 47, 728, 235, 240, 3290, 3295, "group" +355, 19, 48, 729, 241, 242, 3296, 3297, "." +355, 20, 1, 730, 0, 5, 3298, 3303, "There" +355, 20, 2, 731, 6, 10, 3304, 3308, "were" +355, 20, 3, 732, 11, 13, 3309, 3311, "no" +355, 20, 4, 733, 14, 25, 3312, 3323, "significant" +355, 20, 5, 734, 26, 33, 3324, 3331, "changes" +355, 20, 6, 735, 34, 36, 3332, 3334, "in" +355, 20, 7, 736, 37, 41, 3335, 3339, "body" +355, 20, 8, 737, 42, 48, 3340, 3346, "weight" +355, 20, 9, 738, 49, 51, 3347, 3349, "or" +355, 20, 10, 739, 52, 55, 3350, 3353, "the" +355, 20, 11, 740, 56, 66, 3354, 3364, "occurrence" +355, 20, 12, 741, 67, 69, 3365, 3367, "of" +355, 20, 13, 742, 70, 82, 3368, 3380, "hypoglycemia" +355, 20, 14, 743, 83, 90, 3381, 3388, "between" +355, 20, 15, 744, 91, 100, 3389, 3398, "treatment" +355, 20, 16, 745, 101, 107, 3399, 3405, "groups" +355, 20, 17, 746, 108, 109, 3406, 3407, "." +355, 21, 1, 747, 0, 11, 3408, 3419, "CONCLUSIONS" +355, 21, 2, 748, 12, 13, 3420, 3421, ":" +355, 21, 3, 749, 14, 16, 3422, 3424, "In" +355, 21, 4, 750, 17, 22, 3425, 3430, "these" +355, 21, 5, 751, 23, 31, 3431, 3439, "subjects" +355, 21, 6, 752, 32, 36, 3440, 3444, "with" +355, 21, 7, 753, 37, 41, 3445, 3449, "type" +355, 21, 8, 754, 42, 43, 3450, 3451, "2" +355, 21, 9, 755, 44, 52, 3452, 3460, "diabetes" +355, 21, 10, 756, 53, 54, 3461, 3462, "," +355, 21, 11, 757, 55, 57, 3463, 3465, "12" +355, 21, 12, 758, 58, 63, 3466, 3471, "weeks" +355, 21, 13, 759, 64, 66, 3472, 3474, "of" +355, 21, 14, 760, 67, 78, 3475, 3486, "colesevelam" +355, 21, 15, 761, 79, 88, 3487, 3496, "treatment" +355, 21, 16, 762, 89, 93, 3497, 3501, "were" +355, 21, 17, 763, 94, 104, 3502, 3512, "associated" +355, 21, 18, 764, 105, 109, 3513, 3517, "with" +355, 21, 19, 765, 110, 121, 3518, 3529, "significant" +355, 21, 20, 766, 122, 132, 3530, 3540, "reductions" +355, 21, 21, 767, 133, 135, 3541, 3543, "in" +355, 21, 22, 768, 136, 139, 3544, 3547, "HbA" +355, 21, 23, 769, 140, 141, 3548, 3549, "(" +355, 21, 24, 770, 142, 144, 3550, 3552, "1c" +355, 21, 25, 771, 145, 146, 3553, 3554, ")" +355, 21, 26, 772, 147, 150, 3555, 3558, "and" +355, 21, 27, 773, 151, 153, 3559, 3561, "in" +355, 21, 28, 774, 154, 166, 3562, 3574, "fructosamine" +355, 21, 29, 775, 167, 170, 3575, 3578, "and" +355, 21, 30, 776, 171, 183, 3579, 3591, "postprandial" +355, 21, 31, 777, 184, 191, 3592, 3599, "glucose" +355, 21, 32, 778, 192, 198, 3600, 3606, "levels" +355, 21, 33, 779, 199, 207, 3607, 3615, "compared" +355, 21, 34, 780, 208, 212, 3616, 3620, "with" +355, 21, 35, 781, 213, 220, 3621, 3628, "placebo" +355, 21, 36, 782, 221, 222, 3629, 3630, "." +355, 22, 1, 783, 0, 3, 3631, 3634, "The" +355, 22, 2, 784, 4, 5, 3635, 3636, "2" +355, 22, 3, 785, 6, 12, 3637, 3643, "groups" +355, 22, 4, 786, 13, 16, 3644, 3647, "had" +355, 22, 5, 787, 17, 18, 3648, 3649, "a" +355, 22, 6, 788, 19, 26, 3650, 3657, "similar" +355, 22, 7, 789, 27, 34, 3658, 3665, "adverse" +355, 22, 8, 790, 35, 36, 3666, 3667, "-" +355, 22, 9, 791, 37, 42, 3668, 3673, "event" +355, 22, 10, 792, 43, 50, 3674, 3681, "profile" +355, 22, 11, 793, 51, 52, 3682, 3683, "," +355, 22, 12, 794, 53, 57, 3684, 3688, "with" +355, 22, 13, 795, 58, 61, 3689, 3692, "the" +355, 22, 14, 796, 62, 71, 3693, 3702, "exception" +355, 22, 15, 797, 72, 74, 3703, 3705, "of" +355, 22, 16, 798, 75, 77, 3706, 3708, "an" +355, 22, 17, 799, 78, 87, 3709, 3718, "increased" +355, 22, 18, 800, 88, 97, 3719, 3728, "incidence" +355, 22, 19, 801, 98, 100, 3729, 3731, "of" +355, 22, 20, 802, 101, 113, 3732, 3744, "constipation" +355, 22, 21, 803, 114, 116, 3745, 3747, "in" +355, 22, 22, 804, 117, 120, 3748, 3751, "the" +355, 22, 23, 805, 121, 132, 3752, 3763, "colesevelam" +355, 22, 24, 806, 133, 138, 3764, 3769, "group" +355, 22, 25, 807, 139, 140, 3770, 3771, "." +355, 23, 1, 808, 0, 5, 3772, 3777, "These" +355, 23, 2, 809, 6, 13, 3778, 3785, "results" +355, 23, 3, 810, 14, 21, 3786, 3793, "suggest" +355, 23, 4, 811, 22, 26, 3794, 3798, "that" +355, 23, 5, 812, 27, 38, 3799, 3810, "colesevelam" +355, 23, 6, 813, 39, 42, 3811, 3814, "may" +355, 23, 7, 814, 43, 50, 3815, 3822, "improve" +355, 23, 8, 815, 51, 55, 3823, 3827, "both" +355, 23, 9, 816, 56, 61, 3828, 3833, "lipid" +355, 23, 10, 817, 62, 69, 3834, 3841, "control" +355, 23, 11, 818, 70, 73, 3842, 3845, "and" +355, 23, 12, 819, 74, 82, 3846, 3854, "glycemic" +355, 23, 13, 820, 83, 90, 3855, 3862, "control" +355, 23, 14, 821, 91, 93, 3863, 3865, "in" +355, 23, 15, 822, 94, 102, 3866, 3874, "patients" +355, 23, 16, 823, 103, 107, 3875, 3879, "with" +355, 23, 17, 824, 108, 112, 3880, 3884, "type" +355, 23, 18, 825, 113, 114, 3885, 3886, "2" +355, 23, 19, 826, 115, 123, 3887, 3895, "diabetes" +355, 23, 20, 827, 124, 133, 3896, 3905, "receiving" +355, 23, 21, 828, 134, 138, 3906, 3910, "oral" +355, 23, 22, 829, 139, 156, 3911, 3928, "antihyperglycemic" +355, 23, 23, 830, 157, 168, 3929, 3940, "medications" +355, 23, 24, 831, 169, 170, 3941, 3942, "." +355, 24, 1, 832, 0, 3, 3943, 3946, "DOI" +355, 24, 2, 833, 4, 5, 3947, 3948, ":" +355, 24, 3, 834, 6, 8, 3949, 3951, "10" +355, 24, 4, 835, 9, 10, 3952, 3953, "." +355, 24, 5, 836, 11, 15, 3954, 3958, "1016" +355, 24, 6, 837, 16, 17, 3959, 3960, "/" +355, 24, 7, 838, 18, 19, 3961, 3962, "j" +355, 24, 8, 839, 20, 21, 3963, 3964, "." +355, 24, 9, 840, 22, 31, 3965, 3974, "clinthera" +355, 24, 10, 841, 32, 33, 3975, 3976, "." +355, 24, 11, 842, 34, 38, 3977, 3981, "2007" +355, 24, 12, 843, 39, 40, 3982, 3983, "." +355, 24, 13, 844, 41, 43, 3984, 3986, "01" +355, 24, 14, 845, 44, 45, 3987, 3988, "." +355, 24, 15, 846, 46, 49, 3989, 3992, "003" +355, 24, 16, 847, 50, 54, 3993, 3997, "PMID" +355, 24, 17, 848, 55, 56, 3998, 3999, ":" +355, 24, 18, 849, 57, 65, 4000, 4008, "17379048" +355, 24, 19, 850, 66, 67, 4009, 4010, "[" +355, 24, 20, 851, 68, 75, 4011, 4018, "Indexed" +355, 24, 21, 852, 76, 79, 4019, 4022, "for" +355, 24, 22, 853, 80, 87, 4023, 4030, "MEDLINE" +355, 24, 23, 854, 88, 89, 4031, 4032, "]" diff --git a/data/dm2 17379048_kwoodley.annodb b/data/dm2 17379048_kwoodley.annodb new file mode 100644 index 0000000..323e6bb --- /dev/null +++ b/data/dm2 17379048_kwoodley.annodb @@ -0,0 +1,145 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +31662, Journal, 0, 11, "Clin Ther .", "", +4464, PublicationYear, 12, 16, "2007", "", " \"2007\"." +31663, Title, 44, 284, "Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .", "", +4466, Randomized, 116, 126, "randomized", "", " ." +4467, DoubleBlind, 129, 143, "double - blind", "", " ." +31664, Placebo, 146, 153, "placebo", "", +4469, Drug, 204, 229, "colesevelam hydrochloride", "", +4470, Type2Diabetes, 267, 282, "type 2 diabetes", "", +4472, Author, 285, 293, "Zieve FJ", "", " \"Zieve FJ\"." +4473, Author, 302, 310, "Kalin MF", "", " \"Kalin MF\"." +4474, Author, 313, 324, "Schwartz SL", "", " \"Schwartz SL\"." +4475, Author, 327, 335, "Jones MR", "", " \"Jones MR\"." +4476, Author, 338, 347, "Bailey WL", "", " \"Bailey WL\"." +4477, USA, 451, 454, "USA", "", " ." +31665, ObjectiveDescription, 494, 736, "This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .", "", +4478, HbA1c, 519, 542, "glycosylated hemoglobin", "", +4479, HbA1c, 545, 555, "HbA ( 1c )", "", +4480, Drug, 577, 602, "colesevelam hydrochloride", "", +4482, Precondition, 634, 734, "subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy", "", " \"subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy\"." +4481, Type2Diabetes, 648, 663, "type 2 diabetes", "", " ." +4484, Placebo, 764, 771, "placebo", "", +4489, Precondition, 790, 866, "subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %", "", " \"subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %\"." +4485, Type2Diabetes, 804, 819, "type 2 diabetes", "", +4486, HbA1c, 827, 837, "HbA ( 1c )", "", +4487, Percentage, 853, 854, "%", "", +4488, Percentage, 865, 866, "%", "", +4490, Randomized, 872, 882, "randomized", "", +4491, Drug, 894, 905, "colesevelam", "", " . ." +4492, DoseValue, 906, 912, "3 . 75", "", " \"3 . 75\"." +4493, Gram, 913, 914, "g", "", " ." +31666, Frequency, 917, 918, "d", "", +4495, Placebo, 931, 938, "placebo", "", " ." +4496, Duration, 943, 951, "12 weeks", "", " \"12 weeks\". \"12 weeks\". \"12 weeks\"." +4497, OralAntidiabeticAgent, 974, 1008, "oral anti hyperglycemic medication", "", +4498, Sulfonylureas, 1011, 1023, "sulfonylurea", "", +4499, Metformin, 1033, 1042, "metformin", "", +4500, FastingPlasmaGlucose, 1082, 1095, "Fasting blood", "", +4501, HbA1c, 1213, 1223, "HbA ( 1c )", "", +31667, TimePoint, 1229, 1237, "baseline", "", +31668, TimePoint, 1241, 1248, "week 12", "", +4502, Fructosamine, 1292, 1304, "fructosamine", "", +4503, FastingPlasmaGlucose, 1314, 1336, "fasting plasma glucose", "", +31669, PostprandialBloodGlucose, 1346, 1366, "postprandial glucose", "", +4506, MealGlucoseResponse, 1379, 1400, "meal glucose response", "", +4507, EndPointDescription, 1490, 1506, "lipid parameters", "lipid parameters", +31670, TimePoint, 1512, 1520, "baseline", "", +31671, TimePoint, 1524, 1531, "week 12", "", +4508, NumberPatientsCT, 1548, 1550, "65", "", " \"65\"." +4509, Randomized, 1551, 1561, "randomized", "", +4510, NumberPatientsArm, 1573, 1575, "31", "", " \"31\"." +4512, Drug, 1576, 1587, "colesevelam", "", +4511, NumberPatientsArm, 1590, 1592, "34", "", " \"34\"." +4513, Placebo, 1593, 1600, "placebo", "", +4514, AvgAge, 1621, 1627, "56 . 2", "", " \"56 . 2\"." +4515, BMI, 1645, 1660, "body mass index", "", +4516, Kg_per_squareMeter, 1671, 1677, "kg / m", "", +4517, Male, 1686, 1704, "55 . 4 % were male", "", " ." +4518, Ethnicity, 1709, 1728, "53 . 8 % were white", "", " . ." +31672, LeastSquaresMean, 1765, 1767, "LS", "", +4519, HbA1c, 1792, 1802, "HbA ( 1c )", "", +4520, Drug, 1815, 1826, "colesevelam", "", +4521, Placebo, 1841, 1848, "placebo", "", +10294, DiffGroupAbsValue, 1859, 1866, "- 0 . 5", "", +10296, Percentage, 1867, 1868, "%", "", +10297, SdErrorDiff, 1871, 1877, "0 . 18", "", +4526, PvalueDiff, 1882, 1893, "P = 0 . 007", "", +5195, SubGroupDescription, 1901, 1946, "subjects with a baseline HbAIc > or = 8 . 0 %", "", +5196, HbA1c, 1926, 1931, "HbAIc", "", +5197, Percentage, 1945, 1946, "%", "", +31673, LeastSquaresMean, 1967, 1969, "LS", "", +5198, HbA1c, 1985, 1995, "HbA ( 1c )", "", " ." +10298, DiffGroupAbsValue, 2000, 2007, "- 1 . 0", "", +10300, Percentage, 2008, 2009, "%", "", +10301, SdErrorChangeValue, 2012, 2018, "0 . 27", "", +5202, PvalueDiff, 2023, 2034, "P = 0 . 002", "", +5206, Placebo, 2051, 2058, "placebo", "", +5207, Drug, 2061, 2072, "colesevelam", "", +5208, Fructosamine, 2127, 2139, "fructosamine", "", " ." +5209, Reduction, 2144, 2150, "29 . 0", "", +10302, ResultMeasuredValue, 2153, 2159, "10 . 9", "", +5210, Picomole_per_liter, 2162, 2170, "pmol / L", "", " ." +5211, PValueChangeValue, 2173, 2184, "P = 0 . 011", "", +31674, PostprandialBloodGlucose, 2191, 2211, "postprandial glucose", "", +5214, Reduction, 2216, 2222, "31 . 5", "", +5215, ResultMeasuredValue, 2225, 2231, "13 . 6", "", +5216, Mg_per_deciliter, 2234, 2241, "mg / dL", "", " ." +5217, PValueChangeValue, 2244, 2255, "P = 0 . 026", "", +5218, EndPointDescription, 2287, 2324, "low - density lipoprotein cholesterol", "", " . ." +5219, RelativeReduction, 2331, 2336, "9 . 6", "", +5220, Drug, 2346, 2357, "colesevelam", "", +31675, RelativeIncrement, 2380, 2385, "2 . 1", "", +5222, Placebo, 2395, 2402, "placebo", "", +5223, DiffGroupRelValue, 2436, 2442, "11 . 7", "", +5224, DiffGroupAbsValue, 2447, 2452, "4 . 2", "", +5225, PvalueDiff, 2457, 2468, "P = 0 . 007", "", +5226, EndPointDescription, 2518, 2529, "cholesterol", "", " . ." +5227, RelativeReduction, 2537, 2542, "4 . 0", "", +5228, RelativeReduction, 2549, 2554, "3 . 4", "", +5229, DiffGroupRelValue, 2584, 2589, "7 . 3", "", +5230, DiffGroupAbsValue, 2594, 2599, "3 . 0", "", +5231, PvalueDiff, 2604, 2615, "P = 0 . 019", "", +5232, Drug, 2620, 2631, "Colesevelam", "", +5233, EndPointDescription, 2704, 2720, "apolipoprotein B", "", " . ." +5234, PValueChangeValue, 2723, 2734, "P = 0 . 003", "", +5235, EndPointDescription, 2741, 2789, "low - density lipoprotein particle concentration", "", " . ." +5236, PValueChangeValue, 2792, 2803, "P = 0 . 037", "", +5243, ObservedResult, 2808, 2897, "The incidence of treatment - emergent adverse events ( TEAEs ) was similar in both groups", "", +10292, EndPointDescription, 2812, 2860, "incidence of treatment - emergent adverse events", "", +10293, EndPointDescription, 2863, 2868, "TEAEs", "", " . ." +5244, SubGroupDescription, 2909, 2943, "treatment - related adverse events", "", +5238, Drug, 2970, 2981, "colesevelam", "", +5239, Placebo, 3000, 3007, "placebo", "", +5245, PercentageAffected, 3016, 3022, "29 . 0", "", +5246, PercentageAffected, 3028, 3033, "8 . 8", "", +5248, Drug, 3086, 3097, "colesevelam", "", +5247, GastrointestinalProblem, 3109, 3135, "gastrointestinal disorders", "", " ." +5249, PercentageAffected, 3138, 3144, "22 . 6", "", +5252, SubGroupDescription, 3151, 3173, "primarily constipation", "", +5251, PercentageAffected, 3176, 3182, "19 . 4", "", +5253, PercentageAffected, 3206, 3211, "8 . 8", "", +5254, GastrointestinalProblem, 3227, 3253, "gastrointestinal disorders", "", +5256, PercentageAffected, 3256, 3257, "0", "", +5257, SubGroupDescription, 3260, 3272, "constipation", "", +5255, Placebo, 3282, 3289, "placebo", "", +31676, ObservedResult, 3298, 3407, "There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .", "", +5259, BodyWeight, 3335, 3346, "body weight", "", " ." +5260, Hypoglycemia, 3368, 3380, "hypoglycemia", "", " ." +31677, ConclusionComment, 3422, 3630, "In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .", "", +5262, Type2Diabetes, 3445, 3460, "type 2 diabetes", "", +5263, Duration, 3463, 3471, "12 weeks", "", +5264, Drug, 3475, 3486, "colesevelam", "", +5265, HbA1c, 3544, 3554, "HbA ( 1c )", "", +5266, Fructosamine, 3562, 3574, "fructosamine", "", +31682, PostprandialBloodGlucose, 3579, 3599, "postprandial glucose", "", +5268, Placebo, 3621, 3628, "placebo", "", +31678, ConclusionComment, 3631, 3771, "The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .", "", +5271, Constipation, 3732, 3744, "constipation", "", +5272, Drug, 3752, 3763, "colesevelam", "", +31679, ConclusionComment, 3772, 3942, "These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .", "", +5277, Drug, 3799, 3810, "colesevelam", "", +31680, Precondition, 3866, 3940, "patients with type 2 diabetes receiving oral antihyperglycemic medications", "", +5278, Type2Diabetes, 3880, 3895, "type 2 diabetes", "", +31681, OralAntidiabeticAgent, 3906, 3940, "oral antihyperglycemic medications", "", +5282, PMID, 4000, 4008, "17379048", "", " \"17379048\"." diff --git a/data/dm2 17379048_kwoodley.n-triples b/data/dm2 17379048_kwoodley.n-triples new file mode 100644 index 0000000..b677932 --- /dev/null +++ b/data/dm2 17379048_kwoodley.n-triples @@ -0,0 +1,146 @@ +# RDF export of group: Publication + . + "Publication " . + "Zieve FJ" . + "2007" . + "17379048" . + . + "Kalin MF" . + "Schwartz SL" . + "Jones MR" . + "Bailey WL" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "65" . + "12 weeks" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy" . + . + . + . + "56 . 2" . + . + "subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %" . +# RDF export of group: Endpoint + . + "Endpoint HbA1c" . + . + . + . + . + . + "Endpoint Fructosamine" . + . + . + . + . + . + "Endpoint Postprandial Glucose" . + . + . + . + . + "Endpoint cholesterol 1" . + . + . + . + . + . + . + "Endpoint cholesterol 2" . + . + . + . + . + . + . + "Endpoint apolipoprotein 1" . + . + . + . + . + . + . + "Endpoint apolipoprotein 2" . + . + . + . + . + . + . + "Endpoint TEAEs" . + . + . + . + . + . + . + "Endpoint gastrointestinal Problem" . + . + . + . + . + . + "Endpoint body weight" . + . + . + . + . + . + "Endpoint Hypoglycaemia" . + . + . + . + . +# RDF export of group: Arm + . + "Arm Drug" . + "31" . + . + . + . + . + "Arm Placebo" . + "34" . + . + . + . +# RDF export of group: Intervention + . + "Intervention Drug" . + . + "12 weeks" . + . + . + "Intervention Placebo" . + . + "12 weeks" . + . +# RDF export of group: Medication + . + "Medication Drug" . + . + . + "3 . 75" . + . + . + . + "Medication Placebo" . + . + . + . +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17404349_admin.annodb b/data/dm2 17404349_admin.annodb new file mode 100644 index 0000000..1a943bc --- /dev/null +++ b/data/dm2 17404349_admin.annodb @@ -0,0 +1,133 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Ann Intern Med .", "", " \"Ann Intern Med .\"." +1, PublicationYear, 17, 21, "2007", "", " \"2007\"." +124, Title, 53, 172, "The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial .", "", " \"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial .\"." +2, Exenatide, 74, 83, "exenatide", "", +3, Drug, 89, 106, "thiazolidinedione", "", +6, Precondition, 110, 149, "suboptimally controlled type 2 diabetes", "", +4, Type2Diabetes, 134, 149, "type 2 diabetes", "", +5, Randomized, 154, 164, "randomized", "", +7, Author, 173, 181, "Zinman B", "", " \"Zinman B\"." +8, Author, 190, 201, "Hoogwerf BJ", "", " \"Hoogwerf BJ\"." +9, Author, 204, 222, "Dur á n Garc í a S", "", " \"Dur á n Garc í a S\"." +10, Author, 225, 234, "Milton DR", "", " \"Milton DR\"." +11, Author, 237, 248, "Giaconia JM", "", " \"Giaconia JM\"." +12, Author, 251, 257, "Kim DD", "", " \"Kim DD\"." +13, Author, 260, 272, "Trautmann ME", "", " \"Trautmann ME\"." +14, Author, 275, 285, "Brodows RG", "", " \"Brodows RG\"." +15, Canada, 424, 430, "Canada", "", +16, Exenatide, 667, 676, "Exenatide", "", +17, Metformin, 718, 727, "metformin", "", +18, Sulfonylureas, 731, 744, "sulfonylureas", "", +19, Type2Diabetes, 758, 773, "type 2 diabetes", "", +20, Drug, 776, 794, "Thiazolidinediones", "", +21, Drug, 797, 801, "TZDs", "", +23, Exenatide, 849, 858, "exenatide", "", +22, Drug, 866, 869, "TZD", "", +248, ObjectiveDescription, 906, 978, "To compare the effects of exenatide versus placebo on glycemic control .", "", " \"To compare the effects of exenatide versus placebo on glycemic control .\"." +24, Exenatide, 932, 941, "exenatide", "", +25, Placebo, 949, 956, "placebo", "", +138, Placebo, 988, 995, "Placebo", "", +26, Randomized, 1007, 1017, "randomized", "", " ." +27, DoubleBlind, 1020, 1034, "double - blind", "", " ." +141, Placebo, 1037, 1044, "placebo", "", +251, Duration, 1079, 1102, "May 2004 to August 2005", "", +145, Multicenter, 1115, 1123, "49 sites", "", " ." +142, Canada, 1127, 1133, "Canada", "", " ." +143, Spain, 1136, 1141, "Spain", "", " ." +144, USA, 1152, 1165, "United States", "", " ." +28, NumberPatientsCT, 1179, 1182, "233", "", " \"233\"." +31, Exenatide, 1185, 1194, "exenatide", "", +29, NumberPatientsArm, 1207, 1210, "121", "", " \"121\"." +32, Placebo, 1213, 1220, "placebo", "", +30, NumberPatientsArm, 1233, 1236, "112", "", " \"112\"." +36, Precondition, 1239, 1350, "patients with type 2 diabetes that was suboptimally controlled with TZD treatment ( with or without metformin )", "", " \"patients with type 2 diabetes that was suboptimally controlled with TZD treatment ( with or without metformin )\"." +33, Type2Diabetes, 1253, 1268, "type 2 diabetes", "", +34, Drug, 1307, 1310, "TZD", "", +35, Metformin, 1339, 1348, "metformin", "", +155, Mean, 1353, 1357, "Mean", "", +258, TimePoint, 1371, 1379, "baseline", "", +156, HbA1c, 1380, 1403, "glycated hemoglobin A1c", "", +38, BaseLineValue, 1414, 1419, "7 . 9", "", +39, Percentage, 1420, 1421, "%", "", +41, SdErrorBL, 1428, 1433, "0 . 1", "", +40, Percentage, 1434, 1435, "%", "", +161, SubcutaneousInjection, 1454, 1487, "Subcutaneous abdominal injections", "", " . ." +43, DoseValue, 1491, 1493, "10", "", " \"10\"." +44, Microgram, 1494, 1500, "microg", "", " ." +45, Exenatide, 1504, 1513, "exenatide", "", " ." +46, Placebo, 1517, 1524, "placebo", "", " ." +47, Frequency, 1525, 1536, "twice daily", "", " \"twice daily\". \"twice daily\"." +48, Drug, 1550, 1553, "TZD", "", +49, Metformin, 1572, 1581, "metformin", "", +50, Duration, 1588, 1596, "16 weeks", "", " \"16 weeks\"." +253, TimePoint, 1650, 1658, "baseline", "", +254, HbA1c, 1662, 1676, "hemoglobin A1c", "", +171, EndPointDescription, 1705, 1732, "fasting serum glucose level", "", +52, BodyWeight, 1735, 1746, "body weight", "", +255, BloodGlucose, 1749, 1779, "self - monitored blood glucose", "", +53, EndPointDescription, 1796, 1810, "adverse events", "", +54, Exenatide, 1823, 1832, "Exenatide", "", +256, HbA1c, 1851, 1870, "hemoglobin A ( 1c )", "", " ." +202, Mean, 1879, 1883, "mean", "", " . ." +59, DiffGroupAbsValue, 1897, 1905, "- 0 . 98", "", " \"- 0 . 98\"." +58, Percentage, 1906, 1907, "%", "", " ." +55, ConfIntervalDiff, 1910, 1944, "95 % CI , - 1 . 21 % to - 0 . 74 %", "", " \"95 % CI , - 1 . 21 % to - 0 . 74 %\"." +56, Percentage, 1929, 1930, "%", "", +57, Percentage, 1943, 1944, "%", "", +60, FastingPlasmaGlucose, 1951, 1972, "serum fasting glucose", "", " ." +203, Mean, 1981, 1985, "mean", "", " . ." +61, DiffGroupAbsValue, 1999, 2007, "- 1 . 69", "", +62, Millimoles_per_litre, 2008, 2016, "mmol / L", "", " ." +67, DiffGroupAbsValue, 2019, 2027, "- 30 . 5", "", " \"- 30 . 5\"." +66, Mg_per_deciliter, 2028, 2035, "mg / dL", "", +63, ConfIntervalDiff, 2040, 2107, "CI , - 2 . 22 to - 1 . 17 mmol / L { - 40 . 0 to - 21 . 1 mg / dL }", "", " \"CI , - 2 . 22 to - 1 . 17 mmol / L { - 40 . 0 to - 21 . 1 mg / dL }\"." +64, Millimoles_per_litre, 2066, 2074, "mmol / L", "", +65, Mg_per_deciliter, 2098, 2105, "mg / dL", "", +68, BodyWeight, 2118, 2129, "body weight", "", " ." +204, Mean, 2132, 2136, "mean", "", " . ." +70, DiffGroupAbsValue, 2150, 2158, "- 1 . 51", "", " \"- 1 . 51\"." +69, Kg, 2159, 2161, "kg", "", " ." +72, ConfIntervalDiff, 2164, 2192, "CI , - 2 . 15 to - 0 . 88 kg", "", " \"CI , - 2 . 15 to - 0 . 88 kg\"." +71, Kg, 2190, 2192, "kg", "", +76, RelNumPatientsLeftArm, 2199, 2206, "Sixteen", "", " \"Sixteen\"." +73, Exenatide, 2234, 2243, "exenatide", "", +75, RelNumPatientsLeftArm, 2254, 2255, "2", "", " \"2\"." +199, Percentage, 2256, 2257, "%", "", +74, Placebo, 2277, 2284, "placebo", "", +77, Exenatide, 2349, 2358, "exenatide", "", +78, PercentageAffected, 2367, 2369, "40", "", " \"40\"." +79, NumberAffected, 2378, 2380, "48", "", " \"48\"." +80, Nausea, 2407, 2413, "nausea", "", " ." +81, SubGroupDescription, 2416, 2427, "mostly mild", "", " \"mostly mild\"." +214, EndPointDescription, 2423, 2427, "mild", "", +83, NumberAffected, 2434, 2436, "21", "", " \"21\"." +215, EndPointDescription, 2442, 2450, "moderate", "", +82, SubGroupDescription, 2442, 2450, "moderate", "", " \"moderate\"." +84, NumberAffected, 2457, 2459, "19", "", " \"19\"." +85, PercentageAffected, 2466, 2468, "13", "", " \"13\"." +86, EndPointDescription, 2483, 2491, "vomiting", "", " . ." +87, PercentageAffected, 2498, 2500, "11", "", " \"11\"." +88, Hypoglycemia, 2515, 2527, "hypoglycemia", "", " ." +89, Placebo, 2537, 2544, "placebo", "", +90, PercentageAffected, 2553, 2555, "15", "", " \"15\"." +93, Nausea, 2582, 2588, "nausea", "", +91, PercentageAffected, 2591, 2592, "1", "", " \"1\"." +94, EndPointDescription, 2607, 2615, "vomiting", "", +92, PercentageAffected, 2622, 2623, "7", "", " \"7\"." +95, Hypoglycemia, 2638, 2650, "hypoglycemia", "", +96, Drug, 2685, 2689, "TZDs", "", +97, Sulfonylureas, 2694, 2707, "sulfonylureas", "", +96530, RelativeFinalNumPatientsArm, 2769, 2771, "71", "", +96531, RelativeFinalNumPatientsArm, 2778, 2780, "86", "", +100, Exenatide, 2802, 2811, "exenatide", "", +101, Placebo, 2816, 2823, "placebo", "", +244, ConclusionComment, 2884, 3091, "Exenatide therapy improved glycemic control , reduced body weight , and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy .", "", " \"Exenatide therapy improved glycemic control , reduced body weight , and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy .\"." +102, Exenatide, 2884, 2893, "Exenatide", "", +103, BodyWeight, 2938, 2949, "body weight", "", +104, GastrointestinalProblem, 2963, 2988, "gastrointestinal symptoms", "", +105, Placebo, 2999, 3006, "placebo", "", +106, Type2Diabetes, 3024, 3039, "type 2 diabetes", "", +107, Drug, 3078, 3081, "TZD", "", +49487, Exenatide, 3173, 3182, "exenatide", "", +109, PMID, 3263, 3271, "17404349", "", " \"17404349\"." diff --git a/data/dm2 17404349_admin.n-triples b/data/dm2 17404349_admin.n-triples new file mode 100644 index 0000000..b65e849 --- /dev/null +++ b/data/dm2 17404349_admin.n-triples @@ -0,0 +1,208 @@ +# RDF export of group: Publication + . + "Publication " . + "The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial ." . + "Zinman B" . + "2007" . + "Ann Intern Med ." . + "17404349" . + . + "Hoogwerf BJ" . + "Dur á n Garc í a S" . + "Milton DR" . + "Giaconia JM" . + "Kim DD" . + "Trautmann ME" . + "Brodows RG" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the effects of exenatide versus placebo on glycemic control ." . + "233" . + "16 weeks" . + . + . + . + "Exenatide therapy improved glycemic control , reduced body weight , and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with type 2 diabetes that was suboptimally controlled with TZD treatment ( with or without metformin )" . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + . + "Endpoint nausea" . + . + . + . + . + . + "Endpoint vomiting" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . +# RDF export of group: Arm + . + "Arm e" . + "121" . + . + . + . + "Sixteen" . + . + . + . + . + . + . + . + "Arm p " . + "112" . + . + . + . + "2" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention e + tzd" . + "twice daily" . + . + . + . + "Intervention p + tzd" . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication e" . + . + "10" . + . + . + . + "Medication p " . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c e" . + . + . + "Outcome hba1c p" . + . + . + "Outcome fpg e" . + . + . + "Outcome fpg p " . + . + . + "Outcome weight e" . + . + . + "Outcome weight p " . + . + . + "Outcome nausea e" . + . + "48" . + "40" . + . + "Outcome mild n e" . + . + "21" . + "mostly mild" . + . + "Outcome moderate n e" . + . + "19" . + "moderate" . + . + "Outcome vomiting e " . + . + "13" . + . + "Outcome h e" . + . + "11" . + . + "Outcome nausea p " . + . + "15" . + . + "Outcome vomiting p" . + . + "1" . + . + "Outcome h p " . + . + "7" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 98" . + "95 % CI , - 1 . 21 % to - 0 . 74 %" . + . + . + . + "DiffBetweenGroups fpg" . + "- 30 . 5" . + "CI , - 2 . 22 to - 1 . 17 mmol / L { - 40 . 0 to - 21 . 1 mg / dL }" . + . + . + . + "DiffBetweenGroups weight" . + "- 1 . 51" . + "CI , - 2 . 15 to - 0 . 88 kg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17404349_akramersunderbrink.annodb b/data/dm2 17404349_akramersunderbrink.annodb new file mode 100644 index 0000000..0e2a97e --- /dev/null +++ b/data/dm2 17404349_akramersunderbrink.annodb @@ -0,0 +1,140 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +21826, Journal, 0, 14, "Ann Intern Med", "", +21827, PublicationYear, 17, 21, "2007", "", +21840, Title, 53, 172, "The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial .", "", +21841, Drug, 74, 83, "exenatide", "", +21842, Drug, 89, 106, "thiazolidinedione", "", +21830, Precondition, 110, 133, "suboptimally controlled", "", +21828, Type2Diabetes, 134, 149, "type 2 diabetes", "", +21829, Randomized, 154, 164, "randomized", "", +21831, Author, 173, 181, "Zinman B", "", +21832, Author, 190, 201, "Hoogwerf BJ", "", +21833, Author, 204, 222, "Dur á n Garc í a S", "", +21834, Author, 225, 234, "Milton DR", "", +21835, Author, 237, 248, "Giaconia JM", "", +21836, Author, 251, 257, "Kim DD", "", +21837, Author, 260, 272, "Trautmann ME", "", +21838, Author, 275, 285, "Brodows RG", "", +21839, Canada, 424, 430, "Canada", "", +21843, Drug, 667, 676, "Exenatide", "", +21844, Metformin, 718, 727, "metformin", "", +21845, Sulfonylureas, 731, 744, "sulfonylureas", "", +21846, Type2Diabetes, 758, 773, "type 2 diabetes", "", +21847, Drug, 776, 794, "Thiazolidinediones", "", +21848, Drug, 797, 801, "TZDs", "", +21849, Drug, 849, 858, "exenatide", "", +21850, Drug, 866, 869, "TZD", "", +21853, ObjectiveDescription, 906, 976, "To compare the effects of exenatide versus placebo on glycemic control", "", +21851, Drug, 932, 941, "exenatide", "", +21852, Placebo, 949, 956, "placebo", "", +21854, Placebo, 988, 995, "Placebo", "", +21855, Randomized, 1007, 1017, "randomized", "", +21856, DoubleBlind, 1020, 1034, "double - blind", "", +21857, Placebo, 1037, 1044, "placebo", "", +21861, Multicenter, 1115, 1123, "49 sites", "", +21858, Canada, 1127, 1133, "Canada", "", +21859, Spain, 1136, 1141, "Spain", "", +21860, USA, 1152, 1165, "United States", "", +21862, NumberPatientsCT, 1179, 1182, "233", "", +21865, Drug, 1185, 1194, "exenatide", "", +21863, NumberPatientsArm, 1207, 1210, "121", "", +21866, Placebo, 1213, 1220, "placebo", "", +21864, NumberPatientsArm, 1233, 1236, "112", "", +21867, Type2Diabetes, 1253, 1268, "type 2 diabetes", "", +21868, Precondition, 1278, 1350, "suboptimally controlled with TZD treatment ( with or without metformin )", "", +21869, Drug, 1307, 1310, "TZD", "", +21870, Metformin, 1339, 1348, "metformin", "", +21871, Mean, 1353, 1357, "Mean", "", +39153, TimePoint, 1371, 1379, "baseline", "", +21872, HbA1c, 1380, 1409, "glycated hemoglobin A1c level", "", +21873, BaseLineValue, 1414, 1419, "7 . 9", "", +21874, Percentage, 1420, 1421, "%", "", +21876, SdErrorBL, 1428, 1433, "0 . 1", "", +21875, Percentage, 1434, 1435, "%", "", +21877, SubcutaneousInjection, 1454, 1487, "Subcutaneous abdominal injections", "", +21879, DoseValue, 1491, 1493, "10", "", +21878, Microgram, 1494, 1500, "microg", "", +21880, Drug, 1504, 1513, "exenatide", "", +21881, Placebo, 1517, 1524, "placebo", "", +21882, Frequency, 1525, 1536, "twice daily", "", +21883, Drug, 1550, 1553, "TZD", "", +21884, Metformin, 1572, 1581, "metformin", "", +21885, Duration, 1588, 1596, "16 weeks", "", +39154, TimePoint, 1650, 1658, "baseline", "", +21886, HbA1c, 1662, 1682, "hemoglobin A1c level", "", +21887, EndPointDescription, 1705, 1732, "fasting serum glucose level", "", +21888, BodyWeight, 1735, 1746, "body weight", "", +21934, Drug, 1823, 1832, "Exenatide", "", +21889, HbA1c, 1851, 1876, "hemoglobin A ( 1c ) level", "", +21937, Mean, 1879, 1883, "mean", "", +21892, DiffGroupAbsValue, 1897, 1905, "- 0 . 98", "", +21893, Percentage, 1906, 1907, "%", "", +21897, ConfIntervalDiff, 1910, 1944, "95 % CI , - 1 . 21 % to - 0 . 74 %", "", +21894, Percentage, 1913, 1914, "%", "", +21895, Percentage, 1929, 1930, "%", "", +21896, Percentage, 1943, 1944, "%", "", +21890, EndPointDescription, 1951, 1978, "serum fasting glucose level", "", +21938, Mean, 1981, 1985, "mean", "", +21898, DiffGroupAbsValue, 1999, 2007, "- 1 . 69", "", +21900, Millimoles_per_litre, 2008, 2016, "mmol / L", "", +21902, DiffGroupAbsValue, 2019, 2027, "- 30 . 5", "", +21903, Mg_per_deciliter, 2028, 2035, "mg / dL", "", +21904, ConfIntervalDiff, 2040, 2074, "CI , - 2 . 22 to - 1 . 17 mmol / L", "", +21906, Millimoles_per_litre, 2066, 2074, "mmol / L", "", +21905, ConfIntervalDiff, 2077, 2105, "- 40 . 0 to - 21 . 1 mg / dL", "", +21908, Mg_per_deciliter, 2098, 2105, "mg / dL", "", +21891, BodyWeight, 2118, 2129, "body weight", "", +21940, Mean, 2132, 2136, "mean", "", +21899, DiffGroupAbsValue, 2150, 2158, "- 1 . 51", "", +21901, Kg, 2159, 2161, "kg", "", +21911, ConfIntervalDiff, 2164, 2192, "CI , - 2 . 15 to - 0 . 88 kg", "", +21913, Kg, 2190, 2192, "kg", "", +21921, PercentageAffected, 2199, 2206, "Sixteen", "", +21923, Percentage, 2207, 2214, "percent", "", +21926, Drug, 2234, 2243, "exenatide", "", +21929, PercentageAffected, 2254, 2255, "2", "", +21931, Percentage, 2256, 2257, "%", "", +21932, Placebo, 2277, 2284, "placebo", "", +21918, EndPointDescription, 2291, 2339, "discontinued treatment because of adverse events", "", +21942, Drug, 2349, 2358, "exenatide", "", +21946, PercentageAffected, 2367, 2369, "40", "", +21949, Percentage, 2370, 2371, "%", "", +21948, NumberAffected, 2378, 2380, "48", "", +21959, EndPointDescription, 2407, 2413, "nausea", "", +21960, EndPointDescription, 2423, 2427, "mild", "", +21967, NumberAffected, 2434, 2436, "21", "", +21962, EndPointDescription, 2442, 2450, "moderate", "", +21969, NumberAffected, 2457, 2459, "19", "", +21954, PercentageAffected, 2466, 2468, "13", "", +21951, Percentage, 2469, 2470, "%", "", +21963, EndPointDescription, 2483, 2491, "vomiting", "", +21955, PercentageAffected, 2498, 2500, "11", "", +21952, Percentage, 2501, 2502, "%", "", +21964, Hypoglycemia, 2515, 2527, "hypoglycemia", "", +21972, Placebo, 2537, 2544, "placebo", "", +21975, PercentageAffected, 2553, 2555, "15", "", +21982, Percentage, 2556, 2557, "%", "", +21986, EndPointDescription, 2582, 2588, "nausea", "", +21978, PercentageAffected, 2591, 2592, "1", "", +21984, Percentage, 2593, 2594, "%", "", +21987, EndPointDescription, 2607, 2615, "vomiting", "", +21979, PercentageAffected, 2622, 2623, "7", "", +21985, Percentage, 2624, 2625, "%", "", +21988, Hypoglycemia, 2638, 2650, "hypoglycemia", "", +21989, Drug, 2685, 2689, "TZDs", "", +21990, Sulfonylureas, 2694, 2707, "sulfonylureas", "", +21996, RelNumPatientsLeftArm, 2769, 2771, "71", "", +22000, Percentage, 2772, 2773, "%", "", +21997, RelNumPatientsLeftArm, 2778, 2780, "86", "", +22002, Percentage, 2781, 2782, "%", "", +21991, Drug, 2802, 2811, "exenatide", "", +21992, Placebo, 2816, 2823, "placebo", "", +22003, Drug, 2884, 2893, "Exenatide", "", +22014, ConclusionComment, 2884, 3091, "Exenatide therapy improved glycemic control , reduced body weight , and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy .", "", +22005, BodyWeight, 2938, 2949, "body weight", "", +22008, Placebo, 2999, 3006, "placebo", "", +22009, Type2Diabetes, 3024, 3039, "type 2 diabetes", "", +22010, Precondition, 3049, 3089, "suboptimally controlled with TZD therapy", "", +22012, Drug, 3078, 3081, "TZD", "", +22016, Drug, 3173, 3182, "exenatide", "", +22017, PMID, 3263, 3271, "17404349", "", diff --git a/data/dm2 17404349_akramersunderbrink.n-triples b/data/dm2 17404349_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17404349_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17404349_export.csv b/data/dm2 17404349_export.csv new file mode 100644 index 0000000..1a7bb25 --- /dev/null +++ b/data/dm2 17404349_export.csv @@ -0,0 +1,704 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +354, 1, 1, 1, 0, 3, 0, 3, "Ann" +354, 1, 2, 2, 4, 10, 4, 10, "Intern" +354, 1, 3, 3, 11, 14, 11, 14, "Med" +354, 1, 4, 4, 15, 16, 15, 16, "." +354, 2, 1, 5, 0, 4, 17, 21, "2007" +354, 2, 2, 6, 5, 8, 22, 25, "Apr" +354, 2, 3, 7, 9, 10, 26, 27, "3" +354, 2, 4, 8, 11, 12, 28, 29, ";" +354, 2, 5, 9, 13, 16, 30, 33, "146" +354, 2, 6, 10, 17, 18, 34, 35, "(" +354, 2, 7, 11, 19, 20, 36, 37, "7" +354, 2, 8, 12, 21, 22, 38, 39, ")" +354, 2, 9, 13, 23, 24, 40, 41, ":" +354, 2, 10, 14, 25, 28, 42, 45, "477" +354, 2, 11, 15, 29, 30, 46, 47, "-" +354, 2, 12, 16, 31, 33, 48, 50, "85" +354, 2, 13, 17, 34, 35, 51, 52, "." +354, 3, 1, 18, 0, 3, 53, 56, "The" +354, 3, 2, 19, 4, 10, 57, 63, "effect" +354, 3, 3, 20, 11, 13, 64, 66, "of" +354, 3, 4, 21, 14, 20, 67, 73, "adding" +354, 3, 5, 22, 21, 30, 74, 83, "exenatide" +354, 3, 6, 23, 31, 33, 84, 86, "to" +354, 3, 7, 24, 34, 35, 87, 88, "a" +354, 3, 8, 25, 36, 53, 89, 106, "thiazolidinedione" +354, 3, 9, 26, 54, 56, 107, 109, "in" +354, 3, 10, 27, 57, 69, 110, 122, "suboptimally" +354, 3, 11, 28, 70, 80, 123, 133, "controlled" +354, 3, 12, 29, 81, 85, 134, 138, "type" +354, 3, 13, 30, 86, 87, 139, 140, "2" +354, 3, 14, 31, 88, 96, 141, 149, "diabetes" +354, 3, 15, 32, 97, 98, 150, 151, ":" +354, 3, 16, 33, 99, 100, 152, 153, "a" +354, 3, 17, 34, 101, 111, 154, 164, "randomized" +354, 3, 18, 35, 112, 117, 165, 170, "trial" +354, 3, 19, 36, 118, 119, 171, 172, "." +354, 4, 1, 37, 0, 6, 173, 179, "Zinman" +354, 4, 2, 38, 7, 8, 180, 181, "B" +354, 4, 3, 39, 9, 10, 182, 183, "(" +354, 4, 4, 40, 11, 12, 184, 185, "1" +354, 4, 5, 41, 13, 14, 186, 187, ")" +354, 4, 6, 42, 15, 16, 188, 189, "," +354, 4, 7, 43, 17, 25, 190, 198, "Hoogwerf" +354, 4, 8, 44, 26, 28, 199, 201, "BJ" +354, 4, 9, 45, 29, 30, 202, 203, "," +354, 4, 10, 46, 31, 34, 204, 207, "Dur" +354, 4, 11, 47, 35, 36, 208, 209, "á" +354, 4, 12, 48, 37, 38, 210, 211, "n" +354, 4, 13, 49, 39, 43, 212, 216, "Garc" +354, 4, 14, 50, 44, 45, 217, 218, "í" +354, 4, 15, 51, 46, 47, 219, 220, "a" +354, 4, 16, 52, 48, 49, 221, 222, "S" +354, 4, 17, 53, 50, 51, 223, 224, "," +354, 4, 18, 54, 52, 58, 225, 231, "Milton" +354, 4, 19, 55, 59, 61, 232, 234, "DR" +354, 4, 20, 56, 62, 63, 235, 236, "," +354, 4, 21, 57, 64, 72, 237, 245, "Giaconia" +354, 4, 22, 58, 73, 75, 246, 248, "JM" +354, 4, 23, 59, 76, 77, 249, 250, "," +354, 4, 24, 60, 78, 81, 251, 254, "Kim" +354, 4, 25, 61, 82, 84, 255, 257, "DD" +354, 4, 26, 62, 85, 86, 258, 259, "," +354, 4, 27, 63, 87, 96, 260, 269, "Trautmann" +354, 4, 28, 64, 97, 99, 270, 272, "ME" +354, 4, 29, 65, 100, 101, 273, 274, "," +354, 4, 30, 66, 102, 109, 275, 282, "Brodows" +354, 4, 31, 67, 110, 112, 283, 285, "RG" +354, 4, 32, 68, 113, 114, 286, 287, "." +354, 5, 1, 69, 0, 6, 288, 294, "Author" +354, 5, 2, 70, 7, 18, 295, 306, "information" +354, 5, 3, 71, 19, 20, 307, 308, ":" +354, 5, 4, 72, 21, 22, 309, 310, "(" +354, 5, 5, 73, 23, 24, 311, 312, "1" +354, 5, 6, 74, 25, 26, 313, 314, ")" +354, 5, 7, 75, 27, 33, 315, 321, "Samuel" +354, 5, 8, 76, 34, 43, 322, 331, "Lunenfeld" +354, 5, 9, 77, 44, 52, 332, 340, "Research" +354, 5, 10, 78, 53, 62, 341, 350, "Institute" +354, 5, 11, 79, 63, 64, 351, 352, "," +354, 5, 12, 80, 65, 70, 353, 358, "Mount" +354, 5, 13, 81, 71, 76, 359, 364, "Sinai" +354, 5, 14, 82, 77, 85, 365, 373, "Hospital" +354, 5, 15, 83, 86, 87, 374, 375, "," +354, 5, 16, 84, 88, 91, 376, 379, "and" +354, 5, 17, 85, 92, 102, 380, 390, "University" +354, 5, 18, 86, 103, 105, 391, 393, "of" +354, 5, 19, 87, 106, 113, 394, 401, "Toronto" +354, 5, 20, 88, 114, 115, 402, 403, "," +354, 5, 21, 89, 116, 123, 404, 411, "Toronto" +354, 5, 22, 90, 124, 125, 412, 413, "," +354, 5, 23, 91, 126, 133, 414, 421, "Ontario" +354, 5, 24, 92, 134, 135, 422, 423, "," +354, 5, 25, 93, 136, 142, 424, 430, "Canada" +354, 5, 26, 94, 143, 144, 431, 432, "." +354, 6, 1, 95, 0, 6, 433, 439, "zinman" +354, 6, 2, 96, 7, 8, 440, 441, "@" +354, 6, 3, 97, 9, 14, 442, 447, "mshri" +354, 6, 4, 98, 15, 16, 448, 449, "." +354, 6, 5, 99, 17, 19, 450, 452, "on" +354, 6, 6, 100, 20, 21, 453, 454, "." +354, 6, 7, 101, 22, 24, 455, 457, "ca" +354, 6, 8, 102, 25, 32, 458, 465, "Erratum" +354, 6, 9, 103, 33, 35, 466, 468, "in" +354, 6, 10, 104, 36, 39, 469, 472, "Ann" +354, 6, 11, 105, 40, 46, 473, 479, "Intern" +354, 6, 12, 106, 47, 50, 480, 483, "Med" +354, 6, 13, 107, 51, 52, 484, 485, "." +354, 7, 1, 108, 0, 4, 486, 490, "2007" +354, 7, 2, 109, 5, 8, 491, 494, "Jun" +354, 7, 3, 110, 9, 11, 495, 497, "19" +354, 7, 4, 111, 12, 13, 498, 499, ";" +354, 7, 5, 112, 14, 17, 500, 503, "146" +354, 7, 6, 113, 18, 19, 504, 505, "(" +354, 7, 7, 114, 20, 22, 506, 508, "12" +354, 7, 8, 115, 23, 24, 509, 510, ")" +354, 7, 9, 116, 25, 26, 511, 512, ":" +354, 7, 10, 117, 27, 30, 513, 516, "896" +354, 7, 11, 118, 31, 32, 517, 518, "." +354, 8, 1, 119, 0, 7, 519, 526, "Comment" +354, 8, 2, 120, 8, 10, 527, 529, "in" +354, 8, 3, 121, 11, 14, 530, 533, "Ann" +354, 8, 4, 122, 15, 21, 534, 540, "Intern" +354, 8, 5, 123, 22, 25, 541, 544, "Med" +354, 8, 6, 124, 26, 27, 545, 546, "." +354, 9, 1, 125, 0, 4, 547, 551, "2007" +354, 9, 2, 126, 5, 8, 552, 555, "Apr" +354, 9, 3, 127, 9, 10, 556, 557, "3" +354, 9, 4, 128, 11, 12, 558, 559, ";" +354, 9, 5, 129, 13, 16, 560, 563, "146" +354, 9, 6, 130, 17, 18, 564, 565, "(" +354, 9, 7, 131, 19, 20, 566, 567, "7" +354, 9, 8, 132, 21, 22, 568, 569, ")" +354, 9, 9, 133, 23, 24, 570, 571, ":" +354, 9, 10, 134, 25, 28, 572, 575, "527" +354, 9, 11, 135, 29, 30, 576, 577, "-" +354, 9, 12, 136, 31, 32, 578, 579, "8" +354, 9, 13, 137, 33, 34, 580, 581, "." +354, 10, 1, 138, 0, 7, 582, 589, "Summary" +354, 10, 2, 139, 8, 11, 590, 593, "for" +354, 10, 3, 140, 12, 20, 594, 602, "patients" +354, 10, 4, 141, 21, 23, 603, 605, "in" +354, 10, 5, 142, 24, 27, 606, 609, "Ann" +354, 10, 6, 143, 28, 34, 610, 616, "Intern" +354, 10, 7, 144, 35, 38, 617, 620, "Med" +354, 10, 8, 145, 39, 40, 621, 622, "." +354, 11, 1, 146, 0, 4, 623, 627, "2007" +354, 11, 2, 147, 5, 8, 628, 631, "Apr" +354, 11, 3, 148, 9, 10, 632, 633, "3" +354, 11, 4, 149, 11, 12, 634, 635, ";" +354, 11, 5, 150, 13, 16, 636, 639, "146" +354, 11, 6, 151, 17, 18, 640, 641, "(" +354, 11, 7, 152, 19, 20, 642, 643, "7" +354, 11, 8, 153, 21, 22, 644, 645, ")" +354, 11, 9, 154, 23, 24, 646, 647, ":" +354, 11, 10, 155, 25, 28, 648, 651, "I18" +354, 11, 11, 156, 29, 30, 652, 653, "." +354, 12, 1, 157, 0, 10, 654, 664, "BACKGROUND" +354, 12, 2, 158, 11, 12, 665, 666, ":" +354, 12, 3, 159, 13, 22, 667, 676, "Exenatide" +354, 12, 4, 160, 23, 30, 677, 684, "therapy" +354, 12, 5, 161, 31, 33, 685, 687, "is" +354, 12, 6, 162, 34, 43, 688, 697, "effective" +354, 12, 7, 163, 44, 46, 698, 700, "in" +354, 12, 8, 164, 47, 58, 701, 712, "combination" +354, 12, 9, 165, 59, 63, 713, 717, "with" +354, 12, 10, 166, 64, 73, 718, 727, "metformin" +354, 12, 11, 167, 74, 76, 728, 730, "or" +354, 12, 12, 168, 77, 90, 731, 744, "sulfonylureas" +354, 12, 13, 169, 91, 94, 745, 748, "for" +354, 12, 14, 170, 95, 103, 749, 757, "treating" +354, 12, 15, 171, 104, 108, 758, 762, "type" +354, 12, 16, 172, 109, 110, 763, 764, "2" +354, 12, 17, 173, 111, 119, 765, 773, "diabetes" +354, 12, 18, 174, 120, 121, 774, 775, "." +354, 13, 1, 175, 0, 18, 776, 794, "Thiazolidinediones" +354, 13, 2, 176, 19, 20, 795, 796, "(" +354, 13, 3, 177, 21, 25, 797, 801, "TZDs" +354, 13, 4, 178, 26, 27, 802, 803, ")" +354, 13, 5, 179, 28, 32, 804, 808, "also" +354, 13, 6, 180, 33, 36, 809, 812, "are" +354, 13, 7, 181, 37, 45, 813, 821, "commonly" +354, 13, 8, 182, 46, 50, 822, 826, "used" +354, 13, 9, 183, 51, 52, 827, 828, "," +354, 13, 10, 184, 53, 56, 829, 832, "but" +354, 13, 11, 185, 57, 60, 833, 836, "the" +354, 13, 12, 186, 61, 69, 837, 845, "efficacy" +354, 13, 13, 187, 70, 72, 846, 848, "of" +354, 13, 14, 188, 73, 82, 849, 858, "exenatide" +354, 13, 15, 189, 83, 87, 859, 863, "with" +354, 13, 16, 190, 88, 89, 864, 865, "a" +354, 13, 17, 191, 90, 93, 866, 869, "TZD" +354, 13, 18, 192, 94, 97, 870, 873, "has" +354, 13, 19, 193, 98, 101, 874, 877, "not" +354, 13, 20, 194, 102, 106, 878, 882, "been" +354, 13, 21, 195, 107, 115, 883, 891, "reported" +354, 13, 22, 196, 116, 117, 892, 893, "." +354, 14, 1, 197, 0, 9, 894, 903, "OBJECTIVE" +354, 14, 2, 198, 10, 11, 904, 905, ":" +354, 14, 3, 199, 12, 14, 906, 908, "To" +354, 14, 4, 200, 15, 22, 909, 916, "compare" +354, 14, 5, 201, 23, 26, 917, 920, "the" +354, 14, 6, 202, 27, 34, 921, 928, "effects" +354, 14, 7, 203, 35, 37, 929, 931, "of" +354, 14, 8, 204, 38, 47, 932, 941, "exenatide" +354, 14, 9, 205, 48, 54, 942, 948, "versus" +354, 14, 10, 206, 55, 62, 949, 956, "placebo" +354, 14, 11, 207, 63, 65, 957, 959, "on" +354, 14, 12, 208, 66, 74, 960, 968, "glycemic" +354, 14, 13, 209, 75, 82, 969, 976, "control" +354, 14, 14, 210, 83, 84, 977, 978, "." +354, 15, 1, 211, 0, 6, 979, 985, "DESIGN" +354, 15, 2, 212, 7, 8, 986, 987, ":" +354, 15, 3, 213, 9, 16, 988, 995, "Placebo" +354, 15, 4, 214, 17, 20, 996, 999, "run" +354, 15, 5, 215, 21, 22, 1000, 1001, "-" +354, 15, 6, 216, 23, 25, 1002, 1004, "in" +354, 15, 7, 217, 26, 27, 1005, 1006, "," +354, 15, 8, 218, 28, 38, 1007, 1017, "randomized" +354, 15, 9, 219, 39, 40, 1018, 1019, "," +354, 15, 10, 220, 41, 47, 1020, 1026, "double" +354, 15, 11, 221, 48, 49, 1027, 1028, "-" +354, 15, 12, 222, 50, 55, 1029, 1034, "blind" +354, 15, 13, 223, 56, 57, 1035, 1036, "," +354, 15, 14, 224, 58, 65, 1037, 1044, "placebo" +354, 15, 15, 225, 66, 67, 1045, 1046, "-" +354, 15, 16, 226, 68, 78, 1047, 1057, "controlled" +354, 15, 17, 227, 79, 84, 1058, 1063, "trial" +354, 15, 18, 228, 85, 94, 1064, 1073, "conducted" +354, 15, 19, 229, 95, 99, 1074, 1078, "from" +354, 15, 20, 230, 100, 103, 1079, 1082, "May" +354, 15, 21, 231, 104, 108, 1083, 1087, "2004" +354, 15, 22, 232, 109, 111, 1088, 1090, "to" +354, 15, 23, 233, 112, 118, 1091, 1097, "August" +354, 15, 24, 234, 119, 123, 1098, 1102, "2005" +354, 15, 25, 235, 124, 125, 1103, 1104, "." +354, 16, 1, 236, 0, 7, 1105, 1112, "SETTING" +354, 16, 2, 237, 8, 9, 1113, 1114, ":" +354, 16, 3, 238, 10, 12, 1115, 1117, "49" +354, 16, 4, 239, 13, 18, 1118, 1123, "sites" +354, 16, 5, 240, 19, 21, 1124, 1126, "in" +354, 16, 6, 241, 22, 28, 1127, 1133, "Canada" +354, 16, 7, 242, 29, 30, 1134, 1135, "," +354, 16, 8, 243, 31, 36, 1136, 1141, "Spain" +354, 16, 9, 244, 37, 38, 1142, 1143, "," +354, 16, 10, 245, 39, 42, 1144, 1147, "and" +354, 16, 11, 246, 43, 46, 1148, 1151, "the" +354, 16, 12, 247, 47, 53, 1152, 1158, "United" +354, 16, 13, 248, 54, 60, 1159, 1165, "States" +354, 16, 14, 249, 61, 62, 1166, 1167, "." +354, 17, 1, 250, 0, 8, 1168, 1176, "PATIENTS" +354, 17, 2, 251, 9, 10, 1177, 1178, ":" +354, 17, 3, 252, 11, 14, 1179, 1182, "233" +354, 17, 4, 253, 15, 16, 1183, 1184, "(" +354, 17, 5, 254, 17, 26, 1185, 1194, "exenatide" +354, 17, 6, 255, 27, 32, 1195, 1200, "group" +354, 17, 7, 256, 33, 34, 1201, 1202, "," +354, 17, 8, 257, 35, 36, 1203, 1204, "n" +354, 17, 9, 258, 37, 38, 1205, 1206, "=" +354, 17, 10, 259, 39, 42, 1207, 1210, "121" +354, 17, 11, 260, 43, 44, 1211, 1212, ";" +354, 17, 12, 261, 45, 52, 1213, 1220, "placebo" +354, 17, 13, 262, 53, 58, 1221, 1226, "group" +354, 17, 14, 263, 59, 60, 1227, 1228, "," +354, 17, 15, 264, 61, 62, 1229, 1230, "n" +354, 17, 16, 265, 63, 64, 1231, 1232, "=" +354, 17, 17, 266, 65, 68, 1233, 1236, "112" +354, 17, 18, 267, 69, 70, 1237, 1238, ")" +354, 17, 19, 268, 71, 79, 1239, 1247, "patients" +354, 17, 20, 269, 80, 84, 1248, 1252, "with" +354, 17, 21, 270, 85, 89, 1253, 1257, "type" +354, 17, 22, 271, 90, 91, 1258, 1259, "2" +354, 17, 23, 272, 92, 100, 1260, 1268, "diabetes" +354, 17, 24, 273, 101, 105, 1269, 1273, "that" +354, 17, 25, 274, 106, 109, 1274, 1277, "was" +354, 17, 26, 275, 110, 122, 1278, 1290, "suboptimally" +354, 17, 27, 276, 123, 133, 1291, 1301, "controlled" +354, 17, 28, 277, 134, 138, 1302, 1306, "with" +354, 17, 29, 278, 139, 142, 1307, 1310, "TZD" +354, 17, 30, 279, 143, 152, 1311, 1320, "treatment" +354, 17, 31, 280, 153, 154, 1321, 1322, "(" +354, 17, 32, 281, 155, 159, 1323, 1327, "with" +354, 17, 33, 282, 160, 162, 1328, 1330, "or" +354, 17, 34, 283, 163, 170, 1331, 1338, "without" +354, 17, 35, 284, 171, 180, 1339, 1348, "metformin" +354, 17, 36, 285, 181, 182, 1349, 1350, ")" +354, 17, 37, 286, 183, 184, 1351, 1352, "." +354, 18, 1, 287, 0, 4, 1353, 1357, "Mean" +354, 18, 2, 288, 5, 6, 1358, 1359, "(" +354, 18, 3, 289, 7, 8, 1360, 1361, "+" +354, 18, 4, 290, 9, 10, 1362, 1363, "/" +354, 18, 5, 291, 11, 12, 1364, 1365, "-" +354, 18, 6, 292, 13, 15, 1366, 1368, "SE" +354, 18, 7, 293, 16, 17, 1369, 1370, ")" +354, 18, 8, 294, 18, 26, 1371, 1379, "baseline" +354, 18, 9, 295, 27, 35, 1380, 1388, "glycated" +354, 18, 10, 296, 36, 46, 1389, 1399, "hemoglobin" +354, 18, 11, 297, 47, 50, 1400, 1403, "A1c" +354, 18, 12, 298, 51, 56, 1404, 1409, "level" +354, 18, 13, 299, 57, 60, 1410, 1413, "was" +354, 18, 14, 300, 61, 62, 1414, 1415, "7" +354, 18, 15, 301, 63, 64, 1416, 1417, "." +354, 18, 16, 302, 65, 66, 1418, 1419, "9" +354, 18, 17, 303, 67, 68, 1420, 1421, "%" +354, 18, 18, 304, 69, 70, 1422, 1423, "+" +354, 18, 19, 305, 71, 72, 1424, 1425, "/" +354, 18, 20, 306, 73, 74, 1426, 1427, "-" +354, 18, 21, 307, 75, 76, 1428, 1429, "0" +354, 18, 22, 308, 77, 78, 1430, 1431, "." +354, 18, 23, 309, 79, 80, 1432, 1433, "1" +354, 18, 24, 310, 81, 82, 1434, 1435, "%" +354, 18, 25, 311, 83, 84, 1436, 1437, "." +354, 19, 1, 312, 0, 13, 1438, 1451, "INTERVENTIONS" +354, 19, 2, 313, 14, 15, 1452, 1453, ":" +354, 19, 3, 314, 16, 28, 1454, 1466, "Subcutaneous" +354, 19, 4, 315, 29, 38, 1467, 1476, "abdominal" +354, 19, 5, 316, 39, 49, 1477, 1487, "injections" +354, 19, 6, 317, 50, 52, 1488, 1490, "of" +354, 19, 7, 318, 53, 55, 1491, 1493, "10" +354, 19, 8, 319, 56, 62, 1494, 1500, "microg" +354, 19, 9, 320, 63, 65, 1501, 1503, "of" +354, 19, 10, 321, 66, 75, 1504, 1513, "exenatide" +354, 19, 11, 322, 76, 78, 1514, 1516, "or" +354, 19, 12, 323, 79, 86, 1517, 1524, "placebo" +354, 19, 13, 324, 87, 92, 1525, 1530, "twice" +354, 19, 14, 325, 93, 98, 1531, 1536, "daily" +354, 19, 15, 326, 99, 100, 1537, 1538, "," +354, 19, 16, 327, 101, 106, 1539, 1544, "added" +354, 19, 17, 328, 107, 109, 1545, 1547, "to" +354, 19, 18, 329, 110, 111, 1548, 1549, "a" +354, 19, 19, 330, 112, 115, 1550, 1553, "TZD" +354, 19, 20, 331, 116, 117, 1554, 1555, "(" +354, 19, 21, 332, 118, 122, 1556, 1560, "with" +354, 19, 22, 333, 123, 125, 1561, 1563, "or" +354, 19, 23, 334, 126, 133, 1564, 1571, "without" +354, 19, 24, 335, 134, 143, 1572, 1581, "metformin" +354, 19, 25, 336, 144, 145, 1582, 1583, ")" +354, 19, 26, 337, 146, 149, 1584, 1587, "for" +354, 19, 27, 338, 150, 152, 1588, 1590, "16" +354, 19, 28, 339, 153, 158, 1591, 1596, "weeks" +354, 19, 29, 340, 159, 160, 1597, 1598, "." +354, 20, 1, 341, 0, 12, 1599, 1611, "MEASUREMENTS" +354, 20, 2, 342, 13, 14, 1612, 1613, ":" +354, 20, 3, 343, 15, 18, 1614, 1617, "The" +354, 20, 4, 344, 19, 26, 1618, 1625, "primary" +354, 20, 5, 345, 27, 34, 1626, 1633, "outcome" +354, 20, 6, 346, 35, 38, 1634, 1637, "was" +354, 20, 7, 347, 39, 45, 1638, 1644, "change" +354, 20, 8, 348, 46, 50, 1645, 1649, "from" +354, 20, 9, 349, 51, 59, 1650, 1658, "baseline" +354, 20, 10, 350, 60, 62, 1659, 1661, "in" +354, 20, 11, 351, 63, 73, 1662, 1672, "hemoglobin" +354, 20, 12, 352, 74, 77, 1673, 1676, "A1c" +354, 20, 13, 353, 78, 83, 1677, 1682, "level" +354, 20, 14, 354, 84, 85, 1683, 1684, "." +354, 21, 1, 355, 0, 5, 1685, 1690, "Other" +354, 21, 2, 356, 6, 14, 1691, 1699, "outcomes" +354, 21, 3, 357, 15, 19, 1700, 1704, "were" +354, 21, 4, 358, 20, 27, 1705, 1712, "fasting" +354, 21, 5, 359, 28, 33, 1713, 1718, "serum" +354, 21, 6, 360, 34, 41, 1719, 1726, "glucose" +354, 21, 7, 361, 42, 47, 1727, 1732, "level" +354, 21, 8, 362, 48, 49, 1733, 1734, "," +354, 21, 9, 363, 50, 54, 1735, 1739, "body" +354, 21, 10, 364, 55, 61, 1740, 1746, "weight" +354, 21, 11, 365, 62, 63, 1747, 1748, "," +354, 21, 12, 366, 64, 68, 1749, 1753, "self" +354, 21, 13, 367, 69, 70, 1754, 1755, "-" +354, 21, 14, 368, 71, 80, 1756, 1765, "monitored" +354, 21, 15, 369, 81, 86, 1766, 1771, "blood" +354, 21, 16, 370, 87, 94, 1772, 1779, "glucose" +354, 21, 17, 371, 95, 100, 1780, 1785, "level" +354, 21, 18, 372, 101, 102, 1786, 1787, "," +354, 21, 19, 373, 103, 106, 1788, 1791, "and" +354, 21, 20, 374, 107, 110, 1792, 1795, "any" +354, 21, 21, 375, 111, 118, 1796, 1803, "adverse" +354, 21, 22, 376, 119, 125, 1804, 1810, "events" +354, 21, 23, 377, 126, 127, 1811, 1812, "." +354, 22, 1, 378, 0, 7, 1813, 1820, "RESULTS" +354, 22, 2, 379, 8, 9, 1821, 1822, ":" +354, 22, 3, 380, 10, 19, 1823, 1832, "Exenatide" +354, 22, 4, 381, 20, 29, 1833, 1842, "treatment" +354, 22, 5, 382, 30, 37, 1843, 1850, "reduced" +354, 22, 6, 383, 38, 48, 1851, 1861, "hemoglobin" +354, 22, 7, 384, 49, 50, 1862, 1863, "A" +354, 22, 8, 385, 51, 52, 1864, 1865, "(" +354, 22, 9, 386, 53, 55, 1866, 1868, "1c" +354, 22, 10, 387, 56, 57, 1869, 1870, ")" +354, 22, 11, 388, 58, 63, 1871, 1876, "level" +354, 22, 12, 389, 64, 65, 1877, 1878, "(" +354, 22, 13, 390, 66, 70, 1879, 1883, "mean" +354, 22, 14, 391, 71, 81, 1884, 1894, "difference" +354, 22, 15, 392, 82, 83, 1895, 1896, "," +354, 22, 16, 393, 84, 85, 1897, 1898, "-" +354, 22, 17, 394, 86, 87, 1899, 1900, "0" +354, 22, 18, 395, 88, 89, 1901, 1902, "." +354, 22, 19, 396, 90, 92, 1903, 1905, "98" +354, 22, 20, 397, 93, 94, 1906, 1907, "%" +354, 22, 21, 398, 95, 96, 1908, 1909, "[" +354, 22, 22, 399, 97, 99, 1910, 1912, "95" +354, 22, 23, 400, 100, 101, 1913, 1914, "%" +354, 22, 24, 401, 102, 104, 1915, 1917, "CI" +354, 22, 25, 402, 105, 106, 1918, 1919, "," +354, 22, 26, 403, 107, 108, 1920, 1921, "-" +354, 22, 27, 404, 109, 110, 1922, 1923, "1" +354, 22, 28, 405, 111, 112, 1924, 1925, "." +354, 22, 29, 406, 113, 115, 1926, 1928, "21" +354, 22, 30, 407, 116, 117, 1929, 1930, "%" +354, 22, 31, 408, 118, 120, 1931, 1933, "to" +354, 22, 32, 409, 121, 122, 1934, 1935, "-" +354, 22, 33, 410, 123, 124, 1936, 1937, "0" +354, 22, 34, 411, 125, 126, 1938, 1939, "." +354, 22, 35, 412, 127, 129, 1940, 1942, "74" +354, 22, 36, 413, 130, 131, 1943, 1944, "%" +354, 22, 37, 414, 132, 133, 1945, 1946, "]" +354, 22, 38, 415, 134, 135, 1947, 1948, ")" +354, 22, 39, 416, 136, 137, 1949, 1950, "," +354, 22, 40, 417, 138, 143, 1951, 1956, "serum" +354, 22, 41, 418, 144, 151, 1957, 1964, "fasting" +354, 22, 42, 419, 152, 159, 1965, 1972, "glucose" +354, 22, 43, 420, 160, 165, 1973, 1978, "level" +354, 22, 44, 421, 166, 167, 1979, 1980, "(" +354, 22, 45, 422, 168, 172, 1981, 1985, "mean" +354, 22, 46, 423, 173, 183, 1986, 1996, "difference" +354, 22, 47, 424, 184, 185, 1997, 1998, "," +354, 22, 48, 425, 186, 187, 1999, 2000, "-" +354, 22, 49, 426, 188, 189, 2001, 2002, "1" +354, 22, 50, 427, 190, 191, 2003, 2004, "." +354, 22, 51, 428, 192, 194, 2005, 2007, "69" +354, 22, 52, 429, 195, 199, 2008, 2012, "mmol" +354, 22, 53, 430, 200, 201, 2013, 2014, "/" +354, 22, 54, 431, 202, 203, 2015, 2016, "L" +354, 22, 55, 432, 204, 205, 2017, 2018, "[" +354, 22, 56, 433, 206, 207, 2019, 2020, "-" +354, 22, 57, 434, 208, 210, 2021, 2023, "30" +354, 22, 58, 435, 211, 212, 2024, 2025, "." +354, 22, 59, 436, 213, 214, 2026, 2027, "5" +354, 22, 60, 437, 215, 217, 2028, 2030, "mg" +354, 22, 61, 438, 218, 219, 2031, 2032, "/" +354, 22, 62, 439, 220, 222, 2033, 2035, "dL" +354, 22, 63, 440, 223, 224, 2036, 2037, "]" +354, 22, 64, 441, 225, 226, 2038, 2039, "[" +354, 22, 65, 442, 227, 229, 2040, 2042, "CI" +354, 22, 66, 443, 230, 231, 2043, 2044, "," +354, 22, 67, 444, 232, 233, 2045, 2046, "-" +354, 22, 68, 445, 234, 235, 2047, 2048, "2" +354, 22, 69, 446, 236, 237, 2049, 2050, "." +354, 22, 70, 447, 238, 240, 2051, 2053, "22" +354, 22, 71, 448, 241, 243, 2054, 2056, "to" +354, 22, 72, 449, 244, 245, 2057, 2058, "-" +354, 22, 73, 450, 246, 247, 2059, 2060, "1" +354, 22, 74, 451, 248, 249, 2061, 2062, "." +354, 22, 75, 452, 250, 252, 2063, 2065, "17" +354, 22, 76, 453, 253, 257, 2066, 2070, "mmol" +354, 22, 77, 454, 258, 259, 2071, 2072, "/" +354, 22, 78, 455, 260, 261, 2073, 2074, "L" +354, 22, 79, 456, 262, 263, 2075, 2076, "{" +354, 22, 80, 457, 264, 265, 2077, 2078, "-" +354, 22, 81, 458, 266, 268, 2079, 2081, "40" +354, 22, 82, 459, 269, 270, 2082, 2083, "." +354, 22, 83, 460, 271, 272, 2084, 2085, "0" +354, 22, 84, 461, 273, 275, 2086, 2088, "to" +354, 22, 85, 462, 276, 277, 2089, 2090, "-" +354, 22, 86, 463, 278, 280, 2091, 2093, "21" +354, 22, 87, 464, 281, 282, 2094, 2095, "." +354, 22, 88, 465, 283, 284, 2096, 2097, "1" +354, 22, 89, 466, 285, 287, 2098, 2100, "mg" +354, 22, 90, 467, 288, 289, 2101, 2102, "/" +354, 22, 91, 468, 290, 292, 2103, 2105, "dL" +354, 22, 92, 469, 293, 294, 2106, 2107, "}" +354, 22, 93, 470, 295, 296, 2108, 2109, "]" +354, 22, 94, 471, 297, 298, 2110, 2111, ")" +354, 22, 95, 472, 299, 300, 2112, 2113, "," +354, 22, 96, 473, 301, 304, 2114, 2117, "and" +354, 22, 97, 474, 305, 309, 2118, 2122, "body" +354, 22, 98, 475, 310, 316, 2123, 2129, "weight" +354, 22, 99, 476, 317, 318, 2130, 2131, "(" +354, 22, 100, 477, 319, 323, 2132, 2136, "mean" +354, 22, 101, 478, 324, 334, 2137, 2147, "difference" +354, 22, 102, 479, 335, 336, 2148, 2149, "," +354, 22, 103, 480, 337, 338, 2150, 2151, "-" +354, 22, 104, 481, 339, 340, 2152, 2153, "1" +354, 22, 105, 482, 341, 342, 2154, 2155, "." +354, 22, 106, 483, 343, 345, 2156, 2158, "51" +354, 22, 107, 484, 346, 348, 2159, 2161, "kg" +354, 22, 108, 485, 349, 350, 2162, 2163, "[" +354, 22, 109, 486, 351, 353, 2164, 2166, "CI" +354, 22, 110, 487, 354, 355, 2167, 2168, "," +354, 22, 111, 488, 356, 357, 2169, 2170, "-" +354, 22, 112, 489, 358, 359, 2171, 2172, "2" +354, 22, 113, 490, 360, 361, 2173, 2174, "." +354, 22, 114, 491, 362, 364, 2175, 2177, "15" +354, 22, 115, 492, 365, 367, 2178, 2180, "to" +354, 22, 116, 493, 368, 369, 2181, 2182, "-" +354, 22, 117, 494, 370, 371, 2183, 2184, "0" +354, 22, 118, 495, 372, 373, 2185, 2186, "." +354, 22, 119, 496, 374, 376, 2187, 2189, "88" +354, 22, 120, 497, 377, 379, 2190, 2192, "kg" +354, 22, 121, 498, 380, 381, 2193, 2194, "]" +354, 22, 122, 499, 382, 383, 2195, 2196, ")" +354, 22, 123, 500, 384, 385, 2197, 2198, "." +354, 23, 1, 501, 0, 7, 2199, 2206, "Sixteen" +354, 23, 2, 502, 8, 15, 2207, 2214, "percent" +354, 23, 3, 503, 16, 18, 2215, 2217, "of" +354, 23, 4, 504, 19, 27, 2218, 2226, "patients" +354, 23, 5, 505, 28, 30, 2227, 2229, "in" +354, 23, 6, 506, 31, 34, 2230, 2233, "the" +354, 23, 7, 507, 35, 44, 2234, 2243, "exenatide" +354, 23, 8, 508, 45, 50, 2244, 2249, "group" +354, 23, 9, 509, 51, 54, 2250, 2253, "and" +354, 23, 10, 510, 55, 56, 2254, 2255, "2" +354, 23, 11, 511, 57, 58, 2256, 2257, "%" +354, 23, 12, 512, 59, 61, 2258, 2260, "of" +354, 23, 13, 513, 62, 70, 2261, 2269, "patients" +354, 23, 14, 514, 71, 73, 2270, 2272, "in" +354, 23, 15, 515, 74, 77, 2273, 2276, "the" +354, 23, 16, 516, 78, 85, 2277, 2284, "placebo" +354, 23, 17, 517, 86, 91, 2285, 2290, "group" +354, 23, 18, 518, 92, 104, 2291, 2303, "discontinued" +354, 23, 19, 519, 105, 114, 2304, 2313, "treatment" +354, 23, 20, 520, 115, 122, 2314, 2321, "because" +354, 23, 21, 521, 123, 125, 2322, 2324, "of" +354, 23, 22, 522, 126, 133, 2325, 2332, "adverse" +354, 23, 23, 523, 134, 140, 2333, 2339, "events" +354, 23, 24, 524, 141, 142, 2340, 2341, "." +354, 24, 1, 525, 0, 2, 2342, 2344, "In" +354, 24, 2, 526, 3, 6, 2345, 2348, "the" +354, 24, 3, 527, 7, 16, 2349, 2358, "exenatide" +354, 24, 4, 528, 17, 22, 2359, 2364, "group" +354, 24, 5, 529, 23, 24, 2365, 2366, "," +354, 24, 6, 530, 25, 27, 2367, 2369, "40" +354, 24, 7, 531, 28, 29, 2370, 2371, "%" +354, 24, 8, 532, 30, 31, 2372, 2373, "(" +354, 24, 9, 533, 32, 33, 2374, 2375, "n" +354, 24, 10, 534, 34, 35, 2376, 2377, "=" +354, 24, 11, 535, 36, 38, 2378, 2380, "48" +354, 24, 12, 536, 39, 40, 2381, 2382, ")" +354, 24, 13, 537, 41, 43, 2383, 2385, "of" +354, 24, 14, 538, 44, 52, 2386, 2394, "patients" +354, 24, 15, 539, 53, 64, 2395, 2406, "experienced" +354, 24, 16, 540, 65, 71, 2407, 2413, "nausea" +354, 24, 17, 541, 72, 73, 2414, 2415, "(" +354, 24, 18, 542, 74, 80, 2416, 2422, "mostly" +354, 24, 19, 543, 81, 85, 2423, 2427, "mild" +354, 24, 20, 544, 86, 87, 2428, 2429, "[" +354, 24, 21, 545, 88, 89, 2430, 2431, "n" +354, 24, 22, 546, 90, 91, 2432, 2433, "=" +354, 24, 23, 547, 92, 94, 2434, 2436, "21" +354, 24, 24, 548, 95, 96, 2437, 2438, "]" +354, 24, 25, 549, 97, 99, 2439, 2441, "or" +354, 24, 26, 550, 100, 108, 2442, 2450, "moderate" +354, 24, 27, 551, 109, 110, 2451, 2452, "[" +354, 24, 28, 552, 111, 112, 2453, 2454, "n" +354, 24, 29, 553, 113, 114, 2455, 2456, "=" +354, 24, 30, 554, 115, 117, 2457, 2459, "19" +354, 24, 31, 555, 118, 119, 2460, 2461, "]" +354, 24, 32, 556, 120, 121, 2462, 2463, ")" +354, 24, 33, 557, 122, 123, 2464, 2465, "," +354, 24, 34, 558, 124, 126, 2466, 2468, "13" +354, 24, 35, 559, 127, 128, 2469, 2470, "%" +354, 24, 36, 560, 129, 140, 2471, 2482, "experienced" +354, 24, 37, 561, 141, 149, 2483, 2491, "vomiting" +354, 24, 38, 562, 150, 151, 2492, 2493, "," +354, 24, 39, 563, 152, 155, 2494, 2497, "and" +354, 24, 40, 564, 156, 158, 2498, 2500, "11" +354, 24, 41, 565, 159, 160, 2501, 2502, "%" +354, 24, 42, 566, 161, 172, 2503, 2514, "experienced" +354, 24, 43, 567, 173, 185, 2515, 2527, "hypoglycemia" +354, 24, 44, 568, 186, 187, 2528, 2529, "." +354, 25, 1, 569, 0, 2, 2530, 2532, "In" +354, 25, 2, 570, 3, 6, 2533, 2536, "the" +354, 25, 3, 571, 7, 14, 2537, 2544, "placebo" +354, 25, 4, 572, 15, 20, 2545, 2550, "group" +354, 25, 5, 573, 21, 22, 2551, 2552, "," +354, 25, 6, 574, 23, 25, 2553, 2555, "15" +354, 25, 7, 575, 26, 27, 2556, 2557, "%" +354, 25, 8, 576, 28, 30, 2558, 2560, "of" +354, 25, 9, 577, 31, 39, 2561, 2569, "patients" +354, 25, 10, 578, 40, 51, 2570, 2581, "experienced" +354, 25, 11, 579, 52, 58, 2582, 2588, "nausea" +354, 25, 12, 580, 59, 60, 2589, 2590, "," +354, 25, 13, 581, 61, 62, 2591, 2592, "1" +354, 25, 14, 582, 63, 64, 2593, 2594, "%" +354, 25, 15, 583, 65, 76, 2595, 2606, "experienced" +354, 25, 16, 584, 77, 85, 2607, 2615, "vomiting" +354, 25, 17, 585, 86, 87, 2616, 2617, "," +354, 25, 18, 586, 88, 91, 2618, 2621, "and" +354, 25, 19, 587, 92, 93, 2622, 2623, "7" +354, 25, 20, 588, 94, 95, 2624, 2625, "%" +354, 25, 21, 589, 96, 107, 2626, 2637, "experienced" +354, 25, 22, 590, 108, 120, 2638, 2650, "hypoglycemia" +354, 25, 23, 591, 121, 122, 2651, 2652, "." +354, 26, 1, 592, 0, 11, 2653, 2664, "LIMITATIONS" +354, 26, 2, 593, 12, 13, 2665, 2666, ":" +354, 26, 3, 594, 14, 26, 2667, 2679, "Combinations" +354, 26, 4, 595, 27, 31, 2680, 2684, "with" +354, 26, 5, 596, 32, 36, 2685, 2689, "TZDs" +354, 26, 6, 597, 37, 40, 2690, 2693, "and" +354, 26, 7, 598, 41, 54, 2694, 2707, "sulfonylureas" +354, 26, 8, 599, 55, 59, 2708, 2712, "were" +354, 26, 9, 600, 60, 63, 2713, 2716, "not" +354, 26, 10, 601, 64, 70, 2717, 2723, "tested" +354, 26, 11, 602, 71, 72, 2724, 2725, "." +354, 27, 1, 603, 0, 5, 2726, 2731, "Trial" +354, 27, 2, 604, 6, 14, 2732, 2740, "duration" +354, 27, 3, 605, 15, 18, 2741, 2744, "was" +354, 27, 4, 606, 19, 29, 2745, 2755, "relatively" +354, 27, 5, 607, 30, 35, 2756, 2761, "short" +354, 27, 6, 608, 36, 37, 2762, 2763, "." +354, 28, 1, 609, 0, 4, 2764, 2768, "Only" +354, 28, 2, 610, 5, 7, 2769, 2771, "71" +354, 28, 3, 611, 8, 9, 2772, 2773, "%" +354, 28, 4, 612, 10, 13, 2774, 2777, "and" +354, 28, 5, 613, 14, 16, 2778, 2780, "86" +354, 28, 6, 614, 17, 18, 2781, 2782, "%" +354, 28, 7, 615, 19, 21, 2783, 2785, "of" +354, 28, 8, 616, 22, 30, 2786, 2794, "patients" +354, 28, 9, 617, 31, 33, 2795, 2797, "in" +354, 28, 10, 618, 34, 37, 2798, 2801, "the" +354, 28, 11, 619, 38, 47, 2802, 2811, "exenatide" +354, 28, 12, 620, 48, 51, 2812, 2815, "and" +354, 28, 13, 621, 52, 59, 2816, 2823, "placebo" +354, 28, 14, 622, 60, 66, 2824, 2830, "groups" +354, 28, 15, 623, 67, 68, 2831, 2832, "," +354, 28, 16, 624, 69, 81, 2833, 2845, "respectively" +354, 28, 17, 625, 82, 83, 2846, 2847, "," +354, 28, 18, 626, 84, 93, 2848, 2857, "completed" +354, 28, 19, 627, 94, 97, 2858, 2861, "the" +354, 28, 20, 628, 98, 103, 2862, 2867, "study" +354, 28, 21, 629, 104, 105, 2868, 2869, "." +354, 29, 1, 630, 0, 11, 2870, 2881, "CONCLUSIONS" +354, 29, 2, 631, 12, 13, 2882, 2883, ":" +354, 29, 3, 632, 14, 23, 2884, 2893, "Exenatide" +354, 29, 4, 633, 24, 31, 2894, 2901, "therapy" +354, 29, 5, 634, 32, 40, 2902, 2910, "improved" +354, 29, 6, 635, 41, 49, 2911, 2919, "glycemic" +354, 29, 7, 636, 50, 57, 2920, 2927, "control" +354, 29, 8, 637, 58, 59, 2928, 2929, "," +354, 29, 9, 638, 60, 67, 2930, 2937, "reduced" +354, 29, 10, 639, 68, 72, 2938, 2942, "body" +354, 29, 11, 640, 73, 79, 2943, 2949, "weight" +354, 29, 12, 641, 80, 81, 2950, 2951, "," +354, 29, 13, 642, 82, 85, 2952, 2955, "and" +354, 29, 14, 643, 86, 92, 2956, 2962, "caused" +354, 29, 15, 644, 93, 109, 2963, 2979, "gastrointestinal" +354, 29, 16, 645, 110, 118, 2980, 2988, "symptoms" +354, 29, 17, 646, 119, 123, 2989, 2993, "more" +354, 29, 18, 647, 124, 128, 2994, 2998, "than" +354, 29, 19, 648, 129, 136, 2999, 3006, "placebo" +354, 29, 20, 649, 137, 139, 3007, 3009, "in" +354, 29, 21, 650, 140, 148, 3010, 3018, "patients" +354, 29, 22, 651, 149, 153, 3019, 3023, "with" +354, 29, 23, 652, 154, 158, 3024, 3028, "type" +354, 29, 24, 653, 159, 160, 3029, 3030, "2" +354, 29, 25, 654, 161, 169, 3031, 3039, "diabetes" +354, 29, 26, 655, 170, 174, 3040, 3044, "that" +354, 29, 27, 656, 175, 178, 3045, 3048, "was" +354, 29, 28, 657, 179, 191, 3049, 3061, "suboptimally" +354, 29, 29, 658, 192, 202, 3062, 3072, "controlled" +354, 29, 30, 659, 203, 207, 3073, 3077, "with" +354, 29, 31, 660, 208, 211, 3078, 3081, "TZD" +354, 29, 32, 661, 212, 219, 3082, 3089, "therapy" +354, 29, 33, 662, 220, 221, 3090, 3091, "." +354, 30, 1, 663, 0, 14, 3092, 3106, "ClinicalTrials" +354, 30, 2, 664, 15, 16, 3107, 3108, "." +354, 30, 3, 665, 17, 20, 3109, 3112, "gov" +354, 30, 4, 666, 21, 33, 3113, 3125, "registration" +354, 30, 5, 667, 34, 40, 3126, 3132, "number" +354, 30, 6, 668, 41, 42, 3133, 3134, ":" +354, 30, 7, 669, 43, 54, 3135, 3146, "NCT00099320" +354, 30, 8, 670, 55, 56, 3147, 3148, "." +354, 31, 1, 671, 0, 3, 3149, 3152, "For" +354, 31, 2, 672, 4, 8, 3153, 3157, "more" +354, 31, 3, 673, 9, 20, 3158, 3169, "information" +354, 31, 4, 674, 21, 23, 3170, 3172, "on" +354, 31, 5, 675, 24, 33, 3173, 3182, "exenatide" +354, 31, 6, 676, 34, 39, 3183, 3188, "click" +354, 31, 7, 677, 40, 44, 3189, 3193, "here" +354, 31, 8, 678, 45, 46, 3194, 3195, "." +354, 32, 1, 679, 0, 3, 3196, 3199, "DOI" +354, 32, 2, 680, 4, 5, 3200, 3201, ":" +354, 32, 3, 681, 6, 8, 3202, 3204, "10" +354, 32, 4, 682, 9, 10, 3205, 3206, "." +354, 32, 5, 683, 11, 15, 3207, 3211, "7326" +354, 32, 6, 684, 16, 17, 3212, 3213, "/" +354, 32, 7, 685, 18, 22, 3214, 3218, "0003" +354, 32, 8, 686, 23, 24, 3219, 3220, "-" +354, 32, 9, 687, 25, 29, 3221, 3225, "4819" +354, 32, 10, 688, 30, 31, 3226, 3227, "-" +354, 32, 11, 689, 32, 35, 3228, 3231, "146" +354, 32, 12, 690, 36, 37, 3232, 3233, "-" +354, 32, 13, 691, 38, 39, 3234, 3235, "7" +354, 32, 14, 692, 40, 41, 3236, 3237, "-" +354, 32, 15, 693, 42, 51, 3238, 3247, "200704030" +354, 32, 16, 694, 52, 53, 3248, 3249, "-" +354, 32, 17, 695, 54, 59, 3250, 3255, "00003" +354, 32, 18, 696, 60, 64, 3256, 3260, "PMID" +354, 32, 19, 697, 65, 66, 3261, 3262, ":" +354, 32, 20, 698, 67, 75, 3263, 3271, "17404349" +354, 32, 21, 699, 76, 77, 3272, 3273, "[" +354, 32, 22, 700, 78, 85, 3274, 3281, "Indexed" +354, 32, 23, 701, 86, 89, 3282, 3285, "for" +354, 32, 24, 702, 90, 97, 3286, 3293, "MEDLINE" +354, 32, 25, 703, 98, 99, 3294, 3295, "]" diff --git a/data/dm2 17404349_kwoodley.annodb b/data/dm2 17404349_kwoodley.annodb new file mode 100644 index 0000000..d69d7a7 --- /dev/null +++ b/data/dm2 17404349_kwoodley.annodb @@ -0,0 +1,122 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5283, Journal, 0, 14, "Ann Intern Med", "", +5284, PublicationYear, 17, 21, "2007", "", +36831, Title, 53, 172, "The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes : a randomized trial .", "", +11316, Exenatide, 74, 83, "exenatide", "", +11317, Drug, 89, 106, "thiazolidinedione", "", +11320, Precondition, 110, 149, "suboptimally controlled type 2 diabetes", "", +11318, Type2Diabetes, 134, 149, "type 2 diabetes", "", +11319, Randomized, 154, 164, "randomized", "", +11322, Author, 173, 181, "Zinman B", "", +11323, Author, 190, 201, "Hoogwerf BJ", "", +11324, Author, 204, 222, "Dur á n Garc í a S", "", +11325, Author, 225, 234, "Milton DR", "", +11326, Author, 237, 248, "Giaconia JM", "", +11327, Author, 251, 257, "Kim DD", "", +11328, Author, 260, 272, "Trautmann ME", "", +11329, Author, 275, 285, "Brodows RG", "", +11330, Canada, 424, 430, "Canada", "", +11331, Exenatide, 667, 676, "Exenatide", "", +11332, Metformin, 718, 727, "metformin", "", +11333, Sulfonylureas, 731, 744, "sulfonylureas", "", +11334, Type2Diabetes, 758, 773, "type 2 diabetes", "", +11335, Drug, 776, 794, "Thiazolidinediones", "", +11336, Drug, 797, 801, "TZDs", "", +11338, Exenatide, 849, 858, "exenatide", "", +11337, Drug, 866, 869, "TZD", "", +36832, ObjectiveDescription, 906, 978, "To compare the effects of exenatide versus placebo on glycemic control .", "", +11339, Exenatide, 932, 941, "exenatide", "", +11340, Placebo, 949, 956, "placebo", "", +36833, Placebo, 988, 995, "Placebo", "", +11343, Randomized, 1007, 1017, "randomized", "", +11344, DoubleBlind, 1020, 1034, "double - blind", "", +36834, Placebo, 1037, 1044, "placebo", "", +36835, Duration, 1079, 1102, "May 2004 to August 2005", "", +11346, NumberPatientsCT, 1179, 1182, "233", "", +11349, Exenatide, 1185, 1194, "exenatide", "", +11347, NumberPatientsArm, 1207, 1210, "121", "", +11350, Placebo, 1213, 1220, "placebo", "", +11348, NumberPatientsArm, 1233, 1236, "112", "", +11354, Precondition, 1239, 1350, "patients with type 2 diabetes that was suboptimally controlled with TZD treatment ( with or without metformin )", "", +11351, Type2Diabetes, 1253, 1268, "type 2 diabetes", "", +11352, Drug, 1307, 1310, "TZD", "", +11353, Metformin, 1339, 1348, "metformin", "", +11355, Mean, 1360, 1368, "+ / - SE", "", +36836, HbA1c, 1389, 1403, "hemoglobin A1c", "", +11358, BaseLineValue, 1414, 1419, "7 . 9", "", +11359, Percentage, 1420, 1421, "%", "", +11361, SdErrorBL, 1428, 1433, "0 . 1", "", +11360, Percentage, 1434, 1435, "%", "", +11362, DeliveryMethod, 1454, 1487, "Subcutaneous abdominal injections", "", +11363, DoseValue, 1491, 1493, "10", "", +11364, Microgram, 1494, 1500, "microg", "", +11365, Exenatide, 1504, 1513, "exenatide", "", +11366, Placebo, 1517, 1524, "placebo", "", +11367, Frequency, 1525, 1536, "twice daily", "", +11368, Drug, 1550, 1553, "TZD", "", +11369, Metformin, 1572, 1581, "metformin", "", +11370, Duration, 1588, 1596, "16 weeks", "", +36837, TimePoint, 1650, 1658, "baseline", "", +36838, HbA1c, 1662, 1676, "hemoglobin A1c", "", +11373, FastingPlasmaGlucose, 1705, 1726, "fasting serum glucose", "", +11374, BodyWeight, 1735, 1746, "body weight", "", +36839, BloodGlucose, 1749, 1779, "self - monitored blood glucose", "", +11376, EndPointDescription, 1796, 1810, "adverse events", "", +11377, Exenatide, 1823, 1832, "Exenatide", "", +36840, HbA1c, 1851, 1870, "hemoglobin A ( 1c )", "", +11384, DiffGroupAbsValue, 1897, 1905, "- 0 . 98", "", +11383, Percentage, 1906, 1907, "%", "", +11380, ConfIntervalDiff, 1910, 1944, "95 % CI , - 1 . 21 % to - 0 . 74 %", "", +11381, Percentage, 1929, 1930, "%", "", +11382, Percentage, 1943, 1944, "%", "", +11385, FastingPlasmaGlucose, 1951, 1972, "serum fasting glucose", "", +11386, DiffGroupAbsValue, 1999, 2007, "- 1 . 69", "", +11387, Millimoles_per_litre, 2008, 2016, "mmol / L", "", +11392, DiffGroupAbsValue, 2019, 2027, "- 30 . 5", "", +11391, Mg_per_deciliter, 2028, 2035, "mg / dL", "", +11388, ConfIntervalDiff, 2040, 2107, "CI , - 2 . 22 to - 1 . 17 mmol / L { - 40 . 0 to - 21 . 1 mg / dL }", "", +11389, Millimoles_per_litre, 2066, 2074, "mmol / L", "", +11390, Mg_per_deciliter, 2098, 2105, "mg / dL", "", +11393, BodyWeight, 2118, 2129, "body weight", "", +11395, DiffGroupAbsValue, 2150, 2158, "- 1 . 51", "", +11394, Kg, 2159, 2161, "kg", "", +11397, ConfIntervalDiff, 2164, 2192, "CI , - 2 . 15 to - 0 . 88 kg", "", +11396, Kg, 2190, 2192, "kg", "", +11403, RelNumPatientsLeftArm, 2199, 2206, "Sixteen", "", +11400, Exenatide, 2234, 2243, "exenatide", "", +11402, RelNumPatientsLeftArm, 2254, 2255, "2", "", +11401, Placebo, 2277, 2284, "placebo", "", +11404, Exenatide, 2349, 2358, "exenatide", "", +11405, PercentageAffected, 2367, 2369, "40", "", +11406, NumberAffected, 2378, 2380, "48", "", +11407, Nausea, 2407, 2413, "nausea", "", +11408, SubGroupDescription, 2416, 2427, "mostly mild", "", +11410, NumberAffected, 2434, 2436, "21", "", +11409, SubGroupDescription, 2442, 2450, "moderate", "", +11411, NumberAffected, 2457, 2459, "19", "", +11412, PercentageAffected, 2466, 2468, "13", "", +11413, EndPointDescription, 2483, 2491, "vomiting", "", +11414, PercentageAffected, 2498, 2500, "11", "", +11415, Hypoglycemia, 2515, 2527, "hypoglycemia", "", +11416, Placebo, 2537, 2544, "placebo", "", +11417, PercentageAffected, 2553, 2555, "15", "", +11420, Nausea, 2582, 2588, "nausea", "", +11418, PercentageAffected, 2591, 2592, "1", "", +11421, EndPointDescription, 2607, 2615, "vomiting", "", +11419, PercentageAffected, 2622, 2623, "7", "", +11422, Hypoglycemia, 2638, 2650, "hypoglycemia", "", +11423, Drug, 2685, 2689, "TZDs", "", +11424, Sulfonylureas, 2694, 2707, "sulfonylureas", "", +11425, FinalNumPatientsArm, 2769, 2773, "71 %", "", +11427, FinalNumPatientsArm, 2778, 2782, "86 %", "", +11428, Exenatide, 2802, 2811, "exenatide", "", +11429, Placebo, 2816, 2823, "placebo", "", +11430, Exenatide, 2884, 2893, "Exenatide", "", +36841, ConclusionComment, 2884, 3091, "Exenatide therapy improved glycemic control , reduced body weight , and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy .", "", +11431, BodyWeight, 2938, 2949, "body weight", "", +11432, GastrointestinalProblem, 2963, 2988, "gastrointestinal symptoms", "", +11433, Placebo, 2999, 3006, "placebo", "", +11436, Precondition, 3010, 3089, "patients with type 2 diabetes that was suboptimally controlled with TZD therapy", "", +11434, Type2Diabetes, 3024, 3039, "type 2 diabetes", "", +11435, Drug, 3078, 3081, "TZD", "", +11441, PMID, 3263, 3271, "17404349", "", diff --git a/data/dm2 17404349_kwoodley.n-triples b/data/dm2 17404349_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17404349_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17593236_admin.annodb b/data/dm2 17593236_admin.annodb new file mode 100644 index 0000000..aeb0e10 --- /dev/null +++ b/data/dm2 17593236_admin.annodb @@ -0,0 +1,152 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +280, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +0, PublicationYear, 22, 26, "2007", "", " \"2007\"." +1, PublicationYear, 59, 63, "2007", "", +142, Title, 73, 271, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin .", "", " \"Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin .\"." +2, Sitagliptin, 137, 148, "sitagliptin", "", +7, Precondition, 154, 269, "patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin", "", +3, Type2Diabetes, 168, 192, "type 2 diabetes mellitus", "", +4, Glimepiride, 220, 231, "glimepiride", "", +5, Glimepiride, 244, 255, "glimepiride", "", +6, Metformin, 260, 269, "metformin", "", +8, Author, 272, 283, "Hermansen K", "", " \"Hermansen K\"." +9, Author, 292, 300, "Kipnes M", "", " \"Kipnes M\"." +10, Author, 303, 308, "Luo E", "", " \"Luo E\"." +11, Author, 311, 320, "Fanurik D", "", " \"Fanurik D\"." +12, Author, 323, 332, "Khatami H", "", " \"Khatami H\"." +13, Author, 335, 342, "Stein P", "", " \"Stein P\"." +149, Sitagliptin, 345, 356, "Sitagliptin", "", +14, Country, 440, 447, "Denmark", "", " . ." +283, ObjectiveDescription, 456, 619, "To assess the efficacy and safety of a 24 - week treatment with sitagliptin , a highly selective once - daily oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor ,", "", " \"To assess the efficacy and safety of a 24 - week treatment with sitagliptin , a highly selective once - daily oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor ,\"." +15, Duration, 495, 504, "24 - week", "", " \"24 - week\"." +16, Sitagliptin, 520, 531, "sitagliptin", "", +17, Frequency, 553, 565, "once - daily", "", +18, Oral, 566, 570, "oral", "", +282, ObjectiveDescription, 620, 830, "in patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin .", "", " \"in patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin .\"." +26, Precondition, 623, 828, "patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin", "", " \"patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin\"." +19, Type2Diabetes, 637, 652, "type 2 diabetes", "", +20, HbA1c, 692, 716, "glycosylated haemoglobin", "", +21, HbA1c, 719, 729, "HbA ( 1c )", "", +22, Percentage, 745, 746, "%", "", +23, Percentage, 765, 766, "%", "", +24, Glimepiride, 778, 789, "glimepiride", "", +25, Metformin, 819, 828, "metformin", "", +27, Glimepiride, 917, 928, "glimepiride", "", +28, Metformin, 935, 944, "metformin", "", +169, Duration, 989, 997, "2 - week", "", +170, Blind, 1000, 1014, "single - blind", "", " ." +29, Placebo, 1015, 1022, "placebo", "", +30, NumberPatientsCT, 1034, 1037, "441", "", " \"441\"." +31, MinAge, 1057, 1059, "18", "", " \"18\"." +32, MaxAge, 1062, 1064, "75", "", " \"75\"." +131, Randomized, 1078, 1088, "randomized", "", " ." +33, Sitagliptin, 1116, 1127, "sitagliptin", "", " ." +34, DoseValue, 1128, 1131, "100", "", " \"100\"." +35, mg, 1132, 1134, "mg", "", " ." +36, Frequency, 1135, 1145, "once daily", "", " \"once daily\"." +37, Placebo, 1149, 1156, "placebo", "", " ." +38, AllocationRatio, 1162, 1173, "1 : 1 ratio", "", " . ." +39, Duration, 1178, 1186, "24 weeks", "", +41, Glimepiride, 1221, 1232, "glimepiride", "", +183, DoseValue, 1235, 1243, "> or = 4", "", +43, mg, 1244, 1246, "mg", "", +49786, Interval, 1249, 1252, "day", "", +45, Glimepiride, 1283, 1294, "glimepiride", "", +46, DoseValue, 1297, 1305, "> or = 4", "", +47, mg, 1306, 1308, "mg", "", +49787, Interval, 1311, 1314, "day", "", +48, Metformin, 1322, 1331, "metformin", "", +49, DoseValue, 1334, 1348, "> or = 1 , 500", "", +50, mg, 1349, 1351, "mg", "", +49788, Interval, 1354, 1357, "day", "", +51, DoubleBlind, 1449, 1463, "double - blind", "", " ." +52, OpenLabel, 1495, 1507, "open - label", "", " ." +53, Pioglitazone, 1525, 1537, "pioglitazone", "", " ." +296, TimePoint, 1546, 1555, "study end", "", +54, HbA1c, 1612, 1622, "HbA ( 1c )", "", +196, TimePoint, 1628, 1636, "baseline", "", +195, TimePoint, 1640, 1647, "Week 24", "", +55, FastingPlasmaGlucose, 1688, 1710, "fasting plasma glucose", "", +56, FastingPlasmaGlucose, 1713, 1716, "FPG", "", +291, PostprandialBloodGlucose, 1721, 1746, "2 - h post - meal glucose", "", +57, EndPointDescription, 1751, 1769, "lipid measurements", "", +201, Mean, 1782, 1786, "Mean", "", " . ." +295, TimePoint, 1787, 1795, "baseline", "", +58, HbA1c, 1796, 1806, "HbA ( 1c )", "", " ." +59, BaseLineValue, 1811, 1817, "8 . 34", "", " \"8 . 34\". \"8 . 34\"." +60, Percentage, 1818, 1819, "%", "", " ." +61, Sitagliptin, 1827, 1838, "sitagliptin", "", +62, Placebo, 1843, 1850, "placebo", "", +63, Duration, 1866, 1874, "24 weeks", "", +64, Sitagliptin, 1877, 1888, "sitagliptin", "", +65, HbA1c, 1897, 1907, "HbA ( 1c )", "", +49790, DiffGroupAbsValue, 1911, 1917, "0 . 74", "", " \"0 . 74\"." +67, Percentage, 1918, 1919, "%", "", +216, PvalueDiff, 1922, 1933, "p < 0 . 001", "", " \"p < 0 . 001\"." +69, Placebo, 1948, 1955, "placebo", "", +70, Glimepiride, 1987, 1998, "glimepiride", "", +72, SubGroupDescription, 1987, 2013, "glimepiride plus metformin", "", +71, Metformin, 2004, 2013, "metformin", "", +73, Sitagliptin, 2016, 2027, "sitagliptin", "", +74, HbA1c, 2036, 2046, "HbA ( 1c )", "", +221, DiffGroupAbsValue, 2050, 2056, "0 . 89", "", +76, Percentage, 2057, 2058, "%", "", +77, Placebo, 2071, 2078, "placebo", "", +224, DiffGroupAbsValue, 2110, 2116, "0 . 57", "", +79, Percentage, 2117, 2118, "%", "", +49789, SubGroupDescription, 2148, 2165, "glimepiride alone", "", +80, Glimepiride, 2148, 2159, "glimepiride", "", +82, Sitagliptin, 2184, 2195, "sitagliptin", "", +83, FastingPlasmaGlucose, 2204, 2207, "FPG", "", " ." +228, DiffGroupAbsValue, 2211, 2217, "20 . 1", "", " \"20 . 1\"." +85, Mg_per_deciliter, 2218, 2225, "mg / dl", "", " ." +229, PvalueDiff, 2228, 2239, "p < 0 . 001", "", " \"p < 0 . 001\"." +87, EndPointDescription, 2256, 2291, "homeostasis model assessment - beta", "", " . ." +49791, DiffGroupRelValue, 2332, 2334, "12", "", " \"12\"." +230, PvalueDiff, 2339, 2349, "p < 0 . 05", "", " \"p < 0 . 05\"." +90, Placebo, 2364, 2371, "placebo", "", +234, SubGroupDescription, 2377, 2421, "patients who underwent a meal tolerance test", "", +91, MeasurementDevice, 2402, 2421, "meal tolerance test", "", +93, Sitagliptin, 2436, 2447, "sitagliptin", "", +292, PostprandialBloodGlucose, 2458, 2487, "2 - h post - prandial glucose", "", " ." +293, PostprandialBloodGlucose, 2490, 2493, "PPG", "", +238, DiffGroupAbsValue, 2499, 2505, "36 . 1", "", " \"36 . 1\"." +95, Mg_per_deciliter, 2506, 2513, "mg / dl", "", +240, PvalueDiff, 2516, 2527, "p < 0 . 001", "", " \"p < 0 . 001\"." +97, Placebo, 2542, 2549, "placebo", "", +98, Sitagliptin, 2568, 2579, "sitagliptin", "", +99, PercentageAffected, 2662, 2664, "60", "", +100, PercentageAffected, 2670, 2672, "47", "", +132, EndPointDescription, 2696, 2715, "adverse experiences", "", +133, EndPointDescription, 2718, 2721, "AEs", "", +101, PercentageAffected, 2726, 2728, "15", "", +102, PercentageAffected, 2734, 2735, "7", "", +103, Sitagliptin, 2747, 2758, "sitagliptin", "", +104, Placebo, 2777, 2784, "placebo", "", +105, Hypoglycemia, 2843, 2856, "hypoglycaemia", "", +106, PercentageAffected, 2863, 2865, "12", "", +107, PercentageAffected, 2871, 2872, "2", "", +108, Sitagliptin, 2899, 2910, "sitagliptin", "", +109, Placebo, 2935, 2942, "placebo", "", +110, BodyWeight, 2951, 2962, "Body weight", "", +111, Sitagliptin, 2987, 2998, "sitagliptin", "", +112, Placebo, 3011, 3018, "placebo", "", +113, Increment, 3023, 3028, "0 . 8", "", +114, Reduction, 3036, 3041, "0 . 4", "", +115, Kg, 3042, 3044, "kg", "", +116, PvalueDiff, 3047, 3058, "p < 0 . 001", "", +277, ConclusionComment, 3077, 3299, "Sitagliptin 100 mg once daily significantly improved glycaemic control and beta - cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy .", "", " \"Sitagliptin 100 mg once daily significantly improved glycaemic control and beta - cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy .\"." +117, Sitagliptin, 3077, 3088, "Sitagliptin", "", +118, DoseValue, 3089, 3092, "100", "", +119, mg, 3093, 3095, "mg", "", +120, Frequency, 3096, 3106, "once daily", "", +121, Type2Diabetes, 3190, 3205, "type 2 diabetes", "", +122, Glimepiride, 3248, 3259, "glimepiride", "", +123, Glimepiride, 3263, 3274, "glimepiride", "", +124, Metformin, 3280, 3289, "metformin", "", +278, ConclusionComment, 3300, 3503, "The addition of sitagliptin was generally well tolerated , with a modest increase in hypoglycaemia and body weight , consistent with glimepiride therapy and the observed degree of glycaemic improvement .", "", " \"The addition of sitagliptin was generally well tolerated , with a modest increase in hypoglycaemia and body weight , consistent with glimepiride therapy and the observed degree of glycaemic improvement .\"." +126, Sitagliptin, 3316, 3327, "sitagliptin", "", +127, Hypoglycemia, 3385, 3398, "hypoglycaemia", "", +128, BodyWeight, 3403, 3414, "body weight", "", +129, Glimepiride, 3433, 3444, "glimepiride", "", +130, PMID, 3564, 3572, "17593236", "", " \"17593236\"." diff --git a/data/dm2 17593236_admin.n-triples b/data/dm2 17593236_admin.n-triples new file mode 100644 index 0000000..37b2350 --- /dev/null +++ b/data/dm2 17593236_admin.n-triples @@ -0,0 +1,162 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin ." . + "Hermansen K" . + "2007" . + "Diabetes Obes Metab ." . + "17593236" . + . + "Kipnes M" . + "Luo E" . + "Fanurik D" . + "Khatami H" . + "Stein P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To assess the efficacy and safety of a 24 - week treatment with sitagliptin , a highly selective once - daily oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor ," . + "441" . + "24 - week" . + . + . + . + . + "Sitagliptin 100 mg once daily significantly improved glycaemic control and beta - cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy ." . + . + . + . + . + . + "in patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin ." . + . + . + . + "The addition of sitagliptin was generally well tolerated , with a modest increase in hypoglycaemia and body weight , consistent with glimepiride therapy and the observed degree of glycaemic improvement ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin" . + . + . + . + "18" . + "75" . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hmab" . + . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s" . + . + . + . + . + "Arm p" . + . + . + . +# RDF export of group: Intervention + . + "Intervention s" . + . + "once daily" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s" . + . + "8 . 34" . + . + "Outcome hba1c p" . + . + "8 . 34" . + . + "Outcome FPG s" . + . + . + "Outcome FPG p" . + . + . + "Outcome ppg s" . + . + . + "Outcome ppg p" . + . + . + "Outcome hmab s" . + . + . + "Outcome hmab p" . + . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "0 . 74" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups FPG" . + "20 . 1" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups ppg" . + "36 . 1" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups hmab" . + "12" . + "p < 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17593236_akramersunderbrink.annodb b/data/dm2 17593236_akramersunderbrink.annodb new file mode 100644 index 0000000..df23b28 --- /dev/null +++ b/data/dm2 17593236_akramersunderbrink.annodb @@ -0,0 +1,149 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22042, Journal, 0, 19, "Diabetes Obes Metab", "", +22043, PublicationYear, 22, 26, "2007", "", +22058, Title, 73, 271, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin .", "", +22044, Sitagliptin, 137, 148, "sitagliptin", "", +22047, Type2Diabetes, 168, 192, "type 2 diabetes mellitus", "", +22050, Precondition, 193, 269, "inadequately controlled on glimepiride alone or on glimepiride and metformin", "", +22051, Glimepiride, 220, 231, "glimepiride", "", +22053, Glimepiride, 244, 255, "glimepiride", "", +22055, Metformin, 260, 269, "metformin", "", +22060, Author, 272, 283, "Hermansen K", "", +22062, Author, 292, 300, "Kipnes M", "", +22063, Author, 303, 308, "Luo E", "", +22064, Author, 311, 320, "Fanurik D", "", +22065, Author, 323, 332, "Khatami H", "", +22066, Author, 335, 342, "Stein P", "", +22067, Sitagliptin, 345, 356, "Sitagliptin", "", +22069, Country, 440, 447, "Denmark", "", +22095, ObjectiveDescription, 456, 704, "To assess the efficacy and safety of a 24 - week treatment with sitagliptin , a highly selective once - daily oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor , in patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated", "", +22072, Duration, 495, 504, "24 - week", "", +22073, Sitagliptin, 520, 531, "sitagliptin", "", +22076, Frequency, 553, 565, "once - daily", "", +22080, Oral, 566, 570, "oral", "", +22083, Type2Diabetes, 637, 652, "type 2 diabetes", "", +22085, Precondition, 661, 828, "inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin", "", +22088, HbA1c, 692, 716, "glycosylated haemoglobin", "", +22101, ObjectiveDescription, 705, 830, "haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin .", "", +22090, HbA1c, 717, 729, "( HbA ( 1c )", "", +22091, Percentage, 745, 746, "%", "", +22092, Percentage, 765, 766, "%", "", +22093, Glimepiride, 778, 789, "glimepiride", "", +22094, Metformin, 819, 828, "metformin", "", +22111, Precondition, 861, 885, "diet / exercise run - in", "", +22108, Precondition, 890, 912, "drug wash - off period", "", +22115, Glimepiride, 917, 928, "glimepiride", "", +22116, Metformin, 935, 944, "metformin", "", +22120, Duration, 989, 997, "2 - week", "", +22122, Blind, 1000, 1014, "single - blind", "", +22123, Placebo, 1015, 1022, "placebo", "", +22125, NumberPatientsCT, 1034, 1037, "441", "", +22127, MinAge, 1057, 1059, "18", "", +22129, MaxAge, 1062, 1064, "75", "", +22133, Randomized, 1078, 1088, "randomized", "", +22135, Sitagliptin, 1116, 1127, "sitagliptin", "", +22136, DoseValue, 1128, 1131, "100", "", +22137, mg, 1132, 1134, "mg", "", +22139, Frequency, 1135, 1145, "once daily", "", +22140, Placebo, 1149, 1156, "placebo", "", +22142, Duration, 1178, 1186, "24 weeks", "", +22146, Glimepiride, 1221, 1232, "glimepiride", "", +22147, DoseValue, 1242, 1243, "4", "", +22159, BioAndMedicalUnit, 1244, 1252, "mg / day", "", +22156, Glimepiride, 1283, 1294, "glimepiride", "", +22160, DoseValue, 1304, 1305, "4", "", +22162, BioAndMedicalUnit, 1306, 1314, "mg / day", "", +22163, Metformin, 1322, 1331, "metformin", "", +22165, DoseValue, 1341, 1348, "1 , 500", "", +22166, BioAndMedicalUnit, 1349, 1357, "mg / day", "", +22169, DoubleBlind, 1449, 1463, "double - blind", "", +22171, OpenLabel, 1495, 1507, "open - label", "", +22172, Pioglitazone, 1525, 1537, "pioglitazone", "", +39156, TimePoint, 1546, 1555, "study end", "", +22178, HbA1c, 1612, 1622, "HbA ( 1c )", "", +22181, TimePoint, 1628, 1636, "baseline", "", +22180, TimePoint, 1640, 1647, "Week 24", "", +22185, FastingPlasmaGlucose, 1688, 1710, "fasting plasma glucose", "", +22186, FastingPlasmaGlucose, 1713, 1716, "FPG", "", +22189, InsulinDose, 1721, 1746, "2 - h post - meal glucose", "", +22202, Mean, 1782, 1786, "Mean", "", +39155, TimePoint, 1787, 1795, "baseline", "", +22200, HbA1c, 1796, 1806, "HbA ( 1c )", "", +22209, BaseLineValue, 1811, 1817, "8 . 34", "", +22204, Percentage, 1818, 1819, "%", "", +22205, Sitagliptin, 1827, 1838, "sitagliptin", "", +22206, Placebo, 1843, 1850, "placebo", "", +22215, Duration, 1866, 1874, "24 weeks", "", +22217, Sitagliptin, 1877, 1888, "sitagliptin", "", +22218, HbA1c, 1897, 1907, "HbA ( 1c )", "", +22223, DiffGroupAbsValue, 1911, 1917, "0 . 74", "", +22225, Percentage, 1918, 1919, "%", "", +22237, PvalueDiff, 1922, 1933, "p < 0 . 001", "", +22238, Placebo, 1948, 1955, "placebo", "", +22245, SubGroupDescription, 1975, 2013, "patients on glimepiride plus metformin", "", +22248, Sitagliptin, 2016, 2027, "sitagliptin", "", +22249, HbA1c, 2036, 2046, "HbA ( 1c )", "", +22252, DiffGroupAbsValue, 2050, 2056, "0 . 89", "", +22228, Percentage, 2057, 2058, "%", "", +22257, Placebo, 2071, 2078, "placebo", "", +22266, DiffGroupAbsValue, 2110, 2116, "0 . 57", "", +22230, Percentage, 2117, 2118, "%", "", +22261, SubGroupDescription, 2136, 2165, "patients on glimepiride alone", "", +22273, Sitagliptin, 2184, 2195, "sitagliptin", "", +22274, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +22279, DiffGroupAbsValue, 2211, 2217, "20 . 1", "", +22277, Mg_per_deciliter, 2218, 2225, "mg / dl", "", +22281, PvalueDiff, 2228, 2239, "p < 0 . 001", "", +22288, EndPointDescription, 2256, 2326, "homeostasis model assessment - beta , a marker of beta - cell function", "", +22292, DiffBetweenGroups, 2332, 2334, "12", "", +22232, Percentage, 2335, 2336, "%", "", +22283, PvalueDiff, 2339, 2349, "p < 0 . 05", "", +22285, Placebo, 2364, 2371, "placebo", "", +22298, SubGroupDescription, 2377, 2421, "patients who underwent a meal tolerance test", "", +22300, Sitagliptin, 2436, 2447, "sitagliptin", "", +22304, InsulinDose, 2458, 2487, "2 - h post - prandial glucose", "", +22306, InsulinDose, 2490, 2493, "PPG", "", +22308, DiffGroupAbsValue, 2499, 2505, "36 . 1", "", +22309, Mg_per_deciliter, 2506, 2513, "mg / dl", "", +22310, PvalueDiff, 2516, 2527, "p < 0 . 001", "", +22311, Placebo, 2542, 2549, "placebo", "", +22312, Sitagliptin, 2568, 2579, "sitagliptin", "", +22319, EndPointDescription, 2652, 2659, "overall", "", +22314, PercentageAffected, 2662, 2664, "60", "", +22315, PercentageAffected, 2670, 2672, "47", "", +22313, Percentage, 2673, 2674, "%", "", +22318, EndPointDescription, 2681, 2715, "drug - related adverse experiences", "", +22316, PercentageAffected, 2726, 2728, "15", "", +22317, PercentageAffected, 2734, 2735, "7", "", +22234, Percentage, 2736, 2737, "%", "", +22320, Sitagliptin, 2747, 2758, "sitagliptin", "", +22321, Placebo, 2777, 2784, "placebo", "", +22322, Hypoglycemia, 2843, 2860, "hypoglycaemia AEs", "", +22323, PercentageAffected, 2863, 2865, "12", "", +22324, PercentageAffected, 2871, 2872, "2", "", +22236, Percentage, 2873, 2874, "%", "", +22325, Sitagliptin, 2899, 2910, "sitagliptin", "", +22327, Placebo, 2935, 2942, "placebo", "", +22330, BodyWeight, 2951, 2962, "Body weight", "", +22333, Sitagliptin, 2987, 2998, "sitagliptin", "", +22335, Placebo, 3011, 3018, "placebo", "", +22338, ChangeValue, 3021, 3028, "+ 0 . 8", "", +22339, ChangeValue, 3034, 3041, "- 0 . 4", "", +22336, Kg, 3042, 3044, "kg", "", +22337, PvalueDiff, 3047, 3058, "p < 0 . 001", "", +22340, Sitagliptin, 3077, 3088, "Sitagliptin", "", +22353, ConclusionComment, 3077, 3299, "Sitagliptin 100 mg once daily significantly improved glycaemic control and beta - cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy .", "", +22341, DoseValue, 3089, 3092, "100", "", +22342, mg, 3093, 3095, "mg", "", +22343, Frequency, 3096, 3106, "once daily", "", +22344, Type2Diabetes, 3190, 3205, "type 2 diabetes", "", +22345, Precondition, 3206, 3297, "who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy", "", +22346, Glimepiride, 3248, 3259, "glimepiride", "", +22347, Glimepiride, 3263, 3274, "glimepiride", "", +22348, Metformin, 3280, 3289, "metformin", "", +22354, ConclusionComment, 3300, 3503, "The addition of sitagliptin was generally well tolerated , with a modest increase in hypoglycaemia and body weight , consistent with glimepiride therapy and the observed degree of glycaemic improvement .", "", +22349, Sitagliptin, 3316, 3327, "sitagliptin", "", +22350, Hypoglycemia, 3385, 3398, "hypoglycaemia", "", +22351, BodyWeight, 3403, 3414, "body weight", "", +22352, Glimepiride, 3433, 3444, "glimepiride", "", +22355, PMID, 3564, 3572, "17593236", "", diff --git a/data/dm2 17593236_akramersunderbrink.n-triples b/data/dm2 17593236_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17593236_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17593236_export.csv b/data/dm2 17593236_export.csv new file mode 100644 index 0000000..1176e59 --- /dev/null +++ b/data/dm2 17593236_export.csv @@ -0,0 +1,751 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +353, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +353, 1, 2, 2, 9, 13, 9, 13, "Obes" +353, 1, 3, 3, 14, 19, 14, 19, "Metab" +353, 1, 4, 4, 20, 21, 20, 21, "." +353, 2, 1, 5, 0, 4, 22, 26, "2007" +353, 2, 2, 6, 5, 8, 27, 30, "Sep" +353, 2, 3, 7, 9, 10, 31, 32, ";" +353, 2, 4, 8, 11, 12, 33, 34, "9" +353, 2, 5, 9, 13, 14, 35, 36, "(" +353, 2, 6, 10, 15, 16, 37, 38, "5" +353, 2, 7, 11, 17, 18, 39, 40, ")" +353, 2, 8, 12, 19, 20, 41, 42, ":" +353, 2, 9, 13, 21, 24, 43, 46, "733" +353, 2, 10, 14, 25, 26, 47, 48, "-" +353, 2, 11, 15, 27, 29, 49, 51, "45" +353, 2, 12, 16, 30, 31, 52, 53, "." +353, 3, 1, 17, 0, 4, 54, 58, "Epub" +353, 3, 2, 18, 5, 9, 59, 63, "2007" +353, 3, 3, 19, 10, 13, 64, 67, "Jun" +353, 3, 4, 20, 14, 16, 68, 70, "26" +353, 3, 5, 21, 17, 18, 71, 72, "." +353, 4, 1, 22, 0, 8, 73, 81, "Efficacy" +353, 4, 2, 23, 9, 12, 82, 85, "and" +353, 4, 3, 24, 13, 19, 86, 92, "safety" +353, 4, 4, 25, 20, 22, 93, 95, "of" +353, 4, 5, 26, 23, 26, 96, 99, "the" +353, 4, 6, 27, 27, 37, 100, 110, "dipeptidyl" +353, 4, 7, 28, 38, 47, 111, 120, "peptidase" +353, 4, 8, 29, 48, 49, 121, 122, "-" +353, 4, 9, 30, 50, 51, 123, 124, "4" +353, 4, 10, 31, 52, 61, 125, 134, "inhibitor" +353, 4, 11, 32, 62, 63, 135, 136, "," +353, 4, 12, 33, 64, 75, 137, 148, "sitagliptin" +353, 4, 13, 34, 76, 77, 149, 150, "," +353, 4, 14, 35, 78, 80, 151, 153, "in" +353, 4, 15, 36, 81, 89, 154, 162, "patients" +353, 4, 16, 37, 90, 94, 163, 167, "with" +353, 4, 17, 38, 95, 99, 168, 172, "type" +353, 4, 18, 39, 100, 101, 173, 174, "2" +353, 4, 19, 40, 102, 110, 175, 183, "diabetes" +353, 4, 20, 41, 111, 119, 184, 192, "mellitus" +353, 4, 21, 42, 120, 132, 193, 205, "inadequately" +353, 4, 22, 43, 133, 143, 206, 216, "controlled" +353, 4, 23, 44, 144, 146, 217, 219, "on" +353, 4, 24, 45, 147, 158, 220, 231, "glimepiride" +353, 4, 25, 46, 159, 164, 232, 237, "alone" +353, 4, 26, 47, 165, 167, 238, 240, "or" +353, 4, 27, 48, 168, 170, 241, 243, "on" +353, 4, 28, 49, 171, 182, 244, 255, "glimepiride" +353, 4, 29, 50, 183, 186, 256, 259, "and" +353, 4, 30, 51, 187, 196, 260, 269, "metformin" +353, 4, 31, 52, 197, 198, 270, 271, "." +353, 5, 1, 53, 0, 9, 272, 281, "Hermansen" +353, 5, 2, 54, 10, 11, 282, 283, "K" +353, 5, 3, 55, 12, 13, 284, 285, "(" +353, 5, 4, 56, 14, 15, 286, 287, "1" +353, 5, 5, 57, 16, 17, 288, 289, ")" +353, 5, 6, 58, 18, 19, 290, 291, "," +353, 5, 7, 59, 20, 26, 292, 298, "Kipnes" +353, 5, 8, 60, 27, 28, 299, 300, "M" +353, 5, 9, 61, 29, 30, 301, 302, "," +353, 5, 10, 62, 31, 34, 303, 306, "Luo" +353, 5, 11, 63, 35, 36, 307, 308, "E" +353, 5, 12, 64, 37, 38, 309, 310, "," +353, 5, 13, 65, 39, 46, 311, 318, "Fanurik" +353, 5, 14, 66, 47, 48, 319, 320, "D" +353, 5, 15, 67, 49, 50, 321, 322, "," +353, 5, 16, 68, 51, 58, 323, 330, "Khatami" +353, 5, 17, 69, 59, 60, 331, 332, "H" +353, 5, 18, 70, 61, 62, 333, 334, "," +353, 5, 19, 71, 63, 68, 335, 340, "Stein" +353, 5, 20, 72, 69, 70, 341, 342, "P" +353, 5, 21, 73, 71, 72, 343, 344, ";" +353, 5, 22, 74, 73, 84, 345, 356, "Sitagliptin" +353, 5, 23, 75, 85, 90, 357, 362, "Study" +353, 5, 24, 76, 91, 94, 363, 366, "035" +353, 5, 25, 77, 95, 100, 367, 372, "Group" +353, 5, 26, 78, 101, 102, 373, 374, "." +353, 6, 1, 79, 0, 6, 375, 381, "Author" +353, 6, 2, 80, 7, 18, 382, 393, "information" +353, 6, 3, 81, 19, 20, 394, 395, ":" +353, 6, 4, 82, 21, 22, 396, 397, "(" +353, 6, 5, 83, 23, 24, 398, 399, "1" +353, 6, 6, 84, 25, 26, 400, 401, ")" +353, 6, 7, 85, 27, 33, 402, 408, "Aarhus" +353, 6, 8, 86, 34, 44, 409, 419, "University" +353, 6, 9, 87, 45, 53, 420, 428, "Hospital" +353, 6, 10, 88, 54, 55, 429, 430, "," +353, 6, 11, 89, 56, 62, 431, 437, "Aarhus" +353, 6, 12, 90, 63, 64, 438, 439, "," +353, 6, 13, 91, 65, 72, 440, 447, "Denmark" +353, 6, 14, 92, 73, 74, 448, 449, "." +353, 7, 1, 93, 0, 3, 450, 453, "AIM" +353, 7, 2, 94, 4, 5, 454, 455, ":" +353, 7, 3, 95, 6, 8, 456, 458, "To" +353, 7, 4, 96, 9, 15, 459, 465, "assess" +353, 7, 5, 97, 16, 19, 466, 469, "the" +353, 7, 6, 98, 20, 28, 470, 478, "efficacy" +353, 7, 7, 99, 29, 32, 479, 482, "and" +353, 7, 8, 100, 33, 39, 483, 489, "safety" +353, 7, 9, 101, 40, 42, 490, 492, "of" +353, 7, 10, 102, 43, 44, 493, 494, "a" +353, 7, 11, 103, 45, 47, 495, 497, "24" +353, 7, 12, 104, 48, 49, 498, 499, "-" +353, 7, 13, 105, 50, 54, 500, 504, "week" +353, 7, 14, 106, 55, 64, 505, 514, "treatment" +353, 7, 15, 107, 65, 69, 515, 519, "with" +353, 7, 16, 108, 70, 81, 520, 531, "sitagliptin" +353, 7, 17, 109, 82, 83, 532, 533, "," +353, 7, 18, 110, 84, 85, 534, 535, "a" +353, 7, 19, 111, 86, 92, 536, 542, "highly" +353, 7, 20, 112, 93, 102, 543, 552, "selective" +353, 7, 21, 113, 103, 107, 553, 557, "once" +353, 7, 22, 114, 108, 109, 558, 559, "-" +353, 7, 23, 115, 110, 115, 560, 565, "daily" +353, 7, 24, 116, 116, 120, 566, 570, "oral" +353, 7, 25, 117, 121, 131, 571, 581, "dipeptidyl" +353, 7, 26, 118, 132, 141, 582, 591, "peptidase" +353, 7, 27, 119, 142, 143, 592, 593, "-" +353, 7, 28, 120, 144, 145, 594, 595, "4" +353, 7, 29, 121, 146, 147, 596, 597, "(" +353, 7, 30, 122, 148, 151, 598, 601, "DPP" +353, 7, 31, 123, 152, 153, 602, 603, "-" +353, 7, 32, 124, 154, 155, 604, 605, "4" +353, 7, 33, 125, 156, 157, 606, 607, ")" +353, 7, 34, 126, 158, 167, 608, 617, "inhibitor" +353, 7, 35, 127, 168, 169, 618, 619, "," +353, 7, 36, 128, 170, 172, 620, 622, "in" +353, 7, 37, 129, 173, 181, 623, 631, "patients" +353, 7, 38, 130, 182, 186, 632, 636, "with" +353, 7, 39, 131, 187, 191, 637, 641, "type" +353, 7, 40, 132, 192, 193, 642, 643, "2" +353, 7, 41, 133, 194, 202, 644, 652, "diabetes" +353, 7, 42, 134, 203, 206, 653, 656, "who" +353, 7, 43, 135, 207, 210, 657, 660, "had" +353, 7, 44, 136, 211, 221, 661, 671, "inadequate" +353, 7, 45, 137, 222, 231, 672, 681, "glycaemic" +353, 7, 46, 138, 232, 239, 682, 689, "control" +353, 7, 47, 139, 240, 241, 690, 691, "[" +353, 7, 48, 140, 242, 254, 692, 704, "glycosylated" +353, 7, 49, 141, 255, 266, 705, 716, "haemoglobin" +353, 7, 50, 142, 267, 268, 717, 718, "(" +353, 7, 51, 143, 269, 272, 719, 722, "HbA" +353, 7, 52, 144, 273, 274, 723, 724, "(" +353, 7, 53, 145, 275, 277, 725, 727, "1c" +353, 7, 54, 146, 278, 279, 728, 729, ")" +353, 7, 55, 147, 280, 281, 730, 731, ")" +353, 7, 56, 148, 282, 283, 732, 733, ">" +353, 7, 57, 149, 284, 286, 734, 736, "or" +353, 7, 58, 150, 287, 288, 737, 738, "=" +353, 7, 59, 151, 289, 290, 739, 740, "7" +353, 7, 60, 152, 291, 292, 741, 742, "." +353, 7, 61, 153, 293, 294, 743, 744, "5" +353, 7, 62, 154, 295, 296, 745, 746, "%" +353, 7, 63, 155, 297, 300, 747, 750, "and" +353, 7, 64, 156, 301, 302, 751, 752, "<" +353, 7, 65, 157, 303, 305, 753, 755, "or" +353, 7, 66, 158, 306, 307, 756, 757, "=" +353, 7, 67, 159, 308, 310, 758, 760, "10" +353, 7, 68, 160, 311, 312, 761, 762, "." +353, 7, 69, 161, 313, 314, 763, 764, "5" +353, 7, 70, 162, 315, 316, 765, 766, "%" +353, 7, 71, 163, 317, 318, 767, 768, "]" +353, 7, 72, 164, 319, 324, 769, 774, "while" +353, 7, 73, 165, 325, 327, 775, 777, "on" +353, 7, 74, 166, 328, 339, 778, 789, "glimepiride" +353, 7, 75, 167, 340, 345, 790, 795, "alone" +353, 7, 76, 168, 346, 348, 796, 798, "or" +353, 7, 77, 169, 349, 351, 799, 801, "in" +353, 7, 78, 170, 352, 363, 802, 813, "combination" +353, 7, 79, 171, 364, 368, 814, 818, "with" +353, 7, 80, 172, 369, 378, 819, 828, "metformin" +353, 7, 81, 173, 379, 380, 829, 830, "." +353, 8, 1, 174, 0, 7, 831, 838, "METHODS" +353, 8, 2, 175, 8, 9, 839, 840, ":" +353, 8, 3, 176, 10, 15, 841, 846, "After" +353, 8, 4, 177, 16, 17, 847, 848, "a" +353, 8, 5, 178, 18, 27, 849, 858, "screening" +353, 8, 6, 179, 28, 29, 859, 860, "," +353, 8, 7, 180, 30, 34, 861, 865, "diet" +353, 8, 8, 181, 35, 36, 866, 867, "/" +353, 8, 9, 182, 37, 45, 868, 876, "exercise" +353, 8, 10, 183, 46, 49, 877, 880, "run" +353, 8, 11, 184, 50, 51, 881, 882, "-" +353, 8, 12, 185, 52, 54, 883, 885, "in" +353, 8, 13, 186, 55, 58, 886, 889, "and" +353, 8, 14, 187, 59, 63, 890, 894, "drug" +353, 8, 15, 188, 64, 68, 895, 899, "wash" +353, 8, 16, 189, 69, 70, 900, 901, "-" +353, 8, 17, 190, 71, 74, 902, 905, "off" +353, 8, 18, 191, 75, 81, 906, 912, "period" +353, 8, 19, 192, 82, 83, 913, 914, "," +353, 8, 20, 193, 84, 85, 915, 916, "a" +353, 8, 21, 194, 86, 97, 917, 928, "glimepiride" +353, 8, 22, 195, 98, 99, 929, 930, "+" +353, 8, 23, 196, 100, 101, 931, 932, "/" +353, 8, 24, 197, 102, 103, 933, 934, "-" +353, 8, 25, 198, 104, 113, 935, 944, "metformin" +353, 8, 26, 199, 114, 118, 945, 949, "dose" +353, 8, 27, 200, 119, 128, 950, 959, "titration" +353, 8, 28, 201, 129, 130, 960, 961, "/" +353, 8, 29, 202, 131, 144, 962, 975, "stabilization" +353, 8, 30, 203, 145, 151, 976, 982, "period" +353, 8, 31, 204, 152, 155, 983, 986, "and" +353, 8, 32, 205, 156, 157, 987, 988, "a" +353, 8, 33, 206, 158, 159, 989, 990, "2" +353, 8, 34, 207, 160, 161, 991, 992, "-" +353, 8, 35, 208, 162, 166, 993, 997, "week" +353, 8, 36, 209, 167, 168, 998, 999, "," +353, 8, 37, 210, 169, 175, 1000, 1006, "single" +353, 8, 38, 211, 176, 177, 1007, 1008, "-" +353, 8, 39, 212, 178, 183, 1009, 1014, "blind" +353, 8, 40, 213, 184, 191, 1015, 1022, "placebo" +353, 8, 41, 214, 192, 195, 1023, 1026, "run" +353, 8, 42, 215, 196, 197, 1027, 1028, "-" +353, 8, 43, 216, 198, 200, 1029, 1031, "in" +353, 8, 44, 217, 201, 202, 1032, 1033, "," +353, 8, 45, 218, 203, 206, 1034, 1037, "441" +353, 8, 46, 219, 207, 215, 1038, 1046, "patients" +353, 8, 47, 220, 216, 217, 1047, 1048, "(" +353, 8, 48, 221, 218, 220, 1049, 1051, "of" +353, 8, 49, 222, 221, 225, 1052, 1056, "ages" +353, 8, 50, 223, 226, 228, 1057, 1059, "18" +353, 8, 51, 224, 229, 230, 1060, 1061, "-" +353, 8, 52, 225, 231, 233, 1062, 1064, "75" +353, 8, 53, 226, 234, 239, 1065, 1070, "years" +353, 8, 54, 227, 240, 241, 1071, 1072, ")" +353, 8, 55, 228, 242, 246, 1073, 1077, "were" +353, 8, 56, 229, 247, 257, 1078, 1088, "randomized" +353, 8, 57, 230, 258, 260, 1089, 1091, "to" +353, 8, 58, 231, 261, 268, 1092, 1099, "receive" +353, 8, 59, 232, 269, 272, 1100, 1103, "the" +353, 8, 60, 233, 273, 281, 1104, 1112, "addition" +353, 8, 61, 234, 282, 284, 1113, 1115, "of" +353, 8, 62, 235, 285, 296, 1116, 1127, "sitagliptin" +353, 8, 63, 236, 297, 300, 1128, 1131, "100" +353, 8, 64, 237, 301, 303, 1132, 1134, "mg" +353, 8, 65, 238, 304, 308, 1135, 1139, "once" +353, 8, 66, 239, 309, 314, 1140, 1145, "daily" +353, 8, 67, 240, 315, 317, 1146, 1148, "or" +353, 8, 68, 241, 318, 325, 1149, 1156, "placebo" +353, 8, 69, 242, 326, 328, 1157, 1159, "in" +353, 8, 70, 243, 329, 330, 1160, 1161, "a" +353, 8, 71, 244, 331, 332, 1162, 1163, "1" +353, 8, 72, 245, 333, 334, 1164, 1165, ":" +353, 8, 73, 246, 335, 336, 1166, 1167, "1" +353, 8, 74, 247, 337, 342, 1168, 1173, "ratio" +353, 8, 75, 248, 343, 346, 1174, 1177, "for" +353, 8, 76, 249, 347, 349, 1178, 1180, "24" +353, 8, 77, 250, 350, 355, 1181, 1186, "weeks" +353, 8, 78, 251, 356, 357, 1187, 1188, "." +353, 9, 1, 252, 0, 2, 1189, 1191, "Of" +353, 9, 2, 253, 3, 8, 1192, 1197, "these" +353, 9, 3, 254, 9, 17, 1198, 1206, "patients" +353, 9, 4, 255, 18, 19, 1207, 1208, "," +353, 9, 5, 256, 20, 23, 1209, 1212, "212" +353, 9, 6, 257, 24, 28, 1213, 1217, "were" +353, 9, 7, 258, 29, 31, 1218, 1220, "on" +353, 9, 8, 259, 32, 43, 1221, 1232, "glimepiride" +353, 9, 9, 260, 44, 45, 1233, 1234, "(" +353, 9, 10, 261, 46, 47, 1235, 1236, ">" +353, 9, 11, 262, 48, 50, 1237, 1239, "or" +353, 9, 12, 263, 51, 52, 1240, 1241, "=" +353, 9, 13, 264, 53, 54, 1242, 1243, "4" +353, 9, 14, 265, 55, 57, 1244, 1246, "mg" +353, 9, 15, 266, 58, 59, 1247, 1248, "/" +353, 9, 16, 267, 60, 63, 1249, 1252, "day" +353, 9, 17, 268, 64, 65, 1253, 1254, ")" +353, 9, 18, 269, 66, 77, 1255, 1266, "monotherapy" +353, 9, 19, 270, 78, 81, 1267, 1270, "and" +353, 9, 20, 271, 82, 85, 1271, 1274, "229" +353, 9, 21, 272, 86, 90, 1275, 1279, "were" +353, 9, 22, 273, 91, 93, 1280, 1282, "on" +353, 9, 23, 274, 94, 105, 1283, 1294, "glimepiride" +353, 9, 24, 275, 106, 107, 1295, 1296, "(" +353, 9, 25, 276, 108, 109, 1297, 1298, ">" +353, 9, 26, 277, 110, 112, 1299, 1301, "or" +353, 9, 27, 278, 113, 114, 1302, 1303, "=" +353, 9, 28, 279, 115, 116, 1304, 1305, "4" +353, 9, 29, 280, 117, 119, 1306, 1308, "mg" +353, 9, 30, 281, 120, 121, 1309, 1310, "/" +353, 9, 31, 282, 122, 125, 1311, 1314, "day" +353, 9, 32, 283, 126, 127, 1315, 1316, ")" +353, 9, 33, 284, 128, 132, 1317, 1321, "plus" +353, 9, 34, 285, 133, 142, 1322, 1331, "metformin" +353, 9, 35, 286, 143, 144, 1332, 1333, "(" +353, 9, 36, 287, 145, 146, 1334, 1335, ">" +353, 9, 37, 288, 147, 149, 1336, 1338, "or" +353, 9, 38, 289, 150, 151, 1339, 1340, "=" +353, 9, 39, 290, 152, 153, 1341, 1342, "1" +353, 9, 40, 291, 154, 155, 1343, 1344, "," +353, 9, 41, 292, 156, 159, 1345, 1348, "500" +353, 9, 42, 293, 160, 162, 1349, 1351, "mg" +353, 9, 43, 294, 163, 164, 1352, 1353, "/" +353, 9, 44, 295, 165, 168, 1354, 1357, "day" +353, 9, 45, 296, 169, 170, 1358, 1359, ")" +353, 9, 46, 297, 171, 182, 1360, 1371, "combination" +353, 9, 47, 298, 183, 190, 1372, 1379, "therapy" +353, 9, 48, 299, 191, 192, 1380, 1381, "." +353, 10, 1, 300, 0, 8, 1382, 1390, "Patients" +353, 10, 2, 301, 9, 18, 1391, 1400, "exceeding" +353, 10, 3, 302, 19, 22, 1401, 1404, "pre" +353, 10, 4, 303, 23, 24, 1405, 1406, "-" +353, 10, 5, 304, 25, 34, 1407, 1416, "specified" +353, 10, 6, 305, 35, 44, 1417, 1426, "glycaemic" +353, 10, 7, 306, 45, 55, 1427, 1437, "thresholds" +353, 10, 8, 307, 56, 62, 1438, 1444, "during" +353, 10, 9, 308, 63, 66, 1445, 1448, "the" +353, 10, 10, 309, 67, 73, 1449, 1455, "double" +353, 10, 11, 310, 74, 75, 1456, 1457, "-" +353, 10, 12, 311, 76, 81, 1458, 1463, "blind" +353, 10, 13, 312, 82, 91, 1464, 1473, "treatment" +353, 10, 14, 313, 92, 98, 1474, 1480, "period" +353, 10, 15, 314, 99, 103, 1481, 1485, "were" +353, 10, 16, 315, 104, 112, 1486, 1494, "provided" +353, 10, 17, 316, 113, 117, 1495, 1499, "open" +353, 10, 18, 317, 118, 119, 1500, 1501, "-" +353, 10, 19, 318, 120, 125, 1502, 1507, "label" +353, 10, 20, 319, 126, 132, 1508, 1514, "rescue" +353, 10, 21, 320, 133, 140, 1515, 1522, "therapy" +353, 10, 22, 321, 141, 142, 1523, 1524, "(" +353, 10, 23, 322, 143, 155, 1525, 1537, "pioglitazone" +353, 10, 24, 323, 156, 157, 1538, 1539, ")" +353, 10, 25, 324, 158, 163, 1540, 1545, "until" +353, 10, 26, 325, 164, 169, 1546, 1551, "study" +353, 10, 27, 326, 170, 173, 1552, 1555, "end" +353, 10, 28, 327, 174, 175, 1556, 1557, "." +353, 11, 1, 328, 0, 3, 1558, 1561, "The" +353, 11, 2, 329, 4, 11, 1562, 1569, "primary" +353, 11, 3, 330, 12, 20, 1570, 1578, "efficacy" +353, 11, 4, 331, 21, 29, 1579, 1587, "analysis" +353, 11, 5, 332, 30, 39, 1588, 1597, "evaluated" +353, 11, 6, 333, 40, 43, 1598, 1601, "the" +353, 11, 7, 334, 44, 50, 1602, 1608, "change" +353, 11, 8, 335, 51, 53, 1609, 1611, "in" +353, 11, 9, 336, 54, 57, 1612, 1615, "HbA" +353, 11, 10, 337, 58, 59, 1616, 1617, "(" +353, 11, 11, 338, 60, 62, 1618, 1620, "1c" +353, 11, 12, 339, 63, 64, 1621, 1622, ")" +353, 11, 13, 340, 65, 69, 1623, 1627, "from" +353, 11, 14, 341, 70, 78, 1628, 1636, "baseline" +353, 11, 15, 342, 79, 81, 1637, 1639, "to" +353, 11, 16, 343, 82, 86, 1640, 1644, "Week" +353, 11, 17, 344, 87, 89, 1645, 1647, "24" +353, 11, 18, 345, 90, 91, 1648, 1649, "." +353, 12, 1, 346, 0, 9, 1650, 1659, "Secondary" +353, 12, 2, 347, 10, 18, 1660, 1668, "efficacy" +353, 12, 3, 348, 19, 28, 1669, 1678, "endpoints" +353, 12, 4, 349, 29, 37, 1679, 1687, "included" +353, 12, 5, 350, 38, 45, 1688, 1695, "fasting" +353, 12, 6, 351, 46, 52, 1696, 1702, "plasma" +353, 12, 7, 352, 53, 60, 1703, 1710, "glucose" +353, 12, 8, 353, 61, 62, 1711, 1712, "(" +353, 12, 9, 354, 63, 66, 1713, 1716, "FPG" +353, 12, 10, 355, 67, 68, 1717, 1718, ")" +353, 12, 11, 356, 69, 70, 1719, 1720, "," +353, 12, 12, 357, 71, 72, 1721, 1722, "2" +353, 12, 13, 358, 73, 74, 1723, 1724, "-" +353, 12, 14, 359, 75, 76, 1725, 1726, "h" +353, 12, 15, 360, 77, 81, 1727, 1731, "post" +353, 12, 16, 361, 82, 83, 1732, 1733, "-" +353, 12, 17, 362, 84, 88, 1734, 1738, "meal" +353, 12, 18, 363, 89, 96, 1739, 1746, "glucose" +353, 12, 19, 364, 97, 100, 1747, 1750, "and" +353, 12, 20, 365, 101, 106, 1751, 1756, "lipid" +353, 12, 21, 366, 107, 119, 1757, 1769, "measurements" +353, 12, 22, 367, 120, 121, 1770, 1771, "." +353, 13, 1, 368, 0, 7, 1772, 1779, "RESULTS" +353, 13, 2, 369, 8, 9, 1780, 1781, ":" +353, 13, 3, 370, 10, 14, 1782, 1786, "Mean" +353, 13, 4, 371, 15, 23, 1787, 1795, "baseline" +353, 13, 5, 372, 24, 27, 1796, 1799, "HbA" +353, 13, 6, 373, 28, 29, 1800, 1801, "(" +353, 13, 7, 374, 30, 32, 1802, 1804, "1c" +353, 13, 8, 375, 33, 34, 1805, 1806, ")" +353, 13, 9, 376, 35, 38, 1807, 1810, "was" +353, 13, 10, 377, 39, 40, 1811, 1812, "8" +353, 13, 11, 378, 41, 42, 1813, 1814, "." +353, 13, 12, 379, 43, 45, 1815, 1817, "34" +353, 13, 13, 380, 46, 47, 1818, 1819, "%" +353, 13, 14, 381, 48, 50, 1820, 1822, "in" +353, 13, 15, 382, 51, 54, 1823, 1826, "the" +353, 13, 16, 383, 55, 66, 1827, 1838, "sitagliptin" +353, 13, 17, 384, 67, 70, 1839, 1842, "and" +353, 13, 18, 385, 71, 78, 1843, 1850, "placebo" +353, 13, 19, 386, 79, 85, 1851, 1857, "groups" +353, 13, 20, 387, 86, 87, 1858, 1859, "." +353, 14, 1, 388, 0, 5, 1860, 1865, "After" +353, 14, 2, 389, 6, 8, 1866, 1868, "24" +353, 14, 3, 390, 9, 14, 1869, 1874, "weeks" +353, 14, 4, 391, 15, 16, 1875, 1876, "," +353, 14, 5, 392, 17, 28, 1877, 1888, "sitagliptin" +353, 14, 6, 393, 29, 36, 1889, 1896, "reduced" +353, 14, 7, 394, 37, 40, 1897, 1900, "HbA" +353, 14, 8, 395, 41, 42, 1901, 1902, "(" +353, 14, 9, 396, 43, 45, 1903, 1905, "1c" +353, 14, 10, 397, 46, 47, 1906, 1907, ")" +353, 14, 11, 398, 48, 50, 1908, 1910, "by" +353, 14, 12, 399, 51, 52, 1911, 1912, "0" +353, 14, 13, 400, 53, 54, 1913, 1914, "." +353, 14, 14, 401, 55, 57, 1915, 1917, "74" +353, 14, 15, 402, 58, 59, 1918, 1919, "%" +353, 14, 16, 403, 60, 61, 1920, 1921, "(" +353, 14, 17, 404, 62, 63, 1922, 1923, "p" +353, 14, 18, 405, 64, 65, 1924, 1925, "<" +353, 14, 19, 406, 66, 67, 1926, 1927, "0" +353, 14, 20, 407, 68, 69, 1928, 1929, "." +353, 14, 21, 408, 70, 73, 1930, 1933, "001" +353, 14, 22, 409, 74, 75, 1934, 1935, ")" +353, 14, 23, 410, 76, 84, 1936, 1944, "relative" +353, 14, 24, 411, 85, 87, 1945, 1947, "to" +353, 14, 25, 412, 88, 95, 1948, 1955, "placebo" +353, 14, 26, 413, 96, 97, 1956, 1957, "." +353, 15, 1, 414, 0, 2, 1958, 1960, "In" +353, 15, 2, 415, 3, 6, 1961, 1964, "the" +353, 15, 3, 416, 7, 13, 1965, 1971, "subset" +353, 15, 4, 417, 14, 16, 1972, 1974, "of" +353, 15, 5, 418, 17, 25, 1975, 1983, "patients" +353, 15, 6, 419, 26, 28, 1984, 1986, "on" +353, 15, 7, 420, 29, 40, 1987, 1998, "glimepiride" +353, 15, 8, 421, 41, 45, 1999, 2003, "plus" +353, 15, 9, 422, 46, 55, 2004, 2013, "metformin" +353, 15, 10, 423, 56, 57, 2014, 2015, "," +353, 15, 11, 424, 58, 69, 2016, 2027, "sitagliptin" +353, 15, 12, 425, 70, 77, 2028, 2035, "reduced" +353, 15, 13, 426, 78, 81, 2036, 2039, "HbA" +353, 15, 14, 427, 82, 83, 2040, 2041, "(" +353, 15, 15, 428, 84, 86, 2042, 2044, "1c" +353, 15, 16, 429, 87, 88, 2045, 2046, ")" +353, 15, 17, 430, 89, 91, 2047, 2049, "by" +353, 15, 18, 431, 92, 93, 2050, 2051, "0" +353, 15, 19, 432, 94, 95, 2052, 2053, "." +353, 15, 20, 433, 96, 98, 2054, 2056, "89" +353, 15, 21, 434, 99, 100, 2057, 2058, "%" +353, 15, 22, 435, 101, 109, 2059, 2067, "relative" +353, 15, 23, 436, 110, 112, 2068, 2070, "to" +353, 15, 24, 437, 113, 120, 2071, 2078, "placebo" +353, 15, 25, 438, 121, 122, 2079, 2080, "," +353, 15, 26, 439, 123, 131, 2081, 2089, "compared" +353, 15, 27, 440, 132, 136, 2090, 2094, "with" +353, 15, 28, 441, 137, 138, 2095, 2096, "a" +353, 15, 29, 442, 139, 148, 2097, 2106, "reduction" +353, 15, 30, 443, 149, 151, 2107, 2109, "of" +353, 15, 31, 444, 152, 153, 2110, 2111, "0" +353, 15, 32, 445, 154, 155, 2112, 2113, "." +353, 15, 33, 446, 156, 158, 2114, 2116, "57" +353, 15, 34, 447, 159, 160, 2117, 2118, "%" +353, 15, 35, 448, 161, 163, 2119, 2121, "in" +353, 15, 36, 449, 164, 167, 2122, 2125, "the" +353, 15, 37, 450, 168, 174, 2126, 2132, "subset" +353, 15, 38, 451, 175, 177, 2133, 2135, "of" +353, 15, 39, 452, 178, 186, 2136, 2144, "patients" +353, 15, 40, 453, 187, 189, 2145, 2147, "on" +353, 15, 41, 454, 190, 201, 2148, 2159, "glimepiride" +353, 15, 42, 455, 202, 207, 2160, 2165, "alone" +353, 15, 43, 456, 208, 209, 2166, 2167, "." +353, 16, 1, 457, 0, 3, 2168, 2171, "The" +353, 16, 2, 458, 4, 12, 2172, 2180, "addition" +353, 16, 3, 459, 13, 15, 2181, 2183, "of" +353, 16, 4, 460, 16, 27, 2184, 2195, "sitagliptin" +353, 16, 5, 461, 28, 35, 2196, 2203, "reduced" +353, 16, 6, 462, 36, 39, 2204, 2207, "FPG" +353, 16, 7, 463, 40, 42, 2208, 2210, "by" +353, 16, 8, 464, 43, 45, 2211, 2213, "20" +353, 16, 9, 465, 46, 47, 2214, 2215, "." +353, 16, 10, 466, 48, 49, 2216, 2217, "1" +353, 16, 11, 467, 50, 52, 2218, 2220, "mg" +353, 16, 12, 468, 53, 54, 2221, 2222, "/" +353, 16, 13, 469, 55, 57, 2223, 2225, "dl" +353, 16, 14, 470, 58, 59, 2226, 2227, "(" +353, 16, 15, 471, 60, 61, 2228, 2229, "p" +353, 16, 16, 472, 62, 63, 2230, 2231, "<" +353, 16, 17, 473, 64, 65, 2232, 2233, "0" +353, 16, 18, 474, 66, 67, 2234, 2235, "." +353, 16, 19, 475, 68, 71, 2236, 2239, "001" +353, 16, 20, 476, 72, 73, 2240, 2241, ")" +353, 16, 21, 477, 74, 77, 2242, 2245, "and" +353, 16, 22, 478, 78, 87, 2246, 2255, "increased" +353, 16, 23, 479, 88, 99, 2256, 2267, "homeostasis" +353, 16, 24, 480, 100, 105, 2268, 2273, "model" +353, 16, 25, 481, 106, 116, 2274, 2284, "assessment" +353, 16, 26, 482, 117, 118, 2285, 2286, "-" +353, 16, 27, 483, 119, 123, 2287, 2291, "beta" +353, 16, 28, 484, 124, 125, 2292, 2293, "," +353, 16, 29, 485, 126, 127, 2294, 2295, "a" +353, 16, 30, 486, 128, 134, 2296, 2302, "marker" +353, 16, 31, 487, 135, 137, 2303, 2305, "of" +353, 16, 32, 488, 138, 142, 2306, 2310, "beta" +353, 16, 33, 489, 143, 144, 2311, 2312, "-" +353, 16, 34, 490, 145, 149, 2313, 2317, "cell" +353, 16, 35, 491, 150, 158, 2318, 2326, "function" +353, 16, 36, 492, 159, 160, 2327, 2328, "," +353, 16, 37, 493, 161, 163, 2329, 2331, "by" +353, 16, 38, 494, 164, 166, 2332, 2334, "12" +353, 16, 39, 495, 167, 168, 2335, 2336, "%" +353, 16, 40, 496, 169, 170, 2337, 2338, "(" +353, 16, 41, 497, 171, 172, 2339, 2340, "p" +353, 16, 42, 498, 173, 174, 2341, 2342, "<" +353, 16, 43, 499, 175, 176, 2343, 2344, "0" +353, 16, 44, 500, 177, 178, 2345, 2346, "." +353, 16, 45, 501, 179, 181, 2347, 2349, "05" +353, 16, 46, 502, 182, 183, 2350, 2351, ")" +353, 16, 47, 503, 184, 192, 2352, 2360, "relative" +353, 16, 48, 504, 193, 195, 2361, 2363, "to" +353, 16, 49, 505, 196, 203, 2364, 2371, "placebo" +353, 16, 50, 506, 204, 205, 2372, 2373, "." +353, 17, 1, 507, 0, 2, 2374, 2376, "In" +353, 17, 2, 508, 3, 11, 2377, 2385, "patients" +353, 17, 3, 509, 12, 15, 2386, 2389, "who" +353, 17, 4, 510, 16, 25, 2390, 2399, "underwent" +353, 17, 5, 511, 26, 27, 2400, 2401, "a" +353, 17, 6, 512, 28, 32, 2402, 2406, "meal" +353, 17, 7, 513, 33, 42, 2407, 2416, "tolerance" +353, 17, 8, 514, 43, 47, 2417, 2421, "test" +353, 17, 9, 515, 48, 49, 2422, 2423, "(" +353, 17, 10, 516, 50, 51, 2424, 2425, "n" +353, 17, 11, 517, 52, 53, 2426, 2427, "=" +353, 17, 12, 518, 54, 57, 2428, 2431, "134" +353, 17, 13, 519, 58, 59, 2432, 2433, ")" +353, 17, 14, 520, 60, 61, 2434, 2435, "," +353, 17, 15, 521, 62, 73, 2436, 2447, "sitagliptin" +353, 17, 16, 522, 74, 83, 2448, 2457, "decreased" +353, 17, 17, 523, 84, 85, 2458, 2459, "2" +353, 17, 18, 524, 86, 87, 2460, 2461, "-" +353, 17, 19, 525, 88, 89, 2462, 2463, "h" +353, 17, 20, 526, 90, 94, 2464, 2468, "post" +353, 17, 21, 527, 95, 96, 2469, 2470, "-" +353, 17, 22, 528, 97, 105, 2471, 2479, "prandial" +353, 17, 23, 529, 106, 113, 2480, 2487, "glucose" +353, 17, 24, 530, 114, 115, 2488, 2489, "(" +353, 17, 25, 531, 116, 119, 2490, 2493, "PPG" +353, 17, 26, 532, 120, 121, 2494, 2495, ")" +353, 17, 27, 533, 122, 124, 2496, 2498, "by" +353, 17, 28, 534, 125, 127, 2499, 2501, "36" +353, 17, 29, 535, 128, 129, 2502, 2503, "." +353, 17, 30, 536, 130, 131, 2504, 2505, "1" +353, 17, 31, 537, 132, 134, 2506, 2508, "mg" +353, 17, 32, 538, 135, 136, 2509, 2510, "/" +353, 17, 33, 539, 137, 139, 2511, 2513, "dl" +353, 17, 34, 540, 140, 141, 2514, 2515, "(" +353, 17, 35, 541, 142, 143, 2516, 2517, "p" +353, 17, 36, 542, 144, 145, 2518, 2519, "<" +353, 17, 37, 543, 146, 147, 2520, 2521, "0" +353, 17, 38, 544, 148, 149, 2522, 2523, "." +353, 17, 39, 545, 150, 153, 2524, 2527, "001" +353, 17, 40, 546, 154, 155, 2528, 2529, ")" +353, 17, 41, 547, 156, 164, 2530, 2538, "relative" +353, 17, 42, 548, 165, 167, 2539, 2541, "to" +353, 17, 43, 549, 168, 175, 2542, 2549, "placebo" +353, 17, 44, 550, 176, 177, 2550, 2551, "." +353, 18, 1, 551, 0, 3, 2552, 2555, "The" +353, 18, 2, 552, 4, 12, 2556, 2564, "addition" +353, 18, 3, 553, 13, 15, 2565, 2567, "of" +353, 18, 4, 554, 16, 27, 2568, 2579, "sitagliptin" +353, 18, 5, 555, 28, 31, 2580, 2583, "was" +353, 18, 6, 556, 32, 41, 2584, 2593, "generally" +353, 18, 7, 557, 42, 46, 2594, 2598, "well" +353, 18, 8, 558, 47, 56, 2599, 2608, "tolerated" +353, 18, 9, 559, 57, 58, 2609, 2610, "," +353, 18, 10, 560, 59, 67, 2611, 2619, "although" +353, 18, 11, 561, 68, 73, 2620, 2625, "there" +353, 18, 12, 562, 74, 77, 2626, 2629, "was" +353, 18, 13, 563, 78, 79, 2630, 2631, "a" +353, 18, 14, 564, 80, 86, 2632, 2638, "higher" +353, 18, 15, 565, 87, 96, 2639, 2648, "incidence" +353, 18, 16, 566, 97, 99, 2649, 2651, "of" +353, 18, 17, 567, 100, 107, 2652, 2659, "overall" +353, 18, 18, 568, 108, 109, 2660, 2661, "(" +353, 18, 19, 569, 110, 112, 2662, 2664, "60" +353, 18, 20, 570, 113, 115, 2665, 2667, "vs" +353, 18, 21, 571, 116, 117, 2668, 2669, "." +353, 18, 22, 572, 118, 120, 2670, 2672, "47" +353, 18, 23, 573, 121, 122, 2673, 2674, "%" +353, 18, 24, 574, 123, 124, 2675, 2676, ")" +353, 18, 25, 575, 125, 128, 2677, 2680, "and" +353, 18, 26, 576, 129, 133, 2681, 2685, "drug" +353, 18, 27, 577, 134, 135, 2686, 2687, "-" +353, 18, 28, 578, 136, 143, 2688, 2695, "related" +353, 18, 29, 579, 144, 151, 2696, 2703, "adverse" +353, 18, 30, 580, 152, 163, 2704, 2715, "experiences" +353, 18, 31, 581, 164, 165, 2716, 2717, "(" +353, 18, 32, 582, 166, 169, 2718, 2721, "AEs" +353, 18, 33, 583, 170, 171, 2722, 2723, ")" +353, 18, 34, 584, 172, 173, 2724, 2725, "(" +353, 18, 35, 585, 174, 176, 2726, 2728, "15" +353, 18, 36, 586, 177, 179, 2729, 2731, "vs" +353, 18, 37, 587, 180, 181, 2732, 2733, "." +353, 18, 38, 588, 182, 183, 2734, 2735, "7" +353, 18, 39, 589, 184, 185, 2736, 2737, "%" +353, 18, 40, 590, 186, 187, 2738, 2739, ")" +353, 18, 41, 591, 188, 190, 2740, 2742, "in" +353, 18, 42, 592, 191, 194, 2743, 2746, "the" +353, 18, 43, 593, 195, 206, 2747, 2758, "sitagliptin" +353, 18, 44, 594, 207, 212, 2759, 2764, "group" +353, 18, 45, 595, 213, 217, 2765, 2769, "than" +353, 18, 46, 596, 218, 220, 2770, 2772, "in" +353, 18, 47, 597, 221, 224, 2773, 2776, "the" +353, 18, 48, 598, 225, 232, 2777, 2784, "placebo" +353, 18, 49, 599, 233, 238, 2785, 2790, "group" +353, 18, 50, 600, 239, 240, 2791, 2792, "." +353, 19, 1, 601, 0, 4, 2793, 2797, "This" +353, 19, 2, 602, 5, 8, 2798, 2801, "was" +353, 19, 3, 603, 9, 16, 2802, 2809, "largely" +353, 19, 4, 604, 17, 24, 2810, 2817, "because" +353, 19, 5, 605, 25, 27, 2818, 2820, "of" +353, 19, 6, 606, 28, 29, 2821, 2822, "a" +353, 19, 7, 607, 30, 36, 2823, 2829, "higher" +353, 19, 8, 608, 37, 46, 2830, 2839, "incidence" +353, 19, 9, 609, 47, 49, 2840, 2842, "of" +353, 19, 10, 610, 50, 63, 2843, 2856, "hypoglycaemia" +353, 19, 11, 611, 64, 67, 2857, 2860, "AEs" +353, 19, 12, 612, 68, 69, 2861, 2862, "(" +353, 19, 13, 613, 70, 72, 2863, 2865, "12" +353, 19, 14, 614, 73, 75, 2866, 2868, "vs" +353, 19, 15, 615, 76, 77, 2869, 2870, "." +353, 19, 16, 616, 78, 79, 2871, 2872, "2" +353, 19, 17, 617, 80, 81, 2873, 2874, "%" +353, 19, 18, 618, 82, 83, 2875, 2876, "," +353, 19, 19, 619, 84, 96, 2877, 2889, "respectively" +353, 19, 20, 620, 97, 98, 2890, 2891, ")" +353, 19, 21, 621, 99, 101, 2892, 2894, "in" +353, 19, 22, 622, 102, 105, 2895, 2898, "the" +353, 19, 23, 623, 106, 117, 2899, 2910, "sitagliptin" +353, 19, 24, 624, 118, 123, 2911, 2916, "group" +353, 19, 25, 625, 124, 132, 2917, 2925, "compared" +353, 19, 26, 626, 133, 137, 2926, 2930, "with" +353, 19, 27, 627, 138, 141, 2931, 2934, "the" +353, 19, 28, 628, 142, 149, 2935, 2942, "placebo" +353, 19, 29, 629, 150, 155, 2943, 2948, "group" +353, 19, 30, 630, 156, 157, 2949, 2950, "." +353, 20, 1, 631, 0, 4, 2951, 2955, "Body" +353, 20, 2, 632, 5, 11, 2956, 2962, "weight" +353, 20, 3, 633, 12, 20, 2963, 2971, "modestly" +353, 20, 4, 634, 21, 30, 2972, 2981, "increased" +353, 20, 5, 635, 31, 35, 2982, 2986, "with" +353, 20, 6, 636, 36, 47, 2987, 2998, "sitagliptin" +353, 20, 7, 637, 48, 56, 2999, 3007, "relative" +353, 20, 8, 638, 57, 59, 3008, 3010, "to" +353, 20, 9, 639, 60, 67, 3011, 3018, "placebo" +353, 20, 10, 640, 68, 69, 3019, 3020, "(" +353, 20, 11, 641, 70, 71, 3021, 3022, "+" +353, 20, 12, 642, 72, 73, 3023, 3024, "0" +353, 20, 13, 643, 74, 75, 3025, 3026, "." +353, 20, 14, 644, 76, 77, 3027, 3028, "8" +353, 20, 15, 645, 78, 80, 3029, 3031, "vs" +353, 20, 16, 646, 81, 82, 3032, 3033, "." +353, 20, 17, 647, 83, 84, 3034, 3035, "-" +353, 20, 18, 648, 85, 86, 3036, 3037, "0" +353, 20, 19, 649, 87, 88, 3038, 3039, "." +353, 20, 20, 650, 89, 90, 3040, 3041, "4" +353, 20, 21, 651, 91, 93, 3042, 3044, "kg" +353, 20, 22, 652, 94, 95, 3045, 3046, ";" +353, 20, 23, 653, 96, 97, 3047, 3048, "p" +353, 20, 24, 654, 98, 99, 3049, 3050, "<" +353, 20, 25, 655, 100, 101, 3051, 3052, "0" +353, 20, 26, 656, 102, 103, 3053, 3054, "." +353, 20, 27, 657, 104, 107, 3055, 3058, "001" +353, 20, 28, 658, 108, 109, 3059, 3060, ")" +353, 20, 29, 659, 110, 111, 3061, 3062, "." +353, 21, 1, 660, 0, 11, 3063, 3074, "CONCLUSIONS" +353, 21, 2, 661, 12, 13, 3075, 3076, ":" +353, 21, 3, 662, 14, 25, 3077, 3088, "Sitagliptin" +353, 21, 4, 663, 26, 29, 3089, 3092, "100" +353, 21, 5, 664, 30, 32, 3093, 3095, "mg" +353, 21, 6, 665, 33, 37, 3096, 3100, "once" +353, 21, 7, 666, 38, 43, 3101, 3106, "daily" +353, 21, 8, 667, 44, 57, 3107, 3120, "significantly" +353, 21, 9, 668, 58, 66, 3121, 3129, "improved" +353, 21, 10, 669, 67, 76, 3130, 3139, "glycaemic" +353, 21, 11, 670, 77, 84, 3140, 3147, "control" +353, 21, 12, 671, 85, 88, 3148, 3151, "and" +353, 21, 13, 672, 89, 93, 3152, 3156, "beta" +353, 21, 14, 673, 94, 95, 3157, 3158, "-" +353, 21, 15, 674, 96, 100, 3159, 3163, "cell" +353, 21, 16, 675, 101, 109, 3164, 3172, "function" +353, 21, 17, 676, 110, 112, 3173, 3175, "in" +353, 21, 18, 677, 113, 121, 3176, 3184, "patients" +353, 21, 19, 678, 122, 126, 3185, 3189, "with" +353, 21, 20, 679, 127, 131, 3190, 3194, "type" +353, 21, 21, 680, 132, 133, 3195, 3196, "2" +353, 21, 22, 681, 134, 142, 3197, 3205, "diabetes" +353, 21, 23, 682, 143, 146, 3206, 3209, "who" +353, 21, 24, 683, 147, 150, 3210, 3213, "had" +353, 21, 25, 684, 151, 161, 3214, 3224, "inadequate" +353, 21, 26, 685, 162, 171, 3225, 3234, "glycaemic" +353, 21, 27, 686, 172, 179, 3235, 3242, "control" +353, 21, 28, 687, 180, 184, 3243, 3247, "with" +353, 21, 29, 688, 185, 196, 3248, 3259, "glimepiride" +353, 21, 30, 689, 197, 199, 3260, 3262, "or" +353, 21, 31, 690, 200, 211, 3263, 3274, "glimepiride" +353, 21, 32, 691, 212, 216, 3275, 3279, "plus" +353, 21, 33, 692, 217, 226, 3280, 3289, "metformin" +353, 21, 34, 693, 227, 234, 3290, 3297, "therapy" +353, 21, 35, 694, 235, 236, 3298, 3299, "." +353, 22, 1, 695, 0, 3, 3300, 3303, "The" +353, 22, 2, 696, 4, 12, 3304, 3312, "addition" +353, 22, 3, 697, 13, 15, 3313, 3315, "of" +353, 22, 4, 698, 16, 27, 3316, 3327, "sitagliptin" +353, 22, 5, 699, 28, 31, 3328, 3331, "was" +353, 22, 6, 700, 32, 41, 3332, 3341, "generally" +353, 22, 7, 701, 42, 46, 3342, 3346, "well" +353, 22, 8, 702, 47, 56, 3347, 3356, "tolerated" +353, 22, 9, 703, 57, 58, 3357, 3358, "," +353, 22, 10, 704, 59, 63, 3359, 3363, "with" +353, 22, 11, 705, 64, 65, 3364, 3365, "a" +353, 22, 12, 706, 66, 72, 3366, 3372, "modest" +353, 22, 13, 707, 73, 81, 3373, 3381, "increase" +353, 22, 14, 708, 82, 84, 3382, 3384, "in" +353, 22, 15, 709, 85, 98, 3385, 3398, "hypoglycaemia" +353, 22, 16, 710, 99, 102, 3399, 3402, "and" +353, 22, 17, 711, 103, 107, 3403, 3407, "body" +353, 22, 18, 712, 108, 114, 3408, 3414, "weight" +353, 22, 19, 713, 115, 116, 3415, 3416, "," +353, 22, 20, 714, 117, 127, 3417, 3427, "consistent" +353, 22, 21, 715, 128, 132, 3428, 3432, "with" +353, 22, 22, 716, 133, 144, 3433, 3444, "glimepiride" +353, 22, 23, 717, 145, 152, 3445, 3452, "therapy" +353, 22, 24, 718, 153, 156, 3453, 3456, "and" +353, 22, 25, 719, 157, 160, 3457, 3460, "the" +353, 22, 26, 720, 161, 169, 3461, 3469, "observed" +353, 22, 27, 721, 170, 176, 3470, 3476, "degree" +353, 22, 28, 722, 177, 179, 3477, 3479, "of" +353, 22, 29, 723, 180, 189, 3480, 3489, "glycaemic" +353, 22, 30, 724, 190, 201, 3490, 3501, "improvement" +353, 22, 31, 725, 202, 203, 3502, 3503, "." +353, 23, 1, 726, 0, 3, 3504, 3507, "DOI" +353, 23, 2, 727, 4, 5, 3508, 3509, ":" +353, 23, 3, 728, 6, 8, 3510, 3512, "10" +353, 23, 4, 729, 9, 10, 3513, 3514, "." +353, 23, 5, 730, 11, 15, 3515, 3519, "1111" +353, 23, 6, 731, 16, 17, 3520, 3521, "/" +353, 23, 7, 732, 18, 19, 3522, 3523, "j" +353, 23, 8, 733, 20, 21, 3524, 3525, "." +353, 23, 9, 734, 22, 26, 3526, 3530, "1463" +353, 23, 10, 735, 27, 28, 3531, 3532, "-" +353, 23, 11, 736, 29, 33, 3533, 3537, "1326" +353, 23, 12, 737, 34, 35, 3538, 3539, "." +353, 23, 13, 738, 36, 40, 3540, 3544, "2007" +353, 23, 14, 739, 41, 42, 3545, 3546, "." +353, 23, 15, 740, 43, 48, 3547, 3552, "00744" +353, 23, 16, 741, 49, 50, 3553, 3554, "." +353, 23, 17, 742, 51, 52, 3555, 3556, "x" +353, 23, 18, 743, 53, 57, 3557, 3561, "PMID" +353, 23, 19, 744, 58, 59, 3562, 3563, ":" +353, 23, 20, 745, 60, 68, 3564, 3572, "17593236" +353, 23, 21, 746, 69, 70, 3573, 3574, "[" +353, 23, 22, 747, 71, 78, 3575, 3582, "Indexed" +353, 23, 23, 748, 79, 82, 3583, 3586, "for" +353, 23, 24, 749, 83, 90, 3587, 3594, "MEDLINE" +353, 23, 25, 750, 91, 92, 3595, 3596, "]" diff --git a/data/dm2 17593236_kwoodley.annodb b/data/dm2 17593236_kwoodley.annodb new file mode 100644 index 0000000..ebe6b94 --- /dev/null +++ b/data/dm2 17593236_kwoodley.annodb @@ -0,0 +1,150 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32289, Journal, 0, 21, "Diabetes Obes Metab .", "", +5286, PublicationYear, 22, 26, "2007", "", +5287, PublicationYear, 59, 63, "2007", "", +32290, Title, 73, 271, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin .", "", +5288, Sitagliptin, 137, 148, "sitagliptin", "", +5295, Precondition, 154, 269, "patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin", "", +5290, Type2Diabetes, 168, 192, "type 2 diabetes mellitus", "", +5292, Glimepiride, 220, 231, "glimepiride", "", +5293, Glimepiride, 244, 255, "glimepiride", "", +5294, Metformin, 260, 269, "metformin", "", +5297, Author, 272, 283, "Hermansen K", "", +5298, Author, 292, 300, "Kipnes M", "", +5299, Author, 303, 308, "Luo E", "", +5300, Author, 311, 320, "Fanurik D", "", +5301, Author, 323, 332, "Khatami H", "", +5302, Author, 335, 342, "Stein P", "", +5303, Country, 440, 447, "Denmark", "", +32292, ObjectiveDescription, 456, 619, "To assess the efficacy and safety of a 24 - week treatment with sitagliptin , a highly selective once - daily oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor ,", "", +5304, Duration, 495, 504, "24 - week", "", +5305, Sitagliptin, 520, 531, "sitagliptin", "", +5306, Frequency, 553, 565, "once - daily", "", +5308, Oral, 566, 570, "oral", "", +32291, ObjectiveDescription, 620, 830, "in patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin .", "", +5316, Precondition, 623, 828, "patients with type 2 diabetes who had inadequate glycaemic control [ glycosylated haemoglobin ( HbA ( 1c ) ) > or = 7 . 5 % and < or = 10 . 5 % ] while on glimepiride alone or in combination with metformin", "", +5309, Type2Diabetes, 637, 652, "type 2 diabetes", "", +5310, HbA1c, 692, 716, "glycosylated haemoglobin", "", +5311, HbA1c, 719, 729, "HbA ( 1c )", "", +5312, Percentage, 745, 746, "%", "", +5313, Percentage, 765, 766, "%", "", +5314, Glimepiride, 778, 789, "glimepiride", "", +5315, Metformin, 819, 828, "metformin", "", +5319, Glimepiride, 917, 928, "glimepiride", "", +5320, Metformin, 935, 944, "metformin", "", +5321, Placebo, 1015, 1022, "placebo", "", +5322, NumberPatientsCT, 1034, 1037, "441", "", +5323, MinAge, 1057, 1059, "18", "", +5324, MaxAge, 1062, 1064, "75", "", +5448, Randomized, 1078, 1088, "randomized", "", +5328, Sitagliptin, 1116, 1127, "sitagliptin", "", +5329, DoseValue, 1128, 1131, "100", "", +5330, mg, 1132, 1134, "mg", "", +5331, Frequency, 1135, 1145, "once daily", "", +5333, Placebo, 1149, 1156, "placebo", "", +5334, AllocationRatio, 1162, 1173, "1 : 1 ratio", "", +5335, Duration, 1178, 1186, "24 weeks", "", +5336, NumberPatientsArm, 1209, 1212, "212", "", +5337, Glimepiride, 1221, 1232, "glimepiride", "", +5338, DoseValue, 1235, 1243, "> or = 4", "", +5339, mg, 1244, 1246, "mg", "", +32295, Frequency, 1249, 1252, "day", "", +5341, NumberPatientsArm, 1271, 1274, "229", "", +5342, Glimepiride, 1283, 1294, "glimepiride", "", +5344, DoseValue, 1297, 1305, "> or = 4", "", +5345, mg, 1306, 1308, "mg", "", +32296, Frequency, 1311, 1314, "day", "", +5347, Metformin, 1322, 1331, "metformin", "", +5348, DoseValue, 1334, 1348, "> or = 1 , 500", "", +5349, mg, 1349, 1351, "mg", "", +32297, Frequency, 1354, 1357, "day", "", +5351, DoubleBlind, 1449, 1463, "double - blind", "", +5352, OpenLabel, 1495, 1507, "open - label", "", +5353, Pioglitazone, 1525, 1537, "pioglitazone", "", +5354, HbA1c, 1612, 1622, "HbA ( 1c )", "", +32298, TimePoint, 1628, 1636, "baseline", "", +32299, TimePoint, 1640, 1647, "Week 24", "", +5355, FastingPlasmaGlucose, 1688, 1710, "fasting plasma glucose", "", +5356, FastingPlasmaGlucose, 1713, 1716, "FPG", "", +32300, PostprandialBloodGlucose, 1721, 1746, "2 - h post - meal glucose", "", +5360, EndPointDescription, 1751, 1769, "lipid measurements", "lipid ", +5361, HbA1c, 1796, 1806, "HbA ( 1c )", "", +5362, BaseLineValue, 1811, 1817, "8 . 34", "", +5363, Percentage, 1818, 1819, "%", "", +5364, Sitagliptin, 1827, 1838, "sitagliptin", "", +5365, Placebo, 1843, 1850, "placebo", "", +5366, Duration, 1866, 1874, "24 weeks", "", +5367, Sitagliptin, 1877, 1888, "sitagliptin", "", +5368, HbA1c, 1897, 1907, "HbA ( 1c )", "", +5369, Reduction, 1911, 1917, "0 . 74", "", +5370, Percentage, 1918, 1919, "%", "", +5371, PValueChangeValue, 1922, 1933, "p < 0 . 001", "", +5372, Placebo, 1948, 1955, "placebo", "", +5375, SubGroupDescription, 1975, 2013, "patients on glimepiride plus metformin", "", +5373, Glimepiride, 1987, 1998, "glimepiride", "", +5374, Metformin, 2004, 2013, "metformin", "", +5376, Sitagliptin, 2016, 2027, "sitagliptin", "", +5377, HbA1c, 2036, 2046, "HbA ( 1c )", "", +5378, Reduction, 2050, 2056, "0 . 89", "", +5379, Percentage, 2057, 2058, "%", "", +5380, Placebo, 2071, 2078, "placebo", "", +5381, Reduction, 2110, 2116, "0 . 57", "", +5382, Percentage, 2117, 2118, "%", "", +5384, SubGroupDescription, 2136, 2159, "patients on glimepiride", "", +5383, Glimepiride, 2148, 2159, "glimepiride", "", +5385, Sitagliptin, 2184, 2195, "sitagliptin", "", +5386, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +5387, Reduction, 2211, 2217, "20 . 1", "", +5388, Mg_per_deciliter, 2218, 2225, "mg / dl", "", +5389, PValueChangeValue, 2228, 2239, "p < 0 . 001", "", +5390, EndPointDescription, 2256, 2291, "homeostasis model assessment - beta", "", +5391, RelativeIncrement, 2332, 2334, "12", "", +5393, PValueChangeValue, 2339, 2349, "p < 0 . 05", "", +5394, Placebo, 2364, 2371, "placebo", "", +5396, SubGroupDescription, 2377, 2433, "patients who underwent a meal tolerance test ( n = 134 )", "", +5395, MeasurementDevice, 2402, 2421, "meal tolerance test", "", +5397, Sitagliptin, 2436, 2447, "sitagliptin", "", +32301, PostprandialBloodGlucose, 2458, 2487, "2 - h post - prandial glucose", "", +32302, PostprandialBloodGlucose, 2490, 2493, "PPG", "", +5404, Reduction, 2499, 2505, "36 . 1", "", +5405, Mg_per_deciliter, 2506, 2513, "mg / dl", "", +5406, PValueChangeValue, 2516, 2527, "p < 0 . 001", "", +5407, Placebo, 2542, 2549, "placebo", "", +5408, Sitagliptin, 2568, 2579, "sitagliptin", "", +5409, PercentageAffected, 2662, 2664, "60", "", +5410, PercentageAffected, 2670, 2672, "47", "", +32303, SubGroupDescription, 2681, 2695, "drug - related", "", +10305, EndPointDescription, 2696, 2715, "adverse experiences", "", +10306, EndPointDescription, 2718, 2721, "AEs", "", +5415, PercentageAffected, 2726, 2728, "15", "", +5416, PercentageAffected, 2734, 2735, "7", "", +5417, Sitagliptin, 2747, 2758, "sitagliptin", "", +5418, Placebo, 2777, 2784, "placebo", "", +5419, Hypoglycemia, 2843, 2856, "hypoglycaemia", "", +5421, PercentageAffected, 2863, 2865, "12", "", +5422, PercentageAffected, 2871, 2872, "2", "", +5423, Sitagliptin, 2899, 2910, "sitagliptin", "", +5424, Placebo, 2935, 2942, "placebo", "", +5425, BodyWeight, 2951, 2962, "Body weight", "", +5426, Sitagliptin, 2987, 2998, "sitagliptin", "", +5427, Placebo, 3011, 3018, "placebo", "", +5428, Increment, 3023, 3028, "0 . 8", "", +5429, Reduction, 3036, 3041, "0 . 4", "", +5430, Kg, 3042, 3044, "kg", "", +5431, PvalueDiff, 3047, 3058, "p < 0 . 001", "", +32293, ConclusionComment, 3077, 3299, "Sitagliptin 100 mg once daily significantly improved glycaemic control and beta - cell function in patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy .", "", +5432, Sitagliptin, 3077, 3088, "Sitagliptin", "", +5433, DoseValue, 3089, 3092, "100", "", +5434, mg, 3093, 3095, "mg", "", +5435, Frequency, 3096, 3106, "once daily", "", +5440, Precondition, 3176, 3297, "patients with type 2 diabetes who had inadequate glycaemic control with glimepiride or glimepiride plus metformin therapy", "", +5436, Type2Diabetes, 3190, 3205, "type 2 diabetes", "", +5437, Glimepiride, 3248, 3259, "glimepiride", "", +5438, Glimepiride, 3263, 3274, "glimepiride", "", +5439, Metformin, 3280, 3289, "metformin", "", +32294, ConclusionComment, 3300, 3503, "The addition of sitagliptin was generally well tolerated , with a modest increase in hypoglycaemia and body weight , consistent with glimepiride therapy and the observed degree of glycaemic improvement .", "", +5442, Sitagliptin, 3316, 3327, "sitagliptin", "", +5443, Hypoglycemia, 3385, 3398, "hypoglycaemia", "", +5444, BodyWeight, 3403, 3414, "body weight", "", +5445, Glimepiride, 3433, 3444, "glimepiride", "", +5447, PMID, 3564, 3572, "17593236", "", diff --git a/data/dm2 17593236_kwoodley.n-triples b/data/dm2 17593236_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17593236_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17929538_admin.annodb b/data/dm2 17929538_admin.annodb new file mode 100644 index 0000000..7799d3e --- /dev/null +++ b/data/dm2 17929538_admin.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +139, Journal, 0, 19, "Srp Arh Celok Lek .", "", " \"Srp Arh Celok Lek .\"." +0, PublicationYear, 20, 24, "2007", "", " \"2007\"." +140, Title, 64, 187, "[ The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2 ] .", "", " \"[ The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2 ] .\"." +1, Metformin, 80, 89, "metformin", "", +49950, EndPointDescription, 93, 135, "fasting and postprandial insulin secretion", "", +49950, EndPointDescription, 105, 135, "postprandial insulin secretion", "", +2, Insulin, 118, 125, "insulin", "", +4, Precondition, 139, 183, "obese patients with diabetes mellitus type 2", "", +3, Type2Diabetes, 159, 183, "diabetes mellitus type 2", "", +9, Country, 201, 208, "Serbian", "", " . ." +5, Author, 211, 221, "Vukovi ć M", "", " \"Vukovi ć M\"." +6, Author, 224, 235, "Lapcevi ć M", "", " \"Lapcevi ć M\"." +7, Author, 238, 248, "Kalezi ć N", "", " \"Kalezi ć N\"." +8, Author, 251, 266, "Gvozdenovi ć BS", "", " \"Gvozdenovi ć BS\"." +10, Metformin, 333, 342, "metformin", "", +11, Insulin, 379, 386, "insulin", "", +142, ObjectiveDescription, 499, 612, "The purpose of the study was to establish the effect of metformin on fasting and postprandial insulin secretion .", "", " \"The purpose of the study was to establish the effect of metformin on fasting and postprandial insulin secretion .\"." +12, Metformin, 555, 564, "metformin", "", +49954, EndPointDescription, 568, 610, "fasting and postprandial insulin secretion", "", +49953, EndPointDescription, 580, 610, "postprandial insulin secretion", "", +146, Insulin, 593, 600, "insulin", "", +13, DoubleBlind, 648, 660, "double blind", "", " ." +14, CTDesign, 663, 673, "controlled", "", " . ." +15, CTDesign, 676, 687, "comparative", "", " . ." +16, Randomized, 690, 700, "randomized", "", " ." +17, Multicenter, 703, 715, "multicentric", "", " ." +19, NumberPatientsArm, 786, 788, "43", "", +20, Metformin, 816, 825, "metformin", "", " ." +21, NumberPatientsArm, 853, 855, "46", "", " \"46\"." +22, Placebo, 876, 883, "placebo", "", " ." +96, Precondition, 922, 1053, "newly diagnosed with diabetes mellitus ( DM ) type 2 , glycaemia < 12 mmol / l , and had the Body Mass Index ( BMI ) > 30 kg / m2 .", "", " \"newly diagnosed with diabetes mellitus ( DM ) type 2 , glycaemia < 12 mmol / l , and had the Body Mass Index ( BMI ) > 30 kg / m2 .\"." +23, Type2Diabetes, 943, 974, "diabetes mellitus ( DM ) type 2", "", " ." +24, Millimoles_per_litre, 992, 1000, "mmol / l", "", +25, BMI, 1015, 1030, "Body Mass Index", "", +26, BMI, 1033, 1036, "BMI", "", +27, Kg_per_squareMeter, 1044, 1051, "kg / m2", "", +148, FastingBloodGlucose, 1103, 1137, "fasting and postprandial glycaemia", "", +149, PostprandialBloodGlucose, 1115, 1137, "postprandial glycaemia", "", +28, HbA1c, 1140, 1164, "glycosylated haemoglobin", "", +29, HbA1c, 1167, 1172, "HbA1c", "", +49960, EndPointDescription, 1183, 1220, "fasting and postprandial insulinaemia", "", +49961, EndPointDescription, 1195, 1220, "postprandial insulinaemia", "", +30, EndPointDescription, 1223, 1235, "blood lipids", "", +34, EndPointDescription, 1244, 1255, "cholesterol", "", +35, EndPointDescription, 1264, 1277, "triglycerides", "", +36, EndPointDescription, 1280, 1295, "HDL cholesterol", "", +37, EndPointDescription, 1302, 1317, "LDL cholesterol", "", +32, EndPointDescription, 1326, 1352, "gamma glutaryl transferase", "", +33, EndPointDescription, 1355, 1358, "GGT", "", +38, BMI, 1369, 1372, "BMI", "", +39, Duration, 1402, 1409, "42 days", "", +49962, EndPointDescription, 1425, 1462, "fasting and postprandial insulinaemia", "", +49963, EndPointDescription, 1437, 1462, "postprandial insulinaemia", "", +49964, EndPointDescription, 1560, 1597, "fasting and postprandial insulinaemia", "", +49965, EndPointDescription, 1572, 1597, "postprandial insulinaemia", "", +42, MeasurementDevice, 1613, 1626, "ANOVA two way", "", " . . . ." +43, MeasurementDevice, 1631, 1644, "ANCOVA method", "", " . . . ." +44, Metformin, 1675, 1684, "metformin", "", +45, Placebo, 1722, 1729, "placebo", "", +114, EndPointDescription, 1764, 1784, "fasting insulinaemia", "", " . ." +46, Duration, 1798, 1807, "six weeks", "", " \"six weeks\"." +47, Type2Diabetes, 1842, 1851, "DM type 2", "", +49, ResultMeasuredValue, 1854, 1862, "24 . 392", "", " \"24 . 392\"." +117, MilliUnits_per_litre, 1863, 1869, "mU / l", "", " ." +52, ResultMeasuredValue, 1875, 1883, "25 . 667", "", " \"25 . 667\"." +118, MilliUnits_per_litre, 1884, 1890, "mU / l", "", +53, BMI, 1917, 1920, "BMI", "", " \"25 . 667\"." +49959, EndPointDescription, 1958, 1978, "fasting insulinaemia", "", +54, PvalueDiff, 1995, 2006, "p < 0 . 001", "", " \"p < 0 . 001\"." +55, BMI, 2065, 2068, "BMI", "", +56, EndPointDescription, 2073, 2076, "GGT", "", +49956, EndPointDescription, 2123, 2148, "postprandial insulinaemia", "", " . ." +57, BMI, 2228, 2231, "BMI", "", +49958, EndPointDescription, 2268, 2293, "postprandial insulinaemia", "", +58, PvalueDiff, 2342, 2352, "p < 0 . 01", "", " \"p < 0 . 01\"." +121, Mean, 2366, 2370, "mean", "", " . ." +122, EndPointDescription, 2382, 2407, "postprandial insulinaemia", "", " . ." +59, Placebo, 2429, 2436, "placebo", "", +60, Metformin, 2473, 2482, "metformin", "", +63, ResultMeasuredValue, 2491, 2499, "44 . 807", "", " \"44 . 807\"." +128, MilliUnits_per_litre, 2500, 2506, "mU / l", "", " ." +64, ResultMeasuredValue, 2512, 2520, "47 . 114", "", " \"47 . 114\"." +127, MilliUnits_per_litre, 2521, 2527, "mU / l", "", +137, ConclusionComment, 2545, 2693, "It can be concluded that , as compared to place - bo , metformin is more efficient in reducing insulin resistance in obese patients with DM type 2 .", "", " \"It can be concluded that , as compared to place - bo , metformin is more efficient in reducing insulin resistance in obese patients with DM type 2 .\"." +65, Placebo, 2587, 2597, "place - bo", "", +66, Metformin, 2600, 2609, "metformin", "", +67, Insulin, 2640, 2647, "insulin", "", +68, Type2Diabetes, 2682, 2691, "DM type 2", "", +138, ConclusionComment, 2694, 2873, "In addition , as compared to placebo , metformin maintains more efficient productive insulin secretion , indicating that metformin protects the pancreas from beta cell depletion .", "", " \"In addition , as compared to placebo , metformin maintains more efficient productive insulin secretion , indicating that metformin protects the pancreas from beta cell depletion .\"." +70, Placebo, 2723, 2730, "placebo", "", +71, Metformin, 2733, 2742, "metformin", "", +49957, EndPointDescription, 2779, 2796, "insulin secretion", "", +72, Insulin, 2779, 2786, "insulin", "", +73, Metformin, 2815, 2824, "metformin", "", +74, PMID, 2881, 2889, "17929538", "", " \"17929538\"." diff --git a/data/dm2 17929538_admin.n-triples b/data/dm2 17929538_admin.n-triples new file mode 100644 index 0000000..1d0834d --- /dev/null +++ b/data/dm2 17929538_admin.n-triples @@ -0,0 +1,128 @@ +# RDF export of group: Publication + . + "Publication " . + "[ The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2 ] ." . + "Vukovi ć M" . + "2007" . + "Srp Arh Celok Lek ." . + "17929538" . + . + "Lapcevi ć M" . + "Kalezi ć N" . + "Gvozdenovi ć BS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The purpose of the study was to establish the effect of metformin on fasting and postprandial insulin secretion ." . + "six weeks" . + . + . + . + "It can be concluded that , as compared to place - bo , metformin is more efficient in reducing insulin resistance in obese patients with DM type 2 ." . + . + . + . + . + . + . + . + . + . + . + . + "In addition , as compared to placebo , metformin maintains more efficient productive insulin secretion , indicating that metformin protects the pancreas from beta cell depletion ." . + . + . +# RDF export of group: Population + . + "Population " . + "newly diagnosed with diabetes mellitus ( DM ) type 2 , glycaemia < 12 mmol / l , and had the Body Mass Index ( BMI ) > 30 kg / m2 ." . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint fi" . + . + . + . + . + . + . + . + . + . + "Endpoint pi" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm m" . + . + . + . + . + . + "Arm p" . + "46" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention m" . + . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication m" . + . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome fi m " . + . + "24 . 392" . + . + "Outcome fi p " . + . + "25 . 667" . + . + "Outcome pi m " . + . + "47 . 114" . + . + "Outcome pi p " . + . + "44 . 807" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups fi" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups pi" . + "p < 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17929538_akramersunderbrink.annodb b/data/dm2 17929538_akramersunderbrink.annodb new file mode 100644 index 0000000..b24501f --- /dev/null +++ b/data/dm2 17929538_akramersunderbrink.annodb @@ -0,0 +1,65 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22459, Journal, 0, 17, "Srp Arh Celok Lek", "", +22460, PublicationYear, 20, 24, "2007", "", +22464, Title, 66, 183, "The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2", "", +22461, Metformin, 80, 89, "metformin", "", +22462, Precondition, 139, 144, "obese", "", +22463, Type2Diabetes, 159, 183, "diabetes mellitus type 2", "", +22465, Author, 211, 221, "Vukovi ć M", "", +22466, Author, 224, 235, "Lapcevi ć M", "", +22467, Author, 238, 248, "Kalezi ć N", "", +22468, Author, 251, 266, "Gvozdenovi ć BS", "", +22469, Metformin, 333, 342, "metformin", "", +22470, Metformin, 555, 564, "metformin", "", +22471, DoubleBlind, 648, 660, "double blind", "", +22472, Randomized, 690, 700, "randomized", "", +22473, Multicenter, 703, 715, "multicentric", "", +22474, NumberPatientsArm, 786, 788, "43", "", +22476, Metformin, 816, 825, "metformin", "", +22475, NumberPatientsArm, 853, 855, "46", "", +22477, Placebo, 876, 883, "placebo", "", +22480, Precondition, 922, 974, "newly diagnosed with diabetes mellitus ( DM ) type 2", "", +22478, Type2Diabetes, 943, 974, "diabetes mellitus ( DM ) type 2", "", +22479, Precondition, 977, 1000, "glycaemia < 12 mmol / l", "", +22485, Millimoles_per_litre, 992, 1000, "mmol / l", "", +22481, Precondition, 1015, 1051, "Body Mass Index ( BMI ) > 30 kg / m2", "", +22482, BMI, 1015, 1030, "Body Mass Index", "", +22483, BMI, 1033, 1036, "BMI", "", +22484, Kg_per_squareMeter, 1044, 1051, "kg / m2", "", +22488, FastingPlasmaGlucose, 1103, 1110, "fasting", "", +22489, InsulinDose, 1115, 1137, "postprandial glycaemia", "", +22487, HbA1c, 1140, 1164, "glycosylated haemoglobin", "", +22486, HbA1c, 1167, 1172, "HbA1c", "", +22490, BMI, 1369, 1372, "BMI", "", +22491, Duration, 1402, 1409, "42 days", "", +22492, Metformin, 1675, 1684, "metformin", "", +22493, Placebo, 1722, 1729, "placebo", "", +22498, EndPointDescription, 1764, 1790, "fasting insulinaemia value", "", +22494, Duration, 1798, 1807, "six weeks", "", +22495, Precondition, 1822, 1827, "obese", "", +22496, Type2Diabetes, 1842, 1851, "DM type 2", "", +22499, ResultMeasuredValue, 1854, 1862, "24 . 392", "", +22501, MilliUnits_per_litre, 1863, 1869, "mU / l", "", +22500, ResultMeasuredValue, 1875, 1883, "25 . 667", "", +22502, MilliUnits_per_litre, 1884, 1890, "mU / l", "", +22497, BMI, 1917, 1920, "BMI", "", +22503, BMI, 2065, 2068, "BMI", "", +22504, BMI, 2228, 2231, "BMI", "", +22505, Mean, 2366, 2370, "mean", "", +22506, EndPointDescription, 2382, 2407, "postprandial insulinaemia", "", +22507, Placebo, 2429, 2436, "placebo", "", +22508, Metformin, 2473, 2482, "metformin", "", +22509, ResultMeasuredValue, 2491, 2499, "44 . 807", "", +22513, MilliUnits_per_litre, 2500, 2506, "mU / l", "", +22510, ResultMeasuredValue, 2512, 2520, "47 . 114", "", +22512, MilliUnits_per_litre, 2521, 2527, "mU / l", "", +22522, ConclusionComment, 2545, 2693, "It can be concluded that , as compared to place - bo , metformin is more efficient in reducing insulin resistance in obese patients with DM type 2 .", "", +22514, Placebo, 2587, 2597, "place - bo", "", +22515, Metformin, 2600, 2609, "metformin", "", +22516, Precondition, 2662, 2667, "obese", "", +22517, Type2Diabetes, 2682, 2691, "DM type 2", "", +22523, ConclusionComment, 2694, 2873, "In addition , as compared to placebo , metformin maintains more efficient productive insulin secretion , indicating that metformin protects the pancreas from beta cell depletion .", "", +22518, Placebo, 2723, 2730, "placebo", "", +22519, Metformin, 2733, 2742, "metformin", "", +22520, Metformin, 2815, 2824, "metformin", "", +22521, PMID, 2881, 2889, "17929538", "", diff --git a/data/dm2 17929538_akramersunderbrink.n-triples b/data/dm2 17929538_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17929538_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17929538_export.csv b/data/dm2 17929538_export.csv new file mode 100644 index 0000000..5e2cca1 --- /dev/null +++ b/data/dm2 17929538_export.csv @@ -0,0 +1,546 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +351, 1, 1, 1, 0, 3, 0, 3, "Srp" +351, 1, 2, 2, 4, 7, 4, 7, "Arh" +351, 1, 3, 3, 8, 13, 8, 13, "Celok" +351, 1, 4, 4, 14, 17, 14, 17, "Lek" +351, 1, 5, 5, 18, 19, 18, 19, "." +351, 2, 1, 6, 0, 4, 20, 24, "2007" +351, 2, 2, 7, 5, 8, 25, 28, "Jul" +351, 2, 3, 8, 9, 10, 29, 30, "-" +351, 2, 4, 9, 11, 14, 31, 34, "Aug" +351, 2, 5, 10, 15, 16, 35, 36, ";" +351, 2, 6, 11, 17, 20, 37, 40, "135" +351, 2, 7, 12, 21, 22, 41, 42, "(" +351, 2, 8, 13, 23, 24, 43, 44, "7" +351, 2, 9, 14, 25, 26, 45, 46, "-" +351, 2, 10, 15, 27, 28, 47, 48, "8" +351, 2, 11, 16, 29, 30, 49, 50, ")" +351, 2, 12, 17, 31, 32, 51, 52, ":" +351, 2, 13, 18, 33, 36, 53, 56, "447" +351, 2, 14, 19, 37, 38, 57, 58, "-" +351, 2, 15, 20, 39, 41, 59, 61, "52" +351, 2, 16, 21, 42, 43, 62, 63, "." +351, 3, 1, 22, 0, 1, 64, 65, "[" +351, 3, 2, 23, 2, 5, 66, 69, "The" +351, 3, 3, 24, 6, 12, 70, 76, "effect" +351, 3, 4, 25, 13, 15, 77, 79, "of" +351, 3, 5, 26, 16, 25, 80, 89, "metformin" +351, 3, 6, 27, 26, 28, 90, 92, "on" +351, 3, 7, 28, 29, 36, 93, 100, "fasting" +351, 3, 8, 29, 37, 40, 101, 104, "and" +351, 3, 9, 30, 41, 53, 105, 117, "postprandial" +351, 3, 10, 31, 54, 61, 118, 125, "insulin" +351, 3, 11, 32, 62, 71, 126, 135, "secretion" +351, 3, 12, 33, 72, 74, 136, 138, "in" +351, 3, 13, 34, 75, 80, 139, 144, "obese" +351, 3, 14, 35, 81, 89, 145, 153, "patients" +351, 3, 15, 36, 90, 94, 154, 158, "with" +351, 3, 16, 37, 95, 103, 159, 167, "diabetes" +351, 3, 17, 38, 104, 112, 168, 176, "mellitus" +351, 3, 18, 39, 113, 117, 177, 181, "type" +351, 3, 19, 40, 118, 119, 182, 183, "2" +351, 3, 20, 41, 120, 121, 184, 185, "]" +351, 3, 21, 42, 122, 123, 186, 187, "." +351, 4, 1, 43, 0, 1, 188, 189, "[" +351, 4, 2, 44, 2, 9, 190, 197, "Article" +351, 4, 3, 45, 10, 12, 198, 200, "in" +351, 4, 4, 46, 13, 20, 201, 208, "Serbian" +351, 4, 5, 47, 21, 22, 209, 210, "]" +351, 4, 6, 48, 23, 29, 211, 217, "Vukovi" +351, 4, 7, 49, 30, 31, 218, 219, "ć" +351, 4, 8, 50, 32, 33, 220, 221, "M" +351, 4, 9, 51, 34, 35, 222, 223, "," +351, 4, 10, 52, 36, 43, 224, 231, "Lapcevi" +351, 4, 11, 53, 44, 45, 232, 233, "ć" +351, 4, 12, 54, 46, 47, 234, 235, "M" +351, 4, 13, 55, 48, 49, 236, 237, "," +351, 4, 14, 56, 50, 56, 238, 244, "Kalezi" +351, 4, 15, 57, 57, 58, 245, 246, "ć" +351, 4, 16, 58, 59, 60, 247, 248, "N" +351, 4, 17, 59, 61, 62, 249, 250, "," +351, 4, 18, 60, 63, 73, 251, 261, "Gvozdenovi" +351, 4, 19, 61, 74, 75, 262, 263, "ć" +351, 4, 20, 62, 76, 78, 264, 266, "BS" +351, 4, 21, 63, 79, 80, 267, 268, "." +351, 5, 1, 64, 0, 12, 269, 281, "INTRODUCTION" +351, 5, 2, 65, 13, 14, 282, 283, ":" +351, 5, 3, 66, 15, 18, 284, 287, "The" +351, 5, 4, 67, 19, 23, 288, 292, "main" +351, 5, 5, 68, 24, 30, 293, 299, "causes" +351, 5, 6, 69, 31, 33, 300, 302, "of" +351, 5, 7, 70, 34, 41, 303, 310, "reduced" +351, 5, 8, 71, 42, 49, 311, 318, "glucose" +351, 5, 9, 72, 50, 56, 319, 325, "levels" +351, 5, 10, 73, 57, 63, 326, 332, "during" +351, 5, 11, 74, 64, 73, 333, 342, "metformin" +351, 5, 12, 75, 74, 81, 343, 350, "therapy" +351, 5, 13, 76, 82, 88, 351, 357, "appear" +351, 5, 14, 77, 89, 91, 358, 360, "to" +351, 5, 15, 78, 92, 94, 361, 363, "be" +351, 5, 16, 79, 95, 97, 364, 366, "an" +351, 5, 17, 80, 98, 106, 367, 375, "increase" +351, 5, 18, 81, 107, 109, 376, 378, "in" +351, 5, 19, 82, 110, 117, 379, 386, "insulin" +351, 5, 20, 83, 118, 124, 387, 393, "action" +351, 5, 21, 84, 125, 127, 394, 396, "in" +351, 5, 22, 85, 128, 138, 397, 407, "peripheral" +351, 5, 23, 86, 139, 146, 408, 415, "tissues" +351, 5, 24, 87, 147, 150, 416, 419, "and" +351, 5, 25, 88, 151, 158, 420, 427, "reduced" +351, 5, 26, 89, 159, 166, 428, 435, "hepatic" +351, 5, 27, 90, 167, 174, 436, 443, "glucose" +351, 5, 28, 91, 175, 181, 444, 450, "output" +351, 5, 29, 92, 182, 185, 451, 454, "due" +351, 5, 30, 93, 186, 188, 455, 457, "to" +351, 5, 31, 94, 189, 199, 458, 468, "inhibition" +351, 5, 32, 95, 200, 215, 469, 484, "gluconeogenesis" +351, 5, 33, 96, 216, 217, 485, 486, "." +351, 6, 1, 97, 0, 9, 487, 496, "OBJECTIVE" +351, 6, 2, 98, 10, 11, 497, 498, ":" +351, 6, 3, 99, 12, 15, 499, 502, "The" +351, 6, 4, 100, 16, 23, 503, 510, "purpose" +351, 6, 5, 101, 24, 26, 511, 513, "of" +351, 6, 6, 102, 27, 30, 514, 517, "the" +351, 6, 7, 103, 31, 36, 518, 523, "study" +351, 6, 8, 104, 37, 40, 524, 527, "was" +351, 6, 9, 105, 41, 43, 528, 530, "to" +351, 6, 10, 106, 44, 53, 531, 540, "establish" +351, 6, 11, 107, 54, 57, 541, 544, "the" +351, 6, 12, 108, 58, 64, 545, 551, "effect" +351, 6, 13, 109, 65, 67, 552, 554, "of" +351, 6, 14, 110, 68, 77, 555, 564, "metformin" +351, 6, 15, 111, 78, 80, 565, 567, "on" +351, 6, 16, 112, 81, 88, 568, 575, "fasting" +351, 6, 17, 113, 89, 92, 576, 579, "and" +351, 6, 18, 114, 93, 105, 580, 592, "postprandial" +351, 6, 19, 115, 106, 113, 593, 600, "insulin" +351, 6, 20, 116, 114, 123, 601, 610, "secretion" +351, 6, 21, 117, 124, 125, 611, 612, "." +351, 7, 1, 118, 0, 6, 613, 619, "METHOD" +351, 7, 2, 119, 7, 8, 620, 621, ":" +351, 7, 3, 120, 9, 12, 622, 625, "The" +351, 7, 4, 121, 13, 18, 626, 631, "study" +351, 7, 5, 122, 19, 26, 632, 639, "carried" +351, 7, 6, 123, 27, 30, 640, 643, "out" +351, 7, 7, 124, 31, 34, 644, 647, "was" +351, 7, 8, 125, 35, 41, 648, 654, "double" +351, 7, 9, 126, 42, 47, 655, 660, "blind" +351, 7, 10, 127, 48, 49, 661, 662, "," +351, 7, 11, 128, 50, 60, 663, 673, "controlled" +351, 7, 12, 129, 61, 62, 674, 675, "," +351, 7, 13, 130, 63, 74, 676, 687, "comparative" +351, 7, 14, 131, 75, 76, 688, 689, "," +351, 7, 15, 132, 77, 87, 690, 700, "randomized" +351, 7, 16, 133, 88, 89, 701, 702, "," +351, 7, 17, 134, 90, 102, 703, 715, "multicentric" +351, 7, 18, 135, 103, 104, 716, 717, "," +351, 7, 19, 136, 105, 114, 718, 727, "including" +351, 7, 20, 137, 115, 118, 728, 731, "two" +351, 7, 21, 138, 119, 125, 732, 738, "groups" +351, 7, 22, 139, 126, 128, 739, 741, "of" +351, 7, 23, 140, 129, 132, 742, 745, "out" +351, 7, 24, 141, 133, 134, 746, 747, "-" +351, 7, 25, 142, 135, 142, 748, 755, "patient" +351, 7, 26, 143, 143, 153, 756, 766, "department" +351, 7, 27, 144, 154, 155, 767, 768, "(" +351, 7, 28, 145, 156, 159, 769, 772, "OPD" +351, 7, 29, 146, 160, 161, 773, 774, ")" +351, 7, 30, 147, 162, 170, 775, 783, "patients" +351, 7, 31, 148, 171, 172, 784, 785, "." +351, 8, 1, 149, 0, 2, 786, 788, "43" +351, 8, 2, 150, 3, 11, 789, 797, "patients" +351, 8, 3, 151, 12, 16, 798, 802, "were" +351, 8, 4, 152, 17, 29, 803, 815, "administered" +351, 8, 5, 153, 30, 39, 816, 825, "metformin" +351, 8, 6, 154, 40, 41, 826, 827, "(" +351, 8, 7, 155, 42, 47, 828, 833, "Tefor" +351, 8, 8, 156, 48, 51, 834, 837, "ICN" +351, 8, 9, 157, 52, 58, 838, 844, "Canada" +351, 8, 10, 158, 59, 60, 845, 846, ")" +351, 8, 11, 159, 61, 62, 847, 848, "," +351, 8, 12, 160, 63, 66, 849, 852, "and" +351, 8, 13, 161, 67, 69, 853, 855, "46" +351, 8, 14, 162, 70, 78, 856, 864, "patients" +351, 8, 15, 163, 79, 83, 865, 869, "were" +351, 8, 16, 164, 84, 89, 870, 875, "given" +351, 8, 17, 165, 90, 97, 876, 883, "placebo" +351, 8, 18, 166, 98, 99, 884, 885, "." +351, 9, 1, 167, 0, 8, 886, 894, "Patients" +351, 9, 2, 168, 9, 17, 895, 903, "enrolled" +351, 9, 3, 169, 18, 20, 904, 906, "in" +351, 9, 4, 170, 21, 24, 907, 910, "the" +351, 9, 5, 171, 25, 30, 911, 916, "study" +351, 9, 6, 172, 31, 35, 917, 921, "were" +351, 9, 7, 173, 36, 41, 922, 927, "newly" +351, 9, 8, 174, 42, 51, 928, 937, "diagnosed" +351, 9, 9, 175, 52, 56, 938, 942, "with" +351, 9, 10, 176, 57, 65, 943, 951, "diabetes" +351, 9, 11, 177, 66, 74, 952, 960, "mellitus" +351, 9, 12, 178, 75, 76, 961, 962, "(" +351, 9, 13, 179, 77, 79, 963, 965, "DM" +351, 9, 14, 180, 80, 81, 966, 967, ")" +351, 9, 15, 181, 82, 86, 968, 972, "type" +351, 9, 16, 182, 87, 88, 973, 974, "2" +351, 9, 17, 183, 89, 90, 975, 976, "," +351, 9, 18, 184, 91, 100, 977, 986, "glycaemia" +351, 9, 19, 185, 101, 102, 987, 988, "<" +351, 9, 20, 186, 103, 105, 989, 991, "12" +351, 9, 21, 187, 106, 110, 992, 996, "mmol" +351, 9, 22, 188, 111, 112, 997, 998, "/" +351, 9, 23, 189, 113, 114, 999, 1000, "l" +351, 9, 24, 190, 115, 116, 1001, 1002, "," +351, 9, 25, 191, 117, 120, 1003, 1006, "and" +351, 9, 26, 192, 121, 124, 1007, 1010, "had" +351, 9, 27, 193, 125, 128, 1011, 1014, "the" +351, 9, 28, 194, 129, 133, 1015, 1019, "Body" +351, 9, 29, 195, 134, 138, 1020, 1024, "Mass" +351, 9, 30, 196, 139, 144, 1025, 1030, "Index" +351, 9, 31, 197, 145, 146, 1031, 1032, "(" +351, 9, 32, 198, 147, 150, 1033, 1036, "BMI" +351, 9, 33, 199, 151, 152, 1037, 1038, ")" +351, 9, 34, 200, 153, 154, 1039, 1040, ">" +351, 9, 35, 201, 155, 157, 1041, 1043, "30" +351, 9, 36, 202, 158, 160, 1044, 1046, "kg" +351, 9, 37, 203, 161, 162, 1047, 1048, "/" +351, 9, 38, 204, 163, 165, 1049, 1051, "m2" +351, 9, 39, 205, 166, 167, 1052, 1053, "." +351, 10, 1, 206, 0, 6, 1054, 1060, "Before" +351, 10, 2, 207, 7, 16, 1061, 1070, "treatment" +351, 10, 3, 208, 17, 18, 1071, 1072, "," +351, 10, 4, 209, 19, 24, 1073, 1078, "blood" +351, 10, 5, 210, 25, 37, 1079, 1091, "biochemistry" +351, 10, 6, 211, 38, 41, 1092, 1095, "was" +351, 10, 7, 212, 42, 46, 1096, 1100, "done" +351, 10, 8, 213, 47, 48, 1101, 1102, ":" +351, 10, 9, 214, 49, 56, 1103, 1110, "fasting" +351, 10, 10, 215, 57, 60, 1111, 1114, "and" +351, 10, 11, 216, 61, 73, 1115, 1127, "postprandial" +351, 10, 12, 217, 74, 83, 1128, 1137, "glycaemia" +351, 10, 13, 218, 84, 85, 1138, 1139, "," +351, 10, 14, 219, 86, 98, 1140, 1152, "glycosylated" +351, 10, 15, 220, 99, 110, 1153, 1164, "haemoglobin" +351, 10, 16, 221, 111, 112, 1165, 1166, "(" +351, 10, 17, 222, 113, 118, 1167, 1172, "HbA1c" +351, 10, 18, 223, 119, 120, 1173, 1174, ")" +351, 10, 19, 224, 121, 126, 1175, 1180, "value" +351, 10, 20, 225, 127, 128, 1181, 1182, "," +351, 10, 21, 226, 129, 136, 1183, 1190, "fasting" +351, 10, 22, 227, 137, 140, 1191, 1194, "and" +351, 10, 23, 228, 141, 153, 1195, 1207, "postprandial" +351, 10, 24, 229, 154, 166, 1208, 1220, "insulinaemia" +351, 10, 25, 230, 167, 168, 1221, 1222, "," +351, 10, 26, 231, 169, 174, 1223, 1228, "blood" +351, 10, 27, 232, 175, 181, 1229, 1235, "lipids" +351, 10, 28, 233, 182, 183, 1236, 1237, "(" +351, 10, 29, 234, 184, 189, 1238, 1243, "total" +351, 10, 30, 235, 190, 201, 1244, 1255, "cholesterol" +351, 10, 31, 236, 202, 203, 1256, 1257, "," +351, 10, 32, 237, 204, 209, 1258, 1263, "total" +351, 10, 33, 238, 210, 223, 1264, 1277, "triglycerides" +351, 10, 34, 239, 224, 225, 1278, 1279, "," +351, 10, 35, 240, 226, 229, 1280, 1283, "HDL" +351, 10, 36, 241, 230, 241, 1284, 1295, "cholesterol" +351, 10, 37, 242, 242, 243, 1296, 1297, "," +351, 10, 38, 243, 244, 247, 1298, 1301, "and" +351, 10, 39, 244, 248, 251, 1302, 1305, "LDL" +351, 10, 40, 245, 252, 263, 1306, 1317, "cholesterol" +351, 10, 41, 246, 264, 265, 1318, 1319, ")" +351, 10, 42, 247, 266, 267, 1320, 1321, "," +351, 10, 43, 248, 268, 271, 1322, 1325, "and" +351, 10, 44, 249, 272, 277, 1326, 1331, "gamma" +351, 10, 45, 250, 278, 286, 1332, 1340, "glutaryl" +351, 10, 46, 251, 287, 298, 1341, 1352, "transferase" +351, 10, 47, 252, 299, 300, 1353, 1354, "(" +351, 10, 48, 253, 301, 304, 1355, 1358, "GGT" +351, 10, 49, 254, 305, 306, 1359, 1360, ")" +351, 10, 50, 255, 307, 312, 1361, 1366, "level" +351, 10, 51, 256, 313, 314, 1367, 1368, "." +351, 11, 1, 257, 0, 3, 1369, 1372, "BMI" +351, 11, 2, 258, 4, 7, 1373, 1376, "was" +351, 11, 3, 259, 8, 12, 1377, 1381, "also" +351, 11, 4, 260, 13, 24, 1382, 1393, "established" +351, 11, 5, 261, 25, 26, 1394, 1395, "." +351, 12, 1, 262, 0, 5, 1396, 1401, "After" +351, 12, 2, 263, 6, 8, 1402, 1404, "42" +351, 12, 3, 264, 9, 13, 1405, 1409, "days" +351, 12, 4, 265, 14, 16, 1410, 1412, "of" +351, 12, 5, 266, 17, 26, 1413, 1422, "treatment" +351, 12, 6, 267, 27, 28, 1423, 1424, "," +351, 12, 7, 268, 29, 36, 1425, 1432, "fasting" +351, 12, 8, 269, 37, 40, 1433, 1436, "and" +351, 12, 9, 270, 41, 53, 1437, 1449, "postprandial" +351, 12, 10, 271, 54, 66, 1450, 1462, "insulinaemia" +351, 12, 11, 272, 67, 71, 1463, 1467, "were" +351, 12, 12, 273, 72, 78, 1468, 1474, "tested" +351, 12, 13, 274, 79, 84, 1475, 1480, "again" +351, 12, 14, 275, 85, 86, 1481, 1482, "." +351, 13, 1, 276, 0, 8, 1483, 1491, "Analysis" +351, 13, 2, 277, 9, 11, 1492, 1494, "of" +351, 13, 3, 278, 12, 15, 1495, 1498, "the" +351, 13, 4, 279, 16, 23, 1499, 1506, "effects" +351, 13, 5, 280, 24, 26, 1507, 1509, "of" +351, 13, 6, 281, 27, 34, 1510, 1517, "therapy" +351, 13, 7, 282, 35, 36, 1518, 1519, "," +351, 13, 8, 283, 37, 40, 1520, 1523, "and" +351, 13, 9, 284, 41, 55, 1524, 1538, "identification" +351, 13, 10, 285, 56, 58, 1539, 1541, "of" +351, 13, 11, 286, 59, 61, 1542, 1544, "co" +351, 13, 12, 287, 62, 63, 1545, 1546, "-" +351, 13, 13, 288, 64, 72, 1547, 1555, "variants" +351, 13, 14, 289, 73, 76, 1556, 1559, "for" +351, 13, 15, 290, 77, 84, 1560, 1567, "fasting" +351, 13, 16, 291, 85, 88, 1568, 1571, "and" +351, 13, 17, 292, 89, 101, 1572, 1584, "postprandial" +351, 13, 18, 293, 102, 114, 1585, 1597, "insulinaemia" +351, 13, 19, 294, 115, 116, 1598, 1599, "," +351, 13, 20, 295, 117, 121, 1600, 1604, "were" +351, 13, 21, 296, 122, 126, 1605, 1609, "done" +351, 13, 22, 297, 127, 129, 1610, 1612, "by" +351, 13, 23, 298, 130, 135, 1613, 1618, "ANOVA" +351, 13, 24, 299, 136, 139, 1619, 1622, "two" +351, 13, 25, 300, 140, 143, 1623, 1626, "way" +351, 13, 26, 301, 144, 147, 1627, 1630, "and" +351, 13, 27, 302, 148, 154, 1631, 1637, "ANCOVA" +351, 13, 28, 303, 155, 161, 1638, 1644, "method" +351, 13, 29, 304, 162, 163, 1645, 1646, "." +351, 14, 1, 305, 0, 7, 1647, 1654, "RESULTS" +351, 14, 2, 306, 8, 9, 1655, 1656, ":" +351, 14, 3, 307, 10, 12, 1657, 1659, "It" +351, 14, 4, 308, 13, 16, 1660, 1663, "was" +351, 14, 5, 309, 17, 22, 1664, 1669, "shown" +351, 14, 6, 310, 23, 27, 1670, 1674, "that" +351, 14, 7, 311, 28, 37, 1675, 1684, "metformin" +351, 14, 8, 312, 38, 49, 1685, 1696, "accompanied" +351, 14, 9, 313, 50, 52, 1697, 1699, "by" +351, 14, 10, 314, 53, 57, 1700, 1704, "diet" +351, 14, 11, 315, 58, 59, 1705, 1706, "," +351, 14, 12, 316, 60, 62, 1707, 1709, "as" +351, 14, 13, 317, 63, 71, 1710, 1718, "compared" +351, 14, 14, 318, 72, 74, 1719, 1721, "to" +351, 14, 15, 319, 75, 82, 1722, 1729, "placebo" +351, 14, 16, 320, 83, 94, 1730, 1741, "accompanied" +351, 14, 17, 321, 95, 97, 1742, 1744, "by" +351, 14, 18, 322, 98, 102, 1745, 1749, "diet" +351, 14, 19, 323, 103, 104, 1750, 1751, "," +351, 14, 20, 324, 105, 112, 1752, 1759, "lowered" +351, 14, 21, 325, 113, 116, 1760, 1763, "the" +351, 14, 22, 326, 117, 124, 1764, 1771, "fasting" +351, 14, 23, 327, 125, 137, 1772, 1784, "insulinaemia" +351, 14, 24, 328, 138, 143, 1785, 1790, "value" +351, 14, 25, 329, 144, 150, 1791, 1797, "during" +351, 14, 26, 330, 151, 154, 1798, 1801, "six" +351, 14, 27, 331, 155, 160, 1802, 1807, "weeks" +351, 14, 28, 332, 161, 163, 1808, 1810, "of" +351, 14, 29, 333, 164, 171, 1811, 1818, "therapy" +351, 14, 30, 334, 172, 174, 1819, 1821, "in" +351, 14, 31, 335, 175, 180, 1822, 1827, "obese" +351, 14, 32, 336, 181, 189, 1828, 1836, "patients" +351, 14, 33, 337, 190, 194, 1837, 1841, "with" +351, 14, 34, 338, 195, 197, 1842, 1844, "DM" +351, 14, 35, 339, 198, 202, 1845, 1849, "type" +351, 14, 36, 340, 203, 204, 1850, 1851, "2" +351, 14, 37, 341, 205, 206, 1852, 1853, "(" +351, 14, 38, 342, 207, 209, 1854, 1856, "24" +351, 14, 39, 343, 210, 211, 1857, 1858, "." +351, 14, 40, 344, 212, 215, 1859, 1862, "392" +351, 14, 41, 345, 216, 218, 1863, 1865, "mU" +351, 14, 42, 346, 219, 220, 1866, 1867, "/" +351, 14, 43, 347, 221, 222, 1868, 1869, "l" +351, 14, 44, 348, 223, 225, 1870, 1872, "vs" +351, 14, 45, 349, 226, 227, 1873, 1874, "." +351, 14, 46, 350, 228, 230, 1875, 1877, "25" +351, 14, 47, 351, 231, 232, 1878, 1879, "." +351, 14, 48, 352, 233, 236, 1880, 1883, "667" +351, 14, 49, 353, 237, 239, 1884, 1886, "mU" +351, 14, 50, 354, 240, 241, 1887, 1888, "/" +351, 14, 51, 355, 242, 243, 1889, 1890, "l" +351, 14, 52, 356, 244, 245, 1891, 1892, ")" +351, 14, 53, 357, 246, 247, 1893, 1894, "," +351, 14, 54, 358, 248, 259, 1895, 1906, "interacting" +351, 14, 55, 359, 260, 264, 1907, 1911, "both" +351, 14, 56, 360, 265, 269, 1912, 1916, "with" +351, 14, 57, 361, 270, 273, 1917, 1920, "BMI" +351, 14, 58, 362, 274, 277, 1921, 1924, "pre" +351, 14, 59, 363, 278, 279, 1925, 1926, "-" +351, 14, 60, 364, 280, 287, 1927, 1934, "therapy" +351, 14, 61, 365, 288, 289, 1935, 1936, "," +351, 14, 62, 366, 290, 293, 1937, 1940, "and" +351, 14, 63, 367, 294, 305, 1941, 1952, "interacting" +351, 14, 64, 368, 306, 310, 1953, 1957, "with" +351, 14, 65, 369, 311, 318, 1958, 1965, "fasting" +351, 14, 66, 370, 319, 331, 1966, 1978, "insulinaemia" +351, 14, 67, 371, 332, 335, 1979, 1982, "pre" +351, 14, 68, 372, 336, 337, 1983, 1984, "-" +351, 14, 69, 373, 338, 345, 1985, 1992, "therapy" +351, 14, 70, 374, 346, 347, 1993, 1994, "(" +351, 14, 71, 375, 348, 349, 1995, 1996, "p" +351, 14, 72, 376, 350, 351, 1997, 1998, "<" +351, 14, 73, 377, 352, 353, 1999, 2000, "0" +351, 14, 74, 378, 354, 355, 2001, 2002, "." +351, 14, 75, 379, 356, 359, 2003, 2006, "001" +351, 14, 76, 380, 360, 361, 2007, 2008, ")" +351, 14, 77, 381, 362, 363, 2009, 2010, "." +351, 15, 1, 382, 0, 1, 2011, 2012, "A" +351, 15, 2, 383, 2, 13, 2013, 2024, "significant" +351, 15, 3, 384, 14, 20, 2025, 2031, "effect" +351, 15, 4, 385, 21, 23, 2032, 2034, "of" +351, 15, 5, 386, 24, 27, 2035, 2038, "the" +351, 15, 6, 387, 28, 39, 2039, 2050, "interaction" +351, 15, 7, 388, 40, 42, 2051, 2053, "of" +351, 15, 8, 389, 43, 53, 2054, 2064, "covariants" +351, 15, 9, 390, 54, 57, 2065, 2068, "BMI" +351, 15, 10, 391, 58, 61, 2069, 2072, "and" +351, 15, 11, 392, 62, 65, 2073, 2076, "GGT" +351, 15, 12, 393, 66, 69, 2077, 2080, "was" +351, 15, 13, 394, 70, 77, 2081, 2088, "defined" +351, 15, 14, 395, 78, 79, 2089, 2090, "." +351, 16, 1, 396, 0, 2, 2091, 2093, "As" +351, 16, 2, 397, 3, 6, 2094, 2097, "for" +351, 16, 3, 398, 7, 10, 2098, 2101, "the" +351, 16, 4, 399, 11, 17, 2102, 2108, "effect" +351, 16, 5, 400, 18, 20, 2109, 2111, "of" +351, 16, 6, 401, 21, 28, 2112, 2119, "therapy" +351, 16, 7, 402, 29, 31, 2120, 2122, "on" +351, 16, 8, 403, 32, 44, 2123, 2135, "postprandial" +351, 16, 9, 404, 45, 57, 2136, 2148, "insulinaemia" +351, 16, 10, 405, 58, 59, 2149, 2150, "," +351, 16, 11, 406, 60, 62, 2151, 2153, "it" +351, 16, 12, 407, 63, 66, 2154, 2157, "was" +351, 16, 13, 408, 67, 72, 2158, 2163, "found" +351, 16, 14, 409, 73, 77, 2164, 2168, "that" +351, 16, 15, 410, 78, 83, 2169, 2174, "there" +351, 16, 16, 411, 84, 87, 2175, 2178, "was" +351, 16, 17, 412, 88, 89, 2179, 2180, "a" +351, 16, 18, 413, 90, 94, 2181, 2185, "high" +351, 16, 19, 414, 95, 106, 2186, 2197, "statistical" +351, 16, 20, 415, 107, 119, 2198, 2210, "significance" +351, 16, 21, 416, 120, 122, 2211, 2213, "of" +351, 16, 22, 417, 123, 126, 2214, 2217, "the" +351, 16, 23, 418, 127, 133, 2218, 2224, "effect" +351, 16, 24, 419, 134, 136, 2225, 2227, "of" +351, 16, 25, 420, 137, 140, 2228, 2231, "BMI" +351, 16, 26, 421, 141, 152, 2232, 2243, "interacting" +351, 16, 27, 422, 153, 157, 2244, 2248, "with" +351, 16, 28, 423, 158, 165, 2249, 2256, "initial" +351, 16, 29, 424, 166, 172, 2257, 2263, "values" +351, 16, 30, 425, 173, 176, 2264, 2267, "for" +351, 16, 31, 426, 177, 189, 2268, 2280, "postprandial" +351, 16, 32, 427, 190, 202, 2281, 2293, "insulinaemia" +351, 16, 33, 428, 203, 209, 2294, 2300, "before" +351, 16, 34, 429, 210, 217, 2301, 2308, "therapy" +351, 16, 35, 430, 218, 219, 2309, 2310, "," +351, 16, 36, 431, 220, 223, 2311, 2314, "and" +351, 16, 37, 432, 224, 235, 2315, 2326, "interacting" +351, 16, 38, 433, 236, 240, 2327, 2331, "with" +351, 16, 39, 434, 241, 248, 2332, 2339, "therapy" +351, 16, 40, 435, 249, 250, 2340, 2341, "(" +351, 16, 41, 436, 251, 252, 2342, 2343, "p" +351, 16, 42, 437, 253, 254, 2344, 2345, "<" +351, 16, 43, 438, 255, 256, 2346, 2347, "0" +351, 16, 44, 439, 257, 258, 2348, 2349, "." +351, 16, 45, 440, 259, 261, 2350, 2352, "01" +351, 16, 46, 441, 262, 263, 2353, 2354, ")" +351, 16, 47, 442, 264, 265, 2355, 2356, "." +351, 17, 1, 443, 0, 8, 2357, 2365, "Adjusted" +351, 17, 2, 444, 9, 13, 2366, 2370, "mean" +351, 17, 3, 445, 14, 20, 2371, 2377, "values" +351, 17, 4, 446, 21, 24, 2378, 2381, "for" +351, 17, 5, 447, 25, 37, 2382, 2394, "postprandial" +351, 17, 6, 448, 38, 50, 2395, 2407, "insulinaemia" +351, 17, 7, 449, 51, 56, 2408, 2413, "after" +351, 17, 8, 450, 57, 64, 2414, 2421, "therapy" +351, 17, 9, 451, 65, 67, 2422, 2424, "in" +351, 17, 10, 452, 68, 71, 2425, 2428, "the" +351, 17, 11, 453, 72, 79, 2429, 2436, "placebo" +351, 17, 12, 454, 80, 85, 2437, 2442, "group" +351, 17, 13, 455, 86, 90, 2443, 2447, "were" +351, 17, 14, 456, 91, 96, 2448, 2453, "lower" +351, 17, 15, 457, 97, 99, 2454, 2456, "as" +351, 17, 16, 458, 100, 108, 2457, 2465, "compared" +351, 17, 17, 459, 109, 111, 2466, 2468, "to" +351, 17, 18, 460, 112, 115, 2469, 2472, "the" +351, 17, 19, 461, 116, 125, 2473, 2482, "metformin" +351, 17, 20, 462, 126, 131, 2483, 2488, "group" +351, 17, 21, 463, 132, 133, 2489, 2490, "(" +351, 17, 22, 464, 134, 136, 2491, 2493, "44" +351, 17, 23, 465, 137, 138, 2494, 2495, "." +351, 17, 24, 466, 139, 142, 2496, 2499, "807" +351, 17, 25, 467, 143, 145, 2500, 2502, "mU" +351, 17, 26, 468, 146, 147, 2503, 2504, "/" +351, 17, 27, 469, 148, 149, 2505, 2506, "l" +351, 17, 28, 470, 150, 152, 2507, 2509, "vs" +351, 17, 29, 471, 153, 154, 2510, 2511, "." +351, 17, 30, 472, 155, 157, 2512, 2514, "47" +351, 17, 31, 473, 158, 159, 2515, 2516, "." +351, 17, 32, 474, 160, 163, 2517, 2520, "114" +351, 17, 33, 475, 164, 166, 2521, 2523, "mU" +351, 17, 34, 476, 167, 168, 2524, 2525, "/" +351, 17, 35, 477, 169, 170, 2526, 2527, "l" +351, 17, 36, 478, 171, 172, 2528, 2529, ")" +351, 17, 37, 479, 173, 174, 2530, 2531, "." +351, 18, 1, 480, 0, 10, 2532, 2542, "CONCLUSION" +351, 18, 2, 481, 11, 12, 2543, 2544, ":" +351, 18, 3, 482, 13, 15, 2545, 2547, "It" +351, 18, 4, 483, 16, 19, 2548, 2551, "can" +351, 18, 5, 484, 20, 22, 2552, 2554, "be" +351, 18, 6, 485, 23, 32, 2555, 2564, "concluded" +351, 18, 7, 486, 33, 37, 2565, 2569, "that" +351, 18, 8, 487, 38, 39, 2570, 2571, "," +351, 18, 9, 488, 40, 42, 2572, 2574, "as" +351, 18, 10, 489, 43, 51, 2575, 2583, "compared" +351, 18, 11, 490, 52, 54, 2584, 2586, "to" +351, 18, 12, 491, 55, 60, 2587, 2592, "place" +351, 18, 13, 492, 61, 62, 2593, 2594, "-" +351, 18, 14, 493, 63, 65, 2595, 2597, "bo" +351, 18, 15, 494, 66, 67, 2598, 2599, "," +351, 18, 16, 495, 68, 77, 2600, 2609, "metformin" +351, 18, 17, 496, 78, 80, 2610, 2612, "is" +351, 18, 18, 497, 81, 85, 2613, 2617, "more" +351, 18, 19, 498, 86, 95, 2618, 2627, "efficient" +351, 18, 20, 499, 96, 98, 2628, 2630, "in" +351, 18, 21, 500, 99, 107, 2631, 2639, "reducing" +351, 18, 22, 501, 108, 115, 2640, 2647, "insulin" +351, 18, 23, 502, 116, 126, 2648, 2658, "resistance" +351, 18, 24, 503, 127, 129, 2659, 2661, "in" +351, 18, 25, 504, 130, 135, 2662, 2667, "obese" +351, 18, 26, 505, 136, 144, 2668, 2676, "patients" +351, 18, 27, 506, 145, 149, 2677, 2681, "with" +351, 18, 28, 507, 150, 152, 2682, 2684, "DM" +351, 18, 29, 508, 153, 157, 2685, 2689, "type" +351, 18, 30, 509, 158, 159, 2690, 2691, "2" +351, 18, 31, 510, 160, 161, 2692, 2693, "." +351, 19, 1, 511, 0, 2, 2694, 2696, "In" +351, 19, 2, 512, 3, 11, 2697, 2705, "addition" +351, 19, 3, 513, 12, 13, 2706, 2707, "," +351, 19, 4, 514, 14, 16, 2708, 2710, "as" +351, 19, 5, 515, 17, 25, 2711, 2719, "compared" +351, 19, 6, 516, 26, 28, 2720, 2722, "to" +351, 19, 7, 517, 29, 36, 2723, 2730, "placebo" +351, 19, 8, 518, 37, 38, 2731, 2732, "," +351, 19, 9, 519, 39, 48, 2733, 2742, "metformin" +351, 19, 10, 520, 49, 58, 2743, 2752, "maintains" +351, 19, 11, 521, 59, 63, 2753, 2757, "more" +351, 19, 12, 522, 64, 73, 2758, 2767, "efficient" +351, 19, 13, 523, 74, 84, 2768, 2778, "productive" +351, 19, 14, 524, 85, 92, 2779, 2786, "insulin" +351, 19, 15, 525, 93, 102, 2787, 2796, "secretion" +351, 19, 16, 526, 103, 104, 2797, 2798, "," +351, 19, 17, 527, 105, 115, 2799, 2809, "indicating" +351, 19, 18, 528, 116, 120, 2810, 2814, "that" +351, 19, 19, 529, 121, 130, 2815, 2824, "metformin" +351, 19, 20, 530, 131, 139, 2825, 2833, "protects" +351, 19, 21, 531, 140, 143, 2834, 2837, "the" +351, 19, 22, 532, 144, 152, 2838, 2846, "pancreas" +351, 19, 23, 533, 153, 157, 2847, 2851, "from" +351, 19, 24, 534, 158, 162, 2852, 2856, "beta" +351, 19, 25, 535, 163, 167, 2857, 2861, "cell" +351, 19, 26, 536, 168, 177, 2862, 2871, "depletion" +351, 19, 27, 537, 178, 179, 2872, 2873, "." +351, 20, 1, 538, 0, 4, 2874, 2878, "PMID" +351, 20, 2, 539, 5, 6, 2879, 2880, ":" +351, 20, 3, 540, 7, 15, 2881, 2889, "17929538" +351, 20, 4, 541, 16, 17, 2890, 2891, "[" +351, 20, 5, 542, 18, 25, 2892, 2899, "Indexed" +351, 20, 6, 543, 26, 29, 2900, 2903, "for" +351, 20, 7, 544, 30, 37, 2904, 2911, "MEDLINE" +351, 20, 8, 545, 38, 39, 2912, 2913, "]" diff --git a/data/dm2 17929538_kwoodley.annodb b/data/dm2 17929538_kwoodley.annodb new file mode 100644 index 0000000..4dc2722 --- /dev/null +++ b/data/dm2 17929538_kwoodley.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32312, Journal, 0, 19, "Srp Arh Celok Lek .", "", +5758, PublicationYear, 20, 24, "2007", "", +32313, Title, 64, 187, "[ The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2 ] .", "", +5759, Metformin, 80, 89, "metformin", "", +32317, FastingBloodGlucose, 93, 100, "fasting", "", +32314, PostprandialBloodGlucose, 105, 117, "postprandial", "", +5762, Insulin, 118, 125, "insulin", "", +5764, Precondition, 139, 183, "obese patients with diabetes mellitus type 2", "", +5763, Type2Diabetes, 159, 183, "diabetes mellitus type 2", "", +5770, Country, 201, 208, "Serbian", "", +5766, Author, 211, 221, "Vukovi ć M", "", +5767, Author, 224, 235, "Lapcevi ć M", "", +5768, Author, 238, 248, "Kalezi ć N", "", +5769, Author, 251, 266, "Gvozdenovi ć BS", "", +5771, Metformin, 333, 342, "metformin", "", +5772, Insulin, 379, 386, "insulin", "", +32315, ObjectiveDescription, 499, 612, "The purpose of the study was to establish the effect of metformin on fasting and postprandial insulin secretion .", "", +5846, Metformin, 555, 564, "metformin", "", +32316, FastingBloodGlucose, 568, 575, "fasting", "", +32318, PostprandialBloodGlucose, 580, 592, "postprandial", "", +32319, Insulin, 593, 600, "insulin", "", +5850, DoubleBlind, 648, 660, "double blind", "", +5852, CTDesign, 663, 673, "controlled", "", +5855, CTDesign, 676, 687, "comparative", "", +5857, Randomized, 690, 700, "randomized", "", +5858, Multicenter, 703, 715, "multicentric", "", +5859, Precondition, 742, 783, "out - patient department ( OPD ) patients", "", +5860, NumberPatientsArm, 786, 788, "43", "", +5862, Metformin, 816, 825, "metformin", "", +5863, NumberPatientsArm, 853, 855, "46", "", +5865, Placebo, 876, 883, "placebo", "", +32320, Precondition, 886, 1053, "Patients enrolled in the study were newly diagnosed with diabetes mellitus ( DM ) type 2 , glycaemia < 12 mmol / l , and had the Body Mass Index ( BMI ) > 30 kg / m2 .", "", +5867, Type2Diabetes, 943, 974, "diabetes mellitus ( DM ) type 2", "", +5869, Millimoles_per_litre, 992, 1000, "mmol / l", "", +5870, BMI, 1015, 1030, "Body Mass Index", "", +5872, BMI, 1033, 1036, "BMI", "", +5873, Kg_per_squareMeter, 1044, 1051, "kg / m2", "", +32321, FastingBloodGlucose, 1103, 1110, "fasting", "", +32322, PostprandialBloodGlucose, 1115, 1127, "postprandial", "", +5879, HbA1c, 1140, 1164, "glycosylated haemoglobin", "", +5880, HbA1c, 1167, 1172, "HbA1c", "", +5886, FastingPlasmaGlucose, 1183, 1190, "fasting", "", +32323, PostprandialPlasmaGlucose, 1195, 1207, "postprandial", "", +5885, EndPointDescription, 1223, 1235, "blood lipids", "", +5890, EndPointDescription, 1244, 1255, "cholesterol", "", +5892, EndPointDescription, 1264, 1277, "triglycerides", "", +5893, EndPointDescription, 1280, 1295, "HDL cholesterol", "", +5894, EndPointDescription, 1302, 1317, "LDL cholesterol", "", +5888, EndPointDescription, 1326, 1352, "gamma glutaryl transferase", "", +5889, EndPointDescription, 1355, 1358, "GGT", "", +5896, BMI, 1369, 1372, "BMI", "", +5899, Duration, 1402, 1409, "42 days", "", +5901, FastingPlasmaGlucose, 1425, 1432, "fasting", "", +32324, PostprandialPlasmaGlucose, 1437, 1449, "postprandial", "", +5907, FastingPlasmaGlucose, 1560, 1567, "fasting", "", +32325, PostprandialPlasmaGlucose, 1572, 1584, "postprandial", "", +5911, MeasurementDevice, 1613, 1626, "ANOVA two way", "", +5912, MeasurementDevice, 1631, 1644, "ANCOVA method", "", +5913, Metformin, 1675, 1684, "metformin", "", +5914, Placebo, 1722, 1729, "placebo", "", +32326, FastingPlasmaGlucose, 1764, 1784, "fasting insulinaemia", "", +5916, Duration, 1798, 1807, "six weeks", "", +5918, Precondition, 1822, 1851, "obese patients with DM type 2", "", +5917, Type2Diabetes, 1842, 1851, "DM type 2", "", +5919, ResultMeasuredValue, 1854, 1862, "24 . 392", "", +5920, ConcentrationUnit, 1863, 1869, "mU / l", "", +5923, ResultMeasuredValue, 1875, 1883, "25 . 667", "", +5922, ConcentrationUnit, 1884, 1890, "mU / l", "", +5924, BMI, 1917, 1920, "BMI", "", +32327, FastingPlasmaGlucose, 1958, 1978, "fasting insulinaemia", "", +5926, PvalueDiff, 1995, 2006, "p < 0 . 001", "", +5927, BMI, 2065, 2068, "BMI", "", +5928, EndPointDescription, 2073, 2076, "GGT", "", +32328, PostprandialPlasmaGlucose, 2123, 2148, "postprandial insulinaemia", "", +5930, BMI, 2228, 2231, "BMI", "", +32329, PostprandialPlasmaGlucose, 2268, 2293, "postprandial insulinaemia", "", +5932, PvalueDiff, 2342, 2352, "p < 0 . 01", "", +32330, PostprandialPlasmaGlucose, 2382, 2407, "postprandial insulinaemia", "", +5934, Placebo, 2429, 2436, "placebo", "", +5935, Metformin, 2473, 2482, "metformin", "", +5938, ResultMeasuredValue, 2491, 2499, "44 . 807", "", +5936, BioAndMedicalUnit, 2500, 2506, "mU / l", "", +5939, ResultMeasuredValue, 2512, 2520, "47 . 114", "", +5937, BioAndMedicalUnit, 2521, 2527, "mU / l", "", +32331, ConclusionComment, 2545, 2693, "It can be concluded that , as compared to place - bo , metformin is more efficient in reducing insulin resistance in obese patients with DM type 2 .", "", +5940, Placebo, 2587, 2597, "place - bo", "", +5941, Metformin, 2600, 2609, "metformin", "", +5942, Insulin, 2640, 2647, "insulin", "", +5944, Precondition, 2662, 2691, "obese patients with DM type 2", "", +5943, Type2Diabetes, 2682, 2691, "DM type 2", "", +32332, ConclusionComment, 2694, 2873, "In addition , as compared to placebo , metformin maintains more efficient productive insulin secretion , indicating that metformin protects the pancreas from beta cell depletion .", "", +5946, Placebo, 2723, 2730, "placebo", "", +5947, Metformin, 2733, 2742, "metformin", "", +5948, Insulin, 2779, 2786, "insulin", "", +5949, Metformin, 2815, 2824, "metformin", "", +5951, PMID, 2881, 2889, "17929538", "", diff --git a/data/dm2 17929538_kwoodley.n-triples b/data/dm2 17929538_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17929538_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17934150 copy_admin.annodb b/data/dm2 17934150 copy_admin.annodb new file mode 100644 index 0000000..43897dd --- /dev/null +++ b/data/dm2 17934150 copy_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2008", "", +98, Title, 66, 282, "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .", "", " \"Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .\"." +2, Insulin, 76, 83, "insulin", "", +3, Type2Diabetes, 95, 110, "type 2 diabetes", "", " ." +4, InsulinGlargine, 135, 143, "glargine", "", +5, OralAntidiabeticAgent, 149, 160, "oral agents", "", +50159, LisproProtamine, 183, 207, "insulin lispro protamine", "", +97, Lispro, 221, 227, "lispro", "", +6, InsulinGlargine, 253, 261, "glargine", "", +96, Lispro, 264, 270, "lispro", "", +7, Author, 283, 295, "Rosenstock J", "", " \"Rosenstock J\"." +8, Author, 304, 313, "Ahmann AJ", "", " \"Ahmann AJ\"." +9, Author, 316, 323, "Colon G", "", " \"Colon G\"." +10, Author, 326, 341, "Scism - Bacon J", "", " \"Scism - Bacon J\"." +11, Author, 344, 351, "Jiang H", "", " \"Jiang H\"." +12, Author, 354, 362, "Martin S", "", " \"Martin S\"." +13, USA, 467, 470, "USA", "", " ." +27, ObjectiveDescription, 524, 668, "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )", "", " \"The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )\"." +174, ObjectiveDescription, 669, 843, "in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT .", "", " \"in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT .\"." +18, Type2Diabetes, 672, 687, "type 2 diabetic", "", +20, Precondition, 672, 780, "type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents", "", " \"type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents\"." +19, InsulinGlargine, 721, 737, "insulin glargine", "", +21, DoseValue, 740, 749, "> or = 30", "", +22, BioAndMedicalUnit, 750, 755, "units", "", +50160, Interval, 758, 761, "day", "", +24, OralAntidiabeticAgent, 769, 780, "oral agents", "", +28, Randomized, 888, 896, "randomly", "", " ." +51216, Lispro50/50, 915, 933, "lispro mix 50 / 50", "", " ." +51217, LisproProtamine, 941, 965, "insulin lispro protamine", "", +114, Lispro, 986, 992, "lispro", "", +30, NumberPatientsArm, 999, 1002, "187", "", " \"187\"." +31, Frequency, 1005, 1014, "t . i . d", "", " \"t . i . d\"." +33, InsulinGlargine, 1037, 1045, "glargine", "", " ." +51224, Bedtime, 1049, 1056, "bedtime", "", " ." +34, RelativeTime, 1062, 1070, "mealtime", "", " . ." +119, Lispro, 1071, 1077, "lispro", "", " ." +35, NumberPatientsArm, 1084, 1087, "187", "", " \"187\"." +36, Duration, 1095, 1104, "24 - week", "", " \"24 - week\"." +37, Multicenter, 1107, 1118, "multicenter", "", " ." +38, OpenLabel, 1121, 1133, "open - label", "", " ." +39, CTDesign, 1136, 1150, "noninferiority", "", " . ." +51214, Lispro50/50, 1187, 1205, "lispro mix 50 / 50", "", +51215, Lispro75/25, 1218, 1229, "mix 75 / 25", "", +40, Bedtime, 1237, 1249, "evening meal", "", +41, FastingPlasmaGlucose_target, 1257, 1286, "fasting plasma glucose target", "", +181, TimePoint, 1316, 1324, "Baseline", "", +42, HbA1c, 1325, 1328, "A1C", "", " ." +48, BaseLineValue, 1347, 1352, "8 . 8", "", " \"8 . 8\"." +47, Percentage, 1353, 1354, "%", "", " ." +49, BaseLineValue, 1361, 1366, "8 . 9", "", " \"8 . 9\"." +46, Percentage, 1367, 1368, "%", "", +45, PvalueDiff, 1371, 1382, "P = 0 . 598", "", +131, TimePoint, 1390, 1397, "week 24", "", " \"week 24\". \"week 24\"." +50, HbA1c, 1400, 1403, "A1C", "", +52, ResultMeasuredValue, 1425, 1431, "6 . 78", "", " \"6 . 78\"." +53, ResultMeasuredValue, 1437, 1443, "6 . 95", "", " \"6 . 78\"." +54, Percentage, 1444, 1445, "%", "", +55, PvalueDiff, 1448, 1459, "P = 0 . 021", "", " \"P = 0 . 021\"." +56, HbA1c, 1464, 1467, "A1C", "", +57, ObservedResult, 1468, 1526, "was reduced significantly from baseline for both therapies", "", " \"was reduced significantly from baseline for both therapies\". \"was reduced significantly from baseline for both therapies\"." +191, TimePoint, 1499, 1507, "baseline", "", +50165, PValueChangeValue, 1529, 1541, "P < 0 . 0001", "", " \"P < 0 . 0001\". \"P < 0 . 0001\"." +59, HbA1c, 1564, 1567, "A1C", "", +183, TimePoint, 1580, 1588, "baseline", "", +184, TimePoint, 1596, 1605, "end point", "", +65, DiffGroupAbsValue, 1628, 1636, "- 0 . 22", "", " \"- 0 . 22\"." +66, Percentage, 1637, 1638, "%", "", +67, ConfIntervalDiff, 1641, 1669, "90 % CI - 0 . 38 to - 0 . 07", "", " \"90 % CI - 0 . 38 to - 0 . 07\"." +185, ObservedResult, 1674, 1782, "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %", "", " \"Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %\". \"Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %\"." +64, HbA1c_target, 1823, 1843, "target A1C < 7 . 0 %", "", " ." +139, Percentage, 1842, 1843, "%", "", " ." +70, PercentageAffected, 1883, 1885, "54", "", " \"54\"." +71, PercentageAffected, 1891, 1893, "69", "", " \"69\"." +72, PvalueDiff, 1898, 1909, "P = 0 . 009", "", " \"P = 0 . 009\"." +73, HbA1c_target, 1920, 1941, "target < or = 6 . 5 %", "", " ." +141, Percentage, 1940, 1941, "%", "", " ." +74, PercentageAffected, 1947, 1949, "35", "", " \"35\"." +75, PercentageAffected, 1955, 1957, "50", "", " \"50\"." +142, Percentage, 1958, 1959, "%", "", +76, PvalueDiff, 1962, 1972, "P = 0 . 01", "", " \"P = 0 . 01\"." +78, HbA1c_target, 1998, 2032, "target < or = 6 . 0 % or < 7 . 5 %", "", +143, Percentage, 2018, 2019, "%", "", +144, Percentage, 2031, 2032, "%", "", +186, ObservedResult, 2035, 2085, "Rates of hypoglycemia were similar for both groups", "", " \"Rates of hypoglycemia were similar for both groups\"." +79, Hypoglycemia, 2044, 2056, "hypoglycemia", "", " ." +89, ConclusionComment, 2102, 2308, "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered", "", " \"Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered\"." +84, HbA1c, 2176, 2179, "A1C", "", +85, HbA1c_target, 2225, 2236, "A1C targets", "", +86, Hypoglycemia, 2239, 2251, "hypoglycemia", "", +187, ConclusionComment, 2309, 2424, "in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes .", "", " \"in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes .\"." +87, Insulin, 2366, 2373, "insulin", "", +88, Type2Diabetes, 2407, 2422, "type 2 diabetes", "", +90, PMID, 2462, 2470, "17934150", "", " \"17934150\"." diff --git a/data/dm2 17934150 copy_admin.n-triples b/data/dm2 17934150 copy_admin.n-triples new file mode 100644 index 0000000..2852d90 --- /dev/null +++ b/data/dm2 17934150 copy_admin.n-triples @@ -0,0 +1,175 @@ +# RDF export of group: Publication + . + "Publication" . + "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy ." . + "Rosenstock J" . + "Diabetes Care" . + "17934150" . + . + "Ahmann AJ" . + "Colon G" . + "Scism - Bacon J" . + "Jiang H" . + "Martin S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )" . + "24 - week" . + . + . + . + "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered" . + . + . + . + . + . + "in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT ." . + . + . + . + . + "in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_A1C" . + . + . + . + . + . + "Endpoint_A1C_7" . + . + . + . + . + . + "Endpoint_6.5" . + . + . + . + . + . + "Endpoint_AE_H" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_PPT" . + "187" . + . + . + . + . + . + . + "Arm_BBT" . + "187" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_Lis50/50" . + . + "t . i . d" . + . + . + "Intervention_gla" . + . + . + . + "Intervention_lis" . + . + . + . +# RDF export of group: Medication + . + "Medication_Lis50/50" . + . + . + . + . + "Medication_Lis" . + . + . + . + . + "Medication_gla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_A1C_PPT" . + . + "8 . 8" . + "6 . 95" . + "P < 0 . 0001" . + "was reduced significantly from baseline for both therapies" . + "week 24" . + "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %" . + . + "Outcome_A1C_BBT" . + . + "8 . 9" . + "6 . 78" . + "P < 0 . 0001" . + "was reduced significantly from baseline for both therapies" . + "week 24" . + "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %" . + . + "Outcome_7_PPT" . + . + "54" . + . + "Outcome_7_BBT" . + . + "69" . + . + "Outcome_6.5_PPT" . + . + "35" . + . + "Outcome_6.5_BBT" . + . + "50" . + . + "Outcome_AE_H" . + . + "Rates of hypoglycemia were similar for both groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_A1C" . + "- 0 . 22" . + "P = 0 . 021" . + "90 % CI - 0 . 38 to - 0 . 07" . + . + . + . + "DiffBetweenGroups_7" . + "P = 0 . 009" . + . + . + . + "DiffBetweenGroups_6.5" . + "P = 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17934150 copy_export.csv b/data/dm2 17934150 copy_export.csv new file mode 100644 index 0000000..245c0b2 --- /dev/null +++ b/data/dm2 17934150 copy_export.csv @@ -0,0 +1,550 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +816, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +816, 1, 2, 2, 9, 13, 9, 13, "Care" +816, 1, 3, 3, 14, 15, 14, 15, "." +816, 2, 1, 4, 0, 4, 16, 20, "2008" +816, 2, 2, 5, 5, 8, 21, 24, "Jan" +816, 2, 3, 6, 9, 10, 25, 26, ";" +816, 2, 4, 7, 11, 13, 27, 29, "31" +816, 2, 5, 8, 14, 15, 30, 31, "(" +816, 2, 6, 9, 16, 17, 32, 33, "1" +816, 2, 7, 10, 18, 19, 34, 35, ")" +816, 2, 8, 11, 20, 21, 36, 37, ":" +816, 2, 9, 12, 22, 24, 38, 40, "20" +816, 2, 10, 13, 25, 26, 41, 42, "-" +816, 2, 11, 14, 27, 28, 43, 44, "5" +816, 2, 12, 15, 29, 30, 45, 46, "." +816, 3, 1, 16, 0, 4, 47, 51, "Epub" +816, 3, 2, 17, 5, 9, 52, 56, "2007" +816, 3, 3, 18, 10, 13, 57, 60, "Oct" +816, 3, 4, 19, 14, 16, 61, 63, "12" +816, 3, 5, 20, 17, 18, 64, 65, "." +816, 4, 1, 21, 0, 9, 66, 75, "Advancing" +816, 4, 2, 22, 10, 17, 76, 83, "insulin" +816, 4, 3, 23, 18, 25, 84, 91, "therapy" +816, 4, 4, 24, 26, 28, 92, 94, "in" +816, 4, 5, 25, 29, 33, 95, 99, "type" +816, 4, 6, 26, 34, 35, 100, 101, "2" +816, 4, 7, 27, 36, 44, 102, 110, "diabetes" +816, 4, 8, 28, 45, 55, 111, 121, "previously" +816, 4, 9, 29, 56, 63, 122, 129, "treated" +816, 4, 10, 30, 64, 68, 130, 134, "with" +816, 4, 11, 31, 69, 77, 135, 143, "glargine" +816, 4, 12, 32, 78, 82, 144, 148, "plus" +816, 4, 13, 33, 83, 87, 149, 153, "oral" +816, 4, 14, 34, 88, 94, 154, 160, "agents" +816, 4, 15, 35, 95, 96, 161, 162, ":" +816, 4, 16, 36, 97, 105, 163, 171, "prandial" +816, 4, 17, 37, 106, 114, 172, 180, "premixed" +816, 4, 18, 38, 115, 116, 181, 182, "(" +816, 4, 19, 39, 117, 124, 183, 190, "insulin" +816, 4, 20, 40, 125, 131, 191, 197, "lispro" +816, 4, 21, 41, 132, 141, 198, 207, "protamine" +816, 4, 22, 42, 142, 152, 208, 218, "suspension" +816, 4, 23, 43, 153, 154, 219, 220, "/" +816, 4, 24, 44, 155, 161, 221, 227, "lispro" +816, 4, 25, 45, 162, 163, 228, 229, ")" +816, 4, 26, 46, 164, 170, 230, 236, "versus" +816, 4, 27, 47, 171, 176, 237, 242, "basal" +816, 4, 28, 48, 177, 178, 243, 244, "/" +816, 4, 29, 49, 179, 184, 245, 250, "bolus" +816, 4, 30, 50, 185, 186, 251, 252, "(" +816, 4, 31, 51, 187, 195, 253, 261, "glargine" +816, 4, 32, 52, 196, 197, 262, 263, "/" +816, 4, 33, 53, 198, 204, 264, 270, "lispro" +816, 4, 34, 54, 205, 206, 271, 272, ")" +816, 4, 35, 55, 207, 214, 273, 280, "therapy" +816, 4, 36, 56, 215, 216, 281, 282, "." +816, 5, 1, 57, 0, 10, 283, 293, "Rosenstock" +816, 5, 2, 58, 11, 12, 294, 295, "J" +816, 5, 3, 59, 13, 14, 296, 297, "(" +816, 5, 4, 60, 15, 16, 298, 299, "1" +816, 5, 5, 61, 17, 18, 300, 301, ")" +816, 5, 6, 62, 19, 20, 302, 303, "," +816, 5, 7, 63, 21, 27, 304, 310, "Ahmann" +816, 5, 8, 64, 28, 30, 311, 313, "AJ" +816, 5, 9, 65, 31, 32, 314, 315, "," +816, 5, 10, 66, 33, 38, 316, 321, "Colon" +816, 5, 11, 67, 39, 40, 322, 323, "G" +816, 5, 12, 68, 41, 42, 324, 325, "," +816, 5, 13, 69, 43, 48, 326, 331, "Scism" +816, 5, 14, 70, 49, 50, 332, 333, "-" +816, 5, 15, 71, 51, 56, 334, 339, "Bacon" +816, 5, 16, 72, 57, 58, 340, 341, "J" +816, 5, 17, 73, 59, 60, 342, 343, "," +816, 5, 18, 74, 61, 66, 344, 349, "Jiang" +816, 5, 19, 75, 67, 68, 350, 351, "H" +816, 5, 20, 76, 69, 70, 352, 353, "," +816, 5, 21, 77, 71, 77, 354, 360, "Martin" +816, 5, 22, 78, 78, 79, 361, 362, "S" +816, 5, 23, 79, 80, 81, 363, 364, "." +816, 5, 24, 80, 82, 88, 365, 371, "Author" +816, 5, 25, 81, 89, 100, 372, 383, "information" +816, 5, 26, 82, 101, 102, 384, 385, ":" +816, 5, 27, 83, 103, 104, 386, 387, "(" +816, 5, 28, 84, 105, 106, 388, 389, "1" +816, 5, 29, 85, 107, 108, 390, 391, ")" +816, 5, 30, 86, 109, 115, 392, 398, "Dallas" +816, 5, 31, 87, 116, 124, 399, 407, "Diabetes" +816, 5, 32, 88, 125, 128, 408, 411, "and" +816, 5, 33, 89, 129, 138, 412, 421, "Endocrine" +816, 5, 34, 90, 139, 145, 422, 428, "Center" +816, 5, 35, 91, 146, 148, 429, 431, "at" +816, 5, 36, 92, 149, 156, 432, 439, "Medical" +816, 5, 37, 93, 157, 161, 440, 444, "City" +816, 5, 38, 94, 162, 163, 445, 446, "," +816, 5, 39, 95, 164, 170, 447, 453, "Dallas" +816, 5, 40, 96, 171, 172, 454, 455, "," +816, 5, 41, 97, 173, 175, 456, 458, "TX" +816, 5, 42, 98, 176, 181, 459, 464, "75230" +816, 5, 43, 99, 182, 183, 465, 466, "," +816, 5, 44, 100, 184, 187, 467, 470, "USA" +816, 5, 45, 101, 188, 189, 471, 472, "." +816, 6, 1, 102, 0, 15, 473, 488, "juliorosenstock" +816, 6, 2, 103, 16, 17, 489, 490, "@" +816, 6, 3, 104, 18, 32, 491, 505, "dallasdiabetes" +816, 6, 4, 105, 33, 34, 506, 507, "." +816, 6, 5, 106, 35, 38, 508, 511, "com" +816, 6, 6, 107, 39, 48, 512, 521, "OBJECTIVE" +816, 6, 7, 108, 49, 50, 522, 523, ":" +816, 6, 8, 109, 51, 54, 524, 527, "The" +816, 6, 9, 110, 55, 62, 528, 535, "purpose" +816, 6, 10, 111, 63, 65, 536, 538, "of" +816, 6, 11, 112, 66, 70, 539, 543, "this" +816, 6, 12, 113, 71, 76, 544, 549, "study" +816, 6, 13, 114, 77, 80, 550, 553, "was" +816, 6, 14, 115, 81, 83, 554, 556, "to" +816, 6, 15, 116, 84, 91, 557, 564, "compare" +816, 6, 16, 117, 92, 95, 565, 568, "two" +816, 6, 17, 118, 96, 102, 569, 575, "analog" +816, 6, 18, 119, 103, 110, 576, 583, "insulin" +816, 6, 19, 120, 111, 120, 584, 593, "therapies" +816, 6, 20, 121, 121, 122, 594, 595, "(" +816, 6, 21, 122, 123, 131, 596, 604, "prandial" +816, 6, 22, 123, 132, 140, 605, 613, "premixed" +816, 6, 23, 124, 141, 148, 614, 621, "therapy" +816, 6, 24, 125, 149, 150, 622, 623, "[" +816, 6, 25, 126, 151, 154, 624, 627, "PPT" +816, 6, 26, 127, 155, 156, 628, 629, "]" +816, 6, 27, 128, 157, 163, 630, 636, "versus" +816, 6, 28, 129, 164, 169, 637, 642, "basal" +816, 6, 29, 130, 170, 171, 643, 644, "/" +816, 6, 30, 131, 172, 177, 645, 650, "bolus" +816, 6, 31, 132, 178, 185, 651, 658, "therapy" +816, 6, 32, 133, 186, 187, 659, 660, "[" +816, 6, 33, 134, 188, 191, 661, 664, "BBT" +816, 6, 34, 135, 192, 193, 665, 666, "]" +816, 6, 35, 136, 194, 195, 667, 668, ")" +816, 6, 36, 137, 196, 198, 669, 671, "in" +816, 6, 37, 138, 199, 203, 672, 676, "type" +816, 6, 38, 139, 204, 205, 677, 678, "2" +816, 6, 39, 140, 206, 214, 679, 687, "diabetic" +816, 6, 40, 141, 215, 223, 688, 696, "patients" +816, 6, 41, 142, 224, 234, 697, 707, "previously" +816, 6, 42, 143, 235, 242, 708, 715, "treated" +816, 6, 43, 144, 243, 247, 716, 720, "with" +816, 6, 44, 145, 248, 255, 721, 728, "insulin" +816, 6, 45, 146, 256, 264, 729, 737, "glargine" +816, 6, 46, 147, 265, 266, 738, 739, "(" +816, 6, 47, 148, 267, 268, 740, 741, ">" +816, 6, 48, 149, 269, 271, 742, 744, "or" +816, 6, 49, 150, 272, 273, 745, 746, "=" +816, 6, 50, 151, 274, 276, 747, 749, "30" +816, 6, 51, 152, 277, 282, 750, 755, "units" +816, 6, 52, 153, 283, 284, 756, 757, "/" +816, 6, 53, 154, 285, 288, 758, 761, "day" +816, 6, 54, 155, 289, 290, 762, 763, ")" +816, 6, 55, 156, 291, 295, 764, 768, "plus" +816, 6, 56, 157, 296, 300, 769, 773, "oral" +816, 6, 57, 158, 301, 307, 774, 780, "agents" +816, 6, 58, 159, 308, 309, 781, 782, "," +816, 6, 59, 160, 310, 314, 783, 787, "with" +816, 6, 60, 161, 315, 318, 788, 791, "the" +816, 6, 61, 162, 319, 322, 792, 795, "aim" +816, 6, 62, 163, 323, 325, 796, 798, "of" +816, 6, 63, 164, 326, 339, 799, 812, "demonstrating" +816, 6, 64, 165, 340, 354, 813, 827, "noninferiority" +816, 6, 65, 166, 355, 357, 828, 830, "of" +816, 6, 66, 167, 358, 361, 831, 834, "PPT" +816, 6, 67, 168, 362, 364, 835, 837, "to" +816, 6, 68, 169, 365, 368, 838, 841, "BBT" +816, 6, 69, 170, 369, 370, 842, 843, "." +816, 7, 1, 171, 0, 8, 844, 852, "RESEARCH" +816, 7, 2, 172, 9, 15, 853, 859, "DESIGN" +816, 7, 3, 173, 16, 19, 860, 863, "AND" +816, 7, 4, 174, 20, 27, 864, 871, "METHODS" +816, 7, 5, 175, 28, 29, 872, 873, ":" +816, 7, 6, 176, 30, 38, 874, 882, "Patients" +816, 7, 7, 177, 39, 43, 883, 887, "were" +816, 7, 8, 178, 44, 52, 888, 896, "randomly" +816, 7, 9, 179, 53, 61, 897, 905, "assigned" +816, 7, 10, 180, 62, 64, 906, 908, "to" +816, 7, 11, 181, 65, 68, 909, 912, "PPT" +816, 7, 12, 182, 69, 70, 913, 914, "(" +816, 7, 13, 183, 71, 77, 915, 921, "lispro" +816, 7, 14, 184, 78, 81, 922, 925, "mix" +816, 7, 15, 185, 82, 84, 926, 928, "50" +816, 7, 16, 186, 85, 86, 929, 930, "/" +816, 7, 17, 187, 87, 89, 931, 933, "50" +816, 7, 18, 188, 90, 91, 934, 935, ":" +816, 7, 19, 189, 92, 94, 936, 938, "50" +816, 7, 20, 190, 95, 96, 939, 940, "%" +816, 7, 21, 191, 97, 104, 941, 948, "insulin" +816, 7, 22, 192, 105, 111, 949, 955, "lispro" +816, 7, 23, 193, 112, 121, 956, 965, "protamine" +816, 7, 24, 194, 122, 132, 966, 976, "suspension" +816, 7, 25, 195, 133, 136, 977, 980, "and" +816, 7, 26, 196, 137, 139, 981, 983, "50" +816, 7, 27, 197, 140, 141, 984, 985, "%" +816, 7, 28, 198, 142, 148, 986, 992, "lispro" +816, 7, 29, 199, 149, 150, 993, 994, ";" +816, 7, 30, 200, 151, 152, 995, 996, "n" +816, 7, 31, 201, 153, 154, 997, 998, "=" +816, 7, 32, 202, 155, 158, 999, 1002, "187" +816, 7, 33, 203, 159, 160, 1003, 1004, ")" +816, 7, 34, 204, 161, 162, 1005, 1006, "t" +816, 7, 35, 205, 163, 164, 1007, 1008, "." +816, 7, 36, 206, 165, 166, 1009, 1010, "i" +816, 7, 37, 207, 167, 168, 1011, 1012, "." +816, 7, 38, 208, 169, 170, 1013, 1014, "d" +816, 7, 39, 209, 171, 172, 1015, 1016, "." +816, 8, 1, 210, 0, 4, 1017, 1021, "with" +816, 8, 2, 211, 5, 10, 1022, 1027, "meals" +816, 8, 3, 212, 11, 13, 1028, 1030, "or" +816, 8, 4, 213, 14, 17, 1031, 1034, "BBT" +816, 8, 5, 214, 18, 19, 1035, 1036, "(" +816, 8, 6, 215, 20, 28, 1037, 1045, "glargine" +816, 8, 7, 216, 29, 31, 1046, 1048, "at" +816, 8, 8, 217, 32, 39, 1049, 1056, "bedtime" +816, 8, 9, 218, 40, 44, 1057, 1061, "plus" +816, 8, 10, 219, 45, 53, 1062, 1070, "mealtime" +816, 8, 11, 220, 54, 60, 1071, 1077, "lispro" +816, 8, 12, 221, 61, 62, 1078, 1079, ";" +816, 8, 13, 222, 63, 64, 1080, 1081, "n" +816, 8, 14, 223, 65, 66, 1082, 1083, "=" +816, 8, 15, 224, 67, 70, 1084, 1087, "187" +816, 8, 16, 225, 71, 72, 1088, 1089, ")" +816, 8, 17, 226, 73, 75, 1090, 1092, "in" +816, 8, 18, 227, 76, 77, 1093, 1094, "a" +816, 8, 19, 228, 78, 80, 1095, 1097, "24" +816, 8, 20, 229, 81, 82, 1098, 1099, "-" +816, 8, 21, 230, 83, 87, 1100, 1104, "week" +816, 8, 22, 231, 88, 89, 1105, 1106, "," +816, 8, 23, 232, 90, 101, 1107, 1118, "multicenter" +816, 8, 24, 233, 102, 103, 1119, 1120, "," +816, 8, 25, 234, 104, 108, 1121, 1125, "open" +816, 8, 26, 235, 109, 110, 1126, 1127, "-" +816, 8, 27, 236, 111, 116, 1128, 1133, "label" +816, 8, 28, 237, 117, 118, 1134, 1135, "," +816, 8, 29, 238, 119, 133, 1136, 1150, "noninferiority" +816, 8, 30, 239, 134, 139, 1151, 1156, "trial" +816, 8, 31, 240, 140, 141, 1157, 1158, "." +816, 9, 1, 241, 0, 13, 1159, 1172, "Investigators" +816, 9, 2, 242, 14, 19, 1173, 1178, "could" +816, 9, 3, 243, 20, 27, 1179, 1186, "replace" +816, 9, 4, 244, 28, 34, 1187, 1193, "lispro" +816, 9, 5, 245, 35, 38, 1194, 1197, "mix" +816, 9, 6, 246, 39, 41, 1198, 1200, "50" +816, 9, 7, 247, 42, 43, 1201, 1202, "/" +816, 9, 8, 248, 44, 46, 1203, 1205, "50" +816, 9, 9, 249, 47, 51, 1206, 1210, "with" +816, 9, 10, 250, 52, 58, 1211, 1217, "lispro" +816, 9, 11, 251, 59, 62, 1218, 1221, "mix" +816, 9, 12, 252, 63, 65, 1222, 1224, "75" +816, 9, 13, 253, 66, 67, 1225, 1226, "/" +816, 9, 14, 254, 68, 70, 1227, 1229, "25" +816, 9, 15, 255, 71, 73, 1230, 1232, "at" +816, 9, 16, 256, 74, 77, 1233, 1236, "the" +816, 9, 17, 257, 78, 85, 1237, 1244, "evening" +816, 9, 18, 258, 86, 90, 1245, 1249, "meal" +816, 9, 19, 259, 91, 93, 1250, 1252, "if" +816, 9, 20, 260, 94, 97, 1253, 1256, "the" +816, 9, 21, 261, 98, 105, 1257, 1264, "fasting" +816, 9, 22, 262, 106, 112, 1265, 1271, "plasma" +816, 9, 23, 263, 113, 120, 1272, 1279, "glucose" +816, 9, 24, 264, 121, 127, 1280, 1286, "target" +816, 9, 25, 265, 128, 131, 1287, 1290, "was" +816, 9, 26, 266, 132, 144, 1291, 1303, "unachievable" +816, 9, 27, 267, 145, 146, 1304, 1305, "." +816, 10, 1, 268, 0, 7, 1306, 1313, "RESULTS" +816, 10, 2, 269, 8, 9, 1314, 1315, ":" +816, 10, 3, 270, 10, 18, 1316, 1324, "Baseline" +816, 10, 4, 271, 19, 22, 1325, 1328, "A1C" +816, 10, 5, 272, 23, 26, 1329, 1332, "was" +816, 10, 6, 273, 27, 34, 1333, 1340, "similar" +816, 10, 7, 274, 35, 36, 1341, 1342, "(" +816, 10, 8, 275, 37, 40, 1343, 1346, "PPT" +816, 10, 9, 276, 41, 42, 1347, 1348, "8" +816, 10, 10, 277, 43, 44, 1349, 1350, "." +816, 10, 11, 278, 45, 46, 1351, 1352, "8" +816, 10, 12, 279, 47, 48, 1353, 1354, "%" +816, 10, 13, 280, 49, 50, 1355, 1356, ";" +816, 10, 14, 281, 51, 54, 1357, 1360, "BBT" +816, 10, 15, 282, 55, 56, 1361, 1362, "8" +816, 10, 16, 283, 57, 58, 1363, 1364, "." +816, 10, 17, 284, 59, 60, 1365, 1366, "9" +816, 10, 18, 285, 61, 62, 1367, 1368, "%" +816, 10, 19, 286, 63, 64, 1369, 1370, ";" +816, 10, 20, 287, 65, 66, 1371, 1372, "P" +816, 10, 21, 288, 67, 68, 1373, 1374, "=" +816, 10, 22, 289, 69, 70, 1375, 1376, "0" +816, 10, 23, 290, 71, 72, 1377, 1378, "." +816, 10, 24, 291, 73, 76, 1379, 1382, "598" +816, 10, 25, 292, 77, 78, 1383, 1384, ")" +816, 10, 26, 293, 79, 80, 1385, 1386, "." +816, 11, 1, 294, 0, 2, 1387, 1389, "At" +816, 11, 2, 295, 3, 7, 1390, 1394, "week" +816, 11, 3, 296, 8, 10, 1395, 1397, "24" +816, 11, 4, 297, 11, 12, 1398, 1399, "," +816, 11, 5, 298, 13, 16, 1400, 1403, "A1C" +816, 11, 6, 299, 17, 20, 1404, 1407, "was" +816, 11, 7, 300, 21, 26, 1408, 1413, "lower" +816, 11, 8, 301, 27, 31, 1414, 1418, "with" +816, 11, 9, 302, 32, 35, 1419, 1422, "BBT" +816, 11, 10, 303, 36, 37, 1423, 1424, "(" +816, 11, 11, 304, 38, 39, 1425, 1426, "6" +816, 11, 12, 305, 40, 41, 1427, 1428, "." +816, 11, 13, 306, 42, 44, 1429, 1431, "78" +816, 11, 14, 307, 45, 47, 1432, 1434, "vs" +816, 11, 15, 308, 48, 49, 1435, 1436, "." +816, 11, 16, 309, 50, 51, 1437, 1438, "6" +816, 11, 17, 310, 52, 53, 1439, 1440, "." +816, 11, 18, 311, 54, 56, 1441, 1443, "95" +816, 11, 19, 312, 57, 58, 1444, 1445, "%" +816, 11, 20, 313, 59, 60, 1446, 1447, "," +816, 11, 21, 314, 61, 62, 1448, 1449, "P" +816, 11, 22, 315, 63, 64, 1450, 1451, "=" +816, 11, 23, 316, 65, 66, 1452, 1453, "0" +816, 11, 24, 317, 67, 68, 1454, 1455, "." +816, 11, 25, 318, 69, 72, 1456, 1459, "021" +816, 11, 26, 319, 73, 74, 1460, 1461, ")" +816, 11, 27, 320, 75, 76, 1462, 1463, "." +816, 12, 1, 321, 0, 3, 1464, 1467, "A1C" +816, 12, 2, 322, 4, 7, 1468, 1471, "was" +816, 12, 3, 323, 8, 15, 1472, 1479, "reduced" +816, 12, 4, 324, 16, 29, 1480, 1493, "significantly" +816, 12, 5, 325, 30, 34, 1494, 1498, "from" +816, 12, 6, 326, 35, 43, 1499, 1507, "baseline" +816, 12, 7, 327, 44, 47, 1508, 1511, "for" +816, 12, 8, 328, 48, 52, 1512, 1516, "both" +816, 12, 9, 329, 53, 62, 1517, 1526, "therapies" +816, 12, 10, 330, 63, 64, 1527, 1528, "(" +816, 12, 11, 331, 65, 66, 1529, 1530, "P" +816, 12, 12, 332, 67, 68, 1531, 1532, "<" +816, 12, 13, 333, 69, 70, 1533, 1534, "0" +816, 12, 14, 334, 71, 72, 1535, 1536, "." +816, 12, 15, 335, 73, 77, 1537, 1541, "0001" +816, 12, 16, 336, 78, 79, 1542, 1543, ")" +816, 12, 17, 337, 80, 81, 1544, 1545, "." +816, 13, 1, 338, 0, 3, 1546, 1549, "The" +816, 13, 2, 339, 4, 14, 1550, 1560, "difference" +816, 13, 3, 340, 15, 17, 1561, 1563, "in" +816, 13, 4, 341, 18, 21, 1564, 1567, "A1C" +816, 13, 5, 342, 22, 28, 1568, 1574, "change" +816, 13, 6, 343, 29, 33, 1575, 1579, "from" +816, 13, 7, 344, 34, 42, 1580, 1588, "baseline" +816, 13, 8, 345, 43, 45, 1589, 1591, "to" +816, 13, 9, 346, 46, 49, 1592, 1595, "the" +816, 13, 10, 347, 50, 53, 1596, 1599, "end" +816, 13, 11, 348, 54, 59, 1600, 1605, "point" +816, 13, 12, 349, 60, 61, 1606, 1607, "(" +816, 13, 13, 350, 62, 65, 1608, 1611, "BBT" +816, 13, 14, 351, 66, 71, 1612, 1617, "minus" +816, 13, 15, 352, 72, 75, 1618, 1621, "PPT" +816, 13, 16, 353, 76, 77, 1622, 1623, ")" +816, 13, 17, 354, 78, 81, 1624, 1627, "was" +816, 13, 18, 355, 82, 83, 1628, 1629, "-" +816, 13, 19, 356, 84, 85, 1630, 1631, "0" +816, 13, 20, 357, 86, 87, 1632, 1633, "." +816, 13, 21, 358, 88, 90, 1634, 1636, "22" +816, 13, 22, 359, 91, 92, 1637, 1638, "%" +816, 13, 23, 360, 93, 94, 1639, 1640, "(" +816, 13, 24, 361, 95, 97, 1641, 1643, "90" +816, 13, 25, 362, 98, 99, 1644, 1645, "%" +816, 13, 26, 363, 100, 102, 1646, 1648, "CI" +816, 13, 27, 364, 103, 104, 1649, 1650, "-" +816, 13, 28, 365, 105, 106, 1651, 1652, "0" +816, 13, 29, 366, 107, 108, 1653, 1654, "." +816, 13, 30, 367, 109, 111, 1655, 1657, "38" +816, 13, 31, 368, 112, 114, 1658, 1660, "to" +816, 13, 32, 369, 115, 116, 1661, 1662, "-" +816, 13, 33, 370, 117, 118, 1663, 1664, "0" +816, 13, 34, 371, 119, 120, 1665, 1666, "." +816, 13, 35, 372, 121, 123, 1667, 1669, "07" +816, 13, 36, 373, 124, 125, 1670, 1671, ")" +816, 13, 37, 374, 126, 127, 1672, 1673, "." +816, 14, 1, 375, 0, 14, 1674, 1688, "Noninferiority" +816, 14, 2, 376, 15, 17, 1689, 1691, "of" +816, 14, 3, 377, 18, 21, 1692, 1695, "PPT" +816, 14, 4, 378, 22, 24, 1696, 1698, "to" +816, 14, 5, 379, 25, 28, 1699, 1702, "BBT" +816, 14, 6, 380, 29, 32, 1703, 1706, "was" +816, 14, 7, 381, 33, 36, 1707, 1710, "not" +816, 14, 8, 382, 37, 49, 1711, 1723, "demonstrated" +816, 14, 9, 383, 50, 55, 1724, 1729, "based" +816, 14, 10, 384, 56, 58, 1730, 1732, "on" +816, 14, 11, 385, 59, 62, 1733, 1736, "the" +816, 14, 12, 386, 63, 75, 1737, 1749, "prespecified" +816, 14, 13, 387, 76, 90, 1750, 1764, "noninferiority" +816, 14, 14, 388, 91, 97, 1765, 1771, "margin" +816, 14, 15, 389, 98, 100, 1772, 1774, "of" +816, 14, 16, 390, 101, 102, 1775, 1776, "0" +816, 14, 17, 391, 103, 104, 1777, 1778, "." +816, 14, 18, 392, 105, 106, 1779, 1780, "3" +816, 14, 19, 393, 107, 108, 1781, 1782, "%" +816, 14, 20, 394, 109, 110, 1783, 1784, "." +816, 15, 1, 395, 0, 3, 1785, 1788, "The" +816, 15, 2, 396, 4, 15, 1789, 1800, "percentages" +816, 15, 3, 397, 16, 18, 1801, 1803, "of" +816, 15, 4, 398, 19, 27, 1804, 1812, "patients" +816, 15, 5, 399, 28, 37, 1813, 1822, "achieving" +816, 15, 6, 400, 38, 44, 1823, 1829, "target" +816, 15, 7, 401, 45, 48, 1830, 1833, "A1C" +816, 15, 8, 402, 49, 50, 1834, 1835, "<" +816, 15, 9, 403, 51, 52, 1836, 1837, "7" +816, 15, 10, 404, 53, 54, 1838, 1839, "." +816, 15, 11, 405, 55, 56, 1840, 1841, "0" +816, 15, 12, 406, 57, 58, 1842, 1843, "%" +816, 15, 13, 407, 59, 60, 1844, 1845, "(" +816, 15, 14, 408, 61, 64, 1846, 1849, "PPT" +816, 15, 15, 409, 65, 71, 1850, 1856, "versus" +816, 15, 16, 410, 72, 75, 1857, 1860, "BBT" +816, 15, 17, 411, 76, 77, 1861, 1862, "," +816, 15, 18, 412, 78, 90, 1863, 1875, "respectively" +816, 15, 19, 413, 91, 92, 1876, 1877, ")" +816, 15, 20, 414, 93, 97, 1878, 1882, "were" +816, 15, 21, 415, 98, 100, 1883, 1885, "54" +816, 15, 22, 416, 101, 103, 1886, 1888, "vs" +816, 15, 23, 417, 104, 105, 1889, 1890, "." +816, 15, 24, 418, 106, 108, 1891, 1893, "69" +816, 15, 25, 419, 109, 110, 1894, 1895, "%" +816, 15, 26, 420, 111, 112, 1896, 1897, "(" +816, 15, 27, 421, 113, 114, 1898, 1899, "P" +816, 15, 28, 422, 115, 116, 1900, 1901, "=" +816, 15, 29, 423, 117, 118, 1902, 1903, "0" +816, 15, 30, 424, 119, 120, 1904, 1905, "." +816, 15, 31, 425, 121, 124, 1906, 1909, "009" +816, 15, 32, 426, 125, 126, 1910, 1911, ")" +816, 15, 33, 427, 127, 130, 1912, 1915, "and" +816, 15, 34, 428, 131, 134, 1916, 1919, "for" +816, 15, 35, 429, 135, 141, 1920, 1926, "target" +816, 15, 36, 430, 142, 143, 1927, 1928, "<" +816, 15, 37, 431, 144, 146, 1929, 1931, "or" +816, 15, 38, 432, 147, 148, 1932, 1933, "=" +816, 15, 39, 433, 149, 150, 1934, 1935, "6" +816, 15, 40, 434, 151, 152, 1936, 1937, "." +816, 15, 41, 435, 153, 154, 1938, 1939, "5" +816, 15, 42, 436, 155, 156, 1940, 1941, "%" +816, 15, 43, 437, 157, 161, 1942, 1946, "were" +816, 15, 44, 438, 162, 164, 1947, 1949, "35" +816, 15, 45, 439, 165, 167, 1950, 1952, "vs" +816, 15, 46, 440, 168, 169, 1953, 1954, "." +816, 15, 47, 441, 170, 172, 1955, 1957, "50" +816, 15, 48, 442, 173, 174, 1958, 1959, "%" +816, 15, 49, 443, 175, 176, 1960, 1961, "(" +816, 15, 50, 444, 177, 178, 1962, 1963, "P" +816, 15, 51, 445, 179, 180, 1964, 1965, "=" +816, 15, 52, 446, 181, 182, 1966, 1967, "0" +816, 15, 53, 447, 183, 184, 1968, 1969, "." +816, 15, 54, 448, 185, 187, 1970, 1972, "01" +816, 15, 55, 449, 188, 189, 1973, 1974, ")" +816, 15, 56, 450, 190, 193, 1975, 1978, "but" +816, 15, 57, 451, 194, 197, 1979, 1982, "did" +816, 15, 58, 452, 198, 201, 1983, 1986, "not" +816, 15, 59, 453, 202, 208, 1987, 1993, "differ" +816, 15, 60, 454, 209, 212, 1994, 1997, "for" +816, 15, 61, 455, 213, 219, 1998, 2004, "target" +816, 15, 62, 456, 220, 221, 2005, 2006, "<" +816, 15, 63, 457, 222, 224, 2007, 2009, "or" +816, 15, 64, 458, 225, 226, 2010, 2011, "=" +816, 15, 65, 459, 227, 228, 2012, 2013, "6" +816, 15, 66, 460, 229, 230, 2014, 2015, "." +816, 15, 67, 461, 231, 232, 2016, 2017, "0" +816, 15, 68, 462, 233, 234, 2018, 2019, "%" +816, 15, 69, 463, 235, 237, 2020, 2022, "or" +816, 15, 70, 464, 238, 239, 2023, 2024, "<" +816, 15, 71, 465, 240, 241, 2025, 2026, "7" +816, 15, 72, 466, 242, 243, 2027, 2028, "." +816, 15, 73, 467, 244, 245, 2029, 2030, "5" +816, 15, 74, 468, 246, 247, 2031, 2032, "%" +816, 15, 75, 469, 248, 249, 2033, 2034, "." +816, 16, 1, 470, 0, 5, 2035, 2040, "Rates" +816, 16, 2, 471, 6, 8, 2041, 2043, "of" +816, 16, 3, 472, 9, 21, 2044, 2056, "hypoglycemia" +816, 16, 4, 473, 22, 26, 2057, 2061, "were" +816, 16, 5, 474, 27, 34, 2062, 2069, "similar" +816, 16, 6, 475, 35, 38, 2070, 2073, "for" +816, 16, 7, 476, 39, 43, 2074, 2078, "both" +816, 16, 8, 477, 44, 50, 2079, 2085, "groups" +816, 16, 9, 478, 51, 52, 2086, 2087, "." +816, 17, 1, 479, 0, 11, 2088, 2099, "CONCLUSIONS" +816, 17, 2, 480, 12, 13, 2100, 2101, ":" +816, 17, 3, 481, 14, 22, 2102, 2110, "Although" +816, 17, 4, 482, 23, 37, 2111, 2125, "noninferiority" +816, 17, 5, 483, 38, 40, 2126, 2128, "of" +816, 17, 6, 484, 41, 44, 2129, 2132, "PPT" +816, 17, 7, 485, 45, 47, 2133, 2135, "to" +816, 17, 8, 486, 48, 51, 2136, 2139, "BBT" +816, 17, 9, 487, 52, 55, 2140, 2143, "was" +816, 17, 10, 488, 56, 59, 2144, 2147, "not" +816, 17, 11, 489, 60, 72, 2148, 2160, "demonstrated" +816, 17, 12, 490, 73, 74, 2161, 2162, "," +816, 17, 13, 491, 75, 83, 2163, 2171, "findings" +816, 17, 14, 492, 84, 87, 2172, 2175, "for" +816, 17, 15, 493, 88, 91, 2176, 2179, "A1C" +816, 17, 16, 494, 92, 101, 2180, 2189, "reduction" +816, 17, 17, 495, 102, 103, 2190, 2191, "," +816, 17, 18, 496, 104, 114, 2192, 2202, "percentage" +816, 17, 19, 497, 115, 117, 2203, 2205, "of" +816, 17, 20, 498, 118, 126, 2206, 2214, "patients" +816, 17, 21, 499, 127, 136, 2215, 2224, "achieving" +816, 17, 22, 500, 137, 140, 2225, 2228, "A1C" +816, 17, 23, 501, 141, 148, 2229, 2236, "targets" +816, 17, 24, 502, 149, 150, 2237, 2238, "," +816, 17, 25, 503, 151, 163, 2239, 2251, "hypoglycemia" +816, 17, 26, 504, 164, 165, 2252, 2253, "," +816, 17, 27, 505, 166, 169, 2254, 2257, "and" +816, 17, 28, 506, 170, 176, 2258, 2264, "number" +816, 17, 29, 507, 177, 179, 2265, 2267, "of" +816, 17, 30, 508, 180, 188, 2268, 2276, "required" +816, 17, 31, 509, 189, 199, 2277, 2287, "injections" +816, 17, 32, 510, 200, 206, 2288, 2294, "should" +816, 17, 33, 511, 207, 209, 2295, 2297, "be" +816, 17, 34, 512, 210, 220, 2298, 2308, "considered" +816, 17, 35, 513, 221, 223, 2309, 2311, "in" +816, 17, 36, 514, 224, 227, 2312, 2315, "the" +816, 17, 37, 515, 228, 238, 2316, 2326, "individual" +816, 17, 38, 516, 239, 247, 2327, 2335, "decision" +816, 17, 39, 517, 248, 249, 2336, 2337, "-" +816, 17, 40, 518, 250, 256, 2338, 2344, "making" +816, 17, 41, 519, 257, 264, 2345, 2352, "process" +816, 17, 42, 520, 265, 267, 2353, 2355, "of" +816, 17, 43, 521, 268, 277, 2356, 2365, "advancing" +816, 17, 44, 522, 278, 285, 2366, 2373, "insulin" +816, 17, 45, 523, 286, 297, 2374, 2385, "replacement" +816, 17, 46, 524, 298, 300, 2386, 2388, "to" +816, 17, 47, 525, 301, 304, 2389, 2392, "PPT" +816, 17, 48, 526, 305, 311, 2393, 2399, "versus" +816, 17, 49, 527, 312, 315, 2400, 2403, "BBT" +816, 17, 50, 528, 316, 318, 2404, 2406, "in" +816, 17, 51, 529, 319, 323, 2407, 2411, "type" +816, 17, 52, 530, 324, 325, 2412, 2413, "2" +816, 17, 53, 531, 326, 334, 2414, 2422, "diabetes" +816, 17, 54, 532, 335, 336, 2423, 2424, "." +816, 18, 1, 533, 0, 3, 2425, 2428, "DOI" +816, 18, 2, 534, 4, 5, 2429, 2430, ":" +816, 18, 3, 535, 6, 8, 2431, 2433, "10" +816, 18, 4, 536, 9, 10, 2434, 2435, "." +816, 18, 5, 537, 11, 15, 2436, 2440, "2337" +816, 18, 6, 538, 16, 17, 2441, 2442, "/" +816, 18, 7, 539, 18, 22, 2443, 2447, "dc07" +816, 18, 8, 540, 23, 24, 2448, 2449, "-" +816, 18, 9, 541, 25, 29, 2450, 2454, "1122" +816, 18, 10, 542, 30, 34, 2455, 2459, "PMID" +816, 18, 11, 543, 35, 36, 2460, 2461, ":" +816, 18, 12, 544, 37, 45, 2462, 2470, "17934150" +816, 18, 13, 545, 46, 47, 2471, 2472, "[" +816, 18, 14, 546, 48, 55, 2473, 2480, "Indexed" +816, 18, 15, 547, 56, 59, 2481, 2484, "for" +816, 18, 16, 548, 60, 67, 2485, 2492, "MEDLINE" +816, 18, 17, 549, 68, 69, 2493, 2494, "]" diff --git a/data/dm2 17934150_admin.annodb b/data/dm2 17934150_admin.annodb new file mode 100644 index 0000000..6e2755b --- /dev/null +++ b/data/dm2 17934150_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2008", "", " \"2008\"." +98, Title, 66, 282, "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .", "", " \"Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .\"." +2, Insulin, 76, 83, "insulin", "", +3, Type2Diabetes, 95, 110, "type 2 diabetes", "", +4, InsulinGlargine, 135, 143, "glargine", "", +5, OralAntidiabeticAgent, 149, 160, "oral agents", "", +50159, LisproProtamine, 183, 207, "insulin lispro protamine", "", +97, Lispro, 221, 227, "lispro", "", +6, InsulinGlargine, 253, 261, "glargine", "", +96, Lispro, 264, 270, "lispro", "", +7, Author, 283, 295, "Rosenstock J", "", " \"Rosenstock J\"." +8, Author, 304, 313, "Ahmann AJ", "", " \"Ahmann AJ\"." +9, Author, 316, 323, "Colon G", "", " \"Colon G\"." +10, Author, 326, 341, "Scism - Bacon J", "", " \"Scism - Bacon J\"." +11, Author, 344, 351, "Jiang H", "", " \"Jiang H\"." +12, Author, 354, 362, "Martin S", "", " \"Martin S\"." +13, USA, 467, 470, "USA", "", " ." +27, ObjectiveDescription, 524, 668, "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )", "", " \"The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )\"." +174, ObjectiveDescription, 669, 843, "in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT .", "", " \"in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT .\"." +18, Type2Diabetes, 672, 687, "type 2 diabetic", "", +20, Precondition, 672, 780, "type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents", "", " \"type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents\"." +19, InsulinGlargine, 721, 737, "insulin glargine", "", +21, DoseValue, 740, 749, "> or = 30", "", +22, BioAndMedicalUnit, 750, 755, "units", "", +50160, Interval, 758, 761, "day", "", +24, OralAntidiabeticAgent, 769, 780, "oral agents", "", +28, Randomized, 888, 896, "randomly", "", " ." +51216, Lispro50/50, 915, 933, "lispro mix 50 / 50", "", " ." +51217, LisproProtamine, 941, 965, "insulin lispro protamine", "", +114, Lispro, 986, 992, "lispro", "", +30, NumberPatientsArm, 999, 1002, "187", "", " \"187\"." +31, Frequency, 1005, 1014, "t . i . d", "", " \"t . i . d\"." +33, InsulinGlargine, 1037, 1045, "glargine", "", " ." +51224, Bedtime, 1049, 1056, "bedtime", "", " ." +34, RelativeTime, 1062, 1070, "mealtime", "", " . ." +119, Lispro, 1071, 1077, "lispro", "", " ." +35, NumberPatientsArm, 1084, 1087, "187", "", " \"187\"." +36, Duration, 1095, 1104, "24 - week", "", " \"24 - week\"." +37, Multicenter, 1107, 1118, "multicenter", "", " ." +38, OpenLabel, 1121, 1133, "open - label", "", " ." +39, CTDesign, 1136, 1150, "noninferiority", "", " . ." +51214, Lispro50/50, 1187, 1205, "lispro mix 50 / 50", "", +51215, Lispro75/25, 1218, 1229, "mix 75 / 25", "", +40, Bedtime, 1237, 1249, "evening meal", "", +41, FastingPlasmaGlucose_target, 1257, 1286, "fasting plasma glucose target", "", +181, TimePoint, 1316, 1324, "Baseline", "", " \"Baseline\". \"Baseline\"." +42, HbA1c, 1325, 1328, "A1C", "", " ." +48, BaseLineValue, 1347, 1352, "8 . 8", "", " \"8 . 8\". \"8 . 8\"." +47, Percentage, 1353, 1354, "%", "", " ." +49, BaseLineValue, 1361, 1366, "8 . 9", "", " \"8 . 9\". \"8 . 9\"." +46, Percentage, 1367, 1368, "%", "", +45, PvalueDiff, 1371, 1382, "P = 0 . 598", "", " \"P = 0 . 598\"." +131, TimePoint, 1390, 1397, "week 24", "", " \"week 24\". \"week 24\"." +50, HbA1c, 1400, 1403, "A1C", "", +52, ResultMeasuredValue, 1425, 1431, "6 . 78", "", " \"6 . 78\"." +53, ResultMeasuredValue, 1437, 1443, "6 . 95", "", " \"6 . 78\"." +54, Percentage, 1444, 1445, "%", "", +55, PvalueDiff, 1448, 1459, "P = 0 . 021", "", " \"P = 0 . 021\"." +56, HbA1c, 1464, 1467, "A1C", "", +57, ObservedResult, 1468, 1526, "was reduced significantly from baseline for both therapies", "", " \"was reduced significantly from baseline for both therapies\". \"was reduced significantly from baseline for both therapies\"." +191, TimePoint, 1499, 1507, "baseline", "", +50165, PValueChangeValue, 1529, 1541, "P < 0 . 0001", "", " \"P < 0 . 0001\". \"P < 0 . 0001\"." +59, HbA1c, 1564, 1567, "A1C", "", +183, TimePoint, 1580, 1588, "baseline", "", +184, TimePoint, 1596, 1605, "end point", "", +65, DiffGroupAbsValue, 1628, 1636, "- 0 . 22", "", " \"- 0 . 22\"." +66, Percentage, 1637, 1638, "%", "", +67, ConfIntervalDiff, 1641, 1669, "90 % CI - 0 . 38 to - 0 . 07", "", " \"90 % CI - 0 . 38 to - 0 . 07\"." +185, ObservedResult, 1674, 1782, "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %", "", " \"Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %\". \"Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %\"." +64, HbA1c_target, 1823, 1843, "target A1C < 7 . 0 %", "", " ." +139, Percentage, 1842, 1843, "%", "", +70, PercentageAffected, 1883, 1885, "54", "", " \"54\"." +71, PercentageAffected, 1891, 1893, "69", "", " \"69\"." +72, PvalueDiff, 1898, 1909, "P = 0 . 009", "", " \"P = 0 . 009\"." +73, HbA1c_target, 1920, 1941, "target < or = 6 . 5 %", "", " ." +141, Percentage, 1940, 1941, "%", "", +74, PercentageAffected, 1947, 1949, "35", "", " \"35\"." +75, PercentageAffected, 1955, 1957, "50", "", " \"50\"." +142, Percentage, 1958, 1959, "%", "", +76, PvalueDiff, 1962, 1972, "P = 0 . 01", "", " \"P = 0 . 01\"." +78, HbA1c_target, 1998, 2032, "target < or = 6 . 0 % or < 7 . 5 %", "", +143, Percentage, 2018, 2019, "%", "", +144, Percentage, 2031, 2032, "%", "", +186, ObservedResult, 2035, 2085, "Rates of hypoglycemia were similar for both groups", "", " \"Rates of hypoglycemia were similar for both groups\"." +79, Hypoglycemia, 2044, 2056, "hypoglycemia", "", " ." +89, ConclusionComment, 2102, 2308, "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered", "", " \"Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered\"." +84, HbA1c, 2176, 2179, "A1C", "", +85, HbA1c_target, 2225, 2236, "A1C targets", "", +86, Hypoglycemia, 2239, 2251, "hypoglycemia", "", +187, ConclusionComment, 2309, 2424, "in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes .", "", " \"in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes .\"." +87, Insulin, 2366, 2373, "insulin", "", +88, Type2Diabetes, 2407, 2422, "type 2 diabetes", "", +90, PMID, 2462, 2470, "17934150", "", " \"17934150\"." diff --git a/data/dm2 17934150_admin.n-triples b/data/dm2 17934150_admin.n-triples new file mode 100644 index 0000000..e618db2 --- /dev/null +++ b/data/dm2 17934150_admin.n-triples @@ -0,0 +1,191 @@ +# RDF export of group: Publication + . + "Publication " . + "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy ." . + "Rosenstock J" . + "2008" . + "Diabetes Care" . + "17934150" . + . + "Ahmann AJ" . + "Colon G" . + "Scism - Bacon J" . + "Jiang H" . + "Martin S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )" . + "24 - week" . + . + . + . + "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered" . + . + . + . + . + . + "in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT ." . + . + . + . + . + "in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target 1" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint hba1c target 2" . + . + . + . + . +# RDF export of group: Arm + . + "Arm ppt " . + "187" . + . + . + . + . + . + . + . + "Arm bbt" . + "187" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ppt" . + . + "t . i . d" . + . + . + "Intervention bbt" . + . + . + . + . + . +# RDF export of group: Medication + . + "Medication ppt" . + . + . + . + . + "Medication bbt1" . + . + . + . + . + "Medication bbt2" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c ppt baseline" . + . + "8 . 8" . + "Baseline" . + . + "Outcome hba1c bbt baseline" . + . + "8 . 9" . + "Baseline" . + . + "Outcome hba1c ppt" . + . + "8 . 8" . + "6 . 95" . + "P < 0 . 0001" . + "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %" . + "week 24" . + "was reduced significantly from baseline for both therapies" . + . + "Outcome hba1c bbt" . + . + "8 . 9" . + "6 . 78" . + "P < 0 . 0001" . + "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 %" . + "week 24" . + "was reduced significantly from baseline for both therapies" . + . + "Outcome hba1c target 1 ppt" . + . + "54" . + . + "Outcome hba1c target 1 bbt" . + . + "69" . + . + "Outcome hba1c target 2 ppt" . + . + "35" . + . + "Outcome hba1c target 2 bbt " . + . + "50" . + . + "Outcome h both drugs" . + . + "Rates of hypoglycemia were similar for both groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c baseline" . + "P = 0 . 598" . + . + . + . + "DiffBetweenGroups hba1c" . + "- 0 . 22" . + "P = 0 . 021" . + "90 % CI - 0 . 38 to - 0 . 07" . + . + . + . + "DiffBetweenGroups hba1c target 1" . + "P = 0 . 009" . + . + . + . + "DiffBetweenGroups hba1c target 2" . + "P = 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17934150_akramersunderbrink.annodb b/data/dm2 17934150_akramersunderbrink.annodb new file mode 100644 index 0000000..bf99052 --- /dev/null +++ b/data/dm2 17934150_akramersunderbrink.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22524, Journal, 0, 13, "Diabetes Care", "", +22525, PublicationYear, 16, 20, "2008", "", +22532, Title, 66, 282, "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .", "", +22526, Type2Diabetes, 95, 110, "type 2 diabetes", "", +22527, InsulinGlargine, 135, 143, "glargine", "", +22550, Drug, 183, 218, "insulin lispro protamine suspension", "", +22531, Lispro, 221, 227, "lispro", "", +22528, InsulinGlargine, 253, 261, "glargine", "", +22529, Lispro, 264, 270, "lispro", "", +22533, Author, 283, 295, "Rosenstock J", "", +22534, Author, 304, 313, "Ahmann AJ", "", +22535, Author, 316, 323, "Colon G", "", +22536, Author, 326, 341, "Scism - Bacon J", "", +22537, Author, 344, 351, "Jiang H", "", +22538, Author, 354, 362, "Martin S", "", +22539, USA, 467, 470, "USA", "", +22544, ObjectiveDescription, 524, 773, "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] ) in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral", "", +22540, Type2Diabetes, 672, 687, "type 2 diabetic", "", +22541, InsulinGlargine, 721, 737, "insulin glargine", "", +22542, DoseValue, 747, 749, "30", "", +22543, BioAndMedicalUnit, 750, 761, "units / day", "", +22545, ObjectiveDescription, 774, 843, "agents , with the aim of demonstrating noninferiority of PPT to BBT .", "", +22546, Lispro, 915, 921, "lispro", "", +22547, Drug, 941, 976, "insulin lispro protamine suspension", "", +22548, Lispro, 986, 992, "lispro", "", +22549, NumberPatientsArm, 999, 1002, "187", "", +22551, Frequency, 1005, 1014, "t . i . d", "", +22552, InsulinGlargine, 1037, 1045, "glargine", "", +22554, RelativeTime, 1049, 1056, "bedtime", "", +22555, RelativeTime, 1062, 1070, "mealtime", "", +22553, Lispro, 1071, 1077, "lispro", "", +22556, Duration, 1095, 1104, "24 - week", "", +22557, Multicenter, 1107, 1118, "multicenter", "", +22558, OpenLabel, 1121, 1133, "open - label", "", +22559, Lispro, 1187, 1193, "lispro", "", +39159, TimePoint, 1316, 1324, "Baseline", "", +22560, HbA1c, 1325, 1328, "A1C", "", +22561, BaseLineValue, 1347, 1352, "8 . 8", "", +22563, Percentage, 1353, 1354, "%", "", +22562, BaseLineValue, 1361, 1366, "8 . 9", "", +22564, Percentage, 1367, 1368, "%", "", +22581, PvalueDiff, 1371, 1382, "P = 0 . 598", "", +22565, TimePoint, 1390, 1397, "week 24", "", +22567, HbA1c, 1400, 1403, "A1C", "", +22568, ResultMeasuredValue, 1425, 1431, "6 . 78", "", +22569, ResultMeasuredValue, 1437, 1443, "6 . 95", "", +22570, Percentage, 1444, 1445, "%", "", +22580, PvalueDiff, 1448, 1459, "P = 0 . 021", "", +22586, HbA1c, 1464, 1467, "A1C", "", +39160, TimePoint, 1499, 1507, "baseline", "", +22588, PValueChangeValue, 1529, 1541, "P < 0 . 0001", "", +22582, HbA1c, 1564, 1605, "A1C change from baseline to the end point", "", +39157, TimePoint, 1580, 1588, "baseline", "", +39158, TimePoint, 1596, 1605, "end point", "", +22583, DiffBetweenGroups, 1628, 1636, "- 0 . 22", "", +22571, Percentage, 1637, 1638, "%", "", +22585, ConfIntervalDiff, 1641, 1669, "90 % CI - 0 . 38 to - 0 . 07", "", +22572, Percentage, 1644, 1645, "%", "", +22573, Percentage, 1781, 1782, "%", "", +22590, EndPointDescription, 1804, 1843, "patients achieving target A1C < 7 . 0 %", "", +22589, HbA1c, 1830, 1833, "A1C", "", +22574, Percentage, 1842, 1843, "%", "", +22591, PercentageAffected, 1883, 1885, "54", "", +22592, PercentageAffected, 1891, 1893, "69", "", +22575, Percentage, 1894, 1895, "%", "", +22595, PvalueDiff, 1898, 1909, "P = 0 . 009", "", +22596, EndPointDescription, 1920, 1941, "target < or = 6 . 5 %", "", +22576, Percentage, 1940, 1941, "%", "", +22593, PercentageAffected, 1947, 1949, "35", "", +22594, PercentageAffected, 1955, 1957, "50", "", +22577, Percentage, 1958, 1959, "%", "", +22597, PvalueDiff, 1962, 1972, "P = 0 . 01", "", +22598, EndPointDescription, 1998, 2017, "target < or = 6 . 0", "", +22578, Percentage, 2018, 2019, "%", "", +22599, EndPointDescription, 2023, 2030, "< 7 . 5", "", +22579, Percentage, 2031, 2032, "%", "", +22600, Hypoglycemia, 2044, 2056, "hypoglycemia", "", +22605, ConclusionComment, 2102, 2355, "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered in the individual decision - making process of", "", +22601, HbA1c, 2176, 2179, "A1C", "", +22602, HbA1c, 2225, 2228, "A1C", "", +22603, Hypoglycemia, 2239, 2251, "hypoglycemia", "", +22605, ConclusionComment, 2356, 2424, "advancing insulin replacement to PPT versus BBT in type 2 diabetes .", "", +22604, Type2Diabetes, 2407, 2422, "type 2 diabetes", "", +22607, PMID, 2462, 2470, "17934150", "", diff --git a/data/dm2 17934150_akramersunderbrink.n-triples b/data/dm2 17934150_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17934150_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17934150_export.csv b/data/dm2 17934150_export.csv new file mode 100644 index 0000000..2e4b2a1 --- /dev/null +++ b/data/dm2 17934150_export.csv @@ -0,0 +1,550 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +350, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +350, 1, 2, 2, 9, 13, 9, 13, "Care" +350, 1, 3, 3, 14, 15, 14, 15, "." +350, 2, 1, 4, 0, 4, 16, 20, "2008" +350, 2, 2, 5, 5, 8, 21, 24, "Jan" +350, 2, 3, 6, 9, 10, 25, 26, ";" +350, 2, 4, 7, 11, 13, 27, 29, "31" +350, 2, 5, 8, 14, 15, 30, 31, "(" +350, 2, 6, 9, 16, 17, 32, 33, "1" +350, 2, 7, 10, 18, 19, 34, 35, ")" +350, 2, 8, 11, 20, 21, 36, 37, ":" +350, 2, 9, 12, 22, 24, 38, 40, "20" +350, 2, 10, 13, 25, 26, 41, 42, "-" +350, 2, 11, 14, 27, 28, 43, 44, "5" +350, 2, 12, 15, 29, 30, 45, 46, "." +350, 3, 1, 16, 0, 4, 47, 51, "Epub" +350, 3, 2, 17, 5, 9, 52, 56, "2007" +350, 3, 3, 18, 10, 13, 57, 60, "Oct" +350, 3, 4, 19, 14, 16, 61, 63, "12" +350, 3, 5, 20, 17, 18, 64, 65, "." +350, 4, 1, 21, 0, 9, 66, 75, "Advancing" +350, 4, 2, 22, 10, 17, 76, 83, "insulin" +350, 4, 3, 23, 18, 25, 84, 91, "therapy" +350, 4, 4, 24, 26, 28, 92, 94, "in" +350, 4, 5, 25, 29, 33, 95, 99, "type" +350, 4, 6, 26, 34, 35, 100, 101, "2" +350, 4, 7, 27, 36, 44, 102, 110, "diabetes" +350, 4, 8, 28, 45, 55, 111, 121, "previously" +350, 4, 9, 29, 56, 63, 122, 129, "treated" +350, 4, 10, 30, 64, 68, 130, 134, "with" +350, 4, 11, 31, 69, 77, 135, 143, "glargine" +350, 4, 12, 32, 78, 82, 144, 148, "plus" +350, 4, 13, 33, 83, 87, 149, 153, "oral" +350, 4, 14, 34, 88, 94, 154, 160, "agents" +350, 4, 15, 35, 95, 96, 161, 162, ":" +350, 4, 16, 36, 97, 105, 163, 171, "prandial" +350, 4, 17, 37, 106, 114, 172, 180, "premixed" +350, 4, 18, 38, 115, 116, 181, 182, "(" +350, 4, 19, 39, 117, 124, 183, 190, "insulin" +350, 4, 20, 40, 125, 131, 191, 197, "lispro" +350, 4, 21, 41, 132, 141, 198, 207, "protamine" +350, 4, 22, 42, 142, 152, 208, 218, "suspension" +350, 4, 23, 43, 153, 154, 219, 220, "/" +350, 4, 24, 44, 155, 161, 221, 227, "lispro" +350, 4, 25, 45, 162, 163, 228, 229, ")" +350, 4, 26, 46, 164, 170, 230, 236, "versus" +350, 4, 27, 47, 171, 176, 237, 242, "basal" +350, 4, 28, 48, 177, 178, 243, 244, "/" +350, 4, 29, 49, 179, 184, 245, 250, "bolus" +350, 4, 30, 50, 185, 186, 251, 252, "(" +350, 4, 31, 51, 187, 195, 253, 261, "glargine" +350, 4, 32, 52, 196, 197, 262, 263, "/" +350, 4, 33, 53, 198, 204, 264, 270, "lispro" +350, 4, 34, 54, 205, 206, 271, 272, ")" +350, 4, 35, 55, 207, 214, 273, 280, "therapy" +350, 4, 36, 56, 215, 216, 281, 282, "." +350, 5, 1, 57, 0, 10, 283, 293, "Rosenstock" +350, 5, 2, 58, 11, 12, 294, 295, "J" +350, 5, 3, 59, 13, 14, 296, 297, "(" +350, 5, 4, 60, 15, 16, 298, 299, "1" +350, 5, 5, 61, 17, 18, 300, 301, ")" +350, 5, 6, 62, 19, 20, 302, 303, "," +350, 5, 7, 63, 21, 27, 304, 310, "Ahmann" +350, 5, 8, 64, 28, 30, 311, 313, "AJ" +350, 5, 9, 65, 31, 32, 314, 315, "," +350, 5, 10, 66, 33, 38, 316, 321, "Colon" +350, 5, 11, 67, 39, 40, 322, 323, "G" +350, 5, 12, 68, 41, 42, 324, 325, "," +350, 5, 13, 69, 43, 48, 326, 331, "Scism" +350, 5, 14, 70, 49, 50, 332, 333, "-" +350, 5, 15, 71, 51, 56, 334, 339, "Bacon" +350, 5, 16, 72, 57, 58, 340, 341, "J" +350, 5, 17, 73, 59, 60, 342, 343, "," +350, 5, 18, 74, 61, 66, 344, 349, "Jiang" +350, 5, 19, 75, 67, 68, 350, 351, "H" +350, 5, 20, 76, 69, 70, 352, 353, "," +350, 5, 21, 77, 71, 77, 354, 360, "Martin" +350, 5, 22, 78, 78, 79, 361, 362, "S" +350, 5, 23, 79, 80, 81, 363, 364, "." +350, 5, 24, 80, 82, 88, 365, 371, "Author" +350, 5, 25, 81, 89, 100, 372, 383, "information" +350, 5, 26, 82, 101, 102, 384, 385, ":" +350, 5, 27, 83, 103, 104, 386, 387, "(" +350, 5, 28, 84, 105, 106, 388, 389, "1" +350, 5, 29, 85, 107, 108, 390, 391, ")" +350, 5, 30, 86, 109, 115, 392, 398, "Dallas" +350, 5, 31, 87, 116, 124, 399, 407, "Diabetes" +350, 5, 32, 88, 125, 128, 408, 411, "and" +350, 5, 33, 89, 129, 138, 412, 421, "Endocrine" +350, 5, 34, 90, 139, 145, 422, 428, "Center" +350, 5, 35, 91, 146, 148, 429, 431, "at" +350, 5, 36, 92, 149, 156, 432, 439, "Medical" +350, 5, 37, 93, 157, 161, 440, 444, "City" +350, 5, 38, 94, 162, 163, 445, 446, "," +350, 5, 39, 95, 164, 170, 447, 453, "Dallas" +350, 5, 40, 96, 171, 172, 454, 455, "," +350, 5, 41, 97, 173, 175, 456, 458, "TX" +350, 5, 42, 98, 176, 181, 459, 464, "75230" +350, 5, 43, 99, 182, 183, 465, 466, "," +350, 5, 44, 100, 184, 187, 467, 470, "USA" +350, 5, 45, 101, 188, 189, 471, 472, "." +350, 6, 1, 102, 0, 15, 473, 488, "juliorosenstock" +350, 6, 2, 103, 16, 17, 489, 490, "@" +350, 6, 3, 104, 18, 32, 491, 505, "dallasdiabetes" +350, 6, 4, 105, 33, 34, 506, 507, "." +350, 6, 5, 106, 35, 38, 508, 511, "com" +350, 6, 6, 107, 39, 48, 512, 521, "OBJECTIVE" +350, 6, 7, 108, 49, 50, 522, 523, ":" +350, 6, 8, 109, 51, 54, 524, 527, "The" +350, 6, 9, 110, 55, 62, 528, 535, "purpose" +350, 6, 10, 111, 63, 65, 536, 538, "of" +350, 6, 11, 112, 66, 70, 539, 543, "this" +350, 6, 12, 113, 71, 76, 544, 549, "study" +350, 6, 13, 114, 77, 80, 550, 553, "was" +350, 6, 14, 115, 81, 83, 554, 556, "to" +350, 6, 15, 116, 84, 91, 557, 564, "compare" +350, 6, 16, 117, 92, 95, 565, 568, "two" +350, 6, 17, 118, 96, 102, 569, 575, "analog" +350, 6, 18, 119, 103, 110, 576, 583, "insulin" +350, 6, 19, 120, 111, 120, 584, 593, "therapies" +350, 6, 20, 121, 121, 122, 594, 595, "(" +350, 6, 21, 122, 123, 131, 596, 604, "prandial" +350, 6, 22, 123, 132, 140, 605, 613, "premixed" +350, 6, 23, 124, 141, 148, 614, 621, "therapy" +350, 6, 24, 125, 149, 150, 622, 623, "[" +350, 6, 25, 126, 151, 154, 624, 627, "PPT" +350, 6, 26, 127, 155, 156, 628, 629, "]" +350, 6, 27, 128, 157, 163, 630, 636, "versus" +350, 6, 28, 129, 164, 169, 637, 642, "basal" +350, 6, 29, 130, 170, 171, 643, 644, "/" +350, 6, 30, 131, 172, 177, 645, 650, "bolus" +350, 6, 31, 132, 178, 185, 651, 658, "therapy" +350, 6, 32, 133, 186, 187, 659, 660, "[" +350, 6, 33, 134, 188, 191, 661, 664, "BBT" +350, 6, 34, 135, 192, 193, 665, 666, "]" +350, 6, 35, 136, 194, 195, 667, 668, ")" +350, 6, 36, 137, 196, 198, 669, 671, "in" +350, 6, 37, 138, 199, 203, 672, 676, "type" +350, 6, 38, 139, 204, 205, 677, 678, "2" +350, 6, 39, 140, 206, 214, 679, 687, "diabetic" +350, 6, 40, 141, 215, 223, 688, 696, "patients" +350, 6, 41, 142, 224, 234, 697, 707, "previously" +350, 6, 42, 143, 235, 242, 708, 715, "treated" +350, 6, 43, 144, 243, 247, 716, 720, "with" +350, 6, 44, 145, 248, 255, 721, 728, "insulin" +350, 6, 45, 146, 256, 264, 729, 737, "glargine" +350, 6, 46, 147, 265, 266, 738, 739, "(" +350, 6, 47, 148, 267, 268, 740, 741, ">" +350, 6, 48, 149, 269, 271, 742, 744, "or" +350, 6, 49, 150, 272, 273, 745, 746, "=" +350, 6, 50, 151, 274, 276, 747, 749, "30" +350, 6, 51, 152, 277, 282, 750, 755, "units" +350, 6, 52, 153, 283, 284, 756, 757, "/" +350, 6, 53, 154, 285, 288, 758, 761, "day" +350, 6, 54, 155, 289, 290, 762, 763, ")" +350, 6, 55, 156, 291, 295, 764, 768, "plus" +350, 6, 56, 157, 296, 300, 769, 773, "oral" +350, 6, 57, 158, 301, 307, 774, 780, "agents" +350, 6, 58, 159, 308, 309, 781, 782, "," +350, 6, 59, 160, 310, 314, 783, 787, "with" +350, 6, 60, 161, 315, 318, 788, 791, "the" +350, 6, 61, 162, 319, 322, 792, 795, "aim" +350, 6, 62, 163, 323, 325, 796, 798, "of" +350, 6, 63, 164, 326, 339, 799, 812, "demonstrating" +350, 6, 64, 165, 340, 354, 813, 827, "noninferiority" +350, 6, 65, 166, 355, 357, 828, 830, "of" +350, 6, 66, 167, 358, 361, 831, 834, "PPT" +350, 6, 67, 168, 362, 364, 835, 837, "to" +350, 6, 68, 169, 365, 368, 838, 841, "BBT" +350, 6, 69, 170, 369, 370, 842, 843, "." +350, 7, 1, 171, 0, 8, 844, 852, "RESEARCH" +350, 7, 2, 172, 9, 15, 853, 859, "DESIGN" +350, 7, 3, 173, 16, 19, 860, 863, "AND" +350, 7, 4, 174, 20, 27, 864, 871, "METHODS" +350, 7, 5, 175, 28, 29, 872, 873, ":" +350, 7, 6, 176, 30, 38, 874, 882, "Patients" +350, 7, 7, 177, 39, 43, 883, 887, "were" +350, 7, 8, 178, 44, 52, 888, 896, "randomly" +350, 7, 9, 179, 53, 61, 897, 905, "assigned" +350, 7, 10, 180, 62, 64, 906, 908, "to" +350, 7, 11, 181, 65, 68, 909, 912, "PPT" +350, 7, 12, 182, 69, 70, 913, 914, "(" +350, 7, 13, 183, 71, 77, 915, 921, "lispro" +350, 7, 14, 184, 78, 81, 922, 925, "mix" +350, 7, 15, 185, 82, 84, 926, 928, "50" +350, 7, 16, 186, 85, 86, 929, 930, "/" +350, 7, 17, 187, 87, 89, 931, 933, "50" +350, 7, 18, 188, 90, 91, 934, 935, ":" +350, 7, 19, 189, 92, 94, 936, 938, "50" +350, 7, 20, 190, 95, 96, 939, 940, "%" +350, 7, 21, 191, 97, 104, 941, 948, "insulin" +350, 7, 22, 192, 105, 111, 949, 955, "lispro" +350, 7, 23, 193, 112, 121, 956, 965, "protamine" +350, 7, 24, 194, 122, 132, 966, 976, "suspension" +350, 7, 25, 195, 133, 136, 977, 980, "and" +350, 7, 26, 196, 137, 139, 981, 983, "50" +350, 7, 27, 197, 140, 141, 984, 985, "%" +350, 7, 28, 198, 142, 148, 986, 992, "lispro" +350, 7, 29, 199, 149, 150, 993, 994, ";" +350, 7, 30, 200, 151, 152, 995, 996, "n" +350, 7, 31, 201, 153, 154, 997, 998, "=" +350, 7, 32, 202, 155, 158, 999, 1002, "187" +350, 7, 33, 203, 159, 160, 1003, 1004, ")" +350, 7, 34, 204, 161, 162, 1005, 1006, "t" +350, 7, 35, 205, 163, 164, 1007, 1008, "." +350, 7, 36, 206, 165, 166, 1009, 1010, "i" +350, 7, 37, 207, 167, 168, 1011, 1012, "." +350, 7, 38, 208, 169, 170, 1013, 1014, "d" +350, 7, 39, 209, 171, 172, 1015, 1016, "." +350, 8, 1, 210, 0, 4, 1017, 1021, "with" +350, 8, 2, 211, 5, 10, 1022, 1027, "meals" +350, 8, 3, 212, 11, 13, 1028, 1030, "or" +350, 8, 4, 213, 14, 17, 1031, 1034, "BBT" +350, 8, 5, 214, 18, 19, 1035, 1036, "(" +350, 8, 6, 215, 20, 28, 1037, 1045, "glargine" +350, 8, 7, 216, 29, 31, 1046, 1048, "at" +350, 8, 8, 217, 32, 39, 1049, 1056, "bedtime" +350, 8, 9, 218, 40, 44, 1057, 1061, "plus" +350, 8, 10, 219, 45, 53, 1062, 1070, "mealtime" +350, 8, 11, 220, 54, 60, 1071, 1077, "lispro" +350, 8, 12, 221, 61, 62, 1078, 1079, ";" +350, 8, 13, 222, 63, 64, 1080, 1081, "n" +350, 8, 14, 223, 65, 66, 1082, 1083, "=" +350, 8, 15, 224, 67, 70, 1084, 1087, "187" +350, 8, 16, 225, 71, 72, 1088, 1089, ")" +350, 8, 17, 226, 73, 75, 1090, 1092, "in" +350, 8, 18, 227, 76, 77, 1093, 1094, "a" +350, 8, 19, 228, 78, 80, 1095, 1097, "24" +350, 8, 20, 229, 81, 82, 1098, 1099, "-" +350, 8, 21, 230, 83, 87, 1100, 1104, "week" +350, 8, 22, 231, 88, 89, 1105, 1106, "," +350, 8, 23, 232, 90, 101, 1107, 1118, "multicenter" +350, 8, 24, 233, 102, 103, 1119, 1120, "," +350, 8, 25, 234, 104, 108, 1121, 1125, "open" +350, 8, 26, 235, 109, 110, 1126, 1127, "-" +350, 8, 27, 236, 111, 116, 1128, 1133, "label" +350, 8, 28, 237, 117, 118, 1134, 1135, "," +350, 8, 29, 238, 119, 133, 1136, 1150, "noninferiority" +350, 8, 30, 239, 134, 139, 1151, 1156, "trial" +350, 8, 31, 240, 140, 141, 1157, 1158, "." +350, 9, 1, 241, 0, 13, 1159, 1172, "Investigators" +350, 9, 2, 242, 14, 19, 1173, 1178, "could" +350, 9, 3, 243, 20, 27, 1179, 1186, "replace" +350, 9, 4, 244, 28, 34, 1187, 1193, "lispro" +350, 9, 5, 245, 35, 38, 1194, 1197, "mix" +350, 9, 6, 246, 39, 41, 1198, 1200, "50" +350, 9, 7, 247, 42, 43, 1201, 1202, "/" +350, 9, 8, 248, 44, 46, 1203, 1205, "50" +350, 9, 9, 249, 47, 51, 1206, 1210, "with" +350, 9, 10, 250, 52, 58, 1211, 1217, "lispro" +350, 9, 11, 251, 59, 62, 1218, 1221, "mix" +350, 9, 12, 252, 63, 65, 1222, 1224, "75" +350, 9, 13, 253, 66, 67, 1225, 1226, "/" +350, 9, 14, 254, 68, 70, 1227, 1229, "25" +350, 9, 15, 255, 71, 73, 1230, 1232, "at" +350, 9, 16, 256, 74, 77, 1233, 1236, "the" +350, 9, 17, 257, 78, 85, 1237, 1244, "evening" +350, 9, 18, 258, 86, 90, 1245, 1249, "meal" +350, 9, 19, 259, 91, 93, 1250, 1252, "if" +350, 9, 20, 260, 94, 97, 1253, 1256, "the" +350, 9, 21, 261, 98, 105, 1257, 1264, "fasting" +350, 9, 22, 262, 106, 112, 1265, 1271, "plasma" +350, 9, 23, 263, 113, 120, 1272, 1279, "glucose" +350, 9, 24, 264, 121, 127, 1280, 1286, "target" +350, 9, 25, 265, 128, 131, 1287, 1290, "was" +350, 9, 26, 266, 132, 144, 1291, 1303, "unachievable" +350, 9, 27, 267, 145, 146, 1304, 1305, "." +350, 10, 1, 268, 0, 7, 1306, 1313, "RESULTS" +350, 10, 2, 269, 8, 9, 1314, 1315, ":" +350, 10, 3, 270, 10, 18, 1316, 1324, "Baseline" +350, 10, 4, 271, 19, 22, 1325, 1328, "A1C" +350, 10, 5, 272, 23, 26, 1329, 1332, "was" +350, 10, 6, 273, 27, 34, 1333, 1340, "similar" +350, 10, 7, 274, 35, 36, 1341, 1342, "(" +350, 10, 8, 275, 37, 40, 1343, 1346, "PPT" +350, 10, 9, 276, 41, 42, 1347, 1348, "8" +350, 10, 10, 277, 43, 44, 1349, 1350, "." +350, 10, 11, 278, 45, 46, 1351, 1352, "8" +350, 10, 12, 279, 47, 48, 1353, 1354, "%" +350, 10, 13, 280, 49, 50, 1355, 1356, ";" +350, 10, 14, 281, 51, 54, 1357, 1360, "BBT" +350, 10, 15, 282, 55, 56, 1361, 1362, "8" +350, 10, 16, 283, 57, 58, 1363, 1364, "." +350, 10, 17, 284, 59, 60, 1365, 1366, "9" +350, 10, 18, 285, 61, 62, 1367, 1368, "%" +350, 10, 19, 286, 63, 64, 1369, 1370, ";" +350, 10, 20, 287, 65, 66, 1371, 1372, "P" +350, 10, 21, 288, 67, 68, 1373, 1374, "=" +350, 10, 22, 289, 69, 70, 1375, 1376, "0" +350, 10, 23, 290, 71, 72, 1377, 1378, "." +350, 10, 24, 291, 73, 76, 1379, 1382, "598" +350, 10, 25, 292, 77, 78, 1383, 1384, ")" +350, 10, 26, 293, 79, 80, 1385, 1386, "." +350, 11, 1, 294, 0, 2, 1387, 1389, "At" +350, 11, 2, 295, 3, 7, 1390, 1394, "week" +350, 11, 3, 296, 8, 10, 1395, 1397, "24" +350, 11, 4, 297, 11, 12, 1398, 1399, "," +350, 11, 5, 298, 13, 16, 1400, 1403, "A1C" +350, 11, 6, 299, 17, 20, 1404, 1407, "was" +350, 11, 7, 300, 21, 26, 1408, 1413, "lower" +350, 11, 8, 301, 27, 31, 1414, 1418, "with" +350, 11, 9, 302, 32, 35, 1419, 1422, "BBT" +350, 11, 10, 303, 36, 37, 1423, 1424, "(" +350, 11, 11, 304, 38, 39, 1425, 1426, "6" +350, 11, 12, 305, 40, 41, 1427, 1428, "." +350, 11, 13, 306, 42, 44, 1429, 1431, "78" +350, 11, 14, 307, 45, 47, 1432, 1434, "vs" +350, 11, 15, 308, 48, 49, 1435, 1436, "." +350, 11, 16, 309, 50, 51, 1437, 1438, "6" +350, 11, 17, 310, 52, 53, 1439, 1440, "." +350, 11, 18, 311, 54, 56, 1441, 1443, "95" +350, 11, 19, 312, 57, 58, 1444, 1445, "%" +350, 11, 20, 313, 59, 60, 1446, 1447, "," +350, 11, 21, 314, 61, 62, 1448, 1449, "P" +350, 11, 22, 315, 63, 64, 1450, 1451, "=" +350, 11, 23, 316, 65, 66, 1452, 1453, "0" +350, 11, 24, 317, 67, 68, 1454, 1455, "." +350, 11, 25, 318, 69, 72, 1456, 1459, "021" +350, 11, 26, 319, 73, 74, 1460, 1461, ")" +350, 11, 27, 320, 75, 76, 1462, 1463, "." +350, 12, 1, 321, 0, 3, 1464, 1467, "A1C" +350, 12, 2, 322, 4, 7, 1468, 1471, "was" +350, 12, 3, 323, 8, 15, 1472, 1479, "reduced" +350, 12, 4, 324, 16, 29, 1480, 1493, "significantly" +350, 12, 5, 325, 30, 34, 1494, 1498, "from" +350, 12, 6, 326, 35, 43, 1499, 1507, "baseline" +350, 12, 7, 327, 44, 47, 1508, 1511, "for" +350, 12, 8, 328, 48, 52, 1512, 1516, "both" +350, 12, 9, 329, 53, 62, 1517, 1526, "therapies" +350, 12, 10, 330, 63, 64, 1527, 1528, "(" +350, 12, 11, 331, 65, 66, 1529, 1530, "P" +350, 12, 12, 332, 67, 68, 1531, 1532, "<" +350, 12, 13, 333, 69, 70, 1533, 1534, "0" +350, 12, 14, 334, 71, 72, 1535, 1536, "." +350, 12, 15, 335, 73, 77, 1537, 1541, "0001" +350, 12, 16, 336, 78, 79, 1542, 1543, ")" +350, 12, 17, 337, 80, 81, 1544, 1545, "." +350, 13, 1, 338, 0, 3, 1546, 1549, "The" +350, 13, 2, 339, 4, 14, 1550, 1560, "difference" +350, 13, 3, 340, 15, 17, 1561, 1563, "in" +350, 13, 4, 341, 18, 21, 1564, 1567, "A1C" +350, 13, 5, 342, 22, 28, 1568, 1574, "change" +350, 13, 6, 343, 29, 33, 1575, 1579, "from" +350, 13, 7, 344, 34, 42, 1580, 1588, "baseline" +350, 13, 8, 345, 43, 45, 1589, 1591, "to" +350, 13, 9, 346, 46, 49, 1592, 1595, "the" +350, 13, 10, 347, 50, 53, 1596, 1599, "end" +350, 13, 11, 348, 54, 59, 1600, 1605, "point" +350, 13, 12, 349, 60, 61, 1606, 1607, "(" +350, 13, 13, 350, 62, 65, 1608, 1611, "BBT" +350, 13, 14, 351, 66, 71, 1612, 1617, "minus" +350, 13, 15, 352, 72, 75, 1618, 1621, "PPT" +350, 13, 16, 353, 76, 77, 1622, 1623, ")" +350, 13, 17, 354, 78, 81, 1624, 1627, "was" +350, 13, 18, 355, 82, 83, 1628, 1629, "-" +350, 13, 19, 356, 84, 85, 1630, 1631, "0" +350, 13, 20, 357, 86, 87, 1632, 1633, "." +350, 13, 21, 358, 88, 90, 1634, 1636, "22" +350, 13, 22, 359, 91, 92, 1637, 1638, "%" +350, 13, 23, 360, 93, 94, 1639, 1640, "(" +350, 13, 24, 361, 95, 97, 1641, 1643, "90" +350, 13, 25, 362, 98, 99, 1644, 1645, "%" +350, 13, 26, 363, 100, 102, 1646, 1648, "CI" +350, 13, 27, 364, 103, 104, 1649, 1650, "-" +350, 13, 28, 365, 105, 106, 1651, 1652, "0" +350, 13, 29, 366, 107, 108, 1653, 1654, "." +350, 13, 30, 367, 109, 111, 1655, 1657, "38" +350, 13, 31, 368, 112, 114, 1658, 1660, "to" +350, 13, 32, 369, 115, 116, 1661, 1662, "-" +350, 13, 33, 370, 117, 118, 1663, 1664, "0" +350, 13, 34, 371, 119, 120, 1665, 1666, "." +350, 13, 35, 372, 121, 123, 1667, 1669, "07" +350, 13, 36, 373, 124, 125, 1670, 1671, ")" +350, 13, 37, 374, 126, 127, 1672, 1673, "." +350, 14, 1, 375, 0, 14, 1674, 1688, "Noninferiority" +350, 14, 2, 376, 15, 17, 1689, 1691, "of" +350, 14, 3, 377, 18, 21, 1692, 1695, "PPT" +350, 14, 4, 378, 22, 24, 1696, 1698, "to" +350, 14, 5, 379, 25, 28, 1699, 1702, "BBT" +350, 14, 6, 380, 29, 32, 1703, 1706, "was" +350, 14, 7, 381, 33, 36, 1707, 1710, "not" +350, 14, 8, 382, 37, 49, 1711, 1723, "demonstrated" +350, 14, 9, 383, 50, 55, 1724, 1729, "based" +350, 14, 10, 384, 56, 58, 1730, 1732, "on" +350, 14, 11, 385, 59, 62, 1733, 1736, "the" +350, 14, 12, 386, 63, 75, 1737, 1749, "prespecified" +350, 14, 13, 387, 76, 90, 1750, 1764, "noninferiority" +350, 14, 14, 388, 91, 97, 1765, 1771, "margin" +350, 14, 15, 389, 98, 100, 1772, 1774, "of" +350, 14, 16, 390, 101, 102, 1775, 1776, "0" +350, 14, 17, 391, 103, 104, 1777, 1778, "." +350, 14, 18, 392, 105, 106, 1779, 1780, "3" +350, 14, 19, 393, 107, 108, 1781, 1782, "%" +350, 14, 20, 394, 109, 110, 1783, 1784, "." +350, 15, 1, 395, 0, 3, 1785, 1788, "The" +350, 15, 2, 396, 4, 15, 1789, 1800, "percentages" +350, 15, 3, 397, 16, 18, 1801, 1803, "of" +350, 15, 4, 398, 19, 27, 1804, 1812, "patients" +350, 15, 5, 399, 28, 37, 1813, 1822, "achieving" +350, 15, 6, 400, 38, 44, 1823, 1829, "target" +350, 15, 7, 401, 45, 48, 1830, 1833, "A1C" +350, 15, 8, 402, 49, 50, 1834, 1835, "<" +350, 15, 9, 403, 51, 52, 1836, 1837, "7" +350, 15, 10, 404, 53, 54, 1838, 1839, "." +350, 15, 11, 405, 55, 56, 1840, 1841, "0" +350, 15, 12, 406, 57, 58, 1842, 1843, "%" +350, 15, 13, 407, 59, 60, 1844, 1845, "(" +350, 15, 14, 408, 61, 64, 1846, 1849, "PPT" +350, 15, 15, 409, 65, 71, 1850, 1856, "versus" +350, 15, 16, 410, 72, 75, 1857, 1860, "BBT" +350, 15, 17, 411, 76, 77, 1861, 1862, "," +350, 15, 18, 412, 78, 90, 1863, 1875, "respectively" +350, 15, 19, 413, 91, 92, 1876, 1877, ")" +350, 15, 20, 414, 93, 97, 1878, 1882, "were" +350, 15, 21, 415, 98, 100, 1883, 1885, "54" +350, 15, 22, 416, 101, 103, 1886, 1888, "vs" +350, 15, 23, 417, 104, 105, 1889, 1890, "." +350, 15, 24, 418, 106, 108, 1891, 1893, "69" +350, 15, 25, 419, 109, 110, 1894, 1895, "%" +350, 15, 26, 420, 111, 112, 1896, 1897, "(" +350, 15, 27, 421, 113, 114, 1898, 1899, "P" +350, 15, 28, 422, 115, 116, 1900, 1901, "=" +350, 15, 29, 423, 117, 118, 1902, 1903, "0" +350, 15, 30, 424, 119, 120, 1904, 1905, "." +350, 15, 31, 425, 121, 124, 1906, 1909, "009" +350, 15, 32, 426, 125, 126, 1910, 1911, ")" +350, 15, 33, 427, 127, 130, 1912, 1915, "and" +350, 15, 34, 428, 131, 134, 1916, 1919, "for" +350, 15, 35, 429, 135, 141, 1920, 1926, "target" +350, 15, 36, 430, 142, 143, 1927, 1928, "<" +350, 15, 37, 431, 144, 146, 1929, 1931, "or" +350, 15, 38, 432, 147, 148, 1932, 1933, "=" +350, 15, 39, 433, 149, 150, 1934, 1935, "6" +350, 15, 40, 434, 151, 152, 1936, 1937, "." +350, 15, 41, 435, 153, 154, 1938, 1939, "5" +350, 15, 42, 436, 155, 156, 1940, 1941, "%" +350, 15, 43, 437, 157, 161, 1942, 1946, "were" +350, 15, 44, 438, 162, 164, 1947, 1949, "35" +350, 15, 45, 439, 165, 167, 1950, 1952, "vs" +350, 15, 46, 440, 168, 169, 1953, 1954, "." +350, 15, 47, 441, 170, 172, 1955, 1957, "50" +350, 15, 48, 442, 173, 174, 1958, 1959, "%" +350, 15, 49, 443, 175, 176, 1960, 1961, "(" +350, 15, 50, 444, 177, 178, 1962, 1963, "P" +350, 15, 51, 445, 179, 180, 1964, 1965, "=" +350, 15, 52, 446, 181, 182, 1966, 1967, "0" +350, 15, 53, 447, 183, 184, 1968, 1969, "." +350, 15, 54, 448, 185, 187, 1970, 1972, "01" +350, 15, 55, 449, 188, 189, 1973, 1974, ")" +350, 15, 56, 450, 190, 193, 1975, 1978, "but" +350, 15, 57, 451, 194, 197, 1979, 1982, "did" +350, 15, 58, 452, 198, 201, 1983, 1986, "not" +350, 15, 59, 453, 202, 208, 1987, 1993, "differ" +350, 15, 60, 454, 209, 212, 1994, 1997, "for" +350, 15, 61, 455, 213, 219, 1998, 2004, "target" +350, 15, 62, 456, 220, 221, 2005, 2006, "<" +350, 15, 63, 457, 222, 224, 2007, 2009, "or" +350, 15, 64, 458, 225, 226, 2010, 2011, "=" +350, 15, 65, 459, 227, 228, 2012, 2013, "6" +350, 15, 66, 460, 229, 230, 2014, 2015, "." +350, 15, 67, 461, 231, 232, 2016, 2017, "0" +350, 15, 68, 462, 233, 234, 2018, 2019, "%" +350, 15, 69, 463, 235, 237, 2020, 2022, "or" +350, 15, 70, 464, 238, 239, 2023, 2024, "<" +350, 15, 71, 465, 240, 241, 2025, 2026, "7" +350, 15, 72, 466, 242, 243, 2027, 2028, "." +350, 15, 73, 467, 244, 245, 2029, 2030, "5" +350, 15, 74, 468, 246, 247, 2031, 2032, "%" +350, 15, 75, 469, 248, 249, 2033, 2034, "." +350, 16, 1, 470, 0, 5, 2035, 2040, "Rates" +350, 16, 2, 471, 6, 8, 2041, 2043, "of" +350, 16, 3, 472, 9, 21, 2044, 2056, "hypoglycemia" +350, 16, 4, 473, 22, 26, 2057, 2061, "were" +350, 16, 5, 474, 27, 34, 2062, 2069, "similar" +350, 16, 6, 475, 35, 38, 2070, 2073, "for" +350, 16, 7, 476, 39, 43, 2074, 2078, "both" +350, 16, 8, 477, 44, 50, 2079, 2085, "groups" +350, 16, 9, 478, 51, 52, 2086, 2087, "." +350, 17, 1, 479, 0, 11, 2088, 2099, "CONCLUSIONS" +350, 17, 2, 480, 12, 13, 2100, 2101, ":" +350, 17, 3, 481, 14, 22, 2102, 2110, "Although" +350, 17, 4, 482, 23, 37, 2111, 2125, "noninferiority" +350, 17, 5, 483, 38, 40, 2126, 2128, "of" +350, 17, 6, 484, 41, 44, 2129, 2132, "PPT" +350, 17, 7, 485, 45, 47, 2133, 2135, "to" +350, 17, 8, 486, 48, 51, 2136, 2139, "BBT" +350, 17, 9, 487, 52, 55, 2140, 2143, "was" +350, 17, 10, 488, 56, 59, 2144, 2147, "not" +350, 17, 11, 489, 60, 72, 2148, 2160, "demonstrated" +350, 17, 12, 490, 73, 74, 2161, 2162, "," +350, 17, 13, 491, 75, 83, 2163, 2171, "findings" +350, 17, 14, 492, 84, 87, 2172, 2175, "for" +350, 17, 15, 493, 88, 91, 2176, 2179, "A1C" +350, 17, 16, 494, 92, 101, 2180, 2189, "reduction" +350, 17, 17, 495, 102, 103, 2190, 2191, "," +350, 17, 18, 496, 104, 114, 2192, 2202, "percentage" +350, 17, 19, 497, 115, 117, 2203, 2205, "of" +350, 17, 20, 498, 118, 126, 2206, 2214, "patients" +350, 17, 21, 499, 127, 136, 2215, 2224, "achieving" +350, 17, 22, 500, 137, 140, 2225, 2228, "A1C" +350, 17, 23, 501, 141, 148, 2229, 2236, "targets" +350, 17, 24, 502, 149, 150, 2237, 2238, "," +350, 17, 25, 503, 151, 163, 2239, 2251, "hypoglycemia" +350, 17, 26, 504, 164, 165, 2252, 2253, "," +350, 17, 27, 505, 166, 169, 2254, 2257, "and" +350, 17, 28, 506, 170, 176, 2258, 2264, "number" +350, 17, 29, 507, 177, 179, 2265, 2267, "of" +350, 17, 30, 508, 180, 188, 2268, 2276, "required" +350, 17, 31, 509, 189, 199, 2277, 2287, "injections" +350, 17, 32, 510, 200, 206, 2288, 2294, "should" +350, 17, 33, 511, 207, 209, 2295, 2297, "be" +350, 17, 34, 512, 210, 220, 2298, 2308, "considered" +350, 17, 35, 513, 221, 223, 2309, 2311, "in" +350, 17, 36, 514, 224, 227, 2312, 2315, "the" +350, 17, 37, 515, 228, 238, 2316, 2326, "individual" +350, 17, 38, 516, 239, 247, 2327, 2335, "decision" +350, 17, 39, 517, 248, 249, 2336, 2337, "-" +350, 17, 40, 518, 250, 256, 2338, 2344, "making" +350, 17, 41, 519, 257, 264, 2345, 2352, "process" +350, 17, 42, 520, 265, 267, 2353, 2355, "of" +350, 17, 43, 521, 268, 277, 2356, 2365, "advancing" +350, 17, 44, 522, 278, 285, 2366, 2373, "insulin" +350, 17, 45, 523, 286, 297, 2374, 2385, "replacement" +350, 17, 46, 524, 298, 300, 2386, 2388, "to" +350, 17, 47, 525, 301, 304, 2389, 2392, "PPT" +350, 17, 48, 526, 305, 311, 2393, 2399, "versus" +350, 17, 49, 527, 312, 315, 2400, 2403, "BBT" +350, 17, 50, 528, 316, 318, 2404, 2406, "in" +350, 17, 51, 529, 319, 323, 2407, 2411, "type" +350, 17, 52, 530, 324, 325, 2412, 2413, "2" +350, 17, 53, 531, 326, 334, 2414, 2422, "diabetes" +350, 17, 54, 532, 335, 336, 2423, 2424, "." +350, 18, 1, 533, 0, 3, 2425, 2428, "DOI" +350, 18, 2, 534, 4, 5, 2429, 2430, ":" +350, 18, 3, 535, 6, 8, 2431, 2433, "10" +350, 18, 4, 536, 9, 10, 2434, 2435, "." +350, 18, 5, 537, 11, 15, 2436, 2440, "2337" +350, 18, 6, 538, 16, 17, 2441, 2442, "/" +350, 18, 7, 539, 18, 22, 2443, 2447, "dc07" +350, 18, 8, 540, 23, 24, 2448, 2449, "-" +350, 18, 9, 541, 25, 29, 2450, 2454, "1122" +350, 18, 10, 542, 30, 34, 2455, 2459, "PMID" +350, 18, 11, 543, 35, 36, 2460, 2461, ":" +350, 18, 12, 544, 37, 45, 2462, 2470, "17934150" +350, 18, 13, 545, 46, 47, 2471, 2472, "[" +350, 18, 14, 546, 48, 55, 2473, 2480, "Indexed" +350, 18, 15, 547, 56, 59, 2481, 2484, "for" +350, 18, 16, 548, 60, 67, 2485, 2492, "MEDLINE" +350, 18, 17, 549, 68, 69, 2493, 2494, "]" diff --git a/data/dm2 17934150_kwoodley.annodb b/data/dm2 17934150_kwoodley.annodb new file mode 100644 index 0000000..bb9ff04 --- /dev/null +++ b/data/dm2 17934150_kwoodley.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11442, Journal, 0, 13, "Diabetes Care", "", +11443, PublicationYear, 16, 20, "2008", "", +36802, Title, 66, 282, "Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .", "", +11444, Insulin, 76, 83, "insulin", "", +11445, Type2Diabetes, 95, 110, "type 2 diabetes", "", +11446, InsulinGlargine, 135, 143, "glargine", "", +11447, OralAntidiabeticAgent, 149, 160, "oral agents", "", +36803, Lispro, 183, 218, "insulin lispro protamine suspension", "", +36804, Lispro, 221, 227, "lispro", "", +14085, InsulinGlargine, 253, 261, "glargine", "", +36805, Lispro, 264, 270, "lispro", "", +14087, Author, 283, 295, "Rosenstock J", "", +14088, Author, 304, 313, "Ahmann AJ", "", +14089, Author, 316, 323, "Colon G", "", +14090, Author, 326, 341, "Scism - Bacon J", "", +14091, Author, 344, 351, "Jiang H", "", +14092, Author, 354, 362, "Martin S", "", +14093, USA, 467, 470, "USA", "", +14109, ObjectiveDescription, 524, 668, "The purpose of this study was to compare two analog insulin therapies ( prandial premixed therapy [ PPT ] versus basal / bolus therapy [ BBT ] )", "", +14094, Drug, 596, 621, "prandial premixed therapy", "PPT", +14095, Drug, 624, 627, "PPT", "PPT", +14096, Drug, 637, 658, "basal / bolus therapy", "BBT", +14097, Drug, 661, 664, "BBT", "BBT", +36806, ObjectiveDescription, 669, 843, "in type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents , with the aim of demonstrating noninferiority of PPT to BBT .", "", +14098, Type2Diabetes, 672, 687, "type 2 diabetic", "", +14100, Precondition, 672, 780, "type 2 diabetic patients previously treated with insulin glargine ( > or = 30 units / day ) plus oral agents", "", +14099, InsulinGlargine, 721, 737, "insulin glargine", "", +14101, DoseValue, 740, 749, "> or = 30", "", +14102, BioAndMedicalUnit, 750, 755, "units", "", +14103, Frequency, 758, 761, "day", "", +14104, OralAntidiabeticAgent, 769, 780, "oral agents", "", +14105, Drug, 831, 834, "PPT", "PPT", +14106, Drug, 838, 841, "BBT", "BBT", +14111, Randomized, 888, 896, "randomly", "", +14112, Drug, 909, 912, "PPT", "PPT", +36807, Lispro, 915, 928, "lispro mix 50", "", +36808, Lispro, 931, 992, "50 : 50 % insulin lispro protamine suspension and 50 % lispro", "", +14115, NumberPatientsArm, 999, 1002, "187", "PPT", +14116, Frequency, 1005, 1014, "t . i . d", "three times daily", +14117, Drug, 1031, 1034, "BBT", "BBT", +14118, InsulinGlargine, 1037, 1045, "glargine", "BBT", +36809, RelativeTime, 1049, 1056, "bedtime", "", +14120, RelativeTime, 1062, 1070, "mealtime", "", +36810, Lispro, 1071, 1077, "lispro", "", +14122, NumberPatientsArm, 1084, 1087, "187", "BBT", +14123, Duration, 1095, 1104, "24 - week", "", +14125, Multicenter, 1107, 1118, "multicenter", "", +14126, OpenLabel, 1121, 1133, "open - label", "", +14127, CTDesign, 1136, 1150, "noninferiority", "", +36811, Lispro, 1187, 1205, "lispro mix 50 / 50", "", +36812, Lispro, 1211, 1229, "lispro mix 75 / 25", "", +14130, Bedtime, 1237, 1249, "evening meal", "", +14131, FastingPlasmaGlucose_target, 1257, 1286, "fasting plasma glucose target", "", +36813, TimePoint, 1316, 1324, "Baseline", "", +14133, HbA1c, 1325, 1328, "A1C", "", +14134, Drug, 1343, 1346, "PPT", "PPT", +14145, BaseLineValue, 1347, 1352, "8 . 8", "", +14144, Percentage, 1353, 1354, "%", "", +14135, Drug, 1357, 1360, "BBT", "BBT", +14146, BaseLineValue, 1361, 1366, "8 . 9", "", +14143, Percentage, 1367, 1368, "%", "", +14142, PvalueDiff, 1371, 1382, "P = 0 . 598", "", +36814, TimePoint, 1390, 1397, "week 24", "", +14147, HbA1c, 1400, 1403, "A1C", "", +14148, Drug, 1419, 1422, "BBT", "BBT", +14149, ResultMeasuredValue, 1425, 1431, "6 . 78", "BBT", +14150, ResultMeasuredValue, 1437, 1443, "6 . 95", "PPT", +14151, Percentage, 1444, 1445, "%", "", +14152, PvalueDiff, 1448, 1459, "P = 0 . 021", "", +14153, HbA1c, 1464, 1467, "A1C", "", +14154, ObservedResult, 1468, 1526, "was reduced significantly from baseline for both therapies", "", +14155, PvalueDiff, 1529, 1541, "P < 0 . 0001", "", +14156, HbA1c, 1564, 1567, "A1C", "", +36815, TimePoint, 1580, 1588, "baseline", "", +36816, TimePoint, 1596, 1605, "end point", "", +14157, Drug, 1608, 1611, "BBT", "BBT", +14158, Drug, 1618, 1621, "PPT", "PPT", +14168, DiffGroupAbsValue, 1628, 1636, "- 0 . 22", "", +14169, Percentage, 1637, 1638, "%", "", +14170, ConfIntervalDiff, 1641, 1669, "90 % CI - 0 . 38 to - 0 . 07", "", +36817, ObservedResult, 1674, 1784, "Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0 . 3 % .", "", +14162, Drug, 1692, 1695, "PPT", "PPT", +14163, Drug, 1699, 1702, "BBT", "BBT", +14165, HbA1c_target, 1823, 1843, "target A1C < 7 . 0 %", "", +14171, Drug, 1846, 1849, "PPT", "PPT", +14172, Drug, 1857, 1860, "BBT", "BBT", +14173, PercentageAffected, 1883, 1885, "54", "", +14174, PercentageAffected, 1891, 1893, "69", "", +14175, PvalueDiff, 1898, 1909, "P = 0 . 009", "", +14176, HbA1c_target, 1920, 1941, "target < or = 6 . 5 %", "", +14177, PercentageAffected, 1947, 1949, "35", "", +14178, PercentageAffected, 1955, 1957, "50", "", +14179, PvalueDiff, 1962, 1972, "P = 0 . 01", "", +14180, ObservedResult, 1979, 1993, "did not differ", "", +14181, HbA1c_target, 1998, 2032, "target < or = 6 . 0 % or < 7 . 5 %", "", +36818, ObservedResult, 2035, 2087, "Rates of hypoglycemia were similar for both groups .", "", +14182, Hypoglycemia, 2044, 2056, "hypoglycemia", "", +14193, ConclusionComment, 2102, 2308, "Although noninferiority of PPT to BBT was not demonstrated , findings for A1C reduction , percentage of patients achieving A1C targets , hypoglycemia , and number of required injections should be considered", "", +14184, Drug, 2129, 2132, "PPT", "PPT", +14186, Drug, 2136, 2139, "BBT", "BBT", +14188, HbA1c, 2176, 2179, "A1C", "", +14189, HbA1c_target, 2225, 2236, "A1C targets", "", +14190, Hypoglycemia, 2239, 2251, "hypoglycemia", "", +36819, ConclusionComment, 2309, 2424, "in the individual decision - making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes .", "", +14191, Insulin, 2366, 2373, "insulin", "", +14185, Drug, 2389, 2392, "PPT", "PPT", +14187, Drug, 2400, 2403, "BBT", "BBT", +14192, Type2Diabetes, 2407, 2422, "type 2 diabetes", "", +14195, PMID, 2462, 2470, "17934150", "", diff --git a/data/dm2 17934150_kwoodley.n-triples b/data/dm2 17934150_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17934150_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17992639 copy_admin.annodb b/data/dm2 17992639 copy_admin.annodb new file mode 100644 index 0000000..b2bb284 --- /dev/null +++ b/data/dm2 17992639 copy_admin.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +131, Journal, 0, 16, "Horm Metab Res .", "", " \"Horm Metab Res .\"." +0, PublicationYear, 17, 21, "2007", "", " \"2007\"." +68, Title, 50, 217, "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .", "", " \"Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .\"." +1, Insulin, 74, 81, "insulin", "", +2, Vildagliptin, 170, 182, "vildagliptin", "", +3, Type2Diabetes, 200, 215, "type 2 diabetes", "", " ." +4, Author, 218, 227, "Ahr é n B", "", " \"Ahr é n B\"." +5, Author, 236, 244, "Pacini G", "", " \"Pacini G\"." +6, Author, 247, 253, "Tura A", "", " \"Tura A\"." +7, Author, 256, 264, "Foley JE", "", " \"Foley JE\"." +8, Author, 267, 278, "Schweizer A", "", " \"Schweizer A\"." +9, Sweden, 390, 396, "Sweden", "", " ." +97, ObjectiveDescription, 426, 610, "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .", "", " \"The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .\"." +10, Insulin, 484, 491, "insulin", "", +11, Vildagliptin, 596, 608, "vildagliptin", "", +12, NumberPatientsCT, 611, 623, "Fifty - five", "", " \"Fifty - five\"." +106299, Precondition, 624, 746, "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2", "", " \"patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2\"." +13, Type2Diabetes, 638, 653, "type 2 diabetes", "", +14, AvgAge, 656, 662, "56 . 5", "", " \"56 . 5\"." +87, Year, 675, 680, "years", "", +15, BMI, 683, 686, "BMI", "", +85, BaseLineValue, 689, 695, "29 . 6", "", +50307, SdDevBL, 702, 707, "0 . 5", "", +16, Kg_per_squareMeter, 708, 720, "kg / m ( 2 )", "", +17, FastingPlasmaGlucose, 723, 726, "FPG", "", +86, BaseLineValue, 729, 734, "9 . 9", "", +50308, SdDevBL, 741, 746, "0 . 2", "", +18, Millimoles_per_litre, 747, 755, "mmol / l", "", +106299, Precondition, 747, 947, "mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .", "", " \"mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .\"." +19, HbA1c, 758, 763, "HbA1c", "", +84, BaseLineValue, 766, 771, "7 . 7", "", +50309, SdDevBL, 778, 783, "0 . 1", "", +20, Percentage, 784, 785, "%", "", +21, NumberPatientsArm, 803, 805, "29", "", " \"29\"." +22, Vildagliptin, 833, 845, "vildagliptin", "", " ." +23, NumberPatientsArm, 850, 852, "26", "", " \"26\"." +24, Placebo, 867, 874, "placebo", "", " ." +25, Metformin, 902, 911, "metformin", "", " ." +26, DoseValue, 922, 935, "1 . 5 - 3 . 0", "", " \"1 . 5 - 3 . 0\"." +27, Gram, 936, 937, "g", "", " ." +28, Interval, 940, 943, "day", "", " \"day\"." +134, TimePoint, 986, 994, "baseline", "", +30, Duration, 1005, 1013, "52 weeks", "", " \"52 weeks\"." +32, Insulin, 1033, 1043, "proinsulin", "", +50310, EndPointDescription, 1055, 1072, "insulin secretion", "", +35, EndPointDescription, 1179, 1196, "B - cell function", "", +37, Vildagliptin, 1236, 1248, "vildagliptin", "", +38, Placebo, 1251, 1258, "placebo", "", +101, Mean, 1264, 1268, "mean", "", " . ." +139, TimePoint, 1281, 1289, "baseline", "", +50311, EndPointDescription, 1293, 1332, "fasting proinsulin to C - peptide ratio", "", +50312, EndPointDescription, 1335, 1344, "fastP / C", "", " . ." +103, DiffGroupAbsValue, 1351, 1360, "- 0 . 007", "", " \"- 0 . 007\"." +44, SdDevDiff, 1367, 1374, "0 . 009", "", " \"0 . 009\"." +45, PvalueDiff, 1377, 1388, "p = 0 . 052", "", " \"p = 0 . 052\"." +46, Duration, 1428, 1436, "52 weeks", "", +47, Vildagliptin, 1455, 1467, "vildagliptin", "", +41, EndPointDescription, 1496, 1535, "dynamic proinsulin to C - peptide ratio", "", +42, EndPointDescription, 1538, 1546, "dynP / C", "", " . ." +48, Placebo, 1561, 1568, "placebo", "", +50313, Reduction, 1572, 1579, "0 . 010", "", " \"0 . 010\"." +50314, SdDevChangeValue, 1586, 1593, "0 . 008", "", " \"0 . 008\"." +51, PValueChangeValue, 1596, 1607, "p = 0 . 037", "", " \"p = 0 . 037\"." +52, EndPointDescription, 1635, 1640, "P / C", "", " . ." +54, FastingPlasmaGlucose, 1707, 1722, "fasting glucose", "", +55, EndPointDescription, 1727, 1738, "glucose AUC", "", +53, EndPointDescription, 1778, 1783, "P / C", "", " . ." +118, ObservedResult, 1804, 1829, "was significantly reduced", "", " \"was significantly reduced\". \"was significantly reduced\"." +56, Vildagliptin, 1835, 1847, "vildagliptin", "", +57, Placebo, 1853, 1860, "placebo", "", +50315, ObservedResult, 1863, 1939, "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )", "", " \"both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )\". \"both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )\"." +59, PvalueDiff, 1891, 1902, "p = 0 . 023", "", " \"p = 0 . 023\"." +60, PvalueDiff, 1926, 1937, "p = 0 . 004", "", +121, ConclusionComment, 1942, 2130, "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .", "", " \"In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .\"." +61, Insulin, 1984, 1991, "insulin", "", +62, Vildagliptin, 2034, 2046, "vildagliptin", "", +63, Type2Diabetes, 2113, 2128, "type 2 diabetes", "", +64, PMID, 2174, 2182, "17992639", "", " \"17992639\"." diff --git a/data/dm2 17992639 copy_admin.n-triples b/data/dm2 17992639 copy_admin.n-triples new file mode 100644 index 0000000..e258651 --- /dev/null +++ b/data/dm2 17992639 copy_admin.n-triples @@ -0,0 +1,148 @@ +# RDF export of group: Publication + . + "Publication" . + "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes ." . + "Ahr é n B" . + "2007" . + "Horm Metab Res ." . + "17992639" . + . + "Pacini G" . + "Tura A" . + "Foley JE" . + "Schweizer A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin ." . + "Fifty - five" . + "52 weeks" . + . + . + . + "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2" . + "mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) ." . + . + . + "56 . 5" . + . +# RDF export of group: Endpoint + . + "Endpoint_fastP" . + . + . + . + . + . + . + . + "Endpoint_dynP" . + . + . + . + . + . + . + "Endpoint_P" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_vil" . + "29" . + . + . + . + . + . + . + . + "Arm_pla" . + "26" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_met" . + . + "day" . + . + . + "Intervention_vil" . + . + . + . + "Intervention_P" . + . + . +# RDF export of group: Medication + . + "Medication_met" . + . + "1 . 5 - 3 . 0" . + . + . + . + "Medication_vil" . + . + . + . + . + "Medication_pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_fastP_vil" . + . + . + "Outcome_fastP_pla" . + . + . + "Outcome_p_vil" . + . + "was significantly reduced" . + "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )" . + . + "Outcome_p_pla" . + . + "was significantly reduced" . + "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )" . + . + "Outcome_dynP_vil" . + . + "0 . 010" . + "p = 0 . 037" . + "0 . 008" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_fastP" . + "- 0 . 007" . + "p = 0 . 052" . + "0 . 009" . + . + . + . + "DiffBetweenGroups_p" . + "p = 0 . 023" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17992639 copy_export.csv b/data/dm2 17992639 copy_export.csv new file mode 100644 index 0000000..2bad77a --- /dev/null +++ b/data/dm2 17992639 copy_export.csv @@ -0,0 +1,496 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +817, 1, 1, 1, 0, 4, 0, 4, "Horm" +817, 1, 2, 2, 5, 10, 5, 10, "Metab" +817, 1, 3, 3, 11, 14, 11, 14, "Res" +817, 1, 4, 4, 15, 16, 15, 16, "." +817, 2, 1, 5, 0, 4, 17, 21, "2007" +817, 2, 2, 6, 5, 8, 22, 25, "Nov" +817, 2, 3, 7, 9, 10, 26, 27, ";" +817, 2, 4, 8, 11, 13, 28, 30, "39" +817, 2, 5, 9, 14, 15, 31, 32, "(" +817, 2, 6, 10, 16, 18, 33, 35, "11" +817, 2, 7, 11, 19, 20, 36, 37, ")" +817, 2, 8, 12, 21, 22, 38, 39, ":" +817, 2, 9, 13, 23, 26, 40, 43, "826" +817, 2, 10, 14, 27, 28, 44, 45, "-" +817, 2, 11, 15, 29, 30, 46, 47, "9" +817, 2, 12, 16, 31, 32, 48, 49, "." +817, 3, 1, 17, 0, 8, 50, 58, "Improved" +817, 3, 2, 18, 9, 13, 59, 63, "meal" +817, 3, 3, 19, 14, 15, 64, 65, "-" +817, 3, 4, 20, 16, 23, 66, 73, "related" +817, 3, 5, 21, 24, 31, 74, 81, "insulin" +817, 3, 6, 22, 32, 42, 82, 92, "processing" +817, 3, 7, 23, 43, 54, 93, 104, "contributes" +817, 3, 8, 24, 55, 57, 105, 107, "to" +817, 3, 9, 25, 58, 61, 108, 111, "the" +817, 3, 10, 26, 62, 73, 112, 123, "enhancement" +817, 3, 11, 27, 74, 76, 124, 126, "of" +817, 3, 12, 28, 77, 78, 127, 128, "B" +817, 3, 13, 29, 79, 80, 129, 130, "-" +817, 3, 14, 30, 81, 85, 131, 135, "cell" +817, 3, 15, 31, 86, 94, 136, 144, "function" +817, 3, 16, 32, 95, 97, 145, 147, "by" +817, 3, 17, 33, 98, 101, 148, 151, "the" +817, 3, 18, 34, 102, 105, 152, 155, "DPP" +817, 3, 19, 35, 106, 107, 156, 157, "-" +817, 3, 20, 36, 108, 109, 158, 159, "4" +817, 3, 21, 37, 110, 119, 160, 169, "inhibitor" +817, 3, 22, 38, 120, 132, 170, 182, "vildagliptin" +817, 3, 23, 39, 133, 135, 183, 185, "in" +817, 3, 24, 40, 136, 144, 186, 194, "patients" +817, 3, 25, 41, 145, 149, 195, 199, "with" +817, 3, 26, 42, 150, 154, 200, 204, "type" +817, 3, 27, 43, 155, 156, 205, 206, "2" +817, 3, 28, 44, 157, 165, 207, 215, "diabetes" +817, 3, 29, 45, 166, 167, 216, 217, "." +817, 4, 1, 46, 0, 3, 218, 221, "Ahr" +817, 4, 2, 47, 4, 5, 222, 223, "é" +817, 4, 3, 48, 6, 7, 224, 225, "n" +817, 4, 4, 49, 8, 9, 226, 227, "B" +817, 4, 5, 50, 10, 11, 228, 229, "(" +817, 4, 6, 51, 12, 13, 230, 231, "1" +817, 4, 7, 52, 14, 15, 232, 233, ")" +817, 4, 8, 53, 16, 17, 234, 235, "," +817, 4, 9, 54, 18, 24, 236, 242, "Pacini" +817, 4, 10, 55, 25, 26, 243, 244, "G" +817, 4, 11, 56, 27, 28, 245, 246, "," +817, 4, 12, 57, 29, 33, 247, 251, "Tura" +817, 4, 13, 58, 34, 35, 252, 253, "A" +817, 4, 14, 59, 36, 37, 254, 255, "," +817, 4, 15, 60, 38, 43, 256, 261, "Foley" +817, 4, 16, 61, 44, 46, 262, 264, "JE" +817, 4, 17, 62, 47, 48, 265, 266, "," +817, 4, 18, 63, 49, 58, 267, 276, "Schweizer" +817, 4, 19, 64, 59, 60, 277, 278, "A" +817, 4, 20, 65, 61, 62, 279, 280, "." +817, 5, 1, 66, 0, 6, 281, 287, "Author" +817, 5, 2, 67, 7, 18, 288, 299, "information" +817, 5, 3, 68, 19, 20, 300, 301, ":" +817, 5, 4, 69, 21, 22, 302, 303, "(" +817, 5, 5, 70, 23, 24, 304, 305, "1" +817, 5, 6, 71, 25, 26, 306, 307, ")" +817, 5, 7, 72, 27, 37, 308, 318, "Department" +817, 5, 8, 73, 38, 40, 319, 321, "of" +817, 5, 9, 74, 41, 49, 322, 330, "Clinical" +817, 5, 10, 75, 50, 58, 331, 339, "Sciences" +817, 5, 11, 76, 59, 60, 340, 341, "," +817, 5, 12, 77, 61, 69, 342, 350, "Division" +817, 5, 13, 78, 70, 72, 351, 353, "of" +817, 5, 14, 79, 73, 81, 354, 362, "Medicine" +817, 5, 15, 80, 82, 83, 363, 364, "," +817, 5, 16, 81, 84, 88, 365, 369, "Lund" +817, 5, 17, 82, 89, 99, 370, 380, "University" +817, 5, 18, 83, 100, 101, 381, 382, "," +817, 5, 19, 84, 102, 106, 383, 387, "Lund" +817, 5, 20, 85, 107, 108, 388, 389, "," +817, 5, 21, 86, 109, 115, 390, 396, "Sweden" +817, 5, 22, 87, 116, 117, 397, 398, "." +817, 6, 1, 88, 0, 2, 399, 401, "Bo" +817, 6, 2, 89, 3, 4, 402, 403, "." +817, 6, 3, 90, 5, 10, 404, 409, "Ahren" +817, 6, 4, 91, 11, 12, 410, 411, "@" +817, 6, 5, 92, 13, 16, 412, 415, "med" +817, 6, 6, 93, 17, 18, 416, 417, "." +817, 6, 7, 94, 19, 21, 418, 420, "lu" +817, 6, 8, 95, 22, 23, 421, 422, "." +817, 6, 9, 96, 24, 26, 423, 425, "se" +817, 6, 10, 97, 27, 30, 426, 429, "The" +817, 6, 11, 98, 31, 34, 430, 433, "aim" +817, 6, 12, 99, 35, 37, 434, 436, "of" +817, 6, 13, 100, 38, 42, 437, 441, "this" +817, 6, 14, 101, 43, 48, 442, 447, "study" +817, 6, 15, 102, 49, 52, 448, 451, "was" +817, 6, 16, 103, 53, 55, 452, 454, "to" +817, 6, 17, 104, 56, 64, 455, 463, "evaluate" +817, 6, 18, 105, 65, 68, 464, 467, "the" +817, 6, 19, 106, 69, 81, 468, 480, "contribution" +817, 6, 20, 107, 82, 84, 481, 483, "of" +817, 6, 21, 108, 85, 92, 484, 491, "insulin" +817, 6, 22, 109, 93, 103, 492, 502, "processing" +817, 6, 23, 110, 104, 106, 503, 505, "to" +817, 6, 24, 111, 107, 110, 506, 509, "the" +817, 6, 25, 112, 111, 119, 510, 518, "improved" +817, 6, 26, 113, 120, 124, 519, 523, "meal" +817, 6, 27, 114, 125, 126, 524, 525, "-" +817, 6, 28, 115, 127, 134, 526, 533, "related" +817, 6, 29, 116, 135, 136, 534, 535, "B" +817, 6, 30, 117, 137, 138, 536, 537, "-" +817, 6, 31, 118, 139, 143, 538, 542, "cell" +817, 6, 32, 119, 144, 152, 543, 551, "function" +817, 6, 33, 120, 153, 163, 552, 562, "previously" +817, 6, 34, 121, 164, 169, 563, 568, "shown" +817, 6, 35, 122, 170, 174, 569, 573, "with" +817, 6, 36, 123, 175, 178, 574, 577, "the" +817, 6, 37, 124, 179, 182, 578, 581, "DPP" +817, 6, 38, 125, 183, 184, 582, 583, "-" +817, 6, 39, 126, 185, 186, 584, 585, "4" +817, 6, 40, 127, 187, 196, 586, 595, "inhibitor" +817, 6, 41, 128, 197, 209, 596, 608, "vildagliptin" +817, 6, 42, 129, 210, 211, 609, 610, "." +817, 7, 1, 130, 0, 5, 611, 616, "Fifty" +817, 7, 2, 131, 6, 7, 617, 618, "-" +817, 7, 3, 132, 8, 12, 619, 623, "five" +817, 7, 4, 133, 13, 21, 624, 632, "patients" +817, 7, 5, 134, 22, 26, 633, 637, "with" +817, 7, 6, 135, 27, 31, 638, 642, "type" +817, 7, 7, 136, 32, 33, 643, 644, "2" +817, 7, 8, 137, 34, 42, 645, 653, "diabetes" +817, 7, 9, 138, 43, 44, 654, 655, "(" +817, 7, 10, 139, 45, 47, 656, 658, "56" +817, 7, 11, 140, 48, 49, 659, 660, "." +817, 7, 12, 141, 50, 51, 661, 662, "5" +817, 7, 13, 142, 52, 53, 663, 664, "+" +817, 7, 14, 143, 54, 55, 665, 666, "/" +817, 7, 15, 144, 56, 57, 667, 668, "-" +817, 7, 16, 145, 58, 59, 669, 670, "1" +817, 7, 17, 146, 60, 61, 671, 672, "." +817, 7, 18, 147, 62, 63, 673, 674, "5" +817, 7, 19, 148, 64, 69, 675, 680, "years" +817, 7, 20, 149, 70, 71, 681, 682, ";" +817, 7, 21, 150, 72, 75, 683, 686, "BMI" +817, 7, 22, 151, 76, 77, 687, 688, "=" +817, 7, 23, 152, 78, 80, 689, 691, "29" +817, 7, 24, 153, 81, 82, 692, 693, "." +817, 7, 25, 154, 83, 84, 694, 695, "6" +817, 7, 26, 155, 85, 86, 696, 697, "+" +817, 7, 27, 156, 87, 88, 698, 699, "/" +817, 7, 28, 157, 89, 90, 700, 701, "-" +817, 7, 29, 158, 91, 92, 702, 703, "0" +817, 7, 30, 159, 93, 94, 704, 705, "." +817, 7, 31, 160, 95, 96, 706, 707, "5" +817, 7, 32, 161, 97, 99, 708, 710, "kg" +817, 7, 33, 162, 100, 101, 711, 712, "/" +817, 7, 34, 163, 102, 103, 713, 714, "m" +817, 7, 35, 164, 104, 105, 715, 716, "(" +817, 7, 36, 165, 106, 107, 717, 718, "2" +817, 7, 37, 166, 108, 109, 719, 720, ")" +817, 7, 38, 167, 110, 111, 721, 722, ";" +817, 7, 39, 168, 112, 115, 723, 726, "FPG" +817, 7, 40, 169, 116, 117, 727, 728, "=" +817, 7, 41, 170, 118, 119, 729, 730, "9" +817, 7, 42, 171, 120, 121, 731, 732, "." +817, 7, 43, 172, 122, 123, 733, 734, "9" +817, 7, 44, 173, 124, 125, 735, 736, "+" +817, 7, 45, 174, 126, 127, 737, 738, "/" +817, 7, 46, 175, 128, 129, 739, 740, "-" +817, 7, 47, 176, 130, 131, 741, 742, "0" +817, 7, 48, 177, 132, 133, 743, 744, "." +817, 7, 49, 178, 134, 135, 745, 746, "2" +817, 7, 50, 179, 136, 140, 747, 751, "mmol" +817, 7, 51, 180, 141, 142, 752, 753, "/" +817, 7, 52, 181, 143, 144, 754, 755, "l" +817, 7, 53, 182, 145, 146, 756, 757, ";" +817, 7, 54, 183, 147, 152, 758, 763, "HbA1c" +817, 7, 55, 184, 153, 154, 764, 765, "=" +817, 7, 56, 185, 155, 156, 766, 767, "7" +817, 7, 57, 186, 157, 158, 768, 769, "." +817, 7, 58, 187, 159, 160, 770, 771, "7" +817, 7, 59, 188, 161, 162, 772, 773, "+" +817, 7, 60, 189, 163, 164, 774, 775, "/" +817, 7, 61, 190, 165, 166, 776, 777, "-" +817, 7, 62, 191, 167, 168, 778, 779, "0" +817, 7, 63, 192, 169, 170, 780, 781, "." +817, 7, 64, 193, 171, 172, 782, 783, "1" +817, 7, 65, 194, 173, 174, 784, 785, "%" +817, 7, 66, 195, 175, 176, 786, 787, ")" +817, 7, 67, 196, 177, 181, 788, 792, "were" +817, 7, 68, 197, 182, 189, 793, 800, "studied" +817, 7, 69, 198, 190, 191, 801, 802, ":" +817, 7, 70, 199, 192, 194, 803, 805, "29" +817, 7, 71, 200, 195, 203, 806, 814, "patients" +817, 7, 72, 201, 204, 208, 815, 819, "were" +817, 7, 73, 202, 209, 216, 820, 827, "treated" +817, 7, 74, 203, 217, 221, 828, 832, "with" +817, 7, 75, 204, 222, 234, 833, 845, "vildagliptin" +817, 7, 76, 205, 235, 238, 846, 849, "and" +817, 7, 77, 206, 239, 241, 850, 852, "26" +817, 7, 78, 207, 242, 250, 853, 861, "patients" +817, 7, 79, 208, 251, 255, 862, 866, "with" +817, 7, 80, 209, 256, 263, 867, 874, "placebo" +817, 7, 81, 210, 264, 265, 875, 876, "," +817, 7, 82, 211, 266, 270, 877, 881, "both" +817, 7, 83, 212, 271, 276, 882, 887, "added" +817, 7, 84, 213, 277, 279, 888, 890, "to" +817, 7, 85, 214, 280, 282, 891, 893, "an" +817, 7, 86, 215, 283, 290, 894, 901, "ongoing" +817, 7, 87, 216, 291, 300, 902, 911, "metformin" +817, 7, 88, 217, 301, 308, 912, 919, "regimen" +817, 7, 89, 218, 309, 310, 920, 921, "(" +817, 7, 90, 219, 311, 312, 922, 923, "1" +817, 7, 91, 220, 313, 314, 924, 925, "." +817, 7, 92, 221, 315, 316, 926, 927, "5" +817, 7, 93, 222, 317, 318, 928, 929, "-" +817, 7, 94, 223, 319, 320, 930, 931, "3" +817, 7, 95, 224, 321, 322, 932, 933, "." +817, 7, 96, 225, 323, 324, 934, 935, "0" +817, 7, 97, 226, 325, 326, 936, 937, "g" +817, 7, 98, 227, 327, 328, 938, 939, "/" +817, 7, 99, 228, 329, 332, 940, 943, "day" +817, 7, 100, 229, 333, 334, 944, 945, ")" +817, 7, 101, 230, 335, 336, 946, 947, "." +817, 8, 1, 231, 0, 1, 948, 949, "A" +817, 8, 2, 232, 2, 14, 950, 962, "standardized" +817, 8, 3, 233, 15, 24, 963, 972, "breakfast" +817, 8, 4, 234, 25, 28, 973, 976, "was" +817, 8, 5, 235, 29, 34, 977, 982, "given" +817, 8, 6, 236, 35, 37, 983, 985, "at" +817, 8, 7, 237, 38, 46, 986, 994, "baseline" +817, 8, 8, 238, 47, 50, 995, 998, "and" +817, 8, 9, 239, 51, 56, 999, 1004, "after" +817, 8, 10, 240, 57, 59, 1005, 1007, "52" +817, 8, 11, 241, 60, 65, 1008, 1013, "weeks" +817, 8, 12, 242, 66, 68, 1014, 1016, "of" +817, 8, 13, 243, 69, 78, 1017, 1026, "treatment" +817, 8, 14, 244, 79, 80, 1027, 1028, "," +817, 8, 15, 245, 81, 84, 1029, 1032, "and" +817, 8, 16, 246, 85, 95, 1033, 1043, "proinsulin" +817, 8, 17, 247, 96, 103, 1044, 1051, "related" +817, 8, 18, 248, 104, 106, 1052, 1054, "to" +817, 8, 19, 249, 107, 114, 1055, 1062, "insulin" +817, 8, 20, 250, 115, 124, 1063, 1072, "secretion" +817, 8, 21, 251, 125, 128, 1073, 1076, "was" +817, 8, 22, 252, 129, 137, 1077, 1085, "measured" +817, 8, 23, 253, 138, 142, 1086, 1090, "with" +817, 8, 24, 254, 143, 144, 1091, 1092, "C" +817, 8, 25, 255, 145, 146, 1093, 1094, "-" +817, 8, 26, 256, 147, 154, 1095, 1102, "peptide" +817, 8, 27, 257, 155, 157, 1103, 1105, "in" +817, 8, 28, 258, 158, 161, 1106, 1109, "the" +817, 8, 29, 259, 162, 169, 1110, 1117, "fasting" +817, 8, 30, 260, 170, 173, 1118, 1121, "and" +817, 8, 31, 261, 174, 186, 1122, 1134, "postprandial" +817, 8, 32, 262, 187, 188, 1135, 1136, "(" +817, 8, 33, 263, 189, 193, 1137, 1141, "over" +817, 8, 34, 264, 194, 195, 1142, 1143, "4" +817, 8, 35, 265, 196, 197, 1144, 1145, "h" +817, 8, 36, 266, 198, 202, 1146, 1150, "post" +817, 8, 37, 267, 203, 204, 1151, 1152, "-" +817, 8, 38, 268, 205, 209, 1153, 1157, "meal" +817, 8, 39, 269, 210, 211, 1158, 1159, ")" +817, 8, 40, 270, 212, 218, 1160, 1166, "states" +817, 8, 41, 271, 219, 221, 1167, 1169, "to" +817, 8, 42, 272, 222, 230, 1170, 1178, "evaluate" +817, 8, 43, 273, 231, 232, 1179, 1180, "B" +817, 8, 44, 274, 233, 234, 1181, 1182, "-" +817, 8, 45, 275, 235, 239, 1183, 1187, "cell" +817, 8, 46, 276, 240, 248, 1188, 1196, "function" +817, 8, 47, 277, 249, 250, 1197, 1198, "." +817, 9, 1, 278, 0, 3, 1199, 1202, "The" +817, 9, 2, 279, 4, 11, 1203, 1210, "between" +817, 9, 3, 280, 12, 13, 1211, 1212, "-" +817, 9, 4, 281, 14, 23, 1213, 1222, "treatment" +817, 9, 5, 282, 24, 34, 1223, 1233, "difference" +817, 9, 6, 283, 35, 36, 1234, 1235, "(" +817, 9, 7, 284, 37, 49, 1236, 1248, "vildagliptin" +817, 9, 8, 285, 50, 51, 1249, 1250, "-" +817, 9, 9, 286, 52, 59, 1251, 1258, "placebo" +817, 9, 10, 287, 60, 61, 1259, 1260, ")" +817, 9, 11, 288, 62, 64, 1261, 1263, "in" +817, 9, 12, 289, 65, 69, 1264, 1268, "mean" +817, 9, 13, 290, 70, 76, 1269, 1275, "change" +817, 9, 14, 291, 77, 81, 1276, 1280, "from" +817, 9, 15, 292, 82, 90, 1281, 1289, "baseline" +817, 9, 16, 293, 91, 93, 1290, 1292, "in" +817, 9, 17, 294, 94, 101, 1293, 1300, "fasting" +817, 9, 18, 295, 102, 112, 1301, 1311, "proinsulin" +817, 9, 19, 296, 113, 115, 1312, 1314, "to" +817, 9, 20, 297, 116, 117, 1315, 1316, "C" +817, 9, 21, 298, 118, 119, 1317, 1318, "-" +817, 9, 22, 299, 120, 127, 1319, 1326, "peptide" +817, 9, 23, 300, 128, 133, 1327, 1332, "ratio" +817, 9, 24, 301, 134, 135, 1333, 1334, "(" +817, 9, 25, 302, 136, 141, 1335, 1340, "fastP" +817, 9, 26, 303, 142, 143, 1341, 1342, "/" +817, 9, 27, 304, 144, 145, 1343, 1344, "C" +817, 9, 28, 305, 146, 147, 1345, 1346, ")" +817, 9, 29, 306, 148, 151, 1347, 1350, "was" +817, 9, 30, 307, 152, 153, 1351, 1352, "-" +817, 9, 31, 308, 154, 155, 1353, 1354, "0" +817, 9, 32, 309, 156, 157, 1355, 1356, "." +817, 9, 33, 310, 158, 161, 1357, 1360, "007" +817, 9, 34, 311, 162, 163, 1361, 1362, "+" +817, 9, 35, 312, 164, 165, 1363, 1364, "/" +817, 9, 36, 313, 166, 167, 1365, 1366, "-" +817, 9, 37, 314, 168, 169, 1367, 1368, "0" +817, 9, 38, 315, 170, 171, 1369, 1370, "." +817, 9, 39, 316, 172, 175, 1371, 1374, "009" +817, 9, 40, 317, 176, 177, 1375, 1376, "(" +817, 9, 41, 318, 178, 179, 1377, 1378, "p" +817, 9, 42, 319, 180, 181, 1379, 1380, "=" +817, 9, 43, 320, 182, 183, 1381, 1382, "0" +817, 9, 44, 321, 184, 185, 1383, 1384, "." +817, 9, 45, 322, 186, 189, 1385, 1388, "052" +817, 9, 46, 323, 190, 191, 1389, 1390, ")" +817, 9, 47, 324, 192, 193, 1391, 1392, "." +817, 10, 1, 325, 0, 9, 1393, 1402, "Following" +817, 10, 2, 326, 10, 13, 1403, 1406, "the" +817, 10, 3, 327, 14, 22, 1407, 1415, "standard" +817, 10, 4, 328, 23, 32, 1416, 1425, "breakfast" +817, 10, 5, 329, 33, 34, 1426, 1427, "," +817, 10, 6, 330, 35, 37, 1428, 1430, "52" +817, 10, 7, 331, 38, 43, 1431, 1436, "weeks" +817, 10, 8, 332, 44, 46, 1437, 1439, "of" +817, 10, 9, 333, 47, 56, 1440, 1449, "treatment" +817, 10, 10, 334, 57, 61, 1450, 1454, "with" +817, 10, 11, 335, 62, 74, 1455, 1467, "vildagliptin" +817, 10, 12, 336, 75, 88, 1468, 1481, "significantly" +817, 10, 13, 337, 89, 98, 1482, 1491, "decreased" +817, 10, 14, 338, 99, 102, 1492, 1495, "the" +817, 10, 15, 339, 103, 110, 1496, 1503, "dynamic" +817, 10, 16, 340, 111, 121, 1504, 1514, "proinsulin" +817, 10, 17, 341, 122, 124, 1515, 1517, "to" +817, 10, 18, 342, 125, 126, 1518, 1519, "C" +817, 10, 19, 343, 127, 128, 1520, 1521, "-" +817, 10, 20, 344, 129, 136, 1522, 1529, "peptide" +817, 10, 21, 345, 137, 142, 1530, 1535, "ratio" +817, 10, 22, 346, 143, 144, 1536, 1537, "(" +817, 10, 23, 347, 145, 149, 1538, 1542, "dynP" +817, 10, 24, 348, 150, 151, 1543, 1544, "/" +817, 10, 25, 349, 152, 153, 1545, 1546, "C" +817, 10, 26, 350, 154, 155, 1547, 1548, ")" +817, 10, 27, 351, 156, 164, 1549, 1557, "relative" +817, 10, 28, 352, 165, 167, 1558, 1560, "to" +817, 10, 29, 353, 168, 175, 1561, 1568, "placebo" +817, 10, 30, 354, 176, 178, 1569, 1571, "by" +817, 10, 31, 355, 179, 180, 1572, 1573, "0" +817, 10, 32, 356, 181, 182, 1574, 1575, "." +817, 10, 33, 357, 183, 186, 1576, 1579, "010" +817, 10, 34, 358, 187, 188, 1580, 1581, "+" +817, 10, 35, 359, 189, 190, 1582, 1583, "/" +817, 10, 36, 360, 191, 192, 1584, 1585, "-" +817, 10, 37, 361, 193, 194, 1586, 1587, "0" +817, 10, 38, 362, 195, 196, 1588, 1589, "." +817, 10, 39, 363, 197, 200, 1590, 1593, "008" +817, 10, 40, 364, 201, 202, 1594, 1595, "(" +817, 10, 41, 365, 203, 204, 1596, 1597, "p" +817, 10, 42, 366, 205, 206, 1598, 1599, "=" +817, 10, 43, 367, 207, 208, 1600, 1601, "0" +817, 10, 44, 368, 209, 210, 1602, 1603, "." +817, 10, 45, 369, 211, 214, 1604, 1607, "037" +817, 10, 46, 370, 215, 216, 1608, 1609, ")" +817, 10, 47, 371, 217, 218, 1610, 1611, "." +817, 11, 1, 372, 0, 11, 1612, 1623, "Importantly" +817, 11, 2, 373, 12, 13, 1624, 1625, "," +817, 11, 3, 374, 14, 18, 1626, 1630, "when" +817, 11, 4, 375, 19, 22, 1631, 1634, "the" +817, 11, 5, 376, 23, 24, 1635, 1636, "P" +817, 11, 6, 377, 25, 26, 1637, 1638, "/" +817, 11, 7, 378, 27, 28, 1639, 1640, "C" +817, 11, 8, 379, 29, 32, 1641, 1644, "was" +817, 11, 9, 380, 33, 42, 1645, 1654, "expressed" +817, 11, 10, 381, 43, 45, 1655, 1657, "in" +817, 11, 11, 382, 46, 54, 1658, 1666, "relation" +817, 11, 12, 383, 55, 57, 1667, 1669, "to" +817, 11, 13, 384, 58, 61, 1670, 1673, "the" +817, 11, 14, 385, 62, 69, 1674, 1681, "glucose" +817, 11, 15, 386, 70, 78, 1682, 1690, "stimulus" +817, 11, 16, 387, 79, 80, 1691, 1692, "(" +817, 11, 17, 388, 81, 82, 1693, 1694, "i" +817, 11, 18, 389, 83, 84, 1695, 1696, "." +817, 11, 19, 390, 85, 86, 1697, 1698, "e" +817, 11, 20, 391, 87, 88, 1699, 1700, "." +817, 11, 21, 392, 89, 90, 1701, 1702, "," +817, 11, 22, 393, 91, 94, 1703, 1706, "the" +817, 11, 23, 394, 95, 102, 1707, 1714, "fasting" +817, 11, 24, 395, 103, 110, 1715, 1722, "glucose" +817, 11, 25, 396, 111, 114, 1723, 1726, "and" +817, 11, 26, 397, 115, 122, 1727, 1734, "glucose" +817, 11, 27, 398, 123, 126, 1735, 1738, "AUC" +817, 11, 28, 399, 127, 128, 1739, 1740, "(" +817, 11, 29, 400, 129, 130, 1741, 1742, "0" +817, 11, 30, 401, 131, 132, 1743, 1744, "-" +817, 11, 31, 402, 133, 136, 1745, 1748, "240" +817, 11, 32, 403, 137, 140, 1749, 1752, "min" +817, 11, 33, 404, 141, 142, 1753, 1754, ")" +817, 11, 34, 405, 143, 144, 1755, 1756, "," +817, 11, 35, 406, 145, 157, 1757, 1769, "respectively" +817, 11, 36, 407, 158, 159, 1770, 1771, ")" +817, 11, 37, 408, 160, 161, 1772, 1773, "," +817, 11, 38, 409, 162, 165, 1774, 1777, "the" +817, 11, 39, 410, 166, 167, 1778, 1779, "P" +817, 11, 40, 411, 168, 169, 1780, 1781, "/" +817, 11, 41, 412, 170, 171, 1782, 1783, "C" +817, 11, 42, 413, 172, 180, 1784, 1792, "relative" +817, 11, 43, 414, 181, 183, 1793, 1795, "to" +817, 11, 44, 415, 184, 191, 1796, 1803, "glucose" +817, 11, 45, 416, 192, 195, 1804, 1807, "was" +817, 11, 46, 417, 196, 209, 1808, 1821, "significantly" +817, 11, 47, 418, 210, 217, 1822, 1829, "reduced" +817, 11, 48, 419, 218, 222, 1830, 1834, "with" +817, 11, 49, 420, 223, 235, 1835, 1847, "vildagliptin" +817, 11, 50, 421, 236, 238, 1848, 1850, "vs" +817, 11, 51, 422, 239, 240, 1851, 1852, "." +817, 11, 52, 423, 241, 248, 1853, 1860, "placebo" +817, 11, 53, 424, 249, 250, 1861, 1862, "," +817, 11, 54, 425, 251, 255, 1863, 1867, "both" +817, 11, 55, 426, 256, 258, 1868, 1870, "in" +817, 11, 56, 427, 259, 262, 1871, 1874, "the" +817, 11, 57, 428, 263, 270, 1875, 1882, "fasting" +817, 11, 58, 429, 271, 276, 1883, 1888, "state" +817, 11, 59, 430, 277, 278, 1889, 1890, "(" +817, 11, 60, 431, 279, 280, 1891, 1892, "p" +817, 11, 61, 432, 281, 282, 1893, 1894, "=" +817, 11, 62, 433, 283, 284, 1895, 1896, "0" +817, 11, 63, 434, 285, 286, 1897, 1898, "." +817, 11, 64, 435, 287, 290, 1899, 1902, "023" +817, 11, 65, 436, 291, 292, 1903, 1904, ")" +817, 11, 66, 437, 293, 296, 1905, 1908, "and" +817, 11, 67, 438, 297, 311, 1909, 1923, "postprandially" +817, 11, 68, 439, 312, 313, 1924, 1925, "(" +817, 11, 69, 440, 314, 315, 1926, 1927, "p" +817, 11, 70, 441, 316, 317, 1928, 1929, "=" +817, 11, 71, 442, 318, 319, 1930, 1931, "0" +817, 11, 72, 443, 320, 321, 1932, 1933, "." +817, 11, 73, 444, 322, 325, 1934, 1937, "004" +817, 11, 74, 445, 326, 327, 1938, 1939, ")" +817, 11, 75, 446, 328, 329, 1940, 1941, "." +817, 12, 1, 447, 0, 2, 1942, 1944, "In" +817, 12, 2, 448, 3, 13, 1945, 1955, "conclusion" +817, 12, 3, 449, 14, 15, 1956, 1957, "," +817, 12, 4, 450, 16, 17, 1958, 1959, "a" +817, 12, 5, 451, 18, 22, 1960, 1964, "more" +817, 12, 6, 452, 23, 32, 1965, 1974, "efficient" +817, 12, 7, 453, 33, 34, 1975, 1976, "B" +817, 12, 8, 454, 35, 36, 1977, 1978, "-" +817, 12, 9, 455, 37, 41, 1979, 1983, "cell" +817, 12, 10, 456, 42, 49, 1984, 1991, "insulin" +817, 12, 11, 457, 50, 60, 1992, 2002, "processing" +817, 12, 12, 458, 61, 69, 2003, 2011, "provides" +817, 12, 13, 459, 70, 77, 2012, 2019, "further" +817, 12, 14, 460, 78, 86, 2020, 2028, "evidence" +817, 12, 15, 461, 87, 91, 2029, 2033, "that" +817, 12, 16, 462, 92, 104, 2034, 2046, "vildagliptin" +817, 12, 17, 463, 105, 114, 2047, 2056, "treatment" +817, 12, 18, 464, 115, 126, 2057, 2068, "ameliorates" +817, 12, 19, 465, 127, 135, 2069, 2077, "abnormal" +817, 12, 20, 466, 136, 137, 2078, 2079, "B" +817, 12, 21, 467, 138, 139, 2080, 2081, "-" +817, 12, 22, 468, 140, 144, 2082, 2086, "cell" +817, 12, 23, 469, 145, 153, 2087, 2095, "function" +817, 12, 24, 470, 154, 156, 2096, 2098, "in" +817, 12, 25, 471, 157, 165, 2099, 2107, "patients" +817, 12, 26, 472, 166, 170, 2108, 2112, "with" +817, 12, 27, 473, 171, 175, 2113, 2117, "type" +817, 12, 28, 474, 176, 177, 2118, 2119, "2" +817, 12, 29, 475, 178, 186, 2120, 2128, "diabetes" +817, 12, 30, 476, 187, 188, 2129, 2130, "." +817, 13, 1, 477, 0, 3, 2131, 2134, "DOI" +817, 13, 2, 478, 4, 5, 2135, 2136, ":" +817, 13, 3, 479, 6, 8, 2137, 2139, "10" +817, 13, 4, 480, 9, 10, 2140, 2141, "." +817, 13, 5, 481, 11, 15, 2142, 2146, "1055" +817, 13, 6, 482, 16, 17, 2147, 2148, "/" +817, 13, 7, 483, 18, 19, 2149, 2150, "s" +817, 13, 8, 484, 20, 21, 2151, 2152, "-" +817, 13, 9, 485, 22, 26, 2153, 2157, "2007" +817, 13, 10, 486, 27, 28, 2158, 2159, "-" +817, 13, 11, 487, 29, 35, 2160, 2166, "991172" +817, 13, 12, 488, 36, 40, 2167, 2171, "PMID" +817, 13, 13, 489, 41, 42, 2172, 2173, ":" +817, 13, 14, 490, 43, 51, 2174, 2182, "17992639" +817, 13, 15, 491, 52, 53, 2183, 2184, "[" +817, 13, 16, 492, 54, 61, 2185, 2192, "Indexed" +817, 13, 17, 493, 62, 65, 2193, 2196, "for" +817, 13, 18, 494, 66, 73, 2197, 2204, "MEDLINE" +817, 13, 19, 495, 74, 75, 2205, 2206, "]" diff --git a/data/dm2 17992639_admin.annodb b/data/dm2 17992639_admin.annodb new file mode 100644 index 0000000..f509c2d --- /dev/null +++ b/data/dm2 17992639_admin.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +131, Journal, 0, 16, "Horm Metab Res .", "", " \"Horm Metab Res .\"." +0, PublicationYear, 17, 21, "2007", "", " \"2007\"." +68, Title, 50, 217, "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .", "", " \"Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .\"." +1, Insulin, 74, 81, "insulin", "", +2, Vildagliptin, 170, 182, "vildagliptin", "", +3, Type2Diabetes, 200, 215, "type 2 diabetes", "", +4, Author, 218, 227, "Ahr é n B", "", " \"Ahr é n B\"." +5, Author, 236, 244, "Pacini G", "", " \"Pacini G\"." +6, Author, 247, 253, "Tura A", "", " \"Tura A\"." +7, Author, 256, 264, "Foley JE", "", " \"Foley JE\"." +8, Author, 267, 278, "Schweizer A", "", " \"Schweizer A\"." +9, Sweden, 390, 396, "Sweden", "", " ." +97, ObjectiveDescription, 426, 610, "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .", "", " \"The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .\"." +10, Insulin, 484, 491, "insulin", "", +11, Vildagliptin, 596, 608, "vildagliptin", "", +12, NumberPatientsCT, 611, 623, "Fifty - five", "", " \"Fifty - five\"." +106299, Precondition, 624, 746, "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2", "", " \"patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2\". \"mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .\"." +13, Type2Diabetes, 638, 653, "type 2 diabetes", "", " ." +14, AvgAge, 656, 662, "56 . 5", "", " \"56 . 5\"." +87, Year, 675, 680, "years", "", +15, BMI, 683, 686, "BMI", "", +85, BaseLineValue, 689, 695, "29 . 6", "", +50307, SdDevBL, 702, 707, "0 . 5", "", +16, Kg_per_squareMeter, 708, 720, "kg / m ( 2 )", "", +17, FastingPlasmaGlucose, 723, 726, "FPG", "", +86, BaseLineValue, 729, 734, "9 . 9", "", +50308, SdDevBL, 741, 746, "0 . 2", "", +18, Millimoles_per_litre, 747, 755, "mmol / l", "", +106299, Precondition, 747, 947, "mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) .", "", +19, HbA1c, 758, 763, "HbA1c", "", +84, BaseLineValue, 766, 771, "7 . 7", "", +50309, SdDevBL, 778, 783, "0 . 1", "", +20, Percentage, 784, 785, "%", "", +21, NumberPatientsArm, 803, 805, "29", "", " \"29\"." +22, Vildagliptin, 833, 845, "vildagliptin", "", " ." +23, NumberPatientsArm, 850, 852, "26", "", " \"26\"." +24, Placebo, 867, 874, "placebo", "", " ." +25, Metformin, 902, 911, "metformin", "", +26, DoseValue, 922, 935, "1 . 5 - 3 . 0", "", +27, Gram, 936, 937, "g", "", +28, Interval, 940, 943, "day", "", " \"day\". \"day\"." +134, TimePoint, 986, 994, "baseline", "", +30, Duration, 1005, 1013, "52 weeks", "", " \"52 weeks\"." +32, Insulin, 1033, 1043, "proinsulin", "", +50310, EndPointDescription, 1055, 1072, "insulin secretion", "", +35, EndPointDescription, 1179, 1196, "B - cell function", "", +37, Vildagliptin, 1236, 1248, "vildagliptin", "", +38, Placebo, 1251, 1258, "placebo", "", +101, Mean, 1264, 1268, "mean", "", +139, TimePoint, 1281, 1289, "baseline", "", +50311, EndPointDescription, 1293, 1332, "fasting proinsulin to C - peptide ratio", "", " . ." +50312, EndPointDescription, 1335, 1344, "fastP / C", "", +103, DiffGroupAbsValue, 1351, 1360, "- 0 . 007", "", " \"- 0 . 007\"." +44, SdDevDiff, 1367, 1374, "0 . 009", "", " \"0 . 009\"." +45, PvalueDiff, 1377, 1388, "p = 0 . 052", "", " \"p = 0 . 052\"." +46, Duration, 1428, 1436, "52 weeks", "", +47, Vildagliptin, 1455, 1467, "vildagliptin", "", +41, EndPointDescription, 1496, 1535, "dynamic proinsulin to C - peptide ratio", "", " . ." +42, EndPointDescription, 1538, 1546, "dynP / C", "", +48, Placebo, 1561, 1568, "placebo", "", +50313, Reduction, 1572, 1579, "0 . 010", "", " \"0 . 010\"." +50314, SdDevChangeValue, 1586, 1593, "0 . 008", "", " \"0 . 008\"." +51, PValueChangeValue, 1596, 1607, "p = 0 . 037", "", " \"p = 0 . 037\"." +52, EndPointDescription, 1635, 1640, "P / C", "", " . ." +54, FastingPlasmaGlucose, 1707, 1722, "fasting glucose", "", +55, EndPointDescription, 1727, 1738, "glucose AUC", "", +53, EndPointDescription, 1778, 1783, "P / C", "", " . ." +118, ObservedResult, 1804, 1829, "was significantly reduced", "", " \"was significantly reduced\"." +56, Vildagliptin, 1835, 1847, "vildagliptin", "", +57, Placebo, 1853, 1860, "placebo", "", +50315, ObservedResult, 1863, 1939, "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )", "", " \"both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )\"." +59, PvalueDiff, 1891, 1902, "p = 0 . 023", "", " \"p = 0 . 023\"." +60, PvalueDiff, 1926, 1937, "p = 0 . 004", "", " \"p = 0 . 004\"." +121, ConclusionComment, 1942, 2130, "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .", "", " \"In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .\"." +61, Insulin, 1984, 1991, "insulin", "", +62, Vildagliptin, 2034, 2046, "vildagliptin", "", +63, Type2Diabetes, 2113, 2128, "type 2 diabetes", "", +64, PMID, 2174, 2182, "17992639", "", " \"17992639\"." diff --git a/data/dm2 17992639_admin.n-triples b/data/dm2 17992639_admin.n-triples new file mode 100644 index 0000000..9b3487d --- /dev/null +++ b/data/dm2 17992639_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication " . + "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes ." . + "Ahr é n B" . + "2007" . + "Horm Metab Res ." . + "17992639" . + . + "Pacini G" . + "Tura A" . + "Foley JE" . + "Schweizer A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin ." . + "Fifty - five" . + "52 weeks" . + . + . + . + "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + "56 . 5" . + . + "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2" . + "mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % ) were studied : 29 patients were treated with vildagliptin and 26 patients with placebo , both added to an ongoing metformin regimen ( 1 . 5 - 3 . 0 g / day ) ." . +# RDF export of group: Endpoint + . + "Endpoint fastP/C" . + . + . + . + . + . + . + "Endpoint dynP/C" . + . + . + . + . + . + . + "Endpoint P/C" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm v+m" . + "29" . + . + . + . + . + . + . + "Arm p+m" . + "26" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention v+m" . + . + "day" . + . + . + "Intervention p+m" . + . + "day" . + . +# RDF export of group: Medication + . + "Medication v" . + . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome fastP/C v" . + . + . + "Outcome fastP/C p" . + . + . + "Outcome dynP/C v" . + . + "0 . 010" . + "p = 0 . 037" . + "0 . 008" . + . + "Outcome P/C v" . + . + "was significantly reduced" . + "both in the fasting state ( p = 0 . 023 ) and postprandially ( p = 0 . 004 )" . + . + "Outcome P/C p" . + . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups fastP/C" . + "- 0 . 007" . + "p = 0 . 052" . + "0 . 009" . + . + . + . + "DiffBetweenGroups P/C fasting state" . + "p = 0 . 023" . + . + . + . + "DiffBetweenGroups P/C postprandially" . + "p = 0 . 004" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17992639_akramersunderbrink.annodb b/data/dm2 17992639_akramersunderbrink.annodb new file mode 100644 index 0000000..43250f8 --- /dev/null +++ b/data/dm2 17992639_akramersunderbrink.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22808, Journal, 0, 14, "Horm Metab Res", "", +22809, PublicationYear, 17, 21, "2007", "", +22811, Title, 50, 217, "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .", "", +22818, Vildagliptin, 170, 182, "vildagliptin", "", +22810, Type2Diabetes, 200, 215, "type 2 diabetes", "", +22812, Author, 218, 227, "Ahr é n B", "", +22813, Author, 236, 244, "Pacini G", "", +22814, Author, 247, 253, "Tura A", "", +22815, Author, 256, 264, "Foley JE", "", +22816, Author, 267, 278, "Schweizer A", "", +22817, Sweden, 390, 396, "Sweden", "", +22840, ObjectiveDescription, 426, 610, "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .", "", +22839, Vildagliptin, 596, 608, "vildagliptin", "", +22819, NumberPatientsCT, 611, 623, "Fifty - five", "", +22820, Type2Diabetes, 638, 653, "type 2 diabetes", "", +22821, AvgAge, 656, 662, "56 . 5", "", +22830, Year, 675, 680, "years", "", +22822, BMI, 683, 686, "BMI", "", +22874, Precondition, 683, 720, "BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 )", "", +22828, BaseLineValue, 689, 695, "29 . 6", "", +22869, SdErrorBL, 702, 707, "0 . 5", "", +22823, Kg_per_squareMeter, 708, 720, "kg / m ( 2 )", "", +22824, FastingPlasmaGlucose, 723, 726, "FPG", "", +22875, Precondition, 723, 755, "FPG = 9 . 9 + / - 0 . 2 mmol / l", "", +22829, BaseLineValue, 729, 734, "9 . 9", "", +22870, SdErrorBL, 741, 746, "0 . 2", "", +22825, Millimoles_per_litre, 747, 755, "mmol / l", "", +22826, HbA1c, 758, 763, "HbA1c", "", +22876, Precondition, 758, 785, "HbA1c = 7 . 7 + / - 0 . 1 %", "", +22827, BaseLineValue, 766, 771, "7 . 7", "", +22871, SdErrorBL, 778, 783, "0 . 1", "", +22831, Percentage, 784, 785, "%", "", +22832, NumberPatientsArm, 803, 805, "29", "", +22834, Vildagliptin, 833, 845, "vildagliptin", "", +22833, NumberPatientsArm, 850, 852, "26", "", +22835, Placebo, 867, 874, "placebo", "", +22836, Metformin, 902, 911, "metformin", "", +22837, DoseValue, 922, 935, "1 . 5 - 3 . 0", "", +22838, BioAndMedicalUnit, 936, 943, "g / day", "", +39161, TimePoint, 986, 994, "baseline", "", +22843, Duration, 1005, 1013, "52 weeks", "", +22844, Vildagliptin, 1236, 1248, "vildagliptin", "", +22845, Placebo, 1251, 1258, "placebo", "", +22846, Mean, 1264, 1268, "mean", "", +39162, TimePoint, 1281, 1289, "baseline", "", +22847, EndPointDescription, 1293, 1332, "fasting proinsulin to C - peptide ratio", "", +22848, DiffGroupAbsValue, 1351, 1360, "- 0 . 007", "", +22872, SdErrorDiff, 1367, 1374, "0 . 009", "", +22849, PvalueDiff, 1377, 1388, "p = 0 . 052", "", +22850, Duration, 1428, 1436, "52 weeks", "", +22851, Vildagliptin, 1455, 1467, "vildagliptin", "", +22852, EndPointDescription, 1496, 1535, "dynamic proinsulin to C - peptide ratio", "", +22853, Placebo, 1561, 1568, "placebo", "", +22854, DiffBetweenGroups, 1572, 1579, "0 . 010", "", +22873, SdErrorDiff, 1586, 1593, "0 . 008", "", +22855, PvalueDiff, 1596, 1607, "p = 0 . 037", "", +22856, EndPointDescription, 1635, 1771, "P / C was expressed in relation to the glucose stimulus ( i . e . , the fasting glucose and glucose AUC ( 0 - 240 min ) , respectively )", "", +22863, ObservedResult, 1822, 1829, "reduced", "", +22857, Vildagliptin, 1835, 1847, "vildagliptin", "", +22858, Placebo, 1853, 1860, "placebo", "", +22859, EndPointDescription, 1868, 1888, "in the fasting state", "", +22861, PValueChangeValue, 1891, 1902, "p = 0 . 023", "", +22860, EndPointDescription, 1909, 1923, "postprandially", "", +22862, PValueChangeValue, 1926, 1937, "p = 0 . 004", "", +22866, ConclusionComment, 1942, 2130, "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .", "", +22865, Vildagliptin, 2034, 2046, "vildagliptin", "", +22864, Type2Diabetes, 2113, 2128, "type 2 diabetes", "", +22867, PMID, 2174, 2182, "17992639", "", diff --git a/data/dm2 17992639_akramersunderbrink.n-triples b/data/dm2 17992639_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 17992639_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 17992639_export.csv b/data/dm2 17992639_export.csv new file mode 100644 index 0000000..401ace6 --- /dev/null +++ b/data/dm2 17992639_export.csv @@ -0,0 +1,496 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +349, 1, 1, 1, 0, 4, 0, 4, "Horm" +349, 1, 2, 2, 5, 10, 5, 10, "Metab" +349, 1, 3, 3, 11, 14, 11, 14, "Res" +349, 1, 4, 4, 15, 16, 15, 16, "." +349, 2, 1, 5, 0, 4, 17, 21, "2007" +349, 2, 2, 6, 5, 8, 22, 25, "Nov" +349, 2, 3, 7, 9, 10, 26, 27, ";" +349, 2, 4, 8, 11, 13, 28, 30, "39" +349, 2, 5, 9, 14, 15, 31, 32, "(" +349, 2, 6, 10, 16, 18, 33, 35, "11" +349, 2, 7, 11, 19, 20, 36, 37, ")" +349, 2, 8, 12, 21, 22, 38, 39, ":" +349, 2, 9, 13, 23, 26, 40, 43, "826" +349, 2, 10, 14, 27, 28, 44, 45, "-" +349, 2, 11, 15, 29, 30, 46, 47, "9" +349, 2, 12, 16, 31, 32, 48, 49, "." +349, 3, 1, 17, 0, 8, 50, 58, "Improved" +349, 3, 2, 18, 9, 13, 59, 63, "meal" +349, 3, 3, 19, 14, 15, 64, 65, "-" +349, 3, 4, 20, 16, 23, 66, 73, "related" +349, 3, 5, 21, 24, 31, 74, 81, "insulin" +349, 3, 6, 22, 32, 42, 82, 92, "processing" +349, 3, 7, 23, 43, 54, 93, 104, "contributes" +349, 3, 8, 24, 55, 57, 105, 107, "to" +349, 3, 9, 25, 58, 61, 108, 111, "the" +349, 3, 10, 26, 62, 73, 112, 123, "enhancement" +349, 3, 11, 27, 74, 76, 124, 126, "of" +349, 3, 12, 28, 77, 78, 127, 128, "B" +349, 3, 13, 29, 79, 80, 129, 130, "-" +349, 3, 14, 30, 81, 85, 131, 135, "cell" +349, 3, 15, 31, 86, 94, 136, 144, "function" +349, 3, 16, 32, 95, 97, 145, 147, "by" +349, 3, 17, 33, 98, 101, 148, 151, "the" +349, 3, 18, 34, 102, 105, 152, 155, "DPP" +349, 3, 19, 35, 106, 107, 156, 157, "-" +349, 3, 20, 36, 108, 109, 158, 159, "4" +349, 3, 21, 37, 110, 119, 160, 169, "inhibitor" +349, 3, 22, 38, 120, 132, 170, 182, "vildagliptin" +349, 3, 23, 39, 133, 135, 183, 185, "in" +349, 3, 24, 40, 136, 144, 186, 194, "patients" +349, 3, 25, 41, 145, 149, 195, 199, "with" +349, 3, 26, 42, 150, 154, 200, 204, "type" +349, 3, 27, 43, 155, 156, 205, 206, "2" +349, 3, 28, 44, 157, 165, 207, 215, "diabetes" +349, 3, 29, 45, 166, 167, 216, 217, "." +349, 4, 1, 46, 0, 3, 218, 221, "Ahr" +349, 4, 2, 47, 4, 5, 222, 223, "é" +349, 4, 3, 48, 6, 7, 224, 225, "n" +349, 4, 4, 49, 8, 9, 226, 227, "B" +349, 4, 5, 50, 10, 11, 228, 229, "(" +349, 4, 6, 51, 12, 13, 230, 231, "1" +349, 4, 7, 52, 14, 15, 232, 233, ")" +349, 4, 8, 53, 16, 17, 234, 235, "," +349, 4, 9, 54, 18, 24, 236, 242, "Pacini" +349, 4, 10, 55, 25, 26, 243, 244, "G" +349, 4, 11, 56, 27, 28, 245, 246, "," +349, 4, 12, 57, 29, 33, 247, 251, "Tura" +349, 4, 13, 58, 34, 35, 252, 253, "A" +349, 4, 14, 59, 36, 37, 254, 255, "," +349, 4, 15, 60, 38, 43, 256, 261, "Foley" +349, 4, 16, 61, 44, 46, 262, 264, "JE" +349, 4, 17, 62, 47, 48, 265, 266, "," +349, 4, 18, 63, 49, 58, 267, 276, "Schweizer" +349, 4, 19, 64, 59, 60, 277, 278, "A" +349, 4, 20, 65, 61, 62, 279, 280, "." +349, 5, 1, 66, 0, 6, 281, 287, "Author" +349, 5, 2, 67, 7, 18, 288, 299, "information" +349, 5, 3, 68, 19, 20, 300, 301, ":" +349, 5, 4, 69, 21, 22, 302, 303, "(" +349, 5, 5, 70, 23, 24, 304, 305, "1" +349, 5, 6, 71, 25, 26, 306, 307, ")" +349, 5, 7, 72, 27, 37, 308, 318, "Department" +349, 5, 8, 73, 38, 40, 319, 321, "of" +349, 5, 9, 74, 41, 49, 322, 330, "Clinical" +349, 5, 10, 75, 50, 58, 331, 339, "Sciences" +349, 5, 11, 76, 59, 60, 340, 341, "," +349, 5, 12, 77, 61, 69, 342, 350, "Division" +349, 5, 13, 78, 70, 72, 351, 353, "of" +349, 5, 14, 79, 73, 81, 354, 362, "Medicine" +349, 5, 15, 80, 82, 83, 363, 364, "," +349, 5, 16, 81, 84, 88, 365, 369, "Lund" +349, 5, 17, 82, 89, 99, 370, 380, "University" +349, 5, 18, 83, 100, 101, 381, 382, "," +349, 5, 19, 84, 102, 106, 383, 387, "Lund" +349, 5, 20, 85, 107, 108, 388, 389, "," +349, 5, 21, 86, 109, 115, 390, 396, "Sweden" +349, 5, 22, 87, 116, 117, 397, 398, "." +349, 6, 1, 88, 0, 2, 399, 401, "Bo" +349, 6, 2, 89, 3, 4, 402, 403, "." +349, 6, 3, 90, 5, 10, 404, 409, "Ahren" +349, 6, 4, 91, 11, 12, 410, 411, "@" +349, 6, 5, 92, 13, 16, 412, 415, "med" +349, 6, 6, 93, 17, 18, 416, 417, "." +349, 6, 7, 94, 19, 21, 418, 420, "lu" +349, 6, 8, 95, 22, 23, 421, 422, "." +349, 6, 9, 96, 24, 26, 423, 425, "se" +349, 6, 10, 97, 27, 30, 426, 429, "The" +349, 6, 11, 98, 31, 34, 430, 433, "aim" +349, 6, 12, 99, 35, 37, 434, 436, "of" +349, 6, 13, 100, 38, 42, 437, 441, "this" +349, 6, 14, 101, 43, 48, 442, 447, "study" +349, 6, 15, 102, 49, 52, 448, 451, "was" +349, 6, 16, 103, 53, 55, 452, 454, "to" +349, 6, 17, 104, 56, 64, 455, 463, "evaluate" +349, 6, 18, 105, 65, 68, 464, 467, "the" +349, 6, 19, 106, 69, 81, 468, 480, "contribution" +349, 6, 20, 107, 82, 84, 481, 483, "of" +349, 6, 21, 108, 85, 92, 484, 491, "insulin" +349, 6, 22, 109, 93, 103, 492, 502, "processing" +349, 6, 23, 110, 104, 106, 503, 505, "to" +349, 6, 24, 111, 107, 110, 506, 509, "the" +349, 6, 25, 112, 111, 119, 510, 518, "improved" +349, 6, 26, 113, 120, 124, 519, 523, "meal" +349, 6, 27, 114, 125, 126, 524, 525, "-" +349, 6, 28, 115, 127, 134, 526, 533, "related" +349, 6, 29, 116, 135, 136, 534, 535, "B" +349, 6, 30, 117, 137, 138, 536, 537, "-" +349, 6, 31, 118, 139, 143, 538, 542, "cell" +349, 6, 32, 119, 144, 152, 543, 551, "function" +349, 6, 33, 120, 153, 163, 552, 562, "previously" +349, 6, 34, 121, 164, 169, 563, 568, "shown" +349, 6, 35, 122, 170, 174, 569, 573, "with" +349, 6, 36, 123, 175, 178, 574, 577, "the" +349, 6, 37, 124, 179, 182, 578, 581, "DPP" +349, 6, 38, 125, 183, 184, 582, 583, "-" +349, 6, 39, 126, 185, 186, 584, 585, "4" +349, 6, 40, 127, 187, 196, 586, 595, "inhibitor" +349, 6, 41, 128, 197, 209, 596, 608, "vildagliptin" +349, 6, 42, 129, 210, 211, 609, 610, "." +349, 7, 1, 130, 0, 5, 611, 616, "Fifty" +349, 7, 2, 131, 6, 7, 617, 618, "-" +349, 7, 3, 132, 8, 12, 619, 623, "five" +349, 7, 4, 133, 13, 21, 624, 632, "patients" +349, 7, 5, 134, 22, 26, 633, 637, "with" +349, 7, 6, 135, 27, 31, 638, 642, "type" +349, 7, 7, 136, 32, 33, 643, 644, "2" +349, 7, 8, 137, 34, 42, 645, 653, "diabetes" +349, 7, 9, 138, 43, 44, 654, 655, "(" +349, 7, 10, 139, 45, 47, 656, 658, "56" +349, 7, 11, 140, 48, 49, 659, 660, "." +349, 7, 12, 141, 50, 51, 661, 662, "5" +349, 7, 13, 142, 52, 53, 663, 664, "+" +349, 7, 14, 143, 54, 55, 665, 666, "/" +349, 7, 15, 144, 56, 57, 667, 668, "-" +349, 7, 16, 145, 58, 59, 669, 670, "1" +349, 7, 17, 146, 60, 61, 671, 672, "." +349, 7, 18, 147, 62, 63, 673, 674, "5" +349, 7, 19, 148, 64, 69, 675, 680, "years" +349, 7, 20, 149, 70, 71, 681, 682, ";" +349, 7, 21, 150, 72, 75, 683, 686, "BMI" +349, 7, 22, 151, 76, 77, 687, 688, "=" +349, 7, 23, 152, 78, 80, 689, 691, "29" +349, 7, 24, 153, 81, 82, 692, 693, "." +349, 7, 25, 154, 83, 84, 694, 695, "6" +349, 7, 26, 155, 85, 86, 696, 697, "+" +349, 7, 27, 156, 87, 88, 698, 699, "/" +349, 7, 28, 157, 89, 90, 700, 701, "-" +349, 7, 29, 158, 91, 92, 702, 703, "0" +349, 7, 30, 159, 93, 94, 704, 705, "." +349, 7, 31, 160, 95, 96, 706, 707, "5" +349, 7, 32, 161, 97, 99, 708, 710, "kg" +349, 7, 33, 162, 100, 101, 711, 712, "/" +349, 7, 34, 163, 102, 103, 713, 714, "m" +349, 7, 35, 164, 104, 105, 715, 716, "(" +349, 7, 36, 165, 106, 107, 717, 718, "2" +349, 7, 37, 166, 108, 109, 719, 720, ")" +349, 7, 38, 167, 110, 111, 721, 722, ";" +349, 7, 39, 168, 112, 115, 723, 726, "FPG" +349, 7, 40, 169, 116, 117, 727, 728, "=" +349, 7, 41, 170, 118, 119, 729, 730, "9" +349, 7, 42, 171, 120, 121, 731, 732, "." +349, 7, 43, 172, 122, 123, 733, 734, "9" +349, 7, 44, 173, 124, 125, 735, 736, "+" +349, 7, 45, 174, 126, 127, 737, 738, "/" +349, 7, 46, 175, 128, 129, 739, 740, "-" +349, 7, 47, 176, 130, 131, 741, 742, "0" +349, 7, 48, 177, 132, 133, 743, 744, "." +349, 7, 49, 178, 134, 135, 745, 746, "2" +349, 7, 50, 179, 136, 140, 747, 751, "mmol" +349, 7, 51, 180, 141, 142, 752, 753, "/" +349, 7, 52, 181, 143, 144, 754, 755, "l" +349, 7, 53, 182, 145, 146, 756, 757, ";" +349, 7, 54, 183, 147, 152, 758, 763, "HbA1c" +349, 7, 55, 184, 153, 154, 764, 765, "=" +349, 7, 56, 185, 155, 156, 766, 767, "7" +349, 7, 57, 186, 157, 158, 768, 769, "." +349, 7, 58, 187, 159, 160, 770, 771, "7" +349, 7, 59, 188, 161, 162, 772, 773, "+" +349, 7, 60, 189, 163, 164, 774, 775, "/" +349, 7, 61, 190, 165, 166, 776, 777, "-" +349, 7, 62, 191, 167, 168, 778, 779, "0" +349, 7, 63, 192, 169, 170, 780, 781, "." +349, 7, 64, 193, 171, 172, 782, 783, "1" +349, 7, 65, 194, 173, 174, 784, 785, "%" +349, 7, 66, 195, 175, 176, 786, 787, ")" +349, 7, 67, 196, 177, 181, 788, 792, "were" +349, 7, 68, 197, 182, 189, 793, 800, "studied" +349, 7, 69, 198, 190, 191, 801, 802, ":" +349, 7, 70, 199, 192, 194, 803, 805, "29" +349, 7, 71, 200, 195, 203, 806, 814, "patients" +349, 7, 72, 201, 204, 208, 815, 819, "were" +349, 7, 73, 202, 209, 216, 820, 827, "treated" +349, 7, 74, 203, 217, 221, 828, 832, "with" +349, 7, 75, 204, 222, 234, 833, 845, "vildagliptin" +349, 7, 76, 205, 235, 238, 846, 849, "and" +349, 7, 77, 206, 239, 241, 850, 852, "26" +349, 7, 78, 207, 242, 250, 853, 861, "patients" +349, 7, 79, 208, 251, 255, 862, 866, "with" +349, 7, 80, 209, 256, 263, 867, 874, "placebo" +349, 7, 81, 210, 264, 265, 875, 876, "," +349, 7, 82, 211, 266, 270, 877, 881, "both" +349, 7, 83, 212, 271, 276, 882, 887, "added" +349, 7, 84, 213, 277, 279, 888, 890, "to" +349, 7, 85, 214, 280, 282, 891, 893, "an" +349, 7, 86, 215, 283, 290, 894, 901, "ongoing" +349, 7, 87, 216, 291, 300, 902, 911, "metformin" +349, 7, 88, 217, 301, 308, 912, 919, "regimen" +349, 7, 89, 218, 309, 310, 920, 921, "(" +349, 7, 90, 219, 311, 312, 922, 923, "1" +349, 7, 91, 220, 313, 314, 924, 925, "." +349, 7, 92, 221, 315, 316, 926, 927, "5" +349, 7, 93, 222, 317, 318, 928, 929, "-" +349, 7, 94, 223, 319, 320, 930, 931, "3" +349, 7, 95, 224, 321, 322, 932, 933, "." +349, 7, 96, 225, 323, 324, 934, 935, "0" +349, 7, 97, 226, 325, 326, 936, 937, "g" +349, 7, 98, 227, 327, 328, 938, 939, "/" +349, 7, 99, 228, 329, 332, 940, 943, "day" +349, 7, 100, 229, 333, 334, 944, 945, ")" +349, 7, 101, 230, 335, 336, 946, 947, "." +349, 8, 1, 231, 0, 1, 948, 949, "A" +349, 8, 2, 232, 2, 14, 950, 962, "standardized" +349, 8, 3, 233, 15, 24, 963, 972, "breakfast" +349, 8, 4, 234, 25, 28, 973, 976, "was" +349, 8, 5, 235, 29, 34, 977, 982, "given" +349, 8, 6, 236, 35, 37, 983, 985, "at" +349, 8, 7, 237, 38, 46, 986, 994, "baseline" +349, 8, 8, 238, 47, 50, 995, 998, "and" +349, 8, 9, 239, 51, 56, 999, 1004, "after" +349, 8, 10, 240, 57, 59, 1005, 1007, "52" +349, 8, 11, 241, 60, 65, 1008, 1013, "weeks" +349, 8, 12, 242, 66, 68, 1014, 1016, "of" +349, 8, 13, 243, 69, 78, 1017, 1026, "treatment" +349, 8, 14, 244, 79, 80, 1027, 1028, "," +349, 8, 15, 245, 81, 84, 1029, 1032, "and" +349, 8, 16, 246, 85, 95, 1033, 1043, "proinsulin" +349, 8, 17, 247, 96, 103, 1044, 1051, "related" +349, 8, 18, 248, 104, 106, 1052, 1054, "to" +349, 8, 19, 249, 107, 114, 1055, 1062, "insulin" +349, 8, 20, 250, 115, 124, 1063, 1072, "secretion" +349, 8, 21, 251, 125, 128, 1073, 1076, "was" +349, 8, 22, 252, 129, 137, 1077, 1085, "measured" +349, 8, 23, 253, 138, 142, 1086, 1090, "with" +349, 8, 24, 254, 143, 144, 1091, 1092, "C" +349, 8, 25, 255, 145, 146, 1093, 1094, "-" +349, 8, 26, 256, 147, 154, 1095, 1102, "peptide" +349, 8, 27, 257, 155, 157, 1103, 1105, "in" +349, 8, 28, 258, 158, 161, 1106, 1109, "the" +349, 8, 29, 259, 162, 169, 1110, 1117, "fasting" +349, 8, 30, 260, 170, 173, 1118, 1121, "and" +349, 8, 31, 261, 174, 186, 1122, 1134, "postprandial" +349, 8, 32, 262, 187, 188, 1135, 1136, "(" +349, 8, 33, 263, 189, 193, 1137, 1141, "over" +349, 8, 34, 264, 194, 195, 1142, 1143, "4" +349, 8, 35, 265, 196, 197, 1144, 1145, "h" +349, 8, 36, 266, 198, 202, 1146, 1150, "post" +349, 8, 37, 267, 203, 204, 1151, 1152, "-" +349, 8, 38, 268, 205, 209, 1153, 1157, "meal" +349, 8, 39, 269, 210, 211, 1158, 1159, ")" +349, 8, 40, 270, 212, 218, 1160, 1166, "states" +349, 8, 41, 271, 219, 221, 1167, 1169, "to" +349, 8, 42, 272, 222, 230, 1170, 1178, "evaluate" +349, 8, 43, 273, 231, 232, 1179, 1180, "B" +349, 8, 44, 274, 233, 234, 1181, 1182, "-" +349, 8, 45, 275, 235, 239, 1183, 1187, "cell" +349, 8, 46, 276, 240, 248, 1188, 1196, "function" +349, 8, 47, 277, 249, 250, 1197, 1198, "." +349, 9, 1, 278, 0, 3, 1199, 1202, "The" +349, 9, 2, 279, 4, 11, 1203, 1210, "between" +349, 9, 3, 280, 12, 13, 1211, 1212, "-" +349, 9, 4, 281, 14, 23, 1213, 1222, "treatment" +349, 9, 5, 282, 24, 34, 1223, 1233, "difference" +349, 9, 6, 283, 35, 36, 1234, 1235, "(" +349, 9, 7, 284, 37, 49, 1236, 1248, "vildagliptin" +349, 9, 8, 285, 50, 51, 1249, 1250, "-" +349, 9, 9, 286, 52, 59, 1251, 1258, "placebo" +349, 9, 10, 287, 60, 61, 1259, 1260, ")" +349, 9, 11, 288, 62, 64, 1261, 1263, "in" +349, 9, 12, 289, 65, 69, 1264, 1268, "mean" +349, 9, 13, 290, 70, 76, 1269, 1275, "change" +349, 9, 14, 291, 77, 81, 1276, 1280, "from" +349, 9, 15, 292, 82, 90, 1281, 1289, "baseline" +349, 9, 16, 293, 91, 93, 1290, 1292, "in" +349, 9, 17, 294, 94, 101, 1293, 1300, "fasting" +349, 9, 18, 295, 102, 112, 1301, 1311, "proinsulin" +349, 9, 19, 296, 113, 115, 1312, 1314, "to" +349, 9, 20, 297, 116, 117, 1315, 1316, "C" +349, 9, 21, 298, 118, 119, 1317, 1318, "-" +349, 9, 22, 299, 120, 127, 1319, 1326, "peptide" +349, 9, 23, 300, 128, 133, 1327, 1332, "ratio" +349, 9, 24, 301, 134, 135, 1333, 1334, "(" +349, 9, 25, 302, 136, 141, 1335, 1340, "fastP" +349, 9, 26, 303, 142, 143, 1341, 1342, "/" +349, 9, 27, 304, 144, 145, 1343, 1344, "C" +349, 9, 28, 305, 146, 147, 1345, 1346, ")" +349, 9, 29, 306, 148, 151, 1347, 1350, "was" +349, 9, 30, 307, 152, 153, 1351, 1352, "-" +349, 9, 31, 308, 154, 155, 1353, 1354, "0" +349, 9, 32, 309, 156, 157, 1355, 1356, "." +349, 9, 33, 310, 158, 161, 1357, 1360, "007" +349, 9, 34, 311, 162, 163, 1361, 1362, "+" +349, 9, 35, 312, 164, 165, 1363, 1364, "/" +349, 9, 36, 313, 166, 167, 1365, 1366, "-" +349, 9, 37, 314, 168, 169, 1367, 1368, "0" +349, 9, 38, 315, 170, 171, 1369, 1370, "." +349, 9, 39, 316, 172, 175, 1371, 1374, "009" +349, 9, 40, 317, 176, 177, 1375, 1376, "(" +349, 9, 41, 318, 178, 179, 1377, 1378, "p" +349, 9, 42, 319, 180, 181, 1379, 1380, "=" +349, 9, 43, 320, 182, 183, 1381, 1382, "0" +349, 9, 44, 321, 184, 185, 1383, 1384, "." +349, 9, 45, 322, 186, 189, 1385, 1388, "052" +349, 9, 46, 323, 190, 191, 1389, 1390, ")" +349, 9, 47, 324, 192, 193, 1391, 1392, "." +349, 10, 1, 325, 0, 9, 1393, 1402, "Following" +349, 10, 2, 326, 10, 13, 1403, 1406, "the" +349, 10, 3, 327, 14, 22, 1407, 1415, "standard" +349, 10, 4, 328, 23, 32, 1416, 1425, "breakfast" +349, 10, 5, 329, 33, 34, 1426, 1427, "," +349, 10, 6, 330, 35, 37, 1428, 1430, "52" +349, 10, 7, 331, 38, 43, 1431, 1436, "weeks" +349, 10, 8, 332, 44, 46, 1437, 1439, "of" +349, 10, 9, 333, 47, 56, 1440, 1449, "treatment" +349, 10, 10, 334, 57, 61, 1450, 1454, "with" +349, 10, 11, 335, 62, 74, 1455, 1467, "vildagliptin" +349, 10, 12, 336, 75, 88, 1468, 1481, "significantly" +349, 10, 13, 337, 89, 98, 1482, 1491, "decreased" +349, 10, 14, 338, 99, 102, 1492, 1495, "the" +349, 10, 15, 339, 103, 110, 1496, 1503, "dynamic" +349, 10, 16, 340, 111, 121, 1504, 1514, "proinsulin" +349, 10, 17, 341, 122, 124, 1515, 1517, "to" +349, 10, 18, 342, 125, 126, 1518, 1519, "C" +349, 10, 19, 343, 127, 128, 1520, 1521, "-" +349, 10, 20, 344, 129, 136, 1522, 1529, "peptide" +349, 10, 21, 345, 137, 142, 1530, 1535, "ratio" +349, 10, 22, 346, 143, 144, 1536, 1537, "(" +349, 10, 23, 347, 145, 149, 1538, 1542, "dynP" +349, 10, 24, 348, 150, 151, 1543, 1544, "/" +349, 10, 25, 349, 152, 153, 1545, 1546, "C" +349, 10, 26, 350, 154, 155, 1547, 1548, ")" +349, 10, 27, 351, 156, 164, 1549, 1557, "relative" +349, 10, 28, 352, 165, 167, 1558, 1560, "to" +349, 10, 29, 353, 168, 175, 1561, 1568, "placebo" +349, 10, 30, 354, 176, 178, 1569, 1571, "by" +349, 10, 31, 355, 179, 180, 1572, 1573, "0" +349, 10, 32, 356, 181, 182, 1574, 1575, "." +349, 10, 33, 357, 183, 186, 1576, 1579, "010" +349, 10, 34, 358, 187, 188, 1580, 1581, "+" +349, 10, 35, 359, 189, 190, 1582, 1583, "/" +349, 10, 36, 360, 191, 192, 1584, 1585, "-" +349, 10, 37, 361, 193, 194, 1586, 1587, "0" +349, 10, 38, 362, 195, 196, 1588, 1589, "." +349, 10, 39, 363, 197, 200, 1590, 1593, "008" +349, 10, 40, 364, 201, 202, 1594, 1595, "(" +349, 10, 41, 365, 203, 204, 1596, 1597, "p" +349, 10, 42, 366, 205, 206, 1598, 1599, "=" +349, 10, 43, 367, 207, 208, 1600, 1601, "0" +349, 10, 44, 368, 209, 210, 1602, 1603, "." +349, 10, 45, 369, 211, 214, 1604, 1607, "037" +349, 10, 46, 370, 215, 216, 1608, 1609, ")" +349, 10, 47, 371, 217, 218, 1610, 1611, "." +349, 11, 1, 372, 0, 11, 1612, 1623, "Importantly" +349, 11, 2, 373, 12, 13, 1624, 1625, "," +349, 11, 3, 374, 14, 18, 1626, 1630, "when" +349, 11, 4, 375, 19, 22, 1631, 1634, "the" +349, 11, 5, 376, 23, 24, 1635, 1636, "P" +349, 11, 6, 377, 25, 26, 1637, 1638, "/" +349, 11, 7, 378, 27, 28, 1639, 1640, "C" +349, 11, 8, 379, 29, 32, 1641, 1644, "was" +349, 11, 9, 380, 33, 42, 1645, 1654, "expressed" +349, 11, 10, 381, 43, 45, 1655, 1657, "in" +349, 11, 11, 382, 46, 54, 1658, 1666, "relation" +349, 11, 12, 383, 55, 57, 1667, 1669, "to" +349, 11, 13, 384, 58, 61, 1670, 1673, "the" +349, 11, 14, 385, 62, 69, 1674, 1681, "glucose" +349, 11, 15, 386, 70, 78, 1682, 1690, "stimulus" +349, 11, 16, 387, 79, 80, 1691, 1692, "(" +349, 11, 17, 388, 81, 82, 1693, 1694, "i" +349, 11, 18, 389, 83, 84, 1695, 1696, "." +349, 11, 19, 390, 85, 86, 1697, 1698, "e" +349, 11, 20, 391, 87, 88, 1699, 1700, "." +349, 11, 21, 392, 89, 90, 1701, 1702, "," +349, 11, 22, 393, 91, 94, 1703, 1706, "the" +349, 11, 23, 394, 95, 102, 1707, 1714, "fasting" +349, 11, 24, 395, 103, 110, 1715, 1722, "glucose" +349, 11, 25, 396, 111, 114, 1723, 1726, "and" +349, 11, 26, 397, 115, 122, 1727, 1734, "glucose" +349, 11, 27, 398, 123, 126, 1735, 1738, "AUC" +349, 11, 28, 399, 127, 128, 1739, 1740, "(" +349, 11, 29, 400, 129, 130, 1741, 1742, "0" +349, 11, 30, 401, 131, 132, 1743, 1744, "-" +349, 11, 31, 402, 133, 136, 1745, 1748, "240" +349, 11, 32, 403, 137, 140, 1749, 1752, "min" +349, 11, 33, 404, 141, 142, 1753, 1754, ")" +349, 11, 34, 405, 143, 144, 1755, 1756, "," +349, 11, 35, 406, 145, 157, 1757, 1769, "respectively" +349, 11, 36, 407, 158, 159, 1770, 1771, ")" +349, 11, 37, 408, 160, 161, 1772, 1773, "," +349, 11, 38, 409, 162, 165, 1774, 1777, "the" +349, 11, 39, 410, 166, 167, 1778, 1779, "P" +349, 11, 40, 411, 168, 169, 1780, 1781, "/" +349, 11, 41, 412, 170, 171, 1782, 1783, "C" +349, 11, 42, 413, 172, 180, 1784, 1792, "relative" +349, 11, 43, 414, 181, 183, 1793, 1795, "to" +349, 11, 44, 415, 184, 191, 1796, 1803, "glucose" +349, 11, 45, 416, 192, 195, 1804, 1807, "was" +349, 11, 46, 417, 196, 209, 1808, 1821, "significantly" +349, 11, 47, 418, 210, 217, 1822, 1829, "reduced" +349, 11, 48, 419, 218, 222, 1830, 1834, "with" +349, 11, 49, 420, 223, 235, 1835, 1847, "vildagliptin" +349, 11, 50, 421, 236, 238, 1848, 1850, "vs" +349, 11, 51, 422, 239, 240, 1851, 1852, "." +349, 11, 52, 423, 241, 248, 1853, 1860, "placebo" +349, 11, 53, 424, 249, 250, 1861, 1862, "," +349, 11, 54, 425, 251, 255, 1863, 1867, "both" +349, 11, 55, 426, 256, 258, 1868, 1870, "in" +349, 11, 56, 427, 259, 262, 1871, 1874, "the" +349, 11, 57, 428, 263, 270, 1875, 1882, "fasting" +349, 11, 58, 429, 271, 276, 1883, 1888, "state" +349, 11, 59, 430, 277, 278, 1889, 1890, "(" +349, 11, 60, 431, 279, 280, 1891, 1892, "p" +349, 11, 61, 432, 281, 282, 1893, 1894, "=" +349, 11, 62, 433, 283, 284, 1895, 1896, "0" +349, 11, 63, 434, 285, 286, 1897, 1898, "." +349, 11, 64, 435, 287, 290, 1899, 1902, "023" +349, 11, 65, 436, 291, 292, 1903, 1904, ")" +349, 11, 66, 437, 293, 296, 1905, 1908, "and" +349, 11, 67, 438, 297, 311, 1909, 1923, "postprandially" +349, 11, 68, 439, 312, 313, 1924, 1925, "(" +349, 11, 69, 440, 314, 315, 1926, 1927, "p" +349, 11, 70, 441, 316, 317, 1928, 1929, "=" +349, 11, 71, 442, 318, 319, 1930, 1931, "0" +349, 11, 72, 443, 320, 321, 1932, 1933, "." +349, 11, 73, 444, 322, 325, 1934, 1937, "004" +349, 11, 74, 445, 326, 327, 1938, 1939, ")" +349, 11, 75, 446, 328, 329, 1940, 1941, "." +349, 12, 1, 447, 0, 2, 1942, 1944, "In" +349, 12, 2, 448, 3, 13, 1945, 1955, "conclusion" +349, 12, 3, 449, 14, 15, 1956, 1957, "," +349, 12, 4, 450, 16, 17, 1958, 1959, "a" +349, 12, 5, 451, 18, 22, 1960, 1964, "more" +349, 12, 6, 452, 23, 32, 1965, 1974, "efficient" +349, 12, 7, 453, 33, 34, 1975, 1976, "B" +349, 12, 8, 454, 35, 36, 1977, 1978, "-" +349, 12, 9, 455, 37, 41, 1979, 1983, "cell" +349, 12, 10, 456, 42, 49, 1984, 1991, "insulin" +349, 12, 11, 457, 50, 60, 1992, 2002, "processing" +349, 12, 12, 458, 61, 69, 2003, 2011, "provides" +349, 12, 13, 459, 70, 77, 2012, 2019, "further" +349, 12, 14, 460, 78, 86, 2020, 2028, "evidence" +349, 12, 15, 461, 87, 91, 2029, 2033, "that" +349, 12, 16, 462, 92, 104, 2034, 2046, "vildagliptin" +349, 12, 17, 463, 105, 114, 2047, 2056, "treatment" +349, 12, 18, 464, 115, 126, 2057, 2068, "ameliorates" +349, 12, 19, 465, 127, 135, 2069, 2077, "abnormal" +349, 12, 20, 466, 136, 137, 2078, 2079, "B" +349, 12, 21, 467, 138, 139, 2080, 2081, "-" +349, 12, 22, 468, 140, 144, 2082, 2086, "cell" +349, 12, 23, 469, 145, 153, 2087, 2095, "function" +349, 12, 24, 470, 154, 156, 2096, 2098, "in" +349, 12, 25, 471, 157, 165, 2099, 2107, "patients" +349, 12, 26, 472, 166, 170, 2108, 2112, "with" +349, 12, 27, 473, 171, 175, 2113, 2117, "type" +349, 12, 28, 474, 176, 177, 2118, 2119, "2" +349, 12, 29, 475, 178, 186, 2120, 2128, "diabetes" +349, 12, 30, 476, 187, 188, 2129, 2130, "." +349, 13, 1, 477, 0, 3, 2131, 2134, "DOI" +349, 13, 2, 478, 4, 5, 2135, 2136, ":" +349, 13, 3, 479, 6, 8, 2137, 2139, "10" +349, 13, 4, 480, 9, 10, 2140, 2141, "." +349, 13, 5, 481, 11, 15, 2142, 2146, "1055" +349, 13, 6, 482, 16, 17, 2147, 2148, "/" +349, 13, 7, 483, 18, 19, 2149, 2150, "s" +349, 13, 8, 484, 20, 21, 2151, 2152, "-" +349, 13, 9, 485, 22, 26, 2153, 2157, "2007" +349, 13, 10, 486, 27, 28, 2158, 2159, "-" +349, 13, 11, 487, 29, 35, 2160, 2166, "991172" +349, 13, 12, 488, 36, 40, 2167, 2171, "PMID" +349, 13, 13, 489, 41, 42, 2172, 2173, ":" +349, 13, 14, 490, 43, 51, 2174, 2182, "17992639" +349, 13, 15, 491, 52, 53, 2183, 2184, "[" +349, 13, 16, 492, 54, 61, 2185, 2192, "Indexed" +349, 13, 17, 493, 62, 65, 2193, 2196, "for" +349, 13, 18, 494, 66, 73, 2197, 2204, "MEDLINE" +349, 13, 19, 495, 74, 75, 2205, 2206, "]" diff --git a/data/dm2 17992639_kwoodley.annodb b/data/dm2 17992639_kwoodley.annodb new file mode 100644 index 0000000..e442a67 --- /dev/null +++ b/data/dm2 17992639_kwoodley.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +33147, Journal, 0, 16, "Horm Metab Res .", "", +5953, PublicationYear, 17, 21, "2007", "", " \"2007\"." +33148, Title, 50, 217, "Improved meal - related insulin processing contributes to the enhancement of B - cell function by the DPP - 4 inhibitor vildagliptin in patients with type 2 diabetes .", "", +5954, Insulin, 74, 81, "insulin", "", +5955, Vildagliptin, 170, 182, "vildagliptin", "", +5956, Type2Diabetes, 200, 215, "type 2 diabetes", "", +5958, Author, 218, 227, "Ahr é n B", "", " \"Ahr é n B\"." +5959, Author, 236, 244, "Pacini G", "", " \"Pacini G\"." +5960, Author, 247, 253, "Tura A", "", " \"Tura A\"." +5961, Author, 256, 264, "Foley JE", "", " \"Foley JE\"." +5962, Author, 267, 278, "Schweizer A", "", " \"Schweizer A\"." +5963, Sweden, 390, 396, "Sweden", "", " ." +33149, ObjectiveDescription, 426, 610, "The aim of this study was to evaluate the contribution of insulin processing to the improved meal - related B - cell function previously shown with the DPP - 4 inhibitor vildagliptin .", "", +5964, Insulin, 484, 491, "insulin", "", +5965, Vildagliptin, 596, 608, "vildagliptin", "", +5967, NumberPatientsCT, 611, 623, "Fifty - five", "", " \"Fifty - five\"." +5984, Precondition, 624, 787, "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2 mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % )", "", " \"patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2 mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % )\"." +5968, Type2Diabetes, 638, 653, "type 2 diabetes", "", " ." +5969, AvgAge, 656, 662, "56 . 5", "", " \"56 . 5\"." +5970, BMI, 683, 686, "BMI", "", +5971, Kg_per_squareMeter, 708, 720, "kg / m ( 2 )", "", +5972, FastingPlasmaGlucose, 723, 726, "FPG", "", +5973, Millimoles_per_litre, 747, 755, "mmol / l", "", +5974, HbA1c, 758, 763, "HbA1c", "", +5975, Percentage, 784, 785, "%", "", +5976, NumberPatientsArm, 803, 805, "29", "", +5977, Vildagliptin, 833, 845, "vildagliptin", "", +5978, NumberPatientsArm, 850, 852, "26", "", +5979, Placebo, 867, 874, "placebo", "", +5980, Metformin, 902, 911, "metformin", "", +5981, DoseValue, 922, 935, "1 . 5 - 3 . 0", "", +5982, Gram, 936, 937, "g", "", +5983, Interval, 940, 943, "day", "", +33150, TimePoint, 986, 994, "baseline", "", +5985, Duration, 1005, 1013, "52 weeks", "", " \"52 weeks\"." +5987, Insulin, 1033, 1043, "proinsulin", "", +5986, Insulin, 1055, 1062, "insulin", "", +5992, EndPointDescription, 1091, 1102, "C - peptide", "", +5988, FastingPlasmaGlucose, 1110, 1117, "fasting", "", +33151, PostprandialPlasmaGlucose, 1122, 1134, "postprandial", "", +5990, TimePoint, 1142, 1157, "4 h post - meal", "", +5991, EndPointDescription, 1179, 1196, "B - cell function", "", +5993, Vildagliptin, 1236, 1248, "vildagliptin", "", +5994, Placebo, 1251, 1258, "placebo", "", +5995, EndPointDescription, 1293, 1332, "fasting proinsulin to C - peptide ratio", "", +5996, EndPointDescription, 1335, 1344, "fastP / C", "", +6001, DiffGroupRelValue, 1353, 1360, "0 . 007", "", +6002, SdDevDiff, 1367, 1374, "0 . 009", "", +6003, PvalueDiff, 1377, 1388, "p = 0 . 052", "", +6004, Duration, 1428, 1436, "52 weeks", "", +6005, Vildagliptin, 1455, 1467, "vildagliptin", "", +5997, EndPointDescription, 1496, 1535, "dynamic proinsulin to C - peptide ratio", "", +5998, EndPointDescription, 1538, 1546, "dynP / C", "", +6006, Placebo, 1561, 1568, "placebo", "", +6007, Reduction, 1572, 1579, "0 . 010", "", +6008, SdDevChangeValue, 1586, 1593, "0 . 008", "", +6009, PValueChangeValue, 1596, 1607, "p = 0 . 037", "", +6010, EndPointDescription, 1635, 1640, "P / C", "", +6012, FastingPlasmaGlucose, 1707, 1722, "fasting glucose", "", +6013, EndPointDescription, 1727, 1738, "glucose AUC", "", +6011, EndPointDescription, 1778, 1783, "P / C", "", +6014, Vildagliptin, 1835, 1847, "vildagliptin", "", +6015, Placebo, 1853, 1860, "placebo", "", +6016, FastingPlasmaGlucose, 1875, 1882, "fasting", "", +6018, PvalueDiff, 1891, 1902, "p = 0 . 023", "", +33152, PostprandialPlasmaGlucose, 1909, 1923, "postprandially", "", +6019, PvalueDiff, 1926, 1937, "p = 0 . 004", "", +33153, ConclusionComment, 1942, 2130, "In conclusion , a more efficient B - cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B - cell function in patients with type 2 diabetes .", "", +6020, Insulin, 1984, 1991, "insulin", "", +6021, Vildagliptin, 2034, 2046, "vildagliptin", "", +6022, Type2Diabetes, 2113, 2128, "type 2 diabetes", "", +6024, PMID, 2174, 2182, "17992639", "", " \"17992639\"." diff --git a/data/dm2 17992639_kwoodley.n-triples b/data/dm2 17992639_kwoodley.n-triples new file mode 100644 index 0000000..a188d36 --- /dev/null +++ b/data/dm2 17992639_kwoodley.n-triples @@ -0,0 +1,39 @@ +# RDF export of group: Publication + . + "Publication " . + "Ahr é n B" . + "2007" . + "17992639" . + . + "Pacini G" . + "Tura A" . + "Foley JE" . + "Schweizer A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "Fifty - five" . + "52 weeks" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with type 2 diabetes ( 56 . 5 + / - 1 . 5 years ; BMI = 29 . 6 + / - 0 . 5 kg / m ( 2 ) ; FPG = 9 . 9 + / - 0 . 2 mmol / l ; HbA1c = 7 . 7 + / - 0 . 1 % )" . + . + . + "56 . 5" . + . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18158076 copy_admin.annodb b/data/dm2 18158076 copy_admin.annodb new file mode 100644 index 0000000..c297726 --- /dev/null +++ b/data/dm2 18158076 copy_admin.annodb @@ -0,0 +1,291 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", +1, PublicationYear, 12, 16, "2007", "", +37, Title, 47, 245, "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in", "", " \"Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in\"." +9, RelativeTime, 47, 55, "Mealtime", "", +334, Insulin, 56, 105, "50 / 50 basal + prandial insulin analogue mixture", "", +335, Insulin, 113, 135, "basal insulin analogue", "", +2, Metformin, 148, 157, "metformin", "", +3, HbA1c_target, 182, 194, "target HbA1c", "", +51014, PostprandialBloodGlucose, 209, 235, "postprandial blood glucose", "", +37, Title, 246, 365, "patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison .", "", " \"patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison .\"." +4, Type2Diabetes, 260, 275, "type 2 diabetes", "", " ." +452, Multicenter, 280, 293, "multinational", "", " ." +5, Duration, 296, 305, "24 - week", "", " \"24 - week\"." +6, Randomized, 308, 318, "randomized", "", " ." +7, OpenLabel, 321, 333, "open - label", "", " ." +8, Parallel, 336, 352, "parallel - group", "", " ." +12, Author, 366, 376, "Robbins DC", "", +13, Author, 385, 399, "Beisswenger PJ", "", +14, Author, 402, 412, "Ceriello A", "", +15, Author, 415, 426, "Goldberg RB", "", +16, Author, 429, 437, "Moses RG", "", +17, Author, 440, 451, "Pagkalos EM", "", +18, Author, 454, 465, "Milicevic Z", "", +19, Author, 468, 476, "Jones CA", "", +20, Author, 479, 487, "Sarwat S", "", +21, Author, 490, 496, "Tan MH", "", +22, USA, 615, 618, "USA", "", " ." +229, DisorderOrSyndrome, 652, 660, "diabetes", "", +51199, EndPointDescription, 691, 708, "insulin secretion", "", +23, Insulin, 691, 698, "insulin", "", +453, Insulin, 788, 795, "insulin", "", +51198, EndPointDescription, 874, 891, "insulin secretion", "", +24, Insulin, 874, 881, "insulin", "", +26, Frequency, 919, 931, "once - daily", "", +51196, Insulin, 932, 945, "basal insulin", "", +25, Type2Diabetes, 963, 980, "diabetes mellitus", "", +51197, Lispro50/50, 989, 1014, "lispro mix ( LM ) 50 / 50", "", +28, HbA1c, 1086, 1109, "glycosylated hemoglobin", "", +29, HbA1c, 1112, 1122, "HbA ( lc )", "", +455, PreprandialBloodGlucose, 1129, 1132, "pre", "", +456, PostprandialBloodGlucose, 1139, 1165, "postprandial blood glucose", "", +457, BloodGlucose, 1168, 1170, "BG", "", +38, ObjectiveDescription, 1222, 1407, "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve", "", " \"The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve\"." +240, Insulin, 1293, 1318, "premixed insulin analogue", "", +241, Insulin, 1330, 1363, "50 / 50 basal + prandial insulins", "", +234, RelativeTime, 1377, 1393, "before each meal", "", +458, ObjectiveDescription, 1408, 1568, "lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .", "", " \"lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .\"." +32, Frequency, 1457, 1469, "once - daily", "", +242, Insulin, 1470, 1492, "basal insulin analogue", "", +34, Metformin, 1505, 1514, "metformin", "", +35, Metformin, 1517, 1520, "Met", "", +36, Type2Diabetes, 1542, 1566, "type 2 diabetes mellitus", "", " ." +39, Duration, 1584, 1593, "24 - week", "", +40, Randomized, 1596, 1606, "randomized", "", +41, OpenLabel, 1609, 1621, "open - label", "", +42, Parallel, 1624, 1640, "parallel - group", "", +247, Multicenter, 1661, 1672, "at 38 sites", "", +248, Australia, 1680, 1689, "Australia", "", " ." +249, Greece, 1692, 1698, "Greece", "", " ." +250, India, 1701, 1706, "India", "", " ." +251, Netherlands, 1709, 1724, "The Netherlands", "", " ." +252, Poland, 1727, 1733, "Poland", "", " ." +253, Country, 1736, 1747, "Puerto Rico", "", " . ." +254, USA, 1758, 1771, "United States", "", +255, AnyGender, 1774, 1789, "Male and female", "", " ." +44, MinAge, 1804, 1806, "35", "", " \"35\"." +45, MaxAge, 1810, 1812, "75", "", " \"75\"." +258, Year, 1813, 1818, "years", "", +56, Precondition, 1819, 2031, "with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months", "", " \"with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months\"." +46, Type2Diabetes, 1824, 1848, "type 2 diabetes mellitus", "", +47, HbA1c, 1856, 1866, "HbA ( 1c )", "", +48, Percentage, 1882, 1883, "%", "", +49, Percentage, 1894, 1895, "%", "", +50, Metformin, 1917, 1926, "metformin", "", +51, Sulfonylureas, 1938, 1950, "sulfonylurea", "", +100509, DoseDescription, 1956, 2004, "a stable dose of 0 to 2 daily insulin injections", "", +53, Frequency, 1980, 1985, "daily", "", +54, Insulin, 1986, 1993, "insulin", "", +100512, DeliveryMethod, 1994, 2004, "injections", "", +55, Duration, 2023, 2031, "3 months", "", +57, Randomized, 2062, 2070, "randomly", "", +51200, Lispro50/50, 2091, 2100, "LM50 / 50", "", " ." +461, Lispro, 2108, 2143, "insulin lispro protamine suspension", "", +100511, DeliveryMethod, 2133, 2143, "suspension", "", " . ." +462, Lispro, 2146, 2150, "ILPS", "", +283, Lispro, 2162, 2168, "lispro", "", +58, Frequency, 2171, 2174, "TID", "", " \"TID\"." +59, Metformin, 2180, 2189, "metformin", "", " ." +100513, DoseDescription, 2192, 2250, "to a maximally tolerated daily dosage of 500 - 1000 mg BID", "", " \"to a maximally tolerated daily dosage of 500 - 1000 mg BID\"." +60, Frequency, 2217, 2222, "daily", "", +61, DoseValue, 2233, 2243, "500 - 1000", "", " \"500 - 1000\"." +62, mg, 2244, 2246, "mg", "", " ." +63, Frequency, 2247, 2250, "BID", "", " \"BID\"." +464, Lispro, 2255, 2264, "LM50 / 50", "", +64, Metformin, 2267, 2270, "Met", "", +65, InsulinGlargine, 2276, 2292, "insulin glargine", "", " ." +294, Frequency, 2293, 2295, "QD", "", " \"QD\"." +51225, Bedtime, 2299, 2306, "bedtime", "", " ." +66, Metformin, 2312, 2321, "metformin", "", +67, DoseValue, 2324, 2334, "500 - 1000", "", +68, mg, 2335, 2337, "mg", "", +69, Frequency, 2338, 2341, "BID", "", +70, InsulinGlargine, 2346, 2347, "G", "", +71, Metformin, 2350, 2353, "Met", "", +72, Duration, 2360, 2368, "24 weeks", "", +51204, Lispro50/50, 2376, 2385, "LM50 / 50", "", +73, Metformin, 2388, 2391, "Met", "", +74, Insulin, 2398, 2405, "insulin", "", +467, FastingBloodGlucose_target, 2427, 2498, "target a fasting BG ( FBG ) level of < 6 . 7 mmol / L ( < 120 mg / dL )", "", +296, Millimoles_per_litre, 2472, 2480, "mmol / L", "", +298, Mg_per_deciliter, 2489, 2496, "mg / dL", "", +468, PostprandialBloodGlucose, 2505, 2532, "2 - hour post - prandial BG", "", +469, PostprandialBloodGlucose, 2535, 2539, "PPBG", "", +75, Millimoles_per_litre, 2559, 2567, "mmol / L", "", +76, Mg_per_deciliter, 2576, 2583, "mg / dL", "", +470, FastingBloodGlucose_target, 2616, 2626, "FBG target", "", +77, RelativeTime, 2650, 2659, "presupper", "", +51205, Lispro50/50, 2660, 2669, "LM50 / 50", "", +51206, Lispro75/25, 2673, 2682, "LM75 / 25", "", +273, Percentage, 2688, 2689, "%", "", +473, Lispro, 2690, 2694, "ILPS", "", +274, Percentage, 2700, 2701, "%", "", +300, Lispro, 2702, 2708, "lispro", "", +78, NumberPatientsCT, 2734, 2737, "315", "", " \"315\"." +79, Randomized, 2752, 2762, "randomized", "", +80, Female, 2788, 2797, "158 women", "", " ." +81, Male, 2800, 2807, "157 men", "", " ." +303, AvgAge, 2821, 2827, "57 . 7", "", " \"57 . 7\"." +304, Year, 2828, 2833, "years", "", +83, BMI, 2841, 2856, "body mass index", "", +84, Kg_per_squareMeter, 2866, 2873, "kg / m2", "", +475, Lispro, 2876, 2885, "LM50 / 50", "", +85, Metformin, 2888, 2891, "Met", "", +86, NumberPatientsArm, 2894, 2897, "157", "", " \"157\"." +88, InsulinGlargine, 2909, 2910, "G", "", +89, Metformin, 2913, 2916, "Met", "", +87, NumberPatientsArm, 2919, 2922, "158", "", " \"158\"." +476, TimePoint, 2939, 2947, "24 weeks", "", " \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\"." +319, Mean, 2954, 2958, "mean", "", " . ." +90, HbA1c, 2966, 2976, "HbA ( 1c )", "", " ." +51207, Lispro50/50, 3014, 3023, "LM50 / 50", "", +91, Metformin, 3026, 3029, "Met", "", +93, InsulinGlargine, 3048, 3049, "G", "", +92, Metformin, 3052, 3055, "Met", "", +94, ResultMeasuredValue, 3064, 3069, "7 . 1", "", " \"7 . 1\"." +96, Percentage, 3070, 3071, "%", "", " ." +98, SdDevResValue, 3074, 3079, "0 . 9", "", " \"0 . 9\"." +271, Percentage, 3080, 3081, "%", "", +95, ResultMeasuredValue, 3087, 3092, "7 . 5", "", " \"7 . 5\"." +97, Percentage, 3093, 3094, "%", "", +99, SdDevResValue, 3097, 3102, "1 . 0", "", " \"1 . 0\"." +269, Percentage, 3103, 3104, "%", "", +100, PvalueDiff, 3109, 3120, "P < 0 . 001", "", " \"P < 0 . 001\"." +101, HbA1c_target, 3159, 3194, "HbA ( 1c ) target of < or = 7 . 0 %", "", " ." +268, Percentage, 3193, 3194, "%", "", " ." +102, NumberAffected, 3209, 3211, "88", "", " \"88\"." +104, PercentageAffected, 3214, 3220, "56 . 1", "", " \"56 . 1\"." +267, Percentage, 3221, 3222, "%", "", +103, NumberAffected, 3228, 3230, "63", "", " \"63\"." +105, PercentageAffected, 3233, 3239, "39 . 9", "", " \"39 . 9\"." +266, Percentage, 3240, 3241, "%", "", +106, PvalueDiff, 3246, 3257, "P = 0 . 005", "", " \"P = 0 . 005\"." +107, InsulinGlargine, 3266, 3267, "G", "", +108, Metformin, 3270, 3273, "Met", "", +340, Mean, 3292, 3296, "mean", "", " . ." +478, FastingBloodGlucose, 3304, 3307, "FBG", "", " ." +109, ResultMeasuredValue, 3316, 3321, "6 . 5", "", " \"6 . 5\"." +111, SdDevResValue, 3324, 3329, "1 . 6", "", " \"1 . 6\"." +110, ResultMeasuredValue, 3335, 3340, "8 . 1", "", " \"8 . 1\"." +112, SdDevResValue, 3343, 3348, "1 . 8", "", " \"1 . 8\"." +113, Millimoles_per_litre, 3351, 3359, "mmol / L", "", " ." +114, PvalueDiff, 3362, 3373, "P < 0 . 001", "", " \"P < 0 . 001\"." +51212, Lispro50/50, 3382, 3391, "LM50 / 50", "", +115, Metformin, 3394, 3397, "Met", "", +349, Mean, 3414, 3418, "mean", "", " . ." +480, PreprandialBloodGlucose, 3419, 3433, "preprandial BG", "", " ." +116, TimePoint, 3441, 3449, "prelunch", "", " \"prelunch\". \"prelunch\"." +118, ResultMeasuredValue, 3452, 3457, "7 . 4", "", " \"7 . 4\"." +122, SdDevResValue, 3460, 3465, "1 . 9", "", " \"8 . 9\"." +119, ResultMeasuredValue, 3471, 3476, "7 . 9", "", " \"7 . 9\"." +123, SdDevResValue, 3479, 3484, "2 . 1", "", " \"2 . 1\"." +126, Millimoles_per_litre, 3487, 3495, "mmol / L", "", " ." +128, PvalueDiff, 3498, 3508, "P = 0 . 03", "", " \"P = 0 . 03\"." +117, TimePoint, 3515, 3524, "presupper", "", " \"presupper\"." +120, ResultMeasuredValue, 3527, 3532, "8 . 3", "", " \"8 . 3\"." +124, SdDevResValue, 3535, 3540, "2 . 0", "", " \"2 . 0\"." +121, ResultMeasuredValue, 3546, 3551, "8 . 9", "", " \"8 . 9\"." +125, SdDevResValue, 3554, 3559, "2 . 8", "", " \"2 . 8\"." +127, Millimoles_per_litre, 3562, 3570, "mmol / L", "", +129, PvalueDiff, 3573, 3583, "P = 0 . 04", "", " \"P = 0 . 04\"." +481, Lispro, 3592, 3601, "LM50 / 50", "", +130, Metformin, 3604, 3607, "Met", "", +365, Mean, 3629, 3633, "mean", "", " . ." +482, PostprandialBloodGlucose, 3634, 3647, "2 - hour PPBG", "", " ." +131, TimePoint, 3655, 3668, "postbreakfast", "", " \"postbreakfast\". \"postbreakfast\"." +133, ResultMeasuredValue, 3671, 3676, "8 . 7", "", " \"8 . 7\"." +140, SdDevResValue, 3679, 3684, "2 . 2", "", " \"2 . 2\"." +134, ResultMeasuredValue, 3690, 3695, "9 . 2", "", " \"9 . 2\"." +141, SdDevResValue, 3698, 3703, "2 . 5", "", " \"2 . 5\"." +146, Millimoles_per_litre, 3706, 3714, "mmol / L", "", " ." +149, PvalueDiff, 3717, 3727, "P = 0 . 03", "", " \"P = 0 . 03\"." +139, TimePoint, 3732, 3741, "postlunch", "", " \"postlunch\". \"postlunch\"." +135, ResultMeasuredValue, 3744, 3749, "8 . 4", "", " \"8 . 4\"." +142, SdDevResValue, 3752, 3757, "1 . 9", "", " \"1 . 9\"." +136, ResultMeasuredValue, 3763, 3768, "9 . 8", "", " \"9 . 8\"." +143, SdDevResValue, 3771, 3776, "2 . 6", "", " \"2 . 6\"." +147, Millimoles_per_litre, 3781, 3789, "mmol / L", "", +150, PvalueDiff, 3792, 3803, "p < 0 . 001", "", " \"p < 0 . 001\"." +132, TimePoint, 3812, 3822, "postsupper", "", " \"postsupper\". \"postsupper\"." +137, ResultMeasuredValue, 3825, 3830, "8 . 7", "", " \"8 . 7\"." +144, SdDevResValue, 3833, 3838, "2 . 2", "", " \"2 . 2\"." +138, ResultMeasuredValue, 3844, 3850, "10 . 7", "", " \"10 . 7\"." +145, SdDevResValue, 3853, 3858, "3 . 2", "", " \"3 . 2\"." +148, Millimoles_per_litre, 3863, 3871, "mmol / L", "", +151, PvalueDiff, 3874, 3885, "P < 0 . 001", "", " \"P < 0 . 001\"." +387, Mean, 3894, 3898, "mean", "", " . ." +483, InsulinDose, 3912, 3925, "insulin doses", "", " . ." +500, TimePoint, 3929, 3944, "study end point", "", " \"study end point\". \"study end point\"." +152, ResultMeasuredValue, 3950, 3955, "0 . 7", "", " \"0 . 7\"." +154, SdDevResValue, 3958, 3963, "0 . 3", "", " \"0 . 3\"." +156, IntUnit_per_Kg, 3966, 3972, "U / kg", "", " ." +484, Lispro, 3980, 3989, "LM50 / 50", "", +158, Metformin, 3992, 3995, "Met", "", +153, ResultMeasuredValue, 4006, 4011, "0 . 6", "", " \"0 . 6\"." +155, SdDevResValue, 4014, 4019, "0 . 3", "", " \"0 . 3\"." +157, IntUnit_per_Kg, 4022, 4028, "U / kg", "", +159, InsulinGlargine, 4036, 4037, "G", "", +160, Metformin, 4040, 4043, "Met", "", +161, PvalueDiff, 4052, 4063, "P < 0 . 001", "", " \"P < 0 . 001\"." +51210, EndPointDescription, 4072, 4093, "mean ( SD ) M - value", "", " . ." +399, Mean, 4072, 4076, "mean", "", " . ." +400, Mean, 4113, 4117, "mean", "", +485, TimePoint, 4212, 4220, "baseline", "", +51211, Lispro50/50, 4252, 4261, "LM50 / 50", "", +164, Metformin, 4264, 4267, "Met", "", +487, TimePoint, 4277, 4286, "end point", "", " \"end point\". \"end point\"." +165, ResultMeasuredValue, 4289, 4295, "17 . 3", "", " \"17 . 3\"." +167, SdDevResValue, 4298, 4304, "13 . 8", "", " \"13 . 8\"." +166, ResultMeasuredValue, 4310, 4316, "25 . 1", "", " \"25 . 1\"." +168, SdDevResValue, 4319, 4325, "24 . 8", "", " \"24 . 8\"." +169, Millimoles_per_litre, 4328, 4336, "mmol / L", "", " ." +170, PvalueDiff, 4339, 4350, "P < 0 . 001", "", " \"P < 0 . 001\"." +183, TimePoint, 4355, 4389, "During the entire treatment period", "", " \"During the entire treatment period\". \"During the entire treatment period\". \"During the entire treatment period\". \"During the entire treatment period\"." +409, Mean, 4392, 4396, "mean", "", " . . . ." +488, Hypoglycemia, 4404, 4411, "overall", "", " ." +489, NocturnalHypoglycemia, 4416, 4438, "nocturnal hypoglycemia", "", " ." +172, BioAndMedicalUnit, 4447, 4479, "episodes per patient for 30 days", "", +173, ResultMeasuredValue, 4542, 4547, "0 . 8", "", " \"0 . 8\"." +175, SdDevResValue, 4550, 4555, "1 . 4", "", " \"1 . 4\"." +174, ResultMeasuredValue, 4561, 4566, "0 . 5", "", " \"0 . 5\"." +176, SdDevResValue, 4569, 4574, "1 . 0", "", " \"1 . 0\"." +177, NocturnalHypoglycemia, 4579, 4588, "nocturnal", "", +178, ResultMeasuredValue, 4591, 4596, "0 . 2", "", " \"0 . 2\"." +180, SdDevResValue, 4599, 4604, "0 . 7", "", " \"0 . 7\"." +179, ResultMeasuredValue, 4610, 4615, "0 . 3", "", " \"0 . 3\"." +181, SdDevResValue, 4618, 4623, "0 . 6", "", " \"0 . 6\"." +423, TimePoint, 4633, 4642, "end point", "", " \"end point\". \"end point\". \"end point\". \"end point\"." +420, Mean, 4649, 4653, "mean", "", +182, NocturnalHypoglycemia, 4661, 4683, "nocturnal hypoglycemia", "", +184, ResultMeasuredValue, 4726, 4731, "0 . 2", "", " \"0 . 2\"." +186, SdDevResValue, 4734, 4739, "0 . 9", "", " \"0 . 9\"." +185, ResultMeasuredValue, 4745, 4750, "0 . 2", "", " \"0 . 2\"." +187, SdDevResValue, 4753, 4758, "0 . 6", "", " \"0 . 6\"." +437, Hypoglycemia, 4801, 4813, "hypoglycemia", "", +51209, Lispro50/50, 4837, 4846, "LM50 / 50", "", +188, Metformin, 4849, 4852, "Met", "", +190, ResultMeasuredValue, 4865, 4870, "0 . 7", "", " \"0 . 7\"." +196, SdDevResValue, 4873, 4878, "1 . 7", "", " \"1 . 7\"." +191, ResultMeasuredValue, 4884, 4889, "0 . 3", "", " \"0 . 3\"." +197, SdDevResValue, 4892, 4897, "0 . 8", "", " \"0 . 8\"." +198, PvalueDiff, 4902, 4912, "P = 0 . 02", "", " \"P = 0 . 02\"." +192, ResultMeasuredValue, 4933, 4938, "0 . 5", "", +194, SdDevResValue, 4941, 4946, "1 . 2", "", +193, ResultMeasuredValue, 4952, 4957, "0 . 1", "", +195, SdDevResValue, 4960, 4965, "0 . 4", "", +199, PvalueDiff, 4970, 4981, "P = 0 . 002", "", +207, ConclusionComment, 4999, 5148, "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels", "", " \"In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels\"." +200, Type2Diabetes, 5022, 5037, "type 2 diabetes", "", +201, RelativeTime, 5040, 5048, "mealtime", "", +51208, Lispro50/50, 5049, 5058, "LM50 / 50", "", +202, Metformin, 5061, 5064, "Met", "", +203, HbA1c, 5101, 5111, "HbA ( 1c )", "", +496, PreprandialBloodGlucose, 5118, 5132, "preprandial BG", "", +497, PostprandialBloodGlucose, 5137, 5141, "PPBG", "", +498, ConclusionComment, 5149, 5261, "( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met .", "", " \"( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met .\"." +499, FastingBloodGlucose, 5162, 5165, "FBG", "", +204, NocturnalHypoglycemia, 5183, 5205, "nocturnal hypoglycemia", "", +205, InsulinGlargine, 5252, 5253, "G", "", +206, Metformin, 5256, 5259, "Met", "", +208, PMID, 5364, 5372, "18158076", "", diff --git a/data/dm2 18158076 copy_admin.n-triples b/data/dm2 18158076 copy_admin.n-triples new file mode 100644 index 0000000..6f2fbe8 --- /dev/null +++ b/data/dm2 18158076 copy_admin.n-triples @@ -0,0 +1,422 @@ +# RDF export of group: Publication + . + "Publication" . + "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in" . + "patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison ." . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve" . + "315" . + "24 - week" . + . + . + . + "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels" . + . + . + . + . + . + "lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus ." . + . + . + . + "( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months" . + . + . + "35" . + "75" . + "57 . 7" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_Hb1Ac" . + . + . + . + . + . + . + "Endpoint_H1bAc7" . + . + . + . + . + . + "Endpoint_FBG" . + . + . + . + . + . + . + "Endpoint_PBG" . + . + . + . + . + . + . + "Endpoint_PPBG" . + . + . + . + . + . + . + "Endpoint_ID" . + . + . + . + . + . + . + . + "Endpoint_M" . + . + . + . + . + . + . + . + "Endpoint_H" . + . + . + . + . + . + . + "Endpoint_NH" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_LM50" . + "157" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm_G" . + "158" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_LM" . + . + "TID" . + . + . + "Intervention_M" . + . + "BID" . + . + . + "Intervention_G" . + . + "QD" . + . +# RDF export of group: Medication + . + "Medication_LM50" . + . + . + . + . + . + "Medication_Met" . + . + "500 - 1000" . + . + . + "to a maximally tolerated daily dosage of 500 - 1000 mg BID" . + . + "Medication_G" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_Hb1Ac_L" . + . + "7 . 1" . + "0 . 9" . + "24 weeks" . + . + "Outcome_Hb1Ac_G" . + . + "7 . 5" . + "1 . 0" . + "24 weeks" . + . + "Outcome_H1bAc7_L" . + . + "88" . + "56 . 1" . + "24 weeks" . + . + "Outcome_H1bAc7_G" . + . + "63" . + "39 . 9" . + "24 weeks" . + . + "Outcome_FBG_L" . + . + "8 . 1" . + "1 . 8" . + "24 weeks" . + . + "Outcome_FBG_G" . + . + "6 . 5" . + "1 . 6" . + "24 weeks" . + . + "Outcome_PBG_L_prelunch" . + . + "7 . 4" . + "1 . 9" . + "prelunch" . + . + "Outcome_PBG_G_prelunch" . + . + "7 . 9" . + "2 . 1" . + "prelunch" . + . + "Outcome_PBG_L_presupper" . + . + "8 . 3" . + "2 . 0" . + "presupper" . + . + "Outcome_PBG_G_presupper" . + . + "8 . 9" . + "2 . 8" . + . + "Outcome_PPBG_L_postbreakfast" . + . + "8 . 7" . + "2 . 2" . + "postbreakfast" . + . + "Outcome_PPBG_G_postbreakfast" . + . + "9 . 2" . + "2 . 5" . + "postbreakfast" . + . + "Outcome_PPBG_L_postlunch" . + . + "8 . 4" . + "1 . 9" . + "postlunch" . + . + "Outcome_PPBG_G_postluch" . + . + "9 . 8" . + "2 . 6" . + "postlunch" . + . + "Outcome_PPBG_L_postsupper" . + . + "8 . 7" . + "2 . 2" . + "postsupper" . + . + "Outcome_PPBG_G_postsupper" . + . + "10 . 7" . + "3 . 2" . + "postsupper" . + . + "Outcome_ID_L" . + . + "0 . 7" . + "0 . 3" . + "study end point" . + . + "Outcome_ID_G" . + . + "0 . 6" . + "0 . 3" . + "study end point" . + . + "Outcome_M_L" . + . + "17 . 3" . + "13 . 8" . + "end point" . + . + "Outcome_M_G" . + . + "25 . 1" . + "24 . 8" . + "end point" . + . + "Outcome_H_L_during" . + . + "0 . 8" . + "1 . 4" . + "During the entire treatment period" . + . + "Outcome_H_G_during" . + . + "0 . 5" . + "1 . 0" . + "During the entire treatment period" . + . + "Outcome_NH_L_during" . + . + "0 . 2" . + "0 . 7" . + "During the entire treatment period" . + . + "Outcome_NH_G_during" . + . + "0 . 3" . + "0 . 6" . + "During the entire treatment period" . + . + "Outcome_NH_L_end" . + . + "0 . 2" . + "0 . 9" . + "end point" . + . + "Outcome_NH_G_end" . + . + "0 . 2" . + "0 . 6" . + "end point" . + . + "Outcome_H_L_end" . + . + "0 . 7" . + "1 . 7" . + "end point" . + . + "Outcome_H_G_end" . + . + "0 . 3" . + "0 . 8" . + "end point" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_Hb1Ac" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_H1bAc7" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups_FBG" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_PBG_prelunch" . + "P = 0 . 03" . + . + . + . + "DiffBetweenGroups_PBG_presupper" . + "P = 0 . 04" . + . + . + . + "DiffBetweenGroups_PPBG_postbreakfast" . + "P = 0 . 03" . + . + . + . + "DiffBetweenGroups_PPBG_postlunch" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups_PPBG_postsupper" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_ID" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_M" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_H_end" . + "P = 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18158076 copy_export.csv b/data/dm2 18158076 copy_export.csv new file mode 100644 index 0000000..e750af7 --- /dev/null +++ b/data/dm2 18158076 copy_export.csv @@ -0,0 +1,1358 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +818, 1, 1, 1, 0, 4, 0, 4, "Clin" +818, 1, 2, 2, 5, 9, 5, 9, "Ther" +818, 1, 3, 3, 10, 11, 10, 11, "." +818, 2, 1, 4, 0, 4, 12, 16, "2007" +818, 2, 2, 5, 5, 8, 17, 20, "Nov" +818, 2, 3, 6, 9, 10, 21, 22, ";" +818, 2, 4, 7, 11, 13, 23, 25, "29" +818, 2, 5, 8, 14, 15, 26, 27, "(" +818, 2, 6, 9, 16, 18, 28, 30, "11" +818, 2, 7, 10, 19, 20, 31, 32, ")" +818, 2, 8, 11, 21, 22, 33, 34, ":" +818, 2, 9, 12, 23, 27, 35, 39, "2349" +818, 2, 10, 13, 28, 29, 40, 41, "-" +818, 2, 11, 14, 30, 32, 42, 44, "64" +818, 2, 12, 15, 33, 34, 45, 46, "." +818, 3, 1, 16, 0, 8, 47, 55, "Mealtime" +818, 3, 2, 17, 9, 11, 56, 58, "50" +818, 3, 3, 18, 12, 13, 59, 60, "/" +818, 3, 4, 19, 14, 16, 61, 63, "50" +818, 3, 5, 20, 17, 22, 64, 69, "basal" +818, 3, 6, 21, 23, 24, 70, 71, "+" +818, 3, 7, 22, 25, 33, 72, 80, "prandial" +818, 3, 8, 23, 34, 41, 81, 88, "insulin" +818, 3, 9, 24, 42, 50, 89, 97, "analogue" +818, 3, 10, 25, 51, 58, 98, 105, "mixture" +818, 3, 11, 26, 59, 63, 106, 110, "with" +818, 3, 12, 27, 64, 65, 111, 112, "a" +818, 3, 13, 28, 66, 71, 113, 118, "basal" +818, 3, 14, 29, 72, 79, 119, 126, "insulin" +818, 3, 15, 30, 80, 88, 127, 135, "analogue" +818, 3, 16, 31, 89, 90, 136, 137, "," +818, 3, 17, 32, 91, 95, 138, 142, "both" +818, 3, 18, 33, 96, 100, 143, 147, "plus" +818, 3, 19, 34, 101, 110, 148, 157, "metformin" +818, 3, 20, 35, 111, 112, 158, 159, "," +818, 3, 21, 36, 113, 115, 160, 162, "in" +818, 3, 22, 37, 116, 119, 163, 166, "the" +818, 3, 23, 38, 120, 131, 167, 178, "achievement" +818, 3, 24, 39, 132, 134, 179, 181, "of" +818, 3, 25, 40, 135, 141, 182, 188, "target" +818, 3, 26, 41, 142, 147, 189, 194, "HbA1c" +818, 3, 27, 42, 148, 151, 195, 198, "and" +818, 3, 28, 43, 152, 155, 199, 202, "pre" +818, 3, 29, 44, 156, 157, 203, 204, "-" +818, 3, 30, 45, 158, 161, 205, 208, "and" +818, 3, 31, 46, 162, 174, 209, 221, "postprandial" +818, 3, 32, 47, 175, 180, 222, 227, "blood" +818, 3, 33, 48, 181, 188, 228, 235, "glucose" +818, 3, 34, 49, 189, 195, 236, 242, "levels" +818, 3, 35, 50, 196, 198, 243, 245, "in" +818, 3, 36, 51, 199, 207, 246, 254, "patients" +818, 3, 37, 52, 208, 212, 255, 259, "with" +818, 3, 38, 53, 213, 217, 260, 264, "type" +818, 3, 39, 54, 218, 219, 265, 266, "2" +818, 3, 40, 55, 220, 228, 267, 275, "diabetes" +818, 3, 41, 56, 229, 230, 276, 277, ":" +818, 3, 42, 57, 231, 232, 278, 279, "a" +818, 3, 43, 58, 233, 246, 280, 293, "multinational" +818, 3, 44, 59, 247, 248, 294, 295, "," +818, 3, 45, 60, 249, 251, 296, 298, "24" +818, 3, 46, 61, 252, 253, 299, 300, "-" +818, 3, 47, 62, 254, 258, 301, 305, "week" +818, 3, 48, 63, 259, 260, 306, 307, "," +818, 3, 49, 64, 261, 271, 308, 318, "randomized" +818, 3, 50, 65, 272, 273, 319, 320, "," +818, 3, 51, 66, 274, 278, 321, 325, "open" +818, 3, 52, 67, 279, 280, 326, 327, "-" +818, 3, 53, 68, 281, 286, 328, 333, "label" +818, 3, 54, 69, 287, 288, 334, 335, "," +818, 3, 55, 70, 289, 297, 336, 344, "parallel" +818, 3, 56, 71, 298, 299, 345, 346, "-" +818, 3, 57, 72, 300, 305, 347, 352, "group" +818, 3, 58, 73, 306, 316, 353, 363, "comparison" +818, 3, 59, 74, 317, 318, 364, 365, "." +818, 4, 1, 75, 0, 7, 366, 373, "Robbins" +818, 4, 2, 76, 8, 10, 374, 376, "DC" +818, 4, 3, 77, 11, 12, 377, 378, "(" +818, 4, 4, 78, 13, 14, 379, 380, "1" +818, 4, 5, 79, 15, 16, 381, 382, ")" +818, 4, 6, 80, 17, 18, 383, 384, "," +818, 4, 7, 81, 19, 30, 385, 396, "Beisswenger" +818, 4, 8, 82, 31, 33, 397, 399, "PJ" +818, 4, 9, 83, 34, 35, 400, 401, "," +818, 4, 10, 84, 36, 44, 402, 410, "Ceriello" +818, 4, 11, 85, 45, 46, 411, 412, "A" +818, 4, 12, 86, 47, 48, 413, 414, "," +818, 4, 13, 87, 49, 57, 415, 423, "Goldberg" +818, 4, 14, 88, 58, 60, 424, 426, "RB" +818, 4, 15, 89, 61, 62, 427, 428, "," +818, 4, 16, 90, 63, 68, 429, 434, "Moses" +818, 4, 17, 91, 69, 71, 435, 437, "RG" +818, 4, 18, 92, 72, 73, 438, 439, "," +818, 4, 19, 93, 74, 82, 440, 448, "Pagkalos" +818, 4, 20, 94, 83, 85, 449, 451, "EM" +818, 4, 21, 95, 86, 87, 452, 453, "," +818, 4, 22, 96, 88, 97, 454, 463, "Milicevic" +818, 4, 23, 97, 98, 99, 464, 465, "Z" +818, 4, 24, 98, 100, 101, 466, 467, "," +818, 4, 25, 99, 102, 107, 468, 473, "Jones" +818, 4, 26, 100, 108, 110, 474, 476, "CA" +818, 4, 27, 101, 111, 112, 477, 478, "," +818, 4, 28, 102, 113, 119, 479, 485, "Sarwat" +818, 4, 29, 103, 120, 121, 486, 487, "S" +818, 4, 30, 104, 122, 123, 488, 489, "," +818, 4, 31, 105, 124, 127, 490, 493, "Tan" +818, 4, 32, 106, 128, 130, 494, 496, "MH" +818, 4, 33, 107, 131, 132, 497, 498, "." +818, 5, 1, 108, 0, 6, 499, 505, "Author" +818, 5, 2, 109, 7, 18, 506, 517, "information" +818, 5, 3, 110, 19, 20, 518, 519, ":" +818, 5, 4, 111, 21, 22, 520, 521, "(" +818, 5, 5, 112, 23, 24, 522, 523, "1" +818, 5, 6, 113, 25, 26, 524, 525, ")" +818, 5, 7, 114, 27, 35, 526, 534, "Diabetes" +818, 5, 8, 115, 36, 39, 535, 538, "and" +818, 5, 9, 116, 40, 49, 539, 548, "Endocrine" +818, 5, 10, 117, 50, 58, 549, 557, "Platform" +818, 5, 11, 118, 59, 63, 558, 562, "Team" +818, 5, 12, 119, 64, 65, 563, 564, "," +818, 5, 13, 120, 66, 69, 565, 568, "Eli" +818, 5, 14, 121, 70, 75, 569, 574, "Lilly" +818, 5, 15, 122, 76, 79, 575, 578, "and" +818, 5, 16, 123, 80, 87, 579, 586, "Company" +818, 5, 17, 124, 88, 89, 587, 588, "," +818, 5, 18, 125, 90, 102, 589, 601, "Indianapolis" +818, 5, 19, 126, 103, 104, 602, 603, "," +818, 5, 20, 127, 105, 107, 604, 606, "IN" +818, 5, 21, 128, 108, 113, 607, 612, "46285" +818, 5, 22, 129, 114, 115, 613, 614, "," +818, 5, 23, 130, 116, 119, 615, 618, "USA" +818, 5, 24, 131, 120, 121, 619, 620, "." +818, 6, 1, 132, 0, 10, 621, 631, "BACKGROUND" +818, 6, 2, 133, 11, 12, 632, 633, ":" +818, 6, 3, 134, 13, 15, 634, 636, "In" +818, 6, 4, 135, 16, 22, 637, 643, "people" +818, 6, 5, 136, 23, 30, 644, 651, "without" +818, 6, 6, 137, 31, 39, 652, 660, "diabetes" +818, 6, 7, 138, 40, 41, 661, 662, "," +818, 6, 8, 139, 42, 55, 663, 676, "approximately" +818, 6, 9, 140, 56, 58, 677, 679, "50" +818, 6, 10, 141, 59, 60, 680, 681, "%" +818, 6, 11, 142, 61, 63, 682, 684, "of" +818, 6, 12, 143, 64, 69, 685, 690, "daily" +818, 6, 13, 144, 70, 77, 691, 698, "insulin" +818, 6, 14, 145, 78, 87, 699, 708, "secretion" +818, 6, 15, 146, 88, 90, 709, 711, "is" +818, 6, 16, 147, 91, 96, 712, 717, "basal" +818, 6, 17, 148, 97, 100, 718, 721, "and" +818, 6, 18, 149, 101, 104, 722, 725, "the" +818, 6, 19, 150, 105, 114, 726, 735, "remainder" +818, 6, 20, 151, 115, 117, 736, 738, "is" +818, 6, 21, 152, 118, 130, 739, 751, "postprandial" +818, 6, 22, 153, 131, 132, 752, 753, "." +818, 7, 1, 154, 0, 5, 754, 759, "Hence" +818, 7, 2, 155, 6, 7, 760, 761, "," +818, 7, 3, 156, 8, 10, 762, 764, "it" +818, 7, 4, 157, 11, 16, 765, 770, "would" +818, 7, 5, 158, 17, 19, 771, 773, "be" +818, 7, 6, 159, 20, 28, 774, 782, "expected" +818, 7, 7, 160, 29, 33, 783, 787, "that" +818, 7, 8, 161, 34, 41, 788, 795, "insulin" +818, 7, 9, 162, 42, 53, 796, 807, "replacement" +818, 7, 10, 163, 54, 61, 808, 815, "therapy" +818, 7, 11, 164, 62, 64, 816, 818, "in" +818, 7, 12, 165, 65, 66, 819, 820, "a" +818, 7, 13, 166, 67, 69, 821, 823, "50" +818, 7, 14, 167, 70, 71, 824, 825, "/" +818, 7, 15, 168, 72, 74, 826, 828, "50" +818, 7, 16, 169, 75, 80, 829, 834, "ratio" +818, 7, 17, 170, 81, 85, 835, 839, "with" +818, 7, 18, 171, 86, 90, 840, 844, "each" +818, 7, 19, 172, 91, 95, 845, 849, "meal" +818, 7, 20, 173, 96, 101, 850, 855, "would" +818, 7, 21, 174, 102, 107, 856, 861, "mimic" +818, 7, 22, 175, 108, 119, 862, 873, "physiologic" +818, 7, 23, 176, 120, 127, 874, 881, "insulin" +818, 7, 24, 177, 128, 137, 882, 891, "secretion" +818, 7, 25, 178, 138, 144, 892, 898, "better" +818, 7, 26, 179, 145, 149, 899, 903, "than" +818, 7, 27, 180, 150, 159, 904, 913, "treatment" +818, 7, 28, 181, 160, 164, 914, 918, "with" +818, 7, 29, 182, 165, 169, 919, 923, "once" +818, 7, 30, 183, 170, 171, 924, 925, "-" +818, 7, 31, 184, 172, 177, 926, 931, "daily" +818, 7, 32, 185, 178, 183, 932, 937, "basal" +818, 7, 33, 186, 184, 191, 938, 945, "insulin" +818, 7, 34, 187, 192, 194, 946, 948, "in" +818, 7, 35, 188, 195, 203, 949, 957, "patients" +818, 7, 36, 189, 204, 208, 958, 962, "with" +818, 7, 37, 190, 209, 217, 963, 971, "diabetes" +818, 7, 38, 191, 218, 226, 972, 980, "mellitus" +818, 7, 39, 192, 227, 228, 981, 982, "." +818, 8, 1, 193, 0, 5, 983, 988, "Using" +818, 8, 2, 194, 6, 12, 989, 995, "lispro" +818, 8, 3, 195, 13, 16, 996, 999, "mix" +818, 8, 4, 196, 17, 18, 1000, 1001, "(" +818, 8, 5, 197, 19, 21, 1002, 1004, "LM" +818, 8, 6, 198, 22, 23, 1005, 1006, ")" +818, 8, 7, 199, 24, 26, 1007, 1009, "50" +818, 8, 8, 200, 27, 28, 1010, 1011, "/" +818, 8, 9, 201, 29, 31, 1012, 1014, "50" +818, 8, 10, 202, 32, 38, 1015, 1021, "before" +818, 8, 11, 203, 39, 44, 1022, 1027, "meals" +818, 8, 12, 204, 45, 48, 1028, 1031, "may" +818, 8, 13, 205, 49, 51, 1032, 1034, "be" +818, 8, 14, 206, 52, 53, 1035, 1036, "a" +818, 8, 15, 207, 54, 61, 1037, 1044, "logical" +818, 8, 16, 208, 62, 70, 1045, 1053, "approach" +818, 8, 17, 209, 71, 73, 1054, 1056, "to" +818, 8, 18, 210, 74, 83, 1057, 1066, "achieving" +818, 8, 19, 211, 84, 92, 1067, 1075, "glycemic" +818, 8, 20, 212, 93, 100, 1076, 1083, "targets" +818, 8, 21, 213, 101, 102, 1084, 1085, "(" +818, 8, 22, 214, 103, 115, 1086, 1098, "glycosylated" +818, 8, 23, 215, 116, 126, 1099, 1109, "hemoglobin" +818, 8, 24, 216, 127, 128, 1110, 1111, "[" +818, 8, 25, 217, 129, 132, 1112, 1115, "HbA" +818, 8, 26, 218, 133, 134, 1116, 1117, "(" +818, 8, 27, 219, 135, 137, 1118, 1120, "lc" +818, 8, 28, 220, 138, 139, 1121, 1122, ")" +818, 8, 29, 221, 140, 141, 1123, 1124, "]" +818, 8, 30, 222, 142, 145, 1125, 1128, "and" +818, 8, 31, 223, 146, 149, 1129, 1132, "pre" +818, 8, 32, 224, 150, 151, 1133, 1134, "-" +818, 8, 33, 225, 152, 155, 1135, 1138, "and" +818, 8, 34, 226, 156, 168, 1139, 1151, "postprandial" +818, 8, 35, 227, 169, 174, 1152, 1157, "blood" +818, 8, 36, 228, 175, 182, 1158, 1165, "glucose" +818, 8, 37, 229, 183, 184, 1166, 1167, "[" +818, 8, 38, 230, 185, 187, 1168, 1170, "BG" +818, 8, 39, 231, 188, 189, 1171, 1172, "]" +818, 8, 40, 232, 190, 204, 1173, 1187, "concentrations" +818, 8, 41, 233, 205, 206, 1188, 1189, ")" +818, 8, 42, 234, 207, 209, 1190, 1192, "in" +818, 8, 43, 235, 210, 215, 1193, 1198, "these" +818, 8, 44, 236, 216, 224, 1199, 1207, "patients" +818, 8, 45, 237, 225, 226, 1208, 1209, "." +818, 9, 1, 238, 0, 9, 1210, 1219, "OBJECTIVE" +818, 9, 2, 239, 10, 11, 1220, 1221, ":" +818, 9, 3, 240, 12, 15, 1222, 1225, "The" +818, 9, 4, 241, 16, 19, 1226, 1229, "aim" +818, 9, 5, 242, 20, 22, 1230, 1232, "of" +818, 9, 6, 243, 23, 27, 1233, 1237, "this" +818, 9, 7, 244, 28, 33, 1238, 1243, "study" +818, 9, 8, 245, 34, 37, 1244, 1247, "was" +818, 9, 9, 246, 38, 40, 1248, 1250, "to" +818, 9, 10, 247, 41, 45, 1251, 1255, "test" +818, 9, 11, 248, 46, 49, 1256, 1259, "the" +818, 9, 12, 249, 50, 60, 1260, 1270, "hypothesis" +818, 9, 13, 250, 61, 65, 1271, 1275, "that" +818, 9, 14, 251, 66, 75, 1276, 1285, "treatment" +818, 9, 15, 252, 76, 80, 1286, 1290, "with" +818, 9, 16, 253, 81, 82, 1291, 1292, "a" +818, 9, 17, 254, 83, 91, 1293, 1301, "premixed" +818, 9, 18, 255, 92, 99, 1302, 1309, "insulin" +818, 9, 19, 256, 100, 108, 1310, 1318, "analogue" +818, 9, 20, 257, 109, 119, 1319, 1329, "containing" +818, 9, 21, 258, 120, 122, 1330, 1332, "50" +818, 9, 22, 259, 123, 124, 1333, 1334, "/" +818, 9, 23, 260, 125, 127, 1335, 1337, "50" +818, 9, 24, 261, 128, 133, 1338, 1343, "basal" +818, 9, 25, 262, 134, 135, 1344, 1345, "+" +818, 9, 26, 263, 136, 144, 1346, 1354, "prandial" +818, 9, 27, 264, 145, 153, 1355, 1363, "insulins" +818, 9, 28, 265, 154, 166, 1364, 1376, "administered" +818, 9, 29, 266, 167, 173, 1377, 1383, "before" +818, 9, 30, 267, 174, 178, 1384, 1388, "each" +818, 9, 31, 268, 179, 183, 1389, 1393, "meal" +818, 9, 32, 269, 184, 189, 1394, 1399, "would" +818, 9, 33, 270, 190, 197, 1400, 1407, "achieve" +818, 9, 34, 271, 198, 203, 1408, 1413, "lower" +818, 9, 35, 272, 204, 211, 1414, 1421, "overall" +818, 9, 36, 273, 212, 215, 1422, 1425, "and" +818, 9, 37, 274, 216, 224, 1426, 1434, "mealtime" +818, 9, 38, 275, 225, 233, 1435, 1443, "glycemic" +818, 9, 39, 276, 234, 241, 1444, 1451, "control" +818, 9, 40, 277, 242, 246, 1452, 1456, "than" +818, 9, 41, 278, 247, 251, 1457, 1461, "once" +818, 9, 42, 279, 252, 253, 1462, 1463, "-" +818, 9, 43, 280, 254, 259, 1464, 1469, "daily" +818, 9, 44, 281, 260, 265, 1470, 1475, "basal" +818, 9, 45, 282, 266, 273, 1476, 1483, "insulin" +818, 9, 46, 283, 274, 282, 1484, 1492, "analogue" +818, 9, 47, 284, 283, 284, 1493, 1494, "," +818, 9, 48, 285, 285, 289, 1495, 1499, "both" +818, 9, 49, 286, 290, 294, 1500, 1504, "plus" +818, 9, 50, 287, 295, 304, 1505, 1514, "metformin" +818, 9, 51, 288, 305, 306, 1515, 1516, "(" +818, 9, 52, 289, 307, 310, 1517, 1520, "Met" +818, 9, 53, 290, 311, 312, 1521, 1522, ")" +818, 9, 54, 291, 313, 314, 1523, 1524, "," +818, 9, 55, 292, 315, 317, 1525, 1527, "in" +818, 9, 56, 293, 318, 326, 1528, 1536, "patients" +818, 9, 57, 294, 327, 331, 1537, 1541, "with" +818, 9, 58, 295, 332, 336, 1542, 1546, "type" +818, 9, 59, 296, 337, 338, 1547, 1548, "2" +818, 9, 60, 297, 339, 347, 1549, 1557, "diabetes" +818, 9, 61, 298, 348, 356, 1558, 1566, "mellitus" +818, 9, 62, 299, 357, 358, 1567, 1568, "." +818, 10, 1, 300, 0, 7, 1569, 1576, "METHODS" +818, 10, 2, 301, 8, 9, 1577, 1578, ":" +818, 10, 3, 302, 10, 14, 1579, 1583, "This" +818, 10, 4, 303, 15, 17, 1584, 1586, "24" +818, 10, 5, 304, 18, 19, 1587, 1588, "-" +818, 10, 6, 305, 20, 24, 1589, 1593, "week" +818, 10, 7, 306, 25, 26, 1594, 1595, "," +818, 10, 8, 307, 27, 37, 1596, 1606, "randomized" +818, 10, 9, 308, 38, 39, 1607, 1608, "," +818, 10, 10, 309, 40, 44, 1609, 1613, "open" +818, 10, 11, 310, 45, 46, 1614, 1615, "-" +818, 10, 12, 311, 47, 52, 1616, 1621, "label" +818, 10, 13, 312, 53, 54, 1622, 1623, "," +818, 10, 14, 313, 55, 63, 1624, 1632, "parallel" +818, 10, 15, 314, 64, 65, 1633, 1634, "-" +818, 10, 16, 315, 66, 71, 1635, 1640, "group" +818, 10, 17, 316, 72, 77, 1641, 1646, "trial" +818, 10, 18, 317, 78, 81, 1647, 1650, "was" +818, 10, 19, 318, 82, 91, 1651, 1660, "conducted" +818, 10, 20, 319, 92, 94, 1661, 1663, "at" +818, 10, 21, 320, 95, 97, 1664, 1666, "38" +818, 10, 22, 321, 98, 103, 1667, 1672, "sites" +818, 10, 23, 322, 104, 110, 1673, 1679, "across" +818, 10, 24, 323, 111, 120, 1680, 1689, "Australia" +818, 10, 25, 324, 121, 122, 1690, 1691, "," +818, 10, 26, 325, 123, 129, 1692, 1698, "Greece" +818, 10, 27, 326, 130, 131, 1699, 1700, "," +818, 10, 28, 327, 132, 137, 1701, 1706, "India" +818, 10, 29, 328, 138, 139, 1707, 1708, "," +818, 10, 30, 329, 140, 143, 1709, 1712, "The" +818, 10, 31, 330, 144, 155, 1713, 1724, "Netherlands" +818, 10, 32, 331, 156, 157, 1725, 1726, "," +818, 10, 33, 332, 158, 164, 1727, 1733, "Poland" +818, 10, 34, 333, 165, 166, 1734, 1735, "," +818, 10, 35, 334, 167, 173, 1736, 1742, "Puerto" +818, 10, 36, 335, 174, 178, 1743, 1747, "Rico" +818, 10, 37, 336, 179, 180, 1748, 1749, "," +818, 10, 38, 337, 181, 184, 1750, 1753, "and" +818, 10, 39, 338, 185, 188, 1754, 1757, "the" +818, 10, 40, 339, 189, 195, 1758, 1764, "United" +818, 10, 41, 340, 196, 202, 1765, 1771, "States" +818, 10, 42, 341, 203, 204, 1772, 1773, "." +818, 11, 1, 342, 0, 4, 1774, 1778, "Male" +818, 11, 2, 343, 5, 8, 1779, 1782, "and" +818, 11, 3, 344, 9, 15, 1783, 1789, "female" +818, 11, 4, 345, 16, 24, 1790, 1798, "patients" +818, 11, 5, 346, 25, 29, 1799, 1803, "aged" +818, 11, 6, 347, 30, 32, 1804, 1806, "35" +818, 11, 7, 348, 33, 35, 1807, 1809, "to" +818, 11, 8, 349, 36, 38, 1810, 1812, "75" +818, 11, 9, 350, 39, 44, 1813, 1818, "years" +818, 11, 10, 351, 45, 49, 1819, 1823, "with" +818, 11, 11, 352, 50, 54, 1824, 1828, "type" +818, 11, 12, 353, 55, 56, 1829, 1830, "2" +818, 11, 13, 354, 57, 65, 1831, 1839, "diabetes" +818, 11, 14, 355, 66, 74, 1840, 1848, "mellitus" +818, 11, 15, 356, 75, 78, 1849, 1852, "and" +818, 11, 16, 357, 79, 81, 1853, 1855, "an" +818, 11, 17, 358, 82, 85, 1856, 1859, "HbA" +818, 11, 18, 359, 86, 87, 1860, 1861, "(" +818, 11, 19, 360, 88, 90, 1862, 1864, "1c" +818, 11, 20, 361, 91, 92, 1865, 1866, ")" +818, 11, 21, 362, 93, 98, 1867, 1872, "level" +818, 11, 22, 363, 99, 101, 1873, 1875, "of" +818, 11, 23, 364, 102, 103, 1876, 1877, "6" +818, 11, 24, 365, 104, 105, 1878, 1879, "." +818, 11, 25, 366, 106, 107, 1880, 1881, "5" +818, 11, 26, 367, 108, 109, 1882, 1883, "%" +818, 11, 27, 368, 110, 112, 1884, 1886, "to" +818, 11, 28, 369, 113, 115, 1887, 1889, "11" +818, 11, 29, 370, 116, 117, 1890, 1891, "." +818, 11, 30, 371, 118, 119, 1892, 1893, "0" +818, 11, 31, 372, 120, 121, 1894, 1895, "%" +818, 11, 32, 373, 122, 123, 1896, 1897, "," +818, 11, 33, 374, 124, 127, 1898, 1901, "who" +818, 11, 34, 375, 128, 132, 1902, 1906, "were" +818, 11, 35, 376, 133, 142, 1907, 1916, "receiving" +818, 11, 36, 377, 143, 152, 1917, 1926, "metformin" +818, 11, 37, 378, 153, 156, 1927, 1930, "and" +818, 11, 38, 379, 157, 158, 1931, 1932, "/" +818, 11, 39, 380, 159, 161, 1933, 1935, "or" +818, 11, 40, 381, 162, 163, 1936, 1937, "a" +818, 11, 41, 382, 164, 176, 1938, 1950, "sulfonylurea" +818, 11, 42, 383, 177, 181, 1951, 1955, "with" +818, 11, 43, 384, 182, 183, 1956, 1957, "a" +818, 11, 44, 385, 184, 190, 1958, 1964, "stable" +818, 11, 45, 386, 191, 195, 1965, 1969, "dose" +818, 11, 46, 387, 196, 198, 1970, 1972, "of" +818, 11, 47, 388, 199, 200, 1973, 1974, "0" +818, 11, 48, 389, 201, 203, 1975, 1977, "to" +818, 11, 49, 390, 204, 205, 1978, 1979, "2" +818, 11, 50, 391, 206, 211, 1980, 1985, "daily" +818, 11, 51, 392, 212, 219, 1986, 1993, "insulin" +818, 11, 52, 393, 220, 230, 1994, 2004, "injections" +818, 11, 53, 394, 231, 235, 2005, 2009, "over" +818, 11, 54, 395, 236, 239, 2010, 2013, "the" +818, 11, 55, 396, 240, 248, 2014, 2022, "previous" +818, 11, 56, 397, 249, 250, 2023, 2024, "3" +818, 11, 57, 398, 251, 257, 2025, 2031, "months" +818, 11, 58, 399, 258, 262, 2032, 2036, "were" +818, 11, 59, 400, 263, 271, 2037, 2045, "eligible" +818, 11, 60, 401, 272, 273, 2046, 2047, "." +818, 12, 1, 402, 0, 8, 2048, 2056, "Patients" +818, 12, 2, 403, 9, 13, 2057, 2061, "were" +818, 12, 3, 404, 14, 22, 2062, 2070, "randomly" +818, 12, 4, 405, 23, 31, 2071, 2079, "assigned" +818, 12, 5, 406, 32, 34, 2080, 2082, "to" +818, 12, 6, 407, 35, 42, 2083, 2090, "receive" +818, 12, 7, 408, 43, 47, 2091, 2095, "LM50" +818, 12, 8, 409, 48, 49, 2096, 2097, "/" +818, 12, 9, 410, 50, 52, 2098, 2100, "50" +818, 12, 10, 411, 53, 54, 2101, 2102, "(" +818, 12, 11, 412, 55, 57, 2103, 2105, "50" +818, 12, 12, 413, 58, 59, 2106, 2107, "%" +818, 12, 13, 414, 60, 67, 2108, 2115, "insulin" +818, 12, 14, 415, 68, 74, 2116, 2122, "lispro" +818, 12, 15, 416, 75, 84, 2123, 2132, "protamine" +818, 12, 16, 417, 85, 95, 2133, 2143, "suspension" +818, 12, 17, 418, 96, 97, 2144, 2145, "[" +818, 12, 18, 419, 98, 102, 2146, 2150, "ILPS" +818, 12, 19, 420, 103, 104, 2151, 2152, "]" +818, 12, 20, 421, 105, 108, 2153, 2156, "and" +818, 12, 21, 422, 109, 111, 2157, 2159, "50" +818, 12, 22, 423, 112, 113, 2160, 2161, "%" +818, 12, 23, 424, 114, 120, 2162, 2168, "lispro" +818, 12, 24, 425, 121, 122, 2169, 2170, ")" +818, 12, 25, 426, 123, 126, 2171, 2174, "TID" +818, 12, 26, 427, 127, 131, 2175, 2179, "plus" +818, 12, 27, 428, 132, 141, 2180, 2189, "metformin" +818, 12, 28, 429, 142, 143, 2190, 2191, "(" +818, 12, 29, 430, 144, 146, 2192, 2194, "to" +818, 12, 30, 431, 147, 148, 2195, 2196, "a" +818, 12, 31, 432, 149, 158, 2197, 2206, "maximally" +818, 12, 32, 433, 159, 168, 2207, 2216, "tolerated" +818, 12, 33, 434, 169, 174, 2217, 2222, "daily" +818, 12, 34, 435, 175, 181, 2223, 2229, "dosage" +818, 12, 35, 436, 182, 184, 2230, 2232, "of" +818, 12, 36, 437, 185, 188, 2233, 2236, "500" +818, 12, 37, 438, 189, 190, 2237, 2238, "-" +818, 12, 38, 439, 191, 195, 2239, 2243, "1000" +818, 12, 39, 440, 196, 198, 2244, 2246, "mg" +818, 12, 40, 441, 199, 202, 2247, 2250, "BID" +818, 12, 41, 442, 203, 204, 2251, 2252, ")" +818, 12, 42, 443, 205, 206, 2253, 2254, "(" +818, 12, 43, 444, 207, 211, 2255, 2259, "LM50" +818, 12, 44, 445, 212, 213, 2260, 2261, "/" +818, 12, 45, 446, 214, 216, 2262, 2264, "50" +818, 12, 46, 447, 217, 218, 2265, 2266, "+" +818, 12, 47, 448, 219, 222, 2267, 2270, "Met" +818, 12, 48, 449, 223, 224, 2271, 2272, ")" +818, 12, 49, 450, 225, 227, 2273, 2275, "or" +818, 12, 50, 451, 228, 235, 2276, 2283, "insulin" +818, 12, 51, 452, 236, 244, 2284, 2292, "glargine" +818, 12, 52, 453, 245, 247, 2293, 2295, "QD" +818, 12, 53, 454, 248, 250, 2296, 2298, "at" +818, 12, 54, 455, 251, 258, 2299, 2306, "bedtime" +818, 12, 55, 456, 259, 263, 2307, 2311, "plus" +818, 12, 56, 457, 264, 273, 2312, 2321, "metformin" +818, 12, 57, 458, 274, 275, 2322, 2323, "(" +818, 12, 58, 459, 276, 279, 2324, 2327, "500" +818, 12, 59, 460, 280, 281, 2328, 2329, "-" +818, 12, 60, 461, 282, 286, 2330, 2334, "1000" +818, 12, 61, 462, 287, 289, 2335, 2337, "mg" +818, 12, 62, 463, 290, 293, 2338, 2341, "BID" +818, 12, 63, 464, 294, 295, 2342, 2343, ")" +818, 12, 64, 465, 296, 297, 2344, 2345, "(" +818, 12, 65, 466, 298, 299, 2346, 2347, "G" +818, 12, 66, 467, 300, 301, 2348, 2349, "+" +818, 12, 67, 468, 302, 305, 2350, 2353, "Met" +818, 12, 68, 469, 306, 307, 2354, 2355, ")" +818, 12, 69, 470, 308, 311, 2356, 2359, "for" +818, 12, 70, 471, 312, 314, 2360, 2362, "24" +818, 12, 71, 472, 315, 320, 2363, 2368, "weeks" +818, 12, 72, 473, 321, 322, 2369, 2370, "." +818, 13, 1, 474, 0, 4, 2371, 2375, "With" +818, 13, 2, 475, 5, 9, 2376, 2380, "LM50" +818, 13, 3, 476, 10, 11, 2381, 2382, "/" +818, 13, 4, 477, 12, 14, 2383, 2385, "50" +818, 13, 5, 478, 15, 16, 2386, 2387, "+" +818, 13, 6, 479, 17, 20, 2388, 2391, "Met" +818, 13, 7, 480, 21, 22, 2392, 2393, "," +818, 13, 8, 481, 23, 26, 2394, 2397, "the" +818, 13, 9, 482, 27, 34, 2398, 2405, "insulin" +818, 13, 10, 483, 35, 39, 2406, 2410, "dose" +818, 13, 11, 484, 40, 43, 2411, 2414, "was" +818, 13, 12, 485, 44, 52, 2415, 2423, "titrated" +818, 13, 13, 486, 53, 55, 2424, 2426, "to" +818, 13, 14, 487, 56, 62, 2427, 2433, "target" +818, 13, 15, 488, 63, 64, 2434, 2435, "a" +818, 13, 16, 489, 65, 72, 2436, 2443, "fasting" +818, 13, 17, 490, 73, 75, 2444, 2446, "BG" +818, 13, 18, 491, 76, 77, 2447, 2448, "(" +818, 13, 19, 492, 78, 81, 2449, 2452, "FBG" +818, 13, 20, 493, 82, 83, 2453, 2454, ")" +818, 13, 21, 494, 84, 89, 2455, 2460, "level" +818, 13, 22, 495, 90, 92, 2461, 2463, "of" +818, 13, 23, 496, 93, 94, 2464, 2465, "<" +818, 13, 24, 497, 95, 96, 2466, 2467, "6" +818, 13, 25, 498, 97, 98, 2468, 2469, "." +818, 13, 26, 499, 99, 100, 2470, 2471, "7" +818, 13, 27, 500, 101, 105, 2472, 2476, "mmol" +818, 13, 28, 501, 106, 107, 2477, 2478, "/" +818, 13, 29, 502, 108, 109, 2479, 2480, "L" +818, 13, 30, 503, 110, 111, 2481, 2482, "(" +818, 13, 31, 504, 112, 113, 2483, 2484, "<" +818, 13, 32, 505, 114, 117, 2485, 2488, "120" +818, 13, 33, 506, 118, 120, 2489, 2491, "mg" +818, 13, 34, 507, 121, 122, 2492, 2493, "/" +818, 13, 35, 508, 123, 125, 2494, 2496, "dL" +818, 13, 36, 509, 126, 127, 2497, 2498, ")" +818, 13, 37, 510, 128, 131, 2499, 2502, "and" +818, 13, 38, 511, 132, 133, 2503, 2504, "a" +818, 13, 39, 512, 134, 135, 2505, 2506, "2" +818, 13, 40, 513, 136, 137, 2507, 2508, "-" +818, 13, 41, 514, 138, 142, 2509, 2513, "hour" +818, 13, 42, 515, 143, 147, 2514, 2518, "post" +818, 13, 43, 516, 148, 149, 2519, 2520, "-" +818, 13, 44, 517, 150, 158, 2521, 2529, "prandial" +818, 13, 45, 518, 159, 161, 2530, 2532, "BG" +818, 13, 46, 519, 162, 163, 2533, 2534, "(" +818, 13, 47, 520, 164, 168, 2535, 2539, "PPBG" +818, 13, 48, 521, 169, 170, 2540, 2541, ")" +818, 13, 49, 522, 171, 176, 2542, 2547, "level" +818, 13, 50, 523, 177, 179, 2548, 2550, "of" +818, 13, 51, 524, 180, 181, 2551, 2552, "<" +818, 13, 52, 525, 182, 183, 2553, 2554, "8" +818, 13, 53, 526, 184, 185, 2555, 2556, "." +818, 13, 54, 527, 186, 187, 2557, 2558, "0" +818, 13, 55, 528, 188, 192, 2559, 2563, "mmol" +818, 13, 56, 529, 193, 194, 2564, 2565, "/" +818, 13, 57, 530, 195, 196, 2566, 2567, "L" +818, 13, 58, 531, 197, 198, 2568, 2569, "(" +818, 13, 59, 532, 199, 200, 2570, 2571, "<" +818, 13, 60, 533, 201, 204, 2572, 2575, "144" +818, 13, 61, 534, 205, 207, 2576, 2578, "mg" +818, 13, 62, 535, 208, 209, 2579, 2580, "/" +818, 13, 63, 536, 210, 212, 2581, 2583, "dL" +818, 13, 64, 537, 213, 214, 2584, 2585, ")" +818, 13, 65, 538, 215, 216, 2586, 2587, ";" +818, 13, 66, 539, 217, 222, 2588, 2593, "those" +818, 13, 67, 540, 223, 226, 2594, 2597, "who" +818, 13, 68, 541, 227, 230, 2598, 2601, "did" +818, 13, 69, 542, 231, 234, 2602, 2605, "not" +818, 13, 70, 543, 235, 240, 2606, 2611, "reach" +818, 13, 71, 544, 241, 244, 2612, 2615, "the" +818, 13, 72, 545, 245, 248, 2616, 2619, "FBG" +818, 13, 73, 546, 249, 255, 2620, 2626, "target" +818, 13, 74, 547, 256, 261, 2627, 2632, "would" +818, 13, 75, 548, 262, 264, 2633, 2635, "be" +818, 13, 76, 549, 265, 273, 2636, 2644, "switched" +818, 13, 77, 550, 274, 278, 2645, 2649, "from" +818, 13, 78, 551, 279, 288, 2650, 2659, "presupper" +818, 13, 79, 552, 289, 293, 2660, 2664, "LM50" +818, 13, 80, 553, 294, 295, 2665, 2666, "/" +818, 13, 81, 554, 296, 298, 2667, 2669, "50" +818, 13, 82, 555, 299, 301, 2670, 2672, "to" +818, 13, 83, 556, 302, 306, 2673, 2677, "LM75" +818, 13, 84, 557, 307, 308, 2678, 2679, "/" +818, 13, 85, 558, 309, 311, 2680, 2682, "25" +818, 13, 86, 559, 312, 313, 2683, 2684, "(" +818, 13, 87, 560, 314, 316, 2685, 2687, "75" +818, 13, 88, 561, 317, 318, 2688, 2689, "%" +818, 13, 89, 562, 319, 323, 2690, 2694, "ILPS" +818, 13, 90, 563, 324, 325, 2695, 2696, "," +818, 13, 91, 564, 326, 328, 2697, 2699, "25" +818, 13, 92, 565, 329, 330, 2700, 2701, "%" +818, 13, 93, 566, 331, 337, 2702, 2708, "lispro" +818, 13, 94, 567, 338, 339, 2709, 2710, ")" +818, 13, 95, 568, 340, 341, 2711, 2712, "." +818, 14, 1, 569, 0, 7, 2713, 2720, "RESULTS" +818, 14, 2, 570, 8, 9, 2721, 2722, ":" +818, 14, 3, 571, 10, 11, 2723, 2724, "A" +818, 14, 4, 572, 12, 17, 2725, 2730, "total" +818, 14, 5, 573, 18, 20, 2731, 2733, "of" +818, 14, 6, 574, 21, 24, 2734, 2737, "315" +818, 14, 7, 575, 25, 33, 2738, 2746, "patients" +818, 14, 8, 576, 34, 38, 2747, 2751, "were" +818, 14, 9, 577, 39, 49, 2752, 2762, "randomized" +818, 14, 10, 578, 50, 53, 2763, 2766, "and" +818, 14, 11, 579, 54, 62, 2767, 2775, "received" +818, 14, 12, 580, 63, 72, 2776, 2785, "treatment" +818, 14, 13, 581, 73, 74, 2786, 2787, "(" +818, 14, 14, 582, 75, 78, 2788, 2791, "158" +818, 14, 15, 583, 79, 84, 2792, 2797, "women" +818, 14, 16, 584, 85, 86, 2798, 2799, "," +818, 14, 17, 585, 87, 90, 2800, 2803, "157" +818, 14, 18, 586, 91, 94, 2804, 2807, "men" +818, 14, 19, 587, 95, 96, 2808, 2809, ";" +818, 14, 20, 588, 97, 101, 2810, 2814, "mean" +818, 14, 21, 589, 102, 105, 2815, 2818, "age" +818, 14, 22, 590, 106, 107, 2819, 2820, "," +818, 14, 23, 591, 108, 110, 2821, 2823, "57" +818, 14, 24, 592, 111, 112, 2824, 2825, "." +818, 14, 25, 593, 113, 114, 2826, 2827, "7" +818, 14, 26, 594, 115, 120, 2828, 2833, "years" +818, 14, 27, 595, 121, 122, 2834, 2835, ";" +818, 14, 28, 596, 123, 127, 2836, 2840, "mean" +818, 14, 29, 597, 128, 132, 2841, 2845, "body" +818, 14, 30, 598, 133, 137, 2846, 2850, "mass" +818, 14, 31, 599, 138, 143, 2851, 2856, "index" +818, 14, 32, 600, 144, 145, 2857, 2858, "," +818, 14, 33, 601, 146, 148, 2859, 2861, "32" +818, 14, 34, 602, 149, 150, 2862, 2863, "." +818, 14, 35, 603, 151, 152, 2864, 2865, "1" +818, 14, 36, 604, 153, 155, 2866, 2868, "kg" +818, 14, 37, 605, 156, 157, 2869, 2870, "/" +818, 14, 38, 606, 158, 160, 2871, 2873, "m2" +818, 14, 39, 607, 161, 162, 2874, 2875, ";" +818, 14, 40, 608, 163, 167, 2876, 2880, "LM50" +818, 14, 41, 609, 168, 169, 2881, 2882, "/" +818, 14, 42, 610, 170, 172, 2883, 2885, "50" +818, 14, 43, 611, 173, 174, 2886, 2887, "+" +818, 14, 44, 612, 175, 178, 2888, 2891, "Met" +818, 14, 45, 613, 179, 180, 2892, 2893, "," +818, 14, 46, 614, 181, 184, 2894, 2897, "157" +818, 14, 47, 615, 185, 193, 2898, 2906, "patients" +818, 14, 48, 616, 194, 195, 2907, 2908, ";" +818, 14, 49, 617, 196, 197, 2909, 2910, "G" +818, 14, 50, 618, 198, 199, 2911, 2912, "+" +818, 14, 51, 619, 200, 203, 2913, 2916, "Met" +818, 14, 52, 620, 204, 205, 2917, 2918, "," +818, 14, 53, 621, 206, 209, 2919, 2922, "158" +818, 14, 54, 622, 210, 218, 2923, 2931, "patients" +818, 14, 55, 623, 219, 220, 2932, 2933, ")" +818, 14, 56, 624, 221, 222, 2934, 2935, "." +818, 15, 1, 625, 0, 2, 2936, 2938, "At" +818, 15, 2, 626, 3, 5, 2939, 2941, "24" +818, 15, 3, 627, 6, 11, 2942, 2947, "weeks" +818, 15, 4, 628, 12, 13, 2948, 2949, "," +818, 15, 5, 629, 14, 17, 2950, 2953, "the" +818, 15, 6, 630, 18, 22, 2954, 2958, "mean" +818, 15, 7, 631, 23, 24, 2959, 2960, "(" +818, 15, 8, 632, 25, 27, 2961, 2963, "SD" +818, 15, 9, 633, 28, 29, 2964, 2965, ")" +818, 15, 10, 634, 30, 33, 2966, 2969, "HbA" +818, 15, 11, 635, 34, 35, 2970, 2971, "(" +818, 15, 12, 636, 36, 38, 2972, 2974, "1c" +818, 15, 13, 637, 39, 40, 2975, 2976, ")" +818, 15, 14, 638, 41, 46, 2977, 2982, "level" +818, 15, 15, 639, 47, 50, 2983, 2986, "was" +818, 15, 16, 640, 51, 64, 2987, 3000, "significantly" +818, 15, 17, 641, 65, 70, 3001, 3006, "lower" +818, 15, 18, 642, 71, 73, 3007, 3009, "in" +818, 15, 19, 643, 74, 77, 3010, 3013, "the" +818, 15, 20, 644, 78, 82, 3014, 3018, "LM50" +818, 15, 21, 645, 83, 84, 3019, 3020, "/" +818, 15, 22, 646, 85, 87, 3021, 3023, "50" +818, 15, 23, 647, 88, 89, 3024, 3025, "+" +818, 15, 24, 648, 90, 93, 3026, 3029, "Met" +818, 15, 25, 649, 94, 99, 3030, 3035, "group" +818, 15, 26, 650, 100, 104, 3036, 3040, "than" +818, 15, 27, 651, 105, 107, 3041, 3043, "in" +818, 15, 28, 652, 108, 111, 3044, 3047, "the" +818, 15, 29, 653, 112, 113, 3048, 3049, "G" +818, 15, 30, 654, 114, 115, 3050, 3051, "+" +818, 15, 31, 655, 116, 119, 3052, 3055, "Met" +818, 15, 32, 656, 120, 125, 3056, 3061, "group" +818, 15, 33, 657, 126, 127, 3062, 3063, "(" +818, 15, 34, 658, 128, 129, 3064, 3065, "7" +818, 15, 35, 659, 130, 131, 3066, 3067, "." +818, 15, 36, 660, 132, 133, 3068, 3069, "1" +818, 15, 37, 661, 134, 135, 3070, 3071, "%" +818, 15, 38, 662, 136, 137, 3072, 3073, "[" +818, 15, 39, 663, 138, 139, 3074, 3075, "0" +818, 15, 40, 664, 140, 141, 3076, 3077, "." +818, 15, 41, 665, 142, 143, 3078, 3079, "9" +818, 15, 42, 666, 144, 145, 3080, 3081, "%" +818, 15, 43, 667, 146, 147, 3082, 3083, "]" +818, 15, 44, 668, 148, 150, 3084, 3086, "vs" +818, 15, 45, 669, 151, 152, 3087, 3088, "7" +818, 15, 46, 670, 153, 154, 3089, 3090, "." +818, 15, 47, 671, 155, 156, 3091, 3092, "5" +818, 15, 48, 672, 157, 158, 3093, 3094, "%" +818, 15, 49, 673, 159, 160, 3095, 3096, "[" +818, 15, 50, 674, 161, 162, 3097, 3098, "1" +818, 15, 51, 675, 163, 164, 3099, 3100, "." +818, 15, 52, 676, 165, 166, 3101, 3102, "0" +818, 15, 53, 677, 167, 168, 3103, 3104, "%" +818, 15, 54, 678, 169, 170, 3105, 3106, "]" +818, 15, 55, 679, 171, 172, 3107, 3108, ";" +818, 15, 56, 680, 173, 174, 3109, 3110, "P" +818, 15, 57, 681, 175, 176, 3111, 3112, "<" +818, 15, 58, 682, 177, 178, 3113, 3114, "0" +818, 15, 59, 683, 179, 180, 3115, 3116, "." +818, 15, 60, 684, 181, 184, 3117, 3120, "001" +818, 15, 61, 685, 185, 186, 3121, 3122, ")" +818, 15, 62, 686, 187, 188, 3123, 3124, "," +818, 15, 63, 687, 189, 192, 3125, 3128, "and" +818, 15, 64, 688, 193, 196, 3129, 3132, "the" +818, 15, 65, 689, 197, 207, 3133, 3143, "proportion" +818, 15, 66, 690, 208, 211, 3144, 3147, "who" +818, 15, 67, 691, 212, 219, 3148, 3155, "reached" +818, 15, 68, 692, 220, 222, 3156, 3158, "an" +818, 15, 69, 693, 223, 226, 3159, 3162, "HbA" +818, 15, 70, 694, 227, 228, 3163, 3164, "(" +818, 15, 71, 695, 229, 231, 3165, 3167, "1c" +818, 15, 72, 696, 232, 233, 3168, 3169, ")" +818, 15, 73, 697, 234, 240, 3170, 3176, "target" +818, 15, 74, 698, 241, 243, 3177, 3179, "of" +818, 15, 75, 699, 244, 245, 3180, 3181, "<" +818, 15, 76, 700, 246, 248, 3182, 3184, "or" +818, 15, 77, 701, 249, 250, 3185, 3186, "=" +818, 15, 78, 702, 251, 252, 3187, 3188, "7" +818, 15, 79, 703, 253, 254, 3189, 3190, "." +818, 15, 80, 704, 255, 256, 3191, 3192, "0" +818, 15, 81, 705, 257, 258, 3193, 3194, "%" +818, 15, 82, 706, 259, 262, 3195, 3198, "was" +818, 15, 83, 707, 263, 270, 3199, 3206, "greater" +818, 15, 84, 708, 271, 272, 3207, 3208, "(" +818, 15, 85, 709, 273, 275, 3209, 3211, "88" +818, 15, 86, 710, 276, 277, 3212, 3213, "[" +818, 15, 87, 711, 278, 280, 3214, 3216, "56" +818, 15, 88, 712, 281, 282, 3217, 3218, "." +818, 15, 89, 713, 283, 284, 3219, 3220, "1" +818, 15, 90, 714, 285, 286, 3221, 3222, "%" +818, 15, 91, 715, 287, 288, 3223, 3224, "]" +818, 15, 92, 716, 289, 291, 3225, 3227, "vs" +818, 15, 93, 717, 292, 294, 3228, 3230, "63" +818, 15, 94, 718, 295, 296, 3231, 3232, "[" +818, 15, 95, 719, 297, 299, 3233, 3235, "39" +818, 15, 96, 720, 300, 301, 3236, 3237, "." +818, 15, 97, 721, 302, 303, 3238, 3239, "9" +818, 15, 98, 722, 304, 305, 3240, 3241, "%" +818, 15, 99, 723, 306, 307, 3242, 3243, "]" +818, 15, 100, 724, 308, 309, 3244, 3245, ";" +818, 15, 101, 725, 310, 311, 3246, 3247, "P" +818, 15, 102, 726, 312, 313, 3248, 3249, "=" +818, 15, 103, 727, 314, 315, 3250, 3251, "0" +818, 15, 104, 728, 316, 317, 3252, 3253, "." +818, 15, 105, 729, 318, 321, 3254, 3257, "005" +818, 15, 106, 730, 322, 323, 3258, 3259, ")" +818, 15, 107, 731, 324, 325, 3260, 3261, "." +818, 16, 1, 732, 0, 3, 3262, 3265, "The" +818, 16, 2, 733, 4, 5, 3266, 3267, "G" +818, 16, 3, 734, 6, 7, 3268, 3269, "+" +818, 16, 4, 735, 8, 11, 3270, 3273, "Met" +818, 16, 5, 736, 12, 17, 3274, 3279, "group" +818, 16, 6, 737, 18, 21, 3280, 3283, "had" +818, 16, 7, 738, 22, 23, 3284, 3285, "a" +818, 16, 8, 739, 24, 29, 3286, 3291, "lower" +818, 16, 9, 740, 30, 34, 3292, 3296, "mean" +818, 16, 10, 741, 35, 36, 3297, 3298, "(" +818, 16, 11, 742, 37, 39, 3299, 3301, "SD" +818, 16, 12, 743, 40, 41, 3302, 3303, ")" +818, 16, 13, 744, 42, 45, 3304, 3307, "FBG" +818, 16, 14, 745, 46, 51, 3308, 3313, "value" +818, 16, 15, 746, 52, 53, 3314, 3315, "(" +818, 16, 16, 747, 54, 55, 3316, 3317, "6" +818, 16, 17, 748, 56, 57, 3318, 3319, "." +818, 16, 18, 749, 58, 59, 3320, 3321, "5" +818, 16, 19, 750, 60, 61, 3322, 3323, "[" +818, 16, 20, 751, 62, 63, 3324, 3325, "1" +818, 16, 21, 752, 64, 65, 3326, 3327, "." +818, 16, 22, 753, 66, 67, 3328, 3329, "6" +818, 16, 23, 754, 68, 69, 3330, 3331, "]" +818, 16, 24, 755, 70, 72, 3332, 3334, "vs" +818, 16, 25, 756, 73, 74, 3335, 3336, "8" +818, 16, 26, 757, 75, 76, 3337, 3338, "." +818, 16, 27, 758, 77, 78, 3339, 3340, "1" +818, 16, 28, 759, 79, 80, 3341, 3342, "[" +818, 16, 29, 760, 81, 82, 3343, 3344, "1" +818, 16, 30, 761, 83, 84, 3345, 3346, "." +818, 16, 31, 762, 85, 86, 3347, 3348, "8" +818, 16, 32, 763, 87, 88, 3349, 3350, "]" +818, 16, 33, 764, 89, 93, 3351, 3355, "mmol" +818, 16, 34, 765, 94, 95, 3356, 3357, "/" +818, 16, 35, 766, 96, 97, 3358, 3359, "L" +818, 16, 36, 767, 98, 99, 3360, 3361, ";" +818, 16, 37, 768, 100, 101, 3362, 3363, "P" +818, 16, 38, 769, 102, 103, 3364, 3365, "<" +818, 16, 39, 770, 104, 105, 3366, 3367, "0" +818, 16, 40, 771, 106, 107, 3368, 3369, "." +818, 16, 41, 772, 108, 111, 3370, 3373, "001" +818, 16, 42, 773, 112, 113, 3374, 3375, ")" +818, 16, 43, 774, 114, 115, 3376, 3377, "." +818, 17, 1, 775, 0, 3, 3378, 3381, "The" +818, 17, 2, 776, 4, 8, 3382, 3386, "LM50" +818, 17, 3, 777, 9, 10, 3387, 3388, "/" +818, 17, 4, 778, 11, 13, 3389, 3391, "50" +818, 17, 5, 779, 14, 15, 3392, 3393, "+" +818, 17, 6, 780, 16, 19, 3394, 3397, "Met" +818, 17, 7, 781, 20, 25, 3398, 3403, "group" +818, 17, 8, 782, 26, 29, 3404, 3407, "had" +818, 17, 9, 783, 30, 35, 3408, 3413, "lower" +818, 17, 10, 784, 36, 40, 3414, 3418, "mean" +818, 17, 11, 785, 41, 52, 3419, 3430, "preprandial" +818, 17, 12, 786, 53, 55, 3431, 3433, "BG" +818, 17, 13, 787, 56, 62, 3434, 3440, "levels" +818, 17, 14, 788, 63, 71, 3441, 3449, "prelunch" +818, 17, 15, 789, 72, 73, 3450, 3451, "(" +818, 17, 16, 790, 74, 75, 3452, 3453, "7" +818, 17, 17, 791, 76, 77, 3454, 3455, "." +818, 17, 18, 792, 78, 79, 3456, 3457, "4" +818, 17, 19, 793, 80, 81, 3458, 3459, "[" +818, 17, 20, 794, 82, 83, 3460, 3461, "1" +818, 17, 21, 795, 84, 85, 3462, 3463, "." +818, 17, 22, 796, 86, 87, 3464, 3465, "9" +818, 17, 23, 797, 88, 89, 3466, 3467, "]" +818, 17, 24, 798, 90, 92, 3468, 3470, "vs" +818, 17, 25, 799, 93, 94, 3471, 3472, "7" +818, 17, 26, 800, 95, 96, 3473, 3474, "." +818, 17, 27, 801, 97, 98, 3475, 3476, "9" +818, 17, 28, 802, 99, 100, 3477, 3478, "[" +818, 17, 29, 803, 101, 102, 3479, 3480, "2" +818, 17, 30, 804, 103, 104, 3481, 3482, "." +818, 17, 31, 805, 105, 106, 3483, 3484, "1" +818, 17, 32, 806, 107, 108, 3485, 3486, "]" +818, 17, 33, 807, 109, 113, 3487, 3491, "mmol" +818, 17, 34, 808, 114, 115, 3492, 3493, "/" +818, 17, 35, 809, 116, 117, 3494, 3495, "L" +818, 17, 36, 810, 118, 119, 3496, 3497, ";" +818, 17, 37, 811, 120, 121, 3498, 3499, "P" +818, 17, 38, 812, 122, 123, 3500, 3501, "=" +818, 17, 39, 813, 124, 125, 3502, 3503, "0" +818, 17, 40, 814, 126, 127, 3504, 3505, "." +818, 17, 41, 815, 128, 130, 3506, 3508, "03" +818, 17, 42, 816, 131, 132, 3509, 3510, ")" +818, 17, 43, 817, 133, 136, 3511, 3514, "and" +818, 17, 44, 818, 137, 146, 3515, 3524, "presupper" +818, 17, 45, 819, 147, 148, 3525, 3526, "(" +818, 17, 46, 820, 149, 150, 3527, 3528, "8" +818, 17, 47, 821, 151, 152, 3529, 3530, "." +818, 17, 48, 822, 153, 154, 3531, 3532, "3" +818, 17, 49, 823, 155, 156, 3533, 3534, "[" +818, 17, 50, 824, 157, 158, 3535, 3536, "2" +818, 17, 51, 825, 159, 160, 3537, 3538, "." +818, 17, 52, 826, 161, 162, 3539, 3540, "0" +818, 17, 53, 827, 163, 164, 3541, 3542, "]" +818, 17, 54, 828, 165, 167, 3543, 3545, "vs" +818, 17, 55, 829, 168, 169, 3546, 3547, "8" +818, 17, 56, 830, 170, 171, 3548, 3549, "." +818, 17, 57, 831, 172, 173, 3550, 3551, "9" +818, 17, 58, 832, 174, 175, 3552, 3553, "[" +818, 17, 59, 833, 176, 177, 3554, 3555, "2" +818, 17, 60, 834, 178, 179, 3556, 3557, "." +818, 17, 61, 835, 180, 181, 3558, 3559, "8" +818, 17, 62, 836, 182, 183, 3560, 3561, "]" +818, 17, 63, 837, 184, 188, 3562, 3566, "mmol" +818, 17, 64, 838, 189, 190, 3567, 3568, "/" +818, 17, 65, 839, 191, 192, 3569, 3570, "L" +818, 17, 66, 840, 193, 194, 3571, 3572, ";" +818, 17, 67, 841, 195, 196, 3573, 3574, "P" +818, 17, 68, 842, 197, 198, 3575, 3576, "=" +818, 17, 69, 843, 199, 200, 3577, 3578, "0" +818, 17, 70, 844, 201, 202, 3579, 3580, "." +818, 17, 71, 845, 203, 205, 3581, 3583, "04" +818, 17, 72, 846, 206, 207, 3584, 3585, ")" +818, 17, 73, 847, 208, 209, 3586, 3587, "." +818, 18, 1, 848, 0, 3, 3588, 3591, "The" +818, 18, 2, 849, 4, 8, 3592, 3596, "LM50" +818, 18, 3, 850, 9, 10, 3597, 3598, "/" +818, 18, 4, 851, 11, 13, 3599, 3601, "50" +818, 18, 5, 852, 14, 15, 3602, 3603, "+" +818, 18, 6, 853, 16, 19, 3604, 3607, "Met" +818, 18, 7, 854, 20, 25, 3608, 3613, "group" +818, 18, 8, 855, 26, 30, 3614, 3618, "also" +818, 18, 9, 856, 31, 34, 3619, 3622, "had" +818, 18, 10, 857, 35, 40, 3623, 3628, "lower" +818, 18, 11, 858, 41, 45, 3629, 3633, "mean" +818, 18, 12, 859, 46, 47, 3634, 3635, "2" +818, 18, 13, 860, 48, 49, 3636, 3637, "-" +818, 18, 14, 861, 50, 54, 3638, 3642, "hour" +818, 18, 15, 862, 55, 59, 3643, 3647, "PPBG" +818, 18, 16, 863, 60, 66, 3648, 3654, "values" +818, 18, 17, 864, 67, 80, 3655, 3668, "postbreakfast" +818, 18, 18, 865, 81, 82, 3669, 3670, "(" +818, 18, 19, 866, 83, 84, 3671, 3672, "8" +818, 18, 20, 867, 85, 86, 3673, 3674, "." +818, 18, 21, 868, 87, 88, 3675, 3676, "7" +818, 18, 22, 869, 89, 90, 3677, 3678, "[" +818, 18, 23, 870, 91, 92, 3679, 3680, "2" +818, 18, 24, 871, 93, 94, 3681, 3682, "." +818, 18, 25, 872, 95, 96, 3683, 3684, "2" +818, 18, 26, 873, 97, 98, 3685, 3686, "]" +818, 18, 27, 874, 99, 101, 3687, 3689, "vs" +818, 18, 28, 875, 102, 103, 3690, 3691, "9" +818, 18, 29, 876, 104, 105, 3692, 3693, "." +818, 18, 30, 877, 106, 107, 3694, 3695, "2" +818, 18, 31, 878, 108, 109, 3696, 3697, "[" +818, 18, 32, 879, 110, 111, 3698, 3699, "2" +818, 18, 33, 880, 112, 113, 3700, 3701, "." +818, 18, 34, 881, 114, 115, 3702, 3703, "5" +818, 18, 35, 882, 116, 117, 3704, 3705, "]" +818, 18, 36, 883, 118, 122, 3706, 3710, "mmol" +818, 18, 37, 884, 123, 124, 3711, 3712, "/" +818, 18, 38, 885, 125, 126, 3713, 3714, "L" +818, 18, 39, 886, 127, 128, 3715, 3716, ";" +818, 18, 40, 887, 129, 130, 3717, 3718, "P" +818, 18, 41, 888, 131, 132, 3719, 3720, "=" +818, 18, 42, 889, 133, 134, 3721, 3722, "0" +818, 18, 43, 890, 135, 136, 3723, 3724, "." +818, 18, 44, 891, 137, 139, 3725, 3727, "03" +818, 18, 45, 892, 140, 141, 3728, 3729, ")" +818, 18, 46, 893, 142, 143, 3730, 3731, "," +818, 18, 47, 894, 144, 153, 3732, 3741, "postlunch" +818, 18, 48, 895, 154, 155, 3742, 3743, "(" +818, 18, 49, 896, 156, 157, 3744, 3745, "8" +818, 18, 50, 897, 158, 159, 3746, 3747, "." +818, 18, 51, 898, 160, 161, 3748, 3749, "4" +818, 18, 52, 899, 162, 163, 3750, 3751, "[" +818, 18, 53, 900, 164, 165, 3752, 3753, "1" +818, 18, 54, 901, 166, 167, 3754, 3755, "." +818, 18, 55, 902, 168, 169, 3756, 3757, "9" +818, 18, 56, 903, 170, 171, 3758, 3759, "]" +818, 18, 57, 904, 172, 174, 3760, 3762, "vs" +818, 18, 58, 905, 175, 176, 3763, 3764, "9" +818, 18, 59, 906, 177, 178, 3765, 3766, "." +818, 18, 60, 907, 179, 180, 3767, 3768, "8" +818, 18, 61, 908, 181, 182, 3769, 3770, "[" +818, 18, 62, 909, 183, 184, 3771, 3772, "2" +818, 18, 63, 910, 185, 186, 3773, 3774, "." +818, 18, 64, 911, 187, 188, 3775, 3776, "6" +818, 18, 65, 912, 189, 190, 3777, 3778, "]" +818, 18, 66, 913, 191, 192, 3779, 3780, "," +818, 18, 67, 914, 193, 197, 3781, 3785, "mmol" +818, 18, 68, 915, 198, 199, 3786, 3787, "/" +818, 18, 69, 916, 200, 201, 3788, 3789, "L" +818, 18, 70, 917, 202, 203, 3790, 3791, ";" +818, 18, 71, 918, 204, 205, 3792, 3793, "p" +818, 18, 72, 919, 206, 207, 3794, 3795, "<" +818, 18, 73, 920, 208, 209, 3796, 3797, "0" +818, 18, 74, 921, 210, 211, 3798, 3799, "." +818, 18, 75, 922, 212, 215, 3800, 3803, "001" +818, 18, 76, 923, 216, 217, 3804, 3805, ")" +818, 18, 77, 924, 218, 219, 3806, 3807, "," +818, 18, 78, 925, 220, 223, 3808, 3811, "and" +818, 18, 79, 926, 224, 234, 3812, 3822, "postsupper" +818, 18, 80, 927, 235, 236, 3823, 3824, "(" +818, 18, 81, 928, 237, 238, 3825, 3826, "8" +818, 18, 82, 929, 239, 240, 3827, 3828, "." +818, 18, 83, 930, 241, 242, 3829, 3830, "7" +818, 18, 84, 931, 243, 244, 3831, 3832, "[" +818, 18, 85, 932, 245, 246, 3833, 3834, "2" +818, 18, 86, 933, 247, 248, 3835, 3836, "." +818, 18, 87, 934, 249, 250, 3837, 3838, "2" +818, 18, 88, 935, 251, 252, 3839, 3840, "]" +818, 18, 89, 936, 253, 255, 3841, 3843, "vs" +818, 18, 90, 937, 256, 258, 3844, 3846, "10" +818, 18, 91, 938, 259, 260, 3847, 3848, "." +818, 18, 92, 939, 261, 262, 3849, 3850, "7" +818, 18, 93, 940, 263, 264, 3851, 3852, "[" +818, 18, 94, 941, 265, 266, 3853, 3854, "3" +818, 18, 95, 942, 267, 268, 3855, 3856, "." +818, 18, 96, 943, 269, 270, 3857, 3858, "2" +818, 18, 97, 944, 271, 272, 3859, 3860, "]" +818, 18, 98, 945, 273, 274, 3861, 3862, "," +818, 18, 99, 946, 275, 279, 3863, 3867, "mmol" +818, 18, 100, 947, 280, 281, 3868, 3869, "/" +818, 18, 101, 948, 282, 283, 3870, 3871, "L" +818, 18, 102, 949, 284, 285, 3872, 3873, ";" +818, 18, 103, 950, 286, 287, 3874, 3875, "P" +818, 18, 104, 951, 288, 289, 3876, 3877, "<" +818, 18, 105, 952, 290, 291, 3878, 3879, "0" +818, 18, 106, 953, 292, 293, 3880, 3881, "." +818, 18, 107, 954, 294, 297, 3882, 3885, "001" +818, 18, 108, 955, 298, 299, 3886, 3887, ")" +818, 18, 109, 956, 300, 301, 3888, 3889, "." +818, 19, 1, 957, 0, 3, 3890, 3893, "The" +818, 19, 2, 958, 4, 8, 3894, 3898, "mean" +818, 19, 3, 959, 9, 10, 3899, 3900, "(" +818, 19, 4, 960, 11, 13, 3901, 3903, "SD" +818, 19, 5, 961, 14, 15, 3904, 3905, ")" +818, 19, 6, 962, 16, 21, 3906, 3911, "total" +818, 19, 7, 963, 22, 29, 3912, 3919, "insulin" +818, 19, 8, 964, 30, 35, 3920, 3925, "doses" +818, 19, 9, 965, 36, 38, 3926, 3928, "at" +818, 19, 10, 966, 39, 44, 3929, 3934, "study" +818, 19, 11, 967, 45, 48, 3935, 3938, "end" +818, 19, 12, 968, 49, 54, 3939, 3944, "point" +818, 19, 13, 969, 55, 59, 3945, 3949, "were" +818, 19, 14, 970, 60, 61, 3950, 3951, "0" +818, 19, 15, 971, 62, 63, 3952, 3953, "." +818, 19, 16, 972, 64, 65, 3954, 3955, "7" +818, 19, 17, 973, 66, 67, 3956, 3957, "(" +818, 19, 18, 974, 68, 69, 3958, 3959, "0" +818, 19, 19, 975, 70, 71, 3960, 3961, "." +818, 19, 20, 976, 72, 73, 3962, 3963, "3" +818, 19, 21, 977, 74, 75, 3964, 3965, ")" +818, 19, 22, 978, 76, 77, 3966, 3967, "U" +818, 19, 23, 979, 78, 79, 3968, 3969, "/" +818, 19, 24, 980, 80, 82, 3970, 3972, "kg" +818, 19, 25, 981, 83, 85, 3973, 3975, "in" +818, 19, 26, 982, 86, 89, 3976, 3979, "the" +818, 19, 27, 983, 90, 94, 3980, 3984, "LM50" +818, 19, 28, 984, 95, 96, 3985, 3986, "/" +818, 19, 29, 985, 97, 99, 3987, 3989, "50" +818, 19, 30, 986, 100, 101, 3990, 3991, "+" +818, 19, 31, 987, 102, 105, 3992, 3995, "Met" +818, 19, 32, 988, 106, 111, 3996, 4001, "group" +818, 19, 33, 989, 112, 115, 4002, 4005, "and" +818, 19, 34, 990, 116, 117, 4006, 4007, "0" +818, 19, 35, 991, 118, 119, 4008, 4009, "." +818, 19, 36, 992, 120, 121, 4010, 4011, "6" +818, 19, 37, 993, 122, 123, 4012, 4013, "(" +818, 19, 38, 994, 124, 125, 4014, 4015, "0" +818, 19, 39, 995, 126, 127, 4016, 4017, "." +818, 19, 40, 996, 128, 129, 4018, 4019, "3" +818, 19, 41, 997, 130, 131, 4020, 4021, ")" +818, 19, 42, 998, 132, 133, 4022, 4023, "U" +818, 19, 43, 999, 134, 135, 4024, 4025, "/" +818, 19, 44, 1000, 136, 138, 4026, 4028, "kg" +818, 19, 45, 1001, 139, 141, 4029, 4031, "in" +818, 19, 46, 1002, 142, 145, 4032, 4035, "the" +818, 19, 47, 1003, 146, 147, 4036, 4037, "G" +818, 19, 48, 1004, 148, 149, 4038, 4039, "+" +818, 19, 49, 1005, 150, 153, 4040, 4043, "Met" +818, 19, 50, 1006, 154, 159, 4044, 4049, "group" +818, 19, 51, 1007, 160, 161, 4050, 4051, "(" +818, 19, 52, 1008, 162, 163, 4052, 4053, "P" +818, 19, 53, 1009, 164, 165, 4054, 4055, "<" +818, 19, 54, 1010, 166, 167, 4056, 4057, "0" +818, 19, 55, 1011, 168, 169, 4058, 4059, "." +818, 19, 56, 1012, 170, 173, 4060, 4063, "001" +818, 19, 57, 1013, 174, 175, 4064, 4065, ")" +818, 19, 58, 1014, 176, 177, 4066, 4067, "." +818, 20, 1, 1015, 0, 3, 4068, 4071, "The" +818, 20, 2, 1016, 4, 8, 4072, 4076, "mean" +818, 20, 3, 1017, 9, 10, 4077, 4078, "(" +818, 20, 4, 1018, 11, 13, 4079, 4081, "SD" +818, 20, 5, 1019, 14, 15, 4082, 4083, ")" +818, 20, 6, 1020, 16, 17, 4084, 4085, "M" +818, 20, 7, 1021, 18, 19, 4086, 4087, "-" +818, 20, 8, 1022, 20, 25, 4088, 4093, "value" +818, 20, 9, 1023, 26, 27, 4094, 4095, "(" +818, 20, 10, 1024, 28, 30, 4096, 4098, "an" +818, 20, 11, 1025, 31, 41, 4099, 4109, "expression" +818, 20, 12, 1026, 42, 44, 4110, 4112, "of" +818, 20, 13, 1027, 45, 49, 4113, 4117, "mean" +818, 20, 14, 1028, 50, 58, 4118, 4126, "glycemia" +818, 20, 15, 1029, 59, 62, 4127, 4130, "and" +818, 20, 16, 1030, 63, 66, 4131, 4134, "the" +818, 20, 17, 1031, 67, 73, 4135, 4141, "effect" +818, 20, 18, 1032, 74, 76, 4142, 4144, "of" +818, 20, 19, 1033, 77, 84, 4145, 4152, "glucose" +818, 20, 20, 1034, 85, 91, 4153, 4159, "swings" +818, 20, 21, 1035, 92, 93, 4160, 4161, ")" +818, 20, 22, 1036, 94, 97, 4162, 4165, "was" +818, 20, 23, 1037, 98, 111, 4166, 4179, "statistically" +818, 20, 24, 1038, 112, 119, 4180, 4187, "similar" +818, 20, 25, 1039, 120, 127, 4188, 4195, "between" +818, 20, 26, 1040, 128, 131, 4196, 4199, "the" +818, 20, 27, 1041, 132, 133, 4200, 4201, "2" +818, 20, 28, 1042, 134, 140, 4202, 4208, "groups" +818, 20, 29, 1043, 141, 143, 4209, 4211, "at" +818, 20, 30, 1044, 144, 152, 4212, 4220, "baseline" +818, 20, 31, 1045, 153, 156, 4221, 4224, "but" +818, 20, 32, 1046, 157, 170, 4225, 4238, "significantly" +818, 20, 33, 1047, 171, 176, 4239, 4244, "lower" +818, 20, 34, 1048, 177, 179, 4245, 4247, "in" +818, 20, 35, 1049, 180, 183, 4248, 4251, "the" +818, 20, 36, 1050, 184, 188, 4252, 4256, "LM50" +818, 20, 37, 1051, 189, 190, 4257, 4258, "/" +818, 20, 38, 1052, 191, 193, 4259, 4261, "50" +818, 20, 39, 1053, 194, 195, 4262, 4263, "+" +818, 20, 40, 1054, 196, 199, 4264, 4267, "Met" +818, 20, 41, 1055, 200, 205, 4268, 4273, "group" +818, 20, 42, 1056, 206, 208, 4274, 4276, "at" +818, 20, 43, 1057, 209, 212, 4277, 4280, "end" +818, 20, 44, 1058, 213, 218, 4281, 4286, "point" +818, 20, 45, 1059, 219, 220, 4287, 4288, "(" +818, 20, 46, 1060, 221, 223, 4289, 4291, "17" +818, 20, 47, 1061, 224, 225, 4292, 4293, "." +818, 20, 48, 1062, 226, 227, 4294, 4295, "3" +818, 20, 49, 1063, 228, 229, 4296, 4297, "[" +818, 20, 50, 1064, 230, 232, 4298, 4300, "13" +818, 20, 51, 1065, 233, 234, 4301, 4302, "." +818, 20, 52, 1066, 235, 236, 4303, 4304, "8" +818, 20, 53, 1067, 237, 238, 4305, 4306, "]" +818, 20, 54, 1068, 239, 241, 4307, 4309, "vs" +818, 20, 55, 1069, 242, 244, 4310, 4312, "25" +818, 20, 56, 1070, 245, 246, 4313, 4314, "." +818, 20, 57, 1071, 247, 248, 4315, 4316, "1" +818, 20, 58, 1072, 249, 250, 4317, 4318, "[" +818, 20, 59, 1073, 251, 253, 4319, 4321, "24" +818, 20, 60, 1074, 254, 255, 4322, 4323, "." +818, 20, 61, 1075, 256, 257, 4324, 4325, "8" +818, 20, 62, 1076, 258, 259, 4326, 4327, "]" +818, 20, 63, 1077, 260, 264, 4328, 4332, "mmol" +818, 20, 64, 1078, 265, 266, 4333, 4334, "/" +818, 20, 65, 1079, 267, 268, 4335, 4336, "L" +818, 20, 66, 1080, 269, 270, 4337, 4338, ";" +818, 20, 67, 1081, 271, 272, 4339, 4340, "P" +818, 20, 68, 1082, 273, 274, 4341, 4342, "<" +818, 20, 69, 1083, 275, 276, 4343, 4344, "0" +818, 20, 70, 1084, 277, 278, 4345, 4346, "." +818, 20, 71, 1085, 279, 282, 4347, 4350, "001" +818, 20, 72, 1086, 283, 284, 4351, 4352, ")" +818, 20, 73, 1087, 285, 286, 4353, 4354, "." +818, 21, 1, 1088, 0, 6, 4355, 4361, "During" +818, 21, 2, 1089, 7, 10, 4362, 4365, "the" +818, 21, 3, 1090, 11, 17, 4366, 4372, "entire" +818, 21, 4, 1091, 18, 27, 4373, 4382, "treatment" +818, 21, 5, 1092, 28, 34, 4383, 4389, "period" +818, 21, 6, 1093, 35, 36, 4390, 4391, "," +818, 21, 7, 1094, 37, 41, 4392, 4396, "mean" +818, 21, 8, 1095, 42, 43, 4397, 4398, "(" +818, 21, 9, 1096, 44, 46, 4399, 4401, "SD" +818, 21, 10, 1097, 47, 48, 4402, 4403, ")" +818, 21, 11, 1098, 49, 56, 4404, 4411, "overall" +818, 21, 12, 1099, 57, 60, 4412, 4415, "and" +818, 21, 13, 1100, 61, 70, 4416, 4425, "nocturnal" +818, 21, 14, 1101, 71, 83, 4426, 4438, "hypoglycemia" +818, 21, 15, 1102, 84, 89, 4439, 4444, "rates" +818, 21, 16, 1103, 90, 91, 4445, 4446, "(" +818, 21, 17, 1104, 92, 100, 4447, 4455, "episodes" +818, 21, 18, 1105, 101, 104, 4456, 4459, "per" +818, 21, 19, 1106, 105, 112, 4460, 4467, "patient" +818, 21, 20, 1107, 113, 116, 4468, 4471, "for" +818, 21, 21, 1108, 117, 119, 4472, 4474, "30" +818, 21, 22, 1109, 120, 124, 4475, 4479, "days" +818, 21, 23, 1110, 125, 126, 4480, 4481, ")" +818, 21, 24, 1111, 127, 131, 4482, 4486, "were" +818, 21, 25, 1112, 132, 145, 4487, 4500, "statistically" +818, 21, 26, 1113, 146, 153, 4501, 4508, "similar" +818, 21, 27, 1114, 154, 161, 4509, 4516, "between" +818, 21, 28, 1115, 162, 165, 4517, 4520, "the" +818, 21, 29, 1116, 166, 167, 4521, 4522, "2" +818, 21, 30, 1117, 168, 174, 4523, 4529, "groups" +818, 21, 31, 1118, 175, 176, 4530, 4531, "(" +818, 21, 32, 1119, 177, 184, 4532, 4539, "overall" +818, 21, 33, 1120, 185, 186, 4540, 4541, "," +818, 21, 34, 1121, 187, 188, 4542, 4543, "0" +818, 21, 35, 1122, 189, 190, 4544, 4545, "." +818, 21, 36, 1123, 191, 192, 4546, 4547, "8" +818, 21, 37, 1124, 193, 194, 4548, 4549, "[" +818, 21, 38, 1125, 195, 196, 4550, 4551, "1" +818, 21, 39, 1126, 197, 198, 4552, 4553, "." +818, 21, 40, 1127, 199, 200, 4554, 4555, "4" +818, 21, 41, 1128, 201, 202, 4556, 4557, "]" +818, 21, 42, 1129, 203, 205, 4558, 4560, "vs" +818, 21, 43, 1130, 206, 207, 4561, 4562, "0" +818, 21, 44, 1131, 208, 209, 4563, 4564, "." +818, 21, 45, 1132, 210, 211, 4565, 4566, "5" +818, 21, 46, 1133, 212, 213, 4567, 4568, "[" +818, 21, 47, 1134, 214, 215, 4569, 4570, "1" +818, 21, 48, 1135, 216, 217, 4571, 4572, "." +818, 21, 49, 1136, 218, 219, 4573, 4574, "0" +818, 21, 50, 1137, 220, 221, 4575, 4576, "]" +818, 21, 51, 1138, 222, 223, 4577, 4578, ";" +818, 21, 52, 1139, 224, 233, 4579, 4588, "nocturnal" +818, 21, 53, 1140, 234, 235, 4589, 4590, "," +818, 21, 54, 1141, 236, 237, 4591, 4592, "0" +818, 21, 55, 1142, 238, 239, 4593, 4594, "." +818, 21, 56, 1143, 240, 241, 4595, 4596, "2" +818, 21, 57, 1144, 242, 243, 4597, 4598, "[" +818, 21, 58, 1145, 244, 245, 4599, 4600, "0" +818, 21, 59, 1146, 246, 247, 4601, 4602, "." +818, 21, 60, 1147, 248, 249, 4603, 4604, "7" +818, 21, 61, 1148, 250, 251, 4605, 4606, "]" +818, 21, 62, 1149, 252, 254, 4607, 4609, "vs" +818, 21, 63, 1150, 255, 256, 4610, 4611, "0" +818, 21, 64, 1151, 257, 258, 4612, 4613, "." +818, 21, 65, 1152, 259, 260, 4614, 4615, "3" +818, 21, 66, 1153, 261, 262, 4616, 4617, "[" +818, 21, 67, 1154, 263, 264, 4618, 4619, "0" +818, 21, 68, 1155, 265, 266, 4620, 4621, "." +818, 21, 69, 1156, 267, 268, 4622, 4623, "6" +818, 21, 70, 1157, 269, 270, 4624, 4625, "]" +818, 21, 71, 1158, 271, 272, 4626, 4627, ")" +818, 21, 72, 1159, 273, 274, 4628, 4629, "." +818, 22, 1, 1160, 0, 2, 4630, 4632, "At" +818, 22, 2, 1161, 3, 6, 4633, 4636, "end" +818, 22, 3, 1162, 7, 12, 4637, 4642, "point" +818, 22, 4, 1163, 13, 14, 4643, 4644, "," +818, 22, 5, 1164, 15, 18, 4645, 4648, "the" +818, 22, 6, 1165, 19, 23, 4649, 4653, "mean" +818, 22, 7, 1166, 24, 25, 4654, 4655, "(" +818, 22, 8, 1167, 26, 28, 4656, 4658, "SD" +818, 22, 9, 1168, 29, 30, 4659, 4660, ")" +818, 22, 10, 1169, 31, 40, 4661, 4670, "nocturnal" +818, 22, 11, 1170, 41, 53, 4671, 4683, "hypoglycemia" +818, 22, 12, 1171, 54, 59, 4684, 4689, "rates" +818, 22, 13, 1172, 60, 64, 4690, 4694, "were" +818, 22, 14, 1173, 65, 72, 4695, 4702, "similar" +818, 22, 15, 1174, 73, 80, 4703, 4710, "between" +818, 22, 16, 1175, 81, 84, 4711, 4714, "the" +818, 22, 17, 1176, 85, 86, 4715, 4716, "2" +818, 22, 18, 1177, 87, 93, 4717, 4723, "groups" +818, 22, 19, 1178, 94, 95, 4724, 4725, "(" +818, 22, 20, 1179, 96, 97, 4726, 4727, "0" +818, 22, 21, 1180, 98, 99, 4728, 4729, "." +818, 22, 22, 1181, 100, 101, 4730, 4731, "2" +818, 22, 23, 1182, 102, 103, 4732, 4733, "[" +818, 22, 24, 1183, 104, 105, 4734, 4735, "0" +818, 22, 25, 1184, 106, 107, 4736, 4737, "." +818, 22, 26, 1185, 108, 109, 4738, 4739, "9" +818, 22, 27, 1186, 110, 111, 4740, 4741, "]" +818, 22, 28, 1187, 112, 114, 4742, 4744, "vs" +818, 22, 29, 1188, 115, 116, 4745, 4746, "0" +818, 22, 30, 1189, 117, 118, 4747, 4748, "." +818, 22, 31, 1190, 119, 120, 4749, 4750, "2" +818, 22, 32, 1191, 121, 122, 4751, 4752, "[" +818, 22, 33, 1192, 123, 124, 4753, 4754, "0" +818, 22, 34, 1193, 125, 126, 4755, 4756, "." +818, 22, 35, 1194, 127, 128, 4757, 4758, "6" +818, 22, 36, 1195, 129, 130, 4759, 4760, "]" +818, 22, 37, 1196, 131, 132, 4761, 4762, ")" +818, 22, 38, 1197, 133, 134, 4763, 4764, "," +818, 22, 39, 1198, 135, 138, 4765, 4768, "but" +818, 22, 40, 1199, 139, 142, 4769, 4772, "the" +818, 22, 41, 1200, 143, 150, 4773, 4780, "overall" +818, 22, 42, 1201, 151, 154, 4781, 4784, "and" +818, 22, 43, 1202, 155, 158, 4785, 4788, "non" +818, 22, 44, 1203, 159, 160, 4789, 4790, "-" +818, 22, 45, 1204, 161, 170, 4791, 4800, "nocturnal" +818, 22, 46, 1205, 171, 183, 4801, 4813, "hypoglycemia" +818, 22, 47, 1206, 184, 189, 4814, 4819, "rates" +818, 22, 48, 1207, 190, 194, 4820, 4824, "were" +818, 22, 49, 1208, 195, 201, 4825, 4831, "higher" +818, 22, 50, 1209, 202, 206, 4832, 4836, "with" +818, 22, 51, 1210, 207, 211, 4837, 4841, "LM50" +818, 22, 52, 1211, 212, 213, 4842, 4843, "/" +818, 22, 53, 1212, 214, 216, 4844, 4846, "50" +818, 22, 54, 1213, 217, 218, 4847, 4848, "+" +818, 22, 55, 1214, 219, 222, 4849, 4852, "Met" +818, 22, 56, 1215, 223, 224, 4853, 4854, "(" +818, 22, 57, 1216, 225, 232, 4855, 4862, "overall" +818, 22, 58, 1217, 233, 234, 4863, 4864, "," +818, 22, 59, 1218, 235, 236, 4865, 4866, "0" +818, 22, 60, 1219, 237, 238, 4867, 4868, "." +818, 22, 61, 1220, 239, 240, 4869, 4870, "7" +818, 22, 62, 1221, 241, 242, 4871, 4872, "[" +818, 22, 63, 1222, 243, 244, 4873, 4874, "1" +818, 22, 64, 1223, 245, 246, 4875, 4876, "." +818, 22, 65, 1224, 247, 248, 4877, 4878, "7" +818, 22, 66, 1225, 249, 250, 4879, 4880, "]" +818, 22, 67, 1226, 251, 253, 4881, 4883, "vs" +818, 22, 68, 1227, 254, 255, 4884, 4885, "0" +818, 22, 69, 1228, 256, 257, 4886, 4887, "." +818, 22, 70, 1229, 258, 259, 4888, 4889, "3" +818, 22, 71, 1230, 260, 261, 4890, 4891, "[" +818, 22, 72, 1231, 262, 263, 4892, 4893, "0" +818, 22, 73, 1232, 264, 265, 4894, 4895, "." +818, 22, 74, 1233, 266, 267, 4896, 4897, "8" +818, 22, 75, 1234, 268, 269, 4898, 4899, "]" +818, 22, 76, 1235, 270, 271, 4900, 4901, ";" +818, 22, 77, 1236, 272, 273, 4902, 4903, "P" +818, 22, 78, 1237, 274, 275, 4904, 4905, "=" +818, 22, 79, 1238, 276, 277, 4906, 4907, "0" +818, 22, 80, 1239, 278, 279, 4908, 4909, "." +818, 22, 81, 1240, 280, 282, 4910, 4912, "02" +818, 22, 82, 1241, 283, 284, 4913, 4914, ";" +818, 22, 83, 1242, 285, 288, 4915, 4918, "non" +818, 22, 84, 1243, 289, 290, 4919, 4920, "-" +818, 22, 85, 1244, 291, 300, 4921, 4930, "nocturnal" +818, 22, 86, 1245, 301, 302, 4931, 4932, "," +818, 22, 87, 1246, 303, 304, 4933, 4934, "0" +818, 22, 88, 1247, 305, 306, 4935, 4936, "." +818, 22, 89, 1248, 307, 308, 4937, 4938, "5" +818, 22, 90, 1249, 309, 310, 4939, 4940, "[" +818, 22, 91, 1250, 311, 312, 4941, 4942, "1" +818, 22, 92, 1251, 313, 314, 4943, 4944, "." +818, 22, 93, 1252, 315, 316, 4945, 4946, "2" +818, 22, 94, 1253, 317, 318, 4947, 4948, "]" +818, 22, 95, 1254, 319, 321, 4949, 4951, "vs" +818, 22, 96, 1255, 322, 323, 4952, 4953, "0" +818, 22, 97, 1256, 324, 325, 4954, 4955, "." +818, 22, 98, 1257, 326, 327, 4956, 4957, "1" +818, 22, 99, 1258, 328, 329, 4958, 4959, "[" +818, 22, 100, 1259, 330, 331, 4960, 4961, "0" +818, 22, 101, 1260, 332, 333, 4962, 4963, "." +818, 22, 102, 1261, 334, 335, 4964, 4965, "4" +818, 22, 103, 1262, 336, 337, 4966, 4967, "]" +818, 22, 104, 1263, 338, 339, 4968, 4969, ";" +818, 22, 105, 1264, 340, 341, 4970, 4971, "P" +818, 22, 106, 1265, 342, 343, 4972, 4973, "=" +818, 22, 107, 1266, 344, 345, 4974, 4975, "0" +818, 22, 108, 1267, 346, 347, 4976, 4977, "." +818, 22, 109, 1268, 348, 351, 4978, 4981, "002" +818, 22, 110, 1269, 352, 353, 4982, 4983, ")" +818, 22, 111, 1270, 354, 355, 4984, 4985, "." +818, 23, 1, 1271, 0, 10, 4986, 4996, "CONCLUSION" +818, 23, 2, 1272, 11, 12, 4997, 4998, ":" +818, 23, 3, 1273, 13, 15, 4999, 5001, "In" +818, 23, 4, 1274, 16, 21, 5002, 5007, "these" +818, 23, 5, 1275, 22, 30, 5008, 5016, "patients" +818, 23, 6, 1276, 31, 35, 5017, 5021, "with" +818, 23, 7, 1277, 36, 40, 5022, 5026, "type" +818, 23, 8, 1278, 41, 42, 5027, 5028, "2" +818, 23, 9, 1279, 43, 51, 5029, 5037, "diabetes" +818, 23, 10, 1280, 52, 53, 5038, 5039, "," +818, 23, 11, 1281, 54, 62, 5040, 5048, "mealtime" +818, 23, 12, 1282, 63, 67, 5049, 5053, "LM50" +818, 23, 13, 1283, 68, 69, 5054, 5055, "/" +818, 23, 14, 1284, 70, 72, 5056, 5058, "50" +818, 23, 15, 1285, 73, 74, 5059, 5060, "+" +818, 23, 16, 1286, 75, 78, 5061, 5064, "Met" +818, 23, 17, 1287, 79, 82, 5065, 5068, "was" +818, 23, 18, 1288, 83, 93, 5069, 5079, "associated" +818, 23, 19, 1289, 94, 98, 5080, 5084, "with" +818, 23, 20, 1290, 99, 104, 5085, 5090, "lower" +818, 23, 21, 1291, 105, 112, 5091, 5098, "overall" +818, 23, 22, 1292, 113, 114, 5099, 5100, "(" +818, 23, 23, 1293, 115, 118, 5101, 5104, "HbA" +818, 23, 24, 1294, 119, 120, 5105, 5106, "(" +818, 23, 25, 1295, 121, 123, 5107, 5109, "1c" +818, 23, 26, 1296, 124, 125, 5110, 5111, ")" +818, 23, 27, 1297, 126, 127, 5112, 5113, ")" +818, 23, 28, 1298, 128, 131, 5114, 5117, "and" +818, 23, 29, 1299, 132, 143, 5118, 5129, "preprandial" +818, 23, 30, 1300, 144, 146, 5130, 5132, "BG" +818, 23, 31, 1301, 147, 150, 5133, 5136, "and" +818, 23, 32, 1302, 151, 155, 5137, 5141, "PPBG" +818, 23, 33, 1303, 156, 162, 5142, 5148, "levels" +818, 23, 34, 1304, 163, 164, 5149, 5150, "(" +818, 23, 35, 1305, 165, 171, 5151, 5157, "except" +818, 23, 36, 1306, 172, 175, 5158, 5161, "for" +818, 23, 37, 1307, 176, 179, 5162, 5165, "FBG" +818, 23, 38, 1308, 180, 181, 5166, 5167, ")" +818, 23, 39, 1309, 182, 183, 5168, 5169, "," +818, 23, 40, 1310, 184, 188, 5170, 5174, "with" +818, 23, 41, 1311, 189, 196, 5175, 5182, "similar" +818, 23, 42, 1312, 197, 206, 5183, 5192, "nocturnal" +818, 23, 43, 1313, 207, 219, 5193, 5205, "hypoglycemia" +818, 23, 44, 1314, 220, 223, 5206, 5209, "and" +818, 23, 45, 1315, 224, 228, 5210, 5214, "less" +818, 23, 46, 1316, 229, 237, 5215, 5223, "glycemic" +818, 23, 47, 1317, 238, 249, 5224, 5235, "variability" +818, 23, 48, 1318, 250, 251, 5236, 5237, "," +818, 23, 49, 1319, 252, 260, 5238, 5246, "compared" +818, 23, 50, 1320, 261, 265, 5247, 5251, "with" +818, 23, 51, 1321, 266, 267, 5252, 5253, "G" +818, 23, 52, 1322, 268, 269, 5254, 5255, "+" +818, 23, 53, 1323, 270, 273, 5256, 5259, "Met" +818, 23, 54, 1324, 274, 275, 5260, 5261, "." +818, 24, 1, 1325, 0, 9, 5262, 5271, "Copyright" +818, 24, 2, 1326, 10, 11, 5272, 5273, "(" +818, 24, 3, 1327, 12, 13, 5274, 5275, "c" +818, 24, 4, 1328, 14, 15, 5276, 5277, ")" +818, 24, 5, 1329, 16, 20, 5278, 5282, "2007" +818, 24, 6, 1330, 21, 29, 5283, 5291, "Excerpta" +818, 24, 7, 1331, 30, 36, 5292, 5298, "Medica" +818, 24, 8, 1332, 37, 38, 5299, 5300, "," +818, 24, 9, 1333, 39, 42, 5301, 5304, "Inc" +818, 24, 10, 1334, 43, 44, 5305, 5306, "." +818, 24, 11, 1335, 45, 48, 5307, 5310, "DOI" +818, 24, 12, 1336, 49, 50, 5311, 5312, ":" +818, 24, 13, 1337, 51, 53, 5313, 5315, "10" +818, 24, 14, 1338, 54, 55, 5316, 5317, "." +818, 24, 15, 1339, 56, 60, 5318, 5322, "1016" +818, 24, 16, 1340, 61, 62, 5323, 5324, "/" +818, 24, 17, 1341, 63, 64, 5325, 5326, "j" +818, 24, 18, 1342, 65, 66, 5327, 5328, "." +818, 24, 19, 1343, 67, 76, 5329, 5338, "clinthera" +818, 24, 20, 1344, 77, 78, 5339, 5340, "." +818, 24, 21, 1345, 79, 83, 5341, 5345, "2007" +818, 24, 22, 1346, 84, 85, 5346, 5347, "." +818, 24, 23, 1347, 86, 88, 5348, 5350, "11" +818, 24, 24, 1348, 89, 90, 5351, 5352, "." +818, 24, 25, 1349, 91, 94, 5353, 5356, "016" +818, 24, 26, 1350, 95, 99, 5357, 5361, "PMID" +818, 24, 27, 1351, 100, 101, 5362, 5363, ":" +818, 24, 28, 1352, 102, 110, 5364, 5372, "18158076" +818, 24, 29, 1353, 111, 112, 5373, 5374, "[" +818, 24, 30, 1354, 113, 120, 5375, 5382, "Indexed" +818, 24, 31, 1355, 121, 124, 5383, 5386, "for" +818, 24, 32, 1356, 125, 132, 5387, 5394, "MEDLINE" +818, 24, 33, 1357, 133, 134, 5395, 5396, "]" diff --git a/data/dm2 18158076_admin.annodb b/data/dm2 18158076_admin.annodb new file mode 100644 index 0000000..3d0c784 --- /dev/null +++ b/data/dm2 18158076_admin.annodb @@ -0,0 +1,291 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2007", "", " \"2007\"." +9, RelativeTime, 47, 55, "Mealtime", "", +37, Title, 47, 245, "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in", "", " \"Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in\"." +334, Insulin, 56, 105, "50 / 50 basal + prandial insulin analogue mixture", "", +335, Insulin, 113, 135, "basal insulin analogue", "", +2, Metformin, 148, 157, "metformin", "", +3, HbA1c_target, 182, 194, "target HbA1c", "", +51014, PostprandialBloodGlucose, 209, 235, "postprandial blood glucose", "", +37, Title, 246, 365, "patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison .", "", " \"patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison .\"." +4, Type2Diabetes, 260, 275, "type 2 diabetes", "", " ." +452, Multicenter, 280, 293, "multinational", "", " ." +5, Duration, 296, 305, "24 - week", "", +6, Randomized, 308, 318, "randomized", "", " ." +7, OpenLabel, 321, 333, "open - label", "", " ." +8, Parallel, 336, 352, "parallel - group", "", " ." +12, Author, 366, 376, "Robbins DC", "", " \"Robbins DC\"." +13, Author, 385, 399, "Beisswenger PJ", "", " \"Beisswenger PJ\"." +14, Author, 402, 412, "Ceriello A", "", " \"Ceriello A\"." +15, Author, 415, 426, "Goldberg RB", "", " \"Goldberg RB\"." +16, Author, 429, 437, "Moses RG", "", " \"Moses RG\"." +17, Author, 440, 451, "Pagkalos EM", "", " \"Pagkalos EM\"." +18, Author, 454, 465, "Milicevic Z", "", " \"Milicevic Z\"." +19, Author, 468, 476, "Jones CA", "", " \"Jones CA\"." +20, Author, 479, 487, "Sarwat S", "", " \"Sarwat S\"." +21, Author, 490, 496, "Tan MH", "", " \"Tan MH\"." +22, USA, 615, 618, "USA", "", " ." +229, DisorderOrSyndrome, 652, 660, "diabetes", "", +23, Insulin, 691, 698, "insulin", "", +51199, EndPointDescription, 691, 708, "insulin secretion", "", +453, Insulin, 788, 795, "insulin", "", +24, Insulin, 874, 881, "insulin", "", +51198, EndPointDescription, 874, 891, "insulin secretion", "", +26, Frequency, 919, 931, "once - daily", "", +51196, Insulin, 932, 945, "basal insulin", "", +25, Type2Diabetes, 963, 980, "diabetes mellitus", "", +51197, Lispro50/50, 989, 1014, "lispro mix ( LM ) 50 / 50", "", +28, HbA1c, 1086, 1109, "glycosylated hemoglobin", "", +29, HbA1c, 1112, 1122, "HbA ( lc )", "", +455, PreprandialBloodGlucose, 1129, 1132, "pre", "", +456, PostprandialBloodGlucose, 1139, 1165, "postprandial blood glucose", "", +457, BloodGlucose, 1168, 1170, "BG", "", +38, ObjectiveDescription, 1222, 1407, "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve", "", " \"The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve\"." +240, Insulin, 1293, 1318, "premixed insulin analogue", "", +241, Insulin, 1330, 1363, "50 / 50 basal + prandial insulins", "", +234, RelativeTime, 1377, 1393, "before each meal", "", +458, ObjectiveDescription, 1408, 1568, "lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .", "", " \"lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .\"." +32, Frequency, 1457, 1469, "once - daily", "", +242, Insulin, 1470, 1492, "basal insulin analogue", "", +34, Metformin, 1505, 1514, "metformin", "", +35, Metformin, 1517, 1520, "Met", "", +36, Type2Diabetes, 1542, 1566, "type 2 diabetes mellitus", "", +39, Duration, 1584, 1593, "24 - week", "", " \"24 - week\"." +40, Randomized, 1596, 1606, "randomized", "", +41, OpenLabel, 1609, 1621, "open - label", "", +42, Parallel, 1624, 1640, "parallel - group", "", +247, Multicenter, 1661, 1672, "at 38 sites", "", +248, Australia, 1680, 1689, "Australia", "", " ." +249, Greece, 1692, 1698, "Greece", "", " ." +250, India, 1701, 1706, "India", "", " ." +251, Netherlands, 1709, 1724, "The Netherlands", "", " ." +252, Poland, 1727, 1733, "Poland", "", " ." +253, Country, 1736, 1747, "Puerto Rico", "", " . ." +254, USA, 1758, 1771, "United States", "", +255, AnyGender, 1774, 1789, "Male and female", "", " ." +44, MinAge, 1804, 1806, "35", "", " \"35\"." +45, MaxAge, 1810, 1812, "75", "", " \"75\"." +258, Year, 1813, 1818, "years", "", +56, Precondition, 1819, 2031, "with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months", "", " \"with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months\"." +46, Type2Diabetes, 1824, 1848, "type 2 diabetes mellitus", "", +47, HbA1c, 1856, 1866, "HbA ( 1c )", "", +48, Percentage, 1882, 1883, "%", "", +49, Percentage, 1894, 1895, "%", "", +50, Metformin, 1917, 1926, "metformin", "", +51, Sulfonylureas, 1938, 1950, "sulfonylurea", "", +100509, DoseDescription, 1956, 2004, "a stable dose of 0 to 2 daily insulin injections", "", +53, Frequency, 1980, 1985, "daily", "", +54, Insulin, 1986, 1993, "insulin", "", +100512, DeliveryMethod, 1994, 2004, "injections", "", +55, Duration, 2023, 2031, "3 months", "", +57, Randomized, 2062, 2070, "randomly", "", +51200, Lispro50/50, 2091, 2100, "LM50 / 50", "", " ." +461, Lispro, 2108, 2143, "insulin lispro protamine suspension", "", +100511, DeliveryMethod, 2133, 2143, "suspension", "", +462, Lispro, 2146, 2150, "ILPS", "", +283, Lispro, 2162, 2168, "lispro", "", +58, Frequency, 2171, 2174, "TID", "", " \"TID\"." +59, Metformin, 2180, 2189, "metformin", "", " ." +100513, DoseDescription, 2192, 2250, "to a maximally tolerated daily dosage of 500 - 1000 mg BID", "", " \"to a maximally tolerated daily dosage of 500 - 1000 mg BID\"." +60, Frequency, 2217, 2222, "daily", "", +61, DoseValue, 2233, 2243, "500 - 1000", "", " \"500 - 1000\"." +62, mg, 2244, 2246, "mg", "", " ." +63, Frequency, 2247, 2250, "BID", "", " \"BID\"." +464, Lispro, 2255, 2264, "LM50 / 50", "", +64, Metformin, 2267, 2270, "Met", "", +65, InsulinGlargine, 2276, 2292, "insulin glargine", "", " ." +294, Frequency, 2293, 2295, "QD", "", " \"QD\"." +51225, Bedtime, 2299, 2306, "bedtime", "", " ." +66, Metformin, 2312, 2321, "metformin", "", +67, DoseValue, 2324, 2334, "500 - 1000", "", +68, mg, 2335, 2337, "mg", "", +69, Frequency, 2338, 2341, "BID", "", +70, InsulinGlargine, 2346, 2347, "G", "", +71, Metformin, 2350, 2353, "Met", "", +72, Duration, 2360, 2368, "24 weeks", "", +51204, Lispro50/50, 2376, 2385, "LM50 / 50", "", +73, Metformin, 2388, 2391, "Met", "", +74, Insulin, 2398, 2405, "insulin", "", +467, FastingBloodGlucose_target, 2427, 2498, "target a fasting BG ( FBG ) level of < 6 . 7 mmol / L ( < 120 mg / dL )", "", +296, Millimoles_per_litre, 2472, 2480, "mmol / L", "", +298, Mg_per_deciliter, 2489, 2496, "mg / dL", "", +468, PostprandialBloodGlucose, 2505, 2532, "2 - hour post - prandial BG", "", +469, PostprandialBloodGlucose, 2535, 2539, "PPBG", "", +75, Millimoles_per_litre, 2559, 2567, "mmol / L", "", +76, Mg_per_deciliter, 2576, 2583, "mg / dL", "", +470, FastingBloodGlucose_target, 2616, 2626, "FBG target", "", +77, RelativeTime, 2650, 2659, "presupper", "", +51205, Lispro50/50, 2660, 2669, "LM50 / 50", "", +51206, Lispro75/25, 2673, 2682, "LM75 / 25", "", +273, Percentage, 2688, 2689, "%", "", +473, Lispro, 2690, 2694, "ILPS", "", +274, Percentage, 2700, 2701, "%", "", +300, Lispro, 2702, 2708, "lispro", "", +78, NumberPatientsCT, 2734, 2737, "315", "", " \"315\"." +79, Randomized, 2752, 2762, "randomized", "", +80, Female, 2788, 2797, "158 women", "", " ." +81, Male, 2800, 2807, "157 men", "", " ." +303, AvgAge, 2821, 2827, "57 . 7", "", " \"57 . 7\"." +304, Year, 2828, 2833, "years", "", +83, BMI, 2841, 2856, "body mass index", "", +84, Kg_per_squareMeter, 2866, 2873, "kg / m2", "", +475, Lispro, 2876, 2885, "LM50 / 50", "", +85, Metformin, 2888, 2891, "Met", "", +86, NumberPatientsArm, 2894, 2897, "157", "", " \"157\"." +88, InsulinGlargine, 2909, 2910, "G", "", +89, Metformin, 2913, 2916, "Met", "", +87, NumberPatientsArm, 2919, 2922, "158", "", " \"158\"." +476, TimePoint, 2939, 2947, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +319, Mean, 2954, 2958, "mean", "", " . ." +90, HbA1c, 2966, 2976, "HbA ( 1c )", "", " ." +51207, Lispro50/50, 3014, 3023, "LM50 / 50", "", +91, Metformin, 3026, 3029, "Met", "", +93, InsulinGlargine, 3048, 3049, "G", "", +92, Metformin, 3052, 3055, "Met", "", +94, ResultMeasuredValue, 3064, 3069, "7 . 1", "", " \"7 . 1\"." +96, Percentage, 3070, 3071, "%", "", " ." +98, SdDevResValue, 3074, 3079, "0 . 9", "", " \"0 . 9\"." +271, Percentage, 3080, 3081, "%", "", +95, ResultMeasuredValue, 3087, 3092, "7 . 5", "", " \"7 . 5\"." +97, Percentage, 3093, 3094, "%", "", +99, SdDevResValue, 3097, 3102, "1 . 0", "", " \"1 . 0\"." +269, Percentage, 3103, 3104, "%", "", +100, PvalueDiff, 3109, 3120, "P < 0 . 001", "", " \"P < 0 . 001\"." +101, HbA1c_target, 3159, 3194, "HbA ( 1c ) target of < or = 7 . 0 %", "", " ." +268, Percentage, 3193, 3194, "%", "", +102, NumberAffected, 3209, 3211, "88", "", " \"88\"." +104, PercentageAffected, 3214, 3220, "56 . 1", "", " \"56 . 1\"." +267, Percentage, 3221, 3222, "%", "", +103, NumberAffected, 3228, 3230, "63", "", " \"63\"." +105, PercentageAffected, 3233, 3239, "39 . 9", "", " \"39 . 9\"." +266, Percentage, 3240, 3241, "%", "", +106, PvalueDiff, 3246, 3257, "P = 0 . 005", "", " \"P = 0 . 005\"." +107, InsulinGlargine, 3266, 3267, "G", "", +108, Metformin, 3270, 3273, "Met", "", +340, Mean, 3292, 3296, "mean", "", " . ." +478, FastingBloodGlucose, 3304, 3307, "FBG", "", " ." +109, ResultMeasuredValue, 3316, 3321, "6 . 5", "", " \"6 . 5\"." +111, SdDevResValue, 3324, 3329, "1 . 6", "", " \"1 . 6\"." +110, ResultMeasuredValue, 3335, 3340, "8 . 1", "", " \"8 . 1\"." +112, SdDevResValue, 3343, 3348, "1 . 8", "", " \"1 . 8\"." +113, Millimoles_per_litre, 3351, 3359, "mmol / L", "", " ." +114, PvalueDiff, 3362, 3373, "P < 0 . 001", "", " \"P < 0 . 001\"." +51212, Lispro50/50, 3382, 3391, "LM50 / 50", "", +115, Metformin, 3394, 3397, "Met", "", +349, Mean, 3414, 3418, "mean", "", +480, PreprandialBloodGlucose, 3419, 3433, "preprandial BG", "", +116, TimePoint, 3441, 3449, "prelunch", "", " \"prelunch\". \"prelunch\"." +118, ResultMeasuredValue, 3452, 3457, "7 . 4", "", " \"7 . 4\"." +122, SdDevResValue, 3460, 3465, "1 . 9", "", " \"8 . 9\"." +119, ResultMeasuredValue, 3471, 3476, "7 . 9", "", " \"7 . 9\"." +123, SdDevResValue, 3479, 3484, "2 . 1", "", " \"2 . 1\"." +126, Millimoles_per_litre, 3487, 3495, "mmol / L", "", +128, PvalueDiff, 3498, 3508, "P = 0 . 03", "", " \"P = 0 . 03\"." +117, TimePoint, 3515, 3524, "presupper", "", " \"presupper\". \"presupper\"." +120, ResultMeasuredValue, 3527, 3532, "8 . 3", "", " \"8 . 3\"." +124, SdDevResValue, 3535, 3540, "2 . 0", "", " \"2 . 0\"." +121, ResultMeasuredValue, 3546, 3551, "8 . 9", "", " \"8 . 9\"." +125, SdDevResValue, 3554, 3559, "2 . 8", "", " \"2 . 8\"." +127, Millimoles_per_litre, 3562, 3570, "mmol / L", "", +129, PvalueDiff, 3573, 3583, "P = 0 . 04", "", " \"P = 0 . 04\"." +481, Lispro, 3592, 3601, "LM50 / 50", "", +130, Metformin, 3604, 3607, "Met", "", +365, Mean, 3629, 3633, "mean", "", " . . . ." +482, PostprandialBloodGlucose, 3634, 3647, "2 - hour PPBG", "", " ." +131, TimePoint, 3655, 3668, "postbreakfast", "", " \"postbreakfast\". \"postbreakfast\"." +133, ResultMeasuredValue, 3671, 3676, "8 . 7", "", " \"8 . 7\"." +140, SdDevResValue, 3679, 3684, "2 . 2", "", " \"2 . 2\"." +134, ResultMeasuredValue, 3690, 3695, "9 . 2", "", " \"9 . 2\"." +141, SdDevResValue, 3698, 3703, "2 . 5", "", " \"2 . 5\"." +146, Millimoles_per_litre, 3706, 3714, "mmol / L", "", " . ." +149, PvalueDiff, 3717, 3727, "P = 0 . 03", "", " \"P = 0 . 03\"." +139, TimePoint, 3732, 3741, "postlunch", "", " \"postlunch\". \"postlunch\"." +135, ResultMeasuredValue, 3744, 3749, "8 . 4", "", " \"8 . 4\"." +142, SdDevResValue, 3752, 3757, "1 . 9", "", " \"1 . 9\"." +136, ResultMeasuredValue, 3763, 3768, "9 . 8", "", " \"9 . 8\"." +143, SdDevResValue, 3771, 3776, "2 . 6", "", " \"2 . 6\"." +147, Millimoles_per_litre, 3781, 3789, "mmol / L", "", +150, PvalueDiff, 3792, 3803, "p < 0 . 001", "", " \"p < 0 . 001\"." +132, TimePoint, 3812, 3822, "postsupper", "", " \"postsupper\". \"postsupper\"." +137, ResultMeasuredValue, 3825, 3830, "8 . 7", "", " \"8 . 7\"." +144, SdDevResValue, 3833, 3838, "2 . 2", "", " \"2 . 2\"." +138, ResultMeasuredValue, 3844, 3850, "10 . 7", "", " \"10 . 7\"." +145, SdDevResValue, 3853, 3858, "3 . 2", "", " \"3 . 2\"." +148, Millimoles_per_litre, 3863, 3871, "mmol / L", "", +151, PvalueDiff, 3874, 3885, "P < 0 . 001", "", " \"P < 0 . 001\"." +387, Mean, 3894, 3898, "mean", "", " . ." +483, InsulinDose, 3912, 3925, "insulin doses", "", " . ." +500, TimePoint, 3929, 3944, "study end point", "", " \"study end point\". \"study end point\"." +152, ResultMeasuredValue, 3950, 3955, "0 . 7", "", " \"0 . 7\"." +154, SdDevResValue, 3958, 3963, "0 . 3", "", " \"0 . 3\"." +156, IntUnit_per_Kg, 3966, 3972, "U / kg", "", " ." +484, Lispro, 3980, 3989, "LM50 / 50", "", +158, Metformin, 3992, 3995, "Met", "", +153, ResultMeasuredValue, 4006, 4011, "0 . 6", "", " \"0 . 6\"." +155, SdDevResValue, 4014, 4019, "0 . 3", "", " \"0 . 3\"." +157, IntUnit_per_Kg, 4022, 4028, "U / kg", "", +159, InsulinGlargine, 4036, 4037, "G", "", +160, Metformin, 4040, 4043, "Met", "", +161, PvalueDiff, 4052, 4063, "P < 0 . 001", "", " \"P < 0 . 001\"." +51210, EndPointDescription, 4072, 4093, "mean ( SD ) M - value", "", " . ." +399, Mean, 4072, 4076, "mean", "", " . ." +400, Mean, 4113, 4117, "mean", "", +485, TimePoint, 4212, 4220, "baseline", "", +51211, Lispro50/50, 4252, 4261, "LM50 / 50", "", +164, Metformin, 4264, 4267, "Met", "", +487, TimePoint, 4277, 4286, "end point", "", " \"end point\". \"end point\"." +165, ResultMeasuredValue, 4289, 4295, "17 . 3", "", " \"17 . 3\"." +167, SdDevResValue, 4298, 4304, "13 . 8", "", " \"13 . 8\"." +166, ResultMeasuredValue, 4310, 4316, "25 . 1", "", " \"25 . 1\"." +168, SdDevResValue, 4319, 4325, "24 . 8", "", " \"24 . 8\"." +169, Millimoles_per_litre, 4328, 4336, "mmol / L", "", " ." +170, PvalueDiff, 4339, 4350, "P < 0 . 001", "", " \"P < 0 . 001\"." +183, TimePoint, 4355, 4389, "During the entire treatment period", "", " \"During the entire treatment period\". \"During the entire treatment period\". \"During the entire treatment period\". \"During the entire treatment period\"." +409, Mean, 4392, 4396, "mean", "", " . . . ." +488, Hypoglycemia, 4404, 4411, "overall", "", " ." +489, NocturnalHypoglycemia, 4416, 4438, "nocturnal hypoglycemia", "", " ." +172, BioAndMedicalUnit, 4447, 4479, "episodes per patient for 30 days", "", " . . . ." +173, ResultMeasuredValue, 4542, 4547, "0 . 8", "", " \"0 . 8\"." +175, SdDevResValue, 4550, 4555, "1 . 4", "", " \"1 . 4\"." +174, ResultMeasuredValue, 4561, 4566, "0 . 5", "", " \"0 . 5\"." +176, SdDevResValue, 4569, 4574, "1 . 0", "", " \"1 . 0\"." +177, NocturnalHypoglycemia, 4579, 4588, "nocturnal", "", +178, ResultMeasuredValue, 4591, 4596, "0 . 2", "", " \"0 . 2\"." +180, SdDevResValue, 4599, 4604, "0 . 7", "", " \"0 . 7\"." +179, ResultMeasuredValue, 4610, 4615, "0 . 3", "", " \"0 . 3\"." +181, SdDevResValue, 4618, 4623, "0 . 6", "", " \"0 . 6\"." +423, TimePoint, 4633, 4642, "end point", "", " \"end point\". \"end point\". \"end point\". \"end point\"." +420, Mean, 4649, 4653, "mean", "", +182, NocturnalHypoglycemia, 4661, 4683, "nocturnal hypoglycemia", "", +184, ResultMeasuredValue, 4726, 4731, "0 . 2", "", " \"0 . 2\"." +186, SdDevResValue, 4734, 4739, "0 . 9", "", " \"0 . 9\"." +185, ResultMeasuredValue, 4745, 4750, "0 . 2", "", " \"0 . 2\"." +187, SdDevResValue, 4753, 4758, "0 . 6", "", " \"0 . 6\"." +437, Hypoglycemia, 4801, 4813, "hypoglycemia", "", +51209, Lispro50/50, 4837, 4846, "LM50 / 50", "", +188, Metformin, 4849, 4852, "Met", "", +190, ResultMeasuredValue, 4865, 4870, "0 . 7", "", " \"0 . 7\"." +196, SdDevResValue, 4873, 4878, "1 . 7", "", " \"1 . 7\"." +191, ResultMeasuredValue, 4884, 4889, "0 . 3", "", " \"0 . 3\"." +197, SdDevResValue, 4892, 4897, "0 . 8", "", " \"0 . 8\"." +198, PvalueDiff, 4902, 4912, "P = 0 . 02", "", " \"P = 0 . 02\"." +192, ResultMeasuredValue, 4933, 4938, "0 . 5", "", +194, SdDevResValue, 4941, 4946, "1 . 2", "", +193, ResultMeasuredValue, 4952, 4957, "0 . 1", "", +195, SdDevResValue, 4960, 4965, "0 . 4", "", +199, PvalueDiff, 4970, 4981, "P = 0 . 002", "", +207, ConclusionComment, 4999, 5148, "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels", "", " \"In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels\"." +200, Type2Diabetes, 5022, 5037, "type 2 diabetes", "", +201, RelativeTime, 5040, 5048, "mealtime", "", +51208, Lispro50/50, 5049, 5058, "LM50 / 50", "", +202, Metformin, 5061, 5064, "Met", "", +203, HbA1c, 5101, 5111, "HbA ( 1c )", "", +496, PreprandialBloodGlucose, 5118, 5132, "preprandial BG", "", +497, PostprandialBloodGlucose, 5137, 5141, "PPBG", "", +498, ConclusionComment, 5149, 5261, "( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met .", "", " \"( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met .\"." +499, FastingBloodGlucose, 5162, 5165, "FBG", "", +204, NocturnalHypoglycemia, 5183, 5205, "nocturnal hypoglycemia", "", +205, InsulinGlargine, 5252, 5253, "G", "", +206, Metformin, 5256, 5259, "Met", "", +208, PMID, 5364, 5372, "18158076", "", " \"18158076\"." diff --git a/data/dm2 18158076_admin.n-triples b/data/dm2 18158076_admin.n-triples new file mode 100644 index 0000000..7f0dfa9 --- /dev/null +++ b/data/dm2 18158076_admin.n-triples @@ -0,0 +1,431 @@ +# RDF export of group: Publication + . + "Publication " . + "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in" . + "patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison ." . + "Robbins DC" . + "2007" . + "Clin Ther ." . + "18158076" . + . + "Beisswenger PJ" . + "Ceriello A" . + "Goldberg RB" . + "Moses RG" . + "Pagkalos EM" . + "Milicevic Z" . + "Jones CA" . + "Sarwat S" . + "Tan MH" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve" . + "315" . + "24 - week" . + . + . + . + "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels" . + . + . + . + . + . + "lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus ." . + . + . + . + "( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + "35" . + "75" . + "57 . 7" . + . + "with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint fbg" . + . + . + . + . + . + . + "Endpoint pbg" . + . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint M-value" . + . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + . + . + "Endpoint ppbg" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm lispro + met" . + "157" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm ig + met" . + "158" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention lispro " . + . + "TID" . + . + . + "Intervention ig " . + . + "QD" . + . + . + "Intervention met " . + . + "BID" . + . +# RDF export of group: Medication + . + "Medication lispro" . + . + . + . + . + "Medication ig" . + . + . + . + . + "Medication met" . + . + "500 - 1000" . + . + . + "to a maximally tolerated daily dosage of 500 - 1000 mg BID" . +# RDF export of group: Outcome + . + "Outcome hba1c l" . + . + "7 . 1" . + "0 . 9" . + "24 weeks" . + . + "Outcome hba1c ig" . + . + "7 . 5" . + "1 . 0" . + "24 weeks" . + . + "Outcome hba1c target l" . + . + "88" . + "56 . 1" . + . + "Outcome hba1c target ig" . + . + "63" . + "39 . 9" . + . + "Outcome fbg l" . + . + "8 . 1" . + "1 . 8" . + . + "Outcome fbg ig" . + . + "6 . 5" . + "1 . 6" . + . + "Outcome pbg prelunch l" . + . + "7 . 4" . + "1 . 9" . + "prelunch" . + . + "Outcome pbg prelunch ig" . + . + "7 . 9" . + "2 . 1" . + "prelunch" . + . + "Outcome pbg presupper l" . + . + "8 . 3" . + "2 . 0" . + "presupper" . + . + "Outcome pbg presupper ig" . + . + "8 . 9" . + "2 . 8" . + "presupper" . + . + "Outcome ppbg postbreakfast l" . + . + "8 . 7" . + "2 . 2" . + "postbreakfast" . + . + "Outcome ppbg postbreakfast ig" . + . + "9 . 2" . + "2 . 5" . + "postbreakfast" . + . + "Outcome ppbg postlunch l" . + . + "8 . 4" . + "1 . 9" . + "postlunch" . + . + "Outcome ppbg postlunch ig" . + . + "9 . 8" . + "2 . 6" . + "postlunch" . + . + "Outcome ppbg postsupper l" . + . + "8 . 7" . + "2 . 2" . + "postsupper" . + . + "Outcome ppbg postsupper ig" . + . + "10 . 7" . + "3 . 2" . + "postsupper" . + . + "Outcome id l " . + . + "0 . 7" . + "0 . 3" . + "study end point" . + . + "Outcome id ig" . + . + "0 . 6" . + "0 . 3" . + "study end point" . + . + "Outcome M-value l " . + . + "17 . 3" . + "13 . 8" . + "end point" . + . + "Outcome M-value ig" . + . + "25 . 1" . + "24 . 8" . + "end point" . + . + "Outcome h l" . + . + "0 . 8" . + "1 . 4" . + "During the entire treatment period" . + . + "Outcome h ig" . + . + "0 . 5" . + "1 . 0" . + "During the entire treatment period" . + . + "Outcome nh l" . + . + "0 . 2" . + "0 . 7" . + "During the entire treatment period" . + . + "Outcome nh ig" . + . + "0 . 3" . + "0 . 6" . + "During the entire treatment period" . + . + "Outcome nh endpoint l " . + . + "0 . 2" . + "0 . 9" . + "end point" . + . + "Outcome nh endpoint ig " . + . + "0 . 2" . + "0 . 6" . + "end point" . + . + "Outcome h endpoint l " . + . + "0 . 7" . + "1 . 7" . + "end point" . + . + "Outcome h endpoint ig" . + . + "0 . 3" . + "0 . 8" . + "end point" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups hba1c target" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups fbg" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups pbg prelunch" . + "P = 0 . 03" . + . + . + . + "DiffBetweenGroups pbg presupper " . + "P = 0 . 04" . + . + . + . + "DiffBetweenGroups ppbg postbreakfast" . + "P = 0 . 03" . + . + . + . + "DiffBetweenGroups ppbg postlunch" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups ppbg postsupper" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups id" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups M-value" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups h endpoint" . + "P = 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18158076_akramersunderbrink.annodb b/data/dm2 18158076_akramersunderbrink.annodb new file mode 100644 index 0000000..5bb1a48 --- /dev/null +++ b/data/dm2 18158076_akramersunderbrink.annodb @@ -0,0 +1,246 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22975, Journal, 0, 9, "Clin Ther", "", +22976, PublicationYear, 12, 16, "2007", "", +23107, Title, 47, 300, "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in patients with type 2 diabetes : a multinational , 24 -", "", +23105, Insulin, 64, 105, "basal + prandial insulin analogue mixture", "", +23106, Insulin, 113, 135, "basal insulin analogue", "", +22977, Metformin, 148, 157, "metformin", "", +22978, HbA1c, 189, 194, "HbA1c", "", +22979, Type2Diabetes, 260, 275, "type 2 diabetes", "", +22980, Duration, 296, 305, "24 - week", "", +23108, Title, 301, 365, "week , randomized , open - label , parallel - group comparison .", "", +22981, Randomized, 308, 318, "randomized", "", +22982, OpenLabel, 321, 333, "open - label", "", +22983, Parallel, 336, 352, "parallel - group", "", +22984, Author, 366, 376, "Robbins DC", "", +22985, Author, 385, 399, "Beisswenger PJ", "", +22986, Author, 402, 412, "Ceriello A", "", +22987, Author, 415, 426, "Goldberg RB", "", +22988, Author, 429, 437, "Moses RG", "", +22989, Author, 440, 451, "Pagkalos EM", "", +22990, Author, 454, 465, "Milicevic Z", "", +22991, Author, 468, 476, "Jones CA", "", +22992, Author, 479, 487, "Sarwat S", "", +22993, Author, 490, 496, "Tan MH", "", +22994, USA, 615, 618, "USA", "", +22995, DisorderOrSyndrome, 652, 660, "diabetes", "", +22997, Lispro, 989, 995, "lispro", "", +22998, HbA1c, 1086, 1109, "glycosylated hemoglobin", "", +22999, HbA1c, 1112, 1122, "HbA ( lc )", "", +23005, ObjectiveDescription, 1222, 1475, "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve lower overall and mealtime glycemic control than once - daily basal", "", +23007, Insulin, 1293, 1318, "premixed insulin analogue", "", +23008, Insulin, 1330, 1363, "50 / 50 basal + prandial insulins", "", +23001, RelativeTime, 1377, 1393, "before each meal", "", +23000, Frequency, 1457, 1469, "once - daily", "", +23009, Insulin, 1470, 1492, "basal insulin analogue", "", +23006, ObjectiveDescription, 1476, 1568, "insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .", "", +23002, Metformin, 1505, 1514, "metformin", "", +23003, Metformin, 1517, 1520, "Met", "", +23004, Type2Diabetes, 1542, 1566, "type 2 diabetes mellitus", "", +23010, Duration, 1584, 1593, "24 - week", "", +23011, Randomized, 1596, 1606, "randomized", "", +23012, OpenLabel, 1609, 1621, "open - label", "", +23013, Parallel, 1624, 1640, "parallel - group", "", +23014, Multicenter, 1661, 1672, "at 38 sites", "", +23015, Australia, 1680, 1689, "Australia", "", +23016, Greece, 1692, 1698, "Greece", "", +23017, India, 1701, 1706, "India", "", +23018, Netherlands, 1709, 1724, "The Netherlands", "", +23019, Poland, 1727, 1733, "Poland", "", +23020, Country, 1736, 1747, "Puerto Rico", "", +23021, USA, 1758, 1771, "United States", "", +23022, AnyGender, 1774, 1789, "Male and female", "", +23023, MinAge, 1804, 1806, "35", "", +23024, MaxAge, 1810, 1812, "75", "", +23025, Year, 1813, 1818, "years", "", +23026, Type2Diabetes, 1824, 1848, "type 2 diabetes mellitus", "", +23028, Precondition, 1853, 1895, "an HbA ( 1c ) level of 6 . 5 % to 11 . 0 %", "", +23027, HbA1c, 1856, 1866, "HbA ( 1c )", "", +23029, Percentage, 1882, 1883, "%", "", +23030, Percentage, 1894, 1895, "%", "", +23047, Precondition, 1898, 2031, "who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months", "", +23042, Metformin, 1917, 1926, "metformin", "", +23043, Sulfonylureas, 1938, 1950, "sulfonylurea", "", +23044, Frequency, 1973, 1985, "0 to 2 daily", "", +23045, Insulin, 1986, 1993, "insulin", "", +23046, Duration, 2023, 2031, "3 months", "", +23048, Randomized, 2062, 2070, "randomly", "", +23031, Percentage, 2106, 2107, "%", "", +23049, Drug, 2108, 2143, "insulin lispro protamine suspension", "", +23032, Percentage, 2160, 2161, "%", "", +23051, Lispro, 2162, 2168, "lispro", "", +23052, Metformin, 2180, 2189, "metformin", "", +23053, DoseValue, 2233, 2243, "500 - 1000", "", +23055, mg, 2244, 2246, "mg", "", +23054, Frequency, 2247, 2250, "BID", "", +23078, Metformin, 2267, 2270, "Met", "", +23056, InsulinGlargine, 2276, 2292, "insulin glargine", "", +23062, Frequency, 2293, 2295, "QD", "", +23063, Bedtime, 2299, 2306, "bedtime", "", +23057, Metformin, 2312, 2321, "metformin", "", +23058, DoseValue, 2324, 2334, "500 - 1000", "", +23059, mg, 2335, 2337, "mg", "", +23060, Frequency, 2338, 2341, "BID", "", +23083, InsulinGlargine, 2346, 2347, "G", "", +23079, Metformin, 2350, 2353, "Met", "", +23061, Duration, 2360, 2368, "24 weeks", "", +23084, Metformin, 2388, 2391, "Met", "", +23064, Millimoles_per_litre, 2472, 2480, "mmol / L", "", +23066, Mg_per_deciliter, 2489, 2496, "mg / dL", "", +23065, Millimoles_per_litre, 2559, 2567, "mmol / L", "", +23067, Mg_per_deciliter, 2576, 2583, "mg / dL", "", +23040, Percentage, 2688, 2689, "%", "", +23041, Percentage, 2700, 2701, "%", "", +23068, Lispro, 2702, 2708, "lispro", "", +23069, NumberPatientsCT, 2734, 2737, "315", "", +23071, Randomized, 2752, 2762, "randomized", "", +23072, AvgAge, 2821, 2827, "57 . 7", "", +23073, Year, 2828, 2833, "years", "", +23085, Precondition, 2836, 2873, "mean body mass index , 32 . 1 kg / m2", "", +23074, BMI, 2841, 2856, "body mass index", "", +23075, Kg_per_squareMeter, 2866, 2873, "kg / m2", "", +23081, Metformin, 2888, 2891, "Met", "", +23076, NumberPatientsArm, 2894, 2897, "157", "", +23082, InsulinGlargine, 2909, 2910, "G", "", +23080, Metformin, 2913, 2916, "Met", "", +23077, NumberPatientsArm, 2919, 2922, "158", "", +23086, Duration, 2939, 2947, "24 weeks", "", +23088, Mean, 2954, 2958, "mean", "", +23087, HbA1c, 2966, 2976, "HbA ( 1c )", "", +23089, Metformin, 3026, 3029, "Met", "", +23090, InsulinGlargine, 3048, 3049, "G", "", +23091, Metformin, 3052, 3055, "Met", "", +23092, ResultMeasuredValue, 3064, 3069, "7 . 1", "", +23039, Percentage, 3070, 3071, "%", "", +23094, SdDevResValue, 3074, 3079, "0 . 9", "", +23038, Percentage, 3080, 3081, "%", "", +23093, ResultMeasuredValue, 3087, 3092, "7 . 5", "", +23037, Percentage, 3093, 3094, "%", "", +23095, SdDevResValue, 3097, 3102, "1 . 0", "", +23036, Percentage, 3103, 3104, "%", "", +23096, PvalueDiff, 3109, 3120, "P < 0 . 001", "", +23097, HbA1c_target, 3159, 3194, "HbA ( 1c ) target of < or = 7 . 0 %", "", +23035, Percentage, 3193, 3194, "%", "", +23098, NumberAffected, 3209, 3211, "88", "", +23102, PercentageAffected, 3214, 3220, "56 . 1", "", +23034, Percentage, 3221, 3222, "%", "", +23101, NumberAffected, 3228, 3230, "63", "", +23103, PercentageAffected, 3233, 3239, "39 . 9", "", +23033, Percentage, 3240, 3241, "%", "", +23104, PvalueDiff, 3246, 3257, "P = 0 . 005", "", +23109, InsulinGlargine, 3266, 3267, "G", "", +23110, Metformin, 3270, 3273, "Met", "", +23111, Mean, 3292, 3296, "mean", "", +23112, EndPointDescription, 3304, 3307, "FBG", "", +23115, ResultMeasuredValue, 3316, 3321, "6 . 5", "", +23117, SdDevResValue, 3324, 3329, "1 . 6", "", +23116, ResultMeasuredValue, 3335, 3340, "8 . 1", "", +23118, SdDevResValue, 3343, 3348, "1 . 8", "", +23113, Millimoles_per_litre, 3351, 3359, "mmol / L", "", +23114, PvalueDiff, 3362, 3373, "P < 0 . 001", "", +23119, Metformin, 3394, 3397, "Met", "", +23120, Mean, 3414, 3418, "mean", "", +23121, EndPointDescription, 3419, 3449, "preprandial BG levels prelunch", "", +23123, ResultMeasuredValue, 3452, 3457, "7 . 4", "", +23127, SdDevResValue, 3460, 3465, "1 . 9", "", +23124, ResultMeasuredValue, 3471, 3476, "7 . 9", "", +23128, SdDevResValue, 3479, 3484, "2 . 1", "", +23131, Millimoles_per_litre, 3487, 3495, "mmol / L", "", +23133, PvalueDiff, 3498, 3508, "P = 0 . 03", "", +23122, EndPointDescription, 3515, 3524, "presupper", "", +23125, ResultMeasuredValue, 3527, 3532, "8 . 3", "", +23129, SdDevResValue, 3535, 3540, "2 . 0", "", +23126, ResultMeasuredValue, 3546, 3551, "8 . 9", "", +23130, SdDevResValue, 3554, 3559, "2 . 8", "", +23132, Millimoles_per_litre, 3562, 3570, "mmol / L", "", +23134, PvalueDiff, 3573, 3583, "P = 0 . 04", "", +23135, Metformin, 3604, 3607, "Met", "", +23136, Mean, 3629, 3633, "mean", "", +23137, EndPointDescription, 3634, 3668, "2 - hour PPBG values postbreakfast", "", +23140, ResultMeasuredValue, 3671, 3676, "8 . 7", "", +23146, SdDevResValue, 3679, 3684, "2 . 2", "", +23141, ResultMeasuredValue, 3690, 3695, "9 . 2", "", +23147, SdDevResValue, 3698, 3703, "2 . 5", "", +23152, Millimoles_per_litre, 3706, 3714, "mmol / L", "", +23155, PvalueDiff, 3717, 3727, "P = 0 . 03", "", +23138, EndPointDescription, 3732, 3741, "postlunch", "", +23142, ResultMeasuredValue, 3744, 3749, "8 . 4", "", +23148, SdDevResValue, 3752, 3757, "1 . 9", "", +23143, ResultMeasuredValue, 3763, 3768, "9 . 8", "", +23149, SdDevResValue, 3771, 3776, "2 . 6", "", +23153, Millimoles_per_litre, 3781, 3789, "mmol / L", "", +23156, PvalueDiff, 3792, 3803, "p < 0 . 001", "", +23139, EndPointDescription, 3812, 3822, "postsupper", "", +23144, ResultMeasuredValue, 3825, 3830, "8 . 7", "", +23150, SdDevResValue, 3833, 3838, "2 . 2", "", +23145, ResultMeasuredValue, 3844, 3850, "10 . 7", "", +23151, SdDevResValue, 3853, 3858, "3 . 2", "", +23154, Millimoles_per_litre, 3863, 3871, "mmol / L", "", +23157, PvalueDiff, 3874, 3885, "P < 0 . 001", "", +23158, Mean, 3894, 3898, "mean", "", +23159, EndPointDescription, 3906, 3925, "total insulin doses", "", +39166, TimePoint, 3929, 3944, "study end point", "", +23160, ResultMeasuredValue, 3950, 3955, "0 . 7", "", +23162, SdDevResValue, 3958, 3963, "0 . 3", "", +23164, IntUnit_per_Kg, 3966, 3972, "U / kg", "", +23171, Metformin, 3992, 3995, "Met", "", +23161, ResultMeasuredValue, 4006, 4011, "0 . 6", "", +23163, SdDevResValue, 4014, 4019, "0 . 3", "", +23167, IntUnit_per_Kg, 4022, 4028, "U / kg", "", +23168, InsulinGlargine, 4036, 4037, "G", "", +23169, Metformin, 4040, 4043, "Met", "", +23170, PvalueDiff, 4052, 4063, "P < 0 . 001", "", +23172, Mean, 4072, 4076, "mean", "", +23174, EndPointDescription, 4084, 4161, "M - value ( an expression of mean glycemia and the effect of glucose swings )", "", +23173, Mean, 4113, 4117, "mean", "", +39168, TimePoint, 4212, 4220, "baseline", "", +23175, Metformin, 4264, 4267, "Met", "", +39167, TimePoint, 4277, 4286, "end point", "", +23176, ResultMeasuredValue, 4289, 4295, "17 . 3", "", +23178, SdDevResValue, 4298, 4304, "13 . 8", "", +23177, ResultMeasuredValue, 4310, 4316, "25 . 1", "", +23179, SdDevResValue, 4319, 4325, "24 . 8", "", +23180, Millimoles_per_litre, 4328, 4336, "mmol / L", "", +23181, PvalueDiff, 4339, 4350, "P < 0 . 001", "", +23182, Mean, 4392, 4396, "mean", "", +23183, Hypoglycemia, 4426, 4481, "hypoglycemia rates ( episodes per patient for 30 days )", "", +23188, Hypoglycemia, 4532, 4539, "overall", "", +23184, ResultMeasuredValue, 4542, 4547, "0 . 8", "", +23191, SdDevResValue, 4550, 4555, "1 . 4", "", +23185, ResultMeasuredValue, 4561, 4566, "0 . 5", "", +23192, SdDevResValue, 4569, 4574, "1 . 0", "", +23197, NocturnalHypoglycemia, 4579, 4588, "nocturnal", "", +23186, ResultMeasuredValue, 4591, 4596, "0 . 2", "", +23193, SdDevResValue, 4599, 4604, "0 . 7", "", +23187, ResultMeasuredValue, 4610, 4615, "0 . 3", "", +23194, SdDevResValue, 4618, 4623, "0 . 6", "", +23198, TimePoint, 4633, 4642, "end point", "", +23195, Mean, 4649, 4653, "mean", "", +23196, NocturnalHypoglycemia, 4661, 4689, "nocturnal hypoglycemia rates", "", +23199, ResultMeasuredValue, 4726, 4731, "0 . 2", "", +23205, SdDevResValue, 4734, 4739, "0 . 9", "", +23200, ResultMeasuredValue, 4745, 4750, "0 . 2", "", +23206, SdDevResValue, 4753, 4758, "0 . 6", "", +23212, Hypoglycemia, 4801, 4819, "hypoglycemia rates", "", +23211, Metformin, 4849, 4852, "Met", "", +23213, Hypoglycemia, 4855, 4862, "overall", "", +23201, ResultMeasuredValue, 4865, 4870, "0 . 7", "", +23207, SdDevResValue, 4873, 4878, "1 . 7", "", +23202, ResultMeasuredValue, 4884, 4889, "0 . 3", "", +23208, SdDevResValue, 4892, 4897, "0 . 8", "", +23215, PvalueDiff, 4902, 4912, "P = 0 . 02", "", +23214, Hypoglycemia, 4915, 4930, "non - nocturnal", "", +23203, ResultMeasuredValue, 4933, 4938, "0 . 5", "", +23209, SdDevResValue, 4941, 4946, "1 . 2", "", +23204, ResultMeasuredValue, 4952, 4957, "0 . 1", "", +23210, SdDevResValue, 4960, 4965, "0 . 4", "", +23216, PvalueDiff, 4970, 4981, "P = 0 . 002", "", +23223, ConclusionComment, 4999, 5253, "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels ( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G", "", +23217, Type2Diabetes, 5022, 5037, "type 2 diabetes", "", +23218, Metformin, 5061, 5064, "Met", "", +23219, HbA1c, 5101, 5111, "HbA ( 1c )", "", +23220, NocturnalHypoglycemia, 5183, 5205, "nocturnal hypoglycemia", "", +23221, InsulinGlargine, 5252, 5253, "G", "", +23224, ConclusionComment, 5254, 5261, "+ Met .", "", +23222, Metformin, 5256, 5259, "Met", "", +23225, PMID, 5364, 5372, "18158076", "", diff --git a/data/dm2 18158076_akramersunderbrink.n-triples b/data/dm2 18158076_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18158076_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18158076_export.csv b/data/dm2 18158076_export.csv new file mode 100644 index 0000000..f3282f8 --- /dev/null +++ b/data/dm2 18158076_export.csv @@ -0,0 +1,1358 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +347, 1, 1, 1, 0, 4, 0, 4, "Clin" +347, 1, 2, 2, 5, 9, 5, 9, "Ther" +347, 1, 3, 3, 10, 11, 10, 11, "." +347, 2, 1, 4, 0, 4, 12, 16, "2007" +347, 2, 2, 5, 5, 8, 17, 20, "Nov" +347, 2, 3, 6, 9, 10, 21, 22, ";" +347, 2, 4, 7, 11, 13, 23, 25, "29" +347, 2, 5, 8, 14, 15, 26, 27, "(" +347, 2, 6, 9, 16, 18, 28, 30, "11" +347, 2, 7, 10, 19, 20, 31, 32, ")" +347, 2, 8, 11, 21, 22, 33, 34, ":" +347, 2, 9, 12, 23, 27, 35, 39, "2349" +347, 2, 10, 13, 28, 29, 40, 41, "-" +347, 2, 11, 14, 30, 32, 42, 44, "64" +347, 2, 12, 15, 33, 34, 45, 46, "." +347, 3, 1, 16, 0, 8, 47, 55, "Mealtime" +347, 3, 2, 17, 9, 11, 56, 58, "50" +347, 3, 3, 18, 12, 13, 59, 60, "/" +347, 3, 4, 19, 14, 16, 61, 63, "50" +347, 3, 5, 20, 17, 22, 64, 69, "basal" +347, 3, 6, 21, 23, 24, 70, 71, "+" +347, 3, 7, 22, 25, 33, 72, 80, "prandial" +347, 3, 8, 23, 34, 41, 81, 88, "insulin" +347, 3, 9, 24, 42, 50, 89, 97, "analogue" +347, 3, 10, 25, 51, 58, 98, 105, "mixture" +347, 3, 11, 26, 59, 63, 106, 110, "with" +347, 3, 12, 27, 64, 65, 111, 112, "a" +347, 3, 13, 28, 66, 71, 113, 118, "basal" +347, 3, 14, 29, 72, 79, 119, 126, "insulin" +347, 3, 15, 30, 80, 88, 127, 135, "analogue" +347, 3, 16, 31, 89, 90, 136, 137, "," +347, 3, 17, 32, 91, 95, 138, 142, "both" +347, 3, 18, 33, 96, 100, 143, 147, "plus" +347, 3, 19, 34, 101, 110, 148, 157, "metformin" +347, 3, 20, 35, 111, 112, 158, 159, "," +347, 3, 21, 36, 113, 115, 160, 162, "in" +347, 3, 22, 37, 116, 119, 163, 166, "the" +347, 3, 23, 38, 120, 131, 167, 178, "achievement" +347, 3, 24, 39, 132, 134, 179, 181, "of" +347, 3, 25, 40, 135, 141, 182, 188, "target" +347, 3, 26, 41, 142, 147, 189, 194, "HbA1c" +347, 3, 27, 42, 148, 151, 195, 198, "and" +347, 3, 28, 43, 152, 155, 199, 202, "pre" +347, 3, 29, 44, 156, 157, 203, 204, "-" +347, 3, 30, 45, 158, 161, 205, 208, "and" +347, 3, 31, 46, 162, 174, 209, 221, "postprandial" +347, 3, 32, 47, 175, 180, 222, 227, "blood" +347, 3, 33, 48, 181, 188, 228, 235, "glucose" +347, 3, 34, 49, 189, 195, 236, 242, "levels" +347, 3, 35, 50, 196, 198, 243, 245, "in" +347, 3, 36, 51, 199, 207, 246, 254, "patients" +347, 3, 37, 52, 208, 212, 255, 259, "with" +347, 3, 38, 53, 213, 217, 260, 264, "type" +347, 3, 39, 54, 218, 219, 265, 266, "2" +347, 3, 40, 55, 220, 228, 267, 275, "diabetes" +347, 3, 41, 56, 229, 230, 276, 277, ":" +347, 3, 42, 57, 231, 232, 278, 279, "a" +347, 3, 43, 58, 233, 246, 280, 293, "multinational" +347, 3, 44, 59, 247, 248, 294, 295, "," +347, 3, 45, 60, 249, 251, 296, 298, "24" +347, 3, 46, 61, 252, 253, 299, 300, "-" +347, 3, 47, 62, 254, 258, 301, 305, "week" +347, 3, 48, 63, 259, 260, 306, 307, "," +347, 3, 49, 64, 261, 271, 308, 318, "randomized" +347, 3, 50, 65, 272, 273, 319, 320, "," +347, 3, 51, 66, 274, 278, 321, 325, "open" +347, 3, 52, 67, 279, 280, 326, 327, "-" +347, 3, 53, 68, 281, 286, 328, 333, "label" +347, 3, 54, 69, 287, 288, 334, 335, "," +347, 3, 55, 70, 289, 297, 336, 344, "parallel" +347, 3, 56, 71, 298, 299, 345, 346, "-" +347, 3, 57, 72, 300, 305, 347, 352, "group" +347, 3, 58, 73, 306, 316, 353, 363, "comparison" +347, 3, 59, 74, 317, 318, 364, 365, "." +347, 4, 1, 75, 0, 7, 366, 373, "Robbins" +347, 4, 2, 76, 8, 10, 374, 376, "DC" +347, 4, 3, 77, 11, 12, 377, 378, "(" +347, 4, 4, 78, 13, 14, 379, 380, "1" +347, 4, 5, 79, 15, 16, 381, 382, ")" +347, 4, 6, 80, 17, 18, 383, 384, "," +347, 4, 7, 81, 19, 30, 385, 396, "Beisswenger" +347, 4, 8, 82, 31, 33, 397, 399, "PJ" +347, 4, 9, 83, 34, 35, 400, 401, "," +347, 4, 10, 84, 36, 44, 402, 410, "Ceriello" +347, 4, 11, 85, 45, 46, 411, 412, "A" +347, 4, 12, 86, 47, 48, 413, 414, "," +347, 4, 13, 87, 49, 57, 415, 423, "Goldberg" +347, 4, 14, 88, 58, 60, 424, 426, "RB" +347, 4, 15, 89, 61, 62, 427, 428, "," +347, 4, 16, 90, 63, 68, 429, 434, "Moses" +347, 4, 17, 91, 69, 71, 435, 437, "RG" +347, 4, 18, 92, 72, 73, 438, 439, "," +347, 4, 19, 93, 74, 82, 440, 448, "Pagkalos" +347, 4, 20, 94, 83, 85, 449, 451, "EM" +347, 4, 21, 95, 86, 87, 452, 453, "," +347, 4, 22, 96, 88, 97, 454, 463, "Milicevic" +347, 4, 23, 97, 98, 99, 464, 465, "Z" +347, 4, 24, 98, 100, 101, 466, 467, "," +347, 4, 25, 99, 102, 107, 468, 473, "Jones" +347, 4, 26, 100, 108, 110, 474, 476, "CA" +347, 4, 27, 101, 111, 112, 477, 478, "," +347, 4, 28, 102, 113, 119, 479, 485, "Sarwat" +347, 4, 29, 103, 120, 121, 486, 487, "S" +347, 4, 30, 104, 122, 123, 488, 489, "," +347, 4, 31, 105, 124, 127, 490, 493, "Tan" +347, 4, 32, 106, 128, 130, 494, 496, "MH" +347, 4, 33, 107, 131, 132, 497, 498, "." +347, 5, 1, 108, 0, 6, 499, 505, "Author" +347, 5, 2, 109, 7, 18, 506, 517, "information" +347, 5, 3, 110, 19, 20, 518, 519, ":" +347, 5, 4, 111, 21, 22, 520, 521, "(" +347, 5, 5, 112, 23, 24, 522, 523, "1" +347, 5, 6, 113, 25, 26, 524, 525, ")" +347, 5, 7, 114, 27, 35, 526, 534, "Diabetes" +347, 5, 8, 115, 36, 39, 535, 538, "and" +347, 5, 9, 116, 40, 49, 539, 548, "Endocrine" +347, 5, 10, 117, 50, 58, 549, 557, "Platform" +347, 5, 11, 118, 59, 63, 558, 562, "Team" +347, 5, 12, 119, 64, 65, 563, 564, "," +347, 5, 13, 120, 66, 69, 565, 568, "Eli" +347, 5, 14, 121, 70, 75, 569, 574, "Lilly" +347, 5, 15, 122, 76, 79, 575, 578, "and" +347, 5, 16, 123, 80, 87, 579, 586, "Company" +347, 5, 17, 124, 88, 89, 587, 588, "," +347, 5, 18, 125, 90, 102, 589, 601, "Indianapolis" +347, 5, 19, 126, 103, 104, 602, 603, "," +347, 5, 20, 127, 105, 107, 604, 606, "IN" +347, 5, 21, 128, 108, 113, 607, 612, "46285" +347, 5, 22, 129, 114, 115, 613, 614, "," +347, 5, 23, 130, 116, 119, 615, 618, "USA" +347, 5, 24, 131, 120, 121, 619, 620, "." +347, 6, 1, 132, 0, 10, 621, 631, "BACKGROUND" +347, 6, 2, 133, 11, 12, 632, 633, ":" +347, 6, 3, 134, 13, 15, 634, 636, "In" +347, 6, 4, 135, 16, 22, 637, 643, "people" +347, 6, 5, 136, 23, 30, 644, 651, "without" +347, 6, 6, 137, 31, 39, 652, 660, "diabetes" +347, 6, 7, 138, 40, 41, 661, 662, "," +347, 6, 8, 139, 42, 55, 663, 676, "approximately" +347, 6, 9, 140, 56, 58, 677, 679, "50" +347, 6, 10, 141, 59, 60, 680, 681, "%" +347, 6, 11, 142, 61, 63, 682, 684, "of" +347, 6, 12, 143, 64, 69, 685, 690, "daily" +347, 6, 13, 144, 70, 77, 691, 698, "insulin" +347, 6, 14, 145, 78, 87, 699, 708, "secretion" +347, 6, 15, 146, 88, 90, 709, 711, "is" +347, 6, 16, 147, 91, 96, 712, 717, "basal" +347, 6, 17, 148, 97, 100, 718, 721, "and" +347, 6, 18, 149, 101, 104, 722, 725, "the" +347, 6, 19, 150, 105, 114, 726, 735, "remainder" +347, 6, 20, 151, 115, 117, 736, 738, "is" +347, 6, 21, 152, 118, 130, 739, 751, "postprandial" +347, 6, 22, 153, 131, 132, 752, 753, "." +347, 7, 1, 154, 0, 5, 754, 759, "Hence" +347, 7, 2, 155, 6, 7, 760, 761, "," +347, 7, 3, 156, 8, 10, 762, 764, "it" +347, 7, 4, 157, 11, 16, 765, 770, "would" +347, 7, 5, 158, 17, 19, 771, 773, "be" +347, 7, 6, 159, 20, 28, 774, 782, "expected" +347, 7, 7, 160, 29, 33, 783, 787, "that" +347, 7, 8, 161, 34, 41, 788, 795, "insulin" +347, 7, 9, 162, 42, 53, 796, 807, "replacement" +347, 7, 10, 163, 54, 61, 808, 815, "therapy" +347, 7, 11, 164, 62, 64, 816, 818, "in" +347, 7, 12, 165, 65, 66, 819, 820, "a" +347, 7, 13, 166, 67, 69, 821, 823, "50" +347, 7, 14, 167, 70, 71, 824, 825, "/" +347, 7, 15, 168, 72, 74, 826, 828, "50" +347, 7, 16, 169, 75, 80, 829, 834, "ratio" +347, 7, 17, 170, 81, 85, 835, 839, "with" +347, 7, 18, 171, 86, 90, 840, 844, "each" +347, 7, 19, 172, 91, 95, 845, 849, "meal" +347, 7, 20, 173, 96, 101, 850, 855, "would" +347, 7, 21, 174, 102, 107, 856, 861, "mimic" +347, 7, 22, 175, 108, 119, 862, 873, "physiologic" +347, 7, 23, 176, 120, 127, 874, 881, "insulin" +347, 7, 24, 177, 128, 137, 882, 891, "secretion" +347, 7, 25, 178, 138, 144, 892, 898, "better" +347, 7, 26, 179, 145, 149, 899, 903, "than" +347, 7, 27, 180, 150, 159, 904, 913, "treatment" +347, 7, 28, 181, 160, 164, 914, 918, "with" +347, 7, 29, 182, 165, 169, 919, 923, "once" +347, 7, 30, 183, 170, 171, 924, 925, "-" +347, 7, 31, 184, 172, 177, 926, 931, "daily" +347, 7, 32, 185, 178, 183, 932, 937, "basal" +347, 7, 33, 186, 184, 191, 938, 945, "insulin" +347, 7, 34, 187, 192, 194, 946, 948, "in" +347, 7, 35, 188, 195, 203, 949, 957, "patients" +347, 7, 36, 189, 204, 208, 958, 962, "with" +347, 7, 37, 190, 209, 217, 963, 971, "diabetes" +347, 7, 38, 191, 218, 226, 972, 980, "mellitus" +347, 7, 39, 192, 227, 228, 981, 982, "." +347, 8, 1, 193, 0, 5, 983, 988, "Using" +347, 8, 2, 194, 6, 12, 989, 995, "lispro" +347, 8, 3, 195, 13, 16, 996, 999, "mix" +347, 8, 4, 196, 17, 18, 1000, 1001, "(" +347, 8, 5, 197, 19, 21, 1002, 1004, "LM" +347, 8, 6, 198, 22, 23, 1005, 1006, ")" +347, 8, 7, 199, 24, 26, 1007, 1009, "50" +347, 8, 8, 200, 27, 28, 1010, 1011, "/" +347, 8, 9, 201, 29, 31, 1012, 1014, "50" +347, 8, 10, 202, 32, 38, 1015, 1021, "before" +347, 8, 11, 203, 39, 44, 1022, 1027, "meals" +347, 8, 12, 204, 45, 48, 1028, 1031, "may" +347, 8, 13, 205, 49, 51, 1032, 1034, "be" +347, 8, 14, 206, 52, 53, 1035, 1036, "a" +347, 8, 15, 207, 54, 61, 1037, 1044, "logical" +347, 8, 16, 208, 62, 70, 1045, 1053, "approach" +347, 8, 17, 209, 71, 73, 1054, 1056, "to" +347, 8, 18, 210, 74, 83, 1057, 1066, "achieving" +347, 8, 19, 211, 84, 92, 1067, 1075, "glycemic" +347, 8, 20, 212, 93, 100, 1076, 1083, "targets" +347, 8, 21, 213, 101, 102, 1084, 1085, "(" +347, 8, 22, 214, 103, 115, 1086, 1098, "glycosylated" +347, 8, 23, 215, 116, 126, 1099, 1109, "hemoglobin" +347, 8, 24, 216, 127, 128, 1110, 1111, "[" +347, 8, 25, 217, 129, 132, 1112, 1115, "HbA" +347, 8, 26, 218, 133, 134, 1116, 1117, "(" +347, 8, 27, 219, 135, 137, 1118, 1120, "lc" +347, 8, 28, 220, 138, 139, 1121, 1122, ")" +347, 8, 29, 221, 140, 141, 1123, 1124, "]" +347, 8, 30, 222, 142, 145, 1125, 1128, "and" +347, 8, 31, 223, 146, 149, 1129, 1132, "pre" +347, 8, 32, 224, 150, 151, 1133, 1134, "-" +347, 8, 33, 225, 152, 155, 1135, 1138, "and" +347, 8, 34, 226, 156, 168, 1139, 1151, "postprandial" +347, 8, 35, 227, 169, 174, 1152, 1157, "blood" +347, 8, 36, 228, 175, 182, 1158, 1165, "glucose" +347, 8, 37, 229, 183, 184, 1166, 1167, "[" +347, 8, 38, 230, 185, 187, 1168, 1170, "BG" +347, 8, 39, 231, 188, 189, 1171, 1172, "]" +347, 8, 40, 232, 190, 204, 1173, 1187, "concentrations" +347, 8, 41, 233, 205, 206, 1188, 1189, ")" +347, 8, 42, 234, 207, 209, 1190, 1192, "in" +347, 8, 43, 235, 210, 215, 1193, 1198, "these" +347, 8, 44, 236, 216, 224, 1199, 1207, "patients" +347, 8, 45, 237, 225, 226, 1208, 1209, "." +347, 9, 1, 238, 0, 9, 1210, 1219, "OBJECTIVE" +347, 9, 2, 239, 10, 11, 1220, 1221, ":" +347, 9, 3, 240, 12, 15, 1222, 1225, "The" +347, 9, 4, 241, 16, 19, 1226, 1229, "aim" +347, 9, 5, 242, 20, 22, 1230, 1232, "of" +347, 9, 6, 243, 23, 27, 1233, 1237, "this" +347, 9, 7, 244, 28, 33, 1238, 1243, "study" +347, 9, 8, 245, 34, 37, 1244, 1247, "was" +347, 9, 9, 246, 38, 40, 1248, 1250, "to" +347, 9, 10, 247, 41, 45, 1251, 1255, "test" +347, 9, 11, 248, 46, 49, 1256, 1259, "the" +347, 9, 12, 249, 50, 60, 1260, 1270, "hypothesis" +347, 9, 13, 250, 61, 65, 1271, 1275, "that" +347, 9, 14, 251, 66, 75, 1276, 1285, "treatment" +347, 9, 15, 252, 76, 80, 1286, 1290, "with" +347, 9, 16, 253, 81, 82, 1291, 1292, "a" +347, 9, 17, 254, 83, 91, 1293, 1301, "premixed" +347, 9, 18, 255, 92, 99, 1302, 1309, "insulin" +347, 9, 19, 256, 100, 108, 1310, 1318, "analogue" +347, 9, 20, 257, 109, 119, 1319, 1329, "containing" +347, 9, 21, 258, 120, 122, 1330, 1332, "50" +347, 9, 22, 259, 123, 124, 1333, 1334, "/" +347, 9, 23, 260, 125, 127, 1335, 1337, "50" +347, 9, 24, 261, 128, 133, 1338, 1343, "basal" +347, 9, 25, 262, 134, 135, 1344, 1345, "+" +347, 9, 26, 263, 136, 144, 1346, 1354, "prandial" +347, 9, 27, 264, 145, 153, 1355, 1363, "insulins" +347, 9, 28, 265, 154, 166, 1364, 1376, "administered" +347, 9, 29, 266, 167, 173, 1377, 1383, "before" +347, 9, 30, 267, 174, 178, 1384, 1388, "each" +347, 9, 31, 268, 179, 183, 1389, 1393, "meal" +347, 9, 32, 269, 184, 189, 1394, 1399, "would" +347, 9, 33, 270, 190, 197, 1400, 1407, "achieve" +347, 9, 34, 271, 198, 203, 1408, 1413, "lower" +347, 9, 35, 272, 204, 211, 1414, 1421, "overall" +347, 9, 36, 273, 212, 215, 1422, 1425, "and" +347, 9, 37, 274, 216, 224, 1426, 1434, "mealtime" +347, 9, 38, 275, 225, 233, 1435, 1443, "glycemic" +347, 9, 39, 276, 234, 241, 1444, 1451, "control" +347, 9, 40, 277, 242, 246, 1452, 1456, "than" +347, 9, 41, 278, 247, 251, 1457, 1461, "once" +347, 9, 42, 279, 252, 253, 1462, 1463, "-" +347, 9, 43, 280, 254, 259, 1464, 1469, "daily" +347, 9, 44, 281, 260, 265, 1470, 1475, "basal" +347, 9, 45, 282, 266, 273, 1476, 1483, "insulin" +347, 9, 46, 283, 274, 282, 1484, 1492, "analogue" +347, 9, 47, 284, 283, 284, 1493, 1494, "," +347, 9, 48, 285, 285, 289, 1495, 1499, "both" +347, 9, 49, 286, 290, 294, 1500, 1504, "plus" +347, 9, 50, 287, 295, 304, 1505, 1514, "metformin" +347, 9, 51, 288, 305, 306, 1515, 1516, "(" +347, 9, 52, 289, 307, 310, 1517, 1520, "Met" +347, 9, 53, 290, 311, 312, 1521, 1522, ")" +347, 9, 54, 291, 313, 314, 1523, 1524, "," +347, 9, 55, 292, 315, 317, 1525, 1527, "in" +347, 9, 56, 293, 318, 326, 1528, 1536, "patients" +347, 9, 57, 294, 327, 331, 1537, 1541, "with" +347, 9, 58, 295, 332, 336, 1542, 1546, "type" +347, 9, 59, 296, 337, 338, 1547, 1548, "2" +347, 9, 60, 297, 339, 347, 1549, 1557, "diabetes" +347, 9, 61, 298, 348, 356, 1558, 1566, "mellitus" +347, 9, 62, 299, 357, 358, 1567, 1568, "." +347, 10, 1, 300, 0, 7, 1569, 1576, "METHODS" +347, 10, 2, 301, 8, 9, 1577, 1578, ":" +347, 10, 3, 302, 10, 14, 1579, 1583, "This" +347, 10, 4, 303, 15, 17, 1584, 1586, "24" +347, 10, 5, 304, 18, 19, 1587, 1588, "-" +347, 10, 6, 305, 20, 24, 1589, 1593, "week" +347, 10, 7, 306, 25, 26, 1594, 1595, "," +347, 10, 8, 307, 27, 37, 1596, 1606, "randomized" +347, 10, 9, 308, 38, 39, 1607, 1608, "," +347, 10, 10, 309, 40, 44, 1609, 1613, "open" +347, 10, 11, 310, 45, 46, 1614, 1615, "-" +347, 10, 12, 311, 47, 52, 1616, 1621, "label" +347, 10, 13, 312, 53, 54, 1622, 1623, "," +347, 10, 14, 313, 55, 63, 1624, 1632, "parallel" +347, 10, 15, 314, 64, 65, 1633, 1634, "-" +347, 10, 16, 315, 66, 71, 1635, 1640, "group" +347, 10, 17, 316, 72, 77, 1641, 1646, "trial" +347, 10, 18, 317, 78, 81, 1647, 1650, "was" +347, 10, 19, 318, 82, 91, 1651, 1660, "conducted" +347, 10, 20, 319, 92, 94, 1661, 1663, "at" +347, 10, 21, 320, 95, 97, 1664, 1666, "38" +347, 10, 22, 321, 98, 103, 1667, 1672, "sites" +347, 10, 23, 322, 104, 110, 1673, 1679, "across" +347, 10, 24, 323, 111, 120, 1680, 1689, "Australia" +347, 10, 25, 324, 121, 122, 1690, 1691, "," +347, 10, 26, 325, 123, 129, 1692, 1698, "Greece" +347, 10, 27, 326, 130, 131, 1699, 1700, "," +347, 10, 28, 327, 132, 137, 1701, 1706, "India" +347, 10, 29, 328, 138, 139, 1707, 1708, "," +347, 10, 30, 329, 140, 143, 1709, 1712, "The" +347, 10, 31, 330, 144, 155, 1713, 1724, "Netherlands" +347, 10, 32, 331, 156, 157, 1725, 1726, "," +347, 10, 33, 332, 158, 164, 1727, 1733, "Poland" +347, 10, 34, 333, 165, 166, 1734, 1735, "," +347, 10, 35, 334, 167, 173, 1736, 1742, "Puerto" +347, 10, 36, 335, 174, 178, 1743, 1747, "Rico" +347, 10, 37, 336, 179, 180, 1748, 1749, "," +347, 10, 38, 337, 181, 184, 1750, 1753, "and" +347, 10, 39, 338, 185, 188, 1754, 1757, "the" +347, 10, 40, 339, 189, 195, 1758, 1764, "United" +347, 10, 41, 340, 196, 202, 1765, 1771, "States" +347, 10, 42, 341, 203, 204, 1772, 1773, "." +347, 11, 1, 342, 0, 4, 1774, 1778, "Male" +347, 11, 2, 343, 5, 8, 1779, 1782, "and" +347, 11, 3, 344, 9, 15, 1783, 1789, "female" +347, 11, 4, 345, 16, 24, 1790, 1798, "patients" +347, 11, 5, 346, 25, 29, 1799, 1803, "aged" +347, 11, 6, 347, 30, 32, 1804, 1806, "35" +347, 11, 7, 348, 33, 35, 1807, 1809, "to" +347, 11, 8, 349, 36, 38, 1810, 1812, "75" +347, 11, 9, 350, 39, 44, 1813, 1818, "years" +347, 11, 10, 351, 45, 49, 1819, 1823, "with" +347, 11, 11, 352, 50, 54, 1824, 1828, "type" +347, 11, 12, 353, 55, 56, 1829, 1830, "2" +347, 11, 13, 354, 57, 65, 1831, 1839, "diabetes" +347, 11, 14, 355, 66, 74, 1840, 1848, "mellitus" +347, 11, 15, 356, 75, 78, 1849, 1852, "and" +347, 11, 16, 357, 79, 81, 1853, 1855, "an" +347, 11, 17, 358, 82, 85, 1856, 1859, "HbA" +347, 11, 18, 359, 86, 87, 1860, 1861, "(" +347, 11, 19, 360, 88, 90, 1862, 1864, "1c" +347, 11, 20, 361, 91, 92, 1865, 1866, ")" +347, 11, 21, 362, 93, 98, 1867, 1872, "level" +347, 11, 22, 363, 99, 101, 1873, 1875, "of" +347, 11, 23, 364, 102, 103, 1876, 1877, "6" +347, 11, 24, 365, 104, 105, 1878, 1879, "." +347, 11, 25, 366, 106, 107, 1880, 1881, "5" +347, 11, 26, 367, 108, 109, 1882, 1883, "%" +347, 11, 27, 368, 110, 112, 1884, 1886, "to" +347, 11, 28, 369, 113, 115, 1887, 1889, "11" +347, 11, 29, 370, 116, 117, 1890, 1891, "." +347, 11, 30, 371, 118, 119, 1892, 1893, "0" +347, 11, 31, 372, 120, 121, 1894, 1895, "%" +347, 11, 32, 373, 122, 123, 1896, 1897, "," +347, 11, 33, 374, 124, 127, 1898, 1901, "who" +347, 11, 34, 375, 128, 132, 1902, 1906, "were" +347, 11, 35, 376, 133, 142, 1907, 1916, "receiving" +347, 11, 36, 377, 143, 152, 1917, 1926, "metformin" +347, 11, 37, 378, 153, 156, 1927, 1930, "and" +347, 11, 38, 379, 157, 158, 1931, 1932, "/" +347, 11, 39, 380, 159, 161, 1933, 1935, "or" +347, 11, 40, 381, 162, 163, 1936, 1937, "a" +347, 11, 41, 382, 164, 176, 1938, 1950, "sulfonylurea" +347, 11, 42, 383, 177, 181, 1951, 1955, "with" +347, 11, 43, 384, 182, 183, 1956, 1957, "a" +347, 11, 44, 385, 184, 190, 1958, 1964, "stable" +347, 11, 45, 386, 191, 195, 1965, 1969, "dose" +347, 11, 46, 387, 196, 198, 1970, 1972, "of" +347, 11, 47, 388, 199, 200, 1973, 1974, "0" +347, 11, 48, 389, 201, 203, 1975, 1977, "to" +347, 11, 49, 390, 204, 205, 1978, 1979, "2" +347, 11, 50, 391, 206, 211, 1980, 1985, "daily" +347, 11, 51, 392, 212, 219, 1986, 1993, "insulin" +347, 11, 52, 393, 220, 230, 1994, 2004, "injections" +347, 11, 53, 394, 231, 235, 2005, 2009, "over" +347, 11, 54, 395, 236, 239, 2010, 2013, "the" +347, 11, 55, 396, 240, 248, 2014, 2022, "previous" +347, 11, 56, 397, 249, 250, 2023, 2024, "3" +347, 11, 57, 398, 251, 257, 2025, 2031, "months" +347, 11, 58, 399, 258, 262, 2032, 2036, "were" +347, 11, 59, 400, 263, 271, 2037, 2045, "eligible" +347, 11, 60, 401, 272, 273, 2046, 2047, "." +347, 12, 1, 402, 0, 8, 2048, 2056, "Patients" +347, 12, 2, 403, 9, 13, 2057, 2061, "were" +347, 12, 3, 404, 14, 22, 2062, 2070, "randomly" +347, 12, 4, 405, 23, 31, 2071, 2079, "assigned" +347, 12, 5, 406, 32, 34, 2080, 2082, "to" +347, 12, 6, 407, 35, 42, 2083, 2090, "receive" +347, 12, 7, 408, 43, 47, 2091, 2095, "LM50" +347, 12, 8, 409, 48, 49, 2096, 2097, "/" +347, 12, 9, 410, 50, 52, 2098, 2100, "50" +347, 12, 10, 411, 53, 54, 2101, 2102, "(" +347, 12, 11, 412, 55, 57, 2103, 2105, "50" +347, 12, 12, 413, 58, 59, 2106, 2107, "%" +347, 12, 13, 414, 60, 67, 2108, 2115, "insulin" +347, 12, 14, 415, 68, 74, 2116, 2122, "lispro" +347, 12, 15, 416, 75, 84, 2123, 2132, "protamine" +347, 12, 16, 417, 85, 95, 2133, 2143, "suspension" +347, 12, 17, 418, 96, 97, 2144, 2145, "[" +347, 12, 18, 419, 98, 102, 2146, 2150, "ILPS" +347, 12, 19, 420, 103, 104, 2151, 2152, "]" +347, 12, 20, 421, 105, 108, 2153, 2156, "and" +347, 12, 21, 422, 109, 111, 2157, 2159, "50" +347, 12, 22, 423, 112, 113, 2160, 2161, "%" +347, 12, 23, 424, 114, 120, 2162, 2168, "lispro" +347, 12, 24, 425, 121, 122, 2169, 2170, ")" +347, 12, 25, 426, 123, 126, 2171, 2174, "TID" +347, 12, 26, 427, 127, 131, 2175, 2179, "plus" +347, 12, 27, 428, 132, 141, 2180, 2189, "metformin" +347, 12, 28, 429, 142, 143, 2190, 2191, "(" +347, 12, 29, 430, 144, 146, 2192, 2194, "to" +347, 12, 30, 431, 147, 148, 2195, 2196, "a" +347, 12, 31, 432, 149, 158, 2197, 2206, "maximally" +347, 12, 32, 433, 159, 168, 2207, 2216, "tolerated" +347, 12, 33, 434, 169, 174, 2217, 2222, "daily" +347, 12, 34, 435, 175, 181, 2223, 2229, "dosage" +347, 12, 35, 436, 182, 184, 2230, 2232, "of" +347, 12, 36, 437, 185, 188, 2233, 2236, "500" +347, 12, 37, 438, 189, 190, 2237, 2238, "-" +347, 12, 38, 439, 191, 195, 2239, 2243, "1000" +347, 12, 39, 440, 196, 198, 2244, 2246, "mg" +347, 12, 40, 441, 199, 202, 2247, 2250, "BID" +347, 12, 41, 442, 203, 204, 2251, 2252, ")" +347, 12, 42, 443, 205, 206, 2253, 2254, "(" +347, 12, 43, 444, 207, 211, 2255, 2259, "LM50" +347, 12, 44, 445, 212, 213, 2260, 2261, "/" +347, 12, 45, 446, 214, 216, 2262, 2264, "50" +347, 12, 46, 447, 217, 218, 2265, 2266, "+" +347, 12, 47, 448, 219, 222, 2267, 2270, "Met" +347, 12, 48, 449, 223, 224, 2271, 2272, ")" +347, 12, 49, 450, 225, 227, 2273, 2275, "or" +347, 12, 50, 451, 228, 235, 2276, 2283, "insulin" +347, 12, 51, 452, 236, 244, 2284, 2292, "glargine" +347, 12, 52, 453, 245, 247, 2293, 2295, "QD" +347, 12, 53, 454, 248, 250, 2296, 2298, "at" +347, 12, 54, 455, 251, 258, 2299, 2306, "bedtime" +347, 12, 55, 456, 259, 263, 2307, 2311, "plus" +347, 12, 56, 457, 264, 273, 2312, 2321, "metformin" +347, 12, 57, 458, 274, 275, 2322, 2323, "(" +347, 12, 58, 459, 276, 279, 2324, 2327, "500" +347, 12, 59, 460, 280, 281, 2328, 2329, "-" +347, 12, 60, 461, 282, 286, 2330, 2334, "1000" +347, 12, 61, 462, 287, 289, 2335, 2337, "mg" +347, 12, 62, 463, 290, 293, 2338, 2341, "BID" +347, 12, 63, 464, 294, 295, 2342, 2343, ")" +347, 12, 64, 465, 296, 297, 2344, 2345, "(" +347, 12, 65, 466, 298, 299, 2346, 2347, "G" +347, 12, 66, 467, 300, 301, 2348, 2349, "+" +347, 12, 67, 468, 302, 305, 2350, 2353, "Met" +347, 12, 68, 469, 306, 307, 2354, 2355, ")" +347, 12, 69, 470, 308, 311, 2356, 2359, "for" +347, 12, 70, 471, 312, 314, 2360, 2362, "24" +347, 12, 71, 472, 315, 320, 2363, 2368, "weeks" +347, 12, 72, 473, 321, 322, 2369, 2370, "." +347, 13, 1, 474, 0, 4, 2371, 2375, "With" +347, 13, 2, 475, 5, 9, 2376, 2380, "LM50" +347, 13, 3, 476, 10, 11, 2381, 2382, "/" +347, 13, 4, 477, 12, 14, 2383, 2385, "50" +347, 13, 5, 478, 15, 16, 2386, 2387, "+" +347, 13, 6, 479, 17, 20, 2388, 2391, "Met" +347, 13, 7, 480, 21, 22, 2392, 2393, "," +347, 13, 8, 481, 23, 26, 2394, 2397, "the" +347, 13, 9, 482, 27, 34, 2398, 2405, "insulin" +347, 13, 10, 483, 35, 39, 2406, 2410, "dose" +347, 13, 11, 484, 40, 43, 2411, 2414, "was" +347, 13, 12, 485, 44, 52, 2415, 2423, "titrated" +347, 13, 13, 486, 53, 55, 2424, 2426, "to" +347, 13, 14, 487, 56, 62, 2427, 2433, "target" +347, 13, 15, 488, 63, 64, 2434, 2435, "a" +347, 13, 16, 489, 65, 72, 2436, 2443, "fasting" +347, 13, 17, 490, 73, 75, 2444, 2446, "BG" +347, 13, 18, 491, 76, 77, 2447, 2448, "(" +347, 13, 19, 492, 78, 81, 2449, 2452, "FBG" +347, 13, 20, 493, 82, 83, 2453, 2454, ")" +347, 13, 21, 494, 84, 89, 2455, 2460, "level" +347, 13, 22, 495, 90, 92, 2461, 2463, "of" +347, 13, 23, 496, 93, 94, 2464, 2465, "<" +347, 13, 24, 497, 95, 96, 2466, 2467, "6" +347, 13, 25, 498, 97, 98, 2468, 2469, "." +347, 13, 26, 499, 99, 100, 2470, 2471, "7" +347, 13, 27, 500, 101, 105, 2472, 2476, "mmol" +347, 13, 28, 501, 106, 107, 2477, 2478, "/" +347, 13, 29, 502, 108, 109, 2479, 2480, "L" +347, 13, 30, 503, 110, 111, 2481, 2482, "(" +347, 13, 31, 504, 112, 113, 2483, 2484, "<" +347, 13, 32, 505, 114, 117, 2485, 2488, "120" +347, 13, 33, 506, 118, 120, 2489, 2491, "mg" +347, 13, 34, 507, 121, 122, 2492, 2493, "/" +347, 13, 35, 508, 123, 125, 2494, 2496, "dL" +347, 13, 36, 509, 126, 127, 2497, 2498, ")" +347, 13, 37, 510, 128, 131, 2499, 2502, "and" +347, 13, 38, 511, 132, 133, 2503, 2504, "a" +347, 13, 39, 512, 134, 135, 2505, 2506, "2" +347, 13, 40, 513, 136, 137, 2507, 2508, "-" +347, 13, 41, 514, 138, 142, 2509, 2513, "hour" +347, 13, 42, 515, 143, 147, 2514, 2518, "post" +347, 13, 43, 516, 148, 149, 2519, 2520, "-" +347, 13, 44, 517, 150, 158, 2521, 2529, "prandial" +347, 13, 45, 518, 159, 161, 2530, 2532, "BG" +347, 13, 46, 519, 162, 163, 2533, 2534, "(" +347, 13, 47, 520, 164, 168, 2535, 2539, "PPBG" +347, 13, 48, 521, 169, 170, 2540, 2541, ")" +347, 13, 49, 522, 171, 176, 2542, 2547, "level" +347, 13, 50, 523, 177, 179, 2548, 2550, "of" +347, 13, 51, 524, 180, 181, 2551, 2552, "<" +347, 13, 52, 525, 182, 183, 2553, 2554, "8" +347, 13, 53, 526, 184, 185, 2555, 2556, "." +347, 13, 54, 527, 186, 187, 2557, 2558, "0" +347, 13, 55, 528, 188, 192, 2559, 2563, "mmol" +347, 13, 56, 529, 193, 194, 2564, 2565, "/" +347, 13, 57, 530, 195, 196, 2566, 2567, "L" +347, 13, 58, 531, 197, 198, 2568, 2569, "(" +347, 13, 59, 532, 199, 200, 2570, 2571, "<" +347, 13, 60, 533, 201, 204, 2572, 2575, "144" +347, 13, 61, 534, 205, 207, 2576, 2578, "mg" +347, 13, 62, 535, 208, 209, 2579, 2580, "/" +347, 13, 63, 536, 210, 212, 2581, 2583, "dL" +347, 13, 64, 537, 213, 214, 2584, 2585, ")" +347, 13, 65, 538, 215, 216, 2586, 2587, ";" +347, 13, 66, 539, 217, 222, 2588, 2593, "those" +347, 13, 67, 540, 223, 226, 2594, 2597, "who" +347, 13, 68, 541, 227, 230, 2598, 2601, "did" +347, 13, 69, 542, 231, 234, 2602, 2605, "not" +347, 13, 70, 543, 235, 240, 2606, 2611, "reach" +347, 13, 71, 544, 241, 244, 2612, 2615, "the" +347, 13, 72, 545, 245, 248, 2616, 2619, "FBG" +347, 13, 73, 546, 249, 255, 2620, 2626, "target" +347, 13, 74, 547, 256, 261, 2627, 2632, "would" +347, 13, 75, 548, 262, 264, 2633, 2635, "be" +347, 13, 76, 549, 265, 273, 2636, 2644, "switched" +347, 13, 77, 550, 274, 278, 2645, 2649, "from" +347, 13, 78, 551, 279, 288, 2650, 2659, "presupper" +347, 13, 79, 552, 289, 293, 2660, 2664, "LM50" +347, 13, 80, 553, 294, 295, 2665, 2666, "/" +347, 13, 81, 554, 296, 298, 2667, 2669, "50" +347, 13, 82, 555, 299, 301, 2670, 2672, "to" +347, 13, 83, 556, 302, 306, 2673, 2677, "LM75" +347, 13, 84, 557, 307, 308, 2678, 2679, "/" +347, 13, 85, 558, 309, 311, 2680, 2682, "25" +347, 13, 86, 559, 312, 313, 2683, 2684, "(" +347, 13, 87, 560, 314, 316, 2685, 2687, "75" +347, 13, 88, 561, 317, 318, 2688, 2689, "%" +347, 13, 89, 562, 319, 323, 2690, 2694, "ILPS" +347, 13, 90, 563, 324, 325, 2695, 2696, "," +347, 13, 91, 564, 326, 328, 2697, 2699, "25" +347, 13, 92, 565, 329, 330, 2700, 2701, "%" +347, 13, 93, 566, 331, 337, 2702, 2708, "lispro" +347, 13, 94, 567, 338, 339, 2709, 2710, ")" +347, 13, 95, 568, 340, 341, 2711, 2712, "." +347, 14, 1, 569, 0, 7, 2713, 2720, "RESULTS" +347, 14, 2, 570, 8, 9, 2721, 2722, ":" +347, 14, 3, 571, 10, 11, 2723, 2724, "A" +347, 14, 4, 572, 12, 17, 2725, 2730, "total" +347, 14, 5, 573, 18, 20, 2731, 2733, "of" +347, 14, 6, 574, 21, 24, 2734, 2737, "315" +347, 14, 7, 575, 25, 33, 2738, 2746, "patients" +347, 14, 8, 576, 34, 38, 2747, 2751, "were" +347, 14, 9, 577, 39, 49, 2752, 2762, "randomized" +347, 14, 10, 578, 50, 53, 2763, 2766, "and" +347, 14, 11, 579, 54, 62, 2767, 2775, "received" +347, 14, 12, 580, 63, 72, 2776, 2785, "treatment" +347, 14, 13, 581, 73, 74, 2786, 2787, "(" +347, 14, 14, 582, 75, 78, 2788, 2791, "158" +347, 14, 15, 583, 79, 84, 2792, 2797, "women" +347, 14, 16, 584, 85, 86, 2798, 2799, "," +347, 14, 17, 585, 87, 90, 2800, 2803, "157" +347, 14, 18, 586, 91, 94, 2804, 2807, "men" +347, 14, 19, 587, 95, 96, 2808, 2809, ";" +347, 14, 20, 588, 97, 101, 2810, 2814, "mean" +347, 14, 21, 589, 102, 105, 2815, 2818, "age" +347, 14, 22, 590, 106, 107, 2819, 2820, "," +347, 14, 23, 591, 108, 110, 2821, 2823, "57" +347, 14, 24, 592, 111, 112, 2824, 2825, "." +347, 14, 25, 593, 113, 114, 2826, 2827, "7" +347, 14, 26, 594, 115, 120, 2828, 2833, "years" +347, 14, 27, 595, 121, 122, 2834, 2835, ";" +347, 14, 28, 596, 123, 127, 2836, 2840, "mean" +347, 14, 29, 597, 128, 132, 2841, 2845, "body" +347, 14, 30, 598, 133, 137, 2846, 2850, "mass" +347, 14, 31, 599, 138, 143, 2851, 2856, "index" +347, 14, 32, 600, 144, 145, 2857, 2858, "," +347, 14, 33, 601, 146, 148, 2859, 2861, "32" +347, 14, 34, 602, 149, 150, 2862, 2863, "." +347, 14, 35, 603, 151, 152, 2864, 2865, "1" +347, 14, 36, 604, 153, 155, 2866, 2868, "kg" +347, 14, 37, 605, 156, 157, 2869, 2870, "/" +347, 14, 38, 606, 158, 160, 2871, 2873, "m2" +347, 14, 39, 607, 161, 162, 2874, 2875, ";" +347, 14, 40, 608, 163, 167, 2876, 2880, "LM50" +347, 14, 41, 609, 168, 169, 2881, 2882, "/" +347, 14, 42, 610, 170, 172, 2883, 2885, "50" +347, 14, 43, 611, 173, 174, 2886, 2887, "+" +347, 14, 44, 612, 175, 178, 2888, 2891, "Met" +347, 14, 45, 613, 179, 180, 2892, 2893, "," +347, 14, 46, 614, 181, 184, 2894, 2897, "157" +347, 14, 47, 615, 185, 193, 2898, 2906, "patients" +347, 14, 48, 616, 194, 195, 2907, 2908, ";" +347, 14, 49, 617, 196, 197, 2909, 2910, "G" +347, 14, 50, 618, 198, 199, 2911, 2912, "+" +347, 14, 51, 619, 200, 203, 2913, 2916, "Met" +347, 14, 52, 620, 204, 205, 2917, 2918, "," +347, 14, 53, 621, 206, 209, 2919, 2922, "158" +347, 14, 54, 622, 210, 218, 2923, 2931, "patients" +347, 14, 55, 623, 219, 220, 2932, 2933, ")" +347, 14, 56, 624, 221, 222, 2934, 2935, "." +347, 15, 1, 625, 0, 2, 2936, 2938, "At" +347, 15, 2, 626, 3, 5, 2939, 2941, "24" +347, 15, 3, 627, 6, 11, 2942, 2947, "weeks" +347, 15, 4, 628, 12, 13, 2948, 2949, "," +347, 15, 5, 629, 14, 17, 2950, 2953, "the" +347, 15, 6, 630, 18, 22, 2954, 2958, "mean" +347, 15, 7, 631, 23, 24, 2959, 2960, "(" +347, 15, 8, 632, 25, 27, 2961, 2963, "SD" +347, 15, 9, 633, 28, 29, 2964, 2965, ")" +347, 15, 10, 634, 30, 33, 2966, 2969, "HbA" +347, 15, 11, 635, 34, 35, 2970, 2971, "(" +347, 15, 12, 636, 36, 38, 2972, 2974, "1c" +347, 15, 13, 637, 39, 40, 2975, 2976, ")" +347, 15, 14, 638, 41, 46, 2977, 2982, "level" +347, 15, 15, 639, 47, 50, 2983, 2986, "was" +347, 15, 16, 640, 51, 64, 2987, 3000, "significantly" +347, 15, 17, 641, 65, 70, 3001, 3006, "lower" +347, 15, 18, 642, 71, 73, 3007, 3009, "in" +347, 15, 19, 643, 74, 77, 3010, 3013, "the" +347, 15, 20, 644, 78, 82, 3014, 3018, "LM50" +347, 15, 21, 645, 83, 84, 3019, 3020, "/" +347, 15, 22, 646, 85, 87, 3021, 3023, "50" +347, 15, 23, 647, 88, 89, 3024, 3025, "+" +347, 15, 24, 648, 90, 93, 3026, 3029, "Met" +347, 15, 25, 649, 94, 99, 3030, 3035, "group" +347, 15, 26, 650, 100, 104, 3036, 3040, "than" +347, 15, 27, 651, 105, 107, 3041, 3043, "in" +347, 15, 28, 652, 108, 111, 3044, 3047, "the" +347, 15, 29, 653, 112, 113, 3048, 3049, "G" +347, 15, 30, 654, 114, 115, 3050, 3051, "+" +347, 15, 31, 655, 116, 119, 3052, 3055, "Met" +347, 15, 32, 656, 120, 125, 3056, 3061, "group" +347, 15, 33, 657, 126, 127, 3062, 3063, "(" +347, 15, 34, 658, 128, 129, 3064, 3065, "7" +347, 15, 35, 659, 130, 131, 3066, 3067, "." +347, 15, 36, 660, 132, 133, 3068, 3069, "1" +347, 15, 37, 661, 134, 135, 3070, 3071, "%" +347, 15, 38, 662, 136, 137, 3072, 3073, "[" +347, 15, 39, 663, 138, 139, 3074, 3075, "0" +347, 15, 40, 664, 140, 141, 3076, 3077, "." +347, 15, 41, 665, 142, 143, 3078, 3079, "9" +347, 15, 42, 666, 144, 145, 3080, 3081, "%" +347, 15, 43, 667, 146, 147, 3082, 3083, "]" +347, 15, 44, 668, 148, 150, 3084, 3086, "vs" +347, 15, 45, 669, 151, 152, 3087, 3088, "7" +347, 15, 46, 670, 153, 154, 3089, 3090, "." +347, 15, 47, 671, 155, 156, 3091, 3092, "5" +347, 15, 48, 672, 157, 158, 3093, 3094, "%" +347, 15, 49, 673, 159, 160, 3095, 3096, "[" +347, 15, 50, 674, 161, 162, 3097, 3098, "1" +347, 15, 51, 675, 163, 164, 3099, 3100, "." +347, 15, 52, 676, 165, 166, 3101, 3102, "0" +347, 15, 53, 677, 167, 168, 3103, 3104, "%" +347, 15, 54, 678, 169, 170, 3105, 3106, "]" +347, 15, 55, 679, 171, 172, 3107, 3108, ";" +347, 15, 56, 680, 173, 174, 3109, 3110, "P" +347, 15, 57, 681, 175, 176, 3111, 3112, "<" +347, 15, 58, 682, 177, 178, 3113, 3114, "0" +347, 15, 59, 683, 179, 180, 3115, 3116, "." +347, 15, 60, 684, 181, 184, 3117, 3120, "001" +347, 15, 61, 685, 185, 186, 3121, 3122, ")" +347, 15, 62, 686, 187, 188, 3123, 3124, "," +347, 15, 63, 687, 189, 192, 3125, 3128, "and" +347, 15, 64, 688, 193, 196, 3129, 3132, "the" +347, 15, 65, 689, 197, 207, 3133, 3143, "proportion" +347, 15, 66, 690, 208, 211, 3144, 3147, "who" +347, 15, 67, 691, 212, 219, 3148, 3155, "reached" +347, 15, 68, 692, 220, 222, 3156, 3158, "an" +347, 15, 69, 693, 223, 226, 3159, 3162, "HbA" +347, 15, 70, 694, 227, 228, 3163, 3164, "(" +347, 15, 71, 695, 229, 231, 3165, 3167, "1c" +347, 15, 72, 696, 232, 233, 3168, 3169, ")" +347, 15, 73, 697, 234, 240, 3170, 3176, "target" +347, 15, 74, 698, 241, 243, 3177, 3179, "of" +347, 15, 75, 699, 244, 245, 3180, 3181, "<" +347, 15, 76, 700, 246, 248, 3182, 3184, "or" +347, 15, 77, 701, 249, 250, 3185, 3186, "=" +347, 15, 78, 702, 251, 252, 3187, 3188, "7" +347, 15, 79, 703, 253, 254, 3189, 3190, "." +347, 15, 80, 704, 255, 256, 3191, 3192, "0" +347, 15, 81, 705, 257, 258, 3193, 3194, "%" +347, 15, 82, 706, 259, 262, 3195, 3198, "was" +347, 15, 83, 707, 263, 270, 3199, 3206, "greater" +347, 15, 84, 708, 271, 272, 3207, 3208, "(" +347, 15, 85, 709, 273, 275, 3209, 3211, "88" +347, 15, 86, 710, 276, 277, 3212, 3213, "[" +347, 15, 87, 711, 278, 280, 3214, 3216, "56" +347, 15, 88, 712, 281, 282, 3217, 3218, "." +347, 15, 89, 713, 283, 284, 3219, 3220, "1" +347, 15, 90, 714, 285, 286, 3221, 3222, "%" +347, 15, 91, 715, 287, 288, 3223, 3224, "]" +347, 15, 92, 716, 289, 291, 3225, 3227, "vs" +347, 15, 93, 717, 292, 294, 3228, 3230, "63" +347, 15, 94, 718, 295, 296, 3231, 3232, "[" +347, 15, 95, 719, 297, 299, 3233, 3235, "39" +347, 15, 96, 720, 300, 301, 3236, 3237, "." +347, 15, 97, 721, 302, 303, 3238, 3239, "9" +347, 15, 98, 722, 304, 305, 3240, 3241, "%" +347, 15, 99, 723, 306, 307, 3242, 3243, "]" +347, 15, 100, 724, 308, 309, 3244, 3245, ";" +347, 15, 101, 725, 310, 311, 3246, 3247, "P" +347, 15, 102, 726, 312, 313, 3248, 3249, "=" +347, 15, 103, 727, 314, 315, 3250, 3251, "0" +347, 15, 104, 728, 316, 317, 3252, 3253, "." +347, 15, 105, 729, 318, 321, 3254, 3257, "005" +347, 15, 106, 730, 322, 323, 3258, 3259, ")" +347, 15, 107, 731, 324, 325, 3260, 3261, "." +347, 16, 1, 732, 0, 3, 3262, 3265, "The" +347, 16, 2, 733, 4, 5, 3266, 3267, "G" +347, 16, 3, 734, 6, 7, 3268, 3269, "+" +347, 16, 4, 735, 8, 11, 3270, 3273, "Met" +347, 16, 5, 736, 12, 17, 3274, 3279, "group" +347, 16, 6, 737, 18, 21, 3280, 3283, "had" +347, 16, 7, 738, 22, 23, 3284, 3285, "a" +347, 16, 8, 739, 24, 29, 3286, 3291, "lower" +347, 16, 9, 740, 30, 34, 3292, 3296, "mean" +347, 16, 10, 741, 35, 36, 3297, 3298, "(" +347, 16, 11, 742, 37, 39, 3299, 3301, "SD" +347, 16, 12, 743, 40, 41, 3302, 3303, ")" +347, 16, 13, 744, 42, 45, 3304, 3307, "FBG" +347, 16, 14, 745, 46, 51, 3308, 3313, "value" +347, 16, 15, 746, 52, 53, 3314, 3315, "(" +347, 16, 16, 747, 54, 55, 3316, 3317, "6" +347, 16, 17, 748, 56, 57, 3318, 3319, "." +347, 16, 18, 749, 58, 59, 3320, 3321, "5" +347, 16, 19, 750, 60, 61, 3322, 3323, "[" +347, 16, 20, 751, 62, 63, 3324, 3325, "1" +347, 16, 21, 752, 64, 65, 3326, 3327, "." +347, 16, 22, 753, 66, 67, 3328, 3329, "6" +347, 16, 23, 754, 68, 69, 3330, 3331, "]" +347, 16, 24, 755, 70, 72, 3332, 3334, "vs" +347, 16, 25, 756, 73, 74, 3335, 3336, "8" +347, 16, 26, 757, 75, 76, 3337, 3338, "." +347, 16, 27, 758, 77, 78, 3339, 3340, "1" +347, 16, 28, 759, 79, 80, 3341, 3342, "[" +347, 16, 29, 760, 81, 82, 3343, 3344, "1" +347, 16, 30, 761, 83, 84, 3345, 3346, "." +347, 16, 31, 762, 85, 86, 3347, 3348, "8" +347, 16, 32, 763, 87, 88, 3349, 3350, "]" +347, 16, 33, 764, 89, 93, 3351, 3355, "mmol" +347, 16, 34, 765, 94, 95, 3356, 3357, "/" +347, 16, 35, 766, 96, 97, 3358, 3359, "L" +347, 16, 36, 767, 98, 99, 3360, 3361, ";" +347, 16, 37, 768, 100, 101, 3362, 3363, "P" +347, 16, 38, 769, 102, 103, 3364, 3365, "<" +347, 16, 39, 770, 104, 105, 3366, 3367, "0" +347, 16, 40, 771, 106, 107, 3368, 3369, "." +347, 16, 41, 772, 108, 111, 3370, 3373, "001" +347, 16, 42, 773, 112, 113, 3374, 3375, ")" +347, 16, 43, 774, 114, 115, 3376, 3377, "." +347, 17, 1, 775, 0, 3, 3378, 3381, "The" +347, 17, 2, 776, 4, 8, 3382, 3386, "LM50" +347, 17, 3, 777, 9, 10, 3387, 3388, "/" +347, 17, 4, 778, 11, 13, 3389, 3391, "50" +347, 17, 5, 779, 14, 15, 3392, 3393, "+" +347, 17, 6, 780, 16, 19, 3394, 3397, "Met" +347, 17, 7, 781, 20, 25, 3398, 3403, "group" +347, 17, 8, 782, 26, 29, 3404, 3407, "had" +347, 17, 9, 783, 30, 35, 3408, 3413, "lower" +347, 17, 10, 784, 36, 40, 3414, 3418, "mean" +347, 17, 11, 785, 41, 52, 3419, 3430, "preprandial" +347, 17, 12, 786, 53, 55, 3431, 3433, "BG" +347, 17, 13, 787, 56, 62, 3434, 3440, "levels" +347, 17, 14, 788, 63, 71, 3441, 3449, "prelunch" +347, 17, 15, 789, 72, 73, 3450, 3451, "(" +347, 17, 16, 790, 74, 75, 3452, 3453, "7" +347, 17, 17, 791, 76, 77, 3454, 3455, "." +347, 17, 18, 792, 78, 79, 3456, 3457, "4" +347, 17, 19, 793, 80, 81, 3458, 3459, "[" +347, 17, 20, 794, 82, 83, 3460, 3461, "1" +347, 17, 21, 795, 84, 85, 3462, 3463, "." +347, 17, 22, 796, 86, 87, 3464, 3465, "9" +347, 17, 23, 797, 88, 89, 3466, 3467, "]" +347, 17, 24, 798, 90, 92, 3468, 3470, "vs" +347, 17, 25, 799, 93, 94, 3471, 3472, "7" +347, 17, 26, 800, 95, 96, 3473, 3474, "." +347, 17, 27, 801, 97, 98, 3475, 3476, "9" +347, 17, 28, 802, 99, 100, 3477, 3478, "[" +347, 17, 29, 803, 101, 102, 3479, 3480, "2" +347, 17, 30, 804, 103, 104, 3481, 3482, "." +347, 17, 31, 805, 105, 106, 3483, 3484, "1" +347, 17, 32, 806, 107, 108, 3485, 3486, "]" +347, 17, 33, 807, 109, 113, 3487, 3491, "mmol" +347, 17, 34, 808, 114, 115, 3492, 3493, "/" +347, 17, 35, 809, 116, 117, 3494, 3495, "L" +347, 17, 36, 810, 118, 119, 3496, 3497, ";" +347, 17, 37, 811, 120, 121, 3498, 3499, "P" +347, 17, 38, 812, 122, 123, 3500, 3501, "=" +347, 17, 39, 813, 124, 125, 3502, 3503, "0" +347, 17, 40, 814, 126, 127, 3504, 3505, "." +347, 17, 41, 815, 128, 130, 3506, 3508, "03" +347, 17, 42, 816, 131, 132, 3509, 3510, ")" +347, 17, 43, 817, 133, 136, 3511, 3514, "and" +347, 17, 44, 818, 137, 146, 3515, 3524, "presupper" +347, 17, 45, 819, 147, 148, 3525, 3526, "(" +347, 17, 46, 820, 149, 150, 3527, 3528, "8" +347, 17, 47, 821, 151, 152, 3529, 3530, "." +347, 17, 48, 822, 153, 154, 3531, 3532, "3" +347, 17, 49, 823, 155, 156, 3533, 3534, "[" +347, 17, 50, 824, 157, 158, 3535, 3536, "2" +347, 17, 51, 825, 159, 160, 3537, 3538, "." +347, 17, 52, 826, 161, 162, 3539, 3540, "0" +347, 17, 53, 827, 163, 164, 3541, 3542, "]" +347, 17, 54, 828, 165, 167, 3543, 3545, "vs" +347, 17, 55, 829, 168, 169, 3546, 3547, "8" +347, 17, 56, 830, 170, 171, 3548, 3549, "." +347, 17, 57, 831, 172, 173, 3550, 3551, "9" +347, 17, 58, 832, 174, 175, 3552, 3553, "[" +347, 17, 59, 833, 176, 177, 3554, 3555, "2" +347, 17, 60, 834, 178, 179, 3556, 3557, "." +347, 17, 61, 835, 180, 181, 3558, 3559, "8" +347, 17, 62, 836, 182, 183, 3560, 3561, "]" +347, 17, 63, 837, 184, 188, 3562, 3566, "mmol" +347, 17, 64, 838, 189, 190, 3567, 3568, "/" +347, 17, 65, 839, 191, 192, 3569, 3570, "L" +347, 17, 66, 840, 193, 194, 3571, 3572, ";" +347, 17, 67, 841, 195, 196, 3573, 3574, "P" +347, 17, 68, 842, 197, 198, 3575, 3576, "=" +347, 17, 69, 843, 199, 200, 3577, 3578, "0" +347, 17, 70, 844, 201, 202, 3579, 3580, "." +347, 17, 71, 845, 203, 205, 3581, 3583, "04" +347, 17, 72, 846, 206, 207, 3584, 3585, ")" +347, 17, 73, 847, 208, 209, 3586, 3587, "." +347, 18, 1, 848, 0, 3, 3588, 3591, "The" +347, 18, 2, 849, 4, 8, 3592, 3596, "LM50" +347, 18, 3, 850, 9, 10, 3597, 3598, "/" +347, 18, 4, 851, 11, 13, 3599, 3601, "50" +347, 18, 5, 852, 14, 15, 3602, 3603, "+" +347, 18, 6, 853, 16, 19, 3604, 3607, "Met" +347, 18, 7, 854, 20, 25, 3608, 3613, "group" +347, 18, 8, 855, 26, 30, 3614, 3618, "also" +347, 18, 9, 856, 31, 34, 3619, 3622, "had" +347, 18, 10, 857, 35, 40, 3623, 3628, "lower" +347, 18, 11, 858, 41, 45, 3629, 3633, "mean" +347, 18, 12, 859, 46, 47, 3634, 3635, "2" +347, 18, 13, 860, 48, 49, 3636, 3637, "-" +347, 18, 14, 861, 50, 54, 3638, 3642, "hour" +347, 18, 15, 862, 55, 59, 3643, 3647, "PPBG" +347, 18, 16, 863, 60, 66, 3648, 3654, "values" +347, 18, 17, 864, 67, 80, 3655, 3668, "postbreakfast" +347, 18, 18, 865, 81, 82, 3669, 3670, "(" +347, 18, 19, 866, 83, 84, 3671, 3672, "8" +347, 18, 20, 867, 85, 86, 3673, 3674, "." +347, 18, 21, 868, 87, 88, 3675, 3676, "7" +347, 18, 22, 869, 89, 90, 3677, 3678, "[" +347, 18, 23, 870, 91, 92, 3679, 3680, "2" +347, 18, 24, 871, 93, 94, 3681, 3682, "." +347, 18, 25, 872, 95, 96, 3683, 3684, "2" +347, 18, 26, 873, 97, 98, 3685, 3686, "]" +347, 18, 27, 874, 99, 101, 3687, 3689, "vs" +347, 18, 28, 875, 102, 103, 3690, 3691, "9" +347, 18, 29, 876, 104, 105, 3692, 3693, "." +347, 18, 30, 877, 106, 107, 3694, 3695, "2" +347, 18, 31, 878, 108, 109, 3696, 3697, "[" +347, 18, 32, 879, 110, 111, 3698, 3699, "2" +347, 18, 33, 880, 112, 113, 3700, 3701, "." +347, 18, 34, 881, 114, 115, 3702, 3703, "5" +347, 18, 35, 882, 116, 117, 3704, 3705, "]" +347, 18, 36, 883, 118, 122, 3706, 3710, "mmol" +347, 18, 37, 884, 123, 124, 3711, 3712, "/" +347, 18, 38, 885, 125, 126, 3713, 3714, "L" +347, 18, 39, 886, 127, 128, 3715, 3716, ";" +347, 18, 40, 887, 129, 130, 3717, 3718, "P" +347, 18, 41, 888, 131, 132, 3719, 3720, "=" +347, 18, 42, 889, 133, 134, 3721, 3722, "0" +347, 18, 43, 890, 135, 136, 3723, 3724, "." +347, 18, 44, 891, 137, 139, 3725, 3727, "03" +347, 18, 45, 892, 140, 141, 3728, 3729, ")" +347, 18, 46, 893, 142, 143, 3730, 3731, "," +347, 18, 47, 894, 144, 153, 3732, 3741, "postlunch" +347, 18, 48, 895, 154, 155, 3742, 3743, "(" +347, 18, 49, 896, 156, 157, 3744, 3745, "8" +347, 18, 50, 897, 158, 159, 3746, 3747, "." +347, 18, 51, 898, 160, 161, 3748, 3749, "4" +347, 18, 52, 899, 162, 163, 3750, 3751, "[" +347, 18, 53, 900, 164, 165, 3752, 3753, "1" +347, 18, 54, 901, 166, 167, 3754, 3755, "." +347, 18, 55, 902, 168, 169, 3756, 3757, "9" +347, 18, 56, 903, 170, 171, 3758, 3759, "]" +347, 18, 57, 904, 172, 174, 3760, 3762, "vs" +347, 18, 58, 905, 175, 176, 3763, 3764, "9" +347, 18, 59, 906, 177, 178, 3765, 3766, "." +347, 18, 60, 907, 179, 180, 3767, 3768, "8" +347, 18, 61, 908, 181, 182, 3769, 3770, "[" +347, 18, 62, 909, 183, 184, 3771, 3772, "2" +347, 18, 63, 910, 185, 186, 3773, 3774, "." +347, 18, 64, 911, 187, 188, 3775, 3776, "6" +347, 18, 65, 912, 189, 190, 3777, 3778, "]" +347, 18, 66, 913, 191, 192, 3779, 3780, "," +347, 18, 67, 914, 193, 197, 3781, 3785, "mmol" +347, 18, 68, 915, 198, 199, 3786, 3787, "/" +347, 18, 69, 916, 200, 201, 3788, 3789, "L" +347, 18, 70, 917, 202, 203, 3790, 3791, ";" +347, 18, 71, 918, 204, 205, 3792, 3793, "p" +347, 18, 72, 919, 206, 207, 3794, 3795, "<" +347, 18, 73, 920, 208, 209, 3796, 3797, "0" +347, 18, 74, 921, 210, 211, 3798, 3799, "." +347, 18, 75, 922, 212, 215, 3800, 3803, "001" +347, 18, 76, 923, 216, 217, 3804, 3805, ")" +347, 18, 77, 924, 218, 219, 3806, 3807, "," +347, 18, 78, 925, 220, 223, 3808, 3811, "and" +347, 18, 79, 926, 224, 234, 3812, 3822, "postsupper" +347, 18, 80, 927, 235, 236, 3823, 3824, "(" +347, 18, 81, 928, 237, 238, 3825, 3826, "8" +347, 18, 82, 929, 239, 240, 3827, 3828, "." +347, 18, 83, 930, 241, 242, 3829, 3830, "7" +347, 18, 84, 931, 243, 244, 3831, 3832, "[" +347, 18, 85, 932, 245, 246, 3833, 3834, "2" +347, 18, 86, 933, 247, 248, 3835, 3836, "." +347, 18, 87, 934, 249, 250, 3837, 3838, "2" +347, 18, 88, 935, 251, 252, 3839, 3840, "]" +347, 18, 89, 936, 253, 255, 3841, 3843, "vs" +347, 18, 90, 937, 256, 258, 3844, 3846, "10" +347, 18, 91, 938, 259, 260, 3847, 3848, "." +347, 18, 92, 939, 261, 262, 3849, 3850, "7" +347, 18, 93, 940, 263, 264, 3851, 3852, "[" +347, 18, 94, 941, 265, 266, 3853, 3854, "3" +347, 18, 95, 942, 267, 268, 3855, 3856, "." +347, 18, 96, 943, 269, 270, 3857, 3858, "2" +347, 18, 97, 944, 271, 272, 3859, 3860, "]" +347, 18, 98, 945, 273, 274, 3861, 3862, "," +347, 18, 99, 946, 275, 279, 3863, 3867, "mmol" +347, 18, 100, 947, 280, 281, 3868, 3869, "/" +347, 18, 101, 948, 282, 283, 3870, 3871, "L" +347, 18, 102, 949, 284, 285, 3872, 3873, ";" +347, 18, 103, 950, 286, 287, 3874, 3875, "P" +347, 18, 104, 951, 288, 289, 3876, 3877, "<" +347, 18, 105, 952, 290, 291, 3878, 3879, "0" +347, 18, 106, 953, 292, 293, 3880, 3881, "." +347, 18, 107, 954, 294, 297, 3882, 3885, "001" +347, 18, 108, 955, 298, 299, 3886, 3887, ")" +347, 18, 109, 956, 300, 301, 3888, 3889, "." +347, 19, 1, 957, 0, 3, 3890, 3893, "The" +347, 19, 2, 958, 4, 8, 3894, 3898, "mean" +347, 19, 3, 959, 9, 10, 3899, 3900, "(" +347, 19, 4, 960, 11, 13, 3901, 3903, "SD" +347, 19, 5, 961, 14, 15, 3904, 3905, ")" +347, 19, 6, 962, 16, 21, 3906, 3911, "total" +347, 19, 7, 963, 22, 29, 3912, 3919, "insulin" +347, 19, 8, 964, 30, 35, 3920, 3925, "doses" +347, 19, 9, 965, 36, 38, 3926, 3928, "at" +347, 19, 10, 966, 39, 44, 3929, 3934, "study" +347, 19, 11, 967, 45, 48, 3935, 3938, "end" +347, 19, 12, 968, 49, 54, 3939, 3944, "point" +347, 19, 13, 969, 55, 59, 3945, 3949, "were" +347, 19, 14, 970, 60, 61, 3950, 3951, "0" +347, 19, 15, 971, 62, 63, 3952, 3953, "." +347, 19, 16, 972, 64, 65, 3954, 3955, "7" +347, 19, 17, 973, 66, 67, 3956, 3957, "(" +347, 19, 18, 974, 68, 69, 3958, 3959, "0" +347, 19, 19, 975, 70, 71, 3960, 3961, "." +347, 19, 20, 976, 72, 73, 3962, 3963, "3" +347, 19, 21, 977, 74, 75, 3964, 3965, ")" +347, 19, 22, 978, 76, 77, 3966, 3967, "U" +347, 19, 23, 979, 78, 79, 3968, 3969, "/" +347, 19, 24, 980, 80, 82, 3970, 3972, "kg" +347, 19, 25, 981, 83, 85, 3973, 3975, "in" +347, 19, 26, 982, 86, 89, 3976, 3979, "the" +347, 19, 27, 983, 90, 94, 3980, 3984, "LM50" +347, 19, 28, 984, 95, 96, 3985, 3986, "/" +347, 19, 29, 985, 97, 99, 3987, 3989, "50" +347, 19, 30, 986, 100, 101, 3990, 3991, "+" +347, 19, 31, 987, 102, 105, 3992, 3995, "Met" +347, 19, 32, 988, 106, 111, 3996, 4001, "group" +347, 19, 33, 989, 112, 115, 4002, 4005, "and" +347, 19, 34, 990, 116, 117, 4006, 4007, "0" +347, 19, 35, 991, 118, 119, 4008, 4009, "." +347, 19, 36, 992, 120, 121, 4010, 4011, "6" +347, 19, 37, 993, 122, 123, 4012, 4013, "(" +347, 19, 38, 994, 124, 125, 4014, 4015, "0" +347, 19, 39, 995, 126, 127, 4016, 4017, "." +347, 19, 40, 996, 128, 129, 4018, 4019, "3" +347, 19, 41, 997, 130, 131, 4020, 4021, ")" +347, 19, 42, 998, 132, 133, 4022, 4023, "U" +347, 19, 43, 999, 134, 135, 4024, 4025, "/" +347, 19, 44, 1000, 136, 138, 4026, 4028, "kg" +347, 19, 45, 1001, 139, 141, 4029, 4031, "in" +347, 19, 46, 1002, 142, 145, 4032, 4035, "the" +347, 19, 47, 1003, 146, 147, 4036, 4037, "G" +347, 19, 48, 1004, 148, 149, 4038, 4039, "+" +347, 19, 49, 1005, 150, 153, 4040, 4043, "Met" +347, 19, 50, 1006, 154, 159, 4044, 4049, "group" +347, 19, 51, 1007, 160, 161, 4050, 4051, "(" +347, 19, 52, 1008, 162, 163, 4052, 4053, "P" +347, 19, 53, 1009, 164, 165, 4054, 4055, "<" +347, 19, 54, 1010, 166, 167, 4056, 4057, "0" +347, 19, 55, 1011, 168, 169, 4058, 4059, "." +347, 19, 56, 1012, 170, 173, 4060, 4063, "001" +347, 19, 57, 1013, 174, 175, 4064, 4065, ")" +347, 19, 58, 1014, 176, 177, 4066, 4067, "." +347, 20, 1, 1015, 0, 3, 4068, 4071, "The" +347, 20, 2, 1016, 4, 8, 4072, 4076, "mean" +347, 20, 3, 1017, 9, 10, 4077, 4078, "(" +347, 20, 4, 1018, 11, 13, 4079, 4081, "SD" +347, 20, 5, 1019, 14, 15, 4082, 4083, ")" +347, 20, 6, 1020, 16, 17, 4084, 4085, "M" +347, 20, 7, 1021, 18, 19, 4086, 4087, "-" +347, 20, 8, 1022, 20, 25, 4088, 4093, "value" +347, 20, 9, 1023, 26, 27, 4094, 4095, "(" +347, 20, 10, 1024, 28, 30, 4096, 4098, "an" +347, 20, 11, 1025, 31, 41, 4099, 4109, "expression" +347, 20, 12, 1026, 42, 44, 4110, 4112, "of" +347, 20, 13, 1027, 45, 49, 4113, 4117, "mean" +347, 20, 14, 1028, 50, 58, 4118, 4126, "glycemia" +347, 20, 15, 1029, 59, 62, 4127, 4130, "and" +347, 20, 16, 1030, 63, 66, 4131, 4134, "the" +347, 20, 17, 1031, 67, 73, 4135, 4141, "effect" +347, 20, 18, 1032, 74, 76, 4142, 4144, "of" +347, 20, 19, 1033, 77, 84, 4145, 4152, "glucose" +347, 20, 20, 1034, 85, 91, 4153, 4159, "swings" +347, 20, 21, 1035, 92, 93, 4160, 4161, ")" +347, 20, 22, 1036, 94, 97, 4162, 4165, "was" +347, 20, 23, 1037, 98, 111, 4166, 4179, "statistically" +347, 20, 24, 1038, 112, 119, 4180, 4187, "similar" +347, 20, 25, 1039, 120, 127, 4188, 4195, "between" +347, 20, 26, 1040, 128, 131, 4196, 4199, "the" +347, 20, 27, 1041, 132, 133, 4200, 4201, "2" +347, 20, 28, 1042, 134, 140, 4202, 4208, "groups" +347, 20, 29, 1043, 141, 143, 4209, 4211, "at" +347, 20, 30, 1044, 144, 152, 4212, 4220, "baseline" +347, 20, 31, 1045, 153, 156, 4221, 4224, "but" +347, 20, 32, 1046, 157, 170, 4225, 4238, "significantly" +347, 20, 33, 1047, 171, 176, 4239, 4244, "lower" +347, 20, 34, 1048, 177, 179, 4245, 4247, "in" +347, 20, 35, 1049, 180, 183, 4248, 4251, "the" +347, 20, 36, 1050, 184, 188, 4252, 4256, "LM50" +347, 20, 37, 1051, 189, 190, 4257, 4258, "/" +347, 20, 38, 1052, 191, 193, 4259, 4261, "50" +347, 20, 39, 1053, 194, 195, 4262, 4263, "+" +347, 20, 40, 1054, 196, 199, 4264, 4267, "Met" +347, 20, 41, 1055, 200, 205, 4268, 4273, "group" +347, 20, 42, 1056, 206, 208, 4274, 4276, "at" +347, 20, 43, 1057, 209, 212, 4277, 4280, "end" +347, 20, 44, 1058, 213, 218, 4281, 4286, "point" +347, 20, 45, 1059, 219, 220, 4287, 4288, "(" +347, 20, 46, 1060, 221, 223, 4289, 4291, "17" +347, 20, 47, 1061, 224, 225, 4292, 4293, "." +347, 20, 48, 1062, 226, 227, 4294, 4295, "3" +347, 20, 49, 1063, 228, 229, 4296, 4297, "[" +347, 20, 50, 1064, 230, 232, 4298, 4300, "13" +347, 20, 51, 1065, 233, 234, 4301, 4302, "." +347, 20, 52, 1066, 235, 236, 4303, 4304, "8" +347, 20, 53, 1067, 237, 238, 4305, 4306, "]" +347, 20, 54, 1068, 239, 241, 4307, 4309, "vs" +347, 20, 55, 1069, 242, 244, 4310, 4312, "25" +347, 20, 56, 1070, 245, 246, 4313, 4314, "." +347, 20, 57, 1071, 247, 248, 4315, 4316, "1" +347, 20, 58, 1072, 249, 250, 4317, 4318, "[" +347, 20, 59, 1073, 251, 253, 4319, 4321, "24" +347, 20, 60, 1074, 254, 255, 4322, 4323, "." +347, 20, 61, 1075, 256, 257, 4324, 4325, "8" +347, 20, 62, 1076, 258, 259, 4326, 4327, "]" +347, 20, 63, 1077, 260, 264, 4328, 4332, "mmol" +347, 20, 64, 1078, 265, 266, 4333, 4334, "/" +347, 20, 65, 1079, 267, 268, 4335, 4336, "L" +347, 20, 66, 1080, 269, 270, 4337, 4338, ";" +347, 20, 67, 1081, 271, 272, 4339, 4340, "P" +347, 20, 68, 1082, 273, 274, 4341, 4342, "<" +347, 20, 69, 1083, 275, 276, 4343, 4344, "0" +347, 20, 70, 1084, 277, 278, 4345, 4346, "." +347, 20, 71, 1085, 279, 282, 4347, 4350, "001" +347, 20, 72, 1086, 283, 284, 4351, 4352, ")" +347, 20, 73, 1087, 285, 286, 4353, 4354, "." +347, 21, 1, 1088, 0, 6, 4355, 4361, "During" +347, 21, 2, 1089, 7, 10, 4362, 4365, "the" +347, 21, 3, 1090, 11, 17, 4366, 4372, "entire" +347, 21, 4, 1091, 18, 27, 4373, 4382, "treatment" +347, 21, 5, 1092, 28, 34, 4383, 4389, "period" +347, 21, 6, 1093, 35, 36, 4390, 4391, "," +347, 21, 7, 1094, 37, 41, 4392, 4396, "mean" +347, 21, 8, 1095, 42, 43, 4397, 4398, "(" +347, 21, 9, 1096, 44, 46, 4399, 4401, "SD" +347, 21, 10, 1097, 47, 48, 4402, 4403, ")" +347, 21, 11, 1098, 49, 56, 4404, 4411, "overall" +347, 21, 12, 1099, 57, 60, 4412, 4415, "and" +347, 21, 13, 1100, 61, 70, 4416, 4425, "nocturnal" +347, 21, 14, 1101, 71, 83, 4426, 4438, "hypoglycemia" +347, 21, 15, 1102, 84, 89, 4439, 4444, "rates" +347, 21, 16, 1103, 90, 91, 4445, 4446, "(" +347, 21, 17, 1104, 92, 100, 4447, 4455, "episodes" +347, 21, 18, 1105, 101, 104, 4456, 4459, "per" +347, 21, 19, 1106, 105, 112, 4460, 4467, "patient" +347, 21, 20, 1107, 113, 116, 4468, 4471, "for" +347, 21, 21, 1108, 117, 119, 4472, 4474, "30" +347, 21, 22, 1109, 120, 124, 4475, 4479, "days" +347, 21, 23, 1110, 125, 126, 4480, 4481, ")" +347, 21, 24, 1111, 127, 131, 4482, 4486, "were" +347, 21, 25, 1112, 132, 145, 4487, 4500, "statistically" +347, 21, 26, 1113, 146, 153, 4501, 4508, "similar" +347, 21, 27, 1114, 154, 161, 4509, 4516, "between" +347, 21, 28, 1115, 162, 165, 4517, 4520, "the" +347, 21, 29, 1116, 166, 167, 4521, 4522, "2" +347, 21, 30, 1117, 168, 174, 4523, 4529, "groups" +347, 21, 31, 1118, 175, 176, 4530, 4531, "(" +347, 21, 32, 1119, 177, 184, 4532, 4539, "overall" +347, 21, 33, 1120, 185, 186, 4540, 4541, "," +347, 21, 34, 1121, 187, 188, 4542, 4543, "0" +347, 21, 35, 1122, 189, 190, 4544, 4545, "." +347, 21, 36, 1123, 191, 192, 4546, 4547, "8" +347, 21, 37, 1124, 193, 194, 4548, 4549, "[" +347, 21, 38, 1125, 195, 196, 4550, 4551, "1" +347, 21, 39, 1126, 197, 198, 4552, 4553, "." +347, 21, 40, 1127, 199, 200, 4554, 4555, "4" +347, 21, 41, 1128, 201, 202, 4556, 4557, "]" +347, 21, 42, 1129, 203, 205, 4558, 4560, "vs" +347, 21, 43, 1130, 206, 207, 4561, 4562, "0" +347, 21, 44, 1131, 208, 209, 4563, 4564, "." +347, 21, 45, 1132, 210, 211, 4565, 4566, "5" +347, 21, 46, 1133, 212, 213, 4567, 4568, "[" +347, 21, 47, 1134, 214, 215, 4569, 4570, "1" +347, 21, 48, 1135, 216, 217, 4571, 4572, "." +347, 21, 49, 1136, 218, 219, 4573, 4574, "0" +347, 21, 50, 1137, 220, 221, 4575, 4576, "]" +347, 21, 51, 1138, 222, 223, 4577, 4578, ";" +347, 21, 52, 1139, 224, 233, 4579, 4588, "nocturnal" +347, 21, 53, 1140, 234, 235, 4589, 4590, "," +347, 21, 54, 1141, 236, 237, 4591, 4592, "0" +347, 21, 55, 1142, 238, 239, 4593, 4594, "." +347, 21, 56, 1143, 240, 241, 4595, 4596, "2" +347, 21, 57, 1144, 242, 243, 4597, 4598, "[" +347, 21, 58, 1145, 244, 245, 4599, 4600, "0" +347, 21, 59, 1146, 246, 247, 4601, 4602, "." +347, 21, 60, 1147, 248, 249, 4603, 4604, "7" +347, 21, 61, 1148, 250, 251, 4605, 4606, "]" +347, 21, 62, 1149, 252, 254, 4607, 4609, "vs" +347, 21, 63, 1150, 255, 256, 4610, 4611, "0" +347, 21, 64, 1151, 257, 258, 4612, 4613, "." +347, 21, 65, 1152, 259, 260, 4614, 4615, "3" +347, 21, 66, 1153, 261, 262, 4616, 4617, "[" +347, 21, 67, 1154, 263, 264, 4618, 4619, "0" +347, 21, 68, 1155, 265, 266, 4620, 4621, "." +347, 21, 69, 1156, 267, 268, 4622, 4623, "6" +347, 21, 70, 1157, 269, 270, 4624, 4625, "]" +347, 21, 71, 1158, 271, 272, 4626, 4627, ")" +347, 21, 72, 1159, 273, 274, 4628, 4629, "." +347, 22, 1, 1160, 0, 2, 4630, 4632, "At" +347, 22, 2, 1161, 3, 6, 4633, 4636, "end" +347, 22, 3, 1162, 7, 12, 4637, 4642, "point" +347, 22, 4, 1163, 13, 14, 4643, 4644, "," +347, 22, 5, 1164, 15, 18, 4645, 4648, "the" +347, 22, 6, 1165, 19, 23, 4649, 4653, "mean" +347, 22, 7, 1166, 24, 25, 4654, 4655, "(" +347, 22, 8, 1167, 26, 28, 4656, 4658, "SD" +347, 22, 9, 1168, 29, 30, 4659, 4660, ")" +347, 22, 10, 1169, 31, 40, 4661, 4670, "nocturnal" +347, 22, 11, 1170, 41, 53, 4671, 4683, "hypoglycemia" +347, 22, 12, 1171, 54, 59, 4684, 4689, "rates" +347, 22, 13, 1172, 60, 64, 4690, 4694, "were" +347, 22, 14, 1173, 65, 72, 4695, 4702, "similar" +347, 22, 15, 1174, 73, 80, 4703, 4710, "between" +347, 22, 16, 1175, 81, 84, 4711, 4714, "the" +347, 22, 17, 1176, 85, 86, 4715, 4716, "2" +347, 22, 18, 1177, 87, 93, 4717, 4723, "groups" +347, 22, 19, 1178, 94, 95, 4724, 4725, "(" +347, 22, 20, 1179, 96, 97, 4726, 4727, "0" +347, 22, 21, 1180, 98, 99, 4728, 4729, "." +347, 22, 22, 1181, 100, 101, 4730, 4731, "2" +347, 22, 23, 1182, 102, 103, 4732, 4733, "[" +347, 22, 24, 1183, 104, 105, 4734, 4735, "0" +347, 22, 25, 1184, 106, 107, 4736, 4737, "." +347, 22, 26, 1185, 108, 109, 4738, 4739, "9" +347, 22, 27, 1186, 110, 111, 4740, 4741, "]" +347, 22, 28, 1187, 112, 114, 4742, 4744, "vs" +347, 22, 29, 1188, 115, 116, 4745, 4746, "0" +347, 22, 30, 1189, 117, 118, 4747, 4748, "." +347, 22, 31, 1190, 119, 120, 4749, 4750, "2" +347, 22, 32, 1191, 121, 122, 4751, 4752, "[" +347, 22, 33, 1192, 123, 124, 4753, 4754, "0" +347, 22, 34, 1193, 125, 126, 4755, 4756, "." +347, 22, 35, 1194, 127, 128, 4757, 4758, "6" +347, 22, 36, 1195, 129, 130, 4759, 4760, "]" +347, 22, 37, 1196, 131, 132, 4761, 4762, ")" +347, 22, 38, 1197, 133, 134, 4763, 4764, "," +347, 22, 39, 1198, 135, 138, 4765, 4768, "but" +347, 22, 40, 1199, 139, 142, 4769, 4772, "the" +347, 22, 41, 1200, 143, 150, 4773, 4780, "overall" +347, 22, 42, 1201, 151, 154, 4781, 4784, "and" +347, 22, 43, 1202, 155, 158, 4785, 4788, "non" +347, 22, 44, 1203, 159, 160, 4789, 4790, "-" +347, 22, 45, 1204, 161, 170, 4791, 4800, "nocturnal" +347, 22, 46, 1205, 171, 183, 4801, 4813, "hypoglycemia" +347, 22, 47, 1206, 184, 189, 4814, 4819, "rates" +347, 22, 48, 1207, 190, 194, 4820, 4824, "were" +347, 22, 49, 1208, 195, 201, 4825, 4831, "higher" +347, 22, 50, 1209, 202, 206, 4832, 4836, "with" +347, 22, 51, 1210, 207, 211, 4837, 4841, "LM50" +347, 22, 52, 1211, 212, 213, 4842, 4843, "/" +347, 22, 53, 1212, 214, 216, 4844, 4846, "50" +347, 22, 54, 1213, 217, 218, 4847, 4848, "+" +347, 22, 55, 1214, 219, 222, 4849, 4852, "Met" +347, 22, 56, 1215, 223, 224, 4853, 4854, "(" +347, 22, 57, 1216, 225, 232, 4855, 4862, "overall" +347, 22, 58, 1217, 233, 234, 4863, 4864, "," +347, 22, 59, 1218, 235, 236, 4865, 4866, "0" +347, 22, 60, 1219, 237, 238, 4867, 4868, "." +347, 22, 61, 1220, 239, 240, 4869, 4870, "7" +347, 22, 62, 1221, 241, 242, 4871, 4872, "[" +347, 22, 63, 1222, 243, 244, 4873, 4874, "1" +347, 22, 64, 1223, 245, 246, 4875, 4876, "." +347, 22, 65, 1224, 247, 248, 4877, 4878, "7" +347, 22, 66, 1225, 249, 250, 4879, 4880, "]" +347, 22, 67, 1226, 251, 253, 4881, 4883, "vs" +347, 22, 68, 1227, 254, 255, 4884, 4885, "0" +347, 22, 69, 1228, 256, 257, 4886, 4887, "." +347, 22, 70, 1229, 258, 259, 4888, 4889, "3" +347, 22, 71, 1230, 260, 261, 4890, 4891, "[" +347, 22, 72, 1231, 262, 263, 4892, 4893, "0" +347, 22, 73, 1232, 264, 265, 4894, 4895, "." +347, 22, 74, 1233, 266, 267, 4896, 4897, "8" +347, 22, 75, 1234, 268, 269, 4898, 4899, "]" +347, 22, 76, 1235, 270, 271, 4900, 4901, ";" +347, 22, 77, 1236, 272, 273, 4902, 4903, "P" +347, 22, 78, 1237, 274, 275, 4904, 4905, "=" +347, 22, 79, 1238, 276, 277, 4906, 4907, "0" +347, 22, 80, 1239, 278, 279, 4908, 4909, "." +347, 22, 81, 1240, 280, 282, 4910, 4912, "02" +347, 22, 82, 1241, 283, 284, 4913, 4914, ";" +347, 22, 83, 1242, 285, 288, 4915, 4918, "non" +347, 22, 84, 1243, 289, 290, 4919, 4920, "-" +347, 22, 85, 1244, 291, 300, 4921, 4930, "nocturnal" +347, 22, 86, 1245, 301, 302, 4931, 4932, "," +347, 22, 87, 1246, 303, 304, 4933, 4934, "0" +347, 22, 88, 1247, 305, 306, 4935, 4936, "." +347, 22, 89, 1248, 307, 308, 4937, 4938, "5" +347, 22, 90, 1249, 309, 310, 4939, 4940, "[" +347, 22, 91, 1250, 311, 312, 4941, 4942, "1" +347, 22, 92, 1251, 313, 314, 4943, 4944, "." +347, 22, 93, 1252, 315, 316, 4945, 4946, "2" +347, 22, 94, 1253, 317, 318, 4947, 4948, "]" +347, 22, 95, 1254, 319, 321, 4949, 4951, "vs" +347, 22, 96, 1255, 322, 323, 4952, 4953, "0" +347, 22, 97, 1256, 324, 325, 4954, 4955, "." +347, 22, 98, 1257, 326, 327, 4956, 4957, "1" +347, 22, 99, 1258, 328, 329, 4958, 4959, "[" +347, 22, 100, 1259, 330, 331, 4960, 4961, "0" +347, 22, 101, 1260, 332, 333, 4962, 4963, "." +347, 22, 102, 1261, 334, 335, 4964, 4965, "4" +347, 22, 103, 1262, 336, 337, 4966, 4967, "]" +347, 22, 104, 1263, 338, 339, 4968, 4969, ";" +347, 22, 105, 1264, 340, 341, 4970, 4971, "P" +347, 22, 106, 1265, 342, 343, 4972, 4973, "=" +347, 22, 107, 1266, 344, 345, 4974, 4975, "0" +347, 22, 108, 1267, 346, 347, 4976, 4977, "." +347, 22, 109, 1268, 348, 351, 4978, 4981, "002" +347, 22, 110, 1269, 352, 353, 4982, 4983, ")" +347, 22, 111, 1270, 354, 355, 4984, 4985, "." +347, 23, 1, 1271, 0, 10, 4986, 4996, "CONCLUSION" +347, 23, 2, 1272, 11, 12, 4997, 4998, ":" +347, 23, 3, 1273, 13, 15, 4999, 5001, "In" +347, 23, 4, 1274, 16, 21, 5002, 5007, "these" +347, 23, 5, 1275, 22, 30, 5008, 5016, "patients" +347, 23, 6, 1276, 31, 35, 5017, 5021, "with" +347, 23, 7, 1277, 36, 40, 5022, 5026, "type" +347, 23, 8, 1278, 41, 42, 5027, 5028, "2" +347, 23, 9, 1279, 43, 51, 5029, 5037, "diabetes" +347, 23, 10, 1280, 52, 53, 5038, 5039, "," +347, 23, 11, 1281, 54, 62, 5040, 5048, "mealtime" +347, 23, 12, 1282, 63, 67, 5049, 5053, "LM50" +347, 23, 13, 1283, 68, 69, 5054, 5055, "/" +347, 23, 14, 1284, 70, 72, 5056, 5058, "50" +347, 23, 15, 1285, 73, 74, 5059, 5060, "+" +347, 23, 16, 1286, 75, 78, 5061, 5064, "Met" +347, 23, 17, 1287, 79, 82, 5065, 5068, "was" +347, 23, 18, 1288, 83, 93, 5069, 5079, "associated" +347, 23, 19, 1289, 94, 98, 5080, 5084, "with" +347, 23, 20, 1290, 99, 104, 5085, 5090, "lower" +347, 23, 21, 1291, 105, 112, 5091, 5098, "overall" +347, 23, 22, 1292, 113, 114, 5099, 5100, "(" +347, 23, 23, 1293, 115, 118, 5101, 5104, "HbA" +347, 23, 24, 1294, 119, 120, 5105, 5106, "(" +347, 23, 25, 1295, 121, 123, 5107, 5109, "1c" +347, 23, 26, 1296, 124, 125, 5110, 5111, ")" +347, 23, 27, 1297, 126, 127, 5112, 5113, ")" +347, 23, 28, 1298, 128, 131, 5114, 5117, "and" +347, 23, 29, 1299, 132, 143, 5118, 5129, "preprandial" +347, 23, 30, 1300, 144, 146, 5130, 5132, "BG" +347, 23, 31, 1301, 147, 150, 5133, 5136, "and" +347, 23, 32, 1302, 151, 155, 5137, 5141, "PPBG" +347, 23, 33, 1303, 156, 162, 5142, 5148, "levels" +347, 23, 34, 1304, 163, 164, 5149, 5150, "(" +347, 23, 35, 1305, 165, 171, 5151, 5157, "except" +347, 23, 36, 1306, 172, 175, 5158, 5161, "for" +347, 23, 37, 1307, 176, 179, 5162, 5165, "FBG" +347, 23, 38, 1308, 180, 181, 5166, 5167, ")" +347, 23, 39, 1309, 182, 183, 5168, 5169, "," +347, 23, 40, 1310, 184, 188, 5170, 5174, "with" +347, 23, 41, 1311, 189, 196, 5175, 5182, "similar" +347, 23, 42, 1312, 197, 206, 5183, 5192, "nocturnal" +347, 23, 43, 1313, 207, 219, 5193, 5205, "hypoglycemia" +347, 23, 44, 1314, 220, 223, 5206, 5209, "and" +347, 23, 45, 1315, 224, 228, 5210, 5214, "less" +347, 23, 46, 1316, 229, 237, 5215, 5223, "glycemic" +347, 23, 47, 1317, 238, 249, 5224, 5235, "variability" +347, 23, 48, 1318, 250, 251, 5236, 5237, "," +347, 23, 49, 1319, 252, 260, 5238, 5246, "compared" +347, 23, 50, 1320, 261, 265, 5247, 5251, "with" +347, 23, 51, 1321, 266, 267, 5252, 5253, "G" +347, 23, 52, 1322, 268, 269, 5254, 5255, "+" +347, 23, 53, 1323, 270, 273, 5256, 5259, "Met" +347, 23, 54, 1324, 274, 275, 5260, 5261, "." +347, 24, 1, 1325, 0, 9, 5262, 5271, "Copyright" +347, 24, 2, 1326, 10, 11, 5272, 5273, "(" +347, 24, 3, 1327, 12, 13, 5274, 5275, "c" +347, 24, 4, 1328, 14, 15, 5276, 5277, ")" +347, 24, 5, 1329, 16, 20, 5278, 5282, "2007" +347, 24, 6, 1330, 21, 29, 5283, 5291, "Excerpta" +347, 24, 7, 1331, 30, 36, 5292, 5298, "Medica" +347, 24, 8, 1332, 37, 38, 5299, 5300, "," +347, 24, 9, 1333, 39, 42, 5301, 5304, "Inc" +347, 24, 10, 1334, 43, 44, 5305, 5306, "." +347, 24, 11, 1335, 45, 48, 5307, 5310, "DOI" +347, 24, 12, 1336, 49, 50, 5311, 5312, ":" +347, 24, 13, 1337, 51, 53, 5313, 5315, "10" +347, 24, 14, 1338, 54, 55, 5316, 5317, "." +347, 24, 15, 1339, 56, 60, 5318, 5322, "1016" +347, 24, 16, 1340, 61, 62, 5323, 5324, "/" +347, 24, 17, 1341, 63, 64, 5325, 5326, "j" +347, 24, 18, 1342, 65, 66, 5327, 5328, "." +347, 24, 19, 1343, 67, 76, 5329, 5338, "clinthera" +347, 24, 20, 1344, 77, 78, 5339, 5340, "." +347, 24, 21, 1345, 79, 83, 5341, 5345, "2007" +347, 24, 22, 1346, 84, 85, 5346, 5347, "." +347, 24, 23, 1347, 86, 88, 5348, 5350, "11" +347, 24, 24, 1348, 89, 90, 5351, 5352, "." +347, 24, 25, 1349, 91, 94, 5353, 5356, "016" +347, 24, 26, 1350, 95, 99, 5357, 5361, "PMID" +347, 24, 27, 1351, 100, 101, 5362, 5363, ":" +347, 24, 28, 1352, 102, 110, 5364, 5372, "18158076" +347, 24, 29, 1353, 111, 112, 5373, 5374, "[" +347, 24, 30, 1354, 113, 120, 5375, 5382, "Indexed" +347, 24, 31, 1355, 121, 124, 5383, 5386, "for" +347, 24, 32, 1356, 125, 132, 5387, 5394, "MEDLINE" +347, 24, 33, 1357, 133, 134, 5395, 5396, "]" diff --git a/data/dm2 18158076_kwoodley.annodb b/data/dm2 18158076_kwoodley.annodb new file mode 100644 index 0000000..e10754c --- /dev/null +++ b/data/dm2 18158076_kwoodley.annodb @@ -0,0 +1,259 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +14196, Journal, 0, 9, "Clin Ther", "", +14197, PublicationYear, 12, 16, "2007", "", +14207, RelativeTime, 47, 55, "Mealtime", "", +14239, Title, 47, 245, "Mealtime 50 / 50 basal + prandial insulin analogue mixture with a basal insulin analogue , both plus metformin , in the achievement of target HbA1c and pre - and postprandial blood glucose levels in", "", +14209, Drug, 56, 105, "50 / 50 basal + prandial insulin analogue mixture", "", +14208, Drug, 113, 135, "basal insulin analogue", "", +14198, Metformin, 148, 157, "metformin", "", +14199, HbA1c_target, 182, 194, "target HbA1c", "", +36753, Title, 246, 365, "patients with type 2 diabetes : a multinational , 24 - week , randomized , open - label , parallel - group comparison .", "", +14201, Type2Diabetes, 260, 275, "type 2 diabetes", "", +36754, Multicenter, 280, 293, "multinational", "", +14203, Duration, 296, 305, "24 - week", "", +14204, Randomized, 308, 318, "randomized", "", +14205, OpenLabel, 321, 333, "open - label", "", +14206, Parallel, 336, 352, "parallel - group", "", +14210, Author, 366, 376, "Robbins DC", "", +14211, Author, 385, 399, "Beisswenger PJ", "", +14212, Author, 402, 412, "Ceriello A", "", +14213, Author, 415, 426, "Goldberg RB", "", +14214, Author, 429, 437, "Moses RG", "", +14215, Author, 440, 451, "Pagkalos EM", "", +14216, Author, 454, 465, "Milicevic Z", "", +14217, Author, 468, 476, "Jones CA", "", +14218, Author, 479, 487, "Sarwat S", "", +14219, Author, 490, 496, "Tan MH", "", +14220, USA, 615, 618, "USA", "", +14221, Insulin, 691, 698, "insulin", "", +36755, Insulin, 788, 795, "insulin", "", +14222, Insulin, 874, 881, "insulin", "", +14224, Frequency, 919, 931, "once - daily", "", +14225, Drug, 932, 945, "basal insulin", "", +14223, Type2Diabetes, 963, 980, "diabetes mellitus", "", +36756, Lispro, 989, 1014, "lispro mix ( LM ) 50 / 50", "", +14227, HbA1c, 1086, 1109, "glycosylated hemoglobin", "", +14228, HbA1c, 1112, 1122, "HbA ( lc )", "", +36757, PreprandialBloodGlucose, 1129, 1132, "pre", "", +36758, PostprandialBloodGlucose, 1139, 1165, "postprandial blood glucose", "", +36759, BloodGlucose, 1168, 1170, "BG", "", +14241, ObjectiveDescription, 1222, 1407, "The aim of this study was to test the hypothesis that treatment with a premixed insulin analogue containing 50 / 50 basal + prandial insulins administered before each meal would achieve", "", +14231, Drug, 1293, 1318, "premixed insulin analogue", "", +14232, Drug, 1330, 1363, "50 / 50 basal + prandial insulins", "", +36761, Frequency, 1377, 1393, "before each meal", "", +36760, ObjectiveDescription, 1408, 1568, "lower overall and mealtime glycemic control than once - daily basal insulin analogue , both plus metformin ( Met ) , in patients with type 2 diabetes mellitus .", "", +14234, Frequency, 1457, 1469, "once - daily", "", +14235, Drug, 1470, 1492, "basal insulin analogue", "", +14236, Metformin, 1505, 1514, "metformin", "", +14237, Metformin, 1517, 1520, "Met", "", +14238, Type2Diabetes, 1542, 1566, "type 2 diabetes mellitus", "", +14243, Duration, 1584, 1593, "24 - week", "", +14244, Randomized, 1596, 1606, "randomized", "", +14245, OpenLabel, 1609, 1621, "open - label", "", +14246, Parallel, 1624, 1640, "parallel - group", "", +14247, Multicenter, 1664, 1771, "38 sites across Australia , Greece , India , The Netherlands , Poland , Puerto Rico , and the United States", "", +14248, MinAge, 1804, 1806, "35", "", +14249, MaxAge, 1810, 1812, "75", "", +14260, Precondition, 1819, 2045, "with type 2 diabetes mellitus and an HbA ( 1c ) level of 6 . 5 % to 11 . 0 % , who were receiving metformin and / or a sulfonylurea with a stable dose of 0 to 2 daily insulin injections over the previous 3 months were eligible", "", +14250, Type2Diabetes, 1824, 1848, "type 2 diabetes mellitus", "", +14251, HbA1c, 1856, 1866, "HbA ( 1c )", "", +14252, Percentage, 1882, 1883, "%", "", +14253, Percentage, 1894, 1895, "%", "", +14254, Metformin, 1917, 1926, "metformin", "", +14255, Sulfonylureas, 1938, 1950, "sulfonylurea", "", +14256, DoseValue, 1973, 1979, "0 to 2", "", +14257, Frequency, 1980, 1985, "daily", "", +14258, Insulin, 1986, 1993, "insulin", "", +14259, Duration, 2023, 2031, "3 months", "before trial", +14261, Randomized, 2062, 2070, "randomly", "", +36762, Lispro, 2091, 2100, "LM50 / 50", "", +36763, Lispro, 2108, 2143, "insulin lispro protamine suspension", "", +36764, Lispro, 2146, 2150, "ILPS", "", +36765, Lispro, 2162, 2168, "lispro", "", +14266, Frequency, 2171, 2174, "TID", "three times daily", +14268, Metformin, 2180, 2189, "metformin", "", +14269, Frequency, 2217, 2222, "daily", "", +14270, DoseValue, 2233, 2243, "500 - 1000", "", +14271, mg, 2244, 2246, "mg", "", +14272, Frequency, 2247, 2250, "BID", "twice daily", +36766, Lispro, 2255, 2264, "LM50 / 50", "", +14274, Metformin, 2267, 2270, "Met", "", +14275, InsulinGlargine, 2276, 2292, "insulin glargine", "", +36767, RelativeTime, 2299, 2306, "bedtime", "", +14277, Metformin, 2312, 2321, "metformin", "", +14278, DoseValue, 2324, 2334, "500 - 1000", "", +14279, mg, 2335, 2337, "mg", "", +14280, Frequency, 2338, 2341, "BID", "twice daily", +14281, InsulinGlargine, 2346, 2347, "G", "", +14282, Metformin, 2350, 2353, "Met", "", +14283, Duration, 2360, 2368, "24 weeks", "", +36768, Lispro, 2376, 2385, "LM50 / 50", "", +14285, Metformin, 2388, 2391, "Met", "", +14286, Insulin, 2398, 2405, "insulin", "", +36769, FastingBloodGlucose_target, 2427, 2498, "target a fasting BG ( FBG ) level of < 6 . 7 mmol / L ( < 120 mg / dL )", "", +36770, PostprandialBloodGlucose, 2505, 2532, "2 - hour post - prandial BG", "", +36771, PostprandialBloodGlucose, 2535, 2539, "PPBG", "", +14295, Millimoles_per_litre, 2559, 2567, "mmol / L", "", +14296, Mg_per_deciliter, 2576, 2583, "mg / dL", "", +36772, FastingBloodGlucose_target, 2616, 2626, "FBG target", "", +14297, RelativeTime, 2650, 2659, "presupper", "", +36773, Lispro, 2660, 2669, "LM50 / 50", "", +36774, Lispro, 2673, 2682, "LM75 / 25", "", +36775, Lispro, 2690, 2694, "ILPS", "", +36776, Lispro, 2702, 2708, "lispro", "", +14302, NumberPatientsCT, 2734, 2737, "315", "", +14303, Randomized, 2752, 2762, "randomized", "", +14304, Female, 2788, 2797, "158 women", "", +14306, Male, 2800, 2807, "157 men", "", +14307, AvgAge, 2821, 2833, "57 . 7 years", "", +14308, BMI, 2841, 2856, "body mass index", "", +14309, Kg_per_squareMeter, 2866, 2873, "kg / m2", "", +36777, Lispro, 2876, 2885, "LM50 / 50", "", +14311, Metformin, 2888, 2891, "Met", "", +14312, NumberPatientsArm, 2894, 2897, "157", "", +14314, InsulinGlargine, 2909, 2910, "G", "", +14315, Metformin, 2913, 2916, "Met", "", +14313, NumberPatientsArm, 2919, 2922, "158", "", +36778, TimePoint, 2939, 2947, "24 weeks", "", +14317, HbA1c, 2966, 2976, "HbA ( 1c )", "", +36779, Lispro, 3014, 3023, "LM50 / 50", "", +14319, Metformin, 3026, 3029, "Met", "", +14321, InsulinGlargine, 3048, 3049, "G", "", +14320, Metformin, 3052, 3055, "Met", "", +14322, ResultMeasuredValue, 3064, 3069, "7 . 1", "", +14324, Percentage, 3070, 3071, "%", "", +14326, SdDevResValue, 3074, 3079, "0 . 9", "", +14323, ResultMeasuredValue, 3087, 3092, "7 . 5", "", +14325, Percentage, 3093, 3094, "%", "", +14327, SdDevResValue, 3097, 3102, "1 . 0", "", +14328, PvalueDiff, 3109, 3120, "P < 0 . 001", "", +14329, HbA1c_target, 3159, 3194, "HbA ( 1c ) target of < or = 7 . 0 %", "", +14330, NumberAffected, 3209, 3211, "88", "", +14332, PercentageAffected, 3214, 3220, "56 . 1", "", +14331, NumberAffected, 3228, 3230, "63", "", +14333, PercentageAffected, 3233, 3239, "39 . 9", "", +14334, PvalueDiff, 3246, 3257, "P = 0 . 005", "", +14335, InsulinGlargine, 3266, 3267, "G", "", +14336, Metformin, 3270, 3273, "Met", "", +36780, FastingBloodGlucose, 3304, 3307, "FBG", "", +14338, ResultMeasuredValue, 3316, 3321, "6 . 5", "", +14340, SdDevResValue, 3324, 3329, "1 . 6", "", +14339, ResultMeasuredValue, 3335, 3340, "8 . 1", "", +14341, SdDevResValue, 3343, 3348, "1 . 8", "", +14342, Millimoles_per_litre, 3351, 3359, "mmol / L", "", +14343, PvalueDiff, 3362, 3373, "P < 0 . 001", "", +36781, Lispro, 3382, 3391, "LM50 / 50", "", +14345, Metformin, 3394, 3397, "Met", "", +36782, PreprandialBloodGlucose, 3419, 3433, "preprandial BG", "", +14349, TimePoint, 3441, 3449, "prelunch", "", +14351, ResultMeasuredValue, 3452, 3457, "7 . 4", "", +14355, SdDevResValue, 3460, 3465, "1 . 9", "", +14352, ResultMeasuredValue, 3471, 3476, "7 . 9", "", +14356, SdDevResValue, 3479, 3484, "2 . 1", "", +14359, Millimoles_per_litre, 3487, 3495, "mmol / L", "", +14361, PvalueDiff, 3498, 3508, "P = 0 . 03", "", +14350, TimePoint, 3515, 3524, "presupper", "", +14353, ResultMeasuredValue, 3527, 3532, "8 . 3", "", +14357, SdDevResValue, 3535, 3540, "2 . 0", "", +14354, ResultMeasuredValue, 3546, 3551, "8 . 9", "", +14358, SdDevResValue, 3554, 3559, "2 . 8", "", +14360, Millimoles_per_litre, 3562, 3570, "mmol / L", "", +14363, PvalueDiff, 3573, 3583, "P = 0 . 04", "", +36783, Lispro, 3592, 3601, "LM50 / 50", "", +14365, Metformin, 3604, 3607, "Met", "", +36784, PostprandialBloodGlucose, 3634, 3647, "2 - hour PPBG", "", +14368, TimePoint, 3655, 3668, "postbreakfast", "", +14370, ResultMeasuredValue, 3671, 3676, "8 . 7", "", +14377, SdDevResValue, 3679, 3684, "2 . 2", "", +14371, ResultMeasuredValue, 3690, 3695, "9 . 2", "", +14378, SdDevResValue, 3698, 3703, "2 . 5", "", +14383, Millimoles_per_litre, 3706, 3714, "mmol / L", "", +14386, PvalueDiff, 3717, 3727, "P = 0 . 03", "", +14376, TimePoint, 3732, 3741, "postlunch", "", +14372, ResultMeasuredValue, 3744, 3749, "8 . 4", "", +14379, SdDevResValue, 3752, 3757, "1 . 9", "", +14373, ResultMeasuredValue, 3763, 3768, "9 . 8", "", +14380, SdDevResValue, 3771, 3776, "2 . 6", "", +14384, Millimoles_per_litre, 3781, 3789, "mmol / L", "", +14387, PvalueDiff, 3792, 3803, "p < 0 . 001", "", +14369, TimePoint, 3812, 3822, "postsupper", "", +14374, ResultMeasuredValue, 3825, 3830, "8 . 7", "", +14381, SdDevResValue, 3833, 3838, "2 . 2", "", +14375, ResultMeasuredValue, 3844, 3850, "10 . 7", "", +14382, SdDevResValue, 3853, 3858, "3 . 2", "", +14385, Millimoles_per_litre, 3863, 3871, "mmol / L", "", +14388, PvalueDiff, 3874, 3885, "P < 0 . 001", "", +36785, InsulinDose, 3912, 3925, "insulin doses", "", +14390, ResultMeasuredValue, 3950, 3955, "0 . 7", "", +14392, SdDevResValue, 3958, 3963, "0 . 3", "", +14394, IntUnit_per_Kg, 3966, 3972, "U / kg", "", +36786, Lispro, 3980, 3989, "LM50 / 50", "", +14397, Metformin, 3992, 3995, "Met", "", +14391, ResultMeasuredValue, 4006, 4011, "0 . 6", "", +14393, SdDevResValue, 4014, 4019, "0 . 3", "", +14395, IntUnit_per_Kg, 4022, 4028, "U / kg", "", +14398, InsulinGlargine, 4036, 4037, "G", "", +14399, Metformin, 4040, 4043, "Met", "", +14400, PvalueDiff, 4052, 4063, "P < 0 . 001", "", +14401, EndPointDescription, 4084, 4093, "M - value", "", +14402, EndPointDescription, 4096, 4159, "an expression of mean glycemia and the effect of glucose swings", "", +36787, TimePoint, 4212, 4220, "baseline", "", +36788, Lispro, 4252, 4261, "LM50 / 50", "", +14404, Metformin, 4264, 4267, "Met", "", +36789, TimePoint, 4277, 4286, "end point", "", +14405, ResultMeasuredValue, 4289, 4295, "17 . 3", "", +14407, SdDevResValue, 4298, 4304, "13 . 8", "", +14406, ResultMeasuredValue, 4310, 4316, "25 . 1", "", +14408, SdDevResValue, 4319, 4325, "24 . 8", "", +14409, Millimoles_per_litre, 4328, 4336, "mmol / L", "", +14410, PvalueDiff, 4339, 4350, "P < 0 . 001", "", +14426, TimePoint, 4355, 4389, "During the entire treatment period", "", +36790, Hypoglycemia, 4404, 4411, "overall", "", +36791, NocturnalHypoglycemia, 4416, 4438, "nocturnal hypoglycemia", "", +14415, BioAndMedicalUnit, 4447, 4479, "episodes per patient for 30 days", "", +14413, Hypoglycemia, 4532, 4539, "overall", "", +14416, ResultMeasuredValue, 4542, 4547, "0 . 8", "", +14418, SdDevResValue, 4550, 4555, "1 . 4", "", +14417, ResultMeasuredValue, 4561, 4566, "0 . 5", "", +14419, SdDevResValue, 4569, 4574, "1 . 0", "", +14420, NocturnalHypoglycemia, 4579, 4588, "nocturnal", "", +14421, ResultMeasuredValue, 4591, 4596, "0 . 2", "", +14423, SdDevResValue, 4599, 4604, "0 . 7", "", +14422, ResultMeasuredValue, 4610, 4615, "0 . 3", "", +14424, SdDevResValue, 4618, 4623, "0 . 6", "", +36792, TimePoint, 4633, 4642, "end point", "", +14425, NocturnalHypoglycemia, 4661, 4683, "nocturnal hypoglycemia", "", +14428, ResultMeasuredValue, 4726, 4731, "0 . 2", "", +14430, SdDevResValue, 4734, 4739, "0 . 9", "", +14429, ResultMeasuredValue, 4745, 4750, "0 . 2", "", +14431, SdDevResValue, 4753, 4758, "0 . 6", "", +36793, Hypoglycemia, 4773, 4780, "overall", "", +36794, Hypoglycemia, 4785, 4813, "non - nocturnal hypoglycemia", "", +36795, Lispro, 4837, 4846, "LM50 / 50", "", +14448, Metformin, 4849, 4852, "Met", "", +14449, Hypoglycemia, 4855, 4862, "overall", "", +14450, ResultMeasuredValue, 4865, 4870, "0 . 7", "", +14456, SdDevResValue, 4873, 4878, "1 . 7", "", +14451, ResultMeasuredValue, 4884, 4889, "0 . 3", "", +14457, SdDevResValue, 4892, 4897, "0 . 8", "", +14458, PvalueDiff, 4902, 4912, "P = 0 . 02", "", +36796, Hypoglycemia, 4915, 4930, "non - nocturnal", "", +14452, ResultMeasuredValue, 4933, 4938, "0 . 5", "", +14454, SdDevResValue, 4941, 4946, "1 . 2", "", +14453, ResultMeasuredValue, 4952, 4957, "0 . 1", "", +14455, SdDevResValue, 4960, 4965, "0 . 4", "", +14459, PvalueDiff, 4970, 4981, "P = 0 . 002", "", +14473, ConclusionComment, 4999, 5148, "In these patients with type 2 diabetes , mealtime LM50 / 50 + Met was associated with lower overall ( HbA ( 1c ) ) and preprandial BG and PPBG levels", "", +14461, Type2Diabetes, 5022, 5037, "type 2 diabetes", "", +14462, RelativeTime, 5040, 5048, "mealtime", "", +36797, Lispro, 5049, 5058, "LM50 / 50", "", +14464, Metformin, 5061, 5064, "Met", "", +14465, HbA1c, 5101, 5111, "HbA ( 1c )", "", +36798, PreprandialBloodGlucose, 5118, 5132, "preprandial BG", "", +36799, PostprandialBloodGlucose, 5137, 5141, "PPBG", "", +36800, ConclusionComment, 5149, 5261, "( except for FBG ) , with similar nocturnal hypoglycemia and less glycemic variability , compared with G + Met .", "", +36801, FastingBloodGlucose, 5162, 5165, "FBG", "", +14469, NocturnalHypoglycemia, 5183, 5205, "nocturnal hypoglycemia", "", +14471, InsulinGlargine, 5252, 5253, "G", "", +14472, Metformin, 5256, 5259, "Met", "", +14475, PMID, 5364, 5372, "18158076", "", diff --git a/data/dm2 18158076_kwoodley.n-triples b/data/dm2 18158076_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18158076_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18194595 copy_admin.annodb b/data/dm2 18194595 copy_admin.annodb new file mode 100644 index 0000000..aef447a --- /dev/null +++ b/data/dm2 18194595 copy_admin.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2008", "", " \"2008\"." +83, Title, 90, 194, "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .", "", " \"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .\"." +2, Sitagliptin, 113, 124, "sitagliptin", "", +3, Metformin, 142, 151, "metformin", "", +4, Type2Diabetes, 177, 192, "type 2 diabetes", "", " ." +5, Author, 195, 200, "Raz I", "", " \"Raz I\"." +6, Author, 209, 215, "Chen Y", "", " \"Chen Y\"." +7, Author, 218, 222, "Wu M", "", " \"Wu M\"." +8, Author, 225, 234, "Hussain S", "", " \"Hussain S\"." +9, Author, 237, 247, "Kaufman KD", "", " \"Kaufman KD\"." +10, Author, 250, 261, "Amatruda JM", "", " \"Amatruda JM\"." +11, Author, 264, 274, "Langdon RB", "", " \"Langdon RB\"." +12, Author, 277, 285, "Stein PP", "", " \"Stein PP\"." +13, Author, 288, 294, "Alba M", "", " \"Alba M\"." +14, Israel, 424, 430, "Israel", "", " ." +100, ObjectiveDescription, 445, 691, "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .", "", " \"The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .\"." +15, Sitagliptin, 514, 525, "sitagliptin", "", +22, Precondition, 532, 689, "add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )", "", " \"add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )\"." +16, Metformin, 544, 553, "metformin", "", +17, HbA1c, 599, 618, "hemoglobin A ( 1c )", "", +18, Percentage, 632, 633, "%", "", +19, Percentage, 652, 653, "%", "", +20, Type2Diabetes, 656, 680, "type 2 diabetes mellitus", "", +21, Type2Diabetes, 683, 687, "T2DM", "", +101, Multicenter, 733, 746, "multinational", "", " ." +23, Randomized, 749, 759, "randomized", "", " ." +103, Placebo, 762, 769, "placebo", "", +24, Parallel, 785, 801, "parallel - group", "", " ." +25, DoubleBlind, 804, 818, "double - blind", "", " ." +26, NumberPatientsCT, 838, 841, "190", "", " \"190\"." +27, Type2Diabetes, 856, 860, "T2DM", "", +29, Metformin, 894, 903, "metformin", "", " ." +30, DoseValue, 918, 929, "> or = 1500", "", " \"> or = 1500\"." +31, mg, 930, 932, "mg", "", " ." +32, Interval, 935, 938, "day", "", " \"day\"." +33, Randomized, 957, 967, "randomized", "", +34, Sitagliptin, 994, 1005, "sitagliptin", "", " ." +35, DoseValue, 1006, 1009, "100", "", " \"100\"." +36, mg, 1010, 1012, "mg", "", " ." +37, Frequency, 1013, 1023, "once daily", "", " \"once daily\"." +38, Placebo, 1027, 1034, "placebo", "", " ." +39, Metformin, 1046, 1055, "metformin", "", +40, Duration, 1060, 1068, "30 weeks", "", " \"30 weeks\"." +41, HbA1c, 1142, 1161, "hemoglobin A ( 1c )", "", +42, HbA1c, 1164, 1174, "HbA ( 1c )", "", " ." +43, TimePoint, 1186, 1200, "after 18 weeks", "", +44, Sitagliptin, 1204, 1215, "sitagliptin", "", +45, FastingPlasmaGlucose, 1274, 1296, "fasting plasma glucose", "", +46, FastingPlasmaGlucose, 1299, 1302, "FPG", "", +51505, EndPointDescription, 1309, 1355, "2 - hour ( 2 - h ) postprandial plasma glucose", "", +170, PostprandialPlasmaGlucose, 1328, 1355, "postprandial plasma glucose", "", +171, PostprandialPlasmaGlucose, 1358, 1361, "PPG", "", +172, TimePoint, 1367, 1375, "18 weeks", "", +47, HbA1c, 1382, 1392, "HbA ( 1c )", "", +173, TimePoint, 1396, 1404, "30 weeks", "", +48, HbA1c_target, 1454, 1474, "HbA ( 1c ) < 7 . 0 %", "", +132, Percentage, 1473, 1474, "%", "", +49, Sitagliptin, 1505, 1516, "Sitagliptin", "", +50, HbA1c, 1539, 1549, "HbA ( 1c )", "", +51, FastingPlasmaGlucose, 1552, 1555, "FPG", "", " ." +51504, EndPointDescription, 1562, 1571, "2 - h PPG", "", " . ." +51500, PostprandialPlasmaGlucose, 1568, 1571, "PPG", "", +52, Placebo, 1588, 1595, "placebo", "", +77, PvalueDiff, 1602, 1613, "p < 0 . 001", "", " \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\"." +53, HbA1c, 1641, 1651, "HbA ( 1c )", "", +106297, DiffGroupAbsValue, 1656, 1663, "- 1 . 0", "", " \"- 1 . 0\"." +55, Percentage, 1664, 1665, "%", "", +145, TimePoint, 1674, 1689, "18 and 30 weeks", "", " \"18 and 30 weeks\"." +146, TimePoint, 1681, 1689, "30 weeks", "", " \"30 weeks\". \"30 weeks\"." +57, Sitagliptin, 1756, 1767, "sitagliptin", "", +58, HbA1c_target, 1777, 1797, "HbA ( 1c ) < 7 . 0 %", "", " ." +134, Percentage, 1796, 1797, "%", "", +149, TimePoint, 1798, 1821, "by the end of the study", "", +59, PercentageAffected, 1824, 1830, "22 . 1", "", " \"22 . 1\"." +60, PercentageAffected, 1838, 1843, "3 . 3", "", " \"3 . 3\"." +61, PvalueDiff, 1848, 1859, "p < 0 . 001", "", " \"p < 0 . 001\"." +62, Sitagliptin, 1864, 1875, "Sitagliptin", "", +175, ObservedResult, 1899, 2067, "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .", "", " \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\"." +64, Placebo, 1913, 1920, "placebo", "", +63, Sitagliptin, 1923, 1934, "sitagliptin", "", +65, BodyWeight, 1959, 1970, "body weight", "", " ." +66, Hypoglycemia, 2018, 2030, "hypoglycemia", "", " ." +67, GastrointestinalProblem, 2034, 2065, "gastrointestinal adverse events", "", " ." +176, ConclusionComment, 2082, 2294, "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .", "", " \"Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .\"." +69, Sitagliptin, 2094, 2105, "sitagliptin", "", +70, DoseValue, 2106, 2109, "100", "", +71, mg, 2110, 2112, "mg", "", +72, Frequency, 2113, 2123, "once daily", "", +73, Metformin, 2135, 2144, "metformin", "", +74, Type2Diabetes, 2258, 2262, "T2DM", "", +75, Duration, 2284, 2292, "30 weeks", "", +76, PMID, 2337, 2345, "18194595", "", " \"18194595\"." diff --git a/data/dm2 18194595 copy_admin.n-triples b/data/dm2 18194595 copy_admin.n-triples new file mode 100644 index 0000000..32cd061 --- /dev/null +++ b/data/dm2 18194595 copy_admin.n-triples @@ -0,0 +1,211 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes ." . + "Raz I" . + "2008" . + "Curr Med Res Opin ." . + "18194595" . + . + "Chen Y" . + "Wu M" . + "Hussain S" . + "Kaufman KD" . + "Amatruda JM" . + "Langdon RB" . + "Stein PP" . + "Alba M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) ." . + "190" . + "30 weeks" . + . + . + . + "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_H" . + . + . + . + . + . + "Endpoint_H7" . + . + . + . + . + . + "Endpoint_FPG" . + . + . + . + . + . + "Endpoint_PPG" . + . + . + . + . + . + . + "Endpoint_W" . + . + . + . + . + . + "Endpoint_HG" . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_S" . + . + . + . + . + . + . + . + . + . + . + "Arm_P" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_M" . + . + "day" . + . + . + "Intervention_S" . + . + "once daily" . + . + . + "Intervention_P" . + . + . +# RDF export of group: Medication + . + "Medication_M" . + . + "> or = 1500" . + . + . + . + "Medication_S" . + . + "100" . + . + . + . + "Medication_P" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_H_S" . + . + "18 and 30 weeks" . + . + "Outcome_H_P" . + . + . + "Outcome_FPG_S" . + . + . + "Outcome_FPG_P" . + . + . + "Outcome_PPG_S" . + . + . + "Outcome_PPG_P" . + . + . + "Outcome_H7_S" . + . + "22 . 1" . + "30 weeks" . + . + "Outcome_H7_P" . + . + "3 . 3" . + "30 weeks" . + . + "Outcome_W" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . + . + "Outcome_HG" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . + . + "Outcome_AE" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_H" . + "- 1 . 0" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups_FPG" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups_PPG" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups_H7" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18194595 copy_export.csv b/data/dm2 18194595 copy_export.csv new file mode 100644 index 0000000..e56808f --- /dev/null +++ b/data/dm2 18194595 copy_export.csv @@ -0,0 +1,498 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +819, 1, 1, 1, 0, 4, 0, 4, "Curr" +819, 1, 2, 2, 5, 8, 5, 8, "Med" +819, 1, 3, 3, 9, 12, 9, 12, "Res" +819, 1, 4, 4, 13, 17, 13, 17, "Opin" +819, 1, 5, 5, 18, 19, 18, 19, "." +819, 2, 1, 6, 0, 4, 20, 24, "2008" +819, 2, 2, 7, 5, 8, 25, 28, "Feb" +819, 2, 3, 8, 9, 10, 29, 30, ";" +819, 2, 4, 9, 11, 13, 31, 33, "24" +819, 2, 5, 10, 14, 15, 34, 35, "(" +819, 2, 6, 11, 16, 17, 36, 37, "2" +819, 2, 7, 12, 18, 19, 38, 39, ")" +819, 2, 8, 13, 20, 21, 40, 41, ":" +819, 2, 9, 14, 22, 25, 42, 45, "537" +819, 2, 10, 15, 26, 27, 46, 47, "-" +819, 2, 11, 16, 28, 30, 48, 50, "50" +819, 2, 12, 17, 31, 32, 51, 52, "." +819, 2, 13, 18, 33, 36, 53, 56, "doi" +819, 2, 14, 19, 37, 38, 57, 58, ":" +819, 2, 15, 20, 39, 41, 59, 61, "10" +819, 2, 16, 21, 42, 43, 62, 63, "." +819, 2, 17, 22, 44, 48, 64, 68, "1185" +819, 2, 18, 23, 49, 50, 69, 70, "/" +819, 2, 19, 24, 51, 67, 71, 87, "030079908X260925" +819, 2, 20, 25, 68, 69, 88, 89, "." +819, 3, 1, 26, 0, 8, 90, 98, "Efficacy" +819, 3, 2, 27, 9, 12, 99, 102, "and" +819, 3, 3, 28, 13, 19, 103, 109, "safety" +819, 3, 4, 29, 20, 22, 110, 112, "of" +819, 3, 5, 30, 23, 34, 113, 124, "sitagliptin" +819, 3, 6, 31, 35, 40, 125, 130, "added" +819, 3, 7, 32, 41, 43, 131, 133, "to" +819, 3, 8, 33, 44, 51, 134, 141, "ongoing" +819, 3, 9, 34, 52, 61, 142, 151, "metformin" +819, 3, 10, 35, 62, 69, 152, 159, "therapy" +819, 3, 11, 36, 70, 72, 160, 162, "in" +819, 3, 12, 37, 73, 81, 163, 171, "patients" +819, 3, 13, 38, 82, 86, 172, 176, "with" +819, 3, 14, 39, 87, 91, 177, 181, "type" +819, 3, 15, 40, 92, 93, 182, 183, "2" +819, 3, 16, 41, 94, 102, 184, 192, "diabetes" +819, 3, 17, 42, 103, 104, 193, 194, "." +819, 4, 1, 43, 0, 3, 195, 198, "Raz" +819, 4, 2, 44, 4, 5, 199, 200, "I" +819, 4, 3, 45, 6, 7, 201, 202, "(" +819, 4, 4, 46, 8, 9, 203, 204, "1" +819, 4, 5, 47, 10, 11, 205, 206, ")" +819, 4, 6, 48, 12, 13, 207, 208, "," +819, 4, 7, 49, 14, 18, 209, 213, "Chen" +819, 4, 8, 50, 19, 20, 214, 215, "Y" +819, 4, 9, 51, 21, 22, 216, 217, "," +819, 4, 10, 52, 23, 25, 218, 220, "Wu" +819, 4, 11, 53, 26, 27, 221, 222, "M" +819, 4, 12, 54, 28, 29, 223, 224, "," +819, 4, 13, 55, 30, 37, 225, 232, "Hussain" +819, 4, 14, 56, 38, 39, 233, 234, "S" +819, 4, 15, 57, 40, 41, 235, 236, "," +819, 4, 16, 58, 42, 49, 237, 244, "Kaufman" +819, 4, 17, 59, 50, 52, 245, 247, "KD" +819, 4, 18, 60, 53, 54, 248, 249, "," +819, 4, 19, 61, 55, 63, 250, 258, "Amatruda" +819, 4, 20, 62, 64, 66, 259, 261, "JM" +819, 4, 21, 63, 67, 68, 262, 263, "," +819, 4, 22, 64, 69, 76, 264, 271, "Langdon" +819, 4, 23, 65, 77, 79, 272, 274, "RB" +819, 4, 24, 66, 80, 81, 275, 276, "," +819, 4, 25, 67, 82, 87, 277, 282, "Stein" +819, 4, 26, 68, 88, 90, 283, 285, "PP" +819, 4, 27, 69, 91, 92, 286, 287, "," +819, 4, 28, 70, 93, 97, 288, 292, "Alba" +819, 4, 29, 71, 98, 99, 293, 294, "M" +819, 4, 30, 72, 100, 101, 295, 296, "." +819, 4, 31, 73, 102, 108, 297, 303, "Author" +819, 4, 32, 74, 109, 120, 304, 315, "information" +819, 4, 33, 75, 121, 122, 316, 317, ":" +819, 4, 34, 76, 123, 124, 318, 319, "(" +819, 4, 35, 77, 125, 126, 320, 321, "1" +819, 4, 36, 78, 127, 128, 322, 323, ")" +819, 4, 37, 79, 129, 137, 324, 332, "Diabetes" +819, 4, 38, 80, 138, 142, 333, 337, "Unit" +819, 4, 39, 81, 143, 144, 338, 339, "," +819, 4, 40, 82, 145, 155, 340, 350, "Department" +819, 4, 41, 83, 156, 158, 351, 353, "of" +819, 4, 42, 84, 159, 167, 354, 362, "Internal" +819, 4, 43, 85, 168, 176, 363, 371, "Medicine" +819, 4, 44, 86, 177, 178, 372, 373, "," +819, 4, 45, 87, 179, 187, 374, 382, "Hadassah" +819, 4, 46, 88, 188, 194, 383, 389, "Hebrew" +819, 4, 47, 89, 195, 205, 390, 400, "University" +819, 4, 48, 90, 206, 214, 401, 409, "Hospital" +819, 4, 49, 91, 215, 216, 410, 411, "," +819, 4, 50, 92, 217, 226, 412, 421, "Jerusalem" +819, 4, 51, 93, 227, 228, 422, 423, "," +819, 4, 52, 94, 229, 235, 424, 430, "Israel" +819, 4, 53, 95, 236, 237, 431, 432, "." +819, 5, 1, 96, 0, 9, 433, 442, "OBJECTIVE" +819, 5, 2, 97, 10, 11, 443, 444, ":" +819, 5, 3, 98, 12, 15, 445, 448, "The" +819, 5, 4, 99, 16, 23, 449, 456, "purpose" +819, 5, 5, 100, 24, 26, 457, 459, "of" +819, 5, 6, 101, 27, 31, 460, 464, "this" +819, 5, 7, 102, 32, 37, 465, 470, "study" +819, 5, 8, 103, 38, 41, 471, 474, "was" +819, 5, 9, 104, 42, 44, 475, 477, "to" +819, 5, 10, 105, 45, 53, 478, 486, "evaluate" +819, 5, 11, 106, 54, 57, 487, 490, "the" +819, 5, 12, 107, 58, 66, 491, 499, "efficacy" +819, 5, 13, 108, 67, 70, 500, 503, "and" +819, 5, 14, 109, 71, 77, 504, 510, "safety" +819, 5, 15, 110, 78, 80, 511, 513, "of" +819, 5, 16, 111, 81, 92, 514, 525, "sitagliptin" +819, 5, 17, 112, 93, 95, 526, 528, "as" +819, 5, 18, 113, 96, 98, 529, 531, "an" +819, 5, 19, 114, 99, 102, 532, 535, "add" +819, 5, 20, 115, 103, 104, 536, 537, "-" +819, 5, 21, 116, 105, 107, 538, 540, "on" +819, 5, 22, 117, 108, 110, 541, 543, "to" +819, 5, 23, 118, 111, 120, 544, 553, "metformin" +819, 5, 24, 119, 121, 128, 554, 561, "therapy" +819, 5, 25, 120, 129, 131, 562, 564, "in" +819, 5, 26, 121, 132, 140, 565, 573, "patients" +819, 5, 27, 122, 141, 145, 574, 578, "with" +819, 5, 28, 123, 146, 156, 579, 589, "moderately" +819, 5, 29, 124, 157, 163, 590, 596, "severe" +819, 5, 30, 125, 164, 165, 597, 598, "(" +819, 5, 31, 126, 166, 176, 599, 609, "hemoglobin" +819, 5, 32, 127, 177, 178, 610, 611, "A" +819, 5, 33, 128, 179, 180, 612, 613, "(" +819, 5, 34, 129, 181, 183, 614, 616, "1c" +819, 5, 35, 130, 184, 185, 617, 618, ")" +819, 5, 36, 131, 186, 187, 619, 620, ">" +819, 5, 37, 132, 188, 190, 621, 623, "or" +819, 5, 38, 133, 191, 192, 624, 625, "=" +819, 5, 39, 134, 193, 194, 626, 627, "8" +819, 5, 40, 135, 195, 196, 628, 629, "." +819, 5, 41, 136, 197, 198, 630, 631, "0" +819, 5, 42, 137, 199, 200, 632, 633, "%" +819, 5, 43, 138, 201, 204, 634, 637, "and" +819, 5, 44, 139, 205, 206, 638, 639, "<" +819, 5, 45, 140, 207, 209, 640, 642, "or" +819, 5, 46, 141, 210, 211, 643, 644, "=" +819, 5, 47, 142, 212, 214, 645, 647, "11" +819, 5, 48, 143, 215, 216, 648, 649, "." +819, 5, 49, 144, 217, 218, 650, 651, "0" +819, 5, 50, 145, 219, 220, 652, 653, "%" +819, 5, 51, 146, 221, 222, 654, 655, ")" +819, 5, 52, 147, 223, 227, 656, 660, "type" +819, 5, 53, 148, 228, 229, 661, 662, "2" +819, 5, 54, 149, 230, 238, 663, 671, "diabetes" +819, 5, 55, 150, 239, 247, 672, 680, "mellitus" +819, 5, 56, 151, 248, 249, 681, 682, "(" +819, 5, 57, 152, 250, 254, 683, 687, "T2DM" +819, 5, 58, 153, 255, 256, 688, 689, ")" +819, 5, 59, 154, 257, 258, 690, 691, "." +819, 6, 1, 155, 0, 8, 692, 700, "RESEARCH" +819, 6, 2, 156, 9, 15, 701, 707, "DESIGN" +819, 6, 3, 157, 16, 19, 708, 711, "AND" +819, 6, 4, 158, 20, 27, 712, 719, "METHODS" +819, 6, 5, 159, 28, 29, 720, 721, ":" +819, 6, 6, 160, 30, 34, 722, 726, "This" +819, 6, 7, 161, 35, 38, 727, 730, "was" +819, 6, 8, 162, 39, 40, 731, 732, "a" +819, 6, 9, 163, 41, 54, 733, 746, "multinational" +819, 6, 10, 164, 55, 56, 747, 748, "," +819, 6, 11, 165, 57, 67, 749, 759, "randomized" +819, 6, 12, 166, 68, 69, 760, 761, "," +819, 6, 13, 167, 70, 77, 762, 769, "placebo" +819, 6, 14, 168, 78, 79, 770, 771, "-" +819, 6, 15, 169, 80, 90, 772, 782, "controlled" +819, 6, 16, 170, 91, 92, 783, 784, "," +819, 6, 17, 171, 93, 101, 785, 793, "parallel" +819, 6, 18, 172, 102, 103, 794, 795, "-" +819, 6, 19, 173, 104, 109, 796, 801, "group" +819, 6, 20, 174, 110, 111, 802, 803, "," +819, 6, 21, 175, 112, 118, 804, 810, "double" +819, 6, 22, 176, 119, 120, 811, 812, "-" +819, 6, 23, 177, 121, 126, 813, 818, "blind" +819, 6, 24, 178, 127, 132, 819, 824, "study" +819, 6, 25, 179, 133, 142, 825, 834, "conducted" +819, 6, 26, 180, 143, 145, 835, 837, "in" +819, 6, 27, 181, 146, 149, 838, 841, "190" +819, 6, 28, 182, 150, 158, 842, 850, "patients" +819, 6, 29, 183, 159, 163, 851, 855, "with" +819, 6, 30, 184, 164, 168, 856, 860, "T2DM" +819, 6, 31, 185, 169, 170, 861, 862, "." +819, 7, 1, 186, 0, 5, 863, 868, "After" +819, 7, 2, 187, 6, 7, 869, 870, ">" +819, 7, 3, 188, 8, 10, 871, 873, "or" +819, 7, 4, 189, 11, 12, 874, 875, "=" +819, 7, 5, 190, 13, 14, 876, 877, "6" +819, 7, 6, 191, 15, 20, 878, 883, "weeks" +819, 7, 7, 192, 21, 23, 884, 886, "of" +819, 7, 8, 193, 24, 30, 887, 893, "stable" +819, 7, 9, 194, 31, 40, 894, 903, "metformin" +819, 7, 10, 195, 41, 52, 904, 915, "monotherapy" +819, 7, 11, 196, 53, 54, 916, 917, "(" +819, 7, 12, 197, 55, 56, 918, 919, ">" +819, 7, 13, 198, 57, 59, 920, 922, "or" +819, 7, 14, 199, 60, 61, 923, 924, "=" +819, 7, 15, 200, 62, 66, 925, 929, "1500" +819, 7, 16, 201, 67, 69, 930, 932, "mg" +819, 7, 17, 202, 70, 71, 933, 934, "/" +819, 7, 18, 203, 72, 75, 935, 938, "day" +819, 7, 19, 204, 76, 77, 939, 940, ")" +819, 7, 20, 205, 78, 79, 941, 942, "," +819, 7, 21, 206, 80, 88, 943, 951, "patients" +819, 7, 22, 207, 89, 93, 952, 956, "were" +819, 7, 23, 208, 94, 104, 957, 967, "randomized" +819, 7, 24, 209, 105, 107, 968, 970, "to" +819, 7, 25, 210, 108, 114, 971, 977, "either" +819, 7, 26, 211, 115, 118, 978, 981, "the" +819, 7, 27, 212, 119, 127, 982, 990, "addition" +819, 7, 28, 213, 128, 130, 991, 993, "of" +819, 7, 29, 214, 131, 142, 994, 1005, "sitagliptin" +819, 7, 30, 215, 143, 146, 1006, 1009, "100" +819, 7, 31, 216, 147, 149, 1010, 1012, "mg" +819, 7, 32, 217, 150, 154, 1013, 1017, "once" +819, 7, 33, 218, 155, 160, 1018, 1023, "daily" +819, 7, 34, 219, 161, 163, 1024, 1026, "or" +819, 7, 35, 220, 164, 171, 1027, 1034, "placebo" +819, 7, 36, 221, 172, 174, 1035, 1037, "to" +819, 7, 37, 222, 175, 182, 1038, 1045, "ongoing" +819, 7, 38, 223, 183, 192, 1046, 1055, "metformin" +819, 7, 39, 224, 193, 196, 1056, 1059, "for" +819, 7, 40, 225, 197, 199, 1060, 1062, "30" +819, 7, 41, 226, 200, 205, 1063, 1068, "weeks" +819, 7, 42, 227, 206, 207, 1069, 1070, "." +819, 8, 1, 228, 0, 4, 1071, 1075, "MAIN" +819, 8, 2, 229, 5, 12, 1076, 1083, "OUTCOME" +819, 8, 3, 230, 13, 21, 1084, 1092, "MEASURES" +819, 8, 4, 231, 22, 23, 1093, 1094, ":" +819, 8, 5, 232, 24, 27, 1095, 1098, "The" +819, 8, 6, 233, 28, 35, 1099, 1106, "primary" +819, 8, 7, 234, 36, 44, 1107, 1115, "efficacy" +819, 8, 8, 235, 45, 53, 1116, 1124, "endpoint" +819, 8, 9, 236, 54, 57, 1125, 1128, "was" +819, 8, 10, 237, 58, 67, 1129, 1138, "reduction" +819, 8, 11, 238, 68, 70, 1139, 1141, "in" +819, 8, 12, 239, 71, 81, 1142, 1152, "hemoglobin" +819, 8, 13, 240, 82, 83, 1153, 1154, "A" +819, 8, 14, 241, 84, 85, 1155, 1156, "(" +819, 8, 15, 242, 86, 88, 1157, 1159, "1c" +819, 8, 16, 243, 89, 90, 1160, 1161, ")" +819, 8, 17, 244, 91, 92, 1162, 1163, "(" +819, 8, 18, 245, 93, 96, 1164, 1167, "HbA" +819, 8, 19, 246, 97, 98, 1168, 1169, "(" +819, 8, 20, 247, 99, 101, 1170, 1172, "1c" +819, 8, 21, 248, 102, 103, 1173, 1174, ")" +819, 8, 22, 249, 104, 105, 1175, 1176, ")" +819, 8, 23, 250, 106, 114, 1177, 1185, "measured" +819, 8, 24, 251, 115, 120, 1186, 1191, "after" +819, 8, 25, 252, 121, 123, 1192, 1194, "18" +819, 8, 26, 253, 124, 129, 1195, 1200, "weeks" +819, 8, 27, 254, 130, 132, 1201, 1203, "of" +819, 8, 28, 255, 133, 144, 1204, 1215, "sitagliptin" +819, 8, 29, 256, 145, 154, 1216, 1225, "treatment" +819, 8, 30, 257, 155, 156, 1226, 1227, "." +819, 9, 1, 258, 0, 3, 1228, 1231, "Key" +819, 9, 2, 259, 4, 13, 1232, 1241, "secondary" +819, 9, 3, 260, 14, 23, 1242, 1251, "endpoints" +819, 9, 4, 261, 24, 32, 1252, 1260, "included" +819, 9, 5, 262, 33, 42, 1261, 1270, "reduction" +819, 9, 6, 263, 43, 45, 1271, 1273, "in" +819, 9, 7, 264, 46, 53, 1274, 1281, "fasting" +819, 9, 8, 265, 54, 60, 1282, 1288, "plasma" +819, 9, 9, 266, 61, 68, 1289, 1296, "glucose" +819, 9, 10, 267, 69, 70, 1297, 1298, "(" +819, 9, 11, 268, 71, 74, 1299, 1302, "FPG" +819, 9, 12, 269, 75, 76, 1303, 1304, ")" +819, 9, 13, 270, 77, 80, 1305, 1308, "and" +819, 9, 14, 271, 81, 82, 1309, 1310, "2" +819, 9, 15, 272, 83, 84, 1311, 1312, "-" +819, 9, 16, 273, 85, 89, 1313, 1317, "hour" +819, 9, 17, 274, 90, 91, 1318, 1319, "(" +819, 9, 18, 275, 92, 93, 1320, 1321, "2" +819, 9, 19, 276, 94, 95, 1322, 1323, "-" +819, 9, 20, 277, 96, 97, 1324, 1325, "h" +819, 9, 21, 278, 98, 99, 1326, 1327, ")" +819, 9, 22, 279, 100, 112, 1328, 1340, "postprandial" +819, 9, 23, 280, 113, 119, 1341, 1347, "plasma" +819, 9, 24, 281, 120, 127, 1348, 1355, "glucose" +819, 9, 25, 282, 128, 129, 1356, 1357, "(" +819, 9, 26, 283, 130, 133, 1358, 1361, "PPG" +819, 9, 27, 284, 134, 135, 1362, 1363, ")" +819, 9, 28, 285, 136, 138, 1364, 1366, "at" +819, 9, 29, 286, 139, 141, 1367, 1369, "18" +819, 9, 30, 287, 142, 147, 1370, 1375, "weeks" +819, 9, 31, 288, 148, 149, 1376, 1377, "," +819, 9, 32, 289, 150, 153, 1378, 1381, "and" +819, 9, 33, 290, 154, 157, 1382, 1385, "HbA" +819, 9, 34, 291, 158, 159, 1386, 1387, "(" +819, 9, 35, 292, 160, 162, 1388, 1390, "1c" +819, 9, 36, 293, 163, 164, 1391, 1392, ")" +819, 9, 37, 294, 165, 167, 1393, 1395, "at" +819, 9, 38, 295, 168, 170, 1396, 1398, "30" +819, 9, 39, 296, 171, 176, 1399, 1404, "weeks" +819, 9, 40, 297, 177, 178, 1405, 1406, "." +819, 10, 1, 298, 0, 3, 1407, 1410, "The" +819, 10, 2, 299, 4, 14, 1411, 1421, "proportion" +819, 10, 3, 300, 15, 17, 1422, 1424, "of" +819, 10, 4, 301, 18, 26, 1425, 1433, "patients" +819, 10, 5, 302, 27, 34, 1434, 1441, "meeting" +819, 10, 6, 303, 35, 38, 1442, 1445, "the" +819, 10, 7, 304, 39, 43, 1446, 1450, "goal" +819, 10, 8, 305, 44, 46, 1451, 1453, "of" +819, 10, 9, 306, 47, 50, 1454, 1457, "HbA" +819, 10, 10, 307, 51, 52, 1458, 1459, "(" +819, 10, 11, 308, 53, 55, 1460, 1462, "1c" +819, 10, 12, 309, 56, 57, 1463, 1464, ")" +819, 10, 13, 310, 58, 59, 1465, 1466, "<" +819, 10, 14, 311, 60, 61, 1467, 1468, "7" +819, 10, 15, 312, 62, 63, 1469, 1470, "." +819, 10, 16, 313, 64, 65, 1471, 1472, "0" +819, 10, 17, 314, 66, 67, 1473, 1474, "%" +819, 10, 18, 315, 68, 71, 1475, 1478, "was" +819, 10, 19, 316, 72, 76, 1479, 1483, "also" +819, 10, 20, 317, 77, 85, 1484, 1492, "analyzed" +819, 10, 21, 318, 86, 87, 1493, 1494, "." +819, 11, 1, 319, 0, 7, 1495, 1502, "RESULTS" +819, 11, 2, 320, 8, 9, 1503, 1504, ":" +819, 11, 3, 321, 10, 21, 1505, 1516, "Sitagliptin" +819, 11, 4, 322, 22, 35, 1517, 1530, "significantly" +819, 11, 5, 323, 36, 43, 1531, 1538, "reduced" +819, 11, 6, 324, 44, 47, 1539, 1542, "HbA" +819, 11, 7, 325, 48, 49, 1543, 1544, "(" +819, 11, 8, 326, 50, 52, 1545, 1547, "1c" +819, 11, 9, 327, 53, 54, 1548, 1549, ")" +819, 11, 10, 328, 55, 56, 1550, 1551, "," +819, 11, 11, 329, 57, 60, 1552, 1555, "FPG" +819, 11, 12, 330, 61, 62, 1556, 1557, "," +819, 11, 13, 331, 63, 66, 1558, 1561, "and" +819, 11, 14, 332, 67, 68, 1562, 1563, "2" +819, 11, 15, 333, 69, 70, 1564, 1565, "-" +819, 11, 16, 334, 71, 72, 1566, 1567, "h" +819, 11, 17, 335, 73, 76, 1568, 1571, "PPG" +819, 11, 18, 336, 77, 78, 1572, 1573, "," +819, 11, 19, 337, 79, 87, 1574, 1582, "compared" +819, 11, 20, 338, 88, 92, 1583, 1587, "with" +819, 11, 21, 339, 93, 100, 1588, 1595, "placebo" +819, 11, 22, 340, 101, 102, 1596, 1597, "(" +819, 11, 23, 341, 103, 106, 1598, 1601, "all" +819, 11, 24, 342, 107, 108, 1602, 1603, "p" +819, 11, 25, 343, 109, 110, 1604, 1605, "<" +819, 11, 26, 344, 111, 112, 1606, 1607, "0" +819, 11, 27, 345, 113, 114, 1608, 1609, "." +819, 11, 28, 346, 115, 118, 1610, 1613, "001" +819, 11, 29, 347, 119, 120, 1614, 1615, ")" +819, 11, 30, 348, 121, 122, 1616, 1617, "." +819, 12, 1, 349, 0, 3, 1618, 1621, "The" +819, 12, 2, 350, 4, 7, 1622, 1625, "net" +819, 12, 3, 351, 8, 19, 1626, 1637, "improvement" +819, 12, 4, 352, 20, 22, 1638, 1640, "in" +819, 12, 5, 353, 23, 26, 1641, 1644, "HbA" +819, 12, 6, 354, 27, 28, 1645, 1646, "(" +819, 12, 7, 355, 29, 31, 1647, 1649, "1c" +819, 12, 8, 356, 32, 33, 1650, 1651, ")" +819, 12, 9, 357, 34, 37, 1652, 1655, "was" +819, 12, 10, 358, 38, 39, 1656, 1657, "-" +819, 12, 11, 359, 40, 41, 1658, 1659, "1" +819, 12, 12, 360, 42, 43, 1660, 1661, "." +819, 12, 13, 361, 44, 45, 1662, 1663, "0" +819, 12, 14, 362, 46, 47, 1664, 1665, "%" +819, 12, 15, 363, 48, 50, 1666, 1668, "at" +819, 12, 16, 364, 51, 55, 1669, 1673, "both" +819, 12, 17, 365, 56, 58, 1674, 1676, "18" +819, 12, 18, 366, 59, 62, 1677, 1680, "and" +819, 12, 19, 367, 63, 65, 1681, 1683, "30" +819, 12, 20, 368, 66, 71, 1684, 1689, "weeks" +819, 12, 21, 369, 72, 73, 1690, 1691, "," +819, 12, 22, 370, 74, 77, 1692, 1695, "and" +819, 12, 23, 371, 78, 79, 1696, 1697, "a" +819, 12, 24, 372, 80, 93, 1698, 1711, "significantly" +819, 12, 25, 373, 94, 101, 1712, 1719, "greater" +819, 12, 26, 374, 102, 112, 1720, 1730, "proportion" +819, 12, 27, 375, 113, 115, 1731, 1733, "of" +819, 12, 28, 376, 116, 124, 1734, 1742, "patients" +819, 12, 29, 377, 125, 132, 1743, 1750, "treated" +819, 12, 30, 378, 133, 137, 1751, 1755, "with" +819, 12, 31, 379, 138, 149, 1756, 1767, "sitagliptin" +819, 12, 32, 380, 150, 158, 1768, 1776, "achieved" +819, 12, 33, 381, 159, 162, 1777, 1780, "HbA" +819, 12, 34, 382, 163, 164, 1781, 1782, "(" +819, 12, 35, 383, 165, 167, 1783, 1785, "1c" +819, 12, 36, 384, 168, 169, 1786, 1787, ")" +819, 12, 37, 385, 170, 171, 1788, 1789, "<" +819, 12, 38, 386, 172, 173, 1790, 1791, "7" +819, 12, 39, 387, 174, 175, 1792, 1793, "." +819, 12, 40, 388, 176, 177, 1794, 1795, "0" +819, 12, 41, 389, 178, 179, 1796, 1797, "%" +819, 12, 42, 390, 180, 182, 1798, 1800, "by" +819, 12, 43, 391, 183, 186, 1801, 1804, "the" +819, 12, 44, 392, 187, 190, 1805, 1808, "end" +819, 12, 45, 393, 191, 193, 1809, 1811, "of" +819, 12, 46, 394, 194, 197, 1812, 1815, "the" +819, 12, 47, 395, 198, 203, 1816, 1821, "study" +819, 12, 48, 396, 204, 205, 1822, 1823, "(" +819, 12, 49, 397, 206, 208, 1824, 1826, "22" +819, 12, 50, 398, 209, 210, 1827, 1828, "." +819, 12, 51, 399, 211, 212, 1829, 1830, "1" +819, 12, 52, 400, 213, 214, 1831, 1832, "%" +819, 12, 53, 401, 215, 217, 1833, 1835, "vs" +819, 12, 54, 402, 218, 219, 1836, 1837, "." +819, 12, 55, 403, 220, 221, 1838, 1839, "3" +819, 12, 56, 404, 222, 223, 1840, 1841, "." +819, 12, 57, 405, 224, 225, 1842, 1843, "3" +819, 12, 58, 406, 226, 227, 1844, 1845, "%" +819, 12, 59, 407, 228, 229, 1846, 1847, "," +819, 12, 60, 408, 230, 231, 1848, 1849, "p" +819, 12, 61, 409, 232, 233, 1850, 1851, "<" +819, 12, 62, 410, 234, 235, 1852, 1853, "0" +819, 12, 63, 411, 236, 237, 1854, 1855, "." +819, 12, 64, 412, 238, 241, 1856, 1859, "001" +819, 12, 65, 413, 242, 243, 1860, 1861, ")" +819, 12, 66, 414, 244, 245, 1862, 1863, "." +819, 13, 1, 415, 0, 11, 1864, 1875, "Sitagliptin" +819, 13, 2, 416, 12, 15, 1876, 1879, "was" +819, 13, 3, 417, 16, 20, 1880, 1884, "well" +819, 13, 4, 418, 21, 22, 1885, 1886, "-" +819, 13, 5, 419, 23, 32, 1887, 1896, "tolerated" +819, 13, 6, 420, 33, 34, 1897, 1898, "." +819, 14, 1, 421, 0, 8, 1899, 1907, "Compared" +819, 14, 2, 422, 9, 13, 1908, 1912, "with" +819, 14, 3, 423, 14, 21, 1913, 1920, "placebo" +819, 14, 4, 424, 22, 23, 1921, 1922, "," +819, 14, 5, 425, 24, 35, 1923, 1934, "sitagliptin" +819, 14, 6, 426, 36, 39, 1935, 1938, "had" +819, 14, 7, 427, 40, 41, 1939, 1940, "a" +819, 14, 8, 428, 42, 49, 1941, 1948, "neutral" +819, 14, 9, 429, 50, 56, 1949, 1955, "effect" +819, 14, 10, 430, 57, 59, 1956, 1958, "on" +819, 14, 11, 431, 60, 64, 1959, 1963, "body" +819, 14, 12, 432, 65, 71, 1964, 1970, "weight" +819, 14, 13, 433, 72, 75, 1971, 1974, "and" +819, 14, 14, 434, 76, 79, 1975, 1978, "did" +819, 14, 15, 435, 80, 83, 1979, 1982, "not" +819, 14, 16, 436, 84, 97, 1983, 1996, "significantly" +819, 14, 17, 437, 98, 106, 1997, 2005, "increase" +819, 14, 18, 438, 107, 110, 2006, 2009, "the" +819, 14, 19, 439, 111, 115, 2010, 2014, "risk" +819, 14, 20, 440, 116, 118, 2015, 2017, "of" +819, 14, 21, 441, 119, 131, 2018, 2030, "hypoglycemia" +819, 14, 22, 442, 132, 134, 2031, 2033, "or" +819, 14, 23, 443, 135, 151, 2034, 2050, "gastrointestinal" +819, 14, 24, 444, 152, 159, 2051, 2058, "adverse" +819, 14, 25, 445, 160, 166, 2059, 2065, "events" +819, 14, 26, 446, 167, 168, 2066, 2067, "." +819, 15, 1, 447, 0, 11, 2068, 2079, "CONCLUSIONS" +819, 15, 2, 448, 12, 13, 2080, 2081, ":" +819, 15, 3, 449, 14, 22, 2082, 2090, "Addition" +819, 15, 4, 450, 23, 25, 2091, 2093, "of" +819, 15, 5, 451, 26, 37, 2094, 2105, "sitagliptin" +819, 15, 6, 452, 38, 41, 2106, 2109, "100" +819, 15, 7, 453, 42, 44, 2110, 2112, "mg" +819, 15, 8, 454, 45, 49, 2113, 2117, "once" +819, 15, 9, 455, 50, 55, 2118, 2123, "daily" +819, 15, 10, 456, 56, 58, 2124, 2126, "to" +819, 15, 11, 457, 59, 66, 2127, 2134, "ongoing" +819, 15, 12, 458, 67, 76, 2135, 2144, "metformin" +819, 15, 13, 459, 77, 84, 2145, 2152, "therapy" +819, 15, 14, 460, 85, 88, 2153, 2156, "was" +819, 15, 15, 461, 89, 93, 2157, 2161, "well" +819, 15, 16, 462, 94, 95, 2162, 2163, "-" +819, 15, 17, 463, 96, 105, 2164, 2173, "tolerated" +819, 15, 18, 464, 106, 109, 2174, 2177, "and" +819, 15, 19, 465, 110, 118, 2178, 2186, "resulted" +819, 15, 20, 466, 119, 121, 2187, 2189, "in" +819, 15, 21, 467, 122, 133, 2190, 2201, "significant" +819, 15, 22, 468, 134, 142, 2202, 2210, "glycemic" +819, 15, 23, 469, 143, 154, 2211, 2222, "improvement" +819, 15, 24, 470, 155, 157, 2223, 2225, "in" +819, 15, 25, 471, 158, 166, 2226, 2234, "patients" +819, 15, 26, 472, 167, 171, 2235, 2239, "with" +819, 15, 27, 473, 172, 182, 2240, 2250, "moderately" +819, 15, 28, 474, 183, 189, 2251, 2257, "severe" +819, 15, 29, 475, 190, 194, 2258, 2262, "T2DM" +819, 15, 30, 476, 195, 198, 2263, 2266, "who" +819, 15, 31, 477, 199, 203, 2267, 2271, "were" +819, 15, 32, 478, 204, 211, 2272, 2279, "treated" +819, 15, 33, 479, 212, 215, 2280, 2283, "for" +819, 15, 34, 480, 216, 218, 2284, 2286, "30" +819, 15, 35, 481, 219, 224, 2287, 2292, "weeks" +819, 15, 36, 482, 225, 226, 2293, 2294, "." +819, 16, 1, 483, 0, 3, 2295, 2298, "DOI" +819, 16, 2, 484, 4, 5, 2299, 2300, ":" +819, 16, 3, 485, 6, 8, 2301, 2303, "10" +819, 16, 4, 486, 9, 10, 2304, 2305, "." +819, 16, 5, 487, 11, 15, 2306, 2310, "1185" +819, 16, 6, 488, 16, 17, 2311, 2312, "/" +819, 16, 7, 489, 18, 34, 2313, 2329, "030079908X260925" +819, 16, 8, 490, 35, 39, 2330, 2334, "PMID" +819, 16, 9, 491, 40, 41, 2335, 2336, ":" +819, 16, 10, 492, 42, 50, 2337, 2345, "18194595" +819, 16, 11, 493, 51, 52, 2346, 2347, "[" +819, 16, 12, 494, 53, 60, 2348, 2355, "Indexed" +819, 16, 13, 495, 61, 64, 2356, 2359, "for" +819, 16, 14, 496, 65, 72, 2360, 2367, "MEDLINE" +819, 16, 15, 497, 73, 74, 2368, 2369, "]" diff --git a/data/dm2 18194595_admin.annodb b/data/dm2 18194595_admin.annodb new file mode 100644 index 0000000..1c21d63 --- /dev/null +++ b/data/dm2 18194595_admin.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2008", "", " \"2008\"." +83, Title, 90, 194, "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .", "", " \"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .\"." +2, Sitagliptin, 113, 124, "sitagliptin", "", +3, Metformin, 142, 151, "metformin", "", +4, Type2Diabetes, 177, 192, "type 2 diabetes", "", +5, Author, 195, 200, "Raz I", "", " \"Raz I\"." +6, Author, 209, 215, "Chen Y", "", " \"Chen Y\"." +7, Author, 218, 222, "Wu M", "", " \"Wu M\"." +8, Author, 225, 234, "Hussain S", "", " \"Hussain S\"." +9, Author, 237, 247, "Kaufman KD", "", " \"Kaufman KD\"." +10, Author, 250, 261, "Amatruda JM", "", " \"Amatruda JM\"." +11, Author, 264, 274, "Langdon RB", "", " \"Langdon RB\"." +12, Author, 277, 285, "Stein PP", "", " \"Stein PP\"." +13, Author, 288, 294, "Alba M", "", " \"Alba M\"." +14, Israel, 424, 430, "Israel", "", " ." +100, ObjectiveDescription, 445, 691, "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .", "", " \"The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .\"." +15, Sitagliptin, 514, 525, "sitagliptin", "", +22, Precondition, 532, 689, "add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )", "", " \"add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )\"." +16, Metformin, 544, 553, "metformin", "", +17, HbA1c, 599, 618, "hemoglobin A ( 1c )", "", +18, Percentage, 632, 633, "%", "", +19, Percentage, 652, 653, "%", "", +20, Type2Diabetes, 656, 680, "type 2 diabetes mellitus", "", " ." +21, Type2Diabetes, 683, 687, "T2DM", "", +101, Multicenter, 733, 746, "multinational", "", " ." +23, Randomized, 749, 759, "randomized", "", " ." +103, Placebo, 762, 769, "placebo", "", +24, Parallel, 785, 801, "parallel - group", "", " ." +25, DoubleBlind, 804, 818, "double - blind", "", " ." +26, NumberPatientsCT, 838, 841, "190", "", " \"190\"." +27, Type2Diabetes, 856, 860, "T2DM", "", +29, Metformin, 894, 903, "metformin", "", +30, DoseValue, 918, 929, "> or = 1500", "", +31, mg, 930, 932, "mg", "", +32, Interval, 935, 938, "day", "", +33, Randomized, 957, 967, "randomized", "", +34, Sitagliptin, 994, 1005, "sitagliptin", "", " ." +35, DoseValue, 1006, 1009, "100", "", " \"100\"." +36, mg, 1010, 1012, "mg", "", " ." +37, Frequency, 1013, 1023, "once daily", "", " \"once daily\"." +38, Placebo, 1027, 1034, "placebo", "", " ." +39, Metformin, 1046, 1055, "metformin", "", +40, Duration, 1060, 1068, "30 weeks", "", " \"30 weeks\"." +41, HbA1c, 1142, 1161, "hemoglobin A ( 1c )", "", +42, HbA1c, 1164, 1174, "HbA ( 1c )", "", +43, TimePoint, 1186, 1200, "after 18 weeks", "", +44, Sitagliptin, 1204, 1215, "sitagliptin", "", +45, FastingPlasmaGlucose, 1274, 1296, "fasting plasma glucose", "", " ." +46, FastingPlasmaGlucose, 1299, 1302, "FPG", "", +51505, EndPointDescription, 1309, 1355, "2 - hour ( 2 - h ) postprandial plasma glucose", "", +170, PostprandialPlasmaGlucose, 1328, 1355, "postprandial plasma glucose", "", +171, PostprandialPlasmaGlucose, 1358, 1361, "PPG", "", +172, TimePoint, 1367, 1375, "18 weeks", "", +47, HbA1c, 1382, 1392, "HbA ( 1c )", "", +173, TimePoint, 1396, 1404, "30 weeks", "", +48, HbA1c_target, 1454, 1474, "HbA ( 1c ) < 7 . 0 %", "", +132, Percentage, 1473, 1474, "%", "", +49, Sitagliptin, 1505, 1516, "Sitagliptin", "", +50, HbA1c, 1539, 1549, "HbA ( 1c )", "", " ." +51, FastingPlasmaGlucose, 1552, 1555, "FPG", "", +51504, EndPointDescription, 1562, 1571, "2 - h PPG", "", " . ." +51500, PostprandialPlasmaGlucose, 1568, 1571, "PPG", "", +52, Placebo, 1588, 1595, "placebo", "", +77, PvalueDiff, 1602, 1613, "p < 0 . 001", "", " \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\"." +53, HbA1c, 1641, 1651, "HbA ( 1c )", "", +106297, DiffGroupAbsValue, 1656, 1663, "- 1 . 0", "", " \"- 1 . 0\"." +55, Percentage, 1664, 1665, "%", "", " ." +145, TimePoint, 1674, 1689, "18 and 30 weeks", "", +146, TimePoint, 1681, 1689, "30 weeks", "", +57, Sitagliptin, 1756, 1767, "sitagliptin", "", +58, HbA1c_target, 1777, 1797, "HbA ( 1c ) < 7 . 0 %", "", " ." +134, Percentage, 1796, 1797, "%", "", +149, TimePoint, 1798, 1821, "by the end of the study", "", " \"by the end of the study\". \"by the end of the study\"." +59, PercentageAffected, 1824, 1830, "22 . 1", "", " \"22 . 1\"." +60, PercentageAffected, 1838, 1843, "3 . 3", "", " \"3 . 3\"." +61, PvalueDiff, 1848, 1859, "p < 0 . 001", "", " \"p < 0 . 001\"." +62, Sitagliptin, 1864, 1875, "Sitagliptin", "", +175, ObservedResult, 1899, 2067, "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .", "", " \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\"." +64, Placebo, 1913, 1920, "placebo", "", +63, Sitagliptin, 1923, 1934, "sitagliptin", "", +65, BodyWeight, 1959, 1970, "body weight", "", " ." +66, Hypoglycemia, 2018, 2030, "hypoglycemia", "", " ." +67, GastrointestinalProblem, 2034, 2065, "gastrointestinal adverse events", "", " ." +176, ConclusionComment, 2082, 2294, "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .", "", " \"Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .\"." +69, Sitagliptin, 2094, 2105, "sitagliptin", "", +70, DoseValue, 2106, 2109, "100", "", +71, mg, 2110, 2112, "mg", "", +72, Frequency, 2113, 2123, "once daily", "", +73, Metformin, 2135, 2144, "metformin", "", +74, Type2Diabetes, 2258, 2262, "T2DM", "", +75, Duration, 2284, 2292, "30 weeks", "", +76, PMID, 2337, 2345, "18194595", "", " \"18194595\"." diff --git a/data/dm2 18194595_admin.n-triples b/data/dm2 18194595_admin.n-triples new file mode 100644 index 0000000..cb04e42 --- /dev/null +++ b/data/dm2 18194595_admin.n-triples @@ -0,0 +1,195 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes ." . + "Raz I" . + "2008" . + "Curr Med Res Opin ." . + "18194595" . + . + "Chen Y" . + "Wu M" . + "Hussain S" . + "Kaufman KD" . + "Amatruda JM" . + "Langdon RB" . + "Stein PP" . + "Alba M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) ." . + "190" . + "30 weeks" . + . + . + . + "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint ppbg" . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint g aes" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s + met" . + . + . + . + . + . + . + . + . + . + "Arm p + met" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s + met" . + "once daily" . + . + . + . + "Intervention p + met" . + . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s " . + . + . + "Outcome hba1c p " . + . + . + "Outcome ppbg s" . + . + . + "Outcome ppbg p " . + . + . + "Outcome fpg s" . + . + . + "Outcome fpg p " . + . + . + "Outcome hba1c target s" . + . + "22 . 1" . + "by the end of the study" . + . + "Outcome hba1c target p " . + . + "3 . 3" . + "by the end of the study" . + . + "Outcome weight s" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . + . + "Outcome h s" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . + . + "Outcome g aes s" . + . + "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c " . + "- 1 . 0" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups ppbg " . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups fpg " . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups hba1c target" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18194595_akramersunderbrink.annodb b/data/dm2 18194595_akramersunderbrink.annodb new file mode 100644 index 0000000..f9422fa --- /dev/null +++ b/data/dm2 18194595_akramersunderbrink.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23227, Journal, 0, 17, "Curr Med Res Opin", "", +23228, PublicationYear, 20, 24, "2008", "", +23232, Title, 90, 194, "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .", "", +23229, Sitagliptin, 113, 124, "sitagliptin", "", +23230, Metformin, 142, 151, "metformin", "", +23231, Type2Diabetes, 177, 192, "type 2 diabetes", "", +23233, Author, 195, 200, "Raz I", "", +23234, Author, 209, 215, "Chen Y", "", +23235, Author, 218, 222, "Wu M", "", +23236, Author, 225, 234, "Hussain S", "", +23237, Author, 237, 247, "Kaufman KD", "", +23238, Author, 250, 261, "Amatruda JM", "", +23239, Author, 264, 274, "Langdon RB", "", +23240, Author, 277, 285, "Stein PP", "", +23241, Author, 288, 294, "Alba M", "", +23242, Israel, 424, 430, "Israel", "", +23249, ObjectiveDescription, 445, 691, "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .", "", +23243, Sitagliptin, 514, 525, "sitagliptin", "", +23244, Metformin, 544, 553, "metformin", "", +23246, Precondition, 579, 655, "moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % )", "", +23245, HbA1c, 599, 618, "hemoglobin A ( 1c )", "", +39169, Percentage, 632, 633, "%", "", +39170, Percentage, 652, 653, "%", "", +23247, Type2Diabetes, 656, 680, "type 2 diabetes mellitus", "", +23248, Type2Diabetes, 683, 687, "T2DM", "", +23250, Multicenter, 733, 746, "multinational", "", +23251, Randomized, 749, 759, "randomized", "", +23252, Placebo, 762, 769, "placebo", "", +23253, Parallel, 785, 801, "parallel - group", "", +23254, DoubleBlind, 804, 818, "double - blind", "", +23255, NumberPatientsCT, 838, 841, "190", "", +23256, Type2Diabetes, 856, 860, "T2DM", "", +23261, Precondition, 863, 940, "After > or = 6 weeks of stable metformin monotherapy ( > or = 1500 mg / day )", "", +23269, Duration, 869, 883, "> or = 6 weeks", "", +23257, Metformin, 894, 903, "metformin", "", +23258, DoseValue, 925, 929, "1500", "", +23259, BioAndMedicalUnit, 930, 938, "mg / day", "", +23260, Randomized, 957, 967, "randomized", "", +23262, Sitagliptin, 994, 1005, "sitagliptin", "", +23263, DoseValue, 1006, 1009, "100", "", +23264, mg, 1010, 1012, "mg", "", +23265, Frequency, 1013, 1023, "once daily", "", +23266, Placebo, 1027, 1034, "placebo", "", +23267, Metformin, 1046, 1055, "metformin", "", +23268, Duration, 1060, 1068, "30 weeks", "", +23270, HbA1c, 1142, 1161, "hemoglobin A ( 1c )", "", +23271, HbA1c, 1164, 1174, "HbA ( 1c )", "", +23278, TimePoint, 1186, 1200, "after 18 weeks", "", +23273, Sitagliptin, 1204, 1215, "sitagliptin", "", +23274, FastingPlasmaGlucose, 1274, 1296, "fasting plasma glucose", "", +23275, FastingPlasmaGlucose, 1299, 1302, "FPG", "", +23276, InsulinDose, 1309, 1363, "2 - hour ( 2 - h ) postprandial plasma glucose ( PPG )", "", +23281, TimePoint, 1364, 1375, "at 18 weeks", "", +23277, HbA1c, 1382, 1392, "HbA ( 1c )", "", +23282, TimePoint, 1393, 1404, "at 30 weeks", "", +23283, HbA1c_target, 1425, 1474, "patients meeting the goal of HbA ( 1c ) < 7 . 0 %", "", +23284, Percentage, 1473, 1474, "%", "", +23289, Sitagliptin, 1505, 1516, "Sitagliptin", "", +23290, HbA1c, 1539, 1549, "HbA ( 1c )", "", +23291, FastingPlasmaGlucose, 1552, 1555, "FPG", "", +23292, InsulinDose, 1562, 1571, "2 - h PPG", "", +23293, Placebo, 1588, 1595, "placebo", "", +23294, PvalueDiff, 1602, 1613, "p < 0 . 001", "", +23295, HbA1c, 1641, 1651, "HbA ( 1c )", "", +23296, ChangeValue, 1656, 1663, "- 1 . 0", "", +23285, Percentage, 1664, 1665, "%", "", +23297, TimePoint, 1674, 1676, "18", "", +23298, TimePoint, 1681, 1689, "30 weeks", "", +23299, Sitagliptin, 1756, 1767, "sitagliptin", "", +23300, HbA1c_target, 1777, 1797, "HbA ( 1c ) < 7 . 0 %", "", +23286, Percentage, 1796, 1797, "%", "", +23301, TimePoint, 1798, 1821, "by the end of the study", "", +23302, PercentageAffected, 1824, 1830, "22 . 1", "", +23287, Percentage, 1831, 1832, "%", "", +23303, PercentageAffected, 1838, 1843, "3 . 3", "", +23288, Percentage, 1844, 1845, "%", "", +23304, PvalueDiff, 1848, 1859, "p < 0 . 001", "", +23305, Sitagliptin, 1864, 1875, "Sitagliptin", "", +23308, Placebo, 1913, 1920, "placebo", "", +23306, Sitagliptin, 1923, 1934, "sitagliptin", "", +23309, BodyWeight, 1959, 1970, "body weight", "", +23310, Hypoglycemia, 2018, 2030, "hypoglycemia", "", +23307, Sitagliptin, 2094, 2105, "sitagliptin", "", +23311, DoseValue, 2106, 2109, "100", "", +23312, mg, 2110, 2112, "mg", "", +23313, Frequency, 2113, 2123, "once daily", "", +23314, Metformin, 2135, 2144, "metformin", "", +23315, Type2Diabetes, 2258, 2262, "T2DM", "", +23316, Duration, 2284, 2292, "30 weeks", "", +23317, PMID, 2337, 2345, "18194595", "", diff --git a/data/dm2 18194595_akramersunderbrink.n-triples b/data/dm2 18194595_akramersunderbrink.n-triples new file mode 100644 index 0000000..286d413 --- /dev/null +++ b/data/dm2 18194595_akramersunderbrink.n-triples @@ -0,0 +1,13 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint + . +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome + . + "Outcome 19256" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18194595_export.csv b/data/dm2 18194595_export.csv new file mode 100644 index 0000000..0307ab7 --- /dev/null +++ b/data/dm2 18194595_export.csv @@ -0,0 +1,498 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +346, 1, 1, 1, 0, 4, 0, 4, "Curr" +346, 1, 2, 2, 5, 8, 5, 8, "Med" +346, 1, 3, 3, 9, 12, 9, 12, "Res" +346, 1, 4, 4, 13, 17, 13, 17, "Opin" +346, 1, 5, 5, 18, 19, 18, 19, "." +346, 2, 1, 6, 0, 4, 20, 24, "2008" +346, 2, 2, 7, 5, 8, 25, 28, "Feb" +346, 2, 3, 8, 9, 10, 29, 30, ";" +346, 2, 4, 9, 11, 13, 31, 33, "24" +346, 2, 5, 10, 14, 15, 34, 35, "(" +346, 2, 6, 11, 16, 17, 36, 37, "2" +346, 2, 7, 12, 18, 19, 38, 39, ")" +346, 2, 8, 13, 20, 21, 40, 41, ":" +346, 2, 9, 14, 22, 25, 42, 45, "537" +346, 2, 10, 15, 26, 27, 46, 47, "-" +346, 2, 11, 16, 28, 30, 48, 50, "50" +346, 2, 12, 17, 31, 32, 51, 52, "." +346, 2, 13, 18, 33, 36, 53, 56, "doi" +346, 2, 14, 19, 37, 38, 57, 58, ":" +346, 2, 15, 20, 39, 41, 59, 61, "10" +346, 2, 16, 21, 42, 43, 62, 63, "." +346, 2, 17, 22, 44, 48, 64, 68, "1185" +346, 2, 18, 23, 49, 50, 69, 70, "/" +346, 2, 19, 24, 51, 67, 71, 87, "030079908X260925" +346, 2, 20, 25, 68, 69, 88, 89, "." +346, 3, 1, 26, 0, 8, 90, 98, "Efficacy" +346, 3, 2, 27, 9, 12, 99, 102, "and" +346, 3, 3, 28, 13, 19, 103, 109, "safety" +346, 3, 4, 29, 20, 22, 110, 112, "of" +346, 3, 5, 30, 23, 34, 113, 124, "sitagliptin" +346, 3, 6, 31, 35, 40, 125, 130, "added" +346, 3, 7, 32, 41, 43, 131, 133, "to" +346, 3, 8, 33, 44, 51, 134, 141, "ongoing" +346, 3, 9, 34, 52, 61, 142, 151, "metformin" +346, 3, 10, 35, 62, 69, 152, 159, "therapy" +346, 3, 11, 36, 70, 72, 160, 162, "in" +346, 3, 12, 37, 73, 81, 163, 171, "patients" +346, 3, 13, 38, 82, 86, 172, 176, "with" +346, 3, 14, 39, 87, 91, 177, 181, "type" +346, 3, 15, 40, 92, 93, 182, 183, "2" +346, 3, 16, 41, 94, 102, 184, 192, "diabetes" +346, 3, 17, 42, 103, 104, 193, 194, "." +346, 4, 1, 43, 0, 3, 195, 198, "Raz" +346, 4, 2, 44, 4, 5, 199, 200, "I" +346, 4, 3, 45, 6, 7, 201, 202, "(" +346, 4, 4, 46, 8, 9, 203, 204, "1" +346, 4, 5, 47, 10, 11, 205, 206, ")" +346, 4, 6, 48, 12, 13, 207, 208, "," +346, 4, 7, 49, 14, 18, 209, 213, "Chen" +346, 4, 8, 50, 19, 20, 214, 215, "Y" +346, 4, 9, 51, 21, 22, 216, 217, "," +346, 4, 10, 52, 23, 25, 218, 220, "Wu" +346, 4, 11, 53, 26, 27, 221, 222, "M" +346, 4, 12, 54, 28, 29, 223, 224, "," +346, 4, 13, 55, 30, 37, 225, 232, "Hussain" +346, 4, 14, 56, 38, 39, 233, 234, "S" +346, 4, 15, 57, 40, 41, 235, 236, "," +346, 4, 16, 58, 42, 49, 237, 244, "Kaufman" +346, 4, 17, 59, 50, 52, 245, 247, "KD" +346, 4, 18, 60, 53, 54, 248, 249, "," +346, 4, 19, 61, 55, 63, 250, 258, "Amatruda" +346, 4, 20, 62, 64, 66, 259, 261, "JM" +346, 4, 21, 63, 67, 68, 262, 263, "," +346, 4, 22, 64, 69, 76, 264, 271, "Langdon" +346, 4, 23, 65, 77, 79, 272, 274, "RB" +346, 4, 24, 66, 80, 81, 275, 276, "," +346, 4, 25, 67, 82, 87, 277, 282, "Stein" +346, 4, 26, 68, 88, 90, 283, 285, "PP" +346, 4, 27, 69, 91, 92, 286, 287, "," +346, 4, 28, 70, 93, 97, 288, 292, "Alba" +346, 4, 29, 71, 98, 99, 293, 294, "M" +346, 4, 30, 72, 100, 101, 295, 296, "." +346, 4, 31, 73, 102, 108, 297, 303, "Author" +346, 4, 32, 74, 109, 120, 304, 315, "information" +346, 4, 33, 75, 121, 122, 316, 317, ":" +346, 4, 34, 76, 123, 124, 318, 319, "(" +346, 4, 35, 77, 125, 126, 320, 321, "1" +346, 4, 36, 78, 127, 128, 322, 323, ")" +346, 4, 37, 79, 129, 137, 324, 332, "Diabetes" +346, 4, 38, 80, 138, 142, 333, 337, "Unit" +346, 4, 39, 81, 143, 144, 338, 339, "," +346, 4, 40, 82, 145, 155, 340, 350, "Department" +346, 4, 41, 83, 156, 158, 351, 353, "of" +346, 4, 42, 84, 159, 167, 354, 362, "Internal" +346, 4, 43, 85, 168, 176, 363, 371, "Medicine" +346, 4, 44, 86, 177, 178, 372, 373, "," +346, 4, 45, 87, 179, 187, 374, 382, "Hadassah" +346, 4, 46, 88, 188, 194, 383, 389, "Hebrew" +346, 4, 47, 89, 195, 205, 390, 400, "University" +346, 4, 48, 90, 206, 214, 401, 409, "Hospital" +346, 4, 49, 91, 215, 216, 410, 411, "," +346, 4, 50, 92, 217, 226, 412, 421, "Jerusalem" +346, 4, 51, 93, 227, 228, 422, 423, "," +346, 4, 52, 94, 229, 235, 424, 430, "Israel" +346, 4, 53, 95, 236, 237, 431, 432, "." +346, 5, 1, 96, 0, 9, 433, 442, "OBJECTIVE" +346, 5, 2, 97, 10, 11, 443, 444, ":" +346, 5, 3, 98, 12, 15, 445, 448, "The" +346, 5, 4, 99, 16, 23, 449, 456, "purpose" +346, 5, 5, 100, 24, 26, 457, 459, "of" +346, 5, 6, 101, 27, 31, 460, 464, "this" +346, 5, 7, 102, 32, 37, 465, 470, "study" +346, 5, 8, 103, 38, 41, 471, 474, "was" +346, 5, 9, 104, 42, 44, 475, 477, "to" +346, 5, 10, 105, 45, 53, 478, 486, "evaluate" +346, 5, 11, 106, 54, 57, 487, 490, "the" +346, 5, 12, 107, 58, 66, 491, 499, "efficacy" +346, 5, 13, 108, 67, 70, 500, 503, "and" +346, 5, 14, 109, 71, 77, 504, 510, "safety" +346, 5, 15, 110, 78, 80, 511, 513, "of" +346, 5, 16, 111, 81, 92, 514, 525, "sitagliptin" +346, 5, 17, 112, 93, 95, 526, 528, "as" +346, 5, 18, 113, 96, 98, 529, 531, "an" +346, 5, 19, 114, 99, 102, 532, 535, "add" +346, 5, 20, 115, 103, 104, 536, 537, "-" +346, 5, 21, 116, 105, 107, 538, 540, "on" +346, 5, 22, 117, 108, 110, 541, 543, "to" +346, 5, 23, 118, 111, 120, 544, 553, "metformin" +346, 5, 24, 119, 121, 128, 554, 561, "therapy" +346, 5, 25, 120, 129, 131, 562, 564, "in" +346, 5, 26, 121, 132, 140, 565, 573, "patients" +346, 5, 27, 122, 141, 145, 574, 578, "with" +346, 5, 28, 123, 146, 156, 579, 589, "moderately" +346, 5, 29, 124, 157, 163, 590, 596, "severe" +346, 5, 30, 125, 164, 165, 597, 598, "(" +346, 5, 31, 126, 166, 176, 599, 609, "hemoglobin" +346, 5, 32, 127, 177, 178, 610, 611, "A" +346, 5, 33, 128, 179, 180, 612, 613, "(" +346, 5, 34, 129, 181, 183, 614, 616, "1c" +346, 5, 35, 130, 184, 185, 617, 618, ")" +346, 5, 36, 131, 186, 187, 619, 620, ">" +346, 5, 37, 132, 188, 190, 621, 623, "or" +346, 5, 38, 133, 191, 192, 624, 625, "=" +346, 5, 39, 134, 193, 194, 626, 627, "8" +346, 5, 40, 135, 195, 196, 628, 629, "." +346, 5, 41, 136, 197, 198, 630, 631, "0" +346, 5, 42, 137, 199, 200, 632, 633, "%" +346, 5, 43, 138, 201, 204, 634, 637, "and" +346, 5, 44, 139, 205, 206, 638, 639, "<" +346, 5, 45, 140, 207, 209, 640, 642, "or" +346, 5, 46, 141, 210, 211, 643, 644, "=" +346, 5, 47, 142, 212, 214, 645, 647, "11" +346, 5, 48, 143, 215, 216, 648, 649, "." +346, 5, 49, 144, 217, 218, 650, 651, "0" +346, 5, 50, 145, 219, 220, 652, 653, "%" +346, 5, 51, 146, 221, 222, 654, 655, ")" +346, 5, 52, 147, 223, 227, 656, 660, "type" +346, 5, 53, 148, 228, 229, 661, 662, "2" +346, 5, 54, 149, 230, 238, 663, 671, "diabetes" +346, 5, 55, 150, 239, 247, 672, 680, "mellitus" +346, 5, 56, 151, 248, 249, 681, 682, "(" +346, 5, 57, 152, 250, 254, 683, 687, "T2DM" +346, 5, 58, 153, 255, 256, 688, 689, ")" +346, 5, 59, 154, 257, 258, 690, 691, "." +346, 6, 1, 155, 0, 8, 692, 700, "RESEARCH" +346, 6, 2, 156, 9, 15, 701, 707, "DESIGN" +346, 6, 3, 157, 16, 19, 708, 711, "AND" +346, 6, 4, 158, 20, 27, 712, 719, "METHODS" +346, 6, 5, 159, 28, 29, 720, 721, ":" +346, 6, 6, 160, 30, 34, 722, 726, "This" +346, 6, 7, 161, 35, 38, 727, 730, "was" +346, 6, 8, 162, 39, 40, 731, 732, "a" +346, 6, 9, 163, 41, 54, 733, 746, "multinational" +346, 6, 10, 164, 55, 56, 747, 748, "," +346, 6, 11, 165, 57, 67, 749, 759, "randomized" +346, 6, 12, 166, 68, 69, 760, 761, "," +346, 6, 13, 167, 70, 77, 762, 769, "placebo" +346, 6, 14, 168, 78, 79, 770, 771, "-" +346, 6, 15, 169, 80, 90, 772, 782, "controlled" +346, 6, 16, 170, 91, 92, 783, 784, "," +346, 6, 17, 171, 93, 101, 785, 793, "parallel" +346, 6, 18, 172, 102, 103, 794, 795, "-" +346, 6, 19, 173, 104, 109, 796, 801, "group" +346, 6, 20, 174, 110, 111, 802, 803, "," +346, 6, 21, 175, 112, 118, 804, 810, "double" +346, 6, 22, 176, 119, 120, 811, 812, "-" +346, 6, 23, 177, 121, 126, 813, 818, "blind" +346, 6, 24, 178, 127, 132, 819, 824, "study" +346, 6, 25, 179, 133, 142, 825, 834, "conducted" +346, 6, 26, 180, 143, 145, 835, 837, "in" +346, 6, 27, 181, 146, 149, 838, 841, "190" +346, 6, 28, 182, 150, 158, 842, 850, "patients" +346, 6, 29, 183, 159, 163, 851, 855, "with" +346, 6, 30, 184, 164, 168, 856, 860, "T2DM" +346, 6, 31, 185, 169, 170, 861, 862, "." +346, 7, 1, 186, 0, 5, 863, 868, "After" +346, 7, 2, 187, 6, 7, 869, 870, ">" +346, 7, 3, 188, 8, 10, 871, 873, "or" +346, 7, 4, 189, 11, 12, 874, 875, "=" +346, 7, 5, 190, 13, 14, 876, 877, "6" +346, 7, 6, 191, 15, 20, 878, 883, "weeks" +346, 7, 7, 192, 21, 23, 884, 886, "of" +346, 7, 8, 193, 24, 30, 887, 893, "stable" +346, 7, 9, 194, 31, 40, 894, 903, "metformin" +346, 7, 10, 195, 41, 52, 904, 915, "monotherapy" +346, 7, 11, 196, 53, 54, 916, 917, "(" +346, 7, 12, 197, 55, 56, 918, 919, ">" +346, 7, 13, 198, 57, 59, 920, 922, "or" +346, 7, 14, 199, 60, 61, 923, 924, "=" +346, 7, 15, 200, 62, 66, 925, 929, "1500" +346, 7, 16, 201, 67, 69, 930, 932, "mg" +346, 7, 17, 202, 70, 71, 933, 934, "/" +346, 7, 18, 203, 72, 75, 935, 938, "day" +346, 7, 19, 204, 76, 77, 939, 940, ")" +346, 7, 20, 205, 78, 79, 941, 942, "," +346, 7, 21, 206, 80, 88, 943, 951, "patients" +346, 7, 22, 207, 89, 93, 952, 956, "were" +346, 7, 23, 208, 94, 104, 957, 967, "randomized" +346, 7, 24, 209, 105, 107, 968, 970, "to" +346, 7, 25, 210, 108, 114, 971, 977, "either" +346, 7, 26, 211, 115, 118, 978, 981, "the" +346, 7, 27, 212, 119, 127, 982, 990, "addition" +346, 7, 28, 213, 128, 130, 991, 993, "of" +346, 7, 29, 214, 131, 142, 994, 1005, "sitagliptin" +346, 7, 30, 215, 143, 146, 1006, 1009, "100" +346, 7, 31, 216, 147, 149, 1010, 1012, "mg" +346, 7, 32, 217, 150, 154, 1013, 1017, "once" +346, 7, 33, 218, 155, 160, 1018, 1023, "daily" +346, 7, 34, 219, 161, 163, 1024, 1026, "or" +346, 7, 35, 220, 164, 171, 1027, 1034, "placebo" +346, 7, 36, 221, 172, 174, 1035, 1037, "to" +346, 7, 37, 222, 175, 182, 1038, 1045, "ongoing" +346, 7, 38, 223, 183, 192, 1046, 1055, "metformin" +346, 7, 39, 224, 193, 196, 1056, 1059, "for" +346, 7, 40, 225, 197, 199, 1060, 1062, "30" +346, 7, 41, 226, 200, 205, 1063, 1068, "weeks" +346, 7, 42, 227, 206, 207, 1069, 1070, "." +346, 8, 1, 228, 0, 4, 1071, 1075, "MAIN" +346, 8, 2, 229, 5, 12, 1076, 1083, "OUTCOME" +346, 8, 3, 230, 13, 21, 1084, 1092, "MEASURES" +346, 8, 4, 231, 22, 23, 1093, 1094, ":" +346, 8, 5, 232, 24, 27, 1095, 1098, "The" +346, 8, 6, 233, 28, 35, 1099, 1106, "primary" +346, 8, 7, 234, 36, 44, 1107, 1115, "efficacy" +346, 8, 8, 235, 45, 53, 1116, 1124, "endpoint" +346, 8, 9, 236, 54, 57, 1125, 1128, "was" +346, 8, 10, 237, 58, 67, 1129, 1138, "reduction" +346, 8, 11, 238, 68, 70, 1139, 1141, "in" +346, 8, 12, 239, 71, 81, 1142, 1152, "hemoglobin" +346, 8, 13, 240, 82, 83, 1153, 1154, "A" +346, 8, 14, 241, 84, 85, 1155, 1156, "(" +346, 8, 15, 242, 86, 88, 1157, 1159, "1c" +346, 8, 16, 243, 89, 90, 1160, 1161, ")" +346, 8, 17, 244, 91, 92, 1162, 1163, "(" +346, 8, 18, 245, 93, 96, 1164, 1167, "HbA" +346, 8, 19, 246, 97, 98, 1168, 1169, "(" +346, 8, 20, 247, 99, 101, 1170, 1172, "1c" +346, 8, 21, 248, 102, 103, 1173, 1174, ")" +346, 8, 22, 249, 104, 105, 1175, 1176, ")" +346, 8, 23, 250, 106, 114, 1177, 1185, "measured" +346, 8, 24, 251, 115, 120, 1186, 1191, "after" +346, 8, 25, 252, 121, 123, 1192, 1194, "18" +346, 8, 26, 253, 124, 129, 1195, 1200, "weeks" +346, 8, 27, 254, 130, 132, 1201, 1203, "of" +346, 8, 28, 255, 133, 144, 1204, 1215, "sitagliptin" +346, 8, 29, 256, 145, 154, 1216, 1225, "treatment" +346, 8, 30, 257, 155, 156, 1226, 1227, "." +346, 9, 1, 258, 0, 3, 1228, 1231, "Key" +346, 9, 2, 259, 4, 13, 1232, 1241, "secondary" +346, 9, 3, 260, 14, 23, 1242, 1251, "endpoints" +346, 9, 4, 261, 24, 32, 1252, 1260, "included" +346, 9, 5, 262, 33, 42, 1261, 1270, "reduction" +346, 9, 6, 263, 43, 45, 1271, 1273, "in" +346, 9, 7, 264, 46, 53, 1274, 1281, "fasting" +346, 9, 8, 265, 54, 60, 1282, 1288, "plasma" +346, 9, 9, 266, 61, 68, 1289, 1296, "glucose" +346, 9, 10, 267, 69, 70, 1297, 1298, "(" +346, 9, 11, 268, 71, 74, 1299, 1302, "FPG" +346, 9, 12, 269, 75, 76, 1303, 1304, ")" +346, 9, 13, 270, 77, 80, 1305, 1308, "and" +346, 9, 14, 271, 81, 82, 1309, 1310, "2" +346, 9, 15, 272, 83, 84, 1311, 1312, "-" +346, 9, 16, 273, 85, 89, 1313, 1317, "hour" +346, 9, 17, 274, 90, 91, 1318, 1319, "(" +346, 9, 18, 275, 92, 93, 1320, 1321, "2" +346, 9, 19, 276, 94, 95, 1322, 1323, "-" +346, 9, 20, 277, 96, 97, 1324, 1325, "h" +346, 9, 21, 278, 98, 99, 1326, 1327, ")" +346, 9, 22, 279, 100, 112, 1328, 1340, "postprandial" +346, 9, 23, 280, 113, 119, 1341, 1347, "plasma" +346, 9, 24, 281, 120, 127, 1348, 1355, "glucose" +346, 9, 25, 282, 128, 129, 1356, 1357, "(" +346, 9, 26, 283, 130, 133, 1358, 1361, "PPG" +346, 9, 27, 284, 134, 135, 1362, 1363, ")" +346, 9, 28, 285, 136, 138, 1364, 1366, "at" +346, 9, 29, 286, 139, 141, 1367, 1369, "18" +346, 9, 30, 287, 142, 147, 1370, 1375, "weeks" +346, 9, 31, 288, 148, 149, 1376, 1377, "," +346, 9, 32, 289, 150, 153, 1378, 1381, "and" +346, 9, 33, 290, 154, 157, 1382, 1385, "HbA" +346, 9, 34, 291, 158, 159, 1386, 1387, "(" +346, 9, 35, 292, 160, 162, 1388, 1390, "1c" +346, 9, 36, 293, 163, 164, 1391, 1392, ")" +346, 9, 37, 294, 165, 167, 1393, 1395, "at" +346, 9, 38, 295, 168, 170, 1396, 1398, "30" +346, 9, 39, 296, 171, 176, 1399, 1404, "weeks" +346, 9, 40, 297, 177, 178, 1405, 1406, "." +346, 10, 1, 298, 0, 3, 1407, 1410, "The" +346, 10, 2, 299, 4, 14, 1411, 1421, "proportion" +346, 10, 3, 300, 15, 17, 1422, 1424, "of" +346, 10, 4, 301, 18, 26, 1425, 1433, "patients" +346, 10, 5, 302, 27, 34, 1434, 1441, "meeting" +346, 10, 6, 303, 35, 38, 1442, 1445, "the" +346, 10, 7, 304, 39, 43, 1446, 1450, "goal" +346, 10, 8, 305, 44, 46, 1451, 1453, "of" +346, 10, 9, 306, 47, 50, 1454, 1457, "HbA" +346, 10, 10, 307, 51, 52, 1458, 1459, "(" +346, 10, 11, 308, 53, 55, 1460, 1462, "1c" +346, 10, 12, 309, 56, 57, 1463, 1464, ")" +346, 10, 13, 310, 58, 59, 1465, 1466, "<" +346, 10, 14, 311, 60, 61, 1467, 1468, "7" +346, 10, 15, 312, 62, 63, 1469, 1470, "." +346, 10, 16, 313, 64, 65, 1471, 1472, "0" +346, 10, 17, 314, 66, 67, 1473, 1474, "%" +346, 10, 18, 315, 68, 71, 1475, 1478, "was" +346, 10, 19, 316, 72, 76, 1479, 1483, "also" +346, 10, 20, 317, 77, 85, 1484, 1492, "analyzed" +346, 10, 21, 318, 86, 87, 1493, 1494, "." +346, 11, 1, 319, 0, 7, 1495, 1502, "RESULTS" +346, 11, 2, 320, 8, 9, 1503, 1504, ":" +346, 11, 3, 321, 10, 21, 1505, 1516, "Sitagliptin" +346, 11, 4, 322, 22, 35, 1517, 1530, "significantly" +346, 11, 5, 323, 36, 43, 1531, 1538, "reduced" +346, 11, 6, 324, 44, 47, 1539, 1542, "HbA" +346, 11, 7, 325, 48, 49, 1543, 1544, "(" +346, 11, 8, 326, 50, 52, 1545, 1547, "1c" +346, 11, 9, 327, 53, 54, 1548, 1549, ")" +346, 11, 10, 328, 55, 56, 1550, 1551, "," +346, 11, 11, 329, 57, 60, 1552, 1555, "FPG" +346, 11, 12, 330, 61, 62, 1556, 1557, "," +346, 11, 13, 331, 63, 66, 1558, 1561, "and" +346, 11, 14, 332, 67, 68, 1562, 1563, "2" +346, 11, 15, 333, 69, 70, 1564, 1565, "-" +346, 11, 16, 334, 71, 72, 1566, 1567, "h" +346, 11, 17, 335, 73, 76, 1568, 1571, "PPG" +346, 11, 18, 336, 77, 78, 1572, 1573, "," +346, 11, 19, 337, 79, 87, 1574, 1582, "compared" +346, 11, 20, 338, 88, 92, 1583, 1587, "with" +346, 11, 21, 339, 93, 100, 1588, 1595, "placebo" +346, 11, 22, 340, 101, 102, 1596, 1597, "(" +346, 11, 23, 341, 103, 106, 1598, 1601, "all" +346, 11, 24, 342, 107, 108, 1602, 1603, "p" +346, 11, 25, 343, 109, 110, 1604, 1605, "<" +346, 11, 26, 344, 111, 112, 1606, 1607, "0" +346, 11, 27, 345, 113, 114, 1608, 1609, "." +346, 11, 28, 346, 115, 118, 1610, 1613, "001" +346, 11, 29, 347, 119, 120, 1614, 1615, ")" +346, 11, 30, 348, 121, 122, 1616, 1617, "." +346, 12, 1, 349, 0, 3, 1618, 1621, "The" +346, 12, 2, 350, 4, 7, 1622, 1625, "net" +346, 12, 3, 351, 8, 19, 1626, 1637, "improvement" +346, 12, 4, 352, 20, 22, 1638, 1640, "in" +346, 12, 5, 353, 23, 26, 1641, 1644, "HbA" +346, 12, 6, 354, 27, 28, 1645, 1646, "(" +346, 12, 7, 355, 29, 31, 1647, 1649, "1c" +346, 12, 8, 356, 32, 33, 1650, 1651, ")" +346, 12, 9, 357, 34, 37, 1652, 1655, "was" +346, 12, 10, 358, 38, 39, 1656, 1657, "-" +346, 12, 11, 359, 40, 41, 1658, 1659, "1" +346, 12, 12, 360, 42, 43, 1660, 1661, "." +346, 12, 13, 361, 44, 45, 1662, 1663, "0" +346, 12, 14, 362, 46, 47, 1664, 1665, "%" +346, 12, 15, 363, 48, 50, 1666, 1668, "at" +346, 12, 16, 364, 51, 55, 1669, 1673, "both" +346, 12, 17, 365, 56, 58, 1674, 1676, "18" +346, 12, 18, 366, 59, 62, 1677, 1680, "and" +346, 12, 19, 367, 63, 65, 1681, 1683, "30" +346, 12, 20, 368, 66, 71, 1684, 1689, "weeks" +346, 12, 21, 369, 72, 73, 1690, 1691, "," +346, 12, 22, 370, 74, 77, 1692, 1695, "and" +346, 12, 23, 371, 78, 79, 1696, 1697, "a" +346, 12, 24, 372, 80, 93, 1698, 1711, "significantly" +346, 12, 25, 373, 94, 101, 1712, 1719, "greater" +346, 12, 26, 374, 102, 112, 1720, 1730, "proportion" +346, 12, 27, 375, 113, 115, 1731, 1733, "of" +346, 12, 28, 376, 116, 124, 1734, 1742, "patients" +346, 12, 29, 377, 125, 132, 1743, 1750, "treated" +346, 12, 30, 378, 133, 137, 1751, 1755, "with" +346, 12, 31, 379, 138, 149, 1756, 1767, "sitagliptin" +346, 12, 32, 380, 150, 158, 1768, 1776, "achieved" +346, 12, 33, 381, 159, 162, 1777, 1780, "HbA" +346, 12, 34, 382, 163, 164, 1781, 1782, "(" +346, 12, 35, 383, 165, 167, 1783, 1785, "1c" +346, 12, 36, 384, 168, 169, 1786, 1787, ")" +346, 12, 37, 385, 170, 171, 1788, 1789, "<" +346, 12, 38, 386, 172, 173, 1790, 1791, "7" +346, 12, 39, 387, 174, 175, 1792, 1793, "." +346, 12, 40, 388, 176, 177, 1794, 1795, "0" +346, 12, 41, 389, 178, 179, 1796, 1797, "%" +346, 12, 42, 390, 180, 182, 1798, 1800, "by" +346, 12, 43, 391, 183, 186, 1801, 1804, "the" +346, 12, 44, 392, 187, 190, 1805, 1808, "end" +346, 12, 45, 393, 191, 193, 1809, 1811, "of" +346, 12, 46, 394, 194, 197, 1812, 1815, "the" +346, 12, 47, 395, 198, 203, 1816, 1821, "study" +346, 12, 48, 396, 204, 205, 1822, 1823, "(" +346, 12, 49, 397, 206, 208, 1824, 1826, "22" +346, 12, 50, 398, 209, 210, 1827, 1828, "." +346, 12, 51, 399, 211, 212, 1829, 1830, "1" +346, 12, 52, 400, 213, 214, 1831, 1832, "%" +346, 12, 53, 401, 215, 217, 1833, 1835, "vs" +346, 12, 54, 402, 218, 219, 1836, 1837, "." +346, 12, 55, 403, 220, 221, 1838, 1839, "3" +346, 12, 56, 404, 222, 223, 1840, 1841, "." +346, 12, 57, 405, 224, 225, 1842, 1843, "3" +346, 12, 58, 406, 226, 227, 1844, 1845, "%" +346, 12, 59, 407, 228, 229, 1846, 1847, "," +346, 12, 60, 408, 230, 231, 1848, 1849, "p" +346, 12, 61, 409, 232, 233, 1850, 1851, "<" +346, 12, 62, 410, 234, 235, 1852, 1853, "0" +346, 12, 63, 411, 236, 237, 1854, 1855, "." +346, 12, 64, 412, 238, 241, 1856, 1859, "001" +346, 12, 65, 413, 242, 243, 1860, 1861, ")" +346, 12, 66, 414, 244, 245, 1862, 1863, "." +346, 13, 1, 415, 0, 11, 1864, 1875, "Sitagliptin" +346, 13, 2, 416, 12, 15, 1876, 1879, "was" +346, 13, 3, 417, 16, 20, 1880, 1884, "well" +346, 13, 4, 418, 21, 22, 1885, 1886, "-" +346, 13, 5, 419, 23, 32, 1887, 1896, "tolerated" +346, 13, 6, 420, 33, 34, 1897, 1898, "." +346, 14, 1, 421, 0, 8, 1899, 1907, "Compared" +346, 14, 2, 422, 9, 13, 1908, 1912, "with" +346, 14, 3, 423, 14, 21, 1913, 1920, "placebo" +346, 14, 4, 424, 22, 23, 1921, 1922, "," +346, 14, 5, 425, 24, 35, 1923, 1934, "sitagliptin" +346, 14, 6, 426, 36, 39, 1935, 1938, "had" +346, 14, 7, 427, 40, 41, 1939, 1940, "a" +346, 14, 8, 428, 42, 49, 1941, 1948, "neutral" +346, 14, 9, 429, 50, 56, 1949, 1955, "effect" +346, 14, 10, 430, 57, 59, 1956, 1958, "on" +346, 14, 11, 431, 60, 64, 1959, 1963, "body" +346, 14, 12, 432, 65, 71, 1964, 1970, "weight" +346, 14, 13, 433, 72, 75, 1971, 1974, "and" +346, 14, 14, 434, 76, 79, 1975, 1978, "did" +346, 14, 15, 435, 80, 83, 1979, 1982, "not" +346, 14, 16, 436, 84, 97, 1983, 1996, "significantly" +346, 14, 17, 437, 98, 106, 1997, 2005, "increase" +346, 14, 18, 438, 107, 110, 2006, 2009, "the" +346, 14, 19, 439, 111, 115, 2010, 2014, "risk" +346, 14, 20, 440, 116, 118, 2015, 2017, "of" +346, 14, 21, 441, 119, 131, 2018, 2030, "hypoglycemia" +346, 14, 22, 442, 132, 134, 2031, 2033, "or" +346, 14, 23, 443, 135, 151, 2034, 2050, "gastrointestinal" +346, 14, 24, 444, 152, 159, 2051, 2058, "adverse" +346, 14, 25, 445, 160, 166, 2059, 2065, "events" +346, 14, 26, 446, 167, 168, 2066, 2067, "." +346, 15, 1, 447, 0, 11, 2068, 2079, "CONCLUSIONS" +346, 15, 2, 448, 12, 13, 2080, 2081, ":" +346, 15, 3, 449, 14, 22, 2082, 2090, "Addition" +346, 15, 4, 450, 23, 25, 2091, 2093, "of" +346, 15, 5, 451, 26, 37, 2094, 2105, "sitagliptin" +346, 15, 6, 452, 38, 41, 2106, 2109, "100" +346, 15, 7, 453, 42, 44, 2110, 2112, "mg" +346, 15, 8, 454, 45, 49, 2113, 2117, "once" +346, 15, 9, 455, 50, 55, 2118, 2123, "daily" +346, 15, 10, 456, 56, 58, 2124, 2126, "to" +346, 15, 11, 457, 59, 66, 2127, 2134, "ongoing" +346, 15, 12, 458, 67, 76, 2135, 2144, "metformin" +346, 15, 13, 459, 77, 84, 2145, 2152, "therapy" +346, 15, 14, 460, 85, 88, 2153, 2156, "was" +346, 15, 15, 461, 89, 93, 2157, 2161, "well" +346, 15, 16, 462, 94, 95, 2162, 2163, "-" +346, 15, 17, 463, 96, 105, 2164, 2173, "tolerated" +346, 15, 18, 464, 106, 109, 2174, 2177, "and" +346, 15, 19, 465, 110, 118, 2178, 2186, "resulted" +346, 15, 20, 466, 119, 121, 2187, 2189, "in" +346, 15, 21, 467, 122, 133, 2190, 2201, "significant" +346, 15, 22, 468, 134, 142, 2202, 2210, "glycemic" +346, 15, 23, 469, 143, 154, 2211, 2222, "improvement" +346, 15, 24, 470, 155, 157, 2223, 2225, "in" +346, 15, 25, 471, 158, 166, 2226, 2234, "patients" +346, 15, 26, 472, 167, 171, 2235, 2239, "with" +346, 15, 27, 473, 172, 182, 2240, 2250, "moderately" +346, 15, 28, 474, 183, 189, 2251, 2257, "severe" +346, 15, 29, 475, 190, 194, 2258, 2262, "T2DM" +346, 15, 30, 476, 195, 198, 2263, 2266, "who" +346, 15, 31, 477, 199, 203, 2267, 2271, "were" +346, 15, 32, 478, 204, 211, 2272, 2279, "treated" +346, 15, 33, 479, 212, 215, 2280, 2283, "for" +346, 15, 34, 480, 216, 218, 2284, 2286, "30" +346, 15, 35, 481, 219, 224, 2287, 2292, "weeks" +346, 15, 36, 482, 225, 226, 2293, 2294, "." +346, 16, 1, 483, 0, 3, 2295, 2298, "DOI" +346, 16, 2, 484, 4, 5, 2299, 2300, ":" +346, 16, 3, 485, 6, 8, 2301, 2303, "10" +346, 16, 4, 486, 9, 10, 2304, 2305, "." +346, 16, 5, 487, 11, 15, 2306, 2310, "1185" +346, 16, 6, 488, 16, 17, 2311, 2312, "/" +346, 16, 7, 489, 18, 34, 2313, 2329, "030079908X260925" +346, 16, 8, 490, 35, 39, 2330, 2334, "PMID" +346, 16, 9, 491, 40, 41, 2335, 2336, ":" +346, 16, 10, 492, 42, 50, 2337, 2345, "18194595" +346, 16, 11, 493, 51, 52, 2346, 2347, "[" +346, 16, 12, 494, 53, 60, 2348, 2355, "Indexed" +346, 16, 13, 495, 61, 64, 2356, 2359, "for" +346, 16, 14, 496, 65, 72, 2360, 2367, "MEDLINE" +346, 16, 15, 497, 73, 74, 2368, 2369, "]" diff --git a/data/dm2 18194595_kwoodley.annodb b/data/dm2 18194595_kwoodley.annodb new file mode 100644 index 0000000..0b2b1d5 --- /dev/null +++ b/data/dm2 18194595_kwoodley.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6125, Journal, 0, 17, "Curr Med Res Opin", "", +6126, PublicationYear, 20, 24, "2008", "", +36911, Title, 90, 194, "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .", "", +6127, Sitagliptin, 113, 124, "sitagliptin", "", +6128, Metformin, 142, 151, "metformin", "", +6129, Type2Diabetes, 177, 192, "type 2 diabetes", "", +6130, Author, 195, 200, "Raz I", "", +6131, Author, 209, 215, "Chen Y", "", +6132, Author, 218, 222, "Wu M", "", +6133, Author, 225, 234, "Hussain S", "", +6134, Author, 237, 247, "Kaufman KD", "", +6135, Author, 250, 261, "Amatruda JM", "", +6136, Author, 264, 274, "Langdon RB", "", +6137, Author, 277, 285, "Stein PP", "", +6138, Author, 288, 294, "Alba M", "", +6139, Israel, 424, 430, "Israel", "", +36912, ObjectiveDescription, 445, 691, "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .", "", +6140, Sitagliptin, 514, 525, "sitagliptin", "", +6141, Metformin, 544, 553, "metformin", "", +6148, Precondition, 565, 689, "patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )", "", +6142, HbA1c, 599, 618, "hemoglobin A ( 1c )", "", +6143, Percentage, 632, 633, "%", "", +6144, Percentage, 652, 653, "%", "", +6145, Type2Diabetes, 656, 680, "type 2 diabetes mellitus", "", +6147, Type2Diabetes, 683, 687, "T2DM", "", +36913, Multicenter, 733, 746, "multinational", "", +6152, Randomized, 749, 759, "randomized", "", +36914, Placebo, 762, 769, "placebo", "", +6153, Parallel, 785, 801, "parallel - group", "", +6154, DoubleBlind, 804, 818, "double - blind", "", +6155, NumberPatientsCT, 838, 841, "190", "", +6156, Type2Diabetes, 856, 860, "T2DM", "", +6157, Duration, 863, 883, "After > or = 6 weeks", "prior to study?", +6158, Metformin, 894, 903, "metformin", "", +6159, DoseValue, 918, 929, "> or = 1500", "", +6160, mg, 930, 932, "mg", "", +6161, Interval, 935, 938, "day", "", +6162, Randomized, 957, 967, "randomized", "", +6163, Sitagliptin, 994, 1005, "sitagliptin", "", +6164, DoseValue, 1006, 1009, "100", "", +6165, mg, 1010, 1012, "mg", "", +6166, Frequency, 1013, 1023, "once daily", "", +6167, Placebo, 1027, 1034, "placebo", "", +6168, Metformin, 1046, 1055, "metformin", "", +6169, Duration, 1060, 1068, "30 weeks", "", +6170, HbA1c, 1142, 1161, "hemoglobin A ( 1c )", "", +6171, HbA1c, 1164, 1174, "HbA ( 1c )", "", +6172, TimePoint, 1186, 1200, "after 18 weeks", "", +6173, Sitagliptin, 1204, 1215, "sitagliptin", "", +6174, FastingPlasmaGlucose, 1274, 1296, "fasting plasma glucose", "", +6175, FastingPlasmaGlucose, 1299, 1302, "FPG", "", +36915, PostprandialPlasmaGlucose, 1309, 1355, "2 - hour ( 2 - h ) postprandial plasma glucose", "", +36916, PostprandialPlasmaGlucose, 1358, 1361, "PPG", "", +36917, TimePoint, 1367, 1375, "18 weeks", "", +6181, HbA1c, 1382, 1392, "HbA ( 1c )", "", +36918, TimePoint, 1396, 1404, "30 weeks", "", +6183, HbA1c_target, 1454, 1474, "HbA ( 1c ) < 7 . 0 %", "", +6184, Sitagliptin, 1505, 1516, "Sitagliptin", "", +6185, HbA1c, 1539, 1549, "HbA ( 1c )", "", +6186, FastingPlasmaGlucose, 1552, 1555, "FPG", "", +36919, PostprandialPlasmaGlucose, 1562, 1571, "2 - h PPG", "", +6188, Placebo, 1588, 1595, "placebo", "", +6217, PvalueDiff, 1602, 1613, "p < 0 . 001", "p value for all endpoints", +6190, HbA1c, 1641, 1651, "HbA ( 1c )", "", +6191, Reduction, 1658, 1663, "1 . 0", "", +6192, Percentage, 1664, 1665, "%", "", +6193, TimePoint, 1666, 1689, "at both 18 and 30 weeks", "", +6194, Sitagliptin, 1756, 1767, "sitagliptin", "", +6195, HbA1c_target, 1777, 1797, "HbA ( 1c ) < 7 . 0 %", "", +6196, PercentageAffected, 1824, 1830, "22 . 1", "", +6197, PercentageAffected, 1838, 1843, "3 . 3", "", +6198, PvalueDiff, 1848, 1859, "p < 0 . 001", "", +6199, Sitagliptin, 1864, 1875, "Sitagliptin", "", +36920, ObservedResult, 1899, 2067, "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .", "", +6201, Placebo, 1913, 1920, "placebo", "", +6200, Sitagliptin, 1923, 1934, "sitagliptin", "", +6202, BodyWeight, 1959, 1970, "body weight", "", +6203, Hypoglycemia, 2018, 2030, "hypoglycemia", "", +6204, GastrointestinalProblem, 2034, 2050, "gastrointestinal", "", +36921, ConclusionComment, 2082, 2294, "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .", "", +6207, Sitagliptin, 2094, 2105, "sitagliptin", "", +6208, DoseValue, 2106, 2109, "100", "", +6209, mg, 2110, 2112, "mg", "", +6210, Frequency, 2113, 2123, "once daily", "", +6211, Metformin, 2135, 2144, "metformin", "", +6212, Type2Diabetes, 2258, 2262, "T2DM", "", +6213, Duration, 2284, 2292, "30 weeks", "", +6215, PMID, 2337, 2345, "18194595", "", diff --git a/data/dm2 18194595_kwoodley.n-triples b/data/dm2 18194595_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18194595_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18204830 copy_admin.annodb b/data/dm2 18204830 copy_admin.annodb new file mode 100644 index 0000000..c21deaf --- /dev/null +++ b/data/dm2 18204830 copy_admin.annodb @@ -0,0 +1,136 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +1, PublicationYear, 15, 19, "2008", "", " \"2008\"." +129, Title, 111, 318, "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "", " \"A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .\"." +2, Randomized, 113, 123, "randomised", "", " ." +3, Duration, 126, 135, "52 - week", "", " \"52 - week\"." +5, InsulinDetemir, 174, 189, "insulin detemir", "", +6, InsulinGlargine, 195, 211, "insulin glargine", "", +22, OralAntidiabeticAgent, 245, 269, "glucose - lowering drugs", "", +8, Precondition, 273, 316, "insulin - naive people with type 2 diabetes", "", " \"insulin - naive people with type 2 diabetes\"." +7, Type2Diabetes, 301, 316, "type 2 diabetes", "", " ." +9, Author, 319, 331, "Rosenstock J", "", " \"Rosenstock J\"." +10, Author, 340, 348, "Davies M", "", " \"Davies M\"." +11, Author, 351, 358, "Home PD", "", " \"Home PD\"." +12, Author, 361, 369, "Larsen J", "", " \"Larsen J\"." +13, Author, 372, 380, "Koenen C", "", " \"Koenen C\"." +14, Author, 383, 397, "Schernthaner G", "", " \"Schernthaner G\"." +15, USA, 529, 532, "USA", "", " ." +27, ObjectiveDescription, 670, 862, "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with", "", " \"This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with\"." +16, Duration, 675, 684, "52 - week", "", +138, Multicenter, 685, 698, "multinational", "", " ." +17, Randomized, 701, 711, "randomised", "", +18, OpenLabel, 714, 726, "open - label", "", " ." +19, Parallel, 729, 745, "parallel - group", "", " ." +20, CTDesign, 748, 765, "non - inferiority", "", " . ." +21, OralAntidiabeticAgent, 828, 857, "oral glucose - lowering drugs", "", +254, ObjectiveDescription, 863, 937, "basal insulin analogues detemir and glargine in type 2 diabetic patients .", "", " \"basal insulin analogues detemir and glargine in type 2 diabetic patients .\"." +23, Insulin, 869, 876, "insulin", "", +24, InsulinDetemir, 887, 894, "detemir", "", +25, InsulinGlargine, 899, 907, "glargine", "", +26, Type2Diabetes, 911, 926, "type 2 diabetic", "", +147, Precondition, 948, 970, "Insulin - naive adults", "", " \"Insulin - naive adults\"." +28, NumberPatientsCT, 977, 980, "582", "", " \"582\"." +29, HbA1c, 983, 993, "HbA ( 1c )", "", +30, Percentage, 1009, 1010, "%", "", +31, BMI, 1013, 1016, "BMI", "", +32, Kg_per_squareMeter, 1031, 1043, "kg / m ( 2 )", "", +34, Randomized, 1051, 1061, "randomised", "", +35, AllocationRatio, 1062, 1067, "1 : 1", "", " . ." +36, InsulinDetemir, 1079, 1094, "insulin detemir", "", " ." +37, InsulinGlargine, 1098, 1106, "glargine", "", " ." +38, Frequency, 1107, 1117, "once daily", "", " \"once daily\". \"once daily\"." +39, Bedtime, 1120, 1127, "evening", "", " . ." +51767, DoseDescription, 1139, 1210, "titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", " \"titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l\". \"titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l\"." +40, FastingPlasmaGlucose_target, 1158, 1210, "fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", +161, Millimoles_per_litre, 1202, 1210, "mmol / l", "", +41, Morning, 1227, 1234, "morning", "", +42, InsulinDetemir, 1235, 1250, "insulin detemir", "", +51768, RelativeTime, 1273, 1285, "pre - dinner", "", +255, PlasmaGlucose, 1286, 1300, "plasma glucose", "", +256, PlasmaGlucose, 1303, 1305, "PG", "", +44, Millimoles_per_litre, 1320, 1328, "mmol / l", "", +166, FastingPlasmaGlucose_target, 1345, 1365, "FPG < 7 . 0 mmol / l", "", +45, Millimoles_per_litre, 1357, 1365, "mmol / l", "", +47, InsulinGlargine, 1410, 1418, "glargine", "", +260, TimePoint, 1448, 1456, "Baseline", "", +48, HbA1c, 1457, 1467, "HbA ( 1c )", "", " ." +49, BaseLineValue, 1483, 1488, "8 . 6", "", " \"8 . 6\". \"8 . 6\"." +50, ResultMeasuredValue, 1492, 1497, "7 . 2", "", " \"7 . 2\"." +51, ResultMeasuredValue, 1502, 1507, "7 . 1", "", " \"7 . 1\"." +52, Percentage, 1508, 1509, "%", "", " ." +53, InsulinDetemir, 1522, 1529, "detemir", "", " ." +54, InsulinGlargine, 1534, 1542, "glargine", "", +55, FastingPlasmaGlucose, 1560, 1563, "FPG", "", " ." +56, BaseLineValue, 1578, 1584, "10 . 8", "", " \"10 . 8\". \"10 . 8\"." +57, ResultMeasuredValue, 1588, 1593, "7 . 1", "", " \"7 . 1\"." +58, ResultMeasuredValue, 1598, 1603, "7 . 0", "", " \"7 . 0\"." +59, Millimoles_per_litre, 1604, 1612, "mmol / l", "", " ." +60, InsulinDetemir, 1642, 1649, "detemir", "", +61, Frequency, 1696, 1706, "once daily", "", +62, Frequency, 1726, 1737, "twice daily", "", +63, HbA1c, 1769, 1779, "HbA ( 1c )", "", +64, PercentageAffected, 1792, 1794, "52", "", +65, HbA1c_target, 1822, 1847, "HbA ( 1c ) < or = 7 . 0 %", "", " ." +185, Percentage, 1846, 1847, "%", "", " ." +66, PercentageAffected, 1850, 1852, "33", "", " \"33\"." +68, InsulinDetemir, 1857, 1864, "detemir", "", +67, PercentageAffected, 1871, 1873, "35", "", " \"35\"." +69, InsulinGlargine, 1878, 1886, "glargine", "", +201, EndPointDescription, 1889, 1910, "without hypoglycaemia", "", +71, Hypoglycemia, 1897, 1910, "hypoglycaemia", "", +72, FastingPlasmaGlucose, 1967, 1970, "FPG", "", +51769, RelativeTime, 1975, 1987, "pre - dinner", "", +51770, PreprandialPlasmaGlucose, 1975, 1990, "pre - dinner PG", "", +75, Insulin, 2009, 2016, "insulin", "", +76, NocturnalHypoglycemia, 2069, 2092, "nocturnal hypoglycaemia", "", +51771, Hypoglycemia, 2079, 2092, "hypoglycaemia", "", +51772, WeightGain, 2116, 2127, "weight gain", "", " ." +79, InsulinDetemir, 2143, 2150, "detemir", "", +80, InsulinGlargine, 2154, 2162, "glargine", "", +213, SubGroupDescription, 2166, 2176, "completers", "", " \"completers\". \"completers\"." +51773, Reduction, 2179, 2184, "3 . 0", "", " \"3 . 0\"." +51774, Reduction, 2188, 2193, "3 . 9", "", " \"3 . 9\"." +81, Kg, 2194, 2196, "kg", "", " ." +82, PvalueDiff, 2199, 2209, "p = 0 . 01", "", " \"p = 0 . 01\"." +92, SubGroupDescription, 2223, 2256, "intention - to - treat population", "", " \"intention - to - treat population\". \"intention - to - treat population\"." +83, IntentionToTreat, 2223, 2245, "intention - to - treat", "", " ." +51775, Reduction, 2259, 2264, "2 . 7", "", " \"2 . 7\"." +51776, Reduction, 2268, 2273, "3 . 5", "", " \"3 . 5\"." +84, Kg, 2274, 2276, "kg", "", +85, PvalueDiff, 2279, 2289, "p = 0 . 03", "", " \"p = 0 . 03\"." +86, Frequency, 2329, 2341, "once - daily", "", +87, InsulinDetemir, 2342, 2349, "detemir", "", +223, Mean, 2352, 2356, "Mean", "", " . ." +94, Frequency, 2357, 2362, "daily", "", +95, InsulinDetemir, 2363, 2370, "detemir", "", +224, EndPointDescription, 2371, 2375, "dose", "", " . ." +225, ResultMeasuredValue, 2389, 2395, "0 . 78", "", " \"0 . 78\"." +99, IntUnit_per_Kg, 2396, 2402, "U / kg", "", " ." +226, ResultMeasuredValue, 2405, 2411, "0 . 52", "", " \"0 . 52\"." +229, SubGroupDescription, 2412, 2434, "with once daily dosing", "", " \"with once daily dosing\"." +101, Frequency, 2417, 2427, "once daily", "", +227, ResultMeasuredValue, 2437, 2443, "1 . 00", "", " \"1 . 00\"." +100, IntUnit_per_Kg, 2444, 2450, "U / kg", "", +230, SubGroupDescription, 2451, 2474, "with twice daily dosing", "", " \"with twice daily dosing\"." +102, Frequency, 2456, 2467, "twice daily", "", +103, InsulinGlargine, 2484, 2492, "glargine", "", +228, ResultMeasuredValue, 2495, 2501, "0 . 44", "", " \"0 . 44\"." +105, IntUnit_per_Kg, 2502, 2509, "IU / kg", "", +236, EndPointDescription, 2514, 2538, "Injection site reactions", "", " . ." +106, InsulinDetemir, 2563, 2570, "detemir", "", +107, PercentageAffected, 2573, 2578, "4 . 5", "", " \"4 . 5\"." +108, PercentageAffected, 2582, 2587, "1 . 4", "", " \"1 . 4\"." +244, ConclusionComment, 2625, 2777, "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .", "", " \"Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .\"." +109, OralAntidiabeticAgent, 2644, 2655, "oral agents", "", +110, InsulinDetemir, 2661, 2668, "detemir", "", +111, InsulinGlargine, 2672, 2680, "glargine", "", +112, Hypoglycemia, 2762, 2775, "hypoglycaemia", "", +250, ConclusionComment, 2778, 2962, "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .", "", " \"Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .\"." +113, InsulinDetemir, 2817, 2824, "detemir", "", +114, Insulin, 2838, 2845, "insulin", "", +115, Frequency, 2873, 2884, "twice daily", "", +51777, WeightGain, 2896, 2907, "weight gain", "", +117, Frequency, 2934, 2944, "once daily", "", +118, InsulinDetemir, 2945, 2960, "insulin detemir", "", +119, PMID, 3031, 3039, "18204830", "", " \"18204830\"." diff --git a/data/dm2 18204830 copy_admin.n-triples b/data/dm2 18204830 copy_admin.n-triples new file mode 100644 index 0000000..8151f2d --- /dev/null +++ b/data/dm2 18204830 copy_admin.n-triples @@ -0,0 +1,221 @@ +# RDF export of group: Publication + . + "Publication" . + "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes ." . + "Rosenstock J" . + "2008" . + "Diabetologia" . + "18204830" . + . + "Davies M" . + "Home PD" . + "Larsen J" . + "Koenen C" . + "Schernthaner G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with" . + "582" . + "52 - week" . + . + . + . + . + "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia ." . + . + . + . + . + . + "basal insulin analogues detemir and glargine in type 2 diabetic patients ." . + . + . + . + . + . + "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir ." . + . + . +# RDF export of group: Population + . + "Population" . + "insulin - naive people with type 2 diabetes" . + . + . + . + "Insulin - naive adults" . +# RDF export of group: Endpoint + . + "Endpoint_HbA1c" . + . + . + . + . + . + "Endpoint_FPG" . + . + . + . + . + . + "Endpoint_HbA1c7" . + . + . + . + . + . + "Endpoint_W" . + . + . + . + . + . + "Endpoint_D" . + . + . + . + . + . + . + . + "Endpoint_I" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_D" . + . + . + . + . + . + . + . + . + . + . + . + "Arm_G" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_D" . + . + "once daily" . + . + . + "Intervention_G" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_D" . + . + . + . + "titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l" . + . + "Medication_G" . + . + . + . + "titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l" . +# RDF export of group: Outcome + . + "Outcome_H_D" . + . + "8 . 6" . + "7 . 2" . + . + "Outcome_H_G" . + . + "8 . 6" . + "7 . 1" . + . + "Outcome_FPG_D" . + . + "10 . 8" . + "7 . 1" . + . + "Outcome_FPG_G" . + . + "10 . 8" . + "7 . 0" . + . + "Outcome_H7_D" . + . + "33" . + . + "Outcome_H7_G" . + . + "35" . + . + "Outcome_W_D_Sub1" . + . + "3 . 0" . + "completers" . + . + "Outcome_W_G_Sub1" . + . + "3 . 9" . + "completers" . + . + "Outcome_W_D_Sub2" . + . + "2 . 7" . + "intention - to - treat population" . + . + "Outcome_W_G_Sub2" . + . + "3 . 5" . + "intention - to - treat population" . + . + "Outcome_D_D" . + . + "0 . 78" . + . + "Outcome_D_G" . + . + "0 . 44" . + . + "Outcome_D_D_Sub1" . + . + "0 . 52" . + "with once daily dosing" . + . + "Outcome_D_D_Sub2" . + . + "1 . 00" . + "with twice daily dosing" . + . + "Outcome_I_D" . + . + "4 . 5" . + . + "Outcome_I_G" . + . + "1 . 4" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_W_Sub1" . + "p = 0 . 01" . + . + . + . + "DiffBetweenGroups_W_Sub2" . + "p = 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18204830 copy_export.csv b/data/dm2 18204830 copy_export.csv new file mode 100644 index 0000000..cd3f9ea --- /dev/null +++ b/data/dm2 18204830 copy_export.csv @@ -0,0 +1,678 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +820, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +820, 1, 2, 2, 13, 14, 13, 14, "." +820, 2, 1, 3, 0, 4, 15, 19, "2008" +820, 2, 2, 4, 5, 8, 20, 23, "Mar" +820, 2, 3, 5, 9, 10, 24, 25, ";" +820, 2, 4, 6, 11, 13, 26, 28, "51" +820, 2, 5, 7, 14, 15, 29, 30, "(" +820, 2, 6, 8, 16, 17, 31, 32, "3" +820, 2, 7, 9, 18, 19, 33, 34, ")" +820, 2, 8, 10, 20, 21, 35, 36, ":" +820, 2, 9, 11, 22, 25, 37, 40, "408" +820, 2, 10, 12, 26, 27, 41, 42, "-" +820, 2, 11, 13, 28, 30, 43, 45, "16" +820, 2, 12, 14, 31, 32, 46, 47, "." +820, 2, 13, 15, 33, 36, 48, 51, "doi" +820, 2, 14, 16, 37, 38, 52, 53, ":" +820, 2, 15, 17, 39, 41, 54, 56, "10" +820, 2, 16, 18, 42, 43, 57, 58, "." +820, 2, 17, 19, 44, 48, 59, 63, "1007" +820, 2, 18, 20, 49, 50, 64, 65, "/" +820, 2, 19, 21, 51, 57, 66, 72, "s00125" +820, 2, 20, 22, 58, 59, 73, 74, "-" +820, 2, 21, 23, 60, 63, 75, 78, "007" +820, 2, 22, 24, 64, 65, 79, 80, "-" +820, 2, 23, 25, 66, 70, 81, 85, "0911" +820, 2, 24, 26, 71, 72, 86, 87, "-" +820, 2, 25, 27, 73, 74, 88, 89, "x" +820, 2, 26, 28, 75, 76, 90, 91, "." +820, 3, 1, 29, 0, 4, 92, 96, "Epub" +820, 3, 2, 30, 5, 9, 97, 101, "2008" +820, 3, 3, 31, 10, 13, 102, 105, "Jan" +820, 3, 4, 32, 14, 16, 106, 108, "16" +820, 3, 5, 33, 17, 18, 109, 110, "." +820, 4, 1, 34, 0, 1, 111, 112, "A" +820, 4, 2, 35, 2, 12, 113, 123, "randomised" +820, 4, 3, 36, 13, 14, 124, 125, "," +820, 4, 4, 37, 15, 17, 126, 128, "52" +820, 4, 5, 38, 18, 19, 129, 130, "-" +820, 4, 6, 39, 20, 24, 131, 135, "week" +820, 4, 7, 40, 25, 26, 136, 137, "," +820, 4, 8, 41, 27, 32, 138, 143, "treat" +820, 4, 9, 42, 33, 34, 144, 145, "-" +820, 4, 10, 43, 35, 37, 146, 148, "to" +820, 4, 11, 44, 38, 39, 149, 150, "-" +820, 4, 12, 45, 40, 46, 151, 157, "target" +820, 4, 13, 46, 47, 52, 158, 163, "trial" +820, 4, 14, 47, 53, 62, 164, 173, "comparing" +820, 4, 15, 48, 63, 70, 174, 181, "insulin" +820, 4, 16, 49, 71, 78, 182, 189, "detemir" +820, 4, 17, 50, 79, 83, 190, 194, "with" +820, 4, 18, 51, 84, 91, 195, 202, "insulin" +820, 4, 19, 52, 92, 100, 203, 211, "glargine" +820, 4, 20, 53, 101, 105, 212, 216, "when" +820, 4, 21, 54, 106, 118, 217, 229, "administered" +820, 4, 22, 55, 119, 121, 230, 232, "as" +820, 4, 23, 56, 122, 125, 233, 236, "add" +820, 4, 24, 57, 126, 127, 237, 238, "-" +820, 4, 25, 58, 128, 130, 239, 241, "on" +820, 4, 26, 59, 131, 133, 242, 244, "to" +820, 4, 27, 60, 134, 141, 245, 252, "glucose" +820, 4, 28, 61, 142, 143, 253, 254, "-" +820, 4, 29, 62, 144, 152, 255, 263, "lowering" +820, 4, 30, 63, 153, 158, 264, 269, "drugs" +820, 4, 31, 64, 159, 161, 270, 272, "in" +820, 4, 32, 65, 162, 169, 273, 280, "insulin" +820, 4, 33, 66, 170, 171, 281, 282, "-" +820, 4, 34, 67, 172, 177, 283, 288, "naive" +820, 4, 35, 68, 178, 184, 289, 295, "people" +820, 4, 36, 69, 185, 189, 296, 300, "with" +820, 4, 37, 70, 190, 194, 301, 305, "type" +820, 4, 38, 71, 195, 196, 306, 307, "2" +820, 4, 39, 72, 197, 205, 308, 316, "diabetes" +820, 4, 40, 73, 206, 207, 317, 318, "." +820, 5, 1, 74, 0, 10, 319, 329, "Rosenstock" +820, 5, 2, 75, 11, 12, 330, 331, "J" +820, 5, 3, 76, 13, 14, 332, 333, "(" +820, 5, 4, 77, 15, 16, 334, 335, "1" +820, 5, 5, 78, 17, 18, 336, 337, ")" +820, 5, 6, 79, 19, 20, 338, 339, "," +820, 5, 7, 80, 21, 27, 340, 346, "Davies" +820, 5, 8, 81, 28, 29, 347, 348, "M" +820, 5, 9, 82, 30, 31, 349, 350, "," +820, 5, 10, 83, 32, 36, 351, 355, "Home" +820, 5, 11, 84, 37, 39, 356, 358, "PD" +820, 5, 12, 85, 40, 41, 359, 360, "," +820, 5, 13, 86, 42, 48, 361, 367, "Larsen" +820, 5, 14, 87, 49, 50, 368, 369, "J" +820, 5, 15, 88, 51, 52, 370, 371, "," +820, 5, 16, 89, 53, 59, 372, 378, "Koenen" +820, 5, 17, 90, 60, 61, 379, 380, "C" +820, 5, 18, 91, 62, 63, 381, 382, "," +820, 5, 19, 92, 64, 76, 383, 395, "Schernthaner" +820, 5, 20, 93, 77, 78, 396, 397, "G" +820, 5, 21, 94, 79, 80, 398, 399, "." +820, 5, 22, 95, 81, 87, 400, 406, "Author" +820, 5, 23, 96, 88, 99, 407, 418, "information" +820, 5, 24, 97, 100, 101, 419, 420, ":" +820, 5, 25, 98, 102, 103, 421, 422, "(" +820, 5, 26, 99, 104, 105, 423, 424, "1" +820, 5, 27, 100, 106, 107, 425, 426, ")" +820, 5, 28, 101, 108, 114, 427, 433, "Dallas" +820, 5, 29, 102, 115, 123, 434, 442, "Diabetes" +820, 5, 30, 103, 124, 127, 443, 446, "and" +820, 5, 31, 104, 128, 137, 447, 456, "Endocrine" +820, 5, 32, 105, 138, 144, 457, 463, "Center" +820, 5, 33, 106, 145, 147, 464, 466, "at" +820, 5, 34, 107, 148, 155, 467, 474, "Medical" +820, 5, 35, 108, 156, 160, 475, 479, "City" +820, 5, 36, 109, 161, 162, 480, 481, "," +820, 5, 37, 110, 163, 167, 482, 486, "7777" +820, 5, 38, 111, 168, 174, 487, 493, "Forest" +820, 5, 39, 112, 175, 179, 494, 498, "Lane" +820, 5, 40, 113, 180, 181, 499, 500, "C" +820, 5, 41, 114, 182, 183, 501, 502, "-" +820, 5, 42, 115, 184, 187, 503, 506, "685" +820, 5, 43, 116, 188, 189, 507, 508, "," +820, 5, 44, 117, 190, 196, 509, 515, "Dallas" +820, 5, 45, 118, 197, 198, 516, 517, "," +820, 5, 46, 119, 199, 201, 518, 520, "TX" +820, 5, 47, 120, 202, 207, 521, 526, "75230" +820, 5, 48, 121, 208, 209, 527, 528, "," +820, 5, 49, 122, 210, 213, 529, 532, "USA" +820, 5, 50, 123, 214, 215, 533, 534, "." +820, 6, 1, 124, 0, 15, 535, 550, "juliorosenstock" +820, 6, 2, 125, 16, 17, 551, 552, "@" +820, 6, 3, 126, 18, 32, 553, 567, "dallasdiabetes" +820, 6, 4, 127, 33, 34, 568, 569, "." +820, 6, 5, 128, 35, 38, 570, 573, "com" +820, 6, 6, 129, 39, 46, 574, 581, "Comment" +820, 6, 7, 130, 47, 49, 582, 584, "in" +820, 6, 8, 131, 50, 53, 585, 588, "Nat" +820, 6, 9, 132, 54, 58, 589, 593, "Clin" +820, 6, 10, 133, 59, 64, 594, 599, "Pract" +820, 6, 11, 134, 65, 75, 600, 610, "Endocrinol" +820, 6, 12, 135, 76, 81, 611, 616, "Metab" +820, 6, 13, 136, 82, 83, 617, 618, "." +820, 7, 1, 137, 0, 4, 619, 623, "2008" +820, 7, 2, 138, 5, 8, 624, 627, "Sep" +820, 7, 3, 139, 9, 10, 628, 629, ";" +820, 7, 4, 140, 11, 12, 630, 631, "4" +820, 7, 5, 141, 13, 14, 632, 633, "(" +820, 7, 6, 142, 15, 16, 634, 635, "9" +820, 7, 7, 143, 17, 18, 636, 637, ")" +820, 7, 8, 144, 19, 20, 638, 639, ":" +820, 7, 9, 145, 21, 24, 640, 643, "490" +820, 7, 10, 146, 25, 26, 644, 645, "-" +820, 7, 11, 147, 27, 28, 646, 647, "1" +820, 7, 12, 148, 29, 30, 648, 649, "." +820, 8, 1, 149, 0, 4, 650, 654, "AIMS" +820, 8, 2, 150, 5, 6, 655, 656, "/" +820, 8, 3, 151, 7, 17, 657, 667, "HYPOTHESIS" +820, 8, 4, 152, 18, 19, 668, 669, ":" +820, 8, 5, 153, 20, 24, 670, 674, "This" +820, 8, 6, 154, 25, 27, 675, 677, "52" +820, 8, 7, 155, 28, 29, 678, 679, "-" +820, 8, 8, 156, 30, 34, 680, 684, "week" +820, 8, 9, 157, 35, 48, 685, 698, "multinational" +820, 8, 10, 158, 49, 50, 699, 700, "," +820, 8, 11, 159, 51, 61, 701, 711, "randomised" +820, 8, 12, 160, 62, 63, 712, 713, "," +820, 8, 13, 161, 64, 68, 714, 718, "open" +820, 8, 14, 162, 69, 70, 719, 720, "-" +820, 8, 15, 163, 71, 76, 721, 726, "label" +820, 8, 16, 164, 77, 78, 727, 728, "," +820, 8, 17, 165, 79, 87, 729, 737, "parallel" +820, 8, 18, 166, 88, 89, 738, 739, "-" +820, 8, 19, 167, 90, 95, 740, 745, "group" +820, 8, 20, 168, 96, 97, 746, 747, "," +820, 8, 21, 169, 98, 101, 748, 751, "non" +820, 8, 22, 170, 102, 103, 752, 753, "-" +820, 8, 23, 171, 104, 115, 754, 765, "inferiority" +820, 8, 24, 172, 116, 121, 766, 771, "trial" +820, 8, 25, 173, 122, 130, 772, 780, "compared" +820, 8, 26, 174, 131, 139, 781, 789, "clinical" +820, 8, 27, 175, 140, 148, 790, 798, "outcomes" +820, 8, 28, 176, 149, 158, 799, 808, "following" +820, 8, 29, 177, 159, 174, 809, 824, "supplementation" +820, 8, 30, 178, 175, 177, 825, 827, "of" +820, 8, 31, 179, 178, 182, 828, 832, "oral" +820, 8, 32, 180, 183, 190, 833, 840, "glucose" +820, 8, 33, 181, 191, 192, 841, 842, "-" +820, 8, 34, 182, 193, 201, 843, 851, "lowering" +820, 8, 35, 183, 202, 207, 852, 857, "drugs" +820, 8, 36, 184, 208, 212, 858, 862, "with" +820, 8, 37, 185, 213, 218, 863, 868, "basal" +820, 8, 38, 186, 219, 226, 869, 876, "insulin" +820, 8, 39, 187, 227, 236, 877, 886, "analogues" +820, 8, 40, 188, 237, 244, 887, 894, "detemir" +820, 8, 41, 189, 245, 248, 895, 898, "and" +820, 8, 42, 190, 249, 257, 899, 907, "glargine" +820, 8, 43, 191, 258, 260, 908, 910, "in" +820, 8, 44, 192, 261, 265, 911, 915, "type" +820, 8, 45, 193, 266, 267, 916, 917, "2" +820, 8, 46, 194, 268, 276, 918, 926, "diabetic" +820, 8, 47, 195, 277, 285, 927, 935, "patients" +820, 8, 48, 196, 286, 287, 936, 937, "." +820, 9, 1, 197, 0, 7, 938, 945, "METHODS" +820, 9, 2, 198, 8, 9, 946, 947, ":" +820, 9, 3, 199, 10, 17, 948, 955, "Insulin" +820, 9, 4, 200, 18, 19, 956, 957, "-" +820, 9, 5, 201, 20, 25, 958, 963, "naive" +820, 9, 6, 202, 26, 32, 964, 970, "adults" +820, 9, 7, 203, 33, 34, 971, 972, "(" +820, 9, 8, 204, 35, 36, 973, 974, "n" +820, 9, 9, 205, 37, 38, 975, 976, "=" +820, 9, 10, 206, 39, 42, 977, 980, "582" +820, 9, 11, 207, 43, 44, 981, 982, "," +820, 9, 12, 208, 45, 48, 983, 986, "HbA" +820, 9, 13, 209, 49, 50, 987, 988, "(" +820, 9, 14, 210, 51, 53, 989, 991, "1c" +820, 9, 15, 211, 54, 55, 992, 993, ")" +820, 9, 16, 212, 56, 57, 994, 995, "7" +820, 9, 17, 213, 58, 59, 996, 997, "." +820, 9, 18, 214, 60, 61, 998, 999, "5" +820, 9, 19, 215, 62, 63, 1000, 1001, "-" +820, 9, 20, 216, 64, 66, 1002, 1004, "10" +820, 9, 21, 217, 67, 68, 1005, 1006, "." +820, 9, 22, 218, 69, 70, 1007, 1008, "0" +820, 9, 23, 219, 71, 72, 1009, 1010, "%" +820, 9, 24, 220, 73, 74, 1011, 1012, "," +820, 9, 25, 221, 75, 78, 1013, 1016, "BMI" +820, 9, 26, 222, 79, 80, 1017, 1018, "<" +820, 9, 27, 223, 81, 83, 1019, 1021, "or" +820, 9, 28, 224, 84, 85, 1022, 1023, "=" +820, 9, 29, 225, 86, 88, 1024, 1026, "40" +820, 9, 30, 226, 89, 90, 1027, 1028, "." +820, 9, 31, 227, 91, 92, 1029, 1030, "0" +820, 9, 32, 228, 93, 95, 1031, 1033, "kg" +820, 9, 33, 229, 96, 97, 1034, 1035, "/" +820, 9, 34, 230, 98, 99, 1036, 1037, "m" +820, 9, 35, 231, 100, 101, 1038, 1039, "(" +820, 9, 36, 232, 102, 103, 1040, 1041, "2" +820, 9, 37, 233, 104, 105, 1042, 1043, ")" +820, 9, 38, 234, 106, 107, 1044, 1045, ")" +820, 9, 39, 235, 108, 112, 1046, 1050, "were" +820, 9, 40, 236, 113, 123, 1051, 1061, "randomised" +820, 9, 41, 237, 124, 125, 1062, 1063, "1" +820, 9, 42, 238, 126, 127, 1064, 1065, ":" +820, 9, 43, 239, 128, 129, 1066, 1067, "1" +820, 9, 44, 240, 130, 132, 1068, 1070, "to" +820, 9, 45, 241, 133, 140, 1071, 1078, "receive" +820, 9, 46, 242, 141, 148, 1079, 1086, "insulin" +820, 9, 47, 243, 149, 156, 1087, 1094, "detemir" +820, 9, 48, 244, 157, 159, 1095, 1097, "or" +820, 9, 49, 245, 160, 168, 1098, 1106, "glargine" +820, 9, 50, 246, 169, 173, 1107, 1111, "once" +820, 9, 51, 247, 174, 179, 1112, 1117, "daily" +820, 9, 52, 248, 180, 181, 1118, 1119, "(" +820, 9, 53, 249, 182, 189, 1120, 1127, "evening" +820, 9, 54, 250, 190, 191, 1128, 1129, ")" +820, 9, 55, 251, 192, 200, 1130, 1138, "actively" +820, 9, 56, 252, 201, 209, 1139, 1147, "titrated" +820, 9, 57, 253, 210, 212, 1148, 1150, "to" +820, 9, 58, 254, 213, 219, 1151, 1157, "target" +820, 9, 59, 255, 220, 227, 1158, 1165, "fasting" +820, 9, 60, 256, 228, 234, 1166, 1172, "plasma" +820, 9, 61, 257, 235, 242, 1173, 1180, "glucose" +820, 9, 62, 258, 243, 244, 1181, 1182, "(" +820, 9, 63, 259, 245, 248, 1183, 1186, "FPG" +820, 9, 64, 260, 249, 250, 1187, 1188, ")" +820, 9, 65, 261, 251, 252, 1189, 1190, "<" +820, 9, 66, 262, 253, 255, 1191, 1193, "or" +820, 9, 67, 263, 256, 257, 1194, 1195, "=" +820, 9, 68, 264, 258, 259, 1196, 1197, "6" +820, 9, 69, 265, 260, 261, 1198, 1199, "." +820, 9, 70, 266, 262, 263, 1200, 1201, "0" +820, 9, 71, 267, 264, 268, 1202, 1206, "mmol" +820, 9, 72, 268, 269, 270, 1207, 1208, "/" +820, 9, 73, 269, 271, 272, 1209, 1210, "l" +820, 9, 74, 270, 273, 274, 1211, 1212, "." +820, 10, 1, 271, 0, 2, 1213, 1215, "An" +820, 10, 2, 272, 3, 13, 1216, 1226, "additional" +820, 10, 3, 273, 14, 21, 1227, 1234, "morning" +820, 10, 4, 274, 22, 29, 1235, 1242, "insulin" +820, 10, 5, 275, 30, 37, 1243, 1250, "detemir" +820, 10, 6, 276, 38, 42, 1251, 1255, "dose" +820, 10, 7, 277, 43, 46, 1256, 1259, "was" +820, 10, 8, 278, 47, 56, 1260, 1269, "permitted" +820, 10, 9, 279, 57, 59, 1270, 1272, "if" +820, 10, 10, 280, 60, 63, 1273, 1276, "pre" +820, 10, 11, 281, 64, 65, 1277, 1278, "-" +820, 10, 12, 282, 66, 72, 1279, 1285, "dinner" +820, 10, 13, 283, 73, 79, 1286, 1292, "plasma" +820, 10, 14, 284, 80, 87, 1293, 1300, "glucose" +820, 10, 15, 285, 88, 89, 1301, 1302, "(" +820, 10, 16, 286, 90, 92, 1303, 1305, "PG" +820, 10, 17, 287, 93, 94, 1306, 1307, ")" +820, 10, 18, 288, 95, 98, 1308, 1311, "was" +820, 10, 19, 289, 99, 100, 1312, 1313, ">" +820, 10, 20, 290, 101, 102, 1314, 1315, "7" +820, 10, 21, 291, 103, 104, 1316, 1317, "." +820, 10, 22, 292, 105, 106, 1318, 1319, "0" +820, 10, 23, 293, 107, 111, 1320, 1324, "mmol" +820, 10, 24, 294, 112, 113, 1325, 1326, "/" +820, 10, 25, 295, 114, 115, 1327, 1328, "l" +820, 10, 26, 296, 116, 121, 1329, 1334, "after" +820, 10, 27, 297, 122, 131, 1335, 1344, "achieving" +820, 10, 28, 298, 132, 135, 1345, 1348, "FPG" +820, 10, 29, 299, 136, 137, 1349, 1350, "<" +820, 10, 30, 300, 138, 139, 1351, 1352, "7" +820, 10, 31, 301, 140, 141, 1353, 1354, "." +820, 10, 32, 302, 142, 143, 1355, 1356, "0" +820, 10, 33, 303, 144, 148, 1357, 1361, "mmol" +820, 10, 34, 304, 149, 150, 1362, 1363, "/" +820, 10, 35, 305, 151, 152, 1364, 1365, "l" +820, 10, 36, 306, 153, 154, 1366, 1367, "." +820, 11, 1, 307, 0, 3, 1368, 1371, "Due" +820, 11, 2, 308, 4, 6, 1372, 1374, "to" +820, 11, 3, 309, 7, 16, 1375, 1384, "labelling" +820, 11, 4, 310, 17, 29, 1385, 1397, "restrictions" +820, 11, 5, 311, 30, 31, 1398, 1399, "," +820, 11, 6, 312, 32, 34, 1400, 1402, "no" +820, 11, 7, 313, 35, 41, 1403, 1409, "second" +820, 11, 8, 314, 42, 50, 1410, 1418, "glargine" +820, 11, 9, 315, 51, 55, 1419, 1423, "dose" +820, 11, 10, 316, 56, 59, 1424, 1427, "was" +820, 11, 11, 317, 60, 67, 1428, 1435, "allowed" +820, 11, 12, 318, 68, 69, 1436, 1437, "." +820, 12, 1, 319, 0, 7, 1438, 1445, "RESULTS" +820, 12, 2, 320, 8, 9, 1446, 1447, ":" +820, 12, 3, 321, 10, 18, 1448, 1456, "Baseline" +820, 12, 4, 322, 19, 22, 1457, 1460, "HbA" +820, 12, 5, 323, 23, 24, 1461, 1462, "(" +820, 12, 6, 324, 25, 27, 1463, 1465, "1c" +820, 12, 7, 325, 28, 29, 1466, 1467, ")" +820, 12, 8, 326, 30, 39, 1468, 1477, "decreased" +820, 12, 9, 327, 40, 44, 1478, 1482, "from" +820, 12, 10, 328, 45, 46, 1483, 1484, "8" +820, 12, 11, 329, 47, 48, 1485, 1486, "." +820, 12, 12, 330, 49, 50, 1487, 1488, "6" +820, 12, 13, 331, 51, 53, 1489, 1491, "to" +820, 12, 14, 332, 54, 55, 1492, 1493, "7" +820, 12, 15, 333, 56, 57, 1494, 1495, "." +820, 12, 16, 334, 58, 59, 1496, 1497, "2" +820, 12, 17, 335, 60, 63, 1498, 1501, "and" +820, 12, 18, 336, 64, 65, 1502, 1503, "7" +820, 12, 19, 337, 66, 67, 1504, 1505, "." +820, 12, 20, 338, 68, 69, 1506, 1507, "1" +820, 12, 21, 339, 70, 71, 1508, 1509, "%" +820, 12, 22, 340, 72, 73, 1510, 1511, "(" +820, 12, 23, 341, 74, 76, 1512, 1514, "NS" +820, 12, 24, 342, 77, 78, 1515, 1516, ")" +820, 12, 25, 343, 79, 83, 1517, 1521, "with" +820, 12, 26, 344, 84, 91, 1522, 1529, "detemir" +820, 12, 27, 345, 92, 95, 1530, 1533, "and" +820, 12, 28, 346, 96, 104, 1534, 1542, "glargine" +820, 12, 29, 347, 105, 106, 1543, 1544, "," +820, 12, 30, 348, 107, 119, 1545, 1557, "respectively" +820, 12, 31, 349, 120, 121, 1558, 1559, "." +820, 13, 1, 350, 0, 3, 1560, 1563, "FPG" +820, 13, 2, 351, 4, 12, 1564, 1572, "improved" +820, 13, 3, 352, 13, 17, 1573, 1577, "from" +820, 13, 4, 353, 18, 20, 1578, 1580, "10" +820, 13, 5, 354, 21, 22, 1581, 1582, "." +820, 13, 6, 355, 23, 24, 1583, 1584, "8" +820, 13, 7, 356, 25, 27, 1585, 1587, "to" +820, 13, 8, 357, 28, 29, 1588, 1589, "7" +820, 13, 9, 358, 30, 31, 1590, 1591, "." +820, 13, 10, 359, 32, 33, 1592, 1593, "1" +820, 13, 11, 360, 34, 37, 1594, 1597, "and" +820, 13, 12, 361, 38, 39, 1598, 1599, "7" +820, 13, 13, 362, 40, 41, 1600, 1601, "." +820, 13, 14, 363, 42, 43, 1602, 1603, "0" +820, 13, 15, 364, 44, 48, 1604, 1608, "mmol" +820, 13, 16, 365, 49, 50, 1609, 1610, "/" +820, 13, 17, 366, 51, 52, 1611, 1612, "l" +820, 13, 18, 367, 53, 54, 1613, 1614, "(" +820, 13, 19, 368, 55, 57, 1615, 1617, "NS" +820, 13, 20, 369, 58, 59, 1618, 1619, ")" +820, 13, 21, 370, 60, 61, 1620, 1621, "," +820, 13, 22, 371, 62, 74, 1622, 1634, "respectively" +820, 13, 23, 372, 75, 76, 1635, 1636, "." +820, 14, 1, 373, 0, 4, 1637, 1641, "With" +820, 14, 2, 374, 5, 12, 1642, 1649, "detemir" +820, 14, 3, 375, 13, 14, 1650, 1651, "," +820, 14, 4, 376, 15, 17, 1652, 1654, "45" +820, 14, 5, 377, 18, 19, 1655, 1656, "%" +820, 14, 6, 378, 20, 22, 1657, 1659, "of" +820, 14, 7, 379, 23, 35, 1660, 1672, "participants" +820, 14, 8, 380, 36, 45, 1673, 1682, "completed" +820, 14, 9, 381, 46, 49, 1683, 1686, "the" +820, 14, 10, 382, 50, 55, 1687, 1692, "study" +820, 14, 11, 383, 56, 58, 1693, 1695, "on" +820, 14, 12, 384, 59, 63, 1696, 1700, "once" +820, 14, 13, 385, 64, 69, 1701, 1706, "daily" +820, 14, 14, 386, 70, 76, 1707, 1713, "dosing" +820, 14, 15, 387, 77, 80, 1714, 1717, "and" +820, 14, 16, 388, 81, 83, 1718, 1720, "55" +820, 14, 17, 389, 84, 85, 1721, 1722, "%" +820, 14, 18, 390, 86, 88, 1723, 1725, "on" +820, 14, 19, 391, 89, 94, 1726, 1731, "twice" +820, 14, 20, 392, 95, 100, 1732, 1737, "daily" +820, 14, 21, 393, 101, 107, 1738, 1744, "dosing" +820, 14, 22, 394, 108, 109, 1745, 1746, "," +820, 14, 23, 395, 110, 114, 1747, 1751, "with" +820, 14, 24, 396, 115, 117, 1752, 1754, "no" +820, 14, 25, 397, 118, 128, 1755, 1765, "difference" +820, 14, 26, 398, 129, 131, 1766, 1768, "in" +820, 14, 27, 399, 132, 135, 1769, 1772, "HbA" +820, 14, 28, 400, 136, 137, 1773, 1774, "(" +820, 14, 29, 401, 138, 140, 1775, 1777, "1c" +820, 14, 30, 402, 141, 142, 1778, 1779, ")" +820, 14, 31, 403, 143, 144, 1780, 1781, "." +820, 15, 1, 404, 0, 7, 1782, 1789, "Overall" +820, 15, 2, 405, 8, 9, 1790, 1791, "," +820, 15, 3, 406, 10, 12, 1792, 1794, "52" +820, 15, 4, 407, 13, 14, 1795, 1796, "%" +820, 15, 5, 408, 15, 17, 1797, 1799, "of" +820, 15, 6, 409, 18, 30, 1800, 1812, "participants" +820, 15, 7, 410, 31, 39, 1813, 1821, "achieved" +820, 15, 8, 411, 40, 43, 1822, 1825, "HbA" +820, 15, 9, 412, 44, 45, 1826, 1827, "(" +820, 15, 10, 413, 46, 48, 1828, 1830, "1c" +820, 15, 11, 414, 49, 50, 1831, 1832, ")" +820, 15, 12, 415, 51, 52, 1833, 1834, "<" +820, 15, 13, 416, 53, 55, 1835, 1837, "or" +820, 15, 14, 417, 56, 57, 1838, 1839, "=" +820, 15, 15, 418, 58, 59, 1840, 1841, "7" +820, 15, 16, 419, 60, 61, 1842, 1843, "." +820, 15, 17, 420, 62, 63, 1844, 1845, "0" +820, 15, 18, 421, 64, 65, 1846, 1847, "%" +820, 15, 19, 422, 66, 67, 1848, 1849, ":" +820, 15, 20, 423, 68, 70, 1850, 1852, "33" +820, 15, 21, 424, 71, 72, 1853, 1854, "%" +820, 15, 22, 425, 73, 74, 1855, 1856, "(" +820, 15, 23, 426, 75, 82, 1857, 1864, "detemir" +820, 15, 24, 427, 83, 84, 1865, 1866, ")" +820, 15, 25, 428, 85, 88, 1867, 1870, "and" +820, 15, 26, 429, 89, 91, 1871, 1873, "35" +820, 15, 27, 430, 92, 93, 1874, 1875, "%" +820, 15, 28, 431, 94, 95, 1876, 1877, "(" +820, 15, 29, 432, 96, 104, 1878, 1886, "glargine" +820, 15, 30, 433, 105, 106, 1887, 1888, ")" +820, 15, 31, 434, 107, 114, 1889, 1896, "without" +820, 15, 32, 435, 115, 128, 1897, 1910, "hypoglycaemia" +820, 15, 33, 436, 129, 130, 1911, 1912, "." +820, 16, 1, 437, 0, 6, 1913, 1919, "Within" +820, 16, 2, 438, 7, 8, 1920, 1921, "-" +820, 16, 3, 439, 9, 20, 1922, 1933, "participant" +820, 16, 4, 440, 21, 32, 1934, 1945, "variability" +820, 16, 5, 441, 33, 36, 1946, 1949, "for" +820, 16, 6, 442, 37, 41, 1950, 1954, "self" +820, 16, 7, 443, 42, 43, 1955, 1956, "-" +820, 16, 8, 444, 44, 53, 1957, 1966, "monitored" +820, 16, 9, 445, 54, 57, 1967, 1970, "FPG" +820, 16, 10, 446, 58, 61, 1971, 1974, "and" +820, 16, 11, 447, 62, 65, 1975, 1978, "pre" +820, 16, 12, 448, 66, 67, 1979, 1980, "-" +820, 16, 13, 449, 68, 74, 1981, 1987, "dinner" +820, 16, 14, 450, 75, 77, 1988, 1990, "PG" +820, 16, 15, 451, 78, 81, 1991, 1994, "did" +820, 16, 16, 452, 82, 85, 1995, 1998, "not" +820, 16, 17, 453, 86, 92, 1999, 2005, "differ" +820, 16, 18, 454, 93, 95, 2006, 2008, "by" +820, 16, 19, 455, 96, 103, 2009, 2016, "insulin" +820, 16, 20, 456, 104, 113, 2017, 2026, "treatment" +820, 16, 21, 457, 114, 115, 2027, 2028, "," +820, 16, 22, 458, 116, 119, 2029, 2032, "nor" +820, 16, 23, 459, 120, 123, 2033, 2036, "did" +820, 16, 24, 460, 124, 127, 2037, 2040, "the" +820, 16, 25, 461, 128, 136, 2041, 2049, "relative" +820, 16, 26, 462, 137, 141, 2050, 2054, "risk" +820, 16, 27, 463, 142, 144, 2055, 2057, "of" +820, 16, 28, 464, 145, 152, 2058, 2065, "overall" +820, 16, 29, 465, 153, 155, 2066, 2068, "or" +820, 16, 30, 466, 156, 165, 2069, 2078, "nocturnal" +820, 16, 31, 467, 166, 179, 2079, 2092, "hypoglycaemia" +820, 16, 32, 468, 180, 181, 2093, 2094, "." +820, 17, 1, 469, 0, 6, 2095, 2101, "Modest" +820, 17, 2, 470, 7, 17, 2102, 2112, "reductions" +820, 17, 3, 471, 18, 20, 2113, 2115, "in" +820, 17, 4, 472, 21, 27, 2116, 2122, "weight" +820, 17, 5, 473, 28, 32, 2123, 2127, "gain" +820, 17, 6, 474, 33, 37, 2128, 2132, "were" +820, 17, 7, 475, 38, 42, 2133, 2137, "seen" +820, 17, 8, 476, 43, 47, 2138, 2142, "with" +820, 17, 9, 477, 48, 55, 2143, 2150, "detemir" +820, 17, 10, 478, 56, 58, 2151, 2153, "vs" +820, 17, 11, 479, 59, 67, 2154, 2162, "glargine" +820, 17, 12, 480, 68, 70, 2163, 2165, "in" +820, 17, 13, 481, 71, 81, 2166, 2176, "completers" +820, 17, 14, 482, 82, 83, 2177, 2178, "(" +820, 17, 15, 483, 84, 85, 2179, 2180, "3" +820, 17, 16, 484, 86, 87, 2181, 2182, "." +820, 17, 17, 485, 88, 89, 2183, 2184, "0" +820, 17, 18, 486, 90, 92, 2185, 2187, "vs" +820, 17, 19, 487, 93, 94, 2188, 2189, "3" +820, 17, 20, 488, 95, 96, 2190, 2191, "." +820, 17, 21, 489, 97, 98, 2192, 2193, "9" +820, 17, 22, 490, 99, 101, 2194, 2196, "kg" +820, 17, 23, 491, 102, 103, 2197, 2198, "," +820, 17, 24, 492, 104, 105, 2199, 2200, "p" +820, 17, 25, 493, 106, 107, 2201, 2202, "=" +820, 17, 26, 494, 108, 109, 2203, 2204, "0" +820, 17, 27, 495, 110, 111, 2205, 2206, "." +820, 17, 28, 496, 112, 114, 2207, 2209, "01" +820, 17, 29, 497, 115, 116, 2210, 2211, ")" +820, 17, 30, 498, 117, 120, 2212, 2215, "and" +820, 17, 31, 499, 121, 123, 2216, 2218, "in" +820, 17, 32, 500, 124, 127, 2219, 2222, "the" +820, 17, 33, 501, 128, 137, 2223, 2232, "intention" +820, 17, 34, 502, 138, 139, 2233, 2234, "-" +820, 17, 35, 503, 140, 142, 2235, 2237, "to" +820, 17, 36, 504, 143, 144, 2238, 2239, "-" +820, 17, 37, 505, 145, 150, 2240, 2245, "treat" +820, 17, 38, 506, 151, 161, 2246, 2256, "population" +820, 17, 39, 507, 162, 163, 2257, 2258, "(" +820, 17, 40, 508, 164, 165, 2259, 2260, "2" +820, 17, 41, 509, 166, 167, 2261, 2262, "." +820, 17, 42, 510, 168, 169, 2263, 2264, "7" +820, 17, 43, 511, 170, 172, 2265, 2267, "vs" +820, 17, 44, 512, 173, 174, 2268, 2269, "3" +820, 17, 45, 513, 175, 176, 2270, 2271, "." +820, 17, 46, 514, 177, 178, 2272, 2273, "5" +820, 17, 47, 515, 179, 181, 2274, 2276, "kg" +820, 17, 48, 516, 182, 183, 2277, 2278, "," +820, 17, 49, 517, 184, 185, 2279, 2280, "p" +820, 17, 50, 518, 186, 187, 2281, 2282, "=" +820, 17, 51, 519, 188, 189, 2283, 2284, "0" +820, 17, 52, 520, 190, 191, 2285, 2286, "." +820, 17, 53, 521, 192, 194, 2287, 2289, "03" +820, 17, 54, 522, 195, 196, 2290, 2291, ")" +820, 17, 55, 523, 197, 198, 2292, 2293, "," +820, 17, 56, 524, 199, 208, 2294, 2303, "primarily" +820, 17, 57, 525, 209, 216, 2304, 2311, "related" +820, 17, 58, 526, 217, 219, 2312, 2314, "to" +820, 17, 59, 527, 220, 230, 2315, 2325, "completers" +820, 17, 60, 528, 231, 233, 2326, 2328, "on" +820, 17, 61, 529, 234, 238, 2329, 2333, "once" +820, 17, 62, 530, 239, 240, 2334, 2335, "-" +820, 17, 63, 531, 241, 246, 2336, 2341, "daily" +820, 17, 64, 532, 247, 254, 2342, 2349, "detemir" +820, 17, 65, 533, 255, 256, 2350, 2351, "." +820, 18, 1, 534, 0, 4, 2352, 2356, "Mean" +820, 18, 2, 535, 5, 10, 2357, 2362, "daily" +820, 18, 3, 536, 11, 18, 2363, 2370, "detemir" +820, 18, 4, 537, 19, 23, 2371, 2375, "dose" +820, 18, 5, 538, 24, 27, 2376, 2379, "was" +820, 18, 6, 539, 28, 34, 2380, 2386, "higher" +820, 18, 7, 540, 35, 36, 2387, 2388, "(" +820, 18, 8, 541, 37, 38, 2389, 2390, "0" +820, 18, 9, 542, 39, 40, 2391, 2392, "." +820, 18, 10, 543, 41, 43, 2393, 2395, "78" +820, 18, 11, 544, 44, 45, 2396, 2397, "U" +820, 18, 12, 545, 46, 47, 2398, 2399, "/" +820, 18, 13, 546, 48, 50, 2400, 2402, "kg" +820, 18, 14, 547, 51, 52, 2403, 2404, "[" +820, 18, 15, 548, 53, 54, 2405, 2406, "0" +820, 18, 16, 549, 55, 56, 2407, 2408, "." +820, 18, 17, 550, 57, 59, 2409, 2411, "52" +820, 18, 18, 551, 60, 64, 2412, 2416, "with" +820, 18, 19, 552, 65, 69, 2417, 2421, "once" +820, 18, 20, 553, 70, 75, 2422, 2427, "daily" +820, 18, 21, 554, 76, 82, 2428, 2434, "dosing" +820, 18, 22, 555, 83, 84, 2435, 2436, "," +820, 18, 23, 556, 85, 86, 2437, 2438, "1" +820, 18, 24, 557, 87, 88, 2439, 2440, "." +820, 18, 25, 558, 89, 91, 2441, 2443, "00" +820, 18, 26, 559, 92, 93, 2444, 2445, "U" +820, 18, 27, 560, 94, 95, 2446, 2447, "/" +820, 18, 28, 561, 96, 98, 2448, 2450, "kg" +820, 18, 29, 562, 99, 103, 2451, 2455, "with" +820, 18, 30, 563, 104, 109, 2456, 2461, "twice" +820, 18, 31, 564, 110, 115, 2462, 2467, "daily" +820, 18, 32, 565, 116, 122, 2468, 2474, "dosing" +820, 18, 33, 566, 123, 124, 2475, 2476, "]" +820, 18, 34, 567, 125, 126, 2477, 2478, ")" +820, 18, 35, 568, 127, 131, 2479, 2483, "than" +820, 18, 36, 569, 132, 140, 2484, 2492, "glargine" +820, 18, 37, 570, 141, 142, 2493, 2494, "(" +820, 18, 38, 571, 143, 144, 2495, 2496, "0" +820, 18, 39, 572, 145, 146, 2497, 2498, "." +820, 18, 40, 573, 147, 149, 2499, 2501, "44" +820, 18, 41, 574, 150, 152, 2502, 2504, "IU" +820, 18, 42, 575, 153, 154, 2505, 2506, "/" +820, 18, 43, 576, 155, 157, 2507, 2509, "kg" +820, 18, 44, 577, 158, 159, 2510, 2511, ")" +820, 18, 45, 578, 160, 161, 2512, 2513, "." +820, 19, 1, 579, 0, 9, 2514, 2523, "Injection" +820, 19, 2, 580, 10, 14, 2524, 2528, "site" +820, 19, 3, 581, 15, 24, 2529, 2538, "reactions" +820, 19, 4, 582, 25, 29, 2539, 2543, "were" +820, 19, 5, 583, 30, 34, 2544, 2548, "more" +820, 19, 6, 584, 35, 43, 2549, 2557, "frequent" +820, 19, 7, 585, 44, 48, 2558, 2562, "with" +820, 19, 8, 586, 49, 56, 2563, 2570, "detemir" +820, 19, 9, 587, 57, 58, 2571, 2572, "(" +820, 19, 10, 588, 59, 60, 2573, 2574, "4" +820, 19, 11, 589, 61, 62, 2575, 2576, "." +820, 19, 12, 590, 63, 64, 2577, 2578, "5" +820, 19, 13, 591, 65, 67, 2579, 2581, "vs" +820, 19, 14, 592, 68, 69, 2582, 2583, "1" +820, 19, 15, 593, 70, 71, 2584, 2585, "." +820, 19, 16, 594, 72, 73, 2586, 2587, "4" +820, 19, 17, 595, 74, 75, 2588, 2589, "%" +820, 19, 18, 596, 76, 77, 2590, 2591, ")" +820, 19, 19, 597, 78, 79, 2592, 2593, "." +820, 20, 1, 598, 0, 11, 2594, 2605, "CONCLUSIONS" +820, 20, 2, 599, 12, 13, 2606, 2607, "/" +820, 20, 3, 600, 14, 28, 2608, 2622, "INTERPRETATION" +820, 20, 4, 601, 29, 30, 2623, 2624, ":" +820, 20, 5, 602, 31, 46, 2625, 2640, "Supplementation" +820, 20, 6, 603, 47, 49, 2641, 2643, "of" +820, 20, 7, 604, 50, 54, 2644, 2648, "oral" +820, 20, 8, 605, 55, 61, 2649, 2655, "agents" +820, 20, 9, 606, 62, 66, 2656, 2660, "with" +820, 20, 10, 607, 67, 74, 2661, 2668, "detemir" +820, 20, 11, 608, 75, 77, 2669, 2671, "or" +820, 20, 12, 609, 78, 86, 2672, 2680, "glargine" +820, 20, 13, 610, 87, 95, 2681, 2689, "achieves" +820, 20, 14, 611, 96, 106, 2690, 2700, "clinically" +820, 20, 15, 612, 107, 116, 2701, 2710, "important" +820, 20, 16, 613, 117, 129, 2711, 2723, "improvements" +820, 20, 17, 614, 130, 132, 2724, 2726, "in" +820, 20, 18, 615, 133, 142, 2727, 2736, "glycaemic" +820, 20, 19, 616, 143, 150, 2737, 2744, "control" +820, 20, 20, 617, 151, 155, 2745, 2749, "with" +820, 20, 21, 618, 156, 159, 2750, 2753, "low" +820, 20, 22, 619, 160, 164, 2754, 2758, "risk" +820, 20, 23, 620, 165, 167, 2759, 2761, "of" +820, 20, 24, 621, 168, 181, 2762, 2775, "hypoglycaemia" +820, 20, 25, 622, 182, 183, 2776, 2777, "." +820, 21, 1, 623, 0, 3, 2778, 2781, "Non" +820, 21, 2, 624, 4, 5, 2782, 2783, "-" +820, 21, 3, 625, 6, 17, 2784, 2795, "inferiority" +820, 21, 4, 626, 18, 21, 2796, 2799, "was" +820, 21, 5, 627, 22, 34, 2800, 2812, "demonstrated" +820, 21, 6, 628, 35, 38, 2813, 2816, "for" +820, 21, 7, 629, 39, 46, 2817, 2824, "detemir" +820, 21, 8, 630, 47, 52, 2825, 2830, "using" +820, 21, 9, 631, 53, 59, 2831, 2837, "higher" +820, 21, 10, 632, 60, 67, 2838, 2845, "insulin" +820, 21, 11, 633, 68, 73, 2846, 2851, "doses" +820, 21, 12, 634, 74, 75, 2852, 2853, "(" +820, 21, 13, 635, 76, 82, 2854, 2860, "mainly" +820, 21, 14, 636, 83, 91, 2861, 2869, "patients" +820, 21, 15, 637, 92, 94, 2870, 2872, "on" +820, 21, 16, 638, 95, 100, 2873, 2878, "twice" +820, 21, 17, 639, 101, 106, 2879, 2884, "daily" +820, 21, 18, 640, 107, 113, 2885, 2891, "dosing" +820, 21, 19, 641, 114, 115, 2892, 2893, ")" +820, 21, 20, 642, 116, 117, 2894, 2895, ";" +820, 21, 21, 643, 118, 124, 2896, 2902, "weight" +820, 21, 22, 644, 125, 129, 2903, 2907, "gain" +820, 21, 23, 645, 130, 133, 2908, 2911, "was" +820, 21, 24, 646, 134, 142, 2912, 2920, "somewhat" +820, 21, 25, 647, 143, 150, 2921, 2928, "reduced" +820, 21, 26, 648, 151, 155, 2929, 2933, "with" +820, 21, 27, 649, 156, 160, 2934, 2938, "once" +820, 21, 28, 650, 161, 166, 2939, 2944, "daily" +820, 21, 29, 651, 167, 174, 2945, 2952, "insulin" +820, 21, 30, 652, 175, 182, 2953, 2960, "detemir" +820, 21, 31, 653, 183, 184, 2961, 2962, "." +820, 22, 1, 654, 0, 3, 2963, 2966, "DOI" +820, 22, 2, 655, 4, 5, 2967, 2968, ":" +820, 22, 3, 656, 6, 8, 2969, 2971, "10" +820, 22, 4, 657, 9, 10, 2972, 2973, "." +820, 22, 5, 658, 11, 15, 2974, 2978, "1007" +820, 22, 6, 659, 16, 17, 2979, 2980, "/" +820, 22, 7, 660, 18, 24, 2981, 2987, "s00125" +820, 22, 8, 661, 25, 26, 2988, 2989, "-" +820, 22, 9, 662, 27, 30, 2990, 2993, "007" +820, 22, 10, 663, 31, 32, 2994, 2995, "-" +820, 22, 11, 664, 33, 37, 2996, 3000, "0911" +820, 22, 12, 665, 38, 39, 3001, 3002, "-" +820, 22, 13, 666, 40, 41, 3003, 3004, "x" +820, 22, 14, 667, 42, 47, 3005, 3010, "PMCID" +820, 22, 15, 668, 48, 49, 3011, 3012, ":" +820, 22, 16, 669, 50, 60, 3013, 3023, "PMC2235909" +820, 22, 17, 670, 61, 65, 3024, 3028, "PMID" +820, 22, 18, 671, 66, 67, 3029, 3030, ":" +820, 22, 19, 672, 68, 76, 3031, 3039, "18204830" +820, 22, 20, 673, 77, 78, 3040, 3041, "[" +820, 22, 21, 674, 79, 86, 3042, 3049, "Indexed" +820, 22, 22, 675, 87, 90, 3050, 3053, "for" +820, 22, 23, 676, 91, 98, 3054, 3061, "MEDLINE" +820, 22, 24, 677, 99, 100, 3062, 3063, "]" diff --git a/data/dm2 18204830_admin.annodb b/data/dm2 18204830_admin.annodb new file mode 100644 index 0000000..a43f697 --- /dev/null +++ b/data/dm2 18204830_admin.annodb @@ -0,0 +1,136 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +1, PublicationYear, 15, 19, "2008", "", " \"2008\"." +129, Title, 111, 318, "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "", " \"A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .\"." +2, Randomized, 113, 123, "randomised", "", +3, Duration, 126, 135, "52 - week", "", +5, InsulinDetemir, 174, 189, "insulin detemir", "", +6, InsulinGlargine, 195, 211, "insulin glargine", "", +22, OralAntidiabeticAgent, 245, 269, "glucose - lowering drugs", "", +8, Precondition, 273, 316, "insulin - naive people with type 2 diabetes", "", " \"insulin - naive people with type 2 diabetes\"." +7, Type2Diabetes, 301, 316, "type 2 diabetes", "", +9, Author, 319, 331, "Rosenstock J", "", " \"Rosenstock J\"." +10, Author, 340, 348, "Davies M", "", " \"Davies M\"." +11, Author, 351, 358, "Home PD", "", " \"Home PD\"." +12, Author, 361, 369, "Larsen J", "", " \"Larsen J\"." +13, Author, 372, 380, "Koenen C", "", " \"Koenen C\"." +14, Author, 383, 397, "Schernthaner G", "", " \"Schernthaner G\"." +15, USA, 529, 532, "USA", "", " ." +27, ObjectiveDescription, 670, 862, "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with", "", " \"This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with\"." +16, Duration, 675, 684, "52 - week", "", " \"52 - week\"." +138, Multicenter, 685, 698, "multinational", "", " ." +17, Randomized, 701, 711, "randomised", "", " ." +18, OpenLabel, 714, 726, "open - label", "", " ." +19, Parallel, 729, 745, "parallel - group", "", " ." +20, CTDesign, 748, 765, "non - inferiority", "", " . ." +21, OralAntidiabeticAgent, 828, 857, "oral glucose - lowering drugs", "", +254, ObjectiveDescription, 863, 937, "basal insulin analogues detemir and glargine in type 2 diabetic patients .", "", " \"basal insulin analogues detemir and glargine in type 2 diabetic patients .\"." +23, Insulin, 869, 876, "insulin", "", +24, InsulinDetemir, 887, 894, "detemir", "", +25, InsulinGlargine, 899, 907, "glargine", "", +26, Type2Diabetes, 911, 926, "type 2 diabetic", "", " ." +147, Precondition, 948, 970, "Insulin - naive adults", "", " \"Insulin - naive adults\"." +28, NumberPatientsCT, 977, 980, "582", "", " \"582\"." +29, HbA1c, 983, 993, "HbA ( 1c )", "", +30, Percentage, 1009, 1010, "%", "", +31, BMI, 1013, 1016, "BMI", "", +32, Kg_per_squareMeter, 1031, 1043, "kg / m ( 2 )", "", +34, Randomized, 1051, 1061, "randomised", "", +35, AllocationRatio, 1062, 1067, "1 : 1", "", " . ." +36, InsulinDetemir, 1079, 1094, "insulin detemir", "", " ." +37, InsulinGlargine, 1098, 1106, "glargine", "", " ." +38, Frequency, 1107, 1117, "once daily", "", " \"once daily\". \"once daily\"." +39, Bedtime, 1120, 1127, "evening", "", " . ." +51767, DoseDescription, 1139, 1210, "titrated to target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", +40, FastingPlasmaGlucose_target, 1158, 1210, "fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", +161, Millimoles_per_litre, 1202, 1210, "mmol / l", "", +41, Morning, 1227, 1234, "morning", "", +42, InsulinDetemir, 1235, 1250, "insulin detemir", "", +51768, RelativeTime, 1273, 1285, "pre - dinner", "", +255, PlasmaGlucose, 1286, 1300, "plasma glucose", "", +256, PlasmaGlucose, 1303, 1305, "PG", "", +44, Millimoles_per_litre, 1320, 1328, "mmol / l", "", +166, FastingPlasmaGlucose_target, 1345, 1365, "FPG < 7 . 0 mmol / l", "", +45, Millimoles_per_litre, 1357, 1365, "mmol / l", "", +47, InsulinGlargine, 1410, 1418, "glargine", "", +260, TimePoint, 1448, 1456, "Baseline", "", +48, HbA1c, 1457, 1467, "HbA ( 1c )", "", " ." +49, BaseLineValue, 1483, 1488, "8 . 6", "", " \"8 . 6\". \"8 . 6\"." +50, ResultMeasuredValue, 1492, 1497, "7 . 2", "", " \"7 . 2\"." +51, ResultMeasuredValue, 1502, 1507, "7 . 1", "", " \"7 . 1\"." +52, Percentage, 1508, 1509, "%", "", " ." +53, InsulinDetemir, 1522, 1529, "detemir", "", " ." +54, InsulinGlargine, 1534, 1542, "glargine", "", +55, FastingPlasmaGlucose, 1560, 1563, "FPG", "", " ." +56, BaseLineValue, 1578, 1584, "10 . 8", "", " \"10 . 8\". \"10 . 8\"." +57, ResultMeasuredValue, 1588, 1593, "7 . 1", "", " \"7 . 1\"." +58, ResultMeasuredValue, 1598, 1603, "7 . 0", "", " \"7 . 0\"." +59, Millimoles_per_litre, 1604, 1612, "mmol / l", "", " ." +60, InsulinDetemir, 1642, 1649, "detemir", "", +61, Frequency, 1696, 1706, "once daily", "", +62, Frequency, 1726, 1737, "twice daily", "", +63, HbA1c, 1769, 1779, "HbA ( 1c )", "", +64, PercentageAffected, 1792, 1794, "52", "", +65, HbA1c_target, 1822, 1847, "HbA ( 1c ) < or = 7 . 0 %", "", " ." +185, Percentage, 1846, 1847, "%", "", +66, PercentageAffected, 1850, 1852, "33", "", " \"33\"." +68, InsulinDetemir, 1857, 1864, "detemir", "", +67, PercentageAffected, 1871, 1873, "35", "", " \"35\"." +69, InsulinGlargine, 1878, 1886, "glargine", "", +201, EndPointDescription, 1889, 1910, "without hypoglycaemia", "", +71, Hypoglycemia, 1897, 1910, "hypoglycaemia", "", +72, FastingPlasmaGlucose, 1967, 1970, "FPG", "", +51769, RelativeTime, 1975, 1987, "pre - dinner", "", +51770, PreprandialPlasmaGlucose, 1975, 1990, "pre - dinner PG", "", +75, Insulin, 2009, 2016, "insulin", "", +76, NocturnalHypoglycemia, 2069, 2092, "nocturnal hypoglycaemia", "", +51771, Hypoglycemia, 2079, 2092, "hypoglycaemia", "", +51772, WeightGain, 2116, 2127, "weight gain", "", " ." +79, InsulinDetemir, 2143, 2150, "detemir", "", +80, InsulinGlargine, 2154, 2162, "glargine", "", +213, SubGroupDescription, 2166, 2176, "completers", "", " \"completers\". \"completers\"." +51773, Reduction, 2179, 2184, "3 . 0", "", " \"3 . 0\"." +51774, Reduction, 2188, 2193, "3 . 9", "", " \"3 . 9\"." +81, Kg, 2194, 2196, "kg", "", +82, PvalueDiff, 2199, 2209, "p = 0 . 01", "", " \"p = 0 . 01\"." +83, IntentionToTreat, 2223, 2245, "intention - to - treat", "", " ." +92, SubGroupDescription, 2223, 2256, "intention - to - treat population", "", " \"intention - to - treat population\". \"intention - to - treat population\"." +51775, Reduction, 2259, 2264, "2 . 7", "", " \"2 . 7\"." +51776, Reduction, 2268, 2273, "3 . 5", "", " \"3 . 5\"." +84, Kg, 2274, 2276, "kg", "", " ." +85, PvalueDiff, 2279, 2289, "p = 0 . 03", "", " \"p = 0 . 03\"." +86, Frequency, 2329, 2341, "once - daily", "", +87, InsulinDetemir, 2342, 2349, "detemir", "", +223, Mean, 2352, 2356, "Mean", "", " . ." +94, Frequency, 2357, 2362, "daily", "", +95, InsulinDetemir, 2363, 2370, "detemir", "", +224, EndPointDescription, 2371, 2375, "dose", "", " . ." +225, ResultMeasuredValue, 2389, 2395, "0 . 78", "", " \"0 . 78\"." +99, IntUnit_per_Kg, 2396, 2402, "U / kg", "", " ." +226, ResultMeasuredValue, 2405, 2411, "0 . 52", "", " \"0 . 52\"." +229, SubGroupDescription, 2412, 2434, "with once daily dosing", "", " \"with once daily dosing\"." +101, Frequency, 2417, 2427, "once daily", "", +227, ResultMeasuredValue, 2437, 2443, "1 . 00", "", " \"1 . 00\"." +100, IntUnit_per_Kg, 2444, 2450, "U / kg", "", +230, SubGroupDescription, 2451, 2474, "with twice daily dosing", "", " \"with twice daily dosing\"." +102, Frequency, 2456, 2467, "twice daily", "", +103, InsulinGlargine, 2484, 2492, "glargine", "", +228, ResultMeasuredValue, 2495, 2501, "0 . 44", "", " \"0 . 44\"." +105, IntUnit_per_Kg, 2502, 2509, "IU / kg", "", +236, EndPointDescription, 2514, 2538, "Injection site reactions", "", " . ." +106, InsulinDetemir, 2563, 2570, "detemir", "", +107, PercentageAffected, 2573, 2578, "4 . 5", "", " \"4 . 5\"." +108, PercentageAffected, 2582, 2587, "1 . 4", "", " \"1 . 4\"." +244, ConclusionComment, 2625, 2777, "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .", "", " \"Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .\"." +109, OralAntidiabeticAgent, 2644, 2655, "oral agents", "", +110, InsulinDetemir, 2661, 2668, "detemir", "", +111, InsulinGlargine, 2672, 2680, "glargine", "", +112, Hypoglycemia, 2762, 2775, "hypoglycaemia", "", +250, ConclusionComment, 2778, 2962, "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .", "", " \"Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .\"." +113, InsulinDetemir, 2817, 2824, "detemir", "", +114, Insulin, 2838, 2845, "insulin", "", +115, Frequency, 2873, 2884, "twice daily", "", +51777, WeightGain, 2896, 2907, "weight gain", "", +117, Frequency, 2934, 2944, "once daily", "", +118, InsulinDetemir, 2945, 2960, "insulin detemir", "", +119, PMID, 3031, 3039, "18204830", "", " \"18204830\"." diff --git a/data/dm2 18204830_admin.n-triples b/data/dm2 18204830_admin.n-triples new file mode 100644 index 0000000..cff48ec --- /dev/null +++ b/data/dm2 18204830_admin.n-triples @@ -0,0 +1,219 @@ +# RDF export of group: Publication + . + "Publication" . + "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes ." . + "Rosenstock J" . + "2008" . + "Diabetologia" . + "18204830" . + . + "Davies M" . + "Home PD" . + "Larsen J" . + "Koenen C" . + "Schernthaner G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with" . + "582" . + "52 - week" . + . + . + . + . + "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia ." . + . + . + . + . + . + "basal insulin analogues detemir and glargine in type 2 diabetic patients ." . + . + . + . + . + . + "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir ." . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive people with type 2 diabetes" . + . + . + . + "Insulin - naive adults" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint isr" . + . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm id" . + . + . + . + . + . + . + . + . + . + . + . + "Arm ig" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention id" . + . + "once daily" . + . + . + "Intervention ig" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication id" . + . + . + . + . + "Medication ig" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c id " . + . + "8 . 6" . + "7 . 2" . + . + "Outcome hba1c ig " . + . + "8 . 6" . + "7 . 1" . + . + "Outcome fpg id" . + . + "10 . 8" . + "7 . 1" . + . + "Outcome fpg ig" . + . + "10 . 8" . + "7 . 0" . + . + "Outcome hba1c target id " . + . + "33" . + . + "Outcome hba1c target ig" . + . + "35" . + . + "Outcome weight sg1 id" . + . + "3 . 0" . + "completers" . + . + "Outcome weight sg1 ig" . + . + "3 . 9" . + "completers" . + . + "Outcome weight sg2 id " . + . + "2 . 7" . + "intention - to - treat population" . + . + "Outcome weight sg2 ig" . + . + "3 . 5" . + "intention - to - treat population" . + . + "Outcome isr id" . + . + "4 . 5" . + . + "Outcome isr ig" . + . + "1 . 4" . + . + "Outcome id id" . + . + "0 . 78" . + . + "Outcome id ig" . + . + "0 . 44" . + . + "Outcome id sg1 id" . + . + "0 . 52" . + "with once daily dosing" . + . + "Outcome id sg2 id" . + . + "1 . 00" . + "with twice daily dosing" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups weight sg1" . + "p = 0 . 01" . + . + . + . + "DiffBetweenGroups weight sg2" . + "p = 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18204830_akramersunderbrink.annodb b/data/dm2 18204830_akramersunderbrink.annodb new file mode 100644 index 0000000..aa8aeb2 --- /dev/null +++ b/data/dm2 18204830_akramersunderbrink.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23318, Journal, 0, 12, "Diabetologia", "", +23326, Title, 111, 318, "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "", +23320, Randomized, 113, 123, "randomised", "", +23321, Duration, 126, 135, "52 - week", "", +23323, InsulinDetemir, 174, 189, "insulin detemir", "", +23322, InsulinGlargine, 195, 211, "insulin glargine", "", +23325, Precondition, 273, 288, "insulin - naive", "", +23324, Type2Diabetes, 301, 316, "type 2 diabetes", "", +23328, Author, 319, 331, "Rosenstock J", "", +23330, Author, 340, 348, "Davies M", "", +23331, Author, 351, 358, "Home PD", "", +23332, Author, 361, 369, "Larsen J", "", +23333, Author, 372, 380, "Koenen C", "", +23334, Author, 383, 397, "Schernthaner G", "", +23335, USA, 529, 532, "USA", "", +23346, ObjectiveDescription, 670, 917, "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with basal insulin analogues detemir and glargine in type 2", "", +23336, Duration, 675, 684, "52 - week", "", +23337, Multicenter, 685, 698, "multinational", "", +23338, Randomized, 701, 711, "randomised", "", +23339, OpenLabel, 714, 726, "open - label", "", +23340, Parallel, 729, 745, "parallel - group", "", +23341, InsulinDetemir, 887, 894, "detemir", "", +23342, InsulinGlargine, 899, 907, "glargine", "", +23343, Type2Diabetes, 911, 926, "type 2 diabetic", "", +23345, ObjectiveDescription, 918, 937, "diabetic patients .", "", +23348, Precondition, 948, 963, "Insulin - naive", "", +23350, NumberPatientsCT, 977, 980, "582", "", +23351, HbA1c, 983, 993, "HbA ( 1c )", "", +23353, Precondition, 983, 1010, "HbA ( 1c ) 7 . 5 - 10 . 0 %", "", +23352, Percentage, 1009, 1010, "%", "", +23354, Precondition, 1013, 1043, "BMI < or = 40 . 0 kg / m ( 2 )", "", +23355, BMI, 1013, 1016, "BMI", "", +23356, Kg_per_squareMeter, 1031, 1043, "kg / m ( 2 )", "", +23357, Randomized, 1051, 1061, "randomised", "", +23358, InsulinDetemir, 1079, 1094, "insulin detemir", "", +23359, InsulinGlargine, 1098, 1106, "glargine", "", +23360, Frequency, 1107, 1117, "once daily", "", +23361, Bedtime, 1120, 1127, "evening", "", +23362, FastingPlasmaGlucose_target, 1151, 1210, "target fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", +23363, Millimoles_per_litre, 1202, 1210, "mmol / l", "", +23364, Morning, 1227, 1234, "morning", "", +23365, InsulinDetemir, 1235, 1250, "insulin detemir", "", +23366, Millimoles_per_litre, 1320, 1328, "mmol / l", "", +23368, FastingPlasmaGlucose_target, 1345, 1365, "FPG < 7 . 0 mmol / l", "", +23367, Millimoles_per_litre, 1357, 1365, "mmol / l", "", +23369, InsulinGlargine, 1410, 1418, "glargine", "", +39171, TimePoint, 1448, 1456, "Baseline", "", +23370, HbA1c, 1457, 1467, "HbA ( 1c )", "", +23371, BaseLineValue, 1483, 1488, "8 . 6", "", +23372, ResultMeasuredValue, 1492, 1497, "7 . 2", "", +23373, ResultMeasuredValue, 1502, 1507, "7 . 1", "", +23374, Percentage, 1508, 1509, "%", "", +23375, InsulinDetemir, 1522, 1529, "detemir", "", +23376, InsulinGlargine, 1534, 1542, "glargine", "", +23377, FastingPlasmaGlucose, 1560, 1563, "FPG", "", +23378, BaseLineValue, 1578, 1584, "10 . 8", "", +23379, ResultMeasuredValue, 1588, 1593, "7 . 1", "", +23380, ResultMeasuredValue, 1598, 1603, "7 . 0", "", +23381, Millimoles_per_litre, 1604, 1612, "mmol / l", "", +23382, InsulinDetemir, 1642, 1649, "detemir", "", +23383, PercentageAffected, 1652, 1654, "45", "", +23384, Percentage, 1655, 1656, "%", "", +23393, EndPointDescription, 1660, 1713, "participants completed the study on once daily dosing", "", +23392, Frequency, 1696, 1706, "once daily", "", +23394, PercentageAffected, 1718, 1720, "55", "", +23385, Percentage, 1721, 1722, "%", "", +23396, EndPointDescription, 1723, 1744, "on twice daily dosing", "", +23395, Frequency, 1726, 1737, "twice daily", "", +23397, HbA1c, 1769, 1779, "HbA ( 1c )", "", +23401, PercentageAffected, 1792, 1794, "52", "", +23386, Percentage, 1795, 1796, "%", "", +23398, HbA1c_target, 1822, 1847, "HbA ( 1c ) < or = 7 . 0 %", "", +23387, Percentage, 1846, 1847, "%", "", +23399, PercentageAffected, 1850, 1852, "33", "", +23388, Percentage, 1853, 1854, "%", "", +23402, InsulinDetemir, 1857, 1864, "detemir", "", +23400, PercentageAffected, 1871, 1873, "35", "", +23389, Percentage, 1874, 1875, "%", "", +23403, InsulinGlargine, 1878, 1886, "glargine", "", +23404, EndPointDescription, 1889, 1910, "without hypoglycaemia", "", +23407, FastingPlasmaGlucose, 1967, 1970, "FPG", "", +23408, PreprandialGlucose, 1975, 1990, "pre - dinner PG", "", +23406, Hypoglycemia, 2058, 2065, "overall", "", +23405, NocturnalHypoglycemia, 2069, 2092, "nocturnal hypoglycaemia", "", +23409, BodyWeight, 2116, 2127, "weight gain", "", +23410, InsulinDetemir, 2143, 2150, "detemir", "", +23411, InsulinGlargine, 2154, 2162, "glargine", "", +23416, SubGroupDescription, 2166, 2176, "completers", "", +23412, Reduction, 2179, 2184, "3 . 0", "", +23413, Reduction, 2188, 2193, "3 . 9", "", +23414, Kg, 2194, 2196, "kg", "", +23415, PvalueDiff, 2199, 2209, "p = 0 . 01", "", +23417, SubGroupDescription, 2219, 2256, "the intention - to - treat population", "", +23418, Reduction, 2259, 2264, "2 . 7", "", +23419, Reduction, 2268, 2273, "3 . 5", "", +23420, Kg, 2274, 2276, "kg", "", +23421, PvalueDiff, 2279, 2289, "p = 0 . 03", "", +23422, Frequency, 2329, 2341, "once - daily", "", +23423, InsulinDetemir, 2342, 2349, "detemir", "", +23426, Mean, 2352, 2356, "Mean", "", +23427, EndPointDescription, 2357, 2375, "daily detemir dose", "", +23424, InsulinDetemir, 2363, 2370, "detemir", "", +23428, ResultMeasuredValue, 2389, 2395, "0 . 78", "", +23436, IntUnit_per_Kg, 2396, 2402, "U / kg", "", +23429, ResultMeasuredValue, 2405, 2411, "0 . 52", "", +23432, SubGroupDescription, 2412, 2434, "with once daily dosing", "", +23434, Frequency, 2417, 2427, "once daily", "", +23430, ResultMeasuredValue, 2437, 2443, "1 . 00", "", +23437, IntUnit_per_Kg, 2444, 2450, "U / kg", "", +23433, SubGroupDescription, 2451, 2474, "with twice daily dosing", "", +23435, Frequency, 2456, 2467, "twice daily", "", +23425, InsulinGlargine, 2484, 2492, "glargine", "", +23431, ResultMeasuredValue, 2495, 2501, "0 . 44", "", +23438, IntUnit_per_Kg, 2502, 2509, "IU / kg", "", +23439, EndPointDescription, 2514, 2538, "Injection site reactions", "", +23440, InsulinDetemir, 2563, 2570, "detemir", "", +23441, PercentageAffected, 2573, 2578, "4 . 5", "", +23442, PercentageAffected, 2582, 2587, "1 . 4", "", +23390, Percentage, 2588, 2589, "%", "", +23447, ConclusionComment, 2625, 2777, "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .", "", +23443, OralAntidiabeticAgent, 2644, 2655, "oral agents", "", +23444, InsulinDetemir, 2661, 2668, "detemir", "", +23445, InsulinGlargine, 2672, 2680, "glargine", "", +23446, Hypoglycemia, 2762, 2775, "hypoglycaemia", "", +23453, ConclusionComment, 2778, 2962, "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .", "", +23448, InsulinDetemir, 2817, 2824, "detemir", "", +23449, Frequency, 2873, 2884, "twice daily", "", +23450, BodyWeight, 2896, 2907, "weight gain", "", +23451, Frequency, 2934, 2944, "once daily", "", +23452, InsulinDetemir, 2945, 2960, "insulin detemir", "", +23454, PMID, 3031, 3039, "18204830", "", diff --git a/data/dm2 18204830_akramersunderbrink.n-triples b/data/dm2 18204830_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18204830_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18204830_export.csv b/data/dm2 18204830_export.csv new file mode 100644 index 0000000..3bc1baf --- /dev/null +++ b/data/dm2 18204830_export.csv @@ -0,0 +1,678 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +345, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +345, 1, 2, 2, 13, 14, 13, 14, "." +345, 2, 1, 3, 0, 4, 15, 19, "2008" +345, 2, 2, 4, 5, 8, 20, 23, "Mar" +345, 2, 3, 5, 9, 10, 24, 25, ";" +345, 2, 4, 6, 11, 13, 26, 28, "51" +345, 2, 5, 7, 14, 15, 29, 30, "(" +345, 2, 6, 8, 16, 17, 31, 32, "3" +345, 2, 7, 9, 18, 19, 33, 34, ")" +345, 2, 8, 10, 20, 21, 35, 36, ":" +345, 2, 9, 11, 22, 25, 37, 40, "408" +345, 2, 10, 12, 26, 27, 41, 42, "-" +345, 2, 11, 13, 28, 30, 43, 45, "16" +345, 2, 12, 14, 31, 32, 46, 47, "." +345, 2, 13, 15, 33, 36, 48, 51, "doi" +345, 2, 14, 16, 37, 38, 52, 53, ":" +345, 2, 15, 17, 39, 41, 54, 56, "10" +345, 2, 16, 18, 42, 43, 57, 58, "." +345, 2, 17, 19, 44, 48, 59, 63, "1007" +345, 2, 18, 20, 49, 50, 64, 65, "/" +345, 2, 19, 21, 51, 57, 66, 72, "s00125" +345, 2, 20, 22, 58, 59, 73, 74, "-" +345, 2, 21, 23, 60, 63, 75, 78, "007" +345, 2, 22, 24, 64, 65, 79, 80, "-" +345, 2, 23, 25, 66, 70, 81, 85, "0911" +345, 2, 24, 26, 71, 72, 86, 87, "-" +345, 2, 25, 27, 73, 74, 88, 89, "x" +345, 2, 26, 28, 75, 76, 90, 91, "." +345, 3, 1, 29, 0, 4, 92, 96, "Epub" +345, 3, 2, 30, 5, 9, 97, 101, "2008" +345, 3, 3, 31, 10, 13, 102, 105, "Jan" +345, 3, 4, 32, 14, 16, 106, 108, "16" +345, 3, 5, 33, 17, 18, 109, 110, "." +345, 4, 1, 34, 0, 1, 111, 112, "A" +345, 4, 2, 35, 2, 12, 113, 123, "randomised" +345, 4, 3, 36, 13, 14, 124, 125, "," +345, 4, 4, 37, 15, 17, 126, 128, "52" +345, 4, 5, 38, 18, 19, 129, 130, "-" +345, 4, 6, 39, 20, 24, 131, 135, "week" +345, 4, 7, 40, 25, 26, 136, 137, "," +345, 4, 8, 41, 27, 32, 138, 143, "treat" +345, 4, 9, 42, 33, 34, 144, 145, "-" +345, 4, 10, 43, 35, 37, 146, 148, "to" +345, 4, 11, 44, 38, 39, 149, 150, "-" +345, 4, 12, 45, 40, 46, 151, 157, "target" +345, 4, 13, 46, 47, 52, 158, 163, "trial" +345, 4, 14, 47, 53, 62, 164, 173, "comparing" +345, 4, 15, 48, 63, 70, 174, 181, "insulin" +345, 4, 16, 49, 71, 78, 182, 189, "detemir" +345, 4, 17, 50, 79, 83, 190, 194, "with" +345, 4, 18, 51, 84, 91, 195, 202, "insulin" +345, 4, 19, 52, 92, 100, 203, 211, "glargine" +345, 4, 20, 53, 101, 105, 212, 216, "when" +345, 4, 21, 54, 106, 118, 217, 229, "administered" +345, 4, 22, 55, 119, 121, 230, 232, "as" +345, 4, 23, 56, 122, 125, 233, 236, "add" +345, 4, 24, 57, 126, 127, 237, 238, "-" +345, 4, 25, 58, 128, 130, 239, 241, "on" +345, 4, 26, 59, 131, 133, 242, 244, "to" +345, 4, 27, 60, 134, 141, 245, 252, "glucose" +345, 4, 28, 61, 142, 143, 253, 254, "-" +345, 4, 29, 62, 144, 152, 255, 263, "lowering" +345, 4, 30, 63, 153, 158, 264, 269, "drugs" +345, 4, 31, 64, 159, 161, 270, 272, "in" +345, 4, 32, 65, 162, 169, 273, 280, "insulin" +345, 4, 33, 66, 170, 171, 281, 282, "-" +345, 4, 34, 67, 172, 177, 283, 288, "naive" +345, 4, 35, 68, 178, 184, 289, 295, "people" +345, 4, 36, 69, 185, 189, 296, 300, "with" +345, 4, 37, 70, 190, 194, 301, 305, "type" +345, 4, 38, 71, 195, 196, 306, 307, "2" +345, 4, 39, 72, 197, 205, 308, 316, "diabetes" +345, 4, 40, 73, 206, 207, 317, 318, "." +345, 5, 1, 74, 0, 10, 319, 329, "Rosenstock" +345, 5, 2, 75, 11, 12, 330, 331, "J" +345, 5, 3, 76, 13, 14, 332, 333, "(" +345, 5, 4, 77, 15, 16, 334, 335, "1" +345, 5, 5, 78, 17, 18, 336, 337, ")" +345, 5, 6, 79, 19, 20, 338, 339, "," +345, 5, 7, 80, 21, 27, 340, 346, "Davies" +345, 5, 8, 81, 28, 29, 347, 348, "M" +345, 5, 9, 82, 30, 31, 349, 350, "," +345, 5, 10, 83, 32, 36, 351, 355, "Home" +345, 5, 11, 84, 37, 39, 356, 358, "PD" +345, 5, 12, 85, 40, 41, 359, 360, "," +345, 5, 13, 86, 42, 48, 361, 367, "Larsen" +345, 5, 14, 87, 49, 50, 368, 369, "J" +345, 5, 15, 88, 51, 52, 370, 371, "," +345, 5, 16, 89, 53, 59, 372, 378, "Koenen" +345, 5, 17, 90, 60, 61, 379, 380, "C" +345, 5, 18, 91, 62, 63, 381, 382, "," +345, 5, 19, 92, 64, 76, 383, 395, "Schernthaner" +345, 5, 20, 93, 77, 78, 396, 397, "G" +345, 5, 21, 94, 79, 80, 398, 399, "." +345, 5, 22, 95, 81, 87, 400, 406, "Author" +345, 5, 23, 96, 88, 99, 407, 418, "information" +345, 5, 24, 97, 100, 101, 419, 420, ":" +345, 5, 25, 98, 102, 103, 421, 422, "(" +345, 5, 26, 99, 104, 105, 423, 424, "1" +345, 5, 27, 100, 106, 107, 425, 426, ")" +345, 5, 28, 101, 108, 114, 427, 433, "Dallas" +345, 5, 29, 102, 115, 123, 434, 442, "Diabetes" +345, 5, 30, 103, 124, 127, 443, 446, "and" +345, 5, 31, 104, 128, 137, 447, 456, "Endocrine" +345, 5, 32, 105, 138, 144, 457, 463, "Center" +345, 5, 33, 106, 145, 147, 464, 466, "at" +345, 5, 34, 107, 148, 155, 467, 474, "Medical" +345, 5, 35, 108, 156, 160, 475, 479, "City" +345, 5, 36, 109, 161, 162, 480, 481, "," +345, 5, 37, 110, 163, 167, 482, 486, "7777" +345, 5, 38, 111, 168, 174, 487, 493, "Forest" +345, 5, 39, 112, 175, 179, 494, 498, "Lane" +345, 5, 40, 113, 180, 181, 499, 500, "C" +345, 5, 41, 114, 182, 183, 501, 502, "-" +345, 5, 42, 115, 184, 187, 503, 506, "685" +345, 5, 43, 116, 188, 189, 507, 508, "," +345, 5, 44, 117, 190, 196, 509, 515, "Dallas" +345, 5, 45, 118, 197, 198, 516, 517, "," +345, 5, 46, 119, 199, 201, 518, 520, "TX" +345, 5, 47, 120, 202, 207, 521, 526, "75230" +345, 5, 48, 121, 208, 209, 527, 528, "," +345, 5, 49, 122, 210, 213, 529, 532, "USA" +345, 5, 50, 123, 214, 215, 533, 534, "." +345, 6, 1, 124, 0, 15, 535, 550, "juliorosenstock" +345, 6, 2, 125, 16, 17, 551, 552, "@" +345, 6, 3, 126, 18, 32, 553, 567, "dallasdiabetes" +345, 6, 4, 127, 33, 34, 568, 569, "." +345, 6, 5, 128, 35, 38, 570, 573, "com" +345, 6, 6, 129, 39, 46, 574, 581, "Comment" +345, 6, 7, 130, 47, 49, 582, 584, "in" +345, 6, 8, 131, 50, 53, 585, 588, "Nat" +345, 6, 9, 132, 54, 58, 589, 593, "Clin" +345, 6, 10, 133, 59, 64, 594, 599, "Pract" +345, 6, 11, 134, 65, 75, 600, 610, "Endocrinol" +345, 6, 12, 135, 76, 81, 611, 616, "Metab" +345, 6, 13, 136, 82, 83, 617, 618, "." +345, 7, 1, 137, 0, 4, 619, 623, "2008" +345, 7, 2, 138, 5, 8, 624, 627, "Sep" +345, 7, 3, 139, 9, 10, 628, 629, ";" +345, 7, 4, 140, 11, 12, 630, 631, "4" +345, 7, 5, 141, 13, 14, 632, 633, "(" +345, 7, 6, 142, 15, 16, 634, 635, "9" +345, 7, 7, 143, 17, 18, 636, 637, ")" +345, 7, 8, 144, 19, 20, 638, 639, ":" +345, 7, 9, 145, 21, 24, 640, 643, "490" +345, 7, 10, 146, 25, 26, 644, 645, "-" +345, 7, 11, 147, 27, 28, 646, 647, "1" +345, 7, 12, 148, 29, 30, 648, 649, "." +345, 8, 1, 149, 0, 4, 650, 654, "AIMS" +345, 8, 2, 150, 5, 6, 655, 656, "/" +345, 8, 3, 151, 7, 17, 657, 667, "HYPOTHESIS" +345, 8, 4, 152, 18, 19, 668, 669, ":" +345, 8, 5, 153, 20, 24, 670, 674, "This" +345, 8, 6, 154, 25, 27, 675, 677, "52" +345, 8, 7, 155, 28, 29, 678, 679, "-" +345, 8, 8, 156, 30, 34, 680, 684, "week" +345, 8, 9, 157, 35, 48, 685, 698, "multinational" +345, 8, 10, 158, 49, 50, 699, 700, "," +345, 8, 11, 159, 51, 61, 701, 711, "randomised" +345, 8, 12, 160, 62, 63, 712, 713, "," +345, 8, 13, 161, 64, 68, 714, 718, "open" +345, 8, 14, 162, 69, 70, 719, 720, "-" +345, 8, 15, 163, 71, 76, 721, 726, "label" +345, 8, 16, 164, 77, 78, 727, 728, "," +345, 8, 17, 165, 79, 87, 729, 737, "parallel" +345, 8, 18, 166, 88, 89, 738, 739, "-" +345, 8, 19, 167, 90, 95, 740, 745, "group" +345, 8, 20, 168, 96, 97, 746, 747, "," +345, 8, 21, 169, 98, 101, 748, 751, "non" +345, 8, 22, 170, 102, 103, 752, 753, "-" +345, 8, 23, 171, 104, 115, 754, 765, "inferiority" +345, 8, 24, 172, 116, 121, 766, 771, "trial" +345, 8, 25, 173, 122, 130, 772, 780, "compared" +345, 8, 26, 174, 131, 139, 781, 789, "clinical" +345, 8, 27, 175, 140, 148, 790, 798, "outcomes" +345, 8, 28, 176, 149, 158, 799, 808, "following" +345, 8, 29, 177, 159, 174, 809, 824, "supplementation" +345, 8, 30, 178, 175, 177, 825, 827, "of" +345, 8, 31, 179, 178, 182, 828, 832, "oral" +345, 8, 32, 180, 183, 190, 833, 840, "glucose" +345, 8, 33, 181, 191, 192, 841, 842, "-" +345, 8, 34, 182, 193, 201, 843, 851, "lowering" +345, 8, 35, 183, 202, 207, 852, 857, "drugs" +345, 8, 36, 184, 208, 212, 858, 862, "with" +345, 8, 37, 185, 213, 218, 863, 868, "basal" +345, 8, 38, 186, 219, 226, 869, 876, "insulin" +345, 8, 39, 187, 227, 236, 877, 886, "analogues" +345, 8, 40, 188, 237, 244, 887, 894, "detemir" +345, 8, 41, 189, 245, 248, 895, 898, "and" +345, 8, 42, 190, 249, 257, 899, 907, "glargine" +345, 8, 43, 191, 258, 260, 908, 910, "in" +345, 8, 44, 192, 261, 265, 911, 915, "type" +345, 8, 45, 193, 266, 267, 916, 917, "2" +345, 8, 46, 194, 268, 276, 918, 926, "diabetic" +345, 8, 47, 195, 277, 285, 927, 935, "patients" +345, 8, 48, 196, 286, 287, 936, 937, "." +345, 9, 1, 197, 0, 7, 938, 945, "METHODS" +345, 9, 2, 198, 8, 9, 946, 947, ":" +345, 9, 3, 199, 10, 17, 948, 955, "Insulin" +345, 9, 4, 200, 18, 19, 956, 957, "-" +345, 9, 5, 201, 20, 25, 958, 963, "naive" +345, 9, 6, 202, 26, 32, 964, 970, "adults" +345, 9, 7, 203, 33, 34, 971, 972, "(" +345, 9, 8, 204, 35, 36, 973, 974, "n" +345, 9, 9, 205, 37, 38, 975, 976, "=" +345, 9, 10, 206, 39, 42, 977, 980, "582" +345, 9, 11, 207, 43, 44, 981, 982, "," +345, 9, 12, 208, 45, 48, 983, 986, "HbA" +345, 9, 13, 209, 49, 50, 987, 988, "(" +345, 9, 14, 210, 51, 53, 989, 991, "1c" +345, 9, 15, 211, 54, 55, 992, 993, ")" +345, 9, 16, 212, 56, 57, 994, 995, "7" +345, 9, 17, 213, 58, 59, 996, 997, "." +345, 9, 18, 214, 60, 61, 998, 999, "5" +345, 9, 19, 215, 62, 63, 1000, 1001, "-" +345, 9, 20, 216, 64, 66, 1002, 1004, "10" +345, 9, 21, 217, 67, 68, 1005, 1006, "." +345, 9, 22, 218, 69, 70, 1007, 1008, "0" +345, 9, 23, 219, 71, 72, 1009, 1010, "%" +345, 9, 24, 220, 73, 74, 1011, 1012, "," +345, 9, 25, 221, 75, 78, 1013, 1016, "BMI" +345, 9, 26, 222, 79, 80, 1017, 1018, "<" +345, 9, 27, 223, 81, 83, 1019, 1021, "or" +345, 9, 28, 224, 84, 85, 1022, 1023, "=" +345, 9, 29, 225, 86, 88, 1024, 1026, "40" +345, 9, 30, 226, 89, 90, 1027, 1028, "." +345, 9, 31, 227, 91, 92, 1029, 1030, "0" +345, 9, 32, 228, 93, 95, 1031, 1033, "kg" +345, 9, 33, 229, 96, 97, 1034, 1035, "/" +345, 9, 34, 230, 98, 99, 1036, 1037, "m" +345, 9, 35, 231, 100, 101, 1038, 1039, "(" +345, 9, 36, 232, 102, 103, 1040, 1041, "2" +345, 9, 37, 233, 104, 105, 1042, 1043, ")" +345, 9, 38, 234, 106, 107, 1044, 1045, ")" +345, 9, 39, 235, 108, 112, 1046, 1050, "were" +345, 9, 40, 236, 113, 123, 1051, 1061, "randomised" +345, 9, 41, 237, 124, 125, 1062, 1063, "1" +345, 9, 42, 238, 126, 127, 1064, 1065, ":" +345, 9, 43, 239, 128, 129, 1066, 1067, "1" +345, 9, 44, 240, 130, 132, 1068, 1070, "to" +345, 9, 45, 241, 133, 140, 1071, 1078, "receive" +345, 9, 46, 242, 141, 148, 1079, 1086, "insulin" +345, 9, 47, 243, 149, 156, 1087, 1094, "detemir" +345, 9, 48, 244, 157, 159, 1095, 1097, "or" +345, 9, 49, 245, 160, 168, 1098, 1106, "glargine" +345, 9, 50, 246, 169, 173, 1107, 1111, "once" +345, 9, 51, 247, 174, 179, 1112, 1117, "daily" +345, 9, 52, 248, 180, 181, 1118, 1119, "(" +345, 9, 53, 249, 182, 189, 1120, 1127, "evening" +345, 9, 54, 250, 190, 191, 1128, 1129, ")" +345, 9, 55, 251, 192, 200, 1130, 1138, "actively" +345, 9, 56, 252, 201, 209, 1139, 1147, "titrated" +345, 9, 57, 253, 210, 212, 1148, 1150, "to" +345, 9, 58, 254, 213, 219, 1151, 1157, "target" +345, 9, 59, 255, 220, 227, 1158, 1165, "fasting" +345, 9, 60, 256, 228, 234, 1166, 1172, "plasma" +345, 9, 61, 257, 235, 242, 1173, 1180, "glucose" +345, 9, 62, 258, 243, 244, 1181, 1182, "(" +345, 9, 63, 259, 245, 248, 1183, 1186, "FPG" +345, 9, 64, 260, 249, 250, 1187, 1188, ")" +345, 9, 65, 261, 251, 252, 1189, 1190, "<" +345, 9, 66, 262, 253, 255, 1191, 1193, "or" +345, 9, 67, 263, 256, 257, 1194, 1195, "=" +345, 9, 68, 264, 258, 259, 1196, 1197, "6" +345, 9, 69, 265, 260, 261, 1198, 1199, "." +345, 9, 70, 266, 262, 263, 1200, 1201, "0" +345, 9, 71, 267, 264, 268, 1202, 1206, "mmol" +345, 9, 72, 268, 269, 270, 1207, 1208, "/" +345, 9, 73, 269, 271, 272, 1209, 1210, "l" +345, 9, 74, 270, 273, 274, 1211, 1212, "." +345, 10, 1, 271, 0, 2, 1213, 1215, "An" +345, 10, 2, 272, 3, 13, 1216, 1226, "additional" +345, 10, 3, 273, 14, 21, 1227, 1234, "morning" +345, 10, 4, 274, 22, 29, 1235, 1242, "insulin" +345, 10, 5, 275, 30, 37, 1243, 1250, "detemir" +345, 10, 6, 276, 38, 42, 1251, 1255, "dose" +345, 10, 7, 277, 43, 46, 1256, 1259, "was" +345, 10, 8, 278, 47, 56, 1260, 1269, "permitted" +345, 10, 9, 279, 57, 59, 1270, 1272, "if" +345, 10, 10, 280, 60, 63, 1273, 1276, "pre" +345, 10, 11, 281, 64, 65, 1277, 1278, "-" +345, 10, 12, 282, 66, 72, 1279, 1285, "dinner" +345, 10, 13, 283, 73, 79, 1286, 1292, "plasma" +345, 10, 14, 284, 80, 87, 1293, 1300, "glucose" +345, 10, 15, 285, 88, 89, 1301, 1302, "(" +345, 10, 16, 286, 90, 92, 1303, 1305, "PG" +345, 10, 17, 287, 93, 94, 1306, 1307, ")" +345, 10, 18, 288, 95, 98, 1308, 1311, "was" +345, 10, 19, 289, 99, 100, 1312, 1313, ">" +345, 10, 20, 290, 101, 102, 1314, 1315, "7" +345, 10, 21, 291, 103, 104, 1316, 1317, "." +345, 10, 22, 292, 105, 106, 1318, 1319, "0" +345, 10, 23, 293, 107, 111, 1320, 1324, "mmol" +345, 10, 24, 294, 112, 113, 1325, 1326, "/" +345, 10, 25, 295, 114, 115, 1327, 1328, "l" +345, 10, 26, 296, 116, 121, 1329, 1334, "after" +345, 10, 27, 297, 122, 131, 1335, 1344, "achieving" +345, 10, 28, 298, 132, 135, 1345, 1348, "FPG" +345, 10, 29, 299, 136, 137, 1349, 1350, "<" +345, 10, 30, 300, 138, 139, 1351, 1352, "7" +345, 10, 31, 301, 140, 141, 1353, 1354, "." +345, 10, 32, 302, 142, 143, 1355, 1356, "0" +345, 10, 33, 303, 144, 148, 1357, 1361, "mmol" +345, 10, 34, 304, 149, 150, 1362, 1363, "/" +345, 10, 35, 305, 151, 152, 1364, 1365, "l" +345, 10, 36, 306, 153, 154, 1366, 1367, "." +345, 11, 1, 307, 0, 3, 1368, 1371, "Due" +345, 11, 2, 308, 4, 6, 1372, 1374, "to" +345, 11, 3, 309, 7, 16, 1375, 1384, "labelling" +345, 11, 4, 310, 17, 29, 1385, 1397, "restrictions" +345, 11, 5, 311, 30, 31, 1398, 1399, "," +345, 11, 6, 312, 32, 34, 1400, 1402, "no" +345, 11, 7, 313, 35, 41, 1403, 1409, "second" +345, 11, 8, 314, 42, 50, 1410, 1418, "glargine" +345, 11, 9, 315, 51, 55, 1419, 1423, "dose" +345, 11, 10, 316, 56, 59, 1424, 1427, "was" +345, 11, 11, 317, 60, 67, 1428, 1435, "allowed" +345, 11, 12, 318, 68, 69, 1436, 1437, "." +345, 12, 1, 319, 0, 7, 1438, 1445, "RESULTS" +345, 12, 2, 320, 8, 9, 1446, 1447, ":" +345, 12, 3, 321, 10, 18, 1448, 1456, "Baseline" +345, 12, 4, 322, 19, 22, 1457, 1460, "HbA" +345, 12, 5, 323, 23, 24, 1461, 1462, "(" +345, 12, 6, 324, 25, 27, 1463, 1465, "1c" +345, 12, 7, 325, 28, 29, 1466, 1467, ")" +345, 12, 8, 326, 30, 39, 1468, 1477, "decreased" +345, 12, 9, 327, 40, 44, 1478, 1482, "from" +345, 12, 10, 328, 45, 46, 1483, 1484, "8" +345, 12, 11, 329, 47, 48, 1485, 1486, "." +345, 12, 12, 330, 49, 50, 1487, 1488, "6" +345, 12, 13, 331, 51, 53, 1489, 1491, "to" +345, 12, 14, 332, 54, 55, 1492, 1493, "7" +345, 12, 15, 333, 56, 57, 1494, 1495, "." +345, 12, 16, 334, 58, 59, 1496, 1497, "2" +345, 12, 17, 335, 60, 63, 1498, 1501, "and" +345, 12, 18, 336, 64, 65, 1502, 1503, "7" +345, 12, 19, 337, 66, 67, 1504, 1505, "." +345, 12, 20, 338, 68, 69, 1506, 1507, "1" +345, 12, 21, 339, 70, 71, 1508, 1509, "%" +345, 12, 22, 340, 72, 73, 1510, 1511, "(" +345, 12, 23, 341, 74, 76, 1512, 1514, "NS" +345, 12, 24, 342, 77, 78, 1515, 1516, ")" +345, 12, 25, 343, 79, 83, 1517, 1521, "with" +345, 12, 26, 344, 84, 91, 1522, 1529, "detemir" +345, 12, 27, 345, 92, 95, 1530, 1533, "and" +345, 12, 28, 346, 96, 104, 1534, 1542, "glargine" +345, 12, 29, 347, 105, 106, 1543, 1544, "," +345, 12, 30, 348, 107, 119, 1545, 1557, "respectively" +345, 12, 31, 349, 120, 121, 1558, 1559, "." +345, 13, 1, 350, 0, 3, 1560, 1563, "FPG" +345, 13, 2, 351, 4, 12, 1564, 1572, "improved" +345, 13, 3, 352, 13, 17, 1573, 1577, "from" +345, 13, 4, 353, 18, 20, 1578, 1580, "10" +345, 13, 5, 354, 21, 22, 1581, 1582, "." +345, 13, 6, 355, 23, 24, 1583, 1584, "8" +345, 13, 7, 356, 25, 27, 1585, 1587, "to" +345, 13, 8, 357, 28, 29, 1588, 1589, "7" +345, 13, 9, 358, 30, 31, 1590, 1591, "." +345, 13, 10, 359, 32, 33, 1592, 1593, "1" +345, 13, 11, 360, 34, 37, 1594, 1597, "and" +345, 13, 12, 361, 38, 39, 1598, 1599, "7" +345, 13, 13, 362, 40, 41, 1600, 1601, "." +345, 13, 14, 363, 42, 43, 1602, 1603, "0" +345, 13, 15, 364, 44, 48, 1604, 1608, "mmol" +345, 13, 16, 365, 49, 50, 1609, 1610, "/" +345, 13, 17, 366, 51, 52, 1611, 1612, "l" +345, 13, 18, 367, 53, 54, 1613, 1614, "(" +345, 13, 19, 368, 55, 57, 1615, 1617, "NS" +345, 13, 20, 369, 58, 59, 1618, 1619, ")" +345, 13, 21, 370, 60, 61, 1620, 1621, "," +345, 13, 22, 371, 62, 74, 1622, 1634, "respectively" +345, 13, 23, 372, 75, 76, 1635, 1636, "." +345, 14, 1, 373, 0, 4, 1637, 1641, "With" +345, 14, 2, 374, 5, 12, 1642, 1649, "detemir" +345, 14, 3, 375, 13, 14, 1650, 1651, "," +345, 14, 4, 376, 15, 17, 1652, 1654, "45" +345, 14, 5, 377, 18, 19, 1655, 1656, "%" +345, 14, 6, 378, 20, 22, 1657, 1659, "of" +345, 14, 7, 379, 23, 35, 1660, 1672, "participants" +345, 14, 8, 380, 36, 45, 1673, 1682, "completed" +345, 14, 9, 381, 46, 49, 1683, 1686, "the" +345, 14, 10, 382, 50, 55, 1687, 1692, "study" +345, 14, 11, 383, 56, 58, 1693, 1695, "on" +345, 14, 12, 384, 59, 63, 1696, 1700, "once" +345, 14, 13, 385, 64, 69, 1701, 1706, "daily" +345, 14, 14, 386, 70, 76, 1707, 1713, "dosing" +345, 14, 15, 387, 77, 80, 1714, 1717, "and" +345, 14, 16, 388, 81, 83, 1718, 1720, "55" +345, 14, 17, 389, 84, 85, 1721, 1722, "%" +345, 14, 18, 390, 86, 88, 1723, 1725, "on" +345, 14, 19, 391, 89, 94, 1726, 1731, "twice" +345, 14, 20, 392, 95, 100, 1732, 1737, "daily" +345, 14, 21, 393, 101, 107, 1738, 1744, "dosing" +345, 14, 22, 394, 108, 109, 1745, 1746, "," +345, 14, 23, 395, 110, 114, 1747, 1751, "with" +345, 14, 24, 396, 115, 117, 1752, 1754, "no" +345, 14, 25, 397, 118, 128, 1755, 1765, "difference" +345, 14, 26, 398, 129, 131, 1766, 1768, "in" +345, 14, 27, 399, 132, 135, 1769, 1772, "HbA" +345, 14, 28, 400, 136, 137, 1773, 1774, "(" +345, 14, 29, 401, 138, 140, 1775, 1777, "1c" +345, 14, 30, 402, 141, 142, 1778, 1779, ")" +345, 14, 31, 403, 143, 144, 1780, 1781, "." +345, 15, 1, 404, 0, 7, 1782, 1789, "Overall" +345, 15, 2, 405, 8, 9, 1790, 1791, "," +345, 15, 3, 406, 10, 12, 1792, 1794, "52" +345, 15, 4, 407, 13, 14, 1795, 1796, "%" +345, 15, 5, 408, 15, 17, 1797, 1799, "of" +345, 15, 6, 409, 18, 30, 1800, 1812, "participants" +345, 15, 7, 410, 31, 39, 1813, 1821, "achieved" +345, 15, 8, 411, 40, 43, 1822, 1825, "HbA" +345, 15, 9, 412, 44, 45, 1826, 1827, "(" +345, 15, 10, 413, 46, 48, 1828, 1830, "1c" +345, 15, 11, 414, 49, 50, 1831, 1832, ")" +345, 15, 12, 415, 51, 52, 1833, 1834, "<" +345, 15, 13, 416, 53, 55, 1835, 1837, "or" +345, 15, 14, 417, 56, 57, 1838, 1839, "=" +345, 15, 15, 418, 58, 59, 1840, 1841, "7" +345, 15, 16, 419, 60, 61, 1842, 1843, "." +345, 15, 17, 420, 62, 63, 1844, 1845, "0" +345, 15, 18, 421, 64, 65, 1846, 1847, "%" +345, 15, 19, 422, 66, 67, 1848, 1849, ":" +345, 15, 20, 423, 68, 70, 1850, 1852, "33" +345, 15, 21, 424, 71, 72, 1853, 1854, "%" +345, 15, 22, 425, 73, 74, 1855, 1856, "(" +345, 15, 23, 426, 75, 82, 1857, 1864, "detemir" +345, 15, 24, 427, 83, 84, 1865, 1866, ")" +345, 15, 25, 428, 85, 88, 1867, 1870, "and" +345, 15, 26, 429, 89, 91, 1871, 1873, "35" +345, 15, 27, 430, 92, 93, 1874, 1875, "%" +345, 15, 28, 431, 94, 95, 1876, 1877, "(" +345, 15, 29, 432, 96, 104, 1878, 1886, "glargine" +345, 15, 30, 433, 105, 106, 1887, 1888, ")" +345, 15, 31, 434, 107, 114, 1889, 1896, "without" +345, 15, 32, 435, 115, 128, 1897, 1910, "hypoglycaemia" +345, 15, 33, 436, 129, 130, 1911, 1912, "." +345, 16, 1, 437, 0, 6, 1913, 1919, "Within" +345, 16, 2, 438, 7, 8, 1920, 1921, "-" +345, 16, 3, 439, 9, 20, 1922, 1933, "participant" +345, 16, 4, 440, 21, 32, 1934, 1945, "variability" +345, 16, 5, 441, 33, 36, 1946, 1949, "for" +345, 16, 6, 442, 37, 41, 1950, 1954, "self" +345, 16, 7, 443, 42, 43, 1955, 1956, "-" +345, 16, 8, 444, 44, 53, 1957, 1966, "monitored" +345, 16, 9, 445, 54, 57, 1967, 1970, "FPG" +345, 16, 10, 446, 58, 61, 1971, 1974, "and" +345, 16, 11, 447, 62, 65, 1975, 1978, "pre" +345, 16, 12, 448, 66, 67, 1979, 1980, "-" +345, 16, 13, 449, 68, 74, 1981, 1987, "dinner" +345, 16, 14, 450, 75, 77, 1988, 1990, "PG" +345, 16, 15, 451, 78, 81, 1991, 1994, "did" +345, 16, 16, 452, 82, 85, 1995, 1998, "not" +345, 16, 17, 453, 86, 92, 1999, 2005, "differ" +345, 16, 18, 454, 93, 95, 2006, 2008, "by" +345, 16, 19, 455, 96, 103, 2009, 2016, "insulin" +345, 16, 20, 456, 104, 113, 2017, 2026, "treatment" +345, 16, 21, 457, 114, 115, 2027, 2028, "," +345, 16, 22, 458, 116, 119, 2029, 2032, "nor" +345, 16, 23, 459, 120, 123, 2033, 2036, "did" +345, 16, 24, 460, 124, 127, 2037, 2040, "the" +345, 16, 25, 461, 128, 136, 2041, 2049, "relative" +345, 16, 26, 462, 137, 141, 2050, 2054, "risk" +345, 16, 27, 463, 142, 144, 2055, 2057, "of" +345, 16, 28, 464, 145, 152, 2058, 2065, "overall" +345, 16, 29, 465, 153, 155, 2066, 2068, "or" +345, 16, 30, 466, 156, 165, 2069, 2078, "nocturnal" +345, 16, 31, 467, 166, 179, 2079, 2092, "hypoglycaemia" +345, 16, 32, 468, 180, 181, 2093, 2094, "." +345, 17, 1, 469, 0, 6, 2095, 2101, "Modest" +345, 17, 2, 470, 7, 17, 2102, 2112, "reductions" +345, 17, 3, 471, 18, 20, 2113, 2115, "in" +345, 17, 4, 472, 21, 27, 2116, 2122, "weight" +345, 17, 5, 473, 28, 32, 2123, 2127, "gain" +345, 17, 6, 474, 33, 37, 2128, 2132, "were" +345, 17, 7, 475, 38, 42, 2133, 2137, "seen" +345, 17, 8, 476, 43, 47, 2138, 2142, "with" +345, 17, 9, 477, 48, 55, 2143, 2150, "detemir" +345, 17, 10, 478, 56, 58, 2151, 2153, "vs" +345, 17, 11, 479, 59, 67, 2154, 2162, "glargine" +345, 17, 12, 480, 68, 70, 2163, 2165, "in" +345, 17, 13, 481, 71, 81, 2166, 2176, "completers" +345, 17, 14, 482, 82, 83, 2177, 2178, "(" +345, 17, 15, 483, 84, 85, 2179, 2180, "3" +345, 17, 16, 484, 86, 87, 2181, 2182, "." +345, 17, 17, 485, 88, 89, 2183, 2184, "0" +345, 17, 18, 486, 90, 92, 2185, 2187, "vs" +345, 17, 19, 487, 93, 94, 2188, 2189, "3" +345, 17, 20, 488, 95, 96, 2190, 2191, "." +345, 17, 21, 489, 97, 98, 2192, 2193, "9" +345, 17, 22, 490, 99, 101, 2194, 2196, "kg" +345, 17, 23, 491, 102, 103, 2197, 2198, "," +345, 17, 24, 492, 104, 105, 2199, 2200, "p" +345, 17, 25, 493, 106, 107, 2201, 2202, "=" +345, 17, 26, 494, 108, 109, 2203, 2204, "0" +345, 17, 27, 495, 110, 111, 2205, 2206, "." +345, 17, 28, 496, 112, 114, 2207, 2209, "01" +345, 17, 29, 497, 115, 116, 2210, 2211, ")" +345, 17, 30, 498, 117, 120, 2212, 2215, "and" +345, 17, 31, 499, 121, 123, 2216, 2218, "in" +345, 17, 32, 500, 124, 127, 2219, 2222, "the" +345, 17, 33, 501, 128, 137, 2223, 2232, "intention" +345, 17, 34, 502, 138, 139, 2233, 2234, "-" +345, 17, 35, 503, 140, 142, 2235, 2237, "to" +345, 17, 36, 504, 143, 144, 2238, 2239, "-" +345, 17, 37, 505, 145, 150, 2240, 2245, "treat" +345, 17, 38, 506, 151, 161, 2246, 2256, "population" +345, 17, 39, 507, 162, 163, 2257, 2258, "(" +345, 17, 40, 508, 164, 165, 2259, 2260, "2" +345, 17, 41, 509, 166, 167, 2261, 2262, "." +345, 17, 42, 510, 168, 169, 2263, 2264, "7" +345, 17, 43, 511, 170, 172, 2265, 2267, "vs" +345, 17, 44, 512, 173, 174, 2268, 2269, "3" +345, 17, 45, 513, 175, 176, 2270, 2271, "." +345, 17, 46, 514, 177, 178, 2272, 2273, "5" +345, 17, 47, 515, 179, 181, 2274, 2276, "kg" +345, 17, 48, 516, 182, 183, 2277, 2278, "," +345, 17, 49, 517, 184, 185, 2279, 2280, "p" +345, 17, 50, 518, 186, 187, 2281, 2282, "=" +345, 17, 51, 519, 188, 189, 2283, 2284, "0" +345, 17, 52, 520, 190, 191, 2285, 2286, "." +345, 17, 53, 521, 192, 194, 2287, 2289, "03" +345, 17, 54, 522, 195, 196, 2290, 2291, ")" +345, 17, 55, 523, 197, 198, 2292, 2293, "," +345, 17, 56, 524, 199, 208, 2294, 2303, "primarily" +345, 17, 57, 525, 209, 216, 2304, 2311, "related" +345, 17, 58, 526, 217, 219, 2312, 2314, "to" +345, 17, 59, 527, 220, 230, 2315, 2325, "completers" +345, 17, 60, 528, 231, 233, 2326, 2328, "on" +345, 17, 61, 529, 234, 238, 2329, 2333, "once" +345, 17, 62, 530, 239, 240, 2334, 2335, "-" +345, 17, 63, 531, 241, 246, 2336, 2341, "daily" +345, 17, 64, 532, 247, 254, 2342, 2349, "detemir" +345, 17, 65, 533, 255, 256, 2350, 2351, "." +345, 18, 1, 534, 0, 4, 2352, 2356, "Mean" +345, 18, 2, 535, 5, 10, 2357, 2362, "daily" +345, 18, 3, 536, 11, 18, 2363, 2370, "detemir" +345, 18, 4, 537, 19, 23, 2371, 2375, "dose" +345, 18, 5, 538, 24, 27, 2376, 2379, "was" +345, 18, 6, 539, 28, 34, 2380, 2386, "higher" +345, 18, 7, 540, 35, 36, 2387, 2388, "(" +345, 18, 8, 541, 37, 38, 2389, 2390, "0" +345, 18, 9, 542, 39, 40, 2391, 2392, "." +345, 18, 10, 543, 41, 43, 2393, 2395, "78" +345, 18, 11, 544, 44, 45, 2396, 2397, "U" +345, 18, 12, 545, 46, 47, 2398, 2399, "/" +345, 18, 13, 546, 48, 50, 2400, 2402, "kg" +345, 18, 14, 547, 51, 52, 2403, 2404, "[" +345, 18, 15, 548, 53, 54, 2405, 2406, "0" +345, 18, 16, 549, 55, 56, 2407, 2408, "." +345, 18, 17, 550, 57, 59, 2409, 2411, "52" +345, 18, 18, 551, 60, 64, 2412, 2416, "with" +345, 18, 19, 552, 65, 69, 2417, 2421, "once" +345, 18, 20, 553, 70, 75, 2422, 2427, "daily" +345, 18, 21, 554, 76, 82, 2428, 2434, "dosing" +345, 18, 22, 555, 83, 84, 2435, 2436, "," +345, 18, 23, 556, 85, 86, 2437, 2438, "1" +345, 18, 24, 557, 87, 88, 2439, 2440, "." +345, 18, 25, 558, 89, 91, 2441, 2443, "00" +345, 18, 26, 559, 92, 93, 2444, 2445, "U" +345, 18, 27, 560, 94, 95, 2446, 2447, "/" +345, 18, 28, 561, 96, 98, 2448, 2450, "kg" +345, 18, 29, 562, 99, 103, 2451, 2455, "with" +345, 18, 30, 563, 104, 109, 2456, 2461, "twice" +345, 18, 31, 564, 110, 115, 2462, 2467, "daily" +345, 18, 32, 565, 116, 122, 2468, 2474, "dosing" +345, 18, 33, 566, 123, 124, 2475, 2476, "]" +345, 18, 34, 567, 125, 126, 2477, 2478, ")" +345, 18, 35, 568, 127, 131, 2479, 2483, "than" +345, 18, 36, 569, 132, 140, 2484, 2492, "glargine" +345, 18, 37, 570, 141, 142, 2493, 2494, "(" +345, 18, 38, 571, 143, 144, 2495, 2496, "0" +345, 18, 39, 572, 145, 146, 2497, 2498, "." +345, 18, 40, 573, 147, 149, 2499, 2501, "44" +345, 18, 41, 574, 150, 152, 2502, 2504, "IU" +345, 18, 42, 575, 153, 154, 2505, 2506, "/" +345, 18, 43, 576, 155, 157, 2507, 2509, "kg" +345, 18, 44, 577, 158, 159, 2510, 2511, ")" +345, 18, 45, 578, 160, 161, 2512, 2513, "." +345, 19, 1, 579, 0, 9, 2514, 2523, "Injection" +345, 19, 2, 580, 10, 14, 2524, 2528, "site" +345, 19, 3, 581, 15, 24, 2529, 2538, "reactions" +345, 19, 4, 582, 25, 29, 2539, 2543, "were" +345, 19, 5, 583, 30, 34, 2544, 2548, "more" +345, 19, 6, 584, 35, 43, 2549, 2557, "frequent" +345, 19, 7, 585, 44, 48, 2558, 2562, "with" +345, 19, 8, 586, 49, 56, 2563, 2570, "detemir" +345, 19, 9, 587, 57, 58, 2571, 2572, "(" +345, 19, 10, 588, 59, 60, 2573, 2574, "4" +345, 19, 11, 589, 61, 62, 2575, 2576, "." +345, 19, 12, 590, 63, 64, 2577, 2578, "5" +345, 19, 13, 591, 65, 67, 2579, 2581, "vs" +345, 19, 14, 592, 68, 69, 2582, 2583, "1" +345, 19, 15, 593, 70, 71, 2584, 2585, "." +345, 19, 16, 594, 72, 73, 2586, 2587, "4" +345, 19, 17, 595, 74, 75, 2588, 2589, "%" +345, 19, 18, 596, 76, 77, 2590, 2591, ")" +345, 19, 19, 597, 78, 79, 2592, 2593, "." +345, 20, 1, 598, 0, 11, 2594, 2605, "CONCLUSIONS" +345, 20, 2, 599, 12, 13, 2606, 2607, "/" +345, 20, 3, 600, 14, 28, 2608, 2622, "INTERPRETATION" +345, 20, 4, 601, 29, 30, 2623, 2624, ":" +345, 20, 5, 602, 31, 46, 2625, 2640, "Supplementation" +345, 20, 6, 603, 47, 49, 2641, 2643, "of" +345, 20, 7, 604, 50, 54, 2644, 2648, "oral" +345, 20, 8, 605, 55, 61, 2649, 2655, "agents" +345, 20, 9, 606, 62, 66, 2656, 2660, "with" +345, 20, 10, 607, 67, 74, 2661, 2668, "detemir" +345, 20, 11, 608, 75, 77, 2669, 2671, "or" +345, 20, 12, 609, 78, 86, 2672, 2680, "glargine" +345, 20, 13, 610, 87, 95, 2681, 2689, "achieves" +345, 20, 14, 611, 96, 106, 2690, 2700, "clinically" +345, 20, 15, 612, 107, 116, 2701, 2710, "important" +345, 20, 16, 613, 117, 129, 2711, 2723, "improvements" +345, 20, 17, 614, 130, 132, 2724, 2726, "in" +345, 20, 18, 615, 133, 142, 2727, 2736, "glycaemic" +345, 20, 19, 616, 143, 150, 2737, 2744, "control" +345, 20, 20, 617, 151, 155, 2745, 2749, "with" +345, 20, 21, 618, 156, 159, 2750, 2753, "low" +345, 20, 22, 619, 160, 164, 2754, 2758, "risk" +345, 20, 23, 620, 165, 167, 2759, 2761, "of" +345, 20, 24, 621, 168, 181, 2762, 2775, "hypoglycaemia" +345, 20, 25, 622, 182, 183, 2776, 2777, "." +345, 21, 1, 623, 0, 3, 2778, 2781, "Non" +345, 21, 2, 624, 4, 5, 2782, 2783, "-" +345, 21, 3, 625, 6, 17, 2784, 2795, "inferiority" +345, 21, 4, 626, 18, 21, 2796, 2799, "was" +345, 21, 5, 627, 22, 34, 2800, 2812, "demonstrated" +345, 21, 6, 628, 35, 38, 2813, 2816, "for" +345, 21, 7, 629, 39, 46, 2817, 2824, "detemir" +345, 21, 8, 630, 47, 52, 2825, 2830, "using" +345, 21, 9, 631, 53, 59, 2831, 2837, "higher" +345, 21, 10, 632, 60, 67, 2838, 2845, "insulin" +345, 21, 11, 633, 68, 73, 2846, 2851, "doses" +345, 21, 12, 634, 74, 75, 2852, 2853, "(" +345, 21, 13, 635, 76, 82, 2854, 2860, "mainly" +345, 21, 14, 636, 83, 91, 2861, 2869, "patients" +345, 21, 15, 637, 92, 94, 2870, 2872, "on" +345, 21, 16, 638, 95, 100, 2873, 2878, "twice" +345, 21, 17, 639, 101, 106, 2879, 2884, "daily" +345, 21, 18, 640, 107, 113, 2885, 2891, "dosing" +345, 21, 19, 641, 114, 115, 2892, 2893, ")" +345, 21, 20, 642, 116, 117, 2894, 2895, ";" +345, 21, 21, 643, 118, 124, 2896, 2902, "weight" +345, 21, 22, 644, 125, 129, 2903, 2907, "gain" +345, 21, 23, 645, 130, 133, 2908, 2911, "was" +345, 21, 24, 646, 134, 142, 2912, 2920, "somewhat" +345, 21, 25, 647, 143, 150, 2921, 2928, "reduced" +345, 21, 26, 648, 151, 155, 2929, 2933, "with" +345, 21, 27, 649, 156, 160, 2934, 2938, "once" +345, 21, 28, 650, 161, 166, 2939, 2944, "daily" +345, 21, 29, 651, 167, 174, 2945, 2952, "insulin" +345, 21, 30, 652, 175, 182, 2953, 2960, "detemir" +345, 21, 31, 653, 183, 184, 2961, 2962, "." +345, 22, 1, 654, 0, 3, 2963, 2966, "DOI" +345, 22, 2, 655, 4, 5, 2967, 2968, ":" +345, 22, 3, 656, 6, 8, 2969, 2971, "10" +345, 22, 4, 657, 9, 10, 2972, 2973, "." +345, 22, 5, 658, 11, 15, 2974, 2978, "1007" +345, 22, 6, 659, 16, 17, 2979, 2980, "/" +345, 22, 7, 660, 18, 24, 2981, 2987, "s00125" +345, 22, 8, 661, 25, 26, 2988, 2989, "-" +345, 22, 9, 662, 27, 30, 2990, 2993, "007" +345, 22, 10, 663, 31, 32, 2994, 2995, "-" +345, 22, 11, 664, 33, 37, 2996, 3000, "0911" +345, 22, 12, 665, 38, 39, 3001, 3002, "-" +345, 22, 13, 666, 40, 41, 3003, 3004, "x" +345, 22, 14, 667, 42, 47, 3005, 3010, "PMCID" +345, 22, 15, 668, 48, 49, 3011, 3012, ":" +345, 22, 16, 669, 50, 60, 3013, 3023, "PMC2235909" +345, 22, 17, 670, 61, 65, 3024, 3028, "PMID" +345, 22, 18, 671, 66, 67, 3029, 3030, ":" +345, 22, 19, 672, 68, 76, 3031, 3039, "18204830" +345, 22, 20, 673, 77, 78, 3040, 3041, "[" +345, 22, 21, 674, 79, 86, 3042, 3049, "Indexed" +345, 22, 22, 675, 87, 90, 3050, 3053, "for" +345, 22, 23, 676, 91, 98, 3054, 3061, "MEDLINE" +345, 22, 24, 677, 99, 100, 3062, 3063, "]" diff --git a/data/dm2 18204830_kwoodley.annodb b/data/dm2 18204830_kwoodley.annodb new file mode 100644 index 0000000..5059baf --- /dev/null +++ b/data/dm2 18204830_kwoodley.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6647, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +6648, PublicationYear, 15, 19, "2008", "", " \"2008\"." +36903, Title, 111, 318, "A randomised , 52 - week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "", +6650, Randomized, 113, 123, "randomised", "", +6651, Duration, 126, 135, "52 - week", "", +6652, CTAnalysisApproach, 138, 157, "treat - to - target", "", " . ." +6653, InsulinDetemir, 174, 189, "insulin detemir", "", +6654, InsulinGlargine, 195, 211, "insulin glargine", "", +6674, OralAntidiabeticAgent, 245, 269, "glucose - lowering drugs", "", +6657, Precondition, 273, 316, "insulin - naive people with type 2 diabetes", "", " \"insulin - naive people with type 2 diabetes\"." +6656, Type2Diabetes, 301, 316, "type 2 diabetes", "", +6659, Author, 319, 331, "Rosenstock J", "", " \"Rosenstock J\"." +6660, Author, 340, 348, "Davies M", "", " \"Davies M\"." +6661, Author, 351, 358, "Home PD", "", " \"Home PD\"." +6662, Author, 361, 369, "Larsen J", "", " \"Larsen J\"." +6663, Author, 372, 380, "Koenen C", "", " \"Koenen C\"." +6664, Author, 383, 397, "Schernthaner G", "", " \"Schernthaner G\"." +6665, USA, 529, 532, "USA", "", " ." +6679, ObjectiveDescription, 670, 862, "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with", "", " \"This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with\"." +6667, Duration, 675, 684, "52 - week", "", " \"52 - week\"." +36904, Multicenter, 685, 698, "multinational", "", +6669, Randomized, 701, 711, "randomised", "", " ." +6670, OpenLabel, 714, 726, "open - label", "", " ." +6671, Parallel, 729, 745, "parallel - group", "", " ." +6672, CTDesign, 748, 765, "non - inferiority", "", " . ." +6673, OralAntidiabeticAgent, 828, 857, "oral glucose - lowering drugs", "", +36905, ObjectiveDescription, 863, 937, "basal insulin analogues detemir and glargine in type 2 diabetic patients .", "", +6675, Insulin, 869, 876, "insulin", "", +6676, InsulinDetemir, 887, 894, "detemir", "", +6677, InsulinGlargine, 899, 907, "glargine", "", +6678, Type2Diabetes, 911, 926, "type 2 diabetic", "", " ." +6686, Precondition, 948, 1045, "Insulin - naive adults ( n = 582 , HbA ( 1c ) 7 . 5 - 10 . 0 % , BMI < or = 40 . 0 kg / m ( 2 ) )", "", " \"Insulin - naive adults ( n = 582 , HbA ( 1c ) 7 . 5 - 10 . 0 % , BMI < or = 40 . 0 kg / m ( 2 ) )\"." +6681, NumberPatientsCT, 977, 980, "582", "", " \"582\"." +6682, HbA1c, 983, 993, "HbA ( 1c )", "", +6683, Percentage, 1009, 1010, "%", "", +6684, BMI, 1013, 1016, "BMI", "", +6685, Kg_per_squareMeter, 1031, 1043, "kg / m ( 2 )", "", +6687, Randomized, 1051, 1061, "randomised", "", +6688, AllocationRatio, 1062, 1067, "1 : 1", "", " . ." +6689, InsulinDetemir, 1079, 1094, "insulin detemir", "", +6690, InsulinGlargine, 1098, 1106, "glargine", "", +6691, Frequency, 1107, 1117, "once daily", "", +6692, Bedtime, 1120, 1127, "evening", "", +6693, FastingPlasmaGlucose_target, 1158, 1210, "fasting plasma glucose ( FPG ) < or = 6 . 0 mmol / l", "", +6694, Morning, 1227, 1234, "morning", "", +6695, InsulinDetemir, 1235, 1250, "insulin detemir", "", +6696, TimePoint, 1273, 1285, "pre - dinner", "", +36906, PlasmaGlucose, 1286, 1300, "plasma glucose", "", +36907, PlasmaGlucose, 1303, 1305, "PG", "", +6697, Millimoles_per_litre, 1320, 1328, "mmol / l", "", +6699, FastingPlasmaGlucose, 1345, 1348, "FPG", "", +6698, Millimoles_per_litre, 1357, 1365, "mmol / l", "", +6702, InsulinGlargine, 1410, 1418, "glargine", "", +6703, HbA1c, 1457, 1467, "HbA ( 1c )", "", +6704, BaseLineValue, 1483, 1488, "8 . 6", "", +6705, ResultMeasuredValue, 1492, 1497, "7 . 2", "", +6706, ResultMeasuredValue, 1502, 1507, "7 . 1", "", +6707, Percentage, 1508, 1509, "%", "", +6708, InsulinDetemir, 1522, 1529, "detemir", "", +6709, InsulinGlargine, 1534, 1542, "glargine", "", +6710, FastingPlasmaGlucose, 1560, 1563, "FPG", "", +6711, BaseLineValue, 1578, 1584, "10 . 8", "", +6712, ResultMeasuredValue, 1588, 1593, "7 . 1", "", +6713, ResultMeasuredValue, 1598, 1603, "7 . 0", "", +6714, Millimoles_per_litre, 1604, 1612, "mmol / l", "", +6715, InsulinDetemir, 1642, 1649, "detemir", "", +6790, PercentageAffected, 1652, 1654, "45", "", +6718, Frequency, 1696, 1706, "once daily", "", +6793, PercentageAffected, 1718, 1720, "55", "", +6720, Frequency, 1726, 1737, "twice daily", "", +6726, HbA1c, 1769, 1779, "HbA ( 1c )", "", +6727, PercentageAffected, 1792, 1794, "52", "", +6728, HbA1c_target, 1822, 1847, "HbA ( 1c ) < or = 7 . 0 %", "", +6729, PercentageAffected, 1850, 1852, "33", "", +6731, InsulinDetemir, 1857, 1864, "detemir", "", +6730, PercentageAffected, 1871, 1873, "35", "", +6732, InsulinGlargine, 1878, 1886, "glargine", "", +6733, SubGroupDescription, 1889, 1910, "without hypoglycaemia", "", +6734, Hypoglycemia, 1897, 1910, "hypoglycaemia", "", +6740, ObservedResult, 1913, 2092, "Within - participant variability for self - monitored FPG and pre - dinner PG did not differ by insulin treatment , nor did the relative risk of overall or nocturnal hypoglycaemia", "", +6735, FastingPlasmaGlucose, 1967, 1970, "FPG", "", +6736, TimePoint, 1975, 1987, "pre - dinner", "", +6737, EndPointDescription, 1988, 1990, "PG", "", +6738, Insulin, 2009, 2016, "insulin", "", +6739, NocturnalHypoglycemia, 2069, 2092, "nocturnal hypoglycaemia", "", +6741, BodyWeight, 2116, 2122, "weight", "", +6742, InsulinDetemir, 2143, 2150, "detemir", "", +6743, InsulinGlargine, 2154, 2162, "glargine", "", +6755, Increment, 2179, 2184, "3 . 0", "", +6756, Increment, 2188, 2193, "3 . 9", "", +6746, Kg, 2194, 2196, "kg", "", +6747, PvalueDiff, 2199, 2209, "p = 0 . 01", "", +6748, IntentionToTreat, 2223, 2245, "intention - to - treat", "", " ." +6759, SubGroupDescription, 2223, 2256, "intention - to - treat population", "", +6757, Increment, 2259, 2264, "2 . 7", "", +6758, Increment, 2268, 2273, "3 . 5", "", +6751, Kg, 2274, 2276, "kg", "", +6752, PvalueDiff, 2279, 2289, "p = 0 . 03", "", +6760, SubGroupDescription, 2294, 2349, "primarily related to completers on once - daily detemir", "", +6753, Frequency, 2329, 2341, "once - daily", "", +6754, InsulinDetemir, 2342, 2349, "detemir", "", +6761, Frequency, 2357, 2362, "daily", "", +6762, InsulinDetemir, 2363, 2370, "detemir", "", +6763, DoseValue, 2389, 2395, "0 . 78", "", +6766, IntUnit_per_Kg, 2396, 2402, "U / kg", "", +6764, DoseValue, 2405, 2411, "0 . 52", "", +6768, Frequency, 2417, 2427, "once daily", "", +6765, DoseValue, 2437, 2443, "1 . 00", "", +6767, IntUnit_per_Kg, 2444, 2450, "U / kg", "", +6769, Frequency, 2456, 2467, "twice daily", "", +6770, InsulinGlargine, 2484, 2492, "glargine", "", +6771, DoseValue, 2495, 2501, "0 . 44", "", +6772, IntUnit_per_Kg, 2502, 2509, "IU / kg", "", +36908, EndPointDescription, 2514, 2538, "Injection site reactions", "", +6774, InsulinDetemir, 2563, 2570, "detemir", "", +6775, PercentageAffected, 2573, 2578, "4 . 5", "", +6776, PercentageAffected, 2582, 2587, "1 . 4", "", +36909, ConclusionComment, 2625, 2777, "Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia .", "", +6777, OralAntidiabeticAgent, 2644, 2655, "oral agents", "", +6778, InsulinDetemir, 2661, 2668, "detemir", "", +6779, InsulinGlargine, 2672, 2680, "glargine", "", +6780, Hypoglycemia, 2762, 2775, "hypoglycaemia", "", +36910, ConclusionComment, 2778, 2962, "Non - inferiority was demonstrated for detemir using higher insulin doses ( mainly patients on twice daily dosing ) ; weight gain was somewhat reduced with once daily insulin detemir .", "", +6782, InsulinDetemir, 2817, 2824, "detemir", "", +6783, Insulin, 2838, 2845, "insulin", "", +6784, Frequency, 2873, 2884, "twice daily", "", +6785, BodyWeight, 2896, 2902, "weight", "", +6786, Frequency, 2934, 2944, "once daily", "", +6787, InsulinDetemir, 2945, 2960, "insulin detemir", "", +6789, PMID, 3031, 3039, "18204830", "", " \"18204830\"." diff --git a/data/dm2 18204830_kwoodley.n-triples b/data/dm2 18204830_kwoodley.n-triples new file mode 100644 index 0000000..4d8d3e2 --- /dev/null +++ b/data/dm2 18204830_kwoodley.n-triples @@ -0,0 +1,51 @@ +# RDF export of group: Publication + . + "Publication " . + "Rosenstock J" . + "2008" . + "Diabetologia" . + "18204830" . + . + "Davies M" . + "Home PD" . + "Larsen J" . + "Koenen C" . + "Schernthaner G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This 52 - week multinational , randomised , open - label , parallel - group , non - inferiority trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with" . + "582" . + "52 - week" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive people with type 2 diabetes" . + . + . + . + "Insulin - naive adults ( n = 582 , HbA ( 1c ) 7 . 5 - 10 . 0 % , BMI < or = 40 . 0 kg / m ( 2 ) )" . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18761646 copy_admin.annodb b/data/dm2 18761646 copy_admin.annodb new file mode 100644 index 0000000..6a14e7e --- /dev/null +++ b/data/dm2 18761646 copy_admin.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Pediatr Diabetes", "", " \"Pediatr Diabetes\"." +1, PublicationYear, 19, 23, "2008", "", " \"2008\"." +2, PublicationYear, 111, 115, "2008", "", +77, Title, 125, 249, "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .", "", " \"Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .\"." +3, Metformin, 178, 187, "metformin", "", +4, Precondition, 191, 247, "markedly obese adolescents with normal glucose tolerance", "", " \"markedly obese adolescents with normal glucose tolerance\"." +5, Author, 250, 260, "Burgert TS", "", " \"Burgert TS\"." +6, Author, 269, 277, "Duran EJ", "", " \"Duran EJ\"." +7, Author, 280, 297, "Goldberg - Gell R", "", " \"Goldberg - Gell R\"." +8, Author, 300, 308, "Dziura J", "", " \"Dziura J\"." +9, Author, 311, 320, "Yeckel CW", "", " \"Yeckel CW\"." +10, Author, 323, 329, "Katz S", "", " \"Katz S\"." +11, Author, 332, 345, "Tamborlane WV", "", " \"Tamborlane WV\"." +12, Author, 348, 356, "Caprio S", "", " \"Caprio S\"." +13, USA, 473, 476, "USA", "", " ." +19, ObjectiveDescription, 520, 702, "Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus ,", "", " \"Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus ,\"." +14, Metformin, 529, 538, "metformin", "", +15, Metformin, 541, 544, "MET", "", +16, Insulin, 553, 560, "insulin", "", +17, Type2Diabetes, 676, 700, "type 2 diabetes mellitus", "", " ." +148, ObjectiveDescription, 703, 837, "few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .", "", " \"few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .\"." +18, Precondition, 783, 835, "obese children with normal glucose tolerance ( NGT )", "", " \"obese children with normal glucose tolerance ( NGT )\"." +20, Duration, 873, 882, "4 - month", "", " \"4 - month\"." +21, DoubleBlind, 883, 897, "double - blind", "", " ." +22, NumberPatientsCT, 916, 918, "28", "", " \"28\"." +119906, Precondition, 919, 991, "obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]", "", " \"obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]\"." +99, Mean, 927, 931, "mean", "", +23, BMI, 932, 947, "body mass index", "", +24, BMI, 950, 953, "BMI", "", +25, Kg_per_squareMeter, 977, 989, "kg / m ( 2 )", "", " ." +26, Insulin, 994, 1001, "insulin", "", +119908, Precondition, 994, 1085, "insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8", "", " \"insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8\"." +27, Insulin, 1047, 1054, "insulin", "", +119909, Precondition, 1090, 1200, "whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )", "", " \"whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )\"." +28, Insulin, 1101, 1108, "insulin", "", +29, AvgAge, 1177, 1183, "15 . 0", "", " \"15 . 0\"." +30, Randomized, 1201, 1211, "randomized", "", " ." +31, Metformin, 1215, 1218, "MET", "", " ." +32, NumberPatientsArm, 1225, 1227, "15", "", " \"15\"." +33, DoseValue, 1235, 1239, "1500", "", " \"1500\"." +34, mg, 1240, 1242, "mg", "", " ." +35, Frequency, 1243, 1248, "daily", "", " \"daily\"." +36, Placebo, 1254, 1261, "placebo", "", " ." +37, NumberPatientsArm, 1268, 1270, "13", "", " \"13\"." +39, Metformin, 1304, 1307, "MET", "", +40, Metformin, 1329, 1332, "MET", "", +41, BMI, 1375, 1378, "BMI", "", " ." +43, PValueChangeValue, 1381, 1391, "p = 0 . 02", "", " \"p = 0 . 02\"." +42, EndPointDescription, 1425, 1441, "subcutaneous fat", "", " . ." +44, PValueChangeValue, 1444, 1454, "p = 0 . 03", "", " \"p = 0 . 03\"." +71, SubGroupDescription, 1476, 1497, "deep subcutaneous fat", "", " \"deep subcutaneous fat\"." +45, PValueChangeValue, 1500, 1510, "p = 0 . 04", "", " \"p = 0 . 04\"." +46, MeasurementDevice, 1528, 1554, "magnetic resonance imaging", "", " . ." +47, Metformin, 1580, 1583, "MET", "", +48, RelativeChangeValue, 1596, 1598, "35", "", " \"35\"." +124, Percentage, 1599, 1600, "%", "", +51, ObservedResult, 1601, 1612, "improvement", "", " \"improvement\"." +49, EndPointDescription, 1616, 1635, "insulin sensitivity", "", " . ." +50, EndPointDescription, 1638, 1643, "WBISI", "", +52, Placebo, 1664, 1671, "placebo", "", +53, PvalueDiff, 1680, 1691, "p = 0 . 008", "", " \"p = 0 . 008\"." +55, EndPointDescription, 1773, 1792, "insulin sensitivity", "", +54, PvalueDiff, 1795, 1805, "p = 0 . 09", "", +64, ObservedResult, 1816, 1835, "there was no change", "", " \"there was no change\". \"there was no change\"." +56, EndPointDescription, 1839, 1861, "inflammatory cytokines", "", " . ." +57, EndPointDescription, 1865, 1881, "lipid parameters", "", " . ." +58, EndPointDescription, 1884, 1907, "cardiovascular function", "", " . ." +134, ObservedResult, 1958, 1966, "improved", "", " \"improved\"." +59, Metformin, 1972, 1975, "MET", "", +135, ObservedResult, 1980, 1988, "worsened", "", " \"worsened\"." +60, Placebo, 1992, 1999, "placebo", "", +61, PvalueDiff, 2002, 2012, "p = 0 . 03", "", " \"p = 0 . 03\"." +141, ConclusionComment, 2030, 2225, "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .", "", " \"Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .\"." +63, Metformin, 2050, 2053, "MET", "", +66, BMI, 2130, 2133, "BMI", "", +68, EndPointDescription, 2138, 2168, "autonomic control of the heart", "", +67, EndPointDescription, 2204, 2223, "insulin sensitivity", "", +143, ConclusionComment, 2226, 2357, "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .", "", " \"Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .\"." +69, Metformin, 2260, 2263, "MET", "", +70, PMID, 2418, 2426, "18761646", "", " \"18761646\"." diff --git a/data/dm2 18761646 copy_admin.n-triples b/data/dm2 18761646 copy_admin.n-triples new file mode 100644 index 0000000..5154c06 --- /dev/null +++ b/data/dm2 18761646 copy_admin.n-triples @@ -0,0 +1,183 @@ +# RDF export of group: Publication + . + "Publication" . + "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance ." . + "Burgert TS" . + "2008" . + "Pediatr Diabetes" . + "18761646" . + . + "Duran EJ" . + "Goldberg - Gell R" . + "Dziura J" . + "Yeckel CW" . + "Katz S" . + "Tamborlane WV" . + "Caprio S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus ," . + "28" . + "4 - month" . + . + . + . + "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity ." . + . + . + . + . + . + "few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) ." . + . + "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity ." . + . + . +# RDF export of group: Population + . + "Population" . + "markedly obese adolescents with normal glucose tolerance" . + . + . + "15 . 0" . + . + "obese children with normal glucose tolerance ( NGT )" . + "obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]" . + "insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8" . + "whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )" . +# RDF export of group: Endpoint + . + "Endpoint_S" . + . + . + . + . + . + . + . + "Endpoint_BMI" . + . + . + . + . + . + "Endpoint_IS" . + . + . + . + . + . + . + "Endpoint_IC" . + . + . + . + . + . + . + "Endpoint_LP" . + . + . + . + . + . + . + "Endpoint_CF" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_M" . + "15" . + . + . + . + . + . + . + . + . + . + "Arm_P" . + "13" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_M" . + . + "daily" . + . + . + "Intervention_P" . + . + . +# RDF export of group: Medication + . + "Medication_M" . + . + "1500" . + . + . + . + "Medication_P" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_S_M" . + . + "p = 0 . 03" . + . + "Outcome_S_M_Sub" . + . + "p = 0 . 04" . + "deep subcutaneous fat" . + . + "Outcome_BMI_M" . + . + "p = 0 . 02" . + . + "Outcome_IS_M" . + . + "35" . + "improvement" . + . + "Outcome_IS_P" . + . + . + "Outcome_IC" . + . + "there was no change" . + . + "Outcome_LP" . + . + "there was no change" . + . + "Outcome_CF_M" . + . + "improved" . + . + "Outcome_CF_P" . + . + "worsened" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_IS" . + "p = 0 . 008" . + . + . + . + "DiffBetweenGroups_CF" . + "p = 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18761646 copy_export.csv b/data/dm2 18761646 copy_export.csv new file mode 100644 index 0000000..72396a6 --- /dev/null +++ b/data/dm2 18761646 copy_export.csv @@ -0,0 +1,524 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +821, 1, 1, 1, 0, 7, 0, 7, "Pediatr" +821, 1, 2, 2, 8, 16, 8, 16, "Diabetes" +821, 1, 3, 3, 17, 18, 17, 18, "." +821, 2, 1, 4, 0, 4, 19, 23, "2008" +821, 2, 2, 5, 5, 8, 24, 27, "Dec" +821, 2, 3, 6, 9, 10, 28, 29, ";" +821, 2, 4, 7, 11, 12, 30, 31, "9" +821, 2, 5, 8, 13, 14, 32, 33, "(" +821, 2, 6, 9, 15, 16, 34, 35, "6" +821, 2, 7, 10, 17, 18, 36, 37, ")" +821, 2, 8, 11, 19, 20, 38, 39, ":" +821, 2, 9, 12, 21, 24, 40, 43, "567" +821, 2, 10, 13, 25, 26, 44, 45, "-" +821, 2, 11, 14, 27, 29, 46, 48, "76" +821, 2, 12, 15, 30, 31, 49, 50, "." +821, 2, 13, 16, 32, 35, 51, 54, "doi" +821, 2, 14, 17, 36, 37, 55, 56, ":" +821, 2, 15, 18, 38, 40, 57, 59, "10" +821, 2, 16, 19, 41, 42, 60, 61, "." +821, 2, 17, 20, 43, 47, 62, 66, "1111" +821, 2, 18, 21, 48, 49, 67, 68, "/" +821, 2, 19, 22, 50, 51, 69, 70, "j" +821, 2, 20, 23, 52, 53, 71, 72, "." +821, 2, 21, 24, 54, 58, 73, 77, "1399" +821, 2, 22, 25, 59, 60, 78, 79, "-" +821, 2, 23, 26, 61, 65, 80, 84, "5448" +821, 2, 24, 27, 66, 67, 85, 86, "." +821, 2, 25, 28, 68, 72, 87, 91, "2008" +821, 2, 26, 29, 73, 74, 92, 93, "." +821, 2, 27, 30, 75, 80, 94, 99, "00434" +821, 2, 28, 31, 81, 82, 100, 101, "." +821, 2, 29, 32, 83, 84, 102, 103, "x" +821, 2, 30, 33, 85, 86, 104, 105, "." +821, 3, 1, 34, 0, 4, 106, 110, "Epub" +821, 3, 2, 35, 5, 9, 111, 115, "2008" +821, 3, 3, 36, 10, 13, 116, 119, "Aug" +821, 3, 4, 37, 14, 16, 120, 122, "27" +821, 3, 5, 38, 17, 18, 123, 124, "." +821, 4, 1, 39, 0, 5, 125, 130, "Short" +821, 4, 2, 40, 6, 7, 131, 132, "-" +821, 4, 3, 41, 8, 12, 133, 137, "term" +821, 4, 4, 42, 13, 22, 138, 147, "metabolic" +821, 4, 5, 43, 23, 26, 148, 151, "and" +821, 4, 6, 44, 27, 41, 152, 166, "cardiovascular" +821, 4, 7, 45, 42, 49, 167, 174, "effects" +821, 4, 8, 46, 50, 52, 175, 177, "of" +821, 4, 9, 47, 53, 62, 178, 187, "metformin" +821, 4, 10, 48, 63, 65, 188, 190, "in" +821, 4, 11, 49, 66, 74, 191, 199, "markedly" +821, 4, 12, 50, 75, 80, 200, 205, "obese" +821, 4, 13, 51, 81, 92, 206, 217, "adolescents" +821, 4, 14, 52, 93, 97, 218, 222, "with" +821, 4, 15, 53, 98, 104, 223, 229, "normal" +821, 4, 16, 54, 105, 112, 230, 237, "glucose" +821, 4, 17, 55, 113, 122, 238, 247, "tolerance" +821, 4, 18, 56, 123, 124, 248, 249, "." +821, 5, 1, 57, 0, 7, 250, 257, "Burgert" +821, 5, 2, 58, 8, 10, 258, 260, "TS" +821, 5, 3, 59, 11, 12, 261, 262, "(" +821, 5, 4, 60, 13, 14, 263, 264, "1" +821, 5, 5, 61, 15, 16, 265, 266, ")" +821, 5, 6, 62, 17, 18, 267, 268, "," +821, 5, 7, 63, 19, 24, 269, 274, "Duran" +821, 5, 8, 64, 25, 27, 275, 277, "EJ" +821, 5, 9, 65, 28, 29, 278, 279, "," +821, 5, 10, 66, 30, 38, 280, 288, "Goldberg" +821, 5, 11, 67, 39, 40, 289, 290, "-" +821, 5, 12, 68, 41, 45, 291, 295, "Gell" +821, 5, 13, 69, 46, 47, 296, 297, "R" +821, 5, 14, 70, 48, 49, 298, 299, "," +821, 5, 15, 71, 50, 56, 300, 306, "Dziura" +821, 5, 16, 72, 57, 58, 307, 308, "J" +821, 5, 17, 73, 59, 60, 309, 310, "," +821, 5, 18, 74, 61, 67, 311, 317, "Yeckel" +821, 5, 19, 75, 68, 70, 318, 320, "CW" +821, 5, 20, 76, 71, 72, 321, 322, "," +821, 5, 21, 77, 73, 77, 323, 327, "Katz" +821, 5, 22, 78, 78, 79, 328, 329, "S" +821, 5, 23, 79, 80, 81, 330, 331, "," +821, 5, 24, 80, 82, 92, 332, 342, "Tamborlane" +821, 5, 25, 81, 93, 95, 343, 345, "WV" +821, 5, 26, 82, 96, 97, 346, 347, "," +821, 5, 27, 83, 98, 104, 348, 354, "Caprio" +821, 5, 28, 84, 105, 106, 355, 356, "S" +821, 5, 29, 85, 107, 108, 357, 358, "." +821, 5, 30, 86, 109, 115, 359, 365, "Author" +821, 5, 31, 87, 116, 127, 366, 377, "information" +821, 5, 32, 88, 128, 129, 378, 379, ":" +821, 5, 33, 89, 130, 131, 380, 381, "(" +821, 5, 34, 90, 132, 133, 382, 383, "1" +821, 5, 35, 91, 134, 135, 384, 385, ")" +821, 5, 36, 92, 136, 146, 386, 396, "Department" +821, 5, 37, 93, 147, 149, 397, 399, "of" +821, 5, 38, 94, 150, 160, 400, 410, "Pediatrics" +821, 5, 39, 95, 161, 162, 411, 412, "," +821, 5, 40, 96, 163, 167, 413, 417, "Yale" +821, 5, 41, 97, 168, 178, 418, 428, "University" +821, 5, 42, 98, 179, 185, 429, 435, "School" +821, 5, 43, 99, 186, 188, 436, 438, "of" +821, 5, 44, 100, 189, 197, 439, 447, "Medicine" +821, 5, 45, 101, 198, 199, 448, 449, "," +821, 5, 46, 102, 200, 203, 450, 453, "New" +821, 5, 47, 103, 204, 209, 454, 459, "Haven" +821, 5, 48, 104, 210, 211, 460, 461, "," +821, 5, 49, 105, 212, 214, 462, 464, "CT" +821, 5, 50, 106, 215, 220, 465, 470, "06520" +821, 5, 51, 107, 221, 222, 471, 472, "," +821, 5, 52, 108, 223, 226, 473, 476, "USA" +821, 5, 53, 109, 227, 228, 477, 478, "." +821, 6, 1, 110, 0, 5, 479, 484, "tania" +821, 6, 2, 111, 6, 7, 485, 486, "." +821, 6, 3, 112, 8, 15, 487, 494, "burgert" +821, 6, 4, 113, 16, 17, 495, 496, "@" +821, 6, 5, 114, 18, 22, 497, 501, "yale" +821, 6, 6, 115, 23, 24, 502, 503, "." +821, 6, 7, 116, 25, 28, 504, 507, "edu" +821, 6, 8, 117, 29, 38, 508, 517, "OBJECTIVE" +821, 6, 9, 118, 39, 40, 518, 519, ":" +821, 6, 10, 119, 41, 49, 520, 528, "Although" +821, 6, 11, 120, 50, 59, 529, 538, "metformin" +821, 6, 12, 121, 60, 61, 539, 540, "(" +821, 6, 13, 122, 62, 65, 541, 544, "MET" +821, 6, 14, 123, 66, 67, 545, 546, ")" +821, 6, 15, 124, 68, 70, 547, 549, "is" +821, 6, 16, 125, 71, 73, 550, 552, "an" +821, 6, 17, 126, 74, 81, 553, 560, "insulin" +821, 6, 18, 127, 82, 92, 561, 571, "sensitizer" +821, 6, 19, 128, 93, 102, 572, 581, "currently" +821, 6, 20, 129, 103, 107, 582, 586, "used" +821, 6, 21, 130, 108, 110, 587, 589, "as" +821, 6, 22, 131, 111, 113, 590, 592, "an" +821, 6, 23, 132, 114, 121, 593, 600, "adjunct" +821, 6, 24, 133, 122, 124, 601, 603, "to" +821, 6, 25, 134, 125, 128, 604, 607, "the" +821, 6, 26, 135, 129, 138, 608, 617, "treatment" +821, 6, 27, 136, 139, 141, 618, 620, "of" +821, 6, 28, 137, 142, 146, 621, 625, "some" +821, 6, 29, 138, 147, 149, 626, 628, "of" +821, 6, 30, 139, 150, 153, 629, 632, "the" +821, 6, 31, 140, 154, 167, 633, 646, "complications" +821, 6, 32, 141, 168, 170, 647, 649, "of" +821, 6, 33, 142, 171, 180, 650, 659, "childhood" +821, 6, 34, 143, 181, 188, 660, 667, "obesity" +821, 6, 35, 144, 189, 196, 668, 675, "besides" +821, 6, 36, 145, 197, 201, 676, 680, "type" +821, 6, 37, 146, 202, 203, 681, 682, "2" +821, 6, 38, 147, 204, 212, 683, 691, "diabetes" +821, 6, 39, 148, 213, 221, 692, 700, "mellitus" +821, 6, 40, 149, 222, 223, 701, 702, "," +821, 6, 41, 150, 224, 227, 703, 706, "few" +821, 6, 42, 151, 228, 235, 707, 714, "studies" +821, 6, 43, 152, 236, 240, 715, 719, "have" +821, 6, 44, 153, 241, 256, 720, 735, "comprehensively" +821, 6, 45, 154, 257, 265, 736, 744, "examined" +821, 6, 46, 155, 266, 269, 745, 748, "its" +821, 6, 47, 156, 270, 279, 749, 758, "metabolic" +821, 6, 48, 157, 280, 283, 759, 762, "and" +821, 6, 49, 158, 284, 292, 763, 771, "clinical" +821, 6, 50, 159, 293, 300, 772, 779, "effects" +821, 6, 51, 160, 301, 303, 780, 782, "in" +821, 6, 52, 161, 304, 309, 783, 788, "obese" +821, 6, 53, 162, 310, 318, 789, 797, "children" +821, 6, 54, 163, 319, 323, 798, 802, "with" +821, 6, 55, 164, 324, 330, 803, 809, "normal" +821, 6, 56, 165, 331, 338, 810, 817, "glucose" +821, 6, 57, 166, 339, 348, 818, 827, "tolerance" +821, 6, 58, 167, 349, 350, 828, 829, "(" +821, 6, 59, 168, 351, 354, 830, 833, "NGT" +821, 6, 60, 169, 355, 356, 834, 835, ")" +821, 6, 61, 170, 357, 358, 836, 837, "." +821, 7, 1, 171, 0, 7, 838, 845, "METHODS" +821, 7, 2, 172, 8, 9, 846, 847, ":" +821, 7, 3, 173, 10, 12, 848, 850, "We" +821, 7, 4, 174, 13, 22, 851, 860, "therefore" +821, 7, 5, 175, 23, 32, 861, 870, "conducted" +821, 7, 6, 176, 33, 34, 871, 872, "a" +821, 7, 7, 177, 35, 36, 873, 874, "4" +821, 7, 8, 178, 37, 38, 875, 876, "-" +821, 7, 9, 179, 39, 44, 877, 882, "month" +821, 7, 10, 180, 45, 51, 883, 889, "double" +821, 7, 11, 181, 52, 53, 890, 891, "-" +821, 7, 12, 182, 54, 59, 892, 897, "blind" +821, 7, 13, 183, 60, 68, 898, 906, "clinical" +821, 7, 14, 184, 69, 74, 907, 912, "trial" +821, 7, 15, 185, 75, 77, 913, 915, "in" +821, 7, 16, 186, 78, 80, 916, 918, "28" +821, 7, 17, 187, 81, 86, 919, 924, "obese" +821, 7, 18, 188, 87, 88, 925, 926, "[" +821, 7, 19, 189, 89, 93, 927, 931, "mean" +821, 7, 20, 190, 94, 98, 932, 936, "body" +821, 7, 21, 191, 99, 103, 937, 941, "mass" +821, 7, 22, 192, 104, 109, 942, 947, "index" +821, 7, 23, 193, 110, 111, 948, 949, "(" +821, 7, 24, 194, 112, 115, 950, 953, "BMI" +821, 7, 25, 195, 116, 117, 954, 955, ")" +821, 7, 26, 196, 118, 119, 956, 957, ":" +821, 7, 27, 197, 120, 122, 958, 960, "40" +821, 7, 28, 198, 123, 124, 961, 962, "." +821, 7, 29, 199, 125, 126, 963, 964, "3" +821, 7, 30, 200, 127, 128, 965, 966, "+" +821, 7, 31, 201, 129, 130, 967, 968, "/" +821, 7, 32, 202, 131, 132, 969, 970, "-" +821, 7, 33, 203, 133, 134, 971, 972, "5" +821, 7, 34, 204, 135, 136, 973, 974, "." +821, 7, 35, 205, 137, 138, 975, 976, "7" +821, 7, 36, 206, 139, 141, 977, 979, "kg" +821, 7, 37, 207, 142, 143, 980, 981, "/" +821, 7, 38, 208, 144, 145, 982, 983, "m" +821, 7, 39, 209, 146, 147, 984, 985, "(" +821, 7, 40, 210, 148, 149, 986, 987, "2" +821, 7, 41, 211, 150, 151, 988, 989, ")" +821, 7, 42, 212, 152, 153, 990, 991, "]" +821, 7, 43, 213, 154, 155, 992, 993, "," +821, 7, 44, 214, 156, 163, 994, 1001, "insulin" +821, 7, 45, 215, 164, 165, 1002, 1003, "-" +821, 7, 46, 216, 166, 175, 1004, 1013, "resistant" +821, 7, 47, 217, 176, 177, 1014, 1015, "[" +821, 7, 48, 218, 178, 189, 1016, 1027, "homeostasis" +821, 7, 49, 219, 190, 195, 1028, 1033, "model" +821, 7, 50, 220, 196, 206, 1034, 1044, "assessment" +821, 7, 51, 221, 207, 208, 1045, 1046, "-" +821, 7, 52, 222, 209, 216, 1047, 1054, "insulin" +821, 7, 53, 223, 217, 227, 1055, 1065, "resistance" +821, 7, 54, 224, 228, 229, 1066, 1067, ":" +821, 7, 55, 225, 230, 231, 1068, 1069, "7" +821, 7, 56, 226, 232, 233, 1070, 1071, "." +821, 7, 57, 227, 234, 235, 1072, 1073, "6" +821, 7, 58, 228, 236, 237, 1074, 1075, "+" +821, 7, 59, 229, 238, 239, 1076, 1077, "/" +821, 7, 60, 230, 240, 241, 1078, 1079, "-" +821, 7, 61, 231, 242, 243, 1080, 1081, "2" +821, 7, 62, 232, 244, 245, 1082, 1083, "." +821, 7, 63, 233, 246, 247, 1084, 1085, "8" +821, 7, 64, 234, 248, 251, 1086, 1089, "and" +821, 7, 65, 235, 252, 257, 1090, 1095, "whole" +821, 7, 66, 236, 258, 262, 1096, 1100, "body" +821, 7, 67, 237, 263, 270, 1101, 1108, "insulin" +821, 7, 68, 238, 271, 282, 1109, 1120, "sensitivity" +821, 7, 69, 239, 283, 288, 1121, 1126, "index" +821, 7, 70, 240, 289, 290, 1127, 1128, "(" +821, 7, 71, 241, 291, 296, 1129, 1134, "WBISI" +821, 7, 72, 242, 297, 298, 1135, 1136, ")" +821, 7, 73, 243, 299, 300, 1137, 1138, ":" +821, 7, 74, 244, 301, 302, 1139, 1140, "1" +821, 7, 75, 245, 303, 304, 1141, 1142, "." +821, 7, 76, 246, 305, 306, 1143, 1144, "5" +821, 7, 77, 247, 307, 308, 1145, 1146, "+" +821, 7, 78, 248, 309, 310, 1147, 1148, "/" +821, 7, 79, 249, 311, 312, 1149, 1150, "-" +821, 7, 80, 250, 313, 314, 1151, 1152, "0" +821, 7, 81, 251, 315, 316, 1153, 1154, "." +821, 7, 82, 252, 317, 318, 1155, 1156, "7" +821, 7, 83, 253, 319, 320, 1157, 1158, "]" +821, 7, 84, 254, 321, 332, 1159, 1170, "adolescents" +821, 7, 85, 255, 333, 334, 1171, 1172, "(" +821, 7, 86, 256, 335, 338, 1173, 1176, "age" +821, 7, 87, 257, 339, 341, 1177, 1179, "15" +821, 7, 88, 258, 342, 343, 1180, 1181, "." +821, 7, 89, 259, 344, 345, 1182, 1183, "0" +821, 7, 90, 260, 346, 347, 1184, 1185, "+" +821, 7, 91, 261, 348, 349, 1186, 1187, "/" +821, 7, 92, 262, 350, 351, 1188, 1189, "-" +821, 7, 93, 263, 352, 353, 1190, 1191, "1" +821, 7, 94, 264, 354, 355, 1192, 1193, "." +821, 7, 95, 265, 356, 357, 1194, 1195, "3" +821, 7, 96, 266, 358, 360, 1196, 1198, "yr" +821, 7, 97, 267, 361, 362, 1199, 1200, ")" +821, 7, 98, 268, 363, 373, 1201, 1211, "randomized" +821, 7, 99, 269, 374, 376, 1212, 1214, "to" +821, 7, 100, 270, 377, 380, 1215, 1218, "MET" +821, 7, 101, 271, 381, 382, 1219, 1220, "(" +821, 7, 102, 272, 383, 384, 1221, 1222, "n" +821, 7, 103, 273, 385, 386, 1223, 1224, "=" +821, 7, 104, 274, 387, 389, 1225, 1227, "15" +821, 7, 105, 275, 390, 391, 1228, 1229, "," +821, 7, 106, 276, 392, 396, 1230, 1234, "dose" +821, 7, 107, 277, 397, 401, 1235, 1239, "1500" +821, 7, 108, 278, 402, 404, 1240, 1242, "mg" +821, 7, 109, 279, 405, 410, 1243, 1248, "daily" +821, 7, 110, 280, 411, 412, 1249, 1250, ")" +821, 7, 111, 281, 413, 415, 1251, 1253, "or" +821, 7, 112, 282, 416, 423, 1254, 1261, "placebo" +821, 7, 113, 283, 424, 425, 1262, 1263, "(" +821, 7, 114, 284, 426, 427, 1264, 1265, "n" +821, 7, 115, 285, 428, 429, 1266, 1267, "=" +821, 7, 116, 286, 430, 432, 1268, 1270, "13" +821, 7, 117, 287, 433, 434, 1271, 1272, ")" +821, 7, 118, 288, 435, 436, 1273, 1274, "." +821, 8, 1, 289, 0, 7, 1275, 1282, "RESULTS" +821, 8, 2, 290, 8, 9, 1283, 1284, ":" +821, 8, 3, 291, 10, 13, 1285, 1288, "The" +821, 8, 4, 292, 14, 23, 1289, 1298, "treatment" +821, 8, 5, 293, 24, 28, 1299, 1303, "with" +821, 8, 6, 294, 29, 32, 1304, 1307, "MET" +821, 8, 7, 295, 33, 36, 1308, 1311, "was" +821, 8, 8, 296, 37, 41, 1312, 1316, "well" +821, 8, 9, 297, 42, 51, 1317, 1326, "tolerated" +821, 8, 10, 298, 52, 53, 1327, 1328, "." +821, 9, 1, 299, 0, 3, 1329, 1332, "MET" +821, 9, 2, 300, 4, 13, 1333, 1342, "treatment" +821, 9, 3, 301, 14, 17, 1343, 1346, "was" +821, 9, 4, 302, 18, 28, 1347, 1357, "associated" +821, 9, 5, 303, 29, 33, 1358, 1362, "with" +821, 9, 6, 304, 34, 35, 1363, 1364, "a" +821, 9, 7, 305, 36, 45, 1365, 1374, "decreased" +821, 9, 8, 306, 46, 49, 1375, 1378, "BMI" +821, 9, 9, 307, 50, 51, 1379, 1380, "(" +821, 9, 10, 308, 52, 53, 1381, 1382, "p" +821, 9, 11, 309, 54, 55, 1383, 1384, "=" +821, 9, 12, 310, 56, 57, 1385, 1386, "0" +821, 9, 13, 311, 58, 59, 1387, 1388, "." +821, 9, 14, 312, 60, 62, 1389, 1391, "02" +821, 9, 15, 313, 63, 64, 1392, 1393, ")" +821, 9, 16, 314, 65, 67, 1394, 1396, "as" +821, 9, 17, 315, 68, 72, 1397, 1401, "well" +821, 9, 18, 316, 73, 75, 1402, 1404, "as" +821, 9, 19, 317, 76, 80, 1405, 1409, "with" +821, 9, 20, 318, 81, 82, 1410, 1411, "a" +821, 9, 21, 319, 83, 92, 1412, 1421, "reduction" +821, 9, 22, 320, 93, 95, 1422, 1424, "in" +821, 9, 23, 321, 96, 108, 1425, 1437, "subcutaneous" +821, 9, 24, 322, 109, 112, 1438, 1441, "fat" +821, 9, 25, 323, 113, 114, 1442, 1443, "(" +821, 9, 26, 324, 115, 116, 1444, 1445, "p" +821, 9, 27, 325, 117, 118, 1446, 1447, "=" +821, 9, 28, 326, 119, 120, 1448, 1449, "0" +821, 9, 29, 327, 121, 122, 1450, 1451, "." +821, 9, 30, 328, 123, 125, 1452, 1454, "03" +821, 9, 31, 329, 126, 127, 1455, 1456, ")" +821, 9, 32, 330, 128, 129, 1457, 1458, "," +821, 9, 33, 331, 130, 142, 1459, 1471, "particularly" +821, 9, 34, 332, 143, 146, 1472, 1475, "the" +821, 9, 35, 333, 147, 151, 1476, 1480, "deep" +821, 9, 36, 334, 152, 164, 1481, 1493, "subcutaneous" +821, 9, 37, 335, 165, 168, 1494, 1497, "fat" +821, 9, 38, 336, 169, 170, 1498, 1499, "(" +821, 9, 39, 337, 171, 172, 1500, 1501, "p" +821, 9, 40, 338, 173, 174, 1502, 1503, "=" +821, 9, 41, 339, 175, 176, 1504, 1505, "0" +821, 9, 42, 340, 177, 178, 1506, 1507, "." +821, 9, 43, 341, 179, 181, 1508, 1510, "04" +821, 9, 44, 342, 182, 183, 1511, 1512, ")" +821, 9, 45, 343, 184, 186, 1513, 1515, "as" +821, 9, 46, 344, 187, 195, 1516, 1524, "assessed" +821, 9, 47, 345, 196, 198, 1525, 1527, "by" +821, 9, 48, 346, 199, 207, 1528, 1536, "magnetic" +821, 9, 49, 347, 208, 217, 1537, 1546, "resonance" +821, 9, 50, 348, 218, 225, 1547, 1554, "imaging" +821, 9, 51, 349, 226, 227, 1555, 1556, "." +821, 10, 1, 350, 0, 16, 1557, 1573, "Postintervention" +821, 10, 2, 351, 17, 18, 1574, 1575, "," +821, 10, 3, 352, 19, 22, 1576, 1579, "the" +821, 10, 4, 353, 23, 26, 1580, 1583, "MET" +821, 10, 5, 354, 27, 32, 1584, 1589, "group" +821, 10, 6, 355, 33, 36, 1590, 1593, "had" +821, 10, 7, 356, 37, 38, 1594, 1595, "a" +821, 10, 8, 357, 39, 41, 1596, 1598, "35" +821, 10, 9, 358, 42, 43, 1599, 1600, "%" +821, 10, 10, 359, 44, 55, 1601, 1612, "improvement" +821, 10, 11, 360, 56, 58, 1613, 1615, "in" +821, 10, 12, 361, 59, 66, 1616, 1623, "insulin" +821, 10, 13, 362, 67, 78, 1624, 1635, "sensitivity" +821, 10, 14, 363, 79, 80, 1636, 1637, "(" +821, 10, 15, 364, 81, 86, 1638, 1643, "WBISI" +821, 10, 16, 365, 87, 88, 1644, 1645, ")" +821, 10, 17, 366, 89, 97, 1646, 1654, "compared" +821, 10, 18, 367, 98, 102, 1655, 1659, "with" +821, 10, 19, 368, 103, 106, 1660, 1663, "the" +821, 10, 20, 369, 107, 114, 1664, 1671, "placebo" +821, 10, 21, 370, 115, 120, 1672, 1677, "group" +821, 10, 22, 371, 121, 122, 1678, 1679, "(" +821, 10, 23, 372, 123, 124, 1680, 1681, "p" +821, 10, 24, 373, 125, 126, 1682, 1683, "=" +821, 10, 25, 374, 127, 128, 1684, 1685, "0" +821, 10, 26, 375, 129, 130, 1686, 1687, "." +821, 10, 27, 376, 131, 134, 1688, 1691, "008" +821, 10, 28, 377, 135, 136, 1692, 1693, ")" +821, 10, 29, 378, 137, 138, 1694, 1695, "." +821, 11, 1, 379, 0, 7, 1696, 1703, "However" +821, 11, 2, 380, 8, 9, 1704, 1705, "," +821, 11, 3, 381, 10, 22, 1706, 1718, "significance" +821, 11, 4, 382, 23, 26, 1719, 1722, "was" +821, 11, 5, 383, 27, 31, 1723, 1727, "lost" +821, 11, 6, 384, 32, 36, 1728, 1732, "with" +821, 11, 7, 385, 37, 48, 1733, 1744, "adjustments" +821, 11, 8, 386, 49, 52, 1745, 1748, "for" +821, 11, 9, 387, 53, 64, 1749, 1760, "differences" +821, 11, 10, 388, 65, 67, 1761, 1763, "in" +821, 11, 11, 389, 68, 76, 1764, 1772, "baseline" +821, 11, 12, 390, 77, 84, 1773, 1780, "insulin" +821, 11, 13, 391, 85, 96, 1781, 1792, "sensitivity" +821, 11, 14, 392, 97, 98, 1793, 1794, "(" +821, 11, 15, 393, 99, 100, 1795, 1796, "p" +821, 11, 16, 394, 101, 102, 1797, 1798, "=" +821, 11, 17, 395, 103, 104, 1799, 1800, "0" +821, 11, 18, 396, 105, 106, 1801, 1802, "." +821, 11, 19, 397, 107, 109, 1803, 1805, "09" +821, 11, 20, 398, 110, 111, 1806, 1807, ")" +821, 11, 21, 399, 112, 113, 1808, 1809, "." +821, 12, 1, 400, 0, 5, 1810, 1815, "While" +821, 12, 2, 401, 6, 11, 1816, 1821, "there" +821, 12, 3, 402, 12, 15, 1822, 1825, "was" +821, 12, 4, 403, 16, 18, 1826, 1828, "no" +821, 12, 5, 404, 19, 25, 1829, 1835, "change" +821, 12, 6, 405, 26, 28, 1836, 1838, "in" +821, 12, 7, 406, 29, 41, 1839, 1851, "inflammatory" +821, 12, 8, 407, 42, 51, 1852, 1861, "cytokines" +821, 12, 9, 408, 52, 54, 1862, 1864, "or" +821, 12, 10, 409, 55, 60, 1865, 1870, "lipid" +821, 12, 11, 410, 61, 71, 1871, 1881, "parameters" +821, 12, 12, 411, 72, 73, 1882, 1883, "," +821, 12, 13, 412, 74, 88, 1884, 1898, "cardiovascular" +821, 12, 14, 413, 89, 97, 1899, 1907, "function" +821, 12, 15, 414, 98, 100, 1908, 1910, "as" +821, 12, 16, 415, 101, 109, 1911, 1919, "assessed" +821, 12, 17, 416, 110, 112, 1920, 1922, "by" +821, 12, 18, 417, 113, 118, 1923, 1928, "heart" +821, 12, 19, 418, 119, 123, 1929, 1933, "rate" +821, 12, 20, 419, 124, 132, 1934, 1942, "recovery" +821, 12, 21, 420, 133, 138, 1943, 1948, "after" +821, 12, 22, 421, 139, 147, 1949, 1957, "exercise" +821, 12, 23, 422, 148, 156, 1958, 1966, "improved" +821, 12, 24, 423, 157, 161, 1967, 1971, "with" +821, 12, 25, 424, 162, 165, 1972, 1975, "MET" +821, 12, 26, 425, 166, 169, 1976, 1979, "and" +821, 12, 27, 426, 170, 178, 1980, 1988, "worsened" +821, 12, 28, 427, 179, 181, 1989, 1991, "in" +821, 12, 29, 428, 182, 189, 1992, 1999, "placebo" +821, 12, 30, 429, 190, 191, 2000, 2001, "(" +821, 12, 31, 430, 192, 193, 2002, 2003, "p" +821, 12, 32, 431, 194, 195, 2004, 2005, "=" +821, 12, 33, 432, 196, 197, 2006, 2007, "0" +821, 12, 34, 433, 198, 199, 2008, 2009, "." +821, 12, 35, 434, 200, 202, 2010, 2012, "03" +821, 12, 36, 435, 203, 204, 2013, 2014, ")" +821, 12, 37, 436, 205, 206, 2015, 2016, "." +821, 13, 1, 437, 0, 10, 2017, 2027, "CONCLUSION" +821, 13, 2, 438, 11, 12, 2028, 2029, ":" +821, 13, 3, 439, 13, 18, 2030, 2035, "Short" +821, 13, 4, 440, 19, 20, 2036, 2037, "-" +821, 13, 5, 441, 21, 25, 2038, 2042, "term" +821, 13, 6, 442, 26, 29, 2043, 2046, "use" +821, 13, 7, 443, 30, 32, 2047, 2049, "of" +821, 13, 8, 444, 33, 36, 2050, 2053, "MET" +821, 13, 9, 445, 37, 39, 2054, 2056, "is" +821, 13, 10, 446, 40, 44, 2057, 2061, "well" +821, 13, 11, 447, 45, 54, 2062, 2071, "tolerated" +821, 13, 12, 448, 55, 57, 2072, 2074, "by" +821, 13, 13, 449, 58, 63, 2075, 2080, "obese" +821, 13, 14, 450, 64, 72, 2081, 2089, "children" +821, 13, 15, 451, 73, 77, 2090, 2094, "with" +821, 13, 16, 452, 78, 81, 2095, 2098, "NGT" +821, 13, 17, 453, 82, 85, 2099, 2102, "and" +821, 13, 18, 454, 86, 89, 2103, 2106, "has" +821, 13, 19, 455, 90, 91, 2107, 2108, "a" +821, 13, 20, 456, 92, 102, 2109, 2119, "beneficial" +821, 13, 21, 457, 103, 109, 2120, 2126, "effect" +821, 13, 22, 458, 110, 112, 2127, 2129, "on" +821, 13, 23, 459, 113, 116, 2130, 2133, "BMI" +821, 13, 24, 460, 117, 120, 2134, 2137, "and" +821, 13, 25, 461, 121, 130, 2138, 2147, "autonomic" +821, 13, 26, 462, 131, 138, 2148, 2155, "control" +821, 13, 27, 463, 139, 141, 2156, 2158, "of" +821, 13, 28, 464, 142, 145, 2159, 2162, "the" +821, 13, 29, 465, 146, 151, 2163, 2168, "heart" +821, 13, 30, 466, 152, 154, 2169, 2171, "as" +821, 13, 31, 467, 155, 159, 2172, 2176, "well" +821, 13, 32, 468, 160, 162, 2177, 2179, "as" +821, 13, 33, 469, 163, 164, 2180, 2181, "a" +821, 13, 34, 470, 165, 170, 2182, 2187, "trend" +821, 13, 35, 471, 171, 177, 2188, 2194, "toward" +821, 13, 36, 472, 178, 186, 2195, 2203, "improved" +821, 13, 37, 473, 187, 194, 2204, 2211, "insulin" +821, 13, 38, 474, 195, 206, 2212, 2223, "sensitivity" +821, 13, 39, 475, 207, 208, 2224, 2225, "." +821, 14, 1, 476, 0, 4, 2226, 2230, "Thus" +821, 14, 2, 477, 5, 6, 2231, 2232, "," +821, 14, 3, 478, 7, 11, 2233, 2237, "long" +821, 14, 4, 479, 12, 13, 2238, 2239, "-" +821, 14, 5, 480, 14, 18, 2240, 2244, "term" +821, 14, 6, 481, 19, 28, 2245, 2254, "treatment" +821, 14, 7, 482, 29, 33, 2255, 2259, "with" +821, 14, 8, 483, 34, 37, 2260, 2263, "MET" +821, 14, 9, 484, 38, 41, 2264, 2267, "may" +821, 14, 10, 485, 42, 49, 2268, 2275, "provide" +821, 14, 11, 486, 50, 51, 2276, 2277, "a" +821, 14, 12, 487, 52, 57, 2278, 2283, "means" +821, 14, 13, 488, 58, 60, 2284, 2286, "to" +821, 14, 14, 489, 61, 71, 2287, 2297, "ameliorate" +821, 14, 15, 490, 72, 75, 2298, 2301, "the" +821, 14, 16, 491, 76, 82, 2302, 2308, "cardio" +821, 14, 17, 492, 83, 84, 2309, 2310, "-" +821, 14, 18, 493, 85, 94, 2311, 2320, "metabolic" +821, 14, 19, 494, 95, 107, 2321, 2333, "consequences" +821, 14, 20, 495, 108, 110, 2334, 2336, "of" +821, 14, 21, 496, 111, 121, 2337, 2347, "adolescent" +821, 14, 22, 497, 122, 129, 2348, 2355, "obesity" +821, 14, 23, 498, 130, 131, 2356, 2357, "." +821, 15, 1, 499, 0, 3, 2358, 2361, "DOI" +821, 15, 2, 500, 4, 5, 2362, 2363, ":" +821, 15, 3, 501, 6, 8, 2364, 2366, "10" +821, 15, 4, 502, 9, 10, 2367, 2368, "." +821, 15, 5, 503, 11, 15, 2369, 2373, "1111" +821, 15, 6, 504, 16, 17, 2374, 2375, "/" +821, 15, 7, 505, 18, 19, 2376, 2377, "j" +821, 15, 8, 506, 20, 21, 2378, 2379, "." +821, 15, 9, 507, 22, 26, 2380, 2384, "1399" +821, 15, 10, 508, 27, 28, 2385, 2386, "-" +821, 15, 11, 509, 29, 33, 2387, 2391, "5448" +821, 15, 12, 510, 34, 35, 2392, 2393, "." +821, 15, 13, 511, 36, 40, 2394, 2398, "2008" +821, 15, 14, 512, 41, 42, 2399, 2400, "." +821, 15, 15, 513, 43, 48, 2401, 2406, "00434" +821, 15, 16, 514, 49, 50, 2407, 2408, "." +821, 15, 17, 515, 51, 52, 2409, 2410, "x" +821, 15, 18, 516, 53, 57, 2411, 2415, "PMID" +821, 15, 19, 517, 58, 59, 2416, 2417, ":" +821, 15, 20, 518, 60, 68, 2418, 2426, "18761646" +821, 15, 21, 519, 69, 70, 2427, 2428, "[" +821, 15, 22, 520, 71, 78, 2429, 2436, "Indexed" +821, 15, 23, 521, 79, 82, 2437, 2440, "for" +821, 15, 24, 522, 83, 90, 2441, 2448, "MEDLINE" +821, 15, 25, 523, 91, 92, 2449, 2450, "]" diff --git a/data/dm2 18761646_admin.annodb b/data/dm2 18761646_admin.annodb new file mode 100644 index 0000000..689e42f --- /dev/null +++ b/data/dm2 18761646_admin.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Pediatr Diabetes", "", " \"Pediatr Diabetes\"." +1, PublicationYear, 19, 23, "2008", "", +2, PublicationYear, 111, 115, "2008", "", " \"2008\"." +77, Title, 125, 249, "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .", "", " \"Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .\"." +3, Metformin, 178, 187, "metformin", "", +4, Precondition, 191, 247, "markedly obese adolescents with normal glucose tolerance", "", +5, Author, 250, 260, "Burgert TS", "", " \"Burgert TS\"." +6, Author, 269, 277, "Duran EJ", "", " \"Duran EJ\"." +7, Author, 280, 297, "Goldberg - Gell R", "", " \"Goldberg - Gell R\"." +8, Author, 300, 308, "Dziura J", "", " \"Dziura J\"." +9, Author, 311, 320, "Yeckel CW", "", " \"Yeckel CW\"." +10, Author, 323, 329, "Katz S", "", " \"Katz S\"." +11, Author, 332, 345, "Tamborlane WV", "", " \"Tamborlane WV\"." +12, Author, 348, 356, "Caprio S", "", " \"Caprio S\"." +13, USA, 473, 476, "USA", "", " ." +19, ObjectiveDescription, 520, 702, "Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus ,", "", +14, Metformin, 529, 538, "metformin", "", +15, Metformin, 541, 544, "MET", "", +16, Insulin, 553, 560, "insulin", "", +17, Type2Diabetes, 676, 700, "type 2 diabetes mellitus", "", " ." +148, ObjectiveDescription, 703, 837, "few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .", "", " \"few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .\"." +18, Precondition, 783, 835, "obese children with normal glucose tolerance ( NGT )", "", " \"obese children with normal glucose tolerance ( NGT )\"." +20, Duration, 873, 882, "4 - month", "", " \"4 - month\"." +21, DoubleBlind, 883, 897, "double - blind", "", " ." +22, NumberPatientsCT, 916, 918, "28", "", " \"28\"." +119902, Precondition, 919, 991, "obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]", "", " \"obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]\"." +99, Mean, 927, 931, "mean", "", +23, BMI, 932, 947, "body mass index", "", +24, BMI, 950, 953, "BMI", "", +25, Kg_per_squareMeter, 977, 989, "kg / m ( 2 )", "", +26, Insulin, 994, 1001, "insulin", "", +119904, Precondition, 994, 1085, "insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8", "", " \"insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8\"." +27, Insulin, 1047, 1054, "insulin", "", +119905, Precondition, 1090, 1200, "whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )", "", " \"whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )\"." +28, Insulin, 1101, 1108, "insulin", "", +29, AvgAge, 1177, 1183, "15 . 0", "", " \"15 . 0\"." +30, Randomized, 1201, 1211, "randomized", "", " ." +31, Metformin, 1215, 1218, "MET", "", " ." +32, NumberPatientsArm, 1225, 1227, "15", "", " \"15\"." +33, DoseValue, 1235, 1239, "1500", "", " \"1500\"." +34, mg, 1240, 1242, "mg", "", " ." +35, Frequency, 1243, 1248, "daily", "", " \"daily\"." +36, Placebo, 1254, 1261, "placebo", "", " ." +37, NumberPatientsArm, 1268, 1270, "13", "", " \"13\"." +39, Metformin, 1304, 1307, "MET", "", +40, Metformin, 1329, 1332, "MET", "", +41, BMI, 1375, 1378, "BMI", "", " ." +43, PValueChangeValue, 1381, 1391, "p = 0 . 02", "", " \"p = 0 . 02\"." +42, EndPointDescription, 1425, 1441, "subcutaneous fat", "", " . ." +44, PValueChangeValue, 1444, 1454, "p = 0 . 03", "", " \"p = 0 . 03\"." +71, SubGroupDescription, 1476, 1497, "deep subcutaneous fat", "", " \"deep subcutaneous fat\"." +45, PValueChangeValue, 1500, 1510, "p = 0 . 04", "", " \"p = 0 . 04\"." +46, MeasurementDevice, 1528, 1554, "magnetic resonance imaging", "", " . ." +47, Metformin, 1580, 1583, "MET", "", +48, RelativeChangeValue, 1596, 1598, "35", "", " \"35\"." +124, Percentage, 1599, 1600, "%", "", +51, ObservedResult, 1601, 1612, "improvement", "", +49, EndPointDescription, 1616, 1635, "insulin sensitivity", "", " . ." +50, EndPointDescription, 1638, 1643, "WBISI", "", +52, Placebo, 1664, 1671, "placebo", "", +53, PvalueDiff, 1680, 1691, "p = 0 . 008", "", " \"p = 0 . 008\"." +55, EndPointDescription, 1773, 1792, "insulin sensitivity", "", +54, PvalueDiff, 1795, 1805, "p = 0 . 09", "", +64, ObservedResult, 1816, 1835, "there was no change", "", " \"there was no change\". \"there was no change\"." +56, EndPointDescription, 1839, 1861, "inflammatory cytokines", "", " . ." +57, EndPointDescription, 1865, 1881, "lipid parameters", "", " . ." +58, EndPointDescription, 1884, 1907, "cardiovascular function", "", " . ." +134, ObservedResult, 1958, 1966, "improved", "", " \"improved\"." +59, Metformin, 1972, 1975, "MET", "", +135, ObservedResult, 1980, 1988, "worsened", "", " \"worsened\"." +60, Placebo, 1992, 1999, "placebo", "", +61, PvalueDiff, 2002, 2012, "p = 0 . 03", "", " \"p = 0 . 03\"." +141, ConclusionComment, 2030, 2225, "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .", "", " \"Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .\"." +63, Metformin, 2050, 2053, "MET", "", +66, BMI, 2130, 2133, "BMI", "", +68, EndPointDescription, 2138, 2168, "autonomic control of the heart", "", +67, EndPointDescription, 2204, 2223, "insulin sensitivity", "", +143, ConclusionComment, 2226, 2357, "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .", "", " \"Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .\"." +69, Metformin, 2260, 2263, "MET", "", +70, PMID, 2418, 2426, "18761646", "", " \"18761646\"." diff --git a/data/dm2 18761646_admin.n-triples b/data/dm2 18761646_admin.n-triples new file mode 100644 index 0000000..b630f6c --- /dev/null +++ b/data/dm2 18761646_admin.n-triples @@ -0,0 +1,178 @@ +# RDF export of group: Publication + . + "Publication " . + "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance ." . + "Burgert TS" . + "2008" . + "Pediatr Diabetes" . + "18761646" . + . + "Duran EJ" . + "Goldberg - Gell R" . + "Dziura J" . + "Yeckel CW" . + "Katz S" . + "Tamborlane WV" . + "Caprio S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "28" . + "4 - month" . + . + . + . + "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity ." . + . + . + . + . + . + "few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) ." . + . + "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity ." . + . + . +# RDF export of group: Population + . + "Population" . + . + . + "15 . 0" . + . + "obese children with normal glucose tolerance ( NGT )" . + "obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ]" . + "insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8" . + "whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents ( age 15 . 0 + / - 1 . 3 yr )" . +# RDF export of group: Endpoint + . + "Endpoint bmi" . + . + . + . + . + . + "Endpoint sfat" . + . + . + . + . + . + . + . + "Endpoint is" . + . + . + . + . + . + . + "Endpoint ic" . + . + . + . + . + . + . + "Endpoint lp" . + . + . + . + . + . + . + "Endpoint cf" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm met" . + "15" . + . + . + . + . + . + . + . + . + . + "Arm p" . + "13" . + . + . + . +# RDF export of group: Intervention + . + "Intervention met" . + . + "daily" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication met" . + . + "1500" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome bmi met" . + . + "p = 0 . 02" . + . + "Outcome sfat met" . + . + "p = 0 . 03" . + . + "Outcome sfat sg met" . + . + "p = 0 . 04" . + "deep subcutaneous fat" . + . + "Outcome is met" . + . + "35" . + . + "Outcome is p" . + . + . + "Outcome ic met" . + . + "there was no change" . + . + "Outcome lp met" . + . + "there was no change" . + . + "Outcome cf met" . + . + "improved" . + . + "Outcome cf p" . + . + "worsened" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups is" . + "p = 0 . 008" . + . + . + . + "DiffBetweenGroups cf" . + "p = 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18761646_akramersunderbrink.annodb b/data/dm2 18761646_akramersunderbrink.annodb new file mode 100644 index 0000000..5c567f3 --- /dev/null +++ b/data/dm2 18761646_akramersunderbrink.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23455, Journal, 0, 16, "Pediatr Diabetes", "", +23456, PublicationYear, 19, 23, "2008", "", +23460, Title, 125, 249, "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .", "", +23457, Metformin, 178, 187, "metformin", "", +23458, Precondition, 191, 205, "markedly obese", "", +23459, Precondition, 223, 247, "normal glucose tolerance", "", +23461, Author, 250, 260, "Burgert TS", "", +23462, Author, 269, 277, "Duran EJ", "", +23463, Author, 280, 297, "Goldberg - Gell R", "", +23464, Author, 300, 308, "Dziura J", "", +23465, Author, 311, 320, "Yeckel CW", "", +23466, Author, 323, 329, "Katz S", "", +23467, Author, 332, 345, "Tamborlane WV", "", +23468, Author, 348, 356, "Caprio S", "", +23469, USA, 473, 476, "USA", "", +23476, ObjectiveDescription, 520, 714, "Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus , few studies", "", +23470, Metformin, 529, 538, "metformin", "", +23471, Metformin, 541, 544, "MET", "", +23473, Precondition, 650, 667, "childhood obesity", "", +23472, Type2Diabetes, 676, 700, "type 2 diabetes mellitus", "", +23477, ObjectiveDescription, 715, 837, "have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .", "", +23474, Precondition, 783, 788, "obese", "", +23475, Precondition, 803, 827, "normal glucose tolerance", "", +23529, Precondition, 830, 833, "NGT", "", +23478, Duration, 873, 882, "4 - month", "", +23479, DoubleBlind, 883, 897, "double - blind", "", +23480, NumberPatientsCT, 916, 918, "28", "", +23481, Precondition, 919, 924, "obese", "", +23482, Mean, 927, 931, "mean", "", +23486, Precondition, 927, 989, "mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 )", "", +23483, BMI, 932, 947, "body mass index", "", +23484, BMI, 950, 953, "BMI", "", +23485, Kg_per_squareMeter, 977, 989, "kg / m ( 2 )", "", +23487, Precondition, 994, 1013, "insulin - resistant", "", +23488, Precondition, 1016, 1156, "homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8 and whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7", "", +23489, AvgAge, 1177, 1183, "15 . 0", "", +23490, Randomized, 1201, 1211, "randomized", "", +23491, Metformin, 1215, 1218, "MET", "", +23492, NumberPatientsArm, 1225, 1227, "15", "", +23494, DoseValue, 1235, 1239, "1500", "", +23495, mg, 1240, 1242, "mg", "", +23496, Frequency, 1243, 1248, "daily", "", +23497, Placebo, 1254, 1261, "placebo", "", +23493, NumberPatientsArm, 1268, 1270, "13", "", +23498, Metformin, 1304, 1307, "MET", "", +23499, Metformin, 1329, 1332, "MET", "", +23500, BMI, 1375, 1378, "BMI", "", +23501, PvalueDiff, 1381, 1391, "p = 0 . 02", "", +23504, EndPointDescription, 1425, 1441, "subcutaneous fat", "", +23502, PvalueDiff, 1444, 1454, "p = 0 . 03", "", +23505, EndPointDescription, 1476, 1497, "deep subcutaneous fat", "", +23503, PvalueDiff, 1500, 1510, "p = 0 . 04", "", +23506, Metformin, 1580, 1583, "MET", "", +23508, Increment, 1596, 1598, "35", "", +23507, Percentage, 1599, 1600, "%", "", +23509, EndPointDescription, 1616, 1645, "insulin sensitivity ( WBISI )", "", +23510, Placebo, 1664, 1671, "placebo", "", +23511, PvalueDiff, 1680, 1691, "p = 0 . 008", "", +23512, EndPointDescription, 1728, 1792, "with adjustments for differences in baseline insulin sensitivity", "", +23513, PvalueDiff, 1795, 1805, "p = 0 . 09", "", +23514, EndPointDescription, 1884, 1957, "cardiovascular function as assessed by heart rate recovery after exercise", "", +23517, ObservedResult, 1958, 1966, "improved", "", +23515, Metformin, 1972, 1975, "MET", "", +23518, ObservedResult, 1980, 1988, "worsened", "", +23516, Placebo, 1992, 1999, "placebo", "", +23519, PvalueDiff, 2002, 2012, "p = 0 . 03", "", +23524, ConclusionComment, 2030, 2225, "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .", "", +23520, Metformin, 2050, 2053, "MET", "", +23521, Precondition, 2075, 2080, "obese", "", +23522, Precondition, 2095, 2098, "NGT", "", +23523, BMI, 2130, 2133, "BMI", "", +23526, ConclusionComment, 2226, 2357, "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .", "", +23525, Metformin, 2260, 2263, "MET", "", +23527, DisorderOrSyndrome, 2337, 2355, "adolescent obesity", "", +23528, PMID, 2418, 2426, "18761646", "", diff --git a/data/dm2 18761646_akramersunderbrink.n-triples b/data/dm2 18761646_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18761646_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18761646_export.csv b/data/dm2 18761646_export.csv new file mode 100644 index 0000000..55fe8c2 --- /dev/null +++ b/data/dm2 18761646_export.csv @@ -0,0 +1,524 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +344, 1, 1, 1, 0, 7, 0, 7, "Pediatr" +344, 1, 2, 2, 8, 16, 8, 16, "Diabetes" +344, 1, 3, 3, 17, 18, 17, 18, "." +344, 2, 1, 4, 0, 4, 19, 23, "2008" +344, 2, 2, 5, 5, 8, 24, 27, "Dec" +344, 2, 3, 6, 9, 10, 28, 29, ";" +344, 2, 4, 7, 11, 12, 30, 31, "9" +344, 2, 5, 8, 13, 14, 32, 33, "(" +344, 2, 6, 9, 15, 16, 34, 35, "6" +344, 2, 7, 10, 17, 18, 36, 37, ")" +344, 2, 8, 11, 19, 20, 38, 39, ":" +344, 2, 9, 12, 21, 24, 40, 43, "567" +344, 2, 10, 13, 25, 26, 44, 45, "-" +344, 2, 11, 14, 27, 29, 46, 48, "76" +344, 2, 12, 15, 30, 31, 49, 50, "." +344, 2, 13, 16, 32, 35, 51, 54, "doi" +344, 2, 14, 17, 36, 37, 55, 56, ":" +344, 2, 15, 18, 38, 40, 57, 59, "10" +344, 2, 16, 19, 41, 42, 60, 61, "." +344, 2, 17, 20, 43, 47, 62, 66, "1111" +344, 2, 18, 21, 48, 49, 67, 68, "/" +344, 2, 19, 22, 50, 51, 69, 70, "j" +344, 2, 20, 23, 52, 53, 71, 72, "." +344, 2, 21, 24, 54, 58, 73, 77, "1399" +344, 2, 22, 25, 59, 60, 78, 79, "-" +344, 2, 23, 26, 61, 65, 80, 84, "5448" +344, 2, 24, 27, 66, 67, 85, 86, "." +344, 2, 25, 28, 68, 72, 87, 91, "2008" +344, 2, 26, 29, 73, 74, 92, 93, "." +344, 2, 27, 30, 75, 80, 94, 99, "00434" +344, 2, 28, 31, 81, 82, 100, 101, "." +344, 2, 29, 32, 83, 84, 102, 103, "x" +344, 2, 30, 33, 85, 86, 104, 105, "." +344, 3, 1, 34, 0, 4, 106, 110, "Epub" +344, 3, 2, 35, 5, 9, 111, 115, "2008" +344, 3, 3, 36, 10, 13, 116, 119, "Aug" +344, 3, 4, 37, 14, 16, 120, 122, "27" +344, 3, 5, 38, 17, 18, 123, 124, "." +344, 4, 1, 39, 0, 5, 125, 130, "Short" +344, 4, 2, 40, 6, 7, 131, 132, "-" +344, 4, 3, 41, 8, 12, 133, 137, "term" +344, 4, 4, 42, 13, 22, 138, 147, "metabolic" +344, 4, 5, 43, 23, 26, 148, 151, "and" +344, 4, 6, 44, 27, 41, 152, 166, "cardiovascular" +344, 4, 7, 45, 42, 49, 167, 174, "effects" +344, 4, 8, 46, 50, 52, 175, 177, "of" +344, 4, 9, 47, 53, 62, 178, 187, "metformin" +344, 4, 10, 48, 63, 65, 188, 190, "in" +344, 4, 11, 49, 66, 74, 191, 199, "markedly" +344, 4, 12, 50, 75, 80, 200, 205, "obese" +344, 4, 13, 51, 81, 92, 206, 217, "adolescents" +344, 4, 14, 52, 93, 97, 218, 222, "with" +344, 4, 15, 53, 98, 104, 223, 229, "normal" +344, 4, 16, 54, 105, 112, 230, 237, "glucose" +344, 4, 17, 55, 113, 122, 238, 247, "tolerance" +344, 4, 18, 56, 123, 124, 248, 249, "." +344, 5, 1, 57, 0, 7, 250, 257, "Burgert" +344, 5, 2, 58, 8, 10, 258, 260, "TS" +344, 5, 3, 59, 11, 12, 261, 262, "(" +344, 5, 4, 60, 13, 14, 263, 264, "1" +344, 5, 5, 61, 15, 16, 265, 266, ")" +344, 5, 6, 62, 17, 18, 267, 268, "," +344, 5, 7, 63, 19, 24, 269, 274, "Duran" +344, 5, 8, 64, 25, 27, 275, 277, "EJ" +344, 5, 9, 65, 28, 29, 278, 279, "," +344, 5, 10, 66, 30, 38, 280, 288, "Goldberg" +344, 5, 11, 67, 39, 40, 289, 290, "-" +344, 5, 12, 68, 41, 45, 291, 295, "Gell" +344, 5, 13, 69, 46, 47, 296, 297, "R" +344, 5, 14, 70, 48, 49, 298, 299, "," +344, 5, 15, 71, 50, 56, 300, 306, "Dziura" +344, 5, 16, 72, 57, 58, 307, 308, "J" +344, 5, 17, 73, 59, 60, 309, 310, "," +344, 5, 18, 74, 61, 67, 311, 317, "Yeckel" +344, 5, 19, 75, 68, 70, 318, 320, "CW" +344, 5, 20, 76, 71, 72, 321, 322, "," +344, 5, 21, 77, 73, 77, 323, 327, "Katz" +344, 5, 22, 78, 78, 79, 328, 329, "S" +344, 5, 23, 79, 80, 81, 330, 331, "," +344, 5, 24, 80, 82, 92, 332, 342, "Tamborlane" +344, 5, 25, 81, 93, 95, 343, 345, "WV" +344, 5, 26, 82, 96, 97, 346, 347, "," +344, 5, 27, 83, 98, 104, 348, 354, "Caprio" +344, 5, 28, 84, 105, 106, 355, 356, "S" +344, 5, 29, 85, 107, 108, 357, 358, "." +344, 5, 30, 86, 109, 115, 359, 365, "Author" +344, 5, 31, 87, 116, 127, 366, 377, "information" +344, 5, 32, 88, 128, 129, 378, 379, ":" +344, 5, 33, 89, 130, 131, 380, 381, "(" +344, 5, 34, 90, 132, 133, 382, 383, "1" +344, 5, 35, 91, 134, 135, 384, 385, ")" +344, 5, 36, 92, 136, 146, 386, 396, "Department" +344, 5, 37, 93, 147, 149, 397, 399, "of" +344, 5, 38, 94, 150, 160, 400, 410, "Pediatrics" +344, 5, 39, 95, 161, 162, 411, 412, "," +344, 5, 40, 96, 163, 167, 413, 417, "Yale" +344, 5, 41, 97, 168, 178, 418, 428, "University" +344, 5, 42, 98, 179, 185, 429, 435, "School" +344, 5, 43, 99, 186, 188, 436, 438, "of" +344, 5, 44, 100, 189, 197, 439, 447, "Medicine" +344, 5, 45, 101, 198, 199, 448, 449, "," +344, 5, 46, 102, 200, 203, 450, 453, "New" +344, 5, 47, 103, 204, 209, 454, 459, "Haven" +344, 5, 48, 104, 210, 211, 460, 461, "," +344, 5, 49, 105, 212, 214, 462, 464, "CT" +344, 5, 50, 106, 215, 220, 465, 470, "06520" +344, 5, 51, 107, 221, 222, 471, 472, "," +344, 5, 52, 108, 223, 226, 473, 476, "USA" +344, 5, 53, 109, 227, 228, 477, 478, "." +344, 6, 1, 110, 0, 5, 479, 484, "tania" +344, 6, 2, 111, 6, 7, 485, 486, "." +344, 6, 3, 112, 8, 15, 487, 494, "burgert" +344, 6, 4, 113, 16, 17, 495, 496, "@" +344, 6, 5, 114, 18, 22, 497, 501, "yale" +344, 6, 6, 115, 23, 24, 502, 503, "." +344, 6, 7, 116, 25, 28, 504, 507, "edu" +344, 6, 8, 117, 29, 38, 508, 517, "OBJECTIVE" +344, 6, 9, 118, 39, 40, 518, 519, ":" +344, 6, 10, 119, 41, 49, 520, 528, "Although" +344, 6, 11, 120, 50, 59, 529, 538, "metformin" +344, 6, 12, 121, 60, 61, 539, 540, "(" +344, 6, 13, 122, 62, 65, 541, 544, "MET" +344, 6, 14, 123, 66, 67, 545, 546, ")" +344, 6, 15, 124, 68, 70, 547, 549, "is" +344, 6, 16, 125, 71, 73, 550, 552, "an" +344, 6, 17, 126, 74, 81, 553, 560, "insulin" +344, 6, 18, 127, 82, 92, 561, 571, "sensitizer" +344, 6, 19, 128, 93, 102, 572, 581, "currently" +344, 6, 20, 129, 103, 107, 582, 586, "used" +344, 6, 21, 130, 108, 110, 587, 589, "as" +344, 6, 22, 131, 111, 113, 590, 592, "an" +344, 6, 23, 132, 114, 121, 593, 600, "adjunct" +344, 6, 24, 133, 122, 124, 601, 603, "to" +344, 6, 25, 134, 125, 128, 604, 607, "the" +344, 6, 26, 135, 129, 138, 608, 617, "treatment" +344, 6, 27, 136, 139, 141, 618, 620, "of" +344, 6, 28, 137, 142, 146, 621, 625, "some" +344, 6, 29, 138, 147, 149, 626, 628, "of" +344, 6, 30, 139, 150, 153, 629, 632, "the" +344, 6, 31, 140, 154, 167, 633, 646, "complications" +344, 6, 32, 141, 168, 170, 647, 649, "of" +344, 6, 33, 142, 171, 180, 650, 659, "childhood" +344, 6, 34, 143, 181, 188, 660, 667, "obesity" +344, 6, 35, 144, 189, 196, 668, 675, "besides" +344, 6, 36, 145, 197, 201, 676, 680, "type" +344, 6, 37, 146, 202, 203, 681, 682, "2" +344, 6, 38, 147, 204, 212, 683, 691, "diabetes" +344, 6, 39, 148, 213, 221, 692, 700, "mellitus" +344, 6, 40, 149, 222, 223, 701, 702, "," +344, 6, 41, 150, 224, 227, 703, 706, "few" +344, 6, 42, 151, 228, 235, 707, 714, "studies" +344, 6, 43, 152, 236, 240, 715, 719, "have" +344, 6, 44, 153, 241, 256, 720, 735, "comprehensively" +344, 6, 45, 154, 257, 265, 736, 744, "examined" +344, 6, 46, 155, 266, 269, 745, 748, "its" +344, 6, 47, 156, 270, 279, 749, 758, "metabolic" +344, 6, 48, 157, 280, 283, 759, 762, "and" +344, 6, 49, 158, 284, 292, 763, 771, "clinical" +344, 6, 50, 159, 293, 300, 772, 779, "effects" +344, 6, 51, 160, 301, 303, 780, 782, "in" +344, 6, 52, 161, 304, 309, 783, 788, "obese" +344, 6, 53, 162, 310, 318, 789, 797, "children" +344, 6, 54, 163, 319, 323, 798, 802, "with" +344, 6, 55, 164, 324, 330, 803, 809, "normal" +344, 6, 56, 165, 331, 338, 810, 817, "glucose" +344, 6, 57, 166, 339, 348, 818, 827, "tolerance" +344, 6, 58, 167, 349, 350, 828, 829, "(" +344, 6, 59, 168, 351, 354, 830, 833, "NGT" +344, 6, 60, 169, 355, 356, 834, 835, ")" +344, 6, 61, 170, 357, 358, 836, 837, "." +344, 7, 1, 171, 0, 7, 838, 845, "METHODS" +344, 7, 2, 172, 8, 9, 846, 847, ":" +344, 7, 3, 173, 10, 12, 848, 850, "We" +344, 7, 4, 174, 13, 22, 851, 860, "therefore" +344, 7, 5, 175, 23, 32, 861, 870, "conducted" +344, 7, 6, 176, 33, 34, 871, 872, "a" +344, 7, 7, 177, 35, 36, 873, 874, "4" +344, 7, 8, 178, 37, 38, 875, 876, "-" +344, 7, 9, 179, 39, 44, 877, 882, "month" +344, 7, 10, 180, 45, 51, 883, 889, "double" +344, 7, 11, 181, 52, 53, 890, 891, "-" +344, 7, 12, 182, 54, 59, 892, 897, "blind" +344, 7, 13, 183, 60, 68, 898, 906, "clinical" +344, 7, 14, 184, 69, 74, 907, 912, "trial" +344, 7, 15, 185, 75, 77, 913, 915, "in" +344, 7, 16, 186, 78, 80, 916, 918, "28" +344, 7, 17, 187, 81, 86, 919, 924, "obese" +344, 7, 18, 188, 87, 88, 925, 926, "[" +344, 7, 19, 189, 89, 93, 927, 931, "mean" +344, 7, 20, 190, 94, 98, 932, 936, "body" +344, 7, 21, 191, 99, 103, 937, 941, "mass" +344, 7, 22, 192, 104, 109, 942, 947, "index" +344, 7, 23, 193, 110, 111, 948, 949, "(" +344, 7, 24, 194, 112, 115, 950, 953, "BMI" +344, 7, 25, 195, 116, 117, 954, 955, ")" +344, 7, 26, 196, 118, 119, 956, 957, ":" +344, 7, 27, 197, 120, 122, 958, 960, "40" +344, 7, 28, 198, 123, 124, 961, 962, "." +344, 7, 29, 199, 125, 126, 963, 964, "3" +344, 7, 30, 200, 127, 128, 965, 966, "+" +344, 7, 31, 201, 129, 130, 967, 968, "/" +344, 7, 32, 202, 131, 132, 969, 970, "-" +344, 7, 33, 203, 133, 134, 971, 972, "5" +344, 7, 34, 204, 135, 136, 973, 974, "." +344, 7, 35, 205, 137, 138, 975, 976, "7" +344, 7, 36, 206, 139, 141, 977, 979, "kg" +344, 7, 37, 207, 142, 143, 980, 981, "/" +344, 7, 38, 208, 144, 145, 982, 983, "m" +344, 7, 39, 209, 146, 147, 984, 985, "(" +344, 7, 40, 210, 148, 149, 986, 987, "2" +344, 7, 41, 211, 150, 151, 988, 989, ")" +344, 7, 42, 212, 152, 153, 990, 991, "]" +344, 7, 43, 213, 154, 155, 992, 993, "," +344, 7, 44, 214, 156, 163, 994, 1001, "insulin" +344, 7, 45, 215, 164, 165, 1002, 1003, "-" +344, 7, 46, 216, 166, 175, 1004, 1013, "resistant" +344, 7, 47, 217, 176, 177, 1014, 1015, "[" +344, 7, 48, 218, 178, 189, 1016, 1027, "homeostasis" +344, 7, 49, 219, 190, 195, 1028, 1033, "model" +344, 7, 50, 220, 196, 206, 1034, 1044, "assessment" +344, 7, 51, 221, 207, 208, 1045, 1046, "-" +344, 7, 52, 222, 209, 216, 1047, 1054, "insulin" +344, 7, 53, 223, 217, 227, 1055, 1065, "resistance" +344, 7, 54, 224, 228, 229, 1066, 1067, ":" +344, 7, 55, 225, 230, 231, 1068, 1069, "7" +344, 7, 56, 226, 232, 233, 1070, 1071, "." +344, 7, 57, 227, 234, 235, 1072, 1073, "6" +344, 7, 58, 228, 236, 237, 1074, 1075, "+" +344, 7, 59, 229, 238, 239, 1076, 1077, "/" +344, 7, 60, 230, 240, 241, 1078, 1079, "-" +344, 7, 61, 231, 242, 243, 1080, 1081, "2" +344, 7, 62, 232, 244, 245, 1082, 1083, "." +344, 7, 63, 233, 246, 247, 1084, 1085, "8" +344, 7, 64, 234, 248, 251, 1086, 1089, "and" +344, 7, 65, 235, 252, 257, 1090, 1095, "whole" +344, 7, 66, 236, 258, 262, 1096, 1100, "body" +344, 7, 67, 237, 263, 270, 1101, 1108, "insulin" +344, 7, 68, 238, 271, 282, 1109, 1120, "sensitivity" +344, 7, 69, 239, 283, 288, 1121, 1126, "index" +344, 7, 70, 240, 289, 290, 1127, 1128, "(" +344, 7, 71, 241, 291, 296, 1129, 1134, "WBISI" +344, 7, 72, 242, 297, 298, 1135, 1136, ")" +344, 7, 73, 243, 299, 300, 1137, 1138, ":" +344, 7, 74, 244, 301, 302, 1139, 1140, "1" +344, 7, 75, 245, 303, 304, 1141, 1142, "." +344, 7, 76, 246, 305, 306, 1143, 1144, "5" +344, 7, 77, 247, 307, 308, 1145, 1146, "+" +344, 7, 78, 248, 309, 310, 1147, 1148, "/" +344, 7, 79, 249, 311, 312, 1149, 1150, "-" +344, 7, 80, 250, 313, 314, 1151, 1152, "0" +344, 7, 81, 251, 315, 316, 1153, 1154, "." +344, 7, 82, 252, 317, 318, 1155, 1156, "7" +344, 7, 83, 253, 319, 320, 1157, 1158, "]" +344, 7, 84, 254, 321, 332, 1159, 1170, "adolescents" +344, 7, 85, 255, 333, 334, 1171, 1172, "(" +344, 7, 86, 256, 335, 338, 1173, 1176, "age" +344, 7, 87, 257, 339, 341, 1177, 1179, "15" +344, 7, 88, 258, 342, 343, 1180, 1181, "." +344, 7, 89, 259, 344, 345, 1182, 1183, "0" +344, 7, 90, 260, 346, 347, 1184, 1185, "+" +344, 7, 91, 261, 348, 349, 1186, 1187, "/" +344, 7, 92, 262, 350, 351, 1188, 1189, "-" +344, 7, 93, 263, 352, 353, 1190, 1191, "1" +344, 7, 94, 264, 354, 355, 1192, 1193, "." +344, 7, 95, 265, 356, 357, 1194, 1195, "3" +344, 7, 96, 266, 358, 360, 1196, 1198, "yr" +344, 7, 97, 267, 361, 362, 1199, 1200, ")" +344, 7, 98, 268, 363, 373, 1201, 1211, "randomized" +344, 7, 99, 269, 374, 376, 1212, 1214, "to" +344, 7, 100, 270, 377, 380, 1215, 1218, "MET" +344, 7, 101, 271, 381, 382, 1219, 1220, "(" +344, 7, 102, 272, 383, 384, 1221, 1222, "n" +344, 7, 103, 273, 385, 386, 1223, 1224, "=" +344, 7, 104, 274, 387, 389, 1225, 1227, "15" +344, 7, 105, 275, 390, 391, 1228, 1229, "," +344, 7, 106, 276, 392, 396, 1230, 1234, "dose" +344, 7, 107, 277, 397, 401, 1235, 1239, "1500" +344, 7, 108, 278, 402, 404, 1240, 1242, "mg" +344, 7, 109, 279, 405, 410, 1243, 1248, "daily" +344, 7, 110, 280, 411, 412, 1249, 1250, ")" +344, 7, 111, 281, 413, 415, 1251, 1253, "or" +344, 7, 112, 282, 416, 423, 1254, 1261, "placebo" +344, 7, 113, 283, 424, 425, 1262, 1263, "(" +344, 7, 114, 284, 426, 427, 1264, 1265, "n" +344, 7, 115, 285, 428, 429, 1266, 1267, "=" +344, 7, 116, 286, 430, 432, 1268, 1270, "13" +344, 7, 117, 287, 433, 434, 1271, 1272, ")" +344, 7, 118, 288, 435, 436, 1273, 1274, "." +344, 8, 1, 289, 0, 7, 1275, 1282, "RESULTS" +344, 8, 2, 290, 8, 9, 1283, 1284, ":" +344, 8, 3, 291, 10, 13, 1285, 1288, "The" +344, 8, 4, 292, 14, 23, 1289, 1298, "treatment" +344, 8, 5, 293, 24, 28, 1299, 1303, "with" +344, 8, 6, 294, 29, 32, 1304, 1307, "MET" +344, 8, 7, 295, 33, 36, 1308, 1311, "was" +344, 8, 8, 296, 37, 41, 1312, 1316, "well" +344, 8, 9, 297, 42, 51, 1317, 1326, "tolerated" +344, 8, 10, 298, 52, 53, 1327, 1328, "." +344, 9, 1, 299, 0, 3, 1329, 1332, "MET" +344, 9, 2, 300, 4, 13, 1333, 1342, "treatment" +344, 9, 3, 301, 14, 17, 1343, 1346, "was" +344, 9, 4, 302, 18, 28, 1347, 1357, "associated" +344, 9, 5, 303, 29, 33, 1358, 1362, "with" +344, 9, 6, 304, 34, 35, 1363, 1364, "a" +344, 9, 7, 305, 36, 45, 1365, 1374, "decreased" +344, 9, 8, 306, 46, 49, 1375, 1378, "BMI" +344, 9, 9, 307, 50, 51, 1379, 1380, "(" +344, 9, 10, 308, 52, 53, 1381, 1382, "p" +344, 9, 11, 309, 54, 55, 1383, 1384, "=" +344, 9, 12, 310, 56, 57, 1385, 1386, "0" +344, 9, 13, 311, 58, 59, 1387, 1388, "." +344, 9, 14, 312, 60, 62, 1389, 1391, "02" +344, 9, 15, 313, 63, 64, 1392, 1393, ")" +344, 9, 16, 314, 65, 67, 1394, 1396, "as" +344, 9, 17, 315, 68, 72, 1397, 1401, "well" +344, 9, 18, 316, 73, 75, 1402, 1404, "as" +344, 9, 19, 317, 76, 80, 1405, 1409, "with" +344, 9, 20, 318, 81, 82, 1410, 1411, "a" +344, 9, 21, 319, 83, 92, 1412, 1421, "reduction" +344, 9, 22, 320, 93, 95, 1422, 1424, "in" +344, 9, 23, 321, 96, 108, 1425, 1437, "subcutaneous" +344, 9, 24, 322, 109, 112, 1438, 1441, "fat" +344, 9, 25, 323, 113, 114, 1442, 1443, "(" +344, 9, 26, 324, 115, 116, 1444, 1445, "p" +344, 9, 27, 325, 117, 118, 1446, 1447, "=" +344, 9, 28, 326, 119, 120, 1448, 1449, "0" +344, 9, 29, 327, 121, 122, 1450, 1451, "." +344, 9, 30, 328, 123, 125, 1452, 1454, "03" +344, 9, 31, 329, 126, 127, 1455, 1456, ")" +344, 9, 32, 330, 128, 129, 1457, 1458, "," +344, 9, 33, 331, 130, 142, 1459, 1471, "particularly" +344, 9, 34, 332, 143, 146, 1472, 1475, "the" +344, 9, 35, 333, 147, 151, 1476, 1480, "deep" +344, 9, 36, 334, 152, 164, 1481, 1493, "subcutaneous" +344, 9, 37, 335, 165, 168, 1494, 1497, "fat" +344, 9, 38, 336, 169, 170, 1498, 1499, "(" +344, 9, 39, 337, 171, 172, 1500, 1501, "p" +344, 9, 40, 338, 173, 174, 1502, 1503, "=" +344, 9, 41, 339, 175, 176, 1504, 1505, "0" +344, 9, 42, 340, 177, 178, 1506, 1507, "." +344, 9, 43, 341, 179, 181, 1508, 1510, "04" +344, 9, 44, 342, 182, 183, 1511, 1512, ")" +344, 9, 45, 343, 184, 186, 1513, 1515, "as" +344, 9, 46, 344, 187, 195, 1516, 1524, "assessed" +344, 9, 47, 345, 196, 198, 1525, 1527, "by" +344, 9, 48, 346, 199, 207, 1528, 1536, "magnetic" +344, 9, 49, 347, 208, 217, 1537, 1546, "resonance" +344, 9, 50, 348, 218, 225, 1547, 1554, "imaging" +344, 9, 51, 349, 226, 227, 1555, 1556, "." +344, 10, 1, 350, 0, 16, 1557, 1573, "Postintervention" +344, 10, 2, 351, 17, 18, 1574, 1575, "," +344, 10, 3, 352, 19, 22, 1576, 1579, "the" +344, 10, 4, 353, 23, 26, 1580, 1583, "MET" +344, 10, 5, 354, 27, 32, 1584, 1589, "group" +344, 10, 6, 355, 33, 36, 1590, 1593, "had" +344, 10, 7, 356, 37, 38, 1594, 1595, "a" +344, 10, 8, 357, 39, 41, 1596, 1598, "35" +344, 10, 9, 358, 42, 43, 1599, 1600, "%" +344, 10, 10, 359, 44, 55, 1601, 1612, "improvement" +344, 10, 11, 360, 56, 58, 1613, 1615, "in" +344, 10, 12, 361, 59, 66, 1616, 1623, "insulin" +344, 10, 13, 362, 67, 78, 1624, 1635, "sensitivity" +344, 10, 14, 363, 79, 80, 1636, 1637, "(" +344, 10, 15, 364, 81, 86, 1638, 1643, "WBISI" +344, 10, 16, 365, 87, 88, 1644, 1645, ")" +344, 10, 17, 366, 89, 97, 1646, 1654, "compared" +344, 10, 18, 367, 98, 102, 1655, 1659, "with" +344, 10, 19, 368, 103, 106, 1660, 1663, "the" +344, 10, 20, 369, 107, 114, 1664, 1671, "placebo" +344, 10, 21, 370, 115, 120, 1672, 1677, "group" +344, 10, 22, 371, 121, 122, 1678, 1679, "(" +344, 10, 23, 372, 123, 124, 1680, 1681, "p" +344, 10, 24, 373, 125, 126, 1682, 1683, "=" +344, 10, 25, 374, 127, 128, 1684, 1685, "0" +344, 10, 26, 375, 129, 130, 1686, 1687, "." +344, 10, 27, 376, 131, 134, 1688, 1691, "008" +344, 10, 28, 377, 135, 136, 1692, 1693, ")" +344, 10, 29, 378, 137, 138, 1694, 1695, "." +344, 11, 1, 379, 0, 7, 1696, 1703, "However" +344, 11, 2, 380, 8, 9, 1704, 1705, "," +344, 11, 3, 381, 10, 22, 1706, 1718, "significance" +344, 11, 4, 382, 23, 26, 1719, 1722, "was" +344, 11, 5, 383, 27, 31, 1723, 1727, "lost" +344, 11, 6, 384, 32, 36, 1728, 1732, "with" +344, 11, 7, 385, 37, 48, 1733, 1744, "adjustments" +344, 11, 8, 386, 49, 52, 1745, 1748, "for" +344, 11, 9, 387, 53, 64, 1749, 1760, "differences" +344, 11, 10, 388, 65, 67, 1761, 1763, "in" +344, 11, 11, 389, 68, 76, 1764, 1772, "baseline" +344, 11, 12, 390, 77, 84, 1773, 1780, "insulin" +344, 11, 13, 391, 85, 96, 1781, 1792, "sensitivity" +344, 11, 14, 392, 97, 98, 1793, 1794, "(" +344, 11, 15, 393, 99, 100, 1795, 1796, "p" +344, 11, 16, 394, 101, 102, 1797, 1798, "=" +344, 11, 17, 395, 103, 104, 1799, 1800, "0" +344, 11, 18, 396, 105, 106, 1801, 1802, "." +344, 11, 19, 397, 107, 109, 1803, 1805, "09" +344, 11, 20, 398, 110, 111, 1806, 1807, ")" +344, 11, 21, 399, 112, 113, 1808, 1809, "." +344, 12, 1, 400, 0, 5, 1810, 1815, "While" +344, 12, 2, 401, 6, 11, 1816, 1821, "there" +344, 12, 3, 402, 12, 15, 1822, 1825, "was" +344, 12, 4, 403, 16, 18, 1826, 1828, "no" +344, 12, 5, 404, 19, 25, 1829, 1835, "change" +344, 12, 6, 405, 26, 28, 1836, 1838, "in" +344, 12, 7, 406, 29, 41, 1839, 1851, "inflammatory" +344, 12, 8, 407, 42, 51, 1852, 1861, "cytokines" +344, 12, 9, 408, 52, 54, 1862, 1864, "or" +344, 12, 10, 409, 55, 60, 1865, 1870, "lipid" +344, 12, 11, 410, 61, 71, 1871, 1881, "parameters" +344, 12, 12, 411, 72, 73, 1882, 1883, "," +344, 12, 13, 412, 74, 88, 1884, 1898, "cardiovascular" +344, 12, 14, 413, 89, 97, 1899, 1907, "function" +344, 12, 15, 414, 98, 100, 1908, 1910, "as" +344, 12, 16, 415, 101, 109, 1911, 1919, "assessed" +344, 12, 17, 416, 110, 112, 1920, 1922, "by" +344, 12, 18, 417, 113, 118, 1923, 1928, "heart" +344, 12, 19, 418, 119, 123, 1929, 1933, "rate" +344, 12, 20, 419, 124, 132, 1934, 1942, "recovery" +344, 12, 21, 420, 133, 138, 1943, 1948, "after" +344, 12, 22, 421, 139, 147, 1949, 1957, "exercise" +344, 12, 23, 422, 148, 156, 1958, 1966, "improved" +344, 12, 24, 423, 157, 161, 1967, 1971, "with" +344, 12, 25, 424, 162, 165, 1972, 1975, "MET" +344, 12, 26, 425, 166, 169, 1976, 1979, "and" +344, 12, 27, 426, 170, 178, 1980, 1988, "worsened" +344, 12, 28, 427, 179, 181, 1989, 1991, "in" +344, 12, 29, 428, 182, 189, 1992, 1999, "placebo" +344, 12, 30, 429, 190, 191, 2000, 2001, "(" +344, 12, 31, 430, 192, 193, 2002, 2003, "p" +344, 12, 32, 431, 194, 195, 2004, 2005, "=" +344, 12, 33, 432, 196, 197, 2006, 2007, "0" +344, 12, 34, 433, 198, 199, 2008, 2009, "." +344, 12, 35, 434, 200, 202, 2010, 2012, "03" +344, 12, 36, 435, 203, 204, 2013, 2014, ")" +344, 12, 37, 436, 205, 206, 2015, 2016, "." +344, 13, 1, 437, 0, 10, 2017, 2027, "CONCLUSION" +344, 13, 2, 438, 11, 12, 2028, 2029, ":" +344, 13, 3, 439, 13, 18, 2030, 2035, "Short" +344, 13, 4, 440, 19, 20, 2036, 2037, "-" +344, 13, 5, 441, 21, 25, 2038, 2042, "term" +344, 13, 6, 442, 26, 29, 2043, 2046, "use" +344, 13, 7, 443, 30, 32, 2047, 2049, "of" +344, 13, 8, 444, 33, 36, 2050, 2053, "MET" +344, 13, 9, 445, 37, 39, 2054, 2056, "is" +344, 13, 10, 446, 40, 44, 2057, 2061, "well" +344, 13, 11, 447, 45, 54, 2062, 2071, "tolerated" +344, 13, 12, 448, 55, 57, 2072, 2074, "by" +344, 13, 13, 449, 58, 63, 2075, 2080, "obese" +344, 13, 14, 450, 64, 72, 2081, 2089, "children" +344, 13, 15, 451, 73, 77, 2090, 2094, "with" +344, 13, 16, 452, 78, 81, 2095, 2098, "NGT" +344, 13, 17, 453, 82, 85, 2099, 2102, "and" +344, 13, 18, 454, 86, 89, 2103, 2106, "has" +344, 13, 19, 455, 90, 91, 2107, 2108, "a" +344, 13, 20, 456, 92, 102, 2109, 2119, "beneficial" +344, 13, 21, 457, 103, 109, 2120, 2126, "effect" +344, 13, 22, 458, 110, 112, 2127, 2129, "on" +344, 13, 23, 459, 113, 116, 2130, 2133, "BMI" +344, 13, 24, 460, 117, 120, 2134, 2137, "and" +344, 13, 25, 461, 121, 130, 2138, 2147, "autonomic" +344, 13, 26, 462, 131, 138, 2148, 2155, "control" +344, 13, 27, 463, 139, 141, 2156, 2158, "of" +344, 13, 28, 464, 142, 145, 2159, 2162, "the" +344, 13, 29, 465, 146, 151, 2163, 2168, "heart" +344, 13, 30, 466, 152, 154, 2169, 2171, "as" +344, 13, 31, 467, 155, 159, 2172, 2176, "well" +344, 13, 32, 468, 160, 162, 2177, 2179, "as" +344, 13, 33, 469, 163, 164, 2180, 2181, "a" +344, 13, 34, 470, 165, 170, 2182, 2187, "trend" +344, 13, 35, 471, 171, 177, 2188, 2194, "toward" +344, 13, 36, 472, 178, 186, 2195, 2203, "improved" +344, 13, 37, 473, 187, 194, 2204, 2211, "insulin" +344, 13, 38, 474, 195, 206, 2212, 2223, "sensitivity" +344, 13, 39, 475, 207, 208, 2224, 2225, "." +344, 14, 1, 476, 0, 4, 2226, 2230, "Thus" +344, 14, 2, 477, 5, 6, 2231, 2232, "," +344, 14, 3, 478, 7, 11, 2233, 2237, "long" +344, 14, 4, 479, 12, 13, 2238, 2239, "-" +344, 14, 5, 480, 14, 18, 2240, 2244, "term" +344, 14, 6, 481, 19, 28, 2245, 2254, "treatment" +344, 14, 7, 482, 29, 33, 2255, 2259, "with" +344, 14, 8, 483, 34, 37, 2260, 2263, "MET" +344, 14, 9, 484, 38, 41, 2264, 2267, "may" +344, 14, 10, 485, 42, 49, 2268, 2275, "provide" +344, 14, 11, 486, 50, 51, 2276, 2277, "a" +344, 14, 12, 487, 52, 57, 2278, 2283, "means" +344, 14, 13, 488, 58, 60, 2284, 2286, "to" +344, 14, 14, 489, 61, 71, 2287, 2297, "ameliorate" +344, 14, 15, 490, 72, 75, 2298, 2301, "the" +344, 14, 16, 491, 76, 82, 2302, 2308, "cardio" +344, 14, 17, 492, 83, 84, 2309, 2310, "-" +344, 14, 18, 493, 85, 94, 2311, 2320, "metabolic" +344, 14, 19, 494, 95, 107, 2321, 2333, "consequences" +344, 14, 20, 495, 108, 110, 2334, 2336, "of" +344, 14, 21, 496, 111, 121, 2337, 2347, "adolescent" +344, 14, 22, 497, 122, 129, 2348, 2355, "obesity" +344, 14, 23, 498, 130, 131, 2356, 2357, "." +344, 15, 1, 499, 0, 3, 2358, 2361, "DOI" +344, 15, 2, 500, 4, 5, 2362, 2363, ":" +344, 15, 3, 501, 6, 8, 2364, 2366, "10" +344, 15, 4, 502, 9, 10, 2367, 2368, "." +344, 15, 5, 503, 11, 15, 2369, 2373, "1111" +344, 15, 6, 504, 16, 17, 2374, 2375, "/" +344, 15, 7, 505, 18, 19, 2376, 2377, "j" +344, 15, 8, 506, 20, 21, 2378, 2379, "." +344, 15, 9, 507, 22, 26, 2380, 2384, "1399" +344, 15, 10, 508, 27, 28, 2385, 2386, "-" +344, 15, 11, 509, 29, 33, 2387, 2391, "5448" +344, 15, 12, 510, 34, 35, 2392, 2393, "." +344, 15, 13, 511, 36, 40, 2394, 2398, "2008" +344, 15, 14, 512, 41, 42, 2399, 2400, "." +344, 15, 15, 513, 43, 48, 2401, 2406, "00434" +344, 15, 16, 514, 49, 50, 2407, 2408, "." +344, 15, 17, 515, 51, 52, 2409, 2410, "x" +344, 15, 18, 516, 53, 57, 2411, 2415, "PMID" +344, 15, 19, 517, 58, 59, 2416, 2417, ":" +344, 15, 20, 518, 60, 68, 2418, 2426, "18761646" +344, 15, 21, 519, 69, 70, 2427, 2428, "[" +344, 15, 22, 520, 71, 78, 2429, 2436, "Indexed" +344, 15, 23, 521, 79, 82, 2437, 2440, "for" +344, 15, 24, 522, 83, 90, 2441, 2448, "MEDLINE" +344, 15, 25, 523, 91, 92, 2449, 2450, "]" diff --git a/data/dm2 18761646_kwoodley.annodb b/data/dm2 18761646_kwoodley.annodb new file mode 100644 index 0000000..69e2e07 --- /dev/null +++ b/data/dm2 18761646_kwoodley.annodb @@ -0,0 +1,77 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6794, Journal, 0, 16, "Pediatr Diabetes", "", +6795, PublicationYear, 19, 23, "2008", "", +6796, PublicationYear, 111, 115, "2008", "", +36899, Title, 125, 249, "Short - term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance .", "", +6797, Metformin, 178, 187, "metformin", "", +6798, Precondition, 191, 247, "markedly obese adolescents with normal glucose tolerance", "", +6800, Author, 250, 260, "Burgert TS", "", +6801, Author, 269, 277, "Duran EJ", "", +6802, Author, 280, 297, "Goldberg - Gell R", "", +6803, Author, 300, 308, "Dziura J", "", +6804, Author, 311, 320, "Yeckel CW", "", +6805, Author, 323, 329, "Katz S", "", +6806, Author, 332, 345, "Tamborlane WV", "", +6807, Author, 348, 356, "Caprio S", "", +6808, USA, 473, 476, "USA", "", +6814, ObjectiveDescription, 520, 702, "Although metformin ( MET ) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus ,", "", +6809, Metformin, 529, 538, "metformin", "", +6810, Metformin, 541, 544, "MET", "", +6811, Insulin, 553, 560, "insulin", "", +6812, Type2Diabetes, 676, 700, "type 2 diabetes mellitus", "", +36900, ObjectiveDescription, 703, 837, "few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance ( NGT ) .", "", +6813, Precondition, 783, 835, "obese children with normal glucose tolerance ( NGT )", "", +6816, Duration, 873, 882, "4 - month", "", +6817, DoubleBlind, 883, 897, "double - blind", "", +6818, NumberPatientsCT, 916, 918, "28", "", +6834, Precondition, 919, 1170, "obese [ mean body mass index ( BMI ) : 40 . 3 + / - 5 . 7 kg / m ( 2 ) ] , insulin - resistant [ homeostasis model assessment - insulin resistance : 7 . 6 + / - 2 . 8 and whole body insulin sensitivity index ( WBISI ) : 1 . 5 + / - 0 . 7 ] adolescents", "", +6819, BMI, 932, 947, "body mass index", "", +6820, BMI, 950, 953, "BMI", "", +6821, Kg_per_squareMeter, 977, 989, "kg / m ( 2 )", "", +6822, Insulin, 994, 1001, "insulin", "", +6823, Insulin, 1047, 1054, "insulin", "", +6824, Insulin, 1101, 1108, "insulin", "", +6825, AvgAge, 1177, 1183, "15 . 0", "", +6826, Randomized, 1201, 1211, "randomized", "", +6827, Metformin, 1215, 1218, "MET", "", +6828, NumberPatientsArm, 1225, 1227, "15", "", +6829, DoseValue, 1235, 1239, "1500", "", +6830, mg, 1240, 1242, "mg", "", +6831, Frequency, 1243, 1248, "daily", "", +6832, Placebo, 1254, 1261, "placebo", "", +6833, NumberPatientsArm, 1268, 1270, "13", "", +6835, Metformin, 1304, 1307, "MET", "", +6836, Metformin, 1329, 1332, "MET", "", +6837, BMI, 1375, 1378, "BMI", "", +6840, PValueChangeValue, 1381, 1391, "p = 0 . 02", "", +6838, EndPointDescription, 1425, 1441, "subcutaneous fat", "", +6841, PValueChangeValue, 1444, 1454, "p = 0 . 03", "", +8470, SubGroupDescription, 1476, 1497, "deep subcutaneous fat", "", +6842, PValueChangeValue, 1500, 1510, "p = 0 . 04", "", +6843, MeasurementDevice, 1528, 1554, "magnetic resonance imaging", "", +6844, Metformin, 1580, 1583, "MET", "", +6845, RelativeChangeValue, 1596, 1598, "35", "", +6849, ObservedResult, 1601, 1612, "improvement", "", +6847, EndPointDescription, 1616, 1635, "insulin sensitivity", "", +6848, EndPointDescription, 1638, 1643, "WBISI", "", +6850, Placebo, 1664, 1671, "placebo", "", +6851, PvalueDiff, 1680, 1691, "p = 0 . 008", "", +6853, EndPointDescription, 1773, 1792, "insulin sensitivity", "", +6852, PvalueDiff, 1795, 1805, "p = 0 . 09", "", +6862, ObservedResult, 1810, 1835, "While there was no change", "", +6854, EndPointDescription, 1839, 1861, "inflammatory cytokines", "", +6855, EndPointDescription, 1865, 1881, "lipid parameters", "", +6856, EndPointDescription, 1884, 1907, "cardiovascular function", "", +6860, ObservedResult, 1884, 2014, "cardiovascular function as assessed by heart rate recovery after exercise improved with MET and worsened in placebo ( p = 0 . 03 )", "", +6857, Metformin, 1972, 1975, "MET", "", +6858, Placebo, 1992, 1999, "placebo", "", +6859, PvalueDiff, 2002, 2012, "p = 0 . 03", "", +36901, ConclusionComment, 2030, 2225, "Short - term use of MET is well tolerated by obese children with NGT and has a beneficial effect on BMI and autonomic control of the heart as well as a trend toward improved insulin sensitivity .", "", +6861, Metformin, 2050, 2053, "MET", "", +6863, Precondition, 2075, 2098, "obese children with NGT", "", +6864, BMI, 2130, 2133, "BMI", "", +6866, EndPointDescription, 2138, 2168, "autonomic control of the heart", "", +6865, EndPointDescription, 2204, 2223, "insulin sensitivity", "", +36902, ConclusionComment, 2226, 2357, "Thus , long - term treatment with MET may provide a means to ameliorate the cardio - metabolic consequences of adolescent obesity .", "", +6868, Metformin, 2260, 2263, "MET", "", +6869, PMID, 2418, 2426, "18761646", "", diff --git a/data/dm2 18761646_kwoodley.n-triples b/data/dm2 18761646_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18761646_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18936501 copy_admin.annodb b/data/dm2 18936501 copy_admin.annodb new file mode 100644 index 0000000..2de4d78 --- /dev/null +++ b/data/dm2 18936501 copy_admin.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Ann Intern Med .", "", " \"Ann Intern Med .\"." +1, PublicationYear, 17, 21, "2008", "", " \"2008\"." +97, Title, 53, 219, "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .", "", " \"Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .\"." +52171, LisproProtamine, 65, 97, "neutral protamine lispro insulin", "", +2, InsulinGlargine, 101, 117, "insulin glargine", "", +94, Type2Diabetes, 126, 141, "type 2 diabetes", "", " ." +4, Precondition, 155, 196, "patients with suboptimal glycemic control", "", " \"patients with suboptimal glycemic control\"." +5, Randomized, 201, 211, "randomized", "", " ." +6, Author, 220, 230, "Esposito K", "", " \"Esposito K\"." +7, Author, 239, 248, "Ciotola M", "", " \"Ciotola M\"." +8, Author, 251, 262, "Maiorino MI", "", " \"Maiorino MI\"." +9, Author, 265, 276, "Gualdiero R", "", " \"Gualdiero R\"." +10, Author, 279, 289, "Schisano B", "", " \"Schisano B\"." +11, Author, 292, 302, "Ceriello A", "", " \"Ceriello A\"." +12, Author, 305, 315, "Beneduce F", "", " \"Beneduce F\"." +13, Author, 318, 325, "Feola G", "", " \"Feola G\"." +14, Author, 328, 339, "Giugliano D", "", " \"Giugliano D\"." +15, Italy, 446, 451, "Italy", "", " ." +16, Insulin, 686, 693, "insulin", "", +108, Bedtime, 697, 704, "bedtime", "", +19, Precondition, 742, 816, "patients with type 2 diabetes that is poorly controlled with oral regimens", "", " \"patients with type 2 diabetes that is poorly controlled with oral regimens\"." +17, Type2Diabetes, 756, 771, "type 2 diabetes", "", +52176, LisproProtamine, 819, 843, "Neutral protamine lispro", "", +52177, LisproProtamine, 846, 849, "NPL", "", +20, Insulin, 852, 859, "insulin", "", +21, Hypoglycemia, 926, 938, "hypoglycemic", "", +114, Insulin, 959, 993, "neutral protamine Hagedorn insulin", "", +125, ObjectiveDescription, 1008, 1224, "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .", "", " \"To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .\"." +118, Bedtime, 1055, 1062, "bedtime", "", +52179, LisproProtamine, 1063, 1074, "NPL insulin", "", +22, InsulinGlargine, 1078, 1094, "insulin glargine", "", +26, Precondition, 1098, 1222, "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea", "", " \"patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea\"." +23, Type2Diabetes, 1112, 1127, "type 2 diabetes", "", +24, Metformin, 1196, 1205, "metformin", "", +25, Sulfonylureas, 1210, 1222, "sulfonylurea", "", +27, OpenLabel, 1234, 1246, "Open - label", "", " ." +28, Randomized, 1249, 1259, "randomized", "", +29, Italy, 1375, 1380, "Italy", "", +30, NumberPatientsCT, 1394, 1397, "116", "", " \"116\"." +137, Precondition, 1398, 1548, "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %", "", " \"adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %\"." +31, Metformin, 1431, 1440, "metformin", "", +32, Sulfonylureas, 1446, 1458, "sulfonylurea", "", +33, Duration, 1463, 1482, "longer than 90 days", "", +34, HbA1c, 1488, 1507, "hemoglobin A ( 1c )", "", +131, HbA1c, 1510, 1520, "HbA ( 1c )", "", +36, Percentage, 1539, 1540, "%", "", +37, Percentage, 1547, 1548, "%", "", +119911, Precondition, 1553, 1634, "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )", "", " \"fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )\"." +38, FastingPlasmaGlucose, 1553, 1575, "fasting plasma glucose", "", +39, Millimoles_per_litre, 1592, 1600, "mmol / L", "", +40, Mg_per_deciliter, 1625, 1632, "mg / dL", "", +42, DoseValue, 1652, 1654, "10", "", " \"10\". \"10\"." +226, Int_Unit, 1655, 1657, "IU", "", " . ." +52178, LisproProtamine, 1661, 1672, "NPL insulin", "", " ." +43, InsulinGlargine, 1676, 1692, "insulin glargine", "", " ." +144, SubcutaneousInjection, 1693, 1716, "injected subcutaneously", "", " . ." +145, Bedtime, 1720, 1727, "bedtime", "", " . ." +46, Frequency, 1733, 1739, "weekly", "", +102222, DoseDescription, 1740, 1867, "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens", "", " \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\". \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\"." +146, FastingPlasmaGlucose_target, 1766, 1831, "fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +147, Millimoles_per_litre, 1805, 1813, "mmol / L", "", +148, Mg_per_deciliter, 1822, 1829, "mg / dL", "", +45, OralAntidiabeticAgent, 1854, 1867, "oral regimens", "", " ." +149, Bedtime, 1889, 1898, "nighttime", "", +47, Sulfonylureas, 1899, 1911, "sulfonylurea", "", +48, Metformin, 1946, 1955, "metformin", "", +49, HbA1c, 2007, 2017, "HbA ( 1c )", "", " ." +230, TimePoint, 2030, 2038, "baseline", "", +231, TimePoint, 2042, 2049, "week 36", "", " \"week 36\". \"week 36\". \"week 36\". \"week 36\". \"week 36\". \"week 36\". \"week 36\". \"week 36\"." +50, HbA1c_target, 2076, 2107, "HbA ( 1c ) levels less than 7 %", "", " ." +154, Percentage, 2106, 2107, "%", "", " ." +51, Hypoglycemia, 2126, 2147, "hypoglycemic episodes", "", +232, InsulinDose, 2150, 2162, "insulin dose", "", +233, Glucose, 2182, 2195, "glucose level", "", +52, BodyWeight, 2202, 2213, "body weight", "", +53, Insulin, 2317, 2324, "insulin", "", +234, TimePoint, 2332, 2339, "week 36", "", +54, HbA1c, 2367, 2377, "HbA ( 1c )", "", +55, Reduction, 2414, 2420, "1 . 83", "", " \"1 . 83\"." +57, Percentage, 2421, 2422, "%", "", " ." +56, Reduction, 2427, 2433, "1 . 89", "", " \"1 . 89\"." +58, Percentage, 2434, 2435, "%", "", +52180, LisproProtamine, 2440, 2443, "NPL", "", +60, InsulinGlargine, 2448, 2456, "glargine", "", +52181, DiffGroupRelValue, 2514, 2520, "0 . 06", "", " \"0 . 06\"." +63, ConfIntervalDiff, 2540, 2567, "95 % CI , - 0 . 1 to 0 . 15", "", " \"95 % CI , - 0 . 1 to 0 . 15\"." +65, HbA1c_target, 2641, 2681, "Hemoglobin A ( 1c ) levels less than 7 %", "", +172, Percentage, 2680, 2681, "%", "", +66, PercentageAffected, 2694, 2696, "62", "", " \"62\"." +52182, LisproProtamine, 2721, 2724, "NPL", "", +67, PercentageAffected, 2729, 2731, "64", "", " \"64\". \"64\"." +68, InsulinGlargine, 2756, 2764, "glargine", "", +81, DiffGroupRelValue, 2780, 2785, "2 . 0", "", " \"2 . 0\". \"2 . 0\"." +69, ConfIntervalDiff, 2806, 2827, "CI , - 1 . 1 to 5 . 0", "", " \"CI , - 1 . 1 to 5 . 0\". \"CI , - 1 . 1 to 5 . 0\"." +70, FastingPlasmaGlucose_target, 2852, 2924, "Fasting plasma glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", " ." +182, Millimoles_per_litre, 2898, 2906, "mmol / L", "", " ." +183, Mg_per_deciliter, 2915, 2922, "mg / dL", "", +71, PercentageAffected, 2937, 2939, "40", "", " \"40\"." +52183, LisproProtamine, 2964, 2967, "NPL", "", +72, PercentageAffected, 2972, 2974, "41", "", +73, InsulinGlargine, 2999, 3007, "glargine", "", +82, DiffGroupRelValue, 3023, 3028, "1 . 0", "", +74, ConfIntervalDiff, 3048, 3069, "CI , - 0 . 9 to 3 . 0", "", +75, Hypoglycemia, 3098, 3110, "hypoglycemic", "", " ." +76, PercentageAffected, 3129, 3131, "74", "", " \"74\"." +52184, LisproProtamine, 3156, 3159, "NPL", "", +77, PercentageAffected, 3164, 3166, "67", "", " \"67\"." +78, InsulinGlargine, 3191, 3199, "glargine", "", +79, DiffGroupRelValue, 3215, 3216, "7", "", " \"7\"." +80, ConfIntervalDiff, 3237, 3251, "CI , - 5 to 13", "", " \"CI , - 5 to 13\"." +240, ObservedResult, 3276, 3383, "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .", "", " \"Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .\"." +239, Glucose, 3287, 3294, "glucose", "", " . ." +207, OpenLabel, 3411, 3422, "not blinded", "", +83, Hypoglycemia, 3468, 3480, "hypoglycemic", "", +241, Glucose, 3520, 3527, "glucose", "", +213, ConclusionComment, 3577, 3725, "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .", "", " \"Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .\"." +52185, LisproProtamine, 3632, 3635, "NPL", "", +84, InsulinGlargine, 3639, 3655, "glargine insulin", "", +85, OralAntidiabeticAgent, 3659, 3672, "oral regimens", "", +86, Type2Diabetes, 3708, 3723, "type 2 diabetes", "", +88, Hypoglycemia, 3726, 3738, "Hypoglycemia", "", +215, ConclusionComment, 3726, 3843, "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .", "", " \"Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .\"." +89, PMID, 3911, 3919, "18936501", "", " \"18936501\"." diff --git a/data/dm2 18936501 copy_admin.n-triples b/data/dm2 18936501 copy_admin.n-triples new file mode 100644 index 0000000..eac0499 --- /dev/null +++ b/data/dm2 18936501 copy_admin.n-triples @@ -0,0 +1,205 @@ +# RDF export of group: Publication + . + "Publication" . + "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial ." . + "Esposito K" . + "2008" . + "Ann Intern Med ." . + "18936501" . + . + "Ciotola M" . + "Maiorino MI" . + "Gualdiero R" . + "Schisano B" . + "Ceriello A" . + "Beneduce F" . + "Feola G" . + "Giugliano D" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea ." . + "116" . + . + . + . + "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes ." . + . + . + . + . + . + . + "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with suboptimal glycemic control" . + . + . + . + "patients with type 2 diabetes that is poorly controlled with oral regimens" . + "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea" . + "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %" . + "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )" . +# RDF export of group: Endpoint + . + "Endpoint_H" . + . + . + . + . + . + "Endpoint_H7" . + . + . + . + . + . + "Endpoint_FPG" . + . + . + . + . + . + "Endpoint_HG" . + . + . + . + . + . + "Endpoint_Glu" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_L" . + . + . + . + . + . + . + . + . + . + "Arm_G" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_L" . + . + . + . + "Intervention_G" . + . + . + . + "Intervention_O" . + . + . +# RDF export of group: Medication + . + "Medication_L" . + . + "10" . + . + . + "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens" . + . + "Medication_G" . + . + "10" . + . + . + "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens" . + . + "Medication_O" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_H_L" . + . + "1 . 83" . + "week 36" . + . + "Outcome_H_G" . + . + "1 . 89" . + "week 36" . + . + "Outcome_H7_L" . + . + "62" . + "week 36" . + . + "Outcome_H7_G" . + . + "64" . + "week 36" . + . + "Outcome_FPG_L" . + . + "40" . + "week 36" . + . + "Outcome_FPG_G" . + . + "64" . + "week 36" . + . + "Outcome_HG_L" . + . + "74" . + "week 36" . + . + "Outcome_HG_G" . + . + "67" . + "week 36" . + . + "Outcome_Glu" . + . + "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_H" . + "0 . 06" . + "95 % CI , - 0 . 1 to 0 . 15" . + . + . + . + "DiffBetweenGroups_H7" . + "2 . 0" . + "CI , - 1 . 1 to 5 . 0" . + . + . + . + "DiffBetweenGroups_FPG" . + "2 . 0" . + "CI , - 1 . 1 to 5 . 0" . + . + . + . + "DiffBetweenGroups_HG" . + "7" . + "CI , - 5 to 13" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18936501 copy_export.csv b/data/dm2 18936501 copy_export.csv new file mode 100644 index 0000000..468602c --- /dev/null +++ b/data/dm2 18936501 copy_export.csv @@ -0,0 +1,790 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +822, 1, 1, 1, 0, 3, 0, 3, "Ann" +822, 1, 2, 2, 4, 10, 4, 10, "Intern" +822, 1, 3, 3, 11, 14, 11, 14, "Med" +822, 1, 4, 4, 15, 16, 15, 16, "." +822, 2, 1, 5, 0, 4, 17, 21, "2008" +822, 2, 2, 6, 5, 8, 22, 25, "Oct" +822, 2, 3, 7, 9, 11, 26, 28, "21" +822, 2, 4, 8, 12, 13, 29, 30, ";" +822, 2, 5, 9, 14, 17, 31, 34, "149" +822, 2, 6, 10, 18, 19, 35, 36, "(" +822, 2, 7, 11, 20, 21, 37, 38, "8" +822, 2, 8, 12, 22, 23, 39, 40, ")" +822, 2, 9, 13, 24, 25, 41, 42, ":" +822, 2, 10, 14, 26, 29, 43, 46, "531" +822, 2, 11, 15, 30, 31, 47, 48, "-" +822, 2, 12, 16, 32, 33, 49, 50, "9" +822, 2, 13, 17, 34, 35, 51, 52, "." +822, 3, 1, 18, 0, 8, 53, 61, "Addition" +822, 3, 2, 19, 9, 11, 62, 64, "of" +822, 3, 3, 20, 12, 19, 65, 72, "neutral" +822, 3, 4, 21, 20, 29, 73, 82, "protamine" +822, 3, 5, 22, 30, 36, 83, 89, "lispro" +822, 3, 6, 23, 37, 44, 90, 97, "insulin" +822, 3, 7, 24, 45, 47, 98, 100, "or" +822, 3, 8, 25, 48, 55, 101, 108, "insulin" +822, 3, 9, 26, 56, 64, 109, 117, "glargine" +822, 3, 10, 27, 65, 67, 118, 120, "to" +822, 3, 11, 28, 68, 72, 121, 125, "oral" +822, 3, 12, 29, 73, 77, 126, 130, "type" +822, 3, 13, 30, 78, 79, 131, 132, "2" +822, 3, 14, 31, 80, 88, 133, 141, "diabetes" +822, 3, 15, 32, 89, 97, 142, 150, "regimens" +822, 3, 16, 33, 98, 101, 151, 154, "for" +822, 3, 17, 34, 102, 110, 155, 163, "patients" +822, 3, 18, 35, 111, 115, 164, 168, "with" +822, 3, 19, 36, 116, 126, 169, 179, "suboptimal" +822, 3, 20, 37, 127, 135, 180, 188, "glycemic" +822, 3, 21, 38, 136, 143, 189, 196, "control" +822, 3, 22, 39, 144, 145, 197, 198, ":" +822, 3, 23, 40, 146, 147, 199, 200, "a" +822, 3, 24, 41, 148, 158, 201, 211, "randomized" +822, 3, 25, 42, 159, 164, 212, 217, "trial" +822, 3, 26, 43, 165, 166, 218, 219, "." +822, 4, 1, 44, 0, 8, 220, 228, "Esposito" +822, 4, 2, 45, 9, 10, 229, 230, "K" +822, 4, 3, 46, 11, 12, 231, 232, "(" +822, 4, 4, 47, 13, 14, 233, 234, "1" +822, 4, 5, 48, 15, 16, 235, 236, ")" +822, 4, 6, 49, 17, 18, 237, 238, "," +822, 4, 7, 50, 19, 26, 239, 246, "Ciotola" +822, 4, 8, 51, 27, 28, 247, 248, "M" +822, 4, 9, 52, 29, 30, 249, 250, "," +822, 4, 10, 53, 31, 39, 251, 259, "Maiorino" +822, 4, 11, 54, 40, 42, 260, 262, "MI" +822, 4, 12, 55, 43, 44, 263, 264, "," +822, 4, 13, 56, 45, 54, 265, 274, "Gualdiero" +822, 4, 14, 57, 55, 56, 275, 276, "R" +822, 4, 15, 58, 57, 58, 277, 278, "," +822, 4, 16, 59, 59, 67, 279, 287, "Schisano" +822, 4, 17, 60, 68, 69, 288, 289, "B" +822, 4, 18, 61, 70, 71, 290, 291, "," +822, 4, 19, 62, 72, 80, 292, 300, "Ceriello" +822, 4, 20, 63, 81, 82, 301, 302, "A" +822, 4, 21, 64, 83, 84, 303, 304, "," +822, 4, 22, 65, 85, 93, 305, 313, "Beneduce" +822, 4, 23, 66, 94, 95, 314, 315, "F" +822, 4, 24, 67, 96, 97, 316, 317, "," +822, 4, 25, 68, 98, 103, 318, 323, "Feola" +822, 4, 26, 69, 104, 105, 324, 325, "G" +822, 4, 27, 70, 106, 107, 326, 327, "," +822, 4, 28, 71, 108, 117, 328, 337, "Giugliano" +822, 4, 29, 72, 118, 119, 338, 339, "D" +822, 4, 30, 73, 120, 121, 340, 341, "." +822, 4, 31, 74, 122, 128, 342, 348, "Author" +822, 4, 32, 75, 129, 140, 349, 360, "information" +822, 4, 33, 76, 141, 142, 361, 362, ":" +822, 4, 34, 77, 143, 144, 363, 364, "(" +822, 4, 35, 78, 145, 146, 365, 366, "1" +822, 4, 36, 79, 147, 148, 367, 368, ")" +822, 4, 37, 80, 149, 155, 369, 375, "Second" +822, 4, 38, 81, 156, 166, 376, 386, "University" +822, 4, 39, 82, 167, 169, 387, 389, "of" +822, 4, 40, 83, 170, 176, 390, 396, "Naples" +822, 4, 41, 84, 177, 180, 397, 400, "and" +822, 4, 42, 85, 181, 188, 401, 408, "Azienda" +822, 4, 43, 86, 189, 198, 409, 418, "Sanitaria" +822, 4, 44, 87, 199, 205, 419, 425, "Locale" +822, 4, 45, 88, 206, 212, 426, 432, "Napoli" +822, 4, 46, 89, 213, 214, 433, 434, "5" +822, 4, 47, 90, 215, 216, 435, 436, "," +822, 4, 48, 91, 217, 223, 437, 443, "Naples" +822, 4, 49, 92, 224, 225, 444, 445, "," +822, 4, 50, 93, 226, 231, 446, 451, "Italy" +822, 4, 51, 94, 232, 233, 452, 453, "." +822, 5, 1, 95, 0, 7, 454, 461, "Comment" +822, 5, 2, 96, 8, 10, 462, 464, "in" +822, 5, 3, 97, 11, 14, 465, 468, "Ann" +822, 5, 4, 98, 15, 21, 469, 475, "Intern" +822, 5, 5, 99, 22, 25, 476, 479, "Med" +822, 5, 6, 100, 26, 27, 480, 481, "." +822, 6, 1, 101, 0, 4, 482, 486, "2008" +822, 6, 2, 102, 5, 8, 487, 490, "Oct" +822, 6, 3, 103, 9, 11, 491, 493, "21" +822, 6, 4, 104, 12, 13, 494, 495, ";" +822, 6, 5, 105, 14, 17, 496, 499, "149" +822, 6, 6, 106, 18, 19, 500, 501, "(" +822, 6, 7, 107, 20, 21, 502, 503, "8" +822, 6, 8, 108, 22, 23, 504, 505, ")" +822, 6, 9, 109, 24, 25, 506, 507, ":" +822, 6, 10, 110, 26, 29, 508, 511, "586" +822, 6, 11, 111, 30, 31, 512, 513, "-" +822, 6, 12, 112, 32, 33, 514, 515, "8" +822, 6, 13, 113, 34, 35, 516, 517, "." +822, 7, 1, 114, 0, 7, 518, 525, "Summary" +822, 7, 2, 115, 8, 11, 526, 529, "for" +822, 7, 3, 116, 12, 20, 530, 538, "patients" +822, 7, 4, 117, 21, 23, 539, 541, "in" +822, 7, 5, 118, 24, 27, 542, 545, "Ann" +822, 7, 6, 119, 28, 34, 546, 552, "Intern" +822, 7, 7, 120, 35, 38, 553, 556, "Med" +822, 7, 8, 121, 39, 40, 557, 558, "." +822, 8, 1, 122, 0, 4, 559, 563, "2008" +822, 8, 2, 123, 5, 8, 564, 567, "Oct" +822, 8, 3, 124, 9, 11, 568, 570, "21" +822, 8, 4, 125, 12, 13, 571, 572, ";" +822, 8, 5, 126, 14, 17, 573, 576, "149" +822, 8, 6, 127, 18, 19, 577, 578, "(" +822, 8, 7, 128, 20, 21, 579, 580, "8" +822, 8, 8, 129, 22, 23, 581, 582, ")" +822, 8, 9, 130, 24, 25, 583, 584, ":" +822, 8, 10, 131, 26, 27, 585, 586, "I" +822, 8, 11, 132, 28, 29, 587, 588, "-" +822, 8, 12, 133, 30, 32, 589, 591, "46" +822, 8, 13, 134, 33, 34, 592, 593, "." +822, 9, 1, 135, 0, 3, 594, 597, "Ann" +822, 9, 2, 136, 4, 10, 598, 604, "Intern" +822, 9, 3, 137, 11, 14, 605, 608, "Med" +822, 9, 4, 138, 15, 16, 609, 610, "." +822, 10, 1, 139, 0, 4, 611, 615, "2008" +822, 10, 2, 140, 5, 8, 616, 619, "Oct" +822, 10, 3, 141, 9, 11, 620, 622, "21" +822, 10, 4, 142, 12, 13, 623, 624, ";" +822, 10, 5, 143, 14, 17, 625, 628, "149" +822, 10, 6, 144, 18, 19, 629, 630, "(" +822, 10, 7, 145, 20, 21, 631, 632, "8" +822, 10, 8, 146, 22, 23, 633, 634, ")" +822, 10, 9, 147, 24, 25, 635, 636, ":" +822, 10, 10, 148, 26, 27, 637, 638, "I" +822, 10, 11, 149, 28, 29, 639, 640, "-" +822, 10, 12, 150, 30, 32, 641, 643, "52" +822, 10, 13, 151, 33, 34, 644, 645, "." +822, 11, 1, 152, 0, 10, 646, 656, "BACKGROUND" +822, 11, 2, 153, 11, 12, 657, 658, ":" +822, 11, 3, 154, 13, 22, 659, 668, "Injection" +822, 11, 4, 155, 23, 25, 669, 671, "of" +822, 11, 5, 156, 26, 30, 672, 676, "long" +822, 11, 6, 157, 31, 32, 677, 678, "-" +822, 11, 7, 158, 33, 39, 679, 685, "acting" +822, 11, 8, 159, 40, 47, 686, 693, "insulin" +822, 11, 9, 160, 48, 50, 694, 696, "at" +822, 11, 10, 161, 51, 58, 697, 704, "bedtime" +822, 11, 11, 162, 59, 61, 705, 707, "is" +822, 11, 12, 163, 62, 63, 708, 709, "a" +822, 11, 13, 164, 64, 70, 710, 716, "common" +822, 11, 14, 165, 71, 82, 717, 728, "therapeutic" +822, 11, 15, 166, 83, 91, 729, 737, "approach" +822, 11, 16, 167, 92, 95, 738, 741, "for" +822, 11, 17, 168, 96, 104, 742, 750, "patients" +822, 11, 18, 169, 105, 109, 751, 755, "with" +822, 11, 19, 170, 110, 114, 756, 760, "type" +822, 11, 20, 171, 115, 116, 761, 762, "2" +822, 11, 21, 172, 117, 125, 763, 771, "diabetes" +822, 11, 22, 173, 126, 130, 772, 776, "that" +822, 11, 23, 174, 131, 133, 777, 779, "is" +822, 11, 24, 175, 134, 140, 780, 786, "poorly" +822, 11, 25, 176, 141, 151, 787, 797, "controlled" +822, 11, 26, 177, 152, 156, 798, 802, "with" +822, 11, 27, 178, 157, 161, 803, 807, "oral" +822, 11, 28, 179, 162, 170, 808, 816, "regimens" +822, 11, 29, 180, 171, 172, 817, 818, "." +822, 12, 1, 181, 0, 7, 819, 826, "Neutral" +822, 12, 2, 182, 8, 17, 827, 836, "protamine" +822, 12, 3, 183, 18, 24, 837, 843, "lispro" +822, 12, 4, 184, 25, 26, 844, 845, "(" +822, 12, 5, 185, 27, 30, 846, 849, "NPL" +822, 12, 6, 186, 31, 32, 850, 851, ")" +822, 12, 7, 187, 33, 40, 852, 859, "insulin" +822, 12, 8, 188, 41, 44, 860, 863, "has" +822, 12, 9, 189, 45, 57, 864, 876, "demonstrated" +822, 12, 10, 190, 58, 64, 877, 883, "better" +822, 12, 11, 191, 65, 73, 884, 892, "glycemic" +822, 12, 12, 192, 74, 81, 893, 900, "control" +822, 12, 13, 193, 82, 85, 901, 904, "and" +822, 12, 14, 194, 86, 93, 905, 912, "similar" +822, 12, 15, 195, 94, 103, 913, 922, "incidence" +822, 12, 16, 196, 104, 106, 923, 925, "of" +822, 12, 17, 197, 107, 119, 926, 938, "hypoglycemic" +822, 12, 18, 198, 120, 126, 939, 945, "events" +822, 12, 19, 199, 127, 131, 946, 950, "than" +822, 12, 20, 200, 132, 136, 951, 955, "that" +822, 12, 21, 201, 137, 139, 956, 958, "of" +822, 12, 22, 202, 140, 147, 959, 966, "neutral" +822, 12, 23, 203, 148, 157, 967, 976, "protamine" +822, 12, 24, 204, 158, 166, 977, 985, "Hagedorn" +822, 12, 25, 205, 167, 174, 986, 993, "insulin" +822, 12, 26, 206, 175, 176, 994, 995, "." +822, 13, 1, 207, 0, 9, 996, 1005, "OBJECTIVE" +822, 13, 2, 208, 10, 11, 1006, 1007, ":" +822, 13, 3, 209, 12, 14, 1008, 1010, "To" +822, 13, 4, 210, 15, 22, 1011, 1018, "compare" +822, 13, 5, 211, 23, 26, 1019, 1022, "the" +822, 13, 6, 212, 27, 35, 1023, 1031, "clinical" +822, 13, 7, 213, 36, 44, 1032, 1040, "efficacy" +822, 13, 8, 214, 45, 48, 1041, 1044, "and" +822, 13, 9, 215, 49, 55, 1045, 1051, "safety" +822, 13, 10, 216, 56, 58, 1052, 1054, "of" +822, 13, 11, 217, 59, 66, 1055, 1062, "bedtime" +822, 13, 12, 218, 67, 70, 1063, 1066, "NPL" +822, 13, 13, 219, 71, 78, 1067, 1074, "insulin" +822, 13, 14, 220, 79, 81, 1075, 1077, "or" +822, 13, 15, 221, 82, 89, 1078, 1085, "insulin" +822, 13, 16, 222, 90, 98, 1086, 1094, "glargine" +822, 13, 17, 223, 99, 101, 1095, 1097, "in" +822, 13, 18, 224, 102, 110, 1098, 1106, "patients" +822, 13, 19, 225, 111, 115, 1107, 1111, "with" +822, 13, 20, 226, 116, 120, 1112, 1116, "type" +822, 13, 21, 227, 121, 122, 1117, 1118, "2" +822, 13, 22, 228, 123, 131, 1119, 1127, "diabetes" +822, 13, 23, 229, 132, 135, 1128, 1131, "who" +822, 13, 24, 230, 136, 139, 1132, 1135, "had" +822, 13, 25, 231, 140, 150, 1136, 1146, "suboptimal" +822, 13, 26, 232, 151, 159, 1147, 1155, "glycemic" +822, 13, 27, 233, 160, 167, 1156, 1163, "control" +822, 13, 28, 234, 168, 173, 1164, 1169, "while" +822, 13, 29, 235, 174, 183, 1170, 1179, "receiving" +822, 13, 30, 236, 184, 190, 1180, 1186, "stable" +822, 13, 31, 237, 191, 196, 1187, 1192, "doses" +822, 13, 32, 238, 197, 199, 1193, 1195, "of" +822, 13, 33, 239, 200, 209, 1196, 1205, "metformin" +822, 13, 34, 240, 210, 213, 1206, 1209, "and" +822, 13, 35, 241, 214, 226, 1210, 1222, "sulfonylurea" +822, 13, 36, 242, 227, 228, 1223, 1224, "." +822, 14, 1, 243, 0, 6, 1225, 1231, "DESIGN" +822, 14, 2, 244, 7, 8, 1232, 1233, ":" +822, 14, 3, 245, 9, 13, 1234, 1238, "Open" +822, 14, 4, 246, 14, 15, 1239, 1240, "-" +822, 14, 5, 247, 16, 21, 1241, 1246, "label" +822, 14, 6, 248, 22, 23, 1247, 1248, "," +822, 14, 7, 249, 24, 34, 1249, 1259, "randomized" +822, 14, 8, 250, 35, 40, 1260, 1265, "trial" +822, 14, 9, 251, 41, 42, 1266, 1267, "." +822, 15, 1, 252, 0, 7, 1268, 1275, "SETTING" +822, 15, 2, 253, 8, 9, 1276, 1277, ":" +822, 15, 3, 254, 10, 18, 1278, 1286, "Teaching" +822, 15, 4, 255, 19, 27, 1287, 1295, "hospital" +822, 15, 5, 256, 28, 29, 1296, 1297, "(" +822, 15, 6, 257, 30, 37, 1298, 1305, "Azienda" +822, 15, 7, 258, 38, 49, 1306, 1317, "Ospedaliera" +822, 15, 8, 259, 50, 63, 1318, 1331, "Universitaria" +822, 15, 9, 260, 64, 65, 1332, 1333, "," +822, 15, 10, 261, 66, 72, 1334, 1340, "Second" +822, 15, 11, 262, 73, 83, 1341, 1351, "University" +822, 15, 12, 263, 84, 86, 1352, 1354, "of" +822, 15, 13, 264, 87, 93, 1355, 1361, "Naples" +822, 15, 14, 265, 94, 95, 1362, 1363, ")" +822, 15, 15, 266, 96, 97, 1364, 1365, "," +822, 15, 16, 267, 98, 104, 1366, 1372, "Naples" +822, 15, 17, 268, 105, 106, 1373, 1374, "," +822, 15, 18, 269, 107, 112, 1375, 1380, "Italy" +822, 15, 19, 270, 113, 114, 1381, 1382, "." +822, 16, 1, 271, 0, 8, 1383, 1391, "PATIENTS" +822, 16, 2, 272, 9, 10, 1392, 1393, ":" +822, 16, 3, 273, 11, 14, 1394, 1397, "116" +822, 16, 4, 274, 15, 21, 1398, 1404, "adults" +822, 16, 5, 275, 22, 31, 1405, 1414, "receiving" +822, 16, 6, 276, 32, 38, 1415, 1421, "stable" +822, 16, 7, 277, 39, 44, 1422, 1427, "doses" +822, 16, 8, 278, 45, 47, 1428, 1430, "of" +822, 16, 9, 279, 48, 57, 1431, 1440, "metformin" +822, 16, 10, 280, 58, 62, 1441, 1445, "plus" +822, 16, 11, 281, 63, 75, 1446, 1458, "sulfonylurea" +822, 16, 12, 282, 76, 79, 1459, 1462, "for" +822, 16, 13, 283, 80, 86, 1463, 1469, "longer" +822, 16, 14, 284, 87, 91, 1470, 1474, "than" +822, 16, 15, 285, 92, 94, 1475, 1477, "90" +822, 16, 16, 286, 95, 99, 1478, 1482, "days" +822, 16, 17, 287, 100, 104, 1483, 1487, "with" +822, 16, 18, 288, 105, 115, 1488, 1498, "hemoglobin" +822, 16, 19, 289, 116, 117, 1499, 1500, "A" +822, 16, 20, 290, 118, 119, 1501, 1502, "(" +822, 16, 21, 291, 120, 122, 1503, 1505, "1c" +822, 16, 22, 292, 123, 124, 1506, 1507, ")" +822, 16, 23, 293, 125, 126, 1508, 1509, "(" +822, 16, 24, 294, 127, 130, 1510, 1513, "HbA" +822, 16, 25, 295, 131, 132, 1514, 1515, "(" +822, 16, 26, 296, 133, 135, 1516, 1518, "1c" +822, 16, 27, 297, 136, 137, 1519, 1520, ")" +822, 16, 28, 298, 138, 139, 1521, 1522, ")" +822, 16, 29, 299, 140, 146, 1523, 1529, "levels" +822, 16, 30, 300, 147, 149, 1530, 1532, "of" +822, 16, 31, 301, 150, 151, 1533, 1534, "7" +822, 16, 32, 302, 152, 153, 1535, 1536, "." +822, 16, 33, 303, 154, 155, 1537, 1538, "5" +822, 16, 34, 304, 156, 157, 1539, 1540, "%" +822, 16, 35, 305, 158, 160, 1541, 1543, "to" +822, 16, 36, 306, 161, 163, 1544, 1546, "10" +822, 16, 37, 307, 164, 165, 1547, 1548, "%" +822, 16, 38, 308, 166, 169, 1549, 1552, "and" +822, 16, 39, 309, 170, 177, 1553, 1560, "fasting" +822, 16, 40, 310, 178, 184, 1561, 1567, "plasma" +822, 16, 41, 311, 185, 192, 1568, 1575, "glucose" +822, 16, 42, 312, 193, 199, 1576, 1582, "levels" +822, 16, 43, 313, 200, 202, 1583, 1585, "of" +822, 16, 44, 314, 203, 204, 1586, 1587, "6" +822, 16, 45, 315, 205, 206, 1588, 1589, "." +822, 16, 46, 316, 207, 208, 1590, 1591, "7" +822, 16, 47, 317, 209, 213, 1592, 1596, "mmol" +822, 16, 48, 318, 214, 215, 1597, 1598, "/" +822, 16, 49, 319, 216, 217, 1599, 1600, "L" +822, 16, 50, 320, 218, 220, 1601, 1603, "or" +822, 16, 51, 321, 221, 228, 1604, 1611, "greater" +822, 16, 52, 322, 229, 230, 1612, 1613, "(" +822, 16, 53, 323, 231, 232, 1614, 1615, ">" +822, 16, 54, 324, 233, 235, 1616, 1618, "or" +822, 16, 55, 325, 236, 237, 1619, 1620, "=" +822, 16, 56, 326, 238, 241, 1621, 1624, "120" +822, 16, 57, 327, 242, 244, 1625, 1627, "mg" +822, 16, 58, 328, 245, 246, 1628, 1629, "/" +822, 16, 59, 329, 247, 249, 1630, 1632, "dL" +822, 16, 60, 330, 250, 251, 1633, 1634, ")" +822, 16, 61, 331, 252, 253, 1635, 1636, "." +822, 17, 1, 332, 0, 12, 1637, 1649, "INTERVENTION" +822, 17, 2, 333, 13, 14, 1650, 1651, ":" +822, 17, 3, 334, 15, 17, 1652, 1654, "10" +822, 17, 4, 335, 18, 20, 1655, 1657, "IU" +822, 17, 5, 336, 21, 23, 1658, 1660, "of" +822, 17, 6, 337, 24, 27, 1661, 1664, "NPL" +822, 17, 7, 338, 28, 35, 1665, 1672, "insulin" +822, 17, 8, 339, 36, 38, 1673, 1675, "or" +822, 17, 9, 340, 39, 46, 1676, 1683, "insulin" +822, 17, 10, 341, 47, 55, 1684, 1692, "glargine" +822, 17, 11, 342, 56, 64, 1693, 1701, "injected" +822, 17, 12, 343, 65, 79, 1702, 1716, "subcutaneously" +822, 17, 13, 344, 80, 82, 1717, 1719, "at" +822, 17, 14, 345, 83, 90, 1720, 1727, "bedtime" +822, 17, 15, 346, 91, 95, 1728, 1732, "with" +822, 17, 16, 347, 96, 102, 1733, 1739, "weekly" +822, 17, 17, 348, 103, 107, 1740, 1744, "dose" +822, 17, 18, 349, 108, 118, 1745, 1755, "titrations" +822, 17, 19, 350, 119, 121, 1756, 1758, "to" +822, 17, 20, 351, 122, 128, 1759, 1765, "target" +822, 17, 21, 352, 129, 136, 1766, 1773, "fasting" +822, 17, 22, 353, 137, 144, 1774, 1781, "glucose" +822, 17, 23, 354, 145, 151, 1782, 1788, "levels" +822, 17, 24, 355, 152, 156, 1789, 1793, "less" +822, 17, 25, 356, 157, 161, 1794, 1798, "than" +822, 17, 26, 357, 162, 163, 1799, 1800, "5" +822, 17, 27, 358, 164, 165, 1801, 1802, "." +822, 17, 28, 359, 166, 167, 1803, 1804, "6" +822, 17, 29, 360, 168, 172, 1805, 1809, "mmol" +822, 17, 30, 361, 173, 174, 1810, 1811, "/" +822, 17, 31, 362, 175, 176, 1812, 1813, "L" +822, 17, 32, 363, 177, 178, 1814, 1815, "(" +822, 17, 33, 364, 179, 180, 1816, 1817, "<" +822, 17, 34, 365, 181, 184, 1818, 1821, "100" +822, 17, 35, 366, 185, 187, 1822, 1824, "mg" +822, 17, 36, 367, 188, 189, 1825, 1826, "/" +822, 17, 37, 368, 190, 192, 1827, 1829, "dL" +822, 17, 38, 369, 193, 194, 1830, 1831, ")" +822, 17, 39, 370, 195, 197, 1832, 1834, "in" +822, 17, 40, 371, 198, 206, 1835, 1843, "addition" +822, 17, 41, 372, 207, 209, 1844, 1846, "to" +822, 17, 42, 373, 210, 216, 1847, 1853, "stable" +822, 17, 43, 374, 217, 221, 1854, 1858, "oral" +822, 17, 44, 375, 222, 230, 1859, 1867, "regimens" +822, 17, 45, 376, 231, 232, 1868, 1869, "." +822, 18, 1, 377, 0, 8, 1870, 1878, "Patients" +822, 18, 2, 378, 9, 18, 1879, 1888, "receiving" +822, 18, 3, 379, 19, 28, 1889, 1898, "nighttime" +822, 18, 4, 380, 29, 41, 1899, 1911, "sulfonylurea" +822, 18, 5, 381, 42, 48, 1912, 1918, "before" +822, 18, 6, 382, 49, 52, 1919, 1922, "the" +822, 18, 7, 383, 53, 58, 1923, 1928, "study" +822, 18, 8, 384, 59, 63, 1929, 1933, "were" +822, 18, 9, 385, 64, 72, 1934, 1942, "switched" +822, 18, 10, 386, 73, 75, 1943, 1945, "to" +822, 18, 11, 387, 76, 85, 1946, 1955, "metformin" +822, 18, 12, 388, 86, 87, 1956, 1957, "." +822, 19, 1, 389, 0, 12, 1958, 1970, "MEASUREMENTS" +822, 19, 2, 390, 13, 14, 1971, 1972, ":" +822, 19, 3, 391, 15, 18, 1973, 1976, "The" +822, 19, 4, 392, 19, 26, 1977, 1984, "primary" +822, 19, 5, 393, 27, 34, 1985, 1992, "outcome" +822, 19, 6, 394, 35, 38, 1993, 1996, "was" +822, 19, 7, 395, 39, 45, 1997, 2003, "change" +822, 19, 8, 396, 46, 48, 2004, 2006, "in" +822, 19, 9, 397, 49, 52, 2007, 2010, "HbA" +822, 19, 10, 398, 53, 54, 2011, 2012, "(" +822, 19, 11, 399, 55, 57, 2013, 2015, "1c" +822, 19, 12, 400, 58, 59, 2016, 2017, ")" +822, 19, 13, 401, 60, 66, 2018, 2024, "levels" +822, 19, 14, 402, 67, 71, 2025, 2029, "from" +822, 19, 15, 403, 72, 80, 2030, 2038, "baseline" +822, 19, 16, 404, 81, 83, 2039, 2041, "to" +822, 19, 17, 405, 84, 88, 2042, 2046, "week" +822, 19, 18, 406, 89, 91, 2047, 2049, "36" +822, 19, 19, 407, 92, 93, 2050, 2051, "." +822, 20, 1, 408, 0, 9, 2052, 2061, "Secondary" +822, 20, 2, 409, 10, 18, 2062, 2070, "outcomes" +822, 20, 3, 410, 19, 23, 2071, 2075, "were" +822, 20, 4, 411, 24, 27, 2076, 2079, "HbA" +822, 20, 5, 412, 28, 29, 2080, 2081, "(" +822, 20, 6, 413, 30, 32, 2082, 2084, "1c" +822, 20, 7, 414, 33, 34, 2085, 2086, ")" +822, 20, 8, 415, 35, 41, 2087, 2093, "levels" +822, 20, 9, 416, 42, 46, 2094, 2098, "less" +822, 20, 10, 417, 47, 51, 2099, 2103, "than" +822, 20, 11, 418, 52, 53, 2104, 2105, "7" +822, 20, 12, 419, 54, 55, 2106, 2107, "%" +822, 20, 13, 420, 56, 57, 2108, 2109, "," +822, 20, 14, 421, 58, 62, 2110, 2114, "self" +822, 20, 15, 422, 63, 64, 2115, 2116, "-" +822, 20, 16, 423, 65, 73, 2117, 2125, "reported" +822, 20, 17, 424, 74, 86, 2126, 2138, "hypoglycemic" +822, 20, 18, 425, 87, 95, 2139, 2147, "episodes" +822, 20, 19, 426, 96, 97, 2148, 2149, "," +822, 20, 20, 427, 98, 105, 2150, 2157, "insulin" +822, 20, 21, 428, 106, 110, 2158, 2162, "dose" +822, 20, 22, 429, 111, 112, 2163, 2164, "," +822, 20, 23, 430, 113, 117, 2165, 2169, "self" +822, 20, 24, 431, 118, 119, 2170, 2171, "-" +822, 20, 25, 432, 120, 129, 2172, 2181, "monitored" +822, 20, 26, 433, 130, 137, 2182, 2189, "glucose" +822, 20, 27, 434, 138, 143, 2190, 2195, "level" +822, 20, 28, 435, 144, 145, 2196, 2197, "," +822, 20, 29, 436, 146, 149, 2198, 2201, "and" +822, 20, 30, 437, 150, 154, 2202, 2206, "body" +822, 20, 31, 438, 155, 161, 2207, 2213, "weight" +822, 20, 32, 439, 162, 163, 2214, 2215, "." +822, 21, 1, 440, 0, 6, 2216, 2222, "Twenty" +822, 21, 2, 441, 7, 15, 2223, 2231, "patients" +822, 21, 3, 442, 16, 18, 2232, 2234, "in" +822, 21, 4, 443, 19, 23, 2235, 2239, "each" +822, 21, 5, 444, 24, 29, 2240, 2245, "group" +822, 21, 6, 445, 30, 33, 2246, 2249, "had" +822, 21, 7, 446, 34, 44, 2250, 2260, "continuous" +822, 21, 8, 447, 45, 52, 2261, 2268, "glucose" +822, 21, 9, 448, 53, 63, 2269, 2279, "monitoring" +822, 21, 10, 449, 64, 67, 2280, 2283, "for" +822, 21, 11, 450, 68, 69, 2284, 2285, "3" +822, 21, 12, 451, 70, 81, 2286, 2297, "consecutive" +822, 21, 13, 452, 82, 86, 2298, 2302, "days" +822, 21, 14, 453, 87, 93, 2303, 2309, "before" +822, 21, 15, 454, 94, 100, 2310, 2316, "adding" +822, 21, 16, 455, 101, 108, 2317, 2324, "insulin" +822, 21, 17, 456, 109, 112, 2325, 2328, "and" +822, 21, 18, 457, 113, 115, 2329, 2331, "at" +822, 21, 19, 458, 116, 120, 2332, 2336, "week" +822, 21, 20, 459, 121, 123, 2337, 2339, "36" +822, 21, 21, 460, 124, 125, 2340, 2341, "." +822, 22, 1, 461, 0, 7, 2342, 2349, "RESULTS" +822, 22, 2, 462, 8, 9, 2350, 2351, ":" +822, 22, 3, 463, 10, 21, 2352, 2363, "Improvement" +822, 22, 4, 464, 22, 24, 2364, 2366, "in" +822, 22, 5, 465, 25, 28, 2367, 2370, "HbA" +822, 22, 6, 466, 29, 30, 2371, 2372, "(" +822, 22, 7, 467, 31, 33, 2373, 2375, "1c" +822, 22, 8, 468, 34, 35, 2376, 2377, ")" +822, 22, 9, 469, 36, 42, 2378, 2384, "levels" +822, 22, 10, 470, 43, 46, 2385, 2388, "was" +822, 22, 11, 471, 47, 54, 2389, 2396, "similar" +822, 22, 12, 472, 55, 57, 2397, 2399, "in" +822, 22, 13, 473, 58, 62, 2400, 2404, "both" +822, 22, 14, 474, 63, 69, 2405, 2411, "groups" +822, 22, 15, 475, 70, 71, 2412, 2413, "(" +822, 22, 16, 476, 72, 73, 2414, 2415, "1" +822, 22, 17, 477, 74, 75, 2416, 2417, "." +822, 22, 18, 478, 76, 78, 2418, 2420, "83" +822, 22, 19, 479, 79, 80, 2421, 2422, "%" +822, 22, 20, 480, 81, 84, 2423, 2426, "and" +822, 22, 21, 481, 85, 86, 2427, 2428, "1" +822, 22, 22, 482, 87, 88, 2429, 2430, "." +822, 22, 23, 483, 89, 91, 2431, 2433, "89" +822, 22, 24, 484, 92, 93, 2434, 2435, "%" +822, 22, 25, 485, 94, 97, 2436, 2439, "for" +822, 22, 26, 486, 98, 101, 2440, 2443, "NPL" +822, 22, 27, 487, 102, 105, 2444, 2447, "and" +822, 22, 28, 488, 106, 114, 2448, 2456, "glargine" +822, 22, 29, 489, 115, 116, 2457, 2458, "," +822, 22, 30, 490, 117, 129, 2459, 2471, "respectively" +822, 22, 31, 491, 130, 131, 2472, 2473, ")" +822, 22, 32, 492, 132, 133, 2474, 2475, "." +822, 23, 1, 493, 0, 3, 2476, 2479, "The" +822, 23, 2, 494, 4, 14, 2480, 2490, "difference" +822, 23, 3, 495, 15, 22, 2491, 2498, "between" +822, 23, 4, 496, 23, 26, 2499, 2502, "the" +822, 23, 5, 497, 27, 33, 2503, 2509, "groups" +822, 23, 6, 498, 34, 37, 2510, 2513, "was" +822, 23, 7, 499, 38, 39, 2514, 2515, "0" +822, 23, 8, 500, 40, 41, 2516, 2517, "." +822, 23, 9, 501, 42, 44, 2518, 2520, "06" +822, 23, 10, 502, 45, 55, 2521, 2531, "percentage" +822, 23, 11, 503, 56, 61, 2532, 2537, "point" +822, 23, 12, 504, 62, 63, 2538, 2539, "(" +822, 23, 13, 505, 64, 66, 2540, 2542, "95" +822, 23, 14, 506, 67, 68, 2543, 2544, "%" +822, 23, 15, 507, 69, 71, 2545, 2547, "CI" +822, 23, 16, 508, 72, 73, 2548, 2549, "," +822, 23, 17, 509, 74, 75, 2550, 2551, "-" +822, 23, 18, 510, 76, 77, 2552, 2553, "0" +822, 23, 19, 511, 78, 79, 2554, 2555, "." +822, 23, 20, 512, 80, 81, 2556, 2557, "1" +822, 23, 21, 513, 82, 84, 2558, 2560, "to" +822, 23, 22, 514, 85, 86, 2561, 2562, "0" +822, 23, 23, 515, 87, 88, 2563, 2564, "." +822, 23, 24, 516, 89, 91, 2565, 2567, "15" +822, 23, 25, 517, 92, 102, 2568, 2578, "percentage" +822, 23, 26, 518, 103, 109, 2579, 2585, "points" +822, 23, 27, 519, 110, 111, 2586, 2587, ")" +822, 23, 28, 520, 112, 113, 2588, 2589, "." +822, 24, 1, 521, 0, 9, 2590, 2599, "Secondary" +822, 24, 2, 522, 10, 18, 2600, 2608, "outcomes" +822, 24, 3, 523, 19, 22, 2609, 2612, "did" +822, 24, 4, 524, 23, 26, 2613, 2616, "not" +822, 24, 5, 525, 27, 33, 2617, 2623, "differ" +822, 24, 6, 526, 34, 41, 2624, 2631, "between" +822, 24, 7, 527, 42, 48, 2632, 2638, "groups" +822, 24, 8, 528, 49, 50, 2639, 2640, "." +822, 25, 1, 529, 0, 10, 2641, 2651, "Hemoglobin" +822, 25, 2, 530, 11, 12, 2652, 2653, "A" +822, 25, 3, 531, 13, 14, 2654, 2655, "(" +822, 25, 4, 532, 15, 17, 2656, 2658, "1c" +822, 25, 5, 533, 18, 19, 2659, 2660, ")" +822, 25, 6, 534, 20, 26, 2661, 2667, "levels" +822, 25, 7, 535, 27, 31, 2668, 2672, "less" +822, 25, 8, 536, 32, 36, 2673, 2677, "than" +822, 25, 9, 537, 37, 38, 2678, 2679, "7" +822, 25, 10, 538, 39, 40, 2680, 2681, "%" +822, 25, 11, 539, 41, 49, 2682, 2690, "occurred" +822, 25, 12, 540, 50, 52, 2691, 2693, "in" +822, 25, 13, 541, 53, 55, 2694, 2696, "62" +822, 25, 14, 542, 56, 57, 2697, 2698, "%" +822, 25, 15, 543, 58, 60, 2699, 2701, "of" +822, 25, 16, 544, 61, 69, 2702, 2710, "patients" +822, 25, 17, 545, 70, 79, 2711, 2720, "receiving" +822, 25, 18, 546, 80, 83, 2721, 2724, "NPL" +822, 25, 19, 547, 84, 87, 2725, 2728, "and" +822, 25, 20, 548, 88, 90, 2729, 2731, "64" +822, 25, 21, 549, 91, 92, 2732, 2733, "%" +822, 25, 22, 550, 93, 95, 2734, 2736, "of" +822, 25, 23, 551, 96, 104, 2737, 2745, "patients" +822, 25, 24, 552, 105, 114, 2746, 2755, "receiving" +822, 25, 25, 553, 115, 123, 2756, 2764, "glargine" +822, 25, 26, 554, 124, 125, 2765, 2766, "(" +822, 25, 27, 555, 126, 136, 2767, 2777, "difference" +822, 25, 28, 556, 137, 138, 2778, 2779, "," +822, 25, 29, 557, 139, 140, 2780, 2781, "2" +822, 25, 30, 558, 141, 142, 2782, 2783, "." +822, 25, 31, 559, 143, 144, 2784, 2785, "0" +822, 25, 32, 560, 145, 155, 2786, 2796, "percentage" +822, 25, 33, 561, 156, 162, 2797, 2803, "points" +822, 25, 34, 562, 163, 164, 2804, 2805, "[" +822, 25, 35, 563, 165, 167, 2806, 2808, "CI" +822, 25, 36, 564, 168, 169, 2809, 2810, "," +822, 25, 37, 565, 170, 171, 2811, 2812, "-" +822, 25, 38, 566, 172, 173, 2813, 2814, "1" +822, 25, 39, 567, 174, 175, 2815, 2816, "." +822, 25, 40, 568, 176, 177, 2817, 2818, "1" +822, 25, 41, 569, 178, 180, 2819, 2821, "to" +822, 25, 42, 570, 181, 182, 2822, 2823, "5" +822, 25, 43, 571, 183, 184, 2824, 2825, "." +822, 25, 44, 572, 185, 186, 2826, 2827, "0" +822, 25, 45, 573, 187, 197, 2828, 2838, "percentage" +822, 25, 46, 574, 198, 204, 2839, 2845, "points" +822, 25, 47, 575, 205, 206, 2846, 2847, "]" +822, 25, 48, 576, 207, 208, 2848, 2849, ")" +822, 25, 49, 577, 209, 210, 2850, 2851, "." +822, 26, 1, 578, 0, 7, 2852, 2859, "Fasting" +822, 26, 2, 579, 8, 14, 2860, 2866, "plasma" +822, 26, 3, 580, 15, 22, 2867, 2874, "glucose" +822, 26, 4, 581, 23, 29, 2875, 2881, "levels" +822, 26, 5, 582, 30, 34, 2882, 2886, "less" +822, 26, 6, 583, 35, 39, 2887, 2891, "than" +822, 26, 7, 584, 40, 41, 2892, 2893, "5" +822, 26, 8, 585, 42, 43, 2894, 2895, "." +822, 26, 9, 586, 44, 45, 2896, 2897, "6" +822, 26, 10, 587, 46, 50, 2898, 2902, "mmol" +822, 26, 11, 588, 51, 52, 2903, 2904, "/" +822, 26, 12, 589, 53, 54, 2905, 2906, "L" +822, 26, 13, 590, 55, 56, 2907, 2908, "(" +822, 26, 14, 591, 57, 58, 2909, 2910, "<" +822, 26, 15, 592, 59, 62, 2911, 2914, "100" +822, 26, 16, 593, 63, 65, 2915, 2917, "mg" +822, 26, 17, 594, 66, 67, 2918, 2919, "/" +822, 26, 18, 595, 68, 70, 2920, 2922, "dL" +822, 26, 19, 596, 71, 72, 2923, 2924, ")" +822, 26, 20, 597, 73, 81, 2925, 2933, "occurred" +822, 26, 21, 598, 82, 84, 2934, 2936, "in" +822, 26, 22, 599, 85, 87, 2937, 2939, "40" +822, 26, 23, 600, 88, 89, 2940, 2941, "%" +822, 26, 24, 601, 90, 92, 2942, 2944, "of" +822, 26, 25, 602, 93, 101, 2945, 2953, "patients" +822, 26, 26, 603, 102, 111, 2954, 2963, "receiving" +822, 26, 27, 604, 112, 115, 2964, 2967, "NPL" +822, 26, 28, 605, 116, 119, 2968, 2971, "and" +822, 26, 29, 606, 120, 122, 2972, 2974, "41" +822, 26, 30, 607, 123, 124, 2975, 2976, "%" +822, 26, 31, 608, 125, 127, 2977, 2979, "of" +822, 26, 32, 609, 128, 136, 2980, 2988, "patients" +822, 26, 33, 610, 137, 146, 2989, 2998, "receiving" +822, 26, 34, 611, 147, 155, 2999, 3007, "glargine" +822, 26, 35, 612, 156, 157, 3008, 3009, "(" +822, 26, 36, 613, 158, 168, 3010, 3020, "difference" +822, 26, 37, 614, 169, 170, 3021, 3022, "," +822, 26, 38, 615, 171, 172, 3023, 3024, "1" +822, 26, 39, 616, 173, 174, 3025, 3026, "." +822, 26, 40, 617, 175, 176, 3027, 3028, "0" +822, 26, 41, 618, 177, 187, 3029, 3039, "percentage" +822, 26, 42, 619, 188, 193, 3040, 3045, "point" +822, 26, 43, 620, 194, 195, 3046, 3047, "[" +822, 26, 44, 621, 196, 198, 3048, 3050, "CI" +822, 26, 45, 622, 199, 200, 3051, 3052, "," +822, 26, 46, 623, 201, 202, 3053, 3054, "-" +822, 26, 47, 624, 203, 204, 3055, 3056, "0" +822, 26, 48, 625, 205, 206, 3057, 3058, "." +822, 26, 49, 626, 207, 208, 3059, 3060, "9" +822, 26, 50, 627, 209, 211, 3061, 3063, "to" +822, 26, 51, 628, 212, 213, 3064, 3065, "3" +822, 26, 52, 629, 214, 215, 3066, 3067, "." +822, 26, 53, 630, 216, 217, 3068, 3069, "0" +822, 26, 54, 631, 218, 228, 3070, 3080, "percentage" +822, 26, 55, 632, 229, 235, 3081, 3087, "points" +822, 26, 56, 633, 236, 237, 3088, 3089, "]" +822, 26, 57, 634, 238, 239, 3090, 3091, ")" +822, 26, 58, 635, 240, 241, 3092, 3093, "." +822, 27, 1, 636, 0, 3, 3094, 3097, "Any" +822, 27, 2, 637, 4, 16, 3098, 3110, "hypoglycemic" +822, 27, 3, 638, 17, 22, 3111, 3116, "event" +822, 27, 4, 639, 23, 31, 3117, 3125, "occurred" +822, 27, 5, 640, 32, 34, 3126, 3128, "in" +822, 27, 6, 641, 35, 37, 3129, 3131, "74" +822, 27, 7, 642, 38, 39, 3132, 3133, "%" +822, 27, 8, 643, 40, 42, 3134, 3136, "of" +822, 27, 9, 644, 43, 51, 3137, 3145, "patients" +822, 27, 10, 645, 52, 61, 3146, 3155, "receiving" +822, 27, 11, 646, 62, 65, 3156, 3159, "NPL" +822, 27, 12, 647, 66, 69, 3160, 3163, "and" +822, 27, 13, 648, 70, 72, 3164, 3166, "67" +822, 27, 14, 649, 73, 74, 3167, 3168, "%" +822, 27, 15, 650, 75, 77, 3169, 3171, "of" +822, 27, 16, 651, 78, 86, 3172, 3180, "patients" +822, 27, 17, 652, 87, 96, 3181, 3190, "receiving" +822, 27, 18, 653, 97, 105, 3191, 3199, "glargine" +822, 27, 19, 654, 106, 107, 3200, 3201, "(" +822, 27, 20, 655, 108, 118, 3202, 3212, "difference" +822, 27, 21, 656, 119, 120, 3213, 3214, "," +822, 27, 22, 657, 121, 122, 3215, 3216, "7" +822, 27, 23, 658, 123, 133, 3217, 3227, "percentage" +822, 27, 24, 659, 134, 140, 3228, 3234, "points" +822, 27, 25, 660, 141, 142, 3235, 3236, "[" +822, 27, 26, 661, 143, 145, 3237, 3239, "CI" +822, 27, 27, 662, 146, 147, 3240, 3241, "," +822, 27, 28, 663, 148, 149, 3242, 3243, "-" +822, 27, 29, 664, 150, 151, 3244, 3245, "5" +822, 27, 30, 665, 152, 154, 3246, 3248, "to" +822, 27, 31, 666, 155, 157, 3249, 3251, "13" +822, 27, 32, 667, 158, 168, 3252, 3262, "percentage" +822, 27, 33, 668, 169, 175, 3263, 3269, "points" +822, 27, 34, 669, 176, 177, 3270, 3271, "]" +822, 27, 35, 670, 178, 179, 3272, 3273, ")" +822, 27, 36, 671, 180, 181, 3274, 3275, "." +822, 28, 1, 672, 0, 10, 3276, 3286, "Continuous" +822, 28, 2, 673, 11, 18, 3287, 3294, "glucose" +822, 28, 3, 674, 19, 24, 3295, 3300, "level" +822, 28, 4, 675, 25, 35, 3301, 3311, "monitoring" +822, 28, 5, 676, 36, 38, 3312, 3314, "in" +822, 28, 6, 677, 39, 42, 3315, 3318, "the" +822, 28, 7, 678, 43, 51, 3319, 3327, "patients" +822, 28, 8, 679, 52, 55, 3328, 3331, "who" +822, 28, 9, 680, 56, 59, 3332, 3335, "had" +822, 28, 10, 681, 60, 64, 3336, 3340, "this" +822, 28, 11, 682, 65, 76, 3341, 3352, "measurement" +822, 28, 12, 683, 77, 80, 3353, 3356, "did" +822, 28, 13, 684, 81, 84, 3357, 3360, "not" +822, 28, 14, 685, 85, 91, 3361, 3367, "differ" +822, 28, 15, 686, 92, 105, 3368, 3381, "statistically" +822, 28, 16, 687, 106, 107, 3382, 3383, "." +822, 29, 1, 688, 0, 10, 3384, 3394, "LIMITATION" +822, 29, 2, 689, 11, 12, 3395, 3396, ":" +822, 29, 3, 690, 13, 16, 3397, 3400, "The" +822, 29, 4, 691, 17, 22, 3401, 3406, "study" +822, 29, 5, 692, 23, 26, 3407, 3410, "was" +822, 29, 6, 693, 27, 30, 3411, 3414, "not" +822, 29, 7, 694, 31, 38, 3415, 3422, "blinded" +822, 29, 8, 695, 39, 40, 3423, 3424, "," +822, 29, 9, 696, 41, 44, 3425, 3428, "had" +822, 29, 10, 697, 45, 52, 3429, 3436, "limited" +822, 29, 11, 698, 53, 58, 3437, 3442, "power" +822, 29, 12, 699, 59, 61, 3443, 3445, "to" +822, 29, 13, 700, 62, 68, 3446, 3452, "detect" +822, 29, 14, 701, 69, 80, 3453, 3464, "differences" +822, 29, 15, 702, 81, 83, 3465, 3467, "in" +822, 29, 16, 703, 84, 96, 3468, 3480, "hypoglycemic" +822, 29, 17, 704, 97, 103, 3481, 3487, "events" +822, 29, 18, 705, 104, 105, 3488, 3489, "," +822, 29, 19, 706, 106, 109, 3490, 3493, "and" +822, 29, 20, 707, 110, 113, 3494, 3497, "did" +822, 29, 21, 708, 114, 117, 3498, 3501, "not" +822, 29, 22, 709, 118, 124, 3502, 3508, "obtain" +822, 29, 23, 710, 125, 135, 3509, 3519, "continuous" +822, 29, 24, 711, 136, 143, 3520, 3527, "glucose" +822, 29, 25, 712, 144, 149, 3528, 3533, "level" +822, 29, 26, 713, 150, 160, 3534, 3544, "monitoring" +822, 29, 27, 714, 161, 164, 3545, 3548, "for" +822, 29, 28, 715, 165, 168, 3549, 3552, "all" +822, 29, 29, 716, 169, 177, 3553, 3561, "patients" +822, 29, 30, 717, 178, 179, 3562, 3563, "." +822, 30, 1, 718, 0, 10, 3564, 3574, "CONCLUSION" +822, 30, 2, 719, 11, 12, 3575, 3576, ":" +822, 30, 3, 720, 13, 20, 3577, 3584, "Similar" +822, 30, 4, 721, 21, 29, 3585, 3593, "glycemic" +822, 30, 5, 722, 30, 37, 3594, 3601, "control" +822, 30, 6, 723, 38, 46, 3602, 3610, "occurred" +822, 30, 7, 724, 47, 51, 3611, 3615, "with" +822, 30, 8, 725, 52, 55, 3616, 3619, "the" +822, 30, 9, 726, 56, 64, 3620, 3628, "addition" +822, 30, 10, 727, 65, 67, 3629, 3631, "of" +822, 30, 11, 728, 68, 71, 3632, 3635, "NPL" +822, 30, 12, 729, 72, 74, 3636, 3638, "or" +822, 30, 13, 730, 75, 83, 3639, 3647, "glargine" +822, 30, 14, 731, 84, 91, 3648, 3655, "insulin" +822, 30, 15, 732, 92, 94, 3656, 3658, "to" +822, 30, 16, 733, 95, 99, 3659, 3663, "oral" +822, 30, 17, 734, 100, 108, 3664, 3672, "regimens" +822, 30, 18, 735, 109, 111, 3673, 3675, "in" +822, 30, 19, 736, 112, 120, 3676, 3684, "patients" +822, 30, 20, 737, 121, 125, 3685, 3689, "with" +822, 30, 21, 738, 126, 132, 3690, 3696, "poorly" +822, 30, 22, 739, 133, 143, 3697, 3707, "controlled" +822, 30, 23, 740, 144, 148, 3708, 3712, "type" +822, 30, 24, 741, 149, 150, 3713, 3714, "2" +822, 30, 25, 742, 151, 159, 3715, 3723, "diabetes" +822, 30, 26, 743, 160, 161, 3724, 3725, "." +822, 31, 1, 744, 0, 12, 3726, 3738, "Hypoglycemia" +822, 31, 2, 745, 13, 16, 3739, 3742, "was" +822, 31, 3, 746, 17, 24, 3743, 3750, "similar" +822, 31, 4, 747, 25, 27, 3751, 3753, "in" +822, 31, 5, 748, 28, 31, 3754, 3757, "the" +822, 31, 6, 749, 32, 33, 3758, 3759, "2" +822, 31, 7, 750, 34, 40, 3760, 3766, "groups" +822, 31, 8, 751, 41, 42, 3767, 3768, "," +822, 31, 9, 752, 43, 46, 3769, 3772, "but" +822, 31, 10, 753, 47, 53, 3773, 3779, "sample" +822, 31, 11, 754, 54, 58, 3780, 3784, "size" +822, 31, 12, 755, 59, 66, 3785, 3792, "limited" +822, 31, 13, 756, 67, 70, 3793, 3796, "the" +822, 31, 14, 757, 71, 78, 3797, 3804, "ability" +822, 31, 15, 758, 79, 81, 3805, 3807, "to" +822, 31, 16, 759, 82, 86, 3808, 3812, "make" +822, 31, 17, 760, 87, 88, 3813, 3814, "a" +822, 31, 18, 761, 89, 97, 3815, 3823, "definite" +822, 31, 19, 762, 98, 104, 3824, 3830, "safety" +822, 31, 20, 763, 105, 115, 3831, 3841, "assessment" +822, 31, 21, 764, 116, 117, 3842, 3843, "." +822, 32, 1, 765, 0, 3, 3844, 3847, "DOI" +822, 32, 2, 766, 4, 5, 3848, 3849, ":" +822, 32, 3, 767, 6, 8, 3850, 3852, "10" +822, 32, 4, 768, 9, 10, 3853, 3854, "." +822, 32, 5, 769, 11, 15, 3855, 3859, "7326" +822, 32, 6, 770, 16, 17, 3860, 3861, "/" +822, 32, 7, 771, 18, 22, 3862, 3866, "0003" +822, 32, 8, 772, 23, 24, 3867, 3868, "-" +822, 32, 9, 773, 25, 29, 3869, 3873, "4819" +822, 32, 10, 774, 30, 31, 3874, 3875, "-" +822, 32, 11, 775, 32, 35, 3876, 3879, "149" +822, 32, 12, 776, 36, 37, 3880, 3881, "-" +822, 32, 13, 777, 38, 39, 3882, 3883, "8" +822, 32, 14, 778, 40, 41, 3884, 3885, "-" +822, 32, 15, 779, 42, 51, 3886, 3895, "200810210" +822, 32, 16, 780, 52, 53, 3896, 3897, "-" +822, 32, 17, 781, 54, 59, 3898, 3903, "00005" +822, 32, 18, 782, 60, 64, 3904, 3908, "PMID" +822, 32, 19, 783, 65, 66, 3909, 3910, ":" +822, 32, 20, 784, 67, 75, 3911, 3919, "18936501" +822, 32, 21, 785, 76, 77, 3920, 3921, "[" +822, 32, 22, 786, 78, 85, 3922, 3929, "Indexed" +822, 32, 23, 787, 86, 89, 3930, 3933, "for" +822, 32, 24, 788, 90, 97, 3934, 3941, "MEDLINE" +822, 32, 25, 789, 98, 99, 3942, 3943, "]" diff --git a/data/dm2 18936501_admin.annodb b/data/dm2 18936501_admin.annodb new file mode 100644 index 0000000..394788a --- /dev/null +++ b/data/dm2 18936501_admin.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Ann Intern Med .", "", " \"Ann Intern Med .\"." +1, PublicationYear, 17, 21, "2008", "", " \"2008\"." +97, Title, 53, 219, "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .", "", " \"Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .\"." +52171, LisproProtamine, 65, 97, "neutral protamine lispro insulin", "", +2, InsulinGlargine, 101, 117, "insulin glargine", "", +94, Type2Diabetes, 126, 141, "type 2 diabetes", "", +4, Precondition, 155, 196, "patients with suboptimal glycemic control", "", +5, Randomized, 201, 211, "randomized", "", +6, Author, 220, 230, "Esposito K", "", " \"Esposito K\"." +7, Author, 239, 248, "Ciotola M", "", " \"Ciotola M\"." +8, Author, 251, 262, "Maiorino MI", "", " \"Maiorino MI\"." +9, Author, 265, 276, "Gualdiero R", "", " \"Gualdiero R\"." +10, Author, 279, 289, "Schisano B", "", " \"Schisano B\"." +11, Author, 292, 302, "Ceriello A", "", " \"Ceriello A\"." +12, Author, 305, 315, "Beneduce F", "", " \"Beneduce F\"." +13, Author, 318, 325, "Feola G", "", " \"Feola G\"." +14, Author, 328, 339, "Giugliano D", "", " \"Giugliano D\"." +15, Italy, 446, 451, "Italy", "", " ." +16, Insulin, 686, 693, "insulin", "", +108, Bedtime, 697, 704, "bedtime", "", +19, Precondition, 742, 816, "patients with type 2 diabetes that is poorly controlled with oral regimens", "", +17, Type2Diabetes, 756, 771, "type 2 diabetes", "", " ." +52176, LisproProtamine, 819, 843, "Neutral protamine lispro", "", +52177, LisproProtamine, 846, 849, "NPL", "", +20, Insulin, 852, 859, "insulin", "", +21, Hypoglycemia, 926, 938, "hypoglycemic", "", +114, Insulin, 959, 993, "neutral protamine Hagedorn insulin", "", +125, ObjectiveDescription, 1008, 1224, "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .", "", " \"To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .\"." +118, Bedtime, 1055, 1062, "bedtime", "", +52179, LisproProtamine, 1063, 1074, "NPL insulin", "", +22, InsulinGlargine, 1078, 1094, "insulin glargine", "", +26, Precondition, 1098, 1222, "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea", "", " \"patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea\"." +23, Type2Diabetes, 1112, 1127, "type 2 diabetes", "", +24, Metformin, 1196, 1205, "metformin", "", +25, Sulfonylureas, 1210, 1222, "sulfonylurea", "", +27, OpenLabel, 1234, 1246, "Open - label", "", " ." +28, Randomized, 1249, 1259, "randomized", "", " ." +29, Italy, 1375, 1380, "Italy", "", +30, NumberPatientsCT, 1394, 1397, "116", "", " \"116\"." +137, Precondition, 1398, 1548, "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %", "", " \"adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %\"." +31, Metformin, 1431, 1440, "metformin", "", +32, Sulfonylureas, 1446, 1458, "sulfonylurea", "", +33, Duration, 1463, 1482, "longer than 90 days", "", +34, HbA1c, 1488, 1507, "hemoglobin A ( 1c )", "", +131, HbA1c, 1510, 1520, "HbA ( 1c )", "", +36, Percentage, 1539, 1540, "%", "", +37, Percentage, 1547, 1548, "%", "", +119910, Precondition, 1553, 1634, "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )", "", " \"fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )\"." +38, FastingPlasmaGlucose, 1553, 1575, "fasting plasma glucose", "", +39, Millimoles_per_litre, 1592, 1600, "mmol / L", "", +40, Mg_per_deciliter, 1625, 1632, "mg / dL", "", +42, DoseValue, 1652, 1654, "10", "", " \"10\". \"10\"." +226, Int_Unit, 1655, 1657, "IU", "", " . ." +52178, LisproProtamine, 1661, 1672, "NPL insulin", "", " ." +43, InsulinGlargine, 1676, 1692, "insulin glargine", "", " ." +144, SubcutaneousInjection, 1693, 1716, "injected subcutaneously", "", " ." +145, Bedtime, 1720, 1727, "bedtime", "", " . ." +46, Frequency, 1733, 1739, "weekly", "", " \"weekly\". \"weekly\"." +102222, DoseDescription, 1740, 1867, "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens", "", " \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\". \"dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens\"." +146, FastingPlasmaGlucose_target, 1766, 1831, "fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +147, Millimoles_per_litre, 1805, 1813, "mmol / L", "", +148, Mg_per_deciliter, 1822, 1829, "mg / dL", "", +45, OralAntidiabeticAgent, 1854, 1867, "oral regimens", "", +149, Bedtime, 1889, 1898, "nighttime", "", +47, Sulfonylureas, 1899, 1911, "sulfonylurea", "", +48, Metformin, 1946, 1955, "metformin", "", +49, HbA1c, 2007, 2017, "HbA ( 1c )", "", +230, TimePoint, 2030, 2038, "baseline", "", +231, TimePoint, 2042, 2049, "week 36", "", +50, HbA1c_target, 2076, 2107, "HbA ( 1c ) levels less than 7 %", "", +154, Percentage, 2106, 2107, "%", "", +51, Hypoglycemia, 2126, 2147, "hypoglycemic episodes", "", +232, InsulinDose, 2150, 2162, "insulin dose", "", +233, Glucose, 2182, 2195, "glucose level", "", +52, BodyWeight, 2202, 2213, "body weight", "", +53, Insulin, 2317, 2324, "insulin", "", +234, TimePoint, 2332, 2339, "week 36", "", +54, HbA1c, 2367, 2377, "HbA ( 1c )", "", " ." +55, Reduction, 2414, 2420, "1 . 83", "", " \"1 . 83\"." +57, Percentage, 2421, 2422, "%", "", " ." +56, Reduction, 2427, 2433, "1 . 89", "", " \"1 . 89\"." +58, Percentage, 2434, 2435, "%", "", +52180, LisproProtamine, 2440, 2443, "NPL", "", +60, InsulinGlargine, 2448, 2456, "glargine", "", +52181, DiffGroupRelValue, 2514, 2520, "0 . 06", "", " \"0 . 06\"." +63, ConfIntervalDiff, 2540, 2567, "95 % CI , - 0 . 1 to 0 . 15", "", " \"95 % CI , - 0 . 1 to 0 . 15\"." +65, HbA1c_target, 2641, 2681, "Hemoglobin A ( 1c ) levels less than 7 %", "", " ." +172, Percentage, 2680, 2681, "%", "", +66, PercentageAffected, 2694, 2696, "62", "", " \"62\"." +52182, LisproProtamine, 2721, 2724, "NPL", "", +67, PercentageAffected, 2729, 2731, "64", "", " \"64\"." +68, InsulinGlargine, 2756, 2764, "glargine", "", +81, DiffGroupRelValue, 2780, 2785, "2 . 0", "", " \"2 . 0\"." +69, ConfIntervalDiff, 2806, 2827, "CI , - 1 . 1 to 5 . 0", "", " \"CI , - 1 . 1 to 5 . 0\"." +70, FastingPlasmaGlucose_target, 2852, 2924, "Fasting plasma glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", " ." +182, Millimoles_per_litre, 2898, 2906, "mmol / L", "", +183, Mg_per_deciliter, 2915, 2922, "mg / dL", "", +71, PercentageAffected, 2937, 2939, "40", "", " \"40\"." +52183, LisproProtamine, 2964, 2967, "NPL", "", +72, PercentageAffected, 2972, 2974, "41", "", " \"41\"." +73, InsulinGlargine, 2999, 3007, "glargine", "", +82, DiffGroupRelValue, 3023, 3028, "1 . 0", "", " \"1 . 0\"." +74, ConfIntervalDiff, 3048, 3069, "CI , - 0 . 9 to 3 . 0", "", " \"CI , - 0 . 9 to 3 . 0\"." +75, Hypoglycemia, 3098, 3110, "hypoglycemic", "", " ." +76, PercentageAffected, 3129, 3131, "74", "", " \"74\"." +52184, LisproProtamine, 3156, 3159, "NPL", "", +77, PercentageAffected, 3164, 3166, "67", "", " \"67\"." +78, InsulinGlargine, 3191, 3199, "glargine", "", +79, DiffGroupRelValue, 3215, 3216, "7", "", " \"7\"." +80, ConfIntervalDiff, 3237, 3251, "CI , - 5 to 13", "", " \"CI , - 5 to 13\"." +240, ObservedResult, 3276, 3383, "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .", "", " \"Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .\"." +239, Glucose, 3287, 3294, "glucose", "", " . ." +207, OpenLabel, 3411, 3422, "not blinded", "", +83, Hypoglycemia, 3468, 3480, "hypoglycemic", "", +241, Glucose, 3520, 3527, "glucose", "", +213, ConclusionComment, 3577, 3725, "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .", "", " \"Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .\"." +52185, LisproProtamine, 3632, 3635, "NPL", "", +84, InsulinGlargine, 3639, 3655, "glargine insulin", "", +85, OralAntidiabeticAgent, 3659, 3672, "oral regimens", "", +86, Type2Diabetes, 3708, 3723, "type 2 diabetes", "", +88, Hypoglycemia, 3726, 3738, "Hypoglycemia", "", +215, ConclusionComment, 3726, 3843, "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .", "", " \"Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .\"." +89, PMID, 3911, 3919, "18936501", "", " \"18936501\"." diff --git a/data/dm2 18936501_admin.n-triples b/data/dm2 18936501_admin.n-triples new file mode 100644 index 0000000..73bdc79 --- /dev/null +++ b/data/dm2 18936501_admin.n-triples @@ -0,0 +1,184 @@ +# RDF export of group: Publication + . + "Publication " . + "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial ." . + "Esposito K" . + "2008" . + "Ann Intern Med ." . + "18936501" . + . + "Ciotola M" . + "Maiorino MI" . + "Gualdiero R" . + "Schisano B" . + "Ceriello A" . + "Beneduce F" . + "Feola G" . + "Giugliano D" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea ." . + "116" . + . + . + . + "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes ." . + . + . + . + . + . + . + "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . + "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea" . + "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %" . + "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint fpg target" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint glucose" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm npl" . + . + . + . + . + . + . + . + "Arm ig" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention npl+oad" . + "weekly" . + . + . + . + "Intervention ig+oad" . + "weekly" . + . + . +# RDF export of group: Medication + . + "Medication npl" . + . + "10" . + . + . + "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens" . + . + "Medication ig" . + . + "10" . + . + . + "dose titrations to target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL ) in addition to stable oral regimens" . +# RDF export of group: Outcome + . + "Outcome hba1c npl" . + . + "1 . 83" . + . + "Outcome hba1c ig" . + . + "1 . 89" . + . + "Outcome hba1c target npl" . + . + "62" . + . + "Outcome hba1c target ig " . + . + "64" . + . + "Outcome fpg target npl " . + . + "40" . + . + "Outcome fpg target ig" . + . + "41" . + . + "Outcome h npl" . + . + "74" . + . + "Outcome h ig" . + . + "67" . + . + "Outcome glucose both drugs" . + . + "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "0 . 06" . + "95 % CI , - 0 . 1 to 0 . 15" . + . + . + . + "DiffBetweenGroups hba1c target " . + "2 . 0" . + "CI , - 1 . 1 to 5 . 0" . + . + . + . + "DiffBetweenGroups fpg target " . + "1 . 0" . + "CI , - 0 . 9 to 3 . 0" . + . + . + . + "DiffBetweenGroups h" . + "7" . + "CI , - 5 to 13" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18936501_akramersunderbrink.annodb b/data/dm2 18936501_akramersunderbrink.annodb new file mode 100644 index 0000000..09045b6 --- /dev/null +++ b/data/dm2 18936501_akramersunderbrink.annodb @@ -0,0 +1,129 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23623, Journal, 0, 14, "Ann Intern Med", "", +23624, PublicationYear, 17, 21, "2008", "", +23630, Title, 53, 219, "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .", "", +23625, Lispro, 65, 97, "neutral protamine lispro insulin", "", +23626, InsulinGlargine, 101, 117, "insulin glargine", "", +23627, Type2Diabetes, 126, 141, "type 2 diabetes", "", +23628, Precondition, 169, 196, "suboptimal glycemic control", "", +23629, Randomized, 201, 211, "randomized", "", +23631, Author, 220, 230, "Esposito K", "", +23632, Author, 239, 248, "Ciotola M", "", +23633, Author, 251, 262, "Maiorino MI", "", +23634, Author, 265, 276, "Gualdiero R", "", +23635, Author, 279, 289, "Schisano B", "", +23636, Author, 292, 302, "Ceriello A", "", +23637, Author, 305, 315, "Beneduce F", "", +23638, Author, 318, 325, "Feola G", "", +23639, Author, 328, 339, "Giugliano D", "", +23640, Italy, 446, 451, "Italy", "", +23644, Insulin, 672, 693, "long - acting insulin", "", +23641, Bedtime, 697, 704, "bedtime", "", +23642, Type2Diabetes, 756, 771, "type 2 diabetes", "", +23643, Precondition, 780, 816, "poorly controlled with oral regimens", "", +23645, Lispro, 819, 843, "Neutral protamine lispro", "", +23646, Lispro, 846, 849, "NPL", "", +23648, Hypoglycemia, 926, 945, "hypoglycemic events", "", +23647, Insulin, 959, 993, "neutral protamine Hagedorn insulin", "", +23658, ObjectiveDescription, 1008, 1224, "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .", "", +23651, Bedtime, 1055, 1062, "bedtime", "", +23649, Lispro, 1063, 1074, "NPL insulin", "", +23650, InsulinGlargine, 1078, 1094, "insulin glargine", "", +23652, Type2Diabetes, 1112, 1127, "type 2 diabetes", "", +23653, Precondition, 1136, 1222, "suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea", "", +23654, Metformin, 1196, 1205, "metformin", "", +23655, Sulfonylureas, 1210, 1222, "sulfonylurea", "", +23656, OpenLabel, 1234, 1246, "Open - label", "", +23657, Randomized, 1249, 1259, "randomized", "", +23661, Italy, 1375, 1380, "Italy", "", +23662, NumberPatientsCT, 1394, 1397, "116", "", +23672, Precondition, 1398, 1482, "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days", "", +23663, Metformin, 1431, 1440, "metformin", "", +23664, Sulfonylureas, 1446, 1458, "sulfonylurea", "", +23665, HbA1c, 1488, 1507, "hemoglobin A ( 1c )", "", +23673, Precondition, 1488, 1548, "hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 %", "", +23666, HbA1c, 1510, 1520, "HbA ( 1c )", "", +23667, Percentage, 1539, 1540, "%", "", +23668, Percentage, 1547, 1548, "%", "", +23671, FastingPlasmaGlucose, 1553, 1575, "fasting plasma glucose", "", +23674, Precondition, 1553, 1634, "fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )", "", +23669, Millimoles_per_litre, 1592, 1600, "mmol / L", "", +23670, Mg_per_deciliter, 1625, 1632, "mg / dL", "", +23675, DoseValue, 1652, 1654, "10", "", +23676, BioAndMedicalUnit, 1655, 1657, "IU", "", +23677, Lispro, 1661, 1672, "NPL insulin", "", +23678, InsulinGlargine, 1676, 1692, "insulin glargine", "", +23679, SubcutaneousInjection, 1693, 1716, "injected subcutaneously", "", +23680, Bedtime, 1720, 1727, "bedtime", "", +23681, FastingPlasmaGlucose_target, 1766, 1831, "fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +23682, Millimoles_per_litre, 1805, 1813, "mmol / L", "", +23683, Mg_per_deciliter, 1822, 1829, "mg / dL", "", +23684, Bedtime, 1889, 1898, "nighttime", "", +23685, Sulfonylureas, 1899, 1911, "sulfonylurea", "", +23686, Metformin, 1946, 1955, "metformin", "", +23687, HbA1c, 2007, 2024, "HbA ( 1c ) levels", "", +39172, TimePoint, 2030, 2038, "baseline", "", +23688, Duration, 2042, 2049, "week 36", "", +23693, HbA1c_target, 2076, 2107, "HbA ( 1c ) levels less than 7 %", "", +23690, Percentage, 2106, 2107, "%", "", +23691, Hypoglycemia, 2126, 2147, "hypoglycemic episodes", "", +23692, BodyWeight, 2202, 2213, "body weight", "", +23694, Duration, 2332, 2339, "week 36", "", +23695, HbA1c, 2367, 2384, "HbA ( 1c ) levels", "", +23696, ChangeValue, 2414, 2420, "1 . 83", "", +23699, Percentage, 2421, 2422, "%", "", +23698, ChangeValue, 2427, 2433, "1 . 89", "", +23700, Percentage, 2434, 2435, "%", "", +23701, Lispro, 2440, 2443, "NPL", "", +23702, InsulinGlargine, 2448, 2456, "glargine", "", +23734, DiffGroupAbsValue, 2514, 2520, "0 . 06", "", +23704, Percentage, 2521, 2537, "percentage point", "", +23705, ConfIntervalDiff, 2540, 2585, "95 % CI , - 0 . 1 to 0 . 15 percentage points", "", +23707, Percentage, 2543, 2544, "%", "", +23706, Percentage, 2568, 2585, "percentage points", "", +23710, HbA1c_target, 2641, 2681, "Hemoglobin A ( 1c ) levels less than 7 %", "", +23711, Percentage, 2680, 2681, "%", "", +23714, PercentageAffected, 2694, 2696, "62", "", +23712, Percentage, 2697, 2698, "%", "", +23709, Lispro, 2721, 2724, "NPL", "", +23715, PercentageAffected, 2729, 2731, "64", "", +23713, Percentage, 2732, 2733, "%", "", +23716, InsulinGlargine, 2756, 2764, "glargine", "", +23732, DiffGroupAbsValue, 2780, 2785, "2 . 0", "", +23720, Percentage, 2786, 2803, "percentage points", "", +23718, ConfIntervalDiff, 2806, 2845, "CI , - 1 . 1 to 5 . 0 percentage points", "", +23719, Percentage, 2828, 2845, "percentage points", "", +23721, FastingPlasmaGlucose_target, 2852, 2924, "Fasting plasma glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +23723, Millimoles_per_litre, 2898, 2906, "mmol / L", "", +23724, Mg_per_deciliter, 2915, 2922, "mg / dL", "", +23729, PercentageAffected, 2937, 2939, "40", "", +23725, Percentage, 2940, 2941, "%", "", +23736, Lispro, 2964, 2967, "NPL", "", +23730, PercentageAffected, 2972, 2974, "41", "", +23726, Percentage, 2975, 2976, "%", "", +23735, InsulinGlargine, 2999, 3007, "glargine", "", +23731, DiffGroupAbsValue, 3023, 3028, "1 . 0", "", +23727, Percentage, 3029, 3045, "percentage point", "", +23733, ConfIntervalDiff, 3048, 3087, "CI , - 0 . 9 to 3 . 0 percentage points", "", +23728, Percentage, 3070, 3087, "percentage points", "", +23737, Hypoglycemia, 3094, 3125, "Any hypoglycemic event occurred", "", +23744, PercentageAffected, 3129, 3131, "74", "", +23738, Percentage, 3132, 3133, "%", "", +23742, Lispro, 3156, 3159, "NPL", "", +23745, PercentageAffected, 3164, 3166, "67", "", +23739, Percentage, 3167, 3168, "%", "", +23743, InsulinGlargine, 3191, 3199, "glargine", "", +23746, DiffGroupAbsValue, 3215, 3216, "7", "", +23740, Percentage, 3217, 3234, "percentage points", "", +23747, ConfIntervalDiff, 3237, 3269, "CI , - 5 to 13 percentage points", "", +23741, Percentage, 3252, 3269, "percentage points", "", +23748, OpenLabel, 3411, 3422, "not blinded", "", +23754, ConclusionComment, 3577, 3725, "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .", "", +23749, Lispro, 3632, 3635, "NPL", "", +23750, InsulinGlargine, 3639, 3655, "glargine insulin", "", +23751, OralAntidiabeticAgent, 3659, 3672, "oral regimens", "", +23753, Precondition, 3690, 3707, "poorly controlled", "", +23752, Type2Diabetes, 3708, 3723, "type 2 diabetes", "", +23755, Hypoglycemia, 3726, 3738, "Hypoglycemia", "", +23756, ConclusionComment, 3726, 3843, "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .", "", +23757, PMID, 3911, 3919, "18936501", "", diff --git a/data/dm2 18936501_akramersunderbrink.n-triples b/data/dm2 18936501_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18936501_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 18936501_export.csv b/data/dm2 18936501_export.csv new file mode 100644 index 0000000..15b4cfb --- /dev/null +++ b/data/dm2 18936501_export.csv @@ -0,0 +1,790 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +342, 1, 1, 1, 0, 3, 0, 3, "Ann" +342, 1, 2, 2, 4, 10, 4, 10, "Intern" +342, 1, 3, 3, 11, 14, 11, 14, "Med" +342, 1, 4, 4, 15, 16, 15, 16, "." +342, 2, 1, 5, 0, 4, 17, 21, "2008" +342, 2, 2, 6, 5, 8, 22, 25, "Oct" +342, 2, 3, 7, 9, 11, 26, 28, "21" +342, 2, 4, 8, 12, 13, 29, 30, ";" +342, 2, 5, 9, 14, 17, 31, 34, "149" +342, 2, 6, 10, 18, 19, 35, 36, "(" +342, 2, 7, 11, 20, 21, 37, 38, "8" +342, 2, 8, 12, 22, 23, 39, 40, ")" +342, 2, 9, 13, 24, 25, 41, 42, ":" +342, 2, 10, 14, 26, 29, 43, 46, "531" +342, 2, 11, 15, 30, 31, 47, 48, "-" +342, 2, 12, 16, 32, 33, 49, 50, "9" +342, 2, 13, 17, 34, 35, 51, 52, "." +342, 3, 1, 18, 0, 8, 53, 61, "Addition" +342, 3, 2, 19, 9, 11, 62, 64, "of" +342, 3, 3, 20, 12, 19, 65, 72, "neutral" +342, 3, 4, 21, 20, 29, 73, 82, "protamine" +342, 3, 5, 22, 30, 36, 83, 89, "lispro" +342, 3, 6, 23, 37, 44, 90, 97, "insulin" +342, 3, 7, 24, 45, 47, 98, 100, "or" +342, 3, 8, 25, 48, 55, 101, 108, "insulin" +342, 3, 9, 26, 56, 64, 109, 117, "glargine" +342, 3, 10, 27, 65, 67, 118, 120, "to" +342, 3, 11, 28, 68, 72, 121, 125, "oral" +342, 3, 12, 29, 73, 77, 126, 130, "type" +342, 3, 13, 30, 78, 79, 131, 132, "2" +342, 3, 14, 31, 80, 88, 133, 141, "diabetes" +342, 3, 15, 32, 89, 97, 142, 150, "regimens" +342, 3, 16, 33, 98, 101, 151, 154, "for" +342, 3, 17, 34, 102, 110, 155, 163, "patients" +342, 3, 18, 35, 111, 115, 164, 168, "with" +342, 3, 19, 36, 116, 126, 169, 179, "suboptimal" +342, 3, 20, 37, 127, 135, 180, 188, "glycemic" +342, 3, 21, 38, 136, 143, 189, 196, "control" +342, 3, 22, 39, 144, 145, 197, 198, ":" +342, 3, 23, 40, 146, 147, 199, 200, "a" +342, 3, 24, 41, 148, 158, 201, 211, "randomized" +342, 3, 25, 42, 159, 164, 212, 217, "trial" +342, 3, 26, 43, 165, 166, 218, 219, "." +342, 4, 1, 44, 0, 8, 220, 228, "Esposito" +342, 4, 2, 45, 9, 10, 229, 230, "K" +342, 4, 3, 46, 11, 12, 231, 232, "(" +342, 4, 4, 47, 13, 14, 233, 234, "1" +342, 4, 5, 48, 15, 16, 235, 236, ")" +342, 4, 6, 49, 17, 18, 237, 238, "," +342, 4, 7, 50, 19, 26, 239, 246, "Ciotola" +342, 4, 8, 51, 27, 28, 247, 248, "M" +342, 4, 9, 52, 29, 30, 249, 250, "," +342, 4, 10, 53, 31, 39, 251, 259, "Maiorino" +342, 4, 11, 54, 40, 42, 260, 262, "MI" +342, 4, 12, 55, 43, 44, 263, 264, "," +342, 4, 13, 56, 45, 54, 265, 274, "Gualdiero" +342, 4, 14, 57, 55, 56, 275, 276, "R" +342, 4, 15, 58, 57, 58, 277, 278, "," +342, 4, 16, 59, 59, 67, 279, 287, "Schisano" +342, 4, 17, 60, 68, 69, 288, 289, "B" +342, 4, 18, 61, 70, 71, 290, 291, "," +342, 4, 19, 62, 72, 80, 292, 300, "Ceriello" +342, 4, 20, 63, 81, 82, 301, 302, "A" +342, 4, 21, 64, 83, 84, 303, 304, "," +342, 4, 22, 65, 85, 93, 305, 313, "Beneduce" +342, 4, 23, 66, 94, 95, 314, 315, "F" +342, 4, 24, 67, 96, 97, 316, 317, "," +342, 4, 25, 68, 98, 103, 318, 323, "Feola" +342, 4, 26, 69, 104, 105, 324, 325, "G" +342, 4, 27, 70, 106, 107, 326, 327, "," +342, 4, 28, 71, 108, 117, 328, 337, "Giugliano" +342, 4, 29, 72, 118, 119, 338, 339, "D" +342, 4, 30, 73, 120, 121, 340, 341, "." +342, 4, 31, 74, 122, 128, 342, 348, "Author" +342, 4, 32, 75, 129, 140, 349, 360, "information" +342, 4, 33, 76, 141, 142, 361, 362, ":" +342, 4, 34, 77, 143, 144, 363, 364, "(" +342, 4, 35, 78, 145, 146, 365, 366, "1" +342, 4, 36, 79, 147, 148, 367, 368, ")" +342, 4, 37, 80, 149, 155, 369, 375, "Second" +342, 4, 38, 81, 156, 166, 376, 386, "University" +342, 4, 39, 82, 167, 169, 387, 389, "of" +342, 4, 40, 83, 170, 176, 390, 396, "Naples" +342, 4, 41, 84, 177, 180, 397, 400, "and" +342, 4, 42, 85, 181, 188, 401, 408, "Azienda" +342, 4, 43, 86, 189, 198, 409, 418, "Sanitaria" +342, 4, 44, 87, 199, 205, 419, 425, "Locale" +342, 4, 45, 88, 206, 212, 426, 432, "Napoli" +342, 4, 46, 89, 213, 214, 433, 434, "5" +342, 4, 47, 90, 215, 216, 435, 436, "," +342, 4, 48, 91, 217, 223, 437, 443, "Naples" +342, 4, 49, 92, 224, 225, 444, 445, "," +342, 4, 50, 93, 226, 231, 446, 451, "Italy" +342, 4, 51, 94, 232, 233, 452, 453, "." +342, 5, 1, 95, 0, 7, 454, 461, "Comment" +342, 5, 2, 96, 8, 10, 462, 464, "in" +342, 5, 3, 97, 11, 14, 465, 468, "Ann" +342, 5, 4, 98, 15, 21, 469, 475, "Intern" +342, 5, 5, 99, 22, 25, 476, 479, "Med" +342, 5, 6, 100, 26, 27, 480, 481, "." +342, 6, 1, 101, 0, 4, 482, 486, "2008" +342, 6, 2, 102, 5, 8, 487, 490, "Oct" +342, 6, 3, 103, 9, 11, 491, 493, "21" +342, 6, 4, 104, 12, 13, 494, 495, ";" +342, 6, 5, 105, 14, 17, 496, 499, "149" +342, 6, 6, 106, 18, 19, 500, 501, "(" +342, 6, 7, 107, 20, 21, 502, 503, "8" +342, 6, 8, 108, 22, 23, 504, 505, ")" +342, 6, 9, 109, 24, 25, 506, 507, ":" +342, 6, 10, 110, 26, 29, 508, 511, "586" +342, 6, 11, 111, 30, 31, 512, 513, "-" +342, 6, 12, 112, 32, 33, 514, 515, "8" +342, 6, 13, 113, 34, 35, 516, 517, "." +342, 7, 1, 114, 0, 7, 518, 525, "Summary" +342, 7, 2, 115, 8, 11, 526, 529, "for" +342, 7, 3, 116, 12, 20, 530, 538, "patients" +342, 7, 4, 117, 21, 23, 539, 541, "in" +342, 7, 5, 118, 24, 27, 542, 545, "Ann" +342, 7, 6, 119, 28, 34, 546, 552, "Intern" +342, 7, 7, 120, 35, 38, 553, 556, "Med" +342, 7, 8, 121, 39, 40, 557, 558, "." +342, 8, 1, 122, 0, 4, 559, 563, "2008" +342, 8, 2, 123, 5, 8, 564, 567, "Oct" +342, 8, 3, 124, 9, 11, 568, 570, "21" +342, 8, 4, 125, 12, 13, 571, 572, ";" +342, 8, 5, 126, 14, 17, 573, 576, "149" +342, 8, 6, 127, 18, 19, 577, 578, "(" +342, 8, 7, 128, 20, 21, 579, 580, "8" +342, 8, 8, 129, 22, 23, 581, 582, ")" +342, 8, 9, 130, 24, 25, 583, 584, ":" +342, 8, 10, 131, 26, 27, 585, 586, "I" +342, 8, 11, 132, 28, 29, 587, 588, "-" +342, 8, 12, 133, 30, 32, 589, 591, "46" +342, 8, 13, 134, 33, 34, 592, 593, "." +342, 9, 1, 135, 0, 3, 594, 597, "Ann" +342, 9, 2, 136, 4, 10, 598, 604, "Intern" +342, 9, 3, 137, 11, 14, 605, 608, "Med" +342, 9, 4, 138, 15, 16, 609, 610, "." +342, 10, 1, 139, 0, 4, 611, 615, "2008" +342, 10, 2, 140, 5, 8, 616, 619, "Oct" +342, 10, 3, 141, 9, 11, 620, 622, "21" +342, 10, 4, 142, 12, 13, 623, 624, ";" +342, 10, 5, 143, 14, 17, 625, 628, "149" +342, 10, 6, 144, 18, 19, 629, 630, "(" +342, 10, 7, 145, 20, 21, 631, 632, "8" +342, 10, 8, 146, 22, 23, 633, 634, ")" +342, 10, 9, 147, 24, 25, 635, 636, ":" +342, 10, 10, 148, 26, 27, 637, 638, "I" +342, 10, 11, 149, 28, 29, 639, 640, "-" +342, 10, 12, 150, 30, 32, 641, 643, "52" +342, 10, 13, 151, 33, 34, 644, 645, "." +342, 11, 1, 152, 0, 10, 646, 656, "BACKGROUND" +342, 11, 2, 153, 11, 12, 657, 658, ":" +342, 11, 3, 154, 13, 22, 659, 668, "Injection" +342, 11, 4, 155, 23, 25, 669, 671, "of" +342, 11, 5, 156, 26, 30, 672, 676, "long" +342, 11, 6, 157, 31, 32, 677, 678, "-" +342, 11, 7, 158, 33, 39, 679, 685, "acting" +342, 11, 8, 159, 40, 47, 686, 693, "insulin" +342, 11, 9, 160, 48, 50, 694, 696, "at" +342, 11, 10, 161, 51, 58, 697, 704, "bedtime" +342, 11, 11, 162, 59, 61, 705, 707, "is" +342, 11, 12, 163, 62, 63, 708, 709, "a" +342, 11, 13, 164, 64, 70, 710, 716, "common" +342, 11, 14, 165, 71, 82, 717, 728, "therapeutic" +342, 11, 15, 166, 83, 91, 729, 737, "approach" +342, 11, 16, 167, 92, 95, 738, 741, "for" +342, 11, 17, 168, 96, 104, 742, 750, "patients" +342, 11, 18, 169, 105, 109, 751, 755, "with" +342, 11, 19, 170, 110, 114, 756, 760, "type" +342, 11, 20, 171, 115, 116, 761, 762, "2" +342, 11, 21, 172, 117, 125, 763, 771, "diabetes" +342, 11, 22, 173, 126, 130, 772, 776, "that" +342, 11, 23, 174, 131, 133, 777, 779, "is" +342, 11, 24, 175, 134, 140, 780, 786, "poorly" +342, 11, 25, 176, 141, 151, 787, 797, "controlled" +342, 11, 26, 177, 152, 156, 798, 802, "with" +342, 11, 27, 178, 157, 161, 803, 807, "oral" +342, 11, 28, 179, 162, 170, 808, 816, "regimens" +342, 11, 29, 180, 171, 172, 817, 818, "." +342, 12, 1, 181, 0, 7, 819, 826, "Neutral" +342, 12, 2, 182, 8, 17, 827, 836, "protamine" +342, 12, 3, 183, 18, 24, 837, 843, "lispro" +342, 12, 4, 184, 25, 26, 844, 845, "(" +342, 12, 5, 185, 27, 30, 846, 849, "NPL" +342, 12, 6, 186, 31, 32, 850, 851, ")" +342, 12, 7, 187, 33, 40, 852, 859, "insulin" +342, 12, 8, 188, 41, 44, 860, 863, "has" +342, 12, 9, 189, 45, 57, 864, 876, "demonstrated" +342, 12, 10, 190, 58, 64, 877, 883, "better" +342, 12, 11, 191, 65, 73, 884, 892, "glycemic" +342, 12, 12, 192, 74, 81, 893, 900, "control" +342, 12, 13, 193, 82, 85, 901, 904, "and" +342, 12, 14, 194, 86, 93, 905, 912, "similar" +342, 12, 15, 195, 94, 103, 913, 922, "incidence" +342, 12, 16, 196, 104, 106, 923, 925, "of" +342, 12, 17, 197, 107, 119, 926, 938, "hypoglycemic" +342, 12, 18, 198, 120, 126, 939, 945, "events" +342, 12, 19, 199, 127, 131, 946, 950, "than" +342, 12, 20, 200, 132, 136, 951, 955, "that" +342, 12, 21, 201, 137, 139, 956, 958, "of" +342, 12, 22, 202, 140, 147, 959, 966, "neutral" +342, 12, 23, 203, 148, 157, 967, 976, "protamine" +342, 12, 24, 204, 158, 166, 977, 985, "Hagedorn" +342, 12, 25, 205, 167, 174, 986, 993, "insulin" +342, 12, 26, 206, 175, 176, 994, 995, "." +342, 13, 1, 207, 0, 9, 996, 1005, "OBJECTIVE" +342, 13, 2, 208, 10, 11, 1006, 1007, ":" +342, 13, 3, 209, 12, 14, 1008, 1010, "To" +342, 13, 4, 210, 15, 22, 1011, 1018, "compare" +342, 13, 5, 211, 23, 26, 1019, 1022, "the" +342, 13, 6, 212, 27, 35, 1023, 1031, "clinical" +342, 13, 7, 213, 36, 44, 1032, 1040, "efficacy" +342, 13, 8, 214, 45, 48, 1041, 1044, "and" +342, 13, 9, 215, 49, 55, 1045, 1051, "safety" +342, 13, 10, 216, 56, 58, 1052, 1054, "of" +342, 13, 11, 217, 59, 66, 1055, 1062, "bedtime" +342, 13, 12, 218, 67, 70, 1063, 1066, "NPL" +342, 13, 13, 219, 71, 78, 1067, 1074, "insulin" +342, 13, 14, 220, 79, 81, 1075, 1077, "or" +342, 13, 15, 221, 82, 89, 1078, 1085, "insulin" +342, 13, 16, 222, 90, 98, 1086, 1094, "glargine" +342, 13, 17, 223, 99, 101, 1095, 1097, "in" +342, 13, 18, 224, 102, 110, 1098, 1106, "patients" +342, 13, 19, 225, 111, 115, 1107, 1111, "with" +342, 13, 20, 226, 116, 120, 1112, 1116, "type" +342, 13, 21, 227, 121, 122, 1117, 1118, "2" +342, 13, 22, 228, 123, 131, 1119, 1127, "diabetes" +342, 13, 23, 229, 132, 135, 1128, 1131, "who" +342, 13, 24, 230, 136, 139, 1132, 1135, "had" +342, 13, 25, 231, 140, 150, 1136, 1146, "suboptimal" +342, 13, 26, 232, 151, 159, 1147, 1155, "glycemic" +342, 13, 27, 233, 160, 167, 1156, 1163, "control" +342, 13, 28, 234, 168, 173, 1164, 1169, "while" +342, 13, 29, 235, 174, 183, 1170, 1179, "receiving" +342, 13, 30, 236, 184, 190, 1180, 1186, "stable" +342, 13, 31, 237, 191, 196, 1187, 1192, "doses" +342, 13, 32, 238, 197, 199, 1193, 1195, "of" +342, 13, 33, 239, 200, 209, 1196, 1205, "metformin" +342, 13, 34, 240, 210, 213, 1206, 1209, "and" +342, 13, 35, 241, 214, 226, 1210, 1222, "sulfonylurea" +342, 13, 36, 242, 227, 228, 1223, 1224, "." +342, 14, 1, 243, 0, 6, 1225, 1231, "DESIGN" +342, 14, 2, 244, 7, 8, 1232, 1233, ":" +342, 14, 3, 245, 9, 13, 1234, 1238, "Open" +342, 14, 4, 246, 14, 15, 1239, 1240, "-" +342, 14, 5, 247, 16, 21, 1241, 1246, "label" +342, 14, 6, 248, 22, 23, 1247, 1248, "," +342, 14, 7, 249, 24, 34, 1249, 1259, "randomized" +342, 14, 8, 250, 35, 40, 1260, 1265, "trial" +342, 14, 9, 251, 41, 42, 1266, 1267, "." +342, 15, 1, 252, 0, 7, 1268, 1275, "SETTING" +342, 15, 2, 253, 8, 9, 1276, 1277, ":" +342, 15, 3, 254, 10, 18, 1278, 1286, "Teaching" +342, 15, 4, 255, 19, 27, 1287, 1295, "hospital" +342, 15, 5, 256, 28, 29, 1296, 1297, "(" +342, 15, 6, 257, 30, 37, 1298, 1305, "Azienda" +342, 15, 7, 258, 38, 49, 1306, 1317, "Ospedaliera" +342, 15, 8, 259, 50, 63, 1318, 1331, "Universitaria" +342, 15, 9, 260, 64, 65, 1332, 1333, "," +342, 15, 10, 261, 66, 72, 1334, 1340, "Second" +342, 15, 11, 262, 73, 83, 1341, 1351, "University" +342, 15, 12, 263, 84, 86, 1352, 1354, "of" +342, 15, 13, 264, 87, 93, 1355, 1361, "Naples" +342, 15, 14, 265, 94, 95, 1362, 1363, ")" +342, 15, 15, 266, 96, 97, 1364, 1365, "," +342, 15, 16, 267, 98, 104, 1366, 1372, "Naples" +342, 15, 17, 268, 105, 106, 1373, 1374, "," +342, 15, 18, 269, 107, 112, 1375, 1380, "Italy" +342, 15, 19, 270, 113, 114, 1381, 1382, "." +342, 16, 1, 271, 0, 8, 1383, 1391, "PATIENTS" +342, 16, 2, 272, 9, 10, 1392, 1393, ":" +342, 16, 3, 273, 11, 14, 1394, 1397, "116" +342, 16, 4, 274, 15, 21, 1398, 1404, "adults" +342, 16, 5, 275, 22, 31, 1405, 1414, "receiving" +342, 16, 6, 276, 32, 38, 1415, 1421, "stable" +342, 16, 7, 277, 39, 44, 1422, 1427, "doses" +342, 16, 8, 278, 45, 47, 1428, 1430, "of" +342, 16, 9, 279, 48, 57, 1431, 1440, "metformin" +342, 16, 10, 280, 58, 62, 1441, 1445, "plus" +342, 16, 11, 281, 63, 75, 1446, 1458, "sulfonylurea" +342, 16, 12, 282, 76, 79, 1459, 1462, "for" +342, 16, 13, 283, 80, 86, 1463, 1469, "longer" +342, 16, 14, 284, 87, 91, 1470, 1474, "than" +342, 16, 15, 285, 92, 94, 1475, 1477, "90" +342, 16, 16, 286, 95, 99, 1478, 1482, "days" +342, 16, 17, 287, 100, 104, 1483, 1487, "with" +342, 16, 18, 288, 105, 115, 1488, 1498, "hemoglobin" +342, 16, 19, 289, 116, 117, 1499, 1500, "A" +342, 16, 20, 290, 118, 119, 1501, 1502, "(" +342, 16, 21, 291, 120, 122, 1503, 1505, "1c" +342, 16, 22, 292, 123, 124, 1506, 1507, ")" +342, 16, 23, 293, 125, 126, 1508, 1509, "(" +342, 16, 24, 294, 127, 130, 1510, 1513, "HbA" +342, 16, 25, 295, 131, 132, 1514, 1515, "(" +342, 16, 26, 296, 133, 135, 1516, 1518, "1c" +342, 16, 27, 297, 136, 137, 1519, 1520, ")" +342, 16, 28, 298, 138, 139, 1521, 1522, ")" +342, 16, 29, 299, 140, 146, 1523, 1529, "levels" +342, 16, 30, 300, 147, 149, 1530, 1532, "of" +342, 16, 31, 301, 150, 151, 1533, 1534, "7" +342, 16, 32, 302, 152, 153, 1535, 1536, "." +342, 16, 33, 303, 154, 155, 1537, 1538, "5" +342, 16, 34, 304, 156, 157, 1539, 1540, "%" +342, 16, 35, 305, 158, 160, 1541, 1543, "to" +342, 16, 36, 306, 161, 163, 1544, 1546, "10" +342, 16, 37, 307, 164, 165, 1547, 1548, "%" +342, 16, 38, 308, 166, 169, 1549, 1552, "and" +342, 16, 39, 309, 170, 177, 1553, 1560, "fasting" +342, 16, 40, 310, 178, 184, 1561, 1567, "plasma" +342, 16, 41, 311, 185, 192, 1568, 1575, "glucose" +342, 16, 42, 312, 193, 199, 1576, 1582, "levels" +342, 16, 43, 313, 200, 202, 1583, 1585, "of" +342, 16, 44, 314, 203, 204, 1586, 1587, "6" +342, 16, 45, 315, 205, 206, 1588, 1589, "." +342, 16, 46, 316, 207, 208, 1590, 1591, "7" +342, 16, 47, 317, 209, 213, 1592, 1596, "mmol" +342, 16, 48, 318, 214, 215, 1597, 1598, "/" +342, 16, 49, 319, 216, 217, 1599, 1600, "L" +342, 16, 50, 320, 218, 220, 1601, 1603, "or" +342, 16, 51, 321, 221, 228, 1604, 1611, "greater" +342, 16, 52, 322, 229, 230, 1612, 1613, "(" +342, 16, 53, 323, 231, 232, 1614, 1615, ">" +342, 16, 54, 324, 233, 235, 1616, 1618, "or" +342, 16, 55, 325, 236, 237, 1619, 1620, "=" +342, 16, 56, 326, 238, 241, 1621, 1624, "120" +342, 16, 57, 327, 242, 244, 1625, 1627, "mg" +342, 16, 58, 328, 245, 246, 1628, 1629, "/" +342, 16, 59, 329, 247, 249, 1630, 1632, "dL" +342, 16, 60, 330, 250, 251, 1633, 1634, ")" +342, 16, 61, 331, 252, 253, 1635, 1636, "." +342, 17, 1, 332, 0, 12, 1637, 1649, "INTERVENTION" +342, 17, 2, 333, 13, 14, 1650, 1651, ":" +342, 17, 3, 334, 15, 17, 1652, 1654, "10" +342, 17, 4, 335, 18, 20, 1655, 1657, "IU" +342, 17, 5, 336, 21, 23, 1658, 1660, "of" +342, 17, 6, 337, 24, 27, 1661, 1664, "NPL" +342, 17, 7, 338, 28, 35, 1665, 1672, "insulin" +342, 17, 8, 339, 36, 38, 1673, 1675, "or" +342, 17, 9, 340, 39, 46, 1676, 1683, "insulin" +342, 17, 10, 341, 47, 55, 1684, 1692, "glargine" +342, 17, 11, 342, 56, 64, 1693, 1701, "injected" +342, 17, 12, 343, 65, 79, 1702, 1716, "subcutaneously" +342, 17, 13, 344, 80, 82, 1717, 1719, "at" +342, 17, 14, 345, 83, 90, 1720, 1727, "bedtime" +342, 17, 15, 346, 91, 95, 1728, 1732, "with" +342, 17, 16, 347, 96, 102, 1733, 1739, "weekly" +342, 17, 17, 348, 103, 107, 1740, 1744, "dose" +342, 17, 18, 349, 108, 118, 1745, 1755, "titrations" +342, 17, 19, 350, 119, 121, 1756, 1758, "to" +342, 17, 20, 351, 122, 128, 1759, 1765, "target" +342, 17, 21, 352, 129, 136, 1766, 1773, "fasting" +342, 17, 22, 353, 137, 144, 1774, 1781, "glucose" +342, 17, 23, 354, 145, 151, 1782, 1788, "levels" +342, 17, 24, 355, 152, 156, 1789, 1793, "less" +342, 17, 25, 356, 157, 161, 1794, 1798, "than" +342, 17, 26, 357, 162, 163, 1799, 1800, "5" +342, 17, 27, 358, 164, 165, 1801, 1802, "." +342, 17, 28, 359, 166, 167, 1803, 1804, "6" +342, 17, 29, 360, 168, 172, 1805, 1809, "mmol" +342, 17, 30, 361, 173, 174, 1810, 1811, "/" +342, 17, 31, 362, 175, 176, 1812, 1813, "L" +342, 17, 32, 363, 177, 178, 1814, 1815, "(" +342, 17, 33, 364, 179, 180, 1816, 1817, "<" +342, 17, 34, 365, 181, 184, 1818, 1821, "100" +342, 17, 35, 366, 185, 187, 1822, 1824, "mg" +342, 17, 36, 367, 188, 189, 1825, 1826, "/" +342, 17, 37, 368, 190, 192, 1827, 1829, "dL" +342, 17, 38, 369, 193, 194, 1830, 1831, ")" +342, 17, 39, 370, 195, 197, 1832, 1834, "in" +342, 17, 40, 371, 198, 206, 1835, 1843, "addition" +342, 17, 41, 372, 207, 209, 1844, 1846, "to" +342, 17, 42, 373, 210, 216, 1847, 1853, "stable" +342, 17, 43, 374, 217, 221, 1854, 1858, "oral" +342, 17, 44, 375, 222, 230, 1859, 1867, "regimens" +342, 17, 45, 376, 231, 232, 1868, 1869, "." +342, 18, 1, 377, 0, 8, 1870, 1878, "Patients" +342, 18, 2, 378, 9, 18, 1879, 1888, "receiving" +342, 18, 3, 379, 19, 28, 1889, 1898, "nighttime" +342, 18, 4, 380, 29, 41, 1899, 1911, "sulfonylurea" +342, 18, 5, 381, 42, 48, 1912, 1918, "before" +342, 18, 6, 382, 49, 52, 1919, 1922, "the" +342, 18, 7, 383, 53, 58, 1923, 1928, "study" +342, 18, 8, 384, 59, 63, 1929, 1933, "were" +342, 18, 9, 385, 64, 72, 1934, 1942, "switched" +342, 18, 10, 386, 73, 75, 1943, 1945, "to" +342, 18, 11, 387, 76, 85, 1946, 1955, "metformin" +342, 18, 12, 388, 86, 87, 1956, 1957, "." +342, 19, 1, 389, 0, 12, 1958, 1970, "MEASUREMENTS" +342, 19, 2, 390, 13, 14, 1971, 1972, ":" +342, 19, 3, 391, 15, 18, 1973, 1976, "The" +342, 19, 4, 392, 19, 26, 1977, 1984, "primary" +342, 19, 5, 393, 27, 34, 1985, 1992, "outcome" +342, 19, 6, 394, 35, 38, 1993, 1996, "was" +342, 19, 7, 395, 39, 45, 1997, 2003, "change" +342, 19, 8, 396, 46, 48, 2004, 2006, "in" +342, 19, 9, 397, 49, 52, 2007, 2010, "HbA" +342, 19, 10, 398, 53, 54, 2011, 2012, "(" +342, 19, 11, 399, 55, 57, 2013, 2015, "1c" +342, 19, 12, 400, 58, 59, 2016, 2017, ")" +342, 19, 13, 401, 60, 66, 2018, 2024, "levels" +342, 19, 14, 402, 67, 71, 2025, 2029, "from" +342, 19, 15, 403, 72, 80, 2030, 2038, "baseline" +342, 19, 16, 404, 81, 83, 2039, 2041, "to" +342, 19, 17, 405, 84, 88, 2042, 2046, "week" +342, 19, 18, 406, 89, 91, 2047, 2049, "36" +342, 19, 19, 407, 92, 93, 2050, 2051, "." +342, 20, 1, 408, 0, 9, 2052, 2061, "Secondary" +342, 20, 2, 409, 10, 18, 2062, 2070, "outcomes" +342, 20, 3, 410, 19, 23, 2071, 2075, "were" +342, 20, 4, 411, 24, 27, 2076, 2079, "HbA" +342, 20, 5, 412, 28, 29, 2080, 2081, "(" +342, 20, 6, 413, 30, 32, 2082, 2084, "1c" +342, 20, 7, 414, 33, 34, 2085, 2086, ")" +342, 20, 8, 415, 35, 41, 2087, 2093, "levels" +342, 20, 9, 416, 42, 46, 2094, 2098, "less" +342, 20, 10, 417, 47, 51, 2099, 2103, "than" +342, 20, 11, 418, 52, 53, 2104, 2105, "7" +342, 20, 12, 419, 54, 55, 2106, 2107, "%" +342, 20, 13, 420, 56, 57, 2108, 2109, "," +342, 20, 14, 421, 58, 62, 2110, 2114, "self" +342, 20, 15, 422, 63, 64, 2115, 2116, "-" +342, 20, 16, 423, 65, 73, 2117, 2125, "reported" +342, 20, 17, 424, 74, 86, 2126, 2138, "hypoglycemic" +342, 20, 18, 425, 87, 95, 2139, 2147, "episodes" +342, 20, 19, 426, 96, 97, 2148, 2149, "," +342, 20, 20, 427, 98, 105, 2150, 2157, "insulin" +342, 20, 21, 428, 106, 110, 2158, 2162, "dose" +342, 20, 22, 429, 111, 112, 2163, 2164, "," +342, 20, 23, 430, 113, 117, 2165, 2169, "self" +342, 20, 24, 431, 118, 119, 2170, 2171, "-" +342, 20, 25, 432, 120, 129, 2172, 2181, "monitored" +342, 20, 26, 433, 130, 137, 2182, 2189, "glucose" +342, 20, 27, 434, 138, 143, 2190, 2195, "level" +342, 20, 28, 435, 144, 145, 2196, 2197, "," +342, 20, 29, 436, 146, 149, 2198, 2201, "and" +342, 20, 30, 437, 150, 154, 2202, 2206, "body" +342, 20, 31, 438, 155, 161, 2207, 2213, "weight" +342, 20, 32, 439, 162, 163, 2214, 2215, "." +342, 21, 1, 440, 0, 6, 2216, 2222, "Twenty" +342, 21, 2, 441, 7, 15, 2223, 2231, "patients" +342, 21, 3, 442, 16, 18, 2232, 2234, "in" +342, 21, 4, 443, 19, 23, 2235, 2239, "each" +342, 21, 5, 444, 24, 29, 2240, 2245, "group" +342, 21, 6, 445, 30, 33, 2246, 2249, "had" +342, 21, 7, 446, 34, 44, 2250, 2260, "continuous" +342, 21, 8, 447, 45, 52, 2261, 2268, "glucose" +342, 21, 9, 448, 53, 63, 2269, 2279, "monitoring" +342, 21, 10, 449, 64, 67, 2280, 2283, "for" +342, 21, 11, 450, 68, 69, 2284, 2285, "3" +342, 21, 12, 451, 70, 81, 2286, 2297, "consecutive" +342, 21, 13, 452, 82, 86, 2298, 2302, "days" +342, 21, 14, 453, 87, 93, 2303, 2309, "before" +342, 21, 15, 454, 94, 100, 2310, 2316, "adding" +342, 21, 16, 455, 101, 108, 2317, 2324, "insulin" +342, 21, 17, 456, 109, 112, 2325, 2328, "and" +342, 21, 18, 457, 113, 115, 2329, 2331, "at" +342, 21, 19, 458, 116, 120, 2332, 2336, "week" +342, 21, 20, 459, 121, 123, 2337, 2339, "36" +342, 21, 21, 460, 124, 125, 2340, 2341, "." +342, 22, 1, 461, 0, 7, 2342, 2349, "RESULTS" +342, 22, 2, 462, 8, 9, 2350, 2351, ":" +342, 22, 3, 463, 10, 21, 2352, 2363, "Improvement" +342, 22, 4, 464, 22, 24, 2364, 2366, "in" +342, 22, 5, 465, 25, 28, 2367, 2370, "HbA" +342, 22, 6, 466, 29, 30, 2371, 2372, "(" +342, 22, 7, 467, 31, 33, 2373, 2375, "1c" +342, 22, 8, 468, 34, 35, 2376, 2377, ")" +342, 22, 9, 469, 36, 42, 2378, 2384, "levels" +342, 22, 10, 470, 43, 46, 2385, 2388, "was" +342, 22, 11, 471, 47, 54, 2389, 2396, "similar" +342, 22, 12, 472, 55, 57, 2397, 2399, "in" +342, 22, 13, 473, 58, 62, 2400, 2404, "both" +342, 22, 14, 474, 63, 69, 2405, 2411, "groups" +342, 22, 15, 475, 70, 71, 2412, 2413, "(" +342, 22, 16, 476, 72, 73, 2414, 2415, "1" +342, 22, 17, 477, 74, 75, 2416, 2417, "." +342, 22, 18, 478, 76, 78, 2418, 2420, "83" +342, 22, 19, 479, 79, 80, 2421, 2422, "%" +342, 22, 20, 480, 81, 84, 2423, 2426, "and" +342, 22, 21, 481, 85, 86, 2427, 2428, "1" +342, 22, 22, 482, 87, 88, 2429, 2430, "." +342, 22, 23, 483, 89, 91, 2431, 2433, "89" +342, 22, 24, 484, 92, 93, 2434, 2435, "%" +342, 22, 25, 485, 94, 97, 2436, 2439, "for" +342, 22, 26, 486, 98, 101, 2440, 2443, "NPL" +342, 22, 27, 487, 102, 105, 2444, 2447, "and" +342, 22, 28, 488, 106, 114, 2448, 2456, "glargine" +342, 22, 29, 489, 115, 116, 2457, 2458, "," +342, 22, 30, 490, 117, 129, 2459, 2471, "respectively" +342, 22, 31, 491, 130, 131, 2472, 2473, ")" +342, 22, 32, 492, 132, 133, 2474, 2475, "." +342, 23, 1, 493, 0, 3, 2476, 2479, "The" +342, 23, 2, 494, 4, 14, 2480, 2490, "difference" +342, 23, 3, 495, 15, 22, 2491, 2498, "between" +342, 23, 4, 496, 23, 26, 2499, 2502, "the" +342, 23, 5, 497, 27, 33, 2503, 2509, "groups" +342, 23, 6, 498, 34, 37, 2510, 2513, "was" +342, 23, 7, 499, 38, 39, 2514, 2515, "0" +342, 23, 8, 500, 40, 41, 2516, 2517, "." +342, 23, 9, 501, 42, 44, 2518, 2520, "06" +342, 23, 10, 502, 45, 55, 2521, 2531, "percentage" +342, 23, 11, 503, 56, 61, 2532, 2537, "point" +342, 23, 12, 504, 62, 63, 2538, 2539, "(" +342, 23, 13, 505, 64, 66, 2540, 2542, "95" +342, 23, 14, 506, 67, 68, 2543, 2544, "%" +342, 23, 15, 507, 69, 71, 2545, 2547, "CI" +342, 23, 16, 508, 72, 73, 2548, 2549, "," +342, 23, 17, 509, 74, 75, 2550, 2551, "-" +342, 23, 18, 510, 76, 77, 2552, 2553, "0" +342, 23, 19, 511, 78, 79, 2554, 2555, "." +342, 23, 20, 512, 80, 81, 2556, 2557, "1" +342, 23, 21, 513, 82, 84, 2558, 2560, "to" +342, 23, 22, 514, 85, 86, 2561, 2562, "0" +342, 23, 23, 515, 87, 88, 2563, 2564, "." +342, 23, 24, 516, 89, 91, 2565, 2567, "15" +342, 23, 25, 517, 92, 102, 2568, 2578, "percentage" +342, 23, 26, 518, 103, 109, 2579, 2585, "points" +342, 23, 27, 519, 110, 111, 2586, 2587, ")" +342, 23, 28, 520, 112, 113, 2588, 2589, "." +342, 24, 1, 521, 0, 9, 2590, 2599, "Secondary" +342, 24, 2, 522, 10, 18, 2600, 2608, "outcomes" +342, 24, 3, 523, 19, 22, 2609, 2612, "did" +342, 24, 4, 524, 23, 26, 2613, 2616, "not" +342, 24, 5, 525, 27, 33, 2617, 2623, "differ" +342, 24, 6, 526, 34, 41, 2624, 2631, "between" +342, 24, 7, 527, 42, 48, 2632, 2638, "groups" +342, 24, 8, 528, 49, 50, 2639, 2640, "." +342, 25, 1, 529, 0, 10, 2641, 2651, "Hemoglobin" +342, 25, 2, 530, 11, 12, 2652, 2653, "A" +342, 25, 3, 531, 13, 14, 2654, 2655, "(" +342, 25, 4, 532, 15, 17, 2656, 2658, "1c" +342, 25, 5, 533, 18, 19, 2659, 2660, ")" +342, 25, 6, 534, 20, 26, 2661, 2667, "levels" +342, 25, 7, 535, 27, 31, 2668, 2672, "less" +342, 25, 8, 536, 32, 36, 2673, 2677, "than" +342, 25, 9, 537, 37, 38, 2678, 2679, "7" +342, 25, 10, 538, 39, 40, 2680, 2681, "%" +342, 25, 11, 539, 41, 49, 2682, 2690, "occurred" +342, 25, 12, 540, 50, 52, 2691, 2693, "in" +342, 25, 13, 541, 53, 55, 2694, 2696, "62" +342, 25, 14, 542, 56, 57, 2697, 2698, "%" +342, 25, 15, 543, 58, 60, 2699, 2701, "of" +342, 25, 16, 544, 61, 69, 2702, 2710, "patients" +342, 25, 17, 545, 70, 79, 2711, 2720, "receiving" +342, 25, 18, 546, 80, 83, 2721, 2724, "NPL" +342, 25, 19, 547, 84, 87, 2725, 2728, "and" +342, 25, 20, 548, 88, 90, 2729, 2731, "64" +342, 25, 21, 549, 91, 92, 2732, 2733, "%" +342, 25, 22, 550, 93, 95, 2734, 2736, "of" +342, 25, 23, 551, 96, 104, 2737, 2745, "patients" +342, 25, 24, 552, 105, 114, 2746, 2755, "receiving" +342, 25, 25, 553, 115, 123, 2756, 2764, "glargine" +342, 25, 26, 554, 124, 125, 2765, 2766, "(" +342, 25, 27, 555, 126, 136, 2767, 2777, "difference" +342, 25, 28, 556, 137, 138, 2778, 2779, "," +342, 25, 29, 557, 139, 140, 2780, 2781, "2" +342, 25, 30, 558, 141, 142, 2782, 2783, "." +342, 25, 31, 559, 143, 144, 2784, 2785, "0" +342, 25, 32, 560, 145, 155, 2786, 2796, "percentage" +342, 25, 33, 561, 156, 162, 2797, 2803, "points" +342, 25, 34, 562, 163, 164, 2804, 2805, "[" +342, 25, 35, 563, 165, 167, 2806, 2808, "CI" +342, 25, 36, 564, 168, 169, 2809, 2810, "," +342, 25, 37, 565, 170, 171, 2811, 2812, "-" +342, 25, 38, 566, 172, 173, 2813, 2814, "1" +342, 25, 39, 567, 174, 175, 2815, 2816, "." +342, 25, 40, 568, 176, 177, 2817, 2818, "1" +342, 25, 41, 569, 178, 180, 2819, 2821, "to" +342, 25, 42, 570, 181, 182, 2822, 2823, "5" +342, 25, 43, 571, 183, 184, 2824, 2825, "." +342, 25, 44, 572, 185, 186, 2826, 2827, "0" +342, 25, 45, 573, 187, 197, 2828, 2838, "percentage" +342, 25, 46, 574, 198, 204, 2839, 2845, "points" +342, 25, 47, 575, 205, 206, 2846, 2847, "]" +342, 25, 48, 576, 207, 208, 2848, 2849, ")" +342, 25, 49, 577, 209, 210, 2850, 2851, "." +342, 26, 1, 578, 0, 7, 2852, 2859, "Fasting" +342, 26, 2, 579, 8, 14, 2860, 2866, "plasma" +342, 26, 3, 580, 15, 22, 2867, 2874, "glucose" +342, 26, 4, 581, 23, 29, 2875, 2881, "levels" +342, 26, 5, 582, 30, 34, 2882, 2886, "less" +342, 26, 6, 583, 35, 39, 2887, 2891, "than" +342, 26, 7, 584, 40, 41, 2892, 2893, "5" +342, 26, 8, 585, 42, 43, 2894, 2895, "." +342, 26, 9, 586, 44, 45, 2896, 2897, "6" +342, 26, 10, 587, 46, 50, 2898, 2902, "mmol" +342, 26, 11, 588, 51, 52, 2903, 2904, "/" +342, 26, 12, 589, 53, 54, 2905, 2906, "L" +342, 26, 13, 590, 55, 56, 2907, 2908, "(" +342, 26, 14, 591, 57, 58, 2909, 2910, "<" +342, 26, 15, 592, 59, 62, 2911, 2914, "100" +342, 26, 16, 593, 63, 65, 2915, 2917, "mg" +342, 26, 17, 594, 66, 67, 2918, 2919, "/" +342, 26, 18, 595, 68, 70, 2920, 2922, "dL" +342, 26, 19, 596, 71, 72, 2923, 2924, ")" +342, 26, 20, 597, 73, 81, 2925, 2933, "occurred" +342, 26, 21, 598, 82, 84, 2934, 2936, "in" +342, 26, 22, 599, 85, 87, 2937, 2939, "40" +342, 26, 23, 600, 88, 89, 2940, 2941, "%" +342, 26, 24, 601, 90, 92, 2942, 2944, "of" +342, 26, 25, 602, 93, 101, 2945, 2953, "patients" +342, 26, 26, 603, 102, 111, 2954, 2963, "receiving" +342, 26, 27, 604, 112, 115, 2964, 2967, "NPL" +342, 26, 28, 605, 116, 119, 2968, 2971, "and" +342, 26, 29, 606, 120, 122, 2972, 2974, "41" +342, 26, 30, 607, 123, 124, 2975, 2976, "%" +342, 26, 31, 608, 125, 127, 2977, 2979, "of" +342, 26, 32, 609, 128, 136, 2980, 2988, "patients" +342, 26, 33, 610, 137, 146, 2989, 2998, "receiving" +342, 26, 34, 611, 147, 155, 2999, 3007, "glargine" +342, 26, 35, 612, 156, 157, 3008, 3009, "(" +342, 26, 36, 613, 158, 168, 3010, 3020, "difference" +342, 26, 37, 614, 169, 170, 3021, 3022, "," +342, 26, 38, 615, 171, 172, 3023, 3024, "1" +342, 26, 39, 616, 173, 174, 3025, 3026, "." +342, 26, 40, 617, 175, 176, 3027, 3028, "0" +342, 26, 41, 618, 177, 187, 3029, 3039, "percentage" +342, 26, 42, 619, 188, 193, 3040, 3045, "point" +342, 26, 43, 620, 194, 195, 3046, 3047, "[" +342, 26, 44, 621, 196, 198, 3048, 3050, "CI" +342, 26, 45, 622, 199, 200, 3051, 3052, "," +342, 26, 46, 623, 201, 202, 3053, 3054, "-" +342, 26, 47, 624, 203, 204, 3055, 3056, "0" +342, 26, 48, 625, 205, 206, 3057, 3058, "." +342, 26, 49, 626, 207, 208, 3059, 3060, "9" +342, 26, 50, 627, 209, 211, 3061, 3063, "to" +342, 26, 51, 628, 212, 213, 3064, 3065, "3" +342, 26, 52, 629, 214, 215, 3066, 3067, "." +342, 26, 53, 630, 216, 217, 3068, 3069, "0" +342, 26, 54, 631, 218, 228, 3070, 3080, "percentage" +342, 26, 55, 632, 229, 235, 3081, 3087, "points" +342, 26, 56, 633, 236, 237, 3088, 3089, "]" +342, 26, 57, 634, 238, 239, 3090, 3091, ")" +342, 26, 58, 635, 240, 241, 3092, 3093, "." +342, 27, 1, 636, 0, 3, 3094, 3097, "Any" +342, 27, 2, 637, 4, 16, 3098, 3110, "hypoglycemic" +342, 27, 3, 638, 17, 22, 3111, 3116, "event" +342, 27, 4, 639, 23, 31, 3117, 3125, "occurred" +342, 27, 5, 640, 32, 34, 3126, 3128, "in" +342, 27, 6, 641, 35, 37, 3129, 3131, "74" +342, 27, 7, 642, 38, 39, 3132, 3133, "%" +342, 27, 8, 643, 40, 42, 3134, 3136, "of" +342, 27, 9, 644, 43, 51, 3137, 3145, "patients" +342, 27, 10, 645, 52, 61, 3146, 3155, "receiving" +342, 27, 11, 646, 62, 65, 3156, 3159, "NPL" +342, 27, 12, 647, 66, 69, 3160, 3163, "and" +342, 27, 13, 648, 70, 72, 3164, 3166, "67" +342, 27, 14, 649, 73, 74, 3167, 3168, "%" +342, 27, 15, 650, 75, 77, 3169, 3171, "of" +342, 27, 16, 651, 78, 86, 3172, 3180, "patients" +342, 27, 17, 652, 87, 96, 3181, 3190, "receiving" +342, 27, 18, 653, 97, 105, 3191, 3199, "glargine" +342, 27, 19, 654, 106, 107, 3200, 3201, "(" +342, 27, 20, 655, 108, 118, 3202, 3212, "difference" +342, 27, 21, 656, 119, 120, 3213, 3214, "," +342, 27, 22, 657, 121, 122, 3215, 3216, "7" +342, 27, 23, 658, 123, 133, 3217, 3227, "percentage" +342, 27, 24, 659, 134, 140, 3228, 3234, "points" +342, 27, 25, 660, 141, 142, 3235, 3236, "[" +342, 27, 26, 661, 143, 145, 3237, 3239, "CI" +342, 27, 27, 662, 146, 147, 3240, 3241, "," +342, 27, 28, 663, 148, 149, 3242, 3243, "-" +342, 27, 29, 664, 150, 151, 3244, 3245, "5" +342, 27, 30, 665, 152, 154, 3246, 3248, "to" +342, 27, 31, 666, 155, 157, 3249, 3251, "13" +342, 27, 32, 667, 158, 168, 3252, 3262, "percentage" +342, 27, 33, 668, 169, 175, 3263, 3269, "points" +342, 27, 34, 669, 176, 177, 3270, 3271, "]" +342, 27, 35, 670, 178, 179, 3272, 3273, ")" +342, 27, 36, 671, 180, 181, 3274, 3275, "." +342, 28, 1, 672, 0, 10, 3276, 3286, "Continuous" +342, 28, 2, 673, 11, 18, 3287, 3294, "glucose" +342, 28, 3, 674, 19, 24, 3295, 3300, "level" +342, 28, 4, 675, 25, 35, 3301, 3311, "monitoring" +342, 28, 5, 676, 36, 38, 3312, 3314, "in" +342, 28, 6, 677, 39, 42, 3315, 3318, "the" +342, 28, 7, 678, 43, 51, 3319, 3327, "patients" +342, 28, 8, 679, 52, 55, 3328, 3331, "who" +342, 28, 9, 680, 56, 59, 3332, 3335, "had" +342, 28, 10, 681, 60, 64, 3336, 3340, "this" +342, 28, 11, 682, 65, 76, 3341, 3352, "measurement" +342, 28, 12, 683, 77, 80, 3353, 3356, "did" +342, 28, 13, 684, 81, 84, 3357, 3360, "not" +342, 28, 14, 685, 85, 91, 3361, 3367, "differ" +342, 28, 15, 686, 92, 105, 3368, 3381, "statistically" +342, 28, 16, 687, 106, 107, 3382, 3383, "." +342, 29, 1, 688, 0, 10, 3384, 3394, "LIMITATION" +342, 29, 2, 689, 11, 12, 3395, 3396, ":" +342, 29, 3, 690, 13, 16, 3397, 3400, "The" +342, 29, 4, 691, 17, 22, 3401, 3406, "study" +342, 29, 5, 692, 23, 26, 3407, 3410, "was" +342, 29, 6, 693, 27, 30, 3411, 3414, "not" +342, 29, 7, 694, 31, 38, 3415, 3422, "blinded" +342, 29, 8, 695, 39, 40, 3423, 3424, "," +342, 29, 9, 696, 41, 44, 3425, 3428, "had" +342, 29, 10, 697, 45, 52, 3429, 3436, "limited" +342, 29, 11, 698, 53, 58, 3437, 3442, "power" +342, 29, 12, 699, 59, 61, 3443, 3445, "to" +342, 29, 13, 700, 62, 68, 3446, 3452, "detect" +342, 29, 14, 701, 69, 80, 3453, 3464, "differences" +342, 29, 15, 702, 81, 83, 3465, 3467, "in" +342, 29, 16, 703, 84, 96, 3468, 3480, "hypoglycemic" +342, 29, 17, 704, 97, 103, 3481, 3487, "events" +342, 29, 18, 705, 104, 105, 3488, 3489, "," +342, 29, 19, 706, 106, 109, 3490, 3493, "and" +342, 29, 20, 707, 110, 113, 3494, 3497, "did" +342, 29, 21, 708, 114, 117, 3498, 3501, "not" +342, 29, 22, 709, 118, 124, 3502, 3508, "obtain" +342, 29, 23, 710, 125, 135, 3509, 3519, "continuous" +342, 29, 24, 711, 136, 143, 3520, 3527, "glucose" +342, 29, 25, 712, 144, 149, 3528, 3533, "level" +342, 29, 26, 713, 150, 160, 3534, 3544, "monitoring" +342, 29, 27, 714, 161, 164, 3545, 3548, "for" +342, 29, 28, 715, 165, 168, 3549, 3552, "all" +342, 29, 29, 716, 169, 177, 3553, 3561, "patients" +342, 29, 30, 717, 178, 179, 3562, 3563, "." +342, 30, 1, 718, 0, 10, 3564, 3574, "CONCLUSION" +342, 30, 2, 719, 11, 12, 3575, 3576, ":" +342, 30, 3, 720, 13, 20, 3577, 3584, "Similar" +342, 30, 4, 721, 21, 29, 3585, 3593, "glycemic" +342, 30, 5, 722, 30, 37, 3594, 3601, "control" +342, 30, 6, 723, 38, 46, 3602, 3610, "occurred" +342, 30, 7, 724, 47, 51, 3611, 3615, "with" +342, 30, 8, 725, 52, 55, 3616, 3619, "the" +342, 30, 9, 726, 56, 64, 3620, 3628, "addition" +342, 30, 10, 727, 65, 67, 3629, 3631, "of" +342, 30, 11, 728, 68, 71, 3632, 3635, "NPL" +342, 30, 12, 729, 72, 74, 3636, 3638, "or" +342, 30, 13, 730, 75, 83, 3639, 3647, "glargine" +342, 30, 14, 731, 84, 91, 3648, 3655, "insulin" +342, 30, 15, 732, 92, 94, 3656, 3658, "to" +342, 30, 16, 733, 95, 99, 3659, 3663, "oral" +342, 30, 17, 734, 100, 108, 3664, 3672, "regimens" +342, 30, 18, 735, 109, 111, 3673, 3675, "in" +342, 30, 19, 736, 112, 120, 3676, 3684, "patients" +342, 30, 20, 737, 121, 125, 3685, 3689, "with" +342, 30, 21, 738, 126, 132, 3690, 3696, "poorly" +342, 30, 22, 739, 133, 143, 3697, 3707, "controlled" +342, 30, 23, 740, 144, 148, 3708, 3712, "type" +342, 30, 24, 741, 149, 150, 3713, 3714, "2" +342, 30, 25, 742, 151, 159, 3715, 3723, "diabetes" +342, 30, 26, 743, 160, 161, 3724, 3725, "." +342, 31, 1, 744, 0, 12, 3726, 3738, "Hypoglycemia" +342, 31, 2, 745, 13, 16, 3739, 3742, "was" +342, 31, 3, 746, 17, 24, 3743, 3750, "similar" +342, 31, 4, 747, 25, 27, 3751, 3753, "in" +342, 31, 5, 748, 28, 31, 3754, 3757, "the" +342, 31, 6, 749, 32, 33, 3758, 3759, "2" +342, 31, 7, 750, 34, 40, 3760, 3766, "groups" +342, 31, 8, 751, 41, 42, 3767, 3768, "," +342, 31, 9, 752, 43, 46, 3769, 3772, "but" +342, 31, 10, 753, 47, 53, 3773, 3779, "sample" +342, 31, 11, 754, 54, 58, 3780, 3784, "size" +342, 31, 12, 755, 59, 66, 3785, 3792, "limited" +342, 31, 13, 756, 67, 70, 3793, 3796, "the" +342, 31, 14, 757, 71, 78, 3797, 3804, "ability" +342, 31, 15, 758, 79, 81, 3805, 3807, "to" +342, 31, 16, 759, 82, 86, 3808, 3812, "make" +342, 31, 17, 760, 87, 88, 3813, 3814, "a" +342, 31, 18, 761, 89, 97, 3815, 3823, "definite" +342, 31, 19, 762, 98, 104, 3824, 3830, "safety" +342, 31, 20, 763, 105, 115, 3831, 3841, "assessment" +342, 31, 21, 764, 116, 117, 3842, 3843, "." +342, 32, 1, 765, 0, 3, 3844, 3847, "DOI" +342, 32, 2, 766, 4, 5, 3848, 3849, ":" +342, 32, 3, 767, 6, 8, 3850, 3852, "10" +342, 32, 4, 768, 9, 10, 3853, 3854, "." +342, 32, 5, 769, 11, 15, 3855, 3859, "7326" +342, 32, 6, 770, 16, 17, 3860, 3861, "/" +342, 32, 7, 771, 18, 22, 3862, 3866, "0003" +342, 32, 8, 772, 23, 24, 3867, 3868, "-" +342, 32, 9, 773, 25, 29, 3869, 3873, "4819" +342, 32, 10, 774, 30, 31, 3874, 3875, "-" +342, 32, 11, 775, 32, 35, 3876, 3879, "149" +342, 32, 12, 776, 36, 37, 3880, 3881, "-" +342, 32, 13, 777, 38, 39, 3882, 3883, "8" +342, 32, 14, 778, 40, 41, 3884, 3885, "-" +342, 32, 15, 779, 42, 51, 3886, 3895, "200810210" +342, 32, 16, 780, 52, 53, 3896, 3897, "-" +342, 32, 17, 781, 54, 59, 3898, 3903, "00005" +342, 32, 18, 782, 60, 64, 3904, 3908, "PMID" +342, 32, 19, 783, 65, 66, 3909, 3910, ":" +342, 32, 20, 784, 67, 75, 3911, 3919, "18936501" +342, 32, 21, 785, 76, 77, 3920, 3921, "[" +342, 32, 22, 786, 78, 85, 3922, 3929, "Indexed" +342, 32, 23, 787, 86, 89, 3930, 3933, "for" +342, 32, 24, 788, 90, 97, 3934, 3941, "MEDLINE" +342, 32, 25, 789, 98, 99, 3942, 3943, "]" diff --git a/data/dm2 18936501_kwoodley.annodb b/data/dm2 18936501_kwoodley.annodb new file mode 100644 index 0000000..0e73674 --- /dev/null +++ b/data/dm2 18936501_kwoodley.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +14476, Journal, 0, 14, "Ann Intern Med", "", +14477, PublicationYear, 17, 21, "2008", "", +36725, Title, 53, 219, "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control : a randomized trial .", "", +36726, Lispro, 65, 97, "neutral protamine lispro insulin", "", +14479, InsulinGlargine, 101, 117, "insulin glargine", "", +14480, OralAntidiabeticAgent, 121, 150, "oral type 2 diabetes regimens", "", +14481, Precondition, 155, 196, "patients with suboptimal glycemic control", "", +14482, Randomized, 201, 211, "randomized", "", +14484, Author, 220, 230, "Esposito K", "", +14485, Author, 239, 248, "Ciotola M", "", +14486, Author, 251, 262, "Maiorino MI", "", +14487, Author, 265, 276, "Gualdiero R", "", +14488, Author, 279, 289, "Schisano B", "", +14489, Author, 292, 302, "Ceriello A", "", +14490, Author, 305, 315, "Beneduce F", "", +14491, Author, 318, 325, "Feola G", "", +14492, Author, 328, 339, "Giugliano D", "", +14493, Italy, 446, 451, "Italy", "", +14494, Insulin, 686, 693, "insulin", "", +36727, RelativeTime, 697, 704, "bedtime", "", +14498, Precondition, 742, 816, "patients with type 2 diabetes that is poorly controlled with oral regimens", "", +14496, Type2Diabetes, 756, 771, "type 2 diabetes", "", +14497, OralAntidiabeticAgent, 803, 816, "oral regimens", "", +36728, Lispro, 819, 843, "Neutral protamine lispro", "", +36729, Lispro, 846, 849, "NPL", "", +14501, Insulin, 852, 859, "insulin", "gehört aber zu dem vor Klammer", +14502, Hypoglycemia, 926, 945, "hypoglycemic events", "", +36730, Lispro, 959, 993, "neutral protamine Hagedorn insulin", "", +36732, ObjectiveDescription, 1008, 1224, "To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea .", "", +36733, RelativeTime, 1055, 1062, "bedtime", "", +36731, Lispro, 1063, 1074, "NPL insulin", "", +14506, InsulinGlargine, 1078, 1094, "insulin glargine", "", +14510, Precondition, 1098, 1222, "patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea", "", +14507, Type2Diabetes, 1112, 1127, "type 2 diabetes", "", +14508, Metformin, 1196, 1205, "metformin", "", +14509, Sulfonylureas, 1210, 1222, "sulfonylurea", "", +14512, OpenLabel, 1234, 1246, "Open - label", "", +14513, Randomized, 1249, 1259, "randomized", "", +14514, Italy, 1375, 1380, "Italy", "", +14515, NumberPatientsCT, 1394, 1397, "116", "", +14526, Precondition, 1398, 1634, "adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A ( 1c ) ( HbA ( 1c ) ) levels of 7 . 5 % to 10 % and fasting plasma glucose levels of 6 . 7 mmol / L or greater ( > or = 120 mg / dL )", "", +14516, Metformin, 1431, 1440, "metformin", "", +14517, Sulfonylureas, 1446, 1458, "sulfonylurea", "", +14518, Duration, 1463, 1482, "longer than 90 days", "pre treatment", +14519, HbA1c, 1488, 1507, "hemoglobin A ( 1c )", "", +14520, HbA1c, 1508, 1520, "( HbA ( 1c )", "", +14521, Percentage, 1539, 1540, "%", "", +14522, Percentage, 1547, 1548, "%", "", +14523, FastingPlasmaGlucose, 1553, 1575, "fasting plasma glucose", "", +14524, Millimoles_per_litre, 1592, 1600, "mmol / L", "", +14525, Mg_per_deciliter, 1625, 1632, "mg / dL", "", +14527, DoseValue, 1652, 1654, "10", "", +36734, Int_Unit, 1655, 1657, "IU", "", +36735, Lispro, 1661, 1672, "NPL insulin", "", +14530, InsulinGlargine, 1676, 1692, "insulin glargine", "", +36736, RelativeTime, 1720, 1727, "bedtime", "", +14534, Frequency, 1733, 1739, "weekly", "", +14532, FastingPlasmaGlucose_target, 1759, 1831, "target fasting glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +14533, OralAntidiabeticAgent, 1854, 1867, "oral regimens", "", +36737, RelativeTime, 1889, 1898, "nighttime", "", +14536, Sulfonylureas, 1899, 1911, "sulfonylurea", "", +14537, Metformin, 1946, 1955, "metformin", "", +14538, HbA1c, 2007, 2017, "HbA ( 1c )", "", +36738, TimePoint, 2030, 2038, "baseline", "", +36739, TimePoint, 2042, 2049, "week 36", "", +14540, HbA1c_target, 2076, 2107, "HbA ( 1c ) levels less than 7 %", "", +14541, Hypoglycemia, 2126, 2147, "hypoglycemic episodes", "", +36740, InsulinDose, 2150, 2162, "insulin dose", "", +36741, Glucose, 2182, 2195, "glucose level", "", +14544, BodyWeight, 2202, 2213, "body weight", "", +36743, NumberPatientsArm, 2216, 2222, "Twenty", "", +14545, Insulin, 2317, 2324, "insulin", "", +36742, TimePoint, 2332, 2339, "week 36", "", +14547, HbA1c, 2367, 2377, "HbA ( 1c )", "", +14548, Reduction, 2414, 2420, "1 . 83", "", +14550, Percentage, 2421, 2422, "%", "", +14549, Reduction, 2427, 2433, "1 . 89", "", +14551, Percentage, 2434, 2435, "%", "", +14552, Drug, 2440, 2443, "NPL", "", +14553, InsulinGlargine, 2448, 2456, "glargine", "", +14554, DiffGroupAbsValue, 2514, 2520, "0 . 06", "", +14555, Percentage, 2521, 2537, "percentage point", "", +14556, ConfIntervalDiff, 2540, 2585, "95 % CI , - 0 . 1 to 0 . 15 percentage points", "", +14558, Percentage, 2568, 2585, "percentage points", "", +14559, HbA1c_target, 2641, 2681, "Hemoglobin A ( 1c ) levels less than 7 %", "", +14562, PercentageAffected, 2694, 2696, "62", "", +36744, Lispro, 2721, 2724, "NPL", "", +14564, PercentageAffected, 2729, 2731, "64", "", +14565, InsulinGlargine, 2756, 2764, "glargine", "", +14592, DiffGroupRelValue, 2780, 2785, "2 . 0", "", +14568, ConfIntervalDiff, 2806, 2845, "CI , - 1 . 1 to 5 . 0 percentage points", "", +14570, FastingPlasmaGlucose_target, 2852, 2924, "Fasting plasma glucose levels less than 5 . 6 mmol / L ( < 100 mg / dL )", "", +14573, PercentageAffected, 2937, 2939, "40", "", +36745, Lispro, 2964, 2967, "NPL", "", +14574, PercentageAffected, 2972, 2974, "41", "", +14576, InsulinGlargine, 2999, 3007, "glargine", "", +14593, DiffGroupRelValue, 3023, 3028, "1 . 0", "", +14582, ConfIntervalDiff, 3048, 3087, "CI , - 0 . 9 to 3 . 0 percentage points", "", +14583, Hypoglycemia, 3098, 3116, "hypoglycemic event", "", +14584, PercentageAffected, 3129, 3131, "74", "", +36746, Lispro, 3156, 3159, "NPL", "", +14585, PercentageAffected, 3164, 3166, "67", "", +14587, InsulinGlargine, 3191, 3199, "glargine", "", +14588, DiffGroupRelValue, 3215, 3216, "7", "", +14589, ConfIntervalDiff, 3237, 3269, "CI , - 5 to 13 percentage points", "", +36748, ObservedResult, 3276, 3383, "Continuous glucose level monitoring in the patients who had this measurement did not differ statistically .", "", +36747, Glucose, 3287, 3300, "glucose level", "", +14594, Hypoglycemia, 3468, 3487, "hypoglycemic events", "", +36749, Glucose, 3520, 3533, "glucose level", "", +36750, ConclusionComment, 3577, 3725, "Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes .", "", +36752, Lispro, 3632, 3635, "NPL", "", +14597, InsulinGlargine, 3639, 3655, "glargine insulin", "", +14598, OralAntidiabeticAgent, 3659, 3672, "oral regimens", "", +14600, Precondition, 3676, 3723, "patients with poorly controlled type 2 diabetes", "", +14599, Type2Diabetes, 3708, 3723, "type 2 diabetes", "", +14602, Hypoglycemia, 3726, 3738, "Hypoglycemia", "", +36751, ConclusionComment, 3726, 3843, "Hypoglycemia was similar in the 2 groups , but sample size limited the ability to make a definite safety assessment .", "", +14604, PMID, 3911, 3919, "18936501", "", diff --git a/data/dm2 18936501_kwoodley.n-triples b/data/dm2 18936501_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 18936501_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19108786 copy_admin.annodb b/data/dm2 19108786 copy_admin.annodb new file mode 100644 index 0000000..dc78524 --- /dev/null +++ b/data/dm2 19108786 copy_admin.annodb @@ -0,0 +1,178 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2008", "", " \"2008\"." +160, Title, 99, 344, "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "", " \"A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .\"." +2, Duration, 101, 110, "52 - week", "", " \"52 - week\"." +153, Multicenter, 113, 126, "multinational", "", " ." +3, OpenLabel, 129, 141, "open - label", "", " ." +4, Parallel, 144, 160, "parallel - group", "", " ." +5, CTDesign, 163, 177, "noninferiority", "", " . ." +6, CTDesign, 180, 199, "treat - to - target", "", " . ." +7, InsulinDetemir, 216, 231, "insulin detemir", "", +8, InsulinGlargine, 237, 253, "insulin glargine", "", +9, RelativeTime, 286, 294, "mealtime", "", +10, InsulinAspart, 295, 309, "insulin aspart", "", +11, Type2Diabetes, 327, 342, "type 2 diabetes", "", " ." +12, Author, 345, 356, "Hollander P", "", " \"Hollander P\"." +13, Author, 365, 373, "Cooper J", "", " \"Cooper J\"." +14, Author, 376, 388, "Bregnh ø j J", "", " \"Bregnh ø j J\"." +15, Author, 391, 402, "Pedersen CB", "", " \"Pedersen CB\"." +16, USA, 477, 480, "USA", "", " ." +28, ObjectiveDescription, 653, 809, "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen", "", " \"This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen\"." +17, Insulin, 713, 720, "insulin", "", +18, InsulinDetemir, 731, 738, "detemir", "", +19, InsulinGlargine, 743, 751, "glargine", "", +52521, Insulin, 765, 772, "insulin", "", +314, ObjectiveDescription, 810, 955, "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .", "", " \"in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .\"." +27, Precondition, 813, 953, "patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs", "", " \"patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs\"." +21, Type2Diabetes, 827, 851, "type 2 diabetes mellitus", "", +22, Type2Diabetes, 854, 858, "T2DM", "", " ." +23, OralAntidiabeticAgent, 889, 912, "oral antidiabetic drugs", "", +24, OralAntidiabeticAgent, 915, 919, "OADs", "", +26, Insulin, 925, 932, "insulin", "", +25, OralAntidiabeticAgent, 949, 953, "OADs", "", +174, Multicenter, 977, 990, "multinational", "", +29, Duration, 993, 1002, "52 - week", "", +30, OpenLabel, 1005, 1014, "openlabel", "", +31, Parallel, 1017, 1033, "parallel - group", "", +32, CTDesign, 1036, 1050, "noninferiority", "", +33, CTDesign, 1053, 1072, "treat - to - target", "", +42, Precondition, 1081, 1216, "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months", "", " \"Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months\"." +34, Type2Diabetes, 1110, 1114, "T2DM", "", +35, OralAntidiabeticAgent, 1162, 1165, "OAD", "", +37, Insulin, 1169, 1176, "insulin", "", +36, OralAntidiabeticAgent, 1195, 1199, "OADs", "", +38, Randomized, 1222, 1232, "randomized", "", " ." +39, AllocationRatio, 1238, 1243, "2 : 1", "", " . ." +40, InsulinDetemir, 1261, 1268, "detemir", "", +41, InsulinGlargine, 1272, 1280, "glargine", "", +43, InsulinDetemir, 1320, 1327, "detemir", "", " ." +44, Frequency, 1350, 1369, "once or twice daily", "", " \"once or twice daily\"." +45, InsulinGlargine, 1376, 1384, "glargine", "", " ." +46, Frequency, 1402, 1412, "once daily", "", " \"once daily\"." +47, InsulinAspart, 1415, 1429, "Insulin aspart", "", " ." +52522, RelativeTime, 1443, 1452, "mealtimes", "", " . ." +49, Insulin, 1455, 1462, "Insulin", "", +50, OralAntidiabeticAgent, 1556, 1560, "OADs", "", +51, InsulinDetemir, 1587, 1594, "detemir", "", +52, InsulinGlargine, 1599, 1607, "glargine", "", +52525, DoseDescription, 1608, 1749, "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L", "", " \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\". \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\"." +52524, RelativeTime, 1635, 1647, "prebreakfast", "", +52523, RelativeTime, 1654, 1663, "predinner", "", +55, InsulinDetemir, 1668, 1675, "detemir", "", +56, Frequency, 1689, 1700, "twice daily", "", +57, FastingPlasmaGlucose_target, 1703, 1749, "plasma glucose target of < or = 6 . 0 mmol / L", "", +200, Millimoles_per_litre, 1741, 1749, "mmol / L", "", +316, PlasmaGlucose, 1777, 1791, "plasma glucose", "", +58, Insulin, 1893, 1900, "insulin", "", +317, PlasmaGlucose, 1977, 1991, "plasma glucose", "", +318, PlasmaGlucose, 1994, 1998, "SMPG", "", +202, TimePoint, 2004, 2012, "baseline", "", +203, TimePoint, 2017, 2025, "after 24", "", +204, TimePoint, 2030, 2038, "52 weeks", "", +59, HbA1c, 2076, 2099, "glycosylated hemoglobin", "", " ." +60, HbA1c, 2102, 2112, "HbA ( 1c )", "", +206, TimePoint, 2118, 2126, "52 weeks", "", +62, FastingPlasmaGlucose, 2179, 2201, "fasting plasma glucose", "", +63, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +319, PostprandialPlasmaGlucose, 2212, 2239, "postprandial plasma glucose", "", +320, InsulinDose, 2242, 2255, "insulin doses", "", +64, BodyWeight, 2262, 2268, "weight", "", +211, TimePoint, 2279, 2287, "52 weeks", "", +65, Hypoglycemia, 2334, 2346, "hypoglycemia", "", +66, EndPointDescription, 2351, 2365, "adverse events", "", +67, EndPointDescription, 2368, 2371, "AEs", "", +68, IntentionToTreat, 2390, 2412, "intention - to - treat", "", " ." +69, NumberPatientsCT, 2433, 2436, "319", "", " \"319\"." +70, Male, 2448, 2456, "58 . 0 %", "", " ." +71, Female, 2464, 2472, "42 . 0 %", "", " ." +72, Ethnicity, 2482, 2496, "78 . 4 % white", "", " . ." +218, Mean, 2499, 2503, "mean", "", +73, AvgAge, 2510, 2512, "58", "", " \"58\"." +216, Year, 2513, 2518, "years", "", +217, Mean, 2521, 2525, "mean", "", +74, BodyWeight, 2526, 2532, "weight", "", +75, Kg, 2542, 2544, "kg", "", +219, Mean, 2547, 2551, "mean", "", +102224, Duration, 2575, 2587, "13 . 6 years", "", +322, TimePoint, 2595, 2606, "study entry", "", +226, OralAntidiabeticAgent, 2666, 2669, "OAD", "", +228, OralAntidiabeticAgent, 2746, 2749, "OAD", "", +230, TimePoint, 2760, 2768, "52 weeks", "", " \"52 weeks\". \"52 weeks\". \"52 weeks\". \"52 weeks\". \"52 weeks\". \"52 weeks\". \"52 weeks\". \"52 weeks\"." +84, InsulinDetemir, 2815, 2822, "detemir", "", +85, InsulinGlargine, 2827, 2835, "glargine", "", +240, Mean, 2848, 2852, "mean", "", " . ." +86, HbA1c, 2853, 2863, "HbA ( 1c )", "", +89, ResultMeasuredValue, 2866, 2872, "7 . 19", "", " \"7 . 19\"." +91, Percentage, 2873, 2874, "%", "", " ." +90, ResultMeasuredValue, 2879, 2885, "7 . 03", "", " \"7 . 03\"." +92, Percentage, 2886, 2887, "%", "", +241, Mean, 2905, 2909, "mean", "", +88, DiffGroupAbsValue, 2923, 2929, "0 . 17", "", " \"0 . 17\"." +93, Percentage, 2930, 2931, "%", "", +87, ConfIntervalDiff, 2934, 2962, "95 % CI , - 0 . 07 to 0 . 40", "", " \"95 % CI , - 0 . 07 to 0 . 40\"." +242, Mean, 2974, 2978, "mean", "", +96, HbA1c, 2991, 2996, "HbAlc", "", +323, TimePoint, 3002, 3010, "baseline", "", +97, Reduction, 3015, 3021, "1 . 52", "", " \"1 . 52\"." +94, Percentage, 3022, 3023, "%", "", +98, Reduction, 3030, 3036, "1 . 68", "", " \"1 . 68\"." +95, Percentage, 3037, 3038, "%", "", +99, HbA1c, 3060, 3070, "HbA ( 1c )", "", +100, InsulinDetemir, 3113, 3120, "detemir", "", +101, Frequency, 3138, 3157, "once or twice daily", "", +52526, Mean, 3225, 3229, "mean", "", " . ." +102, FastingPlasmaGlucose, 3230, 3233, "FPG", "", " ." +104, ResultMeasuredValue, 3236, 3242, "7 . 05", "", " \"7 . 05\"." +105, ResultMeasuredValue, 3247, 3253, "6 . 68", "", " \"6 . 68\"." +106, Millimoles_per_litre, 3254, 3262, "mmol / L", "", " ." +52527, Mean, 3272, 3276, "mean", "", +103, FastingPlasmaGlucose, 3287, 3290, "FPG", "", +333, TimePoint, 3296, 3304, "baseline", "", +109, Reduction, 3309, 3315, "2 . 56", "", " \"2 . 56\"." +108, Reduction, 3322, 3328, "2 . 92", "", " \"2 . 92\"." +107, Millimoles_per_litre, 3329, 3337, "mmol / L", "", +263, Mean, 3340, 3344, "mean", "", +110, DiffGroupAbsValue, 3358, 3364, "0 . 36", "", " \"0 . 36\"." +111, ConfIntervalDiff, 3367, 3395, "95 % CI , - 0 . 26 to 0 . 99", "", " \"95 % CI , - 0 . 26 to 0 . 99\"." +267, Mean, 3499, 3503, "Mean", "", " . ." +268, WeightGain, 3504, 3515, "weight gain", "", " ." +269, TimePoint, 3519, 3527, "52 weeks", "", " \"52 weeks\". \"52 weeks\"." +115, InsulinDetemir, 3557, 3564, "detemir", "", +116, InsulinGlargine, 3575, 3583, "glargine", "", +272, ResultMeasuredValue, 3586, 3591, "2 . 8", "", " \"2 . 8\"." +273, ResultMeasuredValue, 3595, 3600, "3 . 8", "", " \"3 . 8\"." +119, Kg, 3601, 3603, "kg", "", " ." +275, Mean, 3606, 3610, "mean", "", +120, DiffGroupAbsValue, 3624, 3632, "- 1 . 04", "", " \"- 1 . 04\"." +121, ConfIntervalDiff, 3635, 3665, "95 % CI , - 2 . 08 to - 0 . 01", "", " \"95 % CI , - 2 . 08 to - 0 . 01\"." +122, PvalueDiff, 3668, 3678, "P < 0 . 05", "", " \"95 % CI , - 2 . 08 to - 0 . 01\"." +334, TimePoint, 3723, 3743, "the end of the study", "", +125, Hypoglycemia, 3800, 3812, "hypoglycemic", "", " ." +124, PercentageAffected, 3839, 3844, "4 . 7", "", " \"4 . 7\"." +123, PercentageAffected, 3851, 3856, "5 . 7", "", " \"5 . 7\"." +328, ObservedResult, 3908, 3988, "There was no significant difference in the risk of hypoglycemia between groups .", "", +126, Hypoglycemia, 3959, 3971, "hypoglycemia", "", +127, EndPointDescription, 4021, 4024, "AEs", "", " . ." +128, EndPointDescription, 4043, 4046, "AEs", "", +129, NumberAffected, 4092, 4095, "185", "", " \"185\"." +131, NumberPatientsArm, 4098, 4101, "214", "", " \"214\"." +133, PercentageAffected, 4113, 4119, "86 . 4", "", " \"86 . 4\"." +135, EndPointDescription, 4138, 4141, "AEs", "", +130, NumberAffected, 4146, 4148, "88", "", " \"88\"." +132, NumberPatientsArm, 4151, 4154, "105", "", " \"105\"." +134, PercentageAffected, 4166, 4172, "83 . 8", "", " \"83 . 8\"." +136, EndPointDescription, 4191, 4194, "AEs", "", +304, ConclusionComment, 4213, 4439, "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .", "", " \"when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .\"." +139, Type2Diabetes, 4288, 4292, "T2DM", "", +140, Insulin, 4327, 4334, "insulin", "", +299, OralAntidiabeticAgent, 4344, 4347, "OAD", "", +142, InsulinDetemir, 4359, 4366, "detemir", "", +143, InsulinGlargine, 4386, 4394, "glargine", "", +306, ConclusionComment, 4440, 4530, "Both basal insulins were associated with clinically relevant reductions in hyperglycemia .", "", " \"Both basal insulins were associated with clinically relevant reductions in hyperglycemia .\"." +145, Insulin, 4451, 4459, "insulins", "", +146, Hypoglycemia, 4515, 4528, "hyperglycemia", "", +307, ConclusionComment, 4531, 4630, "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .", "", " \"Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .\"." +147, Hypoglycemia, 4609, 4621, "hypoglycemia", "", +148, EndPointDescription, 4625, 4628, "AEs", "", +149, PMID, 4688, 4696, "19108786", "", " \"19108786\"." diff --git a/data/dm2 19108786 copy_admin.n-triples b/data/dm2 19108786 copy_admin.n-triples new file mode 100644 index 0000000..9887462 --- /dev/null +++ b/data/dm2 19108786 copy_admin.n-triples @@ -0,0 +1,220 @@ +# RDF export of group: Publication + . + "Publication" . + "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes ." . + "Hollander P" . + "2008" . + "Clin Ther ." . + "19108786" . + . + "Cooper J" . + "Bregnh ø j J" . + "Pedersen CB" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen" . + "319" . + "52 - week" . + . + . + . + . + "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control ." . + . + . + . + . + . + "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs ." . + . + . + . + . + . + . + . + "Both basal insulins were associated with clinically relevant reductions in hyperglycemia ." . + "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs" . + . + . + . + "58" . + . + "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months" . + . +# RDF export of group: Endpoint + . + "Endpoint_H" . + . + . + . + . + . + . + "Endpoint_FPG" . + . + . + . + . + . + . + "Endpoint_W" . + . + . + . + . + . + . + "Endpoint_HG" . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_D" . + "214" . + . + . + . + . + . + . + . + . + "Arm_G" . + "105" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_D" . + . + "once or twice daily" . + . + . + "Intervention_G" . + . + "once daily" . + . + . + "Intervention_A" . + . + . + . +# RDF export of group: Medication + . + "Medication_D" . + . + . + . + "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L" . + . + "Medication_G" . + . + . + . + "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L" . + . + "Medication_A" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_H_D" . + . + "7 . 19" . + "1 . 52" . + "52 weeks" . + . + "Outcome_H_G" . + . + "7 . 03" . + "1 . 68" . + "52 weeks" . + . + "Outcome_FPG_D" . + . + "7 . 05" . + "2 . 56" . + "52 weeks" . + . + "Outcome_FPG_G" . + . + "6 . 68" . + "2 . 92" . + "52 weeks" . + . + "Outcome_W_D" . + . + "2 . 8" . + "52 weeks" . + . + "Outcome_W_G" . + . + "3 . 8" . + "52 weeks" . + . + "Outcome_HG_D" . + . + "4 . 7" . + "52 weeks" . + . + "Outcome_HG_G" . + . + "5 . 7" . + "52 weeks" . + . + "Outcome_AE_D" . + . + "185" . + "86 . 4" . + "52 weeks" . + . + "Outcome_AE_G" . + "88" . + "83 . 8" . + "52 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_H" . + "0 . 17" . + "95 % CI , - 0 . 07 to 0 . 40" . + . + . + . + "DiffBetweenGroups_FPG" . + "0 . 36" . + "95 % CI , - 0 . 26 to 0 . 99" . + . + . + . + "DiffBetweenGroups_W" . + "- 1 . 04" . + "P < 0 . 05" . + "95 % CI , - 2 . 08 to - 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19108786 copy_export.csv b/data/dm2 19108786 copy_export.csv new file mode 100644 index 0000000..4090983 --- /dev/null +++ b/data/dm2 19108786 copy_export.csv @@ -0,0 +1,1009 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +823, 1, 1, 1, 0, 4, 0, 4, "Clin" +823, 1, 2, 2, 5, 9, 5, 9, "Ther" +823, 1, 3, 3, 10, 11, 10, 11, "." +823, 2, 1, 4, 0, 4, 12, 16, "2008" +823, 2, 2, 5, 5, 8, 17, 20, "Nov" +823, 2, 3, 6, 9, 10, 21, 22, ";" +823, 2, 4, 7, 11, 13, 23, 25, "30" +823, 2, 5, 8, 14, 15, 26, 27, "(" +823, 2, 6, 9, 16, 18, 28, 30, "11" +823, 2, 7, 10, 19, 20, 31, 32, ")" +823, 2, 8, 11, 21, 22, 33, 34, ":" +823, 2, 9, 12, 23, 27, 35, 39, "1976" +823, 2, 10, 13, 28, 29, 40, 41, "-" +823, 2, 11, 14, 30, 32, 42, 44, "87" +823, 2, 12, 15, 33, 34, 45, 46, "." +823, 2, 13, 16, 35, 38, 47, 50, "doi" +823, 2, 14, 17, 39, 40, 51, 52, ":" +823, 2, 15, 18, 41, 43, 53, 55, "10" +823, 2, 16, 19, 44, 45, 56, 57, "." +823, 2, 17, 20, 46, 50, 58, 62, "1016" +823, 2, 18, 21, 51, 52, 63, 64, "/" +823, 2, 19, 22, 53, 54, 65, 66, "j" +823, 2, 20, 23, 55, 56, 67, 68, "." +823, 2, 21, 24, 57, 66, 69, 78, "clinthera" +823, 2, 22, 25, 67, 68, 79, 80, "." +823, 2, 23, 26, 69, 73, 81, 85, "2008" +823, 2, 24, 27, 74, 75, 86, 87, "." +823, 2, 25, 28, 76, 78, 88, 90, "11" +823, 2, 26, 29, 79, 80, 91, 92, "." +823, 2, 27, 30, 81, 84, 93, 96, "001" +823, 2, 28, 31, 85, 86, 97, 98, "." +823, 3, 1, 32, 0, 1, 99, 100, "A" +823, 3, 2, 33, 2, 4, 101, 103, "52" +823, 3, 3, 34, 5, 6, 104, 105, "-" +823, 3, 4, 35, 7, 11, 106, 110, "week" +823, 3, 5, 36, 12, 13, 111, 112, "," +823, 3, 6, 37, 14, 27, 113, 126, "multinational" +823, 3, 7, 38, 28, 29, 127, 128, "," +823, 3, 8, 39, 30, 34, 129, 133, "open" +823, 3, 9, 40, 35, 36, 134, 135, "-" +823, 3, 10, 41, 37, 42, 136, 141, "label" +823, 3, 11, 42, 43, 44, 142, 143, "," +823, 3, 12, 43, 45, 53, 144, 152, "parallel" +823, 3, 13, 44, 54, 55, 153, 154, "-" +823, 3, 14, 45, 56, 61, 155, 160, "group" +823, 3, 15, 46, 62, 63, 161, 162, "," +823, 3, 16, 47, 64, 78, 163, 177, "noninferiority" +823, 3, 17, 48, 79, 80, 178, 179, "," +823, 3, 18, 49, 81, 86, 180, 185, "treat" +823, 3, 19, 50, 87, 88, 186, 187, "-" +823, 3, 20, 51, 89, 91, 188, 190, "to" +823, 3, 21, 52, 92, 93, 191, 192, "-" +823, 3, 22, 53, 94, 100, 193, 199, "target" +823, 3, 23, 54, 101, 106, 200, 205, "trial" +823, 3, 24, 55, 107, 116, 206, 215, "comparing" +823, 3, 25, 56, 117, 124, 216, 223, "insulin" +823, 3, 26, 57, 125, 132, 224, 231, "detemir" +823, 3, 27, 58, 133, 137, 232, 236, "with" +823, 3, 28, 59, 138, 145, 237, 244, "insulin" +823, 3, 29, 60, 146, 154, 245, 253, "glargine" +823, 3, 30, 61, 155, 157, 254, 256, "in" +823, 3, 31, 62, 158, 159, 257, 258, "a" +823, 3, 32, 63, 160, 165, 259, 264, "basal" +823, 3, 33, 64, 166, 167, 265, 266, "-" +823, 3, 34, 65, 168, 173, 267, 272, "bolus" +823, 3, 35, 66, 174, 181, 273, 280, "regimen" +823, 3, 36, 67, 182, 186, 281, 285, "with" +823, 3, 37, 68, 187, 195, 286, 294, "mealtime" +823, 3, 38, 69, 196, 203, 295, 302, "insulin" +823, 3, 39, 70, 204, 210, 303, 309, "aspart" +823, 3, 40, 71, 211, 213, 310, 312, "in" +823, 3, 41, 72, 214, 222, 313, 321, "patients" +823, 3, 42, 73, 223, 227, 322, 326, "with" +823, 3, 43, 74, 228, 232, 327, 331, "type" +823, 3, 44, 75, 233, 234, 332, 333, "2" +823, 3, 45, 76, 235, 243, 334, 342, "diabetes" +823, 3, 46, 77, 244, 245, 343, 344, "." +823, 4, 1, 78, 0, 9, 345, 354, "Hollander" +823, 4, 2, 79, 10, 11, 355, 356, "P" +823, 4, 3, 80, 12, 13, 357, 358, "(" +823, 4, 4, 81, 14, 15, 359, 360, "1" +823, 4, 5, 82, 16, 17, 361, 362, ")" +823, 4, 6, 83, 18, 19, 363, 364, "," +823, 4, 7, 84, 20, 26, 365, 371, "Cooper" +823, 4, 8, 85, 27, 28, 372, 373, "J" +823, 4, 9, 86, 29, 30, 374, 375, "," +823, 4, 10, 87, 31, 37, 376, 382, "Bregnh" +823, 4, 11, 88, 38, 39, 383, 384, "ø" +823, 4, 12, 89, 40, 41, 385, 386, "j" +823, 4, 13, 90, 42, 43, 387, 388, "J" +823, 4, 14, 91, 44, 45, 389, 390, "," +823, 4, 15, 92, 46, 54, 391, 399, "Pedersen" +823, 4, 16, 93, 55, 57, 400, 402, "CB" +823, 4, 17, 94, 58, 59, 403, 404, "." +823, 5, 1, 95, 0, 6, 405, 411, "Author" +823, 5, 2, 96, 7, 18, 412, 423, "information" +823, 5, 3, 97, 19, 20, 424, 425, ":" +823, 5, 4, 98, 21, 22, 426, 427, "(" +823, 5, 5, 99, 23, 24, 428, 429, "1" +823, 5, 6, 100, 25, 26, 430, 431, ")" +823, 5, 7, 101, 27, 33, 432, 438, "Baylor" +823, 5, 8, 102, 34, 41, 439, 446, "Medical" +823, 5, 9, 103, 42, 48, 447, 453, "Center" +823, 5, 10, 104, 49, 55, 454, 460, "Dallas" +823, 5, 11, 105, 56, 57, 461, 462, "," +823, 5, 12, 106, 58, 63, 463, 468, "Texas" +823, 5, 13, 107, 64, 69, 469, 474, "75246" +823, 5, 14, 108, 70, 71, 475, 476, "," +823, 5, 15, 109, 72, 75, 477, 480, "USA" +823, 5, 16, 110, 76, 77, 481, 482, "." +823, 6, 1, 111, 0, 8, 483, 491, "PriscilH" +823, 6, 2, 112, 9, 10, 492, 493, "@" +823, 6, 3, 113, 11, 23, 494, 506, "baylorhealth" +823, 6, 4, 114, 24, 25, 507, 508, "." +823, 6, 5, 115, 26, 29, 509, 512, "edu" +823, 6, 6, 116, 30, 37, 513, 520, "Comment" +823, 6, 7, 117, 38, 40, 521, 523, "in" +823, 6, 8, 118, 41, 45, 524, 528, "Clin" +823, 6, 9, 119, 46, 50, 529, 533, "Ther" +823, 6, 10, 120, 51, 52, 534, 535, "." +823, 7, 1, 121, 0, 4, 536, 540, "2009" +823, 7, 2, 122, 5, 8, 541, 544, "May" +823, 7, 3, 123, 9, 10, 545, 546, ";" +823, 7, 4, 124, 11, 13, 547, 549, "31" +823, 7, 5, 125, 14, 15, 550, 551, "(" +823, 7, 6, 126, 16, 17, 552, 553, "5" +823, 7, 7, 127, 18, 19, 554, 555, ")" +823, 7, 8, 128, 20, 21, 556, 557, ":" +823, 7, 9, 129, 22, 26, 558, 562, "1124" +823, 7, 10, 130, 27, 28, 563, 564, "-" +823, 7, 11, 131, 29, 30, 565, 566, "5" +823, 7, 12, 132, 31, 32, 567, 568, ";" +823, 7, 13, 133, 33, 39, 569, 575, "author" +823, 7, 14, 134, 40, 45, 576, 581, "reply" +823, 7, 15, 135, 46, 50, 582, 586, "1125" +823, 7, 16, 136, 51, 52, 587, 588, "-" +823, 7, 17, 137, 53, 54, 589, 590, "6" +823, 7, 18, 138, 55, 56, 591, 592, "." +823, 8, 1, 139, 0, 8, 593, 601, "Postgrad" +823, 8, 2, 140, 9, 12, 602, 605, "Med" +823, 8, 3, 141, 13, 14, 606, 607, "." +823, 9, 1, 142, 0, 4, 608, 612, "2010" +823, 9, 2, 143, 5, 8, 613, 616, "Jan" +823, 9, 3, 144, 9, 10, 617, 618, ";" +823, 9, 4, 145, 11, 14, 619, 622, "122" +823, 9, 5, 146, 15, 16, 623, 624, "(" +823, 9, 6, 147, 17, 18, 625, 626, "1" +823, 9, 7, 148, 19, 20, 627, 628, ")" +823, 9, 8, 149, 21, 22, 629, 630, ":" +823, 9, 9, 150, 23, 26, 631, 634, "201" +823, 9, 10, 151, 27, 28, 635, 636, "-" +823, 9, 11, 152, 29, 30, 637, 638, "3" +823, 9, 12, 153, 31, 32, 639, 640, "." +823, 10, 1, 154, 0, 9, 641, 650, "OBJECTIVE" +823, 10, 2, 155, 10, 11, 651, 652, ":" +823, 10, 3, 156, 12, 16, 653, 657, "This" +823, 10, 4, 157, 17, 22, 658, 663, "trial" +823, 10, 5, 158, 23, 31, 664, 672, "compared" +823, 10, 6, 159, 32, 35, 673, 676, "the" +823, 10, 7, 160, 36, 44, 677, 685, "efficacy" +823, 10, 8, 161, 45, 48, 686, 689, "and" +823, 10, 9, 162, 49, 55, 690, 696, "safety" +823, 10, 10, 163, 56, 64, 697, 705, "profiles" +823, 10, 11, 164, 65, 67, 706, 708, "of" +823, 10, 12, 165, 68, 71, 709, 712, "the" +823, 10, 13, 166, 72, 79, 713, 720, "insulin" +823, 10, 14, 167, 80, 89, 721, 730, "analogues" +823, 10, 15, 168, 90, 97, 731, 738, "detemir" +823, 10, 16, 169, 98, 101, 739, 742, "and" +823, 10, 17, 170, 102, 110, 743, 751, "glargine" +823, 10, 18, 171, 111, 113, 752, 754, "as" +823, 10, 19, 172, 114, 117, 755, 758, "the" +823, 10, 20, 173, 118, 123, 759, 764, "basal" +823, 10, 21, 174, 124, 131, 765, 772, "insulin" +823, 10, 22, 175, 132, 141, 773, 782, "component" +823, 10, 23, 176, 142, 144, 783, 785, "of" +823, 10, 24, 177, 145, 146, 786, 787, "a" +823, 10, 25, 178, 147, 152, 788, 793, "basal" +823, 10, 26, 179, 153, 154, 794, 795, "-" +823, 10, 27, 180, 155, 160, 796, 801, "bolus" +823, 10, 28, 181, 161, 168, 802, 809, "regimen" +823, 10, 29, 182, 169, 171, 810, 812, "in" +823, 10, 30, 183, 172, 180, 813, 821, "patients" +823, 10, 31, 184, 181, 185, 822, 826, "with" +823, 10, 32, 185, 186, 190, 827, 831, "type" +823, 10, 33, 186, 191, 192, 832, 833, "2" +823, 10, 34, 187, 193, 201, 834, 842, "diabetes" +823, 10, 35, 188, 202, 210, 843, 851, "mellitus" +823, 10, 36, 189, 211, 212, 852, 853, "(" +823, 10, 37, 190, 213, 217, 854, 858, "T2DM" +823, 10, 38, 191, 218, 219, 859, 860, ")" +823, 10, 39, 192, 220, 223, 861, 864, "who" +823, 10, 40, 193, 224, 228, 865, 869, "were" +823, 10, 41, 194, 229, 234, 870, 875, "being" +823, 10, 42, 195, 235, 242, 876, 883, "treated" +823, 10, 43, 196, 243, 247, 884, 888, "with" +823, 10, 44, 197, 248, 252, 889, 893, "oral" +823, 10, 45, 198, 253, 265, 894, 906, "antidiabetic" +823, 10, 46, 199, 266, 271, 907, 912, "drugs" +823, 10, 47, 200, 272, 273, 913, 914, "(" +823, 10, 48, 201, 274, 278, 915, 919, "OADs" +823, 10, 49, 202, 279, 280, 920, 921, ")" +823, 10, 50, 203, 281, 283, 922, 924, "or" +823, 10, 51, 204, 284, 291, 925, 932, "insulin" +823, 10, 52, 205, 292, 296, 933, 937, "with" +823, 10, 53, 206, 297, 299, 938, 940, "or" +823, 10, 54, 207, 300, 307, 941, 948, "without" +823, 10, 55, 208, 308, 312, 949, 953, "OADs" +823, 10, 56, 209, 313, 314, 954, 955, "." +823, 11, 1, 210, 0, 7, 956, 963, "METHODS" +823, 11, 2, 211, 8, 9, 964, 965, ":" +823, 11, 3, 212, 10, 14, 966, 970, "This" +823, 11, 4, 213, 15, 18, 971, 974, "was" +823, 11, 5, 214, 19, 20, 975, 976, "a" +823, 11, 6, 215, 21, 34, 977, 990, "multinational" +823, 11, 7, 216, 35, 36, 991, 992, "," +823, 11, 8, 217, 37, 39, 993, 995, "52" +823, 11, 9, 218, 40, 41, 996, 997, "-" +823, 11, 10, 219, 42, 46, 998, 1002, "week" +823, 11, 11, 220, 47, 48, 1003, 1004, "," +823, 11, 12, 221, 49, 58, 1005, 1014, "openlabel" +823, 11, 13, 222, 59, 60, 1015, 1016, "," +823, 11, 14, 223, 61, 69, 1017, 1025, "parallel" +823, 11, 15, 224, 70, 71, 1026, 1027, "-" +823, 11, 16, 225, 72, 77, 1028, 1033, "group" +823, 11, 17, 226, 78, 79, 1034, 1035, "," +823, 11, 18, 227, 80, 94, 1036, 1050, "noninferiority" +823, 11, 19, 228, 95, 96, 1051, 1052, "," +823, 11, 20, 229, 97, 102, 1053, 1058, "treat" +823, 11, 21, 230, 103, 104, 1059, 1060, "-" +823, 11, 22, 231, 105, 107, 1061, 1063, "to" +823, 11, 23, 232, 108, 109, 1064, 1065, "-" +823, 11, 24, 233, 110, 116, 1066, 1072, "target" +823, 11, 25, 234, 117, 122, 1073, 1078, "trial" +823, 11, 26, 235, 123, 124, 1079, 1080, "." +823, 12, 1, 236, 0, 8, 1081, 1089, "Patients" +823, 12, 2, 237, 9, 13, 1090, 1094, "with" +823, 12, 3, 238, 14, 15, 1095, 1096, "a" +823, 12, 4, 239, 16, 25, 1097, 1106, "diagnosis" +823, 12, 5, 240, 26, 28, 1107, 1109, "of" +823, 12, 6, 241, 29, 33, 1110, 1114, "T2DM" +823, 12, 7, 242, 34, 37, 1115, 1118, "for" +823, 12, 8, 243, 38, 39, 1119, 1120, ">" +823, 12, 9, 244, 40, 42, 1121, 1123, "or" +823, 12, 10, 245, 43, 44, 1124, 1125, "=" +823, 12, 11, 246, 45, 47, 1126, 1128, "12" +823, 12, 12, 247, 48, 54, 1129, 1135, "months" +823, 12, 13, 248, 55, 58, 1136, 1139, "who" +823, 12, 14, 249, 59, 62, 1140, 1143, "had" +823, 12, 15, 250, 63, 67, 1144, 1148, "been" +823, 12, 16, 251, 68, 77, 1149, 1158, "receiving" +823, 12, 17, 252, 78, 80, 1159, 1161, "an" +823, 12, 18, 253, 81, 84, 1162, 1165, "OAD" +823, 12, 19, 254, 85, 87, 1166, 1168, "or" +823, 12, 20, 255, 88, 95, 1169, 1176, "insulin" +823, 12, 21, 256, 96, 97, 1177, 1178, "," +823, 12, 22, 257, 98, 102, 1179, 1183, "with" +823, 12, 23, 258, 103, 105, 1184, 1186, "or" +823, 12, 24, 259, 106, 113, 1187, 1194, "without" +823, 12, 25, 260, 114, 118, 1195, 1199, "OADs" +823, 12, 26, 261, 119, 120, 1200, 1201, "," +823, 12, 27, 262, 121, 124, 1202, 1205, "for" +823, 12, 28, 263, 125, 126, 1206, 1207, ">" +823, 12, 29, 264, 127, 128, 1208, 1209, "4" +823, 12, 30, 265, 129, 135, 1210, 1216, "months" +823, 12, 31, 266, 136, 140, 1217, 1221, "were" +823, 12, 32, 267, 141, 151, 1222, 1232, "randomized" +823, 12, 33, 268, 152, 154, 1233, 1235, "in" +823, 12, 34, 269, 155, 156, 1236, 1237, "a" +823, 12, 35, 270, 157, 158, 1238, 1239, "2" +823, 12, 36, 271, 159, 160, 1240, 1241, ":" +823, 12, 37, 272, 161, 162, 1242, 1243, "1" +823, 12, 38, 273, 163, 168, 1244, 1249, "ratio" +823, 12, 39, 274, 169, 171, 1250, 1252, "to" +823, 12, 40, 275, 172, 179, 1253, 1260, "receive" +823, 12, 41, 276, 180, 187, 1261, 1268, "detemir" +823, 12, 42, 277, 188, 190, 1269, 1271, "or" +823, 12, 43, 278, 191, 199, 1272, 1280, "glargine" +823, 12, 44, 279, 200, 201, 1281, 1282, "." +823, 13, 1, 280, 0, 9, 1283, 1292, "According" +823, 13, 2, 281, 10, 12, 1293, 1295, "to" +823, 13, 3, 282, 13, 16, 1296, 1299, "the" +823, 13, 4, 283, 17, 25, 1300, 1308, "approved" +823, 13, 5, 284, 26, 34, 1309, 1317, "labeling" +823, 13, 6, 285, 35, 36, 1318, 1319, "," +823, 13, 7, 286, 37, 44, 1320, 1327, "detemir" +823, 13, 8, 287, 45, 50, 1328, 1333, "could" +823, 13, 9, 288, 51, 53, 1334, 1336, "be" +823, 13, 10, 289, 54, 66, 1337, 1349, "administered" +823, 13, 11, 290, 67, 71, 1350, 1354, "once" +823, 13, 12, 291, 72, 74, 1355, 1357, "or" +823, 13, 13, 292, 75, 80, 1358, 1363, "twice" +823, 13, 14, 293, 81, 86, 1364, 1369, "daily" +823, 13, 15, 294, 87, 88, 1370, 1371, "," +823, 13, 16, 295, 89, 92, 1372, 1375, "and" +823, 13, 17, 296, 93, 101, 1376, 1384, "glargine" +823, 13, 18, 297, 102, 105, 1385, 1388, "was" +823, 13, 19, 298, 106, 118, 1389, 1401, "administered" +823, 13, 20, 299, 119, 123, 1402, 1406, "once" +823, 13, 21, 300, 124, 129, 1407, 1412, "daily" +823, 13, 22, 301, 130, 131, 1413, 1414, "." +823, 14, 1, 302, 0, 7, 1415, 1422, "Insulin" +823, 14, 2, 303, 8, 14, 1423, 1429, "aspart" +823, 14, 3, 304, 15, 18, 1430, 1433, "was" +823, 14, 4, 305, 19, 24, 1434, 1439, "given" +823, 14, 5, 306, 25, 27, 1440, 1442, "at" +823, 14, 6, 307, 28, 37, 1443, 1452, "mealtimes" +823, 14, 7, 308, 38, 39, 1453, 1454, "." +823, 15, 1, 309, 0, 7, 1455, 1462, "Insulin" +823, 15, 2, 310, 8, 21, 1463, 1476, "secretagogues" +823, 15, 3, 311, 22, 25, 1477, 1480, "and" +823, 15, 4, 312, 26, 27, 1481, 1482, "a" +823, 15, 5, 313, 28, 29, 1483, 1484, "-" +823, 15, 6, 314, 30, 41, 1485, 1496, "glucosidase" +823, 15, 7, 315, 42, 52, 1497, 1507, "inhibitors" +823, 15, 8, 316, 53, 57, 1508, 1512, "were" +823, 15, 9, 317, 58, 70, 1513, 1525, "discontinued" +823, 15, 10, 318, 71, 73, 1526, 1528, "at" +823, 15, 11, 319, 74, 79, 1529, 1534, "study" +823, 15, 12, 320, 80, 85, 1535, 1540, "entry" +823, 15, 13, 321, 86, 87, 1541, 1542, "," +823, 15, 14, 322, 88, 91, 1543, 1546, "and" +823, 15, 15, 323, 92, 100, 1547, 1555, "existing" +823, 15, 16, 324, 101, 105, 1556, 1560, "OADs" +823, 15, 17, 325, 106, 110, 1561, 1565, "were" +823, 15, 18, 326, 111, 120, 1566, 1575, "continued" +823, 15, 19, 327, 121, 122, 1576, 1577, "." +823, 16, 1, 328, 0, 5, 1578, 1583, "Doses" +823, 16, 2, 329, 6, 8, 1584, 1586, "of" +823, 16, 3, 330, 9, 16, 1587, 1594, "detemir" +823, 16, 4, 331, 17, 20, 1595, 1598, "and" +823, 16, 5, 332, 21, 29, 1599, 1607, "glargine" +823, 16, 6, 333, 30, 34, 1608, 1612, "were" +823, 16, 7, 334, 35, 43, 1613, 1621, "titrated" +823, 16, 8, 335, 44, 46, 1622, 1624, "to" +823, 16, 9, 336, 47, 54, 1625, 1632, "achieve" +823, 16, 10, 337, 55, 56, 1633, 1634, "a" +823, 16, 11, 338, 57, 69, 1635, 1647, "prebreakfast" +823, 16, 12, 339, 70, 71, 1648, 1649, "(" +823, 16, 13, 340, 72, 75, 1650, 1653, "and" +823, 16, 14, 341, 76, 85, 1654, 1663, "predinner" +823, 16, 15, 342, 86, 89, 1664, 1667, "for" +823, 16, 16, 343, 90, 97, 1668, 1675, "detemir" +823, 16, 17, 344, 98, 110, 1676, 1688, "administered" +823, 16, 18, 345, 111, 116, 1689, 1694, "twice" +823, 16, 19, 346, 117, 122, 1695, 1700, "daily" +823, 16, 20, 347, 123, 124, 1701, 1702, ")" +823, 16, 21, 348, 125, 131, 1703, 1709, "plasma" +823, 16, 22, 349, 132, 139, 1710, 1717, "glucose" +823, 16, 23, 350, 140, 146, 1718, 1724, "target" +823, 16, 24, 351, 147, 149, 1725, 1727, "of" +823, 16, 25, 352, 150, 151, 1728, 1729, "<" +823, 16, 26, 353, 152, 154, 1730, 1732, "or" +823, 16, 27, 354, 155, 156, 1733, 1734, "=" +823, 16, 28, 355, 157, 158, 1735, 1736, "6" +823, 16, 29, 356, 159, 160, 1737, 1738, "." +823, 16, 30, 357, 161, 162, 1739, 1740, "0" +823, 16, 31, 358, 163, 167, 1741, 1745, "mmol" +823, 16, 32, 359, 168, 169, 1746, 1747, "/" +823, 16, 33, 360, 170, 171, 1748, 1749, "L" +823, 16, 34, 361, 172, 173, 1750, 1751, "." +823, 17, 1, 362, 0, 8, 1752, 1760, "Patients" +823, 17, 2, 363, 9, 18, 1761, 1770, "monitored" +823, 17, 3, 364, 19, 24, 1771, 1776, "their" +823, 17, 4, 365, 25, 31, 1777, 1783, "plasma" +823, 17, 5, 366, 32, 39, 1784, 1791, "glucose" +823, 17, 6, 367, 40, 46, 1792, 1798, "levels" +823, 17, 7, 368, 47, 53, 1799, 1805, "before" +823, 17, 8, 369, 54, 63, 1806, 1815, "breakfast" +823, 17, 9, 370, 64, 67, 1816, 1819, "and" +823, 17, 10, 371, 68, 74, 1820, 1826, "dinner" +823, 17, 11, 372, 75, 77, 1827, 1829, "on" +823, 17, 12, 373, 78, 81, 1830, 1833, "the" +823, 17, 13, 374, 82, 83, 1834, 1835, "3" +823, 17, 14, 375, 84, 88, 1836, 1840, "days" +823, 17, 15, 376, 89, 95, 1841, 1847, "before" +823, 17, 16, 377, 96, 100, 1848, 1852, "each" +823, 17, 17, 378, 101, 103, 1853, 1855, "of" +823, 17, 18, 379, 104, 106, 1856, 1858, "13" +823, 17, 19, 380, 107, 116, 1859, 1868, "scheduled" +823, 17, 20, 381, 117, 123, 1869, 1875, "visits" +823, 17, 21, 382, 124, 125, 1876, 1877, "," +823, 17, 22, 383, 126, 134, 1878, 1886, "recorded" +823, 17, 23, 384, 135, 140, 1887, 1892, "their" +823, 17, 24, 385, 141, 148, 1893, 1900, "insulin" +823, 17, 25, 386, 149, 154, 1901, 1906, "doses" +823, 17, 26, 387, 155, 157, 1907, 1909, "on" +823, 17, 27, 388, 158, 159, 1910, 1911, "1" +823, 17, 28, 389, 160, 162, 1912, 1914, "of" +823, 17, 29, 390, 163, 168, 1915, 1920, "these" +823, 17, 30, 391, 169, 170, 1921, 1922, "3" +823, 17, 31, 392, 171, 175, 1923, 1927, "days" +823, 17, 32, 393, 176, 177, 1928, 1929, "," +823, 17, 33, 394, 178, 181, 1930, 1933, "and" +823, 17, 34, 395, 182, 190, 1934, 1942, "recorded" +823, 17, 35, 396, 191, 196, 1943, 1948, "their" +823, 17, 36, 397, 197, 199, 1949, 1951, "10" +823, 17, 37, 398, 200, 201, 1952, 1953, "-" +823, 17, 38, 399, 202, 207, 1954, 1959, "point" +823, 17, 39, 400, 208, 212, 1960, 1964, "self" +823, 17, 40, 401, 213, 214, 1965, 1966, "-" +823, 17, 41, 402, 215, 224, 1967, 1976, "monitored" +823, 17, 42, 403, 225, 231, 1977, 1983, "plasma" +823, 17, 43, 404, 232, 239, 1984, 1991, "glucose" +823, 17, 44, 405, 240, 241, 1992, 1993, "(" +823, 17, 45, 406, 242, 246, 1994, 1998, "SMPG" +823, 17, 46, 407, 247, 248, 1999, 2000, ")" +823, 17, 47, 408, 249, 251, 2001, 2003, "at" +823, 17, 48, 409, 252, 260, 2004, 2012, "baseline" +823, 17, 49, 410, 261, 264, 2013, 2016, "and" +823, 17, 50, 411, 265, 270, 2017, 2022, "after" +823, 17, 51, 412, 271, 273, 2023, 2025, "24" +823, 17, 52, 413, 274, 277, 2026, 2029, "and" +823, 17, 53, 414, 278, 280, 2030, 2032, "52" +823, 17, 54, 415, 281, 286, 2033, 2038, "weeks" +823, 17, 55, 416, 287, 288, 2039, 2040, "." +823, 18, 1, 417, 0, 3, 2041, 2044, "The" +823, 18, 2, 418, 4, 11, 2045, 2052, "primary" +823, 18, 3, 419, 12, 20, 2053, 2061, "efficacy" +823, 18, 4, 420, 21, 24, 2062, 2065, "end" +823, 18, 5, 421, 25, 30, 2066, 2071, "point" +823, 18, 6, 422, 31, 34, 2072, 2075, "was" +823, 18, 7, 423, 35, 47, 2076, 2088, "glycosylated" +823, 18, 8, 424, 48, 58, 2089, 2099, "hemoglobin" +823, 18, 9, 425, 59, 60, 2100, 2101, "(" +823, 18, 10, 426, 61, 64, 2102, 2105, "HbA" +823, 18, 11, 427, 65, 66, 2106, 2107, "(" +823, 18, 12, 428, 67, 69, 2108, 2110, "1c" +823, 18, 13, 429, 70, 71, 2111, 2112, ")" +823, 18, 14, 430, 72, 73, 2113, 2114, ")" +823, 18, 15, 431, 74, 76, 2115, 2117, "at" +823, 18, 16, 432, 77, 79, 2118, 2120, "52" +823, 18, 17, 433, 80, 85, 2121, 2126, "weeks" +823, 18, 18, 434, 86, 87, 2127, 2128, ";" +823, 18, 19, 435, 88, 97, 2129, 2138, "secondary" +823, 18, 20, 436, 98, 106, 2139, 2147, "efficacy" +823, 18, 21, 437, 107, 110, 2148, 2151, "end" +823, 18, 22, 438, 111, 117, 2152, 2158, "points" +823, 18, 23, 439, 118, 126, 2159, 2167, "included" +823, 18, 24, 440, 127, 134, 2168, 2175, "changes" +823, 18, 25, 441, 135, 137, 2176, 2178, "in" +823, 18, 26, 442, 138, 145, 2179, 2186, "fasting" +823, 18, 27, 443, 146, 152, 2187, 2193, "plasma" +823, 18, 28, 444, 153, 160, 2194, 2201, "glucose" +823, 18, 29, 445, 161, 162, 2202, 2203, "(" +823, 18, 30, 446, 163, 166, 2204, 2207, "FPG" +823, 18, 31, 447, 167, 168, 2208, 2209, ")" +823, 18, 32, 448, 169, 170, 2210, 2211, "," +823, 18, 33, 449, 171, 183, 2212, 2224, "postprandial" +823, 18, 34, 450, 184, 190, 2225, 2231, "plasma" +823, 18, 35, 451, 191, 198, 2232, 2239, "glucose" +823, 18, 36, 452, 199, 200, 2240, 2241, "," +823, 18, 37, 453, 201, 208, 2242, 2249, "insulin" +823, 18, 38, 454, 209, 214, 2250, 2255, "doses" +823, 18, 39, 455, 215, 216, 2256, 2257, "," +823, 18, 40, 456, 217, 220, 2258, 2261, "and" +823, 18, 41, 457, 221, 227, 2262, 2268, "weight" +823, 18, 42, 458, 228, 234, 2269, 2275, "change" +823, 18, 43, 459, 235, 237, 2276, 2278, "at" +823, 18, 44, 460, 238, 240, 2279, 2281, "52" +823, 18, 45, 461, 241, 246, 2282, 2287, "weeks" +823, 18, 46, 462, 247, 248, 2288, 2289, "." +823, 19, 1, 463, 0, 6, 2290, 2296, "Safety" +823, 19, 2, 464, 7, 10, 2297, 2300, "end" +823, 19, 3, 465, 11, 17, 2301, 2307, "points" +823, 19, 4, 466, 18, 26, 2308, 2316, "included" +823, 19, 5, 467, 27, 30, 2317, 2320, "the" +823, 19, 6, 468, 31, 40, 2321, 2330, "frequency" +823, 19, 7, 469, 41, 43, 2331, 2333, "of" +823, 19, 8, 470, 44, 56, 2334, 2346, "hypoglycemia" +823, 19, 9, 471, 57, 60, 2347, 2350, "and" +823, 19, 10, 472, 61, 68, 2351, 2358, "adverse" +823, 19, 11, 473, 69, 75, 2359, 2365, "events" +823, 19, 12, 474, 76, 77, 2366, 2367, "(" +823, 19, 13, 475, 78, 81, 2368, 2371, "AEs" +823, 19, 14, 476, 82, 83, 2372, 2373, ")" +823, 19, 15, 477, 84, 85, 2374, 2375, "." +823, 20, 1, 478, 0, 7, 2376, 2383, "RESULTS" +823, 20, 2, 479, 8, 9, 2384, 2385, ":" +823, 20, 3, 480, 10, 13, 2386, 2389, "The" +823, 20, 4, 481, 14, 23, 2390, 2399, "intention" +823, 20, 5, 482, 24, 25, 2400, 2401, "-" +823, 20, 6, 483, 26, 28, 2402, 2404, "to" +823, 20, 7, 484, 29, 30, 2405, 2406, "-" +823, 20, 8, 485, 31, 36, 2407, 2412, "treat" +823, 20, 9, 486, 37, 47, 2413, 2423, "population" +823, 20, 10, 487, 48, 56, 2424, 2432, "included" +823, 20, 11, 488, 57, 60, 2433, 2436, "319" +823, 20, 12, 489, 61, 69, 2437, 2445, "patients" +823, 20, 13, 490, 70, 71, 2446, 2447, "(" +823, 20, 14, 491, 72, 74, 2448, 2450, "58" +823, 20, 15, 492, 75, 76, 2451, 2452, "." +823, 20, 16, 493, 77, 78, 2453, 2454, "0" +823, 20, 17, 494, 79, 80, 2455, 2456, "%" +823, 20, 18, 495, 81, 85, 2457, 2461, "male" +823, 20, 19, 496, 86, 87, 2462, 2463, "," +823, 20, 20, 497, 88, 90, 2464, 2466, "42" +823, 20, 21, 498, 91, 92, 2467, 2468, "." +823, 20, 22, 499, 93, 94, 2469, 2470, "0" +823, 20, 23, 500, 95, 96, 2471, 2472, "%" +823, 20, 24, 501, 97, 103, 2473, 2479, "female" +823, 20, 25, 502, 104, 105, 2480, 2481, ";" +823, 20, 26, 503, 106, 108, 2482, 2484, "78" +823, 20, 27, 504, 109, 110, 2485, 2486, "." +823, 20, 28, 505, 111, 112, 2487, 2488, "4" +823, 20, 29, 506, 113, 114, 2489, 2490, "%" +823, 20, 30, 507, 115, 120, 2491, 2496, "white" +823, 20, 31, 508, 121, 122, 2497, 2498, ";" +823, 20, 32, 509, 123, 127, 2499, 2503, "mean" +823, 20, 33, 510, 128, 131, 2504, 2507, "age" +823, 20, 34, 511, 132, 133, 2508, 2509, "," +823, 20, 35, 512, 134, 136, 2510, 2512, "58" +823, 20, 36, 513, 137, 142, 2513, 2518, "years" +823, 20, 37, 514, 143, 144, 2519, 2520, ";" +823, 20, 38, 515, 145, 149, 2521, 2525, "mean" +823, 20, 39, 516, 150, 156, 2526, 2532, "weight" +823, 20, 40, 517, 157, 158, 2533, 2534, "," +823, 20, 41, 518, 159, 161, 2535, 2537, "92" +823, 20, 42, 519, 162, 163, 2538, 2539, "." +823, 20, 43, 520, 164, 165, 2540, 2541, "8" +823, 20, 44, 521, 166, 168, 2542, 2544, "kg" +823, 20, 45, 522, 169, 170, 2545, 2546, ";" +823, 20, 46, 523, 171, 175, 2547, 2551, "mean" +823, 20, 47, 524, 176, 184, 2552, 2560, "duration" +823, 20, 48, 525, 185, 187, 2561, 2563, "of" +823, 20, 49, 526, 188, 196, 2564, 2572, "diabetes" +823, 20, 50, 527, 197, 198, 2573, 2574, "," +823, 20, 51, 528, 199, 201, 2575, 2577, "13" +823, 20, 52, 529, 202, 203, 2578, 2579, "." +823, 20, 53, 530, 204, 205, 2580, 2581, "6" +823, 20, 54, 531, 206, 211, 2582, 2587, "years" +823, 20, 55, 532, 212, 213, 2588, 2589, ")" +823, 20, 56, 533, 214, 215, 2590, 2591, "." +823, 21, 1, 534, 0, 2, 2592, 2594, "At" +823, 21, 2, 535, 3, 8, 2595, 2600, "study" +823, 21, 3, 536, 9, 14, 2601, 2606, "entry" +823, 21, 4, 537, 15, 16, 2607, 2608, "," +823, 21, 5, 538, 17, 19, 2609, 2611, "46" +823, 21, 6, 539, 20, 21, 2612, 2613, "." +823, 21, 7, 540, 22, 23, 2614, 2615, "1" +823, 21, 8, 541, 24, 25, 2616, 2617, "%" +823, 21, 9, 542, 26, 28, 2618, 2620, "of" +823, 21, 10, 543, 29, 37, 2621, 2629, "patients" +823, 21, 11, 544, 38, 42, 2630, 2634, "were" +823, 21, 12, 545, 43, 52, 2635, 2644, "receiving" +823, 21, 13, 546, 53, 60, 2645, 2652, "insulin" +823, 21, 14, 547, 61, 64, 2653, 2656, "and" +823, 21, 15, 548, 65, 66, 2657, 2658, ">" +823, 21, 16, 549, 67, 69, 2659, 2661, "or" +823, 21, 17, 550, 70, 71, 2662, 2663, "=" +823, 21, 18, 551, 72, 73, 2664, 2665, "1" +823, 21, 19, 552, 74, 77, 2666, 2669, "OAD" +823, 21, 20, 553, 78, 79, 2670, 2671, "," +823, 21, 21, 554, 80, 82, 2672, 2674, "35" +823, 21, 22, 555, 83, 84, 2675, 2676, "." +823, 21, 23, 556, 85, 86, 2677, 2678, "4" +823, 21, 24, 557, 87, 91, 2679, 2683, "were" +823, 21, 25, 558, 92, 101, 2684, 2693, "receiving" +823, 21, 26, 559, 102, 109, 2694, 2701, "insulin" +823, 21, 27, 560, 110, 114, 2702, 2706, "only" +823, 21, 28, 561, 115, 116, 2707, 2708, "," +823, 21, 29, 562, 117, 120, 2709, 2712, "and" +823, 21, 30, 563, 121, 123, 2713, 2715, "18" +823, 21, 31, 564, 124, 125, 2716, 2717, "." +823, 21, 32, 565, 126, 127, 2718, 2719, "5" +823, 21, 33, 566, 128, 129, 2720, 2721, "%" +823, 21, 34, 567, 130, 134, 2722, 2726, "were" +823, 21, 35, 568, 135, 144, 2727, 2736, "receiving" +823, 21, 36, 569, 145, 146, 2737, 2738, ">" +823, 21, 37, 570, 147, 149, 2739, 2741, "or" +823, 21, 38, 571, 150, 151, 2742, 2743, "=" +823, 21, 39, 572, 152, 153, 2744, 2745, "1" +823, 21, 40, 573, 154, 157, 2746, 2749, "OAD" +823, 21, 41, 574, 158, 162, 2750, 2754, "only" +823, 21, 42, 575, 163, 164, 2755, 2756, "." +823, 22, 1, 576, 0, 2, 2757, 2759, "At" +823, 22, 2, 577, 3, 5, 2760, 2762, "52" +823, 22, 3, 578, 6, 11, 2763, 2768, "weeks" +823, 22, 4, 579, 12, 13, 2769, 2770, "," +823, 22, 5, 580, 14, 19, 2771, 2776, "there" +823, 22, 6, 581, 20, 23, 2777, 2780, "was" +823, 22, 7, 582, 24, 26, 2781, 2783, "no" +823, 22, 8, 583, 27, 38, 2784, 2795, "significant" +823, 22, 9, 584, 39, 49, 2796, 2806, "difference" +823, 22, 10, 585, 50, 57, 2807, 2814, "between" +823, 22, 11, 586, 58, 65, 2815, 2822, "detemir" +823, 22, 12, 587, 66, 69, 2823, 2826, "and" +823, 22, 13, 588, 70, 78, 2827, 2835, "glargine" +823, 22, 14, 589, 79, 81, 2836, 2838, "in" +823, 22, 15, 590, 82, 87, 2839, 2844, "terms" +823, 22, 16, 591, 88, 90, 2845, 2847, "of" +823, 22, 17, 592, 91, 95, 2848, 2852, "mean" +823, 22, 18, 593, 96, 99, 2853, 2856, "HbA" +823, 22, 19, 594, 100, 101, 2857, 2858, "(" +823, 22, 20, 595, 102, 104, 2859, 2861, "1c" +823, 22, 21, 596, 105, 106, 2862, 2863, ")" +823, 22, 22, 597, 107, 108, 2864, 2865, "(" +823, 22, 23, 598, 109, 110, 2866, 2867, "7" +823, 22, 24, 599, 111, 112, 2868, 2869, "." +823, 22, 25, 600, 113, 115, 2870, 2872, "19" +823, 22, 26, 601, 116, 117, 2873, 2874, "%" +823, 22, 27, 602, 118, 121, 2875, 2878, "and" +823, 22, 28, 603, 122, 123, 2879, 2880, "7" +823, 22, 29, 604, 124, 125, 2881, 2882, "." +823, 22, 30, 605, 126, 128, 2883, 2885, "03" +823, 22, 31, 606, 129, 130, 2886, 2887, "%" +823, 22, 32, 607, 131, 132, 2888, 2889, "," +823, 22, 33, 608, 133, 145, 2890, 2902, "respectively" +823, 22, 34, 609, 146, 147, 2903, 2904, ";" +823, 22, 35, 610, 148, 152, 2905, 2909, "mean" +823, 22, 36, 611, 153, 163, 2910, 2920, "difference" +823, 22, 37, 612, 164, 165, 2921, 2922, "," +823, 22, 38, 613, 166, 167, 2923, 2924, "0" +823, 22, 39, 614, 168, 169, 2925, 2926, "." +823, 22, 40, 615, 170, 172, 2927, 2929, "17" +823, 22, 41, 616, 173, 174, 2930, 2931, "%" +823, 22, 42, 617, 175, 176, 2932, 2933, "[" +823, 22, 43, 618, 177, 179, 2934, 2936, "95" +823, 22, 44, 619, 180, 181, 2937, 2938, "%" +823, 22, 45, 620, 182, 184, 2939, 2941, "CI" +823, 22, 46, 621, 185, 186, 2942, 2943, "," +823, 22, 47, 622, 187, 188, 2944, 2945, "-" +823, 22, 48, 623, 189, 190, 2946, 2947, "0" +823, 22, 49, 624, 191, 192, 2948, 2949, "." +823, 22, 50, 625, 193, 195, 2950, 2952, "07" +823, 22, 51, 626, 196, 198, 2953, 2955, "to" +823, 22, 52, 627, 199, 200, 2956, 2957, "0" +823, 22, 53, 628, 201, 202, 2958, 2959, "." +823, 22, 54, 629, 203, 205, 2960, 2962, "40" +823, 22, 55, 630, 206, 207, 2963, 2964, "]" +823, 22, 56, 631, 208, 209, 2965, 2966, ")" +823, 22, 57, 632, 210, 212, 2967, 2969, "or" +823, 22, 58, 633, 213, 216, 2970, 2973, "the" +823, 22, 59, 634, 217, 221, 2974, 2978, "mean" +823, 22, 60, 635, 222, 230, 2979, 2987, "decrease" +823, 22, 61, 636, 231, 233, 2988, 2990, "in" +823, 22, 62, 637, 234, 239, 2991, 2996, "HbAlc" +823, 22, 63, 638, 240, 244, 2997, 3001, "from" +823, 22, 64, 639, 245, 253, 3002, 3010, "baseline" +823, 22, 65, 640, 254, 255, 3011, 3012, "(" +823, 22, 66, 641, 256, 257, 3013, 3014, "-" +823, 22, 67, 642, 258, 259, 3015, 3016, "1" +823, 22, 68, 643, 260, 261, 3017, 3018, "." +823, 22, 69, 644, 262, 264, 3019, 3021, "52" +823, 22, 70, 645, 265, 266, 3022, 3023, "%" +823, 22, 71, 646, 267, 270, 3024, 3027, "and" +823, 22, 72, 647, 271, 272, 3028, 3029, "-" +823, 22, 73, 648, 273, 274, 3030, 3031, "1" +823, 22, 74, 649, 275, 276, 3032, 3033, "." +823, 22, 75, 650, 277, 279, 3034, 3036, "68" +823, 22, 76, 651, 280, 281, 3037, 3038, "%" +823, 22, 77, 652, 282, 283, 3039, 3040, ")" +823, 22, 78, 653, 284, 285, 3041, 3042, "." +823, 23, 1, 654, 0, 3, 3043, 3046, "The" +823, 23, 2, 655, 4, 13, 3047, 3056, "reduction" +823, 23, 3, 656, 14, 16, 3057, 3059, "in" +823, 23, 4, 657, 17, 20, 3060, 3063, "HbA" +823, 23, 5, 658, 21, 22, 3064, 3065, "(" +823, 23, 6, 659, 23, 25, 3066, 3068, "1c" +823, 23, 7, 660, 26, 27, 3069, 3070, ")" +823, 23, 8, 661, 28, 31, 3071, 3074, "was" +823, 23, 9, 662, 32, 35, 3075, 3078, "not" +823, 23, 10, 663, 36, 49, 3079, 3092, "significantly" +823, 23, 11, 664, 50, 58, 3093, 3101, "affected" +823, 23, 12, 665, 59, 61, 3102, 3104, "by" +823, 23, 13, 666, 62, 69, 3105, 3112, "whether" +823, 23, 14, 667, 70, 77, 3113, 3120, "detemir" +823, 23, 15, 668, 78, 81, 3121, 3124, "was" +823, 23, 16, 669, 82, 94, 3125, 3137, "administered" +823, 23, 17, 670, 95, 99, 3138, 3142, "once" +823, 23, 18, 671, 100, 102, 3143, 3145, "or" +823, 23, 19, 672, 103, 108, 3146, 3151, "twice" +823, 23, 20, 673, 109, 114, 3152, 3157, "daily" +823, 23, 21, 674, 115, 116, 3158, 3159, "." +823, 24, 1, 675, 0, 5, 3160, 3165, "There" +823, 24, 2, 676, 6, 10, 3166, 3170, "were" +823, 24, 3, 677, 11, 13, 3171, 3173, "no" +823, 24, 4, 678, 14, 25, 3174, 3185, "significant" +823, 24, 5, 679, 26, 37, 3186, 3197, "differences" +823, 24, 6, 680, 38, 45, 3198, 3205, "between" +823, 24, 7, 681, 46, 52, 3206, 3212, "groups" +823, 24, 8, 682, 53, 55, 3213, 3215, "in" +823, 24, 9, 683, 56, 61, 3216, 3221, "terms" +823, 24, 10, 684, 62, 64, 3222, 3224, "of" +823, 24, 11, 685, 65, 69, 3225, 3229, "mean" +823, 24, 12, 686, 70, 73, 3230, 3233, "FPG" +823, 24, 13, 687, 74, 75, 3234, 3235, "(" +823, 24, 14, 688, 76, 77, 3236, 3237, "7" +823, 24, 15, 689, 78, 79, 3238, 3239, "." +823, 24, 16, 690, 80, 82, 3240, 3242, "05" +823, 24, 17, 691, 83, 86, 3243, 3246, "and" +823, 24, 18, 692, 87, 88, 3247, 3248, "6" +823, 24, 19, 693, 89, 90, 3249, 3250, "." +823, 24, 20, 694, 91, 93, 3251, 3253, "68" +823, 24, 21, 695, 94, 98, 3254, 3258, "mmol" +823, 24, 22, 696, 99, 100, 3259, 3260, "/" +823, 24, 23, 697, 101, 102, 3261, 3262, "L" +823, 24, 24, 698, 103, 104, 3263, 3264, ")" +823, 24, 25, 699, 105, 107, 3265, 3267, "or" +823, 24, 26, 700, 108, 111, 3268, 3271, "the" +823, 24, 27, 701, 112, 116, 3272, 3276, "mean" +823, 24, 28, 702, 117, 123, 3277, 3283, "change" +823, 24, 29, 703, 124, 126, 3284, 3286, "in" +823, 24, 30, 704, 127, 130, 3287, 3290, "FPG" +823, 24, 31, 705, 131, 135, 3291, 3295, "from" +823, 24, 32, 706, 136, 144, 3296, 3304, "baseline" +823, 24, 33, 707, 145, 146, 3305, 3306, "(" +823, 24, 34, 708, 147, 148, 3307, 3308, "-" +823, 24, 35, 709, 149, 150, 3309, 3310, "2" +823, 24, 36, 710, 151, 152, 3311, 3312, "." +823, 24, 37, 711, 153, 155, 3313, 3315, "56" +823, 24, 38, 712, 156, 159, 3316, 3319, "and" +823, 24, 39, 713, 160, 161, 3320, 3321, "-" +823, 24, 40, 714, 162, 163, 3322, 3323, "2" +823, 24, 41, 715, 164, 165, 3324, 3325, "." +823, 24, 42, 716, 166, 168, 3326, 3328, "92" +823, 24, 43, 717, 169, 173, 3329, 3333, "mmol" +823, 24, 44, 718, 174, 175, 3334, 3335, "/" +823, 24, 45, 719, 176, 177, 3336, 3337, "L" +823, 24, 46, 720, 178, 179, 3338, 3339, ";" +823, 24, 47, 721, 180, 184, 3340, 3344, "mean" +823, 24, 48, 722, 185, 195, 3345, 3355, "difference" +823, 24, 49, 723, 196, 197, 3356, 3357, "," +823, 24, 50, 724, 198, 199, 3358, 3359, "0" +823, 24, 51, 725, 200, 201, 3360, 3361, "." +823, 24, 52, 726, 202, 204, 3362, 3364, "36" +823, 24, 53, 727, 205, 206, 3365, 3366, ";" +823, 24, 54, 728, 207, 209, 3367, 3369, "95" +823, 24, 55, 729, 210, 211, 3370, 3371, "%" +823, 24, 56, 730, 212, 214, 3372, 3374, "CI" +823, 24, 57, 731, 215, 216, 3375, 3376, "," +823, 24, 58, 732, 217, 218, 3377, 3378, "-" +823, 24, 59, 733, 219, 220, 3379, 3380, "0" +823, 24, 60, 734, 221, 222, 3381, 3382, "." +823, 24, 61, 735, 223, 225, 3383, 3385, "26" +823, 24, 62, 736, 226, 228, 3386, 3388, "to" +823, 24, 63, 737, 229, 230, 3389, 3390, "0" +823, 24, 64, 738, 231, 232, 3391, 3392, "." +823, 24, 65, 739, 233, 235, 3393, 3395, "99" +823, 24, 66, 740, 236, 237, 3396, 3397, ")" +823, 24, 67, 741, 238, 239, 3398, 3399, "." +823, 25, 1, 742, 0, 3, 3400, 3403, "The" +823, 25, 2, 743, 4, 11, 3404, 3411, "overall" +823, 25, 3, 744, 12, 17, 3412, 3417, "shape" +823, 25, 4, 745, 18, 20, 3418, 3420, "of" +823, 25, 5, 746, 21, 24, 3421, 3424, "the" +823, 25, 6, 747, 25, 27, 3425, 3427, "10" +823, 25, 7, 748, 28, 29, 3428, 3429, "-" +823, 25, 8, 749, 30, 35, 3430, 3435, "point" +823, 25, 9, 750, 36, 40, 3436, 3440, "SMPG" +823, 25, 10, 751, 41, 49, 3441, 3449, "profiles" +823, 25, 11, 752, 50, 53, 3450, 3453, "was" +823, 25, 12, 753, 54, 57, 3454, 3457, "not" +823, 25, 13, 754, 58, 71, 3458, 3471, "significantly" +823, 25, 14, 755, 72, 81, 3472, 3481, "different" +823, 25, 15, 756, 82, 89, 3482, 3489, "between" +823, 25, 16, 757, 90, 96, 3490, 3496, "groups" +823, 25, 17, 758, 97, 98, 3497, 3498, "." +823, 26, 1, 759, 0, 4, 3499, 3503, "Mean" +823, 26, 2, 760, 5, 11, 3504, 3510, "weight" +823, 26, 3, 761, 12, 16, 3511, 3515, "gain" +823, 26, 4, 762, 17, 19, 3516, 3518, "at" +823, 26, 5, 763, 20, 22, 3519, 3521, "52" +823, 26, 6, 764, 23, 28, 3522, 3527, "weeks" +823, 26, 7, 765, 29, 32, 3528, 3531, "was" +823, 26, 8, 766, 33, 46, 3532, 3545, "significantly" +823, 26, 9, 767, 47, 52, 3546, 3551, "lower" +823, 26, 10, 768, 53, 57, 3552, 3556, "with" +823, 26, 11, 769, 58, 65, 3557, 3564, "detemir" +823, 26, 12, 770, 66, 70, 3565, 3569, "than" +823, 26, 13, 771, 71, 75, 3570, 3574, "with" +823, 26, 14, 772, 76, 84, 3575, 3583, "glargine" +823, 26, 15, 773, 85, 86, 3584, 3585, "(" +823, 26, 16, 774, 87, 88, 3586, 3587, "2" +823, 26, 17, 775, 89, 90, 3588, 3589, "." +823, 26, 18, 776, 91, 92, 3590, 3591, "8" +823, 26, 19, 777, 93, 95, 3592, 3594, "vs" +823, 26, 20, 778, 96, 97, 3595, 3596, "3" +823, 26, 21, 779, 98, 99, 3597, 3598, "." +823, 26, 22, 780, 100, 101, 3599, 3600, "8" +823, 26, 23, 781, 102, 104, 3601, 3603, "kg" +823, 26, 24, 782, 105, 106, 3604, 3605, ";" +823, 26, 25, 783, 107, 111, 3606, 3610, "mean" +823, 26, 26, 784, 112, 122, 3611, 3621, "difference" +823, 26, 27, 785, 123, 124, 3622, 3623, "," +823, 26, 28, 786, 125, 126, 3624, 3625, "-" +823, 26, 29, 787, 127, 128, 3626, 3627, "1" +823, 26, 30, 788, 129, 130, 3628, 3629, "." +823, 26, 31, 789, 131, 133, 3630, 3632, "04" +823, 26, 32, 790, 134, 135, 3633, 3634, ";" +823, 26, 33, 791, 136, 138, 3635, 3637, "95" +823, 26, 34, 792, 139, 140, 3638, 3639, "%" +823, 26, 35, 793, 141, 143, 3640, 3642, "CI" +823, 26, 36, 794, 144, 145, 3643, 3644, "," +823, 26, 37, 795, 146, 147, 3645, 3646, "-" +823, 26, 38, 796, 148, 149, 3647, 3648, "2" +823, 26, 39, 797, 150, 151, 3649, 3650, "." +823, 26, 40, 798, 152, 154, 3651, 3653, "08" +823, 26, 41, 799, 155, 157, 3654, 3656, "to" +823, 26, 42, 800, 158, 159, 3657, 3658, "-" +823, 26, 43, 801, 160, 161, 3659, 3660, "0" +823, 26, 44, 802, 162, 163, 3661, 3662, "." +823, 26, 45, 803, 164, 166, 3663, 3665, "01" +823, 26, 46, 804, 167, 168, 3666, 3667, ";" +823, 26, 47, 805, 169, 170, 3668, 3669, "P" +823, 26, 48, 806, 171, 172, 3670, 3671, "<" +823, 26, 49, 807, 173, 174, 3672, 3673, "0" +823, 26, 50, 808, 175, 176, 3674, 3675, "." +823, 26, 51, 809, 177, 179, 3676, 3678, "05" +823, 26, 52, 810, 180, 181, 3679, 3680, ")" +823, 26, 53, 811, 182, 183, 3681, 3682, "." +823, 27, 1, 812, 0, 5, 3683, 3688, "Doses" +823, 27, 2, 813, 6, 8, 3689, 3691, "of" +823, 27, 3, 814, 9, 14, 3692, 3697, "basal" +823, 27, 4, 815, 15, 18, 3698, 3701, "and" +823, 27, 5, 816, 19, 27, 3702, 3710, "prandial" +823, 27, 6, 817, 28, 36, 3711, 3719, "insulins" +823, 27, 7, 818, 37, 39, 3720, 3722, "at" +823, 27, 8, 819, 40, 43, 3723, 3726, "the" +823, 27, 9, 820, 44, 47, 3727, 3730, "end" +823, 27, 10, 821, 48, 50, 3731, 3733, "of" +823, 27, 11, 822, 51, 54, 3734, 3737, "the" +823, 27, 12, 823, 55, 60, 3738, 3743, "study" +823, 27, 13, 824, 61, 65, 3744, 3748, "were" +823, 27, 14, 825, 66, 69, 3749, 3752, "not" +823, 27, 15, 826, 70, 83, 3753, 3766, "significantly" +823, 27, 16, 827, 84, 93, 3767, 3776, "different" +823, 27, 17, 828, 94, 101, 3777, 3784, "between" +823, 27, 18, 829, 102, 108, 3785, 3791, "groups" +823, 27, 19, 830, 109, 110, 3792, 3793, "." +823, 28, 1, 831, 0, 5, 3794, 3799, "Major" +823, 28, 2, 832, 6, 18, 3800, 3812, "hypoglycemic" +823, 28, 3, 833, 19, 27, 3813, 3821, "episodes" +823, 28, 4, 834, 28, 32, 3822, 3826, "were" +823, 28, 5, 835, 33, 41, 3827, 3835, "reported" +823, 28, 6, 836, 42, 44, 3836, 3838, "by" +823, 28, 7, 837, 45, 46, 3839, 3840, "4" +823, 28, 8, 838, 47, 48, 3841, 3842, "." +823, 28, 9, 839, 49, 50, 3843, 3844, "7" +823, 28, 10, 840, 51, 52, 3845, 3846, "%" +823, 28, 11, 841, 53, 56, 3847, 3850, "and" +823, 28, 12, 842, 57, 58, 3851, 3852, "5" +823, 28, 13, 843, 59, 60, 3853, 3854, "." +823, 28, 14, 844, 61, 62, 3855, 3856, "7" +823, 28, 15, 845, 63, 64, 3857, 3858, "%" +823, 28, 16, 846, 65, 67, 3859, 3861, "of" +823, 28, 17, 847, 68, 76, 3862, 3870, "patients" +823, 28, 18, 848, 77, 79, 3871, 3873, "in" +823, 28, 19, 849, 80, 83, 3874, 3877, "the" +823, 28, 20, 850, 84, 94, 3878, 3888, "respective" +823, 28, 21, 851, 95, 104, 3889, 3898, "treatment" +823, 28, 22, 852, 105, 111, 3899, 3905, "groups" +823, 28, 23, 853, 112, 113, 3906, 3907, "." +823, 29, 1, 854, 0, 5, 3908, 3913, "There" +823, 29, 2, 855, 6, 9, 3914, 3917, "was" +823, 29, 3, 856, 10, 12, 3918, 3920, "no" +823, 29, 4, 857, 13, 24, 3921, 3932, "significant" +823, 29, 5, 858, 25, 35, 3933, 3943, "difference" +823, 29, 6, 859, 36, 38, 3944, 3946, "in" +823, 29, 7, 860, 39, 42, 3947, 3950, "the" +823, 29, 8, 861, 43, 47, 3951, 3955, "risk" +823, 29, 9, 862, 48, 50, 3956, 3958, "of" +823, 29, 10, 863, 51, 63, 3959, 3971, "hypoglycemia" +823, 29, 11, 864, 64, 71, 3972, 3979, "between" +823, 29, 12, 865, 72, 78, 3980, 3986, "groups" +823, 29, 13, 866, 79, 80, 3987, 3988, "." +823, 30, 1, 867, 0, 3, 3989, 3992, "The" +823, 30, 2, 868, 4, 14, 3993, 4003, "proportion" +823, 30, 3, 869, 15, 17, 4004, 4006, "of" +823, 30, 4, 870, 18, 26, 4007, 4015, "patients" +823, 30, 5, 871, 27, 31, 4016, 4020, "with" +823, 30, 6, 872, 32, 35, 4021, 4024, "AEs" +823, 30, 7, 873, 36, 39, 4025, 4028, "and" +823, 30, 8, 874, 40, 43, 4029, 4032, "the" +823, 30, 9, 875, 44, 50, 4033, 4039, "number" +823, 30, 10, 876, 51, 53, 4040, 4042, "of" +823, 30, 11, 877, 54, 57, 4043, 4046, "AEs" +823, 30, 12, 878, 58, 61, 4047, 4050, "per" +823, 30, 13, 879, 62, 69, 4051, 4058, "patient" +823, 30, 14, 880, 70, 74, 4059, 4063, "were" +823, 30, 15, 881, 75, 85, 4064, 4074, "comparable" +823, 30, 16, 882, 86, 93, 4075, 4082, "between" +823, 30, 17, 883, 94, 100, 4083, 4089, "groups" +823, 30, 18, 884, 101, 102, 4090, 4091, "(" +823, 30, 19, 885, 103, 106, 4092, 4095, "185" +823, 30, 20, 886, 107, 108, 4096, 4097, "/" +823, 30, 21, 887, 109, 112, 4098, 4101, "214" +823, 30, 22, 888, 113, 121, 4102, 4110, "patients" +823, 30, 23, 889, 122, 123, 4111, 4112, "[" +823, 30, 24, 890, 124, 126, 4113, 4115, "86" +823, 30, 25, 891, 127, 128, 4116, 4117, "." +823, 30, 26, 892, 129, 130, 4118, 4119, "4" +823, 30, 27, 893, 131, 132, 4120, 4121, "%" +823, 30, 28, 894, 133, 134, 4122, 4123, "]" +823, 30, 29, 895, 135, 144, 4124, 4133, "reporting" +823, 30, 30, 896, 145, 148, 4134, 4137, "743" +823, 30, 31, 897, 149, 152, 4138, 4141, "AEs" +823, 30, 32, 898, 153, 156, 4142, 4145, "and" +823, 30, 33, 899, 157, 159, 4146, 4148, "88" +823, 30, 34, 900, 160, 161, 4149, 4150, "/" +823, 30, 35, 901, 162, 165, 4151, 4154, "105" +823, 30, 36, 902, 166, 174, 4155, 4163, "patients" +823, 30, 37, 903, 175, 176, 4164, 4165, "[" +823, 30, 38, 904, 177, 179, 4166, 4168, "83" +823, 30, 39, 905, 180, 181, 4169, 4170, "." +823, 30, 40, 906, 182, 183, 4171, 4172, "8" +823, 30, 41, 907, 184, 185, 4173, 4174, "%" +823, 30, 42, 908, 186, 187, 4175, 4176, "]" +823, 30, 43, 909, 188, 197, 4177, 4186, "reporting" +823, 30, 44, 910, 198, 201, 4187, 4190, "377" +823, 30, 45, 911, 202, 205, 4191, 4194, "AEs" +823, 30, 46, 912, 206, 207, 4195, 4196, ")" +823, 30, 47, 913, 208, 209, 4197, 4198, "." +823, 31, 1, 914, 0, 11, 4199, 4210, "CONCLUSIONS" +823, 31, 2, 915, 12, 13, 4211, 4212, ":" +823, 31, 3, 916, 14, 18, 4213, 4217, "when" +823, 31, 4, 917, 19, 23, 4218, 4222, "used" +823, 31, 5, 918, 24, 26, 4223, 4225, "as" +823, 31, 6, 919, 27, 36, 4226, 4235, "indicated" +823, 31, 7, 920, 37, 39, 4236, 4238, "as" +823, 31, 8, 921, 40, 44, 4239, 4243, "part" +823, 31, 9, 922, 45, 47, 4244, 4246, "of" +823, 31, 10, 923, 48, 49, 4247, 4248, "a" +823, 31, 11, 924, 50, 55, 4249, 4254, "basal" +823, 31, 12, 925, 56, 57, 4255, 4256, "-" +823, 31, 13, 926, 58, 63, 4257, 4262, "bolus" +823, 31, 14, 927, 64, 71, 4263, 4270, "regimen" +823, 31, 15, 928, 72, 74, 4271, 4273, "in" +823, 31, 16, 929, 75, 83, 4274, 4282, "patients" +823, 31, 17, 930, 84, 88, 4283, 4287, "with" +823, 31, 18, 931, 89, 93, 4288, 4292, "T2DM" +823, 31, 19, 932, 94, 97, 4293, 4296, "who" +823, 31, 20, 933, 98, 101, 4297, 4300, "had" +823, 31, 21, 934, 102, 112, 4301, 4311, "previously" +823, 31, 22, 935, 113, 121, 4312, 4320, "received" +823, 31, 23, 936, 122, 127, 4321, 4326, "other" +823, 31, 24, 937, 128, 135, 4327, 4334, "insulin" +823, 31, 25, 938, 136, 139, 4335, 4338, "and" +823, 31, 26, 939, 140, 141, 4339, 4340, "/" +823, 31, 27, 940, 142, 144, 4341, 4343, "or" +823, 31, 28, 941, 145, 148, 4344, 4347, "OAD" +823, 31, 29, 942, 149, 157, 4348, 4356, "regimens" +823, 31, 30, 943, 158, 159, 4357, 4358, "," +823, 31, 31, 944, 160, 167, 4359, 4366, "detemir" +823, 31, 32, 945, 168, 171, 4367, 4370, "was" +823, 31, 33, 946, 172, 183, 4371, 4382, "noninferior" +823, 31, 34, 947, 184, 186, 4383, 4385, "to" +823, 31, 35, 948, 187, 195, 4386, 4394, "glargine" +823, 31, 36, 949, 196, 198, 4395, 4397, "in" +823, 31, 37, 950, 199, 202, 4398, 4401, "its" +823, 31, 38, 951, 203, 210, 4402, 4409, "effects" +823, 31, 39, 952, 211, 213, 4410, 4412, "on" +823, 31, 40, 953, 214, 221, 4413, 4420, "overall" +823, 31, 41, 954, 222, 230, 4421, 4429, "glycemic" +823, 31, 42, 955, 231, 238, 4430, 4437, "control" +823, 31, 43, 956, 239, 240, 4438, 4439, "." +823, 32, 1, 957, 0, 4, 4440, 4444, "Both" +823, 32, 2, 958, 5, 10, 4445, 4450, "basal" +823, 32, 3, 959, 11, 19, 4451, 4459, "insulins" +823, 32, 4, 960, 20, 24, 4460, 4464, "were" +823, 32, 5, 961, 25, 35, 4465, 4475, "associated" +823, 32, 6, 962, 36, 40, 4476, 4480, "with" +823, 32, 7, 963, 41, 51, 4481, 4491, "clinically" +823, 32, 8, 964, 52, 60, 4492, 4500, "relevant" +823, 32, 9, 965, 61, 71, 4501, 4511, "reductions" +823, 32, 10, 966, 72, 74, 4512, 4514, "in" +823, 32, 11, 967, 75, 88, 4515, 4528, "hyperglycemia" +823, 32, 12, 968, 89, 90, 4529, 4530, "." +823, 33, 1, 969, 0, 4, 4531, 4535, "Both" +823, 33, 2, 970, 5, 9, 4536, 4540, "were" +823, 33, 3, 971, 10, 14, 4541, 4545, "well" +823, 33, 4, 972, 15, 24, 4546, 4555, "tolerated" +823, 33, 5, 973, 25, 26, 4556, 4557, "," +823, 33, 6, 974, 27, 31, 4558, 4562, "with" +823, 33, 7, 975, 32, 34, 4563, 4565, "no" +823, 33, 8, 976, 35, 46, 4566, 4577, "significant" +823, 33, 9, 977, 47, 57, 4578, 4588, "difference" +823, 33, 10, 978, 58, 60, 4589, 4591, "in" +823, 33, 11, 979, 61, 64, 4592, 4595, "the" +823, 33, 12, 980, 65, 74, 4596, 4605, "frequency" +823, 33, 13, 981, 75, 77, 4606, 4608, "of" +823, 33, 14, 982, 78, 90, 4609, 4621, "hypoglycemia" +823, 33, 15, 983, 91, 93, 4622, 4624, "or" +823, 33, 16, 984, 94, 97, 4625, 4628, "AEs" +823, 33, 17, 985, 98, 99, 4629, 4630, "." +823, 34, 1, 986, 0, 3, 4631, 4634, "DOI" +823, 34, 2, 987, 4, 5, 4635, 4636, ":" +823, 34, 3, 988, 6, 8, 4637, 4639, "10" +823, 34, 4, 989, 9, 10, 4640, 4641, "." +823, 34, 5, 990, 11, 15, 4642, 4646, "1016" +823, 34, 6, 991, 16, 17, 4647, 4648, "/" +823, 34, 7, 992, 18, 19, 4649, 4650, "j" +823, 34, 8, 993, 20, 21, 4651, 4652, "." +823, 34, 9, 994, 22, 31, 4653, 4662, "clinthera" +823, 34, 10, 995, 32, 33, 4663, 4664, "." +823, 34, 11, 996, 34, 38, 4665, 4669, "2008" +823, 34, 12, 997, 39, 40, 4670, 4671, "." +823, 34, 13, 998, 41, 43, 4672, 4674, "11" +823, 34, 14, 999, 44, 45, 4675, 4676, "." +823, 34, 15, 1000, 46, 49, 4677, 4680, "001" +823, 34, 16, 1001, 50, 54, 4681, 4685, "PMID" +823, 34, 17, 1002, 55, 56, 4686, 4687, ":" +823, 34, 18, 1003, 57, 65, 4688, 4696, "19108786" +823, 34, 19, 1004, 66, 67, 4697, 4698, "[" +823, 34, 20, 1005, 68, 75, 4699, 4706, "Indexed" +823, 34, 21, 1006, 76, 79, 4707, 4710, "for" +823, 34, 22, 1007, 80, 87, 4711, 4718, "MEDLINE" +823, 34, 23, 1008, 88, 89, 4719, 4720, "]" diff --git a/data/dm2 19108786_admin.annodb b/data/dm2 19108786_admin.annodb new file mode 100644 index 0000000..8aa4e7a --- /dev/null +++ b/data/dm2 19108786_admin.annodb @@ -0,0 +1,178 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2008", "", " \"2008\"." +160, Title, 99, 344, "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "", " \"A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .\"." +2, Duration, 101, 110, "52 - week", "", +153, Multicenter, 113, 126, "multinational", "", +3, OpenLabel, 129, 141, "open - label", "", +4, Parallel, 144, 160, "parallel - group", "", +5, CTDesign, 163, 177, "noninferiority", "", +6, CTDesign, 180, 199, "treat - to - target", "", +7, InsulinDetemir, 216, 231, "insulin detemir", "", +8, InsulinGlargine, 237, 253, "insulin glargine", "", +9, RelativeTime, 286, 294, "mealtime", "", +10, InsulinAspart, 295, 309, "insulin aspart", "", +11, Type2Diabetes, 327, 342, "type 2 diabetes", "", +12, Author, 345, 356, "Hollander P", "", " \"Hollander P\"." +13, Author, 365, 373, "Cooper J", "", " \"Cooper J\"." +14, Author, 376, 388, "Bregnh ø j J", "", " \"Bregnh ø j J\"." +15, Author, 391, 402, "Pedersen CB", "", " \"Pedersen CB\"." +16, USA, 477, 480, "USA", "", " ." +28, ObjectiveDescription, 653, 809, "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen", "", " \"This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen\"." +17, Insulin, 713, 720, "insulin", "", +18, InsulinDetemir, 731, 738, "detemir", "", +19, InsulinGlargine, 743, 751, "glargine", "", +52521, Insulin, 765, 772, "insulin", "", +314, ObjectiveDescription, 810, 955, "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .", "", " \"in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .\"." +27, Precondition, 813, 953, "patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs", "", +21, Type2Diabetes, 827, 851, "type 2 diabetes mellitus", "", " ." +22, Type2Diabetes, 854, 858, "T2DM", "", +23, OralAntidiabeticAgent, 889, 912, "oral antidiabetic drugs", "", +24, OralAntidiabeticAgent, 915, 919, "OADs", "", +26, Insulin, 925, 932, "insulin", "", +25, OralAntidiabeticAgent, 949, 953, "OADs", "", +174, Multicenter, 977, 990, "multinational", "", " ." +29, Duration, 993, 1002, "52 - week", "", " \"52 - week\"." +30, OpenLabel, 1005, 1014, "openlabel", "", " ." +31, Parallel, 1017, 1033, "parallel - group", "", " ." +32, CTDesign, 1036, 1050, "noninferiority", "", " . ." +33, CTDesign, 1053, 1072, "treat - to - target", "", " . ." +42, Precondition, 1081, 1216, "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months", "", " \"Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months\"." +34, Type2Diabetes, 1110, 1114, "T2DM", "", +35, OralAntidiabeticAgent, 1162, 1165, "OAD", "", +37, Insulin, 1169, 1176, "insulin", "", +36, OralAntidiabeticAgent, 1195, 1199, "OADs", "", +38, Randomized, 1222, 1232, "randomized", "", " ." +39, AllocationRatio, 1238, 1243, "2 : 1", "", " . ." +40, InsulinDetemir, 1261, 1268, "detemir", "", +41, InsulinGlargine, 1272, 1280, "glargine", "", +43, InsulinDetemir, 1320, 1327, "detemir", "", " ." +44, Frequency, 1350, 1369, "once or twice daily", "", " \"once or twice daily\"." +45, InsulinGlargine, 1376, 1384, "glargine", "", " ." +46, Frequency, 1402, 1412, "once daily", "", " \"once daily\"." +47, InsulinAspart, 1415, 1429, "Insulin aspart", "", +52522, RelativeTime, 1443, 1452, "mealtimes", "", +49, Insulin, 1455, 1462, "Insulin", "", +50, OralAntidiabeticAgent, 1556, 1560, "OADs", "", +51, InsulinDetemir, 1587, 1594, "detemir", "", +52, InsulinGlargine, 1599, 1607, "glargine", "", +52525, DoseDescription, 1608, 1749, "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L", "", " \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\". \"were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L\"." +52524, RelativeTime, 1635, 1647, "prebreakfast", "", +52523, RelativeTime, 1654, 1663, "predinner", "", +55, InsulinDetemir, 1668, 1675, "detemir", "", +56, Frequency, 1689, 1700, "twice daily", "", +57, FastingPlasmaGlucose_target, 1703, 1749, "plasma glucose target of < or = 6 . 0 mmol / L", "", +200, Millimoles_per_litre, 1741, 1749, "mmol / L", "", +316, PlasmaGlucose, 1777, 1791, "plasma glucose", "", +58, Insulin, 1893, 1900, "insulin", "", +317, PlasmaGlucose, 1977, 1991, "plasma glucose", "", +318, PlasmaGlucose, 1994, 1998, "SMPG", "", +202, TimePoint, 2004, 2012, "baseline", "", +203, TimePoint, 2017, 2025, "after 24", "", +204, TimePoint, 2030, 2038, "52 weeks", "", +59, HbA1c, 2076, 2099, "glycosylated hemoglobin", "", +60, HbA1c, 2102, 2112, "HbA ( 1c )", "", +206, TimePoint, 2118, 2126, "52 weeks", "", +62, FastingPlasmaGlucose, 2179, 2201, "fasting plasma glucose", "", +63, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +319, PostprandialPlasmaGlucose, 2212, 2239, "postprandial plasma glucose", "", +320, InsulinDose, 2242, 2255, "insulin doses", "", +64, BodyWeight, 2262, 2268, "weight", "", +211, TimePoint, 2279, 2287, "52 weeks", "", +65, Hypoglycemia, 2334, 2346, "hypoglycemia", "", +66, EndPointDescription, 2351, 2365, "adverse events", "", +67, EndPointDescription, 2368, 2371, "AEs", "", +68, IntentionToTreat, 2390, 2412, "intention - to - treat", "", " ." +69, NumberPatientsCT, 2433, 2436, "319", "", " \"319\"." +70, Male, 2448, 2456, "58 . 0 %", "", " ." +71, Female, 2464, 2472, "42 . 0 %", "", " ." +72, Ethnicity, 2482, 2496, "78 . 4 % white", "", " . ." +218, Mean, 2499, 2503, "mean", "", +73, AvgAge, 2510, 2512, "58", "", " \"58\"." +216, Year, 2513, 2518, "years", "", +217, Mean, 2521, 2525, "mean", "", +74, BodyWeight, 2526, 2532, "weight", "", +75, Kg, 2542, 2544, "kg", "", +219, Mean, 2547, 2551, "mean", "", +102224, Duration, 2575, 2587, "13 . 6 years", "", +322, TimePoint, 2595, 2606, "study entry", "", +226, OralAntidiabeticAgent, 2666, 2669, "OAD", "", +228, OralAntidiabeticAgent, 2746, 2749, "OAD", "", +230, TimePoint, 2760, 2768, "52 weeks", "", " \"52 weeks\". \"52 weeks\"." +84, InsulinDetemir, 2815, 2822, "detemir", "", +85, InsulinGlargine, 2827, 2835, "glargine", "", +240, Mean, 2848, 2852, "mean", "", " . ." +86, HbA1c, 2853, 2863, "HbA ( 1c )", "", " ." +89, ResultMeasuredValue, 2866, 2872, "7 . 19", "", " \"7 . 19\"." +91, Percentage, 2873, 2874, "%", "", " ." +90, ResultMeasuredValue, 2879, 2885, "7 . 03", "", " \"7 . 03\"." +92, Percentage, 2886, 2887, "%", "", +241, Mean, 2905, 2909, "mean", "", +88, DiffGroupAbsValue, 2923, 2929, "0 . 17", "", " \"0 . 17\"." +93, Percentage, 2930, 2931, "%", "", +87, ConfIntervalDiff, 2934, 2962, "95 % CI , - 0 . 07 to 0 . 40", "", " \"95 % CI , - 0 . 07 to 0 . 40\"." +242, Mean, 2974, 2978, "mean", "", +96, HbA1c, 2991, 2996, "HbAlc", "", +323, TimePoint, 3002, 3010, "baseline", "", +97, Reduction, 3015, 3021, "1 . 52", "", " \"1 . 52\"." +94, Percentage, 3022, 3023, "%", "", +98, Reduction, 3030, 3036, "1 . 68", "", " \"1 . 68\"." +95, Percentage, 3037, 3038, "%", "", +99, HbA1c, 3060, 3070, "HbA ( 1c )", "", +100, InsulinDetemir, 3113, 3120, "detemir", "", +101, Frequency, 3138, 3157, "once or twice daily", "", +52526, Mean, 3225, 3229, "mean", "", " . ." +102, FastingPlasmaGlucose, 3230, 3233, "FPG", "", " ." +104, ResultMeasuredValue, 3236, 3242, "7 . 05", "", " \"7 . 05\"." +105, ResultMeasuredValue, 3247, 3253, "6 . 68", "", " \"6 . 68\"." +106, Millimoles_per_litre, 3254, 3262, "mmol / L", "", " ." +52527, Mean, 3272, 3276, "mean", "", +103, FastingPlasmaGlucose, 3287, 3290, "FPG", "", +333, TimePoint, 3296, 3304, "baseline", "", +109, Reduction, 3309, 3315, "2 . 56", "", " \"2 . 56\"." +108, Reduction, 3322, 3328, "2 . 92", "", " \"2 . 92\"." +107, Millimoles_per_litre, 3329, 3337, "mmol / L", "", +263, Mean, 3340, 3344, "mean", "", +110, DiffGroupAbsValue, 3358, 3364, "0 . 36", "", " \"0 . 36\"." +111, ConfIntervalDiff, 3367, 3395, "95 % CI , - 0 . 26 to 0 . 99", "", " \"95 % CI , - 0 . 26 to 0 . 99\"." +267, Mean, 3499, 3503, "Mean", "", " . ." +268, WeightGain, 3504, 3515, "weight gain", "", " ." +269, TimePoint, 3519, 3527, "52 weeks", "", " \"52 weeks\". \"52 weeks\"." +115, InsulinDetemir, 3557, 3564, "detemir", "", +116, InsulinGlargine, 3575, 3583, "glargine", "", +272, ResultMeasuredValue, 3586, 3591, "2 . 8", "", " \"2 . 8\"." +273, ResultMeasuredValue, 3595, 3600, "3 . 8", "", " \"3 . 8\"." +119, Kg, 3601, 3603, "kg", "", " ." +275, Mean, 3606, 3610, "mean", "", +120, DiffGroupAbsValue, 3624, 3632, "- 1 . 04", "", " \"- 1 . 04\"." +121, ConfIntervalDiff, 3635, 3665, "95 % CI , - 2 . 08 to - 0 . 01", "", " \"95 % CI , - 2 . 08 to - 0 . 01\"." +122, PvalueDiff, 3668, 3678, "P < 0 . 05", "", " \"95 % CI , - 2 . 08 to - 0 . 01\"." +334, TimePoint, 3723, 3743, "the end of the study", "", +125, Hypoglycemia, 3800, 3812, "hypoglycemic", "", " ." +124, PercentageAffected, 3839, 3844, "4 . 7", "", " \"4 . 7\"." +123, PercentageAffected, 3851, 3856, "5 . 7", "", " \"5 . 7\"." +328, ObservedResult, 3908, 3988, "There was no significant difference in the risk of hypoglycemia between groups .", "", " \"There was no significant difference in the risk of hypoglycemia between groups .\". \"There was no significant difference in the risk of hypoglycemia between groups .\"." +126, Hypoglycemia, 3959, 3971, "hypoglycemia", "", +127, EndPointDescription, 4021, 4024, "AEs", "", " . ." +128, EndPointDescription, 4043, 4046, "AEs", "", +129, NumberAffected, 4092, 4095, "185", "", " \"185\"." +131, NumberPatientsArm, 4098, 4101, "214", "", " \"214\"." +133, PercentageAffected, 4113, 4119, "86 . 4", "", " \"86 . 4\"." +135, EndPointDescription, 4138, 4141, "AEs", "", +130, NumberAffected, 4146, 4148, "88", "", " \"88\"." +132, NumberPatientsArm, 4151, 4154, "105", "", " \"105\"." +134, PercentageAffected, 4166, 4172, "83 . 8", "", " \"83 . 8\"." +136, EndPointDescription, 4191, 4194, "AEs", "", +304, ConclusionComment, 4213, 4439, "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .", "", " \"when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .\"." +139, Type2Diabetes, 4288, 4292, "T2DM", "", +140, Insulin, 4327, 4334, "insulin", "", +299, OralAntidiabeticAgent, 4344, 4347, "OAD", "", +142, InsulinDetemir, 4359, 4366, "detemir", "", +143, InsulinGlargine, 4386, 4394, "glargine", "", +306, ConclusionComment, 4440, 4530, "Both basal insulins were associated with clinically relevant reductions in hyperglycemia .", "", " \"Both basal insulins were associated with clinically relevant reductions in hyperglycemia .\"." +145, Insulin, 4451, 4459, "insulins", "", +146, Hypoglycemia, 4515, 4528, "hyperglycemia", "", +307, ConclusionComment, 4531, 4630, "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .", "", " \"Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .\"." +147, Hypoglycemia, 4609, 4621, "hypoglycemia", "", +148, EndPointDescription, 4625, 4628, "AEs", "", +149, PMID, 4688, 4696, "19108786", "", " \"19108786\"." diff --git a/data/dm2 19108786_admin.n-triples b/data/dm2 19108786_admin.n-triples new file mode 100644 index 0000000..513cae8 --- /dev/null +++ b/data/dm2 19108786_admin.n-triples @@ -0,0 +1,203 @@ +# RDF export of group: Publication + . + "Publication " . + "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes ." . + "Hollander P" . + "2008" . + "Clin Ther ." . + "19108786" . + . + "Cooper J" . + "Bregnh ø j J" . + "Pedersen CB" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen" . + "319" . + "52 - week" . + . + . + . + . + "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control ." . + . + . + . + . + . + "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs ." . + . + . + . + . + . + . + . + "Both basal insulins were associated with clinically relevant reductions in hyperglycemia ." . + "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months" . + . + . + . + "58" . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm d" . + "214" . + . + . + . + . + . + . + . + "Arm ig" . + "105" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention d" . + . + "once or twice daily" . + . + . + "Intervention ig" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication d" . + . + . + . + "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L" . + . + "Medication ig" . + . + . + . + "were titrated to achieve a prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L" . +# RDF export of group: Outcome + . + "Outcome hba1c d" . + . + "7 . 19" . + "1 . 52" . + "52 weeks" . + . + "Outcome hba1c ig" . + . + "7 . 03" . + "1 . 68" . + "52 weeks" . + . + "Outcome fpg d" . + . + "7 . 05" . + "2 . 56" . + . + "Outcome fpg ig" . + . + "6 . 68" . + "2 . 92" . + . + "Outcome weight d" . + . + "2 . 8" . + "52 weeks" . + . + "Outcome weight ig" . + . + "3 . 8" . + "52 weeks" . + . + "Outcome h d" . + . + "4 . 7" . + "There was no significant difference in the risk of hypoglycemia between groups ." . + . + "Outcome h ig" . + . + "5 . 7" . + "There was no significant difference in the risk of hypoglycemia between groups ." . + . + "Outcome aes d" . + . + "185" . + "86 . 4" . + . + "Outcome aes ig" . + . + "88" . + "83 . 8" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c " . + "0 . 17" . + "95 % CI , - 0 . 07 to 0 . 40" . + . + . + . + "DiffBetweenGroups fpg" . + "0 . 36" . + "95 % CI , - 0 . 26 to 0 . 99" . + . + . + . + "DiffBetweenGroups weight" . + "- 1 . 04" . + "P < 0 . 05" . + "95 % CI , - 2 . 08 to - 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19108786_akramersunderbrink.annodb b/data/dm2 19108786_akramersunderbrink.annodb new file mode 100644 index 0000000..2f34301 --- /dev/null +++ b/data/dm2 19108786_akramersunderbrink.annodb @@ -0,0 +1,166 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23758, Journal, 0, 9, "Clin Ther", "", +23759, PublicationYear, 12, 16, "2008", "", +23768, Title, 99, 344, "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "", +23760, Duration, 101, 110, "52 - week", "", +23761, Multicenter, 113, 126, "multinational", "", +23762, OpenLabel, 129, 141, "open - label", "", +23763, Parallel, 144, 160, "parallel - group", "", +23764, InsulinDetemir, 216, 231, "insulin detemir", "", +23765, InsulinGlargine, 237, 253, "insulin glargine", "", +23805, RelativeTime, 286, 294, "mealtime", "", +23766, InsulinAspart, 295, 309, "insulin aspart", "", +23767, Type2Diabetes, 327, 342, "type 2 diabetes", "", +23771, Author, 345, 356, "Hollander P", "", +23772, Author, 365, 373, "Cooper J", "", +23773, Author, 376, 388, "Bregnh ø j J", "", +23774, Author, 391, 402, "Pedersen CB", "", +23775, USA, 477, 480, "USA", "", +23788, ObjectiveDescription, 653, 906, "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic", "", +23776, InsulinDetemir, 731, 738, "detemir", "", +23777, InsulinGlargine, 743, 751, "glargine", "", +23778, Type2Diabetes, 827, 851, "type 2 diabetes mellitus", "", +23779, Type2Diabetes, 854, 858, "T2DM", "", +23780, OralAntidiabeticAgent, 889, 912, "oral antidiabetic drugs", "", +23789, ObjectiveDescription, 907, 955, "drugs ( OADs ) or insulin with or without OADs .", "", +23781, OralAntidiabeticAgent, 915, 919, "OADs", "", +23783, Insulin, 925, 932, "insulin", "", +23782, OralAntidiabeticAgent, 949, 953, "OADs", "", +23784, Multicenter, 977, 990, "multinational", "", +23785, Duration, 993, 1002, "52 - week", "", +23786, OpenLabel, 1005, 1014, "openlabel", "", +23787, Parallel, 1017, 1033, "parallel - group", "", +23791, Precondition, 1097, 1135, "diagnosis of T2DM for > or = 12 months", "", +23790, Type2Diabetes, 1110, 1114, "T2DM", "", +23795, Precondition, 1149, 1216, "receiving an OAD or insulin , with or without OADs , for > 4 months", "", +23792, OralAntidiabeticAgent, 1162, 1165, "OAD", "", +23793, Insulin, 1169, 1176, "insulin", "", +23794, Insulin, 1195, 1199, "OADs", "", +23796, Randomized, 1222, 1232, "randomized", "", +23797, InsulinDetemir, 1261, 1268, "detemir", "", +23798, InsulinGlargine, 1272, 1280, "glargine", "", +23799, InsulinDetemir, 1320, 1327, "detemir", "", +23800, Frequency, 1350, 1369, "once or twice daily", "", +23801, InsulinGlargine, 1376, 1384, "glargine", "", +23802, Frequency, 1402, 1412, "once daily", "", +23803, InsulinAspart, 1415, 1429, "Insulin aspart", "", +23804, RelativeTime, 1440, 1452, "at mealtimes", "", +23807, Precondition, 1455, 1540, "Insulin secretagogues and a - glucosidase inhibitors were discontinued at study entry", "", +23806, OralAntidiabeticAgent, 1556, 1560, "OADs", "", +23808, InsulinDetemir, 1587, 1594, "detemir", "", +23809, InsulinGlargine, 1599, 1607, "glargine", "", +23922, FastingPlasmaGlucose_target, 1635, 1749, "prebreakfast ( and predinner for detemir administered twice daily ) plasma glucose target of < or = 6 . 0 mmol / L", "", +23810, Millimoles_per_litre, 1741, 1749, "mmol / L", "", +23811, PreprandialGlucose, 1777, 1826, "plasma glucose levels before breakfast and dinner", "", +23812, TimePoint, 2004, 2012, "baseline", "", +23813, TimePoint, 2017, 2025, "after 24", "", +23814, TimePoint, 2030, 2038, "52 weeks", "", +23815, HbA1c, 2102, 2112, "HbA ( 1c )", "", +23816, TimePoint, 2118, 2126, "52 weeks", "", +23817, FastingPlasmaGlucose, 2179, 2201, "fasting plasma glucose", "", +23818, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +23819, InsulinDose, 2212, 2239, "postprandial plasma glucose", "", +23820, BodyWeight, 2262, 2275, "weight change", "", +23821, TimePoint, 2279, 2287, "52 weeks", "", +23822, NumberPatientsCT, 2433, 2436, "319", "", +23823, Gender, 2448, 2479, "58 . 0 % male , 42 . 0 % female", "", +23824, Ethnicity, 2482, 2496, "78 . 4 % white", "", +23828, Mean, 2499, 2503, "mean", "", +23825, AvgAge, 2510, 2512, "58", "", +23826, Year, 2513, 2518, "years", "", +23827, Mean, 2521, 2525, "mean", "", +23833, Precondition, 2521, 2544, "mean weight , 92 . 8 kg", "", +23830, BodyWeight, 2526, 2532, "weight", "", +23831, Kg, 2542, 2544, "kg", "", +23829, Mean, 2547, 2551, "mean", "", +23834, Precondition, 2547, 2587, "mean duration of diabetes , 13 . 6 years", "", +23832, Year, 2582, 2587, "years", "", +23839, Precondition, 2609, 2754, "46 . 1 % of patients were receiving insulin and > or = 1 OAD , 35 . 4 were receiving insulin only , and 18 . 5 % were receiving > or = 1 OAD only", "", +23835, Percentage, 2616, 2617, "%", "", +23836, OralAntidiabeticAgent, 2666, 2669, "OAD", "", +23837, Percentage, 2720, 2721, "%", "", +23838, OralAntidiabeticAgent, 2746, 2749, "OAD", "", +23840, TimePoint, 2760, 2768, "52 weeks", "", +23841, InsulinDetemir, 2815, 2822, "detemir", "", +23842, InsulinGlargine, 2827, 2835, "glargine", "", +23850, Mean, 2848, 2852, "mean", "", +23843, HbA1c, 2853, 2863, "HbA ( 1c )", "", +23853, ResultMeasuredValue, 2866, 2872, "7 . 19", "", +23844, Percentage, 2873, 2874, "%", "", +23854, ResultMeasuredValue, 2879, 2885, "7 . 03", "", +23845, Percentage, 2886, 2887, "%", "", +23851, Mean, 2905, 2909, "mean", "", +23855, DiffGroupAbsValue, 2923, 2929, "0 . 17", "", +23846, Percentage, 2930, 2931, "%", "", +23856, ConfIntervalDiff, 2934, 2962, "95 % CI , - 0 . 07 to 0 . 40", "", +23847, Percentage, 2937, 2938, "%", "", +23852, Mean, 2974, 2978, "mean", "", +23857, HbA1c, 2991, 2996, "HbAlc", "", +39173, TimePoint, 3002, 3010, "baseline", "", +23858, ChangeValue, 3013, 3021, "- 1 . 52", "", +23848, Percentage, 3022, 3023, "%", "", +23859, ChangeValue, 3028, 3036, "- 1 . 68", "", +23849, Percentage, 3037, 3038, "%", "", +23860, HbA1c, 3060, 3070, "HbA ( 1c )", "", +23861, InsulinDetemir, 3113, 3120, "detemir", "", +23862, Frequency, 3138, 3157, "once or twice daily", "", +23863, LeastSquaresMean, 3225, 3229, "mean", "", +23865, FastingPlasmaGlucose, 3230, 3233, "FPG", "", +23867, ResultMeasuredValue, 3236, 3242, "7 . 05", "", +23868, ResultMeasuredValue, 3247, 3253, "6 . 68", "", +23869, Millimoles_per_litre, 3254, 3262, "mmol / L", "", +23864, LeastSquaresMean, 3272, 3276, "mean", "", +23866, FastingPlasmaGlucose, 3287, 3290, "FPG", "", +39174, TimePoint, 3296, 3304, "baseline", "", +23871, ChangeValue, 3307, 3315, "- 2 . 56", "", +23872, ChangeValue, 3320, 3328, "- 2 . 92", "", +23870, Millimoles_per_litre, 3329, 3337, "mmol / L", "", +23873, Mean, 3340, 3344, "mean", "", +23874, DiffGroupAbsValue, 3358, 3364, "0 . 36", "", +23875, ConfIntervalDiff, 3367, 3395, "95 % CI , - 0 . 26 to 0 . 99", "", +23876, EndPointDescription, 3425, 3449, "10 - point SMPG profiles", "", +23877, Mean, 3499, 3503, "Mean", "", +23878, WeightGain, 3504, 3515, "weight gain", "", +23879, TimePoint, 3519, 3527, "52 weeks", "", +23881, InsulinDetemir, 3557, 3564, "detemir", "", +23880, InsulinGlargine, 3575, 3583, "glargine", "", +23882, ResultMeasuredValue, 3586, 3591, "2 . 8", "", +23883, ResultMeasuredValue, 3595, 3600, "3 . 8", "", +23884, Kg, 3601, 3603, "kg", "", +23886, Mean, 3606, 3610, "mean", "", +23887, DiffGroupAbsValue, 3624, 3632, "- 1 . 04", "", +23888, ConfIntervalDiff, 3635, 3665, "95 % CI , - 2 . 08 to - 0 . 01", "", +23889, PvalueDiff, 3668, 3678, "P < 0 . 05", "", +23890, EndPointDescription, 3683, 3719, "Doses of basal and prandial insulins", "", +39175, TimePoint, 3723, 3743, "the end of the study", "", +23891, Hypoglycemia, 3794, 3821, "Major hypoglycemic episodes", "", +23894, PercentageAffected, 3839, 3844, "4 . 7", "", +23892, Percentage, 3845, 3846, "%", "", +23895, PercentageAffected, 3851, 3856, "5 . 7", "", +23893, Percentage, 3857, 3858, "%", "", +23896, EndPointDescription, 3951, 3971, "risk of hypoglycemia", "", +23897, EndPointDescription, 4007, 4024, "patients with AEs", "", +23898, EndPointDescription, 4033, 4058, "number of AEs per patient", "", +23901, NumberAffected, 4092, 4095, "185", "", +23899, NumberPatientsArm, 4098, 4101, "214", "", +23903, PercentageAffected, 4113, 4119, "86 . 4", "", +23905, Percentage, 4120, 4121, "%", "", +23907, ResultMeasuredValue, 4134, 4137, "743", "", +23902, NumberAffected, 4146, 4148, "88", "", +23900, NumberPatientsArm, 4151, 4154, "105", "", +23904, PercentageAffected, 4166, 4172, "83 . 8", "", +23906, Percentage, 4173, 4174, "%", "", +23908, ResultMeasuredValue, 4187, 4190, "377", "", +23915, ConclusionComment, 4213, 4439, "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .", "", +23909, Type2Diabetes, 4288, 4292, "T2DM", "", +23912, Precondition, 4301, 4356, "previously received other insulin and / or OAD regimens", "", +23911, Insulin, 4327, 4334, "insulin", "", +23910, OralAntidiabeticAgent, 4344, 4347, "OAD", "", +23913, InsulinDetemir, 4359, 4366, "detemir", "", +23914, InsulinGlargine, 4386, 4394, "glargine", "", +23917, ConclusionComment, 4440, 4530, "Both basal insulins were associated with clinically relevant reductions in hyperglycemia .", "", +23921, Insulin, 4445, 4459, "basal insulins", "", +23916, Hypoglycemia, 4515, 4528, "hyperglycemia", "", +23918, ConclusionComment, 4531, 4630, "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .", "", +23919, Hypoglycemia, 4609, 4621, "hypoglycemia", "", +23920, PMID, 4688, 4696, "19108786", "", diff --git a/data/dm2 19108786_akramersunderbrink.n-triples b/data/dm2 19108786_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19108786_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19108786_export.csv b/data/dm2 19108786_export.csv new file mode 100644 index 0000000..0162fb0 --- /dev/null +++ b/data/dm2 19108786_export.csv @@ -0,0 +1,1009 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +341, 1, 1, 1, 0, 4, 0, 4, "Clin" +341, 1, 2, 2, 5, 9, 5, 9, "Ther" +341, 1, 3, 3, 10, 11, 10, 11, "." +341, 2, 1, 4, 0, 4, 12, 16, "2008" +341, 2, 2, 5, 5, 8, 17, 20, "Nov" +341, 2, 3, 6, 9, 10, 21, 22, ";" +341, 2, 4, 7, 11, 13, 23, 25, "30" +341, 2, 5, 8, 14, 15, 26, 27, "(" +341, 2, 6, 9, 16, 18, 28, 30, "11" +341, 2, 7, 10, 19, 20, 31, 32, ")" +341, 2, 8, 11, 21, 22, 33, 34, ":" +341, 2, 9, 12, 23, 27, 35, 39, "1976" +341, 2, 10, 13, 28, 29, 40, 41, "-" +341, 2, 11, 14, 30, 32, 42, 44, "87" +341, 2, 12, 15, 33, 34, 45, 46, "." +341, 2, 13, 16, 35, 38, 47, 50, "doi" +341, 2, 14, 17, 39, 40, 51, 52, ":" +341, 2, 15, 18, 41, 43, 53, 55, "10" +341, 2, 16, 19, 44, 45, 56, 57, "." +341, 2, 17, 20, 46, 50, 58, 62, "1016" +341, 2, 18, 21, 51, 52, 63, 64, "/" +341, 2, 19, 22, 53, 54, 65, 66, "j" +341, 2, 20, 23, 55, 56, 67, 68, "." +341, 2, 21, 24, 57, 66, 69, 78, "clinthera" +341, 2, 22, 25, 67, 68, 79, 80, "." +341, 2, 23, 26, 69, 73, 81, 85, "2008" +341, 2, 24, 27, 74, 75, 86, 87, "." +341, 2, 25, 28, 76, 78, 88, 90, "11" +341, 2, 26, 29, 79, 80, 91, 92, "." +341, 2, 27, 30, 81, 84, 93, 96, "001" +341, 2, 28, 31, 85, 86, 97, 98, "." +341, 3, 1, 32, 0, 1, 99, 100, "A" +341, 3, 2, 33, 2, 4, 101, 103, "52" +341, 3, 3, 34, 5, 6, 104, 105, "-" +341, 3, 4, 35, 7, 11, 106, 110, "week" +341, 3, 5, 36, 12, 13, 111, 112, "," +341, 3, 6, 37, 14, 27, 113, 126, "multinational" +341, 3, 7, 38, 28, 29, 127, 128, "," +341, 3, 8, 39, 30, 34, 129, 133, "open" +341, 3, 9, 40, 35, 36, 134, 135, "-" +341, 3, 10, 41, 37, 42, 136, 141, "label" +341, 3, 11, 42, 43, 44, 142, 143, "," +341, 3, 12, 43, 45, 53, 144, 152, "parallel" +341, 3, 13, 44, 54, 55, 153, 154, "-" +341, 3, 14, 45, 56, 61, 155, 160, "group" +341, 3, 15, 46, 62, 63, 161, 162, "," +341, 3, 16, 47, 64, 78, 163, 177, "noninferiority" +341, 3, 17, 48, 79, 80, 178, 179, "," +341, 3, 18, 49, 81, 86, 180, 185, "treat" +341, 3, 19, 50, 87, 88, 186, 187, "-" +341, 3, 20, 51, 89, 91, 188, 190, "to" +341, 3, 21, 52, 92, 93, 191, 192, "-" +341, 3, 22, 53, 94, 100, 193, 199, "target" +341, 3, 23, 54, 101, 106, 200, 205, "trial" +341, 3, 24, 55, 107, 116, 206, 215, "comparing" +341, 3, 25, 56, 117, 124, 216, 223, "insulin" +341, 3, 26, 57, 125, 132, 224, 231, "detemir" +341, 3, 27, 58, 133, 137, 232, 236, "with" +341, 3, 28, 59, 138, 145, 237, 244, "insulin" +341, 3, 29, 60, 146, 154, 245, 253, "glargine" +341, 3, 30, 61, 155, 157, 254, 256, "in" +341, 3, 31, 62, 158, 159, 257, 258, "a" +341, 3, 32, 63, 160, 165, 259, 264, "basal" +341, 3, 33, 64, 166, 167, 265, 266, "-" +341, 3, 34, 65, 168, 173, 267, 272, "bolus" +341, 3, 35, 66, 174, 181, 273, 280, "regimen" +341, 3, 36, 67, 182, 186, 281, 285, "with" +341, 3, 37, 68, 187, 195, 286, 294, "mealtime" +341, 3, 38, 69, 196, 203, 295, 302, "insulin" +341, 3, 39, 70, 204, 210, 303, 309, "aspart" +341, 3, 40, 71, 211, 213, 310, 312, "in" +341, 3, 41, 72, 214, 222, 313, 321, "patients" +341, 3, 42, 73, 223, 227, 322, 326, "with" +341, 3, 43, 74, 228, 232, 327, 331, "type" +341, 3, 44, 75, 233, 234, 332, 333, "2" +341, 3, 45, 76, 235, 243, 334, 342, "diabetes" +341, 3, 46, 77, 244, 245, 343, 344, "." +341, 4, 1, 78, 0, 9, 345, 354, "Hollander" +341, 4, 2, 79, 10, 11, 355, 356, "P" +341, 4, 3, 80, 12, 13, 357, 358, "(" +341, 4, 4, 81, 14, 15, 359, 360, "1" +341, 4, 5, 82, 16, 17, 361, 362, ")" +341, 4, 6, 83, 18, 19, 363, 364, "," +341, 4, 7, 84, 20, 26, 365, 371, "Cooper" +341, 4, 8, 85, 27, 28, 372, 373, "J" +341, 4, 9, 86, 29, 30, 374, 375, "," +341, 4, 10, 87, 31, 37, 376, 382, "Bregnh" +341, 4, 11, 88, 38, 39, 383, 384, "ø" +341, 4, 12, 89, 40, 41, 385, 386, "j" +341, 4, 13, 90, 42, 43, 387, 388, "J" +341, 4, 14, 91, 44, 45, 389, 390, "," +341, 4, 15, 92, 46, 54, 391, 399, "Pedersen" +341, 4, 16, 93, 55, 57, 400, 402, "CB" +341, 4, 17, 94, 58, 59, 403, 404, "." +341, 5, 1, 95, 0, 6, 405, 411, "Author" +341, 5, 2, 96, 7, 18, 412, 423, "information" +341, 5, 3, 97, 19, 20, 424, 425, ":" +341, 5, 4, 98, 21, 22, 426, 427, "(" +341, 5, 5, 99, 23, 24, 428, 429, "1" +341, 5, 6, 100, 25, 26, 430, 431, ")" +341, 5, 7, 101, 27, 33, 432, 438, "Baylor" +341, 5, 8, 102, 34, 41, 439, 446, "Medical" +341, 5, 9, 103, 42, 48, 447, 453, "Center" +341, 5, 10, 104, 49, 55, 454, 460, "Dallas" +341, 5, 11, 105, 56, 57, 461, 462, "," +341, 5, 12, 106, 58, 63, 463, 468, "Texas" +341, 5, 13, 107, 64, 69, 469, 474, "75246" +341, 5, 14, 108, 70, 71, 475, 476, "," +341, 5, 15, 109, 72, 75, 477, 480, "USA" +341, 5, 16, 110, 76, 77, 481, 482, "." +341, 6, 1, 111, 0, 8, 483, 491, "PriscilH" +341, 6, 2, 112, 9, 10, 492, 493, "@" +341, 6, 3, 113, 11, 23, 494, 506, "baylorhealth" +341, 6, 4, 114, 24, 25, 507, 508, "." +341, 6, 5, 115, 26, 29, 509, 512, "edu" +341, 6, 6, 116, 30, 37, 513, 520, "Comment" +341, 6, 7, 117, 38, 40, 521, 523, "in" +341, 6, 8, 118, 41, 45, 524, 528, "Clin" +341, 6, 9, 119, 46, 50, 529, 533, "Ther" +341, 6, 10, 120, 51, 52, 534, 535, "." +341, 7, 1, 121, 0, 4, 536, 540, "2009" +341, 7, 2, 122, 5, 8, 541, 544, "May" +341, 7, 3, 123, 9, 10, 545, 546, ";" +341, 7, 4, 124, 11, 13, 547, 549, "31" +341, 7, 5, 125, 14, 15, 550, 551, "(" +341, 7, 6, 126, 16, 17, 552, 553, "5" +341, 7, 7, 127, 18, 19, 554, 555, ")" +341, 7, 8, 128, 20, 21, 556, 557, ":" +341, 7, 9, 129, 22, 26, 558, 562, "1124" +341, 7, 10, 130, 27, 28, 563, 564, "-" +341, 7, 11, 131, 29, 30, 565, 566, "5" +341, 7, 12, 132, 31, 32, 567, 568, ";" +341, 7, 13, 133, 33, 39, 569, 575, "author" +341, 7, 14, 134, 40, 45, 576, 581, "reply" +341, 7, 15, 135, 46, 50, 582, 586, "1125" +341, 7, 16, 136, 51, 52, 587, 588, "-" +341, 7, 17, 137, 53, 54, 589, 590, "6" +341, 7, 18, 138, 55, 56, 591, 592, "." +341, 8, 1, 139, 0, 8, 593, 601, "Postgrad" +341, 8, 2, 140, 9, 12, 602, 605, "Med" +341, 8, 3, 141, 13, 14, 606, 607, "." +341, 9, 1, 142, 0, 4, 608, 612, "2010" +341, 9, 2, 143, 5, 8, 613, 616, "Jan" +341, 9, 3, 144, 9, 10, 617, 618, ";" +341, 9, 4, 145, 11, 14, 619, 622, "122" +341, 9, 5, 146, 15, 16, 623, 624, "(" +341, 9, 6, 147, 17, 18, 625, 626, "1" +341, 9, 7, 148, 19, 20, 627, 628, ")" +341, 9, 8, 149, 21, 22, 629, 630, ":" +341, 9, 9, 150, 23, 26, 631, 634, "201" +341, 9, 10, 151, 27, 28, 635, 636, "-" +341, 9, 11, 152, 29, 30, 637, 638, "3" +341, 9, 12, 153, 31, 32, 639, 640, "." +341, 10, 1, 154, 0, 9, 641, 650, "OBJECTIVE" +341, 10, 2, 155, 10, 11, 651, 652, ":" +341, 10, 3, 156, 12, 16, 653, 657, "This" +341, 10, 4, 157, 17, 22, 658, 663, "trial" +341, 10, 5, 158, 23, 31, 664, 672, "compared" +341, 10, 6, 159, 32, 35, 673, 676, "the" +341, 10, 7, 160, 36, 44, 677, 685, "efficacy" +341, 10, 8, 161, 45, 48, 686, 689, "and" +341, 10, 9, 162, 49, 55, 690, 696, "safety" +341, 10, 10, 163, 56, 64, 697, 705, "profiles" +341, 10, 11, 164, 65, 67, 706, 708, "of" +341, 10, 12, 165, 68, 71, 709, 712, "the" +341, 10, 13, 166, 72, 79, 713, 720, "insulin" +341, 10, 14, 167, 80, 89, 721, 730, "analogues" +341, 10, 15, 168, 90, 97, 731, 738, "detemir" +341, 10, 16, 169, 98, 101, 739, 742, "and" +341, 10, 17, 170, 102, 110, 743, 751, "glargine" +341, 10, 18, 171, 111, 113, 752, 754, "as" +341, 10, 19, 172, 114, 117, 755, 758, "the" +341, 10, 20, 173, 118, 123, 759, 764, "basal" +341, 10, 21, 174, 124, 131, 765, 772, "insulin" +341, 10, 22, 175, 132, 141, 773, 782, "component" +341, 10, 23, 176, 142, 144, 783, 785, "of" +341, 10, 24, 177, 145, 146, 786, 787, "a" +341, 10, 25, 178, 147, 152, 788, 793, "basal" +341, 10, 26, 179, 153, 154, 794, 795, "-" +341, 10, 27, 180, 155, 160, 796, 801, "bolus" +341, 10, 28, 181, 161, 168, 802, 809, "regimen" +341, 10, 29, 182, 169, 171, 810, 812, "in" +341, 10, 30, 183, 172, 180, 813, 821, "patients" +341, 10, 31, 184, 181, 185, 822, 826, "with" +341, 10, 32, 185, 186, 190, 827, 831, "type" +341, 10, 33, 186, 191, 192, 832, 833, "2" +341, 10, 34, 187, 193, 201, 834, 842, "diabetes" +341, 10, 35, 188, 202, 210, 843, 851, "mellitus" +341, 10, 36, 189, 211, 212, 852, 853, "(" +341, 10, 37, 190, 213, 217, 854, 858, "T2DM" +341, 10, 38, 191, 218, 219, 859, 860, ")" +341, 10, 39, 192, 220, 223, 861, 864, "who" +341, 10, 40, 193, 224, 228, 865, 869, "were" +341, 10, 41, 194, 229, 234, 870, 875, "being" +341, 10, 42, 195, 235, 242, 876, 883, "treated" +341, 10, 43, 196, 243, 247, 884, 888, "with" +341, 10, 44, 197, 248, 252, 889, 893, "oral" +341, 10, 45, 198, 253, 265, 894, 906, "antidiabetic" +341, 10, 46, 199, 266, 271, 907, 912, "drugs" +341, 10, 47, 200, 272, 273, 913, 914, "(" +341, 10, 48, 201, 274, 278, 915, 919, "OADs" +341, 10, 49, 202, 279, 280, 920, 921, ")" +341, 10, 50, 203, 281, 283, 922, 924, "or" +341, 10, 51, 204, 284, 291, 925, 932, "insulin" +341, 10, 52, 205, 292, 296, 933, 937, "with" +341, 10, 53, 206, 297, 299, 938, 940, "or" +341, 10, 54, 207, 300, 307, 941, 948, "without" +341, 10, 55, 208, 308, 312, 949, 953, "OADs" +341, 10, 56, 209, 313, 314, 954, 955, "." +341, 11, 1, 210, 0, 7, 956, 963, "METHODS" +341, 11, 2, 211, 8, 9, 964, 965, ":" +341, 11, 3, 212, 10, 14, 966, 970, "This" +341, 11, 4, 213, 15, 18, 971, 974, "was" +341, 11, 5, 214, 19, 20, 975, 976, "a" +341, 11, 6, 215, 21, 34, 977, 990, "multinational" +341, 11, 7, 216, 35, 36, 991, 992, "," +341, 11, 8, 217, 37, 39, 993, 995, "52" +341, 11, 9, 218, 40, 41, 996, 997, "-" +341, 11, 10, 219, 42, 46, 998, 1002, "week" +341, 11, 11, 220, 47, 48, 1003, 1004, "," +341, 11, 12, 221, 49, 58, 1005, 1014, "openlabel" +341, 11, 13, 222, 59, 60, 1015, 1016, "," +341, 11, 14, 223, 61, 69, 1017, 1025, "parallel" +341, 11, 15, 224, 70, 71, 1026, 1027, "-" +341, 11, 16, 225, 72, 77, 1028, 1033, "group" +341, 11, 17, 226, 78, 79, 1034, 1035, "," +341, 11, 18, 227, 80, 94, 1036, 1050, "noninferiority" +341, 11, 19, 228, 95, 96, 1051, 1052, "," +341, 11, 20, 229, 97, 102, 1053, 1058, "treat" +341, 11, 21, 230, 103, 104, 1059, 1060, "-" +341, 11, 22, 231, 105, 107, 1061, 1063, "to" +341, 11, 23, 232, 108, 109, 1064, 1065, "-" +341, 11, 24, 233, 110, 116, 1066, 1072, "target" +341, 11, 25, 234, 117, 122, 1073, 1078, "trial" +341, 11, 26, 235, 123, 124, 1079, 1080, "." +341, 12, 1, 236, 0, 8, 1081, 1089, "Patients" +341, 12, 2, 237, 9, 13, 1090, 1094, "with" +341, 12, 3, 238, 14, 15, 1095, 1096, "a" +341, 12, 4, 239, 16, 25, 1097, 1106, "diagnosis" +341, 12, 5, 240, 26, 28, 1107, 1109, "of" +341, 12, 6, 241, 29, 33, 1110, 1114, "T2DM" +341, 12, 7, 242, 34, 37, 1115, 1118, "for" +341, 12, 8, 243, 38, 39, 1119, 1120, ">" +341, 12, 9, 244, 40, 42, 1121, 1123, "or" +341, 12, 10, 245, 43, 44, 1124, 1125, "=" +341, 12, 11, 246, 45, 47, 1126, 1128, "12" +341, 12, 12, 247, 48, 54, 1129, 1135, "months" +341, 12, 13, 248, 55, 58, 1136, 1139, "who" +341, 12, 14, 249, 59, 62, 1140, 1143, "had" +341, 12, 15, 250, 63, 67, 1144, 1148, "been" +341, 12, 16, 251, 68, 77, 1149, 1158, "receiving" +341, 12, 17, 252, 78, 80, 1159, 1161, "an" +341, 12, 18, 253, 81, 84, 1162, 1165, "OAD" +341, 12, 19, 254, 85, 87, 1166, 1168, "or" +341, 12, 20, 255, 88, 95, 1169, 1176, "insulin" +341, 12, 21, 256, 96, 97, 1177, 1178, "," +341, 12, 22, 257, 98, 102, 1179, 1183, "with" +341, 12, 23, 258, 103, 105, 1184, 1186, "or" +341, 12, 24, 259, 106, 113, 1187, 1194, "without" +341, 12, 25, 260, 114, 118, 1195, 1199, "OADs" +341, 12, 26, 261, 119, 120, 1200, 1201, "," +341, 12, 27, 262, 121, 124, 1202, 1205, "for" +341, 12, 28, 263, 125, 126, 1206, 1207, ">" +341, 12, 29, 264, 127, 128, 1208, 1209, "4" +341, 12, 30, 265, 129, 135, 1210, 1216, "months" +341, 12, 31, 266, 136, 140, 1217, 1221, "were" +341, 12, 32, 267, 141, 151, 1222, 1232, "randomized" +341, 12, 33, 268, 152, 154, 1233, 1235, "in" +341, 12, 34, 269, 155, 156, 1236, 1237, "a" +341, 12, 35, 270, 157, 158, 1238, 1239, "2" +341, 12, 36, 271, 159, 160, 1240, 1241, ":" +341, 12, 37, 272, 161, 162, 1242, 1243, "1" +341, 12, 38, 273, 163, 168, 1244, 1249, "ratio" +341, 12, 39, 274, 169, 171, 1250, 1252, "to" +341, 12, 40, 275, 172, 179, 1253, 1260, "receive" +341, 12, 41, 276, 180, 187, 1261, 1268, "detemir" +341, 12, 42, 277, 188, 190, 1269, 1271, "or" +341, 12, 43, 278, 191, 199, 1272, 1280, "glargine" +341, 12, 44, 279, 200, 201, 1281, 1282, "." +341, 13, 1, 280, 0, 9, 1283, 1292, "According" +341, 13, 2, 281, 10, 12, 1293, 1295, "to" +341, 13, 3, 282, 13, 16, 1296, 1299, "the" +341, 13, 4, 283, 17, 25, 1300, 1308, "approved" +341, 13, 5, 284, 26, 34, 1309, 1317, "labeling" +341, 13, 6, 285, 35, 36, 1318, 1319, "," +341, 13, 7, 286, 37, 44, 1320, 1327, "detemir" +341, 13, 8, 287, 45, 50, 1328, 1333, "could" +341, 13, 9, 288, 51, 53, 1334, 1336, "be" +341, 13, 10, 289, 54, 66, 1337, 1349, "administered" +341, 13, 11, 290, 67, 71, 1350, 1354, "once" +341, 13, 12, 291, 72, 74, 1355, 1357, "or" +341, 13, 13, 292, 75, 80, 1358, 1363, "twice" +341, 13, 14, 293, 81, 86, 1364, 1369, "daily" +341, 13, 15, 294, 87, 88, 1370, 1371, "," +341, 13, 16, 295, 89, 92, 1372, 1375, "and" +341, 13, 17, 296, 93, 101, 1376, 1384, "glargine" +341, 13, 18, 297, 102, 105, 1385, 1388, "was" +341, 13, 19, 298, 106, 118, 1389, 1401, "administered" +341, 13, 20, 299, 119, 123, 1402, 1406, "once" +341, 13, 21, 300, 124, 129, 1407, 1412, "daily" +341, 13, 22, 301, 130, 131, 1413, 1414, "." +341, 14, 1, 302, 0, 7, 1415, 1422, "Insulin" +341, 14, 2, 303, 8, 14, 1423, 1429, "aspart" +341, 14, 3, 304, 15, 18, 1430, 1433, "was" +341, 14, 4, 305, 19, 24, 1434, 1439, "given" +341, 14, 5, 306, 25, 27, 1440, 1442, "at" +341, 14, 6, 307, 28, 37, 1443, 1452, "mealtimes" +341, 14, 7, 308, 38, 39, 1453, 1454, "." +341, 15, 1, 309, 0, 7, 1455, 1462, "Insulin" +341, 15, 2, 310, 8, 21, 1463, 1476, "secretagogues" +341, 15, 3, 311, 22, 25, 1477, 1480, "and" +341, 15, 4, 312, 26, 27, 1481, 1482, "a" +341, 15, 5, 313, 28, 29, 1483, 1484, "-" +341, 15, 6, 314, 30, 41, 1485, 1496, "glucosidase" +341, 15, 7, 315, 42, 52, 1497, 1507, "inhibitors" +341, 15, 8, 316, 53, 57, 1508, 1512, "were" +341, 15, 9, 317, 58, 70, 1513, 1525, "discontinued" +341, 15, 10, 318, 71, 73, 1526, 1528, "at" +341, 15, 11, 319, 74, 79, 1529, 1534, "study" +341, 15, 12, 320, 80, 85, 1535, 1540, "entry" +341, 15, 13, 321, 86, 87, 1541, 1542, "," +341, 15, 14, 322, 88, 91, 1543, 1546, "and" +341, 15, 15, 323, 92, 100, 1547, 1555, "existing" +341, 15, 16, 324, 101, 105, 1556, 1560, "OADs" +341, 15, 17, 325, 106, 110, 1561, 1565, "were" +341, 15, 18, 326, 111, 120, 1566, 1575, "continued" +341, 15, 19, 327, 121, 122, 1576, 1577, "." +341, 16, 1, 328, 0, 5, 1578, 1583, "Doses" +341, 16, 2, 329, 6, 8, 1584, 1586, "of" +341, 16, 3, 330, 9, 16, 1587, 1594, "detemir" +341, 16, 4, 331, 17, 20, 1595, 1598, "and" +341, 16, 5, 332, 21, 29, 1599, 1607, "glargine" +341, 16, 6, 333, 30, 34, 1608, 1612, "were" +341, 16, 7, 334, 35, 43, 1613, 1621, "titrated" +341, 16, 8, 335, 44, 46, 1622, 1624, "to" +341, 16, 9, 336, 47, 54, 1625, 1632, "achieve" +341, 16, 10, 337, 55, 56, 1633, 1634, "a" +341, 16, 11, 338, 57, 69, 1635, 1647, "prebreakfast" +341, 16, 12, 339, 70, 71, 1648, 1649, "(" +341, 16, 13, 340, 72, 75, 1650, 1653, "and" +341, 16, 14, 341, 76, 85, 1654, 1663, "predinner" +341, 16, 15, 342, 86, 89, 1664, 1667, "for" +341, 16, 16, 343, 90, 97, 1668, 1675, "detemir" +341, 16, 17, 344, 98, 110, 1676, 1688, "administered" +341, 16, 18, 345, 111, 116, 1689, 1694, "twice" +341, 16, 19, 346, 117, 122, 1695, 1700, "daily" +341, 16, 20, 347, 123, 124, 1701, 1702, ")" +341, 16, 21, 348, 125, 131, 1703, 1709, "plasma" +341, 16, 22, 349, 132, 139, 1710, 1717, "glucose" +341, 16, 23, 350, 140, 146, 1718, 1724, "target" +341, 16, 24, 351, 147, 149, 1725, 1727, "of" +341, 16, 25, 352, 150, 151, 1728, 1729, "<" +341, 16, 26, 353, 152, 154, 1730, 1732, "or" +341, 16, 27, 354, 155, 156, 1733, 1734, "=" +341, 16, 28, 355, 157, 158, 1735, 1736, "6" +341, 16, 29, 356, 159, 160, 1737, 1738, "." +341, 16, 30, 357, 161, 162, 1739, 1740, "0" +341, 16, 31, 358, 163, 167, 1741, 1745, "mmol" +341, 16, 32, 359, 168, 169, 1746, 1747, "/" +341, 16, 33, 360, 170, 171, 1748, 1749, "L" +341, 16, 34, 361, 172, 173, 1750, 1751, "." +341, 17, 1, 362, 0, 8, 1752, 1760, "Patients" +341, 17, 2, 363, 9, 18, 1761, 1770, "monitored" +341, 17, 3, 364, 19, 24, 1771, 1776, "their" +341, 17, 4, 365, 25, 31, 1777, 1783, "plasma" +341, 17, 5, 366, 32, 39, 1784, 1791, "glucose" +341, 17, 6, 367, 40, 46, 1792, 1798, "levels" +341, 17, 7, 368, 47, 53, 1799, 1805, "before" +341, 17, 8, 369, 54, 63, 1806, 1815, "breakfast" +341, 17, 9, 370, 64, 67, 1816, 1819, "and" +341, 17, 10, 371, 68, 74, 1820, 1826, "dinner" +341, 17, 11, 372, 75, 77, 1827, 1829, "on" +341, 17, 12, 373, 78, 81, 1830, 1833, "the" +341, 17, 13, 374, 82, 83, 1834, 1835, "3" +341, 17, 14, 375, 84, 88, 1836, 1840, "days" +341, 17, 15, 376, 89, 95, 1841, 1847, "before" +341, 17, 16, 377, 96, 100, 1848, 1852, "each" +341, 17, 17, 378, 101, 103, 1853, 1855, "of" +341, 17, 18, 379, 104, 106, 1856, 1858, "13" +341, 17, 19, 380, 107, 116, 1859, 1868, "scheduled" +341, 17, 20, 381, 117, 123, 1869, 1875, "visits" +341, 17, 21, 382, 124, 125, 1876, 1877, "," +341, 17, 22, 383, 126, 134, 1878, 1886, "recorded" +341, 17, 23, 384, 135, 140, 1887, 1892, "their" +341, 17, 24, 385, 141, 148, 1893, 1900, "insulin" +341, 17, 25, 386, 149, 154, 1901, 1906, "doses" +341, 17, 26, 387, 155, 157, 1907, 1909, "on" +341, 17, 27, 388, 158, 159, 1910, 1911, "1" +341, 17, 28, 389, 160, 162, 1912, 1914, "of" +341, 17, 29, 390, 163, 168, 1915, 1920, "these" +341, 17, 30, 391, 169, 170, 1921, 1922, "3" +341, 17, 31, 392, 171, 175, 1923, 1927, "days" +341, 17, 32, 393, 176, 177, 1928, 1929, "," +341, 17, 33, 394, 178, 181, 1930, 1933, "and" +341, 17, 34, 395, 182, 190, 1934, 1942, "recorded" +341, 17, 35, 396, 191, 196, 1943, 1948, "their" +341, 17, 36, 397, 197, 199, 1949, 1951, "10" +341, 17, 37, 398, 200, 201, 1952, 1953, "-" +341, 17, 38, 399, 202, 207, 1954, 1959, "point" +341, 17, 39, 400, 208, 212, 1960, 1964, "self" +341, 17, 40, 401, 213, 214, 1965, 1966, "-" +341, 17, 41, 402, 215, 224, 1967, 1976, "monitored" +341, 17, 42, 403, 225, 231, 1977, 1983, "plasma" +341, 17, 43, 404, 232, 239, 1984, 1991, "glucose" +341, 17, 44, 405, 240, 241, 1992, 1993, "(" +341, 17, 45, 406, 242, 246, 1994, 1998, "SMPG" +341, 17, 46, 407, 247, 248, 1999, 2000, ")" +341, 17, 47, 408, 249, 251, 2001, 2003, "at" +341, 17, 48, 409, 252, 260, 2004, 2012, "baseline" +341, 17, 49, 410, 261, 264, 2013, 2016, "and" +341, 17, 50, 411, 265, 270, 2017, 2022, "after" +341, 17, 51, 412, 271, 273, 2023, 2025, "24" +341, 17, 52, 413, 274, 277, 2026, 2029, "and" +341, 17, 53, 414, 278, 280, 2030, 2032, "52" +341, 17, 54, 415, 281, 286, 2033, 2038, "weeks" +341, 17, 55, 416, 287, 288, 2039, 2040, "." +341, 18, 1, 417, 0, 3, 2041, 2044, "The" +341, 18, 2, 418, 4, 11, 2045, 2052, "primary" +341, 18, 3, 419, 12, 20, 2053, 2061, "efficacy" +341, 18, 4, 420, 21, 24, 2062, 2065, "end" +341, 18, 5, 421, 25, 30, 2066, 2071, "point" +341, 18, 6, 422, 31, 34, 2072, 2075, "was" +341, 18, 7, 423, 35, 47, 2076, 2088, "glycosylated" +341, 18, 8, 424, 48, 58, 2089, 2099, "hemoglobin" +341, 18, 9, 425, 59, 60, 2100, 2101, "(" +341, 18, 10, 426, 61, 64, 2102, 2105, "HbA" +341, 18, 11, 427, 65, 66, 2106, 2107, "(" +341, 18, 12, 428, 67, 69, 2108, 2110, "1c" +341, 18, 13, 429, 70, 71, 2111, 2112, ")" +341, 18, 14, 430, 72, 73, 2113, 2114, ")" +341, 18, 15, 431, 74, 76, 2115, 2117, "at" +341, 18, 16, 432, 77, 79, 2118, 2120, "52" +341, 18, 17, 433, 80, 85, 2121, 2126, "weeks" +341, 18, 18, 434, 86, 87, 2127, 2128, ";" +341, 18, 19, 435, 88, 97, 2129, 2138, "secondary" +341, 18, 20, 436, 98, 106, 2139, 2147, "efficacy" +341, 18, 21, 437, 107, 110, 2148, 2151, "end" +341, 18, 22, 438, 111, 117, 2152, 2158, "points" +341, 18, 23, 439, 118, 126, 2159, 2167, "included" +341, 18, 24, 440, 127, 134, 2168, 2175, "changes" +341, 18, 25, 441, 135, 137, 2176, 2178, "in" +341, 18, 26, 442, 138, 145, 2179, 2186, "fasting" +341, 18, 27, 443, 146, 152, 2187, 2193, "plasma" +341, 18, 28, 444, 153, 160, 2194, 2201, "glucose" +341, 18, 29, 445, 161, 162, 2202, 2203, "(" +341, 18, 30, 446, 163, 166, 2204, 2207, "FPG" +341, 18, 31, 447, 167, 168, 2208, 2209, ")" +341, 18, 32, 448, 169, 170, 2210, 2211, "," +341, 18, 33, 449, 171, 183, 2212, 2224, "postprandial" +341, 18, 34, 450, 184, 190, 2225, 2231, "plasma" +341, 18, 35, 451, 191, 198, 2232, 2239, "glucose" +341, 18, 36, 452, 199, 200, 2240, 2241, "," +341, 18, 37, 453, 201, 208, 2242, 2249, "insulin" +341, 18, 38, 454, 209, 214, 2250, 2255, "doses" +341, 18, 39, 455, 215, 216, 2256, 2257, "," +341, 18, 40, 456, 217, 220, 2258, 2261, "and" +341, 18, 41, 457, 221, 227, 2262, 2268, "weight" +341, 18, 42, 458, 228, 234, 2269, 2275, "change" +341, 18, 43, 459, 235, 237, 2276, 2278, "at" +341, 18, 44, 460, 238, 240, 2279, 2281, "52" +341, 18, 45, 461, 241, 246, 2282, 2287, "weeks" +341, 18, 46, 462, 247, 248, 2288, 2289, "." +341, 19, 1, 463, 0, 6, 2290, 2296, "Safety" +341, 19, 2, 464, 7, 10, 2297, 2300, "end" +341, 19, 3, 465, 11, 17, 2301, 2307, "points" +341, 19, 4, 466, 18, 26, 2308, 2316, "included" +341, 19, 5, 467, 27, 30, 2317, 2320, "the" +341, 19, 6, 468, 31, 40, 2321, 2330, "frequency" +341, 19, 7, 469, 41, 43, 2331, 2333, "of" +341, 19, 8, 470, 44, 56, 2334, 2346, "hypoglycemia" +341, 19, 9, 471, 57, 60, 2347, 2350, "and" +341, 19, 10, 472, 61, 68, 2351, 2358, "adverse" +341, 19, 11, 473, 69, 75, 2359, 2365, "events" +341, 19, 12, 474, 76, 77, 2366, 2367, "(" +341, 19, 13, 475, 78, 81, 2368, 2371, "AEs" +341, 19, 14, 476, 82, 83, 2372, 2373, ")" +341, 19, 15, 477, 84, 85, 2374, 2375, "." +341, 20, 1, 478, 0, 7, 2376, 2383, "RESULTS" +341, 20, 2, 479, 8, 9, 2384, 2385, ":" +341, 20, 3, 480, 10, 13, 2386, 2389, "The" +341, 20, 4, 481, 14, 23, 2390, 2399, "intention" +341, 20, 5, 482, 24, 25, 2400, 2401, "-" +341, 20, 6, 483, 26, 28, 2402, 2404, "to" +341, 20, 7, 484, 29, 30, 2405, 2406, "-" +341, 20, 8, 485, 31, 36, 2407, 2412, "treat" +341, 20, 9, 486, 37, 47, 2413, 2423, "population" +341, 20, 10, 487, 48, 56, 2424, 2432, "included" +341, 20, 11, 488, 57, 60, 2433, 2436, "319" +341, 20, 12, 489, 61, 69, 2437, 2445, "patients" +341, 20, 13, 490, 70, 71, 2446, 2447, "(" +341, 20, 14, 491, 72, 74, 2448, 2450, "58" +341, 20, 15, 492, 75, 76, 2451, 2452, "." +341, 20, 16, 493, 77, 78, 2453, 2454, "0" +341, 20, 17, 494, 79, 80, 2455, 2456, "%" +341, 20, 18, 495, 81, 85, 2457, 2461, "male" +341, 20, 19, 496, 86, 87, 2462, 2463, "," +341, 20, 20, 497, 88, 90, 2464, 2466, "42" +341, 20, 21, 498, 91, 92, 2467, 2468, "." +341, 20, 22, 499, 93, 94, 2469, 2470, "0" +341, 20, 23, 500, 95, 96, 2471, 2472, "%" +341, 20, 24, 501, 97, 103, 2473, 2479, "female" +341, 20, 25, 502, 104, 105, 2480, 2481, ";" +341, 20, 26, 503, 106, 108, 2482, 2484, "78" +341, 20, 27, 504, 109, 110, 2485, 2486, "." +341, 20, 28, 505, 111, 112, 2487, 2488, "4" +341, 20, 29, 506, 113, 114, 2489, 2490, "%" +341, 20, 30, 507, 115, 120, 2491, 2496, "white" +341, 20, 31, 508, 121, 122, 2497, 2498, ";" +341, 20, 32, 509, 123, 127, 2499, 2503, "mean" +341, 20, 33, 510, 128, 131, 2504, 2507, "age" +341, 20, 34, 511, 132, 133, 2508, 2509, "," +341, 20, 35, 512, 134, 136, 2510, 2512, "58" +341, 20, 36, 513, 137, 142, 2513, 2518, "years" +341, 20, 37, 514, 143, 144, 2519, 2520, ";" +341, 20, 38, 515, 145, 149, 2521, 2525, "mean" +341, 20, 39, 516, 150, 156, 2526, 2532, "weight" +341, 20, 40, 517, 157, 158, 2533, 2534, "," +341, 20, 41, 518, 159, 161, 2535, 2537, "92" +341, 20, 42, 519, 162, 163, 2538, 2539, "." +341, 20, 43, 520, 164, 165, 2540, 2541, "8" +341, 20, 44, 521, 166, 168, 2542, 2544, "kg" +341, 20, 45, 522, 169, 170, 2545, 2546, ";" +341, 20, 46, 523, 171, 175, 2547, 2551, "mean" +341, 20, 47, 524, 176, 184, 2552, 2560, "duration" +341, 20, 48, 525, 185, 187, 2561, 2563, "of" +341, 20, 49, 526, 188, 196, 2564, 2572, "diabetes" +341, 20, 50, 527, 197, 198, 2573, 2574, "," +341, 20, 51, 528, 199, 201, 2575, 2577, "13" +341, 20, 52, 529, 202, 203, 2578, 2579, "." +341, 20, 53, 530, 204, 205, 2580, 2581, "6" +341, 20, 54, 531, 206, 211, 2582, 2587, "years" +341, 20, 55, 532, 212, 213, 2588, 2589, ")" +341, 20, 56, 533, 214, 215, 2590, 2591, "." +341, 21, 1, 534, 0, 2, 2592, 2594, "At" +341, 21, 2, 535, 3, 8, 2595, 2600, "study" +341, 21, 3, 536, 9, 14, 2601, 2606, "entry" +341, 21, 4, 537, 15, 16, 2607, 2608, "," +341, 21, 5, 538, 17, 19, 2609, 2611, "46" +341, 21, 6, 539, 20, 21, 2612, 2613, "." +341, 21, 7, 540, 22, 23, 2614, 2615, "1" +341, 21, 8, 541, 24, 25, 2616, 2617, "%" +341, 21, 9, 542, 26, 28, 2618, 2620, "of" +341, 21, 10, 543, 29, 37, 2621, 2629, "patients" +341, 21, 11, 544, 38, 42, 2630, 2634, "were" +341, 21, 12, 545, 43, 52, 2635, 2644, "receiving" +341, 21, 13, 546, 53, 60, 2645, 2652, "insulin" +341, 21, 14, 547, 61, 64, 2653, 2656, "and" +341, 21, 15, 548, 65, 66, 2657, 2658, ">" +341, 21, 16, 549, 67, 69, 2659, 2661, "or" +341, 21, 17, 550, 70, 71, 2662, 2663, "=" +341, 21, 18, 551, 72, 73, 2664, 2665, "1" +341, 21, 19, 552, 74, 77, 2666, 2669, "OAD" +341, 21, 20, 553, 78, 79, 2670, 2671, "," +341, 21, 21, 554, 80, 82, 2672, 2674, "35" +341, 21, 22, 555, 83, 84, 2675, 2676, "." +341, 21, 23, 556, 85, 86, 2677, 2678, "4" +341, 21, 24, 557, 87, 91, 2679, 2683, "were" +341, 21, 25, 558, 92, 101, 2684, 2693, "receiving" +341, 21, 26, 559, 102, 109, 2694, 2701, "insulin" +341, 21, 27, 560, 110, 114, 2702, 2706, "only" +341, 21, 28, 561, 115, 116, 2707, 2708, "," +341, 21, 29, 562, 117, 120, 2709, 2712, "and" +341, 21, 30, 563, 121, 123, 2713, 2715, "18" +341, 21, 31, 564, 124, 125, 2716, 2717, "." +341, 21, 32, 565, 126, 127, 2718, 2719, "5" +341, 21, 33, 566, 128, 129, 2720, 2721, "%" +341, 21, 34, 567, 130, 134, 2722, 2726, "were" +341, 21, 35, 568, 135, 144, 2727, 2736, "receiving" +341, 21, 36, 569, 145, 146, 2737, 2738, ">" +341, 21, 37, 570, 147, 149, 2739, 2741, "or" +341, 21, 38, 571, 150, 151, 2742, 2743, "=" +341, 21, 39, 572, 152, 153, 2744, 2745, "1" +341, 21, 40, 573, 154, 157, 2746, 2749, "OAD" +341, 21, 41, 574, 158, 162, 2750, 2754, "only" +341, 21, 42, 575, 163, 164, 2755, 2756, "." +341, 22, 1, 576, 0, 2, 2757, 2759, "At" +341, 22, 2, 577, 3, 5, 2760, 2762, "52" +341, 22, 3, 578, 6, 11, 2763, 2768, "weeks" +341, 22, 4, 579, 12, 13, 2769, 2770, "," +341, 22, 5, 580, 14, 19, 2771, 2776, "there" +341, 22, 6, 581, 20, 23, 2777, 2780, "was" +341, 22, 7, 582, 24, 26, 2781, 2783, "no" +341, 22, 8, 583, 27, 38, 2784, 2795, "significant" +341, 22, 9, 584, 39, 49, 2796, 2806, "difference" +341, 22, 10, 585, 50, 57, 2807, 2814, "between" +341, 22, 11, 586, 58, 65, 2815, 2822, "detemir" +341, 22, 12, 587, 66, 69, 2823, 2826, "and" +341, 22, 13, 588, 70, 78, 2827, 2835, "glargine" +341, 22, 14, 589, 79, 81, 2836, 2838, "in" +341, 22, 15, 590, 82, 87, 2839, 2844, "terms" +341, 22, 16, 591, 88, 90, 2845, 2847, "of" +341, 22, 17, 592, 91, 95, 2848, 2852, "mean" +341, 22, 18, 593, 96, 99, 2853, 2856, "HbA" +341, 22, 19, 594, 100, 101, 2857, 2858, "(" +341, 22, 20, 595, 102, 104, 2859, 2861, "1c" +341, 22, 21, 596, 105, 106, 2862, 2863, ")" +341, 22, 22, 597, 107, 108, 2864, 2865, "(" +341, 22, 23, 598, 109, 110, 2866, 2867, "7" +341, 22, 24, 599, 111, 112, 2868, 2869, "." +341, 22, 25, 600, 113, 115, 2870, 2872, "19" +341, 22, 26, 601, 116, 117, 2873, 2874, "%" +341, 22, 27, 602, 118, 121, 2875, 2878, "and" +341, 22, 28, 603, 122, 123, 2879, 2880, "7" +341, 22, 29, 604, 124, 125, 2881, 2882, "." +341, 22, 30, 605, 126, 128, 2883, 2885, "03" +341, 22, 31, 606, 129, 130, 2886, 2887, "%" +341, 22, 32, 607, 131, 132, 2888, 2889, "," +341, 22, 33, 608, 133, 145, 2890, 2902, "respectively" +341, 22, 34, 609, 146, 147, 2903, 2904, ";" +341, 22, 35, 610, 148, 152, 2905, 2909, "mean" +341, 22, 36, 611, 153, 163, 2910, 2920, "difference" +341, 22, 37, 612, 164, 165, 2921, 2922, "," +341, 22, 38, 613, 166, 167, 2923, 2924, "0" +341, 22, 39, 614, 168, 169, 2925, 2926, "." +341, 22, 40, 615, 170, 172, 2927, 2929, "17" +341, 22, 41, 616, 173, 174, 2930, 2931, "%" +341, 22, 42, 617, 175, 176, 2932, 2933, "[" +341, 22, 43, 618, 177, 179, 2934, 2936, "95" +341, 22, 44, 619, 180, 181, 2937, 2938, "%" +341, 22, 45, 620, 182, 184, 2939, 2941, "CI" +341, 22, 46, 621, 185, 186, 2942, 2943, "," +341, 22, 47, 622, 187, 188, 2944, 2945, "-" +341, 22, 48, 623, 189, 190, 2946, 2947, "0" +341, 22, 49, 624, 191, 192, 2948, 2949, "." +341, 22, 50, 625, 193, 195, 2950, 2952, "07" +341, 22, 51, 626, 196, 198, 2953, 2955, "to" +341, 22, 52, 627, 199, 200, 2956, 2957, "0" +341, 22, 53, 628, 201, 202, 2958, 2959, "." +341, 22, 54, 629, 203, 205, 2960, 2962, "40" +341, 22, 55, 630, 206, 207, 2963, 2964, "]" +341, 22, 56, 631, 208, 209, 2965, 2966, ")" +341, 22, 57, 632, 210, 212, 2967, 2969, "or" +341, 22, 58, 633, 213, 216, 2970, 2973, "the" +341, 22, 59, 634, 217, 221, 2974, 2978, "mean" +341, 22, 60, 635, 222, 230, 2979, 2987, "decrease" +341, 22, 61, 636, 231, 233, 2988, 2990, "in" +341, 22, 62, 637, 234, 239, 2991, 2996, "HbAlc" +341, 22, 63, 638, 240, 244, 2997, 3001, "from" +341, 22, 64, 639, 245, 253, 3002, 3010, "baseline" +341, 22, 65, 640, 254, 255, 3011, 3012, "(" +341, 22, 66, 641, 256, 257, 3013, 3014, "-" +341, 22, 67, 642, 258, 259, 3015, 3016, "1" +341, 22, 68, 643, 260, 261, 3017, 3018, "." +341, 22, 69, 644, 262, 264, 3019, 3021, "52" +341, 22, 70, 645, 265, 266, 3022, 3023, "%" +341, 22, 71, 646, 267, 270, 3024, 3027, "and" +341, 22, 72, 647, 271, 272, 3028, 3029, "-" +341, 22, 73, 648, 273, 274, 3030, 3031, "1" +341, 22, 74, 649, 275, 276, 3032, 3033, "." +341, 22, 75, 650, 277, 279, 3034, 3036, "68" +341, 22, 76, 651, 280, 281, 3037, 3038, "%" +341, 22, 77, 652, 282, 283, 3039, 3040, ")" +341, 22, 78, 653, 284, 285, 3041, 3042, "." +341, 23, 1, 654, 0, 3, 3043, 3046, "The" +341, 23, 2, 655, 4, 13, 3047, 3056, "reduction" +341, 23, 3, 656, 14, 16, 3057, 3059, "in" +341, 23, 4, 657, 17, 20, 3060, 3063, "HbA" +341, 23, 5, 658, 21, 22, 3064, 3065, "(" +341, 23, 6, 659, 23, 25, 3066, 3068, "1c" +341, 23, 7, 660, 26, 27, 3069, 3070, ")" +341, 23, 8, 661, 28, 31, 3071, 3074, "was" +341, 23, 9, 662, 32, 35, 3075, 3078, "not" +341, 23, 10, 663, 36, 49, 3079, 3092, "significantly" +341, 23, 11, 664, 50, 58, 3093, 3101, "affected" +341, 23, 12, 665, 59, 61, 3102, 3104, "by" +341, 23, 13, 666, 62, 69, 3105, 3112, "whether" +341, 23, 14, 667, 70, 77, 3113, 3120, "detemir" +341, 23, 15, 668, 78, 81, 3121, 3124, "was" +341, 23, 16, 669, 82, 94, 3125, 3137, "administered" +341, 23, 17, 670, 95, 99, 3138, 3142, "once" +341, 23, 18, 671, 100, 102, 3143, 3145, "or" +341, 23, 19, 672, 103, 108, 3146, 3151, "twice" +341, 23, 20, 673, 109, 114, 3152, 3157, "daily" +341, 23, 21, 674, 115, 116, 3158, 3159, "." +341, 24, 1, 675, 0, 5, 3160, 3165, "There" +341, 24, 2, 676, 6, 10, 3166, 3170, "were" +341, 24, 3, 677, 11, 13, 3171, 3173, "no" +341, 24, 4, 678, 14, 25, 3174, 3185, "significant" +341, 24, 5, 679, 26, 37, 3186, 3197, "differences" +341, 24, 6, 680, 38, 45, 3198, 3205, "between" +341, 24, 7, 681, 46, 52, 3206, 3212, "groups" +341, 24, 8, 682, 53, 55, 3213, 3215, "in" +341, 24, 9, 683, 56, 61, 3216, 3221, "terms" +341, 24, 10, 684, 62, 64, 3222, 3224, "of" +341, 24, 11, 685, 65, 69, 3225, 3229, "mean" +341, 24, 12, 686, 70, 73, 3230, 3233, "FPG" +341, 24, 13, 687, 74, 75, 3234, 3235, "(" +341, 24, 14, 688, 76, 77, 3236, 3237, "7" +341, 24, 15, 689, 78, 79, 3238, 3239, "." +341, 24, 16, 690, 80, 82, 3240, 3242, "05" +341, 24, 17, 691, 83, 86, 3243, 3246, "and" +341, 24, 18, 692, 87, 88, 3247, 3248, "6" +341, 24, 19, 693, 89, 90, 3249, 3250, "." +341, 24, 20, 694, 91, 93, 3251, 3253, "68" +341, 24, 21, 695, 94, 98, 3254, 3258, "mmol" +341, 24, 22, 696, 99, 100, 3259, 3260, "/" +341, 24, 23, 697, 101, 102, 3261, 3262, "L" +341, 24, 24, 698, 103, 104, 3263, 3264, ")" +341, 24, 25, 699, 105, 107, 3265, 3267, "or" +341, 24, 26, 700, 108, 111, 3268, 3271, "the" +341, 24, 27, 701, 112, 116, 3272, 3276, "mean" +341, 24, 28, 702, 117, 123, 3277, 3283, "change" +341, 24, 29, 703, 124, 126, 3284, 3286, "in" +341, 24, 30, 704, 127, 130, 3287, 3290, "FPG" +341, 24, 31, 705, 131, 135, 3291, 3295, "from" +341, 24, 32, 706, 136, 144, 3296, 3304, "baseline" +341, 24, 33, 707, 145, 146, 3305, 3306, "(" +341, 24, 34, 708, 147, 148, 3307, 3308, "-" +341, 24, 35, 709, 149, 150, 3309, 3310, "2" +341, 24, 36, 710, 151, 152, 3311, 3312, "." +341, 24, 37, 711, 153, 155, 3313, 3315, "56" +341, 24, 38, 712, 156, 159, 3316, 3319, "and" +341, 24, 39, 713, 160, 161, 3320, 3321, "-" +341, 24, 40, 714, 162, 163, 3322, 3323, "2" +341, 24, 41, 715, 164, 165, 3324, 3325, "." +341, 24, 42, 716, 166, 168, 3326, 3328, "92" +341, 24, 43, 717, 169, 173, 3329, 3333, "mmol" +341, 24, 44, 718, 174, 175, 3334, 3335, "/" +341, 24, 45, 719, 176, 177, 3336, 3337, "L" +341, 24, 46, 720, 178, 179, 3338, 3339, ";" +341, 24, 47, 721, 180, 184, 3340, 3344, "mean" +341, 24, 48, 722, 185, 195, 3345, 3355, "difference" +341, 24, 49, 723, 196, 197, 3356, 3357, "," +341, 24, 50, 724, 198, 199, 3358, 3359, "0" +341, 24, 51, 725, 200, 201, 3360, 3361, "." +341, 24, 52, 726, 202, 204, 3362, 3364, "36" +341, 24, 53, 727, 205, 206, 3365, 3366, ";" +341, 24, 54, 728, 207, 209, 3367, 3369, "95" +341, 24, 55, 729, 210, 211, 3370, 3371, "%" +341, 24, 56, 730, 212, 214, 3372, 3374, "CI" +341, 24, 57, 731, 215, 216, 3375, 3376, "," +341, 24, 58, 732, 217, 218, 3377, 3378, "-" +341, 24, 59, 733, 219, 220, 3379, 3380, "0" +341, 24, 60, 734, 221, 222, 3381, 3382, "." +341, 24, 61, 735, 223, 225, 3383, 3385, "26" +341, 24, 62, 736, 226, 228, 3386, 3388, "to" +341, 24, 63, 737, 229, 230, 3389, 3390, "0" +341, 24, 64, 738, 231, 232, 3391, 3392, "." +341, 24, 65, 739, 233, 235, 3393, 3395, "99" +341, 24, 66, 740, 236, 237, 3396, 3397, ")" +341, 24, 67, 741, 238, 239, 3398, 3399, "." +341, 25, 1, 742, 0, 3, 3400, 3403, "The" +341, 25, 2, 743, 4, 11, 3404, 3411, "overall" +341, 25, 3, 744, 12, 17, 3412, 3417, "shape" +341, 25, 4, 745, 18, 20, 3418, 3420, "of" +341, 25, 5, 746, 21, 24, 3421, 3424, "the" +341, 25, 6, 747, 25, 27, 3425, 3427, "10" +341, 25, 7, 748, 28, 29, 3428, 3429, "-" +341, 25, 8, 749, 30, 35, 3430, 3435, "point" +341, 25, 9, 750, 36, 40, 3436, 3440, "SMPG" +341, 25, 10, 751, 41, 49, 3441, 3449, "profiles" +341, 25, 11, 752, 50, 53, 3450, 3453, "was" +341, 25, 12, 753, 54, 57, 3454, 3457, "not" +341, 25, 13, 754, 58, 71, 3458, 3471, "significantly" +341, 25, 14, 755, 72, 81, 3472, 3481, "different" +341, 25, 15, 756, 82, 89, 3482, 3489, "between" +341, 25, 16, 757, 90, 96, 3490, 3496, "groups" +341, 25, 17, 758, 97, 98, 3497, 3498, "." +341, 26, 1, 759, 0, 4, 3499, 3503, "Mean" +341, 26, 2, 760, 5, 11, 3504, 3510, "weight" +341, 26, 3, 761, 12, 16, 3511, 3515, "gain" +341, 26, 4, 762, 17, 19, 3516, 3518, "at" +341, 26, 5, 763, 20, 22, 3519, 3521, "52" +341, 26, 6, 764, 23, 28, 3522, 3527, "weeks" +341, 26, 7, 765, 29, 32, 3528, 3531, "was" +341, 26, 8, 766, 33, 46, 3532, 3545, "significantly" +341, 26, 9, 767, 47, 52, 3546, 3551, "lower" +341, 26, 10, 768, 53, 57, 3552, 3556, "with" +341, 26, 11, 769, 58, 65, 3557, 3564, "detemir" +341, 26, 12, 770, 66, 70, 3565, 3569, "than" +341, 26, 13, 771, 71, 75, 3570, 3574, "with" +341, 26, 14, 772, 76, 84, 3575, 3583, "glargine" +341, 26, 15, 773, 85, 86, 3584, 3585, "(" +341, 26, 16, 774, 87, 88, 3586, 3587, "2" +341, 26, 17, 775, 89, 90, 3588, 3589, "." +341, 26, 18, 776, 91, 92, 3590, 3591, "8" +341, 26, 19, 777, 93, 95, 3592, 3594, "vs" +341, 26, 20, 778, 96, 97, 3595, 3596, "3" +341, 26, 21, 779, 98, 99, 3597, 3598, "." +341, 26, 22, 780, 100, 101, 3599, 3600, "8" +341, 26, 23, 781, 102, 104, 3601, 3603, "kg" +341, 26, 24, 782, 105, 106, 3604, 3605, ";" +341, 26, 25, 783, 107, 111, 3606, 3610, "mean" +341, 26, 26, 784, 112, 122, 3611, 3621, "difference" +341, 26, 27, 785, 123, 124, 3622, 3623, "," +341, 26, 28, 786, 125, 126, 3624, 3625, "-" +341, 26, 29, 787, 127, 128, 3626, 3627, "1" +341, 26, 30, 788, 129, 130, 3628, 3629, "." +341, 26, 31, 789, 131, 133, 3630, 3632, "04" +341, 26, 32, 790, 134, 135, 3633, 3634, ";" +341, 26, 33, 791, 136, 138, 3635, 3637, "95" +341, 26, 34, 792, 139, 140, 3638, 3639, "%" +341, 26, 35, 793, 141, 143, 3640, 3642, "CI" +341, 26, 36, 794, 144, 145, 3643, 3644, "," +341, 26, 37, 795, 146, 147, 3645, 3646, "-" +341, 26, 38, 796, 148, 149, 3647, 3648, "2" +341, 26, 39, 797, 150, 151, 3649, 3650, "." +341, 26, 40, 798, 152, 154, 3651, 3653, "08" +341, 26, 41, 799, 155, 157, 3654, 3656, "to" +341, 26, 42, 800, 158, 159, 3657, 3658, "-" +341, 26, 43, 801, 160, 161, 3659, 3660, "0" +341, 26, 44, 802, 162, 163, 3661, 3662, "." +341, 26, 45, 803, 164, 166, 3663, 3665, "01" +341, 26, 46, 804, 167, 168, 3666, 3667, ";" +341, 26, 47, 805, 169, 170, 3668, 3669, "P" +341, 26, 48, 806, 171, 172, 3670, 3671, "<" +341, 26, 49, 807, 173, 174, 3672, 3673, "0" +341, 26, 50, 808, 175, 176, 3674, 3675, "." +341, 26, 51, 809, 177, 179, 3676, 3678, "05" +341, 26, 52, 810, 180, 181, 3679, 3680, ")" +341, 26, 53, 811, 182, 183, 3681, 3682, "." +341, 27, 1, 812, 0, 5, 3683, 3688, "Doses" +341, 27, 2, 813, 6, 8, 3689, 3691, "of" +341, 27, 3, 814, 9, 14, 3692, 3697, "basal" +341, 27, 4, 815, 15, 18, 3698, 3701, "and" +341, 27, 5, 816, 19, 27, 3702, 3710, "prandial" +341, 27, 6, 817, 28, 36, 3711, 3719, "insulins" +341, 27, 7, 818, 37, 39, 3720, 3722, "at" +341, 27, 8, 819, 40, 43, 3723, 3726, "the" +341, 27, 9, 820, 44, 47, 3727, 3730, "end" +341, 27, 10, 821, 48, 50, 3731, 3733, "of" +341, 27, 11, 822, 51, 54, 3734, 3737, "the" +341, 27, 12, 823, 55, 60, 3738, 3743, "study" +341, 27, 13, 824, 61, 65, 3744, 3748, "were" +341, 27, 14, 825, 66, 69, 3749, 3752, "not" +341, 27, 15, 826, 70, 83, 3753, 3766, "significantly" +341, 27, 16, 827, 84, 93, 3767, 3776, "different" +341, 27, 17, 828, 94, 101, 3777, 3784, "between" +341, 27, 18, 829, 102, 108, 3785, 3791, "groups" +341, 27, 19, 830, 109, 110, 3792, 3793, "." +341, 28, 1, 831, 0, 5, 3794, 3799, "Major" +341, 28, 2, 832, 6, 18, 3800, 3812, "hypoglycemic" +341, 28, 3, 833, 19, 27, 3813, 3821, "episodes" +341, 28, 4, 834, 28, 32, 3822, 3826, "were" +341, 28, 5, 835, 33, 41, 3827, 3835, "reported" +341, 28, 6, 836, 42, 44, 3836, 3838, "by" +341, 28, 7, 837, 45, 46, 3839, 3840, "4" +341, 28, 8, 838, 47, 48, 3841, 3842, "." +341, 28, 9, 839, 49, 50, 3843, 3844, "7" +341, 28, 10, 840, 51, 52, 3845, 3846, "%" +341, 28, 11, 841, 53, 56, 3847, 3850, "and" +341, 28, 12, 842, 57, 58, 3851, 3852, "5" +341, 28, 13, 843, 59, 60, 3853, 3854, "." +341, 28, 14, 844, 61, 62, 3855, 3856, "7" +341, 28, 15, 845, 63, 64, 3857, 3858, "%" +341, 28, 16, 846, 65, 67, 3859, 3861, "of" +341, 28, 17, 847, 68, 76, 3862, 3870, "patients" +341, 28, 18, 848, 77, 79, 3871, 3873, "in" +341, 28, 19, 849, 80, 83, 3874, 3877, "the" +341, 28, 20, 850, 84, 94, 3878, 3888, "respective" +341, 28, 21, 851, 95, 104, 3889, 3898, "treatment" +341, 28, 22, 852, 105, 111, 3899, 3905, "groups" +341, 28, 23, 853, 112, 113, 3906, 3907, "." +341, 29, 1, 854, 0, 5, 3908, 3913, "There" +341, 29, 2, 855, 6, 9, 3914, 3917, "was" +341, 29, 3, 856, 10, 12, 3918, 3920, "no" +341, 29, 4, 857, 13, 24, 3921, 3932, "significant" +341, 29, 5, 858, 25, 35, 3933, 3943, "difference" +341, 29, 6, 859, 36, 38, 3944, 3946, "in" +341, 29, 7, 860, 39, 42, 3947, 3950, "the" +341, 29, 8, 861, 43, 47, 3951, 3955, "risk" +341, 29, 9, 862, 48, 50, 3956, 3958, "of" +341, 29, 10, 863, 51, 63, 3959, 3971, "hypoglycemia" +341, 29, 11, 864, 64, 71, 3972, 3979, "between" +341, 29, 12, 865, 72, 78, 3980, 3986, "groups" +341, 29, 13, 866, 79, 80, 3987, 3988, "." +341, 30, 1, 867, 0, 3, 3989, 3992, "The" +341, 30, 2, 868, 4, 14, 3993, 4003, "proportion" +341, 30, 3, 869, 15, 17, 4004, 4006, "of" +341, 30, 4, 870, 18, 26, 4007, 4015, "patients" +341, 30, 5, 871, 27, 31, 4016, 4020, "with" +341, 30, 6, 872, 32, 35, 4021, 4024, "AEs" +341, 30, 7, 873, 36, 39, 4025, 4028, "and" +341, 30, 8, 874, 40, 43, 4029, 4032, "the" +341, 30, 9, 875, 44, 50, 4033, 4039, "number" +341, 30, 10, 876, 51, 53, 4040, 4042, "of" +341, 30, 11, 877, 54, 57, 4043, 4046, "AEs" +341, 30, 12, 878, 58, 61, 4047, 4050, "per" +341, 30, 13, 879, 62, 69, 4051, 4058, "patient" +341, 30, 14, 880, 70, 74, 4059, 4063, "were" +341, 30, 15, 881, 75, 85, 4064, 4074, "comparable" +341, 30, 16, 882, 86, 93, 4075, 4082, "between" +341, 30, 17, 883, 94, 100, 4083, 4089, "groups" +341, 30, 18, 884, 101, 102, 4090, 4091, "(" +341, 30, 19, 885, 103, 106, 4092, 4095, "185" +341, 30, 20, 886, 107, 108, 4096, 4097, "/" +341, 30, 21, 887, 109, 112, 4098, 4101, "214" +341, 30, 22, 888, 113, 121, 4102, 4110, "patients" +341, 30, 23, 889, 122, 123, 4111, 4112, "[" +341, 30, 24, 890, 124, 126, 4113, 4115, "86" +341, 30, 25, 891, 127, 128, 4116, 4117, "." +341, 30, 26, 892, 129, 130, 4118, 4119, "4" +341, 30, 27, 893, 131, 132, 4120, 4121, "%" +341, 30, 28, 894, 133, 134, 4122, 4123, "]" +341, 30, 29, 895, 135, 144, 4124, 4133, "reporting" +341, 30, 30, 896, 145, 148, 4134, 4137, "743" +341, 30, 31, 897, 149, 152, 4138, 4141, "AEs" +341, 30, 32, 898, 153, 156, 4142, 4145, "and" +341, 30, 33, 899, 157, 159, 4146, 4148, "88" +341, 30, 34, 900, 160, 161, 4149, 4150, "/" +341, 30, 35, 901, 162, 165, 4151, 4154, "105" +341, 30, 36, 902, 166, 174, 4155, 4163, "patients" +341, 30, 37, 903, 175, 176, 4164, 4165, "[" +341, 30, 38, 904, 177, 179, 4166, 4168, "83" +341, 30, 39, 905, 180, 181, 4169, 4170, "." +341, 30, 40, 906, 182, 183, 4171, 4172, "8" +341, 30, 41, 907, 184, 185, 4173, 4174, "%" +341, 30, 42, 908, 186, 187, 4175, 4176, "]" +341, 30, 43, 909, 188, 197, 4177, 4186, "reporting" +341, 30, 44, 910, 198, 201, 4187, 4190, "377" +341, 30, 45, 911, 202, 205, 4191, 4194, "AEs" +341, 30, 46, 912, 206, 207, 4195, 4196, ")" +341, 30, 47, 913, 208, 209, 4197, 4198, "." +341, 31, 1, 914, 0, 11, 4199, 4210, "CONCLUSIONS" +341, 31, 2, 915, 12, 13, 4211, 4212, ":" +341, 31, 3, 916, 14, 18, 4213, 4217, "when" +341, 31, 4, 917, 19, 23, 4218, 4222, "used" +341, 31, 5, 918, 24, 26, 4223, 4225, "as" +341, 31, 6, 919, 27, 36, 4226, 4235, "indicated" +341, 31, 7, 920, 37, 39, 4236, 4238, "as" +341, 31, 8, 921, 40, 44, 4239, 4243, "part" +341, 31, 9, 922, 45, 47, 4244, 4246, "of" +341, 31, 10, 923, 48, 49, 4247, 4248, "a" +341, 31, 11, 924, 50, 55, 4249, 4254, "basal" +341, 31, 12, 925, 56, 57, 4255, 4256, "-" +341, 31, 13, 926, 58, 63, 4257, 4262, "bolus" +341, 31, 14, 927, 64, 71, 4263, 4270, "regimen" +341, 31, 15, 928, 72, 74, 4271, 4273, "in" +341, 31, 16, 929, 75, 83, 4274, 4282, "patients" +341, 31, 17, 930, 84, 88, 4283, 4287, "with" +341, 31, 18, 931, 89, 93, 4288, 4292, "T2DM" +341, 31, 19, 932, 94, 97, 4293, 4296, "who" +341, 31, 20, 933, 98, 101, 4297, 4300, "had" +341, 31, 21, 934, 102, 112, 4301, 4311, "previously" +341, 31, 22, 935, 113, 121, 4312, 4320, "received" +341, 31, 23, 936, 122, 127, 4321, 4326, "other" +341, 31, 24, 937, 128, 135, 4327, 4334, "insulin" +341, 31, 25, 938, 136, 139, 4335, 4338, "and" +341, 31, 26, 939, 140, 141, 4339, 4340, "/" +341, 31, 27, 940, 142, 144, 4341, 4343, "or" +341, 31, 28, 941, 145, 148, 4344, 4347, "OAD" +341, 31, 29, 942, 149, 157, 4348, 4356, "regimens" +341, 31, 30, 943, 158, 159, 4357, 4358, "," +341, 31, 31, 944, 160, 167, 4359, 4366, "detemir" +341, 31, 32, 945, 168, 171, 4367, 4370, "was" +341, 31, 33, 946, 172, 183, 4371, 4382, "noninferior" +341, 31, 34, 947, 184, 186, 4383, 4385, "to" +341, 31, 35, 948, 187, 195, 4386, 4394, "glargine" +341, 31, 36, 949, 196, 198, 4395, 4397, "in" +341, 31, 37, 950, 199, 202, 4398, 4401, "its" +341, 31, 38, 951, 203, 210, 4402, 4409, "effects" +341, 31, 39, 952, 211, 213, 4410, 4412, "on" +341, 31, 40, 953, 214, 221, 4413, 4420, "overall" +341, 31, 41, 954, 222, 230, 4421, 4429, "glycemic" +341, 31, 42, 955, 231, 238, 4430, 4437, "control" +341, 31, 43, 956, 239, 240, 4438, 4439, "." +341, 32, 1, 957, 0, 4, 4440, 4444, "Both" +341, 32, 2, 958, 5, 10, 4445, 4450, "basal" +341, 32, 3, 959, 11, 19, 4451, 4459, "insulins" +341, 32, 4, 960, 20, 24, 4460, 4464, "were" +341, 32, 5, 961, 25, 35, 4465, 4475, "associated" +341, 32, 6, 962, 36, 40, 4476, 4480, "with" +341, 32, 7, 963, 41, 51, 4481, 4491, "clinically" +341, 32, 8, 964, 52, 60, 4492, 4500, "relevant" +341, 32, 9, 965, 61, 71, 4501, 4511, "reductions" +341, 32, 10, 966, 72, 74, 4512, 4514, "in" +341, 32, 11, 967, 75, 88, 4515, 4528, "hyperglycemia" +341, 32, 12, 968, 89, 90, 4529, 4530, "." +341, 33, 1, 969, 0, 4, 4531, 4535, "Both" +341, 33, 2, 970, 5, 9, 4536, 4540, "were" +341, 33, 3, 971, 10, 14, 4541, 4545, "well" +341, 33, 4, 972, 15, 24, 4546, 4555, "tolerated" +341, 33, 5, 973, 25, 26, 4556, 4557, "," +341, 33, 6, 974, 27, 31, 4558, 4562, "with" +341, 33, 7, 975, 32, 34, 4563, 4565, "no" +341, 33, 8, 976, 35, 46, 4566, 4577, "significant" +341, 33, 9, 977, 47, 57, 4578, 4588, "difference" +341, 33, 10, 978, 58, 60, 4589, 4591, "in" +341, 33, 11, 979, 61, 64, 4592, 4595, "the" +341, 33, 12, 980, 65, 74, 4596, 4605, "frequency" +341, 33, 13, 981, 75, 77, 4606, 4608, "of" +341, 33, 14, 982, 78, 90, 4609, 4621, "hypoglycemia" +341, 33, 15, 983, 91, 93, 4622, 4624, "or" +341, 33, 16, 984, 94, 97, 4625, 4628, "AEs" +341, 33, 17, 985, 98, 99, 4629, 4630, "." +341, 34, 1, 986, 0, 3, 4631, 4634, "DOI" +341, 34, 2, 987, 4, 5, 4635, 4636, ":" +341, 34, 3, 988, 6, 8, 4637, 4639, "10" +341, 34, 4, 989, 9, 10, 4640, 4641, "." +341, 34, 5, 990, 11, 15, 4642, 4646, "1016" +341, 34, 6, 991, 16, 17, 4647, 4648, "/" +341, 34, 7, 992, 18, 19, 4649, 4650, "j" +341, 34, 8, 993, 20, 21, 4651, 4652, "." +341, 34, 9, 994, 22, 31, 4653, 4662, "clinthera" +341, 34, 10, 995, 32, 33, 4663, 4664, "." +341, 34, 11, 996, 34, 38, 4665, 4669, "2008" +341, 34, 12, 997, 39, 40, 4670, 4671, "." +341, 34, 13, 998, 41, 43, 4672, 4674, "11" +341, 34, 14, 999, 44, 45, 4675, 4676, "." +341, 34, 15, 1000, 46, 49, 4677, 4680, "001" +341, 34, 16, 1001, 50, 54, 4681, 4685, "PMID" +341, 34, 17, 1002, 55, 56, 4686, 4687, ":" +341, 34, 18, 1003, 57, 65, 4688, 4696, "19108786" +341, 34, 19, 1004, 66, 67, 4697, 4698, "[" +341, 34, 20, 1005, 68, 75, 4699, 4706, "Indexed" +341, 34, 21, 1006, 76, 79, 4707, 4710, "for" +341, 34, 22, 1007, 80, 87, 4711, 4718, "MEDLINE" +341, 34, 23, 1008, 88, 89, 4719, 4720, "]" diff --git a/data/dm2 19108786_kwoodley.annodb b/data/dm2 19108786_kwoodley.annodb new file mode 100644 index 0000000..47cc770 --- /dev/null +++ b/data/dm2 19108786_kwoodley.annodb @@ -0,0 +1,171 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +14605, Journal, 0, 9, "Clin Ther", "", +14606, PublicationYear, 12, 16, "2008", "", +36702, Title, 99, 344, "A 52 - week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "", +14607, Duration, 101, 110, "52 - week", "", +36703, Multicenter, 113, 126, "multinational", "", +14609, OpenLabel, 129, 141, "open - label", "", +14610, Parallel, 144, 160, "parallel - group", "", +14611, CTDesign, 163, 177, "noninferiority", "", +14612, CTDesign, 180, 199, "treat - to - target", "", +14613, InsulinDetemir, 216, 231, "insulin detemir", "", +14614, InsulinGlargine, 237, 253, "insulin glargine", "", +14615, RelativeTime, 286, 294, "mealtime", "", +14616, InsulinAspart, 295, 309, "insulin aspart", "", +14617, Type2Diabetes, 327, 342, "type 2 diabetes", "", +14619, Author, 345, 356, "Hollander P", "", +14620, Author, 365, 373, "Cooper J", "", +14621, Author, 376, 388, "Bregnh ø j J", "", +14622, Author, 391, 402, "Pedersen CB", "", +14623, USA, 477, 480, "USA", "", +14635, ObjectiveDescription, 653, 809, "This trial compared the efficacy and safety profiles of the insulin analogues detemir and glargine as the basal insulin component of a basal - bolus regimen", "", +14624, Insulin, 713, 720, "insulin", "", +14625, InsulinDetemir, 731, 738, "detemir", "", +14626, InsulinGlargine, 743, 751, "glargine", "", +14627, InsulinGlargine, 765, 772, "insulin", "", +36704, ObjectiveDescription, 810, 955, "in patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs .", "", +14634, Precondition, 813, 953, "patients with type 2 diabetes mellitus ( T2DM ) who were being treated with oral antidiabetic drugs ( OADs ) or insulin with or without OADs", "", +14628, Type2Diabetes, 827, 851, "type 2 diabetes mellitus", "", +14629, Type2Diabetes, 854, 858, "T2DM", "", +14630, OralAntidiabeticAgent, 889, 912, "oral antidiabetic drugs", "", +14631, OralAntidiabeticAgent, 915, 919, "OADs", "", +14633, Insulin, 925, 932, "insulin", "", +14632, OralAntidiabeticAgent, 949, 953, "OADs", "", +36705, Multicenter, 977, 990, "multinational", "", +14638, Duration, 993, 1002, "52 - week", "", +14639, OpenLabel, 1005, 1014, "openlabel", "", +14640, Parallel, 1017, 1033, "parallel - group", "", +14641, CTDesign, 1036, 1050, "noninferiority", "", +14642, CTDesign, 1053, 1072, "treat - to - target", "", +14652, Precondition, 1081, 1216, "Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin , with or without OADs , for > 4 months", "", +14643, Type2Diabetes, 1110, 1114, "T2DM", "", +14644, OralAntidiabeticAgent, 1162, 1165, "OAD", "", +14647, Insulin, 1169, 1176, "insulin", "", +14646, OralAntidiabeticAgent, 1195, 1199, "OADs", "", +14648, Randomized, 1222, 1232, "randomized", "", +14649, AllocationRatio, 1238, 1243, "2 : 1", "", +14650, InsulinDetemir, 1261, 1268, "detemir", "", +14651, InsulinGlargine, 1272, 1280, "glargine", "", +14653, InsulinDetemir, 1320, 1327, "detemir", "", +14654, Frequency, 1350, 1369, "once or twice daily", "", +14656, InsulinGlargine, 1376, 1384, "glargine", "", +14657, Frequency, 1402, 1412, "once daily", "", +14658, InsulinAspart, 1415, 1429, "Insulin aspart", "", +14659, RelativeTime, 1443, 1452, "mealtimes", "", +14660, Insulin, 1455, 1462, "Insulin", "", +14661, OralAntidiabeticAgent, 1556, 1560, "OADs", "", +14662, InsulinDetemir, 1587, 1594, "detemir", "", +14663, InsulinGlargine, 1599, 1607, "glargine", "", +14664, TimePoint, 1635, 1647, "prebreakfast", "", +14665, TimePoint, 1654, 1663, "predinner", "", +14666, InsulinDetemir, 1668, 1675, "detemir", "", +14667, Frequency, 1689, 1700, "twice daily", "", +14668, FastingPlasmaGlucose_target, 1703, 1749, "plasma glucose target of < or = 6 . 0 mmol / L", "", +36706, PlasmaGlucose, 1777, 1791, "plasma glucose", "", +14672, Insulin, 1893, 1900, "insulin", "", +36707, PlasmaGlucose, 1960, 1991, "self - monitored plasma glucose", "", +36708, PlasmaGlucose, 1994, 1998, "SMPG", "", +14676, HbA1c, 2076, 2099, "glycosylated hemoglobin", "", +14677, HbA1c, 2102, 2112, "HbA ( 1c )", "", +14678, Duration, 2118, 2126, "52 weeks", "", +14679, FastingPlasmaGlucose, 2179, 2201, "fasting plasma glucose", "", +14680, FastingPlasmaGlucose, 2204, 2207, "FPG", "", +36709, PostprandialPlasmaGlucose, 2212, 2239, "postprandial plasma glucose", "", +36711, InsulinDose, 2242, 2255, "insulin doses", "", +14685, BodyWeight, 2262, 2275, "weight change", "", +36712, TimePoint, 2279, 2287, "52 weeks", "", +14687, Hypoglycemia, 2334, 2346, "hypoglycemia", "", +14688, EndPointDescription, 2351, 2365, "adverse events", "", +14689, EndPointDescription, 2368, 2371, "AEs", "", +14690, IntentionToTreat, 2390, 2445, "intention - to - treat population included 319 patients", "", +14691, NumberPatientsCT, 2433, 2436, "319", "", +14698, Precondition, 2437, 2589, "patients ( 58 . 0 % male , 42 . 0 % female ; 78 . 4 % white ; mean age , 58 years ; mean weight , 92 . 8 kg ; mean duration of diabetes , 13 . 6 years )", "", +14692, Male, 2448, 2456, "58 . 0 %", "", +14693, Female, 2464, 2472, "42 . 0 %", "", +14694, Ethnicity, 2482, 2496, "78 . 4 % white", "", +14695, AvgAge, 2510, 2512, "58", "", +14696, BodyWeight, 2526, 2532, "weight", "", +14697, Kg, 2542, 2544, "kg", "", +36713, TimePoint, 2595, 2606, "study entry", "", +14699, PercentageAffected, 2609, 2615, "46 . 1", "", +14707, EndPointDescription, 2635, 2669, "receiving insulin and > or = 1 OAD", "", +14704, PercentageAffected, 2672, 2678, "35 . 4", "", +14705, EndPointDescription, 2684, 2706, "receiving insulin only", "", +14708, PercentageAffected, 2713, 2719, "18 . 5", "", +14706, EndPointDescription, 2727, 2754, "receiving > or = 1 OAD only", "", +14709, Duration, 2760, 2768, "52 weeks", "", +14710, InsulinDetemir, 2815, 2822, "detemir", "", +14711, InsulinGlargine, 2827, 2835, "glargine", "", +14712, HbA1c, 2853, 2863, "HbA ( 1c )", "", +14715, ResultMeasuredValue, 2866, 2872, "7 . 19", "", +14717, Percentage, 2873, 2874, "%", "", +14716, ResultMeasuredValue, 2879, 2885, "7 . 03", "", +14718, Percentage, 2886, 2887, "%", "", +14714, DiffGroupAbsValue, 2923, 2929, "0 . 17", "", +14719, Percentage, 2930, 2931, "%", "", +14713, ConfIntervalDiff, 2934, 2962, "95 % CI , - 0 . 07 to 0 . 40", "", +14722, HbA1c, 2991, 2996, "HbAlc", "", +36714, TimePoint, 3002, 3010, "baseline", "", +14724, Reduction, 3015, 3021, "1 . 52", "", +14720, Percentage, 3022, 3023, "%", "", +14725, Reduction, 3030, 3036, "1 . 68", "", +14721, Percentage, 3037, 3038, "%", "", +36715, ObservedResult, 3043, 3159, "The reduction in HbA ( 1c ) was not significantly affected by whether detemir was administered once or twice daily .", "", +14726, HbA1c, 3060, 3070, "HbA ( 1c )", "", +14727, InsulinDetemir, 3113, 3120, "detemir", "", +14728, Frequency, 3138, 3157, "once or twice daily", "", +14730, FastingPlasmaGlucose, 3230, 3233, "FPG", "", +14732, ResultMeasuredValue, 3236, 3242, "7 . 05", "", +14733, ResultMeasuredValue, 3247, 3253, "6 . 68", "", +14734, Millimoles_per_litre, 3254, 3262, "mmol / L", "", +14731, FastingPlasmaGlucose, 3287, 3290, "FPG", "", +14737, Reduction, 3309, 3315, "2 . 56", "", +14736, Reduction, 3322, 3328, "2 . 92", "", +14735, Millimoles_per_litre, 3329, 3337, "mmol / L", "", +14738, DiffGroupAbsValue, 3358, 3364, "0 . 36", "", +14739, ConfIntervalDiff, 3367, 3395, "95 % CI , - 0 . 26 to 0 . 99", "", +14741, ObservedResult, 3400, 3496, "The overall shape of the 10 - point SMPG profiles was not significantly different between groups", "", +14740, EndPointDescription, 3425, 3449, "10 - point SMPG profiles", "", +14742, BodyWeight, 3504, 3510, "weight", "", +36716, TimePoint, 3519, 3527, "52 weeks", "", +14744, InsulinDetemir, 3557, 3564, "detemir", "", +14745, InsulinGlargine, 3575, 3583, "glargine", "", +14746, Increment, 3586, 3591, "2 . 8", "", +14747, Increment, 3595, 3600, "3 . 8", "", +14748, Kg, 3601, 3603, "kg", "", +14749, DiffGroupAbsValue, 3624, 3632, "- 1 . 04", "", +14750, ConfIntervalDiff, 3635, 3665, "95 % CI , - 2 . 08 to - 0 . 01", "", +14751, PvalueDiff, 3668, 3678, "P < 0 . 05", "", +36717, ObservedResult, 3683, 3793, "Doses of basal and prandial insulins at the end of the study were not significantly different between groups .", "", +36718, InsulinDose, 3683, 3719, "Doses of basal and prandial insulins", "", +14763, Hypoglycemia, 3800, 3821, "hypoglycemic episodes", "", +14762, PercentageAffected, 3839, 3844, "4 . 7", "", +14761, PercentageAffected, 3851, 3856, "5 . 7", "", +36721, ObservedResult, 3908, 3988, "There was no significant difference in the risk of hypoglycemia between groups .", "", +14766, Hypoglycemia, 3959, 3971, "hypoglycemia", "", +14767, EndPointDescription, 4021, 4024, "AEs", "", +14768, EndPointDescription, 4043, 4046, "AEs", "", +14769, NumberAffected, 4092, 4095, "185", "", +14771, NumberPatientsArm, 4098, 4101, "214", "", +14773, PercentageAffected, 4113, 4119, "86 . 4", "", +14777, ResultMeasuredValue, 4134, 4137, "743", "", +14775, EndPointDescription, 4138, 4141, "AEs", "", +14770, NumberAffected, 4146, 4148, "88", "", +14772, NumberPatientsArm, 4151, 4154, "105", "", +14774, PercentageAffected, 4166, 4172, "83 . 8", "", +14778, ResultMeasuredValue, 4187, 4190, "377", "", +14776, EndPointDescription, 4191, 4194, "AEs", "", +36722, ConclusionComment, 4213, 4439, "when used as indicated as part of a basal - bolus regimen in patients with T2DM who had previously received other insulin and / or OAD regimens , detemir was noninferior to glargine in its effects on overall glycemic control .", "", +14784, Precondition, 4274, 4356, "patients with T2DM who had previously received other insulin and / or OAD regimens", "", +14779, Type2Diabetes, 4288, 4292, "T2DM", "", +14780, Insulin, 4327, 4334, "insulin", "", +14781, OralAntidiabeticAgent, 4344, 4356, "OAD regimens", "", +14782, InsulinDetemir, 4359, 4366, "detemir", "", +14783, InsulinGlargine, 4386, 4394, "glargine", "", +36723, ConclusionComment, 4440, 4530, "Both basal insulins were associated with clinically relevant reductions in hyperglycemia .", "", +14786, Insulin, 4451, 4459, "insulins", "", +14787, Hypoglycemia, 4515, 4528, "hyperglycemia", "", +36724, ConclusionComment, 4531, 4630, "Both were well tolerated , with no significant difference in the frequency of hypoglycemia or AEs .", "", +14789, Hypoglycemia, 4609, 4621, "hypoglycemia", "", +14790, EndPointDescription, 4625, 4628, "AEs", "", +14792, PMID, 4688, 4696, "19108786", "", diff --git a/data/dm2 19108786_kwoodley.n-triples b/data/dm2 19108786_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19108786_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19307526 copy_admin.annodb b/data/dm2 19307526 copy_admin.annodb new file mode 100644 index 0000000..8038841 --- /dev/null +++ b/data/dm2 19307526 copy_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Arch Intern Med .", "", " \"Arch Intern Med .\"." +1, PublicationYear, 18, 22, "2009", "", " \"2009\"." +69, Title, 101, 235, "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .", "", " \"Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .\"." +2, Metformin, 124, 133, "metformin", "", +3, Type2Diabetes, 209, 233, "type 2 diabetes mellitus", "", " ." +4, Author, 236, 242, "Kooy A", "", " \"Kooy A\"." +5, Author, 251, 261, "de Jager J", "", " \"de Jager J\"." +6, Author, 264, 272, "Lehert P", "", " \"Lehert P\"." +7, Author, 275, 281, "Bets D", "", " \"Bets D\"." +8, Author, 284, 296, "Wulffel é MG", "", " \"Wulffel é MG\"." +9, Author, 299, 308, "Donker AJ", "", " \"Donker AJ\"." +10, Author, 311, 323, "Stehouwer CD", "", " \"Stehouwer CD\"." +77, Netherlands, 444, 455, "Netherlands", "", " ." +81, ObjectiveDescription, 660, 826, "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .", "", " \"We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .\"." +12, Metformin, 684, 707, "metformin hydrochloride", "", +13, Type2Diabetes, 792, 816, "type 2 diabetes mellitus", "", +14, Type2Diabetes, 819, 822, "DM2", "", " ." +15, NumberPatientsCT, 848, 851, "390", "", " \"390\"." +18, Precondition, 852, 881, "patients treated with insulin", "", " \"patients treated with insulin\"." +24, Insulin, 874, 881, "insulin", "", +17, Multicenter, 911, 922, "3 hospitals", "", " ." +16, Randomized, 928, 938, "randomized", "", " ." +86, Placebo, 941, 948, "placebo", "", +137, Duration, 997, 1008, "4 . 3 years", "", " \"4 . 3 years\"." +19, Metformin, 1018, 1041, "metformin hydrochloride", "", " ." +20, DoseValue, 1044, 1047, "850", "", " \"850\"." +21, mg, 1048, 1050, "mg", "", " ." +22, Placebo, 1056, 1063, "placebo", "", " ." +23, Frequency, 1066, 1083, "1 - 3 times daily", "", " \"1 - 3 times daily\". \"1 - 3 times daily\"." +25, Insulin, 1099, 1106, "insulin", "", " . ." +144, EndPointDescription, 1159, 1214, "microvascular and macrovascular morbidity and mortality", "", +145, EndPointDescription, 1247, 1302, "microvascular and macrovascular morbidity and mortality", "", +146, EndPointDescription, 1265, 1302, "macrovascular morbidity and mortality", "", +26, HbA1c, 1361, 1380, "hemoglobin A ( 1c )", "", +27, HbA1c, 1383, 1393, "HbA ( 1c )", "", +52695, InsulinDose, 1398, 1417, "insulin requirement", "", +28, EndPointDescription, 1420, 1432, "lipid levels", "", +29, BloodPressure, 1435, 1449, "blood pressure", "", +30, BodyWeight, 1452, 1463, "body weight", "", +31, BMI, 1470, 1485, "body mass index", "", +32, Metformin, 1512, 1521, "Metformin", "", +52689, WeightGain, 1542, 1553, "weight gain", "", +101, Mean, 1556, 1560, "mean", "", " . ." +102, WeightGain, 1561, 1572, "weight gain", "", " ." +38, Reduction, 1577, 1583, "3 . 07", "", " \"3 . 07\"." +36, Kg, 1584, 1586, "kg", "", " ." +37, Kg, 1618, 1620, "kg", "", +105, PValueResValue, 1625, 1634, "P < . 001", "", " \"P < . 001\"." +106, Mean, 1667, 1671, "mean", "", " . ." +34, HbA1c, 1685, 1701, "HbA ( 1c ) level", "", " ." +40, Reduction, 1704, 1709, "0 . 4", "", " \"0 . 4\"." +39, Percentage, 1710, 1711, "%", "", " ." +41, ConfIntervalChangeValue, 1731, 1756, "95 % CI , 0 . 55 - 0 . 25", "", " \"95 % CI , 0 . 55 - 0 . 25\"." +42, PValueChangeValue, 1761, 1770, "P < . 001", "", " \"P < . 001\"." +154, InsulinDose, 1891, 1911, "insulin requirements", "", " . ." +114, Mean, 1914, 1918, "mean", "", " . ." +43, Reduction, 1931, 1938, "19 . 63", "", " \"19 . 63\"." +155, Int_Unit, 1939, 1941, "IU", "", " ." +156, Frequency, 1944, 1945, "d", "", +44, ConfIntervalChangeValue, 1948, 1975, "95 % CI , 24 . 91 - 14 . 36", "", " \"95 % CI , 24 . 91 - 14 . 36\"." +157, Int_Unit, 1976, 1978, "IU", "", +52694, Interval, 1981, 1982, "d", "", +45, PValueChangeValue, 1987, 1996, "P < . 001", "", " \"P < . 001\"." +46, Metformin, 2001, 2010, "Metformin", "", +60, EndPointDescription, 2146, 2169, "macrovascular end point", "", " . ." +126, AggregationMethod, 2172, 2184, "hazard ratio", "", " . ." +48, ResultMeasuredValue, 2187, 2193, "0 . 61", "", " \"0 . 61\"." +47, ConfIntervalResValue, 2196, 2221, "95 % CI , 0 . 40 - 0 . 94", "", " \"95 % CI , 0 . 40 - 0 . 94\"." +49, PValueResValue, 2224, 2232, "P = . 02", "", " \"P = . 02\"." +128, EndPointDescription, 2334, 2357, "macrovascular end point", "", +147, ConclusionComment, 2414, 2576, "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .", "", " \"Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .\"." +54, Metformin, 2414, 2423, "Metformin", "", +57, Insulin, 2435, 2442, "insulin", "", +55, Type2Diabetes, 2460, 2463, "DM2", "", +56, BodyWeight, 2475, 2486, "body weight", "", +52696, InsulinDose, 2512, 2532, "insulin requirements", "", +148, ConclusionComment, 2577, 2687, "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .", "", " \"Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .\"." +58, Metformin, 2577, 2586, "Metformin", "", +52697, ObservedResult, 2603, 2643, "reduce the risk of macrovascular disease", "", +59, EndPointDescription, 2622, 2643, "macrovascular disease", "", +138, Duration, 2674, 2685, "4 . 3 years", "", +149, ConclusionComment, 2688, 2858, "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .", "", " \"These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .\"." +61, Metformin, 2754, 2763, "metformin", "", +62, Insulin, 2800, 2807, "insulin", "", +63, Type2Diabetes, 2828, 2831, "DM2", "", +64, PMID, 2977, 2985, "19307526", "", " \"19307526\"." diff --git a/data/dm2 19307526 copy_admin.n-triples b/data/dm2 19307526 copy_admin.n-triples new file mode 100644 index 0000000..c863fa0 --- /dev/null +++ b/data/dm2 19307526 copy_admin.n-triples @@ -0,0 +1,147 @@ +# RDF export of group: Publication + . + "Publication" . + "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus ." . + "Kooy A" . + "2009" . + "Arch Intern Med ." . + "19307526" . + . + "de Jager J" . + "Lehert P" . + "Bets D" . + "Wulffel é MG" . + "Donker AJ" . + "Stehouwer CD" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) ." . + "390" . + "4 . 3 years" . + . + . + . + "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point ." . + . + . + . + . + . + . + "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years ." . + "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated ." . + . +# RDF export of group: Population + . + "Population" . + "patients treated with insulin" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_H" . + . + . + . + . + . + . + "Endpoint_W" . + . + . + . + . + . + . + "Endpoint_I" . + . + . + . + . + . + . + . + "Endpoint_MV" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_M" . + . + . + . + . + . + . + . + . + "Arm_P" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_M" . + . + "1 - 3 times daily" . + . + . + "Intervention_P" . + . + "1 - 3 times daily" . + . + . + "Intervention_I" . + . + . +# RDF export of group: Medication + . + "Medication_M" . + . + "850" . + . + . + . + "Medication_P" . + . + . + . + . + "Medication_I" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome_W_M" . + . + "P < . 001" . + "3 . 07" . + . + "Outcome_H_M" . + . + "0 . 4" . + "P < . 001" . + "95 % CI , 0 . 55 - 0 . 25" . + . + "Outcome_I_M" . + . + "19 . 63" . + "P < . 001" . + "95 % CI , 24 . 91 - 14 . 36" . + . + "Outcome_MV_M" . + . + "0 . 61" . + "P = . 02" . + "95 % CI , 0 . 40 - 0 . 94" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19307526 copy_export.csv b/data/dm2 19307526 copy_export.csv new file mode 100644 index 0000000..1b11e7d --- /dev/null +++ b/data/dm2 19307526 copy_export.csv @@ -0,0 +1,637 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +824, 1, 1, 1, 0, 4, 0, 4, "Arch" +824, 1, 2, 2, 5, 11, 5, 11, "Intern" +824, 1, 3, 3, 12, 15, 12, 15, "Med" +824, 1, 4, 4, 16, 17, 16, 17, "." +824, 2, 1, 5, 0, 4, 18, 22, "2009" +824, 2, 2, 6, 5, 8, 23, 26, "Mar" +824, 2, 3, 7, 9, 11, 27, 29, "23" +824, 2, 4, 8, 12, 13, 30, 31, ";" +824, 2, 5, 9, 14, 17, 32, 35, "169" +824, 2, 6, 10, 18, 19, 36, 37, "(" +824, 2, 7, 11, 20, 21, 38, 39, "6" +824, 2, 8, 12, 22, 23, 40, 41, ")" +824, 2, 9, 13, 24, 25, 42, 43, ":" +824, 2, 10, 14, 26, 29, 44, 47, "616" +824, 2, 11, 15, 30, 31, 48, 49, "-" +824, 2, 12, 16, 32, 34, 50, 52, "25" +824, 2, 13, 17, 35, 36, 53, 54, "." +824, 2, 14, 18, 37, 40, 55, 58, "doi" +824, 2, 15, 19, 41, 42, 59, 60, ":" +824, 2, 16, 20, 43, 45, 61, 63, "10" +824, 2, 17, 21, 46, 47, 64, 65, "." +824, 2, 18, 22, 48, 52, 66, 70, "1001" +824, 2, 19, 23, 53, 54, 71, 72, "/" +824, 2, 20, 24, 55, 68, 73, 86, "archinternmed" +824, 2, 21, 25, 69, 70, 87, 88, "." +824, 2, 22, 26, 71, 75, 89, 93, "2009" +824, 2, 23, 27, 76, 77, 94, 95, "." +824, 2, 24, 28, 78, 80, 96, 98, "20" +824, 2, 25, 29, 81, 82, 99, 100, "." +824, 3, 1, 30, 0, 4, 101, 105, "Long" +824, 3, 2, 31, 5, 6, 106, 107, "-" +824, 3, 3, 32, 7, 11, 108, 112, "term" +824, 3, 4, 33, 12, 19, 113, 120, "effects" +824, 3, 5, 34, 20, 22, 121, 123, "of" +824, 3, 6, 35, 23, 32, 124, 133, "metformin" +824, 3, 7, 36, 33, 35, 134, 136, "on" +824, 3, 8, 37, 36, 46, 137, 147, "metabolism" +824, 3, 9, 38, 47, 50, 148, 151, "and" +824, 3, 10, 39, 51, 64, 152, 165, "microvascular" +824, 3, 11, 40, 65, 68, 166, 169, "and" +824, 3, 12, 41, 69, 82, 170, 183, "macrovascular" +824, 3, 13, 42, 83, 90, 184, 191, "disease" +824, 3, 14, 43, 91, 93, 192, 194, "in" +824, 3, 15, 44, 94, 102, 195, 203, "patients" +824, 3, 16, 45, 103, 107, 204, 208, "with" +824, 3, 17, 46, 108, 112, 209, 213, "type" +824, 3, 18, 47, 113, 114, 214, 215, "2" +824, 3, 19, 48, 115, 123, 216, 224, "diabetes" +824, 3, 20, 49, 124, 132, 225, 233, "mellitus" +824, 3, 21, 50, 133, 134, 234, 235, "." +824, 4, 1, 51, 0, 4, 236, 240, "Kooy" +824, 4, 2, 52, 5, 6, 241, 242, "A" +824, 4, 3, 53, 7, 8, 243, 244, "(" +824, 4, 4, 54, 9, 10, 245, 246, "1" +824, 4, 5, 55, 11, 12, 247, 248, ")" +824, 4, 6, 56, 13, 14, 249, 250, "," +824, 4, 7, 57, 15, 17, 251, 253, "de" +824, 4, 8, 58, 18, 23, 254, 259, "Jager" +824, 4, 9, 59, 24, 25, 260, 261, "J" +824, 4, 10, 60, 26, 27, 262, 263, "," +824, 4, 11, 61, 28, 34, 264, 270, "Lehert" +824, 4, 12, 62, 35, 36, 271, 272, "P" +824, 4, 13, 63, 37, 38, 273, 274, "," +824, 4, 14, 64, 39, 43, 275, 279, "Bets" +824, 4, 15, 65, 44, 45, 280, 281, "D" +824, 4, 16, 66, 46, 47, 282, 283, "," +824, 4, 17, 67, 48, 55, 284, 291, "Wulffel" +824, 4, 18, 68, 56, 57, 292, 293, "é" +824, 4, 19, 69, 58, 60, 294, 296, "MG" +824, 4, 20, 70, 61, 62, 297, 298, "," +824, 4, 21, 71, 63, 69, 299, 305, "Donker" +824, 4, 22, 72, 70, 72, 306, 308, "AJ" +824, 4, 23, 73, 73, 74, 309, 310, "," +824, 4, 24, 74, 75, 84, 311, 320, "Stehouwer" +824, 4, 25, 75, 85, 87, 321, 323, "CD" +824, 4, 26, 76, 88, 89, 324, 325, "." +824, 5, 1, 77, 0, 6, 326, 332, "Author" +824, 5, 2, 78, 7, 18, 333, 344, "information" +824, 5, 3, 79, 19, 20, 345, 346, ":" +824, 5, 4, 80, 21, 22, 347, 348, "(" +824, 5, 5, 81, 23, 24, 349, 350, "1" +824, 5, 6, 82, 25, 26, 351, 352, ")" +824, 5, 7, 83, 27, 37, 353, 363, "Department" +824, 5, 8, 84, 38, 40, 364, 366, "of" +824, 5, 9, 85, 41, 49, 367, 375, "Internal" +824, 5, 10, 86, 50, 58, 376, 384, "Medicine" +824, 5, 11, 87, 59, 62, 385, 388, "and" +824, 5, 12, 88, 63, 71, 389, 397, "Bethesda" +824, 5, 13, 89, 72, 80, 398, 406, "Diabetes" +824, 5, 14, 90, 81, 89, 407, 415, "Research" +824, 5, 15, 91, 90, 96, 416, 422, "Center" +824, 5, 16, 92, 97, 98, 423, 424, "," +824, 5, 17, 93, 99, 101, 425, 427, "RA" +824, 5, 18, 94, 102, 111, 428, 437, "Hoogeveen" +824, 5, 19, 95, 112, 113, 438, 439, "," +824, 5, 20, 96, 114, 117, 440, 443, "the" +824, 5, 21, 97, 118, 129, 444, 455, "Netherlands" +824, 5, 22, 98, 130, 131, 456, 457, "." +824, 6, 1, 99, 0, 4, 458, 462, "kooy" +824, 6, 2, 100, 5, 6, 463, 464, "." +824, 6, 3, 101, 7, 8, 465, 466, "a" +824, 6, 4, 102, 9, 10, 467, 468, "@" +824, 6, 5, 103, 11, 19, 469, 477, "bethesda" +824, 6, 6, 104, 20, 21, 478, 479, "." +824, 6, 7, 105, 22, 24, 480, 482, "nl" +824, 6, 8, 106, 25, 32, 483, 490, "Comment" +824, 6, 9, 107, 33, 35, 491, 493, "in" +824, 6, 10, 108, 36, 39, 494, 497, "Ann" +824, 6, 11, 109, 40, 46, 498, 504, "Intern" +824, 6, 12, 110, 47, 50, 505, 508, "Med" +824, 6, 13, 111, 51, 52, 509, 510, "." +824, 7, 1, 112, 0, 4, 511, 515, "2009" +824, 7, 2, 113, 5, 8, 516, 519, "Jul" +824, 7, 3, 114, 9, 11, 520, 522, "21" +824, 7, 4, 115, 12, 13, 523, 524, ";" +824, 7, 5, 116, 14, 17, 525, 528, "151" +824, 7, 6, 117, 18, 19, 529, 530, "(" +824, 7, 7, 118, 20, 21, 531, 532, "2" +824, 7, 8, 119, 22, 23, 533, 534, ")" +824, 7, 9, 120, 24, 25, 535, 536, ":" +824, 7, 10, 121, 26, 29, 537, 540, "JC1" +824, 7, 11, 122, 30, 31, 541, 542, "-" +824, 7, 12, 123, 32, 34, 543, 545, "12" +824, 7, 13, 124, 35, 36, 546, 547, "." +824, 8, 1, 125, 0, 4, 548, 552, "Evid" +824, 8, 2, 126, 5, 10, 553, 558, "Based" +824, 8, 3, 127, 11, 14, 559, 562, "Med" +824, 8, 4, 128, 15, 16, 563, 564, "." +824, 9, 1, 129, 0, 4, 565, 569, "2009" +824, 9, 2, 130, 5, 8, 570, 573, "Oct" +824, 9, 3, 131, 9, 10, 574, 575, ";" +824, 9, 4, 132, 11, 13, 576, 578, "14" +824, 9, 5, 133, 14, 15, 579, 580, "(" +824, 9, 6, 134, 16, 17, 581, 582, "5" +824, 9, 7, 135, 18, 19, 583, 584, ")" +824, 9, 8, 136, 20, 21, 585, 586, ":" +824, 9, 9, 137, 22, 25, 587, 590, "139" +824, 9, 10, 138, 26, 27, 591, 592, "." +824, 10, 1, 139, 0, 11, 593, 604, "Republished" +824, 10, 2, 140, 12, 14, 605, 607, "in" +824, 10, 3, 141, 15, 18, 608, 611, "Ned" +824, 10, 4, 142, 19, 27, 612, 620, "Tijdschr" +824, 10, 5, 143, 28, 36, 621, 629, "Geneeskd" +824, 10, 6, 144, 37, 38, 630, 631, "." +824, 11, 1, 145, 0, 4, 632, 636, "2009" +824, 11, 2, 146, 5, 6, 637, 638, ";" +824, 11, 3, 147, 7, 10, 639, 642, "153" +824, 11, 4, 148, 11, 12, 643, 644, ":" +824, 11, 5, 149, 13, 14, 645, 646, "." +824, 12, 1, 150, 0, 10, 647, 657, "BACKGROUND" +824, 12, 2, 151, 11, 12, 658, 659, ":" +824, 12, 3, 152, 13, 15, 660, 662, "We" +824, 12, 4, 153, 16, 28, 663, 675, "investigated" +824, 12, 5, 154, 29, 36, 676, 683, "whether" +824, 12, 6, 155, 37, 46, 684, 693, "metformin" +824, 12, 7, 156, 47, 60, 694, 707, "hydrochloride" +824, 12, 8, 157, 61, 64, 708, 711, "has" +824, 12, 9, 158, 65, 74, 712, 721, "sustained" +824, 12, 10, 159, 75, 85, 722, 732, "beneficial" +824, 12, 11, 160, 86, 95, 733, 742, "metabolic" +824, 12, 12, 161, 96, 99, 743, 746, "and" +824, 12, 13, 162, 100, 101, 747, 748, "(" +824, 12, 14, 163, 102, 108, 749, 755, "cardio" +824, 12, 15, 164, 109, 110, 756, 757, ")" +824, 12, 16, 165, 111, 119, 758, 766, "vascular" +824, 12, 17, 166, 120, 127, 767, 774, "effects" +824, 12, 18, 167, 128, 130, 775, 777, "in" +824, 12, 19, 168, 131, 139, 778, 786, "patients" +824, 12, 20, 169, 140, 144, 787, 791, "with" +824, 12, 21, 170, 145, 149, 792, 796, "type" +824, 12, 22, 171, 150, 151, 797, 798, "2" +824, 12, 23, 172, 152, 160, 799, 807, "diabetes" +824, 12, 24, 173, 161, 169, 808, 816, "mellitus" +824, 12, 25, 174, 170, 171, 817, 818, "(" +824, 12, 26, 175, 172, 175, 819, 822, "DM2" +824, 12, 27, 176, 176, 177, 823, 824, ")" +824, 12, 28, 177, 178, 179, 825, 826, "." +824, 13, 1, 178, 0, 7, 827, 834, "METHODS" +824, 13, 2, 179, 8, 9, 835, 836, ":" +824, 13, 3, 180, 10, 12, 837, 839, "We" +824, 13, 4, 181, 13, 20, 840, 847, "studied" +824, 13, 5, 182, 21, 24, 848, 851, "390" +824, 13, 6, 183, 25, 33, 852, 860, "patients" +824, 13, 7, 184, 34, 41, 861, 868, "treated" +824, 13, 8, 185, 42, 46, 869, 873, "with" +824, 13, 9, 186, 47, 54, 874, 881, "insulin" +824, 13, 10, 187, 55, 57, 882, 884, "in" +824, 13, 11, 188, 58, 61, 885, 888, "the" +824, 13, 12, 189, 62, 72, 889, 899, "outpatient" +824, 13, 13, 190, 73, 80, 900, 907, "clinics" +824, 13, 14, 191, 81, 83, 908, 910, "of" +824, 13, 15, 192, 84, 85, 911, 912, "3" +824, 13, 16, 193, 86, 95, 913, 922, "hospitals" +824, 13, 17, 194, 96, 98, 923, 925, "in" +824, 13, 18, 195, 99, 100, 926, 927, "a" +824, 13, 19, 196, 101, 111, 928, 938, "randomized" +824, 13, 20, 197, 112, 113, 939, 940, "," +824, 13, 21, 198, 114, 121, 941, 948, "placebo" +824, 13, 22, 199, 122, 123, 949, 950, "-" +824, 13, 23, 200, 124, 134, 951, 961, "controlled" +824, 13, 24, 201, 135, 140, 962, 967, "trial" +824, 13, 25, 202, 141, 145, 968, 972, "with" +824, 13, 26, 203, 146, 147, 973, 974, "a" +824, 13, 27, 204, 148, 154, 975, 981, "follow" +824, 13, 28, 205, 155, 156, 982, 983, "-" +824, 13, 29, 206, 157, 159, 984, 986, "up" +824, 13, 30, 207, 160, 166, 987, 993, "period" +824, 13, 31, 208, 167, 169, 994, 996, "of" +824, 13, 32, 209, 170, 171, 997, 998, "4" +824, 13, 33, 210, 172, 173, 999, 1000, "." +824, 13, 34, 211, 174, 175, 1001, 1002, "3" +824, 13, 35, 212, 176, 181, 1003, 1008, "years" +824, 13, 36, 213, 182, 183, 1009, 1010, "." +824, 14, 1, 214, 0, 6, 1011, 1017, "Either" +824, 14, 2, 215, 7, 16, 1018, 1027, "metformin" +824, 14, 3, 216, 17, 30, 1028, 1041, "hydrochloride" +824, 14, 4, 217, 31, 32, 1042, 1043, "," +824, 14, 5, 218, 33, 36, 1044, 1047, "850" +824, 14, 6, 219, 37, 39, 1048, 1050, "mg" +824, 14, 7, 220, 40, 41, 1051, 1052, "," +824, 14, 8, 221, 42, 44, 1053, 1055, "or" +824, 14, 9, 222, 45, 52, 1056, 1063, "placebo" +824, 14, 10, 223, 53, 54, 1064, 1065, "(" +824, 14, 11, 224, 55, 56, 1066, 1067, "1" +824, 14, 12, 225, 57, 58, 1068, 1069, "-" +824, 14, 13, 226, 59, 60, 1070, 1071, "3" +824, 14, 14, 227, 61, 66, 1072, 1077, "times" +824, 14, 15, 228, 67, 72, 1078, 1083, "daily" +824, 14, 16, 229, 73, 74, 1084, 1085, ")" +824, 14, 17, 230, 75, 78, 1086, 1089, "was" +824, 14, 18, 231, 79, 84, 1090, 1095, "added" +824, 14, 19, 232, 85, 87, 1096, 1098, "to" +824, 14, 20, 233, 88, 95, 1099, 1106, "insulin" +824, 14, 21, 234, 96, 103, 1107, 1114, "therapy" +824, 14, 22, 235, 104, 105, 1115, 1116, "." +824, 15, 1, 236, 0, 3, 1117, 1120, "The" +824, 15, 2, 237, 4, 11, 1121, 1128, "primary" +824, 15, 3, 238, 12, 15, 1129, 1132, "end" +824, 15, 4, 239, 16, 21, 1133, 1138, "point" +824, 15, 5, 240, 22, 25, 1139, 1142, "was" +824, 15, 6, 241, 26, 28, 1143, 1145, "an" +824, 15, 7, 242, 29, 38, 1146, 1155, "aggregate" +824, 15, 8, 243, 39, 41, 1156, 1158, "of" +824, 15, 9, 244, 42, 55, 1159, 1172, "microvascular" +824, 15, 10, 245, 56, 59, 1173, 1176, "and" +824, 15, 11, 246, 60, 73, 1177, 1190, "macrovascular" +824, 15, 12, 247, 74, 83, 1191, 1200, "morbidity" +824, 15, 13, 248, 84, 87, 1201, 1204, "and" +824, 15, 14, 249, 88, 97, 1205, 1214, "mortality" +824, 15, 15, 250, 98, 99, 1215, 1216, "." +824, 16, 1, 251, 0, 3, 1217, 1220, "The" +824, 16, 2, 252, 4, 13, 1221, 1230, "secondary" +824, 16, 3, 253, 14, 17, 1231, 1234, "end" +824, 16, 4, 254, 18, 24, 1235, 1241, "points" +824, 16, 5, 255, 25, 29, 1242, 1246, "were" +824, 16, 6, 256, 30, 43, 1247, 1260, "microvascular" +824, 16, 7, 257, 44, 47, 1261, 1264, "and" +824, 16, 8, 258, 48, 61, 1265, 1278, "macrovascular" +824, 16, 9, 259, 62, 71, 1279, 1288, "morbidity" +824, 16, 10, 260, 72, 75, 1289, 1292, "and" +824, 16, 11, 261, 76, 85, 1293, 1302, "mortality" +824, 16, 12, 262, 86, 87, 1303, 1304, "," +824, 16, 13, 263, 88, 90, 1305, 1307, "as" +824, 16, 14, 264, 91, 99, 1308, 1316, "separate" +824, 16, 15, 265, 100, 109, 1317, 1326, "aggregate" +824, 16, 16, 266, 110, 116, 1327, 1333, "scores" +824, 16, 17, 267, 117, 118, 1334, 1335, "." +824, 17, 1, 268, 0, 2, 1336, 1338, "In" +824, 17, 2, 269, 3, 11, 1339, 1347, "addition" +824, 17, 3, 270, 12, 13, 1348, 1349, "," +824, 17, 4, 271, 14, 21, 1350, 1357, "effects" +824, 17, 5, 272, 22, 24, 1358, 1360, "on" +824, 17, 6, 273, 25, 35, 1361, 1371, "hemoglobin" +824, 17, 7, 274, 36, 37, 1372, 1373, "A" +824, 17, 8, 275, 38, 39, 1374, 1375, "(" +824, 17, 9, 276, 40, 42, 1376, 1378, "1c" +824, 17, 10, 277, 43, 44, 1379, 1380, ")" +824, 17, 11, 278, 45, 46, 1381, 1382, "(" +824, 17, 12, 279, 47, 50, 1383, 1386, "HbA" +824, 17, 13, 280, 51, 52, 1387, 1388, "(" +824, 17, 14, 281, 53, 55, 1389, 1391, "1c" +824, 17, 15, 282, 56, 57, 1392, 1393, ")" +824, 17, 16, 283, 58, 59, 1394, 1395, ")" +824, 17, 17, 284, 60, 61, 1396, 1397, "," +824, 17, 18, 285, 62, 69, 1398, 1405, "insulin" +824, 17, 19, 286, 70, 81, 1406, 1417, "requirement" +824, 17, 20, 287, 82, 83, 1418, 1419, "," +824, 17, 21, 288, 84, 89, 1420, 1425, "lipid" +824, 17, 22, 289, 90, 96, 1426, 1432, "levels" +824, 17, 23, 290, 97, 98, 1433, 1434, "," +824, 17, 24, 291, 99, 104, 1435, 1440, "blood" +824, 17, 25, 292, 105, 113, 1441, 1449, "pressure" +824, 17, 26, 293, 114, 115, 1450, 1451, "," +824, 17, 27, 294, 116, 120, 1452, 1456, "body" +824, 17, 28, 295, 121, 127, 1457, 1463, "weight" +824, 17, 29, 296, 128, 129, 1464, 1465, "," +824, 17, 30, 297, 130, 133, 1466, 1469, "and" +824, 17, 31, 298, 134, 138, 1470, 1474, "body" +824, 17, 32, 299, 139, 143, 1475, 1479, "mass" +824, 17, 33, 300, 144, 149, 1480, 1485, "index" +824, 17, 34, 301, 150, 154, 1486, 1490, "were" +824, 17, 35, 302, 155, 163, 1491, 1499, "analyzed" +824, 17, 36, 303, 164, 165, 1500, 1501, "." +824, 18, 1, 304, 0, 7, 1502, 1509, "RESULTS" +824, 18, 2, 305, 8, 9, 1510, 1511, ":" +824, 18, 3, 306, 10, 19, 1512, 1521, "Metformin" +824, 18, 4, 307, 20, 29, 1522, 1531, "treatment" +824, 18, 5, 308, 30, 39, 1532, 1541, "prevented" +824, 18, 6, 309, 40, 46, 1542, 1548, "weight" +824, 18, 7, 310, 47, 51, 1549, 1553, "gain" +824, 18, 8, 311, 52, 53, 1554, 1555, "(" +824, 18, 9, 312, 54, 58, 1556, 1560, "mean" +824, 18, 10, 313, 59, 65, 1561, 1567, "weight" +824, 18, 11, 314, 66, 70, 1568, 1572, "gain" +824, 18, 12, 315, 71, 72, 1573, 1574, "," +824, 18, 13, 316, 73, 74, 1575, 1576, "-" +824, 18, 14, 317, 75, 76, 1577, 1578, "3" +824, 18, 15, 318, 77, 78, 1579, 1580, "." +824, 18, 16, 319, 79, 81, 1581, 1583, "07" +824, 18, 17, 320, 82, 84, 1584, 1586, "kg" +824, 18, 18, 321, 85, 86, 1587, 1588, "[" +824, 18, 19, 322, 87, 92, 1589, 1594, "range" +824, 18, 20, 323, 93, 94, 1595, 1596, "," +824, 18, 21, 324, 95, 96, 1597, 1598, "-" +824, 18, 22, 325, 97, 98, 1599, 1600, "3" +824, 18, 23, 326, 99, 100, 1601, 1602, "." +824, 18, 24, 327, 101, 103, 1603, 1605, "85" +824, 18, 25, 328, 104, 106, 1606, 1608, "to" +824, 18, 26, 329, 107, 108, 1609, 1610, "-" +824, 18, 27, 330, 109, 110, 1611, 1612, "2" +824, 18, 28, 331, 111, 112, 1613, 1614, "." +824, 18, 29, 332, 113, 115, 1615, 1617, "28" +824, 18, 30, 333, 116, 118, 1618, 1620, "kg" +824, 18, 31, 334, 119, 120, 1621, 1622, "]" +824, 18, 32, 335, 121, 122, 1623, 1624, ";" +824, 18, 33, 336, 123, 124, 1625, 1626, "P" +824, 18, 34, 337, 125, 126, 1627, 1628, "<" +824, 18, 35, 338, 127, 128, 1629, 1630, "." +824, 18, 36, 339, 129, 132, 1631, 1634, "001" +824, 18, 37, 340, 133, 134, 1635, 1636, ")" +824, 18, 38, 341, 135, 136, 1637, 1638, "," +824, 18, 39, 342, 137, 145, 1639, 1647, "improved" +824, 18, 40, 343, 146, 154, 1648, 1656, "glycemic" +824, 18, 41, 344, 155, 162, 1657, 1664, "control" +824, 18, 42, 345, 163, 164, 1665, 1666, "(" +824, 18, 43, 346, 165, 169, 1667, 1671, "mean" +824, 18, 44, 347, 170, 179, 1672, 1681, "reduction" +824, 18, 45, 348, 180, 182, 1682, 1684, "in" +824, 18, 46, 349, 183, 186, 1685, 1688, "HbA" +824, 18, 47, 350, 187, 188, 1689, 1690, "(" +824, 18, 48, 351, 189, 191, 1691, 1693, "1c" +824, 18, 49, 352, 192, 193, 1694, 1695, ")" +824, 18, 50, 353, 194, 199, 1696, 1701, "level" +824, 18, 51, 354, 200, 201, 1702, 1703, "," +824, 18, 52, 355, 202, 203, 1704, 1705, "0" +824, 18, 53, 356, 204, 205, 1706, 1707, "." +824, 18, 54, 357, 206, 207, 1708, 1709, "4" +824, 18, 55, 358, 208, 209, 1710, 1711, "%" +824, 18, 56, 359, 210, 220, 1712, 1722, "percentage" +824, 18, 57, 360, 221, 226, 1723, 1728, "point" +824, 18, 58, 361, 227, 228, 1729, 1730, "[" +824, 18, 59, 362, 229, 231, 1731, 1733, "95" +824, 18, 60, 363, 232, 233, 1734, 1735, "%" +824, 18, 61, 364, 234, 236, 1736, 1738, "CI" +824, 18, 62, 365, 237, 238, 1739, 1740, "," +824, 18, 63, 366, 239, 240, 1741, 1742, "0" +824, 18, 64, 367, 241, 242, 1743, 1744, "." +824, 18, 65, 368, 243, 245, 1745, 1747, "55" +824, 18, 66, 369, 246, 247, 1748, 1749, "-" +824, 18, 67, 370, 248, 249, 1750, 1751, "0" +824, 18, 68, 371, 250, 251, 1752, 1753, "." +824, 18, 69, 372, 252, 254, 1754, 1756, "25" +824, 18, 70, 373, 255, 256, 1757, 1758, "]" +824, 18, 71, 374, 257, 258, 1759, 1760, ";" +824, 18, 72, 375, 259, 260, 1761, 1762, "P" +824, 18, 73, 376, 261, 262, 1763, 1764, "<" +824, 18, 74, 377, 263, 264, 1765, 1766, "." +824, 18, 75, 378, 265, 268, 1767, 1770, "001" +824, 18, 76, 379, 269, 270, 1771, 1772, ")" +824, 18, 77, 380, 271, 272, 1773, 1774, "(" +824, 18, 78, 381, 273, 278, 1775, 1780, "where" +824, 18, 79, 382, 279, 281, 1781, 1783, "CI" +824, 18, 80, 383, 282, 291, 1784, 1793, "indicates" +824, 18, 81, 384, 292, 302, 1794, 1804, "confidence" +824, 18, 82, 385, 303, 311, 1805, 1813, "interval" +824, 18, 83, 386, 312, 313, 1814, 1815, ")" +824, 18, 84, 387, 314, 315, 1816, 1817, "," +824, 18, 85, 388, 316, 323, 1818, 1825, "despite" +824, 18, 86, 389, 324, 327, 1826, 1829, "the" +824, 18, 87, 390, 328, 331, 1830, 1833, "aim" +824, 18, 88, 391, 332, 334, 1834, 1836, "of" +824, 18, 89, 392, 335, 342, 1837, 1844, "similar" +824, 18, 90, 393, 343, 351, 1845, 1853, "glycemic" +824, 18, 91, 394, 352, 359, 1854, 1861, "control" +824, 18, 92, 395, 360, 362, 1862, 1864, "in" +824, 18, 93, 396, 363, 367, 1865, 1869, "both" +824, 18, 94, 397, 368, 374, 1870, 1876, "groups" +824, 18, 95, 398, 375, 376, 1877, 1878, "," +824, 18, 96, 399, 377, 380, 1879, 1882, "and" +824, 18, 97, 400, 381, 388, 1883, 1890, "reduced" +824, 18, 98, 401, 389, 396, 1891, 1898, "insulin" +824, 18, 99, 402, 397, 409, 1899, 1911, "requirements" +824, 18, 100, 403, 410, 411, 1912, 1913, "(" +824, 18, 101, 404, 412, 416, 1914, 1918, "mean" +824, 18, 102, 405, 417, 426, 1919, 1928, "reduction" +824, 18, 103, 406, 427, 428, 1929, 1930, "," +824, 18, 104, 407, 429, 431, 1931, 1933, "19" +824, 18, 105, 408, 432, 433, 1934, 1935, "." +824, 18, 106, 409, 434, 436, 1936, 1938, "63" +824, 18, 107, 410, 437, 439, 1939, 1941, "IU" +824, 18, 108, 411, 440, 441, 1942, 1943, "/" +824, 18, 109, 412, 442, 443, 1944, 1945, "d" +824, 18, 110, 413, 444, 445, 1946, 1947, "[" +824, 18, 111, 414, 446, 448, 1948, 1950, "95" +824, 18, 112, 415, 449, 450, 1951, 1952, "%" +824, 18, 113, 416, 451, 453, 1953, 1955, "CI" +824, 18, 114, 417, 454, 455, 1956, 1957, "," +824, 18, 115, 418, 456, 458, 1958, 1960, "24" +824, 18, 116, 419, 459, 460, 1961, 1962, "." +824, 18, 117, 420, 461, 463, 1963, 1965, "91" +824, 18, 118, 421, 464, 465, 1966, 1967, "-" +824, 18, 119, 422, 466, 468, 1968, 1970, "14" +824, 18, 120, 423, 469, 470, 1971, 1972, "." +824, 18, 121, 424, 471, 473, 1973, 1975, "36" +824, 18, 122, 425, 474, 476, 1976, 1978, "IU" +824, 18, 123, 426, 477, 478, 1979, 1980, "/" +824, 18, 124, 427, 479, 480, 1981, 1982, "d" +824, 18, 125, 428, 481, 482, 1983, 1984, "]" +824, 18, 126, 429, 483, 484, 1985, 1986, ";" +824, 18, 127, 430, 485, 486, 1987, 1988, "P" +824, 18, 128, 431, 487, 488, 1989, 1990, "<" +824, 18, 129, 432, 489, 490, 1991, 1992, "." +824, 18, 130, 433, 491, 494, 1993, 1996, "001" +824, 18, 131, 434, 495, 496, 1997, 1998, ")" +824, 18, 132, 435, 497, 498, 1999, 2000, "." +824, 19, 1, 436, 0, 9, 2001, 2010, "Metformin" +824, 19, 2, 437, 10, 13, 2011, 2014, "was" +824, 19, 3, 438, 14, 17, 2015, 2018, "not" +824, 19, 4, 439, 18, 28, 2019, 2029, "associated" +824, 19, 5, 440, 29, 33, 2030, 2034, "with" +824, 19, 6, 441, 34, 36, 2035, 2037, "an" +824, 19, 7, 442, 37, 48, 2038, 2049, "improvement" +824, 19, 8, 443, 49, 51, 2050, 2052, "in" +824, 19, 9, 444, 52, 55, 2053, 2056, "the" +824, 19, 10, 445, 56, 63, 2057, 2064, "primary" +824, 19, 11, 446, 64, 67, 2065, 2068, "end" +824, 19, 12, 447, 68, 73, 2069, 2074, "point" +824, 19, 13, 448, 74, 75, 2075, 2076, "." +824, 20, 1, 449, 0, 2, 2077, 2079, "It" +824, 20, 2, 450, 3, 6, 2080, 2083, "was" +824, 20, 3, 451, 7, 8, 2084, 2085, "," +824, 20, 4, 452, 9, 16, 2086, 2093, "however" +824, 20, 5, 453, 17, 18, 2094, 2095, "," +824, 20, 6, 454, 19, 29, 2096, 2106, "associated" +824, 20, 7, 455, 30, 34, 2107, 2111, "with" +824, 20, 8, 456, 35, 37, 2112, 2114, "an" +824, 20, 9, 457, 38, 49, 2115, 2126, "improvement" +824, 20, 10, 458, 50, 52, 2127, 2129, "in" +824, 20, 11, 459, 53, 56, 2130, 2133, "the" +824, 20, 12, 460, 57, 66, 2134, 2143, "secondary" +824, 20, 13, 461, 67, 68, 2144, 2145, "," +824, 20, 14, 462, 69, 82, 2146, 2159, "macrovascular" +824, 20, 15, 463, 83, 86, 2160, 2163, "end" +824, 20, 16, 464, 87, 92, 2164, 2169, "point" +824, 20, 17, 465, 93, 94, 2170, 2171, "(" +824, 20, 18, 466, 95, 101, 2172, 2178, "hazard" +824, 20, 19, 467, 102, 107, 2179, 2184, "ratio" +824, 20, 20, 468, 108, 109, 2185, 2186, "," +824, 20, 21, 469, 110, 111, 2187, 2188, "0" +824, 20, 22, 470, 112, 113, 2189, 2190, "." +824, 20, 23, 471, 114, 116, 2191, 2193, "61" +824, 20, 24, 472, 117, 118, 2194, 2195, "(" +824, 20, 25, 473, 119, 121, 2196, 2198, "95" +824, 20, 26, 474, 122, 123, 2199, 2200, "%" +824, 20, 27, 475, 124, 126, 2201, 2203, "CI" +824, 20, 28, 476, 127, 128, 2204, 2205, "," +824, 20, 29, 477, 129, 130, 2206, 2207, "0" +824, 20, 30, 478, 131, 132, 2208, 2209, "." +824, 20, 31, 479, 133, 135, 2210, 2212, "40" +824, 20, 32, 480, 136, 137, 2213, 2214, "-" +824, 20, 33, 481, 138, 139, 2215, 2216, "0" +824, 20, 34, 482, 140, 141, 2217, 2218, "." +824, 20, 35, 483, 142, 144, 2219, 2221, "94" +824, 20, 36, 484, 145, 146, 2222, 2223, ";" +824, 20, 37, 485, 147, 148, 2224, 2225, "P" +824, 20, 38, 486, 149, 150, 2226, 2227, "=" +824, 20, 39, 487, 151, 152, 2228, 2229, "." +824, 20, 40, 488, 153, 155, 2230, 2232, "02" +824, 20, 41, 489, 156, 157, 2233, 2234, ")" +824, 20, 42, 490, 158, 159, 2235, 2236, "," +824, 20, 43, 491, 160, 165, 2237, 2242, "which" +824, 20, 44, 492, 166, 169, 2243, 2246, "was" +824, 20, 45, 493, 170, 176, 2247, 2253, "partly" +824, 20, 46, 494, 177, 186, 2254, 2263, "explained" +824, 20, 47, 495, 187, 189, 2264, 2266, "by" +824, 20, 48, 496, 190, 193, 2267, 2270, "the" +824, 20, 49, 497, 194, 204, 2271, 2281, "difference" +824, 20, 50, 498, 205, 207, 2282, 2284, "in" +824, 20, 51, 499, 208, 214, 2285, 2291, "weight" +824, 20, 52, 500, 215, 216, 2292, 2293, "." +824, 21, 1, 501, 0, 3, 2294, 2297, "The" +824, 21, 2, 502, 4, 10, 2298, 2304, "number" +824, 21, 3, 503, 11, 17, 2305, 2311, "needed" +824, 21, 4, 504, 18, 20, 2312, 2314, "to" +824, 21, 5, 505, 21, 26, 2315, 2320, "treat" +824, 21, 6, 506, 27, 29, 2321, 2323, "to" +824, 21, 7, 507, 30, 37, 2324, 2331, "prevent" +824, 21, 8, 508, 38, 39, 2332, 2333, "1" +824, 21, 9, 509, 40, 53, 2334, 2347, "macrovascular" +824, 21, 10, 510, 54, 57, 2348, 2351, "end" +824, 21, 11, 511, 58, 63, 2352, 2357, "point" +824, 21, 12, 512, 64, 67, 2358, 2361, "was" +824, 21, 13, 513, 68, 70, 2362, 2364, "16" +824, 21, 14, 514, 71, 72, 2365, 2366, "." +824, 21, 15, 515, 73, 74, 2367, 2368, "1" +824, 21, 16, 516, 75, 76, 2369, 2370, "(" +824, 21, 17, 517, 77, 79, 2371, 2373, "95" +824, 21, 18, 518, 80, 81, 2374, 2375, "%" +824, 21, 19, 519, 82, 84, 2376, 2378, "CI" +824, 21, 20, 520, 85, 86, 2379, 2380, "," +824, 21, 21, 521, 87, 88, 2381, 2382, "9" +824, 21, 22, 522, 89, 90, 2383, 2384, "." +824, 21, 23, 523, 91, 92, 2385, 2386, "2" +824, 21, 24, 524, 93, 94, 2387, 2388, "-" +824, 21, 25, 525, 95, 97, 2389, 2391, "66" +824, 21, 26, 526, 98, 99, 2392, 2393, "." +824, 21, 27, 527, 100, 101, 2394, 2395, "6" +824, 21, 28, 528, 102, 103, 2396, 2397, ")" +824, 21, 29, 529, 104, 105, 2398, 2399, "." +824, 22, 1, 530, 0, 11, 2400, 2411, "CONCLUSIONS" +824, 22, 2, 531, 12, 13, 2412, 2413, ":" +824, 22, 3, 532, 14, 23, 2414, 2423, "Metformin" +824, 22, 4, 533, 24, 25, 2424, 2425, "," +824, 22, 5, 534, 26, 31, 2426, 2431, "added" +824, 22, 6, 535, 32, 34, 2432, 2434, "to" +824, 22, 7, 536, 35, 42, 2435, 2442, "insulin" +824, 22, 8, 537, 43, 45, 2443, 2445, "in" +824, 22, 9, 538, 46, 54, 2446, 2454, "patients" +824, 22, 10, 539, 55, 59, 2455, 2459, "with" +824, 22, 11, 540, 60, 63, 2460, 2463, "DM2" +824, 22, 12, 541, 64, 65, 2464, 2465, "," +824, 22, 13, 542, 66, 74, 2466, 2474, "improved" +824, 22, 14, 543, 75, 79, 2475, 2479, "body" +824, 22, 15, 544, 80, 86, 2480, 2486, "weight" +824, 22, 16, 545, 87, 88, 2487, 2488, "," +824, 22, 17, 546, 89, 97, 2489, 2497, "glycemic" +824, 22, 18, 547, 98, 105, 2498, 2505, "control" +824, 22, 19, 548, 106, 107, 2506, 2507, "," +824, 22, 20, 549, 108, 111, 2508, 2511, "and" +824, 22, 21, 550, 112, 119, 2512, 2519, "insulin" +824, 22, 22, 551, 120, 132, 2520, 2532, "requirements" +824, 22, 23, 552, 133, 136, 2533, 2536, "but" +824, 22, 24, 553, 137, 140, 2537, 2540, "did" +824, 22, 25, 554, 141, 144, 2541, 2544, "not" +824, 22, 26, 555, 145, 152, 2545, 2552, "improve" +824, 22, 27, 556, 153, 156, 2553, 2556, "the" +824, 22, 28, 557, 157, 164, 2557, 2564, "primary" +824, 22, 29, 558, 165, 168, 2565, 2568, "end" +824, 22, 30, 559, 169, 174, 2569, 2574, "point" +824, 22, 31, 560, 175, 176, 2575, 2576, "." +824, 23, 1, 561, 0, 9, 2577, 2586, "Metformin" +824, 23, 2, 562, 10, 13, 2587, 2590, "did" +824, 23, 3, 563, 14, 15, 2591, 2592, "," +824, 23, 4, 564, 16, 23, 2593, 2600, "however" +824, 23, 5, 565, 24, 25, 2601, 2602, "," +824, 23, 6, 566, 26, 32, 2603, 2609, "reduce" +824, 23, 7, 567, 33, 36, 2610, 2613, "the" +824, 23, 8, 568, 37, 41, 2614, 2618, "risk" +824, 23, 9, 569, 42, 44, 2619, 2621, "of" +824, 23, 10, 570, 45, 58, 2622, 2635, "macrovascular" +824, 23, 11, 571, 59, 66, 2636, 2643, "disease" +824, 23, 12, 572, 67, 72, 2644, 2649, "after" +824, 23, 13, 573, 73, 74, 2650, 2651, "a" +824, 23, 14, 574, 75, 81, 2652, 2658, "follow" +824, 23, 15, 575, 82, 83, 2659, 2660, "-" +824, 23, 16, 576, 84, 86, 2661, 2663, "up" +824, 23, 17, 577, 87, 93, 2664, 2670, "period" +824, 23, 18, 578, 94, 96, 2671, 2673, "of" +824, 23, 19, 579, 97, 98, 2674, 2675, "4" +824, 23, 20, 580, 99, 100, 2676, 2677, "." +824, 23, 21, 581, 101, 102, 2678, 2679, "3" +824, 23, 22, 582, 103, 108, 2680, 2685, "years" +824, 23, 23, 583, 109, 110, 2686, 2687, "." +824, 24, 1, 584, 0, 5, 2688, 2693, "These" +824, 24, 2, 585, 6, 15, 2694, 2703, "sustained" +824, 24, 3, 586, 16, 26, 2704, 2714, "beneficial" +824, 24, 4, 587, 27, 34, 2715, 2722, "effects" +824, 24, 5, 588, 35, 42, 2723, 2730, "support" +824, 24, 6, 589, 43, 46, 2731, 2734, "the" +824, 24, 7, 590, 47, 53, 2735, 2741, "policy" +824, 24, 8, 591, 54, 56, 2742, 2744, "to" +824, 24, 9, 592, 57, 65, 2745, 2753, "continue" +824, 24, 10, 593, 66, 75, 2754, 2763, "metformin" +824, 24, 11, 594, 76, 85, 2764, 2773, "treatment" +824, 24, 12, 595, 86, 91, 2774, 2779, "after" +824, 24, 13, 596, 92, 95, 2780, 2783, "the" +824, 24, 14, 597, 96, 108, 2784, 2796, "introduction" +824, 24, 15, 598, 109, 111, 2797, 2799, "of" +824, 24, 16, 599, 112, 119, 2800, 2807, "insulin" +824, 24, 17, 600, 120, 122, 2808, 2810, "in" +824, 24, 18, 601, 123, 126, 2811, 2814, "any" +824, 24, 19, 602, 127, 134, 2815, 2822, "patient" +824, 24, 20, 603, 135, 139, 2823, 2827, "with" +824, 24, 21, 604, 140, 143, 2828, 2831, "DM2" +824, 24, 22, 605, 144, 145, 2832, 2833, "," +824, 24, 23, 606, 146, 152, 2834, 2840, "unless" +824, 24, 24, 607, 153, 168, 2841, 2856, "contraindicated" +824, 24, 25, 608, 169, 170, 2857, 2858, "." +824, 25, 1, 609, 0, 5, 2859, 2864, "Trial" +824, 25, 2, 610, 6, 18, 2865, 2877, "Registration" +824, 25, 3, 611, 19, 33, 2878, 2892, "ClinicalTrials" +824, 25, 4, 612, 34, 35, 2893, 2894, "." +824, 25, 5, 613, 36, 39, 2895, 2898, "gov" +824, 25, 6, 614, 40, 50, 2899, 2909, "Identifier" +824, 25, 7, 615, 51, 52, 2910, 2911, ":" +824, 25, 8, 616, 53, 64, 2912, 2923, "NCT00375388" +824, 25, 9, 617, 65, 66, 2924, 2925, "." +824, 26, 1, 618, 0, 3, 2926, 2929, "DOI" +824, 26, 2, 619, 4, 5, 2930, 2931, ":" +824, 26, 3, 620, 6, 8, 2932, 2934, "10" +824, 26, 4, 621, 9, 10, 2935, 2936, "." +824, 26, 5, 622, 11, 15, 2937, 2941, "1001" +824, 26, 6, 623, 16, 17, 2942, 2943, "/" +824, 26, 7, 624, 18, 31, 2944, 2957, "archinternmed" +824, 26, 8, 625, 32, 33, 2958, 2959, "." +824, 26, 9, 626, 34, 38, 2960, 2964, "2009" +824, 26, 10, 627, 39, 40, 2965, 2966, "." +824, 26, 11, 628, 41, 43, 2967, 2969, "20" +824, 26, 12, 629, 44, 48, 2970, 2974, "PMID" +824, 26, 13, 630, 49, 50, 2975, 2976, ":" +824, 26, 14, 631, 51, 59, 2977, 2985, "19307526" +824, 26, 15, 632, 60, 61, 2986, 2987, "[" +824, 26, 16, 633, 62, 69, 2988, 2995, "Indexed" +824, 26, 17, 634, 70, 73, 2996, 2999, "for" +824, 26, 18, 635, 74, 81, 3000, 3007, "MEDLINE" +824, 26, 19, 636, 82, 83, 3008, 3009, "]" diff --git a/data/dm2 19307526_admin.annodb b/data/dm2 19307526_admin.annodb new file mode 100644 index 0000000..b6f8706 --- /dev/null +++ b/data/dm2 19307526_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Arch Intern Med .", "", " \"Arch Intern Med .\"." +1, PublicationYear, 18, 22, "2009", "", " \"2009\"." +69, Title, 101, 235, "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .", "", " \"Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .\"." +2, Metformin, 124, 133, "metformin", "", +3, Type2Diabetes, 209, 233, "type 2 diabetes mellitus", "", +4, Author, 236, 242, "Kooy A", "", " \"Kooy A\"." +5, Author, 251, 261, "de Jager J", "", " \"de Jager J\"." +6, Author, 264, 272, "Lehert P", "", " \"Lehert P\"." +7, Author, 275, 281, "Bets D", "", " \"Bets D\"." +8, Author, 284, 296, "Wulffel é MG", "", " \"Wulffel é MG\"." +9, Author, 299, 308, "Donker AJ", "", " \"Donker AJ\"." +10, Author, 311, 323, "Stehouwer CD", "", " \"Stehouwer CD\"." +77, Netherlands, 444, 455, "Netherlands", "", " ." +81, ObjectiveDescription, 660, 826, "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .", "", " \"We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .\"." +12, Metformin, 684, 707, "metformin hydrochloride", "", +13, Type2Diabetes, 792, 816, "type 2 diabetes mellitus", "", " ." +14, Type2Diabetes, 819, 822, "DM2", "", +15, NumberPatientsCT, 848, 851, "390", "", " \"390\"." +18, Precondition, 852, 881, "patients treated with insulin", "", " \"patients treated with insulin\"." +24, Insulin, 874, 881, "insulin", "", +17, Multicenter, 911, 922, "3 hospitals", "", " ." +16, Randomized, 928, 938, "randomized", "", " ." +86, Placebo, 941, 948, "placebo", "", +137, Duration, 997, 1008, "4 . 3 years", "", " \"4 . 3 years\"." +19, Metformin, 1018, 1041, "metformin hydrochloride", "", +20, DoseValue, 1044, 1047, "850", "", " \"850\"." +21, mg, 1048, 1050, "mg", "", " ." +22, Placebo, 1056, 1063, "placebo", "", " ." +23, Frequency, 1066, 1083, "1 - 3 times daily", "", " \"1 - 3 times daily\". \"1 - 3 times daily\"." +25, Insulin, 1099, 1106, "insulin", "", +144, EndPointDescription, 1159, 1214, "microvascular and macrovascular morbidity and mortality", "", +145, EndPointDescription, 1247, 1302, "microvascular and macrovascular morbidity and mortality", "", +146, EndPointDescription, 1265, 1302, "macrovascular morbidity and mortality", "", +26, HbA1c, 1361, 1380, "hemoglobin A ( 1c )", "", +27, HbA1c, 1383, 1393, "HbA ( 1c )", "", +52695, InsulinDose, 1398, 1417, "insulin requirement", "", +28, EndPointDescription, 1420, 1432, "lipid levels", "", +29, BloodPressure, 1435, 1449, "blood pressure", "", +30, BodyWeight, 1452, 1463, "body weight", "", +31, BMI, 1470, 1485, "body mass index", "", +32, Metformin, 1512, 1521, "Metformin", "", +52689, WeightGain, 1542, 1553, "weight gain", "", " ." +101, Mean, 1556, 1560, "mean", "", " . ." +102, WeightGain, 1561, 1572, "weight gain", "", +38, Reduction, 1577, 1583, "3 . 07", "", " \"3 . 07\"." +36, Kg, 1584, 1586, "kg", "", " ." +37, Kg, 1618, 1620, "kg", "", +105, PValueResValue, 1625, 1634, "P < . 001", "", " \"P < . 001\"." +106, Mean, 1667, 1671, "mean", "", " . ." +34, HbA1c, 1685, 1701, "HbA ( 1c ) level", "", " ." +40, Reduction, 1704, 1709, "0 . 4", "", " \"0 . 4\"." +39, Percentage, 1710, 1711, "%", "", " ." +41, ConfIntervalChangeValue, 1731, 1756, "95 % CI , 0 . 55 - 0 . 25", "", " \"95 % CI , 0 . 55 - 0 . 25\"." +42, PValueChangeValue, 1761, 1770, "P < . 001", "", " \"P < . 001\"." +154, InsulinDose, 1891, 1911, "insulin requirements", "", " . ." +114, Mean, 1914, 1918, "mean", "", " . ." +43, Reduction, 1931, 1938, "19 . 63", "", " \"19 . 63\"." +155, Int_Unit, 1939, 1941, "IU", "", " ." +156, Frequency, 1944, 1945, "d", "", +44, ConfIntervalChangeValue, 1948, 1975, "95 % CI , 24 . 91 - 14 . 36", "", " \"95 % CI , 24 . 91 - 14 . 36\"." +157, Int_Unit, 1976, 1978, "IU", "", +52694, Interval, 1981, 1982, "d", "", +45, PValueChangeValue, 1987, 1996, "P < . 001", "", " \"P < . 001\"." +46, Metformin, 2001, 2010, "Metformin", "", +60, EndPointDescription, 2146, 2169, "macrovascular end point", "", " . ." +126, AggregationMethod, 2172, 2184, "hazard ratio", "", " . ." +48, ResultMeasuredValue, 2187, 2193, "0 . 61", "", " \"0 . 61\"." +47, ConfIntervalResValue, 2196, 2221, "95 % CI , 0 . 40 - 0 . 94", "", " \"95 % CI , 0 . 40 - 0 . 94\"." +49, PValueResValue, 2224, 2232, "P = . 02", "", " \"P = . 02\"." +128, EndPointDescription, 2334, 2357, "macrovascular end point", "", +54, Metformin, 2414, 2423, "Metformin", "", +147, ConclusionComment, 2414, 2576, "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .", "", " \"Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .\"." +57, Insulin, 2435, 2442, "insulin", "", +55, Type2Diabetes, 2460, 2463, "DM2", "", +56, BodyWeight, 2475, 2486, "body weight", "", +52696, InsulinDose, 2512, 2532, "insulin requirements", "", +58, Metformin, 2577, 2586, "Metformin", "", +148, ConclusionComment, 2577, 2687, "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .", "", " \"Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .\"." +52697, ObservedResult, 2603, 2643, "reduce the risk of macrovascular disease", "", +59, EndPointDescription, 2622, 2643, "macrovascular disease", "", +138, Duration, 2674, 2685, "4 . 3 years", "", +149, ConclusionComment, 2688, 2858, "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .", "", " \"These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .\"." +61, Metformin, 2754, 2763, "metformin", "", +62, Insulin, 2800, 2807, "insulin", "", +63, Type2Diabetes, 2828, 2831, "DM2", "", +64, PMID, 2977, 2985, "19307526", "", " \"19307526\"." diff --git a/data/dm2 19307526_admin.n-triples b/data/dm2 19307526_admin.n-triples new file mode 100644 index 0000000..50aa635 --- /dev/null +++ b/data/dm2 19307526_admin.n-triples @@ -0,0 +1,134 @@ +# RDF export of group: Publication + . + "Publication " . + "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus ." . + "Kooy A" . + "2009" . + "Arch Intern Med ." . + "19307526" . + . + "de Jager J" . + "Lehert P" . + "Bets D" . + "Wulffel é MG" . + "Donker AJ" . + "Stehouwer CD" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) ." . + "390" . + "4 . 3 years" . + . + . + . + "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point ." . + . + . + . + . + . + . + "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years ." . + "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated ." . + . +# RDF export of group: Population + . + "Population " . + "patients treated with insulin" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint weight" . + . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint m" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm m" . + . + . + . + . + . + . + "Arm p" . + . + . + . +# RDF export of group: Intervention + . + "Intervention m" . + . + "1 - 3 times daily" . + . + . + "Intervention p" . + . + "1 - 3 times daily" . + . +# RDF export of group: Medication + . + "Medication m" . + . + "850" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome weight m" . + . + "P < . 001" . + "3 . 07" . + . + "Outcome hba1c m" . + . + "0 . 4" . + "P < . 001" . + "95 % CI , 0 . 55 - 0 . 25" . + . + "Outcome id m" . + . + "19 . 63" . + "P < . 001" . + "95 % CI , 24 . 91 - 14 . 36" . + . + "Outcome m m" . + . + "0 . 61" . + "P = . 02" . + "95 % CI , 0 . 40 - 0 . 94" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19307526_akramersunderbrink.annodb b/data/dm2 19307526_akramersunderbrink.annodb new file mode 100644 index 0000000..5546bfc --- /dev/null +++ b/data/dm2 19307526_akramersunderbrink.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23923, Journal, 0, 15, "Arch Intern Med", "", +28354, PublicationYear, 18, 22, "2009", "", +28357, Title, 101, 235, "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .", "", +28355, Metformin, 124, 133, "metformin", "", +28356, Type2Diabetes, 209, 233, "type 2 diabetes mellitus", "", +28358, Author, 236, 242, "Kooy A", "", +28359, Author, 251, 261, "de Jager J", "", +28360, Author, 264, 272, "Lehert P", "", +28361, Author, 275, 281, "Bets D", "", +28362, Author, 284, 296, "Wulffel é MG", "", +28363, Author, 299, 308, "Donker AJ", "", +28364, Author, 311, 323, "Stehouwer CD", "", +28365, Netherlands, 444, 455, "Netherlands", "", +28369, ObjectiveDescription, 660, 826, "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .", "", +28366, Metformin, 684, 707, "metformin hydrochloride", "", +28367, Type2Diabetes, 792, 816, "type 2 diabetes mellitus", "", +28368, Type2Diabetes, 819, 822, "DM2", "", +28370, NumberPatientsCT, 848, 851, "390", "", +28371, Insulin, 874, 881, "insulin", "", +28372, Multicenter, 882, 922, "in the outpatient clinics of 3 hospitals", "", +28373, Randomized, 928, 938, "randomized", "", +28374, Placebo, 941, 948, "placebo", "", +28428, Duration, 997, 1008, "4 . 3 years", "", +28375, Metformin, 1018, 1041, "metformin hydrochloride", "", +28376, DoseValue, 1044, 1047, "850", "", +28377, mg, 1048, 1050, "mg", "", +28378, Placebo, 1056, 1063, "placebo", "", +28379, Frequency, 1066, 1083, "1 - 3 times daily", "", +28380, Insulin, 1099, 1106, "insulin", "", +28437, EndPointDescription, 1159, 1214, "microvascular and macrovascular morbidity and mortality", "", +28438, EndPointDescription, 1247, 1302, "microvascular and macrovascular morbidity and mortality", "", +28439, EndPointDescription, 1265, 1302, "macrovascular morbidity and mortality", "", +28381, HbA1c, 1361, 1380, "hemoglobin A ( 1c )", "", +28382, HbA1c, 1383, 1393, "HbA ( 1c )", "", +28383, Insulin, 1398, 1405, "insulin", "", +28384, BloodPressure, 1435, 1449, "blood pressure", "", +28385, BodyWeight, 1452, 1463, "body weight", "", +28386, BMI, 1470, 1485, "body mass index", "", +28387, Metformin, 1512, 1521, "Metformin", "", +28388, WeightGain, 1542, 1553, "weight gain", "", +28389, Mean, 1556, 1560, "mean", "", +28390, WeightGain, 1561, 1572, "weight gain", "", +28391, ResultMeasuredValue, 1575, 1583, "- 3 . 07", "", +28392, Kg, 1584, 1586, "kg", "", +28407, Kg, 1618, 1620, "kg", "", +28393, PValueResValue, 1625, 1634, "P < . 001", "", +28394, Mean, 1667, 1671, "mean", "", +28395, HbA1c, 1685, 1701, "HbA ( 1c ) level", "", +28396, Reduction, 1704, 1709, "0 . 4", "", +28397, Percentage, 1710, 1711, "%", "", +28398, Percentage, 1712, 1728, "percentage point", "", +28399, ConfIntervalChangeValue, 1731, 1756, "95 % CI , 0 . 55 - 0 . 25", "", +28400, PValueChangeValue, 1761, 1770, "P < . 001", "", +28401, Insulin, 1891, 1898, "insulin", "", +28402, Mean, 1914, 1918, "mean", "", +28403, Reduction, 1931, 1938, "19 . 63", "", +28404, BioAndMedicalUnit, 1939, 1945, "IU / d", "", +28405, ConfIntervalChangeValue, 1948, 1982, "95 % CI , 24 . 91 - 14 . 36 IU / d", "", +28406, BioAndMedicalUnit, 1976, 1982, "IU / d", "", +28408, PValueChangeValue, 1987, 1996, "P < . 001", "", +28409, Metformin, 2001, 2010, "Metformin", "", +28410, EndPointDescription, 2146, 2169, "macrovascular end point", "", +28417, AggregationMethod, 2172, 2184, "hazard ratio", "", +28414, ResultMeasuredValue, 2187, 2193, "0 . 61", "", +28415, ConfIntervalResValue, 2196, 2221, "95 % CI , 0 . 40 - 0 . 94", "", +28416, PValueResValue, 2224, 2232, "P = . 02", "", +28418, AggregationMethod, 2298, 2320, "number needed to treat", "", +28419, EndPointDescription, 2324, 2357, "prevent 1 macrovascular end point", "", +28420, ResultMeasuredValue, 2362, 2368, "16 . 1", "", +28421, ConfIntervalResValue, 2371, 2395, "95 % CI , 9 . 2 - 66 . 6", "", +28422, Metformin, 2414, 2423, "Metformin", "", +28606, ConclusionComment, 2414, 2576, "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .", "", +28423, Insulin, 2435, 2442, "insulin", "", +28424, Type2Diabetes, 2460, 2463, "DM2", "", +28425, BodyWeight, 2475, 2486, "body weight", "", +28426, Insulin, 2512, 2519, "insulin", "", +28427, Metformin, 2577, 2586, "Metformin", "", +28607, ConclusionComment, 2577, 2687, "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .", "", +28432, EndPointDescription, 2614, 2643, "risk of macrovascular disease", "", +28430, Duration, 2674, 2685, "4 . 3 years", "", +28608, ConclusionComment, 2688, 2858, "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .", "", +28433, Metformin, 2754, 2763, "metformin", "", +28434, Insulin, 2800, 2807, "insulin", "", +28435, Type2Diabetes, 2828, 2831, "DM2", "", +28436, PMID, 2977, 2985, "19307526", "", diff --git a/data/dm2 19307526_akramersunderbrink.n-triples b/data/dm2 19307526_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19307526_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19307526_export.csv b/data/dm2 19307526_export.csv new file mode 100644 index 0000000..07ed89c --- /dev/null +++ b/data/dm2 19307526_export.csv @@ -0,0 +1,637 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +340, 1, 1, 1, 0, 4, 0, 4, "Arch" +340, 1, 2, 2, 5, 11, 5, 11, "Intern" +340, 1, 3, 3, 12, 15, 12, 15, "Med" +340, 1, 4, 4, 16, 17, 16, 17, "." +340, 2, 1, 5, 0, 4, 18, 22, "2009" +340, 2, 2, 6, 5, 8, 23, 26, "Mar" +340, 2, 3, 7, 9, 11, 27, 29, "23" +340, 2, 4, 8, 12, 13, 30, 31, ";" +340, 2, 5, 9, 14, 17, 32, 35, "169" +340, 2, 6, 10, 18, 19, 36, 37, "(" +340, 2, 7, 11, 20, 21, 38, 39, "6" +340, 2, 8, 12, 22, 23, 40, 41, ")" +340, 2, 9, 13, 24, 25, 42, 43, ":" +340, 2, 10, 14, 26, 29, 44, 47, "616" +340, 2, 11, 15, 30, 31, 48, 49, "-" +340, 2, 12, 16, 32, 34, 50, 52, "25" +340, 2, 13, 17, 35, 36, 53, 54, "." +340, 2, 14, 18, 37, 40, 55, 58, "doi" +340, 2, 15, 19, 41, 42, 59, 60, ":" +340, 2, 16, 20, 43, 45, 61, 63, "10" +340, 2, 17, 21, 46, 47, 64, 65, "." +340, 2, 18, 22, 48, 52, 66, 70, "1001" +340, 2, 19, 23, 53, 54, 71, 72, "/" +340, 2, 20, 24, 55, 68, 73, 86, "archinternmed" +340, 2, 21, 25, 69, 70, 87, 88, "." +340, 2, 22, 26, 71, 75, 89, 93, "2009" +340, 2, 23, 27, 76, 77, 94, 95, "." +340, 2, 24, 28, 78, 80, 96, 98, "20" +340, 2, 25, 29, 81, 82, 99, 100, "." +340, 3, 1, 30, 0, 4, 101, 105, "Long" +340, 3, 2, 31, 5, 6, 106, 107, "-" +340, 3, 3, 32, 7, 11, 108, 112, "term" +340, 3, 4, 33, 12, 19, 113, 120, "effects" +340, 3, 5, 34, 20, 22, 121, 123, "of" +340, 3, 6, 35, 23, 32, 124, 133, "metformin" +340, 3, 7, 36, 33, 35, 134, 136, "on" +340, 3, 8, 37, 36, 46, 137, 147, "metabolism" +340, 3, 9, 38, 47, 50, 148, 151, "and" +340, 3, 10, 39, 51, 64, 152, 165, "microvascular" +340, 3, 11, 40, 65, 68, 166, 169, "and" +340, 3, 12, 41, 69, 82, 170, 183, "macrovascular" +340, 3, 13, 42, 83, 90, 184, 191, "disease" +340, 3, 14, 43, 91, 93, 192, 194, "in" +340, 3, 15, 44, 94, 102, 195, 203, "patients" +340, 3, 16, 45, 103, 107, 204, 208, "with" +340, 3, 17, 46, 108, 112, 209, 213, "type" +340, 3, 18, 47, 113, 114, 214, 215, "2" +340, 3, 19, 48, 115, 123, 216, 224, "diabetes" +340, 3, 20, 49, 124, 132, 225, 233, "mellitus" +340, 3, 21, 50, 133, 134, 234, 235, "." +340, 4, 1, 51, 0, 4, 236, 240, "Kooy" +340, 4, 2, 52, 5, 6, 241, 242, "A" +340, 4, 3, 53, 7, 8, 243, 244, "(" +340, 4, 4, 54, 9, 10, 245, 246, "1" +340, 4, 5, 55, 11, 12, 247, 248, ")" +340, 4, 6, 56, 13, 14, 249, 250, "," +340, 4, 7, 57, 15, 17, 251, 253, "de" +340, 4, 8, 58, 18, 23, 254, 259, "Jager" +340, 4, 9, 59, 24, 25, 260, 261, "J" +340, 4, 10, 60, 26, 27, 262, 263, "," +340, 4, 11, 61, 28, 34, 264, 270, "Lehert" +340, 4, 12, 62, 35, 36, 271, 272, "P" +340, 4, 13, 63, 37, 38, 273, 274, "," +340, 4, 14, 64, 39, 43, 275, 279, "Bets" +340, 4, 15, 65, 44, 45, 280, 281, "D" +340, 4, 16, 66, 46, 47, 282, 283, "," +340, 4, 17, 67, 48, 55, 284, 291, "Wulffel" +340, 4, 18, 68, 56, 57, 292, 293, "é" +340, 4, 19, 69, 58, 60, 294, 296, "MG" +340, 4, 20, 70, 61, 62, 297, 298, "," +340, 4, 21, 71, 63, 69, 299, 305, "Donker" +340, 4, 22, 72, 70, 72, 306, 308, "AJ" +340, 4, 23, 73, 73, 74, 309, 310, "," +340, 4, 24, 74, 75, 84, 311, 320, "Stehouwer" +340, 4, 25, 75, 85, 87, 321, 323, "CD" +340, 4, 26, 76, 88, 89, 324, 325, "." +340, 5, 1, 77, 0, 6, 326, 332, "Author" +340, 5, 2, 78, 7, 18, 333, 344, "information" +340, 5, 3, 79, 19, 20, 345, 346, ":" +340, 5, 4, 80, 21, 22, 347, 348, "(" +340, 5, 5, 81, 23, 24, 349, 350, "1" +340, 5, 6, 82, 25, 26, 351, 352, ")" +340, 5, 7, 83, 27, 37, 353, 363, "Department" +340, 5, 8, 84, 38, 40, 364, 366, "of" +340, 5, 9, 85, 41, 49, 367, 375, "Internal" +340, 5, 10, 86, 50, 58, 376, 384, "Medicine" +340, 5, 11, 87, 59, 62, 385, 388, "and" +340, 5, 12, 88, 63, 71, 389, 397, "Bethesda" +340, 5, 13, 89, 72, 80, 398, 406, "Diabetes" +340, 5, 14, 90, 81, 89, 407, 415, "Research" +340, 5, 15, 91, 90, 96, 416, 422, "Center" +340, 5, 16, 92, 97, 98, 423, 424, "," +340, 5, 17, 93, 99, 101, 425, 427, "RA" +340, 5, 18, 94, 102, 111, 428, 437, "Hoogeveen" +340, 5, 19, 95, 112, 113, 438, 439, "," +340, 5, 20, 96, 114, 117, 440, 443, "the" +340, 5, 21, 97, 118, 129, 444, 455, "Netherlands" +340, 5, 22, 98, 130, 131, 456, 457, "." +340, 6, 1, 99, 0, 4, 458, 462, "kooy" +340, 6, 2, 100, 5, 6, 463, 464, "." +340, 6, 3, 101, 7, 8, 465, 466, "a" +340, 6, 4, 102, 9, 10, 467, 468, "@" +340, 6, 5, 103, 11, 19, 469, 477, "bethesda" +340, 6, 6, 104, 20, 21, 478, 479, "." +340, 6, 7, 105, 22, 24, 480, 482, "nl" +340, 6, 8, 106, 25, 32, 483, 490, "Comment" +340, 6, 9, 107, 33, 35, 491, 493, "in" +340, 6, 10, 108, 36, 39, 494, 497, "Ann" +340, 6, 11, 109, 40, 46, 498, 504, "Intern" +340, 6, 12, 110, 47, 50, 505, 508, "Med" +340, 6, 13, 111, 51, 52, 509, 510, "." +340, 7, 1, 112, 0, 4, 511, 515, "2009" +340, 7, 2, 113, 5, 8, 516, 519, "Jul" +340, 7, 3, 114, 9, 11, 520, 522, "21" +340, 7, 4, 115, 12, 13, 523, 524, ";" +340, 7, 5, 116, 14, 17, 525, 528, "151" +340, 7, 6, 117, 18, 19, 529, 530, "(" +340, 7, 7, 118, 20, 21, 531, 532, "2" +340, 7, 8, 119, 22, 23, 533, 534, ")" +340, 7, 9, 120, 24, 25, 535, 536, ":" +340, 7, 10, 121, 26, 29, 537, 540, "JC1" +340, 7, 11, 122, 30, 31, 541, 542, "-" +340, 7, 12, 123, 32, 34, 543, 545, "12" +340, 7, 13, 124, 35, 36, 546, 547, "." +340, 8, 1, 125, 0, 4, 548, 552, "Evid" +340, 8, 2, 126, 5, 10, 553, 558, "Based" +340, 8, 3, 127, 11, 14, 559, 562, "Med" +340, 8, 4, 128, 15, 16, 563, 564, "." +340, 9, 1, 129, 0, 4, 565, 569, "2009" +340, 9, 2, 130, 5, 8, 570, 573, "Oct" +340, 9, 3, 131, 9, 10, 574, 575, ";" +340, 9, 4, 132, 11, 13, 576, 578, "14" +340, 9, 5, 133, 14, 15, 579, 580, "(" +340, 9, 6, 134, 16, 17, 581, 582, "5" +340, 9, 7, 135, 18, 19, 583, 584, ")" +340, 9, 8, 136, 20, 21, 585, 586, ":" +340, 9, 9, 137, 22, 25, 587, 590, "139" +340, 9, 10, 138, 26, 27, 591, 592, "." +340, 10, 1, 139, 0, 11, 593, 604, "Republished" +340, 10, 2, 140, 12, 14, 605, 607, "in" +340, 10, 3, 141, 15, 18, 608, 611, "Ned" +340, 10, 4, 142, 19, 27, 612, 620, "Tijdschr" +340, 10, 5, 143, 28, 36, 621, 629, "Geneeskd" +340, 10, 6, 144, 37, 38, 630, 631, "." +340, 11, 1, 145, 0, 4, 632, 636, "2009" +340, 11, 2, 146, 5, 6, 637, 638, ";" +340, 11, 3, 147, 7, 10, 639, 642, "153" +340, 11, 4, 148, 11, 12, 643, 644, ":" +340, 11, 5, 149, 13, 14, 645, 646, "." +340, 12, 1, 150, 0, 10, 647, 657, "BACKGROUND" +340, 12, 2, 151, 11, 12, 658, 659, ":" +340, 12, 3, 152, 13, 15, 660, 662, "We" +340, 12, 4, 153, 16, 28, 663, 675, "investigated" +340, 12, 5, 154, 29, 36, 676, 683, "whether" +340, 12, 6, 155, 37, 46, 684, 693, "metformin" +340, 12, 7, 156, 47, 60, 694, 707, "hydrochloride" +340, 12, 8, 157, 61, 64, 708, 711, "has" +340, 12, 9, 158, 65, 74, 712, 721, "sustained" +340, 12, 10, 159, 75, 85, 722, 732, "beneficial" +340, 12, 11, 160, 86, 95, 733, 742, "metabolic" +340, 12, 12, 161, 96, 99, 743, 746, "and" +340, 12, 13, 162, 100, 101, 747, 748, "(" +340, 12, 14, 163, 102, 108, 749, 755, "cardio" +340, 12, 15, 164, 109, 110, 756, 757, ")" +340, 12, 16, 165, 111, 119, 758, 766, "vascular" +340, 12, 17, 166, 120, 127, 767, 774, "effects" +340, 12, 18, 167, 128, 130, 775, 777, "in" +340, 12, 19, 168, 131, 139, 778, 786, "patients" +340, 12, 20, 169, 140, 144, 787, 791, "with" +340, 12, 21, 170, 145, 149, 792, 796, "type" +340, 12, 22, 171, 150, 151, 797, 798, "2" +340, 12, 23, 172, 152, 160, 799, 807, "diabetes" +340, 12, 24, 173, 161, 169, 808, 816, "mellitus" +340, 12, 25, 174, 170, 171, 817, 818, "(" +340, 12, 26, 175, 172, 175, 819, 822, "DM2" +340, 12, 27, 176, 176, 177, 823, 824, ")" +340, 12, 28, 177, 178, 179, 825, 826, "." +340, 13, 1, 178, 0, 7, 827, 834, "METHODS" +340, 13, 2, 179, 8, 9, 835, 836, ":" +340, 13, 3, 180, 10, 12, 837, 839, "We" +340, 13, 4, 181, 13, 20, 840, 847, "studied" +340, 13, 5, 182, 21, 24, 848, 851, "390" +340, 13, 6, 183, 25, 33, 852, 860, "patients" +340, 13, 7, 184, 34, 41, 861, 868, "treated" +340, 13, 8, 185, 42, 46, 869, 873, "with" +340, 13, 9, 186, 47, 54, 874, 881, "insulin" +340, 13, 10, 187, 55, 57, 882, 884, "in" +340, 13, 11, 188, 58, 61, 885, 888, "the" +340, 13, 12, 189, 62, 72, 889, 899, "outpatient" +340, 13, 13, 190, 73, 80, 900, 907, "clinics" +340, 13, 14, 191, 81, 83, 908, 910, "of" +340, 13, 15, 192, 84, 85, 911, 912, "3" +340, 13, 16, 193, 86, 95, 913, 922, "hospitals" +340, 13, 17, 194, 96, 98, 923, 925, "in" +340, 13, 18, 195, 99, 100, 926, 927, "a" +340, 13, 19, 196, 101, 111, 928, 938, "randomized" +340, 13, 20, 197, 112, 113, 939, 940, "," +340, 13, 21, 198, 114, 121, 941, 948, "placebo" +340, 13, 22, 199, 122, 123, 949, 950, "-" +340, 13, 23, 200, 124, 134, 951, 961, "controlled" +340, 13, 24, 201, 135, 140, 962, 967, "trial" +340, 13, 25, 202, 141, 145, 968, 972, "with" +340, 13, 26, 203, 146, 147, 973, 974, "a" +340, 13, 27, 204, 148, 154, 975, 981, "follow" +340, 13, 28, 205, 155, 156, 982, 983, "-" +340, 13, 29, 206, 157, 159, 984, 986, "up" +340, 13, 30, 207, 160, 166, 987, 993, "period" +340, 13, 31, 208, 167, 169, 994, 996, "of" +340, 13, 32, 209, 170, 171, 997, 998, "4" +340, 13, 33, 210, 172, 173, 999, 1000, "." +340, 13, 34, 211, 174, 175, 1001, 1002, "3" +340, 13, 35, 212, 176, 181, 1003, 1008, "years" +340, 13, 36, 213, 182, 183, 1009, 1010, "." +340, 14, 1, 214, 0, 6, 1011, 1017, "Either" +340, 14, 2, 215, 7, 16, 1018, 1027, "metformin" +340, 14, 3, 216, 17, 30, 1028, 1041, "hydrochloride" +340, 14, 4, 217, 31, 32, 1042, 1043, "," +340, 14, 5, 218, 33, 36, 1044, 1047, "850" +340, 14, 6, 219, 37, 39, 1048, 1050, "mg" +340, 14, 7, 220, 40, 41, 1051, 1052, "," +340, 14, 8, 221, 42, 44, 1053, 1055, "or" +340, 14, 9, 222, 45, 52, 1056, 1063, "placebo" +340, 14, 10, 223, 53, 54, 1064, 1065, "(" +340, 14, 11, 224, 55, 56, 1066, 1067, "1" +340, 14, 12, 225, 57, 58, 1068, 1069, "-" +340, 14, 13, 226, 59, 60, 1070, 1071, "3" +340, 14, 14, 227, 61, 66, 1072, 1077, "times" +340, 14, 15, 228, 67, 72, 1078, 1083, "daily" +340, 14, 16, 229, 73, 74, 1084, 1085, ")" +340, 14, 17, 230, 75, 78, 1086, 1089, "was" +340, 14, 18, 231, 79, 84, 1090, 1095, "added" +340, 14, 19, 232, 85, 87, 1096, 1098, "to" +340, 14, 20, 233, 88, 95, 1099, 1106, "insulin" +340, 14, 21, 234, 96, 103, 1107, 1114, "therapy" +340, 14, 22, 235, 104, 105, 1115, 1116, "." +340, 15, 1, 236, 0, 3, 1117, 1120, "The" +340, 15, 2, 237, 4, 11, 1121, 1128, "primary" +340, 15, 3, 238, 12, 15, 1129, 1132, "end" +340, 15, 4, 239, 16, 21, 1133, 1138, "point" +340, 15, 5, 240, 22, 25, 1139, 1142, "was" +340, 15, 6, 241, 26, 28, 1143, 1145, "an" +340, 15, 7, 242, 29, 38, 1146, 1155, "aggregate" +340, 15, 8, 243, 39, 41, 1156, 1158, "of" +340, 15, 9, 244, 42, 55, 1159, 1172, "microvascular" +340, 15, 10, 245, 56, 59, 1173, 1176, "and" +340, 15, 11, 246, 60, 73, 1177, 1190, "macrovascular" +340, 15, 12, 247, 74, 83, 1191, 1200, "morbidity" +340, 15, 13, 248, 84, 87, 1201, 1204, "and" +340, 15, 14, 249, 88, 97, 1205, 1214, "mortality" +340, 15, 15, 250, 98, 99, 1215, 1216, "." +340, 16, 1, 251, 0, 3, 1217, 1220, "The" +340, 16, 2, 252, 4, 13, 1221, 1230, "secondary" +340, 16, 3, 253, 14, 17, 1231, 1234, "end" +340, 16, 4, 254, 18, 24, 1235, 1241, "points" +340, 16, 5, 255, 25, 29, 1242, 1246, "were" +340, 16, 6, 256, 30, 43, 1247, 1260, "microvascular" +340, 16, 7, 257, 44, 47, 1261, 1264, "and" +340, 16, 8, 258, 48, 61, 1265, 1278, "macrovascular" +340, 16, 9, 259, 62, 71, 1279, 1288, "morbidity" +340, 16, 10, 260, 72, 75, 1289, 1292, "and" +340, 16, 11, 261, 76, 85, 1293, 1302, "mortality" +340, 16, 12, 262, 86, 87, 1303, 1304, "," +340, 16, 13, 263, 88, 90, 1305, 1307, "as" +340, 16, 14, 264, 91, 99, 1308, 1316, "separate" +340, 16, 15, 265, 100, 109, 1317, 1326, "aggregate" +340, 16, 16, 266, 110, 116, 1327, 1333, "scores" +340, 16, 17, 267, 117, 118, 1334, 1335, "." +340, 17, 1, 268, 0, 2, 1336, 1338, "In" +340, 17, 2, 269, 3, 11, 1339, 1347, "addition" +340, 17, 3, 270, 12, 13, 1348, 1349, "," +340, 17, 4, 271, 14, 21, 1350, 1357, "effects" +340, 17, 5, 272, 22, 24, 1358, 1360, "on" +340, 17, 6, 273, 25, 35, 1361, 1371, "hemoglobin" +340, 17, 7, 274, 36, 37, 1372, 1373, "A" +340, 17, 8, 275, 38, 39, 1374, 1375, "(" +340, 17, 9, 276, 40, 42, 1376, 1378, "1c" +340, 17, 10, 277, 43, 44, 1379, 1380, ")" +340, 17, 11, 278, 45, 46, 1381, 1382, "(" +340, 17, 12, 279, 47, 50, 1383, 1386, "HbA" +340, 17, 13, 280, 51, 52, 1387, 1388, "(" +340, 17, 14, 281, 53, 55, 1389, 1391, "1c" +340, 17, 15, 282, 56, 57, 1392, 1393, ")" +340, 17, 16, 283, 58, 59, 1394, 1395, ")" +340, 17, 17, 284, 60, 61, 1396, 1397, "," +340, 17, 18, 285, 62, 69, 1398, 1405, "insulin" +340, 17, 19, 286, 70, 81, 1406, 1417, "requirement" +340, 17, 20, 287, 82, 83, 1418, 1419, "," +340, 17, 21, 288, 84, 89, 1420, 1425, "lipid" +340, 17, 22, 289, 90, 96, 1426, 1432, "levels" +340, 17, 23, 290, 97, 98, 1433, 1434, "," +340, 17, 24, 291, 99, 104, 1435, 1440, "blood" +340, 17, 25, 292, 105, 113, 1441, 1449, "pressure" +340, 17, 26, 293, 114, 115, 1450, 1451, "," +340, 17, 27, 294, 116, 120, 1452, 1456, "body" +340, 17, 28, 295, 121, 127, 1457, 1463, "weight" +340, 17, 29, 296, 128, 129, 1464, 1465, "," +340, 17, 30, 297, 130, 133, 1466, 1469, "and" +340, 17, 31, 298, 134, 138, 1470, 1474, "body" +340, 17, 32, 299, 139, 143, 1475, 1479, "mass" +340, 17, 33, 300, 144, 149, 1480, 1485, "index" +340, 17, 34, 301, 150, 154, 1486, 1490, "were" +340, 17, 35, 302, 155, 163, 1491, 1499, "analyzed" +340, 17, 36, 303, 164, 165, 1500, 1501, "." +340, 18, 1, 304, 0, 7, 1502, 1509, "RESULTS" +340, 18, 2, 305, 8, 9, 1510, 1511, ":" +340, 18, 3, 306, 10, 19, 1512, 1521, "Metformin" +340, 18, 4, 307, 20, 29, 1522, 1531, "treatment" +340, 18, 5, 308, 30, 39, 1532, 1541, "prevented" +340, 18, 6, 309, 40, 46, 1542, 1548, "weight" +340, 18, 7, 310, 47, 51, 1549, 1553, "gain" +340, 18, 8, 311, 52, 53, 1554, 1555, "(" +340, 18, 9, 312, 54, 58, 1556, 1560, "mean" +340, 18, 10, 313, 59, 65, 1561, 1567, "weight" +340, 18, 11, 314, 66, 70, 1568, 1572, "gain" +340, 18, 12, 315, 71, 72, 1573, 1574, "," +340, 18, 13, 316, 73, 74, 1575, 1576, "-" +340, 18, 14, 317, 75, 76, 1577, 1578, "3" +340, 18, 15, 318, 77, 78, 1579, 1580, "." +340, 18, 16, 319, 79, 81, 1581, 1583, "07" +340, 18, 17, 320, 82, 84, 1584, 1586, "kg" +340, 18, 18, 321, 85, 86, 1587, 1588, "[" +340, 18, 19, 322, 87, 92, 1589, 1594, "range" +340, 18, 20, 323, 93, 94, 1595, 1596, "," +340, 18, 21, 324, 95, 96, 1597, 1598, "-" +340, 18, 22, 325, 97, 98, 1599, 1600, "3" +340, 18, 23, 326, 99, 100, 1601, 1602, "." +340, 18, 24, 327, 101, 103, 1603, 1605, "85" +340, 18, 25, 328, 104, 106, 1606, 1608, "to" +340, 18, 26, 329, 107, 108, 1609, 1610, "-" +340, 18, 27, 330, 109, 110, 1611, 1612, "2" +340, 18, 28, 331, 111, 112, 1613, 1614, "." +340, 18, 29, 332, 113, 115, 1615, 1617, "28" +340, 18, 30, 333, 116, 118, 1618, 1620, "kg" +340, 18, 31, 334, 119, 120, 1621, 1622, "]" +340, 18, 32, 335, 121, 122, 1623, 1624, ";" +340, 18, 33, 336, 123, 124, 1625, 1626, "P" +340, 18, 34, 337, 125, 126, 1627, 1628, "<" +340, 18, 35, 338, 127, 128, 1629, 1630, "." +340, 18, 36, 339, 129, 132, 1631, 1634, "001" +340, 18, 37, 340, 133, 134, 1635, 1636, ")" +340, 18, 38, 341, 135, 136, 1637, 1638, "," +340, 18, 39, 342, 137, 145, 1639, 1647, "improved" +340, 18, 40, 343, 146, 154, 1648, 1656, "glycemic" +340, 18, 41, 344, 155, 162, 1657, 1664, "control" +340, 18, 42, 345, 163, 164, 1665, 1666, "(" +340, 18, 43, 346, 165, 169, 1667, 1671, "mean" +340, 18, 44, 347, 170, 179, 1672, 1681, "reduction" +340, 18, 45, 348, 180, 182, 1682, 1684, "in" +340, 18, 46, 349, 183, 186, 1685, 1688, "HbA" +340, 18, 47, 350, 187, 188, 1689, 1690, "(" +340, 18, 48, 351, 189, 191, 1691, 1693, "1c" +340, 18, 49, 352, 192, 193, 1694, 1695, ")" +340, 18, 50, 353, 194, 199, 1696, 1701, "level" +340, 18, 51, 354, 200, 201, 1702, 1703, "," +340, 18, 52, 355, 202, 203, 1704, 1705, "0" +340, 18, 53, 356, 204, 205, 1706, 1707, "." +340, 18, 54, 357, 206, 207, 1708, 1709, "4" +340, 18, 55, 358, 208, 209, 1710, 1711, "%" +340, 18, 56, 359, 210, 220, 1712, 1722, "percentage" +340, 18, 57, 360, 221, 226, 1723, 1728, "point" +340, 18, 58, 361, 227, 228, 1729, 1730, "[" +340, 18, 59, 362, 229, 231, 1731, 1733, "95" +340, 18, 60, 363, 232, 233, 1734, 1735, "%" +340, 18, 61, 364, 234, 236, 1736, 1738, "CI" +340, 18, 62, 365, 237, 238, 1739, 1740, "," +340, 18, 63, 366, 239, 240, 1741, 1742, "0" +340, 18, 64, 367, 241, 242, 1743, 1744, "." +340, 18, 65, 368, 243, 245, 1745, 1747, "55" +340, 18, 66, 369, 246, 247, 1748, 1749, "-" +340, 18, 67, 370, 248, 249, 1750, 1751, "0" +340, 18, 68, 371, 250, 251, 1752, 1753, "." +340, 18, 69, 372, 252, 254, 1754, 1756, "25" +340, 18, 70, 373, 255, 256, 1757, 1758, "]" +340, 18, 71, 374, 257, 258, 1759, 1760, ";" +340, 18, 72, 375, 259, 260, 1761, 1762, "P" +340, 18, 73, 376, 261, 262, 1763, 1764, "<" +340, 18, 74, 377, 263, 264, 1765, 1766, "." +340, 18, 75, 378, 265, 268, 1767, 1770, "001" +340, 18, 76, 379, 269, 270, 1771, 1772, ")" +340, 18, 77, 380, 271, 272, 1773, 1774, "(" +340, 18, 78, 381, 273, 278, 1775, 1780, "where" +340, 18, 79, 382, 279, 281, 1781, 1783, "CI" +340, 18, 80, 383, 282, 291, 1784, 1793, "indicates" +340, 18, 81, 384, 292, 302, 1794, 1804, "confidence" +340, 18, 82, 385, 303, 311, 1805, 1813, "interval" +340, 18, 83, 386, 312, 313, 1814, 1815, ")" +340, 18, 84, 387, 314, 315, 1816, 1817, "," +340, 18, 85, 388, 316, 323, 1818, 1825, "despite" +340, 18, 86, 389, 324, 327, 1826, 1829, "the" +340, 18, 87, 390, 328, 331, 1830, 1833, "aim" +340, 18, 88, 391, 332, 334, 1834, 1836, "of" +340, 18, 89, 392, 335, 342, 1837, 1844, "similar" +340, 18, 90, 393, 343, 351, 1845, 1853, "glycemic" +340, 18, 91, 394, 352, 359, 1854, 1861, "control" +340, 18, 92, 395, 360, 362, 1862, 1864, "in" +340, 18, 93, 396, 363, 367, 1865, 1869, "both" +340, 18, 94, 397, 368, 374, 1870, 1876, "groups" +340, 18, 95, 398, 375, 376, 1877, 1878, "," +340, 18, 96, 399, 377, 380, 1879, 1882, "and" +340, 18, 97, 400, 381, 388, 1883, 1890, "reduced" +340, 18, 98, 401, 389, 396, 1891, 1898, "insulin" +340, 18, 99, 402, 397, 409, 1899, 1911, "requirements" +340, 18, 100, 403, 410, 411, 1912, 1913, "(" +340, 18, 101, 404, 412, 416, 1914, 1918, "mean" +340, 18, 102, 405, 417, 426, 1919, 1928, "reduction" +340, 18, 103, 406, 427, 428, 1929, 1930, "," +340, 18, 104, 407, 429, 431, 1931, 1933, "19" +340, 18, 105, 408, 432, 433, 1934, 1935, "." +340, 18, 106, 409, 434, 436, 1936, 1938, "63" +340, 18, 107, 410, 437, 439, 1939, 1941, "IU" +340, 18, 108, 411, 440, 441, 1942, 1943, "/" +340, 18, 109, 412, 442, 443, 1944, 1945, "d" +340, 18, 110, 413, 444, 445, 1946, 1947, "[" +340, 18, 111, 414, 446, 448, 1948, 1950, "95" +340, 18, 112, 415, 449, 450, 1951, 1952, "%" +340, 18, 113, 416, 451, 453, 1953, 1955, "CI" +340, 18, 114, 417, 454, 455, 1956, 1957, "," +340, 18, 115, 418, 456, 458, 1958, 1960, "24" +340, 18, 116, 419, 459, 460, 1961, 1962, "." +340, 18, 117, 420, 461, 463, 1963, 1965, "91" +340, 18, 118, 421, 464, 465, 1966, 1967, "-" +340, 18, 119, 422, 466, 468, 1968, 1970, "14" +340, 18, 120, 423, 469, 470, 1971, 1972, "." +340, 18, 121, 424, 471, 473, 1973, 1975, "36" +340, 18, 122, 425, 474, 476, 1976, 1978, "IU" +340, 18, 123, 426, 477, 478, 1979, 1980, "/" +340, 18, 124, 427, 479, 480, 1981, 1982, "d" +340, 18, 125, 428, 481, 482, 1983, 1984, "]" +340, 18, 126, 429, 483, 484, 1985, 1986, ";" +340, 18, 127, 430, 485, 486, 1987, 1988, "P" +340, 18, 128, 431, 487, 488, 1989, 1990, "<" +340, 18, 129, 432, 489, 490, 1991, 1992, "." +340, 18, 130, 433, 491, 494, 1993, 1996, "001" +340, 18, 131, 434, 495, 496, 1997, 1998, ")" +340, 18, 132, 435, 497, 498, 1999, 2000, "." +340, 19, 1, 436, 0, 9, 2001, 2010, "Metformin" +340, 19, 2, 437, 10, 13, 2011, 2014, "was" +340, 19, 3, 438, 14, 17, 2015, 2018, "not" +340, 19, 4, 439, 18, 28, 2019, 2029, "associated" +340, 19, 5, 440, 29, 33, 2030, 2034, "with" +340, 19, 6, 441, 34, 36, 2035, 2037, "an" +340, 19, 7, 442, 37, 48, 2038, 2049, "improvement" +340, 19, 8, 443, 49, 51, 2050, 2052, "in" +340, 19, 9, 444, 52, 55, 2053, 2056, "the" +340, 19, 10, 445, 56, 63, 2057, 2064, "primary" +340, 19, 11, 446, 64, 67, 2065, 2068, "end" +340, 19, 12, 447, 68, 73, 2069, 2074, "point" +340, 19, 13, 448, 74, 75, 2075, 2076, "." +340, 20, 1, 449, 0, 2, 2077, 2079, "It" +340, 20, 2, 450, 3, 6, 2080, 2083, "was" +340, 20, 3, 451, 7, 8, 2084, 2085, "," +340, 20, 4, 452, 9, 16, 2086, 2093, "however" +340, 20, 5, 453, 17, 18, 2094, 2095, "," +340, 20, 6, 454, 19, 29, 2096, 2106, "associated" +340, 20, 7, 455, 30, 34, 2107, 2111, "with" +340, 20, 8, 456, 35, 37, 2112, 2114, "an" +340, 20, 9, 457, 38, 49, 2115, 2126, "improvement" +340, 20, 10, 458, 50, 52, 2127, 2129, "in" +340, 20, 11, 459, 53, 56, 2130, 2133, "the" +340, 20, 12, 460, 57, 66, 2134, 2143, "secondary" +340, 20, 13, 461, 67, 68, 2144, 2145, "," +340, 20, 14, 462, 69, 82, 2146, 2159, "macrovascular" +340, 20, 15, 463, 83, 86, 2160, 2163, "end" +340, 20, 16, 464, 87, 92, 2164, 2169, "point" +340, 20, 17, 465, 93, 94, 2170, 2171, "(" +340, 20, 18, 466, 95, 101, 2172, 2178, "hazard" +340, 20, 19, 467, 102, 107, 2179, 2184, "ratio" +340, 20, 20, 468, 108, 109, 2185, 2186, "," +340, 20, 21, 469, 110, 111, 2187, 2188, "0" +340, 20, 22, 470, 112, 113, 2189, 2190, "." +340, 20, 23, 471, 114, 116, 2191, 2193, "61" +340, 20, 24, 472, 117, 118, 2194, 2195, "(" +340, 20, 25, 473, 119, 121, 2196, 2198, "95" +340, 20, 26, 474, 122, 123, 2199, 2200, "%" +340, 20, 27, 475, 124, 126, 2201, 2203, "CI" +340, 20, 28, 476, 127, 128, 2204, 2205, "," +340, 20, 29, 477, 129, 130, 2206, 2207, "0" +340, 20, 30, 478, 131, 132, 2208, 2209, "." +340, 20, 31, 479, 133, 135, 2210, 2212, "40" +340, 20, 32, 480, 136, 137, 2213, 2214, "-" +340, 20, 33, 481, 138, 139, 2215, 2216, "0" +340, 20, 34, 482, 140, 141, 2217, 2218, "." +340, 20, 35, 483, 142, 144, 2219, 2221, "94" +340, 20, 36, 484, 145, 146, 2222, 2223, ";" +340, 20, 37, 485, 147, 148, 2224, 2225, "P" +340, 20, 38, 486, 149, 150, 2226, 2227, "=" +340, 20, 39, 487, 151, 152, 2228, 2229, "." +340, 20, 40, 488, 153, 155, 2230, 2232, "02" +340, 20, 41, 489, 156, 157, 2233, 2234, ")" +340, 20, 42, 490, 158, 159, 2235, 2236, "," +340, 20, 43, 491, 160, 165, 2237, 2242, "which" +340, 20, 44, 492, 166, 169, 2243, 2246, "was" +340, 20, 45, 493, 170, 176, 2247, 2253, "partly" +340, 20, 46, 494, 177, 186, 2254, 2263, "explained" +340, 20, 47, 495, 187, 189, 2264, 2266, "by" +340, 20, 48, 496, 190, 193, 2267, 2270, "the" +340, 20, 49, 497, 194, 204, 2271, 2281, "difference" +340, 20, 50, 498, 205, 207, 2282, 2284, "in" +340, 20, 51, 499, 208, 214, 2285, 2291, "weight" +340, 20, 52, 500, 215, 216, 2292, 2293, "." +340, 21, 1, 501, 0, 3, 2294, 2297, "The" +340, 21, 2, 502, 4, 10, 2298, 2304, "number" +340, 21, 3, 503, 11, 17, 2305, 2311, "needed" +340, 21, 4, 504, 18, 20, 2312, 2314, "to" +340, 21, 5, 505, 21, 26, 2315, 2320, "treat" +340, 21, 6, 506, 27, 29, 2321, 2323, "to" +340, 21, 7, 507, 30, 37, 2324, 2331, "prevent" +340, 21, 8, 508, 38, 39, 2332, 2333, "1" +340, 21, 9, 509, 40, 53, 2334, 2347, "macrovascular" +340, 21, 10, 510, 54, 57, 2348, 2351, "end" +340, 21, 11, 511, 58, 63, 2352, 2357, "point" +340, 21, 12, 512, 64, 67, 2358, 2361, "was" +340, 21, 13, 513, 68, 70, 2362, 2364, "16" +340, 21, 14, 514, 71, 72, 2365, 2366, "." +340, 21, 15, 515, 73, 74, 2367, 2368, "1" +340, 21, 16, 516, 75, 76, 2369, 2370, "(" +340, 21, 17, 517, 77, 79, 2371, 2373, "95" +340, 21, 18, 518, 80, 81, 2374, 2375, "%" +340, 21, 19, 519, 82, 84, 2376, 2378, "CI" +340, 21, 20, 520, 85, 86, 2379, 2380, "," +340, 21, 21, 521, 87, 88, 2381, 2382, "9" +340, 21, 22, 522, 89, 90, 2383, 2384, "." +340, 21, 23, 523, 91, 92, 2385, 2386, "2" +340, 21, 24, 524, 93, 94, 2387, 2388, "-" +340, 21, 25, 525, 95, 97, 2389, 2391, "66" +340, 21, 26, 526, 98, 99, 2392, 2393, "." +340, 21, 27, 527, 100, 101, 2394, 2395, "6" +340, 21, 28, 528, 102, 103, 2396, 2397, ")" +340, 21, 29, 529, 104, 105, 2398, 2399, "." +340, 22, 1, 530, 0, 11, 2400, 2411, "CONCLUSIONS" +340, 22, 2, 531, 12, 13, 2412, 2413, ":" +340, 22, 3, 532, 14, 23, 2414, 2423, "Metformin" +340, 22, 4, 533, 24, 25, 2424, 2425, "," +340, 22, 5, 534, 26, 31, 2426, 2431, "added" +340, 22, 6, 535, 32, 34, 2432, 2434, "to" +340, 22, 7, 536, 35, 42, 2435, 2442, "insulin" +340, 22, 8, 537, 43, 45, 2443, 2445, "in" +340, 22, 9, 538, 46, 54, 2446, 2454, "patients" +340, 22, 10, 539, 55, 59, 2455, 2459, "with" +340, 22, 11, 540, 60, 63, 2460, 2463, "DM2" +340, 22, 12, 541, 64, 65, 2464, 2465, "," +340, 22, 13, 542, 66, 74, 2466, 2474, "improved" +340, 22, 14, 543, 75, 79, 2475, 2479, "body" +340, 22, 15, 544, 80, 86, 2480, 2486, "weight" +340, 22, 16, 545, 87, 88, 2487, 2488, "," +340, 22, 17, 546, 89, 97, 2489, 2497, "glycemic" +340, 22, 18, 547, 98, 105, 2498, 2505, "control" +340, 22, 19, 548, 106, 107, 2506, 2507, "," +340, 22, 20, 549, 108, 111, 2508, 2511, "and" +340, 22, 21, 550, 112, 119, 2512, 2519, "insulin" +340, 22, 22, 551, 120, 132, 2520, 2532, "requirements" +340, 22, 23, 552, 133, 136, 2533, 2536, "but" +340, 22, 24, 553, 137, 140, 2537, 2540, "did" +340, 22, 25, 554, 141, 144, 2541, 2544, "not" +340, 22, 26, 555, 145, 152, 2545, 2552, "improve" +340, 22, 27, 556, 153, 156, 2553, 2556, "the" +340, 22, 28, 557, 157, 164, 2557, 2564, "primary" +340, 22, 29, 558, 165, 168, 2565, 2568, "end" +340, 22, 30, 559, 169, 174, 2569, 2574, "point" +340, 22, 31, 560, 175, 176, 2575, 2576, "." +340, 23, 1, 561, 0, 9, 2577, 2586, "Metformin" +340, 23, 2, 562, 10, 13, 2587, 2590, "did" +340, 23, 3, 563, 14, 15, 2591, 2592, "," +340, 23, 4, 564, 16, 23, 2593, 2600, "however" +340, 23, 5, 565, 24, 25, 2601, 2602, "," +340, 23, 6, 566, 26, 32, 2603, 2609, "reduce" +340, 23, 7, 567, 33, 36, 2610, 2613, "the" +340, 23, 8, 568, 37, 41, 2614, 2618, "risk" +340, 23, 9, 569, 42, 44, 2619, 2621, "of" +340, 23, 10, 570, 45, 58, 2622, 2635, "macrovascular" +340, 23, 11, 571, 59, 66, 2636, 2643, "disease" +340, 23, 12, 572, 67, 72, 2644, 2649, "after" +340, 23, 13, 573, 73, 74, 2650, 2651, "a" +340, 23, 14, 574, 75, 81, 2652, 2658, "follow" +340, 23, 15, 575, 82, 83, 2659, 2660, "-" +340, 23, 16, 576, 84, 86, 2661, 2663, "up" +340, 23, 17, 577, 87, 93, 2664, 2670, "period" +340, 23, 18, 578, 94, 96, 2671, 2673, "of" +340, 23, 19, 579, 97, 98, 2674, 2675, "4" +340, 23, 20, 580, 99, 100, 2676, 2677, "." +340, 23, 21, 581, 101, 102, 2678, 2679, "3" +340, 23, 22, 582, 103, 108, 2680, 2685, "years" +340, 23, 23, 583, 109, 110, 2686, 2687, "." +340, 24, 1, 584, 0, 5, 2688, 2693, "These" +340, 24, 2, 585, 6, 15, 2694, 2703, "sustained" +340, 24, 3, 586, 16, 26, 2704, 2714, "beneficial" +340, 24, 4, 587, 27, 34, 2715, 2722, "effects" +340, 24, 5, 588, 35, 42, 2723, 2730, "support" +340, 24, 6, 589, 43, 46, 2731, 2734, "the" +340, 24, 7, 590, 47, 53, 2735, 2741, "policy" +340, 24, 8, 591, 54, 56, 2742, 2744, "to" +340, 24, 9, 592, 57, 65, 2745, 2753, "continue" +340, 24, 10, 593, 66, 75, 2754, 2763, "metformin" +340, 24, 11, 594, 76, 85, 2764, 2773, "treatment" +340, 24, 12, 595, 86, 91, 2774, 2779, "after" +340, 24, 13, 596, 92, 95, 2780, 2783, "the" +340, 24, 14, 597, 96, 108, 2784, 2796, "introduction" +340, 24, 15, 598, 109, 111, 2797, 2799, "of" +340, 24, 16, 599, 112, 119, 2800, 2807, "insulin" +340, 24, 17, 600, 120, 122, 2808, 2810, "in" +340, 24, 18, 601, 123, 126, 2811, 2814, "any" +340, 24, 19, 602, 127, 134, 2815, 2822, "patient" +340, 24, 20, 603, 135, 139, 2823, 2827, "with" +340, 24, 21, 604, 140, 143, 2828, 2831, "DM2" +340, 24, 22, 605, 144, 145, 2832, 2833, "," +340, 24, 23, 606, 146, 152, 2834, 2840, "unless" +340, 24, 24, 607, 153, 168, 2841, 2856, "contraindicated" +340, 24, 25, 608, 169, 170, 2857, 2858, "." +340, 25, 1, 609, 0, 5, 2859, 2864, "Trial" +340, 25, 2, 610, 6, 18, 2865, 2877, "Registration" +340, 25, 3, 611, 19, 33, 2878, 2892, "ClinicalTrials" +340, 25, 4, 612, 34, 35, 2893, 2894, "." +340, 25, 5, 613, 36, 39, 2895, 2898, "gov" +340, 25, 6, 614, 40, 50, 2899, 2909, "Identifier" +340, 25, 7, 615, 51, 52, 2910, 2911, ":" +340, 25, 8, 616, 53, 64, 2912, 2923, "NCT00375388" +340, 25, 9, 617, 65, 66, 2924, 2925, "." +340, 26, 1, 618, 0, 3, 2926, 2929, "DOI" +340, 26, 2, 619, 4, 5, 2930, 2931, ":" +340, 26, 3, 620, 6, 8, 2932, 2934, "10" +340, 26, 4, 621, 9, 10, 2935, 2936, "." +340, 26, 5, 622, 11, 15, 2937, 2941, "1001" +340, 26, 6, 623, 16, 17, 2942, 2943, "/" +340, 26, 7, 624, 18, 31, 2944, 2957, "archinternmed" +340, 26, 8, 625, 32, 33, 2958, 2959, "." +340, 26, 9, 626, 34, 38, 2960, 2964, "2009" +340, 26, 10, 627, 39, 40, 2965, 2966, "." +340, 26, 11, 628, 41, 43, 2967, 2969, "20" +340, 26, 12, 629, 44, 48, 2970, 2974, "PMID" +340, 26, 13, 630, 49, 50, 2975, 2976, ":" +340, 26, 14, 631, 51, 59, 2977, 2985, "19307526" +340, 26, 15, 632, 60, 61, 2986, 2987, "[" +340, 26, 16, 633, 62, 69, 2988, 2995, "Indexed" +340, 26, 17, 634, 70, 73, 2996, 2999, "for" +340, 26, 18, 635, 74, 81, 3000, 3007, "MEDLINE" +340, 26, 19, 636, 82, 83, 3008, 3009, "]" diff --git a/data/dm2 19307526_kwoodley.annodb b/data/dm2 19307526_kwoodley.annodb new file mode 100644 index 0000000..b54a826 --- /dev/null +++ b/data/dm2 19307526_kwoodley.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8476, Journal, 0, 15, "Arch Intern Med", "", +8477, PublicationYear, 18, 22, "2009", "", +36886, Title, 101, 235, "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .", "", +8478, Metformin, 124, 133, "metformin", "", +8479, Type2Diabetes, 209, 233, "type 2 diabetes mellitus", "", +8481, Author, 236, 242, "Kooy A", "", +8482, Author, 251, 261, "de Jager J", "", +8483, Author, 264, 272, "Lehert P", "", +8484, Author, 275, 281, "Bets D", "", +8485, Author, 284, 296, "Wulffel é MG", "", +8486, Author, 299, 308, "Donker AJ", "", +8487, Author, 311, 323, "Stehouwer CD", "", +8488, Netherlands, 440, 455, "the Netherlands", "", +36887, ObjectiveDescription, 660, 826, "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .", "", +8489, Metformin, 684, 707, "metformin hydrochloride", "", +8490, Type2Diabetes, 792, 816, "type 2 diabetes mellitus", "", +8491, Type2Diabetes, 819, 822, "DM2", "", +8493, NumberPatientsCT, 848, 851, "390", "", +8497, Precondition, 852, 881, "patients treated with insulin", "", +8503, Insulin, 874, 881, "insulin", "", +8496, Multicenter, 911, 922, "3 hospitals", "", +8494, Randomized, 928, 938, "randomized", "", +36888, Placebo, 941, 948, "placebo", "", +8498, Metformin, 1018, 1041, "metformin hydrochloride", "", +8499, DoseValue, 1044, 1047, "850", "", +8500, mg, 1048, 1050, "mg", "", +8501, Placebo, 1056, 1063, "placebo", "", +8502, Frequency, 1066, 1083, "1 - 3 times daily", "", +8504, Insulin, 1099, 1106, "insulin", "", +8505, HbA1c, 1361, 1380, "hemoglobin A ( 1c )", "", +8506, HbA1c, 1383, 1393, "HbA ( 1c )", "", +36889, InsulinDose, 1398, 1417, "insulin requirement", "", +8508, EndPointDescription, 1420, 1432, "lipid levels", "", +8509, BloodPressure, 1435, 1449, "blood pressure", "", +8510, BodyWeight, 1452, 1463, "body weight", "", +8512, BMI, 1470, 1485, "body mass index", "", +8513, Metformin, 1512, 1521, "Metformin", "", +8514, BodyWeight, 1542, 1548, "weight", "", +8521, Reduction, 1577, 1583, "3 . 07", "", +8519, Kg, 1584, 1586, "kg", "", +8520, Kg, 1618, 1620, "kg", "", +8518, PValueChangeValue, 1625, 1634, "P < . 001", "", +8516, HbA1c, 1685, 1701, "HbA ( 1c ) level", "", +8523, Reduction, 1704, 1709, "0 . 4", "", +8522, Percentage, 1710, 1711, "%", "", +8524, ConfIntervalChangeValue, 1731, 1756, "95 % CI , 0 . 55 - 0 . 25", "", +8525, PValueChangeValue, 1761, 1770, "P < . 001", "", +36890, InsulinDose, 1891, 1911, "insulin requirements", "", +8526, Reduction, 1931, 1938, "19 . 63", "", +36891, Int_Unit, 1939, 1941, "IU", "", +36892, Frequency, 1944, 1945, "d", "", +8529, ConfIntervalChangeValue, 1948, 1982, "95 % CI , 24 . 91 - 14 . 36 IU / d", "", +36893, Int_Unit, 1976, 1978, "IU", "", +36894, Frequency, 1981, 1982, "d", "", +8530, PValueChangeValue, 1987, 1996, "P < . 001", "", +8532, Metformin, 2001, 2010, "Metformin", "", +8550, EndPointDescription, 2146, 2169, "macrovascular end point", "adverse effect", +8535, ResultMeasuredValue, 2187, 2193, "0 . 61", "", +8534, ConfIntervalResValue, 2196, 2221, "95 % CI , 0 . 40 - 0 . 94", "", +8536, PValueResValue, 2224, 2232, "P = . 02", "", +8537, ObservedResult, 2237, 2291, "which was partly explained by the difference in weight", "", +8538, SubGroupDescription, 2294, 2357, "The number needed to treat to prevent 1 macrovascular end point", "", +8539, NumberAffected, 2362, 2368, "16 . 1", "", +8540, ConfIntervalNumAffected, 2371, 2395, "95 % CI , 9 . 2 - 66 . 6", "", +36896, ConclusionComment, 2414, 2576, "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .", "", +8541, Metformin, 2414, 2423, "Metformin", "", +8544, Insulin, 2435, 2442, "insulin", "", +8542, Type2Diabetes, 2460, 2463, "DM2", "", +8543, BodyWeight, 2475, 2486, "body weight", "", +36895, InsulinDose, 2512, 2532, "insulin requirements", "", +36897, ConclusionComment, 2577, 2687, "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .", "", +8547, Metformin, 2577, 2586, "Metformin", "", +8549, EndPointDescription, 2622, 2643, "macrovascular disease", "", +36898, ConclusionComment, 2688, 2858, "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .", "", +8561, Metformin, 2754, 2763, "metformin", "", +8562, Insulin, 2800, 2807, "insulin", "", +8563, Type2Diabetes, 2828, 2831, "DM2", "", +8564, PMID, 2977, 2985, "19307526", "", diff --git a/data/dm2 19307526_kwoodley.n-triples b/data/dm2 19307526_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19307526_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19336625 copy_admin.annodb b/data/dm2 19336625 copy_admin.annodb new file mode 100644 index 0000000..8ae9159 --- /dev/null +++ b/data/dm2 19336625 copy_admin.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2009", "", " \"2009\"." +114, Title, 101, 348, "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .", "", " \"DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .\"." +52921, Lispro75/25, 128, 154, "lispro mix 75 / 25 insulin", "", +6, Duration, 182, 191, "24 - week", "", " \"24 - week\"." +52922, Lispro75/25, 225, 251, "insulin lispro mix 75 / 25", "", +3, InsulinGlargine, 259, 275, "insulin glargine", "", +4, OralAntidiabeticAgent, 285, 313, "oral antihyperglycemic drugs", "", +5, Type2Diabetes, 331, 346, "type 2 diabetes", "", " ." +7, Author, 349, 356, "Buse JB", "", " \"Buse JB\"." +8, Author, 365, 381, "Wolffenbuttel BH", "", " \"Wolffenbuttel BH\"." +9, Author, 384, 393, "Herman WH", "", " \"Herman WH\"." +10, Author, 396, 408, "Shemonsky NK", "", " \"Shemonsky NK\"." +11, Author, 411, 419, "Jiang HH", "", " \"Jiang HH\"." +12, Author, 422, 433, "Fahrbach JL", "", " \"Fahrbach JL\"." +13, Author, 436, 452, "Scism - Bacon JL", "", " \"Scism - Bacon JL\"." +14, Author, 455, 464, "Martin SA", "", " \"Martin SA\"." +15, USA, 628, 631, "USA", "", " ." +206, ObjectiveDescription, 670, 818, "To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes .", "", " \"To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes .\"." +16, Insulin, 708, 715, "insulin", "", +18, Ethnicity, 766, 784, "ethnically diverse", "", " . ." +17, Type2Diabetes, 801, 816, "type 2 diabetes", "", +19, Randomized, 914, 924, "randomized", "", " ." +20, Frequency, 930, 943, "twice - daily", "", " \"twice - daily\"." +52923, Lispro75/25, 944, 962, "lispro mix 75 / 25", "", " ." +52924, Lispro75/25, 965, 979, "LM75 / 25 ; 75", "", +52925, LisproProtamine, 982, 998, "lispro protamine", "", +121, Lispro, 1017, 1023, "lispro", "", +21, NumberPatientsArm, 1032, 1039, "1 , 045", "", " \"1 , 045\"." +22, Frequency, 1045, 1050, "daily", "", " \"daily\"." +23, InsulinGlargine, 1051, 1059, "glargine", "", " ." +24, InsulinGlargine, 1062, 1064, "GL", "", +25, NumberPatientsArm, 1073, 1080, "1 , 046", "", " \"1 , 046\"." +106269, Precondition, 1088, 1141, "continuation of prestudy oral antihyperglycemic drugs", "", " \"continuation of prestudy oral antihyperglycemic drugs\"." +26, OralAntidiabeticAgent, 1113, 1141, "oral antihyperglycemic drugs", "", +27, HbA1c, 1163, 1166, "A1C", "", " ." +52926, Lispro75/25, 1181, 1190, "LM75 / 25", "", +28, BaseLineValue, 1193, 1198, "9 . 1", "", " \"9 . 1\"." +29, SdDevBL, 1205, 1210, "1 . 3", "", " \"1 . 3\"." +30, Percentage, 1211, 1212, "%", "", " ." +31, InsulinGlargine, 1215, 1217, "GL", "", +32, BaseLineValue, 1220, 1225, "9 . 0", "", " \"9 . 0\"." +33, SdDevBL, 1232, 1237, "1 . 2", "", " \"1 . 2\"." +34, Percentage, 1238, 1239, "%", "", +35, PvalueDiff, 1242, 1253, "P = 0 . 414", "", +210, TimePoint, 1261, 1269, "24 weeks", "", " \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\"." +102230, Lispro75/25, 1272, 1281, "LM75 / 25", "", +36, HbA1c, 1301, 1304, "A1C", "", +37, InsulinGlargine, 1310, 1312, "GL", "", +38, ResultMeasuredValue, 1324, 1329, "7 . 2", "", " \"7 . 2\"." +40, SdDevResValue, 1336, 1341, "1 . 1", "", " \"1 . 1\"." +39, ResultMeasuredValue, 1347, 1352, "7 . 3", "", " \"7 . 3\"." +41, SdDevResValue, 1359, 1364, "1 . 1", "", " \"1 . 1\"." +42, Percentage, 1365, 1366, "%", "", +43, PvalueDiff, 1369, 1380, "P = 0 . 005", "", " \"P = 0 . 005\"." +44, HbA1c, 1393, 1396, "A1C", "", +45, Reduction, 1411, 1416, "1 . 8", "", " \"1 . 8\"." +47, SdDevChangeValue, 1423, 1428, "1 . 3", "", " \"1 . 3\"." +46, Reduction, 1436, 1441, "1 . 7", "", " \"1 . 7\"." +48, SdDevChangeValue, 1448, 1453, "1 . 3", "", " \"1 . 3\"." +49, Percentage, 1454, 1455, "%", "", +50, PvalueDiff, 1458, 1469, "P = 0 . 005", "", " \"P = 0 . 005\"." +51, HbA1c_target, 1505, 1525, "A1C target < 7 . 0 %", "", " ." +197, Percentage, 1524, 1525, "%", "", " ." +52940, PercentageAffected, 1528, 1534, "47 . 5", "", " \"47 . 5\"." +53, PercentageAffected, 1540, 1546, "40 . 3", "", " \"40 . 3\"." +54, PvalueDiff, 1551, 1562, "P < 0 . 001", "", " \"P < 0 . 001\"." +52927, Lispro75/25, 1567, 1576, "LM75 / 25", "", +216, InsulinDose, 1604, 1616, "insulin dose", "", " . ." +55, ResultMeasuredValue, 1619, 1625, "0 . 47", "", " \"0 . 47\"." +57, SdDevResValue, 1632, 1638, "0 . 23", "", " \"0 . 23\"." +56, ResultMeasuredValue, 1644, 1650, "0 . 40", "", " \"0 . 40\"." +58, SdDevResValue, 1657, 1663, "0 . 23", "", " \"0 . 23\"." +59, IntUnit_per_Kg, 1664, 1674, "units x kg", "", " ." +60, PvalueDiff, 1699, 1710, "P < 0 . 001", "", " \"P < 0 . 001\"." +52932, WeightGain, 1722, 1733, "weight gain", "", " ." +157, ResultMeasuredValue, 1736, 1741, "3 . 6", "", " \"3 . 6\"." +52933, SdDevResValue, 1748, 1753, "4 . 0", "", " \"4 . 0\"." +158, ResultMeasuredValue, 1759, 1764, "2 . 5", "", " \"2 . 5\"." +52934, SdDevResValue, 1771, 1776, "4 . 0", "", " \"4 . 0\"." +66, Kg, 1777, 1779, "kg", "", " ." +67, PvalueDiff, 1782, 1794, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +52928, Lispro75/25, 1799, 1808, "LM75 / 25", "", +68, Hypoglycemia, 1839, 1851, "hypoglycemia", "", " ." +102227, AggregationMethod, 1852, 1856, "rate", "", " . ." +69, InsulinGlargine, 1862, 1864, "GL", "", +70, ResultMeasuredValue, 1876, 1882, "28 . 0", "", " \"28 . 0\"." +72, SdDevResValue, 1889, 1895, "41 . 6", "", " \"41 . 6\"." +71, ResultMeasuredValue, 1901, 1907, "23 . 1", "", " \"23 . 1\"." +73, SdDevResValue, 1914, 1920, "40 . 7", "", " \"40 . 7\"." +74, BioAndMedicalUnit, 1921, 1957, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +76, PvalueDiff, 1960, 1971, "P = 0 . 007", "", +75, NocturnalHypoglycemia, 1984, 2006, "nocturnal hypoglycemia", "", " ." +102226, AggregationMethod, 2007, 2011, "rate", "", " . ." +78, ResultMeasuredValue, 2014, 2019, "8 . 9", "", " \"8 . 9\"." +80, SdDevResValue, 2026, 2032, "19 . 3", "", " \"19 . 3\"." +79, ResultMeasuredValue, 2038, 2044, "11 . 4", "", " \"11 . 4\"." +81, SdDevResValue, 2051, 2057, "25 . 3", "", " \"25 . 3\"." +82, BioAndMedicalUnit, 2058, 2094, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +77, PvalueDiff, 2097, 2108, "P = 0 . 009", "", " \"P = 0 . 009\". \"P = 0 . 009\"." +83, SevereHypoglycemia, 2113, 2132, "Severe hypoglycemia", "", " ." +102225, AggregationMethod, 2133, 2138, "rates", "", " . ." +52929, Lispro75/25, 2165, 2174, "LM75 / 25", "", +84, ResultMeasuredValue, 2177, 2183, "0 . 10", "", " \"0 . 10\"." +86, SdDevResValue, 2190, 2195, "1 . 6", "", " \"1 . 6\"." +88, InsulinGlargine, 2201, 2203, "GL", "", +85, ResultMeasuredValue, 2206, 2212, "0 . 03", "", " \"0 . 03\"." +87, SdDevResValue, 2219, 2224, "0 . 3", "", " \"0 . 3\"." +89, BioAndMedicalUnit, 2225, 2261, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +90, PvalueDiff, 2264, 2275, "P = 0 . 167", "", " \"P = 0 . 167\"." +200, ConclusionComment, 2294, 2432, "Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % .", "", +91, InsulinGlargine, 2308, 2310, "GL", "", +52930, Lispro75/25, 2313, 2322, "LM75 / 25", "", +92, HbA1c, 2350, 2353, "A1C", "", +221, TimePoint, 2357, 2365, "24 weeks", "", +93, HbA1c_target, 2410, 2430, "A1C target < 7 . 0 %", "", +199, Percentage, 2429, 2430, "%", "", +201, ConclusionComment, 2433, 2575, "Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia .", "", +52931, Lispro75/25, 2452, 2461, "LM75 / 25", "", +8767, WeightGain, 2479, 2490, "weight gain", "", +102229, AggregationMethod, 2502, 2507, "rates", "", +95, Hypoglycemia, 2519, 2531, "hypoglycemia", "", +102228, AggregationMethod, 2542, 2547, "rates", "", +96, NocturnalHypoglycemia, 2551, 2573, "nocturnal hypoglycemia", "", +202, ConclusionComment, 2576, 2662, "Durability of regimens will be evaluated in the following 2 - year maintenance phase .", "", +189, Duration, 2634, 2642, "2 - year", "", +97, PMID, 2719, 2727, "19336625", "", " \"19336625\"." diff --git a/data/dm2 19336625 copy_admin.n-triples b/data/dm2 19336625 copy_admin.n-triples new file mode 100644 index 0000000..b781160 --- /dev/null +++ b/data/dm2 19336625 copy_admin.n-triples @@ -0,0 +1,273 @@ +# RDF export of group: Publication + . + "Publication" . + "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes ." . + "Buse JB" . + "2009" . + "Diabetes Care" . + "19336625" . + . + "Wolffenbuttel BH" . + "Herman WH" . + "Shemonsky NK" . + "Jiang HH" . + "Fahrbach JL" . + "Scism - Bacon JL" . + "Martin SA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes ." . + "24 - week" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "continuation of prestudy oral antihyperglycemic drugs" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_H" . + . + . + . + . + . + "Endpoint_H7" . + . + . + . + . + . + "Endpoint_ID" . + . + . + . + . + . + . + "Endpoint_W" . + . + . + . + . + . + "Endpoint_HG" . + . + . + . + . + . + . + . + "Endpoint_NHG" . + . + . + . + . + . + . + . + "Endpoint_SHG" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_L" . + "1 , 045" . + . + . + . + . + . + . + . + . + . + "Arm_G" . + "1 , 046" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_L" . + . + "twice - daily" . + . + . + "Intervention_G" . + . + "daily" . + . +# RDF export of group: Medication + . + "Medication_L" . + . + . + . + . + "Medication_G" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_H_L" . + . + "9 . 1" . + "1 . 3" . + "7 . 2" . + "1 . 1" . + "1 . 8" . + "1 . 3" . + "24 weeks" . + . + "Outcome_H_G" . + . + "9 . 0" . + "1 . 2" . + "7 . 3" . + "1 . 1" . + "1 . 7" . + "1 . 3" . + "24 weeks" . + . + "Outcome_H7_L" . + . + "47 . 5" . + "24 weeks" . + . + "Outcome_H7_G" . + . + "40 . 3" . + "24 weeks" . + . + "Outcome_ID_L" . + . + "0 . 47" . + "0 . 23" . + "24 weeks" . + . + "Outcome_ID_G" . + . + "0 . 40" . + "0 . 23" . + "24 weeks" . + . + "Outcome_W_L" . + . + "3 . 6" . + "4 . 0" . + "24 weeks" . + . + "Outcome_W_G" . + . + "2 . 5" . + "4 . 0" . + "24 weeks" . + . + "Outcome_HG_L" . + . + "28 . 0" . + "41 . 6" . + "24 weeks" . + . + "Outcome_HG_G" . + . + "23 . 1" . + "40 . 7" . + "24 weeks" . + . + "Outcome_NHG_L" . + . + "8 . 9" . + "19 . 3" . + "24 weeks" . + . + "Outcome_NHG_G" . + . + "11 . 4" . + "25 . 3" . + "24 weeks" . + . + "Outcome_SHG_L" . + . + "0 . 10" . + "1 . 6" . + "24 weeks" . + . + "Outcome_SHG_G" . + . + "0 . 03" . + "0 . 3" . + "24 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_H_Result" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups_H_Change" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups_H7" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_ID" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_W" . + "P < 0 . 0001" . + . + . + . + "DiffBetweenGroups_HG" . + "P = 0 . 009" . + . + . + . + "DiffBetweenGroups_NHG" . + "P = 0 . 009" . + . + . + . + "DiffBetweenGroups_SHG" . + "P = 0 . 167" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19336625 copy_export.csv b/data/dm2 19336625 copy_export.csv new file mode 100644 index 0000000..2ab3fdb --- /dev/null +++ b/data/dm2 19336625 copy_export.csv @@ -0,0 +1,718 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +825, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +825, 1, 2, 2, 9, 13, 9, 13, "Care" +825, 1, 3, 3, 14, 15, 14, 15, "." +825, 2, 1, 4, 0, 4, 16, 20, "2009" +825, 2, 2, 5, 5, 8, 21, 24, "Jun" +825, 2, 3, 6, 9, 10, 25, 26, ";" +825, 2, 4, 7, 11, 13, 27, 29, "32" +825, 2, 5, 8, 14, 15, 30, 31, "(" +825, 2, 6, 9, 16, 17, 32, 33, "6" +825, 2, 7, 10, 18, 19, 34, 35, ")" +825, 2, 8, 11, 20, 21, 36, 37, ":" +825, 2, 9, 12, 22, 26, 38, 42, "1007" +825, 2, 10, 13, 27, 28, 43, 44, "-" +825, 2, 11, 14, 29, 31, 45, 47, "13" +825, 2, 12, 15, 32, 33, 48, 49, "." +825, 2, 13, 16, 34, 37, 50, 53, "doi" +825, 2, 14, 17, 38, 39, 54, 55, ":" +825, 2, 15, 18, 40, 42, 56, 58, "10" +825, 2, 16, 19, 43, 44, 59, 60, "." +825, 2, 17, 20, 45, 49, 61, 65, "2337" +825, 2, 18, 21, 50, 51, 66, 67, "/" +825, 2, 19, 22, 52, 56, 68, 72, "dc08" +825, 2, 20, 23, 57, 58, 73, 74, "-" +825, 2, 21, 24, 59, 63, 75, 79, "2117" +825, 2, 22, 25, 64, 65, 80, 81, "." +825, 3, 1, 26, 0, 4, 82, 86, "Epub" +825, 3, 2, 27, 5, 9, 87, 91, "2009" +825, 3, 3, 28, 10, 13, 92, 95, "Mar" +825, 3, 4, 29, 14, 16, 96, 98, "31" +825, 3, 5, 30, 17, 18, 99, 100, "." +825, 4, 1, 31, 0, 10, 101, 111, "DURAbility" +825, 4, 2, 32, 11, 13, 112, 114, "of" +825, 4, 3, 33, 14, 19, 115, 120, "basal" +825, 4, 4, 34, 20, 26, 121, 127, "versus" +825, 4, 5, 35, 27, 33, 128, 134, "lispro" +825, 4, 6, 36, 34, 37, 135, 138, "mix" +825, 4, 7, 37, 38, 40, 139, 141, "75" +825, 4, 8, 38, 41, 42, 142, 143, "/" +825, 4, 9, 39, 43, 45, 144, 146, "25" +825, 4, 10, 40, 46, 53, 147, 154, "insulin" +825, 4, 11, 41, 54, 62, 155, 163, "efficacy" +825, 4, 12, 42, 63, 64, 164, 165, "(" +825, 4, 13, 43, 65, 72, 166, 173, "DURABLE" +825, 4, 14, 44, 73, 74, 174, 175, ")" +825, 4, 15, 45, 75, 80, 176, 181, "trial" +825, 4, 16, 46, 81, 83, 182, 184, "24" +825, 4, 17, 47, 84, 85, 185, 186, "-" +825, 4, 18, 48, 86, 90, 187, 191, "week" +825, 4, 19, 49, 91, 98, 192, 199, "results" +825, 4, 20, 50, 99, 100, 200, 201, ":" +825, 4, 21, 51, 101, 107, 202, 208, "safety" +825, 4, 22, 52, 108, 111, 209, 212, "and" +825, 4, 23, 53, 112, 120, 213, 221, "efficacy" +825, 4, 24, 54, 121, 123, 222, 224, "of" +825, 4, 25, 55, 124, 131, 225, 232, "insulin" +825, 4, 26, 56, 132, 138, 233, 239, "lispro" +825, 4, 27, 57, 139, 142, 240, 243, "mix" +825, 4, 28, 58, 143, 145, 244, 246, "75" +825, 4, 29, 59, 146, 147, 247, 248, "/" +825, 4, 30, 60, 148, 150, 249, 251, "25" +825, 4, 31, 61, 151, 157, 252, 258, "versus" +825, 4, 32, 62, 158, 165, 259, 266, "insulin" +825, 4, 33, 63, 166, 174, 267, 275, "glargine" +825, 4, 34, 64, 175, 180, 276, 281, "added" +825, 4, 35, 65, 181, 183, 282, 284, "to" +825, 4, 36, 66, 184, 188, 285, 289, "oral" +825, 4, 37, 67, 189, 206, 290, 307, "antihyperglycemic" +825, 4, 38, 68, 207, 212, 308, 313, "drugs" +825, 4, 39, 69, 213, 215, 314, 316, "in" +825, 4, 40, 70, 216, 224, 317, 325, "patients" +825, 4, 41, 71, 225, 229, 326, 330, "with" +825, 4, 42, 72, 230, 234, 331, 335, "type" +825, 4, 43, 73, 235, 236, 336, 337, "2" +825, 4, 44, 74, 237, 245, 338, 346, "diabetes" +825, 4, 45, 75, 246, 247, 347, 348, "." +825, 5, 1, 76, 0, 4, 349, 353, "Buse" +825, 5, 2, 77, 5, 7, 354, 356, "JB" +825, 5, 3, 78, 8, 9, 357, 358, "(" +825, 5, 4, 79, 10, 11, 359, 360, "1" +825, 5, 5, 80, 12, 13, 361, 362, ")" +825, 5, 6, 81, 14, 15, 363, 364, "," +825, 5, 7, 82, 16, 29, 365, 378, "Wolffenbuttel" +825, 5, 8, 83, 30, 32, 379, 381, "BH" +825, 5, 9, 84, 33, 34, 382, 383, "," +825, 5, 10, 85, 35, 41, 384, 390, "Herman" +825, 5, 11, 86, 42, 44, 391, 393, "WH" +825, 5, 12, 87, 45, 46, 394, 395, "," +825, 5, 13, 88, 47, 56, 396, 405, "Shemonsky" +825, 5, 14, 89, 57, 59, 406, 408, "NK" +825, 5, 15, 90, 60, 61, 409, 410, "," +825, 5, 16, 91, 62, 67, 411, 416, "Jiang" +825, 5, 17, 92, 68, 70, 417, 419, "HH" +825, 5, 18, 93, 71, 72, 420, 421, "," +825, 5, 19, 94, 73, 81, 422, 430, "Fahrbach" +825, 5, 20, 95, 82, 84, 431, 433, "JL" +825, 5, 21, 96, 85, 86, 434, 435, "," +825, 5, 22, 97, 87, 92, 436, 441, "Scism" +825, 5, 23, 98, 93, 94, 442, 443, "-" +825, 5, 24, 99, 95, 100, 444, 449, "Bacon" +825, 5, 25, 100, 101, 103, 450, 452, "JL" +825, 5, 26, 101, 104, 105, 453, 454, "," +825, 5, 27, 102, 106, 112, 455, 461, "Martin" +825, 5, 28, 103, 113, 115, 462, 464, "SA" +825, 5, 29, 104, 116, 117, 465, 466, "." +825, 6, 1, 105, 0, 6, 467, 473, "Author" +825, 6, 2, 106, 7, 18, 474, 485, "information" +825, 6, 3, 107, 19, 20, 486, 487, ":" +825, 6, 4, 108, 21, 22, 488, 489, "(" +825, 6, 5, 109, 23, 24, 490, 491, "1" +825, 6, 6, 110, 25, 26, 492, 493, ")" +825, 6, 7, 111, 27, 35, 494, 502, "Division" +825, 6, 8, 112, 36, 38, 503, 505, "of" +825, 6, 9, 113, 39, 52, 506, 519, "Endocrinology" +825, 6, 10, 114, 53, 54, 520, 521, "," +825, 6, 11, 115, 55, 65, 522, 532, "Department" +825, 6, 12, 116, 66, 68, 533, 535, "of" +825, 6, 13, 117, 69, 77, 536, 544, "Medicine" +825, 6, 14, 118, 78, 79, 545, 546, "," +825, 6, 15, 119, 80, 90, 547, 557, "University" +825, 6, 16, 120, 91, 93, 558, 560, "of" +825, 6, 17, 121, 94, 99, 561, 566, "North" +825, 6, 18, 122, 100, 108, 567, 575, "Carolina" +825, 6, 19, 123, 109, 115, 576, 582, "School" +825, 6, 20, 124, 116, 118, 583, 585, "of" +825, 6, 21, 125, 119, 127, 586, 594, "Medicine" +825, 6, 22, 126, 128, 129, 595, 596, "," +825, 6, 23, 127, 130, 136, 597, 603, "Chapel" +825, 6, 24, 128, 137, 141, 604, 608, "Hill" +825, 6, 25, 129, 142, 143, 609, 610, "," +825, 6, 26, 130, 144, 149, 611, 616, "North" +825, 6, 27, 131, 150, 158, 617, 625, "Carolina" +825, 6, 28, 132, 159, 160, 626, 627, "," +825, 6, 29, 133, 161, 164, 628, 631, "USA" +825, 6, 30, 134, 165, 166, 632, 633, "." +825, 7, 1, 135, 0, 5, 634, 639, "jbuse" +825, 7, 2, 136, 6, 7, 640, 641, "@" +825, 7, 3, 137, 8, 11, 642, 645, "med" +825, 7, 4, 138, 12, 13, 646, 647, "." +825, 7, 5, 139, 14, 17, 648, 651, "unc" +825, 7, 6, 140, 18, 19, 652, 653, "." +825, 7, 7, 141, 20, 23, 654, 657, "edu" +825, 7, 8, 142, 24, 33, 658, 667, "OBJECTIVE" +825, 7, 9, 143, 34, 35, 668, 669, ":" +825, 7, 10, 144, 36, 38, 670, 672, "To" +825, 7, 11, 145, 39, 46, 673, 680, "compare" +825, 7, 12, 146, 47, 50, 681, 684, "the" +825, 7, 13, 147, 51, 58, 685, 692, "ability" +825, 7, 14, 148, 59, 61, 693, 695, "of" +825, 7, 15, 149, 62, 65, 696, 699, "two" +825, 7, 16, 150, 66, 73, 700, 707, "starter" +825, 7, 17, 151, 74, 81, 708, 715, "insulin" +825, 7, 18, 152, 82, 90, 716, 724, "regimens" +825, 7, 19, 153, 91, 93, 725, 727, "to" +825, 7, 20, 154, 94, 101, 728, 735, "achieve" +825, 7, 21, 155, 102, 110, 736, 744, "glycemic" +825, 7, 22, 156, 111, 118, 745, 752, "control" +825, 7, 23, 157, 119, 121, 753, 755, "in" +825, 7, 24, 158, 122, 123, 756, 757, "a" +825, 7, 25, 159, 124, 129, 758, 763, "large" +825, 7, 26, 160, 130, 131, 764, 765, "," +825, 7, 27, 161, 132, 142, 766, 776, "ethnically" +825, 7, 28, 162, 143, 150, 777, 784, "diverse" +825, 7, 29, 163, 151, 161, 785, 795, "population" +825, 7, 30, 164, 162, 166, 796, 800, "with" +825, 7, 31, 165, 167, 171, 801, 805, "type" +825, 7, 32, 166, 172, 173, 806, 807, "2" +825, 7, 33, 167, 174, 182, 808, 816, "diabetes" +825, 7, 34, 168, 183, 184, 817, 818, "." +825, 8, 1, 169, 0, 8, 819, 827, "RESEARCH" +825, 8, 2, 170, 9, 15, 828, 834, "DESIGN" +825, 8, 3, 171, 16, 19, 835, 838, "AND" +825, 8, 4, 172, 20, 27, 839, 846, "METHODS" +825, 8, 5, 173, 28, 29, 847, 848, ":" +825, 8, 6, 174, 30, 36, 849, 855, "During" +825, 8, 7, 175, 37, 40, 856, 859, "the" +825, 8, 8, 176, 41, 51, 860, 870, "initiation" +825, 8, 9, 177, 52, 57, 871, 876, "phase" +825, 8, 10, 178, 58, 60, 877, 879, "of" +825, 8, 11, 179, 61, 64, 880, 883, "the" +825, 8, 12, 180, 65, 72, 884, 891, "DURABLE" +825, 8, 13, 181, 73, 78, 892, 897, "trial" +825, 8, 14, 182, 79, 80, 898, 899, "," +825, 8, 15, 183, 81, 89, 900, 908, "patients" +825, 8, 16, 184, 90, 94, 909, 913, "were" +825, 8, 17, 185, 95, 105, 914, 924, "randomized" +825, 8, 18, 186, 106, 108, 925, 927, "to" +825, 8, 19, 187, 109, 110, 928, 929, "a" +825, 8, 20, 188, 111, 116, 930, 935, "twice" +825, 8, 21, 189, 117, 118, 936, 937, "-" +825, 8, 22, 190, 119, 124, 938, 943, "daily" +825, 8, 23, 191, 125, 131, 944, 950, "lispro" +825, 8, 24, 192, 132, 135, 951, 954, "mix" +825, 8, 25, 193, 136, 138, 955, 957, "75" +825, 8, 26, 194, 139, 140, 958, 959, "/" +825, 8, 27, 195, 141, 143, 960, 962, "25" +825, 8, 28, 196, 144, 145, 963, 964, "(" +825, 8, 29, 197, 146, 150, 965, 969, "LM75" +825, 8, 30, 198, 151, 152, 970, 971, "/" +825, 8, 31, 199, 153, 155, 972, 974, "25" +825, 8, 32, 200, 156, 157, 975, 976, ";" +825, 8, 33, 201, 158, 160, 977, 979, "75" +825, 8, 34, 202, 161, 162, 980, 981, "%" +825, 8, 35, 203, 163, 169, 982, 988, "lispro" +825, 8, 36, 204, 170, 179, 989, 998, "protamine" +825, 8, 37, 205, 180, 190, 999, 1009, "suspension" +825, 8, 38, 206, 191, 192, 1010, 1011, "," +825, 8, 39, 207, 193, 195, 1012, 1014, "25" +825, 8, 40, 208, 196, 197, 1015, 1016, "%" +825, 8, 41, 209, 198, 204, 1017, 1023, "lispro" +825, 8, 42, 210, 205, 206, 1024, 1025, ")" +825, 8, 43, 211, 207, 208, 1026, 1027, "(" +825, 8, 44, 212, 209, 210, 1028, 1029, "n" +825, 8, 45, 213, 211, 212, 1030, 1031, "=" +825, 8, 46, 214, 213, 214, 1032, 1033, "1" +825, 8, 47, 215, 215, 216, 1034, 1035, "," +825, 8, 48, 216, 217, 220, 1036, 1039, "045" +825, 8, 49, 217, 221, 222, 1040, 1041, ")" +825, 8, 50, 218, 223, 225, 1042, 1044, "or" +825, 8, 51, 219, 226, 231, 1045, 1050, "daily" +825, 8, 52, 220, 232, 240, 1051, 1059, "glargine" +825, 8, 53, 221, 241, 242, 1060, 1061, "(" +825, 8, 54, 222, 243, 245, 1062, 1064, "GL" +825, 8, 55, 223, 246, 247, 1065, 1066, ")" +825, 8, 56, 224, 248, 249, 1067, 1068, "(" +825, 8, 57, 225, 250, 251, 1069, 1070, "n" +825, 8, 58, 226, 252, 253, 1071, 1072, "=" +825, 8, 59, 227, 254, 255, 1073, 1074, "1" +825, 8, 60, 228, 256, 257, 1075, 1076, "," +825, 8, 61, 229, 258, 261, 1077, 1080, "046" +825, 8, 62, 230, 262, 263, 1081, 1082, ")" +825, 8, 63, 231, 264, 268, 1083, 1087, "with" +825, 8, 64, 232, 269, 281, 1088, 1100, "continuation" +825, 8, 65, 233, 282, 284, 1101, 1103, "of" +825, 8, 66, 234, 285, 293, 1104, 1112, "prestudy" +825, 8, 67, 235, 294, 298, 1113, 1117, "oral" +825, 8, 68, 236, 299, 316, 1118, 1135, "antihyperglycemic" +825, 8, 69, 237, 317, 322, 1136, 1141, "drugs" +825, 8, 70, 238, 323, 324, 1142, 1143, "." +825, 9, 1, 239, 0, 7, 1144, 1151, "RESULTS" +825, 9, 2, 240, 8, 9, 1152, 1153, ":" +825, 9, 3, 241, 10, 18, 1154, 1162, "Baseline" +825, 9, 4, 242, 19, 22, 1163, 1166, "A1C" +825, 9, 5, 243, 23, 26, 1167, 1170, "was" +825, 9, 6, 244, 27, 34, 1171, 1178, "similar" +825, 9, 7, 245, 35, 36, 1179, 1180, "(" +825, 9, 8, 246, 37, 41, 1181, 1185, "LM75" +825, 9, 9, 247, 42, 43, 1186, 1187, "/" +825, 9, 10, 248, 44, 46, 1188, 1190, "25" +825, 9, 11, 249, 47, 48, 1191, 1192, ":" +825, 9, 12, 250, 49, 50, 1193, 1194, "9" +825, 9, 13, 251, 51, 52, 1195, 1196, "." +825, 9, 14, 252, 53, 54, 1197, 1198, "1" +825, 9, 15, 253, 55, 56, 1199, 1200, "+" +825, 9, 16, 254, 57, 58, 1201, 1202, "/" +825, 9, 17, 255, 59, 60, 1203, 1204, "-" +825, 9, 18, 256, 61, 62, 1205, 1206, "1" +825, 9, 19, 257, 63, 64, 1207, 1208, "." +825, 9, 20, 258, 65, 66, 1209, 1210, "3" +825, 9, 21, 259, 67, 68, 1211, 1212, "%" +825, 9, 22, 260, 69, 70, 1213, 1214, ";" +825, 9, 23, 261, 71, 73, 1215, 1217, "GL" +825, 9, 24, 262, 74, 75, 1218, 1219, ":" +825, 9, 25, 263, 76, 77, 1220, 1221, "9" +825, 9, 26, 264, 78, 79, 1222, 1223, "." +825, 9, 27, 265, 80, 81, 1224, 1225, "0" +825, 9, 28, 266, 82, 83, 1226, 1227, "+" +825, 9, 29, 267, 84, 85, 1228, 1229, "/" +825, 9, 30, 268, 86, 87, 1230, 1231, "-" +825, 9, 31, 269, 88, 89, 1232, 1233, "1" +825, 9, 32, 270, 90, 91, 1234, 1235, "." +825, 9, 33, 271, 92, 93, 1236, 1237, "2" +825, 9, 34, 272, 94, 95, 1238, 1239, "%" +825, 9, 35, 273, 96, 97, 1240, 1241, ";" +825, 9, 36, 274, 98, 99, 1242, 1243, "P" +825, 9, 37, 275, 100, 101, 1244, 1245, "=" +825, 9, 38, 276, 102, 103, 1246, 1247, "0" +825, 9, 39, 277, 104, 105, 1248, 1249, "." +825, 9, 40, 278, 106, 109, 1250, 1253, "414" +825, 9, 41, 279, 110, 111, 1254, 1255, ")" +825, 9, 42, 280, 112, 113, 1256, 1257, "." +825, 10, 1, 281, 0, 2, 1258, 1260, "At" +825, 10, 2, 282, 3, 5, 1261, 1263, "24" +825, 10, 3, 283, 6, 11, 1264, 1269, "weeks" +825, 10, 4, 284, 12, 13, 1270, 1271, "," +825, 10, 5, 285, 14, 18, 1272, 1276, "LM75" +825, 10, 6, 286, 19, 20, 1277, 1278, "/" +825, 10, 7, 287, 21, 23, 1279, 1281, "25" +825, 10, 8, 288, 24, 32, 1282, 1290, "patients" +825, 10, 9, 289, 33, 36, 1291, 1294, "had" +825, 10, 10, 290, 37, 42, 1295, 1300, "lower" +825, 10, 11, 291, 43, 46, 1301, 1304, "A1C" +825, 10, 12, 292, 47, 51, 1305, 1309, "than" +825, 10, 13, 293, 52, 54, 1310, 1312, "GL" +825, 10, 14, 294, 55, 63, 1313, 1321, "patients" +825, 10, 15, 295, 64, 65, 1322, 1323, "(" +825, 10, 16, 296, 66, 67, 1324, 1325, "7" +825, 10, 17, 297, 68, 69, 1326, 1327, "." +825, 10, 18, 298, 70, 71, 1328, 1329, "2" +825, 10, 19, 299, 72, 73, 1330, 1331, "+" +825, 10, 20, 300, 74, 75, 1332, 1333, "/" +825, 10, 21, 301, 76, 77, 1334, 1335, "-" +825, 10, 22, 302, 78, 79, 1336, 1337, "1" +825, 10, 23, 303, 80, 81, 1338, 1339, "." +825, 10, 24, 304, 82, 83, 1340, 1341, "1" +825, 10, 25, 305, 84, 86, 1342, 1344, "vs" +825, 10, 26, 306, 87, 88, 1345, 1346, "." +825, 10, 27, 307, 89, 90, 1347, 1348, "7" +825, 10, 28, 308, 91, 92, 1349, 1350, "." +825, 10, 29, 309, 93, 94, 1351, 1352, "3" +825, 10, 30, 310, 95, 96, 1353, 1354, "+" +825, 10, 31, 311, 97, 98, 1355, 1356, "/" +825, 10, 32, 312, 99, 100, 1357, 1358, "-" +825, 10, 33, 313, 101, 102, 1359, 1360, "1" +825, 10, 34, 314, 103, 104, 1361, 1362, "." +825, 10, 35, 315, 105, 106, 1363, 1364, "1" +825, 10, 36, 316, 107, 108, 1365, 1366, "%" +825, 10, 37, 317, 109, 110, 1367, 1368, "," +825, 10, 38, 318, 111, 112, 1369, 1370, "P" +825, 10, 39, 319, 113, 114, 1371, 1372, "=" +825, 10, 40, 320, 115, 116, 1373, 1374, "0" +825, 10, 41, 321, 117, 118, 1375, 1376, "." +825, 10, 42, 322, 119, 122, 1377, 1380, "005" +825, 10, 43, 323, 123, 124, 1381, 1382, ")" +825, 10, 44, 324, 125, 126, 1383, 1384, "," +825, 10, 45, 325, 127, 134, 1385, 1392, "greater" +825, 10, 46, 326, 135, 138, 1393, 1396, "A1C" +825, 10, 47, 327, 139, 148, 1397, 1406, "reduction" +825, 10, 48, 328, 149, 150, 1407, 1408, "(" +825, 10, 49, 329, 151, 152, 1409, 1410, "-" +825, 10, 50, 330, 153, 154, 1411, 1412, "1" +825, 10, 51, 331, 155, 156, 1413, 1414, "." +825, 10, 52, 332, 157, 158, 1415, 1416, "8" +825, 10, 53, 333, 159, 160, 1417, 1418, "+" +825, 10, 54, 334, 161, 162, 1419, 1420, "/" +825, 10, 55, 335, 163, 164, 1421, 1422, "-" +825, 10, 56, 336, 165, 166, 1423, 1424, "1" +825, 10, 57, 337, 167, 168, 1425, 1426, "." +825, 10, 58, 338, 169, 170, 1427, 1428, "3" +825, 10, 59, 339, 171, 173, 1429, 1431, "vs" +825, 10, 60, 340, 174, 175, 1432, 1433, "." +825, 10, 61, 341, 176, 177, 1434, 1435, "-" +825, 10, 62, 342, 178, 179, 1436, 1437, "1" +825, 10, 63, 343, 180, 181, 1438, 1439, "." +825, 10, 64, 344, 182, 183, 1440, 1441, "7" +825, 10, 65, 345, 184, 185, 1442, 1443, "+" +825, 10, 66, 346, 186, 187, 1444, 1445, "/" +825, 10, 67, 347, 188, 189, 1446, 1447, "-" +825, 10, 68, 348, 190, 191, 1448, 1449, "1" +825, 10, 69, 349, 192, 193, 1450, 1451, "." +825, 10, 70, 350, 194, 195, 1452, 1453, "3" +825, 10, 71, 351, 196, 197, 1454, 1455, "%" +825, 10, 72, 352, 198, 199, 1456, 1457, "," +825, 10, 73, 353, 200, 201, 1458, 1459, "P" +825, 10, 74, 354, 202, 203, 1460, 1461, "=" +825, 10, 75, 355, 204, 205, 1462, 1463, "0" +825, 10, 76, 356, 206, 207, 1464, 1465, "." +825, 10, 77, 357, 208, 211, 1466, 1469, "005" +825, 10, 78, 358, 212, 213, 1470, 1471, ")" +825, 10, 79, 359, 214, 215, 1472, 1473, "," +825, 10, 80, 360, 216, 219, 1474, 1477, "and" +825, 10, 81, 361, 220, 226, 1478, 1484, "higher" +825, 10, 82, 362, 227, 237, 1485, 1495, "percentage" +825, 10, 83, 363, 238, 246, 1496, 1504, "reaching" +825, 10, 84, 364, 247, 250, 1505, 1508, "A1C" +825, 10, 85, 365, 251, 257, 1509, 1515, "target" +825, 10, 86, 366, 258, 259, 1516, 1517, "<" +825, 10, 87, 367, 260, 261, 1518, 1519, "7" +825, 10, 88, 368, 262, 263, 1520, 1521, "." +825, 10, 89, 369, 264, 265, 1522, 1523, "0" +825, 10, 90, 370, 266, 267, 1524, 1525, "%" +825, 10, 91, 371, 268, 269, 1526, 1527, "(" +825, 10, 92, 372, 270, 272, 1528, 1530, "47" +825, 10, 93, 373, 273, 274, 1531, 1532, "." +825, 10, 94, 374, 275, 276, 1533, 1534, "5" +825, 10, 95, 375, 277, 279, 1535, 1537, "vs" +825, 10, 96, 376, 280, 281, 1538, 1539, "." +825, 10, 97, 377, 282, 284, 1540, 1542, "40" +825, 10, 98, 378, 285, 286, 1543, 1544, "." +825, 10, 99, 379, 287, 288, 1545, 1546, "3" +825, 10, 100, 380, 289, 290, 1547, 1548, "%" +825, 10, 101, 381, 291, 292, 1549, 1550, "," +825, 10, 102, 382, 293, 294, 1551, 1552, "P" +825, 10, 103, 383, 295, 296, 1553, 1554, "<" +825, 10, 104, 384, 297, 298, 1555, 1556, "0" +825, 10, 105, 385, 299, 300, 1557, 1558, "." +825, 10, 106, 386, 301, 304, 1559, 1562, "001" +825, 10, 107, 387, 305, 306, 1563, 1564, ")" +825, 10, 108, 388, 307, 308, 1565, 1566, "." +825, 11, 1, 389, 0, 4, 1567, 1571, "LM75" +825, 11, 2, 390, 5, 6, 1572, 1573, "/" +825, 11, 3, 391, 7, 9, 1574, 1576, "25" +825, 11, 4, 392, 10, 13, 1577, 1580, "was" +825, 11, 5, 393, 14, 24, 1581, 1591, "associated" +825, 11, 6, 394, 25, 29, 1592, 1596, "with" +825, 11, 7, 395, 30, 36, 1597, 1603, "higher" +825, 11, 8, 396, 37, 44, 1604, 1611, "insulin" +825, 11, 9, 397, 45, 49, 1612, 1616, "dose" +825, 11, 10, 398, 50, 51, 1617, 1618, "(" +825, 11, 11, 399, 52, 53, 1619, 1620, "0" +825, 11, 12, 400, 54, 55, 1621, 1622, "." +825, 11, 13, 401, 56, 58, 1623, 1625, "47" +825, 11, 14, 402, 59, 60, 1626, 1627, "+" +825, 11, 15, 403, 61, 62, 1628, 1629, "/" +825, 11, 16, 404, 63, 64, 1630, 1631, "-" +825, 11, 17, 405, 65, 66, 1632, 1633, "0" +825, 11, 18, 406, 67, 68, 1634, 1635, "." +825, 11, 19, 407, 69, 71, 1636, 1638, "23" +825, 11, 20, 408, 72, 74, 1639, 1641, "vs" +825, 11, 21, 409, 75, 76, 1642, 1643, "." +825, 11, 22, 410, 77, 78, 1644, 1645, "0" +825, 11, 23, 411, 79, 80, 1646, 1647, "." +825, 11, 24, 412, 81, 83, 1648, 1650, "40" +825, 11, 25, 413, 84, 85, 1651, 1652, "+" +825, 11, 26, 414, 86, 87, 1653, 1654, "/" +825, 11, 27, 415, 88, 89, 1655, 1656, "-" +825, 11, 28, 416, 90, 91, 1657, 1658, "0" +825, 11, 29, 417, 92, 93, 1659, 1660, "." +825, 11, 30, 418, 94, 96, 1661, 1663, "23" +825, 11, 31, 419, 97, 102, 1664, 1669, "units" +825, 11, 32, 420, 103, 104, 1670, 1671, "x" +825, 11, 33, 421, 105, 107, 1672, 1674, "kg" +825, 11, 34, 422, 108, 109, 1675, 1676, "(" +825, 11, 35, 423, 110, 111, 1677, 1678, "-" +825, 11, 36, 424, 112, 113, 1679, 1680, "1" +825, 11, 37, 425, 114, 115, 1681, 1682, ")" +825, 11, 38, 426, 116, 117, 1683, 1684, "x" +825, 11, 39, 427, 118, 121, 1685, 1688, "day" +825, 11, 40, 428, 122, 123, 1689, 1690, "(" +825, 11, 41, 429, 124, 125, 1691, 1692, "-" +825, 11, 42, 430, 126, 127, 1693, 1694, "1" +825, 11, 43, 431, 128, 129, 1695, 1696, ")" +825, 11, 44, 432, 130, 131, 1697, 1698, "," +825, 11, 45, 433, 132, 133, 1699, 1700, "P" +825, 11, 46, 434, 134, 135, 1701, 1702, "<" +825, 11, 47, 435, 136, 137, 1703, 1704, "0" +825, 11, 48, 436, 138, 139, 1705, 1706, "." +825, 11, 49, 437, 140, 143, 1707, 1710, "001" +825, 11, 50, 438, 144, 145, 1711, 1712, ")" +825, 11, 51, 439, 146, 149, 1713, 1716, "and" +825, 11, 52, 440, 150, 154, 1717, 1721, "more" +825, 11, 53, 441, 155, 161, 1722, 1728, "weight" +825, 11, 54, 442, 162, 166, 1729, 1733, "gain" +825, 11, 55, 443, 167, 168, 1734, 1735, "(" +825, 11, 56, 444, 169, 170, 1736, 1737, "3" +825, 11, 57, 445, 171, 172, 1738, 1739, "." +825, 11, 58, 446, 173, 174, 1740, 1741, "6" +825, 11, 59, 447, 175, 176, 1742, 1743, "+" +825, 11, 60, 448, 177, 178, 1744, 1745, "/" +825, 11, 61, 449, 179, 180, 1746, 1747, "-" +825, 11, 62, 450, 181, 182, 1748, 1749, "4" +825, 11, 63, 451, 183, 184, 1750, 1751, "." +825, 11, 64, 452, 185, 186, 1752, 1753, "0" +825, 11, 65, 453, 187, 189, 1754, 1756, "vs" +825, 11, 66, 454, 190, 191, 1757, 1758, "." +825, 11, 67, 455, 192, 193, 1759, 1760, "2" +825, 11, 68, 456, 194, 195, 1761, 1762, "." +825, 11, 69, 457, 196, 197, 1763, 1764, "5" +825, 11, 70, 458, 198, 199, 1765, 1766, "+" +825, 11, 71, 459, 200, 201, 1767, 1768, "/" +825, 11, 72, 460, 202, 203, 1769, 1770, "-" +825, 11, 73, 461, 204, 205, 1771, 1772, "4" +825, 11, 74, 462, 206, 207, 1773, 1774, "." +825, 11, 75, 463, 208, 209, 1775, 1776, "0" +825, 11, 76, 464, 210, 212, 1777, 1779, "kg" +825, 11, 77, 465, 213, 214, 1780, 1781, "," +825, 11, 78, 466, 215, 216, 1782, 1783, "P" +825, 11, 79, 467, 217, 218, 1784, 1785, "<" +825, 11, 80, 468, 219, 220, 1786, 1787, "0" +825, 11, 81, 469, 221, 222, 1788, 1789, "." +825, 11, 82, 470, 223, 227, 1790, 1794, "0001" +825, 11, 83, 471, 228, 229, 1795, 1796, ")" +825, 11, 84, 472, 230, 231, 1797, 1798, "." +825, 12, 1, 473, 0, 4, 1799, 1803, "LM75" +825, 12, 2, 474, 5, 6, 1804, 1805, "/" +825, 12, 3, 475, 7, 9, 1806, 1808, "25" +825, 12, 4, 476, 10, 18, 1809, 1817, "patients" +825, 12, 5, 477, 19, 22, 1818, 1821, "had" +825, 12, 6, 478, 23, 24, 1822, 1823, "a" +825, 12, 7, 479, 25, 31, 1824, 1830, "higher" +825, 12, 8, 480, 32, 39, 1831, 1838, "overall" +825, 12, 9, 481, 40, 52, 1839, 1851, "hypoglycemia" +825, 12, 10, 482, 53, 57, 1852, 1856, "rate" +825, 12, 11, 483, 58, 62, 1857, 1861, "than" +825, 12, 12, 484, 63, 65, 1862, 1864, "GL" +825, 12, 13, 485, 66, 74, 1865, 1873, "patients" +825, 12, 14, 486, 75, 76, 1874, 1875, "(" +825, 12, 15, 487, 77, 79, 1876, 1878, "28" +825, 12, 16, 488, 80, 81, 1879, 1880, "." +825, 12, 17, 489, 82, 83, 1881, 1882, "0" +825, 12, 18, 490, 84, 85, 1883, 1884, "+" +825, 12, 19, 491, 86, 87, 1885, 1886, "/" +825, 12, 20, 492, 88, 89, 1887, 1888, "-" +825, 12, 21, 493, 90, 92, 1889, 1891, "41" +825, 12, 22, 494, 93, 94, 1892, 1893, "." +825, 12, 23, 495, 95, 96, 1894, 1895, "6" +825, 12, 24, 496, 97, 99, 1896, 1898, "vs" +825, 12, 25, 497, 100, 101, 1899, 1900, "." +825, 12, 26, 498, 102, 104, 1901, 1903, "23" +825, 12, 27, 499, 105, 106, 1904, 1905, "." +825, 12, 28, 500, 107, 108, 1906, 1907, "1" +825, 12, 29, 501, 109, 110, 1908, 1909, "+" +825, 12, 30, 502, 111, 112, 1910, 1911, "/" +825, 12, 31, 503, 113, 114, 1912, 1913, "-" +825, 12, 32, 504, 115, 117, 1914, 1916, "40" +825, 12, 33, 505, 118, 119, 1917, 1918, "." +825, 12, 34, 506, 120, 121, 1919, 1920, "7" +825, 12, 35, 507, 122, 130, 1921, 1929, "episodes" +825, 12, 36, 508, 131, 132, 1930, 1931, "x" +825, 12, 37, 509, 133, 135, 1932, 1934, "pt" +825, 12, 38, 510, 136, 137, 1935, 1936, "(" +825, 12, 39, 511, 138, 139, 1937, 1938, "-" +825, 12, 40, 512, 140, 141, 1939, 1940, "1" +825, 12, 41, 513, 142, 143, 1941, 1942, ")" +825, 12, 42, 514, 144, 145, 1943, 1944, "x" +825, 12, 43, 515, 146, 150, 1945, 1949, "year" +825, 12, 44, 516, 151, 152, 1950, 1951, "(" +825, 12, 45, 517, 153, 154, 1952, 1953, "-" +825, 12, 46, 518, 155, 156, 1954, 1955, "1" +825, 12, 47, 519, 157, 158, 1956, 1957, ")" +825, 12, 48, 520, 159, 160, 1958, 1959, "," +825, 12, 49, 521, 161, 162, 1960, 1961, "P" +825, 12, 50, 522, 163, 164, 1962, 1963, "=" +825, 12, 51, 523, 165, 166, 1964, 1965, "0" +825, 12, 52, 524, 167, 168, 1966, 1967, "." +825, 12, 53, 525, 169, 172, 1968, 1971, "007" +825, 12, 54, 526, 173, 174, 1972, 1973, ")" +825, 12, 55, 527, 175, 178, 1974, 1977, "but" +825, 12, 56, 528, 179, 184, 1978, 1983, "lower" +825, 12, 57, 529, 185, 194, 1984, 1993, "nocturnal" +825, 12, 58, 530, 195, 207, 1994, 2006, "hypoglycemia" +825, 12, 59, 531, 208, 212, 2007, 2011, "rate" +825, 12, 60, 532, 213, 214, 2012, 2013, "(" +825, 12, 61, 533, 215, 216, 2014, 2015, "8" +825, 12, 62, 534, 217, 218, 2016, 2017, "." +825, 12, 63, 535, 219, 220, 2018, 2019, "9" +825, 12, 64, 536, 221, 222, 2020, 2021, "+" +825, 12, 65, 537, 223, 224, 2022, 2023, "/" +825, 12, 66, 538, 225, 226, 2024, 2025, "-" +825, 12, 67, 539, 227, 229, 2026, 2028, "19" +825, 12, 68, 540, 230, 231, 2029, 2030, "." +825, 12, 69, 541, 232, 233, 2031, 2032, "3" +825, 12, 70, 542, 234, 236, 2033, 2035, "vs" +825, 12, 71, 543, 237, 238, 2036, 2037, "." +825, 12, 72, 544, 239, 241, 2038, 2040, "11" +825, 12, 73, 545, 242, 243, 2041, 2042, "." +825, 12, 74, 546, 244, 245, 2043, 2044, "4" +825, 12, 75, 547, 246, 247, 2045, 2046, "+" +825, 12, 76, 548, 248, 249, 2047, 2048, "/" +825, 12, 77, 549, 250, 251, 2049, 2050, "-" +825, 12, 78, 550, 252, 254, 2051, 2053, "25" +825, 12, 79, 551, 255, 256, 2054, 2055, "." +825, 12, 80, 552, 257, 258, 2056, 2057, "3" +825, 12, 81, 553, 259, 267, 2058, 2066, "episodes" +825, 12, 82, 554, 268, 269, 2067, 2068, "x" +825, 12, 83, 555, 270, 272, 2069, 2071, "pt" +825, 12, 84, 556, 273, 274, 2072, 2073, "(" +825, 12, 85, 557, 275, 276, 2074, 2075, "-" +825, 12, 86, 558, 277, 278, 2076, 2077, "1" +825, 12, 87, 559, 279, 280, 2078, 2079, ")" +825, 12, 88, 560, 281, 282, 2080, 2081, "x" +825, 12, 89, 561, 283, 287, 2082, 2086, "year" +825, 12, 90, 562, 288, 289, 2087, 2088, "(" +825, 12, 91, 563, 290, 291, 2089, 2090, "-" +825, 12, 92, 564, 292, 293, 2091, 2092, "1" +825, 12, 93, 565, 294, 295, 2093, 2094, ")" +825, 12, 94, 566, 296, 297, 2095, 2096, "," +825, 12, 95, 567, 298, 299, 2097, 2098, "P" +825, 12, 96, 568, 300, 301, 2099, 2100, "=" +825, 12, 97, 569, 302, 303, 2101, 2102, "0" +825, 12, 98, 570, 304, 305, 2103, 2104, "." +825, 12, 99, 571, 306, 309, 2105, 2108, "009" +825, 12, 100, 572, 310, 311, 2109, 2110, ")" +825, 12, 101, 573, 312, 313, 2111, 2112, "." +825, 13, 1, 574, 0, 6, 2113, 2119, "Severe" +825, 13, 2, 575, 7, 19, 2120, 2132, "hypoglycemia" +825, 13, 3, 576, 20, 25, 2133, 2138, "rates" +825, 13, 4, 577, 26, 30, 2139, 2143, "were" +825, 13, 5, 578, 31, 34, 2144, 2147, "low" +825, 13, 6, 579, 35, 37, 2148, 2150, "in" +825, 13, 7, 580, 38, 42, 2151, 2155, "both" +825, 13, 8, 581, 43, 49, 2156, 2162, "groups" +825, 13, 9, 582, 50, 51, 2163, 2164, "(" +825, 13, 10, 583, 52, 56, 2165, 2169, "LM75" +825, 13, 11, 584, 57, 58, 2170, 2171, "/" +825, 13, 12, 585, 59, 61, 2172, 2174, "25" +825, 13, 13, 586, 62, 63, 2175, 2176, ":" +825, 13, 14, 587, 64, 65, 2177, 2178, "0" +825, 13, 15, 588, 66, 67, 2179, 2180, "." +825, 13, 16, 589, 68, 70, 2181, 2183, "10" +825, 13, 17, 590, 71, 72, 2184, 2185, "+" +825, 13, 18, 591, 73, 74, 2186, 2187, "/" +825, 13, 19, 592, 75, 76, 2188, 2189, "-" +825, 13, 20, 593, 77, 78, 2190, 2191, "1" +825, 13, 21, 594, 79, 80, 2192, 2193, "." +825, 13, 22, 595, 81, 82, 2194, 2195, "6" +825, 13, 23, 596, 83, 85, 2196, 2198, "vs" +825, 13, 24, 597, 86, 87, 2199, 2200, "." +825, 13, 25, 598, 88, 90, 2201, 2203, "GL" +825, 13, 26, 599, 91, 92, 2204, 2205, ":" +825, 13, 27, 600, 93, 94, 2206, 2207, "0" +825, 13, 28, 601, 95, 96, 2208, 2209, "." +825, 13, 29, 602, 97, 99, 2210, 2212, "03" +825, 13, 30, 603, 100, 101, 2213, 2214, "+" +825, 13, 31, 604, 102, 103, 2215, 2216, "/" +825, 13, 32, 605, 104, 105, 2217, 2218, "-" +825, 13, 33, 606, 106, 107, 2219, 2220, "0" +825, 13, 34, 607, 108, 109, 2221, 2222, "." +825, 13, 35, 608, 110, 111, 2223, 2224, "3" +825, 13, 36, 609, 112, 120, 2225, 2233, "episodes" +825, 13, 37, 610, 121, 122, 2234, 2235, "x" +825, 13, 38, 611, 123, 125, 2236, 2238, "pt" +825, 13, 39, 612, 126, 127, 2239, 2240, "(" +825, 13, 40, 613, 128, 129, 2241, 2242, "-" +825, 13, 41, 614, 130, 131, 2243, 2244, "1" +825, 13, 42, 615, 132, 133, 2245, 2246, ")" +825, 13, 43, 616, 134, 135, 2247, 2248, "x" +825, 13, 44, 617, 136, 140, 2249, 2253, "year" +825, 13, 45, 618, 141, 142, 2254, 2255, "(" +825, 13, 46, 619, 143, 144, 2256, 2257, "-" +825, 13, 47, 620, 145, 146, 2258, 2259, "1" +825, 13, 48, 621, 147, 148, 2260, 2261, ")" +825, 13, 49, 622, 149, 150, 2262, 2263, "," +825, 13, 50, 623, 151, 152, 2264, 2265, "P" +825, 13, 51, 624, 153, 154, 2266, 2267, "=" +825, 13, 52, 625, 155, 156, 2268, 2269, "0" +825, 13, 53, 626, 157, 158, 2270, 2271, "." +825, 13, 54, 627, 159, 162, 2272, 2275, "167" +825, 13, 55, 628, 163, 164, 2276, 2277, ")" +825, 13, 56, 629, 165, 166, 2278, 2279, "." +825, 14, 1, 630, 0, 11, 2280, 2291, "CONCLUSIONS" +825, 14, 2, 631, 12, 13, 2292, 2293, ":" +825, 14, 3, 632, 14, 22, 2294, 2302, "Compared" +825, 14, 4, 633, 23, 27, 2303, 2307, "with" +825, 14, 5, 634, 28, 30, 2308, 2310, "GL" +825, 14, 6, 635, 31, 32, 2311, 2312, "," +825, 14, 7, 636, 33, 37, 2313, 2317, "LM75" +825, 14, 8, 637, 38, 39, 2318, 2319, "/" +825, 14, 9, 638, 40, 42, 2320, 2322, "25" +825, 14, 10, 639, 43, 51, 2323, 2331, "resulted" +825, 14, 11, 640, 52, 54, 2332, 2334, "in" +825, 14, 12, 641, 55, 63, 2335, 2343, "slightly" +825, 14, 13, 642, 64, 69, 2344, 2349, "lower" +825, 14, 14, 643, 70, 73, 2350, 2353, "A1C" +825, 14, 15, 644, 74, 76, 2354, 2356, "at" +825, 14, 16, 645, 77, 79, 2357, 2359, "24" +825, 14, 17, 646, 80, 85, 2360, 2365, "weeks" +825, 14, 18, 647, 86, 89, 2366, 2369, "and" +825, 14, 19, 648, 90, 91, 2370, 2371, "a" +825, 14, 20, 649, 92, 102, 2372, 2382, "moderately" +825, 14, 21, 650, 103, 109, 2383, 2389, "higher" +825, 14, 22, 651, 110, 120, 2390, 2400, "percentage" +825, 14, 23, 652, 121, 129, 2401, 2409, "reaching" +825, 14, 24, 653, 130, 133, 2410, 2413, "A1C" +825, 14, 25, 654, 134, 140, 2414, 2420, "target" +825, 14, 26, 655, 141, 142, 2421, 2422, "<" +825, 14, 27, 656, 143, 144, 2423, 2424, "7" +825, 14, 28, 657, 145, 146, 2425, 2426, "." +825, 14, 29, 658, 147, 148, 2427, 2428, "0" +825, 14, 30, 659, 149, 150, 2429, 2430, "%" +825, 14, 31, 660, 151, 152, 2431, 2432, "." +825, 15, 1, 661, 0, 8, 2433, 2441, "Patients" +825, 15, 2, 662, 9, 18, 2442, 2451, "receiving" +825, 15, 3, 663, 19, 23, 2452, 2456, "LM75" +825, 15, 4, 664, 24, 25, 2457, 2458, "/" +825, 15, 5, 665, 26, 28, 2459, 2461, "25" +825, 15, 6, 666, 29, 40, 2462, 2473, "experienced" +825, 15, 7, 667, 41, 45, 2474, 2478, "more" +825, 15, 8, 668, 46, 52, 2479, 2485, "weight" +825, 15, 9, 669, 53, 57, 2486, 2490, "gain" +825, 15, 10, 670, 58, 61, 2491, 2494, "and" +825, 15, 11, 671, 62, 68, 2495, 2501, "higher" +825, 15, 12, 672, 69, 74, 2502, 2507, "rates" +825, 15, 13, 673, 75, 77, 2508, 2510, "of" +825, 15, 14, 674, 78, 85, 2511, 2518, "overall" +825, 15, 15, 675, 86, 98, 2519, 2531, "hypoglycemia" +825, 15, 16, 676, 99, 102, 2532, 2535, "but" +825, 15, 17, 677, 103, 108, 2536, 2541, "lower" +825, 15, 18, 678, 109, 114, 2542, 2547, "rates" +825, 15, 19, 679, 115, 117, 2548, 2550, "of" +825, 15, 20, 680, 118, 127, 2551, 2560, "nocturnal" +825, 15, 21, 681, 128, 140, 2561, 2573, "hypoglycemia" +825, 15, 22, 682, 141, 142, 2574, 2575, "." +825, 16, 1, 683, 0, 10, 2576, 2586, "Durability" +825, 16, 2, 684, 11, 13, 2587, 2589, "of" +825, 16, 3, 685, 14, 22, 2590, 2598, "regimens" +825, 16, 4, 686, 23, 27, 2599, 2603, "will" +825, 16, 5, 687, 28, 30, 2604, 2606, "be" +825, 16, 6, 688, 31, 40, 2607, 2616, "evaluated" +825, 16, 7, 689, 41, 43, 2617, 2619, "in" +825, 16, 8, 690, 44, 47, 2620, 2623, "the" +825, 16, 9, 691, 48, 57, 2624, 2633, "following" +825, 16, 10, 692, 58, 59, 2634, 2635, "2" +825, 16, 11, 693, 60, 61, 2636, 2637, "-" +825, 16, 12, 694, 62, 66, 2638, 2642, "year" +825, 16, 13, 695, 67, 78, 2643, 2654, "maintenance" +825, 16, 14, 696, 79, 84, 2655, 2660, "phase" +825, 16, 15, 697, 85, 86, 2661, 2662, "." +825, 17, 1, 698, 0, 3, 2663, 2666, "DOI" +825, 17, 2, 699, 4, 5, 2667, 2668, ":" +825, 17, 3, 700, 6, 8, 2669, 2671, "10" +825, 17, 4, 701, 9, 10, 2672, 2673, "." +825, 17, 5, 702, 11, 15, 2674, 2678, "2337" +825, 17, 6, 703, 16, 17, 2679, 2680, "/" +825, 17, 7, 704, 18, 22, 2681, 2685, "dc08" +825, 17, 8, 705, 23, 24, 2686, 2687, "-" +825, 17, 9, 706, 25, 29, 2688, 2692, "2117" +825, 17, 10, 707, 30, 35, 2693, 2698, "PMCID" +825, 17, 11, 708, 36, 37, 2699, 2700, ":" +825, 17, 12, 709, 38, 48, 2701, 2711, "PMC2681037" +825, 17, 13, 710, 49, 53, 2712, 2716, "PMID" +825, 17, 14, 711, 54, 55, 2717, 2718, ":" +825, 17, 15, 712, 56, 64, 2719, 2727, "19336625" +825, 17, 16, 713, 65, 66, 2728, 2729, "[" +825, 17, 17, 714, 67, 74, 2730, 2737, "Indexed" +825, 17, 18, 715, 75, 78, 2738, 2741, "for" +825, 17, 19, 716, 79, 86, 2742, 2749, "MEDLINE" +825, 17, 20, 717, 87, 88, 2750, 2751, "]" diff --git a/data/dm2 19336625_admin.annodb b/data/dm2 19336625_admin.annodb new file mode 100644 index 0000000..79b6f33 --- /dev/null +++ b/data/dm2 19336625_admin.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2009", "", " \"2009\"." +114, Title, 101, 348, "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .", "", " \"DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .\"." +52921, Lispro75/25, 128, 154, "lispro mix 75 / 25 insulin", "", +6, Duration, 182, 191, "24 - week", "", " \"24 - week\"." +52922, Lispro75/25, 225, 251, "insulin lispro mix 75 / 25", "", +3, InsulinGlargine, 259, 275, "insulin glargine", "", +4, OralAntidiabeticAgent, 285, 313, "oral antihyperglycemic drugs", "", +5, Type2Diabetes, 331, 346, "type 2 diabetes", "", +7, Author, 349, 356, "Buse JB", "", " \"Buse JB\"." +8, Author, 365, 381, "Wolffenbuttel BH", "", " \"Wolffenbuttel BH\"." +9, Author, 384, 393, "Herman WH", "", " \"Herman WH\"." +10, Author, 396, 408, "Shemonsky NK", "", " \"Shemonsky NK\"." +11, Author, 411, 419, "Jiang HH", "", " \"Jiang HH\"." +12, Author, 422, 433, "Fahrbach JL", "", " \"Fahrbach JL\"." +13, Author, 436, 452, "Scism - Bacon JL", "", " \"Scism - Bacon JL\"." +14, Author, 455, 464, "Martin SA", "", " \"Martin SA\"." +15, USA, 628, 631, "USA", "", " ." +206, ObjectiveDescription, 670, 818, "To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes .", "", " \"To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes .\"." +16, Insulin, 708, 715, "insulin", "", +18, Ethnicity, 766, 784, "ethnically diverse", "", " . ." +17, Type2Diabetes, 801, 816, "type 2 diabetes", "", " ." +19, Randomized, 914, 924, "randomized", "", " ." +20, Frequency, 930, 943, "twice - daily", "", " \"twice - daily\"." +52923, Lispro75/25, 944, 962, "lispro mix 75 / 25", "", " ." +52924, Lispro75/25, 965, 979, "LM75 / 25 ; 75", "", +52925, LisproProtamine, 982, 998, "lispro protamine", "", +121, Lispro, 1017, 1023, "lispro", "", +21, NumberPatientsArm, 1032, 1039, "1 , 045", "", " \"1 , 045\"." +22, Frequency, 1045, 1050, "daily", "", " \"daily\"." +23, InsulinGlargine, 1051, 1059, "glargine", "", " ." +24, InsulinGlargine, 1062, 1064, "GL", "", +25, NumberPatientsArm, 1073, 1080, "1 , 046", "", " \"1 , 046\"." +106269, Precondition, 1088, 1141, "continuation of prestudy oral antihyperglycemic drugs", "", " \"continuation of prestudy oral antihyperglycemic drugs\"." +26, OralAntidiabeticAgent, 1113, 1141, "oral antihyperglycemic drugs", "", +27, HbA1c, 1163, 1166, "A1C", "", +52926, Lispro75/25, 1181, 1190, "LM75 / 25", "", +28, BaseLineValue, 1193, 1198, "9 . 1", "", " \"9 . 1\"." +29, SdDevBL, 1205, 1210, "1 . 3", "", " \"1 . 3\"." +30, Percentage, 1211, 1212, "%", "", +31, InsulinGlargine, 1215, 1217, "GL", "", +32, BaseLineValue, 1220, 1225, "9 . 0", "", " \"9 . 0\"." +33, SdDevBL, 1232, 1237, "1 . 2", "", " \"1 . 2\"." +34, Percentage, 1238, 1239, "%", "", +35, PvalueDiff, 1242, 1253, "P = 0 . 414", "", " \"P = 0 . 414\"." +210, TimePoint, 1261, 1269, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +102230, Lispro75/25, 1272, 1281, "LM75 / 25", "", +36, HbA1c, 1301, 1304, "A1C", "", " ." +37, InsulinGlargine, 1310, 1312, "GL", "", +38, ResultMeasuredValue, 1324, 1329, "7 . 2", "", " \"7 . 2\"." +40, SdDevResValue, 1336, 1341, "1 . 1", "", " \"1 . 1\"." +39, ResultMeasuredValue, 1347, 1352, "7 . 3", "", " \"7 . 3\"." +41, SdDevResValue, 1359, 1364, "1 . 1", "", " \"1 . 1\"." +42, Percentage, 1365, 1366, "%", "", " ." +43, PvalueDiff, 1369, 1380, "P = 0 . 005", "", " \"P = 0 . 005\"." +44, HbA1c, 1393, 1396, "A1C", "", +45, Reduction, 1411, 1416, "1 . 8", "", " \"1 . 8\"." +47, SdDevChangeValue, 1423, 1428, "1 . 3", "", " \"1 . 3\"." +46, Reduction, 1436, 1441, "1 . 7", "", " \"1 . 7\"." +48, SdDevChangeValue, 1448, 1453, "1 . 3", "", " \"1 . 3\"." +49, Percentage, 1454, 1455, "%", "", +50, PvalueDiff, 1458, 1469, "P = 0 . 005", "", " \"P = 0 . 005\"." +51, HbA1c_target, 1505, 1525, "A1C target < 7 . 0 %", "", " ." +197, Percentage, 1524, 1525, "%", "", +52940, PercentageAffected, 1528, 1534, "47 . 5", "", " \"47 . 5\"." +53, PercentageAffected, 1540, 1546, "40 . 3", "", " \"40 . 3\"." +54, PvalueDiff, 1551, 1562, "P < 0 . 001", "", " \"P < 0 . 001\"." +52927, Lispro75/25, 1567, 1576, "LM75 / 25", "", +216, InsulinDose, 1604, 1616, "insulin dose", "", " . ." +55, ResultMeasuredValue, 1619, 1625, "0 . 47", "", " \"0 . 47\"." +57, SdDevResValue, 1632, 1638, "0 . 23", "", " \"0 . 23\"." +56, ResultMeasuredValue, 1644, 1650, "0 . 40", "", " \"0 . 40\"." +58, SdDevResValue, 1657, 1663, "0 . 23", "", " \"0 . 23\"." +59, IntUnit_per_Kg, 1664, 1674, "units x kg", "", " ." +60, PvalueDiff, 1699, 1710, "P < 0 . 001", "", " \"P < 0 . 001\"." +52932, WeightGain, 1722, 1733, "weight gain", "", " ." +157, ResultMeasuredValue, 1736, 1741, "3 . 6", "", " \"3 . 6\"." +52933, SdDevResValue, 1748, 1753, "4 . 0", "", " \"4 . 0\"." +158, ResultMeasuredValue, 1759, 1764, "2 . 5", "", " \"2 . 5\"." +52934, SdDevResValue, 1771, 1776, "4 . 0", "", " \"4 . 0\"." +66, Kg, 1777, 1779, "kg", "", " ." +67, PvalueDiff, 1782, 1794, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +52928, Lispro75/25, 1799, 1808, "LM75 / 25", "", +68, Hypoglycemia, 1839, 1851, "hypoglycemia", "", " ." +102227, AggregationMethod, 1852, 1856, "rate", "", " . ." +69, InsulinGlargine, 1862, 1864, "GL", "", +70, ResultMeasuredValue, 1876, 1882, "28 . 0", "", " \"28 . 0\"." +72, SdDevResValue, 1889, 1895, "41 . 6", "", " \"41 . 6\"." +71, ResultMeasuredValue, 1901, 1907, "23 . 1", "", " \"23 . 1\"." +73, SdDevResValue, 1914, 1920, "40 . 7", "", " \"40 . 7\"." +74, BioAndMedicalUnit, 1921, 1957, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +76, PvalueDiff, 1960, 1971, "P = 0 . 007", "", " \"P = 0 . 007\"." +75, NocturnalHypoglycemia, 1984, 2006, "nocturnal hypoglycemia", "", " ." +102226, AggregationMethod, 2007, 2011, "rate", "", " . ." +78, ResultMeasuredValue, 2014, 2019, "8 . 9", "", " \"8 . 9\"." +80, SdDevResValue, 2026, 2032, "19 . 3", "", " \"19 . 3\"." +79, ResultMeasuredValue, 2038, 2044, "11 . 4", "", " \"11 . 4\"." +81, SdDevResValue, 2051, 2057, "25 . 3", "", " \"25 . 3\"." +82, BioAndMedicalUnit, 2058, 2094, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +77, PvalueDiff, 2097, 2108, "P = 0 . 009", "", " \"P = 0 . 009\"." +83, SevereHypoglycemia, 2113, 2132, "Severe hypoglycemia", "", " ." +102225, AggregationMethod, 2133, 2138, "rates", "", " . ." +52929, Lispro75/25, 2165, 2174, "LM75 / 25", "", +84, ResultMeasuredValue, 2177, 2183, "0 . 10", "", " \"0 . 10\"." +86, SdDevResValue, 2190, 2195, "1 . 6", "", " \"1 . 6\"." +88, InsulinGlargine, 2201, 2203, "GL", "", +85, ResultMeasuredValue, 2206, 2212, "0 . 03", "", " \"0 . 03\"." +87, SdDevResValue, 2219, 2224, "0 . 3", "", " \"0 . 3\"." +89, BioAndMedicalUnit, 2225, 2261, "episodes x pt ( - 1 ) x year ( - 1 )", "", " . ." +90, PvalueDiff, 2264, 2275, "P = 0 . 167", "", " \"P = 0 . 167\"." +200, ConclusionComment, 2294, 2432, "Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % .", "", " \"Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % .\"." +91, InsulinGlargine, 2308, 2310, "GL", "", +52930, Lispro75/25, 2313, 2322, "LM75 / 25", "", +92, HbA1c, 2350, 2353, "A1C", "", +221, TimePoint, 2357, 2365, "24 weeks", "", +93, HbA1c_target, 2410, 2430, "A1C target < 7 . 0 %", "", +199, Percentage, 2429, 2430, "%", "", +201, ConclusionComment, 2433, 2575, "Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia .", "", " \"Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia .\"." +52931, Lispro75/25, 2452, 2461, "LM75 / 25", "", +8767, WeightGain, 2479, 2490, "weight gain", "", +102229, AggregationMethod, 2502, 2507, "rates", "", +95, Hypoglycemia, 2519, 2531, "hypoglycemia", "", +102228, AggregationMethod, 2542, 2547, "rates", "", +96, NocturnalHypoglycemia, 2551, 2573, "nocturnal hypoglycemia", "", +202, ConclusionComment, 2576, 2662, "Durability of regimens will be evaluated in the following 2 - year maintenance phase .", "", " \"Durability of regimens will be evaluated in the following 2 - year maintenance phase .\"." +189, Duration, 2634, 2642, "2 - year", "", +97, PMID, 2719, 2727, "19336625", "", " \"19336625\"." diff --git a/data/dm2 19336625_admin.n-triples b/data/dm2 19336625_admin.n-triples new file mode 100644 index 0000000..58a2156 --- /dev/null +++ b/data/dm2 19336625_admin.n-triples @@ -0,0 +1,270 @@ +# RDF export of group: Publication + . + "Publication " . + "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes ." . + "Buse JB" . + "2009" . + "Diabetes Care" . + "19336625" . + . + "Wolffenbuttel BH" . + "Herman WH" . + "Shemonsky NK" . + "Jiang HH" . + "Fahrbach JL" . + "Scism - Bacon JL" . + "Martin SA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes ." . + "24 - week" . + . + . + . + "Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % ." . + . + . + . + . + . + "Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia ." . + "Durability of regimens will be evaluated in the following 2 - year maintenance phase ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "continuation of prestudy oral antihyperglycemic drugs" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + "1 , 045" . + . + . + . + . + . + . + . + . + . + "Arm ig" . + "1 , 046" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + "twice - daily" . + . + . + . + "Intervention ig" . + "daily" . + . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + . + "Medication ig" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c l" . + . + "9 . 1" . + "1 . 3" . + "7 . 2" . + "1 . 1" . + "1 . 8" . + "1 . 3" . + "24 weeks" . + . + "Outcome hba1c ig" . + . + "9 . 0" . + "1 . 2" . + "7 . 3" . + "1 . 1" . + "1 . 7" . + "1 . 3" . + "24 weeks" . + . + "Outcome hba1c target l" . + . + "47 . 5" . + . + "Outcome hba1c target ig" . + . + "40 . 3" . + . + "Outcome id l " . + . + "0 . 47" . + "0 . 23" . + . + "Outcome id ig" . + . + "0 . 40" . + "0 . 23" . + . + "Outcome weight l" . + . + "3 . 6" . + "4 . 0" . + . + "Outcome weight ig" . + . + "2 . 5" . + "4 . 0" . + . + "Outcome h l " . + . + "28 . 0" . + "41 . 6" . + . + "Outcome h ig" . + . + "23 . 1" . + "40 . 7" . + . + "Outcome nh l" . + . + "8 . 9" . + "19 . 3" . + . + "Outcome nh ig" . + . + "11 . 4" . + "25 . 3" . + . + "Outcome sh l" . + . + "0 . 10" . + "1 . 6" . + . + "Outcome sh ig" . + . + "0 . 03" . + "0 . 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c baseline" . + "P = 0 . 414" . + . + . + . + "DiffBetweenGroups hba1c resultvalue" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups hba1c changevalue" . + "P = 0 . 005" . + . + . + . + "DiffBetweenGroups hba1c target" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups id" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups weight" . + "P < 0 . 0001" . + . + . + . + "DiffBetweenGroups h" . + "P = 0 . 007" . + . + . + . + "DiffBetweenGroups nh" . + "P = 0 . 009" . + . + . + . + "DiffBetweenGroups sh" . + "P = 0 . 167" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19336625_akramersunderbrink.annodb b/data/dm2 19336625_akramersunderbrink.annodb new file mode 100644 index 0000000..5f17f1d --- /dev/null +++ b/data/dm2 19336625_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +28440, Journal, 0, 13, "Diabetes Care", "", +28441, PublicationYear, 16, 20, "2009", "", +28457, Title, 101, 348, "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .", "", +28448, Lispro, 128, 146, "lispro mix 75 / 25", "", +28442, Duration, 182, 191, "24 - week", "", +28447, Lispro, 225, 251, "insulin lispro mix 75 / 25", "", +28444, InsulinGlargine, 259, 275, "insulin glargine", "", +28445, OralAntidiabeticAgent, 285, 313, "oral antihyperglycemic drugs", "", +28446, Type2Diabetes, 331, 346, "type 2 diabetes", "", +28449, Author, 349, 356, "Buse JB", "", +28450, Author, 365, 381, "Wolffenbuttel BH", "", +28451, Author, 384, 393, "Herman WH", "", +28452, Author, 396, 408, "Shemonsky NK", "", +28453, Author, 411, 419, "Jiang HH", "", +28454, Author, 422, 433, "Fahrbach JL", "", +28455, Author, 436, 452, "Scism - Bacon JL", "", +28456, Author, 455, 464, "Martin SA", "", +28460, USA, 628, 631, "USA", "", +28461, Insulin, 708, 715, "insulin", "", +28462, Type2Diabetes, 801, 816, "type 2 diabetes", "", +28463, Randomized, 914, 924, "randomized", "", +28464, Frequency, 930, 943, "twice - daily", "", +28465, Lispro, 944, 962, "lispro mix 75 / 25", "", +28467, Lispro, 965, 974, "LM75 / 25", "", +28538, Percentage, 980, 981, "%", "", +28539, Percentage, 1015, 1016, "%", "", +28466, Lispro, 1017, 1023, "lispro", "", +28468, NumberPatientsCT, 1032, 1039, "1 , 045", "", +28469, InsulinGlargine, 1051, 1059, "glargine", "", +28470, InsulinGlargine, 1062, 1064, "GL", "", +28471, NumberPatientsCT, 1073, 1080, "1 , 046", "", +28472, OralAntidiabeticAgent, 1113, 1141, "oral antihyperglycemic drugs", "", +39176, TimePoint, 1154, 1162, "Baseline", "", +28473, HbA1c, 1163, 1166, "A1C", "", +28474, Lispro, 1181, 1190, "LM75 / 25", "", +28476, BaseLineValue, 1193, 1198, "9 . 1", "", +28541, Percentage, 1211, 1212, "%", "", +28475, InsulinGlargine, 1215, 1217, "GL", "", +28477, BaseLineValue, 1220, 1225, "9 . 0", "", +28540, Percentage, 1238, 1239, "%", "", +28478, PvalueDiff, 1242, 1253, "P = 0 . 414", "", +28479, Duration, 1261, 1269, "24 weeks", "", +28480, Lispro, 1272, 1281, "LM75 / 25", "", +28481, HbA1c, 1301, 1304, "A1C", "", +28482, InsulinGlargine, 1310, 1312, "GL", "", +28483, ResultMeasuredValue, 1324, 1329, "7 . 2", "", +28484, ResultMeasuredValue, 1347, 1352, "7 . 3", "", +28542, Percentage, 1365, 1366, "%", "", +28485, PvalueDiff, 1369, 1380, "P = 0 . 005", "", +28486, HbA1c, 1393, 1396, "A1C", "", +28487, ChangeValue, 1409, 1416, "- 1 . 8", "", +28488, ChangeValue, 1434, 1441, "- 1 . 7", "", +28545, Percentage, 1454, 1455, "%", "", +28489, PValueChangeValue, 1458, 1469, "P = 0 . 005", "", +28490, HbA1c_target, 1505, 1525, "A1C target < 7 . 0 %", "", +28544, Percentage, 1524, 1525, "%", "", +28491, PercentageAffected, 1528, 1534, "47 . 5", "", +28492, PercentageAffected, 1540, 1546, "40 . 3", "", +28543, Percentage, 1547, 1548, "%", "", +28493, PvalueDiff, 1551, 1562, "P < 0 . 001", "", +28494, Lispro, 1567, 1576, "LM75 / 25", "", +28495, EndPointDescription, 1604, 1616, "insulin dose", "", +28496, Insulin, 1604, 1611, "insulin", "", +28498, ResultMeasuredValue, 1619, 1625, "0 . 47", "", +28499, ResultMeasuredValue, 1644, 1650, "0 . 40", "", +28500, BioAndMedicalUnit, 1664, 1696, "units x kg ( - 1 ) x day ( - 1 )", "", +28497, PvalueDiff, 1699, 1710, "P < 0 . 001", "", +28501, BodyWeight, 1722, 1733, "weight gain", "", +28502, ResultMeasuredValue, 1736, 1741, "3 . 6", "", +28503, ResultMeasuredValue, 1759, 1764, "2 . 5", "", +28504, Kg, 1777, 1779, "kg", "", +28505, PvalueDiff, 1782, 1794, "P < 0 . 0001", "", +28506, Lispro, 1799, 1808, "LM75 / 25", "", +28514, Hypoglycemia, 1839, 1856, "hypoglycemia rate", "", +28507, InsulinGlargine, 1862, 1864, "GL", "", +28509, ResultMeasuredValue, 1876, 1882, "28 . 0", "", +28510, ResultMeasuredValue, 1901, 1907, "23 . 1", "", +28511, BioAndMedicalUnit, 1921, 1957, "episodes x pt ( - 1 ) x year ( - 1 )", "", +28512, PvalueDiff, 1960, 1971, "P = 0 . 007", "", +28513, NocturnalHypoglycemia, 1984, 2011, "nocturnal hypoglycemia rate", "", +28515, ResultMeasuredValue, 2014, 2019, "8 . 9", "", +28516, ResultMeasuredValue, 2038, 2044, "11 . 4", "", +28517, BioAndMedicalUnit, 2058, 2094, "episodes x pt ( - 1 ) x year ( - 1 )", "", +28518, PvalueDiff, 2097, 2108, "P = 0 . 009", "", +28520, SevereHypoglycemia, 2113, 2138, "Severe hypoglycemia rates", "", +28519, Lispro, 2165, 2174, "LM75 / 25", "", +28521, ResultMeasuredValue, 2177, 2183, "0 . 10", "", +28523, InsulinGlargine, 2201, 2203, "GL", "", +28522, ResultMeasuredValue, 2206, 2212, "0 . 03", "", +28524, BioAndMedicalUnit, 2225, 2261, "episodes x pt ( - 1 ) x year ( - 1 )", "", +28525, PvalueDiff, 2264, 2275, "P = 0 . 167", "", +28603, ConclusionComment, 2294, 2432, "Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % .", "", +28526, InsulinGlargine, 2308, 2310, "GL", "", +28527, Lispro, 2313, 2322, "LM75 / 25", "", +28528, HbA1c, 2350, 2353, "A1C", "", +28529, Duration, 2357, 2365, "24 weeks", "", +28530, HbA1c_target, 2410, 2430, "A1C target < 7 . 0 %", "", +28546, Percentage, 2429, 2430, "%", "", +28604, ConclusionComment, 2433, 2575, "Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia .", "", +28531, Lispro, 2452, 2461, "LM75 / 25", "", +28532, WeightGain, 2479, 2490, "weight gain", "", +28533, Hypoglycemia, 2511, 2531, "overall hypoglycemia", "", +28534, NocturnalHypoglycemia, 2551, 2573, "nocturnal hypoglycemia", "", +28605, ConclusionComment, 2576, 2662, "Durability of regimens will be evaluated in the following 2 - year maintenance phase .", "", +28535, Duration, 2634, 2642, "2 - year", "", +28537, PMID, 2719, 2727, "19336625", "", diff --git a/data/dm2 19336625_akramersunderbrink.n-triples b/data/dm2 19336625_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19336625_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19336625_export.csv b/data/dm2 19336625_export.csv new file mode 100644 index 0000000..5c6749d --- /dev/null +++ b/data/dm2 19336625_export.csv @@ -0,0 +1,718 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +339, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +339, 1, 2, 2, 9, 13, 9, 13, "Care" +339, 1, 3, 3, 14, 15, 14, 15, "." +339, 2, 1, 4, 0, 4, 16, 20, "2009" +339, 2, 2, 5, 5, 8, 21, 24, "Jun" +339, 2, 3, 6, 9, 10, 25, 26, ";" +339, 2, 4, 7, 11, 13, 27, 29, "32" +339, 2, 5, 8, 14, 15, 30, 31, "(" +339, 2, 6, 9, 16, 17, 32, 33, "6" +339, 2, 7, 10, 18, 19, 34, 35, ")" +339, 2, 8, 11, 20, 21, 36, 37, ":" +339, 2, 9, 12, 22, 26, 38, 42, "1007" +339, 2, 10, 13, 27, 28, 43, 44, "-" +339, 2, 11, 14, 29, 31, 45, 47, "13" +339, 2, 12, 15, 32, 33, 48, 49, "." +339, 2, 13, 16, 34, 37, 50, 53, "doi" +339, 2, 14, 17, 38, 39, 54, 55, ":" +339, 2, 15, 18, 40, 42, 56, 58, "10" +339, 2, 16, 19, 43, 44, 59, 60, "." +339, 2, 17, 20, 45, 49, 61, 65, "2337" +339, 2, 18, 21, 50, 51, 66, 67, "/" +339, 2, 19, 22, 52, 56, 68, 72, "dc08" +339, 2, 20, 23, 57, 58, 73, 74, "-" +339, 2, 21, 24, 59, 63, 75, 79, "2117" +339, 2, 22, 25, 64, 65, 80, 81, "." +339, 3, 1, 26, 0, 4, 82, 86, "Epub" +339, 3, 2, 27, 5, 9, 87, 91, "2009" +339, 3, 3, 28, 10, 13, 92, 95, "Mar" +339, 3, 4, 29, 14, 16, 96, 98, "31" +339, 3, 5, 30, 17, 18, 99, 100, "." +339, 4, 1, 31, 0, 10, 101, 111, "DURAbility" +339, 4, 2, 32, 11, 13, 112, 114, "of" +339, 4, 3, 33, 14, 19, 115, 120, "basal" +339, 4, 4, 34, 20, 26, 121, 127, "versus" +339, 4, 5, 35, 27, 33, 128, 134, "lispro" +339, 4, 6, 36, 34, 37, 135, 138, "mix" +339, 4, 7, 37, 38, 40, 139, 141, "75" +339, 4, 8, 38, 41, 42, 142, 143, "/" +339, 4, 9, 39, 43, 45, 144, 146, "25" +339, 4, 10, 40, 46, 53, 147, 154, "insulin" +339, 4, 11, 41, 54, 62, 155, 163, "efficacy" +339, 4, 12, 42, 63, 64, 164, 165, "(" +339, 4, 13, 43, 65, 72, 166, 173, "DURABLE" +339, 4, 14, 44, 73, 74, 174, 175, ")" +339, 4, 15, 45, 75, 80, 176, 181, "trial" +339, 4, 16, 46, 81, 83, 182, 184, "24" +339, 4, 17, 47, 84, 85, 185, 186, "-" +339, 4, 18, 48, 86, 90, 187, 191, "week" +339, 4, 19, 49, 91, 98, 192, 199, "results" +339, 4, 20, 50, 99, 100, 200, 201, ":" +339, 4, 21, 51, 101, 107, 202, 208, "safety" +339, 4, 22, 52, 108, 111, 209, 212, "and" +339, 4, 23, 53, 112, 120, 213, 221, "efficacy" +339, 4, 24, 54, 121, 123, 222, 224, "of" +339, 4, 25, 55, 124, 131, 225, 232, "insulin" +339, 4, 26, 56, 132, 138, 233, 239, "lispro" +339, 4, 27, 57, 139, 142, 240, 243, "mix" +339, 4, 28, 58, 143, 145, 244, 246, "75" +339, 4, 29, 59, 146, 147, 247, 248, "/" +339, 4, 30, 60, 148, 150, 249, 251, "25" +339, 4, 31, 61, 151, 157, 252, 258, "versus" +339, 4, 32, 62, 158, 165, 259, 266, "insulin" +339, 4, 33, 63, 166, 174, 267, 275, "glargine" +339, 4, 34, 64, 175, 180, 276, 281, "added" +339, 4, 35, 65, 181, 183, 282, 284, "to" +339, 4, 36, 66, 184, 188, 285, 289, "oral" +339, 4, 37, 67, 189, 206, 290, 307, "antihyperglycemic" +339, 4, 38, 68, 207, 212, 308, 313, "drugs" +339, 4, 39, 69, 213, 215, 314, 316, "in" +339, 4, 40, 70, 216, 224, 317, 325, "patients" +339, 4, 41, 71, 225, 229, 326, 330, "with" +339, 4, 42, 72, 230, 234, 331, 335, "type" +339, 4, 43, 73, 235, 236, 336, 337, "2" +339, 4, 44, 74, 237, 245, 338, 346, "diabetes" +339, 4, 45, 75, 246, 247, 347, 348, "." +339, 5, 1, 76, 0, 4, 349, 353, "Buse" +339, 5, 2, 77, 5, 7, 354, 356, "JB" +339, 5, 3, 78, 8, 9, 357, 358, "(" +339, 5, 4, 79, 10, 11, 359, 360, "1" +339, 5, 5, 80, 12, 13, 361, 362, ")" +339, 5, 6, 81, 14, 15, 363, 364, "," +339, 5, 7, 82, 16, 29, 365, 378, "Wolffenbuttel" +339, 5, 8, 83, 30, 32, 379, 381, "BH" +339, 5, 9, 84, 33, 34, 382, 383, "," +339, 5, 10, 85, 35, 41, 384, 390, "Herman" +339, 5, 11, 86, 42, 44, 391, 393, "WH" +339, 5, 12, 87, 45, 46, 394, 395, "," +339, 5, 13, 88, 47, 56, 396, 405, "Shemonsky" +339, 5, 14, 89, 57, 59, 406, 408, "NK" +339, 5, 15, 90, 60, 61, 409, 410, "," +339, 5, 16, 91, 62, 67, 411, 416, "Jiang" +339, 5, 17, 92, 68, 70, 417, 419, "HH" +339, 5, 18, 93, 71, 72, 420, 421, "," +339, 5, 19, 94, 73, 81, 422, 430, "Fahrbach" +339, 5, 20, 95, 82, 84, 431, 433, "JL" +339, 5, 21, 96, 85, 86, 434, 435, "," +339, 5, 22, 97, 87, 92, 436, 441, "Scism" +339, 5, 23, 98, 93, 94, 442, 443, "-" +339, 5, 24, 99, 95, 100, 444, 449, "Bacon" +339, 5, 25, 100, 101, 103, 450, 452, "JL" +339, 5, 26, 101, 104, 105, 453, 454, "," +339, 5, 27, 102, 106, 112, 455, 461, "Martin" +339, 5, 28, 103, 113, 115, 462, 464, "SA" +339, 5, 29, 104, 116, 117, 465, 466, "." +339, 6, 1, 105, 0, 6, 467, 473, "Author" +339, 6, 2, 106, 7, 18, 474, 485, "information" +339, 6, 3, 107, 19, 20, 486, 487, ":" +339, 6, 4, 108, 21, 22, 488, 489, "(" +339, 6, 5, 109, 23, 24, 490, 491, "1" +339, 6, 6, 110, 25, 26, 492, 493, ")" +339, 6, 7, 111, 27, 35, 494, 502, "Division" +339, 6, 8, 112, 36, 38, 503, 505, "of" +339, 6, 9, 113, 39, 52, 506, 519, "Endocrinology" +339, 6, 10, 114, 53, 54, 520, 521, "," +339, 6, 11, 115, 55, 65, 522, 532, "Department" +339, 6, 12, 116, 66, 68, 533, 535, "of" +339, 6, 13, 117, 69, 77, 536, 544, "Medicine" +339, 6, 14, 118, 78, 79, 545, 546, "," +339, 6, 15, 119, 80, 90, 547, 557, "University" +339, 6, 16, 120, 91, 93, 558, 560, "of" +339, 6, 17, 121, 94, 99, 561, 566, "North" +339, 6, 18, 122, 100, 108, 567, 575, "Carolina" +339, 6, 19, 123, 109, 115, 576, 582, "School" +339, 6, 20, 124, 116, 118, 583, 585, "of" +339, 6, 21, 125, 119, 127, 586, 594, "Medicine" +339, 6, 22, 126, 128, 129, 595, 596, "," +339, 6, 23, 127, 130, 136, 597, 603, "Chapel" +339, 6, 24, 128, 137, 141, 604, 608, "Hill" +339, 6, 25, 129, 142, 143, 609, 610, "," +339, 6, 26, 130, 144, 149, 611, 616, "North" +339, 6, 27, 131, 150, 158, 617, 625, "Carolina" +339, 6, 28, 132, 159, 160, 626, 627, "," +339, 6, 29, 133, 161, 164, 628, 631, "USA" +339, 6, 30, 134, 165, 166, 632, 633, "." +339, 7, 1, 135, 0, 5, 634, 639, "jbuse" +339, 7, 2, 136, 6, 7, 640, 641, "@" +339, 7, 3, 137, 8, 11, 642, 645, "med" +339, 7, 4, 138, 12, 13, 646, 647, "." +339, 7, 5, 139, 14, 17, 648, 651, "unc" +339, 7, 6, 140, 18, 19, 652, 653, "." +339, 7, 7, 141, 20, 23, 654, 657, "edu" +339, 7, 8, 142, 24, 33, 658, 667, "OBJECTIVE" +339, 7, 9, 143, 34, 35, 668, 669, ":" +339, 7, 10, 144, 36, 38, 670, 672, "To" +339, 7, 11, 145, 39, 46, 673, 680, "compare" +339, 7, 12, 146, 47, 50, 681, 684, "the" +339, 7, 13, 147, 51, 58, 685, 692, "ability" +339, 7, 14, 148, 59, 61, 693, 695, "of" +339, 7, 15, 149, 62, 65, 696, 699, "two" +339, 7, 16, 150, 66, 73, 700, 707, "starter" +339, 7, 17, 151, 74, 81, 708, 715, "insulin" +339, 7, 18, 152, 82, 90, 716, 724, "regimens" +339, 7, 19, 153, 91, 93, 725, 727, "to" +339, 7, 20, 154, 94, 101, 728, 735, "achieve" +339, 7, 21, 155, 102, 110, 736, 744, "glycemic" +339, 7, 22, 156, 111, 118, 745, 752, "control" +339, 7, 23, 157, 119, 121, 753, 755, "in" +339, 7, 24, 158, 122, 123, 756, 757, "a" +339, 7, 25, 159, 124, 129, 758, 763, "large" +339, 7, 26, 160, 130, 131, 764, 765, "," +339, 7, 27, 161, 132, 142, 766, 776, "ethnically" +339, 7, 28, 162, 143, 150, 777, 784, "diverse" +339, 7, 29, 163, 151, 161, 785, 795, "population" +339, 7, 30, 164, 162, 166, 796, 800, "with" +339, 7, 31, 165, 167, 171, 801, 805, "type" +339, 7, 32, 166, 172, 173, 806, 807, "2" +339, 7, 33, 167, 174, 182, 808, 816, "diabetes" +339, 7, 34, 168, 183, 184, 817, 818, "." +339, 8, 1, 169, 0, 8, 819, 827, "RESEARCH" +339, 8, 2, 170, 9, 15, 828, 834, "DESIGN" +339, 8, 3, 171, 16, 19, 835, 838, "AND" +339, 8, 4, 172, 20, 27, 839, 846, "METHODS" +339, 8, 5, 173, 28, 29, 847, 848, ":" +339, 8, 6, 174, 30, 36, 849, 855, "During" +339, 8, 7, 175, 37, 40, 856, 859, "the" +339, 8, 8, 176, 41, 51, 860, 870, "initiation" +339, 8, 9, 177, 52, 57, 871, 876, "phase" +339, 8, 10, 178, 58, 60, 877, 879, "of" +339, 8, 11, 179, 61, 64, 880, 883, "the" +339, 8, 12, 180, 65, 72, 884, 891, "DURABLE" +339, 8, 13, 181, 73, 78, 892, 897, "trial" +339, 8, 14, 182, 79, 80, 898, 899, "," +339, 8, 15, 183, 81, 89, 900, 908, "patients" +339, 8, 16, 184, 90, 94, 909, 913, "were" +339, 8, 17, 185, 95, 105, 914, 924, "randomized" +339, 8, 18, 186, 106, 108, 925, 927, "to" +339, 8, 19, 187, 109, 110, 928, 929, "a" +339, 8, 20, 188, 111, 116, 930, 935, "twice" +339, 8, 21, 189, 117, 118, 936, 937, "-" +339, 8, 22, 190, 119, 124, 938, 943, "daily" +339, 8, 23, 191, 125, 131, 944, 950, "lispro" +339, 8, 24, 192, 132, 135, 951, 954, "mix" +339, 8, 25, 193, 136, 138, 955, 957, "75" +339, 8, 26, 194, 139, 140, 958, 959, "/" +339, 8, 27, 195, 141, 143, 960, 962, "25" +339, 8, 28, 196, 144, 145, 963, 964, "(" +339, 8, 29, 197, 146, 150, 965, 969, "LM75" +339, 8, 30, 198, 151, 152, 970, 971, "/" +339, 8, 31, 199, 153, 155, 972, 974, "25" +339, 8, 32, 200, 156, 157, 975, 976, ";" +339, 8, 33, 201, 158, 160, 977, 979, "75" +339, 8, 34, 202, 161, 162, 980, 981, "%" +339, 8, 35, 203, 163, 169, 982, 988, "lispro" +339, 8, 36, 204, 170, 179, 989, 998, "protamine" +339, 8, 37, 205, 180, 190, 999, 1009, "suspension" +339, 8, 38, 206, 191, 192, 1010, 1011, "," +339, 8, 39, 207, 193, 195, 1012, 1014, "25" +339, 8, 40, 208, 196, 197, 1015, 1016, "%" +339, 8, 41, 209, 198, 204, 1017, 1023, "lispro" +339, 8, 42, 210, 205, 206, 1024, 1025, ")" +339, 8, 43, 211, 207, 208, 1026, 1027, "(" +339, 8, 44, 212, 209, 210, 1028, 1029, "n" +339, 8, 45, 213, 211, 212, 1030, 1031, "=" +339, 8, 46, 214, 213, 214, 1032, 1033, "1" +339, 8, 47, 215, 215, 216, 1034, 1035, "," +339, 8, 48, 216, 217, 220, 1036, 1039, "045" +339, 8, 49, 217, 221, 222, 1040, 1041, ")" +339, 8, 50, 218, 223, 225, 1042, 1044, "or" +339, 8, 51, 219, 226, 231, 1045, 1050, "daily" +339, 8, 52, 220, 232, 240, 1051, 1059, "glargine" +339, 8, 53, 221, 241, 242, 1060, 1061, "(" +339, 8, 54, 222, 243, 245, 1062, 1064, "GL" +339, 8, 55, 223, 246, 247, 1065, 1066, ")" +339, 8, 56, 224, 248, 249, 1067, 1068, "(" +339, 8, 57, 225, 250, 251, 1069, 1070, "n" +339, 8, 58, 226, 252, 253, 1071, 1072, "=" +339, 8, 59, 227, 254, 255, 1073, 1074, "1" +339, 8, 60, 228, 256, 257, 1075, 1076, "," +339, 8, 61, 229, 258, 261, 1077, 1080, "046" +339, 8, 62, 230, 262, 263, 1081, 1082, ")" +339, 8, 63, 231, 264, 268, 1083, 1087, "with" +339, 8, 64, 232, 269, 281, 1088, 1100, "continuation" +339, 8, 65, 233, 282, 284, 1101, 1103, "of" +339, 8, 66, 234, 285, 293, 1104, 1112, "prestudy" +339, 8, 67, 235, 294, 298, 1113, 1117, "oral" +339, 8, 68, 236, 299, 316, 1118, 1135, "antihyperglycemic" +339, 8, 69, 237, 317, 322, 1136, 1141, "drugs" +339, 8, 70, 238, 323, 324, 1142, 1143, "." +339, 9, 1, 239, 0, 7, 1144, 1151, "RESULTS" +339, 9, 2, 240, 8, 9, 1152, 1153, ":" +339, 9, 3, 241, 10, 18, 1154, 1162, "Baseline" +339, 9, 4, 242, 19, 22, 1163, 1166, "A1C" +339, 9, 5, 243, 23, 26, 1167, 1170, "was" +339, 9, 6, 244, 27, 34, 1171, 1178, "similar" +339, 9, 7, 245, 35, 36, 1179, 1180, "(" +339, 9, 8, 246, 37, 41, 1181, 1185, "LM75" +339, 9, 9, 247, 42, 43, 1186, 1187, "/" +339, 9, 10, 248, 44, 46, 1188, 1190, "25" +339, 9, 11, 249, 47, 48, 1191, 1192, ":" +339, 9, 12, 250, 49, 50, 1193, 1194, "9" +339, 9, 13, 251, 51, 52, 1195, 1196, "." +339, 9, 14, 252, 53, 54, 1197, 1198, "1" +339, 9, 15, 253, 55, 56, 1199, 1200, "+" +339, 9, 16, 254, 57, 58, 1201, 1202, "/" +339, 9, 17, 255, 59, 60, 1203, 1204, "-" +339, 9, 18, 256, 61, 62, 1205, 1206, "1" +339, 9, 19, 257, 63, 64, 1207, 1208, "." +339, 9, 20, 258, 65, 66, 1209, 1210, "3" +339, 9, 21, 259, 67, 68, 1211, 1212, "%" +339, 9, 22, 260, 69, 70, 1213, 1214, ";" +339, 9, 23, 261, 71, 73, 1215, 1217, "GL" +339, 9, 24, 262, 74, 75, 1218, 1219, ":" +339, 9, 25, 263, 76, 77, 1220, 1221, "9" +339, 9, 26, 264, 78, 79, 1222, 1223, "." +339, 9, 27, 265, 80, 81, 1224, 1225, "0" +339, 9, 28, 266, 82, 83, 1226, 1227, "+" +339, 9, 29, 267, 84, 85, 1228, 1229, "/" +339, 9, 30, 268, 86, 87, 1230, 1231, "-" +339, 9, 31, 269, 88, 89, 1232, 1233, "1" +339, 9, 32, 270, 90, 91, 1234, 1235, "." +339, 9, 33, 271, 92, 93, 1236, 1237, "2" +339, 9, 34, 272, 94, 95, 1238, 1239, "%" +339, 9, 35, 273, 96, 97, 1240, 1241, ";" +339, 9, 36, 274, 98, 99, 1242, 1243, "P" +339, 9, 37, 275, 100, 101, 1244, 1245, "=" +339, 9, 38, 276, 102, 103, 1246, 1247, "0" +339, 9, 39, 277, 104, 105, 1248, 1249, "." +339, 9, 40, 278, 106, 109, 1250, 1253, "414" +339, 9, 41, 279, 110, 111, 1254, 1255, ")" +339, 9, 42, 280, 112, 113, 1256, 1257, "." +339, 10, 1, 281, 0, 2, 1258, 1260, "At" +339, 10, 2, 282, 3, 5, 1261, 1263, "24" +339, 10, 3, 283, 6, 11, 1264, 1269, "weeks" +339, 10, 4, 284, 12, 13, 1270, 1271, "," +339, 10, 5, 285, 14, 18, 1272, 1276, "LM75" +339, 10, 6, 286, 19, 20, 1277, 1278, "/" +339, 10, 7, 287, 21, 23, 1279, 1281, "25" +339, 10, 8, 288, 24, 32, 1282, 1290, "patients" +339, 10, 9, 289, 33, 36, 1291, 1294, "had" +339, 10, 10, 290, 37, 42, 1295, 1300, "lower" +339, 10, 11, 291, 43, 46, 1301, 1304, "A1C" +339, 10, 12, 292, 47, 51, 1305, 1309, "than" +339, 10, 13, 293, 52, 54, 1310, 1312, "GL" +339, 10, 14, 294, 55, 63, 1313, 1321, "patients" +339, 10, 15, 295, 64, 65, 1322, 1323, "(" +339, 10, 16, 296, 66, 67, 1324, 1325, "7" +339, 10, 17, 297, 68, 69, 1326, 1327, "." +339, 10, 18, 298, 70, 71, 1328, 1329, "2" +339, 10, 19, 299, 72, 73, 1330, 1331, "+" +339, 10, 20, 300, 74, 75, 1332, 1333, "/" +339, 10, 21, 301, 76, 77, 1334, 1335, "-" +339, 10, 22, 302, 78, 79, 1336, 1337, "1" +339, 10, 23, 303, 80, 81, 1338, 1339, "." +339, 10, 24, 304, 82, 83, 1340, 1341, "1" +339, 10, 25, 305, 84, 86, 1342, 1344, "vs" +339, 10, 26, 306, 87, 88, 1345, 1346, "." +339, 10, 27, 307, 89, 90, 1347, 1348, "7" +339, 10, 28, 308, 91, 92, 1349, 1350, "." +339, 10, 29, 309, 93, 94, 1351, 1352, "3" +339, 10, 30, 310, 95, 96, 1353, 1354, "+" +339, 10, 31, 311, 97, 98, 1355, 1356, "/" +339, 10, 32, 312, 99, 100, 1357, 1358, "-" +339, 10, 33, 313, 101, 102, 1359, 1360, "1" +339, 10, 34, 314, 103, 104, 1361, 1362, "." +339, 10, 35, 315, 105, 106, 1363, 1364, "1" +339, 10, 36, 316, 107, 108, 1365, 1366, "%" +339, 10, 37, 317, 109, 110, 1367, 1368, "," +339, 10, 38, 318, 111, 112, 1369, 1370, "P" +339, 10, 39, 319, 113, 114, 1371, 1372, "=" +339, 10, 40, 320, 115, 116, 1373, 1374, "0" +339, 10, 41, 321, 117, 118, 1375, 1376, "." +339, 10, 42, 322, 119, 122, 1377, 1380, "005" +339, 10, 43, 323, 123, 124, 1381, 1382, ")" +339, 10, 44, 324, 125, 126, 1383, 1384, "," +339, 10, 45, 325, 127, 134, 1385, 1392, "greater" +339, 10, 46, 326, 135, 138, 1393, 1396, "A1C" +339, 10, 47, 327, 139, 148, 1397, 1406, "reduction" +339, 10, 48, 328, 149, 150, 1407, 1408, "(" +339, 10, 49, 329, 151, 152, 1409, 1410, "-" +339, 10, 50, 330, 153, 154, 1411, 1412, "1" +339, 10, 51, 331, 155, 156, 1413, 1414, "." +339, 10, 52, 332, 157, 158, 1415, 1416, "8" +339, 10, 53, 333, 159, 160, 1417, 1418, "+" +339, 10, 54, 334, 161, 162, 1419, 1420, "/" +339, 10, 55, 335, 163, 164, 1421, 1422, "-" +339, 10, 56, 336, 165, 166, 1423, 1424, "1" +339, 10, 57, 337, 167, 168, 1425, 1426, "." +339, 10, 58, 338, 169, 170, 1427, 1428, "3" +339, 10, 59, 339, 171, 173, 1429, 1431, "vs" +339, 10, 60, 340, 174, 175, 1432, 1433, "." +339, 10, 61, 341, 176, 177, 1434, 1435, "-" +339, 10, 62, 342, 178, 179, 1436, 1437, "1" +339, 10, 63, 343, 180, 181, 1438, 1439, "." +339, 10, 64, 344, 182, 183, 1440, 1441, "7" +339, 10, 65, 345, 184, 185, 1442, 1443, "+" +339, 10, 66, 346, 186, 187, 1444, 1445, "/" +339, 10, 67, 347, 188, 189, 1446, 1447, "-" +339, 10, 68, 348, 190, 191, 1448, 1449, "1" +339, 10, 69, 349, 192, 193, 1450, 1451, "." +339, 10, 70, 350, 194, 195, 1452, 1453, "3" +339, 10, 71, 351, 196, 197, 1454, 1455, "%" +339, 10, 72, 352, 198, 199, 1456, 1457, "," +339, 10, 73, 353, 200, 201, 1458, 1459, "P" +339, 10, 74, 354, 202, 203, 1460, 1461, "=" +339, 10, 75, 355, 204, 205, 1462, 1463, "0" +339, 10, 76, 356, 206, 207, 1464, 1465, "." +339, 10, 77, 357, 208, 211, 1466, 1469, "005" +339, 10, 78, 358, 212, 213, 1470, 1471, ")" +339, 10, 79, 359, 214, 215, 1472, 1473, "," +339, 10, 80, 360, 216, 219, 1474, 1477, "and" +339, 10, 81, 361, 220, 226, 1478, 1484, "higher" +339, 10, 82, 362, 227, 237, 1485, 1495, "percentage" +339, 10, 83, 363, 238, 246, 1496, 1504, "reaching" +339, 10, 84, 364, 247, 250, 1505, 1508, "A1C" +339, 10, 85, 365, 251, 257, 1509, 1515, "target" +339, 10, 86, 366, 258, 259, 1516, 1517, "<" +339, 10, 87, 367, 260, 261, 1518, 1519, "7" +339, 10, 88, 368, 262, 263, 1520, 1521, "." +339, 10, 89, 369, 264, 265, 1522, 1523, "0" +339, 10, 90, 370, 266, 267, 1524, 1525, "%" +339, 10, 91, 371, 268, 269, 1526, 1527, "(" +339, 10, 92, 372, 270, 272, 1528, 1530, "47" +339, 10, 93, 373, 273, 274, 1531, 1532, "." +339, 10, 94, 374, 275, 276, 1533, 1534, "5" +339, 10, 95, 375, 277, 279, 1535, 1537, "vs" +339, 10, 96, 376, 280, 281, 1538, 1539, "." +339, 10, 97, 377, 282, 284, 1540, 1542, "40" +339, 10, 98, 378, 285, 286, 1543, 1544, "." +339, 10, 99, 379, 287, 288, 1545, 1546, "3" +339, 10, 100, 380, 289, 290, 1547, 1548, "%" +339, 10, 101, 381, 291, 292, 1549, 1550, "," +339, 10, 102, 382, 293, 294, 1551, 1552, "P" +339, 10, 103, 383, 295, 296, 1553, 1554, "<" +339, 10, 104, 384, 297, 298, 1555, 1556, "0" +339, 10, 105, 385, 299, 300, 1557, 1558, "." +339, 10, 106, 386, 301, 304, 1559, 1562, "001" +339, 10, 107, 387, 305, 306, 1563, 1564, ")" +339, 10, 108, 388, 307, 308, 1565, 1566, "." +339, 11, 1, 389, 0, 4, 1567, 1571, "LM75" +339, 11, 2, 390, 5, 6, 1572, 1573, "/" +339, 11, 3, 391, 7, 9, 1574, 1576, "25" +339, 11, 4, 392, 10, 13, 1577, 1580, "was" +339, 11, 5, 393, 14, 24, 1581, 1591, "associated" +339, 11, 6, 394, 25, 29, 1592, 1596, "with" +339, 11, 7, 395, 30, 36, 1597, 1603, "higher" +339, 11, 8, 396, 37, 44, 1604, 1611, "insulin" +339, 11, 9, 397, 45, 49, 1612, 1616, "dose" +339, 11, 10, 398, 50, 51, 1617, 1618, "(" +339, 11, 11, 399, 52, 53, 1619, 1620, "0" +339, 11, 12, 400, 54, 55, 1621, 1622, "." +339, 11, 13, 401, 56, 58, 1623, 1625, "47" +339, 11, 14, 402, 59, 60, 1626, 1627, "+" +339, 11, 15, 403, 61, 62, 1628, 1629, "/" +339, 11, 16, 404, 63, 64, 1630, 1631, "-" +339, 11, 17, 405, 65, 66, 1632, 1633, "0" +339, 11, 18, 406, 67, 68, 1634, 1635, "." +339, 11, 19, 407, 69, 71, 1636, 1638, "23" +339, 11, 20, 408, 72, 74, 1639, 1641, "vs" +339, 11, 21, 409, 75, 76, 1642, 1643, "." +339, 11, 22, 410, 77, 78, 1644, 1645, "0" +339, 11, 23, 411, 79, 80, 1646, 1647, "." +339, 11, 24, 412, 81, 83, 1648, 1650, "40" +339, 11, 25, 413, 84, 85, 1651, 1652, "+" +339, 11, 26, 414, 86, 87, 1653, 1654, "/" +339, 11, 27, 415, 88, 89, 1655, 1656, "-" +339, 11, 28, 416, 90, 91, 1657, 1658, "0" +339, 11, 29, 417, 92, 93, 1659, 1660, "." +339, 11, 30, 418, 94, 96, 1661, 1663, "23" +339, 11, 31, 419, 97, 102, 1664, 1669, "units" +339, 11, 32, 420, 103, 104, 1670, 1671, "x" +339, 11, 33, 421, 105, 107, 1672, 1674, "kg" +339, 11, 34, 422, 108, 109, 1675, 1676, "(" +339, 11, 35, 423, 110, 111, 1677, 1678, "-" +339, 11, 36, 424, 112, 113, 1679, 1680, "1" +339, 11, 37, 425, 114, 115, 1681, 1682, ")" +339, 11, 38, 426, 116, 117, 1683, 1684, "x" +339, 11, 39, 427, 118, 121, 1685, 1688, "day" +339, 11, 40, 428, 122, 123, 1689, 1690, "(" +339, 11, 41, 429, 124, 125, 1691, 1692, "-" +339, 11, 42, 430, 126, 127, 1693, 1694, "1" +339, 11, 43, 431, 128, 129, 1695, 1696, ")" +339, 11, 44, 432, 130, 131, 1697, 1698, "," +339, 11, 45, 433, 132, 133, 1699, 1700, "P" +339, 11, 46, 434, 134, 135, 1701, 1702, "<" +339, 11, 47, 435, 136, 137, 1703, 1704, "0" +339, 11, 48, 436, 138, 139, 1705, 1706, "." +339, 11, 49, 437, 140, 143, 1707, 1710, "001" +339, 11, 50, 438, 144, 145, 1711, 1712, ")" +339, 11, 51, 439, 146, 149, 1713, 1716, "and" +339, 11, 52, 440, 150, 154, 1717, 1721, "more" +339, 11, 53, 441, 155, 161, 1722, 1728, "weight" +339, 11, 54, 442, 162, 166, 1729, 1733, "gain" +339, 11, 55, 443, 167, 168, 1734, 1735, "(" +339, 11, 56, 444, 169, 170, 1736, 1737, "3" +339, 11, 57, 445, 171, 172, 1738, 1739, "." +339, 11, 58, 446, 173, 174, 1740, 1741, "6" +339, 11, 59, 447, 175, 176, 1742, 1743, "+" +339, 11, 60, 448, 177, 178, 1744, 1745, "/" +339, 11, 61, 449, 179, 180, 1746, 1747, "-" +339, 11, 62, 450, 181, 182, 1748, 1749, "4" +339, 11, 63, 451, 183, 184, 1750, 1751, "." +339, 11, 64, 452, 185, 186, 1752, 1753, "0" +339, 11, 65, 453, 187, 189, 1754, 1756, "vs" +339, 11, 66, 454, 190, 191, 1757, 1758, "." +339, 11, 67, 455, 192, 193, 1759, 1760, "2" +339, 11, 68, 456, 194, 195, 1761, 1762, "." +339, 11, 69, 457, 196, 197, 1763, 1764, "5" +339, 11, 70, 458, 198, 199, 1765, 1766, "+" +339, 11, 71, 459, 200, 201, 1767, 1768, "/" +339, 11, 72, 460, 202, 203, 1769, 1770, "-" +339, 11, 73, 461, 204, 205, 1771, 1772, "4" +339, 11, 74, 462, 206, 207, 1773, 1774, "." +339, 11, 75, 463, 208, 209, 1775, 1776, "0" +339, 11, 76, 464, 210, 212, 1777, 1779, "kg" +339, 11, 77, 465, 213, 214, 1780, 1781, "," +339, 11, 78, 466, 215, 216, 1782, 1783, "P" +339, 11, 79, 467, 217, 218, 1784, 1785, "<" +339, 11, 80, 468, 219, 220, 1786, 1787, "0" +339, 11, 81, 469, 221, 222, 1788, 1789, "." +339, 11, 82, 470, 223, 227, 1790, 1794, "0001" +339, 11, 83, 471, 228, 229, 1795, 1796, ")" +339, 11, 84, 472, 230, 231, 1797, 1798, "." +339, 12, 1, 473, 0, 4, 1799, 1803, "LM75" +339, 12, 2, 474, 5, 6, 1804, 1805, "/" +339, 12, 3, 475, 7, 9, 1806, 1808, "25" +339, 12, 4, 476, 10, 18, 1809, 1817, "patients" +339, 12, 5, 477, 19, 22, 1818, 1821, "had" +339, 12, 6, 478, 23, 24, 1822, 1823, "a" +339, 12, 7, 479, 25, 31, 1824, 1830, "higher" +339, 12, 8, 480, 32, 39, 1831, 1838, "overall" +339, 12, 9, 481, 40, 52, 1839, 1851, "hypoglycemia" +339, 12, 10, 482, 53, 57, 1852, 1856, "rate" +339, 12, 11, 483, 58, 62, 1857, 1861, "than" +339, 12, 12, 484, 63, 65, 1862, 1864, "GL" +339, 12, 13, 485, 66, 74, 1865, 1873, "patients" +339, 12, 14, 486, 75, 76, 1874, 1875, "(" +339, 12, 15, 487, 77, 79, 1876, 1878, "28" +339, 12, 16, 488, 80, 81, 1879, 1880, "." +339, 12, 17, 489, 82, 83, 1881, 1882, "0" +339, 12, 18, 490, 84, 85, 1883, 1884, "+" +339, 12, 19, 491, 86, 87, 1885, 1886, "/" +339, 12, 20, 492, 88, 89, 1887, 1888, "-" +339, 12, 21, 493, 90, 92, 1889, 1891, "41" +339, 12, 22, 494, 93, 94, 1892, 1893, "." +339, 12, 23, 495, 95, 96, 1894, 1895, "6" +339, 12, 24, 496, 97, 99, 1896, 1898, "vs" +339, 12, 25, 497, 100, 101, 1899, 1900, "." +339, 12, 26, 498, 102, 104, 1901, 1903, "23" +339, 12, 27, 499, 105, 106, 1904, 1905, "." +339, 12, 28, 500, 107, 108, 1906, 1907, "1" +339, 12, 29, 501, 109, 110, 1908, 1909, "+" +339, 12, 30, 502, 111, 112, 1910, 1911, "/" +339, 12, 31, 503, 113, 114, 1912, 1913, "-" +339, 12, 32, 504, 115, 117, 1914, 1916, "40" +339, 12, 33, 505, 118, 119, 1917, 1918, "." +339, 12, 34, 506, 120, 121, 1919, 1920, "7" +339, 12, 35, 507, 122, 130, 1921, 1929, "episodes" +339, 12, 36, 508, 131, 132, 1930, 1931, "x" +339, 12, 37, 509, 133, 135, 1932, 1934, "pt" +339, 12, 38, 510, 136, 137, 1935, 1936, "(" +339, 12, 39, 511, 138, 139, 1937, 1938, "-" +339, 12, 40, 512, 140, 141, 1939, 1940, "1" +339, 12, 41, 513, 142, 143, 1941, 1942, ")" +339, 12, 42, 514, 144, 145, 1943, 1944, "x" +339, 12, 43, 515, 146, 150, 1945, 1949, "year" +339, 12, 44, 516, 151, 152, 1950, 1951, "(" +339, 12, 45, 517, 153, 154, 1952, 1953, "-" +339, 12, 46, 518, 155, 156, 1954, 1955, "1" +339, 12, 47, 519, 157, 158, 1956, 1957, ")" +339, 12, 48, 520, 159, 160, 1958, 1959, "," +339, 12, 49, 521, 161, 162, 1960, 1961, "P" +339, 12, 50, 522, 163, 164, 1962, 1963, "=" +339, 12, 51, 523, 165, 166, 1964, 1965, "0" +339, 12, 52, 524, 167, 168, 1966, 1967, "." +339, 12, 53, 525, 169, 172, 1968, 1971, "007" +339, 12, 54, 526, 173, 174, 1972, 1973, ")" +339, 12, 55, 527, 175, 178, 1974, 1977, "but" +339, 12, 56, 528, 179, 184, 1978, 1983, "lower" +339, 12, 57, 529, 185, 194, 1984, 1993, "nocturnal" +339, 12, 58, 530, 195, 207, 1994, 2006, "hypoglycemia" +339, 12, 59, 531, 208, 212, 2007, 2011, "rate" +339, 12, 60, 532, 213, 214, 2012, 2013, "(" +339, 12, 61, 533, 215, 216, 2014, 2015, "8" +339, 12, 62, 534, 217, 218, 2016, 2017, "." +339, 12, 63, 535, 219, 220, 2018, 2019, "9" +339, 12, 64, 536, 221, 222, 2020, 2021, "+" +339, 12, 65, 537, 223, 224, 2022, 2023, "/" +339, 12, 66, 538, 225, 226, 2024, 2025, "-" +339, 12, 67, 539, 227, 229, 2026, 2028, "19" +339, 12, 68, 540, 230, 231, 2029, 2030, "." +339, 12, 69, 541, 232, 233, 2031, 2032, "3" +339, 12, 70, 542, 234, 236, 2033, 2035, "vs" +339, 12, 71, 543, 237, 238, 2036, 2037, "." +339, 12, 72, 544, 239, 241, 2038, 2040, "11" +339, 12, 73, 545, 242, 243, 2041, 2042, "." +339, 12, 74, 546, 244, 245, 2043, 2044, "4" +339, 12, 75, 547, 246, 247, 2045, 2046, "+" +339, 12, 76, 548, 248, 249, 2047, 2048, "/" +339, 12, 77, 549, 250, 251, 2049, 2050, "-" +339, 12, 78, 550, 252, 254, 2051, 2053, "25" +339, 12, 79, 551, 255, 256, 2054, 2055, "." +339, 12, 80, 552, 257, 258, 2056, 2057, "3" +339, 12, 81, 553, 259, 267, 2058, 2066, "episodes" +339, 12, 82, 554, 268, 269, 2067, 2068, "x" +339, 12, 83, 555, 270, 272, 2069, 2071, "pt" +339, 12, 84, 556, 273, 274, 2072, 2073, "(" +339, 12, 85, 557, 275, 276, 2074, 2075, "-" +339, 12, 86, 558, 277, 278, 2076, 2077, "1" +339, 12, 87, 559, 279, 280, 2078, 2079, ")" +339, 12, 88, 560, 281, 282, 2080, 2081, "x" +339, 12, 89, 561, 283, 287, 2082, 2086, "year" +339, 12, 90, 562, 288, 289, 2087, 2088, "(" +339, 12, 91, 563, 290, 291, 2089, 2090, "-" +339, 12, 92, 564, 292, 293, 2091, 2092, "1" +339, 12, 93, 565, 294, 295, 2093, 2094, ")" +339, 12, 94, 566, 296, 297, 2095, 2096, "," +339, 12, 95, 567, 298, 299, 2097, 2098, "P" +339, 12, 96, 568, 300, 301, 2099, 2100, "=" +339, 12, 97, 569, 302, 303, 2101, 2102, "0" +339, 12, 98, 570, 304, 305, 2103, 2104, "." +339, 12, 99, 571, 306, 309, 2105, 2108, "009" +339, 12, 100, 572, 310, 311, 2109, 2110, ")" +339, 12, 101, 573, 312, 313, 2111, 2112, "." +339, 13, 1, 574, 0, 6, 2113, 2119, "Severe" +339, 13, 2, 575, 7, 19, 2120, 2132, "hypoglycemia" +339, 13, 3, 576, 20, 25, 2133, 2138, "rates" +339, 13, 4, 577, 26, 30, 2139, 2143, "were" +339, 13, 5, 578, 31, 34, 2144, 2147, "low" +339, 13, 6, 579, 35, 37, 2148, 2150, "in" +339, 13, 7, 580, 38, 42, 2151, 2155, "both" +339, 13, 8, 581, 43, 49, 2156, 2162, "groups" +339, 13, 9, 582, 50, 51, 2163, 2164, "(" +339, 13, 10, 583, 52, 56, 2165, 2169, "LM75" +339, 13, 11, 584, 57, 58, 2170, 2171, "/" +339, 13, 12, 585, 59, 61, 2172, 2174, "25" +339, 13, 13, 586, 62, 63, 2175, 2176, ":" +339, 13, 14, 587, 64, 65, 2177, 2178, "0" +339, 13, 15, 588, 66, 67, 2179, 2180, "." +339, 13, 16, 589, 68, 70, 2181, 2183, "10" +339, 13, 17, 590, 71, 72, 2184, 2185, "+" +339, 13, 18, 591, 73, 74, 2186, 2187, "/" +339, 13, 19, 592, 75, 76, 2188, 2189, "-" +339, 13, 20, 593, 77, 78, 2190, 2191, "1" +339, 13, 21, 594, 79, 80, 2192, 2193, "." +339, 13, 22, 595, 81, 82, 2194, 2195, "6" +339, 13, 23, 596, 83, 85, 2196, 2198, "vs" +339, 13, 24, 597, 86, 87, 2199, 2200, "." +339, 13, 25, 598, 88, 90, 2201, 2203, "GL" +339, 13, 26, 599, 91, 92, 2204, 2205, ":" +339, 13, 27, 600, 93, 94, 2206, 2207, "0" +339, 13, 28, 601, 95, 96, 2208, 2209, "." +339, 13, 29, 602, 97, 99, 2210, 2212, "03" +339, 13, 30, 603, 100, 101, 2213, 2214, "+" +339, 13, 31, 604, 102, 103, 2215, 2216, "/" +339, 13, 32, 605, 104, 105, 2217, 2218, "-" +339, 13, 33, 606, 106, 107, 2219, 2220, "0" +339, 13, 34, 607, 108, 109, 2221, 2222, "." +339, 13, 35, 608, 110, 111, 2223, 2224, "3" +339, 13, 36, 609, 112, 120, 2225, 2233, "episodes" +339, 13, 37, 610, 121, 122, 2234, 2235, "x" +339, 13, 38, 611, 123, 125, 2236, 2238, "pt" +339, 13, 39, 612, 126, 127, 2239, 2240, "(" +339, 13, 40, 613, 128, 129, 2241, 2242, "-" +339, 13, 41, 614, 130, 131, 2243, 2244, "1" +339, 13, 42, 615, 132, 133, 2245, 2246, ")" +339, 13, 43, 616, 134, 135, 2247, 2248, "x" +339, 13, 44, 617, 136, 140, 2249, 2253, "year" +339, 13, 45, 618, 141, 142, 2254, 2255, "(" +339, 13, 46, 619, 143, 144, 2256, 2257, "-" +339, 13, 47, 620, 145, 146, 2258, 2259, "1" +339, 13, 48, 621, 147, 148, 2260, 2261, ")" +339, 13, 49, 622, 149, 150, 2262, 2263, "," +339, 13, 50, 623, 151, 152, 2264, 2265, "P" +339, 13, 51, 624, 153, 154, 2266, 2267, "=" +339, 13, 52, 625, 155, 156, 2268, 2269, "0" +339, 13, 53, 626, 157, 158, 2270, 2271, "." +339, 13, 54, 627, 159, 162, 2272, 2275, "167" +339, 13, 55, 628, 163, 164, 2276, 2277, ")" +339, 13, 56, 629, 165, 166, 2278, 2279, "." +339, 14, 1, 630, 0, 11, 2280, 2291, "CONCLUSIONS" +339, 14, 2, 631, 12, 13, 2292, 2293, ":" +339, 14, 3, 632, 14, 22, 2294, 2302, "Compared" +339, 14, 4, 633, 23, 27, 2303, 2307, "with" +339, 14, 5, 634, 28, 30, 2308, 2310, "GL" +339, 14, 6, 635, 31, 32, 2311, 2312, "," +339, 14, 7, 636, 33, 37, 2313, 2317, "LM75" +339, 14, 8, 637, 38, 39, 2318, 2319, "/" +339, 14, 9, 638, 40, 42, 2320, 2322, "25" +339, 14, 10, 639, 43, 51, 2323, 2331, "resulted" +339, 14, 11, 640, 52, 54, 2332, 2334, "in" +339, 14, 12, 641, 55, 63, 2335, 2343, "slightly" +339, 14, 13, 642, 64, 69, 2344, 2349, "lower" +339, 14, 14, 643, 70, 73, 2350, 2353, "A1C" +339, 14, 15, 644, 74, 76, 2354, 2356, "at" +339, 14, 16, 645, 77, 79, 2357, 2359, "24" +339, 14, 17, 646, 80, 85, 2360, 2365, "weeks" +339, 14, 18, 647, 86, 89, 2366, 2369, "and" +339, 14, 19, 648, 90, 91, 2370, 2371, "a" +339, 14, 20, 649, 92, 102, 2372, 2382, "moderately" +339, 14, 21, 650, 103, 109, 2383, 2389, "higher" +339, 14, 22, 651, 110, 120, 2390, 2400, "percentage" +339, 14, 23, 652, 121, 129, 2401, 2409, "reaching" +339, 14, 24, 653, 130, 133, 2410, 2413, "A1C" +339, 14, 25, 654, 134, 140, 2414, 2420, "target" +339, 14, 26, 655, 141, 142, 2421, 2422, "<" +339, 14, 27, 656, 143, 144, 2423, 2424, "7" +339, 14, 28, 657, 145, 146, 2425, 2426, "." +339, 14, 29, 658, 147, 148, 2427, 2428, "0" +339, 14, 30, 659, 149, 150, 2429, 2430, "%" +339, 14, 31, 660, 151, 152, 2431, 2432, "." +339, 15, 1, 661, 0, 8, 2433, 2441, "Patients" +339, 15, 2, 662, 9, 18, 2442, 2451, "receiving" +339, 15, 3, 663, 19, 23, 2452, 2456, "LM75" +339, 15, 4, 664, 24, 25, 2457, 2458, "/" +339, 15, 5, 665, 26, 28, 2459, 2461, "25" +339, 15, 6, 666, 29, 40, 2462, 2473, "experienced" +339, 15, 7, 667, 41, 45, 2474, 2478, "more" +339, 15, 8, 668, 46, 52, 2479, 2485, "weight" +339, 15, 9, 669, 53, 57, 2486, 2490, "gain" +339, 15, 10, 670, 58, 61, 2491, 2494, "and" +339, 15, 11, 671, 62, 68, 2495, 2501, "higher" +339, 15, 12, 672, 69, 74, 2502, 2507, "rates" +339, 15, 13, 673, 75, 77, 2508, 2510, "of" +339, 15, 14, 674, 78, 85, 2511, 2518, "overall" +339, 15, 15, 675, 86, 98, 2519, 2531, "hypoglycemia" +339, 15, 16, 676, 99, 102, 2532, 2535, "but" +339, 15, 17, 677, 103, 108, 2536, 2541, "lower" +339, 15, 18, 678, 109, 114, 2542, 2547, "rates" +339, 15, 19, 679, 115, 117, 2548, 2550, "of" +339, 15, 20, 680, 118, 127, 2551, 2560, "nocturnal" +339, 15, 21, 681, 128, 140, 2561, 2573, "hypoglycemia" +339, 15, 22, 682, 141, 142, 2574, 2575, "." +339, 16, 1, 683, 0, 10, 2576, 2586, "Durability" +339, 16, 2, 684, 11, 13, 2587, 2589, "of" +339, 16, 3, 685, 14, 22, 2590, 2598, "regimens" +339, 16, 4, 686, 23, 27, 2599, 2603, "will" +339, 16, 5, 687, 28, 30, 2604, 2606, "be" +339, 16, 6, 688, 31, 40, 2607, 2616, "evaluated" +339, 16, 7, 689, 41, 43, 2617, 2619, "in" +339, 16, 8, 690, 44, 47, 2620, 2623, "the" +339, 16, 9, 691, 48, 57, 2624, 2633, "following" +339, 16, 10, 692, 58, 59, 2634, 2635, "2" +339, 16, 11, 693, 60, 61, 2636, 2637, "-" +339, 16, 12, 694, 62, 66, 2638, 2642, "year" +339, 16, 13, 695, 67, 78, 2643, 2654, "maintenance" +339, 16, 14, 696, 79, 84, 2655, 2660, "phase" +339, 16, 15, 697, 85, 86, 2661, 2662, "." +339, 17, 1, 698, 0, 3, 2663, 2666, "DOI" +339, 17, 2, 699, 4, 5, 2667, 2668, ":" +339, 17, 3, 700, 6, 8, 2669, 2671, "10" +339, 17, 4, 701, 9, 10, 2672, 2673, "." +339, 17, 5, 702, 11, 15, 2674, 2678, "2337" +339, 17, 6, 703, 16, 17, 2679, 2680, "/" +339, 17, 7, 704, 18, 22, 2681, 2685, "dc08" +339, 17, 8, 705, 23, 24, 2686, 2687, "-" +339, 17, 9, 706, 25, 29, 2688, 2692, "2117" +339, 17, 10, 707, 30, 35, 2693, 2698, "PMCID" +339, 17, 11, 708, 36, 37, 2699, 2700, ":" +339, 17, 12, 709, 38, 48, 2701, 2711, "PMC2681037" +339, 17, 13, 710, 49, 53, 2712, 2716, "PMID" +339, 17, 14, 711, 54, 55, 2717, 2718, ":" +339, 17, 15, 712, 56, 64, 2719, 2727, "19336625" +339, 17, 16, 713, 65, 66, 2728, 2729, "[" +339, 17, 17, 714, 67, 74, 2730, 2737, "Indexed" +339, 17, 18, 715, 75, 78, 2738, 2741, "for" +339, 17, 19, 716, 79, 86, 2742, 2749, "MEDLINE" +339, 17, 20, 717, 87, 88, 2750, 2751, "]" diff --git a/data/dm2 19336625_kwoodley.annodb b/data/dm2 19336625_kwoodley.annodb new file mode 100644 index 0000000..f741520 --- /dev/null +++ b/data/dm2 19336625_kwoodley.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8565, Journal, 0, 13, "Diabetes Care", "", +8566, PublicationYear, 16, 20, "2009", "", +36866, Title, 101, 348, "DURAbility of basal versus lispro mix 75 / 25 insulin efficacy ( DURABLE ) trial 24 - week results : safety and efficacy of insulin lispro mix 75 / 25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes .", "", +8568, InsulinGlargine, 115, 120, "basal", "", +36867, Lispro, 128, 154, "lispro mix 75 / 25 insulin", "", +8575, Duration, 182, 191, "24 - week", "", +36869, Lispro, 225, 251, "insulin lispro mix 75 / 25", "", +8569, InsulinGlargine, 259, 275, "insulin glargine", "", +8570, OralAntidiabeticAgent, 285, 313, "oral antihyperglycemic drugs", "", +8571, Type2Diabetes, 331, 346, "type 2 diabetes", "", +8577, Author, 349, 356, "Buse JB", "", +8578, Author, 365, 381, "Wolffenbuttel BH", "", +8579, Author, 384, 393, "Herman WH", "", +8580, Author, 396, 408, "Shemonsky NK", "", +8581, Author, 411, 419, "Jiang HH", "", +8582, Author, 422, 433, "Fahrbach JL", "", +8583, Author, 436, 452, "Scism - Bacon JL", "", +8584, Author, 455, 464, "Martin SA", "", +8585, USA, 628, 631, "USA", "", +36870, ObjectiveDescription, 670, 818, "To compare the ability of two starter insulin regimens to achieve glycemic control in a large , ethnically diverse population with type 2 diabetes .", "", +8586, Insulin, 708, 715, "insulin", "", +8588, Ethnicity, 766, 784, "ethnically diverse", "", +8587, Type2Diabetes, 801, 816, "type 2 diabetes", "", +8590, Randomized, 914, 924, "randomized", "", +8591, Frequency, 930, 943, "twice - daily", "", +36871, Lispro, 944, 962, "lispro mix 75 / 25", "", +36872, Lispro, 965, 1023, "LM75 / 25 ; 75 % lispro protamine suspension , 25 % lispro", "", +8594, NumberPatientsArm, 1032, 1039, "1 , 045", "", +8595, Frequency, 1045, 1050, "daily", "", +8596, InsulinGlargine, 1051, 1059, "glargine", "", +8597, InsulinGlargine, 1062, 1064, "GL", "", +8598, NumberPatientsArm, 1073, 1080, "1 , 046", "", +8599, OralAntidiabeticAgent, 1113, 1141, "oral antihyperglycemic drugs", "", +8600, HbA1c, 1163, 1166, "A1C", "", +36873, Lispro, 1181, 1190, "LM75 / 25", "", +8602, BaseLineValue, 1193, 1198, "9 . 1", "", +8603, SdDevBL, 1205, 1210, "1 . 3", "", +8604, Percentage, 1211, 1212, "%", "", +8605, InsulinGlargine, 1215, 1217, "GL", "", +8606, BaseLineValue, 1220, 1225, "9 . 0", "", +8607, SdDevBL, 1232, 1237, "1 . 2", "", +8608, Percentage, 1238, 1239, "%", "", +8609, PvalueDiff, 1242, 1253, "P = 0 . 414", "DiffBL", +36874, TimePoint, 1261, 1269, "24 weeks", "", +36875, Lispro, 1272, 1281, "LM75 / 25", "", +8613, HbA1c, 1301, 1304, "A1C", "", +8614, InsulinGlargine, 1310, 1312, "GL", "", +8615, ResultMeasuredValue, 1324, 1329, "7 . 2", "", +8617, SdDevResValue, 1336, 1341, "1 . 1", "", +8616, ResultMeasuredValue, 1347, 1352, "7 . 3", "", +8618, SdDevResValue, 1359, 1364, "1 . 1", "", +8619, Percentage, 1365, 1366, "%", "", +8620, PvalueDiff, 1369, 1380, "P = 0 . 005", "", +8621, HbA1c, 1393, 1396, "A1C", "", +8622, Reduction, 1411, 1416, "1 . 8", "", +8624, SdDevChangeValue, 1423, 1428, "1 . 3", "", +8623, Reduction, 1436, 1441, "1 . 7", "", +8625, SdDevChangeValue, 1448, 1453, "1 . 3", "", +8626, Percentage, 1454, 1455, "%", "", +8627, PvalueDiff, 1458, 1469, "P = 0 . 005", "", +8628, HbA1c_target, 1505, 1525, "A1C target < 7 . 0 %", "", +8629, PercentageAffected, 1528, 1534, "47 . 5", "", +8630, PercentageAffected, 1540, 1546, "40 . 3", "", +8631, PvalueDiff, 1551, 1562, "P < 0 . 001", "", +36876, Lispro, 1567, 1576, "LM75 / 25", "", +36880, InsulinDose, 1604, 1616, "insulin dose", "", +8634, ResultMeasuredValue, 1619, 1625, "0 . 47", "", +8636, SdDevResValue, 1632, 1638, "0 . 23", "", +8635, ResultMeasuredValue, 1644, 1650, "0 . 40", "", +8637, SdDevResValue, 1657, 1663, "0 . 23", "", +8638, IntUnit_per_Kg, 1664, 1674, "units x kg", "", +8639, PvalueDiff, 1699, 1710, "P < 0 . 001", "", +8640, BodyWeight, 1722, 1728, "weight", "", +8641, Increment, 1736, 1741, "3 . 6", "", +8643, SdDevChangeValue, 1748, 1753, "4 . 0", "", +8642, Increment, 1759, 1764, "2 . 5", "", +8644, SdDevChangeValue, 1771, 1776, "4 . 0", "", +8645, Kg, 1777, 1779, "kg", "", +8646, PvalueDiff, 1782, 1794, "P < 0 . 0001", "", +36877, Lispro, 1799, 1808, "LM75 / 25", "", +8648, Hypoglycemia, 1839, 1851, "hypoglycemia", "", +8649, InsulinGlargine, 1862, 1864, "GL", "", +8650, ResultMeasuredValue, 1876, 1882, "28 . 0", "", +8652, SdDevResValue, 1889, 1895, "41 . 6", "", +8651, ResultMeasuredValue, 1901, 1907, "23 . 1", "", +8653, SdDevResValue, 1914, 1920, "40 . 7", "", +8654, BioAndMedicalUnit, 1921, 1957, "episodes x pt ( - 1 ) x year ( - 1 )", "", +8656, PvalueDiff, 1960, 1971, "P = 0 . 007", "", +8655, NocturnalHypoglycemia, 1984, 2006, "nocturnal hypoglycemia", "", +8658, ResultMeasuredValue, 2014, 2019, "8 . 9", "", +8660, SdDevResValue, 2026, 2032, "19 . 3", "", +8659, ResultMeasuredValue, 2038, 2044, "11 . 4", "", +8661, SdDevResValue, 2051, 2057, "25 . 3", "", +8662, BioAndMedicalUnit, 2058, 2094, "episodes x pt ( - 1 ) x year ( - 1 )", "", +8657, PvalueDiff, 2097, 2108, "P = 0 . 009", "", +8663, SevereHypoglycemia, 2113, 2132, "Severe hypoglycemia", "", +36881, Lispro, 2165, 2174, "LM75 / 25", "", +8665, ResultMeasuredValue, 2177, 2183, "0 . 10", "", +8667, SdDevResValue, 2190, 2195, "1 . 6", "", +8669, InsulinGlargine, 2201, 2203, "GL", "", +8666, ResultMeasuredValue, 2206, 2212, "0 . 03", "", +8668, SdDevResValue, 2219, 2224, "0 . 3", "", +8670, BioAndMedicalUnit, 2225, 2261, "episodes x pt ( - 1 ) x year ( - 1 )", "", +8671, PvalueDiff, 2264, 2275, "P = 0 . 167", "", +36882, ConclusionComment, 2294, 2432, "Compared with GL , LM75 / 25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target < 7 . 0 % .", "", +8672, InsulinGlargine, 2308, 2310, "GL", "", +36878, Lispro, 2313, 2322, "LM75 / 25", "", +8674, HbA1c, 2350, 2353, "A1C", "", +36885, TimePoint, 2357, 2365, "24 weeks", "", +8676, HbA1c_target, 2410, 2430, "A1C target < 7 . 0 %", "", +36883, ConclusionComment, 2433, 2575, "Patients receiving LM75 / 25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia .", "", +36879, Lispro, 2452, 2461, "LM75 / 25", "", +8679, BodyWeight, 2479, 2485, "weight", "", +8680, Hypoglycemia, 2519, 2531, "hypoglycemia", "", +8681, NocturnalHypoglycemia, 2551, 2573, "nocturnal hypoglycemia", "", +36884, ConclusionComment, 2576, 2662, "Durability of regimens will be evaluated in the following 2 - year maintenance phase .", "", +8684, PMID, 2719, 2727, "19336625", "", diff --git a/data/dm2 19336625_kwoodley.n-triples b/data/dm2 19336625_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19336625_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19565569_admin.annodb b/data/dm2 19565569_admin.annodb new file mode 100644 index 0000000..c2ff01f --- /dev/null +++ b/data/dm2 19565569_admin.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 24, "Diabetes Metab Res Rev .", "", " \"Diabetes Metab Res Rev .\"." +1, PublicationYear, 25, 29, "2009", "", " \"2009\"." +117, Title, 88, 247, "Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes .", "", " \"Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes .\"." +2, InsulinDetemir, 102, 117, "insulin detemir", "", +3, InsulinGlargine, 122, 138, "insulin glargine", "", +4, Randomized, 174, 184, "randomized", "", " ." +5, CTDesign, 187, 197, "controlled", "", " . ." +6, Type2Diabetes, 230, 245, "type 2 diabetes", "", +7, Author, 248, 256, "Raskin P", "", " \"Raskin P\"." +8, Author, 265, 273, "Gylvin T", "", " \"Gylvin T\"." +9, Author, 276, 282, "Weng W", "", " \"Weng W\"." +10, Author, 285, 294, "Chaykin L", "", " \"Chaykin L\"." +11, USA, 414, 417, "USA", "", " ." +138, ObjectiveDescription, 472, 660, "This treat - to - target study compared the efficacy and safety of insulin detemir ( IDet ) and insulin glargine ( IGla ) in a basal - bolus ( insulin aspart ) regimen in type 2 diabetes .", "", " \"This treat - to - target study compared the efficacy and safety of insulin detemir ( IDet ) and insulin glargine ( IGla ) in a basal - bolus ( insulin aspart ) regimen in type 2 diabetes .\"." +13, InsulinDetemir, 539, 554, "insulin detemir", "", +14, InsulinDetemir, 557, 561, "IDet", "", +15, InsulinGlargine, 568, 584, "insulin glargine", "", +16, InsulinGlargine, 587, 591, "IGla", "", +68832, Precondition, 599, 658, "basal - bolus ( insulin aspart ) regimen in type 2 diabetes", "", " \"basal - bolus ( insulin aspart ) regimen in type 2 diabetes\"." +18, InsulinAspart, 615, 629, "insulin aspart", "", +17, Type2Diabetes, 643, 658, "type 2 diabetes", "", " ." +19, NumberPatientsCT, 671, 674, "385", "", " \"385\"." +20, Randomized, 689, 699, "randomized", "", +21, AllocationRatio, 700, 705, "2 : 1", "", " . ." +22, InsulinDetemir, 708, 712, "IDet", "", " ." +23, InsulinGlargine, 715, 719, "IGla", "", " ." +24, InsulinDetemir, 745, 749, "IDet", "", +25, InsulinGlargine, 753, 757, "IGla", "", +26, HbA1c, 776, 786, "HbA ( 1c )", "", +242, Percentage, 790, 791, "%", "", +28, InsulinDetemir, 827, 831, "IDet", "", +29, InsulinGlargine, 836, 840, "IGla", "", +30, HbA1c, 868, 878, "HbA ( 1c )", "", " ." +106279, Duration, 892, 900, "26 weeks", "", " \"26 weeks\"." +231, TimePoint, 949, 957, "26 weeks", "", +145, LeastSquaresMean, 960, 967, "LS mean", "", " ." +33, InsulinDetemir, 970, 973, "Det", "", +34, InsulinGlargine, 976, 979, "Gla", "", +226, DiffGroupAbsValue, 984, 991, "0 . 207", "", " \"0 . 207\"." +146, ConfIntervalDiff, 994, 1023, "95 % CI : 0 . 0149 , 0 . 3995", "", " \"95 % CI : 0 . 0149 , 0 . 3995\"." +38, InsulinGlargine, 1045, 1049, "IGla", "", +39, InsulinDetemir, 1080, 1084, "IDet", "", +40, HbA1c, 1097, 1107, "HbA ( 1c )", "", +41, DiffGroupAbsValue, 1131, 1138, "0 . 207", "", +42, Percentage, 1139, 1140, "%", "", " ." +43, MeasurementDevice, 1245, 1258, "LOCF approach", "", " . ." +44, EndPointDescription, 1310, 1321, "delta 0 . 4", "", " . ." +151, LeastSquaresMean, 1324, 1331, "LS mean", "", " ." +46, InsulinDetemir, 1337, 1340, "Det", "", +47, InsulinGlargine, 1343, 1346, "Gla", "", +228, DiffGroupAbsValue, 1351, 1358, "0 . 307", "", " \"0 . 307\"." +154, ConfIntervalDiff, 1361, 1390, "95 % CI : 0 . 1023 , 0 . 5109", "", " \"95 % CI : 0 . 1023 , 0 . 5109\"." +51, HbA1c, 1395, 1405, "HbA ( 1c )", "", +237, TimePoint, 1435, 1443, "baseline", "", +52, InsulinDetemir, 1447, 1451, "IDet", "", +53, Reduction, 1456, 1461, "1 . 1", "", " \"1 . 1\"." +55, Percentage, 1462, 1463, "%", "", +236, TimePoint, 1466, 1474, "26 weeks", "", " \"26 weeks\"." +61, Reduction, 1481, 1486, "0 . 9", "", +62, Percentage, 1487, 1488, "%", "", +57, MeasurementDevice, 1491, 1495, "LOCF", "", " . ." +59, PValueChangeValue, 1500, 1511, "p < 0 . 001", "", " \"p < 0 . 001\"." +63, InsulinGlargine, 1521, 1525, "IGla", "", +54, Reduction, 1530, 1535, "1 . 3", "", " \"1 . 3\"." +56, Percentage, 1536, 1537, "%", "", +235, TimePoint, 1540, 1548, "26 weeks", "", " \"26 weeks\"." +58, MeasurementDevice, 1551, 1555, "LOCF", "", +60, PValueChangeValue, 1560, 1571, "p < 0 . 001", "", " \"p < 0 . 001\"." +64, HbA1c, 1582, 1592, "HbA ( 1c )", "", +65, ResultMeasuredValue, 1598, 1603, "7 . 1", "", " \"7 . 1\"." +69, Percentage, 1604, 1605, "%", "", +238, TimePoint, 1608, 1616, "26 weeks", "", +66, ResultMeasuredValue, 1623, 1628, "7 . 3", "", " \"7 . 3\"." +70, Percentage, 1629, 1630, "%", "", +73, MeasurementDevice, 1633, 1637, "LOCF", "", +75, InsulinDetemir, 1643, 1647, "IDet", "", +67, ResultMeasuredValue, 1654, 1659, "6 . 9", "", " \"6 . 9\"." +71, Percentage, 1660, 1661, "%", "", +232, TimePoint, 1664, 1672, "26 weeks", "", +68, ResultMeasuredValue, 1679, 1684, "7 . 0", "", " \"7 . 0\"." +72, Percentage, 1685, 1686, "%", "", +74, MeasurementDevice, 1689, 1693, "LOCF", "", +76, InsulinGlargine, 1699, 1703, "IGla", "", +77, FastingPlasmaGlucose, 1712, 1715, "FPG", "", " ." +78, ResultMeasuredValue, 1721, 1724, "130", "", " \"130\"." +82, Mg_per_deciliter, 1725, 1732, "mg / dL", "", " ." +233, TimePoint, 1735, 1743, "26 weeks", "", " \"26 weeks\"." +79, ResultMeasuredValue, 1750, 1753, "135", "", " \"135\"." +83, Mg_per_deciliter, 1754, 1761, "mg / dL", "", +86, MeasurementDevice, 1764, 1768, "LOCF", "", " . ." +88, InsulinDetemir, 1774, 1778, "IDet", "", +80, ResultMeasuredValue, 1785, 1788, "134", "", " \"134\"." +84, Mg_per_deciliter, 1789, 1796, "mg / dL", "", +234, TimePoint, 1799, 1807, "26 weeks", "", " \"26 weeks\"." +81, ResultMeasuredValue, 1814, 1817, "137", "", " \"137\"." +85, Mg_per_deciliter, 1818, 1825, "mg / dL", "", +87, MeasurementDevice, 1828, 1832, "LOCF", "", +89, InsulinGlargine, 1838, 1842, "IGla", "", +54998, BodyWeight, 1874, 1880, "weight", "", " ." +91, InsulinDetemir, 1889, 1893, "IDet", "", +92, Increment, 1915, 1920, "1 . 2", "", " \"1 . 2\"." +94, SdDevChangeValue, 1927, 1933, "3 . 96", "", " \"3 . 96\"." +96, Kg, 1934, 1936, "kg", "", " ." +93, Increment, 1944, 1949, "2 . 7", "", " \"2 . 7\"." +95, SdDevChangeValue, 1956, 1962, "3 . 94", "", " \"3 . 94\"." +97, Kg, 1963, 1965, "kg", "", +98, PvalueDiff, 1968, 1979, "p = 0 . 001", "", " \"p = 0 . 001\"." +99, Hypoglycemia, 1984, 1996, "Hypoglycemia", "", " ." +100, ObservedResult, 1997, 2031, "risk was comparable between groups", "", " \"risk was comparable between groups\"." +101, InsulinDetemir, 2050, 2054, "IDet", "", +102, PercentageAffected, 2076, 2082, "87 . 4", "", +210, Frequency, 2101, 2113, "once - daily", "", " \"once - daily\"." +68833, Insulin, 2120, 2127, "insulin", "", +104, InsulinDetemir, 2173, 2177, "IDet", "", +221, ConclusionComment, 2173, 2296, "IDet and IGla were both effective and safe treatments for glycemic control in a basal - bolus regimen for type 2 diabetes .", "", " \"IDet and IGla were both effective and safe treatments for glycemic control in a basal - bolus regimen for type 2 diabetes .\"." +105, InsulinGlargine, 2182, 2186, "IGla", "", +106, Type2Diabetes, 2279, 2294, "type 2 diabetes", "", +222, ConclusionComment, 2297, 2470, "Clinically significant reductions in HbA ( 1c ) were achieved in both groups , but with significantly less weight gain in the IDet group at comparable basal insulin dosage .", "", " \"Clinically significant reductions in HbA ( 1c ) were achieved in both groups , but with significantly less weight gain in the IDet group at comparable basal insulin dosage .\"." +107, HbA1c, 2334, 2344, "HbA ( 1c )", "", +108, BodyWeight, 2404, 2410, "weight", "", +109, InsulinDetemir, 2423, 2427, "IDet", "", +220, Insulin, 2454, 2461, "insulin", "", +110, PMID, 2507, 2515, "19565569", "", " \"19565569\"." diff --git a/data/dm2 19565569_admin.n-triples b/data/dm2 19565569_admin.n-triples new file mode 100644 index 0000000..4ea5525 --- /dev/null +++ b/data/dm2 19565569_admin.n-triples @@ -0,0 +1,182 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes ." . + "Raskin P" . + "2009" . + "Diabetes Metab Res Rev ." . + "19565569" . + . + "Gylvin T" . + "Weng W" . + "Chaykin L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This treat - to - target study compared the efficacy and safety of insulin detemir ( IDet ) and insulin glargine ( IGla ) in a basal - bolus ( insulin aspart ) regimen in type 2 diabetes ." . + "385" . + "26 weeks" . + . + . + . + . + "IDet and IGla were both effective and safe treatments for glycemic control in a basal - bolus regimen for type 2 diabetes ." . + . + . + . + . + . + . + . + "Clinically significant reductions in HbA ( 1c ) were achieved in both groups , but with significantly less weight gain in the IDet group at comparable basal insulin dosage ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "basal - bolus ( insulin aspart ) regimen in type 2 diabetes" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint delta 0,4" . + . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . +# RDF export of group: Arm + . + "Arm idet" . + . + . + . + . + . + . + . + "Arm ig" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention idet" . + . + "once - daily" . + . + . + "Intervention ig" . + . + . +# RDF export of group: Medication + . + "Medication idet" . + . + . + . + . + "Medication ig" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c idet 26" . + . + "7 . 1" . + "1 . 1" . + "p < 0 . 001" . + "26 weeks" . + "7 . 3" . + . + "Outcome hba1c ig 26" . + . + "6 . 9" . + "1 . 3" . + "p < 0 . 001" . + "26 weeks" . + "7 . 0" . + . + "Outcome delta idet" . + . + . + "Outcome delta ig" . + . + . + "Outcome fpg idet" . + . + "130" . + "26 weeks" . + "135" . + . + "Outcome fpg ig" . + . + "134" . + "26 weeks" . + "137" . + . + "Outcome weight idet" . + . + "1 . 2" . + "3 . 96" . + . + "Outcome weight ig" . + . + "2 . 7" . + "3 . 94" . + . + "Outcome h both drugs" . + . + "risk was comparable between groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c 26" . + "0 . 207" . + "95 % CI : 0 . 0149 , 0 . 3995" . + . + . + . + "DiffBetweenGroups delta" . + "0 . 307" . + "95 % CI : 0 . 1023 , 0 . 5109" . + . + . + . + "DiffBetweenGroups weight" . + "p = 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19565569_akramersunderbrink.annodb b/data/dm2 19565569_akramersunderbrink.annodb new file mode 100644 index 0000000..1d3f13c --- /dev/null +++ b/data/dm2 19565569_akramersunderbrink.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +28609, Journal, 0, 22, "Diabetes Metab Res Rev", "", +28610, PublicationYear, 25, 29, "2009", "", +28615, Title, 88, 247, "Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes .", "", +28611, InsulinDetemir, 102, 117, "insulin detemir", "", +28612, InsulinGlargine, 122, 138, "insulin glargine", "", +28613, Randomized, 174, 184, "randomized", "", +28614, Type2Diabetes, 230, 245, "type 2 diabetes", "", +28616, Author, 248, 256, "Raskin P", "", +28617, Author, 265, 273, "Gylvin T", "", +28618, Author, 276, 282, "Weng W", "", +28619, Author, 285, 294, "Chaykin L", "", +28620, USA, 414, 417, "USA", "", +28636, ObjectiveDescription, 472, 660, "This treat - to - target study compared the efficacy and safety of insulin detemir ( IDet ) and insulin glargine ( IGla ) in a basal - bolus ( insulin aspart ) regimen in type 2 diabetes .", "", +28621, InsulinDetemir, 539, 554, "insulin detemir", "", +28622, InsulinDetemir, 557, 561, "IDet", "", +28623, InsulinGlargine, 568, 584, "insulin glargine", "", +28624, InsulinGlargine, 587, 591, "IGla", "", +28625, InsulinAspart, 615, 629, "insulin aspart", "", +28626, Type2Diabetes, 643, 658, "type 2 diabetes", "", +28627, NumberPatientsCT, 671, 674, "385", "", +28628, InsulinDetemir, 708, 712, "IDet", "", +28629, InsulinGlargine, 715, 719, "IGla", "", +28631, InsulinDetemir, 745, 749, "IDet", "", +28630, InsulinGlargine, 753, 757, "IGla", "", +28632, HbA1c, 776, 786, "HbA ( 1c )", "", +39178, Percentage, 790, 791, "%", "", +28633, InsulinDetemir, 827, 831, "IDet", "", +28634, InsulinGlargine, 836, 840, "IGla", "", +28635, HbA1c, 868, 878, "HbA ( 1c )", "", +28637, Duration, 892, 900, "26 weeks", "", +28638, Week, 895, 900, "weeks", "", +28640, Duration, 949, 957, "26 weeks", "", +28639, Week, 952, 957, "weeks", "", +28643, LeastSquaresMean, 960, 967, "LS mean", "", +28641, InsulinDetemir, 970, 973, "Det", "", +28642, InsulinGlargine, 976, 979, "Gla", "", +28842, DiffGroupAbsValue, 984, 991, "0 . 207", "", +28645, ConfIntervalDiff, 994, 1023, "95 % CI : 0 . 0149 , 0 . 3995", "", +28647, InsulinGlargine, 1045, 1049, "IGla", "", +28648, InsulinDetemir, 1080, 1084, "IDet", "", +28649, HbA1c, 1097, 1107, "HbA ( 1c )", "", +28843, DiffGroupAbsValue, 1131, 1138, "0 . 207", "", +28651, Percentage, 1139, 1140, "%", "", +28677, AggregationMethod, 1245, 1249, "LOCF", "", +28652, LeastSquaresMean, 1324, 1331, "LS mean", "", +28653, InsulinDetemir, 1337, 1340, "Det", "", +28654, InsulinGlargine, 1343, 1346, "Gla", "", +28844, DiffGroupAbsValue, 1351, 1358, "0 . 307", "", +28656, ConfIntervalDiff, 1361, 1390, "95 % CI : 0 . 1023 , 0 . 5109", "", +28657, HbA1c, 1395, 1405, "HbA ( 1c )", "", +39181, TimePoint, 1435, 1443, "baseline", "", +28658, InsulinDetemir, 1447, 1451, "IDet", "", +28659, ChangeValue, 1454, 1461, "- 1 . 1", "", +28664, Percentage, 1462, 1463, "%", "", +28667, Duration, 1466, 1474, "26 weeks", "", +28669, ChangeValue, 1479, 1486, "- 0 . 9", "", +28665, Percentage, 1487, 1488, "%", "", +28678, AggregationMethod, 1491, 1495, "LOCF", "", +28661, PValueChangeValue, 1500, 1511, "p < 0 . 001", "", +28663, InsulinGlargine, 1521, 1525, "IGla", "", +28660, ChangeValue, 1528, 1535, "- 1 . 3", "", +28666, Percentage, 1536, 1537, "%", "", +28668, Duration, 1540, 1548, "26 weeks", "", +28679, AggregationMethod, 1551, 1555, "LOCF", "", +28662, PValueChangeValue, 1560, 1571, "p < 0 . 001", "", +28670, HbA1c, 1582, 1592, "HbA ( 1c )", "", +28671, ResultMeasuredValue, 1598, 1603, "7 . 1", "", +28684, Percentage, 1604, 1605, "%", "", +28673, Duration, 1608, 1616, "26 weeks", "", +28675, ResultMeasuredValue, 1623, 1628, "7 . 3", "", +28685, Percentage, 1629, 1630, "%", "", +28680, AggregationMethod, 1633, 1637, "LOCF", "", +28682, InsulinDetemir, 1643, 1647, "IDet", "", +28672, ResultMeasuredValue, 1654, 1659, "6 . 9", "", +28686, Percentage, 1660, 1661, "%", "", +28674, Duration, 1664, 1672, "26 weeks", "", +28676, ResultMeasuredValue, 1679, 1684, "7 . 0", "", +28687, Percentage, 1685, 1686, "%", "", +28681, AggregationMethod, 1689, 1693, "LOCF", "", +28683, InsulinGlargine, 1699, 1703, "IGla", "", +28688, FastingPlasmaGlucose, 1712, 1715, "FPG", "", +28689, ResultMeasuredValue, 1721, 1724, "130", "", +28693, Mg_per_deciliter, 1725, 1732, "mg / dL", "", +28697, Duration, 1735, 1743, "26 weeks", "", +28690, ResultMeasuredValue, 1750, 1753, "135", "", +28694, Mg_per_deciliter, 1754, 1761, "mg / dL", "", +28699, AggregationMethod, 1764, 1768, "LOCF", "", +28701, InsulinDetemir, 1774, 1778, "IDet", "", +28691, ResultMeasuredValue, 1785, 1788, "134", "", +28695, Mg_per_deciliter, 1789, 1796, "mg / dL", "", +28698, Duration, 1799, 1807, "26 weeks", "", +28692, ResultMeasuredValue, 1814, 1817, "137", "", +28696, Mg_per_deciliter, 1818, 1825, "mg / dL", "", +28700, AggregationMethod, 1828, 1832, "LOCF", "", +28702, InsulinGlargine, 1838, 1842, "IGla", "", +28703, WeightGain, 1874, 1885, "weight gain", "", +28704, InsulinDetemir, 1889, 1893, "IDet", "", +28705, ResultMeasuredValue, 1915, 1920, "1 . 2", "", +28727, SdDevResValue, 1921, 1933, "+ / - 3 . 96", "", +28707, Kg, 1934, 1936, "kg", "", +28706, ResultMeasuredValue, 1944, 1949, "2 . 7", "", +28728, SdDevResValue, 1950, 1962, "+ / - 3 . 94", "", +28708, Kg, 1963, 1965, "kg", "", +28709, PvalueDiff, 1968, 1979, "p = 0 . 001", "", +28710, Hypoglycemia, 1984, 2001, "Hypoglycemia risk", "", +28711, InsulinDetemir, 2050, 2054, "IDet", "", +28714, PercentageAffected, 2076, 2082, "87 . 4", "", +28715, Percentage, 2083, 2084, "%", "", +28713, EndPointDescription, 2087, 2156, "remained on a once - daily basal insulin regimen throughout the study", "", +28712, Frequency, 2101, 2113, "once - daily", "", +28716, InsulinDetemir, 2173, 2177, "IDet", "", +28724, ConclusionComment, 2173, 2296, "IDet and IGla were both effective and safe treatments for glycemic control in a basal - bolus regimen for type 2 diabetes .", "", +28717, InsulinGlargine, 2182, 2186, "IGla", "", +28718, Type2Diabetes, 2279, 2294, "type 2 diabetes", "", +28725, ConclusionComment, 2297, 2470, "Clinically significant reductions in HbA ( 1c ) were achieved in both groups , but with significantly less weight gain in the IDet group at comparable basal insulin dosage .", "", +28719, HbA1c, 2334, 2344, "HbA ( 1c )", "", +28720, WeightGain, 2404, 2415, "weight gain", "", +28722, InsulinDetemir, 2423, 2427, "IDet", "", +28723, Insulin, 2454, 2461, "insulin", "", +28726, PMID, 2507, 2515, "19565569", "", diff --git a/data/dm2 19565569_akramersunderbrink.n-triples b/data/dm2 19565569_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19565569_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19565569_export.csv b/data/dm2 19565569_export.csv new file mode 100644 index 0000000..890b634 --- /dev/null +++ b/data/dm2 19565569_export.csv @@ -0,0 +1,612 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +335, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +335, 1, 2, 2, 9, 14, 9, 14, "Metab" +335, 1, 3, 3, 15, 18, 15, 18, "Res" +335, 1, 4, 4, 19, 22, 19, 22, "Rev" +335, 1, 5, 5, 23, 24, 23, 24, "." +335, 2, 1, 6, 0, 4, 25, 29, "2009" +335, 2, 2, 7, 5, 8, 30, 33, "Sep" +335, 2, 3, 8, 9, 10, 34, 35, ";" +335, 2, 4, 9, 11, 13, 36, 38, "25" +335, 2, 5, 10, 14, 15, 39, 40, "(" +335, 2, 6, 11, 16, 17, 41, 42, "6" +335, 2, 7, 12, 18, 19, 43, 44, ")" +335, 2, 8, 13, 20, 21, 45, 46, ":" +335, 2, 9, 14, 22, 25, 47, 50, "542" +335, 2, 10, 15, 26, 27, 51, 52, "-" +335, 2, 11, 16, 28, 29, 53, 54, "8" +335, 2, 12, 17, 30, 31, 55, 56, "." +335, 2, 13, 18, 32, 35, 57, 60, "doi" +335, 2, 14, 19, 36, 37, 61, 62, ":" +335, 2, 15, 20, 38, 40, 63, 65, "10" +335, 2, 16, 21, 41, 42, 66, 67, "." +335, 2, 17, 22, 43, 47, 68, 72, "1002" +335, 2, 18, 23, 48, 49, 73, 74, "/" +335, 2, 19, 24, 50, 54, 75, 79, "dmrr" +335, 2, 20, 25, 55, 56, 80, 81, "." +335, 2, 21, 26, 57, 60, 82, 85, "989" +335, 2, 22, 27, 61, 62, 86, 87, "." +335, 3, 1, 28, 0, 10, 88, 98, "Comparison" +335, 3, 2, 29, 11, 13, 99, 101, "of" +335, 3, 3, 30, 14, 21, 102, 109, "insulin" +335, 3, 4, 31, 22, 29, 110, 117, "detemir" +335, 3, 5, 32, 30, 33, 118, 121, "and" +335, 3, 6, 33, 34, 41, 122, 129, "insulin" +335, 3, 7, 34, 42, 50, 130, 138, "glargine" +335, 3, 8, 35, 51, 56, 139, 144, "using" +335, 3, 9, 36, 57, 58, 145, 146, "a" +335, 3, 10, 37, 59, 64, 147, 152, "basal" +335, 3, 11, 38, 65, 66, 153, 154, "-" +335, 3, 12, 39, 67, 72, 155, 160, "bolus" +335, 3, 13, 40, 73, 80, 161, 168, "regimen" +335, 3, 14, 41, 81, 83, 169, 171, "in" +335, 3, 15, 42, 84, 85, 172, 173, "a" +335, 3, 16, 43, 86, 96, 174, 184, "randomized" +335, 3, 17, 44, 97, 98, 185, 186, "," +335, 3, 18, 45, 99, 109, 187, 197, "controlled" +335, 3, 19, 46, 110, 118, 198, 206, "clinical" +335, 3, 20, 47, 119, 124, 207, 212, "study" +335, 3, 21, 48, 125, 127, 213, 215, "in" +335, 3, 22, 49, 128, 136, 216, 224, "patients" +335, 3, 23, 50, 137, 141, 225, 229, "with" +335, 3, 24, 51, 142, 146, 230, 234, "type" +335, 3, 25, 52, 147, 148, 235, 236, "2" +335, 3, 26, 53, 149, 157, 237, 245, "diabetes" +335, 3, 27, 54, 158, 159, 246, 247, "." +335, 4, 1, 55, 0, 6, 248, 254, "Raskin" +335, 4, 2, 56, 7, 8, 255, 256, "P" +335, 4, 3, 57, 9, 10, 257, 258, "(" +335, 4, 4, 58, 11, 12, 259, 260, "1" +335, 4, 5, 59, 13, 14, 261, 262, ")" +335, 4, 6, 60, 15, 16, 263, 264, "," +335, 4, 7, 61, 17, 23, 265, 271, "Gylvin" +335, 4, 8, 62, 24, 25, 272, 273, "T" +335, 4, 9, 63, 26, 27, 274, 275, "," +335, 4, 10, 64, 28, 32, 276, 280, "Weng" +335, 4, 11, 65, 33, 34, 281, 282, "W" +335, 4, 12, 66, 35, 36, 283, 284, "," +335, 4, 13, 67, 37, 44, 285, 292, "Chaykin" +335, 4, 14, 68, 45, 46, 293, 294, "L" +335, 4, 15, 69, 47, 48, 295, 296, "." +335, 4, 16, 70, 49, 55, 297, 303, "Author" +335, 4, 17, 71, 56, 67, 304, 315, "information" +335, 4, 18, 72, 68, 69, 316, 317, ":" +335, 4, 19, 73, 70, 71, 318, 319, "(" +335, 4, 20, 74, 72, 73, 320, 321, "1" +335, 4, 21, 75, 74, 75, 322, 323, ")" +335, 4, 22, 76, 76, 86, 324, 334, "University" +335, 4, 23, 77, 87, 89, 335, 337, "of" +335, 4, 24, 78, 90, 95, 338, 343, "Texas" +335, 4, 25, 79, 96, 108, 344, 356, "Southwestern" +335, 4, 26, 80, 109, 116, 357, 364, "Medical" +335, 4, 27, 81, 117, 123, 365, 371, "Center" +335, 4, 28, 82, 124, 126, 372, 374, "at" +335, 4, 29, 83, 127, 133, 375, 381, "Dallas" +335, 4, 30, 84, 134, 135, 382, 383, "," +335, 4, 31, 85, 136, 142, 384, 390, "Dallas" +335, 4, 32, 86, 143, 144, 391, 392, "," +335, 4, 33, 87, 145, 150, 393, 398, "Texas" +335, 4, 34, 88, 151, 156, 399, 404, "75390" +335, 4, 35, 89, 157, 158, 405, 406, "-" +335, 4, 36, 90, 159, 163, 407, 411, "8858" +335, 4, 37, 91, 164, 165, 412, 413, "," +335, 4, 38, 92, 166, 169, 414, 417, "USA" +335, 4, 39, 93, 170, 171, 418, 419, "." +335, 5, 1, 94, 0, 6, 420, 426, "Philip" +335, 5, 2, 95, 7, 8, 427, 428, "." +335, 5, 3, 96, 9, 15, 429, 435, "Raskin" +335, 5, 4, 97, 16, 17, 436, 437, "@" +335, 5, 5, 98, 18, 32, 438, 452, "UTSouthwestern" +335, 5, 6, 99, 33, 34, 453, 454, "." +335, 5, 7, 100, 35, 38, 455, 458, "edu" +335, 5, 8, 101, 39, 49, 459, 469, "BACKGROUND" +335, 5, 9, 102, 50, 51, 470, 471, ":" +335, 5, 10, 103, 52, 56, 472, 476, "This" +335, 5, 11, 104, 57, 62, 477, 482, "treat" +335, 5, 12, 105, 63, 64, 483, 484, "-" +335, 5, 13, 106, 65, 67, 485, 487, "to" +335, 5, 14, 107, 68, 69, 488, 489, "-" +335, 5, 15, 108, 70, 76, 490, 496, "target" +335, 5, 16, 109, 77, 82, 497, 502, "study" +335, 5, 17, 110, 83, 91, 503, 511, "compared" +335, 5, 18, 111, 92, 95, 512, 515, "the" +335, 5, 19, 112, 96, 104, 516, 524, "efficacy" +335, 5, 20, 113, 105, 108, 525, 528, "and" +335, 5, 21, 114, 109, 115, 529, 535, "safety" +335, 5, 22, 115, 116, 118, 536, 538, "of" +335, 5, 23, 116, 119, 126, 539, 546, "insulin" +335, 5, 24, 117, 127, 134, 547, 554, "detemir" +335, 5, 25, 118, 135, 136, 555, 556, "(" +335, 5, 26, 119, 137, 141, 557, 561, "IDet" +335, 5, 27, 120, 142, 143, 562, 563, ")" +335, 5, 28, 121, 144, 147, 564, 567, "and" +335, 5, 29, 122, 148, 155, 568, 575, "insulin" +335, 5, 30, 123, 156, 164, 576, 584, "glargine" +335, 5, 31, 124, 165, 166, 585, 586, "(" +335, 5, 32, 125, 167, 171, 587, 591, "IGla" +335, 5, 33, 126, 172, 173, 592, 593, ")" +335, 5, 34, 127, 174, 176, 594, 596, "in" +335, 5, 35, 128, 177, 178, 597, 598, "a" +335, 5, 36, 129, 179, 184, 599, 604, "basal" +335, 5, 37, 130, 185, 186, 605, 606, "-" +335, 5, 38, 131, 187, 192, 607, 612, "bolus" +335, 5, 39, 132, 193, 194, 613, 614, "(" +335, 5, 40, 133, 195, 202, 615, 622, "insulin" +335, 5, 41, 134, 203, 209, 623, 629, "aspart" +335, 5, 42, 135, 210, 211, 630, 631, ")" +335, 5, 43, 136, 212, 219, 632, 639, "regimen" +335, 5, 44, 137, 220, 222, 640, 642, "in" +335, 5, 45, 138, 223, 227, 643, 647, "type" +335, 5, 46, 139, 228, 229, 648, 649, "2" +335, 5, 47, 140, 230, 238, 650, 658, "diabetes" +335, 5, 48, 141, 239, 240, 659, 660, "." +335, 6, 1, 142, 0, 7, 661, 668, "METHODS" +335, 6, 2, 143, 8, 9, 669, 670, ":" +335, 6, 3, 144, 10, 13, 671, 674, "385" +335, 6, 4, 145, 14, 22, 675, 683, "patients" +335, 6, 5, 146, 23, 27, 684, 688, "were" +335, 6, 6, 147, 28, 38, 689, 699, "randomized" +335, 6, 7, 148, 39, 40, 700, 701, "2" +335, 6, 8, 149, 41, 42, 702, 703, ":" +335, 6, 9, 150, 43, 44, 704, 705, "1" +335, 6, 10, 151, 45, 46, 706, 707, "(" +335, 6, 11, 152, 47, 51, 708, 712, "IDet" +335, 6, 12, 153, 52, 53, 713, 714, ":" +335, 6, 13, 154, 54, 58, 715, 719, "IGla" +335, 6, 14, 155, 59, 60, 720, 721, ")" +335, 6, 15, 156, 61, 62, 722, 723, "." +335, 7, 1, 157, 0, 3, 724, 727, "Non" +335, 7, 2, 158, 4, 5, 728, 729, "-" +335, 7, 3, 159, 6, 17, 730, 741, "inferiority" +335, 7, 4, 160, 18, 20, 742, 744, "of" +335, 7, 5, 161, 21, 25, 745, 749, "IDet" +335, 7, 6, 162, 26, 28, 750, 752, "to" +335, 7, 7, 163, 29, 33, 753, 757, "IGla" +335, 7, 8, 164, 34, 37, 758, 761, "was" +335, 7, 9, 165, 38, 48, 762, 772, "determined" +335, 7, 10, 166, 49, 51, 773, 775, "by" +335, 7, 11, 167, 52, 55, 776, 779, "HbA" +335, 7, 12, 168, 56, 57, 780, 781, "(" +335, 7, 13, 169, 58, 60, 782, 784, "1c" +335, 7, 14, 170, 61, 62, 785, 786, ")" +335, 7, 15, 171, 63, 65, 787, 789, "95" +335, 7, 16, 172, 66, 67, 790, 791, "%" +335, 7, 17, 173, 68, 70, 792, 794, "CI" +335, 7, 18, 174, 71, 76, 795, 800, "upper" +335, 7, 19, 175, 77, 82, 801, 806, "limit" +335, 7, 20, 176, 83, 84, 807, 808, "<" +335, 7, 21, 177, 85, 86, 809, 810, "0" +335, 7, 22, 178, 87, 88, 811, 812, "." +335, 7, 23, 179, 89, 90, 813, 814, "4" +335, 7, 24, 180, 91, 92, 815, 816, "." +335, 8, 1, 181, 0, 7, 817, 824, "RESULTS" +335, 8, 2, 182, 8, 9, 825, 826, ":" +335, 8, 3, 183, 10, 14, 827, 831, "IDet" +335, 8, 4, 184, 15, 18, 832, 835, "and" +335, 8, 5, 185, 19, 23, 836, 840, "IGla" +335, 8, 6, 186, 24, 30, 841, 847, "showed" +335, 8, 7, 187, 31, 38, 848, 855, "similar" +335, 8, 8, 188, 39, 47, 856, 864, "efficacy" +335, 8, 9, 189, 48, 50, 865, 867, "in" +335, 8, 10, 190, 51, 54, 868, 871, "HbA" +335, 8, 11, 191, 55, 56, 872, 873, "(" +335, 8, 12, 192, 57, 59, 874, 876, "1c" +335, 8, 13, 193, 60, 61, 877, 878, ")" +335, 8, 14, 194, 62, 71, 879, 888, "reduction" +335, 8, 15, 195, 72, 74, 889, 891, "at" +335, 8, 16, 196, 75, 77, 892, 894, "26" +335, 8, 17, 197, 78, 83, 895, 900, "weeks" +335, 8, 18, 198, 84, 85, 901, 902, "," +335, 8, 19, 199, 86, 88, 903, 905, "as" +335, 8, 20, 200, 89, 92, 906, 909, "the" +335, 8, 21, 201, 93, 96, 910, 913, "non" +335, 8, 22, 202, 97, 98, 914, 915, "-" +335, 8, 23, 203, 99, 110, 916, 927, "inferiority" +335, 8, 24, 204, 111, 120, 928, 937, "criterion" +335, 8, 25, 205, 121, 124, 938, 941, "was" +335, 8, 26, 206, 125, 128, 942, 945, "met" +335, 8, 27, 207, 129, 131, 946, 948, "at" +335, 8, 28, 208, 132, 134, 949, 951, "26" +335, 8, 29, 209, 135, 140, 952, 957, "weeks" +335, 8, 30, 210, 141, 142, 958, 959, "(" +335, 8, 31, 211, 143, 145, 960, 962, "LS" +335, 8, 32, 212, 146, 150, 963, 967, "mean" +335, 8, 33, 213, 151, 152, 968, 969, "[" +335, 8, 34, 214, 153, 156, 970, 973, "Det" +335, 8, 35, 215, 157, 158, 974, 975, "-" +335, 8, 36, 216, 159, 162, 976, 979, "Gla" +335, 8, 37, 217, 163, 164, 980, 981, "]" +335, 8, 38, 218, 165, 166, 982, 983, ":" +335, 8, 39, 219, 167, 168, 984, 985, "0" +335, 8, 40, 220, 169, 170, 986, 987, "." +335, 8, 41, 221, 171, 174, 988, 991, "207" +335, 8, 42, 222, 175, 176, 992, 993, ";" +335, 8, 43, 223, 177, 179, 994, 996, "95" +335, 8, 44, 224, 180, 181, 997, 998, "%" +335, 8, 45, 225, 182, 184, 999, 1001, "CI" +335, 8, 46, 226, 185, 186, 1002, 1003, ":" +335, 8, 47, 227, 187, 188, 1004, 1005, "0" +335, 8, 48, 228, 189, 190, 1006, 1007, "." +335, 8, 49, 229, 191, 195, 1008, 1012, "0149" +335, 8, 50, 230, 196, 197, 1013, 1014, "," +335, 8, 51, 231, 198, 199, 1015, 1016, "0" +335, 8, 52, 232, 200, 201, 1017, 1018, "." +335, 8, 53, 233, 202, 206, 1019, 1023, "3995" +335, 8, 54, 234, 207, 208, 1024, 1025, ")" +335, 8, 55, 235, 209, 210, 1026, 1027, "." +335, 9, 1, 236, 0, 2, 1028, 1030, "It" +335, 9, 2, 237, 3, 11, 1031, 1039, "appeared" +335, 9, 3, 238, 12, 16, 1040, 1044, "that" +335, 9, 4, 239, 17, 21, 1045, 1049, "IGla" +335, 9, 5, 240, 22, 24, 1050, 1052, "in" +335, 9, 6, 241, 25, 29, 1053, 1057, "some" +335, 9, 7, 242, 30, 35, 1058, 1063, "cases" +335, 9, 8, 243, 36, 39, 1064, 1067, "did" +335, 9, 9, 244, 40, 46, 1068, 1074, "better" +335, 9, 10, 245, 47, 51, 1075, 1079, "than" +335, 9, 11, 246, 52, 56, 1080, 1084, "IDet" +335, 9, 12, 247, 57, 59, 1085, 1087, "in" +335, 9, 13, 248, 60, 65, 1088, 1093, "terms" +335, 9, 14, 249, 66, 68, 1094, 1096, "of" +335, 9, 15, 250, 69, 72, 1097, 1100, "HbA" +335, 9, 16, 251, 73, 74, 1101, 1102, "(" +335, 9, 17, 252, 75, 77, 1103, 1105, "1c" +335, 9, 18, 253, 78, 79, 1106, 1107, ")" +335, 9, 19, 254, 80, 81, 1108, 1109, "," +335, 9, 20, 255, 82, 85, 1110, 1113, "but" +335, 9, 21, 256, 86, 89, 1114, 1117, "the" +335, 9, 22, 257, 90, 100, 1118, 1128, "difference" +335, 9, 23, 258, 101, 102, 1129, 1130, "(" +335, 9, 24, 259, 103, 104, 1131, 1132, "0" +335, 9, 25, 260, 105, 106, 1133, 1134, "." +335, 9, 26, 261, 107, 110, 1135, 1138, "207" +335, 9, 27, 262, 111, 112, 1139, 1140, "%" +335, 9, 28, 263, 113, 114, 1141, 1142, ")" +335, 9, 29, 264, 115, 118, 1143, 1146, "was" +335, 9, 30, 265, 119, 122, 1147, 1150, "not" +335, 9, 31, 266, 123, 133, 1151, 1161, "clinically" +335, 9, 32, 267, 134, 144, 1162, 1172, "meaningful" +335, 9, 33, 268, 145, 146, 1173, 1174, "." +335, 10, 1, 269, 0, 5, 1175, 1180, "Based" +335, 10, 2, 270, 6, 8, 1181, 1183, "on" +335, 10, 3, 271, 9, 12, 1184, 1187, "the" +335, 10, 4, 272, 13, 20, 1188, 1195, "CONSORT" +335, 10, 5, 273, 21, 30, 1196, 1205, "guideline" +335, 10, 6, 274, 31, 32, 1206, 1207, "," +335, 10, 7, 275, 33, 36, 1208, 1211, "non" +335, 10, 8, 276, 37, 38, 1212, 1213, "-" +335, 10, 9, 277, 39, 50, 1214, 1225, "inferiority" +335, 10, 10, 278, 51, 59, 1226, 1234, "analysis" +335, 10, 11, 279, 60, 65, 1235, 1240, "using" +335, 10, 12, 280, 66, 69, 1241, 1244, "the" +335, 10, 13, 281, 70, 74, 1245, 1249, "LOCF" +335, 10, 14, 282, 75, 83, 1250, 1258, "approach" +335, 10, 15, 283, 84, 87, 1259, 1262, "was" +335, 10, 16, 284, 88, 100, 1263, 1275, "inconclusive" +335, 10, 17, 285, 101, 110, 1276, 1285, "regarding" +335, 10, 18, 286, 111, 119, 1286, 1294, "possible" +335, 10, 19, 287, 120, 131, 1295, 1306, "inferiority" +335, 10, 20, 288, 132, 134, 1307, 1309, "of" +335, 10, 21, 289, 135, 140, 1310, 1315, "delta" +335, 10, 22, 290, 141, 142, 1316, 1317, "0" +335, 10, 23, 291, 143, 144, 1318, 1319, "." +335, 10, 24, 292, 145, 146, 1320, 1321, "4" +335, 10, 25, 293, 147, 148, 1322, 1323, "(" +335, 10, 26, 294, 149, 151, 1324, 1326, "LS" +335, 10, 27, 295, 152, 156, 1327, 1331, "mean" +335, 10, 28, 296, 157, 159, 1332, 1334, "of" +335, 10, 29, 297, 160, 161, 1335, 1336, "[" +335, 10, 30, 298, 162, 165, 1337, 1340, "Det" +335, 10, 31, 299, 166, 167, 1341, 1342, "-" +335, 10, 32, 300, 168, 171, 1343, 1346, "Gla" +335, 10, 33, 301, 172, 173, 1347, 1348, "]" +335, 10, 34, 302, 174, 175, 1349, 1350, ":" +335, 10, 35, 303, 176, 177, 1351, 1352, "0" +335, 10, 36, 304, 178, 179, 1353, 1354, "." +335, 10, 37, 305, 180, 183, 1355, 1358, "307" +335, 10, 38, 306, 184, 185, 1359, 1360, ";" +335, 10, 39, 307, 186, 188, 1361, 1363, "95" +335, 10, 40, 308, 189, 190, 1364, 1365, "%" +335, 10, 41, 309, 191, 193, 1366, 1368, "CI" +335, 10, 42, 310, 194, 195, 1369, 1370, ":" +335, 10, 43, 311, 196, 197, 1371, 1372, "0" +335, 10, 44, 312, 198, 199, 1373, 1374, "." +335, 10, 45, 313, 200, 204, 1375, 1379, "1023" +335, 10, 46, 314, 205, 206, 1380, 1381, "," +335, 10, 47, 315, 207, 208, 1382, 1383, "0" +335, 10, 48, 316, 209, 210, 1384, 1385, "." +335, 10, 49, 317, 211, 215, 1386, 1390, "5109" +335, 10, 50, 318, 216, 217, 1391, 1392, ")" +335, 10, 51, 319, 218, 219, 1393, 1394, "." +335, 11, 1, 320, 0, 3, 1395, 1398, "HbA" +335, 11, 2, 321, 4, 5, 1399, 1400, "(" +335, 11, 3, 322, 6, 8, 1401, 1403, "1c" +335, 11, 4, 323, 9, 10, 1404, 1405, ")" +335, 11, 5, 324, 11, 20, 1406, 1415, "decreased" +335, 11, 6, 325, 21, 34, 1416, 1429, "significantly" +335, 11, 7, 326, 35, 39, 1430, 1434, "from" +335, 11, 8, 327, 40, 48, 1435, 1443, "baseline" +335, 11, 9, 328, 49, 51, 1444, 1446, "in" +335, 11, 10, 329, 52, 56, 1447, 1451, "IDet" +335, 11, 11, 330, 57, 58, 1452, 1453, "(" +335, 11, 12, 331, 59, 60, 1454, 1455, "-" +335, 11, 13, 332, 61, 62, 1456, 1457, "1" +335, 11, 14, 333, 63, 64, 1458, 1459, "." +335, 11, 15, 334, 65, 66, 1460, 1461, "1" +335, 11, 16, 335, 67, 68, 1462, 1463, "%" +335, 11, 17, 336, 69, 70, 1464, 1465, "[" +335, 11, 18, 337, 71, 73, 1466, 1468, "26" +335, 11, 19, 338, 74, 79, 1469, 1474, "weeks" +335, 11, 20, 339, 80, 81, 1475, 1476, "]" +335, 11, 21, 340, 82, 83, 1477, 1478, "," +335, 11, 22, 341, 84, 85, 1479, 1480, "-" +335, 11, 23, 342, 86, 87, 1481, 1482, "0" +335, 11, 24, 343, 88, 89, 1483, 1484, "." +335, 11, 25, 344, 90, 91, 1485, 1486, "9" +335, 11, 26, 345, 92, 93, 1487, 1488, "%" +335, 11, 27, 346, 94, 95, 1489, 1490, "[" +335, 11, 28, 347, 96, 100, 1491, 1495, "LOCF" +335, 11, 29, 348, 101, 102, 1496, 1497, "]" +335, 11, 30, 349, 103, 104, 1498, 1499, "," +335, 11, 31, 350, 105, 106, 1500, 1501, "p" +335, 11, 32, 351, 107, 108, 1502, 1503, "<" +335, 11, 33, 352, 109, 110, 1504, 1505, "0" +335, 11, 34, 353, 111, 112, 1506, 1507, "." +335, 11, 35, 354, 113, 116, 1508, 1511, "001" +335, 11, 36, 355, 117, 118, 1512, 1513, ")" +335, 11, 37, 356, 119, 122, 1514, 1517, "and" +335, 11, 38, 357, 123, 125, 1518, 1520, "in" +335, 11, 39, 358, 126, 130, 1521, 1525, "IGla" +335, 11, 40, 359, 131, 132, 1526, 1527, "(" +335, 11, 41, 360, 133, 134, 1528, 1529, "-" +335, 11, 42, 361, 135, 136, 1530, 1531, "1" +335, 11, 43, 362, 137, 138, 1532, 1533, "." +335, 11, 44, 363, 139, 140, 1534, 1535, "3" +335, 11, 45, 364, 141, 142, 1536, 1537, "%" +335, 11, 46, 365, 143, 144, 1538, 1539, "[" +335, 11, 47, 366, 145, 147, 1540, 1542, "26" +335, 11, 48, 367, 148, 153, 1543, 1548, "weeks" +335, 11, 49, 368, 154, 155, 1549, 1550, "," +335, 11, 50, 369, 156, 160, 1551, 1555, "LOCF" +335, 11, 51, 370, 161, 162, 1556, 1557, "]" +335, 11, 52, 371, 163, 164, 1558, 1559, "," +335, 11, 53, 372, 165, 166, 1560, 1561, "p" +335, 11, 54, 373, 167, 168, 1562, 1563, "<" +335, 11, 55, 374, 169, 170, 1564, 1565, "0" +335, 11, 56, 375, 171, 172, 1566, 1567, "." +335, 11, 57, 376, 173, 176, 1568, 1571, "001" +335, 11, 58, 377, 177, 178, 1572, 1573, ")" +335, 11, 59, 378, 179, 180, 1574, 1575, "." +335, 12, 1, 379, 0, 5, 1576, 1581, "Final" +335, 12, 2, 380, 6, 9, 1582, 1585, "HbA" +335, 12, 3, 381, 10, 11, 1586, 1587, "(" +335, 12, 4, 382, 12, 14, 1588, 1590, "1c" +335, 12, 5, 383, 15, 16, 1591, 1592, ")" +335, 12, 6, 384, 17, 21, 1593, 1597, "were" +335, 12, 7, 385, 22, 23, 1598, 1599, "7" +335, 12, 8, 386, 24, 25, 1600, 1601, "." +335, 12, 9, 387, 26, 27, 1602, 1603, "1" +335, 12, 10, 388, 28, 29, 1604, 1605, "%" +335, 12, 11, 389, 30, 31, 1606, 1607, "(" +335, 12, 12, 390, 32, 34, 1608, 1610, "26" +335, 12, 13, 391, 35, 40, 1611, 1616, "weeks" +335, 12, 14, 392, 41, 42, 1617, 1618, ")" +335, 12, 15, 393, 43, 46, 1619, 1622, "and" +335, 12, 16, 394, 47, 48, 1623, 1624, "7" +335, 12, 17, 395, 49, 50, 1625, 1626, "." +335, 12, 18, 396, 51, 52, 1627, 1628, "3" +335, 12, 19, 397, 53, 54, 1629, 1630, "%" +335, 12, 20, 398, 55, 56, 1631, 1632, "(" +335, 12, 21, 399, 57, 61, 1633, 1637, "LOCF" +335, 12, 22, 400, 62, 63, 1638, 1639, ")" +335, 12, 23, 401, 64, 66, 1640, 1642, "in" +335, 12, 24, 402, 67, 71, 1643, 1647, "IDet" +335, 12, 25, 403, 72, 73, 1648, 1649, "," +335, 12, 26, 404, 74, 77, 1650, 1653, "and" +335, 12, 27, 405, 78, 79, 1654, 1655, "6" +335, 12, 28, 406, 80, 81, 1656, 1657, "." +335, 12, 29, 407, 82, 83, 1658, 1659, "9" +335, 12, 30, 408, 84, 85, 1660, 1661, "%" +335, 12, 31, 409, 86, 87, 1662, 1663, "(" +335, 12, 32, 410, 88, 90, 1664, 1666, "26" +335, 12, 33, 411, 91, 96, 1667, 1672, "weeks" +335, 12, 34, 412, 97, 98, 1673, 1674, ")" +335, 12, 35, 413, 99, 102, 1675, 1678, "and" +335, 12, 36, 414, 103, 104, 1679, 1680, "7" +335, 12, 37, 415, 105, 106, 1681, 1682, "." +335, 12, 38, 416, 107, 108, 1683, 1684, "0" +335, 12, 39, 417, 109, 110, 1685, 1686, "%" +335, 12, 40, 418, 111, 112, 1687, 1688, "(" +335, 12, 41, 419, 113, 117, 1689, 1693, "LOCF" +335, 12, 42, 420, 118, 119, 1694, 1695, ")" +335, 12, 43, 421, 120, 122, 1696, 1698, "in" +335, 12, 44, 422, 123, 127, 1699, 1703, "IGla" +335, 12, 45, 423, 128, 129, 1704, 1705, "." +335, 13, 1, 424, 0, 5, 1706, 1711, "Final" +335, 13, 2, 425, 6, 9, 1712, 1715, "FPG" +335, 13, 3, 426, 10, 14, 1716, 1720, "were" +335, 13, 4, 427, 15, 18, 1721, 1724, "130" +335, 13, 5, 428, 19, 21, 1725, 1727, "mg" +335, 13, 6, 429, 22, 23, 1728, 1729, "/" +335, 13, 7, 430, 24, 26, 1730, 1732, "dL" +335, 13, 8, 431, 27, 28, 1733, 1734, "(" +335, 13, 9, 432, 29, 31, 1735, 1737, "26" +335, 13, 10, 433, 32, 37, 1738, 1743, "weeks" +335, 13, 11, 434, 38, 39, 1744, 1745, ")" +335, 13, 12, 435, 40, 43, 1746, 1749, "and" +335, 13, 13, 436, 44, 47, 1750, 1753, "135" +335, 13, 14, 437, 48, 50, 1754, 1756, "mg" +335, 13, 15, 438, 51, 52, 1757, 1758, "/" +335, 13, 16, 439, 53, 55, 1759, 1761, "dL" +335, 13, 17, 440, 56, 57, 1762, 1763, "(" +335, 13, 18, 441, 58, 62, 1764, 1768, "LOCF" +335, 13, 19, 442, 63, 64, 1769, 1770, ")" +335, 13, 20, 443, 65, 67, 1771, 1773, "in" +335, 13, 21, 444, 68, 72, 1774, 1778, "IDet" +335, 13, 22, 445, 73, 74, 1779, 1780, "," +335, 13, 23, 446, 75, 78, 1781, 1784, "and" +335, 13, 24, 447, 79, 82, 1785, 1788, "134" +335, 13, 25, 448, 83, 85, 1789, 1791, "mg" +335, 13, 26, 449, 86, 87, 1792, 1793, "/" +335, 13, 27, 450, 88, 90, 1794, 1796, "dL" +335, 13, 28, 451, 91, 92, 1797, 1798, "(" +335, 13, 29, 452, 93, 95, 1799, 1801, "26" +335, 13, 30, 453, 96, 101, 1802, 1807, "weeks" +335, 13, 31, 454, 102, 103, 1808, 1809, ")" +335, 13, 32, 455, 104, 107, 1810, 1813, "and" +335, 13, 33, 456, 108, 111, 1814, 1817, "137" +335, 13, 34, 457, 112, 114, 1818, 1820, "mg" +335, 13, 35, 458, 115, 116, 1821, 1822, "/" +335, 13, 36, 459, 117, 119, 1823, 1825, "dL" +335, 13, 37, 460, 120, 121, 1826, 1827, "(" +335, 13, 38, 461, 122, 126, 1828, 1832, "LOCF" +335, 13, 39, 462, 127, 128, 1833, 1834, ")" +335, 13, 40, 463, 129, 131, 1835, 1837, "in" +335, 13, 41, 464, 132, 136, 1838, 1842, "IGla" +335, 13, 42, 465, 137, 138, 1843, 1844, "." +335, 14, 1, 466, 0, 5, 1845, 1850, "There" +335, 14, 2, 467, 6, 9, 1851, 1854, "was" +335, 14, 3, 468, 10, 23, 1855, 1868, "significantly" +335, 14, 4, 469, 24, 28, 1869, 1873, "less" +335, 14, 5, 470, 29, 35, 1874, 1880, "weight" +335, 14, 6, 471, 36, 40, 1881, 1885, "gain" +335, 14, 7, 472, 41, 43, 1886, 1888, "in" +335, 14, 8, 473, 44, 48, 1889, 1893, "IDet" +335, 14, 9, 474, 49, 50, 1894, 1895, "-" +335, 14, 10, 475, 51, 58, 1896, 1903, "treated" +335, 14, 11, 476, 59, 67, 1904, 1912, "patients" +335, 14, 12, 477, 68, 69, 1913, 1914, "(" +335, 14, 13, 478, 70, 71, 1915, 1916, "1" +335, 14, 14, 479, 72, 73, 1917, 1918, "." +335, 14, 15, 480, 74, 75, 1919, 1920, "2" +335, 14, 16, 481, 76, 77, 1921, 1922, "+" +335, 14, 17, 482, 78, 79, 1923, 1924, "/" +335, 14, 18, 483, 80, 81, 1925, 1926, "-" +335, 14, 19, 484, 82, 83, 1927, 1928, "3" +335, 14, 20, 485, 84, 85, 1929, 1930, "." +335, 14, 21, 486, 86, 88, 1931, 1933, "96" +335, 14, 22, 487, 89, 91, 1934, 1936, "kg" +335, 14, 23, 488, 92, 98, 1937, 1943, "versus" +335, 14, 24, 489, 99, 100, 1944, 1945, "2" +335, 14, 25, 490, 101, 102, 1946, 1947, "." +335, 14, 26, 491, 103, 104, 1948, 1949, "7" +335, 14, 27, 492, 105, 106, 1950, 1951, "+" +335, 14, 28, 493, 107, 108, 1952, 1953, "/" +335, 14, 29, 494, 109, 110, 1954, 1955, "-" +335, 14, 30, 495, 111, 112, 1956, 1957, "3" +335, 14, 31, 496, 113, 114, 1958, 1959, "." +335, 14, 32, 497, 115, 117, 1960, 1962, "94" +335, 14, 33, 498, 118, 120, 1963, 1965, "kg" +335, 14, 34, 499, 121, 122, 1966, 1967, "," +335, 14, 35, 500, 123, 124, 1968, 1969, "p" +335, 14, 36, 501, 125, 126, 1970, 1971, "=" +335, 14, 37, 502, 127, 128, 1972, 1973, "0" +335, 14, 38, 503, 129, 130, 1974, 1975, "." +335, 14, 39, 504, 131, 134, 1976, 1979, "001" +335, 14, 40, 505, 135, 136, 1980, 1981, ")" +335, 14, 41, 506, 137, 138, 1982, 1983, "." +335, 15, 1, 507, 0, 12, 1984, 1996, "Hypoglycemia" +335, 15, 2, 508, 13, 17, 1997, 2001, "risk" +335, 15, 3, 509, 18, 21, 2002, 2005, "was" +335, 15, 4, 510, 22, 32, 2006, 2016, "comparable" +335, 15, 5, 511, 33, 40, 2017, 2024, "between" +335, 15, 6, 512, 41, 47, 2025, 2031, "groups" +335, 15, 7, 513, 48, 49, 2032, 2033, "." +335, 16, 1, 514, 0, 3, 2034, 2037, "The" +335, 16, 2, 515, 4, 12, 2038, 2046, "majority" +335, 16, 3, 516, 13, 15, 2047, 2049, "of" +335, 16, 4, 517, 16, 20, 2050, 2054, "IDet" +335, 16, 5, 518, 21, 22, 2055, 2056, "-" +335, 16, 6, 519, 23, 30, 2057, 2064, "treated" +335, 16, 7, 520, 31, 39, 2065, 2073, "patients" +335, 16, 8, 521, 40, 41, 2074, 2075, "(" +335, 16, 9, 522, 42, 44, 2076, 2078, "87" +335, 16, 10, 523, 45, 46, 2079, 2080, "." +335, 16, 11, 524, 47, 48, 2081, 2082, "4" +335, 16, 12, 525, 49, 50, 2083, 2084, "%" +335, 16, 13, 526, 51, 52, 2085, 2086, ")" +335, 16, 14, 527, 53, 61, 2087, 2095, "remained" +335, 16, 15, 528, 62, 64, 2096, 2098, "on" +335, 16, 16, 529, 65, 66, 2099, 2100, "a" +335, 16, 17, 530, 67, 71, 2101, 2105, "once" +335, 16, 18, 531, 72, 73, 2106, 2107, "-" +335, 16, 19, 532, 74, 79, 2108, 2113, "daily" +335, 16, 20, 533, 80, 85, 2114, 2119, "basal" +335, 16, 21, 534, 86, 93, 2120, 2127, "insulin" +335, 16, 22, 535, 94, 101, 2128, 2135, "regimen" +335, 16, 23, 536, 102, 112, 2136, 2146, "throughout" +335, 16, 24, 537, 113, 116, 2147, 2150, "the" +335, 16, 25, 538, 117, 122, 2151, 2156, "study" +335, 16, 26, 539, 123, 124, 2157, 2158, "." +335, 17, 1, 540, 0, 11, 2159, 2170, "CONCLUSIONS" +335, 17, 2, 541, 12, 13, 2171, 2172, ":" +335, 17, 3, 542, 14, 18, 2173, 2177, "IDet" +335, 17, 4, 543, 19, 22, 2178, 2181, "and" +335, 17, 5, 544, 23, 27, 2182, 2186, "IGla" +335, 17, 6, 545, 28, 32, 2187, 2191, "were" +335, 17, 7, 546, 33, 37, 2192, 2196, "both" +335, 17, 8, 547, 38, 47, 2197, 2206, "effective" +335, 17, 9, 548, 48, 51, 2207, 2210, "and" +335, 17, 10, 549, 52, 56, 2211, 2215, "safe" +335, 17, 11, 550, 57, 67, 2216, 2226, "treatments" +335, 17, 12, 551, 68, 71, 2227, 2230, "for" +335, 17, 13, 552, 72, 80, 2231, 2239, "glycemic" +335, 17, 14, 553, 81, 88, 2240, 2247, "control" +335, 17, 15, 554, 89, 91, 2248, 2250, "in" +335, 17, 16, 555, 92, 93, 2251, 2252, "a" +335, 17, 17, 556, 94, 99, 2253, 2258, "basal" +335, 17, 18, 557, 100, 101, 2259, 2260, "-" +335, 17, 19, 558, 102, 107, 2261, 2266, "bolus" +335, 17, 20, 559, 108, 115, 2267, 2274, "regimen" +335, 17, 21, 560, 116, 119, 2275, 2278, "for" +335, 17, 22, 561, 120, 124, 2279, 2283, "type" +335, 17, 23, 562, 125, 126, 2284, 2285, "2" +335, 17, 24, 563, 127, 135, 2286, 2294, "diabetes" +335, 17, 25, 564, 136, 137, 2295, 2296, "." +335, 18, 1, 565, 0, 10, 2297, 2307, "Clinically" +335, 18, 2, 566, 11, 22, 2308, 2319, "significant" +335, 18, 3, 567, 23, 33, 2320, 2330, "reductions" +335, 18, 4, 568, 34, 36, 2331, 2333, "in" +335, 18, 5, 569, 37, 40, 2334, 2337, "HbA" +335, 18, 6, 570, 41, 42, 2338, 2339, "(" +335, 18, 7, 571, 43, 45, 2340, 2342, "1c" +335, 18, 8, 572, 46, 47, 2343, 2344, ")" +335, 18, 9, 573, 48, 52, 2345, 2349, "were" +335, 18, 10, 574, 53, 61, 2350, 2358, "achieved" +335, 18, 11, 575, 62, 64, 2359, 2361, "in" +335, 18, 12, 576, 65, 69, 2362, 2366, "both" +335, 18, 13, 577, 70, 76, 2367, 2373, "groups" +335, 18, 14, 578, 77, 78, 2374, 2375, "," +335, 18, 15, 579, 79, 82, 2376, 2379, "but" +335, 18, 16, 580, 83, 87, 2380, 2384, "with" +335, 18, 17, 581, 88, 101, 2385, 2398, "significantly" +335, 18, 18, 582, 102, 106, 2399, 2403, "less" +335, 18, 19, 583, 107, 113, 2404, 2410, "weight" +335, 18, 20, 584, 114, 118, 2411, 2415, "gain" +335, 18, 21, 585, 119, 121, 2416, 2418, "in" +335, 18, 22, 586, 122, 125, 2419, 2422, "the" +335, 18, 23, 587, 126, 130, 2423, 2427, "IDet" +335, 18, 24, 588, 131, 136, 2428, 2433, "group" +335, 18, 25, 589, 137, 139, 2434, 2436, "at" +335, 18, 26, 590, 140, 150, 2437, 2447, "comparable" +335, 18, 27, 591, 151, 156, 2448, 2453, "basal" +335, 18, 28, 592, 157, 164, 2454, 2461, "insulin" +335, 18, 29, 593, 165, 171, 2462, 2468, "dosage" +335, 18, 30, 594, 172, 173, 2469, 2470, "." +335, 19, 1, 595, 0, 3, 2471, 2474, "DOI" +335, 19, 2, 596, 4, 5, 2475, 2476, ":" +335, 19, 3, 597, 6, 8, 2477, 2479, "10" +335, 19, 4, 598, 9, 10, 2480, 2481, "." +335, 19, 5, 599, 11, 15, 2482, 2486, "1002" +335, 19, 6, 600, 16, 17, 2487, 2488, "/" +335, 19, 7, 601, 18, 22, 2489, 2493, "dmrr" +335, 19, 8, 602, 23, 24, 2494, 2495, "." +335, 19, 9, 603, 25, 28, 2496, 2499, "989" +335, 19, 10, 604, 29, 33, 2500, 2504, "PMID" +335, 19, 11, 605, 34, 35, 2505, 2506, ":" +335, 19, 12, 606, 36, 44, 2507, 2515, "19565569" +335, 19, 13, 607, 45, 46, 2516, 2517, "[" +335, 19, 14, 608, 47, 54, 2518, 2525, "Indexed" +335, 19, 15, 609, 55, 58, 2526, 2529, "for" +335, 19, 16, 610, 59, 66, 2530, 2537, "MEDLINE" +335, 19, 17, 611, 67, 68, 2538, 2539, "]" diff --git a/data/dm2 19565569_kwoodley.annodb b/data/dm2 19565569_kwoodley.annodb new file mode 100644 index 0000000..91d5c95 --- /dev/null +++ b/data/dm2 19565569_kwoodley.annodb @@ -0,0 +1,125 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +14793, Journal, 0, 22, "Diabetes Metab Res Rev", "", +14794, PublicationYear, 25, 29, "2009", "", +36689, Title, 88, 247, "Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes .", "", +14795, InsulinDetemir, 102, 117, "insulin detemir", "", +14796, InsulinGlargine, 122, 138, "insulin glargine", "", +14797, Randomized, 174, 184, "randomized", "", +14798, CTDesign, 187, 197, "controlled", "", +14799, Type2Diabetes, 230, 245, "type 2 diabetes", "", +14801, Author, 248, 256, "Raskin P", "", +14802, Author, 265, 273, "Gylvin T", "", +14803, Author, 276, 282, "Weng W", "", +14804, Author, 285, 294, "Chaykin L", "", +14805, USA, 414, 417, "USA", "", +36690, ObjectiveDescription, 472, 660, "This treat - to - target study compared the efficacy and safety of insulin detemir ( IDet ) and insulin glargine ( IGla ) in a basal - bolus ( insulin aspart ) regimen in type 2 diabetes .", "", +14806, CTDesign, 477, 496, "treat - to - target", "", +14807, InsulinDetemir, 539, 554, "insulin detemir", "", +14808, InsulinDetemir, 557, 561, "IDet", "", +14809, InsulinGlargine, 568, 584, "insulin glargine", "", +14810, InsulinGlargine, 587, 591, "IGla", "", +14812, InsulinAspart, 615, 629, "insulin aspart", "", +14811, Type2Diabetes, 643, 658, "type 2 diabetes", "", +14813, NumberPatientsCT, 671, 674, "385", "", +14815, Randomized, 689, 699, "randomized", "", +14816, AllocationRatio, 700, 705, "2 : 1", "", +14817, InsulinDetemir, 708, 712, "IDet", "", +14818, InsulinGlargine, 715, 719, "IGla", "", +14819, InsulinDetemir, 745, 749, "IDet", "", +14820, InsulinGlargine, 753, 757, "IGla", "", +14821, HbA1c, 776, 786, "HbA ( 1c )", "", +14822, ConfIntervalBL, 787, 814, "95 % CI upper limit < 0 . 4", "", +14823, InsulinDetemir, 827, 831, "IDet", "", +14824, InsulinGlargine, 836, 840, "IGla", "", +14825, HbA1c, 868, 878, "HbA ( 1c )", "", +14826, Duration, 892, 900, "26 weeks", "", +36691, TimePoint, 949, 957, "26 weeks", "", +14828, Mean, 960, 967, "LS mean", "", +14829, InsulinDetemir, 970, 973, "Det", "", +14830, InsulinGlargine, 976, 979, "Gla", "", +14831, Reduction, 984, 991, "0 . 207", "", +14833, ConfIntervalChangeValue, 994, 1012, "95 % CI : 0 . 0149", "", +14832, Reduction, 1015, 1023, "0 . 3995", "", +14834, InsulinGlargine, 1045, 1049, "IGla", "", +14835, InsulinDetemir, 1080, 1084, "IDet", "", +14836, HbA1c, 1097, 1107, "HbA ( 1c )", "", +14837, DiffGroupAbsValue, 1131, 1138, "0 . 207", "", +14838, Percentage, 1139, 1140, "%", "", +14839, MeasurementDevice, 1245, 1258, "LOCF approach", "", +14840, EndPointDescription, 1310, 1321, "delta 0 . 4", "", +14841, Mean, 1324, 1331, "LS mean", "", +14842, InsulinDetemir, 1337, 1340, "Det", "", +14843, InsulinGlargine, 1343, 1346, "Gla", "", +14845, ResultMeasuredValue, 1351, 1358, "0 . 307", "", +14844, ConfIntervalChangeValue, 1361, 1379, "95 % CI : 0 . 1023", "", +14846, ResultMeasuredValue, 1382, 1390, "0 . 5109", "", +14847, HbA1c, 1395, 1405, "HbA ( 1c )", "", +36697, TimePoint, 1435, 1443, "baseline", "", +14848, InsulinDetemir, 1447, 1451, "IDet", "", +14849, Reduction, 1456, 1461, "1 . 1", "", +14851, Percentage, 1462, 1463, "%", "", +36696, TimePoint, 1466, 1474, "26 weeks", "", +14859, Reduction, 1481, 1486, "0 . 9", "", +14860, Percentage, 1487, 1488, "%", "", +14855, MeasurementDevice, 1491, 1495, "LOCF", "", +14857, PValueChangeValue, 1500, 1511, "p < 0 . 001", "", +14861, InsulinGlargine, 1521, 1525, "IGla", "", +14850, Reduction, 1530, 1535, "1 . 3", "", +14852, Percentage, 1536, 1537, "%", "", +36695, TimePoint, 1540, 1548, "26 weeks", "", +14856, MeasurementDevice, 1551, 1555, "LOCF", "", +14858, PValueChangeValue, 1560, 1571, "p < 0 . 001", "", +14862, HbA1c, 1582, 1592, "HbA ( 1c )", "", +14863, ResultMeasuredValue, 1598, 1603, "7 . 1", "", +14867, Percentage, 1604, 1605, "%", "", +36698, TimePoint, 1608, 1616, "26 weeks", "", +14864, ResultMeasuredValue, 1623, 1628, "7 . 3", "", +14868, Percentage, 1629, 1630, "%", "", +14873, MeasurementDevice, 1633, 1637, "LOCF", "", +14875, InsulinDetemir, 1643, 1647, "IDet", "", +14865, ResultMeasuredValue, 1654, 1659, "6 . 9", "", +14869, Percentage, 1660, 1661, "%", "", +36692, TimePoint, 1664, 1672, "26 weeks", "", +14866, ResultMeasuredValue, 1679, 1684, "7 . 0", "", +14870, Percentage, 1685, 1686, "%", "", +14874, MeasurementDevice, 1689, 1693, "LOCF", "", +14876, InsulinGlargine, 1699, 1703, "IGla", "", +14877, FastingPlasmaGlucose, 1712, 1715, "FPG", "", +14878, ResultMeasuredValue, 1721, 1724, "130", "", +14882, Mg_per_deciliter, 1725, 1732, "mg / dL", "", +36693, TimePoint, 1735, 1743, "26 weeks", "", +14879, ResultMeasuredValue, 1750, 1753, "135", "", +14883, Mg_per_deciliter, 1754, 1761, "mg / dL", "", +14888, MeasurementDevice, 1764, 1768, "LOCF", "", +14890, InsulinDetemir, 1774, 1778, "IDet", "", +14880, ResultMeasuredValue, 1785, 1788, "134", "", +14884, Mg_per_deciliter, 1789, 1796, "mg / dL", "", +36694, TimePoint, 1799, 1807, "26 weeks", "", +14881, ResultMeasuredValue, 1814, 1817, "137", "", +14885, Mg_per_deciliter, 1818, 1825, "mg / dL", "", +14889, MeasurementDevice, 1828, 1832, "LOCF", "", +14891, InsulinGlargine, 1838, 1842, "IGla", "", +14892, BodyWeight, 1874, 1880, "weight", "", +14893, InsulinDetemir, 1889, 1893, "IDet", "", +14894, Increment, 1915, 1920, "1 . 2", "", +14896, SdDevChangeValue, 1927, 1933, "3 . 96", "", +14898, Kg, 1934, 1936, "kg", "", +14895, Increment, 1944, 1949, "2 . 7", "", +14897, SdDevChangeValue, 1956, 1962, "3 . 94", "", +14899, Kg, 1963, 1965, "kg", "", +14900, PvalueDiff, 1968, 1979, "p = 0 . 001", "", +14901, Hypoglycemia, 1984, 1996, "Hypoglycemia", "", +14902, ObservedResult, 1997, 2031, "risk was comparable between groups", "", +14903, InsulinDetemir, 2050, 2054, "IDet", "", +14904, PercentageAffected, 2076, 2082, "87 . 4", "", +14905, EndPointDescription, 2101, 2135, "once - daily basal insulin regimen", "", +14906, InsulinDetemir, 2173, 2177, "IDet", "", +36699, ConclusionComment, 2173, 2296, "IDet and IGla were both effective and safe treatments for glycemic control in a basal - bolus regimen for type 2 diabetes .", "", +14907, InsulinGlargine, 2182, 2186, "IGla", "", +14908, Type2Diabetes, 2279, 2294, "type 2 diabetes", "", +36700, ConclusionComment, 2297, 2470, "Clinically significant reductions in HbA ( 1c ) were achieved in both groups , but with significantly less weight gain in the IDet group at comparable basal insulin dosage .", "", +14909, HbA1c, 2334, 2344, "HbA ( 1c )", "", +14910, BodyWeight, 2404, 2410, "weight", "", +14911, InsulinDetemir, 2423, 2427, "IDet", "", +36701, Insulin, 2454, 2461, "insulin", "", +14915, PMID, 2507, 2515, "19565569", "", diff --git a/data/dm2 19565569_kwoodley.n-triples b/data/dm2 19565569_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19565569_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19821654_admin.annodb b/data/dm2 19821654_admin.annodb new file mode 100644 index 0000000..c9f4b4d --- /dev/null +++ b/data/dm2 19821654_admin.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2009", "", " \"2009\"." +118, Title, 93, 285, "Once - daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open - label , multinational RCT .", "", " \"Once - daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open - label , multinational RCT .\"." +2, Frequency, 93, 105, "Once - daily", "", +55210, Aspart70/30, 122, 148, "biphasic insulin aspart 30", "", +4, InsulinGlargine, 156, 172, "insulin glargine", "", +7, Precondition, 176, 245, "patients with type 2 diabetes inadequately controlled with oral drugs", "", +5, Type2Diabetes, 190, 205, "type 2 diabetes", "", +98, Precondition, 206, 245, "inadequately controlled with oral drugs", "", +8, OpenLabel, 251, 263, "open - label", "", +100, Multicenter, 266, 279, "multinational", "", +9, Randomized, 280, 283, "RCT", "", +10, Author, 286, 295, "Strojek K", "", " \"Strojek K\"." +11, Author, 304, 314, "Bebakar WM", "", " \"Bebakar WM\"." +12, Author, 317, 329, "Khutsoane DT", "", " \"Khutsoane DT\"." +13, Author, 332, 339, "Pesic M", "", " \"Pesic M\"." +14, Author, 342, 354, "Smahelov á A", "", " \"Smahelov á A\"." +15, Author, 357, 367, "Thomsen HF", "", " \"Thomsen HF\"." +16, Author, 370, 377, "Kalra S", "", " \"Kalra S\"." +17, Poland, 507, 513, "Poland", "", " ." +119, ObjectiveDescription, 555, 774, "To assess the efficacy and safety of biphasic insulin aspart 70 / 30 ( BIAsp 30 ) and insulin glargine , administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs .", "", " \"To assess the efficacy and safety of biphasic insulin aspart 70 / 30 ( BIAsp 30 ) and insulin glargine , administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs .\"." +55217, Aspart70/30, 592, 623, "biphasic insulin aspart 70 / 30", "", +55218, Aspart70/30, 626, 634, "BIAsp 30", "", +20, InsulinGlargine, 641, 657, "insulin glargine", "", +21, Frequency, 673, 683, "once daily", "", " \"once daily\". \"once daily\"." +24, Precondition, 687, 772, "subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs", "", " \"subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs\"." +22, Type2Diabetes, 701, 716, "type 2 diabetes", "", " ." +115, Precondition, 717, 772, "inadequately controlled with oral anti - diabetic drugs", "", +23, OralAntidiabeticAgent, 746, 772, "oral anti - diabetic drugs", "", +25, Duration, 813, 822, "26 - week", "", " \"26 - week\"." +26, OpenLabel, 825, 839, "open - labeled", "", " ." +27, Randomized, 842, 852, "randomized", "", " ." +28, Parallel, 855, 871, "parallel - group", "", " ." +124, Multicenter, 874, 887, "multinational", "", " ." +29, CTDesign, 890, 909, "treat - to - target", "", " . ." +30, NumberPatientsCT, 918, 921, "480", "", " \"480\"." +31, Precondition, 922, 948, "insulin - na ï ve subjects", "", " \"insulin - na ï ve subjects\"." +32, Randomized, 954, 964, "randomized", "", +55219, Aspart70/30, 983, 991, "BIAsp 30", "", " ." +34, RelativeTime, 992, 1005, "before dinner", "", " . ." +35, InsulinGlargine, 1009, 1025, "insulin glargine", "", " ." +55229, Bedtime, 1029, 1036, "bedtime", "", " ." +36, Metformin, 1064, 1073, "metformin", "", " ." +37, Glimepiride, 1078, 1089, "glimepiride", "", " ." +38, FinalNumPatientsCT, 1171, 1174, "433", "", " \"433\"." +135, Mean, 1216, 1220, "mean", "", " . ." +39, HbA1c, 1234, 1244, "HbA ( 1c )", "", " ." +206, TimePoint, 1250, 1258, "baseline", "", +207, TimePoint, 1262, 1278, "end of treatment", "", " \"end of treatment\". \"end of treatment\"." +40, Reduction, 1285, 1291, "1 . 41", "", " \"1 . 41\"." +43, Percentage, 1292, 1293, "%", "", " ." +55220, Aspart70/30, 1299, 1307, "BIAsp 30", "", +41, Reduction, 1314, 1320, "1 . 25", "", " \"1 . 25\"." +44, Percentage, 1321, 1322, "%", "", +45, InsulinGlargine, 1328, 1344, "insulin glargine", "", +55221, Aspart70/30, 1347, 1355, "BIAsp 30", "", +46, InsulinGlargine, 1358, 1374, "insulin glargine", "", +48, DiffGroupAbsValue, 1377, 1385, "- 0 . 16", "", " \"- 0 . 16\"." +49, Percentage, 1386, 1387, "%", "", +50, ConfIntervalDiff, 1390, 1421, "95 % CI [ - 0 . 30 ; - 0 . 02 ]", "", " \"95 % CI [ - 0 . 30 ; - 0 . 02 ]\"." +51, PvalueDiff, 1424, 1435, "p = 0 . 029", "", " \"p = 0 . 029\"." +208, TimePoint, 1447, 1463, "end of treatment", "", +149, Mean, 1466, 1470, "mean", "", +52, HbA1c, 1471, 1481, "HbA ( 1c )", "", +53, ResultMeasuredValue, 1486, 1491, "7 . 1", "", " \"7 . 1\"." +55, Percentage, 1492, 1493, "%", "", +54, ResultMeasuredValue, 1498, 1503, "7 . 3", "", " \"7 . 3\"." +56, Percentage, 1504, 1505, "%", "", +55222, Aspart70/30, 1510, 1518, "BIAsp 30", "", +58, InsulinGlargine, 1523, 1539, "insulin glargine", "", +209, PlasmaGlucose, 1577, 1591, "plasma glucose", "", " . ." +55223, Aspart70/30, 1618, 1626, "BIAsp 30", "", +106175, TimePoint, 1627, 1640, "post - dinner", "", " \"post - dinner\". \"post - dinner\"." +61, InsulinAspart, 1643, 1651, "BIAsp 30", "", +62, InsulinGlargine, 1654, 1670, "insulin glargine", "", +63, DiffGroupAbsValue, 1673, 1681, "- 0 . 52", "", " \"- 0 . 52\"." +64, Millimoles_per_litre, 1682, 1690, "mmol / L", "", " ." +65, ConfIntervalDiff, 1693, 1724, "95 % CI [ - 1 . 02 ; - 0 . 03 ]", "", " \"95 % CI [ - 1 . 02 ; - 0 . 03 ]\"." +66, PvalueDiff, 1727, 1737, "p = 0 . 04", "", " \"p = 0 . 04\"." +106176, TimePoint, 1747, 1754, "bedtime", "", " \"bedtime\". \"bedtime\"." +55227, Aspart70/30, 1757, 1765, "BIAsp 30", "", +69, InsulinGlargine, 1768, 1784, "insulin glargine", "", +70, DiffGroupAbsValue, 1787, 1795, "- 0 . 78", "", " \"- 0 . 78\"." +71, Millimoles_per_litre, 1796, 1804, "mmol / L", "", +72, ConfIntervalDiff, 1807, 1838, "95 % CI [ - 1 . 25 ; - 0 . 31 ]", "", " \"95 % CI [ - 1 . 25 ; - 0 . 31 ]\"." +73, PvalueDiff, 1841, 1851, "p < 0 . 01", "", " \"p < 0 . 01\"." +74, NocturnalHypoglycemia, 1899, 1921, "nocturnal hypoglycemic", "", " ." +55228, Aspart70/30, 1990, 1998, "BIAsp 30", "", +76, InsulinGlargine, 2009, 2025, "insulin glargine", "", +77, ResultMeasuredValue, 2028, 2033, "1 . 1", "", " \"1 . 1\"." +78, ResultMeasuredValue, 2041, 2046, "0 . 5", "", " \"0 . 5\"." +79, BioAndMedicalUnit, 2047, 2062, "episodes / year", "", " . ." +80, ConfIntervalDiff, 2079, 2106, "95 % CI [ 1 . 34 ; 4 . 34 ]", "", " \"95 % CI [ 1 . 34 ; 4 . 34 ]\"." +81, PvalueDiff, 2109, 2120, "p = 0 . 003", "", " \"p = 0 . 003\"." +83, ObservedResult, 2129, 2164, "overall hypoglycemia rates were low", "", " \"overall hypoglycemia rates were low\"." +185, Hypoglycemia, 2129, 2149, "overall hypoglycemia", "", " ." +187, NumberAffected, 2178, 2183, "three", "", " \"three\"." +55224, SevereHypoglycemia, 2184, 2202, "major hypoglycemic", "", " ." +197, ConclusionComment, 2242, 2486, "With respect to HbA ( 1c ) , BIAsp 30 fulfilled the statistical criteria for non - inferiority and superiority to insulin glargine and , according to pre - defined criteria , the improvements in HbA ( 1c ) are considered clinically equivalent .", "", " \"With respect to HbA ( 1c ) , BIAsp 30 fulfilled the statistical criteria for non - inferiority and superiority to insulin glargine and , according to pre - defined criteria , the improvements in HbA ( 1c ) are considered clinically equivalent .\"." +85, HbA1c, 2258, 2268, "HbA ( 1c )", "", +55226, Aspart70/30, 2271, 2279, "BIAsp 30", "", +87, InsulinGlargine, 2356, 2372, "insulin glargine", "", +88, HbA1c, 2437, 2447, "HbA ( 1c )", "", +196, ConclusionComment, 2487, 2565, "Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30 .", "", " \"Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30 .\"." +89, NocturnalHypoglycemia, 2527, 2549, "nocturnal hypoglycemia", "", +55225, Aspart70/30, 2555, 2563, "BIAsp 30", "", +195, ConclusionComment, 2566, 2642, "There were no differences in treatment satisfaction between the two groups .", "", " \"There were no differences in treatment satisfaction between the two groups .\"." +91, PMID, 2686, 2694, "19821654", "", " \"19821654\"." diff --git a/data/dm2 19821654_admin.n-triples b/data/dm2 19821654_admin.n-triples new file mode 100644 index 0000000..b48baa8 --- /dev/null +++ b/data/dm2 19821654_admin.n-triples @@ -0,0 +1,212 @@ +# RDF export of group: Publication + . + "Publication " . + "Once - daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open - label , multinational RCT ." . + "Strojek K" . + "2009" . + "Curr Med Res Opin ." . + "19821654" . + . + "Bebakar WM" . + "Khutsoane DT" . + "Pesic M" . + "Smahelov á A" . + "Thomsen HF" . + "Kalra S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To assess the efficacy and safety of biphasic insulin aspart 70 / 30 ( BIAsp 30 ) and insulin glargine , administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs ." . + "480" . + "26 - week" . + . + . + . + "With respect to HbA ( 1c ) , BIAsp 30 fulfilled the statistical criteria for non - inferiority and superiority to insulin glargine and , according to pre - defined criteria , the improvements in HbA ( 1c ) are considered clinically equivalent ." . + . + . + . + . + . + "433" . + . + . + . + . + . + "Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30 ." . + "There were no differences in treatment satisfaction between the two groups ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs" . + . + . + . + "insulin - na ï ve subjects" . +# RDF export of group: Endpoint + . + "Endpoint Hba1c" . + . + . + . + . + . + . + "Endpoint plasma glucose" . + . + . + . + . + . + . + "Endpoint nh" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . +# RDF export of group: Arm + . + "Arm aspart+m+g" . + . + . + . + . + . + . + . + "Arm ig+m+g" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention aspart" . + . + "once daily" . + . + . + . + . + . + "Intervention ig" . + . + "once daily" . + . + . + . +# RDF export of group: Medication + . + "Medication aspart" . + . + . + . + . + "Medication ig" . + . + . + . + . + "Medication m" . + . + . + . + . + "Medication g" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c aspart" . + . + "7 . 1" . + "1 . 41" . + "end of treatment" . + . + "Outcome hba1c ig" . + . + "7 . 3" . + "1 . 25" . + "end of treatment" . + . + "Outcome pg postdinner aspart" . + . + "post - dinner" . + . + "Outcome pg postdinner ig" . + . + "post - dinner" . + . + "Outcome nh aspart" . + . + "1 . 1" . + . + "Outcome nh ig" . + . + "0 . 5" . + . + "Outcome h both drugs" . + . + "overall hypoglycemia rates were low" . + . + "Outcome sh both drugs" . + . + "three" . + . + "Outcome pg bedtime aspart" . + . + "bedtime" . + . + "Outcome pg bedtime ig" . + . + "bedtime" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 16" . + "p = 0 . 029" . + "95 % CI [ - 0 . 30 ; - 0 . 02 ]" . + . + . + . + "DiffBetweenGroups pg post-dinner" . + "- 0 . 52" . + "p = 0 . 04" . + "95 % CI [ - 1 . 02 ; - 0 . 03 ]" . + . + . + . + "DiffBetweenGroups pg bedtime" . + "- 0 . 78" . + "p < 0 . 01" . + "95 % CI [ - 1 . 25 ; - 0 . 31 ]" . + . + . + . + "DiffBetweenGroups nh" . + "p = 0 . 003" . + "95 % CI [ 1 . 34 ; 4 . 34 ]" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19821654_akramersunderbrink.annodb b/data/dm2 19821654_akramersunderbrink.annodb new file mode 100644 index 0000000..547767f --- /dev/null +++ b/data/dm2 19821654_akramersunderbrink.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +28729, Journal, 0, 17, "Curr Med Res Opin", "", +28730, PublicationYear, 20, 24, "2009", "", +28731, Frequency, 93, 105, "Once - daily", "", +28755, Title, 93, 285, "Once - daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open - label , multinational RCT .", "", +28732, InsulinAspart, 122, 148, "biphasic insulin aspart 30", "", +28733, InsulinGlargine, 156, 172, "insulin glargine", "", +28734, Type2Diabetes, 190, 205, "type 2 diabetes", "", +28735, Precondition, 206, 245, "inadequately controlled with oral drugs", "", +28754, OralAntidiabeticAgent, 235, 245, "oral drugs", "", +28736, OpenLabel, 251, 263, "open - label", "", +28737, Multicenter, 266, 279, "multinational", "", +28738, Randomized, 280, 283, "RCT", "", +28739, Author, 286, 295, "Strojek K", "", +28740, Author, 304, 314, "Bebakar WM", "", +28741, Author, 317, 329, "Khutsoane DT", "", +28742, Author, 332, 339, "Pesic M", "", +28743, Author, 342, 354, "Smahelov á A", "", +28744, Author, 357, 367, "Thomsen HF", "", +28745, Author, 370, 377, "Kalra S", "", +28746, Poland, 507, 513, "Poland", "", +28756, ObjectiveDescription, 555, 774, "To assess the efficacy and safety of biphasic insulin aspart 70 / 30 ( BIAsp 30 ) and insulin glargine , administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs .", "", +28747, InsulinAspart, 592, 623, "biphasic insulin aspart 70 / 30", "", +28748, InsulinAspart, 626, 634, "BIAsp 30", "", +28749, InsulinGlargine, 641, 657, "insulin glargine", "", +28750, Frequency, 673, 683, "once daily", "", +28751, Type2Diabetes, 701, 716, "type 2 diabetes", "", +28752, Precondition, 717, 772, "inadequately controlled with oral anti - diabetic drugs", "", +28753, OralAntidiabeticAgent, 746, 772, "oral anti - diabetic drugs", "", +28757, Duration, 813, 822, "26 - week", "", +28758, OpenLabel, 825, 839, "open - labeled", "", +28759, Randomized, 842, 852, "randomized", "", +28760, Parallel, 855, 871, "parallel - group", "", +28761, Multicenter, 874, 887, "multinational", "", +28762, NumberPatientsCT, 918, 921, "480", "", +28763, Precondition, 922, 939, "insulin - na ï ve", "", +28764, Randomized, 954, 964, "randomized", "", +28765, InsulinAspart, 983, 991, "BIAsp 30", "", +28766, RelativeTime, 992, 1005, "before dinner", "", +28768, InsulinGlargine, 1009, 1025, "insulin glargine", "", +28767, RelativeTime, 1029, 1036, "bedtime", "", +28769, Metformin, 1064, 1073, "metformin", "", +28770, Glimepiride, 1078, 1089, "glimepiride", "", +28771, FinalNumPatientsCT, 1171, 1174, "433", "", +28772, Mean, 1216, 1220, "mean", "", +28773, HbA1c, 1234, 1244, "HbA ( 1c )", "", +39182, TimePoint, 1250, 1258, "baseline", "", +39183, TimePoint, 1262, 1278, "end of treatment", "", +28774, ChangeValue, 1283, 1291, "- 1 . 41", "", +28775, Percentage, 1292, 1293, "%", "", +28778, InsulinAspart, 1299, 1307, "BIAsp 30", "", +28779, ChangeValue, 1312, 1320, "- 1 . 25", "", +28776, Percentage, 1321, 1322, "%", "", +28780, InsulinGlargine, 1328, 1344, "insulin glargine", "", +28781, InsulinAspart, 1347, 1355, "BIAsp 30", "", +28782, InsulinGlargine, 1358, 1374, "insulin glargine", "", +28839, DiffGroupAbsValue, 1377, 1385, "- 0 . 16", "", +28777, Percentage, 1386, 1387, "%", "", +28784, ConfIntervalDiff, 1390, 1421, "95 % CI [ - 0 . 30 ; - 0 . 02 ]", "", +28785, Percentage, 1393, 1394, "%", "", +28786, PvalueDiff, 1424, 1435, "p = 0 . 029", "", +39184, TimePoint, 1447, 1463, "end of treatment", "", +28787, Mean, 1466, 1470, "mean", "", +28788, HbA1c, 1471, 1481, "HbA ( 1c )", "", +28791, ResultMeasuredValue, 1486, 1491, "7 . 1", "", +28789, Percentage, 1492, 1493, "%", "", +28792, ResultMeasuredValue, 1498, 1503, "7 . 3", "", +28790, Percentage, 1504, 1505, "%", "", +28793, InsulinAspart, 1510, 1518, "BIAsp 30", "", +28794, InsulinGlargine, 1523, 1539, "insulin glargine", "", +28795, EndPointDescription, 1577, 1598, "plasma glucose levels", "", +28799, InsulinAspart, 1618, 1626, "BIAsp 30", "", +28797, EndPointDescription, 1627, 1640, "post - dinner", "", +28798, RelativeTime, 1627, 1640, "post - dinner", "", +28800, InsulinAspart, 1643, 1651, "BIAsp 30", "", +28802, InsulinGlargine, 1654, 1670, "insulin glargine", "", +28841, DiffGroupAbsValue, 1673, 1681, "- 0 . 52", "", +28806, Millimoles_per_litre, 1682, 1690, "mmol / L", "", +28808, ConfIntervalDiff, 1693, 1724, "95 % CI [ - 1 . 02 ; - 0 . 03 ]", "", +28810, Percentage, 1696, 1697, "%", "", +28812, PvalueDiff, 1727, 1737, "p = 0 . 04", "", +28814, EndPointDescription, 1747, 1754, "bedtime", "", +28815, RelativeTime, 1747, 1754, "bedtime", "", +28801, InsulinAspart, 1757, 1765, "BIAsp 30", "", +28803, InsulinGlargine, 1768, 1784, "insulin glargine", "", +28840, DiffGroupAbsValue, 1787, 1795, "- 0 . 78", "", +28807, Millimoles_per_litre, 1796, 1804, "mmol / L", "", +28809, ConfIntervalDiff, 1807, 1838, "95 % CI [ - 1 . 25 ; - 0 . 31 ]", "", +28811, Percentage, 1810, 1811, "%", "", +28813, PvalueDiff, 1841, 1851, "p < 0 . 01", "", +28816, NocturnalHypoglycemia, 1860, 1959, "relative risk ( RR ) of experiencing a nocturnal hypoglycemic episode ( 00 : 00 - 06 . 00 a . m . )", "", +28817, InsulinAspart, 1990, 1998, "BIAsp 30", "", +28818, InsulinGlargine, 2009, 2025, "insulin glargine", "", +28819, ResultMeasuredValue, 2028, 2033, "1 . 1", "", +28820, ResultMeasuredValue, 2041, 2046, "0 . 5", "", +28821, BioAndMedicalUnit, 2047, 2062, "episodes / year", "", +28822, DiffGroupRelValue, 2070, 2076, "2 . 41", "", +28823, ConfIntervalDiff, 2079, 2106, "95 % CI [ 1 . 34 ; 4 . 34 ]", "", +28824, Percentage, 2082, 2083, "%", "", +28825, PvalueDiff, 2109, 2120, "p = 0 . 003", "", +28826, Hypoglycemia, 2129, 2149, "overall hypoglycemia", "", +28828, NumberAffected, 2178, 2183, "three", "", +28827, SevereHypoglycemia, 2184, 2211, "major hypoglycemic episodes", "", +28838, ConclusionComment, 2242, 2486, "With respect to HbA ( 1c ) , BIAsp 30 fulfilled the statistical criteria for non - inferiority and superiority to insulin glargine and , according to pre - defined criteria , the improvements in HbA ( 1c ) are considered clinically equivalent .", "", +28829, HbA1c, 2258, 2268, "HbA ( 1c )", "", +28830, InsulinAspart, 2271, 2279, "BIAsp 30", "", +28831, InsulinGlargine, 2356, 2372, "insulin glargine", "", +28832, HbA1c, 2437, 2447, "HbA ( 1c )", "", +28837, ConclusionComment, 2487, 2565, "Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30 .", "", +28833, NocturnalHypoglycemia, 2527, 2549, "nocturnal hypoglycemia", "", +28834, InsulinAspart, 2555, 2563, "BIAsp 30", "", +28836, ConclusionComment, 2566, 2642, "There were no differences in treatment satisfaction between the two groups .", "", +28835, PMID, 2686, 2694, "19821654", "", diff --git a/data/dm2 19821654_akramersunderbrink.n-triples b/data/dm2 19821654_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19821654_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 19821654_export.csv b/data/dm2 19821654_export.csv new file mode 100644 index 0000000..27d5c73 --- /dev/null +++ b/data/dm2 19821654_export.csv @@ -0,0 +1,595 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +334, 1, 1, 1, 0, 4, 0, 4, "Curr" +334, 1, 2, 2, 5, 8, 5, 8, "Med" +334, 1, 3, 3, 9, 12, 9, 12, "Res" +334, 1, 4, 4, 13, 17, 13, 17, "Opin" +334, 1, 5, 5, 18, 19, 18, 19, "." +334, 2, 1, 6, 0, 4, 20, 24, "2009" +334, 2, 2, 7, 5, 8, 25, 28, "Dec" +334, 2, 3, 8, 9, 10, 29, 30, ";" +334, 2, 4, 9, 11, 13, 31, 33, "25" +334, 2, 5, 10, 14, 15, 34, 35, "(" +334, 2, 6, 11, 16, 18, 36, 38, "12" +334, 2, 7, 12, 19, 20, 39, 40, ")" +334, 2, 8, 13, 21, 22, 41, 42, ":" +334, 2, 9, 14, 23, 27, 43, 47, "2887" +334, 2, 10, 15, 28, 29, 48, 49, "-" +334, 2, 11, 16, 30, 32, 50, 52, "94" +334, 2, 12, 17, 33, 34, 53, 54, "." +334, 2, 13, 18, 35, 38, 55, 58, "doi" +334, 2, 14, 19, 39, 40, 59, 60, ":" +334, 2, 15, 20, 41, 43, 61, 63, "10" +334, 2, 16, 21, 44, 45, 64, 65, "." +334, 2, 17, 22, 46, 50, 66, 70, "1185" +334, 2, 18, 23, 51, 52, 71, 72, "/" +334, 2, 19, 24, 53, 70, 73, 90, "03007990903354674" +334, 2, 20, 25, 71, 72, 91, 92, "." +334, 3, 1, 26, 0, 4, 93, 97, "Once" +334, 3, 2, 27, 5, 6, 98, 99, "-" +334, 3, 3, 28, 7, 12, 100, 105, "daily" +334, 3, 4, 29, 13, 23, 106, 116, "initiation" +334, 3, 5, 30, 24, 28, 117, 121, "with" +334, 3, 6, 31, 29, 37, 122, 130, "biphasic" +334, 3, 7, 32, 38, 45, 131, 138, "insulin" +334, 3, 8, 33, 46, 52, 139, 145, "aspart" +334, 3, 9, 34, 53, 55, 146, 148, "30" +334, 3, 10, 35, 56, 62, 149, 155, "versus" +334, 3, 11, 36, 63, 70, 156, 163, "insulin" +334, 3, 12, 37, 71, 79, 164, 172, "glargine" +334, 3, 13, 38, 80, 82, 173, 175, "in" +334, 3, 14, 39, 83, 91, 176, 184, "patients" +334, 3, 15, 40, 92, 96, 185, 189, "with" +334, 3, 16, 41, 97, 101, 190, 194, "type" +334, 3, 17, 42, 102, 103, 195, 196, "2" +334, 3, 18, 43, 104, 112, 197, 205, "diabetes" +334, 3, 19, 44, 113, 125, 206, 218, "inadequately" +334, 3, 20, 45, 126, 136, 219, 229, "controlled" +334, 3, 21, 46, 137, 141, 230, 234, "with" +334, 3, 22, 47, 142, 146, 235, 239, "oral" +334, 3, 23, 48, 147, 152, 240, 245, "drugs" +334, 3, 24, 49, 153, 154, 246, 247, ":" +334, 3, 25, 50, 155, 157, 248, 250, "an" +334, 3, 26, 51, 158, 162, 251, 255, "open" +334, 3, 27, 52, 163, 164, 256, 257, "-" +334, 3, 28, 53, 165, 170, 258, 263, "label" +334, 3, 29, 54, 171, 172, 264, 265, "," +334, 3, 30, 55, 173, 186, 266, 279, "multinational" +334, 3, 31, 56, 187, 190, 280, 283, "RCT" +334, 3, 32, 57, 191, 192, 284, 285, "." +334, 4, 1, 58, 0, 7, 286, 293, "Strojek" +334, 4, 2, 59, 8, 9, 294, 295, "K" +334, 4, 3, 60, 10, 11, 296, 297, "(" +334, 4, 4, 61, 12, 13, 298, 299, "1" +334, 4, 5, 62, 14, 15, 300, 301, ")" +334, 4, 6, 63, 16, 17, 302, 303, "," +334, 4, 7, 64, 18, 25, 304, 311, "Bebakar" +334, 4, 8, 65, 26, 28, 312, 314, "WM" +334, 4, 9, 66, 29, 30, 315, 316, "," +334, 4, 10, 67, 31, 40, 317, 326, "Khutsoane" +334, 4, 11, 68, 41, 43, 327, 329, "DT" +334, 4, 12, 69, 44, 45, 330, 331, "," +334, 4, 13, 70, 46, 51, 332, 337, "Pesic" +334, 4, 14, 71, 52, 53, 338, 339, "M" +334, 4, 15, 72, 54, 55, 340, 341, "," +334, 4, 16, 73, 56, 64, 342, 350, "Smahelov" +334, 4, 17, 74, 65, 66, 351, 352, "á" +334, 4, 18, 75, 67, 68, 353, 354, "A" +334, 4, 19, 76, 69, 70, 355, 356, "," +334, 4, 20, 77, 71, 78, 357, 364, "Thomsen" +334, 4, 21, 78, 79, 81, 365, 367, "HF" +334, 4, 22, 79, 82, 83, 368, 369, "," +334, 4, 23, 80, 84, 89, 370, 375, "Kalra" +334, 4, 24, 81, 90, 91, 376, 377, "S" +334, 4, 25, 82, 92, 93, 378, 379, "." +334, 4, 26, 83, 94, 100, 380, 386, "Author" +334, 4, 27, 84, 101, 112, 387, 398, "information" +334, 4, 28, 85, 113, 114, 399, 400, ":" +334, 4, 29, 86, 115, 116, 401, 402, "(" +334, 4, 30, 87, 117, 118, 403, 404, "1" +334, 4, 31, 88, 119, 120, 405, 406, ")" +334, 4, 32, 89, 121, 131, 407, 417, "Department" +334, 4, 33, 90, 132, 134, 418, 420, "of" +334, 4, 34, 91, 135, 143, 421, 429, "Internal" +334, 4, 35, 92, 144, 152, 430, 438, "Diseases" +334, 4, 36, 93, 153, 164, 439, 450, "Diabetology" +334, 4, 37, 94, 165, 168, 451, 454, "and" +334, 4, 38, 95, 169, 179, 455, 465, "Nephrology" +334, 4, 39, 96, 180, 181, 466, 467, "," +334, 4, 40, 97, 182, 190, 468, 476, "Silesian" +334, 4, 41, 98, 191, 198, 477, 484, "Medical" +334, 4, 42, 99, 199, 209, 485, 495, "University" +334, 4, 43, 100, 210, 211, 496, 497, "," +334, 4, 44, 101, 212, 218, 498, 504, "Zabrze" +334, 4, 45, 102, 219, 220, 505, 506, "," +334, 4, 46, 103, 221, 227, 507, 513, "Poland" +334, 4, 47, 104, 228, 229, 514, 515, "." +334, 5, 1, 105, 0, 8, 516, 524, "KSTROJEK" +334, 5, 2, 106, 9, 10, 525, 526, "@" +334, 5, 3, 107, 11, 14, 527, 530, "sum" +334, 5, 4, 108, 15, 16, 531, 532, "." +334, 5, 5, 109, 17, 20, 533, 536, "edu" +334, 5, 6, 110, 21, 22, 537, 538, "." +334, 5, 7, 111, 23, 25, 539, 541, "pl" +334, 5, 8, 112, 26, 36, 542, 552, "OBJECTIVES" +334, 5, 9, 113, 37, 38, 553, 554, ":" +334, 5, 10, 114, 39, 41, 555, 557, "To" +334, 5, 11, 115, 42, 48, 558, 564, "assess" +334, 5, 12, 116, 49, 52, 565, 568, "the" +334, 5, 13, 117, 53, 61, 569, 577, "efficacy" +334, 5, 14, 118, 62, 65, 578, 581, "and" +334, 5, 15, 119, 66, 72, 582, 588, "safety" +334, 5, 16, 120, 73, 75, 589, 591, "of" +334, 5, 17, 121, 76, 84, 592, 600, "biphasic" +334, 5, 18, 122, 85, 92, 601, 608, "insulin" +334, 5, 19, 123, 93, 99, 609, 615, "aspart" +334, 5, 20, 124, 100, 102, 616, 618, "70" +334, 5, 21, 125, 103, 104, 619, 620, "/" +334, 5, 22, 126, 105, 107, 621, 623, "30" +334, 5, 23, 127, 108, 109, 624, 625, "(" +334, 5, 24, 128, 110, 115, 626, 631, "BIAsp" +334, 5, 25, 129, 116, 118, 632, 634, "30" +334, 5, 26, 130, 119, 120, 635, 636, ")" +334, 5, 27, 131, 121, 124, 637, 640, "and" +334, 5, 28, 132, 125, 132, 641, 648, "insulin" +334, 5, 29, 133, 133, 141, 649, 657, "glargine" +334, 5, 30, 134, 142, 143, 658, 659, "," +334, 5, 31, 135, 144, 156, 660, 672, "administered" +334, 5, 32, 136, 157, 161, 673, 677, "once" +334, 5, 33, 137, 162, 167, 678, 683, "daily" +334, 5, 34, 138, 168, 170, 684, 686, "in" +334, 5, 35, 139, 171, 179, 687, 695, "subjects" +334, 5, 36, 140, 180, 184, 696, 700, "with" +334, 5, 37, 141, 185, 189, 701, 705, "type" +334, 5, 38, 142, 190, 191, 706, 707, "2" +334, 5, 39, 143, 192, 200, 708, 716, "diabetes" +334, 5, 40, 144, 201, 213, 717, 729, "inadequately" +334, 5, 41, 145, 214, 224, 730, 740, "controlled" +334, 5, 42, 146, 225, 229, 741, 745, "with" +334, 5, 43, 147, 230, 234, 746, 750, "oral" +334, 5, 44, 148, 235, 239, 751, 755, "anti" +334, 5, 45, 149, 240, 241, 756, 757, "-" +334, 5, 46, 150, 242, 250, 758, 766, "diabetic" +334, 5, 47, 151, 251, 256, 767, 772, "drugs" +334, 5, 48, 152, 257, 258, 773, 774, "." +334, 6, 1, 153, 0, 8, 775, 783, "RESEARCH" +334, 6, 2, 154, 9, 15, 784, 790, "DESIGN" +334, 6, 3, 155, 16, 19, 791, 794, "AND" +334, 6, 4, 156, 20, 27, 795, 802, "METHODS" +334, 6, 5, 157, 28, 29, 803, 804, ":" +334, 6, 6, 158, 30, 32, 805, 807, "In" +334, 6, 7, 159, 33, 37, 808, 812, "this" +334, 6, 8, 160, 38, 40, 813, 815, "26" +334, 6, 9, 161, 41, 42, 816, 817, "-" +334, 6, 10, 162, 43, 47, 818, 822, "week" +334, 6, 11, 163, 48, 49, 823, 824, "," +334, 6, 12, 164, 50, 54, 825, 829, "open" +334, 6, 13, 165, 55, 56, 830, 831, "-" +334, 6, 14, 166, 57, 64, 832, 839, "labeled" +334, 6, 15, 167, 65, 66, 840, 841, "," +334, 6, 16, 168, 67, 77, 842, 852, "randomized" +334, 6, 17, 169, 78, 79, 853, 854, "," +334, 6, 18, 170, 80, 88, 855, 863, "parallel" +334, 6, 19, 171, 89, 90, 864, 865, "-" +334, 6, 20, 172, 91, 96, 866, 871, "group" +334, 6, 21, 173, 97, 98, 872, 873, "," +334, 6, 22, 174, 99, 112, 874, 887, "multinational" +334, 6, 23, 175, 113, 114, 888, 889, "," +334, 6, 24, 176, 115, 120, 890, 895, "treat" +334, 6, 25, 177, 121, 122, 896, 897, "-" +334, 6, 26, 178, 123, 125, 898, 900, "to" +334, 6, 27, 179, 126, 127, 901, 902, "-" +334, 6, 28, 180, 128, 134, 903, 909, "target" +334, 6, 29, 181, 135, 140, 910, 915, "trial" +334, 6, 30, 182, 141, 142, 916, 917, "," +334, 6, 31, 183, 143, 146, 918, 921, "480" +334, 6, 32, 184, 147, 154, 922, 929, "insulin" +334, 6, 33, 185, 155, 156, 930, 931, "-" +334, 6, 34, 186, 157, 159, 932, 934, "na" +334, 6, 35, 187, 160, 161, 935, 936, "ï" +334, 6, 36, 188, 162, 164, 937, 939, "ve" +334, 6, 37, 189, 165, 173, 940, 948, "subjects" +334, 6, 38, 190, 174, 178, 949, 953, "were" +334, 6, 39, 191, 179, 189, 954, 964, "randomized" +334, 6, 40, 192, 190, 192, 965, 967, "to" +334, 6, 41, 193, 193, 200, 968, 975, "receive" +334, 6, 42, 194, 201, 207, 976, 982, "either" +334, 6, 43, 195, 208, 213, 983, 988, "BIAsp" +334, 6, 44, 196, 214, 216, 989, 991, "30" +334, 6, 45, 197, 217, 223, 992, 998, "before" +334, 6, 46, 198, 224, 230, 999, 1005, "dinner" +334, 6, 47, 199, 231, 233, 1006, 1008, "or" +334, 6, 48, 200, 234, 241, 1009, 1016, "insulin" +334, 6, 49, 201, 242, 250, 1017, 1025, "glargine" +334, 6, 50, 202, 251, 253, 1026, 1028, "at" +334, 6, 51, 203, 254, 261, 1029, 1036, "bedtime" +334, 6, 52, 204, 262, 263, 1037, 1038, "," +334, 6, 53, 205, 264, 268, 1039, 1043, "both" +334, 6, 54, 206, 269, 271, 1044, 1046, "in" +334, 6, 55, 207, 272, 283, 1047, 1058, "combination" +334, 6, 56, 208, 284, 288, 1059, 1063, "with" +334, 6, 57, 209, 289, 298, 1064, 1073, "metformin" +334, 6, 58, 210, 299, 302, 1074, 1077, "and" +334, 6, 59, 211, 303, 314, 1078, 1089, "glimepiride" +334, 6, 60, 212, 315, 316, 1090, 1091, "." +334, 7, 1, 213, 0, 5, 1092, 1097, "TRIAL" +334, 7, 2, 214, 6, 18, 1098, 1110, "REGISTRATION" +334, 7, 3, 215, 19, 20, 1111, 1112, ":" +334, 7, 4, 216, 21, 32, 1113, 1124, "NCT00469092" +334, 7, 5, 217, 33, 34, 1125, 1126, "," +334, 7, 6, 218, 35, 49, 1127, 1141, "ClinicalTrials" +334, 7, 7, 219, 50, 51, 1142, 1143, "." +334, 7, 8, 220, 52, 55, 1144, 1147, "gov" +334, 7, 9, 221, 56, 57, 1148, 1149, "." +334, 8, 1, 222, 0, 7, 1150, 1157, "RESULTS" +334, 8, 2, 223, 8, 9, 1158, 1159, ":" +334, 8, 3, 224, 10, 11, 1160, 1161, "A" +334, 8, 4, 225, 12, 17, 1162, 1167, "total" +334, 8, 5, 226, 18, 20, 1168, 1170, "of" +334, 8, 6, 227, 21, 24, 1171, 1174, "433" +334, 8, 7, 228, 25, 33, 1175, 1183, "subjects" +334, 8, 8, 229, 34, 43, 1184, 1193, "completed" +334, 8, 9, 230, 44, 47, 1194, 1197, "the" +334, 8, 10, 231, 48, 53, 1198, 1203, "trial" +334, 8, 11, 232, 54, 55, 1204, 1205, "." +334, 9, 1, 233, 0, 9, 1206, 1215, "Estimated" +334, 9, 2, 234, 10, 14, 1216, 1220, "mean" +334, 9, 3, 235, 15, 24, 1221, 1230, "reduction" +334, 9, 4, 236, 25, 27, 1231, 1233, "in" +334, 9, 5, 237, 28, 31, 1234, 1237, "HbA" +334, 9, 6, 238, 32, 33, 1238, 1239, "(" +334, 9, 7, 239, 34, 36, 1240, 1242, "1c" +334, 9, 8, 240, 37, 38, 1243, 1244, ")" +334, 9, 9, 241, 39, 43, 1245, 1249, "from" +334, 9, 10, 242, 44, 52, 1250, 1258, "baseline" +334, 9, 11, 243, 53, 55, 1259, 1261, "to" +334, 9, 12, 244, 56, 59, 1262, 1265, "end" +334, 9, 13, 245, 60, 62, 1266, 1268, "of" +334, 9, 14, 246, 63, 72, 1269, 1278, "treatment" +334, 9, 15, 247, 73, 76, 1279, 1282, "was" +334, 9, 16, 248, 77, 78, 1283, 1284, "-" +334, 9, 17, 249, 79, 80, 1285, 1286, "1" +334, 9, 18, 250, 81, 82, 1287, 1288, "." +334, 9, 19, 251, 83, 85, 1289, 1291, "41" +334, 9, 20, 252, 86, 87, 1292, 1293, "%" +334, 9, 21, 253, 88, 92, 1294, 1298, "with" +334, 9, 22, 254, 93, 98, 1299, 1304, "BIAsp" +334, 9, 23, 255, 99, 101, 1305, 1307, "30" +334, 9, 24, 256, 102, 105, 1308, 1311, "and" +334, 9, 25, 257, 106, 107, 1312, 1313, "-" +334, 9, 26, 258, 108, 109, 1314, 1315, "1" +334, 9, 27, 259, 110, 111, 1316, 1317, "." +334, 9, 28, 260, 112, 114, 1318, 1320, "25" +334, 9, 29, 261, 115, 116, 1321, 1322, "%" +334, 9, 30, 262, 117, 121, 1323, 1327, "with" +334, 9, 31, 263, 122, 129, 1328, 1335, "insulin" +334, 9, 32, 264, 130, 138, 1336, 1344, "glargine" +334, 9, 33, 265, 139, 140, 1345, 1346, "(" +334, 9, 34, 266, 141, 146, 1347, 1352, "BIAsp" +334, 9, 35, 267, 147, 149, 1353, 1355, "30" +334, 9, 36, 268, 150, 151, 1356, 1357, "-" +334, 9, 37, 269, 152, 159, 1358, 1365, "insulin" +334, 9, 38, 270, 160, 168, 1366, 1374, "glargine" +334, 9, 39, 271, 169, 170, 1375, 1376, "=" +334, 9, 40, 272, 171, 172, 1377, 1378, "-" +334, 9, 41, 273, 173, 174, 1379, 1380, "0" +334, 9, 42, 274, 175, 176, 1381, 1382, "." +334, 9, 43, 275, 177, 179, 1383, 1385, "16" +334, 9, 44, 276, 180, 181, 1386, 1387, "%" +334, 9, 45, 277, 182, 183, 1388, 1389, "," +334, 9, 46, 278, 184, 186, 1390, 1392, "95" +334, 9, 47, 279, 187, 188, 1393, 1394, "%" +334, 9, 48, 280, 189, 191, 1395, 1397, "CI" +334, 9, 49, 281, 192, 193, 1398, 1399, "[" +334, 9, 50, 282, 194, 195, 1400, 1401, "-" +334, 9, 51, 283, 196, 197, 1402, 1403, "0" +334, 9, 52, 284, 198, 199, 1404, 1405, "." +334, 9, 53, 285, 200, 202, 1406, 1408, "30" +334, 9, 54, 286, 203, 204, 1409, 1410, ";" +334, 9, 55, 287, 205, 206, 1411, 1412, "-" +334, 9, 56, 288, 207, 208, 1413, 1414, "0" +334, 9, 57, 289, 209, 210, 1415, 1416, "." +334, 9, 58, 290, 211, 213, 1417, 1419, "02" +334, 9, 59, 291, 214, 215, 1420, 1421, "]" +334, 9, 60, 292, 216, 217, 1422, 1423, "," +334, 9, 61, 293, 218, 219, 1424, 1425, "p" +334, 9, 62, 294, 220, 221, 1426, 1427, "=" +334, 9, 63, 295, 222, 223, 1428, 1429, "0" +334, 9, 64, 296, 224, 225, 1430, 1431, "." +334, 9, 65, 297, 226, 229, 1432, 1435, "029" +334, 9, 66, 298, 230, 231, 1436, 1437, ")" +334, 9, 67, 299, 232, 233, 1438, 1439, "." +334, 10, 1, 300, 0, 2, 1440, 1442, "At" +334, 10, 2, 301, 3, 6, 1443, 1446, "the" +334, 10, 3, 302, 7, 10, 1447, 1450, "end" +334, 10, 4, 303, 11, 13, 1451, 1453, "of" +334, 10, 5, 304, 14, 23, 1454, 1463, "treatment" +334, 10, 6, 305, 24, 25, 1464, 1465, "," +334, 10, 7, 306, 26, 30, 1466, 1470, "mean" +334, 10, 8, 307, 31, 34, 1471, 1474, "HbA" +334, 10, 9, 308, 35, 36, 1475, 1476, "(" +334, 10, 10, 309, 37, 39, 1477, 1479, "1c" +334, 10, 11, 310, 40, 41, 1480, 1481, ")" +334, 10, 12, 311, 42, 45, 1482, 1485, "was" +334, 10, 13, 312, 46, 47, 1486, 1487, "7" +334, 10, 14, 313, 48, 49, 1488, 1489, "." +334, 10, 15, 314, 50, 51, 1490, 1491, "1" +334, 10, 16, 315, 52, 53, 1492, 1493, "%" +334, 10, 17, 316, 54, 57, 1494, 1497, "and" +334, 10, 18, 317, 58, 59, 1498, 1499, "7" +334, 10, 19, 318, 60, 61, 1500, 1501, "." +334, 10, 20, 319, 62, 63, 1502, 1503, "3" +334, 10, 21, 320, 64, 65, 1504, 1505, "%" +334, 10, 22, 321, 66, 69, 1506, 1509, "for" +334, 10, 23, 322, 70, 75, 1510, 1515, "BIAsp" +334, 10, 24, 323, 76, 78, 1516, 1518, "30" +334, 10, 25, 324, 79, 82, 1519, 1522, "and" +334, 10, 26, 325, 83, 90, 1523, 1530, "insulin" +334, 10, 27, 326, 91, 99, 1531, 1539, "glargine" +334, 10, 28, 327, 100, 101, 1540, 1541, "," +334, 10, 29, 328, 102, 114, 1542, 1554, "respectively" +334, 10, 30, 329, 115, 116, 1555, 1556, "." +334, 11, 1, 330, 0, 13, 1557, 1570, "Significantly" +334, 11, 2, 331, 14, 19, 1571, 1576, "lower" +334, 11, 3, 332, 20, 26, 1577, 1583, "plasma" +334, 11, 4, 333, 27, 34, 1584, 1591, "glucose" +334, 11, 5, 334, 35, 41, 1592, 1598, "levels" +334, 11, 6, 335, 42, 46, 1599, 1603, "were" +334, 11, 7, 336, 47, 55, 1604, 1612, "observed" +334, 11, 8, 337, 56, 60, 1613, 1617, "with" +334, 11, 9, 338, 61, 66, 1618, 1623, "BIAsp" +334, 11, 10, 339, 67, 69, 1624, 1626, "30" +334, 11, 11, 340, 70, 74, 1627, 1631, "post" +334, 11, 12, 341, 75, 76, 1632, 1633, "-" +334, 11, 13, 342, 77, 83, 1634, 1640, "dinner" +334, 11, 14, 343, 84, 85, 1641, 1642, "(" +334, 11, 15, 344, 86, 91, 1643, 1648, "BIAsp" +334, 11, 16, 345, 92, 94, 1649, 1651, "30" +334, 11, 17, 346, 95, 96, 1652, 1653, "-" +334, 11, 18, 347, 97, 104, 1654, 1661, "insulin" +334, 11, 19, 348, 105, 113, 1662, 1670, "glargine" +334, 11, 20, 349, 114, 115, 1671, 1672, "=" +334, 11, 21, 350, 116, 117, 1673, 1674, "-" +334, 11, 22, 351, 118, 119, 1675, 1676, "0" +334, 11, 23, 352, 120, 121, 1677, 1678, "." +334, 11, 24, 353, 122, 124, 1679, 1681, "52" +334, 11, 25, 354, 125, 129, 1682, 1686, "mmol" +334, 11, 26, 355, 130, 131, 1687, 1688, "/" +334, 11, 27, 356, 132, 133, 1689, 1690, "L" +334, 11, 28, 357, 134, 135, 1691, 1692, "," +334, 11, 29, 358, 136, 138, 1693, 1695, "95" +334, 11, 30, 359, 139, 140, 1696, 1697, "%" +334, 11, 31, 360, 141, 143, 1698, 1700, "CI" +334, 11, 32, 361, 144, 145, 1701, 1702, "[" +334, 11, 33, 362, 146, 147, 1703, 1704, "-" +334, 11, 34, 363, 148, 149, 1705, 1706, "1" +334, 11, 35, 364, 150, 151, 1707, 1708, "." +334, 11, 36, 365, 152, 154, 1709, 1711, "02" +334, 11, 37, 366, 155, 156, 1712, 1713, ";" +334, 11, 38, 367, 157, 158, 1714, 1715, "-" +334, 11, 39, 368, 159, 160, 1716, 1717, "0" +334, 11, 40, 369, 161, 162, 1718, 1719, "." +334, 11, 41, 370, 163, 165, 1720, 1722, "03" +334, 11, 42, 371, 166, 167, 1723, 1724, "]" +334, 11, 43, 372, 168, 169, 1725, 1726, "," +334, 11, 44, 373, 170, 171, 1727, 1728, "p" +334, 11, 45, 374, 172, 173, 1729, 1730, "=" +334, 11, 46, 375, 174, 175, 1731, 1732, "0" +334, 11, 47, 376, 176, 177, 1733, 1734, "." +334, 11, 48, 377, 178, 180, 1735, 1737, "04" +334, 11, 49, 378, 181, 182, 1738, 1739, ")" +334, 11, 50, 379, 183, 186, 1740, 1743, "and" +334, 11, 51, 380, 187, 189, 1744, 1746, "at" +334, 11, 52, 381, 190, 197, 1747, 1754, "bedtime" +334, 11, 53, 382, 198, 199, 1755, 1756, "(" +334, 11, 54, 383, 200, 205, 1757, 1762, "BIAsp" +334, 11, 55, 384, 206, 208, 1763, 1765, "30" +334, 11, 56, 385, 209, 210, 1766, 1767, "-" +334, 11, 57, 386, 211, 218, 1768, 1775, "insulin" +334, 11, 58, 387, 219, 227, 1776, 1784, "glargine" +334, 11, 59, 388, 228, 229, 1785, 1786, "=" +334, 11, 60, 389, 230, 231, 1787, 1788, "-" +334, 11, 61, 390, 232, 233, 1789, 1790, "0" +334, 11, 62, 391, 234, 235, 1791, 1792, "." +334, 11, 63, 392, 236, 238, 1793, 1795, "78" +334, 11, 64, 393, 239, 243, 1796, 1800, "mmol" +334, 11, 65, 394, 244, 245, 1801, 1802, "/" +334, 11, 66, 395, 246, 247, 1803, 1804, "L" +334, 11, 67, 396, 248, 249, 1805, 1806, "," +334, 11, 68, 397, 250, 252, 1807, 1809, "95" +334, 11, 69, 398, 253, 254, 1810, 1811, "%" +334, 11, 70, 399, 255, 257, 1812, 1814, "CI" +334, 11, 71, 400, 258, 259, 1815, 1816, "[" +334, 11, 72, 401, 260, 261, 1817, 1818, "-" +334, 11, 73, 402, 262, 263, 1819, 1820, "1" +334, 11, 74, 403, 264, 265, 1821, 1822, "." +334, 11, 75, 404, 266, 268, 1823, 1825, "25" +334, 11, 76, 405, 269, 270, 1826, 1827, ";" +334, 11, 77, 406, 271, 272, 1828, 1829, "-" +334, 11, 78, 407, 273, 274, 1830, 1831, "0" +334, 11, 79, 408, 275, 276, 1832, 1833, "." +334, 11, 80, 409, 277, 279, 1834, 1836, "31" +334, 11, 81, 410, 280, 281, 1837, 1838, "]" +334, 11, 82, 411, 282, 283, 1839, 1840, "," +334, 11, 83, 412, 284, 285, 1841, 1842, "p" +334, 11, 84, 413, 286, 287, 1843, 1844, "<" +334, 11, 85, 414, 288, 289, 1845, 1846, "0" +334, 11, 86, 415, 290, 291, 1847, 1848, "." +334, 11, 87, 416, 292, 294, 1849, 1851, "01" +334, 11, 88, 417, 295, 296, 1852, 1853, ")" +334, 11, 89, 418, 297, 298, 1854, 1855, "." +334, 12, 1, 419, 0, 3, 1856, 1859, "The" +334, 12, 2, 420, 4, 12, 1860, 1868, "relative" +334, 12, 3, 421, 13, 17, 1869, 1873, "risk" +334, 12, 4, 422, 18, 19, 1874, 1875, "(" +334, 12, 5, 423, 20, 22, 1876, 1878, "RR" +334, 12, 6, 424, 23, 24, 1879, 1880, ")" +334, 12, 7, 425, 25, 27, 1881, 1883, "of" +334, 12, 8, 426, 28, 40, 1884, 1896, "experiencing" +334, 12, 9, 427, 41, 42, 1897, 1898, "a" +334, 12, 10, 428, 43, 52, 1899, 1908, "nocturnal" +334, 12, 11, 429, 53, 65, 1909, 1921, "hypoglycemic" +334, 12, 12, 430, 66, 73, 1922, 1929, "episode" +334, 12, 13, 431, 74, 75, 1930, 1931, "(" +334, 12, 14, 432, 76, 78, 1932, 1934, "00" +334, 12, 15, 433, 79, 80, 1935, 1936, ":" +334, 12, 16, 434, 81, 83, 1937, 1939, "00" +334, 12, 17, 435, 84, 85, 1940, 1941, "-" +334, 12, 18, 436, 86, 88, 1942, 1944, "06" +334, 12, 19, 437, 89, 90, 1945, 1946, "." +334, 12, 20, 438, 91, 93, 1947, 1949, "00" +334, 12, 21, 439, 94, 95, 1950, 1951, "a" +334, 12, 22, 440, 96, 97, 1952, 1953, "." +334, 12, 23, 441, 98, 99, 1954, 1955, "m" +334, 12, 24, 442, 100, 101, 1956, 1957, "." +334, 12, 25, 443, 102, 103, 1958, 1959, ")" +334, 12, 26, 444, 104, 107, 1960, 1963, "was" +334, 12, 27, 445, 108, 121, 1964, 1977, "significantly" +334, 12, 28, 446, 122, 128, 1978, 1984, "higher" +334, 12, 29, 447, 129, 133, 1985, 1989, "with" +334, 12, 30, 448, 134, 139, 1990, 1995, "BIAsp" +334, 12, 31, 449, 140, 142, 1996, 1998, "30" +334, 12, 32, 450, 143, 147, 1999, 2003, "than" +334, 12, 33, 451, 148, 152, 2004, 2008, "with" +334, 12, 34, 452, 153, 160, 2009, 2016, "insulin" +334, 12, 35, 453, 161, 169, 2017, 2025, "glargine" +334, 12, 36, 454, 170, 171, 2026, 2027, "(" +334, 12, 37, 455, 172, 173, 2028, 2029, "1" +334, 12, 38, 456, 174, 175, 2030, 2031, "." +334, 12, 39, 457, 176, 177, 2032, 2033, "1" +334, 12, 40, 458, 178, 184, 2034, 2040, "versus" +334, 12, 41, 459, 185, 186, 2041, 2042, "0" +334, 12, 42, 460, 187, 188, 2043, 2044, "." +334, 12, 43, 461, 189, 190, 2045, 2046, "5" +334, 12, 44, 462, 191, 199, 2047, 2055, "episodes" +334, 12, 45, 463, 200, 201, 2056, 2057, "/" +334, 12, 46, 464, 202, 206, 2058, 2062, "year" +334, 12, 47, 465, 207, 208, 2063, 2064, "," +334, 12, 48, 466, 209, 211, 2065, 2067, "RR" +334, 12, 49, 467, 212, 213, 2068, 2069, "=" +334, 12, 50, 468, 214, 215, 2070, 2071, "2" +334, 12, 51, 469, 216, 217, 2072, 2073, "." +334, 12, 52, 470, 218, 220, 2074, 2076, "41" +334, 12, 53, 471, 221, 222, 2077, 2078, "," +334, 12, 54, 472, 223, 225, 2079, 2081, "95" +334, 12, 55, 473, 226, 227, 2082, 2083, "%" +334, 12, 56, 474, 228, 230, 2084, 2086, "CI" +334, 12, 57, 475, 231, 232, 2087, 2088, "[" +334, 12, 58, 476, 233, 234, 2089, 2090, "1" +334, 12, 59, 477, 235, 236, 2091, 2092, "." +334, 12, 60, 478, 237, 239, 2093, 2095, "34" +334, 12, 61, 479, 240, 241, 2096, 2097, ";" +334, 12, 62, 480, 242, 243, 2098, 2099, "4" +334, 12, 63, 481, 244, 245, 2100, 2101, "." +334, 12, 64, 482, 246, 248, 2102, 2104, "34" +334, 12, 65, 483, 249, 250, 2105, 2106, "]" +334, 12, 66, 484, 251, 252, 2107, 2108, "," +334, 12, 67, 485, 253, 254, 2109, 2110, "p" +334, 12, 68, 486, 255, 256, 2111, 2112, "=" +334, 12, 69, 487, 257, 258, 2113, 2114, "0" +334, 12, 70, 488, 259, 260, 2115, 2116, "." +334, 12, 71, 489, 261, 264, 2117, 2120, "003" +334, 12, 72, 490, 265, 266, 2121, 2122, ")" +334, 12, 73, 491, 267, 268, 2123, 2124, "," +334, 12, 74, 492, 269, 272, 2125, 2128, "but" +334, 12, 75, 493, 273, 280, 2129, 2136, "overall" +334, 12, 76, 494, 281, 293, 2137, 2149, "hypoglycemia" +334, 12, 77, 495, 294, 299, 2150, 2155, "rates" +334, 12, 78, 496, 300, 304, 2156, 2160, "were" +334, 12, 79, 497, 305, 308, 2161, 2164, "low" +334, 12, 80, 498, 309, 310, 2165, 2166, "." +334, 13, 1, 499, 0, 5, 2167, 2172, "There" +334, 13, 2, 500, 6, 10, 2173, 2177, "were" +334, 13, 3, 501, 11, 16, 2178, 2183, "three" +334, 13, 4, 502, 17, 22, 2184, 2189, "major" +334, 13, 5, 503, 23, 35, 2190, 2202, "hypoglycemic" +334, 13, 6, 504, 36, 44, 2203, 2211, "episodes" +334, 13, 7, 505, 45, 47, 2212, 2214, "in" +334, 13, 8, 506, 48, 52, 2215, 2219, "each" +334, 13, 9, 507, 53, 58, 2220, 2225, "group" +334, 13, 10, 508, 59, 60, 2226, 2227, "." +334, 14, 1, 509, 0, 11, 2228, 2239, "CONCLUSIONS" +334, 14, 2, 510, 12, 13, 2240, 2241, ":" +334, 14, 3, 511, 14, 18, 2242, 2246, "With" +334, 14, 4, 512, 19, 26, 2247, 2254, "respect" +334, 14, 5, 513, 27, 29, 2255, 2257, "to" +334, 14, 6, 514, 30, 33, 2258, 2261, "HbA" +334, 14, 7, 515, 34, 35, 2262, 2263, "(" +334, 14, 8, 516, 36, 38, 2264, 2266, "1c" +334, 14, 9, 517, 39, 40, 2267, 2268, ")" +334, 14, 10, 518, 41, 42, 2269, 2270, "," +334, 14, 11, 519, 43, 48, 2271, 2276, "BIAsp" +334, 14, 12, 520, 49, 51, 2277, 2279, "30" +334, 14, 13, 521, 52, 61, 2280, 2289, "fulfilled" +334, 14, 14, 522, 62, 65, 2290, 2293, "the" +334, 14, 15, 523, 66, 77, 2294, 2305, "statistical" +334, 14, 16, 524, 78, 86, 2306, 2314, "criteria" +334, 14, 17, 525, 87, 90, 2315, 2318, "for" +334, 14, 18, 526, 91, 94, 2319, 2322, "non" +334, 14, 19, 527, 95, 96, 2323, 2324, "-" +334, 14, 20, 528, 97, 108, 2325, 2336, "inferiority" +334, 14, 21, 529, 109, 112, 2337, 2340, "and" +334, 14, 22, 530, 113, 124, 2341, 2352, "superiority" +334, 14, 23, 531, 125, 127, 2353, 2355, "to" +334, 14, 24, 532, 128, 135, 2356, 2363, "insulin" +334, 14, 25, 533, 136, 144, 2364, 2372, "glargine" +334, 14, 26, 534, 145, 148, 2373, 2376, "and" +334, 14, 27, 535, 149, 150, 2377, 2378, "," +334, 14, 28, 536, 151, 160, 2379, 2388, "according" +334, 14, 29, 537, 161, 163, 2389, 2391, "to" +334, 14, 30, 538, 164, 167, 2392, 2395, "pre" +334, 14, 31, 539, 168, 169, 2396, 2397, "-" +334, 14, 32, 540, 170, 177, 2398, 2405, "defined" +334, 14, 33, 541, 178, 186, 2406, 2414, "criteria" +334, 14, 34, 542, 187, 188, 2415, 2416, "," +334, 14, 35, 543, 189, 192, 2417, 2420, "the" +334, 14, 36, 544, 193, 205, 2421, 2433, "improvements" +334, 14, 37, 545, 206, 208, 2434, 2436, "in" +334, 14, 38, 546, 209, 212, 2437, 2440, "HbA" +334, 14, 39, 547, 213, 214, 2441, 2442, "(" +334, 14, 40, 548, 215, 217, 2443, 2445, "1c" +334, 14, 41, 549, 218, 219, 2446, 2447, ")" +334, 14, 42, 550, 220, 223, 2448, 2451, "are" +334, 14, 43, 551, 224, 234, 2452, 2462, "considered" +334, 14, 44, 552, 235, 245, 2463, 2473, "clinically" +334, 14, 45, 553, 246, 256, 2474, 2484, "equivalent" +334, 14, 46, 554, 257, 258, 2485, 2486, "." +334, 15, 1, 555, 0, 8, 2487, 2495, "Subjects" +334, 15, 2, 556, 9, 12, 2496, 2499, "had" +334, 15, 3, 557, 13, 15, 2500, 2502, "an" +334, 15, 4, 558, 16, 25, 2503, 2512, "increased" +334, 15, 5, 559, 26, 30, 2513, 2517, "risk" +334, 15, 6, 560, 31, 33, 2518, 2520, "of" +334, 15, 7, 561, 34, 39, 2521, 2526, "minor" +334, 15, 8, 562, 40, 49, 2527, 2536, "nocturnal" +334, 15, 9, 563, 50, 62, 2537, 2549, "hypoglycemia" +334, 15, 10, 564, 63, 67, 2550, 2554, "with" +334, 15, 11, 565, 68, 73, 2555, 2560, "BIAsp" +334, 15, 12, 566, 74, 76, 2561, 2563, "30" +334, 15, 13, 567, 77, 78, 2564, 2565, "." +334, 16, 1, 568, 0, 5, 2566, 2571, "There" +334, 16, 2, 569, 6, 10, 2572, 2576, "were" +334, 16, 3, 570, 11, 13, 2577, 2579, "no" +334, 16, 4, 571, 14, 25, 2580, 2591, "differences" +334, 16, 5, 572, 26, 28, 2592, 2594, "in" +334, 16, 6, 573, 29, 38, 2595, 2604, "treatment" +334, 16, 7, 574, 39, 51, 2605, 2617, "satisfaction" +334, 16, 8, 575, 52, 59, 2618, 2625, "between" +334, 16, 9, 576, 60, 63, 2626, 2629, "the" +334, 16, 10, 577, 64, 67, 2630, 2633, "two" +334, 16, 11, 578, 68, 74, 2634, 2640, "groups" +334, 16, 12, 579, 75, 76, 2641, 2642, "." +334, 17, 1, 580, 0, 3, 2643, 2646, "DOI" +334, 17, 2, 581, 4, 5, 2647, 2648, ":" +334, 17, 3, 582, 6, 8, 2649, 2651, "10" +334, 17, 4, 583, 9, 10, 2652, 2653, "." +334, 17, 5, 584, 11, 15, 2654, 2658, "1185" +334, 17, 6, 585, 16, 17, 2659, 2660, "/" +334, 17, 7, 586, 18, 35, 2661, 2678, "03007990903354674" +334, 17, 8, 587, 36, 40, 2679, 2683, "PMID" +334, 17, 9, 588, 41, 42, 2684, 2685, ":" +334, 17, 10, 589, 43, 51, 2686, 2694, "19821654" +334, 17, 11, 590, 52, 53, 2695, 2696, "[" +334, 17, 12, 591, 54, 61, 2697, 2704, "Indexed" +334, 17, 13, 592, 62, 65, 2705, 2708, "for" +334, 17, 14, 593, 66, 73, 2709, 2716, "MEDLINE" +334, 17, 15, 594, 74, 75, 2717, 2718, "]" diff --git a/data/dm2 19821654_kwoodley.annodb b/data/dm2 19821654_kwoodley.annodb new file mode 100644 index 0000000..d2defb7 --- /dev/null +++ b/data/dm2 19821654_kwoodley.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +14916, Journal, 0, 17, "Curr Med Res Opin", "", +14917, PublicationYear, 20, 24, "2009", "", +36676, Title, 93, 285, "Once - daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs : an open - label , multinational RCT .", "", +14918, Frequency, 93, 105, "Once - daily", "", +14919, InsulinAspart, 122, 148, "biphasic insulin aspart 30", "", +14920, InsulinGlargine, 156, 172, "insulin glargine", "", +14923, Precondition, 176, 245, "patients with type 2 diabetes inadequately controlled with oral drugs", "", +14921, Type2Diabetes, 190, 205, "type 2 diabetes", "", +14922, OralAntidiabeticAgent, 235, 245, "oral drugs", "", +14924, OpenLabel, 251, 263, "open - label", "", +36677, Multicenter, 266, 279, "multinational", "", +14926, Randomized, 280, 283, "RCT", "", +14928, Author, 286, 295, "Strojek K", "", +14929, Author, 304, 314, "Bebakar WM", "", +14930, Author, 317, 329, "Khutsoane DT", "", +14931, Author, 332, 339, "Pesic M", "", +14932, Author, 342, 354, "Smahelov á A", "", +14933, Author, 357, 367, "Thomsen HF", "", +14934, Author, 370, 377, "Kalra S", "", +14935, Poland, 507, 513, "Poland", "", +36678, ObjectiveDescription, 555, 774, "To assess the efficacy and safety of biphasic insulin aspart 70 / 30 ( BIAsp 30 ) and insulin glargine , administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs .", "", +14936, InsulinAspart, 592, 623, "biphasic insulin aspart 70 / 30", "", +14937, InsulinAspart, 626, 634, "BIAsp 30", "", +14938, InsulinGlargine, 641, 657, "insulin glargine", "", +14939, Frequency, 673, 683, "once daily", "", +14942, Precondition, 687, 772, "subjects with type 2 diabetes inadequately controlled with oral anti - diabetic drugs", "", +14940, Type2Diabetes, 701, 716, "type 2 diabetes", "", +14941, OralAntidiabeticAgent, 746, 772, "oral anti - diabetic drugs", "", +14944, Duration, 813, 822, "26 - week", "", +14945, OpenLabel, 825, 839, "open - labeled", "", +14946, Randomized, 842, 852, "randomized", "", +14947, Parallel, 855, 871, "parallel - group", "", +36679, Multicenter, 874, 887, "multinational", "", +14949, CTDesign, 890, 909, "treat - to - target", "", +14950, NumberPatientsCT, 918, 921, "480", "", +14952, Precondition, 922, 948, "insulin - na ï ve subjects", "", +14953, Randomized, 954, 964, "randomized", "", +14954, InsulinAspart, 983, 991, "BIAsp 30", "", +14955, RelativeTime, 992, 1005, "before dinner", "", +14956, InsulinGlargine, 1009, 1025, "insulin glargine", "", +36680, RelativeTime, 1029, 1036, "bedtime", "", +14958, Metformin, 1064, 1073, "metformin", "", +14959, Glimepiride, 1078, 1089, "glimepiride", "", +14960, FinalNumPatientsCT, 1171, 1174, "433", "", +14961, HbA1c, 1234, 1244, "HbA ( 1c )", "", +36681, TimePoint, 1250, 1258, "baseline", "", +36682, TimePoint, 1262, 1278, "end of treatment", "", +14962, Reduction, 1285, 1291, "1 . 41", "", +14965, Percentage, 1292, 1293, "%", "", +14964, InsulinAspart, 1299, 1307, "BIAsp 30", "", +14963, Reduction, 1314, 1320, "1 . 25", "", +14966, Percentage, 1321, 1322, "%", "", +14967, InsulinGlargine, 1328, 1344, "insulin glargine", "", +14969, InsulinAspart, 1347, 1355, "BIAsp 30", "", +14968, InsulinGlargine, 1358, 1374, "insulin glargine", "", +14970, DiffGroupAbsValue, 1377, 1385, "- 0 . 16", "", +14971, Percentage, 1386, 1387, "%", "", +14972, ConfIntervalDiff, 1390, 1421, "95 % CI [ - 0 . 30 ; - 0 . 02 ]", "", +14973, PvalueDiff, 1424, 1435, "p = 0 . 029", "", +36683, TimePoint, 1447, 1463, "end of treatment", "", +14974, HbA1c, 1471, 1481, "HbA ( 1c )", "", +14975, ResultMeasuredValue, 1486, 1491, "7 . 1", "", +14977, Percentage, 1492, 1493, "%", "", +14976, ResultMeasuredValue, 1498, 1503, "7 . 3", "", +14978, Percentage, 1504, 1505, "%", "", +14979, InsulinAspart, 1510, 1518, "BIAsp 30", "", +14980, InsulinGlargine, 1523, 1539, "insulin glargine", "", +36684, PlasmaGlucose, 1577, 1591, "plasma glucose", "", +14982, InsulinAspart, 1618, 1626, "BIAsp 30", "", +14983, TimePoint, 1627, 1640, "post - dinner", "", +14984, InsulinAspart, 1643, 1651, "BIAsp 30", "", +14985, InsulinGlargine, 1654, 1670, "insulin glargine", "", +14986, DiffGroupAbsValue, 1673, 1681, "- 0 . 52", "", +14987, Millimoles_per_litre, 1682, 1690, "mmol / L", "", +14988, ConfIntervalDiff, 1693, 1724, "95 % CI [ - 1 . 02 ; - 0 . 03 ]", "", +14989, PvalueDiff, 1727, 1737, "p = 0 . 04", "", +14990, TimePoint, 1747, 1754, "bedtime", "", +14991, InsulinAspart, 1757, 1765, "BIAsp 30", "", +14992, InsulinGlargine, 1768, 1784, "insulin glargine", "", +14993, DiffGroupAbsValue, 1787, 1795, "- 0 . 78", "", +14994, Millimoles_per_litre, 1796, 1804, "mmol / L", "", +14995, ConfIntervalDiff, 1807, 1838, "95 % CI [ - 1 . 25 ; - 0 . 31 ]", "", +14996, PvalueDiff, 1841, 1851, "p < 0 . 01", "", +14997, NocturnalHypoglycemia, 1899, 1929, "nocturnal hypoglycemic episode", "", +14998, InsulinAspart, 1990, 1998, "BIAsp 30", "", +14999, InsulinGlargine, 2009, 2025, "insulin glargine", "", +15000, ResultMeasuredValue, 2028, 2033, "1 . 1", "", +15001, ResultMeasuredValue, 2041, 2046, "0 . 5", "", +15002, BioAndMedicalUnit, 2047, 2062, "episodes / year", "", +15003, ConfIntervalDiff, 2079, 2106, "95 % CI [ 1 . 34 ; 4 . 34 ]", "", +15004, PvalueDiff, 2109, 2120, "p = 0 . 003", "", +15006, ObservedResult, 2129, 2164, "overall hypoglycemia rates were low", "", +15005, Hypoglycemia, 2137, 2149, "hypoglycemia", "", +36685, ObservedResult, 2167, 2227, "There were three major hypoglycemic episodes in each group .", "", +15007, Hypoglycemia, 2190, 2211, "hypoglycemic episodes", "", +36686, ConclusionComment, 2242, 2486, "With respect to HbA ( 1c ) , BIAsp 30 fulfilled the statistical criteria for non - inferiority and superiority to insulin glargine and , according to pre - defined criteria , the improvements in HbA ( 1c ) are considered clinically equivalent .", "", +15009, HbA1c, 2258, 2268, "HbA ( 1c )", "", +15010, InsulinAspart, 2271, 2279, "BIAsp 30", "", +15011, InsulinGlargine, 2356, 2372, "insulin glargine", "", +15012, HbA1c, 2437, 2447, "HbA ( 1c )", "", +36687, ConclusionComment, 2487, 2565, "Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30 .", "", +15013, NocturnalHypoglycemia, 2527, 2549, "nocturnal hypoglycemia", "", +15014, InsulinAspart, 2555, 2563, "BIAsp 30", "", +36688, ConclusionComment, 2566, 2642, "There were no differences in treatment satisfaction between the two groups .", "", +15018, PMID, 2686, 2694, "19821654", "", diff --git a/data/dm2 19821654_kwoodley.n-triples b/data/dm2 19821654_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 19821654_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092584_admin.annodb b/data/dm2 20092584_admin.annodb new file mode 100644 index 0000000..ce35cbd --- /dev/null +++ b/data/dm2 20092584_admin.annodb @@ -0,0 +1,136 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2010", "", " \"2010\"." +108, Title, 110, 243, "Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "", " \"Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .\"." +55486, PremixedInsulin, 151, 167, "premixed insulin", "", +3, Type2Diabetes, 196, 211, "type 2 diabetes", "", +4, Author, 244, 254, "Fritsche A", "", " \"Fritsche A\"." +5, Author, 263, 271, "Larbig M", "", " \"Larbig M\"." +6, Author, 274, 281, "Owens D", "", " \"Owens D\"." +7, Author, 284, 295, "H ä ring HU", "", " \"H ä ring HU\"." +8, Germany, 507, 514, "Germany", "", " ." +240, ObjectiveDescription, 652, 866, "To compare the efficacy and safety of an intensified insulin regimen , using insulin glargine ( glargine ) once daily and pre - meal insulin glulisine ( glulisine ) ( basal - bolus ) , with a conventional therapy ,", "", " \"To compare the efficacy and safety of an intensified insulin regimen , using insulin glargine ( glargine ) once daily and pre - meal insulin glulisine ( glulisine ) ( basal - bolus ) , with a conventional therapy ,\"." +9, Insulin, 705, 712, "insulin", "", +10, InsulinGlargine, 729, 745, "insulin glargine", "", +11, InsulinGlargine, 748, 756, "glargine", "", +12, Frequency, 759, 769, "once daily", "", " \"once daily\"." +121, RelativeTime, 774, 784, "pre - meal", "", " . ." +13, InsulinGlulisine, 785, 802, "insulin glulisine", "", +14, InsulinGlulisine, 805, 814, "glulisine", "", +239, ObjectiveDescription, 867, 914, "using premixed insulin ( premix ) twice daily .", "", " \"using premixed insulin ( premix ) twice daily .\"." +55488, PremixedInsulin, 873, 889, "premixed insulin", "", " ." +55487, PremixedInsulin, 892, 898, "premix", "", +16, Frequency, 901, 912, "twice daily", "", " \"twice daily\"." +17, Duration, 930, 939, "52 - week", "", " \"52 - week\"." +18, OpenLabel, 942, 954, "open - label", "", " ." +19, Randomized, 957, 967, "randomized", "", " ." +127, Multicenter, 970, 983, "multinational", "", " ." +20, Multicenter, 986, 997, "multicentre", "", " ." +21, NumberPatientsCT, 1013, 1016, "310", "", " \"310\"." +25, Precondition, 1017, 1092, "subjects with type 2 diabetes ( T2D ) on premix , with or without metformin", "", " \"subjects with type 2 diabetes ( T2D ) on premix , with or without metformin\"." +22, Type2Diabetes, 1031, 1046, "type 2 diabetes", "", " ." +23, Type2Diabetes, 1049, 1052, "T2D", "", +55489, PremixedInsulin, 1058, 1064, "premix", "", +24, Metformin, 1083, 1092, "metformin", "", +26, Randomized, 1104, 1114, "randomized", "", +27, InsulinGlargine, 1147, 1155, "glargine", "", " ." +28, InsulinGlulisine, 1160, 1169, "glulisine", "", " ." +35, NumberPatientsArm, 1176, 1179, "153", "", " \"153\"." +170, Mean, 1182, 1186, "mean", "", +41, AvgAge, 1205, 1229, "60 . 2 + / - 7 . 5 years", "", " \"60 . 2 + / - 7 . 5 years\"." +30, HbA1c, 1232, 1237, "HbA1c", "", +142, BaseLineValue, 1238, 1243, "8 . 6", "", " \"8 . 6\"." +146, SdDevBL, 1250, 1255, "0 . 8", "", " \"0 . 8\"." +31, Percentage, 1256, 1257, "%", "", +32, BodyWeight, 1260, 1266, "weight", "", +154, BaseLineValue, 1267, 1273, "87 . 0", "", " \"87 . 0\"." +148, SdDevBL, 1280, 1286, "15 . 1", "", " \"15 . 1\"." +33, Kg, 1287, 1289, "kg", "", +34, Type2Diabetes, 1292, 1295, "T2D", "", +55485, Duration, 1305, 1329, "12 . 8 + / - 5 . 8 years", "", +36, Frequency, 1335, 1348, "twice - daily", "", +55490, PremixedInsulin, 1349, 1355, "premix", "", +37, NumberPatientsArm, 1362, 1365, "157", "", " \"157\"." +40, AvgAge, 1372, 1396, "60 . 9 + / - 7 . 8 years", "", +42, HbA1c, 1399, 1404, "HbA1c", "", +143, BaseLineValue, 1405, 1410, "8 . 5", "", " \"8 . 5\"." +147, SdDevBL, 1417, 1422, "0 . 9", "", " \"0 . 9\"." +43, Percentage, 1423, 1424, "%", "", +44, BodyWeight, 1427, 1433, "weight", "", +155, BaseLineValue, 1434, 1440, "84 . 3", "", " \"84 . 3\"." +149, SdDevBL, 1447, 1453, "15 . 0", "", " \"15 . 0\"." +45, Kg, 1454, 1456, "kg", "", +46, Type2Diabetes, 1459, 1462, "T2D", "", +55484, Duration, 1472, 1496, "12 . 5 + / - 6 . 8 years", "", +47, HbA1c, 1536, 1541, "HbA1c", "", +242, TimePoint, 1547, 1555, "baseline", "", +243, TimePoint, 1559, 1567, "endpoint", "", +169, Mean, 1580, 1584, "Mean", "", " . ." +244, TimePoint, 1597, 1605, "baseline", "", +245, TimePoint, 1613, 1621, "endpoint", "", +48, HbA1c, 1622, 1627, "HbA1c", "", " ." +55491, PremixedInsulin, 1651, 1657, "premix", "", +49, Reduction, 1664, 1670, "1 . 31", "", " \"1 . 31\"." +50, Reduction, 1678, 1684, "0 . 80", "", " \"0 . 80\"." +51, Percentage, 1685, 1686, "%", "", " ." +52, DiffGroupAbsValue, 1702, 1711, "- 0 . 476", "", " \"- 0 . 476\"." +53, Percentage, 1712, 1713, "%", "", " \"- 0 . 476\"." +54, ConfIntervalDiff, 1716, 1747, "95 % Cl : - 0 . 714 , - 0 . 238", "", " \"95 % Cl : - 0 . 714 , - 0 . 238\"." +55, PvalueDiff, 1750, 1762, "p = 0 . 0001", "", " \"p = 0 . 0001\"." +56, HbA1c_target, 1798, 1818, "HbA1c < or = 7 . 0 %", "", " ." +180, Percentage, 1817, 1818, "%", "", +55492, PremixedInsulin, 1858, 1864, "premix", "", +57, NumberAffected, 1873, 1875, "68", "", " \"68\"." +59, PercentageAffected, 1878, 1884, "46 . 6", "", " \"46 . 6\"." +58, NumberAffected, 1894, 1896, "43", "", " \"43\"." +60, PercentageAffected, 1899, 1905, "27 . 9", "", " \"27 . 9\"." +61, PvalueDiff, 1912, 1924, "p = 0 . 0004", "", " \"p = 0 . 0004\"." +198, Mean, 1977, 1981, "mean", "", " . ." +55495, SubGroupDescription, 1996, 2003, "daytime", "", " \"daytime\". \"daytime\"." +66, Reduction, 2008, 2013, "2 . 7", "", " \"2 . 7\"." +70, SdDevChangeValue, 2020, 2025, "2 . 3", "", " \"2 . 3\"." +67, Reduction, 2033, 2038, "2 . 3", "", " \"2 . 3\"." +71, SdDevChangeValue, 2045, 2050, "2 . 5", "", " \"2 . 5\"." +74, Millimoles_per_litre, 2051, 2059, "mmol / l", "", " ." +76, PvalueDiff, 2062, 2074, "p = 0 . 0033", "", " \"p = 0 . 0033\"." +55494, SubGroupDescription, 2081, 2093, "postprandial", "", " \"postprandial\". \"postprandial\"." +68, Reduction, 2098, 2103, "3 . 1", "", " \"3 . 1\"." +72, SdDevChangeValue, 2110, 2115, "2 . 6", "", " \"2 . 6\"." +69, Reduction, 2123, 2128, "2 . 5", "", " \"2 . 5\"." +73, SdDevChangeValue, 2135, 2140, "2 . 8", "", " \"2 . 8\"." +75, Millimoles_per_litre, 2141, 2149, "mmol / l", "", +77, PvalueDiff, 2152, 2164, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +65, FastingPlasmaGlucose, 2167, 2180, "blood glucose", "", " ." +252, TimePoint, 2183, 2191, "Endpoint", "", " \"Endpoint\". \"Endpoint\"." +246, InsulinDose, 2192, 2211, "daily insulin doses", "", " . ." +78, ResultMeasuredValue, 2217, 2223, "98 . 0", "", " \"98 . 0\"." +80, SdDevResValue, 2230, 2236, "48 . 7", "", " \"48 . 7\"." +79, ResultMeasuredValue, 2242, 2248, "91 . 3", "", " \"91 . 3\"." +81, SdDevResValue, 2255, 2261, "44 . 3", "", " \"44 . 3\"." +212, Int_Unit, 2262, 2264, "IU", "", " ." +83, PvalueDiff, 2267, 2279, "p = 0 . 2104", "", " \"p = 0 . 2104\"." +214, Mean, 2284, 2288, "mean", "", " . ." +84, BodyWeight, 2289, 2295, "weight", "", " ." +85, Increment, 2307, 2312, "3 . 6", "", " \"3 . 6\"." +55496, SdDevChangeValue, 2319, 2324, "4 . 0", "", " \"4 . 0\"." +86, Increment, 2332, 2337, "2 . 2", "", " \"2 . 2\"." +55497, SdDevChangeValue, 2344, 2349, "4 . 5", "", " \"4 . 5\"." +89, Kg, 2350, 2352, "kg", "", " ." +90, PvalueDiff, 2355, 2367, "p = 0 . 0073", "", " \"p = 0 . 0073\"." +222, Mean, 2372, 2376, "Mean", "", " . ." +91, Hypoglycemia, 2395, 2408, "hypoglycaemic", "", " ." +55498, PremixedInsulin, 2439, 2445, "premix", "", +92, ResultMeasuredValue, 2450, 2457, "13 . 99", "", " \"13 . 99\"." +93, ResultMeasuredValue, 2462, 2469, "18 . 54", "", " \"18 . 54\"." +94, BioAndMedicalUnit, 2470, 2491, "events / patient year", "", " . ." +227, DiffGroupAbsValue, 2522, 2530, "- 3 . 90", "", " \"- 3 . 90\"." +96, ConfIntervalDiff, 2533, 2561, "95 % CI : - 10 . 40 , 2 . 60", "", " \"95 % CI : - 10 . 40 , 2 . 60\"." +97, PvalueDiff, 2564, 2576, "p = 0 . 2385", "", " \"p = 0 . 2385\"." +247, ConclusionComment, 2595, 2842, "An intensified basal - bolus regimen using glargine / glulisine results in a significantly superior glycaemic control vs . premix therapy in a population with long - standing insulin - treated T2D , with no increase in the rates of hypoglycaemia .", "", " \"An intensified basal - bolus regimen using glargine / glulisine results in a significantly superior glycaemic control vs . premix therapy in a population with long - standing insulin - treated T2D , with no increase in the rates of hypoglycaemia .\"." +98, InsulinGlargine, 2638, 2646, "glargine", "", +99, InsulinGlulisine, 2649, 2658, "glulisine", "", +55499, PremixedInsulin, 2718, 2724, "premix", "", +100, Insulin, 2770, 2777, "insulin", "", +101, Type2Diabetes, 2788, 2791, "T2D", "", +102, Hypoglycemia, 2827, 2840, "hypoglycaemia", "", +103, PMID, 2903, 2911, "20092584", "", " \"20092584\"." diff --git a/data/dm2 20092584_admin.n-triples b/data/dm2 20092584_admin.n-triples new file mode 100644 index 0000000..0a0ab5c --- /dev/null +++ b/data/dm2 20092584_admin.n-triples @@ -0,0 +1,266 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study ." . + "Fritsche A" . + "2010" . + "Diabetes Obes Metab ." . + "20092584" . + . + "Larbig M" . + "Owens D" . + "H ä ring HU" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy and safety of an intensified insulin regimen , using insulin glargine ( glargine ) once daily and pre - meal insulin glulisine ( glulisine ) ( basal - bolus ) , with a conventional therapy ," . + "310" . + "52 - week" . + . + . + . + "An intensified basal - bolus regimen using glargine / glulisine results in a significantly superior glycaemic control vs . premix therapy in a population with long - standing insulin - treated T2D , with no increase in the rates of hypoglycaemia ." . + . + . + . + . + . + "using premixed insulin ( premix ) twice daily ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with type 2 diabetes ( T2D ) on premix , with or without metformin" . + . + . + "60 . 2 + / - 7 . 5 years" . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm glargine+gluisine" . + "153" . + . + . + . + . + . + . + . + . + . + . + "Arm premixed" . + "157" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention glargine" . + . + "once daily" . + . + . + "Intervention gluisine" . + . + . + . + . + "Intervention premixed" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication glargine" . + . + . + . + . + "Medication gluisine" . + . + . + . + . + "Medication premixed" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c g+g" . + . + "8 . 6" . + "0 . 8" . + "1 . 31" . + . + "Outcome hba1c p" . + . + "8 . 5" . + "0 . 9" . + "0 . 80" . + . + "Outcome weight g+g" . + . + "87 . 0" . + "15 . 1" . + "3 . 6" . + "4 . 0" . + . + "Outcome weight p " . + . + "84 . 3" . + "15 . 0" . + "2 . 2" . + "4 . 5" . + . + "Outcome hba1c target g+g" . + . + "68" . + "46 . 6" . + . + "Outcome hba1c target p" . + . + "43" . + "27 . 9" . + . + "Outcome fpg sg daytime g+g" . + . + "2 . 7" . + "2 . 3" . + "daytime" . + . + "Outcome fpg sg daytime p" . + . + "2 . 3" . + "2 . 5" . + "daytime" . + . + "Outcome fpg sg postprandial g+g" . + . + "3 . 1" . + "2 . 6" . + "postprandial" . + . + "Outcome fpg sg postprandial p" . + . + "2 . 5" . + "2 . 8" . + "postprandial" . + . + "Outcome id g+g" . + . + "98 . 0" . + "48 . 7" . + "Endpoint" . + . + "Outcome id p " . + . + "91 . 3" . + "44 . 3" . + "Endpoint" . + . + "Outcome h g+g" . + . + "13 . 99" . + . + "Outcome h p" . + . + "18 . 54" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 476" . + "p = 0 . 0001" . + "95 % Cl : - 0 . 714 , - 0 . 238" . + . + . + . + "DiffBetweenGroups hba1c target" . + "p = 0 . 0004" . + . + . + . + "DiffBetweenGroups fpg sg daytime" . + "p = 0 . 0033" . + . + . + . + "DiffBetweenGroups fpg sg postprandial" . + "p < 0 . 0001" . + . + . + . + "DiffBetweenGroups id" . + "p = 0 . 2104" . + . + . + . + "DiffBetweenGroups weight" . + "p = 0 . 0073" . + . + . + . + "DiffBetweenGroups h" . + "- 3 . 90" . + "p = 0 . 2385" . + "95 % CI : - 10 . 40 , 2 . 60" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092584_akramersunderbrink.annodb b/data/dm2 20092584_akramersunderbrink.annodb new file mode 100644 index 0000000..45b5a28 --- /dev/null +++ b/data/dm2 20092584_akramersunderbrink.annodb @@ -0,0 +1,140 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +28845, Journal, 0, 19, "Diabetes Obes Metab", "", +28846, PublicationYear, 22, 26, "2010", "", +28849, Title, 110, 243, "Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "", +28848, Insulin, 160, 167, "insulin", "", +28847, Type2Diabetes, 196, 211, "type 2 diabetes", "", +28850, Author, 244, 254, "Fritsche A", "", +28851, Author, 263, 271, "Larbig M", "", +28852, Author, 274, 281, "Owens D", "", +28853, Author, 284, 295, "H ä ring HU", "", +28854, Germany, 507, 514, "Germany", "", +28865, ObjectiveDescription, 652, 906, "To compare the efficacy and safety of an intensified insulin regimen , using insulin glargine ( glargine ) once daily and pre - meal insulin glulisine ( glulisine ) ( basal - bolus ) , with a conventional therapy , using premixed insulin ( premix ) twice", "", +28855, Insulin, 705, 712, "insulin", "", +28856, InsulinGlargine, 729, 745, "insulin glargine", "", +28857, InsulinGlargine, 748, 756, "glargine", "", +28858, Frequency, 759, 769, "once daily", "", +28863, RelativeTime, 774, 784, "pre - meal", "", +28859, InsulinGlulisine, 785, 802, "insulin glulisine", "", +28861, InsulinGlulisine, 805, 814, "glulisine", "", +28908, Insulin, 873, 889, "premixed insulin", "", +28909, Insulin, 892, 898, "premix", "", +28862, Frequency, 901, 912, "twice daily", "", +28866, ObjectiveDescription, 907, 914, "daily .", "", +28864, Duration, 930, 939, "52 - week", "", +28867, OpenLabel, 942, 954, "open - label", "", +28868, Randomized, 957, 967, "randomized", "", +28869, Multicenter, 970, 983, "multinational", "", +28870, Multicenter, 986, 997, "multicentre", "", +28871, NumberPatientsCT, 1013, 1016, "310", "", +28872, Type2Diabetes, 1031, 1046, "type 2 diabetes", "", +28873, Type2Diabetes, 1049, 1052, "T2D", "", +28874, Metformin, 1083, 1092, "metformin", "", +28875, Randomized, 1104, 1114, "randomized", "", +28876, InsulinGlargine, 1147, 1155, "glargine", "", +28877, InsulinGlulisine, 1160, 1169, "glulisine", "", +28878, NumberPatientsArm, 1176, 1179, "153", "", +28913, Mean, 1182, 1186, "mean", "", +28880, AvgAge, 1205, 1211, "60 . 2", "", +28886, Year, 1224, 1229, "years", "", +28882, HbA1c, 1232, 1237, "HbA1c", "", +28884, BaseLineValue, 1238, 1243, "8 . 6", "", +28888, SdDevBL, 1244, 1255, "+ / - 0 . 8", "", +28892, Percentage, 1256, 1257, "%", "", +28894, BodyWeight, 1260, 1266, "weight", "", +28896, BaseLineValue, 1267, 1273, "87 . 0", "", +28890, SdDevBL, 1274, 1286, "+ / - 15 . 1", "", +28898, Kg, 1287, 1289, "kg", "", +28900, Precondition, 1292, 1329, "T2D duration 12 . 8 + / - 5 . 8 years", "", +28902, Type2Diabetes, 1292, 1295, "T2D", "", +28904, Year, 1324, 1329, "years", "", +28906, Frequency, 1335, 1348, "twice - daily", "", +28910, Insulin, 1349, 1355, "premix", "", +28879, NumberPatientsArm, 1362, 1365, "157", "", +28881, AvgAge, 1372, 1378, "60 . 9", "", +28887, Year, 1391, 1396, "years", "", +28883, HbA1c, 1399, 1404, "HbA1c", "", +28885, BaseLineValue, 1405, 1410, "8 . 5", "", +28889, SdDevBL, 1411, 1422, "+ / - 0 . 9", "", +28893, Percentage, 1423, 1424, "%", "", +28895, BodyWeight, 1427, 1433, "weight", "", +28897, BaseLineValue, 1434, 1440, "84 . 3", "", +28891, SdDevBL, 1441, 1453, "+ / - 15 . 0", "", +28899, Kg, 1454, 1456, "kg", "", +28901, Precondition, 1459, 1496, "T2D duration 12 . 5 + / - 6 . 8 years", "", +28903, Type2Diabetes, 1459, 1462, "T2D", "", +28905, Year, 1491, 1496, "years", "", +28911, HbA1c, 1536, 1541, "HbA1c", "", +39185, TimePoint, 1547, 1555, "baseline", "", +39186, TimePoint, 1559, 1567, "endpoint", "", +28912, Mean, 1580, 1584, "Mean", "", +39187, TimePoint, 1597, 1605, "baseline", "", +39188, TimePoint, 1613, 1621, "endpoint", "", +28914, HbA1c, 1622, 1627, "HbA1c", "", +28928, Insulin, 1651, 1657, "premix", "", +28915, ChangeValue, 1662, 1670, "- 1 . 31", "", +28916, ChangeValue, 1676, 1684, "- 0 . 80", "", +28917, Percentage, 1685, 1686, "%", "", +28923, DiffGroupAbsValue, 1702, 1711, "- 0 . 476", "", +28918, Percentage, 1712, 1713, "%", "", +28920, ConfIntervalDiff, 1716, 1747, "95 % Cl : - 0 . 714 , - 0 . 238", "", +28919, Percentage, 1719, 1720, "%", "", +28922, PvalueDiff, 1750, 1762, "p = 0 . 0001", "", +28936, HbA1c_target, 1798, 1818, "HbA1c < or = 7 . 0 %", "", +28926, Percentage, 1817, 1818, "%", "", +28927, Insulin, 1858, 1864, "premix", "", +28929, NumberAffected, 1873, 1875, "68", "", +28931, PercentageAffected, 1878, 1884, "46 . 6", "", +28933, Percentage, 1885, 1886, "%", "", +28930, NumberAffected, 1894, 1896, "43", "", +28932, PercentageAffected, 1899, 1905, "27 . 9", "", +28934, Percentage, 1906, 1907, "%", "", +28935, PvalueDiff, 1912, 1924, "p = 0 . 0004", "", +28944, Mean, 1977, 1981, "mean", "", +28942, EndPointDescription, 1996, 2003, "daytime", "", +28938, ChangeValue, 2006, 2013, "- 2 . 7", "", +28945, SdDevChangeValue, 2014, 2025, "+ / - 2 . 3", "", +28939, ChangeValue, 2031, 2038, "- 2 . 3", "", +28946, SdDevChangeValue, 2039, 2050, "+ / - 2 . 5", "", +28949, Millimoles_per_litre, 2051, 2059, "mmol / l", "", +28951, PvalueDiff, 2062, 2074, "p = 0 . 0033", "", +28937, InsulinDose, 2081, 2093, "postprandial", "", +28940, ChangeValue, 2096, 2103, "- 3 . 1", "", +28947, SdDevChangeValue, 2104, 2115, "+ / - 2 . 6", "", +28941, ChangeValue, 2121, 2128, "- 2 . 5", "", +28948, SdDevChangeValue, 2129, 2140, "+ / - 2 . 8", "", +28950, Millimoles_per_litre, 2141, 2149, "mmol / l", "", +28952, PvalueDiff, 2152, 2164, "p < 0 . 0001", "", +28943, EndPointDescription, 2167, 2180, "blood glucose", "", +39189, TimePoint, 2183, 2191, "Endpoint", "", +28953, EndPointDescription, 2192, 2211, "daily insulin doses", "", +28954, ResultMeasuredValue, 2217, 2223, "98 . 0", "", +28956, SdDevResValue, 2224, 2236, "+ / - 48 . 7", "", +28955, ResultMeasuredValue, 2242, 2248, "91 . 3", "", +28957, SdDevResValue, 2249, 2261, "+ / - 44 . 3", "", +28958, Int_Unit, 2262, 2264, "IU", "", +28959, PvalueDiff, 2267, 2279, "p = 0 . 2104", "", +28960, Mean, 2284, 2288, "mean", "", +28961, WeightGain, 2289, 2300, "weight gain", "", +28962, ResultMeasuredValue, 2305, 2312, "+ 3 . 6", "", +28964, SdDevResValue, 2313, 2324, "+ / - 4 . 0", "", +28963, ResultMeasuredValue, 2330, 2337, "+ 2 . 2", "", +28965, SdDevResValue, 2338, 2349, "+ / - 4 . 5", "", +28966, Kg, 2350, 2352, "kg", "", +28968, PvalueDiff, 2355, 2367, "p = 0 . 0073", "", +28969, Mean, 2372, 2376, "Mean", "", +28970, Hypoglycemia, 2377, 2415, "number of overall hypoglycaemic events", "", +28971, ResultMeasuredValue, 2450, 2457, "13 . 99", "", +28972, ResultMeasuredValue, 2462, 2469, "18 . 54", "", +28973, BioAndMedicalUnit, 2470, 2491, "events / patient year", "", +28974, DiffGroupAbsValue, 2522, 2530, "- 3 . 90", "", +28975, ConfIntervalDiff, 2533, 2561, "95 % CI : - 10 . 40 , 2 . 60", "", +28976, Percentage, 2536, 2537, "%", "", +28977, PvalueDiff, 2564, 2576, "p = 0 . 2385", "", +28978, InsulinGlargine, 2638, 2646, "glargine", "", +28979, InsulinGlulisine, 2649, 2658, "glulisine", "", +28980, Insulin, 2718, 2724, "premix", "", +28982, Precondition, 2754, 2787, "long - standing insulin - treated", "", +28981, Type2Diabetes, 2788, 2791, "T2D", "", +28983, Hypoglycemia, 2827, 2840, "hypoglycaemia", "", +28984, PMID, 2903, 2911, "20092584", "", diff --git a/data/dm2 20092584_akramersunderbrink.n-triples b/data/dm2 20092584_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20092584_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092584_export.csv b/data/dm2 20092584_export.csv new file mode 100644 index 0000000..ede696c --- /dev/null +++ b/data/dm2 20092584_export.csv @@ -0,0 +1,772 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +333, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +333, 1, 2, 2, 9, 13, 9, 13, "Obes" +333, 1, 3, 3, 14, 19, 14, 19, "Metab" +333, 1, 4, 4, 20, 21, 20, 21, "." +333, 2, 1, 5, 0, 4, 22, 26, "2010" +333, 2, 2, 6, 5, 8, 27, 30, "Feb" +333, 2, 3, 7, 9, 10, 31, 32, ";" +333, 2, 4, 8, 11, 13, 33, 35, "12" +333, 2, 5, 9, 14, 15, 36, 37, "(" +333, 2, 6, 10, 16, 17, 38, 39, "2" +333, 2, 7, 11, 18, 19, 40, 41, ")" +333, 2, 8, 12, 20, 21, 42, 43, ":" +333, 2, 9, 13, 22, 25, 44, 47, "115" +333, 2, 10, 14, 26, 27, 48, 49, "-" +333, 2, 11, 15, 28, 30, 50, 52, "23" +333, 2, 12, 16, 31, 32, 53, 54, "." +333, 2, 13, 17, 33, 36, 55, 58, "doi" +333, 2, 14, 18, 37, 38, 59, 60, ":" +333, 2, 15, 19, 39, 41, 61, 63, "10" +333, 2, 16, 20, 42, 43, 64, 65, "." +333, 2, 17, 21, 44, 48, 66, 70, "1111" +333, 2, 18, 22, 49, 50, 71, 72, "/" +333, 2, 19, 23, 51, 52, 73, 74, "j" +333, 2, 20, 24, 53, 54, 75, 76, "." +333, 2, 21, 25, 55, 59, 77, 81, "1463" +333, 2, 22, 26, 60, 61, 82, 83, "-" +333, 2, 23, 27, 62, 66, 84, 88, "1326" +333, 2, 24, 28, 67, 68, 89, 90, "." +333, 2, 25, 29, 69, 73, 91, 95, "2009" +333, 2, 26, 30, 74, 75, 96, 97, "." +333, 2, 27, 31, 76, 81, 98, 103, "01165" +333, 2, 28, 32, 82, 83, 104, 105, "." +333, 2, 29, 33, 84, 85, 106, 107, "x" +333, 2, 30, 34, 86, 87, 108, 109, "." +333, 3, 1, 35, 0, 10, 110, 120, "Comparison" +333, 3, 2, 36, 11, 18, 121, 128, "between" +333, 3, 3, 37, 19, 20, 129, 130, "a" +333, 3, 4, 38, 21, 26, 131, 136, "basal" +333, 3, 5, 39, 27, 28, 137, 138, "-" +333, 3, 6, 40, 29, 34, 139, 144, "bolus" +333, 3, 7, 41, 35, 38, 145, 148, "and" +333, 3, 8, 42, 39, 40, 149, 150, "a" +333, 3, 9, 43, 41, 49, 151, 159, "premixed" +333, 3, 10, 44, 50, 57, 160, 167, "insulin" +333, 3, 11, 45, 58, 65, 168, 175, "regimen" +333, 3, 12, 46, 66, 68, 176, 178, "in" +333, 3, 13, 47, 69, 80, 179, 190, "individuals" +333, 3, 14, 48, 81, 85, 191, 195, "with" +333, 3, 15, 49, 86, 90, 196, 200, "type" +333, 3, 16, 50, 91, 92, 201, 202, "2" +333, 3, 17, 51, 93, 101, 203, 211, "diabetes" +333, 3, 18, 52, 102, 103, 212, 213, "-" +333, 3, 19, 53, 104, 111, 214, 221, "results" +333, 3, 20, 54, 112, 114, 222, 224, "of" +333, 3, 21, 55, 115, 118, 225, 228, "the" +333, 3, 22, 56, 119, 125, 229, 235, "GINGER" +333, 3, 23, 57, 126, 131, 236, 241, "study" +333, 3, 24, 58, 132, 133, 242, 243, "." +333, 4, 1, 59, 0, 8, 244, 252, "Fritsche" +333, 4, 2, 60, 9, 10, 253, 254, "A" +333, 4, 3, 61, 11, 12, 255, 256, "(" +333, 4, 4, 62, 13, 14, 257, 258, "1" +333, 4, 5, 63, 15, 16, 259, 260, ")" +333, 4, 6, 64, 17, 18, 261, 262, "," +333, 4, 7, 65, 19, 25, 263, 269, "Larbig" +333, 4, 8, 66, 26, 27, 270, 271, "M" +333, 4, 9, 67, 28, 29, 272, 273, "," +333, 4, 10, 68, 30, 35, 274, 279, "Owens" +333, 4, 11, 69, 36, 37, 280, 281, "D" +333, 4, 12, 70, 38, 39, 282, 283, "," +333, 4, 13, 71, 40, 41, 284, 285, "H" +333, 4, 14, 72, 42, 43, 286, 287, "ä" +333, 4, 15, 73, 44, 48, 288, 292, "ring" +333, 4, 16, 74, 49, 51, 293, 295, "HU" +333, 4, 17, 75, 52, 53, 296, 297, ";" +333, 4, 18, 76, 54, 60, 298, 304, "GINGER" +333, 4, 19, 77, 61, 66, 305, 310, "study" +333, 4, 20, 78, 67, 72, 311, 316, "group" +333, 4, 21, 79, 73, 74, 317, 318, "." +333, 5, 1, 80, 0, 6, 319, 325, "Author" +333, 5, 2, 81, 7, 18, 326, 337, "information" +333, 5, 3, 82, 19, 20, 338, 339, ":" +333, 5, 4, 83, 21, 22, 340, 341, "(" +333, 5, 5, 84, 23, 24, 342, 343, "1" +333, 5, 6, 85, 25, 26, 344, 345, ")" +333, 5, 7, 86, 27, 39, 346, 358, "Medizinische" +333, 5, 8, 87, 40, 49, 359, 368, "Universit" +333, 5, 9, 88, 50, 51, 369, 370, "ä" +333, 5, 10, 89, 52, 60, 371, 379, "tsklinik" +333, 5, 11, 90, 61, 62, 380, 381, "," +333, 5, 12, 91, 63, 72, 382, 391, "Abteilung" +333, 5, 13, 92, 73, 74, 392, 393, "f" +333, 5, 14, 93, 75, 76, 394, 395, "ü" +333, 5, 15, 94, 77, 78, 396, 397, "r" +333, 5, 16, 95, 79, 93, 398, 412, "Endokrinologie" +333, 5, 17, 96, 94, 95, 413, 414, "," +333, 5, 18, 97, 96, 108, 415, 427, "Stoffwechsel" +333, 5, 19, 98, 109, 112, 428, 431, "und" +333, 5, 20, 99, 113, 127, 432, 446, "Pathobiochemie" +333, 5, 21, 100, 128, 129, 447, 448, "," +333, 5, 22, 101, 130, 138, 449, 457, "Eberhard" +333, 5, 23, 102, 139, 140, 458, 459, "-" +333, 5, 24, 103, 141, 146, 460, 465, "Karls" +333, 5, 25, 104, 147, 148, 466, 467, "-" +333, 5, 26, 105, 149, 158, 468, 477, "Universit" +333, 5, 27, 106, 159, 160, 478, 479, "ä" +333, 5, 28, 107, 161, 162, 480, 481, "t" +333, 5, 29, 108, 163, 164, 482, 483, "," +333, 5, 30, 109, 165, 166, 484, 485, "D" +333, 5, 31, 110, 167, 168, 486, 487, "-" +333, 5, 32, 111, 169, 174, 488, 493, "72076" +333, 5, 33, 112, 175, 176, 494, 495, "T" +333, 5, 34, 113, 177, 178, 496, 497, "ü" +333, 5, 35, 114, 179, 185, 498, 504, "bingen" +333, 5, 36, 115, 186, 187, 505, 506, "," +333, 5, 37, 116, 188, 195, 507, 514, "Germany" +333, 5, 38, 117, 196, 197, 515, 516, "." +333, 6, 1, 118, 0, 7, 517, 524, "Erratum" +333, 6, 2, 119, 8, 10, 525, 527, "in" +333, 6, 3, 120, 11, 19, 528, 536, "Diabetes" +333, 6, 4, 121, 20, 24, 537, 541, "Obes" +333, 6, 5, 122, 25, 30, 542, 547, "Metab" +333, 6, 6, 123, 31, 32, 548, 549, "." +333, 7, 1, 124, 0, 4, 550, 554, "2010" +333, 7, 2, 125, 5, 8, 555, 558, "Nov" +333, 7, 3, 126, 9, 10, 559, 560, ";" +333, 7, 4, 127, 11, 13, 561, 563, "12" +333, 7, 5, 128, 14, 15, 564, 565, "(" +333, 7, 6, 129, 16, 18, 566, 568, "11" +333, 7, 7, 130, 19, 20, 569, 570, ")" +333, 7, 8, 131, 21, 22, 571, 572, ":" +333, 7, 9, 132, 23, 27, 573, 577, "1022" +333, 7, 10, 133, 28, 29, 578, 579, "." +333, 8, 1, 134, 0, 7, 580, 587, "Comment" +333, 8, 2, 135, 8, 10, 588, 590, "in" +333, 8, 3, 136, 11, 19, 591, 599, "Diabetes" +333, 8, 4, 137, 20, 24, 600, 604, "Obes" +333, 8, 5, 138, 25, 30, 605, 610, "Metab" +333, 8, 6, 139, 31, 32, 611, 612, "." +333, 9, 1, 140, 0, 4, 613, 617, "2010" +333, 9, 2, 141, 5, 8, 618, 621, "Oct" +333, 9, 3, 142, 9, 10, 622, 623, ";" +333, 9, 4, 143, 11, 13, 624, 626, "12" +333, 9, 5, 144, 14, 15, 627, 628, "(" +333, 9, 6, 145, 16, 18, 629, 631, "10" +333, 9, 7, 146, 19, 20, 632, 633, ")" +333, 9, 8, 147, 21, 22, 634, 635, ":" +333, 9, 9, 148, 23, 26, 636, 639, "926" +333, 9, 10, 149, 27, 28, 640, 641, "-" +333, 9, 11, 150, 29, 30, 642, 643, "7" +333, 9, 12, 151, 31, 32, 644, 645, "." +333, 10, 1, 152, 0, 3, 646, 649, "AIM" +333, 10, 2, 153, 4, 5, 650, 651, ":" +333, 10, 3, 154, 6, 8, 652, 654, "To" +333, 10, 4, 155, 9, 16, 655, 662, "compare" +333, 10, 5, 156, 17, 20, 663, 666, "the" +333, 10, 6, 157, 21, 29, 667, 675, "efficacy" +333, 10, 7, 158, 30, 33, 676, 679, "and" +333, 10, 8, 159, 34, 40, 680, 686, "safety" +333, 10, 9, 160, 41, 43, 687, 689, "of" +333, 10, 10, 161, 44, 46, 690, 692, "an" +333, 10, 11, 162, 47, 58, 693, 704, "intensified" +333, 10, 12, 163, 59, 66, 705, 712, "insulin" +333, 10, 13, 164, 67, 74, 713, 720, "regimen" +333, 10, 14, 165, 75, 76, 721, 722, "," +333, 10, 15, 166, 77, 82, 723, 728, "using" +333, 10, 16, 167, 83, 90, 729, 736, "insulin" +333, 10, 17, 168, 91, 99, 737, 745, "glargine" +333, 10, 18, 169, 100, 101, 746, 747, "(" +333, 10, 19, 170, 102, 110, 748, 756, "glargine" +333, 10, 20, 171, 111, 112, 757, 758, ")" +333, 10, 21, 172, 113, 117, 759, 763, "once" +333, 10, 22, 173, 118, 123, 764, 769, "daily" +333, 10, 23, 174, 124, 127, 770, 773, "and" +333, 10, 24, 175, 128, 131, 774, 777, "pre" +333, 10, 25, 176, 132, 133, 778, 779, "-" +333, 10, 26, 177, 134, 138, 780, 784, "meal" +333, 10, 27, 178, 139, 146, 785, 792, "insulin" +333, 10, 28, 179, 147, 156, 793, 802, "glulisine" +333, 10, 29, 180, 157, 158, 803, 804, "(" +333, 10, 30, 181, 159, 168, 805, 814, "glulisine" +333, 10, 31, 182, 169, 170, 815, 816, ")" +333, 10, 32, 183, 171, 172, 817, 818, "(" +333, 10, 33, 184, 173, 178, 819, 824, "basal" +333, 10, 34, 185, 179, 180, 825, 826, "-" +333, 10, 35, 186, 181, 186, 827, 832, "bolus" +333, 10, 36, 187, 187, 188, 833, 834, ")" +333, 10, 37, 188, 189, 190, 835, 836, "," +333, 10, 38, 189, 191, 195, 837, 841, "with" +333, 10, 39, 190, 196, 197, 842, 843, "a" +333, 10, 40, 191, 198, 210, 844, 856, "conventional" +333, 10, 41, 192, 211, 218, 857, 864, "therapy" +333, 10, 42, 193, 219, 220, 865, 866, "," +333, 10, 43, 194, 221, 226, 867, 872, "using" +333, 10, 44, 195, 227, 235, 873, 881, "premixed" +333, 10, 45, 196, 236, 243, 882, 889, "insulin" +333, 10, 46, 197, 244, 245, 890, 891, "(" +333, 10, 47, 198, 246, 252, 892, 898, "premix" +333, 10, 48, 199, 253, 254, 899, 900, ")" +333, 10, 49, 200, 255, 260, 901, 906, "twice" +333, 10, 50, 201, 261, 266, 907, 912, "daily" +333, 10, 51, 202, 267, 268, 913, 914, "." +333, 11, 1, 203, 0, 7, 915, 922, "METHODS" +333, 11, 2, 204, 8, 9, 923, 924, ":" +333, 11, 3, 205, 10, 14, 925, 929, "This" +333, 11, 4, 206, 15, 17, 930, 932, "52" +333, 11, 5, 207, 18, 19, 933, 934, "-" +333, 11, 6, 208, 20, 24, 935, 939, "week" +333, 11, 7, 209, 25, 26, 940, 941, "," +333, 11, 8, 210, 27, 31, 942, 946, "open" +333, 11, 9, 211, 32, 33, 947, 948, "-" +333, 11, 10, 212, 34, 39, 949, 954, "label" +333, 11, 11, 213, 40, 41, 955, 956, "," +333, 11, 12, 214, 42, 52, 957, 967, "randomized" +333, 11, 13, 215, 53, 54, 968, 969, "," +333, 11, 14, 216, 55, 68, 970, 983, "multinational" +333, 11, 15, 217, 69, 70, 984, 985, "," +333, 11, 16, 218, 71, 82, 986, 997, "multicentre" +333, 11, 17, 219, 83, 88, 998, 1003, "trial" +333, 11, 18, 220, 89, 97, 1004, 1012, "included" +333, 11, 19, 221, 98, 101, 1013, 1016, "310" +333, 11, 20, 222, 102, 110, 1017, 1025, "subjects" +333, 11, 21, 223, 111, 115, 1026, 1030, "with" +333, 11, 22, 224, 116, 120, 1031, 1035, "type" +333, 11, 23, 225, 121, 122, 1036, 1037, "2" +333, 11, 24, 226, 123, 131, 1038, 1046, "diabetes" +333, 11, 25, 227, 132, 133, 1047, 1048, "(" +333, 11, 26, 228, 134, 137, 1049, 1052, "T2D" +333, 11, 27, 229, 138, 139, 1053, 1054, ")" +333, 11, 28, 230, 140, 142, 1055, 1057, "on" +333, 11, 29, 231, 143, 149, 1058, 1064, "premix" +333, 11, 30, 232, 150, 151, 1065, 1066, "," +333, 11, 31, 233, 152, 156, 1067, 1071, "with" +333, 11, 32, 234, 157, 159, 1072, 1074, "or" +333, 11, 33, 235, 160, 167, 1075, 1082, "without" +333, 11, 34, 236, 168, 177, 1083, 1092, "metformin" +333, 11, 35, 237, 178, 179, 1093, 1094, "," +333, 11, 36, 238, 180, 183, 1095, 1098, "who" +333, 11, 37, 239, 184, 188, 1099, 1103, "were" +333, 11, 38, 240, 189, 199, 1104, 1114, "randomized" +333, 11, 39, 241, 200, 202, 1115, 1117, "to" +333, 11, 40, 242, 203, 204, 1118, 1119, "a" +333, 11, 41, 243, 205, 210, 1120, 1125, "basal" +333, 11, 42, 244, 211, 212, 1126, 1127, "-" +333, 11, 43, 245, 213, 218, 1128, 1133, "bolus" +333, 11, 44, 246, 219, 226, 1134, 1141, "regimen" +333, 11, 45, 247, 227, 231, 1142, 1146, "with" +333, 11, 46, 248, 232, 240, 1147, 1155, "glargine" +333, 11, 47, 249, 241, 244, 1156, 1159, "and" +333, 11, 48, 250, 245, 254, 1160, 1169, "glulisine" +333, 11, 49, 251, 255, 256, 1170, 1171, "(" +333, 11, 50, 252, 257, 258, 1172, 1173, "n" +333, 11, 51, 253, 259, 260, 1174, 1175, "=" +333, 11, 52, 254, 261, 264, 1176, 1179, "153" +333, 11, 53, 255, 265, 266, 1180, 1181, ";" +333, 11, 54, 256, 267, 271, 1182, 1186, "mean" +333, 11, 55, 257, 272, 273, 1187, 1188, "+" +333, 11, 56, 258, 274, 275, 1189, 1190, "/" +333, 11, 57, 259, 276, 277, 1191, 1192, "-" +333, 11, 58, 260, 278, 279, 1193, 1194, "s" +333, 11, 59, 261, 280, 281, 1195, 1196, "." +333, 11, 60, 262, 282, 283, 1197, 1198, "d" +333, 11, 61, 263, 284, 285, 1199, 1200, "." +333, 12, 1, 264, 0, 3, 1201, 1204, "age" +333, 12, 2, 265, 4, 6, 1205, 1207, "60" +333, 12, 3, 266, 7, 8, 1208, 1209, "." +333, 12, 4, 267, 9, 10, 1210, 1211, "2" +333, 12, 5, 268, 11, 12, 1212, 1213, "+" +333, 12, 6, 269, 13, 14, 1214, 1215, "/" +333, 12, 7, 270, 15, 16, 1216, 1217, "-" +333, 12, 8, 271, 17, 18, 1218, 1219, "7" +333, 12, 9, 272, 19, 20, 1220, 1221, "." +333, 12, 10, 273, 21, 22, 1222, 1223, "5" +333, 12, 11, 274, 23, 28, 1224, 1229, "years" +333, 12, 12, 275, 29, 30, 1230, 1231, ";" +333, 12, 13, 276, 31, 36, 1232, 1237, "HbA1c" +333, 12, 14, 277, 37, 38, 1238, 1239, "8" +333, 12, 15, 278, 39, 40, 1240, 1241, "." +333, 12, 16, 279, 41, 42, 1242, 1243, "6" +333, 12, 17, 280, 43, 44, 1244, 1245, "+" +333, 12, 18, 281, 45, 46, 1246, 1247, "/" +333, 12, 19, 282, 47, 48, 1248, 1249, "-" +333, 12, 20, 283, 49, 50, 1250, 1251, "0" +333, 12, 21, 284, 51, 52, 1252, 1253, "." +333, 12, 22, 285, 53, 54, 1254, 1255, "8" +333, 12, 23, 286, 55, 56, 1256, 1257, "%" +333, 12, 24, 287, 57, 58, 1258, 1259, ";" +333, 12, 25, 288, 59, 65, 1260, 1266, "weight" +333, 12, 26, 289, 66, 68, 1267, 1269, "87" +333, 12, 27, 290, 69, 70, 1270, 1271, "." +333, 12, 28, 291, 71, 72, 1272, 1273, "0" +333, 12, 29, 292, 73, 74, 1274, 1275, "+" +333, 12, 30, 293, 75, 76, 1276, 1277, "/" +333, 12, 31, 294, 77, 78, 1278, 1279, "-" +333, 12, 32, 295, 79, 81, 1280, 1282, "15" +333, 12, 33, 296, 82, 83, 1283, 1284, "." +333, 12, 34, 297, 84, 85, 1285, 1286, "1" +333, 12, 35, 298, 86, 88, 1287, 1289, "kg" +333, 12, 36, 299, 89, 90, 1290, 1291, ";" +333, 12, 37, 300, 91, 94, 1292, 1295, "T2D" +333, 12, 38, 301, 95, 103, 1296, 1304, "duration" +333, 12, 39, 302, 104, 106, 1305, 1307, "12" +333, 12, 40, 303, 107, 108, 1308, 1309, "." +333, 12, 41, 304, 109, 110, 1310, 1311, "8" +333, 12, 42, 305, 111, 112, 1312, 1313, "+" +333, 12, 43, 306, 113, 114, 1314, 1315, "/" +333, 12, 44, 307, 115, 116, 1316, 1317, "-" +333, 12, 45, 308, 117, 118, 1318, 1319, "5" +333, 12, 46, 309, 119, 120, 1320, 1321, "." +333, 12, 47, 310, 121, 122, 1322, 1323, "8" +333, 12, 48, 311, 123, 128, 1324, 1329, "years" +333, 12, 49, 312, 129, 130, 1330, 1331, ")" +333, 12, 50, 313, 131, 133, 1332, 1334, "or" +333, 12, 51, 314, 134, 139, 1335, 1340, "twice" +333, 12, 52, 315, 140, 141, 1341, 1342, "-" +333, 12, 53, 316, 142, 147, 1343, 1348, "daily" +333, 12, 54, 317, 148, 154, 1349, 1355, "premix" +333, 12, 55, 318, 155, 156, 1356, 1357, "(" +333, 12, 56, 319, 157, 158, 1358, 1359, "n" +333, 12, 57, 320, 159, 160, 1360, 1361, "=" +333, 12, 58, 321, 161, 164, 1362, 1365, "157" +333, 12, 59, 322, 165, 166, 1366, 1367, ";" +333, 12, 60, 323, 167, 170, 1368, 1371, "age" +333, 12, 61, 324, 171, 173, 1372, 1374, "60" +333, 12, 62, 325, 174, 175, 1375, 1376, "." +333, 12, 63, 326, 176, 177, 1377, 1378, "9" +333, 12, 64, 327, 178, 179, 1379, 1380, "+" +333, 12, 65, 328, 180, 181, 1381, 1382, "/" +333, 12, 66, 329, 182, 183, 1383, 1384, "-" +333, 12, 67, 330, 184, 185, 1385, 1386, "7" +333, 12, 68, 331, 186, 187, 1387, 1388, "." +333, 12, 69, 332, 188, 189, 1389, 1390, "8" +333, 12, 70, 333, 190, 195, 1391, 1396, "years" +333, 12, 71, 334, 196, 197, 1397, 1398, ";" +333, 12, 72, 335, 198, 203, 1399, 1404, "HbA1c" +333, 12, 73, 336, 204, 205, 1405, 1406, "8" +333, 12, 74, 337, 206, 207, 1407, 1408, "." +333, 12, 75, 338, 208, 209, 1409, 1410, "5" +333, 12, 76, 339, 210, 211, 1411, 1412, "+" +333, 12, 77, 340, 212, 213, 1413, 1414, "/" +333, 12, 78, 341, 214, 215, 1415, 1416, "-" +333, 12, 79, 342, 216, 217, 1417, 1418, "0" +333, 12, 80, 343, 218, 219, 1419, 1420, "." +333, 12, 81, 344, 220, 221, 1421, 1422, "9" +333, 12, 82, 345, 222, 223, 1423, 1424, "%" +333, 12, 83, 346, 224, 225, 1425, 1426, ";" +333, 12, 84, 347, 226, 232, 1427, 1433, "weight" +333, 12, 85, 348, 233, 235, 1434, 1436, "84" +333, 12, 86, 349, 236, 237, 1437, 1438, "." +333, 12, 87, 350, 238, 239, 1439, 1440, "3" +333, 12, 88, 351, 240, 241, 1441, 1442, "+" +333, 12, 89, 352, 242, 243, 1443, 1444, "/" +333, 12, 90, 353, 244, 245, 1445, 1446, "-" +333, 12, 91, 354, 246, 248, 1447, 1449, "15" +333, 12, 92, 355, 249, 250, 1450, 1451, "." +333, 12, 93, 356, 251, 252, 1452, 1453, "0" +333, 12, 94, 357, 253, 255, 1454, 1456, "kg" +333, 12, 95, 358, 256, 257, 1457, 1458, ";" +333, 12, 96, 359, 258, 261, 1459, 1462, "T2D" +333, 12, 97, 360, 262, 270, 1463, 1471, "duration" +333, 12, 98, 361, 271, 273, 1472, 1474, "12" +333, 12, 99, 362, 274, 275, 1475, 1476, "." +333, 12, 100, 363, 276, 277, 1477, 1478, "5" +333, 12, 101, 364, 278, 279, 1479, 1480, "+" +333, 12, 102, 365, 280, 281, 1481, 1482, "/" +333, 12, 103, 366, 282, 283, 1483, 1484, "-" +333, 12, 104, 367, 284, 285, 1485, 1486, "6" +333, 12, 105, 368, 286, 287, 1487, 1488, "." +333, 12, 106, 369, 288, 289, 1489, 1490, "8" +333, 12, 107, 370, 290, 295, 1491, 1496, "years" +333, 12, 108, 371, 296, 297, 1497, 1498, ")" +333, 12, 109, 372, 298, 299, 1499, 1500, "." +333, 13, 1, 373, 0, 3, 1501, 1504, "The" +333, 13, 2, 374, 4, 11, 1505, 1512, "primary" +333, 13, 3, 375, 12, 20, 1513, 1521, "endpoint" +333, 13, 4, 376, 21, 24, 1522, 1525, "was" +333, 13, 5, 377, 25, 31, 1526, 1532, "change" +333, 13, 6, 378, 32, 34, 1533, 1535, "in" +333, 13, 7, 379, 35, 40, 1536, 1541, "HbA1c" +333, 13, 8, 380, 41, 45, 1542, 1546, "from" +333, 13, 9, 381, 46, 54, 1547, 1555, "baseline" +333, 13, 10, 382, 55, 57, 1556, 1558, "to" +333, 13, 11, 383, 58, 66, 1559, 1567, "endpoint" +333, 13, 12, 384, 67, 68, 1568, 1569, "." +333, 14, 1, 385, 0, 7, 1570, 1577, "RESULTS" +333, 14, 2, 386, 8, 9, 1578, 1579, ":" +333, 14, 3, 387, 10, 14, 1580, 1584, "Mean" +333, 14, 4, 388, 15, 23, 1585, 1593, "decrease" +333, 14, 5, 389, 24, 26, 1594, 1596, "in" +333, 14, 6, 390, 27, 35, 1597, 1605, "baseline" +333, 14, 7, 391, 36, 37, 1606, 1607, "-" +333, 14, 8, 392, 38, 40, 1608, 1610, "to" +333, 14, 9, 393, 41, 42, 1611, 1612, "-" +333, 14, 10, 394, 43, 51, 1613, 1621, "endpoint" +333, 14, 11, 395, 52, 57, 1622, 1627, "HbA1c" +333, 14, 12, 396, 58, 61, 1628, 1631, "for" +333, 14, 13, 397, 62, 67, 1632, 1637, "basal" +333, 14, 14, 398, 68, 69, 1638, 1639, "-" +333, 14, 15, 399, 70, 75, 1640, 1645, "bolus" +333, 14, 16, 400, 76, 78, 1646, 1648, "vs" +333, 14, 17, 401, 79, 80, 1649, 1650, "." +333, 14, 18, 402, 81, 87, 1651, 1657, "premix" +333, 14, 19, 403, 88, 91, 1658, 1661, "was" +333, 14, 20, 404, 92, 93, 1662, 1663, "-" +333, 14, 21, 405, 94, 95, 1664, 1665, "1" +333, 14, 22, 406, 96, 97, 1666, 1667, "." +333, 14, 23, 407, 98, 100, 1668, 1670, "31" +333, 14, 24, 408, 101, 103, 1671, 1673, "vs" +333, 14, 25, 409, 104, 105, 1674, 1675, "." +333, 14, 26, 410, 106, 107, 1676, 1677, "-" +333, 14, 27, 411, 108, 109, 1678, 1679, "0" +333, 14, 28, 412, 110, 111, 1680, 1681, "." +333, 14, 29, 413, 112, 114, 1682, 1684, "80" +333, 14, 30, 414, 115, 116, 1685, 1686, "%" +333, 14, 31, 415, 117, 118, 1687, 1688, "(" +333, 14, 32, 416, 119, 129, 1689, 1699, "difference" +333, 14, 33, 417, 130, 131, 1700, 1701, ":" +333, 14, 34, 418, 132, 133, 1702, 1703, "-" +333, 14, 35, 419, 134, 135, 1704, 1705, "0" +333, 14, 36, 420, 136, 137, 1706, 1707, "." +333, 14, 37, 421, 138, 141, 1708, 1711, "476" +333, 14, 38, 422, 142, 143, 1712, 1713, "%" +333, 14, 39, 423, 144, 145, 1714, 1715, ";" +333, 14, 40, 424, 146, 148, 1716, 1718, "95" +333, 14, 41, 425, 149, 150, 1719, 1720, "%" +333, 14, 42, 426, 151, 153, 1721, 1723, "Cl" +333, 14, 43, 427, 154, 155, 1724, 1725, ":" +333, 14, 44, 428, 156, 157, 1726, 1727, "-" +333, 14, 45, 429, 158, 159, 1728, 1729, "0" +333, 14, 46, 430, 160, 161, 1730, 1731, "." +333, 14, 47, 431, 162, 165, 1732, 1735, "714" +333, 14, 48, 432, 166, 167, 1736, 1737, "," +333, 14, 49, 433, 168, 169, 1738, 1739, "-" +333, 14, 50, 434, 170, 171, 1740, 1741, "0" +333, 14, 51, 435, 172, 173, 1742, 1743, "." +333, 14, 52, 436, 174, 177, 1744, 1747, "238" +333, 14, 53, 437, 178, 179, 1748, 1749, ";" +333, 14, 54, 438, 180, 181, 1750, 1751, "p" +333, 14, 55, 439, 182, 183, 1752, 1753, "=" +333, 14, 56, 440, 184, 185, 1754, 1755, "0" +333, 14, 57, 441, 186, 187, 1756, 1757, "." +333, 14, 58, 442, 188, 192, 1758, 1762, "0001" +333, 14, 59, 443, 193, 194, 1763, 1764, "," +333, 14, 60, 444, 195, 201, 1765, 1771, "ancova" +333, 14, 61, 445, 202, 203, 1772, 1773, ")" +333, 14, 62, 446, 204, 205, 1774, 1775, "." +333, 15, 1, 447, 0, 4, 1776, 1780, "More" +333, 15, 2, 448, 5, 13, 1781, 1789, "subjects" +333, 15, 3, 449, 14, 21, 1790, 1797, "reached" +333, 15, 4, 450, 22, 27, 1798, 1803, "HbA1c" +333, 15, 5, 451, 28, 29, 1804, 1805, "<" +333, 15, 6, 452, 30, 32, 1806, 1808, "or" +333, 15, 7, 453, 33, 34, 1809, 1810, "=" +333, 15, 8, 454, 35, 36, 1811, 1812, "7" +333, 15, 9, 455, 37, 38, 1813, 1814, "." +333, 15, 10, 456, 39, 40, 1815, 1816, "0" +333, 15, 11, 457, 41, 42, 1817, 1818, "%" +333, 15, 12, 458, 43, 45, 1819, 1821, "in" +333, 15, 13, 459, 46, 49, 1822, 1825, "the" +333, 15, 14, 460, 50, 55, 1826, 1831, "basal" +333, 15, 15, 461, 56, 57, 1832, 1833, "-" +333, 15, 16, 462, 58, 63, 1834, 1839, "bolus" +333, 15, 17, 463, 64, 69, 1840, 1845, "group" +333, 15, 18, 464, 70, 74, 1846, 1850, "than" +333, 15, 19, 465, 75, 77, 1851, 1853, "in" +333, 15, 20, 466, 78, 81, 1854, 1857, "the" +333, 15, 21, 467, 82, 88, 1858, 1864, "premix" +333, 15, 22, 468, 89, 94, 1865, 1870, "group" +333, 15, 23, 469, 95, 96, 1871, 1872, "[" +333, 15, 24, 470, 97, 99, 1873, 1875, "68" +333, 15, 25, 471, 100, 101, 1876, 1877, "(" +333, 15, 26, 472, 102, 104, 1878, 1880, "46" +333, 15, 27, 473, 105, 106, 1881, 1882, "." +333, 15, 28, 474, 107, 108, 1883, 1884, "6" +333, 15, 29, 475, 109, 110, 1885, 1886, "%" +333, 15, 30, 476, 111, 112, 1887, 1888, ")" +333, 15, 31, 477, 113, 115, 1889, 1891, "vs" +333, 15, 32, 478, 116, 117, 1892, 1893, "." +333, 15, 33, 479, 118, 120, 1894, 1896, "43" +333, 15, 34, 480, 121, 122, 1897, 1898, "(" +333, 15, 35, 481, 123, 125, 1899, 1901, "27" +333, 15, 36, 482, 126, 127, 1902, 1903, "." +333, 15, 37, 483, 128, 129, 1904, 1905, "9" +333, 15, 38, 484, 130, 131, 1906, 1907, "%" +333, 15, 39, 485, 132, 133, 1908, 1909, ")" +333, 15, 40, 486, 134, 135, 1910, 1911, ";" +333, 15, 41, 487, 136, 137, 1912, 1913, "p" +333, 15, 42, 488, 138, 139, 1914, 1915, "=" +333, 15, 43, 489, 140, 141, 1916, 1917, "0" +333, 15, 44, 490, 142, 143, 1918, 1919, "." +333, 15, 45, 491, 144, 148, 1920, 1924, "0004" +333, 15, 46, 492, 149, 150, 1925, 1926, "]" +333, 15, 47, 493, 151, 152, 1927, 1928, "," +333, 15, 48, 494, 153, 158, 1929, 1934, "while" +333, 15, 49, 495, 159, 163, 1935, 1939, "they" +333, 15, 50, 496, 164, 168, 1940, 1944, "also" +333, 15, 51, 497, 169, 180, 1945, 1956, "experienced" +333, 15, 52, 498, 181, 194, 1957, 1970, "significantly" +333, 15, 53, 499, 195, 200, 1971, 1976, "lower" +333, 15, 54, 500, 201, 205, 1977, 1981, "mean" +333, 15, 55, 501, 206, 207, 1982, 1983, "+" +333, 15, 56, 502, 208, 209, 1984, 1985, "/" +333, 15, 57, 503, 210, 211, 1986, 1987, "-" +333, 15, 58, 504, 212, 213, 1988, 1989, "s" +333, 15, 59, 505, 214, 215, 1990, 1991, "." +333, 15, 60, 506, 216, 217, 1992, 1993, "d" +333, 15, 61, 507, 218, 219, 1994, 1995, "." +333, 16, 1, 508, 0, 7, 1996, 2003, "daytime" +333, 16, 2, 509, 8, 9, 2004, 2005, "(" +333, 16, 3, 510, 10, 11, 2006, 2007, "-" +333, 16, 4, 511, 12, 13, 2008, 2009, "2" +333, 16, 5, 512, 14, 15, 2010, 2011, "." +333, 16, 6, 513, 16, 17, 2012, 2013, "7" +333, 16, 7, 514, 18, 19, 2014, 2015, "+" +333, 16, 8, 515, 20, 21, 2016, 2017, "/" +333, 16, 9, 516, 22, 23, 2018, 2019, "-" +333, 16, 10, 517, 24, 25, 2020, 2021, "2" +333, 16, 11, 518, 26, 27, 2022, 2023, "." +333, 16, 12, 519, 28, 29, 2024, 2025, "3" +333, 16, 13, 520, 30, 32, 2026, 2028, "vs" +333, 16, 14, 521, 33, 34, 2029, 2030, "." +333, 16, 15, 522, 35, 36, 2031, 2032, "-" +333, 16, 16, 523, 37, 38, 2033, 2034, "2" +333, 16, 17, 524, 39, 40, 2035, 2036, "." +333, 16, 18, 525, 41, 42, 2037, 2038, "3" +333, 16, 19, 526, 43, 44, 2039, 2040, "+" +333, 16, 20, 527, 45, 46, 2041, 2042, "/" +333, 16, 21, 528, 47, 48, 2043, 2044, "-" +333, 16, 22, 529, 49, 50, 2045, 2046, "2" +333, 16, 23, 530, 51, 52, 2047, 2048, "." +333, 16, 24, 531, 53, 54, 2049, 2050, "5" +333, 16, 25, 532, 55, 59, 2051, 2055, "mmol" +333, 16, 26, 533, 60, 61, 2056, 2057, "/" +333, 16, 27, 534, 62, 63, 2058, 2059, "l" +333, 16, 28, 535, 64, 65, 2060, 2061, ";" +333, 16, 29, 536, 66, 67, 2062, 2063, "p" +333, 16, 30, 537, 68, 69, 2064, 2065, "=" +333, 16, 31, 538, 70, 71, 2066, 2067, "0" +333, 16, 32, 539, 72, 73, 2068, 2069, "." +333, 16, 33, 540, 74, 78, 2070, 2074, "0033" +333, 16, 34, 541, 79, 80, 2075, 2076, ")" +333, 16, 35, 542, 81, 84, 2077, 2080, "and" +333, 16, 36, 543, 85, 97, 2081, 2093, "postprandial" +333, 16, 37, 544, 98, 99, 2094, 2095, "(" +333, 16, 38, 545, 100, 101, 2096, 2097, "-" +333, 16, 39, 546, 102, 103, 2098, 2099, "3" +333, 16, 40, 547, 104, 105, 2100, 2101, "." +333, 16, 41, 548, 106, 107, 2102, 2103, "1" +333, 16, 42, 549, 108, 109, 2104, 2105, "+" +333, 16, 43, 550, 110, 111, 2106, 2107, "/" +333, 16, 44, 551, 112, 113, 2108, 2109, "-" +333, 16, 45, 552, 114, 115, 2110, 2111, "2" +333, 16, 46, 553, 116, 117, 2112, 2113, "." +333, 16, 47, 554, 118, 119, 2114, 2115, "6" +333, 16, 48, 555, 120, 122, 2116, 2118, "vs" +333, 16, 49, 556, 123, 124, 2119, 2120, "." +333, 16, 50, 557, 125, 126, 2121, 2122, "-" +333, 16, 51, 558, 127, 128, 2123, 2124, "2" +333, 16, 52, 559, 129, 130, 2125, 2126, "." +333, 16, 53, 560, 131, 132, 2127, 2128, "5" +333, 16, 54, 561, 133, 134, 2129, 2130, "+" +333, 16, 55, 562, 135, 136, 2131, 2132, "/" +333, 16, 56, 563, 137, 138, 2133, 2134, "-" +333, 16, 57, 564, 139, 140, 2135, 2136, "2" +333, 16, 58, 565, 141, 142, 2137, 2138, "." +333, 16, 59, 566, 143, 144, 2139, 2140, "8" +333, 16, 60, 567, 145, 149, 2141, 2145, "mmol" +333, 16, 61, 568, 150, 151, 2146, 2147, "/" +333, 16, 62, 569, 152, 153, 2148, 2149, "l" +333, 16, 63, 570, 154, 155, 2150, 2151, ";" +333, 16, 64, 571, 156, 157, 2152, 2153, "p" +333, 16, 65, 572, 158, 159, 2154, 2155, "<" +333, 16, 66, 573, 160, 161, 2156, 2157, "0" +333, 16, 67, 574, 162, 163, 2158, 2159, "." +333, 16, 68, 575, 164, 168, 2160, 2164, "0001" +333, 16, 69, 576, 169, 170, 2165, 2166, ")" +333, 16, 70, 577, 171, 176, 2167, 2172, "blood" +333, 16, 71, 578, 177, 184, 2173, 2180, "glucose" +333, 16, 72, 579, 185, 186, 2181, 2182, "." +333, 17, 1, 580, 0, 8, 2183, 2191, "Endpoint" +333, 17, 2, 581, 9, 14, 2192, 2197, "daily" +333, 17, 3, 582, 15, 22, 2198, 2205, "insulin" +333, 17, 4, 583, 23, 28, 2206, 2211, "doses" +333, 17, 5, 584, 29, 33, 2212, 2216, "were" +333, 17, 6, 585, 34, 36, 2217, 2219, "98" +333, 17, 7, 586, 37, 38, 2220, 2221, "." +333, 17, 8, 587, 39, 40, 2222, 2223, "0" +333, 17, 9, 588, 41, 42, 2224, 2225, "+" +333, 17, 10, 589, 43, 44, 2226, 2227, "/" +333, 17, 11, 590, 45, 46, 2228, 2229, "-" +333, 17, 12, 591, 47, 49, 2230, 2232, "48" +333, 17, 13, 592, 50, 51, 2233, 2234, "." +333, 17, 14, 593, 52, 53, 2235, 2236, "7" +333, 17, 15, 594, 54, 56, 2237, 2239, "vs" +333, 17, 16, 595, 57, 58, 2240, 2241, "." +333, 17, 17, 596, 59, 61, 2242, 2244, "91" +333, 17, 18, 597, 62, 63, 2245, 2246, "." +333, 17, 19, 598, 64, 65, 2247, 2248, "3" +333, 17, 20, 599, 66, 67, 2249, 2250, "+" +333, 17, 21, 600, 68, 69, 2251, 2252, "/" +333, 17, 22, 601, 70, 71, 2253, 2254, "-" +333, 17, 23, 602, 72, 74, 2255, 2257, "44" +333, 17, 24, 603, 75, 76, 2258, 2259, "." +333, 17, 25, 604, 77, 78, 2260, 2261, "3" +333, 17, 26, 605, 79, 81, 2262, 2264, "IU" +333, 17, 27, 606, 82, 83, 2265, 2266, "(" +333, 17, 28, 607, 84, 85, 2267, 2268, "p" +333, 17, 29, 608, 86, 87, 2269, 2270, "=" +333, 17, 30, 609, 88, 89, 2271, 2272, "0" +333, 17, 31, 610, 90, 91, 2273, 2274, "." +333, 17, 32, 611, 92, 96, 2275, 2279, "2104" +333, 17, 33, 612, 97, 98, 2280, 2281, ")" +333, 17, 34, 613, 99, 100, 2282, 2283, ";" +333, 17, 35, 614, 101, 105, 2284, 2288, "mean" +333, 17, 36, 615, 106, 112, 2289, 2295, "weight" +333, 17, 37, 616, 113, 117, 2296, 2300, "gain" +333, 17, 38, 617, 118, 121, 2301, 2304, "was" +333, 17, 39, 618, 122, 123, 2305, 2306, "+" +333, 17, 40, 619, 124, 125, 2307, 2308, "3" +333, 17, 41, 620, 126, 127, 2309, 2310, "." +333, 17, 42, 621, 128, 129, 2311, 2312, "6" +333, 17, 43, 622, 130, 131, 2313, 2314, "+" +333, 17, 44, 623, 132, 133, 2315, 2316, "/" +333, 17, 45, 624, 134, 135, 2317, 2318, "-" +333, 17, 46, 625, 136, 137, 2319, 2320, "4" +333, 17, 47, 626, 138, 139, 2321, 2322, "." +333, 17, 48, 627, 140, 141, 2323, 2324, "0" +333, 17, 49, 628, 142, 144, 2325, 2327, "vs" +333, 17, 50, 629, 145, 146, 2328, 2329, "." +333, 17, 51, 630, 147, 148, 2330, 2331, "+" +333, 17, 52, 631, 149, 150, 2332, 2333, "2" +333, 17, 53, 632, 151, 152, 2334, 2335, "." +333, 17, 54, 633, 153, 154, 2336, 2337, "2" +333, 17, 55, 634, 155, 156, 2338, 2339, "+" +333, 17, 56, 635, 157, 158, 2340, 2341, "/" +333, 17, 57, 636, 159, 160, 2342, 2343, "-" +333, 17, 58, 637, 161, 162, 2344, 2345, "4" +333, 17, 59, 638, 163, 164, 2346, 2347, "." +333, 17, 60, 639, 165, 166, 2348, 2349, "5" +333, 17, 61, 640, 167, 169, 2350, 2352, "kg" +333, 17, 62, 641, 170, 171, 2353, 2354, "(" +333, 17, 63, 642, 172, 173, 2355, 2356, "p" +333, 17, 64, 643, 174, 175, 2357, 2358, "=" +333, 17, 65, 644, 176, 177, 2359, 2360, "0" +333, 17, 66, 645, 178, 179, 2361, 2362, "." +333, 17, 67, 646, 180, 184, 2363, 2367, "0073" +333, 17, 68, 647, 185, 186, 2368, 2369, ")" +333, 17, 69, 648, 187, 188, 2370, 2371, "." +333, 18, 1, 649, 0, 4, 2372, 2376, "Mean" +333, 18, 2, 650, 5, 11, 2377, 2383, "number" +333, 18, 3, 651, 12, 14, 2384, 2386, "of" +333, 18, 4, 652, 15, 22, 2387, 2394, "overall" +333, 18, 5, 653, 23, 36, 2395, 2408, "hypoglycaemic" +333, 18, 6, 654, 37, 43, 2409, 2415, "events" +333, 18, 7, 655, 44, 48, 2416, 2420, "with" +333, 18, 8, 656, 49, 54, 2421, 2426, "basal" +333, 18, 9, 657, 55, 56, 2427, 2428, "-" +333, 18, 10, 658, 57, 62, 2429, 2434, "bolus" +333, 18, 11, 659, 63, 66, 2435, 2438, "and" +333, 18, 12, 660, 67, 73, 2439, 2445, "premix" +333, 18, 13, 661, 74, 77, 2446, 2449, "was" +333, 18, 14, 662, 78, 80, 2450, 2452, "13" +333, 18, 15, 663, 81, 82, 2453, 2454, "." +333, 18, 16, 664, 83, 85, 2455, 2457, "99" +333, 18, 17, 665, 86, 89, 2458, 2461, "and" +333, 18, 18, 666, 90, 92, 2462, 2464, "18" +333, 18, 19, 667, 93, 94, 2465, 2466, "." +333, 18, 20, 668, 95, 97, 2467, 2469, "54" +333, 18, 21, 669, 98, 104, 2470, 2476, "events" +333, 18, 22, 670, 105, 106, 2477, 2478, "/" +333, 18, 23, 671, 107, 114, 2479, 2486, "patient" +333, 18, 24, 672, 115, 119, 2487, 2491, "year" +333, 18, 25, 673, 120, 121, 2492, 2493, "," +333, 18, 26, 674, 122, 134, 2494, 2506, "respectively" +333, 18, 27, 675, 135, 136, 2507, 2508, "(" +333, 18, 28, 676, 137, 147, 2509, 2519, "difference" +333, 18, 29, 677, 148, 149, 2520, 2521, ":" +333, 18, 30, 678, 150, 151, 2522, 2523, "-" +333, 18, 31, 679, 152, 153, 2524, 2525, "3" +333, 18, 32, 680, 154, 155, 2526, 2527, "." +333, 18, 33, 681, 156, 158, 2528, 2530, "90" +333, 18, 34, 682, 159, 160, 2531, 2532, ";" +333, 18, 35, 683, 161, 163, 2533, 2535, "95" +333, 18, 36, 684, 164, 165, 2536, 2537, "%" +333, 18, 37, 685, 166, 168, 2538, 2540, "CI" +333, 18, 38, 686, 169, 170, 2541, 2542, ":" +333, 18, 39, 687, 171, 172, 2543, 2544, "-" +333, 18, 40, 688, 173, 175, 2545, 2547, "10" +333, 18, 41, 689, 176, 177, 2548, 2549, "." +333, 18, 42, 690, 178, 180, 2550, 2552, "40" +333, 18, 43, 691, 181, 182, 2553, 2554, "," +333, 18, 44, 692, 183, 184, 2555, 2556, "2" +333, 18, 45, 693, 185, 186, 2557, 2558, "." +333, 18, 46, 694, 187, 189, 2559, 2561, "60" +333, 18, 47, 695, 190, 191, 2562, 2563, ";" +333, 18, 48, 696, 192, 193, 2564, 2565, "p" +333, 18, 49, 697, 194, 195, 2566, 2567, "=" +333, 18, 50, 698, 196, 197, 2568, 2569, "0" +333, 18, 51, 699, 198, 199, 2570, 2571, "." +333, 18, 52, 700, 200, 204, 2572, 2576, "2385" +333, 18, 53, 701, 205, 206, 2577, 2578, ")" +333, 18, 54, 702, 207, 208, 2579, 2580, "." +333, 19, 1, 703, 0, 11, 2581, 2592, "CONCLUSIONS" +333, 19, 2, 704, 12, 13, 2593, 2594, ":" +333, 19, 3, 705, 14, 16, 2595, 2597, "An" +333, 19, 4, 706, 17, 28, 2598, 2609, "intensified" +333, 19, 5, 707, 29, 34, 2610, 2615, "basal" +333, 19, 6, 708, 35, 36, 2616, 2617, "-" +333, 19, 7, 709, 37, 42, 2618, 2623, "bolus" +333, 19, 8, 710, 43, 50, 2624, 2631, "regimen" +333, 19, 9, 711, 51, 56, 2632, 2637, "using" +333, 19, 10, 712, 57, 65, 2638, 2646, "glargine" +333, 19, 11, 713, 66, 67, 2647, 2648, "/" +333, 19, 12, 714, 68, 77, 2649, 2658, "glulisine" +333, 19, 13, 715, 78, 85, 2659, 2666, "results" +333, 19, 14, 716, 86, 88, 2667, 2669, "in" +333, 19, 15, 717, 89, 90, 2670, 2671, "a" +333, 19, 16, 718, 91, 104, 2672, 2685, "significantly" +333, 19, 17, 719, 105, 113, 2686, 2694, "superior" +333, 19, 18, 720, 114, 123, 2695, 2704, "glycaemic" +333, 19, 19, 721, 124, 131, 2705, 2712, "control" +333, 19, 20, 722, 132, 134, 2713, 2715, "vs" +333, 19, 21, 723, 135, 136, 2716, 2717, "." +333, 19, 22, 724, 137, 143, 2718, 2724, "premix" +333, 19, 23, 725, 144, 151, 2725, 2732, "therapy" +333, 19, 24, 726, 152, 154, 2733, 2735, "in" +333, 19, 25, 727, 155, 156, 2736, 2737, "a" +333, 19, 26, 728, 157, 167, 2738, 2748, "population" +333, 19, 27, 729, 168, 172, 2749, 2753, "with" +333, 19, 28, 730, 173, 177, 2754, 2758, "long" +333, 19, 29, 731, 178, 179, 2759, 2760, "-" +333, 19, 30, 732, 180, 188, 2761, 2769, "standing" +333, 19, 31, 733, 189, 196, 2770, 2777, "insulin" +333, 19, 32, 734, 197, 198, 2778, 2779, "-" +333, 19, 33, 735, 199, 206, 2780, 2787, "treated" +333, 19, 34, 736, 207, 210, 2788, 2791, "T2D" +333, 19, 35, 737, 211, 212, 2792, 2793, "," +333, 19, 36, 738, 213, 217, 2794, 2798, "with" +333, 19, 37, 739, 218, 220, 2799, 2801, "no" +333, 19, 38, 740, 221, 229, 2802, 2810, "increase" +333, 19, 39, 741, 230, 232, 2811, 2813, "in" +333, 19, 40, 742, 233, 236, 2814, 2817, "the" +333, 19, 41, 743, 237, 242, 2818, 2823, "rates" +333, 19, 42, 744, 243, 245, 2824, 2826, "of" +333, 19, 43, 745, 246, 259, 2827, 2840, "hypoglycaemia" +333, 19, 44, 746, 260, 261, 2841, 2842, "." +333, 20, 1, 747, 0, 3, 2843, 2846, "DOI" +333, 20, 2, 748, 4, 5, 2847, 2848, ":" +333, 20, 3, 749, 6, 8, 2849, 2851, "10" +333, 20, 4, 750, 9, 10, 2852, 2853, "." +333, 20, 5, 751, 11, 15, 2854, 2858, "1111" +333, 20, 6, 752, 16, 17, 2859, 2860, "/" +333, 20, 7, 753, 18, 19, 2861, 2862, "j" +333, 20, 8, 754, 20, 21, 2863, 2864, "." +333, 20, 9, 755, 22, 26, 2865, 2869, "1463" +333, 20, 10, 756, 27, 28, 2870, 2871, "-" +333, 20, 11, 757, 29, 33, 2872, 2876, "1326" +333, 20, 12, 758, 34, 35, 2877, 2878, "." +333, 20, 13, 759, 36, 40, 2879, 2883, "2009" +333, 20, 14, 760, 41, 42, 2884, 2885, "." +333, 20, 15, 761, 43, 48, 2886, 2891, "01165" +333, 20, 16, 762, 49, 50, 2892, 2893, "." +333, 20, 17, 763, 51, 52, 2894, 2895, "x" +333, 20, 18, 764, 53, 57, 2896, 2900, "PMID" +333, 20, 19, 765, 58, 59, 2901, 2902, ":" +333, 20, 20, 766, 60, 68, 2903, 2911, "20092584" +333, 20, 21, 767, 69, 70, 2912, 2913, "[" +333, 20, 22, 768, 71, 78, 2914, 2921, "Indexed" +333, 20, 23, 769, 79, 82, 2922, 2925, "for" +333, 20, 24, 770, 83, 90, 2926, 2933, "MEDLINE" +333, 20, 25, 771, 91, 92, 2934, 2935, "]" diff --git a/data/dm2 20092584_kwoodley.annodb b/data/dm2 20092584_kwoodley.annodb new file mode 100644 index 0000000..5622db9 --- /dev/null +++ b/data/dm2 20092584_kwoodley.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15019, Journal, 0, 19, "Diabetes Obes Metab", "", +15020, PublicationYear, 22, 26, "2010", "", +36666, Title, 110, 243, "Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "", +15021, Insulin, 160, 167, "insulin", "", +15022, Type2Diabetes, 196, 211, "type 2 diabetes", "", +15024, Author, 244, 254, "Fritsche A", "", +15025, Author, 263, 271, "Larbig M", "", +15026, Author, 274, 281, "Owens D", "", +15027, Author, 284, 295, "H ä ring HU", "", +15028, Germany, 507, 514, "Germany", "", +36668, ObjectiveDescription, 652, 866, "To compare the efficacy and safety of an intensified insulin regimen , using insulin glargine ( glargine ) once daily and pre - meal insulin glulisine ( glulisine ) ( basal - bolus ) , with a conventional therapy ,", "", +15029, Insulin, 705, 712, "insulin", "", +15030, InsulinGlargine, 729, 745, "insulin glargine", "", +15031, InsulinGlargine, 748, 756, "glargine", "", +15032, Frequency, 759, 769, "once daily", "", +15033, InsulinGlulisine, 785, 802, "insulin glulisine", "", +15034, InsulinGlulisine, 805, 814, "glulisine", "", +36667, ObjectiveDescription, 867, 914, "using premixed insulin ( premix ) twice daily .", "", +15035, InsulinGlulisine, 882, 889, "insulin", "", +15036, Frequency, 901, 912, "twice daily", "", +15039, Duration, 930, 939, "52 - week", "", +15040, OpenLabel, 942, 954, "open - label", "", +15041, Randomized, 957, 967, "randomized", "", +36669, Multicenter, 970, 983, "multinational", "", +15043, Multicenter, 986, 997, "multicentre", "", +15044, NumberPatientsCT, 1013, 1016, "310", "", +15048, Precondition, 1017, 1092, "subjects with type 2 diabetes ( T2D ) on premix , with or without metformin", "", +15045, Type2Diabetes, 1031, 1046, "type 2 diabetes", "", +15046, Type2Diabetes, 1049, 1052, "T2D", "", +15047, Metformin, 1083, 1092, "metformin", "", +15049, Randomized, 1104, 1114, "randomized", "", +15050, InsulinGlargine, 1147, 1155, "glargine", "", +15051, InsulinGlulisine, 1160, 1169, "glulisine", "", +15060, NumberPatientsArm, 1176, 1179, "153", "", +15053, Mean, 1182, 1198, "mean + / - s . d", "", +15070, AvgAge, 1205, 1211, "60 . 2", "differs between arms", +15055, HbA1c, 1232, 1237, "HbA1c", "", +15065, NumberPatientsArm, 1232, 1329, "HbA1c 8 . 6 + / - 0 . 8 % ; weight 87 . 0 + / - 15 . 1 kg ; T2D duration 12 . 8 + / - 5 . 8 years", "precondition differentiated by arms", +15056, Percentage, 1256, 1257, "%", "", +15057, BodyWeight, 1260, 1266, "weight", "", +15058, Kg, 1287, 1289, "kg", "", +15059, Type2Diabetes, 1292, 1295, "T2D", "", +15062, Frequency, 1335, 1348, "twice - daily", "", +15064, NumberPatientsArm, 1362, 1365, "157", "", +15069, AvgAge, 1372, 1378, "60 . 9", "differs between arms", +15066, Precondition, 1399, 1496, "HbA1c 8 . 5 + / - 0 . 9 % ; weight 84 . 3 + / - 15 . 0 kg ; T2D duration 12 . 5 + / - 6 . 8 years", "precondition differentiated by arms", +15071, HbA1c, 1399, 1404, "HbA1c", "", +15073, Percentage, 1423, 1424, "%", "", +15074, BodyWeight, 1427, 1433, "weight", "", +15075, Kg, 1454, 1456, "kg", "", +15076, Type2Diabetes, 1459, 1462, "T2D", "", +15077, HbA1c, 1536, 1541, "HbA1c", "", +36670, TimePoint, 1547, 1555, "baseline", "", +36671, TimePoint, 1559, 1567, "endpoint", "", +36672, TimePoint, 1597, 1605, "baseline", "", +36673, TimePoint, 1613, 1621, "endpoint", "", +15078, HbA1c, 1622, 1627, "HbA1c", "", +15079, Reduction, 1664, 1670, "1 . 31", "", +15080, Reduction, 1678, 1684, "0 . 80", "", +15081, Percentage, 1685, 1686, "%", "", +15082, DiffGroupAbsValue, 1702, 1711, "- 0 . 476", "", +15083, Percentage, 1712, 1713, "%", "", +15084, ConfIntervalDiff, 1716, 1747, "95 % Cl : - 0 . 714 , - 0 . 238", "", +15085, PvalueDiff, 1750, 1762, "p = 0 . 0001", "", +15086, HbA1c_target, 1798, 1818, "HbA1c < or = 7 . 0 %", "", +15087, NumberAffected, 1873, 1875, "68", "", +15089, PercentageAffected, 1878, 1884, "46 . 6", "", +15088, NumberAffected, 1894, 1896, "43", "", +15090, PercentageAffected, 1899, 1905, "27 . 9", "", +15091, PvalueDiff, 1912, 1924, "p = 0 . 0004", "", +15092, Mean, 1977, 1993, "mean + / - s . d", "", +15094, TimePoint, 1996, 2003, "daytime", "", +15097, Reduction, 2008, 2013, "2 . 7", "", +15101, SdDevChangeValue, 2020, 2025, "2 . 3", "", +15098, Reduction, 2033, 2038, "2 . 3", "", +15102, SdDevChangeValue, 2045, 2050, "2 . 5", "", +15105, Millimoles_per_litre, 2051, 2059, "mmol / l", "", +15107, PvalueDiff, 2062, 2074, "p = 0 . 0033", "", +15095, TimePoint, 2081, 2093, "postprandial", "", +15099, Reduction, 2098, 2103, "3 . 1", "", +15103, SdDevChangeValue, 2110, 2115, "2 . 6", "", +15100, Reduction, 2123, 2128, "2 . 5", "", +15104, SdDevChangeValue, 2135, 2140, "2 . 8", "", +15106, Millimoles_per_litre, 2141, 2149, "mmol / l", "", +15108, PvalueDiff, 2152, 2164, "p < 0 . 0001", "", +15096, FastingPlasmaGlucose, 2167, 2180, "blood glucose", "", +36674, InsulinDose, 2192, 2211, "daily insulin doses", "", +15110, ResultMeasuredValue, 2217, 2223, "98 . 0", "", +15112, SdDevResValue, 2230, 2236, "48 . 7", "", +15111, ResultMeasuredValue, 2242, 2248, "91 . 3", "", +15113, SdDevResValue, 2255, 2261, "44 . 3", "", +15114, BioAndMedicalUnit, 2262, 2264, "IU", "", +15115, PvalueDiff, 2267, 2279, "p = 0 . 2104", "", +15116, BodyWeight, 2289, 2295, "weight", "", +15117, Increment, 2307, 2312, "3 . 6", "", +15119, SdDevResValue, 2319, 2324, "4 . 0", "", +15118, Increment, 2332, 2337, "2 . 2", "", +15120, SdDevResValue, 2344, 2349, "4 . 5", "", +15121, Kg, 2350, 2352, "kg", "", +15122, PvalueDiff, 2355, 2367, "p = 0 . 0073", "", +15123, Hypoglycemia, 2395, 2415, "hypoglycaemic events", "", +15124, ResultMeasuredValue, 2450, 2457, "13 . 99", "", +15125, ResultMeasuredValue, 2462, 2469, "18 . 54", "", +15126, BioAndMedicalUnit, 2470, 2491, "events / patient year", "", +15127, DiffGroupRelValue, 2522, 2530, "- 3 . 90", "", +15129, ConfIntervalDiff, 2533, 2561, "95 % CI : - 10 . 40 , 2 . 60", "", +15130, PvalueDiff, 2564, 2576, "p = 0 . 2385", "", +36675, ConclusionComment, 2595, 2842, "An intensified basal - bolus regimen using glargine / glulisine results in a significantly superior glycaemic control vs . premix therapy in a population with long - standing insulin - treated T2D , with no increase in the rates of hypoglycaemia .", "", +15131, InsulinGlargine, 2638, 2646, "glargine", "", +15132, InsulinGlulisine, 2649, 2658, "glulisine", "", +15133, Insulin, 2770, 2777, "insulin", "", +15134, Type2Diabetes, 2788, 2791, "T2D", "", +15135, Hypoglycemia, 2827, 2840, "hypoglycaemia", "", +15137, PMID, 2903, 2911, "20092584", "", diff --git a/data/dm2 20092584_kwoodley.n-triples b/data/dm2 20092584_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20092584_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092585_admin.annodb b/data/dm2 20092585_admin.annodb new file mode 100644 index 0000000..579123f --- /dev/null +++ b/data/dm2 20092585_admin.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +106230, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2010", "", " \"2010\"." +117, Title, 110, 209, "Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes .", "", " \"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes .\"." +2, Sitagliptin, 133, 144, "sitagliptin", "", +3, Insulin, 159, 166, "insulin", "", +4, Type2Diabetes, 192, 207, "type 2 diabetes", "", +5, Author, 210, 222, "Vilsb ø ll T", "", " \"Vilsb ø ll T\"." +6, Author, 231, 243, "Rosenstock J", "", " \"Rosenstock J\"." +7, Author, 246, 264, "Yki - J ä rvinen H", "", " \"Yki - J ä rvinen H\"." +8, Author, 267, 276, "Cefalu WT", "", " \"Cefalu WT\"." +9, Author, 279, 285, "Chen Y", "", " \"Chen Y\"." +10, Author, 288, 293, "Luo E", "", " \"Luo E\"." +11, Author, 296, 304, "Musser B", "", " \"Musser B\"." +12, Author, 307, 317, "Andryuk PJ", "", " \"Andryuk PJ\"." +13, Author, 320, 326, "Ling Y", "", " \"Ling Y\"." +14, Author, 329, 339, "Kaufman KD", "", " \"Kaufman KD\"." +15, Author, 342, 353, "Amatruda JM", "", " \"Amatruda JM\"." +16, Author, 356, 364, "Engel SS", "", " \"Engel SS\"." +17, Author, 367, 373, "Katz L", "", " \"Katz L\"." +18, Country, 528, 535, "Denmark", "", +136, ObjectiveDescription, 550, 710, "To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes .", "", " \"To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes .\"." +19, Sitagliptin, 595, 606, "sitagliptin", "", +20, Insulin, 621, 628, "insulin", "", +21, Metformin, 666, 675, "metformin", "", +22, Type2Diabetes, 693, 708, "type 2 diabetes", "", " ." +23, Duration, 729, 735, "2 week", "", +24, Placebo, 736, 743, "placebo", "", +29, Precondition, 771, 905, "patients inadequately controlled on long - acting , intermediate - acting or premixed insulin ( HbA1c > or = 7 . 5 % and < or = 11 % )", "", " \"patients inadequately controlled on long - acting , intermediate - acting or premixed insulin ( HbA1c > or = 7 . 5 % and < or = 11 % )\"." +56643, PremixedInsulin, 848, 864, "premixed insulin", "", +26, HbA1c, 867, 872, "HbA1c", "", +140, Precondition, 867, 903, "HbA1c > or = 7 . 5 % and < or = 11 %", "", +27, Percentage, 886, 887, "%", "", +28, Percentage, 902, 903, "%", "", +30, Randomized, 913, 923, "randomised", "", " ." +31, AllocationRatio, 924, 929, "1 : 1", "", " . ." +32, Frequency, 949, 961, "once - daily", "", " \"once - daily\". \"once - daily\"." +33, Sitagliptin, 962, 973, "sitagliptin", "", " ." +34, DoseValue, 974, 977, "100", "", " \"100\"." +35, mg, 978, 980, "mg", "", " ." +36, Placebo, 993, 1000, "placebo", "", " ." +37, Duration, 1008, 1017, "24 - week", "", " \"24 - week\"." +38, Randomized, 1068, 1078, "randomised", "", +39, Insulin, 1091, 1098, "insulin", "", +40, Metformin, 1104, 1113, "metformin", "", " ." +41, Randomized, 1169, 1179, "randomised", "", +106231, PremixedInsulin, 1192, 1208, "premixed insulin", "", +43, Metformin, 1223, 1232, "metformin", "", +44, Insulin, 1246, 1253, "insulin", "", +45, HbA1c, 1329, 1334, "HbA1c", "", +244, TimePoint, 1347, 1355, "baseline", "", +157, TimePoint, 1359, 1366, "week 24", "", +158, Mean, 1379, 1383, "Mean", "", " . . . . . ." +245, TimePoint, 1384, 1392, "baseline", "", +47, Sitagliptin, 1434, 1445, "sitagliptin", "", +48, NumberPatientsArm, 1452, 1455, "322", "", " \"322\"." +50, Placebo, 1462, 1469, "placebo", "", +49, NumberPatientsArm, 1476, 1479, "319", "", " \"319\"." +51, HbA1c, 1501, 1506, "HbA1c", "", " ." +56, BaseLineValue, 1509, 1514, "8 . 7", "", " \"8 . 7\"." +57, BaseLineValue, 1520, 1525, "8 . 6", "", " \"8 . 6\"." +58, Percentage, 1526, 1527, "%", "", " ." +52, BMI, 1573, 1588, "body mass index", "", " ." +169, BaseLineValue, 1591, 1597, "31 . 4", "", " \"31 . 4\"." +170, BaseLineValue, 1603, 1609, "31 . 4", "", " \"31 . 4\"." +171, Kg_per_squareMeter, 1610, 1622, "kg / m ( 2 )", "", " ." +56636, InsulinDose, 1643, 1655, "insulin dose", "", " . ." +173, BaseLineValue, 1658, 1660, "51", "", " \"51\"." +174, BaseLineValue, 1666, 1668, "52", "", " \"52\"." +175, Int_Unit, 1669, 1671, "IU", "", " ." +177, TimePoint, 1694, 1702, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +59, Sitagliptin, 1721, 1732, "sitagliptin", "", +178, PvalueDiff, 1749, 1760, "p < 0 . 001", "", " \"p < 0 . 001\"." +60, HbA1c, 1771, 1776, "HbA1c", "", +56638, Reduction, 1780, 1785, "0 . 6", "", " \"0 . 6\"." +56640, Percentage, 1786, 1787, "%", "", +238, Placebo, 1802, 1809, "placebo", "", +106232, NoChange, 1812, 1817, "0 . 0", "", " \"0 . 0\"." +64, Percentage, 1818, 1819, "%", "", +65, HbA1c_target, 1869, 1886, "HbA1c level < 7 %", "", " ." +66, Randomized, 1893, 1903, "randomised", "", +67, Sitagliptin, 1907, 1918, "sitagliptin", "", +68, Placebo, 1936, 1943, "placebo", "", +69, PercentageAffected, 1946, 1948, "13", "", " \"13\"." +70, PercentageAffected, 1954, 1955, "5", "", " \"5\"." +71, PvalueDiff, 1973, 1984, "p < 0 . 001", "", " \"p < 0 . 001\"." +72, HbA1c, 1997, 2002, "HbA1c", "", +73, Insulin, 2061, 2068, "insulin", "", +74, Insulin, 2116, 2124, "insulins", "", +56642, PremixedInsulin, 2128, 2145, "premixed insulins", "", +243, TimePoint, 2155, 2163, "baseline", "", +76, Metformin, 2164, 2173, "metformin", "", +77, Sitagliptin, 2202, 2213, "sitagliptin", "", +198, PvalueDiff, 2230, 2241, "p < 0 . 001", "", " \"p < 0 . 001\"." +80, FastingPlasmaGlucose, 2252, 2274, "fasting plasma glucose", "", " ." +81, Reduction, 2278, 2284, "15 . 0", "", " \"15 . 0\"." +82, Mg_per_deciliter, 2285, 2292, "mg / dl", "", " ." +83, Reduction, 2295, 2300, "0 . 8", "", +84, Millimoles_per_litre, 2301, 2309, "mmol / l", "", +239, PostprandialBloodGlucose, 2316, 2338, "2 - h postmeal glucose", "", " ." +85, Reduction, 2342, 2348, "36 . 1", "", " \"36 . 1\"." +87, Mg_per_deciliter, 2349, 2356, "mg / dl", "", " ." +86, Reduction, 2359, 2364, "2 . 0", "", +88, Millimoles_per_litre, 2365, 2373, "mmol / l", "", +89, Placebo, 2388, 2395, "placebo", "", +90, EndPointDescription, 2420, 2439, "adverse experiences", "", " . ." +91, Sitagliptin, 2458, 2469, "sitagliptin", "", +93, PercentageAffected, 2472, 2474, "52", "", " \"52\"." +92, Placebo, 2493, 2500, "placebo", "", +94, PercentageAffected, 2503, 2505, "43", "", " \"43\"." +95, Hypoglycemia, 2553, 2566, "hypoglycaemia", "", " ." +96, Sitagliptin, 2569, 2580, "sitagliptin", "", +98, PercentageAffected, 2583, 2585, "16", "", " \"16\"." +97, Placebo, 2593, 2600, "placebo", "", +99, PercentageAffected, 2603, 2604, "8", "", " \"8\"." +100, Hypoglycemia, 2625, 2645, "hypoglycaemic events", "", +101, Sitagliptin, 2714, 2725, "sitagliptin", "", +103, NumberAffected, 2732, 2733, "2", "", " \"2\"." +102, Placebo, 2740, 2747, "placebo", "", +104, NumberAffected, 2754, 2755, "1", "", " \"1\"." +227, ObservedResult, 2763, 2795, "significant change from baseline", "", " \"significant change from baseline\"." +246, TimePoint, 2787, 2795, "baseline", "", +105, BodyWeight, 2799, 2810, "body weight", "", " ." +233, ConclusionComment, 2855, 3084, "In this 24 - week study , the addition of sitagliptin to ongoing , stable - dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes .", "", " \"In this 24 - week study , the addition of sitagliptin to ongoing , stable - dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes .\"." +106, Duration, 2863, 2872, "24 - week", "", +107, Sitagliptin, 2897, 2908, "sitagliptin", "", +108, Insulin, 2936, 2943, "insulin", "", +109, Metformin, 2980, 2989, "metformin", "", +110, Type2Diabetes, 3067, 3082, "type 2 diabetes", "", +111, PMID, 3145, 3153, "20092585", "", " \"20092585\"." diff --git a/data/dm2 20092585_admin.n-triples b/data/dm2 20092585_admin.n-triples new file mode 100644 index 0000000..81bbb16 --- /dev/null +++ b/data/dm2 20092585_admin.n-triples @@ -0,0 +1,262 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes ." . + "Vilsb ø ll T" . + "2010" . + "Diabetes Obes Metab ." . + "20092585" . + . + "Rosenstock J" . + "Yki - J ä rvinen H" . + "Cefalu WT" . + "Chen Y" . + "Luo E" . + "Musser B" . + "Andryuk PJ" . + "Ling Y" . + "Kaufman KD" . + "Amatruda JM" . + "Engel SS" . + "Katz L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes ." . + "24 - week" . + . + . + . + . + "In this 24 - week study , the addition of sitagliptin to ongoing , stable - dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients inadequately controlled on long - acting , intermediate - acting or premixed insulin ( HbA1c > or = 7 . 5 % and < or = 11 % )" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint bmi" . + . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s" . + "322" . + . + . + . + . + . + . + . + . + . + . + . + "Arm p" . + "319" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s" . + . + "once - daily" . + . + . + "Intervention p" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . + . + "Medication metformin??" . + . + . + . + . + "Medication insulin therapy??" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s" . + . + "8 . 7" . + "0 . 6" . + "24 weeks" . + . + "Outcome hba1c p" . + . + "8 . 6" . + "24 weeks" . + "0 . 0" . + . + "Outcome bmi s" . + . + "31 . 4" . + . + "Outcome bmi p" . + . + "31 . 4" . + . + "Outcome id s" . + . + "51" . + . + "Outcome id p " . + . + "52" . + . + "Outcome hba1c target s" . + . + "13" . + . + "Outcome hba1c target p" . + . + "5" . + . + "Outcome fpg s" . + . + "15 . 0" . + . + "Outcome fpg p" . + . + . + "Outcome ppg s" . + . + "36 . 1" . + . + "Outcome ppg p" . + . + . + "Outcome aes s" . + . + "52" . + . + "Outcome aes p " . + . + "43" . + . + "Outcome h s" . + . + "2" . + "16" . + . + "Outcome h p " . + . + "1" . + "8" . + . + "Outcome weight both drugs" . + . + "significant change from baseline" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups hba1c target" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups fpg" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups ppg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092585_akramersunderbrink.annodb b/data/dm2 20092585_akramersunderbrink.annodb new file mode 100644 index 0000000..7ad8b47 --- /dev/null +++ b/data/dm2 20092585_akramersunderbrink.annodb @@ -0,0 +1,129 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +28985, Journal, 0, 19, "Diabetes Obes Metab", "", +29191, PublicationYear, 22, 26, "2010", "", +29196, Title, 110, 209, "Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes .", "", +29193, Sitagliptin, 133, 144, "sitagliptin", "", +29194, Insulin, 159, 166, "insulin", "", +29195, Type2Diabetes, 192, 207, "type 2 diabetes", "", +29197, Author, 210, 222, "Vilsb ø ll T", "", +29199, Author, 231, 243, "Rosenstock J", "", +29200, Author, 246, 264, "Yki - J ä rvinen H", "", +29201, Author, 267, 276, "Cefalu WT", "", +29202, Author, 279, 285, "Chen Y", "", +29203, Author, 288, 293, "Luo E", "", +29205, Author, 296, 304, "Musser B", "", +29206, Author, 307, 317, "Andryuk PJ", "", +29208, Author, 320, 326, "Ling Y", "", +29209, Author, 329, 339, "Kaufman KD", "", +29210, Author, 342, 353, "Amatruda JM", "", +29211, Author, 356, 364, "Engel SS", "", +29213, Author, 367, 373, "Katz L", "", +29215, Country, 528, 535, "Denmark", "", +29223, ObjectiveDescription, 550, 710, "To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes .", "", +29217, Sitagliptin, 595, 606, "sitagliptin", "", +29219, Insulin, 621, 628, "insulin", "", +29220, Metformin, 666, 675, "metformin", "", +29222, Type2Diabetes, 693, 708, "type 2 diabetes", "", +29224, Duration, 729, 735, "2 week", "", +29225, Placebo, 736, 743, "placebo", "", +29244, Precondition, 780, 864, "inadequately controlled on long - acting , intermediate - acting or premixed insulin", "", +29229, Insulin, 807, 864, "long - acting , intermediate - acting or premixed insulin", "", +29231, Precondition, 867, 903, "HbA1c > or = 7 . 5 % and < or = 11 %", "", +29233, Percentage, 886, 887, "%", "", +29235, Percentage, 902, 903, "%", "", +29237, Randomized, 913, 923, "randomised", "", +29238, Frequency, 949, 961, "once - daily", "", +29239, Sitagliptin, 962, 973, "sitagliptin", "", +29240, DoseValue, 974, 977, "100", "", +29241, mg, 978, 980, "mg", "", +29242, Placebo, 993, 1000, "placebo", "", +29243, Duration, 1008, 1017, "24 - week", "", +29246, Randomized, 1068, 1078, "randomised", "", +29245, Percentage, 1120, 1121, "%", "", +29247, Randomized, 1169, 1179, "randomised", "", +29248, Metformin, 1223, 1232, "metformin", "", +29249, Insulin, 1246, 1253, "insulin", "", +29250, HbA1c, 1329, 1334, "HbA1c", "", +39192, TimePoint, 1347, 1355, "baseline", "", +29251, TimePoint, 1359, 1366, "week 24", "", +29252, Mean, 1379, 1383, "Mean", "", +39193, TimePoint, 1384, 1392, "baseline", "", +29257, Sitagliptin, 1434, 1445, "sitagliptin", "", +29253, NumberPatientsArm, 1452, 1455, "322", "", +29258, Placebo, 1462, 1469, "placebo", "", +29256, NumberPatientsArm, 1476, 1479, "319", "", +29259, HbA1c, 1501, 1506, "HbA1c", "", +29260, BaseLineValue, 1509, 1514, "8 . 7", "", +29261, BaseLineValue, 1520, 1525, "8 . 6", "", +29262, Percentage, 1526, 1527, "%", "", +29263, Precondition, 1532, 1570, "diabetes duration ( 13 vs . 12 years )", "", +29264, BMI, 1573, 1588, "body mass index", "", +29265, BaseLineValue, 1591, 1597, "31 . 4", "", +29266, BaseLineValue, 1603, 1609, "31 . 4", "", +29267, Kg_per_squareMeter, 1610, 1622, "kg / m ( 2 )", "", +29268, EndPointDescription, 1631, 1655, "total daily insulin dose", "", +29269, BaseLineValue, 1658, 1660, "51", "", +29270, BaseLineValue, 1666, 1668, "52", "", +29271, Int_Unit, 1669, 1671, "IU", "", +29274, TimePoint, 1694, 1702, "24 weeks", "", +29273, Sitagliptin, 1721, 1732, "sitagliptin", "", +29279, PvalueDiff, 1749, 1760, "p < 0 . 001", "", +29280, HbA1c, 1771, 1776, "HbA1c", "", +29289, Reduction, 1780, 1785, "0 . 6", "", +29292, Percentage, 1786, 1787, "%", "", +39190, Placebo, 1802, 1809, "placebo", "", +29290, Reduction, 1812, 1817, "0 . 0", "", +29293, Percentage, 1818, 1819, "%", "", +29295, HbA1c_target, 1869, 1886, "HbA1c level < 7 %", "", +29296, Percentage, 1885, 1886, "%", "", +29298, Randomized, 1893, 1903, "randomised", "", +29299, Sitagliptin, 1907, 1918, "sitagliptin", "", +29300, Placebo, 1936, 1943, "placebo", "", +29301, PercentageAffected, 1946, 1948, "13", "", +29302, PercentageAffected, 1954, 1955, "5", "", +29303, Percentage, 1956, 1957, "%", "", +29304, PvalueDiff, 1973, 1984, "p < 0 . 001", "", +29305, HbA1c, 1997, 2002, "HbA1c", "", +39191, TimePoint, 2155, 2163, "baseline", "", +29306, Sitagliptin, 2202, 2213, "sitagliptin", "", +29313, PvalueDiff, 2230, 2241, "p < 0 . 001", "", +29307, FastingPlasmaGlucose, 2252, 2274, "fasting plasma glucose", "", +29314, DiffGroupAbsValue, 2278, 2284, "15 . 0", "", +29318, Mg_per_deciliter, 2285, 2292, "mg / dl", "", +29321, DiffGroupAbsValue, 2295, 2300, "0 . 8", "", +29327, Millimoles_per_litre, 2301, 2309, "mmol / l", "", +29309, InsulinDose, 2316, 2338, "2 - h postmeal glucose", "", +29316, DiffGroupAbsValue, 2342, 2348, "36 . 1", "", +29319, Mg_per_deciliter, 2349, 2356, "mg / dl", "", +29323, DiffGroupAbsValue, 2359, 2364, "2 . 0", "", +29328, Millimoles_per_litre, 2365, 2373, "mmol / l", "", +29310, Placebo, 2388, 2395, "placebo", "", +29336, EndPointDescription, 2407, 2439, "incidence of adverse experiences", "", +29330, Sitagliptin, 2458, 2469, "sitagliptin", "", +29338, PercentageAffected, 2472, 2474, "52", "", +29345, Percentage, 2475, 2476, "%", "", +29331, Placebo, 2493, 2500, "placebo", "", +29339, PercentageAffected, 2503, 2505, "43", "", +29348, Percentage, 2506, 2507, "%", "", +29334, Hypoglycemia, 2553, 2566, "hypoglycaemia", "", +29354, Sitagliptin, 2569, 2580, "sitagliptin", "", +29340, PercentageAffected, 2583, 2585, "16", "", +29350, Percentage, 2586, 2587, "%", "", +29356, Placebo, 2593, 2600, "placebo", "", +29342, PercentageAffected, 2603, 2604, "8", "", +29351, Percentage, 2605, 2606, "%", "", +29357, SevereHypoglycemia, 2615, 2700, "number of hypoglycaemic events meeting the protocol - specified criteria for severity", "", +29359, Sitagliptin, 2714, 2725, "sitagliptin", "", +29362, NumberAffected, 2732, 2733, "2", "", +29360, Placebo, 2740, 2747, "placebo", "", +29363, NumberAffected, 2754, 2755, "1", "", +29371, ObservedResult, 2763, 2795, "significant change from baseline", "", +39194, TimePoint, 2787, 2795, "baseline", "", +29368, BodyWeight, 2799, 2810, "body weight", "", +29387, ConclusionComment, 2855, 3084, "In this 24 - week study , the addition of sitagliptin to ongoing , stable - dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes .", "", +29373, Duration, 2863, 2872, "24 - week", "", +29375, Sitagliptin, 2897, 2908, "sitagliptin", "", +29378, Insulin, 2936, 2943, "insulin", "", +29381, Metformin, 2980, 2989, "metformin", "", +29383, Type2Diabetes, 3067, 3082, "type 2 diabetes", "", +29389, PMID, 3145, 3153, "20092585", "", diff --git a/data/dm2 20092585_akramersunderbrink.n-triples b/data/dm2 20092585_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20092585_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20092585_export.csv b/data/dm2 20092585_export.csv new file mode 100644 index 0000000..6303d86 --- /dev/null +++ b/data/dm2 20092585_export.csv @@ -0,0 +1,677 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +332, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +332, 1, 2, 2, 9, 13, 9, 13, "Obes" +332, 1, 3, 3, 14, 19, 14, 19, "Metab" +332, 1, 4, 4, 20, 21, 20, 21, "." +332, 2, 1, 5, 0, 4, 22, 26, "2010" +332, 2, 2, 6, 5, 8, 27, 30, "Feb" +332, 2, 3, 7, 9, 10, 31, 32, ";" +332, 2, 4, 8, 11, 13, 33, 35, "12" +332, 2, 5, 9, 14, 15, 36, 37, "(" +332, 2, 6, 10, 16, 17, 38, 39, "2" +332, 2, 7, 11, 18, 19, 40, 41, ")" +332, 2, 8, 12, 20, 21, 42, 43, ":" +332, 2, 9, 13, 22, 25, 44, 47, "167" +332, 2, 10, 14, 26, 27, 48, 49, "-" +332, 2, 11, 15, 28, 30, 50, 52, "77" +332, 2, 12, 16, 31, 32, 53, 54, "." +332, 2, 13, 17, 33, 36, 55, 58, "doi" +332, 2, 14, 18, 37, 38, 59, 60, ":" +332, 2, 15, 19, 39, 41, 61, 63, "10" +332, 2, 16, 20, 42, 43, 64, 65, "." +332, 2, 17, 21, 44, 48, 66, 70, "1111" +332, 2, 18, 22, 49, 50, 71, 72, "/" +332, 2, 19, 23, 51, 52, 73, 74, "j" +332, 2, 20, 24, 53, 54, 75, 76, "." +332, 2, 21, 25, 55, 59, 77, 81, "1463" +332, 2, 22, 26, 60, 61, 82, 83, "-" +332, 2, 23, 27, 62, 66, 84, 88, "1326" +332, 2, 24, 28, 67, 68, 89, 90, "." +332, 2, 25, 29, 69, 73, 91, 95, "2009" +332, 2, 26, 30, 74, 75, 96, 97, "." +332, 2, 27, 31, 76, 81, 98, 103, "01173" +332, 2, 28, 32, 82, 83, 104, 105, "." +332, 2, 29, 33, 84, 85, 106, 107, "x" +332, 2, 30, 34, 86, 87, 108, 109, "." +332, 3, 1, 35, 0, 8, 110, 118, "Efficacy" +332, 3, 2, 36, 9, 12, 119, 122, "and" +332, 3, 3, 37, 13, 19, 123, 129, "safety" +332, 3, 4, 38, 20, 22, 130, 132, "of" +332, 3, 5, 39, 23, 34, 133, 144, "sitagliptin" +332, 3, 6, 40, 35, 39, 145, 149, "when" +332, 3, 7, 41, 40, 45, 150, 155, "added" +332, 3, 8, 42, 46, 48, 156, 158, "to" +332, 3, 9, 43, 49, 56, 159, 166, "insulin" +332, 3, 10, 44, 57, 64, 167, 174, "therapy" +332, 3, 11, 45, 65, 67, 175, 177, "in" +332, 3, 12, 46, 68, 76, 178, 186, "patients" +332, 3, 13, 47, 77, 81, 187, 191, "with" +332, 3, 14, 48, 82, 86, 192, 196, "type" +332, 3, 15, 49, 87, 88, 197, 198, "2" +332, 3, 16, 50, 89, 97, 199, 207, "diabetes" +332, 3, 17, 51, 98, 99, 208, 209, "." +332, 4, 1, 52, 0, 5, 210, 215, "Vilsb" +332, 4, 2, 53, 6, 7, 216, 217, "ø" +332, 4, 3, 54, 8, 10, 218, 220, "ll" +332, 4, 4, 55, 11, 12, 221, 222, "T" +332, 4, 5, 56, 13, 14, 223, 224, "(" +332, 4, 6, 57, 15, 16, 225, 226, "1" +332, 4, 7, 58, 17, 18, 227, 228, ")" +332, 4, 8, 59, 19, 20, 229, 230, "," +332, 4, 9, 60, 21, 31, 231, 241, "Rosenstock" +332, 4, 10, 61, 32, 33, 242, 243, "J" +332, 4, 11, 62, 34, 35, 244, 245, "," +332, 4, 12, 63, 36, 39, 246, 249, "Yki" +332, 4, 13, 64, 40, 41, 250, 251, "-" +332, 4, 14, 65, 42, 43, 252, 253, "J" +332, 4, 15, 66, 44, 45, 254, 255, "ä" +332, 4, 16, 67, 46, 52, 256, 262, "rvinen" +332, 4, 17, 68, 53, 54, 263, 264, "H" +332, 4, 18, 69, 55, 56, 265, 266, "," +332, 4, 19, 70, 57, 63, 267, 273, "Cefalu" +332, 4, 20, 71, 64, 66, 274, 276, "WT" +332, 4, 21, 72, 67, 68, 277, 278, "," +332, 4, 22, 73, 69, 73, 279, 283, "Chen" +332, 4, 23, 74, 74, 75, 284, 285, "Y" +332, 4, 24, 75, 76, 77, 286, 287, "," +332, 4, 25, 76, 78, 81, 288, 291, "Luo" +332, 4, 26, 77, 82, 83, 292, 293, "E" +332, 4, 27, 78, 84, 85, 294, 295, "," +332, 4, 28, 79, 86, 92, 296, 302, "Musser" +332, 4, 29, 80, 93, 94, 303, 304, "B" +332, 4, 30, 81, 95, 96, 305, 306, "," +332, 4, 31, 82, 97, 104, 307, 314, "Andryuk" +332, 4, 32, 83, 105, 107, 315, 317, "PJ" +332, 4, 33, 84, 108, 109, 318, 319, "," +332, 4, 34, 85, 110, 114, 320, 324, "Ling" +332, 4, 35, 86, 115, 116, 325, 326, "Y" +332, 4, 36, 87, 117, 118, 327, 328, "," +332, 4, 37, 88, 119, 126, 329, 336, "Kaufman" +332, 4, 38, 89, 127, 129, 337, 339, "KD" +332, 4, 39, 90, 130, 131, 340, 341, "," +332, 4, 40, 91, 132, 140, 342, 350, "Amatruda" +332, 4, 41, 92, 141, 143, 351, 353, "JM" +332, 4, 42, 93, 144, 145, 354, 355, "," +332, 4, 43, 94, 146, 151, 356, 361, "Engel" +332, 4, 44, 95, 152, 154, 362, 364, "SS" +332, 4, 45, 96, 155, 156, 365, 366, "," +332, 4, 46, 97, 157, 161, 367, 371, "Katz" +332, 4, 47, 98, 162, 163, 372, 373, "L" +332, 4, 48, 99, 164, 165, 374, 375, "." +332, 4, 49, 100, 166, 172, 376, 382, "Author" +332, 4, 50, 101, 173, 184, 383, 394, "information" +332, 4, 51, 102, 185, 186, 395, 396, ":" +332, 4, 52, 103, 187, 188, 397, 398, "(" +332, 4, 53, 104, 189, 190, 399, 400, "1" +332, 4, 54, 105, 191, 192, 401, 402, ")" +332, 4, 55, 106, 193, 201, 403, 411, "Diabetes" +332, 4, 56, 107, 202, 210, 412, 420, "Research" +332, 4, 57, 108, 211, 219, 421, 429, "Division" +332, 4, 58, 109, 220, 221, 430, 431, "," +332, 4, 59, 110, 222, 232, 432, 442, "Department" +332, 4, 60, 111, 233, 235, 443, 445, "of" +332, 4, 61, 112, 236, 244, 446, 454, "Internal" +332, 4, 62, 113, 245, 253, 455, 463, "Medicine" +332, 4, 63, 114, 254, 255, 464, 465, "F" +332, 4, 64, 115, 256, 257, 466, 467, "," +332, 4, 65, 116, 258, 266, 468, 476, "Gentofte" +332, 4, 66, 117, 267, 275, 477, 485, "Hospital" +332, 4, 67, 118, 276, 277, 486, 487, "," +332, 4, 68, 119, 278, 288, 488, 498, "University" +332, 4, 69, 120, 289, 291, 499, 501, "of" +332, 4, 70, 121, 292, 302, 502, 512, "Copenhagen" +332, 4, 71, 122, 303, 304, 513, 514, "," +332, 4, 72, 123, 305, 315, 515, 525, "Copenhagen" +332, 4, 73, 124, 316, 317, 526, 527, "," +332, 4, 74, 125, 318, 325, 528, 535, "Denmark" +332, 4, 75, 126, 326, 327, 536, 537, "." +332, 5, 1, 127, 0, 9, 538, 547, "OBJECTIVE" +332, 5, 2, 128, 10, 11, 548, 549, ":" +332, 5, 3, 129, 12, 14, 550, 552, "To" +332, 5, 4, 130, 15, 23, 553, 561, "evaluate" +332, 5, 5, 131, 24, 27, 562, 565, "the" +332, 5, 6, 132, 28, 36, 566, 574, "efficacy" +332, 5, 7, 133, 37, 40, 575, 578, "and" +332, 5, 8, 134, 41, 53, 579, 591, "tolerability" +332, 5, 9, 135, 54, 56, 592, 594, "of" +332, 5, 10, 136, 57, 68, 595, 606, "sitagliptin" +332, 5, 11, 137, 69, 73, 607, 611, "when" +332, 5, 12, 138, 74, 79, 612, 617, "added" +332, 5, 13, 139, 80, 82, 618, 620, "to" +332, 5, 14, 140, 83, 90, 621, 628, "insulin" +332, 5, 15, 141, 91, 98, 629, 636, "therapy" +332, 5, 16, 142, 99, 104, 637, 642, "alone" +332, 5, 17, 143, 105, 107, 643, 645, "or" +332, 5, 18, 144, 108, 110, 646, 648, "in" +332, 5, 19, 145, 111, 122, 649, 660, "combination" +332, 5, 20, 146, 123, 127, 661, 665, "with" +332, 5, 21, 147, 128, 137, 666, 675, "metformin" +332, 5, 22, 148, 138, 140, 676, 678, "in" +332, 5, 23, 149, 141, 149, 679, 687, "patients" +332, 5, 24, 150, 150, 154, 688, 692, "with" +332, 5, 25, 151, 155, 159, 693, 697, "type" +332, 5, 26, 152, 160, 161, 698, 699, "2" +332, 5, 27, 153, 162, 170, 700, 708, "diabetes" +332, 5, 28, 154, 171, 172, 709, 710, "." +332, 6, 1, 155, 0, 7, 711, 718, "METHODS" +332, 6, 2, 156, 8, 9, 719, 720, ":" +332, 6, 3, 157, 10, 15, 721, 726, "After" +332, 6, 4, 158, 16, 17, 727, 728, "a" +332, 6, 5, 159, 18, 19, 729, 730, "2" +332, 6, 6, 160, 20, 24, 731, 735, "week" +332, 6, 7, 161, 25, 32, 736, 743, "placebo" +332, 6, 8, 162, 33, 36, 744, 747, "run" +332, 6, 9, 163, 37, 38, 748, 749, "-" +332, 6, 10, 164, 39, 41, 750, 752, "in" +332, 6, 11, 165, 42, 48, 753, 759, "period" +332, 6, 12, 166, 49, 50, 760, 761, "," +332, 6, 13, 167, 51, 59, 762, 770, "eligible" +332, 6, 14, 168, 60, 68, 771, 779, "patients" +332, 6, 15, 169, 69, 81, 780, 792, "inadequately" +332, 6, 16, 170, 82, 92, 793, 803, "controlled" +332, 6, 17, 171, 93, 95, 804, 806, "on" +332, 6, 18, 172, 96, 100, 807, 811, "long" +332, 6, 19, 173, 101, 102, 812, 813, "-" +332, 6, 20, 174, 103, 109, 814, 820, "acting" +332, 6, 21, 175, 110, 111, 821, 822, "," +332, 6, 22, 176, 112, 124, 823, 835, "intermediate" +332, 6, 23, 177, 125, 126, 836, 837, "-" +332, 6, 24, 178, 127, 133, 838, 844, "acting" +332, 6, 25, 179, 134, 136, 845, 847, "or" +332, 6, 26, 180, 137, 145, 848, 856, "premixed" +332, 6, 27, 181, 146, 153, 857, 864, "insulin" +332, 6, 28, 182, 154, 155, 865, 866, "(" +332, 6, 29, 183, 156, 161, 867, 872, "HbA1c" +332, 6, 30, 184, 162, 163, 873, 874, ">" +332, 6, 31, 185, 164, 166, 875, 877, "or" +332, 6, 32, 186, 167, 168, 878, 879, "=" +332, 6, 33, 187, 169, 170, 880, 881, "7" +332, 6, 34, 188, 171, 172, 882, 883, "." +332, 6, 35, 189, 173, 174, 884, 885, "5" +332, 6, 36, 190, 175, 176, 886, 887, "%" +332, 6, 37, 191, 177, 180, 888, 891, "and" +332, 6, 38, 192, 181, 182, 892, 893, "<" +332, 6, 39, 193, 183, 185, 894, 896, "or" +332, 6, 40, 194, 186, 187, 897, 898, "=" +332, 6, 41, 195, 188, 190, 899, 901, "11" +332, 6, 42, 196, 191, 192, 902, 903, "%" +332, 6, 43, 197, 193, 194, 904, 905, ")" +332, 6, 44, 198, 195, 196, 906, 907, "," +332, 6, 45, 199, 197, 201, 908, 912, "were" +332, 6, 46, 200, 202, 212, 913, 923, "randomised" +332, 6, 47, 201, 213, 214, 924, 925, "1" +332, 6, 48, 202, 215, 216, 926, 927, ":" +332, 6, 49, 203, 217, 218, 928, 929, "1" +332, 6, 50, 204, 219, 221, 930, 932, "to" +332, 6, 51, 205, 222, 225, 933, 936, "the" +332, 6, 52, 206, 226, 234, 937, 945, "addition" +332, 6, 53, 207, 235, 237, 946, 948, "of" +332, 6, 54, 208, 238, 242, 949, 953, "once" +332, 6, 55, 209, 243, 244, 954, 955, "-" +332, 6, 56, 210, 245, 250, 956, 961, "daily" +332, 6, 57, 211, 251, 262, 962, 973, "sitagliptin" +332, 6, 58, 212, 263, 266, 974, 977, "100" +332, 6, 59, 213, 267, 269, 978, 980, "mg" +332, 6, 60, 214, 270, 272, 981, 983, "or" +332, 6, 61, 215, 273, 281, 984, 992, "matching" +332, 6, 62, 216, 282, 289, 993, 1000, "placebo" +332, 6, 63, 217, 290, 294, 1001, 1005, "over" +332, 6, 64, 218, 295, 296, 1006, 1007, "a" +332, 6, 65, 219, 297, 299, 1008, 1010, "24" +332, 6, 66, 220, 300, 301, 1011, 1012, "-" +332, 6, 67, 221, 302, 306, 1013, 1017, "week" +332, 6, 68, 222, 307, 312, 1018, 1023, "study" +332, 6, 69, 223, 313, 319, 1024, 1030, "period" +332, 6, 70, 224, 320, 321, 1031, 1032, "." +332, 7, 1, 225, 0, 3, 1033, 1036, "The" +332, 7, 2, 226, 4, 9, 1037, 1042, "study" +332, 7, 3, 227, 10, 16, 1043, 1049, "capped" +332, 7, 4, 228, 17, 20, 1050, 1053, "the" +332, 7, 5, 229, 21, 31, 1054, 1064, "proportion" +332, 7, 6, 230, 32, 34, 1065, 1067, "of" +332, 7, 7, 231, 35, 45, 1068, 1078, "randomised" +332, 7, 8, 232, 46, 54, 1079, 1087, "patients" +332, 7, 9, 233, 55, 57, 1088, 1090, "on" +332, 7, 10, 234, 58, 65, 1091, 1098, "insulin" +332, 7, 11, 235, 66, 70, 1099, 1103, "plus" +332, 7, 12, 236, 71, 80, 1104, 1113, "metformin" +332, 7, 13, 237, 81, 83, 1114, 1116, "at" +332, 7, 14, 238, 84, 86, 1117, 1119, "75" +332, 7, 15, 239, 87, 88, 1120, 1121, "%" +332, 7, 16, 240, 89, 90, 1122, 1123, "." +332, 8, 1, 241, 0, 7, 1124, 1131, "Further" +332, 8, 2, 242, 8, 9, 1132, 1133, "," +332, 8, 3, 243, 10, 13, 1134, 1137, "the" +332, 8, 4, 244, 14, 19, 1138, 1143, "study" +332, 8, 5, 245, 20, 26, 1144, 1150, "capped" +332, 8, 6, 246, 27, 30, 1151, 1154, "the" +332, 8, 7, 247, 31, 41, 1155, 1165, "proportion" +332, 8, 8, 248, 42, 44, 1166, 1168, "of" +332, 8, 9, 249, 45, 55, 1169, 1179, "randomised" +332, 8, 10, 250, 56, 64, 1180, 1188, "patients" +332, 8, 11, 251, 65, 67, 1189, 1191, "on" +332, 8, 12, 252, 68, 76, 1192, 1200, "premixed" +332, 8, 13, 253, 77, 84, 1201, 1208, "insulin" +332, 8, 14, 254, 85, 87, 1209, 1211, "at" +332, 8, 15, 255, 88, 90, 1212, 1214, "25" +332, 8, 16, 256, 91, 92, 1215, 1216, "%" +332, 8, 17, 257, 93, 94, 1217, 1218, "." +332, 9, 1, 258, 0, 3, 1219, 1222, "The" +332, 9, 2, 259, 4, 13, 1223, 1232, "metformin" +332, 9, 3, 260, 14, 18, 1233, 1237, "dose" +332, 9, 4, 261, 19, 22, 1238, 1241, "and" +332, 9, 5, 262, 23, 26, 1242, 1245, "the" +332, 9, 6, 263, 27, 34, 1246, 1253, "insulin" +332, 9, 7, 264, 35, 39, 1254, 1258, "dose" +332, 9, 8, 265, 40, 44, 1259, 1263, "were" +332, 9, 9, 266, 45, 47, 1264, 1266, "to" +332, 9, 10, 267, 48, 54, 1267, 1273, "remain" +332, 9, 11, 268, 55, 61, 1274, 1280, "stable" +332, 9, 12, 269, 62, 72, 1281, 1291, "throughout" +332, 9, 13, 270, 73, 76, 1292, 1295, "the" +332, 9, 14, 271, 77, 82, 1296, 1301, "study" +332, 9, 15, 272, 83, 84, 1302, 1303, "." +332, 10, 1, 273, 0, 3, 1304, 1307, "The" +332, 10, 2, 274, 4, 11, 1308, 1315, "primary" +332, 10, 3, 275, 12, 20, 1316, 1324, "endpoint" +332, 10, 4, 276, 21, 24, 1325, 1328, "was" +332, 10, 5, 277, 25, 30, 1329, 1334, "HbA1c" +332, 10, 6, 278, 31, 37, 1335, 1341, "change" +332, 10, 7, 279, 38, 42, 1342, 1346, "from" +332, 10, 8, 280, 43, 51, 1347, 1355, "baseline" +332, 10, 9, 281, 52, 54, 1356, 1358, "at" +332, 10, 10, 282, 55, 59, 1359, 1363, "week" +332, 10, 11, 283, 60, 62, 1364, 1366, "24" +332, 10, 12, 284, 63, 64, 1367, 1368, "." +332, 11, 1, 285, 0, 7, 1369, 1376, "RESULTS" +332, 11, 2, 286, 8, 9, 1377, 1378, ":" +332, 11, 3, 287, 10, 14, 1379, 1383, "Mean" +332, 11, 4, 288, 15, 23, 1384, 1392, "baseline" +332, 11, 5, 289, 24, 39, 1393, 1408, "characteristics" +332, 11, 6, 290, 40, 44, 1409, 1413, "were" +332, 11, 7, 291, 45, 52, 1414, 1421, "similar" +332, 11, 8, 292, 53, 60, 1422, 1429, "between" +332, 11, 9, 293, 61, 64, 1430, 1433, "the" +332, 11, 10, 294, 65, 76, 1434, 1445, "sitagliptin" +332, 11, 11, 295, 77, 78, 1446, 1447, "(" +332, 11, 12, 296, 79, 80, 1448, 1449, "n" +332, 11, 13, 297, 81, 82, 1450, 1451, "=" +332, 11, 14, 298, 83, 86, 1452, 1455, "322" +332, 11, 15, 299, 87, 88, 1456, 1457, ")" +332, 11, 16, 300, 89, 92, 1458, 1461, "and" +332, 11, 17, 301, 93, 100, 1462, 1469, "placebo" +332, 11, 18, 302, 101, 102, 1470, 1471, "(" +332, 11, 19, 303, 103, 104, 1472, 1473, "n" +332, 11, 20, 304, 105, 106, 1474, 1475, "=" +332, 11, 21, 305, 107, 110, 1476, 1479, "319" +332, 11, 22, 306, 111, 112, 1480, 1481, ")" +332, 11, 23, 307, 113, 119, 1482, 1488, "groups" +332, 11, 24, 308, 120, 121, 1489, 1490, "," +332, 11, 25, 309, 122, 131, 1491, 1500, "including" +332, 11, 26, 310, 132, 137, 1501, 1506, "HbA1c" +332, 11, 27, 311, 138, 139, 1507, 1508, "(" +332, 11, 28, 312, 140, 141, 1509, 1510, "8" +332, 11, 29, 313, 142, 143, 1511, 1512, "." +332, 11, 30, 314, 144, 145, 1513, 1514, "7" +332, 11, 31, 315, 146, 148, 1515, 1517, "vs" +332, 11, 32, 316, 149, 150, 1518, 1519, "." +332, 11, 33, 317, 151, 152, 1520, 1521, "8" +332, 11, 34, 318, 153, 154, 1522, 1523, "." +332, 11, 35, 319, 155, 156, 1524, 1525, "6" +332, 11, 36, 320, 157, 158, 1526, 1527, "%" +332, 11, 37, 321, 159, 160, 1528, 1529, ")" +332, 11, 38, 322, 161, 162, 1530, 1531, "," +332, 11, 39, 323, 163, 171, 1532, 1540, "diabetes" +332, 11, 40, 324, 172, 180, 1541, 1549, "duration" +332, 11, 41, 325, 181, 182, 1550, 1551, "(" +332, 11, 42, 326, 183, 185, 1552, 1554, "13" +332, 11, 43, 327, 186, 188, 1555, 1557, "vs" +332, 11, 44, 328, 189, 190, 1558, 1559, "." +332, 11, 45, 329, 191, 193, 1560, 1562, "12" +332, 11, 46, 330, 194, 199, 1563, 1568, "years" +332, 11, 47, 331, 200, 201, 1569, 1570, ")" +332, 11, 48, 332, 202, 203, 1571, 1572, "," +332, 11, 49, 333, 204, 208, 1573, 1577, "body" +332, 11, 50, 334, 209, 213, 1578, 1582, "mass" +332, 11, 51, 335, 214, 219, 1583, 1588, "index" +332, 11, 52, 336, 220, 221, 1589, 1590, "(" +332, 11, 53, 337, 222, 224, 1591, 1593, "31" +332, 11, 54, 338, 225, 226, 1594, 1595, "." +332, 11, 55, 339, 227, 228, 1596, 1597, "4" +332, 11, 56, 340, 229, 231, 1598, 1600, "vs" +332, 11, 57, 341, 232, 233, 1601, 1602, "." +332, 11, 58, 342, 234, 236, 1603, 1605, "31" +332, 11, 59, 343, 237, 238, 1606, 1607, "." +332, 11, 60, 344, 239, 240, 1608, 1609, "4" +332, 11, 61, 345, 241, 243, 1610, 1612, "kg" +332, 11, 62, 346, 244, 245, 1613, 1614, "/" +332, 11, 63, 347, 246, 247, 1615, 1616, "m" +332, 11, 64, 348, 248, 249, 1617, 1618, "(" +332, 11, 65, 349, 250, 251, 1619, 1620, "2" +332, 11, 66, 350, 252, 253, 1621, 1622, ")" +332, 11, 67, 351, 254, 255, 1623, 1624, ")" +332, 11, 68, 352, 256, 257, 1625, 1626, "," +332, 11, 69, 353, 258, 261, 1627, 1630, "and" +332, 11, 70, 354, 262, 267, 1631, 1636, "total" +332, 11, 71, 355, 268, 273, 1637, 1642, "daily" +332, 11, 72, 356, 274, 281, 1643, 1650, "insulin" +332, 11, 73, 357, 282, 286, 1651, 1655, "dose" +332, 11, 74, 358, 287, 288, 1656, 1657, "(" +332, 11, 75, 359, 289, 291, 1658, 1660, "51" +332, 11, 76, 360, 292, 294, 1661, 1663, "vs" +332, 11, 77, 361, 295, 296, 1664, 1665, "." +332, 11, 78, 362, 297, 299, 1666, 1668, "52" +332, 11, 79, 363, 300, 302, 1669, 1671, "IU" +332, 11, 80, 364, 303, 304, 1672, 1673, ")" +332, 11, 81, 365, 305, 306, 1674, 1675, "," +332, 11, 82, 366, 307, 319, 1676, 1688, "respectively" +332, 11, 83, 367, 320, 321, 1689, 1690, "." +332, 12, 1, 368, 0, 2, 1691, 1693, "At" +332, 12, 2, 369, 3, 5, 1694, 1696, "24" +332, 12, 3, 370, 6, 11, 1697, 1702, "weeks" +332, 12, 4, 371, 12, 13, 1703, 1704, "," +332, 12, 5, 372, 14, 17, 1705, 1708, "the" +332, 12, 6, 373, 18, 26, 1709, 1717, "addition" +332, 12, 7, 374, 27, 29, 1718, 1720, "of" +332, 12, 8, 375, 30, 41, 1721, 1732, "sitagliptin" +332, 12, 9, 376, 42, 55, 1733, 1746, "significantly" +332, 12, 10, 377, 56, 57, 1747, 1748, "(" +332, 12, 11, 378, 58, 59, 1749, 1750, "p" +332, 12, 12, 379, 60, 61, 1751, 1752, "<" +332, 12, 13, 380, 62, 63, 1753, 1754, "0" +332, 12, 14, 381, 64, 65, 1755, 1756, "." +332, 12, 15, 382, 66, 69, 1757, 1760, "001" +332, 12, 16, 383, 70, 71, 1761, 1762, ")" +332, 12, 17, 384, 72, 79, 1763, 1770, "reduced" +332, 12, 18, 385, 80, 85, 1771, 1776, "HbA1c" +332, 12, 19, 386, 86, 88, 1777, 1779, "by" +332, 12, 20, 387, 89, 90, 1780, 1781, "0" +332, 12, 21, 388, 91, 92, 1782, 1783, "." +332, 12, 22, 389, 93, 94, 1784, 1785, "6" +332, 12, 23, 390, 95, 96, 1786, 1787, "%" +332, 12, 24, 391, 97, 105, 1788, 1796, "compared" +332, 12, 25, 392, 106, 110, 1797, 1801, "with" +332, 12, 26, 393, 111, 118, 1802, 1809, "placebo" +332, 12, 27, 394, 119, 120, 1810, 1811, "(" +332, 12, 28, 395, 121, 122, 1812, 1813, "0" +332, 12, 29, 396, 123, 124, 1814, 1815, "." +332, 12, 30, 397, 125, 126, 1816, 1817, "0" +332, 12, 31, 398, 127, 128, 1818, 1819, "%" +332, 12, 32, 399, 129, 130, 1820, 1821, ")" +332, 12, 33, 400, 131, 132, 1822, 1823, "." +332, 13, 1, 401, 0, 1, 1824, 1825, "A" +332, 13, 2, 402, 2, 9, 1826, 1833, "greater" +332, 13, 3, 403, 10, 20, 1834, 1844, "proportion" +332, 13, 4, 404, 21, 23, 1845, 1847, "of" +332, 13, 5, 405, 24, 32, 1848, 1856, "patients" +332, 13, 6, 406, 33, 41, 1857, 1865, "achieved" +332, 13, 7, 407, 42, 44, 1866, 1868, "an" +332, 13, 8, 408, 45, 50, 1869, 1874, "HbA1c" +332, 13, 9, 409, 51, 56, 1875, 1880, "level" +332, 13, 10, 410, 57, 58, 1881, 1882, "<" +332, 13, 11, 411, 59, 60, 1883, 1884, "7" +332, 13, 12, 412, 61, 62, 1885, 1886, "%" +332, 13, 13, 413, 63, 68, 1887, 1892, "while" +332, 13, 14, 414, 69, 79, 1893, 1903, "randomised" +332, 13, 15, 415, 80, 82, 1904, 1906, "to" +332, 13, 16, 416, 83, 94, 1907, 1918, "sitagliptin" +332, 13, 17, 417, 95, 97, 1919, 1921, "as" +332, 13, 18, 418, 98, 106, 1922, 1930, "compared" +332, 13, 19, 419, 107, 111, 1931, 1935, "with" +332, 13, 20, 420, 112, 119, 1936, 1943, "placebo" +332, 13, 21, 421, 120, 121, 1944, 1945, "(" +332, 13, 22, 422, 122, 124, 1946, 1948, "13" +332, 13, 23, 423, 125, 127, 1949, 1951, "vs" +332, 13, 24, 424, 128, 129, 1952, 1953, "." +332, 13, 25, 425, 130, 131, 1954, 1955, "5" +332, 13, 26, 426, 132, 133, 1956, 1957, "%" +332, 13, 27, 427, 134, 146, 1958, 1970, "respectively" +332, 13, 28, 428, 147, 148, 1971, 1972, ";" +332, 13, 29, 429, 149, 150, 1973, 1974, "p" +332, 13, 30, 430, 151, 152, 1975, 1976, "<" +332, 13, 31, 431, 153, 154, 1977, 1978, "0" +332, 13, 32, 432, 155, 156, 1979, 1980, "." +332, 13, 33, 433, 157, 160, 1981, 1984, "001" +332, 13, 34, 434, 161, 162, 1985, 1986, ")" +332, 13, 35, 435, 163, 164, 1987, 1988, "." +332, 14, 1, 436, 0, 7, 1989, 1996, "Similar" +332, 14, 2, 437, 8, 13, 1997, 2002, "HbA1c" +332, 14, 3, 438, 14, 24, 2003, 2013, "reductions" +332, 14, 4, 439, 25, 29, 2014, 2018, "were" +332, 14, 5, 440, 30, 38, 2019, 2027, "observed" +332, 14, 6, 441, 39, 41, 2028, 2030, "in" +332, 14, 7, 442, 42, 45, 2031, 2034, "the" +332, 14, 8, 443, 46, 53, 2035, 2042, "patient" +332, 14, 9, 444, 54, 60, 2043, 2049, "strata" +332, 14, 10, 445, 61, 68, 2050, 2057, "defined" +332, 14, 11, 446, 69, 71, 2058, 2060, "by" +332, 14, 12, 447, 72, 79, 2061, 2068, "insulin" +332, 14, 13, 448, 80, 84, 2069, 2073, "type" +332, 14, 14, 449, 85, 86, 2074, 2075, "(" +332, 14, 15, 450, 87, 91, 2076, 2080, "long" +332, 14, 16, 451, 92, 93, 2081, 2082, "-" +332, 14, 17, 452, 94, 100, 2083, 2089, "acting" +332, 14, 18, 453, 101, 104, 2090, 2093, "and" +332, 14, 19, 454, 105, 117, 2094, 2106, "intermediate" +332, 14, 20, 455, 118, 119, 2107, 2108, "-" +332, 14, 21, 456, 120, 126, 2109, 2115, "acting" +332, 14, 22, 457, 127, 135, 2116, 2124, "insulins" +332, 14, 23, 458, 136, 138, 2125, 2127, "or" +332, 14, 24, 459, 139, 147, 2128, 2136, "premixed" +332, 14, 25, 460, 148, 156, 2137, 2145, "insulins" +332, 14, 26, 461, 157, 158, 2146, 2147, ")" +332, 14, 27, 462, 159, 162, 2148, 2151, "and" +332, 14, 28, 463, 163, 165, 2152, 2154, "by" +332, 14, 29, 464, 166, 174, 2155, 2163, "baseline" +332, 14, 30, 465, 175, 184, 2164, 2173, "metformin" +332, 14, 31, 466, 185, 194, 2174, 2183, "treatment" +332, 14, 32, 467, 195, 196, 2184, 2185, "." +332, 15, 1, 468, 0, 3, 2186, 2189, "The" +332, 15, 2, 469, 4, 12, 2190, 2198, "addition" +332, 15, 3, 470, 13, 15, 2199, 2201, "of" +332, 15, 4, 471, 16, 27, 2202, 2213, "sitagliptin" +332, 15, 5, 472, 28, 41, 2214, 2227, "significantly" +332, 15, 6, 473, 42, 43, 2228, 2229, "(" +332, 15, 7, 474, 44, 45, 2230, 2231, "p" +332, 15, 8, 475, 46, 47, 2232, 2233, "<" +332, 15, 9, 476, 48, 49, 2234, 2235, "0" +332, 15, 10, 477, 50, 51, 2236, 2237, "." +332, 15, 11, 478, 52, 55, 2238, 2241, "001" +332, 15, 12, 479, 56, 57, 2242, 2243, ")" +332, 15, 13, 480, 58, 65, 2244, 2251, "reduced" +332, 15, 14, 481, 66, 73, 2252, 2259, "fasting" +332, 15, 15, 482, 74, 80, 2260, 2266, "plasma" +332, 15, 16, 483, 81, 88, 2267, 2274, "glucose" +332, 15, 17, 484, 89, 91, 2275, 2277, "by" +332, 15, 18, 485, 92, 94, 2278, 2280, "15" +332, 15, 19, 486, 95, 96, 2281, 2282, "." +332, 15, 20, 487, 97, 98, 2283, 2284, "0" +332, 15, 21, 488, 99, 101, 2285, 2287, "mg" +332, 15, 22, 489, 102, 103, 2288, 2289, "/" +332, 15, 23, 490, 104, 106, 2290, 2292, "dl" +332, 15, 24, 491, 107, 108, 2293, 2294, "(" +332, 15, 25, 492, 109, 110, 2295, 2296, "0" +332, 15, 26, 493, 111, 112, 2297, 2298, "." +332, 15, 27, 494, 113, 114, 2299, 2300, "8" +332, 15, 28, 495, 115, 119, 2301, 2305, "mmol" +332, 15, 29, 496, 120, 121, 2306, 2307, "/" +332, 15, 30, 497, 122, 123, 2308, 2309, "l" +332, 15, 31, 498, 124, 125, 2310, 2311, ")" +332, 15, 32, 499, 126, 129, 2312, 2315, "and" +332, 15, 33, 500, 130, 131, 2316, 2317, "2" +332, 15, 34, 501, 132, 133, 2318, 2319, "-" +332, 15, 35, 502, 134, 135, 2320, 2321, "h" +332, 15, 36, 503, 136, 144, 2322, 2330, "postmeal" +332, 15, 37, 504, 145, 152, 2331, 2338, "glucose" +332, 15, 38, 505, 153, 155, 2339, 2341, "by" +332, 15, 39, 506, 156, 158, 2342, 2344, "36" +332, 15, 40, 507, 159, 160, 2345, 2346, "." +332, 15, 41, 508, 161, 162, 2347, 2348, "1" +332, 15, 42, 509, 163, 165, 2349, 2351, "mg" +332, 15, 43, 510, 166, 167, 2352, 2353, "/" +332, 15, 44, 511, 168, 170, 2354, 2356, "dl" +332, 15, 45, 512, 171, 172, 2357, 2358, "(" +332, 15, 46, 513, 173, 174, 2359, 2360, "2" +332, 15, 47, 514, 175, 176, 2361, 2362, "." +332, 15, 48, 515, 177, 178, 2363, 2364, "0" +332, 15, 49, 516, 179, 183, 2365, 2369, "mmol" +332, 15, 50, 517, 184, 185, 2370, 2371, "/" +332, 15, 51, 518, 186, 187, 2372, 2373, "l" +332, 15, 52, 519, 188, 189, 2374, 2375, ")" +332, 15, 53, 520, 190, 198, 2376, 2384, "relative" +332, 15, 54, 521, 199, 201, 2385, 2387, "to" +332, 15, 55, 522, 202, 209, 2388, 2395, "placebo" +332, 15, 56, 523, 210, 211, 2396, 2397, "." +332, 16, 1, 524, 0, 1, 2398, 2399, "A" +332, 16, 2, 525, 2, 8, 2400, 2406, "higher" +332, 16, 3, 526, 9, 18, 2407, 2416, "incidence" +332, 16, 4, 527, 19, 21, 2417, 2419, "of" +332, 16, 5, 528, 22, 29, 2420, 2427, "adverse" +332, 16, 6, 529, 30, 41, 2428, 2439, "experiences" +332, 16, 7, 530, 42, 45, 2440, 2443, "was" +332, 16, 8, 531, 46, 54, 2444, 2452, "reported" +332, 16, 9, 532, 55, 59, 2453, 2457, "with" +332, 16, 10, 533, 60, 71, 2458, 2469, "sitagliptin" +332, 16, 11, 534, 72, 73, 2470, 2471, "(" +332, 16, 12, 535, 74, 76, 2472, 2474, "52" +332, 16, 13, 536, 77, 78, 2475, 2476, "%" +332, 16, 14, 537, 79, 80, 2477, 2478, ")" +332, 16, 15, 538, 81, 89, 2479, 2487, "compared" +332, 16, 16, 539, 90, 94, 2488, 2492, "with" +332, 16, 17, 540, 95, 102, 2493, 2500, "placebo" +332, 16, 18, 541, 103, 104, 2501, 2502, "(" +332, 16, 19, 542, 105, 107, 2503, 2505, "43" +332, 16, 20, 543, 108, 109, 2506, 2507, "%" +332, 16, 21, 544, 110, 111, 2508, 2509, ")" +332, 16, 22, 545, 112, 113, 2510, 2511, "," +332, 16, 23, 546, 114, 117, 2512, 2515, "due" +332, 16, 24, 547, 118, 124, 2516, 2522, "mainly" +332, 16, 25, 548, 125, 127, 2523, 2525, "to" +332, 16, 26, 549, 128, 131, 2526, 2529, "the" +332, 16, 27, 550, 132, 141, 2530, 2539, "increased" +332, 16, 28, 551, 142, 151, 2540, 2549, "incidence" +332, 16, 29, 552, 152, 154, 2550, 2552, "of" +332, 16, 30, 553, 155, 168, 2553, 2566, "hypoglycaemia" +332, 16, 31, 554, 169, 170, 2567, 2568, "(" +332, 16, 32, 555, 171, 182, 2569, 2580, "sitagliptin" +332, 16, 33, 556, 183, 184, 2581, 2582, "," +332, 16, 34, 557, 185, 187, 2583, 2585, "16" +332, 16, 35, 558, 188, 189, 2586, 2587, "%" +332, 16, 36, 559, 190, 192, 2588, 2590, "vs" +332, 16, 37, 560, 193, 194, 2591, 2592, "." +332, 16, 38, 561, 195, 202, 2593, 2600, "placebo" +332, 16, 39, 562, 203, 204, 2601, 2602, "," +332, 16, 40, 563, 205, 206, 2603, 2604, "8" +332, 16, 41, 564, 207, 208, 2605, 2606, "%" +332, 16, 42, 565, 209, 210, 2607, 2608, ")" +332, 16, 43, 566, 211, 212, 2609, 2610, "." +332, 17, 1, 567, 0, 3, 2611, 2614, "The" +332, 17, 2, 568, 4, 10, 2615, 2621, "number" +332, 17, 3, 569, 11, 13, 2622, 2624, "of" +332, 17, 4, 570, 14, 27, 2625, 2638, "hypoglycaemic" +332, 17, 5, 571, 28, 34, 2639, 2645, "events" +332, 17, 6, 572, 35, 42, 2646, 2653, "meeting" +332, 17, 7, 573, 43, 46, 2654, 2657, "the" +332, 17, 8, 574, 47, 55, 2658, 2666, "protocol" +332, 17, 9, 575, 56, 57, 2667, 2668, "-" +332, 17, 10, 576, 58, 67, 2669, 2678, "specified" +332, 17, 11, 577, 68, 76, 2679, 2687, "criteria" +332, 17, 12, 578, 77, 80, 2688, 2691, "for" +332, 17, 13, 579, 81, 89, 2692, 2700, "severity" +332, 17, 14, 580, 90, 93, 2701, 2704, "was" +332, 17, 15, 581, 94, 97, 2705, 2708, "low" +332, 17, 16, 582, 98, 102, 2709, 2713, "with" +332, 17, 17, 583, 103, 114, 2714, 2725, "sitagliptin" +332, 17, 18, 584, 115, 116, 2726, 2727, "(" +332, 17, 19, 585, 117, 118, 2728, 2729, "n" +332, 17, 20, 586, 119, 120, 2730, 2731, "=" +332, 17, 21, 587, 121, 122, 2732, 2733, "2" +332, 17, 22, 588, 123, 124, 2734, 2735, ")" +332, 17, 23, 589, 125, 128, 2736, 2739, "and" +332, 17, 24, 590, 129, 136, 2740, 2747, "placebo" +332, 17, 25, 591, 137, 138, 2748, 2749, "(" +332, 17, 26, 592, 139, 140, 2750, 2751, "n" +332, 17, 27, 593, 141, 142, 2752, 2753, "=" +332, 17, 28, 594, 143, 144, 2754, 2755, "1" +332, 17, 29, 595, 145, 146, 2756, 2757, ")" +332, 17, 30, 596, 147, 148, 2758, 2759, "." +332, 18, 1, 597, 0, 2, 2760, 2762, "No" +332, 18, 2, 598, 3, 14, 2763, 2774, "significant" +332, 18, 3, 599, 15, 21, 2775, 2781, "change" +332, 18, 4, 600, 22, 26, 2782, 2786, "from" +332, 18, 5, 601, 27, 35, 2787, 2795, "baseline" +332, 18, 6, 602, 36, 38, 2796, 2798, "in" +332, 18, 7, 603, 39, 43, 2799, 2803, "body" +332, 18, 8, 604, 44, 50, 2804, 2810, "weight" +332, 18, 9, 605, 51, 54, 2811, 2814, "was" +332, 18, 10, 606, 55, 63, 2815, 2823, "observed" +332, 18, 11, 607, 64, 66, 2824, 2826, "in" +332, 18, 12, 608, 67, 73, 2827, 2833, "either" +332, 18, 13, 609, 74, 79, 2834, 2839, "group" +332, 18, 14, 610, 80, 81, 2840, 2841, "." +332, 19, 1, 611, 0, 10, 2842, 2852, "CONCLUSION" +332, 19, 2, 612, 11, 12, 2853, 2854, ":" +332, 19, 3, 613, 13, 15, 2855, 2857, "In" +332, 19, 4, 614, 16, 20, 2858, 2862, "this" +332, 19, 5, 615, 21, 23, 2863, 2865, "24" +332, 19, 6, 616, 24, 25, 2866, 2867, "-" +332, 19, 7, 617, 26, 30, 2868, 2872, "week" +332, 19, 8, 618, 31, 36, 2873, 2878, "study" +332, 19, 9, 619, 37, 38, 2879, 2880, "," +332, 19, 10, 620, 39, 42, 2881, 2884, "the" +332, 19, 11, 621, 43, 51, 2885, 2893, "addition" +332, 19, 12, 622, 52, 54, 2894, 2896, "of" +332, 19, 13, 623, 55, 66, 2897, 2908, "sitagliptin" +332, 19, 14, 624, 67, 69, 2909, 2911, "to" +332, 19, 15, 625, 70, 77, 2912, 2919, "ongoing" +332, 19, 16, 626, 78, 79, 2920, 2921, "," +332, 19, 17, 627, 80, 86, 2922, 2928, "stable" +332, 19, 18, 628, 87, 88, 2929, 2930, "-" +332, 19, 19, 629, 89, 93, 2931, 2935, "dose" +332, 19, 20, 630, 94, 101, 2936, 2943, "insulin" +332, 19, 21, 631, 102, 109, 2944, 2951, "therapy" +332, 19, 22, 632, 110, 114, 2952, 2956, "with" +332, 19, 23, 633, 115, 117, 2957, 2959, "or" +332, 19, 24, 634, 118, 125, 2960, 2967, "without" +332, 19, 25, 635, 126, 137, 2968, 2979, "concomitant" +332, 19, 26, 636, 138, 147, 2980, 2989, "metformin" +332, 19, 27, 637, 148, 156, 2990, 2998, "improved" +332, 19, 28, 638, 157, 166, 2999, 3008, "glycaemic" +332, 19, 29, 639, 167, 174, 3009, 3016, "control" +332, 19, 30, 640, 175, 178, 3017, 3020, "and" +332, 19, 31, 641, 179, 182, 3021, 3024, "was" +332, 19, 32, 642, 183, 192, 3025, 3034, "generally" +332, 19, 33, 643, 193, 197, 3035, 3039, "well" +332, 19, 34, 644, 198, 207, 3040, 3049, "tolerated" +332, 19, 35, 645, 208, 210, 3050, 3052, "in" +332, 19, 36, 646, 211, 219, 3053, 3061, "patients" +332, 19, 37, 647, 220, 224, 3062, 3066, "with" +332, 19, 38, 648, 225, 229, 3067, 3071, "type" +332, 19, 39, 649, 230, 231, 3072, 3073, "2" +332, 19, 40, 650, 232, 240, 3074, 3082, "diabetes" +332, 19, 41, 651, 241, 242, 3083, 3084, "." +332, 20, 1, 652, 0, 3, 3085, 3088, "DOI" +332, 20, 2, 653, 4, 5, 3089, 3090, ":" +332, 20, 3, 654, 6, 8, 3091, 3093, "10" +332, 20, 4, 655, 9, 10, 3094, 3095, "." +332, 20, 5, 656, 11, 15, 3096, 3100, "1111" +332, 20, 6, 657, 16, 17, 3101, 3102, "/" +332, 20, 7, 658, 18, 19, 3103, 3104, "j" +332, 20, 8, 659, 20, 21, 3105, 3106, "." +332, 20, 9, 660, 22, 26, 3107, 3111, "1463" +332, 20, 10, 661, 27, 28, 3112, 3113, "-" +332, 20, 11, 662, 29, 33, 3114, 3118, "1326" +332, 20, 12, 663, 34, 35, 3119, 3120, "." +332, 20, 13, 664, 36, 40, 3121, 3125, "2009" +332, 20, 14, 665, 41, 42, 3126, 3127, "." +332, 20, 15, 666, 43, 48, 3128, 3133, "01173" +332, 20, 16, 667, 49, 50, 3134, 3135, "." +332, 20, 17, 668, 51, 52, 3136, 3137, "x" +332, 20, 18, 669, 53, 57, 3138, 3142, "PMID" +332, 20, 19, 670, 58, 59, 3143, 3144, ":" +332, 20, 20, 671, 60, 68, 3145, 3153, "20092585" +332, 20, 21, 672, 69, 70, 3154, 3155, "[" +332, 20, 22, 673, 71, 78, 3156, 3163, "Indexed" +332, 20, 23, 674, 79, 82, 3164, 3167, "for" +332, 20, 24, 675, 83, 90, 3168, 3175, "MEDLINE" +332, 20, 25, 676, 91, 92, 3176, 3177, "]" diff --git a/data/dm2 20092585_kwoodley.annodb b/data/dm2 20092585_kwoodley.annodb new file mode 100644 index 0000000..6454af2 --- /dev/null +++ b/data/dm2 20092585_kwoodley.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15138, Journal, 0, 19, "Diabetes Obes Metab", "", +15139, PublicationYear, 22, 26, "2010", "", +36659, Title, 110, 209, "Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes .", "", +15140, Sitagliptin, 133, 144, "sitagliptin", "", +15141, Insulin, 159, 166, "insulin", "", +15142, Type2Diabetes, 192, 207, "type 2 diabetes", "", +15144, Author, 210, 222, "Vilsb ø ll T", "", +15145, Author, 231, 243, "Rosenstock J", "", +15146, Author, 246, 264, "Yki - J ä rvinen H", "", +15147, Author, 267, 276, "Cefalu WT", "", +15148, Author, 279, 285, "Chen Y", "", +15149, Author, 288, 293, "Luo E", "", +15150, Author, 296, 304, "Musser B", "", +15151, Author, 307, 317, "Andryuk PJ", "", +15152, Author, 320, 326, "Ling Y", "", +15153, Author, 329, 339, "Kaufman KD", "", +15154, Author, 342, 353, "Amatruda JM", "", +15155, Author, 356, 364, "Engel SS", "", +15156, Author, 367, 373, "Katz L", "", +15157, Country, 528, 535, "Denmark", "", +36660, ObjectiveDescription, 550, 710, "To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes .", "", +15158, Sitagliptin, 595, 606, "sitagliptin", "", +15159, Insulin, 621, 628, "insulin", "", +15160, Metformin, 666, 675, "metformin", "", +15161, Type2Diabetes, 693, 708, "type 2 diabetes", "", +15163, Duration, 729, 735, "2 week", "run in period", +15164, Placebo, 736, 743, "placebo", "run in period", +15169, Precondition, 771, 903, "patients inadequately controlled on long - acting , intermediate - acting or premixed insulin ( HbA1c > or = 7 . 5 % and < or = 11 %", "", +15165, Insulin, 857, 864, "insulin", "", +15166, HbA1c, 867, 872, "HbA1c", "", +15167, Percentage, 886, 887, "%", "", +15168, Percentage, 902, 903, "%", "", +15170, Randomized, 913, 923, "randomised", "", +15171, AllocationRatio, 924, 929, "1 : 1", "", +15172, Frequency, 949, 961, "once - daily", "", +15173, Sitagliptin, 962, 973, "sitagliptin", "", +15174, DoseValue, 974, 977, "100", "", +15175, mg, 978, 980, "mg", "", +15176, Placebo, 993, 1000, "placebo", "", +15177, Duration, 1008, 1017, "24 - week", "", +15189, Randomized, 1068, 1078, "randomised", "", +15190, Insulin, 1091, 1098, "insulin", "", +15191, Metformin, 1104, 1113, "metformin", "", +15192, Randomized, 1169, 1179, "randomised", "", +15193, Insulin, 1201, 1208, "insulin", "", +15194, Metformin, 1223, 1232, "metformin", "", +15195, Insulin, 1246, 1253, "insulin", "", +15196, HbA1c, 1329, 1334, "HbA1c", "", +15197, Duration, 1359, 1366, "week 24", "", +15198, Sitagliptin, 1434, 1445, "sitagliptin", "", +15199, NumberPatientsArm, 1452, 1455, "322", "", +15201, Placebo, 1462, 1469, "placebo", "", +15200, NumberPatientsArm, 1476, 1479, "319", "", +15202, HbA1c, 1501, 1506, "HbA1c", "", +15209, BaseLineValue, 1509, 1514, "8 . 7", "baseline value differentiated by arms", +15211, BaseLineValue, 1520, 1525, "8 . 6", "baseline value differentiated by arms", +15212, Percentage, 1526, 1527, "%", "", +15205, BMI, 1573, 1588, "body mass index", "", +15206, IntUnit_per_Kg, 1610, 1622, "kg / m ( 2 )", "", +15207, Insulin, 1643, 1650, "insulin", "", +15208, BioAndMedicalUnit, 1669, 1671, "IU", "", +36661, TimePoint, 1694, 1702, "24 weeks", "", +15215, Sitagliptin, 1721, 1732, "sitagliptin", "", +15234, PValueChangeValue, 1749, 1760, "p < 0 . 001", "", +15216, HbA1c, 1771, 1776, "HbA1c", "", +15217, Reduction, 1780, 1785, "0 . 6", "", +15219, Percentage, 1786, 1787, "%", "", +36662, Placebo, 1802, 1809, "placebo", "", +15218, ResultMeasuredValue, 1812, 1817, "0 . 0", "", +15220, Percentage, 1818, 1819, "%", "", +15221, HbA1c_target, 1869, 1886, "HbA1c level < 7 %", "", +15222, Randomized, 1893, 1903, "randomised", "", +15223, Sitagliptin, 1907, 1918, "sitagliptin", "", +15224, Placebo, 1936, 1943, "placebo", "", +15225, PercentageAffected, 1946, 1948, "13", "", +15226, PercentageAffected, 1954, 1955, "5", "", +15227, PvalueDiff, 1973, 1984, "p < 0 . 001", "", +15228, HbA1c, 1997, 2002, "HbA1c", "", +15229, Insulin, 2061, 2068, "insulin", "", +15230, Insulin, 2116, 2124, "insulins", "", +15231, Insulin, 2137, 2145, "insulins", "", +15232, Metformin, 2164, 2173, "metformin", "", +15233, Sitagliptin, 2202, 2213, "sitagliptin", "", +15235, PValueChangeValue, 2230, 2241, "p < 0 . 001", "", +15236, FastingPlasmaGlucose, 2252, 2274, "fasting plasma glucose", "", +15237, Reduction, 2278, 2284, "15 . 0", "", +15238, Mg_per_deciliter, 2285, 2292, "mg / dl", "", +15239, Reduction, 2295, 2300, "0 . 8", "", +15240, Millimoles_per_litre, 2301, 2309, "mmol / l", "", +36663, PostprandialBloodGlucose, 2316, 2338, "2 - h postmeal glucose", "", +15242, Reduction, 2342, 2348, "36 . 1", "", +15244, Mg_per_deciliter, 2349, 2356, "mg / dl", "", +15243, Reduction, 2359, 2364, "2 . 0", "", +15245, Millimoles_per_litre, 2365, 2373, "mmol / l", "", +15246, Placebo, 2388, 2395, "placebo", "", +15247, EndPointDescription, 2420, 2439, "adverse experiences", "", +15248, Sitagliptin, 2458, 2469, "sitagliptin", "", +15250, PercentageAffected, 2472, 2474, "52", "", +15249, Placebo, 2493, 2500, "placebo", "", +15251, PercentageAffected, 2503, 2505, "43", "", +15252, Hypoglycemia, 2553, 2566, "hypoglycaemia", "", +15253, Sitagliptin, 2569, 2580, "sitagliptin", "", +15255, PercentageAffected, 2583, 2585, "16", "", +15254, Placebo, 2593, 2600, "placebo", "", +15256, PercentageAffected, 2603, 2604, "8", "", +15257, Hypoglycemia, 2625, 2645, "hypoglycaemic events", "", +15258, Sitagliptin, 2714, 2725, "sitagliptin", "", +15260, NumberAffected, 2732, 2733, "2", "", +15259, Placebo, 2740, 2747, "placebo", "", +15261, NumberAffected, 2754, 2755, "1", "", +36664, ObservedResult, 2760, 2841, "No significant change from baseline in body weight was observed in either group .", "", +15262, BodyWeight, 2799, 2810, "body weight", "", +36665, ConclusionComment, 2855, 3084, "In this 24 - week study , the addition of sitagliptin to ongoing , stable - dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes .", "", +15264, Duration, 2863, 2872, "24 - week", "", +15265, Sitagliptin, 2897, 2908, "sitagliptin", "", +15266, Insulin, 2936, 2943, "insulin", "", +15267, Metformin, 2980, 2989, "metformin", "", +15268, Type2Diabetes, 3067, 3082, "type 2 diabetes", "", +15270, PMID, 3145, 3153, "20092585", "", diff --git a/data/dm2 20092585_kwoodley.n-triples b/data/dm2 20092585_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20092585_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20200301_admin.annodb b/data/dm2 20200301_admin.annodb new file mode 100644 index 0000000..9acda3f --- /dev/null +++ b/data/dm2 20200301_admin.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2010", "", " \"2010\"." +94, Title, 99, 332, "A 24 - week , randomized , treat - to - target trial comparing initiation of insulin glargine once - daily with insulin detemir twice - daily in patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs .", "", " \"A 24 - week , randomized , treat - to - target trial comparing initiation of insulin glargine once - daily with insulin detemir twice - daily in patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs .\"." +2, Duration, 101, 110, "24 - week", "", +3, Randomized, 113, 123, "randomized", "", " ." +4, CTDesign, 126, 145, "treat - to - target", "", " . ." +5, InsulinGlargine, 176, 192, "insulin glargine", "", +6, Frequency, 193, 205, "once - daily", "", +7, InsulinDetemir, 211, 226, "insulin detemir", "", +8, Frequency, 227, 240, "twice - daily", "", +11, Precondition, 244, 330, "patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs", "", +9, Type2Diabetes, 258, 273, "type 2 diabetes", "", +10, OralAntidiabeticAgent, 301, 330, "oral glucose - lowering drugs", "", +12, Author, 333, 343, "Swinnen SG", "", " \"Swinnen SG\"." +13, Author, 352, 359, "Dain MP", "", " \"Dain MP\"." +14, Author, 362, 371, "Aronson R", "", " \"Aronson R\"." +15, Author, 374, 382, "Davies M", "", " \"Davies M\"." +16, Author, 385, 396, "Gerstein HC", "", " \"Gerstein HC\"." +17, Author, 399, 410, "Pfeiffer AF", "", " \"Pfeiffer AF\"." +18, Author, 413, 421, "Snoek FJ", "", " \"Snoek FJ\"." +19, Author, 424, 434, "Devries JH", "", " \"Devries JH\"." +20, Author, 437, 448, "Hoekstra JB", "", " \"Hoekstra JB\"." +21, Author, 451, 461, "Holleman F", "", " \"Holleman F\"." +22, Netherlands, 563, 578, "the Netherlands", "", " ." +113, ObjectiveDescription, 626, 794, "To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l .", "", " \"To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l .\"." +23, InsulinGlargine, 647, 655, "glargine", "", +24, InsulinDetemir, 674, 681, "detemir", "", +25, HbA1c_target, 728, 737, "A1C < 7 %", "", +109, Percentage, 736, 737, "%", "", +26, SymptomaticHypoglycemia, 746, 770, "symptomatic hypoglycemia", "", +27, Millimoles_per_litre, 784, 792, "mmol / l", "", +28, Duration, 833, 842, "24 - week", "", " \"24 - week\"." +29, NumberPatientsCT, 851, 854, "973", "", " \"973\"." +35, Precondition, 855, 961, "insulin - naive type 2 diabetic patients on stable oral glucose - lowering drugs with A1C 7 . 0 - 10 . 5 %", "", " \"insulin - naive type 2 diabetic patients on stable oral glucose - lowering drugs with A1C 7 . 0 - 10 . 5 %\"." +30, Type2Diabetes, 871, 886, "type 2 diabetic", "", " ." +31, OralAntidiabeticAgent, 906, 935, "oral glucose - lowering drugs", "", +32, HbA1c, 941, 944, "A1C", "", +33, Percentage, 960, 961, "%", "", +34, Randomized, 967, 977, "randomized", "", +36, InsulinGlargine, 981, 989, "glargine", "", " ." +37, Frequency, 990, 1000, "once daily", "", " \"once daily\"." +39, InsulinDetemir, 1004, 1011, "detemir", "", " ." +38, Frequency, 1012, 1023, "twice daily", "", " \"twice daily\"." +57585, DoseDescription, 1026, 1068, "Insulin doses were systematically titrated", "", " \"Insulin doses were systematically titrated\". \"Insulin doses were systematically titrated\"." +41, PercentageAffected, 1079, 1085, "27 . 5", "", +42, PercentageAffected, 1090, 1096, "25 . 6", "", +128, Percentage, 1097, 1098, "%", "", +43, InsulinGlargine, 1144, 1152, "glargine", "", +44, InsulinDetemir, 1157, 1164, "detemir", "", +45, InsulinGlargine, 1218, 1226, "glargine", "", +46, HbA1c, 1245, 1248, "A1C", "", " ." +47, Reduction, 1256, 1262, "1 . 46", "", " \"1 . 46\"." +49, SdDevChangeValue, 1269, 1275, "1 . 09", "", " \"1 . 09\"." +51, Percentage, 1276, 1277, "%", "", " ." +53, InsulinGlargine, 1282, 1290, "glargine", "", +48, Reduction, 1297, 1303, "1 . 54", "", " \"1 . 54\"." +50, SdDevChangeValue, 1310, 1316, "1 . 11", "", " \"1 . 11\"." +52, Percentage, 1317, 1318, "%", "", +54, InsulinDetemir, 1323, 1330, "detemir", "", +55, PvalueDiff, 1333, 1344, "P = 0 . 149", "", " \"P = 0 . 149\"." +56, HbA1c_target, 1396, 1405, "A1C < 7 %", "", " ." +140, Percentage, 1404, 1405, "%", "", +57, PvalueDiff, 1408, 1419, "P = 0 . 254", "", " \"P = 0 . 254\"." +58, InsulinDetemir, 1431, 1438, "detemir", "", +59, HbA1c_target, 1467, 1480, "A1C < 6 . 5 %", "", " ." +146, Percentage, 1479, 1480, "%", "", +60, PvalueDiff, 1483, 1494, "P = 0 . 017", "", " \"P = 0 . 017\"." +61, Hypoglycemia, 1499, 1511, "Hypoglycemia", "", " ." +62, ObservedResult, 1499, 1528, "Hypoglycemia risk was similar", "", " \"Hypoglycemia risk was similar\"." +65, ObservedResult, 1531, 1566, "Weight gain was higher for glargine", "", " \"Weight gain was higher for glargine\". \"Weight gain was higher for glargine\"." +63, BodyWeight, 1531, 1537, "Weight", "", " ." +64, InsulinGlargine, 1558, 1566, "glargine", "", +66, DiffGroupAbsValue, 1582, 1588, "0 . 77", "", " \"0 . 77\"." +67, Kg, 1589, 1591, "kg", "", " ." +68, PvalueDiff, 1594, 1605, "P < 0 . 001", "", " \"P < 0 . 001\"." +69, InsulinGlargine, 1610, 1618, "Glargine", "", +61009, InsulinDose, 1619, 1624, "doses", "", " . ." +56815, InsulinDetemir, 1641, 1648, "detemir", "", +61010, InsulinDose, 1649, 1654, "doses", "", +61011, ResultMeasuredValue, 1657, 1663, "43 . 5", "", " \"43 . 5\"." +61013, SdDevResValue, 1670, 1676, "29 . 0", "", " \"29 . 0\"." +61012, ResultMeasuredValue, 1682, 1688, "76 . 5", "", " \"76 . 5\"." +61014, SdDevResValue, 1695, 1701, "50 . 5", "", " \"50 . 5\"." +61015, BioAndMedicalUnit, 1702, 1713, "units / day", "", " . ." +76, PvalueDiff, 1716, 1727, "P < 0 . 001", "", " \"P < 0 . 001\"." +164, ConclusionComment, 1746, 1902, "In insulin - naive type 2 diabetic patients , glargine reached similar control as detemir , with more weight gain , but required significantly lower doses .", "", " \"In insulin - naive type 2 diabetic patients , glargine reached similar control as detemir , with more weight gain , but required significantly lower doses .\"." +77, Type2Diabetes, 1765, 1780, "type 2 diabetic", "", +79, InsulinGlargine, 1792, 1800, "glargine", "", +80, InsulinDetemir, 1828, 1835, "detemir", "", +162, WeightGain, 1848, 1859, "weight gain", "", +82, PMID, 1959, 1967, "20200301", "", " \"20200301\"." diff --git a/data/dm2 20200301_admin.n-triples b/data/dm2 20200301_admin.n-triples new file mode 100644 index 0000000..e87bb9e --- /dev/null +++ b/data/dm2 20200301_admin.n-triples @@ -0,0 +1,202 @@ +# RDF export of group: Publication + . + "Publication " . + "A 24 - week , randomized , treat - to - target trial comparing initiation of insulin glargine once - daily with insulin detemir twice - daily in patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs ." . + "Swinnen SG" . + "2010" . + "Diabetes Care" . + "20200301" . + . + "Dain MP" . + "Aronson R" . + "Davies M" . + "Gerstein HC" . + "Pfeiffer AF" . + "Snoek FJ" . + "Devries JH" . + "Hoekstra JB" . + "Holleman F" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l ." . + "973" . + "24 - week" . + . + . + . + "In insulin - naive type 2 diabetic patients , glargine reached similar control as detemir , with more weight gain , but required significantly lower doses ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "insulin - naive type 2 diabetic patients on stable oral glucose - lowering drugs with A1C 7 . 0 - 10 . 5 %" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target 1" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint weight " . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint hba1c target 2" . + . + . + . + . +# RDF export of group: Arm + . + "Arm ig" . + . + . + . + . + . + . + . + . + "Arm id" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention ig" . + . + "once daily" . + . + . + "Intervention id" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication ig" . + . + . + . + "Insulin doses were systematically titrated" . + . + "Medication id" . + . + . + . + "Insulin doses were systematically titrated" . +# RDF export of group: Outcome + . + "Outcome hba1c ig" . + . + "1 . 46" . + "1 . 09" . + . + "Outcome hba1c id" . + . + "1 . 54" . + "1 . 11" . + . + "Outcome hba1c target 1 ig" . + . + . + "Outcome hba1c target 1 id" . + . + . + "Outcome hba1c target 2 ig" . + . + . + "Outcome hba1c target 2 id" . + . + . + "Outcome h both drugs" . + . + "Hypoglycemia risk was similar" . + . + "Outcome weight ig" . + . + "Weight gain was higher for glargine" . + . + "Outcome weight id" . + . + "Weight gain was higher for glargine" . + . + "Outcome id ig" . + . + "43 . 5" . + "29 . 0" . + . + "Outcome id id" . + . + "76 . 5" . + "50 . 5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "P = 0 . 149" . + . + . + . + "DiffBetweenGroups hba1c target 1" . + "P = 0 . 254" . + . + . + . + "DiffBetweenGroups hba1c target 2" . + "P = 0 . 017" . + . + . + . + "DiffBetweenGroups weight" . + "0 . 77" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups id" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20200301_akramersunderbrink.annodb b/data/dm2 20200301_akramersunderbrink.annodb new file mode 100644 index 0000000..b31b796 --- /dev/null +++ b/data/dm2 20200301_akramersunderbrink.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29391, Journal, 0, 13, "Diabetes Care", "", +29392, PublicationYear, 16, 20, "2010", "", +29420, Title, 99, 332, "A 24 - week , randomized , treat - to - target trial comparing initiation of insulin glargine once - daily with insulin detemir twice - daily in patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs .", "", +29393, Duration, 101, 110, "24 - week", "", +29395, Randomized, 113, 123, "randomized", "", +29396, InsulinGlargine, 176, 192, "insulin glargine", "", +29397, Frequency, 193, 205, "once - daily", "", +29398, InsulinDetemir, 211, 226, "insulin detemir", "", +29405, Frequency, 227, 240, "twice - daily", "", +29407, Type2Diabetes, 258, 273, "type 2 diabetes", "", +29410, Precondition, 274, 330, "inadequately controlled on oral glucose - lowering drugs", "", +29411, OralAntidiabeticAgent, 301, 330, "oral glucose - lowering drugs", "", +29423, Author, 333, 343, "Swinnen SG", "", +29425, Author, 352, 359, "Dain MP", "", +29426, Author, 362, 371, "Aronson R", "", +29427, Author, 374, 382, "Davies M", "", +29429, Author, 385, 396, "Gerstein HC", "", +29431, Author, 399, 410, "Pfeiffer AF", "", +29432, Author, 413, 421, "Snoek FJ", "", +29433, Author, 424, 434, "Devries JH", "", +29435, Author, 437, 448, "Hoekstra JB", "", +29436, Author, 451, 461, "Holleman F", "", +29439, Netherlands, 567, 578, "Netherlands", "", +29456, ObjectiveDescription, 626, 794, "To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l .", "", +29441, InsulinGlargine, 647, 655, "glargine", "", +29444, InsulinDetemir, 674, 681, "detemir", "", +29487, EndPointDescription, 710, 792, "patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l", "", +29447, HbA1c_target, 728, 737, "A1C < 7 %", "", +29448, Percentage, 736, 737, "%", "", +29449, Hypoglycemia, 746, 770, "symptomatic hypoglycemia", "", +29452, Millimoles_per_litre, 784, 792, "mmol / l", "", +29453, Duration, 833, 842, "24 - week", "", +29457, NumberPatientsCT, 851, 854, "973", "", +29458, Precondition, 855, 870, "insulin - naive", "", +29459, Type2Diabetes, 871, 886, "type 2 diabetic", "", +29471, Precondition, 896, 935, "on stable oral glucose - lowering drugs", "", +29460, OralAntidiabeticAgent, 906, 935, "oral glucose - lowering drugs", "", +29461, HbA1c, 941, 944, "A1C", "", +29467, Precondition, 941, 961, "A1C 7 . 0 - 10 . 5 %", "", +29474, Randomized, 967, 977, "randomized", "", +29476, InsulinGlargine, 981, 989, "glargine", "", +29478, Frequency, 990, 1000, "once daily", "", +29480, InsulinDetemir, 1004, 1011, "detemir", "", +29481, Frequency, 1012, 1023, "twice daily", "", +29482, PercentageAffected, 1079, 1085, "27 . 5", "", +29483, PercentageAffected, 1090, 1096, "25 . 6", "", +29484, Percentage, 1097, 1098, "%", "", +29488, InsulinGlargine, 1144, 1152, "glargine", "", +29489, InsulinDetemir, 1157, 1164, "detemir", "", +29492, InsulinGlargine, 1218, 1226, "glargine", "", +29493, HbA1c, 1245, 1248, "A1C", "", +29495, ChangeValue, 1254, 1262, "- 1 . 46", "", +29498, Percentage, 1276, 1277, "%", "", +29510, InsulinGlargine, 1282, 1290, "glargine", "", +29497, ChangeValue, 1295, 1303, "- 1 . 54", "", +29499, Percentage, 1317, 1318, "%", "", +29508, InsulinDetemir, 1323, 1330, "detemir", "", +29500, PvalueDiff, 1333, 1344, "P = 0 . 149", "", +29502, HbA1c_target, 1396, 1405, "A1C < 7 %", "", +29503, Percentage, 1404, 1405, "%", "", +29505, PvalueDiff, 1408, 1419, "P = 0 . 254", "", +29507, InsulinDetemir, 1431, 1438, "detemir", "", +29512, HbA1c_target, 1467, 1480, "A1C < 6 . 5 %", "", +29514, Percentage, 1479, 1480, "%", "", +29516, PvalueDiff, 1483, 1494, "P = 0 . 017", "", +29517, WeightGain, 1531, 1542, "Weight gain", "", +29518, InsulinGlargine, 1558, 1566, "glargine", "", +29522, DiffGroupAbsValue, 1582, 1588, "0 . 77", "", +29520, Kg, 1589, 1591, "kg", "", +29523, PvalueDiff, 1594, 1605, "P < 0 . 001", "", +29524, EndPointDescription, 1610, 1654, "Glargine doses were lower than detemir doses", "", +29525, ResultMeasuredValue, 1657, 1663, "43 . 5", "", +29526, ResultMeasuredValue, 1682, 1688, "76 . 5", "", +29527, BioAndMedicalUnit, 1702, 1713, "units / day", "", +29528, PvalueDiff, 1716, 1727, "P < 0 . 001", "", +29535, ConclusionComment, 1746, 1902, "In insulin - naive type 2 diabetic patients , glargine reached similar control as detemir , with more weight gain , but required significantly lower doses .", "", +29529, Precondition, 1749, 1764, "insulin - naive", "", +29530, Type2Diabetes, 1765, 1780, "type 2 diabetic", "", +29531, InsulinGlargine, 1792, 1800, "glargine", "", +29532, InsulinDetemir, 1828, 1835, "detemir", "", +29533, WeightGain, 1848, 1859, "weight gain", "", +29534, PMID, 1959, 1967, "20200301", "", diff --git a/data/dm2 20200301_akramersunderbrink.n-triples b/data/dm2 20200301_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20200301_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20200301_export.csv b/data/dm2 20200301_export.csv new file mode 100644 index 0000000..397fea9 --- /dev/null +++ b/data/dm2 20200301_export.csv @@ -0,0 +1,443 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +331, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +331, 1, 2, 2, 9, 13, 9, 13, "Care" +331, 1, 3, 3, 14, 15, 14, 15, "." +331, 2, 1, 4, 0, 4, 16, 20, "2010" +331, 2, 2, 5, 5, 8, 21, 24, "Jun" +331, 2, 3, 6, 9, 10, 25, 26, ";" +331, 2, 4, 7, 11, 13, 27, 29, "33" +331, 2, 5, 8, 14, 15, 30, 31, "(" +331, 2, 6, 9, 16, 17, 32, 33, "6" +331, 2, 7, 10, 18, 19, 34, 35, ")" +331, 2, 8, 11, 20, 21, 36, 37, ":" +331, 2, 9, 12, 22, 26, 38, 42, "1176" +331, 2, 10, 13, 27, 28, 43, 44, "-" +331, 2, 11, 14, 29, 30, 45, 46, "8" +331, 2, 12, 15, 31, 32, 47, 48, "." +331, 2, 13, 16, 33, 36, 49, 52, "doi" +331, 2, 14, 17, 37, 38, 53, 54, ":" +331, 2, 15, 18, 39, 41, 55, 57, "10" +331, 2, 16, 19, 42, 43, 58, 59, "." +331, 2, 17, 20, 44, 48, 60, 64, "2337" +331, 2, 18, 21, 49, 50, 65, 66, "/" +331, 2, 19, 22, 51, 55, 67, 71, "dc09" +331, 2, 20, 23, 56, 57, 72, 73, "-" +331, 2, 21, 24, 58, 62, 74, 78, "2294" +331, 2, 22, 25, 63, 64, 79, 80, "." +331, 3, 1, 26, 0, 4, 81, 85, "Epub" +331, 3, 2, 27, 5, 9, 86, 90, "2010" +331, 3, 3, 28, 10, 13, 91, 94, "Mar" +331, 3, 4, 29, 14, 15, 95, 96, "3" +331, 3, 5, 30, 16, 17, 97, 98, "." +331, 4, 1, 31, 0, 1, 99, 100, "A" +331, 4, 2, 32, 2, 4, 101, 103, "24" +331, 4, 3, 33, 5, 6, 104, 105, "-" +331, 4, 4, 34, 7, 11, 106, 110, "week" +331, 4, 5, 35, 12, 13, 111, 112, "," +331, 4, 6, 36, 14, 24, 113, 123, "randomized" +331, 4, 7, 37, 25, 26, 124, 125, "," +331, 4, 8, 38, 27, 32, 126, 131, "treat" +331, 4, 9, 39, 33, 34, 132, 133, "-" +331, 4, 10, 40, 35, 37, 134, 136, "to" +331, 4, 11, 41, 38, 39, 137, 138, "-" +331, 4, 12, 42, 40, 46, 139, 145, "target" +331, 4, 13, 43, 47, 52, 146, 151, "trial" +331, 4, 14, 44, 53, 62, 152, 161, "comparing" +331, 4, 15, 45, 63, 73, 162, 172, "initiation" +331, 4, 16, 46, 74, 76, 173, 175, "of" +331, 4, 17, 47, 77, 84, 176, 183, "insulin" +331, 4, 18, 48, 85, 93, 184, 192, "glargine" +331, 4, 19, 49, 94, 98, 193, 197, "once" +331, 4, 20, 50, 99, 100, 198, 199, "-" +331, 4, 21, 51, 101, 106, 200, 205, "daily" +331, 4, 22, 52, 107, 111, 206, 210, "with" +331, 4, 23, 53, 112, 119, 211, 218, "insulin" +331, 4, 24, 54, 120, 127, 219, 226, "detemir" +331, 4, 25, 55, 128, 133, 227, 232, "twice" +331, 4, 26, 56, 134, 135, 233, 234, "-" +331, 4, 27, 57, 136, 141, 235, 240, "daily" +331, 4, 28, 58, 142, 144, 241, 243, "in" +331, 4, 29, 59, 145, 153, 244, 252, "patients" +331, 4, 30, 60, 154, 158, 253, 257, "with" +331, 4, 31, 61, 159, 163, 258, 262, "type" +331, 4, 32, 62, 164, 165, 263, 264, "2" +331, 4, 33, 63, 166, 174, 265, 273, "diabetes" +331, 4, 34, 64, 175, 187, 274, 286, "inadequately" +331, 4, 35, 65, 188, 198, 287, 297, "controlled" +331, 4, 36, 66, 199, 201, 298, 300, "on" +331, 4, 37, 67, 202, 206, 301, 305, "oral" +331, 4, 38, 68, 207, 214, 306, 313, "glucose" +331, 4, 39, 69, 215, 216, 314, 315, "-" +331, 4, 40, 70, 217, 225, 316, 324, "lowering" +331, 4, 41, 71, 226, 231, 325, 330, "drugs" +331, 4, 42, 72, 232, 233, 331, 332, "." +331, 5, 1, 73, 0, 7, 333, 340, "Swinnen" +331, 5, 2, 74, 8, 10, 341, 343, "SG" +331, 5, 3, 75, 11, 12, 344, 345, "(" +331, 5, 4, 76, 13, 14, 346, 347, "1" +331, 5, 5, 77, 15, 16, 348, 349, ")" +331, 5, 6, 78, 17, 18, 350, 351, "," +331, 5, 7, 79, 19, 23, 352, 356, "Dain" +331, 5, 8, 80, 24, 26, 357, 359, "MP" +331, 5, 9, 81, 27, 28, 360, 361, "," +331, 5, 10, 82, 29, 36, 362, 369, "Aronson" +331, 5, 11, 83, 37, 38, 370, 371, "R" +331, 5, 12, 84, 39, 40, 372, 373, "," +331, 5, 13, 85, 41, 47, 374, 380, "Davies" +331, 5, 14, 86, 48, 49, 381, 382, "M" +331, 5, 15, 87, 50, 51, 383, 384, "," +331, 5, 16, 88, 52, 60, 385, 393, "Gerstein" +331, 5, 17, 89, 61, 63, 394, 396, "HC" +331, 5, 18, 90, 64, 65, 397, 398, "," +331, 5, 19, 91, 66, 74, 399, 407, "Pfeiffer" +331, 5, 20, 92, 75, 77, 408, 410, "AF" +331, 5, 21, 93, 78, 79, 411, 412, "," +331, 5, 22, 94, 80, 85, 413, 418, "Snoek" +331, 5, 23, 95, 86, 88, 419, 421, "FJ" +331, 5, 24, 96, 89, 90, 422, 423, "," +331, 5, 25, 97, 91, 98, 424, 431, "Devries" +331, 5, 26, 98, 99, 101, 432, 434, "JH" +331, 5, 27, 99, 102, 103, 435, 436, "," +331, 5, 28, 100, 104, 112, 437, 445, "Hoekstra" +331, 5, 29, 101, 113, 115, 446, 448, "JB" +331, 5, 30, 102, 116, 117, 449, 450, "," +331, 5, 31, 103, 118, 126, 451, 459, "Holleman" +331, 5, 32, 104, 127, 128, 460, 461, "F" +331, 5, 33, 105, 129, 130, 462, 463, "." +331, 5, 34, 106, 131, 137, 464, 470, "Author" +331, 5, 35, 107, 138, 149, 471, 482, "information" +331, 5, 36, 108, 150, 151, 483, 484, ":" +331, 5, 37, 109, 152, 153, 485, 486, "(" +331, 5, 38, 110, 154, 155, 487, 488, "1" +331, 5, 39, 111, 156, 157, 489, 490, ")" +331, 5, 40, 112, 158, 168, 491, 501, "Department" +331, 5, 41, 113, 169, 171, 502, 504, "of" +331, 5, 42, 114, 172, 180, 505, 513, "Internal" +331, 5, 43, 115, 181, 189, 514, 522, "Medicine" +331, 5, 44, 116, 190, 191, 523, 524, "," +331, 5, 45, 117, 192, 200, 525, 533, "Academic" +331, 5, 46, 118, 201, 208, 534, 541, "Medical" +331, 5, 47, 119, 209, 215, 542, 548, "Center" +331, 5, 48, 120, 216, 217, 549, 550, "," +331, 5, 49, 121, 218, 227, 551, 560, "Amsterdam" +331, 5, 50, 122, 228, 229, 561, 562, "," +331, 5, 51, 123, 230, 233, 563, 566, "the" +331, 5, 52, 124, 234, 245, 567, 578, "Netherlands" +331, 5, 53, 125, 246, 247, 579, 580, "." +331, 6, 1, 126, 0, 1, 581, 582, "s" +331, 6, 2, 127, 2, 3, 583, 584, "." +331, 6, 3, 128, 4, 5, 585, 586, "g" +331, 6, 4, 129, 6, 7, 587, 588, "." +331, 6, 5, 130, 8, 15, 589, 596, "swinnen" +331, 6, 6, 131, 16, 17, 597, 598, "@" +331, 6, 7, 132, 18, 21, 599, 602, "amc" +331, 6, 8, 133, 22, 23, 603, 604, "." +331, 6, 9, 134, 24, 27, 605, 608, "uva" +331, 6, 10, 135, 28, 29, 609, 610, "." +331, 6, 11, 136, 30, 32, 611, 613, "nl" +331, 6, 12, 137, 33, 42, 614, 623, "OBJECTIVE" +331, 6, 13, 138, 43, 44, 624, 625, ":" +331, 6, 14, 139, 45, 47, 626, 628, "To" +331, 6, 15, 140, 48, 57, 629, 638, "determine" +331, 6, 16, 141, 58, 65, 639, 646, "whether" +331, 6, 17, 142, 66, 74, 647, 655, "glargine" +331, 6, 18, 143, 75, 77, 656, 658, "is" +331, 6, 19, 144, 78, 89, 659, 670, "noninferior" +331, 6, 20, 145, 90, 92, 671, 673, "to" +331, 6, 21, 146, 93, 100, 674, 681, "detemir" +331, 6, 22, 147, 101, 110, 682, 691, "regarding" +331, 6, 23, 148, 111, 114, 692, 695, "the" +331, 6, 24, 149, 115, 125, 696, 706, "percentage" +331, 6, 25, 150, 126, 128, 707, 709, "of" +331, 6, 26, 151, 129, 137, 710, 718, "patients" +331, 6, 27, 152, 138, 146, 719, 727, "reaching" +331, 6, 28, 153, 147, 150, 728, 731, "A1C" +331, 6, 29, 154, 151, 152, 732, 733, "<" +331, 6, 30, 155, 153, 154, 734, 735, "7" +331, 6, 31, 156, 155, 156, 736, 737, "%" +331, 6, 32, 157, 157, 164, 738, 745, "without" +331, 6, 33, 158, 165, 176, 746, 757, "symptomatic" +331, 6, 34, 159, 177, 189, 758, 770, "hypoglycemia" +331, 6, 35, 160, 190, 191, 771, 772, "<" +331, 6, 36, 161, 192, 194, 773, 775, "or" +331, 6, 37, 162, 195, 196, 776, 777, "=" +331, 6, 38, 163, 197, 198, 778, 779, "3" +331, 6, 39, 164, 199, 200, 780, 781, "." +331, 6, 40, 165, 201, 202, 782, 783, "1" +331, 6, 41, 166, 203, 207, 784, 788, "mmol" +331, 6, 42, 167, 208, 209, 789, 790, "/" +331, 6, 43, 168, 210, 211, 791, 792, "l" +331, 6, 44, 169, 212, 213, 793, 794, "." +331, 7, 1, 170, 0, 8, 795, 803, "RESEARCH" +331, 7, 2, 171, 9, 15, 804, 810, "DESIGN" +331, 7, 3, 172, 16, 19, 811, 814, "AND" +331, 7, 4, 173, 20, 27, 815, 822, "METHODS" +331, 7, 5, 174, 28, 29, 823, 824, ":" +331, 7, 6, 175, 30, 32, 825, 827, "In" +331, 7, 7, 176, 33, 37, 828, 832, "this" +331, 7, 8, 177, 38, 40, 833, 835, "24" +331, 7, 9, 178, 41, 42, 836, 837, "-" +331, 7, 10, 179, 43, 47, 838, 842, "week" +331, 7, 11, 180, 48, 53, 843, 848, "trial" +331, 7, 12, 181, 54, 55, 849, 850, "," +331, 7, 13, 182, 56, 59, 851, 854, "973" +331, 7, 14, 183, 60, 67, 855, 862, "insulin" +331, 7, 15, 184, 68, 69, 863, 864, "-" +331, 7, 16, 185, 70, 75, 865, 870, "naive" +331, 7, 17, 186, 76, 80, 871, 875, "type" +331, 7, 18, 187, 81, 82, 876, 877, "2" +331, 7, 19, 188, 83, 91, 878, 886, "diabetic" +331, 7, 20, 189, 92, 100, 887, 895, "patients" +331, 7, 21, 190, 101, 103, 896, 898, "on" +331, 7, 22, 191, 104, 110, 899, 905, "stable" +331, 7, 23, 192, 111, 115, 906, 910, "oral" +331, 7, 24, 193, 116, 123, 911, 918, "glucose" +331, 7, 25, 194, 124, 125, 919, 920, "-" +331, 7, 26, 195, 126, 134, 921, 929, "lowering" +331, 7, 27, 196, 135, 140, 930, 935, "drugs" +331, 7, 28, 197, 141, 145, 936, 940, "with" +331, 7, 29, 198, 146, 149, 941, 944, "A1C" +331, 7, 30, 199, 150, 151, 945, 946, "7" +331, 7, 31, 200, 152, 153, 947, 948, "." +331, 7, 32, 201, 154, 155, 949, 950, "0" +331, 7, 33, 202, 156, 157, 951, 952, "-" +331, 7, 34, 203, 158, 160, 953, 955, "10" +331, 7, 35, 204, 161, 162, 956, 957, "." +331, 7, 36, 205, 163, 164, 958, 959, "5" +331, 7, 37, 206, 165, 166, 960, 961, "%" +331, 7, 38, 207, 167, 171, 962, 966, "were" +331, 7, 39, 208, 172, 182, 967, 977, "randomized" +331, 7, 40, 209, 183, 185, 978, 980, "to" +331, 7, 41, 210, 186, 194, 981, 989, "glargine" +331, 7, 42, 211, 195, 199, 990, 994, "once" +331, 7, 43, 212, 200, 205, 995, 1000, "daily" +331, 7, 44, 213, 206, 208, 1001, 1003, "or" +331, 7, 45, 214, 209, 216, 1004, 1011, "detemir" +331, 7, 46, 215, 217, 222, 1012, 1017, "twice" +331, 7, 47, 216, 223, 228, 1018, 1023, "daily" +331, 7, 48, 217, 229, 230, 1024, 1025, "." +331, 8, 1, 218, 0, 7, 1026, 1033, "Insulin" +331, 8, 2, 219, 8, 13, 1034, 1039, "doses" +331, 8, 3, 220, 14, 18, 1040, 1044, "were" +331, 8, 4, 221, 19, 33, 1045, 1059, "systematically" +331, 8, 5, 222, 34, 42, 1060, 1068, "titrated" +331, 8, 6, 223, 43, 44, 1069, 1070, "." +331, 9, 1, 224, 0, 7, 1071, 1078, "RESULTS" +331, 9, 2, 225, 8, 10, 1079, 1081, "27" +331, 9, 3, 226, 11, 12, 1082, 1083, "." +331, 9, 4, 227, 13, 14, 1084, 1085, "5" +331, 9, 5, 228, 15, 18, 1086, 1089, "and" +331, 9, 6, 229, 19, 21, 1090, 1092, "25" +331, 9, 7, 230, 22, 23, 1093, 1094, "." +331, 9, 8, 231, 24, 25, 1095, 1096, "6" +331, 9, 9, 232, 26, 27, 1097, 1098, "%" +331, 9, 10, 233, 28, 30, 1099, 1101, "of" +331, 9, 11, 234, 31, 39, 1102, 1110, "patients" +331, 9, 12, 235, 40, 47, 1111, 1118, "reached" +331, 9, 13, 236, 48, 51, 1119, 1122, "the" +331, 9, 14, 237, 52, 59, 1123, 1130, "primary" +331, 9, 15, 238, 60, 67, 1131, 1138, "outcome" +331, 9, 16, 239, 68, 72, 1139, 1143, "with" +331, 9, 17, 240, 73, 81, 1144, 1152, "glargine" +331, 9, 18, 241, 82, 85, 1153, 1156, "and" +331, 9, 19, 242, 86, 93, 1157, 1164, "detemir" +331, 9, 20, 243, 94, 95, 1165, 1166, "," +331, 9, 21, 244, 96, 108, 1167, 1179, "respectively" +331, 9, 22, 245, 109, 110, 1180, 1181, "," +331, 9, 23, 246, 111, 124, 1182, 1195, "demonstrating" +331, 9, 24, 247, 125, 128, 1196, 1199, "the" +331, 9, 25, 248, 129, 143, 1200, 1214, "noninferiority" +331, 9, 26, 249, 144, 146, 1215, 1217, "of" +331, 9, 27, 250, 147, 155, 1218, 1226, "glargine" +331, 9, 28, 251, 156, 157, 1227, 1228, "." +331, 10, 1, 252, 0, 12, 1229, 1241, "Improvements" +331, 10, 2, 253, 13, 15, 1242, 1244, "in" +331, 10, 3, 254, 16, 19, 1245, 1248, "A1C" +331, 10, 4, 255, 20, 24, 1249, 1253, "were" +331, 10, 5, 256, 25, 26, 1254, 1255, "-" +331, 10, 6, 257, 27, 28, 1256, 1257, "1" +331, 10, 7, 258, 29, 30, 1258, 1259, "." +331, 10, 8, 259, 31, 33, 1260, 1262, "46" +331, 10, 9, 260, 34, 35, 1263, 1264, "+" +331, 10, 10, 261, 36, 37, 1265, 1266, "/" +331, 10, 11, 262, 38, 39, 1267, 1268, "-" +331, 10, 12, 263, 40, 41, 1269, 1270, "1" +331, 10, 13, 264, 42, 43, 1271, 1272, "." +331, 10, 14, 265, 44, 46, 1273, 1275, "09" +331, 10, 15, 266, 47, 48, 1276, 1277, "%" +331, 10, 16, 267, 49, 52, 1278, 1281, "for" +331, 10, 17, 268, 53, 61, 1282, 1290, "glargine" +331, 10, 18, 269, 62, 65, 1291, 1294, "and" +331, 10, 19, 270, 66, 67, 1295, 1296, "-" +331, 10, 20, 271, 68, 69, 1297, 1298, "1" +331, 10, 21, 272, 70, 71, 1299, 1300, "." +331, 10, 22, 273, 72, 74, 1301, 1303, "54" +331, 10, 23, 274, 75, 76, 1304, 1305, "+" +331, 10, 24, 275, 77, 78, 1306, 1307, "/" +331, 10, 25, 276, 79, 80, 1308, 1309, "-" +331, 10, 26, 277, 81, 82, 1310, 1311, "1" +331, 10, 27, 278, 83, 84, 1312, 1313, "." +331, 10, 28, 279, 85, 87, 1314, 1316, "11" +331, 10, 29, 280, 88, 89, 1317, 1318, "%" +331, 10, 30, 281, 90, 93, 1319, 1322, "for" +331, 10, 31, 282, 94, 101, 1323, 1330, "detemir" +331, 10, 32, 283, 102, 103, 1331, 1332, "(" +331, 10, 33, 284, 104, 105, 1333, 1334, "P" +331, 10, 34, 285, 106, 107, 1335, 1336, "=" +331, 10, 35, 286, 108, 109, 1337, 1338, "0" +331, 10, 36, 287, 110, 111, 1339, 1340, "." +331, 10, 37, 288, 112, 115, 1341, 1344, "149" +331, 10, 38, 289, 116, 117, 1345, 1346, ")" +331, 10, 39, 290, 118, 119, 1347, 1348, "," +331, 10, 40, 291, 120, 124, 1349, 1353, "with" +331, 10, 41, 292, 125, 132, 1354, 1361, "similar" +331, 10, 42, 293, 133, 144, 1362, 1373, "proportions" +331, 10, 43, 294, 145, 147, 1374, 1376, "of" +331, 10, 44, 295, 148, 156, 1377, 1385, "patients" +331, 10, 45, 296, 157, 166, 1386, 1395, "achieving" +331, 10, 46, 297, 167, 170, 1396, 1399, "A1C" +331, 10, 47, 298, 171, 172, 1400, 1401, "<" +331, 10, 48, 299, 173, 174, 1402, 1403, "7" +331, 10, 49, 300, 175, 176, 1404, 1405, "%" +331, 10, 50, 301, 177, 178, 1406, 1407, "(" +331, 10, 51, 302, 179, 180, 1408, 1409, "P" +331, 10, 52, 303, 181, 182, 1410, 1411, "=" +331, 10, 53, 304, 183, 184, 1412, 1413, "0" +331, 10, 54, 305, 185, 186, 1414, 1415, "." +331, 10, 55, 306, 187, 190, 1416, 1419, "254" +331, 10, 56, 307, 191, 192, 1420, 1421, ")" +331, 10, 57, 308, 193, 196, 1422, 1425, "but" +331, 10, 58, 309, 197, 201, 1426, 1430, "more" +331, 10, 59, 310, 202, 209, 1431, 1438, "detemir" +331, 10, 60, 311, 210, 211, 1439, 1440, "-" +331, 10, 61, 312, 212, 219, 1441, 1448, "treated" +331, 10, 62, 313, 220, 228, 1449, 1457, "patients" +331, 10, 63, 314, 229, 237, 1458, 1466, "reaching" +331, 10, 64, 315, 238, 241, 1467, 1470, "A1C" +331, 10, 65, 316, 242, 243, 1471, 1472, "<" +331, 10, 66, 317, 244, 245, 1473, 1474, "6" +331, 10, 67, 318, 246, 247, 1475, 1476, "." +331, 10, 68, 319, 248, 249, 1477, 1478, "5" +331, 10, 69, 320, 250, 251, 1479, 1480, "%" +331, 10, 70, 321, 252, 253, 1481, 1482, "(" +331, 10, 71, 322, 254, 255, 1483, 1484, "P" +331, 10, 72, 323, 256, 257, 1485, 1486, "=" +331, 10, 73, 324, 258, 259, 1487, 1488, "0" +331, 10, 74, 325, 260, 261, 1489, 1490, "." +331, 10, 75, 326, 262, 265, 1491, 1494, "017" +331, 10, 76, 327, 266, 267, 1495, 1496, ")" +331, 10, 77, 328, 268, 269, 1497, 1498, "." +331, 11, 1, 329, 0, 12, 1499, 1511, "Hypoglycemia" +331, 11, 2, 330, 13, 17, 1512, 1516, "risk" +331, 11, 3, 331, 18, 21, 1517, 1520, "was" +331, 11, 4, 332, 22, 29, 1521, 1528, "similar" +331, 11, 5, 333, 30, 31, 1529, 1530, "." +331, 12, 1, 334, 0, 6, 1531, 1537, "Weight" +331, 12, 2, 335, 7, 11, 1538, 1542, "gain" +331, 12, 3, 336, 12, 15, 1543, 1546, "was" +331, 12, 4, 337, 16, 22, 1547, 1553, "higher" +331, 12, 5, 338, 23, 26, 1554, 1557, "for" +331, 12, 6, 339, 27, 35, 1558, 1566, "glargine" +331, 12, 7, 340, 36, 37, 1567, 1568, "(" +331, 12, 8, 341, 38, 48, 1569, 1579, "difference" +331, 12, 9, 342, 49, 50, 1580, 1581, ":" +331, 12, 10, 343, 51, 52, 1582, 1583, "0" +331, 12, 11, 344, 53, 54, 1584, 1585, "." +331, 12, 12, 345, 55, 57, 1586, 1588, "77" +331, 12, 13, 346, 58, 60, 1589, 1591, "kg" +331, 12, 14, 347, 61, 62, 1592, 1593, "," +331, 12, 15, 348, 63, 64, 1594, 1595, "P" +331, 12, 16, 349, 65, 66, 1596, 1597, "<" +331, 12, 17, 350, 67, 68, 1598, 1599, "0" +331, 12, 18, 351, 69, 70, 1600, 1601, "." +331, 12, 19, 352, 71, 74, 1602, 1605, "001" +331, 12, 20, 353, 75, 76, 1606, 1607, ")" +331, 12, 21, 354, 77, 78, 1608, 1609, "." +331, 13, 1, 355, 0, 8, 1610, 1618, "Glargine" +331, 13, 2, 356, 9, 14, 1619, 1624, "doses" +331, 13, 3, 357, 15, 19, 1625, 1629, "were" +331, 13, 4, 358, 20, 25, 1630, 1635, "lower" +331, 13, 5, 359, 26, 30, 1636, 1640, "than" +331, 13, 6, 360, 31, 38, 1641, 1648, "detemir" +331, 13, 7, 361, 39, 44, 1649, 1654, "doses" +331, 13, 8, 362, 45, 46, 1655, 1656, ":" +331, 13, 9, 363, 47, 49, 1657, 1659, "43" +331, 13, 10, 364, 50, 51, 1660, 1661, "." +331, 13, 11, 365, 52, 53, 1662, 1663, "5" +331, 13, 12, 366, 54, 55, 1664, 1665, "+" +331, 13, 13, 367, 56, 57, 1666, 1667, "/" +331, 13, 14, 368, 58, 59, 1668, 1669, "-" +331, 13, 15, 369, 60, 62, 1670, 1672, "29" +331, 13, 16, 370, 63, 64, 1673, 1674, "." +331, 13, 17, 371, 65, 66, 1675, 1676, "0" +331, 13, 18, 372, 67, 69, 1677, 1679, "vs" +331, 13, 19, 373, 70, 71, 1680, 1681, "." +331, 13, 20, 374, 72, 74, 1682, 1684, "76" +331, 13, 21, 375, 75, 76, 1685, 1686, "." +331, 13, 22, 376, 77, 78, 1687, 1688, "5" +331, 13, 23, 377, 79, 80, 1689, 1690, "+" +331, 13, 24, 378, 81, 82, 1691, 1692, "/" +331, 13, 25, 379, 83, 84, 1693, 1694, "-" +331, 13, 26, 380, 85, 87, 1695, 1697, "50" +331, 13, 27, 381, 88, 89, 1698, 1699, "." +331, 13, 28, 382, 90, 91, 1700, 1701, "5" +331, 13, 29, 383, 92, 97, 1702, 1707, "units" +331, 13, 30, 384, 98, 99, 1708, 1709, "/" +331, 13, 31, 385, 100, 103, 1710, 1713, "day" +331, 13, 32, 386, 104, 105, 1714, 1715, "(" +331, 13, 33, 387, 106, 107, 1716, 1717, "P" +331, 13, 34, 388, 108, 109, 1718, 1719, "<" +331, 13, 35, 389, 110, 111, 1720, 1721, "0" +331, 13, 36, 390, 112, 113, 1722, 1723, "." +331, 13, 37, 391, 114, 117, 1724, 1727, "001" +331, 13, 38, 392, 118, 119, 1728, 1729, ")" +331, 13, 39, 393, 120, 121, 1730, 1731, "." +331, 14, 1, 394, 0, 11, 1732, 1743, "CONCLUSIONS" +331, 14, 2, 395, 12, 13, 1744, 1745, ":" +331, 14, 3, 396, 14, 16, 1746, 1748, "In" +331, 14, 4, 397, 17, 24, 1749, 1756, "insulin" +331, 14, 5, 398, 25, 26, 1757, 1758, "-" +331, 14, 6, 399, 27, 32, 1759, 1764, "naive" +331, 14, 7, 400, 33, 37, 1765, 1769, "type" +331, 14, 8, 401, 38, 39, 1770, 1771, "2" +331, 14, 9, 402, 40, 48, 1772, 1780, "diabetic" +331, 14, 10, 403, 49, 57, 1781, 1789, "patients" +331, 14, 11, 404, 58, 59, 1790, 1791, "," +331, 14, 12, 405, 60, 68, 1792, 1800, "glargine" +331, 14, 13, 406, 69, 76, 1801, 1808, "reached" +331, 14, 14, 407, 77, 84, 1809, 1816, "similar" +331, 14, 15, 408, 85, 92, 1817, 1824, "control" +331, 14, 16, 409, 93, 95, 1825, 1827, "as" +331, 14, 17, 410, 96, 103, 1828, 1835, "detemir" +331, 14, 18, 411, 104, 105, 1836, 1837, "," +331, 14, 19, 412, 106, 110, 1838, 1842, "with" +331, 14, 20, 413, 111, 115, 1843, 1847, "more" +331, 14, 21, 414, 116, 122, 1848, 1854, "weight" +331, 14, 22, 415, 123, 127, 1855, 1859, "gain" +331, 14, 23, 416, 128, 129, 1860, 1861, "," +331, 14, 24, 417, 130, 133, 1862, 1865, "but" +331, 14, 25, 418, 134, 142, 1866, 1874, "required" +331, 14, 26, 419, 143, 156, 1875, 1888, "significantly" +331, 14, 27, 420, 157, 162, 1889, 1894, "lower" +331, 14, 28, 421, 163, 168, 1895, 1900, "doses" +331, 14, 29, 422, 169, 170, 1901, 1902, "." +331, 15, 1, 423, 0, 3, 1903, 1906, "DOI" +331, 15, 2, 424, 4, 5, 1907, 1908, ":" +331, 15, 3, 425, 6, 8, 1909, 1911, "10" +331, 15, 4, 426, 9, 10, 1912, 1913, "." +331, 15, 5, 427, 11, 15, 1914, 1918, "2337" +331, 15, 6, 428, 16, 17, 1919, 1920, "/" +331, 15, 7, 429, 18, 22, 1921, 1925, "dc09" +331, 15, 8, 430, 23, 24, 1926, 1927, "-" +331, 15, 9, 431, 25, 29, 1928, 1932, "2294" +331, 15, 10, 432, 30, 35, 1933, 1938, "PMCID" +331, 15, 11, 433, 36, 37, 1939, 1940, ":" +331, 15, 12, 434, 38, 48, 1941, 1951, "PMC2875419" +331, 15, 13, 435, 49, 53, 1952, 1956, "PMID" +331, 15, 14, 436, 54, 55, 1957, 1958, ":" +331, 15, 15, 437, 56, 64, 1959, 1967, "20200301" +331, 15, 16, 438, 65, 66, 1968, 1969, "[" +331, 15, 17, 439, 67, 74, 1970, 1977, "Indexed" +331, 15, 18, 440, 75, 78, 1978, 1981, "for" +331, 15, 19, 441, 79, 86, 1982, 1989, "MEDLINE" +331, 15, 20, 442, 87, 88, 1990, 1991, "]" diff --git a/data/dm2 20200301_kwoodley.annodb b/data/dm2 20200301_kwoodley.annodb new file mode 100644 index 0000000..e94f685 --- /dev/null +++ b/data/dm2 20200301_kwoodley.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15271, Journal, 0, 13, "Diabetes Care", "", +15272, PublicationYear, 16, 20, "2010", "", +36653, Title, 99, 332, "A 24 - week , randomized , treat - to - target trial comparing initiation of insulin glargine once - daily with insulin detemir twice - daily in patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs .", "", +15273, Duration, 101, 110, "24 - week", "", +15274, Randomized, 113, 123, "randomized", "", +15275, CTDesign, 126, 145, "treat - to - target", "", +15276, InsulinGlargine, 176, 192, "insulin glargine", "", +15277, Frequency, 193, 205, "once - daily", "", +15278, InsulinDetemir, 211, 226, "insulin detemir", "", +15279, Frequency, 227, 240, "twice - daily", "", +15282, Precondition, 244, 330, "patients with type 2 diabetes inadequately controlled on oral glucose - lowering drugs", "", +15280, Type2Diabetes, 258, 273, "type 2 diabetes", "", +15281, OralAntidiabeticAgent, 301, 330, "oral glucose - lowering drugs", "", +15285, Author, 333, 343, "Swinnen SG", "", +15286, Author, 352, 359, "Dain MP", "", +15287, Author, 362, 371, "Aronson R", "", +15288, Author, 374, 382, "Davies M", "", +15289, Author, 385, 396, "Gerstein HC", "", +15290, Author, 399, 410, "Pfeiffer AF", "", +15291, Author, 413, 421, "Snoek FJ", "", +15292, Author, 424, 434, "Devries JH", "", +15293, Author, 437, 448, "Hoekstra JB", "", +15294, Author, 451, 461, "Holleman F", "", +15295, Netherlands, 563, 578, "the Netherlands", "", +36655, ObjectiveDescription, 626, 794, "To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C < 7 % without symptomatic hypoglycemia < or = 3 . 1 mmol / l .", "", +15296, InsulinGlargine, 647, 655, "glargine", "", +15297, InsulinDetemir, 674, 681, "detemir", "", +15298, HbA1c_target, 728, 737, "A1C < 7 %", "", +15299, SymptomaticHypoglycemia, 746, 770, "symptomatic hypoglycemia", "", +15300, Millimoles_per_litre, 784, 792, "mmol / l", "", +15302, Duration, 833, 842, "24 - week", "", +15303, NumberPatientsCT, 851, 854, "973", "", +15310, Precondition, 855, 961, "insulin - naive type 2 diabetic patients on stable oral glucose - lowering drugs with A1C 7 . 0 - 10 . 5 %", "", +15304, Type2Diabetes, 871, 886, "type 2 diabetic", "", +15306, OralAntidiabeticAgent, 906, 935, "oral glucose - lowering drugs", "", +15307, HbA1c, 941, 944, "A1C", "", +15308, Percentage, 960, 961, "%", "", +15309, Randomized, 967, 977, "randomized", "", +15311, InsulinGlargine, 981, 989, "glargine", "", +15312, Frequency, 990, 1000, "once daily", "", +15314, InsulinDetemir, 1004, 1011, "detemir", "", +15313, Frequency, 1012, 1023, "twice daily", "", +15315, InsulinDetemir, 1026, 1033, "Insulin", "", +15316, PercentageAffected, 1079, 1085, "27 . 5", "", +15317, PercentageAffected, 1090, 1096, "25 . 6", "", +15318, InsulinGlargine, 1144, 1152, "glargine", "", +15319, InsulinDetemir, 1157, 1164, "detemir", "", +15320, InsulinGlargine, 1218, 1226, "glargine", "", +15321, HbA1c, 1245, 1248, "A1C", "", +15322, Reduction, 1256, 1262, "1 . 46", "", +15324, SdDevChangeValue, 1269, 1275, "1 . 09", "", +15326, Percentage, 1276, 1277, "%", "", +15328, InsulinGlargine, 1282, 1290, "glargine", "", +15323, Reduction, 1297, 1303, "1 . 54", "", +15325, SdDevChangeValue, 1310, 1316, "1 . 11", "", +15327, Percentage, 1317, 1318, "%", "", +15329, InsulinDetemir, 1323, 1330, "detemir", "", +15330, PvalueDiff, 1333, 1344, "P = 0 . 149", "", +15331, HbA1c_target, 1396, 1405, "A1C < 7 %", "", +15332, PvalueDiff, 1408, 1419, "P = 0 . 254", "", +15333, InsulinDetemir, 1431, 1438, "detemir", "", +15334, HbA1c_target, 1467, 1480, "A1C < 6 . 5 %", "", +15335, PvalueDiff, 1483, 1494, "P = 0 . 017", "", +15336, Hypoglycemia, 1499, 1511, "Hypoglycemia", "", +15337, ObservedResult, 1499, 1528, "Hypoglycemia risk was similar", "", +15338, BodyWeight, 1531, 1537, "Weight", "", +15340, ObservedResult, 1531, 1566, "Weight gain was higher for glargine", "", +15339, InsulinGlargine, 1558, 1566, "glargine", "", +15341, DiffGroupAbsValue, 1582, 1588, "0 . 77", "", +15342, Kg, 1589, 1591, "kg", "", +15344, PvalueDiff, 1594, 1605, "P < 0 . 001", "", +15345, InsulinGlargine, 1610, 1618, "Glargine", "", +36656, InsulinDose, 1619, 1624, "doses", "", +15346, InsulinDetemir, 1641, 1648, "detemir", "", +36657, InsulinDose, 1649, 1654, "doses", "", +15349, ResultMeasuredValue, 1657, 1663, "43 . 5", "", +15351, SdDevResValue, 1670, 1676, "29 . 0", "", +15350, ResultMeasuredValue, 1682, 1688, "76 . 5", "", +15352, SdDevResValue, 1695, 1701, "50 . 5", "", +15353, BioAndMedicalUnit, 1702, 1713, "units / day", "", +15354, PvalueDiff, 1716, 1727, "P < 0 . 001", "", +36658, ConclusionComment, 1746, 1902, "In insulin - naive type 2 diabetic patients , glargine reached similar control as detemir , with more weight gain , but required significantly lower doses .", "", +15357, Precondition, 1749, 1789, "insulin - naive type 2 diabetic patients", "", +15356, Type2Diabetes, 1765, 1780, "type 2 diabetic", "", +15358, InsulinGlargine, 1792, 1800, "glargine", "", +15359, InsulinDetemir, 1828, 1835, "detemir", "", +15360, BodyWeight, 1848, 1854, "weight", "", +15362, PMID, 1959, 1967, "20200301", "", diff --git a/data/dm2 20200301_kwoodley.n-triples b/data/dm2 20200301_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20200301_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20415692_admin.annodb b/data/dm2 20415692_admin.annodb new file mode 100644 index 0000000..03c139e --- /dev/null +++ b/data/dm2 20415692_admin.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +86, PublicationYear, 22, 26, "2010", "", " \"2010\"." +91, Title, 110, 265, "Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes .", "", " \"Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes .\"." +2, InsulinGlargine, 117, 133, "insulin glargine", "", +3, IsophaneInsulin_NPH, 139, 150, "NPH insulin", "", +4, Metformin, 154, 163, "metformin", "", +5, Type2Diabetes, 248, 263, "type 2 diabetes", "", " ." +6, Author, 266, 273, "Forst T", "", " \"Forst T\"." +7, Author, 282, 290, "Larbig M", "", " \"Larbig M\"." +8, Author, 293, 302, "Hohberg C", "", " \"Hohberg C\"." +9, Author, 305, 312, "Forst S", "", " \"Forst S\"." +10, Author, 315, 324, "Diessel S", "", " \"Diessel S\"." +11, Author, 327, 337, "Borchert M", "", " \"Borchert M\"." +12, Author, 340, 346, "Roth W", "", " \"Roth W\"." +13, Author, 349, 361, "Pf ü tzner A", "", " \"Pf ü tzner A\"." +14, Germany, 471, 478, "Germany", "", +57091, Drug, 531, 548, "intact proinsulin", "", +57094, Drug, 551, 553, "IP", "", +15, Type2Diabetes, 626, 641, "type 2 diabetes", "", +108, ObjectiveDescription, 644, 824, "This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin .", "", " \"This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin .\"." +16, OpenLabel, 649, 661, "open - label", "", " ." +17, Parallel, 664, 680, "parallel - group", "", " ." +19, CTDesign, 695, 700, "pilot", "", +20, InsulinGlargine, 760, 776, "insulin glargine", "", +21, InsulinGlargine, 779, 782, "GLA", "", +22, IsophaneInsulin_NPH, 790, 801, "NPH insulin", "", +23, Metformin, 813, 822, "metformin", "", +24, NumberPatientsCT, 858, 860, "28", "", " \"28\"." +61016, Precondition, 861, 901, "insulin - naive type 2 diabetes subjects", "", " \"insulin - naive type 2 diabetes subjects\". \"treated with metformin and sulfonylurea\"." +25, Type2Diabetes, 877, 892, "type 2 diabetes", "", +112, Mean, 904, 908, "mean", "", +27, AvgAge, 924, 930, "61 . 5", "", " \"61 . 5\"." +115, Year, 943, 948, "years", "", +116, Year, 989, 994, "years", "", +28, HbA1c, 997, 1002, "HbA1c", "", +29, Percentage, 1023, 1024, "%", "", +30, BMI, 1027, 1030, "BMI", "", +31, Kg_per_squareMeter, 1052, 1064, "kg / m ( 2 )", "", +61016, Precondition, 1067, 1106, "treated with metformin and sulfonylurea", "", +32, Metformin, 1080, 1089, "metformin", "", +33, Sulfonylureas, 1094, 1106, "sulfonylurea", "", +34, Randomized, 1112, 1122, "randomized", "", " ." +35, Frequency, 1130, 1142, "once - daily", "", " \"once - daily\". \"once - daily\"." +36, InsulinGlargine, 1143, 1146, "GLA", "", " ." +37, IsophaneInsulin_NPH, 1150, 1153, "NPH", "", +129, Bedtime, 1157, 1164, "bedtime", "", " . ." +170, TimePoint, 1170, 1178, "baseline", "", +39, Duration, 1189, 1197, "3 months", "", " \"3 months\"." +57100, RelativeTime, 1233, 1242, "breakfast", "", +57101, RelativeTime, 1245, 1250, "lunch", "", +57099, RelativeTime, 1255, 1261, "dinner", "", +57098, PostprandialBloodGlucose, 1279, 1297, "postprandial blood", "", +57096, Drug, 1325, 1327, "IP", "", +171, BloodGlucose, 1348, 1361, "blood glucose", "", +172, BloodGlucose, 1364, 1366, "BG", "", +61018, InsulinDose, 1381, 1393, "Insulin dose", "", " . ." +186, TimePoint, 1400, 1408, "3 months", "", +43, InsulinGlargine, 1441, 1444, "GLA", "", +44, IsophaneInsulin_NPH, 1450, 1453, "NPH", "", +61020, ResultMeasuredValue, 1456, 1462, "23 . 6", "", " \"23 . 6\"." +61022, SdDevResValue, 1469, 1475, "13 . 4", "", " \"13 . 4\"." +61021, ResultMeasuredValue, 1481, 1487, "23 . 3", "", " \"23 . 3\"." +61023, SdDevResValue, 1494, 1500, "12 . 7", "", " \"12 . 7\"." +49, PvalueDiff, 1503, 1509, "p = NS", "", " \"p = NS\"." +174, FastingBloodGlucose, 1552, 1562, "fasting BG", "", " ." +50, InsulinGlargine, 1572, 1575, "GLA", "", +52, BaseLineValue, 1578, 1581, "158", "", " \"158\"." +56, SdDevBL, 1588, 1590, "19", "", " \"19\"." +54, ResultMeasuredValue, 1594, 1597, "121", "", +58, SdDevResValue, 1604, 1606, "23", "", " \"23\"." +60, Mg_per_deciliter, 1607, 1614, "mg / dl", "", +51, IsophaneInsulin_NPH, 1617, 1620, "NPH", "", +53, BaseLineValue, 1623, 1626, "156", "", " \"158\"." +57, SdDevBL, 1633, 1635, "34", "", " \"34\"." +55, ResultMeasuredValue, 1639, 1642, "119", "", " \"119\"." +59, SdDevResValue, 1649, 1651, "29", "", " \"29\"." +61, Mg_per_deciliter, 1652, 1659, "mg / dl", "", +92883, PValueChangeValue, 1667, 1677, "p < 0 . 01", "", " \"p < 0 . 01\". \"p < 0 . 01\"." +175, TimePoint, 1683, 1691, "baseline", "", +176, FastingBloodGlucose, 1696, 1703, "Fasting", "", +178, ObservedResult, 1696, 1762, "Fasting and postprandial BG levels did not differ between groups .", "", +177, PostprandialBloodGlucose, 1708, 1723, "postprandial BG", "", +176, FastingBloodGlucose, 1721, 1723, "BG", "", +65, ObservedResult, 1763, 1797, "IP levels decreased in both groups", "", " \"IP levels decreased in both groups\". \"IP levels decreased in both groups\"." +153, EndPointDescription, 1763, 1772, "IP levels", "", " . ." +92884, PValueChangeValue, 1800, 1810, "p < 0 . 05", "", " \"p < 0 . 05\". \"p < 0 . 05\"." +179, TimePoint, 1811, 1828, "at all timepoints", "", " \"at all timepoints\". \"at all timepoints\"." +57095, Drug, 1842, 1844, "IP", "", +57106, EndPointDescription, 1842, 1852, "IP release", "", +57105, RelativeTime, 1853, 1868, "after breakfast", "", +67, InsulinGlargine, 1905, 1908, "GLA", "", +73, ObservedResult, 1909, 1936, "induced a greater reduction", "", +57107, Drug, 1940, 1942, "IP", "", +57108, EndPointDescription, 1940, 1950, "IP release", "", " . . . ." +57102, RelativeTime, 1951, 1962, "after lunch", "", +156, PvalueDiff, 1965, 1975, "p = 0 . 08", "", " \"p = 0 . 08\"." +57104, RelativeTime, 1982, 1988, "dinner", "", +157, PvalueDiff, 1991, 2001, "p = 0 . 04", "", " \"p = 0 . 04\"." +74, EndPointDescription, 2006, 2026, "Total plasma insulin", "", +75, ObservedResult, 2006, 2063, "Total plasma insulin levels did not differ between groups", "", +161, ConclusionComment, 2080, 2153, "Adding basal insulin to metformin reduces postprandial beta - cell load .", "", " \"Adding basal insulin to metformin reduces postprandial beta - cell load .\"." +76, Insulin, 2093, 2100, "insulin", "", +77, Metformin, 2104, 2113, "metformin", "", +165, ConclusionComment, 2154, 2367, "While GLA and NPH had comparable effects at breakfast , GLA reduces beta - cell stress more effectively at dinner , and with a trend at lunch , most probably because of its longer lasting pharmacodynamic profile .", "", " \"While GLA and NPH had comparable effects at breakfast , GLA reduces beta - cell stress more effectively at dinner , and with a trend at lunch , most probably because of its longer lasting pharmacodynamic profile .\"." +78, InsulinGlargine, 2160, 2163, "GLA", "", +79, IsophaneInsulin_NPH, 2168, 2171, "NPH", "", +80, TimePoint, 2195, 2207, "at breakfast", "", +81, InsulinGlargine, 2210, 2213, "GLA", "", +82, TimePoint, 2258, 2267, "at dinner", "", +83, TimePoint, 2287, 2295, "at lunch", "", +84, PMID, 2447, 2455, "20415692", "", " \"20415692\"." diff --git a/data/dm2 20415692_admin.n-triples b/data/dm2 20415692_admin.n-triples new file mode 100644 index 0000000..374867f --- /dev/null +++ b/data/dm2 20415692_admin.n-triples @@ -0,0 +1,191 @@ +# RDF export of group: Publication + . + "Publication 27104" . + "Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes ." . + "Forst T" . + "2010" . + "Diabetes Obes Metab ." . + "20415692" . + . + "Larbig M" . + "Hohberg C" . + "Forst S" . + "Diessel S" . + "Borchert M" . + "Roth W" . + "Pf ü tzner A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 27111" . + "This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin ." . + "28" . + "3 months" . + . + . + . + "Adding basal insulin to metformin reduces postprandial beta - cell load ." . + . + . + . + . + . + . + . + . + . + . + "While GLA and NPH had comparable effects at breakfast , GLA reduces beta - cell stress more effectively at dinner , and with a trend at lunch , most probably because of its longer lasting pharmacodynamic profile ." . + . + . +# RDF export of group: Population + . + "Population 27127" . + "insulin - naive type 2 diabetes subjects" . + "treated with metformin and sulfonylurea" . + . + . + "61 . 5" . + . +# RDF export of group: Endpoint + . + "ins" . + . + . + . + . + . + . + "fbg" . + . + . + . + . + . + "ip" . + . + . + . + . + . + . + "iprl" . + . + . + . + . + . + . + "iprd" . + . + . + . + . + . +# RDF export of group: Arm + . + "gla" . + . + . + . + . + . + . + . + . + "nph" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "gla" . + . + "once - daily" . + . + . + "nph" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "gla" . + . + . + . + . + "nph" . + . + . + . +# RDF export of group: Outcome + . + "ins gla" . + . + "23 . 6" . + "13 . 4" . + . + "ins nph" . + . + "23 . 3" . + "12 . 7" . + . + "fbg gla" . + . + "158" . + "19" . + "23" . + "p < 0 . 01" . + . + "fbg nph" . + . + "156" . + "34" . + "119" . + "29" . + "p < 0 . 01" . + . + "ip gla" . + . + "p < 0 . 05" . + "IP levels decreased in both groups" . + "at all timepoints" . + . + "ip nph" . + . + "p < 0 . 05" . + "IP levels decreased in both groups" . + "at all timepoints" . + . + "iprl gla" . + . + . + "iprl nph" . + . + . + "iprd gla" . + . + . + "iprd nph" . + . +# RDF export of group: DiffBetweenGroups + . + "ins" . + "p = NS" . + . + . + . + "iprl" . + "p = 0 . 08" . + . + . + . + "iprd" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20415692_akramersunderbrink.annodb b/data/dm2 20415692_akramersunderbrink.annodb new file mode 100644 index 0000000..2bf1a0a --- /dev/null +++ b/data/dm2 20415692_akramersunderbrink.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29539, Journal, 0, 19, "Diabetes Obes Metab", "", " \"Diabetes Obes Metab\"." +29540, PublicationYear, 22, 26, "2010", "", " \"2010\"." +29551, Title, 110, 265, "Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes .", "", " \"Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes .\"." +29542, InsulinGlargine, 117, 133, "insulin glargine", "", " ." +29544, IsophaneInsulin_NPH, 139, 150, "NPH insulin", "", " ." +29546, Metformin, 154, 163, "metformin", "", " ." +29548, Type2Diabetes, 248, 263, "type 2 diabetes", "", " ." +29553, Author, 266, 273, "Forst T", "", " \"Forst T\"." +29555, Author, 282, 290, "Larbig M", "", " \"Larbig M\"." +29557, Author, 293, 302, "Hohberg C", "", " \"Hohberg C\"." +29559, Author, 305, 312, "Forst S", "", " \"Forst S\"." +29560, Author, 315, 324, "Diessel S", "", " \"Diessel S\"." +29561, Author, 327, 337, "Borchert M", "", " \"Borchert M\"." +29563, Author, 340, 346, "Roth W", "", " \"Roth W\"." +29566, Author, 349, 361, "Pf ü tzner A", "", " \"Pf ü tzner A\"." +29567, Germany, 471, 478, "Germany", "", " ." +29572, Type2Diabetes, 626, 641, "type 2 diabetes", "", +29586, ObjectiveDescription, 644, 824, "This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin .", "", " \"This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin .\"." +29577, OpenLabel, 649, 661, "open - label", "", " ." +29578, Parallel, 664, 680, "parallel - group", "", " ." +29581, InsulinGlargine, 760, 776, "insulin glargine", "", +29582, InsulinGlargine, 779, 782, "GLA", "", +29583, IsophaneInsulin_NPH, 790, 801, "NPH insulin", "", +29584, Metformin, 813, 822, "metformin", "", +29591, NumberPatientsCT, 858, 860, "28", "", " \"28\"." +29593, Precondition, 861, 876, "insulin - naive", "", " \"insulin - naive\"." +29595, Type2Diabetes, 877, 892, "type 2 diabetes", "", +29598, Mean, 904, 908, "mean", "", +29600, AvgAge, 924, 930, "61 . 5", "", " \"61 . 5\"." +29605, Year, 943, 948, "years", "", +29603, Precondition, 951, 994, "diabetes duration , 9 . 8 + / - 6 . 5 years", "", +29606, Year, 989, 994, "years", "", +29607, HbA1c, 997, 1002, "HbA1c", "", +29609, Precondition, 997, 1024, "HbA1c , 7 . 1 + / - 0 . 5 %", "", +29610, Percentage, 1023, 1024, "%", "", +29612, Precondition, 1027, 1064, "BMI , 30 . 7 + / - 4 . 3 kg / m ( 2 )", "", +29614, BMI, 1027, 1030, "BMI", "", +29616, Kg_per_squareMeter, 1052, 1064, "kg / m ( 2 )", "", +29617, Metformin, 1080, 1089, "metformin", "", +29619, Sulfonylureas, 1094, 1106, "sulfonylurea", "", " ." +29621, Randomized, 1112, 1122, "randomized", "", " ." +29629, Frequency, 1130, 1142, "once - daily", "", " \"once - daily\". \"once - daily\"." +29623, InsulinGlargine, 1143, 1146, "GLA", "", +29625, IsophaneInsulin_NPH, 1150, 1153, "NPH", "", +29630, Bedtime, 1157, 1164, "bedtime", "", " . ." +39195, TimePoint, 1170, 1178, "baseline", "", +39200, TimePoint, 1189, 1197, "3 months", "", +39196, BloodGlucose, 1348, 1361, "blood glucose", "", +39197, BloodGlucose, 1364, 1366, "BG", "", +29637, EndPointDescription, 1381, 1393, "Insulin dose", "", " . ." +39199, TimePoint, 1400, 1408, "3 months", "", " \"3 months\"." +29639, InsulinGlargine, 1441, 1444, "GLA", "", +29640, IsophaneInsulin_NPH, 1450, 1453, "NPH", "", +29685, ResultMeasuredValue, 1456, 1462, "23 . 6", "", " \"23 . 6\"." +29687, SdDevResValue, 1463, 1475, "+ / - 13 . 4", "", " \"+ / - 13 . 4\"." +29686, ResultMeasuredValue, 1481, 1487, "23 . 3", "", " \"23 . 3\"." +29688, SdDevResValue, 1488, 1500, "+ / - 12 . 7", "", " \"+ / - 12 . 7\"." +29689, PvalueDiff, 1503, 1509, "p = NS", "", " \"p = NS\"." +80241, FastingBloodGlucose, 1552, 1569, "fasting BG levels", "", " ." +29692, InsulinGlargine, 1572, 1575, "GLA", "", +29694, BaseLineValue, 1578, 1581, "158", "", " \"158\"." +29698, SdDevBL, 1582, 1590, "+ / - 19", "", " \"+ / - 19\"." +29696, ResultMeasuredValue, 1594, 1597, "121", "", " \"121\"." +29700, SdDevResValue, 1598, 1606, "+ / - 23", "", " \"+ / - 23\"." +29702, Mg_per_deciliter, 1607, 1614, "mg / dl", "", " ." +29693, IsophaneInsulin_NPH, 1617, 1620, "NPH", "", +29695, BaseLineValue, 1623, 1626, "156", "", " \"156\"." +29699, SdDevBL, 1627, 1635, "+ / - 34", "", " \"+ / - 34\"." +29697, ResultMeasuredValue, 1639, 1642, "119", "", " \"119\"." +29701, SdDevResValue, 1643, 1651, "+ / - 29", "", " \"+ / - 29\"." +29703, Mg_per_deciliter, 1652, 1659, "mg / dl", "", +29704, PValueChangeValue, 1667, 1677, "p < 0 . 01", "", " \"p < 0 . 01\". \"p < 0 . 01\"." +39198, TimePoint, 1683, 1691, "baseline", "", +29705, InsulinDose, 1708, 1723, "postprandial BG", "", +29706, EndPointDescription, 1763, 1772, "IP levels", "", " . ." +29707, PValueChangeValue, 1800, 1810, "p < 0 . 05", "", " \"p < 0 . 05\". \"p < 0 . 05\"." +29708, InsulinGlargine, 1905, 1908, "GLA", "", +29711, EndPointDescription, 1927, 1962, "reduction in IP release after lunch", "", " . ." +29709, PvalueDiff, 1965, 1975, "p = 0 . 08", "", " \"p = 0 . 08\"." +29712, EndPointDescription, 1982, 1988, "dinner", "", " . ." +29710, PvalueDiff, 1991, 2001, "p = 0 . 04", "", " \"p = 0 . 04\"." +29714, ConclusionComment, 2080, 2153, "Adding basal insulin to metformin reduces postprandial beta - cell load .", "", " \"Adding basal insulin to metformin reduces postprandial beta - cell load .\"." +29713, Metformin, 2104, 2113, "metformin", "", +29718, ConclusionComment, 2154, 2367, "While GLA and NPH had comparable effects at breakfast , GLA reduces beta - cell stress more effectively at dinner , and with a trend at lunch , most probably because of its longer lasting pharmacodynamic profile .", "", +29715, InsulinGlargine, 2160, 2163, "GLA", "", +29716, IsophaneInsulin_NPH, 2168, 2171, "NPH", "", +29717, InsulinGlargine, 2210, 2213, "GLA", "", +29719, PMID, 2447, 2455, "20415692", "", " \"20415692\"." diff --git a/data/dm2 20415692_akramersunderbrink.n-triples b/data/dm2 20415692_akramersunderbrink.n-triples new file mode 100644 index 0000000..a8403ef --- /dev/null +++ b/data/dm2 20415692_akramersunderbrink.n-triples @@ -0,0 +1,206 @@ +# RDF export of group: Publication + . + "Publication 19634" . + "Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes ." . + "Forst T" . + "2010" . + "Diabetes Obes Metab" . + "20415692" . + . + "Larbig M" . + "Hohberg C" . + "Forst S" . + "Diessel S" . + "Borchert M" . + "Roth W" . + "Pf ü tzner A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 19648" . + "This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin ." . + "28" . + . + . + . + "Adding basal insulin to metformin reduces postprandial beta - cell load ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 19725" . + "insulin - naive" . + . + . + "61 . 5" . + . +# RDF export of group: Endpoint + . + "ins" . + . + . + . + . + . + . + "fbg" . + . + . + . + . + . + "ip" . + . + . + . + . + . + . + "ip lunch" . + . + . + . + . + . + . + "ip dinner" . + . + . + . + . + . +# RDF export of group: Arm + . + "gla" . + . + . + . + . + . + . + . + . + . + . + "nph" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "gla" . + . + "once - daily" . + . + . + "nph" . + . + "once - daily" . + . + . + "met" . + . + . + . + "sul" . + . + . +# RDF export of group: Medication + . + "gla" . + . + . + . + . + "nph" . + . + . + . + . + "met" . + . + . + . + . + "sul" . + . + . + . +# RDF export of group: Outcome + . + "ins gla" . + . + "23 . 6" . + "+ / - 13 . 4" . + "3 months" . + . + "ins nph" . + . + "23 . 3" . + "+ / - 12 . 7" . + . + "fbg gla" . + . + "158" . + "+ / - 19" . + "121" . + "+ / - 23" . + "p < 0 . 01" . + . + "fbg nph" . + . + "156" . + "+ / - 34" . + "119" . + "+ / - 29" . + "p < 0 . 01" . + . + "ip gla" . + . + "p < 0 . 05" . + . + "ip nph" . + . + "p < 0 . 05" . + . + "ip lunch gla" . + . + . + "ip lunch nph" . + . + . + "ip dinner nph" . + . + . + "ip dinner gla" . + . +# RDF export of group: DiffBetweenGroups + . + "ins" . + "p = NS" . + . + . + . + "ip lunch" . + "p = 0 . 08" . + . + . + . + "ip dinner" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20415692_export.csv b/data/dm2 20415692_export.csv new file mode 100644 index 0000000..8338cc5 --- /dev/null +++ b/data/dm2 20415692_export.csv @@ -0,0 +1,565 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +330, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +330, 1, 2, 2, 9, 13, 9, 13, "Obes" +330, 1, 3, 3, 14, 19, 14, 19, "Metab" +330, 1, 4, 4, 20, 21, 20, 21, "." +330, 2, 1, 5, 0, 4, 22, 26, "2010" +330, 2, 2, 6, 5, 8, 27, 30, "May" +330, 2, 3, 7, 9, 10, 31, 32, ";" +330, 2, 4, 8, 11, 13, 33, 35, "12" +330, 2, 5, 9, 14, 15, 36, 37, "(" +330, 2, 6, 10, 16, 17, 38, 39, "5" +330, 2, 7, 11, 18, 19, 40, 41, ")" +330, 2, 8, 12, 20, 21, 42, 43, ":" +330, 2, 9, 13, 22, 25, 44, 47, "437" +330, 2, 10, 14, 26, 27, 48, 49, "-" +330, 2, 11, 15, 28, 30, 50, 52, "41" +330, 2, 12, 16, 31, 32, 53, 54, "." +330, 2, 13, 17, 33, 36, 55, 58, "doi" +330, 2, 14, 18, 37, 38, 59, 60, ":" +330, 2, 15, 19, 39, 41, 61, 63, "10" +330, 2, 16, 20, 42, 43, 64, 65, "." +330, 2, 17, 21, 44, 48, 66, 70, "1111" +330, 2, 18, 22, 49, 50, 71, 72, "/" +330, 2, 19, 23, 51, 52, 73, 74, "j" +330, 2, 20, 24, 53, 54, 75, 76, "." +330, 2, 21, 25, 55, 59, 77, 81, "1463" +330, 2, 22, 26, 60, 61, 82, 83, "-" +330, 2, 23, 27, 62, 66, 84, 88, "1326" +330, 2, 24, 28, 67, 68, 89, 90, "." +330, 2, 25, 29, 69, 73, 91, 95, "2010" +330, 2, 26, 30, 74, 75, 96, 97, "." +330, 2, 27, 31, 76, 81, 98, 103, "01209" +330, 2, 28, 32, 82, 83, 104, 105, "." +330, 2, 29, 33, 84, 85, 106, 107, "x" +330, 2, 30, 34, 86, 87, 108, 109, "." +330, 3, 1, 35, 0, 6, 110, 116, "Adding" +330, 3, 2, 36, 7, 14, 117, 124, "insulin" +330, 3, 3, 37, 15, 23, 125, 133, "glargine" +330, 3, 4, 38, 24, 26, 134, 136, "vs" +330, 3, 5, 39, 27, 28, 137, 138, "." +330, 3, 6, 40, 29, 32, 139, 142, "NPH" +330, 3, 7, 41, 33, 40, 143, 150, "insulin" +330, 3, 8, 42, 41, 43, 151, 153, "to" +330, 3, 9, 43, 44, 53, 154, 163, "metformin" +330, 3, 10, 44, 54, 61, 164, 171, "results" +330, 3, 11, 45, 62, 64, 172, 174, "in" +330, 3, 12, 46, 65, 66, 175, 176, "a" +330, 3, 13, 47, 67, 71, 177, 181, "more" +330, 3, 14, 48, 72, 81, 182, 191, "efficient" +330, 3, 15, 49, 82, 94, 192, 204, "postprandial" +330, 3, 16, 50, 95, 99, 205, 209, "beta" +330, 3, 17, 51, 100, 101, 210, 211, "-" +330, 3, 18, 52, 102, 106, 212, 216, "cell" +330, 3, 19, 53, 107, 117, 217, 227, "protection" +330, 3, 20, 54, 118, 120, 228, 230, "in" +330, 3, 21, 55, 121, 132, 231, 242, "individuals" +330, 3, 22, 56, 133, 137, 243, 247, "with" +330, 3, 23, 57, 138, 142, 248, 252, "type" +330, 3, 24, 58, 143, 144, 253, 254, "2" +330, 3, 25, 59, 145, 153, 255, 263, "diabetes" +330, 3, 26, 60, 154, 155, 264, 265, "." +330, 4, 1, 61, 0, 5, 266, 271, "Forst" +330, 4, 2, 62, 6, 7, 272, 273, "T" +330, 4, 3, 63, 8, 9, 274, 275, "(" +330, 4, 4, 64, 10, 11, 276, 277, "1" +330, 4, 5, 65, 12, 13, 278, 279, ")" +330, 4, 6, 66, 14, 15, 280, 281, "," +330, 4, 7, 67, 16, 22, 282, 288, "Larbig" +330, 4, 8, 68, 23, 24, 289, 290, "M" +330, 4, 9, 69, 25, 26, 291, 292, "," +330, 4, 10, 70, 27, 34, 293, 300, "Hohberg" +330, 4, 11, 71, 35, 36, 301, 302, "C" +330, 4, 12, 72, 37, 38, 303, 304, "," +330, 4, 13, 73, 39, 44, 305, 310, "Forst" +330, 4, 14, 74, 45, 46, 311, 312, "S" +330, 4, 15, 75, 47, 48, 313, 314, "," +330, 4, 16, 76, 49, 56, 315, 322, "Diessel" +330, 4, 17, 77, 57, 58, 323, 324, "S" +330, 4, 18, 78, 59, 60, 325, 326, "," +330, 4, 19, 79, 61, 69, 327, 335, "Borchert" +330, 4, 20, 80, 70, 71, 336, 337, "M" +330, 4, 21, 81, 72, 73, 338, 339, "," +330, 4, 22, 82, 74, 78, 340, 344, "Roth" +330, 4, 23, 83, 79, 80, 345, 346, "W" +330, 4, 24, 84, 81, 82, 347, 348, "," +330, 4, 25, 85, 83, 85, 349, 351, "Pf" +330, 4, 26, 86, 86, 87, 352, 353, "ü" +330, 4, 27, 87, 88, 93, 354, 359, "tzner" +330, 4, 28, 88, 94, 95, 360, 361, "A" +330, 4, 29, 89, 96, 97, 362, 363, "." +330, 5, 1, 90, 0, 6, 364, 370, "Author" +330, 5, 2, 91, 7, 18, 371, 382, "information" +330, 5, 3, 92, 19, 20, 383, 384, ":" +330, 5, 4, 93, 21, 22, 385, 386, "(" +330, 5, 5, 94, 23, 24, 387, 388, "1" +330, 5, 6, 95, 25, 26, 389, 390, ")" +330, 5, 7, 96, 27, 36, 391, 400, "Institute" +330, 5, 8, 97, 37, 40, 401, 404, "for" +330, 5, 9, 98, 41, 49, 405, 413, "Clinical" +330, 5, 10, 99, 50, 58, 414, 422, "Research" +330, 5, 11, 100, 59, 62, 423, 426, "and" +330, 5, 12, 101, 63, 74, 427, 438, "Development" +330, 5, 13, 102, 75, 76, 439, 440, "," +330, 5, 14, 103, 77, 85, 441, 449, "Clinical" +330, 5, 15, 104, 86, 96, 450, 460, "Department" +330, 5, 16, 105, 97, 98, 461, 462, "," +330, 5, 17, 106, 99, 104, 463, 468, "Mainz" +330, 5, 18, 107, 105, 106, 469, 470, "," +330, 5, 19, 108, 107, 114, 471, 478, "Germany" +330, 5, 20, 109, 115, 116, 479, 480, "." +330, 6, 1, 110, 0, 7, 481, 488, "ThomasF" +330, 6, 2, 111, 8, 9, 489, 490, "@" +330, 6, 3, 112, 10, 14, 491, 495, "ikfe" +330, 6, 4, 113, 15, 16, 496, 497, "." +330, 6, 5, 114, 17, 19, 498, 500, "de" +330, 6, 6, 115, 20, 23, 501, 504, "AIM" +330, 6, 7, 116, 24, 25, 505, 506, ":" +330, 6, 8, 117, 26, 38, 507, 519, "Postprandial" +330, 6, 9, 118, 39, 46, 520, 527, "release" +330, 6, 10, 119, 47, 49, 528, 530, "of" +330, 6, 11, 120, 50, 56, 531, 537, "intact" +330, 6, 12, 121, 57, 67, 538, 548, "proinsulin" +330, 6, 13, 122, 68, 69, 549, 550, "(" +330, 6, 14, 123, 70, 72, 551, 553, "IP" +330, 6, 15, 124, 73, 74, 554, 555, ")" +330, 6, 16, 125, 75, 77, 556, 558, "is" +330, 6, 17, 126, 78, 80, 559, 561, "an" +330, 6, 18, 127, 81, 92, 562, 573, "independent" +330, 6, 19, 128, 93, 99, 574, 580, "marker" +330, 6, 20, 129, 100, 103, 581, 584, "for" +330, 6, 21, 130, 104, 108, 585, 589, "beta" +330, 6, 22, 131, 109, 110, 590, 591, "-" +330, 6, 23, 132, 111, 115, 592, 596, "cell" +330, 6, 24, 133, 116, 127, 597, 608, "dysfunction" +330, 6, 25, 134, 128, 130, 609, 611, "in" +330, 6, 26, 135, 131, 139, 612, 620, "patients" +330, 6, 27, 136, 140, 144, 621, 625, "with" +330, 6, 28, 137, 145, 149, 626, 630, "type" +330, 6, 29, 138, 150, 151, 631, 632, "2" +330, 6, 30, 139, 152, 160, 633, 641, "diabetes" +330, 6, 31, 140, 161, 162, 642, 643, "." +330, 7, 1, 141, 0, 4, 644, 648, "This" +330, 7, 2, 142, 5, 9, 649, 653, "open" +330, 7, 3, 143, 10, 11, 654, 655, "-" +330, 7, 4, 144, 12, 17, 656, 661, "label" +330, 7, 5, 145, 18, 19, 662, 663, "," +330, 7, 6, 146, 20, 28, 664, 672, "parallel" +330, 7, 7, 147, 29, 30, 673, 674, "-" +330, 7, 8, 148, 31, 36, 675, 680, "group" +330, 7, 9, 149, 37, 38, 681, 682, "," +330, 7, 10, 150, 39, 42, 683, 686, "two" +330, 7, 11, 151, 43, 44, 687, 688, "-" +330, 7, 12, 152, 45, 48, 689, 692, "arm" +330, 7, 13, 153, 49, 50, 693, 694, "," +330, 7, 14, 154, 51, 56, 695, 700, "pilot" +330, 7, 15, 155, 57, 62, 701, 706, "study" +330, 7, 16, 156, 63, 71, 707, 715, "compared" +330, 7, 17, 157, 72, 75, 716, 719, "the" +330, 7, 18, 158, 76, 80, 720, 724, "beta" +330, 7, 19, 159, 81, 82, 725, 726, "-" +330, 7, 20, 160, 83, 87, 727, 731, "cell" +330, 7, 21, 161, 88, 98, 732, 742, "protective" +330, 7, 22, 162, 99, 105, 743, 749, "effect" +330, 7, 23, 163, 106, 108, 750, 752, "of" +330, 7, 24, 164, 109, 115, 753, 759, "adding" +330, 7, 25, 165, 116, 123, 760, 767, "insulin" +330, 7, 26, 166, 124, 132, 768, 776, "glargine" +330, 7, 27, 167, 133, 134, 777, 778, "(" +330, 7, 28, 168, 135, 138, 779, 782, "GLA" +330, 7, 29, 169, 139, 140, 783, 784, ")" +330, 7, 30, 170, 141, 143, 785, 787, "vs" +330, 7, 31, 171, 144, 145, 788, 789, "." +330, 7, 32, 172, 146, 149, 790, 793, "NPH" +330, 7, 33, 173, 150, 157, 794, 801, "insulin" +330, 7, 34, 174, 158, 160, 802, 804, "to" +330, 7, 35, 175, 161, 168, 805, 812, "ongoing" +330, 7, 36, 176, 169, 178, 813, 822, "metformin" +330, 7, 37, 177, 179, 180, 823, 824, "." +330, 8, 1, 178, 0, 8, 825, 833, "MATERIAL" +330, 8, 2, 179, 9, 12, 834, 837, "AND" +330, 8, 3, 180, 13, 20, 838, 845, "METHODS" +330, 8, 4, 181, 21, 22, 846, 847, ":" +330, 8, 5, 182, 23, 30, 848, 855, "Overall" +330, 8, 6, 183, 31, 32, 856, 857, "," +330, 8, 7, 184, 33, 35, 858, 860, "28" +330, 8, 8, 185, 36, 43, 861, 868, "insulin" +330, 8, 9, 186, 44, 45, 869, 870, "-" +330, 8, 10, 187, 46, 51, 871, 876, "naive" +330, 8, 11, 188, 52, 56, 877, 881, "type" +330, 8, 12, 189, 57, 58, 882, 883, "2" +330, 8, 13, 190, 59, 67, 884, 892, "diabetes" +330, 8, 14, 191, 68, 76, 893, 901, "subjects" +330, 8, 15, 192, 77, 78, 902, 903, "(" +330, 8, 16, 193, 79, 83, 904, 908, "mean" +330, 8, 17, 194, 84, 85, 909, 910, "+" +330, 8, 18, 195, 86, 87, 911, 912, "/" +330, 8, 19, 196, 88, 89, 913, 914, "-" +330, 8, 20, 197, 90, 92, 915, 917, "SD" +330, 8, 21, 198, 93, 96, 918, 921, "age" +330, 8, 22, 199, 97, 98, 922, 923, "," +330, 8, 23, 200, 99, 101, 924, 926, "61" +330, 8, 24, 201, 102, 103, 927, 928, "." +330, 8, 25, 202, 104, 105, 929, 930, "5" +330, 8, 26, 203, 106, 107, 931, 932, "+" +330, 8, 27, 204, 108, 109, 933, 934, "/" +330, 8, 28, 205, 110, 111, 935, 936, "-" +330, 8, 29, 206, 112, 113, 937, 938, "6" +330, 8, 30, 207, 114, 115, 939, 940, "." +330, 8, 31, 208, 116, 117, 941, 942, "7" +330, 8, 32, 209, 118, 123, 943, 948, "years" +330, 8, 33, 210, 124, 125, 949, 950, ";" +330, 8, 34, 211, 126, 134, 951, 959, "diabetes" +330, 8, 35, 212, 135, 143, 960, 968, "duration" +330, 8, 36, 213, 144, 145, 969, 970, "," +330, 8, 37, 214, 146, 147, 971, 972, "9" +330, 8, 38, 215, 148, 149, 973, 974, "." +330, 8, 39, 216, 150, 151, 975, 976, "8" +330, 8, 40, 217, 152, 153, 977, 978, "+" +330, 8, 41, 218, 154, 155, 979, 980, "/" +330, 8, 42, 219, 156, 157, 981, 982, "-" +330, 8, 43, 220, 158, 159, 983, 984, "6" +330, 8, 44, 221, 160, 161, 985, 986, "." +330, 8, 45, 222, 162, 163, 987, 988, "5" +330, 8, 46, 223, 164, 169, 989, 994, "years" +330, 8, 47, 224, 170, 171, 995, 996, ";" +330, 8, 48, 225, 172, 177, 997, 1002, "HbA1c" +330, 8, 49, 226, 178, 179, 1003, 1004, "," +330, 8, 50, 227, 180, 181, 1005, 1006, "7" +330, 8, 51, 228, 182, 183, 1007, 1008, "." +330, 8, 52, 229, 184, 185, 1009, 1010, "1" +330, 8, 53, 230, 186, 187, 1011, 1012, "+" +330, 8, 54, 231, 188, 189, 1013, 1014, "/" +330, 8, 55, 232, 190, 191, 1015, 1016, "-" +330, 8, 56, 233, 192, 193, 1017, 1018, "0" +330, 8, 57, 234, 194, 195, 1019, 1020, "." +330, 8, 58, 235, 196, 197, 1021, 1022, "5" +330, 8, 59, 236, 198, 199, 1023, 1024, "%" +330, 8, 60, 237, 200, 201, 1025, 1026, ";" +330, 8, 61, 238, 202, 205, 1027, 1030, "BMI" +330, 8, 62, 239, 206, 207, 1031, 1032, "," +330, 8, 63, 240, 208, 210, 1033, 1035, "30" +330, 8, 64, 241, 211, 212, 1036, 1037, "." +330, 8, 65, 242, 213, 214, 1038, 1039, "7" +330, 8, 66, 243, 215, 216, 1040, 1041, "+" +330, 8, 67, 244, 217, 218, 1042, 1043, "/" +330, 8, 68, 245, 219, 220, 1044, 1045, "-" +330, 8, 69, 246, 221, 222, 1046, 1047, "4" +330, 8, 70, 247, 223, 224, 1048, 1049, "." +330, 8, 71, 248, 225, 226, 1050, 1051, "3" +330, 8, 72, 249, 227, 229, 1052, 1054, "kg" +330, 8, 73, 250, 230, 231, 1055, 1056, "/" +330, 8, 74, 251, 232, 233, 1057, 1058, "m" +330, 8, 75, 252, 234, 235, 1059, 1060, "(" +330, 8, 76, 253, 236, 237, 1061, 1062, "2" +330, 8, 77, 254, 238, 239, 1063, 1064, ")" +330, 8, 78, 255, 240, 241, 1065, 1066, ")" +330, 8, 79, 256, 242, 249, 1067, 1074, "treated" +330, 8, 80, 257, 250, 254, 1075, 1079, "with" +330, 8, 81, 258, 255, 264, 1080, 1089, "metformin" +330, 8, 82, 259, 265, 268, 1090, 1093, "and" +330, 8, 83, 260, 269, 281, 1094, 1106, "sulfonylurea" +330, 8, 84, 261, 282, 286, 1107, 1111, "were" +330, 8, 85, 262, 287, 297, 1112, 1122, "randomized" +330, 8, 86, 263, 298, 300, 1123, 1125, "to" +330, 8, 87, 264, 301, 304, 1126, 1129, "add" +330, 8, 88, 265, 305, 309, 1130, 1134, "once" +330, 8, 89, 266, 310, 311, 1135, 1136, "-" +330, 8, 90, 267, 312, 317, 1137, 1142, "daily" +330, 8, 91, 268, 318, 321, 1143, 1146, "GLA" +330, 8, 92, 269, 322, 324, 1147, 1149, "or" +330, 8, 93, 270, 325, 328, 1150, 1153, "NPH" +330, 8, 94, 271, 329, 331, 1154, 1156, "at" +330, 8, 95, 272, 332, 339, 1157, 1164, "bedtime" +330, 8, 96, 273, 340, 341, 1165, 1166, "." +330, 9, 1, 274, 0, 2, 1167, 1169, "At" +330, 9, 2, 275, 3, 11, 1170, 1178, "baseline" +330, 9, 3, 276, 12, 15, 1179, 1182, "and" +330, 9, 4, 277, 16, 21, 1183, 1188, "after" +330, 9, 5, 278, 22, 23, 1189, 1190, "3" +330, 9, 6, 279, 24, 30, 1191, 1197, "months" +330, 9, 7, 280, 31, 32, 1198, 1199, "," +330, 9, 8, 281, 33, 41, 1200, 1208, "subjects" +330, 9, 9, 282, 42, 50, 1209, 1217, "received" +330, 9, 10, 283, 51, 52, 1218, 1219, "a" +330, 9, 11, 284, 53, 65, 1220, 1232, "standardized" +330, 9, 12, 285, 66, 75, 1233, 1242, "breakfast" +330, 9, 13, 286, 76, 77, 1243, 1244, "," +330, 9, 14, 287, 78, 83, 1245, 1250, "lunch" +330, 9, 15, 288, 84, 87, 1251, 1254, "and" +330, 9, 16, 289, 88, 94, 1255, 1261, "dinner" +330, 9, 17, 290, 95, 96, 1262, 1263, "," +330, 9, 18, 291, 97, 101, 1264, 1268, "with" +330, 9, 19, 292, 102, 105, 1269, 1272, "pre" +330, 9, 20, 293, 106, 107, 1273, 1274, "-" +330, 9, 21, 294, 108, 111, 1275, 1278, "and" +330, 9, 22, 295, 112, 124, 1279, 1291, "postprandial" +330, 9, 23, 296, 125, 130, 1292, 1297, "blood" +330, 9, 24, 297, 131, 139, 1298, 1306, "sampling" +330, 9, 25, 298, 140, 142, 1307, 1309, "to" +330, 9, 26, 299, 143, 150, 1310, 1317, "measure" +330, 9, 27, 300, 151, 157, 1318, 1324, "plasma" +330, 9, 28, 301, 158, 160, 1325, 1327, "IP" +330, 9, 29, 302, 161, 162, 1328, 1329, "," +330, 9, 30, 303, 163, 168, 1330, 1335, "total" +330, 9, 31, 304, 169, 176, 1336, 1343, "insulin" +330, 9, 32, 305, 177, 180, 1344, 1347, "and" +330, 9, 33, 306, 181, 186, 1348, 1353, "blood" +330, 9, 34, 307, 187, 194, 1354, 1361, "glucose" +330, 9, 35, 308, 195, 196, 1362, 1363, "(" +330, 9, 36, 309, 197, 199, 1364, 1366, "BG" +330, 9, 37, 310, 200, 201, 1367, 1368, ")" +330, 9, 38, 311, 202, 203, 1369, 1370, "." +330, 10, 1, 312, 0, 7, 1371, 1378, "RESULTS" +330, 10, 2, 313, 8, 9, 1379, 1380, ":" +330, 10, 3, 314, 10, 17, 1381, 1388, "Insulin" +330, 10, 4, 315, 18, 22, 1389, 1393, "dose" +330, 10, 5, 316, 23, 28, 1394, 1399, "after" +330, 10, 6, 317, 29, 30, 1400, 1401, "3" +330, 10, 7, 318, 31, 37, 1402, 1408, "months" +330, 10, 8, 319, 38, 41, 1409, 1412, "was" +330, 10, 9, 320, 42, 52, 1413, 1423, "comparable" +330, 10, 10, 321, 53, 55, 1424, 1426, "in" +330, 10, 11, 322, 56, 60, 1427, 1431, "both" +330, 10, 12, 323, 61, 67, 1432, 1438, "groups" +330, 10, 13, 324, 68, 69, 1439, 1440, "(" +330, 10, 14, 325, 70, 73, 1441, 1444, "GLA" +330, 10, 15, 326, 74, 76, 1445, 1447, "vs" +330, 10, 16, 327, 77, 78, 1448, 1449, "." +330, 10, 17, 328, 79, 82, 1450, 1453, "NPH" +330, 10, 18, 329, 83, 84, 1454, 1455, ":" +330, 10, 19, 330, 85, 87, 1456, 1458, "23" +330, 10, 20, 331, 88, 89, 1459, 1460, "." +330, 10, 21, 332, 90, 91, 1461, 1462, "6" +330, 10, 22, 333, 92, 93, 1463, 1464, "+" +330, 10, 23, 334, 94, 95, 1465, 1466, "/" +330, 10, 24, 335, 96, 97, 1467, 1468, "-" +330, 10, 25, 336, 98, 100, 1469, 1471, "13" +330, 10, 26, 337, 101, 102, 1472, 1473, "." +330, 10, 27, 338, 103, 104, 1474, 1475, "4" +330, 10, 28, 339, 105, 107, 1476, 1478, "vs" +330, 10, 29, 340, 108, 109, 1479, 1480, "." +330, 10, 30, 341, 110, 112, 1481, 1483, "23" +330, 10, 31, 342, 113, 114, 1484, 1485, "." +330, 10, 32, 343, 115, 116, 1486, 1487, "3" +330, 10, 33, 344, 117, 118, 1488, 1489, "+" +330, 10, 34, 345, 119, 120, 1490, 1491, "/" +330, 10, 35, 346, 121, 122, 1492, 1493, "-" +330, 10, 36, 347, 123, 125, 1494, 1496, "12" +330, 10, 37, 348, 126, 127, 1497, 1498, "." +330, 10, 38, 349, 128, 129, 1499, 1500, "7" +330, 10, 39, 350, 130, 131, 1501, 1502, ";" +330, 10, 40, 351, 132, 133, 1503, 1504, "p" +330, 10, 41, 352, 134, 135, 1505, 1506, "=" +330, 10, 42, 353, 136, 138, 1507, 1509, "NS" +330, 10, 43, 354, 139, 140, 1510, 1511, ")" +330, 10, 44, 355, 141, 142, 1512, 1513, "." +330, 11, 1, 356, 0, 4, 1514, 1518, "Both" +330, 11, 2, 357, 5, 15, 1519, 1529, "treatments" +330, 11, 3, 358, 16, 29, 1530, 1543, "significantly" +330, 11, 4, 359, 30, 37, 1544, 1551, "reduced" +330, 11, 5, 360, 38, 45, 1552, 1559, "fasting" +330, 11, 6, 361, 46, 48, 1560, 1562, "BG" +330, 11, 7, 362, 49, 55, 1563, 1569, "levels" +330, 11, 8, 363, 56, 57, 1570, 1571, "(" +330, 11, 9, 364, 58, 61, 1572, 1575, "GLA" +330, 11, 10, 365, 62, 63, 1576, 1577, ":" +330, 11, 11, 366, 64, 67, 1578, 1581, "158" +330, 11, 12, 367, 68, 69, 1582, 1583, "+" +330, 11, 13, 368, 70, 71, 1584, 1585, "/" +330, 11, 14, 369, 72, 73, 1586, 1587, "-" +330, 11, 15, 370, 74, 76, 1588, 1590, "19" +330, 11, 16, 371, 77, 79, 1591, 1593, "to" +330, 11, 17, 372, 80, 83, 1594, 1597, "121" +330, 11, 18, 373, 84, 85, 1598, 1599, "+" +330, 11, 19, 374, 86, 87, 1600, 1601, "/" +330, 11, 20, 375, 88, 89, 1602, 1603, "-" +330, 11, 21, 376, 90, 92, 1604, 1606, "23" +330, 11, 22, 377, 93, 95, 1607, 1609, "mg" +330, 11, 23, 378, 96, 97, 1610, 1611, "/" +330, 11, 24, 379, 98, 100, 1612, 1614, "dl" +330, 11, 25, 380, 101, 102, 1615, 1616, ";" +330, 11, 26, 381, 103, 106, 1617, 1620, "NPH" +330, 11, 27, 382, 107, 108, 1621, 1622, ":" +330, 11, 28, 383, 109, 112, 1623, 1626, "156" +330, 11, 29, 384, 113, 114, 1627, 1628, "+" +330, 11, 30, 385, 115, 116, 1629, 1630, "/" +330, 11, 31, 386, 117, 118, 1631, 1632, "-" +330, 11, 32, 387, 119, 121, 1633, 1635, "34" +330, 11, 33, 388, 122, 124, 1636, 1638, "to" +330, 11, 34, 389, 125, 128, 1639, 1642, "119" +330, 11, 35, 390, 129, 130, 1643, 1644, "+" +330, 11, 36, 391, 131, 132, 1645, 1646, "/" +330, 11, 37, 392, 133, 134, 1647, 1648, "-" +330, 11, 38, 393, 135, 137, 1649, 1651, "29" +330, 11, 39, 394, 138, 140, 1652, 1654, "mg" +330, 11, 40, 395, 141, 142, 1655, 1656, "/" +330, 11, 41, 396, 143, 145, 1657, 1659, "dl" +330, 11, 42, 397, 146, 147, 1660, 1661, ";" +330, 11, 43, 398, 148, 152, 1662, 1666, "both" +330, 11, 44, 399, 153, 154, 1667, 1668, "p" +330, 11, 45, 400, 155, 156, 1669, 1670, "<" +330, 11, 46, 401, 157, 158, 1671, 1672, "0" +330, 11, 47, 402, 159, 160, 1673, 1674, "." +330, 11, 48, 403, 161, 163, 1675, 1677, "01" +330, 11, 49, 404, 164, 166, 1678, 1680, "vs" +330, 11, 50, 405, 167, 168, 1681, 1682, "." +330, 11, 51, 406, 169, 177, 1683, 1691, "baseline" +330, 11, 52, 407, 178, 179, 1692, 1693, ")" +330, 11, 53, 408, 180, 181, 1694, 1695, "." +330, 12, 1, 409, 0, 7, 1696, 1703, "Fasting" +330, 12, 2, 410, 8, 11, 1704, 1707, "and" +330, 12, 3, 411, 12, 24, 1708, 1720, "postprandial" +330, 12, 4, 412, 25, 27, 1721, 1723, "BG" +330, 12, 5, 413, 28, 34, 1724, 1730, "levels" +330, 12, 6, 414, 35, 38, 1731, 1734, "did" +330, 12, 7, 415, 39, 42, 1735, 1738, "not" +330, 12, 8, 416, 43, 49, 1739, 1745, "differ" +330, 12, 9, 417, 50, 57, 1746, 1753, "between" +330, 12, 10, 418, 58, 64, 1754, 1760, "groups" +330, 12, 11, 419, 65, 66, 1761, 1762, "." +330, 13, 1, 420, 0, 2, 1763, 1765, "IP" +330, 13, 2, 421, 3, 9, 1766, 1772, "levels" +330, 13, 3, 422, 10, 19, 1773, 1782, "decreased" +330, 13, 4, 423, 20, 22, 1783, 1785, "in" +330, 13, 5, 424, 23, 27, 1786, 1790, "both" +330, 13, 6, 425, 28, 34, 1791, 1797, "groups" +330, 13, 7, 426, 35, 36, 1798, 1799, "(" +330, 13, 8, 427, 37, 38, 1800, 1801, "p" +330, 13, 9, 428, 39, 40, 1802, 1803, "<" +330, 13, 10, 429, 41, 42, 1804, 1805, "0" +330, 13, 11, 430, 43, 44, 1806, 1807, "." +330, 13, 12, 431, 45, 47, 1808, 1810, "05" +330, 13, 13, 432, 48, 50, 1811, 1813, "at" +330, 13, 14, 433, 51, 54, 1814, 1817, "all" +330, 13, 15, 434, 55, 65, 1818, 1828, "timepoints" +330, 13, 16, 435, 66, 67, 1829, 1830, ")" +330, 13, 17, 436, 68, 69, 1831, 1832, "." +330, 14, 1, 437, 0, 8, 1833, 1841, "Although" +330, 14, 2, 438, 9, 11, 1842, 1844, "IP" +330, 14, 3, 439, 12, 19, 1845, 1852, "release" +330, 14, 4, 440, 20, 25, 1853, 1858, "after" +330, 14, 5, 441, 26, 35, 1859, 1868, "breakfast" +330, 14, 6, 442, 36, 39, 1869, 1872, "did" +330, 14, 7, 443, 40, 43, 1873, 1876, "not" +330, 14, 8, 444, 44, 50, 1877, 1883, "differ" +330, 14, 9, 445, 51, 58, 1884, 1891, "between" +330, 14, 10, 446, 59, 69, 1892, 1902, "treatments" +330, 14, 11, 447, 70, 71, 1903, 1904, "," +330, 14, 12, 448, 72, 75, 1905, 1908, "GLA" +330, 14, 13, 449, 76, 83, 1909, 1916, "induced" +330, 14, 14, 450, 84, 85, 1917, 1918, "a" +330, 14, 15, 451, 86, 93, 1919, 1926, "greater" +330, 14, 16, 452, 94, 103, 1927, 1936, "reduction" +330, 14, 17, 453, 104, 106, 1937, 1939, "in" +330, 14, 18, 454, 107, 109, 1940, 1942, "IP" +330, 14, 19, 455, 110, 117, 1943, 1950, "release" +330, 14, 20, 456, 118, 123, 1951, 1956, "after" +330, 14, 21, 457, 124, 129, 1957, 1962, "lunch" +330, 14, 22, 458, 130, 131, 1963, 1964, "(" +330, 14, 23, 459, 132, 133, 1965, 1966, "p" +330, 14, 24, 460, 134, 135, 1967, 1968, "=" +330, 14, 25, 461, 136, 137, 1969, 1970, "0" +330, 14, 26, 462, 138, 139, 1971, 1972, "." +330, 14, 27, 463, 140, 142, 1973, 1975, "08" +330, 14, 28, 464, 143, 144, 1976, 1977, ")" +330, 14, 29, 465, 145, 148, 1978, 1981, "and" +330, 14, 30, 466, 149, 155, 1982, 1988, "dinner" +330, 14, 31, 467, 156, 157, 1989, 1990, "(" +330, 14, 32, 468, 158, 159, 1991, 1992, "p" +330, 14, 33, 469, 160, 161, 1993, 1994, "=" +330, 14, 34, 470, 162, 163, 1995, 1996, "0" +330, 14, 35, 471, 164, 165, 1997, 1998, "." +330, 14, 36, 472, 166, 168, 1999, 2001, "04" +330, 14, 37, 473, 169, 170, 2002, 2003, ")" +330, 14, 38, 474, 171, 172, 2004, 2005, "." +330, 15, 1, 475, 0, 5, 2006, 2011, "Total" +330, 15, 2, 476, 6, 12, 2012, 2018, "plasma" +330, 15, 3, 477, 13, 20, 2019, 2026, "insulin" +330, 15, 4, 478, 21, 27, 2027, 2033, "levels" +330, 15, 5, 479, 28, 31, 2034, 2037, "did" +330, 15, 6, 480, 32, 35, 2038, 2041, "not" +330, 15, 7, 481, 36, 42, 2042, 2048, "differ" +330, 15, 8, 482, 43, 50, 2049, 2056, "between" +330, 15, 9, 483, 51, 57, 2057, 2063, "groups" +330, 15, 10, 484, 58, 59, 2064, 2065, "." +330, 16, 1, 485, 0, 11, 2066, 2077, "CONCLUSIONS" +330, 16, 2, 486, 12, 13, 2078, 2079, ":" +330, 16, 3, 487, 14, 20, 2080, 2086, "Adding" +330, 16, 4, 488, 21, 26, 2087, 2092, "basal" +330, 16, 5, 489, 27, 34, 2093, 2100, "insulin" +330, 16, 6, 490, 35, 37, 2101, 2103, "to" +330, 16, 7, 491, 38, 47, 2104, 2113, "metformin" +330, 16, 8, 492, 48, 55, 2114, 2121, "reduces" +330, 16, 9, 493, 56, 68, 2122, 2134, "postprandial" +330, 16, 10, 494, 69, 73, 2135, 2139, "beta" +330, 16, 11, 495, 74, 75, 2140, 2141, "-" +330, 16, 12, 496, 76, 80, 2142, 2146, "cell" +330, 16, 13, 497, 81, 85, 2147, 2151, "load" +330, 16, 14, 498, 86, 87, 2152, 2153, "." +330, 17, 1, 499, 0, 5, 2154, 2159, "While" +330, 17, 2, 500, 6, 9, 2160, 2163, "GLA" +330, 17, 3, 501, 10, 13, 2164, 2167, "and" +330, 17, 4, 502, 14, 17, 2168, 2171, "NPH" +330, 17, 5, 503, 18, 21, 2172, 2175, "had" +330, 17, 6, 504, 22, 32, 2176, 2186, "comparable" +330, 17, 7, 505, 33, 40, 2187, 2194, "effects" +330, 17, 8, 506, 41, 43, 2195, 2197, "at" +330, 17, 9, 507, 44, 53, 2198, 2207, "breakfast" +330, 17, 10, 508, 54, 55, 2208, 2209, "," +330, 17, 11, 509, 56, 59, 2210, 2213, "GLA" +330, 17, 12, 510, 60, 67, 2214, 2221, "reduces" +330, 17, 13, 511, 68, 72, 2222, 2226, "beta" +330, 17, 14, 512, 73, 74, 2227, 2228, "-" +330, 17, 15, 513, 75, 79, 2229, 2233, "cell" +330, 17, 16, 514, 80, 86, 2234, 2240, "stress" +330, 17, 17, 515, 87, 91, 2241, 2245, "more" +330, 17, 18, 516, 92, 103, 2246, 2257, "effectively" +330, 17, 19, 517, 104, 106, 2258, 2260, "at" +330, 17, 20, 518, 107, 113, 2261, 2267, "dinner" +330, 17, 21, 519, 114, 115, 2268, 2269, "," +330, 17, 22, 520, 116, 119, 2270, 2273, "and" +330, 17, 23, 521, 120, 124, 2274, 2278, "with" +330, 17, 24, 522, 125, 126, 2279, 2280, "a" +330, 17, 25, 523, 127, 132, 2281, 2286, "trend" +330, 17, 26, 524, 133, 135, 2287, 2289, "at" +330, 17, 27, 525, 136, 141, 2290, 2295, "lunch" +330, 17, 28, 526, 142, 143, 2296, 2297, "," +330, 17, 29, 527, 144, 148, 2298, 2302, "most" +330, 17, 30, 528, 149, 157, 2303, 2311, "probably" +330, 17, 31, 529, 158, 165, 2312, 2319, "because" +330, 17, 32, 530, 166, 168, 2320, 2322, "of" +330, 17, 33, 531, 169, 172, 2323, 2326, "its" +330, 17, 34, 532, 173, 179, 2327, 2333, "longer" +330, 17, 35, 533, 180, 187, 2334, 2341, "lasting" +330, 17, 36, 534, 188, 203, 2342, 2357, "pharmacodynamic" +330, 17, 37, 535, 204, 211, 2358, 2365, "profile" +330, 17, 38, 536, 212, 213, 2366, 2367, "." +330, 18, 1, 537, 0, 3, 2368, 2371, "DOI" +330, 18, 2, 538, 4, 5, 2372, 2373, ":" +330, 18, 3, 539, 6, 8, 2374, 2376, "10" +330, 18, 4, 540, 9, 10, 2377, 2378, "." +330, 18, 5, 541, 11, 15, 2379, 2383, "1111" +330, 18, 6, 542, 16, 17, 2384, 2385, "/" +330, 18, 7, 543, 18, 19, 2386, 2387, "j" +330, 18, 8, 544, 20, 21, 2388, 2389, "." +330, 18, 9, 545, 22, 26, 2390, 2394, "1463" +330, 18, 10, 546, 27, 28, 2395, 2396, "-" +330, 18, 11, 547, 29, 33, 2397, 2401, "1326" +330, 18, 12, 548, 34, 35, 2402, 2403, "." +330, 18, 13, 549, 36, 40, 2404, 2408, "2010" +330, 18, 14, 550, 41, 42, 2409, 2410, "." +330, 18, 15, 551, 43, 48, 2411, 2416, "01209" +330, 18, 16, 552, 49, 50, 2417, 2418, "." +330, 18, 17, 553, 51, 52, 2419, 2420, "x" +330, 18, 18, 554, 53, 58, 2421, 2426, "PMCID" +330, 18, 19, 555, 59, 60, 2427, 2428, ":" +330, 18, 20, 556, 61, 71, 2429, 2439, "PMC2871167" +330, 18, 21, 557, 72, 76, 2440, 2444, "PMID" +330, 18, 22, 558, 77, 78, 2445, 2446, ":" +330, 18, 23, 559, 79, 87, 2447, 2455, "20415692" +330, 18, 24, 560, 88, 89, 2456, 2457, "[" +330, 18, 25, 561, 90, 97, 2458, 2465, "Indexed" +330, 18, 26, 562, 98, 101, 2466, 2469, "for" +330, 18, 27, 563, 102, 109, 2470, 2477, "MEDLINE" +330, 18, 28, 564, 110, 111, 2478, 2479, "]" diff --git a/data/dm2 20415692_kwoodley.annodb b/data/dm2 20415692_kwoodley.annodb new file mode 100644 index 0000000..bc404b5 --- /dev/null +++ b/data/dm2 20415692_kwoodley.annodb @@ -0,0 +1,101 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15363, Journal, 0, 19, "Diabetes Obes Metab", "", +15364, Publication, 22, 26, "2010", "", +36637, Title, 110, 265, "Adding insulin glargine vs . NPH insulin to metformin results in a more efficient postprandial beta - cell protection in individuals with type 2 diabetes .", "", +15365, InsulinGlargine, 117, 133, "insulin glargine", "", +15366, IsophaneInsulin_NPH, 139, 150, "NPH insulin", "", +15367, Metformin, 154, 163, "metformin", "", +15368, Type2Diabetes, 248, 263, "type 2 diabetes", "", +15370, Author, 266, 273, "Forst T", "", +15371, Author, 282, 290, "Larbig M", "", +15372, Author, 293, 302, "Hohberg C", "", +15373, Author, 305, 312, "Forst S", "", +15374, Author, 315, 324, "Diessel S", "", +15375, Author, 327, 337, "Borchert M", "", +15376, Author, 340, 346, "Roth W", "", +15377, Author, 349, 361, "Pf ü tzner A", "", +15378, Germany, 471, 478, "Germany", "", +15379, Type2Diabetes, 626, 641, "type 2 diabetes", "", +36638, ObjectiveDescription, 644, 824, "This open - label , parallel - group , two - arm , pilot study compared the beta - cell protective effect of adding insulin glargine ( GLA ) vs . NPH insulin to ongoing metformin .", "", +15380, OpenLabel, 649, 661, "open - label", "", +15381, Parallel, 664, 680, "parallel - group", "", +15382, CTDesign, 683, 692, "two - arm", "", +15383, CTDesign, 695, 700, "pilot", "", +15384, InsulinGlargine, 760, 776, "insulin glargine", "", +15385, InsulinGlargine, 779, 782, "GLA", "", +15386, IsophaneInsulin_NPH, 790, 801, "NPH insulin", "", +15387, Metformin, 813, 822, "metformin", "", +15388, NumberPatientsCT, 858, 860, "28", "", +15404, Precondition, 861, 1106, "insulin - naive type 2 diabetes subjects ( mean + / - SD age , 61 . 5 + / - 6 . 7 years ; diabetes duration , 9 . 8 + / - 6 . 5 years ; HbA1c , 7 . 1 + / - 0 . 5 % ; BMI , 30 . 7 + / - 4 . 3 kg / m ( 2 ) ) treated with metformin and sulfonylurea", "", +15390, Type2Diabetes, 877, 892, "type 2 diabetes", "", +15391, Mean, 904, 917, "mean + / - SD", "", +15392, AvgAge, 924, 930, "61 . 5", "", +15393, HbA1c, 997, 1002, "HbA1c", "", +15394, Percentage, 1023, 1024, "%", "", +15395, BMI, 1027, 1030, "BMI", "", +15396, Kg_per_squareMeter, 1052, 1064, "kg / m ( 2 )", "", +15397, Metformin, 1080, 1089, "metformin", "", +15398, Sulfonylureas, 1094, 1106, "sulfonylurea", "", +15399, Randomized, 1112, 1122, "randomized", "", +15400, Frequency, 1130, 1142, "once - daily", "", +15401, InsulinGlargine, 1143, 1146, "GLA", "", +15402, IsophaneInsulin_NPH, 1150, 1153, "NPH", "", +36639, RelativeTime, 1157, 1164, "bedtime", "", +36640, TimePoint, 1170, 1178, "baseline", "", +15406, Duration, 1189, 1197, "3 months", "", +15408, EndPointDescription, 1318, 1327, "plasma IP", "", +15409, EndPointDescription, 1336, 1343, "insulin", "", +36641, BloodGlucose, 1348, 1361, "blood glucose", "", +36642, BloodGlucose, 1364, 1366, "BG", "", +36643, InsulinDose, 1381, 1393, "Insulin dose", "", +15412, Duration, 1400, 1408, "3 months", "", +15414, InsulinGlargine, 1441, 1444, "GLA", "", +15415, IsophaneInsulin_NPH, 1450, 1453, "NPH", "", +15416, ResultMeasuredValue, 1456, 1462, "23 . 6", "", +15418, SdDevResValue, 1469, 1475, "13 . 4", "", +15417, ResultMeasuredValue, 1481, 1487, "23 . 3", "", +15420, SdDevResValue, 1494, 1500, "12 . 7", "", +15421, PvalueDiff, 1503, 1509, "p = NS", "", +36644, FastingBloodGlucose, 1552, 1562, "fasting BG", "", +15425, InsulinGlargine, 1572, 1575, "GLA", "", +15427, BaseLineValue, 1578, 1581, "158", "", +15431, SdDevBL, 1588, 1590, "19", "", +15429, ResultMeasuredValue, 1594, 1597, "121", "", +15433, SdDevResValue, 1604, 1606, "23", "", +15435, Mg_per_deciliter, 1607, 1614, "mg / dl", "", +15426, IsophaneInsulin_NPH, 1617, 1620, "NPH", "", +15428, BaseLineValue, 1623, 1626, "156", "", +15432, SdDevBL, 1633, 1635, "34", "", +15430, ResultMeasuredValue, 1639, 1642, "119", "", +15434, SdDevResValue, 1649, 1651, "29", "", +15436, Mg_per_deciliter, 1652, 1659, "mg / dl", "", +15437, PValueResValue, 1667, 1677, "p < 0 . 01", "", +36646, TimePoint, 1683, 1691, "baseline", "", +36647, FastingBloodGlucose, 1696, 1703, "Fasting", "", +36649, ObservedResult, 1696, 1762, "Fasting and postprandial BG levels did not differ between groups .", "", +36648, PostprandialBloodGlucose, 1708, 1723, "postprandial BG", "", +15443, ObservedResult, 1763, 1797, "IP levels decreased in both groups", "", +15441, EndPointDescription, 1763, 1765, "IP", "", +15442, PvalueDiff, 1800, 1810, "p < 0 . 05", "", +36650, TimePoint, 1811, 1828, "at all timepoints", "", +15445, EndPointDescription, 1842, 1844, "IP", "", +15446, InsulinGlargine, 1905, 1908, "GLA", "", +15452, ObservedResult, 1909, 1936, "induced a greater reduction", "", +15447, EndPointDescription, 1940, 1942, "IP", "", +15448, TimePoint, 1951, 1962, "after lunch", "", +15450, PValueChangeValue, 1965, 1975, "p = 0 . 08", "", +15449, TimePoint, 1982, 1988, "dinner", "", +15451, PValueChangeValue, 1991, 2001, "p = 0 . 04", "", +15454, ObservedResult, 2006, 2063, "Total plasma insulin levels did not differ between groups", "", +15453, EndPointDescription, 2012, 2026, "plasma insulin", "", +36651, ConclusionComment, 2080, 2153, "Adding basal insulin to metformin reduces postprandial beta - cell load .", "", +15455, Insulin, 2093, 2100, "insulin", "", +15456, Metformin, 2104, 2113, "metformin", "", +36652, ConclusionComment, 2154, 2367, "While GLA and NPH had comparable effects at breakfast , GLA reduces beta - cell stress more effectively at dinner , and with a trend at lunch , most probably because of its longer lasting pharmacodynamic profile .", "", +15459, InsulinGlargine, 2160, 2163, "GLA", "", +15460, IsophaneInsulin_NPH, 2168, 2171, "NPH", "", +15461, TimePoint, 2195, 2207, "at breakfast", "", +15462, InsulinGlargine, 2210, 2213, "GLA", "", +15463, TimePoint, 2258, 2267, "at dinner", "", +15464, TimePoint, 2287, 2295, "at lunch", "", +15466, PMID, 2447, 2455, "20415692", "", diff --git a/data/dm2 20415692_kwoodley.n-triples b/data/dm2 20415692_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20415692_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20880343_admin.annodb b/data/dm2 20880343_admin.annodb new file mode 100644 index 0000000..14a158e --- /dev/null +++ b/data/dm2 20880343_admin.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2010", "", " \"2010\"." +105, Title, 111, 284, "Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .", "", " \"Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .\"." +2, Insulin, 128, 135, "insulin", "", +3, OralAntidiabeticAgent, 150, 180, "oral antihyperglycaemic agents", "", +102, Hypoglycemia, 201, 210, "glycaemia", "", +4, Insulin, 248, 255, "insulin", "", +5, Type2Diabetes, 267, 282, "type 2 diabetes", "", " ." +6, Author, 285, 292, "Jain SM", "", " \"Jain SM\"." +7, Author, 301, 306, "Mao X", "", " \"Mao X\"." +8, Author, 309, 329, "Escalante - Pulido M", "", " \"Escalante - Pulido M\"." +9, Author, 332, 345, "Vorokhobina N", "", " \"Vorokhobina N\"." +10, Author, 348, 355, "Lopez I", "", " \"Lopez I\"." +11, Author, 358, 365, "Ilag LL", "", " \"Ilag LL\"." +12, India, 440, 445, "India", "", " ." +29, ObjectiveDescription, 455, 671, "To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ]", "", " \"To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ]\"." +13, Frequency, 495, 507, "once - daily", "", " \"once - daily\"." +14, InsulinGlargine, 508, 524, "insulin glargine", "", " ." +121, Frequency, 530, 533, "≤ 3", "", " \"≤ 3\"." +15, RelativeTime, 534, 542, "mealtime", "", " . ." +115, Lispro, 543, 549, "lispro", "", " ." +16, InsulinGlargine, 552, 553, "G", "", +187, Lispro, 556, 557, "L", "", +57337, Lispro50/50, 565, 591, "insulin lispro mix 50 / 50", "", +57338, Lispro50/50, 594, 603, "LM50 / 50", "", +57340, Frequency, 618, 641, "once up to thrice daily", "", " \"once up to thrice daily\"." +185, ObjectiveDescription, 672, 857, "of beginning and advancing insulin in patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy , with the aim of showing non - inferiority of PP to G + L .", "", " \"of beginning and advancing insulin in patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy , with the aim of showing non - inferiority of PP to G + L .\"." +24, Insulin, 699, 706, "insulin", "", +28, Precondition, 710, 796, "patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy", "", " \"patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy\"." +23, Type2Diabetes, 724, 739, "type 2 diabetes", "", +22, Type2Diabetes, 742, 745, "T2D", "", +57339, Oral, 784, 788, "oral", "", +27, InsulinGlargine, 850, 851, "G", "", +188, Lispro, 854, 855, "L", "", +30, Randomized, 882, 892, "randomized", "", " ." +33, NumberPatientsArm, 905, 908, "242", "", " \"242\"." +32, InsulinGlargine, 914, 915, "G", "", +189, Lispro, 918, 919, "L", "", +34, NumberPatientsArm, 926, 929, "242", "", " \"242\"." +35, Duration, 937, 946, "36 - week", "", " \"36 - week\"." +126, Multicenter, 949, 962, "multinational", "", " ." +36, OpenLabel, 965, 977, "open - label", "", " ." +37, RelativeTime, 986, 996, "Dinnertime", "", +57341, Lispro50/50, 1005, 1015, "LM 50 / 50", "", " ." +57342, Lispro75/25, 1039, 1065, "insulin lispro mix 75 / 25", "", +227, TimePoint, 1118, 1126, "Baseline", "", +39, HbA1c, 1127, 1142, "haemoglobin A1c", "", " ." +41, HbA1c, 1145, 1150, "HbA1c", "", +42, BaseLineValue, 1158, 1163, "9 . 5", "", " \"9 . 5\"." +44, Percentage, 1164, 1165, "%", "", " ." +43, BaseLineValue, 1177, 1182, "9 . 3", "", " \"9 . 3\"." +45, Percentage, 1183, 1184, "%", "", +47, InsulinGlargine, 1187, 1188, "G", "", +192, Lispro, 1191, 1192, "L", "", +48, PvalueDiff, 1197, 1208, "p = 0 . 095", "", +49, HbA1c, 1221, 1224, "A1C", "", +193, TimePoint, 1227, 1235, "baseline", "", +194, TimePoint, 1239, 1247, "endpoint", "", " \"endpoint\". \"endpoint\"." +50, Reduction, 1256, 1262, "1 . 76", "", " \"1 . 76\"." +52, Percentage, 1263, 1264, "%", "", +51, Reduction, 1278, 1284, "1 . 93", "", " \"1 . 93\"." +53, Percentage, 1285, 1286, "%", "", +55, InsulinGlargine, 1289, 1290, "G", "", +195, Lispro, 1293, 1294, "L", "", +56, PvalueDiff, 1299, 1310, "p = 0 . 097", "", " \"p = 0 . 097\"." +57, DiffGroupAbsValue, 1345, 1351, "0 . 17", "", " \"0 . 17\"." +58, ConfIntervalDiff, 1354, 1398, "95 % confidence interval : - 0 . 03 , 0 . 37", "", " \"95 % confidence interval : - 0 . 03 , 0 . 37\"." +197, ObservedResult, 1405, 1515, "Non - inferiority of PP to G + L was not shown based on the prespecified non - inferiority margin of 0 . 3 % .", "", +60, InsulinGlargine, 1432, 1433, "G", "", +196, Lispro, 1436, 1437, "L", "", +61, HbA1c, 1516, 1519, "A1C", "", +62, InsulinGlargine, 1535, 1536, "G", "", +198, Lispro, 1539, 1540, "L", "", +63, TimePoint, 1544, 1552, "weeks 12", "", " \"weeks 12\". \"weeks 12\"." +64, ResultMeasuredValue, 1555, 1560, "7 . 8", "", +65, ResultMeasuredValue, 1566, 1571, "7 . 9", "", " \"7 . 9\"." +68, Percentage, 1572, 1573, "%", "", +71, PvalueDiff, 1576, 1587, "p = 0 . 042", "", +75, TimePoint, 1592, 1594, "24", "", " \"24\". \"24\"." +73, ResultMeasuredValue, 1597, 1602, "7 . 4", "", " \"7 . 4\"." +74, ResultMeasuredValue, 1608, 1613, "7 . 6", "", " \"7 . 6\"." +69, Percentage, 1614, 1615, "%", "", +76, PvalueDiff, 1618, 1629, "p = 0 . 046", "", " \"p = 0 . 046\"." +151, TimePoint, 1645, 1652, "week 36", "", " \"week 36\". \"week 36\"." +66, ResultMeasuredValue, 1655, 1660, "7 . 5", "", " \"7 . 5\"." +67, ResultMeasuredValue, 1666, 1671, "7 . 6", "", " \"7 . 6\"." +70, Percentage, 1672, 1673, "%", "", +72, PvalueDiff, 1676, 1687, "p = 0 . 405", "", +200, ObservedResult, 1692, 1838, "There were no significant differences in percentages of patients achieving A1C ≤ 7 % , overall hypoglycaemia incidence and rate or weight change .", "", +77, HbA1c_target, 1767, 1776, "A1C ≤ 7 %", "", +165, Percentage, 1775, 1776, "%", "", +78, Hypoglycemia, 1787, 1800, "hypoglycaemia", "", +79, BodyWeight, 1823, 1829, "weight", "", +92885, InsulinDose, 1845, 1866, "daily insulin dosages", "", " . ." +57590, Interval, 1845, 1850, "daily", "", +202, TimePoint, 1870, 1878, "endpoint", "", +81, InsulinGlargine, 1904, 1905, "G", "", +203, Lispro, 1908, 1909, "L", "", +92886, ResultMeasuredValue, 1912, 1918, "0 . 57", "", " \"0 . 57\"." +92887, ResultMeasuredValue, 1924, 1930, "0 . 51", "", " \"0 . 51\"." +84, IntUnit_per_Kg, 1931, 1937, "U / kg", "", " ." +85, PvalueDiff, 1940, 1951, "p = 0 . 017", "", " \"p = 0 . 017\"." +92888, EndPointDescription, 1975, 1985, "injections", "", " . ." +86, ResultMeasuredValue, 1988, 1994, "1 . 98", "", " \"1 . 98\"." +87, ResultMeasuredValue, 2000, 2006, "1 . 79", "", " \"1 . 79\"." +88, PvalueDiff, 2009, 2020, "p = 0 . 011", "", " \"p = 0 . 011\"." +178, ConclusionComment, 2039, 2192, "Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown .", "", " \"Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown .\"." +89, Type2Diabetes, 2113, 2116, "T2D", "", +90, OralAntidiabeticAgent, 2120, 2132, "oral therapy", "", +93, InsulinGlargine, 2171, 2172, "G", "", +206, Lispro, 2175, 2176, "L", "", +179, ConclusionComment, 2193, 2317, "Higher insulin doses were observed with PP with no between - treatment differences in overall hypoglycaemia or weight gain .", "", " \"Higher insulin doses were observed with PP with no between - treatment differences in overall hypoglycaemia or weight gain .\"." +180, Insulin, 2200, 2207, "insulin", "", +95, Hypoglycemia, 2287, 2300, "hypoglycaemia", "", +57345, BodyWeight, 2304, 2310, "weight", "", +97, PMID, 2428, 2436, "20880343", "", " \"20880343\"." diff --git a/data/dm2 20880343_admin.n-triples b/data/dm2 20880343_admin.n-triples new file mode 100644 index 0000000..5adbfa6 --- /dev/null +++ b/data/dm2 20880343_admin.n-triples @@ -0,0 +1,213 @@ +# RDF export of group: Publication + . + "Publication 27563" . + "Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes ." . + "Jain SM" . + "2010" . + "Diabetes Obes Metab ." . + "20880343" . + . + "Mao X" . + "Escalante - Pulido M" . + "Vorokhobina N" . + "Lopez I" . + "Ilag LL" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 27570" . + "To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ]" . + "36 - week" . + . + . + . + "Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown ." . + . + . + . + . + . + . + "of beginning and advancing insulin in patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy , with the aim of showing non - inferiority of PP to G + L ." . + . + . + "Higher insulin doses were observed with PP with no between - treatment differences in overall hypoglycaemia or weight gain ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population 27586" . + "patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + "inj" . + . + . + . + . + . +# RDF export of group: Arm + . + "gl+lispro" . + "242" . + . + . + . + . + . + . + . + . + . + . + "lisrpo505" . + "242" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "gla" . + . + "once - daily" . + . + . + "lispro5050" . + . + "once up to thrice daily" . + . + . + "lispro" . + . + "≤ 3" . + . + . +# RDF export of group: Medication + . + "gla" . + . + . + . + . + "lis5050" . + . + . + . + . + "lispro" . + . + . + . +# RDF export of group: Outcome + . + "hba gl" . + . + "9 . 3" . + "1 . 93" . + "endpoint" . + . + "hba 55" . + . + "9 . 5" . + "1 . 76" . + "endpoint" . + . + "hba12 gl" . + . + "weeks 12" . + . + "hba12 55" . + . + "7 . 9" . + "weeks 12" . + . + "hba24 gl" . + . + "7 . 4" . + "24" . + . + "hba24 55" . + . + "7 . 6" . + "24" . + . + "hba36 gl" . + . + "7 . 5" . + "week 36" . + . + "hba36 55" . + . + "7 . 6" . + "week 36" . + . + "ins gl" . + . + "0 . 51" . + . + "ins 55" . + . + "0 . 57" . + . + "inj gl" . + . + "1 . 79" . + . + "inj 55" . + . + "1 . 98" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "0 . 17" . + "p = 0 . 097" . + "95 % confidence interval : - 0 . 03 , 0 . 37" . + . + . + . + "hba12" . + . + . + . + "hba24" . + "p = 0 . 046" . + . + . + . + "hba36" . + . + . + . + "ins" . + "p = 0 . 017" . + . + . + . + "inj" . + "p = 0 . 011" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20880343_akramersunderbrink.annodb b/data/dm2 20880343_akramersunderbrink.annodb new file mode 100644 index 0000000..3d6ae01 --- /dev/null +++ b/data/dm2 20880343_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29720, Journal, 0, 19, "Diabetes Obes Metab", "", " \"Diabetes Obes Metab\"." +29721, PublicationYear, 22, 26, "2010", "", " \"2010\"." +29727, Title, 111, 284, "Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .", "", " \"Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .\"." +29722, Insulin, 128, 135, "insulin", "", +29723, OralAntidiabeticAgent, 150, 180, "oral antihyperglycaemic agents", "", +29724, Hypoglycemia, 201, 210, "glycaemia", "", +29725, Insulin, 248, 255, "insulin", "", +29726, Type2Diabetes, 267, 282, "type 2 diabetes", "", " ." +29728, Author, 285, 292, "Jain SM", "", " \"Jain SM\"." +29729, Author, 301, 306, "Mao X", "", " \"Mao X\"." +29730, Author, 309, 329, "Escalante - Pulido M", "", " \"Escalante - Pulido M\"." +29731, Author, 332, 345, "Vorokhobina N", "", " \"Vorokhobina N\"." +29732, Author, 348, 355, "Lopez I", "", " \"Lopez I\"." +29733, Author, 358, 365, "Ilag LL", "", " \"Ilag LL\"." +29734, India, 440, 445, "India", "", +29751, ObjectiveDescription, 455, 684, "To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ] of beginning", "", " \"To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ] of beginning\"." +29735, Frequency, 495, 507, "once - daily", "", " \"once - daily\"." +29736, InsulinGlargine, 508, 524, "insulin glargine", "", " ." +29744, Frequency, 530, 533, "≤ 3", "", " \"≤ 3\"." +29737, Lispro, 543, 549, "lispro", "", " ." +39204, InsulinGlargine, 552, 553, "G", "", +39209, Lispro, 556, 557, "L", "", +29738, Lispro, 565, 579, "insulin lispro", "", " ." +29739, Frequency, 618, 641, "once up to thrice daily", "", " \"once up to thrice daily\"." +29752, ObjectiveDescription, 685, 857, "and advancing insulin in patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy , with the aim of showing non - inferiority of PP to G + L .", "", +29741, Type2Diabetes, 724, 739, "type 2 diabetes", "", +29742, Type2Diabetes, 742, 745, "T2D", "", +29743, Precondition, 752, 796, "inadequate glycaemic control on oral therapy", "", " \"inadequate glycaemic control on oral therapy\"." +29745, Randomized, 882, 892, "randomized", "", " ." +29746, NumberPatientsArm, 905, 908, "242", "", " \"242\"." +39201, InsulinGlargine, 914, 915, "G", "", +39210, Lispro, 918, 919, "L", "", +29747, NumberPatientsArm, 926, 929, "242", "", " \"242\"." +29748, Duration, 937, 946, "36 - week", "", " \"36 - week\"." +29749, Multicenter, 949, 962, "multinational", "", " ." +29750, OpenLabel, 965, 977, "open - label", "", " ." +29753, Lispro, 1039, 1053, "insulin lispro", "", +39220, TimePoint, 1118, 1126, "Baseline", "", +29754, HbA1c, 1127, 1142, "haemoglobin A1c", "", " ." +29755, HbA1c, 1145, 1150, "HbA1c", "", +29756, BaseLineValue, 1158, 1163, "9 . 5", "", " \"9 . 5\"." +29759, Percentage, 1164, 1165, "%", "", " ." +29757, BaseLineValue, 1177, 1182, "9 . 3", "", " \"9 . 3\"." +29760, Percentage, 1183, 1184, "%", "", +39202, InsulinGlargine, 1187, 1188, "G", "", +39211, Lispro, 1191, 1192, "L", "", +29758, PValueBL, 1197, 1208, "p = 0 . 095", "", " \"p = 0 . 095\". \"p = 0 . 095\"." +29761, HbA1c, 1221, 1224, "A1C", "", +39219, TimePoint, 1227, 1235, "baseline", "", +39218, TimePoint, 1239, 1247, "endpoint", "", +29762, ChangeValue, 1254, 1262, "- 1 . 76", "", " \"- 1 . 76\"." +29764, Percentage, 1263, 1264, "%", "", +29763, ChangeValue, 1276, 1284, "- 1 . 93", "", " \"- 1 . 93\"." +29765, Percentage, 1285, 1286, "%", "", +39203, InsulinGlargine, 1289, 1290, "G", "", +39212, Lispro, 1293, 1294, "L", "", +29766, PvalueDiff, 1299, 1310, "p = 0 . 097", "", " \"p = 0 . 097\"." +29767, DiffGroupAbsValue, 1345, 1351, "0 . 17", "", " \"0 . 17\"." +29768, ConfIntervalDiff, 1354, 1398, "95 % confidence interval : - 0 . 03 , 0 . 37", "", " \"95 % confidence interval : - 0 . 03 , 0 . 37\"." +29769, Percentage, 1357, 1358, "%", "", +39205, InsulinGlargine, 1432, 1433, "G", "", +39213, Lispro, 1436, 1437, "L", "", +29770, Percentage, 1512, 1513, "%", "", +29771, HbA1c, 1516, 1519, "A1C", "", +39206, InsulinGlargine, 1535, 1536, "G", "", +39214, Lispro, 1539, 1540, "L", "", +29772, TimePoint, 1544, 1552, "weeks 12", "", " \"weeks 12\". \"weeks 12\"." +29775, ResultMeasuredValue, 1555, 1560, "7 . 8", "", " \"7 . 8\"." +29776, ResultMeasuredValue, 1566, 1571, "7 . 9", "", " \"7 . 9\"." +29781, Percentage, 1572, 1573, "%", "", +29784, PvalueDiff, 1576, 1587, "p = 0 . 042", "", " \"p = 0 . 042\"." +29773, TimePoint, 1592, 1594, "24", "", " \"24\". \"24\"." +29777, ResultMeasuredValue, 1597, 1602, "7 . 4", "", " \"7 . 4\"." +29778, ResultMeasuredValue, 1608, 1613, "7 . 6", "", " \"7 . 6\"." +29782, Percentage, 1614, 1615, "%", "", +29785, PvalueDiff, 1618, 1629, "p = 0 . 046", "", " \"p = 0 . 046\"." +29774, TimePoint, 1645, 1652, "week 36", "", " \"week 36\". \"week 36\"." +29779, ResultMeasuredValue, 1655, 1660, "7 . 5", "", " \"7 . 5\"." +29780, ResultMeasuredValue, 1666, 1671, "7 . 6", "", " \"7 . 6\"." +29783, Percentage, 1672, 1673, "%", "", +29786, PvalueDiff, 1676, 1687, "p = 0 . 405", "", " \"p = 0 . 405\"." +29787, HbA1c_target, 1767, 1776, "A1C ≤ 7 %", "", +29788, Percentage, 1775, 1776, "%", "", +29789, Hypoglycemia, 1779, 1810, "overall hypoglycaemia incidence", "", +29790, BodyWeight, 1823, 1836, "weight change", "", +85561, InsulinDose, 1845, 1866, "daily insulin dosages", "", " . ." +39217, TimePoint, 1870, 1878, "endpoint", "", " \"endpoint\". \"endpoint\"." +39207, InsulinGlargine, 1904, 1905, "G", "", +39215, Lispro, 1908, 1909, "L", "", +29792, ResultMeasuredValue, 1912, 1918, "0 . 57", "", " \"0 . 57\"." +29793, ResultMeasuredValue, 1924, 1930, "0 . 51", "", " \"0 . 51\"." +29794, IntUnit_per_Kg, 1931, 1937, "U / kg", "", " ." +29795, PvalueDiff, 1940, 1951, "p = 0 . 017", "", " \"p = 0 . 017\"." +29798, EndPointDescription, 1975, 1985, "injections", "", " . ." +29797, ResultMeasuredValue, 1988, 1994, "1 . 98", "", " \"1 . 98\"." +29799, ResultMeasuredValue, 2000, 2006, "1 . 79", "", " \"1 . 79\"." +29800, PvalueDiff, 2009, 2020, "p = 0 . 011", "", " \"p = 0 . 011\"." +29802, ConclusionComment, 2039, 2192, "Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown .", "", " \"Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown .\"." +29801, Type2Diabetes, 2113, 2116, "T2D", "", +39208, InsulinGlargine, 2171, 2172, "G", "", +39216, Lispro, 2175, 2176, "L", "", +29803, ConclusionComment, 2193, 2317, "Higher insulin doses were observed with PP with no between - treatment differences in overall hypoglycaemia or weight gain .", "", +29804, Insulin, 2200, 2207, "insulin", "", +29805, Hypoglycemia, 2287, 2300, "hypoglycaemia", "", +29806, WeightGain, 2304, 2315, "weight gain", "", +29807, PMID, 2428, 2436, "20880343", "", " \"20880343\"." diff --git a/data/dm2 20880343_akramersunderbrink.n-triples b/data/dm2 20880343_akramersunderbrink.n-triples new file mode 100644 index 0000000..dd0ea99 --- /dev/null +++ b/data/dm2 20880343_akramersunderbrink.n-triples @@ -0,0 +1,214 @@ +# RDF export of group: Publication + . + "Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes ." . + "Jain SM" . + "2010" . + "Diabetes Obes Metab" . + "20880343" . + . + "Mao X" . + "Escalante - Pulido M" . + "Vorokhobina N" . + "Lopez I" . + "Ilag LL" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 20163" . + "To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ] of beginning" . + "36 - week" . + . + . + . + "Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 20181" . + "inadequate glycaemic control on oral therapy" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + "inj" . + . + . + . + . + . +# RDF export of group: Arm + . + "pp" . + "242" . + . + . + . + . + . + . + . + . + . + "gl" . + "242" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "gla" . + . + "once - daily" . + . + . + "lis" . + . + "≤ 3" . + . + . + "pp" . + . + "once up to thrice daily" . + . +# RDF export of group: Medication + . + "gla" . + . + . + . + . + "lis" . + . + . + . + . + "pp" . + . + . + . +# RDF export of group: Outcome + . + "gl hba" . + . + "9 . 3" . + "p = 0 . 095" . + "- 1 . 93" . + . + "pp hba" . + . + "9 . 5" . + "p = 0 . 095" . + "- 1 . 76" . + . + "gl hba12" . + . + "7 . 8" . + "weeks 12" . + . + "pp hba12" . + . + "7 . 9" . + "weeks 12" . + . + "gla hba24" . + . + "7 . 4" . + "24" . + . + "pp hba24" . + . + "7 . 6" . + "24" . + . + "gl hba36" . + . + "7 . 5" . + "week 36" . + . + "pp hba 36" . + . + "7 . 6" . + "week 36" . + . + "pp ins" . + . + "0 . 57" . + "endpoint" . + . + "gl ins" . + . + "0 . 51" . + "endpoint" . + . + "pp inj" . + . + "1 . 98" . + . + "gl inj" . + . + "1 . 79" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "0 . 17" . + "p = 0 . 097" . + "95 % confidence interval : - 0 . 03 , 0 . 37" . + . + . + . + "hba12" . + "p = 0 . 042" . + . + . + . + "hba24" . + "p = 0 . 046" . + . + . + . + "hba36" . + "p = 0 . 405" . + . + . + . + "ins" . + "p = 0 . 017" . + . + . + . + "inj" . + "p = 0 . 011" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20880343_export.csv b/data/dm2 20880343_export.csv new file mode 100644 index 0000000..b102fd1 --- /dev/null +++ b/data/dm2 20880343_export.csv @@ -0,0 +1,597 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +329, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +329, 1, 2, 2, 9, 13, 9, 13, "Obes" +329, 1, 3, 3, 14, 19, 14, 19, "Metab" +329, 1, 4, 4, 20, 21, 20, 21, "." +329, 2, 1, 5, 0, 4, 22, 26, "2010" +329, 2, 2, 6, 5, 8, 27, 30, "Nov" +329, 2, 3, 7, 9, 10, 31, 32, ";" +329, 2, 4, 8, 11, 13, 33, 35, "12" +329, 2, 5, 9, 14, 15, 36, 37, "(" +329, 2, 6, 10, 16, 18, 38, 40, "11" +329, 2, 7, 11, 19, 20, 41, 42, ")" +329, 2, 8, 12, 21, 22, 43, 44, ":" +329, 2, 9, 13, 23, 26, 45, 48, "967" +329, 2, 10, 14, 27, 28, 49, 50, "-" +329, 2, 11, 15, 29, 31, 51, 53, "75" +329, 2, 12, 16, 32, 33, 54, 55, "." +329, 2, 13, 17, 34, 37, 56, 59, "doi" +329, 2, 14, 18, 38, 39, 60, 61, ":" +329, 2, 15, 19, 40, 42, 62, 64, "10" +329, 2, 16, 20, 43, 44, 65, 66, "." +329, 2, 17, 21, 45, 49, 67, 71, "1111" +329, 2, 18, 22, 50, 51, 72, 73, "/" +329, 2, 19, 23, 52, 53, 74, 75, "j" +329, 2, 20, 24, 54, 55, 76, 77, "." +329, 2, 21, 25, 56, 60, 78, 82, "1463" +329, 2, 22, 26, 61, 62, 83, 84, "-" +329, 2, 23, 27, 63, 67, 85, 89, "1326" +329, 2, 24, 28, 68, 69, 90, 91, "." +329, 2, 25, 29, 70, 74, 92, 96, "2010" +329, 2, 26, 30, 75, 76, 97, 98, "." +329, 2, 27, 31, 77, 82, 99, 104, "01287" +329, 2, 28, 32, 83, 84, 105, 106, "." +329, 2, 29, 33, 85, 86, 107, 108, "x" +329, 2, 30, 34, 87, 88, 109, 110, "." +329, 3, 1, 35, 0, 8, 111, 119, "Prandial" +329, 3, 2, 36, 9, 10, 120, 121, "-" +329, 3, 3, 37, 11, 16, 122, 127, "basal" +329, 3, 4, 38, 17, 24, 128, 135, "insulin" +329, 3, 5, 39, 25, 33, 136, 144, "regimens" +329, 3, 6, 40, 34, 38, 145, 149, "plus" +329, 3, 7, 41, 39, 43, 150, 154, "oral" +329, 3, 8, 42, 44, 62, 155, 173, "antihyperglycaemic" +329, 3, 9, 43, 63, 69, 174, 180, "agents" +329, 3, 10, 44, 70, 72, 181, 183, "to" +329, 3, 11, 45, 73, 80, 184, 191, "improve" +329, 3, 12, 46, 81, 89, 192, 200, "mealtime" +329, 3, 13, 47, 90, 99, 201, 210, "glycaemia" +329, 3, 14, 48, 100, 101, 211, 212, ":" +329, 3, 15, 49, 102, 110, 213, 221, "initiate" +329, 3, 16, 50, 111, 114, 222, 225, "and" +329, 3, 17, 51, 115, 128, 226, 239, "progressively" +329, 3, 18, 52, 129, 136, 240, 247, "advance" +329, 3, 19, 53, 137, 144, 248, 255, "insulin" +329, 3, 20, 54, 145, 152, 256, 263, "therapy" +329, 3, 21, 55, 153, 155, 264, 266, "in" +329, 3, 22, 56, 156, 160, 267, 271, "type" +329, 3, 23, 57, 161, 162, 272, 273, "2" +329, 3, 24, 58, 163, 171, 274, 282, "diabetes" +329, 3, 25, 59, 172, 173, 283, 284, "." +329, 4, 1, 60, 0, 4, 285, 289, "Jain" +329, 4, 2, 61, 5, 7, 290, 292, "SM" +329, 4, 3, 62, 8, 9, 293, 294, "(" +329, 4, 4, 63, 10, 11, 295, 296, "1" +329, 4, 5, 64, 12, 13, 297, 298, ")" +329, 4, 6, 65, 14, 15, 299, 300, "," +329, 4, 7, 66, 16, 19, 301, 304, "Mao" +329, 4, 8, 67, 20, 21, 305, 306, "X" +329, 4, 9, 68, 22, 23, 307, 308, "," +329, 4, 10, 69, 24, 33, 309, 318, "Escalante" +329, 4, 11, 70, 34, 35, 319, 320, "-" +329, 4, 12, 71, 36, 42, 321, 327, "Pulido" +329, 4, 13, 72, 43, 44, 328, 329, "M" +329, 4, 14, 73, 45, 46, 330, 331, "," +329, 4, 15, 74, 47, 58, 332, 343, "Vorokhobina" +329, 4, 16, 75, 59, 60, 344, 345, "N" +329, 4, 17, 76, 61, 62, 346, 347, "," +329, 4, 18, 77, 63, 68, 348, 353, "Lopez" +329, 4, 19, 78, 69, 70, 354, 355, "I" +329, 4, 20, 79, 71, 72, 356, 357, "," +329, 4, 21, 80, 73, 77, 358, 362, "Ilag" +329, 4, 22, 81, 78, 80, 363, 365, "LL" +329, 4, 23, 82, 81, 82, 366, 367, "." +329, 5, 1, 83, 0, 6, 368, 374, "Author" +329, 5, 2, 84, 7, 18, 375, 386, "information" +329, 5, 3, 85, 19, 20, 387, 388, ":" +329, 5, 4, 86, 21, 22, 389, 390, "(" +329, 5, 5, 87, 23, 24, 391, 392, "1" +329, 5, 6, 88, 25, 26, 393, 394, ")" +329, 5, 7, 89, 27, 33, 395, 401, "TOTALL" +329, 5, 8, 90, 34, 42, 402, 410, "Diabetes" +329, 5, 9, 91, 43, 50, 411, 418, "Hormone" +329, 5, 10, 92, 51, 60, 419, 428, "Institute" +329, 5, 11, 93, 61, 62, 429, 430, "," +329, 5, 12, 94, 63, 69, 431, 437, "Indore" +329, 5, 13, 95, 70, 71, 438, 439, "," +329, 5, 14, 96, 72, 77, 440, 445, "India" +329, 5, 15, 97, 78, 79, 446, 447, "." +329, 6, 1, 98, 0, 4, 448, 452, "AIMS" +329, 6, 2, 99, 5, 6, 453, 454, ":" +329, 6, 3, 100, 7, 9, 455, 457, "To" +329, 6, 4, 101, 10, 17, 458, 465, "compare" +329, 6, 5, 102, 18, 21, 466, 469, "two" +329, 6, 6, 103, 22, 33, 470, 481, "progressive" +329, 6, 7, 104, 34, 44, 482, 492, "approaches" +329, 6, 8, 105, 45, 46, 493, 494, "[" +329, 6, 9, 106, 47, 51, 495, 499, "once" +329, 6, 10, 107, 52, 53, 500, 501, "-" +329, 6, 11, 108, 54, 59, 502, 507, "daily" +329, 6, 12, 109, 60, 67, 508, 515, "insulin" +329, 6, 13, 110, 68, 76, 516, 524, "glargine" +329, 6, 14, 111, 77, 81, 525, 529, "plus" +329, 6, 15, 112, 82, 83, 530, 531, "≤" +329, 6, 16, 113, 84, 85, 532, 533, "3" +329, 6, 17, 114, 86, 94, 534, 542, "mealtime" +329, 6, 18, 115, 95, 101, 543, 549, "lispro" +329, 6, 19, 116, 102, 103, 550, 551, "(" +329, 6, 20, 117, 104, 105, 552, 553, "G" +329, 6, 21, 118, 106, 107, 554, 555, "+" +329, 6, 22, 119, 108, 109, 556, 557, "L" +329, 6, 23, 120, 110, 111, 558, 559, ")" +329, 6, 24, 121, 112, 114, 560, 562, "vs" +329, 6, 25, 122, 115, 116, 563, 564, "." +329, 6, 26, 123, 117, 124, 565, 572, "insulin" +329, 6, 27, 124, 125, 131, 573, 579, "lispro" +329, 6, 28, 125, 132, 135, 580, 583, "mix" +329, 6, 29, 126, 136, 138, 584, 586, "50" +329, 6, 30, 127, 139, 140, 587, 588, "/" +329, 6, 31, 128, 141, 143, 589, 591, "50" +329, 6, 32, 129, 144, 145, 592, 593, "(" +329, 6, 33, 130, 146, 150, 594, 598, "LM50" +329, 6, 34, 131, 151, 152, 599, 600, "/" +329, 6, 35, 132, 153, 155, 601, 603, "50" +329, 6, 36, 133, 156, 157, 604, 605, ")" +329, 6, 37, 134, 158, 169, 606, 617, "progression" +329, 6, 38, 135, 170, 174, 618, 622, "once" +329, 6, 39, 136, 175, 177, 623, 625, "up" +329, 6, 40, 137, 178, 180, 626, 628, "to" +329, 6, 41, 138, 181, 187, 629, 635, "thrice" +329, 6, 42, 139, 188, 193, 636, 641, "daily" +329, 6, 43, 140, 194, 195, 642, 643, "(" +329, 6, 44, 141, 196, 202, 644, 650, "premix" +329, 6, 45, 142, 203, 214, 651, 662, "progression" +329, 6, 46, 143, 215, 216, 663, 664, "," +329, 6, 47, 144, 217, 219, 665, 667, "PP" +329, 6, 48, 145, 220, 221, 668, 669, ")" +329, 6, 49, 146, 222, 223, 670, 671, "]" +329, 6, 50, 147, 224, 226, 672, 674, "of" +329, 6, 51, 148, 227, 236, 675, 684, "beginning" +329, 6, 52, 149, 237, 240, 685, 688, "and" +329, 6, 53, 150, 241, 250, 689, 698, "advancing" +329, 6, 54, 151, 251, 258, 699, 706, "insulin" +329, 6, 55, 152, 259, 261, 707, 709, "in" +329, 6, 56, 153, 262, 270, 710, 718, "patients" +329, 6, 57, 154, 271, 275, 719, 723, "with" +329, 6, 58, 155, 276, 280, 724, 728, "type" +329, 6, 59, 156, 281, 282, 729, 730, "2" +329, 6, 60, 157, 283, 291, 731, 739, "diabetes" +329, 6, 61, 158, 292, 293, 740, 741, "(" +329, 6, 62, 159, 294, 297, 742, 745, "T2D" +329, 6, 63, 160, 298, 299, 746, 747, ")" +329, 6, 64, 161, 300, 303, 748, 751, "and" +329, 6, 65, 162, 304, 314, 752, 762, "inadequate" +329, 6, 66, 163, 315, 324, 763, 772, "glycaemic" +329, 6, 67, 164, 325, 332, 773, 780, "control" +329, 6, 68, 165, 333, 335, 781, 783, "on" +329, 6, 69, 166, 336, 340, 784, 788, "oral" +329, 6, 70, 167, 341, 348, 789, 796, "therapy" +329, 6, 71, 168, 349, 350, 797, 798, "," +329, 6, 72, 169, 351, 355, 799, 803, "with" +329, 6, 73, 170, 356, 359, 804, 807, "the" +329, 6, 74, 171, 360, 363, 808, 811, "aim" +329, 6, 75, 172, 364, 366, 812, 814, "of" +329, 6, 76, 173, 367, 374, 815, 822, "showing" +329, 6, 77, 174, 375, 378, 823, 826, "non" +329, 6, 78, 175, 379, 380, 827, 828, "-" +329, 6, 79, 176, 381, 392, 829, 840, "inferiority" +329, 6, 80, 177, 393, 395, 841, 843, "of" +329, 6, 81, 178, 396, 398, 844, 846, "PP" +329, 6, 82, 179, 399, 401, 847, 849, "to" +329, 6, 83, 180, 402, 403, 850, 851, "G" +329, 6, 84, 181, 404, 405, 852, 853, "+" +329, 6, 85, 182, 406, 407, 854, 855, "L" +329, 6, 86, 183, 408, 409, 856, 857, "." +329, 7, 1, 184, 0, 7, 858, 865, "METHODS" +329, 7, 2, 185, 8, 9, 866, 867, ":" +329, 7, 3, 186, 10, 18, 868, 876, "Patients" +329, 7, 4, 187, 19, 23, 877, 881, "were" +329, 7, 5, 188, 24, 34, 882, 892, "randomized" +329, 7, 6, 189, 35, 37, 893, 895, "to" +329, 7, 7, 190, 38, 40, 896, 898, "PP" +329, 7, 8, 191, 41, 42, 899, 900, "(" +329, 7, 9, 192, 43, 44, 901, 902, "n" +329, 7, 10, 193, 45, 46, 903, 904, "=" +329, 7, 11, 194, 47, 50, 905, 908, "242" +329, 7, 12, 195, 51, 52, 909, 910, ")" +329, 7, 13, 196, 53, 55, 911, 913, "or" +329, 7, 14, 197, 56, 57, 914, 915, "G" +329, 7, 15, 198, 58, 59, 916, 917, "+" +329, 7, 16, 199, 60, 61, 918, 919, "L" +329, 7, 17, 200, 62, 63, 920, 921, "(" +329, 7, 18, 201, 64, 65, 922, 923, "n" +329, 7, 19, 202, 66, 67, 924, 925, "=" +329, 7, 20, 203, 68, 71, 926, 929, "242" +329, 7, 21, 204, 72, 73, 930, 931, ")" +329, 7, 22, 205, 74, 76, 932, 934, "in" +329, 7, 23, 206, 77, 78, 935, 936, "a" +329, 7, 24, 207, 79, 81, 937, 939, "36" +329, 7, 25, 208, 82, 83, 940, 941, "-" +329, 7, 26, 209, 84, 88, 942, 946, "week" +329, 7, 27, 210, 89, 90, 947, 948, "," +329, 7, 28, 211, 91, 104, 949, 962, "multinational" +329, 7, 29, 212, 105, 106, 963, 964, "," +329, 7, 30, 213, 107, 111, 965, 969, "open" +329, 7, 31, 214, 112, 113, 970, 971, "-" +329, 7, 32, 215, 114, 119, 972, 977, "label" +329, 7, 33, 216, 120, 125, 978, 983, "trial" +329, 7, 34, 217, 126, 127, 984, 985, "." +329, 8, 1, 218, 0, 10, 986, 996, "Dinnertime" +329, 8, 2, 219, 11, 18, 997, 1004, "insulin" +329, 8, 3, 220, 19, 21, 1005, 1007, "LM" +329, 8, 4, 221, 22, 24, 1008, 1010, "50" +329, 8, 5, 222, 25, 26, 1011, 1012, "/" +329, 8, 6, 223, 27, 29, 1013, 1015, "50" +329, 8, 7, 224, 30, 35, 1016, 1021, "could" +329, 8, 8, 225, 36, 38, 1022, 1024, "be" +329, 8, 9, 226, 39, 47, 1025, 1033, "replaced" +329, 8, 10, 227, 48, 52, 1034, 1038, "with" +329, 8, 11, 228, 53, 60, 1039, 1046, "insulin" +329, 8, 12, 229, 61, 67, 1047, 1053, "lispro" +329, 8, 13, 230, 68, 71, 1054, 1057, "mix" +329, 8, 14, 231, 72, 74, 1058, 1060, "75" +329, 8, 15, 232, 75, 76, 1061, 1062, "/" +329, 8, 16, 233, 77, 79, 1063, 1065, "25" +329, 8, 17, 234, 80, 82, 1066, 1068, "if" +329, 8, 18, 235, 83, 89, 1069, 1075, "needed" +329, 8, 19, 236, 90, 93, 1076, 1079, "for" +329, 8, 20, 237, 94, 101, 1080, 1087, "fasting" +329, 8, 21, 238, 102, 111, 1088, 1097, "glycaemic" +329, 8, 22, 239, 112, 119, 1098, 1105, "control" +329, 8, 23, 240, 120, 121, 1106, 1107, "." +329, 9, 1, 241, 0, 7, 1108, 1115, "RESULTS" +329, 9, 2, 242, 8, 9, 1116, 1117, ":" +329, 9, 3, 243, 10, 18, 1118, 1126, "Baseline" +329, 9, 4, 244, 19, 30, 1127, 1138, "haemoglobin" +329, 9, 5, 245, 31, 34, 1139, 1142, "A1c" +329, 9, 6, 246, 35, 36, 1143, 1144, "(" +329, 9, 7, 247, 37, 42, 1145, 1150, "HbA1c" +329, 9, 8, 248, 43, 44, 1151, 1152, ")" +329, 9, 9, 249, 45, 49, 1153, 1157, "were" +329, 9, 10, 250, 50, 51, 1158, 1159, "9" +329, 9, 11, 251, 52, 53, 1160, 1161, "." +329, 9, 12, 252, 54, 55, 1162, 1163, "5" +329, 9, 13, 253, 56, 57, 1164, 1165, "%" +329, 9, 14, 254, 58, 59, 1166, 1167, "(" +329, 9, 15, 255, 60, 62, 1168, 1170, "PP" +329, 9, 16, 256, 63, 64, 1171, 1172, ")" +329, 9, 17, 257, 65, 68, 1173, 1176, "and" +329, 9, 18, 258, 69, 70, 1177, 1178, "9" +329, 9, 19, 259, 71, 72, 1179, 1180, "." +329, 9, 20, 260, 73, 74, 1181, 1182, "3" +329, 9, 21, 261, 75, 76, 1183, 1184, "%" +329, 9, 22, 262, 77, 78, 1185, 1186, "(" +329, 9, 23, 263, 79, 80, 1187, 1188, "G" +329, 9, 24, 264, 81, 82, 1189, 1190, "+" +329, 9, 25, 265, 83, 84, 1191, 1192, "L" +329, 9, 26, 266, 85, 86, 1193, 1194, ")" +329, 9, 27, 267, 87, 88, 1195, 1196, ";" +329, 9, 28, 268, 89, 90, 1197, 1198, "p" +329, 9, 29, 269, 91, 92, 1199, 1200, "=" +329, 9, 30, 270, 93, 94, 1201, 1202, "0" +329, 9, 31, 271, 95, 96, 1203, 1204, "." +329, 9, 32, 272, 97, 100, 1205, 1208, "095" +329, 9, 33, 273, 101, 102, 1209, 1210, "." +329, 10, 1, 274, 0, 6, 1211, 1217, "Change" +329, 10, 2, 275, 7, 9, 1218, 1220, "in" +329, 10, 3, 276, 10, 13, 1221, 1224, "A1C" +329, 10, 4, 277, 14, 15, 1225, 1226, "(" +329, 10, 5, 278, 16, 24, 1227, 1235, "baseline" +329, 10, 6, 279, 25, 27, 1236, 1238, "to" +329, 10, 7, 280, 28, 36, 1239, 1247, "endpoint" +329, 10, 8, 281, 37, 38, 1248, 1249, ")" +329, 10, 9, 282, 39, 42, 1250, 1253, "was" +329, 10, 10, 283, 43, 44, 1254, 1255, "-" +329, 10, 11, 284, 45, 46, 1256, 1257, "1" +329, 10, 12, 285, 47, 48, 1258, 1259, "." +329, 10, 13, 286, 49, 51, 1260, 1262, "76" +329, 10, 14, 287, 52, 53, 1263, 1264, "%" +329, 10, 15, 288, 54, 55, 1265, 1266, "(" +329, 10, 16, 289, 56, 58, 1267, 1269, "PP" +329, 10, 17, 290, 59, 60, 1270, 1271, ")" +329, 10, 18, 291, 61, 64, 1272, 1275, "and" +329, 10, 19, 292, 65, 66, 1276, 1277, "-" +329, 10, 20, 293, 67, 68, 1278, 1279, "1" +329, 10, 21, 294, 69, 70, 1280, 1281, "." +329, 10, 22, 295, 71, 73, 1282, 1284, "93" +329, 10, 23, 296, 74, 75, 1285, 1286, "%" +329, 10, 24, 297, 76, 77, 1287, 1288, "(" +329, 10, 25, 298, 78, 79, 1289, 1290, "G" +329, 10, 26, 299, 80, 81, 1291, 1292, "+" +329, 10, 27, 300, 82, 83, 1293, 1294, "L" +329, 10, 28, 301, 84, 85, 1295, 1296, ")" +329, 10, 29, 302, 86, 87, 1297, 1298, "(" +329, 10, 30, 303, 88, 89, 1299, 1300, "p" +329, 10, 31, 304, 90, 91, 1301, 1302, "=" +329, 10, 32, 305, 92, 93, 1303, 1304, "0" +329, 10, 33, 306, 94, 95, 1305, 1306, "." +329, 10, 34, 307, 96, 99, 1307, 1310, "097" +329, 10, 35, 308, 100, 101, 1311, 1312, ")" +329, 10, 36, 309, 102, 103, 1313, 1314, "[" +329, 10, 37, 310, 104, 111, 1315, 1322, "between" +329, 10, 38, 311, 112, 113, 1323, 1324, "-" +329, 10, 39, 312, 114, 119, 1325, 1330, "group" +329, 10, 40, 313, 120, 130, 1331, 1341, "difference" +329, 10, 41, 314, 131, 133, 1342, 1344, "of" +329, 10, 42, 315, 134, 135, 1345, 1346, "0" +329, 10, 43, 316, 136, 137, 1347, 1348, "." +329, 10, 44, 317, 138, 140, 1349, 1351, "17" +329, 10, 45, 318, 141, 142, 1352, 1353, "(" +329, 10, 46, 319, 143, 145, 1354, 1356, "95" +329, 10, 47, 320, 146, 147, 1357, 1358, "%" +329, 10, 48, 321, 148, 158, 1359, 1369, "confidence" +329, 10, 49, 322, 159, 167, 1370, 1378, "interval" +329, 10, 50, 323, 168, 169, 1379, 1380, ":" +329, 10, 51, 324, 170, 171, 1381, 1382, "-" +329, 10, 52, 325, 172, 173, 1383, 1384, "0" +329, 10, 53, 326, 174, 175, 1385, 1386, "." +329, 10, 54, 327, 176, 178, 1387, 1389, "03" +329, 10, 55, 328, 179, 180, 1390, 1391, "," +329, 10, 56, 329, 181, 182, 1392, 1393, "0" +329, 10, 57, 330, 183, 184, 1394, 1395, "." +329, 10, 58, 331, 185, 187, 1396, 1398, "37" +329, 10, 59, 332, 188, 189, 1399, 1400, ")" +329, 10, 60, 333, 190, 191, 1401, 1402, "]" +329, 10, 61, 334, 192, 193, 1403, 1404, "." +329, 11, 1, 335, 0, 3, 1405, 1408, "Non" +329, 11, 2, 336, 4, 5, 1409, 1410, "-" +329, 11, 3, 337, 6, 17, 1411, 1422, "inferiority" +329, 11, 4, 338, 18, 20, 1423, 1425, "of" +329, 11, 5, 339, 21, 23, 1426, 1428, "PP" +329, 11, 6, 340, 24, 26, 1429, 1431, "to" +329, 11, 7, 341, 27, 28, 1432, 1433, "G" +329, 11, 8, 342, 29, 30, 1434, 1435, "+" +329, 11, 9, 343, 31, 32, 1436, 1437, "L" +329, 11, 10, 344, 33, 36, 1438, 1441, "was" +329, 11, 11, 345, 37, 40, 1442, 1445, "not" +329, 11, 12, 346, 41, 46, 1446, 1451, "shown" +329, 11, 13, 347, 47, 52, 1452, 1457, "based" +329, 11, 14, 348, 53, 55, 1458, 1460, "on" +329, 11, 15, 349, 56, 59, 1461, 1464, "the" +329, 11, 16, 350, 60, 72, 1465, 1477, "prespecified" +329, 11, 17, 351, 73, 76, 1478, 1481, "non" +329, 11, 18, 352, 77, 78, 1482, 1483, "-" +329, 11, 19, 353, 79, 90, 1484, 1495, "inferiority" +329, 11, 20, 354, 91, 97, 1496, 1502, "margin" +329, 11, 21, 355, 98, 100, 1503, 1505, "of" +329, 11, 22, 356, 101, 102, 1506, 1507, "0" +329, 11, 23, 357, 103, 104, 1508, 1509, "." +329, 11, 24, 358, 105, 106, 1510, 1511, "3" +329, 11, 25, 359, 107, 108, 1512, 1513, "%" +329, 11, 26, 360, 109, 110, 1514, 1515, "." +329, 12, 1, 361, 0, 3, 1516, 1519, "A1C" +329, 12, 2, 362, 4, 7, 1520, 1523, "was" +329, 12, 3, 363, 8, 13, 1524, 1529, "lower" +329, 12, 4, 364, 14, 18, 1530, 1534, "with" +329, 12, 5, 365, 19, 20, 1535, 1536, "G" +329, 12, 6, 366, 21, 22, 1537, 1538, "+" +329, 12, 7, 367, 23, 24, 1539, 1540, "L" +329, 12, 8, 368, 25, 27, 1541, 1543, "at" +329, 12, 9, 369, 28, 33, 1544, 1549, "weeks" +329, 12, 10, 370, 34, 36, 1550, 1552, "12" +329, 12, 11, 371, 37, 38, 1553, 1554, "(" +329, 12, 12, 372, 39, 40, 1555, 1556, "7" +329, 12, 13, 373, 41, 42, 1557, 1558, "." +329, 12, 14, 374, 43, 44, 1559, 1560, "8" +329, 12, 15, 375, 45, 47, 1561, 1563, "vs" +329, 12, 16, 376, 48, 49, 1564, 1565, "." +329, 12, 17, 377, 50, 51, 1566, 1567, "7" +329, 12, 18, 378, 52, 53, 1568, 1569, "." +329, 12, 19, 379, 54, 55, 1570, 1571, "9" +329, 12, 20, 380, 56, 57, 1572, 1573, "%" +329, 12, 21, 381, 58, 59, 1574, 1575, ";" +329, 12, 22, 382, 60, 61, 1576, 1577, "p" +329, 12, 23, 383, 62, 63, 1578, 1579, "=" +329, 12, 24, 384, 64, 65, 1580, 1581, "0" +329, 12, 25, 385, 66, 67, 1582, 1583, "." +329, 12, 26, 386, 68, 71, 1584, 1587, "042" +329, 12, 27, 387, 72, 73, 1588, 1589, ")" +329, 12, 28, 388, 74, 75, 1590, 1591, "," +329, 12, 29, 389, 76, 78, 1592, 1594, "24" +329, 12, 30, 390, 79, 80, 1595, 1596, "(" +329, 12, 31, 391, 81, 82, 1597, 1598, "7" +329, 12, 32, 392, 83, 84, 1599, 1600, "." +329, 12, 33, 393, 85, 86, 1601, 1602, "4" +329, 12, 34, 394, 87, 89, 1603, 1605, "vs" +329, 12, 35, 395, 90, 91, 1606, 1607, "." +329, 12, 36, 396, 92, 93, 1608, 1609, "7" +329, 12, 37, 397, 94, 95, 1610, 1611, "." +329, 12, 38, 398, 96, 97, 1612, 1613, "6" +329, 12, 39, 399, 98, 99, 1614, 1615, "%" +329, 12, 40, 400, 100, 101, 1616, 1617, ";" +329, 12, 41, 401, 102, 103, 1618, 1619, "p" +329, 12, 42, 402, 104, 105, 1620, 1621, "=" +329, 12, 43, 403, 106, 107, 1622, 1623, "0" +329, 12, 44, 404, 108, 109, 1624, 1625, "." +329, 12, 45, 405, 110, 113, 1626, 1629, "046" +329, 12, 46, 406, 114, 115, 1630, 1631, ")" +329, 12, 47, 407, 116, 117, 1632, 1633, "," +329, 12, 48, 408, 118, 121, 1634, 1637, "but" +329, 12, 49, 409, 122, 125, 1638, 1641, "not" +329, 12, 50, 410, 126, 128, 1642, 1644, "at" +329, 12, 51, 411, 129, 133, 1645, 1649, "week" +329, 12, 52, 412, 134, 136, 1650, 1652, "36" +329, 12, 53, 413, 137, 138, 1653, 1654, "(" +329, 12, 54, 414, 139, 140, 1655, 1656, "7" +329, 12, 55, 415, 141, 142, 1657, 1658, "." +329, 12, 56, 416, 143, 144, 1659, 1660, "5" +329, 12, 57, 417, 145, 147, 1661, 1663, "vs" +329, 12, 58, 418, 148, 149, 1664, 1665, "." +329, 12, 59, 419, 150, 151, 1666, 1667, "7" +329, 12, 60, 420, 152, 153, 1668, 1669, "." +329, 12, 61, 421, 154, 155, 1670, 1671, "6" +329, 12, 62, 422, 156, 157, 1672, 1673, "%" +329, 12, 63, 423, 158, 159, 1674, 1675, ";" +329, 12, 64, 424, 160, 161, 1676, 1677, "p" +329, 12, 65, 425, 162, 163, 1678, 1679, "=" +329, 12, 66, 426, 164, 165, 1680, 1681, "0" +329, 12, 67, 427, 166, 167, 1682, 1683, "." +329, 12, 68, 428, 168, 171, 1684, 1687, "405" +329, 12, 69, 429, 172, 173, 1688, 1689, ")" +329, 12, 70, 430, 174, 175, 1690, 1691, "." +329, 13, 1, 431, 0, 5, 1692, 1697, "There" +329, 13, 2, 432, 6, 10, 1698, 1702, "were" +329, 13, 3, 433, 11, 13, 1703, 1705, "no" +329, 13, 4, 434, 14, 25, 1706, 1717, "significant" +329, 13, 5, 435, 26, 37, 1718, 1729, "differences" +329, 13, 6, 436, 38, 40, 1730, 1732, "in" +329, 13, 7, 437, 41, 52, 1733, 1744, "percentages" +329, 13, 8, 438, 53, 55, 1745, 1747, "of" +329, 13, 9, 439, 56, 64, 1748, 1756, "patients" +329, 13, 10, 440, 65, 74, 1757, 1766, "achieving" +329, 13, 11, 441, 75, 78, 1767, 1770, "A1C" +329, 13, 12, 442, 79, 80, 1771, 1772, "≤" +329, 13, 13, 443, 81, 82, 1773, 1774, "7" +329, 13, 14, 444, 83, 84, 1775, 1776, "%" +329, 13, 15, 445, 85, 86, 1777, 1778, "," +329, 13, 16, 446, 87, 94, 1779, 1786, "overall" +329, 13, 17, 447, 95, 108, 1787, 1800, "hypoglycaemia" +329, 13, 18, 448, 109, 118, 1801, 1810, "incidence" +329, 13, 19, 449, 119, 122, 1811, 1814, "and" +329, 13, 20, 450, 123, 127, 1815, 1819, "rate" +329, 13, 21, 451, 128, 130, 1820, 1822, "or" +329, 13, 22, 452, 131, 137, 1823, 1829, "weight" +329, 13, 23, 453, 138, 144, 1830, 1836, "change" +329, 13, 24, 454, 145, 146, 1837, 1838, "." +329, 14, 1, 455, 0, 5, 1839, 1844, "Total" +329, 14, 2, 456, 6, 11, 1845, 1850, "daily" +329, 14, 3, 457, 12, 19, 1851, 1858, "insulin" +329, 14, 4, 458, 20, 27, 1859, 1866, "dosages" +329, 14, 5, 459, 28, 30, 1867, 1869, "at" +329, 14, 6, 460, 31, 39, 1870, 1878, "endpoint" +329, 14, 7, 461, 40, 44, 1879, 1883, "were" +329, 14, 8, 462, 45, 51, 1884, 1890, "higher" +329, 14, 9, 463, 52, 56, 1891, 1895, "with" +329, 14, 10, 464, 57, 59, 1896, 1898, "PP" +329, 14, 11, 465, 60, 62, 1899, 1901, "vs" +329, 14, 12, 466, 63, 64, 1902, 1903, "." +329, 14, 13, 467, 65, 66, 1904, 1905, "G" +329, 14, 14, 468, 67, 68, 1906, 1907, "+" +329, 14, 15, 469, 69, 70, 1908, 1909, "L" +329, 14, 16, 470, 71, 72, 1910, 1911, "(" +329, 14, 17, 471, 73, 74, 1912, 1913, "0" +329, 14, 18, 472, 75, 76, 1914, 1915, "." +329, 14, 19, 473, 77, 79, 1916, 1918, "57" +329, 14, 20, 474, 80, 82, 1919, 1921, "vs" +329, 14, 21, 475, 83, 84, 1922, 1923, "." +329, 14, 22, 476, 85, 86, 1924, 1925, "0" +329, 14, 23, 477, 87, 88, 1926, 1927, "." +329, 14, 24, 478, 89, 91, 1928, 1930, "51" +329, 14, 25, 479, 92, 93, 1931, 1932, "U" +329, 14, 26, 480, 94, 95, 1933, 1934, "/" +329, 14, 27, 481, 96, 98, 1935, 1937, "kg" +329, 14, 28, 482, 99, 100, 1938, 1939, ";" +329, 14, 29, 483, 101, 102, 1940, 1941, "p" +329, 14, 30, 484, 103, 104, 1942, 1943, "=" +329, 14, 31, 485, 105, 106, 1944, 1945, "0" +329, 14, 32, 486, 107, 108, 1946, 1947, "." +329, 14, 33, 487, 109, 112, 1948, 1951, "017" +329, 14, 34, 488, 113, 114, 1952, 1953, ")" +329, 14, 35, 489, 115, 116, 1954, 1955, "," +329, 14, 36, 490, 117, 123, 1956, 1962, "likely" +329, 14, 37, 491, 124, 127, 1963, 1966, "due" +329, 14, 38, 492, 128, 130, 1967, 1969, "to" +329, 14, 39, 493, 131, 135, 1970, 1974, "more" +329, 14, 40, 494, 136, 146, 1975, 1985, "injections" +329, 14, 41, 495, 147, 148, 1986, 1987, "(" +329, 14, 42, 496, 149, 150, 1988, 1989, "1" +329, 14, 43, 497, 151, 152, 1990, 1991, "." +329, 14, 44, 498, 153, 155, 1992, 1994, "98" +329, 14, 45, 499, 156, 158, 1995, 1997, "vs" +329, 14, 46, 500, 159, 160, 1998, 1999, "." +329, 14, 47, 501, 161, 162, 2000, 2001, "1" +329, 14, 48, 502, 163, 164, 2002, 2003, "." +329, 14, 49, 503, 165, 167, 2004, 2006, "79" +329, 14, 50, 504, 168, 169, 2007, 2008, ";" +329, 14, 51, 505, 170, 171, 2009, 2010, "p" +329, 14, 52, 506, 172, 173, 2011, 2012, "=" +329, 14, 53, 507, 174, 175, 2013, 2014, "0" +329, 14, 54, 508, 176, 177, 2015, 2016, "." +329, 14, 55, 509, 178, 181, 2017, 2020, "011" +329, 14, 56, 510, 182, 183, 2021, 2022, ")" +329, 14, 57, 511, 184, 185, 2023, 2024, "." +329, 15, 1, 512, 0, 11, 2025, 2036, "CONCLUSIONS" +329, 15, 2, 513, 12, 13, 2037, 2038, ":" +329, 15, 3, 514, 14, 18, 2039, 2043, "Both" +329, 15, 4, 515, 19, 29, 2044, 2054, "treatments" +329, 15, 5, 516, 30, 43, 2055, 2068, "progressively" +329, 15, 6, 517, 44, 52, 2069, 2077, "improved" +329, 15, 7, 518, 53, 62, 2078, 2087, "glycaemic" +329, 15, 8, 519, 63, 70, 2088, 2095, "control" +329, 15, 9, 520, 71, 73, 2096, 2098, "in" +329, 15, 10, 521, 74, 82, 2099, 2107, "patients" +329, 15, 11, 522, 83, 87, 2108, 2112, "with" +329, 15, 12, 523, 88, 91, 2113, 2116, "T2D" +329, 15, 13, 524, 92, 94, 2117, 2119, "on" +329, 15, 14, 525, 95, 99, 2120, 2124, "oral" +329, 15, 15, 526, 100, 107, 2125, 2132, "therapy" +329, 15, 16, 527, 108, 109, 2133, 2134, "," +329, 15, 17, 528, 110, 118, 2135, 2143, "although" +329, 15, 18, 529, 119, 122, 2144, 2147, "non" +329, 15, 19, 530, 123, 124, 2148, 2149, "-" +329, 15, 20, 531, 125, 136, 2150, 2161, "inferiority" +329, 15, 21, 532, 137, 139, 2162, 2164, "of" +329, 15, 22, 533, 140, 142, 2165, 2167, "PP" +329, 15, 23, 534, 143, 145, 2168, 2170, "to" +329, 15, 24, 535, 146, 147, 2171, 2172, "G" +329, 15, 25, 536, 148, 149, 2173, 2174, "+" +329, 15, 26, 537, 150, 151, 2175, 2176, "L" +329, 15, 27, 538, 152, 155, 2177, 2180, "was" +329, 15, 28, 539, 156, 159, 2181, 2184, "not" +329, 15, 29, 540, 160, 165, 2185, 2190, "shown" +329, 15, 30, 541, 166, 167, 2191, 2192, "." +329, 16, 1, 542, 0, 6, 2193, 2199, "Higher" +329, 16, 2, 543, 7, 14, 2200, 2207, "insulin" +329, 16, 3, 544, 15, 20, 2208, 2213, "doses" +329, 16, 4, 545, 21, 25, 2214, 2218, "were" +329, 16, 5, 546, 26, 34, 2219, 2227, "observed" +329, 16, 6, 547, 35, 39, 2228, 2232, "with" +329, 16, 7, 548, 40, 42, 2233, 2235, "PP" +329, 16, 8, 549, 43, 47, 2236, 2240, "with" +329, 16, 9, 550, 48, 50, 2241, 2243, "no" +329, 16, 10, 551, 51, 58, 2244, 2251, "between" +329, 16, 11, 552, 59, 60, 2252, 2253, "-" +329, 16, 12, 553, 61, 70, 2254, 2263, "treatment" +329, 16, 13, 554, 71, 82, 2264, 2275, "differences" +329, 16, 14, 555, 83, 85, 2276, 2278, "in" +329, 16, 15, 556, 86, 93, 2279, 2286, "overall" +329, 16, 16, 557, 94, 107, 2287, 2300, "hypoglycaemia" +329, 16, 17, 558, 108, 110, 2301, 2303, "or" +329, 16, 18, 559, 111, 117, 2304, 2310, "weight" +329, 16, 19, 560, 118, 122, 2311, 2315, "gain" +329, 16, 20, 561, 123, 124, 2316, 2317, "." +329, 17, 1, 562, 0, 1, 2318, 2319, "©" +329, 17, 2, 563, 2, 6, 2320, 2324, "2010" +329, 17, 3, 564, 7, 10, 2325, 2328, "Eli" +329, 17, 4, 565, 11, 16, 2329, 2334, "Lilly" +329, 17, 5, 566, 17, 20, 2335, 2338, "and" +329, 17, 6, 567, 21, 28, 2339, 2346, "Company" +329, 17, 7, 568, 29, 30, 2347, 2348, "." +329, 18, 1, 569, 0, 3, 2349, 2352, "DOI" +329, 18, 2, 570, 4, 5, 2353, 2354, ":" +329, 18, 3, 571, 6, 8, 2355, 2357, "10" +329, 18, 4, 572, 9, 10, 2358, 2359, "." +329, 18, 5, 573, 11, 15, 2360, 2364, "1111" +329, 18, 6, 574, 16, 17, 2365, 2366, "/" +329, 18, 7, 575, 18, 19, 2367, 2368, "j" +329, 18, 8, 576, 20, 21, 2369, 2370, "." +329, 18, 9, 577, 22, 26, 2371, 2375, "1463" +329, 18, 10, 578, 27, 28, 2376, 2377, "-" +329, 18, 11, 579, 29, 33, 2378, 2382, "1326" +329, 18, 12, 580, 34, 35, 2383, 2384, "." +329, 18, 13, 581, 36, 40, 2385, 2389, "2010" +329, 18, 14, 582, 41, 42, 2390, 2391, "." +329, 18, 15, 583, 43, 48, 2392, 2397, "01287" +329, 18, 16, 584, 49, 50, 2398, 2399, "." +329, 18, 17, 585, 51, 52, 2400, 2401, "x" +329, 18, 18, 586, 53, 58, 2402, 2407, "PMCID" +329, 18, 19, 587, 59, 60, 2408, 2409, ":" +329, 18, 20, 588, 61, 71, 2410, 2420, "PMC2997325" +329, 18, 21, 589, 72, 76, 2421, 2425, "PMID" +329, 18, 22, 590, 77, 78, 2426, 2427, ":" +329, 18, 23, 591, 79, 87, 2428, 2436, "20880343" +329, 18, 24, 592, 88, 89, 2437, 2438, "[" +329, 18, 25, 593, 90, 97, 2439, 2446, "Indexed" +329, 18, 26, 594, 98, 101, 2447, 2450, "for" +329, 18, 27, 595, 102, 109, 2451, 2458, "MEDLINE" +329, 18, 28, 596, 110, 111, 2459, 2460, "]" diff --git a/data/dm2 20880343_kwoodley.annodb b/data/dm2 20880343_kwoodley.annodb new file mode 100644 index 0000000..b2e1d23 --- /dev/null +++ b/data/dm2 20880343_kwoodley.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16123, Journal, 0, 19, "Diabetes Obes Metab", "", +16125, PublicationYear, 22, 26, "2010", "", +36613, Title, 111, 284, "Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .", "", +16127, Insulin, 128, 135, "insulin", "", +16128, OralAntidiabeticAgent, 150, 180, "oral antihyperglycaemic agents", "", +16131, Insulin, 248, 255, "insulin", "", +16133, Type2Diabetes, 267, 282, "type 2 diabetes", "", +16137, Author, 285, 292, "Jain SM", "", +16138, Author, 301, 306, "Mao X", "", +16139, Author, 309, 329, "Escalante - Pulido M", "", +16140, Author, 332, 345, "Vorokhobina N", "", +16141, Author, 348, 355, "Lopez I", "", +16142, Author, 358, 365, "Ilag LL", "", +16143, India, 440, 445, "India", "", +16165, ObjectiveDescription, 455, 671, "To compare two progressive approaches [ once - daily insulin glargine plus ≤ 3 mealtime lispro ( G + L ) vs . insulin lispro mix 50 / 50 ( LM50 / 50 ) progression once up to thrice daily ( premix progression , PP ) ]", "", +16144, Frequency, 495, 507, "once - daily", "", +16145, InsulinGlargine, 508, 524, "insulin glargine", "", +16146, RelativeTime, 534, 542, "mealtime", "", +36615, Lispro, 543, 549, "lispro", "", +16148, InsulinGlargine, 552, 553, "G", "", +36616, Lispro, 556, 557, "L", "", +16150, Drug, 565, 591, "insulin lispro mix 50 / 50", "2", +16151, Drug, 594, 603, "LM50 / 50", "2", +16153, Frequency, 618, 641, "once up to thrice daily", "", +16154, Drug, 665, 667, "PP", "2?", +36614, ObjectiveDescription, 672, 857, "of beginning and advancing insulin in patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy , with the aim of showing non - inferiority of PP to G + L .", "", +16159, Insulin, 699, 706, "insulin", "", +16164, Precondition, 710, 796, "patients with type 2 diabetes ( T2D ) and inadequate glycaemic control on oral therapy", "", +16158, Type2Diabetes, 724, 739, "type 2 diabetes", "", +16157, Type2Diabetes, 742, 745, "T2D", "", +16160, OralAntidiabeticAgent, 784, 796, "oral therapy", "", +16161, Drug, 844, 846, "PP", "", +16162, InsulinGlargine, 850, 851, "G", "", +36617, Lispro, 854, 855, "L", "", +16167, Randomized, 882, 892, "randomized", "", +16168, Drug, 896, 898, "PP", "", +16171, NumberPatientsArm, 905, 908, "242", "", +16170, InsulinGlargine, 914, 915, "G", "", +36618, Lispro, 918, 919, "L", "", +16172, NumberPatientsArm, 926, 929, "242", "", +16174, Duration, 937, 946, "36 - week", "", +36619, Multicenter, 949, 962, "multinational", "", +16176, OpenLabel, 965, 977, "open - label", "", +16178, RelativeTime, 986, 996, "Dinnertime", "", +16152, Drug, 1005, 1015, "LM 50 / 50", "2", +16180, Drug, 1039, 1065, "insulin lispro mix 75 / 25", "", +36620, FastingBloodGlucose, 1080, 1105, "fasting glycaemic control", "", +16183, HbA1c, 1127, 1138, "haemoglobin", "", +16184, HbA1c, 1139, 1142, "A1c", "", +16185, HbA1c, 1145, 1150, "HbA1c", "", +16187, BaseLineValue, 1158, 1163, "9 . 5", "", +16190, Percentage, 1164, 1165, "%", "", +16194, Drug, 1168, 1170, "PP", "", +16189, BaseLineValue, 1177, 1182, "9 . 3", "", +16192, Percentage, 1183, 1184, "%", "", +16197, InsulinGlargine, 1187, 1188, "G", "", +36621, Lispro, 1191, 1192, "L", "", +16200, PvalueDiff, 1197, 1208, "p = 0 . 095", "", +16202, HbA1c, 1221, 1224, "A1C", "", +36622, TimePoint, 1227, 1235, "baseline", "", +36623, TimePoint, 1239, 1247, "endpoint", "", +16206, Reduction, 1256, 1262, "1 . 76", "", +16211, Percentage, 1263, 1264, "%", "", +16213, Drug, 1267, 1269, "PP", "", +16208, Reduction, 1278, 1284, "1 . 93", "", +16212, Percentage, 1285, 1286, "%", "", +16215, InsulinGlargine, 1289, 1290, "G", "", +36624, Lispro, 1293, 1294, "L", "", +16217, PvalueDiff, 1299, 1310, "p = 0 . 097", "", +16219, DiffGroupAbsValue, 1345, 1351, "0 . 17", "", +16224, ConfIntervalDiff, 1354, 1398, "95 % confidence interval : - 0 . 03 , 0 . 37", "", +36626, ObservedResult, 1405, 1515, "Non - inferiority of PP to G + L was not shown based on the prespecified non - inferiority margin of 0 . 3 % .", "", +16225, Drug, 1426, 1428, "PP", "", +16227, InsulinGlargine, 1432, 1433, "G", "", +36625, Lispro, 1436, 1437, "L", "", +16232, HbA1c, 1516, 1519, "A1C", "", +16233, InsulinGlargine, 1535, 1536, "G", "", +36627, Lispro, 1539, 1540, "L", "", +16235, TimePoint, 1544, 1552, "weeks 12", "", +16237, ResultMeasuredValue, 1555, 1560, "7 . 8", "", +16238, ResultMeasuredValue, 1566, 1571, "7 . 9", "", +16246, Percentage, 1572, 1573, "%", "", +16250, PvalueDiff, 1576, 1587, "p = 0 . 042", "", +16256, TimePoint, 1592, 1594, "24", "", +16253, ResultMeasuredValue, 1597, 1602, "7 . 4", "", +16255, ResultMeasuredValue, 1608, 1613, "7 . 6", "", +16247, Percentage, 1614, 1615, "%", "", +16259, PvalueDiff, 1618, 1629, "p = 0 . 046", "", +36628, TimePoint, 1645, 1652, "week 36", "", +16240, ResultMeasuredValue, 1655, 1660, "7 . 5", "", +16242, ResultMeasuredValue, 1666, 1671, "7 . 6", "", +16248, Percentage, 1672, 1673, "%", "", +16251, PvalueDiff, 1676, 1687, "p = 0 . 405", "", +36629, ObservedResult, 1692, 1838, "There were no significant differences in percentages of patients achieving A1C ≤ 7 % , overall hypoglycaemia incidence and rate or weight change .", "", +16261, HbA1c_target, 1767, 1776, "A1C ≤ 7 %", "", +16263, Hypoglycemia, 1787, 1800, "hypoglycaemia", "", +16265, BodyWeight, 1823, 1829, "weight", "", +36630, InsulinDose, 1851, 1866, "insulin dosages", "", +36631, TimePoint, 1870, 1878, "endpoint", "", +16270, Drug, 1896, 1898, "PP", "", +16273, InsulinGlargine, 1904, 1905, "G", "", +36632, Lispro, 1908, 1909, "L", "", +16275, ResultMeasuredValue, 1912, 1918, "0 . 57", "", +16276, ResultMeasuredValue, 1924, 1930, "0 . 51", "", +16277, IntUnit_per_Kg, 1931, 1937, "U / kg", "", +16278, PvalueDiff, 1940, 1951, "p = 0 . 017", "", +16279, ResultMeasuredValue, 1988, 1994, "1 . 98", "", +16280, ResultMeasuredValue, 2000, 2006, "1 . 79", "", +16281, PvalueDiff, 2009, 2020, "p = 0 . 011", "", +36633, ConclusionComment, 2039, 2192, "Both treatments progressively improved glycaemic control in patients with T2D on oral therapy , although non - inferiority of PP to G + L was not shown .", "", +16284, Precondition, 2099, 2132, "patients with T2D on oral therapy", "", +16282, Type2Diabetes, 2113, 2116, "T2D", "", +16283, OralAntidiabeticAgent, 2120, 2132, "oral therapy", "", +16286, Drug, 2165, 2167, "PP", "", +16288, InsulinGlargine, 2171, 2172, "G", "", +36635, Lispro, 2175, 2176, "L", "", +36634, ConclusionComment, 2193, 2317, "Higher insulin doses were observed with PP with no between - treatment differences in overall hypoglycaemia or weight gain .", "", +36636, InsulinDose, 2200, 2213, "insulin doses", "", +16291, Drug, 2233, 2235, "PP", "", +16292, Hypoglycemia, 2287, 2300, "hypoglycaemia", "", +16293, BodyWeight, 2304, 2310, "weight", "", +16297, PMID, 2428, 2436, "20880343", "", diff --git a/data/dm2 20880343_kwoodley.n-triples b/data/dm2 20880343_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20880343_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20920045_admin.annodb b/data/dm2 20920045_admin.annodb new file mode 100644 index 0000000..d130c25 --- /dev/null +++ b/data/dm2 20920045_admin.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +106241, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +106239, PublicationYear, 22, 26, "2010", "", " \"2010\"." +96, Title, 111, 234, "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial .", "", " \"Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial .\"." +61038, LisproProtamine, 123, 158, "insulin lispro protamine suspension", "", +2, InsulinGlargine, 162, 178, "insulin glargine", "", +57576, Oral, 182, 186, "oral", "", +4, Type2Diabetes, 187, 202, "type 2 diabetes", "", " ." +5, Randomized, 216, 226, "randomized", "", +106235, Author, 235, 244, "Strojek K", "", " \"Strojek K\"." +106236, Author, 253, 258, "Shi C", "", " \"Shi C\"." +106237, Author, 261, 269, "Carey MA", "", " \"Carey MA\"." +106238, Author, 272, 282, "Jacober SJ", "", " \"Jacober SJ\"." +10, Poland, 414, 420, "Poland", "", " ." +137, ObjectiveDescription, 430, 559, "The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets .", "", " \"The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets .\"." +11, Insulin, 452, 459, "insulin", "", +13, Type2Diabetes, 508, 523, "type 2 diabetes", "", +14, Type2Diabetes, 526, 529, "T2D", "", +112, ObjectiveDescription, 560, 780, "This study compares the efficacy and safety of insulin lispro protamine suspension ( ILPS ) and insulin glargine in insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM ) .", "", " \"This study compares the efficacy and safety of insulin lispro protamine suspension ( ILPS ) and insulin glargine in insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM ) .\"." +61024, LisproProtamine, 607, 642, "insulin lispro protamine suspension", "", +61025, LisproProtamine, 645, 649, "ILPS", "", +15, InsulinGlargine, 656, 672, "insulin glargine", "", +16, Insulin, 676, 683, "insulin", "", +20, Precondition, 676, 778, "insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM )", "", " \"insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM )\"." +17, Type2Diabetes, 706, 709, "T2D", "", +18, OralAntidiabeticAgent, 736, 770, "oral antihyperglycaemic medication", "", +19, OralAntidiabeticAgent, 773, 776, "OAM", "", +21, OpenLabel, 808, 820, "open - label", "", " ." +22, Randomized, 823, 833, "randomized", "", " ." +23, Multicenter, 836, 847, "multicentre", "", " ." +24, Duration, 864, 873, "24 - week", "", " \"24 - week\"." +25, NumberPatientsCT, 883, 886, "471", "", " \"471\"." +26, OralAntidiabeticAgent, 910, 914, "OAMs", "", +27, BMI, 937, 952, "body mass index", "", +100, Kg_per_squareMeter, 971, 983, "kg / m ( 2 )", "", +28, HbA1c, 988, 993, "HbA1c", "", +29, Percentage, 1009, 1010, "%", "", +61026, LisproProtamine, 1027, 1031, "ILPS", "", " ." +57578, IntramuscularInjection, 1036, 1044, "injected", "", " ." +31, Frequency, 1045, 1064, "once or twice daily", "", " \"once or twice daily\"." +32, InsulinGlargine, 1070, 1078, "glargine", "", " ." +57577, IntramuscularInjection, 1079, 1087, "injected", "", " ." +33, Frequency, 1088, 1098, "once daily", "", " \"once daily\"." +34, OralAntidiabeticAgent, 1113, 1117, "OAMs", "", +35, HbA1c, 1151, 1156, "HbA1c", "", +157, TimePoint, 1169, 1177, "baseline", "", +36, HbA1c, 1190, 1195, "HbA1c", "", " ." +160, TimePoint, 1208, 1216, "baseline", "", +161, TimePoint, 1220, 1228, "endpoint", "", " \"endpoint\". \"endpoint\"." +37, Reduction, 1260, 1266, "1 . 46", "", " \"1 . 46\"." +39, Percentage, 1267, 1268, "%", "", +61027, LisproProtamine, 1271, 1275, "ILPS", "", +38, Reduction, 1284, 1290, "1 . 41", "", " \"1 . 41\"." +40, Percentage, 1291, 1292, "%", "", " ." +41, InsulinGlargine, 1295, 1303, "glargine", "", +168, LeastSquaresMean, 1310, 1330, "Least - squares mean", "", +45, ConfIntervalDiff, 1344, 1351, "95 % CI", "", +42, HbA1c, 1358, 1363, "HbA1c", "", +43, DiffGroupAbsValue, 1366, 1374, "- 0 . 05", "", " \"- 0 . 05\"." +44, ConfIntervalDiff, 1377, 1394, "- 0 . 21 , 0 . 11", "", " \"- 0 . 21 , 0 . 11\"." +48, Percentage, 1397, 1398, "%", "", +49, EndPointDescription, 1403, 1424, "glycaemic variability", "", " . ." +50, DiffGroupAbsValue, 1427, 1433, "0 . 06", "", " \"0 . 06\"." +46, ConfIntervalDiff, 1436, 1453, "- 0 . 06 , 0 . 19", "", " \"- 0 . 06 , 0 . 19\"." +52, Millimoles_per_litre, 1456, 1464, "mmol / l", "", " ." +51, BodyWeight, 1471, 1477, "weight", "", " ." +53, DiffGroupAbsValue, 1487, 1495, "- 0 . 01", "", " ." +47, ConfIntervalDiff, 1498, 1515, "- 0 . 61 , 0 . 59", "", " \"- 0 . 61 , 0 . 59\"." +54, Kg, 1518, 1520, "kg", "", +57579, Percentage, 1567, 1568, "%", "", +56, Millimoles_per_litre, 1577, 1585, "mmol / l", "", +57, Kg, 1596, 1598, "kg", "", +58, HbA1c_target, 1652, 1667, "HbA1c < 7 . 0 %", "", " ." +181, Percentage, 1666, 1667, "%", "", +59, PercentageAffected, 1673, 1679, "43 . 8", "", " \"43 . 8\". \"43 . 8\"." +61028, LisproProtamine, 1682, 1686, "ILPS", "", +60, PercentageAffected, 1691, 1697, "41 . 2", "", +61, InsulinGlargine, 1700, 1708, "glargine", "", +61029, Mean, 1711, 1715, "Mean", "", " . ." +61030, InsulinDose, 1722, 1734, "insulin dose", "", " . ." +61031, ResultMeasuredValue, 1739, 1745, "0 . 39", "", " \"0 . 39\"." +61032, ResultMeasuredValue, 1751, 1757, "0 . 35", "", " \"0 . 35\"." +57582, IntUnit_per_Kg, 1758, 1764, "U / kg", "", " ." +70, PvalueDiff, 1767, 1777, "p = 0 . 02", "", " \"p = 0 . 02\"." +65, BodyWeight, 1784, 1790, "weight", "", +66, Increment, 1800, 1806, "1 . 04", "", " \"1 . 04\"." +67, Increment, 1812, 1818, "1 . 07", "", " \"1 . 07\"." +68, Kg, 1819, 1821, "kg", "", " ." +61033, LisproProtamine, 1826, 1830, "ILPS", "", +69, InsulinGlargine, 1836, 1844, "glargine", "", +106177, PvalueDiff, 1847, 1857, "p = 0 . 98", "", " \"p = 0 . 98\"." +72, Hypoglycemia, 1870, 1883, "hypoglycaemia", "", " ." +73, BioAndMedicalUnit, 1886, 1911, "episodes / patient / year", "", " . . . ." +61034, LisproProtamine, 1930, 1934, "ILPS", "", +74, InsulinGlargine, 1939, 1947, "glargine", "", +75, ResultMeasuredValue, 1950, 1956, "24 . 2", "", " \"24 . 2\"." +77, SdDevResValue, 1959, 1965, "28 . 8", "", " \"28 . 8\"." +76, ResultMeasuredValue, 1971, 1977, "23 . 0", "", " \"23 . 0\"." +78, SdDevResValue, 1980, 1986, "30 . 9", "", " \"30 . 9\"." +79, NocturnalHypoglycemia, 1991, 2000, "nocturnal", "", " ." +80, ResultMeasuredValue, 2003, 2008, "6 . 1", "", " \"6 . 1\"." +82, SdDevResValue, 2011, 2017, "10 . 6", "", " \"10 . 6\"." +81, ResultMeasuredValue, 2023, 2028, "4 . 1", "", " \"4 . 1\"." +83, SdDevResValue, 2031, 2036, "9 . 4", "", " \"9 . 4\"." +84, PvalueDiff, 2039, 2050, "p < 0 . 001", "", " \"p < 0 . 001\"." +61035, LisproProtamine, 2075, 2079, "ILPS", "", +85, SevereHypoglycemia, 2082, 2102, "Severe hypoglycaemia", "", " ." +61036, LisproProtamine, 2118, 2122, "ILPS", "", +86, InsulinGlargine, 2128, 2136, "glargine", "", +87, NumberAffected, 2143, 2144, "9", "", " \"9\"." +88, NumberAffected, 2154, 2155, "2", "", " \"2\"." +89, PvalueDiff, 2158, 2168, "p = 0 . 04", "", " \"p = 0 . 04\"." +110, ConclusionComment, 2187, 2322, "At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia .", "", " \"At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia .\"." +111, TimePoint, 2190, 2198, "endpoint", "", +61037, LisproProtamine, 2201, 2205, "ILPS", "", +90, InsulinGlargine, 2228, 2236, "glargine", "", +91, HbA1c, 2240, 2245, "HbA1c", "", +222, TimePoint, 2258, 2266, "baseline", "", +92, Hypoglycemia, 2307, 2320, "hypoglycaemia", "", +106240, PMID, 2414, 2422, "20920045", "", " \"20920045\"." diff --git a/data/dm2 20920045_admin.n-triples b/data/dm2 20920045_admin.n-triples new file mode 100644 index 0000000..1589644 --- /dev/null +++ b/data/dm2 20920045_admin.n-triples @@ -0,0 +1,247 @@ +# RDF export of group: Publication + . + "Publication 28072" . + "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial ." . + "Diabetes Obes Metab ." . + "20920045" . + . + "Strojek K" . + "2010" . + "Shi C" . + "Carey MA" . + "Jacober SJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 28079" . + "The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets ." . + "471" . + "24 - week" . + . + . + "At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia ." . + . + . + . + . + . + "This study compares the efficacy and safety of insulin lispro protamine suspension ( ILPS ) and insulin glargine in insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM ) ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 28095" . + "insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM )" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "gly" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + . + "noc" . + . + . + . + . + . + . + "sev" . + . + . + . + . +# RDF export of group: Arm + . + "lis" . + . + . + . + . + . + . + . + . + . + . + "gla" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lis" . + . + "once or twice daily" . + . + . + "gla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "lis" . + . + . + . + . + "gla" . + . + . + . +# RDF export of group: Outcome + . + "hba lis" . + . + "endpoint" . + "1 . 46" . + . + "hba gla" . + . + "endpoint" . + "1 . 41" . + . + "gly lis" . + . + . + "gly gla" . + . + . + "bw lis" . + . + "1 . 04" . + . + "bw gla" . + . + "1 . 07" . + . + "hbat gla" . + . + "43 . 8" . + . + "hbat lis" . + . + "43 . 8" . + . + "ins lis" . + . + "0 . 39" . + . + "ins gla" . + . + "0 . 35" . + . + "hyp lis" . + . + "24 . 2" . + "28 . 8" . + . + "hyp gla" . + . + "23 . 0" . + "30 . 9" . + . + "noc lis" . + . + "6 . 1" . + "10 . 6" . + . + "noc gla" . + . + "4 . 1" . + "9 . 4" . + . + "sev lis" . + . + "9" . + . + "sev gla" . + . + "2" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 05" . + . + . + "- 0 . 21 , 0 . 11" . + . + "gly" . + "0 . 06" . + "- 0 . 06 , 0 . 19" . + . + . + . + "bw" . + "- 0 . 01" . + "p = 0 . 98" . + "- 0 . 61 , 0 . 59" . + . + . + . + "ins" . + "p = 0 . 02" . + . + . + . + "noc" . + "p < 0 . 001" . + . + . + . + "sev" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20920045_akramersunderbrink.annodb b/data/dm2 20920045_akramersunderbrink.annodb new file mode 100644 index 0000000..31ee97d --- /dev/null +++ b/data/dm2 20920045_akramersunderbrink.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29808, Journal, 0, 19, "Diabetes Obes Metab", "", " \"Diabetes Obes Metab\"." +39221, PublicationYear, 22, 26, "2010", "", " \"2010\"." +39222, Title, 111, 234, "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial .", "", " \"Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial .\"." +39223, Lispro, 123, 158, "insulin lispro protamine suspension", "", " ." +39224, InsulinGlargine, 162, 178, "insulin glargine", "", " ." +39235, OralAntidiabeticAgent, 182, 211, "oral type 2 diabetes regimens", "", " ." +39225, Type2Diabetes, 187, 202, "type 2 diabetes", "", " ." +39226, Randomized, 216, 226, "randomized", "", +39227, Author, 235, 244, "Strojek K", "", " \"Strojek K\"." +39228, Author, 253, 258, "Shi C", "", " \"Shi C\"." +39229, Author, 261, 269, "Carey MA", "", " \"Carey MA\"." +39230, Author, 272, 282, "Jacober SJ", "", " \"Jacober SJ\"." +39231, Poland, 414, 420, "Poland", "", +39245, ObjectiveDescription, 430, 559, "The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets .", "", " \"The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets .\"." +39234, Insulin, 446, 459, "basal insulin", "", +39236, OralAntidiabeticAgent, 472, 484, "oral therapy", "", +39232, Type2Diabetes, 508, 523, "type 2 diabetes", "", +39233, Type2Diabetes, 526, 529, "T2D", "", +39237, Lispro, 607, 642, "insulin lispro protamine suspension", "", +39238, Lispro, 645, 649, "ILPS", "", +39239, InsulinGlargine, 656, 672, "insulin glargine", "", +39240, Precondition, 676, 700, "insulin - naive patients", "", " \"insulin - naive patients\"." +39241, Type2Diabetes, 706, 709, "T2D", "", +39242, Precondition, 714, 770, "inadequate control on oral antihyperglycaemic medication", "", " \"inadequate control on oral antihyperglycaemic medication\"." +39243, OralAntidiabeticAgent, 736, 770, "oral antihyperglycaemic medication", "", +39244, OralAntidiabeticAgent, 773, 776, "OAM", "", +39246, OpenLabel, 808, 820, "open - label", "", " ." +39247, Randomized, 823, 833, "randomized", "", " ." +39248, Multicenter, 836, 847, "multicentre", "", " ." +39249, Multicenter, 850, 863, "multinational", "", +39250, Duration, 864, 873, "24 - week", "", " \"24 - week\"." +39251, NumberPatientsCT, 883, 886, "471", "", " \"471\"." +39253, Precondition, 896, 929, "receiving ≥ 2 OAMs for ≥ 3 months", "", " \"receiving ≥ 2 OAMs for ≥ 3 months\"." +39252, OralAntidiabeticAgent, 910, 914, "OAMs", "", +39254, Precondition, 930, 983, "with a body mass index between 25 and 45 kg / m ( 2 )", "", " \"with a body mass index between 25 and 45 kg / m ( 2 )\"." +39256, BMI, 937, 952, "body mass index", "", +39257, Kg_per_squareMeter, 971, 983, "kg / m ( 2 )", "", +39255, Precondition, 988, 1010, "HbA1c 7 . 5 - 10 . 0 %", "", " \"HbA1c 7 . 5 - 10 . 0 %\"." +39266, HbA1c, 988, 993, "HbA1c", "", +39258, Percentage, 1009, 1010, "%", "", +39259, Lispro, 1027, 1031, "ILPS", "", +39260, Frequency, 1045, 1064, "once or twice daily", "", " \"once or twice daily\"." +39261, InsulinGlargine, 1070, 1078, "glargine", "", +39262, Frequency, 1088, 1098, "once daily", "", " \"once daily\"." +39263, OralAntidiabeticAgent, 1113, 1117, "OAMs", "", +39264, HbA1c, 1151, 1156, "HbA1c", "", +39265, TimePoint, 1169, 1177, "baseline", "", +39267, HbA1c, 1190, 1195, "HbA1c", "", " ." +39268, TimePoint, 1208, 1216, "baseline", "", +39269, TimePoint, 1220, 1228, "endpoint", "", " \"endpoint\". \"endpoint\"." +39274, ChangeValue, 1258, 1266, "- 1 . 46", "", " \"- 1 . 46\"." +39272, Percentage, 1267, 1268, "%", "", " ." +39270, Lispro, 1271, 1275, "ILPS", "", +39275, ChangeValue, 1282, 1290, "- 1 . 41", "", " \"- 1 . 41\"." +39273, Percentage, 1291, 1292, "%", "", +39271, InsulinGlargine, 1295, 1303, "glargine", "", +39276, LeastSquaresMean, 1310, 1330, "Least - squares mean", "", +39277, Percentage, 1347, 1348, "%", "", +39278, HbA1c, 1358, 1363, "HbA1c", "", +87084, DiffGroupAbsValue, 1366, 1374, "- 0 . 05", "", " \"- 0 . 05\"." +39282, Percentage, 1397, 1398, "%", "", +87082, EndPointDescription, 1403, 1424, "glycaemic variability", "", " . ." +87085, DiffGroupAbsValue, 1427, 1433, "0 . 06", "", " \"0 . 06\"." +39283, Millimoles_per_litre, 1456, 1464, "mmol / l", "", " ." +87083, WeightGain, 1471, 1484, "weight change", "", " ." +87086, DiffGroupAbsValue, 1487, 1495, "- 0 . 01", "", " \"- 0 . 01\"." +39284, Kg, 1518, 1520, "kg", "", " ." +39285, Percentage, 1567, 1568, "%", "", +39286, Millimoles_per_litre, 1577, 1585, "mmol / l", "", +39287, Kg, 1596, 1598, "kg", "", +39288, HbA1c_target, 1652, 1667, "HbA1c < 7 . 0 %", "", " ." +39289, Percentage, 1666, 1667, "%", "", +39290, PercentageAffected, 1673, 1679, "43 . 8", "", " \"43 . 8\"." +39292, Percentage, 1680, 1681, "%", "", " ." +39294, Lispro, 1682, 1686, "ILPS", "", +39291, PercentageAffected, 1691, 1697, "41 . 2", "", " \"41 . 2\"." +39293, Percentage, 1698, 1699, "%", "", +39295, InsulinGlargine, 1700, 1708, "glargine", "", +39296, Mean, 1711, 1715, "Mean", "", " . ." +39298, InsulinDose, 1716, 1734, "daily insulin dose", "", " . ." +39297, Insulin, 1722, 1729, "insulin", "", +39299, ResultMeasuredValue, 1739, 1745, "0 . 39", "", " \"0 . 39\"." +39300, ResultMeasuredValue, 1751, 1757, "0 . 35", "", " \"0 . 35\"." +39301, IntUnit_per_Kg, 1758, 1764, "U / kg", "", " ." +39302, PvalueDiff, 1767, 1777, "p = 0 . 02", "", " \"p = 0 . 02\"." +39303, WeightGain, 1784, 1795, "weight gain", "", +39304, ResultMeasuredValue, 1800, 1806, "1 . 04", "", " \"1 . 04\"." +39305, ResultMeasuredValue, 1812, 1818, "1 . 07", "", " \"1 . 07\"." +39306, Kg, 1819, 1821, "kg", "", +39307, Lispro, 1826, 1830, "ILPS", "", +39308, InsulinGlargine, 1836, 1844, "glargine", "", +39309, PvalueDiff, 1847, 1857, "p = 0 . 98", "", " \"p = 0 . 98\"." +39310, Hypoglycemia, 1862, 1883, "Overall hypoglycaemia", "", " ." +39311, BioAndMedicalUnit, 1886, 1911, "episodes / patient / year", "", " . . . ." +39312, Lispro, 1930, 1934, "ILPS", "", +39313, InsulinGlargine, 1939, 1947, "glargine", "", +39314, ResultMeasuredValue, 1950, 1956, "24 . 2", "", " \"24 . 2\"." +39334, SdErrorResValue, 1959, 1965, "28 . 8", "", " \"28 . 8\"." +39315, ResultMeasuredValue, 1971, 1977, "23 . 0", "", " \"23 . 0\"." +39335, SdErrorResValue, 1980, 1986, "30 . 9", "", " \"30 . 9\"." +39318, NocturnalHypoglycemia, 1991, 2000, "nocturnal", "", " ." +39316, ResultMeasuredValue, 2003, 2008, "6 . 1", "", " \"6 . 1\"." +39336, SdErrorResValue, 2011, 2017, "10 . 6", "", " \"10 . 6\"." +39317, ResultMeasuredValue, 2023, 2028, "4 . 1", "", " \"4 . 1\"." +39337, SdErrorResValue, 2031, 2036, "9 . 4", "", " \"9 . 4\"." +39319, PvalueDiff, 2039, 2050, "p < 0 . 001", "", " \"p < 0 . 001\"." +39320, Lispro, 2075, 2079, "ILPS", "", +39321, SevereHypoglycemia, 2082, 2102, "Severe hypoglycaemia", "", " ." +39322, Lispro, 2118, 2122, "ILPS", "", +39323, InsulinGlargine, 2128, 2136, "glargine", "", +39324, NumberAffected, 2143, 2144, "9", "", " \"9\"." +39325, NumberAffected, 2154, 2155, "2", "", " \"2\"." +39326, PvalueDiff, 2158, 2168, "p = 0 . 04", "", " \"p = 0 . 04\"." +87081, ConclusionComment, 2187, 2320, "At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia", "", " \"At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia\"." +39328, Lispro, 2201, 2205, "ILPS", "", +39329, InsulinGlargine, 2228, 2236, "glargine", "", +39330, HbA1c, 2240, 2245, "HbA1c", "", +39331, TimePoint, 2258, 2266, "baseline", "", +39332, Hypoglycemia, 2307, 2320, "hypoglycaemia", "", +39333, PMID, 2414, 2422, "20920045", "", " \"20920045\"." diff --git a/data/dm2 20920045_akramersunderbrink.n-triples b/data/dm2 20920045_akramersunderbrink.n-triples new file mode 100644 index 0000000..b2ac667 --- /dev/null +++ b/data/dm2 20920045_akramersunderbrink.n-triples @@ -0,0 +1,258 @@ +# RDF export of group: Publication + . + "Publication 20657" . + "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial ." . + "Strojek K" . + "2010" . + "Diabetes Obes Metab" . + "20920045" . + . + "Shi C" . + "Carey MA" . + "Jacober SJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 20667" . + "The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes ( T2D ) achieve glycaemic targets ." . + "471" . + "24 - week" . + . + . + . + "At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia" . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 20685" . + "insulin - naive patients" . + . + . + . + "inadequate control on oral antihyperglycaemic medication" . + "receiving ≥ 2 OAMs for ≥ 3 months" . + "with a body mass index between 25 and 45 kg / m ( 2 )" . + "HbA1c 7 . 5 - 10 . 0 %" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "gly" . + . + . + . + . + . + . + "wei" . + . + . + . + . + . + "hbatarget" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + . + "noc" . + . + . + . + . + . + . + "sev" . + . + . + . + . +# RDF export of group: Arm + . + "lis" . + . + . + . + . + . + . + . + . + . + . + . + . + "glar" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lis" . + . + "once or twice daily" . + . + . + "gla" . + . + "once daily" . + . + . + "oda" . + . + . +# RDF export of group: Medication + . + "lis" . + . + . + . + . + "gla" . + . + . + . + . + "oda" . + . + . + . +# RDF export of group: Outcome + . + "hba lis" . + . + "- 1 . 46" . + "endpoint" . + . + "hba gla" . + . + "- 1 . 41" . + "endpoint" . + . + "gly lis" . + . + . + "gly gla" . + . + . + "wei lis" . + . + "1 . 04" . + . + "wei gla" . + . + "1 . 07" . + . + "hbatar lis" . + . + "43 . 8" . + . + "hbatar gla" . + . + "41 . 2" . + . + "ins lis" . + . + "0 . 39" . + . + "ins gla" . + . + "0 . 35" . + . + . + . + "hyp lis" . + . + "24 . 2" . + "28 . 8" . + . + "hyp gla" . + . + "23 . 0" . + "30 . 9" . + . + "noc lis" . + . + "6 . 1" . + "10 . 6" . + . + "noc gla" . + . + "4 . 1" . + "9 . 4" . + . + "sev ins" . + . + "9" . + . + "sev gla" . + . + "2" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 05" . + . + . + . + "gly" . + "0 . 06" . + . + . + . + "wei" . + "- 0 . 01" . + "p = 0 . 98" . + . + . + . + "ins" . + "p = 0 . 02" . + . + "noc" . + "p < 0 . 001" . + . + . + . + "sev" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 20920045_export.csv b/data/dm2 20920045_export.csv new file mode 100644 index 0000000..74dd2c7 --- /dev/null +++ b/data/dm2 20920045_export.csv @@ -0,0 +1,588 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +328, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +328, 1, 2, 2, 9, 13, 9, 13, "Obes" +328, 1, 3, 3, 14, 19, 14, 19, "Metab" +328, 1, 4, 4, 20, 21, 20, 21, "." +328, 2, 1, 5, 0, 4, 22, 26, "2010" +328, 2, 2, 6, 5, 8, 27, 30, "Oct" +328, 2, 3, 7, 9, 10, 31, 32, ";" +328, 2, 4, 8, 11, 13, 33, 35, "12" +328, 2, 5, 9, 14, 15, 36, 37, "(" +328, 2, 6, 10, 16, 18, 38, 40, "10" +328, 2, 7, 11, 19, 20, 41, 42, ")" +328, 2, 8, 12, 21, 22, 43, 44, ":" +328, 2, 9, 13, 23, 26, 45, 48, "916" +328, 2, 10, 14, 27, 28, 49, 50, "-" +328, 2, 11, 15, 29, 31, 51, 53, "22" +328, 2, 12, 16, 32, 33, 54, 55, "." +328, 2, 13, 17, 34, 37, 56, 59, "doi" +328, 2, 14, 18, 38, 39, 60, 61, ":" +328, 2, 15, 19, 40, 42, 62, 64, "10" +328, 2, 16, 20, 43, 44, 65, 66, "." +328, 2, 17, 21, 45, 49, 67, 71, "1111" +328, 2, 18, 22, 50, 51, 72, 73, "/" +328, 2, 19, 23, 52, 53, 74, 75, "j" +328, 2, 20, 24, 54, 55, 76, 77, "." +328, 2, 21, 25, 56, 60, 78, 82, "1463" +328, 2, 22, 26, 61, 62, 83, 84, "-" +328, 2, 23, 27, 63, 67, 85, 89, "1326" +328, 2, 24, 28, 68, 69, 90, 91, "." +328, 2, 25, 29, 70, 74, 92, 96, "2010" +328, 2, 26, 30, 75, 76, 97, 98, "." +328, 2, 27, 31, 77, 82, 99, 104, "01257" +328, 2, 28, 32, 83, 84, 105, 106, "." +328, 2, 29, 33, 85, 86, 107, 108, "x" +328, 2, 30, 34, 87, 88, 109, 110, "." +328, 3, 1, 35, 0, 8, 111, 119, "Addition" +328, 3, 2, 36, 9, 11, 120, 122, "of" +328, 3, 3, 37, 12, 19, 123, 130, "insulin" +328, 3, 4, 38, 20, 26, 131, 137, "lispro" +328, 3, 5, 39, 27, 36, 138, 147, "protamine" +328, 3, 6, 40, 37, 47, 148, 158, "suspension" +328, 3, 7, 41, 48, 50, 159, 161, "or" +328, 3, 8, 42, 51, 58, 162, 169, "insulin" +328, 3, 9, 43, 59, 67, 170, 178, "glargine" +328, 3, 10, 44, 68, 70, 179, 181, "to" +328, 3, 11, 45, 71, 75, 182, 186, "oral" +328, 3, 12, 46, 76, 80, 187, 191, "type" +328, 3, 13, 47, 81, 82, 192, 193, "2" +328, 3, 14, 48, 83, 91, 194, 202, "diabetes" +328, 3, 15, 49, 92, 100, 203, 211, "regimens" +328, 3, 16, 50, 101, 102, 212, 213, ":" +328, 3, 17, 51, 103, 104, 214, 215, "a" +328, 3, 18, 52, 105, 115, 216, 226, "randomized" +328, 3, 19, 53, 116, 121, 227, 232, "trial" +328, 3, 20, 54, 122, 123, 233, 234, "." +328, 4, 1, 55, 0, 7, 235, 242, "Strojek" +328, 4, 2, 56, 8, 9, 243, 244, "K" +328, 4, 3, 57, 10, 11, 245, 246, "(" +328, 4, 4, 58, 12, 13, 247, 248, "1" +328, 4, 5, 59, 14, 15, 249, 250, ")" +328, 4, 6, 60, 16, 17, 251, 252, "," +328, 4, 7, 61, 18, 21, 253, 256, "Shi" +328, 4, 8, 62, 22, 23, 257, 258, "C" +328, 4, 9, 63, 24, 25, 259, 260, "," +328, 4, 10, 64, 26, 31, 261, 266, "Carey" +328, 4, 11, 65, 32, 34, 267, 269, "MA" +328, 4, 12, 66, 35, 36, 270, 271, "," +328, 4, 13, 67, 37, 44, 272, 279, "Jacober" +328, 4, 14, 68, 45, 47, 280, 282, "SJ" +328, 4, 15, 69, 48, 49, 283, 284, "." +328, 5, 1, 70, 0, 6, 285, 291, "Author" +328, 5, 2, 71, 7, 18, 292, 303, "information" +328, 5, 3, 72, 19, 20, 304, 305, ":" +328, 5, 4, 73, 21, 22, 306, 307, "(" +328, 5, 5, 74, 23, 24, 308, 309, "1" +328, 5, 6, 75, 25, 26, 310, 311, ")" +328, 5, 7, 76, 27, 37, 312, 322, "Department" +328, 5, 8, 77, 38, 40, 323, 325, "of" +328, 5, 9, 78, 41, 49, 326, 334, "Internal" +328, 5, 10, 79, 50, 58, 335, 343, "Diseases" +328, 5, 11, 80, 59, 60, 344, 345, "," +328, 5, 12, 81, 61, 72, 346, 357, "Diabetology" +328, 5, 13, 82, 73, 76, 358, 361, "and" +328, 5, 14, 83, 77, 87, 362, 372, "Nephrology" +328, 5, 15, 84, 88, 89, 373, 374, "," +328, 5, 16, 85, 90, 98, 375, 383, "Silesian" +328, 5, 17, 86, 99, 106, 384, 391, "Medical" +328, 5, 18, 87, 107, 117, 392, 402, "University" +328, 5, 19, 88, 118, 119, 403, 404, "," +328, 5, 20, 89, 120, 126, 405, 411, "Zabrze" +328, 5, 21, 90, 127, 128, 412, 413, "," +328, 5, 22, 91, 129, 135, 414, 420, "Poland" +328, 5, 23, 92, 136, 137, 421, 422, "." +328, 6, 1, 93, 0, 4, 423, 427, "AIMS" +328, 6, 2, 94, 5, 6, 428, 429, ":" +328, 6, 3, 95, 7, 10, 430, 433, "The" +328, 6, 4, 96, 11, 19, 434, 442, "addition" +328, 6, 5, 97, 20, 22, 443, 445, "of" +328, 6, 6, 98, 23, 28, 446, 451, "basal" +328, 6, 7, 99, 29, 36, 452, 459, "insulin" +328, 6, 8, 100, 37, 39, 460, 462, "to" +328, 6, 9, 101, 40, 48, 463, 471, "existing" +328, 6, 10, 102, 49, 53, 472, 476, "oral" +328, 6, 11, 103, 54, 61, 477, 484, "therapy" +328, 6, 12, 104, 62, 65, 485, 488, "can" +328, 6, 13, 105, 66, 70, 489, 493, "help" +328, 6, 14, 106, 71, 79, 494, 502, "patients" +328, 6, 15, 107, 80, 84, 503, 507, "with" +328, 6, 16, 108, 85, 89, 508, 512, "type" +328, 6, 17, 109, 90, 91, 513, 514, "2" +328, 6, 18, 110, 92, 100, 515, 523, "diabetes" +328, 6, 19, 111, 101, 102, 524, 525, "(" +328, 6, 20, 112, 103, 106, 526, 529, "T2D" +328, 6, 21, 113, 107, 108, 530, 531, ")" +328, 6, 22, 114, 109, 116, 532, 539, "achieve" +328, 6, 23, 115, 117, 126, 540, 549, "glycaemic" +328, 6, 24, 116, 127, 134, 550, 557, "targets" +328, 6, 25, 117, 135, 136, 558, 559, "." +328, 7, 1, 118, 0, 4, 560, 564, "This" +328, 7, 2, 119, 5, 10, 565, 570, "study" +328, 7, 3, 120, 11, 19, 571, 579, "compares" +328, 7, 4, 121, 20, 23, 580, 583, "the" +328, 7, 5, 122, 24, 32, 584, 592, "efficacy" +328, 7, 6, 123, 33, 36, 593, 596, "and" +328, 7, 7, 124, 37, 43, 597, 603, "safety" +328, 7, 8, 125, 44, 46, 604, 606, "of" +328, 7, 9, 126, 47, 54, 607, 614, "insulin" +328, 7, 10, 127, 55, 61, 615, 621, "lispro" +328, 7, 11, 128, 62, 71, 622, 631, "protamine" +328, 7, 12, 129, 72, 82, 632, 642, "suspension" +328, 7, 13, 130, 83, 84, 643, 644, "(" +328, 7, 14, 131, 85, 89, 645, 649, "ILPS" +328, 7, 15, 132, 90, 91, 650, 651, ")" +328, 7, 16, 133, 92, 95, 652, 655, "and" +328, 7, 17, 134, 96, 103, 656, 663, "insulin" +328, 7, 18, 135, 104, 112, 664, 672, "glargine" +328, 7, 19, 136, 113, 115, 673, 675, "in" +328, 7, 20, 137, 116, 123, 676, 683, "insulin" +328, 7, 21, 138, 124, 125, 684, 685, "-" +328, 7, 22, 139, 126, 131, 686, 691, "naive" +328, 7, 23, 140, 132, 140, 692, 700, "patients" +328, 7, 24, 141, 141, 145, 701, 705, "with" +328, 7, 25, 142, 146, 149, 706, 709, "T2D" +328, 7, 26, 143, 150, 153, 710, 713, "and" +328, 7, 27, 144, 154, 164, 714, 724, "inadequate" +328, 7, 28, 145, 165, 172, 725, 732, "control" +328, 7, 29, 146, 173, 175, 733, 735, "on" +328, 7, 30, 147, 176, 180, 736, 740, "oral" +328, 7, 31, 148, 181, 199, 741, 759, "antihyperglycaemic" +328, 7, 32, 149, 200, 210, 760, 770, "medication" +328, 7, 33, 150, 211, 212, 771, 772, "(" +328, 7, 34, 151, 213, 216, 773, 776, "OAM" +328, 7, 35, 152, 217, 218, 777, 778, ")" +328, 7, 36, 153, 219, 220, 779, 780, "." +328, 8, 1, 154, 0, 9, 781, 790, "MATERIALS" +328, 8, 2, 155, 10, 13, 791, 794, "AND" +328, 8, 3, 156, 14, 21, 795, 802, "METHODS" +328, 8, 4, 157, 22, 23, 803, 804, ":" +328, 8, 5, 158, 24, 26, 805, 807, "An" +328, 8, 6, 159, 27, 31, 808, 812, "open" +328, 8, 7, 160, 32, 33, 813, 814, "-" +328, 8, 8, 161, 34, 39, 815, 820, "label" +328, 8, 9, 162, 40, 41, 821, 822, "," +328, 8, 10, 163, 42, 52, 823, 833, "randomized" +328, 8, 11, 164, 53, 54, 834, 835, "," +328, 8, 12, 165, 55, 66, 836, 847, "multicentre" +328, 8, 13, 166, 67, 68, 848, 849, "," +328, 8, 14, 167, 69, 82, 850, 863, "multinational" +328, 8, 15, 168, 83, 85, 864, 866, "24" +328, 8, 16, 169, 86, 87, 867, 868, "-" +328, 8, 17, 170, 88, 92, 869, 873, "week" +328, 8, 18, 171, 93, 98, 874, 879, "study" +328, 8, 19, 172, 99, 101, 880, 882, "of" +328, 8, 20, 173, 102, 105, 883, 886, "471" +328, 8, 21, 174, 106, 114, 887, 895, "patients" +328, 8, 22, 175, 115, 124, 896, 905, "receiving" +328, 8, 23, 176, 125, 126, 906, 907, "≥" +328, 8, 24, 177, 127, 128, 908, 909, "2" +328, 8, 25, 178, 129, 133, 910, 914, "OAMs" +328, 8, 26, 179, 134, 137, 915, 918, "for" +328, 8, 27, 180, 138, 139, 919, 920, "≥" +328, 8, 28, 181, 140, 141, 921, 922, "3" +328, 8, 29, 182, 142, 148, 923, 929, "months" +328, 8, 30, 183, 149, 153, 930, 934, "with" +328, 8, 31, 184, 154, 155, 935, 936, "a" +328, 8, 32, 185, 156, 160, 937, 941, "body" +328, 8, 33, 186, 161, 165, 942, 946, "mass" +328, 8, 34, 187, 166, 171, 947, 952, "index" +328, 8, 35, 188, 172, 179, 953, 960, "between" +328, 8, 36, 189, 180, 182, 961, 963, "25" +328, 8, 37, 190, 183, 186, 964, 967, "and" +328, 8, 38, 191, 187, 189, 968, 970, "45" +328, 8, 39, 192, 190, 192, 971, 973, "kg" +328, 8, 40, 193, 193, 194, 974, 975, "/" +328, 8, 41, 194, 195, 196, 976, 977, "m" +328, 8, 42, 195, 197, 198, 978, 979, "(" +328, 8, 43, 196, 199, 200, 980, 981, "2" +328, 8, 44, 197, 201, 202, 982, 983, ")" +328, 8, 45, 198, 203, 206, 984, 987, "and" +328, 8, 46, 199, 207, 212, 988, 993, "HbA1c" +328, 8, 47, 200, 213, 214, 994, 995, "7" +328, 8, 48, 201, 215, 216, 996, 997, "." +328, 8, 49, 202, 217, 218, 998, 999, "5" +328, 8, 50, 203, 219, 220, 1000, 1001, "-" +328, 8, 51, 204, 221, 223, 1002, 1004, "10" +328, 8, 52, 205, 224, 225, 1005, 1006, "." +328, 8, 53, 206, 226, 227, 1007, 1008, "0" +328, 8, 54, 207, 228, 229, 1009, 1010, "%" +328, 8, 55, 208, 230, 233, 1011, 1014, "was" +328, 8, 56, 209, 234, 243, 1015, 1024, "conducted" +328, 8, 57, 210, 244, 245, 1025, 1026, "." +328, 9, 1, 211, 0, 4, 1027, 1031, "ILPS" +328, 9, 2, 212, 5, 8, 1032, 1035, "was" +328, 9, 3, 213, 9, 17, 1036, 1044, "injected" +328, 9, 4, 214, 18, 22, 1045, 1049, "once" +328, 9, 5, 215, 23, 25, 1050, 1052, "or" +328, 9, 6, 216, 26, 31, 1053, 1058, "twice" +328, 9, 7, 217, 32, 37, 1059, 1064, "daily" +328, 9, 8, 218, 38, 40, 1065, 1067, "vs" +328, 9, 9, 219, 41, 42, 1068, 1069, "." +328, 9, 10, 220, 43, 51, 1070, 1078, "glargine" +328, 9, 11, 221, 52, 60, 1079, 1087, "injected" +328, 9, 12, 222, 61, 65, 1088, 1092, "once" +328, 9, 13, 223, 66, 71, 1093, 1098, "daily" +328, 9, 14, 224, 72, 76, 1099, 1103, "plus" +328, 9, 15, 225, 77, 85, 1104, 1112, "prestudy" +328, 9, 16, 226, 86, 90, 1113, 1117, "OAMs" +328, 9, 17, 227, 91, 92, 1118, 1119, "." +328, 10, 1, 228, 0, 7, 1120, 1127, "Primary" +328, 10, 2, 229, 8, 17, 1128, 1137, "objective" +328, 10, 3, 230, 18, 26, 1138, 1146, "compared" +328, 10, 4, 231, 27, 30, 1147, 1150, "the" +328, 10, 5, 232, 31, 36, 1151, 1156, "HbA1c" +328, 10, 6, 233, 37, 43, 1157, 1163, "change" +328, 10, 7, 234, 44, 48, 1164, 1168, "from" +328, 10, 8, 235, 49, 57, 1169, 1177, "baseline" +328, 10, 9, 236, 58, 59, 1178, 1179, "." +328, 11, 1, 237, 0, 7, 1180, 1187, "RESULTS" +328, 11, 2, 238, 8, 9, 1188, 1189, ":" +328, 11, 3, 239, 10, 15, 1190, 1195, "HbA1c" +328, 11, 4, 240, 16, 22, 1196, 1202, "change" +328, 11, 5, 241, 23, 27, 1203, 1207, "from" +328, 11, 6, 242, 28, 36, 1208, 1216, "baseline" +328, 11, 7, 243, 37, 39, 1217, 1219, "to" +328, 11, 8, 244, 40, 48, 1220, 1228, "endpoint" +328, 11, 9, 245, 49, 52, 1229, 1232, "was" +328, 11, 10, 246, 53, 60, 1233, 1240, "similar" +328, 11, 11, 247, 61, 63, 1241, 1243, "in" +328, 11, 12, 248, 64, 68, 1244, 1248, "both" +328, 11, 13, 249, 69, 75, 1249, 1255, "groups" +328, 11, 14, 250, 76, 77, 1256, 1257, "[" +328, 11, 15, 251, 78, 79, 1258, 1259, "-" +328, 11, 16, 252, 80, 81, 1260, 1261, "1" +328, 11, 17, 253, 82, 83, 1262, 1263, "." +328, 11, 18, 254, 84, 86, 1264, 1266, "46" +328, 11, 19, 255, 87, 88, 1267, 1268, "%" +328, 11, 20, 256, 89, 90, 1269, 1270, "(" +328, 11, 21, 257, 91, 95, 1271, 1275, "ILPS" +328, 11, 22, 258, 96, 97, 1276, 1277, ")" +328, 11, 23, 259, 98, 101, 1278, 1281, "and" +328, 11, 24, 260, 102, 103, 1282, 1283, "-" +328, 11, 25, 261, 104, 105, 1284, 1285, "1" +328, 11, 26, 262, 106, 107, 1286, 1287, "." +328, 11, 27, 263, 108, 110, 1288, 1290, "41" +328, 11, 28, 264, 111, 112, 1291, 1292, "%" +328, 11, 29, 265, 113, 114, 1293, 1294, "(" +328, 11, 30, 266, 115, 123, 1295, 1303, "glargine" +328, 11, 31, 267, 124, 125, 1304, 1305, ")" +328, 11, 32, 268, 126, 127, 1306, 1307, "]" +328, 11, 33, 269, 128, 129, 1308, 1309, "." +328, 12, 1, 270, 0, 5, 1310, 1315, "Least" +328, 12, 2, 271, 6, 7, 1316, 1317, "-" +328, 12, 3, 272, 8, 15, 1318, 1325, "squares" +328, 12, 4, 273, 16, 20, 1326, 1330, "mean" +328, 12, 5, 274, 21, 31, 1331, 1341, "difference" +328, 12, 6, 275, 32, 33, 1342, 1343, "(" +328, 12, 7, 276, 34, 36, 1344, 1346, "95" +328, 12, 8, 277, 37, 38, 1347, 1348, "%" +328, 12, 9, 278, 39, 41, 1349, 1351, "CI" +328, 12, 10, 279, 42, 43, 1352, 1353, ")" +328, 12, 11, 280, 44, 47, 1354, 1357, "for" +328, 12, 12, 281, 48, 53, 1358, 1363, "HbA1c" +328, 12, 13, 282, 54, 55, 1364, 1365, "(" +328, 12, 14, 283, 56, 57, 1366, 1367, "-" +328, 12, 15, 284, 58, 59, 1368, 1369, "0" +328, 12, 16, 285, 60, 61, 1370, 1371, "." +328, 12, 17, 286, 62, 64, 1372, 1374, "05" +328, 12, 18, 287, 65, 66, 1375, 1376, "[" +328, 12, 19, 288, 67, 68, 1377, 1378, "-" +328, 12, 20, 289, 69, 70, 1379, 1380, "0" +328, 12, 21, 290, 71, 72, 1381, 1382, "." +328, 12, 22, 291, 73, 75, 1383, 1385, "21" +328, 12, 23, 292, 76, 77, 1386, 1387, "," +328, 12, 24, 293, 78, 79, 1388, 1389, "0" +328, 12, 25, 294, 80, 81, 1390, 1391, "." +328, 12, 26, 295, 82, 84, 1392, 1394, "11" +328, 12, 27, 296, 85, 86, 1395, 1396, "]" +328, 12, 28, 297, 87, 88, 1397, 1398, "%" +328, 12, 29, 298, 89, 90, 1399, 1400, ")" +328, 12, 30, 299, 91, 92, 1401, 1402, "," +328, 12, 31, 300, 93, 102, 1403, 1412, "glycaemic" +328, 12, 32, 301, 103, 114, 1413, 1424, "variability" +328, 12, 33, 302, 115, 116, 1425, 1426, "(" +328, 12, 34, 303, 117, 118, 1427, 1428, "0" +328, 12, 35, 304, 119, 120, 1429, 1430, "." +328, 12, 36, 305, 121, 123, 1431, 1433, "06" +328, 12, 37, 306, 124, 125, 1434, 1435, "[" +328, 12, 38, 307, 126, 127, 1436, 1437, "-" +328, 12, 39, 308, 128, 129, 1438, 1439, "0" +328, 12, 40, 309, 130, 131, 1440, 1441, "." +328, 12, 41, 310, 132, 134, 1442, 1444, "06" +328, 12, 42, 311, 135, 136, 1445, 1446, "," +328, 12, 43, 312, 137, 138, 1447, 1448, "0" +328, 12, 44, 313, 139, 140, 1449, 1450, "." +328, 12, 45, 314, 141, 143, 1451, 1453, "19" +328, 12, 46, 315, 144, 145, 1454, 1455, "]" +328, 12, 47, 316, 146, 150, 1456, 1460, "mmol" +328, 12, 48, 317, 151, 152, 1461, 1462, "/" +328, 12, 49, 318, 153, 154, 1463, 1464, "l" +328, 12, 50, 319, 155, 156, 1465, 1466, ")" +328, 12, 51, 320, 157, 160, 1467, 1470, "and" +328, 12, 52, 321, 161, 167, 1471, 1477, "weight" +328, 12, 53, 322, 168, 174, 1478, 1484, "change" +328, 12, 54, 323, 175, 176, 1485, 1486, "(" +328, 12, 55, 324, 177, 178, 1487, 1488, "-" +328, 12, 56, 325, 179, 180, 1489, 1490, "0" +328, 12, 57, 326, 181, 182, 1491, 1492, "." +328, 12, 58, 327, 183, 185, 1493, 1495, "01" +328, 12, 59, 328, 186, 187, 1496, 1497, "[" +328, 12, 60, 329, 188, 189, 1498, 1499, "-" +328, 12, 61, 330, 190, 191, 1500, 1501, "0" +328, 12, 62, 331, 192, 193, 1502, 1503, "." +328, 12, 63, 332, 194, 196, 1504, 1506, "61" +328, 12, 64, 333, 197, 198, 1507, 1508, "," +328, 12, 65, 334, 199, 200, 1509, 1510, "0" +328, 12, 66, 335, 201, 202, 1511, 1512, "." +328, 12, 67, 336, 203, 205, 1513, 1515, "59" +328, 12, 68, 337, 206, 207, 1516, 1517, "]" +328, 12, 69, 338, 208, 210, 1518, 1520, "kg" +328, 12, 70, 339, 211, 212, 1521, 1522, ")" +328, 12, 71, 340, 213, 219, 1523, 1529, "showed" +328, 12, 72, 341, 220, 223, 1530, 1533, "non" +328, 12, 73, 342, 224, 225, 1534, 1535, "-" +328, 12, 74, 343, 226, 237, 1536, 1547, "inferiority" +328, 12, 75, 344, 238, 239, 1548, 1549, "(" +328, 12, 76, 345, 240, 247, 1550, 1557, "margins" +328, 12, 77, 346, 248, 250, 1558, 1560, "of" +328, 12, 78, 347, 251, 252, 1561, 1562, "0" +328, 12, 79, 348, 253, 254, 1563, 1564, "." +328, 12, 80, 349, 255, 256, 1565, 1566, "4" +328, 12, 81, 350, 257, 258, 1567, 1568, "%" +328, 12, 82, 351, 259, 260, 1569, 1570, "," +328, 12, 83, 352, 261, 262, 1571, 1572, "0" +328, 12, 84, 353, 263, 264, 1573, 1574, "." +328, 12, 85, 354, 265, 266, 1575, 1576, "8" +328, 12, 86, 355, 267, 271, 1577, 1581, "mmol" +328, 12, 87, 356, 272, 273, 1582, 1583, "/" +328, 12, 88, 357, 274, 275, 1584, 1585, "l" +328, 12, 89, 358, 276, 279, 1586, 1589, "and" +328, 12, 90, 359, 280, 281, 1590, 1591, "1" +328, 12, 91, 360, 282, 283, 1592, 1593, "." +328, 12, 92, 361, 284, 285, 1594, 1595, "5" +328, 12, 93, 362, 286, 288, 1596, 1598, "kg" +328, 12, 94, 363, 289, 290, 1599, 1600, "," +328, 12, 95, 364, 291, 303, 1601, 1613, "respectively" +328, 12, 96, 365, 304, 305, 1614, 1615, ")" +328, 12, 97, 366, 306, 307, 1616, 1617, "." +328, 13, 1, 367, 0, 11, 1618, 1629, "Percentages" +328, 13, 2, 368, 12, 14, 1630, 1632, "of" +328, 13, 3, 369, 15, 23, 1633, 1641, "patients" +328, 13, 4, 370, 24, 33, 1642, 1651, "achieving" +328, 13, 5, 371, 34, 39, 1652, 1657, "HbA1c" +328, 13, 6, 372, 40, 41, 1658, 1659, "<" +328, 13, 7, 373, 42, 43, 1660, 1661, "7" +328, 13, 8, 374, 44, 45, 1662, 1663, "." +328, 13, 9, 375, 46, 47, 1664, 1665, "0" +328, 13, 10, 376, 48, 49, 1666, 1667, "%" +328, 13, 11, 377, 50, 54, 1668, 1672, "were" +328, 13, 12, 378, 55, 57, 1673, 1675, "43" +328, 13, 13, 379, 58, 59, 1676, 1677, "." +328, 13, 14, 380, 60, 61, 1678, 1679, "8" +328, 13, 15, 381, 62, 63, 1680, 1681, "%" +328, 13, 16, 382, 64, 68, 1682, 1686, "ILPS" +328, 13, 17, 383, 69, 72, 1687, 1690, "and" +328, 13, 18, 384, 73, 75, 1691, 1693, "41" +328, 13, 19, 385, 76, 77, 1694, 1695, "." +328, 13, 20, 386, 78, 79, 1696, 1697, "2" +328, 13, 21, 387, 80, 81, 1698, 1699, "%" +328, 13, 22, 388, 82, 90, 1700, 1708, "glargine" +328, 13, 23, 389, 91, 92, 1709, 1710, "." +328, 14, 1, 390, 0, 4, 1711, 1715, "Mean" +328, 14, 2, 391, 5, 10, 1716, 1721, "daily" +328, 14, 3, 392, 11, 18, 1722, 1729, "insulin" +328, 14, 4, 393, 19, 23, 1730, 1734, "dose" +328, 14, 5, 394, 24, 27, 1735, 1738, "was" +328, 14, 6, 395, 28, 29, 1739, 1740, "0" +328, 14, 7, 396, 30, 31, 1741, 1742, "." +328, 14, 8, 397, 32, 34, 1743, 1745, "39" +328, 14, 9, 398, 35, 37, 1746, 1748, "vs" +328, 14, 10, 399, 38, 39, 1749, 1750, "." +328, 14, 11, 400, 40, 41, 1751, 1752, "0" +328, 14, 12, 401, 42, 43, 1753, 1754, "." +328, 14, 13, 402, 44, 46, 1755, 1757, "35" +328, 14, 14, 403, 47, 48, 1758, 1759, "U" +328, 14, 15, 404, 49, 50, 1760, 1761, "/" +328, 14, 16, 405, 51, 53, 1762, 1764, "kg" +328, 14, 17, 406, 54, 55, 1765, 1766, "(" +328, 14, 18, 407, 56, 57, 1767, 1768, "p" +328, 14, 19, 408, 58, 59, 1769, 1770, "=" +328, 14, 20, 409, 60, 61, 1771, 1772, "0" +328, 14, 21, 410, 62, 63, 1773, 1774, "." +328, 14, 22, 411, 64, 66, 1775, 1777, "02" +328, 14, 23, 412, 67, 68, 1778, 1779, ")" +328, 14, 24, 413, 69, 72, 1780, 1783, "and" +328, 14, 25, 414, 73, 79, 1784, 1790, "weight" +328, 14, 26, 415, 80, 84, 1791, 1795, "gain" +328, 14, 27, 416, 85, 88, 1796, 1799, "was" +328, 14, 28, 417, 89, 90, 1800, 1801, "1" +328, 14, 29, 418, 91, 92, 1802, 1803, "." +328, 14, 30, 419, 93, 95, 1804, 1806, "04" +328, 14, 31, 420, 96, 98, 1807, 1809, "vs" +328, 14, 32, 421, 99, 100, 1810, 1811, "." +328, 14, 33, 422, 101, 102, 1812, 1813, "1" +328, 14, 34, 423, 103, 104, 1814, 1815, "." +328, 14, 35, 424, 105, 107, 1816, 1818, "07" +328, 14, 36, 425, 108, 110, 1819, 1821, "kg" +328, 14, 37, 426, 111, 114, 1822, 1825, "for" +328, 14, 38, 427, 115, 119, 1826, 1830, "ILPS" +328, 14, 39, 428, 120, 122, 1831, 1833, "vs" +328, 14, 40, 429, 123, 124, 1834, 1835, "." +328, 14, 41, 430, 125, 133, 1836, 1844, "glargine" +328, 14, 42, 431, 134, 135, 1845, 1846, "(" +328, 14, 43, 432, 136, 137, 1847, 1848, "p" +328, 14, 44, 433, 138, 139, 1849, 1850, "=" +328, 14, 45, 434, 140, 141, 1851, 1852, "0" +328, 14, 46, 435, 142, 143, 1853, 1854, "." +328, 14, 47, 436, 144, 146, 1855, 1857, "98" +328, 14, 48, 437, 147, 148, 1858, 1859, ")" +328, 14, 49, 438, 149, 150, 1860, 1861, "." +328, 15, 1, 439, 0, 7, 1862, 1869, "Overall" +328, 15, 2, 440, 8, 21, 1870, 1883, "hypoglycaemia" +328, 15, 3, 441, 22, 23, 1884, 1885, "(" +328, 15, 4, 442, 24, 32, 1886, 1894, "episodes" +328, 15, 5, 443, 33, 34, 1895, 1896, "/" +328, 15, 6, 444, 35, 42, 1897, 1904, "patient" +328, 15, 7, 445, 43, 44, 1905, 1906, "/" +328, 15, 8, 446, 45, 49, 1907, 1911, "year" +328, 15, 9, 447, 50, 51, 1912, 1913, ")" +328, 15, 10, 448, 52, 55, 1914, 1917, "was" +328, 15, 11, 449, 56, 63, 1918, 1925, "similar" +328, 15, 12, 450, 64, 67, 1926, 1929, "for" +328, 15, 13, 451, 68, 72, 1930, 1934, "ILPS" +328, 15, 14, 452, 73, 76, 1935, 1938, "and" +328, 15, 15, 453, 77, 85, 1939, 1947, "glargine" +328, 15, 16, 454, 86, 87, 1948, 1949, "(" +328, 15, 17, 455, 88, 90, 1950, 1952, "24" +328, 15, 18, 456, 91, 92, 1953, 1954, "." +328, 15, 19, 457, 93, 94, 1955, 1956, "2" +328, 15, 20, 458, 95, 96, 1957, 1958, "±" +328, 15, 21, 459, 97, 99, 1959, 1961, "28" +328, 15, 22, 460, 100, 101, 1962, 1963, "." +328, 15, 23, 461, 102, 103, 1964, 1965, "8" +328, 15, 24, 462, 104, 106, 1966, 1968, "vs" +328, 15, 25, 463, 107, 108, 1969, 1970, "." +328, 15, 26, 464, 109, 111, 1971, 1973, "23" +328, 15, 27, 465, 112, 113, 1974, 1975, "." +328, 15, 28, 466, 114, 115, 1976, 1977, "0" +328, 15, 29, 467, 116, 117, 1978, 1979, "±" +328, 15, 30, 468, 118, 120, 1980, 1982, "30" +328, 15, 31, 469, 121, 122, 1983, 1984, "." +328, 15, 32, 470, 123, 124, 1985, 1986, "9" +328, 15, 33, 471, 125, 126, 1987, 1988, ")" +328, 15, 34, 472, 127, 128, 1989, 1990, ";" +328, 15, 35, 473, 129, 138, 1991, 2000, "nocturnal" +328, 15, 36, 474, 139, 140, 2001, 2002, "(" +328, 15, 37, 475, 141, 142, 2003, 2004, "6" +328, 15, 38, 476, 143, 144, 2005, 2006, "." +328, 15, 39, 477, 145, 146, 2007, 2008, "1" +328, 15, 40, 478, 147, 148, 2009, 2010, "±" +328, 15, 41, 479, 149, 151, 2011, 2013, "10" +328, 15, 42, 480, 152, 153, 2014, 2015, "." +328, 15, 43, 481, 154, 155, 2016, 2017, "6" +328, 15, 44, 482, 156, 158, 2018, 2020, "vs" +328, 15, 45, 483, 159, 160, 2021, 2022, "." +328, 15, 46, 484, 161, 162, 2023, 2024, "4" +328, 15, 47, 485, 163, 164, 2025, 2026, "." +328, 15, 48, 486, 165, 166, 2027, 2028, "1" +328, 15, 49, 487, 167, 168, 2029, 2030, "±" +328, 15, 50, 488, 169, 170, 2031, 2032, "9" +328, 15, 51, 489, 171, 172, 2033, 2034, "." +328, 15, 52, 490, 173, 174, 2035, 2036, "4" +328, 15, 53, 491, 175, 176, 2037, 2038, "," +328, 15, 54, 492, 177, 178, 2039, 2040, "p" +328, 15, 55, 493, 179, 180, 2041, 2042, "<" +328, 15, 56, 494, 181, 182, 2043, 2044, "0" +328, 15, 57, 495, 183, 184, 2045, 2046, "." +328, 15, 58, 496, 185, 188, 2047, 2050, "001" +328, 15, 59, 497, 189, 190, 2051, 2052, ")" +328, 15, 60, 498, 191, 196, 2053, 2058, "rates" +328, 15, 61, 499, 197, 201, 2059, 2063, "were" +328, 15, 62, 500, 202, 208, 2064, 2070, "higher" +328, 15, 63, 501, 209, 212, 2071, 2074, "for" +328, 15, 64, 502, 213, 217, 2075, 2079, "ILPS" +328, 15, 65, 503, 218, 219, 2080, 2081, "." +328, 16, 1, 504, 0, 6, 2082, 2088, "Severe" +328, 16, 2, 505, 7, 20, 2089, 2102, "hypoglycaemia" +328, 16, 3, 506, 21, 24, 2103, 2106, "was" +328, 16, 4, 507, 25, 31, 2107, 2113, "higher" +328, 16, 5, 508, 32, 35, 2114, 2117, "for" +328, 16, 6, 509, 36, 40, 2118, 2122, "ILPS" +328, 16, 7, 510, 41, 43, 2123, 2125, "vs" +328, 16, 8, 511, 44, 45, 2126, 2127, "." +328, 16, 9, 512, 46, 54, 2128, 2136, "glargine" +328, 16, 10, 513, 55, 56, 2137, 2138, "(" +328, 16, 11, 514, 57, 58, 2139, 2140, "n" +328, 16, 12, 515, 59, 60, 2141, 2142, "=" +328, 16, 13, 516, 61, 62, 2143, 2144, "9" +328, 16, 14, 517, 63, 65, 2145, 2147, "vs" +328, 16, 15, 518, 66, 67, 2148, 2149, "." +328, 16, 16, 519, 68, 69, 2150, 2151, "n" +328, 16, 17, 520, 70, 71, 2152, 2153, "=" +328, 16, 18, 521, 72, 73, 2154, 2155, "2" +328, 16, 19, 522, 74, 75, 2156, 2157, ";" +328, 16, 20, 523, 76, 77, 2158, 2159, "p" +328, 16, 21, 524, 78, 79, 2160, 2161, "=" +328, 16, 22, 525, 80, 81, 2162, 2163, "0" +328, 16, 23, 526, 82, 83, 2164, 2165, "." +328, 16, 24, 527, 84, 86, 2166, 2168, "04" +328, 16, 25, 528, 87, 88, 2169, 2170, ")" +328, 16, 26, 529, 89, 90, 2171, 2172, "." +328, 17, 1, 530, 0, 11, 2173, 2184, "CONCLUSIONS" +328, 17, 2, 531, 12, 13, 2185, 2186, ":" +328, 17, 3, 532, 14, 16, 2187, 2189, "At" +328, 17, 4, 533, 17, 25, 2190, 2198, "endpoint" +328, 17, 5, 534, 26, 27, 2199, 2200, "," +328, 17, 6, 535, 28, 32, 2201, 2205, "ILPS" +328, 17, 7, 536, 33, 36, 2206, 2209, "was" +328, 17, 8, 537, 37, 40, 2210, 2213, "non" +328, 17, 9, 538, 41, 42, 2214, 2215, "-" +328, 17, 10, 539, 43, 51, 2216, 2224, "inferior" +328, 17, 11, 540, 52, 54, 2225, 2227, "to" +328, 17, 12, 541, 55, 63, 2228, 2236, "glargine" +328, 17, 13, 542, 64, 66, 2237, 2239, "in" +328, 17, 14, 543, 67, 72, 2240, 2245, "HbA1c" +328, 17, 15, 544, 73, 79, 2246, 2252, "change" +328, 17, 16, 545, 80, 84, 2253, 2257, "from" +328, 17, 17, 546, 85, 93, 2258, 2266, "baseline" +328, 17, 18, 547, 94, 95, 2267, 2268, "," +328, 17, 19, 548, 96, 99, 2269, 2272, "but" +328, 17, 20, 549, 100, 110, 2273, 2283, "associated" +328, 17, 21, 550, 111, 115, 2284, 2288, "with" +328, 17, 22, 551, 116, 125, 2289, 2298, "increased" +328, 17, 23, 552, 126, 130, 2299, 2303, "risk" +328, 17, 24, 553, 131, 133, 2304, 2306, "of" +328, 17, 25, 554, 134, 147, 2307, 2320, "hypoglycaemia" +328, 17, 26, 555, 148, 149, 2321, 2322, "." +328, 18, 1, 556, 0, 1, 2323, 2324, "©" +328, 18, 2, 557, 2, 6, 2325, 2329, "2010" +328, 18, 3, 558, 7, 10, 2330, 2333, "Eli" +328, 18, 4, 559, 11, 16, 2334, 2339, "Lilly" +328, 18, 5, 560, 17, 20, 2340, 2343, "and" +328, 18, 6, 561, 21, 28, 2344, 2351, "Company" +328, 18, 7, 562, 29, 30, 2352, 2353, "." +328, 19, 1, 563, 0, 3, 2354, 2357, "DOI" +328, 19, 2, 564, 4, 5, 2358, 2359, ":" +328, 19, 3, 565, 6, 8, 2360, 2362, "10" +328, 19, 4, 566, 9, 10, 2363, 2364, "." +328, 19, 5, 567, 11, 15, 2365, 2369, "1111" +328, 19, 6, 568, 16, 17, 2370, 2371, "/" +328, 19, 7, 569, 18, 19, 2372, 2373, "j" +328, 19, 8, 570, 20, 21, 2374, 2375, "." +328, 19, 9, 571, 22, 26, 2376, 2380, "1463" +328, 19, 10, 572, 27, 28, 2381, 2382, "-" +328, 19, 11, 573, 29, 33, 2383, 2387, "1326" +328, 19, 12, 574, 34, 35, 2388, 2389, "." +328, 19, 13, 575, 36, 40, 2390, 2394, "2010" +328, 19, 14, 576, 41, 42, 2395, 2396, "." +328, 19, 15, 577, 43, 48, 2397, 2402, "01257" +328, 19, 16, 578, 49, 50, 2403, 2404, "." +328, 19, 17, 579, 51, 52, 2405, 2406, "x" +328, 19, 18, 580, 53, 57, 2407, 2411, "PMID" +328, 19, 19, 581, 58, 59, 2412, 2413, ":" +328, 19, 20, 582, 60, 68, 2414, 2422, "20920045" +328, 19, 21, 583, 69, 70, 2423, 2424, "[" +328, 19, 22, 584, 71, 78, 2425, 2432, "Indexed" +328, 19, 23, 585, 79, 82, 2433, 2436, "for" +328, 19, 24, 586, 83, 90, 2437, 2444, "MEDLINE" +328, 19, 25, 587, 91, 92, 2445, 2446, "]" diff --git a/data/dm2 20920045_kwoodley.annodb b/data/dm2 20920045_kwoodley.annodb new file mode 100644 index 0000000..d0a482d --- /dev/null +++ b/data/dm2 20920045_kwoodley.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16309, Journal, 0, 19, "Diabetes Obes Metab", "", +16310, PublicationYear, 22, 26, "2010", "", +36594, Title, 111, 234, "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens : a randomized trial .", "", +36595, Lispro, 123, 158, "insulin lispro protamine suspension", "", +16312, InsulinGlargine, 162, 178, "insulin glargine", "", +16313, OralAntidiabeticAgent, 182, 211, "oral type 2 diabetes regimens", "", +16314, Type2Diabetes, 187, 202, "type 2 diabetes", "", +16315, Randomized, 216, 226, "randomized", "", +16317, Author, 235, 244, "Strojek K", "", +16318, Author, 253, 258, "Shi C", "", +16319, Author, 261, 269, "Carey MA", "", +16320, Author, 272, 282, "Jacober SJ", "", +16321, Poland, 414, 420, "Poland", "", +16322, Insulin, 452, 459, "insulin", "", +16323, OralAntidiabeticAgent, 472, 484, "oral therapy", "", +16324, Type2Diabetes, 508, 523, "type 2 diabetes", "", +16325, Type2Diabetes, 526, 529, "T2D", "", +36612, ObjectiveDescription, 560, 780, "This study compares the efficacy and safety of insulin lispro protamine suspension ( ILPS ) and insulin glargine in insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM ) .", "", +36596, Lispro, 607, 642, "insulin lispro protamine suspension", "", +36597, Lispro, 645, 649, "ILPS", "", +16328, InsulinGlargine, 656, 672, "insulin glargine", "", +16329, Insulin, 676, 683, "insulin", "", +16333, Precondition, 676, 778, "insulin - naive patients with T2D and inadequate control on oral antihyperglycaemic medication ( OAM )", "", +16330, Type2Diabetes, 706, 709, "T2D", "", +16331, OralAntidiabeticAgent, 736, 770, "oral antihyperglycaemic medication", "", +16332, OralAntidiabeticAgent, 773, 776, "OAM", "", +16334, OpenLabel, 808, 820, "open - label", "", +16335, Randomized, 823, 833, "randomized", "", +16336, Multicenter, 836, 847, "multicentre", "", +24733, Multicenter, 850, 863, "multinational", "", +16338, Duration, 864, 873, "24 - week", "", +16339, NumberPatientsCT, 883, 886, "471", "", +16345, Precondition, 887, 1010, "patients receiving ≥ 2 OAMs for ≥ 3 months with a body mass index between 25 and 45 kg / m ( 2 ) and HbA1c 7 . 5 - 10 . 0 %", "", +16340, OralAntidiabeticAgent, 910, 914, "OAMs", "", +16341, BMI, 937, 952, "body mass index", "", +36598, Kg_per_squareMeter, 971, 983, "kg / m ( 2 )", "", +16343, HbA1c, 988, 993, "HbA1c", "", +16344, Percentage, 1009, 1010, "%", "", +36599, Lispro, 1027, 1031, "ILPS", "", +16347, Frequency, 1045, 1064, "once or twice daily", "", +16348, InsulinGlargine, 1070, 1078, "glargine", "", +16349, Frequency, 1088, 1098, "once daily", "", +16350, OralAntidiabeticAgent, 1113, 1117, "OAMs", "", +16351, HbA1c, 1151, 1156, "HbA1c", "", +16352, HbA1c, 1190, 1195, "HbA1c", "", +16353, Reduction, 1260, 1266, "1 . 46", "", +16355, Percentage, 1267, 1268, "%", "", +36600, Lispro, 1271, 1275, "ILPS", "", +16354, Reduction, 1284, 1290, "1 . 41", "", +16356, Percentage, 1291, 1292, "%", "", +16358, InsulinGlargine, 1295, 1303, "glargine", "", +19529, ConfIntervalDiff, 1344, 1351, "95 % CI", "", +19526, HbA1c, 1358, 1363, "HbA1c", "", +19527, DiffGroupAbsValue, 1366, 1374, "- 0 . 05", "", +19528, ConfIntervalDiff, 1377, 1394, "- 0 . 21 , 0 . 11", "", +19532, Percentage, 1397, 1398, "%", "", +19533, EndPointDescription, 1403, 1424, "glycaemic variability", "", +19534, DiffGroupAbsValue, 1427, 1433, "0 . 06", "", +19530, ConfIntervalDiff, 1436, 1453, "- 0 . 06 , 0 . 19", "", +19536, Millimoles_per_litre, 1456, 1464, "mmol / l", "", +19535, BodyWeight, 1471, 1484, "weight change", "", +19537, DiffGroupAbsValue, 1487, 1495, "- 0 . 01", "", +19531, ConfIntervalDiff, 1498, 1515, "- 0 . 61 , 0 . 59", "", +19538, Kg, 1518, 1520, "kg", "", +19539, Percentage, 1567, 1568, "%", "", +19540, Millimoles_per_litre, 1577, 1585, "mmol / l", "", +19541, Kg, 1596, 1598, "kg", "", +19542, HbA1c_target, 1652, 1667, "HbA1c < 7 . 0 %", "", +19543, PercentageAffected, 1673, 1679, "43 . 8", "", +36602, Lispro, 1682, 1686, "ILPS", "", +19544, PercentageAffected, 1691, 1697, "41 . 2", "", +19546, InsulinGlargine, 1700, 1708, "glargine", "", +36609, InsulinDose, 1722, 1734, "insulin dose", "", +19548, ResultMeasuredValue, 1739, 1745, "0 . 39", "", +19549, ResultMeasuredValue, 1751, 1757, "0 . 35", "", +19550, IntUnit_per_Kg, 1758, 1764, "U / kg", "", +19558, PvalueDiff, 1767, 1777, "p = 0 . 02", "", +19552, BodyWeight, 1784, 1790, "weight", "", +19553, Increment, 1800, 1806, "1 . 04", "", +19554, Increment, 1812, 1818, "1 . 07", "", +19555, Kg, 1819, 1821, "kg", "", +36603, Lispro, 1826, 1830, "ILPS", "", +19557, InsulinGlargine, 1836, 1844, "glargine", "", +19559, PvalueDiff, 1847, 1857, "p = 0 . 98", "", +19560, Hypoglycemia, 1870, 1883, "hypoglycaemia", "", +19561, BioAndMedicalUnit, 1886, 1911, "episodes / patient / year", "", +36604, Lispro, 1930, 1934, "ILPS", "", +19563, InsulinGlargine, 1939, 1947, "glargine", "", +19564, ResultMeasuredValue, 1950, 1956, "24 . 2", "", +19566, SdDevResValue, 1959, 1965, "28 . 8", "", +19565, ResultMeasuredValue, 1971, 1977, "23 . 0", "", +19567, SdDevResValue, 1980, 1986, "30 . 9", "", +19568, NocturnalHypoglycemia, 1991, 2000, "nocturnal", "", +19569, ResultMeasuredValue, 2003, 2008, "6 . 1", "", +19571, SdDevResValue, 2011, 2017, "10 . 6", "", +19570, ResultMeasuredValue, 2023, 2028, "4 . 1", "", +19572, SdDevResValue, 2031, 2036, "9 . 4", "", +19573, PvalueDiff, 2039, 2050, "p < 0 . 001", "", +36605, Lispro, 2075, 2079, "ILPS", "", +19575, SevereHypoglycemia, 2082, 2102, "Severe hypoglycaemia", "", +36607, Lispro, 2118, 2122, "ILPS", "", +19577, InsulinGlargine, 2128, 2136, "glargine", "", +19578, NumberAffected, 2143, 2144, "9", "", +19579, NumberAffected, 2154, 2155, "2", "", +19580, PvalueDiff, 2158, 2168, "p = 0 . 04", "", +36610, ConclusionComment, 2187, 2322, "At endpoint , ILPS was non - inferior to glargine in HbA1c change from baseline , but associated with increased risk of hypoglycaemia .", "", +36611, TimePoint, 2190, 2198, "endpoint", "", +36608, Lispro, 2201, 2205, "ILPS", "", +19582, InsulinGlargine, 2228, 2236, "glargine", "", +19583, HbA1c, 2240, 2245, "HbA1c", "", +19584, Hypoglycemia, 2307, 2320, "hypoglycaemia", "", +19586, PMID, 2414, 2422, "20920045", "", diff --git a/data/dm2 20920045_kwoodley.n-triples b/data/dm2 20920045_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 20920045_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21114605_admin.annodb b/data/dm2 21114605_admin.annodb new file mode 100644 index 0000000..d27d06a --- /dev/null +++ b/data/dm2 21114605_admin.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2011", "", " \"2011\"." +21, Title, 109, 272, "Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "", " \"Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .\"." +2, Linagliptin, 132, 143, "linagliptin", "", +3, Metformin, 167, 176, "metformin", "", +4, Type2Diabetes, 194, 209, "type 2 diabetes", "", " ." +5, Randomized, 214, 224, "randomized", "", " ." +6, DoubleBlind, 227, 241, "double - blind", "", +93, Placebo, 244, 251, "placebo", "", +7, Author, 273, 284, "Taskinen MR", "", " \"Taskinen MR\"." +8, Author, 293, 305, "Rosenstock J", "", " \"Rosenstock J\"." +9, Author, 308, 318, "Tamminen I", "", " \"Tamminen I\"." +10, Author, 321, 329, "Kubiak R", "", " \"Kubiak R\"." +11, Author, 332, 339, "Patel S", "", " \"Patel S\"." +12, Author, 342, 349, "Dugi KA", "", " \"Dugi KA\"." +13, Author, 352, 361, "Woerle HJ", "", " \"Woerle HJ\"." +14, Finland, 455, 462, "Finland", "", " ." +22, ObjectiveDescription, 572, 809, "To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control .", "", " \"To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control .\"." +15, Linagliptin, 683, 694, "linagliptin", "", +16, Metformin, 731, 740, "metformin", "", +18, Precondition, 744, 807, "patients with type 2 diabetes with inadequate glycaemic control", "", +17, Type2Diabetes, 758, 773, "type 2 diabetes", "", +19, Duration, 825, 834, "24 - week", "", " \"24 - week\"." +20, Randomized, 837, 847, "randomized", "", +94, Placebo, 850, 857, "placebo", "", +23, DoubleBlind, 873, 887, "double - blind", "", +24, Parallel, 890, 906, "parallel - group", "", " ." +95, Multicenter, 932, 958, "82 centres in 10 countries", "", " ." +28, Precondition, 961, 1076, "Patients with HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication", "", " \"Patients with HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication\"." +25, HbA1c, 975, 980, "HbA1c", "", +26, Percentage, 1006, 1007, "%", "", +27, Metformin, 1011, 1020, "metformin", "", +29, Metformin, 1130, 1139, "metformin", "", +30, DoseValue, 1140, 1146, "≥ 1500", "", +31, mg, 1147, 1149, "mg", "", +58037, Interval, 1152, 1155, "day", "", +132, Duration, 1160, 1167, "6 weeks", "", +33, Placebo, 1182, 1189, "placebo", "", +135, Duration, 1209, 1216, "2 weeks", "", +34, Randomized, 1232, 1242, "randomized", "", +35, Linagliptin, 1246, 1257, "linagliptin", "", " ." +36, DoseValue, 1258, 1259, "5", "", " \"5\"." +37, mg, 1260, 1262, "mg", "", +38, Frequency, 1263, 1273, "once daily", "", +39, NumberPatientsArm, 1280, 1283, "524", "", " \"524\"." +40, Placebo, 1289, 1296, "placebo", "", " ." +41, NumberPatientsArm, 1303, 1306, "177", "", " \"177\"." +96, TimePoint, 1360, 1368, "baseline", "", +42, HbA1c, 1372, 1377, "HbA1c", "", +43, Duration, 1384, 1392, "24 weeks", "", +44, MeasurementDevice, 1426, 1448, "analysis of covariance", "", +45, MeasurementDevice, 1451, 1457, "ANCOVA", "", +146, Mean, 1472, 1476, "Mean", "", " . . . ." +147, TimePoint, 1477, 1485, "baseline", "", +46, HbA1c, 1486, 1491, "HbA1c", "", " ." +47, FastingPlasmaGlucose, 1496, 1518, "fasting plasma glucose", "", " ." +48, FastingPlasmaGlucose, 1521, 1524, "FPG", "", +49, BaseLineValue, 1532, 1537, "8 . 1", "", " \"8 . 1\". \"8 . 1\"." +51, Percentage, 1538, 1539, "%", "", " ." +50, BaseLineValue, 1544, 1549, "9 . 4", "", " \"9 . 4\". \"9 . 4\"." +52, Millimoles_per_litre, 1550, 1558, "mmol / l", "", " ." +53, Linagliptin, 1576, 1587, "Linagliptin", "", " ." +54, Placebo, 1623, 1630, "placebo", "", +157, Mean, 1643, 1647, "mean", "", +158, TimePoint, 1661, 1669, "baseline", "", +55, HbA1c, 1673, 1678, "HbA1c", "", +56, Reduction, 1683, 1689, "0 . 49", "", " \"0 . 49\"." +58043, Increment, 1695, 1701, "0 . 15", "", " \"0 . 15\"." +62, Percentage, 1702, 1703, "%", "", +63, FastingPlasmaGlucose, 1708, 1711, "FPG", "", +58, Reduction, 1716, 1722, "0 . 59", "", " \"0 . 59\"." +58044, Increment, 1728, 1734, "0 . 58", "", " \"0 . 58\"." +64, Millimoles_per_litre, 1735, 1743, "mmol / l", "", +161, PostprandialPlasmaGlucose, 1750, 1755, "2hPPG", "", " ." +60, Reduction, 1760, 1765, "2 . 7", "", +58045, Increment, 1771, 1776, "1 . 0", "", " \"1 . 0\"." +66, Millimoles_per_litre, 1777, 1785, "mmol / l", "", " ." +67, PvalueDiff, 1794, 1806, "p < 0 . 0001", "", " \"p < 0 . 0001\". \"p < 0 . 0001\". \"p < 0 . 0001\"." +68, Hypoglycemia, 1809, 1822, "Hypoglycaemia", "", " ." +69, NumberAffected, 1847, 1852, "three", "", " \"three\"." +70, PercentageAffected, 1864, 1869, "0 . 6", "", " \"0 . 6\"." +71, Linagliptin, 1887, 1898, "linagliptin", "", +72, NumberAffected, 1903, 1907, "five", "", +73, PercentageAffected, 1919, 1924, "2 . 8", "", " \"2 . 8\"." +74, Placebo, 1936, 1943, "placebo", "", +75, BodyWeight, 1952, 1963, "Body weight", "", " ." +97, TimePoint, 1998, 2006, "baseline", "", +76, Reduction, 2026, 2031, "0 . 5", "", " \"0 . 5\"." +78, Kg, 2032, 2034, "kg", "", " ." +80, Placebo, 2035, 2042, "placebo", "", +77, Reduction, 2047, 2052, "0 . 4", "", " \"0 . 4\"." +79, Kg, 2053, 2055, "kg", "", +81, Linagliptin, 2056, 2067, "linagliptin", "", +92, ConclusionComment, 2086, 2341, "The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia .", "", " \"The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia .\"." +82, Linagliptin, 2102, 2113, "linagliptin", "", +83, DoseValue, 2114, 2115, "5", "", +84, mg, 2116, 2118, "mg", "", +85, Frequency, 2119, 2129, "once daily", "", +88, Precondition, 2133, 2199, "patients with type 2 diabetes inadequately controlled on metformin", "", " \"patients with type 2 diabetes inadequately controlled on metformin\"." +86, Type2Diabetes, 2147, 2162, "type 2 diabetes", "", +87, Metformin, 2190, 2199, "metformin", "", +58041, BodyWeight, 2293, 2299, "weight", "", +90, Hypoglycemia, 2326, 2339, "hypoglycaemia", "", +91, PMID, 2436, 2444, "21114605", "", " \"21114605\"." diff --git a/data/dm2 21114605_admin.n-triples b/data/dm2 21114605_admin.n-triples new file mode 100644 index 0000000..674cd93 --- /dev/null +++ b/data/dm2 21114605_admin.n-triples @@ -0,0 +1,178 @@ +# RDF export of group: Publication + . + "Publication 28713" . + "Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study ." . + "Taskinen MR" . + "2011" . + "Diabetes Obes Metab ." . + "21114605" . + . + "Rosenstock J" . + "Tamminen I" . + "Kubiak R" . + "Patel S" . + "Dugi KA" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 28720" . + "To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control ." . + "24 - week" . + . + . + . + "The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 28736" . + . + . + . + "Patients with HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication" . + "patients with type 2 diabetes inadequately controlled on metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + "524" . + . + . + . + . + . + . + . + "pla" . + "177" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba lin" . + . + "8 . 1" . + "0 . 49" . + . + "hba pla" . + . + "8 . 1" . + "0 . 15" . + . + "fpg lin" . + . + "9 . 4" . + "0 . 59" . + . + "fpg pla" . + . + "9 . 4" . + "0 . 58" . + . + "ppg lin" . + . + . + "ppg pla" . + . + "1 . 0" . + . + "hyp lin" . + . + "three" . + "0 . 6" . + . + "hyp pla" . + . + "2 . 8" . + . + "bw lin" . + . + "0 . 4" . + . + "bw pla" . + . + "0 . 5" . +# RDF export of group: DiffBetweenGroups + . + "fba" . + "p < 0 . 0001" . + . + . + . + "fpg" . + "p < 0 . 0001" . + . + . + . + "ppg" . + "p < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21114605_akramersunderbrink.annodb b/data/dm2 21114605_akramersunderbrink.annodb new file mode 100644 index 0000000..6206ddf --- /dev/null +++ b/data/dm2 21114605_akramersunderbrink.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +39338, Journal, 0, 19, "Diabetes Obes Metab", "", " \"Diabetes Obes Metab\"." +39339, PublicationYear, 22, 26, "2011", "", " \"2011\"." +39340, Title, 109, 272, "Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "", " \"Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .\"." +39341, Linagliptin, 132, 143, "linagliptin", "", +39342, Metformin, 167, 176, "metformin", "", +39343, Type2Diabetes, 194, 209, "type 2 diabetes", "", " ." +39344, Randomized, 214, 224, "randomized", "", +39345, DoubleBlind, 227, 241, "double - blind", "", +39346, Placebo, 244, 251, "placebo", "", +39347, Author, 273, 284, "Taskinen MR", "", " \"Taskinen MR\"." +39348, Author, 293, 305, "Rosenstock J", "", " \"Rosenstock J\"." +39349, Author, 308, 318, "Tamminen I", "", " \"Tamminen I\"." +39350, Author, 321, 329, "Kubiak R", "", " \"Kubiak R\"." +39351, Author, 332, 339, "Patel S", "", " \"Patel S\"." +39352, Author, 342, 349, "Dugi KA", "", " \"Dugi KA\"." +39353, Author, 352, 361, "Woerle HJ", "", " \"Woerle HJ\"." +39354, Finland, 455, 462, "Finland", "", +39359, ObjectiveDescription, 572, 809, "To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control .", "", " \"To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control .\"." +39355, Linagliptin, 683, 694, "linagliptin", "", +39356, Metformin, 731, 740, "metformin", "", +39357, Type2Diabetes, 758, 773, "type 2 diabetes", "", +39358, Precondition, 779, 807, "inadequate glycaemic control", "", " \"inadequate glycaemic control\"." +39360, Duration, 825, 834, "24 - week", "", " \"24 - week\"." +39361, Randomized, 837, 847, "randomized", "", " ." +39362, Placebo, 850, 857, "placebo", "", +39363, DoubleBlind, 873, 887, "double - blind", "", " ." +39364, Parallel, 890, 906, "parallel - group", "", " ." +39365, Multicenter, 932, 958, "82 centres in 10 countries", "", " ." +39366, HbA1c, 975, 980, "HbA1c", "", +39369, Precondition, 975, 1076, "HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication", "", " \"HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication\"." +39367, Percentage, 1006, 1007, "%", "", +39368, Metformin, 1011, 1020, "metformin", "", +39370, Metformin, 1130, 1139, "metformin", "", " ." +39374, DoseValue, 1140, 1155, "≥ 1500 mg / day", "", " \"≥ 1500 mg / day\"." +39372, BioAndMedicalUnit, 1147, 1155, "mg / day", "", +39373, Duration, 1160, 1167, "6 weeks", "", +39375, Placebo, 1182, 1189, "placebo", "", +39376, Duration, 1209, 1216, "2 weeks", "", +39377, Linagliptin, 1246, 1257, "linagliptin", "", " ." +39378, DoseValue, 1258, 1262, "5 mg", "", " \"5 mg\"." +39379, mg, 1260, 1262, "mg", "", +39380, Frequency, 1263, 1273, "once daily", "", " \"once daily\"." +39381, NumberPatientsArm, 1280, 1283, "524", "", " \"524\"." +39383, Placebo, 1289, 1296, "placebo", "", " ." +39382, NumberPatientsArm, 1303, 1306, "177", "", " \"177\"." +39384, TimePoint, 1360, 1368, "baseline", "", +39386, HbA1c, 1372, 1377, "HbA1c", "", +39387, Duration, 1384, 1392, "24 weeks", "", +39388, Mean, 1472, 1476, "Mean", "", " . ." +39389, TimePoint, 1477, 1485, "baseline", "", +39390, HbA1c, 1486, 1491, "HbA1c", "", " ." +39391, FastingBloodGlucose, 1496, 1518, "fasting plasma glucose", "", " ." +39392, FastingBloodGlucose, 1521, 1524, "FPG", "", +39393, BaseLineValue, 1532, 1537, "8 . 1", "", " \"8 . 1\". \"8 . 1\"." +39395, Percentage, 1538, 1539, "%", "", " ." +39394, BaseLineValue, 1544, 1549, "9 . 4", "", " \"9 . 4\". \"9 . 4\"." +39396, Millimoles_per_litre, 1550, 1558, "mmol / l", "", " ." +39397, Linagliptin, 1576, 1587, "Linagliptin", "", +39398, Placebo, 1623, 1630, "placebo", "", +39399, Mean, 1643, 1647, "mean", "", +39400, TimePoint, 1661, 1669, "baseline", "", +39401, HbA1c, 1673, 1678, "HbA1c", "", +39405, ChangeValue, 1681, 1689, "- 0 . 49", "", " \"- 0 . 49\"." +39406, ChangeValue, 1695, 1701, "0 . 15", "", " \"0 . 15\"." +39411, Percentage, 1702, 1703, "%", "", +39402, FastingPlasmaGlucose, 1708, 1711, "FPG", "", +39407, ChangeValue, 1714, 1722, "- 0 . 59", "", " \"- 0 . 59\"." +39408, ChangeValue, 1728, 1734, "0 . 58", "", " \"0 . 58\"." +39412, Millimoles_per_litre, 1735, 1743, "mmol / l", "", +39403, PostprandialPlasmaGlucose, 1750, 1755, "2hPPG", "", " ." +39409, ChangeValue, 1758, 1765, "- 2 . 7", "", " \"- 2 . 7\"." +39410, ChangeValue, 1771, 1776, "1 . 0", "", " \"1 . 0\"." +39413, Millimoles_per_litre, 1777, 1785, "mmol / l", "", " ." +39404, PvalueDiff, 1794, 1806, "p < 0 . 0001", "", " \"p < 0 . 0001\". \"p < 0 . 0001\". \"p < 0 . 0001\"." +39414, Hypoglycemia, 1809, 1822, "Hypoglycaemia", "", " ." +39415, NumberAffected, 1847, 1852, "three", "", " \"three\"." +39417, PercentageAffected, 1864, 1869, "0 . 6", "", " \"0 . 6\"." +39419, Percentage, 1870, 1871, "%", "", +39421, Linagliptin, 1887, 1898, "linagliptin", "", +39416, NumberAffected, 1903, 1907, "five", "", " \"five\"." +39418, PercentageAffected, 1919, 1924, "2 . 8", "", " \"2 . 8\"." +39420, Percentage, 1925, 1926, "%", "", +39422, Placebo, 1936, 1943, "placebo", "", +39423, BodyWeight, 1952, 1963, "Body weight", "", " ." +39424, TimePoint, 1998, 2006, "baseline", "", +39425, ChangeValue, 2024, 2031, "- 0 . 5", "", " \"- 0 . 5\"." +39427, Kg, 2032, 2034, "kg", "", " ." +39429, Placebo, 2035, 2042, "placebo", "", +39426, ChangeValue, 2045, 2052, "- 0 . 4", "", " \"- 0 . 4\"." +39428, Kg, 2053, 2055, "kg", "", +39430, Linagliptin, 2056, 2067, "linagliptin", "", +39440, ConclusionComment, 2086, 2341, "The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia .", "", " \"The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia .\"." +39431, Linagliptin, 2102, 2113, "linagliptin", "", +39432, DoseValue, 2114, 2118, "5 mg", "", +39433, mg, 2116, 2118, "mg", "", +39434, Frequency, 2119, 2129, "once daily", "", +39435, Type2Diabetes, 2147, 2162, "type 2 diabetes", "", +39436, Precondition, 2163, 2199, "inadequately controlled on metformin", "", " \"inadequately controlled on metformin\"." +39437, Metformin, 2190, 2199, "metformin", "", +39438, WeightGain, 2293, 2304, "weight gain", "", +39439, Hypoglycemia, 2326, 2339, "hypoglycaemia", "", +39441, PMID, 2436, 2444, "21114605", "", " \"21114605\"." diff --git a/data/dm2 21114605_akramersunderbrink.n-triples b/data/dm2 21114605_akramersunderbrink.n-triples new file mode 100644 index 0000000..c2388c5 --- /dev/null +++ b/data/dm2 21114605_akramersunderbrink.n-triples @@ -0,0 +1,193 @@ +# RDF export of group: Publication + . + "Publication 21282" . + "Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study ." . + "Taskinen MR" . + "2011" . + "Diabetes Obes Metab" . + "21114605" . + . + "Rosenstock J" . + "Tamminen I" . + "Kubiak R" . + "Patel S" . + "Dugi KA" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 21289" . + "To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control ." . + "24 - week" . + . + . + . + "The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 21305" . + "inadequate glycaemic control" . + . + . + . + "HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication" . + "inadequately controlled on metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "wei" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + "524" . + . + . + . + . + . + . + . + . + "pla" . + "177" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + "once daily" . + . + . + "pla" . + . + . + . + "met" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5 mg" . + . + . + . + "pla" . + . + . + . + . + "met" . + . + "≥ 1500 mg / day" . + . + . +# RDF export of group: Outcome + . + "hba lin" . + . + "8 . 1" . + "- 0 . 49" . + . + "hba pla" . + . + "8 . 1" . + "0 . 15" . + . + "fpg lin" . + . + "9 . 4" . + "- 0 . 59" . + . + "fpg pla" . + . + "9 . 4" . + "0 . 58" . + . + "ppg lin" . + . + "- 2 . 7" . + . + "ppg pla" . + . + "1 . 0" . + . + "hyp lin" . + . + "three" . + "0 . 6" . + . + "hyp pla" . + . + "five" . + "2 . 8" . + . + "wei lin" . + . + "- 0 . 5" . + . + "wei pla" . + . + "- 0 . 4" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "p < 0 . 0001" . + . + . + . + "fpg" . + "p < 0 . 0001" . + . + . + . + "ppg" . + "p < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21114605_export.csv b/data/dm2 21114605_export.csv new file mode 100644 index 0000000..98e135d --- /dev/null +++ b/data/dm2 21114605_export.csv @@ -0,0 +1,534 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +327, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +327, 1, 2, 2, 9, 13, 9, 13, "Obes" +327, 1, 3, 3, 14, 19, 14, 19, "Metab" +327, 1, 4, 4, 20, 21, 20, 21, "." +327, 2, 1, 5, 0, 4, 22, 26, "2011" +327, 2, 2, 6, 5, 8, 27, 30, "Jan" +327, 2, 3, 7, 9, 10, 31, 32, ";" +327, 2, 4, 8, 11, 13, 33, 35, "13" +327, 2, 5, 9, 14, 15, 36, 37, "(" +327, 2, 6, 10, 16, 17, 38, 39, "1" +327, 2, 7, 11, 18, 19, 40, 41, ")" +327, 2, 8, 12, 20, 21, 42, 43, ":" +327, 2, 9, 13, 22, 24, 44, 46, "65" +327, 2, 10, 14, 25, 26, 47, 48, "-" +327, 2, 11, 15, 27, 29, 49, 51, "74" +327, 2, 12, 16, 30, 31, 52, 53, "." +327, 2, 13, 17, 32, 35, 54, 57, "doi" +327, 2, 14, 18, 36, 37, 58, 59, ":" +327, 2, 15, 19, 38, 40, 60, 62, "10" +327, 2, 16, 20, 41, 42, 63, 64, "." +327, 2, 17, 21, 43, 47, 65, 69, "1111" +327, 2, 18, 22, 48, 49, 70, 71, "/" +327, 2, 19, 23, 50, 51, 72, 73, "j" +327, 2, 20, 24, 52, 53, 74, 75, "." +327, 2, 21, 25, 54, 58, 76, 80, "1463" +327, 2, 22, 26, 59, 60, 81, 82, "-" +327, 2, 23, 27, 61, 65, 83, 87, "1326" +327, 2, 24, 28, 66, 67, 88, 89, "." +327, 2, 25, 29, 68, 72, 90, 94, "2010" +327, 2, 26, 30, 73, 74, 95, 96, "." +327, 2, 27, 31, 75, 80, 97, 102, "01326" +327, 2, 28, 32, 81, 82, 103, 104, "." +327, 2, 29, 33, 83, 84, 105, 106, "x" +327, 2, 30, 34, 85, 86, 107, 108, "." +327, 3, 1, 35, 0, 6, 109, 115, "Safety" +327, 3, 2, 36, 7, 10, 116, 119, "and" +327, 3, 3, 37, 11, 19, 120, 128, "efficacy" +327, 3, 4, 38, 20, 22, 129, 131, "of" +327, 3, 5, 39, 23, 34, 132, 143, "linagliptin" +327, 3, 6, 40, 35, 37, 144, 146, "as" +327, 3, 7, 41, 38, 41, 147, 150, "add" +327, 3, 8, 42, 42, 43, 151, 152, "-" +327, 3, 9, 43, 44, 46, 153, 155, "on" +327, 3, 10, 44, 47, 54, 156, 163, "therapy" +327, 3, 11, 45, 55, 57, 164, 166, "to" +327, 3, 12, 46, 58, 67, 167, 176, "metformin" +327, 3, 13, 47, 68, 70, 177, 179, "in" +327, 3, 14, 48, 71, 79, 180, 188, "patients" +327, 3, 15, 49, 80, 84, 189, 193, "with" +327, 3, 16, 50, 85, 89, 194, 198, "type" +327, 3, 17, 51, 90, 91, 199, 200, "2" +327, 3, 18, 52, 92, 100, 201, 209, "diabetes" +327, 3, 19, 53, 101, 102, 210, 211, ":" +327, 3, 20, 54, 103, 104, 212, 213, "a" +327, 3, 21, 55, 105, 115, 214, 224, "randomized" +327, 3, 22, 56, 116, 117, 225, 226, "," +327, 3, 23, 57, 118, 124, 227, 233, "double" +327, 3, 24, 58, 125, 126, 234, 235, "-" +327, 3, 25, 59, 127, 132, 236, 241, "blind" +327, 3, 26, 60, 133, 134, 242, 243, "," +327, 3, 27, 61, 135, 142, 244, 251, "placebo" +327, 3, 28, 62, 143, 144, 252, 253, "-" +327, 3, 29, 63, 145, 155, 254, 264, "controlled" +327, 3, 30, 64, 156, 161, 265, 270, "study" +327, 3, 31, 65, 162, 163, 271, 272, "." +327, 4, 1, 66, 0, 8, 273, 281, "Taskinen" +327, 4, 2, 67, 9, 11, 282, 284, "MR" +327, 4, 3, 68, 12, 13, 285, 286, "(" +327, 4, 4, 69, 14, 15, 287, 288, "1" +327, 4, 5, 70, 16, 17, 289, 290, ")" +327, 4, 6, 71, 18, 19, 291, 292, "," +327, 4, 7, 72, 20, 30, 293, 303, "Rosenstock" +327, 4, 8, 73, 31, 32, 304, 305, "J" +327, 4, 9, 74, 33, 34, 306, 307, "," +327, 4, 10, 75, 35, 43, 308, 316, "Tamminen" +327, 4, 11, 76, 44, 45, 317, 318, "I" +327, 4, 12, 77, 46, 47, 319, 320, "," +327, 4, 13, 78, 48, 54, 321, 327, "Kubiak" +327, 4, 14, 79, 55, 56, 328, 329, "R" +327, 4, 15, 80, 57, 58, 330, 331, "," +327, 4, 16, 81, 59, 64, 332, 337, "Patel" +327, 4, 17, 82, 65, 66, 338, 339, "S" +327, 4, 18, 83, 67, 68, 340, 341, "," +327, 4, 19, 84, 69, 73, 342, 346, "Dugi" +327, 4, 20, 85, 74, 76, 347, 349, "KA" +327, 4, 21, 86, 77, 78, 350, 351, "," +327, 4, 22, 87, 79, 85, 352, 358, "Woerle" +327, 4, 23, 88, 86, 88, 359, 361, "HJ" +327, 4, 24, 89, 89, 90, 362, 363, "." +327, 5, 1, 90, 0, 6, 364, 370, "Author" +327, 5, 2, 91, 7, 18, 371, 382, "information" +327, 5, 3, 92, 19, 20, 383, 384, ":" +327, 5, 4, 93, 21, 22, 385, 386, "(" +327, 5, 5, 94, 23, 24, 387, 388, "1" +327, 5, 6, 95, 25, 26, 389, 390, ")" +327, 5, 7, 96, 27, 37, 391, 401, "Department" +327, 5, 8, 97, 38, 40, 402, 404, "of" +327, 5, 9, 98, 41, 49, 405, 413, "Medicine" +327, 5, 10, 99, 50, 51, 414, 415, "," +327, 5, 11, 100, 52, 60, 416, 424, "Helsinki" +327, 5, 12, 101, 61, 71, 425, 435, "University" +327, 5, 13, 102, 72, 79, 436, 443, "Central" +327, 5, 14, 103, 80, 88, 444, 452, "Hospital" +327, 5, 15, 104, 89, 90, 453, 454, "," +327, 5, 16, 105, 91, 98, 455, 462, "Finland" +327, 5, 17, 106, 99, 100, 463, 464, "." +327, 6, 1, 107, 0, 5, 465, 470, "marja" +327, 6, 2, 108, 6, 7, 471, 472, "-" +327, 6, 3, 109, 8, 14, 473, 479, "riitta" +327, 6, 4, 110, 15, 16, 480, 481, "." +327, 6, 5, 111, 17, 25, 482, 490, "taskinen" +327, 6, 6, 112, 26, 27, 491, 492, "@" +327, 6, 7, 113, 28, 36, 493, 501, "helsinki" +327, 6, 8, 114, 37, 38, 502, 503, "." +327, 6, 9, 115, 39, 41, 504, 506, "fi" +327, 6, 10, 116, 42, 49, 507, 514, "Comment" +327, 6, 11, 117, 50, 52, 515, 517, "in" +327, 6, 12, 118, 53, 61, 518, 526, "Postgrad" +327, 6, 13, 119, 62, 65, 527, 530, "Med" +327, 6, 14, 120, 66, 67, 531, 532, "." +327, 7, 1, 121, 0, 4, 533, 537, "2011" +327, 7, 2, 122, 5, 8, 538, 541, "Jul" +327, 7, 3, 123, 9, 10, 542, 543, ";" +327, 7, 4, 124, 11, 14, 544, 547, "123" +327, 7, 5, 125, 15, 16, 548, 549, "(" +327, 7, 6, 126, 17, 18, 550, 551, "4" +327, 7, 7, 127, 19, 20, 552, 553, ")" +327, 7, 8, 128, 21, 22, 554, 555, ":" +327, 7, 9, 129, 23, 26, 556, 559, "183" +327, 7, 10, 130, 27, 28, 560, 561, "-" +327, 7, 11, 131, 29, 30, 562, 563, "6" +327, 7, 12, 132, 31, 32, 564, 565, "." +327, 8, 1, 133, 0, 3, 566, 569, "AIM" +327, 8, 2, 134, 4, 5, 570, 571, ":" +327, 8, 3, 135, 6, 8, 572, 574, "To" +327, 8, 4, 136, 9, 17, 575, 583, "evaluate" +327, 8, 5, 137, 18, 21, 584, 587, "the" +327, 8, 6, 138, 22, 30, 588, 596, "efficacy" +327, 8, 7, 139, 31, 34, 597, 600, "and" +327, 8, 8, 140, 35, 41, 601, 607, "safety" +327, 8, 9, 141, 42, 44, 608, 610, "of" +327, 8, 10, 142, 45, 48, 611, 614, "the" +327, 8, 11, 143, 49, 55, 615, 621, "potent" +327, 8, 12, 144, 56, 59, 622, 625, "and" +327, 8, 13, 145, 60, 69, 626, 635, "selective" +327, 8, 14, 146, 70, 80, 636, 646, "dipeptidyl" +327, 8, 15, 147, 81, 90, 647, 656, "peptidase" +327, 8, 16, 148, 91, 92, 657, 658, "-" +327, 8, 17, 149, 93, 94, 659, 660, "4" +327, 8, 18, 150, 95, 96, 661, 662, "(" +327, 8, 19, 151, 97, 100, 663, 666, "DPP" +327, 8, 20, 152, 101, 102, 667, 668, "-" +327, 8, 21, 153, 103, 104, 669, 670, "4" +327, 8, 22, 154, 105, 106, 671, 672, ")" +327, 8, 23, 155, 107, 116, 673, 682, "inhibitor" +327, 8, 24, 156, 117, 128, 683, 694, "linagliptin" +327, 8, 25, 157, 129, 141, 695, 707, "administered" +327, 8, 26, 158, 142, 144, 708, 710, "as" +327, 8, 27, 159, 145, 148, 711, 714, "add" +327, 8, 28, 160, 149, 150, 715, 716, "-" +327, 8, 29, 161, 151, 153, 717, 719, "on" +327, 8, 30, 162, 154, 161, 720, 727, "therapy" +327, 8, 31, 163, 162, 164, 728, 730, "to" +327, 8, 32, 164, 165, 174, 731, 740, "metformin" +327, 8, 33, 165, 175, 177, 741, 743, "in" +327, 8, 34, 166, 178, 186, 744, 752, "patients" +327, 8, 35, 167, 187, 191, 753, 757, "with" +327, 8, 36, 168, 192, 196, 758, 762, "type" +327, 8, 37, 169, 197, 198, 763, 764, "2" +327, 8, 38, 170, 199, 207, 765, 773, "diabetes" +327, 8, 39, 171, 208, 212, 774, 778, "with" +327, 8, 40, 172, 213, 223, 779, 789, "inadequate" +327, 8, 41, 173, 224, 233, 790, 799, "glycaemic" +327, 8, 42, 174, 234, 241, 800, 807, "control" +327, 8, 43, 175, 242, 243, 808, 809, "." +327, 9, 1, 176, 0, 7, 810, 817, "METHODS" +327, 9, 2, 177, 8, 9, 818, 819, ":" +327, 9, 3, 178, 10, 14, 820, 824, "This" +327, 9, 4, 179, 15, 17, 825, 827, "24" +327, 9, 5, 180, 18, 19, 828, 829, "-" +327, 9, 6, 181, 20, 24, 830, 834, "week" +327, 9, 7, 182, 25, 26, 835, 836, "," +327, 9, 8, 183, 27, 37, 837, 847, "randomized" +327, 9, 9, 184, 38, 39, 848, 849, "," +327, 9, 10, 185, 40, 47, 850, 857, "placebo" +327, 9, 11, 186, 48, 49, 858, 859, "-" +327, 9, 12, 187, 50, 60, 860, 870, "controlled" +327, 9, 13, 188, 61, 62, 871, 872, "," +327, 9, 14, 189, 63, 69, 873, 879, "double" +327, 9, 15, 190, 70, 71, 880, 881, "-" +327, 9, 16, 191, 72, 77, 882, 887, "blind" +327, 9, 17, 192, 78, 79, 888, 889, "," +327, 9, 18, 193, 80, 88, 890, 898, "parallel" +327, 9, 19, 194, 89, 90, 899, 900, "-" +327, 9, 20, 195, 91, 96, 901, 906, "group" +327, 9, 21, 196, 97, 102, 907, 912, "study" +327, 9, 22, 197, 103, 106, 913, 916, "was" +327, 9, 23, 198, 107, 114, 917, 924, "carried" +327, 9, 24, 199, 115, 118, 925, 928, "out" +327, 9, 25, 200, 119, 121, 929, 931, "in" +327, 9, 26, 201, 122, 124, 932, 934, "82" +327, 9, 27, 202, 125, 132, 935, 942, "centres" +327, 9, 28, 203, 133, 135, 943, 945, "in" +327, 9, 29, 204, 136, 138, 946, 948, "10" +327, 9, 30, 205, 139, 148, 949, 958, "countries" +327, 9, 31, 206, 149, 150, 959, 960, "." +327, 10, 1, 207, 0, 8, 961, 969, "Patients" +327, 10, 2, 208, 9, 13, 970, 974, "with" +327, 10, 3, 209, 14, 19, 975, 980, "HbA1c" +327, 10, 4, 210, 20, 26, 981, 987, "levels" +327, 10, 5, 211, 27, 29, 988, 990, "of" +327, 10, 6, 212, 30, 31, 991, 992, "7" +327, 10, 7, 213, 32, 33, 993, 994, "." +327, 10, 8, 214, 34, 35, 995, 996, "0" +327, 10, 9, 215, 36, 37, 997, 998, "-" +327, 10, 10, 216, 38, 40, 999, 1001, "10" +327, 10, 11, 217, 41, 42, 1002, 1003, "." +327, 10, 12, 218, 43, 44, 1004, 1005, "0" +327, 10, 13, 219, 45, 46, 1006, 1007, "%" +327, 10, 14, 220, 47, 49, 1008, 1010, "on" +327, 10, 15, 221, 50, 59, 1011, 1020, "metformin" +327, 10, 16, 222, 60, 63, 1021, 1024, "and" +327, 10, 17, 223, 64, 65, 1025, 1026, "a" +327, 10, 18, 224, 66, 73, 1027, 1034, "maximum" +327, 10, 19, 225, 74, 76, 1035, 1037, "of" +327, 10, 20, 226, 77, 80, 1038, 1041, "one" +327, 10, 21, 227, 81, 91, 1042, 1052, "additional" +327, 10, 22, 228, 92, 104, 1053, 1065, "antidiabetes" +327, 10, 23, 229, 105, 115, 1066, 1076, "medication" +327, 10, 24, 230, 116, 117, 1077, 1078, "," +327, 10, 25, 231, 118, 123, 1079, 1084, "which" +327, 10, 26, 232, 124, 127, 1085, 1088, "was" +327, 10, 27, 233, 128, 140, 1089, 1101, "discontinued" +327, 10, 28, 234, 141, 143, 1102, 1104, "at" +327, 10, 29, 235, 144, 153, 1105, 1114, "screening" +327, 10, 30, 236, 154, 155, 1115, 1116, "," +327, 10, 31, 237, 156, 165, 1117, 1126, "continued" +327, 10, 32, 238, 166, 168, 1127, 1129, "on" +327, 10, 33, 239, 169, 178, 1130, 1139, "metformin" +327, 10, 34, 240, 179, 180, 1140, 1141, "≥" +327, 10, 35, 241, 181, 185, 1142, 1146, "1500" +327, 10, 36, 242, 186, 188, 1147, 1149, "mg" +327, 10, 37, 243, 189, 190, 1150, 1151, "/" +327, 10, 38, 244, 191, 194, 1152, 1155, "day" +327, 10, 39, 245, 195, 198, 1156, 1159, "for" +327, 10, 40, 246, 199, 200, 1160, 1161, "6" +327, 10, 41, 247, 201, 206, 1162, 1167, "weeks" +327, 10, 42, 248, 207, 208, 1168, 1169, "," +327, 10, 43, 249, 209, 218, 1170, 1179, "including" +327, 10, 44, 250, 219, 220, 1180, 1181, "a" +327, 10, 45, 251, 221, 228, 1182, 1189, "placebo" +327, 10, 46, 252, 229, 232, 1190, 1193, "run" +327, 10, 47, 253, 233, 234, 1194, 1195, "-" +327, 10, 48, 254, 235, 237, 1196, 1198, "in" +327, 10, 49, 255, 238, 244, 1199, 1205, "period" +327, 10, 50, 256, 245, 247, 1206, 1208, "of" +327, 10, 51, 257, 248, 249, 1209, 1210, "2" +327, 10, 52, 258, 250, 255, 1211, 1216, "weeks" +327, 10, 53, 259, 256, 257, 1217, 1218, "," +327, 10, 54, 260, 258, 264, 1219, 1225, "before" +327, 10, 55, 261, 265, 270, 1226, 1231, "being" +327, 10, 56, 262, 271, 281, 1232, 1242, "randomized" +327, 10, 57, 263, 282, 284, 1243, 1245, "to" +327, 10, 58, 264, 285, 296, 1246, 1257, "linagliptin" +327, 10, 59, 265, 297, 298, 1258, 1259, "5" +327, 10, 60, 266, 299, 301, 1260, 1262, "mg" +327, 10, 61, 267, 302, 306, 1263, 1267, "once" +327, 10, 62, 268, 307, 312, 1268, 1273, "daily" +327, 10, 63, 269, 313, 314, 1274, 1275, "(" +327, 10, 64, 270, 315, 316, 1276, 1277, "n" +327, 10, 65, 271, 317, 318, 1278, 1279, "=" +327, 10, 66, 272, 319, 322, 1280, 1283, "524" +327, 10, 67, 273, 323, 324, 1284, 1285, ")" +327, 10, 68, 274, 325, 327, 1286, 1288, "or" +327, 10, 69, 275, 328, 335, 1289, 1296, "placebo" +327, 10, 70, 276, 336, 337, 1297, 1298, "(" +327, 10, 71, 277, 338, 339, 1299, 1300, "n" +327, 10, 72, 278, 340, 341, 1301, 1302, "=" +327, 10, 73, 279, 342, 345, 1303, 1306, "177" +327, 10, 74, 280, 346, 347, 1307, 1308, ")" +327, 10, 75, 281, 348, 351, 1309, 1312, "add" +327, 10, 76, 282, 352, 353, 1313, 1314, "-" +327, 10, 77, 283, 354, 356, 1315, 1317, "on" +327, 10, 78, 284, 357, 358, 1318, 1319, "." +327, 11, 1, 285, 0, 3, 1320, 1323, "The" +327, 11, 2, 286, 4, 11, 1324, 1331, "primary" +327, 11, 3, 287, 12, 19, 1332, 1339, "outcome" +327, 11, 4, 288, 20, 23, 1340, 1343, "was" +327, 11, 5, 289, 24, 27, 1344, 1347, "the" +327, 11, 6, 290, 28, 34, 1348, 1354, "change" +327, 11, 7, 291, 35, 39, 1355, 1359, "from" +327, 11, 8, 292, 40, 48, 1360, 1368, "baseline" +327, 11, 9, 293, 49, 51, 1369, 1371, "in" +327, 11, 10, 294, 52, 57, 1372, 1377, "HbA1c" +327, 11, 11, 295, 58, 63, 1378, 1383, "after" +327, 11, 12, 296, 64, 66, 1384, 1386, "24" +327, 11, 13, 297, 67, 72, 1387, 1392, "weeks" +327, 11, 14, 298, 73, 75, 1393, 1395, "of" +327, 11, 15, 299, 76, 85, 1396, 1405, "treatment" +327, 11, 16, 300, 86, 87, 1406, 1407, "," +327, 11, 17, 301, 88, 97, 1408, 1417, "evaluated" +327, 11, 18, 302, 98, 102, 1418, 1422, "with" +327, 11, 19, 303, 103, 105, 1423, 1425, "an" +327, 11, 20, 304, 106, 114, 1426, 1434, "analysis" +327, 11, 21, 305, 115, 117, 1435, 1437, "of" +327, 11, 22, 306, 118, 128, 1438, 1448, "covariance" +327, 11, 23, 307, 129, 130, 1449, 1450, "(" +327, 11, 24, 308, 131, 137, 1451, 1457, "ANCOVA" +327, 11, 25, 309, 138, 139, 1458, 1459, ")" +327, 11, 26, 310, 140, 141, 1460, 1461, "." +327, 12, 1, 311, 0, 7, 1462, 1469, "RESULTS" +327, 12, 2, 312, 8, 9, 1470, 1471, ":" +327, 12, 3, 313, 10, 14, 1472, 1476, "Mean" +327, 12, 4, 314, 15, 23, 1477, 1485, "baseline" +327, 12, 5, 315, 24, 29, 1486, 1491, "HbA1c" +327, 12, 6, 316, 30, 33, 1492, 1495, "and" +327, 12, 7, 317, 34, 41, 1496, 1503, "fasting" +327, 12, 8, 318, 42, 48, 1504, 1510, "plasma" +327, 12, 9, 319, 49, 56, 1511, 1518, "glucose" +327, 12, 10, 320, 57, 58, 1519, 1520, "(" +327, 12, 11, 321, 59, 62, 1521, 1524, "FPG" +327, 12, 12, 322, 63, 64, 1525, 1526, ")" +327, 12, 13, 323, 65, 69, 1527, 1531, "were" +327, 12, 14, 324, 70, 71, 1532, 1533, "8" +327, 12, 15, 325, 72, 73, 1534, 1535, "." +327, 12, 16, 326, 74, 75, 1536, 1537, "1" +327, 12, 17, 327, 76, 77, 1538, 1539, "%" +327, 12, 18, 328, 78, 81, 1540, 1543, "and" +327, 12, 19, 329, 82, 83, 1544, 1545, "9" +327, 12, 20, 330, 84, 85, 1546, 1547, "." +327, 12, 21, 331, 86, 87, 1548, 1549, "4" +327, 12, 22, 332, 88, 92, 1550, 1554, "mmol" +327, 12, 23, 333, 93, 94, 1555, 1556, "/" +327, 12, 24, 334, 95, 96, 1557, 1558, "l" +327, 12, 25, 335, 97, 98, 1559, 1560, "," +327, 12, 26, 336, 99, 111, 1561, 1573, "respectively" +327, 12, 27, 337, 112, 113, 1574, 1575, "." +327, 13, 1, 338, 0, 11, 1576, 1587, "Linagliptin" +327, 13, 2, 339, 12, 18, 1588, 1594, "showed" +327, 13, 3, 340, 19, 30, 1595, 1606, "significant" +327, 13, 4, 341, 31, 41, 1607, 1617, "reductions" +327, 13, 5, 342, 42, 44, 1618, 1620, "vs" +327, 13, 6, 343, 45, 46, 1621, 1622, "." +327, 13, 7, 344, 47, 54, 1623, 1630, "placebo" +327, 13, 8, 345, 55, 57, 1631, 1633, "in" +327, 13, 9, 346, 58, 66, 1634, 1642, "adjusted" +327, 13, 10, 347, 67, 71, 1643, 1647, "mean" +327, 13, 11, 348, 72, 79, 1648, 1655, "changes" +327, 13, 12, 349, 80, 84, 1656, 1660, "from" +327, 13, 13, 350, 85, 93, 1661, 1669, "baseline" +327, 13, 14, 351, 94, 96, 1670, 1672, "of" +327, 13, 15, 352, 97, 102, 1673, 1678, "HbA1c" +327, 13, 16, 353, 103, 104, 1679, 1680, "(" +327, 13, 17, 354, 105, 106, 1681, 1682, "-" +327, 13, 18, 355, 107, 108, 1683, 1684, "0" +327, 13, 19, 356, 109, 110, 1685, 1686, "." +327, 13, 20, 357, 111, 113, 1687, 1689, "49" +327, 13, 21, 358, 114, 116, 1690, 1692, "vs" +327, 13, 22, 359, 117, 118, 1693, 1694, "." +327, 13, 23, 360, 119, 120, 1695, 1696, "0" +327, 13, 24, 361, 121, 122, 1697, 1698, "." +327, 13, 25, 362, 123, 125, 1699, 1701, "15" +327, 13, 26, 363, 126, 127, 1702, 1703, "%" +327, 13, 27, 364, 128, 129, 1704, 1705, ")" +327, 13, 28, 365, 130, 131, 1706, 1707, "," +327, 13, 29, 366, 132, 135, 1708, 1711, "FPG" +327, 13, 30, 367, 136, 137, 1712, 1713, "(" +327, 13, 31, 368, 138, 139, 1714, 1715, "-" +327, 13, 32, 369, 140, 141, 1716, 1717, "0" +327, 13, 33, 370, 142, 143, 1718, 1719, "." +327, 13, 34, 371, 144, 146, 1720, 1722, "59" +327, 13, 35, 372, 147, 149, 1723, 1725, "vs" +327, 13, 36, 373, 150, 151, 1726, 1727, "." +327, 13, 37, 374, 152, 153, 1728, 1729, "0" +327, 13, 38, 375, 154, 155, 1730, 1731, "." +327, 13, 39, 376, 156, 158, 1732, 1734, "58" +327, 13, 40, 377, 159, 163, 1735, 1739, "mmol" +327, 13, 41, 378, 164, 165, 1740, 1741, "/" +327, 13, 42, 379, 166, 167, 1742, 1743, "l" +327, 13, 43, 380, 168, 169, 1744, 1745, ")" +327, 13, 44, 381, 170, 173, 1746, 1749, "and" +327, 13, 45, 382, 174, 179, 1750, 1755, "2hPPG" +327, 13, 46, 383, 180, 181, 1756, 1757, "(" +327, 13, 47, 384, 182, 183, 1758, 1759, "-" +327, 13, 48, 385, 184, 185, 1760, 1761, "2" +327, 13, 49, 386, 186, 187, 1762, 1763, "." +327, 13, 50, 387, 188, 189, 1764, 1765, "7" +327, 13, 51, 388, 190, 192, 1766, 1768, "vs" +327, 13, 52, 389, 193, 194, 1769, 1770, "." +327, 13, 53, 390, 195, 196, 1771, 1772, "1" +327, 13, 54, 391, 197, 198, 1773, 1774, "." +327, 13, 55, 392, 199, 200, 1775, 1776, "0" +327, 13, 56, 393, 201, 205, 1777, 1781, "mmol" +327, 13, 57, 394, 206, 207, 1782, 1783, "/" +327, 13, 58, 395, 208, 209, 1784, 1785, "l" +327, 13, 59, 396, 210, 211, 1786, 1787, ")" +327, 13, 60, 397, 212, 213, 1788, 1789, ";" +327, 13, 61, 398, 214, 217, 1790, 1793, "all" +327, 13, 62, 399, 218, 219, 1794, 1795, "p" +327, 13, 63, 400, 220, 221, 1796, 1797, "<" +327, 13, 64, 401, 222, 223, 1798, 1799, "0" +327, 13, 65, 402, 224, 225, 1800, 1801, "." +327, 13, 66, 403, 226, 230, 1802, 1806, "0001" +327, 13, 67, 404, 231, 232, 1807, 1808, "." +327, 14, 1, 405, 0, 13, 1809, 1822, "Hypoglycaemia" +327, 14, 2, 406, 14, 17, 1823, 1826, "was" +327, 14, 3, 407, 18, 22, 1827, 1831, "rare" +327, 14, 4, 408, 23, 24, 1832, 1833, "," +327, 14, 5, 409, 25, 34, 1834, 1843, "occurring" +327, 14, 6, 410, 35, 37, 1844, 1846, "in" +327, 14, 7, 411, 38, 43, 1847, 1852, "three" +327, 14, 8, 412, 44, 52, 1853, 1861, "patients" +327, 14, 9, 413, 53, 54, 1862, 1863, "(" +327, 14, 10, 414, 55, 56, 1864, 1865, "0" +327, 14, 11, 415, 57, 58, 1866, 1867, "." +327, 14, 12, 416, 59, 60, 1868, 1869, "6" +327, 14, 13, 417, 61, 62, 1870, 1871, "%" +327, 14, 14, 418, 63, 64, 1872, 1873, ")" +327, 14, 15, 419, 65, 72, 1874, 1881, "treated" +327, 14, 16, 420, 73, 77, 1882, 1886, "with" +327, 14, 17, 421, 78, 89, 1887, 1898, "linagliptin" +327, 14, 18, 422, 90, 93, 1899, 1902, "and" +327, 14, 19, 423, 94, 98, 1903, 1907, "five" +327, 14, 20, 424, 99, 107, 1908, 1916, "patients" +327, 14, 21, 425, 108, 109, 1917, 1918, "(" +327, 14, 22, 426, 110, 111, 1919, 1920, "2" +327, 14, 23, 427, 112, 113, 1921, 1922, "." +327, 14, 24, 428, 114, 115, 1923, 1924, "8" +327, 14, 25, 429, 116, 117, 1925, 1926, "%" +327, 14, 26, 430, 118, 119, 1927, 1928, ")" +327, 14, 27, 431, 120, 122, 1929, 1931, "in" +327, 14, 28, 432, 123, 126, 1932, 1935, "the" +327, 14, 29, 433, 127, 134, 1936, 1943, "placebo" +327, 14, 30, 434, 135, 140, 1944, 1949, "group" +327, 14, 31, 435, 141, 142, 1950, 1951, "." +327, 15, 1, 436, 0, 4, 1952, 1956, "Body" +327, 15, 2, 437, 5, 11, 1957, 1963, "weight" +327, 15, 3, 438, 12, 15, 1964, 1967, "did" +327, 15, 4, 439, 16, 19, 1968, 1971, "not" +327, 15, 5, 440, 20, 26, 1972, 1978, "change" +327, 15, 6, 441, 27, 40, 1979, 1992, "significantly" +327, 15, 7, 442, 41, 45, 1993, 1997, "from" +327, 15, 8, 443, 46, 54, 1998, 2006, "baseline" +327, 15, 9, 444, 55, 57, 2007, 2009, "in" +327, 15, 10, 445, 58, 62, 2010, 2014, "both" +327, 15, 11, 446, 63, 69, 2015, 2021, "groups" +327, 15, 12, 447, 70, 71, 2022, 2023, "(" +327, 15, 13, 448, 72, 73, 2024, 2025, "-" +327, 15, 14, 449, 74, 75, 2026, 2027, "0" +327, 15, 15, 450, 76, 77, 2028, 2029, "." +327, 15, 16, 451, 78, 79, 2030, 2031, "5" +327, 15, 17, 452, 80, 82, 2032, 2034, "kg" +327, 15, 18, 453, 83, 90, 2035, 2042, "placebo" +327, 15, 19, 454, 91, 92, 2043, 2044, "," +327, 15, 20, 455, 93, 94, 2045, 2046, "-" +327, 15, 21, 456, 95, 96, 2047, 2048, "0" +327, 15, 22, 457, 97, 98, 2049, 2050, "." +327, 15, 23, 458, 99, 100, 2051, 2052, "4" +327, 15, 24, 459, 101, 103, 2053, 2055, "kg" +327, 15, 25, 460, 104, 115, 2056, 2067, "linagliptin" +327, 15, 26, 461, 116, 117, 2068, 2069, ")" +327, 15, 27, 462, 118, 119, 2070, 2071, "." +327, 16, 1, 463, 0, 11, 2072, 2083, "CONCLUSIONS" +327, 16, 2, 464, 12, 13, 2084, 2085, ":" +327, 16, 3, 465, 14, 17, 2086, 2089, "The" +327, 16, 4, 466, 18, 26, 2090, 2098, "addition" +327, 16, 5, 467, 27, 29, 2099, 2101, "of" +327, 16, 6, 468, 30, 41, 2102, 2113, "linagliptin" +327, 16, 7, 469, 42, 43, 2114, 2115, "5" +327, 16, 8, 470, 44, 46, 2116, 2118, "mg" +327, 16, 9, 471, 47, 51, 2119, 2123, "once" +327, 16, 10, 472, 52, 57, 2124, 2129, "daily" +327, 16, 11, 473, 58, 60, 2130, 2132, "in" +327, 16, 12, 474, 61, 69, 2133, 2141, "patients" +327, 16, 13, 475, 70, 74, 2142, 2146, "with" +327, 16, 14, 476, 75, 79, 2147, 2151, "type" +327, 16, 15, 477, 80, 81, 2152, 2153, "2" +327, 16, 16, 478, 82, 90, 2154, 2162, "diabetes" +327, 16, 17, 479, 91, 103, 2163, 2175, "inadequately" +327, 16, 18, 480, 104, 114, 2176, 2186, "controlled" +327, 16, 19, 481, 115, 117, 2187, 2189, "on" +327, 16, 20, 482, 118, 127, 2190, 2199, "metformin" +327, 16, 21, 483, 128, 136, 2200, 2208, "resulted" +327, 16, 22, 484, 137, 139, 2209, 2211, "in" +327, 16, 23, 485, 140, 141, 2212, 2213, "a" +327, 16, 24, 486, 142, 153, 2214, 2225, "significant" +327, 16, 25, 487, 154, 157, 2226, 2229, "and" +327, 16, 26, 488, 158, 168, 2230, 2240, "clinically" +327, 16, 27, 489, 169, 179, 2241, 2251, "meaningful" +327, 16, 28, 490, 180, 191, 2252, 2263, "improvement" +327, 16, 29, 491, 192, 194, 2264, 2266, "in" +327, 16, 30, 492, 195, 204, 2267, 2276, "glycaemic" +327, 16, 31, 493, 205, 212, 2277, 2284, "control" +327, 16, 32, 494, 213, 220, 2285, 2292, "without" +327, 16, 33, 495, 221, 227, 2293, 2299, "weight" +327, 16, 34, 496, 228, 232, 2300, 2304, "gain" +327, 16, 35, 497, 233, 235, 2305, 2307, "or" +327, 16, 36, 498, 236, 245, 2308, 2317, "increased" +327, 16, 37, 499, 246, 250, 2318, 2322, "risk" +327, 16, 38, 500, 251, 253, 2323, 2325, "of" +327, 16, 39, 501, 254, 267, 2326, 2339, "hypoglycaemia" +327, 16, 40, 502, 268, 269, 2340, 2341, "." +327, 17, 1, 503, 0, 1, 2342, 2343, "©" +327, 17, 2, 504, 2, 6, 2344, 2348, "2010" +327, 17, 3, 505, 7, 16, 2349, 2358, "Blackwell" +327, 17, 4, 506, 17, 27, 2359, 2369, "Publishing" +327, 17, 5, 507, 28, 31, 2370, 2373, "Ltd" +327, 17, 6, 508, 32, 33, 2374, 2375, "." +327, 17, 7, 509, 34, 37, 2376, 2379, "DOI" +327, 17, 8, 510, 38, 39, 2380, 2381, ":" +327, 17, 9, 511, 40, 42, 2382, 2384, "10" +327, 17, 10, 512, 43, 44, 2385, 2386, "." +327, 17, 11, 513, 45, 49, 2387, 2391, "1111" +327, 17, 12, 514, 50, 51, 2392, 2393, "/" +327, 17, 13, 515, 52, 53, 2394, 2395, "j" +327, 17, 14, 516, 54, 55, 2396, 2397, "." +327, 17, 15, 517, 56, 60, 2398, 2402, "1463" +327, 17, 16, 518, 61, 62, 2403, 2404, "-" +327, 17, 17, 519, 63, 67, 2405, 2409, "1326" +327, 17, 18, 520, 68, 69, 2410, 2411, "." +327, 17, 19, 521, 70, 74, 2412, 2416, "2010" +327, 17, 20, 522, 75, 76, 2417, 2418, "." +327, 17, 21, 523, 77, 82, 2419, 2424, "01326" +327, 17, 22, 524, 83, 84, 2425, 2426, "." +327, 17, 23, 525, 85, 86, 2427, 2428, "x" +327, 17, 24, 526, 87, 91, 2429, 2433, "PMID" +327, 17, 25, 527, 92, 93, 2434, 2435, ":" +327, 17, 26, 528, 94, 102, 2436, 2444, "21114605" +327, 17, 27, 529, 103, 104, 2445, 2446, "[" +327, 17, 28, 530, 105, 112, 2447, 2454, "Indexed" +327, 17, 29, 531, 113, 116, 2455, 2458, "for" +327, 17, 30, 532, 117, 124, 2459, 2466, "MEDLINE" +327, 17, 31, 533, 125, 126, 2467, 2468, "]" diff --git a/data/dm2 21114605_kwoodley.annodb b/data/dm2 21114605_kwoodley.annodb new file mode 100644 index 0000000..ce29dc3 --- /dev/null +++ b/data/dm2 21114605_kwoodley.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +19587, Journal, 0, 19, "Diabetes Obes Metab", "", +19588, PublicationYear, 22, 26, "2011", "", +19611, Title, 109, 272, "Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "", +19589, Linagliptin, 132, 143, "linagliptin", "", +19590, Metformin, 167, 176, "metformin", "", +19591, Type2Diabetes, 194, 209, "type 2 diabetes", "", +19592, Randomized, 214, 224, "randomized", "", +19593, DoubleBlind, 227, 241, "double - blind", "", +24744, Placebo, 244, 251, "placebo", "", +19596, Author, 273, 284, "Taskinen MR", "", +19597, Author, 293, 305, "Rosenstock J", "", +19598, Author, 308, 318, "Tamminen I", "", +19599, Author, 321, 329, "Kubiak R", "", +19600, Author, 332, 339, "Patel S", "", +19601, Author, 342, 349, "Dugi KA", "", +19602, Author, 352, 361, "Woerle HJ", "", +19603, Finland, 455, 462, "Finland", "", +19614, ObjectiveDescription, 572, 809, "To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor linagliptin administered as add - on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control .", "", +19604, Linagliptin, 683, 694, "linagliptin", "", +19605, Metformin, 731, 740, "metformin", "", +19607, Precondition, 744, 807, "patients with type 2 diabetes with inadequate glycaemic control", "", +19606, Type2Diabetes, 758, 773, "type 2 diabetes", "", +19609, Duration, 825, 834, "24 - week", "", +19610, Randomized, 837, 847, "randomized", "", +24745, Placebo, 850, 857, "placebo", "", +19616, DoubleBlind, 873, 887, "double - blind", "", +19617, Parallel, 890, 906, "parallel - group", "", +36591, Multicenter, 932, 958, "82 centres in 10 countries", "", +19621, Precondition, 961, 1076, "Patients with HbA1c levels of 7 . 0 - 10 . 0 % on metformin and a maximum of one additional antidiabetes medication", "", +19618, HbA1c, 975, 980, "HbA1c", "", +19619, Percentage, 1006, 1007, "%", "", +19620, Metformin, 1011, 1020, "metformin", "", +19622, Metformin, 1130, 1139, "metformin", "", +19623, DoseValue, 1140, 1146, "≥ 1500", "", +19624, mg, 1147, 1149, "mg", "", +19625, Frequency, 1152, 1155, "day", "", +19626, Placebo, 1182, 1189, "placebo", "", +19627, Randomized, 1232, 1242, "randomized", "", +19628, Linagliptin, 1246, 1257, "linagliptin", "", +19629, DoseValue, 1258, 1259, "5", "", +19630, mg, 1260, 1262, "mg", "", +19631, Frequency, 1263, 1273, "once daily", "", +19632, NumberPatientsArm, 1280, 1283, "524", "", +19633, Placebo, 1289, 1296, "placebo", "", +19634, NumberPatientsArm, 1303, 1306, "177", "", +36592, TimePoint, 1360, 1368, "baseline", "", +19635, HbA1c, 1372, 1377, "HbA1c", "", +19636, Duration, 1384, 1392, "24 weeks", "", +19637, MeasurementDevice, 1426, 1448, "analysis of covariance", "", +19638, MeasurementDevice, 1451, 1457, "ANCOVA", "", +19639, HbA1c, 1486, 1491, "HbA1c", "", +19640, FastingPlasmaGlucose, 1496, 1518, "fasting plasma glucose", "", +19641, FastingPlasmaGlucose, 1521, 1524, "FPG", "", +19642, BaseLineValue, 1532, 1537, "8 . 1", "", +19644, Percentage, 1538, 1539, "%", "", +19643, BaseLineValue, 1544, 1549, "9 . 4", "", +19645, Millimoles_per_litre, 1550, 1558, "mmol / l", "", +19646, Linagliptin, 1576, 1587, "Linagliptin", "", +19647, Placebo, 1623, 1630, "placebo", "", +19648, HbA1c, 1673, 1678, "HbA1c", "", +19649, Reduction, 1683, 1689, "0 . 49", "", +19650, Reduction, 1695, 1701, "0 . 15", "", +19655, Percentage, 1702, 1703, "%", "", +19656, FastingPlasmaGlucose, 1708, 1711, "FPG", "", +19651, Reduction, 1716, 1722, "0 . 59", "", +19652, Reduction, 1728, 1734, "0 . 58", "", +19657, Millimoles_per_litre, 1735, 1743, "mmol / l", "", +19658, InsulinDose, 1750, 1755, "2hPPG", "", +19653, Reduction, 1760, 1765, "2 . 7", "", +19654, Reduction, 1771, 1776, "1 . 0", "", +19659, Millimoles_per_litre, 1777, 1785, "mmol / l", "", +19660, PvalueDiff, 1794, 1806, "p < 0 . 0001", "for all three endpoints ", +19661, Hypoglycemia, 1809, 1822, "Hypoglycaemia", "", +19662, NumberAffected, 1847, 1852, "three", "", +19663, PercentageAffected, 1864, 1869, "0 . 6", "", +19664, Linagliptin, 1887, 1898, "linagliptin", "", +19665, NumberAffected, 1903, 1907, "five", "", +19666, PercentageAffected, 1919, 1924, "2 . 8", "", +19667, Placebo, 1936, 1943, "placebo", "", +19668, BodyWeight, 1952, 1963, "Body weight", "", +36593, TimePoint, 1998, 2006, "baseline", "", +19669, Reduction, 2026, 2031, "0 . 5", "", +19671, Kg, 2032, 2034, "kg", "", +19673, Placebo, 2035, 2042, "placebo", "", +19670, Reduction, 2047, 2052, "0 . 4", "", +19672, Kg, 2053, 2055, "kg", "", +19674, Linagliptin, 2056, 2067, "linagliptin", "", +19685, ConclusionComment, 2086, 2341, "The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia .", "", +19675, Linagliptin, 2102, 2113, "linagliptin", "", +19676, DoseValue, 2114, 2115, "5", "", +19677, mg, 2116, 2118, "mg", "", +19678, Frequency, 2119, 2129, "once daily", "", +19681, Precondition, 2133, 2199, "patients with type 2 diabetes inadequately controlled on metformin", "", +19679, Type2Diabetes, 2147, 2162, "type 2 diabetes", "", +19680, Metformin, 2190, 2199, "metformin", "", +19682, BodyWeight, 2293, 2299, "weight", "", +19683, Hypoglycemia, 2326, 2339, "hypoglycaemia", "", +19684, PMID, 2436, 2444, "21114605", "", diff --git a/data/dm2 21114605_kwoodley.n-triples b/data/dm2 21114605_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21114605_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21138825_admin.annodb b/data/dm2 21138825_admin.annodb new file mode 100644 index 0000000..63a04f9 --- /dev/null +++ b/data/dm2 21138825_admin.annodb @@ -0,0 +1,149 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Ann Intern Med .", "", " \"Ann Intern Med .\"." +1, PublicationYear, 17, 21, "2011", "", " \"2011\"." +8, Title, 134, 257, "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .", "", " \"Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .\"." +2, Frequency, 141, 154, "twice - daily", "", +3, Exenatide, 155, 164, "exenatide", "", +7, Precondition, 168, 221, "Basal insulin - treated patients with type 2 diabetes", "", " \"Basal insulin - treated patients with type 2 diabetes\"." +4, Insulin, 174, 181, "insulin", "", +5, Type2Diabetes, 206, 221, "type 2 diabetes", "", " ." +6, Randomized, 226, 236, "randomized", "", " ." +9, Author, 258, 265, "Buse JB", "", " \"Buse JB\"." +10, Author, 274, 287, "Bergenstal RM", "", " \"Bergenstal RM\"." +11, Author, 290, 298, "Glass LC", "", " \"Glass LC\"." +12, Author, 301, 312, "Heilmann CR", "", " \"Heilmann CR\"." +13, Author, 315, 323, "Lewis MS", "", " \"Lewis MS\"." +14, Author, 326, 333, "Kwan AY", "", " \"Kwan AY\"." +15, Author, 336, 347, "Hoogwerf BJ", "", " \"Hoogwerf BJ\"." +16, Author, 350, 362, "Rosenstock J", "", " \"Rosenstock J\"." +17, USA, 464, 467, "USA", "", +18, Insulin, 623, 630, "Insulin", "", +19, HbA1c, 701, 721, "hemoglobin A ₁ ( c )", "", +20, HbA1c, 724, 735, "HbA ₁ ( c )", "", +27, ObjectiveDescription, 760, 893, "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .", "", " \"To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .\"." +21, Frequency, 776, 789, "twice - daily", "", " \"twice - daily\"." +25, Exenatide, 790, 799, "exenatide", "", +58316, DeliveryMethod, 800, 810, "injections", "", +22, HbA1c, 818, 829, "HbA ₁ ( c )", "", +23, Placebo, 847, 854, "placebo", "", +26, Precondition, 858, 891, "people receiving insulin glargine", "", " \"people receiving insulin glargine\"." +24, InsulinGlargine, 875, 891, "insulin glargine", "", +28, Parallel, 903, 911, "Parallel", "", " ." +29, Randomized, 914, 924, "randomized", "", +134, Placebo, 927, 934, "placebo", "", +30, HbA1c, 982, 993, "HbA ₁ ( c )", "", +31, Duration, 1020, 1053, "from October 2008 to January 2010", "", +58326, DoubleBlind, 1127, 1133, "masked", "", " ." +135, Multicenter, 1230, 1255, "59 centers in 5 countries", "", " ." +39, Precondition, 1269, 1454, "Adults with type 2 diabetes and an HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 % who were receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )", "", " \"Adults with type 2 diabetes and an HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 % who were receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )\"." +32, Type2Diabetes, 1281, 1296, "type 2 diabetes", "", +33, HbA1c, 1304, 1315, "HbA ₁ ( c )", "", +34, Percentage, 1331, 1332, "%", "", +35, Percentage, 1343, 1344, "%", "", +36, InsulinGlargine, 1364, 1380, "insulin glargine", "", +37, Metformin, 1410, 1419, "metformin", "", +38, Pioglitazone, 1423, 1435, "pioglitazone", "", +178, Randomized, 1525, 1531, "random", "", +40, Exenatide, 1582, 1591, "exenatide", "", +41, DoseValue, 1594, 1596, "10", "", " \"10\"." +42, Microgram, 1597, 1600, "µ g", "", " ." +43, Frequency, 1601, 1612, "twice daily", "", " \"twice daily\"." +44, Placebo, 1618, 1625, "placebo", "", +45, Duration, 1630, 1638, "30 weeks", "", " \"30 weeks\"." +46, HbA1c, 1690, 1701, "HbA ₁ ( c )", "", +186, HbA1c_target, 1774, 1785, "HbA ₁ ( c )", "", +58327, EndPointDescription, 1861, 1877, "glucose profiles", "", +49, BodyWeight, 1880, 1891, "body weight", "", +50, EndPointDescription, 1894, 1913, "waist circumference", "", +136, InsulinDose, 1916, 1928, "insulin dose", "", +51, Hypoglycemia, 1931, 1943, "hypoglycemia", "", +52, EndPointDescription, 1950, 1964, "adverse events", "", +54, FinalNumPatientsArm, 1977, 1980, "112", "", +53, NumberPatientsArm, 1984, 1987, "138", "", " \"138\"." +55, Exenatide, 1988, 1997, "exenatide", "", +56, FinalNumPatientsArm, 2013, 2016, "101", "", " \"101\"." +57, NumberPatientsArm, 2020, 2023, "123", "", " \"123\"." +58, Placebo, 2024, 2031, "placebo", "", +59, HbA1c, 2069, 2080, "HbA ₁ ( c )", "", " ." +60, Reduction, 2100, 2106, "1 . 74", "", +62, Percentage, 2107, 2108, "%", "", " ." +64, Exenatide, 2114, 2123, "exenatide", "", " ." +61, Reduction, 2128, 2134, "1 . 04", "", " \"1 . 04\"." +63, Percentage, 2135, 2136, "%", "", +65, Placebo, 2142, 2149, "placebo", "", +66, DiffGroupAbsValue, 2181, 2189, "- 0 . 69", "", " \"- 0 . 69\"." +67, Percentage, 2190, 2191, "%", "", +70, ConfIntervalDiff, 2194, 2228, "95 % CI , - 0 . 93 % to - 0 . 46 %", "", " \"95 % CI , - 0 . 93 % to - 0 . 46 %\"." +68, Percentage, 2213, 2214, "%", "", +69, Percentage, 2227, 2228, "%", "", +71, PvalueDiff, 2233, 2244, "P < 0 . 001", "", +72, BodyWeight, 2249, 2255, "Weight", "", +73, Reduction, 2269, 2274, "1 . 8", "", " \"1 . 8\"." +74, Kg, 2275, 2277, "kg", "", " ." +78, Exenatide, 2283, 2292, "exenatide", "", +77, Increment, 2310, 2315, "1 . 0", "", " \"1 . 0\"." +75, Kg, 2316, 2318, "kg", "", +79, Placebo, 2324, 2331, "placebo", "", +80, DiffGroupAbsValue, 2363, 2370, "- 2 . 7", "", " \"- 2 . 7\"." +76, Kg, 2371, 2373, "kg", "", +81, ConfIntervalDiff, 2376, 2399, "CI , - 3 . 7 to - 1 . 7", "", " \"CI , - 3 . 7 to - 1 . 7\"." +137, InsulinDose, 2427, 2441, "insulin dosage", "", " . ." +82, Exenatide, 2447, 2456, "exenatide", "", +83, Placebo, 2461, 2468, "placebo", "", +84, ResultMeasuredValue, 2474, 2476, "13", "", " \"13\"." +86, BioAndMedicalUnit, 2477, 2482, "U / d", "", " . ." +85, ResultMeasuredValue, 2487, 2489, "20", "", " \"20\"." +87, BioAndMedicalUnit, 2490, 2495, "U / d", "", +89, ObservedResult, 2498, 2567, "The estimated rate of minor hypoglycemia was similar between groups .", "", +88, Hypoglycemia, 2526, 2538, "hypoglycemia", "", +231, NumberAffected, 2568, 2576, "Thirteen", "", " \"Thirteen\"." +58328, NumPatientsLeftArm, 2568, 2576, "Thirteen", "", +92, Exenatide, 2577, 2586, "exenatide", "", +232, NumberAffected, 2602, 2603, "1", "", " \"1\"." +58329, NumPatientsLeftArm, 2602, 2603, "1", "", +93, Placebo, 2604, 2611, "placebo", "", " ." +94, EndPointDescription, 2656, 2670, "adverse events", "", " . ." +101, PvalueDiff, 2673, 2684, "P < 0 . 010", "", " \"P < 0 . 010\"." +95, Nausea, 2698, 2704, "nausea", "", " ." +102, PercentageAffected, 2707, 2709, "41", "", " \"41\"." +103, PercentageAffected, 2717, 2718, "8", "", " \"8\"." +96, EndPointDescription, 2725, 2733, "diarrhea", "", " . ." +104, PercentageAffected, 2736, 2738, "18", "", " \"18\"." +254, Percentage, 2739, 2740, "%", "", +105, PercentageAffected, 2746, 2747, "8", "", " \"8\"." +255, Percentage, 2748, 2749, "%", "", +129, EndPointDescription, 2754, 2762, "vomiting", "", " . ." +106, PercentageAffected, 2765, 2767, "18", "", " \"18\"." +256, Percentage, 2768, 2769, "%", "", +107, PercentageAffected, 2775, 2776, "4", "", " \"4\"." +257, Percentage, 2777, 2778, "%", "", +97, Headache, 2783, 2791, "headache", "", " ." +108, PercentageAffected, 2794, 2796, "14", "", " \"14\"." +258, Percentage, 2797, 2798, "%", "", +109, PercentageAffected, 2804, 2805, "4", "", " \"4\"." +98, Constipation, 2816, 2828, "constipation", "", " ." +110, PercentageAffected, 2831, 2833, "10", "", " \"10\"." +111, PercentageAffected, 2841, 2842, "2", "", " \"2\"." +99, Exenatide, 2864, 2873, "exenatide", "", +100, Placebo, 2884, 2891, "placebo", "", +262, TimePoint, 2989, 2997, "baseline", "", +112, HbA1c, 3072, 3083, "HbA ₁ ( c )", "", +113, Exenatide, 3102, 3111, "exenatide", "", +114, Placebo, 3128, 3135, "placebo", "", +115, EndPointDescription, 3167, 3181, "adverse events", "", +124, ConclusionComment, 3197, 3408, "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .", "", " \"Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .\"." +116, Frequency, 3204, 3217, "twice - daily", "", +117, Exenatide, 3218, 3227, "exenatide", "", +119, Hypoglycemia, 3283, 3295, "hypoglycemia", "", +120, BodyWeight, 3299, 3305, "weight", "", +121, Type2Diabetes, 3345, 3360, "type 2 diabetes", "", +122, InsulinGlargine, 3380, 3396, "insulin glargine", "", +125, EndPointDescription, 3409, 3423, "Adverse events", "", +133, ConclusionComment, 3409, 3506, "Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation .", "", " \"Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation .\"." +118, Exenatide, 3427, 3436, "exenatide", "", +126, Nausea, 3446, 3452, "nausea", "", +127, EndPointDescription, 3455, 3463, "diarrhea", "", +128, EndPointDescription, 3466, 3474, "vomiting", "", +130, Headache, 3477, 3485, "headache", "", +131, Constipation, 3492, 3504, "constipation", "", +132, PMID, 3662, 3670, "21138825", "", " \"21138825\"." diff --git a/data/dm2 21138825_admin.n-triples b/data/dm2 21138825_admin.n-triples new file mode 100644 index 0000000..75189b9 --- /dev/null +++ b/data/dm2 21138825_admin.n-triples @@ -0,0 +1,248 @@ +# RDF export of group: Publication + . + "Publication 29139" . + "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial ." . + "Buse JB" . + "2011" . + "Ann Intern Med ." . + "21138825" . + . + "Bergenstal RM" . + "Glass LC" . + "Heilmann CR" . + "Lewis MS" . + "Kwan AY" . + "Hoogwerf BJ" . + "Rosenstock J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 29146" . + "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine ." . + "30 weeks" . + . + . + . + "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment ." . + . + . + . + . + . + . + . + . + "Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation ." . + . + . + . +# RDF export of group: Population + . + "Population 29162" . + "Basal insulin - treated patients with type 2 diabetes" . + . + . + . + "people receiving insulin glargine" . + "Adults with type 2 diabetes and an HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 % who were receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "adv" . + . + . + . + . + . + . + "nau" . + . + . + . + . + . + "dia" . + . + . + . + . + . + . + "vom" . + . + . + . + . + . + . + "hea" . + . + . + . + . + . + "con" . + . + . + . + . +# RDF export of group: Arm + . + "ex" . + "138" . + . + . + . + . + . + . + . + . + . + . + . + "pl" . + "123" . + "101" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "ex" . + . + "twice daily" . + . + . + "pl" . + . + "twice - daily" . + . +# RDF export of group: Medication + . + "ex" . + . + "10" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba ex" . + . + . + "hba pl" . + . + "1 . 04" . + . + "bw ex" . + . + "1 . 8" . + . + "bw gl" . + . + "1 . 0" . + . + "ins ex" . + . + "13" . + . + "ins pl" . + . + "20" . + . + "adv ex" . + . + "Thirteen" . + . + "adv pl" . + . + "1" . + . + "nau ex" . + . + "41" . + . + "nau pl" . + . + "8" . + . + "dia ex" . + . + "18" . + . + "dia pl" . + . + "8" . + . + "vom ex" . + . + "18" . + . + "vom pla" . + . + "4" . + . + "hea ex" . + . + "14" . + . + "heapl" . + . + "4" . + . + "con ex" . + . + "10" . + . + "con pl" . + . + "2" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 69" . + "95 % CI , - 0 . 93 % to - 0 . 46 %" . + . + . + . + "bw" . + "- 2 . 7" . + "CI , - 3 . 7 to - 1 . 7" . + . + . + . + "adv" . + "P < 0 . 010" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21138825_akramersunderbrink.annodb b/data/dm2 21138825_akramersunderbrink.annodb new file mode 100644 index 0000000..630ffc5 --- /dev/null +++ b/data/dm2 21138825_akramersunderbrink.annodb @@ -0,0 +1,142 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +39442, Journal, 0, 14, "Ann Intern Med", "", " \"Ann Intern Med\"." +39443, PublicationYear, 17, 21, "2011", "", " \"2011\"." +39444, Title, 134, 257, "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .", "", " \"Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .\"." +39445, Frequency, 141, 154, "twice - daily", "", +39446, Exenatide, 155, 164, "exenatide", "", +39447, Insulin, 168, 181, "Basal insulin", "", +39448, Type2Diabetes, 206, 221, "type 2 diabetes", "", " ." +39449, Randomized, 226, 236, "randomized", "", +39450, Author, 258, 265, "Buse JB", "", " \"Buse JB\"." +39451, Author, 274, 287, "Bergenstal RM", "", " \"Bergenstal RM\"." +39452, Author, 290, 298, "Glass LC", "", " \"Glass LC\"." +39453, Author, 301, 312, "Heilmann CR", "", " \"Heilmann CR\"." +39454, Author, 315, 323, "Lewis MS", "", " \"Lewis MS\"." +39455, Author, 326, 333, "Kwan AY", "", " \"Kwan AY\"." +39456, Author, 336, 347, "Hoogwerf BJ", "", " \"Hoogwerf BJ\"." +39457, Author, 350, 362, "Rosenstock J", "", " \"Rosenstock J\"." +39458, USA, 464, 467, "USA", "", +39459, Insulin, 623, 630, "Insulin", "", +39460, HbA1c_target, 701, 745, "hemoglobin A ₁ ( c ) ( HbA ₁ ( c ) ) targets", "", +39462, ObjectiveDescription, 760, 893, "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .", "", " \"To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .\"." +39463, Frequency, 776, 789, "twice - daily", "", +39464, Exenatide, 790, 799, "exenatide", "", +39465, HbA1c, 818, 836, "HbA ₁ ( c ) levels", "", +39466, Placebo, 847, 854, "placebo", "", +39467, InsulinGlargine, 875, 891, "insulin glargine", "", +39468, Parallel, 903, 911, "Parallel", "", " ." +39469, Randomized, 914, 924, "randomized", "", " ." +39470, Placebo, 927, 934, "placebo", "", +39471, HbA1c, 982, 999, "HbA ₁ ( c ) level", "", +39472, DoubleBlind, 1056, 1158, "Participants , investigators , and personnel conducting the study were masked to treatment assignments", "", " ." +39473, Multicenter, 1230, 1255, "59 centers in 5 countries", "", " ." +39474, Type2Diabetes, 1281, 1296, "type 2 diabetes", "", +39475, HbA1c, 1304, 1321, "HbA ₁ ( c ) level", "", +39476, Precondition, 1304, 1344, "HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 %", "", " \"HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 %\"." +39478, Percentage, 1331, 1332, "%", "", +39477, Percentage, 1343, 1344, "%", "", +39482, Precondition, 1354, 1454, "receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )", "", " \"receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )\"." +39479, InsulinGlargine, 1372, 1380, "glargine", "", " ." +39480, Metformin, 1410, 1419, "metformin", "", " ." +39481, Pioglitazone, 1423, 1435, "pioglitazone", "", " ." +39483, Randomized, 1525, 1531, "random", "", +39484, Exenatide, 1582, 1591, "exenatide", "", " ." +39485, DoseValue, 1594, 1600, "10 µ g", "", " \"10 µ g\"." +39486, Microgram, 1597, 1600, "µ g", "", " ." +39487, Frequency, 1601, 1612, "twice daily", "", " \"twice daily\"." +39488, Placebo, 1618, 1625, "placebo", "", " ." +39489, Duration, 1630, 1638, "30 weeks", "", " \"30 weeks\"." +39490, HbA1c, 1690, 1707, "HbA ₁ ( c ) level", "", +39491, HbA1c_target, 1774, 1811, "HbA ₁ ( c ) values of 7 . 0 % or less", "", +39492, HbA1c_target, 1816, 1831, "6 . 5 % or less", "", +39493, BodyWeight, 1880, 1891, "body weight", "", +39494, InsulinDose, 1916, 1928, "insulin dose", "", +39495, Hypoglycemia, 1931, 1943, "hypoglycemia", "", +87547, FinalNumPatientsArm, 1977, 1980, "112", "", " \"112\"." +39496, NumberPatientsArm, 1984, 1987, "138", "", " \"138\"." +39500, Exenatide, 1988, 1997, "exenatide", "", +87548, FinalNumPatientsArm, 2013, 2016, "101", "", " \"101\"." +39499, NumberPatientsArm, 2020, 2023, "123", "", " \"123\"." +39501, Placebo, 2024, 2031, "placebo", "", +39502, HbA1c, 2069, 2086, "HbA ₁ ( c ) level", "", " ." +87549, Reduction, 2100, 2106, "1 . 74", "", " \"1 . 74\"." +39505, Percentage, 2107, 2108, "%", "", " ." +39507, Exenatide, 2114, 2123, "exenatide", "", +87550, Reduction, 2128, 2134, "1 . 04", "", " \"1 . 04\"." +39506, Percentage, 2135, 2136, "%", "", +39508, Placebo, 2142, 2149, "placebo", "", +39509, DiffGroupAbsValue, 2181, 2189, "- 0 . 69", "", " \"- 0 . 69\"." +39510, Percentage, 2190, 2191, "%", "", +39511, ConfIntervalDiff, 2194, 2228, "95 % CI , - 0 . 93 % to - 0 . 46 %", "", " \"95 % CI , - 0 . 93 % to - 0 . 46 %\"." +39512, Percentage, 2197, 2198, "%", "", +39513, Percentage, 2213, 2214, "%", "", +39514, Percentage, 2227, 2228, "%", "", +39515, PvalueDiff, 2233, 2244, "P < 0 . 001", "", " \"P < 0 . 001\"." +39516, BodyWeight, 2249, 2255, "Weight", "", " ." +39518, Reduction, 2269, 2274, "1 . 8", "", " \"1 . 8\"." +39520, Kg, 2275, 2277, "kg", "", " ." +39522, Exenatide, 2283, 2292, "exenatide", "", +39519, Increment, 2310, 2315, "1 . 0", "", " \"1 . 0\"." +39521, Kg, 2316, 2318, "kg", "", +39523, Placebo, 2324, 2331, "placebo", "", +39524, DiffGroupAbsValue, 2363, 2370, "- 2 . 7", "", " \"- 2 . 7\"." +39526, Kg, 2371, 2373, "kg", "", +39527, ConfIntervalDiff, 2376, 2399, "CI , - 3 . 7 to - 1 . 7", "", " \"CI , - 3 . 7 to - 1 . 7\"." +39534, InsulinDose, 2427, 2441, "insulin dosage", "", " . ." +39528, Exenatide, 2447, 2456, "exenatide", "", +39529, Placebo, 2461, 2468, "placebo", "", +87551, Increment, 2474, 2476, "13", "", " \"13\"." +39532, BioAndMedicalUnit, 2477, 2482, "U / d", "", " . ." +87552, Increment, 2487, 2489, "20", "", " \"20\"." +39533, BioAndMedicalUnit, 2490, 2495, "U / d", "", +39535, Hypoglycemia, 2520, 2538, "minor hypoglycemia", "", +39538, NumberAffected, 2568, 2576, "Thirteen", "", " \"Thirteen\"." +39536, Exenatide, 2577, 2586, "exenatide", "", +39539, NumberAffected, 2602, 2603, "1", "", " \"1\"." +39537, Placebo, 2604, 2611, "placebo", "", +39540, EndPointDescription, 2622, 2670, "discontinued the study because of adverse events", "", " . ." +39541, PvalueDiff, 2673, 2684, "P < 0 . 010", "", " \"P < 0 . 010\"." +39542, Nausea, 2698, 2704, "nausea", "", " ." +39549, PercentageAffected, 2707, 2709, "41", "", " \"41\"." +39559, Percentage, 2710, 2711, "%", "", +39550, PercentageAffected, 2717, 2718, "8", "", " \"8\"." +39560, Percentage, 2719, 2720, "%", "", +39543, EndPointDescription, 2725, 2733, "diarrhea", "", " . ." +39551, PercentageAffected, 2736, 2738, "18", "", " \"18\"." +39561, Percentage, 2739, 2740, "%", "", +39552, PercentageAffected, 2746, 2747, "8", "", " \"8\"." +39562, Percentage, 2748, 2749, "%", "", +39544, EndPointDescription, 2754, 2762, "vomiting", "", " . ." +39553, PercentageAffected, 2765, 2767, "18", "", " \"18\"." +39563, Percentage, 2768, 2769, "%", "", +39554, PercentageAffected, 2775, 2776, "4", "", " \"4\"." +39564, Percentage, 2777, 2778, "%", "", +39545, Headache, 2783, 2791, "headache", "", " ." +39555, PercentageAffected, 2794, 2796, "14", "", " \"14\"." +39565, Percentage, 2797, 2798, "%", "", +39556, PercentageAffected, 2804, 2805, "4", "", " \"4\"." +39566, Percentage, 2806, 2807, "%", "", +39546, Constipation, 2816, 2828, "constipation", "", " ." +39557, PercentageAffected, 2831, 2833, "10", "", " \"10\"." +39567, Percentage, 2834, 2835, "%", "", +39558, PercentageAffected, 2841, 2842, "2", "", " \"2\"." +39568, Percentage, 2843, 2844, "%", "", +39547, Exenatide, 2864, 2873, "exenatide", "", +39548, Placebo, 2884, 2891, "placebo", "", +39569, TimePoint, 2989, 2997, "baseline", "", +39570, HbA1c, 3072, 3090, "HbA ₁ ( c ) levels", "", +39571, Exenatide, 3102, 3111, "exenatide", "", +39572, Placebo, 3128, 3135, "placebo", "", +39579, ConclusionComment, 3197, 3408, "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .", "", " \"Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .\"." +39573, Frequency, 3204, 3217, "twice - daily", "", +39574, Exenatide, 3218, 3227, "exenatide", "", +39575, Hypoglycemia, 3283, 3295, "hypoglycemia", "", +39576, WeightGain, 3299, 3310, "weight gain", "", +39577, Type2Diabetes, 3345, 3360, "type 2 diabetes", "", +39578, InsulinGlargine, 3380, 3396, "insulin glargine", "", +39580, ConclusionComment, 3409, 3506, "Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation .", "", +39581, Exenatide, 3427, 3436, "exenatide", "", +39582, Nausea, 3446, 3452, "nausea", "", +39583, Headache, 3477, 3485, "headache", "", +39584, Constipation, 3492, 3504, "constipation", "", +39585, PMID, 3662, 3670, "21138825", "", " \"21138825\"." diff --git a/data/dm2 21138825_akramersunderbrink.n-triples b/data/dm2 21138825_akramersunderbrink.n-triples new file mode 100644 index 0000000..85d81ba --- /dev/null +++ b/data/dm2 21138825_akramersunderbrink.n-triples @@ -0,0 +1,281 @@ +# RDF export of group: Publication + . + "Publication 21732" . + "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial ." . + "Buse JB" . + "2011" . + "Ann Intern Med" . + "21138825" . + . + "Bergenstal RM" . + "Glass LC" . + "Heilmann CR" . + "Lewis MS" . + "Kwan AY" . + "Hoogwerf BJ" . + "Rosenstock J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 21739" . + "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine ." . + "30 weeks" . + . + . + . + "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 21755" . + "HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 %" . + . + . + . + "receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "adv" . + . + . + . + . + . + . + "nau" . + . + . + . + . + . + "dia" . + . + . + . + . + . + . + "vom" . + . + . + . + . + . + . + "head" . + . + . + . + . + . + "const" . + . + . + . + . +# RDF export of group: Arm + . + "exe" . + "138" . + "112" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + "123" . + "101" . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "exe" . + . + "twice daily" . + . + . + "pla" . + . + . + . + "gla" . + . + . + . + "met" . + . + . + . + "pio" . + . + . +# RDF export of group: Medication + . + "exe" . + . + "10 µ g" . + . + . + . + "pla" . + . + . + . + . + "gla" . + . + . + . + . + "met" . + . + . + . + . + "pio" . + . + . + . +# RDF export of group: Outcome + . + "hba exe" . + . + "1 . 74" . + . + "hba pla" . + . + "1 . 04" . + . + "bw exe" . + . + "1 . 8" . + . + "bw pla" . + . + "1 . 0" . + . + "ins exe" . + . + "13" . + . + "ins pla" . + . + "20" . + . + "adv exe" . + . + "Thirteen" . + . + "adv pla" . + . + "1" . + . + . + . + "nau ex" . + . + "41" . + . + "nau pl" . + . + "8" . + . + "dia ex" . + . + "18" . + . + "dia pla" . + . + "8" . + . + "vom ex" . + . + "18" . + . + "vom pla" . + . + "4" . + . + "head ex" . + . + "14" . + . + "head pl" . + . + "4" . + . + "const ex" . + . + "10" . + . + "const pla" . + . + "2" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 69" . + "P < 0 . 001" . + "95 % CI , - 0 . 93 % to - 0 . 46 %" . + . + . + . + "bw" . + "- 2 . 7" . + "CI , - 3 . 7 to - 1 . 7" . + . + . + . + "adv" . + "P < 0 . 010" . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21138825_export.csv b/data/dm2 21138825_export.csv new file mode 100644 index 0000000..ec4b6bc --- /dev/null +++ b/data/dm2 21138825_export.csv @@ -0,0 +1,787 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +326, 1, 1, 1, 0, 3, 0, 3, "Ann" +326, 1, 2, 2, 4, 10, 4, 10, "Intern" +326, 1, 3, 3, 11, 14, 11, 14, "Med" +326, 1, 4, 4, 15, 16, 15, 16, "." +326, 2, 1, 5, 0, 4, 17, 21, "2011" +326, 2, 2, 6, 5, 8, 22, 25, "Jan" +326, 2, 3, 7, 9, 11, 26, 28, "18" +326, 2, 4, 8, 12, 13, 29, 30, ";" +326, 2, 5, 9, 14, 17, 31, 34, "154" +326, 2, 6, 10, 18, 19, 35, 36, "(" +326, 2, 7, 11, 20, 21, 37, 38, "2" +326, 2, 8, 12, 22, 23, 39, 40, ")" +326, 2, 9, 13, 24, 25, 41, 42, ":" +326, 2, 10, 14, 26, 29, 43, 46, "103" +326, 2, 11, 15, 30, 31, 47, 48, "-" +326, 2, 12, 16, 32, 34, 49, 51, "12" +326, 2, 13, 17, 35, 36, 52, 53, "." +326, 2, 14, 18, 37, 40, 54, 57, "doi" +326, 2, 15, 19, 41, 42, 58, 59, ":" +326, 2, 16, 20, 43, 45, 60, 62, "10" +326, 2, 17, 21, 46, 47, 63, 64, "." +326, 2, 18, 22, 48, 52, 65, 69, "7326" +326, 2, 19, 23, 53, 54, 70, 71, "/" +326, 2, 20, 24, 55, 59, 72, 76, "0003" +326, 2, 21, 25, 60, 61, 77, 78, "-" +326, 2, 22, 26, 62, 66, 79, 83, "4819" +326, 2, 23, 27, 67, 68, 84, 85, "-" +326, 2, 24, 28, 69, 72, 86, 89, "154" +326, 2, 25, 29, 73, 74, 90, 91, "-" +326, 2, 26, 30, 75, 76, 92, 93, "2" +326, 2, 27, 31, 77, 78, 94, 95, "-" +326, 2, 28, 32, 79, 88, 96, 105, "201101180" +326, 2, 29, 33, 89, 90, 106, 107, "-" +326, 2, 30, 34, 91, 96, 108, 113, "00300" +326, 2, 31, 35, 97, 98, 114, 115, "." +326, 3, 1, 36, 0, 4, 116, 120, "Epub" +326, 3, 2, 37, 5, 9, 121, 125, "2010" +326, 3, 3, 38, 10, 13, 126, 129, "Dec" +326, 3, 4, 39, 14, 15, 130, 131, "6" +326, 3, 5, 40, 16, 17, 132, 133, "." +326, 4, 1, 41, 0, 3, 134, 137, "Use" +326, 4, 2, 42, 4, 6, 138, 140, "of" +326, 4, 3, 43, 7, 12, 141, 146, "twice" +326, 4, 4, 44, 13, 14, 147, 148, "-" +326, 4, 5, 45, 15, 20, 149, 154, "daily" +326, 4, 6, 46, 21, 30, 155, 164, "exenatide" +326, 4, 7, 47, 31, 33, 165, 167, "in" +326, 4, 8, 48, 34, 39, 168, 173, "Basal" +326, 4, 9, 49, 40, 47, 174, 181, "insulin" +326, 4, 10, 50, 48, 49, 182, 183, "-" +326, 4, 11, 51, 50, 57, 184, 191, "treated" +326, 4, 12, 52, 58, 66, 192, 200, "patients" +326, 4, 13, 53, 67, 71, 201, 205, "with" +326, 4, 14, 54, 72, 76, 206, 210, "type" +326, 4, 15, 55, 77, 78, 211, 212, "2" +326, 4, 16, 56, 79, 87, 213, 221, "diabetes" +326, 4, 17, 57, 88, 89, 222, 223, ":" +326, 4, 18, 58, 90, 91, 224, 225, "a" +326, 4, 19, 59, 92, 102, 226, 236, "randomized" +326, 4, 20, 60, 103, 104, 237, 238, "," +326, 4, 21, 61, 105, 115, 239, 249, "controlled" +326, 4, 22, 62, 116, 121, 250, 255, "trial" +326, 4, 23, 63, 122, 123, 256, 257, "." +326, 5, 1, 64, 0, 4, 258, 262, "Buse" +326, 5, 2, 65, 5, 7, 263, 265, "JB" +326, 5, 3, 66, 8, 9, 266, 267, "(" +326, 5, 4, 67, 10, 11, 268, 269, "1" +326, 5, 5, 68, 12, 13, 270, 271, ")" +326, 5, 6, 69, 14, 15, 272, 273, "," +326, 5, 7, 70, 16, 26, 274, 284, "Bergenstal" +326, 5, 8, 71, 27, 29, 285, 287, "RM" +326, 5, 9, 72, 30, 31, 288, 289, "," +326, 5, 10, 73, 32, 37, 290, 295, "Glass" +326, 5, 11, 74, 38, 40, 296, 298, "LC" +326, 5, 12, 75, 41, 42, 299, 300, "," +326, 5, 13, 76, 43, 51, 301, 309, "Heilmann" +326, 5, 14, 77, 52, 54, 310, 312, "CR" +326, 5, 15, 78, 55, 56, 313, 314, "," +326, 5, 16, 79, 57, 62, 315, 320, "Lewis" +326, 5, 17, 80, 63, 65, 321, 323, "MS" +326, 5, 18, 81, 66, 67, 324, 325, "," +326, 5, 19, 82, 68, 72, 326, 330, "Kwan" +326, 5, 20, 83, 73, 75, 331, 333, "AY" +326, 5, 21, 84, 76, 77, 334, 335, "," +326, 5, 22, 85, 78, 86, 336, 344, "Hoogwerf" +326, 5, 23, 86, 87, 89, 345, 347, "BJ" +326, 5, 24, 87, 90, 91, 348, 349, "," +326, 5, 25, 88, 92, 102, 350, 360, "Rosenstock" +326, 5, 26, 89, 103, 104, 361, 362, "J" +326, 5, 27, 90, 105, 106, 363, 364, "." +326, 6, 1, 91, 0, 6, 365, 371, "Author" +326, 6, 2, 92, 7, 18, 372, 383, "information" +326, 6, 3, 93, 19, 20, 384, 385, ":" +326, 6, 4, 94, 21, 22, 386, 387, "(" +326, 6, 5, 95, 23, 24, 388, 389, "1" +326, 6, 6, 96, 25, 26, 390, 391, ")" +326, 6, 7, 97, 27, 37, 392, 402, "University" +326, 6, 8, 98, 38, 40, 403, 405, "of" +326, 6, 9, 99, 41, 46, 406, 411, "North" +326, 6, 10, 100, 47, 55, 412, 420, "Carolina" +326, 6, 11, 101, 56, 62, 421, 427, "School" +326, 6, 12, 102, 63, 65, 428, 430, "of" +326, 6, 13, 103, 66, 74, 431, 439, "Medicine" +326, 6, 14, 104, 75, 76, 440, 441, "," +326, 6, 15, 105, 77, 83, 442, 448, "Chapel" +326, 6, 16, 106, 84, 88, 449, 453, "Hill" +326, 6, 17, 107, 89, 90, 454, 455, "," +326, 6, 18, 108, 91, 96, 456, 461, "27599" +326, 6, 19, 109, 97, 98, 462, 463, "," +326, 6, 20, 110, 99, 102, 464, 467, "USA" +326, 6, 21, 111, 103, 104, 468, 469, "." +326, 7, 1, 112, 0, 5, 470, 475, "jbuse" +326, 7, 2, 113, 6, 7, 476, 477, "@" +326, 7, 3, 114, 8, 11, 478, 481, "med" +326, 7, 4, 115, 12, 13, 482, 483, "." +326, 7, 5, 116, 14, 17, 484, 487, "unc" +326, 7, 6, 117, 18, 19, 488, 489, "." +326, 7, 7, 118, 20, 23, 490, 493, "edu" +326, 7, 8, 119, 24, 31, 494, 501, "Comment" +326, 7, 9, 120, 32, 34, 502, 504, "in" +326, 7, 10, 121, 35, 38, 505, 508, "Ann" +326, 7, 11, 122, 39, 45, 509, 515, "Intern" +326, 7, 12, 123, 46, 49, 516, 519, "Med" +326, 7, 13, 124, 50, 51, 520, 521, "." +326, 8, 1, 125, 0, 4, 522, 526, "2011" +326, 8, 2, 126, 5, 8, 527, 530, "Jan" +326, 8, 3, 127, 9, 11, 531, 533, "18" +326, 8, 4, 128, 12, 13, 534, 535, ";" +326, 8, 5, 129, 14, 17, 536, 539, "154" +326, 8, 6, 130, 18, 19, 540, 541, "(" +326, 8, 7, 131, 20, 21, 542, 543, "2" +326, 8, 8, 132, 22, 23, 544, 545, ")" +326, 8, 9, 133, 24, 25, 546, 547, ":" +326, 8, 10, 134, 26, 29, 548, 551, "131" +326, 8, 11, 135, 30, 31, 552, 553, "-" +326, 8, 12, 136, 32, 33, 554, 555, "2" +326, 8, 13, 137, 34, 35, 556, 557, "." +326, 9, 1, 138, 0, 3, 558, 561, "Ann" +326, 9, 2, 139, 4, 10, 562, 568, "Intern" +326, 9, 3, 140, 11, 14, 569, 572, "Med" +326, 9, 4, 141, 15, 16, 573, 574, "." +326, 10, 1, 142, 0, 4, 575, 579, "2011" +326, 10, 2, 143, 5, 8, 580, 583, "Jan" +326, 10, 3, 144, 9, 11, 584, 586, "18" +326, 10, 4, 145, 12, 13, 587, 588, ";" +326, 10, 5, 146, 14, 17, 589, 592, "154" +326, 10, 6, 147, 18, 19, 593, 594, "(" +326, 10, 7, 148, 20, 21, 595, 596, "2" +326, 10, 8, 149, 22, 23, 597, 598, ")" +326, 10, 9, 150, 24, 25, 599, 600, ":" +326, 10, 10, 151, 26, 27, 601, 602, "I" +326, 10, 11, 152, 28, 29, 603, 604, "-" +326, 10, 12, 153, 30, 32, 605, 607, "40" +326, 10, 13, 154, 33, 34, 608, 609, "." +326, 11, 1, 155, 0, 10, 610, 620, "BACKGROUND" +326, 11, 2, 156, 11, 12, 621, 622, ":" +326, 11, 3, 157, 13, 20, 623, 630, "Insulin" +326, 11, 4, 158, 21, 32, 631, 642, "replacement" +326, 11, 5, 159, 33, 35, 643, 645, "in" +326, 11, 6, 160, 36, 44, 646, 654, "diabetes" +326, 11, 7, 161, 45, 50, 655, 660, "often" +326, 11, 8, 162, 51, 59, 661, 669, "requires" +326, 11, 9, 163, 60, 68, 670, 678, "prandial" +326, 11, 10, 164, 69, 81, 679, 691, "intervention" +326, 11, 11, 165, 82, 84, 692, 694, "to" +326, 11, 12, 166, 85, 90, 695, 700, "reach" +326, 11, 13, 167, 91, 101, 701, 711, "hemoglobin" +326, 11, 14, 168, 102, 103, 712, 713, "A" +326, 11, 15, 169, 104, 105, 714, 715, "₁" +326, 11, 16, 170, 106, 107, 716, 717, "(" +326, 11, 17, 171, 108, 109, 718, 719, "c" +326, 11, 18, 172, 110, 111, 720, 721, ")" +326, 11, 19, 173, 112, 113, 722, 723, "(" +326, 11, 20, 174, 114, 117, 724, 727, "HbA" +326, 11, 21, 175, 118, 119, 728, 729, "₁" +326, 11, 22, 176, 120, 121, 730, 731, "(" +326, 11, 23, 177, 122, 123, 732, 733, "c" +326, 11, 24, 178, 124, 125, 734, 735, ")" +326, 11, 25, 179, 126, 127, 736, 737, ")" +326, 11, 26, 180, 128, 135, 738, 745, "targets" +326, 11, 27, 181, 136, 137, 746, 747, "." +326, 12, 1, 182, 0, 9, 748, 757, "OBJECTIVE" +326, 12, 2, 183, 10, 11, 758, 759, ":" +326, 12, 3, 184, 12, 14, 760, 762, "To" +326, 12, 4, 185, 15, 19, 763, 767, "test" +326, 12, 5, 186, 20, 27, 768, 775, "whether" +326, 12, 6, 187, 28, 33, 776, 781, "twice" +326, 12, 7, 188, 34, 35, 782, 783, "-" +326, 12, 8, 189, 36, 41, 784, 789, "daily" +326, 12, 9, 190, 42, 51, 790, 799, "exenatide" +326, 12, 10, 191, 52, 62, 800, 810, "injections" +326, 12, 11, 192, 63, 69, 811, 817, "reduce" +326, 12, 12, 193, 70, 73, 818, 821, "HbA" +326, 12, 13, 194, 74, 75, 822, 823, "₁" +326, 12, 14, 195, 76, 77, 824, 825, "(" +326, 12, 15, 196, 78, 79, 826, 827, "c" +326, 12, 16, 197, 80, 81, 828, 829, ")" +326, 12, 17, 198, 82, 88, 830, 836, "levels" +326, 12, 18, 199, 89, 93, 837, 841, "more" +326, 12, 19, 200, 94, 98, 842, 846, "than" +326, 12, 20, 201, 99, 106, 847, 854, "placebo" +326, 12, 21, 202, 107, 109, 855, 857, "in" +326, 12, 22, 203, 110, 116, 858, 864, "people" +326, 12, 23, 204, 117, 126, 865, 874, "receiving" +326, 12, 24, 205, 127, 134, 875, 882, "insulin" +326, 12, 25, 206, 135, 143, 883, 891, "glargine" +326, 12, 26, 207, 144, 145, 892, 893, "." +326, 13, 1, 208, 0, 6, 894, 900, "DESIGN" +326, 13, 2, 209, 7, 8, 901, 902, ":" +326, 13, 3, 210, 9, 17, 903, 911, "Parallel" +326, 13, 4, 211, 18, 19, 912, 913, "," +326, 13, 5, 212, 20, 30, 914, 924, "randomized" +326, 13, 6, 213, 31, 32, 925, 926, "," +326, 13, 7, 214, 33, 40, 927, 934, "placebo" +326, 13, 8, 215, 41, 42, 935, 936, "-" +326, 13, 9, 216, 43, 53, 937, 947, "controlled" +326, 13, 10, 217, 54, 59, 948, 953, "trial" +326, 13, 11, 218, 60, 61, 954, 955, "," +326, 13, 12, 219, 62, 69, 956, 963, "blocked" +326, 13, 13, 220, 70, 73, 964, 967, "and" +326, 13, 14, 221, 74, 84, 968, 978, "stratified" +326, 13, 15, 222, 85, 87, 979, 981, "by" +326, 13, 16, 223, 88, 91, 982, 985, "HbA" +326, 13, 17, 224, 92, 93, 986, 987, "₁" +326, 13, 18, 225, 94, 95, 988, 989, "(" +326, 13, 19, 226, 96, 97, 990, 991, "c" +326, 13, 20, 227, 98, 99, 992, 993, ")" +326, 13, 21, 228, 100, 105, 994, 999, "level" +326, 13, 22, 229, 106, 108, 1000, 1002, "at" +326, 13, 23, 230, 109, 113, 1003, 1007, "site" +326, 13, 24, 231, 114, 115, 1008, 1009, "," +326, 13, 25, 232, 116, 125, 1010, 1019, "performed" +326, 13, 26, 233, 126, 130, 1020, 1024, "from" +326, 13, 27, 234, 131, 138, 1025, 1032, "October" +326, 13, 28, 235, 139, 143, 1033, 1037, "2008" +326, 13, 29, 236, 144, 146, 1038, 1040, "to" +326, 13, 30, 237, 147, 154, 1041, 1048, "January" +326, 13, 31, 238, 155, 159, 1049, 1053, "2010" +326, 13, 32, 239, 160, 161, 1054, 1055, "." +326, 14, 1, 240, 0, 12, 1056, 1068, "Participants" +326, 14, 2, 241, 13, 14, 1069, 1070, "," +326, 14, 3, 242, 15, 28, 1071, 1084, "investigators" +326, 14, 4, 243, 29, 30, 1085, 1086, "," +326, 14, 5, 244, 31, 34, 1087, 1090, "and" +326, 14, 6, 245, 35, 44, 1091, 1100, "personnel" +326, 14, 7, 246, 45, 55, 1101, 1111, "conducting" +326, 14, 8, 247, 56, 59, 1112, 1115, "the" +326, 14, 9, 248, 60, 65, 1116, 1121, "study" +326, 14, 10, 249, 66, 70, 1122, 1126, "were" +326, 14, 11, 250, 71, 77, 1127, 1133, "masked" +326, 14, 12, 251, 78, 80, 1134, 1136, "to" +326, 14, 13, 252, 81, 90, 1137, 1146, "treatment" +326, 14, 14, 253, 91, 102, 1147, 1158, "assignments" +326, 14, 15, 254, 103, 104, 1159, 1160, "." +326, 15, 1, 255, 0, 1, 1161, 1162, "(" +326, 15, 2, 256, 2, 16, 1163, 1177, "ClinicalTrials" +326, 15, 3, 257, 17, 18, 1178, 1179, "." +326, 15, 4, 258, 19, 22, 1180, 1183, "gov" +326, 15, 5, 259, 23, 35, 1184, 1196, "registration" +326, 15, 6, 260, 36, 42, 1197, 1203, "number" +326, 15, 7, 261, 43, 44, 1204, 1205, ":" +326, 15, 8, 262, 45, 56, 1206, 1217, "NCT00765817" +326, 15, 9, 263, 57, 58, 1218, 1219, ")" +326, 15, 10, 264, 59, 66, 1220, 1227, "SETTING" +326, 15, 11, 265, 67, 68, 1228, 1229, ":" +326, 15, 12, 266, 69, 71, 1230, 1232, "59" +326, 15, 13, 267, 72, 79, 1233, 1240, "centers" +326, 15, 14, 268, 80, 82, 1241, 1243, "in" +326, 15, 15, 269, 83, 84, 1244, 1245, "5" +326, 15, 16, 270, 85, 94, 1246, 1255, "countries" +326, 15, 17, 271, 95, 96, 1256, 1257, "." +326, 16, 1, 272, 0, 8, 1258, 1266, "PATIENTS" +326, 16, 2, 273, 9, 10, 1267, 1268, ":" +326, 16, 3, 274, 11, 17, 1269, 1275, "Adults" +326, 16, 4, 275, 18, 22, 1276, 1280, "with" +326, 16, 5, 276, 23, 27, 1281, 1285, "type" +326, 16, 6, 277, 28, 29, 1286, 1287, "2" +326, 16, 7, 278, 30, 38, 1288, 1296, "diabetes" +326, 16, 8, 279, 39, 42, 1297, 1300, "and" +326, 16, 9, 280, 43, 45, 1301, 1303, "an" +326, 16, 10, 281, 46, 49, 1304, 1307, "HbA" +326, 16, 11, 282, 50, 51, 1308, 1309, "₁" +326, 16, 12, 283, 52, 53, 1310, 1311, "(" +326, 16, 13, 284, 54, 55, 1312, 1313, "c" +326, 16, 14, 285, 56, 57, 1314, 1315, ")" +326, 16, 15, 286, 58, 63, 1316, 1321, "level" +326, 16, 16, 287, 64, 66, 1322, 1324, "of" +326, 16, 17, 288, 67, 68, 1325, 1326, "7" +326, 16, 18, 289, 69, 70, 1327, 1328, "." +326, 16, 19, 290, 71, 72, 1329, 1330, "1" +326, 16, 20, 291, 73, 74, 1331, 1332, "%" +326, 16, 21, 292, 75, 77, 1333, 1335, "to" +326, 16, 22, 293, 78, 80, 1336, 1338, "10" +326, 16, 23, 294, 81, 82, 1339, 1340, "." +326, 16, 24, 295, 83, 84, 1341, 1342, "5" +326, 16, 25, 296, 85, 86, 1343, 1344, "%" +326, 16, 26, 297, 87, 90, 1345, 1348, "who" +326, 16, 27, 298, 91, 95, 1349, 1353, "were" +326, 16, 28, 299, 96, 105, 1354, 1363, "receiving" +326, 16, 29, 300, 106, 113, 1364, 1371, "insulin" +326, 16, 30, 301, 114, 122, 1372, 1380, "glargine" +326, 16, 31, 302, 123, 128, 1381, 1386, "alone" +326, 16, 32, 303, 129, 131, 1387, 1389, "or" +326, 16, 33, 304, 132, 134, 1390, 1392, "in" +326, 16, 34, 305, 135, 146, 1393, 1404, "combination" +326, 16, 35, 306, 147, 151, 1405, 1409, "with" +326, 16, 36, 307, 152, 161, 1410, 1419, "metformin" +326, 16, 37, 308, 162, 164, 1420, 1422, "or" +326, 16, 38, 309, 165, 177, 1423, 1435, "pioglitazone" +326, 16, 39, 310, 178, 179, 1436, 1437, "(" +326, 16, 40, 311, 180, 182, 1438, 1440, "or" +326, 16, 41, 312, 183, 187, 1441, 1445, "both" +326, 16, 42, 313, 188, 194, 1446, 1452, "agents" +326, 16, 43, 314, 195, 196, 1453, 1454, ")" +326, 16, 44, 315, 197, 198, 1455, 1456, "." +326, 17, 1, 316, 0, 12, 1457, 1469, "INTERVENTION" +326, 17, 2, 317, 13, 14, 1470, 1471, ":" +326, 17, 3, 318, 15, 25, 1472, 1482, "Assignment" +326, 17, 4, 319, 26, 28, 1483, 1485, "by" +326, 17, 5, 320, 29, 30, 1486, 1487, "a" +326, 17, 6, 321, 31, 42, 1488, 1499, "centralized" +326, 17, 7, 322, 43, 44, 1500, 1501, "," +326, 17, 8, 323, 45, 53, 1502, 1510, "computer" +326, 17, 9, 324, 54, 55, 1511, 1512, "-" +326, 17, 10, 325, 56, 65, 1513, 1522, "generated" +326, 17, 11, 326, 66, 67, 1523, 1524, "," +326, 17, 12, 327, 68, 74, 1525, 1531, "random" +326, 17, 13, 328, 75, 76, 1532, 1533, "-" +326, 17, 14, 329, 77, 85, 1534, 1542, "sequence" +326, 17, 15, 330, 86, 97, 1543, 1554, "interactive" +326, 17, 16, 331, 98, 103, 1555, 1560, "voice" +326, 17, 17, 332, 104, 105, 1561, 1562, "-" +326, 17, 18, 333, 106, 114, 1563, 1571, "response" +326, 17, 19, 334, 115, 121, 1572, 1578, "system" +326, 17, 20, 335, 122, 124, 1579, 1581, "to" +326, 17, 21, 336, 125, 134, 1582, 1591, "exenatide" +326, 17, 22, 337, 135, 136, 1592, 1593, "," +326, 17, 23, 338, 137, 139, 1594, 1596, "10" +326, 17, 24, 339, 140, 141, 1597, 1598, "µ" +326, 17, 25, 340, 142, 143, 1599, 1600, "g" +326, 17, 26, 341, 144, 149, 1601, 1606, "twice" +326, 17, 27, 342, 150, 155, 1607, 1612, "daily" +326, 17, 28, 343, 156, 157, 1613, 1614, "," +326, 17, 29, 344, 158, 160, 1615, 1617, "or" +326, 17, 30, 345, 161, 168, 1618, 1625, "placebo" +326, 17, 31, 346, 169, 172, 1626, 1629, "for" +326, 17, 32, 347, 173, 175, 1630, 1632, "30" +326, 17, 33, 348, 176, 181, 1633, 1638, "weeks" +326, 17, 34, 349, 182, 183, 1639, 1640, "." +326, 18, 1, 350, 0, 12, 1641, 1653, "MEASUREMENTS" +326, 18, 2, 351, 13, 14, 1654, 1655, ":" +326, 18, 3, 352, 15, 18, 1656, 1659, "The" +326, 18, 4, 353, 19, 26, 1660, 1667, "primary" +326, 18, 5, 354, 27, 34, 1668, 1675, "outcome" +326, 18, 6, 355, 35, 38, 1676, 1679, "was" +326, 18, 7, 356, 39, 45, 1680, 1686, "change" +326, 18, 8, 357, 46, 48, 1687, 1689, "in" +326, 18, 9, 358, 49, 52, 1690, 1693, "HbA" +326, 18, 10, 359, 53, 54, 1694, 1695, "₁" +326, 18, 11, 360, 55, 56, 1696, 1697, "(" +326, 18, 12, 361, 57, 58, 1698, 1699, "c" +326, 18, 13, 362, 59, 60, 1700, 1701, ")" +326, 18, 14, 363, 61, 66, 1702, 1707, "level" +326, 18, 15, 364, 67, 68, 1708, 1709, "." +326, 19, 1, 365, 0, 9, 1710, 1719, "Secondary" +326, 19, 2, 366, 10, 18, 1720, 1728, "outcomes" +326, 19, 3, 367, 19, 27, 1729, 1737, "included" +326, 19, 4, 368, 28, 31, 1738, 1741, "the" +326, 19, 5, 369, 32, 42, 1742, 1752, "percentage" +326, 19, 6, 370, 43, 45, 1753, 1755, "of" +326, 19, 7, 371, 46, 58, 1756, 1768, "participants" +326, 19, 8, 372, 59, 63, 1769, 1773, "with" +326, 19, 9, 373, 64, 67, 1774, 1777, "HbA" +326, 19, 10, 374, 68, 69, 1778, 1779, "₁" +326, 19, 11, 375, 70, 71, 1780, 1781, "(" +326, 19, 12, 376, 72, 73, 1782, 1783, "c" +326, 19, 13, 377, 74, 75, 1784, 1785, ")" +326, 19, 14, 378, 76, 82, 1786, 1792, "values" +326, 19, 15, 379, 83, 85, 1793, 1795, "of" +326, 19, 16, 380, 86, 87, 1796, 1797, "7" +326, 19, 17, 381, 88, 89, 1798, 1799, "." +326, 19, 18, 382, 90, 91, 1800, 1801, "0" +326, 19, 19, 383, 92, 93, 1802, 1803, "%" +326, 19, 20, 384, 94, 96, 1804, 1806, "or" +326, 19, 21, 385, 97, 101, 1807, 1811, "less" +326, 19, 22, 386, 102, 105, 1812, 1815, "and" +326, 19, 23, 387, 106, 107, 1816, 1817, "6" +326, 19, 24, 388, 108, 109, 1818, 1819, "." +326, 19, 25, 389, 110, 111, 1820, 1821, "5" +326, 19, 26, 390, 112, 113, 1822, 1823, "%" +326, 19, 27, 391, 114, 116, 1824, 1826, "or" +326, 19, 28, 392, 117, 121, 1827, 1831, "less" +326, 19, 29, 393, 122, 123, 1832, 1833, "," +326, 19, 30, 394, 124, 125, 1834, 1835, "7" +326, 19, 31, 395, 126, 127, 1836, 1837, "-" +326, 19, 32, 396, 128, 133, 1838, 1843, "point" +326, 19, 33, 397, 134, 138, 1844, 1848, "self" +326, 19, 34, 398, 139, 140, 1849, 1850, "-" +326, 19, 35, 399, 141, 150, 1851, 1860, "monitored" +326, 19, 36, 400, 151, 158, 1861, 1868, "glucose" +326, 19, 37, 401, 159, 167, 1869, 1877, "profiles" +326, 19, 38, 402, 168, 169, 1878, 1879, "," +326, 19, 39, 403, 170, 174, 1880, 1884, "body" +326, 19, 40, 404, 175, 181, 1885, 1891, "weight" +326, 19, 41, 405, 182, 183, 1892, 1893, "," +326, 19, 42, 406, 184, 189, 1894, 1899, "waist" +326, 19, 43, 407, 190, 203, 1900, 1913, "circumference" +326, 19, 44, 408, 204, 205, 1914, 1915, "," +326, 19, 45, 409, 206, 213, 1916, 1923, "insulin" +326, 19, 46, 410, 214, 218, 1924, 1928, "dose" +326, 19, 47, 411, 219, 220, 1929, 1930, "," +326, 19, 48, 412, 221, 233, 1931, 1943, "hypoglycemia" +326, 19, 49, 413, 234, 235, 1944, 1945, "," +326, 19, 50, 414, 236, 239, 1946, 1949, "and" +326, 19, 51, 415, 240, 247, 1950, 1957, "adverse" +326, 19, 52, 416, 248, 254, 1958, 1964, "events" +326, 19, 53, 417, 255, 256, 1965, 1966, "." +326, 20, 1, 418, 0, 7, 1967, 1974, "RESULTS" +326, 20, 2, 419, 8, 9, 1975, 1976, ":" +326, 20, 3, 420, 10, 13, 1977, 1980, "112" +326, 20, 4, 421, 14, 16, 1981, 1983, "of" +326, 20, 5, 422, 17, 20, 1984, 1987, "138" +326, 20, 6, 423, 21, 30, 1988, 1997, "exenatide" +326, 20, 7, 424, 31, 41, 1998, 2008, "recipients" +326, 20, 8, 425, 42, 45, 2009, 2012, "and" +326, 20, 9, 426, 46, 49, 2013, 2016, "101" +326, 20, 10, 427, 50, 52, 2017, 2019, "of" +326, 20, 11, 428, 53, 56, 2020, 2023, "123" +326, 20, 12, 429, 57, 64, 2024, 2031, "placebo" +326, 20, 13, 430, 65, 75, 2032, 2042, "recipients" +326, 20, 14, 431, 76, 85, 2043, 2052, "completed" +326, 20, 15, 432, 86, 89, 2053, 2056, "the" +326, 20, 16, 433, 90, 95, 2057, 2062, "study" +326, 20, 17, 434, 96, 97, 2063, 2064, "." +326, 21, 1, 435, 0, 3, 2065, 2068, "The" +326, 21, 2, 436, 4, 7, 2069, 2072, "HbA" +326, 21, 3, 437, 8, 9, 2073, 2074, "₁" +326, 21, 4, 438, 10, 11, 2075, 2076, "(" +326, 21, 5, 439, 12, 13, 2077, 2078, "c" +326, 21, 6, 440, 14, 15, 2079, 2080, ")" +326, 21, 7, 441, 16, 21, 2081, 2086, "level" +326, 21, 8, 442, 22, 31, 2087, 2096, "decreased" +326, 21, 9, 443, 32, 34, 2097, 2099, "by" +326, 21, 10, 444, 35, 36, 2100, 2101, "1" +326, 21, 11, 445, 37, 38, 2102, 2103, "." +326, 21, 12, 446, 39, 41, 2104, 2106, "74" +326, 21, 13, 447, 42, 43, 2107, 2108, "%" +326, 21, 14, 448, 44, 48, 2109, 2113, "with" +326, 21, 15, 449, 49, 58, 2114, 2123, "exenatide" +326, 21, 16, 450, 59, 62, 2124, 2127, "and" +326, 21, 17, 451, 63, 64, 2128, 2129, "1" +326, 21, 18, 452, 65, 66, 2130, 2131, "." +326, 21, 19, 453, 67, 69, 2132, 2134, "04" +326, 21, 20, 454, 70, 71, 2135, 2136, "%" +326, 21, 21, 455, 72, 76, 2137, 2141, "with" +326, 21, 22, 456, 77, 84, 2142, 2149, "placebo" +326, 21, 23, 457, 85, 86, 2150, 2151, "(" +326, 21, 24, 458, 87, 94, 2152, 2159, "between" +326, 21, 25, 459, 95, 96, 2160, 2161, "-" +326, 21, 26, 460, 97, 102, 2162, 2167, "group" +326, 21, 27, 461, 103, 113, 2168, 2178, "difference" +326, 21, 28, 462, 114, 115, 2179, 2180, "," +326, 21, 29, 463, 116, 117, 2181, 2182, "-" +326, 21, 30, 464, 118, 119, 2183, 2184, "0" +326, 21, 31, 465, 120, 121, 2185, 2186, "." +326, 21, 32, 466, 122, 124, 2187, 2189, "69" +326, 21, 33, 467, 125, 126, 2190, 2191, "%" +326, 21, 34, 468, 127, 128, 2192, 2193, "[" +326, 21, 35, 469, 129, 131, 2194, 2196, "95" +326, 21, 36, 470, 132, 133, 2197, 2198, "%" +326, 21, 37, 471, 134, 136, 2199, 2201, "CI" +326, 21, 38, 472, 137, 138, 2202, 2203, "," +326, 21, 39, 473, 139, 140, 2204, 2205, "-" +326, 21, 40, 474, 141, 142, 2206, 2207, "0" +326, 21, 41, 475, 143, 144, 2208, 2209, "." +326, 21, 42, 476, 145, 147, 2210, 2212, "93" +326, 21, 43, 477, 148, 149, 2213, 2214, "%" +326, 21, 44, 478, 150, 152, 2215, 2217, "to" +326, 21, 45, 479, 153, 154, 2218, 2219, "-" +326, 21, 46, 480, 155, 156, 2220, 2221, "0" +326, 21, 47, 481, 157, 158, 2222, 2223, "." +326, 21, 48, 482, 159, 161, 2224, 2226, "46" +326, 21, 49, 483, 162, 163, 2227, 2228, "%" +326, 21, 50, 484, 164, 165, 2229, 2230, "]" +326, 21, 51, 485, 166, 167, 2231, 2232, ";" +326, 21, 52, 486, 168, 169, 2233, 2234, "P" +326, 21, 53, 487, 170, 171, 2235, 2236, "<" +326, 21, 54, 488, 172, 173, 2237, 2238, "0" +326, 21, 55, 489, 174, 175, 2239, 2240, "." +326, 21, 56, 490, 176, 179, 2241, 2244, "001" +326, 21, 57, 491, 180, 181, 2245, 2246, ")" +326, 21, 58, 492, 182, 183, 2247, 2248, "." +326, 22, 1, 493, 0, 6, 2249, 2255, "Weight" +326, 22, 2, 494, 7, 16, 2256, 2265, "decreased" +326, 22, 3, 495, 17, 19, 2266, 2268, "by" +326, 22, 4, 496, 20, 21, 2269, 2270, "1" +326, 22, 5, 497, 22, 23, 2271, 2272, "." +326, 22, 6, 498, 24, 25, 2273, 2274, "8" +326, 22, 7, 499, 26, 28, 2275, 2277, "kg" +326, 22, 8, 500, 29, 33, 2278, 2282, "with" +326, 22, 9, 501, 34, 43, 2283, 2292, "exenatide" +326, 22, 10, 502, 44, 47, 2293, 2296, "and" +326, 22, 11, 503, 48, 57, 2297, 2306, "increased" +326, 22, 12, 504, 58, 60, 2307, 2309, "by" +326, 22, 13, 505, 61, 62, 2310, 2311, "1" +326, 22, 14, 506, 63, 64, 2312, 2313, "." +326, 22, 15, 507, 65, 66, 2314, 2315, "0" +326, 22, 16, 508, 67, 69, 2316, 2318, "kg" +326, 22, 17, 509, 70, 74, 2319, 2323, "with" +326, 22, 18, 510, 75, 82, 2324, 2331, "placebo" +326, 22, 19, 511, 83, 84, 2332, 2333, "(" +326, 22, 20, 512, 85, 92, 2334, 2341, "between" +326, 22, 21, 513, 93, 94, 2342, 2343, "-" +326, 22, 22, 514, 95, 100, 2344, 2349, "group" +326, 22, 23, 515, 101, 111, 2350, 2360, "difference" +326, 22, 24, 516, 112, 113, 2361, 2362, "," +326, 22, 25, 517, 114, 115, 2363, 2364, "-" +326, 22, 26, 518, 116, 117, 2365, 2366, "2" +326, 22, 27, 519, 118, 119, 2367, 2368, "." +326, 22, 28, 520, 120, 121, 2369, 2370, "7" +326, 22, 29, 521, 122, 124, 2371, 2373, "kg" +326, 22, 30, 522, 125, 126, 2374, 2375, "[" +326, 22, 31, 523, 127, 129, 2376, 2378, "CI" +326, 22, 32, 524, 130, 131, 2379, 2380, "," +326, 22, 33, 525, 132, 133, 2381, 2382, "-" +326, 22, 34, 526, 134, 135, 2383, 2384, "3" +326, 22, 35, 527, 136, 137, 2385, 2386, "." +326, 22, 36, 528, 138, 139, 2387, 2388, "7" +326, 22, 37, 529, 140, 142, 2389, 2391, "to" +326, 22, 38, 530, 143, 144, 2392, 2393, "-" +326, 22, 39, 531, 145, 146, 2394, 2395, "1" +326, 22, 40, 532, 147, 148, 2396, 2397, "." +326, 22, 41, 533, 149, 150, 2398, 2399, "7" +326, 22, 42, 534, 151, 152, 2400, 2401, "]" +326, 22, 43, 535, 153, 154, 2402, 2403, ")" +326, 22, 44, 536, 155, 156, 2404, 2405, "." +326, 23, 1, 537, 0, 7, 2406, 2413, "Average" +326, 23, 2, 538, 8, 17, 2414, 2423, "increases" +326, 23, 3, 539, 18, 20, 2424, 2426, "in" +326, 23, 4, 540, 21, 28, 2427, 2434, "insulin" +326, 23, 5, 541, 29, 35, 2435, 2441, "dosage" +326, 23, 6, 542, 36, 40, 2442, 2446, "with" +326, 23, 7, 543, 41, 50, 2447, 2456, "exenatide" +326, 23, 8, 544, 51, 54, 2457, 2460, "and" +326, 23, 9, 545, 55, 62, 2461, 2468, "placebo" +326, 23, 10, 546, 63, 67, 2469, 2473, "were" +326, 23, 11, 547, 68, 70, 2474, 2476, "13" +326, 23, 12, 548, 71, 72, 2477, 2478, "U" +326, 23, 13, 549, 73, 74, 2479, 2480, "/" +326, 23, 14, 550, 75, 76, 2481, 2482, "d" +326, 23, 15, 551, 77, 80, 2483, 2486, "and" +326, 23, 16, 552, 81, 83, 2487, 2489, "20" +326, 23, 17, 553, 84, 85, 2490, 2491, "U" +326, 23, 18, 554, 86, 87, 2492, 2493, "/" +326, 23, 19, 555, 88, 89, 2494, 2495, "d" +326, 23, 20, 556, 90, 91, 2496, 2497, "." +326, 24, 1, 557, 0, 3, 2498, 2501, "The" +326, 24, 2, 558, 4, 13, 2502, 2511, "estimated" +326, 24, 3, 559, 14, 18, 2512, 2516, "rate" +326, 24, 4, 560, 19, 21, 2517, 2519, "of" +326, 24, 5, 561, 22, 27, 2520, 2525, "minor" +326, 24, 6, 562, 28, 40, 2526, 2538, "hypoglycemia" +326, 24, 7, 563, 41, 44, 2539, 2542, "was" +326, 24, 8, 564, 45, 52, 2543, 2550, "similar" +326, 24, 9, 565, 53, 60, 2551, 2558, "between" +326, 24, 10, 566, 61, 67, 2559, 2565, "groups" +326, 24, 11, 567, 68, 69, 2566, 2567, "." +326, 25, 1, 568, 0, 8, 2568, 2576, "Thirteen" +326, 25, 2, 569, 9, 18, 2577, 2586, "exenatide" +326, 25, 3, 570, 19, 29, 2587, 2597, "recipients" +326, 25, 4, 571, 30, 33, 2598, 2601, "and" +326, 25, 5, 572, 34, 35, 2602, 2603, "1" +326, 25, 6, 573, 36, 43, 2604, 2611, "placebo" +326, 25, 7, 574, 44, 53, 2612, 2621, "recipient" +326, 25, 8, 575, 54, 66, 2622, 2634, "discontinued" +326, 25, 9, 576, 67, 70, 2635, 2638, "the" +326, 25, 10, 577, 71, 76, 2639, 2644, "study" +326, 25, 11, 578, 77, 84, 2645, 2652, "because" +326, 25, 12, 579, 85, 87, 2653, 2655, "of" +326, 25, 13, 580, 88, 95, 2656, 2663, "adverse" +326, 25, 14, 581, 96, 102, 2664, 2670, "events" +326, 25, 15, 582, 103, 104, 2671, 2672, "(" +326, 25, 16, 583, 105, 106, 2673, 2674, "P" +326, 25, 17, 584, 107, 108, 2675, 2676, "<" +326, 25, 18, 585, 109, 110, 2677, 2678, "0" +326, 25, 19, 586, 111, 112, 2679, 2680, "." +326, 25, 20, 587, 113, 116, 2681, 2684, "010" +326, 25, 21, 588, 117, 118, 2685, 2686, ")" +326, 25, 22, 589, 119, 120, 2687, 2688, ";" +326, 25, 23, 590, 121, 126, 2689, 2694, "rates" +326, 25, 24, 591, 127, 129, 2695, 2697, "of" +326, 25, 25, 592, 130, 136, 2698, 2704, "nausea" +326, 25, 26, 593, 137, 138, 2705, 2706, "(" +326, 25, 27, 594, 139, 141, 2707, 2709, "41" +326, 25, 28, 595, 142, 143, 2710, 2711, "%" +326, 25, 29, 596, 144, 146, 2712, 2714, "vs" +326, 25, 30, 597, 147, 148, 2715, 2716, "." +326, 25, 31, 598, 149, 150, 2717, 2718, "8" +326, 25, 32, 599, 151, 152, 2719, 2720, "%" +326, 25, 33, 600, 153, 154, 2721, 2722, ")" +326, 25, 34, 601, 155, 156, 2723, 2724, "," +326, 25, 35, 602, 157, 165, 2725, 2733, "diarrhea" +326, 25, 36, 603, 166, 167, 2734, 2735, "(" +326, 25, 37, 604, 168, 170, 2736, 2738, "18" +326, 25, 38, 605, 171, 172, 2739, 2740, "%" +326, 25, 39, 606, 173, 175, 2741, 2743, "vs" +326, 25, 40, 607, 176, 177, 2744, 2745, "." +326, 25, 41, 608, 178, 179, 2746, 2747, "8" +326, 25, 42, 609, 180, 181, 2748, 2749, "%" +326, 25, 43, 610, 182, 183, 2750, 2751, ")" +326, 25, 44, 611, 184, 185, 2752, 2753, "," +326, 25, 45, 612, 186, 194, 2754, 2762, "vomiting" +326, 25, 46, 613, 195, 196, 2763, 2764, "(" +326, 25, 47, 614, 197, 199, 2765, 2767, "18" +326, 25, 48, 615, 200, 201, 2768, 2769, "%" +326, 25, 49, 616, 202, 204, 2770, 2772, "vs" +326, 25, 50, 617, 205, 206, 2773, 2774, "." +326, 25, 51, 618, 207, 208, 2775, 2776, "4" +326, 25, 52, 619, 209, 210, 2777, 2778, "%" +326, 25, 53, 620, 211, 212, 2779, 2780, ")" +326, 25, 54, 621, 213, 214, 2781, 2782, "," +326, 25, 55, 622, 215, 223, 2783, 2791, "headache" +326, 25, 56, 623, 224, 225, 2792, 2793, "(" +326, 25, 57, 624, 226, 228, 2794, 2796, "14" +326, 25, 58, 625, 229, 230, 2797, 2798, "%" +326, 25, 59, 626, 231, 233, 2799, 2801, "vs" +326, 25, 60, 627, 234, 235, 2802, 2803, "." +326, 25, 61, 628, 236, 237, 2804, 2805, "4" +326, 25, 62, 629, 238, 239, 2806, 2807, "%" +326, 25, 63, 630, 240, 241, 2808, 2809, ")" +326, 25, 64, 631, 242, 243, 2810, 2811, "," +326, 25, 65, 632, 244, 247, 2812, 2815, "and" +326, 25, 66, 633, 248, 260, 2816, 2828, "constipation" +326, 25, 67, 634, 261, 262, 2829, 2830, "(" +326, 25, 68, 635, 263, 265, 2831, 2833, "10" +326, 25, 69, 636, 266, 267, 2834, 2835, "%" +326, 25, 70, 637, 268, 270, 2836, 2838, "vs" +326, 25, 71, 638, 271, 272, 2839, 2840, "." +326, 25, 72, 639, 273, 274, 2841, 2842, "2" +326, 25, 73, 640, 275, 276, 2843, 2844, "%" +326, 25, 74, 641, 277, 278, 2845, 2846, ")" +326, 25, 75, 642, 279, 283, 2847, 2851, "were" +326, 25, 76, 643, 284, 290, 2852, 2858, "higher" +326, 25, 77, 644, 291, 295, 2859, 2863, "with" +326, 25, 78, 645, 296, 305, 2864, 2873, "exenatide" +326, 25, 79, 646, 306, 310, 2874, 2878, "than" +326, 25, 80, 647, 311, 315, 2879, 2883, "with" +326, 25, 81, 648, 316, 323, 2884, 2891, "placebo" +326, 25, 82, 649, 324, 325, 2892, 2893, "." +326, 26, 1, 650, 0, 11, 2894, 2905, "LIMITATIONS" +326, 26, 2, 651, 12, 13, 2906, 2907, ":" +326, 26, 3, 652, 14, 17, 2908, 2911, "The" +326, 26, 4, 653, 18, 23, 2912, 2917, "study" +326, 26, 5, 654, 24, 27, 2918, 2921, "was" +326, 26, 6, 655, 28, 30, 2922, 2924, "of" +326, 26, 7, 656, 31, 36, 2925, 2930, "short" +326, 26, 8, 657, 37, 45, 2931, 2939, "duration" +326, 26, 9, 658, 46, 47, 2940, 2941, "." +326, 27, 1, 659, 0, 5, 2942, 2947, "There" +326, 27, 2, 660, 6, 10, 2948, 2952, "were" +326, 27, 3, 661, 11, 17, 2953, 2959, "slight" +326, 27, 4, 662, 18, 28, 2960, 2970, "imbalances" +326, 27, 5, 663, 29, 36, 2971, 2978, "between" +326, 27, 6, 664, 37, 43, 2979, 2985, "groups" +326, 27, 7, 665, 44, 46, 2986, 2988, "at" +326, 27, 8, 666, 47, 55, 2989, 2997, "baseline" +326, 27, 9, 667, 56, 58, 2998, 3000, "in" +326, 27, 10, 668, 59, 64, 3001, 3006, "terms" +326, 27, 11, 669, 65, 67, 3007, 3009, "of" +326, 27, 12, 670, 68, 71, 3010, 3013, "sex" +326, 27, 13, 671, 72, 73, 3014, 3015, "," +326, 27, 14, 672, 74, 77, 3016, 3019, "use" +326, 27, 15, 673, 78, 80, 3020, 3022, "of" +326, 27, 16, 674, 81, 92, 3023, 3034, "concomitant" +326, 27, 17, 675, 93, 100, 3035, 3042, "glucose" +326, 27, 18, 676, 101, 102, 3043, 3044, "-" +326, 27, 19, 677, 103, 111, 3045, 3053, "lowering" +326, 27, 20, 678, 112, 123, 3054, 3065, "medications" +326, 27, 21, 679, 124, 125, 3066, 3067, "," +326, 27, 22, 680, 126, 129, 3068, 3071, "and" +326, 27, 23, 681, 130, 133, 3072, 3075, "HbA" +326, 27, 24, 682, 134, 135, 3076, 3077, "₁" +326, 27, 25, 683, 136, 137, 3078, 3079, "(" +326, 27, 26, 684, 138, 139, 3080, 3081, "c" +326, 27, 27, 685, 140, 141, 3082, 3083, ")" +326, 27, 28, 686, 142, 148, 3084, 3090, "levels" +326, 27, 29, 687, 149, 150, 3091, 3092, "," +326, 27, 30, 688, 151, 154, 3093, 3096, "and" +326, 27, 31, 689, 155, 159, 3097, 3101, "more" +326, 27, 32, 690, 160, 169, 3102, 3111, "exenatide" +326, 27, 33, 691, 170, 180, 3112, 3122, "recipients" +326, 27, 34, 692, 181, 185, 3123, 3127, "than" +326, 27, 35, 693, 186, 193, 3128, 3135, "placebo" +326, 27, 36, 694, 194, 204, 3136, 3146, "recipients" +326, 27, 37, 695, 205, 213, 3147, 3155, "withdrew" +326, 27, 38, 696, 214, 221, 3156, 3163, "because" +326, 27, 39, 697, 222, 224, 3164, 3166, "of" +326, 27, 40, 698, 225, 232, 3167, 3174, "adverse" +326, 27, 41, 699, 233, 239, 3175, 3181, "events" +326, 27, 42, 700, 240, 241, 3182, 3183, "." +326, 28, 1, 701, 0, 10, 3184, 3194, "CONCLUSION" +326, 28, 2, 702, 11, 12, 3195, 3196, ":" +326, 28, 3, 703, 13, 19, 3197, 3203, "Adding" +326, 28, 4, 704, 20, 25, 3204, 3209, "twice" +326, 28, 5, 705, 26, 27, 3210, 3211, "-" +326, 28, 6, 706, 28, 33, 3212, 3217, "daily" +326, 28, 7, 707, 34, 43, 3218, 3227, "exenatide" +326, 28, 8, 708, 44, 54, 3228, 3238, "injections" +326, 28, 9, 709, 55, 63, 3239, 3247, "improved" +326, 28, 10, 710, 64, 72, 3248, 3256, "glycemic" +326, 28, 11, 711, 73, 80, 3257, 3264, "control" +326, 28, 12, 712, 81, 88, 3265, 3272, "without" +326, 28, 13, 713, 89, 98, 3273, 3282, "increased" +326, 28, 14, 714, 99, 111, 3283, 3295, "hypoglycemia" +326, 28, 15, 715, 112, 114, 3296, 3298, "or" +326, 28, 16, 716, 115, 121, 3299, 3305, "weight" +326, 28, 17, 717, 122, 126, 3306, 3310, "gain" +326, 28, 18, 718, 127, 129, 3311, 3313, "in" +326, 28, 19, 719, 130, 142, 3314, 3326, "participants" +326, 28, 20, 720, 143, 147, 3327, 3331, "with" +326, 28, 21, 721, 148, 160, 3332, 3344, "uncontrolled" +326, 28, 22, 722, 161, 165, 3345, 3349, "type" +326, 28, 23, 723, 166, 167, 3350, 3351, "2" +326, 28, 24, 724, 168, 176, 3352, 3360, "diabetes" +326, 28, 25, 725, 177, 180, 3361, 3364, "who" +326, 28, 26, 726, 181, 185, 3365, 3369, "were" +326, 28, 27, 727, 186, 195, 3370, 3379, "receiving" +326, 28, 28, 728, 196, 203, 3380, 3387, "insulin" +326, 28, 29, 729, 204, 212, 3388, 3396, "glargine" +326, 28, 30, 730, 213, 222, 3397, 3406, "treatment" +326, 28, 31, 731, 223, 224, 3407, 3408, "." +326, 29, 1, 732, 0, 7, 3409, 3416, "Adverse" +326, 29, 2, 733, 8, 14, 3417, 3423, "events" +326, 29, 3, 734, 15, 17, 3424, 3426, "of" +326, 29, 4, 735, 18, 27, 3427, 3436, "exenatide" +326, 29, 5, 736, 28, 36, 3437, 3445, "included" +326, 29, 6, 737, 37, 43, 3446, 3452, "nausea" +326, 29, 7, 738, 44, 45, 3453, 3454, "," +326, 29, 8, 739, 46, 54, 3455, 3463, "diarrhea" +326, 29, 9, 740, 55, 56, 3464, 3465, "," +326, 29, 10, 741, 57, 65, 3466, 3474, "vomiting" +326, 29, 11, 742, 66, 67, 3475, 3476, "," +326, 29, 12, 743, 68, 76, 3477, 3485, "headache" +326, 29, 13, 744, 77, 78, 3486, 3487, "," +326, 29, 14, 745, 79, 82, 3488, 3491, "and" +326, 29, 15, 746, 83, 95, 3492, 3504, "constipation" +326, 29, 16, 747, 96, 97, 3505, 3506, "." +326, 30, 1, 748, 0, 7, 3507, 3514, "PRIMARY" +326, 30, 2, 749, 8, 15, 3515, 3522, "FUNDING" +326, 30, 3, 750, 16, 22, 3523, 3529, "SOURCE" +326, 30, 4, 751, 23, 24, 3530, 3531, ":" +326, 30, 5, 752, 25, 33, 3532, 3540, "Alliance" +326, 30, 6, 753, 34, 36, 3541, 3543, "of" +326, 30, 7, 754, 37, 40, 3544, 3547, "Eli" +326, 30, 8, 755, 41, 46, 3548, 3553, "Lilly" +326, 30, 9, 756, 47, 50, 3554, 3557, "and" +326, 30, 10, 757, 51, 58, 3558, 3565, "Company" +326, 30, 11, 758, 59, 62, 3566, 3569, "and" +326, 30, 12, 759, 63, 69, 3570, 3576, "Amylin" +326, 30, 13, 760, 70, 85, 3577, 3592, "Pharmaceuticals" +326, 30, 14, 761, 86, 87, 3593, 3594, "." +326, 31, 1, 762, 0, 3, 3595, 3598, "DOI" +326, 31, 2, 763, 4, 5, 3599, 3600, ":" +326, 31, 3, 764, 6, 8, 3601, 3603, "10" +326, 31, 4, 765, 9, 10, 3604, 3605, "." +326, 31, 5, 766, 11, 15, 3606, 3610, "7326" +326, 31, 6, 767, 16, 17, 3611, 3612, "/" +326, 31, 7, 768, 18, 22, 3613, 3617, "0003" +326, 31, 8, 769, 23, 24, 3618, 3619, "-" +326, 31, 9, 770, 25, 29, 3620, 3624, "4819" +326, 31, 10, 771, 30, 31, 3625, 3626, "-" +326, 31, 11, 772, 32, 35, 3627, 3630, "154" +326, 31, 12, 773, 36, 37, 3631, 3632, "-" +326, 31, 13, 774, 38, 39, 3633, 3634, "2" +326, 31, 14, 775, 40, 41, 3635, 3636, "-" +326, 31, 15, 776, 42, 51, 3637, 3646, "201101180" +326, 31, 16, 777, 52, 53, 3647, 3648, "-" +326, 31, 17, 778, 54, 59, 3649, 3654, "00300" +326, 31, 18, 779, 60, 64, 3655, 3659, "PMID" +326, 31, 19, 780, 65, 66, 3660, 3661, ":" +326, 31, 20, 781, 67, 75, 3662, 3670, "21138825" +326, 31, 21, 782, 76, 77, 3671, 3672, "[" +326, 31, 22, 783, 78, 85, 3673, 3680, "Indexed" +326, 31, 23, 784, 86, 89, 3681, 3684, "for" +326, 31, 24, 785, 90, 97, 3685, 3692, "MEDLINE" +326, 31, 25, 786, 98, 99, 3693, 3694, "]" diff --git a/data/dm2 21138825_kwoodley.annodb b/data/dm2 21138825_kwoodley.annodb new file mode 100644 index 0000000..e57e50f --- /dev/null +++ b/data/dm2 21138825_kwoodley.annodb @@ -0,0 +1,139 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +19686, Journal, 0, 14, "Ann Intern Med", "", +19687, PublicationYear, 17, 21, "2011", "", +19695, Title, 134, 257, "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .", "", +19688, Frequency, 141, 154, "twice - daily", "", +19689, Exenatide, 155, 164, "exenatide", "", +19694, Precondition, 168, 221, "Basal insulin - treated patients with type 2 diabetes", "", +19690, Insulin, 174, 181, "insulin", "", +19691, Type2Diabetes, 206, 221, "type 2 diabetes", "", +19692, Randomized, 226, 236, "randomized", "", +19697, Author, 258, 265, "Buse JB", "", +19698, Author, 274, 287, "Bergenstal RM", "", +19699, Author, 290, 298, "Glass LC", "", +19700, Author, 301, 312, "Heilmann CR", "", +19701, Author, 315, 323, "Lewis MS", "", +19702, Author, 326, 333, "Kwan AY", "", +19703, Author, 336, 347, "Hoogwerf BJ", "", +19704, Author, 350, 362, "Rosenstock J", "", +19705, USA, 464, 467, "USA", "", +19706, Insulin, 623, 630, "Insulin", "", +19707, HbA1c, 701, 721, "hemoglobin A ₁ ( c )", "", +19708, HbA1c, 724, 735, "HbA ₁ ( c )", "", +19715, ObjectiveDescription, 760, 893, "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .", "", +19709, Frequency, 776, 789, "twice - daily", "", +19713, Exenatide, 790, 799, "exenatide", "", +19710, HbA1c, 818, 829, "HbA ₁ ( c )", "", +19711, Placebo, 847, 854, "placebo", "", +19714, Precondition, 858, 891, "people receiving insulin glargine", "", +19712, InsulinGlargine, 875, 891, "insulin glargine", "", +19716, Parallel, 903, 911, "Parallel", "", +19717, Randomized, 914, 924, "randomized", "", +24746, Placebo, 927, 934, "placebo", "", +19719, HbA1c, 982, 993, "HbA ₁ ( c )", "", +19720, Duration, 1020, 1053, "from October 2008 to January 2010", "", +36588, Multicenter, 1230, 1255, "59 centers in 5 countries", "", +19728, Precondition, 1269, 1456, "Adults with type 2 diabetes and an HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 % who were receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents ) .", "", +19721, Type2Diabetes, 1281, 1296, "type 2 diabetes", "", +19722, HbA1c, 1304, 1315, "HbA ₁ ( c )", "", +19723, Percentage, 1331, 1332, "%", "", +19724, Percentage, 1343, 1344, "%", "", +19725, InsulinGlargine, 1364, 1380, "insulin glargine", "", +19726, Metformin, 1410, 1419, "metformin", "", +19727, Pioglitazone, 1423, 1435, "pioglitazone", "", +19729, Exenatide, 1582, 1591, "exenatide", "", +19730, DoseValue, 1594, 1596, "10", "", +19731, Microgram, 1597, 1600, "µ g", "", +19734, Frequency, 1601, 1612, "twice daily", "", +19735, Placebo, 1618, 1625, "placebo", "", +19736, Duration, 1630, 1638, "30 weeks", "", +19737, HbA1c, 1690, 1701, "HbA ₁ ( c )", "", +19738, HbA1c_target, 1774, 1831, "HbA ₁ ( c ) values of 7 . 0 % or less and 6 . 5 % or less", "", +19741, FastingPlasmaGlucose, 1861, 1868, "glucose", "", +19742, BodyWeight, 1880, 1891, "body weight", "", +19743, EndPointDescription, 1894, 1913, "waist circumference", "", +36589, InsulinDose, 1916, 1928, "insulin dose", "", +19745, Hypoglycemia, 1931, 1943, "hypoglycemia", "", +19746, EndPointDescription, 1950, 1964, "adverse events", "", +19751, FinalNumPatientsArm, 1977, 1980, "112", "", +19749, NumberPatientsArm, 1984, 1987, "138", "", +19752, Exenatide, 1988, 1997, "exenatide", "", +19753, FinalNumPatientsArm, 2013, 2016, "101", "", +19754, NumberPatientsArm, 2020, 2023, "123", "", +19755, Placebo, 2024, 2031, "placebo", "", +19756, HbA1c, 2069, 2080, "HbA ₁ ( c )", "", +19757, Reduction, 2100, 2106, "1 . 74", "", +19759, Percentage, 2107, 2108, "%", "", +19761, Exenatide, 2114, 2123, "exenatide", "", +19758, Reduction, 2128, 2134, "1 . 04", "", +19760, Percentage, 2135, 2136, "%", "", +19762, Placebo, 2142, 2149, "placebo", "", +19763, DiffGroupAbsValue, 2181, 2189, "- 0 . 69", "", +19764, Percentage, 2190, 2191, "%", "", +19767, ConfIntervalDiff, 2194, 2228, "95 % CI , - 0 . 93 % to - 0 . 46 %", "", +19765, Percentage, 2213, 2214, "%", "", +19766, Percentage, 2227, 2228, "%", "", +19768, PvalueDiff, 2233, 2244, "P < 0 . 001", "", +19769, BodyWeight, 2249, 2255, "Weight", "", +19770, Reduction, 2269, 2274, "1 . 8", "", +19771, Kg, 2275, 2277, "kg", "", +19775, Exenatide, 2283, 2292, "exenatide", "", +19774, Increment, 2310, 2315, "1 . 0", "", +19772, Kg, 2316, 2318, "kg", "", +19776, Placebo, 2324, 2331, "placebo", "", +19777, DiffGroupAbsValue, 2363, 2370, "- 2 . 7", "", +19773, Kg, 2371, 2373, "kg", "", +19778, ConfIntervalDiff, 2376, 2399, "CI , - 3 . 7 to - 1 . 7", "", +36590, InsulinDose, 2427, 2441, "insulin dosage", "", +19780, Exenatide, 2447, 2456, "exenatide", "", +19781, Placebo, 2461, 2468, "placebo", "", +19782, ResultMeasuredValue, 2474, 2476, "13", "", +19786, BioAndMedicalUnit, 2477, 2482, "U / d", "", +19783, ResultMeasuredValue, 2487, 2489, "20", "", +19788, BioAndMedicalUnit, 2490, 2495, "U / d", "", +19791, ObservedResult, 2498, 2567, "The estimated rate of minor hypoglycemia was similar between groups .", "", +19789, Hypoglycemia, 2526, 2538, "hypoglycemia", "", +19792, NumPatientsLeftArm, 2568, 2576, "Thirteen", "", +19794, Exenatide, 2577, 2586, "exenatide", "", +19793, NumPatientsLeftArm, 2602, 2603, "1", "", +19795, Placebo, 2604, 2611, "placebo", "", +19796, EndPointDescription, 2656, 2670, "adverse events", "", +19804, PvalueDiff, 2673, 2684, "P < 0 . 010", "", +19797, Nausea, 2698, 2704, "nausea", "", +19805, PercentageAffected, 2707, 2709, "41", "", +19806, PercentageAffected, 2717, 2718, "8", "", +19798, EndPointDescription, 2725, 2733, "diarrhea", "", +19807, PercentageAffected, 2736, 2738, "18", "", +19808, PercentageAffected, 2746, 2747, "8", "", +19832, EndPointDescription, 2754, 2762, "vomiting", "", +19809, PercentageAffected, 2765, 2767, "18", "", +19810, PercentageAffected, 2775, 2776, "4", "", +19800, Headache, 2783, 2791, "headache", "", +19811, PercentageAffected, 2794, 2796, "14", "", +19812, PercentageAffected, 2804, 2805, "4", "", +19801, Constipation, 2816, 2828, "constipation", "", +19813, PercentageAffected, 2831, 2833, "10", "", +19814, PercentageAffected, 2841, 2842, "2", "", +19802, Exenatide, 2864, 2873, "exenatide", "", +19803, Placebo, 2884, 2891, "placebo", "", +19815, HbA1c, 3072, 3083, "HbA ₁ ( c )", "", +19816, Exenatide, 3102, 3111, "exenatide", "", +19817, Placebo, 3128, 3135, "placebo", "", +19818, EndPointDescription, 3167, 3181, "adverse events", "", +19827, ConclusionComment, 3197, 3408, "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .", "", +19819, Frequency, 3204, 3217, "twice - daily", "", +19820, Exenatide, 3218, 3227, "exenatide", "", +19822, Hypoglycemia, 3283, 3295, "hypoglycemia", "", +19823, BodyWeight, 3299, 3305, "weight", "", +19826, Precondition, 3332, 3406, "uncontrolled type 2 diabetes who were receiving insulin glargine treatment", "", +19824, Type2Diabetes, 3345, 3360, "type 2 diabetes", "", +19825, InsulinGlargine, 3380, 3396, "insulin glargine", "", +19828, EndPointDescription, 3409, 3423, "Adverse events", "", +19836, ConclusionComment, 3409, 3506, "Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation .", "", +19821, Exenatide, 3427, 3436, "exenatide", "", +19829, Nausea, 3446, 3452, "nausea", "", +19830, EndPointDescription, 3455, 3463, "diarrhea", "", +19831, EndPointDescription, 3466, 3474, "vomiting", "", +19833, Headache, 3477, 3485, "headache", "", +19834, Constipation, 3492, 3504, "constipation", "", +19835, PMID, 3662, 3670, "21138825", "", diff --git a/data/dm2 21138825_kwoodley.n-triples b/data/dm2 21138825_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21138825_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21781152_admin.annodb b/data/dm2 21781152_admin.annodb new file mode 100644 index 0000000..6046b72 --- /dev/null +++ b/data/dm2 21781152_admin.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +1, PublicationYear, 13, 17, "2011", "", " \"2011\"." +9, Title, 103, 274, "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .", "", " \"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .\"." +2, Linagliptin, 126, 137, "linagliptin", "", +8, Precondition, 141, 241, "persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea", "", +3, Type2Diabetes, 154, 169, "type 2 diabetes", "", " ." +4, Metformin, 214, 223, "metformin", "", +5, Sulfonylureas, 228, 241, "sulphonylurea", "", +6, Duration, 246, 255, "24 - week", "", " \"24 - week\"." +7, Randomized, 256, 266, "randomized", "", " ." +10, Author, 275, 283, "Owens DR", "", " \"Owens DR\"." +11, Author, 292, 301, "Swallow R", "", " \"Swallow R\"." +12, Author, 304, 311, "Dugi KA", "", " \"Dugi KA\"." +13, Author, 314, 323, "Woerle HJ", "", " \"Woerle HJ\"." +14, UK, 395, 397, "UK", "", " ." +23, ObjectiveDescription, 531, 619, "To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin", "", +15, Linagliptin, 608, 619, "linagliptin", "", +24, ObjectiveDescription, 620, 794, "in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment .", "", " \"in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment .\"." +22, Precondition, 623, 792, "persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment", "", " \"persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment\"." +16, Type2Diabetes, 636, 660, "Type 2 diabetes mellitus", "", +17, HbA1c, 687, 697, "HbA ( 1c )", "", +79730, Millimoles_per_mole, 706, 710, "mmol", "", +18, Percentage, 734, 735, "%", "", +20, Metformin, 743, 752, "metformin", "", +21, Sulfonylureas, 757, 770, "sulphonylurea", "", +25, Multicenter, 807, 821, "multi - centre", "", " ." +26, Duration, 824, 833, "24 - week", "", +27, Randomized, 836, 846, "randomized", "", +28, DoubleBlind, 849, 863, "double - blind", "", " ." +29, Parallel, 866, 882, "parallel - group", "", " ." +30, NumberPatientsCT, 892, 896, "1058", "", " \"1058\"." +31, Linagliptin, 916, 927, "linagliptin", "", " ." +32, DoseValue, 930, 931, "5", "", " \"5\"." +33, mg, 932, 934, "mg", "", " ." +34, Frequency, 935, 945, "once daily", "", " \"once daily\"." +35, Placebo, 952, 959, "placebo", "", " ." +36, Metformin, 974, 983, "metformin", "", +37, Sulfonylureas, 989, 1002, "sulphonylurea", "", +38, HbA1c, 1044, 1054, "HbA ( 1c )", "", +139, TimePoint, 1061, 1069, "24 weeks", "", +99, TimePoint, 1085, 1092, "week 24", "", " \"week 24\". \"week 24\"." +40, Linagliptin, 1099, 1110, "linagliptin", "", +41, Placebo, 1111, 1118, "placebo", "", +42, HbA1c, 1131, 1141, "HbA ( 1c )", "", " ." +144, Mean, 1151, 1155, "mean", "", " . ." +145, TimePoint, 1168, 1176, "baseline", "", +106305, DiffGroupAbsValue, 1181, 1184, "- 7", "", +79735, Millimoles_per_mole, 1185, 1195, "mmol / mol", "", " ." +106307, DiffGroupAbsValue, 1198, 1206, "- 0 . 62", "", " \"- 0 . 62\"." +46, Percentage, 1207, 1208, "%", "", +106309, ConfIntervalDiff, 1213, 1267, "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %", "", " \"95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %\"." +79741, Millimoles_per_mole, 1232, 1242, "mmol / mol", "", +49, Percentage, 1266, 1267, "%", "", +106308, PvalueDiff, 1272, 1284, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +166, SubGroupDescription, 1294, 1361, "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )", "", " \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\". \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\"." +156, HbA1c, 1321, 1331, "HbA ( 1c )", "", +79745, Millimoles_per_mole, 1337, 1347, "mmol / mol", "", +158, Percentage, 1358, 1359, "%", "", +59540, HbA1c_target, 1374, 1414, "HbA ( 1c ) < 53 mmol / mol ( < 7 . 0 % )", "", " ." +79747, Millimoles_per_mole, 1390, 1400, "mmol / mol", "", +160, Percentage, 1411, 1412, "%", "", +50, Linagliptin, 1420, 1431, "linagliptin", "", +51, Placebo, 1446, 1453, "placebo", "", +54, PercentageAffected, 1456, 1462, "29 . 2", "", +55, PercentageAffected, 1470, 1475, "8 . 1", "", " \"8 . 1\"." +56, PvalueDiff, 1480, 1492, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +58, FastingPlasmaGlucose, 1497, 1519, "Fasting plasma glucose", "", " ." +59, Linagliptin, 1537, 1548, "linagliptin", "", +60, Placebo, 1561, 1568, "placebo", "", +106310, DiffGroupAbsValue, 1571, 1578, "- 0 . 7", "", " \"- 0 . 7\"." +62, Millimoles_per_litre, 1579, 1587, "mmol / l", "", " ." +106311, ConfIntervalDiff, 1590, 1616, "95 % CI - 1 . 0 to - 0 . 4", "", " \"95 % CI - 1 . 0 to - 0 . 4\"." +106312, PvalueDiff, 1619, 1631, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +106313, ObservedResult, 1636, 1727, "Improvements in homeostasis model assessment of β- cell function were seen with linagliptin", "", " \"Improvements in homeostasis model assessment of β- cell function were seen with linagliptin\"." +65, EndPointDescription, 1652, 1700, "homeostasis model assessment of β- cell function", "", " . ." +66, Linagliptin, 1716, 1727, "linagliptin", "", +180, PValueChangeValue, 1730, 1741, "P < 0 . 001", "", " \"P < 0 . 001\"." +181, EndPointDescription, 1788, 1808, "severe adverse event", "", " . ." +71, Linagliptin, 1834, 1845, "linagliptin", "", +69, PercentageAffected, 1846, 1851, "2 . 4", "", " \"2 . 4\"." +72, Placebo, 1856, 1863, "placebo", "", +70, PercentageAffected, 1864, 1869, "1 . 5", "", " \"1 . 5\"." +73, SymptomaticHypoglycemia, 1876, 1901, "Symptomatic hypoglycaemia", "", " ." +74, PercentageAffected, 1914, 1920, "16 . 7", "", " \"16 . 7\"." +75, PercentageAffected, 1925, 1931, "10 . 3", "", " \"10 . 3\"." +76, Linagliptin, 1941, 1952, "linagliptin", "", +77, Placebo, 1957, 1964, "placebo", "", +78, Hypoglycemia, 1989, 2002, "Hypoglycaemia", "", +82, ObservedResult, 2003, 2033, "was generally mild or moderate", "", +79, SevereHypoglycemia, 2036, 2056, "severe hypoglycaemia", "", " ." +80, PercentageAffected, 2073, 2078, "2 . 7", "", " \"2 . 7\"." +81, PercentageAffected, 2083, 2088, "4 . 8", "", " \"4 . 8\"." +199, SubGroupDescription, 2098, 2146, "participants experiencing hypoglycaemic episodes", "", " \"participants experiencing hypoglycaemic episodes\". \"participants experiencing hypoglycaemic episodes\"." +83, Hypoglycemia, 2124, 2146, "hypoglycaemic episodes", "", +84, Linagliptin, 2154, 2165, "linagliptin", "", +85, Placebo, 2170, 2177, "placebo", "", +88, ObservedResult, 2202, 2242, "No significant weight changes were noted", "", +202, BodyWeight, 2217, 2223, "weight", "", +93, ConclusionComment, 2259, 2438, "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .", "", " \"In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .\"." +89, Type2Diabetes, 2276, 2291, "Type 2 diabetes", "", +90, Linagliptin, 2301, 2312, "linagliptin", "", +91, Metformin, 2316, 2325, "metformin", "", +92, Sulfonylureas, 2354, 2367, "sulphonylurea", "", +94, Linagliptin, 2439, 2450, "Linagliptin", "", +97, ConclusionComment, 2439, 2615, "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .", "", " \"Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .\"." +95, Metformin, 2584, 2593, "metformin", "", +96, Sulfonylureas, 2600, 2613, "sulphonylurea", "", +98, PMID, 2736, 2744, "21781152", "", " \"21781152\"." diff --git a/data/dm2 21781152_admin.n-triples b/data/dm2 21781152_admin.n-triples new file mode 100644 index 0000000..82ce440 --- /dev/null +++ b/data/dm2 21781152_admin.n-triples @@ -0,0 +1,201 @@ +# RDF export of group: Publication + . + "Publication 29847" . + "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study ." . + "Owens DR" . + "2011" . + "Diabet Med ." . + "21781152" . + . + "Swallow R" . + "Dugi KA" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 29854" . + "1058" . + "24 - week" . + . + . + . + "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated ." . + . + . + . + . + . + "in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment ." . + . + . + . + "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea ." . + . + . + . +# RDF export of group: Population + . + "Population 29870" . + "persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "beta" . + . + . + . + . + . + . + "sev" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "sevhyp" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . +# RDF export of group: Intervention + . + "llin" . + . + "once daily" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba" . + . + "week 24" . + . + "hbat lin" . + . + "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )" . + . + "hbat pl" . + . + "8 . 1" . + "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )" . + . + "fpg l" . + . + . + "beta" . + . + "P < 0 . 001" . + "Improvements in homeostasis model assessment of β- cell function were seen with linagliptin" . + . + "sev lin" . + . + "2 . 4" . + . + "sev pl" . + . + "1 . 5" . + . + "hyp lin" . + . + "16 . 7" . + . + "hyp pla" . + . + "10 . 3" . + . + "sevhyp lin" . + . + "2 . 7" . + "participants experiencing hypoglycaemic episodes" . + . + "sevhyp pla" . + . + "4 . 8" . + "participants experiencing hypoglycaemic episodes" . + . + "hba p" . + . + "week 24" . + . + "fpg p" . + . +# RDF export of group: DiffBetweenGroups + . + "hbat" . + "P < 0 . 0001" . + . + . + . + "hba" . + "- 0 . 62" . + "P < 0 . 0001" . + "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %" . + . + . + . + "fpg" . + "- 0 . 7" . + "P < 0 . 0001" . + "95 % CI - 1 . 0 to - 0 . 4" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21781152_akramersunderbrink.annodb b/data/dm2 21781152_akramersunderbrink.annodb new file mode 100644 index 0000000..dd39e44 --- /dev/null +++ b/data/dm2 21781152_akramersunderbrink.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +39772, Journal, 0, 10, "Diabet Med", "", " \"Diabet Med\"." +39773, PublicationYear, 13, 17, "2011", "", " \"2011\"." +39781, Title, 103, 274, "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .", "", " \"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .\"." +39774, Linagliptin, 126, 137, "linagliptin", "", +39775, Type2Diabetes, 154, 169, "type 2 diabetes", "", +39780, Precondition, 170, 241, "inadequately controlled by a combination of metformin and sulphonylurea", "", +39776, Metformin, 214, 223, "metformin", "", +39777, Drug, 228, 241, "sulphonylurea", "", +39778, Duration, 246, 255, "24 - week", "", " \"24 - week\"." +39779, Randomized, 256, 266, "randomized", "", " ." +39782, Author, 275, 283, "Owens DR", "", " \"Owens DR\"." +39783, Author, 292, 301, "Swallow R", "", " \"Swallow R\"." +39784, Author, 304, 311, "Dugi KA", "", " \"Dugi KA\"." +39785, Author, 314, 323, "Woerle HJ", "", " \"Woerle HJ\"." +39786, UK, 395, 397, "UK", "", +39795, ObjectiveDescription, 531, 782, "To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination", "", " \"To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination\"." +39787, Linagliptin, 608, 619, "linagliptin", "", +39788, Type2Diabetes, 636, 660, "Type 2 diabetes mellitus", "", " ." +39789, Precondition, 661, 792, "inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment", "", " \"inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment\"." +39790, HbA1c, 687, 697, "HbA ( 1c )", "", +39791, BioAndMedicalUnit, 706, 716, "mmol / mol", "", +39792, Percentage, 734, 735, "%", "", +39793, Metformin, 743, 752, "metformin", "", +39794, Drug, 757, 770, "sulphonylurea", "", +39796, ObjectiveDescription, 783, 794, "treatment .", "", " \"treatment .\"." +39797, Multicenter, 807, 821, "multi - centre", "", " ." +39798, Duration, 824, 833, "24 - week", "", +39799, Randomized, 836, 846, "randomized", "", +39800, DoubleBlind, 849, 863, "double - blind", "", " ." +39801, Parallel, 866, 882, "parallel - group", "", " ." +39802, NumberPatientsCT, 892, 896, "1058", "", " \"1058\"." +39803, Linagliptin, 916, 927, "linagliptin", "", " ." +39804, DoseValue, 930, 934, "5 mg", "", " \"5 mg\"." +39805, mg, 932, 934, "mg", "", " ." +39806, Frequency, 935, 945, "once daily", "", " \"once daily\"." +39807, Placebo, 952, 959, "placebo", "", " ." +39808, Metformin, 974, 983, "metformin", "", " ." +39809, Drug, 989, 1002, "sulphonylurea", "", " . ." +39810, HbA1c, 1044, 1054, "HbA ( 1c )", "", +39811, TimePoint, 1061, 1069, "24 weeks", "", +39812, TimePoint, 1085, 1092, "week 24", "", +39813, Linagliptin, 1099, 1110, "linagliptin", "", +39814, Placebo, 1111, 1118, "placebo", "", +39815, HbA1c, 1131, 1141, "HbA ( 1c )", "", " ." +39816, Mean, 1151, 1155, "mean", "", " . ." +39817, TimePoint, 1168, 1176, "baseline", "", +39818, ChangeValue, 1181, 1184, "- 7", "", " \"- 7\"." +39819, BioAndMedicalUnit, 1185, 1195, "mmol / mol", "", " . ." +92458, ChangeValue, 1198, 1206, "- 0 . 62", "", +39821, Percentage, 1207, 1208, "%", "", +39822, ConfIntervalChangeValue, 1213, 1267, "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %", "", " \"95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %\"." +39823, Percentage, 1216, 1217, "%", "", +39825, BioAndMedicalUnit, 1232, 1242, "mmol / mol", "", +39824, Percentage, 1266, 1267, "%", "", +39826, PValueChangeValue, 1272, 1284, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +39839, SubGroupDescription, 1294, 1361, "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )", "", " \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\". \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\"." +39827, TimePoint, 1312, 1320, "baseline", "", +39828, HbA1c, 1321, 1331, "HbA ( 1c )", "", +39829, BioAndMedicalUnit, 1337, 1347, "mmol / mol", "", +39830, Percentage, 1358, 1359, "%", "", +39840, HbA1c_target, 1374, 1414, "HbA ( 1c ) < 53 mmol / mol ( < 7 . 0 % )", "", " ." +39832, BioAndMedicalUnit, 1390, 1400, "mmol / mol", "", +39833, Percentage, 1411, 1412, "%", "", +39834, Linagliptin, 1420, 1431, "linagliptin", "", +39835, Placebo, 1446, 1453, "placebo", "", +39841, PercentageAffected, 1456, 1462, "29 . 2", "", " \"29 . 2\"." +39836, Percentage, 1463, 1464, "%", "", +39842, PercentageAffected, 1470, 1475, "8 . 1", "", " \"8 . 1\"." +39837, Percentage, 1476, 1477, "%", "", +39838, PvalueDiff, 1480, 1492, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +39843, FastingBloodGlucose, 1497, 1519, "Fasting plasma glucose", "", " ." +39844, Linagliptin, 1537, 1548, "linagliptin", "", +39845, Placebo, 1561, 1568, "placebo", "", +39846, ChangeValue, 1571, 1578, "- 0 . 7", "", " \"- 0 . 7\"." +39847, Millimoles_per_litre, 1579, 1587, "mmol / l", "", " ." +39848, ConfIntervalChangeValue, 1590, 1616, "95 % CI - 1 . 0 to - 0 . 4", "", " \"95 % CI - 1 . 0 to - 0 . 4\"." +39849, Percentage, 1593, 1594, "%", "", +39850, PValueChangeValue, 1619, 1631, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +39851, EndPointDescription, 1636, 1700, "Improvements in homeostasis model assessment of β- cell function", "", " . ." +39852, Linagliptin, 1716, 1727, "linagliptin", "", +39853, PValueChangeValue, 1730, 1741, "P < 0 . 001", "", " \"P < 0 . 001\"." +39854, EndPointDescription, 1788, 1808, "severe adverse event", "", " . ." +39855, Linagliptin, 1834, 1845, "linagliptin", "", +39857, PercentageAffected, 1846, 1851, "2 . 4", "", " \"2 . 4\"." +39859, Percentage, 1852, 1853, "%", "", +39856, Placebo, 1856, 1863, "placebo", "", +39858, PercentageAffected, 1864, 1869, "1 . 5", "", " \"1 . 5\"." +39860, Percentage, 1870, 1871, "%", "", +39861, SymptomaticHypoglycemia, 1876, 1901, "Symptomatic hypoglycaemia", "", " ." +39862, PercentageAffected, 1914, 1920, "16 . 7", "", " \"16 . 7\"." +39863, PercentageAffected, 1925, 1931, "10 . 3", "", " \"10 . 3\"." +39864, Percentage, 1932, 1933, "%", "", +39865, Linagliptin, 1941, 1952, "linagliptin", "", +39866, Placebo, 1957, 1964, "placebo", "", +39867, Hypoglycemia, 1989, 2002, "Hypoglycaemia", "", +39868, SevereHypoglycemia, 2036, 2056, "severe hypoglycaemia", "", " ." +39869, PercentageAffected, 2073, 2078, "2 . 7", "", " \"2 . 7\"." +39870, PercentageAffected, 2083, 2088, "4 . 8", "", " \"4 . 8\"." +39871, Percentage, 2089, 2090, "%", "", +39872, SubGroupDescription, 2098, 2146, "participants experiencing hypoglycaemic episodes", "", " \"participants experiencing hypoglycaemic episodes\". \"participants experiencing hypoglycaemic episodes\"." +39873, Linagliptin, 2154, 2165, "linagliptin", "", +39874, Placebo, 2170, 2177, "placebo", "", +39875, BodyWeight, 2217, 2223, "weight", "", +39884, ConclusionComment, 2259, 2438, "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .", "", " \"In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .\"." +39876, Type2Diabetes, 2276, 2291, "Type 2 diabetes", "", +39877, Linagliptin, 2301, 2312, "linagliptin", "", +39878, Metformin, 2316, 2325, "metformin", "", +39879, Drug, 2354, 2367, "sulphonylurea", "", +39880, Linagliptin, 2439, 2450, "Linagliptin", "", +39885, ConclusionComment, 2439, 2615, "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .", "", " \"Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .\"." +39881, Precondition, 2514, 2613, "inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea", "", +39882, Metformin, 2584, 2593, "metformin", "", +39883, Drug, 2600, 2613, "sulphonylurea", "", +39886, PMID, 2736, 2744, "21781152", "", " \"21781152\"." diff --git a/data/dm2 21781152_akramersunderbrink.n-triples b/data/dm2 21781152_akramersunderbrink.n-triples new file mode 100644 index 0000000..484c623 --- /dev/null +++ b/data/dm2 21781152_akramersunderbrink.n-triples @@ -0,0 +1,210 @@ +# RDF export of group: Publication + . + "Publication 23506" . + "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study ." . + "Owens DR" . + "2011" . + "Diabet Med" . + "21781152" . + . + "Swallow R" . + "Dugi KA" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 23513" . + "To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination" . + "1058" . + "24 - week" . + . + . + . + "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated ." . + . + . + . + . + . + "treatment ." . + . + . + . + "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea ." . + . +# RDF export of group: Population + . + "Population 23529" . + "inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + . + "hba t" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "beta" . + . + . + . + . + . + . + "adv" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "sev" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + "once daily" . + . + . + "pla" . + . + . + . + "met" . + . + . + . + "sul" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5 mg" . + . + . + . + "pla" . + . + . + . + . + "met" . + . + . + . + . + "sul" . + . + . + . + . +# RDF export of group: Outcome + . + "hba lin" . + . + "- 7" . + "P < 0 . 0001" . + "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %" . + . + "hba t lin" . + . + "29 . 2" . + "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )" . + . + "hba t pla" . + . + "8 . 1" . + "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )" . + . + "fpg lin" . + . + "- 0 . 7" . + "P < 0 . 0001" . + "95 % CI - 1 . 0 to - 0 . 4" . + . + "beta lin" . + . + "P < 0 . 001" . + . + "adv lin" . + . + "2 . 4" . + . + "adv pla" . + . + "1 . 5" . + . + "hyp lin" . + . + "16 . 7" . + . + "hyp pla" . + . + "10 . 3" . + . + "sev lin" . + . + "2 . 7" . + "participants experiencing hypoglycaemic episodes" . + . + "sev pla" . + . + "4 . 8" . + "participants experiencing hypoglycaemic episodes" . +# RDF export of group: DiffBetweenGroups + . + "hba t" . + "P < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21781152_export.csv b/data/dm2 21781152_export.csv new file mode 100644 index 0000000..1d0c08b --- /dev/null +++ b/data/dm2 21781152_export.csv @@ -0,0 +1,602 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +322, 1, 1, 1, 0, 6, 0, 6, "Diabet" +322, 1, 2, 2, 7, 10, 7, 10, "Med" +322, 1, 3, 3, 11, 12, 11, 12, "." +322, 2, 1, 4, 0, 4, 13, 17, "2011" +322, 2, 2, 5, 5, 8, 18, 21, "Nov" +322, 2, 3, 6, 9, 10, 22, 23, ";" +322, 2, 4, 7, 11, 13, 24, 26, "28" +322, 2, 5, 8, 14, 15, 27, 28, "(" +322, 2, 6, 9, 16, 18, 29, 31, "11" +322, 2, 7, 10, 19, 20, 32, 33, ")" +322, 2, 8, 11, 21, 22, 34, 35, ":" +322, 2, 9, 12, 23, 27, 36, 40, "1352" +322, 2, 10, 13, 28, 29, 41, 42, "-" +322, 2, 11, 14, 30, 32, 43, 45, "61" +322, 2, 12, 15, 33, 34, 46, 47, "." +322, 2, 13, 16, 35, 38, 48, 51, "doi" +322, 2, 14, 17, 39, 40, 52, 53, ":" +322, 2, 15, 18, 41, 43, 54, 56, "10" +322, 2, 16, 19, 44, 45, 57, 58, "." +322, 2, 17, 20, 46, 50, 59, 63, "1111" +322, 2, 18, 21, 51, 52, 64, 65, "/" +322, 2, 19, 22, 53, 54, 66, 67, "j" +322, 2, 20, 23, 55, 56, 68, 69, "." +322, 2, 21, 24, 57, 61, 70, 74, "1464" +322, 2, 22, 25, 62, 63, 75, 76, "-" +322, 2, 23, 26, 64, 68, 77, 81, "5491" +322, 2, 24, 27, 69, 70, 82, 83, "." +322, 2, 25, 28, 71, 75, 84, 88, "2011" +322, 2, 26, 29, 76, 77, 89, 90, "." +322, 2, 27, 30, 78, 83, 91, 96, "03387" +322, 2, 28, 31, 84, 85, 97, 98, "." +322, 2, 29, 32, 86, 87, 99, 100, "x" +322, 2, 30, 33, 88, 89, 101, 102, "." +322, 3, 1, 34, 0, 8, 103, 111, "Efficacy" +322, 3, 2, 35, 9, 12, 112, 115, "and" +322, 3, 3, 36, 13, 19, 116, 122, "safety" +322, 3, 4, 37, 20, 22, 123, 125, "of" +322, 3, 5, 38, 23, 34, 126, 137, "linagliptin" +322, 3, 6, 39, 35, 37, 138, 140, "in" +322, 3, 7, 40, 38, 45, 141, 148, "persons" +322, 3, 8, 41, 46, 50, 149, 153, "with" +322, 3, 9, 42, 51, 55, 154, 158, "type" +322, 3, 10, 43, 56, 57, 159, 160, "2" +322, 3, 11, 44, 58, 66, 161, 169, "diabetes" +322, 3, 12, 45, 67, 79, 170, 182, "inadequately" +322, 3, 13, 46, 80, 90, 183, 193, "controlled" +322, 3, 14, 47, 91, 93, 194, 196, "by" +322, 3, 15, 48, 94, 95, 197, 198, "a" +322, 3, 16, 49, 96, 107, 199, 210, "combination" +322, 3, 17, 50, 108, 110, 211, 213, "of" +322, 3, 18, 51, 111, 120, 214, 223, "metformin" +322, 3, 19, 52, 121, 124, 224, 227, "and" +322, 3, 20, 53, 125, 138, 228, 241, "sulphonylurea" +322, 3, 21, 54, 139, 140, 242, 243, ":" +322, 3, 22, 55, 141, 142, 244, 245, "a" +322, 3, 23, 56, 143, 145, 246, 248, "24" +322, 3, 24, 57, 146, 147, 249, 250, "-" +322, 3, 25, 58, 148, 152, 251, 255, "week" +322, 3, 26, 59, 153, 163, 256, 266, "randomized" +322, 3, 27, 60, 164, 169, 267, 272, "study" +322, 3, 28, 61, 170, 171, 273, 274, "." +322, 4, 1, 62, 0, 5, 275, 280, "Owens" +322, 4, 2, 63, 6, 8, 281, 283, "DR" +322, 4, 3, 64, 9, 10, 284, 285, "(" +322, 4, 4, 65, 11, 12, 286, 287, "1" +322, 4, 5, 66, 13, 14, 288, 289, ")" +322, 4, 6, 67, 15, 16, 290, 291, "," +322, 4, 7, 68, 17, 24, 292, 299, "Swallow" +322, 4, 8, 69, 25, 26, 300, 301, "R" +322, 4, 9, 70, 27, 28, 302, 303, "," +322, 4, 10, 71, 29, 33, 304, 308, "Dugi" +322, 4, 11, 72, 34, 36, 309, 311, "KA" +322, 4, 12, 73, 37, 38, 312, 313, "," +322, 4, 13, 74, 39, 45, 314, 320, "Woerle" +322, 4, 14, 75, 46, 48, 321, 323, "HJ" +322, 4, 15, 76, 49, 50, 324, 325, "." +322, 5, 1, 77, 0, 6, 326, 332, "Author" +322, 5, 2, 78, 7, 18, 333, 344, "information" +322, 5, 3, 79, 19, 20, 345, 346, ":" +322, 5, 4, 80, 21, 22, 347, 348, "(" +322, 5, 5, 81, 23, 24, 349, 350, "1" +322, 5, 6, 82, 25, 26, 351, 352, ")" +322, 5, 7, 83, 27, 37, 353, 363, "University" +322, 5, 8, 84, 38, 46, 364, 372, "Hospital" +322, 5, 9, 85, 47, 56, 373, 382, "Llandough" +322, 5, 10, 86, 57, 58, 383, 384, "," +322, 5, 11, 87, 59, 66, 385, 392, "Cardiff" +322, 5, 12, 88, 67, 68, 393, 394, "," +322, 5, 13, 89, 69, 71, 395, 397, "UK" +322, 5, 14, 90, 72, 73, 398, 399, "." +322, 6, 1, 91, 0, 7, 400, 407, "Erratum" +322, 6, 2, 92, 8, 10, 408, 410, "in" +322, 6, 3, 93, 11, 17, 411, 417, "Diabet" +322, 6, 4, 94, 18, 21, 418, 421, "Med" +322, 6, 5, 95, 22, 23, 422, 423, "." +322, 7, 1, 96, 0, 4, 424, 428, "2012" +322, 7, 2, 97, 5, 8, 429, 432, "Jan" +322, 7, 3, 98, 9, 10, 433, 434, ";" +322, 7, 4, 99, 11, 13, 435, 437, "29" +322, 7, 5, 100, 14, 15, 438, 439, "(" +322, 7, 6, 101, 16, 17, 440, 441, "1" +322, 7, 7, 102, 18, 19, 442, 443, ")" +322, 7, 8, 103, 20, 21, 444, 445, ":" +322, 7, 9, 104, 22, 25, 446, 449, "158" +322, 7, 10, 105, 26, 27, 450, 451, "." +322, 8, 1, 106, 0, 7, 452, 459, "Comment" +322, 8, 2, 107, 8, 10, 460, 462, "in" +322, 8, 3, 108, 11, 17, 463, 469, "Expert" +322, 8, 4, 109, 18, 22, 470, 474, "Opin" +322, 8, 5, 110, 23, 35, 475, 487, "Pharmacother" +322, 8, 6, 111, 36, 37, 488, 489, "." +322, 9, 1, 112, 0, 4, 490, 494, "2012" +322, 9, 2, 113, 5, 8, 495, 498, "Jul" +322, 9, 3, 114, 9, 10, 499, 500, ";" +322, 9, 4, 115, 11, 13, 501, 503, "13" +322, 9, 5, 116, 14, 15, 504, 505, "(" +322, 9, 6, 117, 16, 18, 506, 508, "10" +322, 9, 7, 118, 19, 20, 509, 510, ")" +322, 9, 8, 119, 21, 22, 511, 512, ":" +322, 9, 9, 120, 23, 27, 513, 517, "1535" +322, 9, 10, 121, 28, 29, 518, 519, "-" +322, 9, 11, 122, 30, 31, 520, 521, "9" +322, 9, 12, 123, 32, 33, 522, 523, "." +322, 10, 1, 124, 0, 4, 524, 528, "AIMS" +322, 10, 2, 125, 5, 6, 529, 530, ":" +322, 10, 3, 126, 7, 9, 531, 533, "To" +322, 10, 4, 127, 10, 17, 534, 541, "examine" +322, 10, 5, 128, 18, 21, 542, 545, "the" +322, 10, 6, 129, 22, 30, 546, 554, "efficacy" +322, 10, 7, 130, 31, 34, 555, 558, "and" +322, 10, 8, 131, 35, 41, 559, 565, "safety" +322, 10, 9, 132, 42, 44, 566, 568, "of" +322, 10, 10, 133, 45, 48, 569, 572, "the" +322, 10, 11, 134, 49, 59, 573, 583, "dipeptidyl" +322, 10, 12, 135, 60, 69, 584, 593, "peptidase" +322, 10, 13, 136, 70, 71, 594, 595, "-" +322, 10, 14, 137, 72, 73, 596, 597, "4" +322, 10, 15, 138, 74, 83, 598, 607, "inhibitor" +322, 10, 16, 139, 84, 95, 608, 619, "linagliptin" +322, 10, 17, 140, 96, 98, 620, 622, "in" +322, 10, 18, 141, 99, 106, 623, 630, "persons" +322, 10, 19, 142, 107, 111, 631, 635, "with" +322, 10, 20, 143, 112, 116, 636, 640, "Type" +322, 10, 21, 144, 117, 118, 641, 642, "2" +322, 10, 22, 145, 119, 127, 643, 651, "diabetes" +322, 10, 23, 146, 128, 136, 652, 660, "mellitus" +322, 10, 24, 147, 137, 149, 661, 673, "inadequately" +322, 10, 25, 148, 150, 160, 674, 684, "controlled" +322, 10, 26, 149, 161, 162, 685, 686, "[" +322, 10, 27, 150, 163, 166, 687, 690, "HbA" +322, 10, 28, 151, 167, 168, 691, 692, "(" +322, 10, 29, 152, 169, 171, 693, 695, "1c" +322, 10, 30, 153, 172, 173, 696, 697, ")" +322, 10, 31, 154, 174, 176, 698, 700, "53" +322, 10, 32, 155, 177, 178, 701, 702, "-" +322, 10, 33, 156, 179, 181, 703, 705, "86" +322, 10, 34, 157, 182, 186, 706, 710, "mmol" +322, 10, 35, 158, 187, 188, 711, 712, "/" +322, 10, 36, 159, 189, 192, 713, 716, "mol" +322, 10, 37, 160, 193, 194, 717, 718, "(" +322, 10, 38, 161, 195, 196, 719, 720, "7" +322, 10, 39, 162, 197, 198, 721, 722, "." +322, 10, 40, 163, 199, 200, 723, 724, "0" +322, 10, 41, 164, 201, 202, 725, 726, "-" +322, 10, 42, 165, 203, 205, 727, 729, "10" +322, 10, 43, 166, 206, 207, 730, 731, "." +322, 10, 44, 167, 208, 209, 732, 733, "0" +322, 10, 45, 168, 210, 211, 734, 735, "%" +322, 10, 46, 169, 212, 213, 736, 737, ")" +322, 10, 47, 170, 214, 215, 738, 739, "]" +322, 10, 48, 171, 216, 218, 740, 742, "by" +322, 10, 49, 172, 219, 228, 743, 752, "metformin" +322, 10, 50, 173, 229, 232, 753, 756, "and" +322, 10, 51, 174, 233, 246, 757, 770, "sulphonylurea" +322, 10, 52, 175, 247, 258, 771, 782, "combination" +322, 10, 53, 176, 259, 268, 783, 792, "treatment" +322, 10, 54, 177, 269, 270, 793, 794, "." +322, 11, 1, 178, 0, 7, 795, 802, "METHODS" +322, 11, 2, 179, 8, 9, 803, 804, ":" +322, 11, 3, 180, 10, 11, 805, 806, "A" +322, 11, 4, 181, 12, 17, 807, 812, "multi" +322, 11, 5, 182, 18, 19, 813, 814, "-" +322, 11, 6, 183, 20, 26, 815, 821, "centre" +322, 11, 7, 184, 27, 28, 822, 823, "," +322, 11, 8, 185, 29, 31, 824, 826, "24" +322, 11, 9, 186, 32, 33, 827, 828, "-" +322, 11, 10, 187, 34, 38, 829, 833, "week" +322, 11, 11, 188, 39, 40, 834, 835, "," +322, 11, 12, 189, 41, 51, 836, 846, "randomized" +322, 11, 13, 190, 52, 53, 847, 848, "," +322, 11, 14, 191, 54, 60, 849, 855, "double" +322, 11, 15, 192, 61, 62, 856, 857, "-" +322, 11, 16, 193, 63, 68, 858, 863, "blind" +322, 11, 17, 194, 69, 70, 864, 865, "," +322, 11, 18, 195, 71, 79, 866, 874, "parallel" +322, 11, 19, 196, 80, 81, 875, 876, "-" +322, 11, 20, 197, 82, 87, 877, 882, "group" +322, 11, 21, 198, 88, 93, 883, 888, "study" +322, 11, 22, 199, 94, 96, 889, 891, "in" +322, 11, 23, 200, 97, 101, 892, 896, "1058" +322, 11, 24, 201, 102, 110, 897, 905, "patients" +322, 11, 25, 202, 111, 120, 906, 915, "comparing" +322, 11, 26, 203, 121, 132, 916, 927, "linagliptin" +322, 11, 27, 204, 133, 134, 928, 929, "(" +322, 11, 28, 205, 135, 136, 930, 931, "5" +322, 11, 29, 206, 137, 139, 932, 934, "mg" +322, 11, 30, 207, 140, 144, 935, 939, "once" +322, 11, 31, 208, 145, 150, 940, 945, "daily" +322, 11, 32, 209, 151, 152, 946, 947, ")" +322, 11, 33, 210, 153, 156, 948, 951, "and" +322, 11, 34, 211, 157, 164, 952, 959, "placebo" +322, 11, 35, 212, 165, 169, 960, 964, "when" +322, 11, 36, 213, 170, 175, 965, 970, "added" +322, 11, 37, 214, 176, 178, 971, 973, "to" +322, 11, 38, 215, 179, 188, 974, 983, "metformin" +322, 11, 39, 216, 189, 193, 984, 988, "plus" +322, 11, 40, 217, 194, 207, 989, 1002, "sulphonylurea" +322, 11, 41, 218, 208, 209, 1003, 1004, "." +322, 12, 1, 219, 0, 3, 1005, 1008, "The" +322, 12, 2, 220, 4, 11, 1009, 1016, "primary" +322, 12, 3, 221, 12, 20, 1017, 1025, "endpoint" +322, 12, 4, 222, 21, 24, 1026, 1029, "was" +322, 12, 5, 223, 25, 28, 1030, 1033, "the" +322, 12, 6, 224, 29, 35, 1034, 1040, "change" +322, 12, 7, 225, 36, 38, 1041, 1043, "in" +322, 12, 8, 226, 39, 42, 1044, 1047, "HbA" +322, 12, 9, 227, 43, 44, 1048, 1049, "(" +322, 12, 10, 228, 45, 47, 1050, 1052, "1c" +322, 12, 11, 229, 48, 49, 1053, 1054, ")" +322, 12, 12, 230, 50, 55, 1055, 1060, "after" +322, 12, 13, 231, 56, 58, 1061, 1063, "24" +322, 12, 14, 232, 59, 64, 1064, 1069, "weeks" +322, 12, 15, 233, 65, 66, 1070, 1071, "." +322, 13, 1, 234, 0, 7, 1072, 1079, "RESULTS" +322, 13, 2, 235, 8, 9, 1080, 1081, ":" +322, 13, 3, 236, 10, 12, 1082, 1084, "At" +322, 13, 4, 237, 13, 17, 1085, 1089, "week" +322, 13, 5, 238, 18, 20, 1090, 1092, "24" +322, 13, 6, 239, 21, 22, 1093, 1094, "," +322, 13, 7, 240, 23, 26, 1095, 1098, "the" +322, 13, 8, 241, 27, 38, 1099, 1110, "linagliptin" +322, 13, 9, 242, 39, 46, 1111, 1118, "placebo" +322, 13, 10, 243, 47, 48, 1119, 1120, "-" +322, 13, 11, 244, 49, 58, 1121, 1130, "corrected" +322, 13, 12, 245, 59, 62, 1131, 1134, "HbA" +322, 13, 13, 246, 63, 64, 1135, 1136, "(" +322, 13, 14, 247, 65, 67, 1137, 1139, "1c" +322, 13, 15, 248, 68, 69, 1140, 1141, ")" +322, 13, 16, 249, 70, 78, 1142, 1150, "adjusted" +322, 13, 17, 250, 79, 83, 1151, 1155, "mean" +322, 13, 18, 251, 84, 90, 1156, 1162, "change" +322, 13, 19, 252, 91, 95, 1163, 1167, "from" +322, 13, 20, 253, 96, 104, 1168, 1176, "baseline" +322, 13, 21, 254, 105, 108, 1177, 1180, "was" +322, 13, 22, 255, 109, 110, 1181, 1182, "-" +322, 13, 23, 256, 111, 112, 1183, 1184, "7" +322, 13, 24, 257, 113, 117, 1185, 1189, "mmol" +322, 13, 25, 258, 118, 119, 1190, 1191, "/" +322, 13, 26, 259, 120, 123, 1192, 1195, "mol" +322, 13, 27, 260, 124, 125, 1196, 1197, "(" +322, 13, 28, 261, 126, 127, 1198, 1199, "-" +322, 13, 29, 262, 128, 129, 1200, 1201, "0" +322, 13, 30, 263, 130, 131, 1202, 1203, "." +322, 13, 31, 264, 132, 134, 1204, 1206, "62" +322, 13, 32, 265, 135, 136, 1207, 1208, "%" +322, 13, 33, 266, 137, 138, 1209, 1210, ")" +322, 13, 34, 267, 139, 140, 1211, 1212, "[" +322, 13, 35, 268, 141, 143, 1213, 1215, "95" +322, 13, 36, 269, 144, 145, 1216, 1217, "%" +322, 13, 37, 270, 146, 148, 1218, 1220, "CI" +322, 13, 38, 271, 149, 150, 1221, 1222, "-" +322, 13, 39, 272, 151, 152, 1223, 1224, "8" +322, 13, 40, 273, 153, 155, 1225, 1227, "to" +322, 13, 41, 274, 156, 157, 1228, 1229, "-" +322, 13, 42, 275, 158, 159, 1230, 1231, "6" +322, 13, 43, 276, 160, 164, 1232, 1236, "mmol" +322, 13, 44, 277, 165, 166, 1237, 1238, "/" +322, 13, 45, 278, 167, 170, 1239, 1242, "mol" +322, 13, 46, 279, 171, 172, 1243, 1244, "(" +322, 13, 47, 280, 173, 174, 1245, 1246, "-" +322, 13, 48, 281, 175, 176, 1247, 1248, "0" +322, 13, 49, 282, 177, 178, 1249, 1250, "." +322, 13, 50, 283, 179, 181, 1251, 1253, "73" +322, 13, 51, 284, 182, 184, 1254, 1256, "to" +322, 13, 52, 285, 185, 186, 1257, 1258, "-" +322, 13, 53, 286, 187, 188, 1259, 1260, "0" +322, 13, 54, 287, 189, 190, 1261, 1262, "." +322, 13, 55, 288, 191, 193, 1263, 1265, "50" +322, 13, 56, 289, 194, 195, 1266, 1267, "%" +322, 13, 57, 290, 196, 197, 1268, 1269, ")" +322, 13, 58, 291, 198, 199, 1270, 1271, ";" +322, 13, 59, 292, 200, 201, 1272, 1273, "P" +322, 13, 60, 293, 202, 203, 1274, 1275, "<" +322, 13, 61, 294, 204, 205, 1276, 1277, "0" +322, 13, 62, 295, 206, 207, 1278, 1279, "." +322, 13, 63, 296, 208, 212, 1280, 1284, "0001" +322, 13, 64, 297, 213, 214, 1285, 1286, "]" +322, 13, 65, 298, 215, 216, 1287, 1288, "." +322, 14, 1, 299, 0, 4, 1289, 1293, "More" +322, 14, 2, 300, 5, 17, 1294, 1306, "participants" +322, 14, 3, 301, 18, 22, 1307, 1311, "with" +322, 14, 4, 302, 23, 31, 1312, 1320, "baseline" +322, 14, 5, 303, 32, 35, 1321, 1324, "HbA" +322, 14, 6, 304, 36, 37, 1325, 1326, "(" +322, 14, 7, 305, 38, 40, 1327, 1329, "1c" +322, 14, 8, 306, 41, 42, 1330, 1331, ")" +322, 14, 9, 307, 43, 44, 1332, 1333, "≥" +322, 14, 10, 308, 45, 47, 1334, 1336, "53" +322, 14, 11, 309, 48, 52, 1337, 1341, "mmol" +322, 14, 12, 310, 53, 54, 1342, 1343, "/" +322, 14, 13, 311, 55, 58, 1344, 1347, "mol" +322, 14, 14, 312, 59, 60, 1348, 1349, "(" +322, 14, 15, 313, 61, 62, 1350, 1351, "≥" +322, 14, 16, 314, 63, 64, 1352, 1353, "7" +322, 14, 17, 315, 65, 66, 1354, 1355, "." +322, 14, 18, 316, 67, 68, 1356, 1357, "0" +322, 14, 19, 317, 69, 70, 1358, 1359, "%" +322, 14, 20, 318, 71, 72, 1360, 1361, ")" +322, 14, 21, 319, 73, 81, 1362, 1370, "achieved" +322, 14, 22, 320, 82, 84, 1371, 1373, "an" +322, 14, 23, 321, 85, 88, 1374, 1377, "HbA" +322, 14, 24, 322, 89, 90, 1378, 1379, "(" +322, 14, 25, 323, 91, 93, 1380, 1382, "1c" +322, 14, 26, 324, 94, 95, 1383, 1384, ")" +322, 14, 27, 325, 96, 97, 1385, 1386, "<" +322, 14, 28, 326, 98, 100, 1387, 1389, "53" +322, 14, 29, 327, 101, 105, 1390, 1394, "mmol" +322, 14, 30, 328, 106, 107, 1395, 1396, "/" +322, 14, 31, 329, 108, 111, 1397, 1400, "mol" +322, 14, 32, 330, 112, 113, 1401, 1402, "(" +322, 14, 33, 331, 114, 115, 1403, 1404, "<" +322, 14, 34, 332, 116, 117, 1405, 1406, "7" +322, 14, 35, 333, 118, 119, 1407, 1408, "." +322, 14, 36, 334, 120, 121, 1409, 1410, "0" +322, 14, 37, 335, 122, 123, 1411, 1412, "%" +322, 14, 38, 336, 124, 125, 1413, 1414, ")" +322, 14, 39, 337, 126, 130, 1415, 1419, "with" +322, 14, 40, 338, 131, 142, 1420, 1431, "linagliptin" +322, 14, 41, 339, 143, 151, 1432, 1440, "compared" +322, 14, 42, 340, 152, 156, 1441, 1445, "with" +322, 14, 43, 341, 157, 164, 1446, 1453, "placebo" +322, 14, 44, 342, 165, 166, 1454, 1455, "(" +322, 14, 45, 343, 167, 169, 1456, 1458, "29" +322, 14, 46, 344, 170, 171, 1459, 1460, "." +322, 14, 47, 345, 172, 173, 1461, 1462, "2" +322, 14, 48, 346, 174, 175, 1463, 1464, "%" +322, 14, 49, 347, 176, 178, 1465, 1467, "vs" +322, 14, 50, 348, 179, 180, 1468, 1469, "." +322, 14, 51, 349, 181, 182, 1470, 1471, "8" +322, 14, 52, 350, 183, 184, 1472, 1473, "." +322, 14, 53, 351, 185, 186, 1474, 1475, "1" +322, 14, 54, 352, 187, 188, 1476, 1477, "%" +322, 14, 55, 353, 189, 190, 1478, 1479, "," +322, 14, 56, 354, 191, 192, 1480, 1481, "P" +322, 14, 57, 355, 193, 194, 1482, 1483, "<" +322, 14, 58, 356, 195, 196, 1484, 1485, "0" +322, 14, 59, 357, 197, 198, 1486, 1487, "." +322, 14, 60, 358, 199, 203, 1488, 1492, "0001" +322, 14, 61, 359, 204, 205, 1493, 1494, ")" +322, 14, 62, 360, 206, 207, 1495, 1496, "." +322, 15, 1, 361, 0, 7, 1497, 1504, "Fasting" +322, 15, 2, 362, 8, 14, 1505, 1511, "plasma" +322, 15, 3, 363, 15, 22, 1512, 1519, "glucose" +322, 15, 4, 364, 23, 26, 1520, 1523, "was" +322, 15, 5, 365, 27, 34, 1524, 1531, "reduced" +322, 15, 6, 366, 35, 39, 1532, 1536, "with" +322, 15, 7, 367, 40, 51, 1537, 1548, "linagliptin" +322, 15, 8, 368, 52, 60, 1549, 1557, "relative" +322, 15, 9, 369, 61, 63, 1558, 1560, "to" +322, 15, 10, 370, 64, 71, 1561, 1568, "placebo" +322, 15, 11, 371, 72, 73, 1569, 1570, "(" +322, 15, 12, 372, 74, 75, 1571, 1572, "-" +322, 15, 13, 373, 76, 77, 1573, 1574, "0" +322, 15, 14, 374, 78, 79, 1575, 1576, "." +322, 15, 15, 375, 80, 81, 1577, 1578, "7" +322, 15, 16, 376, 82, 86, 1579, 1583, "mmol" +322, 15, 17, 377, 87, 88, 1584, 1585, "/" +322, 15, 18, 378, 89, 90, 1586, 1587, "l" +322, 15, 19, 379, 91, 92, 1588, 1589, "," +322, 15, 20, 380, 93, 95, 1590, 1592, "95" +322, 15, 21, 381, 96, 97, 1593, 1594, "%" +322, 15, 22, 382, 98, 100, 1595, 1597, "CI" +322, 15, 23, 383, 101, 102, 1598, 1599, "-" +322, 15, 24, 384, 103, 104, 1600, 1601, "1" +322, 15, 25, 385, 105, 106, 1602, 1603, "." +322, 15, 26, 386, 107, 108, 1604, 1605, "0" +322, 15, 27, 387, 109, 111, 1606, 1608, "to" +322, 15, 28, 388, 112, 113, 1609, 1610, "-" +322, 15, 29, 389, 114, 115, 1611, 1612, "0" +322, 15, 30, 390, 116, 117, 1613, 1614, "." +322, 15, 31, 391, 118, 119, 1615, 1616, "4" +322, 15, 32, 392, 120, 121, 1617, 1618, ";" +322, 15, 33, 393, 122, 123, 1619, 1620, "P" +322, 15, 34, 394, 124, 125, 1621, 1622, "<" +322, 15, 35, 395, 126, 127, 1623, 1624, "0" +322, 15, 36, 396, 128, 129, 1625, 1626, "." +322, 15, 37, 397, 130, 134, 1627, 1631, "0001" +322, 15, 38, 398, 135, 136, 1632, 1633, ")" +322, 15, 39, 399, 137, 138, 1634, 1635, "." +322, 16, 1, 400, 0, 12, 1636, 1648, "Improvements" +322, 16, 2, 401, 13, 15, 1649, 1651, "in" +322, 16, 3, 402, 16, 27, 1652, 1663, "homeostasis" +322, 16, 4, 403, 28, 33, 1664, 1669, "model" +322, 16, 5, 404, 34, 44, 1670, 1680, "assessment" +322, 16, 6, 405, 45, 47, 1681, 1683, "of" +322, 16, 7, 406, 48, 50, 1684, 1686, "β-" +322, 16, 8, 407, 51, 55, 1687, 1691, "cell" +322, 16, 9, 408, 56, 64, 1692, 1700, "function" +322, 16, 10, 409, 65, 69, 1701, 1705, "were" +322, 16, 11, 410, 70, 74, 1706, 1710, "seen" +322, 16, 12, 411, 75, 79, 1711, 1715, "with" +322, 16, 13, 412, 80, 91, 1716, 1727, "linagliptin" +322, 16, 14, 413, 92, 93, 1728, 1729, "(" +322, 16, 15, 414, 94, 95, 1730, 1731, "P" +322, 16, 16, 415, 96, 97, 1732, 1733, "<" +322, 16, 17, 416, 98, 99, 1734, 1735, "0" +322, 16, 18, 417, 100, 101, 1736, 1737, "." +322, 16, 19, 418, 102, 105, 1738, 1741, "001" +322, 16, 20, 419, 106, 107, 1742, 1743, ")" +322, 16, 21, 420, 108, 109, 1744, 1745, "." +322, 17, 1, 421, 0, 3, 1746, 1749, "The" +322, 17, 2, 422, 4, 14, 1750, 1760, "proportion" +322, 17, 3, 423, 15, 17, 1761, 1763, "of" +322, 17, 4, 424, 18, 26, 1764, 1772, "patients" +322, 17, 5, 425, 27, 30, 1773, 1776, "who" +322, 17, 6, 426, 31, 39, 1777, 1785, "reported" +322, 17, 7, 427, 40, 41, 1786, 1787, "a" +322, 17, 8, 428, 42, 48, 1788, 1794, "severe" +322, 17, 9, 429, 49, 56, 1795, 1802, "adverse" +322, 17, 10, 430, 57, 62, 1803, 1808, "event" +322, 17, 11, 431, 63, 66, 1809, 1812, "was" +322, 17, 12, 432, 67, 70, 1813, 1816, "low" +322, 17, 13, 433, 71, 73, 1817, 1819, "in" +322, 17, 14, 434, 74, 78, 1820, 1824, "both" +322, 17, 15, 435, 79, 85, 1825, 1831, "groups" +322, 17, 16, 436, 86, 87, 1832, 1833, "(" +322, 17, 17, 437, 88, 99, 1834, 1845, "linagliptin" +322, 17, 18, 438, 100, 101, 1846, 1847, "2" +322, 17, 19, 439, 102, 103, 1848, 1849, "." +322, 17, 20, 440, 104, 105, 1850, 1851, "4" +322, 17, 21, 441, 106, 107, 1852, 1853, "%" +322, 17, 22, 442, 108, 109, 1854, 1855, ";" +322, 17, 23, 443, 110, 117, 1856, 1863, "placebo" +322, 17, 24, 444, 118, 119, 1864, 1865, "1" +322, 17, 25, 445, 120, 121, 1866, 1867, "." +322, 17, 26, 446, 122, 123, 1868, 1869, "5" +322, 17, 27, 447, 124, 125, 1870, 1871, "%" +322, 17, 28, 448, 126, 127, 1872, 1873, ")" +322, 17, 29, 449, 128, 129, 1874, 1875, "." +322, 18, 1, 450, 0, 11, 1876, 1887, "Symptomatic" +322, 18, 2, 451, 12, 25, 1888, 1901, "hypoglycaemia" +322, 18, 3, 452, 26, 34, 1902, 1910, "occurred" +322, 18, 4, 453, 35, 37, 1911, 1913, "in" +322, 18, 5, 454, 38, 40, 1914, 1916, "16" +322, 18, 6, 455, 41, 42, 1917, 1918, "." +322, 18, 7, 456, 43, 44, 1919, 1920, "7" +322, 18, 8, 457, 45, 48, 1921, 1924, "and" +322, 18, 9, 458, 49, 51, 1925, 1927, "10" +322, 18, 10, 459, 52, 53, 1928, 1929, "." +322, 18, 11, 460, 54, 55, 1930, 1931, "3" +322, 18, 12, 461, 56, 57, 1932, 1933, "%" +322, 18, 13, 462, 58, 60, 1934, 1936, "of" +322, 18, 14, 463, 61, 64, 1937, 1940, "the" +322, 18, 15, 464, 65, 76, 1941, 1952, "linagliptin" +322, 18, 16, 465, 77, 80, 1953, 1956, "and" +322, 18, 17, 466, 81, 88, 1957, 1964, "placebo" +322, 18, 18, 467, 89, 95, 1965, 1971, "groups" +322, 18, 19, 468, 96, 97, 1972, 1973, "," +322, 18, 20, 469, 98, 110, 1974, 1986, "respectively" +322, 18, 21, 470, 111, 112, 1987, 1988, "." +322, 19, 1, 471, 0, 13, 1989, 2002, "Hypoglycaemia" +322, 19, 2, 472, 14, 17, 2003, 2006, "was" +322, 19, 3, 473, 18, 27, 2007, 2016, "generally" +322, 19, 4, 474, 28, 32, 2017, 2021, "mild" +322, 19, 5, 475, 33, 35, 2022, 2024, "or" +322, 19, 6, 476, 36, 44, 2025, 2033, "moderate" +322, 19, 7, 477, 45, 46, 2034, 2035, ";" +322, 19, 8, 478, 47, 53, 2036, 2042, "severe" +322, 19, 9, 479, 54, 67, 2043, 2056, "hypoglycaemia" +322, 19, 10, 480, 68, 71, 2057, 2060, "was" +322, 19, 11, 481, 72, 80, 2061, 2069, "reported" +322, 19, 12, 482, 81, 83, 2070, 2072, "in" +322, 19, 13, 483, 84, 85, 2073, 2074, "2" +322, 19, 14, 484, 86, 87, 2075, 2076, "." +322, 19, 15, 485, 88, 89, 2077, 2078, "7" +322, 19, 16, 486, 90, 93, 2079, 2082, "and" +322, 19, 17, 487, 94, 95, 2083, 2084, "4" +322, 19, 18, 488, 96, 97, 2085, 2086, "." +322, 19, 19, 489, 98, 99, 2087, 2088, "8" +322, 19, 20, 490, 100, 101, 2089, 2090, "%" +322, 19, 21, 491, 102, 104, 2091, 2093, "of" +322, 19, 22, 492, 105, 108, 2094, 2097, "the" +322, 19, 23, 493, 109, 121, 2098, 2110, "participants" +322, 19, 24, 494, 122, 134, 2111, 2123, "experiencing" +322, 19, 25, 495, 135, 148, 2124, 2137, "hypoglycaemic" +322, 19, 26, 496, 149, 157, 2138, 2146, "episodes" +322, 19, 27, 497, 158, 160, 2147, 2149, "in" +322, 19, 28, 498, 161, 164, 2150, 2153, "the" +322, 19, 29, 499, 165, 176, 2154, 2165, "linagliptin" +322, 19, 30, 500, 177, 180, 2166, 2169, "and" +322, 19, 31, 501, 181, 188, 2170, 2177, "placebo" +322, 19, 32, 502, 189, 195, 2178, 2184, "groups" +322, 19, 33, 503, 196, 197, 2185, 2186, "," +322, 19, 34, 504, 198, 210, 2187, 2199, "respectively" +322, 19, 35, 505, 211, 212, 2200, 2201, "." +322, 20, 1, 506, 0, 2, 2202, 2204, "No" +322, 20, 2, 507, 3, 14, 2205, 2216, "significant" +322, 20, 3, 508, 15, 21, 2217, 2223, "weight" +322, 20, 4, 509, 22, 29, 2224, 2231, "changes" +322, 20, 5, 510, 30, 34, 2232, 2236, "were" +322, 20, 6, 511, 35, 40, 2237, 2242, "noted" +322, 20, 7, 512, 41, 42, 2243, 2244, "." +322, 21, 1, 513, 0, 11, 2245, 2256, "CONCLUSIONS" +322, 21, 2, 514, 12, 13, 2257, 2258, ":" +322, 21, 3, 515, 14, 16, 2259, 2261, "In" +322, 21, 4, 516, 17, 25, 2262, 2270, "patients" +322, 21, 5, 517, 26, 30, 2271, 2275, "with" +322, 21, 6, 518, 31, 35, 2276, 2280, "Type" +322, 21, 7, 519, 36, 37, 2281, 2282, "2" +322, 21, 8, 520, 38, 46, 2283, 2291, "diabetes" +322, 21, 9, 521, 47, 48, 2292, 2293, "," +322, 21, 10, 522, 49, 55, 2294, 2300, "adding" +322, 21, 11, 523, 56, 67, 2301, 2312, "linagliptin" +322, 21, 12, 524, 68, 70, 2313, 2315, "to" +322, 21, 13, 525, 71, 80, 2316, 2325, "metformin" +322, 21, 14, 526, 81, 86, 2326, 2331, "given" +322, 21, 15, 527, 87, 89, 2332, 2334, "in" +322, 21, 16, 528, 90, 101, 2335, 2346, "combination" +322, 21, 17, 529, 102, 106, 2347, 2351, "with" +322, 21, 18, 530, 107, 108, 2352, 2353, "a" +322, 21, 19, 531, 109, 122, 2354, 2367, "sulphonylurea" +322, 21, 20, 532, 123, 136, 2368, 2381, "significantly" +322, 21, 21, 533, 137, 145, 2382, 2390, "improved" +322, 21, 22, 534, 146, 155, 2391, 2400, "glycaemic" +322, 21, 23, 535, 156, 163, 2401, 2408, "control" +322, 21, 24, 536, 164, 167, 2409, 2412, "and" +322, 21, 25, 537, 168, 172, 2413, 2417, "this" +322, 21, 26, 538, 173, 176, 2418, 2421, "was" +322, 21, 27, 539, 177, 181, 2422, 2426, "well" +322, 21, 28, 540, 182, 191, 2427, 2436, "tolerated" +322, 21, 29, 541, 192, 193, 2437, 2438, "." +322, 22, 1, 542, 0, 11, 2439, 2450, "Linagliptin" +322, 22, 2, 543, 12, 17, 2451, 2456, "could" +322, 22, 3, 544, 18, 25, 2457, 2464, "provide" +322, 22, 4, 545, 26, 27, 2465, 2466, "a" +322, 22, 5, 546, 28, 36, 2467, 2475, "valuable" +322, 22, 6, 547, 37, 46, 2476, 2485, "treatment" +322, 22, 7, 548, 47, 53, 2486, 2492, "option" +322, 22, 8, 549, 54, 57, 2493, 2496, "for" +322, 22, 9, 550, 58, 69, 2497, 2508, "individuals" +322, 22, 10, 551, 70, 74, 2509, 2513, "with" +322, 22, 11, 552, 75, 85, 2514, 2524, "inadequate" +322, 22, 12, 553, 86, 95, 2525, 2534, "glycaemic" +322, 22, 13, 554, 96, 103, 2535, 2542, "control" +322, 22, 14, 555, 104, 111, 2543, 2550, "despite" +322, 22, 15, 556, 112, 119, 2551, 2558, "ongoing" +322, 22, 16, 557, 120, 131, 2559, 2570, "combination" +322, 22, 17, 558, 132, 139, 2571, 2578, "therapy" +322, 22, 18, 559, 140, 144, 2579, 2583, "with" +322, 22, 19, 560, 145, 154, 2584, 2593, "metformin" +322, 22, 20, 561, 155, 158, 2594, 2597, "and" +322, 22, 21, 562, 159, 160, 2598, 2599, "a" +322, 22, 22, 563, 161, 174, 2600, 2613, "sulphonylurea" +322, 22, 23, 564, 175, 176, 2614, 2615, "." +322, 23, 1, 565, 0, 1, 2616, 2617, "©" +322, 23, 2, 566, 2, 6, 2618, 2622, "2011" +322, 23, 3, 567, 7, 10, 2623, 2626, "The" +322, 23, 4, 568, 11, 18, 2627, 2634, "Authors" +322, 23, 5, 569, 19, 20, 2635, 2636, "." +322, 24, 1, 570, 0, 8, 2637, 2645, "Diabetic" +322, 24, 2, 571, 9, 17, 2646, 2654, "Medicine" +322, 24, 3, 572, 18, 19, 2655, 2656, "©" +322, 24, 4, 573, 20, 24, 2657, 2661, "2011" +322, 24, 5, 574, 25, 33, 2662, 2670, "Diabetes" +322, 24, 6, 575, 34, 36, 2671, 2673, "UK" +322, 24, 7, 576, 37, 38, 2674, 2675, "." +322, 25, 1, 577, 0, 3, 2676, 2679, "DOI" +322, 25, 2, 578, 4, 5, 2680, 2681, ":" +322, 25, 3, 579, 6, 8, 2682, 2684, "10" +322, 25, 4, 580, 9, 10, 2685, 2686, "." +322, 25, 5, 581, 11, 15, 2687, 2691, "1111" +322, 25, 6, 582, 16, 17, 2692, 2693, "/" +322, 25, 7, 583, 18, 19, 2694, 2695, "j" +322, 25, 8, 584, 20, 21, 2696, 2697, "." +322, 25, 9, 585, 22, 26, 2698, 2702, "1464" +322, 25, 10, 586, 27, 28, 2703, 2704, "-" +322, 25, 11, 587, 29, 33, 2705, 2709, "5491" +322, 25, 12, 588, 34, 35, 2710, 2711, "." +322, 25, 13, 589, 36, 40, 2712, 2716, "2011" +322, 25, 14, 590, 41, 42, 2717, 2718, "." +322, 25, 15, 591, 43, 48, 2719, 2724, "03387" +322, 25, 16, 592, 49, 50, 2725, 2726, "." +322, 25, 17, 593, 51, 52, 2727, 2728, "x" +322, 25, 18, 594, 53, 57, 2729, 2733, "PMID" +322, 25, 19, 595, 58, 59, 2734, 2735, ":" +322, 25, 20, 596, 60, 68, 2736, 2744, "21781152" +322, 25, 21, 597, 69, 70, 2745, 2746, "[" +322, 25, 22, 598, 71, 78, 2747, 2754, "Indexed" +322, 25, 23, 599, 79, 82, 2755, 2758, "for" +322, 25, 24, 600, 83, 90, 2759, 2766, "MEDLINE" +322, 25, 25, 601, 91, 92, 2767, 2768, "]" diff --git a/data/dm2 21781152_kwoodley.annodb b/data/dm2 21781152_kwoodley.annodb new file mode 100644 index 0000000..471a6b3 --- /dev/null +++ b/data/dm2 21781152_kwoodley.annodb @@ -0,0 +1,101 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +20070, Journal, 0, 10, "Diabet Med", "", +20071, PublicationYear, 13, 17, "2011", "", +20413, Title, 103, 274, "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .", "", +20406, Linagliptin, 126, 137, "linagliptin", "", +20412, Precondition, 141, 241, "persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea", "", +20407, Type2Diabetes, 154, 169, "type 2 diabetes", "", +20408, Metformin, 214, 223, "metformin", "", +20409, Sulfonylureas, 228, 241, "sulphonylurea", "", +20410, Duration, 246, 255, "24 - week", "", +20411, Randomized, 256, 266, "randomized", "", +20414, Author, 275, 283, "Owens DR", "", +20415, Author, 292, 301, "Swallow R", "", +20416, Author, 304, 311, "Dugi KA", "", +20417, Author, 314, 323, "Woerle HJ", "", +20418, UK, 395, 397, "UK", "", +20872, ObjectiveDescription, 531, 619, "To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin", "", +20863, Linagliptin, 608, 619, "linagliptin", "", +20873, ObjectiveDescription, 620, 794, "in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment .", "", +20871, Precondition, 623, 792, "persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment", "", +20864, Type2Diabetes, 636, 660, "Type 2 diabetes mellitus", "", +20865, HbA1c, 687, 697, "HbA ( 1c )", "", +20867, BioAndMedicalUnit, 706, 716, "mmol / mol", "", +20866, Percentage, 734, 735, "%", "", +20869, Metformin, 743, 752, "metformin", "", +20870, Sulfonylureas, 757, 770, "sulphonylurea", "", +20874, Multicenter, 807, 821, "multi - centre", "", +20875, Duration, 824, 833, "24 - week", "", +20876, Randomized, 836, 846, "randomized", "", +20877, DoubleBlind, 849, 863, "double - blind", "", +20878, Parallel, 866, 882, "parallel - group", "", +20879, NumberPatientsCT, 892, 896, "1058", "", +20880, Linagliptin, 916, 927, "linagliptin", "", +20881, DoseValue, 930, 931, "5", "", +20882, mg, 932, 934, "mg", "", +20883, Frequency, 935, 945, "once daily", "", +20884, Placebo, 952, 959, "placebo", "", +20885, Metformin, 974, 983, "metformin", "", +20886, Sulfonylureas, 989, 1002, "sulphonylurea", "", +20887, HbA1c, 1044, 1054, "HbA ( 1c )", "", +20888, Duration, 1061, 1069, "24 weeks", "", +33193, TimePoint, 1085, 1092, "week 24", "", +20890, Linagliptin, 1099, 1110, "linagliptin", "", +20891, Placebo, 1111, 1118, "placebo", "", +20892, HbA1c, 1131, 1141, "HbA ( 1c )", "", +20895, Reduction, 1183, 1184, "7", "", +20893, BioAndMedicalUnit, 1185, 1195, "mmol / mol", "", +20896, Reduction, 1200, 1206, "0 . 62", "", +20897, Percentage, 1207, 1208, "%", "", +20898, ConfIntervalChangeValue, 1213, 1269, "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 % )", "", +20899, BioAndMedicalUnit, 1232, 1242, "mmol / mol", "", +20900, Percentage, 1266, 1267, "%", "", +20912, PValueChangeValue, 1272, 1284, "P < 0 . 0001", "", +20906, HbA1c_target, 1321, 1361, "HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )", "", +20908, HbA1c_target, 1374, 1414, "HbA ( 1c ) < 53 mmol / mol ( < 7 . 0 % )", "", +20904, Linagliptin, 1420, 1431, "linagliptin", "", +20905, Placebo, 1446, 1453, "placebo", "", +20909, PercentageAffected, 1456, 1462, "29 . 2", "", +20910, PercentageAffected, 1470, 1475, "8 . 1", "", +20911, PvalueDiff, 1480, 1492, "P < 0 . 0001", "", +20913, FastingPlasmaGlucose, 1497, 1519, "Fasting plasma glucose", "", +20914, Linagliptin, 1537, 1548, "linagliptin", "", +20915, Placebo, 1561, 1568, "placebo", "", +20916, Reduction, 1573, 1578, "0 . 7", "", +20917, Millimoles_per_litre, 1579, 1587, "mmol / l", "", +20918, ConfIntervalChangeValue, 1590, 1616, "95 % CI - 1 . 0 to - 0 . 4", "", +20919, PValueChangeValue, 1619, 1631, "P < 0 . 0001", "", +20920, EndPointDescription, 1652, 1700, "homeostasis model assessment of β- cell function", "", +20921, Linagliptin, 1716, 1727, "linagliptin", "", +20922, PValueResValue, 1730, 1741, "P < 0 . 001", "", +20923, EndPointDescription, 1795, 1808, "adverse event", "", +20926, Linagliptin, 1834, 1845, "linagliptin", "", +20924, PercentageAffected, 1846, 1851, "2 . 4", "", +20927, Placebo, 1856, 1863, "placebo", "", +20925, PercentageAffected, 1864, 1869, "1 . 5", "", +20928, SymptomaticHypoglycemia, 1876, 1901, "Symptomatic hypoglycaemia", "", +20929, PercentageAffected, 1914, 1920, "16 . 7", "", +20930, PercentageAffected, 1925, 1931, "10 . 3", "", +20931, Linagliptin, 1941, 1952, "linagliptin", "", +20932, Placebo, 1957, 1964, "placebo", "", +20933, Hypoglycemia, 1989, 2002, "Hypoglycaemia", "", +20937, ObservedResult, 2003, 2033, "was generally mild or moderate", "", +20934, SevereHypoglycemia, 2036, 2056, "severe hypoglycaemia", "", +20941, SubGroupDescription, 2036, 2060, "severe hypoglycaemia was", "subgroup or endpoint? ", +20935, PercentageAffected, 2073, 2078, "2 . 7", "", +20936, PercentageAffected, 2083, 2088, "4 . 8", "", +20938, Hypoglycemia, 2124, 2146, "hypoglycaemic episodes", "", +20939, Linagliptin, 2154, 2165, "linagliptin", "", +20940, Placebo, 2170, 2177, "placebo", "", +20943, ObservedResult, 2202, 2242, "No significant weight changes were noted", "", +20942, BodyWeight, 2217, 2231, "weight changes", "", +20948, ConclusionComment, 2259, 2438, "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .", "", +20944, Type2Diabetes, 2276, 2291, "Type 2 diabetes", "", +20945, Linagliptin, 2301, 2312, "linagliptin", "", +20946, Metformin, 2316, 2325, "metformin", "", +20947, Sulfonylureas, 2354, 2367, "sulphonylurea", "", +20949, Linagliptin, 2439, 2450, "Linagliptin", "", +20952, ConclusionComment, 2439, 2615, "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .", "", +20950, Metformin, 2584, 2593, "metformin", "", +20951, Sulfonylureas, 2600, 2613, "sulphonylurea", "", +20953, PMID, 2736, 2744, "21781152", "", diff --git a/data/dm2 21781152_kwoodley.n-triples b/data/dm2 21781152_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21781152_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21802161_admin.annodb b/data/dm2 21802161_admin.annodb new file mode 100644 index 0000000..6cc4048 --- /dev/null +++ b/data/dm2 21802161_admin.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 25, "Diabetes Res Clin Pract .", "", " \"Diabetes Res Clin Pract .\"." +1, PublicationYear, 26, 30, "2011", "", " \"2011\"." +6, Title, 126, 236, "Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes .", "", " \"Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes .\"." +99, Drug, 136, 146, "folic acid", "", +4, Precondition, 189, 234, "overweight and obese men with type 2 diabetes", "", +3, Male, 210, 213, "men", "", +2, Type2Diabetes, 219, 234, "type 2 diabetes", "", " ." +66, Author, 237, 247, "Gargari BP", "", " \"Gargari BP\"." +7, Author, 256, 271, "Aghamohammadi V", "", " \"Aghamohammadi V\"." +8, Author, 274, 290, "Aliasgharzadeh A", "", " \"Aliasgharzadeh A\"." +9, Iran, 472, 476, "Iran", "", " ." +18, ObjectiveDescription, 509, 754, "This study performed to determine the effects of folate supplementation on indices of glycemic control , insulin resistance and lipid profile in overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment .", "", " \"This study performed to determine the effects of folate supplementation on indices of glycemic control , insulin resistance and lipid profile in overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment .\"." +100, Drug, 558, 564, "folate", "", +101, Insulin, 614, 621, "insulin", "", +17, Precondition, 654, 752, "overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment", "", " \"overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment\"." +11, Male, 675, 678, "men", "", +12, Type2Diabetes, 684, 699, "type 2 diabetes", "", +13, Metformin, 706, 715, "metformin", "", +14, DoseValue, 718, 731, "at least 1500", "", +15, mg, 732, 734, "mg", "", +16, Frequency, 735, 740, "daily", "", +19, DoubleBlind, 781, 795, "double - blind", "", +20, Randomized, 796, 806, "randomized", "", " ." +21, NumberPatientsCT, 835, 848, "Forty - eight", "", " \"Forty - eight\"." +22, Male, 870, 873, "men", "", " ." +23, AvgAge, 881, 887, "58 . 2", "", " \"58 . 2\"." +24, BMI, 904, 907, "BMI", "", +25, Kg_per_squareMeter, 925, 937, "kg / m ( 2 )", "", +26, Type2Diabetes, 945, 960, "type 2 diabetes", "", +28, Randomized, 1011, 1019, "randomly", "", +29, Drug, 1039, 1049, "folic acid", "", +30, DoseValue, 1052, 1053, "5", "", " \"5\"." +31, mg, 1054, 1056, "mg", "", " ." +59680, Interval, 1059, 1060, "d", "", " \"d\"." +33, Placebo, 1067, 1074, "placebo", "", " ." +34, Duration, 1115, 1126, "eight weeks", "", " \"eight weeks\". \"eight weeks\". \"eight weeks\"." +35, Drug, 1160, 1170, "folic acid", "", +59684, RelativeReduction, 1178, 1179, "8", "", " \"8\"." +36, HbA1c, 1194, 1199, "HbA1C", "", " ." +39, PValueChangeValue, 1202, 1213, "p = 0 . 048", "", " \"p = 0 . 048\"." +40, RelativeReduction, 1218, 1223, "7 . 5", "", " \"7 . 5\"." +67, FastingBloodGlucose, 1229, 1250, "fasting blood glucose", "", " ." +47, PValueChangeValue, 1253, 1264, "p = 0 . 051", "", " \"p = 0 . 051\"." +41, RelativeReduction, 1269, 1275, "16 . 2", "", " \"16 . 2\"." +44, EndPointDescription, 1281, 1294, "serum insulin", "", " . ." +48, PValueChangeValue, 1297, 1308, "p = 0 . 021", "", " \"p = 0 . 021\"." +42, RelativeReduction, 1313, 1319, "20 . 5", "", " \"20 . 5\"." +45, EndPointDescription, 1325, 1343, "insulin resistance", "", " . ." +49, PValueChangeValue, 1346, 1357, "p = 0 . 041", "", " \"p = 0 . 041\"." +43, RelativeReduction, 1364, 1370, "21 . 2", "", " \"21 . 2\"." +46, EndPointDescription, 1376, 1395, "plasma homocysteine", "", " . ." +50, PValueChangeValue, 1398, 1409, "p = 0 . 000", "", " \"p = 0 . 000\"." +51, EndPointDescription, 1440, 1452, "serum folate", "", " . ." +52, EndPointDescription, 1457, 1467, "B12 levels", "", " . ." +53, RelativeIncrement, 1470, 1472, "19", "", " . ." +54, RelativeIncrement, 1479, 1485, "17 . 3", "", " \"17 . 3\"." +55, PValueChangeValue, 1490, 1501, "p = 0 . 000", "", " \"p = 0 . 000\". \"p = 0 . 000\"." +56, Drug, 1540, 1550, "folic acid", "", +128, ObservedResult, 1567, 1589, "no significant changes", "", " \"no significant changes\". \"no significant changes\"." +57, Placebo, 1606, 1613, "placebo", "", +58, Drug, 1636, 1646, "folic acid", "", +59, Placebo, 1651, 1658, "placebo", "", +61, ObservedResult, 1668, 1701, "there were no significant changes", "", +60, BodyWeight, 1705, 1716, "body weight", "", +138, Drug, 1733, 1743, "Folic acid", "", +65, ConclusionComment, 1733, 1882, "Folic acid supplementation lowered plasma level of homocysteine , improved glycemic control and insulin resistance in patients with type 2 diabetes .", "", " \"Folic acid supplementation lowered plasma level of homocysteine , improved glycemic control and insulin resistance in patients with type 2 diabetes .\"." +63, Type2Diabetes, 1865, 1880, "type 2 diabetes", "", +64, PMID, 2000, 2008, "21802161", "", " \"21802161\"." diff --git a/data/dm2 21802161_admin.n-triples b/data/dm2 21802161_admin.n-triples new file mode 100644 index 0000000..6339a92 --- /dev/null +++ b/data/dm2 21802161_admin.n-triples @@ -0,0 +1,171 @@ +# RDF export of group: Publication + . + "Publication 33584" . + "Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes ." . + "Gargari BP" . + "2011" . + "Diabetes Res Clin Pract ." . + "21802161" . + . + "Aghamohammadi V" . + "Aliasgharzadeh A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 33591" . + "This study performed to determine the effects of folate supplementation on indices of glycemic control , insulin resistance and lipid profile in overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment ." . + "Forty - eight" . + "eight weeks" . + . + . + . + "Folic acid supplementation lowered plasma level of homocysteine , improved glycemic control and insulin resistance in patients with type 2 diabetes ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 33607" . + . + . + "58 . 2" . + . + "overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fbg" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + "res" . + . + . + . + . + . + . + "hom" . + . + . + . + . + . + . + "fol" . + . + . + . + . + . + . + "b12" . + . + . + . + . + . +# RDF export of group: Arm + . + "fo" . + . + . + . + . + . + . + . + . + . + . + "pl" . + . + . + . +# RDF export of group: Intervention + . + "fo" . + . + "d" . + "eight weeks" . + . + . + "pl" . + . + "eight weeks" . + . +# RDF export of group: Medication + . + "fo" . + . + "5" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba" . + . + "8" . + "p = 0 . 048" . + . + "fbg" . + . + "7 . 5" . + "p = 0 . 051" . + . + "ins" . + . + "16 . 2" . + "p = 0 . 021" . + . + "res" . + . + "20 . 5" . + "p = 0 . 041" . + . + "hom" . + . + "21 . 2" . + "p = 0 . 000" . + . + "fol" . + . + "19" . + "p = 0 . 000" . + . + "b12" . + . + "17 . 3" . + "p = 0 . 000" . + . + "b2 p" . + . + "no significant changes" . + . + "fol p" . + . + "no significant changes" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21802161_akramersunderbrink.annodb b/data/dm2 21802161_akramersunderbrink.annodb new file mode 100644 index 0000000..978f41e --- /dev/null +++ b/data/dm2 21802161_akramersunderbrink.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +39887, Journal, 0, 23, "Diabetes Res Clin Pract", "", +39888, PublicationYear, 26, 30, "2011", "", +39892, Title, 126, 236, "Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes .", "", +39918, Drug, 136, 146, "folic acid", "", +39890, Precondition, 189, 209, "overweight and obese", "", +39891, Male, 210, 213, "men", "", +39889, Type2Diabetes, 219, 234, "type 2 diabetes", "", +39893, Author, 237, 247, "Gargari BP", "", +39894, Author, 256, 271, "Aghamohammadi V", "", +39895, Author, 274, 290, "Aliasgharzadeh A", "", +39896, Iran, 472, 476, "Iran", "", +39921, ObjectiveDescription, 509, 754, "This study performed to determine the effects of folate supplementation on indices of glycemic control , insulin resistance and lipid profile in overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment .", "", +39919, Drug, 558, 564, "folate", "", +39920, Insulin, 614, 621, "insulin", "", +39897, Precondition, 654, 674, "overweight and obese", "", +39898, Male, 675, 678, "men", "", +39899, Type2Diabetes, 684, 699, "type 2 diabetes", "", +39900, Metformin, 706, 715, "metformin", "", +39901, DoseValue, 718, 740, "at least 1500 mg daily", "", +39902, DoubleBlind, 781, 795, "double - blind", "", +39903, Randomized, 796, 806, "randomized", "", +39904, NumberPatientsCT, 835, 848, "Forty - eight", "", +39905, Precondition, 849, 869, "overweight and obese", "", +39906, Male, 870, 873, "men", "", +39907, AvgAge, 881, 887, "58 . 2", "", +39908, BMI, 904, 907, "BMI", "", +39911, Precondition, 904, 937, "BMI = 28 . 6 ± 2 . 9 kg / m ( 2 )", "", +39909, Kg_per_squareMeter, 925, 937, "kg / m ( 2 )", "", +39910, Type2Diabetes, 945, 960, "type 2 diabetes", "", +39912, Randomized, 1011, 1019, "randomly", "", +39917, Drug, 1039, 1049, "folic acid", "", +39914, DoseValue, 1052, 1060, "5 mg / d", "", +39915, BioAndMedicalUnit, 1054, 1060, "mg / d", "", +39913, Placebo, 1067, 1074, "placebo", "", +39916, Duration, 1115, 1126, "eight weeks", "", +39922, Drug, 1160, 1170, "folic acid", "", +39927, RelativeChangeValue, 1178, 1179, "8", "", +39923, Percentage, 1180, 1181, "%", "", +39924, HbA1c, 1194, 1199, "HbA1C", "", +39926, PValueChangeValue, 1202, 1213, "p = 0 . 048", "", +39928, RelativeChangeValue, 1218, 1223, "7 . 5", "", +39932, Percentage, 1224, 1225, "%", "", +39936, FastingBloodGlucose, 1229, 1250, "fasting blood glucose", "", +39940, PValueChangeValue, 1253, 1264, "p = 0 . 051", "", +39929, RelativeChangeValue, 1269, 1275, "16 . 2", "", +39933, Percentage, 1276, 1277, "%", "", +39937, EndPointDescription, 1281, 1294, "serum insulin", "", +39941, PValueChangeValue, 1297, 1308, "p = 0 . 021", "", +39930, RelativeChangeValue, 1313, 1319, "20 . 5", "", +39934, Percentage, 1320, 1321, "%", "", +39938, EndPointDescription, 1325, 1343, "insulin resistance", "", +39942, PValueChangeValue, 1346, 1357, "p = 0 . 041", "", +39931, RelativeChangeValue, 1364, 1370, "21 . 2", "", +39935, Percentage, 1371, 1372, "%", "", +39939, EndPointDescription, 1376, 1395, "plasma homocysteine", "", +39943, PValueChangeValue, 1398, 1409, "p = 0 . 000", "", +39944, EndPointDescription, 1440, 1452, "serum folate", "", +39945, EndPointDescription, 1457, 1467, "B12 levels", "", +39949, RelativeChangeValue, 1470, 1472, "19", "", +39952, Percentage, 1473, 1474, "%", "", +39950, RelativeChangeValue, 1479, 1485, "17 . 3", "", +39953, Percentage, 1486, 1487, "%", "", +39951, PValueChangeValue, 1490, 1501, "p = 0 . 000", "", +39946, Drug, 1540, 1550, "folic acid", "", +39948, ObservedResult, 1567, 1589, "no significant changes", "", +39947, Placebo, 1606, 1613, "placebo", "", +39954, Drug, 1636, 1646, "folic acid", "", +39955, Placebo, 1651, 1658, "placebo", "", +39957, ObservedResult, 1679, 1701, "no significant changes", "", +39956, BodyWeight, 1705, 1716, "body weight", "", +39958, Drug, 1733, 1743, "Folic acid", "", +39961, ConclusionComment, 1733, 1882, "Folic acid supplementation lowered plasma level of homocysteine , improved glycemic control and insulin resistance in patients with type 2 diabetes .", "", +39959, Type2Diabetes, 1865, 1880, "type 2 diabetes", "", +39960, PMID, 2000, 2008, "21802161", "", diff --git a/data/dm2 21802161_akramersunderbrink.n-triples b/data/dm2 21802161_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21802161_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21802161_export.csv b/data/dm2 21802161_export.csv new file mode 100644 index 0000000..503dd6f --- /dev/null +++ b/data/dm2 21802161_export.csv @@ -0,0 +1,437 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +321, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +321, 1, 2, 2, 9, 12, 9, 12, "Res" +321, 1, 3, 3, 13, 17, 13, 17, "Clin" +321, 1, 4, 4, 18, 23, 18, 23, "Pract" +321, 1, 5, 5, 24, 25, 24, 25, "." +321, 2, 1, 6, 0, 4, 26, 30, "2011" +321, 2, 2, 7, 5, 8, 31, 34, "Oct" +321, 2, 3, 8, 9, 10, 35, 36, ";" +321, 2, 4, 9, 11, 13, 37, 39, "94" +321, 2, 5, 10, 14, 15, 40, 41, "(" +321, 2, 6, 11, 16, 17, 42, 43, "1" +321, 2, 7, 12, 18, 19, 44, 45, ")" +321, 2, 8, 13, 20, 21, 46, 47, ":" +321, 2, 9, 14, 22, 24, 48, 50, "33" +321, 2, 10, 15, 25, 26, 51, 52, "-" +321, 2, 11, 16, 27, 28, 53, 54, "8" +321, 2, 12, 17, 29, 30, 55, 56, "." +321, 2, 13, 18, 31, 34, 57, 60, "doi" +321, 2, 14, 19, 35, 36, 61, 62, ":" +321, 2, 15, 20, 37, 39, 63, 65, "10" +321, 2, 16, 21, 40, 41, 66, 67, "." +321, 2, 17, 22, 42, 46, 68, 72, "1016" +321, 2, 18, 23, 47, 48, 73, 74, "/" +321, 2, 19, 24, 49, 50, 75, 76, "j" +321, 2, 20, 25, 51, 52, 77, 78, "." +321, 2, 21, 26, 53, 60, 79, 86, "diabres" +321, 2, 22, 27, 61, 62, 87, 88, "." +321, 2, 23, 28, 63, 67, 89, 93, "2011" +321, 2, 24, 29, 68, 69, 94, 95, "." +321, 2, 25, 30, 70, 72, 96, 98, "07" +321, 2, 26, 31, 73, 74, 99, 100, "." +321, 2, 27, 32, 75, 78, 101, 104, "003" +321, 2, 28, 33, 79, 80, 105, 106, "." +321, 3, 1, 34, 0, 4, 107, 111, "Epub" +321, 3, 2, 35, 5, 9, 112, 116, "2011" +321, 3, 3, 36, 10, 13, 117, 120, "Jul" +321, 3, 4, 37, 14, 16, 121, 123, "28" +321, 3, 5, 38, 17, 18, 124, 125, "." +321, 4, 1, 39, 0, 6, 126, 132, "Effect" +321, 4, 2, 40, 7, 9, 133, 135, "of" +321, 4, 3, 41, 10, 15, 136, 141, "folic" +321, 4, 4, 42, 16, 20, 142, 146, "acid" +321, 4, 5, 43, 21, 36, 147, 162, "supplementation" +321, 4, 6, 44, 37, 39, 163, 165, "on" +321, 4, 7, 45, 40, 51, 166, 177, "biochemical" +321, 4, 8, 46, 52, 59, 178, 185, "indices" +321, 4, 9, 47, 60, 62, 186, 188, "in" +321, 4, 10, 48, 63, 73, 189, 199, "overweight" +321, 4, 11, 49, 74, 77, 200, 203, "and" +321, 4, 12, 50, 78, 83, 204, 209, "obese" +321, 4, 13, 51, 84, 87, 210, 213, "men" +321, 4, 14, 52, 88, 92, 214, 218, "with" +321, 4, 15, 53, 93, 97, 219, 223, "type" +321, 4, 16, 54, 98, 99, 224, 225, "2" +321, 4, 17, 55, 100, 108, 226, 234, "diabetes" +321, 4, 18, 56, 109, 110, 235, 236, "." +321, 5, 1, 57, 0, 7, 237, 244, "Gargari" +321, 5, 2, 58, 8, 10, 245, 247, "BP" +321, 5, 3, 59, 11, 12, 248, 249, "(" +321, 5, 4, 60, 13, 14, 250, 251, "1" +321, 5, 5, 61, 15, 16, 252, 253, ")" +321, 5, 6, 62, 17, 18, 254, 255, "," +321, 5, 7, 63, 19, 32, 256, 269, "Aghamohammadi" +321, 5, 8, 64, 33, 34, 270, 271, "V" +321, 5, 9, 65, 35, 36, 272, 273, "," +321, 5, 10, 66, 37, 51, 274, 288, "Aliasgharzadeh" +321, 5, 11, 67, 52, 53, 289, 290, "A" +321, 5, 12, 68, 54, 55, 291, 292, "." +321, 6, 1, 69, 0, 6, 293, 299, "Author" +321, 6, 2, 70, 7, 18, 300, 311, "information" +321, 6, 3, 71, 19, 20, 312, 313, ":" +321, 6, 4, 72, 21, 22, 314, 315, "(" +321, 6, 5, 73, 23, 24, 316, 317, "1" +321, 6, 6, 74, 25, 26, 318, 319, ")" +321, 6, 7, 75, 27, 38, 320, 331, "Nutritional" +321, 6, 8, 76, 39, 47, 332, 340, "Research" +321, 6, 9, 77, 48, 54, 341, 347, "Center" +321, 6, 10, 78, 55, 56, 348, 349, "," +321, 6, 11, 79, 57, 67, 350, 360, "Department" +321, 6, 12, 80, 68, 70, 361, 363, "of" +321, 6, 13, 81, 71, 83, 364, 376, "Biochemistry" +321, 6, 14, 82, 84, 85, 377, 378, "&" +321, 6, 15, 83, 86, 95, 379, 388, "Nutrition" +321, 6, 16, 84, 96, 97, 389, 390, "," +321, 6, 17, 85, 98, 105, 391, 398, "Faculty" +321, 6, 18, 86, 106, 108, 399, 401, "of" +321, 6, 19, 87, 109, 115, 402, 408, "Health" +321, 6, 20, 88, 116, 117, 409, 410, "&" +321, 6, 21, 89, 118, 127, 411, 420, "Nutrition" +321, 6, 22, 90, 128, 129, 421, 422, "," +321, 6, 23, 91, 130, 136, 423, 429, "Tabriz" +321, 6, 24, 92, 137, 147, 430, 440, "University" +321, 6, 25, 93, 148, 150, 441, 443, "of" +321, 6, 26, 94, 151, 158, 444, 451, "Medical" +321, 6, 27, 95, 159, 167, 452, 460, "Sciences" +321, 6, 28, 96, 168, 169, 461, 462, "," +321, 6, 29, 97, 170, 176, 463, 469, "Tabriz" +321, 6, 30, 98, 177, 178, 470, 471, "," +321, 6, 31, 99, 179, 183, 472, 476, "Iran" +321, 6, 32, 100, 184, 185, 477, 478, "." +321, 7, 1, 101, 0, 8, 479, 487, "bahrampg" +321, 7, 2, 102, 9, 10, 488, 489, "@" +321, 7, 3, 103, 11, 16, 490, 495, "yahoo" +321, 7, 4, 104, 17, 18, 496, 497, "." +321, 7, 5, 105, 19, 22, 498, 501, "com" +321, 7, 6, 106, 23, 27, 502, 506, "AIMS" +321, 7, 7, 107, 28, 29, 507, 508, ":" +321, 7, 8, 108, 30, 34, 509, 513, "This" +321, 7, 9, 109, 35, 40, 514, 519, "study" +321, 7, 10, 110, 41, 50, 520, 529, "performed" +321, 7, 11, 111, 51, 53, 530, 532, "to" +321, 7, 12, 112, 54, 63, 533, 542, "determine" +321, 7, 13, 113, 64, 67, 543, 546, "the" +321, 7, 14, 114, 68, 75, 547, 554, "effects" +321, 7, 15, 115, 76, 78, 555, 557, "of" +321, 7, 16, 116, 79, 85, 558, 564, "folate" +321, 7, 17, 117, 86, 101, 565, 580, "supplementation" +321, 7, 18, 118, 102, 104, 581, 583, "on" +321, 7, 19, 119, 105, 112, 584, 591, "indices" +321, 7, 20, 120, 113, 115, 592, 594, "of" +321, 7, 21, 121, 116, 124, 595, 603, "glycemic" +321, 7, 22, 122, 125, 132, 604, 611, "control" +321, 7, 23, 123, 133, 134, 612, 613, "," +321, 7, 24, 124, 135, 142, 614, 621, "insulin" +321, 7, 25, 125, 143, 153, 622, 632, "resistance" +321, 7, 26, 126, 154, 157, 633, 636, "and" +321, 7, 27, 127, 158, 163, 637, 642, "lipid" +321, 7, 28, 128, 164, 171, 643, 650, "profile" +321, 7, 29, 129, 172, 174, 651, 653, "in" +321, 7, 30, 130, 175, 185, 654, 664, "overweight" +321, 7, 31, 131, 186, 189, 665, 668, "and" +321, 7, 32, 132, 190, 195, 669, 674, "obese" +321, 7, 33, 133, 196, 199, 675, 678, "men" +321, 7, 34, 134, 200, 204, 679, 683, "with" +321, 7, 35, 135, 205, 209, 684, 688, "type" +321, 7, 36, 136, 210, 211, 689, 690, "2" +321, 7, 37, 137, 212, 220, 691, 699, "diabetes" +321, 7, 38, 138, 221, 226, 700, 705, "under" +321, 7, 39, 139, 227, 236, 706, 715, "metformin" +321, 7, 40, 140, 237, 238, 716, 717, "(" +321, 7, 41, 141, 239, 241, 718, 720, "at" +321, 7, 42, 142, 242, 247, 721, 726, "least" +321, 7, 43, 143, 248, 252, 727, 731, "1500" +321, 7, 44, 144, 253, 255, 732, 734, "mg" +321, 7, 45, 145, 256, 261, 735, 740, "daily" +321, 7, 46, 146, 262, 263, 741, 742, ")" +321, 7, 47, 147, 264, 273, 743, 752, "treatment" +321, 7, 48, 148, 274, 275, 753, 754, "." +321, 8, 1, 149, 0, 7, 755, 762, "METHODS" +321, 8, 2, 150, 8, 9, 763, 764, ":" +321, 8, 3, 151, 10, 13, 765, 768, "The" +321, 8, 4, 152, 14, 19, 769, 774, "study" +321, 8, 5, 153, 20, 23, 775, 778, "was" +321, 8, 6, 154, 24, 25, 779, 780, "a" +321, 8, 7, 155, 26, 32, 781, 787, "double" +321, 8, 8, 156, 33, 34, 788, 789, "-" +321, 8, 9, 157, 35, 40, 790, 795, "blind" +321, 8, 10, 158, 41, 51, 796, 806, "randomized" +321, 8, 11, 159, 52, 62, 807, 817, "controlled" +321, 8, 12, 160, 63, 71, 818, 826, "clinical" +321, 8, 13, 161, 72, 77, 827, 832, "trial" +321, 8, 14, 162, 78, 79, 833, 834, "." +321, 9, 1, 163, 0, 5, 835, 840, "Forty" +321, 9, 2, 164, 6, 7, 841, 842, "-" +321, 9, 3, 165, 8, 13, 843, 848, "eight" +321, 9, 4, 166, 14, 24, 849, 859, "overweight" +321, 9, 5, 167, 25, 28, 860, 863, "and" +321, 9, 6, 168, 29, 34, 864, 869, "obese" +321, 9, 7, 169, 35, 38, 870, 873, "men" +321, 9, 8, 170, 39, 40, 874, 875, "(" +321, 9, 9, 171, 41, 45, 876, 880, "aged" +321, 9, 10, 172, 46, 48, 881, 883, "58" +321, 9, 11, 173, 49, 50, 884, 885, "." +321, 9, 12, 174, 51, 52, 886, 887, "2" +321, 9, 13, 175, 53, 54, 888, 889, "±" +321, 9, 14, 176, 55, 56, 890, 891, "8" +321, 9, 15, 177, 57, 58, 892, 893, "." +321, 9, 16, 178, 59, 60, 894, 895, "9" +321, 9, 17, 179, 61, 66, 896, 901, "years" +321, 9, 18, 180, 67, 68, 902, 903, ";" +321, 9, 19, 181, 69, 72, 904, 907, "BMI" +321, 9, 20, 182, 73, 74, 908, 909, "=" +321, 9, 21, 183, 75, 77, 910, 912, "28" +321, 9, 22, 184, 78, 79, 913, 914, "." +321, 9, 23, 185, 80, 81, 915, 916, "6" +321, 9, 24, 186, 82, 83, 917, 918, "±" +321, 9, 25, 187, 84, 85, 919, 920, "2" +321, 9, 26, 188, 86, 87, 921, 922, "." +321, 9, 27, 189, 88, 89, 923, 924, "9" +321, 9, 28, 190, 90, 92, 925, 927, "kg" +321, 9, 29, 191, 93, 94, 928, 929, "/" +321, 9, 30, 192, 95, 96, 930, 931, "m" +321, 9, 31, 193, 97, 98, 932, 933, "(" +321, 9, 32, 194, 99, 100, 934, 935, "2" +321, 9, 33, 195, 101, 102, 936, 937, ")" +321, 9, 34, 196, 103, 104, 938, 939, ")" +321, 9, 35, 197, 105, 109, 940, 944, "with" +321, 9, 36, 198, 110, 114, 945, 949, "type" +321, 9, 37, 199, 115, 116, 950, 951, "2" +321, 9, 38, 200, 117, 125, 952, 960, "diabetes" +321, 9, 39, 201, 126, 138, 961, 973, "participated" +321, 9, 40, 202, 139, 141, 974, 976, "in" +321, 9, 41, 203, 142, 145, 977, 980, "the" +321, 9, 42, 204, 146, 151, 981, 986, "study" +321, 9, 43, 205, 152, 153, 987, 988, "." +321, 10, 1, 206, 0, 8, 989, 997, "Patients" +321, 10, 2, 207, 9, 13, 998, 1002, "were" +321, 10, 3, 208, 14, 21, 1003, 1010, "divided" +321, 10, 4, 209, 22, 30, 1011, 1019, "randomly" +321, 10, 5, 210, 31, 35, 1020, 1024, "into" +321, 10, 6, 211, 36, 39, 1025, 1028, "two" +321, 10, 7, 212, 40, 46, 1029, 1035, "groups" +321, 10, 8, 213, 47, 49, 1036, 1038, "of" +321, 10, 9, 214, 50, 55, 1039, 1044, "folic" +321, 10, 10, 215, 56, 60, 1045, 1049, "acid" +321, 10, 11, 216, 61, 62, 1050, 1051, "(" +321, 10, 12, 217, 63, 64, 1052, 1053, "5" +321, 10, 13, 218, 65, 67, 1054, 1056, "mg" +321, 10, 14, 219, 68, 69, 1057, 1058, "/" +321, 10, 15, 220, 70, 71, 1059, 1060, "d" +321, 10, 16, 221, 72, 73, 1061, 1062, ")" +321, 10, 17, 222, 74, 77, 1063, 1066, "and" +321, 10, 18, 223, 78, 85, 1067, 1074, "placebo" +321, 10, 19, 224, 86, 87, 1075, 1076, "." +321, 11, 1, 225, 0, 3, 1077, 1080, "All" +321, 11, 2, 226, 4, 12, 1081, 1089, "patients" +321, 11, 3, 227, 13, 21, 1090, 1098, "received" +321, 11, 4, 228, 22, 25, 1099, 1102, "the" +321, 11, 5, 229, 26, 33, 1103, 1110, "tablets" +321, 11, 6, 230, 34, 37, 1111, 1114, "for" +321, 11, 7, 231, 38, 43, 1115, 1120, "eight" +321, 11, 8, 232, 44, 49, 1121, 1126, "weeks" +321, 11, 9, 233, 50, 51, 1127, 1128, "." +321, 12, 1, 234, 0, 7, 1129, 1136, "RESULTS" +321, 12, 2, 235, 8, 9, 1137, 1138, ":" +321, 12, 3, 236, 10, 25, 1139, 1154, "Supplementation" +321, 12, 4, 237, 26, 30, 1155, 1159, "with" +321, 12, 5, 238, 31, 36, 1160, 1165, "folic" +321, 12, 6, 239, 37, 41, 1166, 1170, "acid" +321, 12, 7, 240, 42, 45, 1171, 1174, "led" +321, 12, 8, 241, 46, 48, 1175, 1177, "to" +321, 12, 9, 242, 49, 50, 1178, 1179, "8" +321, 12, 10, 243, 51, 52, 1180, 1181, "%" +321, 12, 11, 244, 53, 61, 1182, 1190, "decrease" +321, 12, 12, 245, 62, 64, 1191, 1193, "in" +321, 12, 13, 246, 65, 70, 1194, 1199, "HbA1C" +321, 12, 14, 247, 71, 72, 1200, 1201, "(" +321, 12, 15, 248, 73, 74, 1202, 1203, "p" +321, 12, 16, 249, 75, 76, 1204, 1205, "=" +321, 12, 17, 250, 77, 78, 1206, 1207, "0" +321, 12, 18, 251, 79, 80, 1208, 1209, "." +321, 12, 19, 252, 81, 84, 1210, 1213, "048" +321, 12, 20, 253, 85, 86, 1214, 1215, ")" +321, 12, 21, 254, 87, 88, 1216, 1217, "," +321, 12, 22, 255, 89, 90, 1218, 1219, "7" +321, 12, 23, 256, 91, 92, 1220, 1221, "." +321, 12, 24, 257, 93, 94, 1222, 1223, "5" +321, 12, 25, 258, 95, 96, 1224, 1225, "%" +321, 12, 26, 259, 97, 99, 1226, 1228, "in" +321, 12, 27, 260, 100, 107, 1229, 1236, "fasting" +321, 12, 28, 261, 108, 113, 1237, 1242, "blood" +321, 12, 29, 262, 114, 121, 1243, 1250, "glucose" +321, 12, 30, 263, 122, 123, 1251, 1252, "(" +321, 12, 31, 264, 124, 125, 1253, 1254, "p" +321, 12, 32, 265, 126, 127, 1255, 1256, "=" +321, 12, 33, 266, 128, 129, 1257, 1258, "0" +321, 12, 34, 267, 130, 131, 1259, 1260, "." +321, 12, 35, 268, 132, 135, 1261, 1264, "051" +321, 12, 36, 269, 136, 137, 1265, 1266, ")" +321, 12, 37, 270, 138, 139, 1267, 1268, "," +321, 12, 38, 271, 140, 142, 1269, 1271, "16" +321, 12, 39, 272, 143, 144, 1272, 1273, "." +321, 12, 40, 273, 145, 146, 1274, 1275, "2" +321, 12, 41, 274, 147, 148, 1276, 1277, "%" +321, 12, 42, 275, 149, 151, 1278, 1280, "in" +321, 12, 43, 276, 152, 157, 1281, 1286, "serum" +321, 12, 44, 277, 158, 165, 1287, 1294, "insulin" +321, 12, 45, 278, 166, 167, 1295, 1296, "(" +321, 12, 46, 279, 168, 169, 1297, 1298, "p" +321, 12, 47, 280, 170, 171, 1299, 1300, "=" +321, 12, 48, 281, 172, 173, 1301, 1302, "0" +321, 12, 49, 282, 174, 175, 1303, 1304, "." +321, 12, 50, 283, 176, 179, 1305, 1308, "021" +321, 12, 51, 284, 180, 181, 1309, 1310, ")" +321, 12, 52, 285, 182, 183, 1311, 1312, "," +321, 12, 53, 286, 184, 186, 1313, 1315, "20" +321, 12, 54, 287, 187, 188, 1316, 1317, "." +321, 12, 55, 288, 189, 190, 1318, 1319, "5" +321, 12, 56, 289, 191, 192, 1320, 1321, "%" +321, 12, 57, 290, 193, 195, 1322, 1324, "in" +321, 12, 58, 291, 196, 203, 1325, 1332, "insulin" +321, 12, 59, 292, 204, 214, 1333, 1343, "resistance" +321, 12, 60, 293, 215, 216, 1344, 1345, "(" +321, 12, 61, 294, 217, 218, 1346, 1347, "p" +321, 12, 62, 295, 219, 220, 1348, 1349, "=" +321, 12, 63, 296, 221, 222, 1350, 1351, "0" +321, 12, 64, 297, 223, 224, 1352, 1353, "." +321, 12, 65, 298, 225, 228, 1354, 1357, "041" +321, 12, 66, 299, 229, 230, 1358, 1359, ")" +321, 12, 67, 300, 231, 234, 1360, 1363, "and" +321, 12, 68, 301, 235, 237, 1364, 1366, "21" +321, 12, 69, 302, 238, 239, 1367, 1368, "." +321, 12, 70, 303, 240, 241, 1369, 1370, "2" +321, 12, 71, 304, 242, 243, 1371, 1372, "%" +321, 12, 72, 305, 244, 246, 1373, 1375, "in" +321, 12, 73, 306, 247, 253, 1376, 1382, "plasma" +321, 12, 74, 307, 254, 266, 1383, 1395, "homocysteine" +321, 12, 75, 308, 267, 268, 1396, 1397, "(" +321, 12, 76, 309, 269, 270, 1398, 1399, "p" +321, 12, 77, 310, 271, 272, 1400, 1401, "=" +321, 12, 78, 311, 273, 274, 1402, 1403, "0" +321, 12, 79, 312, 275, 276, 1404, 1405, "." +321, 12, 80, 313, 277, 280, 1406, 1409, "000" +321, 12, 81, 314, 281, 282, 1410, 1411, ")" +321, 12, 82, 315, 283, 284, 1412, 1413, "." +321, 13, 1, 316, 0, 1, 1414, 1415, "A" +321, 13, 2, 317, 2, 13, 1416, 1427, "significant" +321, 13, 3, 318, 14, 22, 1428, 1436, "increase" +321, 13, 4, 319, 23, 25, 1437, 1439, "in" +321, 13, 5, 320, 26, 31, 1440, 1445, "serum" +321, 13, 6, 321, 32, 38, 1446, 1452, "folate" +321, 13, 7, 322, 39, 42, 1453, 1456, "and" +321, 13, 8, 323, 43, 46, 1457, 1460, "B12" +321, 13, 9, 324, 47, 53, 1461, 1467, "levels" +321, 13, 10, 325, 54, 55, 1468, 1469, "(" +321, 13, 11, 326, 56, 58, 1470, 1472, "19" +321, 13, 12, 327, 59, 60, 1473, 1474, "%" +321, 13, 13, 328, 61, 64, 1475, 1478, "and" +321, 13, 14, 329, 65, 67, 1479, 1481, "17" +321, 13, 15, 330, 68, 69, 1482, 1483, "." +321, 13, 16, 331, 70, 71, 1484, 1485, "3" +321, 13, 17, 332, 72, 73, 1486, 1487, "%" +321, 13, 18, 333, 74, 75, 1488, 1489, "," +321, 13, 19, 334, 76, 77, 1490, 1491, "p" +321, 13, 20, 335, 78, 79, 1492, 1493, "=" +321, 13, 21, 336, 80, 81, 1494, 1495, "0" +321, 13, 22, 337, 82, 83, 1496, 1497, "." +321, 13, 23, 338, 84, 87, 1498, 1501, "000" +321, 13, 24, 339, 88, 89, 1502, 1503, "," +321, 13, 25, 340, 90, 102, 1504, 1516, "respectively" +321, 13, 26, 341, 103, 104, 1517, 1518, ")" +321, 13, 27, 342, 105, 109, 1519, 1523, "were" +321, 13, 28, 343, 110, 118, 1524, 1532, "observed" +321, 13, 29, 344, 119, 121, 1533, 1535, "in" +321, 13, 30, 345, 122, 125, 1536, 1539, "the" +321, 13, 31, 346, 126, 131, 1540, 1545, "folic" +321, 13, 32, 347, 132, 136, 1546, 1550, "acid" +321, 13, 33, 348, 137, 142, 1551, 1556, "group" +321, 13, 34, 349, 143, 144, 1557, 1558, "," +321, 13, 35, 350, 145, 152, 1559, 1566, "whereas" +321, 13, 36, 351, 153, 155, 1567, 1569, "no" +321, 13, 37, 352, 156, 167, 1570, 1581, "significant" +321, 13, 38, 353, 168, 175, 1582, 1589, "changes" +321, 13, 39, 354, 176, 184, 1590, 1598, "occurred" +321, 13, 40, 355, 185, 187, 1599, 1601, "in" +321, 13, 41, 356, 188, 191, 1602, 1605, "the" +321, 13, 42, 357, 192, 199, 1606, 1613, "placebo" +321, 13, 43, 358, 200, 205, 1614, 1619, "group" +321, 13, 44, 359, 206, 207, 1620, 1621, "." +321, 14, 1, 360, 0, 4, 1622, 1626, "Also" +321, 14, 2, 361, 5, 6, 1627, 1628, "," +321, 14, 3, 362, 7, 9, 1629, 1631, "in" +321, 14, 4, 363, 10, 13, 1632, 1635, "the" +321, 14, 5, 364, 14, 19, 1636, 1641, "folic" +321, 14, 6, 365, 20, 24, 1642, 1646, "acid" +321, 14, 7, 366, 25, 28, 1647, 1650, "and" +321, 14, 8, 367, 29, 36, 1651, 1658, "placebo" +321, 14, 9, 368, 37, 43, 1659, 1665, "groups" +321, 14, 10, 369, 44, 45, 1666, 1667, "," +321, 14, 11, 370, 46, 51, 1668, 1673, "there" +321, 14, 12, 371, 52, 56, 1674, 1678, "were" +321, 14, 13, 372, 57, 59, 1679, 1681, "no" +321, 14, 14, 373, 60, 71, 1682, 1693, "significant" +321, 14, 15, 374, 72, 79, 1694, 1701, "changes" +321, 14, 16, 375, 80, 82, 1702, 1704, "in" +321, 14, 17, 376, 83, 87, 1705, 1709, "body" +321, 14, 18, 377, 88, 94, 1710, 1716, "weight" +321, 14, 19, 378, 95, 96, 1717, 1718, "." +321, 15, 1, 379, 0, 11, 1719, 1730, "CONCLUSIONS" +321, 15, 2, 380, 12, 13, 1731, 1732, ":" +321, 15, 3, 381, 14, 19, 1733, 1738, "Folic" +321, 15, 4, 382, 20, 24, 1739, 1743, "acid" +321, 15, 5, 383, 25, 40, 1744, 1759, "supplementation" +321, 15, 6, 384, 41, 48, 1760, 1767, "lowered" +321, 15, 7, 385, 49, 55, 1768, 1774, "plasma" +321, 15, 8, 386, 56, 61, 1775, 1780, "level" +321, 15, 9, 387, 62, 64, 1781, 1783, "of" +321, 15, 10, 388, 65, 77, 1784, 1796, "homocysteine" +321, 15, 11, 389, 78, 79, 1797, 1798, "," +321, 15, 12, 390, 80, 88, 1799, 1807, "improved" +321, 15, 13, 391, 89, 97, 1808, 1816, "glycemic" +321, 15, 14, 392, 98, 105, 1817, 1824, "control" +321, 15, 15, 393, 106, 109, 1825, 1828, "and" +321, 15, 16, 394, 110, 117, 1829, 1836, "insulin" +321, 15, 17, 395, 118, 128, 1837, 1847, "resistance" +321, 15, 18, 396, 129, 131, 1848, 1850, "in" +321, 15, 19, 397, 132, 140, 1851, 1859, "patients" +321, 15, 20, 398, 141, 145, 1860, 1864, "with" +321, 15, 21, 399, 146, 150, 1865, 1869, "type" +321, 15, 22, 400, 151, 152, 1870, 1871, "2" +321, 15, 23, 401, 153, 161, 1872, 1880, "diabetes" +321, 15, 24, 402, 162, 163, 1881, 1882, "." +321, 16, 1, 403, 0, 9, 1883, 1892, "Copyright" +321, 16, 2, 404, 10, 11, 1893, 1894, "©" +321, 16, 3, 405, 12, 16, 1895, 1899, "2011" +321, 16, 4, 406, 17, 25, 1900, 1908, "Elsevier" +321, 16, 5, 407, 26, 33, 1909, 1916, "Ireland" +321, 16, 6, 408, 34, 37, 1917, 1920, "Ltd" +321, 16, 7, 409, 38, 39, 1921, 1922, "." +321, 16, 8, 410, 40, 43, 1923, 1926, "All" +321, 16, 9, 411, 44, 50, 1927, 1933, "rights" +321, 16, 10, 412, 51, 59, 1934, 1942, "reserved" +321, 16, 11, 413, 60, 61, 1943, 1944, "." +321, 17, 1, 414, 0, 3, 1945, 1948, "DOI" +321, 17, 2, 415, 4, 5, 1949, 1950, ":" +321, 17, 3, 416, 6, 8, 1951, 1953, "10" +321, 17, 4, 417, 9, 10, 1954, 1955, "." +321, 17, 5, 418, 11, 15, 1956, 1960, "1016" +321, 17, 6, 419, 16, 17, 1961, 1962, "/" +321, 17, 7, 420, 18, 19, 1963, 1964, "j" +321, 17, 8, 421, 20, 21, 1965, 1966, "." +321, 17, 9, 422, 22, 29, 1967, 1974, "diabres" +321, 17, 10, 423, 30, 31, 1975, 1976, "." +321, 17, 11, 424, 32, 36, 1977, 1981, "2011" +321, 17, 12, 425, 37, 38, 1982, 1983, "." +321, 17, 13, 426, 39, 41, 1984, 1986, "07" +321, 17, 14, 427, 42, 43, 1987, 1988, "." +321, 17, 15, 428, 44, 47, 1989, 1992, "003" +321, 17, 16, 429, 48, 52, 1993, 1997, "PMID" +321, 17, 17, 430, 53, 54, 1998, 1999, ":" +321, 17, 18, 431, 55, 63, 2000, 2008, "21802161" +321, 17, 19, 432, 64, 65, 2009, 2010, "[" +321, 17, 20, 433, 66, 73, 2011, 2018, "Indexed" +321, 17, 21, 434, 74, 77, 2019, 2022, "for" +321, 17, 22, 435, 78, 85, 2023, 2030, "MEDLINE" +321, 17, 23, 436, 86, 87, 2031, 2032, "]" diff --git a/data/dm2 21802161_kwoodley.annodb b/data/dm2 21802161_kwoodley.annodb new file mode 100644 index 0000000..cc4e4a4 --- /dev/null +++ b/data/dm2 21802161_kwoodley.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +20954, Journal, 0, 25, "Diabetes Res Clin Pract .", "", +20955, PublicationYear, 26, 30, "2011", "", +20960, Title, 126, 236, "Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes .", "", +20959, Drug, 136, 162, "folic acid supplementation", "", +20958, Precondition, 189, 234, "overweight and obese men with type 2 diabetes", "", +20957, Male, 210, 213, "men", "", +20956, Type2Diabetes, 219, 234, "type 2 diabetes", "", +21038, Author, 237, 247, "Gargari BP", "", +20962, Author, 256, 271, "Aghamohammadi V", "", +20963, Author, 274, 290, "Aliasgharzadeh A", "", +20964, Iran, 472, 476, "Iran", "", +20974, ObjectiveDescription, 509, 754, "This study performed to determine the effects of folate supplementation on indices of glycemic control , insulin resistance and lipid profile in overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment .", "", +20965, Drug, 558, 580, "folate supplementation", "", +20973, Precondition, 654, 752, "overweight and obese men with type 2 diabetes under metformin ( at least 1500 mg daily ) treatment", "", +20966, Male, 675, 678, "men", "", +20968, Type2Diabetes, 684, 699, "type 2 diabetes", "", +20969, Metformin, 706, 715, "metformin", "", +20970, DoseValue, 718, 731, "at least 1500", "", +20971, mg, 732, 734, "mg", "", +20972, Frequency, 735, 740, "daily", "", +20975, DoubleBlind, 781, 795, "double - blind", "", +20976, Randomized, 796, 806, "randomized", "", +20979, NumberPatientsCT, 835, 848, "Forty - eight", "", +20985, Precondition, 849, 960, "overweight and obese men ( aged 58 . 2 ± 8 . 9 years ; BMI = 28 . 6 ± 2 . 9 kg / m ( 2 ) ) with type 2 diabetes", "", +20980, Male, 870, 873, "men", "", +20981, AvgAge, 881, 887, "58 . 2", "", +20982, BMI, 904, 907, "BMI", "", +20983, Kg_per_squareMeter, 925, 937, "kg / m ( 2 )", "", +20984, Type2Diabetes, 945, 960, "type 2 diabetes", "", +20986, Randomized, 1011, 1019, "randomly", "", +20988, Drug, 1039, 1049, "folic acid", "", +20989, DoseValue, 1052, 1053, "5", "", +20990, mg, 1054, 1056, "mg", "", +20991, Frequency, 1059, 1060, "d", "", +20992, Placebo, 1067, 1074, "placebo", "", +20993, Duration, 1115, 1126, "eight weeks", "", +20994, Drug, 1160, 1170, "folic acid", "", +20996, Reduction, 1178, 1179, "8", "", +20997, Percentage, 1180, 1181, "%", "", +20995, HbA1c, 1194, 1199, "HbA1C", "", +20998, PValueChangeValue, 1202, 1213, "p = 0 . 048", "", +21001, RelativeReduction, 1218, 1223, "7 . 5", "", +33192, FastingBloodGlucose, 1229, 1250, "fasting blood glucose", "", +21009, PValueChangeValue, 1253, 1264, "p = 0 . 051", "", +21002, RelativeReduction, 1269, 1275, "16 . 2", "", +21006, EndPointDescription, 1281, 1294, "serum insulin", "", +21010, PValueChangeValue, 1297, 1308, "p = 0 . 021", "", +21003, RelativeReduction, 1313, 1319, "20 . 5", "", +21007, EndPointDescription, 1325, 1343, "insulin resistance", "", +21011, PValueChangeValue, 1346, 1357, "p = 0 . 041", "", +21004, RelativeReduction, 1364, 1370, "21 . 2", "", +21008, EndPointDescription, 1376, 1395, "plasma homocysteine", "", +21012, PValueChangeValue, 1398, 1409, "p = 0 . 000", "", +21013, EndPointDescription, 1440, 1452, "serum folate", "", +21014, EndPointDescription, 1457, 1467, "B12 levels", "", +21015, RelativeIncrement, 1470, 1472, "19", "", +21016, RelativeIncrement, 1479, 1485, "17 . 3", "", +21017, PValueChangeValue, 1490, 1501, "p = 0 . 000", "", +21018, Drug, 1540, 1550, "folic acid", "", +21019, Placebo, 1606, 1613, "placebo", "", +21020, Drug, 1636, 1646, "folic acid", "", +21021, Placebo, 1651, 1658, "placebo", "", +21023, ObservedResult, 1668, 1701, "there were no significant changes", "", +21022, BodyWeight, 1705, 1716, "body weight", "", +21024, Drug, 1733, 1759, "Folic acid supplementation", "", +21027, ConclusionComment, 1733, 1882, "Folic acid supplementation lowered plasma level of homocysteine , improved glycemic control and insulin resistance in patients with type 2 diabetes .", "", +21025, Type2Diabetes, 1865, 1880, "type 2 diabetes", "", +21026, PMID, 2000, 2008, "21802161", "", diff --git a/data/dm2 21802161_kwoodley.n-triples b/data/dm2 21802161_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21802161_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21819517_admin.annodb b/data/dm2 21819517_admin.annodb new file mode 100644 index 0000000..f5a6e20 --- /dev/null +++ b/data/dm2 21819517_admin.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2011", "", " \"2011\"." +22, Title, 112, 319, "Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal - bolus therapies with insulin lispro in type 2 diabetes patients : a prospective randomized open - label trial .", "", " \"Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal - bolus therapies with insulin lispro in type 2 diabetes patients : a prospective randomized open - label trial .\"." +180, LisproProtamine, 126, 161, "insulin lispro protamine suspension", "", +3, InsulinGlargine, 169, 185, "insulin glargine", "", +4, Frequency, 186, 196, "once daily", "", +106314, Precondition, 229, 271, "insulin lispro in type 2 diabetes patients", "", " \"insulin lispro in type 2 diabetes patients\"." +5, Lispro, 229, 243, "insulin lispro", "", +6, Type2Diabetes, 247, 262, "type 2 diabetes", "", " ." +60975, Prospective, 276, 287, "prospective", "", " ." +7, Randomized, 288, 298, "randomized", "", " ." +9, OpenLabel, 299, 311, "open - label", "", " ." +10, Author, 320, 330, "Koivisto V", "", " \"Koivisto V\"." +11, Author, 339, 347, "Cleall S", "", " \"Cleall S\"." +12, Author, 350, 362, "Pontiroli AE", "", " \"Pontiroli AE\"." +13, Author, 365, 376, "Giugliano D", "", " \"Giugliano D\"." +14, Germany, 445, 452, "Germany", "", " ." +21, ObjectiveDescription, 492, 684, "To compare the efficacy and safety of insulin lispro protamine suspension ( ILPS ) versus insulin glargine once daily in a basal - bolus regimen in type 2 diabetes mellitus ( T2DM ) patients .", "", " \"To compare the efficacy and safety of insulin lispro protamine suspension ( ILPS ) versus insulin glargine once daily in a basal - bolus regimen in type 2 diabetes mellitus ( T2DM ) patients .\"." +181, LisproProtamine, 530, 565, "insulin lispro protamine suspension", "", +60976, LisproProtamine, 568, 572, "ILPS", "", +17, InsulinGlargine, 582, 598, "insulin glargine", "", +18, Frequency, 599, 609, "once daily", "", +19, Type2Diabetes, 640, 664, "type 2 diabetes mellitus", "", +20, Type2Diabetes, 667, 671, "T2DM", "", +23, NumberPatientsCT, 695, 723, "Three hundred eighty - three", "", " \"Three hundred eighty - three\"." +24, Insulin, 724, 731, "insulin", "", +32, Precondition, 724, 750, "insulin - treated patients", "", +25, Randomized, 756, 766, "randomized", "", +183, LisproProtamine, 777, 781, "ILPS", "", " ." +27, Lispro, 787, 793, "lispro", "", +28, InsulinGlargine, 797, 805, "glargine", "", " ." +29, Lispro, 811, 817, "lispro", "", +30, OpenLabel, 826, 838, "open - label", "", +31, Duration, 839, 848, "24 - week", "", " \"24 - week\"." +123, Multicenter, 849, 863, "European study", "", " ." +60977, DoseDescription, 866, 936, "Insulin doses were titrated to predefined blood glucose ( BG ) targets", "", +33, Insulin, 866, 873, "Insulin", "", +185, BloodGlucose, 908, 921, "blood glucose", "", +186, BloodGlucose, 924, 926, "BG", "", +184, LisproProtamine, 960, 964, "ILPS", "", +35, InsulinGlargine, 972, 980, "glargine", "", +36, HbA1c, 1080, 1085, "HbA1c", "", +88, TimePoint, 1091, 1099, "baseline", "", +87, TimePoint, 1103, 1110, "week 24", "", +37, HbA1c, 1147, 1152, "HbA1c", "", +126, Percentage, 1198, 1199, "%", "", +38, HbA1c, 1231, 1236, "HbA1c", "", +128, BloodGlucose, 1250, 1252, "BG", "", +89, InsulinDose, 1264, 1277, "insulin doses", "", +40, Hypoglycemia, 1280, 1302, "hypoglycaemic episodes", "", +41, EndPointDescription, 1305, 1319, "adverse events", "", +42, EndPointDescription, 1324, 1335, "vital signs", "", +187, LisproProtamine, 1369, 1373, "ILPS", "", +44, InsulinGlargine, 1381, 1389, "glargine", "", +45, HbA1c, 1407, 1412, "HbA1c", "", " ." +133, TimePoint, 1418, 1426, "baseline", "", +134, LeastSquaresMean, 1439, 1458, "least - square mean", "", +60978, ConfIntervalDiff, 1490, 1501, "( 95 % CI )", "", " \"( 95 % CI )\". \"( - 0 . 11 ; 0 . 31 )\"." +135, DiffGroupAbsValue, 1506, 1511, "0 . 1", "", " \"0 . 1\"." +49, Percentage, 1512, 1513, "%", "", " ." +60978, ConfIntervalDiff, 1514, 1535, "( - 0 . 11 ; 0 . 31 )", "", +139, Mean, 1538, 1542, "Mean", "", " . ." +90, TimePoint, 1554, 1561, "week 24", "", " \"week 24\". \"week 24\"." +52, Reduction, 1569, 1575, "1 . 05", "", " \"1 . 05\"." +54, Percentage, 1576, 1577, "%", "", +188, LisproProtamine, 1580, 1584, "ILPS", "", +53, Reduction, 1593, 1599, "1 . 20", "", " \"1 . 05\"." +55, Percentage, 1600, 1601, "%", "", +51, InsulinGlargine, 1604, 1612, "glargine", "", +56, HbA1c_target, 1617, 1632, "HbA1c < 7 . 0 %", "", " ." +145, Percentage, 1631, 1632, "%", "", +57, PercentageAffected, 1649, 1655, "21 . 7", "", " \"21 . 7\"." +58, PercentageAffected, 1663, 1669, "29 . 4", "", " \"29 . 4\"." +151, Mean, 1686, 1690, "Mean", "", " . . . ." +60987, InsulinDose, 1691, 1696, "basal", "", +60990, InsulinDose, 1699, 1721, "mealtime insulin doses", "", " . ." +60987, InsulinDose, 1708, 1721, "insulin doses", "", " . ." +92, TimePoint, 1725, 1732, "week 24", "", " \"week 24\". \"week 24\". \"week 24\". \"week 24\"." +60, ResultMeasuredValue, 1738, 1744, "29 . 6", "", " \"29 . 6\"." +61, ResultMeasuredValue, 1747, 1753, "36 . 2", "", " \"36 . 2\"." +60986, BioAndMedicalUnit, 1754, 1762, "IU / day", "", " . . . ." +189, LisproProtamine, 1765, 1769, "ILPS", "", +62, ResultMeasuredValue, 1779, 1785, "32 . 8", "", " \"32 . 8\"." +63, ResultMeasuredValue, 1788, 1794, "42 . 2", "", " \"42 . 2\"." +60985, BioAndMedicalUnit, 1795, 1803, "IU / day", "", +67, InsulinGlargine, 1806, 1814, "glargine", "", +92976, InsulinDose, 1872, 1882, "total dose", "", " . ." +68, PvalueDiff, 1885, 1894, "p = 0 . 7", "", " \"p = 0 . 7\"." +166, PercentageAffected, 1916, 1922, "56 . 1", "", " \"56 . 1\"." +71, PercentageAffected, 1925, 1931, "25 . 7", "", " \"25 . 7\"." +168, PercentageAffected, 1941, 1947, "63 . 6", "", " \"63 . 6\"." +72, PercentageAffected, 1950, 1956, "19 . 3", "", " \"19 . 3\"." +73, NocturnalHypoglycemia, 1989, 2012, "nocturnal hypoglycaemia", "", " ." +93014, Hypoglycemia, 1999, 2012, "hypoglycaemia", "", " ." +164, Hypoglycemia, 2013, 2012, "", "", +92984, PvalueDiff, 2015, 2024, "p = 0 . 2", "", " \"p = 0 . 2\". \"p = 0 . 2\"." +80, ConclusionComment, 2112, 2335, "A basal - bolus regimen with ILPS once daily resulted in non - inferior glycaemic control compared to a similar regimen with glargine , without statistically significant or clinically relevant differences in hypoglycaemia .", "", " \"A basal - bolus regimen with ILPS once daily resulted in non - inferior glycaemic control compared to a similar regimen with glargine , without statistically significant or clinically relevant differences in hypoglycaemia .\"." +190, LisproProtamine, 2141, 2145, "ILPS", "", +77, Frequency, 2146, 2156, "once daily", "", +78, InsulinGlargine, 2237, 2245, "glargine", "", +79, Hypoglycemia, 2320, 2333, "hypoglycaemia", "", +191, LisproProtamine, 2336, 2340, "ILPS", "", +84, ConclusionComment, 2336, 2450, "ILPS - based regimens can be considered an alternative to basal - bolus regimens with glargine for T2DM patients .", "", " \"ILPS - based regimens can be considered an alternative to basal - bolus regimens with glargine for T2DM patients .\"." +82, InsulinGlargine, 2422, 2430, "glargine", "", +83, Type2Diabetes, 2435, 2439, "T2DM", "", +85, PMID, 2545, 2553, "21819517", "", " \"21819517\"." diff --git a/data/dm2 21819517_admin.n-triples b/data/dm2 21819517_admin.n-triples new file mode 100644 index 0000000..86b2d4e --- /dev/null +++ b/data/dm2 21819517_admin.n-triples @@ -0,0 +1,219 @@ +# RDF export of group: Publication + . + "Publication 33909" . + "Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal - bolus therapies with insulin lispro in type 2 diabetes patients : a prospective randomized open - label trial ." . + "Koivisto V" . + "2011" . + "Diabetes Obes Metab ." . + "21819517" . + . + "Cleall S" . + "Pontiroli AE" . + "Giugliano D" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 33916" . + "To compare the efficacy and safety of insulin lispro protamine suspension ( ILPS ) versus insulin glargine once daily in a basal - bolus regimen in type 2 diabetes mellitus ( T2DM ) patients ." . + "Three hundred eighty - three" . + "24 - week" . + . + . + . + "A basal - bolus regimen with ILPS once daily resulted in non - inferior glycaemic control compared to a similar regimen with glargine , without statistically significant or clinically relevant differences in hypoglycaemia ." . + . + . + . + . + . + . + . + . + "ILPS - based regimens can be considered an alternative to basal - bolus regimens with glargine for T2DM patients ." . + . + . + . + . +# RDF export of group: Population + . + "Population 33932" . + "insulin lispro in type 2 diabetes patients" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbatar" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + . + "insmea" . + . + . + . + . + . + . + . + . + "instot" . + . + . + . + . + . + . + "hyo" . + . + . + . + . + . + "noc" . + . + . + . + . +# RDF export of group: Arm + . + "ilp" . + . + . + . + . + . + . + . + . + . + "gla" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "ilps" . + . + . + . + "glar" . + . + . +# RDF export of group: Medication + . + "ilps" . + . + . + . + . + "gla" . + . + . + . +# RDF export of group: Outcome + . + "hba lip" . + . + "1 . 05" . + "week 24" . + . + "hba glar" . + . + "1 . 20" . + "week 24" . + . + "hbatar lip" . + . + "21 . 7" . + . + "hbatar gla" . + . + "29 . 4" . + . + "ins lip" . + . + "29 . 6" . + "week 24" . + . + "ins glar" . + . + "32 . 8" . + "week 24" . + . + "insmea lip" . + . + "36 . 2" . + "week 24" . + . + "insmea gla" . + . + "42 . 2" . + "week 24" . + . + "instot lip" . + . + . + "instot gla" . + . + . + "hyp lip" . + . + "56 . 1" . + . + "hyp gla" . + . + "63 . 6" . + . + "noc lip" . + . + "25 . 7" . + . + "noc gla" . + . + "19 . 3" . +# RDF export of group: DiffBetweenGroups + . + "hb" . + "0 . 1" . + . + . + "( 95 % CI )" . + "( - 0 . 11 ; 0 . 31 )" . + . + "instot" . + "p = 0 . 7" . + . + . + . + "hyp" . + "p = 0 . 2" . + . + . + . + "noc" . + "p = 0 . 2" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21819517_akramersunderbrink.annodb b/data/dm2 21819517_akramersunderbrink.annodb new file mode 100644 index 0000000..db9b2bd --- /dev/null +++ b/data/dm2 21819517_akramersunderbrink.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +39962, Journal, 0, 19, "Diabetes Obes Metab", "", +39963, PublicationYear, 22, 26, "2011", "", +39971, Title, 112, 319, "Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal - bolus therapies with insulin lispro in type 2 diabetes patients : a prospective randomized open - label trial .", "", +40592, LisproProtamine, 126, 161, "insulin lispro protamine suspension", "", +39965, InsulinGlargine, 169, 185, "insulin glargine", "", +39966, Frequency, 186, 196, "once daily", "", +39967, Lispro, 229, 243, "insulin lispro", "", +39968, Type2Diabetes, 247, 262, "type 2 diabetes", "", +39969, Randomized, 288, 298, "randomized", "", +39970, OpenLabel, 299, 311, "open - label", "", +39972, Author, 320, 330, "Koivisto V", "", +39973, Author, 339, 347, "Cleall S", "", +39974, Author, 350, 362, "Pontiroli AE", "", +39975, Author, 365, 376, "Giugliano D", "", +39976, Germany, 445, 452, "Germany", "", +39983, ObjectiveDescription, 492, 684, "To compare the efficacy and safety of insulin lispro protamine suspension ( ILPS ) versus insulin glargine once daily in a basal - bolus regimen in type 2 diabetes mellitus ( T2DM ) patients .", "", +40593, LisproProtamine, 530, 565, "insulin lispro protamine suspension", "", +40594, LisproProtamine, 568, 572, "ILPS", "", +39979, InsulinGlargine, 582, 598, "insulin glargine", "", +39980, Frequency, 599, 609, "once daily", "", +39981, Type2Diabetes, 640, 664, "type 2 diabetes mellitus", "", +39982, Type2Diabetes, 667, 671, "T2DM", "", +39984, NumberPatientsCT, 695, 723, "Three hundred eighty - three", "", +39985, Randomized, 756, 766, "randomized", "", +40595, LisproProtamine, 777, 781, "ILPS", "", +39986, Lispro, 787, 793, "lispro", "", +39988, InsulinGlargine, 797, 805, "glargine", "", +39987, Lispro, 811, 817, "lispro", "", +39989, OpenLabel, 826, 838, "open - label", "", +39990, Duration, 839, 848, "24 - week", "", +39995, Multicenter, 849, 863, "European study", "", +40597, BloodGlucose, 908, 921, "blood glucose", "", +40598, BloodGlucose, 924, 926, "BG", "", +40596, LisproProtamine, 960, 964, "ILPS", "", +39991, InsulinGlargine, 972, 980, "glargine", "", +39992, HbA1c, 1080, 1085, "HbA1c", "", +39993, TimePoint, 1091, 1099, "baseline", "", +39994, TimePoint, 1103, 1110, "week 24", "", +39997, TimePoint, 1138, 1146, "baseline", "", +39996, HbA1c, 1147, 1152, "HbA1c", "", +39998, Percentage, 1198, 1199, "%", "", +39999, HbA1c, 1231, 1236, "HbA1c", "", +40000, BloodGlucose, 1250, 1252, "BG", "", +40001, InsulinDose, 1264, 1277, "insulin doses", "", +40002, Hypoglycemia, 1280, 1302, "hypoglycaemic episodes", "", +40599, LisproProtamine, 1369, 1373, "ILPS", "", +40003, InsulinGlargine, 1381, 1389, "glargine", "", +40004, HbA1c, 1407, 1412, "HbA1c", "", +40005, TimePoint, 1418, 1426, "baseline", "", +40006, LeastSquaresMean, 1439, 1458, "least - square mean", "", +40008, Percentage, 1495, 1496, "%", "", +40007, DiffGroupAbsValue, 1506, 1511, "0 . 1", "", +40009, Percentage, 1512, 1513, "%", "", +40010, ConfIntervalDiff, 1516, 1533, "- 0 . 11 ; 0 . 31", "", +40011, Mean, 1538, 1542, "Mean", "", +40012, TimePoint, 1554, 1561, "week 24", "", +40013, ChangeValue, 1567, 1575, "- 1 . 05", "", +40015, Percentage, 1576, 1577, "%", "", +40600, LisproProtamine, 1580, 1584, "ILPS", "", +40014, ChangeValue, 1591, 1599, "- 1 . 20", "", +40016, Percentage, 1600, 1601, "%", "", +40019, InsulinGlargine, 1604, 1612, "glargine", "", +40020, HbA1c_target, 1617, 1632, "HbA1c < 7 . 0 %", "", +40017, Percentage, 1631, 1632, "%", "", +40021, PercentageAffected, 1649, 1655, "21 . 7", "", +40022, PercentageAffected, 1663, 1669, "29 . 4", "", +40018, Percentage, 1670, 1671, "%", "", +40023, Mean, 1686, 1690, "Mean", "", +40024, InsulinDose, 1691, 1721, "basal / mealtime insulin doses", "", +40026, InsulinDose, 1699, 1721, "mealtime insulin doses", "", +40025, TimePoint, 1725, 1732, "week 24", "", +40027, ResultMeasuredValue, 1738, 1744, "29 . 6", "", +40028, ResultMeasuredValue, 1747, 1753, "36 . 2", "", +40031, BioAndMedicalUnit, 1754, 1762, "IU / day", "", +40601, LisproProtamine, 1765, 1769, "ILPS", "", +40029, ResultMeasuredValue, 1779, 1785, "32 . 8", "", +40030, ResultMeasuredValue, 1788, 1794, "42 . 2", "", +40032, BioAndMedicalUnit, 1795, 1803, "IU / day", "", +40033, InsulinGlargine, 1806, 1814, "glargine", "", +40034, InsulinDose, 1872, 1882, "total dose", "", +40035, PvalueDiff, 1885, 1894, "p = 0 . 7", "", +40038, PercentageAffected, 1916, 1922, "56 . 1", "", +40039, PercentageAffected, 1925, 1931, "25 . 7", "", +40043, Percentage, 1932, 1933, "%", "", +40040, PercentageAffected, 1941, 1947, "63 . 6", "", +40041, PercentageAffected, 1950, 1956, "19 . 3", "", +40044, Percentage, 1957, 1958, "%", "", +40036, Hypoglycemia, 1983, 2012, "any / nocturnal hypoglycaemia", "", +40037, NocturnalHypoglycemia, 1989, 2012, "nocturnal hypoglycaemia", "", +40042, PvalueDiff, 2015, 2024, "p = 0 . 2", "", +40048, ConclusionComment, 2112, 2335, "A basal - bolus regimen with ILPS once daily resulted in non - inferior glycaemic control compared to a similar regimen with glargine , without statistically significant or clinically relevant differences in hypoglycaemia .", "", +40602, LisproProtamine, 2141, 2145, "ILPS", "", +40045, Frequency, 2146, 2156, "once daily", "", +40046, InsulinGlargine, 2237, 2245, "glargine", "", +40047, Hypoglycemia, 2320, 2333, "hypoglycaemia", "", +40603, LisproProtamine, 2336, 2340, "ILPS", "", +40052, InsulinGlargine, 2422, 2430, "glargine", "", +40051, Type2Diabetes, 2435, 2439, "T2DM", "", +40053, PMID, 2545, 2553, "21819517", "", diff --git a/data/dm2 21819517_akramersunderbrink.n-triples b/data/dm2 21819517_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21819517_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 21819517_export.csv b/data/dm2 21819517_export.csv new file mode 100644 index 0000000..3973856 --- /dev/null +++ b/data/dm2 21819517_export.csv @@ -0,0 +1,542 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +320, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +320, 1, 2, 2, 9, 13, 9, 13, "Obes" +320, 1, 3, 3, 14, 19, 14, 19, "Metab" +320, 1, 4, 4, 20, 21, 20, 21, "." +320, 2, 1, 5, 0, 4, 22, 26, "2011" +320, 2, 2, 6, 5, 8, 27, 30, "Dec" +320, 2, 3, 7, 9, 10, 31, 32, ";" +320, 2, 4, 8, 11, 13, 33, 35, "13" +320, 2, 5, 9, 14, 15, 36, 37, "(" +320, 2, 6, 10, 16, 18, 38, 40, "12" +320, 2, 7, 11, 19, 20, 41, 42, ")" +320, 2, 8, 12, 21, 22, 43, 44, ":" +320, 2, 9, 13, 23, 27, 45, 49, "1149" +320, 2, 10, 14, 28, 29, 50, 51, "-" +320, 2, 11, 15, 30, 32, 52, 54, "57" +320, 2, 12, 16, 33, 34, 55, 56, "." +320, 2, 13, 17, 35, 38, 57, 60, "doi" +320, 2, 14, 18, 39, 40, 61, 62, ":" +320, 2, 15, 19, 41, 43, 63, 65, "10" +320, 2, 16, 20, 44, 45, 66, 67, "." +320, 2, 17, 21, 46, 50, 68, 72, "1111" +320, 2, 18, 22, 51, 52, 73, 74, "/" +320, 2, 19, 23, 53, 54, 75, 76, "j" +320, 2, 20, 24, 55, 56, 77, 78, "." +320, 2, 21, 25, 57, 61, 79, 83, "1463" +320, 2, 22, 26, 62, 63, 84, 85, "-" +320, 2, 23, 27, 64, 68, 86, 90, "1326" +320, 2, 24, 28, 69, 70, 91, 92, "." +320, 2, 25, 29, 71, 75, 93, 97, "2011" +320, 2, 26, 30, 76, 77, 98, 99, "." +320, 2, 27, 31, 78, 83, 100, 105, "01484" +320, 2, 28, 32, 84, 85, 106, 107, "." +320, 2, 29, 33, 86, 87, 108, 109, "x" +320, 2, 30, 34, 88, 89, 110, 111, "." +320, 3, 1, 35, 0, 10, 112, 122, "Comparison" +320, 3, 2, 36, 11, 13, 123, 125, "of" +320, 3, 3, 37, 14, 21, 126, 133, "insulin" +320, 3, 4, 38, 22, 28, 134, 140, "lispro" +320, 3, 5, 39, 29, 38, 141, 150, "protamine" +320, 3, 6, 40, 39, 49, 151, 161, "suspension" +320, 3, 7, 41, 50, 56, 162, 168, "versus" +320, 3, 8, 42, 57, 64, 169, 176, "insulin" +320, 3, 9, 43, 65, 73, 177, 185, "glargine" +320, 3, 10, 44, 74, 78, 186, 190, "once" +320, 3, 11, 45, 79, 84, 191, 196, "daily" +320, 3, 12, 46, 85, 87, 197, 199, "in" +320, 3, 13, 47, 88, 93, 200, 205, "basal" +320, 3, 14, 48, 94, 95, 206, 207, "-" +320, 3, 15, 49, 96, 101, 208, 213, "bolus" +320, 3, 16, 50, 102, 111, 214, 223, "therapies" +320, 3, 17, 51, 112, 116, 224, 228, "with" +320, 3, 18, 52, 117, 124, 229, 236, "insulin" +320, 3, 19, 53, 125, 131, 237, 243, "lispro" +320, 3, 20, 54, 132, 134, 244, 246, "in" +320, 3, 21, 55, 135, 139, 247, 251, "type" +320, 3, 22, 56, 140, 141, 252, 253, "2" +320, 3, 23, 57, 142, 150, 254, 262, "diabetes" +320, 3, 24, 58, 151, 159, 263, 271, "patients" +320, 3, 25, 59, 160, 161, 272, 273, ":" +320, 3, 26, 60, 162, 163, 274, 275, "a" +320, 3, 27, 61, 164, 175, 276, 287, "prospective" +320, 3, 28, 62, 176, 186, 288, 298, "randomized" +320, 3, 29, 63, 187, 191, 299, 303, "open" +320, 3, 30, 64, 192, 193, 304, 305, "-" +320, 3, 31, 65, 194, 199, 306, 311, "label" +320, 3, 32, 66, 200, 205, 312, 317, "trial" +320, 3, 33, 67, 206, 207, 318, 319, "." +320, 4, 1, 68, 0, 8, 320, 328, "Koivisto" +320, 4, 2, 69, 9, 10, 329, 330, "V" +320, 4, 3, 70, 11, 12, 331, 332, "(" +320, 4, 4, 71, 13, 14, 333, 334, "1" +320, 4, 5, 72, 15, 16, 335, 336, ")" +320, 4, 6, 73, 17, 18, 337, 338, "," +320, 4, 7, 74, 19, 25, 339, 345, "Cleall" +320, 4, 8, 75, 26, 27, 346, 347, "S" +320, 4, 9, 76, 28, 29, 348, 349, "," +320, 4, 10, 77, 30, 39, 350, 359, "Pontiroli" +320, 4, 11, 78, 40, 42, 360, 362, "AE" +320, 4, 12, 79, 43, 44, 363, 364, "," +320, 4, 13, 80, 45, 54, 365, 374, "Giugliano" +320, 4, 14, 81, 55, 56, 375, 376, "D" +320, 4, 15, 82, 57, 58, 377, 378, "." +320, 4, 16, 83, 59, 65, 379, 385, "Author" +320, 4, 17, 84, 66, 77, 386, 397, "information" +320, 4, 18, 85, 78, 79, 398, 399, ":" +320, 4, 19, 86, 80, 81, 400, 401, "(" +320, 4, 20, 87, 82, 83, 402, 403, "1" +320, 4, 21, 88, 84, 85, 404, 405, ")" +320, 4, 22, 89, 86, 91, 406, 411, "Lilly" +320, 4, 23, 90, 92, 103, 412, 423, "Deutschland" +320, 4, 24, 91, 104, 108, 424, 428, "GmbH" +320, 4, 25, 92, 109, 110, 429, 430, "," +320, 4, 26, 93, 111, 114, 431, 434, "Bad" +320, 4, 27, 94, 115, 122, 435, 442, "Homburg" +320, 4, 28, 95, 123, 124, 443, 444, "," +320, 4, 29, 96, 125, 132, 445, 452, "Germany" +320, 4, 30, 97, 133, 134, 453, 454, "." +320, 5, 1, 98, 0, 15, 455, 470, "koivisto_veikko" +320, 5, 2, 99, 16, 17, 471, 472, "@" +320, 5, 3, 100, 18, 23, 473, 478, "lilly" +320, 5, 4, 101, 24, 25, 479, 480, "." +320, 5, 5, 102, 26, 29, 481, 484, "com" +320, 5, 6, 103, 30, 34, 485, 489, "AIMS" +320, 5, 7, 104, 35, 36, 490, 491, ":" +320, 5, 8, 105, 37, 39, 492, 494, "To" +320, 5, 9, 106, 40, 47, 495, 502, "compare" +320, 5, 10, 107, 48, 51, 503, 506, "the" +320, 5, 11, 108, 52, 60, 507, 515, "efficacy" +320, 5, 12, 109, 61, 64, 516, 519, "and" +320, 5, 13, 110, 65, 71, 520, 526, "safety" +320, 5, 14, 111, 72, 74, 527, 529, "of" +320, 5, 15, 112, 75, 82, 530, 537, "insulin" +320, 5, 16, 113, 83, 89, 538, 544, "lispro" +320, 5, 17, 114, 90, 99, 545, 554, "protamine" +320, 5, 18, 115, 100, 110, 555, 565, "suspension" +320, 5, 19, 116, 111, 112, 566, 567, "(" +320, 5, 20, 117, 113, 117, 568, 572, "ILPS" +320, 5, 21, 118, 118, 119, 573, 574, ")" +320, 5, 22, 119, 120, 126, 575, 581, "versus" +320, 5, 23, 120, 127, 134, 582, 589, "insulin" +320, 5, 24, 121, 135, 143, 590, 598, "glargine" +320, 5, 25, 122, 144, 148, 599, 603, "once" +320, 5, 26, 123, 149, 154, 604, 609, "daily" +320, 5, 27, 124, 155, 157, 610, 612, "in" +320, 5, 28, 125, 158, 159, 613, 614, "a" +320, 5, 29, 126, 160, 165, 615, 620, "basal" +320, 5, 30, 127, 166, 167, 621, 622, "-" +320, 5, 31, 128, 168, 173, 623, 628, "bolus" +320, 5, 32, 129, 174, 181, 629, 636, "regimen" +320, 5, 33, 130, 182, 184, 637, 639, "in" +320, 5, 34, 131, 185, 189, 640, 644, "type" +320, 5, 35, 132, 190, 191, 645, 646, "2" +320, 5, 36, 133, 192, 200, 647, 655, "diabetes" +320, 5, 37, 134, 201, 209, 656, 664, "mellitus" +320, 5, 38, 135, 210, 211, 665, 666, "(" +320, 5, 39, 136, 212, 216, 667, 671, "T2DM" +320, 5, 40, 137, 217, 218, 672, 673, ")" +320, 5, 41, 138, 219, 227, 674, 682, "patients" +320, 5, 42, 139, 228, 229, 683, 684, "." +320, 6, 1, 140, 0, 7, 685, 692, "METHODS" +320, 6, 2, 141, 8, 9, 693, 694, ":" +320, 6, 3, 142, 10, 15, 695, 700, "Three" +320, 6, 4, 143, 16, 23, 701, 708, "hundred" +320, 6, 5, 144, 24, 30, 709, 715, "eighty" +320, 6, 6, 145, 31, 32, 716, 717, "-" +320, 6, 7, 146, 33, 38, 718, 723, "three" +320, 6, 8, 147, 39, 46, 724, 731, "insulin" +320, 6, 9, 148, 47, 48, 732, 733, "-" +320, 6, 10, 149, 49, 56, 734, 741, "treated" +320, 6, 11, 150, 57, 65, 742, 750, "patients" +320, 6, 12, 151, 66, 70, 751, 755, "were" +320, 6, 13, 152, 71, 81, 756, 766, "randomized" +320, 6, 14, 153, 82, 84, 767, 769, "to" +320, 6, 15, 154, 85, 91, 770, 776, "either" +320, 6, 16, 155, 92, 96, 777, 781, "ILPS" +320, 6, 17, 156, 97, 101, 782, 786, "plus" +320, 6, 18, 157, 102, 108, 787, 793, "lispro" +320, 6, 19, 158, 109, 111, 794, 796, "or" +320, 6, 20, 159, 112, 120, 797, 805, "glargine" +320, 6, 21, 160, 121, 125, 806, 810, "plus" +320, 6, 22, 161, 126, 132, 811, 817, "lispro" +320, 6, 23, 162, 133, 135, 818, 820, "in" +320, 6, 24, 163, 136, 140, 821, 825, "this" +320, 6, 25, 164, 141, 145, 826, 830, "open" +320, 6, 26, 165, 146, 147, 831, 832, "-" +320, 6, 27, 166, 148, 153, 833, 838, "label" +320, 6, 28, 167, 154, 156, 839, 841, "24" +320, 6, 29, 168, 157, 158, 842, 843, "-" +320, 6, 30, 169, 159, 163, 844, 848, "week" +320, 6, 31, 170, 164, 172, 849, 857, "European" +320, 6, 32, 171, 173, 178, 858, 863, "study" +320, 6, 33, 172, 179, 180, 864, 865, "." +320, 7, 1, 173, 0, 7, 866, 873, "Insulin" +320, 7, 2, 174, 8, 13, 874, 879, "doses" +320, 7, 3, 175, 14, 18, 880, 884, "were" +320, 7, 4, 176, 19, 27, 885, 893, "titrated" +320, 7, 5, 177, 28, 30, 894, 896, "to" +320, 7, 6, 178, 31, 41, 897, 907, "predefined" +320, 7, 7, 179, 42, 47, 908, 913, "blood" +320, 7, 8, 180, 48, 55, 914, 921, "glucose" +320, 7, 9, 181, 56, 57, 922, 923, "(" +320, 7, 10, 182, 58, 60, 924, 926, "BG" +320, 7, 11, 183, 61, 62, 927, 928, ")" +320, 7, 12, 184, 63, 70, 929, 936, "targets" +320, 7, 13, 185, 71, 72, 937, 938, "." +320, 8, 1, 186, 0, 3, 939, 942, "Non" +320, 8, 2, 187, 4, 5, 943, 944, "-" +320, 8, 3, 188, 6, 17, 945, 956, "inferiority" +320, 8, 4, 189, 18, 20, 957, 959, "of" +320, 8, 5, 190, 21, 25, 960, 964, "ILPS" +320, 8, 6, 191, 26, 32, 965, 971, "versus" +320, 8, 7, 192, 33, 41, 972, 980, "glargine" +320, 8, 8, 193, 42, 45, 981, 984, "was" +320, 8, 9, 194, 46, 54, 985, 993, "assessed" +320, 8, 10, 195, 55, 57, 994, 996, "by" +320, 8, 11, 196, 58, 67, 997, 1006, "comparing" +320, 8, 12, 197, 68, 71, 1007, 1010, "the" +320, 8, 13, 198, 72, 77, 1011, 1016, "upper" +320, 8, 14, 199, 78, 83, 1017, 1022, "limit" +320, 8, 15, 200, 84, 86, 1023, 1025, "of" +320, 8, 16, 201, 87, 90, 1026, 1029, "the" +320, 8, 17, 202, 91, 93, 1030, 1032, "95" +320, 8, 18, 203, 94, 95, 1033, 1034, "%" +320, 8, 19, 204, 96, 106, 1035, 1045, "confidence" +320, 8, 20, 205, 107, 115, 1046, 1054, "interval" +320, 8, 21, 206, 116, 117, 1055, 1056, "(" +320, 8, 22, 207, 118, 120, 1057, 1059, "CI" +320, 8, 23, 208, 121, 122, 1060, 1061, ")" +320, 8, 24, 209, 123, 126, 1062, 1065, "for" +320, 8, 25, 210, 127, 130, 1066, 1069, "the" +320, 8, 26, 211, 131, 137, 1070, 1076, "change" +320, 8, 27, 212, 138, 140, 1077, 1079, "of" +320, 8, 28, 213, 141, 146, 1080, 1085, "HbA1c" +320, 8, 29, 214, 147, 151, 1086, 1090, "from" +320, 8, 30, 215, 152, 160, 1091, 1099, "baseline" +320, 8, 31, 216, 161, 163, 1100, 1102, "to" +320, 8, 32, 217, 164, 168, 1103, 1107, "week" +320, 8, 33, 218, 169, 171, 1108, 1110, "24" +320, 8, 34, 219, 172, 173, 1111, 1112, "(" +320, 8, 35, 220, 174, 182, 1113, 1121, "adjusted" +320, 8, 36, 221, 183, 186, 1122, 1125, "for" +320, 8, 37, 222, 187, 194, 1126, 1133, "country" +320, 8, 38, 223, 195, 198, 1134, 1137, "and" +320, 8, 39, 224, 199, 207, 1138, 1146, "baseline" +320, 8, 40, 225, 208, 213, 1147, 1152, "HbA1c" +320, 8, 41, 226, 214, 215, 1153, 1154, ")" +320, 8, 42, 227, 216, 220, 1155, 1159, "with" +320, 8, 43, 228, 221, 224, 1160, 1163, "the" +320, 8, 44, 229, 225, 228, 1164, 1167, "non" +320, 8, 45, 230, 229, 230, 1168, 1169, "-" +320, 8, 46, 231, 231, 242, 1170, 1181, "inferiority" +320, 8, 47, 232, 243, 249, 1182, 1188, "margin" +320, 8, 48, 233, 250, 252, 1189, 1191, "of" +320, 8, 49, 234, 253, 254, 1192, 1193, "0" +320, 8, 50, 235, 255, 256, 1194, 1195, "." +320, 8, 51, 236, 257, 258, 1196, 1197, "4" +320, 8, 52, 237, 259, 260, 1198, 1199, "%" +320, 8, 53, 238, 261, 262, 1200, 1201, "." +320, 9, 1, 239, 0, 9, 1202, 1211, "Secondary" +320, 9, 2, 240, 10, 19, 1212, 1221, "endpoints" +320, 9, 3, 241, 20, 28, 1222, 1230, "included" +320, 9, 4, 242, 29, 34, 1231, 1236, "HbA1c" +320, 9, 5, 243, 35, 45, 1237, 1247, "categories" +320, 9, 6, 244, 46, 47, 1248, 1249, "," +320, 9, 7, 245, 48, 50, 1250, 1252, "BG" +320, 9, 8, 246, 51, 59, 1253, 1261, "profiles" +320, 9, 9, 247, 60, 61, 1262, 1263, "," +320, 9, 10, 248, 62, 69, 1264, 1271, "insulin" +320, 9, 11, 249, 70, 75, 1272, 1277, "doses" +320, 9, 12, 250, 76, 77, 1278, 1279, "," +320, 9, 13, 251, 78, 91, 1280, 1293, "hypoglycaemic" +320, 9, 14, 252, 92, 100, 1294, 1302, "episodes" +320, 9, 15, 253, 101, 102, 1303, 1304, "," +320, 9, 16, 254, 103, 110, 1305, 1312, "adverse" +320, 9, 17, 255, 111, 117, 1313, 1319, "events" +320, 9, 18, 256, 118, 121, 1320, 1323, "and" +320, 9, 19, 257, 122, 127, 1324, 1329, "vital" +320, 9, 20, 258, 128, 133, 1330, 1335, "signs" +320, 9, 21, 259, 134, 135, 1336, 1337, "." +320, 10, 1, 260, 0, 7, 1338, 1345, "RESULTS" +320, 10, 2, 261, 8, 9, 1346, 1347, ":" +320, 10, 3, 262, 10, 13, 1348, 1351, "Non" +320, 10, 4, 263, 14, 15, 1352, 1353, "-" +320, 10, 5, 264, 16, 27, 1354, 1365, "inferiority" +320, 10, 6, 265, 28, 30, 1366, 1368, "of" +320, 10, 7, 266, 31, 35, 1369, 1373, "ILPS" +320, 10, 8, 267, 36, 42, 1374, 1380, "versus" +320, 10, 9, 268, 43, 51, 1381, 1389, "glargine" +320, 10, 10, 269, 52, 54, 1390, 1392, "in" +320, 10, 11, 270, 55, 58, 1393, 1396, "the" +320, 10, 12, 271, 59, 65, 1397, 1403, "change" +320, 10, 13, 272, 66, 68, 1404, 1406, "of" +320, 10, 14, 273, 69, 74, 1407, 1412, "HbA1c" +320, 10, 15, 274, 75, 79, 1413, 1417, "from" +320, 10, 16, 275, 80, 88, 1418, 1426, "baseline" +320, 10, 17, 276, 89, 92, 1427, 1430, "was" +320, 10, 18, 277, 93, 98, 1431, 1436, "shown" +320, 10, 19, 278, 99, 100, 1437, 1438, ":" +320, 10, 20, 279, 101, 106, 1439, 1444, "least" +320, 10, 21, 280, 107, 108, 1445, 1446, "-" +320, 10, 22, 281, 109, 115, 1447, 1453, "square" +320, 10, 23, 282, 116, 120, 1454, 1458, "mean" +320, 10, 24, 283, 121, 128, 1459, 1466, "between" +320, 10, 25, 284, 129, 130, 1467, 1468, "-" +320, 10, 26, 285, 131, 140, 1469, 1478, "treatment" +320, 10, 27, 286, 141, 151, 1479, 1489, "difference" +320, 10, 28, 287, 152, 153, 1490, 1491, "(" +320, 10, 29, 288, 154, 156, 1492, 1494, "95" +320, 10, 30, 289, 157, 158, 1495, 1496, "%" +320, 10, 31, 290, 159, 161, 1497, 1499, "CI" +320, 10, 32, 291, 162, 163, 1500, 1501, ")" +320, 10, 33, 292, 164, 167, 1502, 1505, "was" +320, 10, 34, 293, 168, 169, 1506, 1507, "0" +320, 10, 35, 294, 170, 171, 1508, 1509, "." +320, 10, 36, 295, 172, 173, 1510, 1511, "1" +320, 10, 37, 296, 174, 175, 1512, 1513, "%" +320, 10, 38, 297, 176, 177, 1514, 1515, "(" +320, 10, 39, 298, 178, 179, 1516, 1517, "-" +320, 10, 40, 299, 180, 181, 1518, 1519, "0" +320, 10, 41, 300, 182, 183, 1520, 1521, "." +320, 10, 42, 301, 184, 186, 1522, 1524, "11" +320, 10, 43, 302, 187, 188, 1525, 1526, ";" +320, 10, 44, 303, 189, 190, 1527, 1528, "0" +320, 10, 45, 304, 191, 192, 1529, 1530, "." +320, 10, 46, 305, 193, 195, 1531, 1533, "31" +320, 10, 47, 306, 196, 197, 1534, 1535, ")" +320, 10, 48, 307, 198, 199, 1536, 1537, "." +320, 11, 1, 308, 0, 4, 1538, 1542, "Mean" +320, 11, 2, 309, 5, 12, 1543, 1550, "changes" +320, 11, 3, 310, 13, 15, 1551, 1553, "at" +320, 11, 4, 311, 16, 20, 1554, 1558, "week" +320, 11, 5, 312, 21, 23, 1559, 1561, "24" +320, 11, 6, 313, 24, 28, 1562, 1566, "were" +320, 11, 7, 314, 29, 30, 1567, 1568, "-" +320, 11, 8, 315, 31, 32, 1569, 1570, "1" +320, 11, 9, 316, 33, 34, 1571, 1572, "." +320, 11, 10, 317, 35, 37, 1573, 1575, "05" +320, 11, 11, 318, 38, 39, 1576, 1577, "%" +320, 11, 12, 319, 40, 41, 1578, 1579, "(" +320, 11, 13, 320, 42, 46, 1580, 1584, "ILPS" +320, 11, 14, 321, 47, 48, 1585, 1586, ")" +320, 11, 15, 322, 49, 52, 1587, 1590, "and" +320, 11, 16, 323, 53, 54, 1591, 1592, "-" +320, 11, 17, 324, 55, 56, 1593, 1594, "1" +320, 11, 18, 325, 57, 58, 1595, 1596, "." +320, 11, 19, 326, 59, 61, 1597, 1599, "20" +320, 11, 20, 327, 62, 63, 1600, 1601, "%" +320, 11, 21, 328, 64, 65, 1602, 1603, "(" +320, 11, 22, 329, 66, 74, 1604, 1612, "glargine" +320, 11, 23, 330, 75, 76, 1613, 1614, ")" +320, 11, 24, 331, 77, 78, 1615, 1616, "." +320, 12, 1, 332, 0, 5, 1617, 1622, "HbA1c" +320, 12, 2, 333, 6, 7, 1623, 1624, "<" +320, 12, 3, 334, 8, 9, 1625, 1626, "7" +320, 12, 4, 335, 10, 11, 1627, 1628, "." +320, 12, 5, 336, 12, 13, 1629, 1630, "0" +320, 12, 6, 337, 14, 15, 1631, 1632, "%" +320, 12, 7, 338, 16, 19, 1633, 1636, "was" +320, 12, 8, 339, 20, 28, 1637, 1645, "achieved" +320, 12, 9, 340, 29, 31, 1646, 1648, "by" +320, 12, 10, 341, 32, 34, 1649, 1651, "21" +320, 12, 11, 342, 35, 36, 1652, 1653, "." +320, 12, 12, 343, 37, 38, 1654, 1655, "7" +320, 12, 13, 344, 39, 45, 1656, 1662, "versus" +320, 12, 14, 345, 46, 48, 1663, 1665, "29" +320, 12, 15, 346, 49, 50, 1666, 1667, "." +320, 12, 16, 347, 51, 52, 1668, 1669, "4" +320, 12, 17, 348, 53, 54, 1670, 1671, "%" +320, 12, 18, 349, 55, 57, 1672, 1674, "of" +320, 12, 19, 350, 58, 66, 1675, 1683, "patients" +320, 12, 20, 351, 67, 68, 1684, 1685, "." +320, 13, 1, 352, 0, 4, 1686, 1690, "Mean" +320, 13, 2, 353, 5, 10, 1691, 1696, "basal" +320, 13, 3, 354, 11, 12, 1697, 1698, "/" +320, 13, 4, 355, 13, 21, 1699, 1707, "mealtime" +320, 13, 5, 356, 22, 29, 1708, 1715, "insulin" +320, 13, 6, 357, 30, 35, 1716, 1721, "doses" +320, 13, 7, 358, 36, 38, 1722, 1724, "at" +320, 13, 8, 359, 39, 43, 1725, 1729, "week" +320, 13, 9, 360, 44, 46, 1730, 1732, "24" +320, 13, 10, 361, 47, 51, 1733, 1737, "were" +320, 13, 11, 362, 52, 54, 1738, 1740, "29" +320, 13, 12, 363, 55, 56, 1741, 1742, "." +320, 13, 13, 364, 57, 58, 1743, 1744, "6" +320, 13, 14, 365, 59, 60, 1745, 1746, "/" +320, 13, 15, 366, 61, 63, 1747, 1749, "36" +320, 13, 16, 367, 64, 65, 1750, 1751, "." +320, 13, 17, 368, 66, 67, 1752, 1753, "2" +320, 13, 18, 369, 68, 70, 1754, 1756, "IU" +320, 13, 19, 370, 71, 72, 1757, 1758, "/" +320, 13, 20, 371, 73, 76, 1759, 1762, "day" +320, 13, 21, 372, 77, 78, 1763, 1764, "(" +320, 13, 22, 373, 79, 83, 1765, 1769, "ILPS" +320, 13, 23, 374, 84, 85, 1770, 1771, ")" +320, 13, 24, 375, 86, 92, 1772, 1778, "versus" +320, 13, 25, 376, 93, 95, 1779, 1781, "32" +320, 13, 26, 377, 96, 97, 1782, 1783, "." +320, 13, 27, 378, 98, 99, 1784, 1785, "8" +320, 13, 28, 379, 100, 101, 1786, 1787, "/" +320, 13, 29, 380, 102, 104, 1788, 1790, "42" +320, 13, 30, 381, 105, 106, 1791, 1792, "." +320, 13, 31, 382, 107, 108, 1793, 1794, "2" +320, 13, 32, 383, 109, 111, 1795, 1797, "IU" +320, 13, 33, 384, 112, 113, 1798, 1799, "/" +320, 13, 34, 385, 114, 117, 1800, 1803, "day" +320, 13, 35, 386, 118, 119, 1804, 1805, "(" +320, 13, 36, 387, 120, 128, 1806, 1814, "glargine" +320, 13, 37, 388, 129, 130, 1815, 1816, ")" +320, 13, 38, 389, 131, 132, 1817, 1818, ";" +320, 13, 39, 390, 133, 136, 1819, 1822, "the" +320, 13, 40, 391, 137, 147, 1823, 1833, "difference" +320, 13, 41, 392, 148, 151, 1834, 1837, "was" +320, 13, 42, 393, 152, 155, 1838, 1841, "not" +320, 13, 43, 394, 156, 169, 1842, 1855, "statistically" +320, 13, 44, 395, 170, 181, 1856, 1867, "significant" +320, 13, 45, 396, 182, 185, 1868, 1871, "for" +320, 13, 46, 397, 186, 191, 1872, 1877, "total" +320, 13, 47, 398, 192, 196, 1878, 1882, "dose" +320, 13, 48, 399, 197, 198, 1883, 1884, "(" +320, 13, 49, 400, 199, 200, 1885, 1886, "p" +320, 13, 50, 401, 201, 202, 1887, 1888, "=" +320, 13, 51, 402, 203, 204, 1889, 1890, "0" +320, 13, 52, 403, 205, 206, 1891, 1892, "." +320, 13, 53, 404, 207, 208, 1893, 1894, "7" +320, 13, 54, 405, 209, 210, 1895, 1896, ")" +320, 13, 55, 406, 211, 212, 1897, 1898, "." +320, 14, 1, 407, 0, 2, 1899, 1901, "In" +320, 14, 2, 408, 3, 7, 1902, 1906, "both" +320, 14, 3, 409, 8, 14, 1907, 1913, "groups" +320, 14, 4, 410, 15, 16, 1914, 1915, "," +320, 14, 5, 411, 17, 19, 1916, 1918, "56" +320, 14, 6, 412, 20, 21, 1919, 1920, "." +320, 14, 7, 413, 22, 23, 1921, 1922, "1" +320, 14, 8, 414, 24, 25, 1923, 1924, "/" +320, 14, 9, 415, 26, 28, 1925, 1927, "25" +320, 14, 10, 416, 29, 30, 1928, 1929, "." +320, 14, 11, 417, 31, 32, 1930, 1931, "7" +320, 14, 12, 418, 33, 34, 1932, 1933, "%" +320, 14, 13, 419, 35, 41, 1934, 1940, "versus" +320, 14, 14, 420, 42, 44, 1941, 1943, "63" +320, 14, 15, 421, 45, 46, 1944, 1945, "." +320, 14, 16, 422, 47, 48, 1946, 1947, "6" +320, 14, 17, 423, 49, 50, 1948, 1949, "/" +320, 14, 18, 424, 51, 53, 1950, 1952, "19" +320, 14, 19, 425, 54, 55, 1953, 1954, "." +320, 14, 20, 426, 56, 57, 1955, 1956, "3" +320, 14, 21, 427, 58, 59, 1957, 1958, "%" +320, 14, 22, 428, 60, 62, 1959, 1961, "of" +320, 14, 23, 429, 63, 71, 1962, 1970, "patients" +320, 14, 24, 430, 72, 83, 1971, 1982, "experienced" +320, 14, 25, 431, 84, 87, 1983, 1986, "any" +320, 14, 26, 432, 88, 89, 1987, 1988, "/" +320, 14, 27, 433, 90, 99, 1989, 1998, "nocturnal" +320, 14, 28, 434, 100, 113, 1999, 2012, "hypoglycaemia" +320, 14, 29, 435, 114, 115, 2013, 2014, "(" +320, 14, 30, 436, 116, 117, 2015, 2016, "p" +320, 14, 31, 437, 118, 119, 2017, 2018, "=" +320, 14, 32, 438, 120, 121, 2019, 2020, "0" +320, 14, 33, 439, 122, 123, 2021, 2022, "." +320, 14, 34, 440, 124, 125, 2023, 2024, "2" +320, 14, 35, 441, 126, 129, 2025, 2028, "for" +320, 14, 36, 442, 130, 134, 2029, 2033, "both" +320, 14, 37, 443, 135, 136, 2034, 2035, ")" +320, 14, 38, 444, 137, 138, 2036, 2037, "." +320, 15, 1, 445, 0, 2, 2038, 2040, "No" +320, 15, 2, 446, 3, 11, 2041, 2049, "relevant" +320, 15, 3, 447, 12, 23, 2050, 2061, "differences" +320, 15, 4, 448, 24, 28, 2062, 2066, "were" +320, 15, 5, 449, 29, 34, 2067, 2072, "noted" +320, 15, 6, 450, 35, 37, 2073, 2075, "in" +320, 15, 7, 451, 38, 41, 2076, 2079, "any" +320, 15, 8, 452, 42, 47, 2080, 2085, "other" +320, 15, 9, 453, 48, 57, 2086, 2095, "variables" +320, 15, 10, 454, 58, 59, 2096, 2097, "." +320, 16, 1, 455, 0, 11, 2098, 2109, "CONCLUSIONS" +320, 16, 2, 456, 12, 13, 2110, 2111, ":" +320, 16, 3, 457, 14, 15, 2112, 2113, "A" +320, 16, 4, 458, 16, 21, 2114, 2119, "basal" +320, 16, 5, 459, 22, 23, 2120, 2121, "-" +320, 16, 6, 460, 24, 29, 2122, 2127, "bolus" +320, 16, 7, 461, 30, 37, 2128, 2135, "regimen" +320, 16, 8, 462, 38, 42, 2136, 2140, "with" +320, 16, 9, 463, 43, 47, 2141, 2145, "ILPS" +320, 16, 10, 464, 48, 52, 2146, 2150, "once" +320, 16, 11, 465, 53, 58, 2151, 2156, "daily" +320, 16, 12, 466, 59, 67, 2157, 2165, "resulted" +320, 16, 13, 467, 68, 70, 2166, 2168, "in" +320, 16, 14, 468, 71, 74, 2169, 2172, "non" +320, 16, 15, 469, 75, 76, 2173, 2174, "-" +320, 16, 16, 470, 77, 85, 2175, 2183, "inferior" +320, 16, 17, 471, 86, 95, 2184, 2193, "glycaemic" +320, 16, 18, 472, 96, 103, 2194, 2201, "control" +320, 16, 19, 473, 104, 112, 2202, 2210, "compared" +320, 16, 20, 474, 113, 115, 2211, 2213, "to" +320, 16, 21, 475, 116, 117, 2214, 2215, "a" +320, 16, 22, 476, 118, 125, 2216, 2223, "similar" +320, 16, 23, 477, 126, 133, 2224, 2231, "regimen" +320, 16, 24, 478, 134, 138, 2232, 2236, "with" +320, 16, 25, 479, 139, 147, 2237, 2245, "glargine" +320, 16, 26, 480, 148, 149, 2246, 2247, "," +320, 16, 27, 481, 150, 157, 2248, 2255, "without" +320, 16, 28, 482, 158, 171, 2256, 2269, "statistically" +320, 16, 29, 483, 172, 183, 2270, 2281, "significant" +320, 16, 30, 484, 184, 186, 2282, 2284, "or" +320, 16, 31, 485, 187, 197, 2285, 2295, "clinically" +320, 16, 32, 486, 198, 206, 2296, 2304, "relevant" +320, 16, 33, 487, 207, 218, 2305, 2316, "differences" +320, 16, 34, 488, 219, 221, 2317, 2319, "in" +320, 16, 35, 489, 222, 235, 2320, 2333, "hypoglycaemia" +320, 16, 36, 490, 236, 237, 2334, 2335, "." +320, 17, 1, 491, 0, 4, 2336, 2340, "ILPS" +320, 17, 2, 492, 5, 6, 2341, 2342, "-" +320, 17, 3, 493, 7, 12, 2343, 2348, "based" +320, 17, 4, 494, 13, 21, 2349, 2357, "regimens" +320, 17, 5, 495, 22, 25, 2358, 2361, "can" +320, 17, 6, 496, 26, 28, 2362, 2364, "be" +320, 17, 7, 497, 29, 39, 2365, 2375, "considered" +320, 17, 8, 498, 40, 42, 2376, 2378, "an" +320, 17, 9, 499, 43, 54, 2379, 2390, "alternative" +320, 17, 10, 500, 55, 57, 2391, 2393, "to" +320, 17, 11, 501, 58, 63, 2394, 2399, "basal" +320, 17, 12, 502, 64, 65, 2400, 2401, "-" +320, 17, 13, 503, 66, 71, 2402, 2407, "bolus" +320, 17, 14, 504, 72, 80, 2408, 2416, "regimens" +320, 17, 15, 505, 81, 85, 2417, 2421, "with" +320, 17, 16, 506, 86, 94, 2422, 2430, "glargine" +320, 17, 17, 507, 95, 98, 2431, 2434, "for" +320, 17, 18, 508, 99, 103, 2435, 2439, "T2DM" +320, 17, 19, 509, 104, 112, 2440, 2448, "patients" +320, 17, 20, 510, 113, 114, 2449, 2450, "." +320, 18, 1, 511, 0, 1, 2451, 2452, "©" +320, 18, 2, 512, 2, 6, 2453, 2457, "2011" +320, 18, 3, 513, 7, 16, 2458, 2467, "Blackwell" +320, 18, 4, 514, 17, 27, 2468, 2478, "Publishing" +320, 18, 5, 515, 28, 31, 2479, 2482, "Ltd" +320, 18, 6, 516, 32, 33, 2483, 2484, "." +320, 18, 7, 517, 34, 37, 2485, 2488, "DOI" +320, 18, 8, 518, 38, 39, 2489, 2490, ":" +320, 18, 9, 519, 40, 42, 2491, 2493, "10" +320, 18, 10, 520, 43, 44, 2494, 2495, "." +320, 18, 11, 521, 45, 49, 2496, 2500, "1111" +320, 18, 12, 522, 50, 51, 2501, 2502, "/" +320, 18, 13, 523, 52, 53, 2503, 2504, "j" +320, 18, 14, 524, 54, 55, 2505, 2506, "." +320, 18, 15, 525, 56, 60, 2507, 2511, "1463" +320, 18, 16, 526, 61, 62, 2512, 2513, "-" +320, 18, 17, 527, 63, 67, 2514, 2518, "1326" +320, 18, 18, 528, 68, 69, 2519, 2520, "." +320, 18, 19, 529, 70, 74, 2521, 2525, "2011" +320, 18, 20, 530, 75, 76, 2526, 2527, "." +320, 18, 21, 531, 77, 82, 2528, 2533, "01484" +320, 18, 22, 532, 83, 84, 2534, 2535, "." +320, 18, 23, 533, 85, 86, 2536, 2537, "x" +320, 18, 24, 534, 87, 91, 2538, 2542, "PMID" +320, 18, 25, 535, 92, 93, 2543, 2544, ":" +320, 18, 26, 536, 94, 102, 2545, 2553, "21819517" +320, 18, 27, 537, 103, 104, 2554, 2555, "[" +320, 18, 28, 538, 105, 112, 2556, 2563, "Indexed" +320, 18, 29, 539, 113, 116, 2564, 2567, "for" +320, 18, 30, 540, 117, 124, 2568, 2575, "MEDLINE" +320, 18, 31, 541, 125, 126, 2576, 2577, "]" diff --git a/data/dm2 21819517_kwoodley.annodb b/data/dm2 21819517_kwoodley.annodb new file mode 100644 index 0000000..80953ab --- /dev/null +++ b/data/dm2 21819517_kwoodley.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +21028, Journal, 0, 21, "Diabetes Obes Metab .", "", +21029, PublicationYear, 22, 26, "2011", "", +21051, Title, 112, 319, "Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal - bolus therapies with insulin lispro in type 2 diabetes patients : a prospective randomized open - label trial .", "", +21030, Lispro, 126, 161, "insulin lispro protamine suspension", "", +21031, InsulinGlargine, 169, 185, "insulin glargine", "", +21032, Frequency, 186, 196, "once daily", "", +21033, Lispro, 229, 243, "insulin lispro", "", +21034, Type2Diabetes, 247, 262, "type 2 diabetes", "", +21036, CTDesign, 276, 287, "prospective", "", +21035, Randomized, 288, 298, "randomized", "", +21037, OpenLabel, 299, 311, "open - label", "", +21039, Author, 320, 330, "Koivisto V", "", +21040, Author, 339, 347, "Cleall S", "", +21041, Author, 350, 362, "Pontiroli AE", "", +21042, Author, 365, 376, "Giugliano D", "", +21043, Germany, 445, 452, "Germany", "", +21050, ObjectiveDescription, 492, 684, "To compare the efficacy and safety of insulin lispro protamine suspension ( ILPS ) versus insulin glargine once daily in a basal - bolus regimen in type 2 diabetes mellitus ( T2DM ) patients .", "", +21044, Lispro, 530, 565, "insulin lispro protamine suspension", "", +21045, Lispro, 568, 572, "ILPS", "", +21046, InsulinGlargine, 582, 598, "insulin glargine", "", +21047, Frequency, 599, 609, "once daily", "", +21048, Type2Diabetes, 640, 664, "type 2 diabetes mellitus", "", +21049, Type2Diabetes, 667, 671, "T2DM", "", +21052, NumberPatientsCT, 695, 723, "Three hundred eighty - three", "", +21053, Insulin, 724, 731, "insulin", "", +21061, Precondition, 724, 750, "insulin - treated patients", "", +21054, Randomized, 756, 766, "randomized", "", +21055, Lispro, 777, 781, "ILPS", "", +21056, Lispro, 787, 793, "lispro", "", +21057, InsulinGlargine, 797, 805, "glargine", "", +21058, Lispro, 811, 817, "lispro", "", +21059, OpenLabel, 826, 838, "open - label", "", +21060, Duration, 839, 848, "24 - week", "", +21062, Insulin, 866, 873, "Insulin", "", +33183, BloodGlucose, 908, 936, "blood glucose ( BG ) targets", "blood glucose target", +21064, Lispro, 960, 964, "ILPS", "", +21065, InsulinGlargine, 972, 980, "glargine", "", +21066, HbA1c, 1080, 1085, "HbA1c", "", +33187, TimePoint, 1091, 1099, "baseline", "", +33185, TimePoint, 1103, 1110, "week 24", "", +21068, HbA1c, 1147, 1152, "HbA1c", "", +21069, HbA1c, 1231, 1236, "HbA1c", "", +21070, EndPointDescription, 1250, 1261, "BG profiles", "", +33188, InsulinDose, 1264, 1277, "insulin doses", "", +21072, Hypoglycemia, 1280, 1302, "hypoglycaemic episodes", "", +21073, EndPointDescription, 1305, 1319, "adverse events", "", +21074, EndPointDescription, 1324, 1335, "vital signs", "", +21075, Lispro, 1369, 1373, "ILPS", "", +21076, InsulinGlargine, 1381, 1389, "glargine", "", +21077, HbA1c, 1407, 1412, "HbA1c", "", +21080, ConfIntervalChangeValue, 1492, 1499, "95 % CI", "", +21082, ChangeValue, 1506, 1511, "0 . 1", "", +21083, Percentage, 1512, 1513, "%", "", +21081, ConfIntervalChangeValue, 1516, 1533, "- 0 . 11 ; 0 . 31", "", +33189, TimePoint, 1554, 1561, "week 24", "", +21087, Reduction, 1569, 1575, "1 . 05", "", +21089, Percentage, 1576, 1577, "%", "", +21085, Lispro, 1580, 1584, "ILPS", "", +21088, Reduction, 1593, 1599, "1 . 20", "", +21090, Percentage, 1600, 1601, "%", "", +21086, InsulinGlargine, 1604, 1612, "glargine", "", +21091, HbA1c_target, 1617, 1632, "HbA1c < 7 . 0 %", "", +21092, PercentageAffected, 1649, 1655, "21 . 7", "", +21093, PercentageAffected, 1663, 1669, "29 . 4", "", +33190, InsulinDose, 1691, 1721, "basal / mealtime insulin doses", "", +21094, RelativeTime, 1699, 1707, "mealtime", "", +33191, TimePoint, 1725, 1732, "week 24", "", +21097, ResultMeasuredValue, 1738, 1744, "29 . 6", "", +21098, ResultMeasuredValue, 1747, 1753, "36 . 2", "", +21101, BioAndMedicalUnit, 1754, 1762, "IU / day", "", +21103, Lispro, 1765, 1769, "ILPS", "", +21099, ResultMeasuredValue, 1779, 1785, "32 . 8", "", +21100, ResultMeasuredValue, 1788, 1794, "42 . 2", "", +21102, BioAndMedicalUnit, 1795, 1803, "IU / day", "", +21104, InsulinGlargine, 1806, 1814, "glargine", "", +21105, PvalueDiff, 1885, 1894, "p = 0 . 7", "", +21106, NumberAffected, 1916, 1922, "56 . 1", "", +21108, PercentageAffected, 1925, 1931, "25 . 7", "", +21107, NumberAffected, 1941, 1947, "63 . 6", "", +21109, PercentageAffected, 1950, 1956, "19 . 3", "", +21111, NocturnalHypoglycemia, 1989, 2012, "nocturnal hypoglycaemia", "", +21112, NocturnalHypoglycemia, 1999, 2012, "hypoglycaemia", "because of “any“", +21113, PValueResValue, 2015, 2024, "p = 0 . 2", "", +21118, ConclusionComment, 2112, 2335, "A basal - bolus regimen with ILPS once daily resulted in non - inferior glycaemic control compared to a similar regimen with glargine , without statistically significant or clinically relevant differences in hypoglycaemia .", "", +21114, Lispro, 2141, 2145, "ILPS", "", +21115, Frequency, 2146, 2156, "once daily", "", +21116, InsulinGlargine, 2237, 2245, "glargine", "", +21117, Hypoglycemia, 2320, 2333, "hypoglycaemia", "", +21119, Lispro, 2336, 2340, "ILPS", "", +21122, ConclusionComment, 2336, 2450, "ILPS - based regimens can be considered an alternative to basal - bolus regimens with glargine for T2DM patients .", "", +21120, InsulinGlargine, 2422, 2430, "glargine", "", +21121, Type2Diabetes, 2435, 2439, "T2DM", "", +21123, PMID, 2545, 2553, "21819517", "", diff --git a/data/dm2 21819517_kwoodley.n-triples b/data/dm2 21819517_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 21819517_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22134839_admin.annodb b/data/dm2 22134839_admin.annodb new file mode 100644 index 0000000..6ca9636 --- /dev/null +++ b/data/dm2 22134839_admin.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +114, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +1, PublicationYear, 15, 19, "2012", "", " \"2012\"." +5, Title, 110, 288, "Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .", "", " \"Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .\"." +3, Type2Diabetes, 239, 254, "type 2 diabetes", "", " ." +4, Randomized, 259, 269, "randomised", "", " ." +6, Author, 289, 297, "Beysen C", "", " \"Beysen C\"." +7, Author, 306, 315, "Murphy EJ", "", " \"Murphy EJ\"." +8, Author, 318, 326, "Deines K", "", " \"Deines K\"." +9, Author, 329, 335, "Chan M", "", " \"Chan M\"." +10, Author, 338, 345, "Tsang E", "", " \"Tsang E\"." +11, Author, 348, 355, "Glass A", "", " \"Glass A\"." +12, Author, 358, 367, "Turner SM", "", " \"Turner SM\"." +13, Author, 370, 380, "Protasio J", "", " \"Protasio J\"." +14, Author, 383, 390, "Riiff T", "", " \"Riiff T\"." +15, Author, 393, 407, "Hellerstein MK", "", " \"Hellerstein MK\"." +16, USA, 510, 513, "USA", "", +22, ObjectiveDescription, 619, 801, "The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam", "", " \"The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam\"." +17, Multicenter, 653, 664, "multicentre", "", " ." +18, Randomized, 665, 675, "randomised", "", +19, Parallel, 678, 686, "parallel", "", +20, DoubleBlind, 689, 703, "double - blind", "", " ." +110, Placebo, 704, 711, "placebo", "", +79764, Colesevelam, 790, 801, "colesevelam", "", +23, ObjectiveDescription, 802, 936, "and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .", "", " \"and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .\"." +61256, Precondition, 947, 980, "Participants with type 2 diabetes", "", " \"Participants with type 2 diabetes\"." +24, Type2Diabetes, 965, 980, "type 2 diabetes", "", +137, HbA1c, 983, 993, "HbA ( 1c )", "", +26, Percentage, 1009, 1010, "%", "", +79759, Millimoles_per_mole, 1021, 1031, "mmol / mol", "", +140, FastingBloodGlucose, 1036, 1051, "fasting glucose", "", +29, Millimoles_per_litre, 1061, 1069, "mmol / l", "", +30, EndPointDescription, 1072, 1096, "fasting triacylglycerols", "", +32, Millimoles_per_litre, 1105, 1113, "mmol / l", "", +147, Precondition, 1118, 1153, "LDL - cholesterol > 1 . 55 mmol / l", "", " \"LDL - cholesterol > 1 . 55 mmol / l\"." +31, EndPointDescription, 1118, 1135, "LDL - cholesterol", "", +33, Millimoles_per_litre, 1145, 1153, "mmol / l", "", +150, Precondition, 1156, 1238, "treated with diet and exercise , sulfonylurea , metformin or a combination thereof", "", " \"treated with diet and exercise , sulfonylurea , metformin or a combination thereof\"." +34, Sulfonylureas, 1189, 1201, "sulfonylurea", "", +35, Metformin, 1204, 1213, "metformin", "", +38, Randomized, 1246, 1256, "randomised", "", +39, DoseValue, 1292, 1298, "3 . 75", "", " \"3 . 75\"." +40, Gram, 1299, 1300, "g", "", " ." +41, Frequency, 1303, 1306, "day", "", " \"day\"." +79765, Colesevelam, 1307, 1318, "colesevelam", "", " ." +43, NumberPatientsArm, 1325, 1327, "30", "", " \"30\"." +45, Placebo, 1333, 1340, "placebo", "", " ." +44, NumberPatientsArm, 1347, 1349, "30", "", " \"30\"." +46, Duration, 1356, 1364, "12 weeks", "", " \"12 weeks\"." +157, Multicenter, 1368, 1388, "three clinical sites", "", +47, USA, 1396, 1399, "USA", "", +162, TimePoint, 1442, 1450, "baseline", "", +79762, Colesevelam, 1476, 1487, "colesevelam", "", +49, Placebo, 1500, 1507, "placebo", "", +61270, EndPointDescription, 1520, 1552, "Fasting and postprandial glucose", "", +61271, EndPointDescription, 1555, 1560, "lipid", "", +61272, EndPointDescription, 1565, 1583, "bile acid pathways", "", +61271, EndPointDescription, 1575, 1583, "pathways", "", +165, TimePoint, 1601, 1609, "baseline", "", +166, TimePoint, 1614, 1630, "post - treatment", "", +53, MeasurementDevice, 1644, 1662, "isotope techniques", "", +61268, PlasmaGlucose, 1665, 1679, "Plasma glucose", "", +61269, Insulin, 1682, 1689, "insulin", "", +55, EndPointDescription, 1698, 1725, "glucagon - like peptide - 1", "", +56, EndPointDescription, 1728, 1735, "GLP - 1", "", +57, EndPointDescription, 1746, 1792, "glucose - dependent insulinotropic polypeptide", "", +58, EndPointDescription, 1795, 1798, "GIP", "", +59, EndPointDescription, 1803, 1845, "glucagon and fibroblast growth factor - 19", "", +60, EndPointDescription, 1848, 1856, "FGF - 19", "", +167, DoubleBlind, 1951, 2000, "Data was collected by people blinded to treatment", "", +61, Placebo, 2027, 2034, "placebo", "", +79768, Colesevelam, 2037, 2048, "colesevelam", "", +73, ObservedResult, 2049, 2057, "improved", "", +62, HbA1c, 2058, 2068, "HbA ( 1c )", "", " ." +171, Mean, 2071, 2075, "mean", "", " . ." +172, TimePoint, 2088, 2096, "baseline", "", +61267, Increment, 2100, 2105, "0 . 3", "", " \"0 . 3\"." +61264, SdDevChangeValue, 2111, 2116, "1 . 1", "", " \"1 . 1\"." +63, Percentage, 2119, 2120, "%", "", " ." +212, Placebo, 2125, 2132, "placebo", "", +65, FinalNumPatientsArm, 2139, 2141, "28", "", " \"28\"." +69, Reduction, 2150, 2155, "0 . 3", "", " \"0 . 3\"." +68, SdDevChangeValue, 2158, 2163, "1 . 1", "", " \"1 . 1\"." +64, Percentage, 2166, 2167, "%", "", +79767, Colesevelam, 2172, 2183, "colesevelam", "", +71, FinalNumPatientsArm, 2190, 2192, "26", "", " \"26\"." +74, EndPointDescription, 2199, 2221, "glucose concentrations", "", +216, EndPointDescription, 2224, 2256, "fasting plasma glucose clearance", "", +76, FastingPlasmaGlucose, 2224, 2246, "fasting plasma glucose", "", +75, EndPointDescription, 2261, 2296, "glycolytic disposal of oral glucose", "", +79772, Colesevelam, 2299, 2310, "Colesevelam", "", +187, EndPointDescription, 2394, 2431, "Fasting endogenous glucose production", "", " . ." +82, EndPointDescription, 2436, 2450, "glycogenolysis", "", " . ." +189, ObservedResult, 2451, 2474, "significantly increased", "", " \"significantly increased\". \"significantly increased\"." +90, Placebo, 2480, 2487, "placebo", "", +190, ObservedResult, 2497, 2506, "unchanged", "", +79766, Colesevelam, 2512, 2523, "colesevelam", "", +95, Placebo, 2600, 2607, "placebo", "", +79769, Colesevelam, 2610, 2621, "colesevelam", "", +96, ObservedResult, 2622, 2631, "increased", "", " \"increased\". \"increased\"." +83, EndPointDescription, 2638, 2645, "GLP - 1", "", " . ." +84, EndPointDescription, 2650, 2653, "GIP", "", +97, ObservedResult, 2673, 2681, "improved", "", " \"improved\"." +85, EndPointDescription, 2682, 2707, "HOMA - beta cell function", "", " . ." +86, EndPointDescription, 2714, 2721, "insulin", "", +87, EndPointDescription, 2724, 2732, "glucagon", "", +88, EndPointDescription, 2737, 2762, "HOMA - insulin resistance", "", +98, ObservedResult, 2763, 2777, "were unchanged", "", +79770, Colesevelam, 2780, 2791, "Colesevelam", "", +99, ObservedResult, 2792, 2801, "increased", "", " \"increased\". \"increased\"." +101, EndPointDescription, 2802, 2813, "cholesterol", "", " . ." +102, EndPointDescription, 2818, 2837, "bile acid synthesis", "", " . ." +100, ObservedResult, 2842, 2851, "decreased", "", " \"decreased\"." +103, EndPointDescription, 2852, 2875, "FGF - 19 concentrations", "", " . ." +208, ObservedResult, 2888, 2897, "no effect", "", +104, EndPointDescription, 2910, 2948, "fractional hepatic de novo lipogenesis", "", +79774, Colesevelam, 2982, 2993, "Colesevelam", "", +108, ConclusionComment, 2982, 3207, "Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .", "", " \"Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .\"." +107, OralAntidiabeticAgent, 3194, 3205, "oral agents", "", +109, PMID, 3362, 3370, "22134839", "", " \"22134839\"." diff --git a/data/dm2 22134839_admin.n-triples b/data/dm2 22134839_admin.n-triples new file mode 100644 index 0000000..01d7986 --- /dev/null +++ b/data/dm2 22134839_admin.n-triples @@ -0,0 +1,199 @@ +# RDF export of group: Publication + . + "Publication 34511" . + "Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study ." . + "Beysen C" . + "2012" . + "Diabetologia" . + "22134839" . + . + "Murphy EJ" . + "Deines K" . + "Chan M" . + "Tsang E" . + "Glass A" . + "Turner SM" . + "Protasio J" . + "Riiff T" . + "Hellerstein MK" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 34518" . + "The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam" . + "12 weeks" . + . + . + . + "Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents ." . + . + . + . + . + . + "and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) ." . + . + . + . + . +# RDF export of group: Population + . + "Population 34534" . + "Participants with type 2 diabetes" . + . + . + . + "LDL - cholesterol > 1 . 55 mmol / l" . + "treated with diet and exercise , sulfonylurea , metformin or a combination thereof" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "glu" . + . + . + . + . + . + . + "gly" . + . + . + . + . + . + . + "glp" . + . + . + . + . + . + . + "gip" . + . + . + . + . + . + "beta" . + . + . + . + . + . + . + "chol" . + . + . + . + . + . + . + "bile" . + . + . + . + . + . + . + "fgf" . + . + . + . + . + . +# RDF export of group: Arm + . + "col" . + "30" . + "26" . + . + . + . + . + . + . + . + . + . + . + "pl" . + "30" . + "28" . + . + . + . + . + . +# RDF export of group: Intervention + . + "col" . + . + "day" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "col" . + . + "3 . 75" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba co" . + . + "0 . 3" . + "1 . 1" . + . + "hba pl" . + . + "0 . 3" . + "1 . 1" . + . + "glu pl" . + . + "significantly increased" . + . + "gly pl" . + . + "significantly increased" . + . + "glp col" . + . + "increased" . + . + "gip co" . + . + "increased" . + . + "beta co" . + . + "improved" . + . + "chol col" . + . + "increased" . + . + "bil col" . + . + "increased" . + . + "fgf co" . + . + "decreased" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22134839_akramersunderbrink.annodb b/data/dm2 22134839_akramersunderbrink.annodb new file mode 100644 index 0000000..cdea456 --- /dev/null +++ b/data/dm2 22134839_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +40054, Journal, 0, 12, "Diabetologia", "", +40055, PublicationYear, 15, 19, "2012", "", +40058, Title, 110, 288, "Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .", "", +40056, Type2Diabetes, 239, 254, "type 2 diabetes", "", +40057, Randomized, 259, 269, "randomised", "", +40059, Author, 289, 297, "Beysen C", "", +40060, Author, 306, 315, "Murphy EJ", "", +40061, Author, 318, 326, "Deines K", "", +40062, Author, 329, 335, "Chan M", "", +40063, Author, 338, 345, "Tsang E", "", +40064, Author, 348, 355, "Glass A", "", +40065, Author, 358, 367, "Turner SM", "", +40066, Author, 370, 380, "Protasio J", "", +40067, Author, 383, 390, "Riiff T", "", +40068, Author, 393, 407, "Hellerstein MK", "", +40069, USA, 510, 513, "USA", "", +40100, ObjectiveDescription, 619, 832, "The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam and secondarily to investigate", "", +40070, Multicenter, 653, 664, "multicentre", "", +40071, Randomized, 665, 675, "randomised", "", +40072, Parallel, 678, 686, "parallel", "", +40073, DoubleBlind, 689, 703, "double - blind", "", +40074, Placebo, 704, 711, "placebo", "", +40075, Drug, 790, 801, "colesevelam", "", +40101, ObjectiveDescription, 833, 936, "its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .", "", +40076, Type2Diabetes, 965, 980, "type 2 diabetes", "", +40077, HbA1c, 983, 993, "HbA ( 1c )", "", +40084, Precondition, 983, 1033, "HbA ( 1c ) 6 . 7 - 10 . 0 % [ 50 - 86 mmol / mol ]", "", +40078, Percentage, 1009, 1010, "%", "", +40079, BioAndMedicalUnit, 1021, 1031, "mmol / mol", "", +40080, FastingBloodGlucose, 1036, 1051, "fasting glucose", "", +40085, Precondition, 1036, 1069, "fasting glucose < 16 . 7 mmol / l", "", +40081, Millimoles_per_litre, 1061, 1069, "mmol / l", "", +40086, Precondition, 1072, 1113, "fasting triacylglycerols < 3 . 9 mmol / l", "", +40082, Millimoles_per_litre, 1105, 1113, "mmol / l", "", +40087, Precondition, 1118, 1153, "LDL - cholesterol > 1 . 55 mmol / l", "", +40083, Millimoles_per_litre, 1145, 1153, "mmol / l", "", +40090, Precondition, 1156, 1238, "treated with diet and exercise , sulfonylurea , metformin or a combination thereof", "", +40088, Sulfonylureas, 1189, 1201, "sulfonylurea", "", +40089, Metformin, 1204, 1213, "metformin", "", +40098, DoseValue, 1292, 1306, "3 . 75 g / day", "", +40099, BioAndMedicalUnit, 1299, 1306, "g / day", "", +40091, Drug, 1307, 1318, "colesevelam", "", +40093, NumberPatientsArm, 1325, 1327, "30", "", +40092, Placebo, 1333, 1340, "placebo", "", +40094, NumberPatientsArm, 1347, 1349, "30", "", +40095, Duration, 1356, 1364, "12 weeks", "", +40097, Multicenter, 1368, 1388, "three clinical sites", "", +40096, USA, 1396, 1399, "USA", "", +40102, TimePoint, 1442, 1450, "baseline", "", +40103, Drug, 1476, 1487, "colesevelam", "", +40104, Placebo, 1500, 1507, "placebo", "", +40125, FastingPlasmaGlucose, 1520, 1552, "Fasting and postprandial glucose", "", +40126, PostprandialPlasmaGlucose, 1532, 1552, "postprandial glucose", "", +40107, TimePoint, 1601, 1609, "baseline", "", +40108, TimePoint, 1614, 1630, "post - treatment", "", +40109, DoubleBlind, 1951, 2000, "Data was collected by people blinded to treatment", "", +40110, Placebo, 2027, 2034, "placebo", "", +40111, Drug, 2037, 2048, "colesevelam", "", +40157, ObservedResult, 2049, 2057, "improved", "", +40112, HbA1c, 2058, 2068, "HbA ( 1c )", "", +40113, Mean, 2071, 2075, "mean", "", +40114, TimePoint, 2088, 2096, "baseline", "", +40115, ChangeValue, 2100, 2105, "0 . 3", "", +40117, SdDevChangeValue, 2111, 2116, "1 . 1", "", +40119, Percentage, 2119, 2120, "%", "", +40156, Placebo, 2125, 2132, "placebo", "", +40121, FinalNumPatientsArm, 2139, 2141, "28", "", +40116, ChangeValue, 2148, 2155, "- 0 . 3", "", +40118, SdDevChangeValue, 2158, 2163, "1 . 1", "", +40120, Percentage, 2166, 2167, "%", "", +40123, Drug, 2172, 2183, "colesevelam", "", +40122, FinalNumPatientsArm, 2190, 2192, "26", "", +40158, EndPointDescription, 2199, 2221, "glucose concentrations", "", +40160, EndPointDescription, 2224, 2256, "fasting plasma glucose clearance", "", +40159, EndPointDescription, 2261, 2296, "glycolytic disposal of oral glucose", "", +40127, Drug, 2299, 2310, "Colesevelam", "", +40153, ObservedResult, 2311, 2325, "did not affect", "", +40154, EndPointDescription, 2326, 2341, "gluconeogenesis", "", +40155, EndPointDescription, 2345, 2391, "appearance rate ( absorption ) of oral glucose", "", +40130, EndPointDescription, 2394, 2431, "Fasting endogenous glucose production", "", +40131, EndPointDescription, 2436, 2450, "glycogenolysis", "", +40132, ObservedResult, 2451, 2474, "significantly increased", "", +40128, Placebo, 2480, 2487, "placebo", "", +40133, ObservedResult, 2497, 2506, "unchanged", "", +40129, Drug, 2512, 2523, "colesevelam", "", +40134, Placebo, 2600, 2607, "placebo", "", +40135, Drug, 2610, 2621, "colesevelam", "", +40142, ObservedResult, 2622, 2631, "increased", "", +40136, EndPointDescription, 2632, 2668, "total GLP - 1 and GIP concentrations", "", +40143, ObservedResult, 2673, 2681, "improved", "", +40137, EndPointDescription, 2682, 2707, "HOMA - beta cell function", "", +40138, EndPointDescription, 2714, 2721, "insulin", "", +40139, EndPointDescription, 2724, 2732, "glucagon", "", +40140, EndPointDescription, 2737, 2762, "HOMA - insulin resistance", "", +40141, ObservedResult, 2768, 2777, "unchanged", "", +40144, Drug, 2780, 2791, "Colesevelam", "", +40149, ObservedResult, 2792, 2801, "increased", "", +40145, EndPointDescription, 2802, 2813, "cholesterol", "", +40147, EndPointDescription, 2818, 2837, "bile acid synthesis", "", +40150, ObservedResult, 2842, 2851, "decreased", "", +40148, EndPointDescription, 2852, 2875, "FGF - 19 concentrations", "", +40152, ObservedResult, 2888, 2897, "no effect", "", +40151, EndPointDescription, 2910, 2948, "fractional hepatic de novo lipogenesis", "", +40161, Drug, 2982, 2993, "Colesevelam", "", +40162, ConclusionComment, 2982, 3207, "Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .", "", +40163, PMID, 3362, 3370, "22134839", "", diff --git a/data/dm2 22134839_akramersunderbrink.n-triples b/data/dm2 22134839_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22134839_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22134839_export.csv b/data/dm2 22134839_export.csv new file mode 100644 index 0000000..22496f9 --- /dev/null +++ b/data/dm2 22134839_export.csv @@ -0,0 +1,658 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +319, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +319, 1, 2, 2, 13, 14, 13, 14, "." +319, 2, 1, 3, 0, 4, 15, 19, "2012" +319, 2, 2, 4, 5, 8, 20, 23, "Feb" +319, 2, 3, 5, 9, 10, 24, 25, ";" +319, 2, 4, 6, 11, 13, 26, 28, "55" +319, 2, 5, 7, 14, 15, 29, 30, "(" +319, 2, 6, 8, 16, 17, 31, 32, "2" +319, 2, 7, 9, 18, 19, 33, 34, ")" +319, 2, 8, 10, 20, 21, 35, 36, ":" +319, 2, 9, 11, 22, 25, 37, 40, "432" +319, 2, 10, 12, 26, 27, 41, 42, "-" +319, 2, 11, 13, 28, 30, 43, 45, "42" +319, 2, 12, 14, 31, 32, 46, 47, "." +319, 2, 13, 15, 33, 36, 48, 51, "doi" +319, 2, 14, 16, 37, 38, 52, 53, ":" +319, 2, 15, 17, 39, 41, 54, 56, "10" +319, 2, 16, 18, 42, 43, 57, 58, "." +319, 2, 17, 19, 44, 48, 59, 63, "1007" +319, 2, 18, 20, 49, 50, 64, 65, "/" +319, 2, 19, 21, 51, 57, 66, 72, "s00125" +319, 2, 20, 22, 58, 59, 73, 74, "-" +319, 2, 21, 23, 60, 63, 75, 78, "011" +319, 2, 22, 24, 64, 65, 79, 80, "-" +319, 2, 23, 25, 66, 70, 81, 85, "2382" +319, 2, 24, 26, 71, 72, 86, 87, "-" +319, 2, 25, 27, 73, 74, 88, 89, "3" +319, 2, 26, 28, 75, 76, 90, 91, "." +319, 3, 1, 29, 0, 4, 92, 96, "Epub" +319, 3, 2, 30, 5, 9, 97, 101, "2011" +319, 3, 3, 31, 10, 13, 102, 105, "Dec" +319, 3, 4, 32, 14, 15, 106, 107, "2" +319, 3, 5, 33, 16, 17, 108, 109, "." +319, 4, 1, 34, 0, 6, 110, 116, "Effect" +319, 4, 2, 35, 7, 9, 117, 119, "of" +319, 4, 3, 36, 10, 14, 120, 124, "bile" +319, 4, 4, 37, 15, 19, 125, 129, "acid" +319, 4, 5, 38, 20, 32, 130, 142, "sequestrants" +319, 4, 6, 39, 33, 35, 143, 145, "on" +319, 4, 7, 40, 36, 43, 146, 153, "glucose" +319, 4, 8, 41, 44, 54, 154, 164, "metabolism" +319, 4, 9, 42, 55, 56, 165, 166, "," +319, 4, 10, 43, 57, 64, 167, 174, "hepatic" +319, 4, 11, 44, 65, 67, 175, 177, "de" +319, 4, 12, 45, 68, 72, 178, 182, "novo" +319, 4, 13, 46, 73, 84, 183, 194, "lipogenesis" +319, 4, 14, 47, 85, 86, 195, 196, "," +319, 4, 15, 48, 87, 90, 197, 200, "and" +319, 4, 16, 49, 91, 102, 201, 212, "cholesterol" +319, 4, 17, 50, 103, 106, 213, 216, "and" +319, 4, 18, 51, 107, 111, 217, 221, "bile" +319, 4, 19, 52, 112, 116, 222, 226, "acid" +319, 4, 20, 53, 117, 125, 227, 235, "kinetics" +319, 4, 21, 54, 126, 128, 236, 238, "in" +319, 4, 22, 55, 129, 133, 239, 243, "type" +319, 4, 23, 56, 134, 135, 244, 245, "2" +319, 4, 24, 57, 136, 144, 246, 254, "diabetes" +319, 4, 25, 58, 145, 146, 255, 256, ":" +319, 4, 26, 59, 147, 148, 257, 258, "a" +319, 4, 27, 60, 149, 159, 259, 269, "randomised" +319, 4, 28, 61, 160, 170, 270, 280, "controlled" +319, 4, 29, 62, 171, 176, 281, 286, "study" +319, 4, 30, 63, 177, 178, 287, 288, "." +319, 5, 1, 64, 0, 6, 289, 295, "Beysen" +319, 5, 2, 65, 7, 8, 296, 297, "C" +319, 5, 3, 66, 9, 10, 298, 299, "(" +319, 5, 4, 67, 11, 12, 300, 301, "1" +319, 5, 5, 68, 13, 14, 302, 303, ")" +319, 5, 6, 69, 15, 16, 304, 305, "," +319, 5, 7, 70, 17, 23, 306, 312, "Murphy" +319, 5, 8, 71, 24, 26, 313, 315, "EJ" +319, 5, 9, 72, 27, 28, 316, 317, "," +319, 5, 10, 73, 29, 35, 318, 324, "Deines" +319, 5, 11, 74, 36, 37, 325, 326, "K" +319, 5, 12, 75, 38, 39, 327, 328, "," +319, 5, 13, 76, 40, 44, 329, 333, "Chan" +319, 5, 14, 77, 45, 46, 334, 335, "M" +319, 5, 15, 78, 47, 48, 336, 337, "," +319, 5, 16, 79, 49, 54, 338, 343, "Tsang" +319, 5, 17, 80, 55, 56, 344, 345, "E" +319, 5, 18, 81, 57, 58, 346, 347, "," +319, 5, 19, 82, 59, 64, 348, 353, "Glass" +319, 5, 20, 83, 65, 66, 354, 355, "A" +319, 5, 21, 84, 67, 68, 356, 357, "," +319, 5, 22, 85, 69, 75, 358, 364, "Turner" +319, 5, 23, 86, 76, 78, 365, 367, "SM" +319, 5, 24, 87, 79, 80, 368, 369, "," +319, 5, 25, 88, 81, 89, 370, 378, "Protasio" +319, 5, 26, 89, 90, 91, 379, 380, "J" +319, 5, 27, 90, 92, 93, 381, 382, "," +319, 5, 28, 91, 94, 99, 383, 388, "Riiff" +319, 5, 29, 92, 100, 101, 389, 390, "T" +319, 5, 30, 93, 102, 103, 391, 392, "," +319, 5, 31, 94, 104, 115, 393, 404, "Hellerstein" +319, 5, 32, 95, 116, 118, 405, 407, "MK" +319, 5, 33, 96, 119, 120, 408, 409, "." +319, 6, 1, 97, 0, 6, 410, 416, "Author" +319, 6, 2, 98, 7, 18, 417, 428, "information" +319, 6, 3, 99, 19, 20, 429, 430, ":" +319, 6, 4, 100, 21, 22, 431, 432, "(" +319, 6, 5, 101, 23, 24, 433, 434, "1" +319, 6, 6, 102, 25, 26, 435, 436, ")" +319, 6, 7, 103, 27, 34, 437, 444, "Kinemed" +319, 6, 8, 104, 35, 36, 445, 446, "," +319, 6, 9, 105, 37, 40, 447, 450, "Inc" +319, 6, 10, 106, 41, 42, 451, 452, "." +319, 6, 11, 107, 43, 44, 453, 454, "," +319, 6, 12, 108, 45, 49, 455, 459, "5980" +319, 6, 13, 109, 50, 56, 460, 466, "Horton" +319, 6, 14, 110, 57, 63, 467, 473, "Street" +319, 6, 15, 111, 64, 69, 474, 479, "Suite" +319, 6, 16, 112, 70, 73, 480, 483, "470" +319, 6, 17, 113, 74, 75, 484, 485, "," +319, 6, 18, 114, 76, 86, 486, 496, "Emeryville" +319, 6, 19, 115, 87, 88, 497, 498, "," +319, 6, 20, 116, 89, 91, 499, 501, "CA" +319, 6, 21, 117, 92, 97, 502, 507, "94608" +319, 6, 22, 118, 98, 99, 508, 509, "," +319, 6, 23, 119, 100, 103, 510, 513, "USA" +319, 6, 24, 120, 104, 105, 514, 515, "." +319, 7, 1, 121, 0, 7, 516, 523, "cbeysen" +319, 7, 2, 122, 8, 9, 524, 525, "@" +319, 7, 3, 123, 10, 17, 526, 533, "kinemed" +319, 7, 4, 124, 18, 19, 534, 535, "." +319, 7, 5, 125, 20, 23, 536, 539, "com" +319, 7, 6, 126, 24, 31, 540, 547, "Comment" +319, 7, 7, 127, 32, 34, 548, 550, "in" +319, 7, 8, 128, 35, 38, 551, 554, "Nat" +319, 7, 9, 129, 39, 42, 555, 558, "Rev" +319, 7, 10, 130, 43, 53, 559, 569, "Endocrinol" +319, 7, 11, 131, 54, 55, 570, 571, "." +319, 8, 1, 132, 0, 4, 572, 576, "2012" +319, 8, 2, 133, 5, 8, 577, 580, "Mar" +319, 8, 3, 134, 9, 10, 581, 582, ";" +319, 8, 4, 135, 11, 12, 583, 584, "8" +319, 8, 5, 136, 13, 14, 585, 586, "(" +319, 8, 6, 137, 15, 16, 587, 588, "3" +319, 8, 7, 138, 17, 18, 589, 590, ")" +319, 8, 8, 139, 19, 20, 591, 592, ":" +319, 8, 9, 140, 21, 24, 593, 596, "128" +319, 8, 10, 141, 25, 26, 597, 598, "." +319, 9, 1, 142, 0, 4, 599, 603, "AIMS" +319, 9, 2, 143, 5, 6, 604, 605, "/" +319, 9, 3, 144, 7, 17, 606, 616, "HYPOTHESIS" +319, 9, 4, 145, 18, 19, 617, 618, ":" +319, 9, 5, 146, 20, 23, 619, 622, "The" +319, 9, 6, 147, 24, 31, 623, 630, "primary" +319, 9, 7, 148, 32, 35, 631, 634, "aim" +319, 9, 8, 149, 36, 38, 635, 637, "of" +319, 9, 9, 150, 39, 43, 638, 642, "this" +319, 9, 10, 151, 44, 53, 643, 652, "completed" +319, 9, 11, 152, 54, 65, 653, 664, "multicentre" +319, 9, 12, 153, 66, 76, 665, 675, "randomised" +319, 9, 13, 154, 77, 78, 676, 677, "," +319, 9, 14, 155, 79, 87, 678, 686, "parallel" +319, 9, 15, 156, 88, 89, 687, 688, "," +319, 9, 16, 157, 90, 96, 689, 695, "double" +319, 9, 17, 158, 97, 98, 696, 697, "-" +319, 9, 18, 159, 99, 104, 698, 703, "blind" +319, 9, 19, 160, 105, 112, 704, 711, "placebo" +319, 9, 20, 161, 113, 114, 712, 713, "-" +319, 9, 21, 162, 115, 125, 714, 724, "controlled" +319, 9, 22, 163, 126, 131, 725, 730, "study" +319, 9, 23, 164, 132, 135, 731, 734, "was" +319, 9, 24, 165, 136, 138, 735, 737, "to" +319, 9, 25, 166, 139, 148, 738, 747, "elucidate" +319, 9, 26, 167, 149, 152, 748, 751, "the" +319, 9, 27, 168, 153, 163, 752, 762, "mechanisms" +319, 9, 28, 169, 164, 166, 763, 765, "of" +319, 9, 29, 170, 167, 174, 766, 773, "glucose" +319, 9, 30, 171, 175, 176, 774, 775, "-" +319, 9, 31, 172, 177, 185, 776, 784, "lowering" +319, 9, 32, 173, 186, 190, 785, 789, "with" +319, 9, 33, 174, 191, 202, 790, 801, "colesevelam" +319, 9, 34, 175, 203, 206, 802, 805, "and" +319, 9, 35, 176, 207, 218, 806, 817, "secondarily" +319, 9, 36, 177, 219, 221, 818, 820, "to" +319, 9, 37, 178, 222, 233, 821, 832, "investigate" +319, 9, 38, 179, 234, 237, 833, 836, "its" +319, 9, 39, 180, 238, 245, 837, 844, "effects" +319, 9, 40, 181, 246, 248, 845, 847, "on" +319, 9, 41, 182, 249, 254, 848, 853, "lipid" +319, 9, 42, 183, 255, 265, 854, 864, "metabolism" +319, 9, 43, 184, 266, 267, 865, 866, "(" +319, 9, 44, 185, 268, 275, 867, 874, "hepatic" +319, 9, 45, 186, 276, 278, 875, 877, "de" +319, 9, 46, 187, 279, 283, 878, 882, "novo" +319, 9, 47, 188, 284, 295, 883, 894, "lipogenesis" +319, 9, 48, 189, 296, 297, 895, 896, "," +319, 9, 49, 190, 298, 309, 897, 908, "cholesterol" +319, 9, 50, 191, 310, 313, 909, 912, "and" +319, 9, 51, 192, 314, 318, 913, 917, "bile" +319, 9, 52, 193, 319, 323, 918, 922, "acid" +319, 9, 53, 194, 324, 333, 923, 932, "synthesis" +319, 9, 54, 195, 334, 335, 933, 934, ")" +319, 9, 55, 196, 336, 337, 935, 936, "." +319, 10, 1, 197, 0, 7, 937, 944, "METHODS" +319, 10, 2, 198, 8, 9, 945, 946, ":" +319, 10, 3, 199, 10, 22, 947, 959, "Participants" +319, 10, 4, 200, 23, 27, 960, 964, "with" +319, 10, 5, 201, 28, 32, 965, 969, "type" +319, 10, 6, 202, 33, 34, 970, 971, "2" +319, 10, 7, 203, 35, 43, 972, 980, "diabetes" +319, 10, 8, 204, 44, 45, 981, 982, "(" +319, 10, 9, 205, 46, 49, 983, 986, "HbA" +319, 10, 10, 206, 50, 51, 987, 988, "(" +319, 10, 11, 207, 52, 54, 989, 991, "1c" +319, 10, 12, 208, 55, 56, 992, 993, ")" +319, 10, 13, 209, 57, 58, 994, 995, "6" +319, 10, 14, 210, 59, 60, 996, 997, "." +319, 10, 15, 211, 61, 62, 998, 999, "7" +319, 10, 16, 212, 63, 64, 1000, 1001, "-" +319, 10, 17, 213, 65, 67, 1002, 1004, "10" +319, 10, 18, 214, 68, 69, 1005, 1006, "." +319, 10, 19, 215, 70, 71, 1007, 1008, "0" +319, 10, 20, 216, 72, 73, 1009, 1010, "%" +319, 10, 21, 217, 74, 75, 1011, 1012, "[" +319, 10, 22, 218, 76, 78, 1013, 1015, "50" +319, 10, 23, 219, 79, 80, 1016, 1017, "-" +319, 10, 24, 220, 81, 83, 1018, 1020, "86" +319, 10, 25, 221, 84, 88, 1021, 1025, "mmol" +319, 10, 26, 222, 89, 90, 1026, 1027, "/" +319, 10, 27, 223, 91, 94, 1028, 1031, "mol" +319, 10, 28, 224, 95, 96, 1032, 1033, "]" +319, 10, 29, 225, 97, 98, 1034, 1035, "," +319, 10, 30, 226, 99, 106, 1036, 1043, "fasting" +319, 10, 31, 227, 107, 114, 1044, 1051, "glucose" +319, 10, 32, 228, 115, 116, 1052, 1053, "<" +319, 10, 33, 229, 117, 119, 1054, 1056, "16" +319, 10, 34, 230, 120, 121, 1057, 1058, "." +319, 10, 35, 231, 122, 123, 1059, 1060, "7" +319, 10, 36, 232, 124, 128, 1061, 1065, "mmol" +319, 10, 37, 233, 129, 130, 1066, 1067, "/" +319, 10, 38, 234, 131, 132, 1068, 1069, "l" +319, 10, 39, 235, 133, 134, 1070, 1071, "," +319, 10, 40, 236, 135, 142, 1072, 1079, "fasting" +319, 10, 41, 237, 143, 159, 1080, 1096, "triacylglycerols" +319, 10, 42, 238, 160, 161, 1097, 1098, "<" +319, 10, 43, 239, 162, 163, 1099, 1100, "3" +319, 10, 44, 240, 164, 165, 1101, 1102, "." +319, 10, 45, 241, 166, 167, 1103, 1104, "9" +319, 10, 46, 242, 168, 172, 1105, 1109, "mmol" +319, 10, 47, 243, 173, 174, 1110, 1111, "/" +319, 10, 48, 244, 175, 176, 1112, 1113, "l" +319, 10, 49, 245, 177, 180, 1114, 1117, "and" +319, 10, 50, 246, 181, 184, 1118, 1121, "LDL" +319, 10, 51, 247, 185, 186, 1122, 1123, "-" +319, 10, 52, 248, 187, 198, 1124, 1135, "cholesterol" +319, 10, 53, 249, 199, 200, 1136, 1137, ">" +319, 10, 54, 250, 201, 202, 1138, 1139, "1" +319, 10, 55, 251, 203, 204, 1140, 1141, "." +319, 10, 56, 252, 205, 207, 1142, 1144, "55" +319, 10, 57, 253, 208, 212, 1145, 1149, "mmol" +319, 10, 58, 254, 213, 214, 1150, 1151, "/" +319, 10, 59, 255, 215, 216, 1152, 1153, "l" +319, 10, 60, 256, 217, 218, 1154, 1155, ")" +319, 10, 61, 257, 219, 226, 1156, 1163, "treated" +319, 10, 62, 258, 227, 231, 1164, 1168, "with" +319, 10, 63, 259, 232, 236, 1169, 1173, "diet" +319, 10, 64, 260, 237, 240, 1174, 1177, "and" +319, 10, 65, 261, 241, 249, 1178, 1186, "exercise" +319, 10, 66, 262, 250, 251, 1187, 1188, "," +319, 10, 67, 263, 252, 264, 1189, 1201, "sulfonylurea" +319, 10, 68, 264, 265, 266, 1202, 1203, "," +319, 10, 69, 265, 267, 276, 1204, 1213, "metformin" +319, 10, 70, 266, 277, 279, 1214, 1216, "or" +319, 10, 71, 267, 280, 281, 1217, 1218, "a" +319, 10, 72, 268, 282, 293, 1219, 1230, "combination" +319, 10, 73, 269, 294, 301, 1231, 1238, "thereof" +319, 10, 74, 270, 302, 303, 1239, 1240, "," +319, 10, 75, 271, 304, 308, 1241, 1245, "were" +319, 10, 76, 272, 309, 319, 1246, 1256, "randomised" +319, 10, 77, 273, 320, 322, 1257, 1259, "by" +319, 10, 78, 274, 323, 324, 1260, 1261, "a" +319, 10, 79, 275, 325, 332, 1262, 1269, "central" +319, 10, 80, 276, 333, 344, 1270, 1281, "coordinator" +319, 10, 81, 277, 345, 347, 1282, 1284, "to" +319, 10, 82, 278, 348, 354, 1285, 1291, "either" +319, 10, 83, 279, 355, 356, 1292, 1293, "3" +319, 10, 84, 280, 357, 358, 1294, 1295, "." +319, 10, 85, 281, 359, 361, 1296, 1298, "75" +319, 10, 86, 282, 362, 363, 1299, 1300, "g" +319, 10, 87, 283, 364, 365, 1301, 1302, "/" +319, 10, 88, 284, 366, 369, 1303, 1306, "day" +319, 10, 89, 285, 370, 381, 1307, 1318, "colesevelam" +319, 10, 90, 286, 382, 383, 1319, 1320, "(" +319, 10, 91, 287, 384, 385, 1321, 1322, "n" +319, 10, 92, 288, 386, 387, 1323, 1324, "=" +319, 10, 93, 289, 388, 390, 1325, 1327, "30" +319, 10, 94, 290, 391, 392, 1328, 1329, ")" +319, 10, 95, 291, 393, 395, 1330, 1332, "or" +319, 10, 96, 292, 396, 403, 1333, 1340, "placebo" +319, 10, 97, 293, 404, 405, 1341, 1342, "(" +319, 10, 98, 294, 406, 407, 1343, 1344, "n" +319, 10, 99, 295, 408, 409, 1345, 1346, "=" +319, 10, 100, 296, 410, 412, 1347, 1349, "30" +319, 10, 101, 297, 413, 414, 1350, 1351, ")" +319, 10, 102, 298, 415, 418, 1352, 1355, "for" +319, 10, 103, 299, 419, 421, 1356, 1358, "12" +319, 10, 104, 300, 422, 427, 1359, 1364, "weeks" +319, 10, 105, 301, 428, 430, 1365, 1367, "at" +319, 10, 106, 302, 431, 436, 1368, 1373, "three" +319, 10, 107, 303, 437, 445, 1374, 1382, "clinical" +319, 10, 108, 304, 446, 451, 1383, 1388, "sites" +319, 10, 109, 305, 452, 454, 1389, 1391, "in" +319, 10, 110, 306, 455, 458, 1392, 1395, "the" +319, 10, 111, 307, 459, 462, 1396, 1399, "USA" +319, 10, 112, 308, 463, 464, 1400, 1401, "." +319, 11, 1, 309, 0, 3, 1402, 1405, "The" +319, 11, 2, 310, 4, 11, 1406, 1413, "primary" +319, 11, 3, 311, 12, 19, 1414, 1421, "measure" +319, 11, 4, 312, 20, 23, 1422, 1425, "was" +319, 11, 5, 313, 24, 27, 1426, 1429, "the" +319, 11, 6, 314, 28, 34, 1430, 1436, "change" +319, 11, 7, 315, 35, 39, 1437, 1441, "from" +319, 11, 8, 316, 40, 48, 1442, 1450, "baseline" +319, 11, 9, 317, 49, 51, 1451, 1453, "in" +319, 11, 10, 318, 52, 59, 1454, 1461, "glucose" +319, 11, 11, 319, 60, 68, 1462, 1470, "kinetics" +319, 11, 12, 320, 69, 73, 1471, 1475, "with" +319, 11, 13, 321, 74, 85, 1476, 1487, "colesevelam" +319, 11, 14, 322, 86, 94, 1488, 1496, "compared" +319, 11, 15, 323, 95, 97, 1497, 1499, "to" +319, 11, 16, 324, 98, 105, 1500, 1507, "placebo" +319, 11, 17, 325, 106, 115, 1508, 1517, "treatment" +319, 11, 18, 326, 116, 117, 1518, 1519, "." +319, 12, 1, 327, 0, 7, 1520, 1527, "Fasting" +319, 12, 2, 328, 8, 11, 1528, 1531, "and" +319, 12, 3, 329, 12, 24, 1532, 1544, "postprandial" +319, 12, 4, 330, 25, 32, 1545, 1552, "glucose" +319, 12, 5, 331, 33, 34, 1553, 1554, "," +319, 12, 6, 332, 35, 40, 1555, 1560, "lipid" +319, 12, 7, 333, 41, 44, 1561, 1564, "and" +319, 12, 8, 334, 45, 49, 1565, 1569, "bile" +319, 12, 9, 335, 50, 54, 1570, 1574, "acid" +319, 12, 10, 336, 55, 63, 1575, 1583, "pathways" +319, 12, 11, 337, 64, 68, 1584, 1588, "were" +319, 12, 12, 338, 69, 77, 1589, 1597, "measured" +319, 12, 13, 339, 78, 80, 1598, 1600, "at" +319, 12, 14, 340, 81, 89, 1601, 1609, "baseline" +319, 12, 15, 341, 90, 93, 1610, 1613, "and" +319, 12, 16, 342, 94, 98, 1614, 1618, "post" +319, 12, 17, 343, 99, 100, 1619, 1620, "-" +319, 12, 18, 344, 101, 110, 1621, 1630, "treatment" +319, 12, 19, 345, 111, 116, 1631, 1636, "using" +319, 12, 20, 346, 117, 123, 1637, 1643, "stable" +319, 12, 21, 347, 124, 131, 1644, 1651, "isotope" +319, 12, 22, 348, 132, 142, 1652, 1662, "techniques" +319, 12, 23, 349, 143, 144, 1663, 1664, "." +319, 13, 1, 350, 0, 6, 1665, 1671, "Plasma" +319, 13, 2, 351, 7, 14, 1672, 1679, "glucose" +319, 13, 3, 352, 15, 16, 1680, 1681, "," +319, 13, 4, 353, 17, 24, 1682, 1689, "insulin" +319, 13, 5, 354, 25, 26, 1690, 1691, "," +319, 13, 6, 355, 27, 32, 1692, 1697, "total" +319, 13, 7, 356, 33, 41, 1698, 1706, "glucagon" +319, 13, 8, 357, 42, 43, 1707, 1708, "-" +319, 13, 9, 358, 44, 48, 1709, 1713, "like" +319, 13, 10, 359, 49, 56, 1714, 1721, "peptide" +319, 13, 11, 360, 57, 58, 1722, 1723, "-" +319, 13, 12, 361, 59, 60, 1724, 1725, "1" +319, 13, 13, 362, 61, 62, 1726, 1727, "(" +319, 13, 14, 363, 63, 66, 1728, 1731, "GLP" +319, 13, 15, 364, 67, 68, 1732, 1733, "-" +319, 13, 16, 365, 69, 70, 1734, 1735, "1" +319, 13, 17, 366, 71, 72, 1736, 1737, ")" +319, 13, 18, 367, 73, 74, 1738, 1739, "," +319, 13, 19, 368, 75, 80, 1740, 1745, "total" +319, 13, 20, 369, 81, 88, 1746, 1753, "glucose" +319, 13, 21, 370, 89, 90, 1754, 1755, "-" +319, 13, 22, 371, 91, 100, 1756, 1765, "dependent" +319, 13, 23, 372, 101, 115, 1766, 1780, "insulinotropic" +319, 13, 24, 373, 116, 127, 1781, 1792, "polypeptide" +319, 13, 25, 374, 128, 129, 1793, 1794, "(" +319, 13, 26, 375, 130, 133, 1795, 1798, "GIP" +319, 13, 27, 376, 134, 135, 1799, 1800, ")" +319, 13, 28, 377, 136, 137, 1801, 1802, "," +319, 13, 29, 378, 138, 146, 1803, 1811, "glucagon" +319, 13, 30, 379, 147, 150, 1812, 1815, "and" +319, 13, 31, 380, 151, 161, 1816, 1826, "fibroblast" +319, 13, 32, 381, 162, 168, 1827, 1833, "growth" +319, 13, 33, 382, 169, 175, 1834, 1840, "factor" +319, 13, 34, 383, 176, 177, 1841, 1842, "-" +319, 13, 35, 384, 178, 180, 1843, 1845, "19" +319, 13, 36, 385, 181, 182, 1846, 1847, "(" +319, 13, 37, 386, 183, 186, 1848, 1851, "FGF" +319, 13, 38, 387, 187, 188, 1852, 1853, "-" +319, 13, 39, 388, 189, 191, 1854, 1856, "19" +319, 13, 40, 389, 192, 193, 1857, 1858, ")" +319, 13, 41, 390, 194, 208, 1859, 1873, "concentrations" +319, 13, 42, 391, 209, 213, 1874, 1878, "were" +319, 13, 43, 392, 214, 222, 1879, 1887, "measured" +319, 13, 44, 393, 223, 229, 1888, 1894, "during" +319, 13, 45, 394, 230, 233, 1895, 1898, "the" +319, 13, 46, 395, 234, 241, 1899, 1906, "fasting" +319, 13, 47, 396, 242, 247, 1907, 1912, "state" +319, 13, 48, 397, 248, 251, 1913, 1916, "and" +319, 13, 49, 398, 252, 261, 1917, 1926, "following" +319, 13, 50, 399, 262, 263, 1927, 1928, "a" +319, 13, 51, 400, 264, 268, 1929, 1933, "meal" +319, 13, 52, 401, 269, 278, 1934, 1943, "tolerance" +319, 13, 53, 402, 279, 283, 1944, 1948, "test" +319, 13, 54, 403, 284, 285, 1949, 1950, "." +319, 14, 1, 404, 0, 4, 1951, 1955, "Data" +319, 14, 2, 405, 5, 8, 1956, 1959, "was" +319, 14, 3, 406, 9, 18, 1960, 1969, "collected" +319, 14, 4, 407, 19, 21, 1970, 1972, "by" +319, 14, 5, 408, 22, 28, 1973, 1979, "people" +319, 14, 6, 409, 29, 36, 1980, 1987, "blinded" +319, 14, 7, 410, 37, 39, 1988, 1990, "to" +319, 14, 8, 411, 40, 49, 1991, 2000, "treatment" +319, 14, 9, 412, 50, 51, 2001, 2002, "." +319, 15, 1, 413, 0, 7, 2003, 2010, "RESULTS" +319, 15, 2, 414, 8, 9, 2011, 2012, ":" +319, 15, 3, 415, 10, 18, 2013, 2021, "Compared" +319, 15, 4, 416, 19, 23, 2022, 2026, "with" +319, 15, 5, 417, 24, 31, 2027, 2034, "placebo" +319, 15, 6, 418, 32, 33, 2035, 2036, "," +319, 15, 7, 419, 34, 45, 2037, 2048, "colesevelam" +319, 15, 8, 420, 46, 54, 2049, 2057, "improved" +319, 15, 9, 421, 55, 58, 2058, 2061, "HbA" +319, 15, 10, 422, 59, 60, 2062, 2063, "(" +319, 15, 11, 423, 61, 63, 2064, 2066, "1c" +319, 15, 12, 424, 64, 65, 2067, 2068, ")" +319, 15, 13, 425, 66, 67, 2069, 2070, "(" +319, 15, 14, 426, 68, 72, 2071, 2075, "mean" +319, 15, 15, 427, 73, 79, 2076, 2082, "change" +319, 15, 16, 428, 80, 84, 2083, 2087, "from" +319, 15, 17, 429, 85, 93, 2088, 2096, "baseline" +319, 15, 18, 430, 94, 96, 2097, 2099, "of" +319, 15, 19, 431, 97, 98, 2100, 2101, "0" +319, 15, 20, 432, 99, 100, 2102, 2103, "." +319, 15, 21, 433, 101, 102, 2104, 2105, "3" +319, 15, 22, 434, 103, 104, 2106, 2107, "[" +319, 15, 23, 435, 105, 107, 2108, 2110, "SD" +319, 15, 24, 436, 108, 109, 2111, 2112, "1" +319, 15, 25, 437, 110, 111, 2113, 2114, "." +319, 15, 26, 438, 112, 113, 2115, 2116, "1" +319, 15, 27, 439, 114, 115, 2117, 2118, "]" +319, 15, 28, 440, 116, 117, 2119, 2120, "%" +319, 15, 29, 441, 118, 121, 2121, 2124, "for" +319, 15, 30, 442, 122, 129, 2125, 2132, "placebo" +319, 15, 31, 443, 130, 131, 2133, 2134, "[" +319, 15, 32, 444, 132, 133, 2135, 2136, "n" +319, 15, 33, 445, 134, 135, 2137, 2138, "=" +319, 15, 34, 446, 136, 138, 2139, 2141, "28" +319, 15, 35, 447, 139, 140, 2142, 2143, "]" +319, 15, 36, 448, 141, 144, 2144, 2147, "and" +319, 15, 37, 449, 145, 146, 2148, 2149, "-" +319, 15, 38, 450, 147, 148, 2150, 2151, "0" +319, 15, 39, 451, 149, 150, 2152, 2153, "." +319, 15, 40, 452, 151, 152, 2154, 2155, "3" +319, 15, 41, 453, 153, 154, 2156, 2157, "[" +319, 15, 42, 454, 155, 156, 2158, 2159, "1" +319, 15, 43, 455, 157, 158, 2160, 2161, "." +319, 15, 44, 456, 159, 160, 2162, 2163, "1" +319, 15, 45, 457, 161, 162, 2164, 2165, "]" +319, 15, 46, 458, 163, 164, 2166, 2167, "%" +319, 15, 47, 459, 165, 168, 2168, 2171, "for" +319, 15, 48, 460, 169, 180, 2172, 2183, "colesevelam" +319, 15, 49, 461, 181, 182, 2184, 2185, "[" +319, 15, 50, 462, 183, 184, 2186, 2187, "n" +319, 15, 51, 463, 185, 186, 2188, 2189, "=" +319, 15, 52, 464, 187, 189, 2190, 2192, "26" +319, 15, 53, 465, 190, 191, 2193, 2194, "]" +319, 15, 54, 466, 192, 193, 2195, 2196, ")" +319, 15, 55, 467, 194, 195, 2197, 2198, "," +319, 15, 56, 468, 196, 203, 2199, 2206, "glucose" +319, 15, 57, 469, 204, 218, 2207, 2221, "concentrations" +319, 15, 58, 470, 219, 220, 2222, 2223, "," +319, 15, 59, 471, 221, 228, 2224, 2231, "fasting" +319, 15, 60, 472, 229, 235, 2232, 2238, "plasma" +319, 15, 61, 473, 236, 243, 2239, 2246, "glucose" +319, 15, 62, 474, 244, 253, 2247, 2256, "clearance" +319, 15, 63, 475, 254, 257, 2257, 2260, "and" +319, 15, 64, 476, 258, 268, 2261, 2271, "glycolytic" +319, 15, 65, 477, 269, 277, 2272, 2280, "disposal" +319, 15, 66, 478, 278, 280, 2281, 2283, "of" +319, 15, 67, 479, 281, 285, 2284, 2288, "oral" +319, 15, 68, 480, 286, 293, 2289, 2296, "glucose" +319, 15, 69, 481, 294, 295, 2297, 2298, "." +319, 16, 1, 482, 0, 11, 2299, 2310, "Colesevelam" +319, 16, 2, 483, 12, 15, 2311, 2314, "did" +319, 16, 3, 484, 16, 19, 2315, 2318, "not" +319, 16, 4, 485, 20, 26, 2319, 2325, "affect" +319, 16, 5, 486, 27, 42, 2326, 2341, "gluconeogenesis" +319, 16, 6, 487, 43, 45, 2342, 2344, "or" +319, 16, 7, 488, 46, 56, 2345, 2355, "appearance" +319, 16, 8, 489, 57, 61, 2356, 2360, "rate" +319, 16, 9, 490, 62, 63, 2361, 2362, "(" +319, 16, 10, 491, 64, 74, 2363, 2373, "absorption" +319, 16, 11, 492, 75, 76, 2374, 2375, ")" +319, 16, 12, 493, 77, 79, 2376, 2378, "of" +319, 16, 13, 494, 80, 84, 2379, 2383, "oral" +319, 16, 14, 495, 85, 92, 2384, 2391, "glucose" +319, 16, 15, 496, 93, 94, 2392, 2393, "." +319, 17, 1, 497, 0, 7, 2394, 2401, "Fasting" +319, 17, 2, 498, 8, 18, 2402, 2412, "endogenous" +319, 17, 3, 499, 19, 26, 2413, 2420, "glucose" +319, 17, 4, 500, 27, 37, 2421, 2431, "production" +319, 17, 5, 501, 38, 41, 2432, 2435, "and" +319, 17, 6, 502, 42, 56, 2436, 2450, "glycogenolysis" +319, 17, 7, 503, 57, 70, 2451, 2464, "significantly" +319, 17, 8, 504, 71, 80, 2465, 2474, "increased" +319, 17, 9, 505, 81, 85, 2475, 2479, "with" +319, 17, 10, 506, 86, 93, 2480, 2487, "placebo" +319, 17, 11, 507, 94, 97, 2488, 2491, "but" +319, 17, 12, 508, 98, 102, 2492, 2496, "were" +319, 17, 13, 509, 103, 112, 2497, 2506, "unchanged" +319, 17, 14, 510, 113, 117, 2507, 2511, "with" +319, 17, 15, 511, 118, 129, 2512, 2523, "colesevelam" +319, 17, 16, 512, 130, 131, 2524, 2525, "(" +319, 17, 17, 513, 132, 141, 2526, 2535, "treatment" +319, 17, 18, 514, 142, 148, 2536, 2542, "effect" +319, 17, 19, 515, 149, 152, 2543, 2546, "did" +319, 17, 20, 516, 153, 156, 2547, 2550, "not" +319, 17, 21, 517, 157, 162, 2551, 2556, "reach" +319, 17, 22, 518, 163, 174, 2557, 2568, "statistical" +319, 17, 23, 519, 175, 187, 2569, 2581, "significance" +319, 17, 24, 520, 188, 189, 2582, 2583, ")" +319, 17, 25, 521, 190, 191, 2584, 2585, "." +319, 18, 1, 522, 0, 8, 2586, 2594, "Compared" +319, 18, 2, 523, 9, 13, 2595, 2599, "with" +319, 18, 3, 524, 14, 21, 2600, 2607, "placebo" +319, 18, 4, 525, 22, 23, 2608, 2609, "," +319, 18, 5, 526, 24, 35, 2610, 2621, "colesevelam" +319, 18, 6, 527, 36, 45, 2622, 2631, "increased" +319, 18, 7, 528, 46, 51, 2632, 2637, "total" +319, 18, 8, 529, 52, 55, 2638, 2641, "GLP" +319, 18, 9, 530, 56, 57, 2642, 2643, "-" +319, 18, 10, 531, 58, 59, 2644, 2645, "1" +319, 18, 11, 532, 60, 63, 2646, 2649, "and" +319, 18, 12, 533, 64, 67, 2650, 2653, "GIP" +319, 18, 13, 534, 68, 82, 2654, 2668, "concentrations" +319, 18, 14, 535, 83, 86, 2669, 2672, "and" +319, 18, 15, 536, 87, 95, 2673, 2681, "improved" +319, 18, 16, 537, 96, 100, 2682, 2686, "HOMA" +319, 18, 17, 538, 101, 102, 2687, 2688, "-" +319, 18, 18, 539, 103, 107, 2689, 2693, "beta" +319, 18, 19, 540, 108, 112, 2694, 2698, "cell" +319, 18, 20, 541, 113, 121, 2699, 2707, "function" +319, 18, 21, 542, 122, 127, 2708, 2713, "while" +319, 18, 22, 543, 128, 135, 2714, 2721, "insulin" +319, 18, 23, 544, 136, 137, 2722, 2723, "," +319, 18, 24, 545, 138, 146, 2724, 2732, "glucagon" +319, 18, 25, 546, 147, 150, 2733, 2736, "and" +319, 18, 26, 547, 151, 155, 2737, 2741, "HOMA" +319, 18, 27, 548, 156, 157, 2742, 2743, "-" +319, 18, 28, 549, 158, 165, 2744, 2751, "insulin" +319, 18, 29, 550, 166, 176, 2752, 2762, "resistance" +319, 18, 30, 551, 177, 181, 2763, 2767, "were" +319, 18, 31, 552, 182, 191, 2768, 2777, "unchanged" +319, 18, 32, 553, 192, 193, 2778, 2779, "." +319, 19, 1, 554, 0, 11, 2780, 2791, "Colesevelam" +319, 19, 2, 555, 12, 21, 2792, 2801, "increased" +319, 19, 3, 556, 22, 33, 2802, 2813, "cholesterol" +319, 19, 4, 557, 34, 37, 2814, 2817, "and" +319, 19, 5, 558, 38, 42, 2818, 2822, "bile" +319, 19, 6, 559, 43, 47, 2823, 2827, "acid" +319, 19, 7, 560, 48, 57, 2828, 2837, "synthesis" +319, 19, 8, 561, 58, 61, 2838, 2841, "and" +319, 19, 9, 562, 62, 71, 2842, 2851, "decreased" +319, 19, 10, 563, 72, 75, 2852, 2855, "FGF" +319, 19, 11, 564, 76, 77, 2856, 2857, "-" +319, 19, 12, 565, 78, 80, 2858, 2860, "19" +319, 19, 13, 566, 81, 95, 2861, 2875, "concentrations" +319, 19, 14, 567, 96, 97, 2876, 2877, "." +319, 20, 1, 568, 0, 7, 2878, 2885, "However" +319, 20, 2, 569, 8, 9, 2886, 2887, "," +319, 20, 3, 570, 10, 12, 2888, 2890, "no" +319, 20, 4, 571, 13, 19, 2891, 2897, "effect" +319, 20, 5, 572, 20, 23, 2898, 2901, "was" +319, 20, 6, 573, 24, 28, 2902, 2906, "seen" +319, 20, 7, 574, 29, 31, 2907, 2909, "on" +319, 20, 8, 575, 32, 42, 2910, 2920, "fractional" +319, 20, 9, 576, 43, 50, 2921, 2928, "hepatic" +319, 20, 10, 577, 51, 53, 2929, 2931, "de" +319, 20, 11, 578, 54, 58, 2932, 2936, "novo" +319, 20, 12, 579, 59, 70, 2937, 2948, "lipogenesis" +319, 20, 13, 580, 71, 72, 2949, 2950, "." +319, 21, 1, 581, 0, 11, 2951, 2962, "CONCLUSIONS" +319, 21, 2, 582, 12, 13, 2963, 2964, "/" +319, 21, 3, 583, 14, 28, 2965, 2979, "INTERPRETATION" +319, 21, 4, 584, 29, 30, 2980, 2981, ":" +319, 21, 5, 585, 31, 42, 2982, 2993, "Colesevelam" +319, 21, 6, 586, 43, 44, 2994, 2995, "," +319, 21, 7, 587, 45, 46, 2996, 2997, "a" +319, 21, 8, 588, 47, 50, 2998, 3001, "non" +319, 21, 9, 589, 51, 52, 3002, 3003, "-" +319, 21, 10, 590, 53, 61, 3004, 3012, "absorbed" +319, 21, 11, 591, 62, 66, 3013, 3017, "bile" +319, 21, 12, 592, 67, 71, 3018, 3022, "acid" +319, 21, 13, 593, 72, 83, 3023, 3034, "sequestrant" +319, 21, 14, 594, 84, 85, 3035, 3036, "," +319, 21, 15, 595, 86, 95, 3037, 3046, "increased" +319, 21, 16, 596, 96, 107, 3047, 3058, "circulating" +319, 21, 17, 597, 108, 117, 3059, 3068, "incretins" +319, 21, 18, 598, 118, 121, 3069, 3072, "and" +319, 21, 19, 599, 122, 130, 3073, 3081, "improved" +319, 21, 20, 600, 131, 137, 3082, 3088, "tissue" +319, 21, 21, 601, 138, 145, 3089, 3096, "glucose" +319, 21, 22, 602, 146, 156, 3097, 3107, "metabolism" +319, 21, 23, 603, 157, 159, 3108, 3110, "in" +319, 21, 24, 604, 160, 164, 3111, 3115, "both" +319, 21, 25, 605, 165, 168, 3116, 3119, "the" +319, 21, 26, 606, 169, 176, 3120, 3127, "fasting" +319, 21, 27, 607, 177, 180, 3128, 3131, "and" +319, 21, 28, 608, 181, 193, 3132, 3144, "postprandial" +319, 21, 29, 609, 194, 200, 3145, 3151, "states" +319, 21, 30, 610, 201, 203, 3152, 3154, "in" +319, 21, 31, 611, 204, 205, 3155, 3156, "a" +319, 21, 32, 612, 206, 212, 3157, 3163, "manner" +319, 21, 33, 613, 213, 222, 3164, 3173, "different" +319, 21, 34, 614, 223, 227, 3174, 3178, "from" +319, 21, 35, 615, 228, 233, 3179, 3184, "other" +319, 21, 36, 616, 234, 242, 3185, 3193, "approved" +319, 21, 37, 617, 243, 247, 3194, 3198, "oral" +319, 21, 38, 618, 248, 254, 3199, 3205, "agents" +319, 21, 39, 619, 255, 256, 3206, 3207, "." +319, 22, 1, 620, 0, 5, 3208, 3213, "TRIAL" +319, 22, 2, 621, 6, 18, 3214, 3226, "REGISTRATION" +319, 22, 3, 622, 19, 20, 3227, 3228, ":" +319, 22, 4, 623, 21, 35, 3229, 3243, "ClinicalTrials" +319, 22, 5, 624, 36, 37, 3244, 3245, "." +319, 22, 6, 625, 38, 41, 3246, 3249, "gov" +319, 22, 7, 626, 42, 53, 3250, 3261, "NCT00596427" +319, 22, 8, 627, 54, 61, 3262, 3269, "FUNDING" +319, 22, 9, 628, 62, 63, 3270, 3271, ":" +319, 22, 10, 629, 64, 67, 3272, 3275, "The" +319, 22, 11, 630, 68, 73, 3276, 3281, "study" +319, 22, 12, 631, 74, 77, 3282, 3285, "was" +319, 22, 13, 632, 78, 84, 3286, 3292, "funded" +319, 22, 14, 633, 85, 87, 3293, 3295, "by" +319, 22, 15, 634, 88, 95, 3296, 3303, "Daiichi" +319, 22, 16, 635, 96, 102, 3304, 3310, "Sankyo" +319, 22, 17, 636, 103, 104, 3311, 3312, "." +319, 23, 1, 637, 0, 3, 3313, 3316, "DOI" +319, 23, 2, 638, 4, 5, 3317, 3318, ":" +319, 23, 3, 639, 6, 8, 3319, 3321, "10" +319, 23, 4, 640, 9, 10, 3322, 3323, "." +319, 23, 5, 641, 11, 15, 3324, 3328, "1007" +319, 23, 6, 642, 16, 17, 3329, 3330, "/" +319, 23, 7, 643, 18, 24, 3331, 3337, "s00125" +319, 23, 8, 644, 25, 26, 3338, 3339, "-" +319, 23, 9, 645, 27, 30, 3340, 3343, "011" +319, 23, 10, 646, 31, 32, 3344, 3345, "-" +319, 23, 11, 647, 33, 37, 3346, 3350, "2382" +319, 23, 12, 648, 38, 39, 3351, 3352, "-" +319, 23, 13, 649, 40, 41, 3353, 3354, "3" +319, 23, 14, 650, 42, 46, 3355, 3359, "PMID" +319, 23, 15, 651, 47, 48, 3360, 3361, ":" +319, 23, 16, 652, 49, 57, 3362, 3370, "22134839" +319, 23, 17, 653, 58, 59, 3371, 3372, "[" +319, 23, 18, 654, 60, 67, 3373, 3380, "Indexed" +319, 23, 19, 655, 68, 71, 3381, 3384, "for" +319, 23, 20, 656, 72, 79, 3385, 3392, "MEDLINE" +319, 23, 21, 657, 80, 81, 3393, 3394, "]" diff --git a/data/dm2 22134839_kwoodley.annodb b/data/dm2 22134839_kwoodley.annodb new file mode 100644 index 0000000..72a909f --- /dev/null +++ b/data/dm2 22134839_kwoodley.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +21124, Journal, 0, 14, "Diabetologia .", "", +21125, PublicationYear, 15, 19, "2012", "", +21130, Title, 110, 288, "Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .", "", +21126, Drug, 120, 142, "bile acid sequestrants", "", +21127, Type2Diabetes, 239, 254, "type 2 diabetes", "", +21128, Randomized, 259, 269, "randomised", "", +21131, Author, 289, 297, "Beysen C", "", +21132, Author, 306, 315, "Murphy EJ", "", +21133, Author, 318, 326, "Deines K", "", +21134, Author, 329, 335, "Chan M", "", +21135, Author, 338, 345, "Tsang E", "", +21136, Author, 348, 355, "Glass A", "", +21137, Author, 358, 367, "Turner SM", "", +21138, Author, 370, 380, "Protasio J", "", +21139, Author, 383, 390, "Riiff T", "", +21140, Author, 393, 407, "Hellerstein MK", "", +21141, USA, 510, 513, "USA", "", +21148, ObjectiveDescription, 619, 801, "The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam", "", +21142, Multicenter, 653, 664, "multicentre", "", +21143, Randomized, 665, 675, "randomised", "", +21144, Parallel, 678, 686, "parallel", "", +21145, DoubleBlind, 689, 703, "double - blind", "", +24747, Placebo, 704, 711, "placebo", "", +21147, Drug, 790, 801, "colesevelam", "", +21149, ObjectiveDescription, 802, 936, "and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .", "", +21162, Precondition, 947, 1113, "Participants with type 2 diabetes ( HbA ( 1c ) 6 . 7 - 10 . 0 % [ 50 - 86 mmol / mol ] , fasting glucose < 16 . 7 mmol / l , fasting triacylglycerols < 3 . 9 mmol / l", "split in two", +21150, Type2Diabetes, 965, 980, "type 2 diabetes", "", +21151, HbA1c, 983, 991, "HbA ( 1c", "", +21152, Percentage, 1009, 1010, "%", "", +21153, BioAndMedicalUnit, 1021, 1031, "mmol / mol", "", +21154, FastingPlasmaGlucose, 1036, 1051, "fasting glucose", "", +21155, Millimoles_per_litre, 1061, 1069, "mmol / l", "", +21156, EndPointDescription, 1072, 1096, "fasting triacylglycerols", "", +21158, Millimoles_per_litre, 1105, 1113, "mmol / l", "", +21163, Precondition, 1114, 1238, "and LDL - cholesterol > 1 . 55 mmol / l ) treated with diet and exercise , sulfonylurea , metformin or a combination thereof", "split in two", +21157, EndPointDescription, 1118, 1135, "LDL - cholesterol", "", +21159, Millimoles_per_litre, 1145, 1153, "mmol / l", "", +21160, Sulfonylureas, 1189, 1201, "sulfonylurea", "", +21161, Metformin, 1204, 1213, "metformin", "", +21164, Randomized, 1246, 1256, "randomised", "", +21165, DoseValue, 1292, 1298, "3 . 75", "", +21166, Gram, 1299, 1300, "g", "", +21167, Frequency, 1303, 1306, "day", "", +21168, Drug, 1307, 1318, "colesevelam", "", +21169, NumberPatientsArm, 1325, 1327, "30", "", +21171, Placebo, 1333, 1340, "placebo", "", +21170, NumberPatientsArm, 1347, 1349, "30", "", +21172, Duration, 1356, 1364, "12 weeks", "", +21173, USA, 1396, 1399, "USA", "", +21174, Drug, 1476, 1487, "colesevelam", "", +21175, Placebo, 1500, 1507, "placebo", "", +21176, FastingPlasmaGlucose, 1520, 1527, "Fasting", "", +33180, PostprandialBloodGlucose, 1532, 1552, "postprandial glucose", "", +21178, EndPointDescription, 1555, 1560, "lipid", "", +21179, EndPointDescription, 1565, 1574, "bile acid", "", +21180, MeasurementDevice, 1644, 1662, "isotope techniques", "", +21181, FastingPlasmaGlucose, 1665, 1679, "Plasma glucose", "", +33181, InsulinDose, 1682, 1689, "insulin", "", +21183, EndPointDescription, 1698, 1725, "glucagon - like peptide - 1", "", +21184, EndPointDescription, 1728, 1735, "GLP - 1", "", +21185, EndPointDescription, 1746, 1792, "glucose - dependent insulinotropic polypeptide", "", +21186, EndPointDescription, 1795, 1798, "GIP", "", +21187, EndPointDescription, 1803, 1845, "glucagon and fibroblast growth factor - 19", "", +21188, EndPointDescription, 1848, 1856, "FGF - 19", "", +21189, Placebo, 2027, 2034, "placebo", "", +21202, Drug, 2037, 2048, "colesevelam", "", +21203, ObservedResult, 2049, 2057, "improved", "for the endpoints listet at the end of the sentence", +21190, HbA1c, 2058, 2068, "HbA ( 1c )", "", +21196, ChangeValue, 2100, 2105, "0 . 3", "", +21197, SdDevChangeValue, 2111, 2116, "1 . 1", "", +21193, Percentage, 2119, 2120, "%", "", +21195, FinalNumPatientsArm, 2139, 2141, "28", "", +21199, Reduction, 2150, 2155, "0 . 3", "", +21198, SdDevChangeValue, 2158, 2163, "1 . 1", "", +21194, Percentage, 2166, 2167, "%", "", +21200, Drug, 2172, 2183, "colesevelam", "", +21201, FinalNumPatientsArm, 2190, 2192, "26", "", +21204, EndPointDescription, 2199, 2221, "glucose concentrations", "", +21206, FastingPlasmaGlucose, 2224, 2246, "fasting plasma glucose", "", +21205, EndPointDescription, 2261, 2296, "glycolytic disposal of oral glucose", "", +21207, Drug, 2299, 2310, "Colesevelam", "", +21208, ObservedResult, 2311, 2325, "did not affect", "", +21209, EndPointDescription, 2326, 2341, "gluconeogenesis", "", +21210, EndPointDescription, 2345, 2391, "appearance rate ( absorption ) of oral glucose", "", +21211, EndPointDescription, 2394, 2420, "Fasting endogenous glucose", "", +21212, EndPointDescription, 2436, 2450, "glycogenolysis", "", +21219, ObservedResult, 2451, 2583, "significantly increased with placebo but were unchanged with colesevelam ( treatment effect did not reach statistical significance )", "", +21220, Placebo, 2480, 2487, "placebo", "", +21221, Drug, 2512, 2523, "colesevelam", "", +21225, Placebo, 2600, 2607, "placebo", "", +21222, Drug, 2610, 2621, "colesevelam", "", +21226, ObservedResult, 2622, 2631, "increased", "", +21213, EndPointDescription, 2638, 2645, "GLP - 1", "", +21214, EndPointDescription, 2650, 2653, "GIP", "", +21227, ObservedResult, 2673, 2681, "improved", "", +21215, EndPointDescription, 2682, 2707, "HOMA - beta cell function", "", +21216, EndPointDescription, 2714, 2721, "insulin", "here not drug", +21217, EndPointDescription, 2724, 2732, "glucagon", "", +21218, EndPointDescription, 2737, 2762, "HOMA - insulin resistance", "", +21228, ObservedResult, 2763, 2777, "were unchanged", "", +21223, Drug, 2780, 2791, "Colesevelam", "", +21229, ObservedResult, 2792, 2801, "increased", "", +21231, EndPointDescription, 2802, 2813, "cholesterol", "", +21232, EndPointDescription, 2818, 2837, "bile acid synthesis", "", +21230, ObservedResult, 2842, 2851, "decreased", "", +21233, EndPointDescription, 2852, 2875, "FGF - 19 concentrations", "", +21235, ObservedResult, 2888, 2906, "no effect was seen", "", +21234, EndPointDescription, 2910, 2948, "fractional hepatic de novo lipogenesis", "", +21224, Drug, 2982, 2993, "Colesevelam", "", +21239, ConclusionComment, 2982, 3207, "Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .", "", +21236, FastingPlasmaGlucose, 3120, 3127, "fasting", "", +33182, PostprandialBloodGlucose, 3132, 3144, "postprandial", "", +21238, OralAntidiabeticAgent, 3194, 3205, "oral agents", "", +21240, PMID, 3362, 3370, "22134839", "", diff --git a/data/dm2 22134839_kwoodley.n-triples b/data/dm2 22134839_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22134839_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22313154_admin.annodb b/data/dm2 22313154_admin.annodb new file mode 100644 index 0000000..2b9bffd --- /dev/null +++ b/data/dm2 22313154_admin.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2012", "", " \"2012\"." +8, Title, 116, 262, "Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin .", "", " \"Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin .\"." +2, Saxagliptin, 126, 137, "saxagliptin", "", +7, Precondition, 161, 260, "patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin", "", " \"patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin\"." +3, Type2Diabetes, 193, 208, "type 2 diabetes", "", " ." +4, Insulin, 212, 219, "insulin", "", +5, Insulin, 229, 236, "insulin", "", +6, Metformin, 251, 260, "metformin", "", +9, Author, 263, 273, "Barnett AH", "", " \"Barnett AH\"." +10, Author, 282, 294, "Charbonnel B", "", " \"Charbonnel B\"." +11, Author, 297, 306, "Donovan M", "", " \"Donovan M\"." +12, Author, 309, 318, "Fleming D", "", " \"Fleming D\"." +13, Author, 321, 327, "Chen R", "", " \"Chen R\"." +14, UK, 488, 490, "UK", "", +21, ObjectiveDescription, 551, 737, "To evaluate efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin .", "", " \"To evaluate efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin .\"." +15, Saxagliptin, 586, 597, "saxagliptin", "", +20, Precondition, 621, 735, "patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin", "", " \"patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin\"." +16, Type2Diabetes, 635, 650, "type 2 diabetes", "", +17, Type2Diabetes, 653, 656, "T2D", "", +18, Insulin, 695, 702, "insulin", "", +19, Metformin, 726, 735, "metformin", "", +22, NumberPatientsCT, 763, 766, "455", "", " \"455\"." +23, HbA1c, 774, 784, "HbA ( 1c )", "", +24, Percentage, 796, 797, "%", "", +25, Insulin, 808, 815, "insulin", "", +28, DoseValue, 826, 834, "30 - 150", "", +26, BioAndMedicalUnit, 837, 844, "U / day", "", +27, Metformin, 849, 858, "metformin", "", +152, Duration, 874, 881, "8 weeks", "", +29, Metformin, 901, 910, "metformin", "", +30, Randomized, 919, 927, "randomly", "", " ." +31, AllocationRatio, 937, 942, "2 : 1", "", " . ." +32, Saxagliptin, 954, 965, "saxagliptin", "", " ." +33, DoseValue, 966, 967, "5", "", " \"5\"." +34, mg, 970, 972, "mg", "", " ." +35, Placebo, 976, 983, "placebo", "", " ." +36, Frequency, 984, 994, "once daily", "", " \"once daily\". \"once daily\"." +37, Duration, 999, 1007, "24 weeks", "", " \"24 weeks\"." +39, Insulin, 1043, 1050, "insulin", "", +40, Hypoglycemia, 1104, 1116, "hypoglycemia", "", +41, Hypoglycemia, 1133, 1146, "hyperglycemia", "", +164, Insulin, 1174, 1181, "insulin", "", +163, Insulin, 1215, 1222, "insulin", "", +43, Metformin, 1259, 1268, "Metformin", "", +44, HbA1c, 1338, 1348, "HbA ( 1c )", "", +167, TimePoint, 1354, 1362, "baseline", "", +45, Duration, 1366, 1373, "week 24", "", +46, Saxagliptin, 1422, 1433, "saxagliptin", "", +53, Placebo, 1441, 1448, "placebo", "", +171, Mean, 1498, 1502, "mean", "", " . ." +58, HbA1c, 1503, 1513, "HbA ( 1c )", "", " ." +60, DiffGroupAbsValue, 1529, 1537, "- 0 . 41", "", " \"- 0 . 41\"." +61, Percentage, 1538, 1539, "%", "", " ." +62, PvalueDiff, 1542, 1556, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +118, PostprandialBloodGlucose, 1561, 1581, "postprandial glucose", "", +119, PostprandialBloodGlucose, 1584, 1587, "PPG", "", +119924, EndPointDescription, 1584, 1623, "PPG ) 180 - minute area under the curve", "", +65, DiffGroupAbsValue, 1626, 1636, "- 3829 . 8", "", " \"- 3829 . 8\"." +67, BioAndMedicalUnit, 1639, 1652, "mg · min / dL", "", " . ." +69, PvalueDiff, 1655, 1669, "p  =  0 . 0011", "", " \"p  =  0 . 0011\"." +92988, EndPointDescription, 1678, 1694, "120 - minute PPG", "", " . ." +120, PostprandialBloodGlucose, 1691, 1694, "PPG", "", +66, DiffGroupAbsValue, 1697, 1705, "- 23 . 0", "", " \"- 23 . 0\"." +68, Mg_per_deciliter, 1708, 1715, "mg / dL", "", " ." +70, PvalueDiff, 1718, 1732, "p  =  0 . 0016", "", " \"p  =  0 . 0016\"." +178, TimePoint, 1738, 1746, "24 weeks", "", +47, Saxagliptin, 1764, 1775, "saxagliptin", "", +59, HbA1c, 1810, 1820, "HBA ( 1c )", "", +72, Placebo, 1833, 1840, "placebo", "", +73, Metformin, 1859, 1868, "metformin", "", +121, TimePoint, 1884, 1892, "24 weeks", "", +184, Mean, 1918, 1922, "mean", "", " . ." +75, FastingPlasmaGlucose, 1923, 1945, "fasting plasma glucose", "", " ." +48, Saxagliptin, 1950, 1961, "saxagliptin", "", +54, Placebo, 1969, 1976, "placebo", "", +76, DiffGroupAbsValue, 1981, 1989, "- 4 . 02", "", " \"- 4 . 02\"." +77, Mg_per_deciliter, 1992, 1999, "mg / dL", "", " ." +78, PvalueDiff, 2002, 2016, "p  =  0 . 3958", "", " \"p  =  0 . 3958\"." +79, PercentageAffected, 2021, 2027, "17 . 3", "", " \"17 . 3\"." +80, PercentageAffected, 2034, 2039, "6 . 7", "", " \"6 . 7\"." +49, Saxagliptin, 2061, 2072, "saxagliptin", "", +55, Placebo, 2077, 2084, "placebo", "", +81, HbA1c_target, 2118, 2136, "HbA ( 1c )  <  7 %", "", " ." +204, Percentage, 2135, 2136, "%", "", +205, Mean, 2139, 2143, "Mean", "", " . ." +206, TimePoint, 2156, 2164, "baseline", "", +82, BodyWeight, 2168, 2179, "body weight", "", " ." +208, TimePoint, 2183, 2190, "week 24", "", " \"week 24\". \"week 24\"." +106369, Increment, 2195, 2201, "0 . 39", "", " \"0 . 39\"." +86, Kg, 2204, 2206, "kg", "", " ." +88, Saxagliptin, 2211, 2222, "saxagliptin", "", +106370, Increment, 2227, 2233, "0 . 18", "", " \"0 . 18\"." +87, Kg, 2236, 2238, "kg", "", +89, Placebo, 2243, 2250, "placebo", "", +90, Hypoglycemia, 2253, 2265, "Hypoglycemia", "", " ." +91, PercentageAffected, 2282, 2288, "18 . 4", "", " \"18 . 4\"." +92, PercentageAffected, 2295, 2301, "19 . 9", "", " \"19 . 9\"." +50, Saxagliptin, 2323, 2334, "saxagliptin", "", +56, Placebo, 2339, 2346, "placebo", "", +93, Hypoglycemia, 2371, 2393, "confirmed hypoglycemia", "", " ." +95, PercentageAffected, 2396, 2401, "5 . 3", "", " \"5 . 3\"." +96, PercentageAffected, 2406, 2411, "3 . 3", "", " \"3 . 3\"." +99, EndPointDescription, 2481, 2504, "urinary tract infection", "", " . ." +51, Saxagliptin, 2507, 2518, "saxagliptin", "", +57, Placebo, 2521, 2528, "placebo", "", +102, PercentageAffected, 2531, 2536, "5 . 9", "", " \"5 . 9\"." +103, PercentageAffected, 2541, 2546, "6 . 0", "", " \"6 . 0\"." +100, EndPointDescription, 2553, 2562, "influenza", "", " . ." +104, PercentageAffected, 2565, 2570, "3 . 0", "", " \"3 . 0\"." +105, PercentageAffected, 2575, 2580, "6 . 6", "", " \"6 . 6\"." +101, EndPointDescription, 2591, 2608, "pain in extremity", "", " . ." +106, PercentageAffected, 2611, 2616, "1 . 6", "", " \"1 . 6\"." +107, PercentageAffected, 2621, 2626, "6 . 0", "", " \"6 . 0\"." +115, ConclusionComment, 2647, 2817, "Saxagliptin 5 - mg once - daily add - on therapy improves glycemic control in T2D patients on insulin alone or combined with metformin and is generally well - tolerated .", "", " \"Saxagliptin 5 - mg once - daily add - on therapy improves glycemic control in T2D patients on insulin alone or combined with metformin and is generally well - tolerated .\"." +52, Saxagliptin, 2647, 2658, "Saxagliptin", "", +108, DoseValue, 2659, 2660, "5", "", +109, mg, 2663, 2665, "mg", "", +110, Frequency, 2666, 2678, "once - daily", "", +111, Type2Diabetes, 2725, 2728, "T2D", "", +112, Insulin, 2741, 2748, "insulin", "", +113, Metformin, 2772, 2781, "metformin", "", +116, PMID, 2882, 2890, "22313154", "", " \"22313154\"." diff --git a/data/dm2 22313154_admin.n-triples b/data/dm2 22313154_admin.n-triples new file mode 100644 index 0000000..252e641 --- /dev/null +++ b/data/dm2 22313154_admin.n-triples @@ -0,0 +1,277 @@ +# RDF export of group: Publication + . + "Publication 34955" . + "Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin ." . + "Barnett AH" . + "2012" . + "Curr Med Res Opin ." . + "22313154" . + . + "Charbonnel B" . + "Donovan M" . + "Fleming D" . + "Chen R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 34962" . + "To evaluate efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin ." . + "455" . + "24 weeks" . + . + . + . + . + "Saxagliptin 5 - mg once - daily add - on therapy improves glycemic control in T2D patients on insulin alone or combined with metformin and is generally well - tolerated ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 34978" . + "patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin" . + . + . + . + "patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ppg180" . + . + . + . + . + . + . + "ppg120" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "hbatar" . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "hypconf" . + . + . + . + . + . + "uri" . + . + . + . + . + . + . + "inf" . + . + . + . + . + . + . + "pai" . + . + . + . + . + . +# RDF export of group: Arm + . + "sax" . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sax" . + . + "once daily" . + . + . + "pla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "sax" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . + . + "pbg180 1" . + . + . + "pbg180 2" . + . + . + "ppg 120 1" . + . + . + "ppg 120 2" . + . + . + "fpg 1" . + . + . + "fpg 2" . + . + . + "hbatar 1" . + . + "17 . 3" . + . + "hbatar 2" . + . + "6 . 7" . + . + "bw 1" . + . + "0 . 39" . + "week 24" . + . + "bw 2" . + . + "0 . 18" . + "week 24" . + . + "hyp 1" . + . + "18 . 4" . + . + "hyp 2" . + . + "19 . 9" . + . + "hypconf 1" . + . + "5 . 3" . + . + "hypconf 2" . + . + "3 . 3" . + . + "uri 1" . + . + "5 . 9" . + . + "uri 2" . + . + "6 . 0" . + . + "inf 1" . + . + "3 . 0" . + . + "inf 2" . + . + "6 . 6" . + . + "pai 1" . + . + "1 . 6" . + . + "pai 2" . + . + "6 . 0" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 41" . + "p  <  0 . 0001" . + . + . + . + "ppg180" . + "- 3829 . 8" . + "p  =  0 . 0011" . + . + . + . + "ppg120" . + "- 23 . 0" . + "p  =  0 . 0016" . + . + . + . + "fpg" . + "- 4 . 02" . + "p  =  0 . 3958" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22313154_akramersunderbrink.annodb b/data/dm2 22313154_akramersunderbrink.annodb new file mode 100644 index 0000000..cb52c9a --- /dev/null +++ b/data/dm2 22313154_akramersunderbrink.annodb @@ -0,0 +1,133 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +40604, Journal, 0, 17, "Curr Med Res Opin", "", +40605, PublicationYear, 20, 24, "2012", "", +40612, Title, 116, 262, "Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin .", "", +40606, Saxagliptin, 126, 137, "saxagliptin", "", +40607, Precondition, 175, 192, "poorly controlled", "", +40608, Type2Diabetes, 193, 208, "type 2 diabetes", "", +40609, Insulin, 212, 219, "insulin", "", +40610, Insulin, 229, 236, "insulin", "", +40611, Metformin, 251, 260, "metformin", "", +40613, Author, 263, 273, "Barnett AH", "", +40614, Author, 282, 294, "Charbonnel B", "", +40615, Author, 297, 306, "Donovan M", "", +40616, Author, 309, 318, "Fleming D", "", +40617, Author, 321, 327, "Chen R", "", +40618, UK, 488, 490, "UK", "", +40625, ObjectiveDescription, 551, 737, "To evaluate efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin .", "", +40619, Saxagliptin, 586, 597, "saxagliptin", "", +40620, Type2Diabetes, 635, 650, "type 2 diabetes", "", +40621, Type2Diabetes, 653, 656, "T2D", "", +40622, Precondition, 664, 735, "inadequate glycemic control on insulin alone or combined with metformin", "", +40623, Insulin, 695, 702, "insulin", "", +40624, Metformin, 726, 735, "metformin", "", +40626, NumberPatientsCT, 763, 766, "455", "", +40627, HbA1c, 774, 784, "HbA ( 1c )", "", +40628, Precondition, 774, 797, "HbA ( 1c ) 7 . 5 - 11 %", "", +40629, Precondition, 798, 881, "on stable insulin therapy ( 30 - 150   U / day  ±  metformin ) for at least 8 weeks", "", +40630, Insulin, 808, 815, "insulin", "", +40631, DoseValue, 826, 844, "30 - 150   U / day", "", +40632, BioAndMedicalUnit, 837, 844, "U / day", "", +40633, Metformin, 849, 858, "metformin", "", +40634, Duration, 874, 881, "8 weeks", "", +40635, Metformin, 901, 910, "metformin", "", +40636, Randomized, 919, 927, "randomly", "", +40637, Saxagliptin, 954, 965, "saxagliptin", "", +40638, DoseValue, 966, 972, "5   mg", "", +40639, mg, 970, 972, "mg", "", +40640, Placebo, 976, 983, "placebo", "", +40641, Frequency, 984, 994, "once daily", "", +40642, Duration, 999, 1007, "24 weeks", "", +40643, Hypoglycemia, 1104, 1116, "hypoglycemia", "", +40644, Hypoglycemia, 1133, 1146, "hyperglycemia", "", +40646, Insulin, 1174, 1181, "insulin", "", +40645, Insulin, 1215, 1222, "insulin", "", +40647, Metformin, 1259, 1268, "Metformin", "", +40648, HbA1c, 1338, 1348, "HbA ( 1c )", "", +40649, TimePoint, 1354, 1362, "baseline", "", +40650, Duration, 1366, 1373, "week 24", "", +40651, Saxagliptin, 1422, 1433, "saxagliptin", "", +40652, Placebo, 1441, 1448, "placebo", "", +40653, Mean, 1498, 1502, "mean", "", +40654, HbA1c, 1503, 1513, "HbA ( 1c )", "", +40677, DiffGroupAbsValue, 1529, 1537, "- 0 . 41", "", +40658, Percentage, 1538, 1539, "%", "", +40680, PvalueDiff, 1542, 1556, "p  <  0 . 0001", "", +40662, PostprandialPlasmaGlucose, 1561, 1623, "postprandial glucose ( PPG ) 180 - minute area under the curve", "", +40678, DiffGroupAbsValue, 1626, 1636, "- 3829 . 8", "", +40664, BioAndMedicalUnit, 1639, 1652, "mg · min / dL", "", +40681, PvalueDiff, 1655, 1669, "p  =  0 . 0011", "", +40663, PostprandialPlasmaGlucose, 1678, 1694, "120 - minute PPG", "", +40679, DiffGroupAbsValue, 1697, 1705, "- 23 . 0", "", +40665, BioAndMedicalUnit, 1708, 1715, "mg / dL", "", +40682, PvalueDiff, 1718, 1732, "p  =  0 . 0016", "", +40666, TimePoint, 1738, 1746, "24 weeks", "", +40667, Saxagliptin, 1764, 1775, "saxagliptin", "", +40668, HbA1c, 1810, 1820, "HBA ( 1c )", "", +40669, Placebo, 1833, 1840, "placebo", "", +40670, Metformin, 1859, 1868, "metformin", "", +40671, TimePoint, 1884, 1892, "24 weeks", "", +40672, Mean, 1918, 1922, "mean", "", +40673, FastingPlasmaGlucose, 1923, 1945, "fasting plasma glucose", "", +40674, Saxagliptin, 1950, 1961, "saxagliptin", "", +40675, Placebo, 1969, 1976, "placebo", "", +40676, DiffGroupAbsValue, 1981, 1989, "- 4 . 02", "", +40909, BioAndMedicalUnit, 1992, 1999, "mg / dL", "", +40910, PvalueDiff, 2002, 2016, "p  =  0 . 3958", "", +40914, PercentageAffected, 2021, 2027, "17 . 3", "", +40916, Percentage, 2028, 2029, "%", "", +40915, PercentageAffected, 2034, 2039, "6 . 7", "", +40917, Percentage, 2040, 2041, "%", "", +40911, Saxagliptin, 2061, 2072, "saxagliptin", "", +40912, Placebo, 2077, 2084, "placebo", "", +40913, HbA1c_target, 2118, 2136, "HbA ( 1c )  <  7 %", "", +40918, Percentage, 2135, 2136, "%", "", +40919, Mean, 2139, 2143, "Mean", "", +40920, TimePoint, 2156, 2164, "baseline", "", +40921, BodyWeight, 2168, 2179, "body weight", "", +40922, TimePoint, 2183, 2190, "week 24", "", +40925, ChangeValue, 2195, 2201, "0 . 39", "", +40927, Kg, 2204, 2206, "kg", "", +40923, Saxagliptin, 2211, 2222, "saxagliptin", "", +40926, ChangeValue, 2227, 2233, "0 . 18", "", +40929, Kg, 2236, 2238, "kg", "", +40924, Placebo, 2243, 2250, "placebo", "", +40930, Hypoglycemia, 2253, 2265, "Hypoglycemia", "", +40934, PercentageAffected, 2282, 2288, "18 . 4", "", +40938, Percentage, 2289, 2290, "%", "", +40935, PercentageAffected, 2295, 2301, "19 . 9", "", +40939, Percentage, 2302, 2303, "%", "", +40931, Saxagliptin, 2323, 2334, "saxagliptin", "", +40932, Placebo, 2339, 2346, "placebo", "", +40933, Hypoglycemia, 2371, 2393, "confirmed hypoglycemia", "", +40936, PercentageAffected, 2396, 2401, "5 . 3", "", +40940, Percentage, 2402, 2403, "%", "", +40937, PercentageAffected, 2406, 2411, "3 . 3", "", +40941, Percentage, 2412, 2413, "%", "", +40942, Percentage, 2462, 2463, "%", "", +40951, EndPointDescription, 2481, 2504, "urinary tract infection", "", +40949, Saxagliptin, 2507, 2518, "saxagliptin", "", +40950, Placebo, 2521, 2528, "placebo", "", +40954, PercentageAffected, 2531, 2536, "5 . 9", "", +40943, Percentage, 2537, 2538, "%", "", +40955, PercentageAffected, 2541, 2546, "6 . 0", "", +40944, Percentage, 2547, 2548, "%", "", +40952, EndPointDescription, 2553, 2562, "influenza", "", +40956, PercentageAffected, 2565, 2570, "3 . 0", "", +40945, Percentage, 2571, 2572, "%", "", +40957, PercentageAffected, 2575, 2580, "6 . 6", "", +40946, Percentage, 2581, 2582, "%", "", +40953, EndPointDescription, 2591, 2608, "pain in extremity", "", +40958, PercentageAffected, 2611, 2616, "1 . 6", "", +40947, Percentage, 2617, 2618, "%", "", +40959, PercentageAffected, 2621, 2626, "6 . 0", "", +40948, Percentage, 2627, 2628, "%", "", +40960, Saxagliptin, 2647, 2658, "Saxagliptin", "", +40968, ConclusionComment, 2647, 2817, "Saxagliptin 5 - mg once - daily add - on therapy improves glycemic control in T2D patients on insulin alone or combined with metformin and is generally well - tolerated .", "", +40964, DoseValue, 2659, 2665, "5 - mg", "", +40965, mg, 2663, 2665, "mg", "", +40966, Frequency, 2666, 2678, "once - daily", "", +40961, Type2Diabetes, 2725, 2728, "T2D", "", +40962, Insulin, 2741, 2748, "insulin", "", +40963, Metformin, 2772, 2781, "metformin", "", +40967, PMID, 2882, 2890, "22313154", "", diff --git a/data/dm2 22313154_akramersunderbrink.n-triples b/data/dm2 22313154_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22313154_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22313154_export.csv b/data/dm2 22313154_export.csv new file mode 100644 index 0000000..495a2c0 --- /dev/null +++ b/data/dm2 22313154_export.csv @@ -0,0 +1,631 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +316, 1, 1, 1, 0, 4, 0, 4, "Curr" +316, 1, 2, 2, 5, 8, 5, 8, "Med" +316, 1, 3, 3, 9, 12, 9, 12, "Res" +316, 1, 4, 4, 13, 17, 13, 17, "Opin" +316, 1, 5, 5, 18, 19, 18, 19, "." +316, 2, 1, 6, 0, 4, 20, 24, "2012" +316, 2, 2, 7, 5, 8, 25, 28, "Apr" +316, 2, 3, 8, 9, 10, 29, 30, ";" +316, 2, 4, 9, 11, 13, 31, 33, "28" +316, 2, 5, 10, 14, 15, 34, 35, "(" +316, 2, 6, 11, 16, 17, 36, 37, "4" +316, 2, 7, 12, 18, 19, 38, 39, ")" +316, 2, 8, 13, 20, 21, 40, 41, ":" +316, 2, 9, 14, 22, 25, 42, 45, "513" +316, 2, 10, 15, 26, 27, 46, 47, "-" +316, 2, 11, 16, 28, 30, 48, 50, "23" +316, 2, 12, 17, 31, 32, 51, 52, "." +316, 2, 13, 18, 33, 36, 53, 56, "doi" +316, 2, 14, 19, 37, 38, 57, 58, ":" +316, 2, 15, 20, 39, 41, 59, 61, "10" +316, 2, 16, 21, 42, 43, 62, 63, "." +316, 2, 17, 22, 44, 48, 64, 68, "1185" +316, 2, 18, 23, 49, 50, 69, 70, "/" +316, 2, 19, 24, 51, 59, 71, 79, "03007995" +316, 2, 20, 25, 60, 61, 80, 81, "." +316, 2, 21, 26, 62, 66, 82, 86, "2012" +316, 2, 22, 27, 67, 68, 87, 88, "." +316, 2, 23, 28, 69, 75, 89, 95, "665046" +316, 2, 24, 29, 76, 77, 96, 97, "." +316, 3, 1, 30, 0, 4, 98, 102, "Epub" +316, 3, 2, 31, 5, 9, 103, 107, "2012" +316, 3, 3, 32, 10, 13, 108, 111, "Mar" +316, 3, 4, 33, 14, 15, 112, 113, "1" +316, 3, 5, 34, 16, 17, 114, 115, "." +316, 4, 1, 35, 0, 6, 116, 122, "Effect" +316, 4, 2, 36, 7, 9, 123, 125, "of" +316, 4, 3, 37, 10, 21, 126, 137, "saxagliptin" +316, 4, 4, 38, 22, 24, 138, 140, "as" +316, 4, 5, 39, 25, 28, 141, 144, "add" +316, 4, 6, 40, 29, 30, 145, 146, "-" +316, 4, 7, 41, 31, 33, 147, 149, "on" +316, 4, 8, 42, 34, 41, 150, 157, "therapy" +316, 4, 9, 43, 42, 44, 158, 160, "in" +316, 4, 10, 44, 45, 53, 161, 169, "patients" +316, 4, 11, 45, 54, 58, 170, 174, "with" +316, 4, 12, 46, 59, 65, 175, 181, "poorly" +316, 4, 13, 47, 66, 76, 182, 192, "controlled" +316, 4, 14, 48, 77, 81, 193, 197, "type" +316, 4, 15, 49, 82, 83, 198, 199, "2" +316, 4, 16, 50, 84, 92, 200, 208, "diabetes" +316, 4, 17, 51, 93, 95, 209, 211, "on" +316, 4, 18, 52, 96, 103, 212, 219, "insulin" +316, 4, 19, 53, 104, 109, 220, 225, "alone" +316, 4, 20, 54, 110, 112, 226, 228, "or" +316, 4, 21, 55, 113, 120, 229, 236, "insulin" +316, 4, 22, 56, 121, 129, 237, 245, "combined" +316, 4, 23, 57, 130, 134, 246, 250, "with" +316, 4, 24, 58, 135, 144, 251, 260, "metformin" +316, 4, 25, 59, 145, 146, 261, 262, "." +316, 5, 1, 60, 0, 7, 263, 270, "Barnett" +316, 5, 2, 61, 8, 10, 271, 273, "AH" +316, 5, 3, 62, 11, 12, 274, 275, "(" +316, 5, 4, 63, 13, 14, 276, 277, "1" +316, 5, 5, 64, 15, 16, 278, 279, ")" +316, 5, 6, 65, 17, 18, 280, 281, "," +316, 5, 7, 66, 19, 29, 282, 292, "Charbonnel" +316, 5, 8, 67, 30, 31, 293, 294, "B" +316, 5, 9, 68, 32, 33, 295, 296, "," +316, 5, 10, 69, 34, 41, 297, 304, "Donovan" +316, 5, 11, 70, 42, 43, 305, 306, "M" +316, 5, 12, 71, 44, 45, 307, 308, "," +316, 5, 13, 72, 46, 53, 309, 316, "Fleming" +316, 5, 14, 73, 54, 55, 317, 318, "D" +316, 5, 15, 74, 56, 57, 319, 320, "," +316, 5, 16, 75, 58, 62, 321, 325, "Chen" +316, 5, 17, 76, 63, 64, 326, 327, "R" +316, 5, 18, 77, 65, 66, 328, 329, "." +316, 5, 19, 78, 67, 73, 330, 336, "Author" +316, 5, 20, 79, 74, 85, 337, 348, "information" +316, 5, 21, 80, 86, 87, 349, 350, ":" +316, 5, 22, 81, 88, 89, 351, 352, "(" +316, 5, 23, 82, 90, 91, 353, 354, "1" +316, 5, 24, 83, 92, 93, 355, 356, ")" +316, 5, 25, 84, 94, 104, 357, 367, "University" +316, 5, 26, 85, 105, 107, 368, 370, "of" +316, 5, 27, 86, 108, 118, 371, 381, "Birmingham" +316, 5, 28, 87, 119, 122, 382, 385, "and" +316, 5, 29, 88, 123, 133, 386, 396, "BioMedical" +316, 5, 30, 89, 134, 142, 397, 405, "Research" +316, 5, 31, 90, 143, 149, 406, 412, "Centre" +316, 5, 32, 91, 150, 151, 413, 414, "," +316, 5, 33, 92, 152, 157, 415, 420, "Heart" +316, 5, 34, 93, 158, 160, 421, 423, "of" +316, 5, 35, 94, 161, 168, 424, 431, "England" +316, 5, 36, 95, 169, 177, 432, 440, "National" +316, 5, 37, 96, 178, 184, 441, 447, "Health" +316, 5, 38, 97, 185, 192, 448, 455, "Service" +316, 5, 39, 98, 193, 203, 456, 466, "Foundation" +316, 5, 40, 99, 204, 209, 467, 472, "Trust" +316, 5, 41, 100, 210, 211, 473, 474, "," +316, 5, 42, 101, 212, 222, 475, 485, "Birmingham" +316, 5, 43, 102, 223, 224, 486, 487, "," +316, 5, 44, 103, 225, 227, 488, 490, "UK" +316, 5, 45, 104, 228, 229, 491, 492, "." +316, 6, 1, 105, 0, 7, 493, 500, "anthony" +316, 6, 2, 106, 8, 9, 501, 502, "." +316, 6, 3, 107, 10, 17, 503, 510, "barnett" +316, 6, 4, 108, 18, 19, 511, 512, "@" +316, 6, 5, 109, 20, 34, 513, 527, "heartofengland" +316, 6, 6, 110, 35, 36, 528, 529, "." +316, 6, 7, 111, 37, 40, 530, 533, "nhs" +316, 6, 8, 112, 41, 42, 534, 535, "." +316, 6, 9, 113, 43, 45, 536, 538, "uk" +316, 6, 10, 114, 46, 55, 539, 548, "OBJECTIVE" +316, 6, 11, 115, 56, 57, 549, 550, ":" +316, 6, 12, 116, 58, 60, 551, 553, "To" +316, 6, 13, 117, 61, 69, 554, 562, "evaluate" +316, 6, 14, 118, 70, 78, 563, 571, "efficacy" +316, 6, 15, 119, 79, 82, 572, 575, "and" +316, 6, 16, 120, 83, 89, 576, 582, "safety" +316, 6, 17, 121, 90, 92, 583, 585, "of" +316, 6, 18, 122, 93, 104, 586, 597, "saxagliptin" +316, 6, 19, 123, 105, 107, 598, 600, "as" +316, 6, 20, 124, 108, 111, 601, 604, "add" +316, 6, 21, 125, 112, 113, 605, 606, "-" +316, 6, 22, 126, 114, 116, 607, 609, "on" +316, 6, 23, 127, 117, 124, 610, 617, "therapy" +316, 6, 24, 128, 125, 127, 618, 620, "in" +316, 6, 25, 129, 128, 136, 621, 629, "patients" +316, 6, 26, 130, 137, 141, 630, 634, "with" +316, 6, 27, 131, 142, 146, 635, 639, "type" +316, 6, 28, 132, 147, 148, 640, 641, "2" +316, 6, 29, 133, 149, 157, 642, 650, "diabetes" +316, 6, 30, 134, 158, 159, 651, 652, "(" +316, 6, 31, 135, 160, 163, 653, 656, "T2D" +316, 6, 32, 136, 164, 165, 657, 658, ")" +316, 6, 33, 137, 166, 170, 659, 663, "with" +316, 6, 34, 138, 171, 181, 664, 674, "inadequate" +316, 6, 35, 139, 182, 190, 675, 683, "glycemic" +316, 6, 36, 140, 191, 198, 684, 691, "control" +316, 6, 37, 141, 199, 201, 692, 694, "on" +316, 6, 38, 142, 202, 209, 695, 702, "insulin" +316, 6, 39, 143, 210, 215, 703, 708, "alone" +316, 6, 40, 144, 216, 218, 709, 711, "or" +316, 6, 41, 145, 219, 227, 712, 720, "combined" +316, 6, 42, 146, 228, 232, 721, 725, "with" +316, 6, 43, 147, 233, 242, 726, 735, "metformin" +316, 6, 44, 148, 243, 244, 736, 737, "." +316, 7, 1, 149, 0, 7, 738, 745, "METHODS" +316, 7, 2, 150, 8, 9, 746, 747, ":" +316, 7, 3, 151, 10, 16, 748, 754, "Adults" +316, 7, 4, 152, 17, 18, 755, 756, "(" +316, 7, 5, 153, 19, 20, 757, 758, "n" +316, 7, 6, 154, 21, 24, 759, 762, " = " +316, 7, 7, 155, 25, 28, 763, 766, "455" +316, 7, 8, 156, 29, 30, 767, 768, ")" +316, 7, 9, 157, 31, 35, 769, 773, "with" +316, 7, 10, 158, 36, 39, 774, 777, "HbA" +316, 7, 11, 159, 40, 41, 778, 779, "(" +316, 7, 12, 160, 42, 44, 780, 782, "1c" +316, 7, 13, 161, 45, 46, 783, 784, ")" +316, 7, 14, 162, 47, 48, 785, 786, "7" +316, 7, 15, 163, 49, 50, 787, 788, "." +316, 7, 16, 164, 51, 52, 789, 790, "5" +316, 7, 17, 165, 53, 54, 791, 792, "-" +316, 7, 18, 166, 55, 57, 793, 795, "11" +316, 7, 19, 167, 58, 59, 796, 797, "%" +316, 7, 20, 168, 60, 62, 798, 800, "on" +316, 7, 21, 169, 63, 69, 801, 807, "stable" +316, 7, 22, 170, 70, 77, 808, 815, "insulin" +316, 7, 23, 171, 78, 85, 816, 823, "therapy" +316, 7, 24, 172, 86, 87, 824, 825, "(" +316, 7, 25, 173, 88, 90, 826, 828, "30" +316, 7, 26, 174, 91, 92, 829, 830, "-" +316, 7, 27, 175, 93, 96, 831, 834, "150" +316, 7, 28, 176, 97, 98, 835, 836, " " +316, 7, 29, 177, 99, 100, 837, 838, "U" +316, 7, 30, 178, 101, 102, 839, 840, "/" +316, 7, 31, 179, 103, 106, 841, 844, "day" +316, 7, 32, 180, 107, 110, 845, 848, " ± " +316, 7, 33, 181, 111, 120, 849, 858, "metformin" +316, 7, 34, 182, 121, 122, 859, 860, ")" +316, 7, 35, 183, 123, 126, 861, 864, "for" +316, 7, 36, 184, 127, 129, 865, 867, "at" +316, 7, 37, 185, 130, 135, 868, 873, "least" +316, 7, 38, 186, 136, 137, 874, 875, "8" +316, 7, 39, 187, 138, 143, 876, 881, "weeks" +316, 7, 40, 188, 144, 148, 882, 886, "were" +316, 7, 41, 189, 149, 159, 887, 897, "stratified" +316, 7, 42, 190, 160, 162, 898, 900, "by" +316, 7, 43, 191, 163, 172, 901, 910, "metformin" +316, 7, 44, 192, 173, 176, 911, 914, "use" +316, 7, 45, 193, 177, 180, 915, 918, "and" +316, 7, 46, 194, 181, 189, 919, 927, "randomly" +316, 7, 47, 195, 190, 198, 928, 936, "assigned" +316, 7, 48, 196, 199, 200, 937, 938, "2" +316, 7, 49, 197, 201, 202, 939, 940, ":" +316, 7, 50, 198, 203, 204, 941, 942, "1" +316, 7, 51, 199, 205, 207, 943, 945, "to" +316, 7, 52, 200, 208, 215, 946, 953, "receive" +316, 7, 53, 201, 216, 227, 954, 965, "saxagliptin" +316, 7, 54, 202, 228, 229, 966, 967, "5" +316, 7, 55, 203, 230, 231, 968, 969, " " +316, 7, 56, 204, 232, 234, 970, 972, "mg" +316, 7, 57, 205, 235, 237, 973, 975, "or" +316, 7, 58, 206, 238, 245, 976, 983, "placebo" +316, 7, 59, 207, 246, 250, 984, 988, "once" +316, 7, 60, 208, 251, 256, 989, 994, "daily" +316, 7, 61, 209, 257, 260, 995, 998, "for" +316, 7, 62, 210, 261, 263, 999, 1001, "24" +316, 7, 63, 211, 264, 269, 1002, 1007, "weeks" +316, 7, 64, 212, 270, 271, 1008, 1009, "." +316, 8, 1, 213, 0, 8, 1010, 1018, "Patients" +316, 8, 2, 214, 9, 13, 1019, 1023, "were" +316, 8, 3, 215, 14, 16, 1024, 1026, "to" +316, 8, 4, 216, 17, 25, 1027, 1035, "maintain" +316, 8, 5, 217, 26, 32, 1036, 1042, "stable" +316, 8, 6, 218, 33, 40, 1043, 1050, "insulin" +316, 8, 7, 219, 41, 46, 1051, 1056, "doses" +316, 8, 8, 220, 47, 50, 1057, 1060, "but" +316, 8, 9, 221, 51, 56, 1061, 1066, "these" +316, 8, 10, 222, 57, 62, 1067, 1072, "could" +316, 8, 11, 223, 63, 65, 1073, 1075, "be" +316, 8, 12, 224, 66, 75, 1076, 1085, "decreased" +316, 8, 13, 225, 76, 78, 1086, 1088, "to" +316, 8, 14, 226, 79, 85, 1089, 1095, "reduce" +316, 8, 15, 227, 86, 90, 1096, 1100, "risk" +316, 8, 16, 228, 91, 93, 1101, 1103, "of" +316, 8, 17, 229, 94, 106, 1104, 1116, "hypoglycemia" +316, 8, 18, 230, 107, 108, 1117, 1118, "." +316, 9, 1, 231, 0, 8, 1119, 1127, "Patients" +316, 9, 2, 232, 9, 13, 1128, 1132, "with" +316, 9, 3, 233, 14, 27, 1133, 1146, "hyperglycemia" +316, 9, 4, 234, 28, 30, 1147, 1149, "or" +316, 9, 5, 235, 31, 44, 1150, 1163, "substantially" +316, 9, 6, 236, 45, 54, 1164, 1173, "increased" +316, 9, 7, 237, 55, 62, 1174, 1181, "insulin" +316, 9, 8, 238, 63, 66, 1182, 1185, "use" +316, 9, 9, 239, 67, 71, 1186, 1190, "were" +316, 9, 10, 240, 72, 79, 1191, 1198, "rescued" +316, 9, 11, 241, 80, 84, 1199, 1203, "with" +316, 9, 12, 242, 85, 86, 1204, 1205, "a" +316, 9, 13, 243, 87, 95, 1206, 1214, "flexible" +316, 9, 14, 244, 96, 103, 1215, 1222, "insulin" +316, 9, 15, 245, 104, 111, 1223, 1230, "regimen" +316, 9, 16, 246, 112, 115, 1231, 1234, "and" +316, 9, 17, 247, 116, 124, 1235, 1243, "remained" +316, 9, 18, 248, 125, 127, 1244, 1246, "in" +316, 9, 19, 249, 128, 131, 1247, 1250, "the" +316, 9, 20, 250, 132, 137, 1251, 1256, "study" +316, 9, 21, 251, 138, 139, 1257, 1258, "." +316, 10, 1, 252, 0, 9, 1259, 1268, "Metformin" +316, 10, 2, 253, 10, 15, 1269, 1274, "doses" +316, 10, 3, 254, 16, 20, 1275, 1279, "were" +316, 10, 4, 255, 21, 25, 1280, 1284, "kept" +316, 10, 5, 256, 26, 32, 1285, 1291, "stable" +316, 10, 6, 257, 33, 34, 1292, 1293, "." +316, 11, 1, 258, 0, 3, 1294, 1297, "The" +316, 11, 2, 259, 4, 11, 1298, 1305, "primary" +316, 11, 3, 260, 12, 20, 1306, 1314, "efficacy" +316, 11, 4, 261, 21, 29, 1315, 1323, "endpoint" +316, 11, 5, 262, 30, 33, 1324, 1327, "was" +316, 11, 6, 263, 34, 40, 1328, 1334, "change" +316, 11, 7, 264, 41, 43, 1335, 1337, "in" +316, 11, 8, 265, 44, 47, 1338, 1341, "HbA" +316, 11, 9, 266, 48, 49, 1342, 1343, "(" +316, 11, 10, 267, 50, 52, 1344, 1346, "1c" +316, 11, 11, 268, 53, 54, 1347, 1348, ")" +316, 11, 12, 269, 55, 59, 1349, 1353, "from" +316, 11, 13, 270, 60, 68, 1354, 1362, "baseline" +316, 11, 14, 271, 69, 71, 1363, 1365, "to" +316, 11, 15, 272, 72, 76, 1366, 1370, "week" +316, 11, 16, 273, 77, 79, 1371, 1373, "24" +316, 11, 17, 274, 80, 81, 1374, 1375, "(" +316, 11, 18, 275, 82, 84, 1376, 1378, "or" +316, 11, 19, 276, 85, 91, 1379, 1385, "rescue" +316, 11, 20, 277, 92, 93, 1386, 1387, ")" +316, 11, 21, 278, 94, 95, 1388, 1389, "." +316, 12, 1, 279, 0, 7, 1390, 1397, "RESULTS" +316, 12, 2, 280, 8, 9, 1398, 1399, ":" +316, 12, 3, 281, 10, 18, 1400, 1408, "Patients" +316, 12, 4, 282, 19, 26, 1409, 1416, "treated" +316, 12, 5, 283, 27, 31, 1417, 1421, "with" +316, 12, 6, 284, 32, 43, 1422, 1433, "saxagliptin" +316, 12, 7, 285, 44, 50, 1434, 1440, "versus" +316, 12, 8, 286, 51, 58, 1441, 1448, "placebo" +316, 12, 9, 287, 59, 62, 1449, 1452, "had" +316, 12, 10, 288, 63, 76, 1453, 1466, "significantly" +316, 12, 11, 289, 77, 84, 1467, 1474, "greater" +316, 12, 12, 290, 85, 95, 1475, 1485, "reductions" +316, 12, 13, 291, 96, 98, 1486, 1488, "in" +316, 12, 14, 292, 99, 107, 1489, 1497, "adjusted" +316, 12, 15, 293, 108, 112, 1498, 1502, "mean" +316, 12, 16, 294, 113, 116, 1503, 1506, "HbA" +316, 12, 17, 295, 117, 118, 1507, 1508, "(" +316, 12, 18, 296, 119, 121, 1509, 1511, "1c" +316, 12, 19, 297, 122, 123, 1512, 1513, ")" +316, 12, 20, 298, 124, 125, 1514, 1515, "(" +316, 12, 21, 299, 126, 136, 1516, 1526, "difference" +316, 12, 22, 300, 137, 138, 1527, 1528, ":" +316, 12, 23, 301, 139, 140, 1529, 1530, "-" +316, 12, 24, 302, 141, 142, 1531, 1532, "0" +316, 12, 25, 303, 143, 144, 1533, 1534, "." +316, 12, 26, 304, 145, 147, 1535, 1537, "41" +316, 12, 27, 305, 148, 149, 1538, 1539, "%" +316, 12, 28, 306, 150, 151, 1540, 1541, "," +316, 12, 29, 307, 152, 153, 1542, 1543, "p" +316, 12, 30, 308, 154, 157, 1544, 1547, " < " +316, 12, 31, 309, 158, 159, 1548, 1549, "0" +316, 12, 32, 310, 160, 161, 1550, 1551, "." +316, 12, 33, 311, 162, 166, 1552, 1556, "0001" +316, 12, 34, 312, 167, 168, 1557, 1558, ")" +316, 12, 35, 313, 169, 170, 1559, 1560, "," +316, 12, 36, 314, 171, 183, 1561, 1573, "postprandial" +316, 12, 37, 315, 184, 191, 1574, 1581, "glucose" +316, 12, 38, 316, 192, 193, 1582, 1583, "(" +316, 12, 39, 317, 194, 197, 1584, 1587, "PPG" +316, 12, 40, 318, 198, 199, 1588, 1589, ")" +316, 12, 41, 319, 200, 203, 1590, 1593, "180" +316, 12, 42, 320, 204, 205, 1594, 1595, "-" +316, 12, 43, 321, 206, 212, 1596, 1602, "minute" +316, 12, 44, 322, 213, 217, 1603, 1607, "area" +316, 12, 45, 323, 218, 223, 1608, 1613, "under" +316, 12, 46, 324, 224, 227, 1614, 1617, "the" +316, 12, 47, 325, 228, 233, 1618, 1623, "curve" +316, 12, 48, 326, 234, 235, 1624, 1625, "(" +316, 12, 49, 327, 236, 237, 1626, 1627, "-" +316, 12, 50, 328, 238, 242, 1628, 1632, "3829" +316, 12, 51, 329, 243, 244, 1633, 1634, "." +316, 12, 52, 330, 245, 246, 1635, 1636, "8" +316, 12, 53, 331, 247, 248, 1637, 1638, " " +316, 12, 54, 332, 249, 251, 1639, 1641, "mg" +316, 12, 55, 333, 252, 253, 1642, 1643, "·" +316, 12, 56, 334, 254, 257, 1644, 1647, "min" +316, 12, 57, 335, 258, 259, 1648, 1649, "/" +316, 12, 58, 336, 260, 262, 1650, 1652, "dL" +316, 12, 59, 337, 263, 264, 1653, 1654, "," +316, 12, 60, 338, 265, 266, 1655, 1656, "p" +316, 12, 61, 339, 267, 270, 1657, 1660, " = " +316, 12, 62, 340, 271, 272, 1661, 1662, "0" +316, 12, 63, 341, 273, 274, 1663, 1664, "." +316, 12, 64, 342, 275, 279, 1665, 1669, "0011" +316, 12, 65, 343, 280, 281, 1670, 1671, ")" +316, 12, 66, 344, 282, 283, 1672, 1673, "," +316, 12, 67, 345, 284, 287, 1674, 1677, "and" +316, 12, 68, 346, 288, 291, 1678, 1681, "120" +316, 12, 69, 347, 292, 293, 1682, 1683, "-" +316, 12, 70, 348, 294, 300, 1684, 1690, "minute" +316, 12, 71, 349, 301, 304, 1691, 1694, "PPG" +316, 12, 72, 350, 305, 306, 1695, 1696, "(" +316, 12, 73, 351, 307, 308, 1697, 1698, "-" +316, 12, 74, 352, 309, 311, 1699, 1701, "23" +316, 12, 75, 353, 312, 313, 1702, 1703, "." +316, 12, 76, 354, 314, 315, 1704, 1705, "0" +316, 12, 77, 355, 316, 317, 1706, 1707, " " +316, 12, 78, 356, 318, 320, 1708, 1710, "mg" +316, 12, 79, 357, 321, 322, 1711, 1712, "/" +316, 12, 80, 358, 323, 325, 1713, 1715, "dL" +316, 12, 81, 359, 326, 327, 1716, 1717, "," +316, 12, 82, 360, 328, 329, 1718, 1719, "p" +316, 12, 83, 361, 330, 333, 1720, 1723, " = " +316, 12, 84, 362, 334, 335, 1724, 1725, "0" +316, 12, 85, 363, 336, 337, 1726, 1727, "." +316, 12, 86, 364, 338, 342, 1728, 1732, "0016" +316, 12, 87, 365, 343, 344, 1733, 1734, ")" +316, 12, 88, 366, 345, 347, 1735, 1737, "at" +316, 12, 89, 367, 348, 350, 1738, 1740, "24" +316, 12, 90, 368, 351, 356, 1741, 1746, "weeks" +316, 12, 91, 369, 357, 358, 1747, 1748, "." +316, 13, 1, 370, 0, 9, 1749, 1758, "Treatment" +316, 13, 2, 371, 10, 14, 1759, 1763, "with" +316, 13, 3, 372, 15, 26, 1764, 1775, "saxagliptin" +316, 13, 4, 373, 27, 35, 1776, 1784, "resulted" +316, 13, 5, 374, 36, 38, 1785, 1787, "in" +316, 13, 6, 375, 39, 46, 1788, 1795, "similar" +316, 13, 7, 376, 47, 57, 1796, 1806, "reductions" +316, 13, 8, 377, 58, 60, 1807, 1809, "in" +316, 13, 9, 378, 61, 64, 1810, 1813, "HBA" +316, 13, 10, 379, 65, 66, 1814, 1815, "(" +316, 13, 11, 380, 67, 69, 1816, 1818, "1c" +316, 13, 12, 381, 70, 71, 1819, 1820, ")" +316, 13, 13, 382, 72, 80, 1821, 1829, "relative" +316, 13, 14, 383, 81, 83, 1830, 1832, "to" +316, 13, 15, 384, 84, 91, 1833, 1840, "placebo" +316, 13, 16, 385, 92, 93, 1841, 1842, "," +316, 13, 17, 386, 94, 106, 1843, 1855, "irrespective" +316, 13, 18, 387, 107, 109, 1856, 1858, "of" +316, 13, 19, 388, 110, 119, 1859, 1868, "metformin" +316, 13, 20, 389, 120, 129, 1869, 1878, "treatment" +316, 13, 21, 390, 130, 131, 1879, 1880, "." +316, 14, 1, 391, 0, 2, 1881, 1883, "At" +316, 14, 2, 392, 3, 5, 1884, 1886, "24" +316, 14, 3, 393, 6, 11, 1887, 1892, "weeks" +316, 14, 4, 394, 12, 13, 1893, 1894, "," +316, 14, 5, 395, 14, 24, 1895, 1905, "difference" +316, 14, 6, 396, 25, 27, 1906, 1908, "in" +316, 14, 7, 397, 28, 36, 1909, 1917, "adjusted" +316, 14, 8, 398, 37, 41, 1918, 1922, "mean" +316, 14, 9, 399, 42, 49, 1923, 1930, "fasting" +316, 14, 10, 400, 50, 56, 1931, 1937, "plasma" +316, 14, 11, 401, 57, 64, 1938, 1945, "glucose" +316, 14, 12, 402, 65, 68, 1946, 1949, "for" +316, 14, 13, 403, 69, 80, 1950, 1961, "saxagliptin" +316, 14, 14, 404, 81, 87, 1962, 1968, "versus" +316, 14, 15, 405, 88, 95, 1969, 1976, "placebo" +316, 14, 16, 406, 96, 99, 1977, 1980, "was" +316, 14, 17, 407, 100, 101, 1981, 1982, "-" +316, 14, 18, 408, 102, 103, 1983, 1984, "4" +316, 14, 19, 409, 104, 105, 1985, 1986, "." +316, 14, 20, 410, 106, 108, 1987, 1989, "02" +316, 14, 21, 411, 109, 110, 1990, 1991, " " +316, 14, 22, 412, 111, 113, 1992, 1994, "mg" +316, 14, 23, 413, 114, 115, 1995, 1996, "/" +316, 14, 24, 414, 116, 118, 1997, 1999, "dL" +316, 14, 25, 415, 119, 120, 2000, 2001, "(" +316, 14, 26, 416, 121, 122, 2002, 2003, "p" +316, 14, 27, 417, 123, 126, 2004, 2007, " = " +316, 14, 28, 418, 127, 128, 2008, 2009, "0" +316, 14, 29, 419, 129, 130, 2010, 2011, "." +316, 14, 30, 420, 131, 135, 2012, 2016, "3958" +316, 14, 31, 421, 136, 137, 2017, 2018, ")" +316, 14, 32, 422, 138, 139, 2019, 2020, ";" +316, 14, 33, 423, 140, 142, 2021, 2023, "17" +316, 14, 34, 424, 143, 144, 2024, 2025, "." +316, 14, 35, 425, 145, 146, 2026, 2027, "3" +316, 14, 36, 426, 147, 148, 2028, 2029, "%" +316, 14, 37, 427, 149, 152, 2030, 2033, "and" +316, 14, 38, 428, 153, 154, 2034, 2035, "6" +316, 14, 39, 429, 155, 156, 2036, 2037, "." +316, 14, 40, 430, 157, 158, 2038, 2039, "7" +316, 14, 41, 431, 159, 160, 2040, 2041, "%" +316, 14, 42, 432, 161, 163, 2042, 2044, "of" +316, 14, 43, 433, 164, 172, 2045, 2053, "patients" +316, 14, 44, 434, 173, 175, 2054, 2056, "in" +316, 14, 45, 435, 176, 179, 2057, 2060, "the" +316, 14, 46, 436, 180, 191, 2061, 2072, "saxagliptin" +316, 14, 47, 437, 192, 195, 2073, 2076, "and" +316, 14, 48, 438, 196, 203, 2077, 2084, "placebo" +316, 14, 49, 439, 204, 210, 2085, 2091, "groups" +316, 14, 50, 440, 211, 212, 2092, 2093, "," +316, 14, 51, 441, 213, 225, 2094, 2106, "respectively" +316, 14, 52, 442, 226, 227, 2107, 2108, "," +316, 14, 53, 443, 228, 236, 2109, 2117, "achieved" +316, 14, 54, 444, 237, 240, 2118, 2121, "HbA" +316, 14, 55, 445, 241, 242, 2122, 2123, "(" +316, 14, 56, 446, 243, 245, 2124, 2126, "1c" +316, 14, 57, 447, 246, 247, 2127, 2128, ")" +316, 14, 58, 448, 248, 251, 2129, 2132, " < " +316, 14, 59, 449, 252, 253, 2133, 2134, "7" +316, 14, 60, 450, 254, 255, 2135, 2136, "%" +316, 14, 61, 451, 256, 257, 2137, 2138, "." +316, 15, 1, 452, 0, 4, 2139, 2143, "Mean" +316, 15, 2, 453, 5, 11, 2144, 2150, "change" +316, 15, 3, 454, 12, 16, 2151, 2155, "from" +316, 15, 4, 455, 17, 25, 2156, 2164, "baseline" +316, 15, 5, 456, 26, 28, 2165, 2167, "in" +316, 15, 6, 457, 29, 33, 2168, 2172, "body" +316, 15, 7, 458, 34, 40, 2173, 2179, "weight" +316, 15, 8, 459, 41, 43, 2180, 2182, "at" +316, 15, 9, 460, 44, 48, 2183, 2187, "week" +316, 15, 10, 461, 49, 51, 2188, 2190, "24" +316, 15, 11, 462, 52, 55, 2191, 2194, "was" +316, 15, 12, 463, 56, 57, 2195, 2196, "0" +316, 15, 13, 464, 58, 59, 2197, 2198, "." +316, 15, 14, 465, 60, 62, 2199, 2201, "39" +316, 15, 15, 466, 63, 64, 2202, 2203, " " +316, 15, 16, 467, 65, 67, 2204, 2206, "kg" +316, 15, 17, 468, 68, 71, 2207, 2210, "for" +316, 15, 18, 469, 72, 83, 2211, 2222, "saxagliptin" +316, 15, 19, 470, 84, 87, 2223, 2226, "and" +316, 15, 20, 471, 88, 89, 2227, 2228, "0" +316, 15, 21, 472, 90, 91, 2229, 2230, "." +316, 15, 22, 473, 92, 94, 2231, 2233, "18" +316, 15, 23, 474, 95, 96, 2234, 2235, " " +316, 15, 24, 475, 97, 99, 2236, 2238, "kg" +316, 15, 25, 476, 100, 103, 2239, 2242, "for" +316, 15, 26, 477, 104, 111, 2243, 2250, "placebo" +316, 15, 27, 478, 112, 113, 2251, 2252, "." +316, 16, 1, 479, 0, 12, 2253, 2265, "Hypoglycemia" +316, 16, 2, 480, 13, 16, 2266, 2269, "was" +316, 16, 3, 481, 17, 25, 2270, 2278, "reported" +316, 16, 4, 482, 26, 28, 2279, 2281, "in" +316, 16, 5, 483, 29, 31, 2282, 2284, "18" +316, 16, 6, 484, 32, 33, 2285, 2286, "." +316, 16, 7, 485, 34, 35, 2287, 2288, "4" +316, 16, 8, 486, 36, 37, 2289, 2290, "%" +316, 16, 9, 487, 38, 41, 2291, 2294, "and" +316, 16, 10, 488, 42, 44, 2295, 2297, "19" +316, 16, 11, 489, 45, 46, 2298, 2299, "." +316, 16, 12, 490, 47, 48, 2300, 2301, "9" +316, 16, 13, 491, 49, 50, 2302, 2303, "%" +316, 16, 14, 492, 51, 53, 2304, 2306, "of" +316, 16, 15, 493, 54, 62, 2307, 2315, "patients" +316, 16, 16, 494, 63, 65, 2316, 2318, "in" +316, 16, 17, 495, 66, 69, 2319, 2322, "the" +316, 16, 18, 496, 70, 81, 2323, 2334, "saxagliptin" +316, 16, 19, 497, 82, 85, 2335, 2338, "and" +316, 16, 20, 498, 86, 93, 2339, 2346, "placebo" +316, 16, 21, 499, 94, 100, 2347, 2353, "groups" +316, 16, 22, 500, 101, 102, 2354, 2355, "," +316, 16, 23, 501, 103, 115, 2356, 2368, "respectively" +316, 16, 24, 502, 116, 117, 2369, 2370, "(" +316, 16, 25, 503, 118, 127, 2371, 2380, "confirmed" +316, 16, 26, 504, 128, 140, 2381, 2393, "hypoglycemia" +316, 16, 27, 505, 141, 142, 2394, 2395, ":" +316, 16, 28, 506, 143, 144, 2396, 2397, "5" +316, 16, 29, 507, 145, 146, 2398, 2399, "." +316, 16, 30, 508, 147, 148, 2400, 2401, "3" +316, 16, 31, 509, 149, 150, 2402, 2403, "%" +316, 16, 32, 510, 151, 152, 2404, 2405, "," +316, 16, 33, 511, 153, 154, 2406, 2407, "3" +316, 16, 34, 512, 155, 156, 2408, 2409, "." +316, 16, 35, 513, 157, 158, 2410, 2411, "3" +316, 16, 36, 514, 159, 160, 2412, 2413, "%" +316, 16, 37, 515, 161, 162, 2414, 2415, ")" +316, 16, 38, 516, 163, 164, 2416, 2417, "." +316, 17, 1, 517, 0, 5, 2418, 2423, "Other" +316, 17, 2, 518, 6, 13, 2424, 2431, "adverse" +316, 17, 3, 519, 14, 20, 2432, 2438, "events" +316, 17, 4, 520, 21, 29, 2439, 2447, "reported" +316, 17, 5, 521, 30, 32, 2448, 2450, "in" +316, 17, 6, 522, 33, 35, 2451, 2453, "at" +316, 17, 7, 523, 36, 41, 2454, 2459, "least" +316, 17, 8, 524, 42, 43, 2460, 2461, "5" +316, 17, 9, 525, 44, 45, 2462, 2463, "%" +316, 17, 10, 526, 46, 48, 2464, 2466, "of" +316, 17, 11, 527, 49, 57, 2467, 2475, "patients" +316, 17, 12, 528, 58, 62, 2476, 2480, "were" +316, 17, 13, 529, 63, 70, 2481, 2488, "urinary" +316, 17, 14, 530, 71, 76, 2489, 2494, "tract" +316, 17, 15, 531, 77, 86, 2495, 2504, "infection" +316, 17, 16, 532, 87, 88, 2505, 2506, "(" +316, 17, 17, 533, 89, 100, 2507, 2518, "saxagliptin" +316, 17, 18, 534, 101, 102, 2519, 2520, "," +316, 17, 19, 535, 103, 110, 2521, 2528, "placebo" +316, 17, 20, 536, 111, 112, 2529, 2530, ":" +316, 17, 21, 537, 113, 114, 2531, 2532, "5" +316, 17, 22, 538, 115, 116, 2533, 2534, "." +316, 17, 23, 539, 117, 118, 2535, 2536, "9" +316, 17, 24, 540, 119, 120, 2537, 2538, "%" +316, 17, 25, 541, 121, 122, 2539, 2540, "," +316, 17, 26, 542, 123, 124, 2541, 2542, "6" +316, 17, 27, 543, 125, 126, 2543, 2544, "." +316, 17, 28, 544, 127, 128, 2545, 2546, "0" +316, 17, 29, 545, 129, 130, 2547, 2548, "%" +316, 17, 30, 546, 131, 132, 2549, 2550, ")" +316, 17, 31, 547, 133, 134, 2551, 2552, "," +316, 17, 32, 548, 135, 144, 2553, 2562, "influenza" +316, 17, 33, 549, 145, 146, 2563, 2564, "(" +316, 17, 34, 550, 147, 148, 2565, 2566, "3" +316, 17, 35, 551, 149, 150, 2567, 2568, "." +316, 17, 36, 552, 151, 152, 2569, 2570, "0" +316, 17, 37, 553, 153, 154, 2571, 2572, "%" +316, 17, 38, 554, 155, 156, 2573, 2574, "," +316, 17, 39, 555, 157, 158, 2575, 2576, "6" +316, 17, 40, 556, 159, 160, 2577, 2578, "." +316, 17, 41, 557, 161, 162, 2579, 2580, "6" +316, 17, 42, 558, 163, 164, 2581, 2582, "%" +316, 17, 43, 559, 165, 166, 2583, 2584, ")" +316, 17, 44, 560, 167, 168, 2585, 2586, "," +316, 17, 45, 561, 169, 172, 2587, 2590, "and" +316, 17, 46, 562, 173, 177, 2591, 2595, "pain" +316, 17, 47, 563, 178, 180, 2596, 2598, "in" +316, 17, 48, 564, 181, 190, 2599, 2608, "extremity" +316, 17, 49, 565, 191, 192, 2609, 2610, "(" +316, 17, 50, 566, 193, 194, 2611, 2612, "1" +316, 17, 51, 567, 195, 196, 2613, 2614, "." +316, 17, 52, 568, 197, 198, 2615, 2616, "6" +316, 17, 53, 569, 199, 200, 2617, 2618, "%" +316, 17, 54, 570, 201, 202, 2619, 2620, "," +316, 17, 55, 571, 203, 204, 2621, 2622, "6" +316, 17, 56, 572, 205, 206, 2623, 2624, "." +316, 17, 57, 573, 207, 208, 2625, 2626, "0" +316, 17, 58, 574, 209, 210, 2627, 2628, "%" +316, 17, 59, 575, 211, 212, 2629, 2630, ")" +316, 17, 60, 576, 213, 214, 2631, 2632, "." +316, 18, 1, 577, 0, 11, 2633, 2644, "CONCLUSIONS" +316, 18, 2, 578, 12, 13, 2645, 2646, ":" +316, 18, 3, 579, 14, 25, 2647, 2658, "Saxagliptin" +316, 18, 4, 580, 26, 27, 2659, 2660, "5" +316, 18, 5, 581, 28, 29, 2661, 2662, "-" +316, 18, 6, 582, 30, 32, 2663, 2665, "mg" +316, 18, 7, 583, 33, 37, 2666, 2670, "once" +316, 18, 8, 584, 38, 39, 2671, 2672, "-" +316, 18, 9, 585, 40, 45, 2673, 2678, "daily" +316, 18, 10, 586, 46, 49, 2679, 2682, "add" +316, 18, 11, 587, 50, 51, 2683, 2684, "-" +316, 18, 12, 588, 52, 54, 2685, 2687, "on" +316, 18, 13, 589, 55, 62, 2688, 2695, "therapy" +316, 18, 14, 590, 63, 71, 2696, 2704, "improves" +316, 18, 15, 591, 72, 80, 2705, 2713, "glycemic" +316, 18, 16, 592, 81, 88, 2714, 2721, "control" +316, 18, 17, 593, 89, 91, 2722, 2724, "in" +316, 18, 18, 594, 92, 95, 2725, 2728, "T2D" +316, 18, 19, 595, 96, 104, 2729, 2737, "patients" +316, 18, 20, 596, 105, 107, 2738, 2740, "on" +316, 18, 21, 597, 108, 115, 2741, 2748, "insulin" +316, 18, 22, 598, 116, 121, 2749, 2754, "alone" +316, 18, 23, 599, 122, 124, 2755, 2757, "or" +316, 18, 24, 600, 125, 133, 2758, 2766, "combined" +316, 18, 25, 601, 134, 138, 2767, 2771, "with" +316, 18, 26, 602, 139, 148, 2772, 2781, "metformin" +316, 18, 27, 603, 149, 152, 2782, 2785, "and" +316, 18, 28, 604, 153, 155, 2786, 2788, "is" +316, 18, 29, 605, 156, 165, 2789, 2798, "generally" +316, 18, 30, 606, 166, 170, 2799, 2803, "well" +316, 18, 31, 607, 171, 172, 2804, 2805, "-" +316, 18, 32, 608, 173, 182, 2806, 2815, "tolerated" +316, 18, 33, 609, 183, 184, 2816, 2817, "." +316, 19, 1, 610, 0, 11, 2818, 2829, "NCT00757588" +316, 19, 2, 611, 12, 13, 2830, 2831, "." +316, 20, 1, 612, 0, 3, 2832, 2835, "DOI" +316, 20, 2, 613, 4, 5, 2836, 2837, ":" +316, 20, 3, 614, 6, 8, 2838, 2840, "10" +316, 20, 4, 615, 9, 10, 2841, 2842, "." +316, 20, 5, 616, 11, 15, 2843, 2847, "1185" +316, 20, 6, 617, 16, 17, 2848, 2849, "/" +316, 20, 7, 618, 18, 26, 2850, 2858, "03007995" +316, 20, 8, 619, 27, 28, 2859, 2860, "." +316, 20, 9, 620, 29, 33, 2861, 2865, "2012" +316, 20, 10, 621, 34, 35, 2866, 2867, "." +316, 20, 11, 622, 36, 42, 2868, 2874, "665046" +316, 20, 12, 623, 43, 47, 2875, 2879, "PMID" +316, 20, 13, 624, 48, 49, 2880, 2881, ":" +316, 20, 14, 625, 50, 58, 2882, 2890, "22313154" +316, 20, 15, 626, 59, 60, 2891, 2892, "[" +316, 20, 16, 627, 61, 68, 2893, 2900, "Indexed" +316, 20, 17, 628, 69, 72, 2901, 2904, "for" +316, 20, 18, 629, 73, 80, 2905, 2912, "MEDLINE" +316, 20, 19, 630, 81, 82, 2913, 2914, "]" diff --git a/data/dm2 22313154_kwoodley.annodb b/data/dm2 22313154_kwoodley.annodb new file mode 100644 index 0000000..1aa094d --- /dev/null +++ b/data/dm2 22313154_kwoodley.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +21445, Journal, 0, 19, "Curr Med Res Opin .", "", +21446, PublicationYear, 20, 24, "2012", "", +21453, Title, 116, 262, "Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin .", "", +21447, Saxagliptin, 126, 137, "saxagliptin", "", +21452, Precondition, 161, 260, "patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin", "", +21448, Type2Diabetes, 193, 208, "type 2 diabetes", "", +21449, Insulin, 212, 219, "insulin", "", +21450, Insulin, 229, 236, "insulin", "", +21451, Metformin, 251, 260, "metformin", "", +21454, Author, 263, 273, "Barnett AH", "", +21455, Author, 282, 294, "Charbonnel B", "", +21456, Author, 297, 306, "Donovan M", "", +21457, Author, 309, 318, "Fleming D", "", +21458, Author, 321, 327, "Chen R", "", +21459, UK, 488, 490, "UK", "", +21466, ObjectiveDescription, 551, 737, "To evaluate efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin .", "", +21460, Saxagliptin, 586, 597, "saxagliptin", "", +21465, Precondition, 621, 735, "patients with type 2 diabetes ( T2D ) with inadequate glycemic control on insulin alone or combined with metformin", "", +21461, Type2Diabetes, 635, 650, "type 2 diabetes", "", +21462, Type2Diabetes, 653, 656, "T2D", "", +21463, Insulin, 695, 702, "insulin", "", +21464, Metformin, 726, 735, "metformin", "", +21483, Precondition, 748, 881, "Adults ( n  =  455 ) with HbA ( 1c ) 7 . 5 - 11 % on stable insulin therapy ( 30 - 150   U / day  ±  metformin ) for at least 8 weeks", "", +21467, NumberPatientsCT, 763, 766, "455", "", +21468, HbA1c, 774, 784, "HbA ( 1c )", "", +21469, Percentage, 796, 797, "%", "", +21470, Insulin, 808, 815, "insulin", "", +21473, DoseValue, 826, 834, "30 - 150", "", +21471, BioAndMedicalUnit, 837, 844, "U / day", "", +21472, Metformin, 849, 858, "metformin", "", +21474, Metformin, 901, 910, "metformin", "", +21475, Randomized, 919, 927, "randomly", "", +21476, AllocationRatio, 937, 942, "2 : 1", "", +21477, Saxagliptin, 954, 965, "saxagliptin", "", +21478, DoseValue, 966, 967, "5", "", +21479, mg, 970, 972, "mg", "", +21480, Placebo, 976, 983, "placebo", "", +21481, Frequency, 984, 994, "once daily", "", +21482, Duration, 999, 1007, "24 weeks", "", +21484, Insulin, 1043, 1050, "insulin", "", +21485, Hypoglycemia, 1104, 1116, "hypoglycemia", "", +21486, Hypoglycemia, 1133, 1146, "hyperglycemia", "", +33173, InsulinDose, 1174, 1185, "insulin use", "", +21489, Insulin, 1206, 1230, "flexible insulin regimen", "", +21491, Metformin, 1259, 1268, "Metformin", "", +21492, HbA1c, 1338, 1348, "HbA ( 1c )", "", +21493, Duration, 1366, 1373, "week 24", "", +21494, Saxagliptin, 1422, 1433, "saxagliptin", "", +21501, Placebo, 1441, 1448, "placebo", "", +21506, HbA1c, 1503, 1513, "HbA ( 1c )", "", +21508, DiffGroupAbsValue, 1529, 1537, "- 0 . 41", "", +21509, Percentage, 1538, 1539, "%", "", +21510, PvalueDiff, 1542, 1556, "p  <  0 . 0001", "", +33174, PostprandialBloodGlucose, 1561, 1581, "postprandial glucose", "", +33175, PostprandialBloodGlucose, 1584, 1587, "PPG", "", +21514, TimePoint, 1590, 1623, "180 - minute area under the curve", "", +21516, DiffGroupAbsValue, 1626, 1636, "- 3829 . 8", "", +21518, BioAndMedicalUnit, 1639, 1652, "mg · min / dL", "", +21520, PvalueDiff, 1655, 1669, "p  =  0 . 0011", "", +21515, TimePoint, 1674, 1690, "and 120 - minute", "", +33176, PostprandialBloodGlucose, 1691, 1694, "PPG", "", +21517, DiffGroupAbsValue, 1697, 1705, "- 23 . 0", "", +21519, Mg_per_deciliter, 1708, 1715, "mg / dL", "", +21521, PvalueDiff, 1718, 1732, "p  =  0 . 0016", "", +21522, Duration, 1738, 1746, "24 weeks", "", +21525, ObservedResult, 1749, 1880, "Treatment with saxagliptin resulted in similar reductions in HBA ( 1c ) relative to placebo , irrespective of metformin treatment .", "", +21495, Saxagliptin, 1764, 1775, "saxagliptin", "", +21507, HbA1c, 1810, 1820, "HBA ( 1c )", "", +21523, Placebo, 1833, 1840, "placebo", "", +21524, Metformin, 1859, 1868, "metformin", "", +33177, TimePoint, 1884, 1892, "24 weeks", "", +21527, FastingPlasmaGlucose, 1923, 1945, "fasting plasma glucose", "", +21496, Saxagliptin, 1950, 1961, "saxagliptin", "", +21502, Placebo, 1969, 1976, "placebo", "", +21528, DiffGroupAbsValue, 1981, 1989, "- 4 . 02", "", +21529, Mg_per_deciliter, 1992, 1999, "mg / dL", "", +21530, PvalueDiff, 2002, 2016, "p  =  0 . 3958", "", +21531, PercentageAffected, 2021, 2027, "17 . 3", "", +21532, PercentageAffected, 2034, 2039, "6 . 7", "", +21497, Saxagliptin, 2061, 2072, "saxagliptin", "", +21503, Placebo, 2077, 2084, "placebo", "", +21533, HbA1c_target, 2118, 2136, "HbA ( 1c )  <  7 %", "", +21534, BodyWeight, 2168, 2179, "body weight", "", +21535, Duration, 2183, 2190, "week 24", "", +21536, ChangeValue, 2195, 2201, "0 . 39", "", +21538, Kg, 2204, 2206, "kg", "", +21540, Saxagliptin, 2211, 2222, "saxagliptin", "", +21537, ChangeValue, 2227, 2233, "0 . 18", "", +21539, Kg, 2236, 2238, "kg", "", +21541, Placebo, 2243, 2250, "placebo", "", +21542, Hypoglycemia, 2253, 2265, "Hypoglycemia", "", +21543, PercentageAffected, 2282, 2288, "18 . 4", "", +21544, PercentageAffected, 2295, 2301, "19 . 9", "", +21498, Saxagliptin, 2323, 2334, "saxagliptin", "", +21504, Placebo, 2339, 2346, "placebo", "", +21546, SubGroupDescription, 2371, 2393, "confirmed hypoglycemia", "", +21545, Hypoglycemia, 2381, 2393, "hypoglycemia", "", +21547, PercentageAffected, 2396, 2401, "5 . 3", "", +21548, PercentageAffected, 2406, 2411, "3 . 3", "", +21549, EndPointDescription, 2424, 2438, "adverse events", "", +21550, PercentageAffected, 2451, 2461, "at least 5", "", +21551, EndPointDescription, 2481, 2504, "urinary tract infection", "", +21499, Saxagliptin, 2507, 2518, "saxagliptin", "", +21505, Placebo, 2521, 2528, "placebo", "", +21554, PercentageAffected, 2531, 2536, "5 . 9", "", +21555, PercentageAffected, 2541, 2546, "6 . 0", "", +21552, EndPointDescription, 2553, 2562, "influenza", "", +21556, PercentageAffected, 2565, 2570, "3 . 0", "", +21557, PercentageAffected, 2575, 2580, "6 . 6", "", +21553, EndPointDescription, 2591, 2608, "pain in extremity", "", +21558, PercentageAffected, 2611, 2616, "1 . 6", "", +21559, PercentageAffected, 2621, 2626, "6 . 0", "", +21567, ConclusionComment, 2647, 2817, "Saxagliptin 5 - mg once - daily add - on therapy improves glycemic control in T2D patients on insulin alone or combined with metformin and is generally well - tolerated .", "", +21500, Saxagliptin, 2647, 2658, "Saxagliptin", "", +21560, DoseValue, 2659, 2660, "5", "", +21561, mg, 2663, 2665, "mg", "", +21562, Frequency, 2666, 2678, "once - daily", "", +21563, Type2Diabetes, 2725, 2728, "T2D", "", +21566, Precondition, 2725, 2781, "T2D patients on insulin alone or combined with metformin", "", +21564, Insulin, 2741, 2748, "insulin", "", +21565, Metformin, 2772, 2781, "metformin", "", +21568, PMID, 2882, 2890, "22313154", "", diff --git a/data/dm2 22313154_kwoodley.n-triples b/data/dm2 22313154_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22313154_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672081_admin.annodb b/data/dm2 22672081_admin.annodb new file mode 100644 index 0000000..3a21a4d --- /dev/null +++ b/data/dm2 22672081_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +1, PublicationYear, 13, 17, "2012", "", " \"2012\"." +18, Title, 102, 321, "A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication : results of the PARADIGM study .", "", " \"A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication : results of the PARADIGM study .\"." +62981, Lispro75/25, 120, 141, "insulin lispro mix 25", "", +12, InsulinGlargine, 147, 155, "glargine", "", +3, Lispro, 161, 167, "lispro", "", +17, Precondition, 179, 287, "patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication", "", " \"patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication\"." +13, Type2Diabetes, 193, 208, "Type 2 diabetes", "", " ." +62994, OralAntidiabeticAgent, 250, 287, "oral anti - hyperglycaemic medication", "", +19, Author, 322, 332, "Bowering K", "", " \"Bowering K\"." +20, Author, 341, 348, "Reed VA", "", " \"Reed VA\"." +21, Author, 351, 361, "Felicio JS", "", " \"Felicio JS\"." +22, Author, 364, 372, "Landry J", "", " \"Landry J\"." +23, Author, 375, 379, "Ji L", "", " \"Ji L\"." +24, Author, 382, 392, "Oliveira J", "", " \"Oliveira J\"." +25, Canada, 535, 541, "Canada", "", " ." +29, ObjectiveDescription, 650, 878, "To test the hypothesis that initiation and intensification with 25 % insulin lispro , 75 % insulin lispro protamine suspension ( LM25 ) , is non - inferior to initiation and intensification with glargine + insulin lispro therapy", "", " \"To test the hypothesis that initiation and intensification with 25 % insulin lispro , 75 % insulin lispro protamine suspension ( LM25 ) , is non - inferior to initiation and intensification with glargine + insulin lispro therapy\"." +62982, Lispro75/25, 714, 765, "25 % insulin lispro , 75 % insulin lispro protamine", "", +62983, Lispro75/25, 779, 783, "LM25", "", +26, InsulinGlargine, 845, 853, "glargine", "", +27, Lispro, 856, 870, "insulin lispro", "", +30, ObjectiveDescription, 879, 918, "on change from baseline in HbA ( 1c ) .", "", " \"on change from baseline in HbA ( 1c ) .\"." +95, TimePoint, 894, 902, "baseline", "", +28, HbA1c, 906, 916, "HbA ( 1c )", "", +31, Randomized, 937, 947, "randomized", "", " ." +32, CTDesign, 950, 967, "non - inferiority", "", " . ." +33, Parallel, 992, 1000, "parallel", "", " ." +34, CTDesign, 1003, 1014, "prospective", "", " . ." +75, Multicenter, 1017, 1032, "multi - country", "", " ." +36, Duration, 1035, 1044, "48 - week", "", " \"48 - week\"." +35, OpenLabel, 1047, 1059, "open - label", "", " ." +37, NumberPatientsCT, 1083, 1086, "426", "", " \"426\"." +15, Type2Diabetes, 1094, 1109, "Type 2 diabetes", "", +108, Precondition, 1094, 1177, "Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications", "", +62995, OralAntidiabeticAgent, 1139, 1177, "oral anti - hyperglycaemic medications", "", +110, Frequency, 1226, 1235, "one daily", "", " \"one daily\"." +62984, Lispro75/25, 1236, 1240, "LM25", "", " ." +62987, IntramuscularInjection, 1241, 1250, "injection", "", " ." +111, Frequency, 1271, 1282, "three daily", "", +62986, IntramuscularInjection, 1283, 1293, "injections", "", +44, NumberPatientsArm, 1318, 1321, "211", "", " \"211\"." +62988, PerProtocol, 1324, 1336, "per protocol", "", " ." +46, FinalNumPatientsArm, 1345, 1348, "177", "", " \"177\"." +42, Frequency, 1378, 1387, "one daily", "", " \"one daily\"." +41, InsulinGlargine, 1388, 1396, "glargine", "", " ." +62989, IntramuscularInjection, 1397, 1406, "injection", "", " ." +114, Frequency, 1429, 1440, "three daily", "", " \"three daily\"." +7, Lispro, 1441, 1455, "insulin lispro", "", +62990, IntramuscularInjection, 1456, 1466, "injections", "", " ." +45, NumberPatientsArm, 1491, 1494, "212", "", " \"212\"." +62991, PerProtocol, 1497, 1509, "per protocol", "", +47, FinalNumPatientsArm, 1518, 1521, "184", "", " \"184\"." +62992, Lispro75/25, 1536, 1540, "LM25", "", +48, InsulinGlargine, 1583, 1591, "glargine", "", +49, Lispro, 1594, 1608, "insulin lispro", "", +50, ConfIntervalResValue, 1632, 1662, "upper limit of 95 % CI < 0 . 4", "", +127, LeastSquaresMean, 1674, 1694, "least - squares mean", "", " ." +51, ConfIntervalResValue, 1708, 1715, "95 % CI", "", +52, HbA1c, 1721, 1731, "HbA ( 1c )", "", " ." +62996, Lispro75/25, 1734, 1738, "LM25", "", +54, InsulinGlargine, 1745, 1753, "glargine", "", +9, Lispro, 1756, 1770, "insulin lispro", "", +57, DiffGroupAbsValue, 1776, 1783, "- 0 . 4", "", " \"- 0 . 4\"." +79775, Millimoles_per_mole, 1784, 1794, "mmol / mol", "", " ." +55, ConfIntervalDiff, 1797, 1821, "95 % CI - 2 . 7 to 1 . 9", "", " \"95 % CI - 2 . 7 to 1 . 9\"." +58, DiffGroupAbsValue, 1826, 1834, "- 0 . 04", "", +60, Percentage, 1835, 1836, "%", "", +56, ConfIntervalDiff, 1839, 1865, "95 % CI - 0 . 25 to 0 . 17", "", +136, HbA1c, 1987, 1997, "HbA ( 1c )", "", +76, PostprandialBloodGlucose, 2009, 2035, "postprandial blood glucose", "", +77, InsulinDose, 2061, 2073, "insulin dose", "", +63, EndPointDescription, 2076, 2096, "number of injections", "", +137, BodyWeight, 2101, 2107, "weight", "", +65, ObservedResult, 2108, 2175, "change during the course of the study were similar in both groups .", "", +68, ObservedResult, 2176, 2219, "Patients in both groups experienced similar", "", +66, Hypoglycemia, 2220, 2233, "hypoglycaemia", "", +68, ObservedResult, 2234, 2239, "rates", "", +67, EndPointDescription, 2244, 2258, "safety profile", "", +72, ConclusionComment, 2275, 2496, "For patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications , glycaemic control when initiating and intensifying with LM25 therapy was found to be non - inferior to treatment with", "", " \"For patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications , glycaemic control when initiating and intensifying with LM25 therapy was found to be non - inferior to treatment with\"." +14, Type2Diabetes, 2293, 2308, "Type 2 diabetes", "", +69, OralAntidiabeticAgent, 2338, 2376, "oral anti - hyperglycaemic medications", "", +62993, Lispro75/25, 2435, 2439, "LM25", "", +71, InsulinGlargine, 2497, 2505, "glargine", "", +73, ConclusionComment, 2497, 2532, "glargine + insulin lispro therapy .", "", " \"glargine + insulin lispro therapy .\"." +11, Lispro, 2508, 2522, "insulin lispro", "", +74, PMID, 2663, 2671, "22672081", "", " \"22672081\"." diff --git a/data/dm2 22672081_admin.n-triples b/data/dm2 22672081_admin.n-triples new file mode 100644 index 0000000..82ff4d7 --- /dev/null +++ b/data/dm2 22672081_admin.n-triples @@ -0,0 +1,116 @@ +# RDF export of group: Publication + . + "Publication 35769" . + "A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication : results of the PARADIGM study ." . + "Bowering K" . + "2012" . + "Diabet Med ." . + "22672081" . + . + "Reed VA" . + "Felicio JS" . + "Landry J" . + "Ji L" . + "Oliveira J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 35776" . + "To test the hypothesis that initiation and intensification with 25 % insulin lispro , 75 % insulin lispro protamine suspension ( LM25 ) , is non - inferior to initiation and intensification with glargine + insulin lispro therapy" . + "426" . + "48 - week" . + . + . + . + "For patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications , glycaemic control when initiating and intensifying with LM25 therapy was found to be non - inferior to treatment with" . + . + . + . + . + . + "on change from baseline in HbA ( 1c ) ." . + . + . + . + . + . + . + . + "glargine + insulin lispro therapy ." . + . +# RDF export of group: Population + . + "Population 35792" . + "patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . +# RDF export of group: Arm + . + "lm" . + "211" . + "177" . + . + . + . + . + "gla" . + "212" . + "184" . + . + . + . + . +# RDF export of group: Intervention + . + "lm" . + . + "one daily" . + . + . + "gla" . + . + "one daily" . + . + . + "lis" . + . + "three daily" . + . +# RDF export of group: Medication + . + "lm" . + . + . + . + . + "gla" . + . + . + . + . + "lis" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 4" . + "95 % CI - 2 . 7 to 1 . 9" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672081_akramersunderbrink.annodb b/data/dm2 22672081_akramersunderbrink.annodb new file mode 100644 index 0000000..017233f --- /dev/null +++ b/data/dm2 22672081_akramersunderbrink.annodb @@ -0,0 +1,71 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +41397, Journal, 0, 10, "Diabet Med", "", +41398, PublicationYear, 13, 17, "2012", "", +41407, Title, 102, 321, "A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication : results of the PARADIGM study .", "", +41400, InsulinGlargine, 147, 155, "glargine", "", +41404, Lispro, 161, 167, "lispro", "", +41405, Type2Diabetes, 193, 208, "Type 2 diabetes", "", +41406, Precondition, 218, 287, "inadequate glycaemic control on oral anti - hyperglycaemic medication", "", +41433, OralAntidiabeticAgent, 250, 287, "oral anti - hyperglycaemic medication", "", +41408, Author, 322, 332, "Bowering K", "", +41409, Author, 341, 348, "Reed VA", "", +41410, Author, 351, 361, "Felicio JS", "", +41411, Author, 364, 372, "Landry J", "", +41412, Author, 375, 379, "Ji L", "", +41413, Author, 382, 392, "Oliveira J", "", +41423, Canada, 535, 541, "Canada", "", +41420, ObjectiveDescription, 650, 905, "To test the hypothesis that initiation and intensification with 25 % insulin lispro , 75 % insulin lispro protamine suspension ( LM25 ) , is non - inferior to initiation and intensification with glargine + insulin lispro therapy on change from baseline in", "", +41401, Lispro, 719, 733, "insulin lispro", "", +41402, LisproProtamine, 741, 776, "insulin lispro protamine suspension", "", +41415, InsulinGlargine, 845, 853, "glargine", "", +41416, Lispro, 856, 870, "insulin lispro", "", +41417, TimePoint, 894, 902, "baseline", "", +41418, HbA1c, 906, 916, "HbA ( 1c )", "", +41424, ObjectiveDescription, 906, 918, "HbA ( 1c ) .", "", +41425, Randomized, 937, 947, "randomized", "", +41427, Parallel, 992, 1000, "parallel", "", +41428, Multicenter, 1017, 1032, "multi - country", "", +41429, Duration, 1035, 1044, "48 - week", "", +41430, OpenLabel, 1047, 1059, "open - label", "", +41431, NumberPatientsCT, 1083, 1086, "426", "", +41432, Type2Diabetes, 1094, 1109, "Type 2 diabetes", "", +41434, Precondition, 1110, 1177, "inadequately controlled with oral anti - hyperglycaemic medications", "", +41435, OralAntidiabeticAgent, 1139, 1177, "oral anti - hyperglycaemic medications", "", +41436, Frequency, 1226, 1235, "one daily", "", +41437, Frequency, 1271, 1282, "three daily", "", +41442, NumberPatientsArm, 1318, 1321, "211", "", +41444, FinalNumPatientsArm, 1345, 1348, "177", "", +41438, Frequency, 1378, 1387, "one daily", "", +41439, InsulinGlargine, 1388, 1396, "glargine", "", +41440, Frequency, 1429, 1440, "three daily", "", +41441, Lispro, 1441, 1455, "insulin lispro", "", +41443, NumberPatientsArm, 1491, 1494, "212", "", +41445, FinalNumPatientsArm, 1518, 1521, "184", "", +41446, InsulinGlargine, 1583, 1591, "glargine", "", +41447, Lispro, 1594, 1608, "insulin lispro", "", +41448, Percentage, 1650, 1651, "%", "", +41453, LeastSquaresMean, 1674, 1694, "least - squares mean", "", +41449, Percentage, 1711, 1712, "%", "", +41450, HbA1c, 1721, 1731, "HbA ( 1c )", "", +41451, InsulinGlargine, 1745, 1753, "glargine", "", +41452, Lispro, 1756, 1770, "insulin lispro", "", +41454, DiffGroupAbsValue, 1776, 1783, "- 0 . 4", "", +41455, BioAndMedicalUnit, 1784, 1794, "mmol / mol", "", +41456, ConfIntervalDiff, 1797, 1821, "95 % CI - 2 . 7 to 1 . 9", "", +41645, Percentage, 1800, 1801, "%", "", +41457, DiffGroupRelValue, 1826, 1834, "- 0 . 04", "", +41644, Percentage, 1835, 1836, "%", "", +41642, ConfIntervalDiff, 1839, 1865, "95 % CI - 0 . 25 to 0 . 17", "", +41646, Percentage, 1842, 1843, "%", "", +41647, HbA1c, 1987, 1997, "HbA ( 1c )", "", +41649, InsulinDose, 2061, 2073, "insulin dose", "", +41648, BodyWeight, 2101, 2107, "weight", "", +41659, Hypoglycemia, 2220, 2233, "hypoglycaemia", "", +41658, ConclusionComment, 2275, 2530, "For patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications , glycaemic control when initiating and intensifying with LM25 therapy was found to be non - inferior to treatment with glargine + insulin lispro therapy", "", +41651, Type2Diabetes, 2293, 2308, "Type 2 diabetes", "", +41652, Precondition, 2309, 2376, "inadequately controlled with oral anti - hyperglycaemic medications", "", +41653, OralAntidiabeticAgent, 2338, 2376, "oral anti - hyperglycaemic medications", "", +41654, InsulinGlargine, 2497, 2505, "glargine", "", +41655, Lispro, 2508, 2522, "insulin lispro", "", +41661, ConclusionComment, 2531, 2532, ".", "", +41656, PMID, 2663, 2671, "22672081", "", diff --git a/data/dm2 22672081_akramersunderbrink.n-triples b/data/dm2 22672081_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22672081_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672081_export.csv b/data/dm2 22672081_export.csv new file mode 100644 index 0000000..41b21c3 --- /dev/null +++ b/data/dm2 22672081_export.csv @@ -0,0 +1,556 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +313, 1, 1, 1, 0, 6, 0, 6, "Diabet" +313, 1, 2, 2, 7, 10, 7, 10, "Med" +313, 1, 3, 3, 11, 12, 11, 12, "." +313, 2, 1, 4, 0, 4, 13, 17, "2012" +313, 2, 2, 5, 5, 8, 18, 21, "Sep" +313, 2, 3, 6, 9, 10, 22, 23, ";" +313, 2, 4, 7, 11, 13, 24, 26, "29" +313, 2, 5, 8, 14, 15, 27, 28, "(" +313, 2, 6, 9, 16, 17, 29, 30, "9" +313, 2, 7, 10, 18, 19, 31, 32, ")" +313, 2, 8, 11, 20, 21, 33, 34, ":" +313, 2, 9, 12, 22, 26, 35, 39, "e263" +313, 2, 10, 13, 27, 28, 40, 41, "-" +313, 2, 11, 14, 29, 31, 42, 44, "72" +313, 2, 12, 15, 32, 33, 45, 46, "." +313, 3, 1, 16, 0, 3, 47, 50, "doi" +313, 3, 2, 17, 4, 5, 51, 52, ":" +313, 3, 3, 18, 6, 8, 53, 55, "10" +313, 3, 4, 19, 9, 10, 56, 57, "." +313, 3, 5, 20, 11, 15, 58, 62, "1111" +313, 3, 6, 21, 16, 17, 63, 64, "/" +313, 3, 7, 22, 18, 19, 65, 66, "j" +313, 3, 8, 23, 20, 21, 67, 68, "." +313, 3, 9, 24, 22, 26, 69, 73, "1464" +313, 3, 10, 25, 27, 28, 74, 75, "-" +313, 3, 11, 26, 29, 33, 76, 80, "5491" +313, 3, 12, 27, 34, 35, 81, 82, "." +313, 3, 13, 28, 36, 40, 83, 87, "2012" +313, 3, 14, 29, 41, 42, 88, 89, "." +313, 3, 15, 30, 43, 48, 90, 95, "03722" +313, 3, 16, 31, 49, 50, 96, 97, "." +313, 3, 17, 32, 51, 52, 98, 99, "x" +313, 3, 18, 33, 53, 54, 100, 101, "." +313, 4, 1, 34, 0, 1, 102, 103, "A" +313, 4, 2, 35, 2, 7, 104, 109, "study" +313, 4, 3, 36, 8, 17, 110, 119, "comparing" +313, 4, 4, 37, 18, 25, 120, 127, "insulin" +313, 4, 5, 38, 26, 32, 128, 134, "lispro" +313, 4, 6, 39, 33, 36, 135, 138, "mix" +313, 4, 7, 40, 37, 39, 139, 141, "25" +313, 4, 8, 41, 40, 44, 142, 146, "with" +313, 4, 9, 42, 45, 53, 147, 155, "glargine" +313, 4, 10, 43, 54, 58, 156, 160, "plus" +313, 4, 11, 44, 59, 65, 161, 167, "lispro" +313, 4, 12, 45, 66, 73, 168, 175, "therapy" +313, 4, 13, 46, 74, 76, 176, 178, "in" +313, 4, 14, 47, 77, 85, 179, 187, "patients" +313, 4, 15, 48, 86, 90, 188, 192, "with" +313, 4, 16, 49, 91, 95, 193, 197, "Type" +313, 4, 17, 50, 96, 97, 198, 199, "2" +313, 4, 18, 51, 98, 106, 200, 208, "diabetes" +313, 4, 19, 52, 107, 110, 209, 212, "who" +313, 4, 20, 53, 111, 115, 213, 217, "have" +313, 4, 21, 54, 116, 126, 218, 228, "inadequate" +313, 4, 22, 55, 127, 136, 229, 238, "glycaemic" +313, 4, 23, 56, 137, 144, 239, 246, "control" +313, 4, 24, 57, 145, 147, 247, 249, "on" +313, 4, 25, 58, 148, 152, 250, 254, "oral" +313, 4, 26, 59, 153, 157, 255, 259, "anti" +313, 4, 27, 60, 158, 159, 260, 261, "-" +313, 4, 28, 61, 160, 174, 262, 276, "hyperglycaemic" +313, 4, 29, 62, 175, 185, 277, 287, "medication" +313, 4, 30, 63, 186, 187, 288, 289, ":" +313, 4, 31, 64, 188, 195, 290, 297, "results" +313, 4, 32, 65, 196, 198, 298, 300, "of" +313, 4, 33, 66, 199, 202, 301, 304, "the" +313, 4, 34, 67, 203, 211, 305, 313, "PARADIGM" +313, 4, 35, 68, 212, 217, 314, 319, "study" +313, 4, 36, 69, 218, 219, 320, 321, "." +313, 5, 1, 70, 0, 8, 322, 330, "Bowering" +313, 5, 2, 71, 9, 10, 331, 332, "K" +313, 5, 3, 72, 11, 12, 333, 334, "(" +313, 5, 4, 73, 13, 14, 335, 336, "1" +313, 5, 5, 74, 15, 16, 337, 338, ")" +313, 5, 6, 75, 17, 18, 339, 340, "," +313, 5, 7, 76, 19, 23, 341, 345, "Reed" +313, 5, 8, 77, 24, 26, 346, 348, "VA" +313, 5, 9, 78, 27, 28, 349, 350, "," +313, 5, 10, 79, 29, 36, 351, 358, "Felicio" +313, 5, 11, 80, 37, 39, 359, 361, "JS" +313, 5, 12, 81, 40, 41, 362, 363, "," +313, 5, 13, 82, 42, 48, 364, 370, "Landry" +313, 5, 14, 83, 49, 50, 371, 372, "J" +313, 5, 15, 84, 51, 52, 373, 374, "," +313, 5, 16, 85, 53, 55, 375, 377, "Ji" +313, 5, 17, 86, 56, 57, 378, 379, "L" +313, 5, 18, 87, 58, 59, 380, 381, "," +313, 5, 19, 88, 60, 68, 382, 390, "Oliveira" +313, 5, 20, 89, 69, 70, 391, 392, "J" +313, 5, 21, 90, 71, 72, 393, 394, "." +313, 6, 1, 91, 0, 6, 395, 401, "Author" +313, 6, 2, 92, 7, 18, 402, 413, "information" +313, 6, 3, 93, 19, 20, 414, 415, ":" +313, 6, 4, 94, 21, 22, 416, 417, "(" +313, 6, 5, 95, 23, 24, 418, 419, "1" +313, 6, 6, 96, 25, 26, 420, 421, ")" +313, 6, 7, 97, 27, 37, 422, 432, "University" +313, 6, 8, 98, 38, 40, 433, 435, "of" +313, 6, 9, 99, 41, 48, 436, 443, "Alberta" +313, 6, 10, 100, 49, 50, 444, 445, "," +313, 6, 11, 101, 51, 59, 446, 454, "Division" +313, 6, 12, 102, 60, 62, 455, 457, "of" +313, 6, 13, 103, 63, 76, 458, 471, "Endocrinology" +313, 6, 14, 104, 77, 80, 472, 475, "and" +313, 6, 15, 105, 81, 91, 476, 486, "Metabolism" +313, 6, 16, 106, 92, 94, 487, 489, "in" +313, 6, 17, 107, 95, 98, 490, 493, "the" +313, 6, 18, 108, 99, 109, 494, 504, "Department" +313, 6, 19, 109, 110, 112, 505, 507, "of" +313, 6, 20, 110, 113, 121, 508, 516, "Medicine" +313, 6, 21, 111, 122, 123, 517, 518, "," +313, 6, 22, 112, 124, 132, 519, 527, "Edmonton" +313, 6, 23, 113, 133, 134, 528, 529, "," +313, 6, 24, 114, 135, 137, 530, 532, "AB" +313, 6, 25, 115, 138, 139, 533, 534, "," +313, 6, 26, 116, 140, 146, 535, 541, "Canada" +313, 6, 27, 117, 147, 148, 542, 543, "." +313, 7, 1, 118, 0, 7, 544, 551, "Erratum" +313, 7, 2, 119, 8, 10, 552, 554, "in" +313, 7, 3, 120, 11, 17, 555, 561, "Diabet" +313, 7, 4, 121, 18, 21, 562, 565, "Med" +313, 7, 5, 122, 22, 23, 566, 567, "." +313, 8, 1, 123, 0, 4, 568, 572, "2012" +313, 8, 2, 124, 5, 8, 573, 576, "Nov" +313, 8, 3, 125, 9, 10, 577, 578, ";" +313, 8, 4, 126, 11, 13, 579, 581, "29" +313, 8, 5, 127, 14, 15, 582, 583, "(" +313, 8, 6, 128, 16, 18, 584, 586, "11" +313, 8, 7, 129, 19, 20, 587, 588, ")" +313, 8, 8, 130, 21, 22, 589, 590, ":" +313, 8, 9, 131, 23, 27, 591, 595, "1473" +313, 8, 10, 132, 28, 29, 596, 597, "." +313, 9, 1, 133, 0, 7, 598, 605, "Felicio" +313, 9, 2, 134, 8, 9, 606, 607, "," +313, 9, 3, 135, 10, 11, 608, 609, "J" +313, 9, 4, 136, 12, 13, 610, 611, "[" +313, 9, 5, 137, 14, 23, 612, 621, "corrected" +313, 9, 6, 138, 24, 26, 622, 624, "to" +313, 9, 7, 139, 27, 34, 625, 632, "Felicio" +313, 9, 8, 140, 35, 36, 633, 634, "," +313, 9, 9, 141, 37, 38, 635, 636, "J" +313, 9, 10, 142, 39, 40, 637, 638, "S" +313, 9, 11, 143, 41, 42, 639, 640, "]" +313, 9, 12, 144, 43, 44, 641, 642, "." +313, 10, 1, 145, 0, 4, 643, 647, "AIMS" +313, 10, 2, 146, 5, 6, 648, 649, ":" +313, 10, 3, 147, 7, 9, 650, 652, "To" +313, 10, 4, 148, 10, 14, 653, 657, "test" +313, 10, 5, 149, 15, 18, 658, 661, "the" +313, 10, 6, 150, 19, 29, 662, 672, "hypothesis" +313, 10, 7, 151, 30, 34, 673, 677, "that" +313, 10, 8, 152, 35, 45, 678, 688, "initiation" +313, 10, 9, 153, 46, 49, 689, 692, "and" +313, 10, 10, 154, 50, 65, 693, 708, "intensification" +313, 10, 11, 155, 66, 70, 709, 713, "with" +313, 10, 12, 156, 71, 73, 714, 716, "25" +313, 10, 13, 157, 74, 75, 717, 718, "%" +313, 10, 14, 158, 76, 83, 719, 726, "insulin" +313, 10, 15, 159, 84, 90, 727, 733, "lispro" +313, 10, 16, 160, 91, 92, 734, 735, "," +313, 10, 17, 161, 93, 95, 736, 738, "75" +313, 10, 18, 162, 96, 97, 739, 740, "%" +313, 10, 19, 163, 98, 105, 741, 748, "insulin" +313, 10, 20, 164, 106, 112, 749, 755, "lispro" +313, 10, 21, 165, 113, 122, 756, 765, "protamine" +313, 10, 22, 166, 123, 133, 766, 776, "suspension" +313, 10, 23, 167, 134, 135, 777, 778, "(" +313, 10, 24, 168, 136, 140, 779, 783, "LM25" +313, 10, 25, 169, 141, 142, 784, 785, ")" +313, 10, 26, 170, 143, 144, 786, 787, "," +313, 10, 27, 171, 145, 147, 788, 790, "is" +313, 10, 28, 172, 148, 151, 791, 794, "non" +313, 10, 29, 173, 152, 153, 795, 796, "-" +313, 10, 30, 174, 154, 162, 797, 805, "inferior" +313, 10, 31, 175, 163, 165, 806, 808, "to" +313, 10, 32, 176, 166, 176, 809, 819, "initiation" +313, 10, 33, 177, 177, 180, 820, 823, "and" +313, 10, 34, 178, 181, 196, 824, 839, "intensification" +313, 10, 35, 179, 197, 201, 840, 844, "with" +313, 10, 36, 180, 202, 210, 845, 853, "glargine" +313, 10, 37, 181, 211, 212, 854, 855, "+" +313, 10, 38, 182, 213, 220, 856, 863, "insulin" +313, 10, 39, 183, 221, 227, 864, 870, "lispro" +313, 10, 40, 184, 228, 235, 871, 878, "therapy" +313, 10, 41, 185, 236, 238, 879, 881, "on" +313, 10, 42, 186, 239, 245, 882, 888, "change" +313, 10, 43, 187, 246, 250, 889, 893, "from" +313, 10, 44, 188, 251, 259, 894, 902, "baseline" +313, 10, 45, 189, 260, 262, 903, 905, "in" +313, 10, 46, 190, 263, 266, 906, 909, "HbA" +313, 10, 47, 191, 267, 268, 910, 911, "(" +313, 10, 48, 192, 269, 271, 912, 914, "1c" +313, 10, 49, 193, 272, 273, 915, 916, ")" +313, 10, 50, 194, 274, 275, 917, 918, "." +313, 11, 1, 195, 0, 7, 919, 926, "METHODS" +313, 11, 2, 196, 8, 9, 927, 928, ":" +313, 11, 3, 197, 10, 12, 929, 931, "In" +313, 11, 4, 198, 13, 17, 932, 936, "this" +313, 11, 5, 199, 18, 28, 937, 947, "randomized" +313, 11, 6, 200, 29, 30, 948, 949, "," +313, 11, 7, 201, 31, 34, 950, 953, "non" +313, 11, 8, 202, 35, 36, 954, 955, "-" +313, 11, 9, 203, 37, 48, 956, 967, "inferiority" +313, 11, 10, 204, 49, 50, 968, 969, "(" +313, 11, 11, 205, 51, 57, 970, 976, "margin" +313, 11, 12, 206, 58, 60, 977, 979, "of" +313, 11, 13, 207, 61, 62, 980, 981, "0" +313, 11, 14, 208, 63, 64, 982, 983, "." +313, 11, 15, 209, 65, 66, 984, 985, "4" +313, 11, 16, 210, 67, 68, 986, 987, "%" +313, 11, 17, 211, 69, 70, 988, 989, ")" +313, 11, 18, 212, 71, 72, 990, 991, "," +313, 11, 19, 213, 73, 81, 992, 1000, "parallel" +313, 11, 20, 214, 82, 83, 1001, 1002, "," +313, 11, 21, 215, 84, 95, 1003, 1014, "prospective" +313, 11, 22, 216, 96, 97, 1015, 1016, "," +313, 11, 23, 217, 98, 103, 1017, 1022, "multi" +313, 11, 24, 218, 104, 105, 1023, 1024, "-" +313, 11, 25, 219, 106, 113, 1025, 1032, "country" +313, 11, 26, 220, 114, 115, 1033, 1034, "," +313, 11, 27, 221, 116, 118, 1035, 1037, "48" +313, 11, 28, 222, 119, 120, 1038, 1039, "-" +313, 11, 29, 223, 121, 125, 1040, 1044, "week" +313, 11, 30, 224, 126, 127, 1045, 1046, "," +313, 11, 31, 225, 128, 132, 1047, 1051, "open" +313, 11, 32, 226, 133, 134, 1052, 1053, "-" +313, 11, 33, 227, 135, 140, 1054, 1059, "label" +313, 11, 34, 228, 141, 146, 1060, 1065, "study" +313, 11, 35, 229, 147, 148, 1066, 1067, "," +313, 11, 36, 230, 149, 157, 1068, 1076, "patients" +313, 11, 37, 231, 158, 159, 1077, 1078, "(" +313, 11, 38, 232, 160, 161, 1079, 1080, "n" +313, 11, 39, 233, 162, 163, 1081, 1082, "=" +313, 11, 40, 234, 164, 167, 1083, 1086, "426" +313, 11, 41, 235, 168, 169, 1087, 1088, ")" +313, 11, 42, 236, 170, 174, 1089, 1093, "with" +313, 11, 43, 237, 175, 179, 1094, 1098, "Type" +313, 11, 44, 238, 180, 181, 1099, 1100, "2" +313, 11, 45, 239, 182, 190, 1101, 1109, "diabetes" +313, 11, 46, 240, 191, 203, 1110, 1122, "inadequately" +313, 11, 47, 241, 204, 214, 1123, 1133, "controlled" +313, 11, 48, 242, 215, 219, 1134, 1138, "with" +313, 11, 49, 243, 220, 224, 1139, 1143, "oral" +313, 11, 50, 244, 225, 229, 1144, 1148, "anti" +313, 11, 51, 245, 230, 231, 1149, 1150, "-" +313, 11, 52, 246, 232, 246, 1151, 1165, "hyperglycaemic" +313, 11, 53, 247, 247, 258, 1166, 1177, "medications" +313, 11, 54, 248, 259, 263, 1178, 1182, "were" +313, 11, 55, 249, 264, 272, 1183, 1191, "assigned" +313, 11, 56, 250, 273, 275, 1192, 1194, "to" +313, 11, 57, 251, 276, 282, 1195, 1201, "either" +313, 11, 58, 252, 283, 293, 1202, 1212, "initiating" +313, 11, 59, 253, 294, 301, 1213, 1220, "therapy" +313, 11, 60, 254, 302, 306, 1221, 1225, "with" +313, 11, 61, 255, 307, 310, 1226, 1229, "one" +313, 11, 62, 256, 311, 316, 1230, 1235, "daily" +313, 11, 63, 257, 317, 321, 1236, 1240, "LM25" +313, 11, 64, 258, 322, 331, 1241, 1250, "injection" +313, 11, 65, 259, 332, 333, 1251, 1252, "," +313, 11, 66, 260, 334, 345, 1253, 1264, "progressing" +313, 11, 67, 261, 346, 348, 1265, 1267, "up" +313, 11, 68, 262, 349, 351, 1268, 1270, "to" +313, 11, 69, 263, 352, 357, 1271, 1276, "three" +313, 11, 70, 264, 358, 363, 1277, 1282, "daily" +313, 11, 71, 265, 364, 374, 1283, 1293, "injections" +313, 11, 72, 266, 375, 376, 1294, 1295, "(" +313, 11, 73, 267, 377, 381, 1296, 1300, "full" +313, 11, 74, 268, 382, 390, 1301, 1309, "analysis" +313, 11, 75, 269, 391, 394, 1310, 1313, "set" +313, 11, 76, 270, 395, 396, 1314, 1315, "n" +313, 11, 77, 271, 397, 398, 1316, 1317, "=" +313, 11, 78, 272, 399, 402, 1318, 1321, "211" +313, 11, 79, 273, 403, 404, 1322, 1323, ";" +313, 11, 80, 274, 405, 408, 1324, 1327, "per" +313, 11, 81, 275, 409, 417, 1328, 1336, "protocol" +313, 11, 82, 276, 418, 421, 1337, 1340, "set" +313, 11, 83, 277, 422, 423, 1341, 1342, "n" +313, 11, 84, 278, 424, 425, 1343, 1344, "=" +313, 11, 85, 279, 426, 429, 1345, 1348, "177" +313, 11, 86, 280, 430, 431, 1349, 1350, ")" +313, 11, 87, 281, 432, 434, 1351, 1353, "or" +313, 11, 88, 282, 435, 445, 1354, 1364, "initiating" +313, 11, 89, 283, 446, 453, 1365, 1372, "therapy" +313, 11, 90, 284, 454, 458, 1373, 1377, "with" +313, 11, 91, 285, 459, 462, 1378, 1381, "one" +313, 11, 92, 286, 463, 468, 1382, 1387, "daily" +313, 11, 93, 287, 469, 477, 1388, 1396, "glargine" +313, 11, 94, 288, 478, 487, 1397, 1406, "injection" +313, 11, 95, 289, 488, 491, 1407, 1410, "and" +313, 11, 96, 290, 492, 503, 1411, 1422, "progressing" +313, 11, 97, 291, 504, 506, 1423, 1425, "up" +313, 11, 98, 292, 507, 509, 1426, 1428, "to" +313, 11, 99, 293, 510, 515, 1429, 1434, "three" +313, 11, 100, 294, 516, 521, 1435, 1440, "daily" +313, 11, 101, 295, 522, 529, 1441, 1448, "insulin" +313, 11, 102, 296, 530, 536, 1449, 1455, "lispro" +313, 11, 103, 297, 537, 547, 1456, 1466, "injections" +313, 11, 104, 298, 548, 549, 1467, 1468, "(" +313, 11, 105, 299, 550, 554, 1469, 1473, "full" +313, 11, 106, 300, 555, 563, 1474, 1482, "analysis" +313, 11, 107, 301, 564, 567, 1483, 1486, "set" +313, 11, 108, 302, 568, 569, 1487, 1488, "n" +313, 11, 109, 303, 570, 571, 1489, 1490, "=" +313, 11, 110, 304, 572, 575, 1491, 1494, "212" +313, 11, 111, 305, 576, 577, 1495, 1496, ";" +313, 11, 112, 306, 578, 581, 1497, 1500, "per" +313, 11, 113, 307, 582, 590, 1501, 1509, "protocol" +313, 11, 114, 308, 591, 594, 1510, 1513, "set" +313, 11, 115, 309, 595, 596, 1514, 1515, "n" +313, 11, 116, 310, 597, 598, 1516, 1517, "=" +313, 11, 117, 311, 599, 602, 1518, 1521, "184" +313, 11, 118, 312, 603, 604, 1522, 1523, ")" +313, 11, 119, 313, 605, 606, 1524, 1525, "." +313, 12, 1, 314, 0, 7, 1526, 1533, "RESULTS" +313, 12, 2, 315, 8, 9, 1534, 1535, ":" +313, 12, 3, 316, 10, 14, 1536, 1540, "LM25" +313, 12, 4, 317, 15, 22, 1541, 1548, "therapy" +313, 12, 5, 318, 23, 26, 1549, 1552, "was" +313, 12, 6, 319, 27, 32, 1553, 1558, "found" +313, 12, 7, 320, 33, 35, 1559, 1561, "to" +313, 12, 8, 321, 36, 38, 1562, 1564, "be" +313, 12, 9, 322, 39, 42, 1565, 1568, "non" +313, 12, 10, 323, 43, 44, 1569, 1570, "-" +313, 12, 11, 324, 45, 53, 1571, 1579, "inferior" +313, 12, 12, 325, 54, 56, 1580, 1582, "to" +313, 12, 13, 326, 57, 65, 1583, 1591, "glargine" +313, 12, 14, 327, 66, 67, 1592, 1593, "+" +313, 12, 15, 328, 68, 75, 1594, 1601, "insulin" +313, 12, 16, 329, 76, 82, 1602, 1608, "lispro" +313, 12, 17, 330, 83, 90, 1609, 1616, "therapy" +313, 12, 18, 331, 91, 93, 1617, 1619, "by" +313, 12, 19, 332, 94, 99, 1620, 1625, "study" +313, 12, 20, 333, 100, 103, 1626, 1629, "end" +313, 12, 21, 334, 104, 105, 1630, 1631, "(" +313, 12, 22, 335, 106, 111, 1632, 1637, "upper" +313, 12, 23, 336, 112, 117, 1638, 1643, "limit" +313, 12, 24, 337, 118, 120, 1644, 1646, "of" +313, 12, 25, 338, 121, 123, 1647, 1649, "95" +313, 12, 26, 339, 124, 125, 1650, 1651, "%" +313, 12, 27, 340, 126, 128, 1652, 1654, "CI" +313, 12, 28, 341, 129, 130, 1655, 1656, "<" +313, 12, 29, 342, 131, 132, 1657, 1658, "0" +313, 12, 30, 343, 133, 134, 1659, 1660, "." +313, 12, 31, 344, 135, 136, 1661, 1662, "4" +313, 12, 32, 345, 137, 138, 1663, 1664, ")" +313, 12, 33, 346, 139, 140, 1665, 1666, "," +313, 12, 34, 347, 141, 145, 1667, 1671, "with" +313, 12, 35, 348, 146, 147, 1672, 1673, "a" +313, 12, 36, 349, 148, 153, 1674, 1679, "least" +313, 12, 37, 350, 154, 155, 1680, 1681, "-" +313, 12, 38, 351, 156, 163, 1682, 1689, "squares" +313, 12, 39, 352, 164, 168, 1690, 1694, "mean" +313, 12, 40, 353, 169, 179, 1695, 1705, "difference" +313, 12, 41, 354, 180, 181, 1706, 1707, "(" +313, 12, 42, 355, 182, 184, 1708, 1710, "95" +313, 12, 43, 356, 185, 186, 1711, 1712, "%" +313, 12, 44, 357, 187, 189, 1713, 1715, "CI" +313, 12, 45, 358, 190, 191, 1716, 1717, ")" +313, 12, 46, 359, 192, 194, 1718, 1720, "in" +313, 12, 47, 360, 195, 198, 1721, 1724, "HbA" +313, 12, 48, 361, 199, 200, 1725, 1726, "(" +313, 12, 49, 362, 201, 203, 1727, 1729, "1c" +313, 12, 50, 363, 204, 205, 1730, 1731, ")" +313, 12, 51, 364, 206, 207, 1732, 1733, "(" +313, 12, 52, 365, 208, 212, 1734, 1738, "LM25" +313, 12, 53, 366, 213, 218, 1739, 1744, "minus" +313, 12, 54, 367, 219, 227, 1745, 1753, "glargine" +313, 12, 55, 368, 228, 229, 1754, 1755, "+" +313, 12, 56, 369, 230, 237, 1756, 1763, "insulin" +313, 12, 57, 370, 238, 244, 1764, 1770, "lispro" +313, 12, 58, 371, 245, 246, 1771, 1772, ")" +313, 12, 59, 372, 247, 249, 1773, 1775, "of" +313, 12, 60, 373, 250, 251, 1776, 1777, "-" +313, 12, 61, 374, 252, 253, 1778, 1779, "0" +313, 12, 62, 375, 254, 255, 1780, 1781, "." +313, 12, 63, 376, 256, 257, 1782, 1783, "4" +313, 12, 64, 377, 258, 262, 1784, 1788, "mmol" +313, 12, 65, 378, 263, 264, 1789, 1790, "/" +313, 12, 66, 379, 265, 268, 1791, 1794, "mol" +313, 12, 67, 380, 269, 270, 1795, 1796, "(" +313, 12, 68, 381, 271, 273, 1797, 1799, "95" +313, 12, 69, 382, 274, 275, 1800, 1801, "%" +313, 12, 70, 383, 276, 278, 1802, 1804, "CI" +313, 12, 71, 384, 279, 280, 1805, 1806, "-" +313, 12, 72, 385, 281, 282, 1807, 1808, "2" +313, 12, 73, 386, 283, 284, 1809, 1810, "." +313, 12, 74, 387, 285, 286, 1811, 1812, "7" +313, 12, 75, 388, 287, 289, 1813, 1815, "to" +313, 12, 76, 389, 290, 291, 1816, 1817, "1" +313, 12, 77, 390, 292, 293, 1818, 1819, "." +313, 12, 78, 391, 294, 295, 1820, 1821, "9" +313, 12, 79, 392, 296, 297, 1822, 1823, ")" +313, 12, 80, 393, 298, 299, 1824, 1825, ";" +313, 12, 81, 394, 300, 301, 1826, 1827, "-" +313, 12, 82, 395, 302, 303, 1828, 1829, "0" +313, 12, 83, 396, 304, 305, 1830, 1831, "." +313, 12, 84, 397, 306, 308, 1832, 1834, "04" +313, 12, 85, 398, 309, 310, 1835, 1836, "%" +313, 12, 86, 399, 311, 312, 1837, 1838, "(" +313, 12, 87, 400, 313, 315, 1839, 1841, "95" +313, 12, 88, 401, 316, 317, 1842, 1843, "%" +313, 12, 89, 402, 318, 320, 1844, 1846, "CI" +313, 12, 90, 403, 321, 322, 1847, 1848, "-" +313, 12, 91, 404, 323, 324, 1849, 1850, "0" +313, 12, 92, 405, 325, 326, 1851, 1852, "." +313, 12, 93, 406, 327, 329, 1853, 1855, "25" +313, 12, 94, 407, 330, 332, 1856, 1858, "to" +313, 12, 95, 408, 333, 334, 1859, 1860, "0" +313, 12, 96, 409, 335, 336, 1861, 1862, "." +313, 12, 97, 410, 337, 339, 1863, 1865, "17" +313, 12, 98, 411, 340, 341, 1866, 1867, ")" +313, 12, 99, 412, 342, 343, 1868, 1869, "." +313, 13, 1, 413, 0, 2, 1870, 1872, "No" +313, 13, 2, 414, 3, 16, 1873, 1886, "statistically" +313, 13, 3, 415, 17, 28, 1887, 1898, "significant" +313, 13, 4, 416, 29, 40, 1899, 1910, "differences" +313, 13, 5, 417, 41, 48, 1911, 1918, "between" +313, 13, 6, 418, 49, 58, 1919, 1928, "treatment" +313, 13, 7, 419, 59, 65, 1929, 1935, "groups" +313, 13, 8, 420, 66, 70, 1936, 1940, "were" +313, 13, 9, 421, 71, 76, 1941, 1946, "found" +313, 13, 10, 422, 77, 79, 1947, 1949, "in" +313, 13, 11, 423, 80, 83, 1950, 1953, "the" +313, 13, 12, 424, 84, 94, 1954, 1964, "percentage" +313, 13, 13, 425, 95, 97, 1965, 1967, "of" +313, 13, 14, 426, 98, 106, 1968, 1976, "patients" +313, 13, 15, 427, 107, 116, 1977, 1986, "achieving" +313, 13, 16, 428, 117, 120, 1987, 1990, "HbA" +313, 13, 17, 429, 121, 122, 1991, 1992, "(" +313, 13, 18, 430, 123, 125, 1993, 1995, "1c" +313, 13, 19, 431, 126, 127, 1996, 1997, ")" +313, 13, 20, 432, 128, 135, 1998, 2005, "targets" +313, 13, 21, 433, 136, 138, 2006, 2008, "or" +313, 13, 22, 434, 139, 151, 2009, 2021, "postprandial" +313, 13, 23, 435, 152, 157, 2022, 2027, "blood" +313, 13, 24, 436, 158, 165, 2028, 2035, "glucose" +313, 13, 25, 437, 166, 172, 2036, 2042, "levels" +313, 13, 26, 438, 173, 174, 2043, 2044, "." +313, 14, 1, 439, 0, 3, 2045, 2048, "The" +313, 14, 2, 440, 4, 12, 2049, 2057, "increase" +313, 14, 3, 441, 13, 15, 2058, 2060, "in" +313, 14, 4, 442, 16, 23, 2061, 2068, "insulin" +313, 14, 5, 443, 24, 28, 2069, 2073, "dose" +313, 14, 6, 444, 29, 30, 2074, 2075, "," +313, 14, 7, 445, 31, 37, 2076, 2082, "number" +313, 14, 8, 446, 38, 40, 2083, 2085, "of" +313, 14, 9, 447, 41, 51, 2086, 2096, "injections" +313, 14, 10, 448, 52, 55, 2097, 2100, "and" +313, 14, 11, 449, 56, 62, 2101, 2107, "weight" +313, 14, 12, 450, 63, 69, 2108, 2114, "change" +313, 14, 13, 451, 70, 76, 2115, 2121, "during" +313, 14, 14, 452, 77, 80, 2122, 2125, "the" +313, 14, 15, 453, 81, 87, 2126, 2132, "course" +313, 14, 16, 454, 88, 90, 2133, 2135, "of" +313, 14, 17, 455, 91, 94, 2136, 2139, "the" +313, 14, 18, 456, 95, 100, 2140, 2145, "study" +313, 14, 19, 457, 101, 105, 2146, 2150, "were" +313, 14, 20, 458, 106, 113, 2151, 2158, "similar" +313, 14, 21, 459, 114, 116, 2159, 2161, "in" +313, 14, 22, 460, 117, 121, 2162, 2166, "both" +313, 14, 23, 461, 122, 128, 2167, 2173, "groups" +313, 14, 24, 462, 129, 130, 2174, 2175, "." +313, 15, 1, 463, 0, 8, 2176, 2184, "Patients" +313, 15, 2, 464, 9, 11, 2185, 2187, "in" +313, 15, 3, 465, 12, 16, 2188, 2192, "both" +313, 15, 4, 466, 17, 23, 2193, 2199, "groups" +313, 15, 5, 467, 24, 35, 2200, 2211, "experienced" +313, 15, 6, 468, 36, 43, 2212, 2219, "similar" +313, 15, 7, 469, 44, 57, 2220, 2233, "hypoglycaemia" +313, 15, 8, 470, 58, 63, 2234, 2239, "rates" +313, 15, 9, 471, 64, 67, 2240, 2243, "and" +313, 15, 10, 472, 68, 74, 2244, 2250, "safety" +313, 15, 11, 473, 75, 82, 2251, 2258, "profile" +313, 15, 12, 474, 83, 84, 2259, 2260, "." +313, 16, 1, 475, 0, 11, 2261, 2272, "CONCLUSIONS" +313, 16, 2, 476, 12, 13, 2273, 2274, ":" +313, 16, 3, 477, 14, 17, 2275, 2278, "For" +313, 16, 4, 478, 18, 26, 2279, 2287, "patients" +313, 16, 5, 479, 27, 31, 2288, 2292, "with" +313, 16, 6, 480, 32, 36, 2293, 2297, "Type" +313, 16, 7, 481, 37, 38, 2298, 2299, "2" +313, 16, 8, 482, 39, 47, 2300, 2308, "diabetes" +313, 16, 9, 483, 48, 60, 2309, 2321, "inadequately" +313, 16, 10, 484, 61, 71, 2322, 2332, "controlled" +313, 16, 11, 485, 72, 76, 2333, 2337, "with" +313, 16, 12, 486, 77, 81, 2338, 2342, "oral" +313, 16, 13, 487, 82, 86, 2343, 2347, "anti" +313, 16, 14, 488, 87, 88, 2348, 2349, "-" +313, 16, 15, 489, 89, 103, 2350, 2364, "hyperglycaemic" +313, 16, 16, 490, 104, 115, 2365, 2376, "medications" +313, 16, 17, 491, 116, 117, 2377, 2378, "," +313, 16, 18, 492, 118, 127, 2379, 2388, "glycaemic" +313, 16, 19, 493, 128, 135, 2389, 2396, "control" +313, 16, 20, 494, 136, 140, 2397, 2401, "when" +313, 16, 21, 495, 141, 151, 2402, 2412, "initiating" +313, 16, 22, 496, 152, 155, 2413, 2416, "and" +313, 16, 23, 497, 156, 168, 2417, 2429, "intensifying" +313, 16, 24, 498, 169, 173, 2430, 2434, "with" +313, 16, 25, 499, 174, 178, 2435, 2439, "LM25" +313, 16, 26, 500, 179, 186, 2440, 2447, "therapy" +313, 16, 27, 501, 187, 190, 2448, 2451, "was" +313, 16, 28, 502, 191, 196, 2452, 2457, "found" +313, 16, 29, 503, 197, 199, 2458, 2460, "to" +313, 16, 30, 504, 200, 202, 2461, 2463, "be" +313, 16, 31, 505, 203, 206, 2464, 2467, "non" +313, 16, 32, 506, 207, 208, 2468, 2469, "-" +313, 16, 33, 507, 209, 217, 2470, 2478, "inferior" +313, 16, 34, 508, 218, 220, 2479, 2481, "to" +313, 16, 35, 509, 221, 230, 2482, 2491, "treatment" +313, 16, 36, 510, 231, 235, 2492, 2496, "with" +313, 16, 37, 511, 236, 244, 2497, 2505, "glargine" +313, 16, 38, 512, 245, 246, 2506, 2507, "+" +313, 16, 39, 513, 247, 254, 2508, 2515, "insulin" +313, 16, 40, 514, 255, 261, 2516, 2522, "lispro" +313, 16, 41, 515, 262, 269, 2523, 2530, "therapy" +313, 16, 42, 516, 270, 271, 2531, 2532, "." +313, 17, 1, 517, 0, 1, 2533, 2534, "©" +313, 17, 2, 518, 2, 6, 2535, 2539, "2012" +313, 17, 3, 519, 7, 10, 2540, 2543, "Eli" +313, 17, 4, 520, 11, 16, 2544, 2549, "Lilly" +313, 17, 5, 521, 17, 20, 2550, 2553, "and" +313, 17, 6, 522, 21, 28, 2554, 2561, "Company" +313, 17, 7, 523, 29, 30, 2562, 2563, "." +313, 18, 1, 524, 0, 8, 2564, 2572, "Diabetic" +313, 18, 2, 525, 9, 17, 2573, 2581, "Medicine" +313, 18, 3, 526, 18, 19, 2582, 2583, "©" +313, 18, 4, 527, 20, 24, 2584, 2588, "2012" +313, 18, 5, 528, 25, 33, 2589, 2597, "Diabetes" +313, 18, 6, 529, 34, 36, 2598, 2600, "UK" +313, 18, 7, 530, 37, 38, 2601, 2602, "." +313, 19, 1, 531, 0, 3, 2603, 2606, "DOI" +313, 19, 2, 532, 4, 5, 2607, 2608, ":" +313, 19, 3, 533, 6, 8, 2609, 2611, "10" +313, 19, 4, 534, 9, 10, 2612, 2613, "." +313, 19, 5, 535, 11, 15, 2614, 2618, "1111" +313, 19, 6, 536, 16, 17, 2619, 2620, "/" +313, 19, 7, 537, 18, 19, 2621, 2622, "j" +313, 19, 8, 538, 20, 21, 2623, 2624, "." +313, 19, 9, 539, 22, 26, 2625, 2629, "1464" +313, 19, 10, 540, 27, 28, 2630, 2631, "-" +313, 19, 11, 541, 29, 33, 2632, 2636, "5491" +313, 19, 12, 542, 34, 35, 2637, 2638, "." +313, 19, 13, 543, 36, 40, 2639, 2643, "2012" +313, 19, 14, 544, 41, 42, 2644, 2645, "." +313, 19, 15, 545, 43, 48, 2646, 2651, "03722" +313, 19, 16, 546, 49, 50, 2652, 2653, "." +313, 19, 17, 547, 51, 52, 2654, 2655, "x" +313, 19, 18, 548, 53, 57, 2656, 2660, "PMID" +313, 19, 19, 549, 58, 59, 2661, 2662, ":" +313, 19, 20, 550, 60, 68, 2663, 2671, "22672081" +313, 19, 21, 551, 69, 70, 2672, 2673, "[" +313, 19, 22, 552, 71, 78, 2674, 2681, "Indexed" +313, 19, 23, 553, 79, 82, 2682, 2685, "for" +313, 19, 24, 554, 83, 90, 2686, 2693, "MEDLINE" +313, 19, 25, 555, 91, 92, 2694, 2695, "]" diff --git a/data/dm2 22672081_kwoodley.annodb b/data/dm2 22672081_kwoodley.annodb new file mode 100644 index 0000000..4400ece --- /dev/null +++ b/data/dm2 22672081_kwoodley.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22068, Journal, 0, 12, "Diabet Med .", "", +22070, PublicationYear, 13, 17, "2012", "", +22102, Title, 102, 321, "A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication : results of the PARADIGM study .", "", +22074, Lispro, 120, 141, "insulin lispro mix 25", "", +22089, InsulinGlargine, 147, 155, "glargine", "", +22075, Lispro, 161, 167, "lispro", "", +22100, Precondition, 179, 287, "patients with Type 2 diabetes who have inadequate glycaemic control on oral anti - hyperglycaemic medication", "", +22096, Type2Diabetes, 193, 208, "Type 2 diabetes", "", +22099, OralAntidiabeticAgent, 250, 287, "oral anti - hyperglycaemic medication", "", +22103, Author, 322, 332, "Bowering K", "", +22104, Author, 341, 348, "Reed VA", "", +22105, Author, 351, 361, "Felicio JS", "", +22106, Author, 364, 372, "Landry J", "", +22107, Author, 375, 379, "Ji L", "", +22109, Author, 382, 392, "Oliveira J", "", +22110, Canada, 535, 541, "Canada", "", +22117, ObjectiveDescription, 650, 878, "To test the hypothesis that initiation and intensification with 25 % insulin lispro , 75 % insulin lispro protamine suspension ( LM25 ) , is non - inferior to initiation and intensification with glargine + insulin lispro therapy", "", +22077, Lispro, 714, 776, "25 % insulin lispro , 75 % insulin lispro protamine suspension", "", +22078, Lispro, 779, 783, "LM25", "", +22112, InsulinGlargine, 845, 853, "glargine", "", +22113, Lispro, 856, 870, "insulin lispro", "", +22118, ObjectiveDescription, 879, 918, "on change from baseline in HbA ( 1c ) .", "", +22114, HbA1c, 906, 916, "HbA ( 1c )", "", +22119, Randomized, 937, 947, "randomized", "", +22121, CTDesign, 950, 967, "non - inferiority", "", +22124, Parallel, 992, 1000, "parallel", "", +22126, CTDesign, 1003, 1014, "prospective", "", +24752, Multicenter, 1017, 1032, "multi - country", "", +22131, Duration, 1035, 1044, "48 - week", "", +22130, OpenLabel, 1047, 1059, "open - label", "", +22138, Precondition, 1068, 1177, "patients ( n = 426 ) with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications", "", +22132, NumberPatientsCT, 1083, 1086, "426", "", +22098, Type2Diabetes, 1094, 1109, "Type 2 diabetes", "", +22134, OralAntidiabeticAgent, 1139, 1177, "oral anti - hyperglycaemic medications", "", +22145, Frequency, 1226, 1293, "one daily LM25 injection , progressing up to three daily injections", "", +22079, Lispro, 1236, 1240, "LM25", "", +22152, NumberPatientsArm, 1318, 1321, "211", "", +22154, FinalNumPatientsArm, 1345, 1348, "177", "", +22150, Frequency, 1378, 1387, "one daily", "", +22148, InsulinGlargine, 1388, 1396, "glargine", "", +22151, Frequency, 1411, 1440, "progressing up to three daily", "", +22081, Lispro, 1441, 1455, "insulin lispro", "", +22153, NumberPatientsArm, 1491, 1494, "212", "", +22155, FinalNumPatientsArm, 1518, 1521, "184", "", +22082, Lispro, 1536, 1540, "LM25", "", +22157, InsulinGlargine, 1583, 1591, "glargine", "", +22158, Lispro, 1594, 1608, "insulin lispro", "", +22161, ConfIntervalResValue, 1632, 1662, "upper limit of 95 % CI < 0 . 4", "", +22164, ConfIntervalResValue, 1708, 1715, "95 % CI", "", +22167, HbA1c, 1721, 1731, "HbA ( 1c )", "", +22168, Lispro, 1734, 1738, "LM25", "", +22170, InsulinGlargine, 1745, 1753, "glargine", "", +22084, Lispro, 1756, 1770, "insulin lispro", "", +22175, DiffGroupAbsValue, 1776, 1783, "- 0 . 4", "", +22177, BioAndMedicalUnit, 1784, 1794, "mmol / mol", "", +22173, ConfIntervalDiff, 1797, 1821, "95 % CI - 2 . 7 to 1 . 9", "", +22176, DiffGroupAbsValue, 1826, 1834, "- 0 . 04", "", +22179, Percentage, 1835, 1836, "%", "", +22174, ConfIntervalDiff, 1839, 1865, "95 % CI - 0 . 25 to 0 . 17", "", +22184, ObservedResult, 1870, 2044, "No statistically significant differences between treatment groups were found in the percentage of patients achieving HbA ( 1c ) targets or postprandial blood glucose levels .", "", +22182, HbA1c_target, 1987, 2005, "HbA ( 1c ) targets", "", +33169, PostprandialBloodGlucose, 2009, 2035, "postprandial blood glucose", "", +22191, ObservedResult, 2045, 2175, "The increase in insulin dose , number of injections and weight change during the course of the study were similar in both groups .", "", +33170, InsulinDose, 2061, 2073, "insulin dose", "", +22188, EndPointDescription, 2076, 2096, "number of injections", "", +22190, BodyWeight, 2101, 2114, "weight change", "", +22194, ObservedResult, 2176, 2260, "Patients in both groups experienced similar hypoglycaemia rates and safety profile .", "", +22192, Hypoglycemia, 2220, 2233, "hypoglycaemia", "", +22193, EndPointDescription, 2244, 2258, "safety profile", "", +22199, ConclusionComment, 2275, 2496, "For patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications , glycaemic control when initiating and intensifying with LM25 therapy was found to be non - inferior to treatment with", "", +22196, Precondition, 2279, 2376, "patients with Type 2 diabetes inadequately controlled with oral anti - hyperglycaemic medications", "", +22097, Type2Diabetes, 2293, 2308, "Type 2 diabetes", "", +22195, OralAntidiabeticAgent, 2338, 2376, "oral anti - hyperglycaemic medications", "", +22086, Lispro, 2435, 2439, "LM25", "", +22198, InsulinGlargine, 2497, 2505, "glargine", "", +22201, ConclusionComment, 2497, 2532, "glargine + insulin lispro therapy .", "", +22087, Lispro, 2508, 2522, "insulin lispro", "", +22203, PMID, 2663, 2671, "22672081", "", diff --git a/data/dm2 22672081_kwoodley.n-triples b/data/dm2 22672081_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22672081_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672586_admin.annodb b/data/dm2 22672586_admin.annodb new file mode 100644 index 0000000..71540ad --- /dev/null +++ b/data/dm2 22672586_admin.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82, Journal, 0, 10, "J Diabetes", "", " \"J Diabetes\"." +1, PublicationYear, 13, 17, "2012", "", " \"2012\"." +79, Title, 100, 239, "The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes .", "", " \"The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes .\"." +2, Sitagliptin, 116, 127, "sitagliptin", "", +3, Metformin, 139, 148, "metformin", "", +86, China, 200, 207, "Chinese", "", " ." +4, Type2Diabetes, 222, 237, "type 2 diabetes", "", " ." +5, Author, 240, 246, "Yang W", "", " \"Yang W\"." +6, Author, 255, 261, "Guan Y", "", " \"Guan Y\"." +7, Author, 264, 272, "Shentu Y", "", " \"Shentu Y\"." +8, Author, 275, 279, "Li Z", "", " \"Li Z\"." +9, Author, 282, 302, "Johnson - Levonas AO", "", " \"Johnson - Levonas AO\"." +10, Author, 305, 313, "Engel SS", "", " \"Engel SS\"." +11, Author, 316, 326, "Kaufman KD", "", " \"Kaufman KD\"." +12, Author, 329, 341, "Goldstein BJ", "", " \"Goldstein BJ\"." +13, Author, 344, 350, "Alba M", "", " \"Alba M\"." +98, China, 380, 385, "China", "", +99, Japan, 388, 393, "Japan", "", +80, China, 426, 431, "China", "", +14, ObjectiveDescription, 449, 581, "The present study was conducted to evaluate the efficacy , safety and tolerability of sitagliptin added to ongoing metformin therapy", "", " \"The present study was conducted to evaluate the efficacy , safety and tolerability of sitagliptin added to ongoing metformin therapy\"." +18, Sitagliptin, 535, 546, "sitagliptin", "", +16, Metformin, 564, 573, "metformin", "", +15, ObjectiveDescription, 582, 708, "in Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy .", "", " \"in Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy .\"." +19, Precondition, 585, 706, "Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy", "", " \"Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy\"." +103, China, 585, 592, "Chinese", "", +20, Type2Diabetes, 607, 622, "type 2 diabetes", "", +21, Type2Diabetes, 625, 629, "T2DM", "", +106, Metformin, 685, 694, "metformin", "", +22, Metformin, 729, 738, "metformin", "", +25, Duration, 778, 786, "2 - week", "", +111, Blind, 789, 803, "single - blind", "", +27, Placebo, 806, 813, "placebo", "", +28, NumberPatientsCT, 832, 835, "395", "", " \"395\"." +114, China, 836, 843, "Chinese", "", +29, Type2Diabetes, 858, 862, "T2DM", "", +30, MinAge, 868, 870, "25", "", " \"25\"." +31, MaxAge, 873, 875, "77", "", " \"77\"." +118, TimePoint, 884, 892, "baseline", "", +32, HbA1c, 893, 898, "HbA1c", "", +33, BaseLineValue, 899, 904, "8 . 5", "", +34, Percentage, 905, 906, "%", "", +35, Randomized, 914, 924, "randomized", "", " ." +36, AllocationRatio, 927, 932, "1 : 1", "", " . ." +37, DoubleBlind, 938, 952, "double - blind", "", " ." +38, Placebo, 953, 960, "placebo", "", " ." +39, Sitagliptin, 964, 975, "sitagliptin", "", " ." +40, DoseValue, 976, 979, "100", "", " \"100\"." +41, mg, 980, 982, "mg", "", " ." +42, Frequency, 983, 990, "q . d .", "", " \"q . d .\"." +43, OpenLabel, 1008, 1020, "open - label", "", +44, Metformin, 1021, 1030, "metformin", "", " ." +45, DoseValue, 1033, 1045, "1000 or 1700", "", " \"1000 or 1700\"." +46, mg, 1046, 1048, "mg", "", " ." +47, Frequency, 1051, 1054, "day", "", " \"day\"." +48, Duration, 1061, 1069, "24 weeks", "", " \"24 weeks\"." +53, PValueChangeValue, 1098, 1111, "P  <  0 . 001", "", " \"P  <  0 . 001\". \"P  <  0 . 001\". \"P  <  0 . 001\"." +133, TimePoint, 1127, 1135, "baseline", "", +49, HbA1c, 1139, 1144, "HbA1c", "", " ." +54, Reduction, 1149, 1154, "0 . 9", "", " \"0 . 9\"." +57, Percentage, 1155, 1156, "%", "", " ." +50, FastingPlasmaGlucose, 1161, 1183, "fasting plasma glucose", "", " ." +55, Reduction, 1188, 1193, "1 . 2", "", " \"1 . 2\"." +58, Millimoles_per_litre, 1194, 1202, "mmol / L", "", " ." +81, PostprandialPlasmaGlucose, 1211, 1243, "2 - h post - meal plasma glucose", "", " ." +56, Reduction, 1248, 1253, "1 . 9", "", " \"1 . 9\"." +59, Millimoles_per_litre, 1254, 1262, "mmol / L", "", " ." +51, Sitagliptin, 1280, 1291, "sitagliptin", "", +52, Placebo, 1306, 1313, "placebo", "", +67, ObservedResult, 1316, 1385, "There were no significant differences between sitagliptin and placebo", "", +60, Sitagliptin, 1362, 1373, "sitagliptin", "", +63, Placebo, 1378, 1385, "placebo", "", +65, Hypoglycemia, 1406, 1418, "hypoglycemia", "", +66, GastrointestinalProblem, 1422, 1453, "gastrointestinal adverse events", "", +69, ObservedResult, 1458, 1472, "small decrease", "", " \"small decrease\"." +148, TimePoint, 1478, 1486, "baseline", "", +68, BodyWeight, 1487, 1498, "body weight", "", " ." +64, Placebo, 1519, 1526, "placebo", "", +70, ObservedResult, 1547, 1556, "no change", "", " \"no change\"." +61, Sitagliptin, 1564, 1575, "sitagliptin", "", +71, DiffGroupAbsValue, 1611, 1618, "0 . 5kg", "", " \"0 . 5kg\"." +153, Kg, 1615, 1618, "5kg", "", " ." +72, PvalueDiff, 1621, 1632, "P = 0 . 018", "", " \"P = 0 . 018\"." +77, ConclusionComment, 1653, 1876, "The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone .", "", " \"The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone .\"." +62, Sitagliptin, 1669, 1680, "sitagliptin", "", +73, DoseValue, 1681, 1684, "100", "", +74, mg, 1685, 1687, "mg", "", +24, Metformin, 1699, 1708, "metformin", "", +159, China, 1793, 1800, "Chinese", "", +75, Type2Diabetes, 1815, 1819, "T2DM", "", +23, Metformin, 1859, 1868, "metformin", "", +78, PMID, 2046, 2054, "22672586", "", " \"22672586\"." diff --git a/data/dm2 22672586_admin.n-triples b/data/dm2 22672586_admin.n-triples new file mode 100644 index 0000000..e6abd50 --- /dev/null +++ b/data/dm2 22672586_admin.n-triples @@ -0,0 +1,149 @@ +# RDF export of group: Publication + . + "Publication 39321" . + "The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes ." . + "Yang W" . + "2012" . + "J Diabetes" . + "22672586" . + . + "Guan Y" . + "Shentu Y" . + "Li Z" . + "Johnson - Levonas AO" . + "Engel SS" . + "Kaufman KD" . + "Goldstein BJ" . + "Alba M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 39328" . + "The present study was conducted to evaluate the efficacy , safety and tolerability of sitagliptin added to ongoing metformin therapy" . + "395" . + "24 weeks" . + . + . + . + . + "The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone ." . + . + . + . + . + . + "in Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy ." . + . + . +# RDF export of group: Population + . + "Population 39344" . + "Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy" . + . + . + "25" . + "77" . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + . + . + . + . + . + . + . + "pl" . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "q . d ." . + . + . + "pla" . + . + . + . + "met" . + . + "day" . + . +# RDF export of group: Medication + . + "sit" . + . + "100" . + . + . + . + "pla " . + . + . + . + . + "met" . + . + "1000 or 1700" . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "0 . 9" . + "P  <  0 . 001" . + . + "fpg 1" . + . + "1 . 2" . + "P  <  0 . 001" . + . + "ppg 1" . + . + "1 . 9" . + "P  <  0 . 001" . + . + "bw 1" . + . + "no change" . + . + "bw 2" . + . + "small decrease" . +# RDF export of group: DiffBetweenGroups + . + "bw" . + "0 . 5kg" . + "P = 0 . 018" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672586_akramersunderbrink.annodb b/data/dm2 22672586_akramersunderbrink.annodb new file mode 100644 index 0000000..972b6de --- /dev/null +++ b/data/dm2 22672586_akramersunderbrink.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +41662, Journal, 0, 10, "J Diabetes", "", +41663, PublicationYear, 13, 17, "2012", "", +41668, Title, 100, 239, "The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes .", "", +41664, Sitagliptin, 116, 127, "sitagliptin", "", +41665, Metformin, 139, 148, "metformin", "", +41666, China, 200, 207, "Chinese", "", +41667, Type2Diabetes, 222, 237, "type 2 diabetes", "", +41669, Author, 240, 246, "Yang W", "", +41670, Author, 255, 261, "Guan Y", "", +41671, Author, 264, 272, "Shentu Y", "", +41672, Author, 275, 279, "Li Z", "", +41673, Author, 282, 302, "Johnson - Levonas AO", "", +41674, Author, 305, 313, "Engel SS", "", +41675, Author, 316, 326, "Kaufman KD", "", +41676, Author, 329, 341, "Goldstein BJ", "", +41677, Author, 344, 350, "Alba M", "", +41678, China, 380, 385, "China", "", +41679, Japan, 388, 393, "Japan", "", +41680, China, 426, 431, "China", "", +41688, ObjectiveDescription, 449, 642, "The present study was conducted to evaluate the efficacy , safety and tolerability of sitagliptin added to ongoing metformin therapy in Chinese patients with type 2 diabetes ( T2DM ) who failed", "", +41681, Sitagliptin, 535, 546, "sitagliptin", "", +41682, Metformin, 564, 573, "metformin", "", +41683, China, 585, 592, "Chinese", "", +41684, Type2Diabetes, 607, 622, "type 2 diabetes", "", +41685, Type2Diabetes, 625, 629, "T2DM", "", +41689, ObjectiveDescription, 643, 708, "to achieve adequate glycemic control with metformin monotherapy .", "", +41686, Metformin, 685, 694, "metformin", "", +41690, Metformin, 729, 738, "metformin", "", +41691, Duration, 778, 786, "2 - week", "", +41692, Blind, 789, 803, "single - blind", "", +41693, Placebo, 806, 813, "placebo", "", +41694, NumberPatientsCT, 832, 835, "395", "", +41695, China, 836, 843, "Chinese", "", +41696, Type2Diabetes, 858, 862, "T2DM", "", +41697, MinAge, 868, 870, "25", "", +41698, MaxAge, 873, 875, "77", "", +41699, TimePoint, 884, 892, "baseline", "", +41700, Precondition, 884, 906, "baseline HbA1c 8 . 5 %", "", +41701, HbA1c, 893, 898, "HbA1c", "", +41702, Percentage, 905, 906, "%", "", +41703, Randomized, 914, 924, "randomized", "", +41704, DoubleBlind, 938, 952, "double - blind", "", +41705, Placebo, 953, 960, "placebo", "", +41706, Sitagliptin, 964, 975, "sitagliptin", "", +41707, DoseValue, 976, 982, "100 mg", "", +41708, mg, 980, 982, "mg", "", +41710, Frequency, 983, 990, "q . d .", "", +41711, OpenLabel, 1008, 1020, "open - label", "", +41712, Metformin, 1021, 1030, "metformin", "", +41714, DoseValue, 1033, 1054, "1000 or 1700 mg / day", "", +41713, Duration, 1061, 1069, "24 weeks", "", +41724, PValueChangeValue, 1098, 1111, "P  <  0 . 001", "", +41715, TimePoint, 1127, 1135, "baseline", "", +41716, HbA1c, 1139, 1144, "HbA1c", "", +41721, ChangeValue, 1147, 1154, "- 0 . 9", "", +41717, FastingPlasmaGlucose, 1161, 1183, "fasting plasma glucose", "", +41722, ChangeValue, 1186, 1193, "- 1 . 2", "", +41725, Millimoles_per_litre, 1194, 1202, "mmol / L", "", +41718, PostprandialPlasmaGlucose, 1211, 1243, "2 - h post - meal plasma glucose", "", +41723, ChangeValue, 1246, 1253, "- 1 . 9", "", +41726, Millimoles_per_litre, 1254, 1262, "mmol / L", "", +41719, Sitagliptin, 1280, 1291, "sitagliptin", "", +41720, Placebo, 1306, 1313, "placebo", "", +41727, Sitagliptin, 1362, 1373, "sitagliptin", "", +41728, Placebo, 1378, 1385, "placebo", "", +41729, Hypoglycemia, 1406, 1418, "hypoglycemia", "", +41730, TimePoint, 1478, 1486, "baseline", "", +41731, BodyWeight, 1487, 1498, "body weight", "", +41732, Placebo, 1519, 1526, "placebo", "", +41733, Sitagliptin, 1564, 1575, "sitagliptin", "", +41734, DiffGroupAbsValue, 1611, 1618, "0 . 5kg", "", +41735, Kg, 1615, 1618, "5kg", "", +41736, PvalueDiff, 1621, 1632, "P = 0 . 018", "", +41744, ConclusionComment, 1653, 1876, "The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone .", "", +41737, Sitagliptin, 1669, 1680, "sitagliptin", "", +41738, DoseValue, 1681, 1687, "100 mg", "", +41739, mg, 1685, 1687, "mg", "", +41740, Metformin, 1699, 1708, "metformin", "", +41741, China, 1793, 1800, "Chinese", "", +41742, Type2Diabetes, 1815, 1819, "T2DM", "", +41743, Metformin, 1859, 1868, "metformin", "", +41745, PMID, 2046, 2054, "22672586", "", diff --git a/data/dm2 22672586_akramersunderbrink.n-triples b/data/dm2 22672586_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22672586_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22672586_export.csv b/data/dm2 22672586_export.csv new file mode 100644 index 0000000..809a033 --- /dev/null +++ b/data/dm2 22672586_export.csv @@ -0,0 +1,427 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +312, 1, 1, 1, 0, 1, 0, 1, "J" +312, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +312, 1, 3, 3, 11, 12, 11, 12, "." +312, 2, 1, 4, 0, 4, 13, 17, "2012" +312, 2, 2, 5, 5, 8, 18, 21, "Sep" +312, 2, 3, 6, 9, 10, 22, 23, ";" +312, 2, 4, 7, 11, 12, 24, 25, "4" +312, 2, 5, 8, 13, 14, 26, 27, "(" +312, 2, 6, 9, 15, 16, 28, 29, "3" +312, 2, 7, 10, 17, 18, 30, 31, ")" +312, 2, 8, 11, 19, 20, 32, 33, ":" +312, 2, 9, 12, 21, 24, 34, 37, "227" +312, 2, 10, 13, 25, 26, 38, 39, "-" +312, 2, 11, 14, 27, 29, 40, 42, "37" +312, 2, 12, 15, 30, 31, 43, 44, "." +312, 2, 13, 16, 32, 35, 45, 48, "doi" +312, 2, 14, 17, 36, 37, 49, 50, ":" +312, 2, 15, 18, 38, 40, 51, 53, "10" +312, 2, 16, 19, 41, 42, 54, 55, "." +312, 2, 17, 20, 43, 47, 56, 60, "1111" +312, 2, 18, 21, 48, 49, 61, 62, "/" +312, 2, 19, 22, 50, 51, 63, 64, "j" +312, 2, 20, 23, 52, 53, 65, 66, "." +312, 2, 21, 24, 54, 58, 67, 71, "1753" +312, 2, 22, 25, 59, 60, 72, 73, "-" +312, 2, 23, 26, 61, 65, 74, 78, "0407" +312, 2, 24, 27, 66, 67, 79, 80, "." +312, 2, 25, 28, 68, 72, 81, 85, "2012" +312, 2, 26, 29, 73, 74, 86, 87, "." +312, 2, 27, 30, 75, 80, 88, 93, "00213" +312, 2, 28, 31, 81, 82, 94, 95, "." +312, 2, 29, 32, 83, 84, 96, 97, "x" +312, 2, 30, 33, 85, 86, 98, 99, "." +312, 3, 1, 34, 0, 3, 100, 103, "The" +312, 3, 2, 35, 4, 12, 104, 112, "addition" +312, 3, 3, 36, 13, 15, 113, 115, "of" +312, 3, 4, 37, 16, 27, 116, 127, "sitagliptin" +312, 3, 5, 38, 28, 30, 128, 130, "to" +312, 3, 6, 39, 31, 38, 131, 138, "ongoing" +312, 3, 7, 40, 39, 48, 139, 148, "metformin" +312, 3, 8, 41, 49, 56, 149, 156, "therapy" +312, 3, 9, 42, 57, 70, 157, 170, "significantly" +312, 3, 10, 43, 71, 79, 171, 179, "improves" +312, 3, 11, 44, 80, 88, 180, 188, "glycemic" +312, 3, 12, 45, 89, 96, 189, 196, "control" +312, 3, 13, 46, 97, 99, 197, 199, "in" +312, 3, 14, 47, 100, 107, 200, 207, "Chinese" +312, 3, 15, 48, 108, 116, 208, 216, "patients" +312, 3, 16, 49, 117, 121, 217, 221, "with" +312, 3, 17, 50, 122, 126, 222, 226, "type" +312, 3, 18, 51, 127, 128, 227, 228, "2" +312, 3, 19, 52, 129, 137, 229, 237, "diabetes" +312, 3, 20, 53, 138, 139, 238, 239, "." +312, 4, 1, 54, 0, 4, 240, 244, "Yang" +312, 4, 2, 55, 5, 6, 245, 246, "W" +312, 4, 3, 56, 7, 8, 247, 248, "(" +312, 4, 4, 57, 9, 10, 249, 250, "1" +312, 4, 5, 58, 11, 12, 251, 252, ")" +312, 4, 6, 59, 13, 14, 253, 254, "," +312, 4, 7, 60, 15, 19, 255, 259, "Guan" +312, 4, 8, 61, 20, 21, 260, 261, "Y" +312, 4, 9, 62, 22, 23, 262, 263, "," +312, 4, 10, 63, 24, 30, 264, 270, "Shentu" +312, 4, 11, 64, 31, 32, 271, 272, "Y" +312, 4, 12, 65, 33, 34, 273, 274, "," +312, 4, 13, 66, 35, 37, 275, 277, "Li" +312, 4, 14, 67, 38, 39, 278, 279, "Z" +312, 4, 15, 68, 40, 41, 280, 281, "," +312, 4, 16, 69, 42, 49, 282, 289, "Johnson" +312, 4, 17, 70, 50, 51, 290, 291, "-" +312, 4, 18, 71, 52, 59, 292, 299, "Levonas" +312, 4, 19, 72, 60, 62, 300, 302, "AO" +312, 4, 20, 73, 63, 64, 303, 304, "," +312, 4, 21, 74, 65, 70, 305, 310, "Engel" +312, 4, 22, 75, 71, 73, 311, 313, "SS" +312, 4, 23, 76, 74, 75, 314, 315, "," +312, 4, 24, 77, 76, 83, 316, 323, "Kaufman" +312, 4, 25, 78, 84, 86, 324, 326, "KD" +312, 4, 26, 79, 87, 88, 327, 328, "," +312, 4, 27, 80, 89, 98, 329, 338, "Goldstein" +312, 4, 28, 81, 99, 101, 339, 341, "BJ" +312, 4, 29, 82, 102, 103, 342, 343, "," +312, 4, 30, 83, 104, 108, 344, 348, "Alba" +312, 4, 31, 84, 109, 110, 349, 350, "M" +312, 4, 32, 85, 111, 112, 351, 352, "." +312, 4, 33, 86, 113, 119, 353, 359, "Author" +312, 4, 34, 87, 120, 131, 360, 371, "information" +312, 4, 35, 88, 132, 133, 372, 373, ":" +312, 4, 36, 89, 134, 135, 374, 375, "(" +312, 4, 37, 90, 136, 137, 376, 377, "1" +312, 4, 38, 91, 138, 139, 378, 379, ")" +312, 4, 39, 92, 140, 145, 380, 385, "China" +312, 4, 40, 93, 146, 147, 386, 387, "-" +312, 4, 41, 94, 148, 153, 388, 393, "Japan" +312, 4, 42, 95, 154, 164, 394, 404, "Friendship" +312, 4, 43, 96, 165, 173, 405, 413, "Hospital" +312, 4, 44, 97, 174, 175, 414, 415, "," +312, 4, 45, 98, 176, 183, 416, 423, "Beijing" +312, 4, 46, 99, 184, 185, 424, 425, "," +312, 4, 47, 100, 186, 191, 426, 431, "China" +312, 4, 48, 101, 192, 193, 432, 433, "." +312, 5, 1, 102, 0, 10, 434, 444, "BACKGROUND" +312, 5, 2, 103, 11, 12, 445, 446, ":" +312, 5, 3, 104, 13, 14, 447, 448, " " +312, 5, 4, 105, 15, 18, 449, 452, "The" +312, 5, 5, 106, 19, 26, 453, 460, "present" +312, 5, 6, 107, 27, 32, 461, 466, "study" +312, 5, 7, 108, 33, 36, 467, 470, "was" +312, 5, 8, 109, 37, 46, 471, 480, "conducted" +312, 5, 9, 110, 47, 49, 481, 483, "to" +312, 5, 10, 111, 50, 58, 484, 492, "evaluate" +312, 5, 11, 112, 59, 62, 493, 496, "the" +312, 5, 12, 113, 63, 71, 497, 505, "efficacy" +312, 5, 13, 114, 72, 73, 506, 507, "," +312, 5, 14, 115, 74, 80, 508, 514, "safety" +312, 5, 15, 116, 81, 84, 515, 518, "and" +312, 5, 16, 117, 85, 97, 519, 531, "tolerability" +312, 5, 17, 118, 98, 100, 532, 534, "of" +312, 5, 18, 119, 101, 112, 535, 546, "sitagliptin" +312, 5, 19, 120, 113, 118, 547, 552, "added" +312, 5, 20, 121, 119, 121, 553, 555, "to" +312, 5, 21, 122, 122, 129, 556, 563, "ongoing" +312, 5, 22, 123, 130, 139, 564, 573, "metformin" +312, 5, 23, 124, 140, 147, 574, 581, "therapy" +312, 5, 24, 125, 148, 150, 582, 584, "in" +312, 5, 25, 126, 151, 158, 585, 592, "Chinese" +312, 5, 26, 127, 159, 167, 593, 601, "patients" +312, 5, 27, 128, 168, 172, 602, 606, "with" +312, 5, 28, 129, 173, 177, 607, 611, "type" +312, 5, 29, 130, 178, 179, 612, 613, "2" +312, 5, 30, 131, 180, 188, 614, 622, "diabetes" +312, 5, 31, 132, 189, 190, 623, 624, "(" +312, 5, 32, 133, 191, 195, 625, 629, "T2DM" +312, 5, 33, 134, 196, 197, 630, 631, ")" +312, 5, 34, 135, 198, 201, 632, 635, "who" +312, 5, 35, 136, 202, 208, 636, 642, "failed" +312, 5, 36, 137, 209, 211, 643, 645, "to" +312, 5, 37, 138, 212, 219, 646, 653, "achieve" +312, 5, 38, 139, 220, 228, 654, 662, "adequate" +312, 5, 39, 140, 229, 237, 663, 671, "glycemic" +312, 5, 40, 141, 238, 245, 672, 679, "control" +312, 5, 41, 142, 246, 250, 680, 684, "with" +312, 5, 42, 143, 251, 260, 685, 694, "metformin" +312, 5, 43, 144, 261, 272, 695, 706, "monotherapy" +312, 5, 44, 145, 273, 274, 707, 708, "." +312, 6, 1, 146, 0, 7, 709, 716, "METHODS" +312, 6, 2, 147, 8, 9, 717, 718, ":" +312, 6, 3, 148, 10, 11, 719, 720, " " +312, 6, 4, 149, 12, 17, 721, 726, "After" +312, 6, 5, 150, 18, 19, 727, 728, "a" +312, 6, 6, 151, 20, 29, 729, 738, "metformin" +312, 6, 7, 152, 30, 39, 739, 748, "titration" +312, 6, 8, 153, 40, 41, 749, 750, "/" +312, 6, 9, 154, 42, 55, 751, 764, "stabilization" +312, 6, 10, 155, 56, 62, 765, 771, "period" +312, 6, 11, 156, 63, 66, 772, 775, "and" +312, 6, 12, 157, 67, 68, 776, 777, "a" +312, 6, 13, 158, 69, 70, 778, 779, "2" +312, 6, 14, 159, 71, 72, 780, 781, "-" +312, 6, 15, 160, 73, 77, 782, 786, "week" +312, 6, 16, 161, 78, 79, 787, 788, "," +312, 6, 17, 162, 80, 86, 789, 795, "single" +312, 6, 18, 163, 87, 88, 796, 797, "-" +312, 6, 19, 164, 89, 94, 798, 803, "blind" +312, 6, 20, 165, 95, 96, 804, 805, "," +312, 6, 21, 166, 97, 104, 806, 813, "placebo" +312, 6, 22, 167, 105, 108, 814, 817, "run" +312, 6, 23, 168, 109, 110, 818, 819, "-" +312, 6, 24, 169, 111, 113, 820, 822, "in" +312, 6, 25, 170, 114, 120, 823, 829, "period" +312, 6, 26, 171, 121, 122, 830, 831, "," +312, 6, 27, 172, 123, 126, 832, 835, "395" +312, 6, 28, 173, 127, 134, 836, 843, "Chinese" +312, 6, 29, 174, 135, 143, 844, 852, "patients" +312, 6, 30, 175, 144, 148, 853, 857, "with" +312, 6, 31, 176, 149, 153, 858, 862, "T2DM" +312, 6, 32, 177, 154, 158, 863, 867, "aged" +312, 6, 33, 178, 159, 161, 868, 870, "25" +312, 6, 34, 179, 162, 163, 871, 872, "-" +312, 6, 35, 180, 164, 166, 873, 875, "77" +312, 6, 36, 181, 167, 172, 876, 881, "years" +312, 6, 37, 182, 173, 174, 882, 883, "(" +312, 6, 38, 183, 175, 183, 884, 892, "baseline" +312, 6, 39, 184, 184, 189, 893, 898, "HbA1c" +312, 6, 40, 185, 190, 191, 899, 900, "8" +312, 6, 41, 186, 192, 193, 901, 902, "." +312, 6, 42, 187, 194, 195, 903, 904, "5" +312, 6, 43, 188, 196, 197, 905, 906, "%" +312, 6, 44, 189, 198, 199, 907, 908, ")" +312, 6, 45, 190, 200, 204, 909, 913, "were" +312, 6, 46, 191, 205, 215, 914, 924, "randomized" +312, 6, 47, 192, 216, 217, 925, 926, "(" +312, 6, 48, 193, 218, 219, 927, 928, "1" +312, 6, 49, 194, 220, 221, 929, 930, ":" +312, 6, 50, 195, 222, 223, 931, 932, "1" +312, 6, 51, 196, 224, 225, 933, 934, ")" +312, 6, 52, 197, 226, 228, 935, 937, "to" +312, 6, 53, 198, 229, 235, 938, 944, "double" +312, 6, 54, 199, 236, 237, 945, 946, "-" +312, 6, 55, 200, 238, 243, 947, 952, "blind" +312, 6, 56, 201, 244, 251, 953, 960, "placebo" +312, 6, 57, 202, 252, 254, 961, 963, "or" +312, 6, 58, 203, 255, 266, 964, 975, "sitagliptin" +312, 6, 59, 204, 267, 270, 976, 979, "100" +312, 6, 60, 205, 271, 273, 980, 982, "mg" +312, 6, 61, 206, 274, 275, 983, 984, "q" +312, 6, 62, 207, 276, 277, 985, 986, "." +312, 6, 63, 208, 278, 279, 987, 988, "d" +312, 6, 64, 209, 280, 281, 989, 990, "." +312, 7, 1, 210, 0, 5, 991, 996, "added" +312, 7, 2, 211, 6, 8, 997, 999, "to" +312, 7, 3, 212, 9, 16, 1000, 1007, "ongoing" +312, 7, 4, 213, 17, 21, 1008, 1012, "open" +312, 7, 5, 214, 22, 23, 1013, 1014, "-" +312, 7, 6, 215, 24, 29, 1015, 1020, "label" +312, 7, 7, 216, 30, 39, 1021, 1030, "metformin" +312, 7, 8, 217, 40, 41, 1031, 1032, "(" +312, 7, 9, 218, 42, 46, 1033, 1037, "1000" +312, 7, 10, 219, 47, 49, 1038, 1040, "or" +312, 7, 11, 220, 50, 54, 1041, 1045, "1700" +312, 7, 12, 221, 55, 57, 1046, 1048, "mg" +312, 7, 13, 222, 58, 59, 1049, 1050, "/" +312, 7, 14, 223, 60, 63, 1051, 1054, "day" +312, 7, 15, 224, 64, 65, 1055, 1056, ")" +312, 7, 16, 225, 66, 69, 1057, 1060, "for" +312, 7, 17, 226, 70, 72, 1061, 1063, "24" +312, 7, 18, 227, 73, 78, 1064, 1069, "weeks" +312, 7, 19, 228, 79, 80, 1070, 1071, "." +312, 8, 1, 229, 0, 7, 1072, 1079, "RESULTS" +312, 8, 2, 230, 8, 9, 1080, 1081, ":" +312, 8, 3, 231, 10, 11, 1082, 1083, " " +312, 8, 4, 232, 12, 23, 1084, 1095, "Significant" +312, 8, 5, 233, 24, 25, 1096, 1097, "(" +312, 8, 6, 234, 26, 27, 1098, 1099, "P" +312, 8, 7, 235, 28, 31, 1100, 1103, " < " +312, 8, 8, 236, 32, 33, 1104, 1105, "0" +312, 8, 9, 237, 34, 35, 1106, 1107, "." +312, 8, 10, 238, 36, 39, 1108, 1111, "001" +312, 8, 11, 239, 40, 41, 1112, 1113, ")" +312, 8, 12, 240, 42, 49, 1114, 1121, "changes" +312, 8, 13, 241, 50, 54, 1122, 1126, "from" +312, 8, 14, 242, 55, 63, 1127, 1135, "baseline" +312, 8, 15, 243, 64, 66, 1136, 1138, "in" +312, 8, 16, 244, 67, 72, 1139, 1144, "HbA1c" +312, 8, 17, 245, 73, 74, 1145, 1146, "(" +312, 8, 18, 246, 75, 76, 1147, 1148, "-" +312, 8, 19, 247, 77, 78, 1149, 1150, "0" +312, 8, 20, 248, 79, 80, 1151, 1152, "." +312, 8, 21, 249, 81, 82, 1153, 1154, "9" +312, 8, 22, 250, 83, 84, 1155, 1156, "%" +312, 8, 23, 251, 85, 86, 1157, 1158, ")" +312, 8, 24, 252, 87, 88, 1159, 1160, "," +312, 8, 25, 253, 89, 96, 1161, 1168, "fasting" +312, 8, 26, 254, 97, 103, 1169, 1175, "plasma" +312, 8, 27, 255, 104, 111, 1176, 1183, "glucose" +312, 8, 28, 256, 112, 113, 1184, 1185, "(" +312, 8, 29, 257, 114, 115, 1186, 1187, "-" +312, 8, 30, 258, 116, 117, 1188, 1189, "1" +312, 8, 31, 259, 118, 119, 1190, 1191, "." +312, 8, 32, 260, 120, 121, 1192, 1193, "2" +312, 8, 33, 261, 122, 126, 1194, 1198, "mmol" +312, 8, 34, 262, 127, 128, 1199, 1200, "/" +312, 8, 35, 263, 129, 130, 1201, 1202, "L" +312, 8, 36, 264, 131, 132, 1203, 1204, ")" +312, 8, 37, 265, 133, 134, 1205, 1206, "," +312, 8, 38, 266, 135, 138, 1207, 1210, "and" +312, 8, 39, 267, 139, 140, 1211, 1212, "2" +312, 8, 40, 268, 141, 142, 1213, 1214, "-" +312, 8, 41, 269, 143, 144, 1215, 1216, "h" +312, 8, 42, 270, 145, 149, 1217, 1221, "post" +312, 8, 43, 271, 150, 151, 1222, 1223, "-" +312, 8, 44, 272, 152, 156, 1224, 1228, "meal" +312, 8, 45, 273, 157, 163, 1229, 1235, "plasma" +312, 8, 46, 274, 164, 171, 1236, 1243, "glucose" +312, 8, 47, 275, 172, 173, 1244, 1245, "(" +312, 8, 48, 276, 174, 175, 1246, 1247, "-" +312, 8, 49, 277, 176, 177, 1248, 1249, "1" +312, 8, 50, 278, 178, 179, 1250, 1251, "." +312, 8, 51, 279, 180, 181, 1252, 1253, "9" +312, 8, 52, 280, 182, 186, 1254, 1258, "mmol" +312, 8, 53, 281, 187, 188, 1259, 1260, "/" +312, 8, 54, 282, 189, 190, 1261, 1262, "L" +312, 8, 55, 283, 191, 192, 1263, 1264, ")" +312, 8, 56, 284, 193, 197, 1265, 1269, "were" +312, 8, 57, 285, 198, 202, 1270, 1274, "seen" +312, 8, 58, 286, 203, 207, 1275, 1279, "with" +312, 8, 59, 287, 208, 219, 1280, 1291, "sitagliptin" +312, 8, 60, 288, 220, 228, 1292, 1300, "compared" +312, 8, 61, 289, 229, 233, 1301, 1305, "with" +312, 8, 62, 290, 234, 241, 1306, 1313, "placebo" +312, 8, 63, 291, 242, 243, 1314, 1315, "." +312, 9, 1, 292, 0, 5, 1316, 1321, "There" +312, 9, 2, 293, 6, 10, 1322, 1326, "were" +312, 9, 3, 294, 11, 13, 1327, 1329, "no" +312, 9, 4, 295, 14, 25, 1330, 1341, "significant" +312, 9, 5, 296, 26, 37, 1342, 1353, "differences" +312, 9, 6, 297, 38, 45, 1354, 1361, "between" +312, 9, 7, 298, 46, 57, 1362, 1373, "sitagliptin" +312, 9, 8, 299, 58, 61, 1374, 1377, "and" +312, 9, 9, 300, 62, 69, 1378, 1385, "placebo" +312, 9, 10, 301, 70, 72, 1386, 1388, "in" +312, 9, 11, 302, 73, 76, 1389, 1392, "the" +312, 9, 12, 303, 77, 86, 1393, 1402, "incidence" +312, 9, 13, 304, 87, 89, 1403, 1405, "of" +312, 9, 14, 305, 90, 102, 1406, 1418, "hypoglycemia" +312, 9, 15, 306, 103, 105, 1419, 1421, "or" +312, 9, 16, 307, 106, 122, 1422, 1438, "gastrointestinal" +312, 9, 17, 308, 123, 130, 1439, 1446, "adverse" +312, 9, 18, 309, 131, 137, 1447, 1453, "events" +312, 9, 19, 310, 138, 139, 1454, 1455, "." +312, 10, 1, 311, 0, 1, 1456, 1457, "A" +312, 10, 2, 312, 2, 7, 1458, 1463, "small" +312, 10, 3, 313, 8, 16, 1464, 1472, "decrease" +312, 10, 4, 314, 17, 21, 1473, 1477, "from" +312, 10, 5, 315, 22, 30, 1478, 1486, "baseline" +312, 10, 6, 316, 31, 35, 1487, 1491, "body" +312, 10, 7, 317, 36, 42, 1492, 1498, "weight" +312, 10, 8, 318, 43, 46, 1499, 1502, "was" +312, 10, 9, 319, 47, 55, 1503, 1511, "observed" +312, 10, 10, 320, 56, 58, 1512, 1514, "in" +312, 10, 11, 321, 59, 62, 1515, 1518, "the" +312, 10, 12, 322, 63, 70, 1519, 1526, "placebo" +312, 10, 13, 323, 71, 76, 1527, 1532, "group" +312, 10, 14, 324, 77, 85, 1533, 1541, "compared" +312, 10, 15, 325, 86, 90, 1542, 1546, "with" +312, 10, 16, 326, 91, 93, 1547, 1549, "no" +312, 10, 17, 327, 94, 100, 1550, 1556, "change" +312, 10, 18, 328, 101, 103, 1557, 1559, "in" +312, 10, 19, 329, 104, 107, 1560, 1563, "the" +312, 10, 20, 330, 108, 119, 1564, 1575, "sitagliptin" +312, 10, 21, 331, 120, 125, 1576, 1581, "group" +312, 10, 22, 332, 126, 127, 1582, 1583, "(" +312, 10, 23, 333, 128, 135, 1584, 1591, "between" +312, 10, 24, 334, 136, 137, 1592, 1593, "-" +312, 10, 25, 335, 138, 143, 1594, 1599, "group" +312, 10, 26, 336, 144, 154, 1600, 1610, "difference" +312, 10, 27, 337, 155, 156, 1611, 1612, "0" +312, 10, 28, 338, 157, 158, 1613, 1614, "." +312, 10, 29, 339, 159, 162, 1615, 1618, "5kg" +312, 10, 30, 340, 163, 164, 1619, 1620, ";" +312, 10, 31, 341, 165, 166, 1621, 1622, "P" +312, 10, 32, 342, 167, 168, 1623, 1624, "=" +312, 10, 33, 343, 169, 170, 1625, 1626, "0" +312, 10, 34, 344, 171, 172, 1627, 1628, "." +312, 10, 35, 345, 173, 176, 1629, 1632, "018" +312, 10, 36, 346, 177, 178, 1633, 1634, ")" +312, 10, 37, 347, 179, 180, 1635, 1636, "." +312, 11, 1, 348, 0, 11, 1637, 1648, "CONCLUSIONS" +312, 11, 2, 349, 12, 13, 1649, 1650, ":" +312, 11, 3, 350, 14, 15, 1651, 1652, " " +312, 11, 4, 351, 16, 19, 1653, 1656, "The" +312, 11, 5, 352, 20, 28, 1657, 1665, "addition" +312, 11, 6, 353, 29, 31, 1666, 1668, "of" +312, 11, 7, 354, 32, 43, 1669, 1680, "sitagliptin" +312, 11, 8, 355, 44, 47, 1681, 1684, "100" +312, 11, 9, 356, 48, 50, 1685, 1687, "mg" +312, 11, 10, 357, 51, 53, 1688, 1690, "to" +312, 11, 11, 358, 54, 61, 1691, 1698, "ongoing" +312, 11, 12, 359, 62, 71, 1699, 1708, "metformin" +312, 11, 13, 360, 72, 79, 1709, 1716, "therapy" +312, 11, 14, 361, 80, 93, 1717, 1730, "significantly" +312, 11, 15, 362, 94, 102, 1731, 1739, "improved" +312, 11, 16, 363, 103, 111, 1740, 1748, "glycemic" +312, 11, 17, 364, 112, 119, 1749, 1756, "control" +312, 11, 18, 365, 120, 123, 1757, 1760, "and" +312, 11, 19, 366, 124, 127, 1761, 1764, "was" +312, 11, 20, 367, 128, 137, 1765, 1774, "generally" +312, 11, 21, 368, 138, 142, 1775, 1779, "well" +312, 11, 22, 369, 143, 152, 1780, 1789, "tolerated" +312, 11, 23, 370, 153, 155, 1790, 1792, "in" +312, 11, 24, 371, 156, 163, 1793, 1800, "Chinese" +312, 11, 25, 372, 164, 172, 1801, 1809, "patients" +312, 11, 26, 373, 173, 177, 1810, 1814, "with" +312, 11, 27, 374, 178, 182, 1815, 1819, "T2DM" +312, 11, 28, 375, 183, 186, 1820, 1823, "who" +312, 11, 29, 376, 187, 190, 1824, 1827, "had" +312, 11, 30, 377, 191, 201, 1828, 1838, "inadequate" +312, 11, 31, 378, 202, 210, 1839, 1847, "glycemic" +312, 11, 32, 379, 211, 218, 1848, 1855, "control" +312, 11, 33, 380, 219, 221, 1856, 1858, "on" +312, 11, 34, 381, 222, 231, 1859, 1868, "metformin" +312, 11, 35, 382, 232, 237, 1869, 1874, "alone" +312, 11, 36, 383, 238, 239, 1875, 1876, "." +312, 12, 1, 384, 0, 1, 1877, 1878, "©" +312, 12, 2, 385, 2, 6, 1879, 1883, "2012" +312, 12, 3, 386, 7, 13, 1884, 1890, "Ruijin" +312, 12, 4, 387, 14, 22, 1891, 1899, "Hospital" +312, 12, 5, 388, 23, 24, 1900, 1901, "," +312, 12, 6, 389, 25, 33, 1902, 1910, "Shanghai" +312, 12, 7, 390, 34, 42, 1911, 1919, "Jiaotong" +312, 12, 8, 391, 43, 53, 1920, 1930, "University" +312, 12, 9, 392, 54, 60, 1931, 1937, "School" +312, 12, 10, 393, 61, 63, 1938, 1940, "of" +312, 12, 11, 394, 64, 72, 1941, 1949, "Medicine" +312, 12, 12, 395, 73, 76, 1950, 1953, "and" +312, 12, 13, 396, 77, 82, 1954, 1959, "Wiley" +312, 12, 14, 397, 83, 93, 1960, 1970, "Publishing" +312, 12, 15, 398, 94, 98, 1971, 1975, "Asia" +312, 12, 16, 399, 99, 102, 1976, 1979, "Pty" +312, 12, 17, 400, 103, 106, 1980, 1983, "Ltd" +312, 12, 18, 401, 107, 108, 1984, 1985, "." +312, 12, 19, 402, 109, 112, 1986, 1989, "DOI" +312, 12, 20, 403, 113, 114, 1990, 1991, ":" +312, 12, 21, 404, 115, 117, 1992, 1994, "10" +312, 12, 22, 405, 118, 119, 1995, 1996, "." +312, 12, 23, 406, 120, 124, 1997, 2001, "1111" +312, 12, 24, 407, 125, 126, 2002, 2003, "/" +312, 12, 25, 408, 127, 128, 2004, 2005, "j" +312, 12, 26, 409, 129, 130, 2006, 2007, "." +312, 12, 27, 410, 131, 135, 2008, 2012, "1753" +312, 12, 28, 411, 136, 137, 2013, 2014, "-" +312, 12, 29, 412, 138, 142, 2015, 2019, "0407" +312, 12, 30, 413, 143, 144, 2020, 2021, "." +312, 12, 31, 414, 145, 149, 2022, 2026, "2012" +312, 12, 32, 415, 150, 151, 2027, 2028, "." +312, 12, 33, 416, 152, 157, 2029, 2034, "00213" +312, 12, 34, 417, 158, 159, 2035, 2036, "." +312, 12, 35, 418, 160, 161, 2037, 2038, "x" +312, 12, 36, 419, 162, 166, 2039, 2043, "PMID" +312, 12, 37, 420, 167, 168, 2044, 2045, ":" +312, 12, 38, 421, 169, 177, 2046, 2054, "22672586" +312, 12, 39, 422, 178, 179, 2055, 2056, "[" +312, 12, 40, 423, 180, 187, 2057, 2064, "Indexed" +312, 12, 41, 424, 188, 191, 2065, 2068, "for" +312, 12, 42, 425, 192, 199, 2069, 2076, "MEDLINE" +312, 12, 43, 426, 200, 201, 2077, 2078, "]" diff --git a/data/dm2 22672586_kwoodley.annodb b/data/dm2 22672586_kwoodley.annodb new file mode 100644 index 0000000..d9ad9cf --- /dev/null +++ b/data/dm2 22672586_kwoodley.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22207, Journal, 0, 12, "J Diabetes .", "", +22208, PublicationYear, 13, 17, "2012", "", +33166, Title, 100, 239, "The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes .", "", +22210, Sitagliptin, 116, 127, "sitagliptin", "", +22211, Metformin, 139, 148, "metformin", "", +22214, Type2Diabetes, 222, 237, "type 2 diabetes", "", +22250, Author, 240, 246, "Yang W", "", +22251, Author, 255, 261, "Guan Y", "", +22253, Author, 264, 272, "Shentu Y", "", +22254, Author, 275, 279, "Li Z", "", +22255, Author, 282, 302, "Johnson - Levonas AO", "", +22256, Author, 305, 313, "Engel SS", "", +22258, Author, 316, 326, "Kaufman KD", "", +22259, Author, 329, 341, "Goldstein BJ", "", +22260, Author, 344, 350, "Alba M", "", +33167, China, 426, 431, "China", "", +22263, ObjectiveDescription, 449, 581, "The present study was conducted to evaluate the efficacy , safety and tolerability of sitagliptin added to ongoing metformin therapy", "", +22268, Sitagliptin, 535, 546, "sitagliptin", "", +22265, Metformin, 564, 573, "metformin", "", +22264, ObjectiveDescription, 582, 708, "in Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy .", "", +22269, Precondition, 585, 706, "Chinese patients with type 2 diabetes ( T2DM ) who failed to achieve adequate glycemic control with metformin monotherapy", "", +22270, Type2Diabetes, 607, 622, "type 2 diabetes", "", +22271, Type2Diabetes, 625, 629, "T2DM", "", +22267, Male, 685, 694, "metformin", "", +22272, Metformin, 729, 738, "metformin", "", +22280, Duration, 778, 786, "2 - week", "pre study", +22282, CTDesign, 789, 803, "single - blind", "pre study", +22286, Placebo, 806, 813, "placebo", "", +22287, NumberPatientsCT, 832, 835, "395", "", +22289, Type2Diabetes, 858, 862, "T2DM", "", +22290, MinAge, 868, 870, "25", "", +22291, MaxAge, 873, 875, "77", "", +22293, HbA1c, 893, 898, "HbA1c", "", +22294, BaseLineValue, 899, 904, "8 . 5", "", +22295, Percentage, 905, 906, "%", "", +22296, Randomized, 914, 924, "randomized", "", +22297, AllocationRatio, 927, 932, "1 : 1", "", +22299, DoubleBlind, 938, 952, "double - blind", "", +22301, Placebo, 953, 960, "placebo", "", +22302, Sitagliptin, 964, 975, "sitagliptin", "", +22303, DoseValue, 976, 979, "100", "", +22305, mg, 980, 982, "mg", "", +22307, Frequency, 983, 990, "q . d .", "", +22326, OpenLabel, 1008, 1020, "open - label", "", +22328, Metformin, 1021, 1030, "metformin", "", +22329, DoseValue, 1033, 1045, "1000 or 1700", "", +22331, mg, 1046, 1048, "mg", "", +22332, Frequency, 1051, 1054, "day", "", +22334, Duration, 1061, 1069, "24 weeks", "", +22363, PValueChangeValue, 1098, 1111, "P  <  0 . 001", "", +22356, HbA1c, 1139, 1144, "HbA1c", "", +22365, Reduction, 1149, 1154, "0 . 9", "", +22371, Percentage, 1155, 1156, "%", "", +22357, FastingPlasmaGlucose, 1161, 1183, "fasting plasma glucose", "", +22367, Reduction, 1188, 1193, "1 . 2", "", +22372, Millimoles_per_litre, 1194, 1202, "mmol / L", "", +33168, PostprandialPlasmaGlucose, 1211, 1243, "2 - h post - meal plasma glucose", "", +22368, Reduction, 1248, 1253, "1 . 9", "", +22373, Millimoles_per_litre, 1254, 1262, "mmol / L", "", +22360, Sitagliptin, 1280, 1291, "sitagliptin", "", +22362, Placebo, 1306, 1313, "placebo", "", +22384, ObservedResult, 1316, 1455, "There were no significant differences between sitagliptin and placebo in the incidence of hypoglycemia or gastrointestinal adverse events .", "", +22375, Sitagliptin, 1362, 1373, "sitagliptin", "", +22380, Placebo, 1378, 1385, "placebo", "", +22382, Hypoglycemia, 1406, 1418, "hypoglycemia", "", +22383, GastrointestinalProblem, 1422, 1453, "gastrointestinal adverse events", "", +22388, ObservedResult, 1458, 1472, "small decrease", "", +22386, BodyWeight, 1487, 1498, "body weight", "", +22381, Placebo, 1519, 1526, "placebo", "", +22389, ObservedResult, 1547, 1556, "no change", "", +22377, Sitagliptin, 1564, 1575, "sitagliptin", "", +22396, DiffGroupAbsValue, 1611, 1618, "0 . 5kg", "kg not separable", +22398, PvalueDiff, 1621, 1632, "P = 0 . 018", "", +22409, ConclusionComment, 1653, 1876, "The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone .", "", +22379, Sitagliptin, 1669, 1680, "sitagliptin", "", +22400, DoseValue, 1681, 1684, "100", "", +22402, mg, 1685, 1687, "mg", "", +22276, Metformin, 1699, 1708, "metformin", "", +22408, Precondition, 1793, 1874, "Chinese patients with T2DM who had inadequate glycemic control on metformin alone", "", +22407, Type2Diabetes, 1815, 1819, "T2DM", "", +22275, Metformin, 1859, 1868, "metformin", "", +22410, PMID, 2046, 2054, "22672586", "", diff --git a/data/dm2 22672586_kwoodley.n-triples b/data/dm2 22672586_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22672586_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22742523_admin.annodb b/data/dm2 22742523_admin.annodb new file mode 100644 index 0000000..849fb91 --- /dev/null +++ b/data/dm2 22742523_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +107, Journal, 0, 10, "J Diabetes", "", " \"J Diabetes\"." +1, PublicationYear, 13, 17, "2013", "", " \"2013\"." +26, Title, 99, 286, "Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo - controlled 54 - week trial in patients with type 2 diabetes .", "", " \"Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo - controlled 54 - week trial in patients with type 2 diabetes .\"." +2, Sitagliptin, 122, 133, "sitagliptin", "", +9, Metformin, 151, 160, "metformin", "", +13, Rosiglitazone, 165, 178, "rosiglitazone", "", +17, Randomized, 204, 214, "randomized", "", " ." +104, Placebo, 215, 222, "placebo", "", +18, Duration, 236, 245, "54 - week", "", " \"54 - week\"." +20, Type2Diabetes, 269, 284, "type 2 diabetes", "", " ." +27, Author, 287, 294, "Dobs AS", "", " \"Dobs AS\"." +28, Author, 303, 315, "Goldstein BJ", "", " \"Goldstein BJ\"." +29, Author, 318, 327, "Aschner P", "", " \"Aschner P\"." +30, Author, 330, 339, "Horton ES", "", " \"Horton ES\"." +31, Author, 342, 354, "Umpierrez GE", "", " \"Umpierrez GE\"." +32, Author, 357, 364, "Duran L", "", " \"Duran L\"." +33, Author, 367, 374, "Hill JS", "", +34, Author, 377, 383, "Chen Y", "", +35, Author, 386, 393, "Golm GT", "", +36, Author, 396, 406, "Langdon RB", "", +37, Author, 409, 429, "Williams - Herman DE", "", +38, Author, 432, 442, "Kaufman KD", "", +39, Author, 445, 456, "Amatruda JM", "", +40, Author, 459, 470, "Ferreira JC", "", +41, USA, 563, 566, "USA", "", " ." +21, Type2Diabetes, 665, 680, "type 2 diabetes", "", +22, Type2Diabetes, 683, 686, "T2D", "", +42, ObjectiveDescription, 756, 895, "The present study assessed the efficacy and safety of sitagliptin as add - on therapy to metformin and rosiglitazone in patients with T2D .", "", " \"The present study assessed the efficacy and safety of sitagliptin as add - on therapy to metformin and rosiglitazone in patients with T2D .\"." +4, Sitagliptin, 810, 821, "sitagliptin", "", +63533, Precondition, 825, 893, "add - on therapy to metformin and rosiglitazone in patients with T2D", "", " \"add - on therapy to metformin and rosiglitazone in patients with T2D\"." +10, Metformin, 845, 854, "metformin", "", +14, Rosiglitazone, 859, 872, "rosiglitazone", "", +23, Type2Diabetes, 890, 893, "T2D", "", +43, Randomized, 930, 940, "randomized", "", +44, DoubleBlind, 941, 955, "double - blind", "", " ." +105, Placebo, 956, 963, "placebo", "", +45, Parallel, 977, 993, "parallel - group", "", " ." +46, Duration, 994, 1003, "54 - week", "", +144, Multicenter, 1023, 1031, "41 sites", "", " ." +47, NumberPatientsCT, 1086, 1089, "278", "", " \"278\"." +48, HbA1c, 1104, 1109, "HbA1c", "", +49, Percentage, 1131, 1132, "%", "", +50, Percentage, 1145, 1146, "%", "", +11, Metformin, 1188, 1197, "metformin", "", +52, DoseValue, 1200, 1206, "≥ 1500", "", +54, mg, 1207, 1209, "mg", "", +56, Frequency, 1212, 1215, "day", "", +15, Rosiglitazone, 1222, 1235, "rosiglitazone", "", +53, DoseValue, 1238, 1241, "≥ 4", "", +55, mg, 1242, 1244, "mg", "", +57, Frequency, 1247, 1250, "day", "", +58, Randomized, 1269, 1279, "randomized", "", +59, AllocationRatio, 1282, 1287, "2 : 1", "", " . ." +5, Sitagliptin, 1301, 1312, "sitagliptin", "", " ." +60, DoseValue, 1313, 1316, "100", "", " \"100\"." +61, mg, 1317, 1319, "mg", "", " ." +62, Placebo, 1323, 1330, "placebo", "", " ." +63, Frequency, 1331, 1341, "once daily", "", " \"once daily\". \"once daily\"." +162, TimePoint, 1385, 1393, "baseline", "", +64, HbA1c, 1397, 1402, "HbA1c", "", +65, TimePoint, 1406, 1413, "Week 18", "", +165, Mean, 1426, 1430, "Mean", "", +166, TimePoint, 1431, 1439, "baseline", "", +66, HbA1c, 1440, 1445, "HbA1c", "", +67, BaseLineValue, 1450, 1455, "8 . 8", "", +68, Percentage, 1456, 1457, "%", "", +170, Mean, 1464, 1468, "mean", "", " . ." +69, Placebo, 1469, 1476, "placebo", "", +172, TimePoint, 1500, 1508, "baseline", "", +70, HbA1c, 1512, 1517, "HbA1c", "", " ." +6, Sitagliptin, 1523, 1534, "sitagliptin", "", +106315, DiffGroupAbsValue, 1549, 1556, "- 0 . 7", "", " \"- 0 . 7\"." +73, Percentage, 1557, 1558, "%", "", " ." +106316, PvalueDiff, 1561, 1572, "P < 0 . 001", "", " \"P < 0 . 001\"." +77, TimePoint, 1578, 1585, "Week 18", "", " \"Week 18\". \"Week 18\"." +106318, DiffGroupAbsValue, 1590, 1597, "- 0 . 8", "", " \"- 0 . 8\"." +74, Percentage, 1598, 1599, "%", "", +106317, PvalueDiff, 1602, 1613, "P < 0 . 001", "", " \"P < 0 . 001\"." +78, TimePoint, 1619, 1626, "Week 54", "", " \"Week 54\". \"Week 54\"." +85, ObservedResult, 1629, 1683, "There were also significant ( P < 0 . 001 ) reductions", "", " \"There were also significant ( P < 0 . 001 ) reductions\". \"There were also significant ( P < 0 . 001 ) reductions\". \"There were also significant ( P < 0 . 001 ) reductions\". \"There were also significant ( P < 0 . 001 ) reductions\"." +80, PValueChangeValue, 1659, 1670, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\". \"P < 0 . 001\". \"P < 0 . 001\"." +106, PostprandialBloodGlucose, 1687, 1712, "2 - h post - meal glucose", "", " ." +79, FastingPlasmaGlucose, 1717, 1739, "fasting plasma glucose", "", " ." +81, Placebo, 1754, 1761, "placebo", "", +187, TimePoint, 1765, 1780, "Weeks 18 and 54", "", " \"Weeks 18 and 54\". \"Weeks 18 and 54\"." +82, TimePoint, 1765, 1773, "Weeks 18", "", " \"Weeks 18\". \"Weeks 18\"." +7, Sitagliptin, 1819, 1830, "sitagliptin", "", +84, Placebo, 1838, 1845, "placebo", "", +86, HbA1c_target, 1869, 1884, "HbA1c < 7 . 0 %", "", " ." +192, Percentage, 1883, 1884, "%", "", +87, TimePoint, 1888, 1896, "Weeks 18", "", " \"Weeks 18\". \"Weeks 18\"." +89, PercentageAffected, 1899, 1901, "22", "", " \"22\"." +90, PercentageAffected, 1907, 1908, "9", "", " \"9\"." +203, PvalueDiff, 1913, 1924, "P = 0 . 003", "", " \"P = 0 . 003\"." +88, TimePoint, 1931, 1933, "54", "", " \"54\". \"54\"." +91, PercentageAffected, 1936, 1938, "26", "", " \"26\"." +92, PercentageAffected, 1944, 1946, "14", "", " \"14\"." +204, PvalueDiff, 1951, 1962, "P = 0 . 015", "", " \"P = 0 . 015\"." +95, BodyWeight, 1978, 1989, "body weight", "", +96, BodyWeight, 2007, 2021, "adverse events", "", +97, Hypoglycemia, 2032, 2044, "hypoglycemia", "", +98, GastrointestinalProblem, 2051, 2082, "gastrointestinal adverse events", "", +100, ObservedResult, 2083, 2133, "were similar in the sitagliptin and placebo groups", "", +8, Sitagliptin, 2103, 2114, "sitagliptin", "", +99, Placebo, 2119, 2126, "placebo", "", +19, Duration, 2145, 2154, "54 - week", "", +102, ConclusionComment, 2177, 2375, "In patients with T2D , the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo .", "", " \"In patients with T2D , the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo .\"." +24, Type2Diabetes, 2194, 2197, "T2D", "", +3, Sitagliptin, 2216, 2227, "sitagliptin", "", +25, Duration, 2232, 2240, "54 weeks", "", +12, Metformin, 2265, 2274, "metformin", "", +16, Rosiglitazone, 2279, 2292, "rosiglitazone", "", +101, Placebo, 2366, 2373, "placebo", "", +103, PMID, 2545, 2553, "22742523", "", " \"22742523\"." diff --git a/data/dm2 22742523_admin.n-triples b/data/dm2 22742523_admin.n-triples new file mode 100644 index 0000000..995937b --- /dev/null +++ b/data/dm2 22742523_admin.n-triples @@ -0,0 +1,195 @@ +# RDF export of group: Publication + . + "Publication 39616" . + "Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo - controlled 54 - week trial in patients with type 2 diabetes ." . + "Dobs AS" . + "2013" . + "J Diabetes" . + "22742523" . + . + "Goldstein BJ" . + "Aschner P" . + "Horton ES" . + "Umpierrez GE" . + "Duran L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 39623" . + "The present study assessed the efficacy and safety of sitagliptin as add - on therapy to metformin and rosiglitazone in patients with T2D ." . + "278" . + "54 - week" . + . + . + . + . + "In patients with T2D , the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 39639" . + "add - on therapy to metformin and rosiglitazone in patients with T2D" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "hbat" . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + . + . + . + . + . + . + . + . + . + . + . + "pls" . + . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "once daily" . + . + . + "pla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "sit" . + . + "100" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "Week 18" . + . + "hba54 1" . + . + "Week 54" . + . + "ppg 1" . + . + "P < 0 . 001" . + "There were also significant ( P < 0 . 001 ) reductions" . + "Weeks 18" . + . + "ppg 1 54" . + . + "P < 0 . 001" . + "There were also significant ( P < 0 . 001 ) reductions" . + "Weeks 18 and 54" . + . + "fpg 1" . + . + "P < 0 . 001" . + "There were also significant ( P < 0 . 001 ) reductions" . + "Weeks 18" . + . + "fpg54 1" . + . + "P < 0 . 001" . + "There were also significant ( P < 0 . 001 ) reductions" . + "Weeks 18 and 54" . + . + "hbat 1" . + . + "22" . + "Weeks 18" . + . + "hbat 2" . + . + "9" . + "Weeks 18" . + . + "hbat54 1" . + . + "26" . + "54" . + . + "hbat54 2" . + . + "14" . + "54" . + . + "hba p" . + . + "Week 18" . + . + "hba54 p" . + . + "Week 54" . +# RDF export of group: DiffBetweenGroups + . + "hbat " . + "P = 0 . 003" . + . + . + . + "hbat54" . + "P = 0 . 015" . + . + . + . + "hba18" . + "- 0 . 7" . + "P < 0 . 001" . + . + . + . + "hba54" . + "- 0 . 8" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22742523_akramersunderbrink.annodb b/data/dm2 22742523_akramersunderbrink.annodb new file mode 100644 index 0000000..1cd6515 --- /dev/null +++ b/data/dm2 22742523_akramersunderbrink.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +41828, Journal, 0, 10, "J Diabetes", "", +41829, PublicationYear, 13, 17, "2013", "", +41837, Title, 99, 286, "Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo - controlled 54 - week trial in patients with type 2 diabetes .", "", +41830, Sitagliptin, 122, 133, "sitagliptin", "", +41831, Metformin, 151, 160, "metformin", "", +41832, Rosiglitazone, 165, 178, "rosiglitazone", "", +41833, Randomized, 204, 214, "randomized", "", +41834, Placebo, 215, 222, "placebo", "", +41835, Duration, 236, 245, "54 - week", "", +41836, Type2Diabetes, 269, 284, "type 2 diabetes", "", +41838, Author, 287, 294, "Dobs AS", "", +41839, Author, 303, 315, "Goldstein BJ", "", +41840, Author, 318, 327, "Aschner P", "", +41841, Author, 330, 339, "Horton ES", "", +41842, Author, 342, 354, "Umpierrez GE", "", +41843, Author, 357, 364, "Duran L", "", +41844, Author, 367, 374, "Hill JS", "", +41845, Author, 377, 383, "Chen Y", "", +41846, Author, 386, 393, "Golm GT", "", +41847, Author, 396, 406, "Langdon RB", "", +41848, Author, 409, 429, "Williams - Herman DE", "", +41849, Author, 432, 442, "Kaufman KD", "", +41850, Author, 445, 456, "Amatruda JM", "", +41851, Author, 459, 470, "Ferreira JC", "", +41852, USA, 563, 566, "USA", "", +41853, Type2Diabetes, 665, 680, "type 2 diabetes", "", +41854, Type2Diabetes, 683, 686, "T2D", "", +41859, ObjectiveDescription, 756, 895, "The present study assessed the efficacy and safety of sitagliptin as add - on therapy to metformin and rosiglitazone in patients with T2D .", "", +41855, Sitagliptin, 810, 821, "sitagliptin", "", +41856, Metformin, 845, 854, "metformin", "", +41857, Rosiglitazone, 859, 872, "rosiglitazone", "", +41858, Type2Diabetes, 890, 893, "T2D", "", +41860, Randomized, 930, 940, "randomized", "", +41861, DoubleBlind, 941, 955, "double - blind", "", +41862, Placebo, 956, 963, "placebo", "", +41863, Parallel, 977, 993, "parallel - group", "", +41864, Duration, 994, 1003, "54 - week", "", +41865, Multicenter, 1023, 1031, "41 sites", "", +41866, NumberPatientsCT, 1086, 1089, "278", "", +41867, HbA1c, 1104, 1109, "HbA1c", "", +41868, Precondition, 1104, 1252, "HbA1c ranging from ≥ 7 . 5 % to ≤ 11 . 0 % despite ongoing combination therapy with metformin ( ≥ 1500 mg / day ) and rosiglitazone ( ≥ 4 mg / day )", "", +41869, Percentage, 1131, 1132, "%", "", +41870, Percentage, 1145, 1146, "%", "", +41871, Metformin, 1188, 1197, "metformin", "", +41874, DoseValue, 1202, 1215, "1500 mg / day", "", +41875, BioAndMedicalUnit, 1207, 1215, "mg / day", "", +41872, Rosiglitazone, 1222, 1235, "rosiglitazone", "", +41873, DoseValue, 1240, 1250, "4 mg / day", "", +41876, BioAndMedicalUnit, 1242, 1250, "mg / day", "", +41877, Randomized, 1269, 1279, "randomized", "", +41878, Sitagliptin, 1301, 1312, "sitagliptin", "", +41879, DoseValue, 1313, 1319, "100 mg", "", +41880, mg, 1317, 1319, "mg", "", +41881, Placebo, 1323, 1330, "placebo", "", +41882, Frequency, 1331, 1341, "once daily", "", +41883, TimePoint, 1385, 1393, "baseline", "", +41884, HbA1c, 1397, 1402, "HbA1c", "", +41885, TimePoint, 1406, 1413, "Week 18", "", +41886, Mean, 1426, 1430, "Mean", "", +41887, TimePoint, 1431, 1439, "baseline", "", +41888, HbA1c, 1440, 1445, "HbA1c", "", +41889, BaseLineValue, 1450, 1455, "8 . 8", "", +41890, Percentage, 1456, 1457, "%", "", +41891, Mean, 1464, 1468, "mean", "", +41892, Placebo, 1469, 1476, "placebo", "", +41893, TimePoint, 1500, 1508, "baseline", "", +41894, HbA1c, 1512, 1517, "HbA1c", "", +41895, Sitagliptin, 1523, 1534, "sitagliptin", "", +41896, ChangeValue, 1549, 1556, "- 0 . 7", "", +41898, Percentage, 1557, 1558, "%", "", +41900, PValueChangeValue, 1561, 1572, "P < 0 . 001", "", +41903, TimePoint, 1578, 1585, "Week 18", "", +41897, ChangeValue, 1590, 1597, "- 0 . 8", "", +41899, Percentage, 1598, 1599, "%", "", +41901, PValueChangeValue, 1602, 1613, "P < 0 . 001", "", +41902, TimePoint, 1619, 1626, "Week 54", "", +41909, PValueChangeValue, 1659, 1670, "P < 0 . 001", "", +41905, PostprandialPlasmaGlucose, 1687, 1712, "2 - h post - meal glucose", "", +41904, FastingPlasmaGlucose, 1717, 1739, "fasting plasma glucose", "", +41906, Placebo, 1754, 1761, "placebo", "", +41907, TimePoint, 1765, 1773, "Weeks 18", "", +41908, TimePoint, 1765, 1780, "Weeks 18 and 54", "", +41910, Sitagliptin, 1819, 1830, "sitagliptin", "", +41911, Placebo, 1838, 1845, "placebo", "", +41912, HbA1c_target, 1869, 1884, "HbA1c < 7 . 0 %", "", +41913, Percentage, 1883, 1884, "%", "", +41918, TimePoint, 1888, 1896, "Weeks 18", "", +41920, PercentageAffected, 1899, 1901, "22", "", +41914, Percentage, 1902, 1903, "%", "", +41921, PercentageAffected, 1907, 1908, "9", "", +41915, Percentage, 1909, 1910, "%", "", +41924, PvalueDiff, 1913, 1924, "P = 0 . 003", "", +41919, TimePoint, 1931, 1933, "54", "", +41922, PercentageAffected, 1936, 1938, "26", "", +41916, Percentage, 1939, 1940, "%", "", +41923, PercentageAffected, 1944, 1946, "14", "", +41917, Percentage, 1947, 1948, "%", "", +41925, PvalueDiff, 1951, 1962, "P = 0 . 015", "", +41926, BodyWeight, 1978, 1989, "body weight", "", +41927, Hypoglycemia, 2032, 2044, "hypoglycemia", "", +41928, Sitagliptin, 2103, 2114, "sitagliptin", "", +41929, Placebo, 2119, 2126, "placebo", "", +41930, Duration, 2145, 2154, "54 - week", "", +41937, ConclusionComment, 2177, 2375, "In patients with T2D , the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo .", "", +41931, Type2Diabetes, 2194, 2197, "T2D", "", +41932, Sitagliptin, 2216, 2227, "sitagliptin", "", +41933, Duration, 2232, 2240, "54 weeks", "", +41934, Metformin, 2265, 2274, "metformin", "", +41935, Rosiglitazone, 2279, 2292, "rosiglitazone", "", +41936, Placebo, 2366, 2373, "placebo", "", +41938, PMID, 2545, 2553, "22742523", "", diff --git a/data/dm2 22742523_akramersunderbrink.n-triples b/data/dm2 22742523_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22742523_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 22742523_export.csv b/data/dm2 22742523_export.csv new file mode 100644 index 0000000..0668ef1 --- /dev/null +++ b/data/dm2 22742523_export.csv @@ -0,0 +1,541 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +310, 1, 1, 1, 0, 1, 0, 1, "J" +310, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +310, 1, 3, 3, 11, 12, 11, 12, "." +310, 2, 1, 4, 0, 4, 13, 17, "2013" +310, 2, 2, 5, 5, 8, 18, 21, "Mar" +310, 2, 3, 6, 9, 10, 22, 23, ";" +310, 2, 4, 7, 11, 12, 24, 25, "5" +310, 2, 5, 8, 13, 14, 26, 27, "(" +310, 2, 6, 9, 15, 16, 28, 29, "1" +310, 2, 7, 10, 17, 18, 30, 31, ")" +310, 2, 8, 11, 19, 20, 32, 33, ":" +310, 2, 9, 12, 21, 23, 34, 36, "68" +310, 2, 10, 13, 24, 25, 37, 38, "-" +310, 2, 11, 14, 26, 28, 39, 41, "79" +310, 2, 12, 15, 29, 30, 42, 43, "." +310, 2, 13, 16, 31, 34, 44, 47, "doi" +310, 2, 14, 17, 35, 36, 48, 49, ":" +310, 2, 15, 18, 37, 39, 50, 52, "10" +310, 2, 16, 19, 40, 41, 53, 54, "." +310, 2, 17, 20, 42, 46, 55, 59, "1111" +310, 2, 18, 21, 47, 48, 60, 61, "/" +310, 2, 19, 22, 49, 50, 62, 63, "j" +310, 2, 20, 23, 51, 52, 64, 65, "." +310, 2, 21, 24, 53, 57, 66, 70, "1753" +310, 2, 22, 25, 58, 59, 71, 72, "-" +310, 2, 23, 26, 60, 64, 73, 77, "0407" +310, 2, 24, 27, 65, 66, 78, 79, "." +310, 2, 25, 28, 67, 71, 80, 84, "2012" +310, 2, 26, 29, 72, 73, 85, 86, "." +310, 2, 27, 30, 74, 79, 87, 92, "00223" +310, 2, 28, 31, 80, 81, 93, 94, "." +310, 2, 29, 32, 82, 83, 95, 96, "x" +310, 2, 30, 33, 84, 85, 97, 98, "." +310, 3, 1, 34, 0, 8, 99, 107, "Efficacy" +310, 3, 2, 35, 9, 12, 108, 111, "and" +310, 3, 3, 36, 13, 19, 112, 118, "safety" +310, 3, 4, 37, 20, 22, 119, 121, "of" +310, 3, 5, 38, 23, 34, 122, 133, "sitagliptin" +310, 3, 6, 39, 35, 40, 134, 139, "added" +310, 3, 7, 40, 41, 43, 140, 142, "to" +310, 3, 8, 41, 44, 51, 143, 150, "ongoing" +310, 3, 9, 42, 52, 61, 151, 160, "metformin" +310, 3, 10, 43, 62, 65, 161, 164, "and" +310, 3, 11, 44, 66, 79, 165, 178, "rosiglitazone" +310, 3, 12, 45, 80, 91, 179, 190, "combination" +310, 3, 13, 46, 92, 99, 191, 198, "therapy" +310, 3, 14, 47, 100, 102, 199, 201, "in" +310, 3, 15, 48, 103, 104, 202, 203, "a" +310, 3, 16, 49, 105, 115, 204, 214, "randomized" +310, 3, 17, 50, 116, 123, 215, 222, "placebo" +310, 3, 18, 51, 124, 125, 223, 224, "-" +310, 3, 19, 52, 126, 136, 225, 235, "controlled" +310, 3, 20, 53, 137, 139, 236, 238, "54" +310, 3, 21, 54, 140, 141, 239, 240, "-" +310, 3, 22, 55, 142, 146, 241, 245, "week" +310, 3, 23, 56, 147, 152, 246, 251, "trial" +310, 3, 24, 57, 153, 155, 252, 254, "in" +310, 3, 25, 58, 156, 164, 255, 263, "patients" +310, 3, 26, 59, 165, 169, 264, 268, "with" +310, 3, 27, 60, 170, 174, 269, 273, "type" +310, 3, 28, 61, 175, 176, 274, 275, "2" +310, 3, 29, 62, 177, 185, 276, 284, "diabetes" +310, 3, 30, 63, 186, 187, 285, 286, "." +310, 4, 1, 64, 0, 4, 287, 291, "Dobs" +310, 4, 2, 65, 5, 7, 292, 294, "AS" +310, 4, 3, 66, 8, 9, 295, 296, "(" +310, 4, 4, 67, 10, 11, 297, 298, "1" +310, 4, 5, 68, 12, 13, 299, 300, ")" +310, 4, 6, 69, 14, 15, 301, 302, "," +310, 4, 7, 70, 16, 25, 303, 312, "Goldstein" +310, 4, 8, 71, 26, 28, 313, 315, "BJ" +310, 4, 9, 72, 29, 30, 316, 317, "," +310, 4, 10, 73, 31, 38, 318, 325, "Aschner" +310, 4, 11, 74, 39, 40, 326, 327, "P" +310, 4, 12, 75, 41, 42, 328, 329, "," +310, 4, 13, 76, 43, 49, 330, 336, "Horton" +310, 4, 14, 77, 50, 52, 337, 339, "ES" +310, 4, 15, 78, 53, 54, 340, 341, "," +310, 4, 16, 79, 55, 64, 342, 351, "Umpierrez" +310, 4, 17, 80, 65, 67, 352, 354, "GE" +310, 4, 18, 81, 68, 69, 355, 356, "," +310, 4, 19, 82, 70, 75, 357, 362, "Duran" +310, 4, 20, 83, 76, 77, 363, 364, "L" +310, 4, 21, 84, 78, 79, 365, 366, "," +310, 4, 22, 85, 80, 84, 367, 371, "Hill" +310, 4, 23, 86, 85, 87, 372, 374, "JS" +310, 4, 24, 87, 88, 89, 375, 376, "," +310, 4, 25, 88, 90, 94, 377, 381, "Chen" +310, 4, 26, 89, 95, 96, 382, 383, "Y" +310, 4, 27, 90, 97, 98, 384, 385, "," +310, 4, 28, 91, 99, 103, 386, 390, "Golm" +310, 4, 29, 92, 104, 106, 391, 393, "GT" +310, 4, 30, 93, 107, 108, 394, 395, "," +310, 4, 31, 94, 109, 116, 396, 403, "Langdon" +310, 4, 32, 95, 117, 119, 404, 406, "RB" +310, 4, 33, 96, 120, 121, 407, 408, "," +310, 4, 34, 97, 122, 130, 409, 417, "Williams" +310, 4, 35, 98, 131, 132, 418, 419, "-" +310, 4, 36, 99, 133, 139, 420, 426, "Herman" +310, 4, 37, 100, 140, 142, 427, 429, "DE" +310, 4, 38, 101, 143, 144, 430, 431, "," +310, 4, 39, 102, 145, 152, 432, 439, "Kaufman" +310, 4, 40, 103, 153, 155, 440, 442, "KD" +310, 4, 41, 104, 156, 157, 443, 444, "," +310, 4, 42, 105, 158, 166, 445, 453, "Amatruda" +310, 4, 43, 106, 167, 169, 454, 456, "JM" +310, 4, 44, 107, 170, 171, 457, 458, "," +310, 4, 45, 108, 172, 180, 459, 467, "Ferreira" +310, 4, 46, 109, 181, 183, 468, 470, "JC" +310, 4, 47, 110, 184, 185, 471, 472, "." +310, 5, 1, 111, 0, 6, 473, 479, "Author" +310, 5, 2, 112, 7, 18, 480, 491, "information" +310, 5, 3, 113, 19, 20, 492, 493, ":" +310, 5, 4, 114, 21, 22, 494, 495, "(" +310, 5, 5, 115, 23, 24, 496, 497, "1" +310, 5, 6, 116, 25, 26, 498, 499, ")" +310, 5, 7, 117, 27, 32, 500, 505, "Johns" +310, 5, 8, 118, 33, 40, 506, 513, "Hopkins" +310, 5, 9, 119, 41, 51, 514, 524, "University" +310, 5, 10, 120, 52, 58, 525, 531, "School" +310, 5, 11, 121, 59, 61, 532, 534, "of" +310, 5, 12, 122, 62, 70, 535, 543, "Medicine" +310, 5, 13, 123, 71, 72, 544, 545, "," +310, 5, 14, 124, 73, 82, 546, 555, "Baltimore" +310, 5, 15, 125, 83, 84, 556, 557, "," +310, 5, 16, 126, 85, 87, 558, 560, "MD" +310, 5, 17, 127, 88, 89, 561, 562, "," +310, 5, 18, 128, 90, 93, 563, 566, "USA" +310, 5, 19, 129, 94, 95, 567, 568, "." +310, 6, 1, 130, 0, 10, 569, 579, "BACKGROUND" +310, 6, 2, 131, 11, 12, 580, 581, ":" +310, 6, 3, 132, 13, 16, 582, 585, "New" +310, 6, 4, 133, 17, 28, 586, 597, "therapeutic" +310, 6, 5, 134, 29, 39, 598, 608, "approaches" +310, 6, 6, 135, 40, 43, 609, 612, "are" +310, 6, 7, 136, 44, 50, 613, 619, "needed" +310, 6, 8, 137, 51, 53, 620, 622, "to" +310, 6, 9, 138, 54, 61, 623, 630, "improve" +310, 6, 10, 139, 62, 70, 631, 639, "glycemic" +310, 6, 11, 140, 71, 78, 640, 647, "control" +310, 6, 12, 141, 79, 81, 648, 650, "in" +310, 6, 13, 142, 82, 90, 651, 659, "patients" +310, 6, 14, 143, 91, 95, 660, 664, "with" +310, 6, 15, 144, 96, 100, 665, 669, "type" +310, 6, 16, 145, 101, 102, 670, 671, "2" +310, 6, 17, 146, 103, 111, 672, 680, "diabetes" +310, 6, 18, 147, 112, 113, 681, 682, "(" +310, 6, 19, 148, 114, 117, 683, 686, "T2D" +310, 6, 20, 149, 118, 119, 687, 688, ")" +310, 6, 21, 150, 120, 121, 689, 690, "," +310, 6, 22, 151, 122, 123, 691, 692, "a" +310, 6, 23, 152, 124, 135, 693, 704, "progressive" +310, 6, 24, 153, 136, 144, 705, 713, "disorder" +310, 6, 25, 154, 145, 149, 714, 718, "that" +310, 6, 26, 155, 150, 155, 719, 724, "often" +310, 6, 27, 156, 156, 164, 725, 733, "requires" +310, 6, 28, 157, 165, 176, 734, 745, "combination" +310, 6, 29, 158, 177, 184, 746, 753, "therapy" +310, 6, 30, 159, 185, 186, 754, 755, "." +310, 7, 1, 160, 0, 3, 756, 759, "The" +310, 7, 2, 161, 4, 11, 760, 767, "present" +310, 7, 3, 162, 12, 17, 768, 773, "study" +310, 7, 4, 163, 18, 26, 774, 782, "assessed" +310, 7, 5, 164, 27, 30, 783, 786, "the" +310, 7, 6, 165, 31, 39, 787, 795, "efficacy" +310, 7, 7, 166, 40, 43, 796, 799, "and" +310, 7, 8, 167, 44, 50, 800, 806, "safety" +310, 7, 9, 168, 51, 53, 807, 809, "of" +310, 7, 10, 169, 54, 65, 810, 821, "sitagliptin" +310, 7, 11, 170, 66, 68, 822, 824, "as" +310, 7, 12, 171, 69, 72, 825, 828, "add" +310, 7, 13, 172, 73, 74, 829, 830, "-" +310, 7, 14, 173, 75, 77, 831, 833, "on" +310, 7, 15, 174, 78, 85, 834, 841, "therapy" +310, 7, 16, 175, 86, 88, 842, 844, "to" +310, 7, 17, 176, 89, 98, 845, 854, "metformin" +310, 7, 18, 177, 99, 102, 855, 858, "and" +310, 7, 19, 178, 103, 116, 859, 872, "rosiglitazone" +310, 7, 20, 179, 117, 119, 873, 875, "in" +310, 7, 21, 180, 120, 128, 876, 884, "patients" +310, 7, 22, 181, 129, 133, 885, 889, "with" +310, 7, 23, 182, 134, 137, 890, 893, "T2D" +310, 7, 24, 183, 138, 139, 894, 895, "." +310, 8, 1, 184, 0, 7, 896, 903, "METHODS" +310, 8, 2, 185, 8, 9, 904, 905, ":" +310, 8, 3, 186, 10, 13, 906, 909, "The" +310, 8, 4, 187, 14, 21, 910, 917, "present" +310, 8, 5, 188, 22, 27, 918, 923, "study" +310, 8, 6, 189, 28, 31, 924, 927, "was" +310, 8, 7, 190, 32, 33, 928, 929, "a" +310, 8, 8, 191, 34, 44, 930, 940, "randomized" +310, 8, 9, 192, 45, 51, 941, 947, "double" +310, 8, 10, 193, 52, 53, 948, 949, "-" +310, 8, 11, 194, 54, 59, 950, 955, "blind" +310, 8, 12, 195, 60, 67, 956, 963, "placebo" +310, 8, 13, 196, 68, 69, 964, 965, "-" +310, 8, 14, 197, 70, 80, 966, 976, "controlled" +310, 8, 15, 198, 81, 89, 977, 985, "parallel" +310, 8, 16, 199, 90, 91, 986, 987, "-" +310, 8, 17, 200, 92, 97, 988, 993, "group" +310, 8, 18, 201, 98, 100, 994, 996, "54" +310, 8, 19, 202, 101, 102, 997, 998, "-" +310, 8, 20, 203, 103, 107, 999, 1003, "week" +310, 8, 21, 204, 108, 113, 1004, 1009, "study" +310, 8, 22, 205, 114, 123, 1010, 1019, "conducted" +310, 8, 23, 206, 124, 126, 1020, 1022, "at" +310, 8, 24, 207, 127, 129, 1023, 1025, "41" +310, 8, 25, 208, 130, 135, 1026, 1031, "sites" +310, 8, 26, 209, 136, 142, 1032, 1038, "across" +310, 8, 27, 210, 143, 148, 1039, 1044, "North" +310, 8, 28, 211, 149, 152, 1045, 1048, "and" +310, 8, 29, 212, 153, 158, 1049, 1054, "South" +310, 8, 30, 213, 159, 166, 1055, 1062, "America" +310, 8, 31, 214, 167, 168, 1063, 1064, "," +310, 8, 32, 215, 169, 175, 1065, 1071, "Europe" +310, 8, 33, 216, 176, 177, 1072, 1073, "," +310, 8, 34, 217, 178, 181, 1074, 1077, "and" +310, 8, 35, 218, 182, 186, 1078, 1082, "Asia" +310, 8, 36, 219, 187, 189, 1083, 1085, "in" +310, 8, 37, 220, 190, 193, 1086, 1089, "278" +310, 8, 38, 221, 194, 202, 1090, 1098, "patients" +310, 8, 39, 222, 203, 207, 1099, 1103, "with" +310, 8, 40, 223, 208, 213, 1104, 1109, "HbA1c" +310, 8, 41, 224, 214, 221, 1110, 1117, "ranging" +310, 8, 42, 225, 222, 226, 1118, 1122, "from" +310, 8, 43, 226, 227, 228, 1123, 1124, "≥" +310, 8, 44, 227, 229, 230, 1125, 1126, "7" +310, 8, 45, 228, 231, 232, 1127, 1128, "." +310, 8, 46, 229, 233, 234, 1129, 1130, "5" +310, 8, 47, 230, 235, 236, 1131, 1132, "%" +310, 8, 48, 231, 237, 239, 1133, 1135, "to" +310, 8, 49, 232, 240, 241, 1136, 1137, "≤" +310, 8, 50, 233, 242, 244, 1138, 1140, "11" +310, 8, 51, 234, 245, 246, 1141, 1142, "." +310, 8, 52, 235, 247, 248, 1143, 1144, "0" +310, 8, 53, 236, 249, 250, 1145, 1146, "%" +310, 8, 54, 237, 251, 258, 1147, 1154, "despite" +310, 8, 55, 238, 259, 266, 1155, 1162, "ongoing" +310, 8, 56, 239, 267, 278, 1163, 1174, "combination" +310, 8, 57, 240, 279, 286, 1175, 1182, "therapy" +310, 8, 58, 241, 287, 291, 1183, 1187, "with" +310, 8, 59, 242, 292, 301, 1188, 1197, "metformin" +310, 8, 60, 243, 302, 303, 1198, 1199, "(" +310, 8, 61, 244, 304, 305, 1200, 1201, "≥" +310, 8, 62, 245, 306, 310, 1202, 1206, "1500" +310, 8, 63, 246, 311, 313, 1207, 1209, "mg" +310, 8, 64, 247, 314, 315, 1210, 1211, "/" +310, 8, 65, 248, 316, 319, 1212, 1215, "day" +310, 8, 66, 249, 320, 321, 1216, 1217, ")" +310, 8, 67, 250, 322, 325, 1218, 1221, "and" +310, 8, 68, 251, 326, 339, 1222, 1235, "rosiglitazone" +310, 8, 69, 252, 340, 341, 1236, 1237, "(" +310, 8, 70, 253, 342, 343, 1238, 1239, "≥" +310, 8, 71, 254, 344, 345, 1240, 1241, "4" +310, 8, 72, 255, 346, 348, 1242, 1244, "mg" +310, 8, 73, 256, 349, 350, 1245, 1246, "/" +310, 8, 74, 257, 351, 354, 1247, 1250, "day" +310, 8, 75, 258, 355, 356, 1251, 1252, ")" +310, 8, 76, 259, 357, 358, 1253, 1254, "." +310, 9, 1, 260, 0, 8, 1255, 1263, "Patients" +310, 9, 2, 261, 9, 13, 1264, 1268, "were" +310, 9, 3, 262, 14, 24, 1269, 1279, "randomized" +310, 9, 4, 263, 25, 26, 1280, 1281, "(" +310, 9, 5, 264, 27, 28, 1282, 1283, "2" +310, 9, 6, 265, 29, 30, 1284, 1285, ":" +310, 9, 7, 266, 31, 32, 1286, 1287, "1" +310, 9, 8, 267, 33, 34, 1288, 1289, ")" +310, 9, 9, 268, 35, 37, 1290, 1292, "to" +310, 9, 10, 269, 38, 45, 1293, 1300, "receive" +310, 9, 11, 270, 46, 57, 1301, 1312, "sitagliptin" +310, 9, 12, 271, 58, 61, 1313, 1316, "100" +310, 9, 13, 272, 62, 64, 1317, 1319, "mg" +310, 9, 14, 273, 65, 67, 1320, 1322, "or" +310, 9, 15, 274, 68, 75, 1323, 1330, "placebo" +310, 9, 16, 275, 76, 80, 1331, 1335, "once" +310, 9, 17, 276, 81, 86, 1336, 1341, "daily" +310, 9, 18, 277, 87, 88, 1342, 1343, "." +310, 10, 1, 278, 0, 3, 1344, 1347, "The" +310, 10, 2, 279, 4, 8, 1348, 1352, "main" +310, 10, 3, 280, 9, 16, 1353, 1360, "outcome" +310, 10, 4, 281, 17, 24, 1361, 1368, "measure" +310, 10, 5, 282, 25, 28, 1369, 1372, "was" +310, 10, 6, 283, 29, 35, 1373, 1379, "change" +310, 10, 7, 284, 36, 40, 1380, 1384, "from" +310, 10, 8, 285, 41, 49, 1385, 1393, "baseline" +310, 10, 9, 286, 50, 52, 1394, 1396, "in" +310, 10, 10, 287, 53, 58, 1397, 1402, "HbA1c" +310, 10, 11, 288, 59, 61, 1403, 1405, "at" +310, 10, 12, 289, 62, 66, 1406, 1410, "Week" +310, 10, 13, 290, 67, 69, 1411, 1413, "18" +310, 10, 14, 291, 70, 71, 1414, 1415, "." +310, 11, 1, 292, 0, 7, 1416, 1423, "RESULTS" +310, 11, 2, 293, 8, 9, 1424, 1425, ":" +310, 11, 3, 294, 10, 14, 1426, 1430, "Mean" +310, 11, 4, 295, 15, 23, 1431, 1439, "baseline" +310, 11, 5, 296, 24, 29, 1440, 1445, "HbA1c" +310, 11, 6, 297, 30, 33, 1446, 1449, "was" +310, 11, 7, 298, 34, 35, 1450, 1451, "8" +310, 11, 8, 299, 36, 37, 1452, 1453, "." +310, 11, 9, 300, 38, 39, 1454, 1455, "8" +310, 11, 10, 301, 40, 41, 1456, 1457, "%" +310, 11, 11, 302, 42, 43, 1458, 1459, "." +310, 12, 1, 303, 0, 3, 1460, 1463, "The" +310, 12, 2, 304, 4, 8, 1464, 1468, "mean" +310, 12, 3, 305, 9, 16, 1469, 1476, "placebo" +310, 12, 4, 306, 17, 18, 1477, 1478, "-" +310, 12, 5, 307, 19, 27, 1479, 1487, "adjusted" +310, 12, 6, 308, 28, 34, 1488, 1494, "change" +310, 12, 7, 309, 35, 39, 1495, 1499, "from" +310, 12, 8, 310, 40, 48, 1500, 1508, "baseline" +310, 12, 9, 311, 49, 51, 1509, 1511, "in" +310, 12, 10, 312, 52, 57, 1512, 1517, "HbA1c" +310, 12, 11, 313, 58, 62, 1518, 1522, "with" +310, 12, 12, 314, 63, 74, 1523, 1534, "sitagliptin" +310, 12, 13, 315, 75, 84, 1535, 1544, "treatment" +310, 12, 14, 316, 85, 88, 1545, 1548, "was" +310, 12, 15, 317, 89, 90, 1549, 1550, "-" +310, 12, 16, 318, 91, 92, 1551, 1552, "0" +310, 12, 17, 319, 93, 94, 1553, 1554, "." +310, 12, 18, 320, 95, 96, 1555, 1556, "7" +310, 12, 19, 321, 97, 98, 1557, 1558, "%" +310, 12, 20, 322, 99, 100, 1559, 1560, "(" +310, 12, 21, 323, 101, 102, 1561, 1562, "P" +310, 12, 22, 324, 103, 104, 1563, 1564, "<" +310, 12, 23, 325, 105, 106, 1565, 1566, "0" +310, 12, 24, 326, 107, 108, 1567, 1568, "." +310, 12, 25, 327, 109, 112, 1569, 1572, "001" +310, 12, 26, 328, 113, 114, 1573, 1574, ")" +310, 12, 27, 329, 115, 117, 1575, 1577, "at" +310, 12, 28, 330, 118, 122, 1578, 1582, "Week" +310, 12, 29, 331, 123, 125, 1583, 1585, "18" +310, 12, 30, 332, 126, 129, 1586, 1589, "and" +310, 12, 31, 333, 130, 131, 1590, 1591, "-" +310, 12, 32, 334, 132, 133, 1592, 1593, "0" +310, 12, 33, 335, 134, 135, 1594, 1595, "." +310, 12, 34, 336, 136, 137, 1596, 1597, "8" +310, 12, 35, 337, 138, 139, 1598, 1599, "%" +310, 12, 36, 338, 140, 141, 1600, 1601, "(" +310, 12, 37, 339, 142, 143, 1602, 1603, "P" +310, 12, 38, 340, 144, 145, 1604, 1605, "<" +310, 12, 39, 341, 146, 147, 1606, 1607, "0" +310, 12, 40, 342, 148, 149, 1608, 1609, "." +310, 12, 41, 343, 150, 153, 1610, 1613, "001" +310, 12, 42, 344, 154, 155, 1614, 1615, ")" +310, 12, 43, 345, 156, 158, 1616, 1618, "at" +310, 12, 44, 346, 159, 163, 1619, 1623, "Week" +310, 12, 45, 347, 164, 166, 1624, 1626, "54" +310, 12, 46, 348, 167, 168, 1627, 1628, "." +310, 13, 1, 349, 0, 5, 1629, 1634, "There" +310, 13, 2, 350, 6, 10, 1635, 1639, "were" +310, 13, 3, 351, 11, 15, 1640, 1644, "also" +310, 13, 4, 352, 16, 27, 1645, 1656, "significant" +310, 13, 5, 353, 28, 29, 1657, 1658, "(" +310, 13, 6, 354, 30, 31, 1659, 1660, "P" +310, 13, 7, 355, 32, 33, 1661, 1662, "<" +310, 13, 8, 356, 34, 35, 1663, 1664, "0" +310, 13, 9, 357, 36, 37, 1665, 1666, "." +310, 13, 10, 358, 38, 41, 1667, 1670, "001" +310, 13, 11, 359, 42, 43, 1671, 1672, ")" +310, 13, 12, 360, 44, 54, 1673, 1683, "reductions" +310, 13, 13, 361, 55, 57, 1684, 1686, "in" +310, 13, 14, 362, 58, 59, 1687, 1688, "2" +310, 13, 15, 363, 60, 61, 1689, 1690, "-" +310, 13, 16, 364, 62, 63, 1691, 1692, "h" +310, 13, 17, 365, 64, 68, 1693, 1697, "post" +310, 13, 18, 366, 69, 70, 1698, 1699, "-" +310, 13, 19, 367, 71, 75, 1700, 1704, "meal" +310, 13, 20, 368, 76, 83, 1705, 1712, "glucose" +310, 13, 21, 369, 84, 87, 1713, 1716, "and" +310, 13, 22, 370, 88, 95, 1717, 1724, "fasting" +310, 13, 23, 371, 96, 102, 1725, 1731, "plasma" +310, 13, 24, 372, 103, 110, 1732, 1739, "glucose" +310, 13, 25, 373, 111, 119, 1740, 1748, "compared" +310, 13, 26, 374, 120, 124, 1749, 1753, "with" +310, 13, 27, 375, 125, 132, 1754, 1761, "placebo" +310, 13, 28, 376, 133, 135, 1762, 1764, "at" +310, 13, 29, 377, 136, 141, 1765, 1770, "Weeks" +310, 13, 30, 378, 142, 144, 1771, 1773, "18" +310, 13, 31, 379, 145, 148, 1774, 1777, "and" +310, 13, 32, 380, 149, 151, 1778, 1780, "54" +310, 13, 33, 381, 152, 153, 1781, 1782, "." +310, 14, 1, 382, 0, 13, 1783, 1796, "Significantly" +310, 14, 2, 383, 14, 20, 1797, 1803, "higher" +310, 14, 3, 384, 21, 32, 1804, 1815, "proportions" +310, 14, 4, 385, 33, 35, 1816, 1818, "of" +310, 14, 5, 386, 36, 47, 1819, 1830, "sitagliptin" +310, 14, 6, 387, 48, 49, 1831, 1832, "-" +310, 14, 7, 388, 50, 54, 1833, 1837, "than" +310, 14, 8, 389, 55, 62, 1838, 1845, "placebo" +310, 14, 9, 390, 63, 64, 1846, 1847, "-" +310, 14, 10, 391, 65, 72, 1848, 1855, "treated" +310, 14, 11, 392, 73, 81, 1856, 1864, "patients" +310, 14, 12, 393, 82, 85, 1865, 1868, "had" +310, 14, 13, 394, 86, 91, 1869, 1874, "HbA1c" +310, 14, 14, 395, 92, 93, 1875, 1876, "<" +310, 14, 15, 396, 94, 95, 1877, 1878, "7" +310, 14, 16, 397, 96, 97, 1879, 1880, "." +310, 14, 17, 398, 98, 99, 1881, 1882, "0" +310, 14, 18, 399, 100, 101, 1883, 1884, "%" +310, 14, 19, 400, 102, 104, 1885, 1887, "at" +310, 14, 20, 401, 105, 110, 1888, 1893, "Weeks" +310, 14, 21, 402, 111, 113, 1894, 1896, "18" +310, 14, 22, 403, 114, 115, 1897, 1898, "(" +310, 14, 23, 404, 116, 118, 1899, 1901, "22" +310, 14, 24, 405, 119, 120, 1902, 1903, "%" +310, 14, 25, 406, 121, 123, 1904, 1906, "vs" +310, 14, 26, 407, 124, 125, 1907, 1908, "9" +310, 14, 27, 408, 126, 127, 1909, 1910, "%" +310, 14, 28, 409, 128, 129, 1911, 1912, ";" +310, 14, 29, 410, 130, 131, 1913, 1914, "P" +310, 14, 30, 411, 132, 133, 1915, 1916, "=" +310, 14, 31, 412, 134, 135, 1917, 1918, "0" +310, 14, 32, 413, 136, 137, 1919, 1920, "." +310, 14, 33, 414, 138, 141, 1921, 1924, "003" +310, 14, 34, 415, 142, 143, 1925, 1926, ")" +310, 14, 35, 416, 144, 147, 1927, 1930, "and" +310, 14, 36, 417, 148, 150, 1931, 1933, "54" +310, 14, 37, 418, 151, 152, 1934, 1935, "(" +310, 14, 38, 419, 153, 155, 1936, 1938, "26" +310, 14, 39, 420, 156, 157, 1939, 1940, "%" +310, 14, 40, 421, 158, 160, 1941, 1943, "vs" +310, 14, 41, 422, 161, 163, 1944, 1946, "14" +310, 14, 42, 423, 164, 165, 1947, 1948, "%" +310, 14, 43, 424, 166, 167, 1949, 1950, ";" +310, 14, 44, 425, 168, 169, 1951, 1952, "P" +310, 14, 45, 426, 170, 171, 1953, 1954, "=" +310, 14, 46, 427, 172, 173, 1955, 1956, "0" +310, 14, 47, 428, 174, 175, 1957, 1958, "." +310, 14, 48, 429, 176, 179, 1959, 1962, "015" +310, 14, 49, 430, 180, 181, 1963, 1964, ")" +310, 14, 50, 431, 182, 183, 1965, 1966, "." +310, 15, 1, 432, 0, 7, 1967, 1974, "Changes" +310, 15, 2, 433, 8, 10, 1975, 1977, "in" +310, 15, 3, 434, 11, 15, 1978, 1982, "body" +310, 15, 4, 435, 16, 22, 1983, 1989, "weight" +310, 15, 5, 436, 23, 26, 1990, 1993, "and" +310, 15, 6, 437, 27, 30, 1994, 1997, "the" +310, 15, 7, 438, 31, 36, 1998, 2003, "rates" +310, 15, 8, 439, 37, 39, 2004, 2006, "of" +310, 15, 9, 440, 40, 47, 2007, 2014, "adverse" +310, 15, 10, 441, 48, 54, 2015, 2021, "events" +310, 15, 11, 442, 55, 62, 2022, 2029, "overall" +310, 15, 12, 443, 63, 64, 2030, 2031, "," +310, 15, 13, 444, 65, 77, 2032, 2044, "hypoglycemia" +310, 15, 14, 445, 78, 79, 2045, 2046, "," +310, 15, 15, 446, 80, 83, 2047, 2050, "and" +310, 15, 16, 447, 84, 100, 2051, 2067, "gastrointestinal" +310, 15, 17, 448, 101, 108, 2068, 2075, "adverse" +310, 15, 18, 449, 109, 115, 2076, 2082, "events" +310, 15, 19, 450, 116, 120, 2083, 2087, "were" +310, 15, 20, 451, 121, 128, 2088, 2095, "similar" +310, 15, 21, 452, 129, 131, 2096, 2098, "in" +310, 15, 22, 453, 132, 135, 2099, 2102, "the" +310, 15, 23, 454, 136, 147, 2103, 2114, "sitagliptin" +310, 15, 24, 455, 148, 151, 2115, 2118, "and" +310, 15, 25, 456, 152, 159, 2119, 2126, "placebo" +310, 15, 26, 457, 160, 166, 2127, 2133, "groups" +310, 15, 27, 458, 167, 173, 2134, 2140, "during" +310, 15, 28, 459, 174, 177, 2141, 2144, "the" +310, 15, 29, 460, 178, 180, 2145, 2147, "54" +310, 15, 30, 461, 181, 182, 2148, 2149, "-" +310, 15, 31, 462, 183, 187, 2150, 2154, "week" +310, 15, 32, 463, 188, 193, 2155, 2160, "study" +310, 15, 33, 464, 194, 195, 2161, 2162, "." +310, 16, 1, 465, 0, 11, 2163, 2174, "CONCLUSIONS" +310, 16, 2, 466, 12, 13, 2175, 2176, ":" +310, 16, 3, 467, 14, 16, 2177, 2179, "In" +310, 16, 4, 468, 17, 25, 2180, 2188, "patients" +310, 16, 5, 469, 26, 30, 2189, 2193, "with" +310, 16, 6, 470, 31, 34, 2194, 2197, "T2D" +310, 16, 7, 471, 35, 36, 2198, 2199, "," +310, 16, 8, 472, 37, 40, 2200, 2203, "the" +310, 16, 9, 473, 41, 49, 2204, 2212, "addition" +310, 16, 10, 474, 50, 52, 2213, 2215, "of" +310, 16, 11, 475, 53, 64, 2216, 2227, "sitagliptin" +310, 16, 12, 476, 65, 68, 2228, 2231, "for" +310, 16, 13, 477, 69, 71, 2232, 2234, "54" +310, 16, 14, 478, 72, 77, 2235, 2240, "weeks" +310, 16, 15, 479, 78, 80, 2241, 2243, "to" +310, 16, 16, 480, 81, 88, 2244, 2251, "ongoing" +310, 16, 17, 481, 89, 96, 2252, 2259, "therapy" +310, 16, 18, 482, 97, 101, 2260, 2264, "with" +310, 16, 19, 483, 102, 111, 2265, 2274, "metformin" +310, 16, 20, 484, 112, 115, 2275, 2278, "and" +310, 16, 21, 485, 116, 129, 2279, 2292, "rosiglitazone" +310, 16, 22, 486, 130, 138, 2293, 2301, "improved" +310, 16, 23, 487, 139, 147, 2302, 2310, "glycemic" +310, 16, 24, 488, 148, 155, 2311, 2318, "control" +310, 16, 25, 489, 156, 159, 2319, 2322, "and" +310, 16, 26, 490, 160, 163, 2323, 2326, "was" +310, 16, 27, 491, 164, 173, 2327, 2336, "generally" +310, 16, 28, 492, 174, 178, 2337, 2341, "well" +310, 16, 29, 493, 179, 188, 2342, 2351, "tolerated" +310, 16, 30, 494, 189, 197, 2352, 2360, "compared" +310, 16, 31, 495, 198, 202, 2361, 2365, "with" +310, 16, 32, 496, 203, 210, 2366, 2373, "placebo" +310, 16, 33, 497, 211, 212, 2374, 2375, "." +310, 17, 1, 498, 0, 1, 2376, 2377, "©" +310, 17, 2, 499, 2, 6, 2378, 2382, "2012" +310, 17, 3, 500, 7, 13, 2383, 2389, "Ruijin" +310, 17, 4, 501, 14, 22, 2390, 2398, "Hospital" +310, 17, 5, 502, 23, 24, 2399, 2400, "," +310, 17, 6, 503, 25, 33, 2401, 2409, "Shanghai" +310, 17, 7, 504, 34, 42, 2410, 2418, "Jiaotong" +310, 17, 8, 505, 43, 53, 2419, 2429, "University" +310, 17, 9, 506, 54, 60, 2430, 2436, "School" +310, 17, 10, 507, 61, 63, 2437, 2439, "of" +310, 17, 11, 508, 64, 72, 2440, 2448, "Medicine" +310, 17, 12, 509, 73, 76, 2449, 2452, "and" +310, 17, 13, 510, 77, 82, 2453, 2458, "Wiley" +310, 17, 14, 511, 83, 93, 2459, 2469, "Publishing" +310, 17, 15, 512, 94, 98, 2470, 2474, "Asia" +310, 17, 16, 513, 99, 102, 2475, 2478, "Pty" +310, 17, 17, 514, 103, 106, 2479, 2482, "Ltd" +310, 17, 18, 515, 107, 108, 2483, 2484, "." +310, 17, 19, 516, 109, 112, 2485, 2488, "DOI" +310, 17, 20, 517, 113, 114, 2489, 2490, ":" +310, 17, 21, 518, 115, 117, 2491, 2493, "10" +310, 17, 22, 519, 118, 119, 2494, 2495, "." +310, 17, 23, 520, 120, 124, 2496, 2500, "1111" +310, 17, 24, 521, 125, 126, 2501, 2502, "/" +310, 17, 25, 522, 127, 128, 2503, 2504, "j" +310, 17, 26, 523, 129, 130, 2505, 2506, "." +310, 17, 27, 524, 131, 135, 2507, 2511, "1753" +310, 17, 28, 525, 136, 137, 2512, 2513, "-" +310, 17, 29, 526, 138, 142, 2514, 2518, "0407" +310, 17, 30, 527, 143, 144, 2519, 2520, "." +310, 17, 31, 528, 145, 149, 2521, 2525, "2012" +310, 17, 32, 529, 150, 151, 2526, 2527, "." +310, 17, 33, 530, 152, 157, 2528, 2533, "00223" +310, 17, 34, 531, 158, 159, 2534, 2535, "." +310, 17, 35, 532, 160, 161, 2536, 2537, "x" +310, 17, 36, 533, 162, 166, 2538, 2542, "PMID" +310, 17, 37, 534, 167, 168, 2543, 2544, ":" +310, 17, 38, 535, 169, 177, 2545, 2553, "22742523" +310, 17, 39, 536, 178, 179, 2554, 2555, "[" +310, 17, 40, 537, 180, 187, 2556, 2563, "Indexed" +310, 17, 41, 538, 188, 191, 2564, 2567, "for" +310, 17, 42, 539, 192, 199, 2568, 2575, "MEDLINE" +310, 17, 43, 540, 200, 201, 2576, 2577, "]" diff --git a/data/dm2 22742523_kwoodley.annodb b/data/dm2 22742523_kwoodley.annodb new file mode 100644 index 0000000..abd4c00 --- /dev/null +++ b/data/dm2 22742523_kwoodley.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +22697, Journal, 0, 12, "J Diabetes .", "", +22698, PublicationYear, 13, 17, "2013", "", +22724, Title, 99, 286, "Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo - controlled 54 - week trial in patients with type 2 diabetes .", "", +22699, Sitagliptin, 122, 133, "sitagliptin", "", +22706, Metformin, 151, 160, "metformin", "", +22710, Rosiglitazone, 165, 178, "rosiglitazone", "", +22714, Randomized, 204, 214, "randomized", "", +24753, Placebo, 215, 222, "placebo", "", +22716, Duration, 236, 245, "54 - week", "", +22718, Type2Diabetes, 269, 284, "type 2 diabetes", "", +22725, Author, 287, 294, "Dobs AS", "", +22726, Author, 303, 315, "Goldstein BJ", "", +22727, Author, 318, 327, "Aschner P", "", +22728, Author, 330, 339, "Horton ES", "", +22729, Author, 342, 354, "Umpierrez GE", "", +22730, Author, 357, 364, "Duran L", "", +22731, Author, 367, 374, "Hill JS", "", +22732, Author, 377, 383, "Chen Y", "", +22733, Author, 386, 393, "Golm GT", "", +22734, Author, 396, 406, "Langdon RB", "", +22735, Author, 409, 429, "Williams - Herman DE", "", +22736, Author, 432, 442, "Kaufman KD", "", +22737, Author, 445, 456, "Amatruda JM", "", +22738, Author, 459, 470, "Ferreira JC", "", +22739, USA, 563, 566, "USA", "", +22719, Type2Diabetes, 665, 680, "type 2 diabetes", "", +22720, Type2Diabetes, 683, 686, "T2D", "", +22741, ObjectiveDescription, 756, 895, "The present study assessed the efficacy and safety of sitagliptin as add - on therapy to metformin and rosiglitazone in patients with T2D .", "", +22701, Sitagliptin, 810, 821, "sitagliptin", "", +22707, Metformin, 845, 854, "metformin", "", +22711, Rosiglitazone, 859, 872, "rosiglitazone", "", +22721, Type2Diabetes, 890, 893, "T2D", "", +22742, Randomized, 930, 940, "randomized", "", +22743, DoubleBlind, 941, 955, "double - blind", "", +24754, Placebo, 956, 963, "placebo", "", +22745, Parallel, 977, 993, "parallel - group", "", +22746, Duration, 994, 1003, "54 - week", "", +22747, NumberPatientsCT, 1086, 1089, "278", "", +22751, Precondition, 1090, 1252, "patients with HbA1c ranging from ≥ 7 . 5 % to ≤ 11 . 0 % despite ongoing combination therapy with metformin ( ≥ 1500 mg / day ) and rosiglitazone ( ≥ 4 mg / day )", "", +22748, HbA1c, 1104, 1109, "HbA1c", "", +22749, Percentage, 1131, 1132, "%", "", +22750, Percentage, 1145, 1146, "%", "", +22708, Metformin, 1188, 1197, "metformin", "", +22752, DoseValue, 1200, 1206, "≥ 1500", "", +22754, mg, 1207, 1209, "mg", "", +22756, Frequency, 1212, 1215, "day", "", +22712, Rosiglitazone, 1222, 1235, "rosiglitazone", "", +22753, DoseValue, 1238, 1241, "≥ 4", "", +22755, mg, 1242, 1244, "mg", "", +22757, Frequency, 1247, 1250, "day", "", +22758, Randomized, 1269, 1279, "randomized", "", +22759, AllocationRatio, 1282, 1287, "2 : 1", "", +22702, Sitagliptin, 1301, 1312, "sitagliptin", "", +22760, DoseValue, 1313, 1316, "100", "", +22761, mg, 1317, 1319, "mg", "", +22762, Placebo, 1323, 1330, "placebo", "", +22763, Frequency, 1331, 1341, "once daily", "", +22764, HbA1c, 1397, 1402, "HbA1c", "", +22765, TimePoint, 1406, 1413, "Week 18", "", +22766, HbA1c, 1440, 1445, "HbA1c", "", +22767, BaseLineValue, 1450, 1455, "8 . 8", "", +22769, Percentage, 1456, 1457, "%", "", +22770, Placebo, 1469, 1476, "placebo", "", +22771, HbA1c, 1512, 1517, "HbA1c", "", +22703, Sitagliptin, 1523, 1534, "sitagliptin", "", +22772, Reduction, 1551, 1556, "0 . 7", "", +22774, Percentage, 1557, 1558, "%", "", +22776, PValueChangeValue, 1561, 1572, "P < 0 . 001", "", +22778, TimePoint, 1578, 1585, "Week 18", "", +22773, Reduction, 1592, 1597, "0 . 8", "", +22775, Percentage, 1598, 1599, "%", "", +22777, PValueChangeValue, 1602, 1613, "P < 0 . 001", "", +22779, TimePoint, 1619, 1626, "Week 54", "", +22787, ObservedResult, 1629, 1683, "There were also significant ( P < 0 . 001 ) reductions", "", +22782, PValueChangeValue, 1659, 1670, "P < 0 . 001", "", +33165, PostprandialBloodGlucose, 1687, 1712, "2 - h post - meal glucose", "", +22781, FastingPlasmaGlucose, 1717, 1739, "fasting plasma glucose", "", +22783, Placebo, 1754, 1761, "placebo", "", +22784, TimePoint, 1765, 1773, "Weeks 18", "", +22785, TimePoint, 1778, 1780, "54", "", +22704, Sitagliptin, 1819, 1830, "sitagliptin", "", +22786, Placebo, 1838, 1845, "placebo", "", +22788, HbA1c_target, 1869, 1884, "HbA1c < 7 . 0 %", "", +22789, TimePoint, 1888, 1896, "Weeks 18", "", +22791, PercentageAffected, 1899, 1901, "22", "", +22792, PercentageAffected, 1907, 1908, "9", "", +22795, PValueNumAffected, 1913, 1924, "P = 0 . 003", "but percentage", +22790, TimePoint, 1931, 1933, "54", "", +22793, PercentageAffected, 1936, 1938, "26", "", +22794, PercentageAffected, 1944, 1946, "14", "", +22796, PValueNumAffected, 1951, 1962, "P = 0 . 015", "but percentage", +22797, BodyWeight, 1978, 1989, "body weight", "", +22798, BodyWeight, 2007, 2021, "adverse events", "", +22799, Hypoglycemia, 2032, 2044, "hypoglycemia", "", +22800, GastrointestinalProblem, 2051, 2082, "gastrointestinal adverse events", "", +22802, ObservedResult, 2083, 2133, "were similar in the sitagliptin and placebo groups", "", +22705, Sitagliptin, 2103, 2114, "sitagliptin", "", +22801, Placebo, 2119, 2126, "placebo", "", +22717, Duration, 2145, 2154, "54 - week", "", +22806, ConclusionComment, 2177, 2375, "In patients with T2D , the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo .", "", +22722, Type2Diabetes, 2194, 2197, "T2D", "", +22700, Sitagliptin, 2216, 2227, "sitagliptin", "", +22723, Duration, 2232, 2240, "54 weeks", "", +22709, Metformin, 2265, 2274, "metformin", "", +22713, Rosiglitazone, 2279, 2292, "rosiglitazone", "", +22805, Placebo, 2366, 2373, "placebo", "", +22807, PMID, 2545, 2553, "22742523", "", diff --git a/data/dm2 22742523_kwoodley.n-triples b/data/dm2 22742523_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 22742523_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23039321_admin.annodb b/data/dm2 23039321_admin.annodb new file mode 100644 index 0000000..afc6c48 --- /dev/null +++ b/data/dm2 23039321_admin.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2013", "", " \"2013\"." +6, Title, 104, 239, "Improved glycaemic control with vildagliptin added to insulin , with or without metformin , in patients with type 2 diabetes mellitus .", "", " \"Improved glycaemic control with vildagliptin added to insulin , with or without metformin , in patients with type 2 diabetes mellitus .\"." +2, Vildagliptin, 136, 148, "vildagliptin", "", +3, Insulin, 158, 165, "insulin", "", +4, Metformin, 184, 193, "metformin", "", +5, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", " ." +99, Author, 240, 248, "Kothny W", "", " \"Kothny W\"." +8, Author, 257, 264, "Foley J", "", " \"Foley J\"." +9, Author, 267, 278, "Kozlovski P", "", " \"Kozlovski P\"." +10, Author, 281, 287, "Shao Q", "", " \"Shao Q\"." +11, Author, 290, 300, "Gallwitz B", "", " \"Gallwitz B\"." +12, Author, 303, 316, "Lukashevich V", "", " \"Lukashevich V\"." +13, USA, 399, 402, "USA", "", +21, ObjectiveDescription, 446, 600, "The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add - on therapy to insulin in type 2 diabetes mellitus ( T2DM ) .", "", " \"The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add - on therapy to insulin in type 2 diabetes mellitus ( T2DM ) .\"." +14, Vildagliptin, 508, 520, "vildagliptin", "", +15, DoseValue, 521, 523, "50", "", +16, mg, 524, 526, "mg", "", +17, Frequency, 527, 530, "bid", "", +18, Insulin, 554, 561, "insulin", "", +19, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +20, Type2Diabetes, 592, 596, "T2DM", "", +22, Multicenter, 621, 632, "multicentre", "", " ." +23, DoubleBlind, 635, 649, "double - blind", "", " ." +91, Placebo, 652, 659, "placebo", "", +24, Parallel, 675, 689, "parallel group", "", " ." +25, Type2Diabetes, 710, 714, "T2DM", "", +28, Precondition, 710, 801, "T2DM patients inadequately controlled by stable insulin therapy , with or without metformin", "", " \"T2DM patients inadequately controlled by stable insulin therapy , with or without metformin\"." +26, Insulin, 758, 765, "insulin", "", +27, Metformin, 792, 801, "metformin", "", +29, Vildagliptin, 837, 849, "vildagliptin", "", " ." +30, DoseValue, 850, 852, "50", "", " \"50\"." +31, mg, 853, 855, "mg", "", " ." +32, Frequency, 856, 859, "bid", "", " \"bid\"." +33, Placebo, 863, 870, "placebo", "", " ." +34, Duration, 875, 883, "24 weeks", "", " \"24 weeks\"." +35, NumberPatientsCT, 905, 908, "449", "", " \"449\"." +36, Randomized, 923, 933, "randomized", "", " ." +37, Vildagliptin, 937, 949, "vildagliptin", "", +38, NumberPatientsArm, 958, 961, "228", "", " \"228\"." +40, Placebo, 967, 974, "placebo", "", +39, NumberPatientsArm, 983, 986, "221", "", " \"221\"." +134, TimePoint, 997, 1005, "24 weeks", "", " \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\". \"24 weeks\"." +135, Mean, 1035, 1039, "mean", "", " . ." +42, HbA1c, 1050, 1065, "haemoglobin A1c", "", " ." +43, HbA1c, 1068, 1073, "HbA1c", "", +44, Vildagliptin, 1084, 1096, "vildagliptin", "", +48, Placebo, 1101, 1108, "placebo", "", +51, DiffGroupAbsValue, 1113, 1120, "- 0 . 7", "", " \"- 0 . 7\"." +54, SdDevDiff, 1125, 1130, "0 . 1", "", " \"0 . 1\"." +57, Percentage, 1131, 1132, "%", "", " ." +59, PvalueDiff, 1135, 1148, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +52, DiffGroupAbsValue, 1185, 1192, "- 0 . 6", "", " \"- 0 . 6\"." +55, SdDevDiff, 1197, 1202, "0 . 1", "", " \"0 . 1\"." +58, Percentage, 1203, 1204, "%", "", +60, PvalueDiff, 1207, 1220, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +142, SubGroupDescription, 1244, 1263, "receiving metformin", "", " \"receiving metformin\". \"receiving metformin\"." +63, Metformin, 1254, 1263, "metformin", "", +53, DiffGroupAbsValue, 1268, 1275, "- 0 . 8", "", " \"- 0 . 6\"." +56, SdDevDiff, 1280, 1285, "0 . 2", "", " \"0 . 2\"." +62, Percentage, 1286, 1287, "%", "", +61, PvalueDiff, 1290, 1303, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +66, SubGroupDescription, 1322, 1339, "without metformin", "", " \"without metformin\". \"without metformin\"." +64, Metformin, 1330, 1339, "metformin", "", +45, Vildagliptin, 1342, 1354, "Vildagliptin", "", +67, Hypoglycemia, 1419, 1432, "hypoglycaemia", "", " ." +49, Placebo, 1447, 1454, "placebo", "", +68, PercentageAffected, 1457, 1462, "8 . 4", "", " \"8 . 4\"." +69, PercentageAffected, 1468, 1473, "7 . 2", "", " \"7 . 2\"." +70, PvalueDiff, 1478, 1490, "p  =  0 . 66", "", " \"p  =  0 . 66\"." +72, ObservedResult, 1538, 1573, "was not associated with weight gain", "", " \"was not associated with weight gain\"." +63726, BodyWeight, 1562, 1568, "weight", "", " ." +73, Increment, 1580, 1585, "0 . 1", "", " \"0 . 1\"." +74, Reduction, 1593, 1598, "0 . 4", "", " \"0 . 4\"." +75, Kg, 1599, 1601, "kg", "", " ." +46, Vildagliptin, 1620, 1632, "Vildagliptin", "", +85, ConclusionComment, 1620, 1774, "Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin , with or without metformin .", "", " \"Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin , with or without metformin .\"." +76, DoseValue, 1633, 1635, "50", "", +77, mg, 1636, 1638, "mg", "", +78, Frequency, 1639, 1642, "bid", "", +79, Insulin, 1652, 1659, "insulin", "", +80, HbA1c, 1682, 1687, "HbA1c", "", +81, Type2Diabetes, 1705, 1709, "T2DM", "", +82, Insulin, 1737, 1744, "insulin", "", +83, Metformin, 1763, 1772, "metformin", "", +47, Vildagliptin, 1775, 1787, "Vildagliptin", "", +86, ConclusionComment, 1775, 1851, "Vildagliptin was well tolerated , with a safety profile similar to placebo .", "", " \"Vildagliptin was well tolerated , with a safety profile similar to placebo .\"." +50, Placebo, 1842, 1849, "placebo", "", +87, ConclusionComment, 1852, 1994, "These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control .", "", " \"These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control .\"." +178, WeightGain, 1888, 1899, "weight gain", "", +89, Hypoglycemia, 1918, 1931, "hypoglycaemia", "", +90, PMID, 2066, 2074, "23039321", "", " \"23039321\"." diff --git a/data/dm2 23039321_admin.n-triples b/data/dm2 23039321_admin.n-triples new file mode 100644 index 0000000..16bbc93 --- /dev/null +++ b/data/dm2 23039321_admin.n-triples @@ -0,0 +1,180 @@ +# RDF export of group: Publication + . + "Publication 40042" . + "Improved glycaemic control with vildagliptin added to insulin , with or without metformin , in patients with type 2 diabetes mellitus ." . + "Kothny W" . + "2013" . + "Diabetes Obes Metab ." . + "23039321" . + . + "Foley J" . + "Kozlovski P" . + "Shao Q" . + "Gallwitz B" . + "Lukashevich V" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 40049" . + "The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add - on therapy to insulin in type 2 diabetes mellitus ( T2DM ) ." . + "449" . + "24 weeks" . + . + . + . + "Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin , with or without metformin ." . + . + . + . + . + . + . + . + . + "Vildagliptin was well tolerated , with a safety profile similar to placebo ." . + "These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control ." . + . + . + . + . +# RDF export of group: Population + . + "Population 40065" . + "T2DM patients inadequately controlled by stable insulin therapy , with or without metformin" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + "228" . + . + . + . + . + . + . + . + "pla" . + "221" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + "bid" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "vil" . + . + "50" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "24 weeks" . + . + "hba 2" . + . + "24 weeks" . + . + "hbas 1" . + . + "24 weeks" . + "receiving metformin" . + . + "hbas 2" . + . + "24 weeks" . + "receiving metformin" . + . + "hbat 1" . + . + "24 weeks" . + "without metformin" . + . + "hbat2" . + . + "24 weeks" . + "without metformin" . + . + "hyp 1" . + . + "8 . 4" . + . + "hyp 2" . + . + "7 . 2" . + . + "bw 1" . + . + "0 . 1" . + "was not associated with weight gain" . + . + "bw 2" . + . + "0 . 4" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 7" . + "p  <  0 . 001" . + "0 . 1" . + . + . + . + "hbas" . + "- 0 . 6" . + "p  <  0 . 001" . + "0 . 1" . + . + . + . + "hbat" . + "- 0 . 8" . + "p  <  0 . 001" . + "0 . 2" . + . + . + . + "hyo" . + "p  =  0 . 66" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23039321_akramersunderbrink.annodb b/data/dm2 23039321_akramersunderbrink.annodb new file mode 100644 index 0000000..1f4794c --- /dev/null +++ b/data/dm2 23039321_akramersunderbrink.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42140, Journal, 0, 19, "Diabetes Obes Metab", "", +42141, PublicationYear, 22, 26, "2013", "", +42146, Title, 104, 239, "Improved glycaemic control with vildagliptin added to insulin , with or without metformin , in patients with type 2 diabetes mellitus .", "", +42142, Vildagliptin, 136, 148, "vildagliptin", "", +42143, Insulin, 158, 165, "insulin", "", +42144, Metformin, 184, 193, "metformin", "", +42145, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", +42147, Author, 240, 248, "Kothny W", "", +42148, Author, 257, 264, "Foley J", "", +42149, Author, 267, 278, "Kozlovski P", "", +42150, Author, 281, 287, "Shao Q", "", +42151, Author, 290, 300, "Gallwitz B", "", +42152, Author, 303, 316, "Lukashevich V", "", +42153, USA, 399, 402, "USA", "", +42161, ObjectiveDescription, 446, 600, "The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add - on therapy to insulin in type 2 diabetes mellitus ( T2DM ) .", "", +42154, Vildagliptin, 508, 520, "vildagliptin", "", +42155, DoseValue, 521, 526, "50 mg", "", +42156, mg, 524, 526, "mg", "", +42157, Frequency, 527, 530, "bid", "", +42160, Insulin, 554, 561, "insulin", "", +42158, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +42159, Type2Diabetes, 592, 596, "T2DM", "", +42162, Multicenter, 621, 632, "multicentre", "", +42163, DoubleBlind, 635, 649, "double - blind", "", +42164, Placebo, 652, 659, "placebo", "", +42165, Parallel, 675, 689, "parallel group", "", +42166, Type2Diabetes, 710, 714, "T2DM", "", +42167, Precondition, 724, 801, "inadequately controlled by stable insulin therapy , with or without metformin", "", +42168, Insulin, 758, 765, "insulin", "", +42169, Metformin, 792, 801, "metformin", "", +42170, Vildagliptin, 837, 849, "vildagliptin", "", +42172, DoseValue, 850, 855, "50 mg", "", +42173, mg, 853, 855, "mg", "", +42174, Frequency, 856, 859, "bid", "", +42171, Placebo, 863, 870, "placebo", "", +42175, Duration, 875, 883, "24 weeks", "", +42176, NumberPatientsCT, 905, 908, "449", "", +42177, Randomized, 923, 933, "randomized", "", +42178, Vildagliptin, 937, 949, "vildagliptin", "", +42179, NumberPatientsArm, 958, 961, "228", "", +42181, Placebo, 967, 974, "placebo", "", +42180, NumberPatientsArm, 983, 986, "221", "", +42182, TimePoint, 997, 1005, "24 weeks", "", +42183, Mean, 1035, 1039, "mean", "", +42184, HbA1c, 1050, 1065, "haemoglobin A1c", "", +42185, HbA1c, 1068, 1073, "HbA1c", "", +42186, Vildagliptin, 1084, 1096, "vildagliptin", "", +42188, Placebo, 1101, 1108, "placebo", "", +42189, DiffGroupAbsValue, 1113, 1120, "- 0 . 7", "", +42200, Percentage, 1131, 1132, "%", "", +42197, PvalueDiff, 1135, 1148, "p  <  0 . 001", "", +42190, DiffGroupAbsValue, 1185, 1192, "- 0 . 6", "", +42232, SdErrorDiff, 1197, 1202, "0 . 1", "", +42201, Percentage, 1203, 1204, "%", "", +42199, PvalueDiff, 1207, 1220, "p  <  0 . 001", "", +42191, SubGroupDescription, 1226, 1263, "the subgroup also receiving metformin", "", +42192, Metformin, 1254, 1263, "metformin", "", +42196, DiffGroupAbsValue, 1268, 1275, "- 0 . 8", "", +42233, SdErrorDiff, 1280, 1285, "0 . 2", "", +42202, Percentage, 1286, 1287, "%", "", +42198, PvalueDiff, 1290, 1303, "p  <  0 . 001", "", +42195, SubGroupDescription, 1309, 1339, "the subgroup without metformin", "", +42193, Metformin, 1330, 1339, "metformin", "", +42203, Vildagliptin, 1342, 1354, "Vildagliptin", "", +42204, Hypoglycemia, 1419, 1432, "hypoglycaemia", "", +42205, Placebo, 1447, 1454, "placebo", "", +42207, PercentageAffected, 1457, 1462, "8 . 4", "", +42208, PercentageAffected, 1468, 1473, "7 . 2", "", +42210, Percentage, 1474, 1475, "%", "", +42209, PvalueDiff, 1478, 1490, "p  =  0 . 66", "", +42206, WeightGain, 1562, 1573, "weight gain", "", +42211, ResultMeasuredValue, 1578, 1585, "+ 0 . 1", "", +42212, ResultMeasuredValue, 1591, 1598, "- 0 . 4", "", +42213, Kg, 1599, 1601, "kg", "", +42214, Vildagliptin, 1620, 1632, "Vildagliptin", "", +42224, ConclusionComment, 1620, 1774, "Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin , with or without metformin .", "", +42215, DoseValue, 1633, 1638, "50 mg", "", +42216, mg, 1636, 1638, "mg", "", +42217, Frequency, 1639, 1642, "bid", "", +42218, Insulin, 1652, 1659, "insulin", "", +42219, HbA1c, 1682, 1687, "HbA1c", "", +42220, Type2Diabetes, 1705, 1709, "T2DM", "", +42221, Precondition, 1710, 1772, "inadequately controlled by insulin , with or without metformin", "", +42222, Insulin, 1737, 1744, "insulin", "", +42223, Metformin, 1763, 1772, "metformin", "", +42225, Vildagliptin, 1775, 1787, "Vildagliptin", "", +42227, ConclusionComment, 1775, 1851, "Vildagliptin was well tolerated , with a safety profile similar to placebo .", "", +42226, Placebo, 1842, 1849, "placebo", "", +42231, ConclusionComment, 1852, 1994, "These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control .", "", +42228, WeightGain, 1888, 1899, "weight gain", "", +42229, Hypoglycemia, 1918, 1931, "hypoglycaemia", "", +42230, PMID, 2066, 2074, "23039321", "", diff --git a/data/dm2 23039321_akramersunderbrink.n-triples b/data/dm2 23039321_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23039321_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23039321_export.csv b/data/dm2 23039321_export.csv new file mode 100644 index 0000000..a81d3a1 --- /dev/null +++ b/data/dm2 23039321_export.csv @@ -0,0 +1,441 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +309, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +309, 1, 2, 2, 9, 13, 9, 13, "Obes" +309, 1, 3, 3, 14, 19, 14, 19, "Metab" +309, 1, 4, 4, 20, 21, 20, 21, "." +309, 2, 1, 5, 0, 4, 22, 26, "2013" +309, 2, 2, 6, 5, 8, 27, 30, "Mar" +309, 2, 3, 7, 9, 10, 31, 32, ";" +309, 2, 4, 8, 11, 13, 33, 35, "15" +309, 2, 5, 9, 14, 15, 36, 37, "(" +309, 2, 6, 10, 16, 17, 38, 39, "3" +309, 2, 7, 11, 18, 19, 40, 41, ")" +309, 2, 8, 12, 20, 21, 42, 43, ":" +309, 2, 9, 13, 22, 25, 44, 47, "252" +309, 2, 10, 14, 26, 27, 48, 49, "-" +309, 2, 11, 15, 28, 29, 50, 51, "7" +309, 2, 12, 16, 30, 31, 52, 53, "." +309, 2, 13, 17, 32, 35, 54, 57, "doi" +309, 2, 14, 18, 36, 37, 58, 59, ":" +309, 2, 15, 19, 38, 40, 60, 62, "10" +309, 2, 16, 20, 41, 42, 63, 64, "." +309, 2, 17, 21, 43, 47, 65, 69, "1111" +309, 2, 18, 22, 48, 49, 70, 71, "/" +309, 2, 19, 23, 50, 53, 72, 75, "dom" +309, 2, 20, 24, 54, 55, 76, 77, "." +309, 2, 21, 25, 56, 61, 78, 83, "12020" +309, 2, 22, 26, 62, 63, 84, 85, "." +309, 3, 1, 27, 0, 4, 86, 90, "Epub" +309, 3, 2, 28, 5, 9, 91, 95, "2012" +309, 3, 3, 29, 10, 13, 96, 99, "Nov" +309, 3, 4, 30, 14, 15, 100, 101, "1" +309, 3, 5, 31, 16, 17, 102, 103, "." +309, 4, 1, 32, 0, 8, 104, 112, "Improved" +309, 4, 2, 33, 9, 18, 113, 122, "glycaemic" +309, 4, 3, 34, 19, 26, 123, 130, "control" +309, 4, 4, 35, 27, 31, 131, 135, "with" +309, 4, 5, 36, 32, 44, 136, 148, "vildagliptin" +309, 4, 6, 37, 45, 50, 149, 154, "added" +309, 4, 7, 38, 51, 53, 155, 157, "to" +309, 4, 8, 39, 54, 61, 158, 165, "insulin" +309, 4, 9, 40, 62, 63, 166, 167, "," +309, 4, 10, 41, 64, 68, 168, 172, "with" +309, 4, 11, 42, 69, 71, 173, 175, "or" +309, 4, 12, 43, 72, 79, 176, 183, "without" +309, 4, 13, 44, 80, 89, 184, 193, "metformin" +309, 4, 14, 45, 90, 91, 194, 195, "," +309, 4, 15, 46, 92, 94, 196, 198, "in" +309, 4, 16, 47, 95, 103, 199, 207, "patients" +309, 4, 17, 48, 104, 108, 208, 212, "with" +309, 4, 18, 49, 109, 113, 213, 217, "type" +309, 4, 19, 50, 114, 115, 218, 219, "2" +309, 4, 20, 51, 116, 124, 220, 228, "diabetes" +309, 4, 21, 52, 125, 133, 229, 237, "mellitus" +309, 4, 22, 53, 134, 135, 238, 239, "." +309, 5, 1, 54, 0, 6, 240, 246, "Kothny" +309, 5, 2, 55, 7, 8, 247, 248, "W" +309, 5, 3, 56, 9, 10, 249, 250, "(" +309, 5, 4, 57, 11, 12, 251, 252, "1" +309, 5, 5, 58, 13, 14, 253, 254, ")" +309, 5, 6, 59, 15, 16, 255, 256, "," +309, 5, 7, 60, 17, 22, 257, 262, "Foley" +309, 5, 8, 61, 23, 24, 263, 264, "J" +309, 5, 9, 62, 25, 26, 265, 266, "," +309, 5, 10, 63, 27, 36, 267, 276, "Kozlovski" +309, 5, 11, 64, 37, 38, 277, 278, "P" +309, 5, 12, 65, 39, 40, 279, 280, "," +309, 5, 13, 66, 41, 45, 281, 285, "Shao" +309, 5, 14, 67, 46, 47, 286, 287, "Q" +309, 5, 15, 68, 48, 49, 288, 289, "," +309, 5, 16, 69, 50, 58, 290, 298, "Gallwitz" +309, 5, 17, 70, 59, 60, 299, 300, "B" +309, 5, 18, 71, 61, 62, 301, 302, "," +309, 5, 19, 72, 63, 74, 303, 314, "Lukashevich" +309, 5, 20, 73, 75, 76, 315, 316, "V" +309, 5, 21, 74, 77, 78, 317, 318, "." +309, 5, 22, 75, 79, 85, 319, 325, "Author" +309, 5, 23, 76, 86, 97, 326, 337, "information" +309, 5, 24, 77, 98, 99, 338, 339, ":" +309, 5, 25, 78, 100, 101, 340, 341, "(" +309, 5, 26, 79, 102, 103, 342, 343, "1" +309, 5, 27, 80, 104, 105, 344, 345, ")" +309, 5, 28, 81, 106, 114, 346, 354, "Novartis" +309, 5, 29, 82, 115, 130, 355, 370, "Pharmaceuticals" +309, 5, 30, 83, 131, 132, 371, 372, "," +309, 5, 31, 84, 133, 137, 373, 377, "East" +309, 5, 32, 85, 138, 145, 378, 385, "Hanover" +309, 5, 33, 86, 146, 147, 386, 387, "," +309, 5, 34, 87, 148, 150, 388, 390, "NJ" +309, 5, 35, 88, 151, 156, 391, 396, "07936" +309, 5, 36, 89, 157, 158, 397, 398, "," +309, 5, 37, 90, 159, 162, 399, 402, "USA" +309, 5, 38, 91, 163, 164, 403, 404, "." +309, 6, 1, 92, 0, 8, 405, 413, "wolfgang" +309, 6, 2, 93, 9, 10, 414, 415, "." +309, 6, 3, 94, 11, 17, 416, 422, "kothny" +309, 6, 4, 95, 18, 19, 423, 424, "@" +309, 6, 5, 96, 20, 28, 425, 433, "novartis" +309, 6, 6, 97, 29, 30, 434, 435, "." +309, 6, 7, 98, 31, 34, 436, 439, "com" +309, 6, 8, 99, 35, 38, 440, 443, "AIM" +309, 6, 9, 100, 39, 40, 444, 445, ":" +309, 6, 10, 101, 41, 44, 446, 449, "The" +309, 6, 11, 102, 45, 48, 450, 453, "aim" +309, 6, 12, 103, 49, 51, 454, 456, "of" +309, 6, 13, 104, 52, 56, 457, 461, "this" +309, 6, 14, 105, 57, 62, 462, 467, "study" +309, 6, 15, 106, 63, 65, 468, 470, "is" +309, 6, 16, 107, 66, 68, 471, 473, "to" +309, 6, 17, 108, 69, 75, 474, 480, "assess" +309, 6, 18, 109, 76, 79, 481, 484, "the" +309, 6, 19, 110, 80, 88, 485, 493, "efficacy" +309, 6, 20, 111, 89, 92, 494, 497, "and" +309, 6, 21, 112, 93, 99, 498, 504, "safety" +309, 6, 22, 113, 100, 102, 505, 507, "of" +309, 6, 23, 114, 103, 115, 508, 520, "vildagliptin" +309, 6, 24, 115, 116, 118, 521, 523, "50" +309, 6, 25, 116, 119, 121, 524, 526, "mg" +309, 6, 26, 117, 122, 125, 527, 530, "bid" +309, 6, 27, 118, 126, 128, 531, 533, "as" +309, 6, 28, 119, 129, 132, 534, 537, "add" +309, 6, 29, 120, 133, 134, 538, 539, "-" +309, 6, 30, 121, 135, 137, 540, 542, "on" +309, 6, 31, 122, 138, 145, 543, 550, "therapy" +309, 6, 32, 123, 146, 148, 551, 553, "to" +309, 6, 33, 124, 149, 156, 554, 561, "insulin" +309, 6, 34, 125, 157, 159, 562, 564, "in" +309, 6, 35, 126, 160, 164, 565, 569, "type" +309, 6, 36, 127, 165, 166, 570, 571, "2" +309, 6, 37, 128, 167, 175, 572, 580, "diabetes" +309, 6, 38, 129, 176, 184, 581, 589, "mellitus" +309, 6, 39, 130, 185, 186, 590, 591, "(" +309, 6, 40, 131, 187, 191, 592, 596, "T2DM" +309, 6, 41, 132, 192, 193, 597, 598, ")" +309, 6, 42, 133, 194, 195, 599, 600, "." +309, 7, 1, 134, 0, 7, 601, 608, "METHODS" +309, 7, 2, 135, 8, 9, 609, 610, ":" +309, 7, 3, 136, 10, 14, 611, 615, "This" +309, 7, 4, 137, 15, 17, 616, 618, "is" +309, 7, 5, 138, 18, 19, 619, 620, "a" +309, 7, 6, 139, 20, 31, 621, 632, "multicentre" +309, 7, 7, 140, 32, 33, 633, 634, "," +309, 7, 8, 141, 34, 40, 635, 641, "double" +309, 7, 9, 142, 41, 42, 642, 643, "-" +309, 7, 10, 143, 43, 48, 644, 649, "blind" +309, 7, 11, 144, 49, 50, 650, 651, "," +309, 7, 12, 145, 51, 58, 652, 659, "placebo" +309, 7, 13, 146, 59, 60, 660, 661, "-" +309, 7, 14, 147, 61, 71, 662, 672, "controlled" +309, 7, 15, 148, 72, 73, 673, 674, "," +309, 7, 16, 149, 74, 82, 675, 683, "parallel" +309, 7, 17, 150, 83, 88, 684, 689, "group" +309, 7, 18, 151, 89, 90, 690, 691, "," +309, 7, 19, 152, 91, 99, 692, 700, "clinical" +309, 7, 20, 153, 100, 105, 701, 706, "trial" +309, 7, 21, 154, 106, 108, 707, 709, "in" +309, 7, 22, 155, 109, 113, 710, 714, "T2DM" +309, 7, 23, 156, 114, 122, 715, 723, "patients" +309, 7, 24, 157, 123, 135, 724, 736, "inadequately" +309, 7, 25, 158, 136, 146, 737, 747, "controlled" +309, 7, 26, 159, 147, 149, 748, 750, "by" +309, 7, 27, 160, 150, 156, 751, 757, "stable" +309, 7, 28, 161, 157, 164, 758, 765, "insulin" +309, 7, 29, 162, 165, 172, 766, 773, "therapy" +309, 7, 30, 163, 173, 174, 774, 775, "," +309, 7, 31, 164, 175, 179, 776, 780, "with" +309, 7, 32, 165, 180, 182, 781, 783, "or" +309, 7, 33, 166, 183, 190, 784, 791, "without" +309, 7, 34, 167, 191, 200, 792, 801, "metformin" +309, 7, 35, 168, 201, 202, 802, 803, "." +309, 8, 1, 169, 0, 8, 804, 812, "Patients" +309, 8, 2, 170, 9, 17, 813, 821, "received" +309, 8, 3, 171, 18, 27, 822, 831, "treatment" +309, 8, 4, 172, 28, 32, 832, 836, "with" +309, 8, 5, 173, 33, 45, 837, 849, "vildagliptin" +309, 8, 6, 174, 46, 48, 850, 852, "50" +309, 8, 7, 175, 49, 51, 853, 855, "mg" +309, 8, 8, 176, 52, 55, 856, 859, "bid" +309, 8, 9, 177, 56, 58, 860, 862, "or" +309, 8, 10, 178, 59, 66, 863, 870, "placebo" +309, 8, 11, 179, 67, 70, 871, 874, "for" +309, 8, 12, 180, 71, 73, 875, 877, "24" +309, 8, 13, 181, 74, 79, 878, 883, "weeks" +309, 8, 14, 182, 80, 81, 884, 885, "." +309, 9, 1, 183, 0, 7, 886, 893, "RESULTS" +309, 9, 2, 184, 8, 9, 894, 895, ":" +309, 9, 3, 185, 10, 12, 896, 898, "In" +309, 9, 4, 186, 13, 16, 899, 902, "all" +309, 9, 5, 187, 17, 18, 903, 904, "," +309, 9, 6, 188, 19, 22, 905, 908, "449" +309, 9, 7, 189, 23, 31, 909, 917, "patients" +309, 9, 8, 190, 32, 36, 918, 922, "were" +309, 9, 9, 191, 37, 47, 923, 933, "randomized" +309, 9, 10, 192, 48, 50, 934, 936, "to" +309, 9, 11, 193, 51, 63, 937, 949, "vildagliptin" +309, 9, 12, 194, 64, 65, 950, 951, "(" +309, 9, 13, 195, 66, 67, 952, 953, "n" +309, 9, 14, 196, 68, 71, 954, 957, " = " +309, 9, 15, 197, 72, 75, 958, 961, "228" +309, 9, 16, 198, 76, 77, 962, 963, ")" +309, 9, 17, 199, 78, 80, 964, 966, "or" +309, 9, 18, 200, 81, 88, 967, 974, "placebo" +309, 9, 19, 201, 89, 90, 975, 976, "(" +309, 9, 20, 202, 91, 92, 977, 978, "n" +309, 9, 21, 203, 93, 96, 979, 982, " = " +309, 9, 22, 204, 97, 100, 983, 986, "221" +309, 9, 23, 205, 101, 102, 987, 988, ")" +309, 9, 24, 206, 103, 104, 989, 990, "." +309, 10, 1, 207, 0, 5, 991, 996, "After" +309, 10, 2, 208, 6, 8, 997, 999, "24" +309, 10, 3, 209, 9, 14, 1000, 1005, "weeks" +309, 10, 4, 210, 15, 16, 1006, 1007, "," +309, 10, 5, 211, 17, 20, 1008, 1011, "the" +309, 10, 6, 212, 21, 31, 1012, 1022, "difference" +309, 10, 7, 213, 32, 34, 1023, 1025, "in" +309, 10, 8, 214, 35, 43, 1026, 1034, "adjusted" +309, 10, 9, 215, 44, 48, 1035, 1039, "mean" +309, 10, 10, 216, 49, 55, 1040, 1046, "change" +309, 10, 11, 217, 56, 58, 1047, 1049, "in" +309, 10, 12, 218, 59, 70, 1050, 1061, "haemoglobin" +309, 10, 13, 219, 71, 74, 1062, 1065, "A1c" +309, 10, 14, 220, 75, 76, 1066, 1067, "(" +309, 10, 15, 221, 77, 82, 1068, 1073, "HbA1c" +309, 10, 16, 222, 83, 84, 1074, 1075, ")" +309, 10, 17, 223, 85, 92, 1076, 1083, "between" +309, 10, 18, 224, 93, 105, 1084, 1096, "vildagliptin" +309, 10, 19, 225, 106, 109, 1097, 1100, "and" +309, 10, 20, 226, 110, 117, 1101, 1108, "placebo" +309, 10, 21, 227, 118, 121, 1109, 1112, "was" +309, 10, 22, 228, 122, 123, 1113, 1114, "-" +309, 10, 23, 229, 124, 125, 1115, 1116, "0" +309, 10, 24, 230, 126, 127, 1117, 1118, "." +309, 10, 25, 231, 128, 129, 1119, 1120, "7" +309, 10, 26, 232, 130, 133, 1121, 1124, " ± " +309, 10, 27, 233, 134, 135, 1125, 1126, "0" +309, 10, 28, 234, 136, 137, 1127, 1128, "." +309, 10, 29, 235, 138, 139, 1129, 1130, "1" +309, 10, 30, 236, 140, 141, 1131, 1132, "%" +309, 10, 31, 237, 142, 143, 1133, 1134, "(" +309, 10, 32, 238, 144, 145, 1135, 1136, "p" +309, 10, 33, 239, 146, 149, 1137, 1140, " < " +309, 10, 34, 240, 150, 151, 1141, 1142, "0" +309, 10, 35, 241, 152, 153, 1143, 1144, "." +309, 10, 36, 242, 154, 157, 1145, 1148, "001" +309, 10, 37, 243, 158, 159, 1149, 1150, ")" +309, 10, 38, 244, 160, 162, 1151, 1153, "in" +309, 10, 39, 245, 163, 166, 1154, 1157, "the" +309, 10, 40, 246, 167, 174, 1158, 1165, "overall" +309, 10, 41, 247, 175, 180, 1166, 1171, "study" +309, 10, 42, 248, 181, 191, 1172, 1182, "population" +309, 10, 43, 249, 192, 193, 1183, 1184, "," +309, 10, 44, 250, 194, 195, 1185, 1186, "-" +309, 10, 45, 251, 196, 197, 1187, 1188, "0" +309, 10, 46, 252, 198, 199, 1189, 1190, "." +309, 10, 47, 253, 200, 201, 1191, 1192, "6" +309, 10, 48, 254, 202, 205, 1193, 1196, " ± " +309, 10, 49, 255, 206, 207, 1197, 1198, "0" +309, 10, 50, 256, 208, 209, 1199, 1200, "." +309, 10, 51, 257, 210, 211, 1201, 1202, "1" +309, 10, 52, 258, 212, 213, 1203, 1204, "%" +309, 10, 53, 259, 214, 215, 1205, 1206, "(" +309, 10, 54, 260, 216, 217, 1207, 1208, "p" +309, 10, 55, 261, 218, 221, 1209, 1212, " < " +309, 10, 56, 262, 222, 223, 1213, 1214, "0" +309, 10, 57, 263, 224, 225, 1215, 1216, "." +309, 10, 58, 264, 226, 229, 1217, 1220, "001" +309, 10, 59, 265, 230, 231, 1221, 1222, ")" +309, 10, 60, 266, 232, 234, 1223, 1225, "in" +309, 10, 61, 267, 235, 238, 1226, 1229, "the" +309, 10, 62, 268, 239, 247, 1230, 1238, "subgroup" +309, 10, 63, 269, 248, 252, 1239, 1243, "also" +309, 10, 64, 270, 253, 262, 1244, 1253, "receiving" +309, 10, 65, 271, 263, 272, 1254, 1263, "metformin" +309, 10, 66, 272, 273, 276, 1264, 1267, "and" +309, 10, 67, 273, 277, 278, 1268, 1269, "-" +309, 10, 68, 274, 279, 280, 1270, 1271, "0" +309, 10, 69, 275, 281, 282, 1272, 1273, "." +309, 10, 70, 276, 283, 284, 1274, 1275, "8" +309, 10, 71, 277, 285, 288, 1276, 1279, " ± " +309, 10, 72, 278, 289, 290, 1280, 1281, "0" +309, 10, 73, 279, 291, 292, 1282, 1283, "." +309, 10, 74, 280, 293, 294, 1284, 1285, "2" +309, 10, 75, 281, 295, 296, 1286, 1287, "%" +309, 10, 76, 282, 297, 298, 1288, 1289, "(" +309, 10, 77, 283, 299, 300, 1290, 1291, "p" +309, 10, 78, 284, 301, 304, 1292, 1295, " < " +309, 10, 79, 285, 305, 306, 1296, 1297, "0" +309, 10, 80, 286, 307, 308, 1298, 1299, "." +309, 10, 81, 287, 309, 312, 1300, 1303, "001" +309, 10, 82, 288, 313, 314, 1304, 1305, ")" +309, 10, 83, 289, 315, 317, 1306, 1308, "in" +309, 10, 84, 290, 318, 321, 1309, 1312, "the" +309, 10, 85, 291, 322, 330, 1313, 1321, "subgroup" +309, 10, 86, 292, 331, 338, 1322, 1329, "without" +309, 10, 87, 293, 339, 348, 1330, 1339, "metformin" +309, 10, 88, 294, 349, 350, 1340, 1341, "." +309, 11, 1, 295, 0, 12, 1342, 1354, "Vildagliptin" +309, 11, 2, 296, 13, 20, 1355, 1362, "therapy" +309, 11, 3, 297, 21, 24, 1363, 1366, "was" +309, 11, 4, 298, 25, 29, 1367, 1371, "well" +309, 11, 5, 299, 30, 39, 1372, 1381, "tolerated" +309, 11, 6, 300, 40, 43, 1382, 1385, "and" +309, 11, 7, 301, 44, 47, 1386, 1389, "had" +309, 11, 8, 302, 48, 49, 1390, 1391, "a" +309, 11, 9, 303, 50, 59, 1392, 1401, "similarly" +309, 11, 10, 304, 60, 63, 1402, 1405, "low" +309, 11, 11, 305, 64, 73, 1406, 1415, "incidence" +309, 11, 12, 306, 74, 76, 1416, 1418, "of" +309, 11, 13, 307, 77, 90, 1419, 1432, "hypoglycaemia" +309, 11, 14, 308, 91, 99, 1433, 1441, "compared" +309, 11, 15, 309, 100, 104, 1442, 1446, "with" +309, 11, 16, 310, 105, 112, 1447, 1454, "placebo" +309, 11, 17, 311, 113, 114, 1455, 1456, "(" +309, 11, 18, 312, 115, 116, 1457, 1458, "8" +309, 11, 19, 313, 117, 118, 1459, 1460, "." +309, 11, 20, 314, 119, 120, 1461, 1462, "4" +309, 11, 21, 315, 121, 123, 1463, 1465, "vs" +309, 11, 22, 316, 124, 125, 1466, 1467, "." +309, 11, 23, 317, 126, 127, 1468, 1469, "7" +309, 11, 24, 318, 128, 129, 1470, 1471, "." +309, 11, 25, 319, 130, 131, 1472, 1473, "2" +309, 11, 26, 320, 132, 133, 1474, 1475, "%" +309, 11, 27, 321, 134, 135, 1476, 1477, "," +309, 11, 28, 322, 136, 137, 1478, 1479, "p" +309, 11, 29, 323, 138, 141, 1480, 1483, " = " +309, 11, 30, 324, 142, 143, 1484, 1485, "0" +309, 11, 31, 325, 144, 145, 1486, 1487, "." +309, 11, 32, 326, 146, 148, 1488, 1490, "66" +309, 11, 33, 327, 149, 150, 1491, 1492, ")" +309, 11, 34, 328, 151, 153, 1493, 1495, "in" +309, 11, 35, 329, 154, 159, 1496, 1501, "spite" +309, 11, 36, 330, 160, 162, 1502, 1504, "of" +309, 11, 37, 331, 163, 171, 1505, 1513, "improved" +309, 11, 38, 332, 172, 181, 1514, 1523, "glycaemic" +309, 11, 39, 333, 182, 189, 1524, 1531, "control" +309, 11, 40, 334, 190, 191, 1532, 1533, "," +309, 11, 41, 335, 192, 195, 1534, 1537, "and" +309, 11, 42, 336, 196, 199, 1538, 1541, "was" +309, 11, 43, 337, 200, 203, 1542, 1545, "not" +309, 11, 44, 338, 204, 214, 1546, 1556, "associated" +309, 11, 45, 339, 215, 219, 1557, 1561, "with" +309, 11, 46, 340, 220, 226, 1562, 1568, "weight" +309, 11, 47, 341, 227, 231, 1569, 1573, "gain" +309, 11, 48, 342, 232, 233, 1574, 1575, "." +309, 12, 1, 343, 0, 1, 1576, 1577, "(" +309, 12, 2, 344, 2, 3, 1578, 1579, "+" +309, 12, 3, 345, 4, 5, 1580, 1581, "0" +309, 12, 4, 346, 6, 7, 1582, 1583, "." +309, 12, 5, 347, 8, 9, 1584, 1585, "1" +309, 12, 6, 348, 10, 12, 1586, 1588, "vs" +309, 12, 7, 349, 13, 14, 1589, 1590, "." +309, 12, 8, 350, 15, 16, 1591, 1592, "-" +309, 12, 9, 351, 17, 18, 1593, 1594, "0" +309, 12, 10, 352, 19, 20, 1595, 1596, "." +309, 12, 11, 353, 21, 22, 1597, 1598, "4" +309, 12, 12, 354, 23, 25, 1599, 1601, "kg" +309, 12, 13, 355, 26, 27, 1602, 1603, ")" +309, 12, 14, 356, 28, 29, 1604, 1605, "." +309, 13, 1, 357, 0, 11, 1606, 1617, "CONCLUSIONS" +309, 13, 2, 358, 12, 13, 1618, 1619, ":" +309, 13, 3, 359, 14, 26, 1620, 1632, "Vildagliptin" +309, 13, 4, 360, 27, 29, 1633, 1635, "50" +309, 13, 5, 361, 30, 32, 1636, 1638, "mg" +309, 13, 6, 362, 33, 36, 1639, 1642, "bid" +309, 13, 7, 363, 37, 42, 1643, 1648, "added" +309, 13, 8, 364, 43, 45, 1649, 1651, "to" +309, 13, 9, 365, 46, 53, 1652, 1659, "insulin" +309, 13, 10, 366, 54, 67, 1660, 1673, "significantly" +309, 13, 11, 367, 68, 75, 1674, 1681, "reduced" +309, 13, 12, 368, 76, 81, 1682, 1687, "HbA1c" +309, 13, 13, 369, 82, 84, 1688, 1690, "in" +309, 13, 14, 370, 85, 93, 1691, 1699, "patients" +309, 13, 15, 371, 94, 98, 1700, 1704, "with" +309, 13, 16, 372, 99, 103, 1705, 1709, "T2DM" +309, 13, 17, 373, 104, 116, 1710, 1722, "inadequately" +309, 13, 18, 374, 117, 127, 1723, 1733, "controlled" +309, 13, 19, 375, 128, 130, 1734, 1736, "by" +309, 13, 20, 376, 131, 138, 1737, 1744, "insulin" +309, 13, 21, 377, 139, 140, 1745, 1746, "," +309, 13, 22, 378, 141, 145, 1747, 1751, "with" +309, 13, 23, 379, 146, 148, 1752, 1754, "or" +309, 13, 24, 380, 149, 156, 1755, 1762, "without" +309, 13, 25, 381, 157, 166, 1763, 1772, "metformin" +309, 13, 26, 382, 167, 168, 1773, 1774, "." +309, 14, 1, 383, 0, 12, 1775, 1787, "Vildagliptin" +309, 14, 2, 384, 13, 16, 1788, 1791, "was" +309, 14, 3, 385, 17, 21, 1792, 1796, "well" +309, 14, 4, 386, 22, 31, 1797, 1806, "tolerated" +309, 14, 5, 387, 32, 33, 1807, 1808, "," +309, 14, 6, 388, 34, 38, 1809, 1813, "with" +309, 14, 7, 389, 39, 40, 1814, 1815, "a" +309, 14, 8, 390, 41, 47, 1816, 1822, "safety" +309, 14, 9, 391, 48, 55, 1823, 1830, "profile" +309, 14, 10, 392, 56, 63, 1831, 1838, "similar" +309, 14, 11, 393, 64, 66, 1839, 1841, "to" +309, 14, 12, 394, 67, 74, 1842, 1849, "placebo" +309, 14, 13, 395, 75, 76, 1850, 1851, "." +309, 15, 1, 396, 0, 5, 1852, 1857, "These" +309, 15, 2, 397, 6, 13, 1858, 1865, "results" +309, 15, 3, 398, 14, 18, 1866, 1870, "were" +309, 15, 4, 399, 19, 27, 1871, 1879, "achieved" +309, 15, 5, 400, 28, 35, 1880, 1887, "without" +309, 15, 6, 401, 36, 42, 1888, 1894, "weight" +309, 15, 7, 402, 43, 47, 1895, 1899, "gain" +309, 15, 8, 403, 48, 50, 1900, 1902, "or" +309, 15, 9, 404, 51, 53, 1903, 1905, "an" +309, 15, 10, 405, 54, 62, 1906, 1914, "increase" +309, 15, 11, 406, 63, 65, 1915, 1917, "in" +309, 15, 12, 407, 66, 79, 1918, 1931, "hypoglycaemia" +309, 15, 13, 408, 80, 89, 1932, 1941, "incidence" +309, 15, 14, 409, 90, 92, 1942, 1944, "or" +309, 15, 15, 410, 93, 101, 1945, 1953, "severity" +309, 15, 16, 411, 102, 104, 1954, 1956, "in" +309, 15, 17, 412, 105, 110, 1957, 1962, "spite" +309, 15, 18, 413, 111, 113, 1963, 1965, "of" +309, 15, 19, 414, 114, 122, 1966, 1974, "improved" +309, 15, 20, 415, 123, 132, 1975, 1984, "glycaemic" +309, 15, 21, 416, 133, 140, 1985, 1992, "control" +309, 15, 22, 417, 141, 142, 1993, 1994, "." +309, 16, 1, 418, 0, 1, 1995, 1996, "©" +309, 16, 2, 419, 2, 6, 1997, 2001, "2012" +309, 16, 3, 420, 7, 16, 2002, 2011, "Blackwell" +309, 16, 4, 421, 17, 27, 2012, 2022, "Publishing" +309, 16, 5, 422, 28, 31, 2023, 2026, "Ltd" +309, 16, 6, 423, 32, 33, 2027, 2028, "." +309, 16, 7, 424, 34, 37, 2029, 2032, "DOI" +309, 16, 8, 425, 38, 39, 2033, 2034, ":" +309, 16, 9, 426, 40, 42, 2035, 2037, "10" +309, 16, 10, 427, 43, 44, 2038, 2039, "." +309, 16, 11, 428, 45, 49, 2040, 2044, "1111" +309, 16, 12, 429, 50, 51, 2045, 2046, "/" +309, 16, 13, 430, 52, 55, 2047, 2050, "dom" +309, 16, 14, 431, 56, 57, 2051, 2052, "." +309, 16, 15, 432, 58, 63, 2053, 2058, "12020" +309, 16, 16, 433, 64, 68, 2059, 2063, "PMID" +309, 16, 17, 434, 69, 70, 2064, 2065, ":" +309, 16, 18, 435, 71, 79, 2066, 2074, "23039321" +309, 16, 19, 436, 80, 81, 2075, 2076, "[" +309, 16, 20, 437, 82, 89, 2077, 2084, "Indexed" +309, 16, 21, 438, 90, 93, 2085, 2088, "for" +309, 16, 22, 439, 94, 101, 2089, 2096, "MEDLINE" +309, 16, 23, 440, 102, 103, 2097, 2098, "]" diff --git a/data/dm2 23039321_kwoodley.annodb b/data/dm2 23039321_kwoodley.annodb new file mode 100644 index 0000000..b46d84d --- /dev/null +++ b/data/dm2 23039321_kwoodley.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +23924, Journal, 0, 21, "Diabetes Obes Metab .", "", +23925, PublicationYear, 22, 26, "2013", "", +23930, Title, 104, 239, "Improved glycaemic control with vildagliptin added to insulin , with or without metformin , in patients with type 2 diabetes mellitus .", "", +23926, Vildagliptin, 136, 148, "vildagliptin", "", +23927, Insulin, 158, 165, "insulin", "", +23928, Metformin, 184, 193, "metformin", "", +23929, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", +23931, Author, 240, 254, "Kothny W ( 1 )", "", +23932, Author, 257, 264, "Foley J", "", +23933, Author, 267, 278, "Kozlovski P", "", +23934, Author, 281, 287, "Shao Q", "", +23935, Author, 290, 300, "Gallwitz B", "", +23936, Author, 303, 316, "Lukashevich V", "", +23937, USA, 399, 402, "USA", "", +23945, ObjectiveDescription, 446, 600, "The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add - on therapy to insulin in type 2 diabetes mellitus ( T2DM ) .", "", +23938, Vildagliptin, 508, 520, "vildagliptin", "", +23939, DoseValue, 521, 523, "50", "", +23940, mg, 524, 526, "mg", "", +23941, Frequency, 527, 530, "bid", "twice daily", +23942, Insulin, 554, 561, "insulin", "", +23943, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +23944, Type2Diabetes, 592, 596, "T2DM", "", +23946, Multicenter, 621, 632, "multicentre", "", +23947, DoubleBlind, 635, 649, "double - blind", "", +24755, Placebo, 652, 659, "placebo", "", +23950, Parallel, 675, 689, "parallel group", "", +23951, Type2Diabetes, 710, 714, "T2DM", "", +23954, Precondition, 710, 773, "T2DM patients inadequately controlled by stable insulin therapy", "", +23952, Insulin, 758, 765, "insulin", "", +23953, Metformin, 792, 801, "metformin", "", +23955, Vildagliptin, 837, 849, "vildagliptin", "", +23956, DoseValue, 850, 852, "50", "", +23957, mg, 853, 855, "mg", "", +23958, Frequency, 856, 859, "bid", "", +23959, Placebo, 863, 870, "placebo", "", +23960, Duration, 875, 883, "24 weeks", "", +23961, NumberPatientsCT, 905, 908, "449", "", +23962, Randomized, 923, 933, "randomized", "", +23963, Vildagliptin, 937, 949, "vildagliptin", "", +23964, NumberPatientsArm, 958, 961, "228", "", +23966, Placebo, 967, 974, "placebo", "", +23965, NumberPatientsArm, 983, 986, "221", "", +23967, Duration, 997, 1005, "24 weeks", "", +23968, HbA1c, 1050, 1065, "haemoglobin A1c", "", +23969, HbA1c, 1068, 1073, "HbA1c", "", +23970, Vildagliptin, 1084, 1096, "vildagliptin", "", +23974, Placebo, 1101, 1108, "placebo", "", +23977, DiffGroupAbsValue, 1113, 1120, "- 0 . 7", "", +23980, SdDevDiff, 1125, 1130, "0 . 1", "", +23984, Percentage, 1131, 1132, "%", "", +23986, PvalueDiff, 1135, 1148, "p  <  0 . 001", "", +23978, DiffGroupAbsValue, 1185, 1192, "- 0 . 6", "", +23982, SdDevDiff, 1197, 1202, "0 . 1", "", +23985, Percentage, 1203, 1204, "%", "", +23987, PvalueDiff, 1207, 1220, "p  <  0 . 001", "", +23992, SubGroupDescription, 1239, 1263, "also receiving metformin", "", +23990, Metformin, 1254, 1263, "metformin", "", +23979, DiffGroupAbsValue, 1268, 1275, "- 0 . 8", "", +23983, SdDevDiff, 1280, 1285, "0 . 2", "", +23989, Percentage, 1286, 1287, "%", "", +23988, PvalueDiff, 1290, 1303, "p  <  0 . 001", "", +23993, SubGroupDescription, 1322, 1339, "without metformin", "", +23991, Metformin, 1330, 1339, "metformin", "", +23971, Vildagliptin, 1342, 1354, "Vildagliptin", "", +23994, Hypoglycemia, 1419, 1432, "hypoglycaemia", "", +23975, Placebo, 1447, 1454, "placebo", "", +23995, PercentageAffected, 1457, 1462, "8 . 4", "", +23996, PercentageAffected, 1468, 1473, "7 . 2", "", +23997, PvalueDiff, 1478, 1490, "p  =  0 . 66", "", +24001, ObservedResult, 1538, 1573, "was not associated with weight gain", "", +23999, BodyWeight, 1562, 1568, "weight", "", +24002, Increment, 1580, 1585, "0 . 1", "", +24003, Reduction, 1593, 1598, "0 . 4", "", +24004, Kg, 1599, 1601, "kg", "", +23972, Vildagliptin, 1620, 1632, "Vildagliptin", "", +24014, ConclusionComment, 1620, 1774, "Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin , with or without metformin .", "", +24005, DoseValue, 1633, 1635, "50", "", +24006, mg, 1636, 1638, "mg", "", +24007, Frequency, 1639, 1642, "bid", "", +24008, Insulin, 1652, 1659, "insulin", "", +24009, HbA1c, 1682, 1687, "HbA1c", "", +24013, Precondition, 1691, 1772, "patients with T2DM inadequately controlled by insulin , with or without metformin", "", +24010, Type2Diabetes, 1705, 1709, "T2DM", "", +24011, Insulin, 1737, 1744, "insulin", "", +24012, Metformin, 1763, 1772, "metformin", "", +23973, Vildagliptin, 1775, 1787, "Vildagliptin", "", +24016, ConclusionComment, 1775, 1851, "Vildagliptin was well tolerated , with a safety profile similar to placebo .", "", +23976, Placebo, 1842, 1849, "placebo", "", +24017, ConclusionComment, 1852, 1994, "These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control .", "", +24018, BodyWeight, 1888, 1894, "weight", "", +24019, Hypoglycemia, 1918, 1931, "hypoglycaemia", "", +24021, PMID, 2066, 2074, "23039321", "", diff --git a/data/dm2 23039321_kwoodley.n-triples b/data/dm2 23039321_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23039321_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23082447_admin.annodb b/data/dm2 23082447_admin.annodb new file mode 100644 index 0000000..9f6ece4 --- /dev/null +++ b/data/dm2 23082447_admin.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +78, Journal, 0, 14, "Med J Malaysia", "", " \"Med J Malaysia\"." +1, PublicationYear, 17, 21, "2012", "", " \"2012\"." +64055, Cabergoline, 49, 60, "Cabergoline", "", +17, Title, 49, 136, "Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure .", "", " \"Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure .\"." +80, BloodGlucose, 71, 82, "blood sugar", "", +9, Type2Diabetes, 86, 101, "type 2 diabetic", "", " ." +15, Precondition, 86, 134, "type 2 diabetic patients with oral agent failure", "", " \"type 2 diabetic patients with oral agent failure\"." +13, OralAntidiabeticAgent, 116, 126, "oral agent", "", +18, Author, 137, 147, "Taghavi SM", "", " \"Taghavi SM\"." +19, Author, 156, 165, "Fatemi SS", "", " \"Fatemi SS\"." +20, Author, 168, 175, "Rokni H", "", " \"Rokni H\"." +21, Iran, 293, 297, "Iran", "", +22, Bromocriptine, 480, 493, "bromocriptine", "", +10, Type2Diabetes, 533, 548, "type 2 diabetes", "", +33, ObjectiveDescription, 551, 722, "The aim of this study was the evaluation of short - term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy .", "", " \"The aim of this study was the evaluation of short - term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy .\"." +64051, Cabergoline, 618, 629, "cabergoline", "", +26, Precondition, 633, 720, "poorly controlled diabetic patients with oral agent failure who refused insulin therapy", "", " \"poorly controlled diabetic patients with oral agent failure who refused insulin therapy\"." +23, Type2Diabetes, 651, 659, "diabetic", "", +24, OralAntidiabeticAgent, 674, 684, "oral agent", "", +25, Insulin, 705, 712, "insulin", "", +27, NumberPatientsCT, 761, 763, "17", "", " \"17\"." +32, Precondition, 764, 924, "overweight women and men with type 2 diabetes with persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea , metformin and pioglitazone", "", " \"overweight women and men with type 2 diabetes with persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea , metformin and pioglitazone\"." +100, AnyGender, 775, 788, "women and men", "", " ." +11, Type2Diabetes, 794, 809, "type 2 diabetes", "", +28, Hypoglycemia, 826, 839, "hyperglycemia", "", +29, Sulfonylureas, 883, 895, "sulfonylurea", "", +30, Metformin, 898, 907, "metformin", "", +31, Pioglitazone, 912, 924, "pioglitazone", "", +34, NumberPatientsArm, 927, 929, "10", "", " \"10\"." +36, Randomized, 951, 961, "randomized", "", " ." +64052, Cabergoline, 981, 992, "cabergoline", "", " ." +37, DoseValue, 993, 998, "0 . 5", "", " \"0 . 5\"." +38, mg, 999, 1001, "mg", "", " ." +39, Frequency, 1002, 1008, "weekly", "", " \"weekly\"." +40, Duration, 1013, 1021, "3 months", "", " \"3 months\"." +35, NumberPatientsArm, 1026, 1027, "7", "", " \"7\"." +41, Placebo, 1055, 1062, "placebo", "", " ." +43, FastingPlasmaGlucose, 1065, 1072, "Fasting", "", +75, PostprandialPlasmaGlucose, 1077, 1104, "postprandial plasma glucose", "", +43, FastingPlasmaGlucose, 1090, 1104, "plasma glucose", "", +42, HbA1c, 1123, 1128, "HbAlc", "", +119, TimePoint, 1141, 1150, "beginning", "", +120, TimePoint, 1155, 1171, "end of the study", "", +124, FastingBloodGlucose, 1184, 1187, "FBS", "", " ." +44, BaseLineValue, 1203, 1211, "210 . 70", "", " \"210 . 70\"." +53, SdDevBL, 1218, 1225, "21 . 29", "", " \"28\"." +45, ResultMeasuredValue, 1229, 1237, "144 . 90", "", " \"144 . 90\"." +46, SdDevResValue, 1244, 1251, "26 . 56", "", " \"26 . 56\"." +47, Mg_per_deciliter, 1252, 1259, "mg / dl", "", " ." +64050, Cabergoline, 1263, 1274, "cabergoline", "", +49, ObservedResult, 1292, 1334, "decreased in placebo group insignificantly", "", " \"decreased in placebo group insignificantly\"." +48, Placebo, 1305, 1312, "placebo", "", +123, PostprandialBloodGlucose, 1337, 1363, "Postprandial blood glucose", "", " ." +51, BaseLineValue, 1379, 1386, "264 . 2", "", " \"264 . 2\"." +52, SdDevBL, 1393, 1395, "28", "", " \"28\"." +56, Mg_per_deciliter, 1396, 1403, "mg / dl", "", " ." +54, ResultMeasuredValue, 1407, 1414, "203 . 6", "", " \"203 . 6\"." +55, SdDevResValue, 1421, 1428, "34 . 34", "", " \"34 . 34\"." +57, Mg_per_deciliter, 1429, 1436, "mg / dl", "", +64048, Cabergoline, 1440, 1451, "cabergoline", "", +59, ObservedResult, 1469, 1511, "increased in placebo group insignificantly", "", " \"increased in placebo group insignificantly\"." +58, Placebo, 1482, 1489, "placebo", "", +60, HbA1c, 1514, 1519, "HbA1c", "", " ." +64053, Cabergoline, 1533, 1544, "cabergoline", "", +62, BaseLineValue, 1556, 1562, "8 . 48", "", " \"8 . 48\"." +64, SdDevBL, 1569, 1575, "0 . 44", "", " \"0 . 44\"." +66, ResultMeasuredValue, 1579, 1584, "7 . 7", "", " \"7 . 7\"." +68, SdDevResValue, 1591, 1597, "0 . 11", "", " \"0 . 11\"." +63, BaseLineValue, 1657, 1662, "8 . 7", "", " \"8 . 7\"." +65, SdDevBL, 1669, 1675, "0 . 33", "", " \"0 . 33\"." +67, ResultMeasuredValue, 1679, 1684, "8 . 8", "", " \"8 . 8\"." +69, SdDevResValue, 1691, 1697, "0 . 16", "", " \"0 . 16\"." +64054, Cabergoline, 1713, 1724, "Cabergoline", "", +70, ConclusionComment, 1713, 1804, "Cabergoline improves glycemic control in type 2 diabetic patients with oral agent failure .", "", +12, Type2Diabetes, 1754, 1769, "type 2 diabetic", "", +14, OralAntidiabeticAgent, 1784, 1794, "oral agent", "", +71, ConclusionComment, 1805, 1915, "It reduces both fasting and postprandial plasma glucose levels and causes 0 . 45 - 1 . 11 reduction in HbA1c .", "", +72, FastingPlasmaGlucose, 1821, 1828, "fasting", "", +72, FastingPlasmaGlucose, 1833, 1860, "postprandial plasma glucose", "", +77, PostprandialPlasmaGlucose, 1833, 1860, "postprandial plasma glucose", "", +73, HbA1c, 1908, 1913, "HbA1c", "", +74, PMID, 1923, 1931, "23082447", "", " \"23082447\"." diff --git a/data/dm2 23082447_admin.n-triples b/data/dm2 23082447_admin.n-triples new file mode 100644 index 0000000..a6c1d64 --- /dev/null +++ b/data/dm2 23082447_admin.n-triples @@ -0,0 +1,132 @@ +# RDF export of group: Publication + . + "Publication 40489" . + "Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure ." . + "Taghavi SM" . + "2012" . + "Med J Malaysia" . + "23082447" . + . + "Fatemi SS" . + "Rokni H" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 40496" . + "The aim of this study was the evaluation of short - term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy ." . + "17" . + "3 months" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 40512" . + "type 2 diabetic patients with oral agent failure" . + . + . + . + "poorly controlled diabetic patients with oral agent failure who refused insulin therapy" . + "overweight women and men with type 2 diabetes with persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea , metformin and pioglitazone" . +# RDF export of group: Endpoint + . + "fbg" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "hba" . + . + . + . + . +# RDF export of group: Arm + . + "cab" . + "10" . + . + . + . + . + . + . + "pla" . + "7" . + . + . + . + . + . +# RDF export of group: Intervention + . + "cab" . + . + "weekly" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "cab" . + . + "0 . 5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "fbg 1" . + . + "210 . 70" . + "21 . 29" . + "144 . 90" . + "26 . 56" . + . + "fbg 2" . + . + "decreased in placebo group insignificantly" . + . + "pbg 1" . + . + "264 . 2" . + "28" . + "203 . 6" . + "34 . 34" . + . + "ppg 2" . + . + "increased in placebo group insignificantly" . + . + "hba 1" . + . + "8 . 48" . + "0 . 44" . + "7 . 7" . + "0 . 11" . + . + "hba 2" . + . + "8 . 7" . + "0 . 33" . + "8 . 8" . + "0 . 16" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23082447_akramersunderbrink.annodb b/data/dm2 23082447_akramersunderbrink.annodb new file mode 100644 index 0000000..674a929 --- /dev/null +++ b/data/dm2 23082447_akramersunderbrink.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42314, Journal, 0, 14, "Med J Malaysia", "", +42315, PublicationYear, 17, 21, "2012", "", +42320, Title, 49, 136, "Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure .", "", +42329, Drug, 49, 60, "Cabergoline", "", +42316, BloodGlucose, 71, 82, "blood sugar", "", +42317, Type2Diabetes, 86, 101, "type 2 diabetic", "", +42318, OralAntidiabeticAgent, 116, 126, "oral agent", "", +42319, Precondition, 116, 134, "oral agent failure", "", +42321, Author, 137, 147, "Taghavi SM", "", +42322, Author, 156, 165, "Fatemi SS", "", +42323, Author, 168, 175, "Rokni H", "", +42324, Iran, 293, 297, "Iran", "", +42325, Bromocriptine, 480, 493, "bromocriptine", "", +42326, Type2Diabetes, 533, 548, "type 2 diabetes", "", +42348, ObjectiveDescription, 551, 722, "The aim of this study was the evaluation of short - term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy .", "", +42327, Drug, 618, 629, "cabergoline", "", +42333, Precondition, 633, 650, "poorly controlled", "", +42336, Type2Diabetes, 651, 659, "diabetic", "", +42340, OralAntidiabeticAgent, 674, 692, "oral agent failure", "", +42347, Precondition, 693, 720, "who refused insulin therapy", "", +42351, NumberPatientsCT, 761, 763, "17", "", +42354, Precondition, 764, 774, "overweight", "", +42357, AnyGender, 775, 788, "women and men", "", +42359, Type2Diabetes, 794, 809, "type 2 diabetes", "", +42364, Precondition, 815, 924, "persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea , metformin and pioglitazone", "", +42361, Hypoglycemia, 826, 839, "hyperglycemia", "", +42365, Sulfonylureas, 883, 895, "sulfonylurea", "", +42367, Metformin, 898, 907, "metformin", "", +42369, Pioglitazone, 912, 924, "pioglitazone", "", +42373, NumberPatientsArm, 927, 929, "10", "", +42377, Randomized, 951, 961, "randomized", "", +42379, Drug, 981, 992, "cabergoline", "", +42384, DoseValue, 993, 1001, "0 . 5 mg", "", +42386, mg, 999, 1001, "mg", "", +42391, Frequency, 1002, 1008, "weekly", "", +42389, Duration, 1013, 1021, "3 months", "", +42375, NumberPatientsArm, 1026, 1027, "7", "", +42394, Placebo, 1055, 1062, "placebo", "", +42395, FastingPlasmaGlucose, 1065, 1104, "Fasting and postprandial plasma glucose", "", +42397, PostprandialPlasmaGlucose, 1077, 1104, "postprandial plasma glucose", "", +42400, HbA1c, 1123, 1128, "HbAlc", "", +42402, TimePoint, 1141, 1150, "beginning", "", +42404, TimePoint, 1155, 1171, "end of the study", "", +42421, FastingBloodGlucose, 1184, 1187, "FBS", "", +42435, BaseLineValue, 1203, 1211, "210 . 70", "", +42443, ResultMeasuredValue, 1229, 1237, "144 . 90", "", +42457, ConcentrationUnit, 1252, 1259, "mg / dl", "", +42412, Drug, 1263, 1274, "cabergoline", "", +42414, Placebo, 1305, 1312, "placebo", "", +42418, PostprandialBloodGlucose, 1337, 1363, "Postprandial blood glucose", "", +42437, BaseLineValue, 1379, 1386, "264 . 2", "", +42452, ConcentrationUnit, 1396, 1403, "mg / dl", "", +42444, ResultMeasuredValue, 1407, 1414, "203 . 6", "", +42454, ConcentrationUnit, 1429, 1436, "mg / dl", "", +42424, Drug, 1440, 1451, "cabergoline", "", +42426, Placebo, 1482, 1489, "placebo", "", +42429, HbA1c, 1514, 1519, "HbA1c", "", +42431, Drug, 1533, 1544, "cabergoline", "", +42439, BaseLineValue, 1556, 1562, "8 . 48", "", +42446, ResultMeasuredValue, 1579, 1584, "7 . 7", "", +42440, BaseLineValue, 1657, 1662, "8 . 7", "", +42450, ResultMeasuredValue, 1679, 1684, "8 . 8", "", +42459, Drug, 1713, 1724, "Cabergoline", "", +42466, ConclusionComment, 1713, 1804, "Cabergoline improves glycemic control in type 2 diabetic patients with oral agent failure .", "", +42462, Type2Diabetes, 1754, 1769, "type 2 diabetic", "", +42463, OralAntidiabeticAgent, 1784, 1794, "oral agent", "", +42464, Precondition, 1784, 1802, "oral agent failure", "", +42468, ConclusionComment, 1805, 1915, "It reduces both fasting and postprandial plasma glucose levels and causes 0 . 45 - 1 . 11 reduction in HbA1c .", "", +42470, FastingPlasmaGlucose, 1821, 1860, "fasting and postprandial plasma glucose", "", +42472, PostprandialPlasmaGlucose, 1833, 1860, "postprandial plasma glucose", "", +42474, HbA1c, 1908, 1913, "HbA1c", "", +42476, PMID, 1923, 1931, "23082447", "", diff --git a/data/dm2 23082447_akramersunderbrink.n-triples b/data/dm2 23082447_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23082447_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23082447_export.csv b/data/dm2 23082447_export.csv new file mode 100644 index 0000000..a4a8228 --- /dev/null +++ b/data/dm2 23082447_export.csv @@ -0,0 +1,393 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +307, 1, 1, 1, 0, 3, 0, 3, "Med" +307, 1, 2, 2, 4, 5, 4, 5, "J" +307, 1, 3, 3, 6, 14, 6, 14, "Malaysia" +307, 1, 4, 4, 15, 16, 15, 16, "." +307, 2, 1, 5, 0, 4, 17, 21, "2012" +307, 2, 2, 6, 5, 8, 22, 25, "Aug" +307, 2, 3, 7, 9, 10, 26, 27, ";" +307, 2, 4, 8, 11, 13, 28, 30, "67" +307, 2, 5, 9, 14, 15, 31, 32, "(" +307, 2, 6, 10, 16, 17, 33, 34, "4" +307, 2, 7, 11, 18, 19, 35, 36, ")" +307, 2, 8, 12, 20, 21, 37, 38, ":" +307, 2, 9, 13, 22, 25, 39, 42, "390" +307, 2, 10, 14, 26, 27, 43, 44, "-" +307, 2, 11, 15, 28, 29, 45, 46, "2" +307, 2, 12, 16, 30, 31, 47, 48, "." +307, 3, 1, 17, 0, 11, 49, 60, "Cabergoline" +307, 3, 2, 18, 12, 18, 61, 67, "effect" +307, 3, 3, 19, 19, 21, 68, 70, "on" +307, 3, 4, 20, 22, 27, 71, 76, "blood" +307, 3, 5, 21, 28, 33, 77, 82, "sugar" +307, 3, 6, 22, 34, 36, 83, 85, "in" +307, 3, 7, 23, 37, 41, 86, 90, "type" +307, 3, 8, 24, 42, 43, 91, 92, "2" +307, 3, 9, 25, 44, 52, 93, 101, "diabetic" +307, 3, 10, 26, 53, 61, 102, 110, "patients" +307, 3, 11, 27, 62, 66, 111, 115, "with" +307, 3, 12, 28, 67, 71, 116, 120, "oral" +307, 3, 13, 29, 72, 77, 121, 126, "agent" +307, 3, 14, 30, 78, 85, 127, 134, "failure" +307, 3, 15, 31, 86, 87, 135, 136, "." +307, 4, 1, 32, 0, 7, 137, 144, "Taghavi" +307, 4, 2, 33, 8, 10, 145, 147, "SM" +307, 4, 3, 34, 11, 12, 148, 149, "(" +307, 4, 4, 35, 13, 14, 150, 151, "1" +307, 4, 5, 36, 15, 16, 152, 153, ")" +307, 4, 6, 37, 17, 18, 154, 155, "," +307, 4, 7, 38, 19, 25, 156, 162, "Fatemi" +307, 4, 8, 39, 26, 28, 163, 165, "SS" +307, 4, 9, 40, 29, 30, 166, 167, "," +307, 4, 10, 41, 31, 36, 168, 173, "Rokni" +307, 4, 11, 42, 37, 38, 174, 175, "H" +307, 4, 12, 43, 39, 40, 176, 177, "." +307, 4, 13, 44, 41, 47, 178, 184, "Author" +307, 4, 14, 45, 48, 59, 185, 196, "information" +307, 4, 15, 46, 60, 61, 197, 198, ":" +307, 4, 16, 47, 62, 63, 199, 200, "(" +307, 4, 17, 48, 64, 65, 201, 202, "1" +307, 4, 18, 49, 66, 67, 203, 204, ")" +307, 4, 19, 50, 68, 75, 205, 212, "Mashhad" +307, 4, 20, 51, 76, 83, 213, 220, "Medical" +307, 4, 21, 52, 84, 94, 221, 231, "University" +307, 4, 22, 53, 95, 96, 232, 233, "," +307, 4, 23, 54, 97, 110, 234, 247, "Endocrinology" +307, 4, 24, 55, 111, 112, 248, 249, "," +307, 4, 25, 56, 113, 118, 250, 255, "Ahmad" +307, 4, 26, 57, 119, 123, 256, 260, "Abad" +307, 4, 27, 58, 124, 125, 261, 262, "," +307, 4, 28, 59, 126, 133, 263, 270, "Mashhad" +307, 4, 29, 60, 134, 135, 271, 272, "," +307, 4, 30, 61, 136, 144, 273, 281, "Khorasan" +307, 4, 31, 62, 145, 155, 282, 292, "9187883655" +307, 4, 32, 63, 156, 160, 293, 297, "Iran" +307, 4, 33, 64, 161, 162, 298, 299, "," +307, 4, 34, 65, 163, 170, 300, 307, "Islamic" +307, 4, 35, 66, 171, 179, 308, 316, "Republic" +307, 4, 36, 67, 180, 182, 317, 319, "Of" +307, 4, 37, 68, 183, 184, 320, 321, "." +307, 5, 1, 69, 0, 9, 322, 331, "taghavimr" +307, 5, 2, 70, 10, 11, 332, 333, "@" +307, 5, 3, 71, 12, 16, 334, 338, "mums" +307, 5, 4, 72, 17, 18, 339, 340, "." +307, 5, 5, 73, 19, 21, 341, 343, "ac" +307, 5, 6, 74, 22, 23, 344, 345, "." +307, 5, 7, 75, 24, 26, 346, 348, "ir" +307, 5, 8, 76, 27, 32, 349, 354, "Ergot" +307, 5, 9, 77, 33, 34, 355, 356, "-" +307, 5, 10, 78, 35, 42, 357, 364, "derived" +307, 5, 11, 79, 43, 51, 365, 373, "dopamine" +307, 5, 12, 80, 52, 54, 374, 376, "D2" +307, 5, 13, 81, 55, 63, 377, 385, "receptor" +307, 5, 14, 82, 64, 72, 386, 394, "agonists" +307, 5, 15, 83, 73, 76, 395, 398, "are" +307, 5, 16, 84, 77, 80, 399, 402, "the" +307, 5, 17, 85, 81, 86, 403, 408, "usual" +307, 5, 18, 86, 87, 96, 409, 418, "treatment" +307, 5, 19, 87, 97, 99, 419, 421, "of" +307, 5, 20, 88, 100, 118, 422, 440, "hyperprolactinemia" +307, 5, 21, 89, 119, 122, 441, 444, "and" +307, 5, 22, 90, 123, 132, 445, 454, "Parkinson" +307, 5, 23, 91, 133, 134, 455, 456, "'" +307, 5, 24, 92, 135, 136, 457, 458, "s" +307, 5, 25, 93, 137, 144, 459, 466, "disease" +307, 5, 26, 94, 145, 148, 467, 470, "and" +307, 5, 27, 95, 149, 157, 471, 479, "recently" +307, 5, 28, 96, 158, 171, 480, 493, "bromocriptine" +307, 5, 29, 97, 172, 175, 494, 497, "has" +307, 5, 30, 98, 176, 180, 498, 502, "been" +307, 5, 31, 99, 181, 189, 503, 511, "approved" +307, 5, 32, 100, 190, 193, 512, 515, "for" +307, 5, 33, 101, 194, 197, 516, 519, "the" +307, 5, 34, 102, 198, 207, 520, 529, "treatment" +307, 5, 35, 103, 208, 210, 530, 532, "of" +307, 5, 36, 104, 211, 215, 533, 537, "type" +307, 5, 37, 105, 216, 217, 538, 539, "2" +307, 5, 38, 106, 218, 226, 540, 548, "diabetes" +307, 5, 39, 107, 227, 228, 549, 550, "." +307, 6, 1, 108, 0, 3, 551, 554, "The" +307, 6, 2, 109, 4, 7, 555, 558, "aim" +307, 6, 3, 110, 8, 10, 559, 561, "of" +307, 6, 4, 111, 11, 15, 562, 566, "this" +307, 6, 5, 112, 16, 21, 567, 572, "study" +307, 6, 6, 113, 22, 25, 573, 576, "was" +307, 6, 7, 114, 26, 29, 577, 580, "the" +307, 6, 8, 115, 30, 40, 581, 591, "evaluation" +307, 6, 9, 116, 41, 43, 592, 594, "of" +307, 6, 10, 117, 44, 49, 595, 600, "short" +307, 6, 11, 118, 50, 51, 601, 602, "-" +307, 6, 12, 119, 52, 56, 603, 607, "term" +307, 6, 13, 120, 57, 63, 608, 614, "effect" +307, 6, 14, 121, 64, 66, 615, 617, "of" +307, 6, 15, 122, 67, 78, 618, 629, "cabergoline" +307, 6, 16, 123, 79, 81, 630, 632, "in" +307, 6, 17, 124, 82, 88, 633, 639, "poorly" +307, 6, 18, 125, 89, 99, 640, 650, "controlled" +307, 6, 19, 126, 100, 108, 651, 659, "diabetic" +307, 6, 20, 127, 109, 117, 660, 668, "patients" +307, 6, 21, 128, 118, 122, 669, 673, "with" +307, 6, 22, 129, 123, 127, 674, 678, "oral" +307, 6, 23, 130, 128, 133, 679, 684, "agent" +307, 6, 24, 131, 134, 141, 685, 692, "failure" +307, 6, 25, 132, 142, 145, 693, 696, "who" +307, 6, 26, 133, 146, 153, 697, 704, "refused" +307, 6, 27, 134, 154, 161, 705, 712, "insulin" +307, 6, 28, 135, 162, 169, 713, 720, "therapy" +307, 6, 29, 136, 170, 171, 721, 722, "." +307, 6, 30, 137, 172, 179, 723, 730, "METHODS" +307, 6, 31, 138, 180, 181, 731, 732, ":" +307, 6, 32, 139, 182, 186, 733, 737, "This" +307, 6, 33, 140, 187, 192, 738, 743, "study" +307, 6, 34, 141, 193, 196, 744, 747, "was" +307, 6, 35, 142, 197, 206, 748, 757, "performed" +307, 6, 36, 143, 207, 209, 758, 760, "in" +307, 6, 37, 144, 210, 212, 761, 763, "17" +307, 6, 38, 145, 213, 223, 764, 774, "overweight" +307, 6, 39, 146, 224, 229, 775, 780, "women" +307, 6, 40, 147, 230, 233, 781, 784, "and" +307, 6, 41, 148, 234, 237, 785, 788, "men" +307, 6, 42, 149, 238, 242, 789, 793, "with" +307, 6, 43, 150, 243, 247, 794, 798, "type" +307, 6, 44, 151, 248, 249, 799, 800, "2" +307, 6, 45, 152, 250, 258, 801, 809, "diabetes" +307, 6, 46, 153, 259, 263, 810, 814, "with" +307, 6, 47, 154, 264, 274, 815, 825, "persistent" +307, 6, 48, 155, 275, 288, 826, 839, "hyperglycemia" +307, 6, 49, 156, 289, 291, 840, 842, "in" +307, 6, 50, 157, 292, 297, 843, 848, "spite" +307, 6, 51, 158, 298, 300, 849, 851, "of" +307, 6, 52, 159, 301, 310, 852, 861, "treatment" +307, 6, 53, 160, 311, 315, 862, 866, "with" +307, 6, 54, 161, 316, 323, 867, 874, "maximum" +307, 6, 55, 162, 324, 328, 875, 879, "dose" +307, 6, 56, 163, 329, 331, 880, 882, "of" +307, 6, 57, 164, 332, 344, 883, 895, "sulfonylurea" +307, 6, 58, 165, 345, 346, 896, 897, "," +307, 6, 59, 166, 347, 356, 898, 907, "metformin" +307, 6, 60, 167, 357, 360, 908, 911, "and" +307, 6, 61, 168, 361, 373, 912, 924, "pioglitazone" +307, 6, 62, 169, 374, 375, 925, 926, "." +307, 7, 1, 170, 0, 2, 927, 929, "10" +307, 7, 2, 171, 3, 11, 930, 938, "patients" +307, 7, 3, 172, 12, 13, 939, 940, "(" +307, 7, 4, 173, 14, 19, 941, 946, "group" +307, 7, 5, 174, 20, 21, 947, 948, "I" +307, 7, 6, 175, 22, 23, 949, 950, ")" +307, 7, 7, 176, 24, 34, 951, 961, "randomized" +307, 7, 8, 177, 35, 37, 962, 964, "to" +307, 7, 9, 178, 38, 40, 965, 967, "be" +307, 7, 10, 179, 41, 48, 968, 975, "treated" +307, 7, 11, 180, 49, 53, 976, 980, "with" +307, 7, 12, 181, 54, 65, 981, 992, "cabergoline" +307, 7, 13, 182, 66, 67, 993, 994, "0" +307, 7, 14, 183, 68, 69, 995, 996, "." +307, 7, 15, 184, 70, 71, 997, 998, "5" +307, 7, 16, 185, 72, 74, 999, 1001, "mg" +307, 7, 17, 186, 75, 81, 1002, 1008, "weekly" +307, 7, 18, 187, 82, 85, 1009, 1012, "for" +307, 7, 19, 188, 86, 87, 1013, 1014, "3" +307, 7, 20, 189, 88, 94, 1015, 1021, "months" +307, 7, 21, 190, 95, 98, 1022, 1025, "and" +307, 7, 22, 191, 99, 100, 1026, 1027, "7" +307, 7, 23, 192, 101, 109, 1028, 1036, "patients" +307, 7, 24, 193, 110, 111, 1037, 1038, "(" +307, 7, 25, 194, 112, 117, 1039, 1044, "group" +307, 7, 26, 195, 118, 120, 1045, 1047, "II" +307, 7, 27, 196, 121, 122, 1048, 1049, ")" +307, 7, 28, 197, 123, 127, 1050, 1054, "with" +307, 7, 29, 198, 128, 135, 1055, 1062, "placebo" +307, 7, 30, 199, 136, 137, 1063, 1064, "." +307, 8, 1, 200, 0, 7, 1065, 1072, "Fasting" +307, 8, 2, 201, 8, 11, 1073, 1076, "and" +307, 8, 3, 202, 12, 24, 1077, 1089, "postprandial" +307, 8, 4, 203, 25, 31, 1090, 1096, "plasma" +307, 8, 5, 204, 32, 39, 1097, 1104, "glucose" +307, 8, 6, 205, 40, 53, 1105, 1118, "concentration" +307, 8, 7, 206, 54, 57, 1119, 1122, "and" +307, 8, 8, 207, 58, 63, 1123, 1128, "HbAlc" +307, 8, 9, 208, 64, 72, 1129, 1137, "measured" +307, 8, 10, 209, 73, 75, 1138, 1140, "in" +307, 8, 11, 210, 76, 85, 1141, 1150, "beginning" +307, 8, 12, 211, 86, 89, 1151, 1154, "and" +307, 8, 13, 212, 90, 93, 1155, 1158, "end" +307, 8, 14, 213, 94, 96, 1159, 1161, "of" +307, 8, 15, 214, 97, 100, 1162, 1165, "the" +307, 8, 16, 215, 101, 106, 1166, 1171, "study" +307, 8, 17, 216, 107, 108, 1172, 1173, "." +307, 9, 1, 217, 0, 7, 1174, 1181, "RESULTS" +307, 9, 2, 218, 8, 9, 1182, 1183, ":" +307, 9, 3, 219, 10, 13, 1184, 1187, "FBS" +307, 9, 4, 220, 14, 23, 1188, 1197, "decreased" +307, 9, 5, 221, 24, 28, 1198, 1202, "from" +307, 9, 6, 222, 29, 32, 1203, 1206, "210" +307, 9, 7, 223, 33, 34, 1207, 1208, "." +307, 9, 8, 224, 35, 37, 1209, 1211, "70" +307, 9, 9, 225, 38, 39, 1212, 1213, "+" +307, 9, 10, 226, 40, 41, 1214, 1215, "/" +307, 9, 11, 227, 42, 43, 1216, 1217, "-" +307, 9, 12, 228, 44, 46, 1218, 1220, "21" +307, 9, 13, 229, 47, 48, 1221, 1222, "." +307, 9, 14, 230, 49, 51, 1223, 1225, "29" +307, 9, 15, 231, 52, 54, 1226, 1228, "to" +307, 9, 16, 232, 55, 58, 1229, 1232, "144" +307, 9, 17, 233, 59, 60, 1233, 1234, "." +307, 9, 18, 234, 61, 63, 1235, 1237, "90" +307, 9, 19, 235, 64, 65, 1238, 1239, "+" +307, 9, 20, 236, 66, 67, 1240, 1241, "/" +307, 9, 21, 237, 68, 69, 1242, 1243, "-" +307, 9, 22, 238, 70, 72, 1244, 1246, "26" +307, 9, 23, 239, 73, 74, 1247, 1248, "." +307, 9, 24, 240, 75, 77, 1249, 1251, "56" +307, 9, 25, 241, 78, 80, 1252, 1254, "mg" +307, 9, 26, 242, 81, 82, 1255, 1256, "/" +307, 9, 27, 243, 83, 85, 1257, 1259, "dl" +307, 9, 28, 244, 86, 88, 1260, 1262, "in" +307, 9, 29, 245, 89, 100, 1263, 1274, "cabergoline" +307, 9, 30, 246, 101, 106, 1275, 1280, "group" +307, 9, 31, 247, 107, 114, 1281, 1288, "whereas" +307, 9, 32, 248, 115, 117, 1289, 1291, "it" +307, 9, 33, 249, 118, 127, 1292, 1301, "decreased" +307, 9, 34, 250, 128, 130, 1302, 1304, "in" +307, 9, 35, 251, 131, 138, 1305, 1312, "placebo" +307, 9, 36, 252, 139, 144, 1313, 1318, "group" +307, 9, 37, 253, 145, 160, 1319, 1334, "insignificantly" +307, 9, 38, 254, 161, 162, 1335, 1336, "." +307, 10, 1, 255, 0, 12, 1337, 1349, "Postprandial" +307, 10, 2, 256, 13, 18, 1350, 1355, "blood" +307, 10, 3, 257, 19, 26, 1356, 1363, "glucose" +307, 10, 4, 258, 27, 36, 1364, 1373, "decreased" +307, 10, 5, 259, 37, 41, 1374, 1378, "from" +307, 10, 6, 260, 42, 45, 1379, 1382, "264" +307, 10, 7, 261, 46, 47, 1383, 1384, "." +307, 10, 8, 262, 48, 49, 1385, 1386, "2" +307, 10, 9, 263, 50, 51, 1387, 1388, "+" +307, 10, 10, 264, 52, 53, 1389, 1390, "/" +307, 10, 11, 265, 54, 55, 1391, 1392, "-" +307, 10, 12, 266, 56, 58, 1393, 1395, "28" +307, 10, 13, 267, 59, 61, 1396, 1398, "mg" +307, 10, 14, 268, 62, 63, 1399, 1400, "/" +307, 10, 15, 269, 64, 66, 1401, 1403, "dl" +307, 10, 16, 270, 67, 69, 1404, 1406, "to" +307, 10, 17, 271, 70, 73, 1407, 1410, "203" +307, 10, 18, 272, 74, 75, 1411, 1412, "." +307, 10, 19, 273, 76, 77, 1413, 1414, "6" +307, 10, 20, 274, 78, 79, 1415, 1416, "+" +307, 10, 21, 275, 80, 81, 1417, 1418, "/" +307, 10, 22, 276, 82, 83, 1419, 1420, "-" +307, 10, 23, 277, 84, 86, 1421, 1423, "34" +307, 10, 24, 278, 87, 88, 1424, 1425, "." +307, 10, 25, 279, 89, 91, 1426, 1428, "34" +307, 10, 26, 280, 92, 94, 1429, 1431, "mg" +307, 10, 27, 281, 95, 96, 1432, 1433, "/" +307, 10, 28, 282, 97, 99, 1434, 1436, "dl" +307, 10, 29, 283, 100, 102, 1437, 1439, "in" +307, 10, 30, 284, 103, 114, 1440, 1451, "cabergoline" +307, 10, 31, 285, 115, 120, 1452, 1457, "group" +307, 10, 32, 286, 121, 128, 1458, 1465, "whereas" +307, 10, 33, 287, 129, 131, 1466, 1468, "it" +307, 10, 34, 288, 132, 141, 1469, 1478, "increased" +307, 10, 35, 289, 142, 144, 1479, 1481, "in" +307, 10, 36, 290, 145, 152, 1482, 1489, "placebo" +307, 10, 37, 291, 153, 158, 1490, 1495, "group" +307, 10, 38, 292, 159, 174, 1496, 1511, "insignificantly" +307, 10, 39, 293, 175, 176, 1512, 1513, "." +307, 11, 1, 294, 0, 5, 1514, 1519, "HbA1c" +307, 11, 2, 295, 6, 15, 1520, 1529, "decreased" +307, 11, 3, 296, 16, 18, 1530, 1532, "in" +307, 11, 4, 297, 19, 30, 1533, 1544, "cabergoline" +307, 11, 5, 298, 31, 36, 1545, 1550, "group" +307, 11, 6, 299, 37, 41, 1551, 1555, "from" +307, 11, 7, 300, 42, 43, 1556, 1557, "8" +307, 11, 8, 301, 44, 45, 1558, 1559, "." +307, 11, 9, 302, 46, 48, 1560, 1562, "48" +307, 11, 10, 303, 49, 50, 1563, 1564, "+" +307, 11, 11, 304, 51, 52, 1565, 1566, "/" +307, 11, 12, 305, 53, 54, 1567, 1568, "-" +307, 11, 13, 306, 55, 56, 1569, 1570, "0" +307, 11, 14, 307, 57, 58, 1571, 1572, "." +307, 11, 15, 308, 59, 61, 1573, 1575, "44" +307, 11, 16, 309, 62, 64, 1576, 1578, "to" +307, 11, 17, 310, 65, 66, 1579, 1580, "7" +307, 11, 18, 311, 67, 68, 1581, 1582, "." +307, 11, 19, 312, 69, 70, 1583, 1584, "7" +307, 11, 20, 313, 71, 72, 1585, 1586, "+" +307, 11, 21, 314, 73, 74, 1587, 1588, "/" +307, 11, 22, 315, 75, 76, 1589, 1590, "-" +307, 11, 23, 316, 77, 78, 1591, 1592, "0" +307, 11, 24, 317, 79, 80, 1593, 1594, "." +307, 11, 25, 318, 81, 83, 1595, 1597, "11" +307, 11, 26, 319, 84, 91, 1598, 1605, "whereas" +307, 11, 27, 320, 92, 94, 1606, 1608, "in" +307, 11, 28, 321, 95, 102, 1609, 1616, "control" +307, 11, 29, 322, 103, 108, 1617, 1622, "group" +307, 11, 30, 323, 109, 111, 1623, 1625, "it" +307, 11, 31, 324, 112, 121, 1626, 1635, "increased" +307, 11, 32, 325, 122, 137, 1636, 1651, "insignificantly" +307, 11, 33, 326, 138, 142, 1652, 1656, "from" +307, 11, 34, 327, 143, 144, 1657, 1658, "8" +307, 11, 35, 328, 145, 146, 1659, 1660, "." +307, 11, 36, 329, 147, 148, 1661, 1662, "7" +307, 11, 37, 330, 149, 150, 1663, 1664, "+" +307, 11, 38, 331, 151, 152, 1665, 1666, "/" +307, 11, 39, 332, 153, 154, 1667, 1668, "-" +307, 11, 40, 333, 155, 156, 1669, 1670, "0" +307, 11, 41, 334, 157, 158, 1671, 1672, "." +307, 11, 42, 335, 159, 161, 1673, 1675, "33" +307, 11, 43, 336, 162, 164, 1676, 1678, "to" +307, 11, 44, 337, 165, 166, 1679, 1680, "8" +307, 11, 45, 338, 167, 168, 1681, 1682, "." +307, 11, 46, 339, 169, 170, 1683, 1684, "8" +307, 11, 47, 340, 171, 172, 1685, 1686, "+" +307, 11, 48, 341, 173, 174, 1687, 1688, "/" +307, 11, 49, 342, 175, 176, 1689, 1690, "-" +307, 11, 50, 343, 177, 178, 1691, 1692, "0" +307, 11, 51, 344, 179, 180, 1693, 1694, "." +307, 11, 52, 345, 181, 183, 1695, 1697, "16" +307, 11, 53, 346, 184, 185, 1698, 1699, "." +307, 12, 1, 347, 0, 10, 1700, 1710, "CONCLUSION" +307, 12, 2, 348, 11, 12, 1711, 1712, ":" +307, 12, 3, 349, 13, 24, 1713, 1724, "Cabergoline" +307, 12, 4, 350, 25, 33, 1725, 1733, "improves" +307, 12, 5, 351, 34, 42, 1734, 1742, "glycemic" +307, 12, 6, 352, 43, 50, 1743, 1750, "control" +307, 12, 7, 353, 51, 53, 1751, 1753, "in" +307, 12, 8, 354, 54, 58, 1754, 1758, "type" +307, 12, 9, 355, 59, 60, 1759, 1760, "2" +307, 12, 10, 356, 61, 69, 1761, 1769, "diabetic" +307, 12, 11, 357, 70, 78, 1770, 1778, "patients" +307, 12, 12, 358, 79, 83, 1779, 1783, "with" +307, 12, 13, 359, 84, 88, 1784, 1788, "oral" +307, 12, 14, 360, 89, 94, 1789, 1794, "agent" +307, 12, 15, 361, 95, 102, 1795, 1802, "failure" +307, 12, 16, 362, 103, 104, 1803, 1804, "." +307, 13, 1, 363, 0, 2, 1805, 1807, "It" +307, 13, 2, 364, 3, 10, 1808, 1815, "reduces" +307, 13, 3, 365, 11, 15, 1816, 1820, "both" +307, 13, 4, 366, 16, 23, 1821, 1828, "fasting" +307, 13, 5, 367, 24, 27, 1829, 1832, "and" +307, 13, 6, 368, 28, 40, 1833, 1845, "postprandial" +307, 13, 7, 369, 41, 47, 1846, 1852, "plasma" +307, 13, 8, 370, 48, 55, 1853, 1860, "glucose" +307, 13, 9, 371, 56, 62, 1861, 1867, "levels" +307, 13, 10, 372, 63, 66, 1868, 1871, "and" +307, 13, 11, 373, 67, 73, 1872, 1878, "causes" +307, 13, 12, 374, 74, 75, 1879, 1880, "0" +307, 13, 13, 375, 76, 77, 1881, 1882, "." +307, 13, 14, 376, 78, 80, 1883, 1885, "45" +307, 13, 15, 377, 81, 82, 1886, 1887, "-" +307, 13, 16, 378, 83, 84, 1888, 1889, "1" +307, 13, 17, 379, 85, 86, 1890, 1891, "." +307, 13, 18, 380, 87, 89, 1892, 1894, "11" +307, 13, 19, 381, 90, 99, 1895, 1904, "reduction" +307, 13, 20, 382, 100, 102, 1905, 1907, "in" +307, 13, 21, 383, 103, 108, 1908, 1913, "HbA1c" +307, 13, 22, 384, 109, 110, 1914, 1915, "." +307, 14, 1, 385, 0, 4, 1916, 1920, "PMID" +307, 14, 2, 386, 5, 6, 1921, 1922, ":" +307, 14, 3, 387, 7, 15, 1923, 1931, "23082447" +307, 14, 4, 388, 16, 17, 1932, 1933, "[" +307, 14, 5, 389, 18, 25, 1934, 1941, "Indexed" +307, 14, 6, 390, 26, 29, 1942, 1945, "for" +307, 14, 7, 391, 30, 37, 1946, 1953, "MEDLINE" +307, 14, 8, 392, 38, 39, 1954, 1955, "]" diff --git a/data/dm2 23082447_kwoodley.annodb b/data/dm2 23082447_kwoodley.annodb new file mode 100644 index 0000000..5af07fd --- /dev/null +++ b/data/dm2 23082447_kwoodley.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +24108, Journal, 0, 16, "Med J Malaysia .", "", +24109, PublicationYear, 17, 21, "2012", "", +24110, Drug, 49, 60, "Cabergoline", "", +24125, Title, 49, 136, "Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure .", "", +24116, HbA1c, 71, 82, "blood sugar", "", +24117, Type2Diabetes, 86, 101, "type 2 diabetic", "", +24123, Precondition, 86, 134, "type 2 diabetic patients with oral agent failure", "", +24121, OralAntidiabeticAgent, 116, 126, "oral agent", "", +24126, Author, 137, 147, "Taghavi SM", "", +24127, Author, 156, 165, "Fatemi SS", "", +24128, Author, 168, 175, "Rokni H", "", +24129, Iran, 293, 297, "Iran", "", +24130, Bromocriptine, 480, 493, "bromocriptine", "", +24118, Type2Diabetes, 533, 548, "type 2 diabetes", "", +24141, ObjectiveDescription, 551, 722, "The aim of this study was the evaluation of short - term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy .", "", +24115, Drug, 618, 629, "cabergoline", "", +24134, Precondition, 633, 720, "poorly controlled diabetic patients with oral agent failure who refused insulin therapy", "", +24131, Type2Diabetes, 651, 659, "diabetic", "", +24132, OralAntidiabeticAgent, 674, 684, "oral agent", "", +24133, Insulin, 705, 712, "insulin", "", +24135, NumberPatientsCT, 761, 763, "17", "", +24140, Precondition, 764, 924, "overweight women and men with type 2 diabetes with persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea , metformin and pioglitazone", "", +24119, Type2Diabetes, 794, 809, "type 2 diabetes", "", +24136, Hypoglycemia, 826, 839, "hyperglycemia", "", +24137, Sulfonylureas, 883, 895, "sulfonylurea", "", +24138, Metformin, 898, 907, "metformin", "", +24139, Pioglitazone, 912, 924, "pioglitazone", "", +24142, NumberPatientsArm, 927, 929, "10", "", +24144, Randomized, 951, 961, "randomized", "", +24114, Drug, 981, 992, "cabergoline", "", +24145, DoseValue, 993, 998, "0 . 5", "", +24146, mg, 999, 1001, "mg", "", +24147, Frequency, 1002, 1008, "weekly", "", +24148, Duration, 1013, 1021, "3 months", "", +24143, NumberPatientsArm, 1026, 1027, "7", "", +24149, Placebo, 1055, 1062, "placebo", "", +24151, FastingPlasmaGlucose, 1065, 1072, "Fasting", "", +33161, PostprandialPlasmaGlucose, 1077, 1104, "postprandial plasma glucose", "", +24150, HbA1c, 1123, 1128, "HbAlc", "", +24161, FastingPlasmaGlucose, 1184, 1187, "FBS", "", +24154, BaseLineValue, 1203, 1211, "210 . 70", "", +24165, SdDevBL, 1218, 1225, "21 . 29", "", +24155, ResultMeasuredValue, 1229, 1237, "144 . 90", "", +24157, SdDevResValue, 1244, 1251, "26 . 56", "", +24158, Mg_per_deciliter, 1252, 1259, "mg / dl", "", +24113, Drug, 1263, 1274, "cabergoline", "", +24160, ObservedResult, 1292, 1334, "decreased in placebo group insignificantly", "", +24159, Placebo, 1305, 1312, "placebo", "", +33162, PostprandialPlasmaGlucose, 1337, 1363, "Postprandial blood glucose", "", +24163, BaseLineValue, 1379, 1386, "264 . 2", "", +24164, SdDevBL, 1393, 1395, "28", "", +24168, Mg_per_deciliter, 1396, 1403, "mg / dl", "", +24166, ResultMeasuredValue, 1407, 1414, "203 . 6", "", +24167, SdDevResValue, 1421, 1428, "34 . 34", "", +24169, Mg_per_deciliter, 1429, 1436, "mg / dl", "", +24112, Drug, 1440, 1451, "cabergoline", "", +24171, ObservedResult, 1469, 1511, "increased in placebo group insignificantly", "", +24170, Placebo, 1482, 1489, "placebo", "", +24172, HbA1c, 1514, 1519, "HbA1c", "", +24173, Drug, 1533, 1544, "cabergoline", "", +24174, BaseLineValue, 1556, 1562, "8 . 48", "", +24176, SdDevBL, 1569, 1575, "0 . 44", "", +24178, ResultMeasuredValue, 1579, 1584, "7 . 7", "", +24180, SdDevResValue, 1591, 1597, "0 . 11", "", +24175, BaseLineValue, 1657, 1662, "8 . 7", "", +24177, SdDevBL, 1669, 1675, "0 . 33", "", +24179, ResultMeasuredValue, 1679, 1684, "8 . 8", "", +24181, SdDevResValue, 1691, 1697, "0 . 16", "", +24111, Drug, 1713, 1724, "Cabergoline", "", +24183, ConclusionComment, 1713, 1804, "Cabergoline improves glycemic control in type 2 diabetic patients with oral agent failure .", "", +24120, Type2Diabetes, 1754, 1769, "type 2 diabetic", "", +24124, Precondition, 1754, 1802, "type 2 diabetic patients with oral agent failure", "", +24122, OralAntidiabeticAgent, 1784, 1794, "oral agent", "", +24184, ConclusionComment, 1805, 1915, "It reduces both fasting and postprandial plasma glucose levels and causes 0 . 45 - 1 . 11 reduction in HbA1c .", "", +24185, FastingPlasmaGlucose, 1821, 1828, "fasting", "", +33163, PostprandialPlasmaGlucose, 1833, 1860, "postprandial plasma glucose", "", +24187, HbA1c, 1908, 1913, "HbA1c", "", +24188, PMID, 1923, 1931, "23082447", "", diff --git a/data/dm2 23082447_kwoodley.n-triples b/data/dm2 23082447_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23082447_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23116881_admin.annodb b/data/dm2 23116881_admin.annodb new file mode 100644 index 0000000..12778a2 --- /dev/null +++ b/data/dm2 23116881_admin.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +96, Journal, 0, 24, "J Diabetes Complications", "", " \"J Diabetes Complications\"." +1, PublicationYear, 27, 31, "2013", "", " \"2013\"." +24, Title, 136, 326, "Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized , placebo - controlled , 26 - week trial in patients with type 2 diabetes .", "", " \"Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized , placebo - controlled , 26 - week trial in patients with type 2 diabetes .\"." +2, Sitagliptin, 159, 170, "sitagliptin", "", +106280, Precondition, 180, 234, "ongoing metformin and pioglitazone combination therapy", "", " \"ongoing metformin and pioglitazone combination therapy\"." +9, Metformin, 188, 197, "metformin", "", +12, Pioglitazone, 202, 214, "pioglitazone", "", +15, Randomized, 240, 250, "randomized", "", " ." +16, Placebo, 253, 260, "placebo", "", +22, Duration, 276, 285, "26 - week", "", " \"26 - week\"." +23, Type2Diabetes, 309, 324, "type 2 diabetes", "", " ." +43, Author, 327, 336, "Fonseca V", "", " \"Fonseca V\"." +44, Author, 345, 353, "Staels B", "", " \"Staels B\"." +45, Author, 356, 369, "Morgan JD 2nd", "", " \"Morgan JD 2nd\"." +46, Author, 372, 380, "Shentu Y", "", " \"Shentu Y\"." +47, Author, 383, 390, "Golm GT", "", " \"Golm GT\"." +48, Author, 393, 413, "Johnson - Levonas AO", "", " \"Johnson - Levonas AO\"." +49, Author, 416, 426, "Kaufman KD", "", " \"Kaufman KD\"." +50, Author, 429, 441, "Goldstein BJ", "", " \"Goldstein BJ\"." +51, Author, 444, 455, "Steinberg H", "", " \"Steinberg H\"." +52, USA, 539, 542, "USA", "", " ." +41, ObjectiveDescription, 552, 730, "To assess efficacy and safety of sitagliptin , a dipeptidyl peptidase - 4 inhibitor , in combination therapy with metformin ( ≥ 1500 mg / day ) and pioglitazone ( ≥ 30 mg / day )", "", " \"To assess efficacy and safety of sitagliptin , a dipeptidyl peptidase - 4 inhibitor , in combination therapy with metformin ( ≥ 1500 mg / day ) and pioglitazone ( ≥ 30 mg / day )\"." +3, Sitagliptin, 585, 596, "sitagliptin", "", +10, Metformin, 666, 675, "metformin", "", +25, DoseValue, 678, 684, "≥ 1500", "", +28, mg, 685, 687, "mg", "", +31, Frequency, 690, 693, "day", "", +14, Pioglitazone, 700, 712, "pioglitazone", "", +26, DoseValue, 715, 719, "≥ 30", "", +29, mg, 720, 722, "mg", "", +32, Frequency, 725, 728, "day", "", +42, ObjectiveDescription, 731, 857, "in patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % ) .", "", " \"in patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % ) .\"." +40, Precondition, 734, 855, "patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", " \"patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )\"." +34, Type2Diabetes, 748, 763, "type 2 diabetes", "", +35, Type2Diabetes, 766, 770, "T2DM", "", +36, HbA1c, 808, 822, "hemoglobin A1c", "", +37, HbA1c, 825, 830, "HbA1c", "", +38, Percentage, 841, 842, "%", "", +39, Percentage, 852, 853, "%", "", +17, Placebo, 873, 880, "placebo", "", +53, DoubleBlind, 896, 910, "double - blind", "", " ." +54, NumberPatientsCT, 926, 929, "313", "", " \"313\"." +133, Mean, 941, 945, "mean", "", +134, TimePoint, 946, 954, "baseline", "", +55, HbA1c, 955, 960, "HbA1c", "", +56, BaseLineValue, 963, 968, "8 . 7", "", +57, Percentage, 969, 970, "%", "", +58, Randomized, 982, 992, "randomized", "", +4, Sitagliptin, 1004, 1015, "sitagliptin", "", " ." +27, DoseValue, 1016, 1019, "100", "", " \"100\"." +30, mg, 1020, 1022, "mg", "", " ." +33, Frequency, 1025, 1028, "day", "", " \"day\"." +18, Placebo, 1032, 1039, "placebo", "", +59, Duration, 1044, 1052, "26 weeks", "", +5, Sitagliptin, 1081, 1092, "sitagliptin", "", +60, PValueChangeValue, 1114, 1123, "P < . 001", "", " \"P < . 001\". \"P < . 001\". \"P < . 001\". \"P < . 001\". \"P < . 001\". \"P < . 001\"." +147, Mean, 1126, 1130, "mean", "", " . . . . . ." +148, TimePoint, 1144, 1152, "baseline", "", +61, Placebo, 1165, 1172, "placebo", "", +62, HbA1c, 1176, 1181, "HbA1c", "", " ." +106281, DiffGroupAbsValue, 1184, 1191, "- 0 . 7", "", " \"- 0 . 7\"." +66, Percentage, 1192, 1193, "%", "", " ." +63, FastingPlasmaGlucose, 1198, 1220, "fasting plasma glucose", "", " ." +106282, DiffGroupAbsValue, 1223, 1230, "- 1 . 0", "", " \"- 1 . 0\"." +65, Millimoles_per_litre, 1231, 1239, "mmol / L", "", " ." +95, PostprandialBloodGlucose, 1248, 1273, "2 - h post - meal glucose", "", " ." +106283, DiffGroupAbsValue, 1276, 1283, "- 2 . 2", "", " \"- 2 . 2\"." +64, Millimoles_per_litre, 1284, 1292, "mmol / L", "", " ." +71, SubGroupDescription, 1300, 1338, "patients with baseline HbA1c ≥ 9 . 0 %", "", " \"patients with baseline HbA1c ≥ 9 . 0 %\". \"patients with baseline HbA1c ≥ 9 . 0 %\"." +161, TimePoint, 1314, 1322, "baseline", "", +70, HbA1c, 1323, 1328, "HbA1c", "", +72, Percentage, 1337, 1338, "%", "", +164, Mean, 1341, 1345, "mean", "", +165, BaseLineValue, 1359, 1367, "baseline", "", +73, HbA1c, 1371, 1376, "HbA1c", "", +74, Reduction, 1384, 1389, "1 . 6", "", " \"1 . 6\"." +76, Percentage, 1390, 1391, "%", "", +75, Reduction, 1398, 1403, "0 . 8", "", " \"0 . 8\"." +77, Percentage, 1404, 1405, "%", "", +6, Sitagliptin, 1414, 1425, "sitagliptin", "", +20, Placebo, 1430, 1437, "placebo", "", +78, DiffGroupAbsValue, 1489, 1496, "- 0 . 8", "", " \"- 0 . 8\"." +79, Percentage, 1497, 1498, "%", "", +80, PvalueDiff, 1501, 1510, "P < . 001", "", " \"P < . 001\"." +82, ObservedResult, 1515, 1610, "The incidences of reported adverse events were generally similar between the treatment groups .", "", +85, SymptomaticHypoglycemia, 1625, 1649, "symptomatic hypoglycemia", "", " ." +89, NumberAffected, 1655, 1656, "7", "", " \"7\"." +91, NumberPatientsArm, 1659, 1662, "157", "", " \"157\"." +87, PercentageAffected, 1665, 1670, "4 . 5", "", " \"4 . 5\"." +90, NumberAffected, 1679, 1680, "6", "", " \"6\"." +92, NumberPatientsArm, 1683, 1686, "156", "", " \"156\"." +88, PercentageAffected, 1689, 1694, "3 . 8", "", " \"3 . 8\"." +7, Sitagliptin, 1706, 1717, "sitagliptin", "", +19, Placebo, 1722, 1729, "placebo", "", +86, PvalueDiff, 1754, 1763, "P = . 786", "", " \"P = . 786\"." +83, NumberAffected, 1768, 1771, "Two", "", " \"Two\"." +21, Placebo, 1795, 1802, "placebo", "", +93015, Hypoglycemia, 1837, 1888, "hypoglycemia that required non - medical assistance", "", " ." +195, ConclusionComment, 1905, 2070, "In this 26 - week study , addition of sitagliptin to combination therapy with metformin and pioglitazone improved glycemic control and was generally well tolerated .", "", " \"In this 26 - week study , addition of sitagliptin to combination therapy with metformin and pioglitazone improved glycemic control and was generally well tolerated .\"." +93, Duration, 1913, 1922, "26 - week", "", +8, Sitagliptin, 1943, 1954, "sitagliptin", "", +11, Metformin, 1983, 1992, "metformin", "", +13, Pioglitazone, 1997, 2009, "pioglitazone", "", +94, PMID, 2181, 2189, "23116881", "", " \"23116881\"." diff --git a/data/dm2 23116881_admin.n-triples b/data/dm2 23116881_admin.n-triples new file mode 100644 index 0000000..82e6013 --- /dev/null +++ b/data/dm2 23116881_admin.n-triples @@ -0,0 +1,194 @@ +# RDF export of group: Publication + . + "Publication 40795" . + "Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized , placebo - controlled , 26 - week trial in patients with type 2 diabetes ." . + "Fonseca V" . + "2013" . + "J Diabetes Complications" . + "23116881" . + . + "Staels B" . + "Morgan JD 2nd" . + "Shentu Y" . + "Golm GT" . + "Johnson - Levonas AO" . + "Kaufman KD" . + "Goldstein BJ" . + "Steinberg H" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 40802" . + "To assess efficacy and safety of sitagliptin , a dipeptidyl peptidase - 4 inhibitor , in combination therapy with metformin ( ≥ 1500 mg / day ) and pioglitazone ( ≥ 30 mg / day )" . + "313" . + "26 - week" . + . + . + . + "In this 26 - week study , addition of sitagliptin to combination therapy with metformin and pioglitazone improved glycemic control and was generally well tolerated ." . + . + . + . + . + . + . + . + "in patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % ) ." . + . +# RDF export of group: Population + . + "Population 40818" . + "patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )" . + . + . + . + "ongoing metformin and pioglitazone combination therapy" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "ppg" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "hyps" . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + "157" . + . + . + . + . + . + . + . + "pla" . + "156" . + . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "sit" . + . + "100" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "P < . 001" . + . + "fpg 1" . + . + "P < . 001" . + . + "ppg 1" . + . + "P < . 001" . + . + "hbas 1" . + . + "1 . 6" . + "patients with baseline HbA1c ≥ 9 . 0 %" . + . + "hbas 2" . + . + "0 . 8" . + "patients with baseline HbA1c ≥ 9 . 0 %" . + . + "hyp 1" . + . + "7" . + "4 . 5" . + . + "hyp 2" . + . + "6" . + "3 . 8" . + . + "hyps 2" . + . + "Two" . + . + "hba 2" . + . + "P < . 001" . + . + "fpg 2" . + . + "P < . 001" . + . + "ppg 2" . + . + "P < . 001" . +# RDF export of group: DiffBetweenGroups + . + "hbas" . + "- 0 . 8" . + "P < . 001" . + . + . + . + "hyp" . + "P = . 786" . + . + . + . + "hba" . + "- 0 . 7" . + . + . + . + "fpg" . + "- 1 . 0" . + . + . + . + "ppg" . + "- 2 . 2" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23116881_akramersunderbrink.annodb b/data/dm2 23116881_akramersunderbrink.annodb new file mode 100644 index 0000000..06bc0f8 --- /dev/null +++ b/data/dm2 23116881_akramersunderbrink.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42512, Journal, 0, 24, "J Diabetes Complications", "", +42620, PublicationYear, 27, 31, "2013", "", +42632, Title, 136, 326, "Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized , placebo - controlled , 26 - week trial in patients with type 2 diabetes .", "", +42622, Sitagliptin, 159, 170, "sitagliptin", "", +42623, Metformin, 188, 197, "metformin", "", +42624, Pioglitazone, 202, 214, "pioglitazone", "", +42626, Randomized, 240, 250, "randomized", "", +42627, Placebo, 253, 260, "placebo", "", +42628, Duration, 276, 285, "26 - week", "", +42631, Type2Diabetes, 309, 324, "type 2 diabetes", "", +42633, Author, 327, 336, "Fonseca V", "", +42635, Author, 345, 353, "Staels B", "", +42637, Author, 356, 369, "Morgan JD 2nd", "", +42639, Author, 372, 380, "Shentu Y", "", +42640, Author, 383, 390, "Golm GT", "", +42642, Author, 393, 413, "Johnson - Levonas AO", "", +42643, Author, 416, 426, "Kaufman KD", "", +42644, Author, 429, 441, "Goldstein BJ", "", +42645, Author, 444, 455, "Steinberg H", "", +42647, USA, 539, 542, "USA", "", +42693, ObjectiveDescription, 552, 742, "To assess efficacy and safety of sitagliptin , a dipeptidyl peptidase - 4 inhibitor , in combination therapy with metformin ( ≥ 1500 mg / day ) and pioglitazone ( ≥ 30 mg / day ) in patients", "", +42649, Sitagliptin, 585, 596, "sitagliptin", "", +42651, Metformin, 666, 675, "metformin", "", +42653, DoseValue, 678, 693, "≥ 1500 mg / day", "", +42656, BioAndMedicalUnit, 685, 693, "mg / day", "", +42658, Pioglitazone, 700, 712, "pioglitazone", "", +42659, DoseValue, 715, 728, "≥ 30 mg / day", "", +42661, BioAndMedicalUnit, 720, 728, "mg / day", "", +42696, ObjectiveDescription, 743, 857, "with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % ) .", "", +42662, Type2Diabetes, 748, 763, "type 2 diabetes", "", +42664, Type2Diabetes, 766, 770, "T2DM", "", +42666, Precondition, 778, 855, "inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", +42667, HbA1c, 808, 822, "hemoglobin A1c", "", +42668, HbA1c, 825, 830, "HbA1c", "", +42669, Percentage, 841, 842, "%", "", +42670, Percentage, 852, 853, "%", "", +42671, Placebo, 873, 880, "placebo", "", +42672, DoubleBlind, 896, 910, "double - blind", "", +42673, NumberPatientsCT, 926, 929, "313", "", +42674, Mean, 941, 945, "mean", "", +42675, TimePoint, 946, 954, "baseline", "", +42676, HbA1c, 955, 960, "HbA1c", "", +42679, BaseLineValue, 963, 968, "8 . 7", "", +42681, Percentage, 969, 970, "%", "", +42682, Randomized, 982, 992, "randomized", "", +42684, Sitagliptin, 1004, 1015, "sitagliptin", "", +42685, DoseValue, 1016, 1028, "100 mg / day", "", +42686, BioAndMedicalUnit, 1020, 1028, "mg / day", "", +42688, Placebo, 1032, 1039, "placebo", "", +42689, Duration, 1044, 1052, "26 weeks", "", +42697, Sitagliptin, 1081, 1092, "sitagliptin", "", +42720, PValueChangeValue, 1114, 1123, "P < . 001", "", +42698, Mean, 1126, 1130, "mean", "", +42700, TimePoint, 1144, 1152, "baseline", "", +42701, Placebo, 1165, 1172, "placebo", "", +42703, HbA1c, 1176, 1181, "HbA1c", "", +42713, ChangeValue, 1184, 1191, "- 0 . 7", "", +42710, Percentage, 1192, 1193, "%", "", +42706, FastingPlasmaGlucose, 1198, 1220, "fasting plasma glucose", "", +42715, ChangeValue, 1223, 1230, "- 1 . 0", "", +42718, Millimoles_per_litre, 1231, 1239, "mmol / L", "", +42708, PostprandialPlasmaGlucose, 1248, 1273, "2 - h post - meal glucose", "", +42716, ChangeValue, 1276, 1283, "- 2 . 2", "", +42711, Millimoles_per_litre, 1284, 1292, "mmol / L", "", +42725, SubGroupDescription, 1300, 1338, "patients with baseline HbA1c ≥ 9 . 0 %", "", +42722, TimePoint, 1314, 1322, "baseline", "", +42721, HbA1c, 1323, 1328, "HbA1c", "", +42723, Percentage, 1337, 1338, "%", "", +42727, Mean, 1341, 1345, "mean", "", +42728, BaseLineValue, 1359, 1367, "baseline", "", +42729, HbA1c, 1371, 1376, "HbA1c", "", +42741, ChangeValue, 1382, 1389, "- 1 . 6", "", +42730, Percentage, 1390, 1391, "%", "", +42744, ChangeValue, 1396, 1403, "- 0 . 8", "", +42732, Percentage, 1404, 1405, "%", "", +42734, Sitagliptin, 1414, 1425, "sitagliptin", "", +42736, Placebo, 1430, 1437, "placebo", "", +42747, DiffGroupAbsValue, 1489, 1496, "- 0 . 8", "", +42748, Percentage, 1497, 1498, "%", "", +42750, PvalueDiff, 1501, 1510, "P < . 001", "", +42754, SymptomaticHypoglycemia, 1625, 1649, "symptomatic hypoglycemia", "", +42760, NumberAffected, 1655, 1656, "7", "", +42757, NumberPatientsArm, 1659, 1662, "157", "", +42765, PercentageAffected, 1665, 1670, "4 . 5", "", +42769, Percentage, 1671, 1672, "%", "", +42762, NumberAffected, 1679, 1680, "6", "", +42758, NumberPatientsArm, 1683, 1686, "156", "", +42767, PercentageAffected, 1689, 1694, "3 . 8", "", +42770, Percentage, 1695, 1696, "%", "", +42772, Sitagliptin, 1706, 1717, "sitagliptin", "", +42773, Placebo, 1722, 1729, "placebo", "", +42776, PvalueDiff, 1754, 1763, "P = . 786", "", +42781, NumberAffected, 1768, 1771, "Two", "", +42778, Placebo, 1795, 1802, "placebo", "", +42780, Hypoglycemia, 1823, 1888, "an episode of hypoglycemia that required non - medical assistance", "", +42791, ConclusionComment, 1905, 2070, "In this 26 - week study , addition of sitagliptin to combination therapy with metformin and pioglitazone improved glycemic control and was generally well tolerated .", "", +42782, Duration, 1913, 1922, "26 - week", "", +42783, Sitagliptin, 1943, 1954, "sitagliptin", "", +42785, Metformin, 1983, 1992, "metformin", "", +42786, Pioglitazone, 1997, 2009, "pioglitazone", "", +42792, PMID, 2181, 2189, "23116881", "", diff --git a/data/dm2 23116881_akramersunderbrink.n-triples b/data/dm2 23116881_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23116881_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23116881_export.csv b/data/dm2 23116881_export.csv new file mode 100644 index 0000000..537846d --- /dev/null +++ b/data/dm2 23116881_export.csv @@ -0,0 +1,483 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +306, 1, 1, 1, 0, 1, 0, 1, "J" +306, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +306, 1, 3, 3, 11, 24, 11, 24, "Complications" +306, 1, 4, 4, 25, 26, 25, 26, "." +306, 2, 1, 5, 0, 4, 27, 31, "2013" +306, 2, 2, 6, 5, 8, 32, 35, "Mar" +306, 2, 3, 7, 9, 10, 36, 37, "-" +306, 2, 4, 8, 11, 14, 38, 41, "Apr" +306, 2, 5, 9, 15, 16, 42, 43, ";" +306, 2, 6, 10, 17, 19, 44, 46, "27" +306, 2, 7, 11, 20, 21, 47, 48, "(" +306, 2, 8, 12, 22, 23, 49, 50, "2" +306, 2, 9, 13, 24, 25, 51, 52, ")" +306, 2, 10, 14, 26, 27, 53, 54, ":" +306, 2, 11, 15, 28, 31, 55, 58, "177" +306, 2, 12, 16, 32, 33, 59, 60, "-" +306, 2, 13, 17, 34, 36, 61, 63, "83" +306, 2, 14, 18, 37, 38, 64, 65, "." +306, 2, 15, 19, 39, 42, 66, 69, "doi" +306, 2, 16, 20, 43, 44, 70, 71, ":" +306, 2, 17, 21, 45, 47, 72, 74, "10" +306, 2, 18, 22, 48, 49, 75, 76, "." +306, 2, 19, 23, 50, 54, 77, 81, "1016" +306, 2, 20, 24, 55, 56, 82, 83, "/" +306, 2, 21, 25, 57, 58, 84, 85, "j" +306, 2, 22, 26, 59, 60, 86, 87, "." +306, 2, 23, 27, 61, 69, 88, 96, "jdiacomp" +306, 2, 24, 28, 70, 71, 97, 98, "." +306, 2, 25, 29, 72, 76, 99, 103, "2012" +306, 2, 26, 30, 77, 78, 104, 105, "." +306, 2, 27, 31, 79, 81, 106, 108, "09" +306, 2, 28, 32, 82, 83, 109, 110, "." +306, 2, 29, 33, 84, 87, 111, 114, "007" +306, 2, 30, 34, 88, 89, 115, 116, "." +306, 3, 1, 35, 0, 4, 117, 121, "Epub" +306, 3, 2, 36, 5, 9, 122, 126, "2012" +306, 3, 3, 37, 10, 13, 127, 130, "Oct" +306, 3, 4, 38, 14, 16, 131, 133, "30" +306, 3, 5, 39, 17, 18, 134, 135, "." +306, 4, 1, 40, 0, 8, 136, 144, "Efficacy" +306, 4, 2, 41, 9, 12, 145, 148, "and" +306, 4, 3, 42, 13, 19, 149, 155, "safety" +306, 4, 4, 43, 20, 22, 156, 158, "of" +306, 4, 5, 44, 23, 34, 159, 170, "sitagliptin" +306, 4, 6, 45, 35, 40, 171, 176, "added" +306, 4, 7, 46, 41, 43, 177, 179, "to" +306, 4, 8, 47, 44, 51, 180, 187, "ongoing" +306, 4, 9, 48, 52, 61, 188, 197, "metformin" +306, 4, 10, 49, 62, 65, 198, 201, "and" +306, 4, 11, 50, 66, 78, 202, 214, "pioglitazone" +306, 4, 12, 51, 79, 90, 215, 226, "combination" +306, 4, 13, 52, 91, 98, 227, 234, "therapy" +306, 4, 14, 53, 99, 101, 235, 237, "in" +306, 4, 15, 54, 102, 103, 238, 239, "a" +306, 4, 16, 55, 104, 114, 240, 250, "randomized" +306, 4, 17, 56, 115, 116, 251, 252, "," +306, 4, 18, 57, 117, 124, 253, 260, "placebo" +306, 4, 19, 58, 125, 126, 261, 262, "-" +306, 4, 20, 59, 127, 137, 263, 273, "controlled" +306, 4, 21, 60, 138, 139, 274, 275, "," +306, 4, 22, 61, 140, 142, 276, 278, "26" +306, 4, 23, 62, 143, 144, 279, 280, "-" +306, 4, 24, 63, 145, 149, 281, 285, "week" +306, 4, 25, 64, 150, 155, 286, 291, "trial" +306, 4, 26, 65, 156, 158, 292, 294, "in" +306, 4, 27, 66, 159, 167, 295, 303, "patients" +306, 4, 28, 67, 168, 172, 304, 308, "with" +306, 4, 29, 68, 173, 177, 309, 313, "type" +306, 4, 30, 69, 178, 179, 314, 315, "2" +306, 4, 31, 70, 180, 188, 316, 324, "diabetes" +306, 4, 32, 71, 189, 190, 325, 326, "." +306, 5, 1, 72, 0, 7, 327, 334, "Fonseca" +306, 5, 2, 73, 8, 9, 335, 336, "V" +306, 5, 3, 74, 10, 11, 337, 338, "(" +306, 5, 4, 75, 12, 13, 339, 340, "1" +306, 5, 5, 76, 14, 15, 341, 342, ")" +306, 5, 6, 77, 16, 17, 343, 344, "," +306, 5, 7, 78, 18, 24, 345, 351, "Staels" +306, 5, 8, 79, 25, 26, 352, 353, "B" +306, 5, 9, 80, 27, 28, 354, 355, "," +306, 5, 10, 81, 29, 35, 356, 362, "Morgan" +306, 5, 11, 82, 36, 38, 363, 365, "JD" +306, 5, 12, 83, 39, 42, 366, 369, "2nd" +306, 5, 13, 84, 43, 44, 370, 371, "," +306, 5, 14, 85, 45, 51, 372, 378, "Shentu" +306, 5, 15, 86, 52, 53, 379, 380, "Y" +306, 5, 16, 87, 54, 55, 381, 382, "," +306, 5, 17, 88, 56, 60, 383, 387, "Golm" +306, 5, 18, 89, 61, 63, 388, 390, "GT" +306, 5, 19, 90, 64, 65, 391, 392, "," +306, 5, 20, 91, 66, 73, 393, 400, "Johnson" +306, 5, 21, 92, 74, 75, 401, 402, "-" +306, 5, 22, 93, 76, 83, 403, 410, "Levonas" +306, 5, 23, 94, 84, 86, 411, 413, "AO" +306, 5, 24, 95, 87, 88, 414, 415, "," +306, 5, 25, 96, 89, 96, 416, 423, "Kaufman" +306, 5, 26, 97, 97, 99, 424, 426, "KD" +306, 5, 27, 98, 100, 101, 427, 428, "," +306, 5, 28, 99, 102, 111, 429, 438, "Goldstein" +306, 5, 29, 100, 112, 114, 439, 441, "BJ" +306, 5, 30, 101, 115, 116, 442, 443, "," +306, 5, 31, 102, 117, 126, 444, 453, "Steinberg" +306, 5, 32, 103, 127, 128, 454, 455, "H" +306, 5, 33, 104, 129, 130, 456, 457, "." +306, 5, 34, 105, 131, 137, 458, 464, "Author" +306, 5, 35, 106, 138, 149, 465, 476, "information" +306, 5, 36, 107, 150, 151, 477, 478, ":" +306, 5, 37, 108, 152, 153, 479, 480, "(" +306, 5, 38, 109, 154, 155, 481, 482, "1" +306, 5, 39, 110, 156, 157, 483, 484, ")" +306, 5, 40, 111, 158, 164, 485, 491, "Tulane" +306, 5, 41, 112, 165, 175, 492, 502, "University" +306, 5, 42, 113, 176, 183, 503, 510, "Medical" +306, 5, 43, 114, 184, 190, 511, 517, "Center" +306, 5, 44, 115, 191, 192, 518, 519, "," +306, 5, 45, 116, 193, 196, 520, 523, "New" +306, 5, 46, 117, 197, 204, 524, 531, "Orleans" +306, 5, 47, 118, 205, 206, 532, 533, "," +306, 5, 48, 119, 207, 209, 534, 536, "LA" +306, 5, 49, 120, 210, 211, 537, 538, "," +306, 5, 50, 121, 212, 215, 539, 542, "USA" +306, 5, 51, 122, 216, 217, 543, 544, "." +306, 6, 1, 123, 0, 4, 545, 549, "AIMS" +306, 6, 2, 124, 5, 6, 550, 551, ":" +306, 6, 3, 125, 7, 9, 552, 554, "To" +306, 6, 4, 126, 10, 16, 555, 561, "assess" +306, 6, 5, 127, 17, 25, 562, 570, "efficacy" +306, 6, 6, 128, 26, 29, 571, 574, "and" +306, 6, 7, 129, 30, 36, 575, 581, "safety" +306, 6, 8, 130, 37, 39, 582, 584, "of" +306, 6, 9, 131, 40, 51, 585, 596, "sitagliptin" +306, 6, 10, 132, 52, 53, 597, 598, "," +306, 6, 11, 133, 54, 55, 599, 600, "a" +306, 6, 12, 134, 56, 66, 601, 611, "dipeptidyl" +306, 6, 13, 135, 67, 76, 612, 621, "peptidase" +306, 6, 14, 136, 77, 78, 622, 623, "-" +306, 6, 15, 137, 79, 80, 624, 625, "4" +306, 6, 16, 138, 81, 90, 626, 635, "inhibitor" +306, 6, 17, 139, 91, 92, 636, 637, "," +306, 6, 18, 140, 93, 95, 638, 640, "in" +306, 6, 19, 141, 96, 107, 641, 652, "combination" +306, 6, 20, 142, 108, 115, 653, 660, "therapy" +306, 6, 21, 143, 116, 120, 661, 665, "with" +306, 6, 22, 144, 121, 130, 666, 675, "metformin" +306, 6, 23, 145, 131, 132, 676, 677, "(" +306, 6, 24, 146, 133, 134, 678, 679, "≥" +306, 6, 25, 147, 135, 139, 680, 684, "1500" +306, 6, 26, 148, 140, 142, 685, 687, "mg" +306, 6, 27, 149, 143, 144, 688, 689, "/" +306, 6, 28, 150, 145, 148, 690, 693, "day" +306, 6, 29, 151, 149, 150, 694, 695, ")" +306, 6, 30, 152, 151, 154, 696, 699, "and" +306, 6, 31, 153, 155, 167, 700, 712, "pioglitazone" +306, 6, 32, 154, 168, 169, 713, 714, "(" +306, 6, 33, 155, 170, 171, 715, 716, "≥" +306, 6, 34, 156, 172, 174, 717, 719, "30" +306, 6, 35, 157, 175, 177, 720, 722, "mg" +306, 6, 36, 158, 178, 179, 723, 724, "/" +306, 6, 37, 159, 180, 183, 725, 728, "day" +306, 6, 38, 160, 184, 185, 729, 730, ")" +306, 6, 39, 161, 186, 188, 731, 733, "in" +306, 6, 40, 162, 189, 197, 734, 742, "patients" +306, 6, 41, 163, 198, 202, 743, 747, "with" +306, 6, 42, 164, 203, 207, 748, 752, "type" +306, 6, 43, 165, 208, 209, 753, 754, "2" +306, 6, 44, 166, 210, 218, 755, 763, "diabetes" +306, 6, 45, 167, 219, 220, 764, 765, "(" +306, 6, 46, 168, 221, 225, 766, 770, "T2DM" +306, 6, 47, 169, 226, 227, 771, 772, ")" +306, 6, 48, 170, 228, 232, 773, 777, "with" +306, 6, 49, 171, 233, 243, 778, 788, "inadequate" +306, 6, 50, 172, 244, 252, 789, 797, "glycemic" +306, 6, 51, 173, 253, 260, 798, 805, "control" +306, 6, 52, 174, 261, 262, 806, 807, "(" +306, 6, 53, 175, 263, 273, 808, 818, "hemoglobin" +306, 6, 54, 176, 274, 277, 819, 822, "A1c" +306, 6, 55, 177, 278, 279, 823, 824, "[" +306, 6, 56, 178, 280, 285, 825, 830, "HbA1c" +306, 6, 57, 179, 286, 287, 831, 832, "]" +306, 6, 58, 180, 288, 289, 833, 834, "≥" +306, 6, 59, 181, 290, 291, 835, 836, "7" +306, 6, 60, 182, 292, 293, 837, 838, "." +306, 6, 61, 183, 294, 295, 839, 840, "5" +306, 6, 62, 184, 296, 297, 841, 842, "%" +306, 6, 63, 185, 298, 301, 843, 846, "and" +306, 6, 64, 186, 302, 303, 847, 848, "≤" +306, 6, 65, 187, 304, 306, 849, 851, "11" +306, 6, 66, 188, 307, 308, 852, 853, "%" +306, 6, 67, 189, 309, 310, 854, 855, ")" +306, 6, 68, 190, 311, 312, 856, 857, "." +306, 7, 1, 191, 0, 7, 858, 865, "METHODS" +306, 7, 2, 192, 8, 9, 866, 867, ":" +306, 7, 3, 193, 10, 14, 868, 872, "This" +306, 7, 4, 194, 15, 22, 873, 880, "placebo" +306, 7, 5, 195, 23, 24, 881, 882, "-" +306, 7, 6, 196, 25, 35, 883, 893, "controlled" +306, 7, 7, 197, 36, 37, 894, 895, "," +306, 7, 8, 198, 38, 44, 896, 902, "double" +306, 7, 9, 199, 45, 46, 903, 904, "-" +306, 7, 10, 200, 47, 52, 905, 910, "blind" +306, 7, 11, 201, 53, 58, 911, 916, "study" +306, 7, 12, 202, 59, 67, 917, 925, "included" +306, 7, 13, 203, 68, 71, 926, 929, "313" +306, 7, 14, 204, 72, 80, 930, 938, "patients" +306, 7, 15, 205, 81, 82, 939, 940, "," +306, 7, 16, 206, 83, 87, 941, 945, "mean" +306, 7, 17, 207, 88, 96, 946, 954, "baseline" +306, 7, 18, 208, 97, 102, 955, 960, "HbA1c" +306, 7, 19, 209, 103, 104, 961, 962, "=" +306, 7, 20, 210, 105, 106, 963, 964, "8" +306, 7, 21, 211, 107, 108, 965, 966, "." +306, 7, 22, 212, 109, 110, 967, 968, "7" +306, 7, 23, 213, 111, 112, 969, 970, "%" +306, 7, 24, 214, 113, 114, 971, 972, "," +306, 7, 25, 215, 115, 118, 973, 976, "who" +306, 7, 26, 216, 119, 123, 977, 981, "were" +306, 7, 27, 217, 124, 134, 982, 992, "randomized" +306, 7, 28, 218, 135, 137, 993, 995, "to" +306, 7, 29, 219, 138, 145, 996, 1003, "receive" +306, 7, 30, 220, 146, 157, 1004, 1015, "sitagliptin" +306, 7, 31, 221, 158, 161, 1016, 1019, "100" +306, 7, 32, 222, 162, 164, 1020, 1022, "mg" +306, 7, 33, 223, 165, 166, 1023, 1024, "/" +306, 7, 34, 224, 167, 170, 1025, 1028, "day" +306, 7, 35, 225, 171, 173, 1029, 1031, "or" +306, 7, 36, 226, 174, 181, 1032, 1039, "placebo" +306, 7, 37, 227, 182, 185, 1040, 1043, "for" +306, 7, 38, 228, 186, 188, 1044, 1046, "26" +306, 7, 39, 229, 189, 194, 1047, 1052, "weeks" +306, 7, 40, 230, 195, 196, 1053, 1054, "." +306, 8, 1, 231, 0, 7, 1055, 1062, "RESULTS" +306, 8, 2, 232, 8, 9, 1063, 1064, ":" +306, 8, 3, 233, 10, 13, 1065, 1068, "The" +306, 8, 4, 234, 14, 22, 1069, 1077, "addition" +306, 8, 5, 235, 23, 25, 1078, 1080, "of" +306, 8, 6, 236, 26, 37, 1081, 1092, "sitagliptin" +306, 8, 7, 237, 38, 41, 1093, 1096, "led" +306, 8, 8, 238, 42, 44, 1097, 1099, "to" +306, 8, 9, 239, 45, 56, 1100, 1111, "significant" +306, 8, 10, 240, 57, 58, 1112, 1113, "(" +306, 8, 11, 241, 59, 60, 1114, 1115, "P" +306, 8, 12, 242, 61, 62, 1116, 1117, "<" +306, 8, 13, 243, 63, 64, 1118, 1119, "." +306, 8, 14, 244, 65, 68, 1120, 1123, "001" +306, 8, 15, 245, 69, 70, 1124, 1125, ")" +306, 8, 16, 246, 71, 75, 1126, 1130, "mean" +306, 8, 17, 247, 76, 83, 1131, 1138, "changes" +306, 8, 18, 248, 84, 88, 1139, 1143, "from" +306, 8, 19, 249, 89, 97, 1144, 1152, "baseline" +306, 8, 20, 250, 98, 106, 1153, 1161, "relative" +306, 8, 21, 251, 107, 109, 1162, 1164, "to" +306, 8, 22, 252, 110, 117, 1165, 1172, "placebo" +306, 8, 23, 253, 118, 120, 1173, 1175, "in" +306, 8, 24, 254, 121, 126, 1176, 1181, "HbA1c" +306, 8, 25, 255, 127, 128, 1182, 1183, "(" +306, 8, 26, 256, 129, 130, 1184, 1185, "-" +306, 8, 27, 257, 131, 132, 1186, 1187, "0" +306, 8, 28, 258, 133, 134, 1188, 1189, "." +306, 8, 29, 259, 135, 136, 1190, 1191, "7" +306, 8, 30, 260, 137, 138, 1192, 1193, "%" +306, 8, 31, 261, 139, 140, 1194, 1195, ")" +306, 8, 32, 262, 141, 142, 1196, 1197, "," +306, 8, 33, 263, 143, 150, 1198, 1205, "fasting" +306, 8, 34, 264, 151, 157, 1206, 1212, "plasma" +306, 8, 35, 265, 158, 165, 1213, 1220, "glucose" +306, 8, 36, 266, 166, 167, 1221, 1222, "(" +306, 8, 37, 267, 168, 169, 1223, 1224, "-" +306, 8, 38, 268, 170, 171, 1225, 1226, "1" +306, 8, 39, 269, 172, 173, 1227, 1228, "." +306, 8, 40, 270, 174, 175, 1229, 1230, "0" +306, 8, 41, 271, 176, 180, 1231, 1235, "mmol" +306, 8, 42, 272, 181, 182, 1236, 1237, "/" +306, 8, 43, 273, 183, 184, 1238, 1239, "L" +306, 8, 44, 274, 185, 186, 1240, 1241, ")" +306, 8, 45, 275, 187, 188, 1242, 1243, "," +306, 8, 46, 276, 189, 192, 1244, 1247, "and" +306, 8, 47, 277, 193, 194, 1248, 1249, "2" +306, 8, 48, 278, 195, 196, 1250, 1251, "-" +306, 8, 49, 279, 197, 198, 1252, 1253, "h" +306, 8, 50, 280, 199, 203, 1254, 1258, "post" +306, 8, 51, 281, 204, 205, 1259, 1260, "-" +306, 8, 52, 282, 206, 210, 1261, 1265, "meal" +306, 8, 53, 283, 211, 218, 1266, 1273, "glucose" +306, 8, 54, 284, 219, 220, 1274, 1275, "(" +306, 8, 55, 285, 221, 222, 1276, 1277, "-" +306, 8, 56, 286, 223, 224, 1278, 1279, "2" +306, 8, 57, 287, 225, 226, 1280, 1281, "." +306, 8, 58, 288, 227, 228, 1282, 1283, "2" +306, 8, 59, 289, 229, 233, 1284, 1288, "mmol" +306, 8, 60, 290, 234, 235, 1289, 1290, "/" +306, 8, 61, 291, 236, 237, 1291, 1292, "L" +306, 8, 62, 292, 238, 239, 1293, 1294, ")" +306, 8, 63, 293, 240, 241, 1295, 1296, "." +306, 9, 1, 294, 0, 2, 1297, 1299, "In" +306, 9, 2, 295, 3, 11, 1300, 1308, "patients" +306, 9, 3, 296, 12, 16, 1309, 1313, "with" +306, 9, 4, 297, 17, 25, 1314, 1322, "baseline" +306, 9, 5, 298, 26, 31, 1323, 1328, "HbA1c" +306, 9, 6, 299, 32, 33, 1329, 1330, "≥" +306, 9, 7, 300, 34, 35, 1331, 1332, "9" +306, 9, 8, 301, 36, 37, 1333, 1334, "." +306, 9, 9, 302, 38, 39, 1335, 1336, "0" +306, 9, 10, 303, 40, 41, 1337, 1338, "%" +306, 9, 11, 304, 42, 43, 1339, 1340, "," +306, 9, 12, 305, 44, 48, 1341, 1345, "mean" +306, 9, 13, 306, 49, 56, 1346, 1353, "changes" +306, 9, 14, 307, 57, 61, 1354, 1358, "from" +306, 9, 15, 308, 62, 70, 1359, 1367, "baseline" +306, 9, 16, 309, 71, 73, 1368, 1370, "in" +306, 9, 17, 310, 74, 79, 1371, 1376, "HbA1c" +306, 9, 18, 311, 80, 84, 1377, 1381, "were" +306, 9, 19, 312, 85, 86, 1382, 1383, "-" +306, 9, 20, 313, 87, 88, 1384, 1385, "1" +306, 9, 21, 314, 89, 90, 1386, 1387, "." +306, 9, 22, 315, 91, 92, 1388, 1389, "6" +306, 9, 23, 316, 93, 94, 1390, 1391, "%" +306, 9, 24, 317, 95, 98, 1392, 1395, "and" +306, 9, 25, 318, 99, 100, 1396, 1397, "-" +306, 9, 26, 319, 101, 102, 1398, 1399, "0" +306, 9, 27, 320, 103, 104, 1400, 1401, "." +306, 9, 28, 321, 105, 106, 1402, 1403, "8" +306, 9, 29, 322, 107, 108, 1404, 1405, "%" +306, 9, 30, 323, 109, 112, 1406, 1409, "for" +306, 9, 31, 324, 113, 116, 1410, 1413, "the" +306, 9, 32, 325, 117, 128, 1414, 1425, "sitagliptin" +306, 9, 33, 326, 129, 132, 1426, 1429, "and" +306, 9, 34, 327, 133, 140, 1430, 1437, "placebo" +306, 9, 35, 328, 141, 147, 1438, 1444, "groups" +306, 9, 36, 329, 148, 149, 1445, 1446, "," +306, 9, 37, 330, 150, 162, 1447, 1459, "respectively" +306, 9, 38, 331, 163, 164, 1460, 1461, "(" +306, 9, 39, 332, 165, 172, 1462, 1469, "between" +306, 9, 40, 333, 173, 174, 1470, 1471, "-" +306, 9, 41, 334, 175, 180, 1472, 1477, "group" +306, 9, 42, 335, 181, 191, 1478, 1488, "difference" +306, 9, 43, 336, 192, 193, 1489, 1490, "-" +306, 9, 44, 337, 194, 195, 1491, 1492, "0" +306, 9, 45, 338, 196, 197, 1493, 1494, "." +306, 9, 46, 339, 198, 199, 1495, 1496, "8" +306, 9, 47, 340, 200, 201, 1497, 1498, "%" +306, 9, 48, 341, 202, 203, 1499, 1500, ";" +306, 9, 49, 342, 204, 205, 1501, 1502, "P" +306, 9, 50, 343, 206, 207, 1503, 1504, "<" +306, 9, 51, 344, 208, 209, 1505, 1506, "." +306, 9, 52, 345, 210, 213, 1507, 1510, "001" +306, 9, 53, 346, 214, 215, 1511, 1512, ")" +306, 9, 54, 347, 216, 217, 1513, 1514, "." +306, 10, 1, 348, 0, 3, 1515, 1518, "The" +306, 10, 2, 349, 4, 14, 1519, 1529, "incidences" +306, 10, 3, 350, 15, 17, 1530, 1532, "of" +306, 10, 4, 351, 18, 26, 1533, 1541, "reported" +306, 10, 5, 352, 27, 34, 1542, 1549, "adverse" +306, 10, 6, 353, 35, 41, 1550, 1556, "events" +306, 10, 7, 354, 42, 46, 1557, 1561, "were" +306, 10, 8, 355, 47, 56, 1562, 1571, "generally" +306, 10, 9, 356, 57, 64, 1572, 1579, "similar" +306, 10, 10, 357, 65, 72, 1580, 1587, "between" +306, 10, 11, 358, 73, 76, 1588, 1591, "the" +306, 10, 12, 359, 77, 86, 1592, 1601, "treatment" +306, 10, 13, 360, 87, 93, 1602, 1608, "groups" +306, 10, 14, 361, 94, 95, 1609, 1610, "." +306, 11, 1, 362, 0, 10, 1611, 1621, "Incidences" +306, 11, 2, 363, 11, 13, 1622, 1624, "of" +306, 11, 3, 364, 14, 25, 1625, 1636, "symptomatic" +306, 11, 4, 365, 26, 38, 1637, 1649, "hypoglycemia" +306, 11, 5, 366, 39, 43, 1650, 1654, "were" +306, 11, 6, 367, 44, 45, 1655, 1656, "7" +306, 11, 7, 368, 46, 47, 1657, 1658, "/" +306, 11, 8, 369, 48, 51, 1659, 1662, "157" +306, 11, 9, 370, 52, 53, 1663, 1664, "[" +306, 11, 10, 371, 54, 55, 1665, 1666, "4" +306, 11, 11, 372, 56, 57, 1667, 1668, "." +306, 11, 12, 373, 58, 59, 1669, 1670, "5" +306, 11, 13, 374, 60, 61, 1671, 1672, "%" +306, 11, 14, 375, 62, 63, 1673, 1674, "]" +306, 11, 15, 376, 64, 67, 1675, 1678, "and" +306, 11, 16, 377, 68, 69, 1679, 1680, "6" +306, 11, 17, 378, 70, 71, 1681, 1682, "/" +306, 11, 18, 379, 72, 75, 1683, 1686, "156" +306, 11, 19, 380, 76, 77, 1687, 1688, "[" +306, 11, 20, 381, 78, 79, 1689, 1690, "3" +306, 11, 21, 382, 80, 81, 1691, 1692, "." +306, 11, 22, 383, 82, 83, 1693, 1694, "8" +306, 11, 23, 384, 84, 85, 1695, 1696, "%" +306, 11, 24, 385, 86, 87, 1697, 1698, "]" +306, 11, 25, 386, 88, 90, 1699, 1701, "in" +306, 11, 26, 387, 91, 94, 1702, 1705, "the" +306, 11, 27, 388, 95, 106, 1706, 1717, "sitagliptin" +306, 11, 28, 389, 107, 110, 1718, 1721, "and" +306, 11, 29, 390, 111, 118, 1722, 1729, "placebo" +306, 11, 30, 391, 119, 125, 1730, 1736, "groups" +306, 11, 31, 392, 126, 127, 1737, 1738, "," +306, 11, 32, 393, 128, 140, 1739, 1751, "respectively" +306, 11, 33, 394, 141, 142, 1752, 1753, "(" +306, 11, 34, 395, 143, 144, 1754, 1755, "P" +306, 11, 35, 396, 145, 146, 1756, 1757, "=" +306, 11, 36, 397, 147, 148, 1758, 1759, "." +306, 11, 37, 398, 149, 152, 1760, 1763, "786" +306, 11, 38, 399, 153, 154, 1764, 1765, ")" +306, 11, 39, 400, 155, 156, 1766, 1767, "." +306, 12, 1, 401, 0, 3, 1768, 1771, "Two" +306, 12, 2, 402, 4, 12, 1772, 1780, "patients" +306, 12, 3, 403, 13, 14, 1781, 1782, "," +306, 12, 4, 404, 15, 19, 1783, 1787, "both" +306, 12, 5, 405, 20, 22, 1788, 1790, "in" +306, 12, 6, 406, 23, 26, 1791, 1794, "the" +306, 12, 7, 407, 27, 34, 1795, 1802, "placebo" +306, 12, 8, 408, 35, 40, 1803, 1808, "group" +306, 12, 9, 409, 41, 42, 1809, 1810, "," +306, 12, 10, 410, 43, 54, 1811, 1822, "experienced" +306, 12, 11, 411, 55, 57, 1823, 1825, "an" +306, 12, 12, 412, 58, 65, 1826, 1833, "episode" +306, 12, 13, 413, 66, 68, 1834, 1836, "of" +306, 12, 14, 414, 69, 81, 1837, 1849, "hypoglycemia" +306, 12, 15, 415, 82, 86, 1850, 1854, "that" +306, 12, 16, 416, 87, 95, 1855, 1863, "required" +306, 12, 17, 417, 96, 99, 1864, 1867, "non" +306, 12, 18, 418, 100, 101, 1868, 1869, "-" +306, 12, 19, 419, 102, 109, 1870, 1877, "medical" +306, 12, 20, 420, 110, 120, 1878, 1888, "assistance" +306, 12, 21, 421, 121, 122, 1889, 1890, "." +306, 13, 1, 422, 0, 11, 1891, 1902, "CONCLUSIONS" +306, 13, 2, 423, 12, 13, 1903, 1904, ":" +306, 13, 3, 424, 14, 16, 1905, 1907, "In" +306, 13, 4, 425, 17, 21, 1908, 1912, "this" +306, 13, 5, 426, 22, 24, 1913, 1915, "26" +306, 13, 6, 427, 25, 26, 1916, 1917, "-" +306, 13, 7, 428, 27, 31, 1918, 1922, "week" +306, 13, 8, 429, 32, 37, 1923, 1928, "study" +306, 13, 9, 430, 38, 39, 1929, 1930, "," +306, 13, 10, 431, 40, 48, 1931, 1939, "addition" +306, 13, 11, 432, 49, 51, 1940, 1942, "of" +306, 13, 12, 433, 52, 63, 1943, 1954, "sitagliptin" +306, 13, 13, 434, 64, 66, 1955, 1957, "to" +306, 13, 14, 435, 67, 78, 1958, 1969, "combination" +306, 13, 15, 436, 79, 86, 1970, 1977, "therapy" +306, 13, 16, 437, 87, 91, 1978, 1982, "with" +306, 13, 17, 438, 92, 101, 1983, 1992, "metformin" +306, 13, 18, 439, 102, 105, 1993, 1996, "and" +306, 13, 19, 440, 106, 118, 1997, 2009, "pioglitazone" +306, 13, 20, 441, 119, 127, 2010, 2018, "improved" +306, 13, 21, 442, 128, 136, 2019, 2027, "glycemic" +306, 13, 22, 443, 137, 144, 2028, 2035, "control" +306, 13, 23, 444, 145, 148, 2036, 2039, "and" +306, 13, 24, 445, 149, 152, 2040, 2043, "was" +306, 13, 25, 446, 153, 162, 2044, 2053, "generally" +306, 13, 26, 447, 163, 167, 2054, 2058, "well" +306, 13, 27, 448, 168, 177, 2059, 2068, "tolerated" +306, 13, 28, 449, 178, 179, 2069, 2070, "." +306, 14, 1, 450, 0, 9, 2071, 2080, "Copyright" +306, 14, 2, 451, 10, 11, 2081, 2082, "©" +306, 14, 3, 452, 12, 16, 2083, 2087, "2013" +306, 14, 4, 453, 17, 25, 2088, 2096, "Elsevier" +306, 14, 5, 454, 26, 29, 2097, 2100, "Inc" +306, 14, 6, 455, 30, 31, 2101, 2102, "." +306, 14, 7, 456, 32, 35, 2103, 2106, "All" +306, 14, 8, 457, 36, 42, 2107, 2113, "rights" +306, 14, 9, 458, 43, 51, 2114, 2122, "reserved" +306, 14, 10, 459, 52, 53, 2123, 2124, "." +306, 15, 1, 460, 0, 3, 2125, 2128, "DOI" +306, 15, 2, 461, 4, 5, 2129, 2130, ":" +306, 15, 3, 462, 6, 8, 2131, 2133, "10" +306, 15, 4, 463, 9, 10, 2134, 2135, "." +306, 15, 5, 464, 11, 15, 2136, 2140, "1016" +306, 15, 6, 465, 16, 17, 2141, 2142, "/" +306, 15, 7, 466, 18, 19, 2143, 2144, "j" +306, 15, 8, 467, 20, 21, 2145, 2146, "." +306, 15, 9, 468, 22, 30, 2147, 2155, "jdiacomp" +306, 15, 10, 469, 31, 32, 2156, 2157, "." +306, 15, 11, 470, 33, 37, 2158, 2162, "2012" +306, 15, 12, 471, 38, 39, 2163, 2164, "." +306, 15, 13, 472, 40, 42, 2165, 2167, "09" +306, 15, 14, 473, 43, 44, 2168, 2169, "." +306, 15, 15, 474, 45, 48, 2170, 2173, "007" +306, 15, 16, 475, 49, 53, 2174, 2178, "PMID" +306, 15, 17, 476, 54, 55, 2179, 2180, ":" +306, 15, 18, 477, 56, 64, 2181, 2189, "23116881" +306, 15, 19, 478, 65, 66, 2190, 2191, "[" +306, 15, 20, 479, 67, 74, 2192, 2199, "Indexed" +306, 15, 21, 480, 75, 78, 2200, 2203, "for" +306, 15, 22, 481, 79, 86, 2204, 2211, "MEDLINE" +306, 15, 23, 482, 87, 88, 2212, 2213, "]" diff --git a/data/dm2 23116881_kwoodley.annodb b/data/dm2 23116881_kwoodley.annodb new file mode 100644 index 0000000..2de484c --- /dev/null +++ b/data/dm2 23116881_kwoodley.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +27578, Journal, 0, 26, "J Diabetes Complications .", "", +27579, PublicationYear, 27, 31, "2013", "", +27602, Title, 136, 326, "Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized , placebo - controlled , 26 - week trial in patients with type 2 diabetes .", "", +27580, Sitagliptin, 159, 170, "sitagliptin", "", +27587, Metformin, 188, 197, "metformin", "", +27590, Pioglitazone, 202, 214, "pioglitazone", "", +27593, Randomized, 240, 250, "randomized", "", +27594, Placebo, 253, 260, "placebo", "", +27600, Duration, 276, 285, "26 - week", "", +27601, Type2Diabetes, 309, 324, "type 2 diabetes", "", +27621, Author, 327, 336, "Fonseca V", "", +27622, Author, 345, 353, "Staels B", "", +27623, Author, 356, 369, "Morgan JD 2nd", "", +27624, Author, 372, 380, "Shentu Y", "", +27625, Author, 383, 390, "Golm GT", "", +27626, Author, 393, 413, "Johnson - Levonas AO", "", +27627, Author, 416, 426, "Kaufman KD", "", +27628, Author, 429, 441, "Goldstein BJ", "", +27629, Author, 444, 455, "Steinberg H", "", +27630, USA, 539, 542, "USA", "", +27619, ObjectiveDescription, 552, 730, "To assess efficacy and safety of sitagliptin , a dipeptidyl peptidase - 4 inhibitor , in combination therapy with metformin ( ≥ 1500 mg / day ) and pioglitazone ( ≥ 30 mg / day )", "", +27581, Sitagliptin, 585, 596, "sitagliptin", "", +27588, Metformin, 666, 675, "metformin", "", +27603, DoseValue, 678, 684, "≥ 1500", "", +27606, mg, 685, 687, "mg", "", +27609, Frequency, 690, 693, "day", "", +27592, Pioglitazone, 700, 712, "pioglitazone", "", +27604, DoseValue, 715, 719, "≥ 30", "", +27607, mg, 720, 722, "mg", "", +27610, Frequency, 725, 728, "day", "", +27620, ObjectiveDescription, 731, 857, "in patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % ) .", "", +27618, Precondition, 734, 855, "patients with type 2 diabetes ( T2DM ) with inadequate glycemic control ( hemoglobin A1c [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", +27612, Type2Diabetes, 748, 763, "type 2 diabetes", "", +27613, Type2Diabetes, 766, 770, "T2DM", "", +27614, HbA1c, 808, 822, "hemoglobin A1c", "", +27615, HbA1c, 825, 830, "HbA1c", "", +27616, Percentage, 841, 842, "%", "", +27617, Percentage, 852, 853, "%", "", +27595, Placebo, 873, 880, "placebo", "", +27631, DoubleBlind, 896, 910, "double - blind", "", +27632, NumberPatientsCT, 926, 929, "313", "", +27633, HbA1c, 955, 960, "HbA1c", "", +27634, BaseLineValue, 963, 968, "8 . 7", "", +27635, Percentage, 969, 970, "%", "", +27636, Randomized, 982, 992, "randomized", "", +27582, Sitagliptin, 1004, 1015, "sitagliptin", "", +27605, DoseValue, 1016, 1019, "100", "", +27608, mg, 1020, 1022, "mg", "", +27611, Frequency, 1025, 1028, "day", "", +27596, Placebo, 1032, 1039, "placebo", "", +27637, Duration, 1044, 1052, "26 weeks", "", +27583, Sitagliptin, 1081, 1092, "sitagliptin", "", +27638, PValueChangeValue, 1114, 1123, "P < . 001", "", +27639, Placebo, 1165, 1172, "placebo", "", +27640, HbA1c, 1176, 1181, "HbA1c", "", +27646, Reduction, 1186, 1191, "0 . 7", "", +27645, Percentage, 1192, 1193, "%", "", +27641, FastingPlasmaGlucose, 1198, 1220, "fasting plasma glucose", "", +27647, Reduction, 1225, 1230, "1 . 0", "", +27644, Millimoles_per_litre, 1231, 1239, "mmol / L", "", +33160, PostprandialBloodGlucose, 1248, 1273, "2 - h post - meal glucose", "", +27648, Reduction, 1278, 1283, "2 . 2", "", +27643, Millimoles_per_litre, 1284, 1292, "mmol / L", "", +27650, SubGroupDescription, 1300, 1338, "patients with baseline HbA1c ≥ 9 . 0 %", "", +27649, HbA1c, 1323, 1328, "HbA1c", "", +27652, Percentage, 1337, 1338, "%", "", +27653, HbA1c, 1371, 1376, "HbA1c", "", +27654, Reduction, 1384, 1389, "1 . 6", "", +27656, Percentage, 1390, 1391, "%", "", +27655, Reduction, 1398, 1403, "0 . 8", "", +27657, Percentage, 1404, 1405, "%", "", +27584, Sitagliptin, 1414, 1425, "sitagliptin", "", +27598, Placebo, 1430, 1437, "placebo", "", +27658, DiffGroupAbsValue, 1489, 1496, "- 0 . 8", "", +27659, Percentage, 1497, 1498, "%", "", +27660, PvalueDiff, 1501, 1510, "P < . 001", "", +27662, ObservedResult, 1515, 1610, "The incidences of reported adverse events were generally similar between the treatment groups .", "", +27665, SymptomaticHypoglycemia, 1625, 1649, "symptomatic hypoglycemia", "", +27669, NumberAffected, 1655, 1656, "7", "", +27671, NumberPatientsArm, 1659, 1662, "157", "", +27667, PercentageAffected, 1665, 1670, "4 . 5", "", +27670, NumberAffected, 1679, 1680, "6", "", +27672, NumberPatientsArm, 1683, 1686, "156", "", +27668, PercentageAffected, 1689, 1694, "3 . 8", "", +27585, Sitagliptin, 1706, 1717, "sitagliptin", "", +27597, Placebo, 1722, 1729, "placebo", "", +27666, PvalueDiff, 1754, 1763, "P = . 786", "", +27663, NumberAffected, 1768, 1771, "Two", "", +27599, Placebo, 1795, 1802, "placebo", "", +27664, Hypoglycemia, 1837, 1849, "hypoglycemia", "", +27673, Duration, 1913, 1922, "26 - week", "", +27586, Sitagliptin, 1943, 1954, "sitagliptin", "", +27589, Metformin, 1983, 1992, "metformin", "", +27591, Pioglitazone, 1997, 2009, "pioglitazone", "", +27674, PMID, 2181, 2189, "23116881", "", diff --git a/data/dm2 23116881_kwoodley.n-triples b/data/dm2 23116881_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23116881_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23160726_admin.annodb b/data/dm2 23160726_admin.annodb new file mode 100644 index 0000000..3473fa9 --- /dev/null +++ b/data/dm2 23160726_admin.annodb @@ -0,0 +1,70 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +67, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2013", "", " \"2013\"." +23, Title, 99, 241, "The efficacy and safety of imeglimin as add - on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy .", "", " \"The efficacy and safety of imeglimin as add - on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy .\"." +2, Drug, 126, 135, "imeglimin", "", +21, Precondition, 159, 239, "patients with type 2 diabetes inadequately controlled with metformin monotherapy", "", " \"patients with type 2 diabetes inadequately controlled with metformin monotherapy\"." +9, Type2Diabetes, 173, 188, "type 2 diabetes", "", " ." +12, Metformin, 218, 227, "metformin", "", +24, Author, 242, 253, "Fouqueray P", "", " \"Fouqueray P\"." +25, Author, 262, 270, "Pirags V", "", " \"Pirags V\"." +26, Author, 273, 284, "Inzucchi SE", "", " \"Inzucchi SE\"." +27, Author, 287, 296, "Bailey CJ", "", " \"Bailey CJ\"." +28, Author, 299, 313, "Schernthaner G", "", " \"Schernthaner G\"." +29, Author, 316, 325, "Diamant M", "", " \"Diamant M\"." +30, Author, 328, 339, "Lebovitz HE", "", " \"Lebovitz HE\"." +66, France, 387, 393, "France", "", " ." +34, ObjectiveDescription, 448, 640, "A 12 - week study assessed the efficacy and safety of a new oral antidiabetic agent , imeglimin , as add - on therapy in type 2 diabetes patients inadequately controlled with metformin alone .", "", " \"A 12 - week study assessed the efficacy and safety of a new oral antidiabetic agent , imeglimin , as add - on therapy in type 2 diabetes patients inadequately controlled with metformin alone .\"." +31, Duration, 450, 459, "12 - week", "", " \"12 - week\"." +33, OralAntidiabeticAgent, 508, 531, "oral antidiabetic agent", "", +3, Drug, 534, 543, "imeglimin", "", +10, Type2Diabetes, 569, 584, "type 2 diabetes", "", +22, Precondition, 569, 638, "type 2 diabetes patients inadequately controlled with metformin alone", "", " \"type 2 diabetes patients inadequately controlled with metformin alone\"." +13, Metformin, 623, 632, "metformin", "", +35, NumberPatientsCT, 682, 685, "156", "", " \"156\"." +36, Randomized, 700, 710, "randomized", "", " ." +37, AllocationRatio, 711, 716, "1 : 1", "", " . ." +4, Drug, 728, 737, "imeglimin", "", " . ." +38, DoseValue, 740, 747, "1 , 500", "", " \"1 , 500\"." +39, mg, 748, 750, "mg", "", " ." +40, Frequency, 751, 762, "twice a day", "", " \"twice a day\"." +41, Placebo, 768, 775, "placebo", "", " ." +14, Metformin, 802, 811, "metformin", "", +42, DoseValue, 814, 831, "1 , 500 - 2 , 000", "", +43, mg, 832, 834, "mg", "", +44, Frequency, 837, 840, "day", "", +45, HbA1c, 855, 858, "A1C", "", +93, TimePoint, 864, 872, "baseline", "", +46, FastingPlasmaGlucose, 936, 958, "fasting plasma glucose", "", +47, FastingPlasmaGlucose, 961, 964, "FPG", "", +48, EndPointDescription, 971, 997, "proinsulin / insulin ratio", "", +102, TimePoint, 1016, 1024, "12 weeks", "", +49, Placebo, 1031, 1038, "placebo", "", +52, HbA1c, 1064, 1067, "A1C", "", " ." +15, Metformin, 1073, 1082, "metformin", "", +5, Drug, 1085, 1094, "imeglimin", "", +53, Reduction, 1101, 1107, "0 . 44", "", " ." +54, Percentage, 1108, 1109, "%", "", " ." +55, PValueChangeValue, 1112, 1123, "P < 0 . 001", "", " \"P < 0 . 001\"." +16, Metformin, 1128, 1137, "Metformin", "", +6, Drug, 1140, 1149, "imeglimin", "", +56, FastingPlasmaGlucose, 1178, 1181, "FPG", "", " ." +57, EndPointDescription, 1190, 1216, "proinsulin / insulin ratio", "", " . ." +114, TimePoint, 1222, 1230, "baseline", "", +58, Reduction, 1235, 1241, "0 . 91", "", " \"0 . 91\"." +59, Mg_per_deciliter, 1242, 1249, "mg / dL", "", " ." +60, Reduction, 1256, 1261, "7 . 5", "", " \"7 . 5\"." +19, Metformin, 1293, 1302, "metformin", "", +50, Placebo, 1305, 1312, "placebo", "", +61, Increment, 1315, 1321, "0 . 36", "", " \"0 . 36\"." +62, Mg_per_deciliter, 1322, 1329, "mg / dL", "", +63, Increment, 1334, 1341, "11 . 81", "", " \"11 . 81\"." +17, Metformin, 1346, 1355, "Metformin", "", +7, Drug, 1358, 1367, "imeglimin", "", +18, Metformin, 1443, 1452, "metformin", "", +51, Placebo, 1455, 1462, "placebo", "", +64, ConclusionComment, 1479, 1601, "Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes .", "", " \"Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes .\"." +8, Drug, 1491, 1500, "imeglimin", "", +20, Metformin, 1504, 1513, "metformin", "", +11, Type2Diabetes, 1584, 1599, "type 2 diabetes", "", +65, PMID, 1658, 1666, "23160726", "", " \"23160726\"." diff --git a/data/dm2 23160726_admin.n-triples b/data/dm2 23160726_admin.n-triples new file mode 100644 index 0000000..f4d6363 --- /dev/null +++ b/data/dm2 23160726_admin.n-triples @@ -0,0 +1,121 @@ +# RDF export of group: Publication + . + "Publication 41231" . + "The efficacy and safety of imeglimin as add - on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy ." . + "Fouqueray P" . + "2013" . + "Diabetes Care" . + "23160726" . + . + "Pirags V" . + "Inzucchi SE" . + "Bailey CJ" . + "Schernthaner G" . + "Diamant M" . + "Lebovitz HE" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 41238" . + "A 12 - week study assessed the efficacy and safety of a new oral antidiabetic agent , imeglimin , as add - on therapy in type 2 diabetes patients inadequately controlled with metformin alone ." . + "156" . + "12 - week" . + . + . + . + . + "Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes ." . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 41254" . + "patients with type 2 diabetes inadequately controlled with metformin monotherapy" . + . + . + . + "type 2 diabetes patients inadequately controlled with metformin alone" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "rat" . + . + . + . + . + . +# RDF export of group: Arm + . + "im" . + . + . + . + . + . + . + "pla" . + . + . + . + . +# RDF export of group: Intervention + . + "im " . + . + "twice a day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "im" . + . + . + "1 , 500" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "0 . 44" . + "P < 0 . 001" . + . + "fpg 1" . + . + "0 . 91" . + . + "fpg 2" . + . + "0 . 36" . + . + "rat 1" . + . + "7 . 5" . + . + "rat 2" . + . + "11 . 81" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23160726_akramersunderbrink.annodb b/data/dm2 23160726_akramersunderbrink.annodb new file mode 100644 index 0000000..20a1670 --- /dev/null +++ b/data/dm2 23160726_akramersunderbrink.annodb @@ -0,0 +1,66 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42797, Journal, 0, 13, "Diabetes Care", "", +42798, PublicationYear, 16, 20, "2013", "", +42803, Title, 99, 241, "The efficacy and safety of imeglimin as add - on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy .", "", +42799, Drug, 126, 135, "imeglimin", "", +42800, Type2Diabetes, 173, 188, "type 2 diabetes", "", +42802, Precondition, 189, 239, "inadequately controlled with metformin monotherapy", "", +42801, Metformin, 218, 227, "metformin", "", +42804, Author, 242, 253, "Fouqueray P", "", +42805, Author, 262, 270, "Pirags V", "", +42806, Author, 273, 284, "Inzucchi SE", "", +42807, Author, 287, 296, "Bailey CJ", "", +42808, Author, 299, 313, "Schernthaner G", "", +42809, Author, 316, 325, "Diamant M", "", +42810, Author, 328, 339, "Lebovitz HE", "", +42811, France, 387, 393, "France", "", +42812, Duration, 448, 459, "A 12 - week", "", +42817, ObjectiveDescription, 450, 640, "12 - week study assessed the efficacy and safety of a new oral antidiabetic agent , imeglimin , as add - on therapy in type 2 diabetes patients inadequately controlled with metformin alone .", "", +42813, Drug, 534, 543, "imeglimin", "", +42814, Type2Diabetes, 569, 584, "type 2 diabetes", "", +42815, Precondition, 594, 638, "inadequately controlled with metformin alone", "", +42816, Metformin, 623, 632, "metformin", "", +42818, NumberPatientsCT, 682, 685, "156", "", +42819, Randomized, 700, 710, "randomized", "", +42820, Drug, 728, 737, "imeglimin", "", +42821, DoseValue, 740, 750, "1 , 500 mg", "", +42822, Frequency, 751, 762, "twice a day", "", +43229, Placebo, 768, 775, "placebo", "", +43230, Metformin, 802, 811, "metformin", "", +43231, DoseValue, 814, 840, "1 , 500 - 2 , 000 mg / day", "", +43232, BioAndMedicalUnit, 832, 840, "mg / day", "", +43233, HbA1c, 855, 858, "A1C", "", +42844, TimePoint, 864, 872, "baseline", "", +43234, FastingPlasmaGlucose, 936, 958, "fasting plasma glucose", "", +43235, FastingPlasmaGlucose, 961, 964, "FPG", "", +43236, EndPointDescription, 971, 997, "proinsulin / insulin ratio", "", +43237, TimePoint, 1016, 1024, "12 weeks", "", +43238, Placebo, 1031, 1038, "placebo", "", +43239, HbA1c, 1064, 1067, "A1C", "", +43244, Metformin, 1073, 1082, "metformin", "", +43245, Drug, 1085, 1094, "imeglimin", "", +43240, ChangeValue, 1099, 1107, "- 0 . 44", "", +43241, Percentage, 1108, 1109, "%", "", +43242, PValueChangeValue, 1112, 1123, "P < 0 . 001", "", +43243, Metformin, 1128, 1137, "Metformin", "", +43246, Drug, 1140, 1149, "imeglimin", "", +43247, FastingPlasmaGlucose, 1178, 1181, "FPG", "", +43249, EndPointDescription, 1190, 1216, "proinsulin / insulin ratio", "", +43251, TimePoint, 1222, 1230, "baseline", "", +43252, ChangeValue, 1233, 1241, "- 0 . 91", "", +43254, ConcentrationUnit, 1242, 1249, "mg / dL", "", +43253, ChangeValue, 1254, 1261, "- 7 . 5", "", +43255, Metformin, 1293, 1302, "metformin", "", +43256, Placebo, 1305, 1312, "placebo", "", +43257, ChangeValue, 1315, 1321, "0 . 36", "", +43259, ConcentrationUnit, 1322, 1329, "mg / dL", "", +43258, ChangeValue, 1334, 1341, "11 . 81", "", +43260, Metformin, 1346, 1355, "Metformin", "", +43261, Drug, 1358, 1367, "imeglimin", "", +43262, Metformin, 1443, 1452, "metformin", "", +43263, Placebo, 1455, 1462, "placebo", "", +43268, ConclusionComment, 1479, 1601, "Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes .", "", +43264, Drug, 1491, 1500, "imeglimin", "", +43265, Metformin, 1504, 1513, "metformin", "", +43266, Type2Diabetes, 1584, 1599, "type 2 diabetes", "", +43267, PMID, 1658, 1666, "23160726", "", diff --git a/data/dm2 23160726_akramersunderbrink.n-triples b/data/dm2 23160726_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23160726_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23160726_export.csv b/data/dm2 23160726_export.csv new file mode 100644 index 0000000..97996de --- /dev/null +++ b/data/dm2 23160726_export.csv @@ -0,0 +1,351 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +305, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +305, 1, 2, 2, 9, 13, 9, 13, "Care" +305, 1, 3, 3, 14, 15, 14, 15, "." +305, 2, 1, 4, 0, 4, 16, 20, "2013" +305, 2, 2, 5, 5, 8, 21, 24, "Mar" +305, 2, 3, 6, 9, 10, 25, 26, ";" +305, 2, 4, 7, 11, 13, 27, 29, "36" +305, 2, 5, 8, 14, 15, 30, 31, "(" +305, 2, 6, 9, 16, 17, 32, 33, "3" +305, 2, 7, 10, 18, 19, 34, 35, ")" +305, 2, 8, 11, 20, 21, 36, 37, ":" +305, 2, 9, 12, 22, 25, 38, 41, "565" +305, 2, 10, 13, 26, 27, 42, 43, "-" +305, 2, 11, 14, 28, 29, 44, 45, "8" +305, 2, 12, 15, 30, 31, 46, 47, "." +305, 2, 13, 16, 32, 35, 48, 51, "doi" +305, 2, 14, 17, 36, 37, 52, 53, ":" +305, 2, 15, 18, 38, 40, 54, 56, "10" +305, 2, 16, 19, 41, 42, 57, 58, "." +305, 2, 17, 20, 43, 47, 59, 63, "2337" +305, 2, 18, 21, 48, 49, 64, 65, "/" +305, 2, 19, 22, 50, 54, 66, 70, "dc12" +305, 2, 20, 23, 55, 56, 71, 72, "-" +305, 2, 21, 24, 57, 61, 73, 77, "0453" +305, 2, 22, 25, 62, 63, 78, 79, "." +305, 3, 1, 26, 0, 4, 80, 84, "Epub" +305, 3, 2, 27, 5, 9, 85, 89, "2012" +305, 3, 3, 28, 10, 13, 90, 93, "Nov" +305, 3, 4, 29, 14, 16, 94, 96, "16" +305, 3, 5, 30, 17, 18, 97, 98, "." +305, 4, 1, 31, 0, 3, 99, 102, "The" +305, 4, 2, 32, 4, 12, 103, 111, "efficacy" +305, 4, 3, 33, 13, 16, 112, 115, "and" +305, 4, 4, 34, 17, 23, 116, 122, "safety" +305, 4, 5, 35, 24, 26, 123, 125, "of" +305, 4, 6, 36, 27, 36, 126, 135, "imeglimin" +305, 4, 7, 37, 37, 39, 136, 138, "as" +305, 4, 8, 38, 40, 43, 139, 142, "add" +305, 4, 9, 39, 44, 45, 143, 144, "-" +305, 4, 10, 40, 46, 48, 145, 147, "on" +305, 4, 11, 41, 49, 56, 148, 155, "therapy" +305, 4, 12, 42, 57, 59, 156, 158, "in" +305, 4, 13, 43, 60, 68, 159, 167, "patients" +305, 4, 14, 44, 69, 73, 168, 172, "with" +305, 4, 15, 45, 74, 78, 173, 177, "type" +305, 4, 16, 46, 79, 80, 178, 179, "2" +305, 4, 17, 47, 81, 89, 180, 188, "diabetes" +305, 4, 18, 48, 90, 102, 189, 201, "inadequately" +305, 4, 19, 49, 103, 113, 202, 212, "controlled" +305, 4, 20, 50, 114, 118, 213, 217, "with" +305, 4, 21, 51, 119, 128, 218, 227, "metformin" +305, 4, 22, 52, 129, 140, 228, 239, "monotherapy" +305, 4, 23, 53, 141, 142, 240, 241, "." +305, 5, 1, 54, 0, 9, 242, 251, "Fouqueray" +305, 5, 2, 55, 10, 11, 252, 253, "P" +305, 5, 3, 56, 12, 13, 254, 255, "(" +305, 5, 4, 57, 14, 15, 256, 257, "1" +305, 5, 5, 58, 16, 17, 258, 259, ")" +305, 5, 6, 59, 18, 19, 260, 261, "," +305, 5, 7, 60, 20, 26, 262, 268, "Pirags" +305, 5, 8, 61, 27, 28, 269, 270, "V" +305, 5, 9, 62, 29, 30, 271, 272, "," +305, 5, 10, 63, 31, 39, 273, 281, "Inzucchi" +305, 5, 11, 64, 40, 42, 282, 284, "SE" +305, 5, 12, 65, 43, 44, 285, 286, "," +305, 5, 13, 66, 45, 51, 287, 293, "Bailey" +305, 5, 14, 67, 52, 54, 294, 296, "CJ" +305, 5, 15, 68, 55, 56, 297, 298, "," +305, 5, 16, 69, 57, 69, 299, 311, "Schernthaner" +305, 5, 17, 70, 70, 71, 312, 313, "G" +305, 5, 18, 71, 72, 73, 314, 315, "," +305, 5, 19, 72, 74, 81, 316, 323, "Diamant" +305, 5, 20, 73, 82, 83, 324, 325, "M" +305, 5, 21, 74, 84, 85, 326, 327, "," +305, 5, 22, 75, 86, 94, 328, 336, "Lebovitz" +305, 5, 23, 76, 95, 97, 337, 339, "HE" +305, 5, 24, 77, 98, 99, 340, 341, "." +305, 6, 1, 78, 0, 6, 342, 348, "Author" +305, 6, 2, 79, 7, 18, 349, 360, "information" +305, 6, 3, 80, 19, 20, 361, 362, ":" +305, 6, 4, 81, 21, 22, 363, 364, "(" +305, 6, 5, 82, 23, 24, 365, 366, "1" +305, 6, 6, 83, 25, 26, 367, 368, ")" +305, 6, 7, 84, 27, 32, 369, 374, "Poxel" +305, 6, 8, 85, 33, 35, 375, 377, "SA" +305, 6, 9, 86, 36, 37, 378, 379, "," +305, 6, 10, 87, 38, 42, 380, 384, "Lyon" +305, 6, 11, 88, 43, 44, 385, 386, "," +305, 6, 12, 89, 45, 51, 387, 393, "France" +305, 6, 13, 90, 52, 53, 394, 395, "." +305, 7, 1, 91, 0, 7, 396, 403, "pascale" +305, 7, 2, 92, 8, 9, 404, 405, "." +305, 7, 3, 93, 10, 19, 406, 415, "fouqueray" +305, 7, 4, 94, 20, 21, 416, 417, "@" +305, 7, 5, 95, 22, 33, 418, 429, "poxelpharma" +305, 7, 6, 96, 34, 35, 430, 431, "." +305, 7, 7, 97, 36, 39, 432, 435, "com" +305, 7, 8, 98, 40, 49, 436, 445, "OBJECTIVE" +305, 7, 9, 99, 50, 51, 446, 447, ":" +305, 7, 10, 100, 52, 53, 448, 449, "A" +305, 7, 11, 101, 54, 56, 450, 452, "12" +305, 7, 12, 102, 57, 58, 453, 454, "-" +305, 7, 13, 103, 59, 63, 455, 459, "week" +305, 7, 14, 104, 64, 69, 460, 465, "study" +305, 7, 15, 105, 70, 78, 466, 474, "assessed" +305, 7, 16, 106, 79, 82, 475, 478, "the" +305, 7, 17, 107, 83, 91, 479, 487, "efficacy" +305, 7, 18, 108, 92, 95, 488, 491, "and" +305, 7, 19, 109, 96, 102, 492, 498, "safety" +305, 7, 20, 110, 103, 105, 499, 501, "of" +305, 7, 21, 111, 106, 107, 502, 503, "a" +305, 7, 22, 112, 108, 111, 504, 507, "new" +305, 7, 23, 113, 112, 116, 508, 512, "oral" +305, 7, 24, 114, 117, 129, 513, 525, "antidiabetic" +305, 7, 25, 115, 130, 135, 526, 531, "agent" +305, 7, 26, 116, 136, 137, 532, 533, "," +305, 7, 27, 117, 138, 147, 534, 543, "imeglimin" +305, 7, 28, 118, 148, 149, 544, 545, "," +305, 7, 29, 119, 150, 152, 546, 548, "as" +305, 7, 30, 120, 153, 156, 549, 552, "add" +305, 7, 31, 121, 157, 158, 553, 554, "-" +305, 7, 32, 122, 159, 161, 555, 557, "on" +305, 7, 33, 123, 162, 169, 558, 565, "therapy" +305, 7, 34, 124, 170, 172, 566, 568, "in" +305, 7, 35, 125, 173, 177, 569, 573, "type" +305, 7, 36, 126, 178, 179, 574, 575, "2" +305, 7, 37, 127, 180, 188, 576, 584, "diabetes" +305, 7, 38, 128, 189, 197, 585, 593, "patients" +305, 7, 39, 129, 198, 210, 594, 606, "inadequately" +305, 7, 40, 130, 211, 221, 607, 617, "controlled" +305, 7, 41, 131, 222, 226, 618, 622, "with" +305, 7, 42, 132, 227, 236, 623, 632, "metformin" +305, 7, 43, 133, 237, 242, 633, 638, "alone" +305, 7, 44, 134, 243, 244, 639, 640, "." +305, 8, 1, 135, 0, 8, 641, 649, "RESEARCH" +305, 8, 2, 136, 9, 15, 650, 656, "DESIGN" +305, 8, 3, 137, 16, 19, 657, 660, "AND" +305, 8, 4, 138, 20, 27, 661, 668, "METHODS" +305, 8, 5, 139, 28, 29, 669, 670, ":" +305, 8, 6, 140, 30, 31, 671, 672, "A" +305, 8, 7, 141, 32, 37, 673, 678, "total" +305, 8, 8, 142, 38, 40, 679, 681, "of" +305, 8, 9, 143, 41, 44, 682, 685, "156" +305, 8, 10, 144, 45, 53, 686, 694, "patients" +305, 8, 11, 145, 54, 58, 695, 699, "were" +305, 8, 12, 146, 59, 69, 700, 710, "randomized" +305, 8, 13, 147, 70, 71, 711, 712, "1" +305, 8, 14, 148, 72, 73, 713, 714, ":" +305, 8, 15, 149, 74, 75, 715, 716, "1" +305, 8, 16, 150, 76, 78, 717, 719, "to" +305, 8, 17, 151, 79, 86, 720, 727, "receive" +305, 8, 18, 152, 87, 96, 728, 737, "imeglimin" +305, 8, 19, 153, 97, 98, 738, 739, "(" +305, 8, 20, 154, 99, 100, 740, 741, "1" +305, 8, 21, 155, 101, 102, 742, 743, "," +305, 8, 22, 156, 103, 106, 744, 747, "500" +305, 8, 23, 157, 107, 109, 748, 750, "mg" +305, 8, 24, 158, 110, 115, 751, 756, "twice" +305, 8, 25, 159, 116, 117, 757, 758, "a" +305, 8, 26, 160, 118, 121, 759, 762, "day" +305, 8, 27, 161, 122, 123, 763, 764, ")" +305, 8, 28, 162, 124, 126, 765, 767, "or" +305, 8, 29, 163, 127, 134, 768, 775, "placebo" +305, 8, 30, 164, 135, 140, 776, 781, "added" +305, 8, 31, 165, 141, 143, 782, 784, "to" +305, 8, 32, 166, 144, 145, 785, 786, "a" +305, 8, 33, 167, 146, 152, 787, 793, "stable" +305, 8, 34, 168, 153, 157, 794, 798, "dose" +305, 8, 35, 169, 158, 160, 799, 801, "of" +305, 8, 36, 170, 161, 170, 802, 811, "metformin" +305, 8, 37, 171, 171, 172, 812, 813, "(" +305, 8, 38, 172, 173, 174, 814, 815, "1" +305, 8, 39, 173, 175, 176, 816, 817, "," +305, 8, 40, 174, 177, 180, 818, 821, "500" +305, 8, 41, 175, 181, 182, 822, 823, "-" +305, 8, 42, 176, 183, 184, 824, 825, "2" +305, 8, 43, 177, 185, 186, 826, 827, "," +305, 8, 44, 178, 187, 190, 828, 831, "000" +305, 8, 45, 179, 191, 193, 832, 834, "mg" +305, 8, 46, 180, 194, 195, 835, 836, "/" +305, 8, 47, 181, 196, 199, 837, 840, "day" +305, 8, 48, 182, 200, 201, 841, 842, ")" +305, 8, 49, 183, 202, 203, 843, 844, "." +305, 9, 1, 184, 0, 6, 845, 851, "Change" +305, 9, 2, 185, 7, 9, 852, 854, "in" +305, 9, 3, 186, 10, 13, 855, 858, "A1C" +305, 9, 4, 187, 14, 18, 859, 863, "from" +305, 9, 5, 188, 19, 27, 864, 872, "baseline" +305, 9, 6, 189, 28, 31, 873, 876, "was" +305, 9, 7, 190, 32, 35, 877, 880, "the" +305, 9, 8, 191, 36, 43, 881, 888, "primary" +305, 9, 9, 192, 44, 52, 889, 897, "efficacy" +305, 9, 10, 193, 53, 60, 898, 905, "outcome" +305, 9, 11, 194, 61, 62, 906, 907, ";" +305, 9, 12, 195, 63, 72, 908, 917, "secondary" +305, 9, 13, 196, 73, 81, 918, 926, "outcomes" +305, 9, 14, 197, 82, 90, 927, 935, "included" +305, 9, 15, 198, 91, 98, 936, 943, "fasting" +305, 9, 16, 199, 99, 105, 944, 950, "plasma" +305, 9, 17, 200, 106, 113, 951, 958, "glucose" +305, 9, 18, 201, 114, 115, 959, 960, "(" +305, 9, 19, 202, 116, 119, 961, 964, "FPG" +305, 9, 20, 203, 120, 121, 965, 966, ")" +305, 9, 21, 204, 122, 125, 967, 970, "and" +305, 9, 22, 205, 126, 136, 971, 981, "proinsulin" +305, 9, 23, 206, 137, 138, 982, 983, "/" +305, 9, 24, 207, 139, 146, 984, 991, "insulin" +305, 9, 25, 208, 147, 152, 992, 997, "ratio" +305, 9, 26, 209, 153, 154, 998, 999, "." +305, 10, 1, 210, 0, 7, 1000, 1007, "RESULTS" +305, 10, 2, 211, 8, 9, 1008, 1009, ":" +305, 10, 3, 212, 10, 15, 1010, 1015, "After" +305, 10, 4, 213, 16, 18, 1016, 1018, "12" +305, 10, 5, 214, 19, 24, 1019, 1024, "weeks" +305, 10, 6, 215, 25, 26, 1025, 1026, "," +305, 10, 7, 216, 27, 30, 1027, 1030, "the" +305, 10, 8, 217, 31, 38, 1031, 1038, "placebo" +305, 10, 9, 218, 39, 40, 1039, 1040, "-" +305, 10, 10, 219, 41, 51, 1041, 1051, "subtracted" +305, 10, 11, 220, 52, 60, 1052, 1060, "decrease" +305, 10, 12, 221, 61, 63, 1061, 1063, "in" +305, 10, 13, 222, 64, 67, 1064, 1067, "A1C" +305, 10, 14, 223, 68, 72, 1068, 1072, "with" +305, 10, 15, 224, 73, 82, 1073, 1082, "metformin" +305, 10, 16, 225, 83, 84, 1083, 1084, "-" +305, 10, 17, 226, 85, 94, 1085, 1094, "imeglimin" +305, 10, 18, 227, 95, 98, 1095, 1098, "was" +305, 10, 19, 228, 99, 100, 1099, 1100, "-" +305, 10, 20, 229, 101, 102, 1101, 1102, "0" +305, 10, 21, 230, 103, 104, 1103, 1104, "." +305, 10, 22, 231, 105, 107, 1105, 1107, "44" +305, 10, 23, 232, 108, 109, 1108, 1109, "%" +305, 10, 24, 233, 110, 111, 1110, 1111, "(" +305, 10, 25, 234, 112, 113, 1112, 1113, "P" +305, 10, 26, 235, 114, 115, 1114, 1115, "<" +305, 10, 27, 236, 116, 117, 1116, 1117, "0" +305, 10, 28, 237, 118, 119, 1118, 1119, "." +305, 10, 29, 238, 120, 123, 1120, 1123, "001" +305, 10, 30, 239, 124, 125, 1124, 1125, ")" +305, 10, 31, 240, 126, 127, 1126, 1127, "." +305, 11, 1, 241, 0, 9, 1128, 1137, "Metformin" +305, 11, 2, 242, 10, 11, 1138, 1139, "-" +305, 11, 3, 243, 12, 21, 1140, 1149, "imeglimin" +305, 11, 4, 244, 22, 26, 1150, 1154, "also" +305, 11, 5, 245, 27, 40, 1155, 1168, "significantly" +305, 11, 6, 246, 41, 49, 1169, 1177, "improved" +305, 11, 7, 247, 50, 53, 1178, 1181, "FPG" +305, 11, 8, 248, 54, 57, 1182, 1185, "and" +305, 11, 9, 249, 58, 61, 1186, 1189, "the" +305, 11, 10, 250, 62, 72, 1190, 1200, "proinsulin" +305, 11, 11, 251, 73, 74, 1201, 1202, "/" +305, 11, 12, 252, 75, 82, 1203, 1210, "insulin" +305, 11, 13, 253, 83, 88, 1211, 1216, "ratio" +305, 11, 14, 254, 89, 93, 1217, 1221, "from" +305, 11, 15, 255, 94, 102, 1222, 1230, "baseline" +305, 11, 16, 256, 103, 104, 1231, 1232, "(" +305, 11, 17, 257, 105, 106, 1233, 1234, "-" +305, 11, 18, 258, 107, 108, 1235, 1236, "0" +305, 11, 19, 259, 109, 110, 1237, 1238, "." +305, 11, 20, 260, 111, 113, 1239, 1241, "91" +305, 11, 21, 261, 114, 116, 1242, 1244, "mg" +305, 11, 22, 262, 117, 118, 1245, 1246, "/" +305, 11, 23, 263, 119, 121, 1247, 1249, "dL" +305, 11, 24, 264, 122, 125, 1250, 1253, "and" +305, 11, 25, 265, 126, 127, 1254, 1255, "-" +305, 11, 26, 266, 128, 129, 1256, 1257, "7" +305, 11, 27, 267, 130, 131, 1258, 1259, "." +305, 11, 28, 268, 132, 133, 1260, 1261, "5" +305, 11, 29, 269, 134, 135, 1262, 1263, "," +305, 11, 30, 270, 136, 148, 1264, 1276, "respectively" +305, 11, 31, 271, 149, 150, 1277, 1278, ")" +305, 11, 32, 272, 151, 159, 1279, 1287, "compared" +305, 11, 33, 273, 160, 164, 1288, 1292, "with" +305, 11, 34, 274, 165, 174, 1293, 1302, "metformin" +305, 11, 35, 275, 175, 176, 1303, 1304, "-" +305, 11, 36, 276, 177, 184, 1305, 1312, "placebo" +305, 11, 37, 277, 185, 186, 1313, 1314, "(" +305, 11, 38, 278, 187, 188, 1315, 1316, "0" +305, 11, 39, 279, 189, 190, 1317, 1318, "." +305, 11, 40, 280, 191, 193, 1319, 1321, "36" +305, 11, 41, 281, 194, 196, 1322, 1324, "mg" +305, 11, 42, 282, 197, 198, 1325, 1326, "/" +305, 11, 43, 283, 199, 201, 1327, 1329, "dL" +305, 11, 44, 284, 202, 205, 1330, 1333, "and" +305, 11, 45, 285, 206, 208, 1334, 1336, "11" +305, 11, 46, 286, 209, 210, 1337, 1338, "." +305, 11, 47, 287, 211, 213, 1339, 1341, "81" +305, 11, 48, 288, 214, 215, 1342, 1343, ")" +305, 11, 49, 289, 216, 217, 1344, 1345, "." +305, 12, 1, 290, 0, 9, 1346, 1355, "Metformin" +305, 12, 2, 291, 10, 11, 1356, 1357, "-" +305, 12, 3, 292, 12, 21, 1358, 1367, "imeglimin" +305, 12, 4, 293, 22, 29, 1368, 1375, "therapy" +305, 12, 5, 294, 30, 33, 1376, 1379, "was" +305, 12, 6, 295, 34, 43, 1380, 1389, "generally" +305, 12, 7, 296, 44, 48, 1390, 1394, "well" +305, 12, 8, 297, 49, 50, 1395, 1396, "-" +305, 12, 9, 298, 51, 60, 1397, 1406, "tolerated" +305, 12, 10, 299, 61, 65, 1407, 1411, "with" +305, 12, 11, 300, 66, 67, 1412, 1413, "a" +305, 12, 12, 301, 68, 78, 1414, 1424, "comparable" +305, 12, 13, 302, 79, 85, 1425, 1431, "safety" +305, 12, 14, 303, 86, 93, 1432, 1439, "profile" +305, 12, 15, 304, 94, 96, 1440, 1442, "to" +305, 12, 16, 305, 97, 106, 1443, 1452, "metformin" +305, 12, 17, 306, 107, 108, 1453, 1454, "-" +305, 12, 18, 307, 109, 116, 1455, 1462, "placebo" +305, 12, 19, 308, 117, 118, 1463, 1464, "." +305, 13, 1, 309, 0, 11, 1465, 1476, "CONCLUSIONS" +305, 13, 2, 310, 12, 13, 1477, 1478, ":" +305, 13, 3, 311, 14, 22, 1479, 1487, "Addition" +305, 13, 4, 312, 23, 25, 1488, 1490, "of" +305, 13, 5, 313, 26, 35, 1491, 1500, "imeglimin" +305, 13, 6, 314, 36, 38, 1501, 1503, "to" +305, 13, 7, 315, 39, 48, 1504, 1513, "metformin" +305, 13, 8, 316, 49, 57, 1514, 1522, "improved" +305, 13, 9, 317, 58, 66, 1523, 1531, "glycemic" +305, 13, 10, 318, 67, 74, 1532, 1539, "control" +305, 13, 11, 319, 75, 78, 1540, 1543, "and" +305, 13, 12, 320, 79, 85, 1544, 1550, "offers" +305, 13, 13, 321, 86, 95, 1551, 1560, "potential" +305, 13, 14, 322, 96, 98, 1561, 1563, "as" +305, 13, 15, 323, 99, 100, 1564, 1565, "a" +305, 13, 16, 324, 101, 104, 1566, 1569, "new" +305, 13, 17, 325, 105, 114, 1570, 1579, "treatment" +305, 13, 18, 326, 115, 118, 1580, 1583, "for" +305, 13, 19, 327, 119, 123, 1584, 1588, "type" +305, 13, 20, 328, 124, 125, 1589, 1590, "2" +305, 13, 21, 329, 126, 134, 1591, 1599, "diabetes" +305, 13, 22, 330, 135, 136, 1600, 1601, "." +305, 14, 1, 331, 0, 3, 1602, 1605, "DOI" +305, 14, 2, 332, 4, 5, 1606, 1607, ":" +305, 14, 3, 333, 6, 8, 1608, 1610, "10" +305, 14, 4, 334, 9, 10, 1611, 1612, "." +305, 14, 5, 335, 11, 15, 1613, 1617, "2337" +305, 14, 6, 336, 16, 17, 1618, 1619, "/" +305, 14, 7, 337, 18, 22, 1620, 1624, "dc12" +305, 14, 8, 338, 23, 24, 1625, 1626, "-" +305, 14, 9, 339, 25, 29, 1627, 1631, "0453" +305, 14, 10, 340, 30, 35, 1632, 1637, "PMCID" +305, 14, 11, 341, 36, 37, 1638, 1639, ":" +305, 14, 12, 342, 38, 48, 1640, 1650, "PMC3579350" +305, 14, 13, 343, 49, 53, 1651, 1655, "PMID" +305, 14, 14, 344, 54, 55, 1656, 1657, ":" +305, 14, 15, 345, 56, 64, 1658, 1666, "23160726" +305, 14, 16, 346, 65, 66, 1667, 1668, "[" +305, 14, 17, 347, 67, 74, 1669, 1676, "Indexed" +305, 14, 18, 348, 75, 78, 1677, 1680, "for" +305, 14, 19, 349, 79, 86, 1681, 1688, "MEDLINE" +305, 14, 20, 350, 87, 88, 1689, 1690, "]" diff --git a/data/dm2 23160726_kwoodley.annodb b/data/dm2 23160726_kwoodley.annodb new file mode 100644 index 0000000..7e5fdf4 --- /dev/null +++ b/data/dm2 23160726_kwoodley.annodb @@ -0,0 +1,68 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +27675, Journal, 0, 15, "Diabetes Care .", "", +27676, PublicationYear, 16, 20, "2013", "", +27698, Title, 99, 241, "The efficacy and safety of imeglimin as add - on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy .", "", +27677, Drug, 126, 135, "imeglimin", "", +27696, Precondition, 159, 239, "patients with type 2 diabetes inadequately controlled with metformin monotherapy", "", +27684, Type2Diabetes, 173, 188, "type 2 diabetes", "", +27687, Metformin, 218, 227, "metformin", "", +27699, Author, 242, 253, "Fouqueray P", "", +27700, Author, 262, 270, "Pirags V", "", +27701, Author, 273, 284, "Inzucchi SE", "", +27702, Author, 287, 296, "Bailey CJ", "", +27703, Author, 299, 313, "Schernthaner G", "", +27704, Author, 316, 325, "Diamant M", "", +27705, Author, 328, 339, "Lebovitz HE", "", +27756, France, 387, 393, "France", "", +27709, ObjectiveDescription, 448, 640, "A 12 - week study assessed the efficacy and safety of a new oral antidiabetic agent , imeglimin , as add - on therapy in type 2 diabetes patients inadequately controlled with metformin alone .", "", +27706, Duration, 450, 459, "12 - week", "", +27708, OralAntidiabeticAgent, 508, 531, "oral antidiabetic agent", "", +27678, Drug, 534, 543, "imeglimin", "", +27685, Type2Diabetes, 569, 584, "type 2 diabetes", "", +27697, Precondition, 569, 638, "type 2 diabetes patients inadequately controlled with metformin alone", "", +27688, Metformin, 623, 632, "metformin", "", +27710, NumberPatientsCT, 682, 685, "156", "", +27711, Randomized, 700, 710, "randomized", "", +27712, AllocationRatio, 711, 716, "1 : 1", "", +27679, Drug, 728, 737, "imeglimin", "", +27713, DoseValue, 740, 747, "1 , 500", "", +27714, mg, 748, 750, "mg", "", +27715, Frequency, 751, 762, "twice a day", "", +27716, Placebo, 768, 775, "placebo", "", +27689, Metformin, 802, 811, "metformin", "", +27717, DoseValue, 814, 831, "1 , 500 - 2 , 000", "", +27718, mg, 832, 834, "mg", "", +27719, Frequency, 837, 840, "day", "", +27720, HbA1c, 855, 858, "A1C", "", +27721, FastingPlasmaGlucose, 936, 958, "fasting plasma glucose", "", +27722, FastingPlasmaGlucose, 961, 964, "FPG", "", +27723, EndPointDescription, 971, 997, "proinsulin / insulin ratio", "", +27707, Duration, 1016, 1024, "12 weeks", "", +27724, Placebo, 1031, 1038, "placebo", "", +27727, HbA1c, 1064, 1067, "A1C", "", +27690, Metformin, 1073, 1082, "metformin", "", +27680, Drug, 1085, 1094, "imeglimin", "", +27728, Reduction, 1101, 1107, "0 . 44", "", +27729, Percentage, 1108, 1109, "%", "", +27730, PValueChangeValue, 1112, 1123, "P < 0 . 001", "", +27691, Metformin, 1128, 1137, "Metformin", "", +27681, Drug, 1140, 1149, "imeglimin", "", +27731, FastingPlasmaGlucose, 1178, 1181, "FPG", "", +27732, EndPointDescription, 1190, 1216, "proinsulin / insulin ratio", "", +27733, Reduction, 1235, 1241, "0 . 91", "", +27734, Mg_per_deciliter, 1242, 1249, "mg / dL", "", +27735, Reduction, 1256, 1261, "7 . 5", "", +27694, Metformin, 1293, 1302, "metformin", "", +27725, Placebo, 1305, 1312, "placebo", "", +27736, Increment, 1315, 1321, "0 . 36", "", +27737, Mg_per_deciliter, 1322, 1329, "mg / dL", "", +27738, Increment, 1334, 1341, "11 . 81", "", +27692, Metformin, 1346, 1355, "Metformin", "", +27682, Drug, 1358, 1367, "imeglimin", "", +27693, Metformin, 1443, 1452, "metformin", "", +27726, Placebo, 1455, 1462, "placebo", "", +27739, ConclusionComment, 1479, 1601, "Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes .", "", +27683, Drug, 1491, 1500, "imeglimin", "", +27695, Metformin, 1504, 1513, "metformin", "", +27686, Type2Diabetes, 1584, 1599, "type 2 diabetes", "", +27740, PMID, 1658, 1666, "23160726", "", diff --git a/data/dm2 23160726_kwoodley.n-triples b/data/dm2 23160726_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23160726_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23230096_admin.annodb b/data/dm2 23230096_admin.annodb new file mode 100644 index 0000000..2487010 --- /dev/null +++ b/data/dm2 23230096_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +86, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2013", "", " \"2013\"." +6, Title, 101, 228, "Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease .", "", " \"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease .\"." +2, Metformin, 112, 121, "metformin", "", +3, Glipizide, 129, 138, "glipizide", "", +5, Precondition, 169, 226, "patients with type 2 diabetes and coronary artery disease", "", " \"patients with type 2 diabetes and coronary artery disease\"." +4, Type2Diabetes, 183, 198, "type 2 diabetes", "", " ." +7, Author, 229, 235, "Hong J", "", " \"Hong J\"." +8, Author, 244, 251, "Zhang Y", "", " \"Zhang Y\"." +9, Author, 254, 259, "Lai S", "", " \"Lai S\"." +10, Author, 262, 266, "Lv A", "", " \"Lv A\"." +11, Author, 269, 273, "Su Q", "", " \"Su Q\"." +12, Author, 276, 282, "Dong Y", "", " \"Dong Y\"." +13, Author, 285, 291, "Zhou Z", "", " \"Zhou Z\"." +14, Author, 294, 300, "Tang W", "", " \"Tang W\"." +15, Author, 303, 309, "Zhao J", "", " \"Zhao J\"." +16, Author, 312, 317, "Cui L", "", " \"Cui L\"." +17, Author, 320, 325, "Zou D", "", " \"Zou D\"." +18, Author, 328, 334, "Wang D", "", +19, Author, 337, 341, "Li H", "", " \"Li H\"." +20, Author, 344, 349, "Liu C", "", " \"Liu C\"." +21, Author, 352, 356, "Wu G", "", " \"Wu G\"." +22, Author, 359, 365, "Shen J", "", " \"Shen J\"." +23, Author, 368, 373, "Zhu D", "", " \"Zhu D\"." +26, Author, 376, 382, "Wang W", "", " \"Wang W\"." +25, Author, 385, 391, "Shen W", "", " \"Shen W\"." +24, Author, 394, 400, "Ning G", "", " \"Ning G\"." +85, China, 1035, 1040, "China", "", +120, ObjectiveDescription, 1200, 1366, "The two major classes of antidiabetic drugs , sulfonylureas and metformin , may differentially affect macrovascular complications and mortality in diabetic patients .", "", " \"The two major classes of antidiabetic drugs , sulfonylureas and metformin , may differentially affect macrovascular complications and mortality in diabetic patients .\"." +27, Sulfonylureas, 1246, 1259, "sulfonylureas", "", +28, Metformin, 1264, 1273, "metformin", "", +34, ObjectiveDescription, 1367, 1547, "We compared the long - term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease ( CAD ) .", "", " \"We compared the long - term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease ( CAD ) .\"." +30, Glipizide, 1406, 1415, "glipizide", "", +31, Metformin, 1420, 1429, "metformin", "", +32, Type2Diabetes, 1468, 1483, "type 2 diabetic", "", +33, Precondition, 1468, 1545, "type 2 diabetic patients who had a history of coronary artery disease ( CAD )", "", " \"type 2 diabetic patients who had a history of coronary artery disease ( CAD )\"." +35, Multicenter, 1594, 1605, "multicenter", "", " ." +36, Randomized, 1608, 1618, "randomized", "", " ." +37, DoubleBlind, 1621, 1635, "double - blind", "", " ." +38, Placebo, 1638, 1645, "placebo", "", +39, NumberPatientsCT, 1687, 1690, "304", "", " \"304\"." +40, Type2Diabetes, 1691, 1706, "type 2 diabetic", "", +41, Precondition, 1691, 1724, "type 2 diabetic patients with CAD", "", " \"type 2 diabetic patients with CAD\"." +42, AvgAge, 1738, 1744, "63 . 3", "", " \"63 . 3\"." +43, MinAge, 1761, 1763, "36", "", " \"36\"." +44, MaxAge, 1766, 1768, "80", "", " \"80\"." +45, Randomized, 1813, 1821, "randomly", "", +46, Glipizide, 1849, 1858, "glipizide", "", " ." +48, DoseValue, 1861, 1863, "30", "", " \"30\"." +50, mg, 1864, 1866, "mg", "", " ." +51, Frequency, 1867, 1872, "daily", "", " \"daily\"." +47, Metformin, 1878, 1887, "metformin", "", " ." +49, DoseValue, 1890, 1895, "1 . 5", "", " \"1 . 5\"." +53, Gram, 1896, 1897, "g", "", " \"daily\"." +52, Frequency, 1898, 1903, "daily", "", " \"daily\"." +54, Duration, 1910, 1917, "3 years", "", " \"3 years\"." +55, EndPointDescription, 1948, 2005, "times to the composite of recurrent cardiovascular events", "", " . ." +59, ObservedResult, 2247, 2255, "decrease", "", +56, HbA1c, 2272, 2291, "glycated hemoglobin", "", " ." +65071, Reduction, 2294, 2299, "7 . 1", "", " \"7 . 1\"." +60, Percentage, 2300, 2301, "%", "", " ." +62, Glipizide, 2309, 2318, "glipizide", "", +65077, Reduction, 2329, 2334, "7 . 0", "", " \"7 . 0\"." +61, Percentage, 2335, 2336, "%", "", +65, Metformin, 2344, 2353, "metformin", "", +147, TimePoint, 2391, 2402, "5 . 0 years", "", +69, NumberAffected, 2405, 2407, "91", "", +71, ObservedResult, 2421, 2457, "had developed 103 primary end points", "", +72, IntentionToTreat, 2460, 2491, "Intention - to - treat analysis", "", " ." +92996, AggregationMethod, 2511, 2523, "hazard ratio", "", " . ." +92997, AggregationMethod, 2526, 2528, "HR", "", +75, ResultMeasuredValue, 2534, 2540, "0 . 54", "", " \"0 . 54\"." +76, ConfIntervalResValue, 2543, 2566, "95 % CI 0 . 30 - 0 . 90", "", " \"95 % CI 0 . 30 - 0 . 90\"." +77, PValueResValue, 2569, 2580, "P = 0 . 026", "", " \"P = 0 . 026\"." +78, EndPointDescription, 2605, 2626, "cardiovascular events", "", +66, Metformin, 2660, 2669, "metformin", "", +63, Glipizide, 2686, 2695, "glipizide", "", +65079, EndPointDescription, 2702, 2722, "secondary end points", "", +79, EndPointDescription, 2727, 2741, "adverse events", "", +65078, ObservedResult, 2742, 2797, "were not significantly different between the two groups", "", +82, ConclusionComment, 2814, 2965, "Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow - up of 5 . 0 years compared with glipizide .", "", " \"Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow - up of 5 . 0 years compared with glipizide .\"." +67, Metformin, 2829, 2838, "metformin", "", +81, Duration, 2843, 2850, "3 years", "", +154, Duration, 2928, 2939, "5 . 0 years", "", +64, Glipizide, 2954, 2963, "glipizide", "", +83, ConclusionComment, 2966, 3081, "Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high - risk patients .", "", " \"Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high - risk patients .\"." +68, Metformin, 3011, 3020, "metformin", "", +84, PMID, 3138, 3146, "23230096", "", " \"23230096\"." diff --git a/data/dm2 23230096_admin.n-triples b/data/dm2 23230096_admin.n-triples new file mode 100644 index 0000000..03de612 --- /dev/null +++ b/data/dm2 23230096_admin.n-triples @@ -0,0 +1,127 @@ +# RDF export of group: Publication + . + "Publication 41482" . + "Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease ." . + "Hong J" . + "2013" . + "Diabetes Care" . + "23230096" . + . + "Zhang Y" . + "Lai S" . + "Lv A" . + "Su Q" . + "Dong Y" . + "Zhou Z" . + "Tang W" . + "Zhao J" . + "Cui L" . + "Zou D" . + "Ning G" . + "Li H" . + "Liu C" . + "Wu G" . + "Shen J" . + "Zhu D" . + "Wang W" . + "Shen W" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 41489" . + "The two major classes of antidiabetic drugs , sulfonylureas and metformin , may differentially affect macrovascular complications and mortality in diabetic patients ." . + "304" . + "3 years" . + . + . + . + "Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow - up of 5 . 0 years compared with glipizide ." . + . + . + . + . + . + "We compared the long - term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease ( CAD ) ." . + . + . + "Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high - risk patients ." . + . +# RDF export of group: Population + . + "Population 41505" . + "patients with type 2 diabetes and coronary artery disease" . + . + . + "36" . + "80" . + "63 . 3" . + . + "type 2 diabetic patients who had a history of coronary artery disease ( CAD )" . + "type 2 diabetic patients with CAD" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "card" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "gli" . + . + . + . + . + "met" . + . + . + . + . +# RDF export of group: Intervention + . + "gli" . + . + "daily" . + . + . + "met" . + . + "daily" . + . +# RDF export of group: Medication + . + "gli" . + . + "30" . + . + . + . + "met" . + . + "1 . 5" . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 1" . + . + "hba 2" . + . + "7 . 0" . + . + "card 2" . + . + "0 . 54" . + "P = 0 . 026" . + "95 % CI 0 . 30 - 0 . 90" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23230096_akramersunderbrink.annodb b/data/dm2 23230096_akramersunderbrink.annodb new file mode 100644 index 0000000..a20ad9c --- /dev/null +++ b/data/dm2 23230096_akramersunderbrink.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43269, Journal, 0, 13, "Diabetes Care", "", +43270, PublicationYear, 16, 20, "2013", "", +43335, Title, 101, 228, "Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease .", "", +43271, Metformin, 112, 121, "metformin", "", +43272, Glipizide, 129, 138, "glipizide", "", +43273, Type2Diabetes, 183, 198, "type 2 diabetes", "", +43274, Precondition, 203, 226, "coronary artery disease", "", +43275, Author, 229, 235, "Hong J", "", +43276, Author, 244, 251, "Zhang Y", "", +43277, Author, 254, 259, "Lai S", "", +43278, Author, 262, 266, "Lv A", "", +43279, Author, 269, 273, "Su Q", "", +43280, Author, 276, 282, "Dong Y", "", +43281, Author, 285, 291, "Zhou Z", "", +43282, Author, 294, 300, "Tang W", "", +43283, Author, 303, 309, "Zhao J", "", +43284, Author, 312, 317, "Cui L", "", +43285, Author, 320, 325, "Zou D", "", +43286, Author, 328, 334, "Wang D", "", +43287, Author, 337, 341, "Li H", "", +43288, Author, 344, 349, "Liu C", "", +43289, Author, 352, 356, "Wu G", "", +43290, Author, 359, 365, "Shen J", "", +43291, Author, 368, 373, "Zhu D", "", +43292, Author, 376, 382, "Wang W", "", +43293, Author, 385, 391, "Shen W", "", +43294, Author, 394, 400, "Ning G", "", +43295, China, 1035, 1040, "China", "", +43303, ObjectiveDescription, 1200, 1366, "The two major classes of antidiabetic drugs , sulfonylureas and metformin , may differentially affect macrovascular complications and mortality in diabetic patients .", "", +43296, Sulfonylureas, 1246, 1259, "sulfonylureas", "", +43297, Metformin, 1264, 1273, "metformin", "", +43298, Type2Diabetes, 1347, 1355, "diabetic", "", +43304, ObjectiveDescription, 1367, 1547, "We compared the long - term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease ( CAD ) .", "", +43299, Glipizide, 1406, 1415, "glipizide", "", +43300, Metformin, 1420, 1429, "metformin", "", +43301, Type2Diabetes, 1468, 1483, "type 2 diabetic", "", +43302, Precondition, 1497, 1545, "had a history of coronary artery disease ( CAD )", "", +43305, Multicenter, 1594, 1605, "multicenter", "", +43306, Randomized, 1608, 1618, "randomized", "", +43307, DoubleBlind, 1621, 1635, "double - blind", "", +43308, Placebo, 1638, 1645, "placebo", "", +43309, NumberPatientsCT, 1687, 1690, "304", "", +43310, Type2Diabetes, 1691, 1706, "type 2 diabetic", "", +43311, Precondition, 1721, 1724, "CAD", "", +43312, AvgAge, 1738, 1744, "63 . 3", "", +43313, MinAge, 1761, 1763, "36", "", +43314, MaxAge, 1766, 1768, "80", "", +43315, Randomized, 1813, 1821, "randomly", "", +43316, Glipizide, 1849, 1858, "glipizide", "", +43317, DoseValue, 1861, 1866, "30 mg", "", +43318, Frequency, 1867, 1872, "daily", "", +43319, Metformin, 1878, 1887, "metformin", "", +43320, DoseValue, 1890, 1897, "1 . 5 g", "", +43321, Frequency, 1898, 1903, "daily", "", +43322, Duration, 1910, 1917, "3 years", "", +43323, HbA1c, 2272, 2291, "glycated hemoglobin", "", +43324, ChangeValue, 2294, 2299, "7 . 1", "", +43326, Percentage, 2300, 2301, "%", "", +43329, Glipizide, 2309, 2318, "glipizide", "", +43325, ChangeValue, 2329, 2334, "7 . 0", "", +43327, Percentage, 2335, 2336, "%", "", +43328, Metformin, 2344, 2353, "metformin", "", +43330, TimePoint, 2391, 2402, "5 . 0 years", "", +43336, FinalNumPatientsCT, 2405, 2407, "91", "", +43331, Metformin, 2660, 2669, "metformin", "", +43332, Glipizide, 2686, 2695, "glipizide", "", +43339, ConclusionComment, 2814, 2965, "Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow - up of 5 . 0 years compared with glipizide .", "", +43333, Metformin, 2829, 2838, "metformin", "", +43334, Duration, 2843, 2850, "3 years", "", +43337, Duration, 2928, 2939, "5 . 0 years", "", +43338, Glipizide, 2954, 2963, "glipizide", "", +43341, ConclusionComment, 2966, 3081, "Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high - risk patients .", "", +43340, Metformin, 3011, 3020, "metformin", "", +43342, PMID, 3138, 3146, "23230096", "", diff --git a/data/dm2 23230096_akramersunderbrink.n-triples b/data/dm2 23230096_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23230096_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23230096_export.csv b/data/dm2 23230096_export.csv new file mode 100644 index 0000000..0068bb8 --- /dev/null +++ b/data/dm2 23230096_export.csv @@ -0,0 +1,727 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +304, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +304, 1, 2, 2, 9, 13, 9, 13, "Care" +304, 1, 3, 3, 14, 15, 14, 15, "." +304, 2, 1, 4, 0, 4, 16, 20, "2013" +304, 2, 2, 5, 5, 8, 21, 24, "May" +304, 2, 3, 6, 9, 10, 25, 26, ";" +304, 2, 4, 7, 11, 13, 27, 29, "36" +304, 2, 5, 8, 14, 15, 30, 31, "(" +304, 2, 6, 9, 16, 17, 32, 33, "5" +304, 2, 7, 10, 18, 19, 34, 35, ")" +304, 2, 8, 11, 20, 21, 36, 37, ":" +304, 2, 9, 12, 22, 26, 38, 42, "1304" +304, 2, 10, 13, 27, 28, 43, 44, "-" +304, 2, 11, 14, 29, 31, 45, 47, "11" +304, 2, 12, 15, 32, 33, 48, 49, "." +304, 2, 13, 16, 34, 37, 50, 53, "doi" +304, 2, 14, 17, 38, 39, 54, 55, ":" +304, 2, 15, 18, 40, 42, 56, 58, "10" +304, 2, 16, 19, 43, 44, 59, 60, "." +304, 2, 17, 20, 45, 49, 61, 65, "2337" +304, 2, 18, 21, 50, 51, 66, 67, "/" +304, 2, 19, 22, 52, 56, 68, 72, "dc12" +304, 2, 20, 23, 57, 58, 73, 74, "-" +304, 2, 21, 24, 59, 63, 75, 79, "0719" +304, 2, 22, 25, 64, 65, 80, 81, "." +304, 3, 1, 26, 0, 4, 82, 86, "Epub" +304, 3, 2, 27, 5, 9, 87, 91, "2012" +304, 3, 3, 28, 10, 13, 92, 95, "Dec" +304, 3, 4, 29, 14, 16, 96, 98, "10" +304, 3, 5, 30, 17, 18, 99, 100, "." +304, 4, 1, 31, 0, 7, 101, 108, "Effects" +304, 4, 2, 32, 8, 10, 109, 111, "of" +304, 4, 3, 33, 11, 20, 112, 121, "metformin" +304, 4, 4, 34, 21, 27, 122, 128, "versus" +304, 4, 5, 35, 28, 37, 129, 138, "glipizide" +304, 4, 6, 36, 38, 40, 139, 141, "on" +304, 4, 7, 37, 41, 55, 142, 156, "cardiovascular" +304, 4, 8, 38, 56, 64, 157, 165, "outcomes" +304, 4, 9, 39, 65, 67, 166, 168, "in" +304, 4, 10, 40, 68, 76, 169, 177, "patients" +304, 4, 11, 41, 77, 81, 178, 182, "with" +304, 4, 12, 42, 82, 86, 183, 187, "type" +304, 4, 13, 43, 87, 88, 188, 189, "2" +304, 4, 14, 44, 89, 97, 190, 198, "diabetes" +304, 4, 15, 45, 98, 101, 199, 202, "and" +304, 4, 16, 46, 102, 110, 203, 211, "coronary" +304, 4, 17, 47, 111, 117, 212, 218, "artery" +304, 4, 18, 48, 118, 125, 219, 226, "disease" +304, 4, 19, 49, 126, 127, 227, 228, "." +304, 5, 1, 50, 0, 4, 229, 233, "Hong" +304, 5, 2, 51, 5, 6, 234, 235, "J" +304, 5, 3, 52, 7, 8, 236, 237, "(" +304, 5, 4, 53, 9, 10, 238, 239, "1" +304, 5, 5, 54, 11, 12, 240, 241, ")" +304, 5, 6, 55, 13, 14, 242, 243, "," +304, 5, 7, 56, 15, 20, 244, 249, "Zhang" +304, 5, 8, 57, 21, 22, 250, 251, "Y" +304, 5, 9, 58, 23, 24, 252, 253, "," +304, 5, 10, 59, 25, 28, 254, 257, "Lai" +304, 5, 11, 60, 29, 30, 258, 259, "S" +304, 5, 12, 61, 31, 32, 260, 261, "," +304, 5, 13, 62, 33, 35, 262, 264, "Lv" +304, 5, 14, 63, 36, 37, 265, 266, "A" +304, 5, 15, 64, 38, 39, 267, 268, "," +304, 5, 16, 65, 40, 42, 269, 271, "Su" +304, 5, 17, 66, 43, 44, 272, 273, "Q" +304, 5, 18, 67, 45, 46, 274, 275, "," +304, 5, 19, 68, 47, 51, 276, 280, "Dong" +304, 5, 20, 69, 52, 53, 281, 282, "Y" +304, 5, 21, 70, 54, 55, 283, 284, "," +304, 5, 22, 71, 56, 60, 285, 289, "Zhou" +304, 5, 23, 72, 61, 62, 290, 291, "Z" +304, 5, 24, 73, 63, 64, 292, 293, "," +304, 5, 25, 74, 65, 69, 294, 298, "Tang" +304, 5, 26, 75, 70, 71, 299, 300, "W" +304, 5, 27, 76, 72, 73, 301, 302, "," +304, 5, 28, 77, 74, 78, 303, 307, "Zhao" +304, 5, 29, 78, 79, 80, 308, 309, "J" +304, 5, 30, 79, 81, 82, 310, 311, "," +304, 5, 31, 80, 83, 86, 312, 315, "Cui" +304, 5, 32, 81, 87, 88, 316, 317, "L" +304, 5, 33, 82, 89, 90, 318, 319, "," +304, 5, 34, 83, 91, 94, 320, 323, "Zou" +304, 5, 35, 84, 95, 96, 324, 325, "D" +304, 5, 36, 85, 97, 98, 326, 327, "," +304, 5, 37, 86, 99, 103, 328, 332, "Wang" +304, 5, 38, 87, 104, 105, 333, 334, "D" +304, 5, 39, 88, 106, 107, 335, 336, "," +304, 5, 40, 89, 108, 110, 337, 339, "Li" +304, 5, 41, 90, 111, 112, 340, 341, "H" +304, 5, 42, 91, 113, 114, 342, 343, "," +304, 5, 43, 92, 115, 118, 344, 347, "Liu" +304, 5, 44, 93, 119, 120, 348, 349, "C" +304, 5, 45, 94, 121, 122, 350, 351, "," +304, 5, 46, 95, 123, 125, 352, 354, "Wu" +304, 5, 47, 96, 126, 127, 355, 356, "G" +304, 5, 48, 97, 128, 129, 357, 358, "," +304, 5, 49, 98, 130, 134, 359, 363, "Shen" +304, 5, 50, 99, 135, 136, 364, 365, "J" +304, 5, 51, 100, 137, 138, 366, 367, "," +304, 5, 52, 101, 139, 142, 368, 371, "Zhu" +304, 5, 53, 102, 143, 144, 372, 373, "D" +304, 5, 54, 103, 145, 146, 374, 375, "," +304, 5, 55, 104, 147, 151, 376, 380, "Wang" +304, 5, 56, 105, 152, 153, 381, 382, "W" +304, 5, 57, 106, 154, 155, 383, 384, "," +304, 5, 58, 107, 156, 160, 385, 389, "Shen" +304, 5, 59, 108, 161, 162, 390, 391, "W" +304, 5, 60, 109, 163, 164, 392, 393, "," +304, 5, 61, 110, 165, 169, 394, 398, "Ning" +304, 5, 62, 111, 170, 171, 399, 400, "G" +304, 5, 63, 112, 172, 173, 401, 402, ";" +304, 5, 64, 113, 174, 180, 403, 409, "SPREAD" +304, 5, 65, 114, 181, 182, 410, 411, "-" +304, 5, 66, 115, 183, 189, 412, 418, "DIMCAD" +304, 5, 67, 116, 190, 203, 419, 432, "Investigators" +304, 5, 68, 117, 204, 205, 433, 434, "." +304, 6, 1, 118, 0, 13, 435, 448, "Collaborators" +304, 6, 2, 119, 14, 15, 449, 450, ":" +304, 6, 3, 120, 16, 20, 451, 455, "Ning" +304, 6, 4, 121, 21, 22, 456, 457, "G" +304, 6, 5, 122, 23, 24, 458, 459, "," +304, 6, 6, 123, 25, 29, 460, 464, "Hong" +304, 6, 7, 124, 30, 31, 465, 466, "J" +304, 6, 8, 125, 32, 33, 467, 468, "," +304, 6, 9, 126, 34, 39, 469, 474, "Zhang" +304, 6, 10, 127, 40, 41, 475, 476, "Y" +304, 6, 11, 128, 42, 43, 477, 478, "," +304, 6, 12, 129, 44, 48, 479, 483, "Wang" +304, 6, 13, 130, 49, 50, 484, 485, "W" +304, 6, 14, 131, 51, 52, 486, 487, "," +304, 6, 15, 132, 53, 56, 488, 491, "Gui" +304, 6, 16, 133, 57, 58, 492, 493, "M" +304, 6, 17, 134, 59, 60, 494, 495, "," +304, 6, 18, 135, 61, 65, 496, 500, "Chen" +304, 6, 19, 136, 66, 67, 501, 502, "Y" +304, 6, 20, 137, 68, 69, 503, 504, "," +304, 6, 21, 138, 70, 73, 505, 508, "Chi" +304, 6, 22, 139, 74, 75, 509, 510, "Z" +304, 6, 23, 140, 76, 77, 511, 512, "," +304, 6, 24, 141, 78, 81, 513, 516, "Yan" +304, 6, 25, 142, 82, 83, 517, 518, "Q" +304, 6, 26, 143, 84, 85, 519, 520, "," +304, 6, 27, 144, 86, 90, 521, 525, "Zhai" +304, 6, 28, 145, 91, 92, 526, 527, "Y" +304, 6, 29, 146, 93, 94, 528, 529, "," +304, 6, 30, 147, 95, 99, 530, 534, "Shen" +304, 6, 31, 148, 100, 101, 535, 536, "W" +304, 6, 32, 149, 102, 103, 537, 538, "," +304, 6, 33, 150, 104, 106, 539, 541, "Lv" +304, 6, 34, 151, 107, 108, 542, 543, "A" +304, 6, 35, 152, 109, 110, 544, 545, "," +304, 6, 36, 153, 111, 116, 546, 551, "Zhang" +304, 6, 37, 154, 117, 118, 552, 553, "R" +304, 6, 38, 155, 119, 120, 554, 555, "," +304, 6, 39, 156, 121, 125, 556, 560, "Yang" +304, 6, 40, 157, 126, 127, 561, 562, "J" +304, 6, 41, 158, 128, 129, 563, 564, "," +304, 6, 42, 159, 130, 135, 565, 570, "Zhang" +304, 6, 43, 160, 136, 137, 571, 572, "Y" +304, 6, 44, 161, 138, 139, 573, 574, "," +304, 6, 45, 162, 140, 143, 575, 578, "Fan" +304, 6, 46, 163, 144, 145, 579, 580, "X" +304, 6, 47, 164, 146, 147, 581, 582, "," +304, 6, 48, 165, 148, 152, 583, 587, "Hang" +304, 6, 49, 166, 153, 154, 588, 589, "M" +304, 6, 50, 167, 155, 156, 590, 591, "," +304, 6, 51, 168, 157, 162, 592, 597, "Zhang" +304, 6, 52, 169, 163, 164, 598, 599, "D" +304, 6, 53, 170, 165, 166, 600, 601, "," +304, 6, 54, 171, 167, 169, 602, 604, "Su" +304, 6, 55, 172, 170, 171, 605, 606, "Q" +304, 6, 56, 173, 172, 173, 607, 608, "," +304, 6, 57, 174, 174, 178, 609, 613, "Dong" +304, 6, 58, 175, 179, 180, 614, 615, "Y" +304, 6, 59, 176, 181, 182, 616, 617, "," +304, 6, 60, 177, 183, 187, 618, 622, "Xing" +304, 6, 61, 178, 188, 189, 623, 624, "H" +304, 6, 62, 179, 190, 191, 625, 626, "," +304, 6, 63, 180, 192, 196, 627, 631, "Zhou" +304, 6, 64, 181, 197, 198, 632, 633, "Z" +304, 6, 65, 182, 199, 200, 634, 635, "," +304, 6, 66, 183, 201, 203, 636, 638, "Li" +304, 6, 67, 184, 204, 205, 639, 640, "X" +304, 6, 68, 185, 206, 207, 641, 642, "," +304, 6, 69, 186, 208, 212, 643, 647, "Tang" +304, 6, 70, 187, 213, 214, 648, 649, "W" +304, 6, 71, 188, 215, 216, 650, 651, "," +304, 6, 72, 189, 217, 221, 652, 656, "Zhao" +304, 6, 73, 190, 222, 223, 657, 658, "J" +304, 6, 74, 191, 224, 225, 659, 660, "," +304, 6, 75, 192, 226, 230, 661, 665, "Guan" +304, 6, 76, 193, 231, 232, 666, 667, "Q" +304, 6, 77, 194, 233, 234, 668, 669, "," +304, 6, 78, 195, 235, 240, 670, 675, "Zhang" +304, 6, 79, 196, 241, 242, 676, 677, "X" +304, 6, 80, 197, 243, 244, 678, 679, "," +304, 6, 81, 198, 245, 248, 680, 683, "Cui" +304, 6, 82, 199, 249, 250, 684, 685, "L" +304, 6, 83, 200, 251, 252, 686, 687, "," +304, 6, 84, 201, 253, 257, 688, 692, "Chen" +304, 6, 85, 202, 258, 259, 693, 694, "L" +304, 6, 86, 203, 260, 261, 695, 696, "," +304, 6, 87, 204, 262, 265, 697, 700, "Zou" +304, 6, 88, 205, 266, 267, 701, 702, "D" +304, 6, 89, 206, 268, 269, 703, 704, "," +304, 6, 90, 207, 270, 272, 705, 707, "Li" +304, 6, 91, 208, 273, 274, 708, 709, "J" +304, 6, 92, 209, 275, 276, 710, 711, "," +304, 6, 93, 210, 277, 281, 712, 716, "Chen" +304, 6, 94, 211, 282, 283, 717, 718, "Y" +304, 6, 95, 212, 284, 285, 719, 720, "," +304, 6, 96, 213, 286, 290, 721, 725, "Wang" +304, 6, 97, 214, 291, 292, 726, 727, "D" +304, 6, 98, 215, 293, 294, 728, 729, "," +304, 6, 99, 216, 295, 299, 730, 734, "Shen" +304, 6, 100, 217, 300, 301, 735, 736, "F" +304, 6, 101, 218, 302, 303, 737, 738, "," +304, 6, 102, 219, 304, 306, 739, 741, "Wu" +304, 6, 103, 220, 307, 308, 742, 743, "W" +304, 6, 104, 221, 309, 310, 744, 745, "," +304, 6, 105, 222, 311, 313, 746, 748, "Li" +304, 6, 106, 223, 314, 315, 749, 750, "H" +304, 6, 107, 224, 316, 317, 751, 752, "," +304, 6, 108, 225, 318, 322, 753, 757, "Zhou" +304, 6, 109, 226, 323, 324, 758, 759, "J" +304, 6, 110, 227, 325, 326, 760, 761, "," +304, 6, 111, 228, 327, 330, 762, 765, "Liu" +304, 6, 112, 229, 331, 332, 766, 767, "C" +304, 6, 113, 230, 333, 334, 768, 769, "," +304, 6, 114, 231, 335, 339, 770, 774, "Yang" +304, 6, 115, 232, 340, 341, 775, 776, "T" +304, 6, 116, 233, 342, 343, 777, 778, "," +304, 6, 117, 234, 344, 348, 779, 783, "Shen" +304, 6, 118, 235, 349, 350, 784, 785, "B" +304, 6, 119, 236, 351, 352, 786, 787, "," +304, 6, 120, 237, 353, 355, 788, 790, "Wu" +304, 6, 121, 238, 356, 357, 791, 792, "G" +304, 6, 122, 239, 358, 359, 793, 794, "," +304, 6, 123, 240, 360, 362, 795, 797, "Qu" +304, 6, 124, 241, 363, 364, 798, 799, "S" +304, 6, 125, 242, 365, 366, 800, 801, "," +304, 6, 126, 243, 367, 372, 802, 807, "Sheng" +304, 6, 127, 244, 373, 374, 808, 809, "C" +304, 6, 128, 245, 375, 376, 810, 811, "," +304, 6, 129, 246, 377, 382, 812, 817, "Cheng" +304, 6, 130, 247, 383, 384, 818, 819, "X" +304, 6, 131, 248, 385, 386, 820, 821, "," +304, 6, 132, 249, 387, 391, 822, 826, "Shen" +304, 6, 133, 250, 392, 393, 827, 828, "J" +304, 6, 134, 251, 394, 395, 829, 830, "," +304, 6, 135, 252, 396, 399, 831, 834, "Xue" +304, 6, 136, 253, 400, 401, 835, 836, "Y" +304, 6, 137, 254, 402, 403, 837, 838, "," +304, 6, 138, 255, 404, 408, 839, 843, "Wang" +304, 6, 139, 256, 409, 410, 844, 845, "M" +304, 6, 140, 257, 411, 412, 846, 847, "," +304, 6, 141, 258, 413, 416, 848, 851, "Luo" +304, 6, 142, 259, 417, 418, 852, 853, "X" +304, 6, 143, 260, 419, 420, 854, 855, "," +304, 6, 144, 261, 421, 424, 856, 859, "Zhu" +304, 6, 145, 262, 425, 426, 860, 861, "D" +304, 6, 146, 263, 427, 428, 862, 863, "," +304, 6, 147, 264, 429, 433, 864, 868, "Shen" +304, 6, 148, 265, 434, 435, 869, 870, "S" +304, 6, 149, 266, 436, 437, 871, 872, "," +304, 6, 150, 267, 438, 441, 873, 876, "Yao" +304, 6, 151, 268, 442, 443, 877, 878, "S" +304, 6, 152, 269, 444, 445, 879, 880, "," +304, 6, 153, 270, 446, 448, 881, 883, "Yu" +304, 6, 154, 271, 449, 450, 884, 885, "X" +304, 6, 155, 272, 451, 452, 886, 887, "," +304, 6, 156, 273, 453, 456, 888, 891, "Jin" +304, 6, 157, 274, 457, 458, 892, 893, "H" +304, 6, 158, 275, 459, 460, 894, 895, "," +304, 6, 159, 276, 461, 464, 896, 899, "Shi" +304, 6, 160, 277, 465, 466, 900, 901, "J" +304, 6, 161, 278, 467, 468, 902, 903, "," +304, 6, 162, 279, 469, 473, 904, 908, "Feng" +304, 6, 163, 280, 474, 475, 909, 910, "B" +304, 6, 164, 281, 476, 477, 911, 912, "," +304, 6, 165, 282, 478, 480, 913, 915, "Ni" +304, 6, 166, 283, 481, 482, 916, 917, "Y" +304, 6, 167, 284, 483, 484, 918, 919, "," +304, 6, 168, 285, 485, 488, 920, 923, "Yan" +304, 6, 169, 286, 489, 490, 924, 925, "S" +304, 6, 170, 287, 491, 492, 926, 927, "," +304, 6, 171, 288, 493, 497, 928, 932, "Wang" +304, 6, 172, 289, 498, 499, 933, 934, "Y" +304, 6, 173, 290, 500, 501, 935, 936, "," +304, 6, 174, 291, 502, 506, 937, 941, "Gong" +304, 6, 175, 292, 507, 508, 942, 943, "X" +304, 6, 176, 293, 509, 510, 944, 945, "." +304, 7, 1, 294, 0, 6, 946, 952, "Author" +304, 7, 2, 295, 7, 18, 953, 964, "information" +304, 7, 3, 296, 19, 20, 965, 966, ":" +304, 7, 4, 297, 21, 22, 967, 968, "(" +304, 7, 5, 298, 23, 24, 969, 970, "1" +304, 7, 6, 299, 25, 26, 971, 972, ")" +304, 7, 7, 300, 27, 35, 973, 981, "Shanghai" +304, 7, 8, 301, 36, 40, 982, 986, "Jiao" +304, 7, 9, 302, 41, 45, 987, 991, "Tong" +304, 7, 10, 303, 46, 56, 992, 1002, "University" +304, 7, 11, 304, 57, 63, 1003, 1009, "School" +304, 7, 12, 305, 64, 66, 1010, 1012, "of" +304, 7, 13, 306, 67, 75, 1013, 1021, "Medicine" +304, 7, 14, 307, 76, 77, 1022, 1023, "," +304, 7, 15, 308, 78, 86, 1024, 1032, "Shanghai" +304, 7, 16, 309, 87, 88, 1033, 1034, "," +304, 7, 17, 310, 89, 94, 1035, 1040, "China" +304, 7, 18, 311, 95, 96, 1041, 1042, "." +304, 8, 1, 312, 0, 7, 1043, 1050, "Comment" +304, 8, 2, 313, 8, 10, 1051, 1053, "in" +304, 8, 3, 314, 11, 14, 1054, 1057, "Ann" +304, 8, 4, 315, 15, 21, 1058, 1064, "Intern" +304, 8, 5, 316, 22, 25, 1065, 1068, "Med" +304, 8, 6, 317, 26, 27, 1069, 1070, "." +304, 9, 1, 318, 0, 4, 1071, 1075, "2013" +304, 9, 2, 319, 5, 8, 1076, 1079, "Apr" +304, 9, 3, 320, 9, 11, 1080, 1082, "16" +304, 9, 4, 321, 12, 13, 1083, 1084, ";" +304, 9, 5, 322, 14, 17, 1085, 1088, "158" +304, 9, 6, 323, 18, 19, 1089, 1090, "(" +304, 9, 7, 324, 20, 21, 1091, 1092, "8" +304, 9, 8, 325, 22, 23, 1093, 1094, ")" +304, 9, 9, 326, 24, 25, 1095, 1096, ":" +304, 9, 10, 327, 26, 29, 1097, 1100, "JC4" +304, 9, 11, 328, 30, 31, 1101, 1102, "." +304, 10, 1, 329, 0, 8, 1103, 1111, "Diabetes" +304, 10, 2, 330, 9, 13, 1112, 1116, "Care" +304, 10, 3, 331, 14, 15, 1117, 1118, "." +304, 11, 1, 332, 0, 4, 1119, 1123, "2014" +304, 11, 2, 333, 5, 6, 1124, 1125, ";" +304, 11, 3, 334, 7, 9, 1126, 1128, "37" +304, 11, 4, 335, 10, 11, 1129, 1130, "(" +304, 11, 5, 336, 12, 13, 1131, 1132, "1" +304, 11, 6, 337, 14, 15, 1133, 1134, ")" +304, 11, 7, 338, 16, 17, 1135, 1136, ":" +304, 11, 8, 339, 18, 21, 1137, 1140, "e19" +304, 11, 9, 340, 22, 23, 1141, 1142, "-" +304, 11, 10, 341, 24, 26, 1143, 1145, "20" +304, 11, 11, 342, 27, 28, 1146, 1147, "." +304, 12, 1, 343, 0, 8, 1148, 1156, "Diabetes" +304, 12, 2, 344, 9, 13, 1157, 1161, "Care" +304, 12, 3, 345, 14, 15, 1162, 1163, "." +304, 13, 1, 346, 0, 4, 1164, 1168, "2014" +304, 13, 2, 347, 5, 6, 1169, 1170, ";" +304, 13, 3, 348, 7, 9, 1171, 1173, "37" +304, 13, 4, 349, 10, 11, 1174, 1175, "(" +304, 13, 5, 350, 12, 13, 1176, 1177, "1" +304, 13, 6, 351, 14, 15, 1178, 1179, ")" +304, 13, 7, 352, 16, 17, 1180, 1181, ":" +304, 13, 8, 353, 18, 21, 1182, 1185, "e21" +304, 13, 9, 354, 22, 23, 1186, 1187, "." +304, 14, 1, 355, 0, 9, 1188, 1197, "OBJECTIVE" +304, 14, 2, 356, 10, 11, 1198, 1199, ":" +304, 14, 3, 357, 12, 15, 1200, 1203, "The" +304, 14, 4, 358, 16, 19, 1204, 1207, "two" +304, 14, 5, 359, 20, 25, 1208, 1213, "major" +304, 14, 6, 360, 26, 33, 1214, 1221, "classes" +304, 14, 7, 361, 34, 36, 1222, 1224, "of" +304, 14, 8, 362, 37, 49, 1225, 1237, "antidiabetic" +304, 14, 9, 363, 50, 55, 1238, 1243, "drugs" +304, 14, 10, 364, 56, 57, 1244, 1245, "," +304, 14, 11, 365, 58, 71, 1246, 1259, "sulfonylureas" +304, 14, 12, 366, 72, 75, 1260, 1263, "and" +304, 14, 13, 367, 76, 85, 1264, 1273, "metformin" +304, 14, 14, 368, 86, 87, 1274, 1275, "," +304, 14, 15, 369, 88, 91, 1276, 1279, "may" +304, 14, 16, 370, 92, 106, 1280, 1294, "differentially" +304, 14, 17, 371, 107, 113, 1295, 1301, "affect" +304, 14, 18, 372, 114, 127, 1302, 1315, "macrovascular" +304, 14, 19, 373, 128, 141, 1316, 1329, "complications" +304, 14, 20, 374, 142, 145, 1330, 1333, "and" +304, 14, 21, 375, 146, 155, 1334, 1343, "mortality" +304, 14, 22, 376, 156, 158, 1344, 1346, "in" +304, 14, 23, 377, 159, 167, 1347, 1355, "diabetic" +304, 14, 24, 378, 168, 176, 1356, 1364, "patients" +304, 14, 25, 379, 177, 178, 1365, 1366, "." +304, 15, 1, 380, 0, 2, 1367, 1369, "We" +304, 15, 2, 381, 3, 11, 1370, 1378, "compared" +304, 15, 3, 382, 12, 15, 1379, 1382, "the" +304, 15, 4, 383, 16, 20, 1383, 1387, "long" +304, 15, 5, 384, 21, 22, 1388, 1389, "-" +304, 15, 6, 385, 23, 27, 1390, 1394, "term" +304, 15, 7, 386, 28, 35, 1395, 1402, "effects" +304, 15, 8, 387, 36, 38, 1403, 1405, "of" +304, 15, 9, 388, 39, 48, 1406, 1415, "glipizide" +304, 15, 10, 389, 49, 52, 1416, 1419, "and" +304, 15, 11, 390, 53, 62, 1420, 1429, "metformin" +304, 15, 12, 391, 63, 65, 1430, 1432, "on" +304, 15, 13, 392, 66, 69, 1433, 1436, "the" +304, 15, 14, 393, 70, 75, 1437, 1442, "major" +304, 15, 15, 394, 76, 90, 1443, 1457, "cardiovascular" +304, 15, 16, 395, 91, 97, 1458, 1464, "events" +304, 15, 17, 396, 98, 100, 1465, 1467, "in" +304, 15, 18, 397, 101, 105, 1468, 1472, "type" +304, 15, 19, 398, 106, 107, 1473, 1474, "2" +304, 15, 20, 399, 108, 116, 1475, 1483, "diabetic" +304, 15, 21, 400, 117, 125, 1484, 1492, "patients" +304, 15, 22, 401, 126, 129, 1493, 1496, "who" +304, 15, 23, 402, 130, 133, 1497, 1500, "had" +304, 15, 24, 403, 134, 135, 1501, 1502, "a" +304, 15, 25, 404, 136, 143, 1503, 1510, "history" +304, 15, 26, 405, 144, 146, 1511, 1513, "of" +304, 15, 27, 406, 147, 155, 1514, 1522, "coronary" +304, 15, 28, 407, 156, 162, 1523, 1529, "artery" +304, 15, 29, 408, 163, 170, 1530, 1537, "disease" +304, 15, 30, 409, 171, 172, 1538, 1539, "(" +304, 15, 31, 410, 173, 176, 1540, 1543, "CAD" +304, 15, 32, 411, 177, 178, 1544, 1545, ")" +304, 15, 33, 412, 179, 180, 1546, 1547, "." +304, 16, 1, 413, 0, 8, 1548, 1556, "RESEARCH" +304, 16, 2, 414, 9, 15, 1557, 1563, "DESIGN" +304, 16, 3, 415, 16, 19, 1564, 1567, "AND" +304, 16, 4, 416, 20, 27, 1568, 1575, "METHODS" +304, 16, 5, 417, 28, 29, 1576, 1577, ":" +304, 16, 6, 418, 30, 34, 1578, 1582, "This" +304, 16, 7, 419, 35, 40, 1583, 1588, "study" +304, 16, 8, 420, 41, 43, 1589, 1591, "is" +304, 16, 9, 421, 44, 45, 1592, 1593, "a" +304, 16, 10, 422, 46, 57, 1594, 1605, "multicenter" +304, 16, 11, 423, 58, 59, 1606, 1607, "," +304, 16, 12, 424, 60, 70, 1608, 1618, "randomized" +304, 16, 13, 425, 71, 72, 1619, 1620, "," +304, 16, 14, 426, 73, 79, 1621, 1627, "double" +304, 16, 15, 427, 80, 81, 1628, 1629, "-" +304, 16, 16, 428, 82, 87, 1630, 1635, "blind" +304, 16, 17, 429, 88, 89, 1636, 1637, "," +304, 16, 18, 430, 90, 97, 1638, 1645, "placebo" +304, 16, 19, 431, 98, 99, 1646, 1647, "-" +304, 16, 20, 432, 100, 110, 1648, 1658, "controlled" +304, 16, 21, 433, 111, 119, 1659, 1667, "clinical" +304, 16, 22, 434, 120, 125, 1668, 1673, "trial" +304, 16, 23, 435, 126, 127, 1674, 1675, "." +304, 17, 1, 436, 0, 1, 1676, 1677, "A" +304, 17, 2, 437, 2, 7, 1678, 1683, "total" +304, 17, 3, 438, 8, 10, 1684, 1686, "of" +304, 17, 4, 439, 11, 14, 1687, 1690, "304" +304, 17, 5, 440, 15, 19, 1691, 1695, "type" +304, 17, 6, 441, 20, 21, 1696, 1697, "2" +304, 17, 7, 442, 22, 30, 1698, 1706, "diabetic" +304, 17, 8, 443, 31, 39, 1707, 1715, "patients" +304, 17, 9, 444, 40, 44, 1716, 1720, "with" +304, 17, 10, 445, 45, 48, 1721, 1724, "CAD" +304, 17, 11, 446, 49, 50, 1725, 1726, "," +304, 17, 12, 447, 51, 55, 1727, 1731, "mean" +304, 17, 13, 448, 56, 59, 1732, 1735, "age" +304, 17, 14, 449, 60, 61, 1736, 1737, "=" +304, 17, 15, 450, 62, 64, 1738, 1740, "63" +304, 17, 16, 451, 65, 66, 1741, 1742, "." +304, 17, 17, 452, 67, 68, 1743, 1744, "3" +304, 17, 18, 453, 69, 74, 1745, 1750, "years" +304, 17, 19, 454, 75, 76, 1751, 1752, "(" +304, 17, 20, 455, 77, 82, 1753, 1758, "range" +304, 17, 21, 456, 83, 84, 1759, 1760, "," +304, 17, 22, 457, 85, 87, 1761, 1763, "36" +304, 17, 23, 458, 88, 89, 1764, 1765, "-" +304, 17, 24, 459, 90, 92, 1766, 1768, "80" +304, 17, 25, 460, 93, 98, 1769, 1774, "years" +304, 17, 26, 461, 99, 100, 1775, 1776, ")" +304, 17, 27, 462, 101, 102, 1777, 1778, "," +304, 17, 28, 463, 103, 107, 1779, 1783, "were" +304, 17, 29, 464, 108, 116, 1784, 1792, "enrolled" +304, 17, 30, 465, 117, 118, 1793, 1794, "." +304, 18, 1, 466, 0, 12, 1795, 1807, "Participants" +304, 18, 2, 467, 13, 17, 1808, 1812, "were" +304, 18, 3, 468, 18, 26, 1813, 1821, "randomly" +304, 18, 4, 469, 27, 35, 1822, 1830, "assigned" +304, 18, 5, 470, 36, 38, 1831, 1833, "to" +304, 18, 6, 471, 39, 46, 1834, 1841, "receive" +304, 18, 7, 472, 47, 53, 1842, 1848, "either" +304, 18, 8, 473, 54, 63, 1849, 1858, "glipizide" +304, 18, 9, 474, 64, 65, 1859, 1860, "(" +304, 18, 10, 475, 66, 68, 1861, 1863, "30" +304, 18, 11, 476, 69, 71, 1864, 1866, "mg" +304, 18, 12, 477, 72, 77, 1867, 1872, "daily" +304, 18, 13, 478, 78, 79, 1873, 1874, ")" +304, 18, 14, 479, 80, 82, 1875, 1877, "or" +304, 18, 15, 480, 83, 92, 1878, 1887, "metformin" +304, 18, 16, 481, 93, 94, 1888, 1889, "(" +304, 18, 17, 482, 95, 96, 1890, 1891, "1" +304, 18, 18, 483, 97, 98, 1892, 1893, "." +304, 18, 19, 484, 99, 100, 1894, 1895, "5" +304, 18, 20, 485, 101, 102, 1896, 1897, "g" +304, 18, 21, 486, 103, 108, 1898, 1903, "daily" +304, 18, 22, 487, 109, 110, 1904, 1905, ")" +304, 18, 23, 488, 111, 114, 1906, 1909, "for" +304, 18, 24, 489, 115, 116, 1910, 1911, "3" +304, 18, 25, 490, 117, 122, 1912, 1917, "years" +304, 18, 26, 491, 123, 124, 1918, 1919, "." +304, 19, 1, 492, 0, 3, 1920, 1923, "The" +304, 19, 2, 493, 4, 11, 1924, 1931, "primary" +304, 19, 3, 494, 12, 15, 1932, 1935, "end" +304, 19, 4, 495, 16, 22, 1936, 1942, "points" +304, 19, 5, 496, 23, 27, 1943, 1947, "were" +304, 19, 6, 497, 28, 33, 1948, 1953, "times" +304, 19, 7, 498, 34, 36, 1954, 1956, "to" +304, 19, 8, 499, 37, 40, 1957, 1960, "the" +304, 19, 9, 500, 41, 50, 1961, 1970, "composite" +304, 19, 10, 501, 51, 53, 1971, 1973, "of" +304, 19, 11, 502, 54, 63, 1974, 1983, "recurrent" +304, 19, 12, 503, 64, 78, 1984, 1998, "cardiovascular" +304, 19, 13, 504, 79, 85, 1999, 2005, "events" +304, 19, 14, 505, 86, 87, 2006, 2007, "," +304, 19, 15, 506, 88, 97, 2008, 2017, "including" +304, 19, 16, 507, 98, 103, 2018, 2023, "death" +304, 19, 17, 508, 104, 108, 2024, 2028, "from" +304, 19, 18, 509, 109, 110, 2029, 2030, "a" +304, 19, 19, 510, 111, 125, 2031, 2045, "cardiovascular" +304, 19, 20, 511, 126, 131, 2046, 2051, "cause" +304, 19, 21, 512, 132, 133, 2052, 2053, "," +304, 19, 22, 513, 134, 139, 2054, 2059, "death" +304, 19, 23, 514, 140, 144, 2060, 2064, "from" +304, 19, 24, 515, 145, 148, 2065, 2068, "any" +304, 19, 25, 516, 149, 154, 2069, 2074, "cause" +304, 19, 26, 517, 155, 156, 2075, 2076, "," +304, 19, 27, 518, 157, 165, 2077, 2085, "nonfatal" +304, 19, 28, 519, 166, 176, 2086, 2096, "myocardial" +304, 19, 29, 520, 177, 187, 2097, 2107, "infarction" +304, 19, 30, 521, 188, 189, 2108, 2109, "," +304, 19, 31, 522, 190, 198, 2110, 2118, "nonfatal" +304, 19, 32, 523, 199, 205, 2119, 2125, "stroke" +304, 19, 33, 524, 206, 207, 2126, 2127, "," +304, 19, 34, 525, 208, 210, 2128, 2130, "or" +304, 19, 35, 526, 211, 219, 2131, 2139, "arterial" +304, 19, 36, 527, 220, 237, 2140, 2157, "revascularization" +304, 19, 37, 528, 238, 239, 2158, 2159, "." +304, 20, 1, 529, 0, 7, 2160, 2167, "RESULTS" +304, 20, 2, 530, 8, 9, 2168, 2169, ":" +304, 20, 3, 531, 10, 12, 2170, 2172, "At" +304, 20, 4, 532, 13, 16, 2173, 2176, "the" +304, 20, 5, 533, 17, 20, 2177, 2180, "end" +304, 20, 6, 534, 21, 23, 2181, 2183, "of" +304, 20, 7, 535, 24, 29, 2184, 2189, "study" +304, 20, 8, 536, 30, 34, 2190, 2194, "drug" +304, 20, 9, 537, 35, 49, 2195, 2209, "administration" +304, 20, 10, 538, 50, 51, 2210, 2211, "," +304, 20, 11, 539, 52, 56, 2212, 2216, "both" +304, 20, 12, 540, 57, 63, 2217, 2223, "groups" +304, 20, 13, 541, 64, 72, 2224, 2232, "achieved" +304, 20, 14, 542, 73, 74, 2233, 2234, "a" +304, 20, 15, 543, 75, 86, 2235, 2246, "significant" +304, 20, 16, 544, 87, 95, 2247, 2255, "decrease" +304, 20, 17, 545, 96, 98, 2256, 2258, "in" +304, 20, 18, 546, 99, 102, 2259, 2262, "the" +304, 20, 19, 547, 103, 108, 2263, 2268, "level" +304, 20, 20, 548, 109, 111, 2269, 2271, "of" +304, 20, 21, 549, 112, 120, 2272, 2280, "glycated" +304, 20, 22, 550, 121, 131, 2281, 2291, "hemoglobin" +304, 20, 23, 551, 132, 133, 2292, 2293, "(" +304, 20, 24, 552, 134, 135, 2294, 2295, "7" +304, 20, 25, 553, 136, 137, 2296, 2297, "." +304, 20, 26, 554, 138, 139, 2298, 2299, "1" +304, 20, 27, 555, 140, 141, 2300, 2301, "%" +304, 20, 28, 556, 142, 144, 2302, 2304, "in" +304, 20, 29, 557, 145, 148, 2305, 2308, "the" +304, 20, 30, 558, 149, 158, 2309, 2318, "glipizide" +304, 20, 31, 559, 159, 164, 2319, 2324, "group" +304, 20, 32, 560, 165, 168, 2325, 2328, "and" +304, 20, 33, 561, 169, 170, 2329, 2330, "7" +304, 20, 34, 562, 171, 172, 2331, 2332, "." +304, 20, 35, 563, 173, 174, 2333, 2334, "0" +304, 20, 36, 564, 175, 176, 2335, 2336, "%" +304, 20, 37, 565, 177, 179, 2337, 2339, "in" +304, 20, 38, 566, 180, 183, 2340, 2343, "the" +304, 20, 39, 567, 184, 193, 2344, 2353, "metformin" +304, 20, 40, 568, 194, 199, 2354, 2359, "group" +304, 20, 41, 569, 200, 201, 2360, 2361, ")" +304, 20, 42, 570, 202, 203, 2362, 2363, "." +304, 21, 1, 571, 0, 2, 2364, 2366, "At" +304, 21, 2, 572, 3, 4, 2367, 2368, "a" +304, 21, 3, 573, 5, 11, 2369, 2375, "median" +304, 21, 4, 574, 12, 18, 2376, 2382, "follow" +304, 21, 5, 575, 19, 20, 2383, 2384, "-" +304, 21, 6, 576, 21, 23, 2385, 2387, "up" +304, 21, 7, 577, 24, 26, 2388, 2390, "of" +304, 21, 8, 578, 27, 28, 2391, 2392, "5" +304, 21, 9, 579, 29, 30, 2393, 2394, "." +304, 21, 10, 580, 31, 32, 2395, 2396, "0" +304, 21, 11, 581, 33, 38, 2397, 2402, "years" +304, 21, 12, 582, 39, 40, 2403, 2404, "," +304, 21, 13, 583, 41, 43, 2405, 2407, "91" +304, 21, 14, 584, 44, 56, 2408, 2420, "participants" +304, 21, 15, 585, 57, 60, 2421, 2424, "had" +304, 21, 16, 586, 61, 70, 2425, 2434, "developed" +304, 21, 17, 587, 71, 74, 2435, 2438, "103" +304, 21, 18, 588, 75, 82, 2439, 2446, "primary" +304, 21, 19, 589, 83, 86, 2447, 2450, "end" +304, 21, 20, 590, 87, 93, 2451, 2457, "points" +304, 21, 21, 591, 94, 95, 2458, 2459, "." +304, 22, 1, 592, 0, 9, 2460, 2469, "Intention" +304, 22, 2, 593, 10, 11, 2470, 2471, "-" +304, 22, 3, 594, 12, 14, 2472, 2474, "to" +304, 22, 4, 595, 15, 16, 2475, 2476, "-" +304, 22, 5, 596, 17, 22, 2477, 2482, "treat" +304, 22, 6, 597, 23, 31, 2483, 2491, "analysis" +304, 22, 7, 598, 32, 38, 2492, 2498, "showed" +304, 22, 8, 599, 39, 41, 2499, 2501, "an" +304, 22, 9, 600, 42, 50, 2502, 2510, "adjusted" +304, 22, 10, 601, 51, 57, 2511, 2517, "hazard" +304, 22, 11, 602, 58, 63, 2518, 2523, "ratio" +304, 22, 12, 603, 64, 65, 2524, 2525, "(" +304, 22, 13, 604, 66, 68, 2526, 2528, "HR" +304, 22, 14, 605, 69, 70, 2529, 2530, ")" +304, 22, 15, 606, 71, 73, 2531, 2533, "of" +304, 22, 16, 607, 74, 75, 2534, 2535, "0" +304, 22, 17, 608, 76, 77, 2536, 2537, "." +304, 22, 18, 609, 78, 80, 2538, 2540, "54" +304, 22, 19, 610, 81, 82, 2541, 2542, "(" +304, 22, 20, 611, 83, 85, 2543, 2545, "95" +304, 22, 21, 612, 86, 87, 2546, 2547, "%" +304, 22, 22, 613, 88, 90, 2548, 2550, "CI" +304, 22, 23, 614, 91, 92, 2551, 2552, "0" +304, 22, 24, 615, 93, 94, 2553, 2554, "." +304, 22, 25, 616, 95, 97, 2555, 2557, "30" +304, 22, 26, 617, 98, 99, 2558, 2559, "-" +304, 22, 27, 618, 100, 101, 2560, 2561, "0" +304, 22, 28, 619, 102, 103, 2562, 2563, "." +304, 22, 29, 620, 104, 106, 2564, 2566, "90" +304, 22, 30, 621, 107, 108, 2567, 2568, ";" +304, 22, 31, 622, 109, 110, 2569, 2570, "P" +304, 22, 32, 623, 111, 112, 2571, 2572, "=" +304, 22, 33, 624, 113, 114, 2573, 2574, "0" +304, 22, 34, 625, 115, 116, 2575, 2576, "." +304, 22, 35, 626, 117, 120, 2577, 2580, "026" +304, 22, 36, 627, 121, 122, 2581, 2582, ")" +304, 22, 37, 628, 123, 126, 2583, 2586, "for" +304, 22, 38, 629, 127, 130, 2587, 2590, "the" +304, 22, 39, 630, 131, 141, 2591, 2601, "composites" +304, 22, 40, 631, 142, 144, 2602, 2604, "of" +304, 22, 41, 632, 145, 159, 2605, 2619, "cardiovascular" +304, 22, 42, 633, 160, 166, 2620, 2626, "events" +304, 22, 43, 634, 167, 172, 2627, 2632, "among" +304, 22, 44, 635, 173, 176, 2633, 2636, "the" +304, 22, 45, 636, 177, 185, 2637, 2645, "patients" +304, 22, 46, 637, 186, 190, 2646, 2650, "that" +304, 22, 47, 638, 191, 199, 2651, 2659, "received" +304, 22, 48, 639, 200, 209, 2660, 2669, "metformin" +304, 22, 49, 640, 210, 211, 2670, 2671, "," +304, 22, 50, 641, 212, 220, 2672, 2680, "compared" +304, 22, 51, 642, 221, 225, 2681, 2685, "with" +304, 22, 52, 643, 226, 235, 2686, 2695, "glipizide" +304, 22, 53, 644, 236, 237, 2696, 2697, "." +304, 23, 1, 645, 0, 3, 2698, 2701, "The" +304, 23, 2, 646, 4, 13, 2702, 2711, "secondary" +304, 23, 3, 647, 14, 17, 2712, 2715, "end" +304, 23, 4, 648, 18, 24, 2716, 2722, "points" +304, 23, 5, 649, 25, 28, 2723, 2726, "and" +304, 23, 6, 650, 29, 36, 2727, 2734, "adverse" +304, 23, 7, 651, 37, 43, 2735, 2741, "events" +304, 23, 8, 652, 44, 48, 2742, 2746, "were" +304, 23, 9, 653, 49, 52, 2747, 2750, "not" +304, 23, 10, 654, 53, 66, 2751, 2764, "significantly" +304, 23, 11, 655, 67, 76, 2765, 2774, "different" +304, 23, 12, 656, 77, 84, 2775, 2782, "between" +304, 23, 13, 657, 85, 88, 2783, 2786, "the" +304, 23, 14, 658, 89, 92, 2787, 2790, "two" +304, 23, 15, 659, 93, 99, 2791, 2797, "groups" +304, 23, 16, 660, 100, 101, 2798, 2799, "." +304, 24, 1, 661, 0, 11, 2800, 2811, "CONCLUSIONS" +304, 24, 2, 662, 12, 13, 2812, 2813, ":" +304, 24, 3, 663, 14, 23, 2814, 2823, "Treatment" +304, 24, 4, 664, 24, 28, 2824, 2828, "with" +304, 24, 5, 665, 29, 38, 2829, 2838, "metformin" +304, 24, 6, 666, 39, 42, 2839, 2842, "for" +304, 24, 7, 667, 43, 44, 2843, 2844, "3" +304, 24, 8, 668, 45, 50, 2845, 2850, "years" +304, 24, 9, 669, 51, 64, 2851, 2864, "substantially" +304, 24, 10, 670, 65, 72, 2865, 2872, "reduced" +304, 24, 11, 671, 73, 78, 2873, 2878, "major" +304, 24, 12, 672, 79, 93, 2879, 2893, "cardiovascular" +304, 24, 13, 673, 94, 100, 2894, 2900, "events" +304, 24, 14, 674, 101, 103, 2901, 2903, "in" +304, 24, 15, 675, 104, 105, 2904, 2905, "a" +304, 24, 16, 676, 106, 112, 2906, 2912, "median" +304, 24, 17, 677, 113, 119, 2913, 2919, "follow" +304, 24, 18, 678, 120, 121, 2920, 2921, "-" +304, 24, 19, 679, 122, 124, 2922, 2924, "up" +304, 24, 20, 680, 125, 127, 2925, 2927, "of" +304, 24, 21, 681, 128, 129, 2928, 2929, "5" +304, 24, 22, 682, 130, 131, 2930, 2931, "." +304, 24, 23, 683, 132, 133, 2932, 2933, "0" +304, 24, 24, 684, 134, 139, 2934, 2939, "years" +304, 24, 25, 685, 140, 148, 2940, 2948, "compared" +304, 24, 26, 686, 149, 153, 2949, 2953, "with" +304, 24, 27, 687, 154, 163, 2954, 2963, "glipizide" +304, 24, 28, 688, 164, 165, 2964, 2965, "." +304, 25, 1, 689, 0, 3, 2966, 2969, "Our" +304, 25, 2, 690, 4, 11, 2970, 2977, "results" +304, 25, 3, 691, 12, 21, 2978, 2987, "indicated" +304, 25, 4, 692, 22, 23, 2988, 2989, "a" +304, 25, 5, 693, 24, 33, 2990, 2999, "potential" +304, 25, 6, 694, 34, 41, 3000, 3007, "benefit" +304, 25, 7, 695, 42, 44, 3008, 3010, "of" +304, 25, 8, 696, 45, 54, 3011, 3020, "metformin" +304, 25, 9, 697, 55, 62, 3021, 3028, "therapy" +304, 25, 10, 698, 63, 65, 3029, 3031, "on" +304, 25, 11, 699, 66, 80, 3032, 3046, "cardiovascular" +304, 25, 12, 700, 81, 89, 3047, 3055, "outcomes" +304, 25, 13, 701, 90, 92, 3056, 3058, "in" +304, 25, 14, 702, 93, 97, 3059, 3063, "high" +304, 25, 15, 703, 98, 99, 3064, 3065, "-" +304, 25, 16, 704, 100, 104, 3066, 3070, "risk" +304, 25, 17, 705, 105, 113, 3071, 3079, "patients" +304, 25, 18, 706, 114, 115, 3080, 3081, "." +304, 26, 1, 707, 0, 3, 3082, 3085, "DOI" +304, 26, 2, 708, 4, 5, 3086, 3087, ":" +304, 26, 3, 709, 6, 8, 3088, 3090, "10" +304, 26, 4, 710, 9, 10, 3091, 3092, "." +304, 26, 5, 711, 11, 15, 3093, 3097, "2337" +304, 26, 6, 712, 16, 17, 3098, 3099, "/" +304, 26, 7, 713, 18, 22, 3100, 3104, "dc12" +304, 26, 8, 714, 23, 24, 3105, 3106, "-" +304, 26, 9, 715, 25, 29, 3107, 3111, "0719" +304, 26, 10, 716, 30, 35, 3112, 3117, "PMCID" +304, 26, 11, 717, 36, 37, 3118, 3119, ":" +304, 26, 12, 718, 38, 48, 3120, 3130, "PMC3631843" +304, 26, 13, 719, 49, 53, 3131, 3135, "PMID" +304, 26, 14, 720, 54, 55, 3136, 3137, ":" +304, 26, 15, 721, 56, 64, 3138, 3146, "23230096" +304, 26, 16, 722, 65, 66, 3147, 3148, "[" +304, 26, 17, 723, 67, 74, 3149, 3156, "Indexed" +304, 26, 18, 724, 75, 78, 3157, 3160, "for" +304, 26, 19, 725, 79, 86, 3161, 3168, "MEDLINE" +304, 26, 20, 726, 87, 88, 3169, 3170, "]" diff --git a/data/dm2 23230096_kwoodley.annodb b/data/dm2 23230096_kwoodley.annodb new file mode 100644 index 0000000..e23904d --- /dev/null +++ b/data/dm2 23230096_kwoodley.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29111, Journal, 0, 15, "Diabetes Care .", "", +29117, PublicationYear, 16, 20, "2013", "", +29123, Title, 101, 228, "Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease .", "", +29118, Metformin, 112, 121, "metformin", "", +29119, Glipizide, 129, 138, "glipizide", "", +29122, Precondition, 169, 226, "patients with type 2 diabetes and coronary artery disease", "", +29121, Type2Diabetes, 183, 198, "type 2 diabetes", "", +29124, Author, 229, 235, "Hong J", "", +29125, Author, 244, 251, "Zhang Y", "", +29126, Author, 254, 259, "Lai S", "", +29127, Author, 262, 266, "Lv A", "", +29128, Author, 269, 273, "Su Q", "", +29129, Author, 276, 282, "Dong Y", "", +29130, Author, 285, 291, "Zhou Z", "", +29131, Author, 294, 300, "Tang W", "", +29132, Author, 303, 309, "Zhao J", "", +29133, Author, 312, 317, "Cui L", "", +29134, Author, 320, 325, "Zou D", "", +29135, Author, 328, 334, "Wang D", "", +29136, Author, 337, 341, "Li H", "", +29137, Author, 344, 349, "Liu C", "", +29138, Author, 352, 356, "Wu G", "", +29139, Author, 359, 365, "Shen J", "", +29140, Author, 368, 373, "Zhu D", "", +29143, Author, 376, 382, "Wang W", "", +29142, Author, 385, 391, "Shen W", "", +29141, Author, 394, 400, "Ning G", "", +33157, China, 1035, 1040, "China", "", +29145, Sulfonylureas, 1246, 1259, "sulfonylureas", "", +29146, Metformin, 1264, 1273, "metformin", "", +29147, Type2Diabetes, 1347, 1355, "diabetic", "", +29153, ObjectiveDescription, 1367, 1547, "We compared the long - term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease ( CAD ) .", "", +29148, Glipizide, 1406, 1415, "glipizide", "", +29149, Metformin, 1420, 1429, "metformin", "", +29151, Type2Diabetes, 1468, 1483, "type 2 diabetic", "", +29152, Precondition, 1468, 1545, "type 2 diabetic patients who had a history of coronary artery disease ( CAD )", "", +29155, Multicenter, 1594, 1605, "multicenter", "", +29156, Randomized, 1608, 1618, "randomized", "", +29157, DoubleBlind, 1621, 1635, "double - blind", "", +29158, Placebo, 1638, 1645, "placebo", "", +29159, NumberPatientsCT, 1687, 1690, "304", "", +29160, Type2Diabetes, 1691, 1706, "type 2 diabetic", "", +29161, Precondition, 1691, 1724, "type 2 diabetic patients with CAD", "", +29162, AvgAge, 1738, 1744, "63 . 3", "", +29163, MinAge, 1761, 1763, "36", "", +29164, MaxAge, 1766, 1768, "80", "", +29165, Randomized, 1813, 1821, "randomly", "", +29166, Glipizide, 1849, 1858, "glipizide", "", +29168, DoseValue, 1861, 1863, "30", "", +29170, mg, 1864, 1866, "mg", "", +29171, Frequency, 1867, 1872, "daily", "", +29167, Metformin, 1878, 1887, "metformin", "", +29169, DoseValue, 1890, 1895, "1 . 5", "", +29173, Gram, 1896, 1897, "g", "", +29172, Frequency, 1898, 1903, "daily", "", +29174, Duration, 1910, 1917, "3 years", "", +29175, EndPointDescription, 1948, 2005, "times to the composite of recurrent cardiovascular events", "", +29179, ObservedResult, 2247, 2255, "decrease", "", +29176, HbA1c, 2272, 2291, "glycated hemoglobin", "", +29177, ResultMeasuredValue, 2294, 2299, "7 . 1", "", +29180, Percentage, 2300, 2301, "%", "", +29182, Glipizide, 2309, 2318, "glipizide", "", +29178, ResultMeasuredValue, 2329, 2334, "7 . 0", "", +29181, Percentage, 2335, 2336, "%", "", +29185, Metformin, 2344, 2353, "metformin", "", +29190, TimePoint, 2369, 2402, "median follow - up of 5 . 0 years", "", +29189, NumberAffected, 2405, 2407, "91", "", +29192, ObservedResult, 2421, 2457, "had developed 103 primary end points", "", +29198, IntentionToTreat, 2460, 2491, "Intention - to - treat analysis", "", +29204, EndPointDescription, 2511, 2523, "hazard ratio", "", +29207, EndPointDescription, 2526, 2528, "HR", "", +29212, ResultMeasuredValue, 2534, 2540, "0 . 54", "", +29214, ConfIntervalResValue, 2543, 2566, "95 % CI 0 . 30 - 0 . 90", "", +29216, PValueResValue, 2569, 2580, "P = 0 . 026", "", +29218, EndPointDescription, 2605, 2626, "cardiovascular events", "", +29186, Metformin, 2660, 2669, "metformin", "", +29183, Glipizide, 2686, 2695, "glipizide", "", +29226, ObservedResult, 2698, 2799, "The secondary end points and adverse events were not significantly different between the two groups .", "", +29221, EndPointDescription, 2727, 2741, "adverse events", "", +29232, ConclusionComment, 2814, 2965, "Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow - up of 5 . 0 years compared with glipizide .", "", +29187, Metformin, 2829, 2838, "metformin", "", +29227, Duration, 2843, 2850, "3 years", "", +29184, Glipizide, 2954, 2963, "glipizide", "", +29234, ConclusionComment, 2966, 3081, "Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high - risk patients .", "", +29188, Metformin, 3011, 3020, "metformin", "", +29236, PMID, 3138, 3146, "23230096", "", diff --git a/data/dm2 23230096_kwoodley.n-triples b/data/dm2 23230096_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23230096_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23250357_admin.annodb b/data/dm2 23250357_admin.annodb new file mode 100644 index 0000000..1c4a490 --- /dev/null +++ b/data/dm2 23250357_admin.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82, Journal, 0, 8, "Diabetes", "", " \"Diabetes\"." +1, PublicationYear, 11, 15, "2013", "", " \"2013\"." +4, Title, 97, 191, "The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes .", "", " \"The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes .\"." +106320, Precondition, 160, 189, "subjects with type 2 diabetes", "", " \"subjects with type 2 diabetes\"." +2, Type2Diabetes, 174, 189, "type 2 diabetes", "", " ." +5, Author, 192, 202, "Smushkin G", "", " \"Smushkin G\"." +6, Author, 211, 225, "Sathananthan M", "", " \"Sathananthan M\"." +7, Author, 228, 239, "Piccinini F", "", " \"Piccinini F\"." +8, Author, 242, 253, "Dalla Man C", "", " \"Dalla Man C\"." +9, Author, 256, 262, "Law JH", "", " \"Law JH\"." +10, Author, 265, 274, "Cobelli C", "", " \"Cobelli C\"." +11, Author, 277, 291, "Zinsmeister AR", "", " \"Zinsmeister AR\"." +12, Author, 294, 302, "Rizza RA", "", " \"Rizza RA\"." +13, Author, 305, 312, "Vella A", "", " \"Vella A\"." +14, USA, 454, 457, "USA", "", " ." +29, ObjectiveDescription, 460, 619, "We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes .", "", " \"We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes .\"." +79881, Colesevelam, 540, 551, "Colesevelam", "", +119923, FastingBloodGlucose, 555, 562, "fasting", "", +65212, PostprandialBloodGlucose, 567, 587, "postprandial glucose", "", +18, Type2Diabetes, 602, 617, "type 2 diabetes", "", +30, ObjectiveDescription, 620, 817, "To do so , we tested the hypothesis that Colesevelam increases the disposition index ( DI ) , and this increase is associated with increased glucagon - like peptide - 1 ( GLP - 1 ) concentrations .", "", " \"To do so , we tested the hypothesis that Colesevelam increases the disposition index ( DI ) , and this increase is associated with increased glucagon - like peptide - 1 ( GLP - 1 ) concentrations .\"." +79882, Colesevelam, 661, 672, "Colesevelam", "", +20, EndPointDescription, 687, 704, "disposition index", "", +21, EndPointDescription, 707, 709, "DI", "", +22, EndPointDescription, 761, 788, "glucagon - like peptide - 1", "", +23, EndPointDescription, 791, 798, "GLP - 1", "", +24, NumberPatientsCT, 818, 832, "Thirty - eight", "", " \"Thirty - eight\"." +106319, Precondition, 827, 879, "eight subjects on metformin monotherapy were studied", "", " \"eight subjects on metformin monotherapy were studied\"." +25, Metformin, 845, 854, "metformin", "", +26, DoubleBlind, 888, 902, "double - blind", "", " ." +27, Placebo, 905, 912, "placebo", "", +28, Parallel, 928, 944, "parallel - group", "", " ." +31, Duration, 993, 1001, "12 weeks", "", " \"12 weeks\"." +79883, Colesevelam, 1005, 1016, "Colesevelam", "", " ." +33, Placebo, 1020, 1027, "placebo", "", " ." +34, MeasurementDevice, 1036, 1070, "labeled triple - tracer mixed meal", "", " . ." +35, EndPointDescription, 1086, 1109, "rate of meal appearance", "", +36, EndPointDescription, 1112, 1119, "Meal Ra", "", +37, EndPointDescription, 1124, 1153, "endogenous glucose production", "", +38, EndPointDescription, 1156, 1159, "EGP", "", +39, EndPointDescription, 1168, 1189, "glucose disappearance", "", +40, EndPointDescription, 1192, 1194, "Rd", "", +44, EndPointDescription, 1323, 1325, "DI", "", +79884, Colesevelam, 1341, 1352, "Colesevelam", "", +119922, FastingBloodGlucose, 1387, 1394, "fasting", "", +65232, BaseLineValue, 1397, 1402, "7 . 0", "", " \"7 . 0\"." +65235, SdDevBL, 1405, 1410, "0 . 2", "", " \"0 . 2\"." +65238, ResultMeasuredValue, 1416, 1421, "6 . 6", "", " \"6 . 6\"." +65240, SdDevResValue, 1424, 1429, "0 . 2", "", " \"0 . 2\"." +57, Millimoles_per_litre, 1430, 1438, "mmol / L", "", " ." +65242, PValueResValue, 1441, 1452, "P = 0 . 004", "", " \"P = 0 . 004\"." +65221, PostprandialBloodGlucose, 1459, 1479, "postprandial glucose", "", " ." +65234, BaseLineValue, 1497, 1504, "3 , 145", "", " \"3 , 145\"." +65236, SdDevBL, 1507, 1510, "138", "", " \"138\"." +65237, ResultMeasuredValue, 1516, 1523, "2 , 896", "", " \"2 , 896\"." +65241, SdDevResValue, 1526, 1529, "127", "", " \"127\"." +58, BioAndMedicalUnit, 1530, 1540, "mmol / 6 h", "", " . ." +65243, PValueResValue, 1543, 1553, "P = 0 . 01", "", " \"P = 0 . 01\"." +64, ObservedResult, 1611, 1691, "Minimal model - derived indices of insulin secretion and action were unchanged .", "", +61, EndPointDescription, 1646, 1663, "insulin secretion", "", +65222, ObservedResult, 1675, 1689, "were unchanged", "", +62, EndPointDescription, 1692, 1712, "Postprandial GLP - 1", "", +65, ObservedResult, 1728, 1744, "were not altered", "", +79885, Colesevelam, 1748, 1759, "Colesevelam", "", +66, EndPointDescription, 1771, 1774, "EGP", "", +67, EndPointDescription, 1779, 1781, "Rd", "", +69, ObservedResult, 1782, 1796, "were unchanged", "", +68, EndPointDescription, 1810, 1817, "Meal Ra", "", " . ." +79886, Colesevelam, 1835, 1846, "Colesevelam", "", +71, BaseLineValue, 1849, 1856, "5 , 191", "", " \"5 , 191\"." +72, SdDevBL, 1859, 1862, "204", "", " \"204\"." +78, ResultMeasuredValue, 1868, 1875, "5 , 817", "", " \"5 , 817\"." +73, SdDevResValue, 1878, 1881, "204", "", " \"204\"." +74, MicroMole, 1882, 1887, "μ mol", "", +120, BioAndMedicalUnit, 1882, 1898, "μ mol / kg / 6 h", "", " . ." +75, Kg, 1890, 1892, "kg", "", +77, PValueResValue, 1901, 1911, "P = 0 . 04", "", " \"P = 0 . 04\"." +79, PMID, 2046, 2054, "23250357", "", " \"23250357\"." diff --git a/data/dm2 23250357_admin.n-triples b/data/dm2 23250357_admin.n-triples new file mode 100644 index 0000000..2695a5f --- /dev/null +++ b/data/dm2 23250357_admin.n-triples @@ -0,0 +1,125 @@ +# RDF export of group: Publication + . + "Publication 44178" . + "The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes ." . + "Smushkin G" . + "2013" . + "Diabetes" . + "23250357" . + . + "Sathananthan M" . + "Piccinini F" . + "Dalla Man C" . + "Law JH" . + "Cobelli C" . + "Zinsmeister AR" . + "Rizza RA" . + "Vella A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 44185" . + "We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes ." . + "Thirty - eight" . + "12 weeks" . + . + . + . + . + . + . + . + . + "To do so , we tested the hypothesis that Colesevelam increases the disposition index ( DI ) , and this increase is associated with increased glucagon - like peptide - 1 ( GLP - 1 ) concentrations ." . + . + . +# RDF export of group: Population + . + "Population 44201" . + "subjects with type 2 diabetes" . + . + . + . + "eight subjects on metformin monotherapy were studied" . +# RDF export of group: Endpoint + . + "fpg" . + . + . + . + . + . + "pbg" . + . + . + . + . + . + . + "mea" . + . + . + . + . + . + . + . +# RDF export of group: Arm + . + "col" . + . + . + . + . + . + . + "pla" . + . + . + . +# RDF export of group: Intervention + . + "col" . + . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "col" . + . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "fpg 1" . + . + "7 . 0" . + "0 . 2" . + "6 . 6" . + "P = 0 . 004" . + "0 . 2" . + . + "pbg" . + . + "3 , 145" . + "138" . + "2 , 896" . + "P = 0 . 01" . + "127" . + . + "mea 1" . + . + "5 , 191" . + "204" . + "5 , 817" . + "P = 0 . 04" . + "204" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23250357_akramersunderbrink.annodb b/data/dm2 23250357_akramersunderbrink.annodb new file mode 100644 index 0000000..ef2ff72 --- /dev/null +++ b/data/dm2 23250357_akramersunderbrink.annodb @@ -0,0 +1,55 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43343, Journal, 0, 8, "Diabetes", "", +43344, PublicationYear, 11, 15, "2013", "", +43346, Title, 97, 191, "The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes .", "", +43345, Type2Diabetes, 174, 189, "type 2 diabetes", "", +43347, Author, 192, 202, "Smushkin G", "", +43348, Author, 211, 225, "Sathananthan M", "", +43349, Author, 228, 239, "Piccinini F", "", +43350, Author, 242, 253, "Dalla Man C", "", +43351, Author, 256, 262, "Law JH", "", +43352, Author, 265, 274, "Cobelli C", "", +43353, Author, 277, 291, "Zinsmeister AR", "", +43354, Author, 294, 302, "Rizza RA", "", +43355, Author, 305, 312, "Vella A", "", +43356, USA, 454, 457, "USA", "", +43360, ObjectiveDescription, 460, 619, "We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes .", "", +43358, Drug, 540, 551, "Colesevelam", "", +43357, Type2Diabetes, 602, 617, "type 2 diabetes", "", +43359, Drug, 661, 672, "Colesevelam", "", +43361, NumberPatientsCT, 818, 832, "Thirty - eight", "", +43362, Metformin, 845, 854, "metformin", "", +43363, DoubleBlind, 888, 902, "double - blind", "", +43364, Placebo, 905, 912, "placebo", "", +43365, Parallel, 928, 944, "parallel - group", "", +43366, TimePoint, 993, 1001, "12 weeks", "", +43367, Drug, 1005, 1016, "Colesevelam", "", +43368, Placebo, 1020, 1027, "placebo", "", +43386, EndPointDescription, 1086, 1109, "rate of meal appearance", "", +43387, EndPointDescription, 1112, 1119, "Meal Ra", "", +43388, EndPointDescription, 1124, 1153, "endogenous glucose production", "", +43389, EndPointDescription, 1156, 1159, "EGP", "", +43390, EndPointDescription, 1168, 1189, "glucose disappearance", "", +43391, EndPointDescription, 1192, 1194, "Rd", "", +43369, Drug, 1341, 1352, "Colesevelam", "", +43370, FastingPlasmaGlucose, 1387, 1394, "fasting", "", +43373, BaseLineValue, 1397, 1402, "7 . 0", "", +43376, ResultMeasuredValue, 1416, 1421, "6 . 6", "", +43379, Millimoles_per_litre, 1430, 1438, "mmol / L", "", +43382, PValueChangeValue, 1441, 1452, "P = 0 . 004", "", +43371, PostprandialPlasmaGlucose, 1459, 1479, "postprandial glucose", "", +43374, BaseLineValue, 1497, 1504, "3 , 145", "", +43377, ResultMeasuredValue, 1516, 1523, "2 , 896", "", +43380, BioAndMedicalUnit, 1530, 1540, "mmol / 6 h", "", +43383, PValueChangeValue, 1543, 1553, "P = 0 . 01", "", +43392, EndPointDescription, 1692, 1727, "Postprandial GLP - 1 concentrations", "", +43395, Drug, 1748, 1759, "Colesevelam", "", +43393, EndPointDescription, 1771, 1774, "EGP", "", +43394, EndPointDescription, 1779, 1781, "Rd", "", +43385, EndPointDescription, 1799, 1817, "integrated Meal Ra", "", +43396, Drug, 1835, 1846, "Colesevelam", "", +43375, BaseLineValue, 1849, 1856, "5 , 191", "", +43378, ResultMeasuredValue, 1868, 1875, "5 , 817", "", +43381, BioAndMedicalUnit, 1882, 1898, "μ mol / kg / 6 h", "", +43384, PValueChangeValue, 1901, 1911, "P = 0 . 04", "", +43372, PMID, 2046, 2054, "23250357", "", diff --git a/data/dm2 23250357_akramersunderbrink.n-triples b/data/dm2 23250357_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23250357_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23250357_export.csv b/data/dm2 23250357_export.csv new file mode 100644 index 0000000..fdb7cf6 --- /dev/null +++ b/data/dm2 23250357_export.csv @@ -0,0 +1,429 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +303, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +303, 1, 2, 2, 9, 10, 9, 10, "." +303, 2, 1, 3, 0, 4, 11, 15, "2013" +303, 2, 2, 4, 5, 8, 16, 19, "Apr" +303, 2, 3, 5, 9, 10, 20, 21, ";" +303, 2, 4, 6, 11, 13, 22, 24, "62" +303, 2, 5, 7, 14, 15, 25, 26, "(" +303, 2, 6, 8, 16, 17, 27, 28, "4" +303, 2, 7, 9, 18, 19, 29, 30, ")" +303, 2, 8, 10, 20, 21, 31, 32, ":" +303, 2, 9, 11, 22, 26, 33, 37, "1094" +303, 2, 10, 12, 27, 28, 38, 39, "-" +303, 2, 11, 13, 29, 32, 40, 43, "101" +303, 2, 12, 14, 33, 34, 44, 45, "." +303, 2, 13, 15, 35, 38, 46, 49, "doi" +303, 2, 14, 16, 39, 40, 50, 51, ":" +303, 2, 15, 17, 41, 43, 52, 54, "10" +303, 2, 16, 18, 44, 45, 55, 56, "." +303, 2, 17, 19, 46, 50, 57, 61, "2337" +303, 2, 18, 20, 51, 52, 62, 63, "/" +303, 2, 19, 21, 53, 57, 64, 68, "db12" +303, 2, 20, 22, 58, 59, 69, 70, "-" +303, 2, 21, 23, 60, 64, 71, 75, "0923" +303, 2, 22, 24, 65, 66, 76, 77, "." +303, 3, 1, 25, 0, 4, 78, 82, "Epub" +303, 3, 2, 26, 5, 9, 83, 87, "2012" +303, 3, 3, 27, 10, 13, 88, 91, "Dec" +303, 3, 4, 28, 14, 16, 92, 94, "18" +303, 3, 5, 29, 17, 18, 95, 96, "." +303, 4, 1, 30, 0, 3, 97, 100, "The" +303, 4, 2, 31, 4, 10, 101, 107, "effect" +303, 4, 3, 32, 11, 13, 108, 110, "of" +303, 4, 4, 33, 14, 15, 111, 112, "a" +303, 4, 5, 34, 16, 20, 113, 117, "bile" +303, 4, 6, 35, 21, 25, 118, 122, "acid" +303, 4, 7, 36, 26, 37, 123, 134, "sequestrant" +303, 4, 8, 37, 38, 40, 135, 137, "on" +303, 4, 9, 38, 41, 48, 138, 145, "glucose" +303, 4, 10, 39, 49, 59, 146, 156, "metabolism" +303, 4, 11, 40, 60, 62, 157, 159, "in" +303, 4, 12, 41, 63, 71, 160, 168, "subjects" +303, 4, 13, 42, 72, 76, 169, 173, "with" +303, 4, 14, 43, 77, 81, 174, 178, "type" +303, 4, 15, 44, 82, 83, 179, 180, "2" +303, 4, 16, 45, 84, 92, 181, 189, "diabetes" +303, 4, 17, 46, 93, 94, 190, 191, "." +303, 5, 1, 47, 0, 8, 192, 200, "Smushkin" +303, 5, 2, 48, 9, 10, 201, 202, "G" +303, 5, 3, 49, 11, 12, 203, 204, "(" +303, 5, 4, 50, 13, 14, 205, 206, "1" +303, 5, 5, 51, 15, 16, 207, 208, ")" +303, 5, 6, 52, 17, 18, 209, 210, "," +303, 5, 7, 53, 19, 31, 211, 223, "Sathananthan" +303, 5, 8, 54, 32, 33, 224, 225, "M" +303, 5, 9, 55, 34, 35, 226, 227, "," +303, 5, 10, 56, 36, 45, 228, 237, "Piccinini" +303, 5, 11, 57, 46, 47, 238, 239, "F" +303, 5, 12, 58, 48, 49, 240, 241, "," +303, 5, 13, 59, 50, 55, 242, 247, "Dalla" +303, 5, 14, 60, 56, 59, 248, 251, "Man" +303, 5, 15, 61, 60, 61, 252, 253, "C" +303, 5, 16, 62, 62, 63, 254, 255, "," +303, 5, 17, 63, 64, 67, 256, 259, "Law" +303, 5, 18, 64, 68, 70, 260, 262, "JH" +303, 5, 19, 65, 71, 72, 263, 264, "," +303, 5, 20, 66, 73, 80, 265, 272, "Cobelli" +303, 5, 21, 67, 81, 82, 273, 274, "C" +303, 5, 22, 68, 83, 84, 275, 276, "," +303, 5, 23, 69, 85, 96, 277, 288, "Zinsmeister" +303, 5, 24, 70, 97, 99, 289, 291, "AR" +303, 5, 25, 71, 100, 101, 292, 293, "," +303, 5, 26, 72, 102, 107, 294, 299, "Rizza" +303, 5, 27, 73, 108, 110, 300, 302, "RA" +303, 5, 28, 74, 111, 112, 303, 304, "," +303, 5, 29, 75, 113, 118, 305, 310, "Vella" +303, 5, 30, 76, 119, 120, 311, 312, "A" +303, 5, 31, 77, 121, 122, 313, 314, "." +303, 6, 1, 78, 0, 6, 315, 321, "Author" +303, 6, 2, 79, 7, 18, 322, 333, "information" +303, 6, 3, 80, 19, 20, 334, 335, ":" +303, 6, 4, 81, 21, 22, 336, 337, "(" +303, 6, 5, 82, 23, 24, 338, 339, "1" +303, 6, 6, 83, 25, 26, 340, 341, ")" +303, 6, 7, 84, 27, 35, 342, 350, "Division" +303, 6, 8, 85, 36, 38, 351, 353, "of" +303, 6, 9, 86, 39, 52, 354, 367, "Endocrinology" +303, 6, 10, 87, 53, 54, 368, 369, "," +303, 6, 11, 88, 55, 63, 370, 378, "Diabetes" +303, 6, 12, 89, 64, 67, 379, 382, "and" +303, 6, 13, 90, 68, 78, 383, 393, "Metabolism" +303, 6, 14, 91, 79, 80, 394, 395, "," +303, 6, 15, 92, 81, 85, 396, 400, "Mayo" +303, 6, 16, 93, 86, 92, 401, 407, "Clinic" +303, 6, 17, 94, 93, 100, 408, 415, "College" +303, 6, 18, 95, 101, 103, 416, 418, "of" +303, 6, 19, 96, 104, 112, 419, 427, "Medicine" +303, 6, 20, 97, 113, 114, 428, 429, "," +303, 6, 21, 98, 115, 124, 430, 439, "Rochester" +303, 6, 22, 99, 125, 126, 440, 441, "," +303, 6, 23, 100, 127, 136, 442, 451, "Minnesota" +303, 6, 24, 101, 137, 138, 452, 453, "," +303, 6, 25, 102, 139, 142, 454, 457, "USA" +303, 6, 26, 103, 143, 144, 458, 459, "." +303, 7, 1, 104, 0, 2, 460, 462, "We" +303, 7, 2, 105, 3, 11, 463, 471, "designed" +303, 7, 3, 106, 12, 14, 472, 474, "an" +303, 7, 4, 107, 15, 25, 475, 485, "experiment" +303, 7, 5, 108, 26, 28, 486, 488, "to" +303, 7, 6, 109, 29, 36, 489, 496, "examine" +303, 7, 7, 110, 37, 40, 497, 500, "the" +303, 7, 8, 111, 41, 47, 501, 507, "effect" +303, 7, 9, 112, 48, 50, 508, 510, "of" +303, 7, 10, 113, 51, 55, 511, 515, "bile" +303, 7, 11, 114, 56, 60, 516, 520, "acid" +303, 7, 12, 115, 61, 74, 521, 534, "sequestration" +303, 7, 13, 116, 75, 79, 535, 539, "with" +303, 7, 14, 117, 80, 91, 540, 551, "Colesevelam" +303, 7, 15, 118, 92, 94, 552, 554, "on" +303, 7, 16, 119, 95, 102, 555, 562, "fasting" +303, 7, 17, 120, 103, 106, 563, 566, "and" +303, 7, 18, 121, 107, 119, 567, 579, "postprandial" +303, 7, 19, 122, 120, 127, 580, 587, "glucose" +303, 7, 20, 123, 128, 138, 588, 598, "metabolism" +303, 7, 21, 124, 139, 141, 599, 601, "in" +303, 7, 22, 125, 142, 146, 602, 606, "type" +303, 7, 23, 126, 147, 148, 607, 608, "2" +303, 7, 24, 127, 149, 157, 609, 617, "diabetes" +303, 7, 25, 128, 158, 159, 618, 619, "." +303, 8, 1, 129, 0, 2, 620, 622, "To" +303, 8, 2, 130, 3, 5, 623, 625, "do" +303, 8, 3, 131, 6, 8, 626, 628, "so" +303, 8, 4, 132, 9, 10, 629, 630, "," +303, 8, 5, 133, 11, 13, 631, 633, "we" +303, 8, 6, 134, 14, 20, 634, 640, "tested" +303, 8, 7, 135, 21, 24, 641, 644, "the" +303, 8, 8, 136, 25, 35, 645, 655, "hypothesis" +303, 8, 9, 137, 36, 40, 656, 660, "that" +303, 8, 10, 138, 41, 52, 661, 672, "Colesevelam" +303, 8, 11, 139, 53, 62, 673, 682, "increases" +303, 8, 12, 140, 63, 66, 683, 686, "the" +303, 8, 13, 141, 67, 78, 687, 698, "disposition" +303, 8, 14, 142, 79, 84, 699, 704, "index" +303, 8, 15, 143, 85, 86, 705, 706, "(" +303, 8, 16, 144, 87, 89, 707, 709, "DI" +303, 8, 17, 145, 90, 91, 710, 711, ")" +303, 8, 18, 146, 92, 93, 712, 713, "," +303, 8, 19, 147, 94, 97, 714, 717, "and" +303, 8, 20, 148, 98, 102, 718, 722, "this" +303, 8, 21, 149, 103, 111, 723, 731, "increase" +303, 8, 22, 150, 112, 114, 732, 734, "is" +303, 8, 23, 151, 115, 125, 735, 745, "associated" +303, 8, 24, 152, 126, 130, 746, 750, "with" +303, 8, 25, 153, 131, 140, 751, 760, "increased" +303, 8, 26, 154, 141, 149, 761, 769, "glucagon" +303, 8, 27, 155, 150, 151, 770, 771, "-" +303, 8, 28, 156, 152, 156, 772, 776, "like" +303, 8, 29, 157, 157, 164, 777, 784, "peptide" +303, 8, 30, 158, 165, 166, 785, 786, "-" +303, 8, 31, 159, 167, 168, 787, 788, "1" +303, 8, 32, 160, 169, 170, 789, 790, "(" +303, 8, 33, 161, 171, 174, 791, 794, "GLP" +303, 8, 34, 162, 175, 176, 795, 796, "-" +303, 8, 35, 163, 177, 178, 797, 798, "1" +303, 8, 36, 164, 179, 180, 799, 800, ")" +303, 8, 37, 165, 181, 195, 801, 815, "concentrations" +303, 8, 38, 166, 196, 197, 816, 817, "." +303, 9, 1, 167, 0, 6, 818, 824, "Thirty" +303, 9, 2, 168, 7, 8, 825, 826, "-" +303, 9, 3, 169, 9, 14, 827, 832, "eight" +303, 9, 4, 170, 15, 23, 833, 841, "subjects" +303, 9, 5, 171, 24, 26, 842, 844, "on" +303, 9, 6, 172, 27, 36, 845, 854, "metformin" +303, 9, 7, 173, 37, 48, 855, 866, "monotherapy" +303, 9, 8, 174, 49, 53, 867, 871, "were" +303, 9, 9, 175, 54, 61, 872, 879, "studied" +303, 9, 10, 176, 62, 67, 880, 885, "using" +303, 9, 11, 177, 68, 69, 886, 887, "a" +303, 9, 12, 178, 70, 76, 888, 894, "double" +303, 9, 13, 179, 77, 78, 895, 896, "-" +303, 9, 14, 180, 79, 84, 897, 902, "blind" +303, 9, 15, 181, 85, 86, 903, 904, "," +303, 9, 16, 182, 87, 94, 905, 912, "placebo" +303, 9, 17, 183, 95, 96, 913, 914, "-" +303, 9, 18, 184, 97, 107, 915, 925, "controlled" +303, 9, 19, 185, 108, 109, 926, 927, "," +303, 9, 20, 186, 110, 118, 928, 936, "parallel" +303, 9, 21, 187, 119, 120, 937, 938, "-" +303, 9, 22, 188, 121, 126, 939, 944, "group" +303, 9, 23, 189, 127, 133, 945, 951, "design" +303, 9, 24, 190, 134, 135, 952, 953, "." +303, 10, 1, 191, 0, 8, 954, 962, "Subjects" +303, 10, 2, 192, 9, 13, 963, 967, "were" +303, 10, 3, 193, 14, 21, 968, 975, "studied" +303, 10, 4, 194, 22, 28, 976, 982, "before" +303, 10, 5, 195, 29, 32, 983, 986, "and" +303, 10, 6, 196, 33, 38, 987, 992, "after" +303, 10, 7, 197, 39, 41, 993, 995, "12" +303, 10, 8, 198, 42, 47, 996, 1001, "weeks" +303, 10, 9, 199, 48, 50, 1002, 1004, "of" +303, 10, 10, 200, 51, 62, 1005, 1016, "Colesevelam" +303, 10, 11, 201, 63, 65, 1017, 1019, "or" +303, 10, 12, 202, 66, 73, 1020, 1027, "placebo" +303, 10, 13, 203, 74, 79, 1028, 1033, "using" +303, 10, 14, 204, 80, 81, 1034, 1035, "a" +303, 10, 15, 205, 82, 89, 1036, 1043, "labeled" +303, 10, 16, 206, 90, 96, 1044, 1050, "triple" +303, 10, 17, 207, 97, 98, 1051, 1052, "-" +303, 10, 18, 208, 99, 105, 1053, 1059, "tracer" +303, 10, 19, 209, 106, 111, 1060, 1065, "mixed" +303, 10, 20, 210, 112, 116, 1066, 1070, "meal" +303, 10, 21, 211, 117, 119, 1071, 1073, "to" +303, 10, 22, 212, 120, 127, 1074, 1081, "measure" +303, 10, 23, 213, 128, 131, 1082, 1085, "the" +303, 10, 24, 214, 132, 136, 1086, 1090, "rate" +303, 10, 25, 215, 137, 139, 1091, 1093, "of" +303, 10, 26, 216, 140, 144, 1094, 1098, "meal" +303, 10, 27, 217, 145, 155, 1099, 1109, "appearance" +303, 10, 28, 218, 156, 157, 1110, 1111, "(" +303, 10, 29, 219, 158, 162, 1112, 1116, "Meal" +303, 10, 30, 220, 163, 165, 1117, 1119, "Ra" +303, 10, 31, 221, 166, 167, 1120, 1121, ")" +303, 10, 32, 222, 168, 169, 1122, 1123, "," +303, 10, 33, 223, 170, 180, 1124, 1134, "endogenous" +303, 10, 34, 224, 181, 188, 1135, 1142, "glucose" +303, 10, 35, 225, 189, 199, 1143, 1153, "production" +303, 10, 36, 226, 200, 201, 1154, 1155, "(" +303, 10, 37, 227, 202, 205, 1156, 1159, "EGP" +303, 10, 38, 228, 206, 207, 1160, 1161, ")" +303, 10, 39, 229, 208, 209, 1162, 1163, "," +303, 10, 40, 230, 210, 213, 1164, 1167, "and" +303, 10, 41, 231, 214, 221, 1168, 1175, "glucose" +303, 10, 42, 232, 222, 235, 1176, 1189, "disappearance" +303, 10, 43, 233, 236, 237, 1190, 1191, "(" +303, 10, 44, 234, 238, 240, 1192, 1194, "Rd" +303, 10, 45, 235, 241, 242, 1195, 1196, ")" +303, 10, 46, 236, 243, 244, 1197, 1198, "." +303, 11, 1, 237, 0, 7, 1199, 1206, "Insulin" +303, 11, 2, 238, 8, 19, 1207, 1218, "sensitivity" +303, 11, 3, 239, 20, 23, 1219, 1222, "and" +303, 11, 4, 240, 24, 26, 1223, 1225, "β-" +303, 11, 5, 241, 27, 31, 1226, 1230, "cell" +303, 11, 6, 242, 32, 44, 1231, 1243, "responsivity" +303, 11, 7, 243, 45, 52, 1244, 1251, "indices" +303, 11, 8, 244, 53, 57, 1252, 1256, "were" +303, 11, 9, 245, 58, 67, 1257, 1266, "estimated" +303, 11, 10, 246, 68, 73, 1267, 1272, "using" +303, 11, 11, 247, 74, 77, 1273, 1276, "the" +303, 11, 12, 248, 78, 82, 1277, 1281, "oral" +303, 11, 13, 249, 83, 90, 1282, 1289, "minimal" +303, 11, 14, 250, 91, 96, 1290, 1295, "model" +303, 11, 15, 251, 97, 100, 1296, 1299, "and" +303, 11, 16, 252, 101, 105, 1300, 1304, "then" +303, 11, 17, 253, 106, 110, 1305, 1309, "used" +303, 11, 18, 254, 111, 113, 1310, 1312, "to" +303, 11, 19, 255, 114, 123, 1313, 1322, "calculate" +303, 11, 20, 256, 124, 126, 1323, 1325, "DI" +303, 11, 21, 257, 127, 128, 1326, 1327, "." +303, 12, 1, 258, 0, 7, 1328, 1335, "Therapy" +303, 12, 2, 259, 8, 12, 1336, 1340, "with" +303, 12, 3, 260, 13, 24, 1341, 1352, "Colesevelam" +303, 12, 4, 261, 25, 28, 1353, 1356, "was" +303, 12, 5, 262, 29, 39, 1357, 1367, "associated" +303, 12, 6, 263, 40, 44, 1368, 1372, "with" +303, 12, 7, 264, 45, 46, 1373, 1374, "a" +303, 12, 8, 265, 47, 55, 1375, 1383, "decrease" +303, 12, 9, 266, 56, 58, 1384, 1386, "in" +303, 12, 10, 267, 59, 66, 1387, 1394, "fasting" +303, 12, 11, 268, 67, 68, 1395, 1396, "(" +303, 12, 12, 269, 69, 70, 1397, 1398, "7" +303, 12, 13, 270, 71, 72, 1399, 1400, "." +303, 12, 14, 271, 73, 74, 1401, 1402, "0" +303, 12, 15, 272, 75, 76, 1403, 1404, "±" +303, 12, 16, 273, 77, 78, 1405, 1406, "0" +303, 12, 17, 274, 79, 80, 1407, 1408, "." +303, 12, 18, 275, 81, 82, 1409, 1410, "2" +303, 12, 19, 276, 83, 85, 1411, 1413, "vs" +303, 12, 20, 277, 86, 87, 1414, 1415, "." +303, 12, 21, 278, 88, 89, 1416, 1417, "6" +303, 12, 22, 279, 90, 91, 1418, 1419, "." +303, 12, 23, 280, 92, 93, 1420, 1421, "6" +303, 12, 24, 281, 94, 95, 1422, 1423, "±" +303, 12, 25, 282, 96, 97, 1424, 1425, "0" +303, 12, 26, 283, 98, 99, 1426, 1427, "." +303, 12, 27, 284, 100, 101, 1428, 1429, "2" +303, 12, 28, 285, 102, 106, 1430, 1434, "mmol" +303, 12, 29, 286, 107, 108, 1435, 1436, "/" +303, 12, 30, 287, 109, 110, 1437, 1438, "L" +303, 12, 31, 288, 111, 112, 1439, 1440, ";" +303, 12, 32, 289, 113, 114, 1441, 1442, "P" +303, 12, 33, 290, 115, 116, 1443, 1444, "=" +303, 12, 34, 291, 117, 118, 1445, 1446, "0" +303, 12, 35, 292, 119, 120, 1447, 1448, "." +303, 12, 36, 293, 121, 124, 1449, 1452, "004" +303, 12, 37, 294, 125, 126, 1453, 1454, ")" +303, 12, 38, 295, 127, 130, 1455, 1458, "and" +303, 12, 39, 296, 131, 143, 1459, 1471, "postprandial" +303, 12, 40, 297, 144, 151, 1472, 1479, "glucose" +303, 12, 41, 298, 152, 166, 1480, 1494, "concentrations" +303, 12, 42, 299, 167, 168, 1495, 1496, "(" +303, 12, 43, 300, 169, 170, 1497, 1498, "3" +303, 12, 44, 301, 171, 172, 1499, 1500, "," +303, 12, 45, 302, 173, 176, 1501, 1504, "145" +303, 12, 46, 303, 177, 178, 1505, 1506, "±" +303, 12, 47, 304, 179, 182, 1507, 1510, "138" +303, 12, 48, 305, 183, 185, 1511, 1513, "vs" +303, 12, 49, 306, 186, 187, 1514, 1515, "." +303, 12, 50, 307, 188, 189, 1516, 1517, "2" +303, 12, 51, 308, 190, 191, 1518, 1519, "," +303, 12, 52, 309, 192, 195, 1520, 1523, "896" +303, 12, 53, 310, 196, 197, 1524, 1525, "±" +303, 12, 54, 311, 198, 201, 1526, 1529, "127" +303, 12, 55, 312, 202, 206, 1530, 1534, "mmol" +303, 12, 56, 313, 207, 208, 1535, 1536, "/" +303, 12, 57, 314, 209, 210, 1537, 1538, "6" +303, 12, 58, 315, 211, 212, 1539, 1540, "h" +303, 12, 59, 316, 213, 214, 1541, 1542, ";" +303, 12, 60, 317, 215, 216, 1543, 1544, "P" +303, 12, 61, 318, 217, 218, 1545, 1546, "=" +303, 12, 62, 319, 219, 220, 1547, 1548, "0" +303, 12, 63, 320, 221, 222, 1549, 1550, "." +303, 12, 64, 321, 223, 225, 1551, 1553, "01" +303, 12, 65, 322, 226, 227, 1554, 1555, ")" +303, 12, 66, 323, 228, 230, 1556, 1558, "in" +303, 12, 67, 324, 231, 234, 1559, 1562, "the" +303, 12, 68, 325, 235, 242, 1563, 1570, "absence" +303, 12, 69, 326, 243, 245, 1571, 1573, "of" +303, 12, 70, 327, 246, 247, 1574, 1575, "a" +303, 12, 71, 328, 248, 254, 1576, 1582, "change" +303, 12, 72, 329, 255, 257, 1583, 1585, "in" +303, 12, 73, 330, 258, 265, 1586, 1593, "insulin" +303, 12, 74, 331, 266, 280, 1594, 1608, "concentrations" +303, 12, 75, 332, 281, 282, 1609, 1610, "." +303, 13, 1, 333, 0, 7, 1611, 1618, "Minimal" +303, 13, 2, 334, 8, 13, 1619, 1624, "model" +303, 13, 3, 335, 14, 15, 1625, 1626, "-" +303, 13, 4, 336, 16, 23, 1627, 1634, "derived" +303, 13, 5, 337, 24, 31, 1635, 1642, "indices" +303, 13, 6, 338, 32, 34, 1643, 1645, "of" +303, 13, 7, 339, 35, 42, 1646, 1653, "insulin" +303, 13, 8, 340, 43, 52, 1654, 1663, "secretion" +303, 13, 9, 341, 53, 56, 1664, 1667, "and" +303, 13, 10, 342, 57, 63, 1668, 1674, "action" +303, 13, 11, 343, 64, 68, 1675, 1679, "were" +303, 13, 12, 344, 69, 78, 1680, 1689, "unchanged" +303, 13, 13, 345, 79, 80, 1690, 1691, "." +303, 14, 1, 346, 0, 12, 1692, 1704, "Postprandial" +303, 14, 2, 347, 13, 16, 1705, 1708, "GLP" +303, 14, 3, 348, 17, 18, 1709, 1710, "-" +303, 14, 4, 349, 19, 20, 1711, 1712, "1" +303, 14, 5, 350, 21, 35, 1713, 1727, "concentrations" +303, 14, 6, 351, 36, 40, 1728, 1732, "were" +303, 14, 7, 352, 41, 44, 1733, 1736, "not" +303, 14, 8, 353, 45, 52, 1737, 1744, "altered" +303, 14, 9, 354, 53, 55, 1745, 1747, "by" +303, 14, 10, 355, 56, 67, 1748, 1759, "Colesevelam" +303, 14, 11, 356, 68, 69, 1760, 1761, "." +303, 15, 1, 357, 0, 8, 1762, 1770, "Although" +303, 15, 2, 358, 9, 12, 1771, 1774, "EGP" +303, 15, 3, 359, 13, 16, 1775, 1778, "and" +303, 15, 4, 360, 17, 19, 1779, 1781, "Rd" +303, 15, 5, 361, 20, 24, 1782, 1786, "were" +303, 15, 6, 362, 25, 34, 1787, 1796, "unchanged" +303, 15, 7, 363, 35, 36, 1797, 1798, "," +303, 15, 8, 364, 37, 47, 1799, 1809, "integrated" +303, 15, 9, 365, 48, 52, 1810, 1814, "Meal" +303, 15, 10, 366, 53, 55, 1815, 1817, "Ra" +303, 15, 11, 367, 56, 59, 1818, 1821, "was" +303, 15, 12, 368, 60, 69, 1822, 1831, "decreased" +303, 15, 13, 369, 70, 72, 1832, 1834, "by" +303, 15, 14, 370, 73, 84, 1835, 1846, "Colesevelam" +303, 15, 15, 371, 85, 86, 1847, 1848, "(" +303, 15, 16, 372, 87, 88, 1849, 1850, "5" +303, 15, 17, 373, 89, 90, 1851, 1852, "," +303, 15, 18, 374, 91, 94, 1853, 1856, "191" +303, 15, 19, 375, 95, 96, 1857, 1858, "±" +303, 15, 20, 376, 97, 100, 1859, 1862, "204" +303, 15, 21, 377, 101, 103, 1863, 1865, "vs" +303, 15, 22, 378, 104, 105, 1866, 1867, "." +303, 15, 23, 379, 106, 107, 1868, 1869, "5" +303, 15, 24, 380, 108, 109, 1870, 1871, "," +303, 15, 25, 381, 110, 113, 1872, 1875, "817" +303, 15, 26, 382, 114, 115, 1876, 1877, "±" +303, 15, 27, 383, 116, 119, 1878, 1881, "204" +303, 15, 28, 384, 120, 121, 1882, 1883, "μ" +303, 15, 29, 385, 122, 125, 1884, 1887, "mol" +303, 15, 30, 386, 126, 127, 1888, 1889, "/" +303, 15, 31, 387, 128, 130, 1890, 1892, "kg" +303, 15, 32, 388, 131, 132, 1893, 1894, "/" +303, 15, 33, 389, 133, 134, 1895, 1896, "6" +303, 15, 34, 390, 135, 136, 1897, 1898, "h" +303, 15, 35, 391, 137, 138, 1899, 1900, ";" +303, 15, 36, 392, 139, 140, 1901, 1902, "P" +303, 15, 37, 393, 141, 142, 1903, 1904, "=" +303, 15, 38, 394, 143, 144, 1905, 1906, "0" +303, 15, 39, 395, 145, 146, 1907, 1908, "." +303, 15, 40, 396, 147, 149, 1909, 1911, "04" +303, 15, 41, 397, 150, 151, 1912, 1913, ")" +303, 15, 42, 398, 152, 153, 1914, 1915, "," +303, 15, 43, 399, 154, 164, 1916, 1926, "suggesting" +303, 15, 44, 400, 165, 174, 1927, 1936, "increased" +303, 15, 45, 401, 175, 185, 1937, 1947, "splanchnic" +303, 15, 46, 402, 186, 199, 1948, 1961, "sequestration" +303, 15, 47, 403, 200, 202, 1962, 1964, "of" +303, 15, 48, 404, 203, 207, 1965, 1969, "meal" +303, 15, 49, 405, 208, 209, 1970, 1971, "-" +303, 15, 50, 406, 210, 217, 1972, 1979, "derived" +303, 15, 51, 407, 218, 225, 1980, 1987, "glucose" +303, 15, 52, 408, 226, 227, 1988, 1989, "." +303, 16, 1, 409, 0, 3, 1990, 1993, "DOI" +303, 16, 2, 410, 4, 5, 1994, 1995, ":" +303, 16, 3, 411, 6, 8, 1996, 1998, "10" +303, 16, 4, 412, 9, 10, 1999, 2000, "." +303, 16, 5, 413, 11, 15, 2001, 2005, "2337" +303, 16, 6, 414, 16, 17, 2006, 2007, "/" +303, 16, 7, 415, 18, 22, 2008, 2012, "db12" +303, 16, 8, 416, 23, 24, 2013, 2014, "-" +303, 16, 9, 417, 25, 29, 2015, 2019, "0923" +303, 16, 10, 418, 30, 35, 2020, 2025, "PMCID" +303, 16, 11, 419, 36, 37, 2026, 2027, ":" +303, 16, 12, 420, 38, 48, 2028, 2038, "PMC3609563" +303, 16, 13, 421, 49, 53, 2039, 2043, "PMID" +303, 16, 14, 422, 54, 55, 2044, 2045, ":" +303, 16, 15, 423, 56, 64, 2046, 2054, "23250357" +303, 16, 16, 424, 65, 66, 2055, 2056, "[" +303, 16, 17, 425, 67, 74, 2057, 2064, "Indexed" +303, 16, 18, 426, 75, 78, 2065, 2068, "for" +303, 16, 19, 427, 79, 86, 2069, 2076, "MEDLINE" +303, 16, 20, 428, 87, 88, 2077, 2078, "]" diff --git a/data/dm2 23250357_kwoodley.annodb b/data/dm2 23250357_kwoodley.annodb new file mode 100644 index 0000000..8a2ee6e --- /dev/null +++ b/data/dm2 23250357_kwoodley.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +27741, Journal, 0, 10, "Diabetes .", "", +27742, PublicationYear, 11, 15, "2013", "", +27746, Title, 97, 191, "The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes .", "", +27745, Drug, 113, 134, "bile acid sequestrant", "", +27743, Type2Diabetes, 174, 189, "type 2 diabetes", "", +27747, Author, 192, 202, "Smushkin G", "", +27748, Author, 211, 225, "Sathananthan M", "", +27749, Author, 228, 239, "Piccinini F", "", +27750, Author, 242, 253, "Dalla Man C", "", +27751, Author, 256, 262, "Law JH", "", +27752, Author, 265, 274, "Cobelli C", "", +27753, Author, 277, 291, "Zinsmeister AR", "", +27754, Author, 294, 302, "Rizza RA", "", +27755, Author, 305, 312, "Vella A", "", +27757, USA, 454, 457, "USA", "", +27773, ObjectiveDescription, 460, 619, "We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes .", "", +27758, Drug, 511, 534, "bile acid sequestration", "", +27759, Drug, 540, 551, "Colesevelam", "", +27760, FastingPlasmaGlucose, 555, 562, "fasting", "", +33158, PostprandialPlasmaGlucose, 567, 598, "postprandial glucose metabolism", "", +27762, Type2Diabetes, 602, 617, "type 2 diabetes", "", +27774, ObjectiveDescription, 620, 817, "To do so , we tested the hypothesis that Colesevelam increases the disposition index ( DI ) , and this increase is associated with increased glucagon - like peptide - 1 ( GLP - 1 ) concentrations .", "", +27763, Drug, 661, 672, "Colesevelam", "", +27764, EndPointDescription, 687, 704, "disposition index", "", +27765, EndPointDescription, 707, 709, "DI", "", +27766, EndPointDescription, 761, 788, "glucagon - like peptide - 1", "", +27767, EndPointDescription, 791, 798, "GLP - 1", "", +27768, NumberPatientsCT, 818, 832, "Thirty - eight", "", +27769, Metformin, 845, 854, "metformin", "", +27770, DoubleBlind, 888, 902, "double - blind", "", +27771, Placebo, 905, 912, "placebo", "", +27772, Parallel, 928, 944, "parallel - group", "", +27775, Duration, 993, 1001, "12 weeks", "", +27776, Drug, 1005, 1016, "Colesevelam", "", +27777, Placebo, 1020, 1027, "placebo", "", +27778, MeasurementDevice, 1036, 1070, "labeled triple - tracer mixed meal", "", +27779, EndPointDescription, 1086, 1109, "rate of meal appearance", "", +27780, EndPointDescription, 1112, 1119, "Meal Ra", "", +27781, EndPointDescription, 1124, 1153, "endogenous glucose production", "", +27782, EndPointDescription, 1156, 1159, "EGP", "", +27783, EndPointDescription, 1168, 1189, "glucose disappearance", "", +27784, EndPointDescription, 1192, 1194, "Rd", "", +27785, EndPointDescription, 1199, 1218, "Insulin sensitivity", "", +27786, EndPointDescription, 1223, 1243, "β- cell responsivity", "", +27787, MeasurementDevice, 1277, 1295, "oral minimal model", "", +27788, EndPointDescription, 1323, 1325, "DI", "", +27789, Drug, 1341, 1352, "Colesevelam", "", +27790, FastingPlasmaGlucose, 1387, 1394, "fasting", "", +27794, BaseLineValue, 1397, 1402, "7 . 0", "", +27798, SdDevBL, 1405, 1410, "0 . 2", "", +27796, ResultMeasuredValue, 1416, 1421, "6 . 6", "", +27800, SdDevResValue, 1424, 1429, "0 . 2", "", +27803, Millimoles_per_litre, 1430, 1438, "mmol / L", "", +27805, PValueResValue, 1441, 1452, "P = 0 . 004", "", +33159, PostprandialPlasmaGlucose, 1459, 1479, "postprandial glucose", "", +27795, BaseLineValue, 1497, 1504, "3 , 145", "", +27799, SdDevBL, 1507, 1510, "138", "", +27802, ResultMeasuredValue, 1516, 1523, "2 , 896", "", +27801, SdDevResValue, 1526, 1529, "127", "", +27804, BioAndMedicalUnit, 1530, 1540, "mmol / 6 h", "", +27806, PValueResValue, 1543, 1553, "P = 0 . 01", "", +27793, ObservedResult, 1563, 1608, "absence of a change in insulin concentrations", "", +27792, EndPointDescription, 1586, 1608, "insulin concentrations", "", +27810, ObservedResult, 1611, 1691, "Minimal model - derived indices of insulin secretion and action were unchanged .", "", +27807, EndPointDescription, 1646, 1663, "insulin secretion", "", +27808, EndPointDescription, 1692, 1712, "Postprandial GLP - 1", "", +27811, ObservedResult, 1692, 1761, "Postprandial GLP - 1 concentrations were not altered by Colesevelam .", "", +27809, Drug, 1748, 1759, "Colesevelam", "", +27812, EndPointDescription, 1771, 1774, "EGP", "", +27813, EndPointDescription, 1779, 1781, "Rd", "", +27815, ObservedResult, 1782, 1796, "were unchanged", "", +27814, EndPointDescription, 1810, 1817, "Meal Ra", "", +27816, Drug, 1835, 1846, "Colesevelam", "", +27817, BaseLineValue, 1849, 1856, "5 , 191", "", +27818, SdDevBL, 1859, 1862, "204", "", +27827, ResultMeasuredValue, 1868, 1875, "5 , 817", "", +27821, SdDevResValue, 1878, 1881, "204", "", +27823, MicroMole, 1882, 1887, "μ mol", "", +27824, Kg, 1890, 1892, "kg", "", +27825, BioAndMedicalUnit, 1895, 1898, "6 h", "", +27826, PValueResValue, 1901, 1911, "P = 0 . 04", "", +27828, PMID, 2046, 2054, "23250357", "", diff --git a/data/dm2 23250357_kwoodley.n-triples b/data/dm2 23250357_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23250357_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23404788_admin.annodb b/data/dm2 23404788_admin.annodb new file mode 100644 index 0000000..775fd73 --- /dev/null +++ b/data/dm2 23404788_admin.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +107, Journal, 0, 25, "Obesity ( Silver Spring )", "", " \"Obesity ( Silver Spring )\"." +1, PublicationYear, 28, 32, "2013", "", " \"2013\"." +26, Title, 93, 216, "Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes ( T - emerge 7 study ) .", "", " \"Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes ( T - emerge 7 study ) .\"." +106322, Taspoglutide, 104, 116, "taspoglutide", "", +11, BodyWeight, 141, 152, "body weight", "", +22, Precondition, 156, 191, "obese patients with type 2 diabetes", "", +16, Type2Diabetes, 176, 191, "type 2 diabetes", "", " ." +27, Author, 217, 228, "Hollander P", "", " \"Hollander P\"." +28, Author, 237, 244, "Lasko B", "", " \"Lasko B\"." +29, Author, 247, 257, "Barnett AH", "", " \"Barnett AH\"." +30, Author, 260, 268, "Bengus M", "", " \"Bengus M\"." +31, Author, 271, 280, "Kanitra L", "", " \"Kanitra L\"." +32, Author, 283, 297, "Pi - Sunyer FX", "", " \"Pi - Sunyer FX\"." +33, Author, 300, 308, "Balena R", "", " \"Balena R\"." +34, USA, 402, 405, "USA", "", " ." +127, ObjectiveDescription, 450, 600, "Therapies that lower blood glucose and provide weight loss may provide meaningful benefits for obese patients with type 2 diabetes mellitus ( T2DM ) .", "", " \"Therapies that lower blood glucose and provide weight loss may provide meaningful benefits for obese patients with type 2 diabetes mellitus ( T2DM ) .\"." +122, BloodGlucose, 471, 484, "blood glucose", "", +12, BodyWeight, 497, 503, "weight", "", +23, Precondition, 545, 589, "obese patients with type 2 diabetes mellitus", "", +17, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +18, Type2Diabetes, 592, 596, "T2DM", "", +37, ObjectiveDescription, 601, 783, "This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy .", "", " \"This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy .\"." +106323, Taspoglutide, 637, 649, "taspoglutide", "", +35, Placebo, 664, 671, "placebo", "", +13, BodyWeight, 696, 702, "weight", "", +24, Precondition, 706, 781, "obese patients with T2DM inadequately controlled with metformin monotherapy", "", " \"obese patients with T2DM inadequately controlled with metformin monotherapy\"." +19, Type2Diabetes, 726, 730, "T2DM", "", +36, Metformin, 760, 769, "metformin", "", +38, Duration, 810, 819, "24 - week", "", " \"24 - week\"." +39, Randomized, 822, 832, "randomized", "", " ." +40, DoubleBlind, 835, 849, "double - blind", "", " ." +41, Placebo, 852, 859, "placebo", "", +48, Multicenter, 875, 886, "multicenter", "", " ." +49, Precondition, 895, 917, "obese adults with T2DM", "", +20, Type2Diabetes, 913, 917, "T2DM", "", +50, Randomized, 923, 933, "randomized", "", +51, AllocationRatio, 936, 941, "1 : 1", "", " . ." +52, Frequency, 947, 953, "weekly", "", " \"weekly\". \"weekly\"." +53, Subcutaneous, 954, 966, "subcutaneous", "", " \"weekly\". \"weekly\"." +106324, Taspoglutide, 967, 979, "taspoglutide", "", +54, DoseValue, 980, 982, "20", "", " \"20\"." +55, mg, 983, 985, "mg", "", " ." +57, DoseValue, 988, 990, "10", "", +56, mg, 991, 993, "mg", "", +58, TimePoint, 994, 1011, "for first 4 weeks", "", +59, NumberPatientsArm, 1020, 1023, "154", "", " \"154\"." +42, Placebo, 1029, 1036, "placebo", "", " ." +60, NumberPatientsArm, 1043, 1046, "151", "", " \"151\"." +61, Duration, 1053, 1061, "24 weeks", "", +62, HbA1c, 1091, 1105, "hemoglobin A1c", "", +63, HbA1c, 1108, 1113, "HbA1c", "", +14, BodyWeight, 1125, 1136, "body weight", "", +95, HbA1c_target, 1172, 1199, "HbA1c ≤ 6 . 5 and ≤ 7 . 0 %", "", +157, Percentage, 1198, 1199, "%", "", +66, FastingPlasmaGlucose, 1206, 1228, "fasting plasma glucose", "", +67, FastingPlasmaGlucose, 1231, 1234, "FPG", "", +69, EndPointDescription, 1239, 1253, "Adverse events", "", +70, EndPointDescription, 1256, 1259, "AEs", "", +160, Mean, 1288, 1292, "Mean", "", +162, TimePoint, 1293, 1301, "baseline", "", +64, HbA1c, 1302, 1307, "HbA1c", "", " ." +72, BaseLineValue, 1312, 1318, "7 . 55", "", " \"7 . 55\". \"7 . 55\"." +74, Percentage, 1319, 1320, "%", "", " ." +165, Mean, 1325, 1329, "mean", "", +166, TimePoint, 1330, 1338, "baseline", "", +77, BMI, 1339, 1342, "BMI", "", +73, BaseLineValue, 1347, 1353, "36 . 7", "", +78, Kg_per_squareMeter, 1354, 1366, "kg / m ( 2 )", "", +65, HbA1c, 1369, 1374, "HbA1c", "", +171, TimePoint, 1391, 1399, "baseline", "", +106326, Taspoglutide, 1432, 1444, "taspoglutide", "", +43, Placebo, 1450, 1457, "placebo", "", +79, LeastSquaresMean, 1460, 1477, "least square mean", "", " ." +80, LeastSquaresMean, 1480, 1486, "LSMean", "", +81, Reduction, 1493, 1499, "0 . 81", "", " \"0 . 81\"." +75, Percentage, 1500, 1501, "%", "", +82, Reduction, 1509, 1515, "0 . 09", "", " \"0 . 09\"." +76, Percentage, 1516, 1517, "%", "", +83, PvalueDiff, 1520, 1532, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +15, BodyWeight, 1537, 1543, "Weight", "", " ." +106, TimePoint, 1552, 1559, "week 24", "", " \"week 24\". \"week 24\"." +106325, Taspoglutide, 1591, 1603, "taspoglutide", "", +44, Placebo, 1609, 1616, "placebo", "", +86, LeastSquaresMean, 1619, 1625, "LSMean", "", " ." +87, Reduction, 1630, 1636, "3 . 16", "", " \"3 . 16\"." +88, Reduction, 1644, 1650, "1 . 85", "", " \"1 . 85\"." +89, Kg, 1651, 1653, "kg", "", " ." +84, PvalueDiff, 1656, 1666, "P < 0 . 01", "", " \"P < 0 . 01\"." +106327, Taspoglutide, 1678, 1690, "taspoglutide", "", +45, Placebo, 1695, 1702, "placebo", "", +96, HbA1c_target, 1712, 1745, "target HbA1c levels ( ≤ 6 . 5 % )", "", " ." +198, Percentage, 1742, 1743, "%", "", +193, PercentageAffected, 1763, 1765, "49", "", " \"49\"." +92, PercentageAffected, 1770, 1772, "16", "", " \"16\"." +195, PercentageAffected, 1810, 1812, "72", "", " \"72\"." +93, PercentageAffected, 1817, 1819, "36", "", " \"36\"." +94, HbA1c_target, 1831, 1849, "HbA1c levels ≤ 7 %", "", " ." +201, Percentage, 1848, 1849, "%", "", +68, FastingPlasmaGlucose, 1865, 1868, "FPG", "", " ." +106328, Taspoglutide, 1901, 1913, "taspoglutide", "", +46, Placebo, 1919, 1926, "placebo", "", +97, Reduction, 1931, 1938, "23 . 59", "", " \"23 . 59\"." +98, Increment, 1944, 1950, "0 . 09", "", " \"0 . 09\"." +99, Mg_per_deciliter, 1951, 1958, "mg / dl", "", " ." +85, PvalueDiff, 1961, 1973, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +100, Nausea, 1978, 1984, "Nausea", "", " ." +101, EndPointDescription, 1989, 1997, "vomiting", "", " . ." +102, ObservedResult, 2003, 2111, "the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate", "", " \"the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate\". \"the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate\"." +71, EndPointDescription, 2019, 2022, "AEs", "", +106329, Taspoglutide, 2039, 2051, "taspoglutide", "", +104, ConclusionComment, 2128, 2253, "In obese patients with T2DM , once - weekly taspoglutide provided the combined benefits of glycemic control and weight loss .", "", " \"In obese patients with T2DM , once - weekly taspoglutide provided the combined benefits of glycemic control and weight loss .\"." +21, Type2Diabetes, 2151, 2155, "T2DM", "", +103, Frequency, 2158, 2171, "once - weekly", "", +106330, Taspoglutide, 2172, 2184, "taspoglutide", "", +47, BodyWeight, 2240, 2246, "weight", "", +105, PMID, 2330, 2338, "23404788", "", " \"23404788\"." diff --git a/data/dm2 23404788_admin.n-triples b/data/dm2 23404788_admin.n-triples new file mode 100644 index 0000000..d9553fc --- /dev/null +++ b/data/dm2 23404788_admin.n-triples @@ -0,0 +1,203 @@ +# RDF export of group: Publication + . + "Publication 44377" . + "Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes ( T - emerge 7 study ) ." . + "Hollander P" . + "2013" . + "Obesity ( Silver Spring )" . + "23404788" . + . + "Lasko B" . + "Barnett AH" . + "Bengus M" . + "Kanitra L" . + "Pi - Sunyer FX" . + "Balena R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 44384" . + "Therapies that lower blood glucose and provide weight loss may provide meaningful benefits for obese patients with type 2 diabetes mellitus ( T2DM ) ." . + "24 - week" . + . + . + . + . + "In obese patients with T2DM , once - weekly taspoglutide provided the combined benefits of glycemic control and weight loss ." . + . + . + . + . + . + "This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population 44400" . + "obese patients with T2DM inadequately controlled with metformin monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "wei" . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "hbat7" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "nau" . + . + . + . + . + . + "vom" . + . + . + . + . + . +# RDF export of group: Arm + . + "tas" . + "154" . + . + . + . + . + . + . + . + . + . + "pla" . + "151" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "tas" . + . + "weekly" . + . + . + "pla" . + . + "weekly" . + . +# RDF export of group: Medication + . + "tas" . + . + . + "20" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 55" . + "0 . 81" . + . + "hba 2" . + . + "7 . 55" . + "0 . 09" . + . + "wei 1" . + . + "3 . 16" . + "week 24" . + . + "wei 2" . + . + "1 . 85" . + "week 24" . + . + "hbat 1" . + . + "49" . + . + "hbat 2" . + . + "16" . + . + "hbat7 1" . + . + "72" . + . + "hbat7 2" . + . + "36" . + . + "fpg 1" . + . + "23 . 59" . + . + "fpg 2" . + . + "0 . 09" . + . + "nau 1" . + . + "the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate" . + . + "vom 1" . + . + "the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "P < 0 . 0001" . + . + . + . + "wei" . + "P < 0 . 01" . + . + . + . + "fpg" . + "P < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23404788_akramersunderbrink.annodb b/data/dm2 23404788_akramersunderbrink.annodb new file mode 100644 index 0000000..01801e1 --- /dev/null +++ b/data/dm2 23404788_akramersunderbrink.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43397, Journal, 0, 25, "Obesity ( Silver Spring )", "", +43398, PublicationYear, 28, 32, "2013", "", +43403, Title, 93, 216, "Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes ( T - emerge 7 study ) .", "", +43399, Drug, 104, 116, "taspoglutide", "", +43400, BodyWeight, 141, 152, "body weight", "", +43401, Precondition, 156, 161, "obese", "", +43402, Type2Diabetes, 176, 191, "type 2 diabetes", "", +43404, Author, 217, 228, "Hollander P", "", +43405, Author, 237, 244, "Lasko B", "", +43406, Author, 247, 257, "Barnett AH", "", +43407, Author, 260, 268, "Bengus M", "", +43408, Author, 271, 280, "Kanitra L", "", +43409, Author, 283, 297, "Pi - Sunyer FX", "", +43410, Author, 300, 308, "Balena R", "", +43411, USA, 402, 405, "USA", "", +43417, ObjectiveDescription, 450, 600, "Therapies that lower blood glucose and provide weight loss may provide meaningful benefits for obese patients with type 2 diabetes mellitus ( T2DM ) .", "", +43412, BloodGlucose, 471, 484, "blood glucose", "", +43413, WeightReduction, 497, 508, "weight loss", "", +43414, Precondition, 545, 550, "obese", "", +43415, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +43416, Type2Diabetes, 592, 596, "T2DM", "", +43425, ObjectiveDescription, 601, 783, "This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy .", "", +43418, Drug, 637, 649, "taspoglutide", "", +43419, Placebo, 664, 671, "placebo", "", +43420, BodyWeight, 696, 702, "weight", "", +43421, Precondition, 706, 711, "obese", "", +43422, Type2Diabetes, 726, 730, "T2DM", "", +43423, Precondition, 731, 781, "inadequately controlled with metformin monotherapy", "", +43424, Metformin, 760, 769, "metformin", "", +43426, Duration, 810, 819, "24 - week", "", +43427, Randomized, 822, 832, "randomized", "", +43428, DoubleBlind, 835, 849, "double - blind", "", +43429, Placebo, 852, 859, "placebo", "", +43430, Multicenter, 875, 886, "multicenter", "", +43431, Precondition, 895, 900, "obese", "", +43432, Type2Diabetes, 913, 917, "T2DM", "", +43433, Randomized, 923, 933, "randomized", "", +43434, Drug, 967, 979, "taspoglutide", "", +43435, DoseValue, 980, 985, "20 mg", "", +43436, mg, 983, 985, "mg", "", +43438, DoseValue, 988, 993, "10 mg", "", +43437, mg, 991, 993, "mg", "", +43439, NumberPatientsArm, 1020, 1023, "154", "", +43441, Placebo, 1029, 1036, "placebo", "", +43440, NumberPatientsArm, 1043, 1046, "151", "", +43442, Duration, 1053, 1061, "24 weeks", "", +43443, HbA1c, 1091, 1105, "hemoglobin A1c", "", +43444, HbA1c, 1108, 1113, "HbA1c", "", +43445, BodyWeight, 1125, 1136, "body weight", "", +43446, HbA1c_target, 1172, 1199, "HbA1c ≤ 6 . 5 and ≤ 7 . 0 %", "", +43447, Percentage, 1198, 1199, "%", "", +43448, FastingPlasmaGlucose, 1206, 1228, "fasting plasma glucose", "", +43449, FastingPlasmaGlucose, 1231, 1234, "FPG", "", +43450, Mean, 1288, 1292, "Mean", "", +43452, TimePoint, 1293, 1301, "baseline", "", +43451, HbA1c, 1302, 1307, "HbA1c", "", +43453, BaseLineValue, 1312, 1318, "7 . 55", "", +43454, Percentage, 1319, 1320, "%", "", +43455, Mean, 1325, 1329, "mean", "", +43456, TimePoint, 1330, 1338, "baseline", "", +43457, BMI, 1339, 1342, "BMI", "", +43458, BaseLineValue, 1347, 1353, "36 . 7", "", +43459, Kg_per_squareMeter, 1354, 1366, "kg / m ( 2 )", "", +43460, HbA1c, 1369, 1374, "HbA1c", "", +43461, TimePoint, 1391, 1399, "baseline", "", +43462, Drug, 1432, 1444, "taspoglutide", "", +43463, Placebo, 1450, 1457, "placebo", "", +43464, LeastSquaresMean, 1460, 1477, "least square mean", "", +43465, LeastSquaresMean, 1480, 1486, "LSMean", "", +43466, ChangeValue, 1491, 1499, "- 0 . 81", "", +43468, Percentage, 1500, 1501, "%", "", +43467, ChangeValue, 1507, 1515, "- 0 . 09", "", +43469, Percentage, 1516, 1517, "%", "", +43470, PvalueDiff, 1520, 1532, "P < 0 . 0001", "", +43474, BodyWeight, 1537, 1543, "Weight", "", +43472, TimePoint, 1552, 1559, "week 24", "", +43473, Drug, 1591, 1603, "taspoglutide", "", +43482, Placebo, 1609, 1616, "placebo", "", +43476, LeastSquaresMean, 1619, 1625, "LSMean", "", +43477, ChangeValue, 1628, 1636, "- 3 . 16", "", +43478, ChangeValue, 1642, 1650, "- 1 . 85", "", +43481, Kg, 1651, 1653, "kg", "", +43479, PvalueDiff, 1656, 1666, "P < 0 . 01", "", +43484, Drug, 1678, 1690, "taspoglutide", "", +43483, Placebo, 1695, 1702, "placebo", "", +43485, HbA1c_target, 1712, 1745, "target HbA1c levels ( ≤ 6 . 5 % )", "", +43491, Percentage, 1742, 1743, "%", "", +43486, PercentageAffected, 1763, 1765, "49", "", +43487, PercentageAffected, 1770, 1772, "16", "", +43492, Percentage, 1773, 1774, "%", "", +43488, PercentageAffected, 1810, 1812, "72", "", +43489, PercentageAffected, 1817, 1819, "36", "", +43493, Percentage, 1820, 1821, "%", "", +43490, HbA1c_target, 1831, 1849, "HbA1c levels ≤ 7 %", "", +43494, Percentage, 1848, 1849, "%", "", +43495, FastingPlasmaGlucose, 1865, 1868, "FPG", "", +43497, Drug, 1901, 1913, "taspoglutide", "", +43498, Placebo, 1919, 1926, "placebo", "", +43499, ChangeValue, 1929, 1938, "- 23 . 59", "", +43500, ChangeValue, 1944, 1950, "0 . 09", "", +43501, Mg_per_deciliter, 1951, 1958, "mg / dl", "", +43502, PvalueDiff, 1961, 1973, "P < 0 . 0001", "", +43503, Drug, 2039, 2051, "taspoglutide", "", +43509, ConclusionComment, 2128, 2253, "In obese patients with T2DM , once - weekly taspoglutide provided the combined benefits of glycemic control and weight loss .", "", +43504, Precondition, 2131, 2136, "obese", "", +43505, Type2Diabetes, 2151, 2155, "T2DM", "", +43506, Frequency, 2158, 2171, "once - weekly", "", +43507, Drug, 2172, 2184, "taspoglutide", "", +43508, WeightReduction, 2240, 2251, "weight loss", "", +43510, PMID, 2330, 2338, "23404788", "", diff --git a/data/dm2 23404788_akramersunderbrink.n-triples b/data/dm2 23404788_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23404788_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23404788_export.csv b/data/dm2 23404788_export.csv new file mode 100644 index 0000000..54fa729 --- /dev/null +++ b/data/dm2 23404788_export.csv @@ -0,0 +1,505 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +302, 1, 1, 1, 0, 7, 0, 7, "Obesity" +302, 1, 2, 2, 8, 9, 8, 9, "(" +302, 1, 3, 3, 10, 16, 10, 16, "Silver" +302, 1, 4, 4, 17, 23, 17, 23, "Spring" +302, 1, 5, 5, 24, 25, 24, 25, ")" +302, 1, 6, 6, 26, 27, 26, 27, "." +302, 2, 1, 7, 0, 4, 28, 32, "2013" +302, 2, 2, 8, 5, 8, 33, 36, "Feb" +302, 2, 3, 9, 9, 10, 37, 38, ";" +302, 2, 4, 10, 11, 13, 39, 41, "21" +302, 2, 5, 11, 14, 15, 42, 43, "(" +302, 2, 6, 12, 16, 17, 44, 45, "2" +302, 2, 7, 13, 18, 19, 46, 47, ")" +302, 2, 8, 14, 20, 21, 48, 49, ":" +302, 2, 9, 15, 22, 25, 50, 53, "238" +302, 2, 10, 16, 26, 27, 54, 55, "-" +302, 2, 11, 17, 28, 30, 56, 58, "47" +302, 2, 12, 18, 31, 32, 59, 60, "." +302, 2, 13, 19, 33, 36, 61, 64, "doi" +302, 2, 14, 20, 37, 38, 65, 66, ":" +302, 2, 15, 21, 39, 41, 67, 69, "10" +302, 2, 16, 22, 42, 43, 70, 71, "." +302, 2, 17, 23, 44, 48, 72, 76, "1002" +302, 2, 18, 24, 49, 50, 77, 78, "/" +302, 2, 19, 25, 51, 54, 79, 82, "oby" +302, 2, 20, 26, 55, 56, 83, 84, "." +302, 2, 21, 27, 57, 62, 85, 90, "20042" +302, 2, 22, 28, 63, 64, 91, 92, "." +302, 3, 1, 29, 0, 7, 93, 100, "Effects" +302, 3, 2, 30, 8, 10, 101, 103, "of" +302, 3, 3, 31, 11, 23, 104, 116, "taspoglutide" +302, 3, 4, 32, 24, 26, 117, 119, "on" +302, 3, 5, 33, 27, 35, 120, 128, "glycemic" +302, 3, 6, 34, 36, 43, 129, 136, "control" +302, 3, 7, 35, 44, 47, 137, 140, "and" +302, 3, 8, 36, 48, 52, 141, 145, "body" +302, 3, 9, 37, 53, 59, 146, 152, "weight" +302, 3, 10, 38, 60, 62, 153, 155, "in" +302, 3, 11, 39, 63, 68, 156, 161, "obese" +302, 3, 12, 40, 69, 77, 162, 170, "patients" +302, 3, 13, 41, 78, 82, 171, 175, "with" +302, 3, 14, 42, 83, 87, 176, 180, "type" +302, 3, 15, 43, 88, 89, 181, 182, "2" +302, 3, 16, 44, 90, 98, 183, 191, "diabetes" +302, 3, 17, 45, 99, 100, 192, 193, "(" +302, 3, 18, 46, 101, 102, 194, 195, "T" +302, 3, 19, 47, 103, 104, 196, 197, "-" +302, 3, 20, 48, 105, 111, 198, 204, "emerge" +302, 3, 21, 49, 112, 113, 205, 206, "7" +302, 3, 22, 50, 114, 119, 207, 212, "study" +302, 3, 23, 51, 120, 121, 213, 214, ")" +302, 3, 24, 52, 122, 123, 215, 216, "." +302, 4, 1, 53, 0, 9, 217, 226, "Hollander" +302, 4, 2, 54, 10, 11, 227, 228, "P" +302, 4, 3, 55, 12, 13, 229, 230, "(" +302, 4, 4, 56, 14, 15, 231, 232, "1" +302, 4, 5, 57, 16, 17, 233, 234, ")" +302, 4, 6, 58, 18, 19, 235, 236, "," +302, 4, 7, 59, 20, 25, 237, 242, "Lasko" +302, 4, 8, 60, 26, 27, 243, 244, "B" +302, 4, 9, 61, 28, 29, 245, 246, "," +302, 4, 10, 62, 30, 37, 247, 254, "Barnett" +302, 4, 11, 63, 38, 40, 255, 257, "AH" +302, 4, 12, 64, 41, 42, 258, 259, "," +302, 4, 13, 65, 43, 49, 260, 266, "Bengus" +302, 4, 14, 66, 50, 51, 267, 268, "M" +302, 4, 15, 67, 52, 53, 269, 270, "," +302, 4, 16, 68, 54, 61, 271, 278, "Kanitra" +302, 4, 17, 69, 62, 63, 279, 280, "L" +302, 4, 18, 70, 64, 65, 281, 282, "," +302, 4, 19, 71, 66, 68, 283, 285, "Pi" +302, 4, 20, 72, 69, 70, 286, 287, "-" +302, 4, 21, 73, 71, 77, 288, 294, "Sunyer" +302, 4, 22, 74, 78, 80, 295, 297, "FX" +302, 4, 23, 75, 81, 82, 298, 299, "," +302, 4, 24, 76, 83, 89, 300, 306, "Balena" +302, 4, 25, 77, 90, 91, 307, 308, "R" +302, 4, 26, 78, 92, 93, 309, 310, "." +302, 4, 27, 79, 94, 100, 311, 317, "Author" +302, 4, 28, 80, 101, 112, 318, 329, "information" +302, 4, 29, 81, 113, 114, 330, 331, ":" +302, 4, 30, 82, 115, 116, 332, 333, "(" +302, 4, 31, 83, 117, 118, 334, 335, "1" +302, 4, 32, 84, 119, 120, 336, 337, ")" +302, 4, 33, 85, 121, 134, 338, 351, "Endocrinology" +302, 4, 34, 86, 135, 141, 352, 358, "Center" +302, 4, 35, 87, 142, 143, 359, 360, "," +302, 4, 36, 88, 144, 150, 361, 367, "Baylor" +302, 4, 37, 89, 151, 158, 368, 375, "Medical" +302, 4, 38, 90, 159, 165, 376, 382, "Center" +302, 4, 39, 91, 166, 167, 383, 384, "," +302, 4, 40, 92, 168, 174, 385, 391, "Dallas" +302, 4, 41, 93, 175, 176, 392, 393, "," +302, 4, 42, 94, 177, 182, 394, 399, "Texas" +302, 4, 43, 95, 183, 184, 400, 401, "," +302, 4, 44, 96, 185, 188, 402, 405, "USA" +302, 4, 45, 97, 189, 190, 406, 407, "." +302, 5, 1, 98, 0, 8, 408, 416, "priscilh" +302, 5, 2, 99, 9, 10, 417, 418, "@" +302, 5, 3, 100, 11, 23, 419, 431, "BaylorHealth" +302, 5, 4, 101, 24, 25, 432, 433, "." +302, 5, 5, 102, 26, 29, 434, 437, "edu" +302, 5, 6, 103, 30, 39, 438, 447, "OBJECTIVE" +302, 5, 7, 104, 40, 41, 448, 449, ":" +302, 5, 8, 105, 42, 51, 450, 459, "Therapies" +302, 5, 9, 106, 52, 56, 460, 464, "that" +302, 5, 10, 107, 57, 62, 465, 470, "lower" +302, 5, 11, 108, 63, 68, 471, 476, "blood" +302, 5, 12, 109, 69, 76, 477, 484, "glucose" +302, 5, 13, 110, 77, 80, 485, 488, "and" +302, 5, 14, 111, 81, 88, 489, 496, "provide" +302, 5, 15, 112, 89, 95, 497, 503, "weight" +302, 5, 16, 113, 96, 100, 504, 508, "loss" +302, 5, 17, 114, 101, 104, 509, 512, "may" +302, 5, 18, 115, 105, 112, 513, 520, "provide" +302, 5, 19, 116, 113, 123, 521, 531, "meaningful" +302, 5, 20, 117, 124, 132, 532, 540, "benefits" +302, 5, 21, 118, 133, 136, 541, 544, "for" +302, 5, 22, 119, 137, 142, 545, 550, "obese" +302, 5, 23, 120, 143, 151, 551, 559, "patients" +302, 5, 24, 121, 152, 156, 560, 564, "with" +302, 5, 25, 122, 157, 161, 565, 569, "type" +302, 5, 26, 123, 162, 163, 570, 571, "2" +302, 5, 27, 124, 164, 172, 572, 580, "diabetes" +302, 5, 28, 125, 173, 181, 581, 589, "mellitus" +302, 5, 29, 126, 182, 183, 590, 591, "(" +302, 5, 30, 127, 184, 188, 592, 596, "T2DM" +302, 5, 31, 128, 189, 190, 597, 598, ")" +302, 5, 32, 129, 191, 192, 599, 600, "." +302, 6, 1, 130, 0, 4, 601, 605, "This" +302, 6, 2, 131, 5, 10, 606, 611, "study" +302, 6, 3, 132, 11, 19, 612, 620, "assessed" +302, 6, 4, 133, 20, 23, 621, 624, "the" +302, 6, 5, 134, 24, 32, 625, 633, "efficacy" +302, 6, 6, 135, 33, 35, 634, 636, "of" +302, 6, 7, 136, 36, 48, 637, 649, "taspoglutide" +302, 6, 8, 137, 49, 57, 650, 658, "compared" +302, 6, 9, 138, 58, 62, 659, 663, "with" +302, 6, 10, 139, 63, 70, 664, 671, "placebo" +302, 6, 11, 140, 71, 73, 672, 674, "on" +302, 6, 12, 141, 74, 82, 675, 683, "glycemic" +302, 6, 13, 142, 83, 90, 684, 691, "control" +302, 6, 14, 143, 91, 94, 692, 695, "and" +302, 6, 15, 144, 95, 101, 696, 702, "weight" +302, 6, 16, 145, 102, 104, 703, 705, "in" +302, 6, 17, 146, 105, 110, 706, 711, "obese" +302, 6, 18, 147, 111, 119, 712, 720, "patients" +302, 6, 19, 148, 120, 124, 721, 725, "with" +302, 6, 20, 149, 125, 129, 726, 730, "T2DM" +302, 6, 21, 150, 130, 142, 731, 743, "inadequately" +302, 6, 22, 151, 143, 153, 744, 754, "controlled" +302, 6, 23, 152, 154, 158, 755, 759, "with" +302, 6, 24, 153, 159, 168, 760, 769, "metformin" +302, 6, 25, 154, 169, 180, 770, 781, "monotherapy" +302, 6, 26, 155, 181, 182, 782, 783, "." +302, 7, 1, 156, 0, 6, 784, 790, "DESIGN" +302, 7, 2, 157, 7, 10, 791, 794, "AND" +302, 7, 3, 158, 11, 18, 795, 802, "METHODS" +302, 7, 4, 159, 19, 20, 803, 804, ":" +302, 7, 5, 160, 21, 23, 805, 807, "In" +302, 7, 6, 161, 24, 25, 808, 809, "a" +302, 7, 7, 162, 26, 28, 810, 812, "24" +302, 7, 8, 163, 29, 30, 813, 814, "-" +302, 7, 9, 164, 31, 35, 815, 819, "week" +302, 7, 10, 165, 36, 37, 820, 821, "," +302, 7, 11, 166, 38, 48, 822, 832, "randomized" +302, 7, 12, 167, 49, 50, 833, 834, "," +302, 7, 13, 168, 51, 57, 835, 841, "double" +302, 7, 14, 169, 58, 59, 842, 843, "-" +302, 7, 15, 170, 60, 65, 844, 849, "blind" +302, 7, 16, 171, 66, 67, 850, 851, "," +302, 7, 17, 172, 68, 75, 852, 859, "placebo" +302, 7, 18, 173, 76, 77, 860, 861, "-" +302, 7, 19, 174, 78, 88, 862, 872, "controlled" +302, 7, 20, 175, 89, 90, 873, 874, "," +302, 7, 21, 176, 91, 102, 875, 886, "multicenter" +302, 7, 22, 177, 103, 108, 887, 892, "trial" +302, 7, 23, 178, 109, 110, 893, 894, "," +302, 7, 24, 179, 111, 116, 895, 900, "obese" +302, 7, 25, 180, 117, 123, 901, 907, "adults" +302, 7, 26, 181, 124, 128, 908, 912, "with" +302, 7, 27, 182, 129, 133, 913, 917, "T2DM" +302, 7, 28, 183, 134, 138, 918, 922, "were" +302, 7, 29, 184, 139, 149, 923, 933, "randomized" +302, 7, 30, 185, 150, 151, 934, 935, "(" +302, 7, 31, 186, 152, 153, 936, 937, "1" +302, 7, 32, 187, 154, 155, 938, 939, ":" +302, 7, 33, 188, 156, 157, 940, 941, "1" +302, 7, 34, 189, 158, 159, 942, 943, ")" +302, 7, 35, 190, 160, 162, 944, 946, "to" +302, 7, 36, 191, 163, 169, 947, 953, "weekly" +302, 7, 37, 192, 170, 182, 954, 966, "subcutaneous" +302, 7, 38, 193, 183, 195, 967, 979, "taspoglutide" +302, 7, 39, 194, 196, 198, 980, 982, "20" +302, 7, 40, 195, 199, 201, 983, 985, "mg" +302, 7, 41, 196, 202, 203, 986, 987, "(" +302, 7, 42, 197, 204, 206, 988, 990, "10" +302, 7, 43, 198, 207, 209, 991, 993, "mg" +302, 7, 44, 199, 210, 213, 994, 997, "for" +302, 7, 45, 200, 214, 219, 998, 1003, "first" +302, 7, 46, 201, 220, 221, 1004, 1005, "4" +302, 7, 47, 202, 222, 227, 1006, 1011, "weeks" +302, 7, 48, 203, 228, 229, 1012, 1013, ")" +302, 7, 49, 204, 230, 231, 1014, 1015, "(" +302, 7, 50, 205, 232, 233, 1016, 1017, "n" +302, 7, 51, 206, 234, 235, 1018, 1019, "=" +302, 7, 52, 207, 236, 239, 1020, 1023, "154" +302, 7, 53, 208, 240, 241, 1024, 1025, ")" +302, 7, 54, 209, 242, 244, 1026, 1028, "or" +302, 7, 55, 210, 245, 252, 1029, 1036, "placebo" +302, 7, 56, 211, 253, 254, 1037, 1038, "(" +302, 7, 57, 212, 255, 256, 1039, 1040, "n" +302, 7, 58, 213, 257, 258, 1041, 1042, "=" +302, 7, 59, 214, 259, 262, 1043, 1046, "151" +302, 7, 60, 215, 263, 264, 1047, 1048, ")" +302, 7, 61, 216, 265, 268, 1049, 1052, "for" +302, 7, 62, 217, 269, 271, 1053, 1055, "24" +302, 7, 63, 218, 272, 277, 1056, 1061, "weeks" +302, 7, 64, 219, 278, 279, 1062, 1063, "." +302, 8, 1, 220, 0, 8, 1064, 1072, "Efficacy" +302, 8, 2, 221, 9, 17, 1073, 1081, "measures" +302, 8, 3, 222, 18, 26, 1082, 1090, "included" +302, 8, 4, 223, 27, 37, 1091, 1101, "hemoglobin" +302, 8, 5, 224, 38, 41, 1102, 1105, "A1c" +302, 8, 6, 225, 42, 43, 1106, 1107, "(" +302, 8, 7, 226, 44, 49, 1108, 1113, "HbA1c" +302, 8, 8, 227, 50, 51, 1114, 1115, ")" +302, 8, 9, 228, 52, 58, 1116, 1122, "levels" +302, 8, 10, 229, 59, 60, 1123, 1124, "," +302, 8, 11, 230, 61, 65, 1125, 1129, "body" +302, 8, 12, 231, 66, 72, 1130, 1136, "weight" +302, 8, 13, 232, 73, 74, 1137, 1138, "," +302, 8, 14, 233, 75, 85, 1139, 1149, "percentage" +302, 8, 15, 234, 86, 88, 1150, 1152, "of" +302, 8, 16, 235, 89, 97, 1153, 1161, "patients" +302, 8, 17, 236, 98, 107, 1162, 1171, "achieving" +302, 8, 18, 237, 108, 113, 1172, 1177, "HbA1c" +302, 8, 19, 238, 114, 115, 1178, 1179, "≤" +302, 8, 20, 239, 116, 117, 1180, 1181, "6" +302, 8, 21, 240, 118, 119, 1182, 1183, "." +302, 8, 22, 241, 120, 121, 1184, 1185, "5" +302, 8, 23, 242, 122, 125, 1186, 1189, "and" +302, 8, 24, 243, 126, 127, 1190, 1191, "≤" +302, 8, 25, 244, 128, 129, 1192, 1193, "7" +302, 8, 26, 245, 130, 131, 1194, 1195, "." +302, 8, 27, 246, 132, 133, 1196, 1197, "0" +302, 8, 28, 247, 134, 135, 1198, 1199, "%" +302, 8, 29, 248, 136, 137, 1200, 1201, "," +302, 8, 30, 249, 138, 141, 1202, 1205, "and" +302, 8, 31, 250, 142, 149, 1206, 1213, "fasting" +302, 8, 32, 251, 150, 156, 1214, 1220, "plasma" +302, 8, 33, 252, 157, 164, 1221, 1228, "glucose" +302, 8, 34, 253, 165, 166, 1229, 1230, "(" +302, 8, 35, 254, 167, 170, 1231, 1234, "FPG" +302, 8, 36, 255, 171, 172, 1235, 1236, ")" +302, 8, 37, 256, 173, 174, 1237, 1238, "." +302, 9, 1, 257, 0, 7, 1239, 1246, "Adverse" +302, 9, 2, 258, 8, 14, 1247, 1253, "events" +302, 9, 3, 259, 15, 16, 1254, 1255, "(" +302, 9, 4, 260, 17, 20, 1256, 1259, "AEs" +302, 9, 5, 261, 21, 22, 1260, 1261, ")" +302, 9, 6, 262, 23, 27, 1262, 1266, "were" +302, 9, 7, 263, 28, 36, 1267, 1275, "assessed" +302, 9, 8, 264, 37, 38, 1276, 1277, "." +302, 10, 1, 265, 0, 7, 1278, 1285, "RESULTS" +302, 10, 2, 266, 8, 9, 1286, 1287, ":" +302, 10, 3, 267, 10, 14, 1288, 1292, "Mean" +302, 10, 4, 268, 15, 23, 1293, 1301, "baseline" +302, 10, 5, 269, 24, 29, 1302, 1307, "HbA1c" +302, 10, 6, 270, 30, 33, 1308, 1311, "was" +302, 10, 7, 271, 34, 35, 1312, 1313, "7" +302, 10, 8, 272, 36, 37, 1314, 1315, "." +302, 10, 9, 273, 38, 40, 1316, 1318, "55" +302, 10, 10, 274, 41, 42, 1319, 1320, "%" +302, 10, 11, 275, 43, 46, 1321, 1324, "and" +302, 10, 12, 276, 47, 51, 1325, 1329, "mean" +302, 10, 13, 277, 52, 60, 1330, 1338, "baseline" +302, 10, 14, 278, 61, 64, 1339, 1342, "BMI" +302, 10, 15, 279, 65, 68, 1343, 1346, "was" +302, 10, 16, 280, 69, 71, 1347, 1349, "36" +302, 10, 17, 281, 72, 73, 1350, 1351, "." +302, 10, 18, 282, 74, 75, 1352, 1353, "7" +302, 10, 19, 283, 76, 78, 1354, 1356, "kg" +302, 10, 20, 284, 79, 80, 1357, 1358, "/" +302, 10, 21, 285, 81, 82, 1359, 1360, "m" +302, 10, 22, 286, 83, 84, 1361, 1362, "(" +302, 10, 23, 287, 85, 86, 1363, 1364, "2" +302, 10, 24, 288, 87, 88, 1365, 1366, ")" +302, 10, 25, 289, 89, 90, 1367, 1368, "." +302, 11, 1, 290, 0, 5, 1369, 1374, "HbA1c" +302, 11, 2, 291, 6, 16, 1375, 1385, "reductions" +302, 11, 3, 292, 17, 21, 1386, 1390, "from" +302, 11, 4, 293, 22, 30, 1391, 1399, "baseline" +302, 11, 5, 294, 31, 35, 1400, 1404, "were" +302, 11, 6, 295, 36, 49, 1405, 1418, "significantly" +302, 11, 7, 296, 50, 57, 1419, 1426, "greater" +302, 11, 8, 297, 58, 62, 1427, 1431, "with" +302, 11, 9, 298, 63, 75, 1432, 1444, "taspoglutide" +302, 11, 10, 299, 76, 80, 1445, 1449, "than" +302, 11, 11, 300, 81, 88, 1450, 1457, "placebo" +302, 11, 12, 301, 89, 90, 1458, 1459, "(" +302, 11, 13, 302, 91, 96, 1460, 1465, "least" +302, 11, 14, 303, 97, 103, 1466, 1472, "square" +302, 11, 15, 304, 104, 108, 1473, 1477, "mean" +302, 11, 16, 305, 109, 110, 1478, 1479, "[" +302, 11, 17, 306, 111, 117, 1480, 1486, "LSMean" +302, 11, 18, 307, 118, 119, 1487, 1488, "]" +302, 11, 19, 308, 120, 121, 1489, 1490, "," +302, 11, 20, 309, 122, 123, 1491, 1492, "-" +302, 11, 21, 310, 124, 125, 1493, 1494, "0" +302, 11, 22, 311, 126, 127, 1495, 1496, "." +302, 11, 23, 312, 128, 130, 1497, 1499, "81" +302, 11, 24, 313, 131, 132, 1500, 1501, "%" +302, 11, 25, 314, 133, 135, 1502, 1504, "vs" +302, 11, 26, 315, 136, 137, 1505, 1506, "." +302, 11, 27, 316, 138, 139, 1507, 1508, "-" +302, 11, 28, 317, 140, 141, 1509, 1510, "0" +302, 11, 29, 318, 142, 143, 1511, 1512, "." +302, 11, 30, 319, 144, 146, 1513, 1515, "09" +302, 11, 31, 320, 147, 148, 1516, 1517, "%" +302, 11, 32, 321, 149, 150, 1518, 1519, ";" +302, 11, 33, 322, 151, 152, 1520, 1521, "P" +302, 11, 34, 323, 153, 154, 1522, 1523, "<" +302, 11, 35, 324, 155, 156, 1524, 1525, "0" +302, 11, 36, 325, 157, 158, 1526, 1527, "." +302, 11, 37, 326, 159, 163, 1528, 1532, "0001" +302, 11, 38, 327, 164, 165, 1533, 1534, ")" +302, 11, 39, 328, 166, 167, 1535, 1536, "." +302, 12, 1, 329, 0, 6, 1537, 1543, "Weight" +302, 12, 2, 330, 7, 11, 1544, 1548, "loss" +302, 12, 3, 331, 12, 14, 1549, 1551, "at" +302, 12, 4, 332, 15, 19, 1552, 1556, "week" +302, 12, 5, 333, 20, 22, 1557, 1559, "24" +302, 12, 6, 334, 23, 26, 1560, 1563, "was" +302, 12, 7, 335, 27, 40, 1564, 1577, "significantly" +302, 12, 8, 336, 41, 48, 1578, 1585, "greater" +302, 12, 9, 337, 49, 53, 1586, 1590, "with" +302, 12, 10, 338, 54, 66, 1591, 1603, "taspoglutide" +302, 12, 11, 339, 67, 71, 1604, 1608, "than" +302, 12, 12, 340, 72, 79, 1609, 1616, "placebo" +302, 12, 13, 341, 80, 81, 1617, 1618, "(" +302, 12, 14, 342, 82, 88, 1619, 1625, "LSMean" +302, 12, 15, 343, 89, 90, 1626, 1627, "," +302, 12, 16, 344, 91, 92, 1628, 1629, "-" +302, 12, 17, 345, 93, 94, 1630, 1631, "3" +302, 12, 18, 346, 95, 96, 1632, 1633, "." +302, 12, 19, 347, 97, 99, 1634, 1636, "16" +302, 12, 20, 348, 100, 102, 1637, 1639, "vs" +302, 12, 21, 349, 103, 104, 1640, 1641, "." +302, 12, 22, 350, 105, 106, 1642, 1643, "-" +302, 12, 23, 351, 107, 108, 1644, 1645, "1" +302, 12, 24, 352, 109, 110, 1646, 1647, "." +302, 12, 25, 353, 111, 113, 1648, 1650, "85" +302, 12, 26, 354, 114, 116, 1651, 1653, "kg" +302, 12, 27, 355, 117, 118, 1654, 1655, ";" +302, 12, 28, 356, 119, 120, 1656, 1657, "P" +302, 12, 29, 357, 121, 122, 1658, 1659, "<" +302, 12, 30, 358, 123, 124, 1660, 1661, "0" +302, 12, 31, 359, 125, 126, 1662, 1663, "." +302, 12, 32, 360, 127, 129, 1664, 1666, "01" +302, 12, 33, 361, 130, 131, 1667, 1668, ")" +302, 12, 34, 362, 132, 133, 1669, 1670, "." +302, 13, 1, 363, 0, 2, 1671, 1673, "In" +302, 13, 2, 364, 3, 6, 1674, 1677, "the" +302, 13, 3, 365, 7, 19, 1678, 1690, "taspoglutide" +302, 13, 4, 366, 20, 23, 1691, 1694, "and" +302, 13, 5, 367, 24, 31, 1695, 1702, "placebo" +302, 13, 6, 368, 32, 38, 1703, 1709, "groups" +302, 13, 7, 369, 39, 40, 1710, 1711, "," +302, 13, 8, 370, 41, 47, 1712, 1718, "target" +302, 13, 9, 371, 48, 53, 1719, 1724, "HbA1c" +302, 13, 10, 372, 54, 60, 1725, 1731, "levels" +302, 13, 11, 373, 61, 62, 1732, 1733, "(" +302, 13, 12, 374, 63, 64, 1734, 1735, "≤" +302, 13, 13, 375, 65, 66, 1736, 1737, "6" +302, 13, 14, 376, 67, 68, 1738, 1739, "." +302, 13, 15, 377, 69, 70, 1740, 1741, "5" +302, 13, 16, 378, 71, 72, 1742, 1743, "%" +302, 13, 17, 379, 73, 74, 1744, 1745, ")" +302, 13, 18, 380, 75, 79, 1746, 1750, "were" +302, 13, 19, 381, 80, 88, 1751, 1759, "achieved" +302, 13, 20, 382, 89, 91, 1760, 1762, "by" +302, 13, 21, 383, 92, 94, 1763, 1765, "49" +302, 13, 22, 384, 95, 98, 1766, 1769, "and" +302, 13, 23, 385, 99, 101, 1770, 1772, "16" +302, 13, 24, 386, 102, 103, 1773, 1774, "%" +302, 13, 25, 387, 104, 106, 1775, 1777, "of" +302, 13, 26, 388, 107, 115, 1778, 1786, "patients" +302, 13, 27, 389, 116, 117, 1787, 1788, "," +302, 13, 28, 390, 118, 130, 1789, 1801, "respectively" +302, 13, 29, 391, 131, 132, 1802, 1803, "," +302, 13, 30, 392, 133, 138, 1804, 1809, "while" +302, 13, 31, 393, 139, 141, 1810, 1812, "72" +302, 13, 32, 394, 142, 145, 1813, 1816, "and" +302, 13, 33, 395, 146, 148, 1817, 1819, "36" +302, 13, 34, 396, 149, 150, 1820, 1821, "%" +302, 13, 35, 397, 151, 159, 1822, 1830, "achieved" +302, 13, 36, 398, 160, 165, 1831, 1836, "HbA1c" +302, 13, 37, 399, 166, 172, 1837, 1843, "levels" +302, 13, 38, 400, 173, 174, 1844, 1845, "≤" +302, 13, 39, 401, 175, 176, 1846, 1847, "7" +302, 13, 40, 402, 177, 178, 1848, 1849, "%" +302, 13, 41, 403, 179, 180, 1850, 1851, "." +302, 14, 1, 404, 0, 9, 1852, 1861, "Decreases" +302, 14, 2, 405, 10, 12, 1862, 1864, "in" +302, 14, 3, 406, 13, 16, 1865, 1868, "FPG" +302, 14, 4, 407, 17, 21, 1869, 1873, "were" +302, 14, 5, 408, 22, 35, 1874, 1887, "significantly" +302, 14, 6, 409, 36, 43, 1888, 1895, "greater" +302, 14, 7, 410, 44, 48, 1896, 1900, "with" +302, 14, 8, 411, 49, 61, 1901, 1913, "taspoglutide" +302, 14, 9, 412, 62, 66, 1914, 1918, "than" +302, 14, 10, 413, 67, 74, 1919, 1926, "placebo" +302, 14, 11, 414, 75, 76, 1927, 1928, "(" +302, 14, 12, 415, 77, 78, 1929, 1930, "-" +302, 14, 13, 416, 79, 81, 1931, 1933, "23" +302, 14, 14, 417, 82, 83, 1934, 1935, "." +302, 14, 15, 418, 84, 86, 1936, 1938, "59" +302, 14, 16, 419, 87, 89, 1939, 1941, "vs" +302, 14, 17, 420, 90, 91, 1942, 1943, "." +302, 14, 18, 421, 92, 93, 1944, 1945, "0" +302, 14, 19, 422, 94, 95, 1946, 1947, "." +302, 14, 20, 423, 96, 98, 1948, 1950, "09" +302, 14, 21, 424, 99, 101, 1951, 1953, "mg" +302, 14, 22, 425, 102, 103, 1954, 1955, "/" +302, 14, 23, 426, 104, 106, 1956, 1958, "dl" +302, 14, 24, 427, 107, 108, 1959, 1960, ";" +302, 14, 25, 428, 109, 110, 1961, 1962, "P" +302, 14, 26, 429, 111, 112, 1963, 1964, "<" +302, 14, 27, 430, 113, 114, 1965, 1966, "0" +302, 14, 28, 431, 115, 116, 1967, 1968, "." +302, 14, 29, 432, 117, 121, 1969, 1973, "0001" +302, 14, 30, 433, 122, 123, 1974, 1975, ")" +302, 14, 31, 434, 124, 125, 1976, 1977, "." +302, 15, 1, 435, 0, 6, 1978, 1984, "Nausea" +302, 15, 2, 436, 7, 10, 1985, 1988, "and" +302, 15, 3, 437, 11, 19, 1989, 1997, "vomiting" +302, 15, 4, 438, 20, 24, 1998, 2002, "were" +302, 15, 5, 439, 25, 28, 2003, 2006, "the" +302, 15, 6, 440, 29, 33, 2007, 2011, "most" +302, 15, 7, 441, 34, 40, 2012, 2018, "common" +302, 15, 8, 442, 41, 44, 2019, 2022, "AEs" +302, 15, 9, 443, 45, 55, 2023, 2033, "associated" +302, 15, 10, 444, 56, 60, 2034, 2038, "with" +302, 15, 11, 445, 61, 73, 2039, 2051, "taspoglutide" +302, 15, 12, 446, 74, 75, 2052, 2053, "," +302, 15, 13, 447, 76, 79, 2054, 2057, "but" +302, 15, 14, 448, 80, 86, 2058, 2064, "tended" +302, 15, 15, 449, 87, 89, 2065, 2067, "to" +302, 15, 16, 450, 90, 92, 2068, 2070, "be" +302, 15, 17, 451, 93, 102, 2071, 2080, "transient" +302, 15, 18, 452, 103, 106, 2081, 2084, "and" +302, 15, 19, 453, 107, 116, 2085, 2094, "generally" +302, 15, 20, 454, 117, 121, 2095, 2099, "mild" +302, 15, 21, 455, 122, 124, 2100, 2102, "or" +302, 15, 22, 456, 125, 133, 2103, 2111, "moderate" +302, 15, 23, 457, 134, 135, 2112, 2113, "." +302, 16, 1, 458, 0, 11, 2114, 2125, "CONCLUSIONS" +302, 16, 2, 459, 12, 13, 2126, 2127, ":" +302, 16, 3, 460, 14, 16, 2128, 2130, "In" +302, 16, 4, 461, 17, 22, 2131, 2136, "obese" +302, 16, 5, 462, 23, 31, 2137, 2145, "patients" +302, 16, 6, 463, 32, 36, 2146, 2150, "with" +302, 16, 7, 464, 37, 41, 2151, 2155, "T2DM" +302, 16, 8, 465, 42, 43, 2156, 2157, "," +302, 16, 9, 466, 44, 48, 2158, 2162, "once" +302, 16, 10, 467, 49, 50, 2163, 2164, "-" +302, 16, 11, 468, 51, 57, 2165, 2171, "weekly" +302, 16, 12, 469, 58, 70, 2172, 2184, "taspoglutide" +302, 16, 13, 470, 71, 79, 2185, 2193, "provided" +302, 16, 14, 471, 80, 83, 2194, 2197, "the" +302, 16, 15, 472, 84, 92, 2198, 2206, "combined" +302, 16, 16, 473, 93, 101, 2207, 2215, "benefits" +302, 16, 17, 474, 102, 104, 2216, 2218, "of" +302, 16, 18, 475, 105, 113, 2219, 2227, "glycemic" +302, 16, 19, 476, 114, 121, 2228, 2235, "control" +302, 16, 20, 477, 122, 125, 2236, 2239, "and" +302, 16, 21, 478, 126, 132, 2240, 2246, "weight" +302, 16, 22, 479, 133, 137, 2247, 2251, "loss" +302, 16, 23, 480, 138, 139, 2252, 2253, "." +302, 17, 1, 481, 0, 9, 2254, 2263, "Copyright" +302, 17, 2, 482, 10, 11, 2264, 2265, "©" +302, 17, 3, 483, 12, 16, 2266, 2270, "2012" +302, 17, 4, 484, 17, 20, 2271, 2274, "The" +302, 17, 5, 485, 21, 28, 2275, 2282, "Obesity" +302, 17, 6, 486, 29, 36, 2283, 2290, "Society" +302, 17, 7, 487, 37, 38, 2291, 2292, "." +302, 18, 1, 488, 0, 3, 2293, 2296, "DOI" +302, 18, 2, 489, 4, 5, 2297, 2298, ":" +302, 18, 3, 490, 6, 8, 2299, 2301, "10" +302, 18, 4, 491, 9, 10, 2302, 2303, "." +302, 18, 5, 492, 11, 15, 2304, 2308, "1002" +302, 18, 6, 493, 16, 17, 2309, 2310, "/" +302, 18, 7, 494, 18, 21, 2311, 2314, "oby" +302, 18, 8, 495, 22, 23, 2315, 2316, "." +302, 18, 9, 496, 24, 29, 2317, 2322, "20042" +302, 18, 10, 497, 30, 34, 2323, 2327, "PMID" +302, 18, 11, 498, 35, 36, 2328, 2329, ":" +302, 18, 12, 499, 37, 45, 2330, 2338, "23404788" +302, 18, 13, 500, 46, 47, 2339, 2340, "[" +302, 18, 14, 501, 48, 55, 2341, 2348, "Indexed" +302, 18, 15, 502, 56, 59, 2349, 2352, "for" +302, 18, 16, 503, 60, 67, 2353, 2360, "MEDLINE" +302, 18, 17, 504, 68, 69, 2361, 2362, "]" diff --git a/data/dm2 23404788_kwoodley.annodb b/data/dm2 23404788_kwoodley.annodb new file mode 100644 index 0000000..509b74f --- /dev/null +++ b/data/dm2 23404788_kwoodley.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29276, Journal, 0, 27, "Obesity ( Silver Spring ) .", "", +29277, PublicationYear, 28, 32, "2013", "", +29341, Title, 93, 216, "Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes ( T - emerge 7 study ) .", "", +29278, Drug, 104, 116, "taspoglutide", "", +29308, BodyWeight, 141, 152, "body weight", "", +29332, Precondition, 156, 214, "obese patients with type 2 diabetes ( T - emerge 7 study )", "", +29320, Type2Diabetes, 176, 191, "type 2 diabetes", "", +29343, Author, 217, 228, "Hollander P", "", +29344, Author, 237, 244, "Lasko B", "", +29346, Author, 247, 257, "Barnett AH", "", +29347, Author, 260, 268, "Bengus M", "", +29349, Author, 271, 280, "Kanitra L", "", +29352, Author, 283, 297, "Pi - Sunyer FX", "", +29353, Author, 300, 308, "Balena R", "", +29355, USA, 402, 405, "USA", "", +29311, BodyWeight, 497, 503, "weight", "", +29333, Precondition, 545, 598, "obese patients with type 2 diabetes mellitus ( T2DM )", "", +29322, Type2Diabetes, 565, 589, "type 2 diabetes mellitus", "", +29324, Type2Diabetes, 592, 596, "T2DM", "", +29366, ObjectiveDescription, 601, 783, "This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy .", "", +29281, Drug, 637, 649, "taspoglutide", "", +29364, Placebo, 664, 671, "placebo", "", +29312, BodyWeight, 696, 702, "weight", "", +29335, Precondition, 706, 781, "obese patients with T2DM inadequately controlled with metformin monotherapy", "", +29325, Type2Diabetes, 726, 730, "T2DM", "", +29365, Metformin, 760, 769, "metformin", "", +29367, Duration, 810, 819, "24 - week", "", +29369, Randomized, 822, 832, "randomized", "", +29370, DoubleBlind, 835, 849, "double - blind", "", +29372, Placebo, 852, 859, "placebo", "", +29384, Multicenter, 875, 886, "multicenter", "", +29385, Precondition, 895, 917, "obese adults with T2DM", "", +29326, Type2Diabetes, 913, 917, "T2DM", "", +29386, Randomized, 923, 933, "randomized", "", +29388, AllocationRatio, 936, 941, "1 : 1", "", +29390, Frequency, 947, 953, "weekly", "", +29399, Subcutaneous, 954, 966, "subcutaneous", "", +29282, Drug, 967, 979, "taspoglutide", "", +29400, DoseValue, 980, 982, "20", "", +29401, mg, 983, 985, "mg", "", +29403, DoseValue, 988, 990, "10", "", +29402, mg, 991, 993, "mg", "", +29404, TimePoint, 994, 1011, "for first 4 weeks", "", +29406, NumberPatientsArm, 1020, 1023, "154", "", +29374, Placebo, 1029, 1036, "placebo", "", +29408, NumberPatientsArm, 1043, 1046, "151", "", +29409, Duration, 1053, 1061, "24 weeks", "", +29414, HbA1c, 1091, 1105, "hemoglobin A1c", "", +29415, HbA1c, 1108, 1113, "HbA1c", "", +29315, BodyWeight, 1125, 1136, "body weight", "", +29490, HbA1c_target, 1172, 1199, "HbA1c ≤ 6 . 5 and ≤ 7 . 0 %", "two targets", +29421, FastingPlasmaGlucose, 1206, 1228, "fasting plasma glucose", "", +29422, FastingPlasmaGlucose, 1231, 1234, "FPG", "", +29428, EndPointDescription, 1239, 1253, "Adverse events", "", +29430, EndPointDescription, 1256, 1259, "AEs", "", +29416, HbA1c, 1302, 1307, "HbA1c", "", +29437, BaseLineValue, 1312, 1318, "7 . 55", "", +29440, Percentage, 1319, 1320, "%", "", +29445, BMI, 1339, 1342, "BMI", "", +29438, BaseLineValue, 1347, 1353, "36 . 7", "", +29446, Kg_per_squareMeter, 1354, 1366, "kg / m ( 2 )", "", +29418, HbA1c, 1369, 1374, "HbA1c", "", +29283, Drug, 1432, 1444, "taspoglutide", "", +29376, Placebo, 1450, 1457, "placebo", "", +29450, LeastSquaresMean, 1460, 1477, "least square mean", "", +29451, LeastSquaresMean, 1480, 1486, "LSMean", "", +29454, Reduction, 1493, 1499, "0 . 81", "", +29442, Percentage, 1500, 1501, "%", "", +29455, Reduction, 1509, 1515, "0 . 09", "", +29443, Percentage, 1516, 1517, "%", "", +29462, PvalueDiff, 1520, 1532, "P < 0 . 0001", "", +29317, BodyWeight, 1537, 1543, "Weight", "", +33156, TimePoint, 1552, 1559, "week 24", "", +29284, Drug, 1591, 1603, "taspoglutide", "", +29377, Placebo, 1609, 1616, "placebo", "", +29466, LeastSquaresMean, 1619, 1625, "LSMean", "", +29468, Reduction, 1630, 1636, "3 . 16", "", +29469, Reduction, 1644, 1650, "1 . 85", "", +29470, Kg, 1651, 1653, "kg", "", +29463, PvalueDiff, 1656, 1666, "P < 0 . 01", "", +29285, Drug, 1678, 1690, "taspoglutide", "", +29379, Placebo, 1695, 1702, "placebo", "", +29491, HbA1c_target, 1712, 1745, "target HbA1c levels ( ≤ 6 . 5 % )", "target 1 ", +29473, NumberAffected, 1763, 1765, "49", "", +29477, PercentageAffected, 1770, 1772, "16", "", +29475, NumberAffected, 1810, 1812, "72", "", +29479, PercentageAffected, 1817, 1819, "36", "", +29485, HbA1c_target, 1831, 1849, "HbA1c levels ≤ 7 %", "target 2", +29424, FastingPlasmaGlucose, 1865, 1868, "FPG", "", +29286, Drug, 1901, 1913, "taspoglutide", "", +29380, Placebo, 1919, 1926, "placebo", "", +29494, Reduction, 1931, 1938, "23 . 59", "", +29496, Increment, 1944, 1950, "0 . 09", "", +29501, Mg_per_deciliter, 1951, 1958, "mg / dl", "", +29465, PvalueDiff, 1961, 1973, "P < 0 . 0001", "", +29504, Nausea, 1978, 1984, "Nausea", "", +29506, EndPointDescription, 1989, 1997, "vomiting", "", +29509, ObservedResult, 2003, 2111, "the most common AEs associated with taspoglutide , but tended to be transient and generally mild or moderate", "", +29434, EndPointDescription, 2019, 2022, "AEs", "", +29287, Drug, 2039, 2051, "taspoglutide", "", +29513, ConclusionComment, 2128, 2253, "In obese patients with T2DM , once - weekly taspoglutide provided the combined benefits of glycemic control and weight loss .", "", +29337, Precondition, 2131, 2155, "obese patients with T2DM", "", +29329, Type2Diabetes, 2151, 2155, "T2DM", "", +29511, Frequency, 2158, 2171, "once - weekly", "", +29288, Drug, 2172, 2184, "taspoglutide", "", +29382, BodyWeight, 2240, 2246, "weight", "", +29515, PMID, 2330, 2338, "23404788", "", diff --git a/data/dm2 23404788_kwoodley.n-triples b/data/dm2 23404788_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23404788_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23627775_admin.annodb b/data/dm2 23627775_admin.annodb new file mode 100644 index 0000000..483c192 --- /dev/null +++ b/data/dm2 23627775_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2013", "", " \"2013\"." +42, Title, 107, 247, "Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .", "", " \"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .\"." +79549, Lixisenatide, 130, 142, "lixisenatide", "", +13, Frequency, 143, 153, "once daily", "", +20, Placebo, 161, 168, "placebo", "", +26, Type2Diabetes, 172, 187, "type 2 diabetes", "", " ." +39, Precondition, 172, 245, "type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )", "", " \"type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )\"." +30, Pioglitazone, 217, 229, "pioglitazone", "", +43, Author, 248, 256, "Pinget M", "", " \"Pinget M\"." +44, Author, 265, 277, "Goldenberg R", "", " \"Goldenberg R\"." +45, Author, 280, 292, "Niemoeller E", "", " \"Niemoeller E\"." +46, Author, 295, 314, "Muehlen - Bartmer I", "", " \"Muehlen - Bartmer I\"." +47, Author, 317, 322, "Guo H", "", " \"Guo H\"." +48, Author, 325, 334, "Aronson R", "", " \"Aronson R\"." +49, France, 426, 432, "France", "", +50, ObjectiveDescription, 442, 622, "To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .", "", " \"To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .\"." +14, Frequency, 480, 492, "once - daily", "", +79550, Lixisenatide, 502, 514, "lixisenatide", "", +21, Placebo, 520, 527, "placebo", "", +27, Type2Diabetes, 531, 555, "type 2 diabetes mellitus", "", +40, Precondition, 531, 620, "type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin", "", " \"type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin\"." +28, Type2Diabetes, 558, 562, "T2DM", "", +38, Pioglitazone, 594, 606, "pioglitazone", "", +37, Metformin, 611, 620, "metformin", "", +51, Randomized, 638, 648, "randomized", "", " ." +52, DoubleBlind, 651, 665, "double - blind", "", " ." +59, Duration, 683, 692, "24 - week", "", " \"24 - week\"." +126, Duration, 721, 732, "≥ 52 - week", "", +53, Randomized, 775, 785, "randomized", "", " ." +54, AllocationRatio, 786, 793, "2  :  1", "", " . ." +79551, Lixisenatide, 805, 817, "lixisenatide", "", " ." +55, DoseValue, 818, 820, "20", "", " \"20\"." +130, Microgram, 821, 825, " µ g", "", " ." +15, Frequency, 826, 836, "once daily", "", " \"once daily\"." +22, Placebo, 840, 847, "placebo", "", " ." +57, HbA1c, 885, 905, "glycated haemoglobin", "", +58, HbA1c, 908, 913, "HbA1c", "", +96, TimePoint, 919, 926, "week 24", "", +60, NumberPatientsCT, 950, 953, "484", "", " \"484\"." +61, Randomized, 968, 978, "randomized", "", +62, NumberPatientsArm, 981, 984, "323", "", " \"323\"." +79552, Lixisenatide, 988, 1000, "lixisenatide", "", +63, NumberPatientsArm, 1003, 1006, "161", "", " \"161\"." +23, Placebo, 1010, 1017, "placebo", "", +142, TimePoint, 1026, 1036, "24   weeks", "", " \"24   weeks\". \"24   weeks\"." +79554, Lixisenatide, 1039, 1051, "lixisenatide", "", +16, Frequency, 1052, 1062, "once daily", "", +65, HbA1c, 1086, 1091, "HbA1c", "", " ." +152, DiffGroupAbsValue, 1094, 1102, "- 0 . 56", "", " \"- 0 . 56\"." +67, Percentage, 1103, 1104, "%", "", " ." +32, Placebo, 1110, 1117, "placebo", "", +154, PvalueDiff, 1120, 1134, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +69, HbA1c_target, 1188, 1199, "HbA1c < 7 %", "", " ." +161, Percentage, 1198, 1199, "%", "", +33, Placebo, 1214, 1221, "placebo", "", +70, PercentageAffected, 1224, 1230, "52 . 3", "", " \"52 . 3\"." +71, PercentageAffected, 1238, 1244, "26 . 4", "", " \"26 . 4\"." +72, PvalueDiff, 1264, 1278, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +73, FastingPlasmaGlucose, 1308, 1330, "fasting plasma glucose", "", " ." +153, DiffGroupAbsValue, 1333, 1341, "- 0 . 84", "", " \"- 0 . 84\"." +75, Millimoles_per_litre, 1344, 1352, "mmol / l", "", " ." +34, Placebo, 1358, 1365, "placebo", "", +155, PvalueDiff, 1368, 1382, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +65782, ObservedResult, 1397, 1413, "a small decrease", "", " \"a small decrease\"." +77, BodyWeight, 1417, 1428, "body weight", "", " ." +79555, Lixisenatide, 1434, 1446, "lixisenatide", "", +17, Frequency, 1447, 1457, "once daily", "", +65788, ObservedResult, 1462, 1478, "a small increase", "", " \"a small increase\"." +35, Placebo, 1484, 1491, "placebo", "", +65789, ObservedResult, 1499, 1561, "no statistically significant difference between the two groups", "", +79556, Lixisenatide, 1574, 1586, "lixisenatide", "", +18, Frequency, 1587, 1597, "once daily", "", +171, EndPointDescription, 1648, 1683, "treatment - emergent adverse events", "", " . ." +80, EndPointDescription, 1686, 1691, "TEAEs", "", +173, EndPointDescription, 1698, 1711, "serious TEAEs", "", " . ." +79562, Lixisenatide, 1729, 1741, "lixisenatide", "", +82, PercentageAffected, 1744, 1750, "72 . 4", "", " \"72 . 4\"." +84, PercentageAffected, 1757, 1762, "2 . 5", "", " \"2 . 5\"." +24, Placebo, 1767, 1774, "placebo", "", +83, PercentageAffected, 1777, 1783, "72 . 7", "", " \"72 . 7\"." +85, PercentageAffected, 1790, 1795, "1 . 9", "", " \"1 . 9\"." +86, SymptomaticHypoglycemia, 1802, 1827, "Symptomatic hypoglycaemia", "", " ." +79559, Lixisenatide, 1876, 1888, "lixisenatide", "", +87, PercentageAffected, 1889, 1894, "3 . 4", "", " \"3 . 4\"." +187, Percentage, 1895, 1896, "%", "", +25, Placebo, 1901, 1908, "placebo", "", +88, PercentageAffected, 1909, 1914, "1 . 2", "", " \"1 . 2\"." +188, Percentage, 1915, 1916, "%", "", +89, ObservedResult, 1921, 1944, "with no severe episodes", "", " \"with no severe episodes\". \"with no severe episodes\"." +79557, Lixisenatide, 1947, 1959, "Lixisenatide", "", +93, ConclusionComment, 2060, 2259, "Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period", "", " \"Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period\"." +79560, Lixisenatide, 2060, 2072, "Lixisenatide", "", +19, Frequency, 2073, 2083, "once daily", "", +90, Hypoglycemia, 2144, 2157, "hypoglycaemia", "", +91, Duration, 2188, 2198, "24   weeks", "", +92, DoubleBlind, 2228, 2242, "double - blind", "", +94, ConclusionComment, 2260, 2339, "in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .", "", " \"in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .\"." +29, Type2Diabetes, 2277, 2281, "T2DM", "", +31, Pioglitazone, 2311, 2323, "pioglitazone", "", +36, Metformin, 2328, 2337, "metformin", "", +95, PMID, 2408, 2416, "23627775", "", " \"23627775\"." diff --git a/data/dm2 23627775_admin.n-triples b/data/dm2 23627775_admin.n-triples new file mode 100644 index 0000000..7a3156b --- /dev/null +++ b/data/dm2 23627775_admin.n-triples @@ -0,0 +1,209 @@ +# RDF export of group: Publication + . + "Publication 44875" . + "Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) ." . + "Pinget M" . + "2013" . + "Diabetes Obes Metab ." . + "23627775" . + . + "Goldenberg R" . + "Niemoeller E" . + "Muehlen - Bartmer I" . + "Guo H" . + "Aronson R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 44882" . + "To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin ." . + "484" . + "24 - week" . + . + . + . + . + "Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period" . + . + . + . + . + . + . + "in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin ." . + . + . + . +# RDF export of group: Population + . + "Population 44898" . + "type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )" . + . + . + . + "type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "sae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + "323" . + . + . + . + . + . + . + . + . + . + "pla" . + "161" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + "once daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lix" . + . + "20" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "24   weeks" . + . + "hba 2" . + . + "24   weeks" . + . + "hbat 1" . + . + "52 . 3" . + . + "hbat 2" . + . + "26 . 4" . + . + "fpg 1" . + . + . + "fpg 2" . + . + . + "ae 1" . + . + "72 . 4" . + . + "ae 2" . + . + "72 . 7" . + . + "sae 1" . + . + "2 . 5" . + . + "sae 2" . + . + "1 . 9" . + . + "hyp 1" . + . + "3 . 4" . + "with no severe episodes" . + . + "hyp 2" . + . + "1 . 2" . + "with no severe episodes" . + . + "bw 1" . + . + "a small decrease" . + . + "bw 2" . + . + "a small increase" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 56" . + "p  <  0 . 0001" . + . + . + . + "hbat" . + "p  <  0 . 0001" . + . + . + . + "fpg" . + "- 0 . 84" . + "p  <  0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23627775_akramersunderbrink.annodb b/data/dm2 23627775_akramersunderbrink.annodb new file mode 100644 index 0000000..98414a3 --- /dev/null +++ b/data/dm2 23627775_akramersunderbrink.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43511, Journal, 0, 19, "Diabetes Obes Metab", "", +43512, PublicationYear, 22, 26, "2013", "", +43519, Title, 107, 247, "Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .", "", +43513, Drug, 130, 142, "lixisenatide", "", +43514, Frequency, 143, 153, "once daily", "", +43515, Placebo, 161, 168, "placebo", "", +43516, Type2Diabetes, 172, 187, "type 2 diabetes", "", +43518, Precondition, 188, 229, "insufficiently controlled on pioglitazone", "", +43517, Pioglitazone, 217, 229, "pioglitazone", "", +43520, Author, 248, 256, "Pinget M", "", +43521, Author, 265, 277, "Goldenberg R", "", +43522, Author, 280, 292, "Niemoeller E", "", +43523, Author, 295, 314, "Muehlen - Bartmer I", "", +43524, Author, 317, 322, "Guo H", "", +43525, Author, 325, 334, "Aronson R", "", +43526, France, 426, 432, "France", "", +43535, ObjectiveDescription, 442, 622, "To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .", "", +43527, Frequency, 480, 492, "once - daily", "", +43528, Drug, 502, 514, "lixisenatide", "", +43529, Placebo, 520, 527, "placebo", "", +43530, Type2Diabetes, 531, 555, "type 2 diabetes mellitus", "", +43531, Type2Diabetes, 558, 562, "T2DM", "", +43534, Precondition, 565, 620, "insufficiently controlled by pioglitazone  ±  metformin", "", +43532, Pioglitazone, 594, 606, "pioglitazone", "", +43533, Metformin, 611, 620, "metformin", "", +43536, Randomized, 638, 648, "randomized", "", +43537, DoubleBlind, 651, 665, "double - blind", "", +43538, Duration, 683, 692, "24 - week", "", +43539, Duration, 721, 732, "≥ 52 - week", "", +43540, Randomized, 775, 785, "randomized", "", +43541, Drug, 805, 817, "lixisenatide", "", +43543, DoseValue, 818, 825, "20  µ g", "", +43544, Microgram, 821, 825, " µ g", "", +43545, Frequency, 826, 836, "once daily", "", +43546, Placebo, 840, 847, "placebo", "", +43547, HbA1c, 885, 905, "glycated haemoglobin", "", +43548, HbA1c, 908, 913, "HbA1c", "", +43549, TimePoint, 919, 926, "week 24", "", +43550, NumberPatientsCT, 950, 953, "484", "", +43551, Randomized, 968, 978, "randomized", "", +43552, NumberPatientsArm, 981, 984, "323", "", +43554, Drug, 988, 1000, "lixisenatide", "", +43553, NumberPatientsArm, 1003, 1006, "161", "", +43555, Placebo, 1010, 1017, "placebo", "", +43556, TimePoint, 1026, 1036, "24   weeks", "", +43557, Drug, 1039, 1051, "lixisenatide", "", +43558, Frequency, 1052, 1062, "once daily", "", +43559, HbA1c, 1086, 1091, "HbA1c", "", +43567, DiffGroupAbsValue, 1094, 1102, "- 0 . 56", "", +43573, Percentage, 1103, 1104, "%", "", +43560, Placebo, 1110, 1117, "placebo", "", +43569, PvalueDiff, 1120, 1134, "p  <  0 . 0001", "", +43561, HbA1c_target, 1188, 1199, "HbA1c < 7 %", "", +43576, Percentage, 1198, 1199, "%", "", +43562, Placebo, 1214, 1221, "placebo", "", +43565, ChangeValue, 1224, 1230, "52 . 3", "", +43575, Percentage, 1231, 1232, "%", "", +43566, ChangeValue, 1238, 1244, "26 . 4", "", +43574, Percentage, 1245, 1246, "%", "", +43571, PValueChangeValue, 1264, 1278, "p  <  0 . 0001", "", +43563, FastingPlasmaGlucose, 1308, 1330, "fasting plasma glucose", "", +43568, DiffGroupAbsValue, 1333, 1341, "- 0 . 84", "", +43577, Millimoles_per_litre, 1344, 1352, "mmol / l", "", +43572, Placebo, 1358, 1365, "placebo", "", +43570, PvalueDiff, 1368, 1382, "p  <  0 . 0001", "", +43578, BodyWeight, 1417, 1428, "body weight", "", +43579, Drug, 1434, 1446, "lixisenatide", "", +43580, Frequency, 1447, 1457, "once daily", "", +43581, Placebo, 1484, 1491, "placebo", "", +43582, Drug, 1574, 1586, "lixisenatide", "", +43583, Frequency, 1587, 1597, "once daily", "", +43586, EndPointDescription, 1648, 1683, "treatment - emergent adverse events", "", +43587, EndPointDescription, 1686, 1691, "TEAEs", "", +43588, EndPointDescription, 1698, 1711, "serious TEAEs", "", +43584, Drug, 1729, 1741, "lixisenatide", "", +43589, PercentageAffected, 1744, 1750, "72 . 4", "", +43593, Percentage, 1751, 1752, "%", "", +43590, PercentageAffected, 1757, 1762, "2 . 5", "", +43594, Percentage, 1763, 1764, "%", "", +43585, Placebo, 1767, 1774, "placebo", "", +43591, PercentageAffected, 1777, 1783, "72 . 7", "", +43595, Percentage, 1784, 1785, "%", "", +43592, PercentageAffected, 1790, 1795, "1 . 9", "", +43596, Percentage, 1796, 1797, "%", "", +43597, SymptomaticHypoglycemia, 1802, 1827, "Symptomatic hypoglycaemia", "", +43598, Drug, 1876, 1888, "lixisenatide", "", +43600, PercentageAffected, 1889, 1894, "3 . 4", "", +43602, Percentage, 1895, 1896, "%", "", +43599, Placebo, 1901, 1908, "placebo", "", +43601, PercentageAffected, 1909, 1914, "1 . 2", "", +43603, Percentage, 1915, 1916, "%", "", +43604, Drug, 1947, 1959, "Lixisenatide", "", +43605, Drug, 2060, 2072, "Lixisenatide", "", +43615, ConclusionComment, 2060, 2259, "Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period", "", +43606, Frequency, 2073, 2083, "once daily", "", +43607, Hypoglycemia, 2144, 2157, "hypoglycaemia", "", +43608, Duration, 2188, 2198, "24   weeks", "", +43609, DoubleBlind, 2228, 2242, "double - blind", "", +43616, ConclusionComment, 2260, 2339, "in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .", "", +43610, Type2Diabetes, 2277, 2281, "T2DM", "", +43611, Precondition, 2282, 2337, "insufficiently controlled on pioglitazone  ±  metformin", "", +43612, Pioglitazone, 2311, 2323, "pioglitazone", "", +43613, Metformin, 2328, 2337, "metformin", "", +43614, PMID, 2408, 2416, "23627775", "", diff --git a/data/dm2 23627775_akramersunderbrink.n-triples b/data/dm2 23627775_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23627775_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23627775_export.csv b/data/dm2 23627775_export.csv new file mode 100644 index 0000000..546bf6b --- /dev/null +++ b/data/dm2 23627775_export.csv @@ -0,0 +1,488 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +301, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +301, 1, 2, 2, 9, 13, 9, 13, "Obes" +301, 1, 3, 3, 14, 19, 14, 19, "Metab" +301, 1, 4, 4, 20, 21, 20, 21, "." +301, 2, 1, 5, 0, 4, 22, 26, "2013" +301, 2, 2, 6, 5, 8, 27, 30, "Nov" +301, 2, 3, 7, 9, 10, 31, 32, ";" +301, 2, 4, 8, 11, 13, 33, 35, "15" +301, 2, 5, 9, 14, 15, 36, 37, "(" +301, 2, 6, 10, 16, 18, 38, 40, "11" +301, 2, 7, 11, 19, 20, 41, 42, ")" +301, 2, 8, 12, 21, 22, 43, 44, ":" +301, 2, 9, 13, 23, 27, 45, 49, "1000" +301, 2, 10, 14, 28, 29, 50, 51, "-" +301, 2, 11, 15, 30, 31, 52, 53, "7" +301, 2, 12, 16, 32, 33, 54, 55, "." +301, 2, 13, 17, 34, 37, 56, 59, "doi" +301, 2, 14, 18, 38, 39, 60, 61, ":" +301, 2, 15, 19, 40, 42, 62, 64, "10" +301, 2, 16, 20, 43, 44, 65, 66, "." +301, 2, 17, 21, 45, 49, 67, 71, "1111" +301, 2, 18, 22, 50, 51, 72, 73, "/" +301, 2, 19, 23, 52, 55, 74, 77, "dom" +301, 2, 20, 24, 56, 57, 78, 79, "." +301, 2, 21, 25, 58, 63, 80, 85, "12121" +301, 2, 22, 26, 64, 65, 86, 87, "." +301, 3, 1, 27, 0, 4, 88, 92, "Epub" +301, 3, 2, 28, 5, 9, 93, 97, "2013" +301, 3, 3, 29, 10, 13, 98, 101, "May" +301, 3, 4, 30, 14, 16, 102, 104, "26" +301, 3, 5, 31, 17, 18, 105, 106, "." +301, 4, 1, 32, 0, 8, 107, 115, "Efficacy" +301, 4, 2, 33, 9, 12, 116, 119, "and" +301, 4, 3, 34, 13, 19, 120, 126, "safety" +301, 4, 4, 35, 20, 22, 127, 129, "of" +301, 4, 5, 36, 23, 35, 130, 142, "lixisenatide" +301, 4, 6, 37, 36, 40, 143, 147, "once" +301, 4, 7, 38, 41, 46, 148, 153, "daily" +301, 4, 8, 39, 47, 53, 154, 160, "versus" +301, 4, 9, 40, 54, 61, 161, 168, "placebo" +301, 4, 10, 41, 62, 64, 169, 171, "in" +301, 4, 11, 42, 65, 69, 172, 176, "type" +301, 4, 12, 43, 70, 71, 177, 178, "2" +301, 4, 13, 44, 72, 80, 179, 187, "diabetes" +301, 4, 14, 45, 81, 95, 188, 202, "insufficiently" +301, 4, 15, 46, 96, 106, 203, 213, "controlled" +301, 4, 16, 47, 107, 109, 214, 216, "on" +301, 4, 17, 48, 110, 122, 217, 229, "pioglitazone" +301, 4, 18, 49, 123, 124, 230, 231, "(" +301, 4, 19, 50, 125, 132, 232, 239, "GetGoal" +301, 4, 20, 51, 133, 134, 240, 241, "-" +301, 4, 21, 52, 135, 136, 242, 243, "P" +301, 4, 22, 53, 137, 138, 244, 245, ")" +301, 4, 23, 54, 139, 140, 246, 247, "." +301, 5, 1, 55, 0, 6, 248, 254, "Pinget" +301, 5, 2, 56, 7, 8, 255, 256, "M" +301, 5, 3, 57, 9, 10, 257, 258, "(" +301, 5, 4, 58, 11, 12, 259, 260, "1" +301, 5, 5, 59, 13, 14, 261, 262, ")" +301, 5, 6, 60, 15, 16, 263, 264, "," +301, 5, 7, 61, 17, 27, 265, 275, "Goldenberg" +301, 5, 8, 62, 28, 29, 276, 277, "R" +301, 5, 9, 63, 30, 31, 278, 279, "," +301, 5, 10, 64, 32, 42, 280, 290, "Niemoeller" +301, 5, 11, 65, 43, 44, 291, 292, "E" +301, 5, 12, 66, 45, 46, 293, 294, "," +301, 5, 13, 67, 47, 54, 295, 302, "Muehlen" +301, 5, 14, 68, 55, 56, 303, 304, "-" +301, 5, 15, 69, 57, 64, 305, 312, "Bartmer" +301, 5, 16, 70, 65, 66, 313, 314, "I" +301, 5, 17, 71, 67, 68, 315, 316, "," +301, 5, 18, 72, 69, 72, 317, 320, "Guo" +301, 5, 19, 73, 73, 74, 321, 322, "H" +301, 5, 20, 74, 75, 76, 323, 324, "," +301, 5, 21, 75, 77, 84, 325, 332, "Aronson" +301, 5, 22, 76, 85, 86, 333, 334, "R" +301, 5, 23, 77, 87, 88, 335, 336, "." +301, 5, 24, 78, 89, 95, 337, 343, "Author" +301, 5, 25, 79, 96, 107, 344, 355, "information" +301, 5, 26, 80, 108, 109, 356, 357, ":" +301, 5, 27, 81, 110, 111, 358, 359, "(" +301, 5, 28, 82, 112, 113, 360, 361, "1" +301, 5, 29, 83, 114, 115, 362, 363, ")" +301, 5, 30, 84, 116, 126, 364, 374, "Department" +301, 5, 31, 85, 127, 129, 375, 377, "of" +301, 5, 32, 86, 130, 143, 378, 391, "Endocrinology" +301, 5, 33, 87, 144, 147, 392, 395, "and" +301, 5, 34, 88, 148, 156, 396, 404, "Diabetes" +301, 5, 35, 89, 157, 158, 405, 406, "," +301, 5, 36, 90, 159, 162, 407, 410, "HUS" +301, 5, 37, 91, 163, 164, 411, 412, "," +301, 5, 38, 92, 165, 175, 413, 423, "Strasbourg" +301, 5, 39, 93, 176, 177, 424, 425, "," +301, 5, 40, 94, 178, 184, 426, 432, "France" +301, 5, 41, 95, 185, 186, 433, 434, "." +301, 6, 1, 96, 0, 4, 435, 439, "AIMS" +301, 6, 2, 97, 5, 6, 440, 441, ":" +301, 6, 3, 98, 7, 9, 442, 444, "To" +301, 6, 4, 99, 10, 17, 445, 452, "compare" +301, 6, 5, 100, 18, 21, 453, 456, "the" +301, 6, 6, 101, 22, 30, 457, 465, "efficacy" +301, 6, 7, 102, 31, 34, 466, 469, "and" +301, 6, 8, 103, 35, 41, 470, 476, "safety" +301, 6, 9, 104, 42, 44, 477, 479, "of" +301, 6, 10, 105, 45, 49, 480, 484, "once" +301, 6, 11, 106, 50, 51, 485, 486, "-" +301, 6, 12, 107, 52, 57, 487, 492, "daily" +301, 6, 13, 108, 58, 66, 493, 501, "prandial" +301, 6, 14, 109, 67, 79, 502, 514, "lixisenatide" +301, 6, 15, 110, 80, 84, 515, 519, "with" +301, 6, 16, 111, 85, 92, 520, 527, "placebo" +301, 6, 17, 112, 93, 95, 528, 530, "in" +301, 6, 18, 113, 96, 100, 531, 535, "type" +301, 6, 19, 114, 101, 102, 536, 537, "2" +301, 6, 20, 115, 103, 111, 538, 546, "diabetes" +301, 6, 21, 116, 112, 120, 547, 555, "mellitus" +301, 6, 22, 117, 121, 122, 556, 557, "(" +301, 6, 23, 118, 123, 127, 558, 562, "T2DM" +301, 6, 24, 119, 128, 129, 563, 564, ")" +301, 6, 25, 120, 130, 144, 565, 579, "insufficiently" +301, 6, 26, 121, 145, 155, 580, 590, "controlled" +301, 6, 27, 122, 156, 158, 591, 593, "by" +301, 6, 28, 123, 159, 171, 594, 606, "pioglitazone" +301, 6, 29, 124, 172, 175, 607, 610, " ± " +301, 6, 30, 125, 176, 185, 611, 620, "metformin" +301, 6, 31, 126, 186, 187, 621, 622, "." +301, 7, 1, 127, 0, 7, 623, 630, "METHODS" +301, 7, 2, 128, 8, 9, 631, 632, ":" +301, 7, 3, 129, 10, 14, 633, 637, "This" +301, 7, 4, 130, 15, 25, 638, 648, "randomized" +301, 7, 5, 131, 26, 27, 649, 650, "," +301, 7, 6, 132, 28, 34, 651, 657, "double" +301, 7, 7, 133, 35, 36, 658, 659, "-" +301, 7, 8, 134, 37, 42, 660, 665, "blind" +301, 7, 9, 135, 43, 48, 666, 671, "study" +301, 7, 10, 136, 49, 57, 672, 680, "included" +301, 7, 11, 137, 58, 59, 681, 682, "a" +301, 7, 12, 138, 60, 62, 683, 685, "24" +301, 7, 13, 139, 63, 64, 686, 687, "-" +301, 7, 14, 140, 65, 69, 688, 692, "week" +301, 7, 15, 141, 70, 74, 693, 697, "main" +301, 7, 16, 142, 75, 84, 698, 707, "treatment" +301, 7, 17, 143, 85, 91, 708, 714, "period" +301, 7, 18, 144, 92, 95, 715, 718, "and" +301, 7, 19, 145, 96, 97, 719, 720, "a" +301, 7, 20, 146, 98, 99, 721, 722, "≥" +301, 7, 21, 147, 100, 102, 723, 725, "52" +301, 7, 22, 148, 103, 104, 726, 727, "-" +301, 7, 23, 149, 105, 109, 728, 732, "week" +301, 7, 24, 150, 110, 118, 733, 741, "variable" +301, 7, 25, 151, 119, 128, 742, 751, "extension" +301, 7, 26, 152, 129, 135, 752, 758, "period" +301, 7, 27, 153, 136, 137, 759, 760, "." +301, 8, 1, 154, 0, 8, 761, 769, "Patients" +301, 8, 2, 155, 9, 13, 770, 774, "were" +301, 8, 3, 156, 14, 24, 775, 785, "randomized" +301, 8, 4, 157, 25, 26, 786, 787, "2" +301, 8, 5, 158, 27, 30, 788, 791, " : " +301, 8, 6, 159, 31, 32, 792, 793, "1" +301, 8, 7, 160, 33, 35, 794, 796, "to" +301, 8, 8, 161, 36, 43, 797, 804, "receive" +301, 8, 9, 162, 44, 56, 805, 817, "lixisenatide" +301, 8, 10, 163, 57, 59, 818, 820, "20" +301, 8, 11, 164, 60, 62, 821, 823, " µ" +301, 8, 12, 165, 63, 64, 824, 825, "g" +301, 8, 13, 166, 65, 69, 826, 830, "once" +301, 8, 14, 167, 70, 75, 831, 836, "daily" +301, 8, 15, 168, 76, 78, 837, 839, "or" +301, 8, 16, 169, 79, 86, 840, 847, "placebo" +301, 8, 17, 170, 87, 88, 848, 849, "." +301, 9, 1, 171, 0, 3, 850, 853, "The" +301, 9, 2, 172, 4, 11, 854, 861, "primary" +301, 9, 3, 173, 12, 20, 862, 870, "endpoint" +301, 9, 4, 174, 21, 24, 871, 874, "was" +301, 9, 5, 175, 25, 31, 875, 881, "change" +301, 9, 6, 176, 32, 34, 882, 884, "in" +301, 9, 7, 177, 35, 43, 885, 893, "glycated" +301, 9, 8, 178, 44, 55, 894, 905, "haemoglobin" +301, 9, 9, 179, 56, 57, 906, 907, "(" +301, 9, 10, 180, 58, 63, 908, 913, "HbA1c" +301, 9, 11, 181, 64, 65, 914, 915, ")" +301, 9, 12, 182, 66, 68, 916, 918, "at" +301, 9, 13, 183, 69, 73, 919, 923, "week" +301, 9, 14, 184, 74, 76, 924, 926, "24" +301, 9, 15, 185, 77, 78, 927, 928, "." +301, 10, 1, 186, 0, 7, 929, 936, "RESULTS" +301, 10, 2, 187, 8, 9, 937, 938, ":" +301, 10, 3, 188, 10, 12, 939, 941, "In" +301, 10, 4, 189, 13, 18, 942, 947, "total" +301, 10, 5, 190, 19, 20, 948, 949, "," +301, 10, 6, 191, 21, 24, 950, 953, "484" +301, 10, 7, 192, 25, 33, 954, 962, "patients" +301, 10, 8, 193, 34, 38, 963, 967, "were" +301, 10, 9, 194, 39, 49, 968, 978, "randomized" +301, 10, 10, 195, 50, 51, 979, 980, ":" +301, 10, 11, 196, 52, 55, 981, 984, "323" +301, 10, 12, 197, 56, 58, 985, 987, "to" +301, 10, 13, 198, 59, 71, 988, 1000, "lixisenatide" +301, 10, 14, 199, 72, 73, 1001, 1002, ";" +301, 10, 15, 200, 74, 77, 1003, 1006, "161" +301, 10, 16, 201, 78, 80, 1007, 1009, "to" +301, 10, 17, 202, 81, 88, 1010, 1017, "placebo" +301, 10, 18, 203, 89, 90, 1018, 1019, "." +301, 11, 1, 204, 0, 5, 1020, 1025, "After" +301, 11, 2, 205, 6, 8, 1026, 1028, "24" +301, 11, 3, 206, 9, 10, 1029, 1030, " " +301, 11, 4, 207, 11, 16, 1031, 1036, "weeks" +301, 11, 5, 208, 17, 18, 1037, 1038, "," +301, 11, 6, 209, 19, 31, 1039, 1051, "lixisenatide" +301, 11, 7, 210, 32, 36, 1052, 1056, "once" +301, 11, 8, 211, 37, 42, 1057, 1062, "daily" +301, 11, 9, 212, 43, 56, 1063, 1076, "significantly" +301, 11, 10, 213, 57, 65, 1077, 1085, "improved" +301, 11, 11, 214, 66, 71, 1086, 1091, "HbA1c" +301, 11, 12, 215, 72, 73, 1092, 1093, "(" +301, 11, 13, 216, 74, 75, 1094, 1095, "-" +301, 11, 14, 217, 76, 77, 1096, 1097, "0" +301, 11, 15, 218, 78, 79, 1098, 1099, "." +301, 11, 16, 219, 80, 82, 1100, 1102, "56" +301, 11, 17, 220, 83, 84, 1103, 1104, "%" +301, 11, 18, 221, 85, 87, 1105, 1107, "vs" +301, 11, 19, 222, 88, 89, 1108, 1109, "." +301, 11, 20, 223, 90, 97, 1110, 1117, "placebo" +301, 11, 21, 224, 98, 99, 1118, 1119, ";" +301, 11, 22, 225, 100, 101, 1120, 1121, "p" +301, 11, 23, 226, 102, 105, 1122, 1125, " < " +301, 11, 24, 227, 106, 107, 1126, 1127, "0" +301, 11, 25, 228, 108, 109, 1128, 1129, "." +301, 11, 26, 229, 110, 114, 1130, 1134, "0001" +301, 11, 27, 230, 115, 116, 1135, 1136, ")" +301, 11, 28, 231, 117, 120, 1137, 1140, "and" +301, 11, 29, 232, 121, 130, 1141, 1150, "increased" +301, 11, 30, 233, 131, 134, 1151, 1154, "the" +301, 11, 31, 234, 135, 145, 1155, 1165, "proportion" +301, 11, 32, 235, 146, 148, 1166, 1168, "of" +301, 11, 33, 236, 149, 157, 1169, 1177, "patients" +301, 11, 34, 237, 158, 167, 1178, 1187, "achieving" +301, 11, 35, 238, 168, 173, 1188, 1193, "HbA1c" +301, 11, 36, 239, 174, 175, 1194, 1195, "<" +301, 11, 37, 240, 176, 177, 1196, 1197, "7" +301, 11, 38, 241, 178, 179, 1198, 1199, "%" +301, 11, 39, 242, 180, 188, 1200, 1208, "compared" +301, 11, 40, 243, 189, 193, 1209, 1213, "with" +301, 11, 41, 244, 194, 201, 1214, 1221, "placebo" +301, 11, 42, 245, 202, 203, 1222, 1223, "(" +301, 11, 43, 246, 204, 206, 1224, 1226, "52" +301, 11, 44, 247, 207, 208, 1227, 1228, "." +301, 11, 45, 248, 209, 210, 1229, 1230, "3" +301, 11, 46, 249, 211, 212, 1231, 1232, "%" +301, 11, 47, 250, 213, 215, 1233, 1235, "vs" +301, 11, 48, 251, 216, 217, 1236, 1237, "." +301, 11, 49, 252, 218, 220, 1238, 1240, "26" +301, 11, 50, 253, 221, 222, 1241, 1242, "." +301, 11, 51, 254, 223, 224, 1243, 1244, "4" +301, 11, 52, 255, 225, 226, 1245, 1246, "%" +301, 11, 53, 256, 227, 228, 1247, 1248, "," +301, 11, 54, 257, 229, 241, 1249, 1261, "respectively" +301, 11, 55, 258, 242, 243, 1262, 1263, ";" +301, 11, 56, 259, 244, 245, 1264, 1265, "p" +301, 11, 57, 260, 246, 249, 1266, 1269, " < " +301, 11, 58, 261, 250, 251, 1270, 1271, "0" +301, 11, 59, 262, 252, 253, 1272, 1273, "." +301, 11, 60, 263, 254, 258, 1274, 1278, "0001" +301, 11, 61, 264, 259, 260, 1279, 1280, ")" +301, 11, 62, 265, 261, 264, 1281, 1284, "and" +301, 11, 63, 266, 265, 278, 1285, 1298, "significantly" +301, 11, 64, 267, 279, 287, 1299, 1307, "improved" +301, 11, 65, 268, 288, 295, 1308, 1315, "fasting" +301, 11, 66, 269, 296, 302, 1316, 1322, "plasma" +301, 11, 67, 270, 303, 310, 1323, 1330, "glucose" +301, 11, 68, 271, 311, 312, 1331, 1332, "(" +301, 11, 69, 272, 313, 314, 1333, 1334, "-" +301, 11, 70, 273, 315, 316, 1335, 1336, "0" +301, 11, 71, 274, 317, 318, 1337, 1338, "." +301, 11, 72, 275, 319, 321, 1339, 1341, "84" +301, 11, 73, 276, 322, 323, 1342, 1343, " " +301, 11, 74, 277, 324, 328, 1344, 1348, "mmol" +301, 11, 75, 278, 329, 330, 1349, 1350, "/" +301, 11, 76, 279, 331, 332, 1351, 1352, "l" +301, 11, 77, 280, 333, 335, 1353, 1355, "vs" +301, 11, 78, 281, 336, 337, 1356, 1357, "." +301, 11, 79, 282, 338, 345, 1358, 1365, "placebo" +301, 11, 80, 283, 346, 347, 1366, 1367, ";" +301, 11, 81, 284, 348, 349, 1368, 1369, "p" +301, 11, 82, 285, 350, 353, 1370, 1373, " < " +301, 11, 83, 286, 354, 355, 1374, 1375, "0" +301, 11, 84, 287, 356, 357, 1376, 1377, "." +301, 11, 85, 288, 358, 362, 1378, 1382, "0001" +301, 11, 86, 289, 363, 364, 1383, 1384, ")" +301, 11, 87, 290, 365, 366, 1385, 1386, "." +301, 12, 1, 291, 0, 5, 1387, 1392, "There" +301, 12, 2, 292, 6, 9, 1393, 1396, "was" +301, 12, 3, 293, 10, 11, 1397, 1398, "a" +301, 12, 4, 294, 12, 17, 1399, 1404, "small" +301, 12, 5, 295, 18, 26, 1405, 1413, "decrease" +301, 12, 6, 296, 27, 29, 1414, 1416, "in" +301, 12, 7, 297, 30, 34, 1417, 1421, "body" +301, 12, 8, 298, 35, 41, 1422, 1428, "weight" +301, 12, 9, 299, 42, 46, 1429, 1433, "with" +301, 12, 10, 300, 47, 59, 1434, 1446, "lixisenatide" +301, 12, 11, 301, 60, 64, 1447, 1451, "once" +301, 12, 12, 302, 65, 70, 1452, 1457, "daily" +301, 12, 13, 303, 71, 74, 1458, 1461, "and" +301, 12, 14, 304, 75, 76, 1462, 1463, "a" +301, 12, 15, 305, 77, 82, 1464, 1469, "small" +301, 12, 16, 306, 83, 91, 1470, 1478, "increase" +301, 12, 17, 307, 92, 96, 1479, 1483, "with" +301, 12, 18, 308, 97, 104, 1484, 1491, "placebo" +301, 12, 19, 309, 105, 106, 1492, 1493, "," +301, 12, 20, 310, 107, 111, 1494, 1498, "with" +301, 12, 21, 311, 112, 114, 1499, 1501, "no" +301, 12, 22, 312, 115, 128, 1502, 1515, "statistically" +301, 12, 23, 313, 129, 140, 1516, 1527, "significant" +301, 12, 24, 314, 141, 151, 1528, 1538, "difference" +301, 12, 25, 315, 152, 159, 1539, 1546, "between" +301, 12, 26, 316, 160, 163, 1547, 1550, "the" +301, 12, 27, 317, 164, 167, 1551, 1554, "two" +301, 12, 28, 318, 168, 174, 1555, 1561, "groups" +301, 12, 29, 319, 175, 176, 1562, 1563, "." +301, 13, 1, 320, 0, 7, 1564, 1571, "Overall" +301, 13, 2, 321, 8, 9, 1572, 1573, "," +301, 13, 3, 322, 10, 22, 1574, 1586, "lixisenatide" +301, 13, 4, 323, 23, 27, 1587, 1591, "once" +301, 13, 5, 324, 28, 33, 1592, 1597, "daily" +301, 13, 6, 325, 34, 37, 1598, 1601, "was" +301, 13, 7, 326, 38, 42, 1602, 1606, "well" +301, 13, 8, 327, 43, 52, 1607, 1616, "tolerated" +301, 13, 9, 328, 53, 54, 1617, 1618, "," +301, 13, 10, 329, 55, 59, 1619, 1623, "with" +301, 13, 11, 330, 60, 61, 1624, 1625, "a" +301, 13, 12, 331, 62, 69, 1626, 1633, "similar" +301, 13, 13, 332, 70, 80, 1634, 1644, "proportion" +301, 13, 14, 333, 81, 83, 1645, 1647, "of" +301, 13, 15, 334, 84, 93, 1648, 1657, "treatment" +301, 13, 16, 335, 94, 95, 1658, 1659, "-" +301, 13, 17, 336, 96, 104, 1660, 1668, "emergent" +301, 13, 18, 337, 105, 112, 1669, 1676, "adverse" +301, 13, 19, 338, 113, 119, 1677, 1683, "events" +301, 13, 20, 339, 120, 121, 1684, 1685, "(" +301, 13, 21, 340, 122, 127, 1686, 1691, "TEAEs" +301, 13, 22, 341, 128, 129, 1692, 1693, ")" +301, 13, 23, 342, 130, 133, 1694, 1697, "and" +301, 13, 24, 343, 134, 141, 1698, 1705, "serious" +301, 13, 25, 344, 142, 147, 1706, 1711, "TEAEs" +301, 13, 26, 345, 148, 155, 1712, 1719, "between" +301, 13, 27, 346, 156, 162, 1720, 1726, "groups" +301, 13, 28, 347, 163, 164, 1727, 1728, "(" +301, 13, 29, 348, 165, 177, 1729, 1741, "lixisenatide" +301, 13, 30, 349, 178, 179, 1742, 1743, ":" +301, 13, 31, 350, 180, 182, 1744, 1746, "72" +301, 13, 32, 351, 183, 184, 1747, 1748, "." +301, 13, 33, 352, 185, 186, 1749, 1750, "4" +301, 13, 34, 353, 187, 188, 1751, 1752, "%" +301, 13, 35, 354, 189, 192, 1753, 1756, "and" +301, 13, 36, 355, 193, 194, 1757, 1758, "2" +301, 13, 37, 356, 195, 196, 1759, 1760, "." +301, 13, 38, 357, 197, 198, 1761, 1762, "5" +301, 13, 39, 358, 199, 200, 1763, 1764, "%" +301, 13, 40, 359, 201, 202, 1765, 1766, ";" +301, 13, 41, 360, 203, 210, 1767, 1774, "placebo" +301, 13, 42, 361, 211, 212, 1775, 1776, ":" +301, 13, 43, 362, 213, 215, 1777, 1779, "72" +301, 13, 44, 363, 216, 217, 1780, 1781, "." +301, 13, 45, 364, 218, 219, 1782, 1783, "7" +301, 13, 46, 365, 220, 221, 1784, 1785, "%" +301, 13, 47, 366, 222, 225, 1786, 1789, "and" +301, 13, 48, 367, 226, 227, 1790, 1791, "1" +301, 13, 49, 368, 228, 229, 1792, 1793, "." +301, 13, 50, 369, 230, 231, 1794, 1795, "9" +301, 13, 51, 370, 232, 233, 1796, 1797, "%" +301, 13, 52, 371, 234, 235, 1798, 1799, ")" +301, 13, 53, 372, 236, 237, 1800, 1801, "." +301, 14, 1, 373, 0, 11, 1802, 1813, "Symptomatic" +301, 14, 2, 374, 12, 25, 1814, 1827, "hypoglycaemia" +301, 14, 3, 375, 26, 31, 1828, 1833, "rates" +301, 14, 4, 376, 32, 36, 1834, 1838, "were" +301, 14, 5, 377, 37, 41, 1839, 1843, "also" +301, 14, 6, 378, 42, 52, 1844, 1854, "relatively" +301, 14, 7, 379, 53, 56, 1855, 1858, "low" +301, 14, 8, 380, 57, 59, 1859, 1861, "in" +301, 14, 9, 381, 60, 64, 1862, 1866, "both" +301, 14, 10, 382, 65, 71, 1867, 1873, "groups" +301, 14, 11, 383, 72, 73, 1874, 1875, "(" +301, 14, 12, 384, 74, 86, 1876, 1888, "lixisenatide" +301, 14, 13, 385, 87, 88, 1889, 1890, "3" +301, 14, 14, 386, 89, 90, 1891, 1892, "." +301, 14, 15, 387, 91, 92, 1893, 1894, "4" +301, 14, 16, 388, 93, 94, 1895, 1896, "%" +301, 14, 17, 389, 95, 98, 1897, 1900, "and" +301, 14, 18, 390, 99, 106, 1901, 1908, "placebo" +301, 14, 19, 391, 107, 108, 1909, 1910, "1" +301, 14, 20, 392, 109, 110, 1911, 1912, "." +301, 14, 21, 393, 111, 112, 1913, 1914, "2" +301, 14, 22, 394, 113, 114, 1915, 1916, "%" +301, 14, 23, 395, 115, 116, 1917, 1918, ")" +301, 14, 24, 396, 117, 118, 1919, 1920, "," +301, 14, 25, 397, 119, 123, 1921, 1925, "with" +301, 14, 26, 398, 124, 126, 1926, 1928, "no" +301, 14, 27, 399, 127, 133, 1929, 1935, "severe" +301, 14, 28, 400, 134, 142, 1936, 1944, "episodes" +301, 14, 29, 401, 143, 144, 1945, 1946, "." +301, 15, 1, 402, 0, 12, 1947, 1959, "Lixisenatide" +301, 15, 2, 403, 13, 22, 1960, 1969, "continued" +301, 15, 3, 404, 23, 25, 1970, 1972, "to" +301, 15, 4, 405, 26, 28, 1973, 1975, "be" +301, 15, 5, 406, 29, 40, 1976, 1987, "efficacious" +301, 15, 6, 407, 41, 44, 1988, 1991, "and" +301, 15, 7, 408, 45, 49, 1992, 1996, "well" +301, 15, 8, 409, 50, 59, 1997, 2006, "tolerated" +301, 15, 9, 410, 60, 66, 2007, 2013, "during" +301, 15, 10, 411, 67, 70, 2014, 2017, "the" +301, 15, 11, 412, 71, 79, 2018, 2026, "variable" +301, 15, 12, 413, 80, 89, 2027, 2036, "extension" +301, 15, 13, 414, 90, 96, 2037, 2043, "period" +301, 15, 14, 415, 97, 98, 2044, 2045, "." +301, 16, 1, 416, 0, 11, 2046, 2057, "CONCLUSIONS" +301, 16, 2, 417, 12, 13, 2058, 2059, ":" +301, 16, 3, 418, 14, 26, 2060, 2072, "Lixisenatide" +301, 16, 4, 419, 27, 31, 2073, 2077, "once" +301, 16, 5, 420, 32, 37, 2078, 2083, "daily" +301, 16, 6, 421, 38, 51, 2084, 2097, "significantly" +301, 16, 7, 422, 52, 60, 2098, 2106, "improved" +301, 16, 8, 423, 61, 70, 2107, 2116, "glycaemic" +301, 16, 9, 424, 71, 78, 2117, 2124, "control" +301, 16, 10, 425, 79, 83, 2125, 2129, "with" +301, 16, 11, 426, 84, 85, 2130, 2131, "a" +301, 16, 12, 427, 86, 89, 2132, 2135, "low" +301, 16, 13, 428, 90, 94, 2136, 2140, "risk" +301, 16, 14, 429, 95, 97, 2141, 2143, "of" +301, 16, 15, 430, 98, 111, 2144, 2157, "hypoglycaemia" +301, 16, 16, 431, 112, 113, 2158, 2159, "," +301, 16, 17, 432, 114, 117, 2160, 2163, "and" +301, 16, 18, 433, 118, 121, 2164, 2167, "was" +301, 16, 19, 434, 122, 126, 2168, 2172, "well" +301, 16, 20, 435, 127, 136, 2173, 2182, "tolerated" +301, 16, 21, 436, 137, 141, 2183, 2187, "over" +301, 16, 22, 437, 142, 144, 2188, 2190, "24" +301, 16, 23, 438, 145, 146, 2191, 2192, " " +301, 16, 24, 439, 147, 152, 2193, 2198, "weeks" +301, 16, 25, 440, 153, 156, 2199, 2202, "and" +301, 16, 26, 441, 157, 163, 2203, 2209, "during" +301, 16, 27, 442, 164, 167, 2210, 2213, "the" +301, 16, 28, 443, 168, 172, 2214, 2218, "long" +301, 16, 29, 444, 173, 174, 2219, 2220, "-" +301, 16, 30, 445, 175, 179, 2221, 2225, "term" +301, 16, 31, 446, 180, 181, 2226, 2227, "," +301, 16, 32, 447, 182, 188, 2228, 2234, "double" +301, 16, 33, 448, 189, 190, 2235, 2236, "-" +301, 16, 34, 449, 191, 196, 2237, 2242, "blind" +301, 16, 35, 450, 197, 206, 2243, 2252, "extension" +301, 16, 36, 451, 207, 213, 2253, 2259, "period" +301, 16, 37, 452, 214, 216, 2260, 2262, "in" +301, 16, 38, 453, 217, 225, 2263, 2271, "patients" +301, 16, 39, 454, 226, 230, 2272, 2276, "with" +301, 16, 40, 455, 231, 235, 2277, 2281, "T2DM" +301, 16, 41, 456, 236, 250, 2282, 2296, "insufficiently" +301, 16, 42, 457, 251, 261, 2297, 2307, "controlled" +301, 16, 43, 458, 262, 264, 2308, 2310, "on" +301, 16, 44, 459, 265, 277, 2311, 2323, "pioglitazone" +301, 16, 45, 460, 278, 281, 2324, 2327, " ± " +301, 16, 46, 461, 282, 291, 2328, 2337, "metformin" +301, 16, 47, 462, 292, 293, 2338, 2339, "." +301, 17, 1, 463, 0, 1, 2340, 2341, "©" +301, 17, 2, 464, 2, 6, 2342, 2346, "2013" +301, 17, 3, 465, 7, 11, 2347, 2351, "John" +301, 17, 4, 466, 12, 17, 2352, 2357, "Wiley" +301, 17, 5, 467, 18, 19, 2358, 2359, "&" +301, 17, 6, 468, 20, 24, 2360, 2364, "Sons" +301, 17, 7, 469, 25, 28, 2365, 2368, "Ltd" +301, 17, 8, 470, 29, 30, 2369, 2370, "." +301, 17, 9, 471, 31, 34, 2371, 2374, "DOI" +301, 17, 10, 472, 35, 36, 2375, 2376, ":" +301, 17, 11, 473, 37, 39, 2377, 2379, "10" +301, 17, 12, 474, 40, 41, 2380, 2381, "." +301, 17, 13, 475, 42, 46, 2382, 2386, "1111" +301, 17, 14, 476, 47, 48, 2387, 2388, "/" +301, 17, 15, 477, 49, 52, 2389, 2392, "dom" +301, 17, 16, 478, 53, 54, 2393, 2394, "." +301, 17, 17, 479, 55, 60, 2395, 2400, "12121" +301, 17, 18, 480, 61, 65, 2401, 2405, "PMID" +301, 17, 19, 481, 66, 67, 2406, 2407, ":" +301, 17, 20, 482, 68, 76, 2408, 2416, "23627775" +301, 17, 21, 483, 77, 78, 2417, 2418, "[" +301, 17, 22, 484, 79, 86, 2419, 2426, "Indexed" +301, 17, 23, 485, 87, 90, 2427, 2430, "for" +301, 17, 24, 486, 91, 98, 2431, 2438, "MEDLINE" +301, 17, 25, 487, 99, 100, 2439, 2440, "]" diff --git a/data/dm2 23627775_kwoodley.annodb b/data/dm2 23627775_kwoodley.annodb new file mode 100644 index 0000000..34b08f5 --- /dev/null +++ b/data/dm2 23627775_kwoodley.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29536, Journal, 0, 21, "Diabetes Obes Metab .", "", +29537, PublicationYear, 22, 26, "2013", "", +29615, Title, 107, 247, "Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P ) .", "", +29538, Drug, 130, 142, "lixisenatide", "", +29562, Frequency, 143, 153, "once daily", "", +29573, Placebo, 161, 168, "placebo", "", +29585, Type2Diabetes, 172, 187, "type 2 diabetes", "", +29608, Precondition, 172, 245, "type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal - P )", "", +29590, Pioglitazone, 217, 229, "pioglitazone", "", +29618, Author, 248, 256, "Pinget M", "", +29620, Author, 265, 277, "Goldenberg R", "", +29622, Author, 280, 292, "Niemoeller E", "", +29624, Author, 295, 314, "Muehlen - Bartmer I", "", +29626, Author, 317, 322, "Guo H", "", +29627, Author, 325, 334, "Aronson R", "", +29628, France, 426, 432, "France", "", +29632, ObjectiveDescription, 442, 622, "To compare the efficacy and safety of once - daily prandial lixisenatide with placebo in type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin .", "", +29564, Frequency, 480, 492, "once - daily", "", +29541, Drug, 502, 514, "lixisenatide", "", +29574, Placebo, 520, 527, "placebo", "", +29587, Type2Diabetes, 531, 555, "type 2 diabetes mellitus", "", +29611, Precondition, 531, 620, "type 2 diabetes mellitus ( T2DM ) insufficiently controlled by pioglitazone  ±  metformin", "", +29588, Type2Diabetes, 558, 562, "T2DM", "", +29604, Pioglitazone, 594, 606, "pioglitazone", "", +29602, Metformin, 611, 620, "metformin", "", +29633, Randomized, 638, 648, "randomized", "", +29634, DoubleBlind, 651, 665, "double - blind", "", +29644, Duration, 683, 692, "24 - week", "", +29635, Randomized, 775, 785, "randomized", "", +29636, AllocationRatio, 786, 793, "2  :  1", "", +29543, Drug, 805, 817, "lixisenatide", "", +29638, DoseValue, 818, 820, "20", "", +29641, Microgram, 821, 823, " µ", "I cannot annotate µ g together ", +29565, Frequency, 826, 836, "once daily", "", +29575, Placebo, 840, 847, "placebo", "", +29642, HbA1c, 885, 905, "glycated haemoglobin", "", +29643, HbA1c, 908, 913, "HbA1c", "", +33154, TimePoint, 919, 926, "week 24", "", +29646, NumberPatientsCT, 950, 953, "484", "", +29647, Randomized, 968, 978, "randomized", "", +29648, NumberPatientsArm, 981, 984, "323", "", +29545, Drug, 988, 1000, "lixisenatide", "", +29649, NumberPatientsArm, 1003, 1006, "161", "", +29576, Placebo, 1010, 1017, "placebo", "", +29650, Duration, 1026, 1036, "24   weeks", "", +29547, Drug, 1039, 1051, "lixisenatide", "", +29568, Frequency, 1052, 1062, "once daily", "", +29651, HbA1c, 1086, 1091, "HbA1c", "", +29652, Reduction, 1096, 1102, "0 . 56", "", +29653, Percentage, 1103, 1104, "%", "", +29594, Placebo, 1110, 1117, "placebo", "", +29654, PValueChangeValue, 1120, 1134, "p  <  0 . 0001", "", +29655, HbA1c_target, 1188, 1199, "HbA1c < 7 %", "", +29596, Placebo, 1214, 1221, "placebo", "", +29656, PercentageAffected, 1224, 1230, "52 . 3", "", +29657, PercentageAffected, 1238, 1244, "26 . 4", "", +29658, PvalueDiff, 1264, 1278, "p  <  0 . 0001", "", +29659, FastingPlasmaGlucose, 1308, 1330, "fasting plasma glucose", "", +29660, Reduction, 1335, 1341, "0 . 84", "", +29661, Millimoles_per_litre, 1344, 1352, "mmol / l", "", +29597, Placebo, 1358, 1365, "placebo", "", +29662, PValueChangeValue, 1368, 1382, "p  <  0 . 0001", "", +29664, ObservedResult, 1387, 1563, "There was a small decrease in body weight with lixisenatide once daily and a small increase with placebo , with no statistically significant difference between the two groups .", "", +29663, BodyWeight, 1417, 1428, "body weight", "", +29549, Drug, 1434, 1446, "lixisenatide", "", +29569, Frequency, 1447, 1457, "once daily", "", +29599, Placebo, 1484, 1491, "placebo", "", +29550, Drug, 1574, 1586, "lixisenatide", "", +29570, Frequency, 1587, 1597, "once daily", "", +29665, EndPointDescription, 1669, 1683, "adverse events", "", +29666, EndPointDescription, 1686, 1691, "TEAEs", "", +33155, SubGroupDescription, 1698, 1711, "serious TEAEs", "", +29667, EndPointDescription, 1706, 1711, "TEAEs", "", +29552, Drug, 1729, 1741, "lixisenatide", "", +29669, PercentageAffected, 1744, 1750, "72 . 4", "", +29671, PercentageAffected, 1757, 1762, "2 . 5", "subgroup", +29579, Placebo, 1767, 1774, "placebo", "", +29670, PercentageAffected, 1777, 1783, "72 . 7", "", +29672, PercentageAffected, 1790, 1795, "1 . 9", "subgroup", +29673, SymptomaticHypoglycemia, 1802, 1827, "Symptomatic hypoglycaemia", "", +29554, Drug, 1876, 1888, "lixisenatide", "", +29674, PercentageAffected, 1889, 1894, "3 . 4", "", +29580, Placebo, 1901, 1908, "placebo", "", +29675, PercentageAffected, 1909, 1914, "1 . 2", "", +29676, ObservedResult, 1921, 1944, "with no severe episodes", "", +29556, Drug, 1947, 1959, "Lixisenatide", "", +29558, Drug, 2060, 2072, "Lixisenatide", "", +29681, ConclusionComment, 2060, 2259, "Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia , and was well tolerated over 24   weeks and during the long - term , double - blind extension period", "", +29571, Frequency, 2073, 2083, "once daily", "", +29678, Hypoglycemia, 2144, 2157, "hypoglycaemia", "", +29679, Duration, 2188, 2198, "24   weeks", "", +29680, DoubleBlind, 2228, 2242, "double - blind", "", +29682, ConclusionComment, 2260, 2339, "in patients with T2DM insufficiently controlled on pioglitazone  ±  metformin .", "", +29613, Precondition, 2263, 2337, "patients with T2DM insufficiently controlled on pioglitazone  ±  metformin", "", +29589, Type2Diabetes, 2277, 2281, "T2DM", "", +29592, Pioglitazone, 2311, 2323, "pioglitazone", "", +29601, Metformin, 2328, 2337, "metformin", "", +29683, PMID, 2408, 2416, "23627775", "", diff --git a/data/dm2 23627775_kwoodley.n-triples b/data/dm2 23627775_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23627775_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23628617_admin.annodb b/data/dm2 23628617_admin.annodb new file mode 100644 index 0000000..39dcb7e --- /dev/null +++ b/data/dm2 23628617_admin.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2013", "", " \"2013\"." +9, Title, 101, 285, "Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .", "", " \"Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .\"." +2, Frequency, 108, 120, "once - daily", "", +79568, Lixisenatide, 121, 133, "lixisenatide", "", +4, Type2Diabetes, 138, 153, "type 2 diabetes", "", +28, Precondition, 138, 206, "type 2 diabetes inadequately controlled by established basal insulin", "", " \"type 2 diabetes inadequately controlled by established basal insulin\"." +121, Insulin, 199, 206, "insulin", "", +6, Duration, 211, 220, "24 - week", "", " \"24 - week\"." +7, Randomized, 223, 233, "randomized", "", " ." +8, Placebo, 236, 243, "placebo", "", +10, Author, 286, 295, "Riddle MC", "", " \"Riddle MC\"." +11, Author, 304, 313, "Aronson R", "", " \"Aronson R\"." +12, Author, 316, 322, "Home P", "", " \"Home P\"." +13, Author, 325, 332, "Marre M", "", " \"Marre M\"." +14, Author, 335, 347, "Niemoeller E", "", " \"Niemoeller E\"." +15, Author, 350, 359, "Miossec P", "", " \"Miossec P\"." +16, Author, 362, 368, "Ping L", "", " \"Ping L\"." +17, Author, 371, 375, "Ye J", "", " \"Ye J\"." +18, Author, 378, 390, "Rosenstock J", "", +19, USA, 477, 480, "USA", "", " ." +143, ObjectiveDescription, 516, 731, "To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people", "", " \"To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people\"." +20, Frequency, 565, 577, "once - daily", "", " \"once - daily\"." +79569, Lixisenatide, 637, 649, "lixisenatide", "", +138, Insulin, 671, 678, "insulin", "", +23, Metformin, 710, 719, "metformin", "", +27, Precondition, 725, 795, "people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )", "", " \"people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )\"." +144, ObjectiveDescription, 732, 797, "with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .", "", " \"with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .\"." +24, Type2Diabetes, 737, 752, "type 2 diabetes", "", " ." +25, HbA1c, 766, 785, "glycated hemoglobin", "", +26, HbA1c, 788, 793, "HbA1c", "", +31, DoubleBlind, 843, 857, "double - blind", "", " ." +32, Parallel, 860, 876, "parallel - group", "", " ." +33, Placebo, 879, 886, "placebo", "", +34, NumberPatientsCT, 923, 926, "495", "", " \"495\"." +149, Insulin, 952, 959, "insulin", "", +150, Precondition, 972, 999, "inadequate glycemic control", "", +36, Randomized, 1005, 1015, "randomized", "", +79571, Lixisenatide, 1023, 1035, "lixisenatide", "", " ." +38, DoseValue, 1036, 1038, "20", "", " \"20\"." +39, Microgram, 1039, 1042, "μ g", "", " ." +40, Placebo, 1046, 1053, "placebo", "", " ." +41, Duration, 1058, 1066, "24 weeks", "", +157, Insulin, 1075, 1082, "insulin", "", +43, Hypoglycemia, 1120, 1132, "hypoglycemia", "", +44, HbA1c, 1135, 1140, "HbA1c", "", +160, TimePoint, 1156, 1164, "baseline", "", +161, Mean, 1203, 1207, "Mean", "", +169, Year, 1240, 1245, "years", "", +170, Year, 1282, 1287, "years", "", +48, InsulinDose, 1290, 1304, "insulin dosage", "", +49, BaseLineValue, 1309, 1311, "55", "", +50, BioAndMedicalUnit, 1312, 1323, "units / day", "", +166, TimePoint, 1330, 1338, "baseline", "", +45, HbA1c, 1339, 1344, "HbA1c", "", " ." +46, BaseLineValue, 1349, 1354, "8 . 4", "", +47, Percentage, 1355, 1356, "%", "", " ." +79573, Lixisenatide, 1364, 1376, "lixisenatide", "", +53, Placebo, 1383, 1390, "placebo", "", +54, HbA1c, 1413, 1418, "HbA1c", "", +61, TimePoint, 1424, 1432, "baseline", "", +55, Reduction, 1439, 1444, "0 . 4", "", " \"0 . 4\"." +56, Percentage, 1445, 1446, "%", "", +57, ConfIntervalChangeValue, 1449, 1475, "95 % CI - 0 . 6 to - 0 . 2", "", " \"95 % CI - 0 . 6 to - 0 . 2\"." +58, PValueChangeValue, 1478, 1490, "P = 0 . 0002", "", " \"P = 0 . 0002\"." +183, Mean, 1499, 1503, "mean", "", " . ." +59, HbA1c, 1504, 1509, "HbA1c", "", +60, TimePoint, 1510, 1522, "at end point", "", " \"at end point\"." +62, ResultMeasuredValue, 1527, 1532, "7 . 8", "", " \"7 . 8\"." +63, Percentage, 1533, 1534, "%", "", +64, HbA1c_target, 1537, 1570, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", " ." +187, Percentage, 1551, 1552, "%", "", +79776, Millimoles_per_mole, 1558, 1568, "mmol / mol", "", +79574, Lixisenatide, 1592, 1604, "lixisenatide", "", +67, PercentageAffected, 1607, 1609, "28", "", " \"28\"." +66, Placebo, 1619, 1626, "placebo", "", +68, PercentageAffected, 1629, 1631, "12", "", " \"12\"." +69, PvalueDiff, 1636, 1648, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +79575, Lixisenatide, 1666, 1678, "Lixisenatide", "", +198, PostprandialPlasmaGlucose, 1687, 1739, "plasma glucose levels after a standardized breakfast", "", " ." +73, Placebo, 1742, 1749, "placebo", "", +83, Reduction, 1776, 1781, "3 . 8", "", " \"3 . 8\"." +74, Millimoles_per_litre, 1782, 1790, "mmol / L", "", " ." +75, PValueChangeValue, 1793, 1805, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +77, BodyWeight, 1903, 1914, "body weight", "", " ." +78, Placebo, 1917, 1924, "placebo", "", +82, Reduction, 1939, 1944, "1 . 3", "", " \"1 . 3\"." +79, Kg, 1945, 1947, "kg", "", " ." +80, PValueChangeValue, 1950, 1962, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +81, InsulinDose, 1969, 1983, "insulin dosage", "", " . ." +84, Reduction, 1988, 1993, "3 . 7", "", " \"3 . 7\"." +85, BioAndMedicalUnit, 1994, 2005, "units / day", "", " . ." +86, PValueChangeValue, 2008, 2019, "P = 0 . 012", "", " \"P = 0 . 012\"." +79578, Lixisenatide, 2040, 2052, "lixisenatide", "", +91, ObservedResult, 2055, 2124, "Main adverse events ( AEs ) with lixisenatide were gastrointestinal .", "", " \"Main adverse events ( AEs ) with lixisenatide were gastrointestinal .\"." +88, EndPointDescription, 2060, 2074, "adverse events", "", " . ." +89, EndPointDescription, 2077, 2080, "AEs", "", +79576, Lixisenatide, 2088, 2100, "lixisenatide", "", +92, SymptomaticHypoglycemia, 2125, 2149, "Symptomatic hypoglycemia", "", " ." +93, PercentageAffected, 2154, 2156, "28", "", " \"28\"." +79584, Lixisenatide, 2163, 2175, "lixisenatide", "", +94, PercentageAffected, 2180, 2182, "22", "", " \"22\"." +96, Placebo, 2189, 2196, "placebo", "", +98, NumberAffected, 2199, 2200, "4", "", " \"4\"." +100, NumberPatientsArm, 2204, 2207, "328", "", " \"328\"." +97, PercentageAffected, 2219, 2224, "1 . 2", "", " \"1 . 2\"." +103, SevereHypoglycemia, 2233, 2252, "severe hypoglycemia", "", " ." +79580, Lixisenatide, 2258, 2270, "lixisenatide", "", +99, NumberAffected, 2276, 2277, "0", "", +101, NumberPatientsArm, 2281, 2284, "167", "", " \"167\"." +102, Placebo, 2290, 2297, "placebo", "", +113, ConclusionComment, 2314, 2561, "By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .", "", " \"By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .\"." +105, HbA1c, 2327, 2332, "HbA1c", "", +106, Hypoglycemia, 2337, 2363, "postprandial hyperglycemia", "", +231, WeightGain, 2372, 2383, "weight gain", "", +108, Type2Diabetes, 2387, 2402, "type 2 diabetes", "", +233, Insulin, 2457, 2464, "insulin", "", +79582, Lixisenatide, 2467, 2479, "lixisenatide", "", +112, Insulin, 2525, 2532, "insulin", "", +114, PMID, 2618, 2626, "23628617", "", " \"23628617\"." diff --git a/data/dm2 23628617_admin.n-triples b/data/dm2 23628617_admin.n-triples new file mode 100644 index 0000000..8eeb3cd --- /dev/null +++ b/data/dm2 23628617_admin.n-triples @@ -0,0 +1,197 @@ +# RDF export of group: Publication + . + "Publication 45429" . + "Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) ." . + "Riddle MC" . + "2013" . + "Diabetes Care" . + "23628617" . + . + "Aronson R" . + "Home P" . + "Marre M" . + "Niemoeller E" . + "Miossec P" . + "Ping L" . + "Ye J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 45436" . + "To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people" . + "495" . + "24 - week" . + . + . + . + "By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options ." . + . + . + . + . + . + "with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) ." . + . + . + . +# RDF export of group: Population + . + "Population 45452" . + . + . + . + "type 2 diabetes inadequately controlled by established basal insulin" . + "people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "shyp" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + "328" . + . + . + . + . + . + . + . + . + . + . + "pla" . + "167" . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + "once - daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lix" . + . + "20" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 8" . + "0 . 4" . + "P = 0 . 0002" . + "95 % CI - 0 . 6 to - 0 . 2" . + "at end point" . + . + "hbat 1" . + . + "28" . + . + "hbat 2" . + . + "12" . + . + "ppg 1" . + . + "3 . 8" . + "P < 0 . 0001" . + . + "bw 1" . + . + "1 . 3" . + "P < 0 . 0001" . + . + "ins 1" . + . + "3 . 7" . + "P = 0 . 012" . + . + "ae 1" . + . + "Main adverse events ( AEs ) with lixisenatide were gastrointestinal ." . + . + "hyp 1" . + . + "28" . + . + "hyp 2" . + . + "22" . + . + "shyp 1" . + . + "4" . + "1 . 2" . + . + "shyp 2" . + . +# RDF export of group: DiffBetweenGroups + . + "hbat" . + "P < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23628617_akramersunderbrink.annodb b/data/dm2 23628617_akramersunderbrink.annodb new file mode 100644 index 0000000..f9fcd81 --- /dev/null +++ b/data/dm2 23628617_akramersunderbrink.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43617, Journal, 0, 13, "Diabetes Care", "", +43618, PublicationYear, 16, 20, "2013", "", +43627, Title, 101, 285, "Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .", "", +43619, Frequency, 108, 120, "once - daily", "", +43620, Drug, 121, 133, "lixisenatide", "", +43621, Type2Diabetes, 138, 153, "type 2 diabetes", "", +43622, Precondition, 154, 206, "inadequately controlled by established basal insulin", "", +43623, Insulin, 199, 206, "insulin", "", +43624, Duration, 211, 220, "24 - week", "", +43625, Randomized, 223, 233, "randomized", "", +43626, Placebo, 236, 243, "placebo", "", +43628, Author, 286, 295, "Riddle MC", "", +43629, Author, 304, 313, "Aronson R", "", +43630, Author, 316, 322, "Home P", "", +43631, Author, 325, 332, "Marre M", "", +43632, Author, 335, 347, "Niemoeller E", "", +43633, Author, 350, 359, "Miossec P", "", +43634, Author, 362, 368, "Ping L", "", +43635, Author, 371, 375, "Ye J", "", +43636, Author, 378, 390, "Rosenstock J", "", +43637, USA, 477, 480, "USA", "", +43645, ObjectiveDescription, 516, 731, "To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people", "", +43638, Frequency, 565, 577, "once - daily", "", +43639, Drug, 637, 649, "lixisenatide", "", +43640, Insulin, 671, 678, "insulin", "", +43641, Metformin, 710, 719, "metformin", "", +43646, ObjectiveDescription, 732, 797, "with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .", "", +43642, Type2Diabetes, 737, 752, "type 2 diabetes", "", +43643, HbA1c, 766, 785, "glycated hemoglobin", "", +43644, HbA1c, 788, 793, "HbA1c", "", +43647, DoubleBlind, 843, 857, "double - blind", "", +43648, Parallel, 860, 868, "parallel", "", +43649, Placebo, 879, 886, "placebo", "", +43650, NumberPatientsCT, 923, 926, "495", "", +43651, Insulin, 952, 959, "insulin", "", +43652, Precondition, 972, 999, "inadequate glycemic control", "", +43653, Randomized, 1005, 1015, "randomized", "", +43654, Drug, 1023, 1035, "lixisenatide", "", +43655, DoseValue, 1036, 1042, "20 μ g", "", +43656, Microgram, 1039, 1042, "μ g", "", +43657, Placebo, 1046, 1053, "placebo", "", +43658, Duration, 1058, 1066, "24 weeks", "", +43659, Insulin, 1075, 1082, "insulin", "", +43660, Hypoglycemia, 1120, 1132, "hypoglycemia", "", +43661, HbA1c, 1135, 1140, "HbA1c", "", +43662, TimePoint, 1156, 1164, "baseline", "", +43663, Mean, 1203, 1207, "Mean", "", +43664, Precondition, 1208, 1245, "duration of diabetes was 12 . 5 years", "", +43671, Year, 1240, 1245, "years", "", +43665, Precondition, 1248, 1287, "duration of insulin use was 3 . 1 years", "", +43672, Year, 1282, 1287, "years", "", +43666, Precondition, 1290, 1323, "insulin dosage was 55 units / day", "", +43673, DoseValue, 1309, 1323, "55 units / day", "", +43674, BioAndMedicalUnit, 1312, 1323, "units / day", "", +43668, TimePoint, 1330, 1338, "baseline", "", +43667, HbA1c, 1339, 1344, "HbA1c", "", +43669, BaseLineValue, 1349, 1354, "8 . 4", "", +43670, Percentage, 1355, 1356, "%", "", +43675, Drug, 1364, 1376, "lixisenatide", "", +43676, Placebo, 1383, 1390, "placebo", "", +43677, HbA1c, 1413, 1418, "HbA1c", "", +43678, TimePoint, 1424, 1432, "baseline", "", +43679, ChangeValue, 1437, 1444, "- 0 . 4", "", +43680, Percentage, 1445, 1446, "%", "", +43682, ConfIntervalChangeValue, 1449, 1475, "95 % CI - 0 . 6 to - 0 . 2", "", +43681, Percentage, 1452, 1453, "%", "", +43683, PValueChangeValue, 1478, 1490, "P = 0 . 0002", "", +43685, Mean, 1499, 1503, "mean", "", +43684, HbA1c, 1504, 1509, "HbA1c", "", +43686, TimePoint, 1513, 1522, "end point", "", +43687, ResultMeasuredValue, 1527, 1532, "7 . 8", "", +43688, Percentage, 1533, 1534, "%", "", +43692, HbA1c_target, 1537, 1570, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", +43689, Percentage, 1551, 1552, "%", "", +43693, ConcentrationUnit, 1558, 1568, "mmol / mol", "", +43694, Drug, 1592, 1604, "lixisenatide", "", +43696, PercentageAffected, 1607, 1609, "28", "", +43690, Percentage, 1610, 1611, "%", "", +43695, Placebo, 1619, 1626, "placebo", "", +43697, PercentageAffected, 1629, 1631, "12", "", +43691, Percentage, 1632, 1633, "%", "", +43698, PvalueDiff, 1636, 1648, "P < 0 . 0001", "", +43699, Drug, 1666, 1678, "Lixisenatide", "", +43700, PostprandialPlasmaGlucose, 1687, 1739, "plasma glucose levels after a standardized breakfast", "", +43701, Placebo, 1742, 1749, "placebo", "", +43702, ChangeValue, 1774, 1781, "- 3 . 8", "", +43703, Millimoles_per_litre, 1782, 1790, "mmol / L", "", +43704, PValueChangeValue, 1793, 1805, "P < 0 . 0001", "", +43705, BodyWeight, 1903, 1914, "body weight", "", +43706, Placebo, 1917, 1924, "placebo", "", +43707, ChangeValue, 1937, 1944, "- 1 . 3", "", +43708, Kg, 1945, 1947, "kg", "", +43709, PValueChangeValue, 1950, 1962, "P < 0 . 0001", "", +43710, InsulinDose, 1969, 1983, "insulin dosage", "", +43711, ChangeValue, 1986, 1993, "- 3 . 7", "", +43712, BioAndMedicalUnit, 1994, 2005, "units / day", "", +43713, PValueChangeValue, 2008, 2019, "P = 0 . 012", "", +43714, Drug, 2040, 2052, "lixisenatide", "", +43715, Drug, 2088, 2100, "lixisenatide", "", +43716, SymptomaticHypoglycemia, 2125, 2149, "Symptomatic hypoglycemia", "", +43720, PercentageAffected, 2154, 2156, "28", "", +43717, Percentage, 2157, 2158, "%", "", +43725, Drug, 2163, 2175, "lixisenatide", "", +43721, PercentageAffected, 2180, 2182, "22", "", +43718, Percentage, 2183, 2184, "%", "", +43723, Placebo, 2189, 2196, "placebo", "", +43726, NumberAffected, 2199, 2200, "4", "", +43728, FinalNumPatientsArm, 2204, 2207, "328", "", +43722, PercentageAffected, 2219, 2224, "1 . 2", "", +43719, Percentage, 2225, 2226, "%", "", +43731, SevereHypoglycemia, 2233, 2252, "severe hypoglycemia", "", +43730, Drug, 2258, 2270, "lixisenatide", "", +43727, NumberAffected, 2276, 2277, "0", "", +43729, FinalNumPatientsArm, 2281, 2284, "167", "", +43724, Placebo, 2290, 2297, "placebo", "", +43739, ConclusionComment, 2314, 2561, "By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .", "", +43732, HbA1c, 2327, 2332, "HbA1c", "", +43733, WeightGain, 2372, 2383, "weight gain", "", +43735, Type2Diabetes, 2387, 2402, "type 2 diabetes", "", +43736, Insulin, 2457, 2464, "insulin", "", +43737, Drug, 2467, 2479, "lixisenatide", "", +43738, Insulin, 2525, 2532, "insulin", "", +43740, PMID, 2618, 2626, "23628617", "", diff --git a/data/dm2 23628617_akramersunderbrink.n-triples b/data/dm2 23628617_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23628617_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23628617_export.csv b/data/dm2 23628617_export.csv new file mode 100644 index 0000000..999dd1b --- /dev/null +++ b/data/dm2 23628617_export.csv @@ -0,0 +1,557 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +300, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +300, 1, 2, 2, 9, 13, 9, 13, "Care" +300, 1, 3, 3, 14, 15, 14, 15, "." +300, 2, 1, 4, 0, 4, 16, 20, "2013" +300, 2, 2, 5, 5, 8, 21, 24, "Sep" +300, 2, 3, 6, 9, 10, 25, 26, ";" +300, 2, 4, 7, 11, 13, 27, 29, "36" +300, 2, 5, 8, 14, 15, 30, 31, "(" +300, 2, 6, 9, 16, 17, 32, 33, "9" +300, 2, 7, 10, 18, 19, 34, 35, ")" +300, 2, 8, 11, 20, 21, 36, 37, ":" +300, 2, 9, 12, 22, 26, 38, 42, "2489" +300, 2, 10, 13, 27, 28, 43, 44, "-" +300, 2, 11, 14, 29, 31, 45, 47, "96" +300, 2, 12, 15, 32, 33, 48, 49, "." +300, 2, 13, 16, 34, 37, 50, 53, "doi" +300, 2, 14, 17, 38, 39, 54, 55, ":" +300, 2, 15, 18, 40, 42, 56, 58, "10" +300, 2, 16, 19, 43, 44, 59, 60, "." +300, 2, 17, 20, 45, 49, 61, 65, "2337" +300, 2, 18, 21, 50, 51, 66, 67, "/" +300, 2, 19, 22, 52, 56, 68, 72, "dc12" +300, 2, 20, 23, 57, 58, 73, 74, "-" +300, 2, 21, 24, 59, 63, 75, 79, "2454" +300, 2, 22, 25, 64, 65, 80, 81, "." +300, 3, 1, 26, 0, 4, 82, 86, "Epub" +300, 3, 2, 27, 5, 9, 87, 91, "2013" +300, 3, 3, 28, 10, 13, 92, 95, "Apr" +300, 3, 4, 29, 14, 16, 96, 98, "29" +300, 3, 5, 30, 17, 18, 99, 100, "." +300, 4, 1, 31, 0, 6, 101, 107, "Adding" +300, 4, 2, 32, 7, 11, 108, 112, "once" +300, 4, 3, 33, 12, 13, 113, 114, "-" +300, 4, 4, 34, 14, 19, 115, 120, "daily" +300, 4, 5, 35, 20, 32, 121, 133, "lixisenatide" +300, 4, 6, 36, 33, 36, 134, 137, "for" +300, 4, 7, 37, 37, 41, 138, 142, "type" +300, 4, 8, 38, 42, 43, 143, 144, "2" +300, 4, 9, 39, 44, 52, 145, 153, "diabetes" +300, 4, 10, 40, 53, 65, 154, 166, "inadequately" +300, 4, 11, 41, 66, 76, 167, 177, "controlled" +300, 4, 12, 42, 77, 79, 178, 180, "by" +300, 4, 13, 43, 80, 91, 181, 192, "established" +300, 4, 14, 44, 92, 97, 193, 198, "basal" +300, 4, 15, 45, 98, 105, 199, 206, "insulin" +300, 4, 16, 46, 106, 107, 207, 208, ":" +300, 4, 17, 47, 108, 109, 209, 210, "a" +300, 4, 18, 48, 110, 112, 211, 213, "24" +300, 4, 19, 49, 113, 114, 214, 215, "-" +300, 4, 20, 50, 115, 119, 216, 220, "week" +300, 4, 21, 51, 120, 121, 221, 222, "," +300, 4, 22, 52, 122, 132, 223, 233, "randomized" +300, 4, 23, 53, 133, 134, 234, 235, "," +300, 4, 24, 54, 135, 142, 236, 243, "placebo" +300, 4, 25, 55, 143, 144, 244, 245, "-" +300, 4, 26, 56, 145, 155, 246, 256, "controlled" +300, 4, 27, 57, 156, 166, 257, 267, "comparison" +300, 4, 28, 58, 167, 168, 268, 269, "(" +300, 4, 29, 59, 169, 176, 270, 277, "GetGoal" +300, 4, 30, 60, 177, 178, 278, 279, "-" +300, 4, 31, 61, 179, 180, 280, 281, "L" +300, 4, 32, 62, 181, 182, 282, 283, ")" +300, 4, 33, 63, 183, 184, 284, 285, "." +300, 5, 1, 64, 0, 6, 286, 292, "Riddle" +300, 5, 2, 65, 7, 9, 293, 295, "MC" +300, 5, 3, 66, 10, 11, 296, 297, "(" +300, 5, 4, 67, 12, 13, 298, 299, "1" +300, 5, 5, 68, 14, 15, 300, 301, ")" +300, 5, 6, 69, 16, 17, 302, 303, "," +300, 5, 7, 70, 18, 25, 304, 311, "Aronson" +300, 5, 8, 71, 26, 27, 312, 313, "R" +300, 5, 9, 72, 28, 29, 314, 315, "," +300, 5, 10, 73, 30, 34, 316, 320, "Home" +300, 5, 11, 74, 35, 36, 321, 322, "P" +300, 5, 12, 75, 37, 38, 323, 324, "," +300, 5, 13, 76, 39, 44, 325, 330, "Marre" +300, 5, 14, 77, 45, 46, 331, 332, "M" +300, 5, 15, 78, 47, 48, 333, 334, "," +300, 5, 16, 79, 49, 59, 335, 345, "Niemoeller" +300, 5, 17, 80, 60, 61, 346, 347, "E" +300, 5, 18, 81, 62, 63, 348, 349, "," +300, 5, 19, 82, 64, 71, 350, 357, "Miossec" +300, 5, 20, 83, 72, 73, 358, 359, "P" +300, 5, 21, 84, 74, 75, 360, 361, "," +300, 5, 22, 85, 76, 80, 362, 366, "Ping" +300, 5, 23, 86, 81, 82, 367, 368, "L" +300, 5, 24, 87, 83, 84, 369, 370, "," +300, 5, 25, 88, 85, 87, 371, 373, "Ye" +300, 5, 26, 89, 88, 89, 374, 375, "J" +300, 5, 27, 90, 90, 91, 376, 377, "," +300, 5, 28, 91, 92, 102, 378, 388, "Rosenstock" +300, 5, 29, 92, 103, 104, 389, 390, "J" +300, 5, 30, 93, 105, 106, 391, 392, "." +300, 6, 1, 94, 0, 6, 393, 399, "Author" +300, 6, 2, 95, 7, 18, 400, 411, "information" +300, 6, 3, 96, 19, 20, 412, 413, ":" +300, 6, 4, 97, 21, 22, 414, 415, "(" +300, 6, 5, 98, 23, 24, 416, 417, "1" +300, 6, 6, 99, 25, 26, 418, 419, ")" +300, 6, 7, 100, 27, 33, 420, 426, "Oregon" +300, 6, 8, 101, 34, 40, 427, 433, "Health" +300, 6, 9, 102, 41, 42, 434, 435, "&" +300, 6, 10, 103, 43, 50, 436, 443, "Science" +300, 6, 11, 104, 51, 61, 444, 454, "University" +300, 6, 12, 105, 62, 63, 455, 456, "," +300, 6, 13, 106, 64, 72, 457, 465, "Portland" +300, 6, 14, 107, 73, 74, 466, 467, "," +300, 6, 15, 108, 75, 81, 468, 474, "Oregon" +300, 6, 16, 109, 82, 83, 475, 476, "," +300, 6, 17, 110, 84, 87, 477, 480, "USA" +300, 6, 18, 111, 88, 89, 481, 482, "." +300, 7, 1, 112, 0, 7, 483, 490, "riddlem" +300, 7, 2, 113, 8, 9, 491, 492, "@" +300, 7, 3, 114, 10, 14, 493, 497, "ohsu" +300, 7, 4, 115, 15, 16, 498, 499, "." +300, 7, 5, 116, 17, 20, 500, 503, "edu" +300, 7, 6, 117, 21, 30, 504, 513, "OBJECTIVE" +300, 7, 7, 118, 31, 32, 514, 515, ":" +300, 7, 8, 119, 33, 35, 516, 518, "To" +300, 7, 9, 120, 36, 43, 519, 526, "examine" +300, 7, 10, 121, 44, 47, 527, 530, "the" +300, 7, 11, 122, 48, 56, 531, 539, "efficacy" +300, 7, 12, 123, 57, 60, 540, 543, "and" +300, 7, 13, 124, 61, 67, 544, 550, "safety" +300, 7, 14, 125, 68, 70, 551, 553, "of" +300, 7, 15, 126, 71, 77, 554, 560, "adding" +300, 7, 16, 127, 78, 81, 561, 564, "the" +300, 7, 17, 128, 82, 86, 565, 569, "once" +300, 7, 18, 129, 87, 88, 570, 571, "-" +300, 7, 19, 130, 89, 94, 572, 577, "daily" +300, 7, 20, 131, 95, 103, 578, 586, "glucagon" +300, 7, 21, 132, 104, 105, 587, 588, "-" +300, 7, 22, 133, 106, 110, 589, 593, "like" +300, 7, 23, 134, 111, 118, 594, 601, "peptide" +300, 7, 24, 135, 119, 120, 602, 603, "-" +300, 7, 25, 136, 121, 122, 604, 605, "1" +300, 7, 26, 137, 123, 131, 606, 614, "receptor" +300, 7, 27, 138, 132, 139, 615, 622, "agonist" +300, 7, 28, 139, 140, 141, 623, 624, "(" +300, 7, 29, 140, 142, 145, 625, 628, "GLP" +300, 7, 30, 141, 146, 147, 629, 630, "-" +300, 7, 31, 142, 148, 151, 631, 634, "1RA" +300, 7, 32, 143, 152, 153, 635, 636, ")" +300, 7, 33, 144, 154, 166, 637, 649, "lixisenatide" +300, 7, 34, 145, 167, 169, 650, 652, "to" +300, 7, 35, 146, 170, 181, 653, 664, "established" +300, 7, 36, 147, 182, 187, 665, 670, "basal" +300, 7, 37, 148, 188, 195, 671, 678, "insulin" +300, 7, 38, 149, 196, 203, 679, 686, "therapy" +300, 7, 39, 150, 204, 209, 687, 692, "alone" +300, 7, 40, 151, 210, 212, 693, 695, "or" +300, 7, 41, 152, 213, 221, 696, 704, "together" +300, 7, 42, 153, 222, 226, 705, 709, "with" +300, 7, 43, 154, 227, 236, 710, 719, "metformin" +300, 7, 44, 155, 237, 238, 720, 721, "," +300, 7, 45, 156, 239, 241, 722, 724, "in" +300, 7, 46, 157, 242, 248, 725, 731, "people" +300, 7, 47, 158, 249, 253, 732, 736, "with" +300, 7, 48, 159, 254, 258, 737, 741, "type" +300, 7, 49, 160, 259, 260, 742, 743, "2" +300, 7, 50, 161, 261, 269, 744, 752, "diabetes" +300, 7, 51, 162, 270, 273, 753, 756, "and" +300, 7, 52, 163, 274, 282, 757, 765, "elevated" +300, 7, 53, 164, 283, 291, 766, 774, "glycated" +300, 7, 54, 165, 292, 302, 775, 785, "hemoglobin" +300, 7, 55, 166, 303, 304, 786, 787, "(" +300, 7, 56, 167, 305, 310, 788, 793, "HbA1c" +300, 7, 57, 168, 311, 312, 794, 795, ")" +300, 7, 58, 169, 313, 314, 796, 797, "." +300, 8, 1, 170, 0, 8, 798, 806, "RESEARCH" +300, 8, 2, 171, 9, 15, 807, 813, "DESIGN" +300, 8, 3, 172, 16, 19, 814, 817, "AND" +300, 8, 4, 173, 20, 27, 818, 825, "METHODS" +300, 8, 5, 174, 28, 29, 826, 827, ":" +300, 8, 6, 175, 30, 32, 828, 830, "We" +300, 8, 7, 176, 33, 42, 831, 840, "conducted" +300, 8, 8, 177, 43, 44, 841, 842, "a" +300, 8, 9, 178, 45, 51, 843, 849, "double" +300, 8, 10, 179, 52, 53, 850, 851, "-" +300, 8, 11, 180, 54, 59, 852, 857, "blind" +300, 8, 12, 181, 60, 61, 858, 859, "," +300, 8, 13, 182, 62, 70, 860, 868, "parallel" +300, 8, 14, 183, 71, 72, 869, 870, "-" +300, 8, 15, 184, 73, 78, 871, 876, "group" +300, 8, 16, 185, 79, 80, 877, 878, "," +300, 8, 17, 186, 81, 88, 879, 886, "placebo" +300, 8, 18, 187, 89, 90, 887, 888, "-" +300, 8, 19, 188, 91, 101, 889, 899, "controlled" +300, 8, 20, 189, 102, 107, 900, 905, "trial" +300, 8, 21, 190, 108, 109, 906, 907, "." +300, 9, 1, 191, 0, 8, 908, 916, "Patients" +300, 9, 2, 192, 9, 10, 917, 918, "(" +300, 9, 3, 193, 11, 12, 919, 920, "n" +300, 9, 4, 194, 13, 14, 921, 922, "=" +300, 9, 5, 195, 15, 18, 923, 926, "495" +300, 9, 6, 196, 19, 20, 927, 928, ")" +300, 9, 7, 197, 21, 25, 929, 933, "with" +300, 9, 8, 198, 26, 37, 934, 945, "established" +300, 9, 9, 199, 38, 43, 946, 951, "basal" +300, 9, 10, 200, 44, 51, 952, 959, "insulin" +300, 9, 11, 201, 52, 59, 960, 967, "therapy" +300, 9, 12, 202, 60, 63, 968, 971, "but" +300, 9, 13, 203, 64, 74, 972, 982, "inadequate" +300, 9, 14, 204, 75, 83, 983, 991, "glycemic" +300, 9, 15, 205, 84, 91, 992, 999, "control" +300, 9, 16, 206, 92, 96, 1000, 1004, "were" +300, 9, 17, 207, 97, 107, 1005, 1015, "randomized" +300, 9, 18, 208, 108, 110, 1016, 1018, "to" +300, 9, 19, 209, 111, 114, 1019, 1022, "add" +300, 9, 20, 210, 115, 127, 1023, 1035, "lixisenatide" +300, 9, 21, 211, 128, 130, 1036, 1038, "20" +300, 9, 22, 212, 131, 132, 1039, 1040, "μ" +300, 9, 23, 213, 133, 134, 1041, 1042, "g" +300, 9, 24, 214, 135, 137, 1043, 1045, "or" +300, 9, 25, 215, 138, 145, 1046, 1053, "placebo" +300, 9, 26, 216, 146, 149, 1054, 1057, "for" +300, 9, 27, 217, 150, 152, 1058, 1060, "24" +300, 9, 28, 218, 153, 158, 1061, 1066, "weeks" +300, 9, 29, 219, 159, 160, 1067, 1068, "." +300, 10, 1, 220, 0, 5, 1069, 1074, "Basal" +300, 10, 2, 221, 6, 13, 1075, 1082, "insulin" +300, 10, 3, 222, 14, 20, 1083, 1089, "dosage" +300, 10, 4, 223, 21, 24, 1090, 1093, "was" +300, 10, 5, 224, 25, 34, 1094, 1103, "unchanged" +300, 10, 6, 225, 35, 41, 1104, 1110, "except" +300, 10, 7, 226, 42, 44, 1111, 1113, "to" +300, 10, 8, 227, 45, 50, 1114, 1119, "limit" +300, 10, 9, 228, 51, 63, 1120, 1132, "hypoglycemia" +300, 10, 10, 229, 64, 65, 1133, 1134, "." +300, 11, 1, 230, 0, 5, 1135, 1140, "HbA1c" +300, 11, 2, 231, 6, 15, 1141, 1150, "reduction" +300, 11, 3, 232, 16, 20, 1151, 1155, "from" +300, 11, 4, 233, 21, 29, 1156, 1164, "baseline" +300, 11, 5, 234, 30, 33, 1165, 1168, "was" +300, 11, 6, 235, 34, 37, 1169, 1172, "the" +300, 11, 7, 236, 38, 45, 1173, 1180, "primary" +300, 11, 8, 237, 46, 49, 1181, 1184, "end" +300, 11, 9, 238, 50, 55, 1185, 1190, "point" +300, 11, 10, 239, 56, 57, 1191, 1192, "." +300, 12, 1, 240, 0, 7, 1193, 1200, "RESULTS" +300, 12, 2, 241, 8, 9, 1201, 1202, ":" +300, 12, 3, 242, 10, 14, 1203, 1207, "Mean" +300, 12, 4, 243, 15, 23, 1208, 1216, "duration" +300, 12, 5, 244, 24, 26, 1217, 1219, "of" +300, 12, 6, 245, 27, 35, 1220, 1228, "diabetes" +300, 12, 7, 246, 36, 39, 1229, 1232, "was" +300, 12, 8, 247, 40, 42, 1233, 1235, "12" +300, 12, 9, 248, 43, 44, 1236, 1237, "." +300, 12, 10, 249, 45, 46, 1238, 1239, "5" +300, 12, 11, 250, 47, 52, 1240, 1245, "years" +300, 12, 12, 251, 53, 54, 1246, 1247, "," +300, 12, 13, 252, 55, 63, 1248, 1256, "duration" +300, 12, 14, 253, 64, 66, 1257, 1259, "of" +300, 12, 15, 254, 67, 74, 1260, 1267, "insulin" +300, 12, 16, 255, 75, 78, 1268, 1271, "use" +300, 12, 17, 256, 79, 82, 1272, 1275, "was" +300, 12, 18, 257, 83, 84, 1276, 1277, "3" +300, 12, 19, 258, 85, 86, 1278, 1279, "." +300, 12, 20, 259, 87, 88, 1280, 1281, "1" +300, 12, 21, 260, 89, 94, 1282, 1287, "years" +300, 12, 22, 261, 95, 96, 1288, 1289, "," +300, 12, 23, 262, 97, 104, 1290, 1297, "insulin" +300, 12, 24, 263, 105, 111, 1298, 1304, "dosage" +300, 12, 25, 264, 112, 115, 1305, 1308, "was" +300, 12, 26, 265, 116, 118, 1309, 1311, "55" +300, 12, 27, 266, 119, 124, 1312, 1317, "units" +300, 12, 28, 267, 125, 126, 1318, 1319, "/" +300, 12, 29, 268, 127, 130, 1320, 1323, "day" +300, 12, 30, 269, 131, 132, 1324, 1325, "," +300, 12, 31, 270, 133, 136, 1326, 1329, "and" +300, 12, 32, 271, 137, 145, 1330, 1338, "baseline" +300, 12, 33, 272, 146, 151, 1339, 1344, "HbA1c" +300, 12, 34, 273, 152, 155, 1345, 1348, "was" +300, 12, 35, 274, 156, 157, 1349, 1350, "8" +300, 12, 36, 275, 158, 159, 1351, 1352, "." +300, 12, 37, 276, 160, 161, 1353, 1354, "4" +300, 12, 38, 277, 162, 163, 1355, 1356, "%" +300, 12, 39, 278, 164, 165, 1357, 1358, "." +300, 13, 1, 279, 0, 4, 1359, 1363, "With" +300, 13, 2, 280, 5, 17, 1364, 1376, "lixisenatide" +300, 13, 3, 281, 18, 19, 1377, 1378, "," +300, 13, 4, 282, 20, 23, 1379, 1382, "the" +300, 13, 5, 283, 24, 31, 1383, 1390, "placebo" +300, 13, 6, 284, 32, 33, 1391, 1392, "-" +300, 13, 7, 285, 34, 43, 1393, 1402, "corrected" +300, 13, 8, 286, 44, 50, 1403, 1409, "change" +300, 13, 9, 287, 51, 53, 1410, 1412, "of" +300, 13, 10, 288, 54, 59, 1413, 1418, "HbA1c" +300, 13, 11, 289, 60, 64, 1419, 1423, "from" +300, 13, 12, 290, 65, 73, 1424, 1432, "baseline" +300, 13, 13, 291, 74, 77, 1433, 1436, "was" +300, 13, 14, 292, 78, 79, 1437, 1438, "-" +300, 13, 15, 293, 80, 81, 1439, 1440, "0" +300, 13, 16, 294, 82, 83, 1441, 1442, "." +300, 13, 17, 295, 84, 85, 1443, 1444, "4" +300, 13, 18, 296, 86, 87, 1445, 1446, "%" +300, 13, 19, 297, 88, 89, 1447, 1448, "(" +300, 13, 20, 298, 90, 92, 1449, 1451, "95" +300, 13, 21, 299, 93, 94, 1452, 1453, "%" +300, 13, 22, 300, 95, 97, 1454, 1456, "CI" +300, 13, 23, 301, 98, 99, 1457, 1458, "-" +300, 13, 24, 302, 100, 101, 1459, 1460, "0" +300, 13, 25, 303, 102, 103, 1461, 1462, "." +300, 13, 26, 304, 104, 105, 1463, 1464, "6" +300, 13, 27, 305, 106, 108, 1465, 1467, "to" +300, 13, 28, 306, 109, 110, 1468, 1469, "-" +300, 13, 29, 307, 111, 112, 1470, 1471, "0" +300, 13, 30, 308, 113, 114, 1472, 1473, "." +300, 13, 31, 309, 115, 116, 1474, 1475, "2" +300, 13, 32, 310, 117, 118, 1476, 1477, ";" +300, 13, 33, 311, 119, 120, 1478, 1479, "P" +300, 13, 34, 312, 121, 122, 1480, 1481, "=" +300, 13, 35, 313, 123, 124, 1482, 1483, "0" +300, 13, 36, 314, 125, 126, 1484, 1485, "." +300, 13, 37, 315, 127, 131, 1486, 1490, "0002" +300, 13, 38, 316, 132, 133, 1491, 1492, ")" +300, 13, 39, 317, 134, 135, 1493, 1494, "," +300, 13, 40, 318, 136, 139, 1495, 1498, "and" +300, 13, 41, 319, 140, 144, 1499, 1503, "mean" +300, 13, 42, 320, 145, 150, 1504, 1509, "HbA1c" +300, 13, 43, 321, 151, 153, 1510, 1512, "at" +300, 13, 44, 322, 154, 157, 1513, 1516, "end" +300, 13, 45, 323, 158, 163, 1517, 1522, "point" +300, 13, 46, 324, 164, 167, 1523, 1526, "was" +300, 13, 47, 325, 168, 169, 1527, 1528, "7" +300, 13, 48, 326, 170, 171, 1529, 1530, "." +300, 13, 49, 327, 172, 173, 1531, 1532, "8" +300, 13, 50, 328, 174, 175, 1533, 1534, "%" +300, 13, 51, 329, 176, 177, 1535, 1536, "." +300, 14, 1, 330, 0, 5, 1537, 1542, "HbA1c" +300, 14, 2, 331, 6, 7, 1543, 1544, "<" +300, 14, 3, 332, 8, 9, 1545, 1546, "7" +300, 14, 4, 333, 10, 11, 1547, 1548, "." +300, 14, 5, 334, 12, 13, 1549, 1550, "0" +300, 14, 6, 335, 14, 15, 1551, 1552, "%" +300, 14, 7, 336, 16, 17, 1553, 1554, "(" +300, 14, 8, 337, 18, 20, 1555, 1557, "53" +300, 14, 9, 338, 21, 25, 1558, 1562, "mmol" +300, 14, 10, 339, 26, 27, 1563, 1564, "/" +300, 14, 11, 340, 28, 31, 1565, 1568, "mol" +300, 14, 12, 341, 32, 33, 1569, 1570, ")" +300, 14, 13, 342, 34, 37, 1571, 1574, "was" +300, 14, 14, 343, 38, 46, 1575, 1583, "attained" +300, 14, 15, 344, 47, 49, 1584, 1586, "by" +300, 14, 16, 345, 50, 54, 1587, 1591, "more" +300, 14, 17, 346, 55, 67, 1592, 1604, "lixisenatide" +300, 14, 18, 347, 68, 69, 1605, 1606, "(" +300, 14, 19, 348, 70, 72, 1607, 1609, "28" +300, 14, 20, 349, 73, 74, 1610, 1611, "%" +300, 14, 21, 350, 75, 76, 1612, 1613, ")" +300, 14, 22, 351, 77, 81, 1614, 1618, "than" +300, 14, 23, 352, 82, 89, 1619, 1626, "placebo" +300, 14, 24, 353, 90, 91, 1627, 1628, "(" +300, 14, 25, 354, 92, 94, 1629, 1631, "12" +300, 14, 26, 355, 95, 96, 1632, 1633, "%" +300, 14, 27, 356, 97, 98, 1634, 1635, ";" +300, 14, 28, 357, 99, 100, 1636, 1637, "P" +300, 14, 29, 358, 101, 102, 1638, 1639, "<" +300, 14, 30, 359, 103, 104, 1640, 1641, "0" +300, 14, 31, 360, 105, 106, 1642, 1643, "." +300, 14, 32, 361, 107, 111, 1644, 1648, "0001" +300, 14, 33, 362, 112, 113, 1649, 1650, ")" +300, 14, 34, 363, 114, 126, 1651, 1663, "participants" +300, 14, 35, 364, 127, 128, 1664, 1665, "." +300, 15, 1, 365, 0, 12, 1666, 1678, "Lixisenatide" +300, 15, 2, 366, 13, 20, 1679, 1686, "reduced" +300, 15, 3, 367, 21, 27, 1687, 1693, "plasma" +300, 15, 4, 368, 28, 35, 1694, 1701, "glucose" +300, 15, 5, 369, 36, 42, 1702, 1708, "levels" +300, 15, 6, 370, 43, 48, 1709, 1714, "after" +300, 15, 7, 371, 49, 50, 1715, 1716, "a" +300, 15, 8, 372, 51, 63, 1717, 1729, "standardized" +300, 15, 9, 373, 64, 73, 1730, 1739, "breakfast" +300, 15, 10, 374, 74, 75, 1740, 1741, "(" +300, 15, 11, 375, 76, 83, 1742, 1749, "placebo" +300, 15, 12, 376, 84, 85, 1750, 1751, "-" +300, 15, 13, 377, 86, 95, 1752, 1761, "corrected" +300, 15, 14, 378, 96, 105, 1762, 1771, "reduction" +300, 15, 15, 379, 106, 107, 1772, 1773, "," +300, 15, 16, 380, 108, 109, 1774, 1775, "-" +300, 15, 17, 381, 110, 111, 1776, 1777, "3" +300, 15, 18, 382, 112, 113, 1778, 1779, "." +300, 15, 19, 383, 114, 115, 1780, 1781, "8" +300, 15, 20, 384, 116, 120, 1782, 1786, "mmol" +300, 15, 21, 385, 121, 122, 1787, 1788, "/" +300, 15, 22, 386, 123, 124, 1789, 1790, "L" +300, 15, 23, 387, 125, 126, 1791, 1792, ";" +300, 15, 24, 388, 127, 128, 1793, 1794, "P" +300, 15, 25, 389, 129, 130, 1795, 1796, "<" +300, 15, 26, 390, 131, 132, 1797, 1798, "0" +300, 15, 27, 391, 133, 134, 1799, 1800, "." +300, 15, 28, 392, 135, 139, 1801, 1805, "0001" +300, 15, 29, 393, 140, 141, 1806, 1807, ")" +300, 15, 30, 394, 142, 143, 1808, 1809, ";" +300, 15, 31, 395, 144, 149, 1810, 1815, "seven" +300, 15, 32, 396, 150, 151, 1816, 1817, "-" +300, 15, 33, 397, 152, 157, 1818, 1823, "point" +300, 15, 34, 398, 158, 165, 1824, 1831, "glucose" +300, 15, 35, 399, 166, 174, 1832, 1840, "profiles" +300, 15, 36, 400, 175, 181, 1841, 1847, "showed" +300, 15, 37, 401, 182, 183, 1848, 1849, "a" +300, 15, 38, 402, 184, 193, 1850, 1859, "reduction" +300, 15, 39, 403, 194, 204, 1860, 1870, "persisting" +300, 15, 40, 404, 205, 212, 1871, 1878, "through" +300, 15, 41, 405, 213, 216, 1879, 1882, "the" +300, 15, 42, 406, 217, 220, 1883, 1886, "day" +300, 15, 43, 407, 221, 222, 1887, 1888, "." +300, 16, 1, 408, 0, 10, 1889, 1899, "Reductions" +300, 16, 2, 409, 11, 13, 1900, 1902, "in" +300, 16, 3, 410, 14, 18, 1903, 1907, "body" +300, 16, 4, 411, 19, 25, 1908, 1914, "weight" +300, 16, 5, 412, 26, 27, 1915, 1916, "(" +300, 16, 6, 413, 28, 35, 1917, 1924, "placebo" +300, 16, 7, 414, 36, 45, 1925, 1934, "corrected" +300, 16, 8, 415, 46, 47, 1935, 1936, "," +300, 16, 9, 416, 48, 49, 1937, 1938, "-" +300, 16, 10, 417, 50, 51, 1939, 1940, "1" +300, 16, 11, 418, 52, 53, 1941, 1942, "." +300, 16, 12, 419, 54, 55, 1943, 1944, "3" +300, 16, 13, 420, 56, 58, 1945, 1947, "kg" +300, 16, 14, 421, 59, 60, 1948, 1949, ";" +300, 16, 15, 422, 61, 62, 1950, 1951, "P" +300, 16, 16, 423, 63, 64, 1952, 1953, "<" +300, 16, 17, 424, 65, 66, 1954, 1955, "0" +300, 16, 18, 425, 67, 68, 1956, 1957, "." +300, 16, 19, 426, 69, 73, 1958, 1962, "0001" +300, 16, 20, 427, 74, 75, 1963, 1964, ")" +300, 16, 21, 428, 76, 79, 1965, 1968, "and" +300, 16, 22, 429, 80, 87, 1969, 1976, "insulin" +300, 16, 23, 430, 88, 94, 1977, 1983, "dosage" +300, 16, 24, 431, 95, 96, 1984, 1985, "(" +300, 16, 25, 432, 97, 98, 1986, 1987, "-" +300, 16, 26, 433, 99, 100, 1988, 1989, "3" +300, 16, 27, 434, 101, 102, 1990, 1991, "." +300, 16, 28, 435, 103, 104, 1992, 1993, "7" +300, 16, 29, 436, 105, 110, 1994, 1999, "units" +300, 16, 30, 437, 111, 112, 2000, 2001, "/" +300, 16, 31, 438, 113, 116, 2002, 2005, "day" +300, 16, 32, 439, 117, 118, 2006, 2007, ";" +300, 16, 33, 440, 119, 120, 2008, 2009, "P" +300, 16, 34, 441, 121, 122, 2010, 2011, "=" +300, 16, 35, 442, 123, 124, 2012, 2013, "0" +300, 16, 36, 443, 125, 126, 2014, 2015, "." +300, 16, 37, 444, 127, 130, 2016, 2019, "012" +300, 16, 38, 445, 131, 132, 2020, 2021, ")" +300, 16, 39, 446, 133, 137, 2022, 2026, "were" +300, 16, 40, 447, 138, 145, 2027, 2034, "greater" +300, 16, 41, 448, 146, 150, 2035, 2039, "with" +300, 16, 42, 449, 151, 163, 2040, 2052, "lixisenatide" +300, 16, 43, 450, 164, 165, 2053, 2054, "." +300, 17, 1, 451, 0, 4, 2055, 2059, "Main" +300, 17, 2, 452, 5, 12, 2060, 2067, "adverse" +300, 17, 3, 453, 13, 19, 2068, 2074, "events" +300, 17, 4, 454, 20, 21, 2075, 2076, "(" +300, 17, 5, 455, 22, 25, 2077, 2080, "AEs" +300, 17, 6, 456, 26, 27, 2081, 2082, ")" +300, 17, 7, 457, 28, 32, 2083, 2087, "with" +300, 17, 8, 458, 33, 45, 2088, 2100, "lixisenatide" +300, 17, 9, 459, 46, 50, 2101, 2105, "were" +300, 17, 10, 460, 51, 67, 2106, 2122, "gastrointestinal" +300, 17, 11, 461, 68, 69, 2123, 2124, "." +300, 18, 1, 462, 0, 11, 2125, 2136, "Symptomatic" +300, 18, 2, 463, 12, 24, 2137, 2149, "hypoglycemia" +300, 18, 3, 464, 25, 28, 2150, 2153, "was" +300, 18, 4, 465, 29, 31, 2154, 2156, "28" +300, 18, 5, 466, 32, 33, 2157, 2158, "%" +300, 18, 6, 467, 34, 37, 2159, 2162, "for" +300, 18, 7, 468, 38, 50, 2163, 2175, "lixisenatide" +300, 18, 8, 469, 51, 54, 2176, 2179, "and" +300, 18, 9, 470, 55, 57, 2180, 2182, "22" +300, 18, 10, 471, 58, 59, 2183, 2184, "%" +300, 18, 11, 472, 60, 63, 2185, 2188, "for" +300, 18, 12, 473, 64, 71, 2189, 2196, "placebo" +300, 18, 13, 474, 72, 73, 2197, 2198, ";" +300, 18, 14, 475, 74, 75, 2199, 2200, "4" +300, 18, 15, 476, 76, 78, 2201, 2203, "of" +300, 18, 16, 477, 79, 82, 2204, 2207, "328" +300, 18, 17, 478, 83, 91, 2208, 2216, "subjects" +300, 18, 18, 479, 92, 93, 2217, 2218, "(" +300, 18, 19, 480, 94, 95, 2219, 2220, "1" +300, 18, 20, 481, 96, 97, 2221, 2222, "." +300, 18, 21, 482, 98, 99, 2223, 2224, "2" +300, 18, 22, 483, 100, 101, 2225, 2226, "%" +300, 18, 23, 484, 102, 103, 2227, 2228, ")" +300, 18, 24, 485, 104, 107, 2229, 2232, "had" +300, 18, 25, 486, 108, 114, 2233, 2239, "severe" +300, 18, 26, 487, 115, 127, 2240, 2252, "hypoglycemia" +300, 18, 27, 488, 128, 132, 2253, 2257, "with" +300, 18, 28, 489, 133, 145, 2258, 2270, "lixisenatide" +300, 18, 29, 490, 146, 148, 2271, 2273, "vs" +300, 18, 30, 491, 149, 150, 2274, 2275, "." +300, 18, 31, 492, 151, 152, 2276, 2277, "0" +300, 18, 32, 493, 153, 155, 2278, 2280, "of" +300, 18, 33, 494, 156, 159, 2281, 2284, "167" +300, 18, 34, 495, 160, 164, 2285, 2289, "with" +300, 18, 35, 496, 165, 172, 2290, 2297, "placebo" +300, 18, 36, 497, 173, 174, 2298, 2299, "." +300, 19, 1, 498, 0, 11, 2300, 2311, "CONCLUSIONS" +300, 19, 2, 499, 12, 13, 2312, 2313, ":" +300, 19, 3, 500, 14, 16, 2314, 2316, "By" +300, 19, 4, 501, 17, 26, 2317, 2326, "improving" +300, 19, 5, 502, 27, 32, 2327, 2332, "HbA1c" +300, 19, 6, 503, 33, 36, 2333, 2336, "and" +300, 19, 7, 504, 37, 49, 2337, 2349, "postprandial" +300, 19, 8, 505, 50, 63, 2350, 2363, "hyperglycemia" +300, 19, 9, 506, 64, 71, 2364, 2371, "without" +300, 19, 10, 507, 72, 78, 2372, 2378, "weight" +300, 19, 11, 508, 79, 83, 2379, 2383, "gain" +300, 19, 12, 509, 84, 86, 2384, 2386, "in" +300, 19, 13, 510, 87, 91, 2387, 2391, "type" +300, 19, 14, 511, 92, 93, 2392, 2393, "2" +300, 19, 15, 512, 94, 102, 2394, 2402, "diabetes" +300, 19, 16, 513, 103, 107, 2403, 2407, "with" +300, 19, 17, 514, 108, 118, 2408, 2418, "inadequate" +300, 19, 18, 515, 119, 127, 2419, 2427, "glycemic" +300, 19, 19, 516, 128, 135, 2428, 2435, "control" +300, 19, 20, 517, 136, 143, 2436, 2443, "despite" +300, 19, 21, 518, 144, 150, 2444, 2450, "stable" +300, 19, 22, 519, 151, 156, 2451, 2456, "basal" +300, 19, 23, 520, 157, 164, 2457, 2464, "insulin" +300, 19, 24, 521, 165, 166, 2465, 2466, "," +300, 19, 25, 522, 167, 179, 2467, 2479, "lixisenatide" +300, 19, 26, 523, 180, 183, 2480, 2483, "may" +300, 19, 27, 524, 184, 191, 2484, 2491, "provide" +300, 19, 28, 525, 192, 194, 2492, 2494, "an" +300, 19, 29, 526, 195, 206, 2495, 2506, "alternative" +300, 19, 30, 527, 207, 209, 2507, 2509, "to" +300, 19, 31, 528, 210, 215, 2510, 2515, "rapid" +300, 19, 32, 529, 216, 217, 2516, 2517, "-" +300, 19, 33, 530, 218, 224, 2518, 2524, "acting" +300, 19, 34, 531, 225, 232, 2525, 2532, "insulin" +300, 19, 35, 532, 233, 235, 2533, 2535, "or" +300, 19, 36, 533, 236, 241, 2536, 2541, "other" +300, 19, 37, 534, 242, 251, 2542, 2551, "treatment" +300, 19, 38, 535, 252, 259, 2552, 2559, "options" +300, 19, 39, 536, 260, 261, 2560, 2561, "." +300, 20, 1, 537, 0, 3, 2562, 2565, "DOI" +300, 20, 2, 538, 4, 5, 2566, 2567, ":" +300, 20, 3, 539, 6, 8, 2568, 2570, "10" +300, 20, 4, 540, 9, 10, 2571, 2572, "." +300, 20, 5, 541, 11, 15, 2573, 2577, "2337" +300, 20, 6, 542, 16, 17, 2578, 2579, "/" +300, 20, 7, 543, 18, 22, 2580, 2584, "dc12" +300, 20, 8, 544, 23, 24, 2585, 2586, "-" +300, 20, 9, 545, 25, 29, 2587, 2591, "2454" +300, 20, 10, 546, 30, 35, 2592, 2597, "PMCID" +300, 20, 11, 547, 36, 37, 2598, 2599, ":" +300, 20, 12, 548, 38, 48, 2600, 2610, "PMC3747925" +300, 20, 13, 549, 49, 53, 2611, 2615, "PMID" +300, 20, 14, 550, 54, 55, 2616, 2617, ":" +300, 20, 15, 551, 56, 64, 2618, 2626, "23628617" +300, 20, 16, 552, 65, 66, 2627, 2628, "[" +300, 20, 17, 553, 67, 74, 2629, 2636, "Indexed" +300, 20, 18, 554, 75, 78, 2637, 2640, "for" +300, 20, 19, 555, 79, 86, 2641, 2648, "MEDLINE" +300, 20, 20, 556, 87, 88, 2649, 2650, "]" diff --git a/data/dm2 23628617_kwoodley.annodb b/data/dm2 23628617_kwoodley.annodb new file mode 100644 index 0000000..1d7b6e2 --- /dev/null +++ b/data/dm2 23628617_kwoodley.annodb @@ -0,0 +1,116 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +41939, Journal, 0, 13, "Diabetes Care", "", +41940, PublicationYear, 16, 20, "2013", "", +41949, Title, 101, 285, "Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .", "", +41941, Frequency, 108, 120, "once - daily", "", +41942, Drug, 121, 133, "lixisenatide", "", +41943, Type2Diabetes, 138, 153, "type 2 diabetes", "", +41968, Precondition, 138, 206, "type 2 diabetes inadequately controlled by established basal insulin", "", +41944, Insulin, 193, 206, "basal insulin", "", +41945, Duration, 211, 220, "24 - week", "", +41946, Randomized, 223, 233, "randomized", "", +41947, Placebo, 236, 243, "placebo", "", +41950, Author, 286, 295, "Riddle MC", "", +41951, Author, 304, 313, "Aronson R", "", +41952, Author, 316, 322, "Home P", "", +41953, Author, 325, 332, "Marre M", "", +41954, Author, 335, 347, "Niemoeller E", "", +41955, Author, 350, 359, "Miossec P", "", +41956, Author, 362, 368, "Ping L", "", +41957, Author, 371, 375, "Ye J", "", +41958, Author, 378, 390, "Rosenstock J", "", +41959, USA, 477, 480, "USA", "", +41969, ObjectiveDescription, 516, 721, "To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin ,", "", +41960, Frequency, 565, 577, "once - daily", "", +41961, Drug, 637, 649, "lixisenatide", "", +41962, Insulin, 665, 678, "basal insulin", "", +41963, Metformin, 710, 719, "metformin", "", +41970, ObjectiveDescription, 722, 797, "in people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .", "", +41967, Precondition, 725, 795, "people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )", "", +41964, Type2Diabetes, 737, 752, "type 2 diabetes", "", +41965, HbA1c, 766, 785, "glycated hemoglobin", "", +41966, HbA1c, 788, 793, "HbA1c", "", +41971, DoubleBlind, 843, 857, "double - blind", "", +41972, Parallel, 860, 876, "parallel - group", "", +41973, Placebo, 879, 886, "placebo", "", +41974, NumberPatientsCT, 923, 926, "495", "", +41975, Insulin, 946, 959, "basal insulin", "", +41976, Randomized, 1005, 1015, "randomized", "", +41977, Drug, 1023, 1035, "lixisenatide", "", +41978, DoseValue, 1036, 1038, "20", "", +41979, Microgram, 1039, 1042, "μ g", "", +41980, Placebo, 1046, 1053, "placebo", "", +41981, Duration, 1058, 1066, "24 weeks", "", +41982, Insulin, 1069, 1082, "Basal insulin", "", +41983, Hypoglycemia, 1120, 1132, "hypoglycemia", "", +41984, HbA1c, 1135, 1140, "HbA1c", "", +41991, Precondition, 1203, 1358, "Mean duration of diabetes was 12 . 5 years , duration of insulin use was 3 . 1 years , insulin dosage was 55 units / day , and baseline HbA1c was 8 . 4 % .", "", +41988, InsulinDose, 1290, 1304, "insulin dosage", "", +41989, BaseLineValue, 1309, 1311, "55", "", +41990, BioAndMedicalUnit, 1312, 1323, "units / day", "", +41985, HbA1c, 1339, 1344, "HbA1c", "", +41986, BaseLineValue, 1349, 1354, "8 . 4", "", +41987, Percentage, 1355, 1356, "%", "", +41992, Drug, 1364, 1376, "lixisenatide", "", +41993, Placebo, 1383, 1390, "placebo", "", +41994, HbA1c, 1413, 1418, "HbA1c", "", +42001, TimePoint, 1424, 1432, "baseline", "", +41995, Reduction, 1439, 1444, "0 . 4", "", +41996, Percentage, 1445, 1446, "%", "", +41997, ConfIntervalChangeValue, 1449, 1475, "95 % CI - 0 . 6 to - 0 . 2", "", +41998, PValueChangeValue, 1478, 1490, "P = 0 . 0002", "", +41999, HbA1c, 1504, 1509, "HbA1c", "", +42000, TimePoint, 1510, 1522, "at end point", "", +42002, ResultMeasuredValue, 1527, 1532, "7 . 8", "", +42003, Percentage, 1533, 1534, "%", "", +42004, HbA1c_target, 1537, 1570, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", +42006, Drug, 1592, 1604, "lixisenatide", "", +42008, PercentageAffected, 1607, 1609, "28", "", +42007, Placebo, 1619, 1626, "placebo", "", +42009, PercentageAffected, 1629, 1631, "12", "", +42010, PvalueDiff, 1636, 1648, "P < 0 . 0001", "", +42011, Drug, 1666, 1678, "Lixisenatide", "", +42012, PlasmaGlucose, 1687, 1701, "plasma glucose", "", +42013, TimePoint, 1709, 1739, "after a standardized breakfast", "", +42014, Placebo, 1742, 1749, "placebo", "", +42026, Reduction, 1776, 1781, "3 . 8", "", +42016, Millimoles_per_litre, 1782, 1790, "mmol / L", "", +42017, PValueChangeValue, 1793, 1805, "P < 0 . 0001", "", +42018, ObservedResult, 1810, 1886, "seven - point glucose profiles showed a reduction persisting through the day", "", +42019, BodyWeight, 1903, 1914, "body weight", "", +42020, Placebo, 1917, 1924, "placebo", "", +42025, Reduction, 1939, 1944, "1 . 3", "", +42022, Kg, 1945, 1947, "kg", "", +42023, PValueChangeValue, 1950, 1962, "P < 0 . 0001", "", +42024, InsulinDose, 1969, 1983, "insulin dosage", "", +42027, Reduction, 1988, 1993, "3 . 7", "", +42028, BioAndMedicalUnit, 1994, 2005, "units / day", "", +42029, PValueChangeValue, 2008, 2019, "P = 0 . 012", "", +42030, Drug, 2040, 2052, "lixisenatide", "", +42034, ObservedResult, 2055, 2124, "Main adverse events ( AEs ) with lixisenatide were gastrointestinal .", "", +42031, EndPointDescription, 2060, 2074, "adverse events", "", +42032, EndPointDescription, 2077, 2080, "AEs", "", +42033, Drug, 2088, 2100, "lixisenatide", "", +42035, SymptomaticHypoglycemia, 2125, 2149, "Symptomatic hypoglycemia", "", +42036, PercentageAffected, 2154, 2156, "28", "", +42038, Drug, 2163, 2175, "lixisenatide", "", +42037, PercentageAffected, 2180, 2182, "22", "", +42039, Placebo, 2189, 2196, "placebo", "", +42041, NumberAffected, 2199, 2200, "4", "", +42043, NumberPatientsArm, 2204, 2207, "328", "", +42040, PercentageAffected, 2219, 2224, "1 . 2", "", +42046, SevereHypoglycemia, 2233, 2252, "severe hypoglycemia", "", +42047, Drug, 2258, 2270, "lixisenatide", "", +42042, NumberAffected, 2276, 2277, "0", "", +42044, NumberPatientsArm, 2281, 2284, "167", "", +42045, Placebo, 2290, 2297, "placebo", "", +42056, ConclusionComment, 2314, 2561, "By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .", "", +42048, HbA1c, 2327, 2332, "HbA1c", "", +42049, Hypoglycemia, 2337, 2363, "postprandial hyperglycemia", "", +42050, BodyWeight, 2372, 2378, "weight", "", +42051, Type2Diabetes, 2387, 2402, "type 2 diabetes", "", +42053, Precondition, 2387, 2464, "type 2 diabetes with inadequate glycemic control despite stable basal insulin", "", +42052, Insulin, 2451, 2464, "basal insulin", "", +42054, Drug, 2467, 2479, "lixisenatide", "", +42055, Insulin, 2525, 2532, "insulin", "", +42057, PMID, 2618, 2626, "23628617", "", diff --git a/data/dm2 23628617_kwoodley.n-triples b/data/dm2 23628617_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23628617_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23706759_admin.annodb b/data/dm2 23706759_admin.annodb new file mode 100644 index 0000000..17aed3d --- /dev/null +++ b/data/dm2 23706759_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 6, "Lancet", "", " \"Lancet\"." +1, PublicationYear, 9, 13, "2013", "", " \"2013\"." +9, Title, 118, 322, "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .", "", " \"Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .\"." +82, Precondition, 155, 236, "elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy", "", " \"elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy\"." +3, Type2Diabetes, 177, 192, "type 2 diabetes", "", " ." +2, Vildagliptin, 199, 211, "vildagliptin", "", +4, Duration, 254, 261, "24 week", "", " \"24 week\"." +5, Randomized, 264, 274, "randomised", "", " ." +6, DoubleBlind, 277, 291, "double - blind", "", " ." +7, Placebo, 294, 301, "placebo", "", +10, Author, 323, 332, "Strain WD", "", " \"Strain WD\"." +11, Author, 341, 354, "Lukashevich V", "", " \"Lukashevich V\"." +12, Author, 363, 371, "Kothny W", "", " \"Kothny W\"." +13, Author, 380, 393, "Hoellinger MJ", "", " \"Hoellinger MJ\"." +14, Author, 402, 416, "Pald á nius PM", "", " \"Pald á nius PM\"." +15, UK, 539, 541, "UK", "", +96, USA, 662, 665, "USA", "", +97, Switzerland, 703, 714, "Switzerland", "", +98, Precondition, 912, 949, "elderly patients with type 2 diabetes", "", +16, Type2Diabetes, 934, 949, "type 2 diabetes", "", +22, ObjectiveDescription, 974, 1146, "We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .", "", " \"We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .\"." +18, Duration, 1062, 1070, "24 weeks", "", +19, HbA1c, 1095, 1100, "HbA1c", "", +20, Vildagliptin, 1117, 1129, "vildagliptin", "", +21, Placebo, 1137, 1144, "placebo", "", +23, Multicenter, 1165, 1178, "multinational", "", " ." +24, DoubleBlind, 1181, 1195, "double - blind", "", +25, Duration, 1198, 1205, "24 week", "", +113, HbA1c, 1268, 1296, "glycosylated haemoglobin A1c", "", +27, HbA1c, 1299, 1304, "HbA1c", "", +28, Percentage, 1315, 1316, "%", "", +116, Percentage, 1329, 1330, "%", "", +29, Type2Diabetes, 1347, 1362, "type 2 diabetes", "", +30, MinAge, 1368, 1370, "70", "", " \"70\"." +112, Multicenter, 1391, 1412, "45 outpatient centres", "", +117, TimePoint, 1498, 1506, "baseline", "", +32, HbA1c, 1507, 1512, "HbA1c", "", +119, Randomized, 1586, 1594, "randomly", "", +33, AllocationRatio, 1615, 1620, "1 : 1", "", " . ." +34, Vildagliptin, 1626, 1638, "vildagliptin", "", " ." +35, DoseValue, 1641, 1643, "50", "", " \"50\"." +36, mg, 1644, 1646, "mg", "", " ." +123, Frequency, 1647, 1666, "once or twice daily", "", " \"once or twice daily\"." +38, Placebo, 1685, 1692, "placebo", "", " ." +39, HbA1c_target, 1790, 1802, "HbA1c target", "", +40, HbA1c, 1807, 1812, "HbA1c", "", +41, TimePoint, 1828, 1836, "baseline", "", +42, TimePoint, 1840, 1849, "study end", "", +43, Randomized, 2087, 2095, "randomly", "", +133, NumberPatientsArm, 2105, 2108, "139", "", " \"139\". \"139\"." +45, Vildagliptin, 2130, 2142, "vildagliptin", "", +46, Placebo, 2147, 2154, "placebo", "", +47, NumberAffected, 2164, 2166, "37", "", " \"37\"." +48, PercentageAffected, 2169, 2171, "27", "", " \"27\"." +93017, FinalNumPatientsArm, 2179, 2182, "137", "", " \"137\"." +50, Placebo, 2199, 2206, "placebo", "", +66189, HbA1c_target, 2243, 2250, "targets", "", " ." +51, NumberAffected, 2311, 2313, "72", "", " \"72\"." +52, PercentageAffected, 2316, 2322, "52 · 6", "", " \"52 · 6\"." +93018, FinalNumPatientsArm, 2330, 2333, "137", "", " \"137\"." +66197, HbA1c_target, 2358, 2364, "target", "", +54, Vildagliptin, 2372, 2384, "vildagliptin", "", +56, ConfIntervalDiff, 2431, 2449, "CI 1 · 81 - 5 · 52", "", " \"CI 1 · 81 - 5 · 52\"." +55, PvalueDiff, 2452, 2464, "p < 0 · 0001", "", " \"p < 0 · 0001\"." +57, Reduction, 2523, 2528, "0 · 9", "", " \"0 · 9\"." +58, Percentage, 2529, 2530, "%", "", +59, HbA1c, 2544, 2549, "HbA1c", "", " ." +146, TimePoint, 2557, 2565, "baseline", "", +60, BaseLineValue, 2569, 2574, "7 · 9", "", " \"7 · 9\"." +61, Percentage, 2575, 2576, "%", "", " ." +62, Vildagliptin, 2582, 2594, "vildagliptin", "", +63, DiffGroupAbsValue, 2631, 2638, "- 0 · 6", "", " \"- 0 · 6\"." +64, Percentage, 2639, 2640, "%", "", +65, ConfIntervalDiff, 2643, 2675, "98 · 8 % CI - 0 · 81 to - 0 · 33", "", " \"98 · 8 % CI - 0 · 81 to - 0 · 33\"." +66, PvalueDiff, 2678, 2690, "p < 0 · 0001", "", " \"p < 0 · 0001\"." +67, Vildagliptin, 2750, 2762, "vildagliptin", "", +68, Placebo, 2767, 2774, "placebo", "", +70, ObservedResult, 2789, 2802, "low incidence", "", +69, Hypoglycemia, 2806, 2819, "hypoglycaemia", "", +74, ConclusionComment, 2878, 3028, "This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .", "", " \"This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .\"." +160, HbA1c_target, 2964, 2977, "HbA1c targets", "", +73, Type2Diabetes, 3000, 3015, "type 2 diabetes", "", +78, ConclusionComment, 3029, 3176, "Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .", "", " \"Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .\"." +75, Vildagliptin, 3088, 3100, "vildagliptin", "", +76, Type2Diabetes, 3148, 3163, "type 2 diabetes", "", +79, PMID, 3317, 3325, "23706759", "", " \"23706759\"." diff --git a/data/dm2 23706759_admin.n-triples b/data/dm2 23706759_admin.n-triples new file mode 100644 index 0000000..c1270ec --- /dev/null +++ b/data/dm2 23706759_admin.n-triples @@ -0,0 +1,127 @@ +# RDF export of group: Publication + . + "Publication 45906" . + "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study ." . + "Strain WD" . + "2013" . + "Lancet" . + "23706759" . + . + "Lukashevich V" . + "Kothny W" . + "Hoellinger MJ" . + "Pald á nius PM" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 45913" . + "We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo ." . + "24 week" . + . + . + . + . + "This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population ." . + . + . + . + . + . + . + . + "Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population ." . + . + . +# RDF export of group: Population + . + "Population 45929" . + "elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy" . + . + . + "70" . + . +# RDF export of group: Endpoint + . + "hbat" . + . + . + . + . + . + "hba" . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + "139" . + "137" . + . + . + . + . + . + "pla" . + "139" . + "137" . + . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + "once or twice daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "vil" . + . + "50" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hbat 1" . + . + "72" . + "52 · 6" . + . + "hbat 2" . + . + "37" . + "27" . + . + "hba 1" . + . + "7 · 9" . + "0 · 9" . + . + "hba 2" . + . +# RDF export of group: DiffBetweenGroups + . + "hbat" . + "p < 0 · 0001" . + "CI 1 · 81 - 5 · 52" . + . + . + . + "hba" . + "- 0 · 6" . + "p < 0 · 0001" . + "98 · 8 % CI - 0 · 81 to - 0 · 33" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23706759_akramersunderbrink.annodb b/data/dm2 23706759_akramersunderbrink.annodb new file mode 100644 index 0000000..de77b63 --- /dev/null +++ b/data/dm2 23706759_akramersunderbrink.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43741, Journal, 0, 6, "Lancet", "", +43742, PublicationYear, 9, 13, "2013", "", +43750, Title, 118, 322, "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .", "", +43743, Precondition, 155, 162, "elderly", "", +43744, Type2Diabetes, 177, 192, "type 2 diabetes", "", +43745, Drug, 199, 211, "vildagliptin", "", +43746, Duration, 254, 261, "24 week", "", +43747, Randomized, 264, 274, "randomised", "", +43748, DoubleBlind, 277, 291, "double - blind", "", +43749, Placebo, 294, 301, "placebo", "", +43751, Author, 323, 332, "Strain WD", "", +43752, Author, 341, 354, "Lukashevich V", "", +43753, Author, 363, 371, "Kothny W", "", +43754, Author, 380, 393, "Hoellinger MJ", "", +43755, Author, 402, 416, "Pald á nius PM", "", +43756, UK, 539, 541, "UK", "", +43757, USA, 662, 665, "USA", "", +43758, Switzerland, 703, 714, "Switzerland", "", +43765, ObjectiveDescription, 837, 973, "Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes , despite no evidence .", "", +43759, Precondition, 912, 919, "elderly", "", +43760, Type2Diabetes, 934, 949, "type 2 diabetes", "", +43766, ObjectiveDescription, 974, 1146, "We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .", "", +43761, Duration, 1062, 1070, "24 weeks", "", +43762, HbA1c, 1095, 1100, "HbA1c", "", +43763, Vildagliptin, 1117, 1129, "vildagliptin", "", +43764, Placebo, 1137, 1144, "placebo", "", +43767, Multicenter, 1165, 1178, "multinational", "", +43768, DoubleBlind, 1181, 1195, "double - blind", "", +43769, Duration, 1198, 1205, "24 week", "", +43770, Precondition, 1226, 1332, "drug - naive or inadequately controlled ( glycosylated haemoglobin A1c [ HbA1c ] ≥ 7 · 0 % to ≤ 10 · 0 % )", "", +43774, HbA1c, 1268, 1296, "glycosylated haemoglobin A1c", "", +43775, HbA1c, 1299, 1304, "HbA1c", "", +43776, Percentage, 1315, 1316, "%", "", +43777, Percentage, 1329, 1330, "%", "", +43771, Type2Diabetes, 1347, 1362, "type 2 diabetes", "", +43772, MinAge, 1368, 1376, "70 years", "", +43773, Multicenter, 1391, 1412, "45 outpatient centres", "", +43778, TimePoint, 1498, 1506, "baseline", "", +43779, HbA1c, 1507, 1512, "HbA1c", "", +43780, Randomized, 1586, 1594, "randomly", "", +43781, Vildagliptin, 1626, 1638, "vildagliptin", "", +43782, DoseValue, 1641, 1646, "50 mg", "", +43783, mg, 1644, 1646, "mg", "", +43784, Frequency, 1647, 1666, "once or twice daily", "", +43785, Placebo, 1685, 1692, "placebo", "", +43787, HbA1c_target, 1767, 1802, "investigator - defined HbA1c target", "", +43786, HbA1c, 1807, 1812, "HbA1c", "", +43788, TimePoint, 1828, 1836, "baseline", "", +43789, TimePoint, 1840, 1849, "study end", "", +43790, TimePoint, 2046, 2059, "Dec 22 , 2010", "", +43791, TimePoint, 2066, 2081, "March 14 , 2012", "", +43795, NumberPatientsArm, 2105, 2108, "139", "", +43793, Vildagliptin, 2130, 2142, "vildagliptin", "", +43794, Placebo, 2147, 2154, "placebo", "", +43798, NumberAffected, 2164, 2166, "37", "", +43800, PercentageAffected, 2169, 2171, "27", "", +43802, Percentage, 2172, 2173, "%", "", +43796, FinalNumPatientsArm, 2179, 2182, "137", "", +43804, Placebo, 2199, 2206, "placebo", "", +43799, NumberAffected, 2311, 2313, "72", "", +43801, PercentageAffected, 2316, 2322, "52 · 6", "", +43803, Percentage, 2323, 2324, "%", "", +43797, FinalNumPatientsArm, 2330, 2333, "137", "", +43805, Drug, 2372, 2384, "vildagliptin", "", +43806, Percentage, 2429, 2430, "%", "", +43809, Reduction, 2523, 2528, "0 · 9", "", +43810, Percentage, 2529, 2530, "%", "", +43807, HbA1c, 2544, 2549, "HbA1c", "", +43808, TimePoint, 2557, 2565, "baseline", "", +43812, BaseLineValue, 2569, 2574, "7 · 9", "", +43811, Percentage, 2575, 2576, "%", "", +43813, Vildagliptin, 2582, 2594, "vildagliptin", "", +43814, DiffBetweenGroups, 2631, 2638, "- 0 · 6", "", +43815, Percentage, 2639, 2640, "%", "", +43817, ConfIntervalDiff, 2643, 2675, "98 · 8 % CI - 0 · 81 to - 0 · 33", "", +43816, Percentage, 2650, 2651, "%", "", +43818, PvalueDiff, 2678, 2690, "p < 0 · 0001", "", +43819, Vildagliptin, 2750, 2762, "vildagliptin", "", +43820, Placebo, 2767, 2774, "placebo", "", +43821, Hypoglycemia, 2806, 2819, "hypoglycaemia", "", +43829, ConclusionComment, 2878, 3028, "This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .", "", +43822, HbA1c_target, 2964, 2977, "HbA1c targets", "", +43824, Type2Diabetes, 3000, 3015, "type 2 diabetes", "", +43830, ConclusionComment, 3029, 3176, "Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .", "", +43825, Vildagliptin, 3088, 3100, "vildagliptin", "", +43826, Precondition, 3140, 3147, "elderly", "", +43827, Type2Diabetes, 3148, 3163, "type 2 diabetes", "", +43828, PMID, 3317, 3325, "23706759", "", diff --git a/data/dm2 23706759_akramersunderbrink.n-triples b/data/dm2 23706759_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23706759_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23706759_export.csv b/data/dm2 23706759_export.csv new file mode 100644 index 0000000..591e0c8 --- /dev/null +++ b/data/dm2 23706759_export.csv @@ -0,0 +1,674 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +299, 1, 1, 1, 0, 6, 0, 6, "Lancet" +299, 1, 2, 2, 7, 8, 7, 8, "." +299, 2, 1, 3, 0, 4, 9, 13, "2013" +299, 2, 2, 4, 5, 8, 14, 17, "Aug" +299, 2, 3, 5, 9, 10, 18, 19, "3" +299, 2, 4, 6, 11, 12, 20, 21, ";" +299, 2, 5, 7, 13, 16, 22, 25, "382" +299, 2, 6, 8, 17, 18, 26, 27, "(" +299, 2, 7, 9, 19, 23, 28, 32, "9890" +299, 2, 8, 10, 24, 25, 33, 34, ")" +299, 2, 9, 11, 26, 27, 35, 36, ":" +299, 2, 10, 12, 28, 31, 37, 40, "409" +299, 2, 11, 13, 32, 33, 41, 42, "-" +299, 2, 12, 14, 34, 37, 43, 46, "416" +299, 2, 13, 15, 38, 39, 47, 48, "." +299, 2, 14, 16, 40, 43, 49, 52, "doi" +299, 2, 15, 17, 44, 45, 53, 54, ":" +299, 2, 16, 18, 46, 48, 55, 57, "10" +299, 2, 17, 19, 49, 50, 58, 59, "." +299, 2, 18, 20, 51, 55, 60, 64, "1016" +299, 2, 19, 21, 56, 57, 65, 66, "/" +299, 2, 20, 22, 58, 63, 67, 72, "S0140" +299, 2, 21, 23, 64, 65, 73, 74, "-" +299, 2, 22, 24, 66, 70, 75, 79, "6736" +299, 2, 23, 25, 71, 72, 80, 81, "(" +299, 2, 24, 26, 73, 75, 82, 84, "13" +299, 2, 25, 27, 76, 77, 85, 86, ")" +299, 2, 26, 28, 78, 83, 87, 92, "60995" +299, 2, 27, 29, 84, 85, 93, 94, "-" +299, 2, 28, 30, 86, 87, 95, 96, "2" +299, 2, 29, 31, 88, 89, 97, 98, "." +299, 3, 1, 32, 0, 4, 99, 103, "Epub" +299, 3, 2, 33, 5, 9, 104, 108, "2013" +299, 3, 3, 34, 10, 13, 109, 112, "May" +299, 3, 4, 35, 14, 16, 113, 115, "23" +299, 3, 5, 36, 17, 18, 116, 117, "." +299, 4, 1, 37, 0, 14, 118, 132, "Individualised" +299, 4, 2, 38, 15, 24, 133, 142, "treatment" +299, 4, 3, 39, 25, 32, 143, 150, "targets" +299, 4, 4, 40, 33, 36, 151, 154, "for" +299, 4, 5, 41, 37, 44, 155, 162, "elderly" +299, 4, 6, 42, 45, 53, 163, 171, "patients" +299, 4, 7, 43, 54, 58, 172, 176, "with" +299, 4, 8, 44, 59, 63, 177, 181, "type" +299, 4, 9, 45, 64, 65, 182, 183, "2" +299, 4, 10, 46, 66, 74, 184, 192, "diabetes" +299, 4, 11, 47, 75, 80, 193, 198, "using" +299, 4, 12, 48, 81, 93, 199, 211, "vildagliptin" +299, 4, 13, 49, 94, 97, 212, 215, "add" +299, 4, 14, 50, 98, 99, 216, 217, "-" +299, 4, 15, 51, 100, 102, 218, 220, "on" +299, 4, 16, 52, 103, 105, 221, 223, "or" +299, 4, 17, 53, 106, 110, 224, 228, "lone" +299, 4, 18, 54, 111, 118, 229, 236, "therapy" +299, 4, 19, 55, 119, 120, 237, 238, "(" +299, 4, 20, 56, 121, 129, 239, 247, "INTERVAL" +299, 4, 21, 57, 130, 131, 248, 249, ")" +299, 4, 22, 58, 132, 133, 250, 251, ":" +299, 4, 23, 59, 134, 135, 252, 253, "a" +299, 4, 24, 60, 136, 138, 254, 256, "24" +299, 4, 25, 61, 139, 143, 257, 261, "week" +299, 4, 26, 62, 144, 145, 262, 263, "," +299, 4, 27, 63, 146, 156, 264, 274, "randomised" +299, 4, 28, 64, 157, 158, 275, 276, "," +299, 4, 29, 65, 159, 165, 277, 283, "double" +299, 4, 30, 66, 166, 167, 284, 285, "-" +299, 4, 31, 67, 168, 173, 286, 291, "blind" +299, 4, 32, 68, 174, 175, 292, 293, "," +299, 4, 33, 69, 176, 183, 294, 301, "placebo" +299, 4, 34, 70, 184, 185, 302, 303, "-" +299, 4, 35, 71, 186, 196, 304, 314, "controlled" +299, 4, 36, 72, 197, 202, 315, 320, "study" +299, 4, 37, 73, 203, 204, 321, 322, "." +299, 5, 1, 74, 0, 6, 323, 329, "Strain" +299, 5, 2, 75, 7, 9, 330, 332, "WD" +299, 5, 3, 76, 10, 11, 333, 334, "(" +299, 5, 4, 77, 12, 13, 335, 336, "1" +299, 5, 5, 78, 14, 15, 337, 338, ")" +299, 5, 6, 79, 16, 17, 339, 340, "," +299, 5, 7, 80, 18, 29, 341, 352, "Lukashevich" +299, 5, 8, 81, 30, 31, 353, 354, "V" +299, 5, 9, 82, 32, 33, 355, 356, "(" +299, 5, 10, 83, 34, 35, 357, 358, "2" +299, 5, 11, 84, 36, 37, 359, 360, ")" +299, 5, 12, 85, 38, 39, 361, 362, "," +299, 5, 13, 86, 40, 46, 363, 369, "Kothny" +299, 5, 14, 87, 47, 48, 370, 371, "W" +299, 5, 15, 88, 49, 50, 372, 373, "(" +299, 5, 16, 89, 51, 52, 374, 375, "2" +299, 5, 17, 90, 53, 54, 376, 377, ")" +299, 5, 18, 91, 55, 56, 378, 379, "," +299, 5, 19, 92, 57, 67, 380, 390, "Hoellinger" +299, 5, 20, 93, 68, 70, 391, 393, "MJ" +299, 5, 21, 94, 71, 72, 394, 395, "(" +299, 5, 22, 95, 73, 74, 396, 397, "3" +299, 5, 23, 96, 75, 76, 398, 399, ")" +299, 5, 24, 97, 77, 78, 400, 401, "," +299, 5, 25, 98, 79, 83, 402, 406, "Pald" +299, 5, 26, 99, 84, 85, 407, 408, "á" +299, 5, 27, 100, 86, 90, 409, 413, "nius" +299, 5, 28, 101, 91, 93, 414, 416, "PM" +299, 5, 29, 102, 94, 95, 417, 418, "(" +299, 5, 30, 103, 96, 97, 419, 420, "3" +299, 5, 31, 104, 98, 99, 421, 422, ")" +299, 5, 32, 105, 100, 101, 423, 424, "." +299, 6, 1, 106, 0, 6, 425, 431, "Author" +299, 6, 2, 107, 7, 18, 432, 443, "information" +299, 6, 3, 108, 19, 20, 444, 445, ":" +299, 6, 4, 109, 21, 22, 446, 447, "(" +299, 6, 5, 110, 23, 24, 448, 449, "1" +299, 6, 6, 111, 25, 26, 450, 451, ")" +299, 6, 7, 112, 27, 35, 452, 460, "Diabetes" +299, 6, 8, 113, 36, 39, 461, 464, "and" +299, 6, 9, 114, 40, 48, 465, 473, "Vascular" +299, 6, 10, 115, 49, 57, 474, 482, "Research" +299, 6, 11, 116, 58, 64, 483, 489, "Centre" +299, 6, 12, 117, 65, 66, 490, 491, "," +299, 6, 13, 118, 67, 77, 492, 502, "University" +299, 6, 14, 119, 78, 80, 503, 505, "of" +299, 6, 15, 120, 81, 87, 506, 512, "Exeter" +299, 6, 16, 121, 88, 95, 513, 520, "Medical" +299, 6, 17, 122, 96, 102, 521, 527, "School" +299, 6, 18, 123, 103, 104, 528, 529, "," +299, 6, 19, 124, 105, 111, 530, 536, "Exeter" +299, 6, 20, 125, 112, 113, 537, 538, "," +299, 6, 21, 126, 114, 116, 539, 541, "UK" +299, 6, 22, 127, 117, 118, 542, 543, "." +299, 7, 1, 128, 0, 10, 544, 554, "Electronic" +299, 7, 2, 129, 11, 18, 555, 562, "address" +299, 7, 3, 130, 19, 20, 563, 564, ":" +299, 7, 4, 131, 21, 22, 565, 566, "d" +299, 7, 5, 132, 23, 24, 567, 568, "." +299, 7, 6, 133, 25, 31, 569, 575, "strain" +299, 7, 7, 134, 32, 33, 576, 577, "@" +299, 7, 8, 135, 34, 40, 578, 584, "exeter" +299, 7, 9, 136, 41, 42, 585, 586, "." +299, 7, 10, 137, 43, 45, 587, 589, "ac" +299, 7, 11, 138, 46, 47, 590, 591, "." +299, 7, 12, 139, 48, 50, 592, 594, "uk" +299, 7, 13, 140, 51, 52, 595, 596, "." +299, 8, 1, 141, 0, 1, 597, 598, "(" +299, 8, 2, 142, 2, 3, 599, 600, "2" +299, 8, 3, 143, 4, 5, 601, 602, ")" +299, 8, 4, 144, 6, 14, 603, 611, "Novartis" +299, 8, 5, 145, 15, 30, 612, 627, "Pharmaceuticals" +299, 8, 6, 146, 31, 42, 628, 639, "Corporation" +299, 8, 7, 147, 43, 44, 640, 641, "," +299, 8, 8, 148, 45, 49, 642, 646, "East" +299, 8, 9, 149, 50, 57, 647, 654, "Hanover" +299, 8, 10, 150, 58, 59, 655, 656, "," +299, 8, 11, 151, 60, 62, 657, 659, "NJ" +299, 8, 12, 152, 63, 64, 660, 661, "," +299, 8, 13, 153, 65, 68, 662, 665, "USA" +299, 8, 14, 154, 69, 70, 666, 667, "." +299, 9, 1, 155, 0, 1, 668, 669, "(" +299, 9, 2, 156, 2, 3, 670, 671, "3" +299, 9, 3, 157, 4, 5, 672, 673, ")" +299, 9, 4, 158, 6, 14, 674, 682, "Novartis" +299, 9, 5, 159, 15, 21, 683, 689, "Pharma" +299, 9, 6, 160, 22, 24, 690, 692, "AG" +299, 9, 7, 161, 25, 26, 693, 694, "," +299, 9, 8, 162, 27, 32, 695, 700, "Basel" +299, 9, 9, 163, 33, 34, 701, 702, "," +299, 9, 10, 164, 35, 46, 703, 714, "Switzerland" +299, 9, 11, 165, 47, 48, 715, 716, "." +299, 10, 1, 166, 0, 7, 717, 724, "Comment" +299, 10, 2, 167, 8, 10, 725, 727, "in" +299, 10, 3, 168, 11, 17, 728, 734, "Lancet" +299, 10, 4, 169, 18, 19, 735, 736, "." +299, 11, 1, 170, 0, 4, 737, 741, "2013" +299, 11, 2, 171, 5, 8, 742, 745, "Aug" +299, 11, 3, 172, 9, 10, 746, 747, "3" +299, 11, 4, 173, 11, 12, 748, 749, ";" +299, 11, 5, 174, 13, 16, 750, 753, "382" +299, 11, 6, 175, 17, 18, 754, 755, "(" +299, 11, 7, 176, 19, 23, 756, 760, "9890" +299, 11, 8, 177, 24, 25, 761, 762, ")" +299, 11, 9, 178, 26, 27, 763, 764, ":" +299, 11, 10, 179, 28, 31, 765, 768, "378" +299, 11, 11, 180, 32, 33, 769, 770, "-" +299, 11, 12, 181, 34, 36, 771, 773, "80" +299, 11, 13, 182, 37, 38, 774, 775, "." +299, 12, 1, 183, 0, 3, 776, 779, "Nat" +299, 12, 2, 184, 4, 7, 780, 783, "Rev" +299, 12, 3, 185, 8, 18, 784, 794, "Endocrinol" +299, 12, 4, 186, 19, 20, 795, 796, "." +299, 13, 1, 187, 0, 4, 797, 801, "2013" +299, 13, 2, 188, 5, 8, 802, 805, "Aug" +299, 13, 3, 189, 9, 10, 806, 807, ";" +299, 13, 4, 190, 11, 12, 808, 809, "9" +299, 13, 5, 191, 13, 14, 810, 811, "(" +299, 13, 6, 192, 15, 16, 812, 813, "8" +299, 13, 7, 193, 17, 18, 814, 815, ")" +299, 13, 8, 194, 19, 20, 816, 817, ":" +299, 13, 9, 195, 21, 24, 818, 821, "440" +299, 13, 10, 196, 25, 26, 822, 823, "." +299, 14, 1, 197, 0, 10, 824, 834, "BACKGROUND" +299, 14, 2, 198, 11, 12, 835, 836, ":" +299, 14, 3, 199, 13, 23, 837, 847, "Guidelines" +299, 14, 4, 200, 24, 31, 848, 855, "suggest" +299, 14, 5, 201, 32, 39, 856, 863, "setting" +299, 14, 6, 202, 40, 54, 864, 878, "individualised" +299, 14, 7, 203, 55, 62, 879, 886, "targets" +299, 14, 8, 204, 63, 66, 887, 890, "for" +299, 14, 9, 205, 67, 76, 891, 900, "glycaemic" +299, 14, 10, 206, 77, 84, 901, 908, "control" +299, 14, 11, 207, 85, 87, 909, 911, "in" +299, 14, 12, 208, 88, 95, 912, 919, "elderly" +299, 14, 13, 209, 96, 104, 920, 928, "patients" +299, 14, 14, 210, 105, 109, 929, 933, "with" +299, 14, 15, 211, 110, 114, 934, 938, "type" +299, 14, 16, 212, 115, 116, 939, 940, "2" +299, 14, 17, 213, 117, 125, 941, 949, "diabetes" +299, 14, 18, 214, 126, 127, 950, 951, "," +299, 14, 19, 215, 128, 135, 952, 959, "despite" +299, 14, 20, 216, 136, 138, 960, 962, "no" +299, 14, 21, 217, 139, 147, 963, 971, "evidence" +299, 14, 22, 218, 148, 149, 972, 973, "." +299, 15, 1, 219, 0, 2, 974, 976, "We" +299, 15, 2, 220, 3, 8, 977, 982, "aimed" +299, 15, 3, 221, 9, 11, 983, 985, "to" +299, 15, 4, 222, 12, 18, 986, 992, "assess" +299, 15, 5, 223, 19, 22, 993, 996, "the" +299, 15, 6, 224, 23, 34, 997, 1008, "feasibility" +299, 15, 7, 225, 35, 37, 1009, 1011, "of" +299, 15, 8, 226, 38, 45, 1012, 1019, "setting" +299, 15, 9, 227, 46, 49, 1020, 1023, "and" +299, 15, 10, 228, 50, 59, 1024, 1033, "achieving" +299, 15, 11, 229, 60, 74, 1034, 1048, "individualised" +299, 15, 12, 230, 75, 82, 1049, 1056, "targets" +299, 15, 13, 231, 83, 87, 1057, 1061, "over" +299, 15, 14, 232, 88, 90, 1062, 1064, "24" +299, 15, 15, 233, 91, 96, 1065, 1070, "weeks" +299, 15, 16, 234, 97, 102, 1071, 1076, "along" +299, 15, 17, 235, 103, 107, 1077, 1081, "with" +299, 15, 18, 236, 108, 120, 1082, 1094, "conventional" +299, 15, 19, 237, 121, 126, 1095, 1100, "HbA1c" +299, 15, 20, 238, 127, 136, 1101, 1110, "reduction" +299, 15, 21, 239, 137, 142, 1111, 1116, "using" +299, 15, 22, 240, 143, 155, 1117, 1129, "vildagliptin" +299, 15, 23, 241, 156, 162, 1130, 1136, "versus" +299, 15, 24, 242, 163, 170, 1137, 1144, "placebo" +299, 15, 25, 243, 171, 172, 1145, 1146, "." +299, 16, 1, 244, 0, 7, 1147, 1154, "METHODS" +299, 16, 2, 245, 8, 9, 1155, 1156, ":" +299, 16, 3, 246, 10, 12, 1157, 1159, "In" +299, 16, 4, 247, 13, 17, 1160, 1164, "this" +299, 16, 5, 248, 18, 31, 1165, 1178, "multinational" +299, 16, 6, 249, 32, 33, 1179, 1180, "," +299, 16, 7, 250, 34, 40, 1181, 1187, "double" +299, 16, 8, 251, 41, 42, 1188, 1189, "-" +299, 16, 9, 252, 43, 48, 1190, 1195, "blind" +299, 16, 10, 253, 49, 50, 1196, 1197, "," +299, 16, 11, 254, 51, 53, 1198, 1200, "24" +299, 16, 12, 255, 54, 58, 1201, 1205, "week" +299, 16, 13, 256, 59, 64, 1206, 1211, "study" +299, 16, 14, 257, 65, 66, 1212, 1213, "," +299, 16, 15, 258, 67, 69, 1214, 1216, "we" +299, 16, 16, 259, 70, 78, 1217, 1225, "enrolled" +299, 16, 17, 260, 79, 83, 1226, 1230, "drug" +299, 16, 18, 261, 84, 85, 1231, 1232, "-" +299, 16, 19, 262, 86, 91, 1233, 1238, "naive" +299, 16, 20, 263, 92, 94, 1239, 1241, "or" +299, 16, 21, 264, 95, 107, 1242, 1254, "inadequately" +299, 16, 22, 265, 108, 118, 1255, 1265, "controlled" +299, 16, 23, 266, 119, 120, 1266, 1267, "(" +299, 16, 24, 267, 121, 133, 1268, 1280, "glycosylated" +299, 16, 25, 268, 134, 145, 1281, 1292, "haemoglobin" +299, 16, 26, 269, 146, 149, 1293, 1296, "A1c" +299, 16, 27, 270, 150, 151, 1297, 1298, "[" +299, 16, 28, 271, 152, 157, 1299, 1304, "HbA1c" +299, 16, 29, 272, 158, 159, 1305, 1306, "]" +299, 16, 30, 273, 160, 161, 1307, 1308, "≥" +299, 16, 31, 274, 162, 163, 1309, 1310, "7" +299, 16, 32, 275, 164, 165, 1311, 1312, "·" +299, 16, 33, 276, 166, 167, 1313, 1314, "0" +299, 16, 34, 277, 168, 169, 1315, 1316, "%" +299, 16, 35, 278, 170, 172, 1317, 1319, "to" +299, 16, 36, 279, 173, 174, 1320, 1321, "≤" +299, 16, 37, 280, 175, 177, 1322, 1324, "10" +299, 16, 38, 281, 178, 179, 1325, 1326, "·" +299, 16, 39, 282, 180, 181, 1327, 1328, "0" +299, 16, 40, 283, 182, 183, 1329, 1330, "%" +299, 16, 41, 284, 184, 185, 1331, 1332, ")" +299, 16, 42, 285, 186, 194, 1333, 1341, "patients" +299, 16, 43, 286, 195, 199, 1342, 1346, "with" +299, 16, 44, 287, 200, 204, 1347, 1351, "type" +299, 16, 45, 288, 205, 206, 1352, 1353, "2" +299, 16, 46, 289, 207, 215, 1354, 1362, "diabetes" +299, 16, 47, 290, 216, 220, 1363, 1367, "aged" +299, 16, 48, 291, 221, 223, 1368, 1370, "70" +299, 16, 49, 292, 224, 229, 1371, 1376, "years" +299, 16, 50, 293, 230, 232, 1377, 1379, "or" +299, 16, 51, 294, 233, 238, 1380, 1385, "older" +299, 16, 52, 295, 239, 243, 1386, 1390, "from" +299, 16, 53, 296, 244, 246, 1391, 1393, "45" +299, 16, 54, 297, 247, 257, 1394, 1404, "outpatient" +299, 16, 55, 298, 258, 265, 1405, 1412, "centres" +299, 16, 56, 299, 266, 268, 1413, 1415, "in" +299, 16, 57, 300, 269, 275, 1416, 1422, "Europe" +299, 16, 58, 301, 276, 277, 1423, 1424, "." +299, 17, 1, 302, 0, 13, 1425, 1438, "Investigators" +299, 17, 2, 303, 14, 17, 1439, 1442, "set" +299, 17, 3, 304, 18, 32, 1443, 1457, "individualised" +299, 17, 4, 305, 33, 42, 1458, 1467, "treatment" +299, 17, 5, 306, 43, 50, 1468, 1475, "targets" +299, 17, 6, 307, 51, 53, 1476, 1478, "on" +299, 17, 7, 308, 54, 57, 1479, 1482, "the" +299, 17, 8, 309, 58, 63, 1483, 1488, "basis" +299, 17, 9, 310, 64, 66, 1489, 1491, "of" +299, 17, 10, 311, 67, 70, 1492, 1495, "age" +299, 17, 11, 312, 71, 72, 1496, 1497, "," +299, 17, 12, 313, 73, 81, 1498, 1506, "baseline" +299, 17, 13, 314, 82, 87, 1507, 1512, "HbA1c" +299, 17, 14, 315, 88, 89, 1513, 1514, "," +299, 17, 15, 316, 90, 103, 1515, 1528, "comorbidities" +299, 17, 16, 317, 104, 105, 1529, 1530, "," +299, 17, 17, 318, 106, 109, 1531, 1534, "and" +299, 17, 18, 319, 110, 117, 1535, 1542, "frailty" +299, 17, 19, 320, 118, 124, 1543, 1549, "status" +299, 17, 20, 321, 125, 131, 1550, 1556, "before" +299, 17, 21, 322, 132, 133, 1557, 1558, "a" +299, 17, 22, 323, 134, 143, 1559, 1568, "validated" +299, 17, 23, 324, 144, 153, 1569, 1578, "automated" +299, 17, 24, 325, 154, 160, 1579, 1585, "system" +299, 17, 25, 326, 161, 169, 1586, 1594, "randomly" +299, 17, 26, 327, 170, 178, 1595, 1603, "assigned" +299, 17, 27, 328, 179, 187, 1604, 1612, "patients" +299, 17, 28, 329, 188, 189, 1613, 1614, "(" +299, 17, 29, 330, 190, 191, 1615, 1616, "1" +299, 17, 30, 331, 192, 193, 1617, 1618, ":" +299, 17, 31, 332, 194, 195, 1619, 1620, "1" +299, 17, 32, 333, 196, 197, 1621, 1622, ")" +299, 17, 33, 334, 198, 200, 1623, 1625, "to" +299, 17, 34, 335, 201, 213, 1626, 1638, "vildagliptin" +299, 17, 35, 336, 214, 215, 1639, 1640, "(" +299, 17, 36, 337, 216, 218, 1641, 1643, "50" +299, 17, 37, 338, 219, 221, 1644, 1646, "mg" +299, 17, 38, 339, 222, 226, 1647, 1651, "once" +299, 17, 39, 340, 227, 229, 1652, 1654, "or" +299, 17, 40, 341, 230, 235, 1655, 1660, "twice" +299, 17, 41, 342, 236, 241, 1661, 1666, "daily" +299, 17, 42, 343, 242, 244, 1667, 1669, "as" +299, 17, 43, 344, 245, 248, 1670, 1673, "per" +299, 17, 44, 345, 249, 254, 1674, 1679, "label" +299, 17, 45, 346, 255, 256, 1680, 1681, ")" +299, 17, 46, 347, 257, 259, 1682, 1684, "or" +299, 17, 47, 348, 260, 267, 1685, 1692, "placebo" +299, 17, 48, 349, 268, 269, 1693, 1694, "." +299, 18, 1, 350, 0, 9, 1695, 1704, "Coprimary" +299, 18, 2, 351, 10, 18, 1705, 1713, "efficacy" +299, 18, 3, 352, 19, 28, 1714, 1723, "endpoints" +299, 18, 4, 353, 29, 33, 1724, 1728, "were" +299, 18, 5, 354, 34, 44, 1729, 1739, "proportion" +299, 18, 6, 355, 45, 47, 1740, 1742, "of" +299, 18, 7, 356, 48, 56, 1743, 1751, "patients" +299, 18, 8, 357, 57, 65, 1752, 1760, "reaching" +299, 18, 9, 358, 66, 71, 1761, 1766, "their" +299, 18, 10, 359, 72, 84, 1767, 1779, "investigator" +299, 18, 11, 360, 85, 86, 1780, 1781, "-" +299, 18, 12, 361, 87, 94, 1782, 1789, "defined" +299, 18, 13, 362, 95, 100, 1790, 1795, "HbA1c" +299, 18, 14, 363, 101, 107, 1796, 1802, "target" +299, 18, 15, 364, 108, 111, 1803, 1806, "and" +299, 18, 16, 365, 112, 117, 1807, 1812, "HbA1c" +299, 18, 17, 366, 118, 127, 1813, 1822, "reduction" +299, 18, 18, 367, 128, 132, 1823, 1827, "from" +299, 18, 19, 368, 133, 141, 1828, 1836, "baseline" +299, 18, 20, 369, 142, 144, 1837, 1839, "to" +299, 18, 21, 370, 145, 150, 1840, 1845, "study" +299, 18, 22, 371, 151, 154, 1846, 1849, "end" +299, 18, 23, 372, 155, 156, 1850, 1851, "." +299, 19, 1, 373, 0, 3, 1852, 1855, "The" +299, 19, 2, 374, 4, 9, 1856, 1861, "study" +299, 19, 3, 375, 10, 12, 1862, 1864, "is" +299, 19, 4, 376, 13, 23, 1865, 1875, "registered" +299, 19, 5, 377, 24, 28, 1876, 1880, "with" +299, 19, 6, 378, 29, 43, 1881, 1895, "ClinicalTrials" +299, 19, 7, 379, 44, 45, 1896, 1897, "." +299, 19, 8, 380, 46, 49, 1898, 1901, "gov" +299, 19, 9, 381, 50, 51, 1902, 1903, "," +299, 19, 10, 382, 52, 58, 1904, 1910, "number" +299, 19, 11, 383, 59, 70, 1911, 1922, "NCT01257451" +299, 19, 12, 384, 71, 72, 1923, 1924, "," +299, 19, 13, 385, 73, 76, 1925, 1928, "and" +299, 19, 14, 386, 77, 85, 1929, 1937, "European" +299, 19, 15, 387, 86, 91, 1938, 1943, "Union" +299, 19, 16, 388, 92, 96, 1944, 1948, "Drug" +299, 19, 17, 389, 97, 107, 1949, 1959, "Regulating" +299, 19, 18, 390, 108, 119, 1960, 1971, "Authorities" +299, 19, 19, 391, 120, 128, 1972, 1980, "Clinical" +299, 19, 20, 392, 129, 135, 1981, 1987, "Trials" +299, 19, 21, 393, 136, 144, 1988, 1996, "database" +299, 19, 22, 394, 145, 146, 1997, 1998, "," +299, 19, 23, 395, 147, 153, 1999, 2005, "number" +299, 19, 24, 396, 154, 158, 2006, 2010, "2010" +299, 19, 25, 397, 159, 160, 2011, 2012, "-" +299, 19, 26, 398, 161, 167, 2013, 2019, "022658" +299, 19, 27, 399, 168, 169, 2020, 2021, "-" +299, 19, 28, 400, 170, 172, 2022, 2024, "18" +299, 19, 29, 401, 173, 174, 2025, 2026, "." +299, 20, 1, 402, 0, 8, 2027, 2035, "FINDINGS" +299, 20, 2, 403, 9, 10, 2036, 2037, ":" +299, 20, 3, 404, 11, 18, 2038, 2045, "Between" +299, 20, 4, 405, 19, 22, 2046, 2049, "Dec" +299, 20, 5, 406, 23, 25, 2050, 2052, "22" +299, 20, 6, 407, 26, 27, 2053, 2054, "," +299, 20, 7, 408, 28, 32, 2055, 2059, "2010" +299, 20, 8, 409, 33, 34, 2060, 2061, "," +299, 20, 9, 410, 35, 38, 2062, 2065, "and" +299, 20, 10, 411, 39, 44, 2066, 2071, "March" +299, 20, 11, 412, 45, 47, 2072, 2074, "14" +299, 20, 12, 413, 48, 49, 2075, 2076, "," +299, 20, 13, 414, 50, 54, 2077, 2081, "2012" +299, 20, 14, 415, 55, 56, 2082, 2083, "," +299, 20, 15, 416, 57, 59, 2084, 2086, "we" +299, 20, 16, 417, 60, 68, 2087, 2095, "randomly" +299, 20, 17, 418, 69, 77, 2096, 2104, "assigned" +299, 20, 18, 419, 78, 81, 2105, 2108, "139" +299, 20, 19, 420, 82, 90, 2109, 2117, "patients" +299, 20, 20, 421, 91, 95, 2118, 2122, "each" +299, 20, 21, 422, 96, 98, 2123, 2125, "to" +299, 20, 22, 423, 99, 102, 2126, 2129, "the" +299, 20, 23, 424, 103, 115, 2130, 2142, "vildagliptin" +299, 20, 24, 425, 116, 119, 2143, 2146, "and" +299, 20, 25, 426, 120, 127, 2147, 2154, "placebo" +299, 20, 26, 427, 128, 134, 2155, 2161, "groups" +299, 20, 27, 428, 135, 136, 2162, 2163, "." +299, 21, 1, 429, 0, 2, 2164, 2166, "37" +299, 21, 2, 430, 3, 4, 2167, 2168, "(" +299, 21, 3, 431, 5, 7, 2169, 2171, "27" +299, 21, 4, 432, 8, 9, 2172, 2173, "%" +299, 21, 5, 433, 10, 11, 2174, 2175, ")" +299, 21, 6, 434, 12, 14, 2176, 2178, "of" +299, 21, 7, 435, 15, 18, 2179, 2182, "137" +299, 21, 8, 436, 19, 27, 2183, 2191, "patients" +299, 21, 9, 437, 28, 30, 2192, 2194, "in" +299, 21, 10, 438, 31, 34, 2195, 2198, "the" +299, 21, 11, 439, 35, 42, 2199, 2206, "placebo" +299, 21, 12, 440, 43, 48, 2207, 2212, "group" +299, 21, 13, 441, 49, 57, 2213, 2221, "achieved" +299, 21, 14, 442, 58, 63, 2222, 2227, "their" +299, 21, 15, 443, 64, 78, 2228, 2242, "individualised" +299, 21, 16, 444, 79, 86, 2243, 2250, "targets" +299, 21, 17, 445, 87, 89, 2251, 2253, "by" +299, 21, 18, 446, 90, 99, 2254, 2263, "education" +299, 21, 19, 447, 100, 103, 2264, 2267, "and" +299, 21, 20, 448, 104, 116, 2268, 2280, "interactions" +299, 21, 21, 449, 117, 121, 2281, 2285, "with" +299, 21, 22, 450, 122, 125, 2286, 2289, "the" +299, 21, 23, 451, 126, 131, 2290, 2295, "study" +299, 21, 24, 452, 132, 136, 2296, 2300, "team" +299, 21, 25, 453, 137, 142, 2301, 2306, "alone" +299, 21, 26, 454, 143, 146, 2307, 2310, "and" +299, 21, 27, 455, 147, 149, 2311, 2313, "72" +299, 21, 28, 456, 150, 151, 2314, 2315, "(" +299, 21, 29, 457, 152, 154, 2316, 2318, "52" +299, 21, 30, 458, 155, 156, 2319, 2320, "·" +299, 21, 31, 459, 157, 158, 2321, 2322, "6" +299, 21, 32, 460, 159, 160, 2323, 2324, "%" +299, 21, 33, 461, 161, 162, 2325, 2326, ")" +299, 21, 34, 462, 163, 165, 2327, 2329, "of" +299, 21, 35, 463, 166, 169, 2330, 2333, "137" +299, 21, 36, 464, 170, 178, 2334, 2342, "patients" +299, 21, 37, 465, 179, 187, 2343, 2351, "achieved" +299, 21, 38, 466, 188, 193, 2352, 2357, "their" +299, 21, 39, 467, 194, 200, 2358, 2364, "target" +299, 21, 40, 468, 201, 203, 2365, 2367, "in" +299, 21, 41, 469, 204, 207, 2368, 2371, "the" +299, 21, 42, 470, 208, 220, 2372, 2384, "vildagliptin" +299, 21, 43, 471, 221, 226, 2385, 2390, "group" +299, 21, 44, 472, 227, 228, 2391, 2392, "(" +299, 21, 45, 473, 229, 237, 2393, 2401, "adjusted" +299, 21, 46, 474, 238, 242, 2402, 2406, "odds" +299, 21, 47, 475, 243, 248, 2407, 2412, "ratio" +299, 21, 48, 476, 249, 250, 2413, 2414, "3" +299, 21, 49, 477, 251, 252, 2415, 2416, "·" +299, 21, 50, 478, 253, 255, 2417, 2419, "16" +299, 21, 51, 479, 256, 257, 2420, 2421, "," +299, 21, 52, 480, 258, 260, 2422, 2424, "96" +299, 21, 53, 481, 261, 262, 2425, 2426, "·" +299, 21, 54, 482, 263, 264, 2427, 2428, "2" +299, 21, 55, 483, 265, 266, 2429, 2430, "%" +299, 21, 56, 484, 267, 269, 2431, 2433, "CI" +299, 21, 57, 485, 270, 271, 2434, 2435, "1" +299, 21, 58, 486, 272, 273, 2436, 2437, "·" +299, 21, 59, 487, 274, 276, 2438, 2440, "81" +299, 21, 60, 488, 277, 278, 2441, 2442, "-" +299, 21, 61, 489, 279, 280, 2443, 2444, "5" +299, 21, 62, 490, 281, 282, 2445, 2446, "·" +299, 21, 63, 491, 283, 285, 2447, 2449, "52" +299, 21, 64, 492, 286, 287, 2450, 2451, ";" +299, 21, 65, 493, 288, 289, 2452, 2453, "p" +299, 21, 66, 494, 290, 291, 2454, 2455, "<" +299, 21, 67, 495, 292, 293, 2456, 2457, "0" +299, 21, 68, 496, 294, 295, 2458, 2459, "·" +299, 21, 69, 497, 296, 300, 2460, 2464, "0001" +299, 21, 70, 498, 301, 302, 2465, 2466, ")" +299, 21, 71, 499, 303, 304, 2467, 2468, "." +299, 22, 1, 500, 0, 4, 2469, 2473, "This" +299, 22, 2, 501, 5, 12, 2474, 2481, "finding" +299, 22, 3, 502, 13, 16, 2482, 2485, "was" +299, 22, 4, 503, 17, 28, 2486, 2497, "accompanied" +299, 22, 5, 504, 29, 31, 2498, 2500, "by" +299, 22, 6, 505, 32, 33, 2501, 2502, "a" +299, 22, 7, 506, 34, 44, 2503, 2513, "clinically" +299, 22, 8, 507, 45, 53, 2514, 2522, "relevant" +299, 22, 9, 508, 54, 55, 2523, 2524, "0" +299, 22, 10, 509, 56, 57, 2525, 2526, "·" +299, 22, 11, 510, 58, 59, 2527, 2528, "9" +299, 22, 12, 511, 60, 61, 2529, 2530, "%" +299, 22, 13, 512, 62, 71, 2531, 2540, "reduction" +299, 22, 14, 513, 72, 74, 2541, 2543, "in" +299, 22, 15, 514, 75, 80, 2544, 2549, "HbA1c" +299, 22, 16, 515, 81, 85, 2550, 2554, "from" +299, 22, 17, 516, 86, 87, 2555, 2556, "a" +299, 22, 18, 517, 88, 96, 2557, 2565, "baseline" +299, 22, 19, 518, 97, 99, 2566, 2568, "of" +299, 22, 20, 519, 100, 101, 2569, 2570, "7" +299, 22, 21, 520, 102, 103, 2571, 2572, "·" +299, 22, 22, 521, 104, 105, 2573, 2574, "9" +299, 22, 23, 522, 106, 107, 2575, 2576, "%" +299, 22, 24, 523, 108, 112, 2577, 2581, "with" +299, 22, 25, 524, 113, 125, 2582, 2594, "vildagliptin" +299, 22, 26, 525, 126, 129, 2595, 2598, "and" +299, 22, 27, 526, 130, 131, 2599, 2600, "a" +299, 22, 28, 527, 132, 139, 2601, 2608, "between" +299, 22, 29, 528, 140, 141, 2609, 2610, "-" +299, 22, 30, 529, 142, 147, 2611, 2616, "group" +299, 22, 31, 530, 148, 158, 2617, 2627, "difference" +299, 22, 32, 531, 159, 161, 2628, 2630, "of" +299, 22, 33, 532, 162, 163, 2631, 2632, "-" +299, 22, 34, 533, 164, 165, 2633, 2634, "0" +299, 22, 35, 534, 166, 167, 2635, 2636, "·" +299, 22, 36, 535, 168, 169, 2637, 2638, "6" +299, 22, 37, 536, 170, 171, 2639, 2640, "%" +299, 22, 38, 537, 172, 173, 2641, 2642, "(" +299, 22, 39, 538, 174, 176, 2643, 2645, "98" +299, 22, 40, 539, 177, 178, 2646, 2647, "·" +299, 22, 41, 540, 179, 180, 2648, 2649, "8" +299, 22, 42, 541, 181, 182, 2650, 2651, "%" +299, 22, 43, 542, 183, 185, 2652, 2654, "CI" +299, 22, 44, 543, 186, 187, 2655, 2656, "-" +299, 22, 45, 544, 188, 189, 2657, 2658, "0" +299, 22, 46, 545, 190, 191, 2659, 2660, "·" +299, 22, 47, 546, 192, 194, 2661, 2663, "81" +299, 22, 48, 547, 195, 197, 2664, 2666, "to" +299, 22, 49, 548, 198, 199, 2667, 2668, "-" +299, 22, 50, 549, 200, 201, 2669, 2670, "0" +299, 22, 51, 550, 202, 203, 2671, 2672, "·" +299, 22, 52, 551, 204, 206, 2673, 2675, "33" +299, 22, 53, 552, 207, 208, 2676, 2677, ";" +299, 22, 54, 553, 209, 210, 2678, 2679, "p" +299, 22, 55, 554, 211, 212, 2680, 2681, "<" +299, 22, 56, 555, 213, 214, 2682, 2683, "0" +299, 22, 57, 556, 215, 216, 2684, 2685, "·" +299, 22, 58, 557, 217, 221, 2686, 2690, "0001" +299, 22, 59, 558, 222, 223, 2691, 2692, ")" +299, 22, 60, 559, 224, 225, 2693, 2694, "." +299, 23, 1, 560, 0, 3, 2695, 2698, "The" +299, 23, 2, 561, 4, 11, 2699, 2706, "overall" +299, 23, 3, 562, 12, 18, 2707, 2713, "safety" +299, 23, 4, 563, 19, 22, 2714, 2717, "and" +299, 23, 5, 564, 23, 35, 2718, 2730, "tolerability" +299, 23, 6, 565, 36, 39, 2731, 2734, "was" +299, 23, 7, 566, 40, 47, 2735, 2742, "similar" +299, 23, 8, 567, 48, 50, 2743, 2745, "in" +299, 23, 9, 568, 51, 54, 2746, 2749, "the" +299, 23, 10, 569, 55, 67, 2750, 2762, "vildagliptin" +299, 23, 11, 570, 68, 71, 2763, 2766, "and" +299, 23, 12, 571, 72, 79, 2767, 2774, "placebo" +299, 23, 13, 572, 80, 86, 2775, 2781, "groups" +299, 23, 14, 573, 87, 88, 2782, 2783, "," +299, 23, 15, 574, 89, 93, 2784, 2788, "with" +299, 23, 16, 575, 94, 97, 2789, 2792, "low" +299, 23, 17, 576, 98, 107, 2793, 2802, "incidence" +299, 23, 18, 577, 108, 110, 2803, 2805, "of" +299, 23, 19, 578, 111, 124, 2806, 2819, "hypoglycaemia" +299, 23, 20, 579, 125, 128, 2820, 2823, "and" +299, 23, 21, 580, 129, 131, 2824, 2826, "no" +299, 23, 22, 581, 132, 141, 2827, 2836, "emergence" +299, 23, 23, 582, 142, 144, 2837, 2839, "of" +299, 23, 24, 583, 145, 148, 2840, 2843, "new" +299, 23, 25, 584, 149, 155, 2844, 2850, "safety" +299, 23, 26, 585, 156, 163, 2851, 2858, "signals" +299, 23, 27, 586, 164, 165, 2859, 2860, "." +299, 24, 1, 587, 0, 14, 2861, 2875, "INTERPRETATION" +299, 24, 2, 588, 15, 16, 2876, 2877, ":" +299, 24, 3, 589, 17, 21, 2878, 2882, "This" +299, 24, 4, 590, 22, 27, 2883, 2888, "study" +299, 24, 5, 591, 28, 30, 2889, 2891, "is" +299, 24, 6, 592, 31, 34, 2892, 2895, "the" +299, 24, 7, 593, 35, 40, 2896, 2901, "first" +299, 24, 8, 594, 41, 43, 2902, 2904, "to" +299, 24, 9, 595, 44, 53, 2905, 2914, "introduce" +299, 24, 10, 596, 54, 57, 2915, 2918, "and" +299, 24, 11, 597, 58, 62, 2919, 2923, "show" +299, 24, 12, 598, 63, 66, 2924, 2927, "the" +299, 24, 13, 599, 67, 78, 2928, 2939, "feasibility" +299, 24, 14, 600, 79, 81, 2940, 2942, "of" +299, 24, 15, 601, 82, 87, 2943, 2948, "using" +299, 24, 16, 602, 88, 102, 2949, 2963, "individualised" +299, 24, 17, 603, 103, 108, 2964, 2969, "HbA1c" +299, 24, 18, 604, 109, 116, 2970, 2977, "targets" +299, 24, 19, 605, 117, 119, 2978, 2980, "as" +299, 24, 20, 606, 120, 122, 2981, 2983, "an" +299, 24, 21, 607, 123, 131, 2984, 2992, "endpoint" +299, 24, 22, 608, 132, 134, 2993, 2995, "in" +299, 24, 23, 609, 135, 138, 2996, 2999, "any" +299, 24, 24, 610, 139, 143, 3000, 3004, "type" +299, 24, 25, 611, 144, 145, 3005, 3006, "2" +299, 24, 26, 612, 146, 154, 3007, 3015, "diabetes" +299, 24, 27, 613, 155, 165, 3016, 3026, "population" +299, 24, 28, 614, 166, 167, 3027, 3028, "." +299, 25, 1, 615, 0, 14, 3029, 3043, "Individualised" +299, 25, 2, 616, 15, 24, 3044, 3053, "glycaemic" +299, 25, 3, 617, 25, 31, 3054, 3060, "target" +299, 25, 4, 618, 32, 38, 3061, 3067, "levels" +299, 25, 5, 619, 39, 42, 3068, 3071, "are" +299, 25, 6, 620, 43, 53, 3072, 3082, "achievable" +299, 25, 7, 621, 54, 58, 3083, 3087, "with" +299, 25, 8, 622, 59, 71, 3088, 3100, "vildagliptin" +299, 25, 9, 623, 72, 79, 3101, 3108, "without" +299, 25, 10, 624, 80, 83, 3109, 3112, "any" +299, 25, 11, 625, 84, 96, 3113, 3125, "tolerability" +299, 25, 12, 626, 97, 103, 3126, 3132, "issues" +299, 25, 13, 627, 104, 106, 3133, 3135, "in" +299, 25, 14, 628, 107, 110, 3136, 3139, "the" +299, 25, 15, 629, 111, 118, 3140, 3147, "elderly" +299, 25, 16, 630, 119, 123, 3148, 3152, "type" +299, 25, 17, 631, 124, 125, 3153, 3154, "2" +299, 25, 18, 632, 126, 134, 3155, 3163, "diabetes" +299, 25, 19, 633, 135, 145, 3164, 3174, "population" +299, 25, 20, 634, 146, 147, 3175, 3176, "." +299, 26, 1, 635, 0, 7, 3177, 3184, "FUNDING" +299, 26, 2, 636, 8, 9, 3185, 3186, ":" +299, 26, 3, 637, 10, 18, 3187, 3195, "Novartis" +299, 26, 4, 638, 19, 25, 3196, 3202, "Pharma" +299, 26, 5, 639, 26, 28, 3203, 3205, "AG" +299, 26, 6, 640, 29, 30, 3206, 3207, "." +299, 27, 1, 641, 0, 9, 3208, 3217, "Copyright" +299, 27, 2, 642, 10, 11, 3218, 3219, "©" +299, 27, 3, 643, 12, 16, 3220, 3224, "2013" +299, 27, 4, 644, 17, 25, 3225, 3233, "Elsevier" +299, 27, 5, 645, 26, 29, 3234, 3237, "Ltd" +299, 27, 6, 646, 30, 31, 3238, 3239, "." +299, 27, 7, 647, 32, 35, 3240, 3243, "All" +299, 27, 8, 648, 36, 42, 3244, 3250, "rights" +299, 27, 9, 649, 43, 51, 3251, 3259, "reserved" +299, 27, 10, 650, 52, 53, 3260, 3261, "." +299, 28, 1, 651, 0, 3, 3262, 3265, "DOI" +299, 28, 2, 652, 4, 5, 3266, 3267, ":" +299, 28, 3, 653, 6, 8, 3268, 3270, "10" +299, 28, 4, 654, 9, 10, 3271, 3272, "." +299, 28, 5, 655, 11, 15, 3273, 3277, "1016" +299, 28, 6, 656, 16, 17, 3278, 3279, "/" +299, 28, 7, 657, 18, 23, 3280, 3285, "S0140" +299, 28, 8, 658, 24, 25, 3286, 3287, "-" +299, 28, 9, 659, 26, 30, 3288, 3292, "6736" +299, 28, 10, 660, 31, 32, 3293, 3294, "(" +299, 28, 11, 661, 33, 35, 3295, 3297, "13" +299, 28, 12, 662, 36, 37, 3298, 3299, ")" +299, 28, 13, 663, 38, 43, 3300, 3305, "60995" +299, 28, 14, 664, 44, 45, 3306, 3307, "-" +299, 28, 15, 665, 46, 47, 3308, 3309, "2" +299, 28, 16, 666, 48, 52, 3310, 3314, "PMID" +299, 28, 17, 667, 53, 54, 3315, 3316, ":" +299, 28, 18, 668, 55, 63, 3317, 3325, "23706759" +299, 28, 19, 669, 64, 65, 3326, 3327, "[" +299, 28, 20, 670, 66, 73, 3328, 3335, "Indexed" +299, 28, 21, 671, 74, 77, 3336, 3339, "for" +299, 28, 22, 672, 78, 85, 3340, 3347, "MEDLINE" +299, 28, 23, 673, 86, 87, 3348, 3349, "]" diff --git a/data/dm2 23706759_kwoodley.annodb b/data/dm2 23706759_kwoodley.annodb new file mode 100644 index 0000000..ac788c0 --- /dev/null +++ b/data/dm2 23706759_kwoodley.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42058, Journal, 0, 6, "Lancet", "", +42059, PublicationYear, 9, 13, "2013", "", +42067, Title, 118, 322, "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add - on or lone therapy ( INTERVAL ) : a 24 week , randomised , double - blind , placebo - controlled study .", "", +42066, AvgAge, 155, 162, "elderly", "", +42061, Type2Diabetes, 177, 192, "type 2 diabetes", "", +42060, Vildagliptin, 199, 211, "vildagliptin", "", +42062, Duration, 254, 261, "24 week", "", +42063, Randomized, 264, 274, "randomised", "", +42064, DoubleBlind, 277, 291, "double - blind", "", +42065, Placebo, 294, 301, "placebo", "", +42068, Author, 323, 332, "Strain WD", "", +42069, Author, 341, 354, "Lukashevich V", "", +42070, Author, 363, 371, "Kothny W", "", +42071, Author, 380, 393, "Hoellinger MJ", "", +42072, Author, 402, 416, "Pald á nius PM", "", +42073, UK, 539, 541, "UK", "", +42075, AvgAge, 912, 919, "elderly", "", +42074, Type2Diabetes, 934, 949, "type 2 diabetes", "", +42080, ObjectiveDescription, 974, 1146, "We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA1c reduction using vildagliptin versus placebo .", "", +42076, Duration, 1062, 1070, "24 weeks", "", +42077, HbA1c, 1095, 1100, "HbA1c", "", +42078, Vildagliptin, 1117, 1129, "vildagliptin", "", +42079, Placebo, 1137, 1144, "placebo", "", +42081, Multicenter, 1165, 1178, "multinational", "", +42082, DoubleBlind, 1181, 1195, "double - blind", "", +42083, Duration, 1198, 1205, "24 week", "", +42089, Precondition, 1226, 1362, "drug - naive or inadequately controlled ( glycosylated haemoglobin A1c [ HbA1c ] ≥ 7 · 0 % to ≤ 10 · 0 % ) patients with type 2 diabetes", "", +42084, HbA1c, 1281, 1296, "haemoglobin A1c", "", +42085, HbA1c, 1299, 1304, "HbA1c", "", +42086, Percentage, 1315, 1316, "%", "", +42087, Type2Diabetes, 1347, 1362, "type 2 diabetes", "", +42088, MinAge, 1368, 1370, "70", "", +42090, HbA1c, 1507, 1512, "HbA1c", "", +42091, AllocationRatio, 1615, 1620, "1 : 1", "", +42092, Vildagliptin, 1626, 1638, "vildagliptin", "", +42093, DoseValue, 1641, 1643, "50", "", +42094, mg, 1644, 1646, "mg", "", +42095, Frequency, 1647, 1679, "once or twice daily as per label", "", +42096, Placebo, 1685, 1692, "placebo", "", +42097, HbA1c_target, 1790, 1802, "HbA1c target", "", +42098, HbA1c, 1807, 1812, "HbA1c", "", +42099, TimePoint, 1828, 1836, "baseline", "", +42100, TimePoint, 1840, 1849, "study end", "", +42101, Randomized, 2087, 2095, "randomly", "", +42102, NumberPatientsCT, 2105, 2108, "139", "", +42103, Vildagliptin, 2130, 2142, "vildagliptin", "", +42104, Placebo, 2147, 2154, "placebo", "", +42105, NumberAffected, 2164, 2166, "37", "", +42106, PercentageAffected, 2169, 2171, "27", "", +42107, NumberPatientsArm, 2179, 2182, "137", "", +42108, Placebo, 2199, 2206, "placebo", "", +42132, HbA1c_target, 2228, 2250, "individualised targets", "", +42109, NumberAffected, 2311, 2313, "72", "", +42110, PercentageAffected, 2316, 2322, "52 · 6", "", +42111, NumberPatientsArm, 2330, 2333, "137", "", +42112, Vildagliptin, 2372, 2384, "vildagliptin", "", +42115, ConfIntervalDiff, 2431, 2449, "CI 1 · 81 - 5 · 52", "", +42114, PvalueDiff, 2452, 2464, "p < 0 · 0001", "", +42117, Reduction, 2523, 2528, "0 · 9", "", +42118, Percentage, 2529, 2530, "%", "", +42119, HbA1c, 2544, 2549, "HbA1c", "", +42120, BaseLineValue, 2569, 2574, "7 · 9", "", +42121, Percentage, 2575, 2576, "%", "", +42122, Vildagliptin, 2582, 2594, "vildagliptin", "", +42123, DiffGroupAbsValue, 2631, 2638, "- 0 · 6", "", +42124, Percentage, 2639, 2640, "%", "", +42125, ConfIntervalDiff, 2643, 2675, "98 · 8 % CI - 0 · 81 to - 0 · 33", "", +42126, PvalueDiff, 2678, 2690, "p < 0 · 0001", "", +42127, Vildagliptin, 2750, 2762, "vildagliptin", "", +42128, Placebo, 2767, 2774, "placebo", "", +42130, ObservedResult, 2789, 2802, "low incidence", "", +42129, Hypoglycemia, 2806, 2819, "hypoglycaemia", "", +42134, ConclusionComment, 2878, 3028, "This study is the first to introduce and show the feasibility of using individualised HbA1c targets as an endpoint in any type 2 diabetes population .", "", +42131, HbA1c_target, 2949, 2977, "individualised HbA1c targets", "", +42133, Type2Diabetes, 3000, 3015, "type 2 diabetes", "", +42138, ConclusionComment, 3029, 3176, "Individualised glycaemic target levels are achievable with vildagliptin without any tolerability issues in the elderly type 2 diabetes population .", "", +42135, Vildagliptin, 3088, 3100, "vildagliptin", "", +42137, AvgAge, 3140, 3147, "elderly", "", +42136, Type2Diabetes, 3148, 3163, "type 2 diabetes", "", +42139, PMID, 3317, 3325, "23706759", "", diff --git a/data/dm2 23706759_kwoodley.n-triples b/data/dm2 23706759_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23706759_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23906445_admin.annodb b/data/dm2 23906445_admin.annodb new file mode 100644 index 0000000..aa47642 --- /dev/null +++ b/data/dm2 23906445_admin.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66743, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2014", "", " \"2014\"." +2, Dapagliflozin, 106, 119, "Dapagliflozin", "", +12, Title, 106, 281, "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin .", "", " \"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin .\"." +8, BodyWeight, 163, 169, "weight", "", +112, Duration, 193, 200, "2 years", "", +11, Precondition, 204, 279, "patients with type 2 diabetes mellitus inadequately controlled on metformin", "", " \"patients with type 2 diabetes mellitus inadequately controlled on metformin\"." +9, Type2Diabetes, 218, 242, "type 2 diabetes mellitus", "", " ." +10, Metformin, 270, 279, "metformin", "", +13, Author, 282, 292, "Bolinder J", "", " \"Bolinder J\"." +14, Author, 301, 313, "Ljunggren Ö,", "", " \"Ljunggren Ö,\"." +15, Author, 314, 325, "Johansson L", "", " \"Johansson L\"." +16, Author, 328, 337, "Wilding J", "", " \"Wilding J\"." +17, Author, 340, 352, "Langkilde AM", "", " \"Langkilde AM\"." +18, Author, 355, 370, "Sj ö str ö m CD", "", " \"Sj ö str ö m CD\"." +19, Author, 373, 379, "Sugg J", "", " \"Sugg J\"." +20, Author, 382, 390, "Parikh S", "", " \"Parikh S\"." +21, Sweden, 553, 559, "Sweden", "", " ." +132, ObjectiveDescription, 569, 790, "Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion .", "", " \"Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion .\"." +3, Dapagliflozin, 569, 582, "Dapagliflozin", "", +22, Hypoglycemia, 670, 684, "hyperglycaemia", "", +23, BodyWeight, 689, 695, "weight", "", +24, Type2Diabetes, 713, 739, "type   2 diabetes mellitus", "", +25, Type2Diabetes, 742, 746, "T2DM", "", +29, ObjectiveDescription, 791, 937, "Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .", "", " \"Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .\"." +26, Type2Diabetes, 888, 892, "T2DM", "", +28, Duration, 899, 908, "102 weeks", "", " \"102 weeks\"." +4, Dapagliflozin, 912, 925, "dapagliflozin", "", +30, Randomized, 953, 963, "randomized", "", " ." +31, DoubleBlind, 966, 980, "double - blind", "", " ." +32, Placebo, 983, 990, "placebo", "", +66748, Precondition, 1035, 1053, "patients with T2DM", "", +33, Type2Diabetes, 1049, 1053, "T2DM", "", +139, Mean, 1056, 1060, "mean", "", +34, AvgAge, 1067, 1073, "60 . 7", "", " \"60 . 7\"." +35, HbA1c, 1082, 1087, "HbA1c", "", +44, BaseLineValue, 1088, 1093, "7 . 2", "", +36, Percentage, 1094, 1095, "%", "", +37, BMI, 1098, 1113, "body mass index", "", +38, BMI, 1116, 1119, "BMI", "", +45, BaseLineValue, 1122, 1128, "31 . 9", "", +39, Kg_per_squareMeter, 1129, 1141, "kg / m ( 2 )", "", +40, BodyWeight, 1144, 1155, "body weight", "", +46, BaseLineValue, 1156, 1162, "91 . 5", "", +41, Kg, 1163, 1165, "kg", "", +66748, Precondition, 1168, 1204, "inadequately controlled on metformin", "", +42, Metformin, 1195, 1204, "metformin", "", +47, NumberPatientsCT, 1224, 1227, "182", "", " \"182\"." +48, Randomized, 1235, 1243, "randomly", "", +49, AllocationRatio, 1253, 1260, "1  :  1", "", " . ." +5, Dapagliflozin, 1272, 1285, "dapagliflozin", "", " ." +50, DoseValue, 1286, 1288, "10", "", " \"10\"." +51, mg, 1289, 1291, "mg", "", " ." +52, Frequency, 1294, 1297, "day", "", " \"day\"." +53, Placebo, 1301, 1308, "placebo", "", " \"day\"." +56, OpenLabel, 1318, 1330, "open - label", "", " ." +54, Metformin, 1331, 1340, "metformin", "", +57, Duration, 1347, 1356, "24 - week", "", +58, DoubleBlind, 1357, 1371, "double - blind", "", +162, Duration, 1403, 1412, "78 - week", "", +163, DoubleBlind, 1413, 1441, "site - and patient - blinded", "", +59, TimePoint, 1464, 1472, "week 102", "", +63, TimePoint, 1488, 1496, "baseline", "", +64, HbA1c, 1500, 1505, "HbA1c", "", +65, BodyWeight, 1508, 1514, "weight", "", +66, EndPointDescription, 1517, 1536, "waist circumference", "", +67, EndPointDescription, 1539, 1558, "total body fat mass", "", +68, MeasurementDevice, 1574, 1610, "dual - energy X - ray absorptiometry", "", " . ." +69, MeasurementDevice, 1613, 1616, "DXA", "", +72, EndPointDescription, 1621, 1651, "serum markers of bone turnover", "", +73, EndPointDescription, 1654, 1674, "bone mineral density", "", +74, EndPointDescription, 1677, 1680, "BMD", "", +70, MeasurementDevice, 1698, 1701, "DXA", "", +71, EndPointDescription, 1708, 1722, "adverse events", "", +75, FinalNumPatientsCT, 1761, 1764, "140", "", " \"140\"." +60, TimePoint, 1814, 1823, "102 weeks", "", " \"102 weeks\". \"102 weeks\". \"102 weeks\". \"102 weeks\". \"102 weeks\"." +6, Dapagliflozin, 1826, 1839, "dapagliflozin", "", +76, HbA1c, 1880, 1885, "HbA1c", "", " ." +77, Reduction, 1891, 1896, "0 . 3", "", " \"0 . 3\"." +81, Percentage, 1897, 1898, "%", "", " ." +82, BodyWeight, 1901, 1907, "weight", "", " ." +78, Reduction, 1913, 1919, "4 . 54", "", " \"4 . 54\"." +83, Kg, 1920, 1922, "kg", "", " ." +85, EndPointDescription, 1925, 1944, "waist circumference", "", " . ." +79, Reduction, 1950, 1955, "5 . 0", "", " \"5 . 0\"." +87, BioAndMedicalUnit, 1956, 1958, "cm", "", " . ." +86, EndPointDescription, 1963, 1971, "fat mass", "", " . ." +80, Reduction, 1977, 1983, "2 . 80", "", " \"2 . 80\"." +84, Kg, 1984, 1986, "kg", "", " ." +88, ObservedResult, 1987, 2003, "without increase", "", " \"without increase\"." +89, Hypoglycemia, 2015, 2028, "hypoglycaemia", "", " ." +90, Placebo, 2045, 2052, "placebo", "", +98, ObservedResult, 2055, 2076, "no meaningful changes", "", +91, TimePoint, 2082, 2090, "baseline", "", +196, EndPointDescription, 2094, 2118, "markers of bone turnover", "", +93, EndPointDescription, 2122, 2125, "BMD", "", +61, TimePoint, 2147, 2156, "102 weeks", "", +194, NumberAffected, 2159, 2162, "One", "", " \"One\". \"One\"." +96, EndPointDescription, 2163, 2171, "fracture", "", " . ." +94, EndPointDescription, 2224, 2247, "urinary tract infection", "", +95, EndPointDescription, 2250, 2253, "UTI", "", +97, EndPointDescription, 2260, 2277, "genital infection", "", +66752, ObservedResult, 2278, 2314, "was similar in both treatment groups", "", +106, ConclusionComment, 2331, 2535, "Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .", "", " \"Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .\"." +66753, TimePoint, 2336, 2345, "102 weeks", "", +7, Dapagliflozin, 2348, 2361, "dapagliflozin", "", +101, BodyWeight, 2403, 2409, "weight", "", +102, EndPointDescription, 2414, 2422, "fat mass", "", +103, EndPointDescription, 2443, 2467, "markers of bone turnover", "", +104, EndPointDescription, 2471, 2474, "BMD", "", +27, Type2Diabetes, 2492, 2496, "T2DM", "", +55, Metformin, 2524, 2533, "metformin", "", +107, PMID, 2604, 2612, "23906445", "", " \"23906445\"." diff --git a/data/dm2 23906445_admin.n-triples b/data/dm2 23906445_admin.n-triples new file mode 100644 index 0000000..8772f75 --- /dev/null +++ b/data/dm2 23906445_admin.n-triples @@ -0,0 +1,160 @@ +# RDF export of group: Publication + . + "Publication 46129" . + "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin ." . + "Bolinder J" . + "2014" . + "Diabetes Obes Metab ." . + "23906445" . + . + "Ljunggren Ö," . + "Johansson L" . + "Wilding J" . + "Langkilde AM" . + "Sj ö str ö m CD" . + "Sugg J" . + "Parikh S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 46136" . + "Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion ." . + "182" . + "102 weeks" . + . + . + . + . + "Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin ." . + . + . + . + . + . + "140" . + "Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment ." . + . + . + . +# RDF export of group: Population + . + "Population 46152" . + "patients with type 2 diabetes mellitus inadequately controlled on metformin" . + . + . + "60 . 7" . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "wa" . + . + . + . + . + . + . + . + "fat" . + . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "fra" . + . + . + . + . + . +# RDF export of group: Arm + . + "dap" . + . + . + . + . + . + . + . + . + "pla" . + . + . + . +# RDF export of group: Intervention + . + "dap" . + . + "day" . + . + . + "plda" . + . + . +# RDF export of group: Medication + . + "dap" . + . + "10" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "0 . 3" . + "102 weeks" . + . + "bw 1" . + . + "4 . 54" . + "102 weeks" . + . + "wa 1" . + . + "5 . 0" . + "102 weeks" . + . + "fat 1" . + . + "2 . 80" . + "102 weeks" . + . + "hyp 1" . + . + "without increase" . + "102 weeks" . + . + "fra 1" . + . + "One" . + . + "fra 2" . + . + "One" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23906445_akramersunderbrink.annodb b/data/dm2 23906445_akramersunderbrink.annodb new file mode 100644 index 0000000..f83238b --- /dev/null +++ b/data/dm2 23906445_akramersunderbrink.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43953, Journal, 0, 19, "Diabetes Obes Metab", "", +43954, PublicationYear, 22, 26, "2014", "", +43955, Dapagliflozin, 106, 119, "Dapagliflozin", "", +43956, BodyWeight, 163, 169, "weight", "", +43957, Duration, 193, 200, "2 years", "", +43958, Type2Diabetes, 218, 242, "type 2 diabetes mellitus", "", +43959, Precondition, 243, 279, "inadequately controlled on metformin", "", +43960, Metformin, 270, 279, "metformin", "", +43961, Author, 282, 292, "Bolinder J", "", +43962, Author, 301, 325, "Ljunggren Ö, Johansson L", "", +43963, Author, 328, 337, "Wilding J", "", +43964, Author, 340, 352, "Langkilde AM", "", +43965, Author, 355, 370, "Sj ö str ö m CD", "", +43966, Author, 373, 379, "Sugg J", "", +43967, Author, 382, 390, "Parikh S", "", +43968, Sweden, 553, 559, "Sweden", "", +43969, Dapagliflozin, 569, 582, "Dapagliflozin", "", +43978, ObjectiveDescription, 569, 790, "Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion .", "", +43970, Hypoglycemia, 670, 684, "hyperglycaemia", "", +43971, BodyWeight, 689, 695, "weight", "", +43972, BodyWeight, 713, 739, "type   2 diabetes mellitus", "", +43973, BodyWeight, 742, 746, "T2DM", "", +43979, ObjectiveDescription, 791, 937, "Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .", "", +43974, Type2Diabetes, 888, 892, "T2DM", "", +43976, Duration, 899, 908, "102 weeks", "", +43977, Dapagliflozin, 912, 925, "dapagliflozin", "", +43980, Randomized, 953, 963, "randomized", "", +43981, DoubleBlind, 966, 980, "double - blind", "", +43982, Placebo, 983, 990, "placebo", "", +43983, Type2Diabetes, 1049, 1053, "T2DM", "", +43985, Mean, 1056, 1060, "mean", "", +43984, AvgAge, 1067, 1079, "60 . 7 years", "", +43986, HbA1c, 1082, 1087, "HbA1c", "", +43988, Precondition, 1082, 1095, "HbA1c 7 . 2 %", "", +43987, Percentage, 1094, 1095, "%", "", +43989, BMI, 1098, 1113, "body mass index", "", +43991, Precondition, 1098, 1141, "body mass index ( BMI ) 31 . 9 kg / m ( 2 )", "", +43990, BMI, 1116, 1119, "BMI", "", +43992, Kg_per_squareMeter, 1129, 1141, "kg / m ( 2 )", "", +43993, BodyWeight, 1144, 1155, "body weight", "", +43994, Precondition, 1144, 1165, "body weight 91 . 5 kg", "", +43995, Kg, 1163, 1165, "kg", "", +43997, Precondition, 1168, 1204, "inadequately controlled on metformin", "", +43998, Metformin, 1195, 1204, "metformin", "", +43999, NumberPatientsCT, 1224, 1227, "182", "", +44000, Randomized, 1235, 1243, "randomly", "", +44001, Dapagliflozin, 1272, 1285, "dapagliflozin", "", +44002, DoseValue, 1286, 1297, "10 mg / day", "", +44003, BioAndMedicalUnit, 1289, 1297, "mg / day", "", +44004, Placebo, 1301, 1308, "placebo", "", +44005, OpenLabel, 1318, 1330, "open - label", "", +44006, Metformin, 1331, 1340, "metformin", "", +44007, Duration, 1347, 1356, "24 - week", "", +44008, DoubleBlind, 1357, 1371, "double - blind", "", +44009, Duration, 1403, 1412, "78 - week", "", +44010, DoubleBlind, 1413, 1441, "site - and patient - blinded", "", +44011, TimePoint, 1464, 1472, "week 102", "", +44012, TimePoint, 1488, 1496, "baseline", "", +44013, HbA1c, 1500, 1505, "HbA1c", "", +44014, BodyWeight, 1508, 1514, "weight", "", +44015, EndPointDescription, 1517, 1536, "waist circumference", "", +44016, EndPointDescription, 1539, 1610, "total body fat mass as measured by dual - energy X - ray absorptiometry", "", +44019, EndPointDescription, 1613, 1616, "DXA", "", +44017, EndPointDescription, 1621, 1674, "serum markers of bone turnover , bone mineral density", "", +44018, EndPointDescription, 1677, 1680, "BMD", "", +44020, FinalNumPatientsCT, 1761, 1764, "140", "", +44021, Percentage, 1783, 1784, "%", "", +44022, TimePoint, 1814, 1823, "102 weeks", "", +44023, Dapagliflozin, 1826, 1839, "dapagliflozin", "", +44024, HbA1c, 1880, 1885, "HbA1c", "", +44025, ChangeValue, 1889, 1896, "- 0 . 3", "", +44030, Percentage, 1897, 1898, "%", "", +44032, BodyWeight, 1901, 1907, "weight", "", +44026, ChangeValue, 1911, 1919, "- 4 . 54", "", +44031, Kg, 1920, 1922, "kg", "", +44033, EndPointDescription, 1925, 1944, "waist circumference", "", +44027, ChangeValue, 1948, 1955, "- 5 . 0", "", +44035, BioAndMedicalUnit, 1956, 1958, "cm", "", +44034, EndPointDescription, 1963, 1971, "fat mass", "", +44028, ChangeValue, 1975, 1983, "- 2 . 80", "", +44036, Kg, 1984, 1986, "kg", "", +44037, ObservedResult, 1987, 2003, "without increase", "", +44029, Hypoglycemia, 2007, 2028, "rate of hypoglycaemia", "", +44038, Placebo, 2045, 2052, "placebo", "", +44044, ObservedResult, 2055, 2076, "no meaningful changes", "", +44039, TimePoint, 2082, 2090, "baseline", "", +44043, EndPointDescription, 2094, 2125, "markers of bone turnover or BMD", "", +44040, TimePoint, 2147, 2156, "102 weeks", "", +44041, NumberAffected, 2159, 2162, "One", "", +44042, EndPointDescription, 2163, 2171, "fracture", "", +44045, EndPointDescription, 2224, 2277, "urinary tract infection ( UTI ) and genital infection", "", +44053, ConclusionComment, 2331, 2535, "Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .", "", +44046, Duration, 2336, 2345, "102 weeks", "", +44047, Dapagliflozin, 2348, 2361, "dapagliflozin", "", +44048, BodyWeight, 2403, 2409, "weight", "", +44049, EndPointDescription, 2414, 2422, "fat mass", "", +44050, EndPointDescription, 2443, 2474, "markers of bone turnover or BMD", "", +44051, Type2Diabetes, 2492, 2496, "T2DM", "", +44052, Precondition, 2497, 2533, "inadequately controlled on metformin", "", +44054, Metformin, 2524, 2533, "metformin", "", +44055, PMID, 2604, 2612, "23906445", "", diff --git a/data/dm2 23906445_akramersunderbrink.n-triples b/data/dm2 23906445_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23906445_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23906445_export.csv b/data/dm2 23906445_export.csv new file mode 100644 index 0000000..5d7e14a --- /dev/null +++ b/data/dm2 23906445_export.csv @@ -0,0 +1,525 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +297, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +297, 1, 2, 2, 9, 13, 9, 13, "Obes" +297, 1, 3, 3, 14, 19, 14, 19, "Metab" +297, 1, 4, 4, 20, 21, 20, 21, "." +297, 2, 1, 5, 0, 4, 22, 26, "2014" +297, 2, 2, 6, 5, 8, 27, 30, "Feb" +297, 2, 3, 7, 9, 10, 31, 32, ";" +297, 2, 4, 8, 11, 13, 33, 35, "16" +297, 2, 5, 9, 14, 15, 36, 37, "(" +297, 2, 6, 10, 16, 17, 38, 39, "2" +297, 2, 7, 11, 18, 19, 40, 41, ")" +297, 2, 8, 12, 20, 21, 42, 43, ":" +297, 2, 9, 13, 22, 25, 44, 47, "159" +297, 2, 10, 14, 26, 27, 48, 49, "-" +297, 2, 11, 15, 28, 30, 50, 52, "69" +297, 2, 12, 16, 31, 32, 53, 54, "." +297, 2, 13, 17, 33, 36, 55, 58, "doi" +297, 2, 14, 18, 37, 38, 59, 60, ":" +297, 2, 15, 19, 39, 41, 61, 63, "10" +297, 2, 16, 20, 42, 43, 64, 65, "." +297, 2, 17, 21, 44, 48, 66, 70, "1111" +297, 2, 18, 22, 49, 50, 71, 72, "/" +297, 2, 19, 23, 51, 54, 73, 76, "dom" +297, 2, 20, 24, 55, 56, 77, 78, "." +297, 2, 21, 25, 57, 62, 79, 84, "12189" +297, 2, 22, 26, 63, 64, 85, 86, "." +297, 3, 1, 27, 0, 4, 87, 91, "Epub" +297, 3, 2, 28, 5, 9, 92, 96, "2013" +297, 3, 3, 29, 10, 13, 97, 100, "Aug" +297, 3, 4, 30, 14, 16, 101, 103, "29" +297, 3, 5, 31, 17, 18, 104, 105, "." +297, 4, 1, 32, 0, 13, 106, 119, "Dapagliflozin" +297, 4, 2, 33, 14, 23, 120, 129, "maintains" +297, 4, 3, 34, 24, 33, 130, 139, "glycaemic" +297, 4, 4, 35, 34, 41, 140, 147, "control" +297, 4, 5, 36, 42, 47, 148, 153, "while" +297, 4, 6, 37, 48, 56, 154, 162, "reducing" +297, 4, 7, 38, 57, 63, 163, 169, "weight" +297, 4, 8, 39, 64, 67, 170, 173, "and" +297, 4, 9, 40, 68, 72, 174, 178, "body" +297, 4, 10, 41, 73, 76, 179, 182, "fat" +297, 4, 11, 42, 77, 81, 183, 187, "mass" +297, 4, 12, 43, 82, 86, 188, 192, "over" +297, 4, 13, 44, 87, 88, 193, 194, "2" +297, 4, 14, 45, 89, 94, 195, 200, "years" +297, 4, 15, 46, 95, 97, 201, 203, "in" +297, 4, 16, 47, 98, 106, 204, 212, "patients" +297, 4, 17, 48, 107, 111, 213, 217, "with" +297, 4, 18, 49, 112, 116, 218, 222, "type" +297, 4, 19, 50, 117, 118, 223, 224, "2" +297, 4, 20, 51, 119, 127, 225, 233, "diabetes" +297, 4, 21, 52, 128, 136, 234, 242, "mellitus" +297, 4, 22, 53, 137, 149, 243, 255, "inadequately" +297, 4, 23, 54, 150, 160, 256, 266, "controlled" +297, 4, 24, 55, 161, 163, 267, 269, "on" +297, 4, 25, 56, 164, 173, 270, 279, "metformin" +297, 4, 26, 57, 174, 175, 280, 281, "." +297, 5, 1, 58, 0, 8, 282, 290, "Bolinder" +297, 5, 2, 59, 9, 10, 291, 292, "J" +297, 5, 3, 60, 11, 12, 293, 294, "(" +297, 5, 4, 61, 13, 14, 295, 296, "1" +297, 5, 5, 62, 15, 16, 297, 298, ")" +297, 5, 6, 63, 17, 18, 299, 300, "," +297, 5, 7, 64, 19, 28, 301, 310, "Ljunggren" +297, 5, 8, 65, 29, 31, 311, 313, "Ö," +297, 5, 9, 66, 32, 41, 314, 323, "Johansson" +297, 5, 10, 67, 42, 43, 324, 325, "L" +297, 5, 11, 68, 44, 45, 326, 327, "," +297, 5, 12, 69, 46, 53, 328, 335, "Wilding" +297, 5, 13, 70, 54, 55, 336, 337, "J" +297, 5, 14, 71, 56, 57, 338, 339, "," +297, 5, 15, 72, 58, 67, 340, 349, "Langkilde" +297, 5, 16, 73, 68, 70, 350, 352, "AM" +297, 5, 17, 74, 71, 72, 353, 354, "," +297, 5, 18, 75, 73, 75, 355, 357, "Sj" +297, 5, 19, 76, 76, 77, 358, 359, "ö" +297, 5, 20, 77, 78, 81, 360, 363, "str" +297, 5, 21, 78, 82, 83, 364, 365, "ö" +297, 5, 22, 79, 84, 85, 366, 367, "m" +297, 5, 23, 80, 86, 88, 368, 370, "CD" +297, 5, 24, 81, 89, 90, 371, 372, "," +297, 5, 25, 82, 91, 95, 373, 377, "Sugg" +297, 5, 26, 83, 96, 97, 378, 379, "J" +297, 5, 27, 84, 98, 99, 380, 381, "," +297, 5, 28, 85, 100, 106, 382, 388, "Parikh" +297, 5, 29, 86, 107, 108, 389, 390, "S" +297, 5, 30, 87, 109, 110, 391, 392, "." +297, 5, 31, 88, 111, 117, 393, 399, "Author" +297, 5, 32, 89, 118, 129, 400, 411, "information" +297, 5, 33, 90, 130, 131, 412, 413, ":" +297, 5, 34, 91, 132, 133, 414, 415, "(" +297, 5, 35, 92, 134, 135, 416, 417, "1" +297, 5, 36, 93, 136, 137, 418, 419, ")" +297, 5, 37, 94, 138, 148, 420, 430, "Department" +297, 5, 38, 95, 149, 151, 431, 433, "of" +297, 5, 39, 96, 152, 165, 434, 447, "Endocrinology" +297, 5, 40, 97, 166, 167, 448, 449, "," +297, 5, 41, 98, 168, 178, 450, 460, "Metabolism" +297, 5, 42, 99, 179, 182, 461, 464, "and" +297, 5, 43, 100, 183, 191, 465, 473, "Diabetes" +297, 5, 44, 101, 192, 193, 474, 475, "," +297, 5, 45, 102, 194, 204, 476, 486, "Karolinska" +297, 5, 46, 103, 205, 215, 487, 497, "University" +297, 5, 47, 104, 216, 224, 498, 506, "Hospital" +297, 5, 48, 105, 225, 233, 507, 515, "Huddinge" +297, 5, 49, 106, 234, 235, 516, 517, "," +297, 5, 50, 107, 236, 246, 518, 528, "Karolinska" +297, 5, 51, 108, 247, 256, 529, 538, "Institute" +297, 5, 52, 109, 257, 258, 539, 540, "," +297, 5, 53, 110, 259, 268, 541, 550, "Stockholm" +297, 5, 54, 111, 269, 270, 551, 552, "," +297, 5, 55, 112, 271, 277, 553, 559, "Sweden" +297, 5, 56, 113, 278, 279, 560, 561, "." +297, 6, 1, 114, 0, 4, 562, 566, "AIMS" +297, 6, 2, 115, 5, 6, 567, 568, ":" +297, 6, 3, 116, 7, 20, 569, 582, "Dapagliflozin" +297, 6, 4, 117, 21, 22, 583, 584, "," +297, 6, 5, 118, 23, 24, 585, 586, "a" +297, 6, 6, 119, 25, 31, 587, 593, "highly" +297, 6, 7, 120, 32, 41, 594, 603, "selective" +297, 6, 8, 121, 42, 51, 604, 613, "inhibitor" +297, 6, 9, 122, 52, 54, 614, 616, "of" +297, 6, 10, 123, 55, 61, 617, 623, "sodium" +297, 6, 11, 124, 62, 63, 624, 625, "-" +297, 6, 12, 125, 64, 71, 626, 633, "glucose" +297, 6, 13, 126, 72, 85, 634, 647, "cotransporter" +297, 6, 14, 127, 86, 87, 648, 649, "2" +297, 6, 15, 128, 88, 89, 650, 651, "(" +297, 6, 16, 129, 90, 95, 652, 657, "SGLT2" +297, 6, 17, 130, 96, 97, 658, 659, ")" +297, 6, 18, 131, 98, 99, 660, 661, "," +297, 6, 19, 132, 100, 107, 662, 669, "reduces" +297, 6, 20, 133, 108, 122, 670, 684, "hyperglycaemia" +297, 6, 21, 134, 123, 126, 685, 688, "and" +297, 6, 22, 135, 127, 133, 689, 695, "weight" +297, 6, 23, 136, 134, 136, 696, 698, "in" +297, 6, 24, 137, 137, 145, 699, 707, "patients" +297, 6, 25, 138, 146, 150, 708, 712, "with" +297, 6, 26, 139, 151, 155, 713, 717, "type" +297, 6, 27, 140, 156, 157, 718, 719, " " +297, 6, 28, 141, 158, 159, 720, 721, "2" +297, 6, 29, 142, 160, 168, 722, 730, "diabetes" +297, 6, 30, 143, 169, 177, 731, 739, "mellitus" +297, 6, 31, 144, 178, 179, 740, 741, "(" +297, 6, 32, 145, 180, 184, 742, 746, "T2DM" +297, 6, 33, 146, 185, 186, 747, 748, ")" +297, 6, 34, 147, 187, 189, 749, 751, "by" +297, 6, 35, 148, 190, 200, 752, 762, "increasing" +297, 6, 36, 149, 201, 208, 763, 770, "urinary" +297, 6, 37, 150, 209, 216, 771, 778, "glucose" +297, 6, 38, 151, 217, 226, 779, 788, "excretion" +297, 6, 39, 152, 227, 228, 789, 790, "." +297, 7, 1, 153, 0, 4, 791, 795, "Long" +297, 7, 2, 154, 5, 6, 796, 797, "-" +297, 7, 3, 155, 7, 11, 798, 802, "term" +297, 7, 4, 156, 12, 21, 803, 812, "glycaemic" +297, 7, 5, 157, 22, 29, 813, 820, "control" +297, 7, 6, 158, 30, 31, 821, 822, "," +297, 7, 7, 159, 32, 36, 823, 827, "body" +297, 7, 8, 160, 37, 48, 828, 839, "composition" +297, 7, 9, 161, 49, 52, 840, 843, "and" +297, 7, 10, 162, 53, 57, 844, 848, "bone" +297, 7, 11, 163, 58, 64, 849, 855, "safety" +297, 7, 12, 164, 65, 69, 856, 860, "were" +297, 7, 13, 165, 70, 79, 861, 870, "evaluated" +297, 7, 14, 166, 80, 82, 871, 873, "in" +297, 7, 15, 167, 83, 91, 874, 882, "patients" +297, 7, 16, 168, 92, 96, 883, 887, "with" +297, 7, 17, 169, 97, 101, 888, 892, "T2DM" +297, 7, 18, 170, 102, 107, 893, 898, "after" +297, 7, 19, 171, 108, 111, 899, 902, "102" +297, 7, 20, 172, 112, 117, 903, 908, "weeks" +297, 7, 21, 173, 118, 120, 909, 911, "of" +297, 7, 22, 174, 121, 134, 912, 925, "dapagliflozin" +297, 7, 23, 175, 135, 144, 926, 935, "treatment" +297, 7, 24, 176, 145, 146, 936, 937, "." +297, 8, 1, 177, 0, 7, 938, 945, "METHODS" +297, 8, 2, 178, 8, 9, 946, 947, ":" +297, 8, 3, 179, 10, 14, 948, 952, "This" +297, 8, 4, 180, 15, 25, 953, 963, "randomized" +297, 8, 5, 181, 26, 27, 964, 965, "," +297, 8, 6, 182, 28, 34, 966, 972, "double" +297, 8, 7, 183, 35, 36, 973, 974, "-" +297, 8, 8, 184, 37, 42, 975, 980, "blind" +297, 8, 9, 185, 43, 44, 981, 982, "," +297, 8, 10, 186, 45, 52, 983, 990, "placebo" +297, 8, 11, 187, 53, 54, 991, 992, "-" +297, 8, 12, 188, 55, 65, 993, 1003, "controlled" +297, 8, 13, 189, 66, 71, 1004, 1009, "study" +297, 8, 14, 190, 72, 73, 1010, 1011, "(" +297, 8, 15, 191, 74, 85, 1012, 1023, "NCT00855166" +297, 8, 16, 192, 86, 87, 1024, 1025, ")" +297, 8, 17, 193, 88, 96, 1026, 1034, "enrolled" +297, 8, 18, 194, 97, 105, 1035, 1043, "patients" +297, 8, 19, 195, 106, 110, 1044, 1048, "with" +297, 8, 20, 196, 111, 115, 1049, 1053, "T2DM" +297, 8, 21, 197, 116, 117, 1054, 1055, "[" +297, 8, 22, 198, 118, 122, 1056, 1060, "mean" +297, 8, 23, 199, 123, 124, 1061, 1062, ":" +297, 8, 24, 200, 125, 128, 1063, 1066, "age" +297, 8, 25, 201, 129, 131, 1067, 1069, "60" +297, 8, 26, 202, 132, 133, 1070, 1071, "." +297, 8, 27, 203, 134, 135, 1072, 1073, "7" +297, 8, 28, 204, 136, 141, 1074, 1079, "years" +297, 8, 29, 205, 142, 143, 1080, 1081, ";" +297, 8, 30, 206, 144, 149, 1082, 1087, "HbA1c" +297, 8, 31, 207, 150, 151, 1088, 1089, "7" +297, 8, 32, 208, 152, 153, 1090, 1091, "." +297, 8, 33, 209, 154, 155, 1092, 1093, "2" +297, 8, 34, 210, 156, 157, 1094, 1095, "%" +297, 8, 35, 211, 158, 159, 1096, 1097, ";" +297, 8, 36, 212, 160, 164, 1098, 1102, "body" +297, 8, 37, 213, 165, 169, 1103, 1107, "mass" +297, 8, 38, 214, 170, 175, 1108, 1113, "index" +297, 8, 39, 215, 176, 177, 1114, 1115, "(" +297, 8, 40, 216, 178, 181, 1116, 1119, "BMI" +297, 8, 41, 217, 182, 183, 1120, 1121, ")" +297, 8, 42, 218, 184, 186, 1122, 1124, "31" +297, 8, 43, 219, 187, 188, 1125, 1126, "." +297, 8, 44, 220, 189, 190, 1127, 1128, "9" +297, 8, 45, 221, 191, 193, 1129, 1131, "kg" +297, 8, 46, 222, 194, 195, 1132, 1133, "/" +297, 8, 47, 223, 196, 197, 1134, 1135, "m" +297, 8, 48, 224, 198, 199, 1136, 1137, "(" +297, 8, 49, 225, 200, 201, 1138, 1139, "2" +297, 8, 50, 226, 202, 203, 1140, 1141, ")" +297, 8, 51, 227, 204, 205, 1142, 1143, ";" +297, 8, 52, 228, 206, 210, 1144, 1148, "body" +297, 8, 53, 229, 211, 217, 1149, 1155, "weight" +297, 8, 54, 230, 218, 220, 1156, 1158, "91" +297, 8, 55, 231, 221, 222, 1159, 1160, "." +297, 8, 56, 232, 223, 224, 1161, 1162, "5" +297, 8, 57, 233, 225, 227, 1163, 1165, "kg" +297, 8, 58, 234, 228, 229, 1166, 1167, "]" +297, 8, 59, 235, 230, 242, 1168, 1180, "inadequately" +297, 8, 60, 236, 243, 253, 1181, 1191, "controlled" +297, 8, 61, 237, 254, 256, 1192, 1194, "on" +297, 8, 62, 238, 257, 266, 1195, 1204, "metformin" +297, 8, 63, 239, 267, 268, 1205, 1206, "." +297, 9, 1, 240, 0, 8, 1207, 1215, "Patients" +297, 9, 2, 241, 9, 10, 1216, 1217, "(" +297, 9, 3, 242, 11, 12, 1218, 1219, "N" +297, 9, 4, 243, 13, 16, 1220, 1223, " = " +297, 9, 5, 244, 17, 20, 1224, 1227, "182" +297, 9, 6, 245, 21, 22, 1228, 1229, ")" +297, 9, 7, 246, 23, 27, 1230, 1234, "were" +297, 9, 8, 247, 28, 36, 1235, 1243, "randomly" +297, 9, 9, 248, 37, 45, 1244, 1252, "assigned" +297, 9, 10, 249, 46, 47, 1253, 1254, "1" +297, 9, 11, 250, 48, 51, 1255, 1258, " : " +297, 9, 12, 251, 52, 53, 1259, 1260, "1" +297, 9, 13, 252, 54, 56, 1261, 1263, "to" +297, 9, 14, 253, 57, 64, 1264, 1271, "receive" +297, 9, 15, 254, 65, 78, 1272, 1285, "dapagliflozin" +297, 9, 16, 255, 79, 81, 1286, 1288, "10" +297, 9, 17, 256, 82, 84, 1289, 1291, "mg" +297, 9, 18, 257, 85, 86, 1292, 1293, "/" +297, 9, 19, 258, 87, 90, 1294, 1297, "day" +297, 9, 20, 259, 91, 93, 1298, 1300, "or" +297, 9, 21, 260, 94, 101, 1301, 1308, "placebo" +297, 9, 22, 261, 102, 107, 1309, 1314, "added" +297, 9, 23, 262, 108, 110, 1315, 1317, "to" +297, 9, 24, 263, 111, 115, 1318, 1322, "open" +297, 9, 25, 264, 116, 117, 1323, 1324, "-" +297, 9, 26, 265, 118, 123, 1325, 1330, "label" +297, 9, 27, 266, 124, 133, 1331, 1340, "metformin" +297, 9, 28, 267, 134, 137, 1341, 1344, "for" +297, 9, 29, 268, 138, 139, 1345, 1346, "a" +297, 9, 30, 269, 140, 142, 1347, 1349, "24" +297, 9, 31, 270, 143, 144, 1350, 1351, "-" +297, 9, 32, 271, 145, 149, 1352, 1356, "week" +297, 9, 33, 272, 150, 156, 1357, 1363, "double" +297, 9, 34, 273, 157, 158, 1364, 1365, "-" +297, 9, 35, 274, 159, 164, 1366, 1371, "blind" +297, 9, 36, 275, 165, 174, 1372, 1381, "treatment" +297, 9, 37, 276, 175, 181, 1382, 1388, "period" +297, 9, 38, 277, 182, 190, 1389, 1397, "followed" +297, 9, 39, 278, 191, 193, 1398, 1400, "by" +297, 9, 40, 279, 194, 195, 1401, 1402, "a" +297, 9, 41, 280, 196, 198, 1403, 1405, "78" +297, 9, 42, 281, 199, 200, 1406, 1407, "-" +297, 9, 43, 282, 201, 205, 1408, 1412, "week" +297, 9, 44, 283, 206, 210, 1413, 1417, "site" +297, 9, 45, 284, 211, 212, 1418, 1419, "-" +297, 9, 46, 285, 213, 216, 1420, 1423, "and" +297, 9, 47, 286, 217, 224, 1424, 1431, "patient" +297, 9, 48, 287, 225, 226, 1432, 1433, "-" +297, 9, 49, 288, 227, 234, 1434, 1441, "blinded" +297, 9, 50, 289, 235, 244, 1442, 1451, "extension" +297, 9, 51, 290, 245, 251, 1452, 1458, "period" +297, 9, 52, 291, 252, 253, 1459, 1460, "." +297, 10, 1, 292, 0, 2, 1461, 1463, "At" +297, 10, 2, 293, 3, 7, 1464, 1468, "week" +297, 10, 3, 294, 8, 11, 1469, 1472, "102" +297, 10, 4, 295, 12, 13, 1473, 1474, "," +297, 10, 5, 296, 14, 21, 1475, 1482, "changes" +297, 10, 6, 297, 22, 26, 1483, 1487, "from" +297, 10, 7, 298, 27, 35, 1488, 1496, "baseline" +297, 10, 8, 299, 36, 38, 1497, 1499, "in" +297, 10, 9, 300, 39, 44, 1500, 1505, "HbA1c" +297, 10, 10, 301, 45, 46, 1506, 1507, "," +297, 10, 11, 302, 47, 53, 1508, 1514, "weight" +297, 10, 12, 303, 54, 55, 1515, 1516, "," +297, 10, 13, 304, 56, 61, 1517, 1522, "waist" +297, 10, 14, 305, 62, 75, 1523, 1536, "circumference" +297, 10, 15, 306, 76, 77, 1537, 1538, "," +297, 10, 16, 307, 78, 83, 1539, 1544, "total" +297, 10, 17, 308, 84, 88, 1545, 1549, "body" +297, 10, 18, 309, 89, 92, 1550, 1553, "fat" +297, 10, 19, 310, 93, 97, 1554, 1558, "mass" +297, 10, 20, 311, 98, 100, 1559, 1561, "as" +297, 10, 21, 312, 101, 109, 1562, 1570, "measured" +297, 10, 22, 313, 110, 112, 1571, 1573, "by" +297, 10, 23, 314, 113, 117, 1574, 1578, "dual" +297, 10, 24, 315, 118, 119, 1579, 1580, "-" +297, 10, 25, 316, 120, 126, 1581, 1587, "energy" +297, 10, 26, 317, 127, 128, 1588, 1589, "X" +297, 10, 27, 318, 129, 130, 1590, 1591, "-" +297, 10, 28, 319, 131, 134, 1592, 1595, "ray" +297, 10, 29, 320, 135, 149, 1596, 1610, "absorptiometry" +297, 10, 30, 321, 150, 151, 1611, 1612, "(" +297, 10, 31, 322, 152, 155, 1613, 1616, "DXA" +297, 10, 32, 323, 156, 157, 1617, 1618, ")" +297, 10, 33, 324, 158, 159, 1619, 1620, "," +297, 10, 34, 325, 160, 165, 1621, 1626, "serum" +297, 10, 35, 326, 166, 173, 1627, 1634, "markers" +297, 10, 36, 327, 174, 176, 1635, 1637, "of" +297, 10, 37, 328, 177, 181, 1638, 1642, "bone" +297, 10, 38, 329, 182, 190, 1643, 1651, "turnover" +297, 10, 39, 330, 191, 192, 1652, 1653, "," +297, 10, 40, 331, 193, 197, 1654, 1658, "bone" +297, 10, 41, 332, 198, 205, 1659, 1666, "mineral" +297, 10, 42, 333, 206, 213, 1667, 1674, "density" +297, 10, 43, 334, 214, 215, 1675, 1676, "(" +297, 10, 44, 335, 216, 219, 1677, 1680, "BMD" +297, 10, 45, 336, 220, 221, 1681, 1682, ")" +297, 10, 46, 337, 222, 224, 1683, 1685, "as" +297, 10, 47, 338, 225, 233, 1686, 1694, "measured" +297, 10, 48, 339, 234, 236, 1695, 1697, "by" +297, 10, 49, 340, 237, 240, 1698, 1701, "DXA" +297, 10, 50, 341, 241, 242, 1702, 1703, "," +297, 10, 51, 342, 243, 246, 1704, 1707, "and" +297, 10, 52, 343, 247, 254, 1708, 1715, "adverse" +297, 10, 53, 344, 255, 261, 1716, 1722, "events" +297, 10, 54, 345, 262, 266, 1723, 1727, "were" +297, 10, 55, 346, 267, 276, 1728, 1737, "evaluated" +297, 10, 56, 347, 277, 278, 1738, 1739, "." +297, 11, 1, 348, 0, 7, 1740, 1747, "RESULTS" +297, 11, 2, 349, 8, 9, 1748, 1749, ":" +297, 11, 3, 350, 10, 11, 1750, 1751, "A" +297, 11, 4, 351, 12, 17, 1752, 1757, "total" +297, 11, 5, 352, 18, 20, 1758, 1760, "of" +297, 11, 6, 353, 21, 24, 1761, 1764, "140" +297, 11, 7, 354, 25, 33, 1765, 1773, "patients" +297, 11, 8, 355, 34, 35, 1774, 1775, "(" +297, 11, 9, 356, 36, 38, 1776, 1778, "76" +297, 11, 10, 357, 39, 40, 1779, 1780, "." +297, 11, 11, 358, 41, 42, 1781, 1782, "9" +297, 11, 12, 359, 43, 44, 1783, 1784, "%" +297, 11, 13, 360, 45, 46, 1785, 1786, ")" +297, 11, 14, 361, 47, 56, 1787, 1796, "completed" +297, 11, 15, 362, 57, 60, 1797, 1800, "the" +297, 11, 16, 363, 61, 66, 1801, 1806, "study" +297, 11, 17, 364, 67, 68, 1807, 1808, "." +297, 12, 1, 365, 0, 4, 1809, 1813, "Over" +297, 12, 2, 366, 5, 8, 1814, 1817, "102" +297, 12, 3, 367, 9, 14, 1818, 1823, "weeks" +297, 12, 4, 368, 15, 16, 1824, 1825, "," +297, 12, 5, 369, 17, 30, 1826, 1839, "dapagliflozin" +297, 12, 6, 370, 31, 32, 1840, 1841, "-" +297, 12, 7, 371, 33, 40, 1842, 1849, "treated" +297, 12, 8, 372, 41, 49, 1850, 1858, "patients" +297, 12, 9, 373, 50, 56, 1859, 1865, "showed" +297, 12, 10, 374, 57, 67, 1866, 1876, "reductions" +297, 12, 11, 375, 68, 70, 1877, 1879, "in" +297, 12, 12, 376, 71, 76, 1880, 1885, "HbA1c" +297, 12, 13, 377, 77, 79, 1886, 1888, "by" +297, 12, 14, 378, 80, 81, 1889, 1890, "-" +297, 12, 15, 379, 82, 83, 1891, 1892, "0" +297, 12, 16, 380, 84, 85, 1893, 1894, "." +297, 12, 17, 381, 86, 87, 1895, 1896, "3" +297, 12, 18, 382, 88, 89, 1897, 1898, "%" +297, 12, 19, 383, 90, 91, 1899, 1900, "," +297, 12, 20, 384, 92, 98, 1901, 1907, "weight" +297, 12, 21, 385, 99, 101, 1908, 1910, "by" +297, 12, 22, 386, 102, 103, 1911, 1912, "-" +297, 12, 23, 387, 104, 105, 1913, 1914, "4" +297, 12, 24, 388, 106, 107, 1915, 1916, "." +297, 12, 25, 389, 108, 110, 1917, 1919, "54" +297, 12, 26, 390, 111, 113, 1920, 1922, "kg" +297, 12, 27, 391, 114, 115, 1923, 1924, "," +297, 12, 28, 392, 116, 121, 1925, 1930, "waist" +297, 12, 29, 393, 122, 135, 1931, 1944, "circumference" +297, 12, 30, 394, 136, 138, 1945, 1947, "by" +297, 12, 31, 395, 139, 140, 1948, 1949, "-" +297, 12, 32, 396, 141, 142, 1950, 1951, "5" +297, 12, 33, 397, 143, 144, 1952, 1953, "." +297, 12, 34, 398, 145, 146, 1954, 1955, "0" +297, 12, 35, 399, 147, 149, 1956, 1958, "cm" +297, 12, 36, 400, 150, 153, 1959, 1962, "and" +297, 12, 37, 401, 154, 157, 1963, 1966, "fat" +297, 12, 38, 402, 158, 162, 1967, 1971, "mass" +297, 12, 39, 403, 163, 165, 1972, 1974, "by" +297, 12, 40, 404, 166, 167, 1975, 1976, "-" +297, 12, 41, 405, 168, 169, 1977, 1978, "2" +297, 12, 42, 406, 170, 171, 1979, 1980, "." +297, 12, 43, 407, 172, 174, 1981, 1983, "80" +297, 12, 44, 408, 175, 177, 1984, 1986, "kg" +297, 12, 45, 409, 178, 185, 1987, 1994, "without" +297, 12, 46, 410, 186, 194, 1995, 2003, "increase" +297, 12, 47, 411, 195, 197, 2004, 2006, "in" +297, 12, 48, 412, 198, 202, 2007, 2011, "rate" +297, 12, 49, 413, 203, 205, 2012, 2014, "of" +297, 12, 50, 414, 206, 219, 2015, 2028, "hypoglycaemia" +297, 12, 51, 415, 220, 221, 2029, 2030, "." +297, 13, 1, 416, 0, 8, 2031, 2039, "Compared" +297, 13, 2, 417, 9, 13, 2040, 2044, "with" +297, 13, 3, 418, 14, 21, 2045, 2052, "placebo" +297, 13, 4, 419, 22, 23, 2053, 2054, "," +297, 13, 5, 420, 24, 26, 2055, 2057, "no" +297, 13, 6, 421, 27, 37, 2058, 2068, "meaningful" +297, 13, 7, 422, 38, 45, 2069, 2076, "changes" +297, 13, 8, 423, 46, 50, 2077, 2081, "from" +297, 13, 9, 424, 51, 59, 2082, 2090, "baseline" +297, 13, 10, 425, 60, 62, 2091, 2093, "in" +297, 13, 11, 426, 63, 70, 2094, 2101, "markers" +297, 13, 12, 427, 71, 73, 2102, 2104, "of" +297, 13, 13, 428, 74, 78, 2105, 2109, "bone" +297, 13, 14, 429, 79, 87, 2110, 2118, "turnover" +297, 13, 15, 430, 88, 90, 2119, 2121, "or" +297, 13, 16, 431, 91, 94, 2122, 2125, "BMD" +297, 13, 17, 432, 95, 99, 2126, 2130, "were" +297, 13, 18, 433, 100, 110, 2131, 2141, "identified" +297, 13, 19, 434, 111, 115, 2142, 2146, "over" +297, 13, 20, 435, 116, 119, 2147, 2150, "102" +297, 13, 21, 436, 120, 125, 2151, 2156, "weeks" +297, 13, 22, 437, 126, 127, 2157, 2158, "." +297, 14, 1, 438, 0, 3, 2159, 2162, "One" +297, 14, 2, 439, 4, 12, 2163, 2171, "fracture" +297, 14, 3, 440, 13, 21, 2172, 2180, "occurred" +297, 14, 4, 441, 22, 24, 2181, 2183, "in" +297, 14, 5, 442, 25, 29, 2184, 2188, "each" +297, 14, 6, 443, 30, 39, 2189, 2198, "treatment" +297, 14, 7, 444, 40, 45, 2199, 2204, "group" +297, 14, 8, 445, 46, 47, 2205, 2206, "." +297, 15, 1, 446, 0, 3, 2207, 2210, "The" +297, 15, 2, 447, 4, 13, 2211, 2220, "frequency" +297, 15, 3, 448, 14, 16, 2221, 2223, "of" +297, 15, 4, 449, 17, 24, 2224, 2231, "urinary" +297, 15, 5, 450, 25, 30, 2232, 2237, "tract" +297, 15, 6, 451, 31, 40, 2238, 2247, "infection" +297, 15, 7, 452, 41, 42, 2248, 2249, "(" +297, 15, 8, 453, 43, 46, 2250, 2253, "UTI" +297, 15, 9, 454, 47, 48, 2254, 2255, ")" +297, 15, 10, 455, 49, 52, 2256, 2259, "and" +297, 15, 11, 456, 53, 60, 2260, 2267, "genital" +297, 15, 12, 457, 61, 70, 2268, 2277, "infection" +297, 15, 13, 458, 71, 74, 2278, 2281, "was" +297, 15, 14, 459, 75, 82, 2282, 2289, "similar" +297, 15, 15, 460, 83, 85, 2290, 2292, "in" +297, 15, 16, 461, 86, 90, 2293, 2297, "both" +297, 15, 17, 462, 91, 100, 2298, 2307, "treatment" +297, 15, 18, 463, 101, 107, 2308, 2314, "groups" +297, 15, 19, 464, 108, 109, 2315, 2316, "." +297, 16, 1, 465, 0, 11, 2317, 2328, "CONCLUSIONS" +297, 16, 2, 466, 12, 13, 2329, 2330, ":" +297, 16, 3, 467, 14, 18, 2331, 2335, "Over" +297, 16, 4, 468, 19, 22, 2336, 2339, "102" +297, 16, 5, 469, 23, 28, 2340, 2345, "weeks" +297, 16, 6, 470, 29, 30, 2346, 2347, "," +297, 16, 7, 471, 31, 44, 2348, 2361, "dapagliflozin" +297, 16, 8, 472, 45, 53, 2362, 2370, "improved" +297, 16, 9, 473, 54, 63, 2371, 2380, "glycaemic" +297, 16, 10, 474, 64, 71, 2381, 2388, "control" +297, 16, 11, 475, 72, 73, 2389, 2390, "," +297, 16, 12, 476, 74, 77, 2391, 2394, "and" +297, 16, 13, 477, 78, 85, 2395, 2402, "reduced" +297, 16, 14, 478, 86, 92, 2403, 2409, "weight" +297, 16, 15, 479, 93, 96, 2410, 2413, "and" +297, 16, 16, 480, 97, 100, 2414, 2417, "fat" +297, 16, 17, 481, 101, 105, 2418, 2422, "mass" +297, 16, 18, 482, 106, 107, 2423, 2424, "," +297, 16, 19, 483, 108, 115, 2425, 2432, "without" +297, 16, 20, 484, 116, 125, 2433, 2442, "affecting" +297, 16, 21, 485, 126, 133, 2443, 2450, "markers" +297, 16, 22, 486, 134, 136, 2451, 2453, "of" +297, 16, 23, 487, 137, 141, 2454, 2458, "bone" +297, 16, 24, 488, 142, 150, 2459, 2467, "turnover" +297, 16, 25, 489, 151, 153, 2468, 2470, "or" +297, 16, 26, 490, 154, 157, 2471, 2474, "BMD" +297, 16, 27, 491, 158, 160, 2475, 2477, "in" +297, 16, 28, 492, 161, 169, 2478, 2486, "patients" +297, 16, 29, 493, 170, 174, 2487, 2491, "with" +297, 16, 30, 494, 175, 179, 2492, 2496, "T2DM" +297, 16, 31, 495, 180, 192, 2497, 2509, "inadequately" +297, 16, 32, 496, 193, 203, 2510, 2520, "controlled" +297, 16, 33, 497, 204, 206, 2521, 2523, "on" +297, 16, 34, 498, 207, 216, 2524, 2533, "metformin" +297, 16, 35, 499, 217, 218, 2534, 2535, "." +297, 17, 1, 500, 0, 1, 2536, 2537, "©" +297, 17, 2, 501, 2, 6, 2538, 2542, "2013" +297, 17, 3, 502, 7, 11, 2543, 2547, "John" +297, 17, 4, 503, 12, 17, 2548, 2553, "Wiley" +297, 17, 5, 504, 18, 19, 2554, 2555, "&" +297, 17, 6, 505, 20, 24, 2556, 2560, "Sons" +297, 17, 7, 506, 25, 28, 2561, 2564, "Ltd" +297, 17, 8, 507, 29, 30, 2565, 2566, "." +297, 17, 9, 508, 31, 34, 2567, 2570, "DOI" +297, 17, 10, 509, 35, 36, 2571, 2572, ":" +297, 17, 11, 510, 37, 39, 2573, 2575, "10" +297, 17, 12, 511, 40, 41, 2576, 2577, "." +297, 17, 13, 512, 42, 46, 2578, 2582, "1111" +297, 17, 14, 513, 47, 48, 2583, 2584, "/" +297, 17, 15, 514, 49, 52, 2585, 2588, "dom" +297, 17, 16, 515, 53, 54, 2589, 2590, "." +297, 17, 17, 516, 55, 60, 2591, 2596, "12189" +297, 17, 18, 517, 61, 65, 2597, 2601, "PMID" +297, 17, 19, 518, 66, 67, 2602, 2603, ":" +297, 17, 20, 519, 68, 76, 2604, 2612, "23906445" +297, 17, 21, 520, 77, 78, 2613, 2614, "[" +297, 17, 22, 521, 79, 86, 2615, 2622, "Indexed" +297, 17, 23, 522, 87, 90, 2623, 2626, "for" +297, 17, 24, 523, 91, 98, 2627, 2634, "MEDLINE" +297, 17, 25, 524, 99, 100, 2635, 2636, "]" diff --git a/data/dm2 23906445_kwoodley.annodb b/data/dm2 23906445_kwoodley.annodb new file mode 100644 index 0000000..f055be0 --- /dev/null +++ b/data/dm2 23906445_kwoodley.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42525, Journal, 0, 19, "Diabetes Obes Metab", "", +42526, PublicationYear, 22, 26, "2014", "", +42527, Dapagliflozin, 106, 119, "Dapagliflozin", "", +42537, Title, 106, 281, "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin .", "", +42533, BodyWeight, 163, 169, "weight", "", +42536, Precondition, 204, 279, "patients with type 2 diabetes mellitus inadequately controlled on metformin", "", +42534, Type2Diabetes, 218, 242, "type 2 diabetes mellitus", "", +42535, Metformin, 270, 279, "metformin", "", +42538, Author, 282, 292, "Bolinder J", "", +42539, Author, 301, 313, "Ljunggren Ö,", "", +42540, Author, 314, 325, "Johansson L", "", +42541, Author, 328, 337, "Wilding J", "", +42542, Author, 340, 352, "Langkilde AM", "", +42543, Author, 355, 370, "Sj ö str ö m CD", "", +42544, Author, 373, 379, "Sugg J", "", +42545, Author, 382, 390, "Parikh S", "", +42546, Sweden, 553, 559, "Sweden", "", +42528, Dapagliflozin, 569, 582, "Dapagliflozin", "", +42547, Hypoglycemia, 670, 684, "hyperglycaemia", "", +42548, BodyWeight, 689, 695, "weight", "", +42549, Type2Diabetes, 713, 739, "type   2 diabetes mellitus", "", +42550, Type2Diabetes, 742, 746, "T2DM", "", +42554, ObjectiveDescription, 791, 937, "Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .", "", +42551, Type2Diabetes, 888, 892, "T2DM", "", +42553, Duration, 899, 908, "102 weeks", "", +42529, Dapagliflozin, 912, 925, "dapagliflozin", "", +42555, Randomized, 953, 963, "randomized", "", +42556, DoubleBlind, 966, 980, "double - blind", "", +42557, Placebo, 983, 990, "placebo", "", +42568, Precondition, 1035, 1204, "patients with T2DM [ mean : age 60 . 7 years ; HbA1c 7 . 2 % ; body mass index ( BMI ) 31 . 9 kg / m ( 2 ) ; body weight 91 . 5 kg ] inadequately controlled on metformin", "", +42558, Type2Diabetes, 1049, 1053, "T2DM", "", +42559, AvgAge, 1067, 1073, "60 . 7", "", +42560, HbA1c, 1082, 1087, "HbA1c", "", +42569, BaseLineValue, 1088, 1093, "7 . 2", "", +42561, Percentage, 1094, 1095, "%", "", +42562, BMI, 1098, 1113, "body mass index", "", +42563, BMI, 1116, 1119, "BMI", "", +42570, BaseLineValue, 1122, 1128, "31 . 9", "", +42564, Kg_per_squareMeter, 1129, 1141, "kg / m ( 2 )", "", +42565, BodyWeight, 1144, 1155, "body weight", "", +42571, BaseLineValue, 1156, 1162, "91 . 5", "", +42566, Kg, 1163, 1165, "kg", "", +42567, Metformin, 1195, 1204, "metformin", "", +42572, NumberPatientsCT, 1224, 1227, "182", "", +42573, Randomized, 1235, 1243, "randomly", "", +42574, AllocationRatio, 1253, 1260, "1  :  1", "", +42530, Dapagliflozin, 1272, 1285, "dapagliflozin", "", +42575, DoseValue, 1286, 1288, "10", "", +42576, mg, 1289, 1291, "mg", "", +42577, Frequency, 1294, 1297, "day", "", +42578, Placebo, 1301, 1308, "placebo", "", +42581, OpenLabel, 1318, 1330, "open - label", "", +42579, Metformin, 1331, 1340, "metformin", "", +42582, Duration, 1347, 1356, "24 - week", "", +42583, DoubleBlind, 1357, 1371, "double - blind", "", +42584, TimePoint, 1464, 1472, "week 102", "", +42590, TimePoint, 1488, 1496, "baseline", "", +42591, HbA1c, 1500, 1505, "HbA1c", "", +42592, BodyWeight, 1508, 1514, "weight", "", +42593, EndPointDescription, 1517, 1536, "waist circumference", "", +42594, EndPointDescription, 1539, 1558, "total body fat mass", "", +42595, MeasurementDevice, 1574, 1610, "dual - energy X - ray absorptiometry", "", +42596, MeasurementDevice, 1613, 1616, "DXA", "", +42602, EndPointDescription, 1621, 1651, "serum markers of bone turnover", "", +42603, EndPointDescription, 1654, 1674, "bone mineral density", "", +42604, EndPointDescription, 1677, 1680, "BMD", "", +42600, MeasurementDevice, 1698, 1701, "DXA", "", +42601, EndPointDescription, 1708, 1722, "adverse events", "", +42605, FinalNumPatientsCT, 1761, 1764, "140", "", +42585, TimePoint, 1814, 1823, "102 weeks", "", +42531, Dapagliflozin, 1826, 1839, "dapagliflozin", "", +42606, HbA1c, 1880, 1885, "HbA1c", "", +42607, Reduction, 1891, 1896, "0 . 3", "", +42611, Percentage, 1897, 1898, "%", "", +42612, BodyWeight, 1901, 1907, "weight", "", +42608, Reduction, 1913, 1919, "4 . 54", "", +42613, Kg, 1920, 1922, "kg", "", +42615, EndPointDescription, 1925, 1944, "waist circumference", "", +42609, Reduction, 1950, 1955, "5 . 0", "", +42617, BioAndMedicalUnit, 1956, 1958, "cm", "", +42616, EndPointDescription, 1963, 1971, "fat mass", "", +42610, Reduction, 1977, 1983, "2 . 80", "", +42614, Kg, 1984, 1986, "kg", "", +42618, ObservedResult, 1987, 2003, "without increase", "", +42619, Hypoglycemia, 2015, 2028, "hypoglycaemia", "", +42621, Placebo, 2045, 2052, "placebo", "", +42646, ObservedResult, 2055, 2076, "no meaningful changes", "", +42625, TimePoint, 2082, 2090, "baseline", "", +42629, EndPointDescription, 2105, 2118, "bone turnover", "", +42630, EndPointDescription, 2122, 2125, "BMD", "", +42586, TimePoint, 2147, 2156, "102 weeks", "", +42648, ObservedResult, 2159, 2206, "One fracture occurred in each treatment group .", "", +42638, EndPointDescription, 2163, 2171, "fracture", "", +42650, ObservedResult, 2207, 2316, "The frequency of urinary tract infection ( UTI ) and genital infection was similar in both treatment groups .", "", +42634, EndPointDescription, 2224, 2247, "urinary tract infection", "", +42636, EndPointDescription, 2250, 2253, "UTI", "", +42641, EndPointDescription, 2260, 2277, "genital infection", "", +42663, ConclusionComment, 2331, 2535, "Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .", "", +42587, Duration, 2336, 2345, "102 weeks", "", +42532, Dapagliflozin, 2348, 2361, "dapagliflozin", "", +42652, BodyWeight, 2403, 2409, "weight", "", +42654, EndPointDescription, 2414, 2422, "fat mass", "", +42655, EndPointDescription, 2454, 2467, "bone turnover", "", +42657, EndPointDescription, 2471, 2474, "BMD", "", +42660, Precondition, 2478, 2533, "patients with T2DM inadequately controlled on metformin", "", +42552, Type2Diabetes, 2492, 2496, "T2DM", "", +42580, Metformin, 2524, 2533, "metformin", "", +42665, PMID, 2604, 2612, "23906445", "", diff --git a/data/dm2 23906445_kwoodley.n-triples b/data/dm2 23906445_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23906445_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23948125_admin.annodb b/data/dm2 23948125_admin.annodb new file mode 100644 index 0000000..13f417f --- /dev/null +++ b/data/dm2 23948125_admin.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 6, "Lancet", "", " \"Lancet\"." +1, PublicationYear, 9, 13, "2013", "", " \"2013\"." +2, Linagliptin, 119, 130, "Linagliptin", "", +25, Title, 119, 310, "Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .", "", " \"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .\"." +10, MinAge, 149, 157, "70 years", "", +11, Type2Diabetes, 172, 187, "type 2 diabetes", "", " ." +112, Precondition, 188, 247, "inadequately controlled with common antidiabetes treatments", "", " \"inadequately controlled with common antidiabetes treatments\"." +22, Randomized, 252, 262, "randomised", "", " ." +23, DoubleBlind, 265, 279, "double - blind", "", " ." +24, Placebo, 282, 289, "placebo", "", +26, Author, 311, 321, "Barnett AH", "", " \"Barnett AH\"." +27, Author, 330, 339, "Huisman H", "", " \"Huisman H\"." +28, Author, 342, 349, "Jones R", "", " \"Jones R\"." +29, Author, 352, 366, "von Eynatten M", "", " \"von Eynatten M\"." +30, Author, 369, 376, "Patel S", "", " \"Patel S\"." +31, Author, 379, 388, "Woerle HJ", "", " \"Woerle HJ\"." +32, UK, 534, 536, "UK", "", " ." +12, Type2Diabetes, 907, 922, "type 2 diabetes", "", +67287, MinAge, 939, 947, "65 years", "", +21, ObjectiveDescription, 1043, 1178, "We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .", "", " \"We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .\"." +3, Linagliptin, 1083, 1094, "linagliptin", "", +125, Precondition, 1139, 1176, "elderly patients with type 2 diabetes", "", +13, Type2Diabetes, 1161, 1176, "type 2 diabetes", "", +33, Randomized, 1197, 1207, "randomised", "", +34, DoubleBlind, 1210, 1224, "double - blind", "", +35, Parallel, 1227, 1243, "parallel - group", "", " ." +36, Multicenter, 1246, 1259, "multinational", "", " ." +67378, Precondition, 1276, 1474, "patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs", "", " \"patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs\"." +19, MinAge, 1290, 1298, "70 years", "", +14, Type2Diabetes, 1313, 1328, "type 2 diabetes", "", +37, HbA1c, 1331, 1355, "glycated haemoglobin A1c", "", +38, HbA1c, 1358, 1363, "HbA1c", "", +39, Percentage, 1375, 1376, "%", "", +40, Metformin, 1397, 1406, "metformin", "", +41, Sulfonylureas, 1409, 1422, "sulfonylureas", "", +67375, Insulin, 1434, 1441, "insulin", "", +43, Randomized, 1482, 1492, "randomised", "", +145, Randomized, 1519, 1532, "randomisation", "", +45, HbA1c, 1601, 1606, "HbA1c", "", +46, Percentage, 1623, 1624, "%", "", +47, Percentage, 1636, 1637, "%", "", +67377, Insulin, 1644, 1651, "insulin", "", +48, AllocationRatio, 1695, 1700, "2 : 1", "", " . ." +49, Frequency, 1710, 1722, "once - daily", "", " \"once - daily\". \"once - daily\"." +50, Oral, 1723, 1727, "oral", "", " ." +4, Linagliptin, 1743, 1754, "linagliptin", "", " ." +51, DoseValue, 1755, 1756, "5", "", " \"5\"." +52, mg, 1757, 1759, "mg", "", " ." +53, Placebo, 1772, 1779, "placebo", "", " ." +54, Duration, 1784, 1792, "24 weeks", "", " \"24 weeks\"." +153, DoubleBlind, 1795, 1837, "Investigators and participants were masked", "", +55, HbA1c, 1910, 1915, "HbA1c", "", +56, TimePoint, 1921, 1929, "baseline", "", +57, TimePoint, 1933, 1940, "week 24", "", +59, NumberPatientsCT, 2028, 2031, "241", "", " \"241\"." +60, Randomized, 2068, 2078, "randomised", "", +61, NumberPatientsArm, 2081, 2084, "162", "", " \"162\"." +63, Linagliptin, 2085, 2096, "linagliptin", "", +62, NumberPatientsArm, 2099, 2101, "79", "", " \"79\"." +65, Placebo, 2102, 2109, "placebo", "", +163, Mean, 2114, 2118, "Mean", "", +162, AvgAge, 2127, 2139, "74 · 9 years", "", " \"74 · 9 years\"." +164, Mean, 2155, 2159, "Mean", "", +69, HbA1c, 2160, 2165, "HbA1c", "", +70, BaseLineValue, 2170, 2175, "7 · 8", "", " \"7 · 8\"." +71, Percentage, 2176, 2177, "%", "", +72, SdDevBL, 2183, 2188, "0 · 8", "", " \"0 · 8\"." +58, TimePoint, 2196, 2203, "week 24", "", " \"week 24\"." +67, Placebo, 2206, 2213, "placebo", "", +171, Mean, 2225, 2229, "mean", "", " . ." +73, HbA1c, 2240, 2245, "HbA1c", "", " ." +5, Linagliptin, 2251, 2262, "linagliptin", "", +74, Reduction, 2269, 2275, "0 · 64", "", " \"0 · 64\"." +75, Percentage, 2276, 2277, "%", "", " ." +76, ConfIntervalChangeValue, 2280, 2308, "95 % CI - 0 · 81 to - 0 · 48", "", " \"95 % CI - 0 · 81 to - 0 · 48\"." +77, PValueChangeValue, 2311, 2323, "p < 0 · 0001", "", " \"p < 0 · 0001\"." +6, Linagliptin, 2391, 2402, "linagliptin", "", +66, Placebo, 2407, 2414, "placebo", "", +78, PercentageAffected, 2424, 2430, "75 · 9", "", " \"75 · 9\". \"75 · 9\"." +79, EndPointDescription, 2464, 2480, "an adverse event", "", " . ." +7, Linagliptin, 2483, 2494, "linagliptin", "", +80, NumberAffected, 2499, 2502, "123", "", " \"123\"." +82, Placebo, 2505, 2512, "placebo", "", +81, NumberAffected, 2517, 2519, "60", "", " \"60\"." +84, EndPointDescription, 2545, 2567, "Serious adverse events", "", " . ." +85, PercentageAffected, 2580, 2585, "8 · 6", "", " \"8 · 6\"." +87, NumberAffected, 2590, 2592, "14", "", " \"14\"." +64, Linagliptin, 2614, 2625, "linagliptin", "", +86, PercentageAffected, 2636, 2641, "6 · 3", "", " \"6 · 3\"." +88, NumberAffected, 2646, 2650, "five", "", " \"five\"." +89, Placebo, 2669, 2676, "placebo", "", +90, ObservedResult, 2685, 2723, "none were deemed related to study drug", "", " \"none were deemed related to study drug\"." +91, Hypoglycemia, 2726, 2739, "Hypoglycaemia", "", " ." +93, PercentageAffected, 2827, 2833, "24 · 1", "", " \"24 · 1\"." +95, NumberAffected, 2838, 2840, "39", "", " \"39\"." +8, Linagliptin, 2850, 2861, "linagliptin", "", +94, PercentageAffected, 2870, 2876, "16 · 5", "", " \"16 · 5\"." +96, NumberAffected, 2881, 2883, "13", "", " \"13\"." +97, Placebo, 2893, 2900, "placebo", "", +98, ConfIntervalDiff, 2929, 2952, "95 % CI 0 · 78 - 3 · 78", "", " \"95 % CI 0 · 78 - 3 · 78\"." +99, PvalueDiff, 2955, 2967, "p = 0 · 2083", "", " \"p = 0 · 2083\"." +101, ConclusionComment, 2989, 3120, "In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .", "", " \"In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .\"." +15, Type2Diabetes, 3014, 3029, "type 2 diabetes", "", +9, Linagliptin, 3030, 3041, "linagliptin", "", +100, Placebo, 3111, 3118, "placebo", "", +102, ConclusionComment, 3121, 3274, "These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .", "", " \"These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .\"." +106321, PharmacySponsored, 3285, 3305, "Boehringer Ingelheim", "", " \"Boehringer Ingelheim\"." +103, PMID, 3417, 3425, "23948125", "", " \"23948125\"." diff --git a/data/dm2 23948125_admin.n-triples b/data/dm2 23948125_admin.n-triples new file mode 100644 index 0000000..f905aa7 --- /dev/null +++ b/data/dm2 23948125_admin.n-triples @@ -0,0 +1,164 @@ +# RDF export of group: Publication + . + "Publication 46459" . + "Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial ." . + "Barnett AH" . + "2013" . + "Lancet" . + "23948125" . + . + "Huisman H" . + "Jones R" . + "von Eynatten M" . + "Patel S" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 46466" . + "We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes ." . + "241" . + "24 weeks" . + . + . + . + . + "In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo ." . + . + . + . + . + . + . + . + . + "These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients ." . + . +# RDF export of group: Population + . + "Population 46482" . + "inadequately controlled with common antidiabetes treatments" . + . + . + "74 · 9 years" . + . + "patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "sea" . + . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "1" . + "162" . + . + . + . + . + . + . + "2" . + "79" . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + "once - daily" . + . + . + "pla" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "lin" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 · 8" . + "0 · 8" . + "0 · 64" . + "p < 0 · 0001" . + "95 % CI - 0 · 81 to - 0 · 48" . + "week 24" . + . + "ae 1" . + . + "123" . + "75 · 9" . + . + "ae 2" . + . + "60" . + "75 · 9" . + . + "sae 1" . + . + "14" . + "8 · 6" . + "none were deemed related to study drug" . + . + "sae 2" . + . + "five" . + "6 · 3" . + . + "hyp 1" . + . + "39" . + "24 · 1" . + . + "hyp 2" . + . + "13" . + "16 · 5" . +# RDF export of group: DiffBetweenGroups + . + "hyp" . + "p = 0 · 2083" . + "95 % CI 0 · 78 - 3 · 78" . + . + . +# RDF export of group: EvidenceQuality + . + "EvidenceQuality 92007" . + "Boehringer Ingelheim" . \ No newline at end of file diff --git a/data/dm2 23948125_akramersunderbrink.annodb b/data/dm2 23948125_akramersunderbrink.annodb new file mode 100644 index 0000000..2c2bc62 --- /dev/null +++ b/data/dm2 23948125_akramersunderbrink.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +44056, Journal, 0, 6, "Lancet", "", +44057, PublicationYear, 9, 13, "2013", "", +44058, Linagliptin, 119, 130, "Linagliptin", "", +44065, Title, 119, 310, "Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .", "", +44059, MinAge, 149, 157, "70 years", "", +44060, Type2Diabetes, 172, 187, "type 2 diabetes", "", +44064, Precondition, 188, 247, "inadequately controlled with common antidiabetes treatments", "", +44061, Randomized, 252, 262, "randomised", "", +44062, DoubleBlind, 265, 279, "double - blind", "", +44063, Placebo, 282, 289, "placebo", "", +44066, Author, 311, 321, "Barnett AH", "", +44067, Author, 330, 339, "Huisman H", "", +44068, Author, 342, 349, "Jones R", "", +44069, Author, 356, 366, "Eynatten M", "", +44070, Author, 369, 376, "Patel S", "", +44071, Author, 379, 388, "Woerle HJ", "", +44072, UK, 534, 536, "UK", "", +44078, ObjectiveDescription, 865, 1042, "A substantial proportion of patients with type 2 diabetes are elderly ( ≥ 65 years ) but this group has been largely excluded from clinical studies of glucose - lowering drugs .", "", +44073, Type2Diabetes, 907, 922, "type 2 diabetes", "", +44076, Precondition, 927, 949, "elderly ( ≥ 65 years )", "", +44079, ObjectiveDescription, 1043, 1178, "We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .", "", +44074, Linagliptin, 1083, 1094, "linagliptin", "", +44077, Precondition, 1139, 1146, "elderly", "", +44075, Type2Diabetes, 1161, 1176, "type 2 diabetes", "", +44080, Randomized, 1197, 1207, "randomised", "", +44081, DoubleBlind, 1210, 1224, "double - blind", "", +44082, Parallel, 1227, 1243, "parallel - group", "", +44083, Multicenter, 1246, 1259, "multinational", "", +44084, MinAge, 1290, 1298, "70 years", "", +44085, Type2Diabetes, 1313, 1328, "type 2 diabetes", "", +44086, HbA1c, 1331, 1355, "glycated haemoglobin A1c", "", +44091, Precondition, 1331, 1384, "glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more", "", +44087, HbA1c, 1358, 1363, "HbA1c", "", +44088, Percentage, 1375, 1376, "%", "", +44092, Precondition, 1387, 1474, "receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs", "", +44093, Metformin, 1397, 1406, "metformin", "", +44094, Sulfonylureas, 1409, 1422, "sulfonylureas", "", +44095, Insulin, 1428, 1441, "basal insulin", "", +44096, Randomized, 1482, 1492, "randomised", "", +44097, Randomized, 1519, 1532, "randomisation", "", +44098, HbA1c, 1601, 1606, "HbA1c", "", +44089, Percentage, 1623, 1624, "%", "", +44090, Percentage, 1636, 1637, "%", "", +44099, Frequency, 1710, 1722, "once - daily", "", +44100, Linagliptin, 1743, 1754, "linagliptin", "", +44102, DoseValue, 1755, 1759, "5 mg", "", +44103, mg, 1757, 1759, "mg", "", +44104, Placebo, 1772, 1779, "placebo", "", +44105, Duration, 1784, 1792, "24 weeks", "", +44106, DoubleBlind, 1795, 1872, "Investigators and participants were masked to assignment throughout the study", "", +44107, HbA1c, 1910, 1915, "HbA1c", "", +44108, TimePoint, 1921, 1929, "baseline", "", +44110, TimePoint, 1933, 1940, "week 24", "", +44111, NumberPatientsCT, 2028, 2031, "241", "", +44112, NumberPatientsArm, 2081, 2084, "162", "", +44114, Linagliptin, 2085, 2096, "linagliptin", "", +44113, NumberPatientsArm, 2099, 2101, "79", "", +44115, Placebo, 2102, 2109, "placebo", "", +44117, Mean, 2114, 2118, "Mean", "", +44116, AvgAge, 2127, 2139, "74 · 9 years", "", +44118, Mean, 2155, 2159, "Mean", "", +44119, HbA1c, 2160, 2165, "HbA1c", "", +44120, BaseLineValue, 2170, 2175, "7 · 8", "", +44121, Percentage, 2176, 2177, "%", "", +44122, SdDevBL, 2183, 2188, "0 · 8", "", +44123, TimePoint, 2196, 2203, "week 24", "", +44124, Placebo, 2206, 2213, "placebo", "", +44125, Mean, 2225, 2229, "mean", "", +44126, HbA1c, 2240, 2245, "HbA1c", "", +44127, Linagliptin, 2251, 2262, "linagliptin", "", +44128, ChangeValue, 2267, 2275, "- 0 · 64", "", +44129, Percentage, 2276, 2277, "%", "", +44131, ConfIntervalChangeValue, 2280, 2308, "95 % CI - 0 · 81 to - 0 · 48", "", +44130, Percentage, 2283, 2284, "%", "", +44132, PValueChangeValue, 2311, 2323, "p < 0 · 0001", "", +44133, Linagliptin, 2391, 2402, "linagliptin", "", +44134, Placebo, 2407, 2414, "placebo", "", +44136, PercentageAffected, 2424, 2430, "75 · 9", "", +44137, Percentage, 2431, 2432, "%", "", +44135, EndPointDescription, 2467, 2480, "adverse event", "", +44138, Linagliptin, 2483, 2494, "linagliptin", "", +44140, NumberAffected, 2499, 2502, "123", "", +44139, Placebo, 2505, 2512, "placebo", "", +44141, NumberAffected, 2517, 2519, "60", "", +44142, EndPointDescription, 2545, 2567, "Serious adverse events", "", +44143, PercentageAffected, 2580, 2585, "8 · 6", "", +44147, Percentage, 2586, 2587, "%", "", +44145, NumberAffected, 2590, 2592, "14", "", +44149, Linagliptin, 2614, 2625, "linagliptin", "", +44144, PercentageAffected, 2636, 2641, "6 · 3", "", +44148, Percentage, 2642, 2643, "%", "", +44146, NumberAffected, 2646, 2650, "five", "", +44150, Placebo, 2669, 2676, "placebo", "", +44151, Hypoglycemia, 2726, 2739, "Hypoglycaemia", "", +44152, PercentageAffected, 2827, 2833, "24 · 1", "", +44156, Percentage, 2834, 2835, "%", "", +44154, NumberAffected, 2838, 2840, "39", "", +44159, Linagliptin, 2850, 2861, "linagliptin", "", +44153, PercentageAffected, 2870, 2876, "16 · 5", "", +44157, Percentage, 2877, 2878, "%", "", +44155, NumberAffected, 2881, 2883, "13", "", +44158, Placebo, 2893, 2900, "placebo", "", +44160, Percentage, 2932, 2933, "%", "", +44164, ConclusionComment, 2989, 3120, "In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .", "", +44166, Precondition, 2992, 2999, "elderly", "", +44161, Type2Diabetes, 3014, 3029, "type 2 diabetes", "", +44162, Linagliptin, 3030, 3041, "linagliptin", "", +44163, Placebo, 3111, 3118, "placebo", "", +44165, ConclusionComment, 3121, 3274, "These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .", "", +44167, PMID, 3417, 3425, "23948125", "", diff --git a/data/dm2 23948125_akramersunderbrink.n-triples b/data/dm2 23948125_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23948125_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23948125_export.csv b/data/dm2 23948125_export.csv new file mode 100644 index 0000000..74e39bf --- /dev/null +++ b/data/dm2 23948125_export.csv @@ -0,0 +1,745 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +296, 1, 1, 1, 0, 6, 0, 6, "Lancet" +296, 1, 2, 2, 7, 8, 7, 8, "." +296, 2, 1, 3, 0, 4, 9, 13, "2013" +296, 2, 2, 4, 5, 8, 14, 17, "Oct" +296, 2, 3, 5, 9, 11, 18, 20, "26" +296, 2, 4, 6, 12, 13, 21, 22, ";" +296, 2, 5, 7, 14, 17, 23, 26, "382" +296, 2, 6, 8, 18, 19, 27, 28, "(" +296, 2, 7, 9, 20, 24, 29, 33, "9902" +296, 2, 8, 10, 25, 26, 34, 35, ")" +296, 2, 9, 11, 27, 28, 36, 37, ":" +296, 2, 10, 12, 29, 33, 38, 42, "1413" +296, 2, 11, 13, 34, 35, 43, 44, "-" +296, 2, 12, 14, 36, 38, 45, 47, "23" +296, 2, 13, 15, 39, 40, 48, 49, "." +296, 2, 14, 16, 41, 44, 50, 53, "doi" +296, 2, 15, 17, 45, 46, 54, 55, ":" +296, 2, 16, 18, 47, 49, 56, 58, "10" +296, 2, 17, 19, 50, 51, 59, 60, "." +296, 2, 18, 20, 52, 56, 61, 65, "1016" +296, 2, 19, 21, 57, 58, 66, 67, "/" +296, 2, 20, 22, 59, 64, 68, 73, "S0140" +296, 2, 21, 23, 65, 66, 74, 75, "-" +296, 2, 22, 24, 67, 71, 76, 80, "6736" +296, 2, 23, 25, 72, 73, 81, 82, "(" +296, 2, 24, 26, 74, 76, 83, 85, "13" +296, 2, 25, 27, 77, 78, 86, 87, ")" +296, 2, 26, 28, 79, 84, 88, 93, "61500" +296, 2, 27, 29, 85, 86, 94, 95, "-" +296, 2, 28, 30, 87, 88, 96, 97, "7" +296, 2, 29, 31, 89, 90, 98, 99, "." +296, 3, 1, 32, 0, 4, 100, 104, "Epub" +296, 3, 2, 33, 5, 9, 105, 109, "2013" +296, 3, 3, 34, 10, 13, 110, 113, "Aug" +296, 3, 4, 35, 14, 16, 114, 116, "13" +296, 3, 5, 36, 17, 18, 117, 118, "." +296, 4, 1, 37, 0, 11, 119, 130, "Linagliptin" +296, 4, 2, 38, 12, 15, 131, 134, "for" +296, 4, 3, 39, 16, 24, 135, 143, "patients" +296, 4, 4, 40, 25, 29, 144, 148, "aged" +296, 4, 5, 41, 30, 32, 149, 151, "70" +296, 4, 6, 42, 33, 38, 152, 157, "years" +296, 4, 7, 43, 39, 41, 158, 160, "or" +296, 4, 8, 44, 42, 47, 161, 166, "older" +296, 4, 9, 45, 48, 52, 167, 171, "with" +296, 4, 10, 46, 53, 57, 172, 176, "type" +296, 4, 11, 47, 58, 59, 177, 178, "2" +296, 4, 12, 48, 60, 68, 179, 187, "diabetes" +296, 4, 13, 49, 69, 81, 188, 200, "inadequately" +296, 4, 14, 50, 82, 92, 201, 211, "controlled" +296, 4, 15, 51, 93, 97, 212, 216, "with" +296, 4, 16, 52, 98, 104, 217, 223, "common" +296, 4, 17, 53, 105, 117, 224, 236, "antidiabetes" +296, 4, 18, 54, 118, 128, 237, 247, "treatments" +296, 4, 19, 55, 129, 130, 248, 249, ":" +296, 4, 20, 56, 131, 132, 250, 251, "a" +296, 4, 21, 57, 133, 143, 252, 262, "randomised" +296, 4, 22, 58, 144, 145, 263, 264, "," +296, 4, 23, 59, 146, 152, 265, 271, "double" +296, 4, 24, 60, 153, 154, 272, 273, "-" +296, 4, 25, 61, 155, 160, 274, 279, "blind" +296, 4, 26, 62, 161, 162, 280, 281, "," +296, 4, 27, 63, 163, 170, 282, 289, "placebo" +296, 4, 28, 64, 171, 172, 290, 291, "-" +296, 4, 29, 65, 173, 183, 292, 302, "controlled" +296, 4, 30, 66, 184, 189, 303, 308, "trial" +296, 4, 31, 67, 190, 191, 309, 310, "." +296, 5, 1, 68, 0, 7, 311, 318, "Barnett" +296, 5, 2, 69, 8, 10, 319, 321, "AH" +296, 5, 3, 70, 11, 12, 322, 323, "(" +296, 5, 4, 71, 13, 14, 324, 325, "1" +296, 5, 5, 72, 15, 16, 326, 327, ")" +296, 5, 6, 73, 17, 18, 328, 329, "," +296, 5, 7, 74, 19, 26, 330, 337, "Huisman" +296, 5, 8, 75, 27, 28, 338, 339, "H" +296, 5, 9, 76, 29, 30, 340, 341, "," +296, 5, 10, 77, 31, 36, 342, 347, "Jones" +296, 5, 11, 78, 37, 38, 348, 349, "R" +296, 5, 12, 79, 39, 40, 350, 351, "," +296, 5, 13, 80, 41, 44, 352, 355, "von" +296, 5, 14, 81, 45, 53, 356, 364, "Eynatten" +296, 5, 15, 82, 54, 55, 365, 366, "M" +296, 5, 16, 83, 56, 57, 367, 368, "," +296, 5, 17, 84, 58, 63, 369, 374, "Patel" +296, 5, 18, 85, 64, 65, 375, 376, "S" +296, 5, 19, 86, 66, 67, 377, 378, "," +296, 5, 20, 87, 68, 74, 379, 385, "Woerle" +296, 5, 21, 88, 75, 77, 386, 388, "HJ" +296, 5, 22, 89, 78, 79, 389, 390, "." +296, 6, 1, 90, 0, 6, 391, 397, "Author" +296, 6, 2, 91, 7, 18, 398, 409, "information" +296, 6, 3, 92, 19, 20, 410, 411, ":" +296, 6, 4, 93, 21, 22, 412, 413, "(" +296, 6, 5, 94, 23, 24, 414, 415, "1" +296, 6, 6, 95, 25, 26, 416, 417, ")" +296, 6, 7, 96, 27, 35, 418, 426, "Diabetes" +296, 6, 8, 97, 36, 42, 427, 433, "Centre" +296, 6, 9, 98, 43, 44, 434, 435, "," +296, 6, 10, 99, 45, 50, 436, 441, "Heart" +296, 6, 11, 100, 51, 53, 442, 444, "of" +296, 6, 12, 101, 54, 61, 445, 452, "England" +296, 6, 13, 102, 62, 65, 453, 456, "NHS" +296, 6, 14, 103, 66, 76, 457, 467, "Foundation" +296, 6, 15, 104, 77, 82, 468, 473, "Trust" +296, 6, 16, 105, 83, 84, 474, 475, "," +296, 6, 17, 106, 85, 95, 476, 486, "Birmingham" +296, 6, 18, 107, 96, 97, 487, 488, "," +296, 6, 19, 108, 98, 100, 489, 491, "UK" +296, 6, 20, 109, 101, 102, 492, 493, ";" +296, 6, 21, 110, 103, 113, 494, 504, "University" +296, 6, 22, 111, 114, 116, 505, 507, "of" +296, 6, 23, 112, 117, 127, 508, 518, "Birmingham" +296, 6, 24, 113, 128, 129, 519, 520, "," +296, 6, 25, 114, 130, 140, 521, 531, "Birmingham" +296, 6, 26, 115, 141, 142, 532, 533, "," +296, 6, 27, 116, 143, 145, 534, 536, "UK" +296, 6, 28, 117, 146, 147, 537, 538, "." +296, 7, 1, 118, 0, 10, 539, 549, "Electronic" +296, 7, 2, 119, 11, 18, 550, 557, "address" +296, 7, 3, 120, 19, 20, 558, 559, ":" +296, 7, 4, 121, 21, 28, 560, 567, "anthony" +296, 7, 5, 122, 29, 30, 568, 569, "." +296, 7, 6, 123, 31, 38, 570, 577, "barnett" +296, 7, 7, 124, 39, 40, 578, 579, "@" +296, 7, 8, 125, 41, 55, 580, 594, "heartofengland" +296, 7, 9, 126, 56, 57, 595, 596, "." +296, 7, 10, 127, 58, 61, 597, 600, "nhs" +296, 7, 11, 128, 62, 63, 601, 602, "." +296, 7, 12, 129, 64, 66, 603, 605, "uk" +296, 7, 13, 130, 67, 68, 606, 607, "." +296, 8, 1, 131, 0, 7, 608, 615, "Comment" +296, 8, 2, 132, 8, 10, 616, 618, "in" +296, 8, 3, 133, 11, 17, 619, 625, "Lancet" +296, 8, 4, 134, 18, 19, 626, 627, "." +296, 9, 1, 135, 0, 4, 628, 632, "2013" +296, 9, 2, 136, 5, 8, 633, 636, "Oct" +296, 9, 3, 137, 9, 11, 637, 639, "26" +296, 9, 4, 138, 12, 13, 640, 641, ";" +296, 9, 5, 139, 14, 17, 642, 645, "382" +296, 9, 6, 140, 18, 19, 646, 647, "(" +296, 9, 7, 141, 20, 24, 648, 652, "9902" +296, 9, 8, 142, 25, 26, 653, 654, ")" +296, 9, 9, 143, 27, 28, 655, 656, ":" +296, 9, 10, 144, 29, 33, 657, 661, "1386" +296, 9, 11, 145, 34, 35, 662, 663, "-" +296, 9, 12, 146, 36, 37, 664, 665, "7" +296, 9, 13, 147, 38, 39, 666, 667, "." +296, 10, 1, 148, 0, 6, 668, 674, "Lancet" +296, 10, 2, 149, 7, 8, 675, 676, "." +296, 11, 1, 150, 0, 4, 677, 681, "2014" +296, 11, 2, 151, 5, 8, 682, 685, "Jan" +296, 11, 3, 152, 9, 11, 686, 688, "25" +296, 11, 4, 153, 12, 13, 689, 690, ";" +296, 11, 5, 154, 14, 17, 691, 694, "383" +296, 11, 6, 155, 18, 19, 695, 696, "(" +296, 11, 7, 156, 20, 24, 697, 701, "9914" +296, 11, 8, 157, 25, 26, 702, 703, ")" +296, 11, 9, 158, 27, 28, 704, 705, ":" +296, 11, 10, 159, 29, 32, 706, 709, "306" +296, 11, 11, 160, 33, 34, 710, 711, "." +296, 12, 1, 161, 0, 6, 712, 718, "Lancet" +296, 12, 2, 162, 7, 8, 719, 720, "." +296, 13, 1, 163, 0, 4, 721, 725, "2014" +296, 13, 2, 164, 5, 8, 726, 729, "Jan" +296, 13, 3, 165, 9, 11, 730, 732, "25" +296, 13, 4, 166, 12, 13, 733, 734, ";" +296, 13, 5, 167, 14, 17, 735, 738, "383" +296, 13, 6, 168, 18, 19, 739, 740, "(" +296, 13, 7, 169, 20, 24, 741, 745, "9914" +296, 13, 8, 170, 25, 26, 746, 747, ")" +296, 13, 9, 171, 27, 28, 748, 749, ":" +296, 13, 10, 172, 29, 32, 750, 753, "306" +296, 13, 11, 173, 33, 34, 754, 755, "-" +296, 13, 12, 174, 35, 36, 756, 757, "7" +296, 13, 13, 175, 37, 38, 758, 759, "." +296, 14, 1, 176, 0, 6, 760, 766, "Lancet" +296, 14, 2, 177, 7, 8, 767, 768, "." +296, 15, 1, 178, 0, 4, 769, 773, "2014" +296, 15, 2, 179, 5, 8, 774, 777, "Jan" +296, 15, 3, 180, 9, 11, 778, 780, "25" +296, 15, 4, 181, 12, 13, 781, 782, ";" +296, 15, 5, 182, 14, 17, 783, 786, "383" +296, 15, 6, 183, 18, 19, 787, 788, "(" +296, 15, 7, 184, 20, 24, 789, 793, "9914" +296, 15, 8, 185, 25, 26, 794, 795, ")" +296, 15, 9, 186, 27, 28, 796, 797, ":" +296, 15, 10, 187, 29, 32, 798, 801, "307" +296, 15, 11, 188, 33, 34, 802, 803, "." +296, 16, 1, 189, 0, 6, 804, 810, "Lancet" +296, 16, 2, 190, 7, 8, 811, 812, "." +296, 17, 1, 191, 0, 4, 813, 817, "2014" +296, 17, 2, 192, 5, 8, 818, 821, "Jan" +296, 17, 3, 193, 9, 11, 822, 824, "25" +296, 17, 4, 194, 12, 13, 825, 826, ";" +296, 17, 5, 195, 14, 17, 827, 830, "383" +296, 17, 6, 196, 18, 19, 831, 832, "(" +296, 17, 7, 197, 20, 24, 833, 837, "9914" +296, 17, 8, 198, 25, 26, 838, 839, ")" +296, 17, 9, 199, 27, 28, 840, 841, ":" +296, 17, 10, 200, 29, 32, 842, 845, "307" +296, 17, 11, 201, 33, 34, 846, 847, "-" +296, 17, 12, 202, 35, 36, 848, 849, "8" +296, 17, 13, 203, 37, 38, 850, 851, "." +296, 18, 1, 204, 0, 10, 852, 862, "BACKGROUND" +296, 18, 2, 205, 11, 12, 863, 864, ":" +296, 18, 3, 206, 13, 14, 865, 866, "A" +296, 18, 4, 207, 15, 26, 867, 878, "substantial" +296, 18, 5, 208, 27, 37, 879, 889, "proportion" +296, 18, 6, 209, 38, 40, 890, 892, "of" +296, 18, 7, 210, 41, 49, 893, 901, "patients" +296, 18, 8, 211, 50, 54, 902, 906, "with" +296, 18, 9, 212, 55, 59, 907, 911, "type" +296, 18, 10, 213, 60, 61, 912, 913, "2" +296, 18, 11, 214, 62, 70, 914, 922, "diabetes" +296, 18, 12, 215, 71, 74, 923, 926, "are" +296, 18, 13, 216, 75, 82, 927, 934, "elderly" +296, 18, 14, 217, 83, 84, 935, 936, "(" +296, 18, 15, 218, 85, 86, 937, 938, "≥" +296, 18, 16, 219, 87, 89, 939, 941, "65" +296, 18, 17, 220, 90, 95, 942, 947, "years" +296, 18, 18, 221, 96, 97, 948, 949, ")" +296, 18, 19, 222, 98, 101, 950, 953, "but" +296, 18, 20, 223, 102, 106, 954, 958, "this" +296, 18, 21, 224, 107, 112, 959, 964, "group" +296, 18, 22, 225, 113, 116, 965, 968, "has" +296, 18, 23, 226, 117, 121, 969, 973, "been" +296, 18, 24, 227, 122, 129, 974, 981, "largely" +296, 18, 25, 228, 130, 138, 982, 990, "excluded" +296, 18, 26, 229, 139, 143, 991, 995, "from" +296, 18, 27, 230, 144, 152, 996, 1004, "clinical" +296, 18, 28, 231, 153, 160, 1005, 1012, "studies" +296, 18, 29, 232, 161, 163, 1013, 1015, "of" +296, 18, 30, 233, 164, 171, 1016, 1023, "glucose" +296, 18, 31, 234, 172, 173, 1024, 1025, "-" +296, 18, 32, 235, 174, 182, 1026, 1034, "lowering" +296, 18, 33, 236, 183, 188, 1035, 1040, "drugs" +296, 18, 34, 237, 189, 190, 1041, 1042, "." +296, 19, 1, 238, 0, 2, 1043, 1045, "We" +296, 19, 2, 239, 3, 8, 1046, 1051, "aimed" +296, 19, 3, 240, 9, 11, 1052, 1054, "to" +296, 19, 4, 241, 12, 18, 1055, 1061, "assess" +296, 19, 5, 242, 19, 22, 1062, 1065, "the" +296, 19, 6, 243, 23, 36, 1066, 1079, "effectiveness" +296, 19, 7, 244, 37, 39, 1080, 1082, "of" +296, 19, 8, 245, 40, 51, 1083, 1094, "linagliptin" +296, 19, 9, 246, 52, 53, 1095, 1096, "," +296, 19, 10, 247, 54, 55, 1097, 1098, "a" +296, 19, 11, 248, 56, 66, 1099, 1109, "dipeptidyl" +296, 19, 12, 249, 67, 76, 1110, 1119, "peptidase" +296, 19, 13, 250, 77, 78, 1120, 1121, "-" +296, 19, 14, 251, 79, 80, 1122, 1123, "4" +296, 19, 15, 252, 81, 90, 1124, 1133, "inhibitor" +296, 19, 16, 253, 91, 92, 1134, 1135, "," +296, 19, 17, 254, 93, 95, 1136, 1138, "in" +296, 19, 18, 255, 96, 103, 1139, 1146, "elderly" +296, 19, 19, 256, 104, 112, 1147, 1155, "patients" +296, 19, 20, 257, 113, 117, 1156, 1160, "with" +296, 19, 21, 258, 118, 122, 1161, 1165, "type" +296, 19, 22, 259, 123, 124, 1166, 1167, "2" +296, 19, 23, 260, 125, 133, 1168, 1176, "diabetes" +296, 19, 24, 261, 134, 135, 1177, 1178, "." +296, 20, 1, 262, 0, 7, 1179, 1186, "METHODS" +296, 20, 2, 263, 8, 9, 1187, 1188, ":" +296, 20, 3, 264, 10, 12, 1189, 1191, "In" +296, 20, 4, 265, 13, 17, 1192, 1196, "this" +296, 20, 5, 266, 18, 28, 1197, 1207, "randomised" +296, 20, 6, 267, 29, 30, 1208, 1209, "," +296, 20, 7, 268, 31, 37, 1210, 1216, "double" +296, 20, 8, 269, 38, 39, 1217, 1218, "-" +296, 20, 9, 270, 40, 45, 1219, 1224, "blind" +296, 20, 10, 271, 46, 47, 1225, 1226, "," +296, 20, 11, 272, 48, 56, 1227, 1235, "parallel" +296, 20, 12, 273, 57, 58, 1236, 1237, "-" +296, 20, 13, 274, 59, 64, 1238, 1243, "group" +296, 20, 14, 275, 65, 66, 1244, 1245, "," +296, 20, 15, 276, 67, 80, 1246, 1259, "multinational" +296, 20, 16, 277, 81, 86, 1260, 1265, "phase" +296, 20, 17, 278, 87, 88, 1266, 1267, "3" +296, 20, 18, 279, 89, 94, 1268, 1273, "study" +296, 20, 19, 280, 95, 96, 1274, 1275, "," +296, 20, 20, 281, 97, 105, 1276, 1284, "patients" +296, 20, 21, 282, 106, 110, 1285, 1289, "aged" +296, 20, 22, 283, 111, 113, 1290, 1292, "70" +296, 20, 23, 284, 114, 119, 1293, 1298, "years" +296, 20, 24, 285, 120, 122, 1299, 1301, "or" +296, 20, 25, 286, 123, 128, 1302, 1307, "older" +296, 20, 26, 287, 129, 133, 1308, 1312, "with" +296, 20, 27, 288, 134, 138, 1313, 1317, "type" +296, 20, 28, 289, 139, 140, 1318, 1319, "2" +296, 20, 29, 290, 141, 149, 1320, 1328, "diabetes" +296, 20, 30, 291, 150, 151, 1329, 1330, "," +296, 20, 31, 292, 152, 160, 1331, 1339, "glycated" +296, 20, 32, 293, 161, 172, 1340, 1351, "haemoglobin" +296, 20, 33, 294, 173, 176, 1352, 1355, "A1c" +296, 20, 34, 295, 177, 178, 1356, 1357, "(" +296, 20, 35, 296, 179, 184, 1358, 1363, "HbA1c" +296, 20, 36, 297, 185, 186, 1364, 1365, ")" +296, 20, 37, 298, 187, 189, 1366, 1368, "of" +296, 20, 38, 299, 190, 191, 1369, 1370, "7" +296, 20, 39, 300, 192, 193, 1371, 1372, "·" +296, 20, 40, 301, 194, 195, 1373, 1374, "0" +296, 20, 41, 302, 196, 197, 1375, 1376, "%" +296, 20, 42, 303, 198, 200, 1377, 1379, "or" +296, 20, 43, 304, 201, 205, 1380, 1384, "more" +296, 20, 44, 305, 206, 207, 1385, 1386, "," +296, 20, 45, 306, 208, 217, 1387, 1396, "receiving" +296, 20, 46, 307, 218, 227, 1397, 1406, "metformin" +296, 20, 47, 308, 228, 229, 1407, 1408, "," +296, 20, 48, 309, 230, 243, 1409, 1422, "sulfonylureas" +296, 20, 49, 310, 244, 245, 1423, 1424, "," +296, 20, 50, 311, 246, 248, 1425, 1427, "or" +296, 20, 51, 312, 249, 254, 1428, 1433, "basal" +296, 20, 52, 313, 255, 262, 1434, 1441, "insulin" +296, 20, 53, 314, 263, 264, 1442, 1443, "," +296, 20, 54, 315, 265, 267, 1444, 1446, "or" +296, 20, 55, 316, 268, 280, 1447, 1459, "combinations" +296, 20, 56, 317, 281, 283, 1460, 1462, "of" +296, 20, 57, 318, 284, 289, 1463, 1468, "these" +296, 20, 58, 319, 290, 295, 1469, 1474, "drugs" +296, 20, 59, 320, 296, 297, 1475, 1476, "," +296, 20, 60, 321, 298, 302, 1477, 1481, "were" +296, 20, 61, 322, 303, 313, 1482, 1492, "randomised" +296, 20, 62, 323, 314, 315, 1493, 1494, "(" +296, 20, 63, 324, 316, 318, 1495, 1497, "by" +296, 20, 64, 325, 319, 327, 1498, 1506, "computer" +296, 20, 65, 326, 328, 329, 1507, 1508, "-" +296, 20, 66, 327, 330, 339, 1509, 1518, "generated" +296, 20, 67, 328, 340, 353, 1519, 1532, "randomisation" +296, 20, 68, 329, 354, 362, 1533, 1541, "sequence" +296, 20, 69, 330, 363, 364, 1542, 1543, "," +296, 20, 70, 331, 365, 374, 1544, 1553, "concealed" +296, 20, 71, 332, 375, 379, 1554, 1558, "with" +296, 20, 72, 333, 380, 381, 1559, 1560, "a" +296, 20, 73, 334, 382, 387, 1561, 1566, "voice" +296, 20, 74, 335, 388, 389, 1567, 1568, "-" +296, 20, 75, 336, 390, 398, 1569, 1577, "response" +296, 20, 76, 337, 399, 405, 1578, 1584, "system" +296, 20, 77, 338, 406, 407, 1585, 1586, "," +296, 20, 78, 339, 408, 418, 1587, 1597, "stratified" +296, 20, 79, 340, 419, 421, 1598, 1600, "by" +296, 20, 80, 341, 422, 427, 1601, 1606, "HbA1c" +296, 20, 81, 342, 428, 433, 1607, 1612, "level" +296, 20, 82, 343, 434, 435, 1613, 1614, "[" +296, 20, 83, 344, 436, 437, 1615, 1616, "<" +296, 20, 84, 345, 438, 439, 1617, 1618, "8" +296, 20, 85, 346, 440, 441, 1619, 1620, "·" +296, 20, 86, 347, 442, 443, 1621, 1622, "5" +296, 20, 87, 348, 444, 445, 1623, 1624, "%" +296, 20, 88, 349, 446, 448, 1625, 1627, "vs" +296, 20, 89, 350, 449, 450, 1628, 1629, "≥" +296, 20, 90, 351, 451, 452, 1630, 1631, "8" +296, 20, 91, 352, 453, 454, 1632, 1633, "·" +296, 20, 92, 353, 455, 456, 1634, 1635, "5" +296, 20, 93, 354, 457, 458, 1636, 1637, "%" +296, 20, 94, 355, 459, 460, 1638, 1639, "]" +296, 20, 95, 356, 461, 464, 1640, 1643, "and" +296, 20, 96, 357, 465, 472, 1644, 1651, "insulin" +296, 20, 97, 358, 473, 476, 1652, 1655, "use" +296, 20, 98, 359, 477, 478, 1656, 1657, "[" +296, 20, 99, 360, 479, 482, 1658, 1661, "yes" +296, 20, 100, 361, 483, 485, 1662, 1664, "vs" +296, 20, 101, 362, 486, 488, 1665, 1667, "no" +296, 20, 102, 363, 489, 490, 1668, 1669, "]" +296, 20, 103, 364, 491, 492, 1670, 1671, "," +296, 20, 104, 365, 493, 498, 1672, 1677, "block" +296, 20, 105, 366, 499, 503, 1678, 1682, "size" +296, 20, 106, 367, 504, 508, 1683, 1687, "four" +296, 20, 107, 368, 509, 510, 1688, 1689, ")" +296, 20, 108, 369, 511, 513, 1690, 1692, "in" +296, 20, 109, 370, 514, 515, 1693, 1694, "a" +296, 20, 110, 371, 516, 517, 1695, 1696, "2" +296, 20, 111, 372, 518, 519, 1697, 1698, ":" +296, 20, 112, 373, 520, 521, 1699, 1700, "1" +296, 20, 113, 374, 522, 527, 1701, 1706, "ratio" +296, 20, 114, 375, 528, 530, 1707, 1709, "to" +296, 20, 115, 376, 531, 535, 1710, 1714, "once" +296, 20, 116, 377, 536, 537, 1715, 1716, "-" +296, 20, 117, 378, 538, 543, 1717, 1722, "daily" +296, 20, 118, 379, 544, 548, 1723, 1727, "oral" +296, 20, 119, 380, 549, 558, 1728, 1737, "treatment" +296, 20, 120, 381, 559, 563, 1738, 1742, "with" +296, 20, 121, 382, 564, 575, 1743, 1754, "linagliptin" +296, 20, 122, 383, 576, 577, 1755, 1756, "5" +296, 20, 123, 384, 578, 580, 1757, 1759, "mg" +296, 20, 124, 385, 581, 583, 1760, 1762, "or" +296, 20, 125, 386, 584, 592, 1763, 1771, "matching" +296, 20, 126, 387, 593, 600, 1772, 1779, "placebo" +296, 20, 127, 388, 601, 604, 1780, 1783, "for" +296, 20, 128, 389, 605, 607, 1784, 1786, "24" +296, 20, 129, 390, 608, 613, 1787, 1792, "weeks" +296, 20, 130, 391, 614, 615, 1793, 1794, "." +296, 21, 1, 392, 0, 13, 1795, 1808, "Investigators" +296, 21, 2, 393, 14, 17, 1809, 1812, "and" +296, 21, 3, 394, 18, 30, 1813, 1825, "participants" +296, 21, 4, 395, 31, 35, 1826, 1830, "were" +296, 21, 5, 396, 36, 42, 1831, 1837, "masked" +296, 21, 6, 397, 43, 45, 1838, 1840, "to" +296, 21, 7, 398, 46, 56, 1841, 1851, "assignment" +296, 21, 8, 399, 57, 67, 1852, 1862, "throughout" +296, 21, 9, 400, 68, 71, 1863, 1866, "the" +296, 21, 10, 401, 72, 77, 1867, 1872, "study" +296, 21, 11, 402, 78, 79, 1873, 1874, "." +296, 22, 1, 403, 0, 3, 1875, 1878, "The" +296, 22, 2, 404, 4, 11, 1879, 1886, "primary" +296, 22, 3, 405, 12, 20, 1887, 1895, "endpoint" +296, 22, 4, 406, 21, 24, 1896, 1899, "was" +296, 22, 5, 407, 25, 31, 1900, 1906, "change" +296, 22, 6, 408, 32, 34, 1907, 1909, "in" +296, 22, 7, 409, 35, 40, 1910, 1915, "HbA1c" +296, 22, 8, 410, 41, 45, 1916, 1920, "from" +296, 22, 9, 411, 46, 54, 1921, 1929, "baseline" +296, 22, 10, 412, 55, 57, 1930, 1932, "to" +296, 22, 11, 413, 58, 62, 1933, 1937, "week" +296, 22, 12, 414, 63, 65, 1938, 1940, "24" +296, 22, 13, 415, 66, 67, 1941, 1942, "." +296, 23, 1, 416, 0, 4, 1943, 1947, "This" +296, 23, 2, 417, 5, 10, 1948, 1953, "trial" +296, 23, 3, 418, 11, 13, 1954, 1956, "is" +296, 23, 4, 419, 14, 24, 1957, 1967, "registered" +296, 23, 5, 420, 25, 29, 1968, 1972, "with" +296, 23, 6, 421, 30, 44, 1973, 1987, "ClinicalTrials" +296, 23, 7, 422, 45, 46, 1988, 1989, "." +296, 23, 8, 423, 47, 50, 1990, 1993, "gov" +296, 23, 9, 424, 51, 52, 1994, 1995, "," +296, 23, 10, 425, 53, 59, 1996, 2002, "number" +296, 23, 11, 426, 60, 71, 2003, 2014, "NCT01084005" +296, 23, 12, 427, 72, 73, 2015, 2016, "." +296, 24, 1, 428, 0, 8, 2017, 2025, "FINDINGS" +296, 24, 2, 429, 9, 10, 2026, 2027, ":" +296, 24, 3, 430, 11, 14, 2028, 2031, "241" +296, 24, 4, 431, 15, 24, 2032, 2041, "community" +296, 24, 5, 432, 25, 26, 2042, 2043, "-" +296, 24, 6, 433, 27, 33, 2044, 2050, "living" +296, 24, 7, 434, 34, 45, 2051, 2062, "outpatients" +296, 24, 8, 435, 46, 50, 2063, 2067, "were" +296, 24, 9, 436, 51, 61, 2068, 2078, "randomised" +296, 24, 10, 437, 62, 63, 2079, 2080, "(" +296, 24, 11, 438, 64, 67, 2081, 2084, "162" +296, 24, 12, 439, 68, 79, 2085, 2096, "linagliptin" +296, 24, 13, 440, 80, 81, 2097, 2098, "," +296, 24, 14, 441, 82, 84, 2099, 2101, "79" +296, 24, 15, 442, 85, 92, 2102, 2109, "placebo" +296, 24, 16, 443, 93, 94, 2110, 2111, ")" +296, 24, 17, 444, 95, 96, 2112, 2113, "." +296, 25, 1, 445, 0, 4, 2114, 2118, "Mean" +296, 25, 2, 446, 5, 8, 2119, 2122, "age" +296, 25, 3, 447, 9, 12, 2123, 2126, "was" +296, 25, 4, 448, 13, 15, 2127, 2129, "74" +296, 25, 5, 449, 16, 17, 2130, 2131, "·" +296, 25, 6, 450, 18, 19, 2132, 2133, "9" +296, 25, 7, 451, 20, 25, 2134, 2139, "years" +296, 25, 8, 452, 26, 27, 2140, 2141, "(" +296, 25, 9, 453, 28, 30, 2142, 2144, "SD" +296, 25, 10, 454, 31, 32, 2145, 2146, "4" +296, 25, 11, 455, 33, 34, 2147, 2148, "·" +296, 25, 12, 456, 35, 36, 2149, 2150, "3" +296, 25, 13, 457, 37, 38, 2151, 2152, ")" +296, 25, 14, 458, 39, 40, 2153, 2154, "." +296, 26, 1, 459, 0, 4, 2155, 2159, "Mean" +296, 26, 2, 460, 5, 10, 2160, 2165, "HbA1c" +296, 26, 3, 461, 11, 14, 2166, 2169, "was" +296, 26, 4, 462, 15, 16, 2170, 2171, "7" +296, 26, 5, 463, 17, 18, 2172, 2173, "·" +296, 26, 6, 464, 19, 20, 2174, 2175, "8" +296, 26, 7, 465, 21, 22, 2176, 2177, "%" +296, 26, 8, 466, 23, 24, 2178, 2179, "(" +296, 26, 9, 467, 25, 27, 2180, 2182, "SD" +296, 26, 10, 468, 28, 29, 2183, 2184, "0" +296, 26, 11, 469, 30, 31, 2185, 2186, "·" +296, 26, 12, 470, 32, 33, 2187, 2188, "8" +296, 26, 13, 471, 34, 35, 2189, 2190, ")" +296, 26, 14, 472, 36, 37, 2191, 2192, "." +296, 27, 1, 473, 0, 2, 2193, 2195, "At" +296, 27, 2, 474, 3, 7, 2196, 2200, "week" +296, 27, 3, 475, 8, 10, 2201, 2203, "24" +296, 27, 4, 476, 11, 12, 2204, 2205, "," +296, 27, 5, 477, 13, 20, 2206, 2213, "placebo" +296, 27, 6, 478, 21, 22, 2214, 2215, "-" +296, 27, 7, 479, 23, 31, 2216, 2224, "adjusted" +296, 27, 8, 480, 32, 36, 2225, 2229, "mean" +296, 27, 9, 481, 37, 43, 2230, 2236, "change" +296, 27, 10, 482, 44, 46, 2237, 2239, "in" +296, 27, 11, 483, 47, 52, 2240, 2245, "HbA1c" +296, 27, 12, 484, 53, 57, 2246, 2250, "with" +296, 27, 13, 485, 58, 69, 2251, 2262, "linagliptin" +296, 27, 14, 486, 70, 73, 2263, 2266, "was" +296, 27, 15, 487, 74, 75, 2267, 2268, "-" +296, 27, 16, 488, 76, 77, 2269, 2270, "0" +296, 27, 17, 489, 78, 79, 2271, 2272, "·" +296, 27, 18, 490, 80, 82, 2273, 2275, "64" +296, 27, 19, 491, 83, 84, 2276, 2277, "%" +296, 27, 20, 492, 85, 86, 2278, 2279, "(" +296, 27, 21, 493, 87, 89, 2280, 2282, "95" +296, 27, 22, 494, 90, 91, 2283, 2284, "%" +296, 27, 23, 495, 92, 94, 2285, 2287, "CI" +296, 27, 24, 496, 95, 96, 2288, 2289, "-" +296, 27, 25, 497, 97, 98, 2290, 2291, "0" +296, 27, 26, 498, 99, 100, 2292, 2293, "·" +296, 27, 27, 499, 101, 103, 2294, 2296, "81" +296, 27, 28, 500, 104, 106, 2297, 2299, "to" +296, 27, 29, 501, 107, 108, 2300, 2301, "-" +296, 27, 30, 502, 109, 110, 2302, 2303, "0" +296, 27, 31, 503, 111, 112, 2304, 2305, "·" +296, 27, 32, 504, 113, 115, 2306, 2308, "48" +296, 27, 33, 505, 116, 117, 2309, 2310, "," +296, 27, 34, 506, 118, 119, 2311, 2312, "p" +296, 27, 35, 507, 120, 121, 2313, 2314, "<" +296, 27, 36, 508, 122, 123, 2315, 2316, "0" +296, 27, 37, 509, 124, 125, 2317, 2318, "·" +296, 27, 38, 510, 126, 130, 2319, 2323, "0001" +296, 27, 39, 511, 131, 132, 2324, 2325, ")" +296, 27, 40, 512, 133, 134, 2326, 2327, "." +296, 28, 1, 513, 0, 7, 2328, 2335, "Overall" +296, 28, 2, 514, 8, 14, 2336, 2342, "safety" +296, 28, 3, 515, 15, 18, 2343, 2346, "and" +296, 28, 4, 516, 19, 31, 2347, 2359, "tolerability" +296, 28, 5, 517, 32, 36, 2360, 2364, "were" +296, 28, 6, 518, 37, 41, 2365, 2369, "much" +296, 28, 7, 519, 42, 45, 2370, 2373, "the" +296, 28, 8, 520, 46, 50, 2374, 2378, "same" +296, 28, 9, 521, 51, 58, 2379, 2386, "between" +296, 28, 10, 522, 59, 62, 2387, 2390, "the" +296, 28, 11, 523, 63, 74, 2391, 2402, "linagliptin" +296, 28, 12, 524, 75, 78, 2403, 2406, "and" +296, 28, 13, 525, 79, 86, 2407, 2414, "placebo" +296, 28, 14, 526, 87, 93, 2415, 2421, "groups" +296, 28, 15, 527, 94, 95, 2422, 2423, ";" +296, 28, 16, 528, 96, 98, 2424, 2426, "75" +296, 28, 17, 529, 99, 100, 2427, 2428, "·" +296, 28, 18, 530, 101, 102, 2429, 2430, "9" +296, 28, 19, 531, 103, 104, 2431, 2432, "%" +296, 28, 20, 532, 105, 107, 2433, 2435, "of" +296, 28, 21, 533, 108, 116, 2436, 2444, "patients" +296, 28, 22, 534, 117, 119, 2445, 2447, "in" +296, 28, 23, 535, 120, 124, 2448, 2452, "both" +296, 28, 24, 536, 125, 131, 2453, 2459, "groups" +296, 28, 25, 537, 132, 135, 2460, 2463, "had" +296, 28, 26, 538, 136, 138, 2464, 2466, "an" +296, 28, 27, 539, 139, 146, 2467, 2474, "adverse" +296, 28, 28, 540, 147, 152, 2475, 2480, "event" +296, 28, 29, 541, 153, 154, 2481, 2482, "(" +296, 28, 30, 542, 155, 166, 2483, 2494, "linagliptin" +296, 28, 31, 543, 167, 168, 2495, 2496, "n" +296, 28, 32, 544, 169, 170, 2497, 2498, "=" +296, 28, 33, 545, 171, 174, 2499, 2502, "123" +296, 28, 34, 546, 175, 176, 2503, 2504, "," +296, 28, 35, 547, 177, 184, 2505, 2512, "placebo" +296, 28, 36, 548, 185, 186, 2513, 2514, "n" +296, 28, 37, 549, 187, 188, 2515, 2516, "=" +296, 28, 38, 550, 189, 191, 2517, 2519, "60" +296, 28, 39, 551, 192, 193, 2520, 2521, ")" +296, 28, 40, 552, 194, 195, 2522, 2523, "." +296, 29, 1, 553, 0, 2, 2524, 2526, "No" +296, 29, 2, 554, 3, 9, 2527, 2533, "deaths" +296, 29, 3, 555, 10, 18, 2534, 2542, "occurred" +296, 29, 4, 556, 19, 20, 2543, 2544, "." +296, 30, 1, 557, 0, 7, 2545, 2552, "Serious" +296, 30, 2, 558, 8, 15, 2553, 2560, "adverse" +296, 30, 3, 559, 16, 22, 2561, 2567, "events" +296, 30, 4, 560, 23, 31, 2568, 2576, "occurred" +296, 30, 5, 561, 32, 34, 2577, 2579, "in" +296, 30, 6, 562, 35, 36, 2580, 2581, "8" +296, 30, 7, 563, 37, 38, 2582, 2583, "·" +296, 30, 8, 564, 39, 40, 2584, 2585, "6" +296, 30, 9, 565, 41, 42, 2586, 2587, "%" +296, 30, 10, 566, 43, 44, 2588, 2589, "(" +296, 30, 11, 567, 45, 47, 2590, 2592, "14" +296, 30, 12, 568, 48, 49, 2593, 2594, ")" +296, 30, 13, 569, 50, 52, 2595, 2597, "of" +296, 30, 14, 570, 53, 61, 2598, 2606, "patients" +296, 30, 15, 571, 62, 64, 2607, 2609, "in" +296, 30, 16, 572, 65, 68, 2610, 2613, "the" +296, 30, 17, 573, 69, 80, 2614, 2625, "linagliptin" +296, 30, 18, 574, 81, 86, 2626, 2631, "group" +296, 30, 19, 575, 87, 90, 2632, 2635, "and" +296, 30, 20, 576, 91, 92, 2636, 2637, "6" +296, 30, 21, 577, 93, 94, 2638, 2639, "·" +296, 30, 22, 578, 95, 96, 2640, 2641, "3" +296, 30, 23, 579, 97, 98, 2642, 2643, "%" +296, 30, 24, 580, 99, 100, 2644, 2645, "(" +296, 30, 25, 581, 101, 105, 2646, 2650, "five" +296, 30, 26, 582, 106, 107, 2651, 2652, ")" +296, 30, 27, 583, 108, 116, 2653, 2661, "patients" +296, 30, 28, 584, 117, 119, 2662, 2664, "in" +296, 30, 29, 585, 120, 123, 2665, 2668, "the" +296, 30, 30, 586, 124, 131, 2669, 2676, "placebo" +296, 30, 31, 587, 132, 137, 2677, 2682, "group" +296, 30, 32, 588, 138, 139, 2683, 2684, ";" +296, 30, 33, 589, 140, 144, 2685, 2689, "none" +296, 30, 34, 590, 145, 149, 2690, 2694, "were" +296, 30, 35, 591, 150, 156, 2695, 2701, "deemed" +296, 30, 36, 592, 157, 164, 2702, 2709, "related" +296, 30, 37, 593, 165, 167, 2710, 2712, "to" +296, 30, 38, 594, 168, 173, 2713, 2718, "study" +296, 30, 39, 595, 174, 178, 2719, 2723, "drug" +296, 30, 40, 596, 179, 180, 2724, 2725, "." +296, 31, 1, 597, 0, 13, 2726, 2739, "Hypoglycaemia" +296, 31, 2, 598, 14, 17, 2740, 2743, "was" +296, 31, 3, 599, 18, 21, 2744, 2747, "the" +296, 31, 4, 600, 22, 26, 2748, 2752, "most" +296, 31, 5, 601, 27, 33, 2753, 2759, "common" +296, 31, 6, 602, 34, 41, 2760, 2767, "adverse" +296, 31, 7, 603, 42, 47, 2768, 2773, "event" +296, 31, 8, 604, 48, 50, 2774, 2776, "in" +296, 31, 9, 605, 51, 55, 2777, 2781, "both" +296, 31, 10, 606, 56, 62, 2782, 2788, "groups" +296, 31, 11, 607, 63, 64, 2789, 2790, "," +296, 31, 12, 608, 65, 68, 2791, 2794, "but" +296, 31, 13, 609, 69, 72, 2795, 2798, "did" +296, 31, 14, 610, 73, 76, 2799, 2802, "not" +296, 31, 15, 611, 77, 83, 2803, 2809, "differ" +296, 31, 16, 612, 84, 91, 2810, 2817, "between" +296, 31, 17, 613, 92, 98, 2818, 2824, "groups" +296, 31, 18, 614, 99, 100, 2825, 2826, "(" +296, 31, 19, 615, 101, 103, 2827, 2829, "24" +296, 31, 20, 616, 104, 105, 2830, 2831, "·" +296, 31, 21, 617, 106, 107, 2832, 2833, "1" +296, 31, 22, 618, 108, 109, 2834, 2835, "%" +296, 31, 23, 619, 110, 111, 2836, 2837, "[" +296, 31, 24, 620, 112, 114, 2838, 2840, "39" +296, 31, 25, 621, 115, 116, 2841, 2842, "]" +296, 31, 26, 622, 117, 119, 2843, 2845, "in" +296, 31, 27, 623, 120, 123, 2846, 2849, "the" +296, 31, 28, 624, 124, 135, 2850, 2861, "linagliptin" +296, 31, 29, 625, 136, 141, 2862, 2867, "group" +296, 31, 30, 626, 142, 143, 2868, 2869, "," +296, 31, 31, 627, 144, 146, 2870, 2872, "16" +296, 31, 32, 628, 147, 148, 2873, 2874, "·" +296, 31, 33, 629, 149, 150, 2875, 2876, "5" +296, 31, 34, 630, 151, 152, 2877, 2878, "%" +296, 31, 35, 631, 153, 154, 2879, 2880, "[" +296, 31, 36, 632, 155, 157, 2881, 2883, "13" +296, 31, 37, 633, 158, 159, 2884, 2885, "]" +296, 31, 38, 634, 160, 162, 2886, 2888, "in" +296, 31, 39, 635, 163, 166, 2889, 2892, "the" +296, 31, 40, 636, 167, 174, 2893, 2900, "placebo" +296, 31, 41, 637, 175, 180, 2901, 2906, "group" +296, 31, 42, 638, 181, 182, 2907, 2908, ";" +296, 31, 43, 639, 183, 187, 2909, 2913, "odds" +296, 31, 44, 640, 188, 193, 2914, 2919, "ratio" +296, 31, 45, 641, 194, 195, 2920, 2921, "1" +296, 31, 46, 642, 196, 197, 2922, 2923, "·" +296, 31, 47, 643, 198, 200, 2924, 2926, "58" +296, 31, 48, 644, 201, 202, 2927, 2928, "," +296, 31, 49, 645, 203, 205, 2929, 2931, "95" +296, 31, 50, 646, 206, 207, 2932, 2933, "%" +296, 31, 51, 647, 208, 210, 2934, 2936, "CI" +296, 31, 52, 648, 211, 212, 2937, 2938, "0" +296, 31, 53, 649, 213, 214, 2939, 2940, "·" +296, 31, 54, 650, 215, 217, 2941, 2943, "78" +296, 31, 55, 651, 218, 219, 2944, 2945, "-" +296, 31, 56, 652, 220, 221, 2946, 2947, "3" +296, 31, 57, 653, 222, 223, 2948, 2949, "·" +296, 31, 58, 654, 224, 226, 2950, 2952, "78" +296, 31, 59, 655, 227, 228, 2953, 2954, "," +296, 31, 60, 656, 229, 230, 2955, 2956, "p" +296, 31, 61, 657, 231, 232, 2957, 2958, "=" +296, 31, 62, 658, 233, 234, 2959, 2960, "0" +296, 31, 63, 659, 235, 236, 2961, 2962, "·" +296, 31, 64, 660, 237, 241, 2963, 2967, "2083" +296, 31, 65, 661, 242, 243, 2968, 2969, ")" +296, 31, 66, 662, 244, 245, 2970, 2971, "." +296, 32, 1, 663, 0, 14, 2972, 2986, "INTERPRETATION" +296, 32, 2, 664, 15, 16, 2987, 2988, ":" +296, 32, 3, 665, 17, 19, 2989, 2991, "In" +296, 32, 4, 666, 20, 27, 2992, 2999, "elderly" +296, 32, 5, 667, 28, 36, 3000, 3008, "patients" +296, 32, 6, 668, 37, 41, 3009, 3013, "with" +296, 32, 7, 669, 42, 46, 3014, 3018, "type" +296, 32, 8, 670, 47, 48, 3019, 3020, "2" +296, 32, 9, 671, 49, 57, 3021, 3029, "diabetes" +296, 32, 10, 672, 58, 69, 3030, 3041, "linagliptin" +296, 32, 11, 673, 70, 73, 3042, 3045, "was" +296, 32, 12, 674, 74, 85, 3046, 3057, "efficacious" +296, 32, 13, 675, 86, 88, 3058, 3060, "in" +296, 32, 14, 676, 89, 97, 3061, 3069, "lowering" +296, 32, 15, 677, 98, 105, 3070, 3077, "glucose" +296, 32, 16, 678, 106, 110, 3078, 3082, "with" +296, 32, 17, 679, 111, 112, 3083, 3084, "a" +296, 32, 18, 680, 113, 119, 3085, 3091, "safety" +296, 32, 19, 681, 120, 127, 3092, 3099, "profile" +296, 32, 20, 682, 128, 135, 3100, 3107, "similar" +296, 32, 21, 683, 136, 138, 3108, 3110, "to" +296, 32, 22, 684, 139, 146, 3111, 3118, "placebo" +296, 32, 23, 685, 147, 148, 3119, 3120, "." +296, 33, 1, 686, 0, 5, 3121, 3126, "These" +296, 33, 2, 687, 6, 14, 3127, 3135, "findings" +296, 33, 3, 688, 15, 20, 3136, 3141, "could" +296, 33, 4, 689, 21, 27, 3142, 3148, "inform" +296, 33, 5, 690, 28, 37, 3149, 3158, "treatment" +296, 33, 6, 691, 38, 47, 3159, 3168, "decisions" +296, 33, 7, 692, 48, 51, 3169, 3172, "for" +296, 33, 8, 693, 52, 61, 3173, 3182, "achieving" +296, 33, 9, 694, 62, 76, 3183, 3197, "individualised" +296, 33, 10, 695, 77, 86, 3198, 3207, "glycaemic" +296, 33, 11, 696, 87, 92, 3208, 3213, "goals" +296, 33, 12, 697, 93, 97, 3214, 3218, "with" +296, 33, 13, 698, 98, 105, 3219, 3226, "minimal" +296, 33, 14, 699, 106, 110, 3227, 3231, "risk" +296, 33, 15, 700, 111, 113, 3232, 3234, "in" +296, 33, 16, 701, 114, 118, 3235, 3239, "this" +296, 33, 17, 702, 119, 128, 3240, 3249, "important" +296, 33, 18, 703, 129, 139, 3250, 3260, "population" +296, 33, 19, 704, 140, 142, 3261, 3263, "of" +296, 33, 20, 705, 143, 151, 3264, 3272, "patients" +296, 33, 21, 706, 152, 153, 3273, 3274, "." +296, 34, 1, 707, 0, 7, 3275, 3282, "FUNDING" +296, 34, 2, 708, 8, 9, 3283, 3284, ":" +296, 34, 3, 709, 10, 20, 3285, 3295, "Boehringer" +296, 34, 4, 710, 21, 30, 3296, 3305, "Ingelheim" +296, 34, 5, 711, 31, 32, 3306, 3307, "." +296, 35, 1, 712, 0, 9, 3308, 3317, "Copyright" +296, 35, 2, 713, 10, 11, 3318, 3319, "©" +296, 35, 3, 714, 12, 16, 3320, 3324, "2013" +296, 35, 4, 715, 17, 25, 3325, 3333, "Elsevier" +296, 35, 5, 716, 26, 29, 3334, 3337, "Ltd" +296, 35, 6, 717, 30, 31, 3338, 3339, "." +296, 35, 7, 718, 32, 35, 3340, 3343, "All" +296, 35, 8, 719, 36, 42, 3344, 3350, "rights" +296, 35, 9, 720, 43, 51, 3351, 3359, "reserved" +296, 35, 10, 721, 52, 53, 3360, 3361, "." +296, 36, 1, 722, 0, 3, 3362, 3365, "DOI" +296, 36, 2, 723, 4, 5, 3366, 3367, ":" +296, 36, 3, 724, 6, 8, 3368, 3370, "10" +296, 36, 4, 725, 9, 10, 3371, 3372, "." +296, 36, 5, 726, 11, 15, 3373, 3377, "1016" +296, 36, 6, 727, 16, 17, 3378, 3379, "/" +296, 36, 7, 728, 18, 23, 3380, 3385, "S0140" +296, 36, 8, 729, 24, 25, 3386, 3387, "-" +296, 36, 9, 730, 26, 30, 3388, 3392, "6736" +296, 36, 10, 731, 31, 32, 3393, 3394, "(" +296, 36, 11, 732, 33, 35, 3395, 3397, "13" +296, 36, 12, 733, 36, 37, 3398, 3399, ")" +296, 36, 13, 734, 38, 43, 3400, 3405, "61500" +296, 36, 14, 735, 44, 45, 3406, 3407, "-" +296, 36, 15, 736, 46, 47, 3408, 3409, "7" +296, 36, 16, 737, 48, 52, 3410, 3414, "PMID" +296, 36, 17, 738, 53, 54, 3415, 3416, ":" +296, 36, 18, 739, 55, 63, 3417, 3425, "23948125" +296, 36, 19, 740, 64, 65, 3426, 3427, "[" +296, 36, 20, 741, 66, 73, 3428, 3435, "Indexed" +296, 36, 21, 742, 74, 77, 3436, 3439, "for" +296, 36, 22, 743, 78, 85, 3440, 3447, "MEDLINE" +296, 36, 23, 744, 86, 87, 3448, 3449, "]" diff --git a/data/dm2 23948125_kwoodley.annodb b/data/dm2 23948125_kwoodley.annodb new file mode 100644 index 0000000..2687c85 --- /dev/null +++ b/data/dm2 23948125_kwoodley.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42677, Journal, 0, 6, "Lancet", "", +42678, PublicationYear, 9, 13, "2013", "", +42680, Linagliptin, 119, 130, "Linagliptin", "", +42737, Title, 119, 310, "Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .", "", +42699, MinAge, 149, 151, "70", "", +42702, Type2Diabetes, 172, 187, "type 2 diabetes", "", +42731, Randomized, 252, 262, "randomised", "", +42733, DoubleBlind, 265, 279, "double - blind", "", +42735, Placebo, 282, 289, "placebo", "", +42738, Author, 311, 321, "Barnett AH", "", +42739, Author, 330, 339, "Huisman H", "", +42740, Author, 342, 349, "Jones R", "", +42742, Author, 352, 366, "von Eynatten M", "", +42743, Author, 369, 376, "Patel S", "", +42745, Author, 379, 388, "Woerle HJ", "", +42746, UK, 534, 536, "UK", "", +42704, Type2Diabetes, 907, 922, "type 2 diabetes", "", +42714, AvgAge, 927, 934, "elderly", "", +42712, AvgAge, 937, 947, "≥ 65 years", "", +42726, ObjectiveDescription, 1043, 1178, "We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .", "", +42683, Linagliptin, 1083, 1094, "linagliptin", "", +42724, AvgAge, 1139, 1146, "elderly", "", +42705, Type2Diabetes, 1161, 1176, "type 2 diabetes", "", +42749, Randomized, 1197, 1207, "randomised", "", +42751, DoubleBlind, 1210, 1224, "double - blind", "", +42752, Parallel, 1227, 1243, "parallel - group", "", +42753, Multicenter, 1246, 1259, "multinational", "", +42768, Precondition, 1276, 1474, "patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs", "", +42719, MinAge, 1290, 1292, "70", "", +42707, Type2Diabetes, 1313, 1328, "type 2 diabetes", "", +42755, HbA1c, 1331, 1355, "glycated haemoglobin A1c", "", +42756, HbA1c, 1358, 1363, "HbA1c", "", +42759, Percentage, 1375, 1376, "%", "", +42761, Metformin, 1397, 1406, "metformin", "", +42763, Sulfonylureas, 1409, 1422, "sulfonylureas", "", +42764, Insulin, 1428, 1441, "basal insulin", "", +42766, Randomized, 1482, 1492, "randomised", "", +42771, HbA1c, 1601, 1606, "HbA1c", "", +42774, Percentage, 1623, 1624, "%", "", +42775, Percentage, 1636, 1637, "%", "", +42777, AllocationRatio, 1695, 1700, "2 : 1", "", +42779, Frequency, 1710, 1722, "once - daily", "", +42784, Oral, 1723, 1727, "oral", "", +42687, Linagliptin, 1743, 1754, "linagliptin", "", +42787, DoseValue, 1755, 1756, "5", "", +42788, mg, 1757, 1759, "mg", "", +42789, Placebo, 1772, 1779, "placebo", "", +42790, Duration, 1784, 1792, "24 weeks", "", +42793, HbA1c, 1910, 1915, "HbA1c", "", +42794, TimePoint, 1921, 1929, "baseline", "", +42795, TimePoint, 1933, 1940, "week 24", "", +42823, NumberPatientsCT, 2028, 2031, "241", "", +42824, Randomized, 2068, 2078, "randomised", "", +42825, NumberPatientsArm, 2081, 2084, "162", "", +42827, Linagliptin, 2085, 2096, "linagliptin", "", +42826, NumberPatientsArm, 2099, 2101, "79", "", +42829, Placebo, 2102, 2109, "placebo", "", +42832, AvgAge, 2127, 2133, "74 · 9", "", +42833, HbA1c, 2160, 2165, "HbA1c", "", +42834, BaseLineValue, 2170, 2175, "7 · 8", "", +42835, Percentage, 2176, 2177, "%", "", +42836, SdDevBL, 2183, 2188, "0 · 8", "", +42796, TimePoint, 2196, 2203, "week 24", "", +42831, Placebo, 2206, 2213, "placebo", "", +42837, HbA1c, 2240, 2245, "HbA1c", "", +42690, Linagliptin, 2251, 2262, "linagliptin", "", +42838, Reduction, 2269, 2275, "0 · 64", "", +42839, Percentage, 2276, 2277, "%", "", +42840, ConfIntervalChangeValue, 2280, 2308, "95 % CI - 0 · 81 to - 0 · 48", "", +42841, PValueChangeValue, 2311, 2323, "p < 0 · 0001", "", +42691, Linagliptin, 2391, 2402, "linagliptin", "", +42830, Placebo, 2407, 2414, "placebo", "", +42842, PercentageAffected, 2424, 2430, "75 · 9", "", +42848, ObservedResult, 2460, 2480, "had an adverse event", "", +42843, EndPointDescription, 2467, 2480, "adverse event", "", +42692, Linagliptin, 2483, 2494, "linagliptin", "", +42845, NumberAffected, 2499, 2502, "123", "", +42847, Placebo, 2505, 2512, "placebo", "", +42846, NumberAffected, 2517, 2519, "60", "", +42849, EndPointDescription, 2545, 2567, "Serious adverse events", "", +42850, PercentageAffected, 2580, 2585, "8 · 6", "", +42852, NumberAffected, 2590, 2592, "14", "", +42828, Linagliptin, 2614, 2625, "linagliptin", "", +42851, PercentageAffected, 2636, 2641, "6 · 3", "", +42853, NumberAffected, 2646, 2650, "five", "", +42854, Placebo, 2669, 2676, "placebo", "", +42855, ObservedResult, 2685, 2723, "none were deemed related to study drug", "", +42856, Hypoglycemia, 2726, 2739, "Hypoglycaemia", "", +42857, ObservedResult, 2740, 2824, "was the most common adverse event in both groups , but did not differ between groups", "", +42858, PercentageAffected, 2827, 2833, "24 · 1", "", +42860, NumberAffected, 2838, 2840, "39", "", +42694, Linagliptin, 2850, 2861, "linagliptin", "", +42859, PercentageAffected, 2870, 2876, "16 · 5", "", +42861, NumberAffected, 2881, 2883, "13", "", +42862, Placebo, 2893, 2900, "placebo", "", +42863, ConfIntervalDiff, 2929, 2952, "95 % CI 0 · 78 - 3 · 78", "", +42864, PvalueDiff, 2955, 2967, "p = 0 · 2083", "", +42866, ConclusionComment, 2989, 3120, "In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .", "", +42717, AvgAge, 2992, 2999, "elderly", "", +42709, Type2Diabetes, 3014, 3029, "type 2 diabetes", "", +42695, Linagliptin, 3030, 3041, "linagliptin", "", +42865, Placebo, 3111, 3118, "placebo", "", +42867, ConclusionComment, 3121, 3274, "These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .", "", +42868, PMID, 3417, 3425, "23948125", "", diff --git a/data/dm2 23948125_kwoodley.n-triples b/data/dm2 23948125_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23948125_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23949898_admin.annodb b/data/dm2 23949898_admin.annodb new file mode 100644 index 0000000..bcc4c87 --- /dev/null +++ b/data/dm2 23949898_admin.annodb @@ -0,0 +1,161 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 20, "Clin Drug Investig .", "", " \"Clin Drug Investig .\"." +1, PublicationYear, 21, 25, "2013", "", " \"2013\"." +2, Saxagliptin, 99, 110, "Saxagliptin", "", +27, Title, 99, 227, "Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .", "", " \"Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .\"." +13, Insulin, 131, 138, "insulin", "", +14, Metformin, 155, 164, "metformin", "", +21, Type2Diabetes, 169, 193, "type 2 diabetes mellitus", "", " ." +26, Duration, 196, 205, "52 - week", "", " \"52 - week\"." +28, Author, 228, 238, "Barnett AH", "", " \"Barnett AH\"." +29, Author, 247, 259, "Charbonnel B", "", " \"Charbonnel B\"." +30, Author, 262, 266, "Li J", "", " \"Li J\"." +31, Author, 269, 278, "Donovan M", "", " \"Donovan M\"." +32, Author, 281, 290, "Fleming D", "", " \"Fleming D\"." +33, Author, 293, 300, "Iqbal N", "", " \"Iqbal N\"." +34, UK, 450, 452, "UK", "", +22, Type2Diabetes, 547, 571, "type 2 diabetes mellitus", "", +23, Type2Diabetes, 574, 578, "T2DM", "", +49, ObjectiveDescription, 595, 844, "The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .", "", " \"The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .\"." +3, Saxagliptin, 705, 716, "saxagliptin", "", +35, Placebo, 724, 731, "placebo", "", +48, Precondition, 755, 842, "patients with T2DM inadequately controlled with insulin alone or insulin plus metformin", "", " \"patients with T2DM inadequately controlled with insulin alone or insulin plus metformin\"." +24, Type2Diabetes, 769, 773, "T2DM", "", +46, Insulin, 803, 810, "insulin", "", +47, Insulin, 820, 827, "insulin", "", +15, Metformin, 833, 842, "metformin", "", +50, Duration, 880, 889, "28 - week", "", +51, Duration, 922, 931, "24 - week", "", +52, Randomized, 936, 946, "randomized", "", " ." +53, DoubleBlind, 949, 963, "double - blind", "", " ." +54, Parallel, 966, 982, "parallel - group", "", " ." +4, Saxagliptin, 992, 1003, "saxagliptin", "", " ." +55, DoseValue, 1004, 1005, "5", "", " \"5\"." +56, mg, 1006, 1008, "mg", "", " ." +57, Frequency, 1009, 1019, "once daily", "", +36, Placebo, 1027, 1034, "placebo", "", " ." +58, OpenLabel, 1058, 1070, "open - label", "", " ." +59, Insulin, 1071, 1078, "insulin", "", +60, Insulin, 1082, 1089, "insulin", "", +37, Metformin, 1095, 1104, "metformin", "", +61, Duration, 1122, 1130, "52 weeks", "", +62, InsulinDose, 1196, 1210, "insulin dosage", "", +63, InsulinDose, 1274, 1288, "insulin dosage", "", +71, Precondition, 1463, 1650, "Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening", "", " \"Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening\"." +25, Type2Diabetes, 1477, 1481, "T2DM", "", +64, MinAge, 1487, 1489, "18", "", " \"18\"." +65, MaxAge, 1492, 1494, "78", "", " \"78\"." +196, Year, 1495, 1500, "years", "", +66, HbA1c, 1506, 1525, "glycated hemoglobin", "", +67, HbA1c, 1528, 1533, "HbA1c", "", +68, Percentage, 1547, 1548, "%", "", +70, InsulinDose, 1561, 1576, "insulin regimen", "", +201, Insulin, 1561, 1568, "insulin", "", +204, DoseValue, 1579, 1587, "30 - 150", "", +69, BioAndMedicalUnit, 1588, 1595, "U / day", "", +16, Metformin, 1612, 1621, "metformin", "", +205, Duration, 1630, 1637, "8 weeks", "", +72, Metformin, 1708, 1717, "metformin", "", +73, Randomized, 1726, 1734, "randomly", "", +74, AllocationRatio, 1744, 1749, "2 : 1", "", " . ." +5, Saxagliptin, 1758, 1769, "saxagliptin", "", +75, DoseValue, 1770, 1771, "5", "", +76, mg, 1772, 1774, "mg", "", +77, NumberPatientsArm, 1781, 1784, "304", "", " \"304\"." +38, Placebo, 1790, 1797, "placebo", "", +78, NumberPatientsArm, 1804, 1807, "151", "", " \"151\"." +79, Frequency, 1810, 1820, "once daily", "", " \"once daily\". \"once daily\"." +80, Duration, 1862, 1870, "24 weeks", "", +81, Duration, 1920, 1929, "28 - week", "", +82, HbA1c, 2040, 2045, "HbA1c", "", +83, TimePoint, 2051, 2059, "baseline", "", +84, TimePoint, 2063, 2070, "week 52", "", +85, TimePoint, 2121, 2128, "week 24", "", +86, TimePoint, 2147, 2154, "week 52", "", +225, Mean, 2166, 2170, "mean", "", " . ." +91, TimePoint, 2183, 2191, "baseline", "", +92, HbA1c, 2192, 2197, "HbA1c", "", " ." +87, TimePoint, 2201, 2208, "week 52", "", " \"week 52\"." +6, Saxagliptin, 2226, 2237, "saxagliptin", "", +93, Reduction, 2242, 2248, "0 . 75", "", " \"0 . 75\"." +95, Percentage, 2249, 2250, "%", "", " ." +39, Placebo, 2260, 2267, "placebo", "", +94, Reduction, 2272, 2278, "0 . 38", "", " \"0 . 38\"." +96, Percentage, 2279, 2280, "%", "", +97, DiffGroupAbsValue, 2329, 2337, "- 0 . 37", "", " \"- 0 . 37\"." +98, Percentage, 2338, 2339, "%", "", +99, ConfIntervalDiff, 2342, 2370, "95 % CI - 0 . 55 to - 0 . 19", "", " \"95 % CI - 0 . 55 to - 0 . 19\"." +244, SubGroupDescription, 2419, 2450, "patients treated with metformin", "", " \"patients treated with metformin\". \"patients treated with metformin\"." +17, Metformin, 2441, 2450, "metformin", "", +100, DiffGroupAbsValue, 2453, 2461, "- 0 . 37", "", " \"- 0 . 37\"." +105, Percentage, 2462, 2463, "%", "", +106, ConfIntervalDiff, 2466, 2494, "95 % CI - 0 . 59 to - 0 . 15", "", " \"95 % CI - 0 . 59 to - 0 . 15\"." +103, SubGroupDescription, 2503, 2520, "without metformin", "", " \"without metformin\". \"without metformin\"." +101, DiffGroupAbsValue, 2523, 2531, "- 0 . 37", "", " \"- 0 . 37\"." +104, Percentage, 2532, 2533, "%", "", +107, ConfIntervalDiff, 2536, 2564, "95 % CI - 0 . 69 to - 0 . 04", "", " \"95 % CI - 0 . 69 to - 0 . 04\"." +88, TimePoint, 2574, 2581, "week 52", "", " \"week 52\". \"week 52\"." +7, Saxagliptin, 2627, 2638, "saxagliptin", "", +108, HbA1c_target, 2648, 2659, "HbA1c < 7 %", "", " ." +252, Percentage, 2658, 2659, "%", "", +40, Placebo, 2681, 2688, "placebo", "", +109, PercentageAffected, 2691, 2697, "21 . 3", "", " \"21 . 3\"." +110, PercentageAffected, 2703, 2708, "8 . 7", "", " \"8 . 7\"." +111, DiffGroupRelValue, 2740, 2746, "12 . 6", "", " \"12 . 6\"." +112, ConfIntervalDiff, 2751, 2773, "95 % CI 6 . 1 - 19 . 1", "", " \"95 % CI 6 . 1 - 19 . 1\"." +113, TimePoint, 2798, 2806, "baseline", "", +261, Mean, 2810, 2814, "mean", "", " . ." +114, InsulinDose, 2827, 2839, "insulin dose", "", " . ." +89, TimePoint, 2843, 2850, "week 52", "", " \"week 52\". \"week 52\"." +8, Saxagliptin, 2880, 2891, "saxagliptin", "", +115, ResultMeasuredValue, 2894, 2900, "5 . 67", "", " \"5 . 67\"." +116, ResultMeasuredValue, 2904, 2910, "6 . 67", "", " \"6 . 67\"." +268, Int_Unit, 2911, 2912, "U", "", " ." +41, Placebo, 2918, 2925, "placebo", "", +118, DiffGroupAbsValue, 2941, 2949, "- 1 . 01", "", " \"- 1 . 01\"." +269, Int_Unit, 2950, 2951, "U", "", +120, ConfIntervalDiff, 2954, 2980, "95 % CI - 3 . 24 to 1 . 22", "", " \"95 % CI - 3 . 24 to 1 . 22\"." +90, TimePoint, 2998, 3007, "52 - week", "", " \"52 - week\". \"52 - week\"." +121, EndPointDescription, 3060, 3077, "≥ 1 adverse event", "", " . ." +122, EndPointDescription, 3080, 3082, "AE", "", " . ." +123, PercentageAffected, 3089, 3095, "66 . 4", "", " \"66 . 4\"." +9, Saxagliptin, 3103, 3114, "saxagliptin", "", +124, PercentageAffected, 3119, 3125, "71 . 5", "", " \"71 . 5\"." +42, Placebo, 3133, 3140, "placebo", "", +20, Saxagliptin, 3227, 3238, "saxagliptin", "", +43, Placebo, 3242, 3249, "placebo", "", +67694, EndPointDescription, 3257, 3280, "urinary tract infection", "", +67696, EndPointDescription, 3283, 3298, "nasopharyngitis", "", +67697, EndPointDescription, 3301, 3334, "upper respiratory tract infection", "", +67698, Headache, 3337, 3345, "headache", "", +67699, EndPointDescription, 3348, 3357, "influenza", "", +67700, EndPointDescription, 3364, 3381, "pain in extremity", "", +67686, ObservedResult, 3384, 3445, "the incidence of each AE was similar between treatment groups", "", +10, Saxagliptin, 3455, 3466, "saxagliptin", "", +44, Placebo, 3471, 3478, "placebo", "", +129, Hypoglycemia, 3514, 3526, "hypoglycemia", "", " ." +130, PercentageAffected, 3531, 3537, "22 . 7", "", " \"22 . 7\"." +131, PercentageAffected, 3542, 3548, "26 . 5", "", " \"26 . 5\"." +132, Hypoglycemia, 3595, 3607, "hypoglycemia", "", " ." +135, Mg_per_deciliter, 3635, 3642, "mg / dL", "", +136, Millimoles_per_litre, 3653, 3661, "mmol / L", "", +133, PercentageAffected, 3699, 3704, "7 . 6", "", " \"7 . 6\"." +134, PercentageAffected, 3709, 3714, "6 . 6", "", " \"6 . 6\"." +294, Mean, 3743, 3747, "mean", "", " . ." +138, TimePoint, 3760, 3768, "baseline", "", +139, BodyWeight, 3769, 3780, "body weight", "", " ." +140, Increment, 3787, 3792, "0 . 8", "", " \"0 . 8\"." +142, Kg, 3793, 3795, "kg", "", " ." +11, Saxagliptin, 3801, 3812, "saxagliptin", "", +141, Increment, 3819, 3824, "0 . 5", "", " \"0 . 5\"." +143, Kg, 3825, 3827, "kg", "", +45, Placebo, 3833, 3840, "placebo", "", +12, Saxagliptin, 3856, 3867, "Saxagliptin", "", +149, ConclusionComment, 3856, 4051, "Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .", "", " \"Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .\"." +144, DoseValue, 3868, 3869, "5", "", +145, mg, 3870, 3872, "mg", "", +146, Frequency, 3873, 3883, "once daily", "", +147, Insulin, 3899, 3906, "insulin", "", +19, Metformin, 3937, 3946, "metformin", "", +148, Duration, 4028, 4036, "52 weeks", "", +150, PMID, 4101, 4109, "23949898", "", " \"23949898\"." diff --git a/data/dm2 23949898_admin.n-triples b/data/dm2 23949898_admin.n-triples new file mode 100644 index 0000000..c4a378f --- /dev/null +++ b/data/dm2 23949898_admin.n-triples @@ -0,0 +1,256 @@ +# RDF export of group: Publication + . + "Publication 49090" . + "Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy ." . + "Barnett AH" . + "2013" . + "Clin Drug Investig ." . + "23949898" . + . + "Charbonnel B" . + "Li J" . + "Donovan M" . + "Fleming D" . + "Iqbal N" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 49097" . + "The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin ." . + "52 - week" . + . + . + . + . + "Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 49113" . + "patients with T2DM inadequately controlled with insulin alone or insulin plus metformin" . + . + . + "18" . + "78" . + . + "Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "hypc" . + . + . + . + . + . + "bw" . + . + . + . + . + . +# RDF export of group: Arm + . + "say" . + "304" . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + "151" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sax" . + . + "once daily" . + . + . + "pla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "sax" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "0 . 75" . + "week 52" . + . + "hba met 1" . + . + "patients treated with metformin" . + . + "hba met 2" . + . + "patients treated with metformin" . + . + "hba et 1" . + . + "without metformin" . + . + "hba et 2" . + . + "without metformin" . + . + "hbat 1" . + . + "21 . 3" . + "week 52" . + . + "hbat 2" . + . + "8 . 7" . + "week 52" . + . + "ins 1" . + . + "5 . 67" . + "week 52" . + . + "ins 2" . + . + "6 . 67" . + "week 52" . + . + "ae 1" . + . + "66 . 4" . + "52 - week" . + . + "ae 2" . + . + "71 . 5" . + "52 - week" . + . + "hyp 1" . + . + "22 . 7" . + . + "hyp 2" . + . + "26 . 5" . + . + "hypc 1" . + . + "7 . 6" . + . + "hypc2" . + . + "6 . 6" . + . + "bw 1" . + . + "0 . 8" . + . + "bw 2" . + . + "0 . 5" . + . + "hba 2" . + . + "0 . 38" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 37" . + "95 % CI - 0 . 55 to - 0 . 19" . + . + . + . + "hba met" . + "- 0 . 37" . + "95 % CI - 0 . 59 to - 0 . 15" . + . + . + . + "hba et" . + "- 0 . 37" . + "95 % CI - 0 . 69 to - 0 . 04" . + . + . + . + "hbat" . + "12 . 6" . + "95 % CI 6 . 1 - 19 . 1" . + . + . + . + "ins" . + "- 1 . 01" . + "95 % CI - 3 . 24 to 1 . 22" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23949898_akramersunderbrink.annodb b/data/dm2 23949898_akramersunderbrink.annodb new file mode 100644 index 0000000..62e228c --- /dev/null +++ b/data/dm2 23949898_akramersunderbrink.annodb @@ -0,0 +1,162 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +45876, Journal, 0, 18, "Clin Drug Investig", "", +45877, PublicationYear, 21, 25, "2013", "", +45878, Saxagliptin, 99, 110, "Saxagliptin", "", +45883, Title, 99, 227, "Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .", "", +45879, Insulin, 131, 138, "insulin", "", +45880, Metformin, 155, 164, "metformin", "", +45881, Type2Diabetes, 169, 193, "type 2 diabetes mellitus", "", +45882, Duration, 196, 205, "52 - week", "", +45884, Author, 228, 238, "Barnett AH", "", +45885, Author, 247, 259, "Charbonnel B", "", +45886, Author, 262, 266, "Li J", "", +45887, Author, 269, 278, "Donovan M", "", +45888, Author, 281, 290, "Fleming D", "", +45889, Author, 293, 300, "Iqbal N", "", +45890, UK, 450, 452, "UK", "", +45891, Type2Diabetes, 547, 571, "type 2 diabetes mellitus", "", +45892, Type2Diabetes, 574, 578, "T2DM", "", +45900, ObjectiveDescription, 595, 844, "The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .", "", +45893, Saxagliptin, 705, 716, "saxagliptin", "", +45894, Placebo, 724, 731, "placebo", "", +45895, Type2Diabetes, 769, 773, "T2DM", "", +45896, Precondition, 774, 842, "inadequately controlled with insulin alone or insulin plus metformin", "", +45897, Insulin, 803, 810, "insulin", "", +45898, Insulin, 820, 827, "insulin", "", +45899, Metformin, 833, 842, "metformin", "", +45901, Duration, 880, 889, "28 - week", "", +45902, Duration, 922, 931, "24 - week", "", +45903, Randomized, 936, 946, "randomized", "", +45904, DoubleBlind, 949, 963, "double - blind", "", +45905, Parallel, 966, 982, "parallel - group", "", +45906, Saxagliptin, 992, 1003, "saxagliptin", "", +45907, DoseValue, 1004, 1008, "5 mg", "", +45908, mg, 1006, 1008, "mg", "", +45909, Frequency, 1009, 1019, "once daily", "", +45910, Placebo, 1027, 1034, "placebo", "", +45911, OpenLabel, 1058, 1070, "open - label", "", +45912, Insulin, 1071, 1078, "insulin", "", +45913, Insulin, 1082, 1089, "insulin", "", +45914, Metformin, 1095, 1104, "metformin", "", +45915, Duration, 1122, 1130, "52 weeks", "", +45916, InsulinDose, 1196, 1210, "insulin dosage", "", +45917, InsulinDose, 1274, 1288, "insulin dosage", "", +45918, Type2Diabetes, 1477, 1481, "T2DM", "", +45919, MinAge, 1487, 1489, "18", "", +45920, MaxAge, 1492, 1494, "78", "", +45921, Year, 1495, 1500, "years", "", +45922, HbA1c, 1506, 1525, "glycated hemoglobin", "", +45925, Precondition, 1506, 1650, "glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening", "", +45923, HbA1c, 1528, 1533, "HbA1c", "", +45924, Percentage, 1547, 1548, "%", "", +45926, Insulin, 1561, 1568, "insulin", "", +45929, DoseValue, 1579, 1595, "30 - 150 U / day", "", +45928, BioAndMedicalUnit, 1588, 1595, "U / day", "", +45927, Metformin, 1612, 1621, "metformin", "", +45930, Duration, 1630, 1637, "8 weeks", "", +45932, Metformin, 1708, 1717, "metformin", "", +45933, Randomized, 1726, 1734, "randomly", "", +45934, Saxagliptin, 1758, 1769, "saxagliptin", "", +45935, DoseValue, 1770, 1774, "5 mg", "", +45936, mg, 1772, 1774, "mg", "", +45939, NumberPatientsArm, 1781, 1784, "304", "", +45937, Placebo, 1790, 1797, "placebo", "", +45940, NumberPatientsArm, 1804, 1807, "151", "", +45938, Frequency, 1810, 1820, "once daily", "", +45941, Duration, 1862, 1870, "24 weeks", "", +45942, Duration, 1920, 1929, "28 - week", "", +45943, HbA1c, 2040, 2045, "HbA1c", "", +45944, TimePoint, 2051, 2059, "baseline", "", +45945, TimePoint, 2063, 2070, "week 52", "", +45947, TimePoint, 2121, 2128, "week 24", "", +45946, TimePoint, 2147, 2154, "week 52", "", +45951, Mean, 2166, 2170, "mean", "", +45952, TimePoint, 2183, 2191, "baseline", "", +45953, HbA1c, 2192, 2197, "HbA1c", "", +45948, TimePoint, 2201, 2208, "week 52", "", +45954, Saxagliptin, 2226, 2237, "saxagliptin", "", +45955, ChangeValue, 2240, 2248, "- 0 . 75", "", +45957, Percentage, 2249, 2250, "%", "", +45965, Placebo, 2260, 2267, "placebo", "", +45956, ChangeValue, 2270, 2278, "- 0 . 38", "", +45958, Percentage, 2279, 2280, "%", "", +45966, DiffGroupAbsValue, 2329, 2337, "- 0 . 37", "", +45959, Percentage, 2338, 2339, "%", "", +45967, ConfIntervalDiff, 2342, 2370, "95 % CI - 0 . 55 to - 0 . 19", "", +45960, Percentage, 2345, 2346, "%", "", +45970, SubGroupDescription, 2419, 2450, "patients treated with metformin", "", +45968, Metformin, 2441, 2450, "metformin", "", +45972, DiffGroupAbsValue, 2453, 2461, "- 0 . 37", "", +45961, Percentage, 2462, 2463, "%", "", +45975, ConfIntervalDiff, 2466, 2494, "95 % CI - 0 . 59 to - 0 . 15", "", +45962, Percentage, 2469, 2470, "%", "", +45971, SubGroupDescription, 2503, 2520, "without metformin", "", +45969, Metformin, 2511, 2520, "metformin", "", +45973, DiffGroupAbsValue, 2523, 2531, "- 0 . 37", "", +45963, Percentage, 2532, 2533, "%", "", +45974, ConfIntervalDiff, 2536, 2564, "95 % CI - 0 . 69 to - 0 . 04", "", +45964, Percentage, 2539, 2540, "%", "", +45949, TimePoint, 2574, 2581, "week 52", "", +45976, Saxagliptin, 2627, 2638, "saxagliptin", "", +45977, HbA1c_target, 2648, 2659, "HbA1c < 7 %", "", +45978, Percentage, 2658, 2659, "%", "", +45982, PercentageAffected, 2691, 2697, "21 . 3", "", +45983, PercentageAffected, 2703, 2708, "8 . 7", "", +45979, Percentage, 2709, 2710, "%", "", +45984, DiffGroupAbsValue, 2740, 2746, "12 . 6", "", +45980, Percentage, 2747, 2748, "%", "", +45985, ConfIntervalDiff, 2751, 2773, "95 % CI 6 . 1 - 19 . 1", "", +45981, Percentage, 2754, 2755, "%", "", +45986, TimePoint, 2798, 2806, "baseline", "", +45987, Mean, 2810, 2814, "mean", "", +45988, InsulinDose, 2815, 2839, "total daily insulin dose", "", +45950, TimePoint, 2843, 2850, "week 52", "", +45989, Saxagliptin, 2880, 2891, "saxagliptin", "", +45990, ResultMeasuredValue, 2894, 2900, "5 . 67", "", +45991, ResultMeasuredValue, 2904, 2910, "6 . 67", "", +45994, Int_Unit, 2911, 2912, "U", "", +45992, DiffGroupAbsValue, 2941, 2949, "- 1 . 01", "", +45995, Int_Unit, 2950, 2951, "U", "", +45993, ConfIntervalDiff, 2954, 2980, "95 % CI - 3 . 24 to 1 . 22", "", +45996, Percentage, 2957, 2958, "%", "", +45997, TimePoint, 2998, 3007, "52 - week", "", +46002, EndPointDescription, 3050, 3084, "reporting ≥ 1 adverse event ( AE )", "", +45998, PercentageAffected, 3089, 3095, "66 . 4", "", +46000, Percentage, 3096, 3097, "%", "", +46003, Saxagliptin, 3103, 3114, "saxagliptin", "", +45999, PercentageAffected, 3119, 3125, "71 . 5", "", +46001, Percentage, 3126, 3127, "%", "", +46004, Placebo, 3133, 3140, "placebo", "", +46007, Percentage, 3220, 3221, "%", "", +46006, Saxagliptin, 3227, 3238, "saxagliptin", "", +46005, Placebo, 3242, 3249, "placebo", "", +46008, Saxagliptin, 3455, 3466, "saxagliptin", "", +46009, Placebo, 3471, 3478, "placebo", "", +46010, Hypoglycemia, 3505, 3526, "reported hypoglycemia", "", +46011, PercentageAffected, 3531, 3537, "22 . 7", "", +46012, PercentageAffected, 3542, 3548, "26 . 5", "", +46013, Percentage, 3549, 3550, "%", "", +46017, Hypoglycemia, 3585, 3607, "confirmed hypoglycemia", "", +46018, Mg_per_deciliter, 3635, 3642, "mg / dL", "", +46019, Millimoles_per_litre, 3653, 3661, "mmol / L", "", +46015, PercentageAffected, 3699, 3704, "7 . 6", "", +46016, PercentageAffected, 3709, 3714, "6 . 6", "", +46014, Percentage, 3715, 3716, "%", "", +46020, Mean, 3743, 3747, "mean", "", +46021, TimePoint, 3760, 3768, "baseline", "", +46022, BodyWeight, 3769, 3780, "body weight", "", +46023, ChangeValue, 3785, 3792, "+ 0 . 8", "", +46025, Kg, 3793, 3795, "kg", "", +46028, Saxagliptin, 3801, 3812, "saxagliptin", "", +46024, ChangeValue, 3817, 3824, "+ 0 . 5", "", +46026, Kg, 3825, 3827, "kg", "", +46027, Placebo, 3833, 3840, "placebo", "", +46029, Saxagliptin, 3856, 3867, "Saxagliptin", "", +46036, ConclusionComment, 3856, 4051, "Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .", "", +46030, DoseValue, 3868, 3872, "5 mg", "", +46031, mg, 3870, 3872, "mg", "", +46032, Frequency, 3873, 3883, "once daily", "", +46033, Insulin, 3899, 3906, "insulin", "", +46034, Metformin, 3937, 3946, "metformin", "", +46035, Duration, 4028, 4036, "52 weeks", "", +46037, PMID, 4101, 4109, "23949898", "", diff --git a/data/dm2 23949898_akramersunderbrink.n-triples b/data/dm2 23949898_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23949898_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 23949898_export.csv b/data/dm2 23949898_export.csv new file mode 100644 index 0000000..ee48c16 --- /dev/null +++ b/data/dm2 23949898_export.csv @@ -0,0 +1,877 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +295, 1, 1, 1, 0, 4, 0, 4, "Clin" +295, 1, 2, 2, 5, 9, 5, 9, "Drug" +295, 1, 3, 3, 10, 18, 10, 18, "Investig" +295, 1, 4, 4, 19, 20, 19, 20, "." +295, 2, 1, 5, 0, 4, 21, 25, "2013" +295, 2, 2, 6, 5, 8, 26, 29, "Oct" +295, 2, 3, 7, 9, 10, 30, 31, ";" +295, 2, 4, 8, 11, 13, 32, 34, "33" +295, 2, 5, 9, 14, 15, 35, 36, "(" +295, 2, 6, 10, 16, 18, 37, 39, "10" +295, 2, 7, 11, 19, 20, 40, 41, ")" +295, 2, 8, 12, 21, 22, 42, 43, ":" +295, 2, 9, 13, 23, 26, 44, 47, "707" +295, 2, 10, 14, 27, 28, 48, 49, "-" +295, 2, 11, 15, 29, 31, 50, 52, "17" +295, 2, 12, 16, 32, 33, 53, 54, "." +295, 2, 13, 17, 34, 37, 55, 58, "doi" +295, 2, 14, 18, 38, 39, 59, 60, ":" +295, 2, 15, 19, 40, 42, 61, 63, "10" +295, 2, 16, 20, 43, 44, 64, 65, "." +295, 2, 17, 21, 45, 49, 66, 70, "1007" +295, 2, 18, 22, 50, 51, 71, 72, "/" +295, 2, 19, 23, 52, 58, 73, 79, "s40261" +295, 2, 20, 24, 59, 60, 80, 81, "-" +295, 2, 21, 25, 61, 64, 82, 85, "013" +295, 2, 22, 26, 65, 66, 86, 87, "-" +295, 2, 23, 27, 67, 71, 88, 92, "0107" +295, 2, 24, 28, 72, 73, 93, 94, "-" +295, 2, 25, 29, 74, 75, 95, 96, "8" +295, 2, 26, 30, 76, 77, 97, 98, "." +295, 3, 1, 31, 0, 11, 99, 110, "Saxagliptin" +295, 3, 2, 32, 12, 15, 111, 114, "add" +295, 3, 3, 33, 16, 17, 115, 116, "-" +295, 3, 4, 34, 18, 20, 117, 119, "on" +295, 3, 5, 35, 21, 28, 120, 127, "therapy" +295, 3, 6, 36, 29, 31, 128, 130, "to" +295, 3, 7, 37, 32, 39, 131, 138, "insulin" +295, 3, 8, 38, 40, 44, 139, 143, "with" +295, 3, 9, 39, 45, 47, 144, 146, "or" +295, 3, 10, 40, 48, 55, 147, 154, "without" +295, 3, 11, 41, 56, 65, 155, 164, "metformin" +295, 3, 12, 42, 66, 69, 165, 168, "for" +295, 3, 13, 43, 70, 74, 169, 173, "type" +295, 3, 14, 44, 75, 76, 174, 175, "2" +295, 3, 15, 45, 77, 85, 176, 184, "diabetes" +295, 3, 16, 46, 86, 94, 185, 193, "mellitus" +295, 3, 17, 47, 95, 96, 194, 195, ":" +295, 3, 18, 48, 97, 99, 196, 198, "52" +295, 3, 19, 49, 100, 101, 199, 200, "-" +295, 3, 20, 50, 102, 106, 201, 205, "week" +295, 3, 21, 51, 107, 113, 206, 212, "safety" +295, 3, 22, 52, 114, 117, 213, 216, "and" +295, 3, 23, 53, 118, 126, 217, 225, "efficacy" +295, 3, 24, 54, 127, 128, 226, 227, "." +295, 4, 1, 55, 0, 7, 228, 235, "Barnett" +295, 4, 2, 56, 8, 10, 236, 238, "AH" +295, 4, 3, 57, 11, 12, 239, 240, "(" +295, 4, 4, 58, 13, 14, 241, 242, "1" +295, 4, 5, 59, 15, 16, 243, 244, ")" +295, 4, 6, 60, 17, 18, 245, 246, "," +295, 4, 7, 61, 19, 29, 247, 257, "Charbonnel" +295, 4, 8, 62, 30, 31, 258, 259, "B" +295, 4, 9, 63, 32, 33, 260, 261, "," +295, 4, 10, 64, 34, 36, 262, 264, "Li" +295, 4, 11, 65, 37, 38, 265, 266, "J" +295, 4, 12, 66, 39, 40, 267, 268, "," +295, 4, 13, 67, 41, 48, 269, 276, "Donovan" +295, 4, 14, 68, 49, 50, 277, 278, "M" +295, 4, 15, 69, 51, 52, 279, 280, "," +295, 4, 16, 70, 53, 60, 281, 288, "Fleming" +295, 4, 17, 71, 61, 62, 289, 290, "D" +295, 4, 18, 72, 63, 64, 291, 292, "," +295, 4, 19, 73, 65, 70, 293, 298, "Iqbal" +295, 4, 20, 74, 71, 72, 299, 300, "N" +295, 4, 21, 75, 73, 74, 301, 302, "." +295, 4, 22, 76, 75, 81, 303, 309, "Author" +295, 4, 23, 77, 82, 93, 310, 321, "information" +295, 4, 24, 78, 94, 95, 322, 323, ":" +295, 4, 25, 79, 96, 97, 324, 325, "(" +295, 4, 26, 80, 98, 99, 326, 327, "1" +295, 4, 27, 81, 100, 101, 328, 329, ")" +295, 4, 28, 82, 102, 110, 330, 338, "Diabetes" +295, 4, 29, 83, 111, 117, 339, 345, "Centre" +295, 4, 30, 84, 118, 119, 346, 347, "," +295, 4, 31, 85, 120, 125, 348, 353, "Heart" +295, 4, 32, 86, 126, 128, 354, 356, "of" +295, 4, 33, 87, 129, 136, 357, 364, "England" +295, 4, 34, 88, 137, 145, 365, 373, "National" +295, 4, 35, 89, 146, 152, 374, 380, "Health" +295, 4, 36, 90, 153, 160, 381, 388, "Service" +295, 4, 37, 91, 161, 171, 389, 399, "Foundation" +295, 4, 38, 92, 172, 177, 400, 405, "Trust" +295, 4, 39, 93, 178, 181, 406, 409, "and" +295, 4, 40, 94, 182, 192, 410, 420, "University" +295, 4, 41, 95, 193, 195, 421, 423, "of" +295, 4, 42, 96, 196, 206, 424, 434, "Birmingham" +295, 4, 43, 97, 207, 208, 435, 436, "," +295, 4, 44, 98, 209, 219, 437, 447, "Birmingham" +295, 4, 45, 99, 220, 221, 448, 449, "," +295, 4, 46, 100, 222, 224, 450, 452, "UK" +295, 4, 47, 101, 225, 226, 453, 454, "." +295, 5, 1, 102, 0, 10, 455, 465, "BACKGROUND" +295, 5, 2, 103, 11, 12, 466, 467, ":" +295, 5, 3, 104, 13, 24, 468, 479, "Achievement" +295, 5, 4, 105, 25, 27, 480, 482, "of" +295, 5, 5, 106, 28, 36, 483, 491, "glycemic" +295, 5, 6, 107, 37, 44, 492, 499, "control" +295, 5, 7, 108, 45, 47, 500, 502, "is" +295, 5, 8, 109, 48, 50, 503, 505, "an" +295, 5, 9, 110, 51, 60, 506, 515, "important" +295, 5, 10, 111, 61, 70, 516, 525, "objective" +295, 5, 11, 112, 71, 73, 526, 528, "in" +295, 5, 12, 113, 74, 77, 529, 532, "the" +295, 5, 13, 114, 78, 88, 533, 543, "management" +295, 5, 14, 115, 89, 91, 544, 546, "of" +295, 5, 15, 116, 92, 96, 547, 551, "type" +295, 5, 16, 117, 97, 98, 552, 553, "2" +295, 5, 17, 118, 99, 107, 554, 562, "diabetes" +295, 5, 18, 119, 108, 116, 563, 571, "mellitus" +295, 5, 19, 120, 117, 118, 572, 573, "(" +295, 5, 20, 121, 119, 123, 574, 578, "T2DM" +295, 5, 21, 122, 124, 125, 579, 580, ")" +295, 5, 22, 123, 126, 127, 581, 582, "." +295, 6, 1, 124, 0, 9, 583, 592, "OBJECTIVE" +295, 6, 2, 125, 10, 11, 593, 594, ":" +295, 6, 3, 126, 12, 15, 595, 598, "The" +295, 6, 4, 127, 16, 25, 599, 608, "objective" +295, 6, 5, 128, 26, 28, 609, 611, "of" +295, 6, 6, 129, 29, 33, 612, 616, "this" +295, 6, 7, 130, 34, 39, 617, 622, "study" +295, 6, 8, 131, 40, 43, 623, 626, "was" +295, 6, 9, 132, 44, 46, 627, 629, "to" +295, 6, 10, 133, 47, 55, 630, 638, "evaluate" +295, 6, 11, 134, 56, 59, 639, 642, "the" +295, 6, 12, 135, 60, 66, 643, 649, "safety" +295, 6, 13, 136, 67, 70, 650, 653, "and" +295, 6, 14, 137, 71, 79, 654, 662, "efficacy" +295, 6, 15, 138, 80, 82, 663, 665, "of" +295, 6, 16, 139, 83, 86, 666, 669, "the" +295, 6, 17, 140, 87, 97, 670, 680, "dipeptidyl" +295, 6, 18, 141, 98, 107, 681, 690, "peptidase" +295, 6, 19, 142, 108, 109, 691, 692, "-" +295, 6, 20, 143, 110, 111, 693, 694, "4" +295, 6, 21, 144, 112, 121, 695, 704, "inhibitor" +295, 6, 22, 145, 122, 133, 705, 716, "saxagliptin" +295, 6, 23, 146, 134, 140, 717, 723, "versus" +295, 6, 24, 147, 141, 148, 724, 731, "placebo" +295, 6, 25, 148, 149, 151, 732, 734, "as" +295, 6, 26, 149, 152, 155, 735, 738, "add" +295, 6, 27, 150, 156, 157, 739, 740, "-" +295, 6, 28, 151, 158, 160, 741, 743, "on" +295, 6, 29, 152, 161, 168, 744, 751, "therapy" +295, 6, 30, 153, 169, 171, 752, 754, "in" +295, 6, 31, 154, 172, 180, 755, 763, "patients" +295, 6, 32, 155, 181, 185, 764, 768, "with" +295, 6, 33, 156, 186, 190, 769, 773, "T2DM" +295, 6, 34, 157, 191, 203, 774, 786, "inadequately" +295, 6, 35, 158, 204, 214, 787, 797, "controlled" +295, 6, 36, 159, 215, 219, 798, 802, "with" +295, 6, 37, 160, 220, 227, 803, 810, "insulin" +295, 6, 38, 161, 228, 233, 811, 816, "alone" +295, 6, 39, 162, 234, 236, 817, 819, "or" +295, 6, 40, 163, 237, 244, 820, 827, "insulin" +295, 6, 41, 164, 245, 249, 828, 832, "plus" +295, 6, 42, 165, 250, 259, 833, 842, "metformin" +295, 6, 43, 166, 260, 261, 843, 844, "." +295, 7, 1, 167, 0, 7, 845, 852, "METHODS" +295, 7, 2, 168, 8, 9, 853, 854, ":" +295, 7, 3, 169, 10, 14, 855, 859, "This" +295, 7, 4, 170, 15, 18, 860, 863, "was" +295, 7, 5, 171, 19, 20, 864, 865, "a" +295, 7, 6, 172, 21, 25, 866, 870, "long" +295, 7, 7, 173, 26, 27, 871, 872, "-" +295, 7, 8, 174, 28, 32, 873, 877, "term" +295, 7, 9, 175, 33, 34, 878, 879, "(" +295, 7, 10, 176, 35, 37, 880, 882, "28" +295, 7, 11, 177, 38, 39, 883, 884, "-" +295, 7, 12, 178, 40, 44, 885, 889, "week" +295, 7, 13, 179, 45, 46, 890, 891, ")" +295, 7, 14, 180, 47, 56, 892, 901, "extension" +295, 7, 15, 181, 57, 59, 902, 904, "of" +295, 7, 16, 182, 60, 61, 905, 906, "a" +295, 7, 17, 183, 62, 67, 907, 912, "short" +295, 7, 18, 184, 68, 69, 913, 914, "-" +295, 7, 19, 185, 70, 74, 915, 919, "term" +295, 7, 20, 186, 75, 76, 920, 921, "(" +295, 7, 21, 187, 77, 79, 922, 924, "24" +295, 7, 22, 188, 80, 81, 925, 926, "-" +295, 7, 23, 189, 82, 86, 927, 931, "week" +295, 7, 24, 190, 87, 88, 932, 933, ")" +295, 7, 25, 191, 89, 90, 934, 935, "," +295, 7, 26, 192, 91, 101, 936, 946, "randomized" +295, 7, 27, 193, 102, 103, 947, 948, "," +295, 7, 28, 194, 104, 110, 949, 955, "double" +295, 7, 29, 195, 111, 112, 956, 957, "-" +295, 7, 30, 196, 113, 118, 958, 963, "blind" +295, 7, 31, 197, 119, 120, 964, 965, "," +295, 7, 32, 198, 121, 129, 966, 974, "parallel" +295, 7, 33, 199, 130, 131, 975, 976, "-" +295, 7, 34, 200, 132, 137, 977, 982, "group" +295, 7, 35, 201, 138, 143, 983, 988, "trial" +295, 7, 36, 202, 144, 146, 989, 991, "of" +295, 7, 37, 203, 147, 158, 992, 1003, "saxagliptin" +295, 7, 38, 204, 159, 160, 1004, 1005, "5" +295, 7, 39, 205, 161, 163, 1006, 1008, "mg" +295, 7, 40, 206, 164, 168, 1009, 1013, "once" +295, 7, 41, 207, 169, 174, 1014, 1019, "daily" +295, 7, 42, 208, 175, 181, 1020, 1026, "versus" +295, 7, 43, 209, 182, 189, 1027, 1034, "placebo" +295, 7, 44, 210, 190, 192, 1035, 1037, "as" +295, 7, 45, 211, 193, 196, 1038, 1041, "add" +295, 7, 46, 212, 197, 198, 1042, 1043, "-" +295, 7, 47, 213, 199, 201, 1044, 1046, "on" +295, 7, 48, 214, 202, 209, 1047, 1054, "therapy" +295, 7, 49, 215, 210, 212, 1055, 1057, "to" +295, 7, 50, 216, 213, 217, 1058, 1062, "open" +295, 7, 51, 217, 218, 219, 1063, 1064, "-" +295, 7, 52, 218, 220, 225, 1065, 1070, "label" +295, 7, 53, 219, 226, 233, 1071, 1078, "insulin" +295, 7, 54, 220, 234, 236, 1079, 1081, "or" +295, 7, 55, 221, 237, 244, 1082, 1089, "insulin" +295, 7, 56, 222, 245, 249, 1090, 1094, "plus" +295, 7, 57, 223, 250, 259, 1095, 1104, "metformin" +295, 7, 58, 224, 260, 267, 1105, 1112, "therapy" +295, 7, 59, 225, 268, 276, 1113, 1121, "totaling" +295, 7, 60, 226, 277, 279, 1122, 1124, "52" +295, 7, 61, 227, 280, 285, 1125, 1130, "weeks" +295, 7, 62, 228, 286, 288, 1131, 1133, "of" +295, 7, 63, 229, 289, 298, 1134, 1143, "treatment" +295, 7, 64, 230, 299, 300, 1144, 1145, "." +295, 8, 1, 231, 0, 2, 1146, 1148, "In" +295, 8, 2, 232, 3, 11, 1149, 1157, "contrast" +295, 8, 3, 233, 12, 16, 1158, 1162, "with" +295, 8, 4, 234, 17, 20, 1163, 1166, "the" +295, 8, 5, 235, 21, 25, 1167, 1171, "goal" +295, 8, 6, 236, 26, 28, 1172, 1174, "of" +295, 8, 7, 237, 29, 40, 1175, 1186, "maintaining" +295, 8, 8, 238, 41, 42, 1187, 1188, "a" +295, 8, 9, 239, 43, 49, 1189, 1195, "stable" +295, 8, 10, 240, 50, 57, 1196, 1203, "insulin" +295, 8, 11, 241, 58, 64, 1204, 1210, "dosage" +295, 8, 12, 242, 65, 71, 1211, 1217, "during" +295, 8, 13, 243, 72, 75, 1218, 1221, "the" +295, 8, 14, 244, 76, 81, 1222, 1227, "short" +295, 8, 15, 245, 82, 83, 1228, 1229, "-" +295, 8, 16, 246, 84, 88, 1230, 1234, "term" +295, 8, 17, 247, 89, 94, 1235, 1240, "phase" +295, 8, 18, 248, 95, 96, 1241, 1242, "," +295, 8, 19, 249, 97, 103, 1243, 1249, "during" +295, 8, 20, 250, 104, 107, 1250, 1253, "the" +295, 8, 21, 251, 108, 117, 1254, 1263, "extension" +295, 8, 22, 252, 118, 123, 1264, 1269, "phase" +295, 8, 23, 253, 124, 127, 1270, 1273, "the" +295, 8, 24, 254, 128, 135, 1274, 1281, "insulin" +295, 8, 25, 255, 136, 142, 1282, 1288, "dosage" +295, 8, 26, 256, 143, 146, 1289, 1292, "was" +295, 8, 27, 257, 147, 155, 1293, 1301, "flexible" +295, 8, 28, 258, 156, 159, 1302, 1305, "and" +295, 8, 29, 259, 160, 168, 1306, 1314, "adjusted" +295, 8, 30, 260, 169, 171, 1315, 1317, "as" +295, 8, 31, 261, 172, 178, 1318, 1324, "deemed" +295, 8, 32, 262, 179, 190, 1325, 1336, "appropriate" +295, 8, 33, 263, 191, 193, 1337, 1339, "by" +295, 8, 34, 264, 194, 197, 1340, 1343, "the" +295, 8, 35, 265, 198, 210, 1344, 1356, "investigator" +295, 8, 36, 266, 211, 212, 1357, 1358, "." +295, 9, 1, 267, 0, 3, 1359, 1362, "The" +295, 9, 2, 268, 4, 9, 1363, 1368, "study" +295, 9, 3, 269, 10, 13, 1369, 1372, "was" +295, 9, 4, 270, 14, 23, 1373, 1382, "conducted" +295, 9, 5, 271, 24, 26, 1383, 1385, "in" +295, 9, 6, 272, 27, 28, 1386, 1387, "a" +295, 9, 7, 273, 29, 37, 1388, 1396, "clinical" +295, 9, 8, 274, 38, 46, 1397, 1405, "practice" +295, 9, 9, 275, 47, 54, 1406, 1413, "setting" +295, 9, 10, 276, 55, 56, 1414, 1415, "," +295, 9, 11, 277, 57, 66, 1416, 1425, "including" +295, 9, 12, 278, 67, 73, 1426, 1432, "family" +295, 9, 13, 279, 74, 82, 1433, 1441, "practice" +295, 9, 14, 280, 83, 86, 1442, 1445, "and" +295, 9, 15, 281, 87, 95, 1446, 1454, "hospital" +295, 9, 16, 282, 96, 101, 1455, 1460, "sites" +295, 9, 17, 283, 102, 103, 1461, 1462, "." +295, 10, 1, 284, 0, 8, 1463, 1471, "Patients" +295, 10, 2, 285, 9, 13, 1472, 1476, "with" +295, 10, 3, 286, 14, 18, 1477, 1481, "T2DM" +295, 10, 4, 287, 19, 23, 1482, 1486, "aged" +295, 10, 5, 288, 24, 26, 1487, 1489, "18" +295, 10, 6, 289, 27, 28, 1490, 1491, "-" +295, 10, 7, 290, 29, 31, 1492, 1494, "78" +295, 10, 8, 291, 32, 37, 1495, 1500, "years" +295, 10, 9, 292, 38, 42, 1501, 1505, "with" +295, 10, 10, 293, 43, 51, 1506, 1514, "glycated" +295, 10, 11, 294, 52, 62, 1515, 1525, "hemoglobin" +295, 10, 12, 295, 63, 64, 1526, 1527, "(" +295, 10, 13, 296, 65, 70, 1528, 1533, "HbA1c" +295, 10, 14, 297, 71, 72, 1534, 1535, ")" +295, 10, 15, 298, 73, 74, 1536, 1537, "7" +295, 10, 16, 299, 75, 76, 1538, 1539, "." +295, 10, 17, 300, 77, 78, 1540, 1541, "5" +295, 10, 18, 301, 79, 80, 1542, 1543, "-" +295, 10, 19, 302, 81, 83, 1544, 1546, "11" +295, 10, 20, 303, 84, 85, 1547, 1548, "%" +295, 10, 21, 304, 86, 88, 1549, 1551, "on" +295, 10, 22, 305, 89, 90, 1552, 1553, "a" +295, 10, 23, 306, 91, 97, 1554, 1560, "stable" +295, 10, 24, 307, 98, 105, 1561, 1568, "insulin" +295, 10, 25, 308, 106, 113, 1569, 1576, "regimen" +295, 10, 26, 309, 114, 115, 1577, 1578, "(" +295, 10, 27, 310, 116, 118, 1579, 1581, "30" +295, 10, 28, 311, 119, 120, 1582, 1583, "-" +295, 10, 29, 312, 121, 124, 1584, 1587, "150" +295, 10, 30, 313, 125, 126, 1588, 1589, "U" +295, 10, 31, 314, 127, 128, 1590, 1591, "/" +295, 10, 32, 315, 129, 132, 1592, 1595, "day" +295, 10, 33, 316, 133, 137, 1596, 1600, "with" +295, 10, 34, 317, 138, 140, 1601, 1603, "or" +295, 10, 35, 318, 141, 148, 1604, 1611, "without" +295, 10, 36, 319, 149, 158, 1612, 1621, "metformin" +295, 10, 37, 320, 159, 160, 1622, 1623, ")" +295, 10, 38, 321, 161, 164, 1624, 1627, "for" +295, 10, 39, 322, 165, 166, 1628, 1629, "≥" +295, 10, 40, 323, 167, 168, 1630, 1631, "8" +295, 10, 41, 324, 169, 174, 1632, 1637, "weeks" +295, 10, 42, 325, 175, 177, 1638, 1640, "at" +295, 10, 43, 326, 178, 187, 1641, 1650, "screening" +295, 10, 44, 327, 188, 192, 1651, 1655, "were" +295, 10, 45, 328, 193, 201, 1656, 1664, "included" +295, 10, 46, 329, 202, 204, 1665, 1667, "in" +295, 10, 47, 330, 205, 208, 1668, 1671, "the" +295, 10, 48, 331, 209, 214, 1672, 1677, "study" +295, 10, 49, 332, 215, 216, 1678, 1679, "." +295, 11, 1, 333, 0, 8, 1680, 1688, "Patients" +295, 11, 2, 334, 9, 13, 1689, 1693, "were" +295, 11, 3, 335, 14, 24, 1694, 1704, "stratified" +295, 11, 4, 336, 25, 27, 1705, 1707, "by" +295, 11, 5, 337, 28, 37, 1708, 1717, "metformin" +295, 11, 6, 338, 38, 41, 1718, 1721, "use" +295, 11, 7, 339, 42, 45, 1722, 1725, "and" +295, 11, 8, 340, 46, 54, 1726, 1734, "randomly" +295, 11, 9, 341, 55, 63, 1735, 1743, "assigned" +295, 11, 10, 342, 64, 65, 1744, 1745, "2" +295, 11, 11, 343, 66, 67, 1746, 1747, ":" +295, 11, 12, 344, 68, 69, 1748, 1749, "1" +295, 11, 13, 345, 70, 72, 1750, 1752, "to" +295, 11, 14, 346, 73, 77, 1753, 1757, "oral" +295, 11, 15, 347, 78, 89, 1758, 1769, "saxagliptin" +295, 11, 16, 348, 90, 91, 1770, 1771, "5" +295, 11, 17, 349, 92, 94, 1772, 1774, "mg" +295, 11, 18, 350, 95, 96, 1775, 1776, "(" +295, 11, 19, 351, 97, 98, 1777, 1778, "n" +295, 11, 20, 352, 99, 100, 1779, 1780, "=" +295, 11, 21, 353, 101, 104, 1781, 1784, "304" +295, 11, 22, 354, 105, 106, 1785, 1786, ")" +295, 11, 23, 355, 107, 109, 1787, 1789, "or" +295, 11, 24, 356, 110, 117, 1790, 1797, "placebo" +295, 11, 25, 357, 118, 119, 1798, 1799, "(" +295, 11, 26, 358, 120, 121, 1800, 1801, "n" +295, 11, 27, 359, 122, 123, 1802, 1803, "=" +295, 11, 28, 360, 124, 127, 1804, 1807, "151" +295, 11, 29, 361, 128, 129, 1808, 1809, ")" +295, 11, 30, 362, 130, 134, 1810, 1814, "once" +295, 11, 31, 363, 135, 140, 1815, 1820, "daily" +295, 11, 32, 364, 141, 142, 1821, 1822, "." +295, 12, 1, 365, 0, 3, 1823, 1826, "All" +295, 12, 2, 366, 4, 12, 1827, 1835, "patients" +295, 12, 3, 367, 13, 16, 1836, 1839, "who" +295, 12, 4, 368, 17, 26, 1840, 1849, "completed" +295, 12, 5, 369, 27, 30, 1850, 1853, "the" +295, 12, 6, 370, 31, 38, 1854, 1861, "initial" +295, 12, 7, 371, 39, 41, 1862, 1864, "24" +295, 12, 8, 372, 42, 47, 1865, 1870, "weeks" +295, 12, 9, 373, 48, 50, 1871, 1873, "of" +295, 12, 10, 374, 51, 60, 1874, 1883, "treatment" +295, 12, 11, 375, 61, 65, 1884, 1888, "were" +295, 12, 12, 376, 66, 74, 1889, 1897, "eligible" +295, 12, 13, 377, 75, 77, 1898, 1900, "to" +295, 12, 14, 378, 78, 89, 1901, 1912, "participate" +295, 12, 15, 379, 90, 92, 1913, 1915, "in" +295, 12, 16, 380, 93, 96, 1916, 1919, "the" +295, 12, 17, 381, 97, 99, 1920, 1922, "28" +295, 12, 18, 382, 100, 101, 1923, 1924, "-" +295, 12, 19, 383, 102, 106, 1925, 1929, "week" +295, 12, 20, 384, 107, 116, 1930, 1939, "extension" +295, 12, 21, 385, 117, 118, 1940, 1941, "," +295, 12, 22, 386, 119, 129, 1942, 1952, "regardless" +295, 12, 23, 387, 130, 132, 1953, 1955, "of" +295, 12, 24, 388, 133, 140, 1956, 1963, "whether" +295, 12, 25, 389, 141, 145, 1964, 1968, "they" +295, 12, 26, 390, 146, 149, 1969, 1972, "had" +295, 12, 27, 391, 150, 158, 1973, 1981, "required" +295, 12, 28, 392, 159, 165, 1982, 1988, "rescue" +295, 12, 29, 393, 166, 175, 1989, 1998, "treatment" +295, 12, 30, 394, 176, 177, 1999, 2000, "." +295, 13, 1, 395, 0, 3, 2001, 2004, "The" +295, 13, 2, 396, 4, 8, 2005, 2009, "main" +295, 13, 3, 397, 9, 16, 2010, 2017, "outcome" +295, 13, 4, 398, 17, 24, 2018, 2025, "measure" +295, 13, 5, 399, 25, 28, 2026, 2029, "was" +295, 13, 6, 400, 29, 35, 2030, 2036, "change" +295, 13, 7, 401, 36, 38, 2037, 2039, "in" +295, 13, 8, 402, 39, 44, 2040, 2045, "HbA1c" +295, 13, 9, 403, 45, 49, 2046, 2050, "from" +295, 13, 10, 404, 50, 58, 2051, 2059, "baseline" +295, 13, 11, 405, 59, 61, 2060, 2062, "to" +295, 13, 12, 406, 62, 66, 2063, 2067, "week" +295, 13, 13, 407, 67, 69, 2068, 2070, "52" +295, 13, 14, 408, 70, 71, 2071, 2072, "." +295, 14, 1, 409, 0, 7, 2073, 2080, "RESULTS" +295, 14, 2, 410, 8, 9, 2081, 2082, ":" +295, 14, 3, 411, 10, 12, 2083, 2085, "In" +295, 14, 4, 412, 13, 20, 2086, 2093, "general" +295, 14, 5, 413, 21, 22, 2094, 2095, "," +295, 14, 6, 414, 23, 26, 2096, 2099, "the" +295, 14, 7, 415, 27, 35, 2100, 2108, "outcomes" +295, 14, 8, 416, 36, 44, 2109, 2117, "achieved" +295, 14, 9, 417, 45, 47, 2118, 2120, "at" +295, 14, 10, 418, 48, 52, 2121, 2125, "week" +295, 14, 11, 419, 53, 55, 2126, 2128, "24" +295, 14, 12, 420, 56, 60, 2129, 2133, "were" +295, 14, 13, 421, 61, 70, 2134, 2143, "sustained" +295, 14, 14, 422, 71, 73, 2144, 2146, "to" +295, 14, 15, 423, 74, 78, 2147, 2151, "week" +295, 14, 16, 424, 79, 81, 2152, 2154, "52" +295, 14, 17, 425, 82, 83, 2155, 2156, "." +295, 15, 1, 426, 0, 8, 2157, 2165, "Adjusted" +295, 15, 2, 427, 9, 13, 2166, 2170, "mean" +295, 15, 3, 428, 14, 20, 2171, 2177, "change" +295, 15, 4, 429, 21, 25, 2178, 2182, "from" +295, 15, 5, 430, 26, 34, 2183, 2191, "baseline" +295, 15, 6, 431, 35, 40, 2192, 2197, "HbA1c" +295, 15, 7, 432, 41, 43, 2198, 2200, "at" +295, 15, 8, 433, 44, 48, 2201, 2205, "week" +295, 15, 9, 434, 49, 51, 2206, 2208, "52" +295, 15, 10, 435, 52, 55, 2209, 2212, "was" +295, 15, 11, 436, 56, 63, 2213, 2220, "greater" +295, 15, 12, 437, 64, 68, 2221, 2225, "with" +295, 15, 13, 438, 69, 80, 2226, 2237, "saxagliptin" +295, 15, 14, 439, 81, 82, 2238, 2239, "(" +295, 15, 15, 440, 83, 84, 2240, 2241, "-" +295, 15, 16, 441, 85, 86, 2242, 2243, "0" +295, 15, 17, 442, 87, 88, 2244, 2245, "." +295, 15, 18, 443, 89, 91, 2246, 2248, "75" +295, 15, 19, 444, 92, 93, 2249, 2250, "%" +295, 15, 20, 445, 94, 95, 2251, 2252, ")" +295, 15, 21, 446, 96, 102, 2253, 2259, "versus" +295, 15, 22, 447, 103, 110, 2260, 2267, "placebo" +295, 15, 23, 448, 111, 112, 2268, 2269, "(" +295, 15, 24, 449, 113, 114, 2270, 2271, "-" +295, 15, 25, 450, 115, 116, 2272, 2273, "0" +295, 15, 26, 451, 117, 118, 2274, 2275, "." +295, 15, 27, 452, 119, 121, 2276, 2278, "38" +295, 15, 28, 453, 122, 123, 2279, 2280, "%" +295, 15, 29, 454, 124, 125, 2281, 2282, ")" +295, 15, 30, 455, 126, 127, 2283, 2284, ";" +295, 15, 31, 456, 128, 131, 2285, 2288, "the" +295, 15, 32, 457, 132, 140, 2289, 2297, "adjusted" +295, 15, 33, 458, 141, 148, 2298, 2305, "between" +295, 15, 34, 459, 149, 150, 2306, 2307, "-" +295, 15, 35, 460, 151, 156, 2308, 2313, "group" +295, 15, 36, 461, 157, 167, 2314, 2324, "difference" +295, 15, 37, 462, 168, 171, 2325, 2328, "was" +295, 15, 38, 463, 172, 173, 2329, 2330, "-" +295, 15, 39, 464, 174, 175, 2331, 2332, "0" +295, 15, 40, 465, 176, 177, 2333, 2334, "." +295, 15, 41, 466, 178, 180, 2335, 2337, "37" +295, 15, 42, 467, 181, 182, 2338, 2339, "%" +295, 15, 43, 468, 183, 184, 2340, 2341, "(" +295, 15, 44, 469, 185, 187, 2342, 2344, "95" +295, 15, 45, 470, 188, 189, 2345, 2346, "%" +295, 15, 46, 471, 190, 192, 2347, 2349, "CI" +295, 15, 47, 472, 193, 194, 2350, 2351, "-" +295, 15, 48, 473, 195, 196, 2352, 2353, "0" +295, 15, 49, 474, 197, 198, 2354, 2355, "." +295, 15, 50, 475, 199, 201, 2356, 2358, "55" +295, 15, 51, 476, 202, 204, 2359, 2361, "to" +295, 15, 52, 477, 205, 206, 2362, 2363, "-" +295, 15, 53, 478, 207, 208, 2364, 2365, "0" +295, 15, 54, 479, 209, 210, 2366, 2367, "." +295, 15, 55, 480, 211, 213, 2368, 2370, "19" +295, 15, 56, 481, 214, 215, 2371, 2372, ")" +295, 15, 57, 482, 216, 217, 2373, 2374, ";" +295, 15, 58, 483, 218, 225, 2375, 2382, "between" +295, 15, 59, 484, 226, 227, 2383, 2384, "-" +295, 15, 60, 485, 228, 233, 2385, 2390, "group" +295, 15, 61, 486, 234, 245, 2391, 2402, "differences" +295, 15, 62, 487, 246, 250, 2403, 2407, "were" +295, 15, 63, 488, 251, 258, 2408, 2415, "similar" +295, 15, 64, 489, 259, 261, 2416, 2418, "in" +295, 15, 65, 490, 262, 270, 2419, 2427, "patients" +295, 15, 66, 491, 271, 278, 2428, 2435, "treated" +295, 15, 67, 492, 279, 283, 2436, 2440, "with" +295, 15, 68, 493, 284, 293, 2441, 2450, "metformin" +295, 15, 69, 494, 294, 295, 2451, 2452, "(" +295, 15, 70, 495, 296, 297, 2453, 2454, "-" +295, 15, 71, 496, 298, 299, 2455, 2456, "0" +295, 15, 72, 497, 300, 301, 2457, 2458, "." +295, 15, 73, 498, 302, 304, 2459, 2461, "37" +295, 15, 74, 499, 305, 306, 2462, 2463, "%" +295, 15, 75, 500, 307, 308, 2464, 2465, "[" +295, 15, 76, 501, 309, 311, 2466, 2468, "95" +295, 15, 77, 502, 312, 313, 2469, 2470, "%" +295, 15, 78, 503, 314, 316, 2471, 2473, "CI" +295, 15, 79, 504, 317, 318, 2474, 2475, "-" +295, 15, 80, 505, 319, 320, 2476, 2477, "0" +295, 15, 81, 506, 321, 322, 2478, 2479, "." +295, 15, 82, 507, 323, 325, 2480, 2482, "59" +295, 15, 83, 508, 326, 328, 2483, 2485, "to" +295, 15, 84, 509, 329, 330, 2486, 2487, "-" +295, 15, 85, 510, 331, 332, 2488, 2489, "0" +295, 15, 86, 511, 333, 334, 2490, 2491, "." +295, 15, 87, 512, 335, 337, 2492, 2494, "15" +295, 15, 88, 513, 338, 339, 2495, 2496, "]" +295, 15, 89, 514, 340, 341, 2497, 2498, ")" +295, 15, 90, 515, 342, 345, 2499, 2502, "and" +295, 15, 91, 516, 346, 353, 2503, 2510, "without" +295, 15, 92, 517, 354, 363, 2511, 2520, "metformin" +295, 15, 93, 518, 364, 365, 2521, 2522, "(" +295, 15, 94, 519, 366, 367, 2523, 2524, "-" +295, 15, 95, 520, 368, 369, 2525, 2526, "0" +295, 15, 96, 521, 370, 371, 2527, 2528, "." +295, 15, 97, 522, 372, 374, 2529, 2531, "37" +295, 15, 98, 523, 375, 376, 2532, 2533, "%" +295, 15, 99, 524, 377, 378, 2534, 2535, "[" +295, 15, 100, 525, 379, 381, 2536, 2538, "95" +295, 15, 101, 526, 382, 383, 2539, 2540, "%" +295, 15, 102, 527, 384, 386, 2541, 2543, "CI" +295, 15, 103, 528, 387, 388, 2544, 2545, "-" +295, 15, 104, 529, 389, 390, 2546, 2547, "0" +295, 15, 105, 530, 391, 392, 2548, 2549, "." +295, 15, 106, 531, 393, 395, 2550, 2552, "69" +295, 15, 107, 532, 396, 398, 2553, 2555, "to" +295, 15, 108, 533, 399, 400, 2556, 2557, "-" +295, 15, 109, 534, 401, 402, 2558, 2559, "0" +295, 15, 110, 535, 403, 404, 2560, 2561, "." +295, 15, 111, 536, 405, 407, 2562, 2564, "04" +295, 15, 112, 537, 408, 409, 2565, 2566, "]" +295, 15, 113, 538, 410, 411, 2567, 2568, ")" +295, 15, 114, 539, 412, 413, 2569, 2570, "." +295, 16, 1, 540, 0, 2, 2571, 2573, "At" +295, 16, 2, 541, 3, 7, 2574, 2578, "week" +295, 16, 3, 542, 8, 10, 2579, 2581, "52" +295, 16, 4, 543, 11, 12, 2582, 2583, "," +295, 16, 5, 544, 13, 14, 2584, 2585, "a" +295, 16, 6, 545, 15, 22, 2586, 2593, "greater" +295, 16, 7, 546, 23, 33, 2594, 2604, "proportion" +295, 16, 8, 547, 34, 36, 2605, 2607, "of" +295, 16, 9, 548, 37, 45, 2608, 2616, "patients" +295, 16, 10, 549, 46, 55, 2617, 2626, "receiving" +295, 16, 11, 550, 56, 67, 2627, 2638, "saxagliptin" +295, 16, 12, 551, 68, 76, 2639, 2647, "achieved" +295, 16, 13, 552, 77, 82, 2648, 2653, "HbA1c" +295, 16, 14, 553, 83, 84, 2654, 2655, "<" +295, 16, 15, 554, 85, 86, 2656, 2657, "7" +295, 16, 16, 555, 87, 88, 2658, 2659, "%" +295, 16, 17, 556, 89, 93, 2660, 2664, "than" +295, 16, 18, 557, 94, 99, 2665, 2670, "those" +295, 16, 19, 558, 100, 109, 2671, 2680, "receiving" +295, 16, 20, 559, 110, 117, 2681, 2688, "placebo" +295, 16, 21, 560, 118, 119, 2689, 2690, "(" +295, 16, 22, 561, 120, 122, 2691, 2693, "21" +295, 16, 23, 562, 123, 124, 2694, 2695, "." +295, 16, 24, 563, 125, 126, 2696, 2697, "3" +295, 16, 25, 564, 127, 129, 2698, 2700, "vs" +295, 16, 26, 565, 130, 131, 2701, 2702, "." +295, 16, 27, 566, 132, 133, 2703, 2704, "8" +295, 16, 28, 567, 134, 135, 2705, 2706, "." +295, 16, 29, 568, 136, 137, 2707, 2708, "7" +295, 16, 30, 569, 138, 139, 2709, 2710, "%" +295, 16, 31, 570, 140, 141, 2711, 2712, ";" +295, 16, 32, 571, 142, 149, 2713, 2720, "between" +295, 16, 33, 572, 150, 151, 2721, 2722, "-" +295, 16, 34, 573, 152, 157, 2723, 2728, "group" +295, 16, 35, 574, 158, 168, 2729, 2739, "difference" +295, 16, 36, 575, 169, 171, 2740, 2742, "12" +295, 16, 37, 576, 172, 173, 2743, 2744, "." +295, 16, 38, 577, 174, 175, 2745, 2746, "6" +295, 16, 39, 578, 176, 177, 2747, 2748, "%" +295, 16, 40, 579, 178, 179, 2749, 2750, "[" +295, 16, 41, 580, 180, 182, 2751, 2753, "95" +295, 16, 42, 581, 183, 184, 2754, 2755, "%" +295, 16, 43, 582, 185, 187, 2756, 2758, "CI" +295, 16, 44, 583, 188, 189, 2759, 2760, "6" +295, 16, 45, 584, 190, 191, 2761, 2762, "." +295, 16, 46, 585, 192, 193, 2763, 2764, "1" +295, 16, 47, 586, 194, 195, 2765, 2766, "-" +295, 16, 48, 587, 196, 198, 2767, 2769, "19" +295, 16, 49, 588, 199, 200, 2770, 2771, "." +295, 16, 50, 589, 201, 202, 2772, 2773, "1" +295, 16, 51, 590, 203, 204, 2774, 2775, "]" +295, 16, 52, 591, 205, 206, 2776, 2777, ")" +295, 16, 53, 592, 207, 208, 2778, 2779, "." +295, 17, 1, 593, 0, 3, 2780, 2783, "The" +295, 17, 2, 594, 4, 12, 2784, 2792, "increase" +295, 17, 3, 595, 13, 17, 2793, 2797, "from" +295, 17, 4, 596, 18, 26, 2798, 2806, "baseline" +295, 17, 5, 597, 27, 29, 2807, 2809, "in" +295, 17, 6, 598, 30, 34, 2810, 2814, "mean" +295, 17, 7, 599, 35, 40, 2815, 2820, "total" +295, 17, 8, 600, 41, 46, 2821, 2826, "daily" +295, 17, 9, 601, 47, 54, 2827, 2834, "insulin" +295, 17, 10, 602, 55, 59, 2835, 2839, "dose" +295, 17, 11, 603, 60, 62, 2840, 2842, "at" +295, 17, 12, 604, 63, 67, 2843, 2847, "week" +295, 17, 13, 605, 68, 70, 2848, 2850, "52" +295, 17, 14, 606, 71, 74, 2851, 2854, "was" +295, 17, 15, 607, 75, 86, 2855, 2866, "numerically" +295, 17, 16, 608, 87, 94, 2867, 2874, "smaller" +295, 17, 17, 609, 95, 99, 2875, 2879, "with" +295, 17, 18, 610, 100, 111, 2880, 2891, "saxagliptin" +295, 17, 19, 611, 112, 113, 2892, 2893, "(" +295, 17, 20, 612, 114, 115, 2894, 2895, "5" +295, 17, 21, 613, 116, 117, 2896, 2897, "." +295, 17, 22, 614, 118, 120, 2898, 2900, "67" +295, 17, 23, 615, 121, 123, 2901, 2903, "vs" +295, 17, 24, 616, 124, 125, 2904, 2905, "6" +295, 17, 25, 617, 126, 127, 2906, 2907, "." +295, 17, 26, 618, 128, 130, 2908, 2910, "67" +295, 17, 27, 619, 131, 132, 2911, 2912, "U" +295, 17, 28, 620, 133, 137, 2913, 2917, "with" +295, 17, 29, 621, 138, 145, 2918, 2925, "placebo" +295, 17, 30, 622, 146, 147, 2926, 2927, ";" +295, 17, 31, 623, 148, 158, 2928, 2938, "difference" +295, 17, 32, 624, 159, 160, 2939, 2940, "," +295, 17, 33, 625, 161, 162, 2941, 2942, "-" +295, 17, 34, 626, 163, 164, 2943, 2944, "1" +295, 17, 35, 627, 165, 166, 2945, 2946, "." +295, 17, 36, 628, 167, 169, 2947, 2949, "01" +295, 17, 37, 629, 170, 171, 2950, 2951, "U" +295, 17, 38, 630, 172, 173, 2952, 2953, "[" +295, 17, 39, 631, 174, 176, 2954, 2956, "95" +295, 17, 40, 632, 177, 178, 2957, 2958, "%" +295, 17, 41, 633, 179, 181, 2959, 2961, "CI" +295, 17, 42, 634, 182, 183, 2962, 2963, "-" +295, 17, 43, 635, 184, 185, 2964, 2965, "3" +295, 17, 44, 636, 186, 187, 2966, 2967, "." +295, 17, 45, 637, 188, 190, 2968, 2970, "24" +295, 17, 46, 638, 191, 193, 2971, 2973, "to" +295, 17, 47, 639, 194, 195, 2974, 2975, "1" +295, 17, 48, 640, 196, 197, 2976, 2977, "." +295, 17, 49, 641, 198, 200, 2978, 2980, "22" +295, 17, 50, 642, 201, 202, 2981, 2982, "]" +295, 17, 51, 643, 203, 204, 2983, 2984, ")" +295, 17, 52, 644, 205, 206, 2985, 2986, "." +295, 18, 1, 645, 0, 6, 2987, 2993, "During" +295, 18, 2, 646, 7, 10, 2994, 2997, "the" +295, 18, 3, 647, 11, 13, 2998, 3000, "52" +295, 18, 4, 648, 14, 15, 3001, 3002, "-" +295, 18, 5, 649, 16, 20, 3003, 3007, "week" +295, 18, 6, 650, 21, 26, 3008, 3013, "study" +295, 18, 7, 651, 27, 33, 3014, 3020, "period" +295, 18, 8, 652, 34, 35, 3021, 3022, "," +295, 18, 9, 653, 36, 39, 3023, 3026, "the" +295, 18, 10, 654, 40, 50, 3027, 3037, "proportion" +295, 18, 11, 655, 51, 53, 3038, 3040, "of" +295, 18, 12, 656, 54, 62, 3041, 3049, "patients" +295, 18, 13, 657, 63, 72, 3050, 3059, "reporting" +295, 18, 14, 658, 73, 74, 3060, 3061, "≥" +295, 18, 15, 659, 75, 76, 3062, 3063, "1" +295, 18, 16, 660, 77, 84, 3064, 3071, "adverse" +295, 18, 17, 661, 85, 90, 3072, 3077, "event" +295, 18, 18, 662, 91, 92, 3078, 3079, "(" +295, 18, 19, 663, 93, 95, 3080, 3082, "AE" +295, 18, 20, 664, 96, 97, 3083, 3084, ")" +295, 18, 21, 665, 98, 101, 3085, 3088, "was" +295, 18, 22, 666, 102, 104, 3089, 3091, "66" +295, 18, 23, 667, 105, 106, 3092, 3093, "." +295, 18, 24, 668, 107, 108, 3094, 3095, "4" +295, 18, 25, 669, 109, 110, 3096, 3097, "%" +295, 18, 26, 670, 111, 115, 3098, 3102, "with" +295, 18, 27, 671, 116, 127, 3103, 3114, "saxagliptin" +295, 18, 28, 672, 128, 131, 3115, 3118, "and" +295, 18, 29, 673, 132, 134, 3119, 3121, "71" +295, 18, 30, 674, 135, 136, 3122, 3123, "." +295, 18, 31, 675, 137, 138, 3124, 3125, "5" +295, 18, 32, 676, 139, 140, 3126, 3127, "%" +295, 18, 33, 677, 141, 145, 3128, 3132, "with" +295, 18, 34, 678, 146, 153, 3133, 3140, "placebo" +295, 18, 35, 679, 154, 155, 3141, 3142, "," +295, 18, 36, 680, 156, 159, 3143, 3146, "the" +295, 18, 37, 681, 160, 168, 3147, 3155, "majority" +295, 18, 38, 682, 169, 174, 3156, 3161, "being" +295, 18, 39, 683, 175, 179, 3162, 3166, "mild" +295, 18, 40, 684, 180, 182, 3167, 3169, "or" +295, 18, 41, 685, 183, 191, 3170, 3178, "moderate" +295, 18, 42, 686, 192, 194, 3179, 3181, "in" +295, 18, 43, 687, 195, 204, 3182, 3191, "intensity" +295, 18, 44, 688, 205, 206, 3192, 3193, "." +295, 19, 1, 689, 0, 3, 3194, 3197, "The" +295, 19, 2, 690, 4, 8, 3198, 3202, "most" +295, 19, 3, 691, 9, 15, 3203, 3209, "common" +295, 19, 4, 692, 16, 19, 3210, 3213, "AEs" +295, 19, 5, 693, 20, 21, 3214, 3215, "(" +295, 19, 6, 694, 22, 23, 3216, 3217, "≥" +295, 19, 7, 695, 24, 25, 3218, 3219, "5" +295, 19, 8, 696, 26, 27, 3220, 3221, "%" +295, 19, 9, 697, 28, 32, 3222, 3226, "with" +295, 19, 10, 698, 33, 44, 3227, 3238, "saxagliptin" +295, 19, 11, 699, 45, 47, 3239, 3241, "or" +295, 19, 12, 700, 48, 55, 3242, 3249, "placebo" +295, 19, 13, 701, 56, 57, 3250, 3251, ")" +295, 19, 14, 702, 58, 62, 3252, 3256, "were" +295, 19, 15, 703, 63, 70, 3257, 3264, "urinary" +295, 19, 16, 704, 71, 76, 3265, 3270, "tract" +295, 19, 17, 705, 77, 86, 3271, 3280, "infection" +295, 19, 18, 706, 87, 88, 3281, 3282, "," +295, 19, 19, 707, 89, 104, 3283, 3298, "nasopharyngitis" +295, 19, 20, 708, 105, 106, 3299, 3300, "," +295, 19, 21, 709, 107, 112, 3301, 3306, "upper" +295, 19, 22, 710, 113, 124, 3307, 3318, "respiratory" +295, 19, 23, 711, 125, 130, 3319, 3324, "tract" +295, 19, 24, 712, 131, 140, 3325, 3334, "infection" +295, 19, 25, 713, 141, 142, 3335, 3336, "," +295, 19, 26, 714, 143, 151, 3337, 3345, "headache" +295, 19, 27, 715, 152, 153, 3346, 3347, "," +295, 19, 28, 716, 154, 163, 3348, 3357, "influenza" +295, 19, 29, 717, 164, 165, 3358, 3359, "," +295, 19, 30, 718, 166, 169, 3360, 3363, "and" +295, 19, 31, 719, 170, 174, 3364, 3368, "pain" +295, 19, 32, 720, 175, 177, 3369, 3371, "in" +295, 19, 33, 721, 178, 187, 3372, 3381, "extremity" +295, 19, 34, 722, 188, 189, 3382, 3383, ";" +295, 19, 35, 723, 190, 193, 3384, 3387, "the" +295, 19, 36, 724, 194, 203, 3388, 3397, "incidence" +295, 19, 37, 725, 204, 206, 3398, 3400, "of" +295, 19, 38, 726, 207, 211, 3401, 3405, "each" +295, 19, 39, 727, 212, 214, 3406, 3408, "AE" +295, 19, 40, 728, 215, 218, 3409, 3412, "was" +295, 19, 41, 729, 219, 226, 3413, 3420, "similar" +295, 19, 42, 730, 227, 234, 3421, 3428, "between" +295, 19, 43, 731, 235, 244, 3429, 3438, "treatment" +295, 19, 44, 732, 245, 251, 3439, 3445, "groups" +295, 19, 45, 733, 252, 253, 3446, 3447, "." +295, 20, 1, 734, 0, 2, 3448, 3450, "In" +295, 20, 2, 735, 3, 6, 3451, 3454, "the" +295, 20, 3, 736, 7, 18, 3455, 3466, "saxagliptin" +295, 20, 4, 737, 19, 22, 3467, 3470, "and" +295, 20, 5, 738, 23, 30, 3471, 3478, "placebo" +295, 20, 6, 739, 31, 37, 3479, 3485, "groups" +295, 20, 7, 740, 38, 39, 3486, 3487, "," +295, 20, 8, 741, 40, 43, 3488, 3491, "the" +295, 20, 9, 742, 44, 53, 3492, 3501, "incidence" +295, 20, 10, 743, 54, 56, 3502, 3504, "of" +295, 20, 11, 744, 57, 65, 3505, 3513, "reported" +295, 20, 12, 745, 66, 78, 3514, 3526, "hypoglycemia" +295, 20, 13, 746, 79, 82, 3527, 3530, "was" +295, 20, 14, 747, 83, 85, 3531, 3533, "22" +295, 20, 15, 748, 86, 87, 3534, 3535, "." +295, 20, 16, 749, 88, 89, 3536, 3537, "7" +295, 20, 17, 750, 90, 93, 3538, 3541, "and" +295, 20, 18, 751, 94, 96, 3542, 3544, "26" +295, 20, 19, 752, 97, 98, 3545, 3546, "." +295, 20, 20, 753, 99, 100, 3547, 3548, "5" +295, 20, 21, 754, 101, 102, 3549, 3550, "%" +295, 20, 22, 755, 103, 104, 3551, 3552, "," +295, 20, 23, 756, 105, 117, 3553, 3565, "respectively" +295, 20, 24, 757, 118, 119, 3566, 3567, ";" +295, 20, 25, 758, 120, 123, 3568, 3571, "the" +295, 20, 26, 759, 124, 133, 3572, 3581, "incidence" +295, 20, 27, 760, 134, 136, 3582, 3584, "of" +295, 20, 28, 761, 137, 146, 3585, 3594, "confirmed" +295, 20, 29, 762, 147, 159, 3595, 3607, "hypoglycemia" +295, 20, 30, 763, 160, 161, 3608, 3609, "(" +295, 20, 31, 764, 162, 173, 3610, 3621, "fingerstick" +295, 20, 32, 765, 174, 181, 3622, 3629, "glucose" +295, 20, 33, 766, 182, 183, 3630, 3631, "≤" +295, 20, 34, 767, 184, 186, 3632, 3634, "50" +295, 20, 35, 768, 187, 189, 3635, 3637, "mg" +295, 20, 36, 769, 190, 191, 3638, 3639, "/" +295, 20, 37, 770, 192, 194, 3640, 3642, "dL" +295, 20, 38, 771, 195, 197, 3643, 3645, "[≤" +295, 20, 39, 772, 198, 199, 3646, 3647, "2" +295, 20, 40, 773, 200, 201, 3648, 3649, "." +295, 20, 41, 774, 202, 204, 3650, 3652, "77" +295, 20, 42, 775, 205, 209, 3653, 3657, "mmol" +295, 20, 43, 776, 210, 211, 3658, 3659, "/" +295, 20, 44, 777, 212, 213, 3660, 3661, "L" +295, 20, 45, 778, 214, 215, 3662, 3663, "]" +295, 20, 46, 779, 216, 220, 3664, 3668, "with" +295, 20, 47, 780, 221, 235, 3669, 3683, "characteristic" +295, 20, 48, 781, 236, 244, 3684, 3692, "symptoms" +295, 20, 49, 782, 245, 246, 3693, 3694, ")" +295, 20, 50, 783, 247, 250, 3695, 3698, "was" +295, 20, 51, 784, 251, 252, 3699, 3700, "7" +295, 20, 52, 785, 253, 254, 3701, 3702, "." +295, 20, 53, 786, 255, 256, 3703, 3704, "6" +295, 20, 54, 787, 257, 260, 3705, 3708, "and" +295, 20, 55, 788, 261, 262, 3709, 3710, "6" +295, 20, 56, 789, 263, 264, 3711, 3712, "." +295, 20, 57, 790, 265, 266, 3713, 3714, "6" +295, 20, 58, 791, 267, 268, 3715, 3716, "%" +295, 20, 59, 792, 269, 270, 3717, 3718, "," +295, 20, 60, 793, 271, 283, 3719, 3731, "respectively" +295, 20, 61, 794, 284, 285, 3732, 3733, "." +295, 21, 1, 795, 0, 8, 3734, 3742, "Adjusted" +295, 21, 2, 796, 9, 13, 3743, 3747, "mean" +295, 21, 3, 797, 14, 20, 3748, 3754, "change" +295, 21, 4, 798, 21, 25, 3755, 3759, "from" +295, 21, 5, 799, 26, 34, 3760, 3768, "baseline" +295, 21, 6, 800, 35, 39, 3769, 3773, "body" +295, 21, 7, 801, 40, 46, 3774, 3780, "weight" +295, 21, 8, 802, 47, 50, 3781, 3784, "was" +295, 21, 9, 803, 51, 52, 3785, 3786, "+" +295, 21, 10, 804, 53, 54, 3787, 3788, "0" +295, 21, 11, 805, 55, 56, 3789, 3790, "." +295, 21, 12, 806, 57, 58, 3791, 3792, "8" +295, 21, 13, 807, 59, 61, 3793, 3795, "kg" +295, 21, 14, 808, 62, 66, 3796, 3800, "with" +295, 21, 15, 809, 67, 78, 3801, 3812, "saxagliptin" +295, 21, 16, 810, 79, 82, 3813, 3816, "and" +295, 21, 17, 811, 83, 84, 3817, 3818, "+" +295, 21, 18, 812, 85, 86, 3819, 3820, "0" +295, 21, 19, 813, 87, 88, 3821, 3822, "." +295, 21, 20, 814, 89, 90, 3823, 3824, "5" +295, 21, 21, 815, 91, 93, 3825, 3827, "kg" +295, 21, 22, 816, 94, 98, 3828, 3832, "with" +295, 21, 23, 817, 99, 106, 3833, 3840, "placebo" +295, 21, 24, 818, 107, 108, 3841, 3842, "." +295, 22, 1, 819, 0, 10, 3843, 3853, "CONCLUSION" +295, 22, 2, 820, 11, 12, 3854, 3855, ":" +295, 22, 3, 821, 13, 24, 3856, 3867, "Saxagliptin" +295, 22, 4, 822, 25, 26, 3868, 3869, "5" +295, 22, 5, 823, 27, 29, 3870, 3872, "mg" +295, 22, 6, 824, 30, 34, 3873, 3877, "once" +295, 22, 7, 825, 35, 40, 3878, 3883, "daily" +295, 22, 8, 826, 41, 43, 3884, 3886, "as" +295, 22, 9, 827, 44, 47, 3887, 3890, "add" +295, 22, 10, 828, 48, 49, 3891, 3892, "-" +295, 22, 11, 829, 50, 52, 3893, 3895, "on" +295, 22, 12, 830, 53, 55, 3896, 3898, "to" +295, 22, 13, 831, 56, 63, 3899, 3906, "insulin" +295, 22, 14, 832, 64, 65, 3907, 3908, "," +295, 22, 15, 833, 66, 70, 3909, 3913, "with" +295, 22, 16, 834, 71, 73, 3914, 3916, "or" +295, 22, 17, 835, 74, 81, 3917, 3924, "without" +295, 22, 18, 836, 82, 93, 3925, 3936, "concomitant" +295, 22, 19, 837, 94, 103, 3937, 3946, "metformin" +295, 22, 20, 838, 104, 105, 3947, 3948, "," +295, 22, 21, 839, 106, 114, 3949, 3957, "produced" +295, 22, 22, 840, 115, 116, 3958, 3959, "a" +295, 22, 23, 841, 117, 124, 3960, 3967, "durable" +295, 22, 24, 842, 125, 136, 3968, 3979, "improvement" +295, 22, 25, 843, 137, 139, 3980, 3982, "in" +295, 22, 26, 844, 140, 148, 3983, 3991, "glycemic" +295, 22, 27, 845, 149, 156, 3992, 3999, "control" +295, 22, 28, 846, 157, 160, 4000, 4003, "and" +295, 22, 29, 847, 161, 164, 4004, 4007, "was" +295, 22, 30, 848, 165, 169, 4008, 4012, "well" +295, 22, 31, 849, 170, 179, 4013, 4022, "tolerated" +295, 22, 32, 850, 180, 184, 4023, 4027, "over" +295, 22, 33, 851, 185, 187, 4028, 4030, "52" +295, 22, 34, 852, 188, 193, 4031, 4036, "weeks" +295, 22, 35, 853, 194, 196, 4037, 4039, "of" +295, 22, 36, 854, 197, 206, 4040, 4049, "treatment" +295, 22, 37, 855, 207, 208, 4050, 4051, "." +295, 23, 1, 856, 0, 3, 4052, 4055, "DOI" +295, 23, 2, 857, 4, 5, 4056, 4057, ":" +295, 23, 3, 858, 6, 8, 4058, 4060, "10" +295, 23, 4, 859, 9, 10, 4061, 4062, "." +295, 23, 5, 860, 11, 15, 4063, 4067, "1007" +295, 23, 6, 861, 16, 17, 4068, 4069, "/" +295, 23, 7, 862, 18, 24, 4070, 4076, "s40261" +295, 23, 8, 863, 25, 26, 4077, 4078, "-" +295, 23, 9, 864, 27, 30, 4079, 4082, "013" +295, 23, 10, 865, 31, 32, 4083, 4084, "-" +295, 23, 11, 866, 33, 37, 4085, 4089, "0107" +295, 23, 12, 867, 38, 39, 4090, 4091, "-" +295, 23, 13, 868, 40, 41, 4092, 4093, "8" +295, 23, 14, 869, 42, 46, 4094, 4098, "PMID" +295, 23, 15, 870, 47, 48, 4099, 4100, ":" +295, 23, 16, 871, 49, 57, 4101, 4109, "23949898" +295, 23, 17, 872, 58, 59, 4110, 4111, "[" +295, 23, 18, 873, 60, 67, 4112, 4119, "Indexed" +295, 23, 19, 874, 68, 71, 4120, 4123, "for" +295, 23, 20, 875, 72, 79, 4124, 4131, "MEDLINE" +295, 23, 21, 876, 80, 81, 4132, 4133, "]" diff --git a/data/dm2 23949898_kwoodley.annodb b/data/dm2 23949898_kwoodley.annodb new file mode 100644 index 0000000..fa99a4c --- /dev/null +++ b/data/dm2 23949898_kwoodley.annodb @@ -0,0 +1,151 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +42869, Journal, 0, 18, "Clin Drug Investig", "", +42870, PublicationYear, 21, 25, "2013", "", +42871, Saxagliptin, 99, 110, "Saxagliptin", "", +42896, Title, 99, 227, "Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .", "", +42882, Insulin, 131, 138, "insulin", "", +42883, Metformin, 155, 164, "metformin", "", +42890, Type2Diabetes, 169, 193, "type 2 diabetes mellitus", "", +42895, Duration, 196, 205, "52 - week", "", +42897, Author, 228, 238, "Barnett AH", "", +42898, Author, 247, 259, "Charbonnel B", "", +42899, Author, 262, 266, "Li J", "", +42900, Author, 269, 278, "Donovan M", "", +42901, Author, 281, 290, "Fleming D", "", +42902, Author, 293, 300, "Iqbal N", "", +42903, UK, 450, 452, "UK", "", +42891, Type2Diabetes, 547, 571, "type 2 diabetes mellitus", "", +42892, Type2Diabetes, 574, 578, "T2DM", "", +42918, ObjectiveDescription, 595, 844, "The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .", "", +42872, Saxagliptin, 705, 716, "saxagliptin", "", +42904, Placebo, 724, 731, "placebo", "", +42917, Precondition, 755, 842, "patients with T2DM inadequately controlled with insulin alone or insulin plus metformin", "", +42893, Type2Diabetes, 769, 773, "T2DM", "", +42915, Insulin, 803, 810, "insulin", "", +42916, Insulin, 820, 827, "insulin", "", +42884, Metformin, 833, 842, "metformin", "", +42919, Duration, 880, 889, "28 - week", "", +42920, Duration, 922, 931, "24 - week", "", +42921, Randomized, 936, 946, "randomized", "", +42922, DoubleBlind, 949, 963, "double - blind", "", +42923, Parallel, 966, 982, "parallel - group", "", +42873, Saxagliptin, 992, 1003, "saxagliptin", "", +42924, DoseValue, 1004, 1005, "5", "", +42925, mg, 1006, 1008, "mg", "", +42926, Frequency, 1009, 1019, "once daily", "", +42905, Placebo, 1027, 1034, "placebo", "", +42927, OpenLabel, 1058, 1070, "open - label", "", +42928, Insulin, 1071, 1078, "insulin", "", +42929, Insulin, 1082, 1089, "insulin", "", +42906, Metformin, 1095, 1104, "metformin", "", +42930, Duration, 1122, 1130, "52 weeks", "", +42931, InsulinDose, 1196, 1210, "insulin dosage", "", +42932, InsulinDose, 1274, 1288, "insulin dosage", "", +42940, Precondition, 1463, 1650, "Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening", "", +42894, Type2Diabetes, 1477, 1481, "T2DM", "", +42933, MinAge, 1487, 1489, "18", "", +42934, MaxAge, 1492, 1494, "78", "", +42935, HbA1c, 1506, 1525, "glycated hemoglobin", "", +42936, HbA1c, 1528, 1533, "HbA1c", "", +42937, Percentage, 1547, 1548, "%", "", +42939, InsulinDose, 1561, 1576, "insulin regimen", "", +42938, BioAndMedicalUnit, 1588, 1595, "U / day", "", +42885, Metformin, 1612, 1621, "metformin", "", +42941, Metformin, 1708, 1717, "metformin", "", +42942, Randomized, 1726, 1734, "randomly", "", +42943, AllocationRatio, 1744, 1749, "2 : 1", "", +42874, Saxagliptin, 1758, 1769, "saxagliptin", "", +42944, DoseValue, 1770, 1771, "5", "", +42945, mg, 1772, 1774, "mg", "", +42946, NumberPatientsArm, 1781, 1784, "304", "", +42907, Placebo, 1790, 1797, "placebo", "", +42947, NumberPatientsArm, 1804, 1807, "151", "", +42948, Frequency, 1810, 1820, "once daily", "", +42949, Duration, 1862, 1870, "24 weeks", "", +42950, Duration, 1920, 1929, "28 - week", "", +42951, HbA1c, 2040, 2045, "HbA1c", "", +42952, TimePoint, 2051, 2059, "baseline", "", +42953, TimePoint, 2063, 2070, "week 52", "", +42954, TimePoint, 2121, 2128, "week 24", "", +42955, TimePoint, 2147, 2154, "week 52", "", +42960, TimePoint, 2183, 2191, "baseline", "", +42961, HbA1c, 2192, 2197, "HbA1c", "", +42956, TimePoint, 2201, 2208, "week 52", "", +42875, Saxagliptin, 2226, 2237, "saxagliptin", "", +42962, Reduction, 2242, 2248, "0 . 75", "", +42964, Percentage, 2249, 2250, "%", "", +42908, Placebo, 2260, 2267, "placebo", "", +42963, Reduction, 2272, 2278, "0 . 38", "", +42965, Percentage, 2279, 2280, "%", "", +42966, DiffGroupAbsValue, 2329, 2337, "- 0 . 37", "", +42967, Percentage, 2338, 2339, "%", "", +42968, ConfIntervalDiff, 2342, 2370, "95 % CI - 0 . 55 to - 0 . 19", "", +42972, SubGroupDescription, 2436, 2450, "with metformin", "", +42886, Metformin, 2441, 2450, "metformin", "", +42970, DiffGroupAbsValue, 2453, 2461, "- 0 . 37", "", +42975, Percentage, 2462, 2463, "%", "", +42976, ConfIntervalDiff, 2466, 2494, "95 % CI - 0 . 59 to - 0 . 15", "", +42973, SubGroupDescription, 2503, 2520, "without metformin", "", +42887, Metformin, 2511, 2520, "metformin", "", +42971, DiffGroupAbsValue, 2523, 2531, "- 0 . 37", "", +42974, Percentage, 2532, 2533, "%", "", +42977, ConfIntervalDiff, 2536, 2564, "95 % CI - 0 . 69 to - 0 . 04", "", +42957, TimePoint, 2574, 2581, "week 52", "", +42876, Saxagliptin, 2627, 2638, "saxagliptin", "", +42978, HbA1c_target, 2648, 2659, "HbA1c < 7 %", "", +42909, Placebo, 2681, 2688, "placebo", "", +42979, PercentageAffected, 2691, 2697, "21 . 3", "", +42980, PercentageAffected, 2703, 2708, "8 . 7", "", +42981, DiffGroupRelValue, 2740, 2746, "12 . 6", "", +42982, ConfIntervalDiff, 2751, 2773, "95 % CI 6 . 1 - 19 . 1", "", +42983, TimePoint, 2798, 2806, "baseline", "", +42984, InsulinDose, 2827, 2839, "insulin dose", "", +42958, TimePoint, 2843, 2850, "week 52", "", +42877, Saxagliptin, 2880, 2891, "saxagliptin", "", +42985, ResultMeasuredValue, 2894, 2900, "5 . 67", "", +42986, ResultMeasuredValue, 2904, 2910, "6 . 67", "", +42987, BioAndMedicalUnit, 2911, 2912, "U", "", +42910, Placebo, 2918, 2925, "placebo", "", +42988, DiffGroupAbsValue, 2941, 2949, "- 1 . 01", "", +42989, BioAndMedicalUnit, 2950, 2951, "U", "", +42990, ConfIntervalDiff, 2954, 2980, "95 % CI - 3 . 24 to 1 . 22", "", +42959, TimePoint, 2998, 3007, "52 - week", "", +42997, ObservedResult, 3041, 3063, "patients reporting ≥ 1", "", +42991, EndPointDescription, 3064, 3077, "adverse event", "", +42992, EndPointDescription, 3080, 3082, "AE", "", +42993, PercentageAffected, 3089, 3095, "66 . 4", "", +42878, Saxagliptin, 3103, 3114, "saxagliptin", "", +42994, PercentageAffected, 3119, 3125, "71 . 5", "", +42911, Placebo, 3133, 3140, "placebo", "", +42995, ObservedResult, 3143, 3191, "the majority being mild or moderate in intensity", "", +42998, ObservedResult, 3194, 3447, "The most common AEs ( ≥ 5 % with saxagliptin or placebo ) were urinary tract infection , nasopharyngitis , upper respiratory tract infection , headache , influenza , and pain in extremity ; the incidence of each AE was similar between treatment groups .", "", +42889, Saxagliptin, 3227, 3238, "saxagliptin", "", +42912, Placebo, 3242, 3249, "placebo", "", +42879, Saxagliptin, 3455, 3466, "saxagliptin", "", +42913, Placebo, 3471, 3478, "placebo", "", +42999, Hypoglycemia, 3514, 3526, "hypoglycemia", "", +43000, PercentageAffected, 3531, 3537, "22 . 7", "", +43001, PercentageAffected, 3542, 3548, "26 . 5", "", +43009, SubGroupDescription, 3585, 3694, "confirmed hypoglycemia ( fingerstick glucose ≤ 50 mg / dL [≤ 2 . 77 mmol / L ] with characteristic symptoms )", "", +43002, Hypoglycemia, 3595, 3607, "hypoglycemia", "", +43007, Mg_per_deciliter, 3635, 3642, "mg / dL", "", +43008, Millimoles_per_litre, 3653, 3661, "mmol / L", "", +43005, PercentageAffected, 3699, 3704, "7 . 6", "", +43006, PercentageAffected, 3709, 3714, "6 . 6", "", +43010, TimePoint, 3760, 3768, "baseline", "", +43011, BodyWeight, 3769, 3780, "body weight", "", +43012, Increment, 3787, 3792, "0 . 8", "", +43014, Kg, 3793, 3795, "kg", "", +42880, Saxagliptin, 3801, 3812, "saxagliptin", "", +43013, Increment, 3819, 3824, "0 . 5", "", +43015, Kg, 3825, 3827, "kg", "", +42914, Placebo, 3833, 3840, "placebo", "", +43021, ConclusionComment, 3856, 4051, "Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .", "", +42881, Saxagliptin, 3856, 3867, "Saxagliptin", "", +43016, DoseValue, 3868, 3869, "5", "", +43017, mg, 3870, 3872, "mg", "", +43018, Frequency, 3873, 3883, "once daily", "", +43019, Insulin, 3899, 3906, "insulin", "", +42888, Metformin, 3937, 3946, "metformin", "", +43020, Duration, 4028, 4036, "52 weeks", "", +43022, PMID, 4101, 4109, "23949898", "", diff --git a/data/dm2 23949898_kwoodley.n-triples b/data/dm2 23949898_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 23949898_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24062327_admin.annodb b/data/dm2 24062327_admin.annodb new file mode 100644 index 0000000..bc99530 --- /dev/null +++ b/data/dm2 24062327_admin.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2013", "", " \"2013\"." +14, Title, 102, 252, "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .", "", " \"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .\"." +2, Linagliptin, 120, 131, "linagliptin", "", +32, Insulin, 141, 148, "insulin", "", +13, Precondition, 161, 200, "inadequately controlled type 2 diabetes", "", +8, Type2Diabetes, 185, 200, "type 2 diabetes", "", " ." +10, Duration, 205, 216, "≥ 52 - week", "", " \"≥ 52 - week\"." +11, Randomized, 217, 227, "randomized", "", " ." +12, DoubleBlind, 230, 244, "double - blind", "", " ." +15, Author, 253, 271, "Yki - J ä rvinen H", "", " \"Yki - J ä rvinen H\"." +16, Author, 280, 292, "Rosenstock J", "", " \"Rosenstock J\"." +17, Author, 295, 313, "Dur á n - Garcia S", "", " \"Dur á n - Garcia S\"." +18, Author, 316, 326, "Pinnetti S", "", " \"Pinnetti S\"." +19, Author, 329, 343, "Bhattacharya S", "", " \"Bhattacharya S\"." +20, Author, 346, 356, "Thiemann S", "", " \"Thiemann S\"." +21, Author, 359, 366, "Patel S", "", " \"Patel S\"." +22, Author, 369, 378, "Woerle HJ", "", " \"Woerle HJ\"." +23, Finland, 485, 487, "fi", "", +28, ObjectiveDescription, 502, 678, "To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .", "", " \"To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .\"." +3, Linagliptin, 553, 564, "linagliptin", "", +24, Insulin, 580, 588, "insulins", "", +27, Precondition, 592, 676, "type 2 diabetes inadequately controlled on basal insulin with or without oral agents", "", " \"type 2 diabetes inadequately controlled on basal insulin with or without oral agents\"." +9, Type2Diabetes, 592, 607, "type 2 diabetes", "", +25, Insulin, 641, 648, "insulin", "", +26, OralAntidiabeticAgent, 665, 676, "oral agents", "", +55, NumberPatientsCT, 720, 727, "1 , 261", "", " \"1 , 261\"." +57, HbA1c, 739, 744, "HbA1c", "", +58, Percentage, 753, 754, "%", "", +79777, Millimoles_per_mole, 760, 770, "mmol / mol", "", +59, Percentage, 785, 786, "%", "", +79778, Millimoles_per_mole, 792, 802, "mmol / mol", "", +68827, Precondition, 807, 878, "on basal insulin alone or combined with metformin and / or pioglitazone", "", " \"on basal insulin alone or combined with metformin and / or pioglitazone\"." +62, Insulin, 816, 823, "insulin", "", +63, Metformin, 847, 856, "metformin", "", +64, Pioglitazone, 866, 878, "pioglitazone", "", +65, Randomized, 884, 894, "randomized", "", +162, AllocationRatio, 897, 902, "1 : 1", "", " . ." +66, DoubleBlind, 908, 922, "double - blind", "", +4, Linagliptin, 938, 949, "linagliptin", "", " ." +164, DoseValue, 950, 951, "5", "", " \"5\"." +70, mg, 952, 954, "mg", "", " ." +69, Frequency, 955, 965, "once daily", "", " \"once daily\"." +71, Placebo, 969, 976, "placebo", "", " ." +72, Duration, 981, 991, "≥ 52 weeks", "", +73, Insulin, 998, 1011, "basal insulin", "", +68831, DoseDescription, 998, 1158, "basal insulin dose was kept unchanged for 24 weeks but could thereafter be titrated according to fasting plasma glucose levels at the investigators ' discretion", "", +74, Duration, 1040, 1048, "24 weeks", "", +75, FastingPlasmaGlucose, 1095, 1117, "fasting plasma glucose", "", +76, Mean, 1191, 1195, "mean", "", +77, HbA1c, 1206, 1211, "HbA1c", "", +78, TimePoint, 1217, 1225, "baseline", "", +79, TimePoint, 1229, 1236, "week 24", "", +80, TimePoint, 1296, 1305, "110 weeks", "", +81, TimePoint, 1321, 1328, "week 24", "", " \"week 24\". \"week 24\"." +82, HbA1c, 1331, 1336, "HbA1c", "", " ." +83, BaseLineValue, 1364, 1369, "8 . 3", "", " \"8 . 3\"." +85, Percentage, 1370, 1371, "%", "", " ." +84, BaseLineValue, 1374, 1376, "67", "", +79779, Millimoles_per_mole, 1377, 1387, "mmol / mol", "", +185, Reduction, 1395, 1400, "0 . 6", "", " \"0 . 6\"." +86, Percentage, 1401, 1402, "%", "", +186, Reduction, 1407, 1412, "6 . 6", "", +79780, Millimoles_per_mole, 1413, 1423, "mmol / mol", "", +191, Increment, 1433, 1438, "0 . 1", "", " \"0 . 1\"." +87, Percentage, 1439, 1440, "%", "", +192, Increment, 1443, 1448, "1 . 1", "", +79781, Millimoles_per_mole, 1449, 1459, "mmol / mol", "", +5, Linagliptin, 1467, 1478, "linagliptin", "", +99, Placebo, 1483, 1490, "placebo", "", +100, DiffGroupAbsValue, 1529, 1537, "- 0 . 65", "", " \"- 0 . 65\"." +88, Percentage, 1538, 1539, "%", "", +101, ConfIntervalDiff, 1542, 1570, "95 % CI - 0 . 74 to - 0 . 55", "", " \"95 % CI - 0 . 74 to - 0 . 55\"." +102, DiffGroupAbsValue, 1575, 1582, "- 7 . 1", "", +79782, Millimoles_per_mole, 1583, 1593, "mmol / mol", "", +103, PvalueDiff, 1598, 1610, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +68819, Insulin, 1653, 1660, "insulin", "", +104, TimePoint, 1702, 1709, "week 52", "", " \"week 52\". \"week 52\"." +105, Linagliptin, 1712, 1723, "linagliptin", "", +108, ResultMeasuredValue, 1724, 1729, "2 . 6", "", " \"2 . 6\"." +110, BioAndMedicalUnit, 1730, 1738, "IU / day", "", " . ." +106, Placebo, 1741, 1748, "placebo", "", +109, ResultMeasuredValue, 1749, 1754, "4 . 2", "", " \"4 . 2\"." +111, BioAndMedicalUnit, 1755, 1763, "IU / day", "", +112, PvalueDiff, 1766, 1777, "P < 0 . 003", "", " \"P < 0 . 003\"." +211, ObservedResult, 1782, 1824, "resulting in no further HbA1c improvements", "", " \"resulting in no further HbA1c improvements\". \"resulting in no further HbA1c improvements\"." +107, HbA1c, 1806, 1811, "HbA1c", "", +114, Hypoglycemia, 1842, 1854, "hypoglycemia", "", " ." +115, TimePoint, 1857, 1864, "week 24", "", " \"week 24\". \"week 24\"." +116, Linagliptin, 1867, 1878, "linagliptin", "", +124, PercentageAffected, 1879, 1885, "22 . 0", "", " \"22 . 0\"." +117, Placebo, 1890, 1897, "placebo", "", +125, PercentageAffected, 1898, 1904, "23 . 2", "", " \"23 . 2\"." +118, TimePoint, 1909, 1922, "treatment end", "", " \"treatment end\". \"treatment end\"." +119, Linagliptin, 1925, 1936, "linagliptin", "", +126, PercentageAffected, 1937, 1943, "31 . 4", "", " \"31 . 4\"." +121, Placebo, 1948, 1955, "placebo", "", +127, PercentageAffected, 1956, 1962, "32 . 9", "", " \"32 . 9\"." +123, EndPointDescription, 1971, 1985, "adverse events", "", " . ." +120, Linagliptin, 1988, 1999, "linagliptin", "", +128, PercentageAffected, 2000, 2006, "78 . 4", "", " \"78 . 4\"." +122, Placebo, 2011, 2018, "placebo", "", +129, PercentageAffected, 2019, 2025, "81 . 4", "", " \"81 . 4\"." +136, Mean, 2060, 2064, "Mean", "", " . ." +137, BodyWeight, 2065, 2076, "body weight", "", " ." +138, TimePoint, 2098, 2105, "week 52", "", " \"week 52\". \"week 52\"." +139, Linagliptin, 2108, 2119, "linagliptin", "", +228, Reduction, 2122, 2128, "0 . 30", "", " \"0 . 30\"." +143, Kg, 2129, 2131, "kg", "", " ." +140, Placebo, 2134, 2141, "placebo", "", +229, Reduction, 2144, 2150, "0 . 04", "", " \"0 . 04\"." +144, Kg, 2151, 2153, "kg", "", +150, ConclusionComment, 2172, 2323, "Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .", "", " \"Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .\"." +6, Linagliptin, 2172, 2183, "Linagliptin", "", +146, Insulin, 2199, 2206, "insulin", "", +147, Placebo, 2267, 2274, "placebo", "", +148, Hypoglycemia, 2294, 2306, "hypoglycemia", "", +149, BodyWeight, 2310, 2321, "body weight", "", +151, PMID, 2380, 2388, "24062327", "", " \"24062327\"." diff --git a/data/dm2 24062327_admin.n-triples b/data/dm2 24062327_admin.n-triples new file mode 100644 index 0000000..ce13146 --- /dev/null +++ b/data/dm2 24062327_admin.n-triples @@ -0,0 +1,194 @@ +# RDF export of group: Publication + . + "Publication 49816" . + "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study ." . + "Yki - J ä rvinen H" . + "2013" . + "Diabetes Care" . + "24062327" . + . + "Rosenstock J" . + "Dur á n - Garcia S" . + "Pinnetti S" . + "Bhattacharya S" . + "Thiemann S" . + "Patel S" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 49823" . + "To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents ." . + "1 , 261" . + "≥ 52 - week" . + . + . + . + . + "Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 49839" . + "type 2 diabetes inadequately controlled on basal insulin with or without oral agents" . + . + . + . + "on basal insulin alone or combined with metformin and / or pioglitazone" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "ins" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + "once daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 3" . + "0 . 6" . + "week 24" . + . + "hba 2" . + . + "0 . 1" . + "week 24" . + . + "ins 1" . + . + "2 . 6" . + "resulting in no further HbA1c improvements" . + "week 52" . + . + "ins 2" . + . + "4 . 2" . + "resulting in no further HbA1c improvements" . + "week 52" . + . + "hyp 1" . + . + "22 . 0" . + "week 24" . + . + "hyp 2" . + . + "23 . 2" . + "week 24" . + . + "ae 1" . + . + "78 . 4" . + . + "ae 2" . + . + "81 . 4" . + . + "hyp2 1" . + . + "31 . 4" . + "treatment end" . + . + "hyp2 2" . + . + "32 . 9" . + "treatment end" . + . + "bw 1" . + . + "0 . 30" . + "week 52" . + . + "bw 2" . + . + "0 . 04" . + "week 52" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 65" . + "P < 0 . 0001" . + "95 % CI - 0 . 74 to - 0 . 55" . + . + . + . + "ins" . + "P < 0 . 003" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24062327_akramersunderbrink.annodb b/data/dm2 24062327_akramersunderbrink.annodb new file mode 100644 index 0000000..0bbc2de --- /dev/null +++ b/data/dm2 24062327_akramersunderbrink.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46202, Journal, 0, 13, "Diabetes Care", "", +46203, PublicationYear, 16, 20, "2013", "", +46212, Title, 102, 252, "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .", "", +46204, Linagliptin, 120, 131, "linagliptin", "", +46206, Insulin, 141, 148, "insulin", "", +46207, Precondition, 161, 184, "inadequately controlled", "", +46208, Type2Diabetes, 185, 200, "type 2 diabetes", "", +46209, Duration, 205, 216, "≥ 52 - week", "", +46210, Randomized, 217, 227, "randomized", "", +46211, DoubleBlind, 230, 244, "double - blind", "", +46213, Author, 253, 271, "Yki - J ä rvinen H", "", +46214, Author, 280, 292, "Rosenstock J", "", +46215, Author, 295, 313, "Dur á n - Garcia S", "", +46216, Author, 316, 326, "Pinnetti S", "", +46217, Author, 329, 343, "Bhattacharya S", "", +46218, Author, 346, 356, "Thiemann S", "", +46219, Author, 359, 366, "Patel S", "", +46220, Author, 369, 378, "Woerle HJ", "", +46221, Finland, 485, 487, "fi", "", +46229, ObjectiveDescription, 502, 678, "To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .", "", +46222, Linagliptin, 553, 564, "linagliptin", "", +46224, Insulin, 574, 588, "basal insulins", "", +46225, Type2Diabetes, 592, 607, "type 2 diabetes", "", +46226, Precondition, 608, 676, "inadequately controlled on basal insulin with or without oral agents", "", +46227, Insulin, 635, 648, "basal insulin", "", +46228, OralAntidiabeticAgent, 665, 676, "oral agents", "", +46230, NumberPatientsCT, 720, 727, "1 , 261", "", +46231, Precondition, 739, 804, "HbA1c ≥ 7 . 0 % [ 53 mmol / mol ] to ≤ 10 . 0 % [ 86 mmol / mol ]", "", +46232, HbA1c, 739, 744, "HbA1c", "", +46233, Percentage, 753, 754, "%", "", +46235, ConcentrationUnit, 760, 770, "mmol / mol", "", +46234, Percentage, 785, 786, "%", "", +46236, ConcentrationUnit, 792, 802, "mmol / mol", "", +46237, Insulin, 810, 823, "basal insulin", "", +46238, Metformin, 847, 856, "metformin", "", +46239, Pioglitazone, 866, 878, "pioglitazone", "", +46240, Randomized, 884, 894, "randomized", "", +46241, DoubleBlind, 908, 922, "double - blind", "", +46242, Linagliptin, 938, 949, "linagliptin", "", +46243, DoseValue, 950, 954, "5 mg", "", +46246, mg, 952, 954, "mg", "", +46245, Frequency, 955, 965, "once daily", "", +46247, Placebo, 969, 976, "placebo", "", +46248, Duration, 981, 991, "≥ 52 weeks", "", +46249, Insulin, 998, 1011, "basal insulin", "", +46250, Duration, 1040, 1048, "24 weeks", "", +46251, FastingPlasmaGlucose, 1095, 1117, "fasting plasma glucose", "", +46252, Mean, 1191, 1195, "mean", "", +46253, HbA1c, 1206, 1211, "HbA1c", "", +46254, TimePoint, 1217, 1225, "baseline", "", +46255, TimePoint, 1229, 1236, "week 24", "", +46256, TimePoint, 1296, 1305, "110 weeks", "", +46257, TimePoint, 1321, 1328, "week 24", "", +46258, HbA1c, 1331, 1336, "HbA1c", "", +46259, BaseLineValue, 1364, 1369, "8 . 3", "", +46262, Percentage, 1370, 1371, "%", "", +46261, BaseLineValue, 1374, 1376, "67", "", +46267, ConcentrationUnit, 1377, 1387, "mmol / mol", "", +46270, ChangeValue, 1393, 1400, "- 0 . 6", "", +46263, Percentage, 1401, 1402, "%", "", +46271, ChangeValue, 1405, 1412, "- 6 . 6", "", +46274, ConcentrationUnit, 1413, 1423, "mmol / mol", "", +46272, ChangeValue, 1433, 1438, "0 . 1", "", +46264, Percentage, 1439, 1440, "%", "", +46273, ChangeValue, 1443, 1448, "1 . 1", "", +46268, ConcentrationUnit, 1449, 1459, "mmol / mol", "", +46275, Linagliptin, 1467, 1478, "linagliptin", "", +46276, Placebo, 1483, 1490, "placebo", "", +46277, DiffGroupAbsValue, 1529, 1537, "- 0 . 65", "", +46265, Percentage, 1538, 1539, "%", "", +46278, ConfIntervalDiff, 1542, 1570, "95 % CI - 0 . 74 to - 0 . 55", "", +46266, Percentage, 1545, 1546, "%", "", +46279, DiffGroupAbsValue, 1575, 1582, "- 7 . 1", "", +46269, ConcentrationUnit, 1583, 1593, "mmol / mol", "", +46280, PvalueDiff, 1598, 1610, "P < 0 . 0001", "", +46291, InsulinDose, 1647, 1660, "basal insulin", "", +46282, TimePoint, 1702, 1709, "week 52", "", +46283, Linagliptin, 1712, 1723, "linagliptin", "", +46286, ResultMeasuredValue, 1724, 1729, "2 . 6", "", +46288, BioAndMedicalUnit, 1730, 1738, "IU / day", "", +46284, Placebo, 1741, 1748, "placebo", "", +46287, ResultMeasuredValue, 1749, 1754, "4 . 2", "", +46289, BioAndMedicalUnit, 1755, 1763, "IU / day", "", +46290, PvalueDiff, 1766, 1777, "P < 0 . 003", "", +46285, HbA1c, 1806, 1811, "HbA1c", "", +46292, Hypoglycemia, 1842, 1854, "hypoglycemia", "", +46293, TimePoint, 1857, 1864, "week 24", "", +46294, Linagliptin, 1867, 1878, "linagliptin", "", +46302, PercentageAffected, 1879, 1885, "22 . 0", "", +46308, Percentage, 1886, 1887, "%", "", +46295, Placebo, 1890, 1897, "placebo", "", +46303, PercentageAffected, 1898, 1904, "23 . 2", "", +46309, Percentage, 1905, 1906, "%", "", +46296, TimePoint, 1909, 1922, "treatment end", "", +46297, Linagliptin, 1925, 1936, "linagliptin", "", +46304, PercentageAffected, 1937, 1943, "31 . 4", "", +46310, Percentage, 1944, 1945, "%", "", +46299, Placebo, 1948, 1955, "placebo", "", +46305, PercentageAffected, 1956, 1962, "32 . 9", "", +46311, Percentage, 1963, 1964, "%", "", +46301, EndPointDescription, 1971, 1985, "adverse events", "", +46298, Linagliptin, 1988, 1999, "linagliptin", "", +46306, PercentageAffected, 2000, 2006, "78 . 4", "", +46312, Percentage, 2007, 2008, "%", "", +46300, Placebo, 2011, 2018, "placebo", "", +46307, PercentageAffected, 2019, 2025, "81 . 4", "", +46313, Percentage, 2026, 2027, "%", "", +46314, Mean, 2060, 2064, "Mean", "", +46315, BodyWeight, 2065, 2076, "body weight", "", +46316, TimePoint, 2098, 2105, "week 52", "", +46317, Linagliptin, 2108, 2119, "linagliptin", "", +46319, ChangeValue, 2120, 2128, "- 0 . 30", "", +46321, Kg, 2129, 2131, "kg", "", +46318, Placebo, 2134, 2141, "placebo", "", +46320, ChangeValue, 2142, 2150, "- 0 . 04", "", +46322, Kg, 2151, 2153, "kg", "", +46323, Linagliptin, 2172, 2183, "Linagliptin", "", +46328, ConclusionComment, 2172, 2323, "Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .", "", +46324, Insulin, 2193, 2206, "basal insulin", "", +46325, Placebo, 2267, 2274, "placebo", "", +46326, Hypoglycemia, 2294, 2306, "hypoglycemia", "", +46327, BodyWeight, 2310, 2321, "body weight", "", +46329, PMID, 2380, 2388, "24062327", "", diff --git a/data/dm2 24062327_akramersunderbrink.n-triples b/data/dm2 24062327_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24062327_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24062327_export.csv b/data/dm2 24062327_export.csv new file mode 100644 index 0000000..eeda6c7 --- /dev/null +++ b/data/dm2 24062327_export.csv @@ -0,0 +1,545 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +291, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +291, 1, 2, 2, 9, 13, 9, 13, "Care" +291, 1, 3, 3, 14, 15, 14, 15, "." +291, 2, 1, 4, 0, 4, 16, 20, "2013" +291, 2, 2, 5, 5, 8, 21, 24, "Dec" +291, 2, 3, 6, 9, 10, 25, 26, ";" +291, 2, 4, 7, 11, 13, 27, 29, "36" +291, 2, 5, 8, 14, 15, 30, 31, "(" +291, 2, 6, 9, 16, 18, 32, 34, "12" +291, 2, 7, 10, 19, 20, 35, 36, ")" +291, 2, 8, 11, 21, 22, 37, 38, ":" +291, 2, 9, 12, 23, 27, 39, 43, "3875" +291, 2, 10, 13, 28, 29, 44, 45, "-" +291, 2, 11, 14, 30, 32, 46, 48, "81" +291, 2, 12, 15, 33, 34, 49, 50, "." +291, 2, 13, 16, 35, 38, 51, 54, "doi" +291, 2, 14, 17, 39, 40, 55, 56, ":" +291, 2, 15, 18, 41, 43, 57, 59, "10" +291, 2, 16, 19, 44, 45, 60, 61, "." +291, 2, 17, 20, 46, 50, 62, 66, "2337" +291, 2, 18, 21, 51, 52, 67, 68, "/" +291, 2, 19, 22, 53, 57, 69, 73, "dc12" +291, 2, 20, 23, 58, 59, 74, 75, "-" +291, 2, 21, 24, 60, 64, 76, 80, "2718" +291, 2, 22, 25, 65, 66, 81, 82, "." +291, 3, 1, 26, 0, 4, 83, 87, "Epub" +291, 3, 2, 27, 5, 9, 88, 92, "2013" +291, 3, 3, 28, 10, 13, 93, 96, "Sep" +291, 3, 4, 29, 14, 16, 97, 99, "23" +291, 3, 5, 30, 17, 18, 100, 101, "." +291, 4, 1, 31, 0, 7, 102, 109, "Effects" +291, 4, 2, 32, 8, 10, 110, 112, "of" +291, 4, 3, 33, 11, 17, 113, 119, "adding" +291, 4, 4, 34, 18, 29, 120, 131, "linagliptin" +291, 4, 5, 35, 30, 32, 132, 134, "to" +291, 4, 6, 36, 33, 38, 135, 140, "basal" +291, 4, 7, 37, 39, 46, 141, 148, "insulin" +291, 4, 8, 38, 47, 54, 149, 156, "regimen" +291, 4, 9, 39, 55, 58, 157, 160, "for" +291, 4, 10, 40, 59, 71, 161, 173, "inadequately" +291, 4, 11, 41, 72, 82, 174, 184, "controlled" +291, 4, 12, 42, 83, 87, 185, 189, "type" +291, 4, 13, 43, 88, 89, 190, 191, "2" +291, 4, 14, 44, 90, 98, 192, 200, "diabetes" +291, 4, 15, 45, 99, 100, 201, 202, ":" +291, 4, 16, 46, 101, 102, 203, 204, "a" +291, 4, 17, 47, 103, 104, 205, 206, "≥" +291, 4, 18, 48, 105, 107, 207, 209, "52" +291, 4, 19, 49, 108, 109, 210, 211, "-" +291, 4, 20, 50, 110, 114, 212, 216, "week" +291, 4, 21, 51, 115, 125, 217, 227, "randomized" +291, 4, 22, 52, 126, 127, 228, 229, "," +291, 4, 23, 53, 128, 134, 230, 236, "double" +291, 4, 24, 54, 135, 136, 237, 238, "-" +291, 4, 25, 55, 137, 142, 239, 244, "blind" +291, 4, 26, 56, 143, 148, 245, 250, "study" +291, 4, 27, 57, 149, 150, 251, 252, "." +291, 5, 1, 58, 0, 3, 253, 256, "Yki" +291, 5, 2, 59, 4, 5, 257, 258, "-" +291, 5, 3, 60, 6, 7, 259, 260, "J" +291, 5, 4, 61, 8, 9, 261, 262, "ä" +291, 5, 5, 62, 10, 16, 263, 269, "rvinen" +291, 5, 6, 63, 17, 18, 270, 271, "H" +291, 5, 7, 64, 19, 20, 272, 273, "(" +291, 5, 8, 65, 21, 22, 274, 275, "1" +291, 5, 9, 66, 23, 24, 276, 277, ")" +291, 5, 10, 67, 25, 26, 278, 279, "," +291, 5, 11, 68, 27, 37, 280, 290, "Rosenstock" +291, 5, 12, 69, 38, 39, 291, 292, "J" +291, 5, 13, 70, 40, 41, 293, 294, "," +291, 5, 14, 71, 42, 45, 295, 298, "Dur" +291, 5, 15, 72, 46, 47, 299, 300, "á" +291, 5, 16, 73, 48, 49, 301, 302, "n" +291, 5, 17, 74, 50, 51, 303, 304, "-" +291, 5, 18, 75, 52, 58, 305, 311, "Garcia" +291, 5, 19, 76, 59, 60, 312, 313, "S" +291, 5, 20, 77, 61, 62, 314, 315, "," +291, 5, 21, 78, 63, 71, 316, 324, "Pinnetti" +291, 5, 22, 79, 72, 73, 325, 326, "S" +291, 5, 23, 80, 74, 75, 327, 328, "," +291, 5, 24, 81, 76, 88, 329, 341, "Bhattacharya" +291, 5, 25, 82, 89, 90, 342, 343, "S" +291, 5, 26, 83, 91, 92, 344, 345, "," +291, 5, 27, 84, 93, 101, 346, 354, "Thiemann" +291, 5, 28, 85, 102, 103, 355, 356, "S" +291, 5, 29, 86, 104, 105, 357, 358, "," +291, 5, 30, 87, 106, 111, 359, 364, "Patel" +291, 5, 31, 88, 112, 113, 365, 366, "S" +291, 5, 32, 89, 114, 115, 367, 368, "," +291, 5, 33, 90, 116, 122, 369, 375, "Woerle" +291, 5, 34, 91, 123, 125, 376, 378, "HJ" +291, 5, 35, 92, 126, 127, 379, 380, "." +291, 6, 1, 93, 0, 6, 381, 387, "Author" +291, 6, 2, 94, 7, 18, 388, 399, "information" +291, 6, 3, 95, 19, 20, 400, 401, ":" +291, 6, 4, 96, 21, 22, 402, 403, "(" +291, 6, 5, 97, 23, 24, 404, 405, "1" +291, 6, 6, 98, 25, 26, 406, 407, ")" +291, 6, 7, 99, 27, 40, 408, 421, "Corresponding" +291, 6, 8, 100, 41, 47, 422, 428, "author" +291, 6, 9, 101, 48, 49, 429, 430, ":" +291, 6, 10, 102, 50, 57, 431, 438, "Hannele" +291, 6, 11, 103, 58, 61, 439, 442, "Yki" +291, 6, 12, 104, 62, 63, 443, 444, "-" +291, 6, 13, 105, 64, 65, 445, 446, "J" +291, 6, 14, 106, 66, 67, 447, 448, "ä" +291, 6, 15, 107, 68, 74, 449, 455, "rvinen" +291, 6, 16, 108, 75, 76, 456, 457, "," +291, 6, 17, 109, 77, 85, 458, 466, "ykijarvi" +291, 6, 18, 110, 86, 87, 467, 468, "@" +291, 6, 19, 111, 88, 90, 469, 471, "cc" +291, 6, 20, 112, 91, 92, 472, 473, "." +291, 6, 21, 113, 93, 101, 474, 482, "helsinki" +291, 6, 22, 114, 102, 103, 483, 484, "." +291, 6, 23, 115, 104, 106, 485, 487, "fi" +291, 6, 24, 116, 107, 108, 488, 489, "." +291, 7, 1, 117, 0, 9, 490, 499, "OBJECTIVE" +291, 7, 2, 118, 10, 11, 500, 501, ":" +291, 7, 3, 119, 12, 14, 502, 504, "To" +291, 7, 4, 120, 15, 23, 505, 513, "evaluate" +291, 7, 5, 121, 24, 27, 514, 517, "the" +291, 7, 6, 122, 28, 36, 518, 526, "efficacy" +291, 7, 7, 123, 37, 40, 527, 530, "and" +291, 7, 8, 124, 41, 45, 531, 535, "long" +291, 7, 9, 125, 46, 47, 536, 537, "-" +291, 7, 10, 126, 48, 52, 538, 542, "term" +291, 7, 11, 127, 53, 59, 543, 549, "safety" +291, 7, 12, 128, 60, 62, 550, 552, "of" +291, 7, 13, 129, 63, 74, 553, 564, "linagliptin" +291, 7, 14, 130, 75, 80, 565, 570, "added" +291, 7, 15, 131, 81, 83, 571, 573, "to" +291, 7, 16, 132, 84, 89, 574, 579, "basal" +291, 7, 17, 133, 90, 98, 580, 588, "insulins" +291, 7, 18, 134, 99, 101, 589, 591, "in" +291, 7, 19, 135, 102, 106, 592, 596, "type" +291, 7, 20, 136, 107, 108, 597, 598, "2" +291, 7, 21, 137, 109, 117, 599, 607, "diabetes" +291, 7, 22, 138, 118, 130, 608, 620, "inadequately" +291, 7, 23, 139, 131, 141, 621, 631, "controlled" +291, 7, 24, 140, 142, 144, 632, 634, "on" +291, 7, 25, 141, 145, 150, 635, 640, "basal" +291, 7, 26, 142, 151, 158, 641, 648, "insulin" +291, 7, 27, 143, 159, 163, 649, 653, "with" +291, 7, 28, 144, 164, 166, 654, 656, "or" +291, 7, 29, 145, 167, 174, 657, 664, "without" +291, 7, 30, 146, 175, 179, 665, 669, "oral" +291, 7, 31, 147, 180, 186, 670, 676, "agents" +291, 7, 32, 148, 187, 188, 677, 678, "." +291, 8, 1, 149, 0, 8, 679, 687, "RESEARCH" +291, 8, 2, 150, 9, 15, 688, 694, "DESIGN" +291, 8, 3, 151, 16, 19, 695, 698, "AND" +291, 8, 4, 152, 20, 27, 699, 706, "METHODS" +291, 8, 5, 153, 28, 29, 707, 708, ":" +291, 8, 6, 154, 30, 31, 709, 710, "A" +291, 8, 7, 155, 32, 37, 711, 716, "total" +291, 8, 8, 156, 38, 40, 717, 719, "of" +291, 8, 9, 157, 41, 42, 720, 721, "1" +291, 8, 10, 158, 43, 44, 722, 723, "," +291, 8, 11, 159, 45, 48, 724, 727, "261" +291, 8, 12, 160, 49, 57, 728, 736, "patients" +291, 8, 13, 161, 58, 59, 737, 738, "(" +291, 8, 14, 162, 60, 65, 739, 744, "HbA1c" +291, 8, 15, 163, 66, 67, 745, 746, "≥" +291, 8, 16, 164, 68, 69, 747, 748, "7" +291, 8, 17, 165, 70, 71, 749, 750, "." +291, 8, 18, 166, 72, 73, 751, 752, "0" +291, 8, 19, 167, 74, 75, 753, 754, "%" +291, 8, 20, 168, 76, 77, 755, 756, "[" +291, 8, 21, 169, 78, 80, 757, 759, "53" +291, 8, 22, 170, 81, 85, 760, 764, "mmol" +291, 8, 23, 171, 86, 87, 765, 766, "/" +291, 8, 24, 172, 88, 91, 767, 770, "mol" +291, 8, 25, 173, 92, 93, 771, 772, "]" +291, 8, 26, 174, 94, 96, 773, 775, "to" +291, 8, 27, 175, 97, 98, 776, 777, "≤" +291, 8, 28, 176, 99, 101, 778, 780, "10" +291, 8, 29, 177, 102, 103, 781, 782, "." +291, 8, 30, 178, 104, 105, 783, 784, "0" +291, 8, 31, 179, 106, 107, 785, 786, "%" +291, 8, 32, 180, 108, 109, 787, 788, "[" +291, 8, 33, 181, 110, 112, 789, 791, "86" +291, 8, 34, 182, 113, 117, 792, 796, "mmol" +291, 8, 35, 183, 118, 119, 797, 798, "/" +291, 8, 36, 184, 120, 123, 799, 802, "mol" +291, 8, 37, 185, 124, 125, 803, 804, "]" +291, 8, 38, 186, 126, 127, 805, 806, ")" +291, 8, 39, 187, 128, 130, 807, 809, "on" +291, 8, 40, 188, 131, 136, 810, 815, "basal" +291, 8, 41, 189, 137, 144, 816, 823, "insulin" +291, 8, 42, 190, 145, 150, 824, 829, "alone" +291, 8, 43, 191, 151, 153, 830, 832, "or" +291, 8, 44, 192, 154, 162, 833, 841, "combined" +291, 8, 45, 193, 163, 167, 842, 846, "with" +291, 8, 46, 194, 168, 177, 847, 856, "metformin" +291, 8, 47, 195, 178, 181, 857, 860, "and" +291, 8, 48, 196, 182, 183, 861, 862, "/" +291, 8, 49, 197, 184, 186, 863, 865, "or" +291, 8, 50, 198, 187, 199, 866, 878, "pioglitazone" +291, 8, 51, 199, 200, 204, 879, 883, "were" +291, 8, 52, 200, 205, 215, 884, 894, "randomized" +291, 8, 53, 201, 216, 217, 895, 896, "(" +291, 8, 54, 202, 218, 219, 897, 898, "1" +291, 8, 55, 203, 220, 221, 899, 900, ":" +291, 8, 56, 204, 222, 223, 901, 902, "1" +291, 8, 57, 205, 224, 225, 903, 904, ")" +291, 8, 58, 206, 226, 228, 905, 907, "to" +291, 8, 59, 207, 229, 235, 908, 914, "double" +291, 8, 60, 208, 236, 237, 915, 916, "-" +291, 8, 61, 209, 238, 243, 917, 922, "blind" +291, 8, 62, 210, 244, 253, 923, 932, "treatment" +291, 8, 63, 211, 254, 258, 933, 937, "with" +291, 8, 64, 212, 259, 270, 938, 949, "linagliptin" +291, 8, 65, 213, 271, 272, 950, 951, "5" +291, 8, 66, 214, 273, 275, 952, 954, "mg" +291, 8, 67, 215, 276, 280, 955, 959, "once" +291, 8, 68, 216, 281, 286, 960, 965, "daily" +291, 8, 69, 217, 287, 289, 966, 968, "or" +291, 8, 70, 218, 290, 297, 969, 976, "placebo" +291, 8, 71, 219, 298, 301, 977, 980, "for" +291, 8, 72, 220, 302, 303, 981, 982, "≥" +291, 8, 73, 221, 304, 306, 983, 985, "52" +291, 8, 74, 222, 307, 312, 986, 991, "weeks" +291, 8, 75, 223, 313, 314, 992, 993, "." +291, 9, 1, 224, 0, 3, 994, 997, "The" +291, 9, 2, 225, 4, 9, 998, 1003, "basal" +291, 9, 3, 226, 10, 17, 1004, 1011, "insulin" +291, 9, 4, 227, 18, 22, 1012, 1016, "dose" +291, 9, 5, 228, 23, 26, 1017, 1020, "was" +291, 9, 6, 229, 27, 31, 1021, 1025, "kept" +291, 9, 7, 230, 32, 41, 1026, 1035, "unchanged" +291, 9, 8, 231, 42, 45, 1036, 1039, "for" +291, 9, 9, 232, 46, 48, 1040, 1042, "24" +291, 9, 10, 233, 49, 54, 1043, 1048, "weeks" +291, 9, 11, 234, 55, 58, 1049, 1052, "but" +291, 9, 12, 235, 59, 64, 1053, 1058, "could" +291, 9, 13, 236, 65, 75, 1059, 1069, "thereafter" +291, 9, 14, 237, 76, 78, 1070, 1072, "be" +291, 9, 15, 238, 79, 87, 1073, 1081, "titrated" +291, 9, 16, 239, 88, 97, 1082, 1091, "according" +291, 9, 17, 240, 98, 100, 1092, 1094, "to" +291, 9, 18, 241, 101, 108, 1095, 1102, "fasting" +291, 9, 19, 242, 109, 115, 1103, 1109, "plasma" +291, 9, 20, 243, 116, 123, 1110, 1117, "glucose" +291, 9, 21, 244, 124, 130, 1118, 1124, "levels" +291, 9, 22, 245, 131, 133, 1125, 1127, "at" +291, 9, 23, 246, 134, 137, 1128, 1131, "the" +291, 9, 24, 247, 138, 151, 1132, 1145, "investigators" +291, 9, 25, 248, 152, 153, 1146, 1147, "'" +291, 9, 26, 249, 154, 164, 1148, 1158, "discretion" +291, 9, 27, 250, 165, 166, 1159, 1160, "." +291, 10, 1, 251, 0, 3, 1161, 1164, "The" +291, 10, 2, 252, 4, 11, 1165, 1172, "primary" +291, 10, 3, 253, 12, 15, 1173, 1176, "end" +291, 10, 4, 254, 16, 21, 1177, 1182, "point" +291, 10, 5, 255, 22, 25, 1183, 1186, "was" +291, 10, 6, 256, 26, 29, 1187, 1190, "the" +291, 10, 7, 257, 30, 34, 1191, 1195, "mean" +291, 10, 8, 258, 35, 41, 1196, 1202, "change" +291, 10, 9, 259, 42, 44, 1203, 1205, "in" +291, 10, 10, 260, 45, 50, 1206, 1211, "HbA1c" +291, 10, 11, 261, 51, 55, 1212, 1216, "from" +291, 10, 12, 262, 56, 64, 1217, 1225, "baseline" +291, 10, 13, 263, 65, 67, 1226, 1228, "to" +291, 10, 14, 264, 68, 72, 1229, 1233, "week" +291, 10, 15, 265, 73, 75, 1234, 1236, "24" +291, 10, 16, 266, 76, 77, 1237, 1238, "." +291, 11, 1, 267, 0, 3, 1239, 1242, "The" +291, 11, 2, 268, 4, 10, 1243, 1249, "safety" +291, 11, 3, 269, 11, 19, 1250, 1258, "analysis" +291, 11, 4, 270, 20, 32, 1259, 1271, "incorporated" +291, 11, 5, 271, 33, 37, 1272, 1276, "data" +291, 11, 6, 272, 38, 40, 1277, 1279, "up" +291, 11, 7, 273, 41, 43, 1280, 1282, "to" +291, 11, 8, 274, 44, 45, 1283, 1284, "a" +291, 11, 9, 275, 46, 53, 1285, 1292, "maximum" +291, 11, 10, 276, 54, 56, 1293, 1295, "of" +291, 11, 11, 277, 57, 60, 1296, 1299, "110" +291, 11, 12, 278, 61, 66, 1300, 1305, "weeks" +291, 11, 13, 279, 67, 68, 1306, 1307, "." +291, 12, 1, 280, 0, 7, 1308, 1315, "RESULTS" +291, 12, 2, 281, 8, 9, 1316, 1317, ":" +291, 12, 3, 282, 10, 12, 1318, 1320, "At" +291, 12, 4, 283, 13, 17, 1321, 1325, "week" +291, 12, 5, 284, 18, 20, 1326, 1328, "24" +291, 12, 6, 285, 21, 22, 1329, 1330, "," +291, 12, 7, 286, 23, 28, 1331, 1336, "HbA1c" +291, 12, 8, 287, 29, 36, 1337, 1344, "changed" +291, 12, 9, 288, 37, 41, 1345, 1349, "from" +291, 12, 10, 289, 42, 43, 1350, 1351, "a" +291, 12, 11, 290, 44, 52, 1352, 1360, "baseline" +291, 12, 12, 291, 53, 55, 1361, 1363, "of" +291, 12, 13, 292, 56, 57, 1364, 1365, "8" +291, 12, 14, 293, 58, 59, 1366, 1367, "." +291, 12, 15, 294, 60, 61, 1368, 1369, "3" +291, 12, 16, 295, 62, 63, 1370, 1371, "%" +291, 12, 17, 296, 64, 65, 1372, 1373, "(" +291, 12, 18, 297, 66, 68, 1374, 1376, "67" +291, 12, 19, 298, 69, 73, 1377, 1381, "mmol" +291, 12, 20, 299, 74, 75, 1382, 1383, "/" +291, 12, 21, 300, 76, 79, 1384, 1387, "mol" +291, 12, 22, 301, 80, 81, 1388, 1389, ")" +291, 12, 23, 302, 82, 84, 1390, 1392, "by" +291, 12, 24, 303, 85, 86, 1393, 1394, "-" +291, 12, 25, 304, 87, 88, 1395, 1396, "0" +291, 12, 26, 305, 89, 90, 1397, 1398, "." +291, 12, 27, 306, 91, 92, 1399, 1400, "6" +291, 12, 28, 307, 93, 94, 1401, 1402, "%" +291, 12, 29, 308, 95, 96, 1403, 1404, "(" +291, 12, 30, 309, 97, 98, 1405, 1406, "-" +291, 12, 31, 310, 99, 100, 1407, 1408, "6" +291, 12, 32, 311, 101, 102, 1409, 1410, "." +291, 12, 33, 312, 103, 104, 1411, 1412, "6" +291, 12, 34, 313, 105, 109, 1413, 1417, "mmol" +291, 12, 35, 314, 110, 111, 1418, 1419, "/" +291, 12, 36, 315, 112, 115, 1420, 1423, "mol" +291, 12, 37, 316, 116, 117, 1424, 1425, ")" +291, 12, 38, 317, 118, 121, 1426, 1429, "and" +291, 12, 39, 318, 122, 124, 1430, 1432, "by" +291, 12, 40, 319, 125, 126, 1433, 1434, "0" +291, 12, 41, 320, 127, 128, 1435, 1436, "." +291, 12, 42, 321, 129, 130, 1437, 1438, "1" +291, 12, 43, 322, 131, 132, 1439, 1440, "%" +291, 12, 44, 323, 133, 134, 1441, 1442, "(" +291, 12, 45, 324, 135, 136, 1443, 1444, "1" +291, 12, 46, 325, 137, 138, 1445, 1446, "." +291, 12, 47, 326, 139, 140, 1447, 1448, "1" +291, 12, 48, 327, 141, 145, 1449, 1453, "mmol" +291, 12, 49, 328, 146, 147, 1454, 1455, "/" +291, 12, 50, 329, 148, 151, 1456, 1459, "mol" +291, 12, 51, 330, 152, 153, 1460, 1461, ")" +291, 12, 52, 331, 154, 158, 1462, 1466, "with" +291, 12, 53, 332, 159, 170, 1467, 1478, "linagliptin" +291, 12, 54, 333, 171, 174, 1479, 1482, "and" +291, 12, 55, 334, 175, 182, 1483, 1490, "placebo" +291, 12, 56, 335, 183, 184, 1491, 1492, "," +291, 12, 57, 336, 185, 197, 1493, 1505, "respectively" +291, 12, 58, 337, 198, 199, 1506, 1507, "(" +291, 12, 59, 338, 200, 209, 1508, 1517, "treatment" +291, 12, 60, 339, 210, 220, 1518, 1528, "difference" +291, 12, 61, 340, 221, 222, 1529, 1530, "-" +291, 12, 62, 341, 223, 224, 1531, 1532, "0" +291, 12, 63, 342, 225, 226, 1533, 1534, "." +291, 12, 64, 343, 227, 229, 1535, 1537, "65" +291, 12, 65, 344, 230, 231, 1538, 1539, "%" +291, 12, 66, 345, 232, 233, 1540, 1541, "[" +291, 12, 67, 346, 234, 236, 1542, 1544, "95" +291, 12, 68, 347, 237, 238, 1545, 1546, "%" +291, 12, 69, 348, 239, 241, 1547, 1549, "CI" +291, 12, 70, 349, 242, 243, 1550, 1551, "-" +291, 12, 71, 350, 244, 245, 1552, 1553, "0" +291, 12, 72, 351, 246, 247, 1554, 1555, "." +291, 12, 73, 352, 248, 250, 1556, 1558, "74" +291, 12, 74, 353, 251, 253, 1559, 1561, "to" +291, 12, 75, 354, 254, 255, 1562, 1563, "-" +291, 12, 76, 355, 256, 257, 1564, 1565, "0" +291, 12, 77, 356, 258, 259, 1566, 1567, "." +291, 12, 78, 357, 260, 262, 1568, 1570, "55" +291, 12, 79, 358, 263, 264, 1571, 1572, "]" +291, 12, 80, 359, 265, 266, 1573, 1574, "[" +291, 12, 81, 360, 267, 268, 1575, 1576, "-" +291, 12, 82, 361, 269, 270, 1577, 1578, "7" +291, 12, 83, 362, 271, 272, 1579, 1580, "." +291, 12, 84, 363, 273, 274, 1581, 1582, "1" +291, 12, 85, 364, 275, 279, 1583, 1587, "mmol" +291, 12, 86, 365, 280, 281, 1588, 1589, "/" +291, 12, 87, 366, 282, 285, 1590, 1593, "mol" +291, 12, 88, 367, 286, 287, 1594, 1595, "]" +291, 12, 89, 368, 288, 289, 1596, 1597, ";" +291, 12, 90, 369, 290, 291, 1598, 1599, "P" +291, 12, 91, 370, 292, 293, 1600, 1601, "<" +291, 12, 92, 371, 294, 295, 1602, 1603, "0" +291, 12, 93, 372, 296, 297, 1604, 1605, "." +291, 12, 94, 373, 298, 302, 1606, 1610, "0001" +291, 12, 95, 374, 303, 304, 1611, 1612, ")" +291, 12, 96, 375, 305, 306, 1613, 1614, "." +291, 13, 1, 376, 0, 7, 1615, 1622, "Despite" +291, 13, 2, 377, 8, 11, 1623, 1626, "the" +291, 13, 3, 378, 12, 18, 1627, 1633, "option" +291, 13, 4, 379, 19, 21, 1634, 1636, "to" +291, 13, 5, 380, 22, 31, 1637, 1646, "uptitrate" +291, 13, 6, 381, 32, 37, 1647, 1652, "basal" +291, 13, 7, 382, 38, 45, 1653, 1660, "insulin" +291, 13, 8, 383, 46, 47, 1661, 1662, "," +291, 13, 9, 384, 48, 50, 1663, 1665, "it" +291, 13, 10, 385, 51, 54, 1666, 1669, "was" +291, 13, 11, 386, 55, 63, 1670, 1678, "adjusted" +291, 13, 12, 387, 64, 68, 1679, 1683, "only" +291, 13, 13, 388, 69, 77, 1684, 1692, "slightly" +291, 13, 14, 389, 78, 84, 1693, 1699, "upward" +291, 13, 15, 390, 85, 86, 1700, 1701, "(" +291, 13, 16, 391, 87, 91, 1702, 1706, "week" +291, 13, 17, 392, 92, 94, 1707, 1709, "52" +291, 13, 18, 393, 95, 96, 1710, 1711, "," +291, 13, 19, 394, 97, 108, 1712, 1723, "linagliptin" +291, 13, 20, 395, 109, 110, 1724, 1725, "2" +291, 13, 21, 396, 111, 112, 1726, 1727, "." +291, 13, 22, 397, 113, 114, 1728, 1729, "6" +291, 13, 23, 398, 115, 117, 1730, 1732, "IU" +291, 13, 24, 399, 118, 119, 1733, 1734, "/" +291, 13, 25, 400, 120, 123, 1735, 1738, "day" +291, 13, 26, 401, 124, 125, 1739, 1740, "," +291, 13, 27, 402, 126, 133, 1741, 1748, "placebo" +291, 13, 28, 403, 134, 135, 1749, 1750, "4" +291, 13, 29, 404, 136, 137, 1751, 1752, "." +291, 13, 30, 405, 138, 139, 1753, 1754, "2" +291, 13, 31, 406, 140, 142, 1755, 1757, "IU" +291, 13, 32, 407, 143, 144, 1758, 1759, "/" +291, 13, 33, 408, 145, 148, 1760, 1763, "day" +291, 13, 34, 409, 149, 150, 1764, 1765, ";" +291, 13, 35, 410, 151, 152, 1766, 1767, "P" +291, 13, 36, 411, 153, 154, 1768, 1769, "<" +291, 13, 37, 412, 155, 156, 1770, 1771, "0" +291, 13, 38, 413, 157, 158, 1772, 1773, "." +291, 13, 39, 414, 159, 162, 1774, 1777, "003" +291, 13, 40, 415, 163, 164, 1778, 1779, ")" +291, 13, 41, 416, 165, 166, 1780, 1781, "," +291, 13, 42, 417, 167, 176, 1782, 1791, "resulting" +291, 13, 43, 418, 177, 179, 1792, 1794, "in" +291, 13, 44, 419, 180, 182, 1795, 1797, "no" +291, 13, 45, 420, 183, 190, 1798, 1805, "further" +291, 13, 46, 421, 191, 196, 1806, 1811, "HbA1c" +291, 13, 47, 422, 197, 209, 1812, 1824, "improvements" +291, 13, 48, 423, 210, 211, 1825, 1826, "." +291, 14, 1, 424, 0, 11, 1827, 1838, "Frequencies" +291, 14, 2, 425, 12, 14, 1839, 1841, "of" +291, 14, 3, 426, 15, 27, 1842, 1854, "hypoglycemia" +291, 14, 4, 427, 28, 29, 1855, 1856, "(" +291, 14, 5, 428, 30, 34, 1857, 1861, "week" +291, 14, 6, 429, 35, 37, 1862, 1864, "24" +291, 14, 7, 430, 38, 39, 1865, 1866, "," +291, 14, 8, 431, 40, 51, 1867, 1878, "linagliptin" +291, 14, 9, 432, 52, 54, 1879, 1881, "22" +291, 14, 10, 433, 55, 56, 1882, 1883, "." +291, 14, 11, 434, 57, 58, 1884, 1885, "0" +291, 14, 12, 435, 59, 60, 1886, 1887, "%" +291, 14, 13, 436, 61, 62, 1888, 1889, "," +291, 14, 14, 437, 63, 70, 1890, 1897, "placebo" +291, 14, 15, 438, 71, 73, 1898, 1900, "23" +291, 14, 16, 439, 74, 75, 1901, 1902, "." +291, 14, 17, 440, 76, 77, 1903, 1904, "2" +291, 14, 18, 441, 78, 79, 1905, 1906, "%" +291, 14, 19, 442, 80, 81, 1907, 1908, ";" +291, 14, 20, 443, 82, 91, 1909, 1918, "treatment" +291, 14, 21, 444, 92, 95, 1919, 1922, "end" +291, 14, 22, 445, 96, 97, 1923, 1924, "," +291, 14, 23, 446, 98, 109, 1925, 1936, "linagliptin" +291, 14, 24, 447, 110, 112, 1937, 1939, "31" +291, 14, 25, 448, 113, 114, 1940, 1941, "." +291, 14, 26, 449, 115, 116, 1942, 1943, "4" +291, 14, 27, 450, 117, 118, 1944, 1945, "%" +291, 14, 28, 451, 119, 120, 1946, 1947, "," +291, 14, 29, 452, 121, 128, 1948, 1955, "placebo" +291, 14, 30, 453, 129, 131, 1956, 1958, "32" +291, 14, 31, 454, 132, 133, 1959, 1960, "." +291, 14, 32, 455, 134, 135, 1961, 1962, "9" +291, 14, 33, 456, 136, 137, 1963, 1964, "%" +291, 14, 34, 457, 138, 139, 1965, 1966, ")" +291, 14, 35, 458, 140, 143, 1967, 1970, "and" +291, 14, 36, 459, 144, 151, 1971, 1978, "adverse" +291, 14, 37, 460, 152, 158, 1979, 1985, "events" +291, 14, 38, 461, 159, 160, 1986, 1987, "(" +291, 14, 39, 462, 161, 172, 1988, 1999, "linagliptin" +291, 14, 40, 463, 173, 175, 2000, 2002, "78" +291, 14, 41, 464, 176, 177, 2003, 2004, "." +291, 14, 42, 465, 178, 179, 2005, 2006, "4" +291, 14, 43, 466, 180, 181, 2007, 2008, "%" +291, 14, 44, 467, 182, 183, 2009, 2010, "," +291, 14, 45, 468, 184, 191, 2011, 2018, "placebo" +291, 14, 46, 469, 192, 194, 2019, 2021, "81" +291, 14, 47, 470, 195, 196, 2022, 2023, "." +291, 14, 48, 471, 197, 198, 2024, 2025, "4" +291, 14, 49, 472, 199, 200, 2026, 2027, "%" +291, 14, 50, 473, 201, 202, 2028, 2029, ")" +291, 14, 51, 474, 203, 207, 2030, 2034, "were" +291, 14, 52, 475, 208, 215, 2035, 2042, "similar" +291, 14, 53, 476, 216, 223, 2043, 2050, "between" +291, 14, 54, 477, 224, 230, 2051, 2057, "groups" +291, 14, 55, 478, 231, 232, 2058, 2059, "." +291, 15, 1, 479, 0, 4, 2060, 2064, "Mean" +291, 15, 2, 480, 5, 9, 2065, 2069, "body" +291, 15, 3, 481, 10, 16, 2070, 2076, "weight" +291, 15, 4, 482, 17, 25, 2077, 2085, "remained" +291, 15, 5, 483, 26, 35, 2086, 2095, "unchanged" +291, 15, 6, 484, 36, 37, 2096, 2097, "(" +291, 15, 7, 485, 38, 42, 2098, 2102, "week" +291, 15, 8, 486, 43, 45, 2103, 2105, "52" +291, 15, 9, 487, 46, 47, 2106, 2107, "," +291, 15, 10, 488, 48, 59, 2108, 2119, "linagliptin" +291, 15, 11, 489, 60, 61, 2120, 2121, "-" +291, 15, 12, 490, 62, 63, 2122, 2123, "0" +291, 15, 13, 491, 64, 65, 2124, 2125, "." +291, 15, 14, 492, 66, 68, 2126, 2128, "30" +291, 15, 15, 493, 69, 71, 2129, 2131, "kg" +291, 15, 16, 494, 72, 73, 2132, 2133, "," +291, 15, 17, 495, 74, 81, 2134, 2141, "placebo" +291, 15, 18, 496, 82, 83, 2142, 2143, "-" +291, 15, 19, 497, 84, 85, 2144, 2145, "0" +291, 15, 20, 498, 86, 87, 2146, 2147, "." +291, 15, 21, 499, 88, 90, 2148, 2150, "04" +291, 15, 22, 500, 91, 93, 2151, 2153, "kg" +291, 15, 23, 501, 94, 95, 2154, 2155, ")" +291, 15, 24, 502, 96, 97, 2156, 2157, "." +291, 16, 1, 503, 0, 11, 2158, 2169, "CONCLUSIONS" +291, 16, 2, 504, 12, 13, 2170, 2171, ":" +291, 16, 3, 505, 14, 25, 2172, 2183, "Linagliptin" +291, 16, 4, 506, 26, 31, 2184, 2189, "added" +291, 16, 5, 507, 32, 34, 2190, 2192, "to" +291, 16, 6, 508, 35, 40, 2193, 2198, "basal" +291, 16, 7, 509, 41, 48, 2199, 2206, "insulin" +291, 16, 8, 510, 49, 56, 2207, 2214, "therapy" +291, 16, 9, 511, 57, 70, 2215, 2228, "significantly" +291, 16, 10, 512, 71, 79, 2229, 2237, "improved" +291, 16, 11, 513, 80, 88, 2238, 2246, "glycemic" +291, 16, 12, 514, 89, 96, 2247, 2254, "control" +291, 16, 13, 515, 97, 105, 2255, 2263, "relative" +291, 16, 14, 516, 106, 108, 2264, 2266, "to" +291, 16, 15, 517, 109, 116, 2267, 2274, "placebo" +291, 16, 16, 518, 117, 124, 2275, 2282, "without" +291, 16, 17, 519, 125, 135, 2283, 2293, "increasing" +291, 16, 18, 520, 136, 148, 2294, 2306, "hypoglycemia" +291, 16, 19, 521, 149, 151, 2307, 2309, "or" +291, 16, 20, 522, 152, 156, 2310, 2314, "body" +291, 16, 21, 523, 157, 163, 2315, 2321, "weight" +291, 16, 22, 524, 164, 165, 2322, 2323, "." +291, 17, 1, 525, 0, 3, 2324, 2327, "DOI" +291, 17, 2, 526, 4, 5, 2328, 2329, ":" +291, 17, 3, 527, 6, 8, 2330, 2332, "10" +291, 17, 4, 528, 9, 10, 2333, 2334, "." +291, 17, 5, 529, 11, 15, 2335, 2339, "2337" +291, 17, 6, 530, 16, 17, 2340, 2341, "/" +291, 17, 7, 531, 18, 22, 2342, 2346, "dc12" +291, 17, 8, 532, 23, 24, 2347, 2348, "-" +291, 17, 9, 533, 25, 29, 2349, 2353, "2718" +291, 17, 10, 534, 30, 35, 2354, 2359, "PMCID" +291, 17, 11, 535, 36, 37, 2360, 2361, ":" +291, 17, 12, 536, 38, 48, 2362, 2372, "PMC3836100" +291, 17, 13, 537, 49, 53, 2373, 2377, "PMID" +291, 17, 14, 538, 54, 55, 2378, 2379, ":" +291, 17, 15, 539, 56, 64, 2380, 2388, "24062327" +291, 17, 16, 540, 65, 66, 2389, 2390, "[" +291, 17, 17, 541, 67, 74, 2391, 2398, "Indexed" +291, 17, 18, 542, 75, 78, 2399, 2402, "for" +291, 17, 19, 543, 79, 86, 2403, 2410, "MEDLINE" +291, 17, 20, 544, 87, 88, 2411, 2412, "]" diff --git a/data/dm2 24062327_kwoodley.annodb b/data/dm2 24062327_kwoodley.annodb new file mode 100644 index 0000000..0786aaf --- /dev/null +++ b/data/dm2 24062327_kwoodley.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +43200, Journal, 0, 13, "Diabetes Care", "", +43201, PublicationYear, 16, 20, "2013", "", +43214, Title, 102, 252, "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .", "", +43202, Linagliptin, 120, 131, "linagliptin", "", +43207, Insulin, 135, 148, "basal insulin", "", +43213, Precondition, 161, 200, "inadequately controlled type 2 diabetes", "", +43208, Type2Diabetes, 185, 200, "type 2 diabetes", "", +43210, Duration, 205, 216, "≥ 52 - week", "", +43211, Randomized, 217, 227, "randomized", "", +43212, DoubleBlind, 230, 244, "double - blind", "", +43215, Author, 253, 271, "Yki - J ä rvinen H", "", +43216, Author, 280, 292, "Rosenstock J", "", +43217, Author, 295, 313, "Dur á n - Garcia S", "", +43218, Author, 316, 326, "Pinnetti S", "", +43219, Author, 329, 343, "Bhattacharya S", "", +43220, Author, 346, 356, "Thiemann S", "", +43221, Author, 359, 366, "Patel S", "", +43222, Author, 369, 378, "Woerle HJ", "", +43223, Finland, 485, 487, "fi", "", +43228, ObjectiveDescription, 502, 678, "To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .", "", +43203, Linagliptin, 553, 564, "linagliptin", "", +43224, Insulin, 574, 588, "basal insulins", "", +43209, Type2Diabetes, 592, 607, "type 2 diabetes", "", +43227, Precondition, 592, 676, "type 2 diabetes inadequately controlled on basal insulin with or without oral agents", "", +43225, Insulin, 635, 648, "basal insulin", "", +43226, OralAntidiabeticAgent, 665, 676, "oral agents", "", +46330, NumberPatientsCT, 720, 727, "1 , 261", "", +46331, HbA1c, 739, 744, "HbA1c", "", +46332, PercentageAffected, 753, 754, "%", "", +46334, BioAndMedicalUnit, 760, 770, "mmol / mol", "", +46333, PercentageAffected, 785, 786, "%", "", +46335, BioAndMedicalUnit, 792, 802, "mmol / mol", "", +46336, Insulin, 810, 823, "basal insulin", "", +46337, Metformin, 847, 856, "metformin", "", +46338, Pioglitazone, 866, 878, "pioglitazone", "", +46339, Randomized, 884, 894, "randomized", "", +46340, AllocationRatio, 897, 902, "1 : 1", "", +46341, DoubleBlind, 908, 922, "double - blind", "", +43204, Linagliptin, 938, 949, "linagliptin", "", +46342, DoseValue, 950, 951, "5", "", +46343, mg, 952, 954, "mg", "", +46344, Frequency, 955, 965, "once daily", "", +46345, Placebo, 969, 976, "placebo", "", +46346, Duration, 981, 991, "≥ 52 weeks", "", +46347, Insulin, 998, 1011, "basal insulin", "", +46349, Duration, 1040, 1048, "24 weeks", "", +46350, FastingPlasmaGlucose, 1095, 1117, "fasting plasma glucose", "", +46351, HbA1c, 1206, 1211, "HbA1c", "", +46352, TimePoint, 1217, 1225, "baseline", "", +46353, TimePoint, 1229, 1236, "week 24", "", +46354, TimePoint, 1321, 1328, "week 24", "", +46358, HbA1c, 1331, 1336, "HbA1c", "", +46359, BaseLineValue, 1364, 1369, "8 . 3", "", +46361, Percentage, 1370, 1371, "%", "", +46360, BaseLineValue, 1374, 1376, "67", "", +46362, BioAndMedicalUnit, 1377, 1387, "mmol / mol", "", +46363, Reduction, 1395, 1400, "0 . 6", "", +46365, Percentage, 1401, 1402, "%", "", +46364, Reduction, 1407, 1412, "6 . 6", "", +46367, BioAndMedicalUnit, 1413, 1423, "mmol / mol", "", +46369, Increment, 1433, 1438, "0 . 1", "", +46366, Percentage, 1439, 1440, "%", "", +46370, Increment, 1443, 1448, "1 . 1", "", +46368, BioAndMedicalUnit, 1449, 1459, "mmol / mol", "", +43205, Linagliptin, 1467, 1478, "linagliptin", "", +46371, Placebo, 1483, 1490, "placebo", "", +46381, DiffGroupAbsValue, 1529, 1537, "- 0 . 65", "", +46383, Percentage, 1538, 1539, "%", "", +46384, ConfIntervalDiff, 1542, 1570, "95 % CI - 0 . 74 to - 0 . 55", "", +46382, DiffGroupAbsValue, 1575, 1582, "- 7 . 1", "", +46385, BioAndMedicalUnit, 1583, 1593, "mmol / mol", "", +46386, PvalueDiff, 1598, 1610, "P < 0 . 0001", "", +46397, InsulinDose, 1647, 1660, "basal insulin", "", +46357, TimePoint, 1702, 1709, "week 52", "", +46375, Linagliptin, 1712, 1723, "linagliptin", "", +46391, ResultMeasuredValue, 1724, 1729, "2 . 6", "", +46394, BioAndMedicalUnit, 1730, 1738, "IU / day", "", +46388, Placebo, 1741, 1748, "placebo", "", +46392, ResultMeasuredValue, 1749, 1754, "4 . 2", "", +46395, BioAndMedicalUnit, 1755, 1763, "IU / day", "", +46396, PvalueDiff, 1766, 1777, "P < 0 . 003", "", +46390, ObservedResult, 1782, 1824, "resulting in no further HbA1c improvements", "", +46389, HbA1c, 1806, 1811, "HbA1c", "", +46398, Hypoglycemia, 1842, 1854, "hypoglycemia", "", +46355, TimePoint, 1857, 1864, "week 24", "", +46377, Linagliptin, 1867, 1878, "linagliptin", "", +46399, PercentageAffected, 1879, 1885, "22 . 0", "", +46372, Placebo, 1890, 1897, "placebo", "", +46400, PercentageAffected, 1898, 1904, "23 . 2", "", +46405, TimePoint, 1909, 1922, "treatment end", "", +46376, Linagliptin, 1925, 1936, "linagliptin", "", +46401, PercentageAffected, 1937, 1943, "31 . 4", "", +46373, Placebo, 1948, 1955, "placebo", "", +46402, PercentageAffected, 1956, 1962, "32 . 9", "", +46406, EndPointDescription, 1971, 1985, "adverse events", "", +46378, Linagliptin, 1988, 1999, "linagliptin", "", +46403, PercentageAffected, 2000, 2006, "78 . 4", "", +46380, Placebo, 2011, 2018, "placebo", "", +46404, PercentageAffected, 2019, 2025, "81 . 4", "", +46407, BodyWeight, 2065, 2076, "body weight", "", +46356, TimePoint, 2098, 2105, "week 52", "", +46379, Linagliptin, 2108, 2119, "linagliptin", "", +46408, Reduction, 2122, 2128, "0 . 30", "", +46410, Kg, 2129, 2131, "kg", "", +46374, Placebo, 2134, 2141, "placebo", "", +46409, Reduction, 2144, 2150, "0 . 04", "", +46411, Kg, 2151, 2153, "kg", "", +46415, ConclusionComment, 2172, 2323, "Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .", "", +43206, Linagliptin, 2172, 2183, "Linagliptin", "", +46348, Insulin, 2193, 2206, "basal insulin", "", +46412, Placebo, 2267, 2274, "placebo", "", +46413, Hypoglycemia, 2294, 2306, "hypoglycemia", "", +46414, BodyWeight, 2310, 2321, "body weight", "", +46416, PMID, 2380, 2388, "24062327", "", diff --git a/data/dm2 24062327_kwoodley.n-triples b/data/dm2 24062327_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24062327_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24144654_admin.annodb b/data/dm2 24144654_admin.annodb new file mode 100644 index 0000000..b466fa2 --- /dev/null +++ b/data/dm2 24144654_admin.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2014", "", " \"2014\"." +2, Dapagliflozin, 96, 109, "Dapagliflozin", "", +28, Title, 96, 272, "Dapagliflozin is effective as add - on therapy to sitagliptin with or without metformin : a 24 - week , multicenter , randomized , double - blind , placebo - controlled study .", "", " \"Dapagliflozin is effective as add - on therapy to sitagliptin with or without metformin : a 24 - week , multicenter , randomized , double - blind , placebo - controlled study .\"." +12, Sitagliptin, 146, 157, "sitagliptin", "", +14, Metformin, 174, 183, "metformin", "", +19, Duration, 188, 197, "24 - week", "", " \"24 - week\"." +20, Multicenter, 200, 211, "multicenter", "", " ." +21, Randomized, 214, 224, "randomized", "", " ." +22, DoubleBlind, 227, 241, "double - blind", "", " ." +23, Placebo, 244, 251, "placebo", "", +24, Author, 273, 283, "Jabbour SA", "", " \"Jabbour SA\"." +25, Author, 292, 299, "Hardy E", "", " \"Hardy E\"." +26, Author, 302, 308, "Sugg J", "", " \"Sugg J\"." +27, Author, 311, 319, "Parikh S", "", " \"Parikh S\"." +32, ObjectiveDescription, 2128, 2334, "To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin .", "", " \"To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin .\"." +3, Dapagliflozin, 2165, 2178, "dapagliflozin", "", +31, Precondition, 2202, 2332, "patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin", "", " \"patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin\"." +29, Type2Diabetes, 2216, 2231, "type 2 diabetes", "", +15, Metformin, 2323, 2332, "metformin", "", +33, Duration, 2373, 2382, "24 - week", "", +34, Multicenter, 2385, 2396, "multicenter", "", +35, Randomized, 2399, 2409, "randomized", "", +36, DoubleBlind, 2412, 2426, "double - blind", "", +37, Placebo, 2429, 2436, "placebo", "", +38, Parallel, 2452, 2468, "parallel - group", "", " ." +39, Duration, 2492, 2501, "24 - week", "", +40, NumberPatientsCT, 2529, 2532, "432", "", " \"432\"." +41, Randomized, 2547, 2557, "randomized", "", +4, Dapagliflozin, 2569, 2582, "dapagliflozin", "", " ." +42, DoseValue, 2583, 2585, "10", "", " \"10\"." +45, mg, 2586, 2588, "mg", "", " ." +48, Frequency, 2591, 2594, "day", "", " \"day\"." +51, Placebo, 2598, 2605, "placebo", "", " ." +13, Sitagliptin, 2615, 2626, "sitagliptin", "", +43, DoseValue, 2629, 2632, "100", "", +46, mg, 2633, 2635, "mg", "", +49, Frequency, 2638, 2641, "day", "", +16, Metformin, 2646, 2655, "metformin", "", +44, DoseValue, 2658, 2667, "≥ 1 , 500", "", +47, mg, 2668, 2670, "mg", "", +50, Frequency, 2673, 2676, "day", "", +165, TimePoint, 2691, 2699, "Baseline", "", +57, HbA1c, 2700, 2705, "HbA1c", "", " ." +58, FastingPlasmaGlucose, 2710, 2713, "FPG", "", " ." +59, BaseLineValue, 2726, 2731, "7 . 9", "", " \"7 . 9\"." +67, Percentage, 2732, 2733, "%", "", " ." +60, BaseLineValue, 2736, 2742, "63 . 0", "", +79783, Millimoles_per_mole, 2743, 2753, "mmol / mol", "", +61, BaseLineValue, 2760, 2767, "162 . 2", "", " \"162 . 2\"." +71, Mg_per_deciliter, 2768, 2775, "mg / dL", "", " ." +62, BaseLineValue, 2778, 2783, "9 . 0", "", +73, Millimoles_per_litre, 2784, 2792, "mmol / L", "", +5, Dapagliflozin, 2803, 2816, "dapagliflozin", "", +63, BaseLineValue, 2827, 2832, "8 . 0", "", " \"8 . 0\"." +68, Percentage, 2833, 2834, "%", "", +64, BaseLineValue, 2837, 2843, "64 . 0", "", +79784, Millimoles_per_mole, 2844, 2854, "mmol / mol", "", +65, BaseLineValue, 2861, 2864, "163", "", " \"163\"." +72, Mg_per_deciliter, 2865, 2872, "mg / dL", "", +66, BaseLineValue, 2875, 2880, "9 . 0", "", +74, Millimoles_per_litre, 2881, 2889, "mmol / L", "", +52, Placebo, 2896, 2903, "placebo", "", +75, TimePoint, 2909, 2916, "week 24", "", +6, Dapagliflozin, 2919, 2932, "dapagliflozin", "", +188, Mean, 2955, 2959, "mean", "", " . ." +77, HbA1c, 2960, 2965, "HbA1c", "", +79, Reduction, 2977, 2982, "0 . 5", "", " \"0 . 5\"." +81, Percentage, 2983, 2984, "%", "", +80, Reduction, 2989, 2994, "4 . 9", "", +79785, Millimoles_per_mole, 2995, 3005, "mmol / mol", "", +78, Placebo, 3017, 3024, "placebo", "", +85, NoChange, 3027, 3032, "0 . 0", "", " \"0 . 0\"." +82, Percentage, 3033, 3034, "%", "", +86, Increment, 3039, 3044, "0 . 4", "", +79786, Millimoles_per_mole, 3045, 3055, "mmol / mol", "", +7, Dapagliflozin, 3062, 3075, "Dapagliflozin", "", +87, BodyWeight, 3084, 3095, "body weight", "", " ." +53, Placebo, 3103, 3110, "placebo", "", +89, Reduction, 3115, 3120, "2 . 1", "", " \"2 . 1\"." +90, Reduction, 3127, 3132, "0 . 3", "", " \"0 . 3\"." +204, Kg, 3133, 3135, "kg", "", " ." +88, HbA1c, 3150, 3155, "HbA1c", "", +92, SubGroupDescription, 3166, 3205, "patients with baseline values ≥ 8 . 0 %", "", " \"patients with baseline values ≥ 8 . 0 %\". \"patients with baseline values ≥ 8 . 0 %\"." +93, Percentage, 3204, 3205, "%", "", +94, Reduction, 3210, 3215, "0 . 8", "", " \"0 . 8\"." +209, Percentage, 3216, 3217, "%", "", +96, ResultMeasuredValue, 3220, 3225, "8 . 7", "", +79788, Millimoles_per_mole, 3226, 3236, "mmol / mol", "", +95, NoChange, 3243, 3248, "0 . 0", "", " \"0 . 0\"." +99, Percentage, 3249, 3250, "%", "", +214, ChangeValue, 3253, 3258, "0 . 3", "", +79787, Millimoles_per_mole, 3259, 3269, "mmol / mol", "", +101, FastingPlasmaGlucose, 3278, 3300, "fasting plasma glucose", "", +102, Reduction, 3312, 3318, "24 . 1", "", " \"24 . 1\"." +106, Mg_per_deciliter, 3319, 3326, "mg / dL", "", +103, Reduction, 3331, 3336, "1 . 3", "", +108, Millimoles_per_litre, 3337, 3345, "mmol / L", "", +104, Increment, 3352, 3357, "3 . 8", "", " \"3 . 8\"." +107, Mg_per_deciliter, 3358, 3365, "mg / dL", "", +105, Increment, 3368, 3373, "0 . 2", "", +109, Millimoles_per_litre, 3374, 3382, "mmol / L", "", +110, TimePoint, 3510, 3517, "week 24", "", +111, TimePoint, 3542, 3549, "week 48", "", +112, TimePoint, 3565, 3573, "baseline", "", +114, BloodPressure, 3577, 3600, "systolic blood pressure", "", +115, ObservedResult, 3601, 3670, "at week 8 were not significantly different between treatment groups .", "", +113, TimePoint, 3604, 3610, "week 8", "", +231, TimePoint, 3676, 3684, "48 weeks", "", +8, Dapagliflozin, 3712, 3725, "dapagliflozin", "", +54, Placebo, 3809, 3816, "placebo", "", +116, EndPointDescription, 3819, 3833, "Adverse events", "", +117, ObservedResult, 3834, 3901, "were balanced between groups , and discontinuation rates were low .", "", +76, TimePoint, 3905, 3912, "week 48", "", +118, EndPointDescription, 3948, 3965, "genital infection", "", +9, Dapagliflozin, 3990, 4003, "dapagliflozin", "", +119, PercentageAffected, 4006, 4011, "9 . 8", "", +55, Placebo, 4026, 4033, "placebo", "", +120, PercentageAffected, 4036, 4041, "0 . 4", "", +123, EndPointDescription, 4081, 4104, "urinary tract infection", "", " . ." +10, Dapagliflozin, 4127, 4140, "dapagliflozin", "", +121, PercentageAffected, 4143, 4148, "6 . 7", "", " \"6 . 7\"." +56, Placebo, 4157, 4164, "placebo", "", +122, PercentageAffected, 4167, 4172, "6 . 2", "", " \"6 . 7\"." +124, ConclusionComment, 4193, 4420, "These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated .", "", " \"These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated .\"." +106273, Precondition, 4223, 4319, "patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin", "", " \"patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin\"." +30, Type2Diabetes, 4237, 4252, "type 2 diabetes", "", " ." +18, Sitagliptin, 4282, 4293, "sitagliptin", "", +17, Metformin, 4310, 4319, "metformin", "", +11, Dapagliflozin, 4346, 4359, "dapagliflozin", "", +125, PMID, 4458, 4466, "24144654", "", " \"24144654\"." diff --git a/data/dm2 24144654_admin.n-triples b/data/dm2 24144654_admin.n-triples new file mode 100644 index 0000000..c493a3d --- /dev/null +++ b/data/dm2 24144654_admin.n-triples @@ -0,0 +1,154 @@ +# RDF export of group: Publication + . + "Publication 50322" . + "Dapagliflozin is effective as add - on therapy to sitagliptin with or without metformin : a 24 - week , multicenter , randomized , double - blind , placebo - controlled study ." . + "Jabbour SA" . + "2014" . + "Diabetes Care" . + "24144654" . + . + "Hardy E" . + "Sugg J" . + "Parikh S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 50329" . + "To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin ." . + "432" . + "24 - week" . + . + . + . + "These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 50345" . + "patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin" . + . + . + . + "patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "uri" . + . + . + . + . + . +# RDF export of group: Arm + . + "dap" . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "dap" . + . + "day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "dap" . + . + "10" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 9" . + "0 . 5" . + . + "hba 2" . + . + "8 . 0" . + "0 . 0" . + . + "fpg 1" . + . + "162 . 2" . + "24 . 1" . + . + "fpg 2" . + . + "163" . + "3 . 8" . + . + "bw 1" . + . + "2 . 1" . + . + "bw 2" . + . + "0 . 3" . + . + "hbas 1" . + . + "0 . 8" . + "patients with baseline values ≥ 8 . 0 %" . + . + "hbas 2" . + . + "0 . 0" . + "patients with baseline values ≥ 8 . 0 %" . + . + "uri 1" . + . + "6 . 7" . + . + "uri 2" . + . + "6 . 2" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24144654_akramersunderbrink.annodb b/data/dm2 24144654_akramersunderbrink.annodb new file mode 100644 index 0000000..dc2f325 --- /dev/null +++ b/data/dm2 24144654_akramersunderbrink.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +58718, Journal, 0, 13, "Diabetes Care", "", +58719, PublicationYear, 16, 20, "2014", "", +58720, Dapagliflozin, 96, 109, "Dapagliflozin", "", +58728, Title, 96, 272, "Dapagliflozin is effective as add - on therapy to sitagliptin with or without metformin : a 24 - week , multicenter , randomized , double - blind , placebo - controlled study .", "", +58721, Sitagliptin, 146, 157, "sitagliptin", "", +58722, Metformin, 174, 183, "metformin", "", +58723, Duration, 188, 197, "24 - week", "", +58724, Multicenter, 200, 211, "multicenter", "", +58725, Randomized, 214, 224, "randomized", "", +58726, DoubleBlind, 227, 241, "double - blind", "", +58727, Placebo, 244, 251, "placebo", "", +58729, Author, 273, 283, "Jabbour SA", "", +58730, Author, 292, 299, "Hardy E", "", +58731, Author, 302, 308, "Sugg J", "", +58733, Author, 311, 319, "Parikh S", "", +58738, ObjectiveDescription, 2128, 2334, "To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin .", "", +58734, Dapagliflozin, 2165, 2178, "dapagliflozin", "", +58735, Type2Diabetes, 2216, 2231, "type 2 diabetes", "", +58736, Precondition, 2241, 2332, "inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin", "", +58737, Metformin, 2323, 2332, "metformin", "", +58739, Duration, 2373, 2382, "24 - week", "", +58740, Multicenter, 2385, 2396, "multicenter", "", +58741, Randomized, 2399, 2409, "randomized", "", +58742, DoubleBlind, 2412, 2426, "double - blind", "", +58743, Placebo, 2429, 2436, "placebo", "", +58744, Parallel, 2452, 2468, "parallel - group", "", +58745, Duration, 2492, 2501, "24 - week", "", +58746, NumberPatientsCT, 2529, 2532, "432", "", +58747, Randomized, 2547, 2557, "randomized", "", +58748, Dapagliflozin, 2569, 2582, "dapagliflozin", "", +58750, DoseValue, 2583, 2594, "10 mg / day", "", +58749, BioAndMedicalUnit, 2586, 2594, "mg / day", "", +58751, Placebo, 2598, 2605, "placebo", "", +58752, Sitagliptin, 2615, 2626, "sitagliptin", "", +58753, DoseValue, 2629, 2641, "100 mg / day", "", +58754, BioAndMedicalUnit, 2633, 2641, "mg / day", "", +58755, Metformin, 2646, 2655, "metformin", "", +58756, DoseValue, 2658, 2676, "≥ 1 , 500 mg / day", "", +58757, BioAndMedicalUnit, 2668, 2676, "mg / day", "", +58758, TimePoint, 2691, 2699, "Baseline", "", +58759, HbA1c, 2700, 2705, "HbA1c", "", +58760, FastingPlasmaGlucose, 2710, 2720, "FPG levels", "", +58761, BaseLineValue, 2726, 2731, "7 . 9", "", +58762, Percentage, 2732, 2733, "%", "", +58763, BaseLineValue, 2736, 2742, "63 . 0", "", +58764, ConcentrationUnit, 2743, 2753, "mmol / mol", "", +58765, BaseLineValue, 2760, 2767, "162 . 2", "", +58773, Mg_per_deciliter, 2768, 2775, "mg / dL", "", +58766, BaseLineValue, 2778, 2783, "9 . 0", "", +58775, Millimoles_per_litre, 2784, 2792, "mmol / L", "", +58777, Dapagliflozin, 2803, 2816, "dapagliflozin", "", +58767, BaseLineValue, 2827, 2832, "8 . 0", "", +58771, Percentage, 2833, 2834, "%", "", +58768, BaseLineValue, 2837, 2843, "64 . 0", "", +58772, ConcentrationUnit, 2844, 2854, "mmol / mol", "", +58769, BaseLineValue, 2861, 2864, "163", "", +58774, Mg_per_deciliter, 2865, 2872, "mg / dL", "", +58770, BaseLineValue, 2875, 2880, "9 . 0", "", +58776, Millimoles_per_litre, 2881, 2889, "mmol / L", "", +58778, Placebo, 2896, 2903, "placebo", "", +58779, TimePoint, 2909, 2916, "week 24", "", +58780, Dapagliflozin, 2919, 2932, "dapagliflozin", "", +58781, Mean, 2955, 2959, "mean", "", +58782, HbA1c, 2960, 2972, "HbA1c levels", "", +58783, ChangeValue, 2975, 2982, "- 0 . 5", "", +58787, Percentage, 2983, 2984, "%", "", +58784, ChangeValue, 2987, 2994, "- 4 . 9", "", +58789, ConcentrationUnit, 2995, 3005, "mmol / mol", "", +58791, Placebo, 3017, 3024, "placebo", "", +58785, ChangeValue, 3027, 3032, "0 . 0", "", +58788, Percentage, 3033, 3034, "%", "", +58786, ChangeValue, 3037, 3044, "+ 0 . 4", "", +58790, ConcentrationUnit, 3045, 3055, "mmol / mol", "", +58792, Dapagliflozin, 3062, 3075, "Dapagliflozin", "", +58793, BodyWeight, 3084, 3095, "body weight", "", +58794, Placebo, 3103, 3110, "placebo", "", +58795, ChangeValue, 3113, 3120, "- 2 . 1", "", +58796, ChangeValue, 3125, 3132, "- 0 . 3", "", +58797, Kg, 3133, 3135, "kg", "", +58798, HbA1c, 3150, 3162, "HbA1c levels", "", +58799, SubGroupDescription, 3166, 3205, "patients with baseline values ≥ 8 . 0 %", "", +58800, TimePoint, 3180, 3188, "baseline", "", +58801, Percentage, 3204, 3205, "%", "", +58804, ChangeValue, 3208, 3215, "- 0 . 8", "", +58802, Percentage, 3216, 3217, "%", "", +58805, ChangeValue, 3220, 3225, "8 . 7", "", +58812, ConcentrationUnit, 3226, 3236, "mmol / mol", "", +58806, ChangeValue, 3243, 3248, "0 . 0", "", +58803, Percentage, 3249, 3250, "%", "", +58807, ChangeValue, 3253, 3258, "0 . 3", "", +58813, ConcentrationUnit, 3259, 3269, "mmol / mol", "", +58818, FastingPlasmaGlucose, 3278, 3307, "fasting plasma glucose levels", "", +58808, ChangeValue, 3310, 3318, "- 24 . 1", "", +58814, Mg_per_deciliter, 3319, 3326, "mg / dL", "", +58809, ChangeValue, 3329, 3336, "- 1 . 3", "", +58816, Millimoles_per_litre, 3337, 3345, "mmol / L", "", +58810, ChangeValue, 3352, 3357, "3 . 8", "", +58815, Mg_per_deciliter, 3358, 3365, "mg / dL", "", +58811, ChangeValue, 3368, 3373, "0 . 2", "", +58817, Millimoles_per_litre, 3374, 3382, "mmol / L", "", +58819, TimePoint, 3510, 3517, "week 24", "", +58820, TimePoint, 3542, 3549, "week 48", "", +58821, TimePoint, 3565, 3573, "baseline", "", +58823, BloodPressure, 3577, 3600, "systolic blood pressure", "", +58822, TimePoint, 3604, 3610, "week 8", "", +58824, TimePoint, 3676, 3684, "48 weeks", "", +58825, Dapagliflozin, 3712, 3725, "dapagliflozin", "", +58826, Placebo, 3809, 3816, "placebo", "", +58827, TimePoint, 3905, 3912, "week 48", "", +58828, EndPointDescription, 3915, 3965, "signs and symptoms suggestive of genital infection", "", +58829, Dapagliflozin, 3990, 4003, "dapagliflozin", "", +58831, PercentageAffected, 4006, 4011, "9 . 8", "", +58833, Percentage, 4012, 4013, "%", "", +58830, Placebo, 4026, 4033, "placebo", "", +58832, PercentageAffected, 4036, 4041, "0 . 4", "", +58834, Percentage, 4042, 4043, "%", "", +58835, EndPointDescription, 4048, 4104, "Signs and symptoms suggestive of urinary tract infection", "", +58837, Dapagliflozin, 4127, 4140, "dapagliflozin", "", +58839, PercentageAffected, 4143, 4148, "6 . 7", "", +58841, Percentage, 4149, 4150, "%", "", +58838, Placebo, 4157, 4164, "placebo", "", +58840, PercentageAffected, 4167, 4172, "6 . 2", "", +58842, Percentage, 4173, 4174, "%", "", +58848, ConclusionComment, 4193, 4420, "These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated .", "", +58843, Type2Diabetes, 4237, 4252, "type 2 diabetes", "", +58844, Sitagliptin, 4282, 4293, "sitagliptin", "", +58845, Metformin, 4310, 4319, "metformin", "", +58846, Dapagliflozin, 4346, 4359, "dapagliflozin", "", +58847, PMID, 4458, 4466, "24144654", "", diff --git a/data/dm2 24144654_akramersunderbrink.n-triples b/data/dm2 24144654_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24144654_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24144654_export.csv b/data/dm2 24144654_export.csv new file mode 100644 index 0000000..5bc7586 --- /dev/null +++ b/data/dm2 24144654_export.csv @@ -0,0 +1,1026 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +290, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +290, 1, 2, 2, 9, 13, 9, 13, "Care" +290, 1, 3, 3, 14, 15, 14, 15, "." +290, 2, 1, 4, 0, 4, 16, 20, "2014" +290, 2, 2, 5, 5, 6, 21, 22, ";" +290, 2, 3, 6, 7, 9, 23, 25, "37" +290, 2, 4, 7, 10, 11, 26, 27, "(" +290, 2, 5, 8, 12, 13, 28, 29, "3" +290, 2, 6, 9, 14, 15, 30, 31, ")" +290, 2, 7, 10, 16, 17, 32, 33, ":" +290, 2, 8, 11, 18, 21, 34, 37, "740" +290, 2, 9, 12, 22, 23, 38, 39, "-" +290, 2, 10, 13, 24, 26, 40, 42, "50" +290, 2, 11, 14, 27, 28, 43, 44, "." +290, 2, 12, 15, 29, 32, 45, 48, "doi" +290, 2, 13, 16, 33, 34, 49, 50, ":" +290, 2, 14, 17, 35, 37, 51, 53, "10" +290, 2, 15, 18, 38, 39, 54, 55, "." +290, 2, 16, 19, 40, 44, 56, 60, "2337" +290, 2, 17, 20, 45, 46, 61, 62, "/" +290, 2, 18, 21, 47, 51, 63, 67, "dc13" +290, 2, 19, 22, 52, 53, 68, 69, "-" +290, 2, 20, 23, 54, 58, 70, 74, "0467" +290, 2, 21, 24, 59, 60, 75, 76, "." +290, 3, 1, 25, 0, 4, 77, 81, "Epub" +290, 3, 2, 26, 5, 9, 82, 86, "2013" +290, 3, 3, 27, 10, 13, 87, 90, "Oct" +290, 3, 4, 28, 14, 16, 91, 93, "21" +290, 3, 5, 29, 17, 18, 94, 95, "." +290, 4, 1, 30, 0, 13, 96, 109, "Dapagliflozin" +290, 4, 2, 31, 14, 16, 110, 112, "is" +290, 4, 3, 32, 17, 26, 113, 122, "effective" +290, 4, 4, 33, 27, 29, 123, 125, "as" +290, 4, 5, 34, 30, 33, 126, 129, "add" +290, 4, 6, 35, 34, 35, 130, 131, "-" +290, 4, 7, 36, 36, 38, 132, 134, "on" +290, 4, 8, 37, 39, 46, 135, 142, "therapy" +290, 4, 9, 38, 47, 49, 143, 145, "to" +290, 4, 10, 39, 50, 61, 146, 157, "sitagliptin" +290, 4, 11, 40, 62, 66, 158, 162, "with" +290, 4, 12, 41, 67, 69, 163, 165, "or" +290, 4, 13, 42, 70, 77, 166, 173, "without" +290, 4, 14, 43, 78, 87, 174, 183, "metformin" +290, 4, 15, 44, 88, 89, 184, 185, ":" +290, 4, 16, 45, 90, 91, 186, 187, "a" +290, 4, 17, 46, 92, 94, 188, 190, "24" +290, 4, 18, 47, 95, 96, 191, 192, "-" +290, 4, 19, 48, 97, 101, 193, 197, "week" +290, 4, 20, 49, 102, 103, 198, 199, "," +290, 4, 21, 50, 104, 115, 200, 211, "multicenter" +290, 4, 22, 51, 116, 117, 212, 213, "," +290, 4, 23, 52, 118, 128, 214, 224, "randomized" +290, 4, 24, 53, 129, 130, 225, 226, "," +290, 4, 25, 54, 131, 137, 227, 233, "double" +290, 4, 26, 55, 138, 139, 234, 235, "-" +290, 4, 27, 56, 140, 145, 236, 241, "blind" +290, 4, 28, 57, 146, 147, 242, 243, "," +290, 4, 29, 58, 148, 155, 244, 251, "placebo" +290, 4, 30, 59, 156, 157, 252, 253, "-" +290, 4, 31, 60, 158, 168, 254, 264, "controlled" +290, 4, 32, 61, 169, 174, 265, 270, "study" +290, 4, 33, 62, 175, 176, 271, 272, "." +290, 5, 1, 63, 0, 7, 273, 280, "Jabbour" +290, 5, 2, 64, 8, 10, 281, 283, "SA" +290, 5, 3, 65, 11, 12, 284, 285, "(" +290, 5, 4, 66, 13, 14, 286, 287, "1" +290, 5, 5, 67, 15, 16, 288, 289, ")" +290, 5, 6, 68, 17, 18, 290, 291, "," +290, 5, 7, 69, 19, 24, 292, 297, "Hardy" +290, 5, 8, 70, 25, 26, 298, 299, "E" +290, 5, 9, 71, 27, 28, 300, 301, "," +290, 5, 10, 72, 29, 33, 302, 306, "Sugg" +290, 5, 11, 73, 34, 35, 307, 308, "J" +290, 5, 12, 74, 36, 37, 309, 310, "," +290, 5, 13, 75, 38, 44, 311, 317, "Parikh" +290, 5, 14, 76, 45, 46, 318, 319, "S" +290, 5, 15, 77, 47, 48, 320, 321, ";" +290, 5, 16, 78, 49, 54, 322, 327, "Study" +290, 5, 17, 79, 55, 57, 328, 330, "10" +290, 5, 18, 80, 58, 63, 331, 336, "Group" +290, 5, 19, 81, 64, 65, 337, 338, "." +290, 6, 1, 82, 0, 13, 339, 352, "Collaborators" +290, 6, 2, 83, 14, 15, 353, 354, ":" +290, 6, 3, 84, 16, 24, 355, 363, "Cuadrado" +290, 6, 4, 85, 25, 26, 364, 365, "J" +290, 6, 5, 86, 27, 28, 366, 367, "," +290, 6, 6, 87, 29, 38, 368, 377, "Aizenberg" +290, 6, 7, 88, 39, 40, 378, 379, "D" +290, 6, 8, 89, 41, 42, 380, 381, "," +290, 6, 9, 90, 43, 52, 382, 391, "Mociulsky" +290, 6, 10, 91, 53, 54, 392, 393, "J" +290, 6, 11, 92, 55, 56, 394, 395, "," +290, 6, 12, 93, 57, 63, 396, 402, "Maffei" +290, 6, 13, 94, 64, 65, 403, 404, "L" +290, 6, 14, 95, 66, 67, 405, 406, "," +290, 6, 15, 96, 68, 73, 407, 412, "Sinay" +290, 6, 16, 97, 74, 76, 413, 415, "IR" +290, 6, 17, 98, 77, 78, 416, 417, "," +290, 6, 18, 99, 79, 85, 418, 424, "Fretes" +290, 6, 19, 100, 86, 88, 425, 427, "JO" +290, 6, 20, 101, 89, 90, 428, 429, "," +290, 6, 21, 102, 91, 98, 430, 437, "Baccaro" +290, 6, 22, 103, 99, 101, 438, 440, "CE" +290, 6, 23, 104, 102, 103, 441, 442, "," +290, 6, 24, 105, 104, 110, 443, 449, "Aimone" +290, 6, 25, 106, 111, 112, 450, 451, "D" +290, 6, 26, 107, 113, 114, 452, 453, "," +290, 6, 27, 108, 115, 127, 454, 466, "Alvarisqueta" +290, 6, 28, 109, 128, 129, 467, 468, "A" +290, 6, 29, 110, 130, 131, 469, 470, "," +290, 6, 30, 111, 132, 139, 471, 478, "Cantero" +290, 6, 31, 112, 140, 142, 479, 481, "MC" +290, 6, 32, 113, 143, 144, 482, 483, "," +290, 6, 33, 114, 145, 152, 484, 491, "Hermida" +290, 6, 34, 115, 153, 155, 492, 494, "SG" +290, 6, 35, 116, 156, 157, 495, 496, "," +290, 6, 36, 117, 158, 166, 497, 505, "Sposetti" +290, 6, 37, 118, 167, 168, 506, 507, "G" +290, 6, 38, 119, 169, 170, 508, 509, "," +290, 6, 39, 120, 171, 181, 510, 520, "Lorenzatti" +290, 6, 40, 121, 182, 184, 521, 523, "AL" +290, 6, 41, 122, 185, 186, 524, 525, "," +290, 6, 42, 123, 187, 188, 526, 527, "L" +290, 6, 43, 124, 189, 190, 528, 529, "ú" +290, 6, 44, 125, 191, 195, 530, 534, "quez" +290, 6, 45, 126, 196, 197, 535, 536, "C" +290, 6, 46, 127, 198, 199, 537, 538, "," +290, 6, 47, 128, 200, 208, 539, 547, "Saavedra" +290, 6, 48, 129, 209, 211, 548, 550, "SS" +290, 6, 49, 130, 212, 213, 551, 552, "," +290, 6, 50, 131, 214, 220, 553, 559, "Hamann" +290, 6, 51, 132, 221, 222, 560, 561, "A" +290, 6, 52, 133, 223, 224, 562, 563, "," +290, 6, 53, 134, 225, 235, 564, 574, "Tangerding" +290, 6, 54, 135, 236, 237, 575, 576, "G" +290, 6, 55, 136, 238, 239, 577, 578, "," +290, 6, 56, 137, 240, 245, 579, 584, "Kosch" +290, 6, 57, 138, 246, 247, 585, 586, "C" +290, 6, 58, 139, 248, 249, 587, 588, "," +290, 6, 59, 140, 250, 254, 589, 593, "Rose" +290, 6, 60, 141, 255, 256, 594, 595, "L" +290, 6, 61, 142, 257, 258, 596, 597, "," +290, 6, 62, 143, 259, 260, 598, 599, "Z" +290, 6, 63, 144, 261, 262, 600, 601, "ü" +290, 6, 64, 145, 263, 269, 602, 608, "echner" +290, 6, 65, 146, 270, 271, 609, 610, "D" +290, 6, 66, 147, 272, 273, 611, 612, "," +290, 6, 67, 148, 274, 282, 613, 621, "Wendisch" +290, 6, 68, 149, 283, 284, 622, 623, "U" +290, 6, 69, 150, 285, 286, 624, 625, "," +290, 6, 70, 151, 287, 295, 626, 634, "Keuthage" +290, 6, 71, 152, 296, 297, 635, 636, "W" +290, 6, 72, 153, 298, 299, 637, 638, "," +290, 6, 73, 154, 300, 301, 639, 640, "M" +290, 6, 74, 155, 302, 303, 641, 642, "ö" +290, 6, 75, 156, 304, 307, 643, 646, "lle" +290, 6, 76, 157, 308, 309, 647, 648, "A" +290, 6, 77, 158, 310, 311, 649, 650, "," +290, 6, 78, 159, 312, 313, 651, 652, "B" +290, 6, 79, 160, 314, 315, 653, 654, "ü" +290, 6, 80, 161, 316, 321, 655, 660, "ttner" +290, 6, 81, 162, 322, 323, 661, 662, "C" +290, 6, 82, 163, 324, 325, 663, 664, "," +290, 6, 83, 164, 326, 332, 665, 671, "Hennig" +290, 6, 84, 165, 333, 334, 672, 673, "D" +290, 6, 85, 166, 335, 336, 674, 675, "," +290, 6, 86, 167, 337, 344, 676, 683, "Herrera" +290, 6, 87, 168, 345, 354, 684, 693, "Marmolejo" +290, 6, 88, 169, 355, 356, 694, 695, "M" +290, 6, 89, 170, 357, 358, 696, 697, "," +290, 6, 90, 171, 359, 363, 698, 702, "Gonz" +290, 6, 91, 172, 364, 365, 703, 704, "á" +290, 6, 92, 173, 366, 369, 705, 708, "lez" +290, 6, 93, 174, 370, 371, 709, 710, "G" +290, 6, 94, 175, 372, 373, 711, 712, "á" +290, 6, 95, 176, 374, 378, 713, 717, "lvez" +290, 6, 96, 177, 379, 380, 718, 719, "G" +290, 6, 97, 178, 381, 382, 720, 721, "," +290, 6, 98, 179, 383, 390, 722, 729, "Caracas" +290, 6, 99, 180, 391, 399, 730, 738, "Portilla" +290, 6, 100, 181, 400, 402, 739, 741, "NA" +290, 6, 101, 182, 403, 404, 742, 743, "," +290, 6, 102, 183, 405, 412, 744, 751, "Aguilar" +290, 6, 103, 184, 413, 420, 752, 759, "Salinas" +290, 6, 104, 185, 421, 423, 760, 762, "CA" +290, 6, 105, 186, 424, 425, 763, 764, "," +290, 6, 106, 187, 426, 427, 765, 766, "S" +290, 6, 107, 188, 428, 429, 767, 768, "á" +290, 6, 108, 189, 430, 435, 769, 774, "nchez" +290, 6, 109, 190, 436, 443, 775, 782, "Arriaga" +290, 6, 110, 191, 444, 446, 783, 785, "LF" +290, 6, 111, 192, 447, 448, 786, 787, "," +290, 6, 112, 193, 449, 458, 788, 797, "Pasternak" +290, 6, 113, 194, 459, 460, 798, 799, "D" +290, 6, 114, 195, 461, 462, 800, 801, "," +290, 6, 115, 196, 463, 472, 802, 811, "Wojnowski" +290, 6, 116, 197, 473, 474, 812, 813, "L" +290, 6, 117, 198, 475, 476, 814, 815, "," +290, 6, 118, 199, 477, 487, 816, 826, "Derezinski" +290, 6, 119, 200, 488, 489, 827, 828, "T" +290, 6, 120, 201, 490, 491, 829, 830, "," +290, 6, 121, 202, 492, 497, 831, 836, "Babol" +290, 6, 122, 203, 498, 499, 837, 838, "I" +290, 6, 123, 204, 500, 501, 839, 840, "," +290, 6, 124, 205, 502, 510, 841, 849, "Pomiecko" +290, 6, 125, 206, 511, 512, 850, 851, "W" +290, 6, 126, 207, 513, 514, 852, 853, "," +290, 6, 127, 208, 515, 524, 854, 863, "Romanczuk" +290, 6, 128, 209, 525, 526, 864, 865, "P" +290, 6, 129, 210, 527, 528, 866, 867, "," +290, 6, 130, 211, 529, 538, 868, 877, "Pazdziora" +290, 6, 131, 212, 539, 540, 878, 879, "J" +290, 6, 132, 213, 541, 542, 880, 881, "," +290, 6, 133, 214, 543, 550, 882, 889, "Krzyzag" +290, 6, 134, 215, 551, 552, 890, 891, "ó" +290, 6, 135, 216, 553, 557, 892, 896, "rska" +290, 6, 136, 217, 558, 559, 897, 898, "E" +290, 6, 137, 218, 560, 561, 899, 900, "," +290, 6, 138, 219, 562, 569, 901, 908, "Strojek" +290, 6, 139, 220, 570, 571, 909, 910, "K" +290, 6, 140, 221, 572, 573, 911, 912, "," +290, 6, 141, 222, 574, 584, 913, 923, "Ponikowska" +290, 6, 142, 223, 585, 586, 924, 925, "I" +290, 6, 143, 224, 587, 588, 926, 927, "," +290, 6, 144, 225, 589, 599, 928, 938, "Skudlarski" +290, 6, 145, 226, 600, 601, 939, 940, "D" +290, 6, 146, 227, 602, 603, 941, 942, "," +290, 6, 147, 228, 604, 615, 943, 954, "Winogrodzka" +290, 6, 148, 229, 616, 617, 955, 956, "-" +290, 6, 149, 230, 618, 625, 957, 964, "Pulchny" +290, 6, 150, 231, 626, 627, 965, 966, "B" +290, 6, 151, 232, 628, 629, 967, 968, "," +290, 6, 152, 233, 630, 637, 969, 976, "Bodalia" +290, 6, 153, 234, 638, 639, 977, 978, "B" +290, 6, 154, 235, 640, 641, 979, 980, "," +290, 6, 155, 236, 642, 645, 981, 984, "Tam" +290, 6, 156, 237, 646, 647, 985, 986, "D" +290, 6, 157, 238, 648, 649, 987, 988, "," +290, 6, 158, 239, 650, 655, 989, 994, "Adler" +290, 6, 159, 240, 656, 657, 995, 996, "M" +290, 6, 160, 241, 658, 659, 997, 998, "," +290, 6, 161, 242, 660, 664, 999, 1003, "Conn" +290, 6, 162, 243, 665, 666, 1004, 1005, "P" +290, 6, 163, 244, 667, 668, 1006, 1007, "," +290, 6, 164, 245, 669, 675, 1008, 1014, "Butler" +290, 6, 165, 246, 676, 677, 1015, 1016, "M" +290, 6, 166, 247, 678, 679, 1017, 1018, "," +290, 6, 167, 248, 680, 688, 1019, 1027, "Caldwell" +290, 6, 168, 249, 689, 691, 1028, 1030, "ID" +290, 6, 169, 250, 692, 693, 1031, 1032, "," +290, 6, 170, 251, 694, 698, 1033, 1037, "Saul" +290, 6, 171, 252, 699, 701, 1038, 1040, "PA" +290, 6, 172, 253, 702, 703, 1041, 1042, "," +290, 6, 173, 254, 704, 710, 1043, 1049, "Takhar" +290, 6, 174, 255, 711, 712, 1050, 1051, "A" +290, 6, 175, 256, 713, 714, 1052, 1053, "," +290, 6, 176, 257, 715, 722, 1054, 1061, "McNally" +290, 6, 177, 258, 723, 724, 1062, 1063, "D" +290, 6, 178, 259, 725, 726, 1064, 1065, "," +290, 6, 179, 260, 727, 734, 1066, 1073, "Butcher" +290, 6, 180, 261, 735, 736, 1074, 1075, "G" +290, 6, 181, 262, 737, 738, 1076, 1077, "," +290, 6, 182, 263, 739, 745, 1078, 1084, "Harvey" +290, 6, 183, 264, 746, 747, 1085, 1086, "P" +290, 6, 184, 265, 748, 749, 1087, 1088, "," +290, 6, 185, 266, 750, 756, 1089, 1095, "Turner" +290, 6, 186, 267, 757, 758, 1096, 1097, "W" +290, 6, 187, 268, 759, 760, 1098, 1099, "," +290, 6, 188, 269, 761, 768, 1100, 1107, "Chapman" +290, 6, 189, 270, 769, 770, 1108, 1109, "G" +290, 6, 190, 271, 771, 772, 1110, 1111, "," +290, 6, 191, 272, 773, 781, 1112, 1120, "Gillings" +290, 6, 192, 273, 782, 783, 1121, 1122, "S" +290, 6, 193, 274, 784, 785, 1123, 1124, "," +290, 6, 194, 275, 786, 793, 1125, 1132, "Jabbour" +290, 6, 195, 276, 794, 796, 1133, 1135, "SA" +290, 6, 196, 277, 797, 798, 1136, 1137, "," +290, 6, 197, 278, 799, 808, 1138, 1147, "Bernstein" +290, 6, 198, 279, 809, 811, 1148, 1150, "RI" +290, 6, 199, 280, 812, 813, 1151, 1152, "," +290, 6, 200, 281, 814, 820, 1153, 1159, "Broker" +290, 6, 201, 282, 821, 823, 1160, 1162, "RE" +290, 6, 202, 283, 824, 825, 1163, 1164, "," +290, 6, 203, 284, 826, 830, 1165, 1169, "Buth" +290, 6, 204, 285, 831, 833, 1170, 1172, "DK" +290, 6, 205, 286, 834, 835, 1173, 1174, "," +290, 6, 206, 287, 836, 842, 1175, 1181, "Downey" +290, 6, 207, 288, 843, 845, 1182, 1184, "HJ" +290, 6, 208, 289, 846, 847, 1185, 1186, "," +290, 6, 209, 290, 848, 855, 1187, 1194, "Gabriel" +290, 6, 210, 291, 856, 858, 1195, 1197, "JD" +290, 6, 211, 292, 859, 860, 1198, 1199, "," +290, 6, 212, 293, 861, 870, 1200, 1209, "Heidbrier" +290, 6, 213, 294, 871, 873, 1210, 1212, "EW" +290, 6, 214, 295, 874, 875, 1213, 1214, "," +290, 6, 215, 296, 876, 880, 1215, 1219, "Hill" +290, 6, 216, 297, 881, 883, 1220, 1222, "JM" +290, 6, 217, 298, 884, 885, 1223, 1224, "," +290, 6, 218, 299, 886, 890, 1225, 1229, "Kaye" +290, 6, 219, 300, 891, 893, 1230, 1232, "WA" +290, 6, 220, 301, 894, 895, 1233, 1234, "," +290, 6, 221, 302, 896, 903, 1235, 1242, "Mulford" +290, 6, 222, 303, 904, 906, 1243, 1245, "MI" +290, 6, 223, 304, 907, 908, 1246, 1247, "," +290, 6, 224, 305, 909, 917, 1248, 1256, "Pragalos" +290, 6, 225, 306, 918, 920, 1257, 1259, "AA" +290, 6, 226, 307, 921, 922, 1260, 1261, "," +290, 6, 227, 308, 923, 927, 1262, 1266, "Riff" +290, 6, 228, 309, 928, 930, 1267, 1269, "DS" +290, 6, 229, 310, 931, 932, 1270, 1271, "," +290, 6, 230, 311, 933, 939, 1272, 1278, "Tamayo" +290, 6, 231, 312, 940, 942, 1279, 1281, "RE" +290, 6, 232, 313, 943, 944, 1282, 1283, "," +290, 6, 233, 314, 945, 953, 1284, 1292, "Tannoury" +290, 6, 234, 315, 954, 955, 1293, 1294, "G" +290, 6, 235, 316, 956, 957, 1295, 1296, "," +290, 6, 236, 317, 958, 963, 1297, 1302, "Adams" +290, 6, 237, 318, 964, 966, 1303, 1305, "MR" +290, 6, 238, 319, 967, 968, 1306, 1307, "," +290, 6, 239, 320, 969, 975, 1308, 1314, "Gallen" +290, 6, 240, 321, 976, 977, 1315, 1316, "J" +290, 6, 241, 322, 978, 979, 1317, 1318, "," +290, 6, 242, 323, 980, 988, 1319, 1327, "Andrawis" +290, 6, 243, 324, 989, 991, 1328, 1330, "NS" +290, 6, 244, 325, 992, 993, 1331, 1332, "," +290, 6, 245, 326, 994, 1001, 1333, 1340, "Barreto" +290, 6, 246, 327, 1002, 1003, 1341, 1342, "A" +290, 6, 247, 328, 1004, 1005, 1343, 1344, "," +290, 6, 248, 329, 1006, 1014, 1345, 1353, "Gilliard" +290, 6, 249, 330, 1015, 1017, 1354, 1356, "LM" +290, 6, 250, 331, 1018, 1019, 1357, 1358, "," +290, 6, 251, 332, 1020, 1027, 1359, 1366, "Johnson" +290, 6, 252, 333, 1028, 1030, 1367, 1369, "MK" +290, 6, 253, 334, 1031, 1032, 1370, 1371, "," +290, 6, 254, 335, 1033, 1039, 1372, 1378, "Knopke" +290, 6, 255, 336, 1040, 1042, 1379, 1381, "CG" +290, 6, 256, 337, 1043, 1046, 1382, 1385, "3rd" +290, 6, 257, 338, 1047, 1048, 1386, 1387, "," +290, 6, 258, 339, 1049, 1055, 1388, 1394, "Miller" +290, 6, 259, 340, 1056, 1058, 1395, 1397, "SS" +290, 6, 260, 341, 1059, 1060, 1398, 1399, "," +290, 6, 261, 342, 1061, 1067, 1400, 1406, "Powell" +290, 6, 262, 343, 1068, 1070, 1407, 1409, "SJ" +290, 6, 263, 344, 1071, 1072, 1410, 1411, "," +290, 6, 264, 345, 1073, 1081, 1412, 1420, "Rodstein" +290, 6, 265, 346, 1082, 1084, 1421, 1423, "SR" +290, 6, 266, 347, 1085, 1086, 1424, 1425, "," +290, 6, 267, 348, 1087, 1093, 1426, 1432, "Helmer" +290, 6, 268, 349, 1094, 1095, 1433, 1434, "T" +290, 6, 269, 350, 1096, 1097, 1435, 1436, "," +290, 6, 270, 351, 1098, 1108, 1437, 1447, "Schumacher" +290, 6, 271, 352, 1109, 1111, 1448, 1450, "DR" +290, 6, 272, 353, 1112, 1113, 1451, 1452, "," +290, 6, 273, 354, 1114, 1121, 1453, 1460, "Shachar" +290, 6, 274, 355, 1122, 1124, 1461, 1463, "SB" +290, 6, 275, 356, 1125, 1126, 1464, 1465, "," +290, 6, 276, 357, 1127, 1132, 1466, 1471, "Speer" +290, 6, 277, 358, 1133, 1134, 1472, 1473, "J" +290, 6, 278, 359, 1135, 1136, 1474, 1475, "," +290, 6, 279, 360, 1137, 1143, 1476, 1482, "Streja" +290, 6, 280, 361, 1144, 1146, 1483, 1485, "DA" +290, 6, 281, 362, 1147, 1148, 1486, 1487, "," +290, 6, 282, 363, 1149, 1155, 1488, 1494, "Brusco" +290, 6, 283, 364, 1156, 1158, 1495, 1497, "OA" +290, 6, 284, 365, 1159, 1161, 1498, 1500, "Jr" +290, 6, 285, 366, 1162, 1163, 1501, 1502, "," +290, 6, 286, 367, 1164, 1170, 1503, 1509, "Cuevas" +290, 6, 287, 368, 1171, 1173, 1510, 1512, "ES" +290, 6, 288, 369, 1174, 1175, 1513, 1514, "," +290, 6, 289, 370, 1176, 1182, 1515, 1521, "Ganong" +290, 6, 290, 371, 1183, 1185, 1522, 1524, "KD" +290, 6, 291, 372, 1186, 1187, 1525, 1526, "," +290, 6, 292, 373, 1188, 1196, 1527, 1535, "Hoekstra" +290, 6, 293, 374, 1197, 1199, 1536, 1538, "JA" +290, 6, 294, 375, 1200, 1201, 1539, 1540, "," +290, 6, 295, 376, 1202, 1208, 1541, 1547, "Ibarra" +290, 6, 296, 377, 1209, 1210, 1548, 1549, "S" +290, 6, 297, 378, 1211, 1212, 1550, 1551, "," +290, 6, 298, 379, 1213, 1218, 1552, 1557, "Mills" +290, 6, 299, 380, 1219, 1221, 1558, 1560, "RE" +290, 6, 300, 381, 1222, 1223, 1561, 1562, "," +290, 6, 301, 382, 1224, 1233, 1563, 1572, "Pettyjohn" +290, 6, 302, 383, 1234, 1236, 1573, 1575, "FS" +290, 6, 303, 384, 1237, 1238, 1576, 1577, "," +290, 6, 304, 385, 1239, 1249, 1578, 1588, "Rosenstock" +290, 6, 305, 386, 1250, 1251, 1589, 1590, "J" +290, 6, 306, 387, 1252, 1253, 1591, 1592, "," +290, 6, 307, 388, 1254, 1261, 1593, 1600, "Rothman" +290, 6, 308, 389, 1262, 1264, 1601, 1603, "JG" +290, 6, 309, 390, 1265, 1266, 1604, 1605, "," +290, 6, 310, 391, 1267, 1273, 1606, 1612, "Warren" +290, 6, 311, 392, 1274, 1276, 1613, 1615, "MW" +290, 6, 312, 393, 1277, 1278, 1616, 1617, "," +290, 6, 313, 394, 1279, 1286, 1618, 1625, "Webster" +290, 6, 314, 395, 1287, 1289, 1626, 1628, "BR" +290, 6, 315, 396, 1290, 1291, 1629, 1630, "," +290, 6, 316, 397, 1292, 1297, 1631, 1636, "Patel" +290, 6, 317, 398, 1298, 1300, 1637, 1639, "AB" +290, 6, 318, 399, 1301, 1302, 1640, 1641, "," +290, 6, 319, 400, 1303, 1308, 1642, 1647, "Gabra" +290, 6, 320, 401, 1309, 1311, 1648, 1650, "NW" +290, 6, 321, 402, 1312, 1313, 1651, 1652, "," +290, 6, 322, 403, 1314, 1319, 1653, 1658, "Patel" +290, 6, 323, 404, 1320, 1322, 1659, 1661, "BK" +290, 6, 324, 405, 1323, 1324, 1662, 1663, "," +290, 6, 325, 406, 1325, 1331, 1664, 1670, "Hubach" +290, 6, 326, 407, 1332, 1334, 1671, 1673, "EA" +290, 6, 327, 408, 1335, 1336, 1674, 1675, "," +290, 6, 328, 409, 1337, 1343, 1676, 1682, "Bidair" +290, 6, 329, 410, 1344, 1345, 1683, 1684, "M" +290, 6, 330, 411, 1346, 1347, 1685, 1686, "," +290, 6, 331, 412, 1348, 1355, 1687, 1694, "Hassman" +290, 6, 332, 413, 1356, 1358, 1695, 1697, "DR" +290, 6, 333, 414, 1359, 1360, 1698, 1699, "," +290, 6, 334, 415, 1361, 1368, 1700, 1707, "Michlin" +290, 6, 335, 416, 1369, 1370, 1708, 1709, "B" +290, 6, 336, 417, 1371, 1372, 1710, 1711, "," +290, 6, 337, 418, 1373, 1380, 1712, 1719, "Nabours" +290, 6, 338, 419, 1381, 1383, 1720, 1722, "WC" +290, 6, 339, 420, 1384, 1385, 1723, 1724, "," +290, 6, 340, 421, 1386, 1395, 1725, 1734, "Sotolongo" +290, 6, 341, 422, 1396, 1397, 1735, 1736, "R" +290, 6, 342, 423, 1398, 1399, 1737, 1738, "," +290, 6, 343, 424, 1400, 1406, 1739, 1745, "Arcuri" +290, 6, 344, 425, 1407, 1413, 1746, 1752, "Kimzey" +290, 6, 345, 426, 1414, 1415, 1753, 1754, "N" +290, 6, 346, 427, 1416, 1417, 1755, 1756, "," +290, 6, 347, 428, 1418, 1423, 1757, 1762, "Edris" +290, 6, 348, 429, 1424, 1425, 1763, 1764, "M" +290, 6, 349, 430, 1426, 1427, 1765, 1766, "," +290, 6, 350, 431, 1428, 1433, 1767, 1772, "Hazan" +290, 6, 351, 432, 1434, 1436, 1773, 1775, "LL" +290, 6, 352, 433, 1437, 1438, 1776, 1777, "," +290, 6, 353, 434, 1439, 1446, 1778, 1785, "Jimenez" +290, 6, 354, 435, 1447, 1448, 1786, 1787, "F" +290, 6, 355, 436, 1449, 1450, 1788, 1789, "," +290, 6, 356, 437, 1451, 1459, 1790, 1798, "Freedman" +290, 6, 357, 438, 1460, 1461, 1799, 1800, "D" +290, 6, 358, 439, 1462, 1463, 1801, 1802, "," +290, 6, 359, 440, 1464, 1472, 1803, 1811, "Claassen" +290, 6, 360, 441, 1473, 1475, 1812, 1814, "DA" +290, 6, 361, 442, 1476, 1477, 1815, 1816, "," +290, 6, 362, 443, 1478, 1486, 1817, 1825, "Sugimoto" +290, 6, 363, 444, 1487, 1488, 1826, 1827, "D" +290, 6, 364, 445, 1489, 1490, 1828, 1829, "," +290, 6, 365, 446, 1491, 1497, 1830, 1836, "Marcus" +290, 6, 366, 447, 1498, 1499, 1837, 1838, "A" +290, 6, 367, 448, 1500, 1501, 1839, 1840, "," +290, 6, 368, 449, 1502, 1508, 1841, 1847, "Corder" +290, 6, 369, 450, 1509, 1511, 1848, 1850, "CN" +290, 6, 370, 451, 1512, 1513, 1851, 1852, "," +290, 6, 371, 452, 1514, 1522, 1853, 1861, "Szczesny" +290, 6, 372, 453, 1523, 1524, 1862, 1863, "M" +290, 6, 373, 454, 1525, 1526, 1864, 1865, "," +290, 6, 374, 455, 1527, 1535, 1866, 1874, "McCarthy" +290, 6, 375, 456, 1536, 1537, 1875, 1876, "E" +290, 6, 376, 457, 1538, 1539, 1877, 1878, "," +290, 6, 377, 458, 1540, 1545, 1879, 1884, "Makam" +290, 6, 378, 459, 1546, 1548, 1885, 1887, "SK" +290, 6, 379, 460, 1549, 1550, 1888, 1889, "," +290, 6, 380, 461, 1551, 1558, 1890, 1897, "Venereo" +290, 6, 381, 462, 1559, 1560, 1898, 1899, "J" +290, 6, 382, 463, 1561, 1562, 1900, 1901, "," +290, 6, 383, 464, 1563, 1569, 1902, 1908, "Sewell" +290, 6, 384, 465, 1570, 1571, 1909, 1910, "M" +290, 6, 385, 466, 1572, 1573, 1911, 1912, "," +290, 6, 386, 467, 1574, 1582, 1913, 1921, "Ibraheem" +290, 6, 387, 468, 1583, 1585, 1922, 1924, "MA" +290, 6, 388, 469, 1586, 1587, 1925, 1926, "," +290, 6, 389, 470, 1588, 1593, 1927, 1932, "Sligh" +290, 6, 390, 471, 1594, 1596, 1933, 1935, "TS" +290, 6, 391, 472, 1597, 1598, 1936, 1937, "." +290, 7, 1, 473, 0, 6, 1938, 1944, "Author" +290, 7, 2, 474, 7, 18, 1945, 1956, "information" +290, 7, 3, 475, 19, 20, 1957, 1958, ":" +290, 7, 4, 476, 21, 22, 1959, 1960, "(" +290, 7, 5, 477, 23, 24, 1961, 1962, "1" +290, 7, 6, 478, 25, 26, 1963, 1964, ")" +290, 7, 7, 479, 27, 40, 1965, 1978, "Corresponding" +290, 7, 8, 480, 41, 47, 1979, 1985, "author" +290, 7, 9, 481, 48, 49, 1986, 1987, ":" +290, 7, 10, 482, 50, 55, 1988, 1993, "Serge" +290, 7, 11, 483, 56, 57, 1994, 1995, "A" +290, 7, 12, 484, 58, 59, 1996, 1997, "." +290, 7, 13, 485, 60, 67, 1998, 2005, "Jabbour" +290, 7, 14, 486, 68, 69, 2006, 2007, "," +290, 7, 15, 487, 70, 75, 2008, 2013, "serge" +290, 7, 16, 488, 76, 77, 2014, 2015, "." +290, 7, 17, 489, 78, 85, 2016, 2023, "jabbour" +290, 7, 18, 490, 86, 87, 2024, 2025, "@" +290, 7, 19, 491, 88, 97, 2026, 2035, "jefferson" +290, 7, 20, 492, 98, 99, 2036, 2037, "." +290, 7, 21, 493, 100, 103, 2038, 2041, "edu" +290, 7, 22, 494, 104, 105, 2042, 2043, "." +290, 8, 1, 495, 0, 7, 2044, 2051, "Comment" +290, 8, 2, 496, 8, 10, 2052, 2054, "in" +290, 8, 3, 497, 11, 17, 2055, 2061, "Expert" +290, 8, 4, 498, 18, 22, 2062, 2066, "Opin" +290, 8, 5, 499, 23, 35, 2067, 2079, "Pharmacother" +290, 8, 6, 500, 36, 37, 2080, 2081, "." +290, 9, 1, 501, 0, 4, 2082, 2086, "2014" +290, 9, 2, 502, 5, 8, 2087, 2090, "Aug" +290, 9, 3, 503, 9, 10, 2091, 2092, ";" +290, 9, 4, 504, 11, 13, 2093, 2095, "15" +290, 9, 5, 505, 14, 15, 2096, 2097, "(" +290, 9, 6, 506, 16, 18, 2098, 2100, "11" +290, 9, 7, 507, 19, 20, 2101, 2102, ")" +290, 9, 8, 508, 21, 22, 2103, 2104, ":" +290, 9, 9, 509, 23, 27, 2105, 2109, "1631" +290, 9, 10, 510, 28, 29, 2110, 2111, "-" +290, 9, 11, 511, 30, 31, 2112, 2113, "5" +290, 9, 12, 512, 32, 33, 2114, 2115, "." +290, 10, 1, 513, 0, 9, 2116, 2125, "OBJECTIVE" +290, 10, 2, 514, 10, 11, 2126, 2127, ":" +290, 10, 3, 515, 12, 14, 2128, 2130, "To" +290, 10, 4, 516, 15, 21, 2131, 2137, "assess" +290, 10, 5, 517, 22, 25, 2138, 2141, "the" +290, 10, 6, 518, 26, 34, 2142, 2150, "efficacy" +290, 10, 7, 519, 35, 38, 2151, 2154, "and" +290, 10, 8, 520, 39, 45, 2155, 2161, "safety" +290, 10, 9, 521, 46, 48, 2162, 2164, "of" +290, 10, 10, 522, 49, 62, 2165, 2178, "dapagliflozin" +290, 10, 11, 523, 63, 65, 2179, 2181, "as" +290, 10, 12, 524, 66, 69, 2182, 2185, "add" +290, 10, 13, 525, 70, 71, 2186, 2187, "-" +290, 10, 14, 526, 72, 74, 2188, 2190, "on" +290, 10, 15, 527, 75, 82, 2191, 2198, "therapy" +290, 10, 16, 528, 83, 85, 2199, 2201, "in" +290, 10, 17, 529, 86, 94, 2202, 2210, "patients" +290, 10, 18, 530, 95, 99, 2211, 2215, "with" +290, 10, 19, 531, 100, 104, 2216, 2220, "type" +290, 10, 20, 532, 105, 106, 2221, 2222, "2" +290, 10, 21, 533, 107, 115, 2223, 2231, "diabetes" +290, 10, 22, 534, 116, 119, 2232, 2235, "who" +290, 10, 23, 535, 120, 124, 2236, 2240, "were" +290, 10, 24, 536, 125, 137, 2241, 2253, "inadequately" +290, 10, 25, 537, 138, 148, 2254, 2264, "controlled" +290, 10, 26, 538, 149, 153, 2265, 2269, "with" +290, 10, 27, 539, 154, 155, 2270, 2271, "a" +290, 10, 28, 540, 156, 166, 2272, 2282, "dipeptidyl" +290, 10, 29, 541, 167, 176, 2283, 2292, "peptidase" +290, 10, 30, 542, 177, 178, 2293, 2294, "-" +290, 10, 31, 543, 179, 180, 2295, 2296, "4" +290, 10, 32, 544, 181, 190, 2297, 2306, "inhibitor" +290, 10, 33, 545, 191, 195, 2307, 2311, "with" +290, 10, 34, 546, 196, 198, 2312, 2314, "or" +290, 10, 35, 547, 199, 206, 2315, 2322, "without" +290, 10, 36, 548, 207, 216, 2323, 2332, "metformin" +290, 10, 37, 549, 217, 218, 2333, 2334, "." +290, 11, 1, 550, 0, 8, 2335, 2343, "RESEARCH" +290, 11, 2, 551, 9, 15, 2344, 2350, "DESIGN" +290, 11, 3, 552, 16, 19, 2351, 2354, "AND" +290, 11, 4, 553, 20, 27, 2355, 2362, "METHODS" +290, 11, 5, 554, 28, 29, 2363, 2364, ":" +290, 11, 6, 555, 30, 32, 2365, 2367, "In" +290, 11, 7, 556, 33, 37, 2368, 2372, "this" +290, 11, 8, 557, 38, 40, 2373, 2375, "24" +290, 11, 9, 558, 41, 42, 2376, 2377, "-" +290, 11, 10, 559, 43, 47, 2378, 2382, "week" +290, 11, 11, 560, 48, 49, 2383, 2384, "," +290, 11, 12, 561, 50, 61, 2385, 2396, "multicenter" +290, 11, 13, 562, 62, 63, 2397, 2398, "," +290, 11, 14, 563, 64, 74, 2399, 2409, "randomized" +290, 11, 15, 564, 75, 76, 2410, 2411, "," +290, 11, 16, 565, 77, 83, 2412, 2418, "double" +290, 11, 17, 566, 84, 85, 2419, 2420, "-" +290, 11, 18, 567, 86, 91, 2421, 2426, "blind" +290, 11, 19, 568, 92, 93, 2427, 2428, "," +290, 11, 20, 569, 94, 101, 2429, 2436, "placebo" +290, 11, 21, 570, 102, 103, 2437, 2438, "-" +290, 11, 22, 571, 104, 114, 2439, 2449, "controlled" +290, 11, 23, 572, 115, 116, 2450, 2451, "," +290, 11, 24, 573, 117, 125, 2452, 2460, "parallel" +290, 11, 25, 574, 126, 127, 2461, 2462, "-" +290, 11, 26, 575, 128, 133, 2463, 2468, "group" +290, 11, 27, 576, 134, 135, 2469, 2470, "," +290, 11, 28, 577, 136, 141, 2471, 2476, "phase" +290, 11, 29, 578, 142, 143, 2477, 2478, "3" +290, 11, 30, 579, 144, 149, 2479, 2484, "study" +290, 11, 31, 580, 150, 154, 2485, 2489, "with" +290, 11, 32, 581, 155, 156, 2490, 2491, "a" +290, 11, 33, 582, 157, 159, 2492, 2494, "24" +290, 11, 34, 583, 160, 161, 2495, 2496, "-" +290, 11, 35, 584, 162, 166, 2497, 2501, "week" +290, 11, 36, 585, 167, 174, 2502, 2509, "blinded" +290, 11, 37, 586, 175, 184, 2510, 2519, "extension" +290, 11, 38, 587, 185, 191, 2520, 2526, "period" +290, 11, 39, 588, 192, 193, 2527, 2528, "," +290, 11, 40, 589, 194, 197, 2529, 2532, "432" +290, 11, 41, 590, 198, 206, 2533, 2541, "patients" +290, 11, 42, 591, 207, 211, 2542, 2546, "were" +290, 11, 43, 592, 212, 222, 2547, 2557, "randomized" +290, 11, 44, 593, 223, 225, 2558, 2560, "to" +290, 11, 45, 594, 226, 233, 2561, 2568, "receive" +290, 11, 46, 595, 234, 247, 2569, 2582, "dapagliflozin" +290, 11, 47, 596, 248, 250, 2583, 2585, "10" +290, 11, 48, 597, 251, 253, 2586, 2588, "mg" +290, 11, 49, 598, 254, 255, 2589, 2590, "/" +290, 11, 50, 599, 256, 259, 2591, 2594, "day" +290, 11, 51, 600, 260, 262, 2595, 2597, "or" +290, 11, 52, 601, 263, 270, 2598, 2605, "placebo" +290, 11, 53, 602, 271, 276, 2606, 2611, "added" +290, 11, 54, 603, 277, 279, 2612, 2614, "to" +290, 11, 55, 604, 280, 291, 2615, 2626, "sitagliptin" +290, 11, 56, 605, 292, 293, 2627, 2628, "(" +290, 11, 57, 606, 294, 297, 2629, 2632, "100" +290, 11, 58, 607, 298, 300, 2633, 2635, "mg" +290, 11, 59, 608, 301, 302, 2636, 2637, "/" +290, 11, 60, 609, 303, 306, 2638, 2641, "day" +290, 11, 61, 610, 307, 308, 2642, 2643, ")" +290, 11, 62, 611, 309, 310, 2644, 2645, "±" +290, 11, 63, 612, 311, 320, 2646, 2655, "metformin" +290, 11, 64, 613, 321, 322, 2656, 2657, "(" +290, 11, 65, 614, 323, 324, 2658, 2659, "≥" +290, 11, 66, 615, 325, 326, 2660, 2661, "1" +290, 11, 67, 616, 327, 328, 2662, 2663, "," +290, 11, 68, 617, 329, 332, 2664, 2667, "500" +290, 11, 69, 618, 333, 335, 2668, 2670, "mg" +290, 11, 70, 619, 336, 337, 2671, 2672, "/" +290, 11, 71, 620, 338, 341, 2673, 2676, "day" +290, 11, 72, 621, 342, 343, 2677, 2678, ")" +290, 11, 73, 622, 344, 345, 2679, 2680, "." +290, 12, 1, 623, 0, 7, 2681, 2688, "RESULTS" +290, 12, 2, 624, 8, 9, 2689, 2690, ":" +290, 12, 3, 625, 10, 18, 2691, 2699, "Baseline" +290, 12, 4, 626, 19, 24, 2700, 2705, "HbA1c" +290, 12, 5, 627, 25, 28, 2706, 2709, "and" +290, 12, 6, 628, 29, 32, 2710, 2713, "FPG" +290, 12, 7, 629, 33, 39, 2714, 2720, "levels" +290, 12, 8, 630, 40, 44, 2721, 2725, "were" +290, 12, 9, 631, 45, 46, 2726, 2727, "7" +290, 12, 10, 632, 47, 48, 2728, 2729, "." +290, 12, 11, 633, 49, 50, 2730, 2731, "9" +290, 12, 12, 634, 51, 52, 2732, 2733, "%" +290, 12, 13, 635, 53, 54, 2734, 2735, "(" +290, 12, 14, 636, 55, 57, 2736, 2738, "63" +290, 12, 15, 637, 58, 59, 2739, 2740, "." +290, 12, 16, 638, 60, 61, 2741, 2742, "0" +290, 12, 17, 639, 62, 66, 2743, 2747, "mmol" +290, 12, 18, 640, 67, 68, 2748, 2749, "/" +290, 12, 19, 641, 69, 72, 2750, 2753, "mol" +290, 12, 20, 642, 73, 74, 2754, 2755, ")" +290, 12, 21, 643, 75, 78, 2756, 2759, "and" +290, 12, 22, 644, 79, 82, 2760, 2763, "162" +290, 12, 23, 645, 83, 84, 2764, 2765, "." +290, 12, 24, 646, 85, 86, 2766, 2767, "2" +290, 12, 25, 647, 87, 89, 2768, 2770, "mg" +290, 12, 26, 648, 90, 91, 2771, 2772, "/" +290, 12, 27, 649, 92, 94, 2773, 2775, "dL" +290, 12, 28, 650, 95, 96, 2776, 2777, "(" +290, 12, 29, 651, 97, 98, 2778, 2779, "9" +290, 12, 30, 652, 99, 100, 2780, 2781, "." +290, 12, 31, 653, 101, 102, 2782, 2783, "0" +290, 12, 32, 654, 103, 107, 2784, 2788, "mmol" +290, 12, 33, 655, 108, 109, 2789, 2790, "/" +290, 12, 34, 656, 110, 111, 2791, 2792, "L" +290, 12, 35, 657, 112, 113, 2793, 2794, ")" +290, 12, 36, 658, 114, 117, 2795, 2798, "for" +290, 12, 37, 659, 118, 121, 2799, 2802, "the" +290, 12, 38, 660, 122, 135, 2803, 2816, "dapagliflozin" +290, 12, 39, 661, 136, 141, 2817, 2822, "group" +290, 12, 40, 662, 142, 145, 2823, 2826, "and" +290, 12, 41, 663, 146, 147, 2827, 2828, "8" +290, 12, 42, 664, 148, 149, 2829, 2830, "." +290, 12, 43, 665, 150, 151, 2831, 2832, "0" +290, 12, 44, 666, 152, 153, 2833, 2834, "%" +290, 12, 45, 667, 154, 155, 2835, 2836, "(" +290, 12, 46, 668, 156, 158, 2837, 2839, "64" +290, 12, 47, 669, 159, 160, 2840, 2841, "." +290, 12, 48, 670, 161, 162, 2842, 2843, "0" +290, 12, 49, 671, 163, 167, 2844, 2848, "mmol" +290, 12, 50, 672, 168, 169, 2849, 2850, "/" +290, 12, 51, 673, 170, 173, 2851, 2854, "mol" +290, 12, 52, 674, 174, 175, 2855, 2856, ")" +290, 12, 53, 675, 176, 179, 2857, 2860, "and" +290, 12, 54, 676, 180, 183, 2861, 2864, "163" +290, 12, 55, 677, 184, 186, 2865, 2867, "mg" +290, 12, 56, 678, 187, 188, 2868, 2869, "/" +290, 12, 57, 679, 189, 191, 2870, 2872, "dL" +290, 12, 58, 680, 192, 193, 2873, 2874, "(" +290, 12, 59, 681, 194, 195, 2875, 2876, "9" +290, 12, 60, 682, 196, 197, 2877, 2878, "." +290, 12, 61, 683, 198, 199, 2879, 2880, "0" +290, 12, 62, 684, 200, 204, 2881, 2885, "mmol" +290, 12, 63, 685, 205, 206, 2886, 2887, "/" +290, 12, 64, 686, 207, 208, 2888, 2889, "L" +290, 12, 65, 687, 209, 210, 2890, 2891, ")" +290, 12, 66, 688, 211, 214, 2892, 2895, "for" +290, 12, 67, 689, 215, 222, 2896, 2903, "placebo" +290, 12, 68, 690, 223, 224, 2904, 2905, "." +290, 13, 1, 691, 0, 2, 2906, 2908, "At" +290, 13, 2, 692, 3, 7, 2909, 2913, "week" +290, 13, 3, 693, 8, 10, 2914, 2916, "24" +290, 13, 4, 694, 11, 12, 2917, 2918, "," +290, 13, 5, 695, 13, 26, 2919, 2932, "dapagliflozin" +290, 13, 6, 696, 27, 40, 2933, 2946, "significantly" +290, 13, 7, 697, 41, 48, 2947, 2954, "reduced" +290, 13, 8, 698, 49, 53, 2955, 2959, "mean" +290, 13, 9, 699, 54, 59, 2960, 2965, "HbA1c" +290, 13, 10, 700, 60, 66, 2966, 2972, "levels" +290, 13, 11, 701, 67, 68, 2973, 2974, "(" +290, 13, 12, 702, 69, 70, 2975, 2976, "-" +290, 13, 13, 703, 71, 72, 2977, 2978, "0" +290, 13, 14, 704, 73, 74, 2979, 2980, "." +290, 13, 15, 705, 75, 76, 2981, 2982, "5" +290, 13, 16, 706, 77, 78, 2983, 2984, "%" +290, 13, 17, 707, 79, 80, 2985, 2986, "[" +290, 13, 18, 708, 81, 82, 2987, 2988, "-" +290, 13, 19, 709, 83, 84, 2989, 2990, "4" +290, 13, 20, 710, 85, 86, 2991, 2992, "." +290, 13, 21, 711, 87, 88, 2993, 2994, "9" +290, 13, 22, 712, 89, 93, 2995, 2999, "mmol" +290, 13, 23, 713, 94, 95, 3000, 3001, "/" +290, 13, 24, 714, 96, 99, 3002, 3005, "mol" +290, 13, 25, 715, 100, 101, 3006, 3007, "]" +290, 13, 26, 716, 102, 103, 3008, 3009, ")" +290, 13, 27, 717, 104, 110, 3010, 3016, "versus" +290, 13, 28, 718, 111, 118, 3017, 3024, "placebo" +290, 13, 29, 719, 119, 120, 3025, 3026, "(" +290, 13, 30, 720, 121, 122, 3027, 3028, "0" +290, 13, 31, 721, 123, 124, 3029, 3030, "." +290, 13, 32, 722, 125, 126, 3031, 3032, "0" +290, 13, 33, 723, 127, 128, 3033, 3034, "%" +290, 13, 34, 724, 129, 130, 3035, 3036, "[" +290, 13, 35, 725, 131, 132, 3037, 3038, "+" +290, 13, 36, 726, 133, 134, 3039, 3040, "0" +290, 13, 37, 727, 135, 136, 3041, 3042, "." +290, 13, 38, 728, 137, 138, 3043, 3044, "4" +290, 13, 39, 729, 139, 143, 3045, 3049, "mmol" +290, 13, 40, 730, 144, 145, 3050, 3051, "/" +290, 13, 41, 731, 146, 149, 3052, 3055, "mol" +290, 13, 42, 732, 150, 151, 3056, 3057, "]" +290, 13, 43, 733, 152, 153, 3058, 3059, ")" +290, 13, 44, 734, 154, 155, 3060, 3061, "." +290, 14, 1, 735, 0, 13, 3062, 3075, "Dapagliflozin" +290, 14, 2, 736, 14, 21, 3076, 3083, "reduced" +290, 14, 3, 737, 22, 26, 3084, 3088, "body" +290, 14, 4, 738, 27, 33, 3089, 3095, "weight" +290, 14, 5, 739, 34, 40, 3096, 3102, "versus" +290, 14, 6, 740, 41, 48, 3103, 3110, "placebo" +290, 14, 7, 741, 49, 50, 3111, 3112, "(" +290, 14, 8, 742, 51, 52, 3113, 3114, "-" +290, 14, 9, 743, 53, 54, 3115, 3116, "2" +290, 14, 10, 744, 55, 56, 3117, 3118, "." +290, 14, 11, 745, 57, 58, 3119, 3120, "1" +290, 14, 12, 746, 59, 62, 3121, 3124, "and" +290, 14, 13, 747, 63, 64, 3125, 3126, "-" +290, 14, 14, 748, 65, 66, 3127, 3128, "0" +290, 14, 15, 749, 67, 68, 3129, 3130, "." +290, 14, 16, 750, 69, 70, 3131, 3132, "3" +290, 14, 17, 751, 71, 73, 3133, 3135, "kg" +290, 14, 18, 752, 74, 75, 3136, 3137, ")" +290, 14, 19, 753, 76, 79, 3138, 3141, "and" +290, 14, 20, 754, 80, 87, 3142, 3149, "reduced" +290, 14, 21, 755, 88, 93, 3150, 3155, "HbA1c" +290, 14, 22, 756, 94, 100, 3156, 3162, "levels" +290, 14, 23, 757, 101, 103, 3163, 3165, "in" +290, 14, 24, 758, 104, 112, 3166, 3174, "patients" +290, 14, 25, 759, 113, 117, 3175, 3179, "with" +290, 14, 26, 760, 118, 126, 3180, 3188, "baseline" +290, 14, 27, 761, 127, 133, 3189, 3195, "values" +290, 14, 28, 762, 134, 135, 3196, 3197, "≥" +290, 14, 29, 763, 136, 137, 3198, 3199, "8" +290, 14, 30, 764, 138, 139, 3200, 3201, "." +290, 14, 31, 765, 140, 141, 3202, 3203, "0" +290, 14, 32, 766, 142, 143, 3204, 3205, "%" +290, 14, 33, 767, 144, 145, 3206, 3207, "(" +290, 14, 34, 768, 146, 147, 3208, 3209, "-" +290, 14, 35, 769, 148, 149, 3210, 3211, "0" +290, 14, 36, 770, 150, 151, 3212, 3213, "." +290, 14, 37, 771, 152, 153, 3214, 3215, "8" +290, 14, 38, 772, 154, 155, 3216, 3217, "%" +290, 14, 39, 773, 156, 157, 3218, 3219, "[" +290, 14, 40, 774, 158, 159, 3220, 3221, "8" +290, 14, 41, 775, 160, 161, 3222, 3223, "." +290, 14, 42, 776, 162, 163, 3224, 3225, "7" +290, 14, 43, 777, 164, 168, 3226, 3230, "mmol" +290, 14, 44, 778, 169, 170, 3231, 3232, "/" +290, 14, 45, 779, 171, 174, 3233, 3236, "mol" +290, 14, 46, 780, 175, 176, 3237, 3238, "]" +290, 14, 47, 781, 177, 180, 3239, 3242, "and" +290, 14, 48, 782, 181, 182, 3243, 3244, "0" +290, 14, 49, 783, 183, 184, 3245, 3246, "." +290, 14, 50, 784, 185, 186, 3247, 3248, "0" +290, 14, 51, 785, 187, 188, 3249, 3250, "%" +290, 14, 52, 786, 189, 190, 3251, 3252, "[" +290, 14, 53, 787, 191, 192, 3253, 3254, "0" +290, 14, 54, 788, 193, 194, 3255, 3256, "." +290, 14, 55, 789, 195, 196, 3257, 3258, "3" +290, 14, 56, 790, 197, 201, 3259, 3263, "mmol" +290, 14, 57, 791, 202, 203, 3264, 3265, "/" +290, 14, 58, 792, 204, 207, 3266, 3269, "mol" +290, 14, 59, 793, 208, 209, 3270, 3271, "]" +290, 14, 60, 794, 210, 211, 3272, 3273, ")" +290, 14, 61, 795, 212, 215, 3274, 3277, "and" +290, 14, 62, 796, 216, 223, 3278, 3285, "fasting" +290, 14, 63, 797, 224, 230, 3286, 3292, "plasma" +290, 14, 64, 798, 231, 238, 3293, 3300, "glucose" +290, 14, 65, 799, 239, 245, 3301, 3307, "levels" +290, 14, 66, 800, 246, 247, 3308, 3309, "(" +290, 14, 67, 801, 248, 249, 3310, 3311, "-" +290, 14, 68, 802, 250, 252, 3312, 3314, "24" +290, 14, 69, 803, 253, 254, 3315, 3316, "." +290, 14, 70, 804, 255, 256, 3317, 3318, "1" +290, 14, 71, 805, 257, 259, 3319, 3321, "mg" +290, 14, 72, 806, 260, 261, 3322, 3323, "/" +290, 14, 73, 807, 262, 264, 3324, 3326, "dL" +290, 14, 74, 808, 265, 266, 3327, 3328, "[" +290, 14, 75, 809, 267, 268, 3329, 3330, "-" +290, 14, 76, 810, 269, 270, 3331, 3332, "1" +290, 14, 77, 811, 271, 272, 3333, 3334, "." +290, 14, 78, 812, 273, 274, 3335, 3336, "3" +290, 14, 79, 813, 275, 279, 3337, 3341, "mmol" +290, 14, 80, 814, 280, 281, 3342, 3343, "/" +290, 14, 81, 815, 282, 283, 3344, 3345, "L" +290, 14, 82, 816, 284, 285, 3346, 3347, "]" +290, 14, 83, 817, 286, 289, 3348, 3351, "and" +290, 14, 84, 818, 290, 291, 3352, 3353, "3" +290, 14, 85, 819, 292, 293, 3354, 3355, "." +290, 14, 86, 820, 294, 295, 3356, 3357, "8" +290, 14, 87, 821, 296, 298, 3358, 3360, "mg" +290, 14, 88, 822, 299, 300, 3361, 3362, "/" +290, 14, 89, 823, 301, 303, 3363, 3365, "dL" +290, 14, 90, 824, 304, 305, 3366, 3367, "[" +290, 14, 91, 825, 306, 307, 3368, 3369, "0" +290, 14, 92, 826, 308, 309, 3370, 3371, "." +290, 14, 93, 827, 310, 311, 3372, 3373, "2" +290, 14, 94, 828, 312, 316, 3374, 3378, "mmol" +290, 14, 95, 829, 317, 318, 3379, 3380, "/" +290, 14, 96, 830, 319, 320, 3381, 3382, "L" +290, 14, 97, 831, 321, 322, 3383, 3384, "]" +290, 14, 98, 832, 323, 324, 3385, 3386, ")" +290, 14, 99, 833, 325, 326, 3387, 3388, "." +290, 15, 1, 834, 0, 7, 3389, 3396, "Similar" +290, 15, 2, 835, 8, 15, 3397, 3404, "results" +290, 15, 3, 836, 16, 20, 3405, 3409, "were" +290, 15, 4, 837, 21, 29, 3410, 3418, "observed" +290, 15, 5, 838, 30, 34, 3419, 3423, "when" +290, 15, 6, 839, 35, 39, 3424, 3428, "data" +290, 15, 7, 840, 40, 44, 3429, 3433, "were" +290, 15, 8, 841, 45, 55, 3434, 3444, "stratified" +290, 15, 9, 842, 56, 58, 3445, 3447, "by" +290, 15, 10, 843, 59, 69, 3448, 3458, "background" +290, 15, 11, 844, 70, 77, 3459, 3466, "therapy" +290, 15, 12, 845, 78, 79, 3467, 3468, "." +290, 16, 1, 846, 0, 8, 3469, 3477, "Glycemic" +290, 16, 2, 847, 9, 12, 3478, 3481, "and" +290, 16, 3, 848, 13, 19, 3482, 3488, "weight" +290, 16, 4, 849, 20, 28, 3489, 3497, "benefits" +290, 16, 5, 850, 29, 37, 3498, 3506, "observed" +290, 16, 6, 851, 38, 40, 3507, 3509, "at" +290, 16, 7, 852, 41, 45, 3510, 3514, "week" +290, 16, 8, 853, 46, 48, 3515, 3517, "24" +290, 16, 9, 854, 49, 53, 3518, 3522, "were" +290, 16, 10, 855, 54, 64, 3523, 3533, "maintained" +290, 16, 11, 856, 65, 72, 3534, 3541, "through" +290, 16, 12, 857, 73, 77, 3542, 3546, "week" +290, 16, 13, 858, 78, 80, 3547, 3549, "48" +290, 16, 14, 859, 81, 82, 3550, 3551, "." +290, 17, 1, 860, 0, 7, 3552, 3559, "Changes" +290, 17, 2, 861, 8, 12, 3560, 3564, "from" +290, 17, 3, 862, 13, 21, 3565, 3573, "baseline" +290, 17, 4, 863, 22, 24, 3574, 3576, "in" +290, 17, 5, 864, 25, 33, 3577, 3585, "systolic" +290, 17, 6, 865, 34, 39, 3586, 3591, "blood" +290, 17, 7, 866, 40, 48, 3592, 3600, "pressure" +290, 17, 8, 867, 49, 51, 3601, 3603, "at" +290, 17, 9, 868, 52, 56, 3604, 3608, "week" +290, 17, 10, 869, 57, 58, 3609, 3610, "8" +290, 17, 11, 870, 59, 63, 3611, 3615, "were" +290, 17, 12, 871, 64, 67, 3616, 3619, "not" +290, 17, 13, 872, 68, 81, 3620, 3633, "significantly" +290, 17, 14, 873, 82, 91, 3634, 3643, "different" +290, 17, 15, 874, 92, 99, 3644, 3651, "between" +290, 17, 16, 875, 100, 109, 3652, 3661, "treatment" +290, 17, 17, 876, 110, 116, 3662, 3668, "groups" +290, 17, 18, 877, 117, 118, 3669, 3670, "." +290, 18, 1, 878, 0, 4, 3671, 3675, "Over" +290, 18, 2, 879, 5, 7, 3676, 3678, "48" +290, 18, 3, 880, 8, 13, 3679, 3684, "weeks" +290, 18, 4, 881, 14, 15, 3685, 3686, "," +290, 18, 5, 882, 16, 21, 3687, 3692, "fewer" +290, 18, 6, 883, 22, 30, 3693, 3701, "patients" +290, 18, 7, 884, 31, 40, 3702, 3711, "receiving" +290, 18, 8, 885, 41, 54, 3712, 3725, "dapagliflozin" +290, 18, 9, 886, 55, 59, 3726, 3730, "were" +290, 18, 10, 887, 60, 72, 3731, 3743, "discontinued" +290, 18, 11, 888, 73, 75, 3744, 3746, "or" +290, 18, 12, 889, 76, 83, 3747, 3754, "rescued" +290, 18, 13, 890, 84, 87, 3755, 3758, "for" +290, 18, 14, 891, 88, 95, 3759, 3766, "failing" +290, 18, 15, 892, 96, 98, 3767, 3769, "to" +290, 18, 16, 893, 99, 106, 3770, 3777, "achieve" +290, 18, 17, 894, 107, 115, 3778, 3786, "glycemic" +290, 18, 18, 895, 116, 123, 3787, 3794, "targets" +290, 18, 19, 896, 124, 132, 3795, 3803, "compared" +290, 18, 20, 897, 133, 137, 3804, 3808, "with" +290, 18, 21, 898, 138, 145, 3809, 3816, "placebo" +290, 18, 22, 899, 146, 147, 3817, 3818, "." +290, 19, 1, 900, 0, 7, 3819, 3826, "Adverse" +290, 19, 2, 901, 8, 14, 3827, 3833, "events" +290, 19, 3, 902, 15, 19, 3834, 3838, "were" +290, 19, 4, 903, 20, 28, 3839, 3847, "balanced" +290, 19, 5, 904, 29, 36, 3848, 3855, "between" +290, 19, 6, 905, 37, 43, 3856, 3862, "groups" +290, 19, 7, 906, 44, 45, 3863, 3864, "," +290, 19, 8, 907, 46, 49, 3865, 3868, "and" +290, 19, 9, 908, 50, 65, 3869, 3884, "discontinuation" +290, 19, 10, 909, 66, 71, 3885, 3890, "rates" +290, 19, 11, 910, 72, 76, 3891, 3895, "were" +290, 19, 12, 911, 77, 80, 3896, 3899, "low" +290, 19, 13, 912, 81, 82, 3900, 3901, "." +290, 20, 1, 913, 0, 2, 3902, 3904, "At" +290, 20, 2, 914, 3, 7, 3905, 3909, "week" +290, 20, 3, 915, 8, 10, 3910, 3912, "48" +290, 20, 4, 916, 11, 12, 3913, 3914, "," +290, 20, 5, 917, 13, 18, 3915, 3920, "signs" +290, 20, 6, 918, 19, 22, 3921, 3924, "and" +290, 20, 7, 919, 23, 31, 3925, 3933, "symptoms" +290, 20, 8, 920, 32, 42, 3934, 3944, "suggestive" +290, 20, 9, 921, 43, 45, 3945, 3947, "of" +290, 20, 10, 922, 46, 53, 3948, 3955, "genital" +290, 20, 11, 923, 54, 63, 3956, 3965, "infection" +290, 20, 12, 924, 64, 68, 3966, 3970, "were" +290, 20, 13, 925, 69, 73, 3971, 3975, "more" +290, 20, 14, 926, 74, 82, 3976, 3984, "frequent" +290, 20, 15, 927, 83, 87, 3985, 3989, "with" +290, 20, 16, 928, 88, 101, 3990, 4003, "dapagliflozin" +290, 20, 17, 929, 102, 103, 4004, 4005, "(" +290, 20, 18, 930, 104, 105, 4006, 4007, "9" +290, 20, 19, 931, 106, 107, 4008, 4009, "." +290, 20, 20, 932, 108, 109, 4010, 4011, "8" +290, 20, 21, 933, 110, 111, 4012, 4013, "%" +290, 20, 22, 934, 112, 113, 4014, 4015, ")" +290, 20, 23, 935, 114, 118, 4016, 4020, "than" +290, 20, 24, 936, 119, 123, 4021, 4025, "with" +290, 20, 25, 937, 124, 131, 4026, 4033, "placebo" +290, 20, 26, 938, 132, 133, 4034, 4035, "(" +290, 20, 27, 939, 134, 135, 4036, 4037, "0" +290, 20, 28, 940, 136, 137, 4038, 4039, "." +290, 20, 29, 941, 138, 139, 4040, 4041, "4" +290, 20, 30, 942, 140, 141, 4042, 4043, "%" +290, 20, 31, 943, 142, 143, 4044, 4045, ")" +290, 20, 32, 944, 144, 145, 4046, 4047, "." +290, 21, 1, 945, 0, 5, 4048, 4053, "Signs" +290, 21, 2, 946, 6, 9, 4054, 4057, "and" +290, 21, 3, 947, 10, 18, 4058, 4066, "symptoms" +290, 21, 4, 948, 19, 29, 4067, 4077, "suggestive" +290, 21, 5, 949, 30, 32, 4078, 4080, "of" +290, 21, 6, 950, 33, 40, 4081, 4088, "urinary" +290, 21, 7, 951, 41, 46, 4089, 4094, "tract" +290, 21, 8, 952, 47, 56, 4095, 4104, "infection" +290, 21, 9, 953, 57, 61, 4105, 4109, "were" +290, 21, 10, 954, 62, 70, 4110, 4118, "balanced" +290, 21, 11, 955, 71, 78, 4119, 4126, "between" +290, 21, 12, 956, 79, 92, 4127, 4140, "dapagliflozin" +290, 21, 13, 957, 93, 94, 4141, 4142, "(" +290, 21, 14, 958, 95, 96, 4143, 4144, "6" +290, 21, 15, 959, 97, 98, 4145, 4146, "." +290, 21, 16, 960, 99, 100, 4147, 4148, "7" +290, 21, 17, 961, 101, 102, 4149, 4150, "%" +290, 21, 18, 962, 103, 104, 4151, 4152, ")" +290, 21, 19, 963, 105, 108, 4153, 4156, "and" +290, 21, 20, 964, 109, 116, 4157, 4164, "placebo" +290, 21, 21, 965, 117, 118, 4165, 4166, "(" +290, 21, 22, 966, 119, 120, 4167, 4168, "6" +290, 21, 23, 967, 121, 122, 4169, 4170, "." +290, 21, 24, 968, 123, 124, 4171, 4172, "2" +290, 21, 25, 969, 125, 126, 4173, 4174, "%" +290, 21, 26, 970, 127, 128, 4175, 4176, ")" +290, 21, 27, 971, 129, 130, 4177, 4178, "." +290, 22, 1, 972, 0, 11, 4179, 4190, "CONCLUSIONS" +290, 22, 2, 973, 12, 13, 4191, 4192, ":" +290, 22, 3, 974, 14, 19, 4193, 4198, "These" +290, 22, 4, 975, 20, 27, 4199, 4206, "results" +290, 22, 5, 976, 28, 35, 4207, 4214, "suggest" +290, 22, 6, 977, 36, 40, 4215, 4219, "that" +290, 22, 7, 978, 41, 43, 4220, 4222, "in" +290, 22, 8, 979, 44, 52, 4223, 4231, "patients" +290, 22, 9, 980, 53, 57, 4232, 4236, "with" +290, 22, 10, 981, 58, 62, 4237, 4241, "type" +290, 22, 11, 982, 63, 64, 4242, 4243, "2" +290, 22, 12, 983, 65, 73, 4244, 4252, "diabetes" +290, 22, 13, 984, 74, 75, 4253, 4254, "," +290, 22, 14, 985, 76, 88, 4255, 4267, "inadequately" +290, 22, 15, 986, 89, 99, 4268, 4278, "controlled" +290, 22, 16, 987, 100, 102, 4279, 4281, "on" +290, 22, 17, 988, 103, 114, 4282, 4293, "sitagliptin" +290, 22, 18, 989, 115, 119, 4294, 4298, "with" +290, 22, 19, 990, 120, 122, 4299, 4301, "or" +290, 22, 20, 991, 123, 130, 4302, 4309, "without" +290, 22, 21, 992, 131, 140, 4310, 4319, "metformin" +290, 22, 22, 993, 141, 142, 4320, 4321, "," +290, 22, 23, 994, 143, 146, 4322, 4325, "add" +290, 22, 24, 995, 147, 148, 4326, 4327, "-" +290, 22, 25, 996, 149, 151, 4328, 4330, "on" +290, 22, 26, 997, 152, 161, 4331, 4340, "treatment" +290, 22, 27, 998, 162, 166, 4341, 4345, "with" +290, 22, 28, 999, 167, 180, 4346, 4359, "dapagliflozin" +290, 22, 29, 1000, 181, 189, 4360, 4368, "provides" +290, 22, 30, 1001, 190, 200, 4369, 4379, "additional" +290, 22, 31, 1002, 201, 209, 4380, 4388, "clinical" +290, 22, 32, 1003, 210, 217, 4389, 4396, "benefit" +290, 22, 33, 1004, 218, 221, 4397, 4400, "and" +290, 22, 34, 1005, 222, 224, 4401, 4403, "is" +290, 22, 35, 1006, 225, 229, 4404, 4408, "well" +290, 22, 36, 1007, 230, 239, 4409, 4418, "tolerated" +290, 22, 37, 1008, 240, 241, 4419, 4420, "." +290, 23, 1, 1009, 0, 3, 4421, 4424, "DOI" +290, 23, 2, 1010, 4, 5, 4425, 4426, ":" +290, 23, 3, 1011, 6, 8, 4427, 4429, "10" +290, 23, 4, 1012, 9, 10, 4430, 4431, "." +290, 23, 5, 1013, 11, 15, 4432, 4436, "2337" +290, 23, 6, 1014, 16, 17, 4437, 4438, "/" +290, 23, 7, 1015, 18, 22, 4439, 4443, "dc13" +290, 23, 8, 1016, 23, 24, 4444, 4445, "-" +290, 23, 9, 1017, 25, 29, 4446, 4450, "0467" +290, 23, 10, 1018, 30, 34, 4451, 4455, "PMID" +290, 23, 11, 1019, 35, 36, 4456, 4457, ":" +290, 23, 12, 1020, 37, 45, 4458, 4466, "24144654" +290, 23, 13, 1021, 46, 47, 4467, 4468, "[" +290, 23, 14, 1022, 48, 55, 4469, 4476, "Indexed" +290, 23, 15, 1023, 56, 59, 4477, 4480, "for" +290, 23, 16, 1024, 60, 67, 4481, 4488, "MEDLINE" +290, 23, 17, 1025, 68, 69, 4489, 4490, "]" diff --git a/data/dm2 24144654_kwoodley.annodb b/data/dm2 24144654_kwoodley.annodb new file mode 100644 index 0000000..541d9b5 --- /dev/null +++ b/data/dm2 24144654_kwoodley.annodb @@ -0,0 +1,127 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46417, Journal, 0, 13, "Diabetes Care", "", +46418, PublicationYear, 16, 20, "2014", "", +46419, Dapagliflozin, 96, 109, "Dapagliflozin", "", +46445, Title, 96, 272, "Dapagliflozin is effective as add - on therapy to sitagliptin with or without metformin : a 24 - week , multicenter , randomized , double - blind , placebo - controlled study .", "", +46429, Sitagliptin, 146, 157, "sitagliptin", "", +46431, Metformin, 174, 183, "metformin", "", +46436, Duration, 188, 197, "24 - week", "", +46437, Multicenter, 200, 211, "multicenter", "", +46438, Randomized, 214, 224, "randomized", "", +46439, DoubleBlind, 227, 241, "double - blind", "", +46440, Placebo, 244, 251, "placebo", "", +46441, Author, 273, 283, "Jabbour SA", "", +46442, Author, 292, 299, "Hardy E", "", +46443, Author, 302, 308, "Sugg J", "", +46444, Author, 311, 319, "Parikh S", "", +46449, ObjectiveDescription, 2128, 2334, "To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin .", "", +46420, Dapagliflozin, 2165, 2178, "dapagliflozin", "", +46448, Precondition, 2202, 2332, "patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase - 4 inhibitor with or without metformin", "", +46446, Type2Diabetes, 2216, 2231, "type 2 diabetes", "", +46432, Metformin, 2323, 2332, "metformin", "", +46450, Duration, 2373, 2382, "24 - week", "", +46451, Multicenter, 2385, 2396, "multicenter", "", +46452, Randomized, 2399, 2409, "randomized", "", +46453, DoubleBlind, 2412, 2426, "double - blind", "", +46454, Placebo, 2429, 2436, "placebo", "", +46455, Parallel, 2452, 2468, "parallel - group", "", +46456, Duration, 2492, 2501, "24 - week", "", +46457, NumberPatientsCT, 2529, 2532, "432", "", +46458, Randomized, 2547, 2557, "randomized", "", +46421, Dapagliflozin, 2569, 2582, "dapagliflozin", "", +46459, DoseValue, 2583, 2585, "10", "", +46462, mg, 2586, 2588, "mg", "", +46465, Frequency, 2591, 2594, "day", "", +46468, Placebo, 2598, 2605, "placebo", "", +46430, Sitagliptin, 2615, 2626, "sitagliptin", "", +46460, DoseValue, 2629, 2632, "100", "", +46463, mg, 2633, 2635, "mg", "", +46466, Frequency, 2638, 2641, "day", "", +46433, Metformin, 2646, 2655, "metformin", "", +46461, DoseValue, 2658, 2667, "≥ 1 , 500", "", +46464, mg, 2668, 2670, "mg", "", +46467, Frequency, 2673, 2676, "day", "", +46474, HbA1c, 2700, 2705, "HbA1c", "", +46475, FastingPlasmaGlucose, 2710, 2713, "FPG", "", +46476, BaseLineValue, 2726, 2731, "7 . 9", "", +46484, Percentage, 2732, 2733, "%", "", +46477, BaseLineValue, 2736, 2742, "63 . 0", "", +46486, BioAndMedicalUnit, 2743, 2753, "mmol / mol", "", +46478, BaseLineValue, 2760, 2767, "162 . 2", "", +46488, Mg_per_deciliter, 2768, 2775, "mg / dL", "", +46479, BaseLineValue, 2778, 2783, "9 . 0", "", +46490, Millimoles_per_litre, 2784, 2792, "mmol / L", "", +46422, Dapagliflozin, 2803, 2816, "dapagliflozin", "", +46480, BaseLineValue, 2827, 2832, "8 . 0", "", +46485, Percentage, 2833, 2834, "%", "", +46481, BaseLineValue, 2837, 2843, "64 . 0", "", +46487, BioAndMedicalUnit, 2844, 2854, "mmol / mol", "", +46482, BaseLineValue, 2861, 2864, "163", "", +46489, Mg_per_deciliter, 2865, 2872, "mg / dL", "", +46483, BaseLineValue, 2875, 2880, "9 . 0", "", +46491, Millimoles_per_litre, 2881, 2889, "mmol / L", "", +46469, Placebo, 2896, 2903, "placebo", "", +46492, TimePoint, 2909, 2916, "week 24", "", +46423, Dapagliflozin, 2919, 2932, "dapagliflozin", "", +46494, HbA1c, 2960, 2965, "HbA1c", "", +46496, Reduction, 2977, 2982, "0 . 5", "", +46498, Percentage, 2983, 2984, "%", "", +46497, Reduction, 2989, 2994, "4 . 9", "", +46500, BioAndMedicalUnit, 2995, 3005, "mmol / mol", "", +46495, Placebo, 3017, 3024, "placebo", "", +46502, NoChange, 3027, 3032, "0 . 0", "", +46499, Percentage, 3033, 3034, "%", "", +46503, Increment, 3039, 3044, "0 . 4", "", +46501, BioAndMedicalUnit, 3045, 3055, "mmol / mol", "", +46424, Dapagliflozin, 3062, 3075, "Dapagliflozin", "", +46504, BodyWeight, 3084, 3095, "body weight", "", +46470, Placebo, 3103, 3110, "placebo", "", +46506, Reduction, 3115, 3120, "2 . 1", "", +46507, Reduction, 3127, 3132, "0 . 3", "", +46508, IntUnit_per_Kg, 3133, 3135, "kg", "", +46505, HbA1c, 3150, 3155, "HbA1c", "", +46509, SubGroupDescription, 3166, 3205, "patients with baseline values ≥ 8 . 0 %", "", +46510, Percentage, 3204, 3205, "%", "", +46511, Reduction, 3210, 3215, "0 . 8", "", +46513, ResultMeasuredValue, 3220, 3225, "8 . 7", "", +46514, BioAndMedicalUnit, 3226, 3236, "mmol / mol", "", +46512, NoChange, 3243, 3248, "0 . 0", "", +46516, Percentage, 3249, 3250, "%", "", +46517, ResultMeasuredValue, 3253, 3258, "0 . 3", "", +46515, BioAndMedicalUnit, 3259, 3269, "mmol / mol", "", +46518, FastingPlasmaGlucose, 3278, 3300, "fasting plasma glucose", "", +46520, Reduction, 3312, 3318, "24 . 1", "", +46524, Mg_per_deciliter, 3319, 3326, "mg / dL", "", +46521, Reduction, 3331, 3336, "1 . 3", "", +46526, Millimoles_per_litre, 3337, 3345, "mmol / L", "", +46522, Increment, 3352, 3357, "3 . 8", "", +46525, Mg_per_deciliter, 3358, 3365, "mg / dL", "", +46523, Increment, 3368, 3373, "0 . 2", "", +46527, Millimoles_per_litre, 3374, 3382, "mmol / L", "", +46528, TimePoint, 3510, 3517, "week 24", "", +46529, TimePoint, 3542, 3549, "week 48", "", +46533, ObservedResult, 3552, 3670, "Changes from baseline in systolic blood pressure at week 8 were not significantly different between treatment groups .", "", +46530, TimePoint, 3565, 3573, "baseline", "", +46532, BloodPressure, 3577, 3600, "systolic blood pressure", "", +46531, TimePoint, 3604, 3610, "week 8", "", +46425, Dapagliflozin, 3712, 3725, "dapagliflozin", "", +46471, Placebo, 3809, 3816, "placebo", "", +46534, EndPointDescription, 3819, 3833, "Adverse events", "", +46535, ObservedResult, 3819, 3901, "Adverse events were balanced between groups , and discontinuation rates were low .", "", +46493, TimePoint, 3905, 3912, "week 48", "", +46536, EndPointDescription, 3948, 3965, "genital infection", "", +46426, Dapagliflozin, 3990, 4003, "dapagliflozin", "", +46537, PercentageAffected, 4006, 4011, "9 . 8", "", +46472, Placebo, 4026, 4033, "placebo", "", +46538, PercentageAffected, 4036, 4041, "0 . 4", "", +46541, EndPointDescription, 4081, 4104, "urinary tract infection", "", +46427, Dapagliflozin, 4127, 4140, "dapagliflozin", "", +46539, PercentageAffected, 4143, 4148, "6 . 7", "", +46473, Placebo, 4157, 4164, "placebo", "", +46540, PercentageAffected, 4167, 4172, "6 . 2", "", +46542, ConclusionComment, 4193, 4420, "These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated .", "", +46447, Type2Diabetes, 4237, 4252, "type 2 diabetes", "", +46435, Sitagliptin, 4282, 4293, "sitagliptin", "", +46434, Metformin, 4310, 4319, "metformin", "", +46428, Dapagliflozin, 4346, 4359, "dapagliflozin", "", +46543, PMID, 4458, 4466, "24144654", "", diff --git a/data/dm2 24144654_kwoodley.n-triples b/data/dm2 24144654_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24144654_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24199686_admin.annodb b/data/dm2 24199686_admin.annodb new file mode 100644 index 0000000..e6f0f04 --- /dev/null +++ b/data/dm2 24199686_admin.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2014", "", " \"2014\"." +23, Title, 104, 260, "Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea .", "", " \"Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea .\"." +2, Vildagliptin, 127, 139, "vildagliptin", "", +22, Precondition, 143, 258, "patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea", "", " \"patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea\"." +13, Type2Diabetes, 157, 181, "type 2 diabetes mellitus", "", " ." +17, Metformin, 231, 240, "metformin", "", +21, Sulfonylureas, 245, 258, "sulphonylurea", "", +24, Author, 261, 274, "Lukashevich V", "", " \"Lukashevich V\"." +25, Author, 283, 294, "Del Prato S", "", " \"Del Prato S\"." +26, Author, 297, 304, "Araga M", "", " \"Araga M\"." +27, Author, 307, 315, "Kothny W", "", " \"Kothny W\"." +28, USA, 404, 407, "USA", "", +121, ObjectiveDescription, 416, 532, "The broadly used combination of metformin and sulphonylurea ( SU ) often fails to bring patients to glycaemic goal .", "", " \"The broadly used combination of metformin and sulphonylurea ( SU ) often fails to bring patients to glycaemic goal .\"." +18, Metformin, 448, 457, "metformin", "", +29, Sulfonylureas, 462, 475, "sulphonylurea", "", +30, Sulfonylureas, 478, 480, "SU", "", +34, ObjectiveDescription, 533, 744, "This study assessed the efficacy and safety of vildagliptin as add - on therapy to metformin plus glimepiride combination in patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control .", "", " \"This study assessed the efficacy and safety of vildagliptin as add - on therapy to metformin plus glimepiride combination in patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control .\"." +3, Vildagliptin, 580, 592, "vildagliptin", "", +19, Metformin, 616, 625, "metformin", "", +31, Glimepiride, 631, 642, "glimepiride", "", +33, Precondition, 658, 742, "patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control", "", +14, Type2Diabetes, 672, 696, "type 2 diabetes mellitus", "", +15, Type2Diabetes, 699, 703, "T2DM", "", +35, Multicenter, 757, 768, "multicentre", "", " ." +36, DoubleBlind, 771, 785, "double - blind", "", " ." +37, Placebo, 788, 795, "placebo", "", +41, Randomized, 815, 825, "randomized", "", " ." +4, Vildagliptin, 861, 873, "vildagliptin", "", " ." +42, DoseValue, 874, 876, "50", "", " \"50\"." +43, mg, 879, 881, "mg", "", " ." +44, Frequency, 882, 885, "bid", "", " \"bid\"." +45, NumberPatientsArm, 894, 897, "158", "", " \"158\"." +47, Placebo, 903, 910, "placebo", "", " ." +46, NumberPatientsArm, 919, 922, "160", "", " \"160\"." +48, Duration, 929, 939, "24   weeks", "", " \"24   weeks\"." +49, TimePoint, 958, 968, "24   weeks", "", +136, Mean, 984, 988, "mean", "", " . ." +50, HbA1c, 999, 1014, "haemoglobin A1c", "", " ." +51, HbA1c, 1017, 1022, "HbA1c", "", +52, Reduction, 1031, 1037, "1 . 01", "", " \"1 . 01\"." +54, Percentage, 1038, 1039, "%", "", " ." +5, Vildagliptin, 1045, 1057, "vildagliptin", "", +146, TimePoint, 1060, 1068, "baseline", "", +59, BaseLineValue, 1069, 1075, "8 . 75", "", " \"8 . 75\"." +55, Percentage, 1076, 1077, "%", "", +53, Reduction, 1086, 1092, "0 . 25", "", " \"1 . 01\"." +56, Percentage, 1093, 1094, "%", "", +38, Placebo, 1100, 1107, "placebo", "", +147, TimePoint, 1110, 1118, "baseline", "", +60, BaseLineValue, 1119, 1125, "8 . 80", "", " \"8 . 80\"." +57, Percentage, 1126, 1127, "%", "", +61, DiffGroupAbsValue, 1173, 1181, "- 0 . 76", "", " \"- 0 . 76\"." +58, Percentage, 1182, 1183, "%", "", +62, PvalueDiff, 1186, 1199, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +6, Vildagliptin, 1235, 1247, "vildagliptin", "", +155, HbA1c_target, 1261, 1279, "HbA1c target < 7 %", "", " ." +156, Percentage, 1278, 1279, "%", "", +64, PercentageAffected, 1282, 1288, "28 . 3", "", " \"28 . 3\"." +157, Percentage, 1289, 1290, "%", "", +65, PercentageAffected, 1296, 1301, "5 . 6", "", " \"5 . 6\"." +158, Percentage, 1302, 1303, "%", "", +66, PvalueDiff, 1306, 1319, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +67, FastingPlasmaGlucose, 1342, 1364, "fasting plasma glucose", "", " ." +7, Vildagliptin, 1383, 1395, "vildagliptin", "", +39, Placebo, 1400, 1407, "placebo", "", +68, DiffGroupAbsValue, 1412, 1420, "- 1 . 13", "", " \"- 1 . 13\"." +69, Millimoles_per_litre, 1423, 1431, "mmol / l", "", " ." +70, PvalueDiff, 1434, 1447, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +168, SubGroupDescription, 1467, 1501, "patients with baseline HbA1c ≤ 8 %", "", " \"patients with baseline HbA1c ≤ 8 %\". \"patients with baseline HbA1c ≤ 8 %\". \"patients with baseline HbA1c ≤ 8 %\". \"patients with baseline HbA1c ≤ 8 %\"." +72, HbA1c, 1490, 1495, "HbA1c", "", +170, Percentage, 1500, 1501, "%", "", +8, Vildagliptin, 1504, 1516, "vildagliptin", "", +73, HbA1c, 1525, 1530, "HbA1c", "", +74, Reduction, 1534, 1540, "0 . 74", "", " \"0 . 74\"." +76, Percentage, 1541, 1542, "%", "", +181, TimePoint, 1548, 1556, "baseline", "", +75, BaseLineValue, 1557, 1563, "7 . 82", "", " \"7 . 82\"." +77, Percentage, 1564, 1565, "%", "", +79, DiffGroupAbsValue, 1601, 1609, "- 0 . 97", "", " \"- 0 . 97\"." +78, Percentage, 1610, 1611, "%", "", +80, PvalueDiff, 1614, 1625, "p < 0 . 001", "", " \"p < 0 . 001\"." +184, HbA1c_target, 1675, 1693, "HbA1c target < 7 %", "", +174, Percentage, 1692, 1693, "%", "", +82, PercentageAffected, 1696, 1702, "38 . 6", "", " \"38 . 6\"." +83, PercentageAffected, 1710, 1716, "13 . 9", "", " \"13 . 9\"." +84, PvalueDiff, 1721, 1734, "p  =  0 . 014", "", " \"p  =  0 . 014\"." +9, Vildagliptin, 1739, 1751, "Vildagliptin", "", +85, Hypoglycemia, 1793, 1806, "hypoglycaemia", "", " ." +40, Placebo, 1835, 1842, "placebo", "", +86, PercentageAffected, 1845, 1850, "5 . 1", "", " \"5 . 1\"." +87, PercentageAffected, 1858, 1863, "1 . 9", "", " \"1 . 9\"." +89, ObservedResult, 1872, 1906, "no clinically relevant weight gain", "", +195, WeightGain, 1895, 1906, "weight gain", "", +10, Vildagliptin, 1923, 1935, "Vildagliptin", "", +97, ConclusionComment, 1923, 2068, "Vildagliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin plus glimepiride combination .", "", " \"Vildagliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin plus glimepiride combination .\"." +16, Type2Diabetes, 1994, 1998, "T2DM", "", +20, Metformin, 2028, 2037, "metformin", "", +32, Glimepiride, 2043, 2054, "glimepiride", "", +98, ConclusionComment, 2069, 2165, "The addition of vildagliptin was well tolerated with low risk of hypoglycaemia and weight gain .", "", " \"The addition of vildagliptin was well tolerated with low risk of hypoglycaemia and weight gain .\"." +11, Vildagliptin, 2085, 2097, "vildagliptin", "", +90, Hypoglycemia, 2134, 2147, "hypoglycaemia", "", +202, WeightGain, 2152, 2163, "weight gain", "", +99, ConclusionComment, 2166, 2315, "This makes vildagliptin an attractive treatment option for patients failing on metformin plus SU particularly in patients with baseline HbA1c ≤ 8 % .", "", " \"This makes vildagliptin an attractive treatment option for patients failing on metformin plus SU particularly in patients with baseline HbA1c ≤ 8 % .\"." +12, Vildagliptin, 2177, 2189, "vildagliptin", "", +92, Metformin, 2245, 2254, "metformin", "", +93, Sulfonylureas, 2260, 2262, "SU", "", +94, HbA1c, 2302, 2307, "HbA1c", "", +95, Percentage, 2312, 2313, "%", "", +100, PMID, 2464, 2472, "24199686", "", " \"24199686\"." diff --git a/data/dm2 24199686_admin.n-triples b/data/dm2 24199686_admin.n-triples new file mode 100644 index 0000000..f30fe17 --- /dev/null +++ b/data/dm2 24199686_admin.n-triples @@ -0,0 +1,195 @@ +# RDF export of group: Publication + . + "Publication 50735" . + "Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea ." . + "Lukashevich V" . + "2014" . + "Diabetes Obes Metab ." . + "24199686" . + . + "Del Prato S" . + "Araga M" . + "Kothny W" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 50742" . + "The broadly used combination of metformin and sulphonylurea ( SU ) often fails to bring patients to glycaemic goal ." . + "24   weeks" . + . + . + . + "Vildagliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin plus glimepiride combination ." . + . + . + . + . + . + . + "The addition of vildagliptin was well tolerated with low risk of hypoglycaemia and weight gain ." . + "This makes vildagliptin an attractive treatment option for patients failing on metformin plus SU particularly in patients with baseline HbA1c ≤ 8 % ." . + . + . + "This study assessed the efficacy and safety of vildagliptin as add - on therapy to metformin plus glimepiride combination in patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control ." . + . + . + . + . +# RDF export of group: Population + . + "Population 50758" . + "patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "vi" . + "158" . + . + . + . + . + . + . + . + . + "pl" . + "160" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "vi" . + . + "bid" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "vi" . + . + "50" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 75" . + "1 . 01" . + . + "hba 2" . + . + "8 . 80" . + "0 . 25" . + . + "hbat 1" . + . + "28 . 3" . + . + "hbat 2" . + . + "5 . 6" . + . + "fpg 1" . + . + . + "fpg 2" . + . + . + "hbas 1" . + . + "patients with baseline HbA1c ≤ 8 %" . + . + "hbas 2" . + . + "7 . 82" . + "0 . 74" . + "patients with baseline HbA1c ≤ 8 %" . + . + "hbats 1" . + . + "38 . 6" . + "patients with baseline HbA1c ≤ 8 %" . + . + "hbats 2" . + . + "13 . 9" . + "patients with baseline HbA1c ≤ 8 %" . + . + "hyp 1" . + . + "5 . 1" . + . + "hyp 2" . + . + "1 . 9" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 76" . + "p  <  0 . 001" . + . + . + . + "hbat" . + "p  <  0 . 001" . + . + . + . + "fpg" . + "- 1 . 13" . + "p  <  0 . 001" . + . + . + . + "hbas" . + "- 0 . 97" . + "p < 0 . 001" . + . + . + . + "hbats" . + "p  =  0 . 014" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24199686_akramersunderbrink.annodb b/data/dm2 24199686_akramersunderbrink.annodb new file mode 100644 index 0000000..9362adf --- /dev/null +++ b/data/dm2 24199686_akramersunderbrink.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +58849, Journal, 0, 19, "Diabetes Obes Metab", "", +58850, PublicationYear, 22, 26, "2014", "", +58855, Title, 104, 260, "Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea .", "", +58851, Vildagliptin, 127, 139, "vildagliptin", "", +58852, Type2Diabetes, 157, 181, "type 2 diabetes mellitus", "", +58853, Metformin, 231, 240, "metformin", "", +58854, Sulfonylureas, 245, 258, "sulphonylurea", "", +58857, Author, 261, 274, "Lukashevich V", "", +58858, Author, 283, 294, "Del Prato S", "", +58859, Author, 297, 304, "Araga M", "", +58860, Author, 307, 315, "Kothny W", "", +58856, USA, 404, 407, "USA", "", +58869, ObjectiveDescription, 416, 532, "The broadly used combination of metformin and sulphonylurea ( SU ) often fails to bring patients to glycaemic goal .", "", +58861, Metformin, 448, 457, "metformin", "", +58862, Sulfonylureas, 462, 475, "sulphonylurea", "", +58863, Sulfonylureas, 478, 480, "SU", "", +58870, ObjectiveDescription, 533, 744, "This study assessed the efficacy and safety of vildagliptin as add - on therapy to metformin plus glimepiride combination in patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control .", "", +58864, Vildagliptin, 580, 592, "vildagliptin", "", +58865, Metformin, 616, 625, "metformin", "", +58866, Glimepiride, 631, 642, "glimepiride", "", +58867, Type2Diabetes, 672, 696, "type 2 diabetes mellitus", "", +58868, Type2Diabetes, 699, 703, "T2DM", "", +58871, Multicenter, 757, 768, "multicentre", "", +58872, DoubleBlind, 771, 785, "double - blind", "", +58873, Placebo, 788, 795, "placebo", "", +58874, Randomized, 815, 825, "randomized", "", +58875, Vildagliptin, 861, 873, "vildagliptin", "", +58876, DoseValue, 874, 881, "50   mg", "", +58877, mg, 879, 881, "mg", "", +58878, Frequency, 882, 885, "bid", "", +58879, NumberPatientsArm, 894, 897, "158", "", +58881, Placebo, 903, 910, "placebo", "", +58880, NumberPatientsArm, 919, 922, "160", "", +58882, Duration, 929, 939, "24   weeks", "", +58883, TimePoint, 958, 968, "24   weeks", "", +58884, Mean, 984, 988, "mean", "", +58885, HbA1c, 999, 1014, "haemoglobin A1c", "", +58886, HbA1c, 1017, 1022, "HbA1c", "", +58887, ChangeValue, 1029, 1037, "- 1 . 01", "", +58889, Percentage, 1038, 1039, "%", "", +58896, Vildagliptin, 1045, 1057, "vildagliptin", "", +58894, TimePoint, 1060, 1068, "baseline", "", +58898, BaseLineValue, 1069, 1075, "8 . 75", "", +58890, Percentage, 1076, 1077, "%", "", +58888, ChangeValue, 1084, 1092, "- 0 . 25", "", +58891, Percentage, 1093, 1094, "%", "", +58897, Placebo, 1100, 1107, "placebo", "", +58895, TimePoint, 1110, 1118, "baseline", "", +58899, BaseLineValue, 1119, 1125, "8 . 80", "", +58892, Percentage, 1126, 1127, "%", "", +58900, DiffGroupAbsValue, 1173, 1181, "- 0 . 76", "", +58893, Percentage, 1182, 1183, "%", "", +58901, PvalueDiff, 1186, 1199, "p  <  0 . 001", "", +58902, Vildagliptin, 1235, 1247, "vildagliptin", "", +58903, HbA1c_target, 1261, 1279, "HbA1c target < 7 %", "", +58904, Percentage, 1278, 1279, "%", "", +58907, PercentageAffected, 1282, 1288, "28 . 3", "", +58905, Percentage, 1289, 1290, "%", "", +58908, PercentageAffected, 1296, 1301, "5 . 6", "", +58906, Percentage, 1302, 1303, "%", "", +58909, PvalueDiff, 1306, 1319, "p  <  0 . 001", "", +58910, FastingPlasmaGlucose, 1342, 1364, "fasting plasma glucose", "", +58911, Vildagliptin, 1383, 1395, "vildagliptin", "", +58912, Placebo, 1400, 1407, "placebo", "", +58913, DiffGroupAbsValue, 1412, 1420, "- 1 . 13", "", +58914, Millimoles_per_litre, 1423, 1431, "mmol / l", "", +58915, PvalueDiff, 1434, 1447, "p  <  0 . 001", "", +58916, SubGroupDescription, 1467, 1501, "patients with baseline HbA1c ≤ 8 %", "", +58917, HbA1c, 1490, 1495, "HbA1c", "", +58918, Percentage, 1500, 1501, "%", "", +58925, Vildagliptin, 1504, 1516, "vildagliptin", "", +58926, HbA1c, 1525, 1530, "HbA1c", "", +58927, Reduction, 1534, 1540, "0 . 74", "", +58919, Percentage, 1541, 1542, "%", "", +58929, TimePoint, 1548, 1556, "baseline", "", +58928, BaseLineValue, 1557, 1563, "7 . 82", "", +58920, Percentage, 1564, 1565, "%", "", +58930, DiffGroupAbsValue, 1601, 1609, "- 0 . 97", "", +58921, Percentage, 1610, 1611, "%", "", +58931, PvalueDiff, 1614, 1625, "p < 0 . 001", "", +58932, HbA1c_target, 1675, 1693, "HbA1c target < 7 %", "", +58922, Percentage, 1692, 1693, "%", "", +58933, PercentageAffected, 1696, 1702, "38 . 6", "", +58923, Percentage, 1703, 1704, "%", "", +58934, PercentageAffected, 1710, 1716, "13 . 9", "", +58924, Percentage, 1717, 1718, "%", "", +58935, PvalueDiff, 1721, 1734, "p  =  0 . 014", "", +58936, Vildagliptin, 1739, 1751, "Vildagliptin", "", +58937, Hypoglycemia, 1793, 1806, "hypoglycaemia", "", +58938, Placebo, 1835, 1842, "placebo", "", +58939, PercentageAffected, 1845, 1850, "5 . 1", "", +58941, Percentage, 1851, 1852, "%", "", +58940, PercentageAffected, 1858, 1863, "1 . 9", "", +58942, Percentage, 1864, 1865, "%", "", +58943, WeightGain, 1895, 1906, "weight gain", "", +58944, Vildagliptin, 1923, 1935, "Vildagliptin", "", +58959, ConclusionComment, 1923, 2068, "Vildagliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin plus glimepiride combination .", "", +58945, Type2Diabetes, 1994, 1998, "T2DM", "", +58946, Metformin, 2028, 2037, "metformin", "", +58947, Glimepiride, 2043, 2054, "glimepiride", "", +58960, ConclusionComment, 2069, 2165, "The addition of vildagliptin was well tolerated with low risk of hypoglycaemia and weight gain .", "", +58948, Vildagliptin, 2085, 2097, "vildagliptin", "", +58949, Hypoglycemia, 2134, 2147, "hypoglycaemia", "", +58950, WeightGain, 2152, 2163, "weight gain", "", +58961, ConclusionComment, 2166, 2315, "This makes vildagliptin an attractive treatment option for patients failing on metformin plus SU particularly in patients with baseline HbA1c ≤ 8 % .", "", +58951, Vildagliptin, 2177, 2189, "vildagliptin", "", +58952, Metformin, 2245, 2254, "metformin", "", +58957, Sulfonylureas, 2260, 2262, "SU", "", +58954, Precondition, 2279, 2313, "patients with baseline HbA1c ≤ 8 %", "", +58953, TimePoint, 2293, 2301, "baseline", "", +58955, HbA1c, 2302, 2307, "HbA1c", "", +58956, Percentage, 2312, 2313, "%", "", +58958, PMID, 2464, 2472, "24199686", "", diff --git a/data/dm2 24199686_akramersunderbrink.n-triples b/data/dm2 24199686_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24199686_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24199686_export.csv b/data/dm2 24199686_export.csv new file mode 100644 index 0000000..ee46738 --- /dev/null +++ b/data/dm2 24199686_export.csv @@ -0,0 +1,516 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +289, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +289, 1, 2, 2, 9, 13, 9, 13, "Obes" +289, 1, 3, 3, 14, 19, 14, 19, "Metab" +289, 1, 4, 4, 20, 21, 20, 21, "." +289, 2, 1, 5, 0, 4, 22, 26, "2014" +289, 2, 2, 6, 5, 8, 27, 30, "May" +289, 2, 3, 7, 9, 10, 31, 32, ";" +289, 2, 4, 8, 11, 13, 33, 35, "16" +289, 2, 5, 9, 14, 15, 36, 37, "(" +289, 2, 6, 10, 16, 17, 38, 39, "5" +289, 2, 7, 11, 18, 19, 40, 41, ")" +289, 2, 8, 12, 20, 21, 42, 43, ":" +289, 2, 9, 13, 22, 25, 44, 47, "403" +289, 2, 10, 14, 26, 27, 48, 49, "-" +289, 2, 11, 15, 28, 29, 50, 51, "9" +289, 2, 12, 16, 30, 31, 52, 53, "." +289, 2, 13, 17, 32, 35, 54, 57, "doi" +289, 2, 14, 18, 36, 37, 58, 59, ":" +289, 2, 15, 19, 38, 40, 60, 62, "10" +289, 2, 16, 20, 41, 42, 63, 64, "." +289, 2, 17, 21, 43, 47, 65, 69, "1111" +289, 2, 18, 22, 48, 49, 70, 71, "/" +289, 2, 19, 23, 50, 53, 72, 75, "dom" +289, 2, 20, 24, 54, 55, 76, 77, "." +289, 2, 21, 25, 56, 61, 78, 83, "12229" +289, 2, 22, 26, 62, 63, 84, 85, "." +289, 3, 1, 27, 0, 4, 86, 90, "Epub" +289, 3, 2, 28, 5, 9, 91, 95, "2013" +289, 3, 3, 29, 10, 13, 96, 99, "Dec" +289, 3, 4, 30, 14, 15, 100, 101, "2" +289, 3, 5, 31, 16, 17, 102, 103, "." +289, 4, 1, 32, 0, 8, 104, 112, "Efficacy" +289, 4, 2, 33, 9, 12, 113, 116, "and" +289, 4, 3, 34, 13, 19, 117, 123, "safety" +289, 4, 4, 35, 20, 22, 124, 126, "of" +289, 4, 5, 36, 23, 35, 127, 139, "vildagliptin" +289, 4, 6, 37, 36, 38, 140, 142, "in" +289, 4, 7, 38, 39, 47, 143, 151, "patients" +289, 4, 8, 39, 48, 52, 152, 156, "with" +289, 4, 9, 40, 53, 57, 157, 161, "type" +289, 4, 10, 41, 58, 59, 162, 163, "2" +289, 4, 11, 42, 60, 68, 164, 172, "diabetes" +289, 4, 12, 43, 69, 77, 173, 181, "mellitus" +289, 4, 13, 44, 78, 90, 182, 194, "inadequately" +289, 4, 14, 45, 91, 101, 195, 205, "controlled" +289, 4, 15, 46, 102, 106, 206, 210, "with" +289, 4, 16, 47, 107, 111, 211, 215, "dual" +289, 4, 17, 48, 112, 123, 216, 227, "combination" +289, 4, 18, 49, 124, 126, 228, 230, "of" +289, 4, 19, 50, 127, 136, 231, 240, "metformin" +289, 4, 20, 51, 137, 140, 241, 244, "and" +289, 4, 21, 52, 141, 154, 245, 258, "sulphonylurea" +289, 4, 22, 53, 155, 156, 259, 260, "." +289, 5, 1, 54, 0, 11, 261, 272, "Lukashevich" +289, 5, 2, 55, 12, 13, 273, 274, "V" +289, 5, 3, 56, 14, 15, 275, 276, "(" +289, 5, 4, 57, 16, 17, 277, 278, "1" +289, 5, 5, 58, 18, 19, 279, 280, ")" +289, 5, 6, 59, 20, 21, 281, 282, "," +289, 5, 7, 60, 22, 25, 283, 286, "Del" +289, 5, 8, 61, 26, 31, 287, 292, "Prato" +289, 5, 9, 62, 32, 33, 293, 294, "S" +289, 5, 10, 63, 34, 35, 295, 296, "," +289, 5, 11, 64, 36, 41, 297, 302, "Araga" +289, 5, 12, 65, 42, 43, 303, 304, "M" +289, 5, 13, 66, 44, 45, 305, 306, "," +289, 5, 14, 67, 46, 52, 307, 313, "Kothny" +289, 5, 15, 68, 53, 54, 314, 315, "W" +289, 5, 16, 69, 55, 56, 316, 317, "." +289, 5, 17, 70, 57, 63, 318, 324, "Author" +289, 5, 18, 71, 64, 75, 325, 336, "information" +289, 5, 19, 72, 76, 77, 337, 338, ":" +289, 5, 20, 73, 78, 79, 339, 340, "(" +289, 5, 21, 74, 80, 81, 341, 342, "1" +289, 5, 22, 75, 82, 83, 343, 344, ")" +289, 5, 23, 76, 84, 92, 345, 353, "Novartis" +289, 5, 24, 77, 93, 108, 354, 369, "Pharmaceuticals" +289, 5, 25, 78, 109, 120, 370, 381, "Corporation" +289, 5, 26, 79, 121, 122, 382, 383, "," +289, 5, 27, 80, 123, 127, 384, 388, "East" +289, 5, 28, 81, 128, 135, 389, 396, "Hanover" +289, 5, 29, 82, 136, 137, 397, 398, "," +289, 5, 30, 83, 138, 140, 399, 401, "NJ" +289, 5, 31, 84, 141, 142, 402, 403, "," +289, 5, 32, 85, 143, 146, 404, 407, "USA" +289, 5, 33, 86, 147, 148, 408, 409, "." +289, 6, 1, 87, 0, 3, 410, 413, "AIM" +289, 6, 2, 88, 4, 5, 414, 415, ":" +289, 6, 3, 89, 6, 9, 416, 419, "The" +289, 6, 4, 90, 10, 17, 420, 427, "broadly" +289, 6, 5, 91, 18, 22, 428, 432, "used" +289, 6, 6, 92, 23, 34, 433, 444, "combination" +289, 6, 7, 93, 35, 37, 445, 447, "of" +289, 6, 8, 94, 38, 47, 448, 457, "metformin" +289, 6, 9, 95, 48, 51, 458, 461, "and" +289, 6, 10, 96, 52, 65, 462, 475, "sulphonylurea" +289, 6, 11, 97, 66, 67, 476, 477, "(" +289, 6, 12, 98, 68, 70, 478, 480, "SU" +289, 6, 13, 99, 71, 72, 481, 482, ")" +289, 6, 14, 100, 73, 78, 483, 488, "often" +289, 6, 15, 101, 79, 84, 489, 494, "fails" +289, 6, 16, 102, 85, 87, 495, 497, "to" +289, 6, 17, 103, 88, 93, 498, 503, "bring" +289, 6, 18, 104, 94, 102, 504, 512, "patients" +289, 6, 19, 105, 103, 105, 513, 515, "to" +289, 6, 20, 106, 106, 115, 516, 525, "glycaemic" +289, 6, 21, 107, 116, 120, 526, 530, "goal" +289, 6, 22, 108, 121, 122, 531, 532, "." +289, 7, 1, 109, 0, 4, 533, 537, "This" +289, 7, 2, 110, 5, 10, 538, 543, "study" +289, 7, 3, 111, 11, 19, 544, 552, "assessed" +289, 7, 4, 112, 20, 23, 553, 556, "the" +289, 7, 5, 113, 24, 32, 557, 565, "efficacy" +289, 7, 6, 114, 33, 36, 566, 569, "and" +289, 7, 7, 115, 37, 43, 570, 576, "safety" +289, 7, 8, 116, 44, 46, 577, 579, "of" +289, 7, 9, 117, 47, 59, 580, 592, "vildagliptin" +289, 7, 10, 118, 60, 62, 593, 595, "as" +289, 7, 11, 119, 63, 66, 596, 599, "add" +289, 7, 12, 120, 67, 68, 600, 601, "-" +289, 7, 13, 121, 69, 71, 602, 604, "on" +289, 7, 14, 122, 72, 79, 605, 612, "therapy" +289, 7, 15, 123, 80, 82, 613, 615, "to" +289, 7, 16, 124, 83, 92, 616, 625, "metformin" +289, 7, 17, 125, 93, 97, 626, 630, "plus" +289, 7, 18, 126, 98, 109, 631, 642, "glimepiride" +289, 7, 19, 127, 110, 121, 643, 654, "combination" +289, 7, 20, 128, 122, 124, 655, 657, "in" +289, 7, 21, 129, 125, 133, 658, 666, "patients" +289, 7, 22, 130, 134, 138, 667, 671, "with" +289, 7, 23, 131, 139, 143, 672, 676, "type" +289, 7, 24, 132, 144, 145, 677, 678, "2" +289, 7, 25, 133, 146, 154, 679, 687, "diabetes" +289, 7, 26, 134, 155, 163, 688, 696, "mellitus" +289, 7, 27, 135, 164, 165, 697, 698, "(" +289, 7, 28, 136, 166, 170, 699, 703, "T2DM" +289, 7, 29, 137, 171, 172, 704, 705, ")" +289, 7, 30, 138, 173, 176, 706, 709, "who" +289, 7, 31, 139, 177, 180, 710, 713, "had" +289, 7, 32, 140, 181, 191, 714, 724, "inadequate" +289, 7, 33, 141, 192, 201, 725, 734, "glycaemic" +289, 7, 34, 142, 202, 209, 735, 742, "control" +289, 7, 35, 143, 210, 211, 743, 744, "." +289, 8, 1, 144, 0, 7, 745, 752, "METHODS" +289, 8, 2, 145, 8, 9, 753, 754, ":" +289, 8, 3, 146, 10, 11, 755, 756, "A" +289, 8, 4, 147, 12, 23, 757, 768, "multicentre" +289, 8, 5, 148, 24, 25, 769, 770, "," +289, 8, 6, 149, 26, 32, 771, 777, "double" +289, 8, 7, 150, 33, 34, 778, 779, "-" +289, 8, 8, 151, 35, 40, 780, 785, "blind" +289, 8, 9, 152, 41, 42, 786, 787, "," +289, 8, 10, 153, 43, 50, 788, 795, "placebo" +289, 8, 11, 154, 51, 52, 796, 797, "-" +289, 8, 12, 155, 53, 63, 798, 808, "controlled" +289, 8, 13, 156, 64, 69, 809, 814, "study" +289, 8, 14, 157, 70, 80, 815, 825, "randomized" +289, 8, 15, 158, 81, 89, 826, 834, "patients" +289, 8, 16, 159, 90, 92, 835, 837, "to" +289, 8, 17, 160, 93, 100, 838, 845, "receive" +289, 8, 18, 161, 101, 110, 846, 855, "treatment" +289, 8, 19, 162, 111, 115, 856, 860, "with" +289, 8, 20, 163, 116, 128, 861, 873, "vildagliptin" +289, 8, 21, 164, 129, 131, 874, 876, "50" +289, 8, 22, 165, 132, 133, 877, 878, " " +289, 8, 23, 166, 134, 136, 879, 881, "mg" +289, 8, 24, 167, 137, 140, 882, 885, "bid" +289, 8, 25, 168, 141, 142, 886, 887, "(" +289, 8, 26, 169, 143, 144, 888, 889, "n" +289, 8, 27, 170, 145, 148, 890, 893, " = " +289, 8, 28, 171, 149, 152, 894, 897, "158" +289, 8, 29, 172, 153, 154, 898, 899, ")" +289, 8, 30, 173, 155, 157, 900, 902, "or" +289, 8, 31, 174, 158, 165, 903, 910, "placebo" +289, 8, 32, 175, 166, 167, 911, 912, "(" +289, 8, 33, 176, 168, 169, 913, 914, "n" +289, 8, 34, 177, 170, 173, 915, 918, " = " +289, 8, 35, 178, 174, 177, 919, 922, "160" +289, 8, 36, 179, 178, 179, 923, 924, ")" +289, 8, 37, 180, 180, 183, 925, 928, "for" +289, 8, 38, 181, 184, 186, 929, 931, "24" +289, 8, 39, 182, 187, 188, 932, 933, " " +289, 8, 40, 183, 189, 194, 934, 939, "weeks" +289, 8, 41, 184, 195, 196, 940, 941, "." +289, 9, 1, 185, 0, 7, 942, 949, "RESULTS" +289, 9, 2, 186, 8, 9, 950, 951, ":" +289, 9, 3, 187, 10, 15, 952, 957, "After" +289, 9, 4, 188, 16, 18, 958, 960, "24" +289, 9, 5, 189, 19, 20, 961, 962, " " +289, 9, 6, 190, 21, 26, 963, 968, "weeks" +289, 9, 7, 191, 27, 28, 969, 970, "," +289, 9, 8, 192, 29, 32, 971, 974, "the" +289, 9, 9, 193, 33, 41, 975, 983, "adjusted" +289, 9, 10, 194, 42, 46, 984, 988, "mean" +289, 9, 11, 195, 47, 53, 989, 995, "change" +289, 9, 12, 196, 54, 56, 996, 998, "in" +289, 9, 13, 197, 57, 68, 999, 1010, "haemoglobin" +289, 9, 14, 198, 69, 72, 1011, 1014, "A1c" +289, 9, 15, 199, 73, 74, 1015, 1016, "(" +289, 9, 16, 200, 75, 80, 1017, 1022, "HbA1c" +289, 9, 17, 201, 81, 82, 1023, 1024, ")" +289, 9, 18, 202, 83, 86, 1025, 1028, "was" +289, 9, 19, 203, 87, 88, 1029, 1030, "-" +289, 9, 20, 204, 89, 90, 1031, 1032, "1" +289, 9, 21, 205, 91, 92, 1033, 1034, "." +289, 9, 22, 206, 93, 95, 1035, 1037, "01" +289, 9, 23, 207, 96, 97, 1038, 1039, "%" +289, 9, 24, 208, 98, 102, 1040, 1044, "with" +289, 9, 25, 209, 103, 115, 1045, 1057, "vildagliptin" +289, 9, 26, 210, 116, 117, 1058, 1059, "(" +289, 9, 27, 211, 118, 126, 1060, 1068, "baseline" +289, 9, 28, 212, 127, 128, 1069, 1070, "8" +289, 9, 29, 213, 129, 130, 1071, 1072, "." +289, 9, 30, 214, 131, 133, 1073, 1075, "75" +289, 9, 31, 215, 134, 135, 1076, 1077, "%" +289, 9, 32, 216, 136, 137, 1078, 1079, ")" +289, 9, 33, 217, 138, 141, 1080, 1083, "and" +289, 9, 34, 218, 142, 143, 1084, 1085, "-" +289, 9, 35, 219, 144, 145, 1086, 1087, "0" +289, 9, 36, 220, 146, 147, 1088, 1089, "." +289, 9, 37, 221, 148, 150, 1090, 1092, "25" +289, 9, 38, 222, 151, 152, 1093, 1094, "%" +289, 9, 39, 223, 153, 157, 1095, 1099, "with" +289, 9, 40, 224, 158, 165, 1100, 1107, "placebo" +289, 9, 41, 225, 166, 167, 1108, 1109, "(" +289, 9, 42, 226, 168, 176, 1110, 1118, "baseline" +289, 9, 43, 227, 177, 178, 1119, 1120, "8" +289, 9, 44, 228, 179, 180, 1121, 1122, "." +289, 9, 45, 229, 181, 183, 1123, 1125, "80" +289, 9, 46, 230, 184, 185, 1126, 1127, "%" +289, 9, 47, 231, 186, 187, 1128, 1129, ")" +289, 9, 48, 232, 188, 189, 1130, 1131, "," +289, 9, 49, 233, 190, 194, 1132, 1136, "with" +289, 9, 50, 234, 195, 196, 1137, 1138, "a" +289, 9, 51, 235, 197, 204, 1139, 1146, "between" +289, 9, 52, 236, 205, 206, 1147, 1148, "-" +289, 9, 53, 237, 207, 216, 1149, 1158, "treatment" +289, 9, 54, 238, 217, 227, 1159, 1169, "difference" +289, 9, 55, 239, 228, 230, 1170, 1172, "of" +289, 9, 56, 240, 231, 232, 1173, 1174, "-" +289, 9, 57, 241, 233, 234, 1175, 1176, "0" +289, 9, 58, 242, 235, 236, 1177, 1178, "." +289, 9, 59, 243, 237, 239, 1179, 1181, "76" +289, 9, 60, 244, 240, 241, 1182, 1183, "%" +289, 9, 61, 245, 242, 243, 1184, 1185, "(" +289, 9, 62, 246, 244, 245, 1186, 1187, "p" +289, 9, 63, 247, 246, 249, 1188, 1191, " < " +289, 9, 64, 248, 250, 251, 1192, 1193, "0" +289, 9, 65, 249, 252, 253, 1194, 1195, "." +289, 9, 66, 250, 254, 257, 1196, 1199, "001" +289, 9, 67, 251, 258, 259, 1200, 1201, ")" +289, 9, 68, 252, 260, 261, 1202, 1203, "." +289, 10, 1, 253, 0, 13, 1204, 1217, "Significantly" +289, 10, 2, 254, 14, 18, 1218, 1222, "more" +289, 10, 3, 255, 19, 27, 1223, 1231, "patients" +289, 10, 4, 256, 28, 30, 1232, 1234, "on" +289, 10, 5, 257, 31, 43, 1235, 1247, "vildagliptin" +289, 10, 6, 258, 44, 52, 1248, 1256, "achieved" +289, 10, 7, 259, 53, 56, 1257, 1260, "the" +289, 10, 8, 260, 57, 62, 1261, 1266, "HbA1c" +289, 10, 9, 261, 63, 69, 1267, 1273, "target" +289, 10, 10, 262, 70, 71, 1274, 1275, "<" +289, 10, 11, 263, 72, 73, 1276, 1277, "7" +289, 10, 12, 264, 74, 75, 1278, 1279, "%" +289, 10, 13, 265, 76, 77, 1280, 1281, "(" +289, 10, 14, 266, 78, 80, 1282, 1284, "28" +289, 10, 15, 267, 81, 82, 1285, 1286, "." +289, 10, 16, 268, 83, 84, 1287, 1288, "3" +289, 10, 17, 269, 85, 86, 1289, 1290, "%" +289, 10, 18, 270, 87, 89, 1291, 1293, "vs" +289, 10, 19, 271, 90, 91, 1294, 1295, "." +289, 10, 20, 272, 92, 93, 1296, 1297, "5" +289, 10, 21, 273, 94, 95, 1298, 1299, "." +289, 10, 22, 274, 96, 97, 1300, 1301, "6" +289, 10, 23, 275, 98, 99, 1302, 1303, "%" +289, 10, 24, 276, 100, 101, 1304, 1305, ";" +289, 10, 25, 277, 102, 103, 1306, 1307, "p" +289, 10, 26, 278, 104, 107, 1308, 1311, " < " +289, 10, 27, 279, 108, 109, 1312, 1313, "0" +289, 10, 28, 280, 110, 111, 1314, 1315, "." +289, 10, 29, 281, 112, 115, 1316, 1319, "001" +289, 10, 30, 282, 116, 117, 1320, 1321, ")" +289, 10, 31, 283, 118, 119, 1322, 1323, "." +289, 11, 1, 284, 0, 3, 1324, 1327, "The" +289, 11, 2, 285, 4, 14, 1328, 1338, "difference" +289, 11, 3, 286, 15, 17, 1339, 1341, "in" +289, 11, 4, 287, 18, 25, 1342, 1349, "fasting" +289, 11, 5, 288, 26, 32, 1350, 1356, "plasma" +289, 11, 6, 289, 33, 40, 1357, 1364, "glucose" +289, 11, 7, 290, 41, 50, 1365, 1374, "reduction" +289, 11, 8, 291, 51, 58, 1375, 1382, "between" +289, 11, 9, 292, 59, 71, 1383, 1395, "vildagliptin" +289, 11, 10, 293, 72, 75, 1396, 1399, "and" +289, 11, 11, 294, 76, 83, 1400, 1407, "placebo" +289, 11, 12, 295, 84, 87, 1408, 1411, "was" +289, 11, 13, 296, 88, 89, 1412, 1413, "-" +289, 11, 14, 297, 90, 91, 1414, 1415, "1" +289, 11, 15, 298, 92, 93, 1416, 1417, "." +289, 11, 16, 299, 94, 96, 1418, 1420, "13" +289, 11, 17, 300, 97, 98, 1421, 1422, " " +289, 11, 18, 301, 99, 103, 1423, 1427, "mmol" +289, 11, 19, 302, 104, 105, 1428, 1429, "/" +289, 11, 20, 303, 106, 107, 1430, 1431, "l" +289, 11, 21, 304, 108, 109, 1432, 1433, "(" +289, 11, 22, 305, 110, 111, 1434, 1435, "p" +289, 11, 23, 306, 112, 115, 1436, 1439, " < " +289, 11, 24, 307, 116, 117, 1440, 1441, "0" +289, 11, 25, 308, 118, 119, 1442, 1443, "." +289, 11, 26, 309, 120, 123, 1444, 1447, "001" +289, 11, 27, 310, 124, 125, 1448, 1449, ")" +289, 11, 28, 311, 126, 127, 1450, 1451, "." +289, 12, 1, 312, 0, 2, 1452, 1454, "In" +289, 12, 2, 313, 3, 11, 1455, 1463, "subgroup" +289, 12, 3, 314, 12, 14, 1464, 1466, "of" +289, 12, 4, 315, 15, 23, 1467, 1475, "patients" +289, 12, 5, 316, 24, 28, 1476, 1480, "with" +289, 12, 6, 317, 29, 37, 1481, 1489, "baseline" +289, 12, 7, 318, 38, 43, 1490, 1495, "HbA1c" +289, 12, 8, 319, 44, 45, 1496, 1497, "≤" +289, 12, 9, 320, 46, 47, 1498, 1499, "8" +289, 12, 10, 321, 48, 49, 1500, 1501, "%" +289, 12, 11, 322, 50, 51, 1502, 1503, "," +289, 12, 12, 323, 52, 64, 1504, 1516, "vildagliptin" +289, 12, 13, 324, 65, 72, 1517, 1524, "reduced" +289, 12, 14, 325, 73, 78, 1525, 1530, "HbA1c" +289, 12, 15, 326, 79, 81, 1531, 1533, "by" +289, 12, 16, 327, 82, 83, 1534, 1535, "0" +289, 12, 17, 328, 84, 85, 1536, 1537, "." +289, 12, 18, 329, 86, 88, 1538, 1540, "74" +289, 12, 19, 330, 89, 90, 1541, 1542, "%" +289, 12, 20, 331, 91, 95, 1543, 1547, "from" +289, 12, 21, 332, 96, 104, 1548, 1556, "baseline" +289, 12, 22, 333, 105, 106, 1557, 1558, "7" +289, 12, 23, 334, 107, 108, 1559, 1560, "." +289, 12, 24, 335, 109, 111, 1561, 1563, "82" +289, 12, 25, 336, 112, 113, 1564, 1565, "%" +289, 12, 26, 337, 114, 115, 1566, 1567, "(" +289, 12, 27, 338, 116, 123, 1568, 1575, "between" +289, 12, 28, 339, 124, 125, 1576, 1577, "-" +289, 12, 29, 340, 126, 135, 1578, 1587, "treatment" +289, 12, 30, 341, 136, 146, 1588, 1598, "difference" +289, 12, 31, 342, 147, 148, 1599, 1600, ":" +289, 12, 32, 343, 149, 150, 1601, 1602, "-" +289, 12, 33, 344, 151, 152, 1603, 1604, "0" +289, 12, 34, 345, 153, 154, 1605, 1606, "." +289, 12, 35, 346, 155, 157, 1607, 1609, "97" +289, 12, 36, 347, 158, 159, 1610, 1611, "%" +289, 12, 37, 348, 160, 161, 1612, 1613, ";" +289, 12, 38, 349, 162, 163, 1614, 1615, "p" +289, 12, 39, 350, 164, 165, 1616, 1617, "<" +289, 12, 40, 351, 166, 167, 1618, 1619, "0" +289, 12, 41, 352, 168, 169, 1620, 1621, "." +289, 12, 42, 353, 170, 173, 1622, 1625, "001" +289, 12, 43, 354, 174, 175, 1626, 1627, ")" +289, 12, 44, 355, 176, 180, 1628, 1632, "with" +289, 12, 45, 356, 181, 194, 1633, 1646, "significantly" +289, 12, 46, 357, 195, 199, 1647, 1651, "more" +289, 12, 47, 358, 200, 208, 1652, 1660, "patients" +289, 12, 48, 359, 209, 218, 1661, 1670, "achieving" +289, 12, 49, 360, 219, 222, 1671, 1674, "the" +289, 12, 50, 361, 223, 228, 1675, 1680, "HbA1c" +289, 12, 51, 362, 229, 235, 1681, 1687, "target" +289, 12, 52, 363, 236, 237, 1688, 1689, "<" +289, 12, 53, 364, 238, 239, 1690, 1691, "7" +289, 12, 54, 365, 240, 241, 1692, 1693, "%" +289, 12, 55, 366, 242, 243, 1694, 1695, "(" +289, 12, 56, 367, 244, 246, 1696, 1698, "38" +289, 12, 57, 368, 247, 248, 1699, 1700, "." +289, 12, 58, 369, 249, 250, 1701, 1702, "6" +289, 12, 59, 370, 251, 252, 1703, 1704, "%" +289, 12, 60, 371, 253, 255, 1705, 1707, "vs" +289, 12, 61, 372, 256, 257, 1708, 1709, "." +289, 12, 62, 373, 258, 260, 1710, 1712, "13" +289, 12, 63, 374, 261, 262, 1713, 1714, "." +289, 12, 64, 375, 263, 264, 1715, 1716, "9" +289, 12, 65, 376, 265, 266, 1717, 1718, "%" +289, 12, 66, 377, 267, 268, 1719, 1720, ";" +289, 12, 67, 378, 269, 270, 1721, 1722, "p" +289, 12, 68, 379, 271, 274, 1723, 1726, " = " +289, 12, 69, 380, 275, 276, 1727, 1728, "0" +289, 12, 70, 381, 277, 278, 1729, 1730, "." +289, 12, 71, 382, 279, 282, 1731, 1734, "014" +289, 12, 72, 383, 283, 284, 1735, 1736, ")" +289, 12, 73, 384, 285, 286, 1737, 1738, "." +289, 13, 1, 385, 0, 12, 1739, 1751, "Vildagliptin" +289, 13, 2, 386, 13, 16, 1752, 1755, "was" +289, 13, 3, 387, 17, 21, 1756, 1760, "well" +289, 13, 4, 388, 22, 31, 1761, 1770, "tolerated" +289, 13, 5, 389, 32, 36, 1771, 1775, "with" +289, 13, 6, 390, 37, 40, 1776, 1779, "low" +289, 13, 7, 391, 41, 50, 1780, 1789, "incidence" +289, 13, 8, 392, 51, 53, 1790, 1792, "of" +289, 13, 9, 393, 54, 67, 1793, 1806, "hypoglycaemia" +289, 13, 10, 394, 68, 69, 1807, 1808, "," +289, 13, 11, 395, 70, 78, 1809, 1817, "slightly" +289, 13, 12, 396, 79, 85, 1818, 1824, "higher" +289, 13, 13, 397, 86, 90, 1825, 1829, "than" +289, 13, 14, 398, 91, 95, 1830, 1834, "with" +289, 13, 15, 399, 96, 103, 1835, 1842, "placebo" +289, 13, 16, 400, 104, 105, 1843, 1844, "(" +289, 13, 17, 401, 106, 107, 1845, 1846, "5" +289, 13, 18, 402, 108, 109, 1847, 1848, "." +289, 13, 19, 403, 110, 111, 1849, 1850, "1" +289, 13, 20, 404, 112, 113, 1851, 1852, "%" +289, 13, 21, 405, 114, 116, 1853, 1855, "vs" +289, 13, 22, 406, 117, 118, 1856, 1857, "." +289, 13, 23, 407, 119, 120, 1858, 1859, "1" +289, 13, 24, 408, 121, 122, 1860, 1861, "." +289, 13, 25, 409, 123, 124, 1862, 1863, "9" +289, 13, 26, 410, 125, 126, 1864, 1865, "%" +289, 13, 27, 411, 127, 128, 1866, 1867, ")" +289, 13, 28, 412, 129, 132, 1868, 1871, "and" +289, 13, 29, 413, 133, 135, 1872, 1874, "no" +289, 13, 30, 414, 136, 146, 1875, 1885, "clinically" +289, 13, 31, 415, 147, 155, 1886, 1894, "relevant" +289, 13, 32, 416, 156, 162, 1895, 1901, "weight" +289, 13, 33, 417, 163, 167, 1902, 1906, "gain" +289, 13, 34, 418, 168, 169, 1907, 1908, "." +289, 14, 1, 419, 0, 11, 1909, 1920, "CONCLUSIONS" +289, 14, 2, 420, 12, 13, 1921, 1922, ":" +289, 14, 3, 421, 14, 26, 1923, 1935, "Vildagliptin" +289, 14, 4, 422, 27, 40, 1936, 1949, "significantly" +289, 14, 5, 423, 41, 49, 1950, 1958, "improved" +289, 14, 6, 424, 50, 59, 1959, 1968, "glycaemic" +289, 14, 7, 425, 60, 67, 1969, 1976, "control" +289, 14, 8, 426, 68, 70, 1977, 1979, "in" +289, 14, 9, 427, 71, 79, 1980, 1988, "patients" +289, 14, 10, 428, 80, 84, 1989, 1993, "with" +289, 14, 11, 429, 85, 89, 1994, 1998, "T2DM" +289, 14, 12, 430, 90, 102, 1999, 2011, "inadequately" +289, 14, 13, 431, 103, 113, 2012, 2022, "controlled" +289, 14, 14, 432, 114, 118, 2023, 2027, "with" +289, 14, 15, 433, 119, 128, 2028, 2037, "metformin" +289, 14, 16, 434, 129, 133, 2038, 2042, "plus" +289, 14, 17, 435, 134, 145, 2043, 2054, "glimepiride" +289, 14, 18, 436, 146, 157, 2055, 2066, "combination" +289, 14, 19, 437, 158, 159, 2067, 2068, "." +289, 15, 1, 438, 0, 3, 2069, 2072, "The" +289, 15, 2, 439, 4, 12, 2073, 2081, "addition" +289, 15, 3, 440, 13, 15, 2082, 2084, "of" +289, 15, 4, 441, 16, 28, 2085, 2097, "vildagliptin" +289, 15, 5, 442, 29, 32, 2098, 2101, "was" +289, 15, 6, 443, 33, 37, 2102, 2106, "well" +289, 15, 7, 444, 38, 47, 2107, 2116, "tolerated" +289, 15, 8, 445, 48, 52, 2117, 2121, "with" +289, 15, 9, 446, 53, 56, 2122, 2125, "low" +289, 15, 10, 447, 57, 61, 2126, 2130, "risk" +289, 15, 11, 448, 62, 64, 2131, 2133, "of" +289, 15, 12, 449, 65, 78, 2134, 2147, "hypoglycaemia" +289, 15, 13, 450, 79, 82, 2148, 2151, "and" +289, 15, 14, 451, 83, 89, 2152, 2158, "weight" +289, 15, 15, 452, 90, 94, 2159, 2163, "gain" +289, 15, 16, 453, 95, 96, 2164, 2165, "." +289, 16, 1, 454, 0, 4, 2166, 2170, "This" +289, 16, 2, 455, 5, 10, 2171, 2176, "makes" +289, 16, 3, 456, 11, 23, 2177, 2189, "vildagliptin" +289, 16, 4, 457, 24, 26, 2190, 2192, "an" +289, 16, 5, 458, 27, 37, 2193, 2203, "attractive" +289, 16, 6, 459, 38, 47, 2204, 2213, "treatment" +289, 16, 7, 460, 48, 54, 2214, 2220, "option" +289, 16, 8, 461, 55, 58, 2221, 2224, "for" +289, 16, 9, 462, 59, 67, 2225, 2233, "patients" +289, 16, 10, 463, 68, 75, 2234, 2241, "failing" +289, 16, 11, 464, 76, 78, 2242, 2244, "on" +289, 16, 12, 465, 79, 88, 2245, 2254, "metformin" +289, 16, 13, 466, 89, 93, 2255, 2259, "plus" +289, 16, 14, 467, 94, 96, 2260, 2262, "SU" +289, 16, 15, 468, 97, 109, 2263, 2275, "particularly" +289, 16, 16, 469, 110, 112, 2276, 2278, "in" +289, 16, 17, 470, 113, 121, 2279, 2287, "patients" +289, 16, 18, 471, 122, 126, 2288, 2292, "with" +289, 16, 19, 472, 127, 135, 2293, 2301, "baseline" +289, 16, 20, 473, 136, 141, 2302, 2307, "HbA1c" +289, 16, 21, 474, 142, 143, 2308, 2309, "≤" +289, 16, 22, 475, 144, 145, 2310, 2311, "8" +289, 16, 23, 476, 146, 147, 2312, 2313, "%" +289, 16, 24, 477, 148, 149, 2314, 2315, "." +289, 17, 1, 478, 0, 1, 2316, 2317, "©" +289, 17, 2, 479, 2, 6, 2318, 2322, "2013" +289, 17, 3, 480, 7, 10, 2323, 2326, "The" +289, 17, 4, 481, 11, 18, 2327, 2334, "Authors" +289, 17, 5, 482, 19, 20, 2335, 2336, "." +289, 18, 1, 483, 0, 8, 2337, 2345, "Diabetes" +289, 18, 2, 484, 9, 10, 2346, 2347, "," +289, 18, 3, 485, 11, 18, 2348, 2355, "Obesity" +289, 18, 4, 486, 19, 22, 2356, 2359, "and" +289, 18, 5, 487, 23, 33, 2360, 2370, "Metabolism" +289, 18, 6, 488, 34, 43, 2371, 2380, "published" +289, 18, 7, 489, 44, 46, 2381, 2383, "by" +289, 18, 8, 490, 47, 51, 2384, 2388, "John" +289, 18, 9, 491, 52, 57, 2389, 2394, "Wiley" +289, 18, 10, 492, 58, 59, 2395, 2396, "&" +289, 18, 11, 493, 60, 64, 2397, 2401, "Sons" +289, 18, 12, 494, 65, 68, 2402, 2405, "Ltd" +289, 18, 13, 495, 69, 70, 2406, 2407, "." +289, 18, 14, 496, 71, 74, 2408, 2411, "DOI" +289, 18, 15, 497, 75, 76, 2412, 2413, ":" +289, 18, 16, 498, 77, 79, 2414, 2416, "10" +289, 18, 17, 499, 80, 81, 2417, 2418, "." +289, 18, 18, 500, 82, 86, 2419, 2423, "1111" +289, 18, 19, 501, 87, 88, 2424, 2425, "/" +289, 18, 20, 502, 89, 92, 2426, 2429, "dom" +289, 18, 21, 503, 93, 94, 2430, 2431, "." +289, 18, 22, 504, 95, 100, 2432, 2437, "12229" +289, 18, 23, 505, 101, 106, 2438, 2443, "PMCID" +289, 18, 24, 506, 107, 108, 2444, 2445, ":" +289, 18, 25, 507, 109, 119, 2446, 2456, "PMC4237555" +289, 18, 26, 508, 120, 124, 2457, 2461, "PMID" +289, 18, 27, 509, 125, 126, 2462, 2463, ":" +289, 18, 28, 510, 127, 135, 2464, 2472, "24199686" +289, 18, 29, 511, 136, 137, 2473, 2474, "[" +289, 18, 30, 512, 138, 145, 2475, 2482, "Indexed" +289, 18, 31, 513, 146, 149, 2483, 2486, "for" +289, 18, 32, 514, 150, 157, 2487, 2494, "MEDLINE" +289, 18, 33, 515, 158, 159, 2495, 2496, "]" diff --git a/data/dm2 24199686_kwoodley.annodb b/data/dm2 24199686_kwoodley.annodb new file mode 100644 index 0000000..018a24c --- /dev/null +++ b/data/dm2 24199686_kwoodley.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46544, Journal, 0, 19, "Diabetes Obes Metab", "", +46545, PublicationYear, 22, 26, "2014", "", +46567, Title, 104, 260, "Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea .", "", +46546, Vildagliptin, 127, 139, "vildagliptin", "", +46566, Precondition, 143, 258, "patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea", "", +46557, Type2Diabetes, 157, 181, "type 2 diabetes mellitus", "", +46561, Metformin, 231, 240, "metformin", "", +46565, Sulfonylureas, 245, 258, "sulphonylurea", "", +46568, Author, 261, 274, "Lukashevich V", "", +46569, Author, 283, 294, "Del Prato S", "", +46570, Author, 297, 304, "Araga M", "", +46571, Author, 307, 315, "Kothny W", "", +46572, USA, 404, 407, "USA", "", +46562, Metformin, 448, 457, "metformin", "", +46573, Sulfonylureas, 462, 475, "sulphonylurea", "", +46574, Sulfonylureas, 478, 480, "SU", "", +46578, ObjectiveDescription, 533, 744, "This study assessed the efficacy and safety of vildagliptin as add - on therapy to metformin plus glimepiride combination in patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control .", "", +46547, Vildagliptin, 580, 592, "vildagliptin", "", +46563, Metformin, 616, 625, "metformin", "", +46575, Glimepiride, 631, 642, "glimepiride", "", +46577, Precondition, 658, 742, "patients with type 2 diabetes mellitus ( T2DM ) who had inadequate glycaemic control", "", +46558, Type2Diabetes, 672, 696, "type 2 diabetes mellitus", "", +46559, Type2Diabetes, 699, 703, "T2DM", "", +46579, Multicenter, 757, 768, "multicentre", "", +46580, DoubleBlind, 771, 785, "double - blind", "", +46581, Placebo, 788, 795, "placebo", "", +46585, Randomized, 815, 825, "randomized", "", +46548, Vildagliptin, 861, 873, "vildagliptin", "", +46586, DoseValue, 874, 876, "50", "", +46587, mg, 879, 881, "mg", "", +46588, Frequency, 882, 885, "bid", "", +46589, NumberPatientsArm, 894, 897, "158", "", +46591, Placebo, 903, 910, "placebo", "", +46590, NumberPatientsArm, 919, 922, "160", "", +46592, Duration, 929, 939, "24   weeks", "", +46593, TimePoint, 958, 968, "24   weeks", "", +46594, HbA1c, 999, 1014, "haemoglobin A1c", "", +46595, HbA1c, 1017, 1022, "HbA1c", "", +46596, Reduction, 1031, 1037, "1 . 01", "", +46598, Percentage, 1038, 1039, "%", "", +46549, Vildagliptin, 1045, 1057, "vildagliptin", "", +46604, BaseLineValue, 1069, 1075, "8 . 75", "", +46600, Percentage, 1076, 1077, "%", "", +46597, Reduction, 1086, 1092, "0 . 25", "", +46601, Percentage, 1093, 1094, "%", "", +46582, Placebo, 1100, 1107, "placebo", "", +46605, BaseLineValue, 1119, 1125, "8 . 80", "", +46602, Percentage, 1126, 1127, "%", "", +46606, DiffGroupAbsValue, 1173, 1181, "- 0 . 76", "", +46603, Percentage, 1182, 1183, "%", "", +46607, PvalueDiff, 1186, 1199, "p  <  0 . 001", "", +46550, Vildagliptin, 1235, 1247, "vildagliptin", "", +46608, HbA1c, 1261, 1279, "HbA1c target < 7 %", "", +46609, PercentageAffected, 1282, 1288, "28 . 3", "", +46610, PercentageAffected, 1296, 1301, "5 . 6", "", +46611, PvalueDiff, 1306, 1319, "p  <  0 . 001", "", +46612, FastingPlasmaGlucose, 1342, 1364, "fasting plasma glucose", "", +46551, Vildagliptin, 1383, 1395, "vildagliptin", "", +46583, Placebo, 1400, 1407, "placebo", "", +46613, DiffGroupAbsValue, 1412, 1420, "- 1 . 13", "", +46614, Millimoles_per_litre, 1423, 1431, "mmol / l", "", +46615, PvalueDiff, 1434, 1447, "p  <  0 . 001", "", +46616, SubGroupDescription, 1452, 1501, "In subgroup of patients with baseline HbA1c ≤ 8 %", "", +46617, HbA1c, 1490, 1495, "HbA1c", "", +46552, Vildagliptin, 1504, 1516, "vildagliptin", "", +46618, HbA1c, 1525, 1530, "HbA1c", "", +46619, Reduction, 1534, 1540, "0 . 74", "", +46621, Percentage, 1541, 1542, "%", "", +46620, BaseLineValue, 1557, 1563, "7 . 82", "", +46622, Percentage, 1564, 1565, "%", "", +46624, DiffGroupAbsValue, 1601, 1609, "- 0 . 97", "", +46623, Percentage, 1610, 1611, "%", "", +46625, PvalueDiff, 1614, 1625, "p < 0 . 001", "", +46626, HbA1c, 1675, 1693, "HbA1c target < 7 %", "subgroup", +46628, PercentageAffected, 1696, 1702, "38 . 6", "subgroup", +46629, PercentageAffected, 1710, 1716, "13 . 9", "subgroup", +46630, PvalueDiff, 1721, 1734, "p  =  0 . 014", "subgroup", +46553, Vildagliptin, 1739, 1751, "Vildagliptin", "", +46631, Hypoglycemia, 1793, 1806, "hypoglycaemia", "", +46584, Placebo, 1835, 1842, "placebo", "", +46633, PercentageAffected, 1845, 1850, "5 . 1", "", +46634, PercentageAffected, 1858, 1863, "1 . 9", "", +46636, ObservedResult, 1872, 1906, "no clinically relevant weight gain", "", +46635, BodyWeight, 1895, 1901, "weight", "", +46645, ConclusionComment, 1923, 2068, "Vildagliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin plus glimepiride combination .", "", +46554, Vildagliptin, 1923, 1935, "Vildagliptin", "", +46560, Type2Diabetes, 1994, 1998, "T2DM", "", +46564, Metformin, 2028, 2037, "metformin", "", +46576, Glimepiride, 2043, 2054, "glimepiride", "", +46646, ConclusionComment, 2069, 2165, "The addition of vildagliptin was well tolerated with low risk of hypoglycaemia and weight gain .", "", +46555, Vildagliptin, 2085, 2097, "vildagliptin", "", +46638, Hypoglycemia, 2134, 2147, "hypoglycaemia", "", +46639, BodyWeight, 2152, 2158, "weight", "", +46647, ConclusionComment, 2166, 2315, "This makes vildagliptin an attractive treatment option for patients failing on metformin plus SU particularly in patients with baseline HbA1c ≤ 8 % .", "", +46556, Vildagliptin, 2177, 2189, "vildagliptin", "", +46640, Metformin, 2245, 2254, "metformin", "", +46641, Sulfonylureas, 2260, 2262, "SU", "", +46644, Precondition, 2279, 2313, "patients with baseline HbA1c ≤ 8 %", "", +46642, HbA1c, 2302, 2307, "HbA1c", "", +46643, Percentage, 2312, 2313, "%", "", +46648, PMID, 2464, 2472, "24199686", "", diff --git a/data/dm2 24199686_kwoodley.n-triples b/data/dm2 24199686_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24199686_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24205943_admin.annodb b/data/dm2 24205943_admin.annodb new file mode 100644 index 0000000..a1d87e3 --- /dev/null +++ b/data/dm2 24205943_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2014", "", " \"2014\"." +23, Title, 105, 298, "A randomized controlled trial of the efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea .", "", " \"A randomized controlled trial of the efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea .\"." +2, Randomized, 107, 117, "randomized", "", " ." +3, Saxagliptin, 165, 176, "saxagliptin", "", +22, Precondition, 200, 296, "patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea", "", " \"patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea\"." +13, Type2Diabetes, 214, 229, "type 2 diabetes", "", " ." +15, Metformin, 266, 275, "metformin", "", +19, Sulfonylureas, 283, 296, "sulphonylurea", "", +24, Author, 299, 307, "Moses RG", "", " \"Moses RG\"." +25, Author, 316, 323, "Kalra S", "", " \"Kalra S\"." +26, Author, 326, 333, "Brook D", "", " \"Brook D\"." +27, Author, 336, 345, "Sockler J", "", " \"Sockler J\"." +28, Author, 348, 356, "Monyak J", "", " \"Monyak J\"." +29, Author, 359, 372, "Visvanathan J", "", " \"Visvanathan J\"." +30, Author, 375, 386, "Montanaro M", "", " \"Montanaro M\"." +31, Author, 389, 398, "Fisher SA", "", " \"Fisher SA\"." +32, Australia, 516, 525, "Australia", "", +35, ObjectiveDescription, 535, 706, "To evaluate the efficacy and safety of saxagliptin as add - on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea .", "", " \"To evaluate the efficacy and safety of saxagliptin as add - on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea .\"." +4, Saxagliptin, 574, 585, "saxagliptin", "", +34, Precondition, 609, 704, "adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea", "", +14, Type2Diabetes, 621, 636, "type 2 diabetes", "", +16, Metformin, 674, 683, "metformin", "", +33, Sulfonylureas, 691, 704, "sulphonylurea", "", +36, Duration, 725, 734, "24 - week", "", " \"24 - week\"." +37, Multicenter, 737, 748, "multicentre", "", " ." +38, Randomized, 751, 761, "randomized", "", +39, Parallel, 764, 780, "parallel - group", "", " ." +40, DoubleBlind, 783, 797, "double - blind", "", " ." +45, Precondition, 806, 927, "outpatients aged ≥ 18   years with type 2 diabetes , body mass index ≤ 40   kg / m ( 2 ) and inadequate glycaemic control", "", " \"outpatients aged ≥ 18   years with type 2 diabetes , body mass index ≤ 40   kg / m ( 2 ) and inadequate glycaemic control\"." +41, MinAge, 825, 827, "18", "", " \"18\"." +42, Type2Diabetes, 841, 856, "type 2 diabetes", "", +43, BMI, 859, 874, "body mass index", "", +44, Kg_per_squareMeter, 882, 894, "kg / m ( 2 )", "", +5, Saxagliptin, 939, 950, "saxagliptin", "", " ." +46, DoseValue, 951, 952, "5", "", " \"5\"." +47, mg, 955, 957, "mg", "", " ." +48, Placebo, 961, 968, "placebo", "", " ." +55, Frequency, 969, 981, "once - daily", "", " \"once - daily\". \"once - daily\"." +17, Metformin, 1062, 1071, "metformin", "", +20, Sulfonylureas, 1079, 1092, "sulphonylurea", "", +56, HbA1c, 1131, 1151, "glycated haemoglobin", "", +57, HbA1c, 1154, 1159, "HbA1c", "", +59, TimePoint, 1167, 1175, "baseline", "", +60, TimePoint, 1179, 1186, "week 24", "", +61, EndPointDescription, 1234, 1248, "adverse events", "", +62, EndPointDescription, 1251, 1254, "AEs", "", +64, Hypoglycemia, 1259, 1272, "hypoglycaemia", "", +67, BodyWeight, 1277, 1288, "body weight", "", +69, NumberPatientsCT, 1312, 1315, "257", "", " \"257\"." +70, Randomized, 1330, 1340, "randomized", "", +6, Saxagliptin, 1389, 1400, "saxagliptin", "", +71, NumberPatientsArm, 1409, 1412, "129", "", " \"129\"." +49, Placebo, 1415, 1422, "placebo", "", +72, NumberPatientsArm, 1431, 1434, "128", "", " \"128\"." +75, FinalNumPatientsCT, 1439, 1442, "255", "", " \"255\"." +7, Saxagliptin, 1484, 1495, "saxagliptin", "", +73, FinalNumPatientsArm, 1504, 1507, "127", "", " \"127\"." +50, Placebo, 1510, 1517, "placebo", "", +74, FinalNumPatientsArm, 1526, 1529, "128", "", " \"128\"." +58, HbA1c, 1534, 1539, "HbA1c", "", " ." +8, Saxagliptin, 1567, 1578, "saxagliptin", "", +51, Placebo, 1586, 1593, "placebo", "", +163, Mean, 1635, 1639, "mean", "", " . ." +164, TimePoint, 1652, 1660, "baseline", "", +76, DiffGroupAbsValue, 1663, 1671, "- 0 . 66", "", " \"- 0 . 66\"." +77, Percentage, 1672, 1673, "%", "", " ." +78, ConfIntervalDiff, 1676, 1770, "95 % confidence interval ( CI ) , - 0 . 86 to - 0 . 47 ( 7   mmol / mol , - 9 . 4 to - 5 . 1 )", "", " \"95 % confidence interval ( CI ) , - 0 . 86 to - 0 . 47 ( 7   mmol / mol , - 9 . 4 to - 5 . 1 )\"." +79851, Millimoles_per_mole, 1737, 1747, "mmol / mol", "", +80, PvalueDiff, 1773, 1787, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +174, EndPointDescription, 1824, 1830, "≥ 1 AE", "", " . ." +81, PercentageAffected, 1835, 1841, "62 . 8", "", " \"62 . 8\"." +9, Saxagliptin, 1849, 1860, "saxagliptin", "", +82, PercentageAffected, 1865, 1871, "71 . 7", "", " \"71 . 7\"." +52, Placebo, 1879, 1886, "placebo", "", +10, Saxagliptin, 1896, 1907, "saxagliptin", "", +53, Placebo, 1912, 1919, "placebo", "", +65, Hypoglycemia, 1947, 1960, "hypoglycaemia", "", " ." +184, PercentageAffected, 1966, 1972, "10 . 1", "", " \"10 . 1\"." +89, PercentageAffected, 1977, 1982, "6 . 3", "", " \"6 . 3\"." +66, Hypoglycemia, 2025, 2038, "hypoglycaemia", "", " ." +188, BloodGlucose, 2054, 2061, "glucose", "", +86, Millimoles_per_litre, 2074, 2082, "mmol / l", "", +190, PercentageAffected, 2090, 2095, "1 . 6", "", " \"1 . 6\"." +90, PercentageAffected, 2100, 2101, "0", "", +193, Mean, 2106, 2110, "Mean", "", " . ." +68, BodyWeight, 2121, 2132, "body weight", "", " ." +91, Increment, 2137, 2142, "0 . 2", "", " \"0 . 2\"." +93, Kg, 2145, 2147, "kg", "", " ." +11, Saxagliptin, 2152, 2163, "saxagliptin", "", +92, Reduction, 2170, 2175, "0 . 6", "", " \"0 . 6\"." +94, Kg, 2178, 2180, "kg", "", +54, Placebo, 2185, 2192, "placebo", "", +95, PvalueDiff, 2195, 2209, "p  =  0 . 0272", "", " \"p  =  0 . 0272\"." +100, ConclusionComment, 2227, 2394, "Addition of saxagliptin 5   mg / day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated .", "", " \"Addition of saxagliptin 5   mg / day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated .\"." +12, Saxagliptin, 2239, 2250, "saxagliptin", "", +96, DoseValue, 2251, 2252, "5", "", +97, mg, 2255, 2257, "mg", "", +98, Frequency, 2260, 2263, "day", "", +18, Metformin, 2303, 2312, "metformin", "", +21, Sulfonylureas, 2317, 2330, "sulphonylurea", "", +101, PMID, 2463, 2471, "24205943", "", " \"24205943\"." diff --git a/data/dm2 24205943_admin.n-triples b/data/dm2 24205943_admin.n-triples new file mode 100644 index 0000000..5b857b6 --- /dev/null +++ b/data/dm2 24205943_admin.n-triples @@ -0,0 +1,176 @@ +# RDF export of group: Publication + . + "Publication 51250" . + "A randomized controlled trial of the efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea ." . + "Moses RG" . + "2014" . + "Diabetes Obes Metab ." . + "24205943" . + . + "Kalra S" . + "Brook D" . + "Sockler J" . + "Monyak J" . + "Visvanathan J" . + "Montanaro M" . + "Fisher SA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 51257" . + "To evaluate the efficacy and safety of saxagliptin as add - on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea ." . + "257" . + "24 - week" . + . + . + . + "Addition of saxagliptin 5   mg / day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated ." . + . + . + . + . + . + "255" . + . + . + . + . + . +# RDF export of group: Population + . + "Population 51273" . + "patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea" . + . + . + "18" . + . + "outpatients aged ≥ 18   years with type 2 diabetes , body mass index ≤ 40   kg / m ( 2 ) and inadequate glycaemic control" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "hypc" . + . + . + . + . + . + "bw" . + . + . + . + . + . +# RDF export of group: Arm + . + "sax" . + "129" . + "127" . + . + . + . + . + . + . + . + "pla" . + "128" . + "128" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sax" . + . + "once - daily" . + . + . + "pla" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "sax" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . + . + "ae 1" . + . + "62 . 8" . + . + "ae 2" . + . + "71 . 7" . + . + "hyp 1" . + . + "10 . 1" . + . + "hyp 2" . + . + "6 . 3" . + . + "hypc 1" . + . + "1 . 6" . + . + "hypc 2" . + . + . + "bw 1" . + . + "0 . 2" . + . + "bw 2" . + . + "0 . 6" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 66" . + "p  <  0 . 0001" . + "95 % confidence interval ( CI ) , - 0 . 86 to - 0 . 47 ( 7   mmol / mol , - 9 . 4 to - 5 . 1 )" . + . + . + . + "bw" . + "p  =  0 . 0272" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24205943_akramersunderbrink.annodb b/data/dm2 24205943_akramersunderbrink.annodb new file mode 100644 index 0000000..c05c906 --- /dev/null +++ b/data/dm2 24205943_akramersunderbrink.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +58962, Journal, 0, 19, "Diabetes Obes Metab", "", +58963, PublicationYear, 22, 26, "2014", "", +58970, Title, 105, 298, "A randomized controlled trial of the efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea .", "", +58964, Randomized, 107, 117, "randomized", "", +58965, Saxagliptin, 165, 176, "saxagliptin", "", +58966, Type2Diabetes, 214, 229, "type 2 diabetes", "", +58967, Precondition, 234, 296, "inadequate glycaemic control on metformin plus a sulphonylurea", "", +58968, Metformin, 266, 275, "metformin", "", +58969, Sulfonylureas, 283, 296, "sulphonylurea", "", +58971, Author, 299, 307, "Moses RG", "", +58972, Author, 316, 323, "Kalra S", "", +58973, Author, 326, 333, "Brook D", "", +58974, Author, 336, 345, "Sockler J", "", +58975, Author, 348, 356, "Monyak J", "", +58976, Author, 359, 372, "Visvanathan J", "", +58977, Author, 375, 386, "Montanaro M", "", +58978, Author, 389, 398, "Fisher SA", "", +58979, Australia, 516, 525, "Australia", "", +58985, ObjectiveDescription, 535, 706, "To evaluate the efficacy and safety of saxagliptin as add - on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea .", "", +58980, Saxagliptin, 574, 585, "saxagliptin", "", +58981, Type2Diabetes, 621, 636, "type 2 diabetes", "", +58982, Precondition, 642, 704, "inadequate glycaemic control on metformin plus a sulphonylurea", "", +58983, Metformin, 674, 683, "metformin", "", +58984, Sulfonylureas, 691, 704, "sulphonylurea", "", +58986, Duration, 725, 734, "24 - week", "", +58987, Multicenter, 737, 748, "multicentre", "", +58988, Randomized, 751, 761, "randomized", "", +58989, Parallel, 764, 780, "parallel - group", "", +58990, DoubleBlind, 783, 797, "double - blind", "", +58991, MinAge, 825, 827, "18", "", +58992, Type2Diabetes, 841, 856, "type 2 diabetes", "", +58993, BMI, 859, 874, "body mass index", "", +58995, Precondition, 859, 894, "body mass index ≤ 40   kg / m ( 2 )", "", +58994, Kg_per_squareMeter, 882, 894, "kg / m ( 2 )", "", +58996, Precondition, 899, 927, "inadequate glycaemic control", "", +58997, Saxagliptin, 939, 950, "saxagliptin", "", +58998, DoseValue, 951, 957, "5   mg", "", +58999, Placebo, 961, 968, "placebo", "", +59000, Frequency, 969, 981, "once - daily", "", +59001, Metformin, 1062, 1071, "metformin", "", +59002, Sulfonylureas, 1079, 1092, "sulphonylurea", "", +59003, HbA1c, 1131, 1151, "glycated haemoglobin", "", +59004, HbA1c, 1154, 1159, "HbA1c", "", +59005, TimePoint, 1167, 1175, "baseline", "", +59006, TimePoint, 1179, 1186, "week 24", "", +59037, EndPointDescription, 1234, 1248, "adverse events", "", +59038, EndPointDescription, 1251, 1254, "AEs", "", +59007, Hypoglycemia, 1259, 1272, "hypoglycaemia", "", +59008, BodyWeight, 1277, 1288, "body weight", "", +59009, NumberPatientsCT, 1312, 1315, "257", "", +59010, Randomized, 1330, 1340, "randomized", "", +59011, Saxagliptin, 1389, 1400, "saxagliptin", "", +59012, NumberPatientsArm, 1409, 1412, "129", "", +59014, Placebo, 1415, 1422, "placebo", "", +59013, NumberPatientsArm, 1431, 1434, "128", "", +59015, FinalNumPatientsCT, 1439, 1442, "255", "", +59016, Saxagliptin, 1484, 1495, "saxagliptin", "", +59018, FinalNumPatientsArm, 1504, 1507, "127", "", +59017, Placebo, 1510, 1517, "placebo", "", +59019, FinalNumPatientsArm, 1526, 1529, "128", "", +59020, HbA1c, 1534, 1539, "HbA1c", "", +59021, Saxagliptin, 1567, 1578, "saxagliptin", "", +59022, Placebo, 1586, 1593, "placebo", "", +59030, EndPointDescription, 1596, 1660, "between - group difference in adjusted mean change from baseline", "", +59023, Mean, 1635, 1639, "mean", "", +59024, TimePoint, 1652, 1660, "baseline", "", +59026, DiffGroupAbsValue, 1663, 1671, "- 0 . 66", "", +59033, Percentage, 1672, 1673, "%", "", +59028, ConfIntervalDiff, 1676, 1770, "95 % confidence interval ( CI ) , - 0 . 86 to - 0 . 47 ( 7   mmol / mol , - 9 . 4 to - 5 . 1 )", "", +59032, Percentage, 1679, 1680, "%", "", +59031, ConcentrationUnit, 1737, 1747, "mmol / mol", "", +59029, PvalueDiff, 1773, 1787, "p  <  0 . 0001", "", +59036, EndPointDescription, 1824, 1830, "≥ 1 AE", "", +59039, PercentageAffected, 1835, 1841, "62 . 8", "", +59034, Percentage, 1842, 1843, "%", "", +59041, Saxagliptin, 1849, 1860, "saxagliptin", "", +59040, PercentageAffected, 1865, 1871, "71 . 7", "", +59035, Percentage, 1872, 1873, "%", "", +59042, Placebo, 1879, 1886, "placebo", "", +59043, Saxagliptin, 1896, 1907, "saxagliptin", "", +59044, Placebo, 1912, 1919, "placebo", "", +59045, Hypoglycemia, 1947, 1960, "hypoglycaemia", "", +59046, PercentageAffected, 1966, 1972, "10 . 1", "", +59047, PercentageAffected, 1977, 1982, "6 . 3", "", +59048, Percentage, 1983, 1984, "%", "", +59049, Hypoglycemia, 2015, 2084, "confirmed hypoglycaemia ( symptoms  +  glucose  <  2 . 8   mmol / l )", "", +59050, BloodGlucose, 2054, 2061, "glucose", "", +59051, Millimoles_per_litre, 2074, 2084, "mmol / l )", "", +59052, PercentageAffected, 2090, 2095, "1 . 6", "", +59053, PercentageAffected, 2100, 2101, "0", "", +59054, Percentage, 2102, 2103, "%", "", +59055, Mean, 2106, 2110, "Mean", "", +59056, BodyWeight, 2121, 2132, "body weight", "", +59057, ChangeValue, 2137, 2142, "0 . 2", "", +59059, Kg, 2145, 2147, "kg", "", +59061, Saxagliptin, 2152, 2163, "saxagliptin", "", +59058, ChangeValue, 2168, 2175, "- 0 . 6", "", +59060, Kg, 2178, 2180, "kg", "", +59062, Placebo, 2185, 2192, "placebo", "", +59063, PvalueDiff, 2195, 2209, "p  =  0 . 0272", "", +59070, ConclusionComment, 2227, 2394, "Addition of saxagliptin 5   mg / day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated .", "", +59064, Saxagliptin, 2239, 2250, "saxagliptin", "", +59068, DoseValue, 2251, 2263, "5   mg / day", "", +59069, BioAndMedicalUnit, 2255, 2263, "mg / day", "", +59065, Precondition, 2276, 2330, "inadequately controlled on metformin and sulphonylurea", "", +59066, Metformin, 2303, 2312, "metformin", "", +59067, Sulfonylureas, 2317, 2330, "sulphonylurea", "", +59071, PMID, 2463, 2471, "24205943", "", diff --git a/data/dm2 24205943_akramersunderbrink.n-triples b/data/dm2 24205943_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24205943_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24205943_export.csv b/data/dm2 24205943_export.csv new file mode 100644 index 0000000..6e31d81 --- /dev/null +++ b/data/dm2 24205943_export.csv @@ -0,0 +1,526 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +288, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +288, 1, 2, 2, 9, 13, 9, 13, "Obes" +288, 1, 3, 3, 14, 19, 14, 19, "Metab" +288, 1, 4, 4, 20, 21, 20, 21, "." +288, 2, 1, 5, 0, 4, 22, 26, "2014" +288, 2, 2, 6, 5, 8, 27, 30, "May" +288, 2, 3, 7, 9, 10, 31, 32, ";" +288, 2, 4, 8, 11, 13, 33, 35, "16" +288, 2, 5, 9, 14, 15, 36, 37, "(" +288, 2, 6, 10, 16, 17, 38, 39, "5" +288, 2, 7, 11, 18, 19, 40, 41, ")" +288, 2, 8, 12, 20, 21, 42, 43, ":" +288, 2, 9, 13, 22, 25, 44, 47, "443" +288, 2, 10, 14, 26, 27, 48, 49, "-" +288, 2, 11, 15, 28, 30, 50, 52, "50" +288, 2, 12, 16, 31, 32, 53, 54, "." +288, 2, 13, 17, 33, 36, 55, 58, "doi" +288, 2, 14, 18, 37, 38, 59, 60, ":" +288, 2, 15, 19, 39, 41, 61, 63, "10" +288, 2, 16, 20, 42, 43, 64, 65, "." +288, 2, 17, 21, 44, 48, 66, 70, "1111" +288, 2, 18, 22, 49, 50, 71, 72, "/" +288, 2, 19, 23, 51, 54, 73, 76, "dom" +288, 2, 20, 24, 55, 56, 77, 78, "." +288, 2, 21, 25, 57, 62, 79, 84, "12234" +288, 2, 22, 26, 63, 64, 85, 86, "." +288, 3, 1, 27, 0, 4, 87, 91, "Epub" +288, 3, 2, 28, 5, 9, 92, 96, "2013" +288, 3, 3, 29, 10, 13, 97, 100, "Dec" +288, 3, 4, 30, 14, 15, 101, 102, "8" +288, 3, 5, 31, 16, 17, 103, 104, "." +288, 4, 1, 32, 0, 1, 105, 106, "A" +288, 4, 2, 33, 2, 12, 107, 117, "randomized" +288, 4, 3, 34, 13, 23, 118, 128, "controlled" +288, 4, 4, 35, 24, 29, 129, 134, "trial" +288, 4, 5, 36, 30, 32, 135, 137, "of" +288, 4, 6, 37, 33, 36, 138, 141, "the" +288, 4, 7, 38, 37, 45, 142, 150, "efficacy" +288, 4, 8, 39, 46, 49, 151, 154, "and" +288, 4, 9, 40, 50, 56, 155, 161, "safety" +288, 4, 10, 41, 57, 59, 162, 164, "of" +288, 4, 11, 42, 60, 71, 165, 176, "saxagliptin" +288, 4, 12, 43, 72, 74, 177, 179, "as" +288, 4, 13, 44, 75, 78, 180, 183, "add" +288, 4, 14, 45, 79, 80, 184, 185, "-" +288, 4, 15, 46, 81, 83, 186, 188, "on" +288, 4, 16, 47, 84, 91, 189, 196, "therapy" +288, 4, 17, 48, 92, 94, 197, 199, "in" +288, 4, 18, 49, 95, 103, 200, 208, "patients" +288, 4, 19, 50, 104, 108, 209, 213, "with" +288, 4, 20, 51, 109, 113, 214, 218, "type" +288, 4, 21, 52, 114, 115, 219, 220, "2" +288, 4, 22, 53, 116, 124, 221, 229, "diabetes" +288, 4, 23, 54, 125, 128, 230, 233, "and" +288, 4, 24, 55, 129, 139, 234, 244, "inadequate" +288, 4, 25, 56, 140, 149, 245, 254, "glycaemic" +288, 4, 26, 57, 150, 157, 255, 262, "control" +288, 4, 27, 58, 158, 160, 263, 265, "on" +288, 4, 28, 59, 161, 170, 266, 275, "metformin" +288, 4, 29, 60, 171, 175, 276, 280, "plus" +288, 4, 30, 61, 176, 177, 281, 282, "a" +288, 4, 31, 62, 178, 191, 283, 296, "sulphonylurea" +288, 4, 32, 63, 192, 193, 297, 298, "." +288, 5, 1, 64, 0, 5, 299, 304, "Moses" +288, 5, 2, 65, 6, 8, 305, 307, "RG" +288, 5, 3, 66, 9, 10, 308, 309, "(" +288, 5, 4, 67, 11, 12, 310, 311, "1" +288, 5, 5, 68, 13, 14, 312, 313, ")" +288, 5, 6, 69, 15, 16, 314, 315, "," +288, 5, 7, 70, 17, 22, 316, 321, "Kalra" +288, 5, 8, 71, 23, 24, 322, 323, "S" +288, 5, 9, 72, 25, 26, 324, 325, "," +288, 5, 10, 73, 27, 32, 326, 331, "Brook" +288, 5, 11, 74, 33, 34, 332, 333, "D" +288, 5, 12, 75, 35, 36, 334, 335, "," +288, 5, 13, 76, 37, 44, 336, 343, "Sockler" +288, 5, 14, 77, 45, 46, 344, 345, "J" +288, 5, 15, 78, 47, 48, 346, 347, "," +288, 5, 16, 79, 49, 55, 348, 354, "Monyak" +288, 5, 17, 80, 56, 57, 355, 356, "J" +288, 5, 18, 81, 58, 59, 357, 358, "," +288, 5, 19, 82, 60, 71, 359, 370, "Visvanathan" +288, 5, 20, 83, 72, 73, 371, 372, "J" +288, 5, 21, 84, 74, 75, 373, 374, "," +288, 5, 22, 85, 76, 85, 375, 384, "Montanaro" +288, 5, 23, 86, 86, 87, 385, 386, "M" +288, 5, 24, 87, 88, 89, 387, 388, "," +288, 5, 25, 88, 90, 96, 389, 395, "Fisher" +288, 5, 26, 89, 97, 99, 396, 398, "SA" +288, 5, 27, 90, 100, 101, 399, 400, "." +288, 6, 1, 91, 0, 6, 401, 407, "Author" +288, 6, 2, 92, 7, 18, 408, 419, "information" +288, 6, 3, 93, 19, 20, 420, 421, ":" +288, 6, 4, 94, 21, 22, 422, 423, "(" +288, 6, 5, 95, 23, 24, 424, 425, "1" +288, 6, 6, 96, 25, 26, 426, 427, ")" +288, 6, 7, 97, 27, 37, 428, 438, "Wollongong" +288, 6, 8, 98, 38, 46, 439, 447, "Diabetes" +288, 6, 9, 99, 47, 54, 448, 455, "Service" +288, 6, 10, 100, 55, 56, 456, 457, "," +288, 6, 11, 101, 57, 66, 458, 467, "Illawarra" +288, 6, 12, 102, 67, 77, 468, 478, "Shoalhaven" +288, 6, 13, 103, 78, 83, 479, 484, "Local" +288, 6, 14, 104, 84, 90, 485, 491, "Health" +288, 6, 15, 105, 91, 99, 492, 500, "District" +288, 6, 16, 106, 100, 101, 501, 502, "," +288, 6, 17, 107, 102, 112, 503, 513, "Wollongong" +288, 6, 18, 108, 113, 114, 514, 515, "," +288, 6, 19, 109, 115, 124, 516, 525, "Australia" +288, 6, 20, 110, 125, 126, 526, 527, "." +288, 7, 1, 111, 0, 4, 528, 532, "AIMS" +288, 7, 2, 112, 5, 6, 533, 534, ":" +288, 7, 3, 113, 7, 9, 535, 537, "To" +288, 7, 4, 114, 10, 18, 538, 546, "evaluate" +288, 7, 5, 115, 19, 22, 547, 550, "the" +288, 7, 6, 116, 23, 31, 551, 559, "efficacy" +288, 7, 7, 117, 32, 35, 560, 563, "and" +288, 7, 8, 118, 36, 42, 564, 570, "safety" +288, 7, 9, 119, 43, 45, 571, 573, "of" +288, 7, 10, 120, 46, 57, 574, 585, "saxagliptin" +288, 7, 11, 121, 58, 60, 586, 588, "as" +288, 7, 12, 122, 61, 64, 589, 592, "add" +288, 7, 13, 123, 65, 66, 593, 594, "-" +288, 7, 14, 124, 67, 69, 595, 597, "on" +288, 7, 15, 125, 70, 77, 598, 605, "therapy" +288, 7, 16, 126, 78, 80, 606, 608, "in" +288, 7, 17, 127, 81, 87, 609, 615, "adults" +288, 7, 18, 128, 88, 92, 616, 620, "with" +288, 7, 19, 129, 93, 97, 621, 625, "type" +288, 7, 20, 130, 98, 99, 626, 627, "2" +288, 7, 21, 131, 100, 108, 628, 636, "diabetes" +288, 7, 22, 132, 109, 113, 637, 641, "with" +288, 7, 23, 133, 114, 124, 642, 652, "inadequate" +288, 7, 24, 134, 125, 134, 653, 662, "glycaemic" +288, 7, 25, 135, 135, 142, 663, 670, "control" +288, 7, 26, 136, 143, 145, 671, 673, "on" +288, 7, 27, 137, 146, 155, 674, 683, "metformin" +288, 7, 28, 138, 156, 160, 684, 688, "plus" +288, 7, 29, 139, 161, 162, 689, 690, "a" +288, 7, 30, 140, 163, 176, 691, 704, "sulphonylurea" +288, 7, 31, 141, 177, 178, 705, 706, "." +288, 8, 1, 142, 0, 7, 707, 714, "METHODS" +288, 8, 2, 143, 8, 9, 715, 716, ":" +288, 8, 3, 144, 10, 12, 717, 719, "In" +288, 8, 4, 145, 13, 17, 720, 724, "this" +288, 8, 5, 146, 18, 20, 725, 727, "24" +288, 8, 6, 147, 21, 22, 728, 729, "-" +288, 8, 7, 148, 23, 27, 730, 734, "week" +288, 8, 8, 149, 28, 29, 735, 736, "," +288, 8, 9, 150, 30, 41, 737, 748, "multicentre" +288, 8, 10, 151, 42, 43, 749, 750, "," +288, 8, 11, 152, 44, 54, 751, 761, "randomized" +288, 8, 12, 153, 55, 56, 762, 763, "," +288, 8, 13, 154, 57, 65, 764, 772, "parallel" +288, 8, 14, 155, 66, 67, 773, 774, "-" +288, 8, 15, 156, 68, 73, 775, 780, "group" +288, 8, 16, 157, 74, 75, 781, 782, "," +288, 8, 17, 158, 76, 82, 783, 789, "double" +288, 8, 18, 159, 83, 84, 790, 791, "-" +288, 8, 19, 160, 85, 90, 792, 797, "blind" +288, 8, 20, 161, 91, 96, 798, 803, "study" +288, 8, 21, 162, 97, 98, 804, 805, "," +288, 8, 22, 163, 99, 110, 806, 817, "outpatients" +288, 8, 23, 164, 111, 115, 818, 822, "aged" +288, 8, 24, 165, 116, 117, 823, 824, "≥" +288, 8, 25, 166, 118, 120, 825, 827, "18" +288, 8, 26, 167, 121, 122, 828, 829, " " +288, 8, 27, 168, 123, 128, 830, 835, "years" +288, 8, 28, 169, 129, 133, 836, 840, "with" +288, 8, 29, 170, 134, 138, 841, 845, "type" +288, 8, 30, 171, 139, 140, 846, 847, "2" +288, 8, 31, 172, 141, 149, 848, 856, "diabetes" +288, 8, 32, 173, 150, 151, 857, 858, "," +288, 8, 33, 174, 152, 156, 859, 863, "body" +288, 8, 34, 175, 157, 161, 864, 868, "mass" +288, 8, 35, 176, 162, 167, 869, 874, "index" +288, 8, 36, 177, 168, 169, 875, 876, "≤" +288, 8, 37, 178, 170, 172, 877, 879, "40" +288, 8, 38, 179, 173, 174, 880, 881, " " +288, 8, 39, 180, 175, 177, 882, 884, "kg" +288, 8, 40, 181, 178, 179, 885, 886, "/" +288, 8, 41, 182, 180, 181, 887, 888, "m" +288, 8, 42, 183, 182, 183, 889, 890, "(" +288, 8, 43, 184, 184, 185, 891, 892, "2" +288, 8, 44, 185, 186, 187, 893, 894, ")" +288, 8, 45, 186, 188, 191, 895, 898, "and" +288, 8, 46, 187, 192, 202, 899, 909, "inadequate" +288, 8, 47, 188, 203, 212, 910, 919, "glycaemic" +288, 8, 48, 189, 213, 220, 920, 927, "control" +288, 8, 49, 190, 221, 222, 928, 929, "," +288, 8, 50, 191, 223, 231, 930, 938, "received" +288, 8, 51, 192, 232, 243, 939, 950, "saxagliptin" +288, 8, 52, 193, 244, 245, 951, 952, "5" +288, 8, 53, 194, 246, 247, 953, 954, " " +288, 8, 54, 195, 248, 250, 955, 957, "mg" +288, 8, 55, 196, 251, 253, 958, 960, "or" +288, 8, 56, 197, 254, 261, 961, 968, "placebo" +288, 8, 57, 198, 262, 266, 969, 973, "once" +288, 8, 58, 199, 267, 268, 974, 975, "-" +288, 8, 59, 200, 269, 274, 976, 981, "daily" +288, 8, 60, 201, 275, 280, 982, 987, "added" +288, 8, 61, 202, 281, 283, 988, 990, "to" +288, 8, 62, 203, 284, 294, 991, 1001, "background" +288, 8, 63, 204, 295, 305, 1002, 1012, "medication" +288, 8, 64, 205, 306, 316, 1013, 1023, "consisting" +288, 8, 65, 206, 317, 319, 1024, 1026, "of" +288, 8, 66, 207, 320, 321, 1027, 1028, "a" +288, 8, 67, 208, 322, 328, 1029, 1035, "stable" +288, 8, 68, 209, 329, 336, 1036, 1043, "maximum" +288, 8, 69, 210, 337, 346, 1044, 1053, "tolerated" +288, 8, 70, 211, 347, 351, 1054, 1058, "dose" +288, 8, 71, 212, 352, 354, 1059, 1061, "of" +288, 8, 72, 213, 355, 364, 1062, 1071, "metformin" +288, 8, 73, 214, 365, 369, 1072, 1076, "plus" +288, 8, 74, 215, 370, 371, 1077, 1078, "a" +288, 8, 75, 216, 372, 385, 1079, 1092, "sulphonylurea" +288, 8, 76, 217, 386, 387, 1093, 1094, "." +288, 9, 1, 218, 0, 3, 1095, 1098, "The" +288, 9, 2, 219, 4, 11, 1099, 1106, "primary" +288, 9, 3, 220, 12, 15, 1107, 1110, "end" +288, 9, 4, 221, 16, 21, 1111, 1116, "point" +288, 9, 5, 222, 22, 25, 1117, 1120, "was" +288, 9, 6, 223, 26, 32, 1121, 1127, "change" +288, 9, 7, 224, 33, 35, 1128, 1130, "in" +288, 9, 8, 225, 36, 44, 1131, 1139, "glycated" +288, 9, 9, 226, 45, 56, 1140, 1151, "haemoglobin" +288, 9, 10, 227, 57, 58, 1152, 1153, "(" +288, 9, 11, 228, 59, 64, 1154, 1159, "HbA1c" +288, 9, 12, 229, 65, 66, 1160, 1161, ")" +288, 9, 13, 230, 67, 71, 1162, 1166, "from" +288, 9, 14, 231, 72, 80, 1167, 1175, "baseline" +288, 9, 15, 232, 81, 83, 1176, 1178, "to" +288, 9, 16, 233, 84, 88, 1179, 1183, "week" +288, 9, 17, 234, 89, 91, 1184, 1186, "24" +288, 9, 18, 235, 92, 93, 1187, 1188, "." +288, 10, 1, 236, 0, 6, 1189, 1195, "Safety" +288, 10, 2, 237, 7, 10, 1196, 1199, "and" +288, 10, 3, 238, 11, 23, 1200, 1212, "tolerability" +288, 10, 4, 239, 24, 35, 1213, 1224, "assessments" +288, 10, 5, 240, 36, 44, 1225, 1233, "included" +288, 10, 6, 241, 45, 52, 1234, 1241, "adverse" +288, 10, 7, 242, 53, 59, 1242, 1248, "events" +288, 10, 8, 243, 60, 61, 1249, 1250, "(" +288, 10, 9, 244, 62, 65, 1251, 1254, "AEs" +288, 10, 10, 245, 66, 67, 1255, 1256, ")" +288, 10, 11, 246, 68, 69, 1257, 1258, "," +288, 10, 12, 247, 70, 83, 1259, 1272, "hypoglycaemia" +288, 10, 13, 248, 84, 87, 1273, 1276, "and" +288, 10, 14, 249, 88, 92, 1277, 1281, "body" +288, 10, 15, 250, 93, 99, 1282, 1288, "weight" +288, 10, 16, 251, 100, 101, 1289, 1290, "." +288, 11, 1, 252, 0, 7, 1291, 1298, "RESULTS" +288, 11, 2, 253, 8, 9, 1299, 1300, ":" +288, 11, 3, 254, 10, 11, 1301, 1302, "A" +288, 11, 4, 255, 12, 17, 1303, 1308, "total" +288, 11, 5, 256, 18, 20, 1309, 1311, "of" +288, 11, 6, 257, 21, 24, 1312, 1315, "257" +288, 11, 7, 258, 25, 33, 1316, 1324, "patients" +288, 11, 8, 259, 34, 38, 1325, 1329, "were" +288, 11, 9, 260, 39, 49, 1330, 1340, "randomized" +288, 11, 10, 261, 50, 51, 1341, 1342, "," +288, 11, 11, 262, 52, 59, 1343, 1350, "treated" +288, 11, 12, 263, 60, 63, 1351, 1354, "and" +288, 11, 13, 264, 64, 72, 1355, 1363, "included" +288, 11, 14, 265, 73, 75, 1364, 1366, "in" +288, 11, 15, 266, 76, 79, 1367, 1370, "the" +288, 11, 16, 267, 80, 86, 1371, 1377, "safety" +288, 11, 17, 268, 87, 95, 1378, 1386, "analysis" +288, 11, 18, 269, 96, 97, 1387, 1388, "(" +288, 11, 19, 270, 98, 109, 1389, 1400, "saxagliptin" +288, 11, 20, 271, 110, 111, 1401, 1402, "," +288, 11, 21, 272, 112, 113, 1403, 1404, "n" +288, 11, 22, 273, 114, 117, 1405, 1408, " = " +288, 11, 23, 274, 118, 121, 1409, 1412, "129" +288, 11, 24, 275, 122, 123, 1413, 1414, ";" +288, 11, 25, 276, 124, 131, 1415, 1422, "placebo" +288, 11, 26, 277, 132, 133, 1423, 1424, "," +288, 11, 27, 278, 134, 135, 1425, 1426, "n" +288, 11, 28, 279, 136, 139, 1427, 1430, " = " +288, 11, 29, 280, 140, 143, 1431, 1434, "128" +288, 11, 30, 281, 144, 145, 1435, 1436, ")" +288, 11, 31, 282, 146, 147, 1437, 1438, ";" +288, 11, 32, 283, 148, 151, 1439, 1442, "255" +288, 11, 33, 284, 152, 156, 1443, 1447, "were" +288, 11, 34, 285, 157, 165, 1448, 1456, "included" +288, 11, 35, 286, 166, 168, 1457, 1459, "in" +288, 11, 36, 287, 169, 172, 1460, 1463, "the" +288, 11, 37, 288, 173, 181, 1464, 1472, "efficacy" +288, 11, 38, 289, 182, 190, 1473, 1481, "analysis" +288, 11, 39, 290, 191, 192, 1482, 1483, "(" +288, 11, 40, 291, 193, 204, 1484, 1495, "saxagliptin" +288, 11, 41, 292, 205, 206, 1496, 1497, "," +288, 11, 42, 293, 207, 208, 1498, 1499, "n" +288, 11, 43, 294, 209, 212, 1500, 1503, " = " +288, 11, 44, 295, 213, 216, 1504, 1507, "127" +288, 11, 45, 296, 217, 218, 1508, 1509, ";" +288, 11, 46, 297, 219, 226, 1510, 1517, "placebo" +288, 11, 47, 298, 227, 228, 1518, 1519, "," +288, 11, 48, 299, 229, 230, 1520, 1521, "n" +288, 11, 49, 300, 231, 234, 1522, 1525, " = " +288, 11, 50, 301, 235, 238, 1526, 1529, "128" +288, 11, 51, 302, 239, 240, 1530, 1531, ")" +288, 11, 52, 303, 241, 242, 1532, 1533, "." +288, 12, 1, 304, 0, 5, 1534, 1539, "HbA1c" +288, 12, 2, 305, 6, 15, 1540, 1549, "reduction" +288, 12, 3, 306, 16, 19, 1550, 1553, "was" +288, 12, 4, 307, 20, 27, 1554, 1561, "greater" +288, 12, 5, 308, 28, 32, 1562, 1566, "with" +288, 12, 6, 309, 33, 44, 1567, 1578, "saxagliptin" +288, 12, 7, 310, 45, 51, 1579, 1585, "versus" +288, 12, 8, 311, 52, 59, 1586, 1593, "placebo" +288, 12, 9, 312, 60, 61, 1594, 1595, "[" +288, 12, 10, 313, 62, 69, 1596, 1603, "between" +288, 12, 11, 314, 70, 71, 1604, 1605, "-" +288, 12, 12, 315, 72, 77, 1606, 1611, "group" +288, 12, 13, 316, 78, 88, 1612, 1622, "difference" +288, 12, 14, 317, 89, 91, 1623, 1625, "in" +288, 12, 15, 318, 92, 100, 1626, 1634, "adjusted" +288, 12, 16, 319, 101, 105, 1635, 1639, "mean" +288, 12, 17, 320, 106, 112, 1640, 1646, "change" +288, 12, 18, 321, 113, 117, 1647, 1651, "from" +288, 12, 19, 322, 118, 126, 1652, 1660, "baseline" +288, 12, 20, 323, 127, 128, 1661, 1662, "," +288, 12, 21, 324, 129, 130, 1663, 1664, "-" +288, 12, 22, 325, 131, 132, 1665, 1666, "0" +288, 12, 23, 326, 133, 134, 1667, 1668, "." +288, 12, 24, 327, 135, 137, 1669, 1671, "66" +288, 12, 25, 328, 138, 139, 1672, 1673, "%" +288, 12, 26, 329, 140, 141, 1674, 1675, ";" +288, 12, 27, 330, 142, 144, 1676, 1678, "95" +288, 12, 28, 331, 145, 146, 1679, 1680, "%" +288, 12, 29, 332, 147, 157, 1681, 1691, "confidence" +288, 12, 30, 333, 158, 166, 1692, 1700, "interval" +288, 12, 31, 334, 167, 168, 1701, 1702, "(" +288, 12, 32, 335, 169, 171, 1703, 1705, "CI" +288, 12, 33, 336, 172, 173, 1706, 1707, ")" +288, 12, 34, 337, 174, 175, 1708, 1709, "," +288, 12, 35, 338, 176, 177, 1710, 1711, "-" +288, 12, 36, 339, 178, 179, 1712, 1713, "0" +288, 12, 37, 340, 180, 181, 1714, 1715, "." +288, 12, 38, 341, 182, 184, 1716, 1718, "86" +288, 12, 39, 342, 185, 187, 1719, 1721, "to" +288, 12, 40, 343, 188, 189, 1722, 1723, "-" +288, 12, 41, 344, 190, 191, 1724, 1725, "0" +288, 12, 42, 345, 192, 193, 1726, 1727, "." +288, 12, 43, 346, 194, 196, 1728, 1730, "47" +288, 12, 44, 347, 197, 198, 1731, 1732, "(" +288, 12, 45, 348, 199, 200, 1733, 1734, "7" +288, 12, 46, 349, 201, 202, 1735, 1736, " " +288, 12, 47, 350, 203, 207, 1737, 1741, "mmol" +288, 12, 48, 351, 208, 209, 1742, 1743, "/" +288, 12, 49, 352, 210, 213, 1744, 1747, "mol" +288, 12, 50, 353, 214, 215, 1748, 1749, "," +288, 12, 51, 354, 216, 217, 1750, 1751, "-" +288, 12, 52, 355, 218, 219, 1752, 1753, "9" +288, 12, 53, 356, 220, 221, 1754, 1755, "." +288, 12, 54, 357, 222, 223, 1756, 1757, "4" +288, 12, 55, 358, 224, 226, 1758, 1760, "to" +288, 12, 56, 359, 227, 228, 1761, 1762, "-" +288, 12, 57, 360, 229, 230, 1763, 1764, "5" +288, 12, 58, 361, 231, 232, 1765, 1766, "." +288, 12, 59, 362, 233, 234, 1767, 1768, "1" +288, 12, 60, 363, 235, 236, 1769, 1770, ")" +288, 12, 61, 364, 237, 238, 1771, 1772, ";" +288, 12, 62, 365, 239, 240, 1773, 1774, "p" +288, 12, 63, 366, 241, 244, 1775, 1778, " < " +288, 12, 64, 367, 245, 246, 1779, 1780, "0" +288, 12, 65, 368, 247, 248, 1781, 1782, "." +288, 12, 66, 369, 249, 253, 1783, 1787, "0001" +288, 12, 67, 370, 254, 255, 1788, 1789, "]" +288, 12, 68, 371, 256, 257, 1790, 1791, "." +288, 13, 1, 372, 0, 3, 1792, 1795, "The" +288, 13, 2, 373, 4, 14, 1796, 1806, "proportion" +288, 13, 3, 374, 15, 17, 1807, 1809, "of" +288, 13, 4, 375, 18, 26, 1810, 1818, "patients" +288, 13, 5, 376, 27, 31, 1819, 1823, "with" +288, 13, 6, 377, 32, 33, 1824, 1825, "≥" +288, 13, 7, 378, 34, 35, 1826, 1827, "1" +288, 13, 8, 379, 36, 38, 1828, 1830, "AE" +288, 13, 9, 380, 39, 42, 1831, 1834, "was" +288, 13, 10, 381, 43, 45, 1835, 1837, "62" +288, 13, 11, 382, 46, 47, 1838, 1839, "." +288, 13, 12, 383, 48, 49, 1840, 1841, "8" +288, 13, 13, 384, 50, 51, 1842, 1843, "%" +288, 13, 14, 385, 52, 56, 1844, 1848, "with" +288, 13, 15, 386, 57, 68, 1849, 1860, "saxagliptin" +288, 13, 16, 387, 69, 72, 1861, 1864, "and" +288, 13, 17, 388, 73, 75, 1865, 1867, "71" +288, 13, 18, 389, 76, 77, 1868, 1869, "." +288, 13, 19, 390, 78, 79, 1870, 1871, "7" +288, 13, 20, 391, 80, 81, 1872, 1873, "%" +288, 13, 21, 392, 82, 86, 1874, 1878, "with" +288, 13, 22, 393, 87, 94, 1879, 1886, "placebo" +288, 13, 23, 394, 95, 96, 1887, 1888, "." +288, 14, 1, 395, 0, 2, 1889, 1891, "In" +288, 14, 2, 396, 3, 6, 1892, 1895, "the" +288, 14, 3, 397, 7, 18, 1896, 1907, "saxagliptin" +288, 14, 4, 398, 19, 22, 1908, 1911, "and" +288, 14, 5, 399, 23, 30, 1912, 1919, "placebo" +288, 14, 6, 400, 31, 37, 1920, 1926, "groups" +288, 14, 7, 401, 38, 39, 1927, 1928, "," +288, 14, 8, 402, 40, 45, 1929, 1934, "rates" +288, 14, 9, 403, 46, 48, 1935, 1937, "of" +288, 14, 10, 404, 49, 57, 1938, 1946, "reported" +288, 14, 11, 405, 58, 71, 1947, 1960, "hypoglycaemia" +288, 14, 12, 406, 72, 76, 1961, 1965, "were" +288, 14, 13, 407, 77, 79, 1966, 1968, "10" +288, 14, 14, 408, 80, 81, 1969, 1970, "." +288, 14, 15, 409, 82, 83, 1971, 1972, "1" +288, 14, 16, 410, 84, 87, 1973, 1976, "and" +288, 14, 17, 411, 88, 89, 1977, 1978, "6" +288, 14, 18, 412, 90, 91, 1979, 1980, "." +288, 14, 19, 413, 92, 93, 1981, 1982, "3" +288, 14, 20, 414, 94, 95, 1983, 1984, "%" +288, 14, 21, 415, 96, 97, 1985, 1986, "," +288, 14, 22, 416, 98, 110, 1987, 1999, "respectively" +288, 14, 23, 417, 111, 112, 2000, 2001, "," +288, 14, 24, 418, 113, 116, 2002, 2005, "and" +288, 14, 25, 419, 117, 122, 2006, 2011, "rates" +288, 14, 26, 420, 123, 125, 2012, 2014, "of" +288, 14, 27, 421, 126, 135, 2015, 2024, "confirmed" +288, 14, 28, 422, 136, 149, 2025, 2038, "hypoglycaemia" +288, 14, 29, 423, 150, 151, 2039, 2040, "(" +288, 14, 30, 424, 152, 160, 2041, 2049, "symptoms" +288, 14, 31, 425, 161, 164, 2050, 2053, " + " +288, 14, 32, 426, 165, 172, 2054, 2061, "glucose" +288, 14, 33, 427, 173, 176, 2062, 2065, " < " +288, 14, 34, 428, 177, 178, 2066, 2067, "2" +288, 14, 35, 429, 179, 180, 2068, 2069, "." +288, 14, 36, 430, 181, 182, 2070, 2071, "8" +288, 14, 37, 431, 183, 184, 2072, 2073, " " +288, 14, 38, 432, 185, 189, 2074, 2078, "mmol" +288, 14, 39, 433, 190, 191, 2079, 2080, "/" +288, 14, 40, 434, 192, 193, 2081, 2082, "l" +288, 14, 41, 435, 194, 195, 2083, 2084, ")" +288, 14, 42, 436, 196, 200, 2085, 2089, "were" +288, 14, 43, 437, 201, 202, 2090, 2091, "1" +288, 14, 44, 438, 203, 204, 2092, 2093, "." +288, 14, 45, 439, 205, 206, 2094, 2095, "6" +288, 14, 46, 440, 207, 210, 2096, 2099, "and" +288, 14, 47, 441, 211, 212, 2100, 2101, "0" +288, 14, 48, 442, 213, 214, 2102, 2103, "%" +288, 14, 49, 443, 215, 216, 2104, 2105, "." +288, 15, 1, 444, 0, 4, 2106, 2110, "Mean" +288, 15, 2, 445, 5, 11, 2111, 2117, "change" +288, 15, 3, 446, 12, 14, 2118, 2120, "in" +288, 15, 4, 447, 15, 19, 2121, 2125, "body" +288, 15, 5, 448, 20, 26, 2126, 2132, "weight" +288, 15, 6, 449, 27, 30, 2133, 2136, "was" +288, 15, 7, 450, 31, 32, 2137, 2138, "0" +288, 15, 8, 451, 33, 34, 2139, 2140, "." +288, 15, 9, 452, 35, 36, 2141, 2142, "2" +288, 15, 10, 453, 37, 38, 2143, 2144, " " +288, 15, 11, 454, 39, 41, 2145, 2147, "kg" +288, 15, 12, 455, 42, 45, 2148, 2151, "for" +288, 15, 13, 456, 46, 57, 2152, 2163, "saxagliptin" +288, 15, 14, 457, 58, 61, 2164, 2167, "and" +288, 15, 15, 458, 62, 63, 2168, 2169, "-" +288, 15, 16, 459, 64, 65, 2170, 2171, "0" +288, 15, 17, 460, 66, 67, 2172, 2173, "." +288, 15, 18, 461, 68, 69, 2174, 2175, "6" +288, 15, 19, 462, 70, 71, 2176, 2177, " " +288, 15, 20, 463, 72, 74, 2178, 2180, "kg" +288, 15, 21, 464, 75, 78, 2181, 2184, "for" +288, 15, 22, 465, 79, 86, 2185, 2192, "placebo" +288, 15, 23, 466, 87, 88, 2193, 2194, "(" +288, 15, 24, 467, 89, 90, 2195, 2196, "p" +288, 15, 25, 468, 91, 94, 2197, 2200, " = " +288, 15, 26, 469, 95, 96, 2201, 2202, "0" +288, 15, 27, 470, 97, 98, 2203, 2204, "." +288, 15, 28, 471, 99, 103, 2205, 2209, "0272" +288, 15, 29, 472, 104, 105, 2210, 2211, ")" +288, 15, 30, 473, 106, 107, 2212, 2213, "." +288, 16, 1, 474, 0, 10, 2214, 2224, "CONCLUSION" +288, 16, 2, 475, 11, 12, 2225, 2226, ":" +288, 16, 3, 476, 13, 21, 2227, 2235, "Addition" +288, 16, 4, 477, 22, 24, 2236, 2238, "of" +288, 16, 5, 478, 25, 36, 2239, 2250, "saxagliptin" +288, 16, 6, 479, 37, 38, 2251, 2252, "5" +288, 16, 7, 480, 39, 40, 2253, 2254, " " +288, 16, 8, 481, 41, 43, 2255, 2257, "mg" +288, 16, 9, 482, 44, 45, 2258, 2259, "/" +288, 16, 10, 483, 46, 49, 2260, 2263, "day" +288, 16, 11, 484, 50, 52, 2264, 2266, "in" +288, 16, 12, 485, 53, 61, 2267, 2275, "patients" +288, 16, 13, 486, 62, 74, 2276, 2288, "inadequately" +288, 16, 14, 487, 75, 85, 2289, 2299, "controlled" +288, 16, 15, 488, 86, 88, 2300, 2302, "on" +288, 16, 16, 489, 89, 98, 2303, 2312, "metformin" +288, 16, 17, 490, 99, 102, 2313, 2316, "and" +288, 16, 18, 491, 103, 116, 2317, 2330, "sulphonylurea" +288, 16, 19, 492, 117, 128, 2331, 2342, "effectively" +288, 16, 20, 493, 129, 137, 2343, 2351, "improved" +288, 16, 21, 494, 138, 147, 2352, 2361, "glycaemic" +288, 16, 22, 495, 148, 155, 2362, 2369, "control" +288, 16, 23, 496, 156, 159, 2370, 2373, "and" +288, 16, 24, 497, 160, 163, 2374, 2377, "was" +288, 16, 25, 498, 164, 168, 2378, 2382, "well" +288, 16, 26, 499, 169, 178, 2383, 2392, "tolerated" +288, 16, 27, 500, 179, 180, 2393, 2394, "." +288, 17, 1, 501, 0, 1, 2395, 2396, "©" +288, 17, 2, 502, 2, 6, 2397, 2401, "2013" +288, 17, 3, 503, 7, 11, 2402, 2406, "John" +288, 17, 4, 504, 12, 17, 2407, 2412, "Wiley" +288, 17, 5, 505, 18, 19, 2413, 2414, "&" +288, 17, 6, 506, 20, 24, 2415, 2419, "Sons" +288, 17, 7, 507, 25, 28, 2420, 2423, "Ltd" +288, 17, 8, 508, 29, 30, 2424, 2425, "." +288, 17, 9, 509, 31, 34, 2426, 2429, "DOI" +288, 17, 10, 510, 35, 36, 2430, 2431, ":" +288, 17, 11, 511, 37, 39, 2432, 2434, "10" +288, 17, 12, 512, 40, 41, 2435, 2436, "." +288, 17, 13, 513, 42, 46, 2437, 2441, "1111" +288, 17, 14, 514, 47, 48, 2442, 2443, "/" +288, 17, 15, 515, 49, 52, 2444, 2447, "dom" +288, 17, 16, 516, 53, 54, 2448, 2449, "." +288, 17, 17, 517, 55, 60, 2450, 2455, "12234" +288, 17, 18, 518, 61, 65, 2456, 2460, "PMID" +288, 17, 19, 519, 66, 67, 2461, 2462, ":" +288, 17, 20, 520, 68, 76, 2463, 2471, "24205943" +288, 17, 21, 521, 77, 78, 2472, 2473, "[" +288, 17, 22, 522, 79, 86, 2474, 2481, "Indexed" +288, 17, 23, 523, 87, 90, 2482, 2485, "for" +288, 17, 24, 524, 91, 98, 2486, 2493, "MEDLINE" +288, 17, 25, 525, 99, 100, 2494, 2495, "]" diff --git a/data/dm2 24205943_kwoodley.annodb b/data/dm2 24205943_kwoodley.annodb new file mode 100644 index 0000000..b787a7e --- /dev/null +++ b/data/dm2 24205943_kwoodley.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46649, Journal, 0, 19, "Diabetes Obes Metab", "", +46650, PublicationYear, 22, 26, "2014", "", +46672, Title, 105, 298, "A randomized controlled trial of the efficacy and safety of saxagliptin as add - on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea .", "", +46651, Randomized, 107, 117, "randomized", "", +46652, Saxagliptin, 165, 176, "saxagliptin", "", +46671, Precondition, 200, 296, "patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea", "", +46662, Type2Diabetes, 214, 229, "type 2 diabetes", "", +46664, Metformin, 266, 275, "metformin", "", +46668, Sulfonylureas, 283, 296, "sulphonylurea", "", +46673, Author, 299, 307, "Moses RG", "", +46674, Author, 316, 323, "Kalra S", "", +46675, Author, 326, 333, "Brook D", "", +46676, Author, 336, 345, "Sockler J", "", +46677, Author, 348, 356, "Monyak J", "", +46678, Author, 359, 372, "Visvanathan J", "", +46679, Author, 375, 386, "Montanaro M", "", +46680, Author, 389, 398, "Fisher SA", "", +46681, Australia, 516, 525, "Australia", "", +46684, ObjectiveDescription, 535, 706, "To evaluate the efficacy and safety of saxagliptin as add - on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea .", "", +46653, Saxagliptin, 574, 585, "saxagliptin", "", +46683, Precondition, 609, 704, "adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea", "", +46663, Type2Diabetes, 621, 636, "type 2 diabetes", "", +46665, Metformin, 674, 683, "metformin", "", +46682, Sulfonylureas, 691, 704, "sulphonylurea", "", +46685, Duration, 725, 734, "24 - week", "", +46686, Multicenter, 737, 748, "multicentre", "", +46687, Randomized, 751, 761, "randomized", "", +46688, Parallel, 764, 780, "parallel - group", "", +46689, DoubleBlind, 783, 797, "double - blind", "", +46694, Precondition, 806, 927, "outpatients aged ≥ 18   years with type 2 diabetes , body mass index ≤ 40   kg / m ( 2 ) and inadequate glycaemic control", "", +46690, MinAge, 825, 827, "18", "", +46691, Type2Diabetes, 841, 856, "type 2 diabetes", "", +46692, BMI, 859, 874, "body mass index", "", +46693, Kg_per_squareMeter, 882, 894, "kg / m ( 2 )", "", +46654, Saxagliptin, 939, 950, "saxagliptin", "", +46695, DoseValue, 951, 952, "5", "", +46696, mg, 955, 957, "mg", "", +46697, Placebo, 961, 968, "placebo", "", +46704, Frequency, 969, 981, "once - daily", "", +46666, Metformin, 1062, 1071, "metformin", "", +46669, Sulfonylureas, 1079, 1092, "sulphonylurea", "", +46705, HbA1c, 1131, 1151, "glycated haemoglobin", "", +46706, HbA1c, 1154, 1159, "HbA1c", "", +46708, TimePoint, 1167, 1175, "baseline", "", +46709, TimePoint, 1179, 1186, "week 24", "", +46710, EndPointDescription, 1234, 1248, "adverse events", "", +46711, EndPointDescription, 1251, 1254, "AEs", "", +46713, Hypoglycemia, 1259, 1272, "hypoglycaemia", "", +46716, BodyWeight, 1277, 1288, "body weight", "", +46718, NumberPatientsCT, 1312, 1315, "257", "", +46719, Randomized, 1330, 1340, "randomized", "", +46655, Saxagliptin, 1389, 1400, "saxagliptin", "", +46720, NumberPatientsArm, 1409, 1412, "129", "", +46698, Placebo, 1415, 1422, "placebo", "", +46721, NumberPatientsArm, 1431, 1434, "128", "", +46726, FinalNumPatientsCT, 1439, 1442, "255", "", +46656, Saxagliptin, 1484, 1495, "saxagliptin", "", +46724, FinalNumPatientsArm, 1504, 1507, "127", "", +46699, Placebo, 1510, 1517, "placebo", "", +46725, FinalNumPatientsArm, 1526, 1529, "128", "", +46707, HbA1c, 1534, 1539, "HbA1c", "", +46657, Saxagliptin, 1567, 1578, "saxagliptin", "", +46700, Placebo, 1586, 1593, "placebo", "", +46727, DiffGroupAbsValue, 1663, 1671, "- 0 . 66", "", +46728, Percentage, 1672, 1673, "%", "", +46729, ConfIntervalDiff, 1676, 1770, "95 % confidence interval ( CI ) , - 0 . 86 to - 0 . 47 ( 7   mmol / mol , - 9 . 4 to - 5 . 1 )", "", +46730, BioAndMedicalUnit, 1737, 1747, "mmol / mol", "", +46731, PvalueDiff, 1773, 1787, "p  <  0 . 0001", "", +46736, SubGroupDescription, 1796, 1830, "proportion of patients with ≥ 1 AE", "", +46712, EndPointDescription, 1828, 1830, "AE", "", +46732, PercentageAffected, 1835, 1841, "62 . 8", "", +46658, Saxagliptin, 1849, 1860, "saxagliptin", "", +46733, PercentageAffected, 1865, 1871, "71 . 7", "", +46701, Placebo, 1879, 1886, "placebo", "", +46659, Saxagliptin, 1896, 1907, "saxagliptin", "", +46702, Placebo, 1912, 1919, "placebo", "", +46734, SubGroupDescription, 1938, 1960, "reported hypoglycaemia", "", +46714, Hypoglycemia, 1947, 1960, "hypoglycaemia", "", +46739, NumberAffected, 1966, 1972, "10 . 1", "", +46741, PercentageAffected, 1977, 1982, "6 . 3", "", +46737, SubGroupDescription, 2015, 2084, "confirmed hypoglycaemia ( symptoms  +  glucose  <  2 . 8   mmol / l )", "", +46715, Hypoglycemia, 2025, 2038, "hypoglycaemia", "", +46738, Millimoles_per_litre, 2074, 2082, "mmol / l", "", +46740, NumberAffected, 2090, 2095, "1 . 6", "", +46742, PercentageAffected, 2100, 2101, "0", "", +46717, BodyWeight, 2121, 2132, "body weight", "", +46743, Increment, 2137, 2142, "0 . 2", "", +46745, Kg, 2145, 2147, "kg", "", +46660, Saxagliptin, 2152, 2163, "saxagliptin", "", +46744, Reduction, 2170, 2175, "0 . 6", "", +46746, Kg, 2178, 2180, "kg", "", +46703, Placebo, 2185, 2192, "placebo", "", +46747, PvalueDiff, 2195, 2209, "p  =  0 . 0272", "", +46752, ConclusionComment, 2227, 2394, "Addition of saxagliptin 5   mg / day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated .", "", +46661, Saxagliptin, 2239, 2250, "saxagliptin", "", +46748, DoseValue, 2251, 2252, "5", "", +46749, mg, 2255, 2257, "mg", "", +46750, Frequency, 2260, 2263, "day", "", +46751, Precondition, 2267, 2330, "patients inadequately controlled on metformin and sulphonylurea", "", +46667, Metformin, 2303, 2312, "metformin", "", +46670, Sulfonylureas, 2317, 2330, "sulphonylurea", "", +46753, PMID, 2463, 2471, "24205943", "", diff --git a/data/dm2 24205943_kwoodley.n-triples b/data/dm2 24205943_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24205943_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24237386_admin.annodb b/data/dm2 24237386_admin.annodb new file mode 100644 index 0000000..3475236 --- /dev/null +++ b/data/dm2 24237386_admin.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "Diabetes Technol Ther .", "", " \"Diabetes Technol Ther .\"." +1, PublicationYear, 24, 28, "2014", "", " \"2014\"." +9, Title, 114, 232, "Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin .", "", " \"Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin .\"." +42, EndPointDescription, 125, 144, "insulin sensitivity", "", +41, EndPointDescription, 149, 166, "insulin secretion", "", +2, Dapagliflozin, 217, 230, "dapagliflozin", "", +10, Author, 233, 243, "Mudaliar S", "", " \"Mudaliar S\"." +11, Author, 252, 260, "Henry RR", "", " \"Henry RR\"." +12, Author, 263, 270, "Boden G", "", " \"Boden G\"." +13, Author, 273, 280, "Smith S", "", " \"Smith S\"." +14, Author, 283, 299, "Chalamandaris AG", "", " \"Chalamandaris AG\"." +15, Author, 302, 312, "Duchesne D", "", " \"Duchesne D\"." +16, Author, 315, 322, "Iqbal N", "", " \"Iqbal N\"." +17, Author, 325, 331, "List J", "", " \"List J\"." +18, USA, 483, 493, "California", "", " ." +33, ObjectiveDescription, 502, 700, "This randomized , double - blind , placebo - controlled parallel - group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion", "", " \"This randomized , double - blind , placebo - controlled parallel - group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion\"." +19, Randomized, 507, 517, "randomized", "", " ." +20, DoubleBlind, 520, 534, "double - blind", "", " ." +21, Placebo, 537, 544, "placebo", "", +26, Parallel, 558, 574, "parallel - group", "", " ." +3, Dapagliflozin, 650, 663, "dapagliflozin", "", +34, ObjectiveDescription, 701, 850, "in subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) .", "", " \"in subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) .\"." +31, Precondition, 704, 848, "subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue )", "", " \"subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue )\"." +27, Type2Diabetes, 718, 742, "type 2 diabetes mellitus", "", " ." +28, Type2Diabetes, 745, 749, "T2DM", "", +30, Metformin, 795, 804, "metformin", "", +32, Insulin, 826, 833, "insulin", "", +35, NumberPatientsCT, 874, 886, "Forty - four", "", " \"Forty - four\"." +36, Randomized, 901, 911, "randomized", "", +4, Dapagliflozin, 923, 936, "dapagliflozin", "", " ." +37, DoseValue, 937, 938, "5", "", " \"5\"." +38, mg, 939, 941, "mg", "", " ." +22, Placebo, 954, 961, "placebo", "", " ." +39, Frequency, 962, 972, "once daily", "", " \"once daily\". \"once daily\"." +40, Duration, 977, 985, "12 weeks", "", " \"12 weeks\"." +126, EndPointDescription, 1131, 1157, "glucose disappearance rate", "", " . ." +51, EndPointDescription, 1160, 1163, "GDR", "", +128, EndPointDescription, 1278, 1311, "acute insulin response to glucose", "", " . ." +52, EndPointDescription, 1314, 1318, "AIRg", "", +124, TimePoint, 1443, 1451, "baseline", "", +125, Mean, 1522, 1526, "mean", "", " . ." +53, TimePoint, 1541, 1549, "baseline", "", +47, EndPointDescription, 1553, 1556, "GDR", "", +54, TimePoint, 1599, 1606, "Week 12", "", +5, Dapagliflozin, 1627, 1640, "dapagliflozin", "", +59, Increment, 1643, 1649, "7 . 98", "", " \"7 . 98\"." +69989, Percentage, 1650, 1651, "%", "", " ." +23, Placebo, 1677, 1684, "placebo", "", +60, Reduction, 1689, 1695, "9 . 99", "", " \"9 . 99\"." +69990, Percentage, 1696, 1697, "%", "", +64, DiffGroupAbsValue, 1706, 1713, "19 . 97", "", " \"19 . 97\"." +63, Percentage, 1714, 1715, "%", "", +65, ConfIntervalDiff, 1718, 1759, "95 % confidence interval 5 . 75 - 36 . 10", "", " \"95 % confidence interval 5 . 75 - 36 . 10\"." +48, EndPointDescription, 1776, 1779, "GDR", "", +66, Placebo, 1787, 1794, "placebo", "", +67, PvalueDiff, 1827, 1839, "P = 0 . 0059", "", " \"P = 0 . 0059\"." +55, TimePoint, 1858, 1866, "baseline", "", +147, Mean, 1879, 1883, "mean", "", " . ." +49, EndPointDescription, 1884, 1888, "AIRg", "", +70, Increment, 1892, 1899, "15 . 39", "", " \"15 . 39\"." +68, BioAndMedicalUnit, 1900, 1910, "mU / L min", "", " . ." +6, Dapagliflozin, 1929, 1942, "dapagliflozin", "", +56, TimePoint, 1946, 1953, "Week 12", "", " \"Week 12\". \"Week 12\"." +71, Reduction, 1965, 1972, "12 . 73", "", " \"12 . 73\"." +69, BioAndMedicalUnit, 1973, 1983, "mU / L min", "", +24, Placebo, 1989, 1996, "placebo", "", +72, PvalueDiff, 1999, 2011, "P = 0 . 0598", "", " \"P = 0 . 0598\"." +58, TimePoint, 2021, 2029, "12 weeks", "", " \"12 weeks\". \"12 weeks\". \"12 weeks\". \"12 weeks\". \"12 weeks\". \"12 weeks\"." +57, TimePoint, 2058, 2066, "baseline", "", +73, HbA1c, 2070, 2093, "glycosylated hemoglobin", "", " ." +74, HbA1c, 2096, 2101, "HbA1c", "", +75, FastingPlasmaGlucose, 2106, 2128, "fasting plasma glucose", "", " ." +76, BodyWeight, 2135, 2146, "body weight", "", " ." +7, Dapagliflozin, 2166, 2179, "dapagliflozin", "", +77, Reduction, 2184, 2190, "0 . 38", "", " \"0 . 38\"." +80, Percentage, 2191, 2192, "%", "", " ." +78, Reduction, 2197, 2203, "0 . 39", "", " \"0 . 39\"." +84, Millimoles_per_litre, 2204, 2212, "mmol / L", "", " ." +70035, RelativeReduction, 2221, 2227, "1 . 58", "", " \"1 . 58\"." +25, Placebo, 2286, 2293, "placebo", "", +85, Increment, 2296, 2302, "0 . 03", "", " \"0 . 03\"." +82, Percentage, 2303, 2304, "%", "", +86, Increment, 2307, 2313, "0 . 26", "", " \"0 . 26\"." +88, Millimoles_per_litre, 2314, 2322, "mmol / L", "", +70032, RelativeIncrement, 2329, 2335, "0 . 62", "", " \"0 . 62\"." +91, ConclusionComment, 2371, 2530, "In patients with T2DM and inadequate glycemic control , dapagliflozin treatment improved insulin sensitivity in the setting of reductions in HbA1c and weight .", "", " \"In patients with T2DM and inadequate glycemic control , dapagliflozin treatment improved insulin sensitivity in the setting of reductions in HbA1c and weight .\"." +29, Type2Diabetes, 2388, 2392, "T2DM", "", +8, Dapagliflozin, 2427, 2440, "dapagliflozin", "", +89, HbA1c, 2512, 2517, "HbA1c", "", +90, BodyWeight, 2522, 2528, "weight", "", +92, PMID, 2574, 2582, "24237386", "", " \"24237386\"." diff --git a/data/dm2 24237386_admin.n-triples b/data/dm2 24237386_admin.n-triples new file mode 100644 index 0000000..d704662 --- /dev/null +++ b/data/dm2 24237386_admin.n-triples @@ -0,0 +1,184 @@ +# RDF export of group: Publication + . + "Publication 51687" . + "Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin ." . + "Mudaliar S" . + "2014" . + "Diabetes Technol Ther ." . + "24237386" . + . + "Henry RR" . + "Boden G" . + "Smith S" . + "Chalamandaris AG" . + "Duchesne D" . + "Iqbal N" . + "List J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 51694" . + "This randomized , double - blind , placebo - controlled parallel - group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion" . + "Forty - four" . + "12 weeks" . + . + . + . + "In patients with T2DM and inadequate glycemic control , dapagliflozin treatment improved insulin sensitivity in the setting of reductions in HbA1c and weight ." . + . + . + . + . + . + . + . + . + "in subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) ." . + . +# RDF export of group: Population + . + "Population 51710" . + "subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue )" . + . + . + . +# RDF export of group: Endpoint + . + "gdr" . + . + . + . + . + . + . + . + "air" . + . + . + . + . + . + . + . + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "da" . + . + . + . + . + . + . + . + . + "pl" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "da" . + . + "once daily" . + . + . + "pl" . + . + "once daily" . + . +# RDF export of group: Medication + . + "da" . + . + "5" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "gdr 1" . + . + "7 . 98" . + . + "gdr 2" . + . + "9 . 99" . + . + "air 1" . + . + "15 . 39" . + "Week 12" . + . + "air 2" . + . + "12 . 73" . + "Week 12" . + . + "hba 1" . + . + "0 . 38" . + "12 weeks" . + . + "hba 2" . + . + "0 . 03" . + "12 weeks" . + . + "fpg 1" . + . + "0 . 39" . + "12 weeks" . + . + "fpg 2" . + . + "0 . 26" . + "12 weeks" . + . + "bw 1" . + . + "1 . 58" . + "12 weeks" . + . + "bw 2" . + . + "0 . 62" . + "12 weeks" . +# RDF export of group: DiffBetweenGroups + . + "gdr" . + "19 . 97" . + "P = 0 . 0059" . + "95 % confidence interval 5 . 75 - 36 . 10" . + . + . + . + "air" . + "P = 0 . 0598" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24237386_akramersunderbrink.annodb b/data/dm2 24237386_akramersunderbrink.annodb new file mode 100644 index 0000000..b61c7d9 --- /dev/null +++ b/data/dm2 24237386_akramersunderbrink.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59072, Journal, 0, 21, "Diabetes Technol Ther", "", +59073, PublicationYear, 24, 28, "2014", "", +59075, Title, 114, 232, "Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin .", "", +59074, Dapagliflozin, 217, 230, "dapagliflozin", "", +59076, Author, 233, 243, "Mudaliar S", "", +59077, Author, 252, 260, "Henry RR", "", +59078, Author, 263, 270, "Boden G", "", +59079, Author, 273, 280, "Smith S", "", +59080, Author, 283, 299, "Chalamandaris AG", "", +59081, Author, 302, 312, "Duchesne D", "", +59082, Author, 315, 322, "Iqbal N", "", +59083, Author, 325, 331, "List J", "", +59093, ObjectiveDescription, 502, 712, "This randomized , double - blind , placebo - controlled parallel - group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion in subjects", "", +59084, Randomized, 507, 517, "randomized", "", +59085, DoubleBlind, 520, 534, "double - blind", "", +59086, Placebo, 537, 544, "placebo", "", +59087, Parallel, 558, 574, "parallel - group", "", +59088, Dapagliflozin, 650, 663, "dapagliflozin", "", +59094, ObjectiveDescription, 713, 850, "with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) .", "", +59089, Type2Diabetes, 718, 742, "type 2 diabetes mellitus", "", +59090, Type2Diabetes, 745, 749, "T2DM", "", +59091, Precondition, 754, 848, "who had inadequate glycemic control with metformin ( with or without an insulin secretagogue )", "", +59092, Metformin, 795, 804, "metformin", "", +59095, NumberPatientsCT, 874, 886, "Forty - four", "", +59096, Randomized, 901, 911, "randomized", "", +59097, Dapagliflozin, 923, 936, "dapagliflozin", "", +59098, DoseValue, 937, 941, "5 mg", "", +59099, mg, 939, 941, "mg", "", +59100, Placebo, 954, 961, "placebo", "", +59101, Frequency, 962, 972, "once daily", "", +59102, Duration, 977, 985, "12 weeks", "", +59105, EndPointDescription, 1131, 1157, "glucose disappearance rate", "", +59106, EndPointDescription, 1160, 1163, "GDR", "", +59107, EndPointDescription, 1278, 1311, "acute insulin response to glucose", "", +59108, EndPointDescription, 1314, 1318, "AIRg", "", +59103, TimePoint, 1443, 1451, "baseline", "", +59104, Mean, 1522, 1526, "mean", "", +59110, TimePoint, 1541, 1549, "baseline", "", +59109, EndPointDescription, 1553, 1556, "GDR", "", +59112, TimePoint, 1599, 1606, "Week 12", "", +59113, Dapagliflozin, 1627, 1640, "dapagliflozin", "", +59115, ChangeValue, 1643, 1649, "7 . 98", "", +59117, Percentage, 1650, 1651, "%", "", +59114, Placebo, 1677, 1684, "placebo", "", +59116, ChangeValue, 1687, 1695, "- 9 . 99", "", +59118, Percentage, 1696, 1697, "%", "", +59119, DiffGroupAbsValue, 1706, 1713, "19 . 97", "", +59124, Percentage, 1714, 1715, "%", "", +59120, ConfIntervalDiff, 1718, 1759, "95 % confidence interval 5 . 75 - 36 . 10", "", +59125, Percentage, 1721, 1722, "%", "", +59121, EndPointDescription, 1776, 1779, "GDR", "", +59122, Placebo, 1787, 1794, "placebo", "", +59123, PvalueDiff, 1827, 1839, "P = 0 . 0059", "", +59126, TimePoint, 1858, 1866, "baseline", "", +59127, Mean, 1879, 1883, "mean", "", +59128, EndPointDescription, 1884, 1888, "AIRg", "", +59129, ChangeValue, 1892, 1899, "15 . 39", "", +59131, BioAndMedicalUnit, 1900, 1910, "mU / L min", "", +59133, Dapagliflozin, 1929, 1942, "dapagliflozin", "", +59134, TimePoint, 1946, 1953, "Week 12", "", +59130, ChangeValue, 1963, 1972, "- 12 . 73", "", +59132, BioAndMedicalUnit, 1973, 1983, "mU / L min", "", +59135, Placebo, 1989, 1996, "placebo", "", +59136, PvalueDiff, 1999, 2011, "P = 0 . 0598", "", +59137, TimePoint, 2021, 2029, "12 weeks", "", +59138, TimePoint, 2058, 2066, "baseline", "", +59139, HbA1c, 2070, 2093, "glycosylated hemoglobin", "", +59140, HbA1c, 2096, 2101, "HbA1c", "", +59141, FastingPlasmaGlucose, 2106, 2128, "fasting plasma glucose", "", +59142, BodyWeight, 2135, 2146, "body weight", "", +59143, Dapagliflozin, 2166, 2179, "dapagliflozin", "", +59144, ChangeValue, 2182, 2190, "- 0 . 38", "", +59147, Percentage, 2191, 2192, "%", "", +59145, ChangeValue, 2195, 2203, "- 0 . 39", "", +59149, Millimoles_per_litre, 2204, 2212, "mmol / L", "", +59146, ChangeValue, 2219, 2227, "- 1 . 58", "", +59148, Percentage, 2228, 2229, "%", "", +59150, Placebo, 2286, 2293, "placebo", "", +59151, ChangeValue, 2296, 2302, "0 . 03", "", +59154, Percentage, 2303, 2304, "%", "", +59152, ChangeValue, 2307, 2313, "0 . 26", "", +59156, Millimoles_per_litre, 2314, 2322, "mmol / L", "", +59153, ChangeValue, 2329, 2335, "0 . 62", "", +59155, Percentage, 2336, 2337, "%", "", +59162, ConclusionComment, 2371, 2530, "In patients with T2DM and inadequate glycemic control , dapagliflozin treatment improved insulin sensitivity in the setting of reductions in HbA1c and weight .", "", +59157, Type2Diabetes, 2388, 2392, "T2DM", "", +59158, Precondition, 2397, 2424, "inadequate glycemic control", "", +59159, Dapagliflozin, 2427, 2440, "dapagliflozin", "", +59160, HbA1c, 2512, 2517, "HbA1c", "", +59161, BodyWeight, 2522, 2528, "weight", "", +59163, PMID, 2574, 2582, "24237386", "", diff --git a/data/dm2 24237386_akramersunderbrink.n-triples b/data/dm2 24237386_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24237386_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24237386_export.csv b/data/dm2 24237386_export.csv new file mode 100644 index 0000000..f739f64 --- /dev/null +++ b/data/dm2 24237386_export.csv @@ -0,0 +1,517 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +287, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +287, 1, 2, 2, 9, 16, 9, 16, "Technol" +287, 1, 3, 3, 17, 21, 17, 21, "Ther" +287, 1, 4, 4, 22, 23, 22, 23, "." +287, 2, 1, 5, 0, 4, 24, 28, "2014" +287, 2, 2, 6, 5, 8, 29, 32, "Mar" +287, 2, 3, 7, 9, 10, 33, 34, ";" +287, 2, 4, 8, 11, 13, 35, 37, "16" +287, 2, 5, 9, 14, 15, 38, 39, "(" +287, 2, 6, 10, 16, 17, 40, 41, "3" +287, 2, 7, 11, 18, 19, 42, 43, ")" +287, 2, 8, 12, 20, 21, 44, 45, ":" +287, 2, 9, 13, 22, 25, 46, 49, "137" +287, 2, 10, 14, 26, 27, 50, 51, "-" +287, 2, 11, 15, 28, 30, 52, 54, "44" +287, 2, 12, 16, 31, 32, 55, 56, "." +287, 2, 13, 17, 33, 36, 57, 60, "doi" +287, 2, 14, 18, 37, 38, 61, 62, ":" +287, 2, 15, 19, 39, 41, 63, 65, "10" +287, 2, 16, 20, 42, 43, 66, 67, "." +287, 2, 17, 21, 44, 48, 68, 72, "1089" +287, 2, 18, 22, 49, 50, 73, 74, "/" +287, 2, 19, 23, 51, 54, 75, 78, "dia" +287, 2, 20, 24, 55, 56, 79, 80, "." +287, 2, 21, 25, 57, 61, 81, 85, "2013" +287, 2, 22, 26, 62, 63, 86, 87, "." +287, 2, 23, 27, 64, 68, 88, 92, "0167" +287, 2, 24, 28, 69, 70, 93, 94, "." +287, 3, 1, 29, 0, 4, 95, 99, "Epub" +287, 3, 2, 30, 5, 9, 100, 104, "2013" +287, 3, 3, 31, 10, 13, 105, 108, "Nov" +287, 3, 4, 32, 14, 16, 109, 111, "15" +287, 3, 5, 33, 17, 18, 112, 113, "." +287, 4, 1, 34, 0, 7, 114, 121, "Changes" +287, 4, 2, 35, 8, 10, 122, 124, "in" +287, 4, 3, 36, 11, 18, 125, 132, "insulin" +287, 4, 4, 37, 19, 30, 133, 144, "sensitivity" +287, 4, 5, 38, 31, 34, 145, 148, "and" +287, 4, 6, 39, 35, 42, 149, 156, "insulin" +287, 4, 7, 40, 43, 52, 157, 166, "secretion" +287, 4, 8, 41, 53, 57, 167, 171, "with" +287, 4, 9, 42, 58, 61, 172, 175, "the" +287, 4, 10, 43, 62, 68, 176, 182, "sodium" +287, 4, 11, 44, 69, 76, 183, 190, "glucose" +287, 4, 12, 45, 77, 90, 191, 204, "cotransporter" +287, 4, 13, 46, 91, 92, 205, 206, "2" +287, 4, 14, 47, 93, 102, 207, 216, "inhibitor" +287, 4, 15, 48, 103, 116, 217, 230, "dapagliflozin" +287, 4, 16, 49, 117, 118, 231, 232, "." +287, 5, 1, 50, 0, 8, 233, 241, "Mudaliar" +287, 5, 2, 51, 9, 10, 242, 243, "S" +287, 5, 3, 52, 11, 12, 244, 245, "(" +287, 5, 4, 53, 13, 14, 246, 247, "1" +287, 5, 5, 54, 15, 16, 248, 249, ")" +287, 5, 6, 55, 17, 18, 250, 251, "," +287, 5, 7, 56, 19, 24, 252, 257, "Henry" +287, 5, 8, 57, 25, 27, 258, 260, "RR" +287, 5, 9, 58, 28, 29, 261, 262, "," +287, 5, 10, 59, 30, 35, 263, 268, "Boden" +287, 5, 11, 60, 36, 37, 269, 270, "G" +287, 5, 12, 61, 38, 39, 271, 272, "," +287, 5, 13, 62, 40, 45, 273, 278, "Smith" +287, 5, 14, 63, 46, 47, 279, 280, "S" +287, 5, 15, 64, 48, 49, 281, 282, "," +287, 5, 16, 65, 50, 63, 283, 296, "Chalamandaris" +287, 5, 17, 66, 64, 66, 297, 299, "AG" +287, 5, 18, 67, 67, 68, 300, 301, "," +287, 5, 19, 68, 69, 77, 302, 310, "Duchesne" +287, 5, 20, 69, 78, 79, 311, 312, "D" +287, 5, 21, 70, 80, 81, 313, 314, "," +287, 5, 22, 71, 82, 87, 315, 320, "Iqbal" +287, 5, 23, 72, 88, 89, 321, 322, "N" +287, 5, 24, 73, 90, 91, 323, 324, "," +287, 5, 25, 74, 92, 96, 325, 329, "List" +287, 5, 26, 75, 97, 98, 330, 331, "J" +287, 5, 27, 76, 99, 100, 332, 333, "." +287, 6, 1, 77, 0, 6, 334, 340, "Author" +287, 6, 2, 78, 7, 18, 341, 352, "information" +287, 6, 3, 79, 19, 20, 353, 354, ":" +287, 6, 4, 80, 21, 22, 355, 356, "(" +287, 6, 5, 81, 23, 24, 357, 358, "1" +287, 6, 6, 82, 25, 26, 359, 360, ")" +287, 6, 7, 83, 27, 28, 361, 362, "1" +287, 6, 8, 84, 29, 35, 363, 369, "Center" +287, 6, 9, 85, 36, 39, 370, 373, "for" +287, 6, 10, 86, 40, 49, 374, 383, "Metabolic" +287, 6, 11, 87, 50, 58, 384, 392, "Research" +287, 6, 12, 88, 59, 60, 393, 394, "," +287, 6, 13, 89, 61, 63, 395, 397, "VA" +287, 6, 14, 90, 64, 67, 398, 401, "San" +287, 6, 15, 91, 68, 73, 402, 407, "Diego" +287, 6, 16, 92, 74, 84, 408, 418, "Healthcare" +287, 6, 17, 93, 85, 91, 419, 425, "System" +287, 6, 18, 94, 92, 93, 426, 427, "," +287, 6, 19, 95, 94, 97, 428, 431, "and" +287, 6, 20, 96, 98, 108, 432, 442, "University" +287, 6, 21, 97, 109, 111, 443, 445, "of" +287, 6, 22, 98, 112, 122, 446, 456, "California" +287, 6, 23, 99, 123, 124, 457, 458, "," +287, 6, 24, 100, 125, 128, 459, 462, "San" +287, 6, 25, 101, 129, 134, 463, 468, "Diego" +287, 6, 26, 102, 135, 136, 469, 470, "," +287, 6, 27, 103, 137, 140, 471, 474, "San" +287, 6, 28, 104, 141, 146, 475, 480, "Diego" +287, 6, 29, 105, 147, 148, 481, 482, "," +287, 6, 30, 106, 149, 159, 483, 493, "California" +287, 6, 31, 107, 160, 161, 494, 495, "." +287, 7, 1, 108, 0, 3, 496, 499, "AIM" +287, 7, 2, 109, 4, 5, 500, 501, ":" +287, 7, 3, 110, 6, 10, 502, 506, "This" +287, 7, 4, 111, 11, 21, 507, 517, "randomized" +287, 7, 5, 112, 22, 23, 518, 519, "," +287, 7, 6, 113, 24, 30, 520, 526, "double" +287, 7, 7, 114, 31, 32, 527, 528, "-" +287, 7, 8, 115, 33, 38, 529, 534, "blind" +287, 7, 9, 116, 39, 40, 535, 536, "," +287, 7, 10, 117, 41, 48, 537, 544, "placebo" +287, 7, 11, 118, 49, 50, 545, 546, "-" +287, 7, 12, 119, 51, 61, 547, 557, "controlled" +287, 7, 13, 120, 62, 70, 558, 566, "parallel" +287, 7, 14, 121, 71, 72, 567, 568, "-" +287, 7, 15, 122, 73, 78, 569, 574, "group" +287, 7, 16, 123, 79, 84, 575, 580, "study" +287, 7, 17, 124, 85, 93, 581, 589, "assessed" +287, 7, 18, 125, 94, 97, 590, 593, "the" +287, 7, 19, 126, 98, 105, 594, 601, "effects" +287, 7, 20, 127, 106, 108, 602, 604, "of" +287, 7, 21, 128, 109, 115, 605, 611, "sodium" +287, 7, 22, 129, 116, 123, 612, 619, "glucose" +287, 7, 23, 130, 124, 137, 620, 633, "cotransporter" +287, 7, 24, 131, 138, 139, 634, 635, "2" +287, 7, 25, 132, 140, 150, 636, 646, "inhibition" +287, 7, 26, 133, 151, 153, 647, 649, "by" +287, 7, 27, 134, 154, 167, 650, 663, "dapagliflozin" +287, 7, 28, 135, 168, 170, 664, 666, "on" +287, 7, 29, 136, 171, 178, 667, 674, "insulin" +287, 7, 30, 137, 179, 190, 675, 686, "sensitivity" +287, 7, 31, 138, 191, 194, 687, 690, "and" +287, 7, 32, 139, 195, 204, 691, 700, "secretion" +287, 7, 33, 140, 205, 207, 701, 703, "in" +287, 7, 34, 141, 208, 216, 704, 712, "subjects" +287, 7, 35, 142, 217, 221, 713, 717, "with" +287, 7, 36, 143, 222, 226, 718, 722, "type" +287, 7, 37, 144, 227, 228, 723, 724, "2" +287, 7, 38, 145, 229, 237, 725, 733, "diabetes" +287, 7, 39, 146, 238, 246, 734, 742, "mellitus" +287, 7, 40, 147, 247, 248, 743, 744, "(" +287, 7, 41, 148, 249, 253, 745, 749, "T2DM" +287, 7, 42, 149, 254, 255, 750, 751, ")" +287, 7, 43, 150, 256, 257, 752, 753, "," +287, 7, 44, 151, 258, 261, 754, 757, "who" +287, 7, 45, 152, 262, 265, 758, 761, "had" +287, 7, 46, 153, 266, 276, 762, 772, "inadequate" +287, 7, 47, 154, 277, 285, 773, 781, "glycemic" +287, 7, 48, 155, 286, 293, 782, 789, "control" +287, 7, 49, 156, 294, 298, 790, 794, "with" +287, 7, 50, 157, 299, 308, 795, 804, "metformin" +287, 7, 51, 158, 309, 310, 805, 806, "(" +287, 7, 52, 159, 311, 315, 807, 811, "with" +287, 7, 53, 160, 316, 318, 812, 814, "or" +287, 7, 54, 161, 319, 326, 815, 822, "without" +287, 7, 55, 162, 327, 329, 823, 825, "an" +287, 7, 56, 163, 330, 337, 826, 833, "insulin" +287, 7, 57, 164, 338, 350, 834, 846, "secretagogue" +287, 7, 58, 165, 351, 352, 847, 848, ")" +287, 7, 59, 166, 353, 354, 849, 850, "." +287, 8, 1, 167, 0, 8, 851, 859, "SUBJECTS" +287, 8, 2, 168, 9, 12, 860, 863, "AND" +287, 8, 3, 169, 13, 20, 864, 871, "METHODS" +287, 8, 4, 170, 21, 22, 872, 873, ":" +287, 8, 5, 171, 23, 28, 874, 879, "Forty" +287, 8, 6, 172, 29, 30, 880, 881, "-" +287, 8, 7, 173, 31, 35, 882, 886, "four" +287, 8, 8, 174, 36, 44, 887, 895, "subjects" +287, 8, 9, 175, 45, 49, 896, 900, "were" +287, 8, 10, 176, 50, 60, 901, 911, "randomized" +287, 8, 11, 177, 61, 63, 912, 914, "to" +287, 8, 12, 178, 64, 71, 915, 922, "receive" +287, 8, 13, 179, 72, 85, 923, 936, "dapagliflozin" +287, 8, 14, 180, 86, 87, 937, 938, "5" +287, 8, 15, 181, 88, 90, 939, 941, "mg" +287, 8, 16, 182, 91, 93, 942, 944, "or" +287, 8, 17, 183, 94, 102, 945, 953, "matching" +287, 8, 18, 184, 103, 110, 954, 961, "placebo" +287, 8, 19, 185, 111, 115, 962, 966, "once" +287, 8, 20, 186, 116, 121, 967, 972, "daily" +287, 8, 21, 187, 122, 125, 973, 976, "for" +287, 8, 22, 188, 126, 128, 977, 979, "12" +287, 8, 23, 189, 129, 134, 980, 985, "weeks" +287, 8, 24, 190, 135, 136, 986, 987, "." +287, 9, 1, 191, 0, 8, 988, 996, "Subjects" +287, 9, 2, 192, 9, 18, 997, 1006, "continued" +287, 9, 3, 193, 19, 25, 1007, 1013, "stable" +287, 9, 4, 194, 26, 31, 1014, 1019, "doses" +287, 9, 5, 195, 32, 34, 1020, 1022, "of" +287, 9, 6, 196, 35, 45, 1023, 1033, "background" +287, 9, 7, 197, 46, 58, 1034, 1046, "antidiabetes" +287, 9, 8, 198, 59, 69, 1047, 1057, "medication" +287, 9, 9, 199, 70, 80, 1058, 1068, "throughout" +287, 9, 10, 200, 81, 84, 1069, 1072, "the" +287, 9, 11, 201, 85, 90, 1073, 1078, "study" +287, 9, 12, 202, 91, 92, 1079, 1080, "." +287, 10, 1, 203, 0, 7, 1081, 1088, "Insulin" +287, 10, 2, 204, 8, 19, 1089, 1100, "sensitivity" +287, 10, 3, 205, 20, 23, 1101, 1104, "was" +287, 10, 4, 206, 24, 32, 1105, 1113, "assessed" +287, 10, 5, 207, 33, 35, 1114, 1116, "by" +287, 10, 6, 208, 36, 45, 1117, 1126, "measuring" +287, 10, 7, 209, 46, 49, 1127, 1130, "the" +287, 10, 8, 210, 50, 57, 1131, 1138, "glucose" +287, 10, 9, 211, 58, 71, 1139, 1152, "disappearance" +287, 10, 10, 212, 72, 76, 1153, 1157, "rate" +287, 10, 11, 213, 77, 78, 1158, 1159, "(" +287, 10, 12, 214, 79, 82, 1160, 1163, "GDR" +287, 10, 13, 215, 83, 84, 1164, 1165, ")" +287, 10, 14, 216, 85, 91, 1166, 1172, "during" +287, 10, 15, 217, 92, 95, 1173, 1176, "the" +287, 10, 16, 218, 96, 100, 1177, 1181, "last" +287, 10, 17, 219, 101, 103, 1182, 1184, "40" +287, 10, 18, 220, 104, 107, 1185, 1188, "min" +287, 10, 19, 221, 108, 110, 1189, 1191, "of" +287, 10, 20, 222, 111, 112, 1192, 1193, "a" +287, 10, 21, 223, 113, 114, 1194, 1195, "5" +287, 10, 22, 224, 115, 116, 1196, 1197, "-" +287, 10, 23, 225, 117, 118, 1198, 1199, "h" +287, 10, 24, 226, 119, 135, 1200, 1216, "hyperinsulinemic" +287, 10, 25, 227, 136, 137, 1217, 1218, "," +287, 10, 26, 228, 138, 148, 1219, 1229, "euglycemic" +287, 10, 27, 229, 149, 154, 1230, 1235, "clamp" +287, 10, 28, 230, 155, 156, 1236, 1237, "." +287, 11, 1, 231, 0, 7, 1238, 1245, "Insulin" +287, 11, 2, 232, 8, 17, 1246, 1255, "secretion" +287, 11, 3, 233, 18, 21, 1256, 1259, "was" +287, 11, 4, 234, 22, 32, 1260, 1270, "determined" +287, 11, 5, 235, 33, 35, 1271, 1273, "as" +287, 11, 6, 236, 36, 39, 1274, 1277, "the" +287, 11, 7, 237, 40, 45, 1278, 1283, "acute" +287, 11, 8, 238, 46, 53, 1284, 1291, "insulin" +287, 11, 9, 239, 54, 62, 1292, 1300, "response" +287, 11, 10, 240, 63, 65, 1301, 1303, "to" +287, 11, 11, 241, 66, 73, 1304, 1311, "glucose" +287, 11, 12, 242, 74, 75, 1312, 1313, "(" +287, 11, 13, 243, 76, 80, 1314, 1318, "AIRg" +287, 11, 14, 244, 81, 82, 1319, 1320, ")" +287, 11, 15, 245, 83, 89, 1321, 1327, "during" +287, 11, 16, 246, 90, 93, 1328, 1331, "the" +287, 11, 17, 247, 94, 99, 1332, 1337, "first" +287, 11, 18, 248, 100, 102, 1338, 1340, "10" +287, 11, 19, 249, 103, 106, 1341, 1344, "min" +287, 11, 20, 250, 107, 109, 1345, 1347, "of" +287, 11, 21, 251, 110, 111, 1348, 1349, "a" +287, 11, 22, 252, 112, 122, 1350, 1360, "frequently" +287, 11, 23, 253, 123, 130, 1361, 1368, "sampled" +287, 11, 24, 254, 131, 142, 1369, 1380, "intravenous" +287, 11, 25, 255, 143, 150, 1381, 1388, "glucose" +287, 11, 26, 256, 151, 160, 1389, 1398, "tolerance" +287, 11, 27, 257, 161, 165, 1399, 1403, "test" +287, 11, 28, 258, 166, 167, 1404, 1405, "." +287, 12, 1, 259, 0, 5, 1406, 1411, "Where" +287, 12, 2, 260, 6, 11, 1412, 1417, "noted" +287, 12, 3, 261, 12, 13, 1418, 1419, "," +287, 12, 4, 262, 14, 18, 1420, 1424, "data" +287, 12, 5, 263, 19, 23, 1425, 1429, "were" +287, 12, 6, 264, 24, 32, 1430, 1438, "adjusted" +287, 12, 7, 265, 33, 36, 1439, 1442, "for" +287, 12, 8, 266, 37, 45, 1443, 1451, "baseline" +287, 12, 9, 267, 46, 52, 1452, 1458, "values" +287, 12, 10, 268, 53, 56, 1459, 1462, "and" +287, 12, 11, 269, 57, 67, 1463, 1473, "background" +287, 12, 12, 270, 68, 80, 1474, 1486, "antidiabetes" +287, 12, 13, 271, 81, 91, 1487, 1497, "medication" +287, 12, 14, 272, 92, 93, 1498, 1499, "." +287, 13, 1, 273, 0, 7, 1500, 1507, "RESULTS" +287, 13, 2, 274, 8, 9, 1508, 1509, ":" +287, 13, 3, 275, 10, 12, 1510, 1512, "An" +287, 13, 4, 276, 13, 21, 1513, 1521, "adjusted" +287, 13, 5, 277, 22, 26, 1522, 1526, "mean" +287, 13, 6, 278, 27, 35, 1527, 1535, "increase" +287, 13, 7, 279, 36, 40, 1536, 1540, "from" +287, 13, 8, 280, 41, 49, 1541, 1549, "baseline" +287, 13, 9, 281, 50, 52, 1550, 1552, "in" +287, 13, 10, 282, 53, 56, 1553, 1556, "GDR" +287, 13, 11, 283, 57, 58, 1557, 1558, "(" +287, 13, 12, 284, 59, 63, 1559, 1563, "last" +287, 13, 13, 285, 64, 75, 1564, 1575, "observation" +287, 13, 14, 286, 76, 83, 1576, 1583, "carried" +287, 13, 15, 287, 84, 91, 1584, 1591, "forward" +287, 13, 16, 288, 92, 93, 1592, 1593, ")" +287, 13, 17, 289, 94, 95, 1594, 1595, "," +287, 13, 18, 290, 96, 98, 1596, 1598, "at" +287, 13, 19, 291, 99, 103, 1599, 1603, "Week" +287, 13, 20, 292, 104, 106, 1604, 1606, "12" +287, 13, 21, 293, 107, 108, 1607, 1608, "," +287, 13, 22, 294, 109, 112, 1609, 1612, "was" +287, 13, 23, 295, 113, 121, 1613, 1621, "observed" +287, 13, 24, 296, 122, 126, 1622, 1626, "with" +287, 13, 25, 297, 127, 140, 1627, 1640, "dapagliflozin" +287, 13, 26, 298, 141, 142, 1641, 1642, "(" +287, 13, 27, 299, 143, 144, 1643, 1644, "7" +287, 13, 28, 300, 145, 146, 1645, 1646, "." +287, 13, 29, 301, 147, 149, 1647, 1649, "98" +287, 13, 30, 302, 150, 151, 1650, 1651, "%" +287, 13, 31, 303, 152, 153, 1652, 1653, ")" +287, 13, 32, 304, 154, 160, 1654, 1660, "versus" +287, 13, 33, 305, 161, 162, 1661, 1662, "a" +287, 13, 34, 306, 163, 171, 1663, 1671, "decrease" +287, 13, 35, 307, 172, 176, 1672, 1676, "with" +287, 13, 36, 308, 177, 184, 1677, 1684, "placebo" +287, 13, 37, 309, 185, 186, 1685, 1686, "(" +287, 13, 38, 310, 187, 188, 1687, 1688, "-" +287, 13, 39, 311, 189, 190, 1689, 1690, "9" +287, 13, 40, 312, 191, 192, 1691, 1692, "." +287, 13, 41, 313, 193, 195, 1693, 1695, "99" +287, 13, 42, 314, 196, 197, 1696, 1697, "%" +287, 13, 43, 315, 198, 199, 1698, 1699, ")" +287, 13, 44, 316, 200, 201, 1700, 1701, "." +287, 14, 1, 317, 0, 3, 1702, 1705, "The" +287, 14, 2, 318, 4, 6, 1706, 1708, "19" +287, 14, 3, 319, 7, 8, 1709, 1710, "." +287, 14, 4, 320, 9, 11, 1711, 1713, "97" +287, 14, 5, 321, 12, 13, 1714, 1715, "%" +287, 14, 6, 322, 14, 15, 1716, 1717, "(" +287, 14, 7, 323, 16, 18, 1718, 1720, "95" +287, 14, 8, 324, 19, 20, 1721, 1722, "%" +287, 14, 9, 325, 21, 31, 1723, 1733, "confidence" +287, 14, 10, 326, 32, 40, 1734, 1742, "interval" +287, 14, 11, 327, 41, 42, 1743, 1744, "5" +287, 14, 12, 328, 43, 44, 1745, 1746, "." +287, 14, 13, 329, 45, 47, 1747, 1749, "75" +287, 14, 14, 330, 48, 49, 1750, 1751, "-" +287, 14, 15, 331, 50, 52, 1752, 1754, "36" +287, 14, 16, 332, 53, 54, 1755, 1756, "." +287, 14, 17, 333, 55, 57, 1757, 1759, "10" +287, 14, 18, 334, 58, 59, 1760, 1761, ")" +287, 14, 19, 335, 60, 70, 1762, 1772, "difference" +287, 14, 20, 336, 71, 73, 1773, 1775, "in" +287, 14, 21, 337, 74, 77, 1776, 1779, "GDR" +287, 14, 22, 338, 78, 84, 1780, 1786, "versus" +287, 14, 23, 339, 85, 92, 1787, 1794, "placebo" +287, 14, 24, 340, 93, 96, 1795, 1798, "was" +287, 14, 25, 341, 97, 110, 1799, 1812, "statistically" +287, 14, 26, 342, 111, 122, 1813, 1824, "significant" +287, 14, 27, 343, 123, 124, 1825, 1826, "(" +287, 14, 28, 344, 125, 126, 1827, 1828, "P" +287, 14, 29, 345, 127, 128, 1829, 1830, "=" +287, 14, 30, 346, 129, 130, 1831, 1832, "0" +287, 14, 31, 347, 131, 132, 1833, 1834, "." +287, 14, 32, 348, 133, 137, 1835, 1839, "0059" +287, 14, 33, 349, 138, 139, 1840, 1841, ")" +287, 14, 34, 350, 140, 141, 1842, 1843, "." +287, 15, 1, 351, 0, 1, 1844, 1845, "A" +287, 15, 2, 352, 2, 8, 1846, 1852, "change" +287, 15, 3, 353, 9, 13, 1853, 1857, "from" +287, 15, 4, 354, 14, 22, 1858, 1866, "baseline" +287, 15, 5, 355, 23, 25, 1867, 1869, "in" +287, 15, 6, 356, 26, 34, 1870, 1878, "adjusted" +287, 15, 7, 357, 35, 39, 1879, 1883, "mean" +287, 15, 8, 358, 40, 44, 1884, 1888, "AIRg" +287, 15, 9, 359, 45, 47, 1889, 1891, "of" +287, 15, 10, 360, 48, 50, 1892, 1894, "15" +287, 15, 11, 361, 51, 52, 1895, 1896, "." +287, 15, 12, 362, 53, 55, 1897, 1899, "39" +287, 15, 13, 363, 56, 58, 1900, 1902, "mU" +287, 15, 14, 364, 59, 60, 1903, 1904, "/" +287, 15, 15, 365, 61, 62, 1905, 1906, "L" +287, 15, 16, 366, 63, 66, 1907, 1910, "min" +287, 15, 17, 367, 67, 70, 1911, 1914, "was" +287, 15, 18, 368, 71, 79, 1915, 1923, "observed" +287, 15, 19, 369, 80, 84, 1924, 1928, "with" +287, 15, 20, 370, 85, 98, 1929, 1942, "dapagliflozin" +287, 15, 21, 371, 99, 101, 1943, 1945, "at" +287, 15, 22, 372, 102, 106, 1946, 1950, "Week" +287, 15, 23, 373, 107, 109, 1951, 1953, "12" +287, 15, 24, 374, 110, 111, 1954, 1955, "," +287, 15, 25, 375, 112, 118, 1956, 1962, "versus" +287, 15, 26, 376, 119, 120, 1963, 1964, "-" +287, 15, 27, 377, 121, 123, 1965, 1967, "12" +287, 15, 28, 378, 124, 125, 1968, 1969, "." +287, 15, 29, 379, 126, 128, 1970, 1972, "73" +287, 15, 30, 380, 129, 131, 1973, 1975, "mU" +287, 15, 31, 381, 132, 133, 1976, 1977, "/" +287, 15, 32, 382, 134, 135, 1978, 1979, "L" +287, 15, 33, 383, 136, 139, 1980, 1983, "min" +287, 15, 34, 384, 140, 144, 1984, 1988, "with" +287, 15, 35, 385, 145, 152, 1989, 1996, "placebo" +287, 15, 36, 386, 153, 154, 1997, 1998, "(" +287, 15, 37, 387, 155, 156, 1999, 2000, "P" +287, 15, 38, 388, 157, 158, 2001, 2002, "=" +287, 15, 39, 389, 159, 160, 2003, 2004, "0" +287, 15, 40, 390, 161, 162, 2005, 2006, "." +287, 15, 41, 391, 163, 167, 2007, 2011, "0598" +287, 15, 42, 392, 168, 169, 2012, 2013, ")" +287, 15, 43, 393, 170, 171, 2014, 2015, "." +287, 16, 1, 394, 0, 4, 2016, 2020, "Over" +287, 16, 2, 395, 5, 7, 2021, 2023, "12" +287, 16, 3, 396, 8, 13, 2024, 2029, "weeks" +287, 16, 4, 397, 14, 15, 2030, 2031, "," +287, 16, 5, 398, 16, 25, 2032, 2041, "numerical" +287, 16, 6, 399, 26, 36, 2042, 2052, "reductions" +287, 16, 7, 400, 37, 41, 2053, 2057, "from" +287, 16, 8, 401, 42, 50, 2058, 2066, "baseline" +287, 16, 9, 402, 51, 53, 2067, 2069, "in" +287, 16, 10, 403, 54, 66, 2070, 2082, "glycosylated" +287, 16, 11, 404, 67, 77, 2083, 2093, "hemoglobin" +287, 16, 12, 405, 78, 79, 2094, 2095, "(" +287, 16, 13, 406, 80, 85, 2096, 2101, "HbA1c" +287, 16, 14, 407, 86, 87, 2102, 2103, ")" +287, 16, 15, 408, 88, 89, 2104, 2105, "," +287, 16, 16, 409, 90, 97, 2106, 2113, "fasting" +287, 16, 17, 410, 98, 104, 2114, 2120, "plasma" +287, 16, 18, 411, 105, 112, 2121, 2128, "glucose" +287, 16, 19, 412, 113, 114, 2129, 2130, "," +287, 16, 20, 413, 115, 118, 2131, 2134, "and" +287, 16, 21, 414, 119, 123, 2135, 2139, "body" +287, 16, 22, 415, 124, 130, 2140, 2146, "weight" +287, 16, 23, 416, 131, 135, 2147, 2151, "were" +287, 16, 24, 417, 136, 144, 2152, 2160, "observed" +287, 16, 25, 418, 145, 149, 2161, 2165, "with" +287, 16, 26, 419, 150, 163, 2166, 2179, "dapagliflozin" +287, 16, 27, 420, 164, 165, 2180, 2181, "(" +287, 16, 28, 421, 166, 167, 2182, 2183, "-" +287, 16, 29, 422, 168, 169, 2184, 2185, "0" +287, 16, 30, 423, 170, 171, 2186, 2187, "." +287, 16, 31, 424, 172, 174, 2188, 2190, "38" +287, 16, 32, 425, 175, 176, 2191, 2192, "%" +287, 16, 33, 426, 177, 178, 2193, 2194, "," +287, 16, 34, 427, 179, 180, 2195, 2196, "-" +287, 16, 35, 428, 181, 182, 2197, 2198, "0" +287, 16, 36, 429, 183, 184, 2199, 2200, "." +287, 16, 37, 430, 185, 187, 2201, 2203, "39" +287, 16, 38, 431, 188, 192, 2204, 2208, "mmol" +287, 16, 39, 432, 193, 194, 2209, 2210, "/" +287, 16, 40, 433, 195, 196, 2211, 2212, "L" +287, 16, 41, 434, 197, 198, 2213, 2214, "," +287, 16, 42, 435, 199, 202, 2215, 2218, "and" +287, 16, 43, 436, 203, 204, 2219, 2220, "-" +287, 16, 44, 437, 205, 206, 2221, 2222, "1" +287, 16, 45, 438, 207, 208, 2223, 2224, "." +287, 16, 46, 439, 209, 211, 2225, 2227, "58" +287, 16, 47, 440, 212, 213, 2228, 2229, "%" +287, 16, 48, 441, 214, 215, 2230, 2231, "," +287, 16, 49, 442, 216, 228, 2232, 2244, "respectively" +287, 16, 50, 443, 229, 230, 2245, 2246, ")" +287, 16, 51, 444, 231, 237, 2247, 2253, "versus" +287, 16, 52, 445, 238, 244, 2254, 2260, "slight" +287, 16, 53, 446, 245, 254, 2261, 2270, "numerical" +287, 16, 54, 447, 255, 264, 2271, 2280, "increases" +287, 16, 55, 448, 265, 269, 2281, 2285, "with" +287, 16, 56, 449, 270, 277, 2286, 2293, "placebo" +287, 16, 57, 450, 278, 279, 2294, 2295, "(" +287, 16, 58, 451, 280, 281, 2296, 2297, "0" +287, 16, 59, 452, 282, 283, 2298, 2299, "." +287, 16, 60, 453, 284, 286, 2300, 2302, "03" +287, 16, 61, 454, 287, 288, 2303, 2304, "%" +287, 16, 62, 455, 289, 290, 2305, 2306, "," +287, 16, 63, 456, 291, 292, 2307, 2308, "0" +287, 16, 64, 457, 293, 294, 2309, 2310, "." +287, 16, 65, 458, 295, 297, 2311, 2313, "26" +287, 16, 66, 459, 298, 302, 2314, 2318, "mmol" +287, 16, 67, 460, 303, 304, 2319, 2320, "/" +287, 16, 68, 461, 305, 306, 2321, 2322, "L" +287, 16, 69, 462, 307, 308, 2323, 2324, "," +287, 16, 70, 463, 309, 312, 2325, 2328, "and" +287, 16, 71, 464, 313, 314, 2329, 2330, "0" +287, 16, 72, 465, 315, 316, 2331, 2332, "." +287, 16, 73, 466, 317, 319, 2333, 2335, "62" +287, 16, 74, 467, 320, 321, 2336, 2337, "%" +287, 16, 75, 468, 322, 323, 2338, 2339, "," +287, 16, 76, 469, 324, 336, 2340, 2352, "respectively" +287, 16, 77, 470, 337, 338, 2353, 2354, ")" +287, 16, 78, 471, 339, 340, 2355, 2356, "." +287, 17, 1, 472, 0, 11, 2357, 2368, "CONCLUSIONS" +287, 17, 2, 473, 12, 13, 2369, 2370, ":" +287, 17, 3, 474, 14, 16, 2371, 2373, "In" +287, 17, 4, 475, 17, 25, 2374, 2382, "patients" +287, 17, 5, 476, 26, 30, 2383, 2387, "with" +287, 17, 6, 477, 31, 35, 2388, 2392, "T2DM" +287, 17, 7, 478, 36, 39, 2393, 2396, "and" +287, 17, 8, 479, 40, 50, 2397, 2407, "inadequate" +287, 17, 9, 480, 51, 59, 2408, 2416, "glycemic" +287, 17, 10, 481, 60, 67, 2417, 2424, "control" +287, 17, 11, 482, 68, 69, 2425, 2426, "," +287, 17, 12, 483, 70, 83, 2427, 2440, "dapagliflozin" +287, 17, 13, 484, 84, 93, 2441, 2450, "treatment" +287, 17, 14, 485, 94, 102, 2451, 2459, "improved" +287, 17, 15, 486, 103, 110, 2460, 2467, "insulin" +287, 17, 16, 487, 111, 122, 2468, 2479, "sensitivity" +287, 17, 17, 488, 123, 125, 2480, 2482, "in" +287, 17, 18, 489, 126, 129, 2483, 2486, "the" +287, 17, 19, 490, 130, 137, 2487, 2494, "setting" +287, 17, 20, 491, 138, 140, 2495, 2497, "of" +287, 17, 21, 492, 141, 151, 2498, 2508, "reductions" +287, 17, 22, 493, 152, 154, 2509, 2511, "in" +287, 17, 23, 494, 155, 160, 2512, 2517, "HbA1c" +287, 17, 24, 495, 161, 164, 2518, 2521, "and" +287, 17, 25, 496, 165, 171, 2522, 2528, "weight" +287, 17, 26, 497, 172, 173, 2529, 2530, "." +287, 18, 1, 498, 0, 3, 2531, 2534, "DOI" +287, 18, 2, 499, 4, 5, 2535, 2536, ":" +287, 18, 3, 500, 6, 8, 2537, 2539, "10" +287, 18, 4, 501, 9, 10, 2540, 2541, "." +287, 18, 5, 502, 11, 15, 2542, 2546, "1089" +287, 18, 6, 503, 16, 17, 2547, 2548, "/" +287, 18, 7, 504, 18, 21, 2549, 2552, "dia" +287, 18, 8, 505, 22, 23, 2553, 2554, "." +287, 18, 9, 506, 24, 28, 2555, 2559, "2013" +287, 18, 10, 507, 29, 30, 2560, 2561, "." +287, 18, 11, 508, 31, 35, 2562, 2566, "0167" +287, 18, 12, 509, 36, 40, 2567, 2571, "PMID" +287, 18, 13, 510, 41, 42, 2572, 2573, ":" +287, 18, 14, 511, 43, 51, 2574, 2582, "24237386" +287, 18, 15, 512, 52, 53, 2583, 2584, "[" +287, 18, 16, 513, 54, 61, 2585, 2592, "Indexed" +287, 18, 17, 514, 62, 65, 2593, 2596, "for" +287, 18, 18, 515, 66, 73, 2597, 2604, "MEDLINE" +287, 18, 19, 516, 74, 75, 2605, 2606, "]" diff --git a/data/dm2 24237386_kwoodley.annodb b/data/dm2 24237386_kwoodley.annodb new file mode 100644 index 0000000..06f5468 --- /dev/null +++ b/data/dm2 24237386_kwoodley.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46754, Journal, 0, 21, "Diabetes Technol Ther", "", +46755, PublicationYear, 24, 28, "2014", "", +46765, Title, 114, 232, "Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin .", "", +46802, EndPointDescription, 125, 144, "insulin sensitivity", "", +46800, EndPointDescription, 149, 166, "insulin secretion", "", +46758, Dapagliflozin, 217, 230, "dapagliflozin", "", +46766, Author, 233, 243, "Mudaliar S", "", +46767, Author, 252, 260, "Henry RR", "", +46768, Author, 263, 270, "Boden G", "", +46769, Author, 273, 280, "Smith S", "", +46770, Author, 283, 299, "Chalamandaris AG", "", +46771, Author, 302, 312, "Duchesne D", "", +46772, Author, 315, 322, "Iqbal N", "", +46773, Author, 325, 331, "List J", "", +46774, USA, 483, 493, "California", "", +46792, ObjectiveDescription, 502, 700, "This randomized , double - blind , placebo - controlled parallel - group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion", "", +46776, Randomized, 507, 517, "randomized", "", +46777, DoubleBlind, 520, 534, "double - blind", "", +46778, Placebo, 537, 544, "placebo", "", +46783, Parallel, 558, 574, "parallel - group", "", +46759, Dapagliflozin, 650, 663, "dapagliflozin", "", +46803, EndPointDescription, 667, 686, "insulin sensitivity", "", +46804, EndPointDescription, 691, 700, "secretion", "", +46793, ObjectiveDescription, 701, 850, "in subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue ) .", "", +46790, Precondition, 704, 848, "subjects with type 2 diabetes mellitus ( T2DM ) , who had inadequate glycemic control with metformin ( with or without an insulin secretagogue )", "", +46786, Type2Diabetes, 718, 742, "type 2 diabetes mellitus", "", +46787, Type2Diabetes, 745, 749, "T2DM", "", +46789, Metformin, 795, 804, "metformin", "", +46791, Insulin, 826, 833, "insulin", "", +46794, NumberPatientsCT, 874, 886, "Forty - four", "", +46795, Randomized, 901, 911, "randomized", "", +46760, Dapagliflozin, 923, 936, "dapagliflozin", "", +46796, DoseValue, 937, 938, "5", "", +46797, mg, 939, 941, "mg", "", +46779, Placebo, 954, 961, "placebo", "", +46798, Frequency, 962, 972, "once daily", "", +46799, Duration, 977, 985, "12 weeks", "", +46805, EndPointDescription, 1081, 1100, "Insulin sensitivity", "", +46811, EndPointDescription, 1160, 1163, "GDR", "", +46806, EndPointDescription, 1238, 1255, "Insulin secretion", "", +46812, EndPointDescription, 1314, 1318, "AIRg", "", +46813, TimePoint, 1541, 1549, "baseline", "", +46807, EndPointDescription, 1553, 1556, "GDR", "", +46814, TimePoint, 1599, 1606, "Week 12", "", +46761, Dapagliflozin, 1627, 1640, "dapagliflozin", "", +46819, Increment, 1643, 1649, "7 . 98", "", +46821, Percentage, 1650, 1651, "%", "", +46780, Placebo, 1677, 1684, "placebo", "", +46820, Reduction, 1689, 1695, "9 . 99", "", +46822, Percentage, 1696, 1697, "%", "", +46824, DiffGroupAbsValue, 1706, 1713, "19 . 97", "", +46823, Percentage, 1714, 1715, "%", "", +46825, ConfIntervalDiff, 1718, 1759, "95 % confidence interval 5 . 75 - 36 . 10", "", +46808, EndPointDescription, 1776, 1779, "GDR", "", +46826, Placebo, 1787, 1794, "placebo", "", +46827, PvalueDiff, 1827, 1839, "P = 0 . 0059", "", +46815, TimePoint, 1858, 1866, "baseline", "", +46809, EndPointDescription, 1884, 1888, "AIRg", "", +46830, Increment, 1892, 1899, "15 . 39", "", +46828, BioAndMedicalUnit, 1900, 1910, "mU / L min", "", +46762, Dapagliflozin, 1929, 1942, "dapagliflozin", "", +46816, TimePoint, 1946, 1953, "Week 12", "", +46831, Reduction, 1965, 1972, "12 . 73", "", +46829, BioAndMedicalUnit, 1973, 1983, "mU / L min", "", +46781, Placebo, 1989, 1996, "placebo", "", +46832, PvalueDiff, 1999, 2011, "P = 0 . 0598", "", +46818, TimePoint, 2021, 2029, "12 weeks", "", +46817, TimePoint, 2058, 2066, "baseline", "", +46833, HbA1c, 2070, 2093, "glycosylated hemoglobin", "", +46834, HbA1c, 2096, 2101, "HbA1c", "", +46835, FastingPlasmaGlucose, 2106, 2128, "fasting plasma glucose", "", +46836, BodyWeight, 2135, 2146, "body weight", "", +46763, Dapagliflozin, 2166, 2179, "dapagliflozin", "", +46837, Reduction, 2184, 2190, "0 . 38", "", +46840, Percentage, 2191, 2192, "%", "", +46838, Reduction, 2197, 2203, "0 . 39", "", +46844, Millimoles_per_litre, 2204, 2212, "mmol / L", "", +46839, Reduction, 2221, 2227, "1 . 58", "", +46841, Percentage, 2228, 2229, "%", "", +46782, Placebo, 2286, 2293, "placebo", "", +46845, Increment, 2296, 2302, "0 . 03", "", +46842, Percentage, 2303, 2304, "%", "", +46846, Increment, 2307, 2313, "0 . 26", "", +46848, Millimoles_per_litre, 2314, 2322, "mmol / L", "", +46847, Increment, 2329, 2335, "0 . 62", "", +46843, Percentage, 2336, 2337, "%", "", +46851, ConclusionComment, 2371, 2530, "In patients with T2DM and inadequate glycemic control , dapagliflozin treatment improved insulin sensitivity in the setting of reductions in HbA1c and weight .", "", +46788, Type2Diabetes, 2388, 2392, "T2DM", "", +46764, Dapagliflozin, 2427, 2440, "dapagliflozin", "", +46810, EndPointDescription, 2460, 2479, "insulin sensitivity", "", +46849, HbA1c, 2512, 2517, "HbA1c", "", +46850, BodyWeight, 2522, 2528, "weight", "", +46852, PMID, 2574, 2582, "24237386", "", diff --git a/data/dm2 24237386_kwoodley.n-triples b/data/dm2 24237386_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24237386_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24356792_admin.annodb b/data/dm2 24356792_admin.annodb new file mode 100644 index 0000000..8b89b39 --- /dev/null +++ b/data/dm2 24356792_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Horm Metab Res .", "", " \"Horm Metab Res .\"." +1, PublicationYear, 17, 21, "2014", "", " \"2014\"." +15, Title, 108, 203, "The glucose and lipid effects of colesevelam as monotherapy in drug - na ï ve type 2 diabetes .", "", " \"The glucose and lipid effects of colesevelam as monotherapy in drug - na ï ve type 2 diabetes .\"." +79852, Colesevelam, 141, 152, "colesevelam", "", +28, Precondition, 171, 201, "drug - na ï ve type 2 diabetes", "", +10, Type2Diabetes, 186, 201, "type 2 diabetes", "", +16, Author, 204, 216, "Rosenstock J", "", " \"Rosenstock J\"." +17, Author, 225, 233, "Rigby SP", "", " \"Rigby SP\"." +18, Author, 242, 249, "Ford DM", "", +19, Author, 258, 263, "Tao B", "", +20, Author, 272, 279, "Chou HS", "", " \"Chou HS\"." +21, USA, 384, 387, "USA", "", " ." +102, USA, 434, 437, "USA", "", +103, USA, 496, 499, "USA", "", +79854, Colesevelam, 502, 513, "Colesevelam", "", +11, Type2Diabetes, 548, 572, "type 2 diabetes mellitus", "", " ." +12, Type2Diabetes, 575, 579, "T2DM", "", +22, Metformin, 602, 611, "metformin", "", +23, Sulfonylureas, 616, 628, "sulfonylurea", "", +24, Insulin, 636, 643, "insulin", "", +25, HbA1c, 671, 685, "hemoglobin A1c", "", +26, HbA1c, 688, 693, "HbA1c", "", +29, ObjectiveDescription, 747, 846, "A study was conducted to evaluate colesevelam as monotherapy in drug - na ï ve patients with T2DM .", "", " \"A study was conducted to evaluate colesevelam as monotherapy in drug - na ï ve patients with T2DM .\"." +79853, Colesevelam, 781, 792, "colesevelam", "", +27, Precondition, 811, 844, "drug - na ï ve patients with T2DM", "", " \"drug - na ï ve patients with T2DM\"." +13, Type2Diabetes, 840, 844, "T2DM", "", +30, Randomized, 855, 865, "randomized", "", " ." +31, DoubleBlind, 868, 882, "double - blind", "", " ." +32, Placebo, 885, 892, "placebo", "", +33, Parallel, 908, 924, "parallel - group", "", " ." +38, Precondition, 933, 1048, "adults with T2DM who had inadequate glycemic control ( HbA1c ≥ 7 . 5 % and ≤ 9 . 5 % ) with diet and exercise alone", "", " \"adults with T2DM who had inadequate glycemic control ( HbA1c ≥ 7 . 5 % and ≤ 9 . 5 % ) with diet and exercise alone\"." +14, Type2Diabetes, 945, 949, "T2DM", "", +34, HbA1c, 988, 993, "HbA1c", "", +35, Percentage, 1002, 1003, "%", "", +36, Percentage, 1016, 1017, "%", "", +37, Randomized, 1054, 1064, "randomized", "", +79855, Colesevelam, 1076, 1087, "colesevelam", "", " ." +39, DoseValue, 1088, 1094, "3 . 75", "", " \"3 . 75\"." +40, Gram, 1097, 1098, "g", "", " ." +41, Frequency, 1101, 1104, "day", "", " \"day\"." +42, NumberPatientsArm, 1111, 1114, "176", "", " \"176\"." +44, Placebo, 1120, 1127, "placebo", "", " ." +43, NumberPatientsArm, 1134, 1137, "181", "", " \"181\"." +47, Duration, 1144, 1152, "24 weeks", "", " \"24 weeks\"." +48, HbA1c, 1189, 1194, "HbA1c", "", +51, TimePoint, 1198, 1205, "week 24", "", +79856, Colesevelam, 1208, 1219, "Colesevelam", "", +45, Placebo, 1235, 1242, "placebo", "", +53, TimePoint, 1278, 1286, "baseline", "", " \"week 24\". \"week 24\". \"week 24\". \"week 24\"." +49, HbA1c, 1290, 1295, "HbA1c", "", " ." +138, DiffGroupAbsValue, 1298, 1306, "- 2 . 92", "", " \"- 2 . 92\"." +79860, Millimoles_per_mole, 1309, 1319, "mmol / mol", "", " ." +142, DiffGroupRelValue, 1322, 1327, "0 . 3", "", " \"0 . 3\"." +58, Percentage, 1328, 1329, "%", "", +143, PvalueDiff, 1334, 1344, "p = 0 . 01", "", " \"p = 0 . 01\"." +61, FastingPlasmaGlucose, 1351, 1373, "fasting plasma glucose", "", " ." +139, DiffGroupAbsValue, 1376, 1384, "- 10 . 3", "", " \"- 10 . 3\"." +62, Mg_per_deciliter, 1387, 1394, "mg / dl", "", " ." +146, PvalueDiff, 1397, 1407, "p = 0 . 04", "", " \"p = 0 . 04\"." +52, TimePoint, 1413, 1420, "week 24", "", " \"week 24\". \"week 24\". \"week 24\". \"week 24\"." +79857, Colesevelam, 1461, 1472, "Colesevelam", "", +63, EndPointDescription, 1500, 1537, "low - density lipoprotein cholesterol", "", " . ." +70356, RelativeReduction, 1542, 1548, "11 . 2", "", " \"11 . 2\"." +77, PValueChangeValue, 1553, 1565, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +64, EndPointDescription, 1570, 1587, "total cholesterol", "", " . ." +70368, RelativeReduction, 1592, 1597, "5 . 1", "", " \"5 . 1\"." +78, PValueChangeValue, 1602, 1614, "p = 0 . 0005", "", " \"p = 0 . 0005\"." +65, EndPointDescription, 1619, 1663, "non - high - density lipoprotein cholesterol", "", " . ." +70369, RelativeReduction, 1668, 1673, "7 . 4", "", " \"7 . 4\"." +79, PValueChangeValue, 1678, 1690, "p = 0 . 0001", "", " \"p = 0 . 0001\"." +66, EndPointDescription, 1699, 1715, "apolipoprotein B", "", " . ." +70370, RelativeReduction, 1720, 1725, "6 . 5", "", " \"6 . 5\"." +80, PValueChangeValue, 1730, 1742, "p = 0 . 0001", "", " \"p = 0 . 0001\"." +67, EndPointDescription, 1759, 1779, "apolipoprotein A - I", "", " . ." +70371, RelativeIncrement, 1785, 1790, "2 . 4", "", " \"2 . 4\"." +81, PValueChangeValue, 1795, 1805, "p = 0 . 04", "", " \"p = 0 . 04\"." +68, EndPointDescription, 1814, 1827, "triglycerides", "", " . ." +70372, RelativeIncrement, 1833, 1838, "9 . 7", "", " \"9 . 7\"." +82, PValueChangeValue, 1843, 1853, "p = 0 . 03", "", " \"p = 0 . 03\"." +87, ConclusionComment, 1858, 2064, "Colesevelam monotherapy resulted in statistically significant improvements in glycemic and most lipid parameters in subjects with type 2 diabetes , with no new or unexpected safety and tolerability issues .", "", " \"Colesevelam monotherapy resulted in statistically significant improvements in glycemic and most lipid parameters in subjects with type 2 diabetes , with no new or unexpected safety and tolerability issues .\"." +79858, Colesevelam, 1858, 1869, "Colesevelam", "", +46, Type2Diabetes, 1988, 2003, "type 2 diabetes", "", +88, ConclusionComment, 2065, 2310, "Modest reductions in HbA1c and low - density lipoprotein cholesterol levels with colesevelam further support its use in combination with other antidiabetes agents when treatment targets for these parameters are close but are not quite achieved .", "", " \"Modest reductions in HbA1c and low - density lipoprotein cholesterol levels with colesevelam further support its use in combination with other antidiabetes agents when treatment targets for these parameters are close but are not quite achieved .\"." +50, HbA1c, 2086, 2091, "HbA1c", "", +79859, Colesevelam, 2146, 2157, "colesevelam", "", +89, PMID, 2451, 2459, "24356792", "", " \"24356792\"." diff --git a/data/dm2 24356792_admin.n-triples b/data/dm2 24356792_admin.n-triples new file mode 100644 index 0000000..f92bcbe --- /dev/null +++ b/data/dm2 24356792_admin.n-triples @@ -0,0 +1,198 @@ +# RDF export of group: Publication + . + "Publication 55388" . + "The glucose and lipid effects of colesevelam as monotherapy in drug - na ï ve type 2 diabetes ." . + "Rosenstock J" . + "2014" . + "Horm Metab Res ." . + "24356792" . + . + "Rigby SP" . + "Chou HS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 55395" . + "A study was conducted to evaluate colesevelam as monotherapy in drug - na ï ve patients with T2DM ." . + "24 weeks" . + . + . + . + "Colesevelam monotherapy resulted in statistically significant improvements in glycemic and most lipid parameters in subjects with type 2 diabetes , with no new or unexpected safety and tolerability issues ." . + . + . + . + . + . + . + "Modest reductions in HbA1c and low - density lipoprotein cholesterol levels with colesevelam further support its use in combination with other antidiabetes agents when treatment targets for these parameters are close but are not quite achieved ." . + . + . + . +# RDF export of group: Population + . + "Population 55411" . + "adults with T2DM who had inadequate glycemic control ( HbA1c ≥ 7 . 5 % and ≤ 9 . 5 % ) with diet and exercise alone" . + . + . + . + "drug - na ï ve patients with T2DM" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "low" . + . + . + . + . + . + . + "tot" . + . + . + . + . + . + . + "non" . + . + . + . + . + . + . + "apo" . + . + . + . + . + . + . + "apoa" . + . + . + . + . + . + . + "tri" . + . + . + . + . + . +# RDF export of group: Arm + . + "col" . + "176" . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + "181" . + . + . + . + . +# RDF export of group: Intervention + . + "col" . + . + "day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "col" . + . + "3 . 75" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "week 24" . + . + "hba 2" . + . + "week 24" . + . + "fpg 1" . + . + "week 24" . + . + "fpg 2" . + . + "week 24" . + . + "low" . + . + "11 . 2" . + "p < 0 . 0001" . + . + "tot" . + . + "5 . 1" . + "p = 0 . 0005" . + . + "non" . + . + "7 . 4" . + "p = 0 . 0001" . + . + "apo" . + . + "6 . 5" . + "p = 0 . 0001" . + . + "apoa" . + . + "2 . 4" . + "p = 0 . 04" . + . + "tri" . + . + "9 . 7" . + "p = 0 . 03" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 2 . 92" . + "0 . 3" . + "p = 0 . 01" . + . + . + . + "fpg" . + "- 10 . 3" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24356792_akramersunderbrink.annodb b/data/dm2 24356792_akramersunderbrink.annodb new file mode 100644 index 0000000..07c7b3f --- /dev/null +++ b/data/dm2 24356792_akramersunderbrink.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59164, Journal, 0, 14, "Horm Metab Res", "", +59165, PublicationYear, 17, 21, "2014", "", +59168, Title, 108, 203, "The glucose and lipid effects of colesevelam as monotherapy in drug - na ï ve type 2 diabetes .", "", +59169, Drug, 141, 152, "colesevelam", "", +59167, Precondition, 171, 185, "drug - na ï ve", "", +59166, Type2Diabetes, 186, 201, "type 2 diabetes", "", +59170, Author, 204, 216, "Rosenstock J", "", +59171, Author, 225, 233, "Rigby SP", "", +59172, Author, 242, 249, "Ford DM", "", +59173, Author, 258, 263, "Tao B", "", +59174, Author, 272, 279, "Chou HS", "", +59175, USA, 384, 387, "USA", "", +59176, USA, 434, 437, "USA", "", +59177, USA, 496, 499, "USA", "", +59178, Drug, 502, 513, "Colesevelam", "", +59190, ObjectiveDescription, 502, 746, "Colesevelam has shown efficacy in adults with type 2 diabetes mellitus ( T2DM ) in combination with metformin - , sulfonylurea - , or insulin - based therapy , lowering hemoglobin A1c ( HbA1c ) and low - density lipoprotein cholesterol levels .", "", +59179, Type2Diabetes, 548, 572, "type 2 diabetes mellitus", "", +59179, Type2Diabetes, 575, 579, "T2DM", "", +59181, Metformin, 602, 611, "metformin", "", +59183, Sulfonylureas, 616, 628, "sulfonylurea", "", +59184, HbA1c, 671, 685, "hemoglobin A1c", "", +59185, HbA1c, 688, 693, "HbA1c", "", +59191, ObjectiveDescription, 747, 846, "A study was conducted to evaluate colesevelam as monotherapy in drug - na ï ve patients with T2DM .", "", +59186, Drug, 781, 792, "colesevelam", "", +59187, Precondition, 811, 825, "drug - na ï ve", "", +59188, Type2Diabetes, 840, 844, "T2DM", "", +59189, Randomized, 855, 865, "randomized", "", +59192, DoubleBlind, 868, 882, "double - blind", "", +59193, Placebo, 885, 892, "placebo", "", +59194, Parallel, 908, 924, "parallel - group", "", +59195, Type2Diabetes, 945, 949, "T2DM", "", +59196, Precondition, 958, 1017, "inadequate glycemic control ( HbA1c ≥ 7 . 5 % and ≤ 9 . 5 %", "", +59197, HbA1c, 988, 993, "HbA1c", "", +59198, Percentage, 1002, 1003, "%", "", +59199, Percentage, 1016, 1017, "%", "", +59200, Randomized, 1054, 1064, "randomized", "", +59201, Drug, 1076, 1087, "colesevelam", "", +59203, DoseValue, 1088, 1104, "3 . 75   g / day", "", +59204, NumberPatientsArm, 1111, 1114, "176", "", +59202, Placebo, 1120, 1127, "placebo", "", +59205, NumberPatientsArm, 1134, 1137, "181", "", +59206, Duration, 1144, 1152, "24 weeks", "", +59207, HbA1c, 1189, 1194, "HbA1c", "", +59208, TimePoint, 1198, 1205, "week 24", "", +59209, Drug, 1208, 1219, "Colesevelam", "", +59210, Placebo, 1235, 1242, "placebo", "", +59211, TimePoint, 1278, 1286, "baseline", "", +59212, HbA1c, 1290, 1295, "HbA1c", "", +59214, DiffGroupAbsValue, 1298, 1306, "- 2 . 92", "", +59217, ConcentrationUnit, 1309, 1319, "mmol / mol", "", +59219, DiffGroupRelValue, 1322, 1327, "0 . 3", "", +59218, Percentage, 1328, 1329, "%", "", +59220, PvalueDiff, 1334, 1344, "p = 0 . 01", "", +59221, FastingPlasmaGlucose, 1351, 1373, "fasting plasma glucose", "", +59216, DiffGroupAbsValue, 1376, 1384, "- 10 . 3", "", +59222, Mg_per_deciliter, 1387, 1394, "mg / dl", "", +59223, PvalueDiff, 1397, 1407, "p = 0 . 04", "", +59213, TimePoint, 1413, 1420, "week 24", "", +59224, Drug, 1461, 1472, "Colesevelam", "", +59232, EndPointDescription, 1492, 1537, "reduced low - density lipoprotein cholesterol", "", +59238, DiffGroupAbsValue, 1540, 1548, "- 11 . 2", "", +59225, Percentage, 1549, 1550, "%", "", +59226, PvalueDiff, 1553, 1565, "p < 0 . 0001", "", +59233, EndPointDescription, 1570, 1587, "total cholesterol", "", +59239, DiffGroupAbsValue, 1590, 1597, "- 5 . 1", "", +59244, Percentage, 1598, 1599, "%", "", +59227, PvalueDiff, 1602, 1614, "p = 0 . 0005", "", +59234, EndPointDescription, 1619, 1663, "non - high - density lipoprotein cholesterol", "", +59240, DiffGroupAbsValue, 1666, 1673, "- 7 . 4", "", +59245, Percentage, 1674, 1675, "%", "", +59228, PvalueDiff, 1678, 1690, "p = 0 . 0001", "", +59235, EndPointDescription, 1699, 1715, "apolipoprotein B", "", +59241, DiffGroupAbsValue, 1718, 1725, "- 6 . 5", "", +59246, Percentage, 1726, 1727, "%", "", +59229, PvalueDiff, 1730, 1742, "p = 0 . 0001", "", +59236, EndPointDescription, 1749, 1779, "increased apolipoprotein A - I", "", +59242, DiffGroupAbsValue, 1782, 1790, "+  2 . 4", "", +59247, Percentage, 1791, 1792, "%", "", +59230, PvalueDiff, 1795, 1805, "p = 0 . 04", "", +59237, EndPointDescription, 1814, 1827, "triglycerides", "", +59243, DiffGroupAbsValue, 1830, 1838, "+  9 . 7", "", +59248, Percentage, 1839, 1840, "%", "", +59231, PvalueDiff, 1843, 1853, "p = 0 . 03", "", +59249, Drug, 1858, 1869, "Colesevelam", "", +59253, ConclusionComment, 1858, 2064, "Colesevelam monotherapy resulted in statistically significant improvements in glycemic and most lipid parameters in subjects with type 2 diabetes , with no new or unexpected safety and tolerability issues .", "", +59250, Type2Diabetes, 1988, 2003, "type 2 diabetes", "", +59252, ConclusionComment, 2065, 2310, "Modest reductions in HbA1c and low - density lipoprotein cholesterol levels with colesevelam further support its use in combination with other antidiabetes agents when treatment targets for these parameters are close but are not quite achieved .", "", +59251, HbA1c, 2086, 2091, "HbA1c", "", +59254, PMID, 2451, 2459, "24356792", "", diff --git a/data/dm2 24356792_akramersunderbrink.n-triples b/data/dm2 24356792_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24356792_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24356792_export.csv b/data/dm2 24356792_export.csv new file mode 100644 index 0000000..6e9fcd8 --- /dev/null +++ b/data/dm2 24356792_export.csv @@ -0,0 +1,553 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +286, 1, 1, 1, 0, 4, 0, 4, "Horm" +286, 1, 2, 2, 5, 10, 5, 10, "Metab" +286, 1, 3, 3, 11, 14, 11, 14, "Res" +286, 1, 4, 4, 15, 16, 15, 16, "." +286, 2, 1, 5, 0, 4, 17, 21, "2014" +286, 2, 2, 6, 5, 8, 22, 25, "May" +286, 2, 3, 7, 9, 10, 26, 27, ";" +286, 2, 4, 8, 11, 13, 28, 30, "46" +286, 2, 5, 9, 14, 15, 31, 32, "(" +286, 2, 6, 10, 16, 17, 33, 34, "5" +286, 2, 7, 11, 18, 19, 35, 36, ")" +286, 2, 8, 12, 20, 21, 37, 38, ":" +286, 2, 9, 13, 22, 25, 39, 42, "348" +286, 2, 10, 14, 26, 27, 43, 44, "-" +286, 2, 11, 15, 28, 30, 45, 47, "53" +286, 2, 12, 16, 31, 32, 48, 49, "." +286, 2, 13, 17, 33, 36, 50, 53, "doi" +286, 2, 14, 18, 37, 38, 54, 55, ":" +286, 2, 15, 19, 39, 41, 56, 58, "10" +286, 2, 16, 20, 42, 43, 59, 60, "." +286, 2, 17, 21, 44, 48, 61, 65, "1055" +286, 2, 18, 22, 49, 50, 66, 67, "/" +286, 2, 19, 23, 51, 52, 68, 69, "s" +286, 2, 20, 24, 53, 54, 70, 71, "-" +286, 2, 21, 25, 55, 59, 72, 76, "0033" +286, 2, 22, 26, 60, 61, 77, 78, "-" +286, 2, 23, 27, 62, 69, 79, 86, "1358759" +286, 2, 24, 28, 70, 71, 87, 88, "." +286, 3, 1, 29, 0, 4, 89, 93, "Epub" +286, 3, 2, 30, 5, 9, 94, 98, "2013" +286, 3, 3, 31, 10, 13, 99, 102, "Dec" +286, 3, 4, 32, 14, 16, 103, 105, "19" +286, 3, 5, 33, 17, 18, 106, 107, "." +286, 4, 1, 34, 0, 3, 108, 111, "The" +286, 4, 2, 35, 4, 11, 112, 119, "glucose" +286, 4, 3, 36, 12, 15, 120, 123, "and" +286, 4, 4, 37, 16, 21, 124, 129, "lipid" +286, 4, 5, 38, 22, 29, 130, 137, "effects" +286, 4, 6, 39, 30, 32, 138, 140, "of" +286, 4, 7, 40, 33, 44, 141, 152, "colesevelam" +286, 4, 8, 41, 45, 47, 153, 155, "as" +286, 4, 9, 42, 48, 59, 156, 167, "monotherapy" +286, 4, 10, 43, 60, 62, 168, 170, "in" +286, 4, 11, 44, 63, 67, 171, 175, "drug" +286, 4, 12, 45, 68, 69, 176, 177, "-" +286, 4, 13, 46, 70, 72, 178, 180, "na" +286, 4, 14, 47, 73, 74, 181, 182, "ï" +286, 4, 15, 48, 75, 77, 183, 185, "ve" +286, 4, 16, 49, 78, 82, 186, 190, "type" +286, 4, 17, 50, 83, 84, 191, 192, "2" +286, 4, 18, 51, 85, 93, 193, 201, "diabetes" +286, 4, 19, 52, 94, 95, 202, 203, "." +286, 5, 1, 53, 0, 10, 204, 214, "Rosenstock" +286, 5, 2, 54, 11, 12, 215, 216, "J" +286, 5, 3, 55, 13, 14, 217, 218, "(" +286, 5, 4, 56, 15, 16, 219, 220, "1" +286, 5, 5, 57, 17, 18, 221, 222, ")" +286, 5, 6, 58, 19, 20, 223, 224, "," +286, 5, 7, 59, 21, 26, 225, 230, "Rigby" +286, 5, 8, 60, 27, 29, 231, 233, "SP" +286, 5, 9, 61, 30, 31, 234, 235, "(" +286, 5, 10, 62, 32, 33, 236, 237, "2" +286, 5, 11, 63, 34, 35, 238, 239, ")" +286, 5, 12, 64, 36, 37, 240, 241, "," +286, 5, 13, 65, 38, 42, 242, 246, "Ford" +286, 5, 14, 66, 43, 45, 247, 249, "DM" +286, 5, 15, 67, 46, 47, 250, 251, "(" +286, 5, 16, 68, 48, 49, 252, 253, "3" +286, 5, 17, 69, 50, 51, 254, 255, ")" +286, 5, 18, 70, 52, 53, 256, 257, "," +286, 5, 19, 71, 54, 57, 258, 261, "Tao" +286, 5, 20, 72, 58, 59, 262, 263, "B" +286, 5, 21, 73, 60, 61, 264, 265, "(" +286, 5, 22, 74, 62, 63, 266, 267, "3" +286, 5, 23, 75, 64, 65, 268, 269, ")" +286, 5, 24, 76, 66, 67, 270, 271, "," +286, 5, 25, 77, 68, 72, 272, 276, "Chou" +286, 5, 26, 78, 73, 75, 277, 279, "HS" +286, 5, 27, 79, 76, 77, 280, 281, "(" +286, 5, 28, 80, 78, 79, 282, 283, "3" +286, 5, 29, 81, 80, 81, 284, 285, ")" +286, 5, 30, 82, 82, 83, 286, 287, "." +286, 6, 1, 83, 0, 6, 288, 294, "Author" +286, 6, 2, 84, 7, 18, 295, 306, "information" +286, 6, 3, 85, 19, 20, 307, 308, ":" +286, 6, 4, 86, 21, 22, 309, 310, "(" +286, 6, 5, 87, 23, 24, 311, 312, "1" +286, 6, 6, 88, 25, 26, 313, 314, ")" +286, 6, 7, 89, 27, 33, 315, 321, "Dallas" +286, 6, 8, 90, 34, 42, 322, 330, "Diabetes" +286, 6, 9, 91, 43, 46, 331, 334, "and" +286, 6, 10, 92, 47, 56, 335, 344, "Endocrine" +286, 6, 11, 93, 57, 63, 345, 351, "Center" +286, 6, 12, 94, 64, 66, 352, 354, "at" +286, 6, 13, 95, 67, 74, 355, 362, "Medical" +286, 6, 14, 96, 75, 79, 363, 367, "City" +286, 6, 15, 97, 80, 81, 368, 369, "," +286, 6, 16, 98, 82, 88, 370, 376, "Dallas" +286, 6, 17, 99, 89, 90, 377, 378, "," +286, 6, 18, 100, 91, 93, 379, 381, "TX" +286, 6, 19, 101, 94, 95, 382, 383, "," +286, 6, 20, 102, 96, 99, 384, 387, "USA" +286, 6, 21, 103, 100, 101, 388, 389, "." +286, 7, 1, 104, 0, 1, 390, 391, "(" +286, 7, 2, 105, 2, 3, 392, 393, "2" +286, 7, 3, 106, 4, 5, 394, 395, ")" +286, 7, 4, 107, 6, 12, 396, 402, "Summit" +286, 7, 5, 108, 13, 21, 403, 411, "Research" +286, 7, 6, 109, 22, 27, 412, 417, "Group" +286, 7, 7, 110, 28, 29, 418, 419, "," +286, 7, 8, 111, 30, 34, 420, 424, "Stow" +286, 7, 9, 112, 35, 36, 425, 426, "," +286, 7, 10, 113, 37, 41, 427, 431, "Ohio" +286, 7, 11, 114, 42, 43, 432, 433, "," +286, 7, 12, 115, 44, 47, 434, 437, "USA" +286, 7, 13, 116, 48, 49, 438, 439, "." +286, 8, 1, 117, 0, 1, 440, 441, "(" +286, 8, 2, 118, 2, 3, 442, 443, "3" +286, 8, 3, 119, 4, 5, 444, 445, ")" +286, 8, 4, 120, 6, 13, 446, 453, "Daiichi" +286, 8, 5, 121, 14, 20, 454, 460, "Sankyo" +286, 8, 6, 122, 21, 27, 461, 467, "Pharma" +286, 8, 7, 123, 28, 39, 468, 479, "Development" +286, 8, 8, 124, 40, 41, 480, 481, "," +286, 8, 9, 125, 42, 48, 482, 488, "Edison" +286, 8, 10, 126, 49, 50, 489, 490, "," +286, 8, 11, 127, 51, 53, 491, 493, "NJ" +286, 8, 12, 128, 54, 55, 494, 495, "," +286, 8, 13, 129, 56, 59, 496, 499, "USA" +286, 8, 14, 130, 60, 61, 500, 501, "." +286, 9, 1, 131, 0, 11, 502, 513, "Colesevelam" +286, 9, 2, 132, 12, 15, 514, 517, "has" +286, 9, 3, 133, 16, 21, 518, 523, "shown" +286, 9, 4, 134, 22, 30, 524, 532, "efficacy" +286, 9, 5, 135, 31, 33, 533, 535, "in" +286, 9, 6, 136, 34, 40, 536, 542, "adults" +286, 9, 7, 137, 41, 45, 543, 547, "with" +286, 9, 8, 138, 46, 50, 548, 552, "type" +286, 9, 9, 139, 51, 52, 553, 554, "2" +286, 9, 10, 140, 53, 61, 555, 563, "diabetes" +286, 9, 11, 141, 62, 70, 564, 572, "mellitus" +286, 9, 12, 142, 71, 72, 573, 574, "(" +286, 9, 13, 143, 73, 77, 575, 579, "T2DM" +286, 9, 14, 144, 78, 79, 580, 581, ")" +286, 9, 15, 145, 80, 82, 582, 584, "in" +286, 9, 16, 146, 83, 94, 585, 596, "combination" +286, 9, 17, 147, 95, 99, 597, 601, "with" +286, 9, 18, 148, 100, 109, 602, 611, "metformin" +286, 9, 19, 149, 110, 111, 612, 613, "-" +286, 9, 20, 150, 112, 113, 614, 615, "," +286, 9, 21, 151, 114, 126, 616, 628, "sulfonylurea" +286, 9, 22, 152, 127, 128, 629, 630, "-" +286, 9, 23, 153, 129, 130, 631, 632, "," +286, 9, 24, 154, 131, 133, 633, 635, "or" +286, 9, 25, 155, 134, 141, 636, 643, "insulin" +286, 9, 26, 156, 142, 143, 644, 645, "-" +286, 9, 27, 157, 144, 149, 646, 651, "based" +286, 9, 28, 158, 150, 157, 652, 659, "therapy" +286, 9, 29, 159, 158, 159, 660, 661, "," +286, 9, 30, 160, 160, 168, 662, 670, "lowering" +286, 9, 31, 161, 169, 179, 671, 681, "hemoglobin" +286, 9, 32, 162, 180, 183, 682, 685, "A1c" +286, 9, 33, 163, 184, 185, 686, 687, "(" +286, 9, 34, 164, 186, 191, 688, 693, "HbA1c" +286, 9, 35, 165, 192, 193, 694, 695, ")" +286, 9, 36, 166, 194, 197, 696, 699, "and" +286, 9, 37, 167, 198, 201, 700, 703, "low" +286, 9, 38, 168, 202, 203, 704, 705, "-" +286, 9, 39, 169, 204, 211, 706, 713, "density" +286, 9, 40, 170, 212, 223, 714, 725, "lipoprotein" +286, 9, 41, 171, 224, 235, 726, 737, "cholesterol" +286, 9, 42, 172, 236, 242, 738, 744, "levels" +286, 9, 43, 173, 243, 244, 745, 746, "." +286, 10, 1, 174, 0, 1, 747, 748, "A" +286, 10, 2, 175, 2, 7, 749, 754, "study" +286, 10, 3, 176, 8, 11, 755, 758, "was" +286, 10, 4, 177, 12, 21, 759, 768, "conducted" +286, 10, 5, 178, 22, 24, 769, 771, "to" +286, 10, 6, 179, 25, 33, 772, 780, "evaluate" +286, 10, 7, 180, 34, 45, 781, 792, "colesevelam" +286, 10, 8, 181, 46, 48, 793, 795, "as" +286, 10, 9, 182, 49, 60, 796, 807, "monotherapy" +286, 10, 10, 183, 61, 63, 808, 810, "in" +286, 10, 11, 184, 64, 68, 811, 815, "drug" +286, 10, 12, 185, 69, 70, 816, 817, "-" +286, 10, 13, 186, 71, 73, 818, 820, "na" +286, 10, 14, 187, 74, 75, 821, 822, "ï" +286, 10, 15, 188, 76, 78, 823, 825, "ve" +286, 10, 16, 189, 79, 87, 826, 834, "patients" +286, 10, 17, 190, 88, 92, 835, 839, "with" +286, 10, 18, 191, 93, 97, 840, 844, "T2DM" +286, 10, 19, 192, 98, 99, 845, 846, "." +286, 11, 1, 193, 0, 2, 847, 849, "In" +286, 11, 2, 194, 3, 7, 850, 854, "this" +286, 11, 3, 195, 8, 18, 855, 865, "randomized" +286, 11, 4, 196, 19, 20, 866, 867, "," +286, 11, 5, 197, 21, 27, 868, 874, "double" +286, 11, 6, 198, 28, 29, 875, 876, "-" +286, 11, 7, 199, 30, 35, 877, 882, "blind" +286, 11, 8, 200, 36, 37, 883, 884, "," +286, 11, 9, 201, 38, 45, 885, 892, "placebo" +286, 11, 10, 202, 46, 47, 893, 894, "-" +286, 11, 11, 203, 48, 58, 895, 905, "controlled" +286, 11, 12, 204, 59, 60, 906, 907, "," +286, 11, 13, 205, 61, 69, 908, 916, "parallel" +286, 11, 14, 206, 70, 71, 917, 918, "-" +286, 11, 15, 207, 72, 77, 919, 924, "group" +286, 11, 16, 208, 78, 83, 925, 930, "study" +286, 11, 17, 209, 84, 85, 931, 932, "," +286, 11, 18, 210, 86, 92, 933, 939, "adults" +286, 11, 19, 211, 93, 97, 940, 944, "with" +286, 11, 20, 212, 98, 102, 945, 949, "T2DM" +286, 11, 21, 213, 103, 106, 950, 953, "who" +286, 11, 22, 214, 107, 110, 954, 957, "had" +286, 11, 23, 215, 111, 121, 958, 968, "inadequate" +286, 11, 24, 216, 122, 130, 969, 977, "glycemic" +286, 11, 25, 217, 131, 138, 978, 985, "control" +286, 11, 26, 218, 139, 140, 986, 987, "(" +286, 11, 27, 219, 141, 146, 988, 993, "HbA1c" +286, 11, 28, 220, 147, 148, 994, 995, "≥" +286, 11, 29, 221, 149, 150, 996, 997, "7" +286, 11, 30, 222, 151, 152, 998, 999, "." +286, 11, 31, 223, 153, 154, 1000, 1001, "5" +286, 11, 32, 224, 155, 156, 1002, 1003, "%" +286, 11, 33, 225, 157, 160, 1004, 1007, "and" +286, 11, 34, 226, 161, 162, 1008, 1009, "≤" +286, 11, 35, 227, 163, 164, 1010, 1011, "9" +286, 11, 36, 228, 165, 166, 1012, 1013, "." +286, 11, 37, 229, 167, 168, 1014, 1015, "5" +286, 11, 38, 230, 169, 170, 1016, 1017, "%" +286, 11, 39, 231, 171, 172, 1018, 1019, ")" +286, 11, 40, 232, 173, 177, 1020, 1024, "with" +286, 11, 41, 233, 178, 182, 1025, 1029, "diet" +286, 11, 42, 234, 183, 186, 1030, 1033, "and" +286, 11, 43, 235, 187, 195, 1034, 1042, "exercise" +286, 11, 44, 236, 196, 201, 1043, 1048, "alone" +286, 11, 45, 237, 202, 206, 1049, 1053, "were" +286, 11, 46, 238, 207, 217, 1054, 1064, "randomized" +286, 11, 47, 239, 218, 220, 1065, 1067, "to" +286, 11, 48, 240, 221, 228, 1068, 1075, "receive" +286, 11, 49, 241, 229, 240, 1076, 1087, "colesevelam" +286, 11, 50, 242, 241, 242, 1088, 1089, "3" +286, 11, 51, 243, 243, 244, 1090, 1091, "." +286, 11, 52, 244, 245, 247, 1092, 1094, "75" +286, 11, 53, 245, 248, 249, 1095, 1096, " " +286, 11, 54, 246, 250, 251, 1097, 1098, "g" +286, 11, 55, 247, 252, 253, 1099, 1100, "/" +286, 11, 56, 248, 254, 257, 1101, 1104, "day" +286, 11, 57, 249, 258, 259, 1105, 1106, "(" +286, 11, 58, 250, 260, 261, 1107, 1108, "n" +286, 11, 59, 251, 262, 263, 1109, 1110, "=" +286, 11, 60, 252, 264, 267, 1111, 1114, "176" +286, 11, 61, 253, 268, 269, 1115, 1116, ")" +286, 11, 62, 254, 270, 272, 1117, 1119, "or" +286, 11, 63, 255, 273, 280, 1120, 1127, "placebo" +286, 11, 64, 256, 281, 282, 1128, 1129, "(" +286, 11, 65, 257, 283, 284, 1130, 1131, "n" +286, 11, 66, 258, 285, 286, 1132, 1133, "=" +286, 11, 67, 259, 287, 290, 1134, 1137, "181" +286, 11, 68, 260, 291, 292, 1138, 1139, ")" +286, 11, 69, 261, 293, 296, 1140, 1143, "for" +286, 11, 70, 262, 297, 299, 1144, 1146, "24" +286, 11, 71, 263, 300, 305, 1147, 1152, "weeks" +286, 11, 72, 264, 306, 307, 1153, 1154, "." +286, 12, 1, 265, 0, 3, 1155, 1158, "The" +286, 12, 2, 266, 4, 11, 1159, 1166, "primary" +286, 12, 3, 267, 12, 20, 1167, 1175, "efficacy" +286, 12, 4, 268, 21, 29, 1176, 1184, "variable" +286, 12, 5, 269, 30, 33, 1185, 1188, "was" +286, 12, 6, 270, 34, 39, 1189, 1194, "HbA1c" +286, 12, 7, 271, 40, 42, 1195, 1197, "at" +286, 12, 8, 272, 43, 47, 1198, 1202, "week" +286, 12, 9, 273, 48, 50, 1203, 1205, "24" +286, 12, 10, 274, 51, 52, 1206, 1207, "." +286, 13, 1, 275, 0, 11, 1208, 1219, "Colesevelam" +286, 13, 2, 276, 12, 14, 1220, 1222, "as" +286, 13, 3, 277, 15, 23, 1223, 1231, "compared" +286, 13, 4, 278, 24, 26, 1232, 1234, "to" +286, 13, 5, 279, 27, 34, 1235, 1242, "placebo" +286, 13, 6, 280, 35, 41, 1243, 1249, "showed" +286, 13, 7, 281, 42, 53, 1250, 1261, "significant" +286, 13, 8, 282, 54, 64, 1262, 1272, "reductions" +286, 13, 9, 283, 65, 69, 1273, 1277, "from" +286, 13, 10, 284, 70, 78, 1278, 1286, "baseline" +286, 13, 11, 285, 79, 81, 1287, 1289, "in" +286, 13, 12, 286, 82, 87, 1290, 1295, "HbA1c" +286, 13, 13, 287, 88, 89, 1296, 1297, "(" +286, 13, 14, 288, 90, 91, 1298, 1299, "-" +286, 13, 15, 289, 92, 93, 1300, 1301, "2" +286, 13, 16, 290, 94, 95, 1302, 1303, "." +286, 13, 17, 291, 96, 98, 1304, 1306, "92" +286, 13, 18, 292, 99, 100, 1307, 1308, " " +286, 13, 19, 293, 101, 105, 1309, 1313, "mmol" +286, 13, 20, 294, 106, 107, 1314, 1315, "/" +286, 13, 21, 295, 108, 111, 1316, 1319, "mol" +286, 13, 22, 296, 112, 113, 1320, 1321, "[" +286, 13, 23, 297, 114, 115, 1322, 1323, "0" +286, 13, 24, 298, 116, 117, 1324, 1325, "." +286, 13, 25, 299, 118, 119, 1326, 1327, "3" +286, 13, 26, 300, 120, 121, 1328, 1329, "%" +286, 13, 27, 301, 122, 123, 1330, 1331, "]" +286, 13, 28, 302, 124, 125, 1332, 1333, ";" +286, 13, 29, 303, 126, 127, 1334, 1335, "p" +286, 13, 30, 304, 128, 129, 1336, 1337, "=" +286, 13, 31, 305, 130, 131, 1338, 1339, "0" +286, 13, 32, 306, 132, 133, 1340, 1341, "." +286, 13, 33, 307, 134, 136, 1342, 1344, "01" +286, 13, 34, 308, 137, 138, 1345, 1346, ")" +286, 13, 35, 309, 139, 142, 1347, 1350, "and" +286, 13, 36, 310, 143, 150, 1351, 1358, "fasting" +286, 13, 37, 311, 151, 157, 1359, 1365, "plasma" +286, 13, 38, 312, 158, 165, 1366, 1373, "glucose" +286, 13, 39, 313, 166, 167, 1374, 1375, "(" +286, 13, 40, 314, 168, 169, 1376, 1377, "-" +286, 13, 41, 315, 170, 172, 1378, 1380, "10" +286, 13, 42, 316, 173, 174, 1381, 1382, "." +286, 13, 43, 317, 175, 176, 1383, 1384, "3" +286, 13, 44, 318, 177, 178, 1385, 1386, " " +286, 13, 45, 319, 179, 181, 1387, 1389, "mg" +286, 13, 46, 320, 182, 183, 1390, 1391, "/" +286, 13, 47, 321, 184, 186, 1392, 1394, "dl" +286, 13, 48, 322, 187, 188, 1395, 1396, ";" +286, 13, 49, 323, 189, 190, 1397, 1398, "p" +286, 13, 50, 324, 191, 192, 1399, 1400, "=" +286, 13, 51, 325, 193, 194, 1401, 1402, "0" +286, 13, 52, 326, 195, 196, 1403, 1404, "." +286, 13, 53, 327, 197, 199, 1405, 1407, "04" +286, 13, 54, 328, 200, 201, 1408, 1409, ")" +286, 13, 55, 329, 202, 204, 1410, 1412, "at" +286, 13, 56, 330, 205, 209, 1413, 1417, "week" +286, 13, 57, 331, 210, 212, 1418, 1420, "24" +286, 13, 58, 332, 213, 217, 1421, 1425, "with" +286, 13, 59, 333, 218, 222, 1426, 1430, "last" +286, 13, 60, 334, 223, 234, 1431, 1442, "observation" +286, 13, 61, 335, 235, 242, 1443, 1450, "carried" +286, 13, 62, 336, 243, 250, 1451, 1458, "forward" +286, 13, 63, 337, 251, 252, 1459, 1460, "." +286, 14, 1, 338, 0, 11, 1461, 1472, "Colesevelam" +286, 14, 2, 339, 12, 16, 1473, 1477, "also" +286, 14, 3, 340, 17, 30, 1478, 1491, "significantly" +286, 14, 4, 341, 31, 38, 1492, 1499, "reduced" +286, 14, 5, 342, 39, 42, 1500, 1503, "low" +286, 14, 6, 343, 43, 44, 1504, 1505, "-" +286, 14, 7, 344, 45, 52, 1506, 1513, "density" +286, 14, 8, 345, 53, 64, 1514, 1525, "lipoprotein" +286, 14, 9, 346, 65, 76, 1526, 1537, "cholesterol" +286, 14, 10, 347, 77, 78, 1538, 1539, "(" +286, 14, 11, 348, 79, 80, 1540, 1541, "-" +286, 14, 12, 349, 81, 83, 1542, 1544, "11" +286, 14, 13, 350, 84, 85, 1545, 1546, "." +286, 14, 14, 351, 86, 87, 1547, 1548, "2" +286, 14, 15, 352, 88, 89, 1549, 1550, "%" +286, 14, 16, 353, 90, 91, 1551, 1552, ";" +286, 14, 17, 354, 92, 93, 1553, 1554, "p" +286, 14, 18, 355, 94, 95, 1555, 1556, "<" +286, 14, 19, 356, 96, 97, 1557, 1558, "0" +286, 14, 20, 357, 98, 99, 1559, 1560, "." +286, 14, 21, 358, 100, 104, 1561, 1565, "0001" +286, 14, 22, 359, 105, 106, 1566, 1567, ")" +286, 14, 23, 360, 107, 108, 1568, 1569, "," +286, 14, 24, 361, 109, 114, 1570, 1575, "total" +286, 14, 25, 362, 115, 126, 1576, 1587, "cholesterol" +286, 14, 26, 363, 127, 128, 1588, 1589, "(" +286, 14, 27, 364, 129, 130, 1590, 1591, "-" +286, 14, 28, 365, 131, 132, 1592, 1593, "5" +286, 14, 29, 366, 133, 134, 1594, 1595, "." +286, 14, 30, 367, 135, 136, 1596, 1597, "1" +286, 14, 31, 368, 137, 138, 1598, 1599, "%" +286, 14, 32, 369, 139, 140, 1600, 1601, ";" +286, 14, 33, 370, 141, 142, 1602, 1603, "p" +286, 14, 34, 371, 143, 144, 1604, 1605, "=" +286, 14, 35, 372, 145, 146, 1606, 1607, "0" +286, 14, 36, 373, 147, 148, 1608, 1609, "." +286, 14, 37, 374, 149, 153, 1610, 1614, "0005" +286, 14, 38, 375, 154, 155, 1615, 1616, ")" +286, 14, 39, 376, 156, 157, 1617, 1618, "," +286, 14, 40, 377, 158, 161, 1619, 1622, "non" +286, 14, 41, 378, 162, 163, 1623, 1624, "-" +286, 14, 42, 379, 164, 168, 1625, 1629, "high" +286, 14, 43, 380, 169, 170, 1630, 1631, "-" +286, 14, 44, 381, 171, 178, 1632, 1639, "density" +286, 14, 45, 382, 179, 190, 1640, 1651, "lipoprotein" +286, 14, 46, 383, 191, 202, 1652, 1663, "cholesterol" +286, 14, 47, 384, 203, 204, 1664, 1665, "(" +286, 14, 48, 385, 205, 206, 1666, 1667, "-" +286, 14, 49, 386, 207, 208, 1668, 1669, "7" +286, 14, 50, 387, 209, 210, 1670, 1671, "." +286, 14, 51, 388, 211, 212, 1672, 1673, "4" +286, 14, 52, 389, 213, 214, 1674, 1675, "%" +286, 14, 53, 390, 215, 216, 1676, 1677, ";" +286, 14, 54, 391, 217, 218, 1678, 1679, "p" +286, 14, 55, 392, 219, 220, 1680, 1681, "=" +286, 14, 56, 393, 221, 222, 1682, 1683, "0" +286, 14, 57, 394, 223, 224, 1684, 1685, "." +286, 14, 58, 395, 225, 229, 1686, 1690, "0001" +286, 14, 59, 396, 230, 231, 1691, 1692, ")" +286, 14, 60, 397, 232, 233, 1693, 1694, "," +286, 14, 61, 398, 234, 237, 1695, 1698, "and" +286, 14, 62, 399, 238, 252, 1699, 1713, "apolipoprotein" +286, 14, 63, 400, 253, 254, 1714, 1715, "B" +286, 14, 64, 401, 255, 256, 1716, 1717, "(" +286, 14, 65, 402, 257, 258, 1718, 1719, "-" +286, 14, 66, 403, 259, 260, 1720, 1721, "6" +286, 14, 67, 404, 261, 262, 1722, 1723, "." +286, 14, 68, 405, 263, 264, 1724, 1725, "5" +286, 14, 69, 406, 265, 266, 1726, 1727, "%" +286, 14, 70, 407, 267, 268, 1728, 1729, ";" +286, 14, 71, 408, 269, 270, 1730, 1731, "p" +286, 14, 72, 409, 271, 272, 1732, 1733, "=" +286, 14, 73, 410, 273, 274, 1734, 1735, "0" +286, 14, 74, 411, 275, 276, 1736, 1737, "." +286, 14, 75, 412, 277, 281, 1738, 1742, "0001" +286, 14, 76, 413, 282, 283, 1743, 1744, ")" +286, 14, 77, 414, 284, 287, 1745, 1748, "and" +286, 14, 78, 415, 288, 297, 1749, 1758, "increased" +286, 14, 79, 416, 298, 312, 1759, 1773, "apolipoprotein" +286, 14, 80, 417, 313, 314, 1774, 1775, "A" +286, 14, 81, 418, 315, 316, 1776, 1777, "-" +286, 14, 82, 419, 317, 318, 1778, 1779, "I" +286, 14, 83, 420, 319, 320, 1780, 1781, "(" +286, 14, 84, 421, 321, 323, 1782, 1784, "+ " +286, 14, 85, 422, 324, 325, 1785, 1786, "2" +286, 14, 86, 423, 326, 327, 1787, 1788, "." +286, 14, 87, 424, 328, 329, 1789, 1790, "4" +286, 14, 88, 425, 330, 331, 1791, 1792, "%" +286, 14, 89, 426, 332, 333, 1793, 1794, ";" +286, 14, 90, 427, 334, 335, 1795, 1796, "p" +286, 14, 91, 428, 336, 337, 1797, 1798, "=" +286, 14, 92, 429, 338, 339, 1799, 1800, "0" +286, 14, 93, 430, 340, 341, 1801, 1802, "." +286, 14, 94, 431, 342, 344, 1803, 1805, "04" +286, 14, 95, 432, 345, 346, 1806, 1807, ")" +286, 14, 96, 433, 347, 348, 1808, 1809, "," +286, 14, 97, 434, 349, 352, 1810, 1813, "and" +286, 14, 98, 435, 353, 366, 1814, 1827, "triglycerides" +286, 14, 99, 436, 367, 368, 1828, 1829, "(" +286, 14, 100, 437, 369, 371, 1830, 1832, "+ " +286, 14, 101, 438, 372, 373, 1833, 1834, "9" +286, 14, 102, 439, 374, 375, 1835, 1836, "." +286, 14, 103, 440, 376, 377, 1837, 1838, "7" +286, 14, 104, 441, 378, 379, 1839, 1840, "%" +286, 14, 105, 442, 380, 381, 1841, 1842, ";" +286, 14, 106, 443, 382, 383, 1843, 1844, "p" +286, 14, 107, 444, 384, 385, 1845, 1846, "=" +286, 14, 108, 445, 386, 387, 1847, 1848, "0" +286, 14, 109, 446, 388, 389, 1849, 1850, "." +286, 14, 110, 447, 390, 392, 1851, 1853, "03" +286, 14, 111, 448, 393, 394, 1854, 1855, ")" +286, 14, 112, 449, 395, 396, 1856, 1857, "." +286, 15, 1, 450, 0, 11, 1858, 1869, "Colesevelam" +286, 15, 2, 451, 12, 23, 1870, 1881, "monotherapy" +286, 15, 3, 452, 24, 32, 1882, 1890, "resulted" +286, 15, 4, 453, 33, 35, 1891, 1893, "in" +286, 15, 5, 454, 36, 49, 1894, 1907, "statistically" +286, 15, 6, 455, 50, 61, 1908, 1919, "significant" +286, 15, 7, 456, 62, 74, 1920, 1932, "improvements" +286, 15, 8, 457, 75, 77, 1933, 1935, "in" +286, 15, 9, 458, 78, 86, 1936, 1944, "glycemic" +286, 15, 10, 459, 87, 90, 1945, 1948, "and" +286, 15, 11, 460, 91, 95, 1949, 1953, "most" +286, 15, 12, 461, 96, 101, 1954, 1959, "lipid" +286, 15, 13, 462, 102, 112, 1960, 1970, "parameters" +286, 15, 14, 463, 113, 115, 1971, 1973, "in" +286, 15, 15, 464, 116, 124, 1974, 1982, "subjects" +286, 15, 16, 465, 125, 129, 1983, 1987, "with" +286, 15, 17, 466, 130, 134, 1988, 1992, "type" +286, 15, 18, 467, 135, 136, 1993, 1994, "2" +286, 15, 19, 468, 137, 145, 1995, 2003, "diabetes" +286, 15, 20, 469, 146, 147, 2004, 2005, "," +286, 15, 21, 470, 148, 152, 2006, 2010, "with" +286, 15, 22, 471, 153, 155, 2011, 2013, "no" +286, 15, 23, 472, 156, 159, 2014, 2017, "new" +286, 15, 24, 473, 160, 162, 2018, 2020, "or" +286, 15, 25, 474, 163, 173, 2021, 2031, "unexpected" +286, 15, 26, 475, 174, 180, 2032, 2038, "safety" +286, 15, 27, 476, 181, 184, 2039, 2042, "and" +286, 15, 28, 477, 185, 197, 2043, 2055, "tolerability" +286, 15, 29, 478, 198, 204, 2056, 2062, "issues" +286, 15, 30, 479, 205, 206, 2063, 2064, "." +286, 16, 1, 480, 0, 6, 2065, 2071, "Modest" +286, 16, 2, 481, 7, 17, 2072, 2082, "reductions" +286, 16, 3, 482, 18, 20, 2083, 2085, "in" +286, 16, 4, 483, 21, 26, 2086, 2091, "HbA1c" +286, 16, 5, 484, 27, 30, 2092, 2095, "and" +286, 16, 6, 485, 31, 34, 2096, 2099, "low" +286, 16, 7, 486, 35, 36, 2100, 2101, "-" +286, 16, 8, 487, 37, 44, 2102, 2109, "density" +286, 16, 9, 488, 45, 56, 2110, 2121, "lipoprotein" +286, 16, 10, 489, 57, 68, 2122, 2133, "cholesterol" +286, 16, 11, 490, 69, 75, 2134, 2140, "levels" +286, 16, 12, 491, 76, 80, 2141, 2145, "with" +286, 16, 13, 492, 81, 92, 2146, 2157, "colesevelam" +286, 16, 14, 493, 93, 100, 2158, 2165, "further" +286, 16, 15, 494, 101, 108, 2166, 2173, "support" +286, 16, 16, 495, 109, 112, 2174, 2177, "its" +286, 16, 17, 496, 113, 116, 2178, 2181, "use" +286, 16, 18, 497, 117, 119, 2182, 2184, "in" +286, 16, 19, 498, 120, 131, 2185, 2196, "combination" +286, 16, 20, 499, 132, 136, 2197, 2201, "with" +286, 16, 21, 500, 137, 142, 2202, 2207, "other" +286, 16, 22, 501, 143, 155, 2208, 2220, "antidiabetes" +286, 16, 23, 502, 156, 162, 2221, 2227, "agents" +286, 16, 24, 503, 163, 167, 2228, 2232, "when" +286, 16, 25, 504, 168, 177, 2233, 2242, "treatment" +286, 16, 26, 505, 178, 185, 2243, 2250, "targets" +286, 16, 27, 506, 186, 189, 2251, 2254, "for" +286, 16, 28, 507, 190, 195, 2255, 2260, "these" +286, 16, 29, 508, 196, 206, 2261, 2271, "parameters" +286, 16, 30, 509, 207, 210, 2272, 2275, "are" +286, 16, 31, 510, 211, 216, 2276, 2281, "close" +286, 16, 32, 511, 217, 220, 2282, 2285, "but" +286, 16, 33, 512, 221, 224, 2286, 2289, "are" +286, 16, 34, 513, 225, 228, 2290, 2293, "not" +286, 16, 35, 514, 229, 234, 2294, 2299, "quite" +286, 16, 36, 515, 235, 243, 2300, 2308, "achieved" +286, 16, 37, 516, 244, 245, 2309, 2310, "." +286, 16, 38, 517, 246, 260, 2311, 2325, "ClinicalTrials" +286, 16, 39, 518, 261, 262, 2326, 2327, "." +286, 16, 40, 519, 263, 266, 2328, 2331, "gov" +286, 16, 41, 520, 267, 277, 2332, 2342, "identifier" +286, 16, 42, 521, 278, 279, 2343, 2344, ":" +286, 16, 43, 522, 280, 291, 2345, 2356, "NCT00789737" +286, 16, 44, 523, 292, 293, 2357, 2358, "." +286, 17, 1, 524, 0, 1, 2359, 2360, "©" +286, 17, 2, 525, 2, 7, 2361, 2366, "Georg" +286, 17, 3, 526, 8, 14, 2367, 2373, "Thieme" +286, 17, 4, 527, 15, 21, 2374, 2380, "Verlag" +286, 17, 5, 528, 22, 24, 2381, 2383, "KG" +286, 17, 6, 529, 25, 34, 2384, 2393, "Stuttgart" +286, 17, 7, 530, 35, 36, 2394, 2395, "·" +286, 17, 8, 531, 37, 40, 2396, 2399, "New" +286, 17, 9, 532, 41, 45, 2400, 2404, "York" +286, 17, 10, 533, 46, 47, 2405, 2406, "." +286, 18, 1, 534, 0, 3, 2407, 2410, "DOI" +286, 18, 2, 535, 4, 5, 2411, 2412, ":" +286, 18, 3, 536, 6, 8, 2413, 2415, "10" +286, 18, 4, 537, 9, 10, 2416, 2417, "." +286, 18, 5, 538, 11, 15, 2418, 2422, "1055" +286, 18, 6, 539, 16, 17, 2423, 2424, "/" +286, 18, 7, 540, 18, 19, 2425, 2426, "s" +286, 18, 8, 541, 20, 21, 2427, 2428, "-" +286, 18, 9, 542, 22, 26, 2429, 2433, "0033" +286, 18, 10, 543, 27, 28, 2434, 2435, "-" +286, 18, 11, 544, 29, 36, 2436, 2443, "1358759" +286, 18, 12, 545, 37, 41, 2444, 2448, "PMID" +286, 18, 13, 546, 42, 43, 2449, 2450, ":" +286, 18, 14, 547, 44, 52, 2451, 2459, "24356792" +286, 18, 15, 548, 53, 54, 2460, 2461, "[" +286, 18, 16, 549, 55, 62, 2462, 2469, "Indexed" +286, 18, 17, 550, 63, 66, 2470, 2473, "for" +286, 18, 18, 551, 67, 74, 2474, 2481, "MEDLINE" +286, 18, 19, 552, 75, 76, 2482, 2483, "]" diff --git a/data/dm2 24356792_kwoodley.annodb b/data/dm2 24356792_kwoodley.annodb new file mode 100644 index 0000000..e1bd24b --- /dev/null +++ b/data/dm2 24356792_kwoodley.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +46853, Journal, 0, 14, "Horm Metab Res", "", +46854, PublicationYear, 17, 21, "2014", "", +46868, Title, 108, 203, "The glucose and lipid effects of colesevelam as monotherapy in drug - na ï ve type 2 diabetes .", "", +46855, Drug, 141, 152, "colesevelam", "", +46881, Precondition, 171, 201, "drug - na ï ve type 2 diabetes", "", +46863, Type2Diabetes, 186, 201, "type 2 diabetes", "", +46869, Author, 204, 216, "Rosenstock J", "", +46870, Author, 225, 233, "Rigby SP", "", +46871, Author, 242, 249, "Ford DM", "", +46872, Author, 258, 263, "Tao B", "", +46873, Author, 272, 279, "Chou HS", "", +46874, USA, 384, 387, "USA", "", +46856, Drug, 502, 513, "Colesevelam", "", +46864, Type2Diabetes, 548, 572, "type 2 diabetes mellitus", "", +46865, Type2Diabetes, 575, 579, "T2DM", "", +46875, Metformin, 602, 611, "metformin", "", +46876, Sulfonylureas, 616, 628, "sulfonylurea", "", +46877, Insulin, 636, 643, "insulin", "", +46878, HbA1c, 671, 685, "hemoglobin A1c", "", +46879, HbA1c, 688, 693, "HbA1c", "", +46882, ObjectiveDescription, 747, 846, "A study was conducted to evaluate colesevelam as monotherapy in drug - na ï ve patients with T2DM .", "", +46857, Drug, 781, 792, "colesevelam", "", +46880, Precondition, 811, 844, "drug - na ï ve patients with T2DM", "", +46866, Type2Diabetes, 840, 844, "T2DM", "", +46883, Randomized, 855, 865, "randomized", "", +46884, DoubleBlind, 868, 882, "double - blind", "", +46885, Placebo, 885, 892, "placebo", "", +46886, Parallel, 908, 924, "parallel - group", "", +46891, Precondition, 933, 1048, "adults with T2DM who had inadequate glycemic control ( HbA1c ≥ 7 . 5 % and ≤ 9 . 5 % ) with diet and exercise alone", "", +46867, Type2Diabetes, 945, 949, "T2DM", "", +46887, HbA1c, 988, 993, "HbA1c", "", +46888, Percentage, 1002, 1003, "%", "", +46889, Percentage, 1016, 1017, "%", "", +46890, Randomized, 1054, 1064, "randomized", "", +46858, Drug, 1076, 1087, "colesevelam", "", +46892, DoseValue, 1088, 1094, "3 . 75", "", +46893, Gram, 1097, 1098, "g", "", +46895, Frequency, 1101, 1104, "day", "", +46896, NumberPatientsArm, 1111, 1114, "176", "", +46898, Placebo, 1120, 1127, "placebo", "", +46897, NumberPatientsArm, 1134, 1137, "181", "", +46901, Duration, 1144, 1152, "24 weeks", "", +46902, HbA1c, 1189, 1194, "HbA1c", "", +46905, TimePoint, 1198, 1205, "week 24", "", +46859, Drug, 1208, 1219, "Colesevelam", "", +46899, Placebo, 1235, 1242, "placebo", "", +46907, TimePoint, 1278, 1286, "baseline", "", +46903, HbA1c, 1290, 1295, "HbA1c", "", +46908, Reduction, 1300, 1306, "2 . 92", "", +46910, BioAndMedicalUnit, 1309, 1319, "mmol / mol", "", +46911, ResultMeasuredValue, 1322, 1327, "0 . 3", "", +46912, Percentage, 1328, 1329, "%", "", +46913, PValueChangeValue, 1334, 1344, "p = 0 . 01", "", +46915, FastingPlasmaGlucose, 1351, 1373, "fasting plasma glucose", "", +46909, Reduction, 1378, 1384, "10 . 3", "", +46916, Mg_per_deciliter, 1387, 1394, "mg / dl", "", +46914, PValueChangeValue, 1397, 1407, "p = 0 . 04", "", +46906, TimePoint, 1413, 1420, "week 24", "", +46860, Drug, 1461, 1472, "Colesevelam", "", +46917, EndPointDescription, 1500, 1537, "low - density lipoprotein cholesterol", "", +46923, Reduction, 1542, 1548, "11 . 2", "", +46927, Percentage, 1549, 1550, "%", "", +46931, PValueChangeValue, 1553, 1565, "p < 0 . 0001", "", +46918, EndPointDescription, 1570, 1587, "total cholesterol", "", +46924, Reduction, 1592, 1597, "5 . 1", "", +46928, Percentage, 1598, 1599, "%", "", +46932, PValueChangeValue, 1602, 1614, "p = 0 . 0005", "", +46919, EndPointDescription, 1619, 1663, "non - high - density lipoprotein cholesterol", "", +46925, Reduction, 1668, 1673, "7 . 4", "", +46929, Percentage, 1674, 1675, "%", "", +46933, PValueChangeValue, 1678, 1690, "p = 0 . 0001", "", +46920, EndPointDescription, 1699, 1715, "apolipoprotein B", "", +46926, Reduction, 1720, 1725, "6 . 5", "", +46930, Percentage, 1726, 1727, "%", "", +46934, PValueChangeValue, 1730, 1742, "p = 0 . 0001", "", +46921, EndPointDescription, 1759, 1779, "apolipoprotein A - I", "", +46937, Increment, 1785, 1790, "2 . 4", "", +46939, Percentage, 1791, 1792, "%", "", +46935, PValueChangeValue, 1795, 1805, "p = 0 . 04", "", +46922, EndPointDescription, 1814, 1827, "triglycerides", "", +46938, Increment, 1833, 1838, "9 . 7", "", +46940, Percentage, 1839, 1840, "%", "", +46936, PValueChangeValue, 1843, 1853, "p = 0 . 03", "", +46861, Drug, 1858, 1869, "Colesevelam", "", +46941, ConclusionComment, 1858, 2064, "Colesevelam monotherapy resulted in statistically significant improvements in glycemic and most lipid parameters in subjects with type 2 diabetes , with no new or unexpected safety and tolerability issues .", "", +46900, Type2Diabetes, 1988, 2003, "type 2 diabetes", "", +46942, ConclusionComment, 2065, 2310, "Modest reductions in HbA1c and low - density lipoprotein cholesterol levels with colesevelam further support its use in combination with other antidiabetes agents when treatment targets for these parameters are close but are not quite achieved .", "", +46904, HbA1c, 2086, 2091, "HbA1c", "", +46862, Drug, 2146, 2157, "colesevelam", "", +46943, PMID, 2451, 2459, "24356792", "", diff --git a/data/dm2 24356792_kwoodley.n-triples b/data/dm2 24356792_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24356792_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24639432_admin.annodb b/data/dm2 24639432_admin.annodb new file mode 100644 index 0000000..216a871 --- /dev/null +++ b/data/dm2 24639432_admin.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 24, "Diabetes Metab Res Rev .", "", " \"Diabetes Metab Res Rev .\"." +1, PublicationYear, 25, 29, "2014", "", " \"2014\"." +75312, Lixisenatide, 90, 102, "Lixisenatide", "", +28, Title, 90, 310, "Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea : a randomized , double - blind , placebo - controlled ,", "", " \"Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea : a randomized , double - blind , placebo - controlled ,\"." +15, Type2Diabetes, 163, 187, "type 2 diabetes mellitus", "", " ." +18, Metformin, 215, 224, "metformin", "", +21, Sulfonylureas, 241, 253, "sulfonylurea", "", +24, Randomized, 258, 268, "randomized", "", " ." +25, DoubleBlind, 271, 285, "double - blind", "", " ." +26, Placebo, 288, 295, "placebo", "", +27, Duration, 311, 320, "24 - week", "", " \"24 - week\"." +29, Title, 311, 351, "24 - week trial ( GetGoal - M - Asia ) .", "", +30, Author, 352, 360, "Yu Pan C", "", " \"Yu Pan C\"." +31, Author, 369, 374, "Han P", "", " \"Han P\"." +32, Author, 377, 382, "Liu X", "", " \"Liu X\"." +33, Author, 385, 390, "Yan S", "", " \"Yan S\"." +34, Author, 393, 399, "Feng P", "", " \"Feng P\"." +35, Author, 402, 408, "Zhou Z", "", " \"Zhou Z\"." +36, Author, 411, 415, "Lv X", "", " \"Lv X\"." +37, Author, 418, 424, "Tian H", "", " \"Tian H\"." +38, Author, 427, 436, "Jin Kui Y", "", " \"Jin Kui Y\"." +39, Author, 439, 443, "Su B", "", " \"Su B\"." +40, Author, 446, 453, "Shang S", "", " \"Shang S\"." +41, Author, 456, 468, "Niemoeller E", "", " \"Niemoeller E\"." +42, China, 562, 567, "China", "", +45, ObjectiveDescription, 583, 812, "This study assessed the efficacy and safety of the once - daily glucagon - like peptide - 1 receptor agonist , lixisenatide , in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea .", "", " \"This study assessed the efficacy and safety of the once - daily glucagon - like peptide - 1 receptor agonist , lixisenatide , in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea .\"." +43, Frequency, 634, 646, "once - daily", "", +75310, Lixisenatide, 694, 706, "lixisenatide", "", " ." +106270, Ethnicity, 712, 717, "Asian", "", " . ." +44, Precondition, 712, 810, "Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea", "", " \"Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea\"." +16, Type2Diabetes, 732, 756, "type 2 diabetes mellitus", "", +20, Metformin, 784, 793, "metformin", "", +22, Sulfonylureas, 798, 810, "sulfonylurea", "", +46, Duration, 831, 840, "24 - week", "", +47, DoubleBlind, 843, 857, "double - blind", "", +48, Placebo, 860, 867, "placebo", "", +53, Multicenter, 883, 896, "multinational", "", " ." +54, Randomized, 919, 929, "randomized", "", +75311, Lixisenatide, 933, 945, "lixisenatide", "", +55, DoseValue, 946, 948, "20", "", " \"20\"." +56, Microgram, 949, 952, "µ g", "", " ." +57, Frequency, 953, 963, "once daily", "", " \"once daily\"." +49, Placebo, 967, 974, "placebo", "", " ." +58, HbA1c, 1021, 1041, "glycated haemoglobin", "", +59, HbA1c, 1044, 1049, "HbA1c", "", +61, TimePoint, 1057, 1065, "baseline", "", +62, TimePoint, 1069, 1076, "week 24", "", +63, NumberPatientsCT, 1100, 1103, "391", "", " \"391\"." +64, Randomized, 1118, 1128, "randomized", "", +75298, Lixisenatide, 1131, 1143, "Lixisenatide", "", +60, HbA1c, 1166, 1171, "HbA1c", "", " ." +50, Placebo, 1193, 1200, "placebo", "", +169, LeastSquaresMean, 1203, 1210, "LS mean", "", " ." +65, DiffGroupAbsValue, 1224, 1232, "- 0 . 36", "", " \"- 0 . 36\"." +66, Percentage, 1233, 1234, "%", "", " ." +67, PvalueDiff, 1237, 1251, "p  =  0 . 0004", "", " \"p  =  0 . 0004\"." +75299, Lixisenatide, 1293, 1305, "lixisenatide", "", +69, HbA1c_target, 1334, 1356, "HbA1c targets of < 7 %", "", " ." +74804, Percentage, 1355, 1356, "%", "", +74806, PvalueDiff, 1359, 1372, "p  =  0 . 003", "", " \"p  =  0 . 003\"." +72, HbA1c_target, 1379, 1388, "≤ 6 . 5 %", "", " ." +175, Percentage, 1387, 1388, "%", "", +177, PvalueDiff, 1391, 1404, "p  =  0 . 001", "", " \"p  =  0 . 001\"." +51, Placebo, 1414, 1421, "placebo", "", +75300, Lixisenatide, 1424, 1436, "Lixisenatide", "", +80, ObservedResult, 1441, 1494, "associated with a statistically significant reduction", "", +73, PostprandialPlasmaGlucose, 1498, 1531, "2 - h postprandial plasma glucose", "", " ." +52, Placebo, 1570, 1577, "placebo", "", +183, LeastSquaresMean, 1580, 1587, "LS mean", "", " ." +75, DiffGroupAbsValue, 1601, 1609, "- 4 . 28", "", " \"- 4 . 28\"." +76, Millimoles_per_litre, 1610, 1618, "mmol / L", "", " ." +77, PvalueDiff, 1621, 1635, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +81, ObservedResult, 1644, 1665, "significant reduction", "", " \"significant reduction\"." +78, FastingPlasmaGlucose, 1669, 1691, "fasting plasma glucose", "", " ." +188, PvalueDiff, 1694, 1708, "p  =  0 . 0109", "", " \"p  =  0 . 0109\"." +82, BodyWeight, 1740, 1746, "weight", "", +83, Placebo, 1759, 1766, "placebo", "", +84, BodyWeight, 1796, 1807, "body weight", "", " ." +75303, Lixisenatide, 1835, 1847, "lixisenatide", "", +85, Reduction, 1852, 1858, "1 . 50", "", " \"1 . 50\"." +88, Kg, 1859, 1861, "kg", "", " ." +87, Placebo, 1864, 1871, "placebo", "", +86, Reduction, 1876, 1882, "1 . 24", "", " \"1 . 24\"." +89, Kg, 1883, 1885, "kg", "", +90, PvalueDiff, 1888, 1901, "p  =  0 . 296", "", " \"p  =  0 . 296\"." +91, EndPointDescription, 1923, 1958, "treatment - emergent adverse events", "", " . ." +92, EndPointDescription, 1961, 1966, "TEAEs", "", +95, PercentageAffected, 1973, 1979, "64 . 3", "", " \"64 . 3\"." +75308, Lixisenatide, 1987, 1999, "lixisenatide", "", +96, PercentageAffected, 2007, 2013, "47 . 4", "", " \"47 . 4\"." +99, Placebo, 2021, 2028, "placebo", "", +202, EndPointDescription, 2036, 2049, "serious TEAEs", "", " . ." +97, PercentageAffected, 2062, 2067, "1 . 5", "", " \"1 . 5\"." +98, PercentageAffected, 2077, 2082, "2 . 1", "", " \"2 . 1\"." +94, EndPointDescription, 2130, 2134, "TEAE", "", +75306, Lixisenatide, 2142, 2154, "lixisenatide", "", +102, Nausea, 2165, 2171, "nausea", "", " ." +104, PercentageAffected, 2174, 2180, "16 . 3", "", " \"16 . 3\"." +105, PercentageAffected, 2186, 2191, "2 . 6", "", " \"2 . 6\"." +106, Placebo, 2199, 2206, "placebo", "", +107, SymptomaticHypoglycemia, 2228, 2253, "symptomatic hypoglycaemia", "", " ." +108, PercentageAffected, 2258, 2263, "5 . 6", "", " \"5 . 6\"." +75307, Lixisenatide, 2271, 2283, "lixisenatide", "", +109, PercentageAffected, 2298, 2303, "2 . 6", "", " \"2 . 6\"." +111, Placebo, 2311, 2318, "placebo", "", +112, PvalueDiff, 2321, 2335, "p  =  0 . 1321", "", " \"p  =  0 . 1321\"." +113, ObservedResult, 2340, 2347, "with no", "", " \"with no\". \"events reported\". \"with no\". \"events reported\"." +220, SevereHypoglycemia, 2348, 2380, "severe symptomatic hypoglycaemia", "", " ." +113, ObservedResult, 2381, 2396, "events reported", "", " \"events reported\". \"events reported\"." +116, ConclusionComment, 2413, 2624, "In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea , lixisenatide significantly improved glycaemic control and was well tolerated during the 24 - week study .", "", " \"In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea , lixisenatide significantly improved glycaemic control and was well tolerated during the 24 - week study .\"." +17, Type2Diabetes, 2436, 2460, "type 2 diabetes mellitus", "", +19, Metformin, 2490, 2499, "metformin", "", +23, Sulfonylureas, 2504, 2516, "sulfonylurea", "", +75309, Lixisenatide, 2519, 2531, "lixisenatide", "", +115, Duration, 2607, 2616, "24 - week", "", +117, PMID, 2765, 2773, "24639432", "", " \"24639432\"." diff --git a/data/dm2 24639432_admin.n-triples b/data/dm2 24639432_admin.n-triples new file mode 100644 index 0000000..0f70ac4 --- /dev/null +++ b/data/dm2 24639432_admin.n-triples @@ -0,0 +1,293 @@ +# RDF export of group: Publication + . + "Publication 55809" . + "Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea : a randomized , double - blind , placebo - controlled ," . + "Yu Pan C" . + "2014" . + "Diabetes Metab Res Rev ." . + "24639432" . + . + "Han P" . + "Liu X" . + "Yan S" . + "Feng P" . + "Zhou Z" . + "Lv X" . + "Tian H" . + "Jin Kui Y" . + "Su B" . + "Shang S" . + "Niemoeller E" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 55816" . + "This study assessed the efficacy and safety of the once - daily glucagon - like peptide - 1 receptor agonist , lixisenatide , in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea ." . + "391" . + "24 - week" . + . + . + . + "In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea , lixisenatide significantly improved glycaemic control and was well tolerated during the 24 - week study ." . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 55832" . + "Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea" . + . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "hbat1" . + . + . + . + . + . + "hbat2" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "sae" . + . + . + . + . + . + . + "nau" . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "shyp" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + "once daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lix" . + . + "20" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . + . + "hbat1 1" . + . + . + "hbat1 2" . + . + . + "hbat2 1" . + . + . + "hbat2 2" . + . + . + "ppg 1" . + . + . + "ppg 2" . + . + . + "fpg 1" . + . + "significant reduction" . + . + "fpg 2" . + . + . + "bw 1" . + . + "1 . 50" . + . + "bw 2" . + . + "1 . 24" . + . + "ae 1" . + . + "64 . 3" . + . + "ae 2" . + . + "47 . 4" . + . + "sae 1" . + . + "1 . 5" . + . + "sae 2" . + . + "2 . 1" . + . + "nau 1" . + . + "16 . 3" . + . + "nau 2" . + . + "2 . 6" . + . + "hyp 1" . + . + "5 . 6" . + . + "hyp 2" . + . + "2 . 6" . + . + "shyp 1" . + . + "with no" . + "events reported" . + . + "shyp 2" . + . + "with no" . + "events reported" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 36" . + "p  =  0 . 0004" . + . + . + . + "hbat1" . + "p  =  0 . 003" . + . + . + . + "hbat2" . + "p  =  0 . 001" . + . + . + . + "ppg" . + "- 4 . 28" . + "p  <  0 . 0001" . + . + . + . + "fpg" . + "p  =  0 . 0109" . + . + . + . + "bw" . + "p  =  0 . 296" . + . + . + . + "hyp" . + "p  =  0 . 1321" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24639432_akramersunderbrink.annodb b/data/dm2 24639432_akramersunderbrink.annodb new file mode 100644 index 0000000..900d9f5 --- /dev/null +++ b/data/dm2 24639432_akramersunderbrink.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59297, Journal, 0, 22, "Diabetes Metab Res Rev", "", +59298, PublicationYear, 25, 29, "2014", "", +59299, Drug, 90, 102, "Lixisenatide", "", +59320, Title, 90, 310, "Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea : a randomized , double - blind , placebo - controlled ,", "", +59300, Type2Diabetes, 163, 187, "type 2 diabetes mellitus", "", +59301, Metformin, 215, 224, "metformin", "", +59302, Sulfonylureas, 241, 253, "sulfonylurea", "", +59303, Randomized, 258, 268, "randomized", "", +59304, DoubleBlind, 271, 285, "double - blind", "", +59305, Placebo, 288, 295, "placebo", "", +59306, Duration, 311, 320, "24 - week", "", +59321, Title, 311, 351, "24 - week trial ( GetGoal - M - Asia ) .", "", +59307, Author, 352, 360, "Yu Pan C", "", +59308, Author, 369, 374, "Han P", "", +59309, Author, 377, 382, "Liu X", "", +59310, Author, 385, 390, "Yan S", "", +59311, Author, 393, 399, "Feng P", "", +59312, Author, 402, 408, "Zhou Z", "", +59313, Author, 411, 415, "Lv X", "", +59314, Author, 418, 424, "Tian H", "", +59315, Author, 427, 436, "Jin Kui Y", "", +59316, Author, 439, 443, "Su B", "", +59317, Author, 446, 453, "Shang S", "", +59318, Author, 456, 468, "Niemoeller E", "", +59319, China, 562, 567, "China", "", +59328, ObjectiveDescription, 583, 812, "This study assessed the efficacy and safety of the once - daily glucagon - like peptide - 1 receptor agonist , lixisenatide , in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea .", "", +59322, Frequency, 634, 646, "once - daily", "", +59323, Drug, 694, 706, "lixisenatide", "", +59324, Type2Diabetes, 732, 756, "type 2 diabetes mellitus", "", +59327, Precondition, 757, 810, "inadequately controlled on metformin  ±  sulfonylurea", "", +59325, Metformin, 784, 793, "metformin", "", +59326, Sulfonylureas, 798, 810, "sulfonylurea", "", +59329, Duration, 831, 840, "24 - week", "", +59330, DoubleBlind, 843, 857, "double - blind", "", +59331, Placebo, 860, 867, "placebo", "", +59332, Multicenter, 883, 896, "multinational", "", +59333, Randomized, 919, 929, "randomized", "", +59334, Drug, 933, 945, "lixisenatide", "", +59335, DoseValue, 946, 952, "20 µ g", "", +59336, Microgram, 949, 952, "µ g", "", +59337, Frequency, 953, 963, "once daily", "", +59338, Placebo, 967, 974, "placebo", "", +59339, HbA1c, 1021, 1041, "glycated haemoglobin", "", +59340, HbA1c, 1044, 1049, "HbA1c", "", +59341, TimePoint, 1057, 1065, "baseline", "", +59342, TimePoint, 1069, 1076, "week 24", "", +59343, NumberPatientsCT, 1100, 1103, "391", "", +59344, Randomized, 1118, 1128, "randomized", "", +59345, Drug, 1131, 1143, "Lixisenatide", "", +59346, HbA1c, 1166, 1171, "HbA1c", "", +59347, Placebo, 1193, 1200, "placebo", "", +59348, LeastSquaresMean, 1203, 1221, "LS mean difference", "", +59366, DiffGroupAbsValue, 1224, 1232, "- 0 . 36", "", +59351, Percentage, 1233, 1234, "%", "", +59350, PvalueDiff, 1237, 1251, "p  =  0 . 0004", "", +59352, Drug, 1293, 1305, "lixisenatide", "", +59354, HbA1c_target, 1334, 1356, "HbA1c targets of < 7 %", "", +59355, Percentage, 1355, 1356, "%", "", +59359, PvalueDiff, 1359, 1372, "p  =  0 . 003", "", +59357, HbA1c_target, 1379, 1388, "≤ 6 . 5 %", "", +59356, Percentage, 1387, 1388, "%", "", +59358, PvalueDiff, 1391, 1404, "p  =  0 . 001", "", +59360, Placebo, 1414, 1421, "placebo", "", +59361, Drug, 1424, 1436, "Lixisenatide", "", +59362, PostprandialPlasmaGlucose, 1498, 1562, "2 - h postprandial plasma glucose after a standardized breakfast", "", +59363, Placebo, 1570, 1577, "placebo", "", +59364, LeastSquaresMean, 1580, 1598, "LS mean difference", "", +59365, DiffGroupAbsValue, 1601, 1609, "- 4 . 28", "", +59367, Millimoles_per_litre, 1610, 1618, "mmol / L", "", +59368, PvalueDiff, 1621, 1635, "p  <  0 . 0001", "", +59370, FastingPlasmaGlucose, 1669, 1691, "fasting plasma glucose", "", +59369, PvalueDiff, 1694, 1708, "p  =  0 . 0109", "", +59371, WeightReduction, 1740, 1751, "weight loss", "", +59372, Placebo, 1759, 1766, "placebo", "", +59373, BodyWeight, 1796, 1807, "body weight", "", +59374, Drug, 1835, 1847, "lixisenatide", "", +59376, ChangeValue, 1850, 1858, "- 1 . 50", "", +59378, Kg, 1859, 1861, "kg", "", +59375, Placebo, 1864, 1871, "placebo", "", +59377, ChangeValue, 1874, 1882, "- 1 . 24", "", +59379, Kg, 1883, 1885, "kg", "", +59380, PvalueDiff, 1888, 1901, "p  =  0 . 296", "", +59381, EndPointDescription, 1923, 1958, "treatment - emergent adverse events", "", +59382, EndPointDescription, 1961, 1966, "TEAEs", "", +59384, PercentageAffected, 1973, 1979, "64 . 3", "", +59388, Percentage, 1980, 1981, "%", "", +59392, Drug, 1987, 1999, "lixisenatide", "", +59385, PercentageAffected, 2007, 2013, "47 . 4", "", +59389, Percentage, 2014, 2015, "%", "", +59393, Placebo, 2021, 2028, "placebo", "", +59383, EndPointDescription, 2036, 2049, "serious TEAEs", "", +59386, PercentageAffected, 2062, 2067, "1 . 5", "", +59390, Percentage, 2068, 2069, "%", "", +59387, PercentageAffected, 2077, 2082, "2 . 1", "", +59391, Percentage, 2083, 2084, "%", "", +59394, Nausea, 2165, 2171, "nausea", "", +59395, PercentageAffected, 2174, 2180, "16 . 3", "", +59397, Percentage, 2181, 2182, "%", "", +59396, PercentageAffected, 2186, 2191, "2 . 6", "", +59398, Percentage, 2192, 2193, "%", "", +59399, Placebo, 2199, 2206, "placebo", "", +59400, SymptomaticHypoglycemia, 2228, 2253, "symptomatic hypoglycaemia", "", +59402, PercentageAffected, 2258, 2263, "5 . 6", "", +59405, Percentage, 2264, 2265, "%", "", +59407, Drug, 2271, 2283, "lixisenatide", "", +59403, PercentageAffected, 2298, 2303, "2 . 6", "", +59406, Percentage, 2304, 2305, "%", "", +59408, Placebo, 2311, 2318, "placebo", "", +59409, PvalueDiff, 2321, 2335, "p  =  0 . 1321", "", +59404, NumberAffected, 2345, 2347, "no", "", +59401, SevereHypoglycemia, 2348, 2380, "severe symptomatic hypoglycaemia", "", +59415, ConclusionComment, 2413, 2624, "In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea , lixisenatide significantly improved glycaemic control and was well tolerated during the 24 - week study .", "", +59410, Type2Diabetes, 2436, 2460, "type 2 diabetes mellitus", "", +59416, Precondition, 2461, 2516, "insufficiently controlled on metformin  ±  sulfonylurea", "", +59411, Metformin, 2490, 2499, "metformin", "", +59412, Sulfonylureas, 2504, 2516, "sulfonylurea", "", +59413, Drug, 2519, 2531, "lixisenatide", "", +59414, Duration, 2607, 2616, "24 - week", "", +59417, PMID, 2765, 2773, "24639432", "", diff --git a/data/dm2 24639432_akramersunderbrink.n-triples b/data/dm2 24639432_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24639432_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24639432_export.csv b/data/dm2 24639432_export.csv new file mode 100644 index 0000000..ab68768 --- /dev/null +++ b/data/dm2 24639432_export.csv @@ -0,0 +1,574 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +283, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +283, 1, 2, 2, 9, 14, 9, 14, "Metab" +283, 1, 3, 3, 15, 18, 15, 18, "Res" +283, 1, 4, 4, 19, 22, 19, 22, "Rev" +283, 1, 5, 5, 23, 24, 23, 24, "." +283, 2, 1, 6, 0, 4, 25, 29, "2014" +283, 2, 2, 7, 5, 8, 30, 33, "Nov" +283, 2, 3, 8, 9, 10, 34, 35, ";" +283, 2, 4, 9, 11, 13, 36, 38, "30" +283, 2, 5, 10, 14, 15, 39, 40, "(" +283, 2, 6, 11, 16, 17, 41, 42, "8" +283, 2, 7, 12, 18, 19, 43, 44, ")" +283, 2, 8, 13, 20, 21, 45, 46, ":" +283, 2, 9, 14, 22, 25, 47, 50, "726" +283, 2, 10, 15, 26, 27, 51, 52, "-" +283, 2, 11, 16, 28, 30, 53, 55, "35" +283, 2, 12, 17, 31, 32, 56, 57, "." +283, 2, 13, 18, 33, 36, 58, 61, "doi" +283, 2, 14, 19, 37, 38, 62, 63, ":" +283, 2, 15, 20, 39, 41, 64, 66, "10" +283, 2, 16, 21, 42, 43, 67, 68, "." +283, 2, 17, 22, 44, 48, 69, 73, "1002" +283, 2, 18, 23, 49, 50, 74, 75, "/" +283, 2, 19, 24, 51, 55, 76, 80, "dmrr" +283, 2, 20, 25, 56, 57, 81, 82, "." +283, 2, 21, 26, 58, 62, 83, 87, "2541" +283, 2, 22, 27, 63, 64, 88, 89, "." +283, 3, 1, 28, 0, 12, 90, 102, "Lixisenatide" +283, 3, 2, 29, 13, 22, 103, 112, "treatment" +283, 3, 3, 30, 23, 31, 113, 121, "improves" +283, 3, 4, 31, 32, 41, 122, 131, "glycaemic" +283, 3, 5, 32, 42, 49, 132, 139, "control" +283, 3, 6, 33, 50, 52, 140, 142, "in" +283, 3, 7, 34, 53, 58, 143, 148, "Asian" +283, 3, 8, 35, 59, 67, 149, 157, "patients" +283, 3, 9, 36, 68, 72, 158, 162, "with" +283, 3, 10, 37, 73, 77, 163, 167, "type" +283, 3, 11, 38, 78, 79, 168, 169, "2" +283, 3, 12, 39, 80, 88, 170, 178, "diabetes" +283, 3, 13, 40, 89, 97, 179, 187, "mellitus" +283, 3, 14, 41, 98, 110, 188, 200, "inadequately" +283, 3, 15, 42, 111, 121, 201, 211, "controlled" +283, 3, 16, 43, 122, 124, 212, 214, "on" +283, 3, 17, 44, 125, 134, 215, 224, "metformin" +283, 3, 18, 45, 135, 139, 225, 229, "with" +283, 3, 19, 46, 140, 142, 230, 232, "or" +283, 3, 20, 47, 143, 150, 233, 240, "without" +283, 3, 21, 48, 151, 163, 241, 253, "sulfonylurea" +283, 3, 22, 49, 164, 165, 254, 255, ":" +283, 3, 23, 50, 166, 167, 256, 257, "a" +283, 3, 24, 51, 168, 178, 258, 268, "randomized" +283, 3, 25, 52, 179, 180, 269, 270, "," +283, 3, 26, 53, 181, 187, 271, 277, "double" +283, 3, 27, 54, 188, 189, 278, 279, "-" +283, 3, 28, 55, 190, 195, 280, 285, "blind" +283, 3, 29, 56, 196, 197, 286, 287, "," +283, 3, 30, 57, 198, 205, 288, 295, "placebo" +283, 3, 31, 58, 206, 207, 296, 297, "-" +283, 3, 32, 59, 208, 218, 298, 308, "controlled" +283, 3, 33, 60, 219, 220, 309, 310, "," +283, 3, 34, 61, 221, 223, 311, 313, "24" +283, 3, 35, 62, 224, 225, 314, 315, "-" +283, 3, 36, 63, 226, 230, 316, 320, "week" +283, 3, 37, 64, 231, 236, 321, 326, "trial" +283, 3, 38, 65, 237, 238, 327, 328, "(" +283, 3, 39, 66, 239, 246, 329, 336, "GetGoal" +283, 3, 40, 67, 247, 248, 337, 338, "-" +283, 3, 41, 68, 249, 250, 339, 340, "M" +283, 3, 42, 69, 251, 252, 341, 342, "-" +283, 3, 43, 70, 253, 257, 343, 347, "Asia" +283, 3, 44, 71, 258, 259, 348, 349, ")" +283, 3, 45, 72, 260, 261, 350, 351, "." +283, 4, 1, 73, 0, 2, 352, 354, "Yu" +283, 4, 2, 74, 3, 6, 355, 358, "Pan" +283, 4, 3, 75, 7, 8, 359, 360, "C" +283, 4, 4, 76, 9, 10, 361, 362, "(" +283, 4, 5, 77, 11, 12, 363, 364, "1" +283, 4, 6, 78, 13, 14, 365, 366, ")" +283, 4, 7, 79, 15, 16, 367, 368, "," +283, 4, 8, 80, 17, 20, 369, 372, "Han" +283, 4, 9, 81, 21, 22, 373, 374, "P" +283, 4, 10, 82, 23, 24, 375, 376, "," +283, 4, 11, 83, 25, 28, 377, 380, "Liu" +283, 4, 12, 84, 29, 30, 381, 382, "X" +283, 4, 13, 85, 31, 32, 383, 384, "," +283, 4, 14, 86, 33, 36, 385, 388, "Yan" +283, 4, 15, 87, 37, 38, 389, 390, "S" +283, 4, 16, 88, 39, 40, 391, 392, "," +283, 4, 17, 89, 41, 45, 393, 397, "Feng" +283, 4, 18, 90, 46, 47, 398, 399, "P" +283, 4, 19, 91, 48, 49, 400, 401, "," +283, 4, 20, 92, 50, 54, 402, 406, "Zhou" +283, 4, 21, 93, 55, 56, 407, 408, "Z" +283, 4, 22, 94, 57, 58, 409, 410, "," +283, 4, 23, 95, 59, 61, 411, 413, "Lv" +283, 4, 24, 96, 62, 63, 414, 415, "X" +283, 4, 25, 97, 64, 65, 416, 417, "," +283, 4, 26, 98, 66, 70, 418, 422, "Tian" +283, 4, 27, 99, 71, 72, 423, 424, "H" +283, 4, 28, 100, 73, 74, 425, 426, "," +283, 4, 29, 101, 75, 78, 427, 430, "Jin" +283, 4, 30, 102, 79, 82, 431, 434, "Kui" +283, 4, 31, 103, 83, 84, 435, 436, "Y" +283, 4, 32, 104, 85, 86, 437, 438, "," +283, 4, 33, 105, 87, 89, 439, 441, "Su" +283, 4, 34, 106, 90, 91, 442, 443, "B" +283, 4, 35, 107, 92, 93, 444, 445, "," +283, 4, 36, 108, 94, 99, 446, 451, "Shang" +283, 4, 37, 109, 100, 101, 452, 453, "S" +283, 4, 38, 110, 102, 103, 454, 455, "," +283, 4, 39, 111, 104, 114, 456, 466, "Niemoeller" +283, 4, 40, 112, 115, 116, 467, 468, "E" +283, 4, 41, 113, 117, 118, 469, 470, "." +283, 4, 42, 114, 119, 125, 471, 477, "Author" +283, 4, 43, 115, 126, 137, 478, 489, "information" +283, 4, 44, 116, 138, 139, 490, 491, ":" +283, 4, 45, 117, 140, 141, 492, 493, "(" +283, 4, 46, 118, 142, 143, 494, 495, "1" +283, 4, 47, 119, 144, 145, 496, 497, ")" +283, 4, 48, 120, 146, 153, 498, 505, "Chinese" +283, 4, 49, 121, 154, 160, 506, 512, "People" +283, 4, 50, 122, 161, 162, 513, 514, "'" +283, 4, 51, 123, 163, 164, 515, 516, "s" +283, 4, 52, 124, 165, 175, 517, 527, "Liberation" +283, 4, 53, 125, 176, 180, 528, 532, "Army" +283, 4, 54, 126, 181, 188, 533, 540, "General" +283, 4, 55, 127, 189, 197, 541, 549, "Hospital" +283, 4, 56, 128, 198, 199, 550, 551, "," +283, 4, 57, 129, 200, 207, 552, 559, "Beijing" +283, 4, 58, 130, 208, 209, 560, 561, "," +283, 4, 59, 131, 210, 215, 562, 567, "China" +283, 4, 60, 132, 216, 217, 568, 569, "." +283, 5, 1, 133, 0, 10, 570, 580, "BACKGROUND" +283, 5, 2, 134, 11, 12, 581, 582, ":" +283, 5, 3, 135, 13, 17, 583, 587, "This" +283, 5, 4, 136, 18, 23, 588, 593, "study" +283, 5, 5, 137, 24, 32, 594, 602, "assessed" +283, 5, 6, 138, 33, 36, 603, 606, "the" +283, 5, 7, 139, 37, 45, 607, 615, "efficacy" +283, 5, 8, 140, 46, 49, 616, 619, "and" +283, 5, 9, 141, 50, 56, 620, 626, "safety" +283, 5, 10, 142, 57, 59, 627, 629, "of" +283, 5, 11, 143, 60, 63, 630, 633, "the" +283, 5, 12, 144, 64, 68, 634, 638, "once" +283, 5, 13, 145, 69, 70, 639, 640, "-" +283, 5, 14, 146, 71, 76, 641, 646, "daily" +283, 5, 15, 147, 77, 85, 647, 655, "glucagon" +283, 5, 16, 148, 86, 87, 656, 657, "-" +283, 5, 17, 149, 88, 92, 658, 662, "like" +283, 5, 18, 150, 93, 100, 663, 670, "peptide" +283, 5, 19, 151, 101, 102, 671, 672, "-" +283, 5, 20, 152, 103, 104, 673, 674, "1" +283, 5, 21, 153, 105, 113, 675, 683, "receptor" +283, 5, 22, 154, 114, 121, 684, 691, "agonist" +283, 5, 23, 155, 122, 123, 692, 693, "," +283, 5, 24, 156, 124, 136, 694, 706, "lixisenatide" +283, 5, 25, 157, 137, 138, 707, 708, "," +283, 5, 26, 158, 139, 141, 709, 711, "in" +283, 5, 27, 159, 142, 147, 712, 717, "Asian" +283, 5, 28, 160, 148, 156, 718, 726, "patients" +283, 5, 29, 161, 157, 161, 727, 731, "with" +283, 5, 30, 162, 162, 166, 732, 736, "type" +283, 5, 31, 163, 167, 168, 737, 738, "2" +283, 5, 32, 164, 169, 177, 739, 747, "diabetes" +283, 5, 33, 165, 178, 186, 748, 756, "mellitus" +283, 5, 34, 166, 187, 199, 757, 769, "inadequately" +283, 5, 35, 167, 200, 210, 770, 780, "controlled" +283, 5, 36, 168, 211, 213, 781, 783, "on" +283, 5, 37, 169, 214, 223, 784, 793, "metformin" +283, 5, 38, 170, 224, 227, 794, 797, " ± " +283, 5, 39, 171, 228, 240, 798, 810, "sulfonylurea" +283, 5, 40, 172, 241, 242, 811, 812, "." +283, 6, 1, 173, 0, 7, 813, 820, "METHODS" +283, 6, 2, 174, 8, 9, 821, 822, ":" +283, 6, 3, 175, 10, 12, 823, 825, "In" +283, 6, 4, 176, 13, 17, 826, 830, "this" +283, 6, 5, 177, 18, 20, 831, 833, "24" +283, 6, 6, 178, 21, 22, 834, 835, "-" +283, 6, 7, 179, 23, 27, 836, 840, "week" +283, 6, 8, 180, 28, 29, 841, 842, "," +283, 6, 9, 181, 30, 36, 843, 849, "double" +283, 6, 10, 182, 37, 38, 850, 851, "-" +283, 6, 11, 183, 39, 44, 852, 857, "blind" +283, 6, 12, 184, 45, 46, 858, 859, "," +283, 6, 13, 185, 47, 54, 860, 867, "placebo" +283, 6, 14, 186, 55, 56, 868, 869, "-" +283, 6, 15, 187, 57, 67, 870, 880, "controlled" +283, 6, 16, 188, 68, 69, 881, 882, "," +283, 6, 17, 189, 70, 83, 883, 896, "multinational" +283, 6, 18, 190, 84, 89, 897, 902, "study" +283, 6, 19, 191, 90, 91, 903, 904, "," +283, 6, 20, 192, 92, 100, 905, 913, "patients" +283, 6, 21, 193, 101, 105, 914, 918, "were" +283, 6, 22, 194, 106, 116, 919, 929, "randomized" +283, 6, 23, 195, 117, 119, 930, 932, "to" +283, 6, 24, 196, 120, 132, 933, 945, "lixisenatide" +283, 6, 25, 197, 133, 135, 946, 948, "20" +283, 6, 26, 198, 136, 137, 949, 950, "µ" +283, 6, 27, 199, 138, 139, 951, 952, "g" +283, 6, 28, 200, 140, 144, 953, 957, "once" +283, 6, 29, 201, 145, 150, 958, 963, "daily" +283, 6, 30, 202, 151, 153, 964, 966, "or" +283, 6, 31, 203, 154, 161, 967, 974, "placebo" +283, 6, 32, 204, 162, 163, 975, 976, "." +283, 7, 1, 205, 0, 3, 977, 980, "The" +283, 7, 2, 206, 4, 11, 981, 988, "primary" +283, 7, 3, 207, 12, 20, 989, 997, "endpoint" +283, 7, 4, 208, 21, 24, 998, 1001, "was" +283, 7, 5, 209, 25, 33, 1002, 1010, "absolute" +283, 7, 6, 210, 34, 40, 1011, 1017, "change" +283, 7, 7, 211, 41, 43, 1018, 1020, "in" +283, 7, 8, 212, 44, 52, 1021, 1029, "glycated" +283, 7, 9, 213, 53, 64, 1030, 1041, "haemoglobin" +283, 7, 10, 214, 65, 66, 1042, 1043, "(" +283, 7, 11, 215, 67, 72, 1044, 1049, "HbA1c" +283, 7, 12, 216, 73, 74, 1050, 1051, ")" +283, 7, 13, 217, 75, 79, 1052, 1056, "from" +283, 7, 14, 218, 80, 88, 1057, 1065, "baseline" +283, 7, 15, 219, 89, 91, 1066, 1068, "to" +283, 7, 16, 220, 92, 96, 1069, 1073, "week" +283, 7, 17, 221, 97, 99, 1074, 1076, "24" +283, 7, 18, 222, 100, 101, 1077, 1078, "." +283, 8, 1, 223, 0, 7, 1079, 1086, "RESULTS" +283, 8, 2, 224, 8, 9, 1087, 1088, ":" +283, 8, 3, 225, 10, 11, 1089, 1090, "A" +283, 8, 4, 226, 12, 17, 1091, 1096, "total" +283, 8, 5, 227, 18, 20, 1097, 1099, "of" +283, 8, 6, 228, 21, 24, 1100, 1103, "391" +283, 8, 7, 229, 25, 33, 1104, 1112, "patients" +283, 8, 8, 230, 34, 38, 1113, 1117, "were" +283, 8, 9, 231, 39, 49, 1118, 1128, "randomized" +283, 8, 10, 232, 50, 51, 1129, 1130, "." +283, 9, 1, 233, 0, 12, 1131, 1143, "Lixisenatide" +283, 9, 2, 234, 13, 26, 1144, 1157, "significantly" +283, 9, 3, 235, 27, 34, 1158, 1165, "reduced" +283, 9, 4, 236, 35, 40, 1166, 1171, "HbA1c" +283, 9, 5, 237, 41, 47, 1172, 1178, "levels" +283, 9, 6, 238, 48, 56, 1179, 1187, "compared" +283, 9, 7, 239, 57, 61, 1188, 1192, "with" +283, 9, 8, 240, 62, 69, 1193, 1200, "placebo" +283, 9, 9, 241, 70, 71, 1201, 1202, "(" +283, 9, 10, 242, 72, 74, 1203, 1205, "LS" +283, 9, 11, 243, 75, 79, 1206, 1210, "mean" +283, 9, 12, 244, 80, 90, 1211, 1221, "difference" +283, 9, 13, 245, 91, 92, 1222, 1223, ":" +283, 9, 14, 246, 93, 94, 1224, 1225, "-" +283, 9, 15, 247, 95, 96, 1226, 1227, "0" +283, 9, 16, 248, 97, 98, 1228, 1229, "." +283, 9, 17, 249, 99, 101, 1230, 1232, "36" +283, 9, 18, 250, 102, 103, 1233, 1234, "%" +283, 9, 19, 251, 104, 105, 1235, 1236, "," +283, 9, 20, 252, 106, 107, 1237, 1238, "p" +283, 9, 21, 253, 108, 111, 1239, 1242, " = " +283, 9, 22, 254, 112, 113, 1243, 1244, "0" +283, 9, 23, 255, 114, 115, 1245, 1246, "." +283, 9, 24, 256, 116, 120, 1247, 1251, "0004" +283, 9, 25, 257, 121, 122, 1252, 1253, ")" +283, 9, 26, 258, 123, 124, 1254, 1255, "." +283, 10, 1, 259, 0, 1, 1256, 1257, "A" +283, 10, 2, 260, 2, 15, 1258, 1271, "significantly" +283, 10, 3, 261, 16, 22, 1272, 1278, "higher" +283, 10, 4, 262, 23, 33, 1279, 1289, "proportion" +283, 10, 5, 263, 34, 36, 1290, 1292, "of" +283, 10, 6, 264, 37, 49, 1293, 1305, "lixisenatide" +283, 10, 7, 265, 50, 51, 1306, 1307, "-" +283, 10, 8, 266, 52, 59, 1308, 1315, "treated" +283, 10, 9, 267, 60, 68, 1316, 1324, "patients" +283, 10, 10, 268, 69, 77, 1325, 1333, "achieved" +283, 10, 11, 269, 78, 83, 1334, 1339, "HbA1c" +283, 10, 12, 270, 84, 91, 1340, 1347, "targets" +283, 10, 13, 271, 92, 94, 1348, 1350, "of" +283, 10, 14, 272, 95, 96, 1351, 1352, "<" +283, 10, 15, 273, 97, 98, 1353, 1354, "7" +283, 10, 16, 274, 99, 100, 1355, 1356, "%" +283, 10, 17, 275, 101, 102, 1357, 1358, "(" +283, 10, 18, 276, 103, 104, 1359, 1360, "p" +283, 10, 19, 277, 105, 108, 1361, 1364, " = " +283, 10, 20, 278, 109, 110, 1365, 1366, "0" +283, 10, 21, 279, 111, 112, 1367, 1368, "." +283, 10, 22, 280, 113, 116, 1369, 1372, "003" +283, 10, 23, 281, 117, 118, 1373, 1374, ")" +283, 10, 24, 282, 119, 122, 1375, 1378, "and" +283, 10, 25, 283, 123, 124, 1379, 1380, "≤" +283, 10, 26, 284, 125, 126, 1381, 1382, "6" +283, 10, 27, 285, 127, 128, 1383, 1384, "." +283, 10, 28, 286, 129, 130, 1385, 1386, "5" +283, 10, 29, 287, 131, 132, 1387, 1388, "%" +283, 10, 30, 288, 133, 134, 1389, 1390, "(" +283, 10, 31, 289, 135, 136, 1391, 1392, "p" +283, 10, 32, 290, 137, 140, 1393, 1396, " = " +283, 10, 33, 291, 141, 142, 1397, 1398, "0" +283, 10, 34, 292, 143, 144, 1399, 1400, "." +283, 10, 35, 293, 145, 148, 1401, 1404, "001" +283, 10, 36, 294, 149, 150, 1405, 1406, ")" +283, 10, 37, 295, 151, 157, 1407, 1413, "versus" +283, 10, 38, 296, 158, 165, 1414, 1421, "placebo" +283, 10, 39, 297, 166, 167, 1422, 1423, "." +283, 11, 1, 298, 0, 12, 1424, 1436, "Lixisenatide" +283, 11, 2, 299, 13, 16, 1437, 1440, "was" +283, 11, 3, 300, 17, 27, 1441, 1451, "associated" +283, 11, 4, 301, 28, 32, 1452, 1456, "with" +283, 11, 5, 302, 33, 34, 1457, 1458, "a" +283, 11, 6, 303, 35, 48, 1459, 1472, "statistically" +283, 11, 7, 304, 49, 60, 1473, 1484, "significant" +283, 11, 8, 305, 61, 70, 1485, 1494, "reduction" +283, 11, 9, 306, 71, 73, 1495, 1497, "in" +283, 11, 10, 307, 74, 75, 1498, 1499, "2" +283, 11, 11, 308, 76, 77, 1500, 1501, "-" +283, 11, 12, 309, 78, 79, 1502, 1503, "h" +283, 11, 13, 310, 80, 92, 1504, 1516, "postprandial" +283, 11, 14, 311, 93, 99, 1517, 1523, "plasma" +283, 11, 15, 312, 100, 107, 1524, 1531, "glucose" +283, 11, 16, 313, 108, 113, 1532, 1537, "after" +283, 11, 17, 314, 114, 115, 1538, 1539, "a" +283, 11, 18, 315, 116, 128, 1540, 1552, "standardized" +283, 11, 19, 316, 129, 138, 1553, 1562, "breakfast" +283, 11, 20, 317, 139, 145, 1563, 1569, "versus" +283, 11, 21, 318, 146, 153, 1570, 1577, "placebo" +283, 11, 22, 319, 154, 155, 1578, 1579, "(" +283, 11, 23, 320, 156, 158, 1580, 1582, "LS" +283, 11, 24, 321, 159, 163, 1583, 1587, "mean" +283, 11, 25, 322, 164, 174, 1588, 1598, "difference" +283, 11, 26, 323, 175, 176, 1599, 1600, ":" +283, 11, 27, 324, 177, 178, 1601, 1602, "-" +283, 11, 28, 325, 179, 180, 1603, 1604, "4" +283, 11, 29, 326, 181, 182, 1605, 1606, "." +283, 11, 30, 327, 183, 185, 1607, 1609, "28" +283, 11, 31, 328, 186, 190, 1610, 1614, "mmol" +283, 11, 32, 329, 191, 192, 1615, 1616, "/" +283, 11, 33, 330, 193, 194, 1617, 1618, "L" +283, 11, 34, 331, 195, 196, 1619, 1620, "," +283, 11, 35, 332, 197, 198, 1621, 1622, "p" +283, 11, 36, 333, 199, 202, 1623, 1626, " < " +283, 11, 37, 334, 203, 204, 1627, 1628, "0" +283, 11, 38, 335, 205, 206, 1629, 1630, "." +283, 11, 39, 336, 207, 211, 1631, 1635, "0001" +283, 11, 40, 337, 212, 213, 1636, 1637, ")" +283, 11, 41, 338, 214, 217, 1638, 1641, "and" +283, 11, 42, 339, 218, 219, 1642, 1643, "a" +283, 11, 43, 340, 220, 231, 1644, 1655, "significant" +283, 11, 44, 341, 232, 241, 1656, 1665, "reduction" +283, 11, 45, 342, 242, 244, 1666, 1668, "in" +283, 11, 46, 343, 245, 252, 1669, 1676, "fasting" +283, 11, 47, 344, 253, 259, 1677, 1683, "plasma" +283, 11, 48, 345, 260, 267, 1684, 1691, "glucose" +283, 11, 49, 346, 268, 269, 1692, 1693, "(" +283, 11, 50, 347, 270, 271, 1694, 1695, "p" +283, 11, 51, 348, 272, 275, 1696, 1699, " = " +283, 11, 52, 349, 276, 277, 1700, 1701, "0" +283, 11, 53, 350, 278, 279, 1702, 1703, "." +283, 11, 54, 351, 280, 284, 1704, 1708, "0109" +283, 11, 55, 352, 285, 286, 1709, 1710, ")" +283, 11, 56, 353, 287, 288, 1711, 1712, "." +283, 12, 1, 354, 0, 5, 1713, 1718, "There" +283, 12, 2, 355, 6, 9, 1719, 1722, "was" +283, 12, 3, 356, 10, 12, 1723, 1725, "no" +283, 12, 4, 357, 13, 23, 1726, 1736, "difference" +283, 12, 5, 358, 24, 26, 1737, 1739, "in" +283, 12, 6, 359, 27, 33, 1740, 1746, "weight" +283, 12, 7, 360, 34, 38, 1747, 1751, "loss" +283, 12, 8, 361, 39, 45, 1752, 1758, "versus" +283, 12, 9, 362, 46, 53, 1759, 1766, "placebo" +283, 12, 10, 363, 54, 55, 1767, 1768, "," +283, 12, 11, 364, 56, 60, 1769, 1773, "with" +283, 12, 12, 365, 61, 62, 1774, 1775, "a" +283, 12, 13, 366, 63, 69, 1776, 1782, "modest" +283, 12, 14, 367, 70, 79, 1783, 1792, "reduction" +283, 12, 15, 368, 80, 82, 1793, 1795, "in" +283, 12, 16, 369, 83, 87, 1796, 1800, "body" +283, 12, 17, 370, 88, 94, 1801, 1807, "weight" +283, 12, 18, 371, 95, 103, 1808, 1816, "reported" +283, 12, 19, 372, 104, 107, 1817, 1820, "for" +283, 12, 20, 373, 108, 112, 1821, 1825, "both" +283, 12, 21, 374, 113, 119, 1826, 1832, "groups" +283, 12, 22, 375, 120, 121, 1833, 1834, "(" +283, 12, 23, 376, 122, 134, 1835, 1847, "lixisenatide" +283, 12, 24, 377, 135, 136, 1848, 1849, ":" +283, 12, 25, 378, 137, 138, 1850, 1851, "-" +283, 12, 26, 379, 139, 140, 1852, 1853, "1" +283, 12, 27, 380, 141, 142, 1854, 1855, "." +283, 12, 28, 381, 143, 145, 1856, 1858, "50" +283, 12, 29, 382, 146, 148, 1859, 1861, "kg" +283, 12, 30, 383, 149, 150, 1862, 1863, "," +283, 12, 31, 384, 151, 158, 1864, 1871, "placebo" +283, 12, 32, 385, 159, 160, 1872, 1873, ":" +283, 12, 33, 386, 161, 162, 1874, 1875, "-" +283, 12, 34, 387, 163, 164, 1876, 1877, "1" +283, 12, 35, 388, 165, 166, 1878, 1879, "." +283, 12, 36, 389, 167, 169, 1880, 1882, "24" +283, 12, 37, 390, 170, 172, 1883, 1885, "kg" +283, 12, 38, 391, 173, 174, 1886, 1887, ";" +283, 12, 39, 392, 175, 176, 1888, 1889, "p" +283, 12, 40, 393, 177, 180, 1890, 1893, " = " +283, 12, 41, 394, 181, 182, 1894, 1895, "0" +283, 12, 42, 395, 183, 184, 1896, 1897, "." +283, 12, 43, 396, 185, 188, 1898, 1901, "296" +283, 12, 44, 397, 189, 190, 1902, 1903, ")" +283, 12, 45, 398, 191, 192, 1904, 1905, "." +283, 13, 1, 399, 0, 3, 1906, 1909, "The" +283, 13, 2, 400, 4, 13, 1910, 1919, "incidence" +283, 13, 3, 401, 14, 16, 1920, 1922, "of" +283, 13, 4, 402, 17, 26, 1923, 1932, "treatment" +283, 13, 5, 403, 27, 28, 1933, 1934, "-" +283, 13, 6, 404, 29, 37, 1935, 1943, "emergent" +283, 13, 7, 405, 38, 45, 1944, 1951, "adverse" +283, 13, 8, 406, 46, 52, 1952, 1958, "events" +283, 13, 9, 407, 53, 54, 1959, 1960, "(" +283, 13, 10, 408, 55, 60, 1961, 1966, "TEAEs" +283, 13, 11, 409, 61, 62, 1967, 1968, ")" +283, 13, 12, 410, 63, 66, 1969, 1972, "was" +283, 13, 13, 411, 67, 69, 1973, 1975, "64" +283, 13, 14, 412, 70, 71, 1976, 1977, "." +283, 13, 15, 413, 72, 73, 1978, 1979, "3" +283, 13, 16, 414, 74, 75, 1980, 1981, "%" +283, 13, 17, 415, 76, 80, 1982, 1986, "with" +283, 13, 18, 416, 81, 93, 1987, 1999, "lixisenatide" +283, 13, 19, 417, 94, 100, 2000, 2006, "versus" +283, 13, 20, 418, 101, 103, 2007, 2009, "47" +283, 13, 21, 419, 104, 105, 2010, 2011, "." +283, 13, 22, 420, 106, 107, 2012, 2013, "4" +283, 13, 23, 421, 108, 109, 2014, 2015, "%" +283, 13, 24, 422, 110, 114, 2016, 2020, "with" +283, 13, 25, 423, 115, 122, 2021, 2028, "placebo" +283, 13, 26, 424, 123, 124, 2029, 2030, "," +283, 13, 27, 425, 125, 129, 2031, 2035, "with" +283, 13, 28, 426, 130, 137, 2036, 2043, "serious" +283, 13, 29, 427, 138, 143, 2044, 2049, "TEAEs" +283, 13, 30, 428, 144, 152, 2050, 2058, "reported" +283, 13, 31, 429, 153, 155, 2059, 2061, "in" +283, 13, 32, 430, 156, 157, 2062, 2063, "1" +283, 13, 33, 431, 158, 159, 2064, 2065, "." +283, 13, 34, 432, 160, 161, 2066, 2067, "5" +283, 13, 35, 433, 162, 163, 2068, 2069, "%" +283, 13, 36, 434, 164, 170, 2070, 2076, "versus" +283, 13, 37, 435, 171, 172, 2077, 2078, "2" +283, 13, 38, 436, 173, 174, 2079, 2080, "." +283, 13, 39, 437, 175, 176, 2081, 2082, "1" +283, 13, 40, 438, 177, 178, 2083, 2084, "%" +283, 13, 41, 439, 179, 181, 2085, 2087, "of" +283, 13, 42, 440, 182, 190, 2088, 2096, "patients" +283, 13, 43, 441, 191, 192, 2097, 2098, "," +283, 13, 44, 442, 193, 205, 2099, 2111, "respectively" +283, 13, 45, 443, 206, 207, 2112, 2113, "." +283, 14, 1, 444, 0, 3, 2114, 2117, "The" +283, 14, 2, 445, 4, 8, 2118, 2122, "most" +283, 14, 3, 446, 9, 15, 2123, 2129, "common" +283, 14, 4, 447, 16, 20, 2130, 2134, "TEAE" +283, 14, 5, 448, 21, 23, 2135, 2137, "in" +283, 14, 6, 449, 24, 27, 2138, 2141, "the" +283, 14, 7, 450, 28, 40, 2142, 2154, "lixisenatide" +283, 14, 8, 451, 41, 46, 2155, 2160, "group" +283, 14, 9, 452, 47, 50, 2161, 2164, "was" +283, 14, 10, 453, 51, 57, 2165, 2171, "nausea" +283, 14, 11, 454, 58, 59, 2172, 2173, "(" +283, 14, 12, 455, 60, 62, 2174, 2176, "16" +283, 14, 13, 456, 63, 64, 2177, 2178, "." +283, 14, 14, 457, 65, 66, 2179, 2180, "3" +283, 14, 15, 458, 67, 68, 2181, 2182, "%" +283, 14, 16, 459, 69, 71, 2183, 2185, "vs" +283, 14, 17, 460, 72, 73, 2186, 2187, "2" +283, 14, 18, 461, 74, 75, 2188, 2189, "." +283, 14, 19, 462, 76, 77, 2190, 2191, "6" +283, 14, 20, 463, 78, 79, 2192, 2193, "%" +283, 14, 21, 464, 80, 84, 2194, 2198, "with" +283, 14, 22, 465, 85, 92, 2199, 2206, "placebo" +283, 14, 23, 466, 93, 94, 2207, 2208, ")" +283, 14, 24, 467, 95, 96, 2209, 2210, "." +283, 15, 1, 468, 0, 3, 2211, 2214, "The" +283, 15, 2, 469, 4, 13, 2215, 2224, "incidence" +283, 15, 3, 470, 14, 16, 2225, 2227, "of" +283, 15, 4, 471, 17, 28, 2228, 2239, "symptomatic" +283, 15, 5, 472, 29, 42, 2240, 2253, "hypoglycaemia" +283, 15, 6, 473, 43, 46, 2254, 2257, "was" +283, 15, 7, 474, 47, 48, 2258, 2259, "5" +283, 15, 8, 475, 49, 50, 2260, 2261, "." +283, 15, 9, 476, 51, 52, 2262, 2263, "6" +283, 15, 10, 477, 53, 54, 2264, 2265, "%" +283, 15, 11, 478, 55, 59, 2266, 2270, "with" +283, 15, 12, 479, 60, 72, 2271, 2283, "lixisenatide" +283, 15, 13, 480, 73, 82, 2284, 2293, "treatment" +283, 15, 14, 481, 83, 86, 2294, 2297, "and" +283, 15, 15, 482, 87, 88, 2298, 2299, "2" +283, 15, 16, 483, 89, 90, 2300, 2301, "." +283, 15, 17, 484, 91, 92, 2302, 2303, "6" +283, 15, 18, 485, 93, 94, 2304, 2305, "%" +283, 15, 19, 486, 95, 99, 2306, 2310, "with" +283, 15, 20, 487, 100, 107, 2311, 2318, "placebo" +283, 15, 21, 488, 108, 109, 2319, 2320, "(" +283, 15, 22, 489, 110, 111, 2321, 2322, "p" +283, 15, 23, 490, 112, 115, 2323, 2326, " = " +283, 15, 24, 491, 116, 117, 2327, 2328, "0" +283, 15, 25, 492, 118, 119, 2329, 2330, "." +283, 15, 26, 493, 120, 124, 2331, 2335, "1321" +283, 15, 27, 494, 125, 126, 2336, 2337, ")" +283, 15, 28, 495, 127, 128, 2338, 2339, "," +283, 15, 29, 496, 129, 133, 2340, 2344, "with" +283, 15, 30, 497, 134, 136, 2345, 2347, "no" +283, 15, 31, 498, 137, 143, 2348, 2354, "severe" +283, 15, 32, 499, 144, 155, 2355, 2366, "symptomatic" +283, 15, 33, 500, 156, 169, 2367, 2380, "hypoglycaemia" +283, 15, 34, 501, 170, 176, 2381, 2387, "events" +283, 15, 35, 502, 177, 185, 2388, 2396, "reported" +283, 15, 36, 503, 186, 187, 2397, 2398, "." +283, 16, 1, 504, 0, 11, 2399, 2410, "CONCLUSIONS" +283, 16, 2, 505, 12, 13, 2411, 2412, ":" +283, 16, 3, 506, 14, 16, 2413, 2415, "In" +283, 16, 4, 507, 17, 22, 2416, 2421, "Asian" +283, 16, 5, 508, 23, 31, 2422, 2430, "patients" +283, 16, 6, 509, 32, 36, 2431, 2435, "with" +283, 16, 7, 510, 37, 41, 2436, 2440, "type" +283, 16, 8, 511, 42, 43, 2441, 2442, "2" +283, 16, 9, 512, 44, 52, 2443, 2451, "diabetes" +283, 16, 10, 513, 53, 61, 2452, 2460, "mellitus" +283, 16, 11, 514, 62, 76, 2461, 2475, "insufficiently" +283, 16, 12, 515, 77, 87, 2476, 2486, "controlled" +283, 16, 13, 516, 88, 90, 2487, 2489, "on" +283, 16, 14, 517, 91, 100, 2490, 2499, "metformin" +283, 16, 15, 518, 101, 104, 2500, 2503, " ± " +283, 16, 16, 519, 105, 117, 2504, 2516, "sulfonylurea" +283, 16, 17, 520, 118, 119, 2517, 2518, "," +283, 16, 18, 521, 120, 132, 2519, 2531, "lixisenatide" +283, 16, 19, 522, 133, 146, 2532, 2545, "significantly" +283, 16, 20, 523, 147, 155, 2546, 2554, "improved" +283, 16, 21, 524, 156, 165, 2555, 2564, "glycaemic" +283, 16, 22, 525, 166, 173, 2565, 2572, "control" +283, 16, 23, 526, 174, 177, 2573, 2576, "and" +283, 16, 24, 527, 178, 181, 2577, 2580, "was" +283, 16, 25, 528, 182, 186, 2581, 2585, "well" +283, 16, 26, 529, 187, 196, 2586, 2595, "tolerated" +283, 16, 27, 530, 197, 203, 2596, 2602, "during" +283, 16, 28, 531, 204, 207, 2603, 2606, "the" +283, 16, 29, 532, 208, 210, 2607, 2609, "24" +283, 16, 30, 533, 211, 212, 2610, 2611, "-" +283, 16, 31, 534, 213, 217, 2612, 2616, "week" +283, 16, 32, 535, 218, 223, 2617, 2622, "study" +283, 16, 33, 536, 224, 225, 2623, 2624, "." +283, 17, 1, 537, 0, 1, 2625, 2626, "©" +283, 17, 2, 538, 2, 6, 2627, 2631, "2014" +283, 17, 3, 539, 7, 10, 2632, 2635, "The" +283, 17, 4, 540, 11, 18, 2636, 2643, "Authors" +283, 17, 5, 541, 19, 20, 2644, 2645, "." +283, 18, 1, 542, 0, 8, 2646, 2654, "Diabetes" +283, 18, 2, 543, 9, 10, 2655, 2656, "/" +283, 18, 3, 544, 11, 21, 2657, 2667, "Metabolism" +283, 18, 4, 545, 22, 30, 2668, 2676, "Research" +283, 18, 5, 546, 31, 34, 2677, 2680, "and" +283, 18, 6, 547, 35, 42, 2681, 2688, "Reviews" +283, 18, 7, 548, 43, 52, 2689, 2698, "published" +283, 18, 8, 549, 53, 55, 2699, 2701, "by" +283, 18, 9, 550, 56, 60, 2702, 2706, "John" +283, 18, 10, 551, 61, 66, 2707, 2712, "Wiley" +283, 18, 11, 552, 67, 68, 2713, 2714, "&" +283, 18, 12, 553, 69, 73, 2715, 2719, "Sons" +283, 18, 13, 554, 74, 75, 2720, 2721, "," +283, 18, 14, 555, 76, 79, 2722, 2725, "Ltd" +283, 18, 15, 556, 80, 81, 2726, 2727, "." +283, 18, 16, 557, 82, 85, 2728, 2731, "DOI" +283, 18, 17, 558, 86, 87, 2732, 2733, ":" +283, 18, 18, 559, 88, 90, 2734, 2736, "10" +283, 18, 19, 560, 91, 92, 2737, 2738, "." +283, 18, 20, 561, 93, 97, 2739, 2743, "1002" +283, 18, 21, 562, 98, 99, 2744, 2745, "/" +283, 18, 22, 563, 100, 104, 2746, 2750, "dmrr" +283, 18, 23, 564, 105, 106, 2751, 2752, "." +283, 18, 24, 565, 107, 111, 2753, 2757, "2541" +283, 18, 25, 566, 112, 116, 2758, 2762, "PMID" +283, 18, 26, 567, 117, 118, 2763, 2764, ":" +283, 18, 27, 568, 119, 127, 2765, 2773, "24639432" +283, 18, 28, 569, 128, 129, 2774, 2775, "[" +283, 18, 29, 570, 130, 137, 2776, 2783, "Indexed" +283, 18, 30, 571, 138, 141, 2784, 2787, "for" +283, 18, 31, 572, 142, 149, 2788, 2795, "MEDLINE" +283, 18, 32, 573, 150, 151, 2796, 2797, "]" diff --git a/data/dm2 24639432_kwoodley.annodb b/data/dm2 24639432_kwoodley.annodb new file mode 100644 index 0000000..954266c --- /dev/null +++ b/data/dm2 24639432_kwoodley.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +47087, Journal, 0, 22, "Diabetes Metab Res Rev", "", +47088, PublicationYear, 25, 29, "2014", "", +47115, Title, 90, 310, "Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea : a randomized , double - blind , placebo - controlled ,", "", +47089, Drug, 90, 102, "Lixisenatide", "", +47099, Ethnicity, 143, 148, "Asian", "", +47102, Type2Diabetes, 163, 187, "type 2 diabetes mellitus", "", +47105, Metformin, 215, 224, "metformin", "", +47108, Sulfonylureas, 241, 253, "sulfonylurea", "", +47111, Randomized, 258, 268, "randomized", "", +47112, DoubleBlind, 271, 285, "double - blind", "", +47113, Placebo, 288, 295, "placebo", "", +47114, Duration, 311, 320, "24 - week", "", +47116, Title, 311, 351, "24 - week trial ( GetGoal - M - Asia ) .", "", +47117, Author, 352, 360, "Yu Pan C", "", +47118, Author, 369, 374, "Han P", "", +47119, Author, 377, 382, "Liu X", "", +47120, Author, 385, 390, "Yan S", "", +47121, Author, 393, 399, "Feng P", "", +47122, Author, 402, 408, "Zhou Z", "", +47123, Author, 411, 415, "Lv X", "", +47124, Author, 418, 424, "Tian H", "", +47125, Author, 427, 436, "Jin Kui Y", "", +47126, Author, 439, 443, "Su B", "", +47127, Author, 446, 453, "Shang S", "", +47128, Author, 456, 468, "Niemoeller E", "", +47129, China, 562, 567, "China", "", +47132, ObjectiveDescription, 583, 812, "This study assessed the efficacy and safety of the once - daily glucagon - like peptide - 1 receptor agonist , lixisenatide , in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea .", "", +47130, Frequency, 634, 646, "once - daily", "", +47090, Drug, 694, 706, "lixisenatide", "", +47131, Precondition, 712, 810, "Asian patients with type 2 diabetes mellitus inadequately controlled on metformin  ±  sulfonylurea", "", +47100, Ethnicity, 712, 717, "Asian", "", +47103, Type2Diabetes, 732, 756, "type 2 diabetes mellitus", "", +47107, Metformin, 784, 793, "metformin", "", +47109, Sulfonylureas, 798, 810, "sulfonylurea", "", +47133, Duration, 831, 840, "24 - week", "", +47134, DoubleBlind, 843, 857, "double - blind", "", +47135, Placebo, 860, 867, "placebo", "", +47140, Multicenter, 883, 896, "multinational", "", +47141, Randomized, 919, 929, "randomized", "", +47091, Drug, 933, 945, "lixisenatide", "", +47142, DoseValue, 946, 948, "20", "", +47143, Microgram, 949, 952, "µ g", "", +47144, Frequency, 953, 963, "once daily", "", +47136, Placebo, 967, 974, "placebo", "", +47145, HbA1c, 1021, 1041, "glycated haemoglobin", "", +47146, HbA1c, 1044, 1049, "HbA1c", "", +47148, TimePoint, 1057, 1065, "baseline", "", +47149, TimePoint, 1069, 1076, "week 24", "", +47150, NumberPatientsCT, 1100, 1103, "391", "", +47151, Randomized, 1118, 1128, "randomized", "", +47092, Drug, 1131, 1143, "Lixisenatide", "", +47147, HbA1c, 1166, 1171, "HbA1c", "", +47137, Placebo, 1193, 1200, "placebo", "", +47155, Mean, 1203, 1205, "LS", "", +47152, DiffGroupAbsValue, 1224, 1232, "- 0 . 36", "", +47153, Percentage, 1233, 1234, "%", "", +47154, PvalueDiff, 1237, 1251, "p  =  0 . 0004", "", +47093, Drug, 1293, 1305, "lixisenatide", "", +47156, HbA1c_target, 1334, 1356, "HbA1c targets of < 7 %", "", +47158, PValueResValue, 1359, 1372, "p  =  0 . 003", "", +47160, HbA1c_target, 1379, 1388, "≤ 6 . 5 %", "", +47159, PValueResValue, 1391, 1404, "p  =  0 . 001", "", +47138, Placebo, 1414, 1421, "placebo", "", +47094, Drug, 1424, 1436, "Lixisenatide", "", +47168, ObservedResult, 1441, 1494, "associated with a statistically significant reduction", "", +47161, PostprandialPlasmaGlucose, 1498, 1531, "2 - h postprandial plasma glucose", "", +47139, Placebo, 1570, 1577, "placebo", "", +47162, Mean, 1580, 1582, "LS", "", +47163, DiffGroupAbsValue, 1601, 1609, "- 4 . 28", "", +47164, Millimoles_per_litre, 1610, 1618, "mmol / L", "", +47165, PvalueDiff, 1621, 1635, "p  <  0 . 0001", "", +47169, ObservedResult, 1644, 1665, "significant reduction", "", +47166, FastingPlasmaGlucose, 1669, 1691, "fasting plasma glucose", "", +47167, PValueChangeValue, 1694, 1708, "p  =  0 . 0109", "", +47170, BodyWeight, 1740, 1746, "weight", "", +47171, Placebo, 1759, 1766, "placebo", "", +47172, BodyWeight, 1796, 1807, "body weight", "", +47095, Drug, 1835, 1847, "lixisenatide", "", +47173, Reduction, 1852, 1858, "1 . 50", "", +47179, Kg, 1859, 1861, "kg", "", +47178, Placebo, 1864, 1871, "placebo", "", +47177, Reduction, 1876, 1882, "1 . 24", "", +47180, Kg, 1883, 1885, "kg", "", +47181, PvalueDiff, 1888, 1901, "p  =  0 . 296", "", +47182, EndPointDescription, 1944, 1958, "adverse events", "", +47183, EndPointDescription, 1961, 1966, "TEAEs", "", +47187, PercentageAffected, 1973, 1979, "64 . 3", "", +47096, Drug, 1987, 1999, "lixisenatide", "", +47188, PercentageAffected, 2007, 2013, "47 . 4", "", +47191, Placebo, 2021, 2028, "placebo", "", +47192, SubGroupDescription, 2036, 2049, "serious TEAEs", "", +47184, EndPointDescription, 2044, 2049, "TEAEs", "", +47189, PercentageAffected, 2062, 2067, "1 . 5", "", +47190, PercentageAffected, 2077, 2082, "2 . 1", "", +47195, ObservedResult, 2118, 2134, "most common TEAE", "", +47186, EndPointDescription, 2130, 2134, "TEAE", "", +47193, Drug, 2142, 2154, "lixisenatide", "", +47194, Nausea, 2165, 2171, "nausea", "", +47196, PercentageAffected, 2174, 2180, "16 . 3", "", +47197, PercentageAffected, 2186, 2191, "2 . 6", "", +47198, Placebo, 2199, 2206, "placebo", "", +47199, SymptomaticHypoglycemia, 2228, 2253, "symptomatic hypoglycaemia", "", +47200, PercentageAffected, 2258, 2263, "5 . 6", "", +47097, Drug, 2271, 2283, "lixisenatide", "", +47201, PercentageAffected, 2298, 2303, "2 . 6", "", +47203, Placebo, 2311, 2318, "placebo", "", +47204, PvalueDiff, 2321, 2335, "p  =  0 . 1321", "", +47205, ObservedResult, 2340, 2396, "with no severe symptomatic hypoglycaemia events reported", "", +47202, PercentageAffected, 2355, 2380, "symptomatic hypoglycaemia", "", +47208, ConclusionComment, 2413, 2624, "In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea , lixisenatide significantly improved glycaemic control and was well tolerated during the 24 - week study .", "", +47206, Precondition, 2416, 2516, "Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin  ±  sulfonylurea", "", +47101, Ethnicity, 2416, 2421, "Asian", "", +47104, Type2Diabetes, 2436, 2460, "type 2 diabetes mellitus", "", +47106, Metformin, 2490, 2499, "metformin", "", +47110, Sulfonylureas, 2504, 2516, "sulfonylurea", "", +47098, Drug, 2519, 2531, "lixisenatide", "", +47207, Duration, 2607, 2616, "24 - week", "", +47209, PMID, 2765, 2773, "24639432", "", diff --git a/data/dm2 24639432_kwoodley.n-triples b/data/dm2 24639432_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24639432_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24650952_admin.annodb b/data/dm2 24650952_admin.annodb new file mode 100644 index 0000000..47f9539 --- /dev/null +++ b/data/dm2 24650952_admin.annodb @@ -0,0 +1,127 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 24, "J Diabetes Complications", "", " \"J Diabetes Complications\"." +1, PublicationYear, 27, 31, "2014", "", " \"2014\"." +27, Title, 136, 375, "Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .", "", " \"Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .\"." +2, Frequency, 158, 170, "once - daily", "", +75272, Lixisenatide, 171, 183, "lixisenatide", "", +16, Hypoglycemia, 258, 270, "hypoglycemia", "", +125, Precondition, 274, 357, "type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin", "", +17, Type2Diabetes, 274, 289, "type 2 diabetes", "", " ." +20, Sulfonylureas, 319, 331, "sulfonylurea", "", +24, Metformin, 348, 357, "metformin", "", +28, Author, 376, 388, "Rosenstock J", "", " \"Rosenstock J\"." +29, Author, 397, 407, "Hanefeld M", "", " \"Hanefeld M\"." +30, Author, 416, 426, "Shamanna P", "", " \"Shamanna P\"." +31, Author, 435, 441, "Min KW", "", " \"Min KW\"." +32, Author, 450, 456, "Boka G", "", " \"Boka G\"." +33, Author, 465, 474, "Miossec P", "", +34, Author, 483, 489, "Zhou T", "", +35, Author, 498, 517, "Muehlen - Bartmer I", "", +36, Author, 526, 535, "Ratner RE", "", +37, USA, 640, 643, "USA", "", +38, Germany, 771, 778, "Germany", "", +39, India, 827, 832, "India", "", +40, SouthKorea, 874, 891, "Republic of Korea", "", +141, SouthKorea, 886, 891, "Korea", "", +41, France, 934, 940, "France", "", +42, France, 972, 978, "France", "", +43, USA, 1015, 1018, "USA", "", +45, Germany, 1054, 1061, "Germany", "", +44, USA, 1165, 1168, "USA", "", +52, ObjectiveDescription, 1178, 1358, "To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .", "", " \"To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .\"." +75287, Lixisenatide, 1211, 1223, "lixisenatide", "", +15, Frequency, 1224, 1236, "once - daily", "", +46, Placebo, 1244, 1251, "placebo", "", +51, Precondition, 1255, 1356, "type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin", "", " \"type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin\"." +18, Type2Diabetes, 1255, 1279, "type 2 diabetes mellitus", "", +19, Type2Diabetes, 1282, 1286, "T2DM", "", +152, Precondition, 1298, 1356, "inadequately controlled on sulfonylurea ( SU ) ± metformin", "", +21, Sulfonylureas, 1325, 1337, "sulfonylurea", "", +22, Sulfonylureas, 1340, 1342, "SU", "", +25, Metformin, 1347, 1356, "metformin", "", +53, Randomized, 1377, 1387, "randomized", "", " \"To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .\"." +54, DoubleBlind, 1390, 1404, "double - blind", "", " ." +55, Parallel, 1419, 1435, "parallel - group", "", " ." +56, Multicenter, 1438, 1449, "multicenter", "", " ." +75289, Lixisenatide, 1476, 1488, "lixisenatide", "", " ." +57, DoseValue, 1489, 1491, "20", "", " \"20\"." +58, Microgram, 1492, 1495, "μ g", "", " ." +3, Frequency, 1496, 1508, "once - daily", "", " \"once - daily\"." +59, Placebo, 1512, 1519, "placebo", "", " ." +60, Duration, 1524, 1532, "24 weeks", "", " \"24 weeks\"." +23, Sulfonylureas, 1571, 1574, "SUs", "", +26, Metformin, 1577, 1586, "metformin", "", +62, HbA1c, 1619, 1624, "HbA1c", "", +64, TimePoint, 1630, 1638, "baseline", "", +65, TimePoint, 1642, 1649, "Week 24", "", +75278, Lixisenatide, 1662, 1674, "Lixisenatide", "", +63, HbA1c, 1711, 1716, "HbA1c", "", " ." +66, TimePoint, 1720, 1727, "Week 24", "", +67, Placebo, 1735, 1742, "placebo", "", +176, LeastSquaresMean, 1745, 1752, "LS mean", "", " ." +69, Reduction, 1757, 1763, "0 . 85", "", " \"0 . 85\"." +71, Percentage, 1764, 1765, "%", "", " ." +70, Reduction, 1773, 1779, "0 . 10", "", " \"0 . 10\"." +72, Percentage, 1780, 1781, "%", "", +73, PvalueDiff, 1784, 1796, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +74, HbA1c_target, 1826, 1841, "HbA1c < 7 . 0 %", "", " ." +181, Percentage, 1840, 1841, "%", "", +75, PercentageAffected, 1844, 1850, "36 . 4", "", " \"36 . 4\"." +182, Percentage, 1851, 1852, "%", "", +76, PercentageAffected, 1858, 1864, "13 . 5", "", " \"13 . 5\"." +183, Percentage, 1865, 1866, "%", "", +77, PvalueDiff, 1869, 1881, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +75280, Lixisenatide, 1886, 1898, "Lixisenatide", "", +80, ObservedResult, 1899, 1920, "significantly lowered", "", " \"significantly lowered\". \"significantly lowered\"." +78, FastingPlasmaGlucose, 1921, 1924, "FPG", "", " ." +79, BodyWeight, 1929, 1940, "body weight", "", " ." +47, Placebo, 1948, 1955, "placebo", "", +75281, Lixisenatide, 1992, 2004, "lixisenatide", "", +81, PostprandialPlasmaGlucose, 2013, 2025, "2 - hour PPG", "", " ." +48, Placebo, 2033, 2040, "placebo", "", +196, LeastSquaresMean, 2043, 2050, "LS mean", "", " ." +85, Reduction, 2055, 2063, "111 . 48", "", " \"111 . 48\"." +86, Reduction, 2071, 2077, "3 . 80", "", " \"3 . 80\"." +98, Mg_per_deciliter, 2078, 2085, "mg / dL", "", " ." +87, Reduction, 2090, 2096, "6 . 19", "", +88, Reduction, 2104, 2110, "0 . 21", "", +100, Millimoles_per_litre, 2111, 2119, "mmol / L", "", +102, PvalueDiff, 2124, 2136, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +83, EndPointDescription, 2143, 2160, "glucose excursion", "", " . ." +89, Reduction, 2165, 2172, "94 . 11", "", " \"94 . 11\"." +91, Increment, 2180, 2186, "6 . 24", "", " \"6 . 24\"." +99, Mg_per_deciliter, 2187, 2194, "mg / dL", "", " ." +90, Reduction, 2199, 2205, "5 . 22", "", +92, Increment, 2213, 2219, "0 . 35", "", +101, Millimoles_per_litre, 2220, 2228, "mmol / L", "", +93, ObservedResult, 2239, 2246, "reduced", "", +94, EndPointDescription, 2247, 2264, "2 - hour glucagon", "", +97, InsulinDose, 2267, 2274, "insulin", "", +95, EndPointDescription, 2277, 2287, "proinsulin", "", +96, EndPointDescription, 2294, 2305, "C - peptide", "", +84, EndPointDescription, 2326, 2329, "AEs", "", " . ." +103, PercentageAffected, 2334, 2340, "68 . 3", "", " \"68 . 3\"." +75283, Lixisenatide, 2347, 2359, "lixisenatide", "", +104, PercentageAffected, 2364, 2370, "61 . 1", "", " \"61 . 1\"." +49, Placebo, 2377, 2384, "placebo", "", +107, EndPointDescription, 2395, 2399, "SAEs", "", " . ." +105, PercentageAffected, 2402, 2407, "3 . 5", "", " \"3 . 5\"." +106, PercentageAffected, 2417, 2422, "5 . 6", "", " \"5 . 6\"." +75284, Lixisenatide, 2442, 2454, "Lixisenatide", "", +108, SymptomaticHypoglycemia, 2486, 2510, "symptomatic hypoglycemia", "", " ." +50, Placebo, 2518, 2525, "placebo", "", +109, PercentageAffected, 2528, 2534, "15 . 3", "", " \"15 . 3\"." +110, PercentageAffected, 2542, 2548, "12 . 3", "", " \"12 . 3\"." +232, NumberAffected, 2570, 2591, "one severe episode of", "", " \"one severe episode of\"." +230, SevereHypoglycemia, 2574, 2580, "severe", "", " ." +230, SevereHypoglycemia, 2592, 2604, "hypoglycemia", "", " ." +75285, Lixisenatide, 2623, 2635, "lixisenatide", "", +117, ConclusionComment, 2652, 2867, "Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .", "", " \"Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .\"." +4, Frequency, 2652, 2664, "Once - daily", "", +75292, Lixisenatide, 2665, 2677, "lixisenatide", "", +114, SymptomaticHypoglycemia, 2792, 2803, "symptomatic", "", +115, SevereHypoglycemia, 2806, 2825, "severe hypoglycemia", "", +114, SymptomaticHypoglycemia, 2813, 2825, "hypoglycemia", "", +237, WeightReduction, 2840, 2851, "weight loss", "", +61, Duration, 2857, 2865, "24 weeks", "", +118, PMID, 3005, 3013, "24650952", "", " \"24650952\"." diff --git a/data/dm2 24650952_admin.n-triples b/data/dm2 24650952_admin.n-triples new file mode 100644 index 0000000..5929ba0 --- /dev/null +++ b/data/dm2 24650952_admin.n-triples @@ -0,0 +1,237 @@ +# RDF export of group: Publication + . + "Publication 56664" . + "Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) ." . + "Rosenstock J" . + "2014" . + "J Diabetes Complications" . + "24650952" . + . + "Hanefeld M" . + "Shamanna P" . + "Min KW" . + "Boka G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 56671" . + "To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin ." . + "24 weeks" . + . + . + . + "Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 56687" . + "type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "glu" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "sae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "shyp" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + "once - daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lix" . + . + "20" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "0 . 85" . + . + "hba 2" . + . + "0 . 10" . + . + "hbat 1" . + . + "36 . 4" . + . + "hbat 2" . + . + "13 . 5" . + . + "fpg 1" . + . + "significantly lowered" . + . + "bw 1" . + . + "significantly lowered" . + . + "ppg 1" . + . + "111 . 48" . + . + "ppg 2" . + . + "3 . 80" . + . + "glu 1" . + . + "94 . 11" . + . + "glu 2" . + . + "6 . 24" . + . + "ae 1" . + . + "68 . 3" . + . + "ae 2" . + . + "61 . 1" . + . + "sae 1" . + . + "3 . 5" . + . + "sae 2" . + . + "5 . 6" . + . + "hyp 1" . + . + "15 . 3" . + . + "hyp 2" . + . + "12 . 3" . + . + "shyp 1" . + . + "one severe episode of" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "p < 0 . 0001" . + . + . + . + "hbat" . + "p < 0 . 0001" . + . + . + . + "ppg" . + "p < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24650952_akramersunderbrink.annodb b/data/dm2 24650952_akramersunderbrink.annodb new file mode 100644 index 0000000..0800399 --- /dev/null +++ b/data/dm2 24650952_akramersunderbrink.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59418, Journal, 0, 24, "J Diabetes Complications", "", +59419, PublicationYear, 27, 31, "2014", "", +59427, Title, 136, 375, "Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .", "", +59420, Frequency, 158, 170, "once - daily", "", +59421, Drug, 171, 183, "lixisenatide", "", +59422, Hypoglycemia, 258, 270, "hypoglycemia", "", +59423, Type2Diabetes, 274, 289, "type 2 diabetes", "", +59424, Precondition, 290, 357, "inadequately controlled on a sulfonylurea with or without metformin", "", +59425, Sulfonylureas, 319, 331, "sulfonylurea", "", +59426, Metformin, 348, 357, "metformin", "", +59428, Author, 376, 388, "Rosenstock J", "", +59429, Author, 397, 407, "Hanefeld M", "", +59430, Author, 416, 426, "Shamanna P", "", +59431, Author, 435, 441, "Min KW", "", +59432, Author, 450, 456, "Boka G", "", +59433, Author, 465, 474, "Miossec P", "", +59434, Author, 483, 489, "Zhou T", "", +59435, Author, 498, 517, "Muehlen - Bartmer I", "", +59436, Author, 526, 535, "Ratner RE", "", +59437, USA, 640, 643, "USA", "", +59438, Germany, 771, 778, "Germany", "", +59439, India, 827, 832, "India", "", +59440, SouthKorea, 886, 891, "Korea", "", +59441, France, 934, 940, "France", "", +59442, France, 972, 978, "France", "", +59443, USA, 1015, 1018, "USA", "", +59445, Germany, 1054, 1061, "Germany", "", +59444, USA, 1165, 1168, "USA", "", +59457, ObjectiveDescription, 1178, 1358, "To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .", "", +59446, Drug, 1211, 1223, "lixisenatide", "", +59448, Frequency, 1224, 1236, "once - daily", "", +59447, Placebo, 1244, 1251, "placebo", "", +59449, Type2Diabetes, 1255, 1279, "type 2 diabetes mellitus", "", +59450, Type2Diabetes, 1282, 1286, "T2DM", "", +59451, Precondition, 1298, 1356, "inadequately controlled on sulfonylurea ( SU ) ± metformin", "", +59452, Sulfonylureas, 1325, 1337, "sulfonylurea", "", +59453, Sulfonylureas, 1340, 1342, "SU", "", +59454, Metformin, 1347, 1356, "metformin", "", +59458, Randomized, 1377, 1387, "randomized", "", +59459, DoubleBlind, 1390, 1404, "double - blind", "", +59460, Parallel, 1419, 1435, "parallel - group", "", +59461, Multicenter, 1438, 1449, "multicenter", "", +59462, Drug, 1476, 1488, "lixisenatide", "", +59463, DoseValue, 1489, 1495, "20 μ g", "", +59464, Microgram, 1492, 1495, "μ g", "", +59465, Frequency, 1496, 1508, "once - daily", "", +59466, Placebo, 1512, 1519, "placebo", "", +59467, Duration, 1524, 1532, "24 weeks", "", +59456, Sulfonylureas, 1571, 1574, "SUs", "", +59455, Metformin, 1577, 1586, "metformin", "", +59468, HbA1c, 1619, 1624, "HbA1c", "", +59469, TimePoint, 1630, 1638, "baseline", "", +59470, TimePoint, 1642, 1649, "Week 24", "", +59471, Drug, 1662, 1674, "Lixisenatide", "", +59472, HbA1c, 1711, 1716, "HbA1c", "", +59473, TimePoint, 1720, 1727, "Week 24", "", +59474, Placebo, 1735, 1742, "placebo", "", +59475, LeastSquaresMean, 1745, 1752, "LS mean", "", +59476, ChangeValue, 1755, 1763, "- 0 . 85", "", +59478, Percentage, 1764, 1765, "%", "", +59477, ChangeValue, 1771, 1779, "- 0 . 10", "", +59479, Percentage, 1780, 1781, "%", "", +59483, PvalueDiff, 1784, 1796, "p < 0 . 0001", "", +59485, HbA1c_target, 1817, 1841, "achieved HbA1c < 7 . 0 %", "", +59480, Percentage, 1840, 1841, "%", "", +59486, PercentageAffected, 1844, 1850, "36 . 4", "", +59481, Percentage, 1851, 1852, "%", "", +59487, PercentageAffected, 1858, 1864, "13 . 5", "", +59482, Percentage, 1865, 1866, "%", "", +59484, PvalueDiff, 1869, 1881, "p < 0 . 0001", "", +59488, Drug, 1886, 1898, "Lixisenatide", "", +59489, FastingPlasmaGlucose, 1921, 1924, "FPG", "", +59490, BodyWeight, 1929, 1940, "body weight", "", +59491, Placebo, 1948, 1955, "placebo", "", +59492, Drug, 1992, 2004, "lixisenatide", "", +59493, PostprandialPlasmaGlucose, 2013, 2025, "2 - hour PPG", "", +59494, Placebo, 2033, 2040, "placebo", "", +59495, LeastSquaresMean, 2043, 2050, "LS mean", "", +59496, ChangeValue, 2053, 2063, "- 111 . 48", "", +59497, ChangeValue, 2069, 2077, "- 3 . 80", "", +59504, Mg_per_deciliter, 2078, 2085, "mg / dL", "", +59498, ChangeValue, 2088, 2096, "- 6 . 19", "", +59499, ChangeValue, 2102, 2110, "- 0 . 21", "", +59506, Millimoles_per_litre, 2111, 2119, "mmol / L", "", +59508, PvalueDiff, 2124, 2136, "p < 0 . 0001", "", +59509, EndPointDescription, 2143, 2160, "glucose excursion", "", +59500, ChangeValue, 2163, 2172, "- 94 . 11", "", +59501, ChangeValue, 2178, 2186, "+ 6 . 24", "", +59505, Mg_per_deciliter, 2187, 2194, "mg / dL", "", +59502, ChangeValue, 2197, 2205, "- 5 . 22", "", +59503, ChangeValue, 2211, 2219, "+ 0 . 35", "", +59507, Millimoles_per_litre, 2220, 2228, "mmol / L", "", +59510, EndPointDescription, 2326, 2329, "AEs", "", +59511, PercentageAffected, 2334, 2340, "68 . 3", "", +59518, Percentage, 2341, 2342, "%", "", +59515, Drug, 2347, 2359, "lixisenatide", "", +59512, PercentageAffected, 2364, 2370, "61 . 1", "", +59519, Percentage, 2371, 2372, "%", "", +59516, Placebo, 2377, 2384, "placebo", "", +59517, EndPointDescription, 2395, 2399, "SAEs", "", +59513, PercentageAffected, 2402, 2407, "3 . 5", "", +59520, Percentage, 2408, 2409, "%", "", +59514, PercentageAffected, 2417, 2422, "5 . 6", "", +59521, Percentage, 2423, 2424, "%", "", +59522, Drug, 2442, 2454, "Lixisenatide", "", +59523, SymptomaticHypoglycemia, 2486, 2510, "symptomatic hypoglycemia", "", +59524, Placebo, 2518, 2525, "placebo", "", +59525, PercentageAffected, 2528, 2534, "15 . 3", "", +59527, Percentage, 2535, 2536, "%", "", +59526, PercentageAffected, 2542, 2548, "12 . 3", "", +59528, Percentage, 2549, 2550, "%", "", +59531, NumberAffected, 2570, 2591, "one severe episode of", "", +59529, SevereHypoglycemia, 2574, 2604, "severe episode of hypoglycemia", "", +59530, Drug, 2623, 2635, "lixisenatide", "", +59532, Frequency, 2652, 2664, "Once - daily", "", +59538, ConclusionComment, 2652, 2867, "Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .", "", +59533, Drug, 2665, 2677, "lixisenatide", "", +59534, SymptomaticHypoglycemia, 2792, 2825, "symptomatic / severe hypoglycemia", "", +59535, SevereHypoglycemia, 2806, 2825, "severe hypoglycemia", "", +59536, WeightReduction, 2840, 2851, "weight loss", "", +59537, Duration, 2857, 2865, "24 weeks", "", +59539, PMID, 3005, 3013, "24650952", "", diff --git a/data/dm2 24650952_akramersunderbrink.n-triples b/data/dm2 24650952_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24650952_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24650952_export.csv b/data/dm2 24650952_export.csv new file mode 100644 index 0000000..8ff9459 --- /dev/null +++ b/data/dm2 24650952_export.csv @@ -0,0 +1,684 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +282, 1, 1, 1, 0, 1, 0, 1, "J" +282, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +282, 1, 3, 3, 11, 24, 11, 24, "Complications" +282, 1, 4, 4, 25, 26, 25, 26, "." +282, 2, 1, 5, 0, 4, 27, 31, "2014" +282, 2, 2, 6, 5, 8, 32, 35, "May" +282, 2, 3, 7, 9, 10, 36, 37, "-" +282, 2, 4, 8, 11, 14, 38, 41, "Jun" +282, 2, 5, 9, 15, 16, 42, 43, ";" +282, 2, 6, 10, 17, 19, 44, 46, "28" +282, 2, 7, 11, 20, 21, 47, 48, "(" +282, 2, 8, 12, 22, 23, 49, 50, "3" +282, 2, 9, 13, 24, 25, 51, 52, ")" +282, 2, 10, 14, 26, 27, 53, 54, ":" +282, 2, 11, 15, 28, 31, 55, 58, "386" +282, 2, 12, 16, 32, 33, 59, 60, "-" +282, 2, 13, 17, 34, 36, 61, 63, "92" +282, 2, 14, 18, 37, 38, 64, 65, "." +282, 2, 15, 19, 39, 42, 66, 69, "doi" +282, 2, 16, 20, 43, 44, 70, 71, ":" +282, 2, 17, 21, 45, 47, 72, 74, "10" +282, 2, 18, 22, 48, 49, 75, 76, "." +282, 2, 19, 23, 50, 54, 77, 81, "1016" +282, 2, 20, 24, 55, 56, 82, 83, "/" +282, 2, 21, 25, 57, 58, 84, 85, "j" +282, 2, 22, 26, 59, 60, 86, 87, "." +282, 2, 23, 27, 61, 69, 88, 96, "jdiacomp" +282, 2, 24, 28, 70, 71, 97, 98, "." +282, 2, 25, 29, 72, 76, 99, 103, "2014" +282, 2, 26, 30, 77, 78, 104, 105, "." +282, 2, 27, 31, 79, 81, 106, 108, "01" +282, 2, 28, 32, 82, 83, 109, 110, "." +282, 2, 29, 33, 84, 87, 111, 114, "012" +282, 2, 30, 34, 88, 89, 115, 116, "." +282, 3, 1, 35, 0, 4, 117, 121, "Epub" +282, 3, 2, 36, 5, 9, 122, 126, "2014" +282, 3, 3, 37, 10, 13, 127, 130, "Jan" +282, 3, 4, 38, 14, 16, 131, 133, "28" +282, 3, 5, 39, 17, 18, 134, 135, "." +282, 4, 1, 40, 0, 10, 136, 146, "Beneficial" +282, 4, 2, 41, 11, 18, 147, 154, "effects" +282, 4, 3, 42, 19, 21, 155, 157, "of" +282, 4, 4, 43, 22, 26, 158, 162, "once" +282, 4, 5, 44, 27, 28, 163, 164, "-" +282, 4, 6, 45, 29, 34, 165, 170, "daily" +282, 4, 7, 46, 35, 47, 171, 183, "lixisenatide" +282, 4, 8, 47, 48, 50, 184, 186, "on" +282, 4, 9, 48, 51, 58, 187, 194, "overall" +282, 4, 10, 49, 59, 62, 195, 198, "and" +282, 4, 11, 50, 63, 75, 199, 211, "postprandial" +282, 4, 12, 51, 76, 84, 212, 220, "glycemic" +282, 4, 13, 52, 85, 91, 221, 227, "levels" +282, 4, 14, 53, 92, 99, 228, 235, "without" +282, 4, 15, 54, 100, 111, 236, 247, "significant" +282, 4, 16, 55, 112, 118, 248, 254, "excess" +282, 4, 17, 56, 119, 121, 255, 257, "of" +282, 4, 18, 57, 122, 134, 258, 270, "hypoglycemia" +282, 4, 19, 58, 135, 137, 271, 273, "in" +282, 4, 20, 59, 138, 142, 274, 278, "type" +282, 4, 21, 60, 143, 144, 279, 280, "2" +282, 4, 22, 61, 145, 153, 281, 289, "diabetes" +282, 4, 23, 62, 154, 166, 290, 302, "inadequately" +282, 4, 24, 63, 167, 177, 303, 313, "controlled" +282, 4, 25, 64, 178, 180, 314, 316, "on" +282, 4, 26, 65, 181, 182, 317, 318, "a" +282, 4, 27, 66, 183, 195, 319, 331, "sulfonylurea" +282, 4, 28, 67, 196, 200, 332, 336, "with" +282, 4, 29, 68, 201, 203, 337, 339, "or" +282, 4, 30, 69, 204, 211, 340, 347, "without" +282, 4, 31, 70, 212, 221, 348, 357, "metformin" +282, 4, 32, 71, 222, 223, 358, 359, "(" +282, 4, 33, 72, 224, 231, 360, 367, "GetGoal" +282, 4, 34, 73, 232, 233, 368, 369, "-" +282, 4, 35, 74, 234, 235, 370, 371, "S" +282, 4, 36, 75, 236, 237, 372, 373, ")" +282, 4, 37, 76, 238, 239, 374, 375, "." +282, 5, 1, 77, 0, 10, 376, 386, "Rosenstock" +282, 5, 2, 78, 11, 12, 387, 388, "J" +282, 5, 3, 79, 13, 14, 389, 390, "(" +282, 5, 4, 80, 15, 16, 391, 392, "1" +282, 5, 5, 81, 17, 18, 393, 394, ")" +282, 5, 6, 82, 19, 20, 395, 396, "," +282, 5, 7, 83, 21, 29, 397, 405, "Hanefeld" +282, 5, 8, 84, 30, 31, 406, 407, "M" +282, 5, 9, 85, 32, 33, 408, 409, "(" +282, 5, 10, 86, 34, 35, 410, 411, "2" +282, 5, 11, 87, 36, 37, 412, 413, ")" +282, 5, 12, 88, 38, 39, 414, 415, "," +282, 5, 13, 89, 40, 48, 416, 424, "Shamanna" +282, 5, 14, 90, 49, 50, 425, 426, "P" +282, 5, 15, 91, 51, 52, 427, 428, "(" +282, 5, 16, 92, 53, 54, 429, 430, "3" +282, 5, 17, 93, 55, 56, 431, 432, ")" +282, 5, 18, 94, 57, 58, 433, 434, "," +282, 5, 19, 95, 59, 62, 435, 438, "Min" +282, 5, 20, 96, 63, 65, 439, 441, "KW" +282, 5, 21, 97, 66, 67, 442, 443, "(" +282, 5, 22, 98, 68, 69, 444, 445, "4" +282, 5, 23, 99, 70, 71, 446, 447, ")" +282, 5, 24, 100, 72, 73, 448, 449, "," +282, 5, 25, 101, 74, 78, 450, 454, "Boka" +282, 5, 26, 102, 79, 80, 455, 456, "G" +282, 5, 27, 103, 81, 82, 457, 458, "(" +282, 5, 28, 104, 83, 84, 459, 460, "5" +282, 5, 29, 105, 85, 86, 461, 462, ")" +282, 5, 30, 106, 87, 88, 463, 464, "," +282, 5, 31, 107, 89, 96, 465, 472, "Miossec" +282, 5, 32, 108, 97, 98, 473, 474, "P" +282, 5, 33, 109, 99, 100, 475, 476, "(" +282, 5, 34, 110, 101, 102, 477, 478, "6" +282, 5, 35, 111, 103, 104, 479, 480, ")" +282, 5, 36, 112, 105, 106, 481, 482, "," +282, 5, 37, 113, 107, 111, 483, 487, "Zhou" +282, 5, 38, 114, 112, 113, 488, 489, "T" +282, 5, 39, 115, 114, 115, 490, 491, "(" +282, 5, 40, 116, 116, 117, 492, 493, "7" +282, 5, 41, 117, 118, 119, 494, 495, ")" +282, 5, 42, 118, 120, 121, 496, 497, "," +282, 5, 43, 119, 122, 129, 498, 505, "Muehlen" +282, 5, 44, 120, 130, 131, 506, 507, "-" +282, 5, 45, 121, 132, 139, 508, 515, "Bartmer" +282, 5, 46, 122, 140, 141, 516, 517, "I" +282, 5, 47, 123, 142, 143, 518, 519, "(" +282, 5, 48, 124, 144, 145, 520, 521, "8" +282, 5, 49, 125, 146, 147, 522, 523, ")" +282, 5, 50, 126, 148, 149, 524, 525, "," +282, 5, 51, 127, 150, 156, 526, 532, "Ratner" +282, 5, 52, 128, 157, 159, 533, 535, "RE" +282, 5, 53, 129, 160, 161, 536, 537, "(" +282, 5, 54, 130, 162, 163, 538, 539, "9" +282, 5, 55, 131, 164, 165, 540, 541, ")" +282, 5, 56, 132, 166, 167, 542, 543, "." +282, 6, 1, 133, 0, 6, 544, 550, "Author" +282, 6, 2, 134, 7, 18, 551, 562, "information" +282, 6, 3, 135, 19, 20, 563, 564, ":" +282, 6, 4, 136, 21, 22, 565, 566, "(" +282, 6, 5, 137, 23, 24, 567, 568, "1" +282, 6, 6, 138, 25, 26, 569, 570, ")" +282, 6, 7, 139, 27, 33, 571, 577, "Dallas" +282, 6, 8, 140, 34, 42, 578, 586, "Diabetes" +282, 6, 9, 141, 43, 46, 587, 590, "and" +282, 6, 10, 142, 47, 56, 591, 600, "Endocrine" +282, 6, 11, 143, 57, 63, 601, 607, "Center" +282, 6, 12, 144, 64, 66, 608, 610, "at" +282, 6, 13, 145, 67, 74, 611, 618, "Medical" +282, 6, 14, 146, 75, 79, 619, 623, "City" +282, 6, 15, 147, 80, 81, 624, 625, "," +282, 6, 16, 148, 82, 88, 626, 632, "Dallas" +282, 6, 17, 149, 89, 90, 633, 634, "," +282, 6, 18, 150, 91, 93, 635, 637, "TX" +282, 6, 19, 151, 94, 95, 638, 639, "," +282, 6, 20, 152, 96, 99, 640, 643, "USA" +282, 6, 21, 153, 100, 101, 644, 645, "." +282, 7, 1, 154, 0, 10, 646, 656, "Electronic" +282, 7, 2, 155, 11, 18, 657, 664, "address" +282, 7, 3, 156, 19, 20, 665, 666, ":" +282, 7, 4, 157, 21, 36, 667, 682, "JulioRosenstock" +282, 7, 5, 158, 37, 38, 683, 684, "@" +282, 7, 6, 159, 39, 53, 685, 699, "DallasDiabetes" +282, 7, 7, 160, 54, 55, 700, 701, "." +282, 7, 8, 161, 56, 59, 702, 705, "com" +282, 7, 9, 162, 60, 61, 706, 707, "." +282, 8, 1, 163, 0, 1, 708, 709, "(" +282, 8, 2, 164, 2, 3, 710, 711, "2" +282, 8, 3, 165, 4, 5, 712, 713, ")" +282, 8, 4, 166, 6, 12, 714, 720, "Centre" +282, 8, 5, 167, 13, 16, 721, 724, "for" +282, 8, 6, 168, 17, 25, 725, 733, "Clinical" +282, 8, 7, 169, 26, 33, 734, 741, "Studies" +282, 8, 8, 170, 34, 35, 742, 743, "," +282, 8, 9, 171, 36, 39, 744, 747, "GWT" +282, 8, 10, 172, 40, 41, 748, 749, "-" +282, 8, 11, 173, 42, 45, 750, 753, "TUD" +282, 8, 12, 174, 46, 50, 754, 758, "GmbH" +282, 8, 13, 175, 51, 52, 759, 760, "," +282, 8, 14, 176, 53, 60, 761, 768, "Dresden" +282, 8, 15, 177, 61, 62, 769, 770, "," +282, 8, 16, 178, 63, 70, 771, 778, "Germany" +282, 8, 17, 179, 71, 72, 779, 780, "." +282, 9, 1, 180, 0, 1, 781, 782, "(" +282, 9, 2, 181, 2, 3, 783, 784, "3" +282, 9, 3, 182, 4, 5, 785, 786, ")" +282, 9, 4, 183, 6, 15, 787, 796, "Bangalore" +282, 9, 5, 184, 16, 24, 797, 805, "Diabetes" +282, 9, 6, 185, 25, 31, 806, 812, "Centre" +282, 9, 7, 186, 32, 33, 813, 814, "," +282, 9, 8, 187, 34, 43, 815, 824, "Bangalore" +282, 9, 9, 188, 44, 45, 825, 826, "," +282, 9, 10, 189, 46, 51, 827, 832, "India" +282, 9, 11, 190, 52, 53, 833, 834, "." +282, 10, 1, 191, 0, 1, 835, 836, "(" +282, 10, 2, 192, 2, 3, 837, 838, "4" +282, 10, 3, 193, 4, 5, 839, 840, ")" +282, 10, 4, 194, 6, 11, 841, 846, "Eulji" +282, 10, 5, 195, 12, 19, 847, 854, "General" +282, 10, 6, 196, 20, 28, 855, 863, "Hospital" +282, 10, 7, 197, 29, 30, 864, 865, "," +282, 10, 8, 198, 31, 36, 866, 871, "Seoul" +282, 10, 9, 199, 37, 38, 872, 873, "," +282, 10, 10, 200, 39, 47, 874, 882, "Republic" +282, 10, 11, 201, 48, 50, 883, 885, "of" +282, 10, 12, 202, 51, 56, 886, 891, "Korea" +282, 10, 13, 203, 57, 58, 892, 893, "." +282, 11, 1, 204, 0, 1, 894, 895, "(" +282, 11, 2, 205, 2, 3, 896, 897, "5" +282, 11, 3, 206, 4, 5, 898, 899, ")" +282, 11, 4, 207, 6, 12, 900, 906, "Sanofi" +282, 11, 5, 208, 13, 14, 907, 908, "R" +282, 11, 6, 209, 15, 16, 909, 910, "&" +282, 11, 7, 210, 17, 18, 911, 912, "D" +282, 11, 8, 211, 19, 20, 913, 914, "," +282, 11, 9, 212, 21, 27, 915, 921, "Chilly" +282, 11, 10, 213, 28, 29, 922, 923, "-" +282, 11, 11, 214, 30, 37, 924, 931, "Mazarin" +282, 11, 12, 215, 38, 39, 932, 933, "," +282, 11, 13, 216, 40, 46, 934, 940, "France" +282, 11, 14, 217, 47, 48, 941, 942, "." +282, 12, 1, 218, 0, 1, 943, 944, "(" +282, 12, 2, 219, 2, 3, 945, 946, "6" +282, 12, 3, 220, 4, 5, 947, 948, ")" +282, 12, 4, 221, 6, 12, 949, 955, "Sanofi" +282, 12, 5, 222, 13, 14, 956, 957, "R" +282, 12, 6, 223, 15, 16, 958, 959, "&" +282, 12, 7, 224, 17, 18, 960, 961, "D" +282, 12, 8, 225, 19, 20, 962, 963, "," +282, 12, 9, 226, 21, 26, 964, 969, "Paris" +282, 12, 10, 227, 27, 28, 970, 971, "," +282, 12, 11, 228, 29, 35, 972, 978, "France" +282, 12, 12, 229, 36, 37, 979, 980, "." +282, 13, 1, 230, 0, 1, 981, 982, "(" +282, 13, 2, 231, 2, 3, 983, 984, "7" +282, 13, 3, 232, 4, 5, 985, 986, ")" +282, 13, 4, 233, 6, 12, 987, 993, "Sanofi" +282, 13, 5, 234, 13, 14, 994, 995, "," +282, 13, 6, 235, 15, 26, 996, 1007, "Bridgewater" +282, 13, 7, 236, 27, 28, 1008, 1009, "," +282, 13, 8, 237, 29, 31, 1010, 1012, "NJ" +282, 13, 9, 238, 32, 33, 1013, 1014, "," +282, 13, 10, 239, 34, 37, 1015, 1018, "USA" +282, 13, 11, 240, 38, 39, 1019, 1020, "." +282, 14, 1, 241, 0, 1, 1021, 1022, "(" +282, 14, 2, 242, 2, 3, 1023, 1024, "8" +282, 14, 3, 243, 4, 5, 1025, 1026, ")" +282, 14, 4, 244, 6, 12, 1027, 1033, "Sanofi" +282, 14, 5, 245, 13, 14, 1034, 1035, "R" +282, 14, 6, 246, 15, 16, 1036, 1037, "&" +282, 14, 7, 247, 17, 18, 1038, 1039, "D" +282, 14, 8, 248, 19, 20, 1040, 1041, "," +282, 14, 9, 249, 21, 30, 1042, 1051, "Frankfurt" +282, 14, 10, 250, 31, 32, 1052, 1053, "," +282, 14, 11, 251, 33, 40, 1054, 1061, "Germany" +282, 14, 12, 252, 41, 42, 1062, 1063, "." +282, 15, 1, 253, 0, 1, 1064, 1065, "(" +282, 15, 2, 254, 2, 3, 1066, 1067, "9" +282, 15, 3, 255, 4, 5, 1068, 1069, ")" +282, 15, 4, 256, 6, 13, 1070, 1077, "Medstar" +282, 15, 5, 257, 14, 20, 1078, 1084, "Health" +282, 15, 6, 258, 21, 29, 1085, 1093, "Research" +282, 15, 7, 259, 30, 39, 1094, 1103, "Institute" +282, 15, 8, 260, 40, 43, 1104, 1107, "and" +282, 15, 9, 261, 44, 54, 1108, 1118, "Georgetown" +282, 15, 10, 262, 55, 65, 1119, 1129, "University" +282, 15, 11, 263, 66, 73, 1130, 1137, "Medical" +282, 15, 12, 264, 74, 80, 1138, 1144, "School" +282, 15, 13, 265, 81, 82, 1145, 1146, "," +282, 15, 14, 266, 83, 93, 1147, 1157, "Washington" +282, 15, 15, 267, 94, 95, 1158, 1159, "," +282, 15, 16, 268, 96, 98, 1160, 1162, "DC" +282, 15, 17, 269, 99, 100, 1163, 1164, "," +282, 15, 18, 270, 101, 104, 1165, 1168, "USA" +282, 15, 19, 271, 105, 106, 1169, 1170, "." +282, 16, 1, 272, 0, 4, 1171, 1175, "AIMS" +282, 16, 2, 273, 5, 6, 1176, 1177, ":" +282, 16, 3, 274, 7, 9, 1178, 1180, "To" +282, 16, 4, 275, 10, 16, 1181, 1187, "assess" +282, 16, 5, 276, 17, 25, 1188, 1196, "efficacy" +282, 16, 6, 277, 26, 29, 1197, 1200, "and" +282, 16, 7, 278, 30, 36, 1201, 1207, "safety" +282, 16, 8, 279, 37, 39, 1208, 1210, "of" +282, 16, 9, 280, 40, 52, 1211, 1223, "lixisenatide" +282, 16, 10, 281, 53, 57, 1224, 1228, "once" +282, 16, 11, 282, 58, 59, 1229, 1230, "-" +282, 16, 12, 283, 60, 65, 1231, 1236, "daily" +282, 16, 13, 284, 66, 72, 1237, 1243, "versus" +282, 16, 14, 285, 73, 80, 1244, 1251, "placebo" +282, 16, 15, 286, 81, 83, 1252, 1254, "in" +282, 16, 16, 287, 84, 88, 1255, 1259, "type" +282, 16, 17, 288, 89, 90, 1260, 1261, "2" +282, 16, 18, 289, 91, 99, 1262, 1270, "diabetes" +282, 16, 19, 290, 100, 108, 1271, 1279, "mellitus" +282, 16, 20, 291, 109, 110, 1280, 1281, "(" +282, 16, 21, 292, 111, 115, 1282, 1286, "T2DM" +282, 16, 22, 293, 116, 117, 1287, 1288, ")" +282, 16, 23, 294, 118, 126, 1289, 1297, "patients" +282, 16, 24, 295, 127, 139, 1298, 1310, "inadequately" +282, 16, 25, 296, 140, 150, 1311, 1321, "controlled" +282, 16, 26, 297, 151, 153, 1322, 1324, "on" +282, 16, 27, 298, 154, 166, 1325, 1337, "sulfonylurea" +282, 16, 28, 299, 167, 168, 1338, 1339, "(" +282, 16, 29, 300, 169, 171, 1340, 1342, "SU" +282, 16, 30, 301, 172, 173, 1343, 1344, ")" +282, 16, 31, 302, 174, 175, 1345, 1346, "±" +282, 16, 32, 303, 176, 185, 1347, 1356, "metformin" +282, 16, 33, 304, 186, 187, 1357, 1358, "." +282, 17, 1, 305, 0, 7, 1359, 1366, "METHODS" +282, 17, 2, 306, 8, 9, 1367, 1368, ":" +282, 17, 3, 307, 10, 12, 1369, 1371, "In" +282, 17, 4, 308, 13, 17, 1372, 1376, "this" +282, 17, 5, 309, 18, 28, 1377, 1387, "randomized" +282, 17, 6, 310, 29, 30, 1388, 1389, "," +282, 17, 7, 311, 31, 37, 1390, 1396, "double" +282, 17, 8, 312, 38, 39, 1397, 1398, "-" +282, 17, 9, 313, 40, 45, 1399, 1404, "blind" +282, 17, 10, 314, 46, 47, 1405, 1406, "," +282, 17, 11, 315, 48, 51, 1407, 1410, "two" +282, 17, 12, 316, 52, 53, 1411, 1412, "-" +282, 17, 13, 317, 54, 57, 1413, 1416, "arm" +282, 17, 14, 318, 58, 59, 1417, 1418, "," +282, 17, 15, 319, 60, 68, 1419, 1427, "parallel" +282, 17, 16, 320, 69, 70, 1428, 1429, "-" +282, 17, 17, 321, 71, 76, 1430, 1435, "group" +282, 17, 18, 322, 77, 78, 1436, 1437, "," +282, 17, 19, 323, 79, 90, 1438, 1449, "multicenter" +282, 17, 20, 324, 91, 96, 1450, 1455, "study" +282, 17, 21, 325, 97, 98, 1456, 1457, "," +282, 17, 22, 326, 99, 107, 1458, 1466, "patients" +282, 17, 23, 327, 108, 116, 1467, 1475, "received" +282, 17, 24, 328, 117, 129, 1476, 1488, "lixisenatide" +282, 17, 25, 329, 130, 132, 1489, 1491, "20" +282, 17, 26, 330, 133, 134, 1492, 1493, "μ" +282, 17, 27, 331, 135, 136, 1494, 1495, "g" +282, 17, 28, 332, 137, 141, 1496, 1500, "once" +282, 17, 29, 333, 142, 143, 1501, 1502, "-" +282, 17, 30, 334, 144, 149, 1503, 1508, "daily" +282, 17, 31, 335, 150, 152, 1509, 1511, "or" +282, 17, 32, 336, 153, 160, 1512, 1519, "placebo" +282, 17, 33, 337, 161, 164, 1520, 1523, "for" +282, 17, 34, 338, 165, 167, 1524, 1526, "24" +282, 17, 35, 339, 168, 173, 1527, 1532, "weeks" +282, 17, 36, 340, 174, 176, 1533, 1535, "in" +282, 17, 37, 341, 177, 178, 1536, 1537, "a" +282, 17, 38, 342, 179, 187, 1538, 1546, "stepwise" +282, 17, 39, 343, 188, 192, 1547, 1551, "dose" +282, 17, 40, 344, 193, 201, 1552, 1560, "increase" +282, 17, 41, 345, 202, 204, 1561, 1563, "on" +282, 17, 42, 346, 205, 208, 1564, 1567, "top" +282, 17, 43, 347, 209, 211, 1568, 1570, "of" +282, 17, 44, 348, 212, 215, 1571, 1574, "SUs" +282, 17, 45, 349, 216, 217, 1575, 1576, "±" +282, 17, 46, 350, 218, 227, 1577, 1586, "metformin" +282, 17, 47, 351, 228, 229, 1587, 1588, "." +282, 18, 1, 352, 0, 7, 1589, 1596, "Primary" +282, 18, 2, 353, 8, 15, 1597, 1604, "outcome" +282, 18, 3, 354, 16, 19, 1605, 1608, "was" +282, 18, 4, 355, 20, 26, 1609, 1615, "change" +282, 18, 5, 356, 27, 29, 1616, 1618, "in" +282, 18, 6, 357, 30, 35, 1619, 1624, "HbA1c" +282, 18, 7, 358, 36, 40, 1625, 1629, "from" +282, 18, 8, 359, 41, 49, 1630, 1638, "baseline" +282, 18, 9, 360, 50, 52, 1639, 1641, "to" +282, 18, 10, 361, 53, 57, 1642, 1646, "Week" +282, 18, 11, 362, 58, 60, 1647, 1649, "24" +282, 18, 12, 363, 61, 62, 1650, 1651, "." +282, 19, 1, 364, 0, 7, 1652, 1659, "RESULTS" +282, 19, 2, 365, 8, 9, 1660, 1661, ":" +282, 19, 3, 366, 10, 22, 1662, 1674, "Lixisenatide" +282, 19, 4, 367, 23, 31, 1675, 1683, "provided" +282, 19, 5, 368, 32, 33, 1684, 1685, "a" +282, 19, 6, 369, 34, 45, 1686, 1697, "significant" +282, 19, 7, 370, 46, 55, 1698, 1707, "reduction" +282, 19, 8, 371, 56, 58, 1708, 1710, "in" +282, 19, 9, 372, 59, 64, 1711, 1716, "HbA1c" +282, 19, 10, 373, 65, 67, 1717, 1719, "at" +282, 19, 11, 374, 68, 72, 1720, 1724, "Week" +282, 19, 12, 375, 73, 75, 1725, 1727, "24" +282, 19, 13, 376, 76, 82, 1728, 1734, "versus" +282, 19, 14, 377, 83, 90, 1735, 1742, "placebo" +282, 19, 15, 378, 91, 92, 1743, 1744, "(" +282, 19, 16, 379, 93, 95, 1745, 1747, "LS" +282, 19, 17, 380, 96, 100, 1748, 1752, "mean" +282, 19, 18, 381, 101, 102, 1753, 1754, ":" +282, 19, 19, 382, 103, 104, 1755, 1756, "-" +282, 19, 20, 383, 105, 106, 1757, 1758, "0" +282, 19, 21, 384, 107, 108, 1759, 1760, "." +282, 19, 22, 385, 109, 111, 1761, 1763, "85" +282, 19, 23, 386, 112, 113, 1764, 1765, "%" +282, 19, 24, 387, 114, 116, 1766, 1768, "vs" +282, 19, 25, 388, 117, 118, 1769, 1770, "." +282, 19, 26, 389, 119, 120, 1771, 1772, "-" +282, 19, 27, 390, 121, 122, 1773, 1774, "0" +282, 19, 28, 391, 123, 124, 1775, 1776, "." +282, 19, 29, 392, 125, 127, 1777, 1779, "10" +282, 19, 30, 393, 128, 129, 1780, 1781, "%" +282, 19, 31, 394, 130, 131, 1782, 1783, ";" +282, 19, 32, 395, 132, 133, 1784, 1785, "p" +282, 19, 33, 396, 134, 135, 1786, 1787, "<" +282, 19, 34, 397, 136, 137, 1788, 1789, "0" +282, 19, 35, 398, 138, 139, 1790, 1791, "." +282, 19, 36, 399, 140, 144, 1792, 1796, "0001" +282, 19, 37, 400, 145, 146, 1797, 1798, ")" +282, 19, 38, 401, 147, 150, 1799, 1802, "and" +282, 19, 39, 402, 151, 155, 1803, 1807, "more" +282, 19, 40, 403, 156, 164, 1808, 1816, "patients" +282, 19, 41, 404, 165, 173, 1817, 1825, "achieved" +282, 19, 42, 405, 174, 179, 1826, 1831, "HbA1c" +282, 19, 43, 406, 180, 181, 1832, 1833, "<" +282, 19, 44, 407, 182, 183, 1834, 1835, "7" +282, 19, 45, 408, 184, 185, 1836, 1837, "." +282, 19, 46, 409, 186, 187, 1838, 1839, "0" +282, 19, 47, 410, 188, 189, 1840, 1841, "%" +282, 19, 48, 411, 190, 191, 1842, 1843, "(" +282, 19, 49, 412, 192, 194, 1844, 1846, "36" +282, 19, 50, 413, 195, 196, 1847, 1848, "." +282, 19, 51, 414, 197, 198, 1849, 1850, "4" +282, 19, 52, 415, 199, 200, 1851, 1852, "%" +282, 19, 53, 416, 201, 203, 1853, 1855, "vs" +282, 19, 54, 417, 204, 205, 1856, 1857, "." +282, 19, 55, 418, 206, 208, 1858, 1860, "13" +282, 19, 56, 419, 209, 210, 1861, 1862, "." +282, 19, 57, 420, 211, 212, 1863, 1864, "5" +282, 19, 58, 421, 213, 214, 1865, 1866, "%" +282, 19, 59, 422, 215, 216, 1867, 1868, ";" +282, 19, 60, 423, 217, 218, 1869, 1870, "p" +282, 19, 61, 424, 219, 220, 1871, 1872, "<" +282, 19, 62, 425, 221, 222, 1873, 1874, "0" +282, 19, 63, 426, 223, 224, 1875, 1876, "." +282, 19, 64, 427, 225, 229, 1877, 1881, "0001" +282, 19, 65, 428, 230, 231, 1882, 1883, ")" +282, 19, 66, 429, 232, 233, 1884, 1885, "." +282, 20, 1, 430, 0, 12, 1886, 1898, "Lixisenatide" +282, 20, 2, 431, 13, 26, 1899, 1912, "significantly" +282, 20, 3, 432, 27, 34, 1913, 1920, "lowered" +282, 20, 4, 433, 35, 38, 1921, 1924, "FPG" +282, 20, 5, 434, 39, 42, 1925, 1928, "and" +282, 20, 6, 435, 43, 47, 1929, 1933, "body" +282, 20, 7, 436, 48, 54, 1934, 1940, "weight" +282, 20, 8, 437, 55, 61, 1941, 1947, "versus" +282, 20, 9, 438, 62, 69, 1948, 1955, "placebo" +282, 20, 10, 439, 70, 71, 1956, 1957, "." +282, 21, 1, 440, 0, 2, 1958, 1960, "In" +282, 21, 2, 441, 3, 12, 1961, 1970, "breakfast" +282, 21, 3, 442, 13, 17, 1971, 1975, "meal" +282, 21, 4, 443, 18, 22, 1976, 1980, "test" +282, 21, 5, 444, 23, 31, 1981, 1989, "patients" +282, 21, 6, 445, 32, 33, 1990, 1991, "," +282, 21, 7, 446, 34, 46, 1992, 2004, "lixisenatide" +282, 21, 8, 447, 47, 54, 2005, 2012, "reduced" +282, 21, 9, 448, 55, 56, 2013, 2014, "2" +282, 21, 10, 449, 57, 58, 2015, 2016, "-" +282, 21, 11, 450, 59, 63, 2017, 2021, "hour" +282, 21, 12, 451, 64, 67, 2022, 2025, "PPG" +282, 21, 13, 452, 68, 74, 2026, 2032, "versus" +282, 21, 14, 453, 75, 82, 2033, 2040, "placebo" +282, 21, 15, 454, 83, 84, 2041, 2042, "(" +282, 21, 16, 455, 85, 87, 2043, 2045, "LS" +282, 21, 17, 456, 88, 92, 2046, 2050, "mean" +282, 21, 18, 457, 93, 94, 2051, 2052, ":" +282, 21, 19, 458, 95, 96, 2053, 2054, "-" +282, 21, 20, 459, 97, 100, 2055, 2058, "111" +282, 21, 21, 460, 101, 102, 2059, 2060, "." +282, 21, 22, 461, 103, 105, 2061, 2063, "48" +282, 21, 23, 462, 106, 108, 2064, 2066, "vs" +282, 21, 24, 463, 109, 110, 2067, 2068, "." +282, 21, 25, 464, 111, 112, 2069, 2070, "-" +282, 21, 26, 465, 113, 114, 2071, 2072, "3" +282, 21, 27, 466, 115, 116, 2073, 2074, "." +282, 21, 28, 467, 117, 119, 2075, 2077, "80" +282, 21, 29, 468, 120, 122, 2078, 2080, "mg" +282, 21, 30, 469, 123, 124, 2081, 2082, "/" +282, 21, 31, 470, 125, 127, 2083, 2085, "dL" +282, 21, 32, 471, 128, 129, 2086, 2087, "[" +282, 21, 33, 472, 130, 131, 2088, 2089, "-" +282, 21, 34, 473, 132, 133, 2090, 2091, "6" +282, 21, 35, 474, 134, 135, 2092, 2093, "." +282, 21, 36, 475, 136, 138, 2094, 2096, "19" +282, 21, 37, 476, 139, 141, 2097, 2099, "vs" +282, 21, 38, 477, 142, 143, 2100, 2101, "." +282, 21, 39, 478, 144, 145, 2102, 2103, "-" +282, 21, 40, 479, 146, 147, 2104, 2105, "0" +282, 21, 41, 480, 148, 149, 2106, 2107, "." +282, 21, 42, 481, 150, 152, 2108, 2110, "21" +282, 21, 43, 482, 153, 157, 2111, 2115, "mmol" +282, 21, 44, 483, 158, 159, 2116, 2117, "/" +282, 21, 45, 484, 160, 161, 2118, 2119, "L" +282, 21, 46, 485, 162, 163, 2120, 2121, "]" +282, 21, 47, 486, 164, 165, 2122, 2123, ";" +282, 21, 48, 487, 166, 167, 2124, 2125, "p" +282, 21, 49, 488, 168, 169, 2126, 2127, "<" +282, 21, 50, 489, 170, 171, 2128, 2129, "0" +282, 21, 51, 490, 172, 173, 2130, 2131, "." +282, 21, 52, 491, 174, 178, 2132, 2136, "0001" +282, 21, 53, 492, 179, 180, 2137, 2138, ")" +282, 21, 54, 493, 181, 184, 2139, 2142, "and" +282, 21, 55, 494, 185, 192, 2143, 2150, "glucose" +282, 21, 56, 495, 193, 202, 2151, 2160, "excursion" +282, 21, 57, 496, 203, 204, 2161, 2162, "(" +282, 21, 58, 497, 205, 206, 2163, 2164, "-" +282, 21, 59, 498, 207, 209, 2165, 2167, "94" +282, 21, 60, 499, 210, 211, 2168, 2169, "." +282, 21, 61, 500, 212, 214, 2170, 2172, "11" +282, 21, 62, 501, 215, 217, 2173, 2175, "vs" +282, 21, 63, 502, 218, 219, 2176, 2177, "." +282, 21, 64, 503, 220, 221, 2178, 2179, "+" +282, 21, 65, 504, 222, 223, 2180, 2181, "6" +282, 21, 66, 505, 224, 225, 2182, 2183, "." +282, 21, 67, 506, 226, 228, 2184, 2186, "24" +282, 21, 68, 507, 229, 231, 2187, 2189, "mg" +282, 21, 69, 508, 232, 233, 2190, 2191, "/" +282, 21, 70, 509, 234, 236, 2192, 2194, "dL" +282, 21, 71, 510, 237, 238, 2195, 2196, "[" +282, 21, 72, 511, 239, 240, 2197, 2198, "-" +282, 21, 73, 512, 241, 242, 2199, 2200, "5" +282, 21, 74, 513, 243, 244, 2201, 2202, "." +282, 21, 75, 514, 245, 247, 2203, 2205, "22" +282, 21, 76, 515, 248, 250, 2206, 2208, "vs" +282, 21, 77, 516, 251, 252, 2209, 2210, "." +282, 21, 78, 517, 253, 254, 2211, 2212, "+" +282, 21, 79, 518, 255, 256, 2213, 2214, "0" +282, 21, 80, 519, 257, 258, 2215, 2216, "." +282, 21, 81, 520, 259, 261, 2217, 2219, "35" +282, 21, 82, 521, 262, 266, 2220, 2224, "mmol" +282, 21, 83, 522, 267, 268, 2225, 2226, "/" +282, 21, 84, 523, 269, 270, 2227, 2228, "L" +282, 21, 85, 524, 271, 272, 2229, 2230, "]" +282, 21, 86, 525, 273, 274, 2231, 2232, ")" +282, 21, 87, 526, 275, 276, 2233, 2234, "," +282, 21, 88, 527, 277, 280, 2235, 2238, "and" +282, 21, 89, 528, 281, 288, 2239, 2246, "reduced" +282, 21, 90, 529, 289, 290, 2247, 2248, "2" +282, 21, 91, 530, 291, 292, 2249, 2250, "-" +282, 21, 92, 531, 293, 297, 2251, 2255, "hour" +282, 21, 93, 532, 298, 306, 2256, 2264, "glucagon" +282, 21, 94, 533, 307, 308, 2265, 2266, "," +282, 21, 95, 534, 309, 316, 2267, 2274, "insulin" +282, 21, 96, 535, 317, 318, 2275, 2276, "," +282, 21, 97, 536, 319, 329, 2277, 2287, "proinsulin" +282, 21, 98, 537, 330, 331, 2288, 2289, "," +282, 21, 99, 538, 332, 335, 2290, 2293, "and" +282, 21, 100, 539, 336, 337, 2294, 2295, "C" +282, 21, 101, 540, 338, 339, 2296, 2297, "-" +282, 21, 102, 541, 340, 347, 2298, 2305, "peptide" +282, 21, 103, 542, 348, 349, 2306, 2307, "." +282, 22, 1, 543, 0, 3, 2308, 2311, "The" +282, 22, 2, 544, 4, 14, 2312, 2322, "percentage" +282, 22, 3, 545, 15, 17, 2323, 2325, "of" +282, 22, 4, 546, 18, 21, 2326, 2329, "AEs" +282, 22, 5, 547, 22, 25, 2330, 2333, "was" +282, 22, 6, 548, 26, 28, 2334, 2336, "68" +282, 22, 7, 549, 29, 30, 2337, 2338, "." +282, 22, 8, 550, 31, 32, 2339, 2340, "3" +282, 22, 9, 551, 33, 34, 2341, 2342, "%" +282, 22, 10, 552, 35, 38, 2343, 2346, "for" +282, 22, 11, 553, 39, 51, 2347, 2359, "lixisenatide" +282, 22, 12, 554, 52, 55, 2360, 2363, "and" +282, 22, 13, 555, 56, 58, 2364, 2366, "61" +282, 22, 14, 556, 59, 60, 2367, 2368, "." +282, 22, 15, 557, 61, 62, 2369, 2370, "1" +282, 22, 16, 558, 63, 64, 2371, 2372, "%" +282, 22, 17, 559, 65, 68, 2373, 2376, "for" +282, 22, 18, 560, 69, 76, 2377, 2384, "placebo" +282, 22, 19, 561, 77, 78, 2385, 2386, ";" +282, 22, 20, 562, 79, 82, 2387, 2390, "and" +282, 22, 21, 563, 83, 86, 2391, 2394, "for" +282, 22, 22, 564, 87, 91, 2395, 2399, "SAEs" +282, 22, 23, 565, 92, 93, 2400, 2401, ":" +282, 22, 24, 566, 94, 95, 2402, 2403, "3" +282, 22, 25, 567, 96, 97, 2404, 2405, "." +282, 22, 26, 568, 98, 99, 2406, 2407, "5" +282, 22, 27, 569, 100, 101, 2408, 2409, "%" +282, 22, 28, 570, 102, 108, 2410, 2416, "versus" +282, 22, 29, 571, 109, 110, 2417, 2418, "5" +282, 22, 30, 572, 111, 112, 2419, 2420, "." +282, 22, 31, 573, 113, 114, 2421, 2422, "6" +282, 22, 32, 574, 115, 116, 2423, 2424, "%" +282, 22, 33, 575, 117, 118, 2425, 2426, "," +282, 22, 34, 576, 119, 131, 2427, 2439, "respectively" +282, 22, 35, 577, 132, 133, 2440, 2441, "." +282, 23, 1, 578, 0, 12, 2442, 2454, "Lixisenatide" +282, 23, 2, 579, 13, 16, 2455, 2458, "did" +282, 23, 3, 580, 17, 20, 2459, 2462, "not" +282, 23, 4, 581, 21, 34, 2463, 2476, "significantly" +282, 23, 5, 582, 35, 43, 2477, 2485, "increase" +282, 23, 6, 583, 44, 55, 2486, 2497, "symptomatic" +282, 23, 7, 584, 56, 68, 2498, 2510, "hypoglycemia" +282, 23, 8, 585, 69, 75, 2511, 2517, "versus" +282, 23, 9, 586, 76, 83, 2518, 2525, "placebo" +282, 23, 10, 587, 84, 85, 2526, 2527, "(" +282, 23, 11, 588, 86, 88, 2528, 2530, "15" +282, 23, 12, 589, 89, 90, 2531, 2532, "." +282, 23, 13, 590, 91, 92, 2533, 2534, "3" +282, 23, 14, 591, 93, 94, 2535, 2536, "%" +282, 23, 15, 592, 95, 97, 2537, 2539, "vs" +282, 23, 16, 593, 98, 99, 2540, 2541, "." +282, 23, 17, 594, 100, 102, 2542, 2544, "12" +282, 23, 18, 595, 103, 104, 2545, 2546, "." +282, 23, 19, 596, 105, 106, 2547, 2548, "3" +282, 23, 20, 597, 107, 108, 2549, 2550, "%" +282, 23, 21, 598, 109, 110, 2551, 2552, "," +282, 23, 22, 599, 111, 123, 2553, 2565, "respectively" +282, 23, 23, 600, 124, 125, 2566, 2567, ")" +282, 23, 24, 601, 126, 127, 2568, 2569, ";" +282, 23, 25, 602, 128, 131, 2570, 2573, "one" +282, 23, 26, 603, 132, 138, 2574, 2580, "severe" +282, 23, 27, 604, 139, 146, 2581, 2588, "episode" +282, 23, 28, 605, 147, 149, 2589, 2591, "of" +282, 23, 29, 606, 150, 162, 2592, 2604, "hypoglycemia" +282, 23, 30, 607, 163, 166, 2605, 2608, "was" +282, 23, 31, 608, 167, 175, 2609, 2617, "reported" +282, 23, 32, 609, 176, 180, 2618, 2622, "with" +282, 23, 33, 610, 181, 193, 2623, 2635, "lixisenatide" +282, 23, 34, 611, 194, 195, 2636, 2637, "." +282, 24, 1, 612, 0, 11, 2638, 2649, "CONCLUSIONS" +282, 24, 2, 613, 12, 13, 2650, 2651, ":" +282, 24, 3, 614, 14, 18, 2652, 2656, "Once" +282, 24, 4, 615, 19, 20, 2657, 2658, "-" +282, 24, 5, 616, 21, 26, 2659, 2664, "daily" +282, 24, 6, 617, 27, 39, 2665, 2677, "lixisenatide" +282, 24, 7, 618, 40, 53, 2678, 2691, "significantly" +282, 24, 8, 619, 54, 62, 2692, 2700, "improved" +282, 24, 9, 620, 63, 71, 2701, 2709, "glycemic" +282, 24, 10, 621, 72, 79, 2710, 2717, "control" +282, 24, 11, 622, 80, 81, 2718, 2719, "," +282, 24, 12, 623, 82, 86, 2720, 2724, "with" +282, 24, 13, 624, 87, 88, 2725, 2726, "a" +282, 24, 14, 625, 89, 99, 2727, 2737, "pronounced" +282, 24, 15, 626, 100, 112, 2738, 2750, "postprandial" +282, 24, 16, 627, 113, 119, 2751, 2757, "effect" +282, 24, 17, 628, 120, 121, 2758, 2759, "," +282, 24, 18, 629, 122, 129, 2760, 2767, "without" +282, 24, 19, 630, 130, 141, 2768, 2779, "significant" +282, 24, 20, 631, 142, 150, 2780, 2788, "increase" +282, 24, 21, 632, 151, 153, 2789, 2791, "in" +282, 24, 22, 633, 154, 165, 2792, 2803, "symptomatic" +282, 24, 23, 634, 166, 167, 2804, 2805, "/" +282, 24, 24, 635, 168, 174, 2806, 2812, "severe" +282, 24, 25, 636, 175, 187, 2813, 2825, "hypoglycemia" +282, 24, 26, 637, 188, 192, 2826, 2830, "risk" +282, 24, 27, 638, 193, 196, 2831, 2834, "and" +282, 24, 28, 639, 197, 201, 2835, 2839, "with" +282, 24, 29, 640, 202, 208, 2840, 2846, "weight" +282, 24, 30, 641, 209, 213, 2847, 2851, "loss" +282, 24, 31, 642, 214, 218, 2852, 2856, "over" +282, 24, 32, 643, 219, 221, 2857, 2859, "24" +282, 24, 33, 644, 222, 227, 2860, 2865, "weeks" +282, 24, 34, 645, 228, 229, 2866, 2867, "." +282, 25, 1, 646, 0, 9, 2868, 2877, "Copyright" +282, 25, 2, 647, 10, 11, 2878, 2879, "©" +282, 25, 3, 648, 12, 16, 2880, 2884, "2014" +282, 25, 4, 649, 17, 20, 2885, 2888, "The" +282, 25, 5, 650, 21, 28, 2889, 2896, "Authors" +282, 25, 6, 651, 29, 30, 2897, 2898, "." +282, 26, 1, 652, 0, 9, 2899, 2908, "Published" +282, 26, 2, 653, 10, 12, 2909, 2911, "by" +282, 26, 3, 654, 13, 21, 2912, 2920, "Elsevier" +282, 26, 4, 655, 22, 25, 2921, 2924, "Inc" +282, 26, 5, 656, 26, 27, 2925, 2926, "." +282, 26, 6, 657, 28, 31, 2927, 2930, "All" +282, 26, 7, 658, 32, 38, 2931, 2937, "rights" +282, 26, 8, 659, 39, 47, 2938, 2946, "reserved" +282, 26, 9, 660, 48, 49, 2947, 2948, "." +282, 27, 1, 661, 0, 3, 2949, 2952, "DOI" +282, 27, 2, 662, 4, 5, 2953, 2954, ":" +282, 27, 3, 663, 6, 8, 2955, 2957, "10" +282, 27, 4, 664, 9, 10, 2958, 2959, "." +282, 27, 5, 665, 11, 15, 2960, 2964, "1016" +282, 27, 6, 666, 16, 17, 2965, 2966, "/" +282, 27, 7, 667, 18, 19, 2967, 2968, "j" +282, 27, 8, 668, 20, 21, 2969, 2970, "." +282, 27, 9, 669, 22, 30, 2971, 2979, "jdiacomp" +282, 27, 10, 670, 31, 32, 2980, 2981, "." +282, 27, 11, 671, 33, 37, 2982, 2986, "2014" +282, 27, 12, 672, 38, 39, 2987, 2988, "." +282, 27, 13, 673, 40, 42, 2989, 2991, "01" +282, 27, 14, 674, 43, 44, 2992, 2993, "." +282, 27, 15, 675, 45, 48, 2994, 2997, "012" +282, 27, 16, 676, 49, 53, 2998, 3002, "PMID" +282, 27, 17, 677, 54, 55, 3003, 3004, ":" +282, 27, 18, 678, 56, 64, 3005, 3013, "24650952" +282, 27, 19, 679, 65, 66, 3014, 3015, "[" +282, 27, 20, 680, 67, 74, 3016, 3023, "Indexed" +282, 27, 21, 681, 75, 78, 3024, 3027, "for" +282, 27, 22, 682, 79, 86, 3028, 3035, "MEDLINE" +282, 27, 23, 683, 87, 88, 3036, 3037, "]" diff --git a/data/dm2 24650952_kwoodley.annodb b/data/dm2 24650952_kwoodley.annodb new file mode 100644 index 0000000..9153e08 --- /dev/null +++ b/data/dm2 24650952_kwoodley.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +47210, Journal, 0, 24, "J Diabetes Complications", "", +47211, PublicationYear, 27, 31, "2014", "", +47237, Title, 136, 375, "Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .", "", +47212, Frequency, 158, 170, "once - daily", "", +47215, Drug, 171, 183, "lixisenatide", "", +47226, Hypoglycemia, 258, 270, "hypoglycemia", "", +47227, Type2Diabetes, 274, 289, "type 2 diabetes", "", +47230, Sulfonylureas, 319, 331, "sulfonylurea", "", +47234, Metformin, 348, 357, "metformin", "", +47238, Author, 376, 388, "Rosenstock J", "", +47239, Author, 397, 407, "Hanefeld M", "", +47240, Author, 416, 426, "Shamanna P", "", +47241, Author, 435, 441, "Min KW", "", +47242, Author, 450, 456, "Boka G", "", +47243, Author, 465, 474, "Miossec P", "", +47244, Author, 483, 489, "Zhou T", "", +47245, Author, 498, 517, "Muehlen - Bartmer I", "", +47246, Author, 526, 535, "Ratner RE", "", +47247, USA, 640, 643, "USA", "", +47248, Germany, 771, 778, "Germany", "", +47249, India, 827, 832, "India", "", +47250, SouthKorea, 874, 891, "Republic of Korea", "", +47251, France, 934, 940, "France", "", +47252, France, 972, 978, "France", "", +47253, USA, 1015, 1018, "USA", "", +47255, Germany, 1054, 1061, "Germany", "", +47254, USA, 1165, 1168, "USA", "", +47262, ObjectiveDescription, 1178, 1358, "To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .", "", +47216, Drug, 1211, 1223, "lixisenatide", "", +47225, Frequency, 1224, 1236, "once - daily", "", +47256, Placebo, 1244, 1251, "placebo", "", +47228, Type2Diabetes, 1255, 1279, "type 2 diabetes mellitus", "", +47261, Precondition, 1255, 1356, "type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin", "", +47229, Type2Diabetes, 1282, 1286, "T2DM", "", +47231, Sulfonylureas, 1325, 1337, "sulfonylurea", "", +47232, Sulfonylureas, 1340, 1342, "SU", "", +47235, Metformin, 1347, 1356, "metformin", "", +47263, Randomized, 1377, 1387, "randomized", "", +47264, DoubleBlind, 1390, 1404, "double - blind", "", +47265, Parallel, 1419, 1435, "parallel - group", "", +47266, Multicenter, 1438, 1449, "multicenter", "", +47217, Drug, 1476, 1488, "lixisenatide", "", +47267, DoseValue, 1489, 1491, "20", "", +47268, Microgram, 1492, 1495, "μ g", "", +47213, Frequency, 1496, 1508, "once - daily", "", +47269, Placebo, 1512, 1519, "placebo", "", +47270, Duration, 1524, 1532, "24 weeks", "", +47233, Sulfonylureas, 1571, 1574, "SUs", "", +47236, Metformin, 1577, 1586, "metformin", "", +47272, HbA1c, 1619, 1624, "HbA1c", "", +47274, TimePoint, 1630, 1638, "baseline", "", +47275, TimePoint, 1642, 1649, "Week 24", "", +47218, Drug, 1662, 1674, "Lixisenatide", "", +47273, HbA1c, 1711, 1716, "HbA1c", "", +47276, TimePoint, 1720, 1727, "Week 24", "", +47277, Placebo, 1735, 1742, "placebo", "", +47278, Mean, 1745, 1752, "LS mean", "", +47279, Reduction, 1757, 1763, "0 . 85", "", +47282, Percentage, 1764, 1765, "%", "", +47281, Reduction, 1773, 1779, "0 . 10", "", +47283, Percentage, 1780, 1781, "%", "", +47284, PvalueDiff, 1784, 1796, "p < 0 . 0001", "", +47285, HbA1c_target, 1826, 1841, "HbA1c < 7 . 0 %", "", +47286, PercentageAffected, 1844, 1850, "36 . 4", "", +47287, PercentageAffected, 1858, 1864, "13 . 5", "", +47288, PvalueDiff, 1869, 1881, "p < 0 . 0001", "", +47219, Drug, 1886, 1898, "Lixisenatide", "", +47291, ObservedResult, 1886, 1957, "Lixisenatide significantly lowered FPG and body weight versus placebo .", "", +47289, FastingPlasmaGlucose, 1921, 1924, "FPG", "", +47290, BodyWeight, 1929, 1940, "body weight", "", +47257, Placebo, 1948, 1955, "placebo", "", +47220, Drug, 1992, 2004, "lixisenatide", "", +47292, PostprandialPlasmaGlucose, 2013, 2025, "2 - hour PPG", "", +47258, Placebo, 2033, 2040, "placebo", "", +47293, Mean, 2043, 2050, "LS mean", "", +47297, Reduction, 2055, 2063, "111 . 48", "", +47298, Reduction, 2071, 2077, "3 . 80", "", +47310, Mg_per_deciliter, 2078, 2085, "mg / dL", "", +47299, Reduction, 2090, 2096, "6 . 19", "", +47300, Reduction, 2104, 2110, "0 . 21", "", +47312, Millimoles_per_litre, 2111, 2119, "mmol / L", "", +47314, PvalueDiff, 2124, 2136, "p < 0 . 0001", "", +47294, EndPointDescription, 2143, 2160, "glucose excursion", "", +47301, Reduction, 2165, 2172, "94 . 11", "", +47303, Increment, 2180, 2186, "6 . 24", "", +47311, Mg_per_deciliter, 2187, 2194, "mg / dL", "", +47302, Reduction, 2199, 2205, "5 . 22", "", +47304, Increment, 2213, 2219, "0 . 35", "", +47313, Millimoles_per_litre, 2220, 2228, "mmol / L", "", +47305, ObservedResult, 2239, 2246, "reduced", "", +47306, EndPointDescription, 2247, 2264, "2 - hour glucagon", "", +47309, InsulinDose, 2267, 2274, "insulin", "", +47307, EndPointDescription, 2277, 2287, "proinsulin", "", +47308, EndPointDescription, 2294, 2305, "C - peptide", "", +47295, EndPointDescription, 2326, 2329, "AEs", "", +47315, PercentageAffected, 2334, 2340, "68 . 3", "", +47221, Drug, 2347, 2359, "lixisenatide", "", +47316, PercentageAffected, 2364, 2370, "61 . 1", "", +47259, Placebo, 2377, 2384, "placebo", "", +47319, EndPointDescription, 2395, 2399, "SAEs", "or rather subgroup? ", +47317, PercentageAffected, 2402, 2407, "3 . 5", "", +47318, PercentageAffected, 2417, 2422, "5 . 6", "", +47222, Drug, 2442, 2454, "Lixisenatide", "", +47321, SymptomaticHypoglycemia, 2486, 2510, "symptomatic hypoglycemia", "", +47260, Placebo, 2518, 2525, "placebo", "", +47322, PercentageAffected, 2528, 2534, "15 . 3", "", +47323, PercentageAffected, 2542, 2548, "12 . 3", "", +47326, ObservedResult, 2570, 2637, "one severe episode of hypoglycemia was reported with lixisenatide .", "", +47325, SubGroupDescription, 2574, 2604, "severe episode of hypoglycemia", "", +47324, Hypoglycemia, 2592, 2604, "hypoglycemia", "", +47223, Drug, 2623, 2635, "lixisenatide", "", +47214, Frequency, 2652, 2664, "Once - daily", "", +47330, ConclusionComment, 2652, 2867, "Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .", "", +47224, Drug, 2665, 2677, "lixisenatide", "", +47327, SymptomaticHypoglycemia, 2792, 2825, "symptomatic / severe hypoglycemia", "", +47328, SevereHypoglycemia, 2806, 2825, "severe hypoglycemia", "", +47329, BodyWeight, 2840, 2846, "weight", "", +47271, Duration, 2857, 2865, "24 weeks", "", +47331, PMID, 3005, 3013, "24650952", "", diff --git a/data/dm2 24650952_kwoodley.n-triples b/data/dm2 24650952_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24650952_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24824197_admin.annodb b/data/dm2 24824197_admin.annodb new file mode 100644 index 0000000..efacb28 --- /dev/null +++ b/data/dm2 24824197_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +1, PublicationYear, 13, 17, "2014", "", " \"2014\"." +2, Linagliptin, 98, 109, "Linagliptin", "", +23, Title, 98, 327, "Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .", "", " \"Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .\"." +104, WeightGain, 145, 156, "weight gain", "", +12, Hypoglycemia, 160, 173, "hypoglycaemia", "", +19, Precondition, 177, 277, "patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone", "", +15, Type2Diabetes, 191, 206, "type 2 diabetes", "", " ." +17, Metformin, 251, 260, "metformin", "", +18, Pioglitazone, 265, 277, "pioglitazone", "", +20, Duration, 282, 291, "24 - week", "", " \"24 - week\"." +21, Randomized, 292, 302, "randomized", "", " ." +22, DoubleBlind, 305, 319, "double - blind", "", " ." +24, Author, 328, 335, "Bajaj M", "", " \"Bajaj M\"." +25, Author, 344, 352, "Gilman R", "", " \"Gilman R\"." +26, Author, 355, 362, "Patel S", "", " \"Patel S\"." +27, Author, 365, 386, "Kempthorne - Rawson J", "", " \"Kempthorne - Rawson J\"." +28, Author, 389, 411, "Lewis - D ' Agostino D", "", " \"Lewis - D ' Agostino D\"." +29, Author, 414, 423, "Woerle HJ", "", " \"Woerle HJ\"." +30, USA, 492, 494, "TX", "", " ." +36, ObjectiveDescription, 504, 713, "To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .", "", " \"To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .\"." +3, Linagliptin, 585, 596, "linagliptin", "", +35, Precondition, 600, 711, "patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone", "", " \"patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone\"." +16, Type2Diabetes, 614, 640, "Type   2 diabetes mellitus", "", +31, Metformin, 685, 694, "metformin", "", +33, Pioglitazone, 699, 711, "pioglitazone", "", +37, Multicenter, 735, 749, "multi - centre", "", " ." +39, Randomized, 764, 774, "randomized", "", +40, DoubleBlind, 777, 791, "double - blind", "", +41, Placebo, 794, 801, "placebo", "", +4, Linagliptin, 831, 842, "linagliptin", "", " ." +48, DoseValue, 843, 844, "5", "", " \"5\"." +49, mg, 847, 849, "mg", "", " ." +50, Frequency, 850, 860, "once daily", "", " \"once daily\"." +51, NumberPatientsArm, 869, 872, "183", "", " \"183\"." +42, Placebo, 879, 886, "placebo", "", " ." +52, NumberPatientsArm, 895, 897, "89", "", " \"89\"." +32, Metformin, 915, 924, "metformin", "", +34, Pioglitazone, 929, 941, "pioglitazone", "", +53, TimePoint, 985, 993, "baseline", "", " \"89\"." +56, HbA1c, 997, 1017, "glycated haemoglobin", "", +57, HbA1c, 1020, 1025, "HbA1c", "", +140, Duration, 1034, 1044, "24   weeks", "", +106285, AggregationMethod, 1061, 1094, "placebo - corrected adjusted mean", "", +58, HbA1c, 1112, 1117, "HbA1c", "", " ." +62, TimePoint, 1123, 1131, "baseline", "", +55, TimePoint, 1135, 1145, "24   weeks", "", +106287, DiffGroupAbsValue, 1150, 1153, "- 6", "", " \"- 6\"." +106289, SdErrorDiff, 1156, 1157, "1", "", " \"1\"." +79861, Millimoles_per_mole, 1160, 1170, "mmol / mol", "", " ." +67, Reduction, 1175, 1181, "0 . 57", "", +148, SdErrorChangeValue, 1184, 1190, "0 . 13", "", +69, Percentage, 1193, 1194, "%", "", +75820, PvalueDiff, 1199, 1213, "P  <  0 . 0001", "", " \"P  <  0 . 0001\"." +75822, SubGroupDescription, 1221, 1268, "patients with baseline HbA1c ≥  53   mmol / mol", "", " \"patients with baseline HbA1c ≥  53   mmol / mol\". \"patients with baseline HbA1c ≥  53   mmol / mol\"." +79862, Millimoles_per_mole, 1258, 1268, "mmol / mol", "", +74, BaseLineValue, 1271, 1276, "7 . 0", "", +75, Percentage, 1277, 1278, "%", "", +76, PercentageAffected, 1283, 1289, "32 . 4", "", " \"32 . 4\"." +5, Linagliptin, 1311, 1322, "linagliptin", "", +77, PercentageAffected, 1333, 1339, "13 . 8", "", " \"13 . 8\"." +44, Placebo, 1349, 1356, "placebo", "", +78, HbA1c_target, 1372, 1383, "HbA1c <  53", "", " ." +79863, Millimoles_per_mole, 1386, 1396, "mmol / mol", "", +79, ResultMeasuredValue, 1399, 1404, "7 . 0", "", +80, Percentage, 1405, 1406, "%", "", +106291, AggregationMethod, 1411, 1421, "odds ratio", "", +106290, DiffGroupAbsValue, 1424, 1430, "2 . 94", "", " \"2 . 94\"." +166, PvalueDiff, 1433, 1447, "P  =  0 . 0033", "", " \"P  =  0 . 0033\"." +106284, AggregationMethod, 1456, 1489, "placebo - corrected adjusted mean", "", +60, TimePoint, 1509, 1517, "baseline", "", +83, FastingPlasmaGlucose, 1521, 1543, "fasting plasma glucose", "", " ." +61, TimePoint, 1547, 1556, "week   24", "", " \"week   24\". \"week   24\"." +106286, DiffGroupAbsValue, 1561, 1569, "- 0 . 57", "", " \"- 0 . 57\"." +106288, SdErrorDiff, 1572, 1578, "0 . 26", "", " \"0 . 26\"." +88, Millimoles_per_litre, 1581, 1589, "mmol / l", "", " ." +85, Reduction, 1594, 1600, "10 . 4", "", +175, SdErrorChangeValue, 1603, 1608, "4 . 7", "", +89, Mg_per_deciliter, 1611, 1618, "mg / dl", "", +75823, PvalueDiff, 1623, 1637, "P  =  0 . 0280", "", " \"P  =  0 . 0280\"." +91, EndPointDescription, 1659, 1681, "serious adverse events", "", " . ." +92, PercentageAffected, 1686, 1691, "2 . 2", "", " \"2 . 2\"." +6, Linagliptin, 1699, 1710, "linagliptin", "", +93, PercentageAffected, 1715, 1720, "3 . 4", "", " \"3 . 4\"." +45, Placebo, 1728, 1735, "placebo", "", +13, Hypoglycemia, 1761, 1774, "hypoglycaemia", "", " ." +94, PercentageAffected, 1787, 1792, "5 . 5", "", " \"5 . 5\"." +7, Linagliptin, 1802, 1813, "linagliptin", "", +95, PercentageAffected, 1824, 1829, "5 . 6", "", " \"5 . 6\"." +47, Placebo, 1839, 1846, "placebo", "", +96, ObservedResult, 1855, 1884, "No meaningful changes in mean", "", +194, Mean, 1880, 1884, "mean", "", +11, BodyWeight, 1885, 1896, "body weight", "", +96, ObservedResult, 1897, 1924, "were noted for either group", "", +8, Linagliptin, 1941, 1952, "Linagliptin", "", +99, ConclusionComment, 1941, 2193, "Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .", "", " \"Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .\"." +97, Metformin, 1976, 1985, "metformin", "", +98, Pioglitazone, 1990, 2002, "pioglitazone", "", +14, Hypoglycemia, 2116, 2129, "hypoglycaemia", "", +200, WeightGain, 2133, 2144, "weight gain", "", +202, UK, 2290, 2292, "UK", "", +100, PMID, 2351, 2359, "24824197", "", " \"24824197\"." diff --git a/data/dm2 24824197_admin.n-triples b/data/dm2 24824197_admin.n-triples new file mode 100644 index 0000000..71f8b74 --- /dev/null +++ b/data/dm2 24824197_admin.n-triples @@ -0,0 +1,178 @@ +# RDF export of group: Publication + . + "Publication 57352" . + "Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study ." . + "Bajaj M" . + "2014" . + "Diabet Med ." . + "24824197" . + . + "Gilman R" . + "Patel S" . + "Kempthorne - Rawson J" . + "Lewis - D ' Agostino D" . + "Woerle HJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 57359" . + "To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone ." . + "24 - week" . + . + . + . + "Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 57375" . + "patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + "183" . + . + . + . + . + . + . + . + "pla" . + "89" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lin" . + . + "once daily" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lin" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . + . + "hbat 1" . + . + "32 . 4" . + "patients with baseline HbA1c ≥  53   mmol / mol" . + . + "hbat 2" . + . + "13 . 8" . + "patients with baseline HbA1c ≥  53   mmol / mol" . + . + "fpg 1" . + . + "week   24" . + . + "fpg 2" . + . + "week   24" . + . + "ae 1" . + . + "2 . 2" . + . + "ae 2" . + . + "3 . 4" . + . + "hyp 1" . + . + "5 . 5" . + . + "hyp 2" . + . + "5 . 6" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 6" . + "P  <  0 . 0001" . + "1" . + . + . + . + "hbat" . + "2 . 94" . + "P  =  0 . 0033" . + . + . + . + "fpg" . + "- 0 . 57" . + "P  =  0 . 0280" . + "0 . 26" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24824197_akramersunderbrink.annodb b/data/dm2 24824197_akramersunderbrink.annodb new file mode 100644 index 0000000..1ccc159 --- /dev/null +++ b/data/dm2 24824197_akramersunderbrink.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59778, Journal, 0, 10, "Diabet Med", "", +59779, PublicationYear, 13, 17, "2014", "", +59780, Linagliptin, 98, 109, "Linagliptin", "", +59789, Title, 98, 327, "Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .", "", +59781, WeightGain, 145, 156, "weight gain", "", +59782, Hypoglycemia, 160, 173, "hypoglycaemia", "", +59783, Type2Diabetes, 191, 206, "type 2 diabetes", "", +59784, Metformin, 251, 260, "metformin", "", +59785, Pioglitazone, 265, 277, "pioglitazone", "", +59786, Duration, 282, 291, "24 - week", "", +59787, Randomized, 292, 302, "randomized", "", +59788, DoubleBlind, 305, 319, "double - blind", "", +59790, Author, 328, 335, "Bajaj M", "", +59791, Author, 344, 352, "Gilman R", "", +59792, Author, 355, 362, "Patel S", "", +59793, Author, 365, 386, "Kempthorne - Rawson J", "", +59794, Author, 389, 411, "Lewis - D ' Agostino D", "", +59795, Author, 414, 423, "Woerle HJ", "", +59800, ObjectiveDescription, 504, 713, "To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .", "", +59796, Linagliptin, 585, 596, "linagliptin", "", +59797, Type2Diabetes, 614, 640, "Type   2 diabetes mellitus", "", +59798, Metformin, 685, 694, "metformin", "", +59799, Pioglitazone, 699, 711, "pioglitazone", "", +59801, Multicenter, 735, 749, "multi - centre", "", +59802, Randomized, 764, 774, "randomized", "", +59803, DoubleBlind, 777, 791, "double - blind", "", +59804, Placebo, 794, 801, "placebo", "", +59805, Linagliptin, 831, 842, "linagliptin", "", +59806, DoseValue, 843, 849, "5   mg", "", +59807, mg, 847, 849, "mg", "", +59808, Frequency, 850, 860, "once daily", "", +59809, NumberPatientsArm, 869, 872, "183", "", +59811, Placebo, 879, 886, "placebo", "", +59810, NumberPatientsArm, 895, 897, "89", "", +59812, Metformin, 915, 924, "metformin", "", +59813, Pioglitazone, 929, 941, "pioglitazone", "", +59814, TimePoint, 985, 993, "baseline", "", +59815, HbA1c, 997, 1017, "glycated haemoglobin", "", +59816, HbA1c, 1020, 1025, "HbA1c", "", +59817, Duration, 1034, 1044, "24   weeks", "", +59818, Placebo, 1061, 1068, "placebo", "", +59846, Mean, 1090, 1094, "mean", "", +59819, HbA1c, 1112, 1117, "HbA1c", "", +59820, TimePoint, 1123, 1131, "baseline", "", +59821, TimePoint, 1135, 1145, "24   weeks", "", +59822, ChangeValue, 1150, 1153, "- 6", "", +59824, SdErrorChangeValue, 1156, 1157, "1", "", +59826, ConcentrationUnit, 1160, 1170, "mmol / mol", "", +59823, ChangeValue, 1173, 1181, "- 0 . 57", "", +59825, SdErrorChangeValue, 1184, 1190, "0 . 13", "", +59827, Percentage, 1193, 1194, "%", "", +59828, PValueChangeValue, 1199, 1213, "P  <  0 . 0001", "", +59829, TimePoint, 1235, 1243, "baseline", "", +59838, SubGroupDescription, 1235, 1280, "baseline HbA1c ≥  53   mmol / mol ( 7 . 0 % )", "", +59830, HbA1c, 1244, 1249, "HbA1c", "", +59831, ConcentrationUnit, 1258, 1268, "mmol / mol", "", +59832, Percentage, 1277, 1278, "%", "", +59839, PercentageAffected, 1283, 1289, "32 . 4", "", +59833, Percentage, 1290, 1291, "%", "", +59836, Linagliptin, 1311, 1322, "linagliptin", "", +59840, PercentageAffected, 1333, 1339, "13 . 8", "", +59834, Percentage, 1340, 1341, "%", "", +59837, Placebo, 1349, 1356, "placebo", "", +59841, HbA1c_target, 1372, 1408, "HbA1c <  53   mmol / mol ( 7 . 0 % )", "", +59842, ConcentrationUnit, 1386, 1396, "mmol / mol", "", +59835, Percentage, 1405, 1406, "%", "", +59843, PvalueDiff, 1433, 1447, "P  =  0 . 0033", "", +59844, Placebo, 1456, 1463, "placebo", "", +59845, Mean, 1485, 1489, "mean", "", +59847, TimePoint, 1509, 1517, "baseline", "", +59849, FastingPlasmaGlucose, 1521, 1543, "fasting plasma glucose", "", +59848, TimePoint, 1547, 1556, "week   24", "", +59850, ChangeValue, 1561, 1569, "- 0 . 57", "", +59851, SdErrorChangeValue, 1572, 1578, "0 . 26", "", +59853, Millimoles_per_litre, 1581, 1589, "mmol / l", "", +59854, ChangeValue, 1592, 1600, "- 10 . 4", "", +59852, SdErrorChangeValue, 1603, 1608, "4 . 7", "", +59855, Mg_per_deciliter, 1611, 1618, "mg / dl", "", +59856, PValueChangeValue, 1623, 1637, "P  =  0 . 0280", "", +59857, EndPointDescription, 1659, 1681, "serious adverse events", "", +59863, PercentageAffected, 1686, 1691, "2 . 2", "", +59867, Percentage, 1692, 1693, "%", "", +59858, Linagliptin, 1699, 1710, "linagliptin", "", +59864, PercentageAffected, 1715, 1720, "3 . 4", "", +59869, Percentage, 1721, 1722, "%", "", +59859, Placebo, 1728, 1735, "placebo", "", +59862, Hypoglycemia, 1738, 1774, "Investigator - defined hypoglycaemia", "", +59866, PercentageAffected, 1787, 1792, "5 . 5", "", +59870, Percentage, 1793, 1794, "%", "", +59861, Linagliptin, 1802, 1813, "linagliptin", "", +59865, PercentageAffected, 1824, 1829, "5 . 6", "", +59871, Percentage, 1830, 1831, "%", "", +59860, Placebo, 1839, 1846, "placebo", "", +59872, Mean, 1880, 1884, "mean", "", +59873, BodyWeight, 1885, 1896, "body weight", "", +59874, Linagliptin, 1941, 1952, "Linagliptin", "", +59879, ConclusionComment, 1941, 2193, "Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .", "", +59875, Metformin, 1976, 1985, "metformin", "", +59876, Pioglitazone, 1990, 2002, "pioglitazone", "", +59877, Hypoglycemia, 2116, 2129, "hypoglycaemia", "", +59878, WeightGain, 2133, 2144, "weight gain", "", +59880, UK, 2290, 2292, "UK", "", +59881, PMID, 2351, 2359, "24824197", "", diff --git a/data/dm2 24824197_akramersunderbrink.n-triples b/data/dm2 24824197_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24824197_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24824197_export.csv b/data/dm2 24824197_export.csv new file mode 100644 index 0000000..c9c3005 --- /dev/null +++ b/data/dm2 24824197_export.csv @@ -0,0 +1,522 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +279, 1, 1, 1, 0, 6, 0, 6, "Diabet" +279, 1, 2, 2, 7, 10, 7, 10, "Med" +279, 1, 3, 3, 11, 12, 11, 12, "." +279, 2, 1, 4, 0, 4, 13, 17, "2014" +279, 2, 2, 5, 5, 8, 18, 21, "Dec" +279, 2, 3, 6, 9, 10, 22, 23, ";" +279, 2, 4, 7, 11, 13, 24, 26, "31" +279, 2, 5, 8, 14, 15, 27, 28, "(" +279, 2, 6, 9, 16, 18, 29, 31, "12" +279, 2, 7, 10, 19, 20, 32, 33, ")" +279, 2, 8, 11, 21, 22, 34, 35, ":" +279, 2, 9, 12, 23, 27, 36, 40, "1505" +279, 2, 10, 13, 28, 29, 41, 42, "-" +279, 2, 11, 14, 30, 32, 43, 45, "14" +279, 2, 12, 15, 33, 34, 46, 47, "." +279, 2, 13, 16, 35, 38, 48, 51, "doi" +279, 2, 14, 17, 39, 40, 52, 53, ":" +279, 2, 15, 18, 41, 43, 54, 56, "10" +279, 2, 16, 19, 44, 45, 57, 58, "." +279, 2, 17, 20, 46, 50, 59, 63, "1111" +279, 2, 18, 21, 51, 52, 64, 65, "/" +279, 2, 19, 22, 53, 56, 66, 69, "dme" +279, 2, 20, 23, 57, 58, 70, 71, "." +279, 2, 21, 24, 59, 64, 72, 77, "12495" +279, 2, 22, 25, 65, 66, 78, 79, "." +279, 3, 1, 26, 0, 4, 80, 84, "Epub" +279, 3, 2, 27, 5, 9, 85, 89, "2014" +279, 3, 3, 28, 10, 13, 90, 93, "Jul" +279, 3, 4, 29, 14, 15, 94, 95, "7" +279, 3, 5, 30, 16, 17, 96, 97, "." +279, 4, 1, 31, 0, 11, 98, 109, "Linagliptin" +279, 4, 2, 32, 12, 20, 110, 118, "improved" +279, 4, 3, 33, 21, 30, 119, 128, "glycaemic" +279, 4, 4, 34, 31, 38, 129, 136, "control" +279, 4, 5, 35, 39, 46, 137, 144, "without" +279, 4, 6, 36, 47, 53, 145, 151, "weight" +279, 4, 7, 37, 54, 58, 152, 156, "gain" +279, 4, 8, 38, 59, 61, 157, 159, "or" +279, 4, 9, 39, 62, 75, 160, 173, "hypoglycaemia" +279, 4, 10, 40, 76, 78, 174, 176, "in" +279, 4, 11, 41, 79, 87, 177, 185, "patients" +279, 4, 12, 42, 88, 92, 186, 190, "with" +279, 4, 13, 43, 93, 97, 191, 195, "type" +279, 4, 14, 44, 98, 99, 196, 197, "2" +279, 4, 15, 45, 100, 108, 198, 206, "diabetes" +279, 4, 16, 46, 109, 121, 207, 219, "inadequately" +279, 4, 17, 47, 122, 132, 220, 230, "controlled" +279, 4, 18, 48, 133, 135, 231, 233, "by" +279, 4, 19, 49, 136, 137, 234, 235, "a" +279, 4, 20, 50, 138, 149, 236, 247, "combination" +279, 4, 21, 51, 150, 152, 248, 250, "of" +279, 4, 22, 52, 153, 162, 251, 260, "metformin" +279, 4, 23, 53, 163, 166, 261, 264, "and" +279, 4, 24, 54, 167, 179, 265, 277, "pioglitazone" +279, 4, 25, 55, 180, 181, 278, 279, ":" +279, 4, 26, 56, 182, 183, 280, 281, "a" +279, 4, 27, 57, 184, 186, 282, 284, "24" +279, 4, 28, 58, 187, 188, 285, 286, "-" +279, 4, 29, 59, 189, 193, 287, 291, "week" +279, 4, 30, 60, 194, 204, 292, 302, "randomized" +279, 4, 31, 61, 205, 206, 303, 304, "," +279, 4, 32, 62, 207, 213, 305, 311, "double" +279, 4, 33, 63, 214, 215, 312, 313, "-" +279, 4, 34, 64, 216, 221, 314, 319, "blind" +279, 4, 35, 65, 222, 227, 320, 325, "study" +279, 4, 36, 66, 228, 229, 326, 327, "." +279, 5, 1, 67, 0, 5, 328, 333, "Bajaj" +279, 5, 2, 68, 6, 7, 334, 335, "M" +279, 5, 3, 69, 8, 9, 336, 337, "(" +279, 5, 4, 70, 10, 11, 338, 339, "1" +279, 5, 5, 71, 12, 13, 340, 341, ")" +279, 5, 6, 72, 14, 15, 342, 343, "," +279, 5, 7, 73, 16, 22, 344, 350, "Gilman" +279, 5, 8, 74, 23, 24, 351, 352, "R" +279, 5, 9, 75, 25, 26, 353, 354, "," +279, 5, 10, 76, 27, 32, 355, 360, "Patel" +279, 5, 11, 77, 33, 34, 361, 362, "S" +279, 5, 12, 78, 35, 36, 363, 364, "," +279, 5, 13, 79, 37, 47, 365, 375, "Kempthorne" +279, 5, 14, 80, 48, 49, 376, 377, "-" +279, 5, 15, 81, 50, 56, 378, 384, "Rawson" +279, 5, 16, 82, 57, 58, 385, 386, "J" +279, 5, 17, 83, 59, 60, 387, 388, "," +279, 5, 18, 84, 61, 66, 389, 394, "Lewis" +279, 5, 19, 85, 67, 68, 395, 396, "-" +279, 5, 20, 86, 69, 70, 397, 398, "D" +279, 5, 21, 87, 71, 72, 399, 400, "'" +279, 5, 22, 88, 73, 81, 401, 409, "Agostino" +279, 5, 23, 89, 82, 83, 410, 411, "D" +279, 5, 24, 90, 84, 85, 412, 413, "," +279, 5, 25, 91, 86, 92, 414, 420, "Woerle" +279, 5, 26, 92, 93, 95, 421, 423, "HJ" +279, 5, 27, 93, 96, 97, 424, 425, "." +279, 6, 1, 94, 0, 6, 426, 432, "Author" +279, 6, 2, 95, 7, 18, 433, 444, "information" +279, 6, 3, 96, 19, 20, 445, 446, ":" +279, 6, 4, 97, 21, 22, 447, 448, "(" +279, 6, 5, 98, 23, 24, 449, 450, "1" +279, 6, 6, 99, 25, 26, 451, 452, ")" +279, 6, 7, 100, 27, 33, 453, 459, "Baylor" +279, 6, 8, 101, 34, 41, 460, 467, "College" +279, 6, 9, 102, 42, 44, 468, 470, "of" +279, 6, 10, 103, 45, 53, 471, 479, "Medicine" +279, 6, 11, 104, 54, 55, 480, 481, "," +279, 6, 12, 105, 56, 63, 482, 489, "Houston" +279, 6, 13, 106, 64, 65, 490, 491, "," +279, 6, 14, 107, 66, 68, 492, 494, "TX" +279, 6, 15, 108, 69, 70, 495, 496, "." +279, 7, 1, 109, 0, 4, 497, 501, "AIMS" +279, 7, 2, 110, 5, 6, 502, 503, ":" +279, 7, 3, 111, 7, 9, 504, 506, "To" +279, 7, 4, 112, 10, 21, 507, 518, "investigate" +279, 7, 5, 113, 22, 25, 519, 522, "the" +279, 7, 6, 114, 26, 34, 523, 531, "efficacy" +279, 7, 7, 115, 35, 38, 532, 535, "and" +279, 7, 8, 116, 39, 45, 536, 542, "safety" +279, 7, 9, 117, 46, 48, 543, 545, "of" +279, 7, 10, 118, 49, 52, 546, 549, "the" +279, 7, 11, 119, 53, 63, 550, 560, "dipeptidyl" +279, 7, 12, 120, 64, 73, 561, 570, "peptidase" +279, 7, 13, 121, 74, 75, 571, 572, "-" +279, 7, 14, 122, 76, 77, 573, 574, "4" +279, 7, 15, 123, 78, 87, 575, 584, "inhibitor" +279, 7, 16, 124, 88, 99, 585, 596, "linagliptin" +279, 7, 17, 125, 100, 102, 597, 599, "in" +279, 7, 18, 126, 103, 111, 600, 608, "patients" +279, 7, 19, 127, 112, 116, 609, 613, "with" +279, 7, 20, 128, 117, 121, 614, 618, "Type" +279, 7, 21, 129, 122, 123, 619, 620, " " +279, 7, 22, 130, 124, 125, 621, 622, "2" +279, 7, 23, 131, 126, 134, 623, 631, "diabetes" +279, 7, 24, 132, 135, 143, 632, 640, "mellitus" +279, 7, 25, 133, 144, 156, 641, 653, "inadequately" +279, 7, 26, 134, 157, 167, 654, 664, "controlled" +279, 7, 27, 135, 168, 170, 665, 667, "by" +279, 7, 28, 136, 171, 172, 668, 669, "a" +279, 7, 29, 137, 173, 184, 670, 681, "combination" +279, 7, 30, 138, 185, 187, 682, 684, "of" +279, 7, 31, 139, 188, 197, 685, 694, "metformin" +279, 7, 32, 140, 198, 201, 695, 698, "and" +279, 7, 33, 141, 202, 214, 699, 711, "pioglitazone" +279, 7, 34, 142, 215, 216, 712, 713, "." +279, 8, 1, 143, 0, 7, 714, 721, "METHODS" +279, 8, 2, 144, 8, 9, 722, 723, ":" +279, 8, 3, 145, 10, 14, 724, 728, "This" +279, 8, 4, 146, 15, 18, 729, 732, "was" +279, 8, 5, 147, 19, 20, 733, 734, "a" +279, 8, 6, 148, 21, 26, 735, 740, "multi" +279, 8, 7, 149, 27, 28, 741, 742, "-" +279, 8, 8, 150, 29, 35, 743, 749, "centre" +279, 8, 9, 151, 36, 37, 750, 751, "," +279, 8, 10, 152, 38, 43, 752, 757, "phase" +279, 8, 11, 153, 44, 45, 758, 759, " " +279, 8, 12, 154, 46, 47, 760, 761, "3" +279, 8, 13, 155, 48, 49, 762, 763, "," +279, 8, 14, 156, 50, 60, 764, 774, "randomized" +279, 8, 15, 157, 61, 62, 775, 776, "," +279, 8, 16, 158, 63, 69, 777, 783, "double" +279, 8, 17, 159, 70, 71, 784, 785, "-" +279, 8, 18, 160, 72, 77, 786, 791, "blind" +279, 8, 19, 161, 78, 79, 792, 793, "," +279, 8, 20, 162, 80, 87, 794, 801, "placebo" +279, 8, 21, 163, 88, 89, 802, 803, "-" +279, 8, 22, 164, 90, 100, 804, 814, "controlled" +279, 8, 23, 165, 101, 106, 815, 820, "study" +279, 8, 24, 166, 107, 116, 821, 830, "comparing" +279, 8, 25, 167, 117, 128, 831, 842, "linagliptin" +279, 8, 26, 168, 129, 130, 843, 844, "5" +279, 8, 27, 169, 131, 132, 845, 846, " " +279, 8, 28, 170, 133, 135, 847, 849, "mg" +279, 8, 29, 171, 136, 140, 850, 854, "once" +279, 8, 30, 172, 141, 146, 855, 860, "daily" +279, 8, 31, 173, 147, 148, 861, 862, "(" +279, 8, 32, 174, 149, 150, 863, 864, "n" +279, 8, 33, 175, 151, 154, 865, 868, " = " +279, 8, 34, 176, 155, 158, 869, 872, "183" +279, 8, 35, 177, 159, 160, 873, 874, ")" +279, 8, 36, 178, 161, 164, 875, 878, "and" +279, 8, 37, 179, 165, 172, 879, 886, "placebo" +279, 8, 38, 180, 173, 174, 887, 888, "(" +279, 8, 39, 181, 175, 176, 889, 890, "n" +279, 8, 40, 182, 177, 180, 891, 894, " = " +279, 8, 41, 183, 181, 183, 895, 897, "89" +279, 8, 42, 184, 184, 185, 898, 899, ")" +279, 8, 43, 185, 186, 188, 900, 902, "as" +279, 8, 44, 186, 189, 192, 903, 906, "add" +279, 8, 45, 187, 193, 194, 907, 908, "-" +279, 8, 46, 188, 195, 197, 909, 911, "on" +279, 8, 47, 189, 198, 200, 912, 914, "to" +279, 8, 48, 190, 201, 210, 915, 924, "metformin" +279, 8, 49, 191, 211, 214, 925, 928, "and" +279, 8, 50, 192, 215, 227, 929, 941, "pioglitazone" +279, 8, 51, 193, 228, 229, 942, 943, "." +279, 9, 1, 194, 0, 3, 944, 947, "The" +279, 9, 2, 195, 4, 11, 948, 955, "primary" +279, 9, 3, 196, 12, 20, 956, 964, "endpoint" +279, 9, 4, 197, 21, 24, 965, 968, "was" +279, 9, 5, 198, 25, 28, 969, 972, "the" +279, 9, 6, 199, 29, 35, 973, 979, "change" +279, 9, 7, 200, 36, 40, 980, 984, "from" +279, 9, 8, 201, 41, 49, 985, 993, "baseline" +279, 9, 9, 202, 50, 52, 994, 996, "in" +279, 9, 10, 203, 53, 61, 997, 1005, "glycated" +279, 9, 11, 204, 62, 73, 1006, 1017, "haemoglobin" +279, 9, 12, 205, 74, 75, 1018, 1019, "(" +279, 9, 13, 206, 76, 81, 1020, 1025, "HbA1c" +279, 9, 14, 207, 82, 83, 1026, 1027, ")" +279, 9, 15, 208, 84, 89, 1028, 1033, "after" +279, 9, 16, 209, 90, 92, 1034, 1036, "24" +279, 9, 17, 210, 93, 94, 1037, 1038, " " +279, 9, 18, 211, 95, 100, 1039, 1044, "weeks" +279, 9, 19, 212, 101, 102, 1045, 1046, "." +279, 10, 1, 213, 0, 7, 1047, 1054, "RESULTS" +279, 10, 2, 214, 8, 9, 1055, 1056, ":" +279, 10, 3, 215, 10, 13, 1057, 1060, "The" +279, 10, 4, 216, 14, 21, 1061, 1068, "placebo" +279, 10, 5, 217, 22, 23, 1069, 1070, "-" +279, 10, 6, 218, 24, 33, 1071, 1080, "corrected" +279, 10, 7, 219, 34, 42, 1081, 1089, "adjusted" +279, 10, 8, 220, 43, 47, 1090, 1094, "mean" +279, 10, 9, 221, 48, 49, 1095, 1096, "(" +279, 10, 10, 222, 50, 52, 1097, 1099, "se" +279, 10, 11, 223, 53, 54, 1100, 1101, ")" +279, 10, 12, 224, 55, 61, 1102, 1108, "change" +279, 10, 13, 225, 62, 64, 1109, 1111, "in" +279, 10, 14, 226, 65, 70, 1112, 1117, "HbA1c" +279, 10, 15, 227, 71, 75, 1118, 1122, "from" +279, 10, 16, 228, 76, 84, 1123, 1131, "baseline" +279, 10, 17, 229, 85, 87, 1132, 1134, "to" +279, 10, 18, 230, 88, 90, 1135, 1137, "24" +279, 10, 19, 231, 91, 92, 1138, 1139, " " +279, 10, 20, 232, 93, 98, 1140, 1145, "weeks" +279, 10, 21, 233, 99, 102, 1146, 1149, "was" +279, 10, 22, 234, 103, 104, 1150, 1151, "-" +279, 10, 23, 235, 105, 106, 1152, 1153, "6" +279, 10, 24, 236, 107, 108, 1154, 1155, "(" +279, 10, 25, 237, 109, 110, 1156, 1157, "1" +279, 10, 26, 238, 111, 112, 1158, 1159, ")" +279, 10, 27, 239, 113, 117, 1160, 1164, "mmol" +279, 10, 28, 240, 118, 119, 1165, 1166, "/" +279, 10, 29, 241, 120, 123, 1167, 1170, "mol" +279, 10, 30, 242, 124, 125, 1171, 1172, "[" +279, 10, 31, 243, 126, 127, 1173, 1174, "-" +279, 10, 32, 244, 128, 129, 1175, 1176, "0" +279, 10, 33, 245, 130, 131, 1177, 1178, "." +279, 10, 34, 246, 132, 134, 1179, 1181, "57" +279, 10, 35, 247, 135, 136, 1182, 1183, "(" +279, 10, 36, 248, 137, 138, 1184, 1185, "0" +279, 10, 37, 249, 139, 140, 1186, 1187, "." +279, 10, 38, 250, 141, 143, 1188, 1190, "13" +279, 10, 39, 251, 144, 145, 1191, 1192, ")" +279, 10, 40, 252, 146, 147, 1193, 1194, "%" +279, 10, 41, 253, 148, 149, 1195, 1196, "]" +279, 10, 42, 254, 150, 151, 1197, 1198, "(" +279, 10, 43, 255, 152, 153, 1199, 1200, "P" +279, 10, 44, 256, 154, 157, 1201, 1204, " < " +279, 10, 45, 257, 158, 159, 1205, 1206, "0" +279, 10, 46, 258, 160, 161, 1207, 1208, "." +279, 10, 47, 259, 162, 166, 1209, 1213, "0001" +279, 10, 48, 260, 167, 168, 1214, 1215, ")" +279, 10, 49, 261, 169, 170, 1216, 1217, "." +279, 11, 1, 262, 0, 2, 1218, 1220, "In" +279, 11, 2, 263, 3, 11, 1221, 1229, "patients" +279, 11, 3, 264, 12, 16, 1230, 1234, "with" +279, 11, 4, 265, 17, 25, 1235, 1243, "baseline" +279, 11, 5, 266, 26, 31, 1244, 1249, "HbA1c" +279, 11, 6, 267, 32, 34, 1250, 1252, "≥ " +279, 11, 7, 268, 35, 37, 1253, 1255, "53" +279, 11, 8, 269, 38, 39, 1256, 1257, " " +279, 11, 9, 270, 40, 44, 1258, 1262, "mmol" +279, 11, 10, 271, 45, 46, 1263, 1264, "/" +279, 11, 11, 272, 47, 50, 1265, 1268, "mol" +279, 11, 12, 273, 51, 52, 1269, 1270, "(" +279, 11, 13, 274, 53, 54, 1271, 1272, "7" +279, 11, 14, 275, 55, 56, 1273, 1274, "." +279, 11, 15, 276, 57, 58, 1275, 1276, "0" +279, 11, 16, 277, 59, 60, 1277, 1278, "%" +279, 11, 17, 278, 61, 62, 1279, 1280, ")" +279, 11, 18, 279, 63, 64, 1281, 1282, "," +279, 11, 19, 280, 65, 67, 1283, 1285, "32" +279, 11, 20, 281, 68, 69, 1286, 1287, "." +279, 11, 21, 282, 70, 71, 1288, 1289, "4" +279, 11, 22, 283, 72, 73, 1290, 1291, "%" +279, 11, 23, 284, 74, 76, 1292, 1294, "of" +279, 11, 24, 285, 77, 85, 1295, 1303, "patients" +279, 11, 25, 286, 86, 88, 1304, 1306, "in" +279, 11, 26, 287, 89, 92, 1307, 1310, "the" +279, 11, 27, 288, 93, 104, 1311, 1322, "linagliptin" +279, 11, 28, 289, 105, 110, 1323, 1328, "group" +279, 11, 29, 290, 111, 114, 1329, 1332, "and" +279, 11, 30, 291, 115, 117, 1333, 1335, "13" +279, 11, 31, 292, 118, 119, 1336, 1337, "." +279, 11, 32, 293, 120, 121, 1338, 1339, "8" +279, 11, 33, 294, 122, 123, 1340, 1341, "%" +279, 11, 34, 295, 124, 126, 1342, 1344, "in" +279, 11, 35, 296, 127, 130, 1345, 1348, "the" +279, 11, 36, 297, 131, 138, 1349, 1356, "placebo" +279, 11, 37, 298, 139, 144, 1357, 1362, "group" +279, 11, 38, 299, 145, 153, 1363, 1371, "achieved" +279, 11, 39, 300, 154, 159, 1372, 1377, "HbA1c" +279, 11, 40, 301, 160, 162, 1378, 1380, "< " +279, 11, 41, 302, 163, 165, 1381, 1383, "53" +279, 11, 42, 303, 166, 167, 1384, 1385, " " +279, 11, 43, 304, 168, 172, 1386, 1390, "mmol" +279, 11, 44, 305, 173, 174, 1391, 1392, "/" +279, 11, 45, 306, 175, 178, 1393, 1396, "mol" +279, 11, 46, 307, 179, 180, 1397, 1398, "(" +279, 11, 47, 308, 181, 182, 1399, 1400, "7" +279, 11, 48, 309, 183, 184, 1401, 1402, "." +279, 11, 49, 310, 185, 186, 1403, 1404, "0" +279, 11, 50, 311, 187, 188, 1405, 1406, "%" +279, 11, 51, 312, 189, 190, 1407, 1408, ")" +279, 11, 52, 313, 191, 192, 1409, 1410, "(" +279, 11, 53, 314, 193, 197, 1411, 1415, "odds" +279, 11, 54, 315, 198, 203, 1416, 1421, "ratio" +279, 11, 55, 316, 204, 205, 1422, 1423, " " +279, 11, 56, 317, 206, 207, 1424, 1425, "2" +279, 11, 57, 318, 208, 209, 1426, 1427, "." +279, 11, 58, 319, 210, 212, 1428, 1430, "94" +279, 11, 59, 320, 213, 214, 1431, 1432, ";" +279, 11, 60, 321, 215, 216, 1433, 1434, "P" +279, 11, 61, 322, 217, 220, 1435, 1438, " = " +279, 11, 62, 323, 221, 222, 1439, 1440, "0" +279, 11, 63, 324, 223, 224, 1441, 1442, "." +279, 11, 64, 325, 225, 229, 1443, 1447, "0033" +279, 11, 65, 326, 230, 231, 1448, 1449, ")" +279, 11, 66, 327, 232, 233, 1450, 1451, "." +279, 12, 1, 328, 0, 3, 1452, 1455, "The" +279, 12, 2, 329, 4, 11, 1456, 1463, "placebo" +279, 12, 3, 330, 12, 13, 1464, 1465, "-" +279, 12, 4, 331, 14, 23, 1466, 1475, "corrected" +279, 12, 5, 332, 24, 32, 1476, 1484, "adjusted" +279, 12, 6, 333, 33, 37, 1485, 1489, "mean" +279, 12, 7, 334, 38, 39, 1490, 1491, "(" +279, 12, 8, 335, 40, 42, 1492, 1494, "se" +279, 12, 9, 336, 43, 44, 1495, 1496, ")" +279, 12, 10, 337, 45, 51, 1497, 1503, "change" +279, 12, 11, 338, 52, 56, 1504, 1508, "from" +279, 12, 12, 339, 57, 65, 1509, 1517, "baseline" +279, 12, 13, 340, 66, 68, 1518, 1520, "in" +279, 12, 14, 341, 69, 76, 1521, 1528, "fasting" +279, 12, 15, 342, 77, 83, 1529, 1535, "plasma" +279, 12, 16, 343, 84, 91, 1536, 1543, "glucose" +279, 12, 17, 344, 92, 94, 1544, 1546, "at" +279, 12, 18, 345, 95, 99, 1547, 1551, "week" +279, 12, 19, 346, 100, 101, 1552, 1553, " " +279, 12, 20, 347, 102, 104, 1554, 1556, "24" +279, 12, 21, 348, 105, 108, 1557, 1560, "was" +279, 12, 22, 349, 109, 110, 1561, 1562, "-" +279, 12, 23, 350, 111, 112, 1563, 1564, "0" +279, 12, 24, 351, 113, 114, 1565, 1566, "." +279, 12, 25, 352, 115, 117, 1567, 1569, "57" +279, 12, 26, 353, 118, 119, 1570, 1571, "(" +279, 12, 27, 354, 120, 121, 1572, 1573, "0" +279, 12, 28, 355, 122, 123, 1574, 1575, "." +279, 12, 29, 356, 124, 126, 1576, 1578, "26" +279, 12, 30, 357, 127, 128, 1579, 1580, ")" +279, 12, 31, 358, 129, 133, 1581, 1585, "mmol" +279, 12, 32, 359, 134, 135, 1586, 1587, "/" +279, 12, 33, 360, 136, 137, 1588, 1589, "l" +279, 12, 34, 361, 138, 139, 1590, 1591, "[" +279, 12, 35, 362, 140, 141, 1592, 1593, "-" +279, 12, 36, 363, 142, 144, 1594, 1596, "10" +279, 12, 37, 364, 145, 146, 1597, 1598, "." +279, 12, 38, 365, 147, 148, 1599, 1600, "4" +279, 12, 39, 366, 149, 150, 1601, 1602, "(" +279, 12, 40, 367, 151, 152, 1603, 1604, "4" +279, 12, 41, 368, 153, 154, 1605, 1606, "." +279, 12, 42, 369, 155, 156, 1607, 1608, "7" +279, 12, 43, 370, 157, 158, 1609, 1610, ")" +279, 12, 44, 371, 159, 161, 1611, 1613, "mg" +279, 12, 45, 372, 162, 163, 1614, 1615, "/" +279, 12, 46, 373, 164, 166, 1616, 1618, "dl" +279, 12, 47, 374, 167, 168, 1619, 1620, "]" +279, 12, 48, 375, 169, 170, 1621, 1622, "(" +279, 12, 49, 376, 171, 172, 1623, 1624, "P" +279, 12, 50, 377, 173, 176, 1625, 1628, " = " +279, 12, 51, 378, 177, 178, 1629, 1630, "0" +279, 12, 52, 379, 179, 180, 1631, 1632, "." +279, 12, 53, 380, 181, 185, 1633, 1637, "0280" +279, 12, 54, 381, 186, 187, 1638, 1639, ")" +279, 12, 55, 382, 188, 189, 1640, 1641, "." +279, 13, 1, 383, 0, 3, 1642, 1645, "The" +279, 13, 2, 384, 4, 13, 1646, 1655, "incidence" +279, 13, 3, 385, 14, 16, 1656, 1658, "of" +279, 13, 4, 386, 17, 24, 1659, 1666, "serious" +279, 13, 5, 387, 25, 32, 1667, 1674, "adverse" +279, 13, 6, 388, 33, 39, 1675, 1681, "events" +279, 13, 7, 389, 40, 43, 1682, 1685, "was" +279, 13, 8, 390, 44, 45, 1686, 1687, "2" +279, 13, 9, 391, 46, 47, 1688, 1689, "." +279, 13, 10, 392, 48, 49, 1690, 1691, "2" +279, 13, 11, 393, 50, 51, 1692, 1693, "%" +279, 13, 12, 394, 52, 56, 1694, 1698, "with" +279, 13, 13, 395, 57, 68, 1699, 1710, "linagliptin" +279, 13, 14, 396, 69, 72, 1711, 1714, "and" +279, 13, 15, 397, 73, 74, 1715, 1716, "3" +279, 13, 16, 398, 75, 76, 1717, 1718, "." +279, 13, 17, 399, 77, 78, 1719, 1720, "4" +279, 13, 18, 400, 79, 80, 1721, 1722, "%" +279, 13, 19, 401, 81, 85, 1723, 1727, "with" +279, 13, 20, 402, 86, 93, 1728, 1735, "placebo" +279, 13, 21, 403, 94, 95, 1736, 1737, "." +279, 14, 1, 404, 0, 12, 1738, 1750, "Investigator" +279, 14, 2, 405, 13, 14, 1751, 1752, "-" +279, 14, 3, 406, 15, 22, 1753, 1760, "defined" +279, 14, 4, 407, 23, 36, 1761, 1774, "hypoglycaemia" +279, 14, 5, 408, 37, 45, 1775, 1783, "occurred" +279, 14, 6, 409, 46, 48, 1784, 1786, "in" +279, 14, 7, 410, 49, 50, 1787, 1788, "5" +279, 14, 8, 411, 51, 52, 1789, 1790, "." +279, 14, 9, 412, 53, 54, 1791, 1792, "5" +279, 14, 10, 413, 55, 56, 1793, 1794, "%" +279, 14, 11, 414, 57, 59, 1795, 1797, "of" +279, 14, 12, 415, 60, 63, 1798, 1801, "the" +279, 14, 13, 416, 64, 75, 1802, 1813, "linagliptin" +279, 14, 14, 417, 76, 81, 1814, 1819, "group" +279, 14, 15, 418, 82, 85, 1820, 1823, "and" +279, 14, 16, 419, 86, 87, 1824, 1825, "5" +279, 14, 17, 420, 88, 89, 1826, 1827, "." +279, 14, 18, 421, 90, 91, 1828, 1829, "6" +279, 14, 19, 422, 92, 93, 1830, 1831, "%" +279, 14, 20, 423, 94, 96, 1832, 1834, "of" +279, 14, 21, 424, 97, 100, 1835, 1838, "the" +279, 14, 22, 425, 101, 108, 1839, 1846, "placebo" +279, 14, 23, 426, 109, 114, 1847, 1852, "group" +279, 14, 24, 427, 115, 116, 1853, 1854, "." +279, 15, 1, 428, 0, 2, 1855, 1857, "No" +279, 15, 2, 429, 3, 13, 1858, 1868, "meaningful" +279, 15, 3, 430, 14, 21, 1869, 1876, "changes" +279, 15, 4, 431, 22, 24, 1877, 1879, "in" +279, 15, 5, 432, 25, 29, 1880, 1884, "mean" +279, 15, 6, 433, 30, 34, 1885, 1889, "body" +279, 15, 7, 434, 35, 41, 1890, 1896, "weight" +279, 15, 8, 435, 42, 46, 1897, 1901, "were" +279, 15, 9, 436, 47, 52, 1902, 1907, "noted" +279, 15, 10, 437, 53, 56, 1908, 1911, "for" +279, 15, 11, 438, 57, 63, 1912, 1918, "either" +279, 15, 12, 439, 64, 69, 1919, 1924, "group" +279, 15, 13, 440, 70, 71, 1925, 1926, "." +279, 16, 1, 441, 0, 11, 1927, 1938, "CONCLUSIONS" +279, 16, 2, 442, 12, 13, 1939, 1940, ":" +279, 16, 3, 443, 14, 25, 1941, 1952, "Linagliptin" +279, 16, 4, 444, 26, 28, 1953, 1955, "as" +279, 16, 5, 445, 29, 32, 1956, 1959, "add" +279, 16, 6, 446, 33, 34, 1960, 1961, "-" +279, 16, 7, 447, 35, 37, 1962, 1964, "on" +279, 16, 8, 448, 38, 45, 1965, 1972, "therapy" +279, 16, 9, 449, 46, 48, 1973, 1975, "to" +279, 16, 10, 450, 49, 58, 1976, 1985, "metformin" +279, 16, 11, 451, 59, 62, 1986, 1989, "and" +279, 16, 12, 452, 63, 75, 1990, 2002, "pioglitazone" +279, 16, 13, 453, 76, 84, 2003, 2011, "produced" +279, 16, 14, 454, 85, 96, 2012, 2023, "significant" +279, 16, 15, 455, 97, 100, 2024, 2027, "and" +279, 16, 16, 456, 101, 111, 2028, 2038, "clinically" +279, 16, 17, 457, 112, 122, 2039, 2049, "meaningful" +279, 16, 18, 458, 123, 135, 2050, 2062, "improvements" +279, 16, 19, 459, 136, 138, 2063, 2065, "in" +279, 16, 20, 460, 139, 148, 2066, 2075, "glycaemic" +279, 16, 21, 461, 149, 156, 2076, 2083, "control" +279, 16, 22, 462, 157, 158, 2084, 2085, "," +279, 16, 23, 463, 159, 166, 2086, 2093, "without" +279, 16, 24, 464, 167, 169, 2094, 2096, "an" +279, 16, 25, 465, 170, 180, 2097, 2107, "additional" +279, 16, 26, 466, 181, 185, 2108, 2112, "risk" +279, 16, 27, 467, 186, 188, 2113, 2115, "of" +279, 16, 28, 468, 189, 202, 2116, 2129, "hypoglycaemia" +279, 16, 29, 469, 203, 205, 2130, 2132, "or" +279, 16, 30, 470, 206, 212, 2133, 2139, "weight" +279, 16, 31, 471, 213, 217, 2140, 2144, "gain" +279, 16, 32, 472, 218, 219, 2145, 2146, "(" +279, 16, 33, 473, 220, 228, 2147, 2155, "Clinical" +279, 16, 34, 474, 229, 235, 2156, 2162, "Trials" +279, 16, 35, 475, 236, 244, 2163, 2171, "Registry" +279, 16, 36, 476, 245, 247, 2172, 2174, "No" +279, 16, 37, 477, 248, 249, 2175, 2176, ":" +279, 16, 38, 478, 250, 253, 2177, 2180, "NCT" +279, 16, 39, 479, 254, 262, 2181, 2189, "00996658" +279, 16, 40, 480, 263, 264, 2190, 2191, ")" +279, 16, 41, 481, 265, 266, 2192, 2193, "." +279, 17, 1, 482, 0, 1, 2194, 2195, "©" +279, 17, 2, 483, 2, 6, 2196, 2200, "2014" +279, 17, 3, 484, 7, 10, 2201, 2204, "The" +279, 17, 4, 485, 11, 18, 2205, 2212, "Authors" +279, 17, 5, 486, 19, 20, 2213, 2214, "." +279, 18, 1, 487, 0, 8, 2215, 2223, "Diabetic" +279, 18, 2, 488, 9, 17, 2224, 2232, "Medicine" +279, 18, 3, 489, 18, 27, 2233, 2242, "published" +279, 18, 4, 490, 28, 30, 2243, 2245, "by" +279, 18, 5, 491, 31, 35, 2246, 2250, "John" +279, 18, 6, 492, 36, 41, 2251, 2256, "Wiley" +279, 18, 7, 493, 42, 43, 2257, 2258, "&" +279, 18, 8, 494, 44, 48, 2259, 2263, "Sons" +279, 18, 9, 495, 49, 52, 2264, 2267, "Ltd" +279, 18, 10, 496, 53, 55, 2268, 2270, "on" +279, 18, 11, 497, 56, 62, 2271, 2277, "behalf" +279, 18, 12, 498, 63, 65, 2278, 2280, "of" +279, 18, 13, 499, 66, 74, 2281, 2289, "Diabetes" +279, 18, 14, 500, 75, 77, 2290, 2292, "UK" +279, 18, 15, 501, 78, 79, 2293, 2294, "." +279, 19, 1, 502, 0, 3, 2295, 2298, "DOI" +279, 19, 2, 503, 4, 5, 2299, 2300, ":" +279, 19, 3, 504, 6, 8, 2301, 2303, "10" +279, 19, 4, 505, 9, 10, 2304, 2305, "." +279, 19, 5, 506, 11, 15, 2306, 2310, "1111" +279, 19, 6, 507, 16, 17, 2311, 2312, "/" +279, 19, 7, 508, 18, 21, 2313, 2316, "dme" +279, 19, 8, 509, 22, 23, 2317, 2318, "." +279, 19, 9, 510, 24, 29, 2319, 2324, "12495" +279, 19, 10, 511, 30, 35, 2325, 2330, "PMCID" +279, 19, 11, 512, 36, 37, 2331, 2332, ":" +279, 19, 12, 513, 38, 48, 2333, 2343, "PMC4257097" +279, 19, 13, 514, 49, 53, 2344, 2348, "PMID" +279, 19, 14, 515, 54, 55, 2349, 2350, ":" +279, 19, 15, 516, 56, 64, 2351, 2359, "24824197" +279, 19, 16, 517, 65, 66, 2360, 2361, "[" +279, 19, 17, 518, 67, 74, 2362, 2369, "Indexed" +279, 19, 18, 519, 75, 78, 2370, 2373, "for" +279, 19, 19, 520, 79, 86, 2374, 2381, "MEDLINE" +279, 19, 20, 521, 87, 88, 2382, 2383, "]" diff --git a/data/dm2 24824197_kwoodley.annodb b/data/dm2 24824197_kwoodley.annodb new file mode 100644 index 0000000..6862ba0 --- /dev/null +++ b/data/dm2 24824197_kwoodley.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +47454, Journal, 0, 10, "Diabet Med", "", +47455, PublicationYear, 13, 17, "2014", "", +47456, Linagliptin, 98, 109, "Linagliptin", "", +47477, Title, 98, 327, "Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone : a 24 - week randomized , double - blind study .", "", +47463, BodyWeight, 145, 151, "weight", "", +47466, Hypoglycemia, 160, 173, "hypoglycaemia", "", +47473, Precondition, 177, 277, "patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone", "", +47469, Type2Diabetes, 191, 206, "type 2 diabetes", "", +47471, Metformin, 251, 260, "metformin", "", +47472, Pioglitazone, 265, 277, "pioglitazone", "", +47474, Duration, 282, 291, "24 - week", "", +47475, Randomized, 292, 302, "randomized", "", +47476, DoubleBlind, 305, 319, "double - blind", "", +47478, Author, 328, 335, "Bajaj M", "", +47479, Author, 344, 352, "Gilman R", "", +47480, Author, 355, 362, "Patel S", "", +47481, Author, 365, 386, "Kempthorne - Rawson J", "", +47482, Author, 389, 411, "Lewis - D ' Agostino D", "", +47483, Author, 414, 423, "Woerle HJ", "", +47484, USA, 492, 494, "TX", "", +47490, ObjectiveDescription, 504, 713, "To investigate the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin in patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone .", "", +47457, Linagliptin, 585, 596, "linagliptin", "", +47489, Precondition, 600, 711, "patients with Type   2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone", "", +47470, Type2Diabetes, 614, 640, "Type   2 diabetes mellitus", "", +47485, Metformin, 685, 694, "metformin", "", +47487, Pioglitazone, 699, 711, "pioglitazone", "", +47491, Multicenter, 735, 749, "multi - centre", "", +47492, CTDesign, 752, 761, "phase   3", "", +47493, Randomized, 764, 774, "randomized", "", +47494, DoubleBlind, 777, 791, "double - blind", "", +47495, Placebo, 794, 801, "placebo", "", +47458, Linagliptin, 831, 842, "linagliptin", "", +47502, DoseValue, 843, 844, "5", "", +47503, mg, 847, 849, "mg", "", +47504, Frequency, 850, 860, "once daily", "", +47505, NumberPatientsArm, 869, 872, "183", "", +47496, Placebo, 879, 886, "placebo", "", +47506, NumberPatientsArm, 895, 897, "89", "", +47486, Metformin, 915, 924, "metformin", "", +47488, Pioglitazone, 929, 941, "pioglitazone", "", +47507, TimePoint, 985, 993, "baseline", "", +47510, HbA1c, 997, 1017, "glycated haemoglobin", "", +47511, HbA1c, 1020, 1025, "HbA1c", "", +47508, TimePoint, 1034, 1044, "24   weeks", "", +47497, Placebo, 1061, 1068, "placebo", "", +47517, Mean, 1090, 1101, "mean ( se )", "", +47512, HbA1c, 1112, 1117, "HbA1c", "", +47516, TimePoint, 1123, 1131, "baseline", "", +47509, TimePoint, 1135, 1145, "24   weeks", "", +47523, Reduction, 1152, 1153, "6", "", +47524, Reduction, 1156, 1157, "1", "", +47518, BioAndMedicalUnit, 1160, 1170, "mmol / mol", "", +47525, Reduction, 1175, 1181, "0 . 57", "", +47526, Reduction, 1184, 1190, "0 . 13", "", +47527, Percentage, 1193, 1194, "%", "", +47528, PValueChangeValue, 1199, 1213, "P  <  0 . 0001", "", +47513, HbA1c, 1244, 1249, "HbA1c", "", +47529, BaseLineValue, 1250, 1255, "≥  53", "", +47530, BioAndMedicalUnit, 1258, 1268, "mmol / mol", "", +47532, BaseLineValue, 1271, 1276, "7 . 0", "", +47533, Percentage, 1277, 1278, "%", "", +47534, PercentageAffected, 1283, 1289, "32 . 4", "", +47459, Linagliptin, 1311, 1322, "linagliptin", "", +47535, PercentageAffected, 1333, 1339, "13 . 8", "", +47498, Placebo, 1349, 1356, "placebo", "", +47536, HbA1c_target, 1372, 1383, "HbA1c <  53", "", +47531, BioAndMedicalUnit, 1386, 1396, "mmol / mol", "", +47537, ResultMeasuredValue, 1399, 1404, "7 . 0", "", +47538, Percentage, 1405, 1406, "%", "", +47539, PValueNumAffected, 1433, 1447, "P  =  0 . 0033", "", +47500, Placebo, 1456, 1463, "placebo", "", +47540, Mean, 1485, 1496, "mean ( se )", "", +47514, TimePoint, 1509, 1517, "baseline", "", +47541, FastingPlasmaGlucose, 1521, 1543, "fasting plasma glucose", "", +47515, TimePoint, 1547, 1556, "week   24", "", +47542, Reduction, 1563, 1569, "0 . 57", "", +47544, ResultMeasuredValue, 1572, 1578, "0 . 26", "", +47546, Millimoles_per_litre, 1581, 1589, "mmol / l", "", +47543, Reduction, 1594, 1600, "10 . 4", "", +47545, ResultMeasuredValue, 1603, 1608, "4 . 7", "", +47547, Mg_per_deciliter, 1611, 1618, "mg / dl", "", +47548, PValueChangeValue, 1623, 1637, "P  =  0 . 0280", "", +47549, EndPointDescription, 1659, 1681, "serious adverse events", "", +47550, PercentageAffected, 1686, 1691, "2 . 2", "", +47460, Linagliptin, 1699, 1710, "linagliptin", "", +47551, PercentageAffected, 1715, 1720, "3 . 4", "", +47499, Placebo, 1728, 1735, "placebo", "", +47467, Hypoglycemia, 1761, 1774, "hypoglycaemia", "", +47552, PercentageAffected, 1787, 1792, "5 . 5", "", +47461, Linagliptin, 1802, 1813, "linagliptin", "", +47553, PercentageAffected, 1824, 1829, "5 . 6", "", +47501, Placebo, 1839, 1846, "placebo", "", +47554, ObservedResult, 1855, 1926, "No meaningful changes in mean body weight were noted for either group .", "", +47465, BodyWeight, 1885, 1896, "body weight", "", +47462, Linagliptin, 1941, 1952, "Linagliptin", "", +47557, ConclusionComment, 1941, 2193, "Linagliptin as add - on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control , without an additional risk of hypoglycaemia or weight gain ( Clinical Trials Registry No : NCT 00996658 ) .", "", +47555, Metformin, 1976, 1985, "metformin", "", +47556, Pioglitazone, 1990, 2002, "pioglitazone", "", +47468, Hypoglycemia, 2116, 2129, "hypoglycaemia", "", +47464, BodyWeight, 2133, 2139, "weight", "", +47558, PMID, 2351, 2359, "24824197", "", diff --git a/data/dm2 24824197_kwoodley.n-triples b/data/dm2 24824197_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24824197_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24939043_admin.annodb b/data/dm2 24939043_admin.annodb new file mode 100644 index 0000000..ec3d8b2 --- /dev/null +++ b/data/dm2 24939043_admin.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2014", "", " \"2014\"." +25, Title, 107, 239, "Effect of the sodium glucose co - transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus .", "", " \"Effect of the sodium glucose co - transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus .\"." +79609, Canagliflozin, 165, 178, "canagliflozin", "", +11, EndPointDescription, 182, 195, "plasma volume", "", +23, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", " ." +26, Author, 240, 245, "Sha S", "", " \"Sha S\"." +27, Author, 254, 264, "Polidori D", "", " \"Polidori D\"." +28, Author, 267, 274, "Heise T", "", " \"Heise T\"." +29, Author, 277, 288, "Natarajan J", "", " \"Natarajan J\"." +30, Author, 291, 300, "Farrell K", "", " \"Farrell K\"." +31, Author, 303, 310, "Wang SS", "", " \"Wang SS\"." +32, Author, 313, 319, "Sica D", "", " \"Sica D\"." +33, Author, 322, 334, "Rothenberg P", "", " \"Rothenberg P\"." +34, Author, 337, 356, "Plum - M ö rschel L", "", " \"Plum - M ö rschel L\"." +35, USA, 440, 443, "USA", "", " ." +45, ObjectiveDescription, 452, 615, "To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA1c ) and", "", " \"To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA1c ) and\"." +79611, Canagliflozin, 479, 492, "canagliflozin", "", +12, EndPointDescription, 496, 509, "plasma volume", "", +13, EndPointDescription, 512, 537, "urinary glucose excretion", "", +14, EndPointDescription, 540, 543, "UGE", "", +36, FastingPlasmaGlucose, 548, 570, "fasting plasma glucose", "", +37, FastingPlasmaGlucose, 573, 576, "FPG", "", +40, HbA1c, 581, 601, "glycated haemoglobin", "", +41, HbA1c, 604, 609, "HbA1c", "", +46, ObjectiveDescription, 616, 818, "additional measures of fluid / electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers .", "", " \"additional measures of fluid / electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers .\"." +47, Precondition, 670, 816, "patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers", "", " \"patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers\"." +24, Type2Diabetes, 684, 699, "type 2 diabetes", "", +43, Metformin, 727, 736, "metformin", "", +48, NumberPatientsCT, 844, 846, "36", "", " \"36\"." +49, Randomized, 854, 864, "randomized", "", " ." +50, AllocationRatio, 867, 872, "1 : 1", "", " . ." +79612, Canagliflozin, 886, 899, "canagliflozin", "", " ." +51, DoseValue, 900, 903, "300", "", " \"300\"." +52, mg, 904, 906, "mg", "", " ." +54, Placebo, 910, 917, "placebo", "", " ." +53, Duration, 922, 930, "12 weeks", "", " ." +57, TimePoint, 977, 985, "baseline", "", +58, TimePoint, 993, 1000, "weeks 1", "", +59, TimePoint, 993, 1007, "weeks 1 and 12", "", +15, EndPointDescription, 1030, 1040, "24 - h UGE", "", " . ." +79614, Canagliflozin, 1057, 1070, "canagliflozin", "", +55, Placebo, 1110, 1117, "placebo", "", +60, TimePoint, 1132, 1138, "week 1", "", " \"week 1\". \"week 1\"." +71, Increment, 1141, 1147, "91 . 8", "", " \"91 . 8\"." +73, Reduction, 1155, 1160, "2 . 4", "", " \"2 . 4\"." +75, Gram, 1161, 1162, "g", "", " ." +61, TimePoint, 1169, 1176, "week 12", "", " \"week 12\". \"week 12\"." +72, Increment, 1179, 1185, "82 . 6", "", " \"82 . 6\"." +74, Reduction, 1193, 1198, "0 . 4", "", " \"0 . 4\"." +76, Gram, 1199, 1200, "g", "", +79616, Canagliflozin, 1205, 1218, "Canagliflozin", "", +77, ObservedResult, 1224, 1231, "reduced", "", " \"reduced\". \"reduced\"." +38, FastingPlasmaGlucose, 1237, 1240, "FPG", "", " ." +42, HbA1c, 1245, 1250, "HbA1c", "", " ." +78, ObservedResult, 1253, 1263, "Reductions", "", " \"Reductions\". \"Reductions\". \"Reductions\". \"Reductions\"." +79, BodyWeight, 1267, 1278, "body weight", "", " ." +80, BloodPressure, 1283, 1297, "blood pressure", "", " . ." +62, TimePoint, 1315, 1322, "weeks 1", "", " \"weeks 1\". \"weeks 1\"." +63, TimePoint, 1315, 1329, "weeks 1 and 12", "", " \"weeks 1 and 12\". \"weeks 1 and 12\"." +79621, Canagliflozin, 1332, 1345, "Canagliflozin", "", +16, EndPointDescription, 1356, 1369, "plasma volume", "", " . ." +56, Placebo, 1401, 1408, "placebo", "", +64, TimePoint, 1412, 1418, "week 1", "", " \"week 1\". \"week 1\"." +75919, RelativeReduction, 1423, 1428, "5 . 4", "", " \"5 . 4\"." +75997, RelativeIncrement, 1434, 1439, "4 . 3", "", " \"4 . 3\"." +87, PvalueDiff, 1444, 1454, "p = 0 . 02", "", " \"p = 0 . 02\"." +65, TimePoint, 1494, 1501, "week 12", "", " \"week 12\". \"week 12\"." +75998, RelativeIncrement, 1504, 1509, "4 . 6", "", " \"4 . 6\"." +75999, RelativeIncrement, 1515, 1520, "5 . 8", "", " \"5 . 8\"." +88, PvalueDiff, 1525, 1535, "p = 0 . 76", "", " \"p = 0 . 76\"." +89, ObservedResult, 1540, 1656, "A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12", "", " \"A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12\". \"A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12\"." +17, EndPointDescription, 1571, 1583, "urine volume", "", " . ." +79618, Canagliflozin, 1602, 1615, "canagliflozin", "", +66, TimePoint, 1619, 1625, "week 1", "", " \"week 1\"." +67, TimePoint, 1649, 1656, "week 12", "", " \"week 12\"." +18, EndPointDescription, 1701, 1720, "blood urea nitrogen", "", +19, EndPointDescription, 1723, 1739, "serum creatinine", "", +20, EndPointDescription, 1744, 1755, "haematocrit", "", " . ." +90, ObservedResult, 1758, 1785, "remained modestly increased", "", " \"remained modestly increased\". \"remained modestly increased\". \"remained modestly increased\"." +79620, Canagliflozin, 1791, 1804, "canagliflozin", "", +68, TimePoint, 1808, 1815, "week 12", "", " \"week 12\". \"week 12\". \"week 12\"." +79619, Canagliflozin, 1831, 1844, "Canagliflozin", "", +91, ConclusionComment, 1831, 1984, "Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12 .", "", " \"Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12 .\"." +21, EndPointDescription, 1875, 1878, "UGE", "", +39, FastingPlasmaGlucose, 1883, 1886, "FPG", "", +69, Duration, 1892, 1900, "12 weeks", "", +22, EndPointDescription, 1930, 1943, "plasma volume", "", +70, TimePoint, 1975, 1982, "week 12", "", +92, PMID, 2053, 2061, "24939043", "", " \"24939043\"." diff --git a/data/dm2 24939043_admin.n-triples b/data/dm2 24939043_admin.n-triples new file mode 100644 index 0000000..a51bb77 --- /dev/null +++ b/data/dm2 24939043_admin.n-triples @@ -0,0 +1,266 @@ +# RDF export of group: Publication + . + "Publication 60954" . + "Effect of the sodium glucose co - transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus ." . + "Sha S" . + "2014" . + "Diabetes Obes Metab ." . + "24939043" . + . + "Polidori D" . + "Heise T" . + "Natarajan J" . + "Farrell K" . + "Wang SS" . + "Sica D" . + "Rothenberg P" . + "Plum - M ö rschel L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 60961" . + "To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA1c ) and" . + "36" . + "12 weeks" . + . + . + . + . + "Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12 ." . + . + . + . + . + . + . + "additional measures of fluid / electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers ." . + . +# RDF export of group: Population + . + "Population 60977" . + "patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers" . + . + . + . +# RDF export of group: Endpoint + . + "uge" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "hba" . + . + . + . + . + . + "bw" . + . + . + . + . + . + "bp" . + . + . + . + . + . + . + "pv" . + . + . + . + . + . + . + "ur" . + . + . + . + . + . + . + "bn" . + . + . + . + . + . + . + "sc" . + . + . + . + . + . + . + "hae" . + . + . + . + . + . +# RDF export of group: Arm + . + "can" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "can" . + . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "can" . + . + "300" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "uge 1" . + . + "91 . 8" . + "week 1" . + . + "uge 2" . + . + "2 . 4" . + "week 1" . + . + "uge2 1" . + . + "82 . 6" . + "week 12" . + . + "uge2 2" . + . + "0 . 4" . + "week 12" . + . + "fpg 1" . + . + "reduced" . + . + "hba 1" . + . + "reduced" . + . + "bw1 1" . + . + "Reductions" . + "weeks 1" . + . + "bw2 1" . + . + "Reductions" . + "weeks 1 and 12" . + . + "bp1 1" . + . + "Reductions" . + "weeks 1" . + . + "bp2 1" . + . + "Reductions" . + "weeks 1 and 12" . + . + "pv1 1" . + . + "5 . 4" . + "week 1" . + . + "pv1 2" . + . + "4 . 3" . + "week 1" . + . + "pv2 1" . + . + "4 . 6" . + "week 12" . + . + "pv2 2" . + . + "5 . 8" . + "week 12" . + . + "ur1 1" . + . + "A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12" . + "week 1" . + . + "ur2 1" . + . + "A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12" . + "week 12" . + . + "bu 1" . + . + "remained modestly increased" . + "week 12" . + . + "sc 1" . + . + "remained modestly increased" . + "week 12" . + . + "hae" . + . + "remained modestly increased" . + "week 12" . +# RDF export of group: DiffBetweenGroups + . + "pv1" . + "p = 0 . 02" . + . + . + . + "pv2" . + "p = 0 . 76" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24939043_akramersunderbrink.annodb b/data/dm2 24939043_akramersunderbrink.annodb new file mode 100644 index 0000000..6124ae9 --- /dev/null +++ b/data/dm2 24939043_akramersunderbrink.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59912, Journal, 0, 19, "Diabetes Obes Metab", "", +59913, PublicationYear, 22, 26, "2014", "", +59925, Title, 107, 239, "Effect of the sodium glucose co - transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus .", "", +59927, Drug, 165, 178, "canagliflozin", "", +59914, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", +59915, Author, 240, 245, "Sha S", "", +59916, Author, 254, 264, "Polidori D", "", +59917, Author, 267, 274, "Heise T", "", +59918, Author, 277, 288, "Natarajan J", "", +59919, Author, 291, 300, "Farrell K", "", +59920, Author, 303, 310, "Wang SS", "", +59921, Author, 313, 319, "Sica D", "", +59922, Author, 322, 334, "Rothenberg P", "", +59923, Author, 337, 356, "Plum - M ö rschel L", "", +59924, USA, 440, 443, "USA", "", +59934, ObjectiveDescription, 452, 678, "To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA1c ) and additional measures of fluid / electrolyte balance in patients", "", +59926, Drug, 479, 492, "canagliflozin", "", +59950, EndPointDescription, 512, 545, "urinary glucose excretion ( UGE )", "", +59928, FastingPlasmaGlucose, 548, 570, "fasting plasma glucose", "", +59929, FastingPlasmaGlucose, 573, 576, "FPG", "", +59930, HbA1c, 581, 601, "glycated haemoglobin", "", +59931, HbA1c, 604, 609, "HbA1c", "", +59935, ObjectiveDescription, 679, 818, "with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers .", "", +59932, Type2Diabetes, 684, 699, "type 2 diabetes", "", +59933, Metformin, 727, 736, "metformin", "", +59936, NumberPatientsCT, 844, 846, "36", "", +59937, Drug, 886, 899, "canagliflozin", "", +59938, DoseValue, 900, 906, "300 mg", "", +59939, mg, 904, 906, "mg", "", +59940, Placebo, 910, 917, "placebo", "", +59941, Duration, 922, 930, "12 weeks", "", +59942, TimePoint, 977, 985, "baseline", "", +59943, TimePoint, 993, 1000, "weeks 1", "", +59944, TimePoint, 993, 1007, "weeks 1 and 12", "", +59949, EndPointDescription, 1030, 1040, "24 - h UGE", "", +59945, Drug, 1057, 1070, "canagliflozin", "", +59946, Placebo, 1110, 1117, "placebo", "", +59947, TimePoint, 1132, 1138, "week 1", "", +59951, ChangeValue, 1141, 1147, "91 . 8", "", +59952, ChangeValue, 1153, 1160, "- 2 . 4", "", +59955, Gram, 1161, 1162, "g", "", +59948, TimePoint, 1169, 1176, "week 12", "", +59953, ChangeValue, 1179, 1185, "82 . 6", "", +59954, ChangeValue, 1191, 1198, "- 0 . 4", "", +59956, Gram, 1199, 1200, "g", "", +59957, Drug, 1205, 1218, "Canagliflozin", "", +59958, FastingPlasmaGlucose, 1237, 1240, "FPG", "", +59959, HbA1c, 1245, 1250, "HbA1c", "", +59960, BodyWeight, 1267, 1278, "body weight", "", +59961, BloodPressure, 1283, 1297, "blood pressure", "", +59962, TimePoint, 1315, 1322, "weeks 1", "", +59963, TimePoint, 1315, 1329, "weeks 1 and 12", "", +59964, Drug, 1332, 1345, "Canagliflozin", "", +59968, EndPointDescription, 1356, 1369, "plasma volume", "", +59965, Placebo, 1401, 1408, "placebo", "", +59966, TimePoint, 1412, 1418, "week 1", "", +59969, ChangeValue, 1421, 1428, "- 5 . 4", "", +59970, ChangeValue, 1434, 1439, "4 . 3", "", +59973, Percentage, 1440, 1441, "%", "", +59975, PvalueDiff, 1444, 1454, "p = 0 . 02", "", +59967, TimePoint, 1494, 1501, "week 12", "", +59971, ChangeValue, 1504, 1509, "4 . 6", "", +59972, ChangeValue, 1515, 1520, "5 . 8", "", +59974, Percentage, 1521, 1522, "%", "", +59976, PvalueDiff, 1525, 1535, "p = 0 . 76", "", +59977, Drug, 1602, 1615, "canagliflozin", "", +59978, TimePoint, 1619, 1625, "week 1", "", +59979, TimePoint, 1649, 1656, "week 12", "", +59981, Drug, 1791, 1804, "canagliflozin", "", +59980, TimePoint, 1808, 1815, "week 12", "", +59982, Drug, 1831, 1844, "Canagliflozin", "", +59988, ConclusionComment, 1831, 1984, "Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12 .", "", +59983, EndPointDescription, 1875, 1878, "UGE", "", +59984, FastingPlasmaGlucose, 1883, 1886, "FPG", "", +59985, Duration, 1892, 1900, "12 weeks", "", +59986, TimePoint, 1975, 1982, "week 12", "", +59987, PMID, 2053, 2061, "24939043", "", diff --git a/data/dm2 24939043_akramersunderbrink.n-triples b/data/dm2 24939043_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24939043_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 24939043_export.csv b/data/dm2 24939043_export.csv new file mode 100644 index 0000000..71a007c --- /dev/null +++ b/data/dm2 24939043_export.csv @@ -0,0 +1,443 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +276, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +276, 1, 2, 2, 9, 13, 9, 13, "Obes" +276, 1, 3, 3, 14, 19, 14, 19, "Metab" +276, 1, 4, 4, 20, 21, 20, 21, "." +276, 2, 1, 5, 0, 4, 22, 26, "2014" +276, 2, 2, 6, 5, 8, 27, 30, "Nov" +276, 2, 3, 7, 9, 10, 31, 32, ";" +276, 2, 4, 8, 11, 13, 33, 35, "16" +276, 2, 5, 9, 14, 15, 36, 37, "(" +276, 2, 6, 10, 16, 18, 38, 40, "11" +276, 2, 7, 11, 19, 20, 41, 42, ")" +276, 2, 8, 12, 21, 22, 43, 44, ":" +276, 2, 9, 13, 23, 27, 45, 49, "1087" +276, 2, 10, 14, 28, 29, 50, 51, "-" +276, 2, 11, 15, 30, 32, 52, 54, "95" +276, 2, 12, 16, 33, 34, 55, 56, "." +276, 2, 13, 17, 35, 38, 57, 60, "doi" +276, 2, 14, 18, 39, 40, 61, 62, ":" +276, 2, 15, 19, 41, 43, 63, 65, "10" +276, 2, 16, 20, 44, 45, 66, 67, "." +276, 2, 17, 21, 46, 50, 68, 72, "1111" +276, 2, 18, 22, 51, 52, 73, 74, "/" +276, 2, 19, 23, 53, 56, 75, 78, "dom" +276, 2, 20, 24, 57, 58, 79, 80, "." +276, 2, 21, 25, 59, 64, 81, 86, "12322" +276, 2, 22, 26, 65, 66, 87, 88, "." +276, 3, 1, 27, 0, 4, 89, 93, "Epub" +276, 3, 2, 28, 5, 9, 94, 98, "2014" +276, 3, 3, 29, 10, 13, 99, 102, "Jul" +276, 3, 4, 30, 14, 15, 103, 104, "8" +276, 3, 5, 31, 16, 17, 105, 106, "." +276, 4, 1, 32, 0, 6, 107, 113, "Effect" +276, 4, 2, 33, 7, 9, 114, 116, "of" +276, 4, 3, 34, 10, 13, 117, 120, "the" +276, 4, 4, 35, 14, 20, 121, 127, "sodium" +276, 4, 5, 36, 21, 28, 128, 135, "glucose" +276, 4, 6, 37, 29, 31, 136, 138, "co" +276, 4, 7, 38, 32, 33, 139, 140, "-" +276, 4, 8, 39, 34, 45, 141, 152, "transporter" +276, 4, 9, 40, 46, 47, 153, 154, "2" +276, 4, 10, 41, 48, 57, 155, 164, "inhibitor" +276, 4, 11, 42, 58, 71, 165, 178, "canagliflozin" +276, 4, 12, 43, 72, 74, 179, 181, "on" +276, 4, 13, 44, 75, 81, 182, 188, "plasma" +276, 4, 14, 45, 82, 88, 189, 195, "volume" +276, 4, 15, 46, 89, 91, 196, 198, "in" +276, 4, 16, 47, 92, 100, 199, 207, "patients" +276, 4, 17, 48, 101, 105, 208, 212, "with" +276, 4, 18, 49, 106, 110, 213, 217, "type" +276, 4, 19, 50, 111, 112, 218, 219, "2" +276, 4, 20, 51, 113, 121, 220, 228, "diabetes" +276, 4, 21, 52, 122, 130, 229, 237, "mellitus" +276, 4, 22, 53, 131, 132, 238, 239, "." +276, 5, 1, 54, 0, 3, 240, 243, "Sha" +276, 5, 2, 55, 4, 5, 244, 245, "S" +276, 5, 3, 56, 6, 7, 246, 247, "(" +276, 5, 4, 57, 8, 9, 248, 249, "1" +276, 5, 5, 58, 10, 11, 250, 251, ")" +276, 5, 6, 59, 12, 13, 252, 253, "," +276, 5, 7, 60, 14, 22, 254, 262, "Polidori" +276, 5, 8, 61, 23, 24, 263, 264, "D" +276, 5, 9, 62, 25, 26, 265, 266, "," +276, 5, 10, 63, 27, 32, 267, 272, "Heise" +276, 5, 11, 64, 33, 34, 273, 274, "T" +276, 5, 12, 65, 35, 36, 275, 276, "," +276, 5, 13, 66, 37, 46, 277, 286, "Natarajan" +276, 5, 14, 67, 47, 48, 287, 288, "J" +276, 5, 15, 68, 49, 50, 289, 290, "," +276, 5, 16, 69, 51, 58, 291, 298, "Farrell" +276, 5, 17, 70, 59, 60, 299, 300, "K" +276, 5, 18, 71, 61, 62, 301, 302, "," +276, 5, 19, 72, 63, 67, 303, 307, "Wang" +276, 5, 20, 73, 68, 70, 308, 310, "SS" +276, 5, 21, 74, 71, 72, 311, 312, "," +276, 5, 22, 75, 73, 77, 313, 317, "Sica" +276, 5, 23, 76, 78, 79, 318, 319, "D" +276, 5, 24, 77, 80, 81, 320, 321, "," +276, 5, 25, 78, 82, 92, 322, 332, "Rothenberg" +276, 5, 26, 79, 93, 94, 333, 334, "P" +276, 5, 27, 80, 95, 96, 335, 336, "," +276, 5, 28, 81, 97, 101, 337, 341, "Plum" +276, 5, 29, 82, 102, 103, 342, 343, "-" +276, 5, 30, 83, 104, 105, 344, 345, "M" +276, 5, 31, 84, 106, 107, 346, 347, "ö" +276, 5, 32, 85, 108, 114, 348, 354, "rschel" +276, 5, 33, 86, 115, 116, 355, 356, "L" +276, 5, 34, 87, 117, 118, 357, 358, "." +276, 5, 35, 88, 119, 125, 359, 365, "Author" +276, 5, 36, 89, 126, 137, 366, 377, "information" +276, 5, 37, 90, 138, 139, 378, 379, ":" +276, 5, 38, 91, 140, 141, 380, 381, "(" +276, 5, 39, 92, 142, 143, 382, 383, "1" +276, 5, 40, 93, 144, 145, 384, 385, ")" +276, 5, 41, 94, 146, 153, 386, 393, "Janssen" +276, 5, 42, 95, 154, 162, 394, 402, "Research" +276, 5, 43, 96, 163, 164, 403, 404, "&" +276, 5, 44, 97, 165, 176, 405, 416, "Development" +276, 5, 45, 98, 177, 178, 417, 418, "," +276, 5, 46, 99, 179, 182, 419, 422, "LLC" +276, 5, 47, 100, 183, 184, 423, 424, "," +276, 5, 48, 101, 185, 192, 425, 432, "Raritan" +276, 5, 49, 102, 193, 194, 433, 434, "," +276, 5, 50, 103, 195, 197, 435, 437, "NJ" +276, 5, 51, 104, 198, 199, 438, 439, "," +276, 5, 52, 105, 200, 203, 440, 443, "USA" +276, 5, 53, 106, 204, 205, 444, 445, "." +276, 6, 1, 107, 0, 3, 446, 449, "AIM" +276, 6, 2, 108, 4, 5, 450, 451, ":" +276, 6, 3, 109, 6, 8, 452, 454, "To" +276, 6, 4, 110, 9, 17, 455, 463, "evaluate" +276, 6, 5, 111, 18, 21, 464, 467, "the" +276, 6, 6, 112, 22, 29, 468, 475, "effects" +276, 6, 7, 113, 30, 32, 476, 478, "of" +276, 6, 8, 114, 33, 46, 479, 492, "canagliflozin" +276, 6, 9, 115, 47, 49, 493, 495, "on" +276, 6, 10, 116, 50, 56, 496, 502, "plasma" +276, 6, 11, 117, 57, 63, 503, 509, "volume" +276, 6, 12, 118, 64, 65, 510, 511, "," +276, 6, 13, 119, 66, 73, 512, 519, "urinary" +276, 6, 14, 120, 74, 81, 520, 527, "glucose" +276, 6, 15, 121, 82, 91, 528, 537, "excretion" +276, 6, 16, 122, 92, 93, 538, 539, "(" +276, 6, 17, 123, 94, 97, 540, 543, "UGE" +276, 6, 18, 124, 98, 99, 544, 545, ")" +276, 6, 19, 125, 100, 101, 546, 547, "," +276, 6, 20, 126, 102, 109, 548, 555, "fasting" +276, 6, 21, 127, 110, 116, 556, 562, "plasma" +276, 6, 22, 128, 117, 124, 563, 570, "glucose" +276, 6, 23, 129, 125, 126, 571, 572, "(" +276, 6, 24, 130, 127, 130, 573, 576, "FPG" +276, 6, 25, 131, 131, 132, 577, 578, ")" +276, 6, 26, 132, 133, 134, 579, 580, "," +276, 6, 27, 133, 135, 143, 581, 589, "glycated" +276, 6, 28, 134, 144, 155, 590, 601, "haemoglobin" +276, 6, 29, 135, 156, 157, 602, 603, "(" +276, 6, 30, 136, 158, 163, 604, 609, "HbA1c" +276, 6, 31, 137, 164, 165, 610, 611, ")" +276, 6, 32, 138, 166, 169, 612, 615, "and" +276, 6, 33, 139, 170, 180, 616, 626, "additional" +276, 6, 34, 140, 181, 189, 627, 635, "measures" +276, 6, 35, 141, 190, 192, 636, 638, "of" +276, 6, 36, 142, 193, 198, 639, 644, "fluid" +276, 6, 37, 143, 199, 200, 645, 646, "/" +276, 6, 38, 144, 201, 212, 647, 658, "electrolyte" +276, 6, 39, 145, 213, 220, 659, 666, "balance" +276, 6, 40, 146, 221, 223, 667, 669, "in" +276, 6, 41, 147, 224, 232, 670, 678, "patients" +276, 6, 42, 148, 233, 237, 679, 683, "with" +276, 6, 43, 149, 238, 242, 684, 688, "type" +276, 6, 44, 150, 243, 244, 689, 690, "2" +276, 6, 45, 151, 245, 253, 691, 699, "diabetes" +276, 6, 46, 152, 254, 256, 700, 702, "on" +276, 6, 47, 153, 257, 267, 703, 713, "background" +276, 6, 48, 154, 268, 275, 714, 721, "therapy" +276, 6, 49, 155, 276, 280, 722, 726, "with" +276, 6, 50, 156, 281, 290, 727, 736, "metformin" +276, 6, 51, 157, 291, 294, 737, 740, "and" +276, 6, 52, 158, 295, 306, 741, 752, "angiotensin" +276, 6, 53, 159, 307, 308, 753, 754, "-" +276, 6, 54, 160, 309, 319, 755, 765, "converting" +276, 6, 55, 161, 320, 326, 766, 772, "enzyme" +276, 6, 56, 162, 327, 337, 773, 783, "inhibitors" +276, 6, 57, 163, 338, 340, 784, 786, "or" +276, 6, 58, 164, 341, 352, 787, 798, "angiotensin" +276, 6, 59, 165, 353, 361, 799, 807, "receptor" +276, 6, 60, 166, 362, 370, 808, 816, "blockers" +276, 6, 61, 167, 371, 372, 817, 818, "." +276, 7, 1, 168, 0, 7, 819, 826, "METHODS" +276, 7, 2, 169, 8, 9, 827, 828, ":" +276, 7, 3, 170, 10, 18, 829, 837, "Patients" +276, 7, 4, 171, 19, 20, 838, 839, "(" +276, 7, 5, 172, 21, 22, 840, 841, "N" +276, 7, 6, 173, 23, 24, 842, 843, "=" +276, 7, 7, 174, 25, 27, 844, 846, "36" +276, 7, 8, 175, 28, 29, 847, 848, ")" +276, 7, 9, 176, 30, 34, 849, 853, "were" +276, 7, 10, 177, 35, 45, 854, 864, "randomized" +276, 7, 11, 178, 46, 47, 865, 866, "(" +276, 7, 12, 179, 48, 49, 867, 868, "1" +276, 7, 13, 180, 50, 51, 869, 870, ":" +276, 7, 14, 181, 52, 53, 871, 872, "1" +276, 7, 15, 182, 54, 55, 873, 874, ")" +276, 7, 16, 183, 56, 58, 875, 877, "to" +276, 7, 17, 184, 59, 66, 878, 885, "receive" +276, 7, 18, 185, 67, 80, 886, 899, "canagliflozin" +276, 7, 19, 186, 81, 84, 900, 903, "300" +276, 7, 20, 187, 85, 87, 904, 906, "mg" +276, 7, 21, 188, 88, 90, 907, 909, "or" +276, 7, 22, 189, 91, 98, 910, 917, "placebo" +276, 7, 23, 190, 99, 102, 918, 921, "for" +276, 7, 24, 191, 103, 105, 922, 924, "12" +276, 7, 25, 192, 106, 111, 925, 930, "weeks" +276, 7, 26, 193, 112, 113, 931, 932, "." +276, 8, 1, 194, 0, 15, 933, 948, "Pharmacodynamic" +276, 8, 2, 195, 16, 26, 949, 959, "parameters" +276, 8, 3, 196, 27, 31, 960, 964, "were" +276, 8, 4, 197, 32, 40, 965, 973, "assessed" +276, 8, 5, 198, 41, 43, 974, 976, "at" +276, 8, 6, 199, 44, 52, 977, 985, "baseline" +276, 8, 7, 200, 53, 56, 986, 989, "and" +276, 8, 8, 201, 57, 59, 990, 992, "at" +276, 8, 9, 202, 60, 65, 993, 998, "weeks" +276, 8, 10, 203, 66, 67, 999, 1000, "1" +276, 8, 11, 204, 68, 71, 1001, 1004, "and" +276, 8, 12, 205, 72, 74, 1005, 1007, "12" +276, 8, 13, 206, 75, 76, 1008, 1009, "." +276, 9, 1, 207, 0, 7, 1010, 1017, "RESULTS" +276, 9, 2, 208, 8, 9, 1018, 1019, ":" +276, 9, 3, 209, 10, 19, 1020, 1029, "Increased" +276, 9, 4, 210, 20, 22, 1030, 1032, "24" +276, 9, 5, 211, 23, 24, 1033, 1034, "-" +276, 9, 6, 212, 25, 26, 1035, 1036, "h" +276, 9, 7, 213, 27, 30, 1037, 1040, "UGE" +276, 9, 8, 214, 31, 34, 1041, 1044, "was" +276, 9, 9, 215, 35, 39, 1045, 1049, "seen" +276, 9, 10, 216, 40, 42, 1050, 1052, "in" +276, 9, 11, 217, 43, 46, 1053, 1056, "the" +276, 9, 12, 218, 47, 60, 1057, 1070, "canagliflozin" +276, 9, 13, 219, 61, 66, 1071, 1076, "group" +276, 9, 14, 220, 67, 75, 1077, 1085, "compared" +276, 9, 15, 221, 76, 80, 1086, 1090, "with" +276, 9, 16, 222, 81, 82, 1091, 1092, "a" +276, 9, 17, 223, 83, 92, 1093, 1102, "reduction" +276, 9, 18, 224, 93, 95, 1103, 1105, "in" +276, 9, 19, 225, 96, 99, 1106, 1109, "the" +276, 9, 20, 226, 100, 107, 1110, 1117, "placebo" +276, 9, 21, 227, 108, 113, 1118, 1123, "group" +276, 9, 22, 228, 114, 116, 1124, 1126, "at" +276, 9, 23, 229, 117, 121, 1127, 1131, "both" +276, 9, 24, 230, 122, 126, 1132, 1136, "week" +276, 9, 25, 231, 127, 128, 1137, 1138, "1" +276, 9, 26, 232, 129, 130, 1139, 1140, "(" +276, 9, 27, 233, 131, 133, 1141, 1143, "91" +276, 9, 28, 234, 134, 135, 1144, 1145, "." +276, 9, 29, 235, 136, 137, 1146, 1147, "8" +276, 9, 30, 236, 138, 140, 1148, 1150, "vs" +276, 9, 31, 237, 141, 142, 1151, 1152, "." +276, 9, 32, 238, 143, 144, 1153, 1154, "-" +276, 9, 33, 239, 145, 146, 1155, 1156, "2" +276, 9, 34, 240, 147, 148, 1157, 1158, "." +276, 9, 35, 241, 149, 150, 1159, 1160, "4" +276, 9, 36, 242, 151, 152, 1161, 1162, "g" +276, 9, 37, 243, 153, 154, 1163, 1164, ")" +276, 9, 38, 244, 155, 158, 1165, 1168, "and" +276, 9, 39, 245, 159, 163, 1169, 1173, "week" +276, 9, 40, 246, 164, 166, 1174, 1176, "12" +276, 9, 41, 247, 167, 168, 1177, 1178, "(" +276, 9, 42, 248, 169, 171, 1179, 1181, "82" +276, 9, 43, 249, 172, 173, 1182, 1183, "." +276, 9, 44, 250, 174, 175, 1184, 1185, "6" +276, 9, 45, 251, 176, 178, 1186, 1188, "vs" +276, 9, 46, 252, 179, 180, 1189, 1190, "." +276, 9, 47, 253, 181, 182, 1191, 1192, "-" +276, 9, 48, 254, 183, 184, 1193, 1194, "0" +276, 9, 49, 255, 185, 186, 1195, 1196, "." +276, 9, 50, 256, 187, 188, 1197, 1198, "4" +276, 9, 51, 257, 189, 190, 1199, 1200, "g" +276, 9, 52, 258, 191, 192, 1201, 1202, ")" +276, 9, 53, 259, 193, 194, 1203, 1204, "." +276, 10, 1, 260, 0, 13, 1205, 1218, "Canagliflozin" +276, 10, 2, 261, 14, 18, 1219, 1223, "also" +276, 10, 3, 262, 19, 26, 1224, 1231, "reduced" +276, 10, 4, 263, 27, 31, 1232, 1236, "both" +276, 10, 5, 264, 32, 35, 1237, 1240, "FPG" +276, 10, 6, 265, 36, 39, 1241, 1244, "and" +276, 10, 7, 266, 40, 45, 1245, 1250, "HbA1c" +276, 10, 8, 267, 46, 47, 1251, 1252, "." +276, 11, 1, 268, 0, 10, 1253, 1263, "Reductions" +276, 11, 2, 269, 11, 13, 1264, 1266, "in" +276, 11, 3, 270, 14, 18, 1267, 1271, "body" +276, 11, 4, 271, 19, 25, 1272, 1278, "weight" +276, 11, 5, 272, 26, 29, 1279, 1282, "and" +276, 11, 6, 273, 30, 35, 1283, 1288, "blood" +276, 11, 7, 274, 36, 44, 1289, 1297, "pressure" +276, 11, 8, 275, 45, 49, 1298, 1302, "were" +276, 11, 9, 276, 50, 58, 1303, 1311, "observed" +276, 11, 10, 277, 59, 61, 1312, 1314, "at" +276, 11, 11, 278, 62, 67, 1315, 1320, "weeks" +276, 11, 12, 279, 68, 69, 1321, 1322, "1" +276, 11, 13, 280, 70, 73, 1323, 1326, "and" +276, 11, 14, 281, 74, 76, 1327, 1329, "12" +276, 11, 15, 282, 77, 78, 1330, 1331, "." +276, 12, 1, 283, 0, 13, 1332, 1345, "Canagliflozin" +276, 12, 2, 284, 14, 23, 1346, 1355, "decreased" +276, 12, 3, 285, 24, 30, 1356, 1362, "plasma" +276, 12, 4, 286, 31, 37, 1363, 1369, "volume" +276, 12, 5, 287, 38, 46, 1370, 1378, "compared" +276, 12, 6, 288, 47, 51, 1379, 1383, "with" +276, 12, 7, 289, 52, 54, 1384, 1386, "an" +276, 12, 8, 290, 55, 63, 1387, 1395, "increase" +276, 12, 9, 291, 64, 68, 1396, 1400, "with" +276, 12, 10, 292, 69, 76, 1401, 1408, "placebo" +276, 12, 11, 293, 77, 79, 1409, 1411, "at" +276, 12, 12, 294, 80, 84, 1412, 1416, "week" +276, 12, 13, 295, 85, 86, 1417, 1418, "1" +276, 12, 14, 296, 87, 88, 1419, 1420, "(" +276, 12, 15, 297, 89, 90, 1421, 1422, "-" +276, 12, 16, 298, 91, 92, 1423, 1424, "5" +276, 12, 17, 299, 93, 94, 1425, 1426, "." +276, 12, 18, 300, 95, 96, 1427, 1428, "4" +276, 12, 19, 301, 97, 99, 1429, 1431, "vs" +276, 12, 20, 302, 100, 101, 1432, 1433, "." +276, 12, 21, 303, 102, 103, 1434, 1435, "4" +276, 12, 22, 304, 104, 105, 1436, 1437, "." +276, 12, 23, 305, 106, 107, 1438, 1439, "3" +276, 12, 24, 306, 108, 109, 1440, 1441, "%" +276, 12, 25, 307, 110, 111, 1442, 1443, ";" +276, 12, 26, 308, 112, 113, 1444, 1445, "p" +276, 12, 27, 309, 114, 115, 1446, 1447, "=" +276, 12, 28, 310, 116, 117, 1448, 1449, "0" +276, 12, 29, 311, 118, 119, 1450, 1451, "." +276, 12, 30, 312, 120, 122, 1452, 1454, "02" +276, 12, 31, 313, 123, 124, 1455, 1456, ")" +276, 12, 32, 314, 125, 126, 1457, 1458, "," +276, 12, 33, 315, 127, 130, 1459, 1462, "but" +276, 12, 34, 316, 131, 135, 1463, 1467, "this" +276, 12, 35, 317, 136, 139, 1468, 1471, "was" +276, 12, 36, 318, 140, 147, 1472, 1479, "largely" +276, 12, 37, 319, 148, 158, 1480, 1490, "attenuated" +276, 12, 38, 320, 159, 161, 1491, 1493, "at" +276, 12, 39, 321, 162, 166, 1494, 1498, "week" +276, 12, 40, 322, 167, 169, 1499, 1501, "12" +276, 12, 41, 323, 170, 171, 1502, 1503, "(" +276, 12, 42, 324, 172, 173, 1504, 1505, "4" +276, 12, 43, 325, 174, 175, 1506, 1507, "." +276, 12, 44, 326, 176, 177, 1508, 1509, "6" +276, 12, 45, 327, 178, 180, 1510, 1512, "vs" +276, 12, 46, 328, 181, 182, 1513, 1514, "." +276, 12, 47, 329, 183, 184, 1515, 1516, "5" +276, 12, 48, 330, 185, 186, 1517, 1518, "." +276, 12, 49, 331, 187, 188, 1519, 1520, "8" +276, 12, 50, 332, 189, 190, 1521, 1522, "%" +276, 12, 51, 333, 191, 192, 1523, 1524, ";" +276, 12, 52, 334, 193, 194, 1525, 1526, "p" +276, 12, 53, 335, 195, 196, 1527, 1528, "=" +276, 12, 54, 336, 197, 198, 1529, 1530, "0" +276, 12, 55, 337, 199, 200, 1531, 1532, "." +276, 12, 56, 338, 201, 203, 1533, 1535, "76" +276, 12, 57, 339, 204, 205, 1536, 1537, ")" +276, 12, 58, 340, 206, 207, 1538, 1539, "." +276, 13, 1, 341, 0, 1, 1540, 1541, "A" +276, 13, 2, 342, 2, 8, 1542, 1548, "modest" +276, 13, 3, 343, 9, 18, 1549, 1558, "numerical" +276, 13, 4, 344, 19, 27, 1559, 1567, "increase" +276, 13, 5, 345, 28, 30, 1568, 1570, "in" +276, 13, 6, 346, 31, 36, 1571, 1576, "urine" +276, 13, 7, 347, 37, 43, 1577, 1583, "volume" +276, 13, 8, 348, 44, 47, 1584, 1587, "was" +276, 13, 9, 349, 48, 56, 1588, 1596, "observed" +276, 13, 10, 350, 57, 61, 1597, 1601, "with" +276, 13, 11, 351, 62, 75, 1602, 1615, "canagliflozin" +276, 13, 12, 352, 76, 78, 1616, 1618, "at" +276, 13, 13, 353, 79, 83, 1619, 1623, "week" +276, 13, 14, 354, 84, 85, 1624, 1625, "1" +276, 13, 15, 355, 86, 90, 1626, 1630, "that" +276, 13, 16, 356, 91, 94, 1631, 1634, "was" +276, 13, 17, 357, 95, 105, 1635, 1645, "attenuated" +276, 13, 18, 358, 106, 108, 1646, 1648, "at" +276, 13, 19, 359, 109, 113, 1649, 1653, "week" +276, 13, 20, 360, 114, 116, 1654, 1656, "12" +276, 13, 21, 361, 117, 118, 1657, 1658, ";" +276, 13, 22, 362, 119, 124, 1659, 1664, "other" +276, 13, 23, 363, 125, 133, 1665, 1673, "measures" +276, 13, 24, 364, 134, 136, 1674, 1676, "of" +276, 13, 25, 365, 137, 143, 1677, 1683, "volume" +276, 13, 26, 366, 144, 150, 1684, 1690, "status" +276, 13, 27, 367, 151, 152, 1691, 1692, "(" +276, 13, 28, 368, 153, 154, 1693, 1694, "i" +276, 13, 29, 369, 155, 156, 1695, 1696, "." +276, 13, 30, 370, 157, 158, 1697, 1698, "e" +276, 13, 31, 371, 159, 160, 1699, 1700, "." +276, 14, 1, 372, 0, 5, 1701, 1706, "blood" +276, 14, 2, 373, 6, 10, 1707, 1711, "urea" +276, 14, 3, 374, 11, 19, 1712, 1720, "nitrogen" +276, 14, 4, 375, 20, 21, 1721, 1722, "," +276, 14, 5, 376, 22, 27, 1723, 1728, "serum" +276, 14, 6, 377, 28, 38, 1729, 1739, "creatinine" +276, 14, 7, 378, 39, 42, 1740, 1743, "and" +276, 14, 8, 379, 43, 54, 1744, 1755, "haematocrit" +276, 14, 9, 380, 55, 56, 1756, 1757, ")" +276, 14, 10, 381, 57, 65, 1758, 1766, "remained" +276, 14, 11, 382, 66, 74, 1767, 1775, "modestly" +276, 14, 12, 383, 75, 84, 1776, 1785, "increased" +276, 14, 13, 384, 85, 89, 1786, 1790, "with" +276, 14, 14, 385, 90, 103, 1791, 1804, "canagliflozin" +276, 14, 15, 386, 104, 106, 1805, 1807, "at" +276, 14, 16, 387, 107, 111, 1808, 1812, "week" +276, 14, 17, 388, 112, 114, 1813, 1815, "12" +276, 14, 18, 389, 115, 116, 1816, 1817, "." +276, 15, 1, 390, 0, 10, 1818, 1828, "CONCLUSION" +276, 15, 2, 391, 11, 12, 1829, 1830, ":" +276, 15, 3, 392, 13, 26, 1831, 1844, "Canagliflozin" +276, 15, 4, 393, 27, 35, 1845, 1853, "provided" +276, 15, 5, 394, 36, 45, 1854, 1863, "sustained" +276, 15, 6, 395, 46, 53, 1864, 1871, "effects" +276, 15, 7, 396, 54, 56, 1872, 1874, "on" +276, 15, 8, 397, 57, 60, 1875, 1878, "UGE" +276, 15, 9, 398, 61, 64, 1879, 1882, "and" +276, 15, 10, 399, 65, 68, 1883, 1886, "FPG" +276, 15, 11, 400, 69, 73, 1887, 1891, "over" +276, 15, 12, 401, 74, 76, 1892, 1894, "12" +276, 15, 13, 402, 77, 82, 1895, 1900, "weeks" +276, 15, 14, 403, 83, 86, 1901, 1904, "and" +276, 15, 15, 404, 87, 88, 1905, 1906, "a" +276, 15, 16, 405, 89, 98, 1907, 1916, "transient" +276, 15, 17, 406, 99, 108, 1917, 1926, "reduction" +276, 15, 18, 407, 109, 111, 1927, 1929, "in" +276, 15, 19, 408, 112, 118, 1930, 1936, "plasma" +276, 15, 20, 409, 119, 125, 1937, 1943, "volume" +276, 15, 21, 410, 126, 130, 1944, 1948, "that" +276, 15, 22, 411, 131, 134, 1949, 1952, "was" +276, 15, 23, 412, 135, 142, 1953, 1960, "largely" +276, 15, 24, 413, 143, 153, 1961, 1971, "attenuated" +276, 15, 25, 414, 154, 156, 1972, 1974, "by" +276, 15, 26, 415, 157, 161, 1975, 1979, "week" +276, 15, 27, 416, 162, 164, 1980, 1982, "12" +276, 15, 28, 417, 165, 166, 1983, 1984, "." +276, 16, 1, 418, 0, 1, 1985, 1986, "©" +276, 16, 2, 419, 2, 6, 1987, 1991, "2014" +276, 16, 3, 420, 7, 11, 1992, 1996, "John" +276, 16, 4, 421, 12, 17, 1997, 2002, "Wiley" +276, 16, 5, 422, 18, 19, 2003, 2004, "&" +276, 16, 6, 423, 20, 24, 2005, 2009, "Sons" +276, 16, 7, 424, 25, 28, 2010, 2013, "Ltd" +276, 16, 8, 425, 29, 30, 2014, 2015, "." +276, 16, 9, 426, 31, 34, 2016, 2019, "DOI" +276, 16, 10, 427, 35, 36, 2020, 2021, ":" +276, 16, 11, 428, 37, 39, 2022, 2024, "10" +276, 16, 12, 429, 40, 41, 2025, 2026, "." +276, 16, 13, 430, 42, 46, 2027, 2031, "1111" +276, 16, 14, 431, 47, 48, 2032, 2033, "/" +276, 16, 15, 432, 49, 52, 2034, 2037, "dom" +276, 16, 16, 433, 53, 54, 2038, 2039, "." +276, 16, 17, 434, 55, 60, 2040, 2045, "12322" +276, 16, 18, 435, 61, 65, 2046, 2050, "PMID" +276, 16, 19, 436, 66, 67, 2051, 2052, ":" +276, 16, 20, 437, 68, 76, 2053, 2061, "24939043" +276, 16, 21, 438, 77, 78, 2062, 2063, "[" +276, 16, 22, 439, 79, 86, 2064, 2071, "Indexed" +276, 16, 23, 440, 87, 90, 2072, 2075, "for" +276, 16, 24, 441, 91, 98, 2076, 2083, "MEDLINE" +276, 16, 25, 442, 99, 100, 2084, 2085, "]" diff --git a/data/dm2 24939043_kwoodley.annodb b/data/dm2 24939043_kwoodley.annodb new file mode 100644 index 0000000..fe032c5 --- /dev/null +++ b/data/dm2 24939043_kwoodley.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +47997, Journal, 0, 19, "Diabetes Obes Metab", "", +47998, PublicationYear, 22, 26, "2014", "", +48022, Title, 107, 239, "Effect of the sodium glucose co - transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus .", "", +47999, Drug, 165, 178, "canagliflozin", "", +48008, EndPointDescription, 182, 195, "plasma volume", "", +48020, Type2Diabetes, 213, 237, "type 2 diabetes mellitus", "", +48023, Author, 240, 245, "Sha S", "", +48024, Author, 254, 264, "Polidori D", "", +48025, Author, 267, 274, "Heise T", "", +48026, Author, 277, 288, "Natarajan J", "", +48027, Author, 291, 300, "Farrell K", "", +48028, Author, 303, 310, "Wang SS", "", +48029, Author, 313, 319, "Sica D", "", +48030, Author, 322, 334, "Rothenberg P", "", +48031, Author, 337, 356, "Plum - M ö rschel L", "", +48032, USA, 440, 443, "USA", "", +48045, ObjectiveDescription, 452, 615, "To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA1c ) and", "", +48000, Drug, 479, 492, "canagliflozin", "", +48009, EndPointDescription, 496, 509, "plasma volume", "", +48010, EndPointDescription, 512, 537, "urinary glucose excretion", "", +48011, EndPointDescription, 540, 543, "UGE", "", +48033, FastingPlasmaGlucose, 548, 570, "fasting plasma glucose", "", +48034, FastingPlasmaGlucose, 573, 576, "FPG", "", +48037, HbA1c, 581, 601, "glycated haemoglobin", "", +48038, HbA1c, 604, 609, "HbA1c", "", +48046, ObjectiveDescription, 616, 818, "additional measures of fluid / electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers .", "", +48047, Precondition, 670, 816, "patients with type 2 diabetes on background therapy with metformin and angiotensin - converting enzyme inhibitors or angiotensin receptor blockers", "", +48021, Type2Diabetes, 684, 699, "type 2 diabetes", "", +48040, Metformin, 727, 736, "metformin", "", +48041, Drug, 741, 752, "angiotensin", "not drug in question", +48048, NumberPatientsCT, 844, 846, "36", "", +48049, Randomized, 854, 864, "randomized", "", +48050, AllocationRatio, 867, 872, "1 : 1", "", +48001, Drug, 886, 899, "canagliflozin", "", +48051, DoseValue, 900, 903, "300", "", +48052, mg, 904, 906, "mg", "", +48054, Placebo, 910, 917, "placebo", "", +48053, Duration, 922, 930, "12 weeks", "", +48057, TimePoint, 977, 985, "baseline", "", +48058, TimePoint, 993, 1000, "weeks 1", "", +48059, TimePoint, 993, 1007, "weeks 1 and 12", "", +48012, EndPointDescription, 1030, 1040, "24 - h UGE", "", +48002, Drug, 1057, 1070, "canagliflozin", "", +48055, Placebo, 1110, 1117, "placebo", "", +48060, TimePoint, 1132, 1138, "week 1", "", +48071, Increment, 1141, 1147, "91 . 8", "", +48073, Reduction, 1155, 1160, "2 . 4", "", +48075, Gram, 1161, 1162, "g", "", +48061, TimePoint, 1169, 1176, "week 12", "", +48072, Increment, 1179, 1185, "82 . 6", "", +48074, Reduction, 1193, 1198, "0 . 4", "", +48076, Gram, 1199, 1200, "g", "", +48003, Drug, 1205, 1218, "Canagliflozin", "", +48077, ObservedResult, 1224, 1231, "reduced", "", +48035, FastingPlasmaGlucose, 1237, 1240, "FPG", "", +48039, HbA1c, 1245, 1250, "HbA1c", "", +48078, ObservedResult, 1253, 1263, "Reductions", "", +48079, BodyWeight, 1267, 1278, "body weight", "", +48080, BloodPressure, 1283, 1297, "blood pressure", "", +48062, TimePoint, 1315, 1322, "weeks 1", "", +48063, TimePoint, 1315, 1329, "weeks 1 and 12", "", +48004, Drug, 1332, 1345, "Canagliflozin", "", +48013, EndPointDescription, 1356, 1369, "plasma volume", "", +48056, Placebo, 1401, 1408, "placebo", "", +48064, TimePoint, 1412, 1418, "week 1", "", +48081, Reduction, 1423, 1428, "5 . 4", "", +48082, Increment, 1434, 1439, "4 . 3", "", +48085, Percentage, 1440, 1441, "%", "", +48087, PvalueDiff, 1444, 1454, "p = 0 . 02", "", +48065, TimePoint, 1494, 1501, "week 12", "", +48083, Increment, 1504, 1509, "4 . 6", "", +48084, Increment, 1515, 1520, "5 . 8", "", +48086, Percentage, 1521, 1522, "%", "", +48088, PvalueDiff, 1525, 1535, "p = 0 . 76", "", +48089, ObservedResult, 1540, 1656, "A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12", "", +48014, EndPointDescription, 1571, 1583, "urine volume", "", +48005, Drug, 1602, 1615, "canagliflozin", "", +48066, TimePoint, 1619, 1625, "week 1", "", +48067, TimePoint, 1649, 1656, "week 12", "", +48015, EndPointDescription, 1701, 1720, "blood urea nitrogen", "", +48016, EndPointDescription, 1723, 1739, "serum creatinine", "", +48017, EndPointDescription, 1744, 1755, "haematocrit", "", +48090, ObservedResult, 1758, 1785, "remained modestly increased", "", +48006, Drug, 1791, 1804, "canagliflozin", "", +48068, TimePoint, 1808, 1815, "week 12", "", +48007, Drug, 1831, 1844, "Canagliflozin", "", +48091, ConclusionComment, 1831, 1984, "Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12 .", "", +48018, EndPointDescription, 1875, 1878, "UGE", "", +48036, FastingPlasmaGlucose, 1883, 1886, "FPG", "", +48069, Duration, 1892, 1900, "12 weeks", "", +48019, EndPointDescription, 1930, 1943, "plasma volume", "", +48070, TimePoint, 1975, 1982, "week 12", "", +48092, PMID, 2053, 2061, "24939043", "", diff --git a/data/dm2 24939043_kwoodley.n-triples b/data/dm2 24939043_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 24939043_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25036533_admin.annodb b/data/dm2 25036533_admin.annodb new file mode 100644 index 0000000..43a416a --- /dev/null +++ b/data/dm2 25036533_admin.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "Diabetes Technol Ther .", "", " \"Diabetes Technol Ther .\"." +1, PublicationYear, 24, 28, "2014", "", " \"2014\"." +88, Liraglutide, 115, 126, "Liraglutide", "", +20, Title, 115, 286, "Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .", "", " \"Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .\"." +8, Type2Diabetes, 208, 223, "type 2 diabetes", "", " ." +13, Randomized, 228, 238, "randomized", "", " ." +14, DoubleBlind, 241, 255, "double - blind", "", " ." +15, Placebo, 258, 265, "placebo", "", +21, Author, 287, 295, "Klein DJ", "", " \"Klein DJ\"." +22, Author, 304, 315, "Battelino T", "", " \"Battelino T\"." +23, Author, 318, 331, "Chatterjee DJ", "", " \"Chatterjee DJ\"." +24, Author, 334, 345, "Jacobsen LV", "", " \"Jacobsen LV\"." +25, Author, 348, 355, "Hale PM", "", " \"Hale PM\"." +26, Author, 358, 369, "Arslanian S", "", " \"Arslanian S\"." +27, USA, 718, 722, "Ohio", "", " ." +9, Type2Diabetes, 756, 771, "type 2 diabetes", "", +10, Type2Diabetes, 774, 777, "T2D", "", +28, Metformin, 830, 839, "metformin", "", +29, Insulin, 844, 851, "insulin", "", +36, ObjectiveDescription, 865, 1080, "The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .", "", " \"The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .\"." +104, Liraglutide, 936, 947, "liraglutide", "", +30, Frequency, 948, 958, "once daily", "", +76187, Precondition, 962, 967, "youth", "", " \"youth\". \"with T2D\"." +31, MinAge, 970, 972, "10", "", " \"10\"." +32, MaxAge, 975, 977, "17", "", " \"17\"." +108, Year, 978, 983, "years", "", +76187, Precondition, 990, 998, "with T2D", "", +11, Type2Diabetes, 995, 998, "T2D", "", +33, Randomized, 1022, 1032, "randomized", "", +34, DoubleBlind, 1035, 1049, "double - blind", "", +35, Placebo, 1052, 1059, "placebo", "", +42, Precondition, 1104, 1222, "Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %", "", " \"Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %\"." +37, Metformin, 1153, 1162, "metformin", "", +38, HbA1c, 1176, 1190, "hemoglobin A1c", "", +39, HbA1c, 1193, 1198, "HbA1c", "", +41, Percentage, 1221, 1222, "%", "", +43, Randomized, 1228, 1238, "randomized", "", +120, Liraglutide, 1242, 1253, "liraglutide", "", " ." +44, NumberPatientsArm, 1260, 1262, "14", "", " \"14\"." +18, Placebo, 1268, 1275, "placebo", "", +45, NumberPatientsArm, 1282, 1283, "7", "", " \"7\"." +100514, DoseDescription, 1288, 1390, "Starting at 0 . 3 mg / day , doses were escalated weekly to 0 . 6 , 0 . 9 , 1 . 2 , and 1 . 8 mg / day", "", " \"Starting at 0 . 3 mg / day , doses were escalated weekly to 0 . 6 , 0 . 9 , 1 . 2 , and 1 . 8 mg / day\"." +127, DoseValue, 1300, 1305, "0 . 3", "", +76181, mg, 1306, 1308, "mg", "", " ." +100519, Frequency, 1311, 1314, "day", "", " \"day\"." +129, DoseValue, 1348, 1353, "0 . 6", "", +130, DoseValue, 1356, 1361, "0 . 9", "", +131, DoseValue, 1364, 1369, "1 . 2", "", +46, DoseValue, 1376, 1381, "1 . 8", "", +48, mg, 1382, 1384, "mg", "", +100518, Frequency, 1387, 1390, "day", "", +16, Placebo, 1396, 1403, "placebo", "", +51, Duration, 1421, 1428, "5 weeks", "", " \"5 weeks\"." +52, FinalNumPatientsCT, 1441, 1449, "Nineteen", "", " \"Nineteen\"." +137, TimePoint, 1485, 1493, "Baseline", "", +138, Mean, 1545, 1549, "mean", "", +54, AvgAge, 1575, 1581, "14 . 8", "", " \"14 . 8\"." +151, Year, 1592, 1597, "years", "", +55, BodyWeight, 1600, 1606, "weight", "", +60, BaseLineValue, 1610, 1617, "113 . 2", "", +148, SdDevBL, 1620, 1626, "35 . 6", "", +57, Kg, 1629, 1631, "kg", "", +58, Kg, 1651, 1653, "kg", "", +150, Year, 1695, 1700, "years", "", +62, HbA1c, 1707, 1712, "HbA1c", "", +61, BaseLineValue, 1722, 1727, "8 . 1", "", +63, Percentage, 1728, 1729, "%", "", +149, SdDevBL, 1732, 1737, "1 . 2", "", +65, Percentage, 1738, 1739, "%", "", +69, ObservedResult, 1744, 1769, "No serious adverse events", "", " \"No serious adverse events\". \"No serious adverse events\". \"No serious adverse events\". \"No serious adverse events\"." +66, EndPointDescription, 1747, 1769, "serious adverse events", "", " . ." +67, EndPointDescription, 1772, 1775, "AEs", "", +68, SevereHypoglycemia, 1790, 1809, "severe hypoglycemia", "", " ." +70, GastrointestinalProblem, 1833, 1853, "gastrointestinal AEs", "", " ." +71, ObservedResult, 1854, 1922, "were most common at lower liraglutide doses during dose escalation .", "", " \"were most common at lower liraglutide doses during dose escalation .\"." +155, Liraglutide, 1880, 1891, "liraglutide", "", +73, EndPointDescription, 2020, 2032, "pancreatitis", "", +74, EndPointDescription, 2036, 2042, "lipase", "", +72, EndPointDescription, 2097, 2107, "calcitonin", "", +156, Liraglutide, 2154, 2165, "liraglutide", "", +47, DoseValue, 2166, 2171, "1 . 8", "", +49, mg, 2172, 2174, "mg", "", +157, Mean, 2177, 2181, "mean", "", " . ." +160, EndPointDescription, 2182, 2193, "half - life", "", " . ." +162, ResultMeasuredValue, 2198, 2200, "12", "", " \"12\"." +164, Hour, 2201, 2202, "h", "", " ." +161, EndPointDescription, 2209, 2218, "clearance", "", " . ." +163, ResultMeasuredValue, 2223, 2228, "1 . 7", "", " \"1 . 7\"." +165, BioAndMedicalUnit, 2229, 2234, "L / h", "", " . ." +76, TimePoint, 2243, 2250, "5 weeks", "", " \"5 weeks\". \"5 weeks\". \"5 weeks\". \"5 weeks\"." +40, HbA1c, 2268, 2273, "HbA1c", "", " ." +168, Liraglutide, 2297, 2308, "liraglutide", "", +17, Placebo, 2316, 2323, "placebo", "", +77, Reduction, 2328, 2334, "0 . 86", "", " \"0 . 86\"." +78, Increment, 2340, 2346, "0 . 04", "", " \"0 . 04\"." +79, Percentage, 2347, 2348, "%", "", " ." +80, PvalueDiff, 2351, 2363, "P = 0 . 0007", "", " \"P = 0 . 0007\"." +174, Mean, 2376, 2380, "mean", "", " . ." +56, BodyWeight, 2381, 2392, "body weight", "", " ." +81, Reduction, 2413, 2419, "0 . 50", "", " \"0 . 50\"." +82, Reduction, 2427, 2433, "0 . 54", "", " \"0 . 54\"." +59, Kg, 2434, 2436, "kg", "", " ." +83, PvalueDiff, 2439, 2451, "P = 0 . 9703", "", " \"P = 0 . 9703\"." +84, ConclusionComment, 2470, 2610, "Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .", "", " \"Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .\"." +180, Liraglutide, 2470, 2481, "Liraglutide", "", +12, Type2Diabetes, 2515, 2518, "T2D", "", +85, PMID, 2673, 2681, "25036533", "", " \"25036533\"." diff --git a/data/dm2 25036533_admin.n-triples b/data/dm2 25036533_admin.n-triples new file mode 100644 index 0000000..e03d4e5 --- /dev/null +++ b/data/dm2 25036533_admin.n-triples @@ -0,0 +1,196 @@ +# RDF export of group: Publication + . + "Publication 61653" . + "Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial ." . + "Klein DJ" . + "2014" . + "Diabetes Technol Ther ." . + "25036533" . + . + "Battelino T" . + "Chatterjee DJ" . + "Jacobsen LV" . + "Hale PM" . + "Arslanian S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 61660" . + "The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial ." . + "5 weeks" . + . + . + . + "Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults ." . + . + . + . + . + . + "Nineteen" . + . + . + . +# RDF export of group: Population + . + "Population 61676" . + . + . + "10" . + "17" . + "14 . 8" . + . + "youth" . + "with T2D" . + "Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %" . +# RDF export of group: Endpoint + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "gat" . + . + . + . + . + . + "hl" . + . + . + . + . + . + . + . + "cl" . + . + . + . + . + . + . + . + "hba" . + . + . + . + . + . + "bw" . + . + . + . + . + . +# RDF export of group: Arm + . + "lir" . + "14" . + . + . + . + . + . + . + . + . + . + "pla" . + "7" . + . + . + . + . + . +# RDF export of group: Intervention + . + "lir" . + . + "day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lir" . + . + . + . + "Starting at 0 . 3 mg / day , doses were escalated weekly to 0 . 6 , 0 . 9 , 1 . 2 , and 1 . 8 mg / day" . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "ae 1" . + . + "No serious adverse events" . + . + "ae 2" . + . + "No serious adverse events" . + . + "hyp 1" . + . + "No serious adverse events" . + . + "hyp 2" . + . + "No serious adverse events" . + . + "gast 1" . + . + "were most common at lower liraglutide doses during dose escalation ." . + . + "hl 1" . + . + "12" . + . + "cl 1" . + . + "1 . 7" . + . + "hba 1" . + . + "0 . 86" . + "5 weeks" . + . + "hba 2" . + . + "0 . 04" . + "5 weeks" . + . + "bw 1" . + . + "0 . 50" . + "5 weeks" . + . + "bw 2" . + . + "0 . 54" . + "5 weeks" . +# RDF export of group: DiffBetweenGroups + . + "bw" . + "P = 0 . 9703" . + . + . + . + "hba" . + "P = 0 . 0007" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25036533_akramersunderbrink.annodb b/data/dm2 25036533_akramersunderbrink.annodb new file mode 100644 index 0000000..a21ecea --- /dev/null +++ b/data/dm2 25036533_akramersunderbrink.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +59989, Journal, 0, 21, "Diabetes Technol Ther", "", +59990, PublicationYear, 24, 28, "2014", "", +59991, Liraglutide, 115, 126, "Liraglutide", "", +59996, Title, 115, 286, "Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .", "", +59992, Type2Diabetes, 208, 223, "type 2 diabetes", "", +59993, Randomized, 228, 238, "randomized", "", +59994, DoubleBlind, 241, 255, "double - blind", "", +59995, Placebo, 258, 265, "placebo", "", +59997, Author, 287, 295, "Klein DJ", "", +59998, Author, 304, 315, "Battelino T", "", +59999, Author, 318, 331, "Chatterjee DJ", "", +60000, Author, 334, 345, "Jacobsen LV", "", +60001, Author, 348, 355, "Hale PM", "", +60002, Author, 358, 369, "Arslanian S", "", +60016, ObjectiveDescription, 738, 804, "The prevalence of type 2 diabetes ( T2D ) in youth is increasing .", "", +60003, Type2Diabetes, 756, 771, "type 2 diabetes", "", +60004, Type2Diabetes, 774, 777, "T2D", "", +60017, ObjectiveDescription, 805, 864, "Treatment options beyond metformin and insulin are needed .", "", +60005, Metformin, 830, 839, "metformin", "", +60006, Insulin, 844, 851, "insulin", "", +60018, ObjectiveDescription, 865, 1080, "The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .", "", +60007, Liraglutide, 936, 947, "liraglutide", "", +60008, Frequency, 948, 958, "once daily", "", +60009, MinAge, 970, 972, "10", "", +60010, MaxAge, 975, 977, "17", "", +60011, Year, 978, 983, "years", "", +60012, Type2Diabetes, 995, 998, "T2D", "", +60013, Randomized, 1022, 1032, "randomized", "", +60014, DoubleBlind, 1035, 1049, "double - blind", "", +60015, Placebo, 1052, 1059, "placebo", "", +60028, Precondition, 1110, 1162, "treated with diet / exercise alone or with metformin", "", +60019, Metformin, 1153, 1162, "metformin", "", +60027, Precondition, 1167, 1222, "having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %", "", +60020, HbA1c, 1176, 1190, "hemoglobin A1c", "", +60021, HbA1c, 1193, 1198, "HbA1c", "", +60029, Percentage, 1221, 1222, "%", "", +60022, Randomized, 1228, 1238, "randomized", "", +60023, Liraglutide, 1242, 1253, "liraglutide", "", +60025, NumberPatientsArm, 1260, 1262, "14", "", +60024, Placebo, 1268, 1275, "placebo", "", +60026, NumberPatientsArm, 1282, 1283, "7", "", +60030, DoseValue, 1300, 1314, "0 . 3 mg / day", "", +60031, BioAndMedicalUnit, 1306, 1314, "mg / day", "", +60032, DoseValue, 1348, 1353, "0 . 6", "", +60033, DoseValue, 1356, 1361, "0 . 9", "", +60034, DoseValue, 1364, 1369, "1 . 2", "", +60035, DoseValue, 1376, 1381, "1 . 8", "", +60036, BioAndMedicalUnit, 1382, 1390, "mg / day", "", +60037, Placebo, 1396, 1403, "placebo", "", +60038, Duration, 1421, 1428, "5 weeks", "", +60039, FinalNumPatientsCT, 1441, 1449, "Nineteen", "", +60040, TimePoint, 1485, 1493, "Baseline", "", +60041, Mean, 1545, 1549, "mean", "", +60042, AvgAge, 1575, 1581, "14 . 8", "", +60054, Year, 1592, 1597, "years", "", +60043, BodyWeight, 1600, 1606, "weight", "", +60049, BaseLineValue, 1610, 1617, "113 . 2", "", +60051, SdDevBL, 1620, 1626, "35 . 6", "", +60044, Kg, 1629, 1631, "kg", "", +60045, Kg, 1651, 1653, "kg", "", +60053, Year, 1695, 1700, "years", "", +60046, HbA1c, 1707, 1712, "HbA1c", "", +60050, BaseLineValue, 1722, 1727, "8 . 1", "", +60047, Percentage, 1728, 1729, "%", "", +60052, SdDevBL, 1732, 1737, "1 . 2", "", +60048, Percentage, 1738, 1739, "%", "", +60056, NumberAffected, 1744, 1746, "No", "", +60057, EndPointDescription, 1747, 1769, "serious adverse events", "", +60055, SevereHypoglycemia, 1790, 1809, "severe hypoglycemia", "", +60058, Liraglutide, 1880, 1891, "liraglutide", "", +60059, Liraglutide, 2154, 2165, "liraglutide", "", +60061, DoseValue, 2166, 2174, "1 . 8 mg", "", +60062, mg, 2172, 2174, "mg", "", +60060, Mean, 2177, 2181, "mean", "", +60063, EndPointDescription, 2182, 2193, "half - life", "", +60065, ResultMeasuredValue, 2198, 2200, "12", "", +60067, Hour, 2201, 2202, "h", "", +60064, EndPointDescription, 2209, 2218, "clearance", "", +60066, ResultMeasuredValue, 2223, 2228, "1 . 7", "", +60068, BioAndMedicalUnit, 2229, 2234, "L / h", "", +60069, TimePoint, 2243, 2250, "5 weeks", "", +60070, HbA1c, 2268, 2279, "HbA1c level", "", +60071, Liraglutide, 2297, 2308, "liraglutide", "", +60072, Placebo, 2316, 2323, "placebo", "", +60073, ChangeValue, 2326, 2334, "- 0 . 86", "", +60074, ChangeValue, 2340, 2346, "0 . 04", "", +60075, Percentage, 2347, 2348, "%", "", +60076, PvalueDiff, 2351, 2363, "P = 0 . 0007", "", +60077, Mean, 2376, 2380, "mean", "", +60078, BodyWeight, 2381, 2392, "body weight", "", +60079, ChangeValue, 2411, 2419, "- 0 . 50", "", +60080, ChangeValue, 2425, 2433, "- 0 . 54", "", +60081, Kg, 2434, 2436, "kg", "", +60082, PvalueDiff, 2439, 2451, "P = 0 . 9703", "", +60083, Liraglutide, 2470, 2481, "Liraglutide", "", +60085, ConclusionComment, 2470, 2610, "Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .", "", +60084, Type2Diabetes, 2515, 2518, "T2D", "", +60086, PMID, 2673, 2681, "25036533", "", diff --git a/data/dm2 25036533_akramersunderbrink.n-triples b/data/dm2 25036533_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25036533_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25036533_export.csv b/data/dm2 25036533_export.csv new file mode 100644 index 0000000..c664af1 --- /dev/null +++ b/data/dm2 25036533_export.csv @@ -0,0 +1,593 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +275, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +275, 1, 2, 2, 9, 16, 9, 16, "Technol" +275, 1, 3, 3, 17, 21, 17, 21, "Ther" +275, 1, 4, 4, 22, 23, 22, 23, "." +275, 2, 1, 5, 0, 4, 24, 28, "2014" +275, 2, 2, 6, 5, 8, 29, 32, "Oct" +275, 2, 3, 7, 9, 10, 33, 34, ";" +275, 2, 4, 8, 11, 13, 35, 37, "16" +275, 2, 5, 9, 14, 15, 38, 39, "(" +275, 2, 6, 10, 16, 18, 40, 42, "10" +275, 2, 7, 11, 19, 20, 43, 44, ")" +275, 2, 8, 12, 21, 22, 45, 46, ":" +275, 2, 9, 13, 23, 26, 47, 50, "679" +275, 2, 10, 14, 27, 28, 51, 52, "-" +275, 2, 11, 15, 29, 31, 53, 55, "87" +275, 2, 12, 16, 32, 33, 56, 57, "." +275, 2, 13, 17, 34, 37, 58, 61, "doi" +275, 2, 14, 18, 38, 39, 62, 63, ":" +275, 2, 15, 19, 40, 42, 64, 66, "10" +275, 2, 16, 20, 43, 44, 67, 68, "." +275, 2, 17, 21, 45, 49, 69, 73, "1089" +275, 2, 18, 22, 50, 51, 74, 75, "/" +275, 2, 19, 23, 52, 55, 76, 79, "dia" +275, 2, 20, 24, 56, 57, 80, 81, "." +275, 2, 21, 25, 58, 62, 82, 86, "2013" +275, 2, 22, 26, 63, 64, 87, 88, "." +275, 2, 23, 27, 65, 69, 89, 93, "0366" +275, 2, 24, 28, 70, 71, 94, 95, "." +275, 3, 1, 29, 0, 4, 96, 100, "Epub" +275, 3, 2, 30, 5, 9, 101, 105, "2014" +275, 3, 3, 31, 10, 13, 106, 109, "Jul" +275, 3, 4, 32, 14, 16, 110, 112, "18" +275, 3, 5, 33, 17, 18, 113, 114, "." +275, 4, 1, 34, 0, 11, 115, 126, "Liraglutide" +275, 4, 2, 35, 12, 13, 127, 128, "'" +275, 4, 3, 36, 14, 15, 129, 130, "s" +275, 4, 4, 37, 16, 22, 131, 137, "safety" +275, 4, 5, 38, 23, 24, 138, 139, "," +275, 4, 6, 39, 25, 37, 140, 152, "tolerability" +275, 4, 7, 40, 38, 39, 153, 154, "," +275, 4, 8, 41, 40, 56, 155, 171, "pharmacokinetics" +275, 4, 9, 42, 57, 58, 172, 173, "," +275, 4, 10, 43, 59, 62, 174, 177, "and" +275, 4, 11, 44, 63, 79, 178, 194, "pharmacodynamics" +275, 4, 12, 45, 80, 82, 195, 197, "in" +275, 4, 13, 46, 83, 92, 198, 207, "pediatric" +275, 4, 14, 47, 93, 97, 208, 212, "type" +275, 4, 15, 48, 98, 99, 213, 214, "2" +275, 4, 16, 49, 100, 108, 215, 223, "diabetes" +275, 4, 17, 50, 109, 110, 224, 225, ":" +275, 4, 18, 51, 111, 112, 226, 227, "a" +275, 4, 19, 52, 113, 123, 228, 238, "randomized" +275, 4, 20, 53, 124, 125, 239, 240, "," +275, 4, 21, 54, 126, 132, 241, 247, "double" +275, 4, 22, 55, 133, 134, 248, 249, "-" +275, 4, 23, 56, 135, 140, 250, 255, "blind" +275, 4, 24, 57, 141, 142, 256, 257, "," +275, 4, 25, 58, 143, 150, 258, 265, "placebo" +275, 4, 26, 59, 151, 152, 266, 267, "-" +275, 4, 27, 60, 153, 163, 268, 278, "controlled" +275, 4, 28, 61, 164, 169, 279, 284, "trial" +275, 4, 29, 62, 170, 171, 285, 286, "." +275, 5, 1, 63, 0, 5, 287, 292, "Klein" +275, 5, 2, 64, 6, 8, 293, 295, "DJ" +275, 5, 3, 65, 9, 10, 296, 297, "(" +275, 5, 4, 66, 11, 12, 298, 299, "1" +275, 5, 5, 67, 13, 14, 300, 301, ")" +275, 5, 6, 68, 15, 16, 302, 303, "," +275, 5, 7, 69, 17, 26, 304, 313, "Battelino" +275, 5, 8, 70, 27, 28, 314, 315, "T" +275, 5, 9, 71, 29, 30, 316, 317, "," +275, 5, 10, 72, 31, 41, 318, 328, "Chatterjee" +275, 5, 11, 73, 42, 44, 329, 331, "DJ" +275, 5, 12, 74, 45, 46, 332, 333, "," +275, 5, 13, 75, 47, 55, 334, 342, "Jacobsen" +275, 5, 14, 76, 56, 58, 343, 345, "LV" +275, 5, 15, 77, 59, 60, 346, 347, "," +275, 5, 16, 78, 61, 65, 348, 352, "Hale" +275, 5, 17, 79, 66, 68, 353, 355, "PM" +275, 5, 18, 80, 69, 70, 356, 357, "," +275, 5, 19, 81, 71, 80, 358, 367, "Arslanian" +275, 5, 20, 82, 81, 82, 368, 369, "S" +275, 5, 21, 83, 83, 84, 370, 371, ";" +275, 5, 22, 84, 85, 91, 372, 378, "NN2211" +275, 5, 23, 85, 92, 93, 379, 380, "-" +275, 5, 24, 86, 94, 98, 381, 385, "1800" +275, 5, 25, 87, 99, 104, 386, 391, "Study" +275, 5, 26, 88, 105, 110, 392, 397, "Group" +275, 5, 27, 89, 111, 112, 398, 399, "." +275, 6, 1, 90, 0, 13, 400, 413, "Collaborators" +275, 6, 2, 91, 14, 15, 414, 415, ":" +275, 6, 3, 92, 16, 18, 416, 418, "De" +275, 6, 4, 93, 19, 27, 419, 427, "Schepper" +275, 6, 5, 94, 28, 29, 428, 429, "J" +275, 6, 6, 95, 30, 31, 430, 431, "," +275, 6, 7, 96, 32, 41, 432, 441, "Battelino" +275, 6, 8, 97, 42, 43, 442, 443, "T" +275, 6, 9, 98, 44, 45, 444, 445, "," +275, 6, 10, 99, 46, 53, 446, 453, "Barrett" +275, 6, 11, 100, 54, 55, 454, 455, "T" +275, 6, 12, 101, 56, 57, 456, 457, "," +275, 6, 13, 102, 58, 62, 458, 462, "Bone" +275, 6, 14, 103, 63, 64, 463, 464, "M" +275, 6, 15, 104, 65, 66, 465, 466, "," +275, 6, 16, 105, 67, 74, 467, 474, "Randell" +275, 6, 17, 106, 75, 76, 475, 476, "T" +275, 6, 18, 107, 77, 78, 477, 478, "," +275, 6, 19, 108, 79, 88, 479, 488, "Arslanian" +275, 6, 20, 109, 89, 90, 489, 490, "S" +275, 6, 21, 110, 91, 92, 491, 492, "," +275, 6, 22, 111, 93, 99, 493, 499, "Blumer" +275, 6, 23, 112, 100, 101, 500, 501, "J" +275, 6, 24, 113, 102, 103, 502, 503, "," +275, 6, 25, 114, 104, 115, 504, 515, "Christensen" +275, 6, 26, 115, 116, 117, 516, 517, "M" +275, 6, 27, 116, 118, 119, 518, 519, "," +275, 6, 28, 117, 120, 125, 520, 525, "Ferry" +275, 6, 29, 118, 126, 127, 526, 527, "R" +275, 6, 30, 119, 128, 129, 528, 529, "," +275, 6, 31, 120, 130, 135, 530, 535, "Hazan" +275, 6, 32, 121, 136, 137, 536, 537, "L" +275, 6, 33, 122, 138, 139, 538, 539, "," +275, 6, 34, 123, 140, 145, 540, 545, "Klein" +275, 6, 35, 124, 146, 148, 546, 548, "DJ" +275, 6, 36, 125, 149, 150, 549, 550, "," +275, 6, 37, 126, 151, 156, 551, 556, "Lopez" +275, 6, 38, 127, 157, 158, 557, 558, "X" +275, 6, 39, 128, 159, 160, 559, 560, "," +275, 6, 40, 129, 161, 168, 561, 568, "Neufeld" +275, 6, 41, 130, 169, 170, 569, 570, "N" +275, 6, 42, 131, 171, 172, 571, 572, "," +275, 6, 43, 132, 173, 180, 573, 580, "Toltzis" +275, 6, 44, 133, 181, 182, 581, 582, "P" +275, 6, 45, 134, 183, 184, 583, 584, "," +275, 6, 46, 135, 185, 194, 585, 594, "Tsalikian" +275, 6, 47, 136, 195, 196, 595, 596, "E" +275, 6, 48, 137, 197, 198, 597, 598, "," +275, 6, 49, 138, 199, 204, 599, 604, "Wadwa" +275, 6, 50, 139, 205, 207, 605, 607, "RP" +275, 6, 51, 140, 208, 209, 608, 609, "," +275, 6, 52, 141, 210, 221, 610, 621, "Wintergerst" +275, 6, 53, 142, 222, 223, 622, 623, "K" +275, 6, 54, 143, 224, 225, 624, 625, "." +275, 6, 55, 144, 226, 232, 626, 632, "Author" +275, 6, 56, 145, 233, 244, 633, 644, "information" +275, 6, 57, 146, 245, 246, 645, 646, ":" +275, 6, 58, 147, 247, 248, 647, 648, "(" +275, 6, 59, 148, 249, 250, 649, 650, "1" +275, 6, 60, 149, 251, 252, 651, 652, ")" +275, 6, 61, 150, 253, 254, 653, 654, "1" +275, 6, 62, 151, 255, 265, 655, 665, "Cincinnati" +275, 6, 63, 152, 266, 274, 666, 674, "Children" +275, 6, 64, 153, 275, 276, 675, 676, "'" +275, 6, 65, 154, 277, 278, 677, 678, "s" +275, 6, 66, 155, 279, 287, 679, 687, "Hospital" +275, 6, 67, 156, 288, 295, 688, 695, "Medical" +275, 6, 68, 157, 296, 302, 696, 702, "Center" +275, 6, 69, 158, 303, 304, 703, 704, "," +275, 6, 70, 159, 305, 315, 705, 715, "Cincinnati" +275, 6, 71, 160, 316, 317, 716, 717, "," +275, 6, 72, 161, 318, 322, 718, 722, "Ohio" +275, 6, 73, 162, 323, 324, 723, 724, "." +275, 7, 1, 163, 0, 10, 725, 735, "BACKGROUND" +275, 7, 2, 164, 11, 12, 736, 737, ":" +275, 7, 3, 165, 13, 16, 738, 741, "The" +275, 7, 4, 166, 17, 27, 742, 752, "prevalence" +275, 7, 5, 167, 28, 30, 753, 755, "of" +275, 7, 6, 168, 31, 35, 756, 760, "type" +275, 7, 7, 169, 36, 37, 761, 762, "2" +275, 7, 8, 170, 38, 46, 763, 771, "diabetes" +275, 7, 9, 171, 47, 48, 772, 773, "(" +275, 7, 10, 172, 49, 52, 774, 777, "T2D" +275, 7, 11, 173, 53, 54, 778, 779, ")" +275, 7, 12, 174, 55, 57, 780, 782, "in" +275, 7, 13, 175, 58, 63, 783, 788, "youth" +275, 7, 14, 176, 64, 66, 789, 791, "is" +275, 7, 15, 177, 67, 77, 792, 802, "increasing" +275, 7, 16, 178, 78, 79, 803, 804, "." +275, 8, 1, 179, 0, 9, 805, 814, "Treatment" +275, 8, 2, 180, 10, 17, 815, 822, "options" +275, 8, 3, 181, 18, 24, 823, 829, "beyond" +275, 8, 4, 182, 25, 34, 830, 839, "metformin" +275, 8, 5, 183, 35, 38, 840, 843, "and" +275, 8, 6, 184, 39, 46, 844, 851, "insulin" +275, 8, 7, 185, 47, 50, 852, 855, "are" +275, 8, 8, 186, 51, 57, 856, 862, "needed" +275, 8, 9, 187, 58, 59, 863, 864, "." +275, 9, 1, 188, 0, 3, 865, 868, "The" +275, 9, 2, 189, 4, 10, 869, 875, "safety" +275, 9, 3, 190, 11, 12, 876, 877, "," +275, 9, 4, 191, 13, 25, 878, 890, "tolerability" +275, 9, 5, 192, 26, 27, 891, 892, "," +275, 9, 6, 193, 28, 44, 893, 909, "pharmacokinetics" +275, 9, 7, 194, 45, 46, 910, 911, "," +275, 9, 8, 195, 47, 50, 912, 915, "and" +275, 9, 9, 196, 51, 67, 916, 932, "pharmacodynamics" +275, 9, 10, 197, 68, 70, 933, 935, "of" +275, 9, 11, 198, 71, 82, 936, 947, "liraglutide" +275, 9, 12, 199, 83, 87, 948, 952, "once" +275, 9, 13, 200, 88, 93, 953, 958, "daily" +275, 9, 14, 201, 94, 96, 959, 961, "in" +275, 9, 15, 202, 97, 102, 962, 967, "youth" +275, 9, 16, 203, 103, 104, 968, 969, "(" +275, 9, 17, 204, 105, 107, 970, 972, "10" +275, 9, 18, 205, 108, 109, 973, 974, "-" +275, 9, 19, 206, 110, 112, 975, 977, "17" +275, 9, 20, 207, 113, 118, 978, 983, "years" +275, 9, 21, 208, 119, 122, 984, 987, "old" +275, 9, 22, 209, 123, 124, 988, 989, ")" +275, 9, 23, 210, 125, 129, 990, 994, "with" +275, 9, 24, 211, 130, 133, 995, 998, "T2D" +275, 9, 25, 212, 134, 138, 999, 1003, "were" +275, 9, 26, 213, 139, 151, 1004, 1016, "investigated" +275, 9, 27, 214, 152, 154, 1017, 1019, "in" +275, 9, 28, 215, 155, 156, 1020, 1021, "a" +275, 9, 29, 216, 157, 167, 1022, 1032, "randomized" +275, 9, 30, 217, 168, 169, 1033, 1034, "," +275, 9, 31, 218, 170, 176, 1035, 1041, "double" +275, 9, 32, 219, 177, 178, 1042, 1043, "-" +275, 9, 33, 220, 179, 184, 1044, 1049, "blind" +275, 9, 34, 221, 185, 186, 1050, 1051, "," +275, 9, 35, 222, 187, 194, 1052, 1059, "placebo" +275, 9, 36, 223, 195, 196, 1060, 1061, "-" +275, 9, 37, 224, 197, 207, 1062, 1072, "controlled" +275, 9, 38, 225, 208, 213, 1073, 1078, "trial" +275, 9, 39, 226, 214, 215, 1079, 1080, "." +275, 10, 1, 227, 0, 8, 1081, 1089, "SUBJECTS" +275, 10, 2, 228, 9, 12, 1090, 1093, "AND" +275, 10, 3, 229, 13, 20, 1094, 1101, "METHODS" +275, 10, 4, 230, 21, 22, 1102, 1103, ":" +275, 10, 5, 231, 23, 28, 1104, 1109, "Youth" +275, 10, 6, 232, 29, 36, 1110, 1117, "treated" +275, 10, 7, 233, 37, 41, 1118, 1122, "with" +275, 10, 8, 234, 42, 46, 1123, 1127, "diet" +275, 10, 9, 235, 47, 48, 1128, 1129, "/" +275, 10, 10, 236, 49, 57, 1130, 1138, "exercise" +275, 10, 11, 237, 58, 63, 1139, 1144, "alone" +275, 10, 12, 238, 64, 66, 1145, 1147, "or" +275, 10, 13, 239, 67, 71, 1148, 1152, "with" +275, 10, 14, 240, 72, 81, 1153, 1162, "metformin" +275, 10, 15, 241, 82, 85, 1163, 1166, "and" +275, 10, 16, 242, 86, 92, 1167, 1173, "having" +275, 10, 17, 243, 93, 94, 1174, 1175, "a" +275, 10, 18, 244, 95, 105, 1176, 1186, "hemoglobin" +275, 10, 19, 245, 106, 109, 1187, 1190, "A1c" +275, 10, 20, 246, 110, 111, 1191, 1192, "(" +275, 10, 21, 247, 112, 117, 1193, 1198, "HbA1c" +275, 10, 22, 248, 118, 119, 1199, 1200, ")" +275, 10, 23, 249, 120, 125, 1201, 1206, "level" +275, 10, 24, 250, 126, 128, 1207, 1209, "of" +275, 10, 25, 251, 129, 130, 1210, 1211, "6" +275, 10, 26, 252, 131, 132, 1212, 1213, "." +275, 10, 27, 253, 133, 134, 1214, 1215, "5" +275, 10, 28, 254, 135, 136, 1216, 1217, "-" +275, 10, 29, 255, 137, 139, 1218, 1220, "11" +275, 10, 30, 256, 140, 141, 1221, 1222, "%" +275, 10, 31, 257, 142, 146, 1223, 1227, "were" +275, 10, 32, 258, 147, 157, 1228, 1238, "randomized" +275, 10, 33, 259, 158, 160, 1239, 1241, "to" +275, 10, 34, 260, 161, 172, 1242, 1253, "liraglutide" +275, 10, 35, 261, 173, 174, 1254, 1255, "(" +275, 10, 36, 262, 175, 176, 1256, 1257, "n" +275, 10, 37, 263, 177, 178, 1258, 1259, "=" +275, 10, 38, 264, 179, 181, 1260, 1262, "14" +275, 10, 39, 265, 182, 183, 1263, 1264, ")" +275, 10, 40, 266, 184, 186, 1265, 1267, "or" +275, 10, 41, 267, 187, 194, 1268, 1275, "placebo" +275, 10, 42, 268, 195, 196, 1276, 1277, "(" +275, 10, 43, 269, 197, 198, 1278, 1279, "n" +275, 10, 44, 270, 199, 200, 1280, 1281, "=" +275, 10, 45, 271, 201, 202, 1282, 1283, "7" +275, 10, 46, 272, 203, 204, 1284, 1285, ")" +275, 10, 47, 273, 205, 206, 1286, 1287, "." +275, 11, 1, 274, 0, 8, 1288, 1296, "Starting" +275, 11, 2, 275, 9, 11, 1297, 1299, "at" +275, 11, 3, 276, 12, 13, 1300, 1301, "0" +275, 11, 4, 277, 14, 15, 1302, 1303, "." +275, 11, 5, 278, 16, 17, 1304, 1305, "3" +275, 11, 6, 279, 18, 20, 1306, 1308, "mg" +275, 11, 7, 280, 21, 22, 1309, 1310, "/" +275, 11, 8, 281, 23, 26, 1311, 1314, "day" +275, 11, 9, 282, 27, 28, 1315, 1316, "," +275, 11, 10, 283, 29, 34, 1317, 1322, "doses" +275, 11, 11, 284, 35, 39, 1323, 1327, "were" +275, 11, 12, 285, 40, 49, 1328, 1337, "escalated" +275, 11, 13, 286, 50, 56, 1338, 1344, "weekly" +275, 11, 14, 287, 57, 59, 1345, 1347, "to" +275, 11, 15, 288, 60, 61, 1348, 1349, "0" +275, 11, 16, 289, 62, 63, 1350, 1351, "." +275, 11, 17, 290, 64, 65, 1352, 1353, "6" +275, 11, 18, 291, 66, 67, 1354, 1355, "," +275, 11, 19, 292, 68, 69, 1356, 1357, "0" +275, 11, 20, 293, 70, 71, 1358, 1359, "." +275, 11, 21, 294, 72, 73, 1360, 1361, "9" +275, 11, 22, 295, 74, 75, 1362, 1363, "," +275, 11, 23, 296, 76, 77, 1364, 1365, "1" +275, 11, 24, 297, 78, 79, 1366, 1367, "." +275, 11, 25, 298, 80, 81, 1368, 1369, "2" +275, 11, 26, 299, 82, 83, 1370, 1371, "," +275, 11, 27, 300, 84, 87, 1372, 1375, "and" +275, 11, 28, 301, 88, 89, 1376, 1377, "1" +275, 11, 29, 302, 90, 91, 1378, 1379, "." +275, 11, 30, 303, 92, 93, 1380, 1381, "8" +275, 11, 31, 304, 94, 96, 1382, 1384, "mg" +275, 11, 32, 305, 97, 98, 1385, 1386, "/" +275, 11, 33, 306, 99, 102, 1387, 1390, "day" +275, 11, 34, 307, 103, 104, 1391, 1392, "(" +275, 11, 35, 308, 105, 107, 1393, 1395, "or" +275, 11, 36, 309, 108, 115, 1396, 1403, "placebo" +275, 11, 37, 310, 116, 126, 1404, 1414, "equivalent" +275, 11, 38, 311, 127, 128, 1415, 1416, ")" +275, 11, 39, 312, 129, 132, 1417, 1420, "for" +275, 11, 40, 313, 133, 134, 1421, 1422, "5" +275, 11, 41, 314, 135, 140, 1423, 1428, "weeks" +275, 11, 42, 315, 141, 142, 1429, 1430, "." +275, 12, 1, 316, 0, 7, 1431, 1438, "RESULTS" +275, 12, 2, 317, 8, 9, 1439, 1440, ":" +275, 12, 3, 318, 10, 18, 1441, 1449, "Nineteen" +275, 12, 4, 319, 19, 31, 1450, 1462, "participants" +275, 12, 5, 320, 32, 41, 1463, 1472, "completed" +275, 12, 6, 321, 42, 45, 1473, 1476, "the" +275, 12, 7, 322, 46, 51, 1477, 1482, "trial" +275, 12, 8, 323, 52, 53, 1483, 1484, "." +275, 13, 1, 324, 0, 8, 1485, 1493, "Baseline" +275, 13, 2, 325, 9, 24, 1494, 1509, "characteristics" +275, 13, 3, 326, 25, 29, 1510, 1514, "were" +275, 13, 4, 327, 30, 37, 1515, 1522, "similar" +275, 13, 5, 328, 38, 45, 1523, 1530, "between" +275, 13, 6, 329, 46, 52, 1531, 1537, "groups" +275, 13, 7, 330, 53, 54, 1538, 1539, "," +275, 13, 8, 331, 55, 59, 1540, 1544, "with" +275, 13, 9, 332, 60, 64, 1545, 1549, "mean" +275, 13, 10, 333, 65, 66, 1550, 1551, "(" +275, 13, 11, 334, 67, 69, 1552, 1554, "SD" +275, 13, 12, 335, 70, 71, 1555, 1556, ")" +275, 13, 13, 336, 72, 78, 1557, 1563, "values" +275, 13, 14, 337, 79, 82, 1564, 1567, "for" +275, 13, 15, 338, 83, 86, 1568, 1571, "age" +275, 13, 16, 339, 87, 89, 1572, 1574, "of" +275, 13, 17, 340, 90, 92, 1575, 1577, "14" +275, 13, 18, 341, 93, 94, 1578, 1579, "." +275, 13, 19, 342, 95, 96, 1580, 1581, "8" +275, 13, 20, 343, 97, 98, 1582, 1583, "(" +275, 13, 21, 344, 99, 100, 1584, 1585, "2" +275, 13, 22, 345, 101, 102, 1586, 1587, "." +275, 13, 23, 346, 103, 104, 1588, 1589, "2" +275, 13, 24, 347, 105, 106, 1590, 1591, ")" +275, 13, 25, 348, 107, 112, 1592, 1597, "years" +275, 13, 26, 349, 113, 114, 1598, 1599, "," +275, 13, 27, 350, 115, 121, 1600, 1606, "weight" +275, 13, 28, 351, 122, 124, 1607, 1609, "of" +275, 13, 29, 352, 125, 128, 1610, 1613, "113" +275, 13, 30, 353, 129, 130, 1614, 1615, "." +275, 13, 31, 354, 131, 132, 1616, 1617, "2" +275, 13, 32, 355, 133, 134, 1618, 1619, "(" +275, 13, 33, 356, 135, 137, 1620, 1622, "35" +275, 13, 34, 357, 138, 139, 1623, 1624, "." +275, 13, 35, 358, 140, 141, 1625, 1626, "6" +275, 13, 36, 359, 142, 143, 1627, 1628, ")" +275, 13, 37, 360, 144, 146, 1629, 1631, "kg" +275, 13, 38, 361, 147, 148, 1632, 1633, "(" +275, 13, 39, 362, 149, 154, 1634, 1639, "range" +275, 13, 40, 363, 155, 156, 1640, 1641, "," +275, 13, 41, 364, 157, 159, 1642, 1644, "57" +275, 13, 42, 365, 160, 161, 1645, 1646, "-" +275, 13, 43, 366, 162, 165, 1647, 1650, "214" +275, 13, 44, 367, 166, 168, 1651, 1653, "kg" +275, 13, 45, 368, 169, 170, 1654, 1655, ")" +275, 13, 46, 369, 171, 172, 1656, 1657, "," +275, 13, 47, 370, 173, 181, 1658, 1666, "diabetes" +275, 13, 48, 371, 182, 190, 1667, 1675, "duration" +275, 13, 49, 372, 191, 193, 1676, 1678, "of" +275, 13, 50, 373, 194, 195, 1679, 1680, "1" +275, 13, 51, 374, 196, 197, 1681, 1682, "." +275, 13, 52, 375, 198, 199, 1683, 1684, "7" +275, 13, 53, 376, 200, 201, 1685, 1686, "(" +275, 13, 54, 377, 202, 203, 1687, 1688, "1" +275, 13, 55, 378, 204, 205, 1689, 1690, "." +275, 13, 56, 379, 206, 207, 1691, 1692, "4" +275, 13, 57, 380, 208, 209, 1693, 1694, ")" +275, 13, 58, 381, 210, 215, 1695, 1700, "years" +275, 13, 59, 382, 216, 217, 1701, 1702, "," +275, 13, 60, 383, 218, 221, 1703, 1706, "and" +275, 13, 61, 384, 222, 227, 1707, 1712, "HbA1c" +275, 13, 62, 385, 228, 233, 1713, 1718, "level" +275, 13, 63, 386, 234, 236, 1719, 1721, "of" +275, 13, 64, 387, 237, 238, 1722, 1723, "8" +275, 13, 65, 388, 239, 240, 1724, 1725, "." +275, 13, 66, 389, 241, 242, 1726, 1727, "1" +275, 13, 67, 390, 243, 244, 1728, 1729, "%" +275, 13, 68, 391, 245, 246, 1730, 1731, "(" +275, 13, 69, 392, 247, 248, 1732, 1733, "1" +275, 13, 70, 393, 249, 250, 1734, 1735, "." +275, 13, 71, 394, 251, 252, 1736, 1737, "2" +275, 13, 72, 395, 253, 254, 1738, 1739, "%" +275, 13, 73, 396, 255, 256, 1740, 1741, ")" +275, 13, 74, 397, 257, 258, 1742, 1743, "." +275, 14, 1, 398, 0, 2, 1744, 1746, "No" +275, 14, 2, 399, 3, 10, 1747, 1754, "serious" +275, 14, 3, 400, 11, 18, 1755, 1762, "adverse" +275, 14, 4, 401, 19, 25, 1763, 1769, "events" +275, 14, 5, 402, 26, 27, 1770, 1771, "(" +275, 14, 6, 403, 28, 31, 1772, 1775, "AEs" +275, 14, 7, 404, 32, 33, 1776, 1777, ")" +275, 14, 8, 405, 34, 35, 1778, 1779, "," +275, 14, 9, 406, 36, 45, 1780, 1789, "including" +275, 14, 10, 407, 46, 52, 1790, 1796, "severe" +275, 14, 11, 408, 53, 65, 1797, 1809, "hypoglycemia" +275, 14, 12, 409, 66, 67, 1810, 1811, "," +275, 14, 13, 410, 68, 76, 1812, 1820, "occurred" +275, 14, 14, 411, 77, 78, 1821, 1822, "." +275, 15, 1, 412, 0, 9, 1823, 1832, "Transient" +275, 15, 2, 413, 10, 26, 1833, 1849, "gastrointestinal" +275, 15, 3, 414, 27, 30, 1850, 1853, "AEs" +275, 15, 4, 415, 31, 35, 1854, 1858, "were" +275, 15, 5, 416, 36, 40, 1859, 1863, "most" +275, 15, 6, 417, 41, 47, 1864, 1870, "common" +275, 15, 7, 418, 48, 50, 1871, 1873, "at" +275, 15, 8, 419, 51, 56, 1874, 1879, "lower" +275, 15, 9, 420, 57, 68, 1880, 1891, "liraglutide" +275, 15, 10, 421, 69, 74, 1892, 1897, "doses" +275, 15, 11, 422, 75, 81, 1898, 1904, "during" +275, 15, 12, 423, 82, 86, 1905, 1909, "dose" +275, 15, 13, 424, 87, 97, 1910, 1920, "escalation" +275, 15, 14, 425, 98, 99, 1921, 1922, "." +275, 16, 1, 426, 0, 2, 1923, 1925, "No" +275, 16, 2, 427, 3, 14, 1926, 1937, "significant" +275, 16, 3, 428, 15, 22, 1938, 1945, "changes" +275, 16, 4, 429, 23, 25, 1946, 1948, "in" +275, 16, 5, 430, 26, 32, 1949, 1955, "safety" +275, 16, 6, 431, 33, 36, 1956, 1959, "and" +275, 16, 7, 432, 37, 49, 1960, 1972, "tolerability" +275, 16, 8, 433, 50, 60, 1973, 1983, "parameters" +275, 16, 9, 434, 61, 69, 1984, 1992, "occurred" +275, 16, 10, 435, 70, 71, 1993, 1994, "." +275, 17, 1, 436, 0, 5, 1995, 2000, "There" +275, 17, 2, 437, 6, 9, 2001, 2004, "was" +275, 17, 3, 438, 10, 12, 2005, 2007, "no" +275, 17, 4, 439, 13, 21, 2008, 2016, "evidence" +275, 17, 5, 440, 22, 24, 2017, 2019, "of" +275, 17, 6, 441, 25, 37, 2020, 2032, "pancreatitis" +275, 17, 7, 442, 38, 40, 2033, 2035, "or" +275, 17, 8, 443, 41, 47, 2036, 2042, "lipase" +275, 17, 9, 444, 48, 58, 2043, 2053, "elevations" +275, 17, 10, 445, 59, 64, 2054, 2059, "above" +275, 17, 11, 446, 65, 70, 2060, 2065, "three" +275, 17, 12, 447, 71, 76, 2066, 2071, "times" +275, 17, 13, 448, 77, 80, 2072, 2075, "the" +275, 17, 14, 449, 81, 86, 2076, 2081, "upper" +275, 17, 15, 450, 87, 93, 2082, 2088, "normal" +275, 17, 16, 451, 94, 99, 2089, 2094, "limit" +275, 17, 17, 452, 100, 101, 2095, 2096, ";" +275, 17, 18, 453, 102, 112, 2097, 2107, "calcitonin" +275, 17, 19, 454, 113, 119, 2108, 2114, "levels" +275, 17, 20, 455, 120, 128, 2115, 2123, "remained" +275, 17, 21, 456, 129, 135, 2124, 2130, "within" +275, 17, 22, 457, 136, 139, 2131, 2134, "the" +275, 17, 23, 458, 140, 146, 2135, 2141, "normal" +275, 17, 24, 459, 147, 152, 2142, 2147, "range" +275, 17, 25, 460, 153, 154, 2148, 2149, "." +275, 18, 1, 461, 0, 3, 2150, 2153, "For" +275, 18, 2, 462, 4, 15, 2154, 2165, "liraglutide" +275, 18, 3, 463, 16, 17, 2166, 2167, "1" +275, 18, 4, 464, 18, 19, 2168, 2169, "." +275, 18, 5, 465, 20, 21, 2170, 2171, "8" +275, 18, 6, 466, 22, 24, 2172, 2174, "mg" +275, 18, 7, 467, 25, 26, 2175, 2176, "," +275, 18, 8, 468, 27, 31, 2177, 2181, "mean" +275, 18, 9, 469, 32, 36, 2182, 2186, "half" +275, 18, 10, 470, 37, 38, 2187, 2188, "-" +275, 18, 11, 471, 39, 43, 2189, 2193, "life" +275, 18, 12, 472, 44, 47, 2194, 2197, "was" +275, 18, 13, 473, 48, 50, 2198, 2200, "12" +275, 18, 14, 474, 51, 52, 2201, 2202, "h" +275, 18, 15, 475, 53, 54, 2203, 2204, "," +275, 18, 16, 476, 55, 58, 2205, 2208, "and" +275, 18, 17, 477, 59, 68, 2209, 2218, "clearance" +275, 18, 18, 478, 69, 72, 2219, 2222, "was" +275, 18, 19, 479, 73, 74, 2223, 2224, "1" +275, 18, 20, 480, 75, 76, 2225, 2226, "." +275, 18, 21, 481, 77, 78, 2227, 2228, "7" +275, 18, 22, 482, 79, 80, 2229, 2230, "L" +275, 18, 23, 483, 81, 82, 2231, 2232, "/" +275, 18, 24, 484, 83, 84, 2233, 2234, "h" +275, 18, 25, 485, 85, 86, 2235, 2236, "." +275, 19, 1, 486, 0, 5, 2237, 2242, "After" +275, 19, 2, 487, 6, 7, 2243, 2244, "5" +275, 19, 3, 488, 8, 13, 2245, 2250, "weeks" +275, 19, 4, 489, 14, 15, 2251, 2252, "," +275, 19, 5, 490, 16, 19, 2253, 2256, "the" +275, 19, 6, 491, 20, 27, 2257, 2264, "decline" +275, 19, 7, 492, 28, 30, 2265, 2267, "in" +275, 19, 8, 493, 31, 36, 2268, 2273, "HbA1c" +275, 19, 9, 494, 37, 42, 2274, 2279, "level" +275, 19, 10, 495, 43, 46, 2280, 2283, "was" +275, 19, 11, 496, 47, 54, 2284, 2291, "greater" +275, 19, 12, 497, 55, 59, 2292, 2296, "with" +275, 19, 13, 498, 60, 71, 2297, 2308, "liraglutide" +275, 19, 14, 499, 72, 78, 2309, 2315, "versus" +275, 19, 15, 500, 79, 86, 2316, 2323, "placebo" +275, 19, 16, 501, 87, 88, 2324, 2325, "(" +275, 19, 17, 502, 89, 90, 2326, 2327, "-" +275, 19, 18, 503, 91, 92, 2328, 2329, "0" +275, 19, 19, 504, 93, 94, 2330, 2331, "." +275, 19, 20, 505, 95, 97, 2332, 2334, "86" +275, 19, 21, 506, 98, 100, 2335, 2337, "vs" +275, 19, 22, 507, 101, 102, 2338, 2339, "." +275, 19, 23, 508, 103, 104, 2340, 2341, "0" +275, 19, 24, 509, 105, 106, 2342, 2343, "." +275, 19, 25, 510, 107, 109, 2344, 2346, "04" +275, 19, 26, 511, 110, 111, 2347, 2348, "%" +275, 19, 27, 512, 112, 113, 2349, 2350, "," +275, 19, 28, 513, 114, 115, 2351, 2352, "P" +275, 19, 29, 514, 116, 117, 2353, 2354, "=" +275, 19, 30, 515, 118, 119, 2355, 2356, "0" +275, 19, 31, 516, 120, 121, 2357, 2358, "." +275, 19, 32, 517, 122, 126, 2359, 2363, "0007" +275, 19, 33, 518, 127, 128, 2364, 2365, ")" +275, 19, 34, 519, 129, 130, 2366, 2367, "," +275, 19, 35, 520, 131, 138, 2368, 2375, "whereas" +275, 19, 36, 521, 139, 143, 2376, 2380, "mean" +275, 19, 37, 522, 144, 148, 2381, 2385, "body" +275, 19, 38, 523, 149, 155, 2386, 2392, "weight" +275, 19, 39, 524, 156, 164, 2393, 2401, "remained" +275, 19, 40, 525, 165, 171, 2402, 2408, "stable" +275, 19, 41, 526, 172, 173, 2409, 2410, "(" +275, 19, 42, 527, 174, 175, 2411, 2412, "-" +275, 19, 43, 528, 176, 177, 2413, 2414, "0" +275, 19, 44, 529, 178, 179, 2415, 2416, "." +275, 19, 45, 530, 180, 182, 2417, 2419, "50" +275, 19, 46, 531, 183, 185, 2420, 2422, "vs" +275, 19, 47, 532, 186, 187, 2423, 2424, "." +275, 19, 48, 533, 188, 189, 2425, 2426, "-" +275, 19, 49, 534, 190, 191, 2427, 2428, "0" +275, 19, 50, 535, 192, 193, 2429, 2430, "." +275, 19, 51, 536, 194, 196, 2431, 2433, "54" +275, 19, 52, 537, 197, 199, 2434, 2436, "kg" +275, 19, 53, 538, 200, 201, 2437, 2438, "," +275, 19, 54, 539, 202, 203, 2439, 2440, "P" +275, 19, 55, 540, 204, 205, 2441, 2442, "=" +275, 19, 56, 541, 206, 207, 2443, 2444, "0" +275, 19, 57, 542, 208, 209, 2445, 2446, "." +275, 19, 58, 543, 210, 214, 2447, 2451, "9703" +275, 19, 59, 544, 215, 216, 2452, 2453, ")" +275, 19, 60, 545, 217, 218, 2454, 2455, "." +275, 20, 1, 546, 0, 11, 2456, 2467, "CONCLUSIONS" +275, 20, 2, 547, 12, 13, 2468, 2469, ":" +275, 20, 3, 548, 14, 25, 2470, 2481, "Liraglutide" +275, 20, 4, 549, 26, 29, 2482, 2485, "was" +275, 20, 5, 550, 30, 34, 2486, 2490, "well" +275, 20, 6, 551, 35, 44, 2491, 2500, "tolerated" +275, 20, 7, 552, 45, 47, 2501, 2503, "in" +275, 20, 8, 553, 48, 53, 2504, 2509, "youth" +275, 20, 9, 554, 54, 58, 2510, 2514, "with" +275, 20, 10, 555, 59, 62, 2515, 2518, "T2D" +275, 20, 11, 556, 63, 64, 2519, 2520, "," +275, 20, 12, 557, 65, 69, 2521, 2525, "with" +275, 20, 13, 558, 70, 76, 2526, 2532, "safety" +275, 20, 14, 559, 77, 78, 2533, 2534, "," +275, 20, 15, 560, 79, 91, 2535, 2547, "tolerability" +275, 20, 16, 561, 92, 93, 2548, 2549, "," +275, 20, 17, 562, 94, 97, 2550, 2553, "and" +275, 20, 18, 563, 98, 113, 2554, 2569, "pharmacokinetic" +275, 20, 19, 564, 114, 122, 2570, 2578, "profiles" +275, 20, 20, 565, 123, 130, 2579, 2586, "similar" +275, 20, 21, 566, 131, 133, 2587, 2589, "to" +275, 20, 22, 567, 134, 142, 2590, 2598, "profiles" +275, 20, 23, 568, 143, 145, 2599, 2601, "in" +275, 20, 24, 569, 146, 152, 2602, 2608, "adults" +275, 20, 25, 570, 153, 154, 2609, 2610, "." +275, 21, 1, 571, 0, 3, 2611, 2614, "DOI" +275, 21, 2, 572, 4, 5, 2615, 2616, ":" +275, 21, 3, 573, 6, 8, 2617, 2619, "10" +275, 21, 4, 574, 9, 10, 2620, 2621, "." +275, 21, 5, 575, 11, 15, 2622, 2626, "1089" +275, 21, 6, 576, 16, 17, 2627, 2628, "/" +275, 21, 7, 577, 18, 21, 2629, 2632, "dia" +275, 21, 8, 578, 22, 23, 2633, 2634, "." +275, 21, 9, 579, 24, 28, 2635, 2639, "2013" +275, 21, 10, 580, 29, 30, 2640, 2641, "." +275, 21, 11, 581, 31, 35, 2642, 2646, "0366" +275, 21, 12, 582, 36, 41, 2647, 2652, "PMCID" +275, 21, 13, 583, 42, 43, 2653, 2654, ":" +275, 21, 14, 584, 44, 54, 2655, 2665, "PMC4183917" +275, 21, 15, 585, 55, 59, 2666, 2670, "PMID" +275, 21, 16, 586, 60, 61, 2671, 2672, ":" +275, 21, 17, 587, 62, 70, 2673, 2681, "25036533" +275, 21, 18, 588, 71, 72, 2682, 2683, "[" +275, 21, 19, 589, 73, 80, 2684, 2691, "Indexed" +275, 21, 20, 590, 81, 84, 2692, 2695, "for" +275, 21, 21, 591, 85, 92, 2696, 2703, "MEDLINE" +275, 21, 22, 592, 93, 94, 2704, 2705, "]" diff --git a/data/dm2 25036533_kwoodley.annodb b/data/dm2 25036533_kwoodley.annodb new file mode 100644 index 0000000..ed46ef0 --- /dev/null +++ b/data/dm2 25036533_kwoodley.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +48093, Journal, 0, 21, "Diabetes Technol Ther", "", +48094, PublicationYear, 24, 28, "2014", "", +48095, Drug, 115, 126, "Liraglutide", "", +48113, Title, 115, 286, "Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .", "", +48101, Type2Diabetes, 208, 223, "type 2 diabetes", "", +48106, Randomized, 228, 238, "randomized", "", +48107, DoubleBlind, 241, 255, "double - blind", "", +48108, Placebo, 258, 265, "placebo", "", +48114, Author, 287, 295, "Klein DJ", "", +48115, Author, 304, 315, "Battelino T", "", +48116, Author, 318, 331, "Chatterjee DJ", "", +48117, Author, 334, 345, "Jacobsen LV", "", +48118, Author, 348, 355, "Hale PM", "", +48119, Author, 358, 369, "Arslanian S", "", +48120, USA, 718, 722, "Ohio", "", +48102, Type2Diabetes, 756, 771, "type 2 diabetes", "", +48103, Type2Diabetes, 774, 777, "T2D", "", +48121, Metformin, 830, 839, "metformin", "", +48122, Insulin, 844, 851, "insulin", "", +48129, ObjectiveDescription, 865, 1080, "The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .", "", +48096, Drug, 936, 947, "liraglutide", "", +48123, Frequency, 948, 958, "once daily", "", +48124, MinAge, 970, 972, "10", "", +48125, MaxAge, 975, 977, "17", "", +48104, Type2Diabetes, 995, 998, "T2D", "", +48126, Randomized, 1022, 1032, "randomized", "", +48127, DoubleBlind, 1035, 1049, "double - blind", "", +48128, Placebo, 1052, 1059, "placebo", "", +48135, Precondition, 1104, 1222, "Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %", "", +48130, Metformin, 1153, 1162, "metformin", "", +48131, HbA1c, 1176, 1190, "hemoglobin A1c", "", +48132, HbA1c, 1193, 1198, "HbA1c", "", +48134, Percentage, 1221, 1222, "%", "", +48136, Randomized, 1228, 1238, "randomized", "", +48112, Drug, 1242, 1253, "liraglutide", "", +48137, NumberPatientsArm, 1260, 1262, "14", "", +48111, Placebo, 1268, 1275, "placebo", "", +48138, NumberPatientsArm, 1282, 1283, "7", "", +48139, DoseValue, 1376, 1381, "1 . 8", "", +48141, mg, 1382, 1384, "mg", "", +48143, Frequency, 1387, 1390, "day", "", +48109, Placebo, 1396, 1403, "placebo", "", +48144, Duration, 1421, 1428, "5 weeks", "", +48145, FinalNumPatientsCT, 1441, 1449, "Nineteen", "", +48146, Mean, 1552, 1554, "SD", "", +48147, AvgAge, 1575, 1581, "14 . 8", "", +48148, BodyWeight, 1600, 1606, "weight", "", +48157, Precondition, 1600, 1741, "weight of 113 . 2 ( 35 . 6 ) kg ( range , 57 - 214 kg ) , diabetes duration of 1 . 7 ( 1 . 4 ) years , and HbA1c level of 8 . 1 % ( 1 . 2 % )", "", +48153, BaseLineValue, 1610, 1617, "113 . 2", "", +48150, Kg, 1629, 1631, "kg", "", +48151, Kg, 1651, 1653, "kg", "", +48155, HbA1c, 1707, 1712, "HbA1c", "", +48154, BaseLineValue, 1722, 1727, "8 . 1", "", +48156, Percentage, 1728, 1729, "%", "", +48158, Percentage, 1738, 1739, "%", "", +48162, ObservedResult, 1744, 1822, "No serious adverse events ( AEs ) , including severe hypoglycemia , occurred .", "", +48159, EndPointDescription, 1747, 1769, "serious adverse events", "", +48160, EndPointDescription, 1772, 1775, "AEs", "", +48161, SevereHypoglycemia, 1790, 1809, "severe hypoglycemia", "", +48164, ObservedResult, 1823, 1922, "Transient gastrointestinal AEs were most common at lower liraglutide doses during dose escalation .", "", +48163, GastrointestinalProblem, 1833, 1853, "gastrointestinal AEs", "", +48097, Drug, 1880, 1891, "liraglutide", "", +48168, ObservedResult, 1995, 2149, "There was no evidence of pancreatitis or lipase elevations above three times the upper normal limit ; calcitonin levels remained within the normal range .", "", +48166, EndPointDescription, 2020, 2032, "pancreatitis", "", +48167, EndPointDescription, 2036, 2042, "lipase", "", +48165, EndPointDescription, 2097, 2107, "calcitonin", "", +48098, Drug, 2154, 2165, "liraglutide", "", +48140, DoseValue, 2166, 2171, "1 . 8", "", +48142, mg, 2172, 2174, "mg", "", +48169, TimePoint, 2243, 2250, "5 weeks", "", +48133, HbA1c, 2268, 2273, "HbA1c", "", +48099, Drug, 2297, 2308, "liraglutide", "", +48110, Placebo, 2316, 2323, "placebo", "", +48170, Reduction, 2328, 2334, "0 . 86", "", +48171, Increment, 2340, 2346, "0 . 04", "", +48172, Percentage, 2347, 2348, "%", "", +48173, PvalueDiff, 2351, 2363, "P = 0 . 0007", "", +48149, BodyWeight, 2381, 2392, "body weight", "", +48174, Reduction, 2413, 2419, "0 . 50", "", +48175, Reduction, 2427, 2433, "0 . 54", "", +48152, Kg, 2434, 2436, "kg", "", +48176, PvalueDiff, 2439, 2451, "P = 0 . 9703", "", +48177, ConclusionComment, 2470, 2610, "Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .", "", +48100, Drug, 2470, 2481, "Liraglutide", "", +48105, Type2Diabetes, 2515, 2518, "T2D", "", +48178, PMID, 2673, 2681, "25036533", "", diff --git a/data/dm2 25036533_kwoodley.n-triples b/data/dm2 25036533_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25036533_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25054436_admin.annodb b/data/dm2 25054436_admin.annodb new file mode 100644 index 0000000..c57eda5 --- /dev/null +++ b/data/dm2 25054436_admin.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Horm Metab Res .", "", " \"Horm Metab Res .\"." +76401, PublicationYear, 17, 21, "2014", "", " \"2014\"." +17, Title, 108, 219, "Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .", "", " \"Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .\"." +79622, Colesevelam, 131, 142, "colesevelam", "", +10, Pioglitazone, 163, 175, "pioglitazone", "", +13, Type2Diabetes, 193, 217, "type 2 diabetes mellitus", "", " ." +18, Author, 220, 232, "Rosenstock J", "", " \"Rosenstock J\"." +19, Author, 241, 250, "Truitt KE", "", " \"Truitt KE\"." +20, Author, 259, 272, "Baz - Hecht M", "", " \"Baz - Hecht M\"." +21, Author, 281, 288, "Ford DM", "", " \"Ford DM\"." +22, Author, 297, 302, "Tao B", "", " \"Tao B\"." +23, Author, 311, 318, "Chou HS", "", " \"Chou HS\"." +24, USA, 423, 426, "USA", "", " ." +25, USA, 485, 488, "USA", "", +79623, Colesevelam, 491, 502, "Colesevelam", "", +125, ObjectiveDescription, 491, 645, "Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens .", "", " \"Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens .\"." +14, Type2Diabetes, 546, 561, "type 2 diabetes", "", +26, Metformin, 585, 594, "metformin", "", +27, Sulfonylureas, 599, 611, "sulfonylurea", "", +28, Insulin, 619, 626, "insulin", "", +30, ObjectiveDescription, 646, 735, "We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .", "", " \"We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .\"." +79625, Colesevelam, 659, 670, "colesevelam", "", +29, Pioglitazone, 705, 717, "pioglitazone", "", +31, Duration, 741, 750, "24 - week", "", " \"24 - week\"." +32, Multicenter, 751, 762, "multicenter", "", " ." +33, DoubleBlind, 765, 779, "double - blind", "", " ." +34, Randomized, 782, 792, "randomized", "", " ." +35, Placebo, 795, 802, "placebo", "", +76408, Precondition, 831, 894, "adults with type 2 diabetes who had suboptimal glycemic control", "", " \"adults with type 2 diabetes who had suboptimal glycemic control\". \"on pioglitazone\". \"with or without 1 - 2 other oral antidiabetes medications\"." +15, Type2Diabetes, 843, 858, "type 2 diabetes", "", +40, HbA1c, 897, 902, "HbA1c", "", +79789, Millimoles_per_mole, 908, 918, "mmol / mol", "", +43, Percentage, 927, 928, "%", "", +79790, Millimoles_per_mole, 940, 950, "mmol / mol", "", +44, Percentage, 959, 960, "%", "", +76408, Precondition, 965, 980, "on pioglitazone", "", +45, Pioglitazone, 968, 980, "pioglitazone", "", +47, DoseValue, 983, 985, "30", "", +48, DoseValue, 989, 991, "45", "", +49, mg, 992, 994, "mg", "", +76408, Precondition, 997, 1054, "with or without 1 - 2 other oral antidiabetes medications", "", +46, OralAntidiabeticAgent, 1025, 1054, "oral antidiabetes medications", "", +51, Randomized, 1071, 1081, "randomized", "", +79627, Colesevelam, 1085, 1096, "colesevelam", "", " ." +52, DoseValue, 1097, 1102, "3 . 8", "", " \"3 . 8\"." +53, Gram, 1103, 1104, "g", "", " \"3 . 8\"." +100520, Frequency, 1107, 1110, "day", "", " \"day\"." +55, NumberPatientsArm, 1117, 1120, "280", "", " \"280\"." +36, Placebo, 1126, 1133, "placebo", "", " ." +56, NumberPatientsArm, 1140, 1143, "282", "", " \"282\"." +11, Pioglitazone, 1164, 1176, "pioglitazone", "", +148, Mean, 1225, 1229, "mean", "", +57, HbA1c, 1240, 1245, "HbA1c", "", +58, TimePoint, 1251, 1259, "baseline", "", +59, TimePoint, 1263, 1270, "Week 24", "", +60, FastingPlasmaGlucose, 1328, 1350, "fasting plasma glucose", "", +61, EndPointDescription, 1386, 1399, "lipid profile", "", +62, EndPointDescription, 1430, 1452, "lipid particle profile", "", +79630, Colesevelam, 1493, 1504, "Colesevelam", "", +63, HbA1c, 1515, 1520, "HbA1c", "", " ." +64, LeastSquaresMean, 1523, 1543, "least - squares mean", "", " ." +65, DiffGroupAbsValue, 1567, 1574, "- 3 . 5", "", +79793, Millimoles_per_mole, 1575, 1585, "mmol / mol", "", " ." +68, DiffGroupAbsValue, 1588, 1596, "- 0 . 32", "", " \"- 0 . 32\"." +69, Percentage, 1597, 1598, "%", "", +70, PvalueDiff, 1603, 1614, "p < 0 . 001", "", " \"p < 0 . 001\"." +72, FastingPlasmaGlucose, 1621, 1643, "fasting plasma glucose", "", " ." +66, DiffGroupAbsValue, 1646, 1654, "- 14 . 7", "", " \"- 14 . 7\"." +73, Mg_per_deciliter, 1655, 1662, "mg / dl", "", " ." +71, PvalueDiff, 1665, 1676, "p < 0 . 001", "", " \"p < 0 . 001\"." +37, Placebo, 1684, 1691, "placebo", "", +74, TimePoint, 1695, 1702, "Week 24", "", " \"Week 24\". \"Week 24\". \"Week 24\". \"Week 24\"." +79633, Colesevelam, 1729, 1740, "colesevelam", "", +38, Placebo, 1746, 1753, "placebo", "", +75, HbA1c_target, 1763, 1809, "HbA1c reduction ≥ 7 . 7 mmol / mol ( 0 . 7 % )", "", " ." +79791, Millimoles_per_mole, 1787, 1797, "mmol / mol", "", +177, Percentage, 1806, 1807, "%", "", +77, PercentageAffected, 1812, 1814, "40", "", " \"40\"." +78, PercentageAffected, 1822, 1824, "25", "", " \"25\"." +81, PvalueDiff, 1829, 1840, "p < 0 . 001", "", " \"p < 0 . 001\"." +76, HbA1c_target, 1846, 1879, "HbA1c < 53 mmol / mol ( 7 . 0 % )", "", " ." +79792, Millimoles_per_mole, 1857, 1867, "mmol / mol", "", +182, Percentage, 1876, 1877, "%", "", +79, PercentageAffected, 1882, 1884, "21", "", " \"21\"." +80, PercentageAffected, 1892, 1894, "13", "", " \"13\"." +82, PvalueDiff, 1899, 1910, "p = 0 . 012", "", " \"p = 0 . 012\"." +79635, Colesevelam, 1915, 1926, "Colesevelam", "", +83, EndPointDescription, 1948, 1959, "cholesterol", "", " . ." +200, Mean, 1962, 1966, "mean", "", " . ." +90, DiffGroupRelValue, 1990, 1997, "- 6 . 5", "", " \"- 6 . 5\"." +84, EndPointDescription, 2004, 2021, "LDL - cholesterol", "", " . ." +91, DiffGroupRelValue, 2024, 2032, "- 16 . 4", "", " \"- 16 . 4\"." +85, EndPointDescription, 2039, 2062, "non - HDL - cholesterol", "", " . ." +92, DiffGroupRelValue, 2065, 2072, "- 9 . 8", "", " \"- 9 . 8\"." +86, EndPointDescription, 2079, 2095, "apolipoprotein B", "", " . ." +93, DiffGroupRelValue, 2098, 2105, "- 8 . 8", "", " \"- 8 . 8\"." +87, EndPointDescription, 2122, 2148, "LDL particle concentration", "", " . ." +88, EndPointDescription, 2165, 2182, "apolipoprotein A1", "", " . ." +94, DiffGroupRelValue, 2185, 2192, "+ 3 . 4", "", " \"+ 3 . 4\"." +89, EndPointDescription, 2201, 2214, "triglycerides", "", " . ." +95, DiffGroupRelValue, 2247, 2255, "+ 11 . 3", "", " \"+ 11 . 3\"." +39, Placebo, 2265, 2272, "placebo", "", +96, PvalueDiff, 2279, 2290, "p < 0 . 001", "", " \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\"." +76412, ObservedResult, 2295, 2331, "There were no serious drug - related", "", " \"There were no serious drug - related\". \"There were no serious drug - related\"." +97, EndPointDescription, 2332, 2346, "adverse events", "", " . ." +98, EndPointDescription, 2369, 2383, "adverse events", "", +101, ConclusionComment, 2408, 2601, "In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .", "", " \"In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .\"." +16, Type2Diabetes, 2425, 2440, "type 2 diabetes", "", +12, Pioglitazone, 2470, 2482, "pioglitazone", "", +79637, Colesevelam, 2510, 2521, "colesevelam", "", +102, PMID, 2742, 2750, "25054436", "", " \"25054436\"." diff --git a/data/dm2 25054436_admin.n-triples b/data/dm2 25054436_admin.n-triples new file mode 100644 index 0000000..02bef05 --- /dev/null +++ b/data/dm2 25054436_admin.n-triples @@ -0,0 +1,336 @@ +# RDF export of group: Publication + . + "Publication 62113" . + "Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus ." . + "Rosenstock J" . + "2014" . + "Horm Metab Res ." . + "25054436" . + . + "Truitt KE" . + "Baz - Hecht M" . + "Ford DM" . + "Tao B" . + "Chou HS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 62120" . + "Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens ." . + "24 - week" . + . + . + . + "In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated ." . + . + . + . + . + . + . + . + . + "We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 62136" . + "adults with type 2 diabetes who had suboptimal glycemic control" . + "on pioglitazone" . + "with or without 1 - 2 other oral antidiabetes medications" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "hbat2" . + . + . + . + . + . + "cho" . + . + . + . + . + . + . + . + "ldl" . + . + . + . + . + . + . + "non" . + . + . + . + . + . + . + "apo" . + . + . + . + . + . + . + "ldl2" . + . + . + . + . + . + . + "apo2" . + . + . + . + . + . + . + "tri" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "col" . + "280" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "pla" . + "282" . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "col" . + . + "day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "col" . + . + "3 . 8" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "Week 24" . + . + "hba 2" . + . + "Week 24" . + . + "fpg 1" . + . + "Week 24" . + . + "fpg 2" . + . + "Week 24" . + . + "hbat 1" . + . + "40" . + . + "hbat 2" . + . + "25" . + . + "hbat2 1" . + . + "21" . + . + "hbat2 2" . + . + "13" . + . + "cho1" . + . + . + "cho2" . + . + . + "ldl 1" . + . + . + "ldl 2" . + . + . + "non 1" . + . + . + "non 2" . + . + . + "apo 1" . + . + . + "apo 2" . + . + . + "ldl2 1" . + . + . + "ldl2 2" . + . + . + "apo2 1" . + . + . + "apo2 2" . + . + . + "tri 1" . + . + . + "tri 2" . + . + . + "ae 1" . + . + "There were no serious drug - related" . + . + "ae 2" . + . + "There were no serious drug - related" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 32" . + "p < 0 . 001" . + . + . + . + "fpg" . + "- 14 . 7" . + "p < 0 . 001" . + . + . + . + "hbat" . + "p < 0 . 001" . + . + . + . + "hbat2" . + "p = 0 . 012" . + . + . + . + "cho" . + "- 6 . 5" . + "p < 0 . 001" . + . + . + . + "ldl" . + "- 16 . 4" . + "p < 0 . 001" . + . + . + . + "non" . + "- 9 . 8" . + "p < 0 . 001" . + . + . + . + "apo" . + "- 8 . 8" . + "p < 0 . 001" . + . + . + . + "ldl2" . + "p < 0 . 001" . + . + . + . + "apo2" . + "+ 3 . 4" . + "p < 0 . 001" . + . + . + . + "tri" . + "+ 11 . 3" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25054436_akramersunderbrink.annodb b/data/dm2 25054436_akramersunderbrink.annodb new file mode 100644 index 0000000..0e0aba8 --- /dev/null +++ b/data/dm2 25054436_akramersunderbrink.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +60186, Journal, 0, 14, "Horm Metab Res", "", +60187, PublicationYear, 17, 21, "2014", "", +60191, Title, 108, 219, "Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .", "", +60188, Drug, 131, 142, "colesevelam", "", +60189, Pioglitazone, 163, 175, "pioglitazone", "", +60190, Type2Diabetes, 193, 217, "type 2 diabetes mellitus", "", +60192, Author, 220, 232, "Rosenstock J", "", +60193, Author, 241, 250, "Truitt KE", "", +60194, Author, 259, 272, "Baz - Hecht M", "", +60195, Author, 281, 288, "Ford DM", "", +60196, Author, 297, 302, "Tao B", "", +60197, Author, 311, 318, "Chou HS", "", +60198, USA, 423, 426, "USA", "", +60199, USA, 485, 488, "USA", "", +60200, Drug, 491, 502, "Colesevelam", "", +60208, ObjectiveDescription, 491, 645, "Colesevelam improves glycemic control in patients with type 2 diabetes when added to existing metformin - , sulfonylurea - , or insulin - based regimens .", "", +60201, Type2Diabetes, 546, 561, "type 2 diabetes", "", +60202, Metformin, 585, 594, "metformin", "", +60203, Sulfonylureas, 599, 611, "sulfonylurea", "", +60204, Insulin, 619, 626, "insulin", "", +60207, ObjectiveDescription, 646, 735, "We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .", "", +60205, Drug, 659, 670, "colesevelam", "", +60206, Pioglitazone, 705, 717, "pioglitazone", "", +60209, Duration, 741, 750, "24 - week", "", +60210, Multicenter, 751, 762, "multicenter", "", +60211, DoubleBlind, 765, 779, "double - blind", "", +60212, Randomized, 782, 792, "randomized", "", +60213, Placebo, 795, 802, "placebo", "", +60214, Type2Diabetes, 843, 858, "type 2 diabetes", "", +60218, Precondition, 867, 1054, "suboptimal glycemic control [ HbA1c ≥ 58 mmol / mol ( 7 . 5 % ) and ≤ 80 mmol / mol ( 9 . 5 % ) ] on pioglitazone ( 30 or 45 mg ) with or without 1 - 2 other oral antidiabetes medications", "", +60219, HbA1c, 897, 902, "HbA1c", "", +60220, ConcentrationUnit, 908, 918, "mmol / mol", "", +60222, Percentage, 927, 928, "%", "", +60221, ConcentrationUnit, 940, 950, "mmol / mol", "", +60223, Percentage, 959, 960, "%", "", +60216, Pioglitazone, 968, 980, "pioglitazone", "", +60225, DoseValue, 983, 994, "30 or 45 mg", "", +60224, mg, 992, 994, "mg", "", +60217, OralAntidiabeticAgent, 1025, 1054, "oral antidiabetes medications", "", +60226, Randomized, 1071, 1081, "randomized", "", +60227, Drug, 1085, 1096, "colesevelam", "", +60230, NumberPatientsArm, 1117, 1120, "280", "", +60228, Placebo, 1126, 1133, "placebo", "", +60231, NumberPatientsArm, 1140, 1143, "282", "", +60229, Pioglitazone, 1164, 1176, "pioglitazone", "", +60232, Mean, 1225, 1229, "mean", "", +60233, HbA1c, 1240, 1245, "HbA1c", "", +60234, TimePoint, 1251, 1259, "baseline", "", +60235, TimePoint, 1263, 1270, "Week 24", "", +60236, FastingPlasmaGlucose, 1328, 1350, "fasting plasma glucose", "", +60238, Drug, 1493, 1504, "Colesevelam", "", +60237, HbA1c, 1515, 1520, "HbA1c", "", +60239, LeastSquaresMean, 1523, 1543, "least - squares mean", "", +60240, DiffGroupAbsValue, 1567, 1574, "- 3 . 5", "", +60243, ConcentrationUnit, 1575, 1585, "mmol / mol", "", +60242, DiffGroupAbsValue, 1588, 1596, "- 0 . 32", "", +60244, Percentage, 1597, 1598, "%", "", +60245, PvalueDiff, 1603, 1614, "p < 0 . 001", "", +60250, FastingPlasmaGlucose, 1621, 1643, "fasting plasma glucose", "", +60241, DiffGroupAbsValue, 1646, 1654, "- 14 . 7", "", +60247, Mg_per_deciliter, 1655, 1662, "mg / dl", "", +60246, PvalueDiff, 1665, 1676, "p < 0 . 001", "", +60249, Placebo, 1684, 1691, "placebo", "", +60248, TimePoint, 1695, 1702, "Week 24", "", +60251, Drug, 1729, 1740, "colesevelam", "", +60252, Placebo, 1746, 1753, "placebo", "", +60253, HbA1c_target, 1763, 1809, "HbA1c reduction ≥ 7 . 7 mmol / mol ( 0 . 7 % )", "", +60267, ConcentrationUnit, 1787, 1797, "mmol / mol", "", +60261, Percentage, 1806, 1807, "%", "", +60255, PercentageAffected, 1812, 1814, "40", "", +60262, Percentage, 1815, 1816, "%", "", +60256, PercentageAffected, 1822, 1824, "25", "", +60263, Percentage, 1825, 1826, "%", "", +60259, PvalueDiff, 1829, 1840, "p < 0 . 001", "", +60254, HbA1c_target, 1846, 1879, "HbA1c < 53 mmol / mol ( 7 . 0 % )", "", +60268, ConcentrationUnit, 1857, 1867, "mmol / mol", "", +60266, Percentage, 1876, 1877, "%", "", +60257, PercentageAffected, 1882, 1884, "21", "", +60265, Percentage, 1885, 1886, "%", "", +60258, PercentageAffected, 1892, 1894, "13", "", +60264, Percentage, 1895, 1896, "%", "", +60260, PvalueDiff, 1899, 1910, "p = 0 . 012", "", +60269, Drug, 1915, 1926, "Colesevelam", "", +60270, EndPointDescription, 1942, 1959, "total cholesterol", "", +60284, Mean, 1962, 1966, "mean", "", +60278, DiffGroupAbsValue, 1990, 1997, "- 6 . 5", "", +60285, Percentage, 1998, 1999, "%", "", +60271, EndPointDescription, 2004, 2021, "LDL - cholesterol", "", +60279, DiffGroupAbsValue, 2024, 2032, "- 16 . 4", "", +60326, Percentage, 2033, 2034, "%", "", +60272, EndPointDescription, 2039, 2062, "non - HDL - cholesterol", "", +60280, DiffGroupAbsValue, 2065, 2072, "- 9 . 8", "", +60438, Percentage, 2073, 2074, "%", "", +60273, EndPointDescription, 2079, 2095, "apolipoprotein B", "", +60281, DiffGroupAbsValue, 2098, 2105, "- 8 . 8", "", +60509, Percentage, 2106, 2107, "%", "", +60274, EndPointDescription, 2116, 2148, "total LDL particle concentration", "", +60275, EndPointDescription, 2165, 2182, "apolipoprotein A1", "", +60282, DiffGroupAbsValue, 2185, 2192, "+ 3 . 4", "", +60552, Percentage, 2193, 2194, "%", "", +60276, EndPointDescription, 2201, 2214, "triglycerides", "", +60283, DiffGroupAbsValue, 2247, 2255, "+ 11 . 3", "", +60553, Percentage, 2256, 2257, "%", "", +60277, Placebo, 2265, 2272, "placebo", "", +60554, PvalueDiff, 2279, 2290, "p < 0 . 001", "", +60560, ConclusionComment, 2408, 2601, "In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .", "", +60555, Type2Diabetes, 2425, 2440, "type 2 diabetes", "", +60556, Precondition, 2441, 2498, "inadequately controlled with pioglitazone - based therapy", "", +60557, Pioglitazone, 2470, 2482, "pioglitazone", "", +60558, Drug, 2510, 2521, "colesevelam", "", +60562, PMID, 2742, 2750, "25054436", "", diff --git a/data/dm2 25054436_akramersunderbrink.n-triples b/data/dm2 25054436_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25054436_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25054436_export.csv b/data/dm2 25054436_export.csv new file mode 100644 index 0000000..aea3e98 --- /dev/null +++ b/data/dm2 25054436_export.csv @@ -0,0 +1,616 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +274, 1, 1, 1, 0, 4, 0, 4, "Horm" +274, 1, 2, 2, 5, 10, 5, 10, "Metab" +274, 1, 3, 3, 11, 14, 11, 14, "Res" +274, 1, 4, 4, 15, 16, 15, 16, "." +274, 2, 1, 5, 0, 4, 17, 21, "2014" +274, 2, 2, 6, 5, 8, 22, 25, "Dec" +274, 2, 3, 7, 9, 10, 26, 27, ";" +274, 2, 4, 8, 11, 13, 28, 30, "46" +274, 2, 5, 9, 14, 15, 31, 32, "(" +274, 2, 6, 10, 16, 18, 33, 35, "13" +274, 2, 7, 11, 19, 20, 36, 37, ")" +274, 2, 8, 12, 21, 22, 38, 39, ":" +274, 2, 9, 13, 23, 26, 40, 43, "943" +274, 2, 10, 14, 27, 28, 44, 45, "-" +274, 2, 11, 15, 29, 30, 46, 47, "9" +274, 2, 12, 16, 31, 32, 48, 49, "." +274, 2, 13, 17, 33, 36, 50, 53, "doi" +274, 2, 14, 18, 37, 38, 54, 55, ":" +274, 2, 15, 19, 39, 41, 56, 58, "10" +274, 2, 16, 20, 42, 43, 59, 60, "." +274, 2, 17, 21, 44, 48, 61, 65, "1055" +274, 2, 18, 22, 49, 50, 66, 67, "/" +274, 2, 19, 23, 51, 52, 68, 69, "s" +274, 2, 20, 24, 53, 54, 70, 71, "-" +274, 2, 21, 25, 55, 59, 72, 76, "0034" +274, 2, 22, 26, 60, 61, 77, 78, "-" +274, 2, 23, 27, 62, 69, 79, 86, "1383648" +274, 2, 24, 28, 70, 71, 87, 88, "." +274, 3, 1, 29, 0, 4, 89, 93, "Epub" +274, 3, 2, 30, 5, 9, 94, 98, "2014" +274, 3, 3, 31, 10, 13, 99, 102, "Jul" +274, 3, 4, 32, 14, 16, 103, 105, "23" +274, 3, 5, 33, 17, 18, 106, 107, "." +274, 4, 1, 34, 0, 8, 108, 116, "Efficacy" +274, 4, 2, 35, 9, 12, 117, 120, "and" +274, 4, 3, 36, 13, 19, 121, 127, "safety" +274, 4, 4, 37, 20, 22, 128, 130, "of" +274, 4, 5, 38, 23, 34, 131, 142, "colesevelam" +274, 4, 6, 39, 35, 37, 143, 145, "in" +274, 4, 7, 40, 38, 49, 146, 157, "combination" +274, 4, 8, 41, 50, 54, 158, 162, "with" +274, 4, 9, 42, 55, 67, 163, 175, "pioglitazone" +274, 4, 10, 43, 68, 70, 176, 178, "in" +274, 4, 11, 44, 71, 79, 179, 187, "patients" +274, 4, 12, 45, 80, 84, 188, 192, "with" +274, 4, 13, 46, 85, 89, 193, 197, "type" +274, 4, 14, 47, 90, 91, 198, 199, "2" +274, 4, 15, 48, 92, 100, 200, 208, "diabetes" +274, 4, 16, 49, 101, 109, 209, 217, "mellitus" +274, 4, 17, 50, 110, 111, 218, 219, "." +274, 5, 1, 51, 0, 10, 220, 230, "Rosenstock" +274, 5, 2, 52, 11, 12, 231, 232, "J" +274, 5, 3, 53, 13, 14, 233, 234, "(" +274, 5, 4, 54, 15, 16, 235, 236, "1" +274, 5, 5, 55, 17, 18, 237, 238, ")" +274, 5, 6, 56, 19, 20, 239, 240, "," +274, 5, 7, 57, 21, 27, 241, 247, "Truitt" +274, 5, 8, 58, 28, 30, 248, 250, "KE" +274, 5, 9, 59, 31, 32, 251, 252, "(" +274, 5, 10, 60, 33, 34, 253, 254, "2" +274, 5, 11, 61, 35, 36, 255, 256, ")" +274, 5, 12, 62, 37, 38, 257, 258, "," +274, 5, 13, 63, 39, 42, 259, 262, "Baz" +274, 5, 14, 64, 43, 44, 263, 264, "-" +274, 5, 15, 65, 45, 50, 265, 270, "Hecht" +274, 5, 16, 66, 51, 52, 271, 272, "M" +274, 5, 17, 67, 53, 54, 273, 274, "(" +274, 5, 18, 68, 55, 56, 275, 276, "2" +274, 5, 19, 69, 57, 58, 277, 278, ")" +274, 5, 20, 70, 59, 60, 279, 280, "," +274, 5, 21, 71, 61, 65, 281, 285, "Ford" +274, 5, 22, 72, 66, 68, 286, 288, "DM" +274, 5, 23, 73, 69, 70, 289, 290, "(" +274, 5, 24, 74, 71, 72, 291, 292, "2" +274, 5, 25, 75, 73, 74, 293, 294, ")" +274, 5, 26, 76, 75, 76, 295, 296, "," +274, 5, 27, 77, 77, 80, 297, 300, "Tao" +274, 5, 28, 78, 81, 82, 301, 302, "B" +274, 5, 29, 79, 83, 84, 303, 304, "(" +274, 5, 30, 80, 85, 86, 305, 306, "2" +274, 5, 31, 81, 87, 88, 307, 308, ")" +274, 5, 32, 82, 89, 90, 309, 310, "," +274, 5, 33, 83, 91, 95, 311, 315, "Chou" +274, 5, 34, 84, 96, 98, 316, 318, "HS" +274, 5, 35, 85, 99, 100, 319, 320, "(" +274, 5, 36, 86, 101, 102, 321, 322, "2" +274, 5, 37, 87, 103, 104, 323, 324, ")" +274, 5, 38, 88, 105, 106, 325, 326, "." +274, 6, 1, 89, 0, 6, 327, 333, "Author" +274, 6, 2, 90, 7, 18, 334, 345, "information" +274, 6, 3, 91, 19, 20, 346, 347, ":" +274, 6, 4, 92, 21, 22, 348, 349, "(" +274, 6, 5, 93, 23, 24, 350, 351, "1" +274, 6, 6, 94, 25, 26, 352, 353, ")" +274, 6, 7, 95, 27, 33, 354, 360, "Dallas" +274, 6, 8, 96, 34, 42, 361, 369, "Diabetes" +274, 6, 9, 97, 43, 46, 370, 373, "and" +274, 6, 10, 98, 47, 56, 374, 383, "Endocrine" +274, 6, 11, 99, 57, 63, 384, 390, "Center" +274, 6, 12, 100, 64, 66, 391, 393, "at" +274, 6, 13, 101, 67, 74, 394, 401, "Medical" +274, 6, 14, 102, 75, 79, 402, 406, "City" +274, 6, 15, 103, 80, 81, 407, 408, "," +274, 6, 16, 104, 82, 88, 409, 415, "Dallas" +274, 6, 17, 105, 89, 90, 416, 417, "," +274, 6, 18, 106, 91, 93, 418, 420, "TX" +274, 6, 19, 107, 94, 95, 421, 422, "," +274, 6, 20, 108, 96, 99, 423, 426, "USA" +274, 6, 21, 109, 100, 101, 427, 428, "." +274, 7, 1, 110, 0, 1, 429, 430, "(" +274, 7, 2, 111, 2, 3, 431, 432, "2" +274, 7, 3, 112, 4, 5, 433, 434, ")" +274, 7, 4, 113, 6, 13, 435, 442, "Daiichi" +274, 7, 5, 114, 14, 20, 443, 449, "Sankyo" +274, 7, 6, 115, 21, 27, 450, 456, "Pharma" +274, 7, 7, 116, 28, 39, 457, 468, "Development" +274, 7, 8, 117, 40, 41, 469, 470, "," +274, 7, 9, 118, 42, 48, 471, 477, "Edison" +274, 7, 10, 119, 49, 50, 478, 479, "," +274, 7, 11, 120, 51, 53, 480, 482, "NJ" +274, 7, 12, 121, 54, 55, 483, 484, "," +274, 7, 13, 122, 56, 59, 485, 488, "USA" +274, 7, 14, 123, 60, 61, 489, 490, "." +274, 8, 1, 124, 0, 11, 491, 502, "Colesevelam" +274, 8, 2, 125, 12, 20, 503, 511, "improves" +274, 8, 3, 126, 21, 29, 512, 520, "glycemic" +274, 8, 4, 127, 30, 37, 521, 528, "control" +274, 8, 5, 128, 38, 40, 529, 531, "in" +274, 8, 6, 129, 41, 49, 532, 540, "patients" +274, 8, 7, 130, 50, 54, 541, 545, "with" +274, 8, 8, 131, 55, 59, 546, 550, "type" +274, 8, 9, 132, 60, 61, 551, 552, "2" +274, 8, 10, 133, 62, 70, 553, 561, "diabetes" +274, 8, 11, 134, 71, 75, 562, 566, "when" +274, 8, 12, 135, 76, 81, 567, 572, "added" +274, 8, 13, 136, 82, 84, 573, 575, "to" +274, 8, 14, 137, 85, 93, 576, 584, "existing" +274, 8, 15, 138, 94, 103, 585, 594, "metformin" +274, 8, 16, 139, 104, 105, 595, 596, "-" +274, 8, 17, 140, 106, 107, 597, 598, "," +274, 8, 18, 141, 108, 120, 599, 611, "sulfonylurea" +274, 8, 19, 142, 121, 122, 612, 613, "-" +274, 8, 20, 143, 123, 124, 614, 615, "," +274, 8, 21, 144, 125, 127, 616, 618, "or" +274, 8, 22, 145, 128, 135, 619, 626, "insulin" +274, 8, 23, 146, 136, 137, 627, 628, "-" +274, 8, 24, 147, 138, 143, 629, 634, "based" +274, 8, 25, 148, 144, 152, 635, 643, "regimens" +274, 8, 26, 149, 153, 154, 644, 645, "." +274, 9, 1, 150, 0, 2, 646, 648, "We" +274, 9, 2, 151, 3, 12, 649, 658, "evaluated" +274, 9, 3, 152, 13, 24, 659, 670, "colesevelam" +274, 9, 4, 153, 25, 26, 671, 672, "'" +274, 9, 5, 154, 27, 28, 673, 674, "s" +274, 9, 6, 155, 29, 36, 675, 682, "effects" +274, 9, 7, 156, 37, 39, 683, 685, "in" +274, 9, 8, 157, 40, 48, 686, 694, "subjects" +274, 9, 9, 158, 49, 51, 695, 697, "on" +274, 9, 10, 159, 52, 58, 698, 704, "stable" +274, 9, 11, 160, 59, 71, 705, 717, "pioglitazone" +274, 9, 12, 161, 72, 73, 718, 719, "-" +274, 9, 13, 162, 74, 79, 720, 725, "based" +274, 9, 14, 163, 80, 87, 726, 733, "therapy" +274, 9, 15, 164, 88, 89, 734, 735, "." +274, 10, 1, 165, 0, 4, 736, 740, "This" +274, 10, 2, 166, 5, 7, 741, 743, "24" +274, 10, 3, 167, 8, 9, 744, 745, "-" +274, 10, 4, 168, 10, 14, 746, 750, "week" +274, 10, 5, 169, 15, 26, 751, 762, "multicenter" +274, 10, 6, 170, 27, 28, 763, 764, "," +274, 10, 7, 171, 29, 35, 765, 771, "double" +274, 10, 8, 172, 36, 37, 772, 773, "-" +274, 10, 9, 173, 38, 43, 774, 779, "blind" +274, 10, 10, 174, 44, 45, 780, 781, "," +274, 10, 11, 175, 46, 56, 782, 792, "randomized" +274, 10, 12, 176, 57, 58, 793, 794, "," +274, 10, 13, 177, 59, 66, 795, 802, "placebo" +274, 10, 14, 178, 67, 68, 803, 804, "-" +274, 10, 15, 179, 69, 79, 805, 815, "controlled" +274, 10, 16, 180, 80, 85, 816, 821, "study" +274, 10, 17, 181, 86, 94, 822, 830, "enrolled" +274, 10, 18, 182, 95, 101, 831, 837, "adults" +274, 10, 19, 183, 102, 106, 838, 842, "with" +274, 10, 20, 184, 107, 111, 843, 847, "type" +274, 10, 21, 185, 112, 113, 848, 849, "2" +274, 10, 22, 186, 114, 122, 850, 858, "diabetes" +274, 10, 23, 187, 123, 126, 859, 862, "who" +274, 10, 24, 188, 127, 130, 863, 866, "had" +274, 10, 25, 189, 131, 141, 867, 877, "suboptimal" +274, 10, 26, 190, 142, 150, 878, 886, "glycemic" +274, 10, 27, 191, 151, 158, 887, 894, "control" +274, 10, 28, 192, 159, 160, 895, 896, "[" +274, 10, 29, 193, 161, 166, 897, 902, "HbA1c" +274, 10, 30, 194, 167, 168, 903, 904, "≥" +274, 10, 31, 195, 169, 171, 905, 907, "58" +274, 10, 32, 196, 172, 176, 908, 912, "mmol" +274, 10, 33, 197, 177, 178, 913, 914, "/" +274, 10, 34, 198, 179, 182, 915, 918, "mol" +274, 10, 35, 199, 183, 184, 919, 920, "(" +274, 10, 36, 200, 185, 186, 921, 922, "7" +274, 10, 37, 201, 187, 188, 923, 924, "." +274, 10, 38, 202, 189, 190, 925, 926, "5" +274, 10, 39, 203, 191, 192, 927, 928, "%" +274, 10, 40, 204, 193, 194, 929, 930, ")" +274, 10, 41, 205, 195, 198, 931, 934, "and" +274, 10, 42, 206, 199, 200, 935, 936, "≤" +274, 10, 43, 207, 201, 203, 937, 939, "80" +274, 10, 44, 208, 204, 208, 940, 944, "mmol" +274, 10, 45, 209, 209, 210, 945, 946, "/" +274, 10, 46, 210, 211, 214, 947, 950, "mol" +274, 10, 47, 211, 215, 216, 951, 952, "(" +274, 10, 48, 212, 217, 218, 953, 954, "9" +274, 10, 49, 213, 219, 220, 955, 956, "." +274, 10, 50, 214, 221, 222, 957, 958, "5" +274, 10, 51, 215, 223, 224, 959, 960, "%" +274, 10, 52, 216, 225, 226, 961, 962, ")" +274, 10, 53, 217, 227, 228, 963, 964, "]" +274, 10, 54, 218, 229, 231, 965, 967, "on" +274, 10, 55, 219, 232, 244, 968, 980, "pioglitazone" +274, 10, 56, 220, 245, 246, 981, 982, "(" +274, 10, 57, 221, 247, 249, 983, 985, "30" +274, 10, 58, 222, 250, 252, 986, 988, "or" +274, 10, 59, 223, 253, 255, 989, 991, "45" +274, 10, 60, 224, 256, 258, 992, 994, "mg" +274, 10, 61, 225, 259, 260, 995, 996, ")" +274, 10, 62, 226, 261, 265, 997, 1001, "with" +274, 10, 63, 227, 266, 268, 1002, 1004, "or" +274, 10, 64, 228, 269, 276, 1005, 1012, "without" +274, 10, 65, 229, 277, 278, 1013, 1014, "1" +274, 10, 66, 230, 279, 280, 1015, 1016, "-" +274, 10, 67, 231, 281, 282, 1017, 1018, "2" +274, 10, 68, 232, 283, 288, 1019, 1024, "other" +274, 10, 69, 233, 289, 293, 1025, 1029, "oral" +274, 10, 70, 234, 294, 306, 1030, 1042, "antidiabetes" +274, 10, 71, 235, 307, 318, 1043, 1054, "medications" +274, 10, 72, 236, 319, 320, 1055, 1056, "." +274, 11, 1, 237, 0, 8, 1057, 1065, "Subjects" +274, 11, 2, 238, 9, 13, 1066, 1070, "were" +274, 11, 3, 239, 14, 24, 1071, 1081, "randomized" +274, 11, 4, 240, 25, 27, 1082, 1084, "to" +274, 11, 5, 241, 28, 39, 1085, 1096, "colesevelam" +274, 11, 6, 242, 40, 41, 1097, 1098, "3" +274, 11, 7, 243, 42, 43, 1099, 1100, "." +274, 11, 8, 244, 44, 45, 1101, 1102, "8" +274, 11, 9, 245, 46, 47, 1103, 1104, "g" +274, 11, 10, 246, 48, 49, 1105, 1106, "/" +274, 11, 11, 247, 50, 53, 1107, 1110, "day" +274, 11, 12, 248, 54, 55, 1111, 1112, "(" +274, 11, 13, 249, 56, 57, 1113, 1114, "n" +274, 11, 14, 250, 58, 59, 1115, 1116, "=" +274, 11, 15, 251, 60, 63, 1117, 1120, "280" +274, 11, 16, 252, 64, 65, 1121, 1122, ")" +274, 11, 17, 253, 66, 68, 1123, 1125, "or" +274, 11, 18, 254, 69, 76, 1126, 1133, "placebo" +274, 11, 19, 255, 77, 78, 1134, 1135, "(" +274, 11, 20, 256, 79, 80, 1136, 1137, "n" +274, 11, 21, 257, 81, 82, 1138, 1139, "=" +274, 11, 22, 258, 83, 86, 1140, 1143, "282" +274, 11, 23, 259, 87, 88, 1144, 1145, ")" +274, 11, 24, 260, 89, 94, 1146, 1151, "added" +274, 11, 25, 261, 95, 97, 1152, 1154, "to" +274, 11, 26, 262, 98, 106, 1155, 1163, "existing" +274, 11, 27, 263, 107, 119, 1164, 1176, "pioglitazone" +274, 11, 28, 264, 120, 121, 1177, 1178, "-" +274, 11, 29, 265, 122, 127, 1179, 1184, "based" +274, 11, 30, 266, 128, 135, 1185, 1192, "therapy" +274, 11, 31, 267, 136, 137, 1193, 1194, "." +274, 12, 1, 268, 0, 7, 1195, 1202, "Primary" +274, 12, 2, 269, 8, 16, 1203, 1211, "efficacy" +274, 12, 3, 270, 17, 25, 1212, 1220, "variable" +274, 12, 4, 271, 26, 29, 1221, 1224, "was" +274, 12, 5, 272, 30, 34, 1225, 1229, "mean" +274, 12, 6, 273, 35, 41, 1230, 1236, "change" +274, 12, 7, 274, 42, 44, 1237, 1239, "in" +274, 12, 8, 275, 45, 50, 1240, 1245, "HbA1c" +274, 12, 9, 276, 51, 55, 1246, 1250, "from" +274, 12, 10, 277, 56, 64, 1251, 1259, "baseline" +274, 12, 11, 278, 65, 67, 1260, 1262, "to" +274, 12, 12, 279, 68, 72, 1263, 1267, "Week" +274, 12, 13, 280, 73, 75, 1268, 1270, "24" +274, 12, 14, 281, 76, 77, 1271, 1272, "." +274, 13, 1, 282, 0, 9, 1273, 1282, "Secondary" +274, 13, 2, 283, 10, 19, 1283, 1292, "variables" +274, 13, 3, 284, 20, 28, 1293, 1301, "included" +274, 13, 4, 285, 29, 35, 1302, 1308, "safety" +274, 13, 5, 286, 36, 39, 1309, 1312, "and" +274, 13, 6, 287, 40, 52, 1313, 1325, "tolerability" +274, 13, 7, 288, 53, 54, 1326, 1327, "," +274, 13, 8, 289, 55, 62, 1328, 1335, "fasting" +274, 13, 9, 290, 63, 69, 1336, 1342, "plasma" +274, 13, 10, 291, 70, 77, 1343, 1350, "glucose" +274, 13, 11, 292, 78, 85, 1351, 1358, "changes" +274, 13, 12, 293, 86, 87, 1359, 1360, "," +274, 13, 13, 294, 88, 96, 1361, 1369, "glycemic" +274, 13, 14, 295, 97, 106, 1370, 1379, "responses" +274, 13, 15, 296, 107, 108, 1380, 1381, "," +274, 13, 16, 297, 109, 112, 1382, 1385, "and" +274, 13, 17, 298, 113, 118, 1386, 1391, "lipid" +274, 13, 18, 299, 119, 126, 1392, 1399, "profile" +274, 13, 19, 300, 127, 128, 1400, 1401, "." +274, 14, 1, 301, 0, 8, 1402, 1410, "Tertiary" +274, 14, 2, 302, 9, 18, 1411, 1420, "variables" +274, 14, 3, 303, 19, 27, 1421, 1429, "included" +274, 14, 4, 304, 28, 33, 1430, 1435, "lipid" +274, 14, 5, 305, 34, 42, 1436, 1444, "particle" +274, 14, 6, 306, 43, 50, 1445, 1452, "profile" +274, 14, 7, 307, 51, 58, 1453, 1460, "changes" +274, 14, 8, 308, 59, 61, 1461, 1463, "by" +274, 14, 9, 309, 62, 69, 1464, 1471, "nuclear" +274, 14, 10, 310, 70, 78, 1472, 1480, "magnetic" +274, 14, 11, 311, 79, 88, 1481, 1490, "resonance" +274, 14, 12, 312, 89, 90, 1491, 1492, "." +274, 15, 1, 313, 0, 11, 1493, 1504, "Colesevelam" +274, 15, 2, 314, 12, 21, 1505, 1514, "decreased" +274, 15, 3, 315, 22, 27, 1515, 1520, "HbA1c" +274, 15, 4, 316, 28, 29, 1521, 1522, "[" +274, 15, 5, 317, 30, 35, 1523, 1528, "least" +274, 15, 6, 318, 36, 37, 1529, 1530, "-" +274, 15, 7, 319, 38, 45, 1531, 1538, "squares" +274, 15, 8, 320, 46, 50, 1539, 1543, "mean" +274, 15, 9, 321, 51, 60, 1544, 1553, "treatment" +274, 15, 10, 322, 61, 71, 1554, 1564, "difference" +274, 15, 11, 323, 72, 73, 1565, 1566, "," +274, 15, 12, 324, 74, 75, 1567, 1568, "-" +274, 15, 13, 325, 76, 77, 1569, 1570, "3" +274, 15, 14, 326, 78, 79, 1571, 1572, "." +274, 15, 15, 327, 80, 81, 1573, 1574, "5" +274, 15, 16, 328, 82, 86, 1575, 1579, "mmol" +274, 15, 17, 329, 87, 88, 1580, 1581, "/" +274, 15, 18, 330, 89, 92, 1582, 1585, "mol" +274, 15, 19, 331, 93, 94, 1586, 1587, "(" +274, 15, 20, 332, 95, 96, 1588, 1589, "-" +274, 15, 21, 333, 97, 98, 1590, 1591, "0" +274, 15, 22, 334, 99, 100, 1592, 1593, "." +274, 15, 23, 335, 101, 103, 1594, 1596, "32" +274, 15, 24, 336, 104, 105, 1597, 1598, "%" +274, 15, 25, 337, 106, 107, 1599, 1600, ")" +274, 15, 26, 338, 108, 109, 1601, 1602, ";" +274, 15, 27, 339, 110, 111, 1603, 1604, "p" +274, 15, 28, 340, 112, 113, 1605, 1606, "<" +274, 15, 29, 341, 114, 115, 1607, 1608, "0" +274, 15, 30, 342, 116, 117, 1609, 1610, "." +274, 15, 31, 343, 118, 121, 1611, 1614, "001" +274, 15, 32, 344, 122, 123, 1615, 1616, "]" +274, 15, 33, 345, 124, 127, 1617, 1620, "and" +274, 15, 34, 346, 128, 135, 1621, 1628, "fasting" +274, 15, 35, 347, 136, 142, 1629, 1635, "plasma" +274, 15, 36, 348, 143, 150, 1636, 1643, "glucose" +274, 15, 37, 349, 151, 152, 1644, 1645, "(" +274, 15, 38, 350, 153, 154, 1646, 1647, "-" +274, 15, 39, 351, 155, 157, 1648, 1650, "14" +274, 15, 40, 352, 158, 159, 1651, 1652, "." +274, 15, 41, 353, 160, 161, 1653, 1654, "7" +274, 15, 42, 354, 162, 164, 1655, 1657, "mg" +274, 15, 43, 355, 165, 166, 1658, 1659, "/" +274, 15, 44, 356, 167, 169, 1660, 1662, "dl" +274, 15, 45, 357, 170, 171, 1663, 1664, ";" +274, 15, 46, 358, 172, 173, 1665, 1666, "p" +274, 15, 47, 359, 174, 175, 1667, 1668, "<" +274, 15, 48, 360, 176, 177, 1669, 1670, "0" +274, 15, 49, 361, 178, 179, 1671, 1672, "." +274, 15, 50, 362, 180, 183, 1673, 1676, "001" +274, 15, 51, 363, 184, 185, 1677, 1678, ")" +274, 15, 52, 364, 186, 188, 1679, 1681, "vs" +274, 15, 53, 365, 189, 190, 1682, 1683, "." +274, 15, 54, 366, 191, 198, 1684, 1691, "placebo" +274, 15, 55, 367, 199, 201, 1692, 1694, "at" +274, 15, 56, 368, 202, 206, 1695, 1699, "Week" +274, 15, 57, 369, 207, 209, 1700, 1702, "24" +274, 15, 58, 370, 210, 211, 1703, 1704, "." +274, 16, 1, 371, 0, 4, 1705, 1709, "More" +274, 16, 2, 372, 5, 13, 1710, 1718, "subjects" +274, 16, 3, 373, 14, 23, 1719, 1728, "receiving" +274, 16, 4, 374, 24, 35, 1729, 1740, "colesevelam" +274, 16, 5, 375, 36, 38, 1741, 1743, "vs" +274, 16, 6, 376, 39, 40, 1744, 1745, "." +274, 16, 7, 377, 41, 48, 1746, 1753, "placebo" +274, 16, 8, 378, 49, 57, 1754, 1762, "achieved" +274, 16, 9, 379, 58, 63, 1763, 1768, "HbA1c" +274, 16, 10, 380, 64, 73, 1769, 1778, "reduction" +274, 16, 11, 381, 74, 75, 1779, 1780, "≥" +274, 16, 12, 382, 76, 77, 1781, 1782, "7" +274, 16, 13, 383, 78, 79, 1783, 1784, "." +274, 16, 14, 384, 80, 81, 1785, 1786, "7" +274, 16, 15, 385, 82, 86, 1787, 1791, "mmol" +274, 16, 16, 386, 87, 88, 1792, 1793, "/" +274, 16, 17, 387, 89, 92, 1794, 1797, "mol" +274, 16, 18, 388, 93, 94, 1798, 1799, "(" +274, 16, 19, 389, 95, 96, 1800, 1801, "0" +274, 16, 20, 390, 97, 98, 1802, 1803, "." +274, 16, 21, 391, 99, 100, 1804, 1805, "7" +274, 16, 22, 392, 101, 102, 1806, 1807, "%" +274, 16, 23, 393, 103, 104, 1808, 1809, ")" +274, 16, 24, 394, 105, 106, 1810, 1811, "(" +274, 16, 25, 395, 107, 109, 1812, 1814, "40" +274, 16, 26, 396, 110, 111, 1815, 1816, "%" +274, 16, 27, 397, 112, 114, 1817, 1819, "vs" +274, 16, 28, 398, 115, 116, 1820, 1821, "." +274, 16, 29, 399, 117, 119, 1822, 1824, "25" +274, 16, 30, 400, 120, 121, 1825, 1826, "%" +274, 16, 31, 401, 122, 123, 1827, 1828, ";" +274, 16, 32, 402, 124, 125, 1829, 1830, "p" +274, 16, 33, 403, 126, 127, 1831, 1832, "<" +274, 16, 34, 404, 128, 129, 1833, 1834, "0" +274, 16, 35, 405, 130, 131, 1835, 1836, "." +274, 16, 36, 406, 132, 135, 1837, 1840, "001" +274, 16, 37, 407, 136, 137, 1841, 1842, ")" +274, 16, 38, 408, 138, 140, 1843, 1845, "or" +274, 16, 39, 409, 141, 146, 1846, 1851, "HbA1c" +274, 16, 40, 410, 147, 148, 1852, 1853, "<" +274, 16, 41, 411, 149, 151, 1854, 1856, "53" +274, 16, 42, 412, 152, 156, 1857, 1861, "mmol" +274, 16, 43, 413, 157, 158, 1862, 1863, "/" +274, 16, 44, 414, 159, 162, 1864, 1867, "mol" +274, 16, 45, 415, 163, 164, 1868, 1869, "(" +274, 16, 46, 416, 165, 166, 1870, 1871, "7" +274, 16, 47, 417, 167, 168, 1872, 1873, "." +274, 16, 48, 418, 169, 170, 1874, 1875, "0" +274, 16, 49, 419, 171, 172, 1876, 1877, "%" +274, 16, 50, 420, 173, 174, 1878, 1879, ")" +274, 16, 51, 421, 175, 176, 1880, 1881, "(" +274, 16, 52, 422, 177, 179, 1882, 1884, "21" +274, 16, 53, 423, 180, 181, 1885, 1886, "%" +274, 16, 54, 424, 182, 184, 1887, 1889, "vs" +274, 16, 55, 425, 185, 186, 1890, 1891, "." +274, 16, 56, 426, 187, 189, 1892, 1894, "13" +274, 16, 57, 427, 190, 191, 1895, 1896, "%" +274, 16, 58, 428, 192, 193, 1897, 1898, ";" +274, 16, 59, 429, 194, 195, 1899, 1900, "p" +274, 16, 60, 430, 196, 197, 1901, 1902, "=" +274, 16, 61, 431, 198, 199, 1903, 1904, "0" +274, 16, 62, 432, 200, 201, 1905, 1906, "." +274, 16, 63, 433, 202, 205, 1907, 1910, "012" +274, 16, 64, 434, 206, 207, 1911, 1912, ")" +274, 16, 65, 435, 208, 209, 1913, 1914, "." +274, 17, 1, 436, 0, 11, 1915, 1926, "Colesevelam" +274, 17, 2, 437, 12, 16, 1927, 1931, "also" +274, 17, 3, 438, 17, 26, 1932, 1941, "decreased" +274, 17, 4, 439, 27, 32, 1942, 1947, "total" +274, 17, 5, 440, 33, 44, 1948, 1959, "cholesterol" +274, 17, 6, 441, 45, 46, 1960, 1961, "(" +274, 17, 7, 442, 47, 51, 1962, 1966, "mean" +274, 17, 8, 443, 52, 61, 1967, 1976, "treatment" +274, 17, 9, 444, 62, 72, 1977, 1987, "difference" +274, 17, 10, 445, 73, 74, 1988, 1989, "," +274, 17, 11, 446, 75, 76, 1990, 1991, "-" +274, 17, 12, 447, 77, 78, 1992, 1993, "6" +274, 17, 13, 448, 79, 80, 1994, 1995, "." +274, 17, 14, 449, 81, 82, 1996, 1997, "5" +274, 17, 15, 450, 83, 84, 1998, 1999, "%" +274, 17, 16, 451, 85, 86, 2000, 2001, ")" +274, 17, 17, 452, 87, 88, 2002, 2003, "," +274, 17, 18, 453, 89, 92, 2004, 2007, "LDL" +274, 17, 19, 454, 93, 94, 2008, 2009, "-" +274, 17, 20, 455, 95, 106, 2010, 2021, "cholesterol" +274, 17, 21, 456, 107, 108, 2022, 2023, "(" +274, 17, 22, 457, 109, 110, 2024, 2025, "-" +274, 17, 23, 458, 111, 113, 2026, 2028, "16" +274, 17, 24, 459, 114, 115, 2029, 2030, "." +274, 17, 25, 460, 116, 117, 2031, 2032, "4" +274, 17, 26, 461, 118, 119, 2033, 2034, "%" +274, 17, 27, 462, 120, 121, 2035, 2036, ")" +274, 17, 28, 463, 122, 123, 2037, 2038, "," +274, 17, 29, 464, 124, 127, 2039, 2042, "non" +274, 17, 30, 465, 128, 129, 2043, 2044, "-" +274, 17, 31, 466, 130, 133, 2045, 2048, "HDL" +274, 17, 32, 467, 134, 135, 2049, 2050, "-" +274, 17, 33, 468, 136, 147, 2051, 2062, "cholesterol" +274, 17, 34, 469, 148, 149, 2063, 2064, "(" +274, 17, 35, 470, 150, 151, 2065, 2066, "-" +274, 17, 36, 471, 152, 153, 2067, 2068, "9" +274, 17, 37, 472, 154, 155, 2069, 2070, "." +274, 17, 38, 473, 156, 157, 2071, 2072, "8" +274, 17, 39, 474, 158, 159, 2073, 2074, "%" +274, 17, 40, 475, 160, 161, 2075, 2076, ")" +274, 17, 41, 476, 162, 163, 2077, 2078, "," +274, 17, 42, 477, 164, 178, 2079, 2093, "apolipoprotein" +274, 17, 43, 478, 179, 180, 2094, 2095, "B" +274, 17, 44, 479, 181, 182, 2096, 2097, "(" +274, 17, 45, 480, 183, 184, 2098, 2099, "-" +274, 17, 46, 481, 185, 186, 2100, 2101, "8" +274, 17, 47, 482, 187, 188, 2102, 2103, "." +274, 17, 48, 483, 189, 190, 2104, 2105, "8" +274, 17, 49, 484, 191, 192, 2106, 2107, "%" +274, 17, 50, 485, 193, 194, 2108, 2109, ")" +274, 17, 51, 486, 195, 196, 2110, 2111, "," +274, 17, 52, 487, 197, 200, 2112, 2115, "and" +274, 17, 53, 488, 201, 206, 2116, 2121, "total" +274, 17, 54, 489, 207, 210, 2122, 2125, "LDL" +274, 17, 55, 490, 211, 219, 2126, 2134, "particle" +274, 17, 56, 491, 220, 233, 2135, 2148, "concentration" +274, 17, 57, 492, 234, 235, 2149, 2150, "," +274, 17, 58, 493, 236, 239, 2151, 2154, "and" +274, 17, 59, 494, 240, 249, 2155, 2164, "increased" +274, 17, 60, 495, 250, 264, 2165, 2179, "apolipoprotein" +274, 17, 61, 496, 265, 267, 2180, 2182, "A1" +274, 17, 62, 497, 268, 269, 2183, 2184, "(" +274, 17, 63, 498, 270, 271, 2185, 2186, "+" +274, 17, 64, 499, 272, 273, 2187, 2188, "3" +274, 17, 65, 500, 274, 275, 2189, 2190, "." +274, 17, 66, 501, 276, 277, 2191, 2192, "4" +274, 17, 67, 502, 278, 279, 2193, 2194, "%" +274, 17, 68, 503, 280, 281, 2195, 2196, ")" +274, 17, 69, 504, 282, 285, 2197, 2200, "and" +274, 17, 70, 505, 286, 299, 2201, 2214, "triglycerides" +274, 17, 71, 506, 300, 301, 2215, 2216, "(" +274, 17, 72, 507, 302, 308, 2217, 2223, "median" +274, 17, 73, 508, 309, 318, 2224, 2233, "treatment" +274, 17, 74, 509, 319, 329, 2234, 2244, "difference" +274, 17, 75, 510, 330, 331, 2245, 2246, "," +274, 17, 76, 511, 332, 333, 2247, 2248, "+" +274, 17, 77, 512, 334, 336, 2249, 2251, "11" +274, 17, 78, 513, 337, 338, 2252, 2253, "." +274, 17, 79, 514, 339, 340, 2254, 2255, "3" +274, 17, 80, 515, 341, 342, 2256, 2257, "%" +274, 17, 81, 516, 343, 344, 2258, 2259, ")" +274, 17, 82, 517, 345, 347, 2260, 2262, "vs" +274, 17, 83, 518, 348, 349, 2263, 2264, "." +274, 17, 84, 519, 350, 357, 2265, 2272, "placebo" +274, 17, 85, 520, 358, 359, 2273, 2274, "(" +274, 17, 86, 521, 360, 363, 2275, 2278, "all" +274, 17, 87, 522, 364, 365, 2279, 2280, "p" +274, 17, 88, 523, 366, 367, 2281, 2282, "<" +274, 17, 89, 524, 368, 369, 2283, 2284, "0" +274, 17, 90, 525, 370, 371, 2285, 2286, "." +274, 17, 91, 526, 372, 375, 2287, 2290, "001" +274, 17, 92, 527, 376, 377, 2291, 2292, ")" +274, 17, 93, 528, 378, 379, 2293, 2294, "." +274, 18, 1, 529, 0, 5, 2295, 2300, "There" +274, 18, 2, 530, 6, 10, 2301, 2305, "were" +274, 18, 3, 531, 11, 13, 2306, 2308, "no" +274, 18, 4, 532, 14, 21, 2309, 2316, "serious" +274, 18, 5, 533, 22, 26, 2317, 2321, "drug" +274, 18, 6, 534, 27, 28, 2322, 2323, "-" +274, 18, 7, 535, 29, 36, 2324, 2331, "related" +274, 18, 8, 536, 37, 44, 2332, 2339, "adverse" +274, 18, 9, 537, 45, 51, 2340, 2346, "events" +274, 18, 10, 538, 52, 53, 2347, 2348, "," +274, 18, 11, 539, 54, 57, 2349, 2352, "and" +274, 18, 12, 540, 58, 61, 2353, 2356, "the" +274, 18, 13, 541, 62, 70, 2357, 2365, "majority" +274, 18, 14, 542, 71, 73, 2366, 2368, "of" +274, 18, 15, 543, 74, 81, 2369, 2376, "adverse" +274, 18, 16, 544, 82, 88, 2377, 2383, "events" +274, 18, 17, 545, 89, 93, 2384, 2388, "were" +274, 18, 18, 546, 94, 98, 2389, 2393, "mild" +274, 18, 19, 547, 99, 101, 2394, 2396, "or" +274, 18, 20, 548, 102, 110, 2397, 2405, "moderate" +274, 18, 21, 549, 111, 112, 2406, 2407, "." +274, 19, 1, 550, 0, 2, 2408, 2410, "In" +274, 19, 2, 551, 3, 11, 2411, 2419, "subjects" +274, 19, 3, 552, 12, 16, 2420, 2424, "with" +274, 19, 4, 553, 17, 21, 2425, 2429, "type" +274, 19, 5, 554, 22, 23, 2430, 2431, "2" +274, 19, 6, 555, 24, 32, 2432, 2440, "diabetes" +274, 19, 7, 556, 33, 45, 2441, 2453, "inadequately" +274, 19, 8, 557, 46, 56, 2454, 2464, "controlled" +274, 19, 9, 558, 57, 61, 2465, 2469, "with" +274, 19, 10, 559, 62, 74, 2470, 2482, "pioglitazone" +274, 19, 11, 560, 75, 76, 2483, 2484, "-" +274, 19, 12, 561, 77, 82, 2485, 2490, "based" +274, 19, 13, 562, 83, 90, 2491, 2498, "therapy" +274, 19, 14, 563, 91, 92, 2499, 2500, "," +274, 19, 15, 564, 93, 96, 2501, 2504, "add" +274, 19, 16, 565, 97, 98, 2505, 2506, "-" +274, 19, 17, 566, 99, 101, 2507, 2509, "on" +274, 19, 18, 567, 102, 113, 2510, 2521, "colesevelam" +274, 19, 19, 568, 114, 121, 2522, 2529, "therapy" +274, 19, 20, 569, 122, 130, 2530, 2538, "improved" +274, 19, 21, 570, 131, 139, 2539, 2547, "glycemic" +274, 19, 22, 571, 140, 147, 2548, 2555, "control" +274, 19, 23, 572, 148, 151, 2556, 2559, "and" +274, 19, 24, 573, 152, 157, 2560, 2565, "lipid" +274, 19, 25, 574, 158, 168, 2566, 2576, "parameters" +274, 19, 26, 575, 169, 172, 2577, 2580, "and" +274, 19, 27, 576, 173, 176, 2581, 2584, "was" +274, 19, 28, 577, 177, 181, 2585, 2589, "well" +274, 19, 29, 578, 182, 191, 2590, 2599, "tolerated" +274, 19, 30, 579, 192, 193, 2600, 2601, "." +274, 20, 1, 580, 0, 14, 2602, 2616, "ClinicalTrials" +274, 20, 2, 581, 15, 16, 2617, 2618, "." +274, 20, 3, 582, 17, 20, 2619, 2622, "gov" +274, 20, 4, 583, 21, 31, 2623, 2633, "identifier" +274, 20, 5, 584, 32, 33, 2634, 2635, ":" +274, 20, 6, 585, 34, 45, 2636, 2647, "NCT00789750" +274, 20, 7, 586, 46, 47, 2648, 2649, "." +274, 21, 1, 587, 0, 1, 2650, 2651, "©" +274, 21, 2, 588, 2, 7, 2652, 2657, "Georg" +274, 21, 3, 589, 8, 14, 2658, 2664, "Thieme" +274, 21, 4, 590, 15, 21, 2665, 2671, "Verlag" +274, 21, 5, 591, 22, 24, 2672, 2674, "KG" +274, 21, 6, 592, 25, 34, 2675, 2684, "Stuttgart" +274, 21, 7, 593, 35, 36, 2685, 2686, "·" +274, 21, 8, 594, 37, 40, 2687, 2690, "New" +274, 21, 9, 595, 41, 45, 2691, 2695, "York" +274, 21, 10, 596, 46, 47, 2696, 2697, "." +274, 22, 1, 597, 0, 3, 2698, 2701, "DOI" +274, 22, 2, 598, 4, 5, 2702, 2703, ":" +274, 22, 3, 599, 6, 8, 2704, 2706, "10" +274, 22, 4, 600, 9, 10, 2707, 2708, "." +274, 22, 5, 601, 11, 15, 2709, 2713, "1055" +274, 22, 6, 602, 16, 17, 2714, 2715, "/" +274, 22, 7, 603, 18, 19, 2716, 2717, "s" +274, 22, 8, 604, 20, 21, 2718, 2719, "-" +274, 22, 9, 605, 22, 26, 2720, 2724, "0034" +274, 22, 10, 606, 27, 28, 2725, 2726, "-" +274, 22, 11, 607, 29, 36, 2727, 2734, "1383648" +274, 22, 12, 608, 37, 41, 2735, 2739, "PMID" +274, 22, 13, 609, 42, 43, 2740, 2741, ":" +274, 22, 14, 610, 44, 52, 2742, 2750, "25054436" +274, 22, 15, 611, 53, 54, 2751, 2752, "[" +274, 22, 16, 612, 55, 62, 2753, 2760, "Indexed" +274, 22, 17, 613, 63, 66, 2761, 2764, "for" +274, 22, 18, 614, 67, 74, 2765, 2772, "MEDLINE" +274, 22, 19, 615, 75, 76, 2773, 2774, "]" diff --git a/data/dm2 25054436_kwoodley.annodb b/data/dm2 25054436_kwoodley.annodb new file mode 100644 index 0000000..dc013a8 --- /dev/null +++ b/data/dm2 25054436_kwoodley.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +48179, Journal, 0, 14, "Horm Metab Res", "", +48180, PublicationYear, 17, 21, "2014", "", +48196, Title, 108, 219, "Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus .", "", +48181, Drug, 131, 142, "colesevelam", "", +48189, Pioglitazone, 163, 175, "pioglitazone", "", +48192, Type2Diabetes, 193, 217, "type 2 diabetes mellitus", "", +48197, Author, 220, 232, "Rosenstock J", "", +48198, Author, 241, 250, "Truitt KE", "", +48199, Author, 259, 272, "Baz - Hecht M", "", +48200, Author, 281, 288, "Ford DM", "", +48201, Author, 297, 302, "Tao B", "", +48202, Author, 311, 318, "Chou HS", "", +48203, USA, 423, 426, "USA", "", +48204, USA, 485, 488, "USA", "", +48182, Drug, 491, 502, "Colesevelam", "", +48193, Type2Diabetes, 546, 561, "type 2 diabetes", "", +48205, Metformin, 585, 594, "metformin", "", +48206, Sulfonylureas, 599, 611, "sulfonylurea", "", +48207, Insulin, 619, 626, "insulin", "", +48209, ObjectiveDescription, 646, 735, "We evaluated colesevelam ' s effects in subjects on stable pioglitazone - based therapy .", "", +48183, Drug, 659, 670, "colesevelam", "", +48208, Pioglitazone, 705, 717, "pioglitazone", "", +48210, Duration, 741, 750, "24 - week", "", +48211, Multicenter, 751, 762, "multicenter", "", +48212, DoubleBlind, 765, 779, "double - blind", "", +48213, Randomized, 782, 792, "randomized", "", +48214, Placebo, 795, 802, "placebo", "", +48229, Precondition, 831, 1054, "adults with type 2 diabetes who had suboptimal glycemic control [ HbA1c ≥ 58 mmol / mol ( 7 . 5 % ) and ≤ 80 mmol / mol ( 9 . 5 % ) ] on pioglitazone ( 30 or 45 mg ) with or without 1 - 2 other oral antidiabetes medications", "", +48194, Type2Diabetes, 843, 858, "type 2 diabetes", "", +48219, HbA1c, 897, 902, "HbA1c", "", +48220, BioAndMedicalUnit, 908, 918, "mmol / mol", "", +48222, Percentage, 927, 928, "%", "", +48221, BioAndMedicalUnit, 940, 950, "mmol / mol", "", +48223, Percentage, 959, 960, "%", "", +48224, Pioglitazone, 968, 980, "pioglitazone", "", +48226, DoseValue, 983, 985, "30", "", +48227, DoseValue, 989, 991, "45", "", +48228, mg, 992, 994, "mg", "", +48225, OralAntidiabeticAgent, 1025, 1054, "oral antidiabetes medications", "", +53041, Randomized, 1071, 1081, "randomized", "", +48184, Drug, 1085, 1096, "colesevelam", "", +53045, DoseValue, 1097, 1102, "3 . 8", "", +53046, Gram, 1103, 1104, "g", "", +53047, Frequency, 1107, 1110, "day", "", +53048, NumberPatientsArm, 1117, 1120, "280", "", +48215, Placebo, 1126, 1133, "placebo", "", +53049, NumberPatientsArm, 1140, 1143, "282", "", +48190, Pioglitazone, 1164, 1176, "pioglitazone", "", +53050, HbA1c, 1240, 1245, "HbA1c", "", +53051, TimePoint, 1251, 1259, "baseline", "", +53052, TimePoint, 1263, 1270, "Week 24", "", +53053, FastingPlasmaGlucose, 1328, 1350, "fasting plasma glucose", "", +53054, EndPointDescription, 1386, 1399, "lipid profile", "", +53055, EndPointDescription, 1430, 1452, "lipid particle profile", "", +48185, Drug, 1493, 1504, "Colesevelam", "", +53056, HbA1c, 1515, 1520, "HbA1c", "", +53057, LeastSquaresMean, 1523, 1543, "least - squares mean", "", +53058, DiffGroupAbsValue, 1567, 1574, "- 3 . 5", "", +53060, BioAndMedicalUnit, 1575, 1585, "mmol / mol", "", +53061, DiffGroupAbsValue, 1588, 1596, "- 0 . 32", "", +53062, Percentage, 1597, 1598, "%", "", +53063, PvalueDiff, 1603, 1614, "p < 0 . 001", "", +53065, FastingPlasmaGlucose, 1621, 1643, "fasting plasma glucose", "", +53059, DiffGroupAbsValue, 1646, 1654, "- 14 . 7", "", +53066, Mg_per_deciliter, 1655, 1662, "mg / dl", "", +53064, PvalueDiff, 1665, 1676, "p < 0 . 001", "", +48216, Placebo, 1684, 1691, "placebo", "", +53067, TimePoint, 1695, 1702, "Week 24", "", +48186, Drug, 1729, 1740, "colesevelam", "", +48217, Placebo, 1746, 1753, "placebo", "", +53068, HbA1c_target, 1763, 1809, "HbA1c reduction ≥ 7 . 7 mmol / mol ( 0 . 7 % )", "", +53070, PercentageAffected, 1812, 1814, "40", "", +53071, PercentageAffected, 1822, 1824, "25", "", +53074, PvalueDiff, 1829, 1840, "p < 0 . 001", "", +53069, HbA1c_target, 1846, 1879, "HbA1c < 53 mmol / mol ( 7 . 0 % )", "", +53072, PercentageAffected, 1882, 1884, "21", "", +53073, PercentageAffected, 1892, 1894, "13", "", +53075, PvalueDiff, 1899, 1910, "p = 0 . 012", "", +48187, Drug, 1915, 1926, "Colesevelam", "", +53076, EndPointDescription, 1948, 1959, "cholesterol", "", +53083, DiffGroupRelValue, 1990, 1997, "- 6 . 5", "", +53077, EndPointDescription, 2004, 2021, "LDL - cholesterol", "", +53085, DiffGroupRelValue, 2024, 2032, "- 16 . 4", "", +53078, EndPointDescription, 2039, 2062, "non - HDL - cholesterol", "", +53086, DiffGroupRelValue, 2065, 2072, "- 9 . 8", "", +53079, EndPointDescription, 2079, 2095, "apolipoprotein B", "", +53087, DiffGroupRelValue, 2098, 2105, "- 8 . 8", "", +53080, EndPointDescription, 2122, 2148, "LDL particle concentration", "", +53081, EndPointDescription, 2165, 2182, "apolipoprotein A1", "", +53088, DiffGroupRelValue, 2185, 2192, "+ 3 . 4", "", +53082, EndPointDescription, 2201, 2214, "triglycerides", "", +53089, DiffGroupRelValue, 2247, 2255, "+ 11 . 3", "", +48218, Placebo, 2265, 2272, "placebo", "", +53090, PvalueDiff, 2279, 2290, "p < 0 . 001", "", +53093, ObservedResult, 2295, 2407, "There were no serious drug - related adverse events , and the majority of adverse events were mild or moderate .", "", +53091, EndPointDescription, 2332, 2346, "adverse events", "", +53092, EndPointDescription, 2369, 2383, "adverse events", "", +53095, ConclusionComment, 2408, 2601, "In subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy , add - on colesevelam therapy improved glycemic control and lipid parameters and was well tolerated .", "", +53094, Precondition, 2411, 2498, "subjects with type 2 diabetes inadequately controlled with pioglitazone - based therapy", "", +48195, Type2Diabetes, 2425, 2440, "type 2 diabetes", "", +48191, Pioglitazone, 2470, 2482, "pioglitazone", "", +48188, Drug, 2510, 2521, "colesevelam", "", +53096, PMID, 2742, 2750, "25054436", "", diff --git a/data/dm2 25054436_kwoodley.n-triples b/data/dm2 25054436_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25054436_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25125506_admin.annodb b/data/dm2 25125506_admin.annodb new file mode 100644 index 0000000..d2ea4ca --- /dev/null +++ b/data/dm2 25125506_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2014", "", " \"2014\"." +96, Title, 101, 237, "Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study .", "", " \"Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study .\"." +2, Oral, 124, 128, "oral", "", +79642, Methazolamide, 129, 142, "methazolamide", "", +10, Type2Diabetes, 160, 175, "type 2 diabetes", "", " ." +13, Duration, 180, 189, "24 - week", "", " \"24 - week\"." +15, Placebo, 192, 199, "placebo", "", +18, DoubleBlind, 215, 229, "double - blind", "", +19, Author, 238, 248, "Simpson RW", "", " \"Simpson RW\"." +20, Author, 257, 269, "Nicholson GC", "", " \"Nicholson GC\"." +21, Author, 278, 288, "Proietto J", "", " \"Proietto J\"." +22, Author, 297, 304, "Sarah A", "", " \"Sarah A\"." +23, Author, 313, 323, "Sanders KM", "", " \"Sanders KM\"." +24, Author, 332, 342, "Phillips G", "", " \"Phillips G\"." +25, Author, 351, 361, "Chambers J", "", " \"Chambers J\"." +26, Author, 370, 381, "MacGinley R", "", " \"MacGinley R\"." +27, Author, 390, 398, "Orford N", "", " \"Orford N\"." +28, Author, 407, 415, "Walder K", "", " \"Walder K\"." +29, Author, 424, 434, "Krippner G", "", " \"Krippner G\"." +30, Author, 443, 450, "Skoff K", "", " \"Skoff K\"." +31, Author, 459, 468, "Wacher VJ", "", " \"Wacher VJ\"." +32, Australia, 546, 555, "Australia", "", +33, Australia, 681, 690, "Australia", "", +34, Australia, 783, 792, "Australia", "", +35, Australia, 885, 894, "Australia", "", +36, Australia, 944, 953, "Australia", "", +37, Australia, 1134, 1143, "Australia", "", +38, Australia, 1207, 1216, "Australia", "", +39, Australia, 1280, 1289, "Australia", "", +40, ObjectiveDescription, 1334, 1431, "To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .", "", " \"To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .\"." +79643, Methazolamide, 1373, 1386, "methazolamide", "", +11, Type2Diabetes, 1414, 1429, "type 2 diabetes", "", +41, DoubleBlind, 1467, 1481, "double - blind", "", +42, Placebo, 1484, 1491, "placebo", "", +43, Randomized, 1511, 1521, "randomized", "", " ." +44, NumberPatientsCT, 1522, 1524, "76", "", " \"76\"." +45, Oral, 1537, 1541, "oral", "", " ." +79649, Methazolamide, 1542, 1555, "methazolamide", "", " ." +46, DoseValue, 1558, 1560, "40", "", " \"40\"." +47, mg, 1561, 1563, "mg", "", " ." +48, Frequency, 1564, 1575, "b . i . d .", "", " \"b . i . d .\"." +16, Placebo, 1581, 1588, "placebo", "", " ." +14, Duration, 1593, 1601, "24 weeks", "", +79645, Methazolamide, 1639, 1652, "methazolamide", "", +49, Placebo, 1669, 1676, "placebo", "", +50, HbA1c, 1702, 1707, "HbA1c", "", +54, TimePoint, 1713, 1721, "baseline", "", +55, TimePoint, 1728, 1736, "24 weeks", "", +51, HbA1c, 1741, 1746, "HbA1c", "", +140, Mean, 1761, 1765, "Mean", "", " . ." +56, TimePoint, 1771, 1779, "baseline", "", +52, HbA1c, 1780, 1785, "HbA1c", "", " ." +57, BaseLineValue, 1790, 1795, "7 . 1", "", " \"7 . 1\"." +59, SdDevBL, 1798, 1803, "0 . 7", "", " \"0 . 7\"." +61, Percentage, 1804, 1805, "%", "", " ." +58, BaseLineValue, 1808, 1810, "54", "", +60, SdDevBL, 1813, 1814, "5", "", +79864, Millimoles_per_mole, 1815, 1825, "mmol / mol", "", +65, NumberPatientsArm, 1832, 1834, "37", "", " \"37\"." +67, BaseLineValue, 1841, 1846, "7 . 4", "", " \"7 . 4\"." +69, SdDevBL, 1849, 1854, "0 . 6", "", " \"0 . 6\"." +62, Percentage, 1855, 1856, "%", "", +68, BaseLineValue, 1859, 1861, "57", "", +70, SdDevBL, 1864, 1865, "5", "", +79865, Millimoles_per_mole, 1866, 1876, "mmol / mol", "", +66, NumberPatientsArm, 1883, 1885, "39", "", " \"39\"." +79651, Methazolamide, 1895, 1908, "methazolamide", "", +17, Placebo, 1913, 1920, "placebo", "", +79653, Methazolamide, 1945, 1958, "Methazolamide", "", +53, HbA1c, 1993, 1998, "HbA1c", "", " ." +71, Reduction, 2004, 2010, "0 . 39", "", " \"0 . 39\"." +73, Percentage, 2011, 2012, "%", "", +74, ConfIntervalChangeValue, 2015, 2040, "95 % CI - 0 . 82 , 0 . 04", "", " \"95 % CI - 0 . 82 , 0 . 04\"." +76589, PValueChangeValue, 2043, 2053, "P < 0 . 05", "", " \"P < 0 . 05\"." +72, Reduction, 2060, 2065, "4 . 3", "", +79866, Millimoles_per_mole, 2066, 2076, "mmol / mol", "", +75, ConfIntervalChangeValue, 2079, 2094, "- 9 . 0 , 0 . 4", "", +78, HbA1c_target, 2153, 2168, "HbA1c ≤ 6 . 5 %", "", " ." +166, Percentage, 2167, 2168, "%", "", +79867, Millimoles_per_mole, 2174, 2184, "mmol / mol", "", +174, PercentageAffected, 2192, 2193, "8", "", " \"8\"." +79, PercentageAffected, 2197, 2199, "33", "", " \"33\"." +81, EndPointDescription, 2225, 2249, "alanine aminotransferase", "", " . ." +80, Reduction, 2254, 2256, "10", "", " \"10\"." +84, BioAndMedicalUnit, 2257, 2266, "units / L", "", " . ." +82, BodyWeight, 2275, 2281, "weight", "", " ." +83, RelativeReduction, 2289, 2290, "2", "", " \"2\"." +100521, SubGroupDescription, 2298, 2328, "metformin - cotreated patients", "", " \"metformin - cotreated patients\". \"metformin - cotreated patients\". \"metformin - cotreated patients\". \"metformin - cotreated patients\". \"metformin - cotreated patients\". \"metformin - cotreated patients\"." +85, Metformin, 2298, 2307, "metformin", "", +79655, Methazolamide, 2345, 2358, "Methazolamide", "", +87, ConclusionComment, 2345, 2465, "Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .", "", " \"Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .\"." +12, Type2Diabetes, 2402, 2417, "type 2 diabetes", "", +88, PMID, 2692, 2700, "25125506", "", " \"25125506\"." diff --git a/data/dm2 25125506_admin.n-triples b/data/dm2 25125506_admin.n-triples new file mode 100644 index 0000000..3dfbac1 --- /dev/null +++ b/data/dm2 25125506_admin.n-triples @@ -0,0 +1,149 @@ +# RDF export of group: Publication + . + "Publication 63056" . + "Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study ." . + "Simpson RW" . + "2014" . + "Diabetes Care" . + "25125506" . + . + "Nicholson GC" . + "Proietto J" . + "Sarah A" . + "Sanders KM" . + "Phillips G" . + "Chambers J" . + "MacGinley R" . + "Orford N" . + "Walder K" . + "Krippner G" . + "Skoff K" . + "Wacher VJ" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 63063" . + "To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes ." . + "76" . + "24 - week" . + . + . + . + "Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 63079" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "ala" . + . + . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "met" . + "37" . + . + . + . + . + . + . + . + "pla" . + "39" . + . + . + . + . +# RDF export of group: Intervention + . + "met" . + . + "b . i . d ." . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "met" . + . + "40" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 1" . + "0 . 7" . + "0 . 39" . + "P < 0 . 05" . + "95 % CI - 0 . 82 , 0 . 04" . + "metformin - cotreated patients" . + . + "hba 2" . + . + "7 . 4" . + "0 . 6" . + "metformin - cotreated patients" . + . + "hbat 1" . + . + "33" . + "metformin - cotreated patients" . + . + "hbat 2" . + . + "8" . + "metformin - cotreated patients" . + . + "ala" . + . + "10" . + "metformin - cotreated patients" . + . + "bw" . + . + "2" . + "metformin - cotreated patients" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25125506_akramersunderbrink.annodb b/data/dm2 25125506_akramersunderbrink.annodb new file mode 100644 index 0000000..9c6bc34 --- /dev/null +++ b/data/dm2 25125506_akramersunderbrink.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +60567, Journal, 0, 13, "Diabetes Care", "", +60568, PublicationYear, 16, 20, "2014", "", +60574, Title, 101, 237, "Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study .", "", +60610, Oral, 124, 128, "oral", "", +60569, Drug, 129, 142, "methazolamide", "", +60570, Type2Diabetes, 160, 175, "type 2 diabetes", "", +60571, Duration, 180, 189, "24 - week", "", +60572, Placebo, 192, 199, "placebo", "", +60573, DoubleBlind, 215, 229, "double - blind", "", +60575, Author, 238, 248, "Simpson RW", "", +60576, Author, 257, 269, "Nicholson GC", "", +60577, Author, 278, 288, "Proietto J", "", +60578, Author, 297, 304, "Sarah A", "", +60579, Author, 313, 323, "Sanders KM", "", +60580, Author, 332, 342, "Phillips G", "", +60581, Author, 351, 361, "Chambers J", "", +60583, Author, 370, 381, "MacGinley R", "", +60585, Author, 390, 398, "Orford N", "", +60586, Author, 407, 415, "Walder K", "", +60587, Author, 424, 434, "Krippner G", "", +60588, Author, 443, 450, "Skoff K", "", +60589, Author, 459, 468, "Wacher VJ", "", +60590, Australia, 546, 555, "Australia", "", +60591, Australia, 681, 690, "Australia", "", +60592, Australia, 783, 792, "Australia", "", +60593, Australia, 885, 894, "Australia", "", +60594, Australia, 944, 953, "Australia", "", +60595, Australia, 1134, 1143, "Australia", "", +60596, Australia, 1207, 1216, "Australia", "", +60597, Australia, 1280, 1289, "Australia", "", +60600, ObjectiveDescription, 1334, 1431, "To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .", "", +60601, Drug, 1373, 1386, "methazolamide", "", +60602, Type2Diabetes, 1414, 1429, "type 2 diabetes", "", +60603, DoubleBlind, 1467, 1481, "double - blind", "", +60604, Placebo, 1484, 1491, "placebo", "", +60605, Randomized, 1511, 1521, "randomized", "", +60607, NumberPatientsCT, 1522, 1524, "76", "", +60609, Oral, 1537, 1541, "oral", "", +60608, Drug, 1542, 1555, "methazolamide", "", +60612, DoseValue, 1558, 1563, "40 mg", "", +60613, mg, 1561, 1563, "mg", "", +60614, Frequency, 1564, 1575, "b . i . d .", "", +60615, Placebo, 1581, 1588, "placebo", "", +60616, Duration, 1593, 1601, "24 weeks", "", +60617, Drug, 1639, 1652, "methazolamide", "", +60618, Placebo, 1669, 1676, "placebo", "", +60619, HbA1c, 1702, 1707, "HbA1c", "", +60620, TimePoint, 1713, 1721, "baseline", "", +60621, TimePoint, 1728, 1736, "24 weeks", "", +60622, HbA1c, 1741, 1746, "HbA1c", "", +60625, Mean, 1761, 1765, "Mean", "", +60626, TimePoint, 1771, 1779, "baseline", "", +60623, HbA1c, 1780, 1785, "HbA1c", "", +60630, BaseLineValue, 1790, 1795, "7 . 1", "", +60636, SdDevBL, 1798, 1803, "0 . 7", "", +60638, Percentage, 1804, 1805, "%", "", +60632, BaseLineValue, 1808, 1814, "54 ± 5", "", +60640, ConcentrationUnit, 1815, 1825, "mmol / mol", "", +60634, NumberPatientsArm, 1832, 1834, "37", "", +60631, BaseLineValue, 1841, 1846, "7 . 4", "", +60637, SdDevBL, 1849, 1854, "0 . 6", "", +60639, Percentage, 1855, 1856, "%", "", +60633, BaseLineValue, 1859, 1865, "57 ± 5", "", +60641, ConcentrationUnit, 1866, 1876, "mmol / mol", "", +60635, NumberPatientsArm, 1883, 1885, "39", "", +60627, Drug, 1895, 1908, "methazolamide", "", +60629, Placebo, 1913, 1920, "placebo", "", +60642, Drug, 1945, 1958, "Methazolamide", "", +60643, HbA1c, 1993, 1998, "HbA1c", "", +60644, ChangeValue, 2002, 2010, "- 0 . 39", "", +60651, Percentage, 2011, 2012, "%", "", +60655, ConfIntervalChangeValue, 2015, 2040, "95 % CI - 0 . 82 , 0 . 04", "", +60652, Percentage, 2018, 2019, "%", "", +60656, PValueChangeValue, 2043, 2053, "P < 0 . 05", "", +60646, ChangeValue, 2058, 2065, "- 4 . 3", "", +60657, ConcentrationUnit, 2066, 2076, "mmol / mol", "", +60659, ConfIntervalChangeValue, 2079, 2094, "- 9 . 0 , 0 . 4", "", +60661, HbA1c_target, 2153, 2186, "HbA1c ≤ 6 . 5 % ( 48 mmol / mol )", "", +60653, Percentage, 2167, 2168, "%", "", +60662, ConcentrationUnit, 2174, 2184, "mmol / mol", "", +60663, PercentageAffected, 2192, 2193, "8", "", +60664, PercentageAffected, 2197, 2199, "33", "", +60654, Percentage, 2200, 2201, "%", "", +60668, EndPointDescription, 2225, 2249, "alanine aminotransferase", "", +60647, Reduction, 2252, 2256, "∼ 10", "", +60666, BioAndMedicalUnit, 2257, 2266, "units / L", "", +60649, BodyWeight, 2275, 2281, "weight", "", +60648, RelativeReduction, 2289, 2290, "2", "", +60667, Percentage, 2291, 2292, "%", "", +60650, Metformin, 2298, 2307, "metformin", "", +60670, SubGroupDescription, 2298, 2328, "metformin - cotreated patients", "", +60674, ConclusionComment, 2345, 2465, "Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .", "", +60671, Drug, 2345, 2358, "Methazolamide", "", +60673, Type2Diabetes, 2402, 2417, "type 2 diabetes", "", +60675, PMID, 2692, 2700, "25125506", "", diff --git a/data/dm2 25125506_akramersunderbrink.n-triples b/data/dm2 25125506_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25125506_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25125506_export.csv b/data/dm2 25125506_export.csv new file mode 100644 index 0000000..9d1badb --- /dev/null +++ b/data/dm2 25125506_export.csv @@ -0,0 +1,613 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +273, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +273, 1, 2, 2, 9, 13, 9, 13, "Care" +273, 1, 3, 3, 14, 15, 14, 15, "." +273, 2, 1, 4, 0, 4, 16, 20, "2014" +273, 2, 2, 5, 5, 8, 21, 24, "Nov" +273, 2, 3, 6, 9, 10, 25, 26, ";" +273, 2, 4, 7, 11, 13, 27, 29, "37" +273, 2, 5, 8, 14, 15, 30, 31, "(" +273, 2, 6, 9, 16, 18, 32, 34, "11" +273, 2, 7, 10, 19, 20, 35, 36, ")" +273, 2, 8, 11, 21, 22, 37, 38, ":" +273, 2, 9, 12, 23, 27, 39, 43, "3121" +273, 2, 10, 13, 28, 29, 44, 45, "-" +273, 2, 11, 14, 30, 31, 46, 47, "3" +273, 2, 12, 15, 32, 33, 48, 49, "." +273, 2, 13, 16, 34, 37, 50, 53, "doi" +273, 2, 14, 17, 38, 39, 54, 55, ":" +273, 2, 15, 18, 40, 42, 56, 58, "10" +273, 2, 16, 19, 43, 44, 59, 60, "." +273, 2, 17, 20, 45, 49, 61, 65, "2337" +273, 2, 18, 21, 50, 51, 66, 67, "/" +273, 2, 19, 22, 52, 56, 68, 72, "dc14" +273, 2, 20, 23, 57, 58, 73, 74, "-" +273, 2, 21, 24, 59, 63, 75, 79, "1038" +273, 2, 22, 25, 64, 65, 80, 81, "." +273, 3, 1, 26, 0, 4, 82, 86, "Epub" +273, 3, 2, 27, 5, 9, 87, 91, "2014" +273, 3, 3, 28, 10, 13, 92, 95, "Aug" +273, 3, 4, 29, 14, 16, 96, 98, "14" +273, 3, 5, 30, 17, 18, 99, 100, "." +273, 4, 1, 31, 0, 8, 101, 109, "Efficacy" +273, 4, 2, 32, 9, 12, 110, 113, "and" +273, 4, 3, 33, 13, 19, 114, 120, "safety" +273, 4, 4, 34, 20, 22, 121, 123, "of" +273, 4, 5, 35, 23, 27, 124, 128, "oral" +273, 4, 6, 36, 28, 41, 129, 142, "methazolamide" +273, 4, 7, 37, 42, 44, 143, 145, "in" +273, 4, 8, 38, 45, 53, 146, 154, "patients" +273, 4, 9, 39, 54, 58, 155, 159, "with" +273, 4, 10, 40, 59, 63, 160, 164, "type" +273, 4, 11, 41, 64, 65, 165, 166, "2" +273, 4, 12, 42, 66, 74, 167, 175, "diabetes" +273, 4, 13, 43, 75, 76, 176, 177, ":" +273, 4, 14, 44, 77, 78, 178, 179, "a" +273, 4, 15, 45, 79, 81, 180, 182, "24" +273, 4, 16, 46, 82, 83, 183, 184, "-" +273, 4, 17, 47, 84, 88, 185, 189, "week" +273, 4, 18, 48, 89, 90, 190, 191, "," +273, 4, 19, 49, 91, 98, 192, 199, "placebo" +273, 4, 20, 50, 99, 100, 200, 201, "-" +273, 4, 21, 51, 101, 111, 202, 212, "controlled" +273, 4, 22, 52, 112, 113, 213, 214, "," +273, 4, 23, 53, 114, 120, 215, 221, "double" +273, 4, 24, 54, 121, 122, 222, 223, "-" +273, 4, 25, 55, 123, 128, 224, 229, "blind" +273, 4, 26, 56, 129, 134, 230, 235, "study" +273, 4, 27, 57, 135, 136, 236, 237, "." +273, 5, 1, 58, 0, 7, 238, 245, "Simpson" +273, 5, 2, 59, 8, 10, 246, 248, "RW" +273, 5, 3, 60, 11, 12, 249, 250, "(" +273, 5, 4, 61, 13, 14, 251, 252, "1" +273, 5, 5, 62, 15, 16, 253, 254, ")" +273, 5, 6, 63, 17, 18, 255, 256, "," +273, 5, 7, 64, 19, 28, 257, 266, "Nicholson" +273, 5, 8, 65, 29, 31, 267, 269, "GC" +273, 5, 9, 66, 32, 33, 270, 271, "(" +273, 5, 10, 67, 34, 35, 272, 273, "2" +273, 5, 11, 68, 36, 37, 274, 275, ")" +273, 5, 12, 69, 38, 39, 276, 277, "," +273, 5, 13, 70, 40, 48, 278, 286, "Proietto" +273, 5, 14, 71, 49, 50, 287, 288, "J" +273, 5, 15, 72, 51, 52, 289, 290, "(" +273, 5, 16, 73, 53, 54, 291, 292, "3" +273, 5, 17, 74, 55, 56, 293, 294, ")" +273, 5, 18, 75, 57, 58, 295, 296, "," +273, 5, 19, 76, 59, 64, 297, 302, "Sarah" +273, 5, 20, 77, 65, 66, 303, 304, "A" +273, 5, 21, 78, 67, 68, 305, 306, "(" +273, 5, 22, 79, 69, 70, 307, 308, "4" +273, 5, 23, 80, 71, 72, 309, 310, ")" +273, 5, 24, 81, 73, 74, 311, 312, "," +273, 5, 25, 82, 75, 82, 313, 320, "Sanders" +273, 5, 26, 83, 83, 85, 321, 323, "KM" +273, 5, 27, 84, 86, 87, 324, 325, "(" +273, 5, 28, 85, 88, 89, 326, 327, "2" +273, 5, 29, 86, 90, 91, 328, 329, ")" +273, 5, 30, 87, 92, 93, 330, 331, "," +273, 5, 31, 88, 94, 102, 332, 340, "Phillips" +273, 5, 32, 89, 103, 104, 341, 342, "G" +273, 5, 33, 90, 105, 106, 343, 344, "(" +273, 5, 34, 91, 107, 108, 345, 346, "1" +273, 5, 35, 92, 109, 110, 347, 348, ")" +273, 5, 36, 93, 111, 112, 349, 350, "," +273, 5, 37, 94, 113, 121, 351, 359, "Chambers" +273, 5, 38, 95, 122, 123, 360, 361, "J" +273, 5, 39, 96, 124, 125, 362, 363, "(" +273, 5, 40, 97, 126, 127, 364, 365, "4" +273, 5, 41, 98, 128, 129, 366, 367, ")" +273, 5, 42, 99, 130, 131, 368, 369, "," +273, 5, 43, 100, 132, 141, 370, 379, "MacGinley" +273, 5, 44, 101, 142, 143, 380, 381, "R" +273, 5, 45, 102, 144, 145, 382, 383, "(" +273, 5, 46, 103, 146, 147, 384, 385, "5" +273, 5, 47, 104, 148, 149, 386, 387, ")" +273, 5, 48, 105, 150, 151, 388, 389, "," +273, 5, 49, 106, 152, 158, 390, 396, "Orford" +273, 5, 50, 107, 159, 160, 397, 398, "N" +273, 5, 51, 108, 161, 162, 399, 400, "(" +273, 5, 52, 109, 163, 164, 401, 402, "6" +273, 5, 53, 110, 165, 166, 403, 404, ")" +273, 5, 54, 111, 167, 168, 405, 406, "," +273, 5, 55, 112, 169, 175, 407, 413, "Walder" +273, 5, 56, 113, 176, 177, 414, 415, "K" +273, 5, 57, 114, 178, 179, 416, 417, "(" +273, 5, 58, 115, 180, 181, 418, 419, "5" +273, 5, 59, 116, 182, 183, 420, 421, ")" +273, 5, 60, 117, 184, 185, 422, 423, "," +273, 5, 61, 118, 186, 194, 424, 432, "Krippner" +273, 5, 62, 119, 195, 196, 433, 434, "G" +273, 5, 63, 120, 197, 198, 435, 436, "(" +273, 5, 64, 121, 199, 200, 437, 438, "7" +273, 5, 65, 122, 201, 202, 439, 440, ")" +273, 5, 66, 123, 203, 204, 441, 442, "," +273, 5, 67, 124, 205, 210, 443, 448, "Skoff" +273, 5, 68, 125, 211, 212, 449, 450, "K" +273, 5, 69, 126, 213, 214, 451, 452, "(" +273, 5, 70, 127, 215, 216, 453, 454, "7" +273, 5, 71, 128, 217, 218, 455, 456, ")" +273, 5, 72, 129, 219, 220, 457, 458, "," +273, 5, 73, 130, 221, 227, 459, 465, "Wacher" +273, 5, 74, 131, 228, 230, 466, 468, "VJ" +273, 5, 75, 132, 231, 232, 469, 470, "(" +273, 5, 76, 133, 233, 234, 471, 472, "8" +273, 5, 77, 134, 235, 236, 473, 474, ")" +273, 5, 78, 135, 237, 238, 475, 476, "." +273, 6, 1, 136, 0, 6, 477, 483, "Author" +273, 6, 2, 137, 7, 18, 484, 495, "information" +273, 6, 3, 138, 19, 20, 496, 497, ":" +273, 6, 4, 139, 21, 22, 498, 499, "(" +273, 6, 5, 140, 23, 24, 500, 501, "1" +273, 6, 6, 141, 25, 26, 502, 503, ")" +273, 6, 7, 142, 27, 30, 504, 507, "Box" +273, 6, 8, 143, 31, 35, 508, 512, "Hill" +273, 6, 9, 144, 36, 44, 513, 521, "Hospital" +273, 6, 10, 145, 45, 46, 522, 523, "," +273, 6, 11, 146, 47, 50, 524, 527, "Box" +273, 6, 12, 147, 51, 55, 528, 532, "Hill" +273, 6, 13, 148, 56, 57, 533, 534, "," +273, 6, 14, 149, 58, 66, 535, 543, "Victoria" +273, 6, 15, 150, 67, 68, 544, 545, "," +273, 6, 16, 151, 69, 78, 546, 555, "Australia" +273, 6, 17, 152, 79, 80, 556, 557, "." +273, 7, 1, 153, 0, 1, 558, 559, "(" +273, 7, 2, 154, 2, 3, 560, 561, "2" +273, 7, 3, 155, 4, 5, 562, 563, ")" +273, 7, 4, 156, 6, 16, 564, 574, "Department" +273, 7, 5, 157, 17, 19, 575, 577, "of" +273, 7, 6, 158, 20, 28, 578, 586, "Clinical" +273, 7, 7, 159, 29, 32, 587, 590, "and" +273, 7, 8, 160, 33, 43, 591, 601, "Biomedical" +273, 7, 9, 161, 44, 52, 602, 610, "Sciences" +273, 7, 10, 162, 53, 54, 611, 612, "," +273, 7, 11, 163, 55, 62, 613, 620, "Geelong" +273, 7, 12, 164, 63, 71, 621, 629, "Hospital" +273, 7, 13, 165, 72, 73, 630, 631, "," +273, 7, 14, 166, 74, 84, 632, 642, "University" +273, 7, 15, 167, 85, 87, 643, 645, "of" +273, 7, 16, 168, 88, 97, 646, 655, "Melbourne" +273, 7, 17, 169, 98, 99, 656, 657, "," +273, 7, 18, 170, 100, 109, 658, 667, "Melbourne" +273, 7, 19, 171, 110, 111, 668, 669, "," +273, 7, 20, 172, 112, 120, 670, 678, "Victoria" +273, 7, 21, 173, 121, 122, 679, 680, "," +273, 7, 22, 174, 123, 132, 681, 690, "Australia" +273, 7, 23, 175, 133, 134, 691, 692, "." +273, 8, 1, 176, 0, 1, 693, 694, "(" +273, 8, 2, 177, 2, 3, 695, 696, "3" +273, 8, 3, 178, 4, 5, 697, 698, ")" +273, 8, 4, 179, 6, 16, 699, 709, "Heidelberg" +273, 8, 5, 180, 17, 29, 710, 722, "Repatriation" +273, 8, 6, 181, 30, 38, 723, 731, "Hospital" +273, 8, 7, 182, 39, 40, 732, 733, "," +273, 8, 8, 183, 41, 51, 734, 744, "University" +273, 8, 9, 184, 52, 54, 745, 747, "of" +273, 8, 10, 185, 55, 64, 748, 757, "Melbourne" +273, 8, 11, 186, 65, 66, 758, 759, "," +273, 8, 12, 187, 67, 76, 760, 769, "Melbourne" +273, 8, 13, 188, 77, 78, 770, 771, "," +273, 8, 14, 189, 79, 87, 772, 780, "Victoria" +273, 8, 15, 190, 88, 89, 781, 782, "," +273, 8, 16, 191, 90, 99, 783, 792, "Australia" +273, 8, 17, 192, 100, 101, 793, 794, "." +273, 9, 1, 193, 0, 1, 795, 796, "(" +273, 9, 2, 194, 2, 3, 797, 798, "4" +273, 9, 3, 195, 4, 5, 799, 800, ")" +273, 9, 4, 196, 6, 14, 801, 809, "Clinical" +273, 9, 5, 197, 15, 20, 810, 815, "Trial" +273, 9, 6, 198, 21, 25, 816, 820, "Unit" +273, 9, 7, 199, 26, 27, 821, 822, "," +273, 9, 8, 200, 28, 38, 823, 833, "Department" +273, 9, 9, 201, 39, 41, 834, 836, "of" +273, 9, 10, 202, 42, 50, 837, 845, "Medicine" +273, 9, 11, 203, 51, 52, 846, 847, "," +273, 9, 12, 204, 53, 59, 848, 854, "Barwon" +273, 9, 13, 205, 60, 66, 855, 861, "Health" +273, 9, 14, 206, 67, 68, 862, 863, "," +273, 9, 15, 207, 69, 76, 864, 871, "Geelong" +273, 9, 16, 208, 77, 78, 872, 873, "," +273, 9, 17, 209, 79, 87, 874, 882, "Victoria" +273, 9, 18, 210, 88, 89, 883, 884, "," +273, 9, 19, 211, 90, 99, 885, 894, "Australia" +273, 9, 20, 212, 100, 101, 895, 896, "." +273, 10, 1, 213, 0, 1, 897, 898, "(" +273, 10, 2, 214, 2, 3, 899, 900, "5" +273, 10, 3, 215, 4, 5, 901, 902, ")" +273, 10, 4, 216, 6, 12, 903, 909, "Deakin" +273, 10, 5, 217, 13, 23, 910, 920, "University" +273, 10, 6, 218, 24, 25, 921, 922, "," +273, 10, 7, 219, 26, 33, 923, 930, "Geelong" +273, 10, 8, 220, 34, 35, 931, 932, "," +273, 10, 9, 221, 36, 44, 933, 941, "Victoria" +273, 10, 10, 222, 45, 46, 942, 943, "," +273, 10, 11, 223, 47, 56, 944, 953, "Australia" +273, 10, 12, 224, 57, 58, 954, 955, "." +273, 11, 1, 225, 0, 1, 956, 957, "(" +273, 11, 2, 226, 2, 3, 958, 959, "6" +273, 11, 3, 227, 4, 5, 960, 961, ")" +273, 11, 4, 228, 6, 16, 962, 972, "Department" +273, 11, 5, 229, 17, 19, 973, 975, "of" +273, 11, 6, 230, 20, 32, 976, 988, "Epidemiology" +273, 11, 7, 231, 33, 36, 989, 992, "and" +273, 11, 8, 232, 37, 47, 993, 1003, "Preventive" +273, 11, 9, 233, 48, 56, 1004, 1012, "Medicine" +273, 11, 10, 234, 57, 58, 1013, 1014, "," +273, 11, 11, 235, 59, 65, 1015, 1021, "Barwon" +273, 11, 12, 236, 66, 72, 1022, 1028, "Health" +273, 11, 13, 237, 73, 74, 1029, 1030, "/" +273, 11, 14, 238, 75, 85, 1031, 1041, "Australian" +273, 11, 15, 239, 86, 89, 1042, 1045, "and" +273, 11, 16, 240, 90, 93, 1046, 1049, "New" +273, 11, 17, 241, 94, 101, 1050, 1057, "Zealand" +273, 11, 18, 242, 102, 111, 1058, 1067, "Intensive" +273, 11, 19, 243, 112, 116, 1068, 1072, "Care" +273, 11, 20, 244, 117, 125, 1073, 1081, "Research" +273, 11, 21, 245, 126, 132, 1082, 1088, "Centre" +273, 11, 22, 246, 133, 134, 1089, 1090, "," +273, 11, 23, 247, 135, 141, 1091, 1097, "Monash" +273, 11, 24, 248, 142, 152, 1098, 1108, "University" +273, 11, 25, 249, 153, 154, 1109, 1110, "," +273, 11, 26, 250, 155, 164, 1111, 1120, "Melbourne" +273, 11, 27, 251, 165, 166, 1121, 1122, "," +273, 11, 28, 252, 167, 175, 1123, 1131, "Victoria" +273, 11, 29, 253, 176, 177, 1132, 1133, "," +273, 11, 30, 254, 178, 187, 1134, 1143, "Australia" +273, 11, 31, 255, 188, 189, 1144, 1145, "." +273, 12, 1, 256, 0, 1, 1146, 1147, "(" +273, 12, 2, 257, 2, 3, 1148, 1149, "7" +273, 12, 3, 258, 4, 5, 1150, 1151, ")" +273, 12, 4, 259, 6, 11, 1152, 1157, "Verva" +273, 12, 5, 260, 12, 27, 1158, 1173, "Pharmaceuticals" +273, 12, 6, 261, 28, 29, 1174, 1175, "," +273, 12, 7, 262, 30, 33, 1176, 1179, "Ltd" +273, 12, 8, 263, 34, 35, 1180, 1181, "." +273, 12, 9, 264, 36, 37, 1182, 1183, "," +273, 12, 10, 265, 38, 47, 1184, 1193, "Southbank" +273, 12, 11, 266, 48, 49, 1194, 1195, "," +273, 12, 12, 267, 50, 58, 1196, 1204, "Victoria" +273, 12, 13, 268, 59, 60, 1205, 1206, "," +273, 12, 14, 269, 61, 70, 1207, 1216, "Australia" +273, 12, 15, 270, 71, 72, 1217, 1218, "." +273, 13, 1, 271, 0, 1, 1219, 1220, "(" +273, 13, 2, 272, 2, 3, 1221, 1222, "8" +273, 13, 3, 273, 4, 5, 1223, 1224, ")" +273, 13, 4, 274, 6, 11, 1225, 1230, "Verva" +273, 13, 5, 275, 12, 27, 1231, 1246, "Pharmaceuticals" +273, 13, 6, 276, 28, 29, 1247, 1248, "," +273, 13, 7, 277, 30, 33, 1249, 1252, "Ltd" +273, 13, 8, 278, 34, 35, 1253, 1254, "." +273, 13, 9, 279, 36, 37, 1255, 1256, "," +273, 13, 10, 280, 38, 47, 1257, 1266, "Southbank" +273, 13, 11, 281, 48, 49, 1267, 1268, "," +273, 13, 12, 282, 50, 58, 1269, 1277, "Victoria" +273, 13, 13, 283, 59, 60, 1278, 1279, "," +273, 13, 14, 284, 61, 70, 1280, 1289, "Australia" +273, 13, 15, 285, 71, 72, 1290, 1291, "." +273, 14, 1, 286, 0, 7, 1292, 1299, "vwacher" +273, 14, 2, 287, 8, 9, 1300, 1301, "@" +273, 14, 3, 288, 10, 21, 1302, 1313, "vervapharma" +273, 14, 4, 289, 22, 23, 1314, 1315, "." +273, 14, 5, 290, 24, 27, 1316, 1319, "com" +273, 14, 6, 291, 28, 29, 1320, 1321, "." +273, 15, 1, 292, 0, 9, 1322, 1331, "OBJECTIVE" +273, 15, 2, 293, 10, 11, 1332, 1333, ":" +273, 15, 3, 294, 12, 14, 1334, 1336, "To" +273, 15, 4, 295, 15, 23, 1337, 1345, "evaluate" +273, 15, 5, 296, 24, 27, 1346, 1349, "the" +273, 15, 6, 297, 28, 34, 1350, 1356, "safety" +273, 15, 7, 298, 35, 38, 1357, 1360, "and" +273, 15, 8, 299, 39, 47, 1361, 1369, "efficacy" +273, 15, 9, 300, 48, 50, 1370, 1372, "of" +273, 15, 10, 301, 51, 64, 1373, 1386, "methazolamide" +273, 15, 11, 302, 65, 67, 1387, 1389, "as" +273, 15, 12, 303, 68, 69, 1390, 1391, "a" +273, 15, 13, 304, 70, 79, 1392, 1401, "potential" +273, 15, 14, 305, 80, 87, 1402, 1409, "therapy" +273, 15, 15, 306, 88, 91, 1410, 1413, "for" +273, 15, 16, 307, 92, 96, 1414, 1418, "type" +273, 15, 17, 308, 97, 98, 1419, 1420, "2" +273, 15, 18, 309, 99, 107, 1421, 1429, "diabetes" +273, 15, 19, 310, 108, 109, 1430, 1431, "." +273, 16, 1, 311, 0, 8, 1432, 1440, "RESEARCH" +273, 16, 2, 312, 9, 15, 1441, 1447, "DESIGN" +273, 16, 3, 313, 16, 19, 1448, 1451, "AND" +273, 16, 4, 314, 20, 27, 1452, 1459, "METHODS" +273, 16, 5, 315, 28, 29, 1460, 1461, ":" +273, 16, 6, 316, 30, 34, 1462, 1466, "This" +273, 16, 7, 317, 35, 41, 1467, 1473, "double" +273, 16, 8, 318, 42, 43, 1474, 1475, "-" +273, 16, 9, 319, 44, 49, 1476, 1481, "blind" +273, 16, 10, 320, 50, 51, 1482, 1483, "," +273, 16, 11, 321, 52, 59, 1484, 1491, "placebo" +273, 16, 12, 322, 60, 61, 1492, 1493, "-" +273, 16, 13, 323, 62, 72, 1494, 1504, "controlled" +273, 16, 14, 324, 73, 78, 1505, 1510, "study" +273, 16, 15, 325, 79, 89, 1511, 1521, "randomized" +273, 16, 16, 326, 90, 92, 1522, 1524, "76" +273, 16, 17, 327, 93, 101, 1525, 1533, "patients" +273, 16, 18, 328, 102, 104, 1534, 1536, "to" +273, 16, 19, 329, 105, 109, 1537, 1541, "oral" +273, 16, 20, 330, 110, 123, 1542, 1555, "methazolamide" +273, 16, 21, 331, 124, 125, 1556, 1557, "(" +273, 16, 22, 332, 126, 128, 1558, 1560, "40" +273, 16, 23, 333, 129, 131, 1561, 1563, "mg" +273, 16, 24, 334, 132, 133, 1564, 1565, "b" +273, 16, 25, 335, 134, 135, 1566, 1567, "." +273, 16, 26, 336, 136, 137, 1568, 1569, "i" +273, 16, 27, 337, 138, 139, 1570, 1571, "." +273, 16, 28, 338, 140, 141, 1572, 1573, "d" +273, 16, 29, 339, 142, 143, 1574, 1575, "." +273, 16, 30, 340, 144, 145, 1576, 1577, ")" +273, 17, 1, 341, 0, 2, 1578, 1580, "or" +273, 17, 2, 342, 3, 10, 1581, 1588, "placebo" +273, 17, 3, 343, 11, 14, 1589, 1592, "for" +273, 17, 4, 344, 15, 17, 1593, 1595, "24" +273, 17, 5, 345, 18, 23, 1596, 1601, "weeks" +273, 17, 6, 346, 24, 25, 1602, 1603, "." +273, 18, 1, 347, 0, 3, 1604, 1607, "The" +273, 18, 2, 348, 4, 11, 1608, 1615, "primary" +273, 18, 3, 349, 12, 20, 1616, 1624, "efficacy" +273, 18, 4, 350, 21, 24, 1625, 1628, "end" +273, 18, 5, 351, 25, 30, 1629, 1634, "point" +273, 18, 6, 352, 31, 34, 1635, 1638, "for" +273, 18, 7, 353, 35, 48, 1639, 1652, "methazolamide" +273, 18, 8, 354, 49, 58, 1653, 1662, "treatment" +273, 18, 9, 355, 59, 62, 1663, 1666, "was" +273, 18, 10, 356, 63, 64, 1667, 1668, "a" +273, 18, 11, 357, 65, 72, 1669, 1676, "placebo" +273, 18, 12, 358, 73, 74, 1677, 1678, "-" +273, 18, 13, 359, 75, 84, 1679, 1688, "corrected" +273, 18, 14, 360, 85, 94, 1689, 1698, "reduction" +273, 18, 15, 361, 95, 97, 1699, 1701, "in" +273, 18, 16, 362, 98, 103, 1702, 1707, "HbA1c" +273, 18, 17, 363, 104, 108, 1708, 1712, "from" +273, 18, 18, 364, 109, 117, 1713, 1721, "baseline" +273, 18, 19, 365, 118, 123, 1722, 1727, "after" +273, 18, 20, 366, 124, 126, 1728, 1730, "24" +273, 18, 21, 367, 127, 132, 1731, 1736, "weeks" +273, 18, 22, 368, 133, 134, 1737, 1738, "(" +273, 18, 23, 369, 135, 136, 1739, 1740, "Δ" +273, 18, 24, 370, 137, 142, 1741, 1746, "HbA1c" +273, 18, 25, 371, 143, 144, 1747, 1748, ")" +273, 18, 26, 372, 145, 146, 1749, 1750, "." +273, 19, 1, 373, 0, 7, 1751, 1758, "RESULTS" +273, 19, 2, 374, 8, 9, 1759, 1760, ":" +273, 19, 3, 375, 10, 14, 1761, 1765, "Mean" +273, 19, 4, 376, 15, 16, 1766, 1767, "±" +273, 19, 5, 377, 17, 19, 1768, 1770, "SD" +273, 19, 6, 378, 20, 28, 1771, 1779, "baseline" +273, 19, 7, 379, 29, 34, 1780, 1785, "HbA1c" +273, 19, 8, 380, 35, 38, 1786, 1789, "was" +273, 19, 9, 381, 39, 40, 1790, 1791, "7" +273, 19, 10, 382, 41, 42, 1792, 1793, "." +273, 19, 11, 383, 43, 44, 1794, 1795, "1" +273, 19, 12, 384, 45, 46, 1796, 1797, "±" +273, 19, 13, 385, 47, 48, 1798, 1799, "0" +273, 19, 14, 386, 49, 50, 1800, 1801, "." +273, 19, 15, 387, 51, 52, 1802, 1803, "7" +273, 19, 16, 388, 53, 54, 1804, 1805, "%" +273, 19, 17, 389, 55, 56, 1806, 1807, "(" +273, 19, 18, 390, 57, 59, 1808, 1810, "54" +273, 19, 19, 391, 60, 61, 1811, 1812, "±" +273, 19, 20, 392, 62, 63, 1813, 1814, "5" +273, 19, 21, 393, 64, 68, 1815, 1819, "mmol" +273, 19, 22, 394, 69, 70, 1820, 1821, "/" +273, 19, 23, 395, 71, 74, 1822, 1825, "mol" +273, 19, 24, 396, 75, 76, 1826, 1827, ";" +273, 19, 25, 397, 77, 78, 1828, 1829, "n" +273, 19, 26, 398, 79, 80, 1830, 1831, "=" +273, 19, 27, 399, 81, 83, 1832, 1834, "37" +273, 19, 28, 400, 84, 85, 1835, 1836, ")" +273, 19, 29, 401, 86, 89, 1837, 1840, "and" +273, 19, 30, 402, 90, 91, 1841, 1842, "7" +273, 19, 31, 403, 92, 93, 1843, 1844, "." +273, 19, 32, 404, 94, 95, 1845, 1846, "4" +273, 19, 33, 405, 96, 97, 1847, 1848, "±" +273, 19, 34, 406, 98, 99, 1849, 1850, "0" +273, 19, 35, 407, 100, 101, 1851, 1852, "." +273, 19, 36, 408, 102, 103, 1853, 1854, "6" +273, 19, 37, 409, 104, 105, 1855, 1856, "%" +273, 19, 38, 410, 106, 107, 1857, 1858, "(" +273, 19, 39, 411, 108, 110, 1859, 1861, "57" +273, 19, 40, 412, 111, 112, 1862, 1863, "±" +273, 19, 41, 413, 113, 114, 1864, 1865, "5" +273, 19, 42, 414, 115, 119, 1866, 1870, "mmol" +273, 19, 43, 415, 120, 121, 1871, 1872, "/" +273, 19, 44, 416, 122, 125, 1873, 1876, "mol" +273, 19, 45, 417, 126, 127, 1877, 1878, ";" +273, 19, 46, 418, 128, 129, 1879, 1880, "n" +273, 19, 47, 419, 130, 131, 1881, 1882, "=" +273, 19, 48, 420, 132, 134, 1883, 1885, "39" +273, 19, 49, 421, 135, 136, 1886, 1887, ")" +273, 19, 50, 422, 137, 139, 1888, 1890, "in" +273, 19, 51, 423, 140, 143, 1891, 1894, "the" +273, 19, 52, 424, 144, 157, 1895, 1908, "methazolamide" +273, 19, 53, 425, 158, 161, 1909, 1912, "and" +273, 19, 54, 426, 162, 169, 1913, 1920, "placebo" +273, 19, 55, 427, 170, 176, 1921, 1927, "groups" +273, 19, 56, 428, 177, 178, 1928, 1929, "," +273, 19, 57, 429, 179, 191, 1930, 1942, "respectively" +273, 19, 58, 430, 192, 193, 1943, 1944, "." +273, 20, 1, 431, 0, 13, 1945, 1958, "Methazolamide" +273, 20, 2, 432, 14, 23, 1959, 1968, "treatment" +273, 20, 3, 433, 24, 27, 1969, 1972, "was" +273, 20, 4, 434, 28, 38, 1973, 1983, "associated" +273, 20, 5, 435, 39, 43, 1984, 1988, "with" +273, 20, 6, 436, 44, 45, 1989, 1990, "a" +273, 20, 7, 437, 46, 47, 1991, 1992, "Δ" +273, 20, 8, 438, 48, 53, 1993, 1998, "HbA1c" +273, 20, 9, 439, 54, 56, 1999, 2001, "of" +273, 20, 10, 440, 57, 58, 2002, 2003, "-" +273, 20, 11, 441, 59, 60, 2004, 2005, "0" +273, 20, 12, 442, 61, 62, 2006, 2007, "." +273, 20, 13, 443, 63, 65, 2008, 2010, "39" +273, 20, 14, 444, 66, 67, 2011, 2012, "%" +273, 20, 15, 445, 68, 69, 2013, 2014, "(" +273, 20, 16, 446, 70, 72, 2015, 2017, "95" +273, 20, 17, 447, 73, 74, 2018, 2019, "%" +273, 20, 18, 448, 75, 77, 2020, 2022, "CI" +273, 20, 19, 449, 78, 79, 2023, 2024, "-" +273, 20, 20, 450, 80, 81, 2025, 2026, "0" +273, 20, 21, 451, 82, 83, 2027, 2028, "." +273, 20, 22, 452, 84, 86, 2029, 2031, "82" +273, 20, 23, 453, 87, 88, 2032, 2033, "," +273, 20, 24, 454, 89, 90, 2034, 2035, "0" +273, 20, 25, 455, 91, 92, 2036, 2037, "." +273, 20, 26, 456, 93, 95, 2038, 2040, "04" +273, 20, 27, 457, 96, 97, 2041, 2042, ";" +273, 20, 28, 458, 98, 99, 2043, 2044, "P" +273, 20, 29, 459, 100, 101, 2045, 2046, "<" +273, 20, 30, 460, 102, 103, 2047, 2048, "0" +273, 20, 31, 461, 104, 105, 2049, 2050, "." +273, 20, 32, 462, 106, 108, 2051, 2053, "05" +273, 20, 33, 463, 109, 110, 2054, 2055, ")" +273, 20, 34, 464, 111, 112, 2056, 2057, "(" +273, 20, 35, 465, 113, 114, 2058, 2059, "-" +273, 20, 36, 466, 115, 116, 2060, 2061, "4" +273, 20, 37, 467, 117, 118, 2062, 2063, "." +273, 20, 38, 468, 119, 120, 2064, 2065, "3" +273, 20, 39, 469, 121, 125, 2066, 2070, "mmol" +273, 20, 40, 470, 126, 127, 2071, 2072, "/" +273, 20, 41, 471, 128, 131, 2073, 2076, "mol" +273, 20, 42, 472, 132, 133, 2077, 2078, "[" +273, 20, 43, 473, 134, 135, 2079, 2080, "-" +273, 20, 44, 474, 136, 137, 2081, 2082, "9" +273, 20, 45, 475, 138, 139, 2083, 2084, "." +273, 20, 46, 476, 140, 141, 2085, 2086, "0" +273, 20, 47, 477, 142, 143, 2087, 2088, "," +273, 20, 48, 478, 144, 145, 2089, 2090, "0" +273, 20, 49, 479, 146, 147, 2091, 2092, "." +273, 20, 50, 480, 148, 149, 2093, 2094, "4" +273, 20, 51, 481, 150, 151, 2095, 2096, "]" +273, 20, 52, 482, 152, 153, 2097, 2098, ")" +273, 20, 53, 483, 154, 155, 2099, 2100, "," +273, 20, 54, 484, 156, 158, 2101, 2103, "an" +273, 20, 55, 485, 159, 167, 2104, 2112, "increase" +273, 20, 56, 486, 168, 170, 2113, 2115, "in" +273, 20, 57, 487, 171, 174, 2116, 2119, "the" +273, 20, 58, 488, 175, 185, 2120, 2130, "proportion" +273, 20, 59, 489, 186, 188, 2131, 2133, "of" +273, 20, 60, 490, 189, 197, 2134, 2142, "patients" +273, 20, 61, 491, 198, 207, 2143, 2152, "achieving" +273, 20, 62, 492, 208, 213, 2153, 2158, "HbA1c" +273, 20, 63, 493, 214, 215, 2159, 2160, "≤" +273, 20, 64, 494, 216, 217, 2161, 2162, "6" +273, 20, 65, 495, 218, 219, 2163, 2164, "." +273, 20, 66, 496, 220, 221, 2165, 2166, "5" +273, 20, 67, 497, 222, 223, 2167, 2168, "%" +273, 20, 68, 498, 224, 225, 2169, 2170, "(" +273, 20, 69, 499, 226, 228, 2171, 2173, "48" +273, 20, 70, 500, 229, 233, 2174, 2178, "mmol" +273, 20, 71, 501, 234, 235, 2179, 2180, "/" +273, 20, 72, 502, 236, 239, 2181, 2184, "mol" +273, 20, 73, 503, 240, 241, 2185, 2186, ")" +273, 20, 74, 504, 242, 246, 2187, 2191, "from" +273, 20, 75, 505, 247, 248, 2192, 2193, "8" +273, 20, 76, 506, 249, 251, 2194, 2196, "to" +273, 20, 77, 507, 252, 254, 2197, 2199, "33" +273, 20, 78, 508, 255, 256, 2200, 2201, "%" +273, 20, 79, 509, 257, 258, 2202, 2203, "," +273, 20, 80, 510, 259, 260, 2204, 2205, "a" +273, 20, 81, 511, 261, 266, 2206, 2211, "rapid" +273, 20, 82, 512, 267, 276, 2212, 2221, "reduction" +273, 20, 83, 513, 277, 279, 2222, 2224, "in" +273, 20, 84, 514, 280, 287, 2225, 2232, "alanine" +273, 20, 85, 515, 288, 304, 2233, 2249, "aminotransferase" +273, 20, 86, 516, 305, 306, 2250, 2251, "(" +273, 20, 87, 517, 307, 308, 2252, 2253, "∼" +273, 20, 88, 518, 309, 311, 2254, 2256, "10" +273, 20, 89, 519, 312, 317, 2257, 2262, "units" +273, 20, 90, 520, 318, 319, 2263, 2264, "/" +273, 20, 91, 521, 320, 321, 2265, 2266, "L" +273, 20, 92, 522, 322, 323, 2267, 2268, ")" +273, 20, 93, 523, 324, 325, 2269, 2270, "," +273, 20, 94, 524, 326, 329, 2271, 2274, "and" +273, 20, 95, 525, 330, 336, 2275, 2281, "weight" +273, 20, 96, 526, 337, 341, 2282, 2286, "loss" +273, 20, 97, 527, 342, 343, 2287, 2288, "(" +273, 20, 98, 528, 344, 345, 2289, 2290, "2" +273, 20, 99, 529, 346, 347, 2291, 2292, "%" +273, 20, 100, 530, 348, 349, 2293, 2294, ")" +273, 20, 101, 531, 350, 352, 2295, 2297, "in" +273, 20, 102, 532, 353, 362, 2298, 2307, "metformin" +273, 20, 103, 533, 363, 364, 2308, 2309, "-" +273, 20, 104, 534, 365, 374, 2310, 2319, "cotreated" +273, 20, 105, 535, 375, 383, 2320, 2328, "patients" +273, 20, 106, 536, 384, 385, 2329, 2330, "." +273, 21, 1, 537, 0, 11, 2331, 2342, "CONCLUSIONS" +273, 21, 2, 538, 12, 13, 2343, 2344, ":" +273, 21, 3, 539, 14, 27, 2345, 2358, "Methazolamide" +273, 21, 4, 540, 28, 30, 2359, 2361, "is" +273, 21, 5, 541, 31, 34, 2362, 2365, "the" +273, 21, 6, 542, 35, 44, 2366, 2375, "archetype" +273, 21, 7, 543, 45, 48, 2376, 2379, "for" +273, 21, 8, 544, 49, 50, 2380, 2381, "a" +273, 21, 9, 545, 51, 54, 2382, 2385, "new" +273, 21, 10, 546, 55, 67, 2386, 2398, "intervention" +273, 21, 11, 547, 68, 70, 2399, 2401, "in" +273, 21, 12, 548, 71, 75, 2402, 2406, "type" +273, 21, 13, 549, 76, 77, 2407, 2408, "2" +273, 21, 14, 550, 78, 86, 2409, 2417, "diabetes" +273, 21, 15, 551, 87, 91, 2418, 2422, "with" +273, 21, 16, 552, 92, 100, 2423, 2431, "clinical" +273, 21, 17, 553, 101, 109, 2432, 2440, "benefits" +273, 21, 18, 554, 110, 116, 2441, 2447, "beyond" +273, 21, 19, 555, 117, 124, 2448, 2455, "glucose" +273, 21, 20, 556, 125, 132, 2456, 2463, "control" +273, 21, 21, 557, 133, 134, 2464, 2465, "." +273, 22, 1, 558, 0, 1, 2466, 2467, "©" +273, 22, 2, 559, 2, 6, 2468, 2472, "2014" +273, 22, 3, 560, 7, 9, 2473, 2475, "by" +273, 22, 4, 561, 10, 13, 2476, 2479, "the" +273, 22, 5, 562, 14, 22, 2480, 2488, "American" +273, 22, 6, 563, 23, 31, 2489, 2497, "Diabetes" +273, 22, 7, 564, 32, 43, 2498, 2509, "Association" +273, 22, 8, 565, 44, 45, 2510, 2511, "." +273, 23, 1, 566, 0, 7, 2512, 2519, "Readers" +273, 23, 2, 567, 8, 11, 2520, 2523, "may" +273, 23, 3, 568, 12, 15, 2524, 2527, "use" +273, 23, 4, 569, 16, 20, 2528, 2532, "this" +273, 23, 5, 570, 21, 28, 2533, 2540, "article" +273, 23, 6, 571, 29, 31, 2541, 2543, "as" +273, 23, 7, 572, 32, 36, 2544, 2548, "long" +273, 23, 8, 573, 37, 39, 2549, 2551, "as" +273, 23, 9, 574, 40, 43, 2552, 2555, "the" +273, 23, 10, 575, 44, 48, 2556, 2560, "work" +273, 23, 11, 576, 49, 51, 2561, 2563, "is" +273, 23, 12, 577, 52, 60, 2564, 2572, "properly" +273, 23, 13, 578, 61, 66, 2573, 2578, "cited" +273, 23, 14, 579, 67, 68, 2579, 2580, "," +273, 23, 15, 580, 69, 72, 2581, 2584, "the" +273, 23, 16, 581, 73, 76, 2585, 2588, "use" +273, 23, 17, 582, 77, 79, 2589, 2591, "is" +273, 23, 18, 583, 80, 91, 2592, 2603, "educational" +273, 23, 19, 584, 92, 95, 2604, 2607, "and" +273, 23, 20, 585, 96, 99, 2608, 2611, "not" +273, 23, 21, 586, 100, 103, 2612, 2615, "for" +273, 23, 22, 587, 104, 110, 2616, 2622, "profit" +273, 23, 23, 588, 111, 112, 2623, 2624, "," +273, 23, 24, 589, 113, 116, 2625, 2628, "and" +273, 23, 25, 590, 117, 120, 2629, 2632, "the" +273, 23, 26, 591, 121, 125, 2633, 2637, "work" +273, 23, 27, 592, 126, 128, 2638, 2640, "is" +273, 23, 28, 593, 129, 132, 2641, 2644, "not" +273, 23, 29, 594, 133, 140, 2645, 2652, "altered" +273, 23, 30, 595, 141, 142, 2653, 2654, "." +273, 24, 1, 596, 0, 3, 2655, 2658, "DOI" +273, 24, 2, 597, 4, 5, 2659, 2660, ":" +273, 24, 3, 598, 6, 8, 2661, 2663, "10" +273, 24, 4, 599, 9, 10, 2664, 2665, "." +273, 24, 5, 600, 11, 15, 2666, 2670, "2337" +273, 24, 6, 601, 16, 17, 2671, 2672, "/" +273, 24, 7, 602, 18, 22, 2673, 2677, "dc14" +273, 24, 8, 603, 23, 24, 2678, 2679, "-" +273, 24, 9, 604, 25, 29, 2680, 2684, "1038" +273, 24, 10, 605, 30, 34, 2685, 2689, "PMID" +273, 24, 11, 606, 35, 36, 2690, 2691, ":" +273, 24, 12, 607, 37, 45, 2692, 2700, "25125506" +273, 24, 13, 608, 46, 47, 2701, 2702, "[" +273, 24, 14, 609, 48, 55, 2703, 2710, "Indexed" +273, 24, 15, 610, 56, 59, 2711, 2714, "for" +273, 24, 16, 611, 60, 67, 2715, 2722, "MEDLINE" +273, 24, 17, 612, 68, 69, 2723, 2724, "]" diff --git a/data/dm2 25125506_kwoodley.annodb b/data/dm2 25125506_kwoodley.annodb new file mode 100644 index 0000000..8c8dcdd --- /dev/null +++ b/data/dm2 25125506_kwoodley.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +53097, Journal, 0, 13, "Diabetes Care", "", +53098, PublicationYear, 16, 20, "2014", "", +53099, Oral, 124, 128, "oral", "", +53100, Drug, 129, 142, "methazolamide", "", +53107, Type2Diabetes, 160, 175, "type 2 diabetes", "", +53110, Duration, 180, 189, "24 - week", "", +53112, Placebo, 192, 199, "placebo", "", +53115, DoubleBlind, 215, 229, "double - blind", "", +53116, Author, 238, 248, "Simpson RW", "", +53117, Author, 257, 269, "Nicholson GC", "", +53118, Author, 278, 288, "Proietto J", "", +53119, Author, 297, 304, "Sarah A", "", +53120, Author, 313, 323, "Sanders KM", "", +53121, Author, 332, 342, "Phillips G", "", +53122, Author, 351, 361, "Chambers J", "", +53123, Author, 370, 381, "MacGinley R", "", +53124, Author, 390, 398, "Orford N", "", +53125, Author, 407, 415, "Walder K", "", +53126, Author, 424, 434, "Krippner G", "", +53127, Author, 443, 450, "Skoff K", "", +53128, Author, 459, 468, "Wacher VJ", "", +53129, Australia, 546, 555, "Australia", "", +53130, Australia, 681, 690, "Australia", "", +53131, Australia, 783, 792, "Australia", "", +53132, Australia, 885, 894, "Australia", "", +53133, Australia, 944, 953, "Australia", "", +53134, Australia, 1134, 1143, "Australia", "", +53135, Australia, 1207, 1216, "Australia", "", +53136, Australia, 1280, 1289, "Australia", "", +53137, ObjectiveDescription, 1334, 1431, "To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .", "", +53101, Drug, 1373, 1386, "methazolamide", "", +53108, Type2Diabetes, 1414, 1429, "type 2 diabetes", "", +53138, DoubleBlind, 1467, 1481, "double - blind", "", +53139, Placebo, 1484, 1491, "placebo", "", +53140, Randomized, 1511, 1521, "randomized", "", +53141, NumberPatientsCT, 1522, 1524, "76", "", +53142, Oral, 1537, 1541, "oral", "", +53102, Drug, 1542, 1555, "methazolamide", "", +53143, DoseValue, 1558, 1560, "40", "", +53144, mg, 1561, 1563, "mg", "", +53145, Frequency, 1564, 1575, "b . i . d .", "", +53113, Placebo, 1581, 1588, "placebo", "", +53111, Duration, 1593, 1601, "24 weeks", "", +53103, Drug, 1639, 1652, "methazolamide", "", +53146, Placebo, 1669, 1676, "placebo", "", +53147, HbA1c, 1702, 1707, "HbA1c", "", +53151, TimePoint, 1713, 1721, "baseline", "", +53152, TimePoint, 1728, 1736, "24 weeks", "", +53148, HbA1c, 1741, 1746, "HbA1c", "", +53153, TimePoint, 1771, 1779, "baseline", "", +53149, HbA1c, 1780, 1785, "HbA1c", "", +53154, BaseLineValue, 1790, 1795, "7 . 1", "", +53156, SdDevBL, 1798, 1803, "0 . 7", "", +53158, Percentage, 1804, 1805, "%", "", +53155, BaseLineValue, 1808, 1810, "54", "", +53157, SdDevBL, 1813, 1814, "5", "", +53160, BioAndMedicalUnit, 1815, 1825, "mmol / mol", "", +53162, NumberPatientsArm, 1832, 1834, "37", "", +53164, BaseLineValue, 1841, 1846, "7 . 4", "", +53166, SdDevBL, 1849, 1854, "0 . 6", "", +53159, Percentage, 1855, 1856, "%", "", +53165, BaseLineValue, 1859, 1861, "57", "", +53167, SdDevBL, 1864, 1865, "5", "", +53161, BioAndMedicalUnit, 1866, 1876, "mmol / mol", "", +53163, NumberPatientsArm, 1883, 1885, "39", "", +53104, Drug, 1895, 1908, "methazolamide", "", +53114, Placebo, 1913, 1920, "placebo", "", +53105, Drug, 1945, 1958, "Methazolamide", "", +53150, HbA1c, 1993, 1998, "HbA1c", "", +53168, Reduction, 2004, 2010, "0 . 39", "", +53170, Percentage, 2011, 2012, "%", "", +53171, ConfIntervalChangeValue, 2015, 2040, "95 % CI - 0 . 82 , 0 . 04", "", +53173, PValueChangeValue, 2043, 2053, "P < 0 . 05", "", +53169, Reduction, 2060, 2065, "4 . 3", "", +53174, BioAndMedicalUnit, 2066, 2076, "mmol / mol", "", +53172, ConfIntervalChangeValue, 2079, 2094, "- 9 . 0 , 0 . 4", "", +53175, HbA1c_target, 2153, 2186, "HbA1c ≤ 6 . 5 % ( 48 mmol / mol )", "", +53176, PercentageAffected, 2197, 2199, "33", "", +53178, EndPointDescription, 2225, 2249, "alanine aminotransferase", "", +53177, Reduction, 2254, 2256, "10", "", +53181, BioAndMedicalUnit, 2257, 2266, "units / L", "", +53179, BodyWeight, 2275, 2281, "weight", "", +53180, RelativeReduction, 2289, 2290, "2", "", +53182, Metformin, 2298, 2307, "metformin", "", +53183, SubGroupDescription, 2298, 2328, "metformin - cotreated patients", "", +53106, Drug, 2345, 2358, "Methazolamide", "", +53184, ConclusionComment, 2345, 2465, "Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .", "", +53109, Type2Diabetes, 2402, 2417, "type 2 diabetes", "", +53185, PMID, 2692, 2700, "25125506", "", diff --git a/data/dm2 25125506_kwoodley.n-triples b/data/dm2 25125506_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25125506_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25138574_admin.annodb b/data/dm2 25138574_admin.annodb new file mode 100644 index 0000000..1d04933 --- /dev/null +++ b/data/dm2 25138574_admin.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "J Endocrinol Invest .", "", " \"J Endocrinol Invest .\"." +1, PublicationYear, 22, 26, "2014", "", " \"2014\"." +20, Title, 119, 231, "Comparative effects of metformin and pioglitazone on YKL - 40 in type 2 diabetes : a randomized clinical trial .", "", " \"Comparative effects of metformin and pioglitazone on YKL - 40 in type 2 diabetes : a randomized clinical trial .\"." +2, Metformin, 142, 151, "metformin", "", +10, Pioglitazone, 156, 168, "pioglitazone", "", +78, EndPointDescription, 172, 180, "YKL - 40", "", +16, Type2Diabetes, 184, 199, "type 2 diabetes", "", " ." +18, Randomized, 204, 214, "randomized", "", +21, Author, 232, 245, "Esteghamati A", "", " \"Esteghamati A\"." +22, Author, 254, 263, "Rezvani S", "", " \"Rezvani S\"." +23, Author, 266, 274, "Khajeh E", "", " \"Khajeh E\"." +24, Author, 277, 284, "Ebadi M", "", " \"Ebadi M\"." +25, Author, 287, 299, "Nakhjavani M", "", " \"Nakhjavani M\"." +26, Author, 302, 310, "Noshad S", "", " \"Noshad S\"." +27, Iran, 514, 518, "Iran", "", " ." +3, Metformin, 562, 571, "Metformin", "", +11, Pioglitazone, 576, 588, "pioglitazone", "", +28, ObjectiveDescription, 776, 956, "The present trial was designed to investigate the comparative efficacy of the two anti - diabetes medications on serum concentrations of YKL - 40 , a novel marker of inflammation .", "", " \"The present trial was designed to investigate the comparative efficacy of the two anti - diabetes medications on serum concentrations of YKL - 40 , a novel marker of inflammation .\"." +79, EndPointDescription, 913, 921, "YKL - 40", "", +29, Parallel, 972, 988, "parallel - group", "", " ." +30, OpenLabel, 991, 1003, "open - label", "", " ." +19, Randomized, 1006, 1016, "randomized", "", +31, NumberPatientsCT, 1086, 1088, "84", "", " \"84\"." +32, Precondition, 1089, 1152, "newly diagnosed , medication - na ï ve type 2 diabetes patients", "", " \"newly diagnosed , medication - na ï ve type 2 diabetes patients\"." +17, Type2Diabetes, 1128, 1143, "type 2 diabetes", "", +4, Metformin, 1170, 1179, "metformin", "", " ." +33, DoseValue, 1180, 1187, "1 , 000", "", " \"1 , 000\"." +35, mg, 1188, 1190, "mg", "", " ." +37, Frequency, 1191, 1196, "daily", "", " \"daily\"." +39, NumberPatientsArm, 1203, 1205, "42", "", " \"42\"." +12, Pioglitazone, 1211, 1223, "pioglitazone", "", " ." +34, DoseValue, 1224, 1226, "30", "", " \"30\"." +36, mg, 1227, 1229, "mg", "", " ." +38, Frequency, 1230, 1235, "daily", "", " \"daily\"." +40, NumberPatientsArm, 1242, 1244, "42", "", " \"42\"." +156, EndPointDescription, 1273, 1281, "YKL - 40", "", +41, TimePoint, 1398, 1406, "baseline", "", +42, TimePoint, 1417, 1425, "3 months", "", +5, Metformin, 1463, 1472, "metformin", "", +121, FinalNumPatientsArm, 1475, 1477, "40", "", " \"40\"." +13, Pioglitazone, 1480, 1492, "pioglitazone", "", +122, FinalNumPatientsArm, 1495, 1497, "42", "", " \"40\"." +47, ObservedResult, 1502, 1567, "both medications were equally effective with regard to control of", "", " \"both medications were equally effective with regard to control of\". \"both medications were equally effective with regard to control of\". \"both medications were equally effective with regard to control of\". \"both medications were equally effective with regard to control of\"." +45, Hypoglycemia, 1568, 1581, "hyperglycemia", "", " ." +46, EndPointDescription, 1588, 1593, "hsCRP", "", " . ." +124, PvalueDiff, 1606, 1616, "p > 0 . 05", "", " \"p > 0 . 05\". \"p > 0 . 05\"." +6, Metformin, 1631, 1640, "metformin", "", +51, ObservedResult, 1641, 1672, "caused a significant decline in", "", +49, BodyWeight, 1673, 1679, "weight", "", " ." +53, PValueChangeValue, 1682, 1693, "p = 0 . 005", "", " ." +52, BMI, 1698, 1701, "BMI", "", " ." +54, PValueChangeValue, 1704, 1715, "p = 0 . 004", "", " \"p = 0 . 004\"." +50, EndPointDescription, 1730, 1748, "cholesterol levels", "", " . ." +55, PValueChangeValue, 1751, 1762, "p = 0 . 028", "", " \"p = 0 . 028\"." +7, Metformin, 1783, 1792, "Metformin", "", +56, EndPointDescription, 1820, 1828, "YKL - 40", "", " . ." +57, TimePoint, 1850, 1858, "3 months", "", " \"3 months\"." +77301, BaseLineValue, 1861, 1867, "1 . 90", "", " \"1 . 90\"." +77302, SdDevBL, 1870, 1872, "17", "", " \"17\"." +77303, ResultMeasuredValue, 1878, 1884, "1 . 66", "", " \"1 . 66\"." +77305, SdDevResValue, 1887, 1893, "0 . 15", "", " \"0 . 15\"." +139, ConcentrationUnit, 1894, 1901, "µ g / L", "", " . ." +77306, PValueChangeValue, 1904, 1915, "p = 0 . 019", "", " \"p = 0 . 019\"." +14, Pioglitazone, 1948, 1960, "pioglitazone", "", +64, BaseLineValue, 2006, 2012, "2 . 18", "", " \"2 . 18\"." +65, SdDevBL, 2015, 2021, "0 . 14", "", " \"0 . 14\"." +66, ResultMeasuredValue, 2027, 2033, "2 . 25", "", " \"2 . 25\"." +67, SdDevResValue, 2036, 2042, "0 . 16", "", " \"0 . 16\"." +140, ConcentrationUnit, 2043, 2050, "µ g / L", "", +69, PValueChangeValue, 2053, 2064, "p = 0 . 687", "", " \"p = 0 . 687\"." +8, Metformin, 2085, 2094, "metformin", "", +15, Pioglitazone, 2133, 2145, "pioglitazone", "", +146, EndPointDescription, 2162, 2170, "YKL - 40", "", +73, PvalueDiff, 2202, 2213, "p = 0 . 020", "", " \"p = 0 . 020\"." +77307, DiffGroupRelValue, 2230, 2235, "6 . 7", "", " \"6 . 7\"." +74, PvalueDiff, 2266, 2277, "p = 0 . 047", "", " \"p = 0 . 047\"." +77308, DiffGroupRelValue, 2294, 2299, "5 . 7", "", " \"5 . 7\"." +9, Metformin, 2320, 2329, "Metformin", "", +80, ConclusionComment, 2320, 2492, "Metformin is more effective in reduction of YKL - 40 concentration in short term and the effect seems to be independent of degree of glycemic control , or hsCRP reduction .", "", " \"Metformin is more effective in reduction of YKL - 40 concentration in short term and the effect seems to be independent of degree of glycemic control , or hsCRP reduction .\"." +77, EndPointDescription, 2364, 2372, "YKL - 40", "", +81, PMID, 2542, 2550, "25138574", "", " \"25138574\"." diff --git a/data/dm2 25138574_admin.n-triples b/data/dm2 25138574_admin.n-triples new file mode 100644 index 0000000..533614e --- /dev/null +++ b/data/dm2 25138574_admin.n-triples @@ -0,0 +1,196 @@ +# RDF export of group: Publication + . + "Publication 63389" . + "Comparative effects of metformin and pioglitazone on YKL - 40 in type 2 diabetes : a randomized clinical trial ." . + "Esteghamati A" . + "2014" . + "J Endocrinol Invest ." . + "25138574" . + . + "Rezvani S" . + "Khajeh E" . + "Ebadi M" . + "Nakhjavani M" . + "Noshad S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 63396" . + "The present trial was designed to investigate the comparative efficacy of the two anti - diabetes medications on serum concentrations of YKL - 40 , a novel marker of inflammation ." . + "84" . + . + . + . + "Metformin is more effective in reduction of YKL - 40 concentration in short term and the effect seems to be independent of degree of glycemic control , or hsCRP reduction ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 63412" . + "newly diagnosed , medication - na ï ve type 2 diabetes patients" . + . + . + . +# RDF export of group: Endpoint + . + "hyp" . + . + . + . + . + . + "hsc" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + "bmi" . + . + . + . + . + . + "cho" . + . + . + . + . + . + . + "ykl" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "met" . + "42" . + "40" . + . + . + . + . + . + . + . + . + "pio" . + "42" . + "42" . + . + . + . + . +# RDF export of group: Intervention + . + "met" . + . + "daily" . + . + . + "pio" . + . + "daily" . + . +# RDF export of group: Medication + . + "met" . + . + "1 , 000" . + . + . + . + "pio" . + . + "30" . + . + . +# RDF export of group: Outcome + . + "hyp 1" . + . + "both medications were equally effective with regard to control of" . + . + "hyp 2" . + . + "both medications were equally effective with regard to control of" . + . + "hsc 1" . + . + "both medications were equally effective with regard to control of" . + . + "hsc 2" . + . + "both medications were equally effective with regard to control of" . + . + "bw 1" . + . + "p = 0 . 005" . + . + "bmi 1" . + . + "p = 0 . 004" . + . + "cho 1" . + . + "p = 0 . 028" . + . + "ykl 1" . + . + "1 . 90" . + "17" . + "1 . 66" . + "0 . 15" . + "p = 0 . 019" . + "3 months" . + . + "ykl 2" . + . + "2 . 18" . + "0 . 14" . + "2 . 25" . + "0 . 16" . + "p = 0 . 687" . +# RDF export of group: DiffBetweenGroups + . + "hyp" . + "p > 0 . 05" . + . + . + . + "csp" . + "p > 0 . 05" . + . + . + . + "ykl" . + "6 . 7" . + "p = 0 . 020" . + . + . + . + "ykl2" . + "5 . 7" . + "p = 0 . 047" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25138574_akramersunderbrink.annodb b/data/dm2 25138574_akramersunderbrink.annodb new file mode 100644 index 0000000..b3d88b7 --- /dev/null +++ b/data/dm2 25138574_akramersunderbrink.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +60677, Journal, 0, 19, "J Endocrinol Invest", "", +60678, PublicationYear, 22, 26, "2014", "", +60686, Title, 119, 231, "Comparative effects of metformin and pioglitazone on YKL - 40 in type 2 diabetes : a randomized clinical trial .", "", +60680, Metformin, 142, 151, "metformin", "", +60681, Pioglitazone, 156, 168, "pioglitazone", "", +60767, EndPointDescription, 172, 180, "YKL - 40", "", +60684, Type2Diabetes, 184, 199, "type 2 diabetes", "", +60685, Randomized, 204, 214, "randomized", "", +60690, Author, 232, 245, "Esteghamati A", "", +60692, Author, 254, 263, "Rezvani S", "", +60693, Author, 266, 274, "Khajeh E", "", +60694, Author, 277, 284, "Ebadi M", "", +60695, Author, 287, 299, "Nakhjavani M", "", +60696, Author, 302, 310, "Noshad S", "", +60697, Iran, 514, 518, "Iran", "", +60698, Metformin, 562, 571, "Metformin", "", +60702, ObjectiveDescription, 562, 775, "Metformin and pioglitazone are believed to exert their long - term benefits by means of amelioration of chronic low - grade inflammation , a key event in development of diabetes and its long - term complications .", "", +60699, Pioglitazone, 576, 588, "pioglitazone", "", +60703, ObjectiveDescription, 776, 956, "The present trial was designed to investigate the comparative efficacy of the two anti - diabetes medications on serum concentrations of YKL - 40 , a novel marker of inflammation .", "", +60768, EndPointDescription, 913, 954, "YKL - 40 , a novel marker of inflammation", "", +60705, Parallel, 972, 988, "parallel - group", "", +60706, OpenLabel, 991, 1003, "open - label", "", +60707, Randomized, 1006, 1016, "randomized", "", +60708, NumberPatientsCT, 1086, 1088, "84", "", +60712, Precondition, 1089, 1104, "newly diagnosed", "", +60713, Precondition, 1107, 1127, "medication - na ï ve", "", +60711, Type2Diabetes, 1128, 1143, "type 2 diabetes", "", +60715, Metformin, 1170, 1179, "metformin", "", +60717, DoseValue, 1180, 1190, "1 , 000 mg", "", +60716, mg, 1188, 1190, "mg", "", +60718, Frequency, 1191, 1196, "daily", "", +60719, NumberPatientsArm, 1203, 1205, "42", "", +60721, Pioglitazone, 1211, 1223, "pioglitazone", "", +60723, DoseValue, 1224, 1229, "30 mg", "", +60725, mg, 1227, 1229, "mg", "", +60726, Frequency, 1230, 1235, "daily", "", +60720, NumberPatientsArm, 1242, 1244, "42", "", +60769, EndPointDescription, 1249, 1281, "Serum concentrations of YKL - 40", "", +60727, TimePoint, 1398, 1406, "baseline", "", +60728, TimePoint, 1417, 1425, "3 months", "", +60729, Metformin, 1463, 1472, "metformin", "", +60731, FinalNumPatientsArm, 1475, 1477, "40", "", +60730, Pioglitazone, 1480, 1492, "pioglitazone", "", +60732, FinalNumPatientsArm, 1495, 1497, "42", "", +60733, Hypoglycemia, 1568, 1581, "hyperglycemia", "", +60734, PvalueDiff, 1606, 1616, "p > 0 . 05", "", +60735, Metformin, 1631, 1640, "metformin", "", +60736, BodyWeight, 1673, 1679, "weight", "", +60737, PValueChangeValue, 1682, 1693, "p = 0 . 005", "", +60740, BMI, 1698, 1701, "BMI", "", +60738, PValueChangeValue, 1704, 1715, "p = 0 . 004", "", +60741, EndPointDescription, 1724, 1748, "total cholesterol levels", "", +60739, PValueChangeValue, 1751, 1762, "p = 0 . 028", "", +60742, Metformin, 1783, 1792, "Metformin", "", +60745, EndPointDescription, 1820, 1843, "YKL - 40 concentrations", "", +60744, TimePoint, 1850, 1858, "3 months", "", +60746, BaseLineValue, 1861, 1867, "1 . 90", "", +60748, ResultMeasuredValue, 1878, 1884, "1 . 66", "", +60750, ConcentrationUnit, 1894, 1901, "µ g / L", "", +60753, PValueChangeValue, 1904, 1915, "p = 0 . 019", "", +60755, Pioglitazone, 1948, 1960, "pioglitazone", "", +60747, BaseLineValue, 2006, 2012, "2 . 18", "", +60749, ResultMeasuredValue, 2027, 2033, "2 . 25", "", +60752, ConcentrationUnit, 2043, 2050, "µ g / L", "", +60754, PValueChangeValue, 2053, 2064, "p = 0 . 687", "", +60756, Metformin, 2085, 2094, "metformin", "", +60757, Pioglitazone, 2133, 2145, "pioglitazone", "", +60758, EndPointDescription, 2162, 2199, "YKL - 40 reduction in both univariate", "", +60761, PValueChangeValue, 2202, 2213, "p = 0 . 020", "", +60764, Percentage, 2236, 2237, "%", "", +60759, EndPointDescription, 2244, 2263, "multivariate models", "", +60762, PValueChangeValue, 2266, 2277, "p = 0 . 047", "", +60763, Percentage, 2300, 2301, "%", "", +60765, Metformin, 2320, 2329, "Metformin", "", +60770, ConclusionComment, 2320, 2492, "Metformin is more effective in reduction of YKL - 40 concentration in short term and the effect seems to be independent of degree of glycemic control , or hsCRP reduction .", "", +60766, EndPointDescription, 2364, 2386, "YKL - 40 concentration", "", +60771, PMID, 2542, 2550, "25138574", "", diff --git a/data/dm2 25138574_akramersunderbrink.n-triples b/data/dm2 25138574_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25138574_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25138574_export.csv b/data/dm2 25138574_export.csv new file mode 100644 index 0000000..99941fe --- /dev/null +++ b/data/dm2 25138574_export.csv @@ -0,0 +1,561 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +272, 1, 1, 1, 0, 1, 0, 1, "J" +272, 1, 2, 2, 2, 12, 2, 12, "Endocrinol" +272, 1, 3, 3, 13, 19, 13, 19, "Invest" +272, 1, 4, 4, 20, 21, 20, 21, "." +272, 2, 1, 5, 0, 4, 22, 26, "2014" +272, 2, 2, 6, 5, 8, 27, 30, "Dec" +272, 2, 3, 7, 9, 10, 31, 32, ";" +272, 2, 4, 8, 11, 13, 33, 35, "37" +272, 2, 5, 9, 14, 15, 36, 37, "(" +272, 2, 6, 10, 16, 18, 38, 40, "12" +272, 2, 7, 11, 19, 20, 41, 42, ")" +272, 2, 8, 12, 21, 22, 43, 44, ":" +272, 2, 9, 13, 23, 27, 45, 49, "1211" +272, 2, 10, 14, 28, 29, 50, 51, "-" +272, 2, 11, 15, 30, 31, 52, 53, "8" +272, 2, 12, 16, 32, 33, 54, 55, "." +272, 2, 13, 17, 34, 37, 56, 59, "doi" +272, 2, 14, 18, 38, 39, 60, 61, ":" +272, 2, 15, 19, 40, 42, 62, 64, "10" +272, 2, 16, 20, 43, 44, 65, 66, "." +272, 2, 17, 21, 45, 49, 67, 71, "1007" +272, 2, 18, 22, 50, 51, 72, 73, "/" +272, 2, 19, 23, 52, 58, 74, 80, "s40618" +272, 2, 20, 24, 59, 60, 81, 82, "-" +272, 2, 21, 25, 61, 64, 83, 86, "014" +272, 2, 22, 26, 65, 66, 87, 88, "-" +272, 2, 23, 27, 67, 71, 89, 93, "0154" +272, 2, 24, 28, 72, 73, 94, 95, "-" +272, 2, 25, 29, 74, 75, 96, 97, "x" +272, 2, 26, 30, 76, 77, 98, 99, "." +272, 3, 1, 31, 0, 4, 100, 104, "Epub" +272, 3, 2, 32, 5, 9, 105, 109, "2014" +272, 3, 3, 33, 10, 13, 110, 113, "Aug" +272, 3, 4, 34, 14, 16, 114, 116, "20" +272, 3, 5, 35, 17, 18, 117, 118, "." +272, 4, 1, 36, 0, 11, 119, 130, "Comparative" +272, 4, 2, 37, 12, 19, 131, 138, "effects" +272, 4, 3, 38, 20, 22, 139, 141, "of" +272, 4, 4, 39, 23, 32, 142, 151, "metformin" +272, 4, 5, 40, 33, 36, 152, 155, "and" +272, 4, 6, 41, 37, 49, 156, 168, "pioglitazone" +272, 4, 7, 42, 50, 52, 169, 171, "on" +272, 4, 8, 43, 53, 56, 172, 175, "YKL" +272, 4, 9, 44, 57, 58, 176, 177, "-" +272, 4, 10, 45, 59, 61, 178, 180, "40" +272, 4, 11, 46, 62, 64, 181, 183, "in" +272, 4, 12, 47, 65, 69, 184, 188, "type" +272, 4, 13, 48, 70, 71, 189, 190, "2" +272, 4, 14, 49, 72, 80, 191, 199, "diabetes" +272, 4, 15, 50, 81, 82, 200, 201, ":" +272, 4, 16, 51, 83, 84, 202, 203, "a" +272, 4, 17, 52, 85, 95, 204, 214, "randomized" +272, 4, 18, 53, 96, 104, 215, 223, "clinical" +272, 4, 19, 54, 105, 110, 224, 229, "trial" +272, 4, 20, 55, 111, 112, 230, 231, "." +272, 5, 1, 56, 0, 11, 232, 243, "Esteghamati" +272, 5, 2, 57, 12, 13, 244, 245, "A" +272, 5, 3, 58, 14, 15, 246, 247, "(" +272, 5, 4, 59, 16, 17, 248, 249, "1" +272, 5, 5, 60, 18, 19, 250, 251, ")" +272, 5, 6, 61, 20, 21, 252, 253, "," +272, 5, 7, 62, 22, 29, 254, 261, "Rezvani" +272, 5, 8, 63, 30, 31, 262, 263, "S" +272, 5, 9, 64, 32, 33, 264, 265, "," +272, 5, 10, 65, 34, 40, 266, 272, "Khajeh" +272, 5, 11, 66, 41, 42, 273, 274, "E" +272, 5, 12, 67, 43, 44, 275, 276, "," +272, 5, 13, 68, 45, 50, 277, 282, "Ebadi" +272, 5, 14, 69, 51, 52, 283, 284, "M" +272, 5, 15, 70, 53, 54, 285, 286, "," +272, 5, 16, 71, 55, 65, 287, 297, "Nakhjavani" +272, 5, 17, 72, 66, 67, 298, 299, "M" +272, 5, 18, 73, 68, 69, 300, 301, "," +272, 5, 19, 74, 70, 76, 302, 308, "Noshad" +272, 5, 20, 75, 77, 78, 309, 310, "S" +272, 5, 21, 76, 79, 80, 311, 312, "." +272, 5, 22, 77, 81, 87, 313, 319, "Author" +272, 5, 23, 78, 88, 99, 320, 331, "information" +272, 5, 24, 79, 100, 101, 332, 333, ":" +272, 5, 25, 80, 102, 103, 334, 335, "(" +272, 5, 26, 81, 104, 105, 336, 337, "1" +272, 5, 27, 82, 106, 107, 338, 339, ")" +272, 5, 28, 83, 108, 121, 340, 353, "Endocrinology" +272, 5, 29, 84, 122, 125, 354, 357, "and" +272, 5, 30, 85, 126, 136, 358, 368, "Metabolism" +272, 5, 31, 86, 137, 145, 369, 377, "Research" +272, 5, 32, 87, 146, 152, 378, 384, "Center" +272, 5, 33, 88, 153, 154, 385, 386, "(" +272, 5, 34, 89, 155, 159, 387, 391, "EMRC" +272, 5, 35, 90, 160, 161, 392, 393, ")" +272, 5, 36, 91, 162, 163, 394, 395, "," +272, 5, 37, 92, 164, 170, 396, 402, "School" +272, 5, 38, 93, 171, 173, 403, 405, "of" +272, 5, 39, 94, 174, 182, 406, 414, "Medicine" +272, 5, 40, 95, 183, 184, 415, 416, "," +272, 5, 41, 96, 185, 189, 417, 421, "Vali" +272, 5, 42, 97, 190, 191, 422, 423, "-" +272, 5, 43, 98, 192, 195, 424, 427, "Asr" +272, 5, 44, 99, 196, 204, 428, 436, "Hospital" +272, 5, 45, 100, 205, 206, 437, 438, "," +272, 5, 46, 101, 207, 213, 439, 445, "Tehran" +272, 5, 47, 102, 214, 224, 446, 456, "University" +272, 5, 48, 103, 225, 227, 457, 459, "of" +272, 5, 49, 104, 228, 235, 460, 467, "Medical" +272, 5, 50, 105, 236, 244, 468, 476, "Sciences" +272, 5, 51, 106, 245, 246, 477, 478, "," +272, 5, 52, 107, 247, 248, 479, 480, "P" +272, 5, 53, 108, 249, 250, 481, 482, "." +272, 5, 54, 109, 251, 252, 483, 484, "O" +272, 5, 55, 110, 253, 254, 485, 486, "." +272, 6, 1, 111, 0, 3, 487, 490, "Box" +272, 6, 2, 112, 4, 9, 491, 496, "13145" +272, 6, 3, 113, 10, 11, 497, 498, "-" +272, 6, 4, 114, 12, 15, 499, 502, "784" +272, 6, 5, 115, 16, 17, 503, 504, "," +272, 6, 6, 116, 18, 24, 505, 511, "Tehran" +272, 6, 7, 117, 25, 26, 512, 513, "," +272, 6, 8, 118, 27, 31, 514, 518, "Iran" +272, 6, 9, 119, 32, 33, 519, 520, "," +272, 6, 10, 120, 34, 45, 521, 532, "esteghamati" +272, 6, 11, 121, 46, 47, 533, 534, "@" +272, 6, 12, 122, 48, 52, 535, 539, "tums" +272, 6, 13, 123, 53, 54, 540, 541, "." +272, 6, 14, 124, 55, 57, 542, 544, "ac" +272, 6, 15, 125, 58, 59, 545, 546, "." +272, 6, 16, 126, 60, 62, 547, 549, "ir" +272, 6, 17, 127, 63, 64, 550, 551, "." +272, 7, 1, 128, 0, 7, 552, 559, "PURPOSE" +272, 7, 2, 129, 8, 9, 560, 561, ":" +272, 7, 3, 130, 10, 19, 562, 571, "Metformin" +272, 7, 4, 131, 20, 23, 572, 575, "and" +272, 7, 5, 132, 24, 36, 576, 588, "pioglitazone" +272, 7, 6, 133, 37, 40, 589, 592, "are" +272, 7, 7, 134, 41, 49, 593, 601, "believed" +272, 7, 8, 135, 50, 52, 602, 604, "to" +272, 7, 9, 136, 53, 58, 605, 610, "exert" +272, 7, 10, 137, 59, 64, 611, 616, "their" +272, 7, 11, 138, 65, 69, 617, 621, "long" +272, 7, 12, 139, 70, 71, 622, 623, "-" +272, 7, 13, 140, 72, 76, 624, 628, "term" +272, 7, 14, 141, 77, 85, 629, 637, "benefits" +272, 7, 15, 142, 86, 88, 638, 640, "by" +272, 7, 16, 143, 89, 94, 641, 646, "means" +272, 7, 17, 144, 95, 97, 647, 649, "of" +272, 7, 18, 145, 98, 110, 650, 662, "amelioration" +272, 7, 19, 146, 111, 113, 663, 665, "of" +272, 7, 20, 147, 114, 121, 666, 673, "chronic" +272, 7, 21, 148, 122, 125, 674, 677, "low" +272, 7, 22, 149, 126, 127, 678, 679, "-" +272, 7, 23, 150, 128, 133, 680, 685, "grade" +272, 7, 24, 151, 134, 146, 686, 698, "inflammation" +272, 7, 25, 152, 147, 148, 699, 700, "," +272, 7, 26, 153, 149, 150, 701, 702, "a" +272, 7, 27, 154, 151, 154, 703, 706, "key" +272, 7, 28, 155, 155, 160, 707, 712, "event" +272, 7, 29, 156, 161, 163, 713, 715, "in" +272, 7, 30, 157, 164, 175, 716, 727, "development" +272, 7, 31, 158, 176, 178, 728, 730, "of" +272, 7, 32, 159, 179, 187, 731, 739, "diabetes" +272, 7, 33, 160, 188, 191, 740, 743, "and" +272, 7, 34, 161, 192, 195, 744, 747, "its" +272, 7, 35, 162, 196, 200, 748, 752, "long" +272, 7, 36, 163, 201, 202, 753, 754, "-" +272, 7, 37, 164, 203, 207, 755, 759, "term" +272, 7, 38, 165, 208, 221, 760, 773, "complications" +272, 7, 39, 166, 222, 223, 774, 775, "." +272, 8, 1, 167, 0, 3, 776, 779, "The" +272, 8, 2, 168, 4, 11, 780, 787, "present" +272, 8, 3, 169, 12, 17, 788, 793, "trial" +272, 8, 4, 170, 18, 21, 794, 797, "was" +272, 8, 5, 171, 22, 30, 798, 806, "designed" +272, 8, 6, 172, 31, 33, 807, 809, "to" +272, 8, 7, 173, 34, 45, 810, 821, "investigate" +272, 8, 8, 174, 46, 49, 822, 825, "the" +272, 8, 9, 175, 50, 61, 826, 837, "comparative" +272, 8, 10, 176, 62, 70, 838, 846, "efficacy" +272, 8, 11, 177, 71, 73, 847, 849, "of" +272, 8, 12, 178, 74, 77, 850, 853, "the" +272, 8, 13, 179, 78, 81, 854, 857, "two" +272, 8, 14, 180, 82, 86, 858, 862, "anti" +272, 8, 15, 181, 87, 88, 863, 864, "-" +272, 8, 16, 182, 89, 97, 865, 873, "diabetes" +272, 8, 17, 183, 98, 109, 874, 885, "medications" +272, 8, 18, 184, 110, 112, 886, 888, "on" +272, 8, 19, 185, 113, 118, 889, 894, "serum" +272, 8, 20, 186, 119, 133, 895, 909, "concentrations" +272, 8, 21, 187, 134, 136, 910, 912, "of" +272, 8, 22, 188, 137, 140, 913, 916, "YKL" +272, 8, 23, 189, 141, 142, 917, 918, "-" +272, 8, 24, 190, 143, 145, 919, 921, "40" +272, 8, 25, 191, 146, 147, 922, 923, "," +272, 8, 26, 192, 148, 149, 924, 925, "a" +272, 8, 27, 193, 150, 155, 926, 931, "novel" +272, 8, 28, 194, 156, 162, 932, 938, "marker" +272, 8, 29, 195, 163, 165, 939, 941, "of" +272, 8, 30, 196, 166, 178, 942, 954, "inflammation" +272, 8, 31, 197, 179, 180, 955, 956, "." +272, 9, 1, 198, 0, 7, 957, 964, "METHODS" +272, 9, 2, 199, 8, 9, 965, 966, ":" +272, 9, 3, 200, 10, 12, 967, 969, "In" +272, 9, 4, 201, 13, 14, 970, 971, "a" +272, 9, 5, 202, 15, 23, 972, 980, "parallel" +272, 9, 6, 203, 24, 25, 981, 982, "-" +272, 9, 7, 204, 26, 31, 983, 988, "group" +272, 9, 8, 205, 32, 33, 989, 990, "," +272, 9, 9, 206, 34, 38, 991, 995, "open" +272, 9, 10, 207, 39, 40, 996, 997, "-" +272, 9, 11, 208, 41, 46, 998, 1003, "label" +272, 9, 12, 209, 47, 48, 1004, 1005, "," +272, 9, 13, 210, 49, 59, 1006, 1016, "randomized" +272, 9, 14, 211, 60, 65, 1017, 1022, "trial" +272, 9, 15, 212, 66, 73, 1023, 1030, "setting" +272, 9, 16, 213, 74, 75, 1031, 1032, "(" +272, 9, 17, 214, 76, 90, 1033, 1047, "ClinicalTrials" +272, 9, 18, 215, 91, 92, 1048, 1049, "." +272, 9, 19, 216, 93, 96, 1050, 1053, "gov" +272, 9, 20, 217, 97, 107, 1054, 1064, "Identifier" +272, 9, 21, 218, 108, 110, 1065, 1067, "No" +272, 9, 22, 219, 111, 112, 1068, 1069, "." +272, 10, 1, 220, 0, 11, 1070, 1081, "NCT01521624" +272, 10, 2, 221, 12, 13, 1082, 1083, ")" +272, 10, 3, 222, 14, 15, 1084, 1085, "," +272, 10, 4, 223, 16, 18, 1086, 1088, "84" +272, 10, 5, 224, 19, 24, 1089, 1094, "newly" +272, 10, 6, 225, 25, 34, 1095, 1104, "diagnosed" +272, 10, 7, 226, 35, 36, 1105, 1106, "," +272, 10, 8, 227, 37, 47, 1107, 1117, "medication" +272, 10, 9, 228, 48, 49, 1118, 1119, "-" +272, 10, 10, 229, 50, 52, 1120, 1122, "na" +272, 10, 11, 230, 53, 54, 1123, 1124, "ï" +272, 10, 12, 231, 55, 57, 1125, 1127, "ve" +272, 10, 13, 232, 58, 62, 1128, 1132, "type" +272, 10, 14, 233, 63, 64, 1133, 1134, "2" +272, 10, 15, 234, 65, 73, 1135, 1143, "diabetes" +272, 10, 16, 235, 74, 82, 1144, 1152, "patients" +272, 10, 17, 236, 83, 87, 1153, 1157, "were" +272, 10, 18, 237, 88, 96, 1158, 1166, "assigned" +272, 10, 19, 238, 97, 99, 1167, 1169, "to" +272, 10, 20, 239, 100, 109, 1170, 1179, "metformin" +272, 10, 21, 240, 110, 111, 1180, 1181, "1" +272, 10, 22, 241, 112, 113, 1182, 1183, "," +272, 10, 23, 242, 114, 117, 1184, 1187, "000" +272, 10, 24, 243, 118, 120, 1188, 1190, "mg" +272, 10, 25, 244, 121, 126, 1191, 1196, "daily" +272, 10, 26, 245, 127, 128, 1197, 1198, "(" +272, 10, 27, 246, 129, 130, 1199, 1200, "n" +272, 10, 28, 247, 131, 132, 1201, 1202, "=" +272, 10, 29, 248, 133, 135, 1203, 1205, "42" +272, 10, 30, 249, 136, 137, 1206, 1207, ")" +272, 10, 31, 250, 138, 140, 1208, 1210, "or" +272, 10, 32, 251, 141, 153, 1211, 1223, "pioglitazone" +272, 10, 33, 252, 154, 156, 1224, 1226, "30" +272, 10, 34, 253, 157, 159, 1227, 1229, "mg" +272, 10, 35, 254, 160, 165, 1230, 1235, "daily" +272, 10, 36, 255, 166, 167, 1236, 1237, "(" +272, 10, 37, 256, 168, 169, 1238, 1239, "n" +272, 10, 38, 257, 170, 171, 1240, 1241, "=" +272, 10, 39, 258, 172, 174, 1242, 1244, "42" +272, 10, 40, 259, 175, 176, 1245, 1246, ")" +272, 10, 41, 260, 177, 178, 1247, 1248, "." +272, 11, 1, 261, 0, 5, 1249, 1254, "Serum" +272, 11, 2, 262, 6, 20, 1255, 1269, "concentrations" +272, 11, 3, 263, 21, 23, 1270, 1272, "of" +272, 11, 4, 264, 24, 27, 1273, 1276, "YKL" +272, 11, 5, 265, 28, 29, 1277, 1278, "-" +272, 11, 6, 266, 30, 32, 1279, 1281, "40" +272, 11, 7, 267, 33, 34, 1282, 1283, "," +272, 11, 8, 268, 35, 40, 1284, 1289, "along" +272, 11, 9, 269, 41, 45, 1290, 1294, "with" +272, 11, 10, 270, 46, 52, 1295, 1301, "highly" +272, 11, 11, 271, 53, 62, 1302, 1311, "sensitive" +272, 11, 12, 272, 63, 64, 1312, 1313, "C" +272, 11, 13, 273, 65, 66, 1314, 1315, "-" +272, 11, 14, 274, 67, 75, 1316, 1324, "reactive" +272, 11, 15, 275, 76, 83, 1325, 1332, "protein" +272, 11, 16, 276, 84, 85, 1333, 1334, "," +272, 11, 17, 277, 86, 93, 1335, 1342, "indices" +272, 11, 18, 278, 94, 96, 1343, 1345, "of" +272, 11, 19, 279, 97, 105, 1346, 1354, "glycemic" +272, 11, 20, 280, 106, 113, 1355, 1362, "control" +272, 11, 21, 281, 114, 117, 1363, 1366, "and" +272, 11, 22, 282, 118, 123, 1367, 1372, "lipid" +272, 11, 23, 283, 124, 131, 1373, 1380, "profile" +272, 11, 24, 284, 132, 136, 1381, 1385, "were" +272, 11, 25, 285, 137, 145, 1386, 1394, "measured" +272, 11, 26, 286, 146, 148, 1395, 1397, "at" +272, 11, 27, 287, 149, 157, 1398, 1406, "baseline" +272, 11, 28, 288, 158, 161, 1407, 1410, "and" +272, 11, 29, 289, 162, 167, 1411, 1416, "after" +272, 11, 30, 290, 168, 169, 1417, 1418, "3" +272, 11, 31, 291, 170, 176, 1419, 1425, "months" +272, 11, 32, 292, 177, 178, 1426, 1427, "." +272, 12, 1, 293, 0, 7, 1428, 1435, "RESULTS" +272, 12, 2, 294, 8, 9, 1436, 1437, ":" +272, 12, 3, 295, 10, 12, 1438, 1440, "In" +272, 12, 4, 296, 13, 16, 1441, 1444, "the" +272, 12, 5, 297, 17, 25, 1445, 1453, "analyzed" +272, 12, 6, 298, 26, 32, 1454, 1460, "sample" +272, 12, 7, 299, 33, 34, 1461, 1462, "(" +272, 12, 8, 300, 35, 44, 1463, 1472, "metformin" +272, 12, 9, 301, 45, 46, 1473, 1474, "=" +272, 12, 10, 302, 47, 49, 1475, 1477, "40" +272, 12, 11, 303, 50, 51, 1478, 1479, "," +272, 12, 12, 304, 52, 64, 1480, 1492, "pioglitazone" +272, 12, 13, 305, 65, 66, 1493, 1494, "=" +272, 12, 14, 306, 67, 69, 1495, 1497, "42" +272, 12, 15, 307, 70, 71, 1498, 1499, ")" +272, 12, 16, 308, 72, 73, 1500, 1501, "," +272, 12, 17, 309, 74, 78, 1502, 1506, "both" +272, 12, 18, 310, 79, 90, 1507, 1518, "medications" +272, 12, 19, 311, 91, 95, 1519, 1523, "were" +272, 12, 20, 312, 96, 103, 1524, 1531, "equally" +272, 12, 21, 313, 104, 113, 1532, 1541, "effective" +272, 12, 22, 314, 114, 118, 1542, 1546, "with" +272, 12, 23, 315, 119, 125, 1547, 1553, "regard" +272, 12, 24, 316, 126, 128, 1554, 1556, "to" +272, 12, 25, 317, 129, 136, 1557, 1564, "control" +272, 12, 26, 318, 137, 139, 1565, 1567, "of" +272, 12, 27, 319, 140, 153, 1568, 1581, "hyperglycemia" +272, 12, 28, 320, 154, 155, 1582, 1583, "," +272, 12, 29, 321, 156, 159, 1584, 1587, "and" +272, 12, 30, 322, 160, 165, 1588, 1593, "hsCRP" +272, 12, 31, 323, 166, 175, 1594, 1603, "reduction" +272, 12, 32, 324, 176, 177, 1604, 1605, "(" +272, 12, 33, 325, 178, 179, 1606, 1607, "p" +272, 12, 34, 326, 180, 181, 1608, 1609, ">" +272, 12, 35, 327, 182, 183, 1610, 1611, "0" +272, 12, 36, 328, 184, 185, 1612, 1613, "." +272, 12, 37, 329, 186, 188, 1614, 1616, "05" +272, 12, 38, 330, 189, 190, 1617, 1618, ")" +272, 12, 39, 331, 191, 192, 1619, 1620, "." +272, 13, 1, 332, 0, 7, 1621, 1628, "However" +272, 13, 2, 333, 8, 9, 1629, 1630, "," +272, 13, 3, 334, 10, 19, 1631, 1640, "metformin" +272, 13, 4, 335, 20, 26, 1641, 1647, "caused" +272, 13, 5, 336, 27, 28, 1648, 1649, "a" +272, 13, 6, 337, 29, 40, 1650, 1661, "significant" +272, 13, 7, 338, 41, 48, 1662, 1669, "decline" +272, 13, 8, 339, 49, 51, 1670, 1672, "in" +272, 13, 9, 340, 52, 58, 1673, 1679, "weight" +272, 13, 10, 341, 59, 60, 1680, 1681, "(" +272, 13, 11, 342, 61, 62, 1682, 1683, "p" +272, 13, 12, 343, 63, 64, 1684, 1685, "=" +272, 13, 13, 344, 65, 66, 1686, 1687, "0" +272, 13, 14, 345, 67, 68, 1688, 1689, "." +272, 13, 15, 346, 69, 72, 1690, 1693, "005" +272, 13, 16, 347, 73, 74, 1694, 1695, ")" +272, 13, 17, 348, 75, 76, 1696, 1697, "," +272, 13, 18, 349, 77, 80, 1698, 1701, "BMI" +272, 13, 19, 350, 81, 82, 1702, 1703, "(" +272, 13, 20, 351, 83, 84, 1704, 1705, "p" +272, 13, 21, 352, 85, 86, 1706, 1707, "=" +272, 13, 22, 353, 87, 88, 1708, 1709, "0" +272, 13, 23, 354, 89, 90, 1710, 1711, "." +272, 13, 24, 355, 91, 94, 1712, 1715, "004" +272, 13, 25, 356, 95, 96, 1716, 1717, ")" +272, 13, 26, 357, 97, 98, 1718, 1719, "," +272, 13, 27, 358, 99, 102, 1720, 1723, "and" +272, 13, 28, 359, 103, 108, 1724, 1729, "total" +272, 13, 29, 360, 109, 120, 1730, 1741, "cholesterol" +272, 13, 30, 361, 121, 127, 1742, 1748, "levels" +272, 13, 31, 362, 128, 129, 1749, 1750, "(" +272, 13, 32, 363, 130, 131, 1751, 1752, "p" +272, 13, 33, 364, 132, 133, 1753, 1754, "=" +272, 13, 34, 365, 134, 135, 1755, 1756, "0" +272, 13, 35, 366, 136, 137, 1757, 1758, "." +272, 13, 36, 367, 138, 141, 1759, 1762, "028" +272, 13, 37, 368, 142, 143, 1763, 1764, ")" +272, 13, 38, 369, 144, 146, 1765, 1767, "of" +272, 13, 39, 370, 147, 150, 1768, 1771, "the" +272, 13, 40, 371, 151, 159, 1772, 1780, "patients" +272, 13, 41, 372, 160, 161, 1781, 1782, "." +272, 14, 1, 373, 0, 9, 1783, 1792, "Metformin" +272, 14, 2, 374, 10, 14, 1793, 1797, "also" +272, 14, 3, 375, 15, 28, 1798, 1811, "significantly" +272, 14, 4, 376, 29, 36, 1812, 1819, "reduced" +272, 14, 5, 377, 37, 40, 1820, 1823, "YKL" +272, 14, 6, 378, 41, 42, 1824, 1825, "-" +272, 14, 7, 379, 43, 45, 1826, 1828, "40" +272, 14, 8, 380, 46, 60, 1829, 1843, "concentrations" +272, 14, 9, 381, 61, 66, 1844, 1849, "after" +272, 14, 10, 382, 67, 68, 1850, 1851, "3" +272, 14, 11, 383, 69, 75, 1852, 1858, "months" +272, 14, 12, 384, 76, 77, 1859, 1860, "(" +272, 14, 13, 385, 78, 79, 1861, 1862, "1" +272, 14, 14, 386, 80, 81, 1863, 1864, "." +272, 14, 15, 387, 82, 84, 1865, 1867, "90" +272, 14, 16, 388, 85, 86, 1868, 1869, "±" +272, 14, 17, 389, 87, 89, 1870, 1872, "17" +272, 14, 18, 390, 90, 92, 1873, 1875, "vs" +272, 14, 19, 391, 93, 94, 1876, 1877, "." +272, 14, 20, 392, 95, 96, 1878, 1879, "1" +272, 14, 21, 393, 97, 98, 1880, 1881, "." +272, 14, 22, 394, 99, 101, 1882, 1884, "66" +272, 14, 23, 395, 102, 103, 1885, 1886, "±" +272, 14, 24, 396, 104, 105, 1887, 1888, "0" +272, 14, 25, 397, 106, 107, 1889, 1890, "." +272, 14, 26, 398, 108, 110, 1891, 1893, "15" +272, 14, 27, 399, 111, 112, 1894, 1895, "µ" +272, 14, 28, 400, 113, 114, 1896, 1897, "g" +272, 14, 29, 401, 115, 116, 1898, 1899, "/" +272, 14, 30, 402, 117, 118, 1900, 1901, "L" +272, 14, 31, 403, 119, 120, 1902, 1903, "," +272, 14, 32, 404, 121, 122, 1904, 1905, "p" +272, 14, 33, 405, 123, 124, 1906, 1907, "=" +272, 14, 34, 406, 125, 126, 1908, 1909, "0" +272, 14, 35, 407, 127, 128, 1910, 1911, "." +272, 14, 36, 408, 129, 132, 1912, 1915, "019" +272, 14, 37, 409, 133, 134, 1916, 1917, ")" +272, 14, 38, 410, 135, 136, 1918, 1919, "." +272, 15, 1, 411, 0, 3, 1920, 1923, "The" +272, 15, 2, 412, 4, 10, 1924, 1930, "amount" +272, 15, 3, 413, 11, 13, 1931, 1933, "of" +272, 15, 4, 414, 14, 20, 1934, 1940, "change" +272, 15, 5, 415, 21, 23, 1941, 1943, "in" +272, 15, 6, 416, 24, 27, 1944, 1947, "the" +272, 15, 7, 417, 28, 40, 1948, 1960, "pioglitazone" +272, 15, 8, 418, 41, 44, 1961, 1964, "arm" +272, 15, 9, 419, 45, 48, 1965, 1968, "did" +272, 15, 10, 420, 49, 52, 1969, 1972, "not" +272, 15, 11, 421, 53, 58, 1973, 1978, "reach" +272, 15, 12, 422, 59, 70, 1979, 1990, "statistical" +272, 15, 13, 423, 71, 83, 1991, 2003, "significance" +272, 15, 14, 424, 84, 85, 2004, 2005, "(" +272, 15, 15, 425, 86, 87, 2006, 2007, "2" +272, 15, 16, 426, 88, 89, 2008, 2009, "." +272, 15, 17, 427, 90, 92, 2010, 2012, "18" +272, 15, 18, 428, 93, 94, 2013, 2014, "±" +272, 15, 19, 429, 95, 96, 2015, 2016, "0" +272, 15, 20, 430, 97, 98, 2017, 2018, "." +272, 15, 21, 431, 99, 101, 2019, 2021, "14" +272, 15, 22, 432, 102, 104, 2022, 2024, "vs" +272, 15, 23, 433, 105, 106, 2025, 2026, "." +272, 15, 24, 434, 107, 108, 2027, 2028, "2" +272, 15, 25, 435, 109, 110, 2029, 2030, "." +272, 15, 26, 436, 111, 113, 2031, 2033, "25" +272, 15, 27, 437, 114, 115, 2034, 2035, "±" +272, 15, 28, 438, 116, 117, 2036, 2037, "0" +272, 15, 29, 439, 118, 119, 2038, 2039, "." +272, 15, 30, 440, 120, 122, 2040, 2042, "16" +272, 15, 31, 441, 123, 124, 2043, 2044, "µ" +272, 15, 32, 442, 125, 126, 2045, 2046, "g" +272, 15, 33, 443, 127, 128, 2047, 2048, "/" +272, 15, 34, 444, 129, 130, 2049, 2050, "L" +272, 15, 35, 445, 131, 132, 2051, 2052, "," +272, 15, 36, 446, 133, 134, 2053, 2054, "p" +272, 15, 37, 447, 135, 136, 2055, 2056, "=" +272, 15, 38, 448, 137, 138, 2057, 2058, "0" +272, 15, 39, 449, 139, 140, 2059, 2060, "." +272, 15, 40, 450, 141, 144, 2061, 2064, "687" +272, 15, 41, 451, 145, 146, 2065, 2066, ")" +272, 15, 42, 452, 147, 148, 2067, 2068, "." +272, 16, 1, 453, 0, 4, 2069, 2073, "When" +272, 16, 2, 454, 5, 13, 2074, 2082, "compared" +272, 16, 3, 455, 14, 15, 2083, 2084, "," +272, 16, 4, 456, 16, 25, 2085, 2094, "metformin" +272, 16, 5, 457, 26, 29, 2095, 2098, "was" +272, 16, 6, 458, 30, 43, 2099, 2112, "significantly" +272, 16, 7, 459, 44, 48, 2113, 2117, "more" +272, 16, 8, 460, 49, 58, 2118, 2127, "effective" +272, 16, 9, 461, 59, 63, 2128, 2132, "than" +272, 16, 10, 462, 64, 76, 2133, 2145, "pioglitazone" +272, 16, 11, 463, 77, 81, 2146, 2150, "with" +272, 16, 12, 464, 82, 89, 2151, 2158, "respect" +272, 16, 13, 465, 90, 92, 2159, 2161, "to" +272, 16, 14, 466, 93, 96, 2162, 2165, "YKL" +272, 16, 15, 467, 97, 98, 2166, 2167, "-" +272, 16, 16, 468, 99, 101, 2168, 2170, "40" +272, 16, 17, 469, 102, 111, 2171, 2180, "reduction" +272, 16, 18, 470, 112, 114, 2181, 2183, "in" +272, 16, 19, 471, 115, 119, 2184, 2188, "both" +272, 16, 20, 472, 120, 130, 2189, 2199, "univariate" +272, 16, 21, 473, 131, 132, 2200, 2201, "(" +272, 16, 22, 474, 133, 134, 2202, 2203, "p" +272, 16, 23, 475, 135, 136, 2204, 2205, "=" +272, 16, 24, 476, 137, 138, 2206, 2207, "0" +272, 16, 25, 477, 139, 140, 2208, 2209, "." +272, 16, 26, 478, 141, 144, 2210, 2213, "020" +272, 16, 27, 479, 145, 146, 2214, 2215, "," +272, 16, 28, 480, 147, 153, 2216, 2222, "effect" +272, 16, 29, 481, 154, 158, 2223, 2227, "size" +272, 16, 30, 482, 159, 160, 2228, 2229, "=" +272, 16, 31, 483, 161, 162, 2230, 2231, "6" +272, 16, 32, 484, 163, 164, 2232, 2233, "." +272, 16, 33, 485, 165, 166, 2234, 2235, "7" +272, 16, 34, 486, 167, 168, 2236, 2237, "%" +272, 16, 35, 487, 169, 170, 2238, 2239, ")" +272, 16, 36, 488, 171, 174, 2240, 2243, "and" +272, 16, 37, 489, 175, 187, 2244, 2256, "multivariate" +272, 16, 38, 490, 188, 194, 2257, 2263, "models" +272, 16, 39, 491, 195, 196, 2264, 2265, "(" +272, 16, 40, 492, 197, 198, 2266, 2267, "p" +272, 16, 41, 493, 199, 200, 2268, 2269, "=" +272, 16, 42, 494, 201, 202, 2270, 2271, "0" +272, 16, 43, 495, 203, 204, 2272, 2273, "." +272, 16, 44, 496, 205, 208, 2274, 2277, "047" +272, 16, 45, 497, 209, 210, 2278, 2279, "," +272, 16, 46, 498, 211, 217, 2280, 2286, "effect" +272, 16, 47, 499, 218, 222, 2287, 2291, "size" +272, 16, 48, 500, 223, 224, 2292, 2293, "=" +272, 16, 49, 501, 225, 226, 2294, 2295, "5" +272, 16, 50, 502, 227, 228, 2296, 2297, "." +272, 16, 51, 503, 229, 230, 2298, 2299, "7" +272, 16, 52, 504, 231, 232, 2300, 2301, "%" +272, 16, 53, 505, 233, 234, 2302, 2303, ")" +272, 16, 54, 506, 235, 236, 2304, 2305, "." +272, 17, 1, 507, 0, 11, 2306, 2317, "CONCLUSIONS" +272, 17, 2, 508, 12, 13, 2318, 2319, ":" +272, 17, 3, 509, 14, 23, 2320, 2329, "Metformin" +272, 17, 4, 510, 24, 26, 2330, 2332, "is" +272, 17, 5, 511, 27, 31, 2333, 2337, "more" +272, 17, 6, 512, 32, 41, 2338, 2347, "effective" +272, 17, 7, 513, 42, 44, 2348, 2350, "in" +272, 17, 8, 514, 45, 54, 2351, 2360, "reduction" +272, 17, 9, 515, 55, 57, 2361, 2363, "of" +272, 17, 10, 516, 58, 61, 2364, 2367, "YKL" +272, 17, 11, 517, 62, 63, 2368, 2369, "-" +272, 17, 12, 518, 64, 66, 2370, 2372, "40" +272, 17, 13, 519, 67, 80, 2373, 2386, "concentration" +272, 17, 14, 520, 81, 83, 2387, 2389, "in" +272, 17, 15, 521, 84, 89, 2390, 2395, "short" +272, 17, 16, 522, 90, 94, 2396, 2400, "term" +272, 17, 17, 523, 95, 98, 2401, 2404, "and" +272, 17, 18, 524, 99, 102, 2405, 2408, "the" +272, 17, 19, 525, 103, 109, 2409, 2415, "effect" +272, 17, 20, 526, 110, 115, 2416, 2421, "seems" +272, 17, 21, 527, 116, 118, 2422, 2424, "to" +272, 17, 22, 528, 119, 121, 2425, 2427, "be" +272, 17, 23, 529, 122, 133, 2428, 2439, "independent" +272, 17, 24, 530, 134, 136, 2440, 2442, "of" +272, 17, 25, 531, 137, 143, 2443, 2449, "degree" +272, 17, 26, 532, 144, 146, 2450, 2452, "of" +272, 17, 27, 533, 147, 155, 2453, 2461, "glycemic" +272, 17, 28, 534, 156, 163, 2462, 2469, "control" +272, 17, 29, 535, 164, 165, 2470, 2471, "," +272, 17, 30, 536, 166, 168, 2472, 2474, "or" +272, 17, 31, 537, 169, 174, 2475, 2480, "hsCRP" +272, 17, 32, 538, 175, 184, 2481, 2490, "reduction" +272, 17, 33, 539, 185, 186, 2491, 2492, "." +272, 18, 1, 540, 0, 3, 2493, 2496, "DOI" +272, 18, 2, 541, 4, 5, 2497, 2498, ":" +272, 18, 3, 542, 6, 8, 2499, 2501, "10" +272, 18, 4, 543, 9, 10, 2502, 2503, "." +272, 18, 5, 544, 11, 15, 2504, 2508, "1007" +272, 18, 6, 545, 16, 17, 2509, 2510, "/" +272, 18, 7, 546, 18, 24, 2511, 2517, "s40618" +272, 18, 8, 547, 25, 26, 2518, 2519, "-" +272, 18, 9, 548, 27, 30, 2520, 2523, "014" +272, 18, 10, 549, 31, 32, 2524, 2525, "-" +272, 18, 11, 550, 33, 37, 2526, 2530, "0154" +272, 18, 12, 551, 38, 39, 2531, 2532, "-" +272, 18, 13, 552, 40, 41, 2533, 2534, "x" +272, 18, 14, 553, 42, 46, 2535, 2539, "PMID" +272, 18, 15, 554, 47, 48, 2540, 2541, ":" +272, 18, 16, 555, 49, 57, 2542, 2550, "25138574" +272, 18, 17, 556, 58, 59, 2551, 2552, "[" +272, 18, 18, 557, 60, 67, 2553, 2560, "Indexed" +272, 18, 19, 558, 68, 71, 2561, 2564, "for" +272, 18, 20, 559, 72, 79, 2565, 2572, "MEDLINE" +272, 18, 21, 560, 80, 81, 2573, 2574, "]" diff --git a/data/dm2 25138574_kwoodley.annodb b/data/dm2 25138574_kwoodley.annodb new file mode 100644 index 0000000..b88e907 --- /dev/null +++ b/data/dm2 25138574_kwoodley.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +53186, Journal, 0, 19, "J Endocrinol Invest", "", +53187, PublicationYear, 22, 26, "2014", "", +53206, Title, 119, 231, "Comparative effects of metformin and pioglitazone on YKL - 40 in type 2 diabetes : a randomized clinical trial .", "", +53188, Metformin, 142, 151, "metformin", "", +53196, Pioglitazone, 156, 168, "pioglitazone", "", +53267, EndPointDescription, 172, 180, "YKL - 40", "", +53202, Type2Diabetes, 184, 199, "type 2 diabetes", "", +53204, Randomized, 204, 214, "randomized", "", +53207, Author, 232, 245, "Esteghamati A", "", +53208, Author, 254, 263, "Rezvani S", "", +53209, Author, 266, 274, "Khajeh E", "", +53210, Author, 277, 284, "Ebadi M", "", +53211, Author, 287, 299, "Nakhjavani M", "", +53212, Author, 302, 310, "Noshad S", "", +53213, Iran, 514, 518, "Iran", "", +53189, Metformin, 562, 571, "Metformin", "", +53197, Pioglitazone, 576, 588, "pioglitazone", "", +53214, ObjectiveDescription, 776, 956, "The present trial was designed to investigate the comparative efficacy of the two anti - diabetes medications on serum concentrations of YKL - 40 , a novel marker of inflammation .", "", +53268, EndPointDescription, 913, 921, "YKL - 40", "", +53215, Parallel, 972, 988, "parallel - group", "", +53216, OpenLabel, 991, 1003, "open - label", "", +53205, Randomized, 1006, 1016, "randomized", "", +53217, NumberPatientsCT, 1086, 1088, "84", "", +53218, Precondition, 1089, 1152, "newly diagnosed , medication - na ï ve type 2 diabetes patients", "", +53203, Type2Diabetes, 1128, 1143, "type 2 diabetes", "", +53190, Metformin, 1170, 1179, "metformin", "", +53219, DoseValue, 1180, 1187, "1 , 000", "", +53221, mg, 1188, 1190, "mg", "", +53223, Frequency, 1191, 1196, "daily", "", +53225, NumberPatientsArm, 1203, 1205, "42", "", +53198, Pioglitazone, 1211, 1223, "pioglitazone", "", +53220, DoseValue, 1224, 1226, "30", "", +53222, mg, 1227, 1229, "mg", "", +53224, Frequency, 1230, 1235, "daily", "", +53226, NumberPatientsArm, 1242, 1244, "42", "", +53227, TimePoint, 1398, 1406, "baseline", "", +53228, TimePoint, 1417, 1425, "3 months", "", +53191, Metformin, 1463, 1472, "metformin", "", +53229, NumberPatientsArm, 1475, 1477, "40", "", +53199, Pioglitazone, 1480, 1492, "pioglitazone", "", +53230, NumberPatientsArm, 1495, 1497, "42", "", +53233, ObservedResult, 1502, 1603, "both medications were equally effective with regard to control of hyperglycemia , and hsCRP reduction", "", +53231, Hypoglycemia, 1568, 1581, "hyperglycemia", "", +53232, EndPointDescription, 1588, 1593, "hsCRP", "", +53234, PValueChangeValue, 1606, 1616, "p > 0 . 05", "", +53192, Metformin, 1631, 1640, "metformin", "", +53239, ObservedResult, 1650, 1669, "significant decline", "", +53235, BodyWeight, 1673, 1679, "weight", "", +53241, PValueChangeValue, 1682, 1693, "p = 0 . 005", "", +53240, BMI, 1698, 1701, "BMI", "", +53242, PValueChangeValue, 1704, 1715, "p = 0 . 004", "", +53236, EndPointDescription, 1730, 1748, "cholesterol levels", "", +53243, PValueChangeValue, 1751, 1762, "p = 0 . 028", "", +53193, Metformin, 1783, 1792, "Metformin", "", +53244, EndPointDescription, 1820, 1843, "YKL - 40 concentrations", "", +53245, TimePoint, 1850, 1858, "3 months", "", +53246, ResultMeasuredValue, 1861, 1867, "1 . 90", "", +53248, SdDevResValue, 1870, 1872, "17", "", +53247, ResultMeasuredValue, 1878, 1884, "1 . 66", "", +53250, SdDevResValue, 1887, 1893, "0 . 15", "", +53251, BioAndMedicalUnit, 1894, 1901, "µ g / L", "", +53252, PvalueDiff, 1904, 1915, "p = 0 . 019", "", +53200, Pioglitazone, 1948, 1960, "pioglitazone", "", +53253, BaseLineValue, 2006, 2012, "2 . 18", "", +53254, SdDevBL, 2015, 2021, "0 . 14", "", +53255, ResultMeasuredValue, 2027, 2033, "2 . 25", "", +53256, SdDevResValue, 2036, 2042, "0 . 16", "", +53257, BioAndMedicalUnit, 2043, 2050, "µ g / L", "", +53258, PValueChangeValue, 2053, 2064, "p = 0 . 687", "", +53194, Metformin, 2085, 2094, "metformin", "", +53201, Pioglitazone, 2133, 2145, "pioglitazone", "", +53259, PValueChangeValue, 2162, 2170, "YKL - 40", "", +53260, SubGroupDescription, 2189, 2199, "univariate", "", +53262, PvalueDiff, 2202, 2213, "p = 0 . 020", "", +53264, RelativeChangeValue, 2230, 2235, "6 . 7", "", +53261, SubGroupDescription, 2244, 2263, "multivariate models", "", +53263, PvalueDiff, 2266, 2277, "p = 0 . 047", "", +53265, RelativeChangeValue, 2294, 2299, "5 . 7", "", +53269, ConclusionComment, 2320, 2492, "Metformin is more effective in reduction of YKL - 40 concentration in short term and the effect seems to be independent of degree of glycemic control , or hsCRP reduction .", "", +53195, Metformin, 2320, 2329, "Metformin", "", +53266, EndPointDescription, 2364, 2372, "YKL - 40", "", +53270, PMID, 2542, 2550, "25138574", "", diff --git a/data/dm2 25138574_kwoodley.n-triples b/data/dm2 25138574_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25138574_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25208756_admin.annodb b/data/dm2 25208756_admin.annodb new file mode 100644 index 0000000..180be01 --- /dev/null +++ b/data/dm2 25208756_admin.annodb @@ -0,0 +1,139 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +1, PublicationYear, 15, 19, "2014", "", " \"2014\"." +139, Title, 113, 310, "HARMONY 4 : randomised clinical trial comparing once - weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea .", "", " \"HARMONY 4 : randomised clinical trial comparing once - weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea .\"." +2, Randomized, 125, 135, "randomised", "", " ." +3, Frequency, 161, 174, "once - weekly", "", +79658, Albiglutide, 175, 186, "albiglutide", "", " ." +13, InsulinGlargine, 191, 207, "insulin glargine", "", +31, Precondition, 211, 308, "patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea", "", " \"patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea\"." +22, Type2Diabetes, 225, 240, "type 2 diabetes", "", " ." +25, Metformin, 270, 279, "metformin", "", +28, Sulfonylureas, 296, 308, "sulfonylurea", "", +34, Author, 311, 322, "Weissman PN", "", " \"Weissman PN\"." +35, Author, 331, 338, "Carr MC", "", " \"Carr MC\"." +36, Author, 341, 345, "Ye J", "", " \"Ye J\"." +37, Author, 348, 357, "Cirkel DT", "", " \"Cirkel DT\"." +38, Author, 360, 369, "Stewart M", "", " \"Stewart M\"." +39, Author, 372, 379, "Perry C", "", " \"Perry C\"." +40, Author, 382, 391, "Pratley R", "", " \"Pratley R\"." +41, USA, 494, 497, "USA", "", +47, ObjectiveDescription, 578, 716, "compare the efficacy and safety of once - weekly albiglutide with once - daily insulin glargine ( A21Gly , B31Arg , B32Arg human insulin )", "", " \"compare the efficacy and safety of once - weekly albiglutide with once - daily insulin glargine ( A21Gly , B31Arg , B32Arg human insulin )\"." +42, Frequency, 613, 626, "once - weekly", "", +79660, Albiglutide, 627, 638, "albiglutide", "", +43, Frequency, 644, 656, "once - daily", "", +14, InsulinGlargine, 657, 673, "insulin glargine", "", +46, FixedCombDrug, 676, 714, "A21Gly , B31Arg , B32Arg human insulin", "", +48, ObjectiveDescription, 717, 817, "in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea .", "", " \"in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea .\"." +32, Precondition, 720, 815, "patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea", "", +23, Type2Diabetes, 734, 749, "type 2 diabetes", "", +153, Precondition, 750, 815, "inadequately controlled on metformin with or without sulfonylurea", "", +26, Metformin, 777, 786, "metformin", "", +29, Sulfonylureas, 803, 815, "sulfonylurea", "", +49, Randomized, 839, 849, "randomised", "", +50, OpenLabel, 852, 864, "open - label", "", " ." +51, Multicenter, 867, 878, "multicentre", "", " ." +52, Parallel, 895, 911, "parallel - group", "", " ." +53, CTDesign, 914, 931, "non - inferiority", "", " ." +54, NumberPatientsCT, 968, 971, "779", "", " \"779\"." +77564, Precondition, 1072, 1140, "Patients aged ≥ 18 years with type 2 diabetes treated with metformin", "", " \"Patients aged ≥ 18 years with type 2 diabetes treated with metformin\"." +55, MinAge, 1088, 1090, "18", "", " \"18\"." +165, Year, 1091, 1096, "years", "", +24, Type2Diabetes, 1102, 1117, "type 2 diabetes", "", +27, Metformin, 1131, 1140, "metformin", "", +30, Sulfonylureas, 1145, 1157, "sulfonylurea", "", +183, Duration, 1173, 1181, "3 months", "", " \"3 months\"." +169, TimePoint, 1189, 1197, "baseline", "", +56, HbA1c, 1198, 1203, "HbA1c", "", +57, Percentage, 1219, 1220, "%", "", +79683, Millimoles_per_mole, 1239, 1249, "mmol / mol", "", +60, Randomized, 1257, 1265, "randomly", "", +61, AllocationRatio, 1277, 1282, "2 : 1", "", " . ." +172, Randomized, 1312, 1325, "randomisation", "", +79659, Albiglutide, 1375, 1386, "albiglutide", "", +62, DoseValue, 1389, 1391, "30", "", " \"30\"." +64, mg, 1392, 1394, "mg", "", " ." +44, Frequency, 1395, 1406, "once a week", "", " \"once a week\"." +66, NumberPatientsArm, 1415, 1418, "504", "", " \"504\"." +15, InsulinGlargine, 1424, 1440, "insulin glargine", "", " ." +63, DoseValue, 1443, 1445, "10", "", " \"10\"." +179, Int_Unit, 1446, 1447, "U", "", " ." +45, Frequency, 1448, 1458, "once a day", "", " \"once a day\"." +67, NumberPatientsArm, 1467, 1470, "241", "", " \"241\"." +187, OpenLabel, 1536, 1546, "not masked", "", +68, DoseDescription, 1573, 1652, "Doses of each medication were adjusted on the basis of the glycaemic response .", "", " \"Doses of each medication were adjusted on the basis of the glycaemic response .\". \"Doses of each medication were adjusted on the basis of the glycaemic response .\"." +70, TimePoint, 1690, 1698, "baseline", "", +69, HbA1c, 1702, 1707, "HbA1c", "", +71, TimePoint, 1711, 1718, "week 52", "", +79661, Albiglutide, 1738, 1749, "albiglutide", "", +75, HbA1c, 1758, 1763, "HbA1c", "", " ." +77, BaseLineValue, 1778, 1784, "8 . 28", "", " \"8 . 28\"." +79, SdDevBL, 1789, 1795, "0 . 90", "", " \"0 . 90\"." +81, Percentage, 1796, 1797, "%", "", " ." +78, BaseLineValue, 1800, 1806, "67 . 0", "", +80, SdDevBL, 1811, 1816, "9 . 8", "", +79685, Millimoles_per_mole, 1817, 1827, "mmol / mol", "", +203, Mean, 1832, 1836, "mean", "", " . ." +73, TimePoint, 1849, 1857, "baseline", "", +86, ResultMeasuredValue, 1861, 1867, "7 . 62", "", " \"7 . 62\"." +88, SdDevResValue, 1872, 1878, "1 . 12", "", " \"1 . 12\"." +82, Percentage, 1879, 1880, "%", "", +87, ResultMeasuredValue, 1883, 1889, "59 . 8", "", +89, SdDevResValue, 1894, 1900, "12 . 2", "", +79694, Millimoles_per_mole, 1901, 1911, "mmol / mol", "", +72, TimePoint, 1917, 1924, "week 52", "", " \"week 52\"." +16, InsulinGlargine, 1963, 1979, "insulin glargine", "", +93, BaseLineValue, 1988, 1994, "8 . 36", "", " \"8 . 36\"." +95, SdDevBL, 1999, 2005, "0 . 95", "", " \"0 . 95\"." +97, Percentage, 2006, 2007, "%", "", +92, ResultMeasuredValue, 2011, 2017, "7 . 55", "", " \"7 . 55\"." +90, SdDevResValue, 2022, 2028, "1 . 04", "", " \"1 . 04\"." +98, Percentage, 2029, 2030, "%", "", +94, BaseLineValue, 2033, 2039, "67 . 9", "", +96, SdDevBL, 2044, 2050, "10 . 4", "", +91, ResultMeasuredValue, 2054, 2060, "59 . 0", "", +99, SdDevResValue, 2065, 2071, "11 . 4", "", +79688, Millimoles_per_mole, 2072, 2082, "mmol / mol", "", +101, DiffGroupAbsValue, 2134, 2140, "0 . 11", "", " \"0 . 11\"." +102, Percentage, 2141, 2142, "%", "", +105, ConfIntervalDiff, 2145, 2174, "95 % CI - 0 . 04 % , 0 . 27 %", "", " \"95 % CI - 0 . 04 % , 0 . 27 %\"." +103, Percentage, 2162, 2163, "%", "", +104, Percentage, 2173, 2174, "%", "", +108, DiffGroupAbsValue, 2179, 2184, "1 . 2", "", +79690, Millimoles_per_mole, 2185, 2195, "mmol / mol", "", +106, ConfIntervalDiff, 2198, 2232, "95 % CI - 0 . 4 , 3 . 0 mmol / mol", "", +79697, Millimoles_per_mole, 2222, 2232, "mmol / mol", "", +79662, Albiglutide, 2268, 2279, "albiglutide", "", +17, InsulinGlargine, 2283, 2299, "insulin glargine", "", +228, Percentage, 2363, 2364, "%", "", +79692, Millimoles_per_mole, 2373, 2383, "mmol / mol", "", +110, PvalueDiff, 2386, 2400, "p  =  0 . 0086", "", " \"p  =  0 . 0086\"." +112, BodyWeight, 2405, 2416, "Body weight", "", " ." +113, ObservedResult, 2417, 2426, "increased", "", " \"increased\"." +18, InsulinGlargine, 2434, 2450, "insulin glargine", "", +114, ObservedResult, 2461, 2470, "decreased", "", " \"decreased\"." +79663, Albiglutide, 2478, 2489, "albiglutide", "", +236, Mean, 2505, 2509, "mean", "", " . ." +115, DiffGroupAbsValue, 2534, 2542, "- 2 . 61", "", " \"- 2 . 61\"." +116, Kg, 2543, 2545, "kg", "", " ." +117, ConfIntervalDiff, 2548, 2575, "95 % CI - 3 . 20 , - 2 . 02", "", " \"95 % CI - 3 . 20 , - 2 . 02\"." +118, PvalueDiff, 2578, 2592, "p  <  0 . 0001", "", " \"p  <  0 . 0001\"." +119, SymptomaticHypoglycemia, 2608, 2633, "symptomatic hypoglycaemia", "", " ." +19, InsulinGlargine, 2685, 2701, "insulin glargine", "", +79664, Albiglutide, 2720, 2731, "albiglutide", "", +120, PercentageAffected, 2740, 2746, "27 . 4", "", " \"27 . 4\"." +121, PercentageAffected, 2752, 2758, "17 . 5", "", " \"17 . 5\"." +122, PvalueDiff, 2763, 2777, "p  =  0 . 0377", "", " \"17 . 5\"." +79665, Albiglutide, 2813, 2824, "Albiglutide", "", +125, ConclusionComment, 2813, 2943, "Albiglutide was non - inferior to insulin glargine at reducing HbA1c at week 52 , with modest weight loss and less hypoglycaemia .", "", " \"Albiglutide was non - inferior to insulin glargine at reducing HbA1c at week 52 , with modest weight loss and less hypoglycaemia .\"." +20, InsulinGlargine, 2847, 2863, "insulin glargine", "", +76, HbA1c, 2876, 2881, "HbA1c", "", +74, TimePoint, 2885, 2892, "week 52", "", +254, WeightReduction, 2907, 2918, "weight loss", "", +124, Hypoglycemia, 2928, 2941, "hypoglycaemia", "", +126, ConclusionComment, 2944, 2976, "Both drugs were well tolerated .", "", " \"Both drugs were well tolerated .\"." +79666, Albiglutide, 2977, 2988, "Albiglutide", "", +127, ConclusionComment, 2977, 3070, "Albiglutide may be considered an alternative to insulin glargine in this patient population .", "", " \"Albiglutide may be considered an alternative to insulin glargine in this patient population .\"." +21, InsulinGlargine, 3025, 3041, "insulin glargine", "", +106275, PharmacySponsored, 3149, 3204, "This study was planned and conducted by GlaxoSmithKline", "", " \"This study was planned and conducted by GlaxoSmithKline\"." +128, PMID, 3256, 3264, "25208756", "", " \"25208756\"." diff --git a/data/dm2 25208756_admin.n-triples b/data/dm2 25208756_admin.n-triples new file mode 100644 index 0000000..62211f6 --- /dev/null +++ b/data/dm2 25208756_admin.n-triples @@ -0,0 +1,169 @@ +# RDF export of group: Publication + . + "Publication 67548" . + "HARMONY 4 : randomised clinical trial comparing once - weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea ." . + "Weissman PN" . + "2014" . + "Diabetologia" . + "25208756" . + . + "Carr MC" . + "Ye J" . + "Cirkel DT" . + "Stewart M" . + "Perry C" . + "Pratley R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 67555" . + "compare the efficacy and safety of once - weekly albiglutide with once - daily insulin glargine ( A21Gly , B31Arg , B32Arg human insulin )" . + "779" . + "3 months" . + . + . + . + . + "Albiglutide was non - inferior to insulin glargine at reducing HbA1c at week 52 , with modest weight loss and less hypoglycaemia ." . + . + . + . + . + . + . + "Both drugs were well tolerated ." . + "Albiglutide may be considered an alternative to insulin glargine in this patient population ." . + . + . + . + . + . + "in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea ." . + . + . +# RDF export of group: Population + . + "Population 67571" . + "patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea" . + . + . + "18" . + . + "Patients aged ≥ 18 years with type 2 diabetes treated with metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "abl" . + "504" . + . + . + . + . + . + "gla" . + "241" . + . + . + . + . +# RDF export of group: Intervention + . + "abla" . + . + "once a week" . + . + . + "gla" . + . + "once a day" . + . +# RDF export of group: Medication + . + "abl" . + . + "30" . + . + . + "Doses of each medication were adjusted on the basis of the glycaemic response ." . + . + "gla" . + . + "10" . + . + . + "Doses of each medication were adjusted on the basis of the glycaemic response ." . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 28" . + "0 . 90" . + "7 . 62" . + "1 . 12" . + "week 52" . + . + "hba 2" . + . + "8 . 36" . + "0 . 95" . + "7 . 55" . + "1 . 04" . + . + "bw 1" . + . + "decreased" . + . + "bw 2" . + . + "increased" . + . + "hyp 1" . + . + "17 . 5" . + . + "hyp 2" . + . + "27 . 4" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "0 . 11" . + "p  =  0 . 0086" . + "95 % CI - 0 . 04 % , 0 . 27 %" . + . + . + . + "bw" . + "- 2 . 61" . + "p  <  0 . 0001" . + "95 % CI - 3 . 20 , - 2 . 02" . + . + . + . + "hyp" . + "p  =  0 . 0377" . + . + . +# RDF export of group: EvidenceQuality + . + "EvidenceQuality 91578" . + "This study was planned and conducted by GlaxoSmithKline" . \ No newline at end of file diff --git a/data/dm2 25208756_akramersunderbrink.annodb b/data/dm2 25208756_akramersunderbrink.annodb new file mode 100644 index 0000000..6341814 --- /dev/null +++ b/data/dm2 25208756_akramersunderbrink.annodb @@ -0,0 +1,134 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +61274, Journal, 0, 12, "Diabetologia", "", +61275, PublicationYear, 15, 19, "2014", "", +61284, Title, 113, 310, "HARMONY 4 : randomised clinical trial comparing once - weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea .", "", +61276, Randomized, 125, 135, "randomised", "", +61277, Frequency, 161, 174, "once - weekly", "", +61278, Drug, 175, 186, "albiglutide", "", +61279, InsulinGlargine, 191, 207, "insulin glargine", "", +61280, Type2Diabetes, 225, 240, "type 2 diabetes", "", +61282, Precondition, 241, 308, "inadequately controlled with metformin with or without sulfonylurea", "", +61281, Metformin, 270, 279, "metformin", "", +61283, Sulfonylureas, 296, 308, "sulfonylurea", "", +61285, Author, 311, 322, "Weissman PN", "", +61286, Author, 331, 338, "Carr MC", "", +61287, Author, 341, 345, "Ye J", "", +61288, Author, 348, 357, "Cirkel DT", "", +61289, Author, 360, 369, "Stewart M", "", +61290, Author, 372, 379, "Perry C", "", +61291, Author, 382, 391, "Pratley R", "", +61292, USA, 494, 497, "USA", "", +61301, ObjectiveDescription, 549, 749, "The aim of this study was to compare the efficacy and safety of once - weekly albiglutide with once - daily insulin glargine ( A21Gly , B31Arg , B32Arg human insulin ) in patients with type 2 diabetes", "", +61293, Frequency, 613, 626, "once - weekly", "", +61294, Drug, 627, 638, "albiglutide", "", +61295, Frequency, 644, 656, "once - daily", "", +61296, InsulinGlargine, 657, 673, "insulin glargine", "", +61297, Type2Diabetes, 734, 749, "type 2 diabetes", "", +61298, Precondition, 750, 815, "inadequately controlled on metformin with or without sulfonylurea", "", +61302, ObjectiveDescription, 750, 817, "inadequately controlled on metformin with or without sulfonylurea .", "", +61299, Metformin, 777, 786, "metformin", "", +61300, Sulfonylureas, 803, 815, "sulfonylurea", "", +61303, Randomized, 839, 849, "randomised", "", +61304, OpenLabel, 852, 864, "open - label", "", +61305, Multicenter, 867, 892, "multicentre ( n  =  222 )", "", +61306, Parallel, 895, 911, "parallel - group", "", +61308, NumberPatientsCT, 968, 971, "779", "", +61309, Multicenter, 1032, 1069, "222 centres located in four countries", "", +61310, MinAge, 1088, 1090, "18", "", +61311, Year, 1091, 1096, "years", "", +61312, Type2Diabetes, 1102, 1117, "type 2 diabetes", "", +61328, Precondition, 1118, 1181, "treated with metformin ( ± sulfonylurea ) for at least 3 months", "", +61313, Metformin, 1131, 1140, "metformin", "", +61314, Sulfonylureas, 1145, 1157, "sulfonylurea", "", +61329, Duration, 1173, 1181, "3 months", "", +61315, TimePoint, 1189, 1197, "baseline", "", +61316, HbA1c, 1198, 1203, "HbA1c", "", +61332, Precondition, 1198, 1251, "HbA1c 7 . 0 - 10 . 0 % ( 53 . 0 - 85 . 8 mmol / mol )", "", +61330, Percentage, 1219, 1220, "%", "", +61331, ConcentrationUnit, 1239, 1249, "mmol / mol", "", +61317, Randomized, 1257, 1265, "randomly", "", +61318, Randomized, 1312, 1325, "randomisation", "", +61319, Drug, 1375, 1386, "albiglutide", "", +61320, DoseValue, 1389, 1394, "30 mg", "", +61321, mg, 1392, 1394, "mg", "", +61322, Frequency, 1395, 1406, "once a week", "", +61327, NumberPatientsArm, 1415, 1418, "504", "", +61324, DoseValue, 1443, 1447, "10 U", "", +61325, Int_Unit, 1446, 1447, "U", "", +61323, Frequency, 1448, 1458, "once a day", "", +61326, NumberPatientsArm, 1467, 1470, "241", "", +61333, OpenLabel, 1536, 1546, "not masked", "", +61334, TimePoint, 1690, 1698, "baseline", "", +61339, HbA1c, 1702, 1707, "HbA1c", "", +61335, TimePoint, 1711, 1718, "week 52", "", +61338, Drug, 1738, 1749, "albiglutide", "", +61340, HbA1c, 1758, 1763, "HbA1c", "", +61341, BaseLineValue, 1778, 1784, "8 . 28", "", +61343, SdDevBL, 1789, 1795, "0 . 90", "", +61358, Percentage, 1796, 1797, "%", "", +61347, BaseLineValue, 1800, 1806, "67 . 0", "", +61345, SdDevBL, 1811, 1816, "9 . 8", "", +61362, ConcentrationUnit, 1817, 1827, "mmol / mol", "", +61349, Mean, 1832, 1836, "mean", "", +61336, TimePoint, 1849, 1857, "baseline", "", +61350, ResultMeasuredValue, 1861, 1867, "7 . 62", "", +61354, SdDevResValue, 1872, 1878, "1 . 12", "", +61359, Percentage, 1879, 1880, "%", "", +61351, ResultMeasuredValue, 1883, 1889, "59 . 8", "", +61356, SdDevResValue, 1894, 1900, "12 . 2", "", +61363, ConcentrationUnit, 1901, 1911, "mmol / mol", "", +61337, TimePoint, 1917, 1924, "week 52", "", +61365, InsulinGlargine, 1963, 1979, "insulin glargine", "", +61342, BaseLineValue, 1988, 1994, "8 . 36", "", +61344, SdDevBL, 1999, 2005, "0 . 95", "", +61360, Percentage, 2006, 2007, "%", "", +61352, ResultMeasuredValue, 2011, 2017, "7 . 55", "", +61355, SdDevResValue, 2022, 2028, "1 . 04", "", +61361, Percentage, 2029, 2030, "%", "", +61348, BaseLineValue, 2033, 2039, "67 . 9", "", +61346, SdDevBL, 2044, 2050, "10 . 4", "", +61353, ResultMeasuredValue, 2054, 2060, "59 . 0", "", +61357, SdDevResValue, 2065, 2071, "11 . 4", "", +61364, ConcentrationUnit, 2072, 2082, "mmol / mol", "", +61366, DiffGroupAbsValue, 2134, 2140, "0 . 11", "", +61370, Percentage, 2141, 2142, "%", "", +61368, ConfIntervalDiff, 2145, 2174, "95 % CI - 0 . 04 % , 0 . 27 %", "", +61371, Percentage, 2148, 2149, "%", "", +61372, Percentage, 2162, 2163, "%", "", +61373, Percentage, 2173, 2174, "%", "", +61367, DiffGroupAbsValue, 2179, 2184, "1 . 2", "", +61375, ConcentrationUnit, 2185, 2195, "mmol / mol", "", +61369, ConfIntervalDiff, 2198, 2232, "95 % CI - 0 . 4 , 3 . 0 mmol / mol", "", +61376, ConcentrationUnit, 2222, 2232, "mmol / mol", "", +61374, Percentage, 2363, 2364, "%", "", +61377, ConcentrationUnit, 2373, 2383, "mmol / mol", "", +61378, PvalueDiff, 2386, 2400, "p  =  0 . 0086", "", +61379, BodyWeight, 2405, 2416, "Body weight", "", +61380, InsulinGlargine, 2434, 2450, "insulin glargine", "", +61381, Drug, 2478, 2489, "albiglutide", "", +61382, Mean, 2505, 2509, "mean", "", +61383, DiffGroupAbsValue, 2534, 2542, "- 2 . 61", "", +61384, Kg, 2543, 2545, "kg", "", +61385, ConfIntervalDiff, 2548, 2575, "95 % CI - 3 . 20 , - 2 . 02", "", +61386, Percentage, 2551, 2552, "%", "", +61387, PvalueDiff, 2578, 2592, "p  <  0 . 0001", "", +61388, SymptomaticHypoglycemia, 2608, 2633, "symptomatic hypoglycaemia", "", +61389, InsulinGlargine, 2685, 2701, "insulin glargine", "", +61390, Drug, 2720, 2731, "albiglutide", "", +61391, PercentageAffected, 2740, 2746, "27 . 4", "", +61393, Percentage, 2747, 2748, "%", "", +61392, PercentageAffected, 2752, 2758, "17 . 5", "", +61394, Percentage, 2759, 2760, "%", "", +61395, PvalueDiff, 2763, 2777, "p  =  0 . 0377", "", +61396, Drug, 2813, 2824, "Albiglutide", "", +61404, ConclusionComment, 2813, 2943, "Albiglutide was non - inferior to insulin glargine at reducing HbA1c at week 52 , with modest weight loss and less hypoglycaemia .", "", +61397, InsulinGlargine, 2847, 2863, "insulin glargine", "", +61398, HbA1c, 2876, 2881, "HbA1c", "", +61399, TimePoint, 2885, 2892, "week 52", "", +61400, WeightReduction, 2907, 2918, "weight loss", "", +61401, Hypoglycemia, 2928, 2941, "hypoglycaemia", "", +61405, ConclusionComment, 2944, 2976, "Both drugs were well tolerated .", "", +61403, Drug, 2977, 2988, "Albiglutide", "", +61406, ConclusionComment, 2977, 3070, "Albiglutide may be considered an alternative to insulin glargine in this patient population .", "", +61402, InsulinGlargine, 3025, 3041, "insulin glargine", "", +61407, PMID, 3256, 3264, "25208756", "", diff --git a/data/dm2 25208756_akramersunderbrink.n-triples b/data/dm2 25208756_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25208756_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25208756_export.csv b/data/dm2 25208756_export.csv new file mode 100644 index 0000000..19c5449 --- /dev/null +++ b/data/dm2 25208756_export.csv @@ -0,0 +1,728 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +271, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +271, 1, 2, 2, 13, 14, 13, 14, "." +271, 2, 1, 3, 0, 4, 15, 19, "2014" +271, 2, 2, 4, 5, 8, 20, 23, "Dec" +271, 2, 3, 5, 9, 10, 24, 25, ";" +271, 2, 4, 6, 11, 13, 26, 28, "57" +271, 2, 5, 7, 14, 15, 29, 30, "(" +271, 2, 6, 8, 16, 18, 31, 33, "12" +271, 2, 7, 9, 19, 20, 34, 35, ")" +271, 2, 8, 10, 21, 22, 36, 37, ":" +271, 2, 9, 11, 23, 27, 38, 42, "2475" +271, 2, 10, 12, 28, 29, 43, 44, "-" +271, 2, 11, 13, 30, 32, 45, 47, "84" +271, 2, 12, 14, 33, 34, 48, 49, "." +271, 2, 13, 15, 35, 38, 50, 53, "doi" +271, 2, 14, 16, 39, 40, 54, 55, ":" +271, 2, 15, 17, 41, 43, 56, 58, "10" +271, 2, 16, 18, 44, 45, 59, 60, "." +271, 2, 17, 19, 46, 50, 61, 65, "1007" +271, 2, 18, 20, 51, 52, 66, 67, "/" +271, 2, 19, 21, 53, 59, 68, 74, "s00125" +271, 2, 20, 22, 60, 61, 75, 76, "-" +271, 2, 21, 23, 62, 65, 77, 80, "014" +271, 2, 22, 24, 66, 67, 81, 82, "-" +271, 2, 23, 25, 68, 72, 83, 87, "3360" +271, 2, 24, 26, 73, 74, 88, 89, "-" +271, 2, 25, 27, 75, 76, 90, 91, "3" +271, 2, 26, 28, 77, 78, 92, 93, "." +271, 3, 1, 29, 0, 4, 94, 98, "Epub" +271, 3, 2, 30, 5, 9, 99, 103, "2014" +271, 3, 3, 31, 10, 13, 104, 107, "Sep" +271, 3, 4, 32, 14, 16, 108, 110, "11" +271, 3, 5, 33, 17, 18, 111, 112, "." +271, 4, 1, 34, 0, 7, 113, 120, "HARMONY" +271, 4, 2, 35, 8, 9, 121, 122, "4" +271, 4, 3, 36, 10, 11, 123, 124, ":" +271, 4, 4, 37, 12, 22, 125, 135, "randomised" +271, 4, 5, 38, 23, 31, 136, 144, "clinical" +271, 4, 6, 39, 32, 37, 145, 150, "trial" +271, 4, 7, 40, 38, 47, 151, 160, "comparing" +271, 4, 8, 41, 48, 52, 161, 165, "once" +271, 4, 9, 42, 53, 54, 166, 167, "-" +271, 4, 10, 43, 55, 61, 168, 174, "weekly" +271, 4, 11, 44, 62, 73, 175, 186, "albiglutide" +271, 4, 12, 45, 74, 77, 187, 190, "and" +271, 4, 13, 46, 78, 85, 191, 198, "insulin" +271, 4, 14, 47, 86, 94, 199, 207, "glargine" +271, 4, 15, 48, 95, 97, 208, 210, "in" +271, 4, 16, 49, 98, 106, 211, 219, "patients" +271, 4, 17, 50, 107, 111, 220, 224, "with" +271, 4, 18, 51, 112, 116, 225, 229, "type" +271, 4, 19, 52, 117, 118, 230, 231, "2" +271, 4, 20, 53, 119, 127, 232, 240, "diabetes" +271, 4, 21, 54, 128, 140, 241, 253, "inadequately" +271, 4, 22, 55, 141, 151, 254, 264, "controlled" +271, 4, 23, 56, 152, 156, 265, 269, "with" +271, 4, 24, 57, 157, 166, 270, 279, "metformin" +271, 4, 25, 58, 167, 171, 280, 284, "with" +271, 4, 26, 59, 172, 174, 285, 287, "or" +271, 4, 27, 60, 175, 182, 288, 295, "without" +271, 4, 28, 61, 183, 195, 296, 308, "sulfonylurea" +271, 4, 29, 62, 196, 197, 309, 310, "." +271, 5, 1, 63, 0, 8, 311, 319, "Weissman" +271, 5, 2, 64, 9, 11, 320, 322, "PN" +271, 5, 3, 65, 12, 13, 323, 324, "(" +271, 5, 4, 66, 14, 15, 325, 326, "1" +271, 5, 5, 67, 16, 17, 327, 328, ")" +271, 5, 6, 68, 18, 19, 329, 330, "," +271, 5, 7, 69, 20, 24, 331, 335, "Carr" +271, 5, 8, 70, 25, 27, 336, 338, "MC" +271, 5, 9, 71, 28, 29, 339, 340, "," +271, 5, 10, 72, 30, 32, 341, 343, "Ye" +271, 5, 11, 73, 33, 34, 344, 345, "J" +271, 5, 12, 74, 35, 36, 346, 347, "," +271, 5, 13, 75, 37, 43, 348, 354, "Cirkel" +271, 5, 14, 76, 44, 46, 355, 357, "DT" +271, 5, 15, 77, 47, 48, 358, 359, "," +271, 5, 16, 78, 49, 56, 360, 367, "Stewart" +271, 5, 17, 79, 57, 58, 368, 369, "M" +271, 5, 18, 80, 59, 60, 370, 371, "," +271, 5, 19, 81, 61, 66, 372, 377, "Perry" +271, 5, 20, 82, 67, 68, 378, 379, "C" +271, 5, 21, 83, 69, 70, 380, 381, "," +271, 5, 22, 84, 71, 78, 382, 389, "Pratley" +271, 5, 23, 85, 79, 80, 390, 391, "R" +271, 5, 24, 86, 81, 82, 392, 393, "." +271, 5, 25, 87, 83, 89, 394, 400, "Author" +271, 5, 26, 88, 90, 101, 401, 412, "information" +271, 5, 27, 89, 102, 103, 413, 414, ":" +271, 5, 28, 90, 104, 105, 415, 416, "(" +271, 5, 29, 91, 106, 107, 417, 418, "1" +271, 5, 30, 92, 108, 109, 419, 420, ")" +271, 5, 31, 93, 110, 123, 421, 434, "Endocrinology" +271, 5, 32, 94, 124, 134, 435, 445, "Associates" +271, 5, 33, 95, 135, 136, 446, 447, "," +271, 5, 34, 96, 137, 141, 448, 452, "7867" +271, 5, 35, 97, 142, 143, 453, 454, "N" +271, 5, 36, 98, 144, 151, 455, 462, "Kendall" +271, 5, 37, 99, 152, 154, 463, 465, "Dr" +271, 5, 38, 100, 155, 156, 466, 467, "#" +271, 5, 39, 101, 157, 159, 468, 470, "80" +271, 5, 40, 102, 160, 161, 471, 472, "," +271, 5, 41, 103, 162, 167, 473, 478, "Miami" +271, 5, 42, 104, 168, 169, 479, 480, "," +271, 5, 43, 105, 170, 172, 481, 483, "FL" +271, 5, 44, 106, 173, 174, 484, 485, "," +271, 5, 45, 107, 175, 180, 486, 491, "33156" +271, 5, 46, 108, 181, 182, 492, 493, "," +271, 5, 47, 109, 183, 186, 494, 497, "USA" +271, 5, 48, 110, 187, 188, 498, 499, "," +271, 5, 49, 111, 189, 203, 500, 514, "peternweissman" +271, 5, 50, 112, 204, 205, 515, 516, "@" +271, 5, 51, 113, 206, 209, 517, 520, "att" +271, 5, 52, 114, 210, 211, 521, 522, "." +271, 5, 53, 115, 212, 215, 523, 526, "net" +271, 5, 54, 116, 216, 217, 527, 528, "." +271, 6, 1, 117, 0, 4, 529, 533, "AIMS" +271, 6, 2, 118, 5, 6, 534, 535, "/" +271, 6, 3, 119, 7, 17, 536, 546, "HYPOTHESIS" +271, 6, 4, 120, 18, 19, 547, 548, ":" +271, 6, 5, 121, 20, 23, 549, 552, "The" +271, 6, 6, 122, 24, 27, 553, 556, "aim" +271, 6, 7, 123, 28, 30, 557, 559, "of" +271, 6, 8, 124, 31, 35, 560, 564, "this" +271, 6, 9, 125, 36, 41, 565, 570, "study" +271, 6, 10, 126, 42, 45, 571, 574, "was" +271, 6, 11, 127, 46, 48, 575, 577, "to" +271, 6, 12, 128, 49, 56, 578, 585, "compare" +271, 6, 13, 129, 57, 60, 586, 589, "the" +271, 6, 14, 130, 61, 69, 590, 598, "efficacy" +271, 6, 15, 131, 70, 73, 599, 602, "and" +271, 6, 16, 132, 74, 80, 603, 609, "safety" +271, 6, 17, 133, 81, 83, 610, 612, "of" +271, 6, 18, 134, 84, 88, 613, 617, "once" +271, 6, 19, 135, 89, 90, 618, 619, "-" +271, 6, 20, 136, 91, 97, 620, 626, "weekly" +271, 6, 21, 137, 98, 109, 627, 638, "albiglutide" +271, 6, 22, 138, 110, 114, 639, 643, "with" +271, 6, 23, 139, 115, 119, 644, 648, "once" +271, 6, 24, 140, 120, 121, 649, 650, "-" +271, 6, 25, 141, 122, 127, 651, 656, "daily" +271, 6, 26, 142, 128, 135, 657, 664, "insulin" +271, 6, 27, 143, 136, 144, 665, 673, "glargine" +271, 6, 28, 144, 145, 146, 674, 675, "(" +271, 6, 29, 145, 147, 153, 676, 682, "A21Gly" +271, 6, 30, 146, 154, 155, 683, 684, "," +271, 6, 31, 147, 156, 162, 685, 691, "B31Arg" +271, 6, 32, 148, 163, 164, 692, 693, "," +271, 6, 33, 149, 165, 171, 694, 700, "B32Arg" +271, 6, 34, 150, 172, 177, 701, 706, "human" +271, 6, 35, 151, 178, 185, 707, 714, "insulin" +271, 6, 36, 152, 186, 187, 715, 716, ")" +271, 6, 37, 153, 188, 190, 717, 719, "in" +271, 6, 38, 154, 191, 199, 720, 728, "patients" +271, 6, 39, 155, 200, 204, 729, 733, "with" +271, 6, 40, 156, 205, 209, 734, 738, "type" +271, 6, 41, 157, 210, 211, 739, 740, "2" +271, 6, 42, 158, 212, 220, 741, 749, "diabetes" +271, 6, 43, 159, 221, 233, 750, 762, "inadequately" +271, 6, 44, 160, 234, 244, 763, 773, "controlled" +271, 6, 45, 161, 245, 247, 774, 776, "on" +271, 6, 46, 162, 248, 257, 777, 786, "metformin" +271, 6, 47, 163, 258, 262, 787, 791, "with" +271, 6, 48, 164, 263, 265, 792, 794, "or" +271, 6, 49, 165, 266, 273, 795, 802, "without" +271, 6, 50, 166, 274, 286, 803, 815, "sulfonylurea" +271, 6, 51, 167, 287, 288, 816, 817, "." +271, 7, 1, 168, 0, 7, 818, 825, "METHODS" +271, 7, 2, 169, 8, 9, 826, 827, ":" +271, 7, 3, 170, 10, 14, 828, 832, "This" +271, 7, 4, 171, 15, 18, 833, 836, "was" +271, 7, 5, 172, 19, 20, 837, 838, "a" +271, 7, 6, 173, 21, 31, 839, 849, "randomised" +271, 7, 7, 174, 32, 33, 850, 851, "," +271, 7, 8, 175, 34, 38, 852, 856, "open" +271, 7, 9, 176, 39, 40, 857, 858, "-" +271, 7, 10, 177, 41, 46, 859, 864, "label" +271, 7, 11, 178, 47, 48, 865, 866, "," +271, 7, 12, 179, 49, 60, 867, 878, "multicentre" +271, 7, 13, 180, 61, 62, 879, 880, "(" +271, 7, 14, 181, 63, 64, 881, 882, "n" +271, 7, 15, 182, 65, 68, 883, 886, " = " +271, 7, 16, 183, 69, 72, 887, 890, "222" +271, 7, 17, 184, 73, 74, 891, 892, ")" +271, 7, 18, 185, 75, 76, 893, 894, "," +271, 7, 19, 186, 77, 85, 895, 903, "parallel" +271, 7, 20, 187, 86, 87, 904, 905, "-" +271, 7, 21, 188, 88, 93, 906, 911, "group" +271, 7, 22, 189, 94, 95, 912, 913, "," +271, 7, 23, 190, 96, 99, 914, 917, "non" +271, 7, 24, 191, 100, 101, 918, 919, "-" +271, 7, 25, 192, 102, 113, 920, 931, "inferiority" +271, 7, 26, 193, 114, 117, 932, 935, "out" +271, 7, 27, 194, 118, 119, 936, 937, "-" +271, 7, 28, 195, 120, 127, 938, 945, "patient" +271, 7, 29, 196, 128, 136, 946, 954, "clinical" +271, 7, 30, 197, 137, 142, 955, 960, "trial" +271, 7, 31, 198, 143, 144, 961, 962, "," +271, 7, 32, 199, 145, 149, 963, 967, "with" +271, 7, 33, 200, 150, 153, 968, 971, "779" +271, 7, 34, 201, 154, 162, 972, 980, "patients" +271, 7, 35, 202, 163, 171, 981, 989, "enrolled" +271, 7, 36, 203, 172, 174, 990, 992, "in" +271, 7, 37, 204, 175, 178, 993, 996, "the" +271, 7, 38, 205, 179, 184, 997, 1002, "study" +271, 7, 39, 206, 185, 186, 1003, 1004, "." +271, 8, 1, 207, 0, 3, 1005, 1008, "The" +271, 8, 2, 208, 4, 9, 1009, 1014, "study" +271, 8, 3, 209, 10, 13, 1015, 1018, "was" +271, 8, 4, 210, 14, 23, 1019, 1028, "conducted" +271, 8, 5, 211, 24, 26, 1029, 1031, "in" +271, 8, 6, 212, 27, 30, 1032, 1035, "222" +271, 8, 7, 213, 31, 38, 1036, 1043, "centres" +271, 8, 8, 214, 39, 46, 1044, 1051, "located" +271, 8, 9, 215, 47, 49, 1052, 1054, "in" +271, 8, 10, 216, 50, 54, 1055, 1059, "four" +271, 8, 11, 217, 55, 64, 1060, 1069, "countries" +271, 8, 12, 218, 65, 66, 1070, 1071, "." +271, 9, 1, 219, 0, 8, 1072, 1080, "Patients" +271, 9, 2, 220, 9, 13, 1081, 1085, "aged" +271, 9, 3, 221, 14, 15, 1086, 1087, "≥" +271, 9, 4, 222, 16, 18, 1088, 1090, "18" +271, 9, 5, 223, 19, 24, 1091, 1096, "years" +271, 9, 6, 224, 25, 29, 1097, 1101, "with" +271, 9, 7, 225, 30, 34, 1102, 1106, "type" +271, 9, 8, 226, 35, 36, 1107, 1108, "2" +271, 9, 9, 227, 37, 45, 1109, 1117, "diabetes" +271, 9, 10, 228, 46, 53, 1118, 1125, "treated" +271, 9, 11, 229, 54, 58, 1126, 1130, "with" +271, 9, 12, 230, 59, 68, 1131, 1140, "metformin" +271, 9, 13, 231, 69, 70, 1141, 1142, "(" +271, 9, 14, 232, 71, 72, 1143, 1144, "±" +271, 9, 15, 233, 73, 85, 1145, 1157, "sulfonylurea" +271, 9, 16, 234, 86, 87, 1158, 1159, ")" +271, 9, 17, 235, 88, 91, 1160, 1163, "for" +271, 9, 18, 236, 92, 94, 1164, 1166, "at" +271, 9, 19, 237, 95, 100, 1167, 1172, "least" +271, 9, 20, 238, 101, 102, 1173, 1174, "3" +271, 9, 21, 239, 103, 109, 1175, 1181, "months" +271, 9, 22, 240, 110, 114, 1182, 1186, "with" +271, 9, 23, 241, 115, 116, 1187, 1188, "a" +271, 9, 24, 242, 117, 125, 1189, 1197, "baseline" +271, 9, 25, 243, 126, 131, 1198, 1203, "HbA1c" +271, 9, 26, 244, 132, 133, 1204, 1205, "7" +271, 9, 27, 245, 134, 135, 1206, 1207, "." +271, 9, 28, 246, 136, 137, 1208, 1209, "0" +271, 9, 29, 247, 138, 139, 1210, 1211, "-" +271, 9, 30, 248, 140, 142, 1212, 1214, "10" +271, 9, 31, 249, 143, 144, 1215, 1216, "." +271, 9, 32, 250, 145, 146, 1217, 1218, "0" +271, 9, 33, 251, 147, 148, 1219, 1220, "%" +271, 9, 34, 252, 149, 150, 1221, 1222, "(" +271, 9, 35, 253, 151, 153, 1223, 1225, "53" +271, 9, 36, 254, 154, 155, 1226, 1227, "." +271, 9, 37, 255, 156, 157, 1228, 1229, "0" +271, 9, 38, 256, 158, 159, 1230, 1231, "-" +271, 9, 39, 257, 160, 162, 1232, 1234, "85" +271, 9, 40, 258, 163, 164, 1235, 1236, "." +271, 9, 41, 259, 165, 166, 1237, 1238, "8" +271, 9, 42, 260, 167, 171, 1239, 1243, "mmol" +271, 9, 43, 261, 172, 173, 1244, 1245, "/" +271, 9, 44, 262, 174, 177, 1246, 1249, "mol" +271, 9, 45, 263, 178, 179, 1250, 1251, ")" +271, 9, 46, 264, 180, 184, 1252, 1256, "were" +271, 9, 47, 265, 185, 193, 1257, 1265, "randomly" +271, 9, 48, 266, 194, 202, 1266, 1274, "assigned" +271, 9, 49, 267, 203, 204, 1275, 1276, "(" +271, 9, 50, 268, 205, 206, 1277, 1278, "2" +271, 9, 51, 269, 207, 208, 1279, 1280, ":" +271, 9, 52, 270, 209, 210, 1281, 1282, "1" +271, 9, 53, 271, 211, 212, 1283, 1284, ")" +271, 9, 54, 272, 213, 216, 1285, 1288, "via" +271, 9, 55, 273, 217, 218, 1289, 1290, "a" +271, 9, 56, 274, 219, 227, 1291, 1299, "computer" +271, 9, 57, 275, 228, 229, 1300, 1301, "-" +271, 9, 58, 276, 230, 239, 1302, 1311, "generated" +271, 9, 59, 277, 240, 253, 1312, 1325, "randomisation" +271, 9, 60, 278, 254, 262, 1326, 1334, "sequence" +271, 9, 61, 279, 263, 267, 1335, 1339, "with" +271, 9, 62, 280, 268, 269, 1340, 1341, "a" +271, 9, 63, 281, 270, 275, 1342, 1347, "voice" +271, 9, 64, 282, 276, 284, 1348, 1356, "response" +271, 9, 65, 283, 285, 291, 1357, 1363, "system" +271, 9, 66, 284, 292, 294, 1364, 1366, "to" +271, 9, 67, 285, 295, 302, 1367, 1374, "receive" +271, 9, 68, 286, 303, 314, 1375, 1386, "albiglutide" +271, 9, 69, 287, 315, 316, 1387, 1388, "(" +271, 9, 70, 288, 317, 319, 1389, 1391, "30" +271, 9, 71, 289, 320, 322, 1392, 1394, "mg" +271, 9, 72, 290, 323, 327, 1395, 1399, "once" +271, 9, 73, 291, 328, 329, 1400, 1401, "a" +271, 9, 74, 292, 330, 334, 1402, 1406, "week" +271, 9, 75, 293, 335, 336, 1407, 1408, "," +271, 9, 76, 294, 337, 338, 1409, 1410, "n" +271, 9, 77, 295, 339, 342, 1411, 1414, " = " +271, 9, 78, 296, 343, 346, 1415, 1418, "504" +271, 9, 79, 297, 347, 348, 1419, 1420, ")" +271, 9, 80, 298, 349, 351, 1421, 1423, "or" +271, 9, 81, 299, 352, 359, 1424, 1431, "insulin" +271, 9, 82, 300, 360, 368, 1432, 1440, "glargine" +271, 9, 83, 301, 369, 370, 1441, 1442, "(" +271, 9, 84, 302, 371, 373, 1443, 1445, "10" +271, 9, 85, 303, 374, 375, 1446, 1447, "U" +271, 9, 86, 304, 376, 380, 1448, 1452, "once" +271, 9, 87, 305, 381, 382, 1453, 1454, "a" +271, 9, 88, 306, 383, 386, 1455, 1458, "day" +271, 9, 89, 307, 387, 388, 1459, 1460, "," +271, 9, 90, 308, 389, 390, 1461, 1462, "n" +271, 9, 91, 309, 391, 394, 1463, 1466, " = " +271, 9, 92, 310, 395, 398, 1467, 1470, "241" +271, 9, 93, 311, 399, 400, 1471, 1472, ")" +271, 9, 94, 312, 401, 406, 1473, 1478, "added" +271, 9, 95, 313, 407, 409, 1479, 1481, "to" +271, 9, 96, 314, 410, 417, 1482, 1489, "current" +271, 9, 97, 315, 418, 425, 1490, 1497, "therapy" +271, 9, 98, 316, 426, 427, 1498, 1499, "." +271, 10, 1, 317, 0, 12, 1500, 1512, "Participants" +271, 10, 2, 318, 13, 16, 1513, 1516, "and" +271, 10, 3, 319, 17, 30, 1517, 1530, "investigators" +271, 10, 4, 320, 31, 35, 1531, 1535, "were" +271, 10, 5, 321, 36, 39, 1536, 1539, "not" +271, 10, 6, 322, 40, 46, 1540, 1546, "masked" +271, 10, 7, 323, 47, 49, 1547, 1549, "to" +271, 10, 8, 324, 50, 59, 1550, 1559, "treatment" +271, 10, 9, 325, 60, 70, 1560, 1570, "assignment" +271, 10, 10, 326, 71, 72, 1571, 1572, "." +271, 11, 1, 327, 0, 5, 1573, 1578, "Doses" +271, 11, 2, 328, 6, 8, 1579, 1581, "of" +271, 11, 3, 329, 9, 13, 1582, 1586, "each" +271, 11, 4, 330, 14, 24, 1587, 1597, "medication" +271, 11, 5, 331, 25, 29, 1598, 1602, "were" +271, 11, 6, 332, 30, 38, 1603, 1611, "adjusted" +271, 11, 7, 333, 39, 41, 1612, 1614, "on" +271, 11, 8, 334, 42, 45, 1615, 1618, "the" +271, 11, 9, 335, 46, 51, 1619, 1624, "basis" +271, 11, 10, 336, 52, 54, 1625, 1627, "of" +271, 11, 11, 337, 55, 58, 1628, 1631, "the" +271, 11, 12, 338, 59, 68, 1632, 1641, "glycaemic" +271, 11, 13, 339, 69, 77, 1642, 1650, "response" +271, 11, 14, 340, 78, 79, 1651, 1652, "." +271, 12, 1, 341, 0, 3, 1653, 1656, "The" +271, 12, 2, 342, 4, 11, 1657, 1664, "primary" +271, 12, 3, 343, 12, 20, 1665, 1673, "endpoint" +271, 12, 4, 344, 21, 24, 1674, 1677, "was" +271, 12, 5, 345, 25, 31, 1678, 1684, "change" +271, 12, 6, 346, 32, 36, 1685, 1689, "from" +271, 12, 7, 347, 37, 45, 1690, 1698, "baseline" +271, 12, 8, 348, 46, 48, 1699, 1701, "in" +271, 12, 9, 349, 49, 54, 1702, 1707, "HbA1c" +271, 12, 10, 350, 55, 57, 1708, 1710, "at" +271, 12, 11, 351, 58, 62, 1711, 1715, "week" +271, 12, 12, 352, 63, 65, 1716, 1718, "52" +271, 12, 13, 353, 66, 67, 1719, 1720, "." +271, 13, 1, 354, 0, 7, 1721, 1728, "RESULTS" +271, 13, 2, 355, 8, 9, 1729, 1730, ":" +271, 13, 3, 356, 10, 12, 1731, 1733, "In" +271, 13, 4, 357, 13, 16, 1734, 1737, "the" +271, 13, 5, 358, 17, 28, 1738, 1749, "albiglutide" +271, 13, 6, 359, 29, 34, 1750, 1755, "group" +271, 13, 7, 360, 35, 36, 1756, 1757, "," +271, 13, 8, 361, 37, 42, 1758, 1763, "HbA1c" +271, 13, 9, 362, 43, 51, 1764, 1772, "declined" +271, 13, 10, 363, 52, 56, 1773, 1777, "from" +271, 13, 11, 364, 57, 58, 1778, 1779, "8" +271, 13, 12, 365, 59, 60, 1780, 1781, "." +271, 13, 13, 366, 61, 63, 1782, 1784, "28" +271, 13, 14, 367, 64, 67, 1785, 1788, " ± " +271, 13, 15, 368, 68, 69, 1789, 1790, "0" +271, 13, 16, 369, 70, 71, 1791, 1792, "." +271, 13, 17, 370, 72, 74, 1793, 1795, "90" +271, 13, 18, 371, 75, 76, 1796, 1797, "%" +271, 13, 19, 372, 77, 78, 1798, 1799, "(" +271, 13, 20, 373, 79, 81, 1800, 1802, "67" +271, 13, 21, 374, 82, 83, 1803, 1804, "." +271, 13, 22, 375, 84, 85, 1805, 1806, "0" +271, 13, 23, 376, 86, 89, 1807, 1810, " ± " +271, 13, 24, 377, 90, 91, 1811, 1812, "9" +271, 13, 25, 378, 92, 93, 1813, 1814, "." +271, 13, 26, 379, 94, 95, 1815, 1816, "8" +271, 13, 27, 380, 96, 100, 1817, 1821, "mmol" +271, 13, 28, 381, 101, 102, 1822, 1823, "/" +271, 13, 29, 382, 103, 106, 1824, 1827, "mol" +271, 13, 30, 383, 107, 108, 1828, 1829, ")" +271, 13, 31, 384, 109, 110, 1830, 1831, "(" +271, 13, 32, 385, 111, 115, 1832, 1836, "mean" +271, 13, 33, 386, 116, 119, 1837, 1840, " ± " +271, 13, 34, 387, 120, 122, 1841, 1843, "SD" +271, 13, 35, 388, 123, 124, 1844, 1845, ")" +271, 13, 36, 389, 125, 127, 1846, 1848, "at" +271, 13, 37, 390, 128, 136, 1849, 1857, "baseline" +271, 13, 38, 391, 137, 139, 1858, 1860, "to" +271, 13, 39, 392, 140, 141, 1861, 1862, "7" +271, 13, 40, 393, 142, 143, 1863, 1864, "." +271, 13, 41, 394, 144, 146, 1865, 1867, "62" +271, 13, 42, 395, 147, 150, 1868, 1871, " ± " +271, 13, 43, 396, 151, 152, 1872, 1873, "1" +271, 13, 44, 397, 153, 154, 1874, 1875, "." +271, 13, 45, 398, 155, 157, 1876, 1878, "12" +271, 13, 46, 399, 158, 159, 1879, 1880, "%" +271, 13, 47, 400, 160, 161, 1881, 1882, "(" +271, 13, 48, 401, 162, 164, 1883, 1885, "59" +271, 13, 49, 402, 165, 166, 1886, 1887, "." +271, 13, 50, 403, 167, 168, 1888, 1889, "8" +271, 13, 51, 404, 169, 172, 1890, 1893, " ± " +271, 13, 52, 405, 173, 175, 1894, 1896, "12" +271, 13, 53, 406, 176, 177, 1897, 1898, "." +271, 13, 54, 407, 178, 179, 1899, 1900, "2" +271, 13, 55, 408, 180, 184, 1901, 1905, "mmol" +271, 13, 56, 409, 185, 186, 1906, 1907, "/" +271, 13, 57, 410, 187, 190, 1908, 1911, "mol" +271, 13, 58, 411, 191, 192, 1912, 1913, ")" +271, 13, 59, 412, 193, 195, 1914, 1916, "at" +271, 13, 60, 413, 196, 200, 1917, 1921, "week" +271, 13, 61, 414, 201, 203, 1922, 1924, "52" +271, 13, 62, 415, 204, 205, 1925, 1926, "." +271, 14, 1, 416, 0, 1, 1927, 1928, "A" +271, 14, 2, 417, 2, 9, 1929, 1936, "similar" +271, 14, 3, 418, 10, 19, 1937, 1946, "reduction" +271, 14, 4, 419, 20, 28, 1947, 1955, "occurred" +271, 14, 5, 420, 29, 31, 1956, 1958, "in" +271, 14, 6, 421, 32, 35, 1959, 1962, "the" +271, 14, 7, 422, 36, 43, 1963, 1970, "insulin" +271, 14, 8, 423, 44, 52, 1971, 1979, "glargine" +271, 14, 9, 424, 53, 58, 1980, 1985, "group" +271, 14, 10, 425, 59, 60, 1986, 1987, "(" +271, 14, 11, 426, 61, 62, 1988, 1989, "8" +271, 14, 12, 427, 63, 64, 1990, 1991, "." +271, 14, 13, 428, 65, 67, 1992, 1994, "36" +271, 14, 14, 429, 68, 71, 1995, 1998, " ± " +271, 14, 15, 430, 72, 73, 1999, 2000, "0" +271, 14, 16, 431, 74, 75, 2001, 2002, "." +271, 14, 17, 432, 76, 78, 2003, 2005, "95" +271, 14, 18, 433, 79, 80, 2006, 2007, "%" +271, 14, 19, 434, 81, 83, 2008, 2010, "to" +271, 14, 20, 435, 84, 85, 2011, 2012, "7" +271, 14, 21, 436, 86, 87, 2013, 2014, "." +271, 14, 22, 437, 88, 90, 2015, 2017, "55" +271, 14, 23, 438, 91, 94, 2018, 2021, " ± " +271, 14, 24, 439, 95, 96, 2022, 2023, "1" +271, 14, 25, 440, 97, 98, 2024, 2025, "." +271, 14, 26, 441, 99, 101, 2026, 2028, "04" +271, 14, 27, 442, 102, 103, 2029, 2030, "%" +271, 14, 28, 443, 104, 105, 2031, 2032, "[" +271, 14, 29, 444, 106, 108, 2033, 2035, "67" +271, 14, 30, 445, 109, 110, 2036, 2037, "." +271, 14, 31, 446, 111, 112, 2038, 2039, "9" +271, 14, 32, 447, 113, 116, 2040, 2043, " ± " +271, 14, 33, 448, 117, 119, 2044, 2046, "10" +271, 14, 34, 449, 120, 121, 2047, 2048, "." +271, 14, 35, 450, 122, 123, 2049, 2050, "4" +271, 14, 36, 451, 124, 126, 2051, 2053, "to" +271, 14, 37, 452, 127, 129, 2054, 2056, "59" +271, 14, 38, 453, 130, 131, 2057, 2058, "." +271, 14, 39, 454, 132, 133, 2059, 2060, "0" +271, 14, 40, 455, 134, 137, 2061, 2064, " ± " +271, 14, 41, 456, 138, 140, 2065, 2067, "11" +271, 14, 42, 457, 141, 142, 2068, 2069, "." +271, 14, 43, 458, 143, 144, 2070, 2071, "4" +271, 14, 44, 459, 145, 149, 2072, 2076, "mmol" +271, 14, 45, 460, 150, 151, 2077, 2078, "/" +271, 14, 46, 461, 152, 155, 2079, 2082, "mol" +271, 14, 47, 462, 156, 157, 2083, 2084, "]" +271, 14, 48, 463, 158, 159, 2085, 2086, ")" +271, 14, 49, 464, 160, 161, 2087, 2088, "." +271, 15, 1, 465, 0, 3, 2089, 2092, "The" +271, 15, 2, 466, 4, 9, 2093, 2098, "model" +271, 15, 3, 467, 10, 11, 2099, 2100, "-" +271, 15, 4, 468, 12, 20, 2101, 2109, "adjusted" +271, 15, 5, 469, 21, 30, 2110, 2119, "treatment" +271, 15, 6, 470, 31, 41, 2120, 2130, "difference" +271, 15, 7, 471, 42, 44, 2131, 2133, "of" +271, 15, 8, 472, 45, 46, 2134, 2135, "0" +271, 15, 9, 473, 47, 48, 2136, 2137, "." +271, 15, 10, 474, 49, 51, 2138, 2140, "11" +271, 15, 11, 475, 52, 53, 2141, 2142, "%" +271, 15, 12, 476, 54, 55, 2143, 2144, "(" +271, 15, 13, 477, 56, 58, 2145, 2147, "95" +271, 15, 14, 478, 59, 60, 2148, 2149, "%" +271, 15, 15, 479, 61, 63, 2150, 2152, "CI" +271, 15, 16, 480, 64, 65, 2153, 2154, "-" +271, 15, 17, 481, 66, 67, 2155, 2156, "0" +271, 15, 18, 482, 68, 69, 2157, 2158, "." +271, 15, 19, 483, 70, 72, 2159, 2161, "04" +271, 15, 20, 484, 73, 74, 2162, 2163, "%" +271, 15, 21, 485, 75, 76, 2164, 2165, "," +271, 15, 22, 486, 77, 78, 2166, 2167, "0" +271, 15, 23, 487, 79, 80, 2168, 2169, "." +271, 15, 24, 488, 81, 83, 2170, 2172, "27" +271, 15, 25, 489, 84, 85, 2173, 2174, "%" +271, 15, 26, 490, 86, 87, 2175, 2176, ")" +271, 15, 27, 491, 88, 89, 2177, 2178, "(" +271, 15, 28, 492, 90, 91, 2179, 2180, "1" +271, 15, 29, 493, 92, 93, 2181, 2182, "." +271, 15, 30, 494, 94, 95, 2183, 2184, "2" +271, 15, 31, 495, 96, 100, 2185, 2189, "mmol" +271, 15, 32, 496, 101, 102, 2190, 2191, "/" +271, 15, 33, 497, 103, 106, 2192, 2195, "mol" +271, 15, 34, 498, 107, 108, 2196, 2197, "[" +271, 15, 35, 499, 109, 111, 2198, 2200, "95" +271, 15, 36, 500, 112, 113, 2201, 2202, "%" +271, 15, 37, 501, 114, 116, 2203, 2205, "CI" +271, 15, 38, 502, 117, 118, 2206, 2207, "-" +271, 15, 39, 503, 119, 120, 2208, 2209, "0" +271, 15, 40, 504, 121, 122, 2210, 2211, "." +271, 15, 41, 505, 123, 124, 2212, 2213, "4" +271, 15, 42, 506, 125, 126, 2214, 2215, "," +271, 15, 43, 507, 127, 128, 2216, 2217, "3" +271, 15, 44, 508, 129, 130, 2218, 2219, "." +271, 15, 45, 509, 131, 132, 2220, 2221, "0" +271, 15, 46, 510, 133, 137, 2222, 2226, "mmol" +271, 15, 47, 511, 138, 139, 2227, 2228, "/" +271, 15, 48, 512, 140, 143, 2229, 2232, "mol" +271, 15, 49, 513, 144, 145, 2233, 2234, "]" +271, 15, 50, 514, 146, 147, 2235, 2236, ")" +271, 15, 51, 515, 148, 157, 2237, 2246, "indicated" +271, 15, 52, 516, 158, 161, 2247, 2250, "non" +271, 15, 53, 517, 162, 163, 2251, 2252, "-" +271, 15, 54, 518, 164, 175, 2253, 2264, "inferiority" +271, 15, 55, 519, 176, 178, 2265, 2267, "of" +271, 15, 56, 520, 179, 190, 2268, 2279, "albiglutide" +271, 15, 57, 521, 191, 193, 2280, 2282, "to" +271, 15, 58, 522, 194, 201, 2283, 2290, "insulin" +271, 15, 59, 523, 202, 210, 2291, 2299, "glargine" +271, 15, 60, 524, 211, 216, 2300, 2305, "based" +271, 15, 61, 525, 217, 219, 2306, 2308, "on" +271, 15, 62, 526, 220, 223, 2309, 2312, "the" +271, 15, 63, 527, 224, 227, 2313, 2316, "pre" +271, 15, 64, 528, 228, 229, 2317, 2318, "-" +271, 15, 65, 529, 230, 239, 2319, 2328, "specified" +271, 15, 66, 530, 240, 243, 2329, 2332, "non" +271, 15, 67, 531, 244, 245, 2333, 2334, "-" +271, 15, 68, 532, 246, 257, 2335, 2346, "inferiority" +271, 15, 69, 533, 258, 264, 2347, 2353, "margin" +271, 15, 70, 534, 265, 267, 2354, 2356, "of" +271, 15, 71, 535, 268, 269, 2357, 2358, "0" +271, 15, 72, 536, 270, 271, 2359, 2360, "." +271, 15, 73, 537, 272, 273, 2361, 2362, "3" +271, 15, 74, 538, 274, 275, 2363, 2364, "%" +271, 15, 75, 539, 276, 277, 2365, 2366, "(" +271, 15, 76, 540, 278, 279, 2367, 2368, "3" +271, 15, 77, 541, 280, 281, 2369, 2370, "." +271, 15, 78, 542, 282, 283, 2371, 2372, "3" +271, 15, 79, 543, 284, 288, 2373, 2377, "mmol" +271, 15, 80, 544, 289, 290, 2378, 2379, "/" +271, 15, 81, 545, 291, 294, 2380, 2383, "mol" +271, 15, 82, 546, 295, 296, 2384, 2385, "," +271, 15, 83, 547, 297, 298, 2386, 2387, "p" +271, 15, 84, 548, 299, 302, 2388, 2391, " = " +271, 15, 85, 549, 303, 304, 2392, 2393, "0" +271, 15, 86, 550, 305, 306, 2394, 2395, "." +271, 15, 87, 551, 307, 311, 2396, 2400, "0086" +271, 15, 88, 552, 312, 313, 2401, 2402, ")" +271, 15, 89, 553, 314, 315, 2403, 2404, "." +271, 16, 1, 554, 0, 4, 2405, 2409, "Body" +271, 16, 2, 555, 5, 11, 2410, 2416, "weight" +271, 16, 3, 556, 12, 21, 2417, 2426, "increased" +271, 16, 4, 557, 22, 24, 2427, 2429, "in" +271, 16, 5, 558, 25, 28, 2430, 2433, "the" +271, 16, 6, 559, 29, 36, 2434, 2441, "insulin" +271, 16, 7, 560, 37, 45, 2442, 2450, "glargine" +271, 16, 8, 561, 46, 51, 2451, 2456, "group" +271, 16, 9, 562, 52, 55, 2457, 2460, "and" +271, 16, 10, 563, 56, 65, 2461, 2470, "decreased" +271, 16, 11, 564, 66, 68, 2471, 2473, "in" +271, 16, 12, 565, 69, 72, 2474, 2477, "the" +271, 16, 13, 566, 73, 84, 2478, 2489, "albiglutide" +271, 16, 14, 567, 85, 90, 2490, 2495, "group" +271, 16, 15, 568, 91, 92, 2496, 2497, "," +271, 16, 16, 569, 93, 97, 2498, 2502, "with" +271, 16, 17, 570, 98, 99, 2503, 2504, "a" +271, 16, 18, 571, 100, 104, 2505, 2509, "mean" +271, 16, 19, 572, 105, 114, 2510, 2519, "treatment" +271, 16, 20, 573, 115, 125, 2520, 2530, "difference" +271, 16, 21, 574, 126, 128, 2531, 2533, "of" +271, 16, 22, 575, 129, 130, 2534, 2535, "-" +271, 16, 23, 576, 131, 132, 2536, 2537, "2" +271, 16, 24, 577, 133, 134, 2538, 2539, "." +271, 16, 25, 578, 135, 137, 2540, 2542, "61" +271, 16, 26, 579, 138, 140, 2543, 2545, "kg" +271, 16, 27, 580, 141, 142, 2546, 2547, "(" +271, 16, 28, 581, 143, 145, 2548, 2550, "95" +271, 16, 29, 582, 146, 147, 2551, 2552, "%" +271, 16, 30, 583, 148, 150, 2553, 2555, "CI" +271, 16, 31, 584, 151, 152, 2556, 2557, "-" +271, 16, 32, 585, 153, 154, 2558, 2559, "3" +271, 16, 33, 586, 155, 156, 2560, 2561, "." +271, 16, 34, 587, 157, 159, 2562, 2564, "20" +271, 16, 35, 588, 160, 161, 2565, 2566, "," +271, 16, 36, 589, 162, 163, 2567, 2568, "-" +271, 16, 37, 590, 164, 165, 2569, 2570, "2" +271, 16, 38, 591, 166, 167, 2571, 2572, "." +271, 16, 39, 592, 168, 170, 2573, 2575, "02" +271, 16, 40, 593, 171, 172, 2576, 2577, ";" +271, 16, 41, 594, 173, 174, 2578, 2579, "p" +271, 16, 42, 595, 175, 178, 2580, 2583, " < " +271, 16, 43, 596, 179, 180, 2584, 2585, "0" +271, 16, 44, 597, 181, 182, 2586, 2587, "." +271, 16, 45, 598, 183, 187, 2588, 2592, "0001" +271, 16, 46, 599, 188, 189, 2593, 2594, ")" +271, 16, 47, 600, 190, 191, 2595, 2596, "." +271, 17, 1, 601, 0, 10, 2597, 2607, "Documented" +271, 17, 2, 602, 11, 22, 2608, 2619, "symptomatic" +271, 17, 3, 603, 23, 36, 2620, 2633, "hypoglycaemia" +271, 17, 4, 604, 37, 45, 2634, 2642, "occurred" +271, 17, 5, 605, 46, 48, 2643, 2645, "in" +271, 17, 6, 606, 49, 50, 2646, 2647, "a" +271, 17, 7, 607, 51, 57, 2648, 2654, "higher" +271, 17, 8, 608, 58, 68, 2655, 2665, "proportion" +271, 17, 9, 609, 69, 71, 2666, 2668, "of" +271, 17, 10, 610, 72, 80, 2669, 2677, "patients" +271, 17, 11, 611, 81, 83, 2678, 2680, "in" +271, 17, 12, 612, 84, 87, 2681, 2684, "the" +271, 17, 13, 613, 88, 95, 2685, 2692, "insulin" +271, 17, 14, 614, 96, 104, 2693, 2701, "glargine" +271, 17, 15, 615, 105, 110, 2702, 2707, "group" +271, 17, 16, 616, 111, 115, 2708, 2712, "than" +271, 17, 17, 617, 116, 118, 2713, 2715, "in" +271, 17, 18, 618, 119, 122, 2716, 2719, "the" +271, 17, 19, 619, 123, 134, 2720, 2731, "albiglutide" +271, 17, 20, 620, 135, 140, 2732, 2737, "group" +271, 17, 21, 621, 141, 142, 2738, 2739, "(" +271, 17, 22, 622, 143, 145, 2740, 2742, "27" +271, 17, 23, 623, 146, 147, 2743, 2744, "." +271, 17, 24, 624, 148, 149, 2745, 2746, "4" +271, 17, 25, 625, 150, 151, 2747, 2748, "%" +271, 17, 26, 626, 152, 154, 2749, 2751, "vs" +271, 17, 27, 627, 155, 157, 2752, 2754, "17" +271, 17, 28, 628, 158, 159, 2755, 2756, "." +271, 17, 29, 629, 160, 161, 2757, 2758, "5" +271, 17, 30, 630, 162, 163, 2759, 2760, "%" +271, 17, 31, 631, 164, 165, 2761, 2762, "," +271, 17, 32, 632, 166, 167, 2763, 2764, "p" +271, 17, 33, 633, 168, 171, 2765, 2768, " = " +271, 17, 34, 634, 172, 173, 2769, 2770, "0" +271, 17, 35, 635, 174, 175, 2771, 2772, "." +271, 17, 36, 636, 176, 180, 2773, 2777, "0377" +271, 17, 37, 637, 181, 182, 2778, 2779, ")" +271, 17, 38, 638, 183, 184, 2780, 2781, "." +271, 18, 1, 639, 0, 11, 2782, 2793, "CONCLUSIONS" +271, 18, 2, 640, 12, 13, 2794, 2795, "/" +271, 18, 3, 641, 14, 28, 2796, 2810, "INTERPRETATION" +271, 18, 4, 642, 29, 30, 2811, 2812, ":" +271, 18, 5, 643, 31, 42, 2813, 2824, "Albiglutide" +271, 18, 6, 644, 43, 46, 2825, 2828, "was" +271, 18, 7, 645, 47, 50, 2829, 2832, "non" +271, 18, 8, 646, 51, 52, 2833, 2834, "-" +271, 18, 9, 647, 53, 61, 2835, 2843, "inferior" +271, 18, 10, 648, 62, 64, 2844, 2846, "to" +271, 18, 11, 649, 65, 72, 2847, 2854, "insulin" +271, 18, 12, 650, 73, 81, 2855, 2863, "glargine" +271, 18, 13, 651, 82, 84, 2864, 2866, "at" +271, 18, 14, 652, 85, 93, 2867, 2875, "reducing" +271, 18, 15, 653, 94, 99, 2876, 2881, "HbA1c" +271, 18, 16, 654, 100, 102, 2882, 2884, "at" +271, 18, 17, 655, 103, 107, 2885, 2889, "week" +271, 18, 18, 656, 108, 110, 2890, 2892, "52" +271, 18, 19, 657, 111, 112, 2893, 2894, "," +271, 18, 20, 658, 113, 117, 2895, 2899, "with" +271, 18, 21, 659, 118, 124, 2900, 2906, "modest" +271, 18, 22, 660, 125, 131, 2907, 2913, "weight" +271, 18, 23, 661, 132, 136, 2914, 2918, "loss" +271, 18, 24, 662, 137, 140, 2919, 2922, "and" +271, 18, 25, 663, 141, 145, 2923, 2927, "less" +271, 18, 26, 664, 146, 159, 2928, 2941, "hypoglycaemia" +271, 18, 27, 665, 160, 161, 2942, 2943, "." +271, 19, 1, 666, 0, 4, 2944, 2948, "Both" +271, 19, 2, 667, 5, 10, 2949, 2954, "drugs" +271, 19, 3, 668, 11, 15, 2955, 2959, "were" +271, 19, 4, 669, 16, 20, 2960, 2964, "well" +271, 19, 5, 670, 21, 30, 2965, 2974, "tolerated" +271, 19, 6, 671, 31, 32, 2975, 2976, "." +271, 20, 1, 672, 0, 11, 2977, 2988, "Albiglutide" +271, 20, 2, 673, 12, 15, 2989, 2992, "may" +271, 20, 3, 674, 16, 18, 2993, 2995, "be" +271, 20, 4, 675, 19, 29, 2996, 3006, "considered" +271, 20, 5, 676, 30, 32, 3007, 3009, "an" +271, 20, 6, 677, 33, 44, 3010, 3021, "alternative" +271, 20, 7, 678, 45, 47, 3022, 3024, "to" +271, 20, 8, 679, 48, 55, 3025, 3032, "insulin" +271, 20, 9, 680, 56, 64, 3033, 3041, "glargine" +271, 20, 10, 681, 65, 67, 3042, 3044, "in" +271, 20, 11, 682, 68, 72, 3045, 3049, "this" +271, 20, 12, 683, 73, 80, 3050, 3057, "patient" +271, 20, 13, 684, 81, 91, 3058, 3068, "population" +271, 20, 14, 685, 92, 93, 3069, 3070, "." +271, 21, 1, 686, 0, 5, 3071, 3076, "TRIAL" +271, 21, 2, 687, 6, 18, 3077, 3089, "REGISTRATION" +271, 21, 3, 688, 19, 20, 3090, 3091, ":" +271, 21, 4, 689, 21, 35, 3092, 3106, "ClinicalTrials" +271, 21, 5, 690, 36, 37, 3107, 3108, "." +271, 21, 6, 691, 38, 41, 3109, 3112, "gov" +271, 21, 7, 692, 42, 53, 3113, 3124, "NCT00838916" +271, 21, 8, 693, 54, 55, 3125, 3126, "(" +271, 21, 9, 694, 56, 65, 3127, 3136, "completed" +271, 21, 10, 695, 66, 67, 3137, 3138, ")" +271, 21, 11, 696, 68, 75, 3139, 3146, "FUNDING" +271, 21, 12, 697, 76, 77, 3147, 3148, ":" +271, 21, 13, 698, 78, 82, 3149, 3153, "This" +271, 21, 14, 699, 83, 88, 3154, 3159, "study" +271, 21, 15, 700, 89, 92, 3160, 3163, "was" +271, 21, 16, 701, 93, 100, 3164, 3171, "planned" +271, 21, 17, 702, 101, 104, 3172, 3175, "and" +271, 21, 18, 703, 105, 114, 3176, 3185, "conducted" +271, 21, 19, 704, 115, 117, 3186, 3188, "by" +271, 21, 20, 705, 118, 133, 3189, 3204, "GlaxoSmithKline" +271, 21, 21, 706, 134, 135, 3205, 3206, "." +271, 22, 1, 707, 0, 3, 3207, 3210, "DOI" +271, 22, 2, 708, 4, 5, 3211, 3212, ":" +271, 22, 3, 709, 6, 8, 3213, 3215, "10" +271, 22, 4, 710, 9, 10, 3216, 3217, "." +271, 22, 5, 711, 11, 15, 3218, 3222, "1007" +271, 22, 6, 712, 16, 17, 3223, 3224, "/" +271, 22, 7, 713, 18, 24, 3225, 3231, "s00125" +271, 22, 8, 714, 25, 26, 3232, 3233, "-" +271, 22, 9, 715, 27, 30, 3234, 3237, "014" +271, 22, 10, 716, 31, 32, 3238, 3239, "-" +271, 22, 11, 717, 33, 37, 3240, 3244, "3360" +271, 22, 12, 718, 38, 39, 3245, 3246, "-" +271, 22, 13, 719, 40, 41, 3247, 3248, "3" +271, 22, 14, 720, 42, 46, 3249, 3253, "PMID" +271, 22, 15, 721, 47, 48, 3254, 3255, ":" +271, 22, 16, 722, 49, 57, 3256, 3264, "25208756" +271, 22, 17, 723, 58, 59, 3265, 3266, "[" +271, 22, 18, 724, 60, 67, 3267, 3274, "Indexed" +271, 22, 19, 725, 68, 71, 3275, 3278, "for" +271, 22, 20, 726, 72, 79, 3279, 3286, "MEDLINE" +271, 22, 21, 727, 80, 81, 3287, 3288, "]" diff --git a/data/dm2 25208756_kwoodley.annodb b/data/dm2 25208756_kwoodley.annodb new file mode 100644 index 0000000..4bab77f --- /dev/null +++ b/data/dm2 25208756_kwoodley.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +53271, Journal, 0, 12, "Diabetologia", "", +53272, PublicationYear, 15, 19, "2014", "", +53273, Randomized, 125, 135, "randomised", "", +53304, Title, 125, 310, "randomised clinical trial comparing once - weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea .", "", +53274, Frequency, 161, 174, "once - weekly", "", +53275, Drug, 175, 186, "albiglutide", "", +53284, InsulinGlargine, 191, 207, "insulin glargine", "", +53302, Precondition, 211, 308, "patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea", "", +53293, Type2Diabetes, 225, 240, "type 2 diabetes", "", +53296, Metformin, 270, 279, "metformin", "", +53299, Sulfonylureas, 296, 308, "sulfonylurea", "", +53305, Author, 311, 322, "Weissman PN", "", +53306, Author, 331, 338, "Carr MC", "", +53307, Author, 341, 345, "Ye J", "", +53308, Author, 348, 357, "Cirkel DT", "", +53309, Author, 360, 369, "Stewart M", "", +53310, Author, 372, 379, "Perry C", "", +53311, Author, 382, 391, "Pratley R", "", +53312, USA, 494, 497, "USA", "", +53318, ObjectiveDescription, 549, 716, "The aim of this study was to compare the efficacy and safety of once - weekly albiglutide with once - daily insulin glargine ( A21Gly , B31Arg , B32Arg human insulin )", "", +53313, Frequency, 613, 626, "once - weekly", "", +53276, Drug, 627, 638, "albiglutide", "", +53314, Frequency, 644, 656, "once - daily", "", +53285, InsulinGlargine, 657, 673, "insulin glargine", "", +53317, FixedCombDrug, 676, 714, "A21Gly , B31Arg , B32Arg human insulin", "", +53319, ObjectiveDescription, 717, 817, "in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea .", "", +53303, Precondition, 720, 815, "patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea", "", +53294, Type2Diabetes, 734, 749, "type 2 diabetes", "", +53297, Metformin, 777, 786, "metformin", "", +53300, Sulfonylureas, 803, 815, "sulfonylurea", "", +53320, Randomized, 839, 849, "randomised", "", +53321, OpenLabel, 852, 864, "open - label", "", +53323, Multicenter, 867, 878, "multicentre", "", +53324, Parallel, 895, 911, "parallel - group", "", +53325, CTDesign, 914, 931, "non - inferiority", "", +53326, NumberPatientsCT, 968, 971, "779", "", +53331, Precondition, 1072, 1251, "Patients aged ≥ 18 years with type 2 diabetes treated with metformin ( ± sulfonylurea ) for at least 3 months with a baseline HbA1c 7 . 0 - 10 . 0 % ( 53 . 0 - 85 . 8 mmol / mol )", "", +53327, MinAge, 1088, 1090, "18", "", +53295, Type2Diabetes, 1102, 1117, "type 2 diabetes", "", +53298, Metformin, 1131, 1140, "metformin", "", +53301, Sulfonylureas, 1145, 1157, "sulfonylurea", "", +53328, HbA1c, 1198, 1203, "HbA1c", "", +53329, Percentage, 1219, 1220, "%", "", +53330, BioAndMedicalUnit, 1239, 1249, "mmol / mol", "", +53332, Randomized, 1257, 1265, "randomly", "", +53333, AllocationRatio, 1277, 1282, "2 : 1", "", +53277, Drug, 1375, 1386, "albiglutide", "", +53334, DoseValue, 1389, 1391, "30", "", +53336, mg, 1392, 1394, "mg", "", +53315, Frequency, 1395, 1406, "once a week", "", +53338, NumberPatientsArm, 1415, 1418, "504", "", +53286, InsulinGlargine, 1424, 1440, "insulin glargine", "", +53335, DoseValue, 1443, 1445, "10", "", +53337, BioAndMedicalUnit, 1446, 1447, "U", "", +53316, Frequency, 1448, 1458, "once a day", "", +53339, NumberPatientsArm, 1467, 1470, "241", "", +53340, DoseDescription, 1573, 1652, "Doses of each medication were adjusted on the basis of the glycaemic response .", "", +53342, TimePoint, 1690, 1698, "baseline", "", +53341, HbA1c, 1702, 1707, "HbA1c", "", +53343, TimePoint, 1711, 1718, "week 52", "", +53278, Drug, 1738, 1749, "albiglutide", "", +53347, HbA1c, 1758, 1763, "HbA1c", "", +53349, BaseLineValue, 1778, 1784, "8 . 28", "", +53351, SdDevBL, 1789, 1795, "0 . 90", "", +53353, Percentage, 1796, 1797, "%", "", +53350, BaseLineValue, 1800, 1806, "67 . 0", "", +53352, SdDevBL, 1811, 1816, "9 . 8", "", +53355, BioAndMedicalUnit, 1817, 1827, "mmol / mol", "", +53357, Mean, 1832, 1843, "mean  ±  SD", "", +53345, TimePoint, 1849, 1857, "baseline", "", +53358, ResultMeasuredValue, 1861, 1867, "7 . 62", "", +53360, SdDevResValue, 1872, 1878, "1 . 12", "", +53354, Percentage, 1879, 1880, "%", "", +53359, ResultMeasuredValue, 1883, 1889, "59 . 8", "", +53361, SdDevResValue, 1894, 1900, "12 . 2", "", +53356, BioAndMedicalUnit, 1901, 1911, "mmol / mol", "", +53344, TimePoint, 1917, 1924, "week 52", "", +53287, InsulinGlargine, 1963, 1979, "insulin glargine", "", +53367, BaseLineValue, 1988, 1994, "8 . 36", "", +53369, SdDevBL, 1999, 2005, "0 . 95", "", +53371, Percentage, 2006, 2007, "%", "", +53366, ResultMeasuredValue, 2011, 2017, "7 . 55", "", +53364, SdDevResValue, 2022, 2028, "1 . 04", "", +53372, Percentage, 2029, 2030, "%", "", +53368, BaseLineValue, 2033, 2039, "67 . 9", "", +53370, SdDevBL, 2044, 2050, "10 . 4", "", +53365, ResultMeasuredValue, 2054, 2060, "59 . 0", "", +53373, SdDevResValue, 2065, 2071, "11 . 4", "", +53374, BioAndMedicalUnit, 2072, 2082, "mmol / mol", "", +53375, DiffGroupAbsValue, 2134, 2140, "0 . 11", "", +53376, Percentage, 2141, 2142, "%", "", +53379, ConfIntervalDiff, 2145, 2174, "95 % CI - 0 . 04 % , 0 . 27 %", "", +53377, Percentage, 2162, 2163, "%", "", +53378, Percentage, 2173, 2174, "%", "", +53382, DiffGroupAbsValue, 2179, 2184, "1 . 2", "", +53383, BioAndMedicalUnit, 2185, 2195, "mmol / mol", "", +53380, ConfIntervalDiff, 2198, 2232, "95 % CI - 0 . 4 , 3 . 0 mmol / mol", "", +53381, BioAndMedicalUnit, 2222, 2232, "mmol / mol", "", +53279, Drug, 2268, 2279, "albiglutide", "", +53288, InsulinGlargine, 2283, 2299, "insulin glargine", "", +53385, BioAndMedicalUnit, 2373, 2383, "mmol / mol", "", +53384, PvalueDiff, 2386, 2400, "p  =  0 . 0086", "", +53386, BodyWeight, 2405, 2416, "Body weight", "", +53387, ObservedResult, 2417, 2426, "increased", "", +53289, InsulinGlargine, 2434, 2450, "insulin glargine", "", +53388, ObservedResult, 2461, 2470, "decreased", "", +53280, Drug, 2478, 2489, "albiglutide", "", +53389, DiffGroupAbsValue, 2534, 2542, "- 2 . 61", "", +53390, Kg, 2543, 2545, "kg", "", +53391, ConfIntervalDiff, 2548, 2575, "95 % CI - 3 . 20 , - 2 . 02", "", +53392, PvalueDiff, 2578, 2592, "p  <  0 . 0001", "", +53393, SymptomaticHypoglycemia, 2608, 2633, "symptomatic hypoglycaemia", "", +53290, InsulinGlargine, 2685, 2701, "insulin glargine", "", +53281, Drug, 2720, 2731, "albiglutide", "", +53394, PercentageAffected, 2740, 2746, "27 . 4", "", +53395, PercentageAffected, 2752, 2758, "17 . 5", "", +53396, PvalueDiff, 2763, 2777, "p  =  0 . 0377", "", +53282, Drug, 2813, 2824, "Albiglutide", "", +53399, ConclusionComment, 2813, 2943, "Albiglutide was non - inferior to insulin glargine at reducing HbA1c at week 52 , with modest weight loss and less hypoglycaemia .", "", +53291, InsulinGlargine, 2847, 2863, "insulin glargine", "", +53348, HbA1c, 2876, 2881, "HbA1c", "", +53346, TimePoint, 2885, 2892, "week 52", "", +53397, BodyWeight, 2907, 2913, "weight", "", +53398, Hypoglycemia, 2928, 2941, "hypoglycaemia", "", +53400, ConclusionComment, 2944, 2976, "Both drugs were well tolerated .", "", +53283, Drug, 2977, 2988, "Albiglutide", "", +53401, ConclusionComment, 2977, 3070, "Albiglutide may be considered an alternative to insulin glargine in this patient population .", "", +53292, InsulinGlargine, 3025, 3041, "insulin glargine", "", +53402, PMID, 3256, 3264, "25208756", "", diff --git a/data/dm2 25208756_kwoodley.n-triples b/data/dm2 25208756_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25208756_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25753488_admin.annodb b/data/dm2 25753488_admin.annodb new file mode 100644 index 0000000..b5905df --- /dev/null +++ b/data/dm2 25753488_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Diabetes", "", " \"J Diabetes\"." +1, PublicationYear, 13, 17, "2016", "", " \"2016\"." +29, Title, 104, 281, "Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .", "", " \"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .\"." +2, Linagliptin, 127, 138, "linagliptin", "", +25, Ethnicity, 142, 147, "Asian", "", " . ." +9, Type2Diabetes, 162, 186, "type 2 diabetes mellitus", "", " ." +113, Precondition, 187, 223, "inadequately controlled by metformin", "", " \"inadequately controlled by metformin\"." +14, Metformin, 214, 223, "metformin", "", +20, Multicenter, 228, 241, "multinational", "", " ." +21, Duration, 242, 251, "24 - week", "", " \"24 - week\"." +22, Randomized, 254, 264, "randomized", "", " ." +30, Author, 282, 288, "Wang W", "", " \"Wang W\"." +31, Author, 297, 303, "Yang J", "", " \"Yang J\"." +32, Author, 312, 318, "Yang G", "", " \"Yang G\"." +33, Author, 327, 333, "Gong Y", "", " \"Gong Y\"." +34, Author, 342, 349, "Patel S", "", " \"Patel S\"." +35, Author, 358, 365, "Zhang C", "", " \"Zhang C\"." +36, Author, 374, 383, "Izumoto T", "", " \"Izumoto T\"." +37, Author, 392, 398, "Ning G", "", " \"Ning G\"." +38, China, 514, 519, "China", "", +39, China, 594, 599, "China", "", +40, China, 684, 689, "China", "", +42, Germany, 740, 747, "Germany", "", +43, UK, 791, 793, "UK", "", +41, China, 858, 863, "China", "", +44, Japan, 910, 915, "Japan", "", +12, Type2Diabetes, 968, 992, "type 2 diabetes mellitus", "", +11, Type2Diabetes, 995, 999, "T2DM", "", +228, Ethnicity, 1084, 1093, "Caucasian", "", +54, ObjectiveDescription, 1125, 1343, "The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .", "", " \"The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .\"." +24, Randomized, 1147, 1157, "randomized", "", +45, Placebo, 1158, 1165, "placebo", "", +51, DoubleBlind, 1179, 1193, "double - blind", "", " ." +52, Duration, 1196, 1205, "24 - week", "", +3, Linagliptin, 1288, 1299, "linagliptin", "", +15, Metformin, 1309, 1318, "metformin", "", +53, Ethnicity, 1322, 1327, "Asian", "", +10, Type2Diabetes, 1328, 1332, "T2DM", "", +55, NumberPatientsCT, 1363, 1366, "306", "", " \"306\"." +64, Precondition, 1367, 1526, "patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy", "", " \"patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy\"." +26, Ethnicity, 1388, 1395, "Chinese", "", " . ." +27, Ethnicity, 1407, 1416, "Malaysian", "", " . ." +28, Ethnicity, 1428, 1436, "Filipino", "", " . ." +56, MinAge, 1446, 1448, "18", "", " \"18\"." +57, MaxAge, 1451, 1453, "80", "", " \"80\"." +159, Year, 1454, 1459, "years", "", +58, HbA1c, 1465, 1470, "HbA1c", "", +59, Percentage, 1500, 1501, "%", "", +16, Metformin, 1509, 1518, "metformin", "", +23, Randomized, 1532, 1542, "randomized", "", +60, AllocationRatio, 1545, 1550, "2 : 1", "", " . ." +4, Linagliptin, 1563, 1574, "linagliptin", "", " ." +61, DoseValue, 1575, 1576, "5", "", " \"5\"." +62, mg, 1579, 1581, "mg", "", " ." +63, Frequency, 1582, 1587, "daily", "", " \"daily\"." +46, Placebo, 1591, 1598, "placebo", "", " ." +17, Metformin, 1608, 1617, "metformin", "", +18, Metformin, 1650, 1659, "metformin", "", +164, Randomized, 1685, 1698, "randomization", "", +166, Mean, 1736, 1740, "mean", "", +66, HbA1c, 1741, 1746, "HbA1c", "", +67, TimePoint, 1752, 1760, "baseline", "", +68, TimePoint, 1767, 1775, "24 weeks", "", +171, Mean, 1862, 1866, "mean", "", +69, HbA1c, 1875, 1880, "HbA1c", "", +71, BaseLineValue, 1881, 1886, "8 . 0", "", " \"8 . 0\". \"8 . 0\"." +72, SdDevBL, 1891, 1896, "0 . 8", "", " \"0 . 8\". \"0 . 8\"." +73, Percentage, 1897, 1898, "%", "", +186, Mean, 1912, 1916, "mean", "", " . ." +75, HbA1c, 1926, 1931, "HbA1c", "", " ." +5, Linagliptin, 1949, 1960, "linagliptin", "", +48, Placebo, 1965, 1972, "placebo", "", +76, Reduction, 1985, 1991, "0 . 66", "", " \"0 . 66\"." +78, SdErrorChangeValue, 1996, 2002, "0 . 05", "", " \"0 . 05\"." +77, Reduction, 2009, 2015, "0 . 14", "", " \"0 . 14\"." +79, SdErrorChangeValue, 2020, 2026, "0 . 07", "", " \"0 . 07\"." +80, Percentage, 2027, 2028, "%", "", " ." +47, Placebo, 2046, 2053, "placebo", "", +82, DiffGroupAbsValue, 2077, 2085, "- 0 . 52", "", " \"- 0 . 52\"." +83, SdErrorDiff, 2090, 2096, "0 . 09", "", " \"0 . 09\"." +81, Percentage, 2097, 2098, "%", "", +84, ConfIntervalDiff, 2101, 2152, "95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34", "", " \"95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34\"." +85, PvalueDiff, 2155, 2169, "P  <  0 . 0001", "", " \"P  <  0 . 0001\"." +106171, SubGroupDescription, 2177, 2215, "patients with baseline HbA1c ≥ 8 . 5 %", "", " \"patients with baseline HbA1c ≥ 8 . 5 %\"." +199, HbA1c, 2200, 2205, "HbA1c", "", +179, Percentage, 2214, 2215, "%", "", +49, Placebo, 2222, 2229, "placebo", "", +87, HbA1c, 2254, 2259, "HbA1c", "", +88, Reduction, 2266, 2272, "0 . 89", "", " \"0 . 89\"." +89, SdErrorChangeValue, 2277, 2283, "0 . 17", "", " \"0 . 17\"." +90, Percentage, 2284, 2285, "%", "", +91, PValueChangeValue, 2288, 2302, "P  <  0 . 0001", "", " \"P  <  0 . 0001\"." +92, EndPointDescription, 2307, 2321, "Adverse events", "", " . ." +6, Linagliptin, 2361, 2372, "linagliptin", "", +50, Placebo, 2377, 2384, "placebo", "", +94, PercentageAffected, 2396, 2402, "27 . 3", "", " \"27 . 3\"." +95, PercentageAffected, 2409, 2415, "28 . 0", "", " \"28 . 0\"." +211, EndPointDescription, 2459, 2473, "drug - related", "", " . ." +96, PercentageAffected, 2476, 2481, "2 . 4", "", " \"2 . 4\"." +97, PercentageAffected, 2488, 2493, "0 . 0", "", " \"0 . 0\"." +99, Hypoglycemia, 2515, 2527, "Hypoglycemia", "", " ." +98, PercentageAffected, 2540, 2545, "1 . 0", "", " \"1 . 0\". \"1 . 0\"." +7, Linagliptin, 2577, 2588, "Linagliptin", "", +101, ObservedResult, 2577, 2617, "Linagliptin therapy was weight neutral .", "", " \"Linagliptin therapy was weight neutral .\"." +100, BodyWeight, 2601, 2607, "weight", "", " ." +8, Linagliptin, 2632, 2643, "Linagliptin", "", +107, ConclusionComment, 2632, 2766, "Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .", "", " \"Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .\"." +102, DoseValue, 2644, 2645, "5", "", +103, mg, 2648, 2650, "mg", "", +104, Duration, 2691, 2699, "24 weeks", "", +105, Ethnicity, 2703, 2708, "Asian", "", +13, Type2Diabetes, 2723, 2727, "T2DM", "", +19, Metformin, 2755, 2764, "metformin", "", +108, PMID, 2921, 2929, "25753488", "", " \"25753488\"." diff --git a/data/dm2 25753488_admin.n-triples b/data/dm2 25753488_admin.n-triples new file mode 100644 index 0000000..efdef41 --- /dev/null +++ b/data/dm2 25753488_admin.n-triples @@ -0,0 +1,185 @@ +# RDF export of group: Publication + . + "Publication 67877" . + "Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial ." . + "Wang W" . + "2016" . + "J Diabetes" . + "25753488" . + . + "Yang J" . + "Yang G" . + "Gong Y" . + "Patel S" . + "Zhang C" . + "Izumoto T" . + "Ning G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 67884" . + "The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients ." . + "306" . + "24 - week" . + . + . + . + . + "Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 67900" . + "inadequately controlled by metformin" . + . + . + . + "18" . + "80" . + . + "patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy" . + . + . + . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "aed" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "lin" . + . + . + . + . + . + . + . + . + "pl" . + . + . + . + . + . +# RDF export of group: Intervention + . + "li" . + . + "daily" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "li" . + . + "5" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 0" . + "0 . 8" . + "0 . 66" . + "0 . 05" . + . + "hba 2" . + . + "8 . 0" . + "0 . 8" . + "0 . 14" . + "0 . 07" . + . + . + . + "hbas 1" . + . + "0 . 89" . + "P  <  0 . 0001" . + "0 . 17" . + "patients with baseline HbA1c ≥ 8 . 5 %" . + . + "ae 1" . + . + "27 . 3" . + . + "ae 2" . + . + "28 . 0" . + . + "aed 1" . + . + "2 . 4" . + . + "aed 2" . + . + "0 . 0" . + . + "hyp 1" . + . + "1 . 0" . + . + "hyp 2" . + . + "1 . 0" . + . + "bw 1" . + . + "Linagliptin therapy was weight neutral ." . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 52" . + "P  <  0 . 0001" . + "95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34" . + "0 . 09" . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25753488_akramersunderbrink.annodb b/data/dm2 25753488_akramersunderbrink.annodb new file mode 100644 index 0000000..b53f44a --- /dev/null +++ b/data/dm2 25753488_akramersunderbrink.annodb @@ -0,0 +1,122 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +61408, Journal, 0, 10, "J Diabetes", "", +61409, PublicationYear, 13, 17, "2016", "", +61417, Title, 104, 281, "Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .", "", +61410, Linagliptin, 127, 138, "linagliptin", "", +61529, Ethnicity, 142, 147, "Asian", "", +61411, Type2Diabetes, 162, 186, "type 2 diabetes mellitus", "", +61412, Precondition, 187, 223, "inadequately controlled by metformin", "", +61413, Metformin, 214, 223, "metformin", "", +61414, Multicenter, 228, 241, "multinational", "", +61415, Duration, 242, 251, "24 - week", "", +61416, Randomized, 254, 264, "randomized", "", +61418, Author, 282, 288, "Wang W", "", +61419, Author, 297, 303, "Yang J", "", +61420, Author, 312, 318, "Yang G", "", +61421, Author, 327, 333, "Gong Y", "", +61422, Author, 342, 349, "Patel S", "", +61423, Author, 358, 365, "Zhang C", "", +61424, Author, 374, 383, "Izumoto T", "", +61425, Author, 392, 398, "Ning G", "", +61426, China, 514, 519, "China", "", +61427, China, 594, 599, "China", "", +61428, China, 684, 689, "China", "", +61430, Germany, 740, 747, "Germany", "", +61432, UK, 791, 793, "UK", "", +61429, China, 858, 863, "China", "", +61431, Japan, 910, 915, "Japan", "", +61442, ObjectiveDescription, 931, 1124, "Despite the increasing prevalence of type 2 diabetes mellitus ( T2DM ) in Asia , clinical trials for glucose - lowering therapies are often dominated by Caucasian and / or Western populations .", "", +61433, Type2Diabetes, 968, 992, "type 2 diabetes mellitus", "", +61434, Type2Diabetes, 995, 999, "T2DM", "", +61530, Ethnicity, 1084, 1093, "Caucasian", "", +61531, Ethnicity, 1103, 1110, "Western", "", +61443, ObjectiveDescription, 1125, 1343, "The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .", "", +61435, Randomized, 1147, 1157, "randomized", "", +61436, Placebo, 1158, 1165, "placebo", "", +61437, DoubleBlind, 1179, 1193, "double - blind", "", +61438, Duration, 1196, 1205, "24 - week", "", +61439, Linagliptin, 1288, 1299, "linagliptin", "", +61440, Metformin, 1309, 1318, "metformin", "", +61441, Type2Diabetes, 1328, 1332, "T2DM", "", +61444, NumberPatientsCT, 1363, 1366, "306", "", +61462, Ethnicity, 1388, 1395, "Chinese", "", +61463, Ethnicity, 1407, 1416, "Malaysian", "", +61464, Ethnicity, 1428, 1436, "Filipino", "", +61448, MinAge, 1446, 1448, "18", "", +61449, MaxAge, 1451, 1453, "80", "", +61461, Year, 1454, 1459, "years", "", +61450, HbA1c, 1465, 1470, "HbA1c", "", +61451, Precondition, 1465, 1501, "HbA1c between ≥ 7 . 0 and ≤ 10 . 0 %", "", +61452, Percentage, 1500, 1501, "%", "", +61453, Metformin, 1509, 1518, "metformin", "", +61454, Randomized, 1532, 1542, "randomized", "", +61455, Linagliptin, 1563, 1574, "linagliptin", "", +61456, DoseValue, 1575, 1581, "5   mg", "", +61457, mg, 1579, 1581, "mg", "", +61458, Frequency, 1582, 1587, "daily", "", +61459, Placebo, 1591, 1598, "placebo", "", +61460, Metformin, 1608, 1617, "metformin", "", +61467, Precondition, 1620, 1675, "Antidiabetes drugs other than metformin were washed out", "", +61465, Metformin, 1650, 1659, "metformin", "", +61466, Randomized, 1685, 1698, "randomization", "", +61468, Mean, 1736, 1740, "mean", "", +61469, HbA1c, 1741, 1746, "HbA1c", "", +61470, TimePoint, 1752, 1760, "baseline", "", +61471, TimePoint, 1767, 1775, "24 weeks", "", +61472, TimePoint, 1788, 1796, "Baseline", "", +61473, Mean, 1862, 1866, "mean", "", +61474, HbA1c, 1875, 1880, "HbA1c", "", +61475, BaseLineValue, 1881, 1886, "8 . 0", "", +61476, SdDevBL, 1891, 1896, "0 . 8", "", +61477, Percentage, 1897, 1898, "%", "", +61488, Mean, 1912, 1916, "mean", "", +61489, HbA1c, 1926, 1931, "HbA1c", "", +61490, Linagliptin, 1949, 1960, "linagliptin", "", +61491, Placebo, 1965, 1972, "placebo", "", +61492, ChangeValue, 1983, 1991, "- 0 . 66", "", +61494, SdErrorChangeValue, 1996, 2002, "0 . 05", "", +61493, ChangeValue, 2007, 2015, "- 0 . 14", "", +61495, SdErrorChangeValue, 2020, 2026, "0 . 07", "", +61478, Percentage, 2027, 2028, "%", "", +61496, DiffGroupAbsValue, 2077, 2085, "- 0 . 52", "", +61497, SdErrorDiff, 2090, 2096, "0 . 09", "", +61479, Percentage, 2097, 2098, "%", "", +61498, ConfIntervalDiff, 2101, 2152, "95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34", "", +61480, Percentage, 2104, 2105, "%", "", +61499, PvalueDiff, 2155, 2169, "P  <  0 . 0001", "", +61503, SubGroupDescription, 2177, 2215, "patients with baseline HbA1c ≥ 8 . 5 %", "", +61500, TimePoint, 2191, 2199, "baseline", "", +61501, HbA1c, 2200, 2205, "HbA1c", "", +61481, Percentage, 2214, 2215, "%", "", +61504, Placebo, 2222, 2229, "placebo", "", +61502, HbA1c, 2254, 2259, "HbA1c", "", +61505, DiffGroupAbsValue, 2264, 2272, "- 0 . 89", "", +61506, SdErrorDiff, 2277, 2283, "0 . 17", "", +61482, Percentage, 2284, 2285, "%", "", +61507, PvalueDiff, 2288, 2302, "P  <  0 . 0001", "", +61510, EndPointDescription, 2307, 2321, "Adverse events", "", +61508, Linagliptin, 2361, 2372, "linagliptin", "", +61509, Placebo, 2377, 2384, "placebo", "", +61511, PercentageAffected, 2396, 2402, "27 . 3", "", +61483, Percentage, 2403, 2404, "%", "", +61512, PercentageAffected, 2409, 2415, "28 . 0", "", +61484, Percentage, 2416, 2417, "%", "", +61513, EndPointDescription, 2459, 2473, "drug - related", "", +61514, PercentageAffected, 2476, 2481, "2 . 4", "", +61485, Percentage, 2482, 2483, "%", "", +61515, PercentageAffected, 2488, 2493, "0 . 0", "", +61486, Percentage, 2494, 2495, "%", "", +61517, Hypoglycemia, 2515, 2527, "Hypoglycemia", "", +61516, PercentageAffected, 2540, 2545, "1 . 0", "", +61487, Percentage, 2546, 2547, "%", "", +61518, Linagliptin, 2577, 2588, "Linagliptin", "", +61520, BodyWeight, 2601, 2607, "weight", "", +61519, Linagliptin, 2632, 2643, "Linagliptin", "", +61528, ConclusionComment, 2632, 2766, "Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .", "", +61521, DoseValue, 2644, 2650, "5   mg", "", +61522, mg, 2648, 2650, "mg", "", +61523, Duration, 2691, 2699, "24 weeks", "", +61524, Ethnicity, 2703, 2708, "Asian", "", +61525, Type2Diabetes, 2723, 2727, "T2DM", "", +61526, Metformin, 2755, 2764, "metformin", "", +61527, PMID, 2921, 2929, "25753488", "", diff --git a/data/dm2 25753488_akramersunderbrink.n-triples b/data/dm2 25753488_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25753488_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 25753488_export.csv b/data/dm2 25753488_export.csv new file mode 100644 index 0000000..86975c6 --- /dev/null +++ b/data/dm2 25753488_export.csv @@ -0,0 +1,633 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +266, 1, 1, 1, 0, 1, 0, 1, "J" +266, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +266, 1, 3, 3, 11, 12, 11, 12, "." +266, 2, 1, 4, 0, 4, 13, 17, "2016" +266, 2, 2, 5, 5, 8, 18, 21, "Mar" +266, 2, 3, 6, 9, 10, 22, 23, ";" +266, 2, 4, 7, 11, 12, 24, 25, "8" +266, 2, 5, 8, 13, 14, 26, 27, "(" +266, 2, 6, 9, 15, 16, 28, 29, "2" +266, 2, 7, 10, 17, 18, 30, 31, ")" +266, 2, 8, 11, 19, 20, 32, 33, ":" +266, 2, 9, 12, 21, 24, 34, 37, "229" +266, 2, 10, 13, 25, 26, 38, 39, "-" +266, 2, 11, 14, 27, 29, 40, 42, "37" +266, 2, 12, 15, 30, 31, 43, 44, "." +266, 2, 13, 16, 32, 35, 45, 48, "doi" +266, 2, 14, 17, 36, 37, 49, 50, ":" +266, 2, 15, 18, 38, 40, 51, 53, "10" +266, 2, 16, 19, 41, 42, 54, 55, "." +266, 2, 17, 20, 43, 47, 56, 60, "1111" +266, 2, 18, 21, 48, 49, 61, 62, "/" +266, 2, 19, 22, 50, 54, 63, 67, "1753" +266, 2, 20, 23, 55, 56, 68, 69, "-" +266, 2, 21, 24, 57, 61, 70, 74, "0407" +266, 2, 22, 25, 62, 63, 75, 76, "." +266, 2, 23, 26, 64, 69, 77, 82, "12284" +266, 2, 24, 27, 70, 71, 83, 84, "." +266, 3, 1, 28, 0, 4, 85, 89, "Epub" +266, 3, 2, 29, 5, 9, 90, 94, "2015" +266, 3, 3, 30, 10, 13, 95, 98, "Apr" +266, 3, 4, 31, 14, 16, 99, 101, "28" +266, 3, 5, 32, 17, 18, 102, 103, "." +266, 4, 1, 33, 0, 8, 104, 112, "Efficacy" +266, 4, 2, 34, 9, 12, 113, 116, "and" +266, 4, 3, 35, 13, 19, 117, 123, "safety" +266, 4, 4, 36, 20, 22, 124, 126, "of" +266, 4, 5, 37, 23, 34, 127, 138, "linagliptin" +266, 4, 6, 38, 35, 37, 139, 141, "in" +266, 4, 7, 39, 38, 43, 142, 147, "Asian" +266, 4, 8, 40, 44, 52, 148, 156, "patients" +266, 4, 9, 41, 53, 57, 157, 161, "with" +266, 4, 10, 42, 58, 62, 162, 166, "type" +266, 4, 11, 43, 63, 64, 167, 168, "2" +266, 4, 12, 44, 65, 73, 169, 177, "diabetes" +266, 4, 13, 45, 74, 82, 178, 186, "mellitus" +266, 4, 14, 46, 83, 95, 187, 199, "inadequately" +266, 4, 15, 47, 96, 106, 200, 210, "controlled" +266, 4, 16, 48, 107, 109, 211, 213, "by" +266, 4, 17, 49, 110, 119, 214, 223, "metformin" +266, 4, 18, 50, 120, 121, 224, 225, ":" +266, 4, 19, 51, 122, 123, 226, 227, "A" +266, 4, 20, 52, 124, 137, 228, 241, "multinational" +266, 4, 21, 53, 138, 140, 242, 244, "24" +266, 4, 22, 54, 141, 142, 245, 246, "-" +266, 4, 23, 55, 143, 147, 247, 251, "week" +266, 4, 24, 56, 148, 149, 252, 253, "," +266, 4, 25, 57, 150, 160, 254, 264, "randomized" +266, 4, 26, 58, 161, 169, 265, 273, "clinical" +266, 4, 27, 59, 170, 175, 274, 279, "trial" +266, 4, 28, 60, 176, 177, 280, 281, "." +266, 5, 1, 61, 0, 4, 282, 286, "Wang" +266, 5, 2, 62, 5, 6, 287, 288, "W" +266, 5, 3, 63, 7, 8, 289, 290, "(" +266, 5, 4, 64, 9, 10, 291, 292, "1" +266, 5, 5, 65, 11, 12, 293, 294, ")" +266, 5, 6, 66, 13, 14, 295, 296, "," +266, 5, 7, 67, 15, 19, 297, 301, "Yang" +266, 5, 8, 68, 20, 21, 302, 303, "J" +266, 5, 9, 69, 22, 23, 304, 305, "(" +266, 5, 10, 70, 24, 25, 306, 307, "2" +266, 5, 11, 71, 26, 27, 308, 309, ")" +266, 5, 12, 72, 28, 29, 310, 311, "," +266, 5, 13, 73, 30, 34, 312, 316, "Yang" +266, 5, 14, 74, 35, 36, 317, 318, "G" +266, 5, 15, 75, 37, 38, 319, 320, "(" +266, 5, 16, 76, 39, 40, 321, 322, "3" +266, 5, 17, 77, 41, 42, 323, 324, ")" +266, 5, 18, 78, 43, 44, 325, 326, "," +266, 5, 19, 79, 45, 49, 327, 331, "Gong" +266, 5, 20, 80, 50, 51, 332, 333, "Y" +266, 5, 21, 81, 52, 53, 334, 335, "(" +266, 5, 22, 82, 54, 55, 336, 337, "4" +266, 5, 23, 83, 56, 57, 338, 339, ")" +266, 5, 24, 84, 58, 59, 340, 341, "," +266, 5, 25, 85, 60, 65, 342, 347, "Patel" +266, 5, 26, 86, 66, 67, 348, 349, "S" +266, 5, 27, 87, 68, 69, 350, 351, "(" +266, 5, 28, 88, 70, 71, 352, 353, "5" +266, 5, 29, 89, 72, 73, 354, 355, ")" +266, 5, 30, 90, 74, 75, 356, 357, "," +266, 5, 31, 91, 76, 81, 358, 363, "Zhang" +266, 5, 32, 92, 82, 83, 364, 365, "C" +266, 5, 33, 93, 84, 85, 366, 367, "(" +266, 5, 34, 94, 86, 87, 368, 369, "6" +266, 5, 35, 95, 88, 89, 370, 371, ")" +266, 5, 36, 96, 90, 91, 372, 373, "," +266, 5, 37, 97, 92, 99, 374, 381, "Izumoto" +266, 5, 38, 98, 100, 101, 382, 383, "T" +266, 5, 39, 99, 102, 103, 384, 385, "(" +266, 5, 40, 100, 104, 105, 386, 387, "7" +266, 5, 41, 101, 106, 107, 388, 389, ")" +266, 5, 42, 102, 108, 109, 390, 391, "," +266, 5, 43, 103, 110, 114, 392, 396, "Ning" +266, 5, 44, 104, 115, 116, 397, 398, "G" +266, 5, 45, 105, 117, 118, 399, 400, "(" +266, 5, 46, 106, 119, 120, 401, 402, "1" +266, 5, 47, 107, 121, 122, 403, 404, ")" +266, 5, 48, 108, 123, 124, 405, 406, "." +266, 6, 1, 109, 0, 6, 407, 413, "Author" +266, 6, 2, 110, 7, 18, 414, 425, "information" +266, 6, 3, 111, 19, 20, 426, 427, ":" +266, 6, 4, 112, 21, 22, 428, 429, "(" +266, 6, 5, 113, 23, 24, 430, 431, "1" +266, 6, 6, 114, 25, 26, 432, 433, ")" +266, 6, 7, 115, 27, 33, 434, 440, "Ruijin" +266, 6, 8, 116, 34, 42, 441, 449, "Hospital" +266, 6, 9, 117, 43, 44, 450, 451, "," +266, 6, 10, 118, 45, 53, 452, 460, "Shanghai" +266, 6, 11, 119, 54, 58, 461, 465, "Jiao" +266, 6, 12, 120, 59, 63, 466, 470, "Tong" +266, 6, 13, 121, 64, 74, 471, 481, "University" +266, 6, 14, 122, 75, 81, 482, 488, "School" +266, 6, 15, 123, 82, 84, 489, 491, "of" +266, 6, 16, 124, 85, 93, 492, 500, "Medicine" +266, 6, 17, 125, 94, 95, 501, 502, "," +266, 6, 18, 126, 96, 104, 503, 511, "Shanghai" +266, 6, 19, 127, 105, 106, 512, 513, "," +266, 6, 20, 128, 107, 112, 514, 519, "China" +266, 6, 21, 129, 113, 114, 520, 521, "." +266, 7, 1, 130, 0, 1, 522, 523, "(" +266, 7, 2, 131, 2, 3, 524, 525, "2" +266, 7, 3, 132, 4, 5, 526, 527, ")" +266, 7, 4, 133, 6, 13, 528, 535, "Beijing" +266, 7, 5, 134, 14, 21, 536, 543, "Tongren" +266, 7, 6, 135, 22, 30, 544, 552, "Hospital" +266, 7, 7, 136, 31, 32, 553, 554, "," +266, 7, 8, 137, 33, 40, 555, 562, "Capital" +266, 7, 9, 138, 41, 48, 563, 570, "Medical" +266, 7, 10, 139, 49, 59, 571, 581, "University" +266, 7, 11, 140, 60, 61, 582, 583, "," +266, 7, 12, 141, 62, 69, 584, 591, "Beijing" +266, 7, 13, 142, 70, 71, 592, 593, "," +266, 7, 14, 143, 72, 77, 594, 599, "China" +266, 7, 15, 144, 78, 79, 600, 601, "." +266, 8, 1, 145, 0, 1, 602, 603, "(" +266, 8, 2, 146, 2, 3, 604, 605, "3" +266, 8, 3, 147, 4, 5, 606, 607, ")" +266, 8, 4, 148, 6, 9, 608, 611, "The" +266, 8, 5, 149, 10, 16, 612, 618, "Second" +266, 8, 6, 150, 17, 27, 619, 629, "Affiliated" +266, 8, 7, 151, 28, 36, 630, 638, "Hospital" +266, 8, 8, 152, 37, 38, 639, 640, "," +266, 8, 9, 153, 39, 48, 641, 650, "Chongqing" +266, 8, 10, 154, 49, 56, 651, 658, "Medical" +266, 8, 11, 155, 57, 67, 659, 669, "University" +266, 8, 12, 156, 68, 69, 670, 671, "," +266, 8, 13, 157, 70, 79, 672, 681, "Chongqing" +266, 8, 14, 158, 80, 81, 682, 683, "," +266, 8, 15, 159, 82, 87, 684, 689, "China" +266, 8, 16, 160, 88, 89, 690, 691, "." +266, 9, 1, 161, 0, 1, 692, 693, "(" +266, 9, 2, 162, 2, 3, 694, 695, "4" +266, 9, 3, 163, 4, 5, 696, 697, ")" +266, 9, 4, 164, 6, 16, 698, 708, "Boehringer" +266, 9, 5, 165, 17, 26, 709, 718, "Ingelheim" +266, 9, 6, 166, 27, 33, 719, 725, "Pharma" +266, 9, 7, 167, 34, 35, 726, 727, "," +266, 9, 8, 168, 36, 45, 728, 737, "Ingelheim" +266, 9, 9, 169, 46, 47, 738, 739, "," +266, 9, 10, 170, 48, 55, 740, 747, "Germany" +266, 9, 11, 171, 56, 57, 748, 749, "." +266, 10, 1, 172, 0, 1, 750, 751, "(" +266, 10, 2, 173, 2, 3, 752, 753, "5" +266, 10, 3, 174, 4, 5, 754, 755, ")" +266, 10, 4, 175, 6, 16, 756, 766, "Boehringer" +266, 10, 5, 176, 17, 26, 767, 776, "Ingelheim" +266, 10, 6, 177, 27, 28, 777, 778, "," +266, 10, 7, 178, 29, 38, 779, 788, "Bracknell" +266, 10, 8, 179, 39, 40, 789, 790, "," +266, 10, 9, 180, 41, 43, 791, 793, "UK" +266, 10, 10, 181, 44, 45, 794, 795, "." +266, 11, 1, 182, 0, 1, 796, 797, "(" +266, 11, 2, 183, 2, 3, 798, 799, "6" +266, 11, 3, 184, 4, 5, 800, 801, ")" +266, 11, 4, 185, 6, 16, 802, 812, "Boehringer" +266, 11, 5, 186, 17, 26, 813, 822, "Ingelheim" +266, 11, 6, 187, 27, 40, 823, 836, "International" +266, 11, 7, 188, 41, 48, 837, 844, "Trading" +266, 11, 8, 189, 49, 50, 845, 846, "," +266, 11, 9, 190, 51, 59, 847, 855, "Shanghai" +266, 11, 10, 191, 60, 61, 856, 857, "," +266, 11, 11, 192, 62, 67, 858, 863, "China" +266, 11, 12, 193, 68, 69, 864, 865, "." +266, 12, 1, 194, 0, 1, 866, 867, "(" +266, 12, 2, 195, 2, 3, 868, 869, "7" +266, 12, 3, 196, 4, 5, 870, 871, ")" +266, 12, 4, 197, 6, 12, 872, 878, "Nippon" +266, 12, 5, 198, 13, 23, 879, 889, "Boehringer" +266, 12, 6, 199, 24, 33, 890, 899, "Ingelheim" +266, 12, 7, 200, 34, 35, 900, 901, "," +266, 12, 8, 201, 36, 41, 902, 907, "Tokyo" +266, 12, 9, 202, 42, 43, 908, 909, "," +266, 12, 10, 203, 44, 49, 910, 915, "Japan" +266, 12, 11, 204, 50, 51, 916, 917, "." +266, 13, 1, 205, 0, 10, 918, 928, "BACKGROUND" +266, 13, 2, 206, 11, 12, 929, 930, ":" +266, 13, 3, 207, 13, 20, 931, 938, "Despite" +266, 13, 4, 208, 21, 24, 939, 942, "the" +266, 13, 5, 209, 25, 35, 943, 953, "increasing" +266, 13, 6, 210, 36, 46, 954, 964, "prevalence" +266, 13, 7, 211, 47, 49, 965, 967, "of" +266, 13, 8, 212, 50, 54, 968, 972, "type" +266, 13, 9, 213, 55, 56, 973, 974, "2" +266, 13, 10, 214, 57, 65, 975, 983, "diabetes" +266, 13, 11, 215, 66, 74, 984, 992, "mellitus" +266, 13, 12, 216, 75, 76, 993, 994, "(" +266, 13, 13, 217, 77, 81, 995, 999, "T2DM" +266, 13, 14, 218, 82, 83, 1000, 1001, ")" +266, 13, 15, 219, 84, 86, 1002, 1004, "in" +266, 13, 16, 220, 87, 91, 1005, 1009, "Asia" +266, 13, 17, 221, 92, 93, 1010, 1011, "," +266, 13, 18, 222, 94, 102, 1012, 1020, "clinical" +266, 13, 19, 223, 103, 109, 1021, 1027, "trials" +266, 13, 20, 224, 110, 113, 1028, 1031, "for" +266, 13, 21, 225, 114, 121, 1032, 1039, "glucose" +266, 13, 22, 226, 122, 123, 1040, 1041, "-" +266, 13, 23, 227, 124, 132, 1042, 1050, "lowering" +266, 13, 24, 228, 133, 142, 1051, 1060, "therapies" +266, 13, 25, 229, 143, 146, 1061, 1064, "are" +266, 13, 26, 230, 147, 152, 1065, 1070, "often" +266, 13, 27, 231, 153, 162, 1071, 1080, "dominated" +266, 13, 28, 232, 163, 165, 1081, 1083, "by" +266, 13, 29, 233, 166, 175, 1084, 1093, "Caucasian" +266, 13, 30, 234, 176, 179, 1094, 1097, "and" +266, 13, 31, 235, 180, 181, 1098, 1099, "/" +266, 13, 32, 236, 182, 184, 1100, 1102, "or" +266, 13, 33, 237, 185, 192, 1103, 1110, "Western" +266, 13, 34, 238, 193, 204, 1111, 1122, "populations" +266, 13, 35, 239, 205, 206, 1123, 1124, "." +266, 14, 1, 240, 0, 3, 1125, 1128, "The" +266, 14, 2, 241, 4, 11, 1129, 1136, "present" +266, 14, 3, 242, 12, 17, 1137, 1142, "Phase" +266, 14, 4, 243, 18, 21, 1143, 1146, "III" +266, 14, 5, 244, 22, 32, 1147, 1157, "randomized" +266, 14, 6, 245, 33, 40, 1158, 1165, "placebo" +266, 14, 7, 246, 41, 42, 1166, 1167, "-" +266, 14, 8, 247, 43, 53, 1168, 1178, "controlled" +266, 14, 9, 248, 54, 60, 1179, 1185, "double" +266, 14, 10, 249, 61, 62, 1186, 1187, "-" +266, 14, 11, 250, 63, 68, 1188, 1193, "blind" +266, 14, 12, 251, 69, 70, 1194, 1195, "," +266, 14, 13, 252, 71, 73, 1196, 1198, "24" +266, 14, 14, 253, 74, 75, 1199, 1200, "-" +266, 14, 15, 254, 76, 80, 1201, 1205, "week" +266, 14, 16, 255, 81, 86, 1206, 1211, "study" +266, 14, 17, 256, 87, 96, 1212, 1221, "evaluated" +266, 14, 18, 257, 97, 100, 1222, 1225, "the" +266, 14, 19, 258, 101, 109, 1226, 1234, "efficacy" +266, 14, 20, 259, 110, 113, 1235, 1238, "and" +266, 14, 21, 260, 114, 120, 1239, 1245, "safety" +266, 14, 22, 261, 121, 123, 1246, 1248, "of" +266, 14, 23, 262, 124, 127, 1249, 1252, "the" +266, 14, 24, 263, 128, 138, 1253, 1263, "dipeptidyl" +266, 14, 25, 264, 139, 148, 1264, 1273, "peptidase" +266, 14, 26, 265, 149, 150, 1274, 1275, "-" +266, 14, 27, 266, 151, 152, 1276, 1277, "4" +266, 14, 28, 267, 153, 162, 1278, 1287, "inhibitor" +266, 14, 29, 268, 163, 174, 1288, 1299, "linagliptin" +266, 14, 30, 269, 175, 180, 1300, 1305, "added" +266, 14, 31, 270, 181, 183, 1306, 1308, "to" +266, 14, 32, 271, 184, 193, 1309, 1318, "metformin" +266, 14, 33, 272, 194, 196, 1319, 1321, "in" +266, 14, 34, 273, 197, 202, 1322, 1327, "Asian" +266, 14, 35, 274, 203, 207, 1328, 1332, "T2DM" +266, 14, 36, 275, 208, 216, 1333, 1341, "patients" +266, 14, 37, 276, 217, 218, 1342, 1343, "." +266, 15, 1, 277, 0, 7, 1344, 1351, "METHODS" +266, 15, 2, 278, 8, 9, 1352, 1353, ":" +266, 15, 3, 279, 10, 12, 1354, 1356, "In" +266, 15, 4, 280, 13, 16, 1357, 1360, "all" +266, 15, 5, 281, 17, 18, 1361, 1362, "," +266, 15, 6, 282, 19, 22, 1363, 1366, "306" +266, 15, 7, 283, 23, 31, 1367, 1375, "patients" +266, 15, 8, 284, 32, 33, 1376, 1377, "(" +266, 15, 9, 285, 34, 35, 1378, 1379, "n" +266, 15, 10, 286, 36, 39, 1380, 1383, " = " +266, 15, 11, 287, 40, 43, 1384, 1387, "265" +266, 15, 12, 288, 44, 51, 1388, 1395, "Chinese" +266, 15, 13, 289, 52, 53, 1396, 1397, ";" +266, 15, 14, 290, 54, 55, 1398, 1399, "n" +266, 15, 15, 291, 56, 59, 1400, 1403, " = " +266, 15, 16, 292, 60, 62, 1404, 1406, "24" +266, 15, 17, 293, 63, 72, 1407, 1416, "Malaysian" +266, 15, 18, 294, 73, 74, 1417, 1418, ";" +266, 15, 19, 295, 75, 76, 1419, 1420, "n" +266, 15, 20, 296, 77, 80, 1421, 1424, " = " +266, 15, 21, 297, 81, 83, 1425, 1427, "17" +266, 15, 22, 298, 84, 92, 1428, 1436, "Filipino" +266, 15, 23, 299, 93, 94, 1437, 1438, ")" +266, 15, 24, 300, 95, 96, 1439, 1440, "," +266, 15, 25, 301, 97, 101, 1441, 1445, "aged" +266, 15, 26, 302, 102, 104, 1446, 1448, "18" +266, 15, 27, 303, 105, 106, 1449, 1450, "-" +266, 15, 28, 304, 107, 109, 1451, 1453, "80" +266, 15, 29, 305, 110, 115, 1454, 1459, "years" +266, 15, 30, 306, 116, 120, 1460, 1464, "with" +266, 15, 31, 307, 121, 126, 1465, 1470, "HbA1c" +266, 15, 32, 308, 127, 134, 1471, 1478, "between" +266, 15, 33, 309, 135, 136, 1479, 1480, "≥" +266, 15, 34, 310, 137, 138, 1481, 1482, "7" +266, 15, 35, 311, 139, 140, 1483, 1484, "." +266, 15, 36, 312, 141, 142, 1485, 1486, "0" +266, 15, 37, 313, 143, 146, 1487, 1490, "and" +266, 15, 38, 314, 147, 148, 1491, 1492, "≤" +266, 15, 39, 315, 149, 151, 1493, 1495, "10" +266, 15, 40, 316, 152, 153, 1496, 1497, "." +266, 15, 41, 317, 154, 155, 1498, 1499, "0" +266, 15, 42, 318, 156, 157, 1500, 1501, "%" +266, 15, 43, 319, 158, 161, 1502, 1505, "and" +266, 15, 44, 320, 162, 164, 1506, 1508, "on" +266, 15, 45, 321, 165, 174, 1509, 1518, "metformin" +266, 15, 46, 322, 175, 182, 1519, 1526, "therapy" +266, 15, 47, 323, 183, 187, 1527, 1531, "were" +266, 15, 48, 324, 188, 198, 1532, 1542, "randomized" +266, 15, 49, 325, 199, 200, 1543, 1544, "(" +266, 15, 50, 326, 201, 202, 1545, 1546, "2" +266, 15, 51, 327, 203, 204, 1547, 1548, ":" +266, 15, 52, 328, 205, 206, 1549, 1550, "1" +266, 15, 53, 329, 207, 208, 1551, 1552, ")" +266, 15, 54, 330, 209, 211, 1553, 1555, "to" +266, 15, 55, 331, 212, 218, 1556, 1562, "either" +266, 15, 56, 332, 219, 230, 1563, 1574, "linagliptin" +266, 15, 57, 333, 231, 232, 1575, 1576, "5" +266, 15, 58, 334, 233, 234, 1577, 1578, " " +266, 15, 59, 335, 235, 237, 1579, 1581, "mg" +266, 15, 60, 336, 238, 243, 1582, 1587, "daily" +266, 15, 61, 337, 244, 246, 1588, 1590, "or" +266, 15, 62, 338, 247, 254, 1591, 1598, "placebo" +266, 15, 63, 339, 255, 260, 1599, 1604, "added" +266, 15, 64, 340, 261, 263, 1605, 1607, "to" +266, 15, 65, 341, 264, 273, 1608, 1617, "metformin" +266, 15, 66, 342, 274, 275, 1618, 1619, "." +266, 16, 1, 343, 0, 12, 1620, 1632, "Antidiabetes" +266, 16, 2, 344, 13, 18, 1633, 1638, "drugs" +266, 16, 3, 345, 19, 24, 1639, 1644, "other" +266, 16, 4, 346, 25, 29, 1645, 1649, "than" +266, 16, 5, 347, 30, 39, 1650, 1659, "metformin" +266, 16, 6, 348, 40, 44, 1660, 1664, "were" +266, 16, 7, 349, 45, 51, 1665, 1671, "washed" +266, 16, 8, 350, 52, 55, 1672, 1675, "out" +266, 16, 9, 351, 56, 61, 1676, 1681, "prior" +266, 16, 10, 352, 62, 64, 1682, 1684, "to" +266, 16, 11, 353, 65, 78, 1685, 1698, "randomization" +266, 16, 12, 354, 79, 80, 1699, 1700, "." +266, 17, 1, 355, 0, 3, 1701, 1704, "The" +266, 17, 2, 356, 4, 11, 1705, 1712, "primary" +266, 17, 3, 357, 12, 20, 1713, 1721, "endpoint" +266, 17, 4, 358, 21, 24, 1722, 1725, "was" +266, 17, 5, 359, 25, 31, 1726, 1732, "change" +266, 17, 6, 360, 32, 34, 1733, 1735, "in" +266, 17, 7, 361, 35, 39, 1736, 1740, "mean" +266, 17, 8, 362, 40, 45, 1741, 1746, "HbA1c" +266, 17, 9, 363, 46, 50, 1747, 1751, "from" +266, 17, 10, 364, 51, 59, 1752, 1760, "baseline" +266, 17, 11, 365, 60, 65, 1761, 1766, "after" +266, 17, 12, 366, 66, 68, 1767, 1769, "24" +266, 17, 13, 367, 69, 74, 1770, 1775, "weeks" +266, 17, 14, 368, 75, 76, 1776, 1777, "." +266, 18, 1, 369, 0, 7, 1778, 1785, "RESULTS" +266, 18, 2, 370, 8, 9, 1786, 1787, ":" +266, 18, 3, 371, 10, 18, 1788, 1796, "Baseline" +266, 18, 4, 372, 19, 34, 1797, 1812, "characteristics" +266, 18, 5, 373, 35, 39, 1813, 1817, "were" +266, 18, 6, 374, 40, 44, 1818, 1822, "well" +266, 18, 7, 375, 45, 46, 1823, 1824, "-" +266, 18, 8, 376, 47, 54, 1825, 1832, "matched" +266, 18, 9, 377, 55, 62, 1833, 1840, "between" +266, 18, 10, 378, 63, 66, 1841, 1844, "the" +266, 18, 11, 379, 67, 73, 1845, 1851, "groups" +266, 18, 12, 380, 74, 75, 1852, 1853, "(" +266, 18, 13, 381, 76, 83, 1854, 1861, "overall" +266, 18, 14, 382, 84, 88, 1862, 1866, "mean" +266, 18, 15, 383, 89, 91, 1867, 1869, "[±" +266, 18, 16, 384, 92, 94, 1870, 1872, "SD" +266, 18, 17, 385, 95, 96, 1873, 1874, "]" +266, 18, 18, 386, 97, 102, 1875, 1880, "HbA1c" +266, 18, 19, 387, 103, 104, 1881, 1882, "8" +266, 18, 20, 388, 105, 106, 1883, 1884, "." +266, 18, 21, 389, 107, 108, 1885, 1886, "0" +266, 18, 22, 390, 109, 112, 1887, 1890, " ± " +266, 18, 23, 391, 113, 114, 1891, 1892, "0" +266, 18, 24, 392, 115, 116, 1893, 1894, "." +266, 18, 25, 393, 117, 118, 1895, 1896, "8" +266, 18, 26, 394, 119, 120, 1897, 1898, "%" +266, 18, 27, 395, 121, 122, 1899, 1900, ")" +266, 18, 28, 396, 123, 124, 1901, 1902, "." +266, 19, 1, 397, 0, 8, 1903, 1911, "Adjusted" +266, 19, 2, 398, 9, 13, 1912, 1916, "mean" +266, 19, 3, 399, 14, 15, 1917, 1918, "(" +266, 19, 4, 400, 16, 17, 1919, 1920, "±" +266, 19, 5, 401, 18, 20, 1921, 1923, "SE" +266, 19, 6, 402, 21, 22, 1924, 1925, ")" +266, 19, 7, 403, 23, 28, 1926, 1931, "HbA1c" +266, 19, 8, 404, 29, 38, 1932, 1941, "decreased" +266, 19, 9, 405, 39, 41, 1942, 1944, "in" +266, 19, 10, 406, 42, 45, 1945, 1948, "the" +266, 19, 11, 407, 46, 57, 1949, 1960, "linagliptin" +266, 19, 12, 408, 58, 61, 1961, 1964, "and" +266, 19, 13, 409, 62, 69, 1965, 1972, "placebo" +266, 19, 14, 410, 70, 76, 1973, 1979, "groups" +266, 19, 15, 411, 77, 79, 1980, 1982, "by" +266, 19, 16, 412, 80, 81, 1983, 1984, "-" +266, 19, 17, 413, 82, 83, 1985, 1986, "0" +266, 19, 18, 414, 84, 85, 1987, 1988, "." +266, 19, 19, 415, 86, 88, 1989, 1991, "66" +266, 19, 20, 416, 89, 92, 1992, 1995, " ± " +266, 19, 21, 417, 93, 94, 1996, 1997, "0" +266, 19, 22, 418, 95, 96, 1998, 1999, "." +266, 19, 23, 419, 97, 99, 2000, 2002, "05" +266, 19, 24, 420, 100, 103, 2003, 2006, "and" +266, 19, 25, 421, 104, 105, 2007, 2008, "-" +266, 19, 26, 422, 106, 107, 2009, 2010, "0" +266, 19, 27, 423, 108, 109, 2011, 2012, "." +266, 19, 28, 424, 110, 112, 2013, 2015, "14" +266, 19, 29, 425, 113, 116, 2016, 2019, " ± " +266, 19, 30, 426, 117, 118, 2020, 2021, "0" +266, 19, 31, 427, 119, 120, 2022, 2023, "." +266, 19, 32, 428, 121, 123, 2024, 2026, "07" +266, 19, 33, 429, 124, 125, 2027, 2028, "%" +266, 19, 34, 430, 126, 127, 2029, 2030, "," +266, 19, 35, 431, 128, 140, 2031, 2043, "respectively" +266, 19, 36, 432, 141, 142, 2044, 2045, "(" +266, 19, 37, 433, 143, 150, 2046, 2053, "placebo" +266, 19, 38, 434, 151, 152, 2054, 2055, "-" +266, 19, 39, 435, 153, 162, 2056, 2065, "corrected" +266, 19, 40, 436, 163, 173, 2066, 2076, "difference" +266, 19, 41, 437, 174, 175, 2077, 2078, "-" +266, 19, 42, 438, 176, 177, 2079, 2080, "0" +266, 19, 43, 439, 178, 179, 2081, 2082, "." +266, 19, 44, 440, 180, 182, 2083, 2085, "52" +266, 19, 45, 441, 183, 186, 2086, 2089, " ± " +266, 19, 46, 442, 187, 188, 2090, 2091, "0" +266, 19, 47, 443, 189, 190, 2092, 2093, "." +266, 19, 48, 444, 191, 193, 2094, 2096, "09" +266, 19, 49, 445, 194, 195, 2097, 2098, "%" +266, 19, 50, 446, 196, 197, 2099, 2100, ";" +266, 19, 51, 447, 198, 200, 2101, 2103, "95" +266, 19, 52, 448, 201, 202, 2104, 2105, "%" +266, 19, 53, 449, 203, 213, 2106, 2116, "confidence" +266, 19, 54, 450, 214, 222, 2117, 2125, "interval" +266, 19, 55, 451, 223, 224, 2126, 2127, "[" +266, 19, 56, 452, 225, 227, 2128, 2130, "CI" +266, 19, 57, 453, 228, 229, 2131, 2132, "]" +266, 19, 58, 454, 230, 231, 2133, 2134, "-" +266, 19, 59, 455, 232, 233, 2135, 2136, "0" +266, 19, 60, 456, 234, 235, 2137, 2138, "." +266, 19, 61, 457, 236, 238, 2139, 2141, "70" +266, 19, 62, 458, 239, 240, 2142, 2143, "," +266, 19, 63, 459, 241, 242, 2144, 2145, "-" +266, 19, 64, 460, 243, 244, 2146, 2147, "0" +266, 19, 65, 461, 245, 246, 2148, 2149, "." +266, 19, 66, 462, 247, 249, 2150, 2152, "34" +266, 19, 67, 463, 250, 251, 2153, 2154, ";" +266, 19, 68, 464, 252, 253, 2155, 2156, "P" +266, 19, 69, 465, 254, 257, 2157, 2160, " < " +266, 19, 70, 466, 258, 259, 2161, 2162, "0" +266, 19, 71, 467, 260, 261, 2163, 2164, "." +266, 19, 72, 468, 262, 266, 2165, 2169, "0001" +266, 19, 73, 469, 267, 268, 2170, 2171, ")" +266, 19, 74, 470, 269, 270, 2172, 2173, "." +266, 20, 1, 471, 0, 2, 2174, 2176, "In" +266, 20, 2, 472, 3, 11, 2177, 2185, "patients" +266, 20, 3, 473, 12, 16, 2186, 2190, "with" +266, 20, 4, 474, 17, 25, 2191, 2199, "baseline" +266, 20, 5, 475, 26, 31, 2200, 2205, "HbA1c" +266, 20, 6, 476, 32, 33, 2206, 2207, "≥" +266, 20, 7, 477, 34, 35, 2208, 2209, "8" +266, 20, 8, 478, 36, 37, 2210, 2211, "." +266, 20, 9, 479, 38, 39, 2212, 2213, "5" +266, 20, 10, 480, 40, 41, 2214, 2215, "%" +266, 20, 11, 481, 42, 43, 2216, 2217, "," +266, 20, 12, 482, 44, 47, 2218, 2221, "the" +266, 20, 13, 483, 48, 55, 2222, 2229, "placebo" +266, 20, 14, 484, 56, 57, 2230, 2231, "-" +266, 20, 15, 485, 58, 67, 2232, 2241, "corrected" +266, 20, 16, 486, 68, 76, 2242, 2250, "decrease" +266, 20, 17, 487, 77, 79, 2251, 2253, "in" +266, 20, 18, 488, 80, 85, 2254, 2259, "HbA1c" +266, 20, 19, 489, 86, 89, 2260, 2263, "was" +266, 20, 20, 490, 90, 91, 2264, 2265, "-" +266, 20, 21, 491, 92, 93, 2266, 2267, "0" +266, 20, 22, 492, 94, 95, 2268, 2269, "." +266, 20, 23, 493, 96, 98, 2270, 2272, "89" +266, 20, 24, 494, 99, 102, 2273, 2276, " ± " +266, 20, 25, 495, 103, 104, 2277, 2278, "0" +266, 20, 26, 496, 105, 106, 2279, 2280, "." +266, 20, 27, 497, 107, 109, 2281, 2283, "17" +266, 20, 28, 498, 110, 111, 2284, 2285, "%" +266, 20, 29, 499, 112, 113, 2286, 2287, "(" +266, 20, 30, 500, 114, 115, 2288, 2289, "P" +266, 20, 31, 501, 116, 119, 2290, 2293, " < " +266, 20, 32, 502, 120, 121, 2294, 2295, "0" +266, 20, 33, 503, 122, 123, 2296, 2297, "." +266, 20, 34, 504, 124, 128, 2298, 2302, "0001" +266, 20, 35, 505, 129, 130, 2303, 2304, ")" +266, 20, 36, 506, 131, 132, 2305, 2306, "." +266, 21, 1, 507, 0, 7, 2307, 2314, "Adverse" +266, 21, 2, 508, 8, 14, 2315, 2321, "events" +266, 21, 3, 509, 15, 23, 2322, 2330, "occurred" +266, 21, 4, 510, 24, 26, 2331, 2333, "in" +266, 21, 5, 511, 27, 34, 2334, 2341, "similar" +266, 21, 6, 512, 35, 46, 2342, 2353, "proportions" +266, 21, 7, 513, 47, 49, 2354, 2356, "in" +266, 21, 8, 514, 50, 53, 2357, 2360, "the" +266, 21, 9, 515, 54, 65, 2361, 2372, "linagliptin" +266, 21, 10, 516, 66, 69, 2373, 2376, "and" +266, 21, 11, 517, 70, 77, 2377, 2384, "placebo" +266, 21, 12, 518, 78, 86, 2385, 2393, "patients" +266, 21, 13, 519, 87, 88, 2394, 2395, "(" +266, 21, 14, 520, 89, 91, 2396, 2398, "27" +266, 21, 15, 521, 92, 93, 2399, 2400, "." +266, 21, 16, 522, 94, 95, 2401, 2402, "3" +266, 21, 17, 523, 96, 97, 2403, 2404, "%" +266, 21, 18, 524, 98, 101, 2405, 2408, "and" +266, 21, 19, 525, 102, 104, 2409, 2411, "28" +266, 21, 20, 526, 105, 106, 2412, 2413, "." +266, 21, 21, 527, 107, 108, 2414, 2415, "0" +266, 21, 22, 528, 109, 110, 2416, 2417, "%" +266, 21, 23, 529, 111, 112, 2418, 2419, "," +266, 21, 24, 530, 113, 125, 2420, 2432, "respectively" +266, 21, 25, 531, 126, 127, 2433, 2434, ")" +266, 21, 26, 532, 128, 131, 2435, 2438, "and" +266, 21, 27, 533, 132, 135, 2439, 2442, "few" +266, 21, 28, 534, 136, 140, 2443, 2447, "were" +266, 21, 29, 535, 141, 151, 2448, 2458, "considered" +266, 21, 30, 536, 152, 156, 2459, 2463, "drug" +266, 21, 31, 537, 157, 158, 2464, 2465, "-" +266, 21, 32, 538, 159, 166, 2466, 2473, "related" +266, 21, 33, 539, 167, 168, 2474, 2475, "(" +266, 21, 34, 540, 169, 170, 2476, 2477, "2" +266, 21, 35, 541, 171, 172, 2478, 2479, "." +266, 21, 36, 542, 173, 174, 2480, 2481, "4" +266, 21, 37, 543, 175, 176, 2482, 2483, "%" +266, 21, 38, 544, 177, 180, 2484, 2487, "and" +266, 21, 39, 545, 181, 182, 2488, 2489, "0" +266, 21, 40, 546, 183, 184, 2490, 2491, "." +266, 21, 41, 547, 185, 186, 2492, 2493, "0" +266, 21, 42, 548, 187, 188, 2494, 2495, "%" +266, 21, 43, 549, 189, 190, 2496, 2497, "," +266, 21, 44, 550, 191, 203, 2498, 2510, "respectively" +266, 21, 45, 551, 204, 205, 2511, 2512, ")" +266, 21, 46, 552, 206, 207, 2513, 2514, "." +266, 22, 1, 553, 0, 12, 2515, 2527, "Hypoglycemia" +266, 22, 2, 554, 13, 21, 2528, 2536, "occurred" +266, 22, 3, 555, 22, 24, 2537, 2539, "in" +266, 22, 4, 556, 25, 26, 2540, 2541, "1" +266, 22, 5, 557, 27, 28, 2542, 2543, "." +266, 22, 6, 558, 29, 30, 2544, 2545, "0" +266, 22, 7, 559, 31, 32, 2546, 2547, "%" +266, 22, 8, 560, 33, 35, 2548, 2550, "of" +266, 22, 9, 561, 36, 44, 2551, 2559, "patients" +266, 22, 10, 562, 45, 47, 2560, 2562, "in" +266, 22, 11, 563, 48, 52, 2563, 2567, "both" +266, 22, 12, 564, 53, 59, 2568, 2574, "groups" +266, 22, 13, 565, 60, 61, 2575, 2576, "." +266, 23, 1, 566, 0, 11, 2577, 2588, "Linagliptin" +266, 23, 2, 567, 12, 19, 2589, 2596, "therapy" +266, 23, 3, 568, 20, 23, 2597, 2600, "was" +266, 23, 4, 569, 24, 30, 2601, 2607, "weight" +266, 23, 5, 570, 31, 38, 2608, 2615, "neutral" +266, 23, 6, 571, 39, 40, 2616, 2617, "." +266, 24, 1, 572, 0, 11, 2618, 2629, "CONCLUSIONS" +266, 24, 2, 573, 12, 13, 2630, 2631, ":" +266, 24, 3, 574, 14, 25, 2632, 2643, "Linagliptin" +266, 24, 4, 575, 26, 27, 2644, 2645, "5" +266, 24, 5, 576, 28, 29, 2646, 2647, " " +266, 24, 6, 577, 30, 32, 2648, 2650, "mg" +266, 24, 7, 578, 33, 36, 2651, 2654, "was" +266, 24, 8, 579, 37, 48, 2655, 2666, "efficacious" +266, 24, 9, 580, 49, 52, 2667, 2670, "and" +266, 24, 10, 581, 53, 57, 2671, 2675, "well" +266, 24, 11, 582, 58, 67, 2676, 2685, "tolerated" +266, 24, 12, 583, 68, 72, 2686, 2690, "over" +266, 24, 13, 584, 73, 75, 2691, 2693, "24" +266, 24, 14, 585, 76, 81, 2694, 2699, "weeks" +266, 24, 15, 586, 82, 84, 2700, 2702, "in" +266, 24, 16, 587, 85, 90, 2703, 2708, "Asian" +266, 24, 17, 588, 91, 99, 2709, 2717, "patients" +266, 24, 18, 589, 100, 104, 2718, 2722, "with" +266, 24, 19, 590, 105, 109, 2723, 2727, "T2DM" +266, 24, 20, 591, 110, 122, 2728, 2740, "inadequately" +266, 24, 21, 592, 123, 133, 2741, 2751, "controlled" +266, 24, 22, 593, 134, 136, 2752, 2754, "by" +266, 24, 23, 594, 137, 146, 2755, 2764, "metformin" +266, 24, 24, 595, 147, 148, 2765, 2766, "." +266, 25, 1, 596, 0, 1, 2767, 2768, "©" +266, 25, 2, 597, 2, 6, 2769, 2773, "2015" +266, 25, 3, 598, 7, 13, 2774, 2780, "Ruijin" +266, 25, 4, 599, 14, 22, 2781, 2789, "Hospital" +266, 25, 5, 600, 23, 24, 2790, 2791, "," +266, 25, 6, 601, 25, 33, 2792, 2800, "Shanghai" +266, 25, 7, 602, 34, 42, 2801, 2809, "Jiaotong" +266, 25, 8, 603, 43, 53, 2810, 2820, "University" +266, 25, 9, 604, 54, 60, 2821, 2827, "School" +266, 25, 10, 605, 61, 63, 2828, 2830, "of" +266, 25, 11, 606, 64, 72, 2831, 2839, "Medicine" +266, 25, 12, 607, 73, 76, 2840, 2843, "and" +266, 25, 13, 608, 77, 82, 2844, 2849, "Wiley" +266, 25, 14, 609, 83, 93, 2850, 2860, "Publishing" +266, 25, 15, 610, 94, 98, 2861, 2865, "Asia" +266, 25, 16, 611, 99, 102, 2866, 2869, "Pty" +266, 25, 17, 612, 103, 106, 2870, 2873, "Ltd" +266, 25, 18, 613, 107, 108, 2874, 2875, "." +266, 25, 19, 614, 109, 112, 2876, 2879, "DOI" +266, 25, 20, 615, 113, 114, 2880, 2881, ":" +266, 25, 21, 616, 115, 117, 2882, 2884, "10" +266, 25, 22, 617, 118, 119, 2885, 2886, "." +266, 25, 23, 618, 120, 124, 2887, 2891, "1111" +266, 25, 24, 619, 125, 126, 2892, 2893, "/" +266, 25, 25, 620, 127, 131, 2894, 2898, "1753" +266, 25, 26, 621, 132, 133, 2899, 2900, "-" +266, 25, 27, 622, 134, 138, 2901, 2905, "0407" +266, 25, 28, 623, 139, 140, 2906, 2907, "." +266, 25, 29, 624, 141, 146, 2908, 2913, "12284" +266, 25, 30, 625, 147, 151, 2914, 2918, "PMID" +266, 25, 31, 626, 152, 153, 2919, 2920, ":" +266, 25, 32, 627, 154, 162, 2921, 2929, "25753488" +266, 25, 33, 628, 163, 164, 2930, 2931, "[" +266, 25, 34, 629, 165, 172, 2932, 2939, "Indexed" +266, 25, 35, 630, 173, 176, 2940, 2943, "for" +266, 25, 36, 631, 177, 184, 2944, 2951, "MEDLINE" +266, 25, 37, 632, 185, 186, 2952, 2953, "]" diff --git a/data/dm2 25753488_kwoodley.annodb b/data/dm2 25753488_kwoodley.annodb new file mode 100644 index 0000000..f1d834c --- /dev/null +++ b/data/dm2 25753488_kwoodley.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +53403, Journal, 0, 10, "J Diabetes", "", +53404, PublicationYear, 13, 17, "2016", "", +53433, Title, 104, 281, "Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .", "", +53405, Linagliptin, 127, 138, "linagliptin", "", +53429, Ethnicity, 142, 147, "Asian", "", +53413, Type2Diabetes, 162, 186, "type 2 diabetes mellitus", "", +53418, Metformin, 214, 223, "metformin", "", +53424, Multicenter, 228, 241, "multinational", "", +53425, Duration, 242, 251, "24 - week", "", +53426, Randomized, 254, 264, "randomized", "", +53434, Author, 282, 288, "Wang W", "", +53435, Author, 297, 303, "Yang J", "", +53436, Author, 312, 318, "Yang G", "", +53437, Author, 327, 333, "Gong Y", "", +53438, Author, 342, 349, "Patel S", "", +53439, Author, 358, 365, "Zhang C", "", +53440, Author, 374, 383, "Izumoto T", "", +53441, Author, 392, 398, "Ning G", "", +53442, China, 514, 519, "China", "", +53443, China, 594, 599, "China", "", +53444, China, 684, 689, "China", "", +53446, Germany, 740, 747, "Germany", "", +53447, UK, 791, 793, "UK", "", +53445, China, 858, 863, "China", "", +53448, Japan, 910, 915, "Japan", "", +53416, Type2Diabetes, 968, 992, "type 2 diabetes mellitus", "", +53415, Type2Diabetes, 995, 999, "T2DM", "", +53458, ObjectiveDescription, 1125, 1343, "The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .", "", +53428, Randomized, 1147, 1157, "randomized", "", +53449, Placebo, 1158, 1165, "placebo", "", +53455, DoubleBlind, 1179, 1193, "double - blind", "", +53456, Duration, 1196, 1205, "24 - week", "", +53406, Linagliptin, 1288, 1299, "linagliptin", "", +53419, Metformin, 1309, 1318, "metformin", "", +53457, Ethnicity, 1322, 1327, "Asian", "", +53414, Type2Diabetes, 1328, 1332, "T2DM", "", +53459, NumberPatientsCT, 1363, 1366, "306", "", +53468, Precondition, 1367, 1526, "patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy", "", +53430, Ethnicity, 1388, 1395, "Chinese", "", +53431, Ethnicity, 1407, 1416, "Malaysian", "", +53432, Ethnicity, 1428, 1436, "Filipino", "", +53460, MinAge, 1446, 1448, "18", "", +53461, MaxAge, 1451, 1453, "80", "", +53462, HbA1c, 1465, 1470, "HbA1c", "", +53463, Percentage, 1500, 1501, "%", "", +53420, Metformin, 1509, 1518, "metformin", "", +53427, Randomized, 1532, 1542, "randomized", "", +53464, AllocationRatio, 1545, 1550, "2 : 1", "", +53407, Linagliptin, 1563, 1574, "linagliptin", "", +53465, DoseValue, 1575, 1576, "5", "", +53466, mg, 1579, 1581, "mg", "", +53467, Frequency, 1582, 1587, "daily", "", +53450, Placebo, 1591, 1598, "placebo", "", +53421, Metformin, 1608, 1617, "metformin", "", +53469, DoseDescription, 1620, 1700, "Antidiabetes drugs other than metformin were washed out prior to randomization .", "", +53422, Metformin, 1650, 1659, "metformin", "", +53470, HbA1c, 1741, 1746, "HbA1c", "", +53471, TimePoint, 1752, 1760, "baseline", "", +53472, TimePoint, 1767, 1775, "24 weeks", "", +53474, Mean, 1862, 1874, "mean [± SD ]", "", +53473, HbA1c, 1875, 1880, "HbA1c", "", +53475, BaseLineValue, 1881, 1886, "8 . 0", "", +53476, SdDevBL, 1891, 1896, "0 . 8", "", +53477, Percentage, 1897, 1898, "%", "", +53478, Mean, 1912, 1925, "mean ( ± SE )", "", +53479, HbA1c, 1926, 1931, "HbA1c", "", +53408, Linagliptin, 1949, 1960, "linagliptin", "", +53452, Placebo, 1965, 1972, "placebo", "", +53480, Reduction, 1985, 1991, "0 . 66", "", +53482, SdErrorChangeValue, 1996, 2002, "0 . 05", "", +53481, Reduction, 2009, 2015, "0 . 14", "", +53483, SdErrorChangeValue, 2020, 2026, "0 . 07", "", +53485, Percentage, 2027, 2028, "%", "", +53451, Placebo, 2046, 2053, "placebo", "", +53487, DiffGroupAbsValue, 2077, 2085, "- 0 . 52", "", +53488, SdErrorDiff, 2090, 2096, "0 . 09", "", +53486, Percentage, 2097, 2098, "%", "", +53489, ConfIntervalDiff, 2101, 2152, "95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34", "", +53490, PvalueDiff, 2155, 2169, "P  <  0 . 0001", "", +53491, SubGroupDescription, 2191, 2215, "baseline HbA1c ≥ 8 . 5 %", "", +53453, Placebo, 2222, 2229, "placebo", "", +53492, HbA1c, 2254, 2259, "HbA1c", "", +53493, Reduction, 2266, 2272, "0 . 89", "", +53494, SdErrorChangeValue, 2277, 2283, "0 . 17", "", +53495, Percentage, 2284, 2285, "%", "", +53496, PValueChangeValue, 2288, 2302, "P  <  0 . 0001", "", +53497, EndPointDescription, 2307, 2321, "Adverse events", "", +53409, Linagliptin, 2361, 2372, "linagliptin", "", +53454, Placebo, 2377, 2384, "placebo", "", +53499, PercentageAffected, 2396, 2402, "27 . 3", "", +53500, PercentageAffected, 2409, 2415, "28 . 0", "", +53498, SubGroupDescription, 2439, 2473, "few were considered drug - related", "", +53501, PercentageAffected, 2476, 2481, "2 . 4", "", +53502, PercentageAffected, 2488, 2493, "0 . 0", "", +53504, Hypoglycemia, 2515, 2527, "Hypoglycemia", "", +53503, PercentageAffected, 2540, 2545, "1 . 0", "", +53506, ObservedResult, 2577, 2617, "Linagliptin therapy was weight neutral .", "", +53410, Linagliptin, 2577, 2588, "Linagliptin", "", +53505, BodyWeight, 2601, 2607, "weight", "", +53512, ConclusionComment, 2632, 2766, "Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .", "", +53411, Linagliptin, 2632, 2643, "Linagliptin", "", +53507, DoseValue, 2644, 2645, "5", "", +53508, mg, 2648, 2650, "mg", "", +53509, Duration, 2691, 2699, "24 weeks", "", +53510, Ethnicity, 2703, 2708, "Asian", "", +53511, Precondition, 2709, 2764, "patients with T2DM inadequately controlled by metformin", "", +53417, Type2Diabetes, 2723, 2727, "T2DM", "", +53423, Metformin, 2755, 2764, "metformin", "", +53513, PMID, 2921, 2929, "25753488", "", diff --git a/data/dm2 25753488_kwoodley.n-triples b/data/dm2 25753488_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 25753488_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26067186_admin.annodb b/data/dm2 26067186_admin.annodb new file mode 100644 index 0000000..e2f2b8d --- /dev/null +++ b/data/dm2 26067186_admin.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabetologia", "", " \"Diabetologia\"." +1, PublicationYear, 15, 19, "2015", "", " \"2015\"." +22, Title, 111, 246, "Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .", "", " \"Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .\"." +2, Vildagliptin, 125, 137, "vildagliptin", "", +9, Sitagliptin, 142, 153, "sitagliptin", "", +16, Type2Diabetes, 171, 186, "type 2 diabetes", "", " ." +93450, DisorderOrSyndrome, 198, 214, "renal impairment", "", " . ." +19, Randomized, 219, 229, "randomised", "", +23, Author, 247, 255, "Kothny W", "", " \"Kothny W\"." +24, Author, 264, 277, "Lukashevich V", "", " \"Lukashevich V\"." +25, Author, 280, 288, "Foley JE", "", " \"Foley JE\"." +26, Author, 291, 301, "Rendell MS", "", " \"Rendell MS\"." +27, Author, 304, 315, "Schweizer A", "", " \"Schweizer A\"." +28, Switzerland, 397, 408, "Switzerland", "", +31, ObjectiveDescription, 560, 697, "We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .", "", " \"We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .\"." +3, Vildagliptin, 599, 611, "vildagliptin", "", +10, Sitagliptin, 616, 627, "sitagliptin", "", +29, Precondition, 631, 695, "patients with type 2 diabetes and severe renal impairment ( RI )", "", " \"patients with type 2 diabetes and severe renal impairment ( RI )\"." +17, Type2Diabetes, 645, 660, "type 2 diabetes", "", +93449, DisorderOrSyndrome, 672, 688, "renal impairment", "", +32, Parallel, 725, 739, "parallel - arm", "", " ." +20, Randomized, 742, 752, "randomised", "", +33, Multicenter, 755, 766, "multicentre", "", +34, DoubleBlind, 769, 783, "double - blind", "", " ." +35, Duration, 786, 793, "24 week", "", " \"24 week\"." +121, Multicenter, 813, 849, "87 centres across Brazil and the USA", "", " ." +36, Brazil, 831, 837, "Brazil", "", +37, USA, 846, 849, "USA", "", +93444, Precondition, 852, 986, "Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control", "", " \"Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control\"." +18, Type2Diabetes, 866, 881, "type 2 diabetes", "", +38, HbA1c, 989, 994, "HbA1c", "", +41, Percentage, 1010, 1011, "%", "", +130, ConcentrationUnit, 1022, 1032, "mmol / mol", "", +93448, Precondition, 1044, 1069, "estimated GFR < 30 ml min", "", " \"estimated GFR < 30 ml min\"." +43, BioAndMedicalUnit, 1063, 1069, "ml min", "", +44, BioAndMedicalUnit, 1087, 1088, "m", "", +21, Randomized, 1104, 1114, "randomised", "", +4, Vildagliptin, 1164, 1176, "vildagliptin", "", " ." +46, DoseValue, 1177, 1179, "50", "", " \"50\"." +48, mg, 1180, 1182, "mg", "", " ." +50, Frequency, 1183, 1193, "once daily", "", " \"once daily\"." +11, Sitagliptin, 1197, 1208, "sitagliptin", "", " ." +47, DoseValue, 1209, 1211, "25", "", " \"25\"." +49, mg, 1212, 1214, "mg", "", " ." +51, Frequency, 1215, 1225, "once daily", "", " \"once daily\"." +40, HbA1c, 1438, 1443, "HbA1c", "", +52, FastingPlasmaGlucose, 1448, 1470, "fasting plasma glucose", "", +53, FastingPlasmaGlucose, 1473, 1476, "FPG", "", +55, EndPointDescription, 1564, 1578, "adverse events", "", +56, NumberPatientsCT, 1602, 1605, "148", "", " \"148\"." +57, Randomized, 1620, 1630, "randomised", "", +58, NumberPatientsArm, 1633, 1635, "83", "", " \"83\"." +5, Vildagliptin, 1639, 1651, "vildagliptin", "", +59, NumberPatientsArm, 1656, 1658, "65", "", " \"65\"." +12, Sitagliptin, 1662, 1673, "sitagliptin", "", +60, TimePoint, 1711, 1719, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +152, Mean, 1735, 1739, "mean", "", " . ." +39, HbA1c, 1750, 1755, "HbA1c", "", " ." +62, Reduction, 1762, 1768, "0 . 54", "", " \"0 . 54\"." +67, Percentage, 1769, 1770, "%", "", " ." +64, Reduction, 1773, 1778, "5 . 9", "", +164, ConcentrationUnit, 1779, 1789, "mmol / mol", "", +61, TimePoint, 1799, 1807, "baseline", "", +73, BaseLineValue, 1811, 1817, "7 . 52", "", " \"7 . 52\"." +77, Percentage, 1818, 1819, "%", "", +76, BaseLineValue, 1822, 1824, "59", "", +165, ConcentrationUnit, 1825, 1835, "mmol / mol", "", +6, Vildagliptin, 1843, 1855, "vildagliptin", "", +63, Reduction, 1862, 1868, "0 . 56", "", " \"0 . 56\"." +68, Percentage, 1869, 1870, "%", "", +65, Reduction, 1873, 1878, "6 . 1", "", +166, ConcentrationUnit, 1879, 1889, "mmol / mol", "", +66, TimePoint, 1899, 1907, "baseline", "", +74, BaseLineValue, 1911, 1917, "7 . 80", "", " \"7 . 80\"." +78, Percentage, 1918, 1919, "%", "", +75, BaseLineValue, 1922, 1924, "62", "", +167, ConcentrationUnit, 1925, 1935, "mmol / mol", "", +13, Sitagliptin, 1943, 1954, "sitagliptin", "", +79, PvalueDiff, 1957, 1970, "p  =  0 . 874", "", " \"p  =  0 . 874\"." +54, FastingPlasmaGlucose, 1975, 1978, "FPG", "", " ." +80, Reduction, 1992, 1998, "0 . 47", "", " \"0 . 47\"." +81, SdDevChangeValue, 2003, 2009, "0 . 37", "", " \"0 . 37\"." +83, Millimoles_per_litre, 2010, 2018, "mmol / l", "", " ." +7, Vildagliptin, 2024, 2036, "vildagliptin", "", +85, Increment, 2054, 2060, "0 . 16", "", " \"0 . 16\"." +82, SdDevChangeValue, 2065, 2071, "0 . 43", "", " \"0 . 43\"." +84, Millimoles_per_litre, 2072, 2080, "mmol / l", "", +14, Sitagliptin, 2086, 2097, "sitagliptin", "", +86, PvalueDiff, 2100, 2113, "p  =  0 . 185", "", " \"p  =  0 . 185\"." +94, ConclusionComment, 2224, 2414, "At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .", "", " \"At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .\"." +8, Vildagliptin, 2267, 2279, "vildagliptin", "", +88, DoseValue, 2282, 2284, "50", "", +90, mg, 2285, 2287, "mg", "", +92, Frequency, 2288, 2298, "once daily", "", +15, Sitagliptin, 2315, 2326, "sitagliptin", "", +89, DoseValue, 2329, 2331, "25", "", +91, mg, 2332, 2334, "mg", "", +93, Frequency, 2335, 2345, "once daily", "", +95, ConclusionComment, 2415, 2513, "This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .", "", " \"This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .\"." +93451, PharmacySponsored, 2592, 2640, "This study was planned and conducted by Novartis", "", +96, PMID, 2711, 2719, "26067186", "", " \"26067186\"." diff --git a/data/dm2 26067186_admin.n-triples b/data/dm2 26067186_admin.n-triples new file mode 100644 index 0000000..a761eb0 --- /dev/null +++ b/data/dm2 26067186_admin.n-triples @@ -0,0 +1,133 @@ +# RDF export of group: Publication + . + "Publication 68292" . + "Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial ." . + "Kothny W" . + "2015" . + "Diabetologia" . + "26067186" . + . + "Lukashevich V" . + "Foley JE" . + "Rendell MS" . + "Schweizer A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 68299" . + "We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) ." . + "148" . + "24 week" . + . + . + . + "At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated ." . + . + . + . + . + . + . + . + "This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population 68315" . + "patients with type 2 diabetes and severe renal impairment ( RI )" . + . + . + . + "Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control" . + "estimated GFR < 30 ml min" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + "83" . + . + . + . + . + . + "sit" . + "65" . + . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + "once daily" . + . + . + "sit" . + . + "once daily" . + . +# RDF export of group: Medication + . + "vil" . + . + "50" . + . + . + . + "sit" . + . + "25" . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 52" . + "0 . 54" . + "24 weeks" . + . + "hba 2" . + . + "7 . 80" . + "0 . 56" . + "24 weeks" . + . + "fpg 1" . + . + "0 . 47" . + "0 . 37" . + . + "fpg 2" . + . + "0 . 16" . + "0 . 43" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "p  =  0 . 874" . + . + . + . + "fpg" . + "p  =  0 . 185" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26067186_akramersunderbrink.annodb b/data/dm2 26067186_akramersunderbrink.annodb new file mode 100644 index 0000000..fdf66cd --- /dev/null +++ b/data/dm2 26067186_akramersunderbrink.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +61532, Journal, 0, 12, "Diabetologia", "", +61533, PublicationYear, 15, 19, "2015", "", +61538, Title, 111, 246, "Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .", "", +61534, Vildagliptin, 125, 137, "vildagliptin", "", +61535, Sitagliptin, 142, 153, "sitagliptin", "", +61536, Type2Diabetes, 171, 186, "type 2 diabetes", "", +61537, Randomized, 219, 229, "randomised", "", +61539, Author, 247, 255, "Kothny W", "", +61540, Author, 264, 277, "Lukashevich V", "", +61541, Author, 280, 288, "Foley JE", "", +61542, Author, 291, 301, "Rendell MS", "", +61543, Author, 304, 315, "Schweizer A", "", +61544, Switzerland, 397, 408, "Switzerland", "", +61549, ObjectiveDescription, 468, 559, "There are limited data comparing dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors directly .", "", +61550, ObjectiveDescription, 560, 697, "We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .", "", +61545, Vildagliptin, 599, 611, "vildagliptin", "", +61546, Sitagliptin, 616, 627, "sitagliptin", "", +61547, Type2Diabetes, 645, 660, "type 2 diabetes", "", +61548, Precondition, 665, 695, "severe renal impairment ( RI )", "", +61551, Parallel, 725, 739, "parallel - arm", "", +61552, Randomized, 742, 752, "randomised", "", +61553, Multicenter, 755, 766, "multicentre", "", +61554, DoubleBlind, 769, 783, "double - blind", "", +61555, Duration, 786, 793, "24 week", "", +61556, Multicenter, 813, 849, "87 centres across Brazil and the USA", "", +61557, Brazil, 831, 837, "Brazil", "", +61558, USA, 846, 849, "USA", "", +61559, Type2Diabetes, 866, 881, "type 2 diabetes", "", +61560, Precondition, 884, 947, "either drug naive or treated with any glucose - lowering agents", "", +61561, Precondition, 958, 1036, "inadequate glycaemic control ( HbA1c 6 . 5 - 10 . 0 % [ 48 - 86 mmol / mol ] )", "", +61563, HbA1c, 989, 994, "HbA1c", "", +61564, Percentage, 1010, 1011, "%", "", +61565, ConcentrationUnit, 1022, 1032, "mmol / mol", "", +61562, Precondition, 1044, 1098, "estimated GFR < 30 ml min ( - 1 ) [ 1 . 73 m ] ( - 2 )", "", +61566, BioAndMedicalUnit, 1063, 1077, "ml min ( - 1 )", "", +61567, Randomized, 1104, 1114, "randomised", "", +61568, Vildagliptin, 1164, 1176, "vildagliptin", "", +61569, DoseValue, 1177, 1182, "50 mg", "", +61570, mg, 1180, 1182, "mg", "", +61571, Frequency, 1183, 1193, "once daily", "", +61572, Sitagliptin, 1197, 1208, "sitagliptin", "", +61574, DoseValue, 1209, 1214, "25 mg", "", +61575, mg, 1212, 1214, "mg", "", +61573, Frequency, 1215, 1225, "once daily", "", +61576, DoubleBlind, 1335, 1397, "investigators and the sponsor were blinded to group assignment", "", +61577, HbA1c, 1438, 1443, "HbA1c", "", +61578, FastingPlasmaGlucose, 1448, 1470, "fasting plasma glucose", "", +61579, FastingPlasmaGlucose, 1473, 1476, "FPG", "", +61580, NumberPatientsCT, 1602, 1605, "148", "", +61581, Randomized, 1620, 1630, "randomised", "", +61582, NumberPatientsArm, 1633, 1635, "83", "", +61584, Vildagliptin, 1639, 1651, "vildagliptin", "", +61583, NumberPatientsArm, 1656, 1658, "65", "", +61585, Sitagliptin, 1662, 1673, "sitagliptin", "", +61586, Duration, 1711, 1719, "24 weeks", "", +61587, Mean, 1735, 1739, "mean", "", +61588, HbA1c, 1750, 1755, "HbA1c", "", +61591, ChangeValue, 1760, 1768, "- 0 . 54", "", +61595, Percentage, 1769, 1770, "%", "", +61592, ChangeValue, 1773, 1778, "5 . 9", "", +61599, ConcentrationUnit, 1779, 1789, "mmol / mol", "", +61589, TimePoint, 1799, 1807, "baseline", "", +61603, BaseLineValue, 1811, 1817, "7 . 52", "", +61596, Percentage, 1818, 1819, "%", "", +61606, BaseLineValue, 1822, 1824, "59", "", +61600, ConcentrationUnit, 1825, 1835, "mmol / mol", "", +61607, Vildagliptin, 1843, 1855, "vildagliptin", "", +61593, ChangeValue, 1860, 1868, "- 0 . 56", "", +61597, Percentage, 1869, 1870, "%", "", +61594, ChangeValue, 1873, 1878, "6 . 1", "", +61601, ConcentrationUnit, 1879, 1889, "mmol / mol", "", +61590, TimePoint, 1899, 1907, "baseline", "", +61604, BaseLineValue, 1911, 1917, "7 . 80", "", +61598, Percentage, 1918, 1919, "%", "", +61605, BaseLineValue, 1922, 1924, "62", "", +61602, ConcentrationUnit, 1925, 1935, "mmol / mol", "", +61608, Sitagliptin, 1943, 1954, "sitagliptin", "", +61609, PvalueDiff, 1957, 1970, "p  =  0 . 874", "", +61610, FastingPlasmaGlucose, 1975, 1978, "FPG", "", +61611, Reduction, 1992, 1998, "0 . 47", "", +61631, SdDevChangeValue, 2003, 2009, "0 . 37", "", +61613, Millimoles_per_litre, 2010, 2018, "mmol / l", "", +61615, Vildagliptin, 2024, 2036, "vildagliptin", "", +61612, Increment, 2054, 2060, "0 . 16", "", +61632, SdDevChangeValue, 2065, 2071, "0 . 43", "", +61614, Millimoles_per_litre, 2072, 2080, "mmol / l", "", +61616, Sitagliptin, 2086, 2097, "sitagliptin", "", +61617, PvalueDiff, 2100, 2113, "p  =  0 . 185", "", +61627, ConclusionComment, 2224, 2414, "At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .", "", +61626, Precondition, 2255, 2264, "severe RI", "", +61618, Vildagliptin, 2267, 2279, "vildagliptin", "", +61619, DoseValue, 2282, 2287, "50 mg", "", +61621, mg, 2285, 2287, "mg", "", +61623, Frequency, 2288, 2298, "once daily", "", +61625, Sitagliptin, 2315, 2326, "sitagliptin", "", +61620, DoseValue, 2329, 2334, "25 mg", "", +61622, mg, 2332, 2334, "mg", "", +61624, Frequency, 2335, 2345, "once daily", "", +61628, ConclusionComment, 2415, 2513, "This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .", "", +61629, Precondition, 2502, 2511, "severe RI", "", +61630, PMID, 2711, 2719, "26067186", "", diff --git a/data/dm2 26067186_akramersunderbrink.n-triples b/data/dm2 26067186_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26067186_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26067186_export.csv b/data/dm2 26067186_export.csv new file mode 100644 index 0000000..7d7dc25 --- /dev/null +++ b/data/dm2 26067186_export.csv @@ -0,0 +1,570 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +264, 1, 1, 1, 0, 12, 0, 12, "Diabetologia" +264, 1, 2, 2, 13, 14, 13, 14, "." +264, 2, 1, 3, 0, 4, 15, 19, "2015" +264, 2, 2, 4, 5, 8, 20, 23, "Sep" +264, 2, 3, 5, 9, 10, 24, 25, ";" +264, 2, 4, 6, 11, 13, 26, 28, "58" +264, 2, 5, 7, 14, 15, 29, 30, "(" +264, 2, 6, 8, 16, 17, 31, 32, "9" +264, 2, 7, 9, 18, 19, 33, 34, ")" +264, 2, 8, 10, 20, 21, 35, 36, ":" +264, 2, 9, 11, 22, 26, 37, 41, "2020" +264, 2, 10, 12, 27, 28, 42, 43, "-" +264, 2, 11, 13, 29, 30, 44, 45, "6" +264, 2, 12, 14, 31, 32, 46, 47, "." +264, 2, 13, 15, 33, 36, 48, 51, "doi" +264, 2, 14, 16, 37, 38, 52, 53, ":" +264, 2, 15, 17, 39, 41, 54, 56, "10" +264, 2, 16, 18, 42, 43, 57, 58, "." +264, 2, 17, 19, 44, 48, 59, 63, "1007" +264, 2, 18, 20, 49, 50, 64, 65, "/" +264, 2, 19, 21, 51, 57, 66, 72, "s00125" +264, 2, 20, 22, 58, 59, 73, 74, "-" +264, 2, 21, 23, 60, 63, 75, 78, "015" +264, 2, 22, 24, 64, 65, 79, 80, "-" +264, 2, 23, 25, 66, 70, 81, 85, "3655" +264, 2, 24, 26, 71, 72, 86, 87, "-" +264, 2, 25, 27, 73, 74, 88, 89, "z" +264, 2, 26, 28, 75, 76, 90, 91, "." +264, 3, 1, 29, 0, 4, 92, 96, "Epub" +264, 3, 2, 30, 5, 9, 97, 101, "2015" +264, 3, 3, 31, 10, 13, 102, 105, "Jun" +264, 3, 4, 32, 14, 16, 106, 108, "12" +264, 3, 5, 33, 17, 18, 109, 110, "." +264, 4, 1, 34, 0, 10, 111, 121, "Comparison" +264, 4, 2, 35, 11, 13, 122, 124, "of" +264, 4, 3, 36, 14, 26, 125, 137, "vildagliptin" +264, 4, 4, 37, 27, 30, 138, 141, "and" +264, 4, 5, 38, 31, 42, 142, 153, "sitagliptin" +264, 4, 6, 39, 43, 45, 154, 156, "in" +264, 4, 7, 40, 46, 54, 157, 165, "patients" +264, 4, 8, 41, 55, 59, 166, 170, "with" +264, 4, 9, 42, 60, 64, 171, 175, "type" +264, 4, 10, 43, 65, 66, 176, 177, "2" +264, 4, 11, 44, 67, 75, 178, 186, "diabetes" +264, 4, 12, 45, 76, 79, 187, 190, "and" +264, 4, 13, 46, 80, 86, 191, 197, "severe" +264, 4, 14, 47, 87, 92, 198, 203, "renal" +264, 4, 15, 48, 93, 103, 204, 214, "impairment" +264, 4, 16, 49, 104, 105, 215, 216, ":" +264, 4, 17, 50, 106, 107, 217, 218, "a" +264, 4, 18, 51, 108, 118, 219, 229, "randomised" +264, 4, 19, 52, 119, 127, 230, 238, "clinical" +264, 4, 20, 53, 128, 133, 239, 244, "trial" +264, 4, 21, 54, 134, 135, 245, 246, "." +264, 5, 1, 55, 0, 6, 247, 253, "Kothny" +264, 5, 2, 56, 7, 8, 254, 255, "W" +264, 5, 3, 57, 9, 10, 256, 257, "(" +264, 5, 4, 58, 11, 12, 258, 259, "1" +264, 5, 5, 59, 13, 14, 260, 261, ")" +264, 5, 6, 60, 15, 16, 262, 263, "," +264, 5, 7, 61, 17, 28, 264, 275, "Lukashevich" +264, 5, 8, 62, 29, 30, 276, 277, "V" +264, 5, 9, 63, 31, 32, 278, 279, "," +264, 5, 10, 64, 33, 38, 280, 285, "Foley" +264, 5, 11, 65, 39, 41, 286, 288, "JE" +264, 5, 12, 66, 42, 43, 289, 290, "," +264, 5, 13, 67, 44, 51, 291, 298, "Rendell" +264, 5, 14, 68, 52, 54, 299, 301, "MS" +264, 5, 15, 69, 55, 56, 302, 303, "," +264, 5, 16, 70, 57, 66, 304, 313, "Schweizer" +264, 5, 17, 71, 67, 68, 314, 315, "A" +264, 5, 18, 72, 69, 70, 316, 317, "." +264, 6, 1, 73, 0, 6, 318, 324, "Author" +264, 6, 2, 74, 7, 18, 325, 336, "information" +264, 6, 3, 75, 19, 20, 337, 338, ":" +264, 6, 4, 76, 21, 22, 339, 340, "(" +264, 6, 5, 77, 23, 24, 341, 342, "1" +264, 6, 6, 78, 25, 26, 343, 344, ")" +264, 6, 7, 79, 27, 35, 345, 353, "Novartis" +264, 6, 8, 80, 36, 42, 354, 360, "Pharma" +264, 6, 9, 81, 43, 45, 361, 363, "AG" +264, 6, 10, 82, 46, 47, 364, 365, "," +264, 6, 11, 83, 48, 56, 366, 374, "Postfach" +264, 6, 12, 84, 57, 58, 375, 376, "," +264, 6, 13, 85, 59, 61, 377, 379, "CH" +264, 6, 14, 86, 62, 63, 380, 381, "-" +264, 6, 15, 87, 64, 68, 382, 386, "4002" +264, 6, 16, 88, 69, 70, 387, 388, "," +264, 6, 17, 89, 71, 76, 389, 394, "Basel" +264, 6, 18, 90, 77, 78, 395, 396, "," +264, 6, 19, 91, 79, 90, 397, 408, "Switzerland" +264, 6, 20, 92, 91, 92, 409, 410, "," +264, 6, 21, 93, 93, 101, 411, 419, "wolfgang" +264, 6, 22, 94, 102, 103, 420, 421, "." +264, 6, 23, 95, 104, 110, 422, 428, "kothny" +264, 6, 24, 96, 111, 112, 429, 430, "@" +264, 6, 25, 97, 113, 121, 431, 439, "novartis" +264, 6, 26, 98, 122, 123, 440, 441, "." +264, 6, 27, 99, 124, 127, 442, 445, "com" +264, 6, 28, 100, 128, 129, 446, 447, "." +264, 7, 1, 101, 0, 4, 448, 452, "AIMS" +264, 7, 2, 102, 5, 6, 453, 454, "/" +264, 7, 3, 103, 7, 17, 455, 465, "HYPOTHESIS" +264, 7, 4, 104, 18, 19, 466, 467, ":" +264, 7, 5, 105, 20, 25, 468, 473, "There" +264, 7, 6, 106, 26, 29, 474, 477, "are" +264, 7, 7, 107, 30, 37, 478, 485, "limited" +264, 7, 8, 108, 38, 42, 486, 490, "data" +264, 7, 9, 109, 43, 52, 491, 500, "comparing" +264, 7, 10, 110, 53, 63, 501, 511, "dipeptidyl" +264, 7, 11, 111, 64, 73, 512, 521, "peptidase" +264, 7, 12, 112, 74, 75, 522, 523, "-" +264, 7, 13, 113, 76, 77, 524, 525, "4" +264, 7, 14, 114, 78, 79, 526, 527, "(" +264, 7, 15, 115, 80, 83, 528, 531, "DPP" +264, 7, 16, 116, 84, 85, 532, 533, "-" +264, 7, 17, 117, 86, 87, 534, 535, "4" +264, 7, 18, 118, 88, 89, 536, 537, ")" +264, 7, 19, 119, 90, 100, 538, 548, "inhibitors" +264, 7, 20, 120, 101, 109, 549, 557, "directly" +264, 7, 21, 121, 110, 111, 558, 559, "." +264, 8, 1, 122, 0, 2, 560, 562, "We" +264, 8, 2, 123, 3, 11, 563, 571, "compared" +264, 8, 3, 124, 12, 15, 572, 575, "the" +264, 8, 4, 125, 16, 22, 576, 582, "safety" +264, 8, 5, 126, 23, 26, 583, 586, "and" +264, 8, 6, 127, 27, 35, 587, 595, "efficacy" +264, 8, 7, 128, 36, 38, 596, 598, "of" +264, 8, 8, 129, 39, 51, 599, 611, "vildagliptin" +264, 8, 9, 130, 52, 55, 612, 615, "and" +264, 8, 10, 131, 56, 67, 616, 627, "sitagliptin" +264, 8, 11, 132, 68, 70, 628, 630, "in" +264, 8, 12, 133, 71, 79, 631, 639, "patients" +264, 8, 13, 134, 80, 84, 640, 644, "with" +264, 8, 14, 135, 85, 89, 645, 649, "type" +264, 8, 15, 136, 90, 91, 650, 651, "2" +264, 8, 16, 137, 92, 100, 652, 660, "diabetes" +264, 8, 17, 138, 101, 104, 661, 664, "and" +264, 8, 18, 139, 105, 111, 665, 671, "severe" +264, 8, 19, 140, 112, 117, 672, 677, "renal" +264, 8, 20, 141, 118, 128, 678, 688, "impairment" +264, 8, 21, 142, 129, 130, 689, 690, "(" +264, 8, 22, 143, 131, 133, 691, 693, "RI" +264, 8, 23, 144, 134, 135, 694, 695, ")" +264, 8, 24, 145, 136, 137, 696, 697, "." +264, 9, 1, 146, 0, 7, 698, 705, "METHODS" +264, 9, 2, 147, 8, 9, 706, 707, ":" +264, 9, 3, 148, 10, 14, 708, 712, "This" +264, 9, 4, 149, 15, 20, 713, 718, "study" +264, 9, 5, 150, 21, 24, 719, 722, "was" +264, 9, 6, 151, 25, 26, 723, 724, "a" +264, 9, 7, 152, 27, 35, 725, 733, "parallel" +264, 9, 8, 153, 36, 37, 734, 735, "-" +264, 9, 9, 154, 38, 41, 736, 739, "arm" +264, 9, 10, 155, 42, 43, 740, 741, "," +264, 9, 11, 156, 44, 54, 742, 752, "randomised" +264, 9, 12, 157, 55, 56, 753, 754, "," +264, 9, 13, 158, 57, 68, 755, 766, "multicentre" +264, 9, 14, 159, 69, 70, 767, 768, "," +264, 9, 15, 160, 71, 77, 769, 775, "double" +264, 9, 16, 161, 78, 79, 776, 777, "-" +264, 9, 17, 162, 80, 85, 778, 783, "blind" +264, 9, 18, 163, 86, 87, 784, 785, "," +264, 9, 19, 164, 88, 90, 786, 788, "24" +264, 9, 20, 165, 91, 95, 789, 793, "week" +264, 9, 21, 166, 96, 101, 794, 799, "study" +264, 9, 22, 167, 102, 111, 800, 809, "conducted" +264, 9, 23, 168, 112, 114, 810, 812, "in" +264, 9, 24, 169, 115, 117, 813, 815, "87" +264, 9, 25, 170, 118, 125, 816, 823, "centres" +264, 9, 26, 171, 126, 132, 824, 830, "across" +264, 9, 27, 172, 133, 139, 831, 837, "Brazil" +264, 9, 28, 173, 140, 143, 838, 841, "and" +264, 9, 29, 174, 144, 147, 842, 845, "the" +264, 9, 30, 175, 148, 151, 846, 849, "USA" +264, 9, 31, 176, 152, 153, 850, 851, "." +264, 10, 1, 177, 0, 8, 852, 860, "Patients" +264, 10, 2, 178, 9, 13, 861, 865, "with" +264, 10, 3, 179, 14, 18, 866, 870, "type" +264, 10, 4, 180, 19, 20, 871, 872, "2" +264, 10, 5, 181, 21, 29, 873, 881, "diabetes" +264, 10, 6, 182, 30, 31, 882, 883, "," +264, 10, 7, 183, 32, 38, 884, 890, "either" +264, 10, 8, 184, 39, 43, 891, 895, "drug" +264, 10, 9, 185, 44, 49, 896, 901, "naive" +264, 10, 10, 186, 50, 52, 902, 904, "or" +264, 10, 11, 187, 53, 60, 905, 912, "treated" +264, 10, 12, 188, 61, 65, 913, 917, "with" +264, 10, 13, 189, 66, 69, 918, 921, "any" +264, 10, 14, 190, 70, 77, 922, 929, "glucose" +264, 10, 15, 191, 78, 79, 930, 931, "-" +264, 10, 16, 192, 80, 88, 932, 940, "lowering" +264, 10, 17, 193, 89, 95, 941, 947, "agents" +264, 10, 18, 194, 96, 97, 948, 949, "," +264, 10, 19, 195, 98, 101, 950, 953, "who" +264, 10, 20, 196, 102, 105, 954, 957, "had" +264, 10, 21, 197, 106, 116, 958, 968, "inadequate" +264, 10, 22, 198, 117, 126, 969, 978, "glycaemic" +264, 10, 23, 199, 127, 134, 979, 986, "control" +264, 10, 24, 200, 135, 136, 987, 988, "(" +264, 10, 25, 201, 137, 142, 989, 994, "HbA1c" +264, 10, 26, 202, 143, 144, 995, 996, "6" +264, 10, 27, 203, 145, 146, 997, 998, "." +264, 10, 28, 204, 147, 148, 999, 1000, "5" +264, 10, 29, 205, 149, 150, 1001, 1002, "-" +264, 10, 30, 206, 151, 153, 1003, 1005, "10" +264, 10, 31, 207, 154, 155, 1006, 1007, "." +264, 10, 32, 208, 156, 157, 1008, 1009, "0" +264, 10, 33, 209, 158, 159, 1010, 1011, "%" +264, 10, 34, 210, 160, 161, 1012, 1013, "[" +264, 10, 35, 211, 162, 164, 1014, 1016, "48" +264, 10, 36, 212, 165, 166, 1017, 1018, "-" +264, 10, 37, 213, 167, 169, 1019, 1021, "86" +264, 10, 38, 214, 170, 174, 1022, 1026, "mmol" +264, 10, 39, 215, 175, 176, 1027, 1028, "/" +264, 10, 40, 216, 177, 180, 1029, 1032, "mol" +264, 10, 41, 217, 181, 182, 1033, 1034, "]" +264, 10, 42, 218, 183, 184, 1035, 1036, ")" +264, 10, 43, 219, 185, 188, 1037, 1040, "and" +264, 10, 44, 220, 189, 191, 1041, 1043, "an" +264, 10, 45, 221, 192, 201, 1044, 1053, "estimated" +264, 10, 46, 222, 202, 205, 1054, 1057, "GFR" +264, 10, 47, 223, 206, 207, 1058, 1059, "<" +264, 10, 48, 224, 208, 210, 1060, 1062, "30" +264, 10, 49, 225, 211, 213, 1063, 1065, "ml" +264, 10, 50, 226, 214, 217, 1066, 1069, "min" +264, 10, 51, 227, 218, 219, 1070, 1071, "(" +264, 10, 52, 228, 220, 221, 1072, 1073, "-" +264, 10, 53, 229, 222, 223, 1074, 1075, "1" +264, 10, 54, 230, 224, 225, 1076, 1077, ")" +264, 10, 55, 231, 226, 227, 1078, 1079, "[" +264, 10, 56, 232, 228, 229, 1080, 1081, "1" +264, 10, 57, 233, 230, 231, 1082, 1083, "." +264, 10, 58, 234, 232, 234, 1084, 1086, "73" +264, 10, 59, 235, 235, 236, 1087, 1088, "m" +264, 10, 60, 236, 237, 238, 1089, 1090, "]" +264, 10, 61, 237, 239, 240, 1091, 1092, "(" +264, 10, 62, 238, 241, 242, 1093, 1094, "-" +264, 10, 63, 239, 243, 244, 1095, 1096, "2" +264, 10, 64, 240, 245, 246, 1097, 1098, ")" +264, 10, 65, 241, 247, 251, 1099, 1103, "were" +264, 10, 66, 242, 252, 262, 1104, 1114, "randomised" +264, 10, 67, 243, 263, 264, 1115, 1116, "(" +264, 10, 68, 244, 265, 268, 1117, 1120, "via" +264, 10, 69, 245, 269, 280, 1121, 1132, "interactive" +264, 10, 70, 246, 281, 286, 1133, 1138, "voice" +264, 10, 71, 247, 287, 295, 1139, 1147, "response" +264, 10, 72, 248, 296, 306, 1148, 1158, "technology" +264, 10, 73, 249, 307, 308, 1159, 1160, ")" +264, 10, 74, 250, 309, 311, 1161, 1163, "to" +264, 10, 75, 251, 312, 324, 1164, 1176, "vildagliptin" +264, 10, 76, 252, 325, 327, 1177, 1179, "50" +264, 10, 77, 253, 328, 330, 1180, 1182, "mg" +264, 10, 78, 254, 331, 335, 1183, 1187, "once" +264, 10, 79, 255, 336, 341, 1188, 1193, "daily" +264, 10, 80, 256, 342, 344, 1194, 1196, "or" +264, 10, 81, 257, 345, 356, 1197, 1208, "sitagliptin" +264, 10, 82, 258, 357, 359, 1209, 1211, "25" +264, 10, 83, 259, 360, 362, 1212, 1214, "mg" +264, 10, 84, 260, 363, 367, 1215, 1219, "once" +264, 10, 85, 261, 368, 373, 1220, 1225, "daily" +264, 10, 86, 262, 374, 375, 1226, 1227, "." +264, 11, 1, 263, 0, 5, 1228, 1233, "These" +264, 11, 2, 264, 6, 11, 1234, 1239, "doses" +264, 11, 3, 265, 12, 15, 1240, 1243, "are" +264, 11, 4, 266, 16, 27, 1244, 1255, "recommended" +264, 11, 5, 267, 28, 30, 1256, 1258, "in" +264, 11, 6, 268, 31, 35, 1259, 1263, "this" +264, 11, 7, 269, 36, 43, 1264, 1271, "patient" +264, 11, 8, 270, 44, 54, 1272, 1282, "population" +264, 11, 9, 271, 55, 58, 1283, 1286, "and" +264, 11, 10, 272, 59, 69, 1287, 1297, "considered" +264, 11, 11, 273, 70, 79, 1298, 1307, "maximally" +264, 11, 12, 274, 80, 89, 1308, 1317, "effective" +264, 11, 13, 275, 90, 91, 1318, 1319, "." +264, 12, 1, 276, 0, 12, 1320, 1332, "Participants" +264, 12, 2, 277, 13, 14, 1333, 1334, "," +264, 12, 3, 278, 15, 28, 1335, 1348, "investigators" +264, 12, 4, 279, 29, 32, 1349, 1352, "and" +264, 12, 5, 280, 33, 36, 1353, 1356, "the" +264, 12, 6, 281, 37, 44, 1357, 1364, "sponsor" +264, 12, 7, 282, 45, 49, 1365, 1369, "were" +264, 12, 8, 283, 50, 57, 1370, 1377, "blinded" +264, 12, 9, 284, 58, 60, 1378, 1380, "to" +264, 12, 10, 285, 61, 66, 1381, 1386, "group" +264, 12, 11, 286, 67, 77, 1387, 1397, "assignment" +264, 12, 12, 287, 78, 79, 1398, 1399, "." +264, 13, 1, 288, 0, 8, 1400, 1408, "Efficacy" +264, 13, 2, 289, 9, 18, 1409, 1418, "endpoints" +264, 13, 3, 290, 19, 27, 1419, 1427, "included" +264, 13, 4, 291, 28, 34, 1428, 1434, "change" +264, 13, 5, 292, 35, 37, 1435, 1437, "in" +264, 13, 6, 293, 38, 43, 1438, 1443, "HbA1c" +264, 13, 7, 294, 44, 47, 1444, 1447, "and" +264, 13, 8, 295, 48, 55, 1448, 1455, "fasting" +264, 13, 9, 296, 56, 62, 1456, 1462, "plasma" +264, 13, 10, 297, 63, 70, 1463, 1470, "glucose" +264, 13, 11, 298, 71, 72, 1471, 1472, "(" +264, 13, 12, 299, 73, 76, 1473, 1476, "FPG" +264, 13, 13, 300, 77, 78, 1477, 1478, ")" +264, 13, 14, 301, 79, 81, 1479, 1481, "at" +264, 13, 15, 302, 82, 85, 1482, 1485, "all" +264, 13, 16, 303, 86, 92, 1486, 1492, "visits" +264, 13, 17, 304, 93, 96, 1493, 1496, "and" +264, 13, 18, 305, 97, 100, 1497, 1500, "the" +264, 13, 19, 306, 101, 108, 1501, 1508, "primary" +264, 13, 20, 307, 109, 115, 1509, 1515, "safety" +264, 13, 21, 308, 116, 124, 1516, 1524, "endpoint" +264, 13, 22, 309, 125, 128, 1525, 1528, "was" +264, 13, 23, 310, 129, 139, 1529, 1539, "assessment" +264, 13, 24, 311, 140, 142, 1540, 1542, "of" +264, 13, 25, 312, 143, 152, 1543, 1552, "treatment" +264, 13, 26, 313, 153, 154, 1553, 1554, "-" +264, 13, 27, 314, 155, 163, 1555, 1563, "emergent" +264, 13, 28, 315, 164, 171, 1564, 1571, "adverse" +264, 13, 29, 316, 172, 178, 1572, 1578, "events" +264, 13, 30, 317, 179, 180, 1579, 1580, "." +264, 14, 1, 318, 0, 7, 1581, 1588, "RESULTS" +264, 14, 2, 319, 8, 9, 1589, 1590, ":" +264, 14, 3, 320, 10, 12, 1591, 1593, "In" +264, 14, 4, 321, 13, 18, 1594, 1599, "total" +264, 14, 5, 322, 19, 20, 1600, 1601, "," +264, 14, 6, 323, 21, 24, 1602, 1605, "148" +264, 14, 7, 324, 25, 33, 1606, 1614, "patients" +264, 14, 8, 325, 34, 38, 1615, 1619, "were" +264, 14, 9, 326, 39, 49, 1620, 1630, "randomised" +264, 14, 10, 327, 50, 51, 1631, 1632, "," +264, 14, 11, 328, 52, 54, 1633, 1635, "83" +264, 14, 12, 329, 55, 57, 1636, 1638, "to" +264, 14, 13, 330, 58, 70, 1639, 1651, "vildagliptin" +264, 14, 14, 331, 71, 74, 1652, 1655, "and" +264, 14, 15, 332, 75, 77, 1656, 1658, "65" +264, 14, 16, 333, 78, 80, 1659, 1661, "to" +264, 14, 17, 334, 81, 92, 1662, 1673, "sitagliptin" +264, 14, 18, 335, 93, 94, 1674, 1675, "." +264, 15, 1, 336, 0, 3, 1676, 1679, "All" +264, 15, 2, 337, 4, 12, 1680, 1688, "patients" +264, 15, 3, 338, 13, 17, 1689, 1693, "were" +264, 15, 4, 339, 18, 26, 1694, 1702, "analysed" +264, 15, 5, 340, 27, 28, 1703, 1704, "." +264, 16, 1, 341, 0, 5, 1705, 1710, "After" +264, 16, 2, 342, 6, 8, 1711, 1713, "24" +264, 16, 3, 343, 9, 14, 1714, 1719, "weeks" +264, 16, 4, 344, 15, 16, 1720, 1721, "," +264, 16, 5, 345, 17, 20, 1722, 1725, "the" +264, 16, 6, 346, 21, 29, 1726, 1734, "adjusted" +264, 16, 7, 347, 30, 34, 1735, 1739, "mean" +264, 16, 8, 348, 35, 41, 1740, 1746, "change" +264, 16, 9, 349, 42, 44, 1747, 1749, "in" +264, 16, 10, 350, 45, 50, 1750, 1755, "HbA1c" +264, 16, 11, 351, 51, 54, 1756, 1759, "was" +264, 16, 12, 352, 55, 56, 1760, 1761, "-" +264, 16, 13, 353, 57, 58, 1762, 1763, "0" +264, 16, 14, 354, 59, 60, 1764, 1765, "." +264, 16, 15, 355, 61, 63, 1766, 1768, "54" +264, 16, 16, 356, 64, 65, 1769, 1770, "%" +264, 16, 17, 357, 66, 67, 1771, 1772, "(" +264, 16, 18, 358, 68, 69, 1773, 1774, "5" +264, 16, 19, 359, 70, 71, 1775, 1776, "." +264, 16, 20, 360, 72, 73, 1777, 1778, "9" +264, 16, 21, 361, 74, 78, 1779, 1783, "mmol" +264, 16, 22, 362, 79, 80, 1784, 1785, "/" +264, 16, 23, 363, 81, 84, 1786, 1789, "mol" +264, 16, 24, 364, 85, 86, 1790, 1791, ")" +264, 16, 25, 365, 87, 91, 1792, 1796, "from" +264, 16, 26, 366, 92, 93, 1797, 1798, "a" +264, 16, 27, 367, 94, 102, 1799, 1807, "baseline" +264, 16, 28, 368, 103, 105, 1808, 1810, "of" +264, 16, 29, 369, 106, 107, 1811, 1812, "7" +264, 16, 30, 370, 108, 109, 1813, 1814, "." +264, 16, 31, 371, 110, 112, 1815, 1817, "52" +264, 16, 32, 372, 113, 114, 1818, 1819, "%" +264, 16, 33, 373, 115, 116, 1820, 1821, "(" +264, 16, 34, 374, 117, 119, 1822, 1824, "59" +264, 16, 35, 375, 120, 124, 1825, 1829, "mmol" +264, 16, 36, 376, 125, 126, 1830, 1831, "/" +264, 16, 37, 377, 127, 130, 1832, 1835, "mol" +264, 16, 38, 378, 131, 132, 1836, 1837, ")" +264, 16, 39, 379, 133, 137, 1838, 1842, "with" +264, 16, 40, 380, 138, 150, 1843, 1855, "vildagliptin" +264, 16, 41, 381, 151, 154, 1856, 1859, "and" +264, 16, 42, 382, 155, 156, 1860, 1861, "-" +264, 16, 43, 383, 157, 158, 1862, 1863, "0" +264, 16, 44, 384, 159, 160, 1864, 1865, "." +264, 16, 45, 385, 161, 163, 1866, 1868, "56" +264, 16, 46, 386, 164, 165, 1869, 1870, "%" +264, 16, 47, 387, 166, 167, 1871, 1872, "(" +264, 16, 48, 388, 168, 169, 1873, 1874, "6" +264, 16, 49, 389, 170, 171, 1875, 1876, "." +264, 16, 50, 390, 172, 173, 1877, 1878, "1" +264, 16, 51, 391, 174, 178, 1879, 1883, "mmol" +264, 16, 52, 392, 179, 180, 1884, 1885, "/" +264, 16, 53, 393, 181, 184, 1886, 1889, "mol" +264, 16, 54, 394, 185, 186, 1890, 1891, ")" +264, 16, 55, 395, 187, 191, 1892, 1896, "from" +264, 16, 56, 396, 192, 193, 1897, 1898, "a" +264, 16, 57, 397, 194, 202, 1899, 1907, "baseline" +264, 16, 58, 398, 203, 205, 1908, 1910, "of" +264, 16, 59, 399, 206, 207, 1911, 1912, "7" +264, 16, 60, 400, 208, 209, 1913, 1914, "." +264, 16, 61, 401, 210, 212, 1915, 1917, "80" +264, 16, 62, 402, 213, 214, 1918, 1919, "%" +264, 16, 63, 403, 215, 216, 1920, 1921, "(" +264, 16, 64, 404, 217, 219, 1922, 1924, "62" +264, 16, 65, 405, 220, 224, 1925, 1929, "mmol" +264, 16, 66, 406, 225, 226, 1930, 1931, "/" +264, 16, 67, 407, 227, 230, 1932, 1935, "mol" +264, 16, 68, 408, 231, 232, 1936, 1937, ")" +264, 16, 69, 409, 233, 237, 1938, 1942, "with" +264, 16, 70, 410, 238, 249, 1943, 1954, "sitagliptin" +264, 16, 71, 411, 250, 251, 1955, 1956, "(" +264, 16, 72, 412, 252, 253, 1957, 1958, "p" +264, 16, 73, 413, 254, 257, 1959, 1962, " = " +264, 16, 74, 414, 258, 259, 1963, 1964, "0" +264, 16, 75, 415, 260, 261, 1965, 1966, "." +264, 16, 76, 416, 262, 265, 1967, 1970, "874" +264, 16, 77, 417, 266, 267, 1971, 1972, ")" +264, 16, 78, 418, 268, 269, 1973, 1974, "." +264, 17, 1, 419, 0, 3, 1975, 1978, "FPG" +264, 17, 2, 420, 4, 13, 1979, 1988, "decreased" +264, 17, 3, 421, 14, 16, 1989, 1991, "by" +264, 17, 4, 422, 17, 18, 1992, 1993, "0" +264, 17, 5, 423, 19, 20, 1994, 1995, "." +264, 17, 6, 424, 21, 23, 1996, 1998, "47" +264, 17, 7, 425, 24, 27, 1999, 2002, " ± " +264, 17, 8, 426, 28, 29, 2003, 2004, "0" +264, 17, 9, 427, 30, 31, 2005, 2006, "." +264, 17, 10, 428, 32, 34, 2007, 2009, "37" +264, 17, 11, 429, 35, 39, 2010, 2014, "mmol" +264, 17, 12, 430, 40, 41, 2015, 2016, "/" +264, 17, 13, 431, 42, 43, 2017, 2018, "l" +264, 17, 14, 432, 44, 48, 2019, 2023, "with" +264, 17, 15, 433, 49, 61, 2024, 2036, "vildagliptin" +264, 17, 16, 434, 62, 65, 2037, 2040, "and" +264, 17, 17, 435, 66, 75, 2041, 2050, "increased" +264, 17, 18, 436, 76, 78, 2051, 2053, "by" +264, 17, 19, 437, 79, 80, 2054, 2055, "0" +264, 17, 20, 438, 81, 82, 2056, 2057, "." +264, 17, 21, 439, 83, 85, 2058, 2060, "16" +264, 17, 22, 440, 86, 89, 2061, 2064, " ± " +264, 17, 23, 441, 90, 91, 2065, 2066, "0" +264, 17, 24, 442, 92, 93, 2067, 2068, "." +264, 17, 25, 443, 94, 96, 2069, 2071, "43" +264, 17, 26, 444, 97, 101, 2072, 2076, "mmol" +264, 17, 27, 445, 102, 103, 2077, 2078, "/" +264, 17, 28, 446, 104, 105, 2079, 2080, "l" +264, 17, 29, 447, 106, 110, 2081, 2085, "with" +264, 17, 30, 448, 111, 122, 2086, 2097, "sitagliptin" +264, 17, 31, 449, 123, 124, 2098, 2099, "(" +264, 17, 32, 450, 125, 126, 2100, 2101, "p" +264, 17, 33, 451, 127, 130, 2102, 2105, " = " +264, 17, 34, 452, 131, 132, 2106, 2107, "0" +264, 17, 35, 453, 133, 134, 2108, 2109, "." +264, 17, 36, 454, 135, 138, 2110, 2113, "185" +264, 17, 37, 455, 139, 140, 2114, 2115, ")" +264, 17, 38, 456, 141, 142, 2116, 2117, "." +264, 18, 1, 457, 0, 4, 2118, 2122, "Both" +264, 18, 2, 458, 5, 15, 2123, 2133, "treatments" +264, 18, 3, 459, 16, 20, 2134, 2138, "were" +264, 18, 4, 460, 21, 25, 2139, 2143, "well" +264, 18, 5, 461, 26, 35, 2144, 2153, "tolerated" +264, 18, 6, 462, 36, 40, 2154, 2158, "with" +264, 18, 7, 463, 41, 48, 2159, 2166, "overall" +264, 18, 8, 464, 49, 56, 2167, 2174, "similar" +264, 18, 9, 465, 57, 63, 2175, 2181, "safety" +264, 18, 10, 466, 64, 72, 2182, 2190, "profiles" +264, 18, 11, 467, 73, 74, 2191, 2192, "." +264, 19, 1, 468, 0, 11, 2193, 2204, "CONCLUSIONS" +264, 19, 2, 469, 12, 13, 2205, 2206, "/" +264, 19, 3, 470, 14, 28, 2207, 2221, "INTERPRETATION" +264, 19, 4, 471, 29, 30, 2222, 2223, ":" +264, 19, 5, 472, 31, 33, 2224, 2226, "At" +264, 19, 6, 473, 34, 39, 2227, 2232, "their" +264, 19, 7, 474, 40, 51, 2233, 2244, "recommended" +264, 19, 8, 475, 52, 57, 2245, 2250, "doses" +264, 19, 9, 476, 58, 61, 2251, 2254, "for" +264, 19, 10, 477, 62, 68, 2255, 2261, "severe" +264, 19, 11, 478, 69, 71, 2262, 2264, "RI" +264, 19, 12, 479, 72, 73, 2265, 2266, "," +264, 19, 13, 480, 74, 86, 2267, 2279, "vildagliptin" +264, 19, 14, 481, 87, 88, 2280, 2281, "(" +264, 19, 15, 482, 89, 91, 2282, 2284, "50" +264, 19, 16, 483, 92, 94, 2285, 2287, "mg" +264, 19, 17, 484, 95, 99, 2288, 2292, "once" +264, 19, 18, 485, 100, 105, 2293, 2298, "daily" +264, 19, 19, 486, 106, 107, 2299, 2300, ")" +264, 19, 20, 487, 108, 116, 2301, 2309, "compared" +264, 19, 21, 488, 117, 121, 2310, 2314, "with" +264, 19, 22, 489, 122, 133, 2315, 2326, "sitagliptin" +264, 19, 23, 490, 134, 135, 2327, 2328, "(" +264, 19, 24, 491, 136, 138, 2329, 2331, "25" +264, 19, 25, 492, 139, 141, 2332, 2334, "mg" +264, 19, 26, 493, 142, 146, 2335, 2339, "once" +264, 19, 27, 494, 147, 152, 2340, 2345, "daily" +264, 19, 28, 495, 153, 154, 2346, 2347, ")" +264, 19, 29, 496, 155, 167, 2348, 2360, "demonstrated" +264, 19, 30, 497, 168, 175, 2361, 2368, "similar" +264, 19, 31, 498, 176, 184, 2369, 2377, "efficacy" +264, 19, 32, 499, 185, 188, 2378, 2381, "and" +264, 19, 33, 500, 189, 193, 2382, 2386, "both" +264, 19, 34, 501, 194, 199, 2387, 2392, "drugs" +264, 19, 35, 502, 200, 204, 2393, 2397, "were" +264, 19, 36, 503, 205, 209, 2398, 2402, "well" +264, 19, 37, 504, 210, 219, 2403, 2412, "tolerated" +264, 19, 38, 505, 220, 221, 2413, 2414, "." +264, 20, 1, 506, 0, 4, 2415, 2419, "This" +264, 20, 2, 507, 5, 10, 2420, 2425, "study" +264, 20, 3, 508, 11, 19, 2426, 2434, "provides" +264, 20, 4, 509, 20, 27, 2435, 2442, "further" +264, 20, 5, 510, 28, 35, 2443, 2450, "support" +264, 20, 6, 511, 36, 39, 2451, 2454, "for" +264, 20, 7, 512, 40, 43, 2455, 2458, "the" +264, 20, 8, 513, 44, 47, 2459, 2462, "use" +264, 20, 9, 514, 48, 50, 2463, 2465, "of" +264, 20, 10, 515, 51, 54, 2466, 2469, "DPP" +264, 20, 11, 516, 55, 56, 2470, 2471, "-" +264, 20, 12, 517, 57, 58, 2472, 2473, "4" +264, 20, 13, 518, 59, 69, 2474, 2484, "inhibitors" +264, 20, 14, 519, 70, 72, 2485, 2487, "in" +264, 20, 15, 520, 73, 81, 2488, 2496, "patients" +264, 20, 16, 521, 82, 86, 2497, 2501, "with" +264, 20, 17, 522, 87, 93, 2502, 2508, "severe" +264, 20, 18, 523, 94, 96, 2509, 2511, "RI" +264, 20, 19, 524, 97, 98, 2512, 2513, "." +264, 21, 1, 525, 0, 5, 2514, 2519, "TRIAL" +264, 21, 2, 526, 6, 18, 2520, 2532, "REGISTRATION" +264, 21, 3, 527, 19, 20, 2533, 2534, ":" +264, 21, 4, 528, 21, 35, 2535, 2549, "ClinicalTrials" +264, 21, 5, 529, 36, 37, 2550, 2551, "." +264, 21, 6, 530, 38, 41, 2552, 2555, "gov" +264, 21, 7, 531, 42, 53, 2556, 2567, "NCT00616811" +264, 21, 8, 532, 54, 55, 2568, 2569, "(" +264, 21, 9, 533, 56, 65, 2570, 2579, "completed" +264, 21, 10, 534, 66, 67, 2580, 2581, ")" +264, 21, 11, 535, 68, 75, 2582, 2589, "FUNDING" +264, 21, 12, 536, 76, 77, 2590, 2591, ":" +264, 21, 13, 537, 78, 82, 2592, 2596, "This" +264, 21, 14, 538, 83, 88, 2597, 2602, "study" +264, 21, 15, 539, 89, 92, 2603, 2606, "was" +264, 21, 16, 540, 93, 100, 2607, 2614, "planned" +264, 21, 17, 541, 101, 104, 2615, 2618, "and" +264, 21, 18, 542, 105, 114, 2619, 2628, "conducted" +264, 21, 19, 543, 115, 117, 2629, 2631, "by" +264, 21, 20, 544, 118, 126, 2632, 2640, "Novartis" +264, 21, 21, 545, 127, 128, 2641, 2642, "." +264, 22, 1, 546, 0, 3, 2643, 2646, "DOI" +264, 22, 2, 547, 4, 5, 2647, 2648, ":" +264, 22, 3, 548, 6, 8, 2649, 2651, "10" +264, 22, 4, 549, 9, 10, 2652, 2653, "." +264, 22, 5, 550, 11, 15, 2654, 2658, "1007" +264, 22, 6, 551, 16, 17, 2659, 2660, "/" +264, 22, 7, 552, 18, 24, 2661, 2667, "s00125" +264, 22, 8, 553, 25, 26, 2668, 2669, "-" +264, 22, 9, 554, 27, 30, 2670, 2673, "015" +264, 22, 10, 555, 31, 32, 2674, 2675, "-" +264, 22, 11, 556, 33, 37, 2676, 2680, "3655" +264, 22, 12, 557, 38, 39, 2681, 2682, "-" +264, 22, 13, 558, 40, 41, 2683, 2684, "z" +264, 22, 14, 559, 42, 47, 2685, 2690, "PMCID" +264, 22, 15, 560, 48, 49, 2691, 2692, ":" +264, 22, 16, 561, 50, 60, 2693, 2703, "PMC4526592" +264, 22, 17, 562, 61, 65, 2704, 2708, "PMID" +264, 22, 18, 563, 66, 67, 2709, 2710, ":" +264, 22, 19, 564, 68, 76, 2711, 2719, "26067186" +264, 22, 20, 565, 77, 78, 2720, 2721, "[" +264, 22, 21, 566, 79, 86, 2722, 2729, "Indexed" +264, 22, 22, 567, 87, 90, 2730, 2733, "for" +264, 22, 23, 568, 91, 98, 2734, 2741, "MEDLINE" +264, 22, 24, 569, 99, 100, 2742, 2743, "]" diff --git a/data/dm2 26067186_kwoodley.annodb b/data/dm2 26067186_kwoodley.annodb new file mode 100644 index 0000000..f811c83 --- /dev/null +++ b/data/dm2 26067186_kwoodley.annodb @@ -0,0 +1,98 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +55579, Journal, 0, 12, "Diabetologia", "", +55580, PublicationYear, 15, 19, "2015", "", +55601, Title, 111, 246, "Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .", "", +55581, Vildagliptin, 125, 137, "vildagliptin", "", +55588, Sitagliptin, 142, 153, "sitagliptin", "", +55595, Type2Diabetes, 171, 186, "type 2 diabetes", "", +55598, Randomized, 219, 229, "randomised", "", +55602, Author, 247, 255, "Kothny W", "", +55603, Author, 264, 277, "Lukashevich V", "", +55604, Author, 280, 288, "Foley JE", "", +55605, Author, 291, 301, "Rendell MS", "", +55606, Author, 304, 315, "Schweizer A", "", +55607, Switzerland, 397, 408, "Switzerland", "", +55610, ObjectiveDescription, 560, 697, "We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .", "", +55582, Vildagliptin, 599, 611, "vildagliptin", "", +55589, Sitagliptin, 616, 627, "sitagliptin", "", +55608, Precondition, 631, 695, "patients with type 2 diabetes and severe renal impairment ( RI )", "", +55596, Type2Diabetes, 645, 660, "type 2 diabetes", "", +55611, Parallel, 725, 739, "parallel - arm", "", +55599, Randomized, 742, 752, "randomised", "", +55612, Multicenter, 755, 766, "multicentre", "", +55613, DoubleBlind, 769, 783, "double - blind", "", +55614, Duration, 786, 793, "24 week", "", +55615, Brazil, 831, 837, "Brazil", "", +55616, USA, 846, 849, "USA", "", +55624, Precondition, 852, 1098, "Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control ( HbA1c 6 . 5 - 10 . 0 % [ 48 - 86 mmol / mol ] ) and an estimated GFR < 30 ml min ( - 1 ) [ 1 . 73 m ] ( - 2 )", "", +55597, Type2Diabetes, 866, 881, "type 2 diabetes", "", +55617, HbA1c, 989, 994, "HbA1c", "", +55620, Percentage, 1010, 1011, "%", "", +55621, BioAndMedicalUnit, 1022, 1032, "mmol / mol", "", +55622, BioAndMedicalUnit, 1063, 1069, "ml min", "", +55623, BioAndMedicalUnit, 1087, 1088, "m", "", +55600, Randomized, 1104, 1114, "randomised", "", +55583, Vildagliptin, 1164, 1176, "vildagliptin", "", +55625, DoseValue, 1177, 1179, "50", "", +55628, mg, 1180, 1182, "mg", "", +55630, Frequency, 1183, 1193, "once daily", "", +55590, Sitagliptin, 1197, 1208, "sitagliptin", "", +55627, DoseValue, 1209, 1211, "25", "", +55629, mg, 1212, 1214, "mg", "", +55631, Frequency, 1215, 1225, "once daily", "", +55619, HbA1c, 1438, 1443, "HbA1c", "", +55632, FastingPlasmaGlucose, 1448, 1470, "fasting plasma glucose", "", +55633, FastingPlasmaGlucose, 1473, 1476, "FPG", "", +55635, EndPointDescription, 1564, 1578, "adverse events", "", +55636, NumberPatientsCT, 1602, 1605, "148", "", +55637, Randomized, 1620, 1630, "randomised", "", +55638, NumberPatientsArm, 1633, 1635, "83", "", +55584, Vildagliptin, 1639, 1651, "vildagliptin", "", +55639, NumberPatientsArm, 1656, 1658, "65", "", +55591, Sitagliptin, 1662, 1673, "sitagliptin", "", +55640, TimePoint, 1711, 1719, "24 weeks", "", +55618, HbA1c, 1750, 1755, "HbA1c", "", +55642, Reduction, 1762, 1768, "0 . 54", "", +55648, Percentage, 1769, 1770, "%", "", +55645, Reduction, 1773, 1778, "5 . 9", "", +55650, BioAndMedicalUnit, 1779, 1789, "mmol / mol", "", +55641, TimePoint, 1799, 1807, "baseline", "", +55654, BaseLineValue, 1811, 1817, "7 . 52", "", +55658, Percentage, 1818, 1819, "%", "", +55657, BaseLineValue, 1822, 1824, "59", "", +55651, BioAndMedicalUnit, 1825, 1835, "mmol / mol", "", +55585, Vildagliptin, 1843, 1855, "vildagliptin", "", +55644, Reduction, 1862, 1868, "0 . 56", "", +55649, Percentage, 1869, 1870, "%", "", +55646, Reduction, 1873, 1878, "6 . 1", "", +55652, BioAndMedicalUnit, 1879, 1889, "mmol / mol", "", +55647, TimePoint, 1899, 1907, "baseline", "", +55655, BaseLineValue, 1911, 1917, "7 . 80", "", +55659, Percentage, 1918, 1919, "%", "", +55656, BaseLineValue, 1922, 1924, "62", "", +55653, BioAndMedicalUnit, 1925, 1935, "mmol / mol", "", +55592, Sitagliptin, 1943, 1954, "sitagliptin", "", +55660, PvalueDiff, 1957, 1970, "p  =  0 . 874", "", +55634, FastingPlasmaGlucose, 1975, 1978, "FPG", "", +55661, Reduction, 1992, 1998, "0 . 47", "", +55662, SdDevChangeValue, 2003, 2009, "0 . 37", "", +55664, Millimoles_per_litre, 2010, 2018, "mmol / l", "", +55586, Vildagliptin, 2024, 2036, "vildagliptin", "", +55666, Increment, 2054, 2060, "0 . 16", "", +55663, SdDevChangeValue, 2065, 2071, "0 . 43", "", +55665, Millimoles_per_litre, 2072, 2080, "mmol / l", "", +55593, Sitagliptin, 2086, 2097, "sitagliptin", "", +55667, PvalueDiff, 2100, 2113, "p  =  0 . 185", "", +55675, ConclusionComment, 2224, 2414, "At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .", "", +55668, Precondition, 2255, 2264, "severe RI", "", +55587, Vildagliptin, 2267, 2279, "vildagliptin", "", +55669, DoseValue, 2282, 2284, "50", "", +55671, mg, 2285, 2287, "mg", "", +55673, Frequency, 2288, 2298, "once daily", "", +55594, Sitagliptin, 2315, 2326, "sitagliptin", "", +55670, DoseValue, 2329, 2331, "25", "", +55672, mg, 2332, 2334, "mg", "", +55674, Frequency, 2335, 2345, "once daily", "", +55676, ConclusionComment, 2415, 2513, "This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .", "", +55609, Precondition, 2488, 2511, "patients with severe RI", "", +55677, PMID, 2711, 2719, "26067186", "", diff --git a/data/dm2 26067186_kwoodley.n-triples b/data/dm2 26067186_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26067186_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26598090_admin.annodb b/data/dm2 26598090_admin.annodb new file mode 100644 index 0000000..f02fe85 --- /dev/null +++ b/data/dm2 26598090_admin.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Pharmacotherapy", "", " \"Pharmacotherapy\"." +1, PublicationYear, 18, 22, "2015", "", " \"2015\"." +21, Title, 102, 273, "Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy : A Placebo - Controlled Trial .", "", " \"Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy : A Placebo - Controlled Trial .\"." +100165, Acarbose, 112, 120, "Acarbose", "", +14, Precondition, 148, 240, "Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy", "", " \"Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy\"." +10, Type2Diabetes, 180, 204, "Type 2 Diabetes Mellitus", "", " ." +15, Placebo, 245, 252, "Placebo", "", +22, Author, 274, 282, "Derosa G", "", " \"Derosa G\"." +23, Author, 303, 314, "Franzetti I", "", " \"Franzetti I\"." +24, Author, 323, 331, "Querci F", "", " \"Querci F\"." +25, Author, 340, 352, "D ' Angelo A", "", +26, Author, 367, 377, "Maffioli P", "", " \"Maffioli P\"." +27, Italy, 546, 551, "Italy", "", +28, Italy, 676, 681, "Italy", "", +29, Italy, 755, 760, "Italy", "", +30, Italy, 836, 841, "Italy", "", +31, Italy, 906, 911, "Italy", "", +32, Italy, 988, 993, "Italy", "", +40, ObjectiveDescription, 1014, 1255, "To evaluate the effect of acarbose on glycemic control and glycemic variability , using a continuous glucose - monitoring system , in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy .", "", " \"To evaluate the effect of acarbose on glycemic control and glycemic variability , using a continuous glucose - monitoring system , in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy .\"." +100163, Acarbose, 1040, 1048, "acarbose", "", +39, Precondition, 1148, 1253, "patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy", "", " \"patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy\"." +11, Type2Diabetes, 1162, 1186, "type 2 diabetes mellitus", "", +33, Metformin, 1219, 1228, "metformin", "", +36, Vildagliptin, 1233, 1245, "vildagliptin", "", +41, Multicenter, 1265, 1276, "Multicenter", "", +42, Randomized, 1279, 1289, "randomized", "", " ." +43, DoubleBlind, 1292, 1306, "double - blind", "", " ." +16, Placebo, 1309, 1316, "placebo", "", +145, Multicenter, 1375, 1390, "three hospitals", "", " ." +146, Italy, 1394, 1399, "Italy", "", " ." +147, NumberPatientsCT, 1413, 1426, "Fifty - three", "", " \"Fifty - three\"." +12, Type2Diabetes, 1441, 1456, "type 2 diabetes", "", +46, Metformin, 1491, 1500, "metformin", "", +48, DoseValue, 1501, 1504, "850", "", +50, mg, 1505, 1507, "mg", "", +52, Frequency, 1508, 1521, "3 times / day", "", +47, Vildagliptin, 1526, 1538, "vildagliptin", "", +49, DoseValue, 1539, 1541, "50", "", +51, mg, 1542, 1544, "mg", "", +53, Frequency, 1545, 1556, "twice / day", "", +54, Duration, 1570, 1578, "3 months", "", +56, Randomized, 1670, 1680, "randomized", "", +17, Placebo, 1691, 1698, "placebo", "", " ." +100164, Acarbose, 1702, 1710, "acarbose", "", +57, DoseValue, 1711, 1714, "100", "", " \"100\"." +58, mg, 1715, 1717, "mg", "", " ." +59, Frequency, 1718, 1731, "3 times / day", "", " \"3 times / day\"." +34, Metformin, 1753, 1762, "metformin", "", +37, Vildagliptin, 1765, 1777, "vildagliptin", "", +60, MeasurementDevice, 1865, 1903, "continuous glucose - monitoring system", "", +167, Duration, 1908, 1914, "1 week", "", " \"1 week\"." +100175, Mean, 1955, 1959, "mean", "", " . ." +100173, BloodGlucose, 1960, 1973, "blood glucose", "", " ." +62, BloodGlucose, 1976, 1979, "MBG", "", +100176, EndPointDescription, 1994, 2080, "area under the glucose concentration - time curve for a glucose level above 70 mg / dl", "", " . ." +63, Mg_per_deciliter, 2073, 2080, "mg / dl", "", +186, EndPointDescription, 2083, 2095, "AUC above 70", "", +187, EndPointDescription, 2101, 2112, "180 mg / dl", "", +64, Mg_per_deciliter, 2105, 2112, "mg / dl", "", +188, EndPointDescription, 2115, 2128, "AUC above 180", "", " . ." +195, EndPointDescription, 2137, 2203, "the percentage of time that the glucose level was above 70 mg / dl", "", +65, Mg_per_deciliter, 2196, 2203, "mg / dl", "", +196, EndPointDescription, 2206, 2216, "T above 70", "", +197, EndPointDescription, 2222, 2233, "180 mg / dl", "", +66, Mg_per_deciliter, 2226, 2233, "mg / dl", "", +198, EndPointDescription, 2236, 2247, "T above 180", "", " . ." +67, BloodGlucose, 2328, 2341, "blood glucose", "", +78, EndPointDescription, 2354, 2391, "mean amplitude of glycemic excursions", "", " . ." +77, EndPointDescription, 2394, 2398, "MAGE", "", +79, EndPointDescription, 2407, 2414, "M value", "", +83, EndPointDescription, 2522, 2546, "mean of daily difference", "", " . ." +82, EndPointDescription, 2549, 2553, "MODD", "", +68, EndPointDescription, 2562, 2565, "MBG", "", +85, ObservedResult, 2572, 2703, "was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period", "", " \"was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period\". \"was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period\"." +180, DiffGroupAbsValue, 2576, 2580, "~ 20", "", " \"~ 20\"." +84, Mg_per_deciliter, 2581, 2588, "mg / dl", "", " ." +100166, Acarbose, 2602, 2610, "acarbose", "", +18, Placebo, 2629, 2636, "placebo", "", +183, PvalueDiff, 2645, 2655, "p < 0 . 05", "", " \"p < 0 . 05\"." +184, EndPointDescription, 2710, 2722, "AUC above 70", "", +97, ObservedResult, 2723, 2774, "did not significantly differ between the two groups", "", " \"did not significantly differ between the two groups\". \"did not significantly differ between the two groups\"." +189, EndPointDescription, 2789, 2802, "AUC above 180", "", +98, ObservedResult, 2803, 2886, "was ~ 40 % lower in the acarbose group than in the placebo group during the daytime", "", " \"was ~ 40 % lower in the acarbose group than in the placebo group during the daytime\". \"was ~ 40 % lower in the acarbose group than in the placebo group during the daytime\"." +190, DiffGroupRelValue, 2807, 2811, "~ 40", "", " \"~ 40\"." +100168, Acarbose, 2827, 2835, "acarbose", "", +19, Placebo, 2854, 2861, "placebo", "", +100, RelativeTime, 2879, 2886, "daytime", "", +101, PvalueDiff, 2889, 2899, "p < 0 . 01", "", " \"p < 0 . 01\"." +199, EndPointDescription, 2908, 2919, "T above 180", "", +20, Placebo, 2952, 2959, "placebo", "", +100169, Acarbose, 2978, 2986, "acarbose", "", +102, ResultMeasuredValue, 2995, 2997, "31", "", " \"31\"." +104, Percentage, 2998, 2999, "%", "", +103, ResultMeasuredValue, 3003, 3004, "8", "", " \"8\"." +105, Percentage, 3005, 3006, "%", "", +106, PvalueDiff, 3009, 3019, "p < 0 . 01", "", " \"p < 0 . 01\"." +87, ObservedResult, 3033, 3118, "the standard deviation and MAGE values were significantly lower in the acarbose group", "", " \"the standard deviation and MAGE values were significantly lower in the acarbose group\"." +76, EndPointDescription, 3060, 3064, "MAGE", "", +86, ObservedResult, 3121, 3245, "The MODD value was not significantly changed in either group , and no significant differences were recorded between groups .", "", " \"The MODD value was not significantly changed in either group , and no significant differences were recorded between groups .\". \"The MODD value was not significantly changed in either group , and no significant differences were recorded between groups .\"." +80, EndPointDescription, 3125, 3129, "MODD", "", +93667, ObservedResult, 3246, 3289, "All adverse events were mild in both groups", "", " \"All adverse events were mild in both groups\". \"All adverse events were mild in both groups\"." +81, EndPointDescription, 3250, 3264, "adverse events", "", " . ." +207, EndPointDescription, 3339, 3349, "flatulence", "", " . ." +100170, Acarbose, 3363, 3371, "acarbose", "", +213, PercentageAffected, 3380, 3381, "5", "", " \"5\"." +100171, Acarbose, 3389, 3397, "acarbose", "", +214, PercentageAffected, 3401, 3406, "0 . 5", "", " \"0 . 5\"." +112, Placebo, 3414, 3421, "placebo", "", +113, PvalueDiff, 3424, 3434, "p < 0 . 05", "", " \"p < 0 . 05\"." +114, ConclusionComment, 3452, 3662, "The addition of acarbose to metformin and vildagliptin background therapy in patients with inadequately controlled type 2 diabetes decreased intraday glycemic variability , especially postprandial variability ,", "", " \"The addition of acarbose to metformin and vildagliptin background therapy in patients with inadequately controlled type 2 diabetes decreased intraday glycemic variability , especially postprandial variability ,\"." +100172, Acarbose, 3468, 3476, "acarbose", "", +35, Metformin, 3480, 3489, "metformin", "", +38, Vildagliptin, 3494, 3506, "vildagliptin", "", +13, Type2Diabetes, 3567, 3582, "type 2 diabetes", "", +115, ConclusionComment, 3663, 3749, "but it was not associated with a significant change in interday glycemic variability .", "", " \"but it was not associated with a significant change in interday glycemic variability .\"." +116, PMID, 3831, 3839, "26598090", "", " \"26598090\"." diff --git a/data/dm2 26598090_admin.n-triples b/data/dm2 26598090_admin.n-triples new file mode 100644 index 0000000..48bac26 --- /dev/null +++ b/data/dm2 26598090_admin.n-triples @@ -0,0 +1,228 @@ +# RDF export of group: Publication + . + "Publication 68517" . + "Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy : A Placebo - Controlled Trial ." . + "Derosa G" . + "2015" . + "Pharmacotherapy" . + "26598090" . + . + "Franzetti I" . + "Querci F" . + "Maffioli P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 68524" . + "To evaluate the effect of acarbose on glycemic control and glycemic variability , using a continuous glucose - monitoring system , in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy ." . + "Fifty - three" . + "1 week" . + . + . + . + "The addition of acarbose to metformin and vildagliptin background therapy in patients with inadequately controlled type 2 diabetes decreased intraday glycemic variability , especially postprandial variability ," . + . + . + . + . + . + . + "but it was not associated with a significant change in interday glycemic variability ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population 68540" . + "Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy" . + . + . + . + "patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy" . +# RDF export of group: Endpoint + . + "mbg" . + . + . + . + . + . + . + "auc70" . + . + . + . + . + . + . + "auc18" . + . + . + . + . + . + . + "t18" . + . + . + . + . + . + . + "mag" . + . + . + . + . + . + . + "mod" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "flat" . + . + . + . + . + . +# RDF export of group: Arm + . + "aca" . + . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "aca" . + . + "3 times / day" . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "aca" . + . + "100" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "mbg 1" . + . + "was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period" . + . + "mbg 2" . + . + "was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period" . + . + "auc70 1" . + . + "did not significantly differ between the two groups" . + . + "auc70 2" . + . + "did not significantly differ between the two groups" . + . + "auc18 1" . + . + "was ~ 40 % lower in the acarbose group than in the placebo group during the daytime" . + . + "auc18 2" . + . + "was ~ 40 % lower in the acarbose group than in the placebo group during the daytime" . + . + "t18 1" . + . + "8" . + . + "t18 2" . + . + "31" . + . + "mag 1" . + . + "the standard deviation and MAGE values were significantly lower in the acarbose group" . + . + "mod 1" . + . + "The MODD value was not significantly changed in either group , and no significant differences were recorded between groups ." . + . + "mod 2" . + . + "The MODD value was not significantly changed in either group , and no significant differences were recorded between groups ." . + . + "ae 1" . + . + "All adverse events were mild in both groups" . + . + "ae 2" . + . + "All adverse events were mild in both groups" . + . + "fla 1" . + . + "5" . + . + "fla 2" . + . + "0 . 5" . +# RDF export of group: DiffBetweenGroups + . + "mbg" . + "~ 20" . + "p < 0 . 05" . + . + . + . + "auch18" . + "~ 40" . + "p < 0 . 01" . + . + . + . + "t18" . + "p < 0 . 01" . + . + . + . + "flat" . + "p < 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26598090_akramersunderbrink.annodb b/data/dm2 26598090_akramersunderbrink.annodb new file mode 100644 index 0000000..2d4b8fe --- /dev/null +++ b/data/dm2 26598090_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +61633, Journal, 0, 15, "Pharmacotherapy", "", +61634, PublicationYear, 18, 22, "2015", "", +61651, Title, 102, 273, "Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy : A Placebo - Controlled Trial .", "", +61650, Drug, 112, 120, "Acarbose", "", +61636, Precondition, 162, 179, "Poorly Controlled", "", +61635, Type2Diabetes, 180, 204, "Type 2 Diabetes Mellitus", "", +61637, Placebo, 245, 252, "Placebo", "", +61638, Author, 274, 282, "Derosa G", "", +61639, Author, 303, 314, "Franzetti I", "", +61640, Author, 323, 331, "Querci F", "", +61641, Author, 340, 352, "D ' Angelo A", "", +61642, Author, 367, 377, "Maffioli P", "", +61643, Italy, 546, 551, "Italy", "", +61644, Italy, 676, 681, "Italy", "", +61645, Italy, 755, 760, "Italy", "", +61646, Italy, 836, 841, "Italy", "", +61647, Italy, 906, 911, "Italy", "", +61648, Italy, 988, 993, "Italy", "", +61656, ObjectiveDescription, 1014, 1255, "To evaluate the effect of acarbose on glycemic control and glycemic variability , using a continuous glucose - monitoring system , in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy .", "", +61649, Drug, 1040, 1048, "acarbose", "", +61652, Type2Diabetes, 1162, 1186, "type 2 diabetes mellitus", "", +61655, Precondition, 1196, 1253, "not well controlled on metformin and vildagliptin therapy", "", +61653, Metformin, 1219, 1228, "metformin", "", +61654, Vildagliptin, 1233, 1245, "vildagliptin", "", +61657, Multicenter, 1265, 1276, "Multicenter", "", +61658, Randomized, 1279, 1289, "randomized", "", +61660, DoubleBlind, 1292, 1306, "double - blind", "", +61661, Placebo, 1309, 1316, "placebo", "", +61662, Multicenter, 1375, 1390, "three hospitals", "", +61663, Italy, 1394, 1399, "Italy", "", +61664, NumberPatientsCT, 1413, 1426, "Fifty - three", "", +61665, Type2Diabetes, 1441, 1456, "type 2 diabetes", "", +61666, Metformin, 1491, 1500, "metformin", "", +61667, DoseValue, 1501, 1507, "850 mg", "", +61673, mg, 1505, 1507, "mg", "", +61670, Frequency, 1508, 1521, "3 times / day", "", +61676, Vildagliptin, 1526, 1538, "vildagliptin", "", +61668, DoseValue, 1539, 1544, "50 mg", "", +61674, mg, 1542, 1544, "mg", "", +61671, Frequency, 1545, 1556, "twice / day", "", +61677, Duration, 1570, 1578, "3 months", "", +61678, Precondition, 1592, 1638, "not adequately controlled with these therapies", "", +61679, Randomized, 1670, 1680, "randomized", "", +61680, Placebo, 1691, 1698, "placebo", "", +61681, Drug, 1702, 1710, "acarbose", "", +61669, DoseValue, 1711, 1717, "100 mg", "", +61675, mg, 1715, 1717, "mg", "", +61672, Frequency, 1718, 1731, "3 times / day", "", +61682, Metformin, 1753, 1762, "metformin", "", +61683, Vildagliptin, 1765, 1777, "vildagliptin", "", +61684, Duration, 1908, 1914, "1 week", "", +61685, Mean, 1955, 1959, "mean", "", +61686, BloodGlucose, 1960, 1973, "blood glucose", "", +61687, BloodGlucose, 1976, 1979, "MBG", "", +61702, EndPointDescription, 1994, 2080, "area under the glucose concentration - time curve for a glucose level above 70 mg / dl", "", +61688, Mg_per_deciliter, 2073, 2080, "mg / dl", "", +61703, EndPointDescription, 2083, 2095, "AUC above 70", "", +61704, EndPointDescription, 2101, 2112, "180 mg / dl", "", +61689, Mg_per_deciliter, 2105, 2112, "mg / dl", "", +61705, EndPointDescription, 2115, 2128, "AUC above 180", "", +61712, EndPointDescription, 2137, 2203, "the percentage of time that the glucose level was above 70 mg / dl", "", +61690, Mg_per_deciliter, 2196, 2203, "mg / dl", "", +61713, EndPointDescription, 2206, 2216, "T above 70", "", +61714, EndPointDescription, 2222, 2233, "180 mg / dl", "", +61691, Mg_per_deciliter, 2226, 2233, "mg / dl", "", +61715, EndPointDescription, 2236, 2247, "T above 180", "", +61692, BloodGlucose, 2328, 2347, "blood glucose level", "", +61693, Mean, 2354, 2358, "mean", "", +61694, Mean, 2522, 2526, "mean", "", +61695, BloodGlucose, 2562, 2565, "MBG", "", +61697, DiffGroupAbsValue, 2576, 2580, "~ 20", "", +61696, Mg_per_deciliter, 2581, 2588, "mg / dl", "", +61698, Drug, 2602, 2610, "acarbose", "", +61699, Placebo, 2629, 2636, "placebo", "", +61700, PvalueDiff, 2645, 2655, "p < 0 . 05", "", +61701, EndPointDescription, 2710, 2722, "AUC above 70", "", +61706, EndPointDescription, 2789, 2802, "AUC above 180", "", +61707, DiffGroupRelValue, 2807, 2811, "~ 40", "", +61708, Percentage, 2812, 2813, "%", "", +61709, Drug, 2827, 2835, "acarbose", "", +61710, Placebo, 2854, 2861, "placebo", "", +61711, PvalueDiff, 2889, 2899, "p < 0 . 01", "", +61716, EndPointDescription, 2908, 2919, "T above 180", "", +61717, Placebo, 2952, 2959, "placebo", "", +61718, Drug, 2978, 2986, "acarbose", "", +61721, ResultMeasuredValue, 2995, 2997, "31", "", +61719, Percentage, 2998, 2999, "%", "", +61722, ResultMeasuredValue, 3003, 3004, "8", "", +61720, Percentage, 3005, 3006, "%", "", +61723, PvalueDiff, 3009, 3019, "p < 0 . 01", "", +61724, EndPointDescription, 3339, 3349, "flatulence", "", +61725, Drug, 3363, 3371, "acarbose", "", +61730, PercentageAffected, 3380, 3381, "5", "", +61728, Percentage, 3382, 3383, "%", "", +61726, Drug, 3389, 3397, "acarbose", "", +61731, PercentageAffected, 3401, 3406, "0 . 5", "", +61729, Percentage, 3407, 3408, "%", "", +61727, Placebo, 3414, 3421, "placebo", "", +61732, PvalueDiff, 3424, 3434, "p < 0 . 05", "", +61738, ConclusionComment, 3452, 3662, "The addition of acarbose to metformin and vildagliptin background therapy in patients with inadequately controlled type 2 diabetes decreased intraday glycemic variability , especially postprandial variability ,", "", +61733, Drug, 3468, 3476, "acarbose", "", +61734, Metformin, 3480, 3489, "metformin", "", +61735, Vildagliptin, 3494, 3506, "vildagliptin", "", +61736, Type2Diabetes, 3567, 3582, "type 2 diabetes", "", +61739, ConclusionComment, 3663, 3749, "but it was not associated with a significant change in interday glycemic variability .", "", +61737, PMID, 3831, 3839, "26598090", "", diff --git a/data/dm2 26598090_akramersunderbrink.n-triples b/data/dm2 26598090_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26598090_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26598090_export.csv b/data/dm2 26598090_export.csv new file mode 100644 index 0000000..0e0bd11 --- /dev/null +++ b/data/dm2 26598090_export.csv @@ -0,0 +1,762 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +263, 1, 1, 1, 0, 15, 0, 15, "Pharmacotherapy" +263, 1, 2, 2, 16, 17, 16, 17, "." +263, 2, 1, 3, 0, 4, 18, 22, "2015" +263, 2, 2, 4, 5, 8, 23, 26, "Nov" +263, 2, 3, 5, 9, 10, 27, 28, ";" +263, 2, 4, 6, 11, 13, 29, 31, "35" +263, 2, 5, 7, 14, 15, 32, 33, "(" +263, 2, 6, 8, 16, 18, 34, 36, "11" +263, 2, 7, 9, 19, 20, 37, 38, ")" +263, 2, 8, 10, 21, 22, 39, 40, ":" +263, 2, 9, 11, 23, 26, 41, 44, "983" +263, 2, 10, 12, 27, 28, 45, 46, "-" +263, 2, 11, 13, 29, 31, 47, 49, "90" +263, 2, 12, 14, 32, 33, 50, 51, "." +263, 2, 13, 15, 34, 37, 52, 55, "doi" +263, 2, 14, 16, 38, 39, 56, 57, ":" +263, 2, 15, 17, 40, 42, 58, 60, "10" +263, 2, 16, 18, 43, 44, 61, 62, "." +263, 2, 17, 19, 45, 49, 63, 67, "1002" +263, 2, 18, 20, 50, 51, 68, 69, "/" +263, 2, 19, 21, 52, 56, 70, 74, "phar" +263, 2, 20, 22, 57, 58, 75, 76, "." +263, 2, 21, 23, 59, 63, 77, 81, "1648" +263, 2, 22, 24, 64, 65, 82, 83, "." +263, 3, 1, 25, 0, 4, 84, 88, "Epub" +263, 3, 2, 26, 5, 9, 89, 93, "2015" +263, 3, 3, 27, 10, 13, 94, 97, "Nov" +263, 3, 4, 28, 14, 15, 98, 99, "2" +263, 3, 5, 29, 16, 17, 100, 101, "." +263, 4, 1, 30, 0, 6, 102, 108, "Effect" +263, 4, 2, 31, 7, 9, 109, 111, "of" +263, 4, 3, 32, 10, 18, 112, 120, "Acarbose" +263, 4, 4, 33, 19, 21, 121, 123, "on" +263, 4, 5, 34, 22, 30, 124, 132, "Glycemic" +263, 4, 6, 35, 31, 42, 133, 144, "Variability" +263, 4, 7, 36, 43, 45, 145, 147, "in" +263, 4, 8, 37, 46, 54, 148, 156, "Patients" +263, 4, 9, 38, 55, 59, 157, 161, "with" +263, 4, 10, 39, 60, 66, 162, 168, "Poorly" +263, 4, 11, 40, 67, 77, 169, 179, "Controlled" +263, 4, 12, 41, 78, 82, 180, 184, "Type" +263, 4, 13, 42, 83, 84, 185, 186, "2" +263, 4, 14, 43, 85, 93, 187, 195, "Diabetes" +263, 4, 15, 44, 94, 102, 196, 204, "Mellitus" +263, 4, 16, 45, 103, 112, 205, 214, "Receiving" +263, 4, 17, 46, 113, 119, 215, 221, "Stable" +263, 4, 18, 47, 120, 130, 222, 232, "Background" +263, 4, 19, 48, 131, 138, 233, 240, "Therapy" +263, 4, 20, 49, 139, 140, 241, 242, ":" +263, 4, 21, 50, 141, 142, 243, 244, "A" +263, 4, 22, 51, 143, 150, 245, 252, "Placebo" +263, 4, 23, 52, 151, 152, 253, 254, "-" +263, 4, 24, 53, 153, 163, 255, 265, "Controlled" +263, 4, 25, 54, 164, 169, 266, 271, "Trial" +263, 4, 26, 55, 170, 171, 272, 273, "." +263, 5, 1, 56, 0, 6, 274, 280, "Derosa" +263, 5, 2, 57, 7, 8, 281, 282, "G" +263, 5, 3, 58, 9, 10, 283, 284, "(" +263, 5, 4, 59, 11, 12, 285, 286, "1" +263, 5, 5, 60, 13, 14, 287, 288, ")" +263, 5, 6, 61, 15, 16, 289, 290, "(" +263, 5, 7, 62, 17, 18, 291, 292, "2" +263, 5, 8, 63, 19, 20, 293, 294, ")" +263, 5, 9, 64, 21, 22, 295, 296, "(" +263, 5, 10, 65, 23, 24, 297, 298, "3" +263, 5, 11, 66, 25, 26, 299, 300, ")" +263, 5, 12, 67, 27, 28, 301, 302, "," +263, 5, 13, 68, 29, 38, 303, 312, "Franzetti" +263, 5, 14, 69, 39, 40, 313, 314, "I" +263, 5, 15, 70, 41, 42, 315, 316, "(" +263, 5, 16, 71, 43, 44, 317, 318, "4" +263, 5, 17, 72, 45, 46, 319, 320, ")" +263, 5, 18, 73, 47, 48, 321, 322, "," +263, 5, 19, 74, 49, 55, 323, 329, "Querci" +263, 5, 20, 75, 56, 57, 330, 331, "F" +263, 5, 21, 76, 58, 59, 332, 333, "(" +263, 5, 22, 77, 60, 61, 334, 335, "5" +263, 5, 23, 78, 62, 63, 336, 337, ")" +263, 5, 24, 79, 64, 65, 338, 339, "," +263, 5, 25, 80, 66, 67, 340, 341, "D" +263, 5, 26, 81, 68, 69, 342, 343, "'" +263, 5, 27, 82, 70, 76, 344, 350, "Angelo" +263, 5, 28, 83, 77, 78, 351, 352, "A" +263, 5, 29, 84, 79, 80, 353, 354, "(" +263, 5, 30, 85, 81, 82, 355, 356, "1" +263, 5, 31, 86, 83, 84, 357, 358, ")" +263, 5, 32, 87, 85, 86, 359, 360, "(" +263, 5, 33, 88, 87, 88, 361, 362, "3" +263, 5, 34, 89, 89, 90, 363, 364, ")" +263, 5, 35, 90, 91, 92, 365, 366, "," +263, 5, 36, 91, 93, 101, 367, 375, "Maffioli" +263, 5, 37, 92, 102, 103, 376, 377, "P" +263, 5, 38, 93, 104, 105, 378, 379, "(" +263, 5, 39, 94, 106, 107, 380, 381, "1" +263, 5, 40, 95, 108, 109, 382, 383, ")" +263, 5, 41, 96, 110, 111, 384, 385, "(" +263, 5, 42, 97, 112, 113, 386, 387, "6" +263, 5, 43, 98, 114, 115, 388, 389, ")" +263, 5, 44, 99, 116, 117, 390, 391, "." +263, 6, 1, 100, 0, 6, 392, 398, "Author" +263, 6, 2, 101, 7, 18, 399, 410, "information" +263, 6, 3, 102, 19, 20, 411, 412, ":" +263, 6, 4, 103, 21, 22, 413, 414, "(" +263, 6, 5, 104, 23, 24, 415, 416, "1" +263, 6, 6, 105, 25, 26, 417, 418, ")" +263, 6, 7, 106, 27, 37, 419, 429, "Department" +263, 6, 8, 107, 38, 40, 430, 432, "of" +263, 6, 9, 108, 41, 49, 433, 441, "Internal" +263, 6, 10, 109, 50, 58, 442, 450, "Medicine" +263, 6, 11, 110, 59, 62, 451, 454, "and" +263, 6, 12, 111, 63, 75, 455, 467, "Therapeutics" +263, 6, 13, 112, 76, 77, 468, 469, "," +263, 6, 14, 113, 78, 88, 470, 480, "University" +263, 6, 15, 114, 89, 91, 481, 483, "of" +263, 6, 16, 115, 92, 97, 484, 489, "Pavia" +263, 6, 17, 116, 98, 99, 490, 491, "," +263, 6, 18, 117, 100, 103, 492, 495, "and" +263, 6, 19, 118, 104, 114, 496, 506, "Fondazione" +263, 6, 20, 119, 115, 120, 507, 512, "IRCCS" +263, 6, 21, 120, 121, 132, 513, 524, "Policlinico" +263, 6, 22, 121, 133, 134, 525, 526, "S" +263, 6, 23, 122, 135, 136, 527, 528, "." +263, 6, 24, 123, 137, 143, 529, 535, "Matteo" +263, 6, 25, 124, 144, 145, 536, 537, "," +263, 6, 26, 125, 146, 151, 538, 543, "Pavia" +263, 6, 27, 126, 152, 153, 544, 545, "," +263, 6, 28, 127, 154, 159, 546, 551, "Italy" +263, 6, 29, 128, 160, 161, 552, 553, "." +263, 7, 1, 129, 0, 1, 554, 555, "(" +263, 7, 2, 130, 2, 3, 556, 557, "2" +263, 7, 3, 131, 4, 5, 558, 559, ")" +263, 7, 4, 132, 6, 12, 560, 566, "Center" +263, 7, 5, 133, 13, 16, 567, 570, "for" +263, 7, 6, 134, 17, 20, 571, 574, "the" +263, 7, 7, 135, 21, 26, 575, 580, "Study" +263, 7, 8, 136, 27, 29, 581, 583, "of" +263, 7, 9, 137, 30, 39, 584, 593, "Endocrine" +263, 7, 10, 138, 40, 41, 594, 595, "-" +263, 7, 11, 139, 42, 51, 596, 605, "Metabolic" +263, 7, 12, 140, 52, 67, 606, 621, "Pathophysiology" +263, 7, 13, 141, 68, 71, 622, 625, "and" +263, 7, 14, 142, 72, 80, 626, 634, "Clinical" +263, 7, 15, 143, 81, 89, 635, 643, "Research" +263, 7, 16, 144, 90, 91, 644, 645, "," +263, 7, 17, 145, 92, 102, 646, 656, "University" +263, 7, 18, 146, 103, 105, 657, 659, "of" +263, 7, 19, 147, 106, 111, 660, 665, "Pavia" +263, 7, 20, 148, 112, 113, 666, 667, "," +263, 7, 21, 149, 114, 119, 668, 673, "Pavia" +263, 7, 22, 150, 120, 121, 674, 675, "," +263, 7, 23, 151, 122, 127, 676, 681, "Italy" +263, 7, 24, 152, 128, 129, 682, 683, "." +263, 8, 1, 153, 0, 1, 684, 685, "(" +263, 8, 2, 154, 2, 3, 686, 687, "3" +263, 8, 3, 155, 4, 5, 688, 689, ")" +263, 8, 4, 156, 6, 16, 690, 700, "Laboratory" +263, 8, 5, 157, 17, 19, 701, 703, "of" +263, 8, 6, 158, 20, 29, 704, 713, "Molecular" +263, 8, 7, 159, 30, 38, 714, 722, "Medicine" +263, 8, 8, 160, 39, 40, 723, 724, "," +263, 8, 9, 161, 41, 51, 725, 735, "University" +263, 8, 10, 162, 52, 54, 736, 738, "of" +263, 8, 11, 163, 55, 60, 739, 744, "Pavia" +263, 8, 12, 164, 61, 62, 745, 746, "," +263, 8, 13, 165, 63, 68, 747, 752, "Pavia" +263, 8, 14, 166, 69, 70, 753, 754, "," +263, 8, 15, 167, 71, 76, 755, 760, "Italy" +263, 8, 16, 168, 77, 78, 761, 762, "." +263, 9, 1, 169, 0, 1, 763, 764, "(" +263, 9, 2, 170, 2, 3, 765, 766, "4" +263, 9, 3, 171, 4, 5, 767, 768, ")" +263, 9, 4, 172, 6, 15, 769, 778, "Metabolic" +263, 9, 5, 173, 16, 20, 779, 783, "Unit" +263, 9, 6, 174, 21, 22, 784, 785, "," +263, 9, 7, 175, 23, 24, 786, 787, "S" +263, 9, 8, 176, 25, 26, 788, 789, "." +263, 9, 9, 177, 27, 34, 790, 797, "Antonio" +263, 9, 10, 178, 35, 40, 798, 803, "Abate" +263, 9, 11, 179, 41, 49, 804, 812, "Hospital" +263, 9, 12, 180, 50, 51, 813, 814, "," +263, 9, 13, 181, 52, 61, 815, 824, "Gallarate" +263, 9, 14, 182, 62, 63, 825, 826, "," +263, 9, 15, 183, 64, 70, 827, 833, "Varese" +263, 9, 16, 184, 71, 72, 834, 835, "," +263, 9, 17, 185, 73, 78, 836, 841, "Italy" +263, 9, 18, 186, 79, 80, 842, 843, "." +263, 10, 1, 187, 0, 1, 844, 845, "(" +263, 10, 2, 188, 2, 3, 846, 847, "5" +263, 10, 3, 189, 4, 5, 848, 849, ")" +263, 10, 4, 190, 6, 14, 850, 858, "Ospedale" +263, 10, 5, 191, 15, 22, 859, 866, "Pesenti" +263, 10, 6, 192, 23, 31, 867, 875, "Fenaroli" +263, 10, 7, 193, 32, 33, 876, 877, "," +263, 10, 8, 194, 34, 40, 878, 884, "Alzano" +263, 10, 9, 195, 41, 49, 885, 893, "Lombardo" +263, 10, 10, 196, 50, 51, 894, 895, "," +263, 10, 11, 197, 52, 59, 896, 903, "Bergamo" +263, 10, 12, 198, 60, 61, 904, 905, "," +263, 10, 13, 199, 62, 67, 906, 911, "Italy" +263, 10, 14, 200, 68, 69, 912, 913, "." +263, 11, 1, 201, 0, 1, 914, 915, "(" +263, 11, 2, 202, 2, 3, 916, 917, "6" +263, 11, 3, 203, 4, 5, 918, 919, ")" +263, 11, 4, 204, 6, 9, 920, 923, "PhD" +263, 11, 5, 205, 10, 16, 924, 930, "School" +263, 11, 6, 206, 17, 19, 931, 933, "in" +263, 11, 7, 207, 20, 32, 934, 946, "Experimental" +263, 11, 8, 208, 33, 41, 947, 955, "Medicine" +263, 11, 9, 209, 42, 43, 956, 957, "," +263, 11, 10, 210, 44, 54, 958, 968, "University" +263, 11, 11, 211, 55, 57, 969, 971, "of" +263, 11, 12, 212, 58, 63, 972, 977, "Pavia" +263, 11, 13, 213, 64, 65, 978, 979, "," +263, 11, 14, 214, 66, 71, 980, 985, "Pavia" +263, 11, 15, 215, 72, 73, 986, 987, "," +263, 11, 16, 216, 74, 79, 988, 993, "Italy" +263, 11, 17, 217, 80, 81, 994, 995, "." +263, 12, 1, 218, 0, 5, 996, 1001, "STUDY" +263, 12, 2, 219, 6, 15, 1002, 1011, "OBJECTIVE" +263, 12, 3, 220, 16, 17, 1012, 1013, ":" +263, 12, 4, 221, 18, 20, 1014, 1016, "To" +263, 12, 5, 222, 21, 29, 1017, 1025, "evaluate" +263, 12, 6, 223, 30, 33, 1026, 1029, "the" +263, 12, 7, 224, 34, 40, 1030, 1036, "effect" +263, 12, 8, 225, 41, 43, 1037, 1039, "of" +263, 12, 9, 226, 44, 52, 1040, 1048, "acarbose" +263, 12, 10, 227, 53, 55, 1049, 1051, "on" +263, 12, 11, 228, 56, 64, 1052, 1060, "glycemic" +263, 12, 12, 229, 65, 72, 1061, 1068, "control" +263, 12, 13, 230, 73, 76, 1069, 1072, "and" +263, 12, 14, 231, 77, 85, 1073, 1081, "glycemic" +263, 12, 15, 232, 86, 97, 1082, 1093, "variability" +263, 12, 16, 233, 98, 99, 1094, 1095, "," +263, 12, 17, 234, 100, 105, 1096, 1101, "using" +263, 12, 18, 235, 106, 107, 1102, 1103, "a" +263, 12, 19, 236, 108, 118, 1104, 1114, "continuous" +263, 12, 20, 237, 119, 126, 1115, 1122, "glucose" +263, 12, 21, 238, 127, 128, 1123, 1124, "-" +263, 12, 22, 239, 129, 139, 1125, 1135, "monitoring" +263, 12, 23, 240, 140, 146, 1136, 1142, "system" +263, 12, 24, 241, 147, 148, 1143, 1144, "," +263, 12, 25, 242, 149, 151, 1145, 1147, "in" +263, 12, 26, 243, 152, 160, 1148, 1156, "patients" +263, 12, 27, 244, 161, 165, 1157, 1161, "with" +263, 12, 28, 245, 166, 170, 1162, 1166, "type" +263, 12, 29, 246, 171, 172, 1167, 1168, "2" +263, 12, 30, 247, 173, 181, 1169, 1177, "diabetes" +263, 12, 31, 248, 182, 190, 1178, 1186, "mellitus" +263, 12, 32, 249, 191, 194, 1187, 1190, "who" +263, 12, 33, 250, 195, 199, 1191, 1195, "were" +263, 12, 34, 251, 200, 203, 1196, 1199, "not" +263, 12, 35, 252, 204, 208, 1200, 1204, "well" +263, 12, 36, 253, 209, 219, 1205, 1215, "controlled" +263, 12, 37, 254, 220, 222, 1216, 1218, "on" +263, 12, 38, 255, 223, 232, 1219, 1228, "metformin" +263, 12, 39, 256, 233, 236, 1229, 1232, "and" +263, 12, 40, 257, 237, 249, 1233, 1245, "vildagliptin" +263, 12, 41, 258, 250, 257, 1246, 1253, "therapy" +263, 12, 42, 259, 258, 259, 1254, 1255, "." +263, 13, 1, 260, 0, 6, 1256, 1262, "DESIGN" +263, 13, 2, 261, 7, 8, 1263, 1264, ":" +263, 13, 3, 262, 9, 20, 1265, 1276, "Multicenter" +263, 13, 4, 263, 21, 22, 1277, 1278, "," +263, 13, 5, 264, 23, 33, 1279, 1289, "randomized" +263, 13, 6, 265, 34, 35, 1290, 1291, "," +263, 13, 7, 266, 36, 42, 1292, 1298, "double" +263, 13, 8, 267, 43, 44, 1299, 1300, "-" +263, 13, 9, 268, 45, 50, 1301, 1306, "blind" +263, 13, 10, 269, 51, 52, 1307, 1308, "," +263, 13, 11, 270, 53, 60, 1309, 1316, "placebo" +263, 13, 12, 271, 61, 62, 1317, 1318, "-" +263, 13, 13, 272, 63, 73, 1319, 1329, "controlled" +263, 13, 14, 273, 74, 79, 1330, 1335, "study" +263, 13, 15, 274, 80, 81, 1336, 1337, "." +263, 14, 1, 275, 0, 7, 1338, 1345, "SETTING" +263, 14, 2, 276, 8, 9, 1346, 1347, ":" +263, 14, 3, 277, 10, 18, 1348, 1356, "Clinical" +263, 14, 4, 278, 19, 27, 1357, 1365, "research" +263, 14, 5, 279, 28, 33, 1366, 1371, "units" +263, 14, 6, 280, 34, 36, 1372, 1374, "at" +263, 14, 7, 281, 37, 42, 1375, 1380, "three" +263, 14, 8, 282, 43, 52, 1381, 1390, "hospitals" +263, 14, 9, 283, 53, 55, 1391, 1393, "in" +263, 14, 10, 284, 56, 61, 1394, 1399, "Italy" +263, 14, 11, 285, 62, 63, 1400, 1401, "." +263, 15, 1, 286, 0, 8, 1402, 1410, "PATIENTS" +263, 15, 2, 287, 9, 10, 1411, 1412, ":" +263, 15, 3, 288, 11, 16, 1413, 1418, "Fifty" +263, 15, 4, 289, 17, 18, 1419, 1420, "-" +263, 15, 5, 290, 19, 24, 1421, 1426, "three" +263, 15, 6, 291, 25, 33, 1427, 1435, "patients" +263, 15, 7, 292, 34, 38, 1436, 1440, "with" +263, 15, 8, 293, 39, 43, 1441, 1445, "type" +263, 15, 9, 294, 44, 45, 1446, 1447, "2" +263, 15, 10, 295, 46, 54, 1448, 1456, "diabetes" +263, 15, 11, 296, 55, 58, 1457, 1460, "who" +263, 15, 12, 297, 59, 63, 1461, 1465, "were" +263, 15, 13, 298, 64, 70, 1466, 1472, "taking" +263, 15, 14, 299, 71, 77, 1473, 1479, "stable" +263, 15, 15, 300, 78, 85, 1480, 1487, "dosages" +263, 15, 16, 301, 86, 88, 1488, 1490, "of" +263, 15, 17, 302, 89, 98, 1491, 1500, "metformin" +263, 15, 18, 303, 99, 102, 1501, 1504, "850" +263, 15, 19, 304, 103, 105, 1505, 1507, "mg" +263, 15, 20, 305, 106, 107, 1508, 1509, "3" +263, 15, 21, 306, 108, 113, 1510, 1515, "times" +263, 15, 22, 307, 114, 115, 1516, 1517, "/" +263, 15, 23, 308, 116, 119, 1518, 1521, "day" +263, 15, 24, 309, 120, 123, 1522, 1525, "and" +263, 15, 25, 310, 124, 136, 1526, 1538, "vildagliptin" +263, 15, 26, 311, 137, 139, 1539, 1541, "50" +263, 15, 27, 312, 140, 142, 1542, 1544, "mg" +263, 15, 28, 313, 143, 148, 1545, 1550, "twice" +263, 15, 29, 314, 149, 150, 1551, 1552, "/" +263, 15, 30, 315, 151, 154, 1553, 1556, "day" +263, 15, 31, 316, 155, 158, 1557, 1560, "for" +263, 15, 32, 317, 159, 161, 1561, 1563, "at" +263, 15, 33, 318, 162, 167, 1564, 1569, "least" +263, 15, 34, 319, 168, 169, 1570, 1571, "3" +263, 15, 35, 320, 170, 176, 1572, 1578, "months" +263, 15, 36, 321, 177, 180, 1579, 1582, "and" +263, 15, 37, 322, 181, 184, 1583, 1586, "who" +263, 15, 38, 323, 185, 189, 1587, 1591, "were" +263, 15, 39, 324, 190, 193, 1592, 1595, "not" +263, 15, 40, 325, 194, 204, 1596, 1606, "adequately" +263, 15, 41, 326, 205, 215, 1607, 1617, "controlled" +263, 15, 42, 327, 216, 220, 1618, 1622, "with" +263, 15, 43, 328, 221, 226, 1623, 1628, "these" +263, 15, 44, 329, 227, 236, 1629, 1638, "therapies" +263, 15, 45, 330, 237, 238, 1639, 1640, "." +263, 16, 1, 331, 0, 12, 1641, 1653, "INTERVENTION" +263, 16, 2, 332, 13, 14, 1654, 1655, ":" +263, 16, 3, 333, 15, 23, 1656, 1664, "Patients" +263, 16, 4, 334, 24, 28, 1665, 1669, "were" +263, 16, 5, 335, 29, 39, 1670, 1680, "randomized" +263, 16, 6, 336, 40, 42, 1681, 1683, "to" +263, 16, 7, 337, 43, 49, 1684, 1690, "either" +263, 16, 8, 338, 50, 57, 1691, 1698, "placebo" +263, 16, 9, 339, 58, 60, 1699, 1701, "or" +263, 16, 10, 340, 61, 69, 1702, 1710, "acarbose" +263, 16, 11, 341, 70, 73, 1711, 1714, "100" +263, 16, 12, 342, 74, 76, 1715, 1717, "mg" +263, 16, 13, 343, 77, 78, 1718, 1719, "3" +263, 16, 14, 344, 79, 84, 1720, 1725, "times" +263, 16, 15, 345, 85, 86, 1726, 1727, "/" +263, 16, 16, 346, 87, 90, 1728, 1731, "day" +263, 16, 17, 347, 91, 93, 1732, 1734, "to" +263, 16, 18, 348, 94, 96, 1735, 1737, "be" +263, 16, 19, 349, 97, 102, 1738, 1743, "added" +263, 16, 20, 350, 103, 105, 1744, 1746, "to" +263, 16, 21, 351, 106, 111, 1747, 1752, "their" +263, 16, 22, 352, 112, 121, 1753, 1762, "metformin" +263, 16, 23, 353, 122, 123, 1763, 1764, "-" +263, 16, 24, 354, 124, 136, 1765, 1777, "vildagliptin" +263, 16, 25, 355, 137, 144, 1778, 1785, "regimen" +263, 16, 26, 356, 145, 146, 1786, 1787, "." +263, 17, 1, 357, 0, 12, 1788, 1800, "MEASUREMENTS" +263, 17, 2, 358, 13, 16, 1801, 1804, "AND" +263, 17, 3, 359, 17, 21, 1805, 1809, "MAIN" +263, 17, 4, 360, 22, 29, 1810, 1817, "RESULTS" +263, 17, 5, 361, 30, 31, 1818, 1819, ":" +263, 17, 6, 362, 32, 40, 1820, 1828, "Glycemic" +263, 17, 7, 363, 41, 51, 1829, 1839, "excursions" +263, 17, 8, 364, 52, 56, 1840, 1844, "were" +263, 17, 9, 365, 57, 65, 1845, 1853, "assessed" +263, 17, 10, 366, 66, 68, 1854, 1856, "by" +263, 17, 11, 367, 69, 74, 1857, 1862, "using" +263, 17, 12, 368, 75, 76, 1863, 1864, "a" +263, 17, 13, 369, 77, 87, 1865, 1875, "continuous" +263, 17, 14, 370, 88, 95, 1876, 1883, "glucose" +263, 17, 15, 371, 96, 97, 1884, 1885, "-" +263, 17, 16, 372, 98, 108, 1886, 1896, "monitoring" +263, 17, 17, 373, 109, 115, 1897, 1903, "system" +263, 17, 18, 374, 116, 119, 1904, 1907, "for" +263, 17, 19, 375, 120, 121, 1908, 1909, "1" +263, 17, 20, 376, 122, 126, 1910, 1914, "week" +263, 17, 21, 377, 127, 128, 1915, 1916, "." +263, 18, 1, 378, 0, 8, 1917, 1925, "Glycemic" +263, 18, 2, 379, 9, 16, 1926, 1933, "control" +263, 18, 3, 380, 17, 20, 1934, 1937, "was" +263, 18, 4, 381, 21, 30, 1938, 1947, "estimated" +263, 18, 5, 382, 31, 33, 1948, 1950, "as" +263, 18, 6, 383, 34, 37, 1951, 1954, "the" +263, 18, 7, 384, 38, 42, 1955, 1959, "mean" +263, 18, 8, 385, 43, 48, 1960, 1965, "blood" +263, 18, 9, 386, 49, 56, 1966, 1973, "glucose" +263, 18, 10, 387, 57, 58, 1974, 1975, "(" +263, 18, 11, 388, 59, 62, 1976, 1979, "MBG" +263, 18, 12, 389, 63, 64, 1980, 1981, ")" +263, 18, 13, 390, 65, 70, 1982, 1987, "level" +263, 18, 14, 391, 71, 72, 1988, 1989, "," +263, 18, 15, 392, 73, 76, 1990, 1993, "the" +263, 18, 16, 393, 77, 81, 1994, 1998, "area" +263, 18, 17, 394, 82, 87, 1999, 2004, "under" +263, 18, 18, 395, 88, 91, 2005, 2008, "the" +263, 18, 19, 396, 92, 99, 2009, 2016, "glucose" +263, 18, 20, 397, 100, 113, 2017, 2030, "concentration" +263, 18, 21, 398, 114, 115, 2031, 2032, "-" +263, 18, 22, 399, 116, 120, 2033, 2037, "time" +263, 18, 23, 400, 121, 126, 2038, 2043, "curve" +263, 18, 24, 401, 127, 130, 2044, 2047, "for" +263, 18, 25, 402, 131, 132, 2048, 2049, "a" +263, 18, 26, 403, 133, 140, 2050, 2057, "glucose" +263, 18, 27, 404, 141, 146, 2058, 2063, "level" +263, 18, 28, 405, 147, 152, 2064, 2069, "above" +263, 18, 29, 406, 153, 155, 2070, 2072, "70" +263, 18, 30, 407, 156, 158, 2073, 2075, "mg" +263, 18, 31, 408, 159, 160, 2076, 2077, "/" +263, 18, 32, 409, 161, 163, 2078, 2080, "dl" +263, 18, 33, 410, 164, 165, 2081, 2082, "(" +263, 18, 34, 411, 166, 169, 2083, 2086, "AUC" +263, 18, 35, 412, 170, 175, 2087, 2092, "above" +263, 18, 36, 413, 176, 178, 2093, 2095, "70" +263, 18, 37, 414, 179, 180, 2096, 2097, ")" +263, 18, 38, 415, 181, 183, 2098, 2100, "or" +263, 18, 39, 416, 184, 187, 2101, 2104, "180" +263, 18, 40, 417, 188, 190, 2105, 2107, "mg" +263, 18, 41, 418, 191, 192, 2108, 2109, "/" +263, 18, 42, 419, 193, 195, 2110, 2112, "dl" +263, 18, 43, 420, 196, 197, 2113, 2114, "(" +263, 18, 44, 421, 198, 201, 2115, 2118, "AUC" +263, 18, 45, 422, 202, 207, 2119, 2124, "above" +263, 18, 46, 423, 208, 211, 2125, 2128, "180" +263, 18, 47, 424, 212, 213, 2129, 2130, ")" +263, 18, 48, 425, 214, 215, 2131, 2132, "," +263, 18, 49, 426, 216, 219, 2133, 2136, "and" +263, 18, 50, 427, 220, 223, 2137, 2140, "the" +263, 18, 51, 428, 224, 234, 2141, 2151, "percentage" +263, 18, 52, 429, 235, 237, 2152, 2154, "of" +263, 18, 53, 430, 238, 242, 2155, 2159, "time" +263, 18, 54, 431, 243, 247, 2160, 2164, "that" +263, 18, 55, 432, 248, 251, 2165, 2168, "the" +263, 18, 56, 433, 252, 259, 2169, 2176, "glucose" +263, 18, 57, 434, 260, 265, 2177, 2182, "level" +263, 18, 58, 435, 266, 269, 2183, 2186, "was" +263, 18, 59, 436, 270, 275, 2187, 2192, "above" +263, 18, 60, 437, 276, 278, 2193, 2195, "70" +263, 18, 61, 438, 279, 281, 2196, 2198, "mg" +263, 18, 62, 439, 282, 283, 2199, 2200, "/" +263, 18, 63, 440, 284, 286, 2201, 2203, "dl" +263, 18, 64, 441, 287, 288, 2204, 2205, "(" +263, 18, 65, 442, 289, 290, 2206, 2207, "T" +263, 18, 66, 443, 291, 296, 2208, 2213, "above" +263, 18, 67, 444, 297, 299, 2214, 2216, "70" +263, 18, 68, 445, 300, 301, 2217, 2218, ")" +263, 18, 69, 446, 302, 304, 2219, 2221, "or" +263, 18, 70, 447, 305, 308, 2222, 2225, "180" +263, 18, 71, 448, 309, 311, 2226, 2228, "mg" +263, 18, 72, 449, 312, 313, 2229, 2230, "/" +263, 18, 73, 450, 314, 316, 2231, 2233, "dl" +263, 18, 74, 451, 317, 318, 2234, 2235, "(" +263, 18, 75, 452, 319, 320, 2236, 2237, "T" +263, 18, 76, 453, 321, 326, 2238, 2243, "above" +263, 18, 77, 454, 327, 330, 2244, 2247, "180" +263, 18, 78, 455, 331, 332, 2248, 2249, ")" +263, 18, 79, 456, 333, 334, 2250, 2251, "." +263, 19, 1, 457, 0, 8, 2252, 2260, "Intraday" +263, 19, 2, 458, 9, 17, 2261, 2269, "glycemic" +263, 19, 3, 459, 18, 29, 2270, 2281, "variability" +263, 19, 4, 460, 30, 33, 2282, 2285, "was" +263, 19, 5, 461, 34, 42, 2286, 2294, "assessed" +263, 19, 6, 462, 43, 45, 2295, 2297, "by" +263, 19, 7, 463, 46, 49, 2298, 2301, "the" +263, 19, 8, 464, 50, 58, 2302, 2310, "standard" +263, 19, 9, 465, 59, 68, 2311, 2320, "deviation" +263, 19, 10, 466, 69, 71, 2321, 2323, "of" +263, 19, 11, 467, 72, 75, 2324, 2327, "the" +263, 19, 12, 468, 76, 81, 2328, 2333, "blood" +263, 19, 13, 469, 82, 89, 2334, 2341, "glucose" +263, 19, 14, 470, 90, 95, 2342, 2347, "level" +263, 19, 15, 471, 96, 97, 2348, 2349, "," +263, 19, 16, 472, 98, 101, 2350, 2353, "the" +263, 19, 17, 473, 102, 106, 2354, 2358, "mean" +263, 19, 18, 474, 107, 116, 2359, 2368, "amplitude" +263, 19, 19, 475, 117, 119, 2369, 2371, "of" +263, 19, 20, 476, 120, 128, 2372, 2380, "glycemic" +263, 19, 21, 477, 129, 139, 2381, 2391, "excursions" +263, 19, 22, 478, 140, 141, 2392, 2393, "(" +263, 19, 23, 479, 142, 146, 2394, 2398, "MAGE" +263, 19, 24, 480, 147, 148, 2399, 2400, ")" +263, 19, 25, 481, 149, 150, 2401, 2402, "," +263, 19, 26, 482, 151, 154, 2403, 2406, "the" +263, 19, 27, 483, 155, 156, 2407, 2408, "M" +263, 19, 28, 484, 157, 162, 2409, 2414, "value" +263, 19, 29, 485, 163, 164, 2415, 2416, "," +263, 19, 30, 486, 165, 168, 2417, 2420, "and" +263, 19, 31, 487, 169, 179, 2421, 2431, "continuous" +263, 19, 32, 488, 180, 191, 2432, 2443, "overlapping" +263, 19, 33, 489, 192, 195, 2444, 2447, "net" +263, 19, 34, 490, 196, 204, 2448, 2456, "glycemic" +263, 19, 35, 491, 205, 211, 2457, 2463, "action" +263, 19, 36, 492, 212, 213, 2464, 2465, "." +263, 20, 1, 493, 0, 3, 2466, 2469, "Day" +263, 20, 2, 494, 4, 5, 2470, 2471, "-" +263, 20, 3, 495, 6, 8, 2472, 2474, "to" +263, 20, 4, 496, 9, 10, 2475, 2476, "-" +263, 20, 5, 497, 11, 14, 2477, 2480, "day" +263, 20, 6, 498, 15, 23, 2481, 2489, "glycemic" +263, 20, 7, 499, 24, 35, 2490, 2501, "variability" +263, 20, 8, 500, 36, 39, 2502, 2505, "was" +263, 20, 9, 501, 40, 48, 2506, 2514, "assessed" +263, 20, 10, 502, 49, 51, 2515, 2517, "as" +263, 20, 11, 503, 52, 55, 2518, 2521, "the" +263, 20, 12, 504, 56, 60, 2522, 2526, "mean" +263, 20, 13, 505, 61, 63, 2527, 2529, "of" +263, 20, 14, 506, 64, 69, 2530, 2535, "daily" +263, 20, 15, 507, 70, 80, 2536, 2546, "difference" +263, 20, 16, 508, 81, 82, 2547, 2548, "(" +263, 20, 17, 509, 83, 87, 2549, 2553, "MODD" +263, 20, 18, 510, 88, 89, 2554, 2555, ")" +263, 20, 19, 511, 90, 91, 2556, 2557, "." +263, 21, 1, 512, 0, 3, 2558, 2561, "The" +263, 21, 2, 513, 4, 7, 2562, 2565, "MBG" +263, 21, 3, 514, 8, 13, 2566, 2571, "level" +263, 21, 4, 515, 14, 17, 2572, 2575, "was" +263, 21, 5, 516, 18, 19, 2576, 2577, "~" +263, 21, 6, 517, 20, 22, 2578, 2580, "20" +263, 21, 7, 518, 23, 25, 2581, 2583, "mg" +263, 21, 8, 519, 26, 27, 2584, 2585, "/" +263, 21, 9, 520, 28, 30, 2586, 2588, "dl" +263, 21, 10, 521, 31, 36, 2589, 2594, "lower" +263, 21, 11, 522, 37, 39, 2595, 2597, "in" +263, 21, 12, 523, 40, 43, 2598, 2601, "the" +263, 21, 13, 524, 44, 52, 2602, 2610, "acarbose" +263, 21, 14, 525, 53, 58, 2611, 2616, "group" +263, 21, 15, 526, 59, 63, 2617, 2621, "than" +263, 21, 16, 527, 64, 66, 2622, 2624, "in" +263, 21, 17, 528, 67, 70, 2625, 2628, "the" +263, 21, 18, 529, 71, 78, 2629, 2636, "placebo" +263, 21, 19, 530, 79, 84, 2637, 2642, "group" +263, 21, 20, 531, 85, 86, 2643, 2644, "(" +263, 21, 21, 532, 87, 88, 2645, 2646, "p" +263, 21, 22, 533, 89, 90, 2647, 2648, "<" +263, 21, 23, 534, 91, 92, 2649, 2650, "0" +263, 21, 24, 535, 93, 94, 2651, 2652, "." +263, 21, 25, 536, 95, 97, 2653, 2655, "05" +263, 21, 26, 537, 98, 99, 2656, 2657, ")" +263, 21, 27, 538, 100, 101, 2658, 2659, "," +263, 21, 28, 539, 102, 114, 2660, 2672, "particularly" +263, 21, 29, 540, 115, 121, 2673, 2679, "during" +263, 21, 30, 541, 122, 125, 2680, 2683, "the" +263, 21, 31, 542, 126, 138, 2684, 2696, "postprandial" +263, 21, 32, 543, 139, 145, 2697, 2703, "period" +263, 21, 33, 544, 146, 147, 2704, 2705, "." +263, 22, 1, 545, 0, 3, 2706, 2709, "The" +263, 22, 2, 546, 4, 7, 2710, 2713, "AUC" +263, 22, 3, 547, 8, 13, 2714, 2719, "above" +263, 22, 4, 548, 14, 16, 2720, 2722, "70" +263, 22, 5, 549, 17, 20, 2723, 2726, "did" +263, 22, 6, 550, 21, 24, 2727, 2730, "not" +263, 22, 7, 551, 25, 38, 2731, 2744, "significantly" +263, 22, 8, 552, 39, 45, 2745, 2751, "differ" +263, 22, 9, 553, 46, 53, 2752, 2759, "between" +263, 22, 10, 554, 54, 57, 2760, 2763, "the" +263, 22, 11, 555, 58, 61, 2764, 2767, "two" +263, 22, 12, 556, 62, 68, 2768, 2774, "groups" +263, 22, 13, 557, 69, 70, 2775, 2776, "," +263, 22, 14, 558, 71, 78, 2777, 2784, "whereas" +263, 22, 15, 559, 79, 82, 2785, 2788, "the" +263, 22, 16, 560, 83, 86, 2789, 2792, "AUC" +263, 22, 17, 561, 87, 92, 2793, 2798, "above" +263, 22, 18, 562, 93, 96, 2799, 2802, "180" +263, 22, 19, 563, 97, 100, 2803, 2806, "was" +263, 22, 20, 564, 101, 102, 2807, 2808, "~" +263, 22, 21, 565, 103, 105, 2809, 2811, "40" +263, 22, 22, 566, 106, 107, 2812, 2813, "%" +263, 22, 23, 567, 108, 113, 2814, 2819, "lower" +263, 22, 24, 568, 114, 116, 2820, 2822, "in" +263, 22, 25, 569, 117, 120, 2823, 2826, "the" +263, 22, 26, 570, 121, 129, 2827, 2835, "acarbose" +263, 22, 27, 571, 130, 135, 2836, 2841, "group" +263, 22, 28, 572, 136, 140, 2842, 2846, "than" +263, 22, 29, 573, 141, 143, 2847, 2849, "in" +263, 22, 30, 574, 144, 147, 2850, 2853, "the" +263, 22, 31, 575, 148, 155, 2854, 2861, "placebo" +263, 22, 32, 576, 156, 161, 2862, 2867, "group" +263, 22, 33, 577, 162, 168, 2868, 2874, "during" +263, 22, 34, 578, 169, 172, 2875, 2878, "the" +263, 22, 35, 579, 173, 180, 2879, 2886, "daytime" +263, 22, 36, 580, 181, 182, 2887, 2888, "(" +263, 22, 37, 581, 183, 184, 2889, 2890, "p" +263, 22, 38, 582, 185, 186, 2891, 2892, "<" +263, 22, 39, 583, 187, 188, 2893, 2894, "0" +263, 22, 40, 584, 189, 190, 2895, 2896, "." +263, 22, 41, 585, 191, 193, 2897, 2899, "01" +263, 22, 42, 586, 194, 195, 2900, 2901, ")" +263, 22, 43, 587, 196, 197, 2902, 2903, "." +263, 23, 1, 588, 0, 3, 2904, 2907, "The" +263, 23, 2, 589, 4, 5, 2908, 2909, "T" +263, 23, 3, 590, 6, 11, 2910, 2915, "above" +263, 23, 4, 591, 12, 15, 2916, 2919, "180" +263, 23, 5, 592, 16, 19, 2920, 2923, "was" +263, 23, 6, 593, 20, 33, 2924, 2937, "significantly" +263, 23, 7, 594, 34, 40, 2938, 2944, "higher" +263, 23, 8, 595, 41, 43, 2945, 2947, "in" +263, 23, 9, 596, 44, 47, 2948, 2951, "the" +263, 23, 10, 597, 48, 55, 2952, 2959, "placebo" +263, 23, 11, 598, 56, 61, 2960, 2965, "group" +263, 23, 12, 599, 62, 66, 2966, 2970, "than" +263, 23, 13, 600, 67, 69, 2971, 2973, "in" +263, 23, 14, 601, 70, 73, 2974, 2977, "the" +263, 23, 15, 602, 74, 82, 2978, 2986, "acarbose" +263, 23, 16, 603, 83, 88, 2987, 2992, "group" +263, 23, 17, 604, 89, 90, 2993, 2994, "(" +263, 23, 18, 605, 91, 93, 2995, 2997, "31" +263, 23, 19, 606, 94, 95, 2998, 2999, "%" +263, 23, 20, 607, 96, 98, 3000, 3002, "vs" +263, 23, 21, 608, 99, 100, 3003, 3004, "8" +263, 23, 22, 609, 101, 102, 3005, 3006, "%" +263, 23, 23, 610, 103, 104, 3007, 3008, "," +263, 23, 24, 611, 105, 106, 3009, 3010, "p" +263, 23, 25, 612, 107, 108, 3011, 3012, "<" +263, 23, 26, 613, 109, 110, 3013, 3014, "0" +263, 23, 27, 614, 111, 112, 3015, 3016, "." +263, 23, 28, 615, 113, 115, 3017, 3019, "01" +263, 23, 29, 616, 116, 117, 3020, 3021, "." +263, 24, 1, 617, 0, 8, 3022, 3030, "Moreover" +263, 24, 2, 618, 9, 10, 3031, 3032, "," +263, 24, 3, 619, 11, 14, 3033, 3036, "the" +263, 24, 4, 620, 15, 23, 3037, 3045, "standard" +263, 24, 5, 621, 24, 33, 3046, 3055, "deviation" +263, 24, 6, 622, 34, 37, 3056, 3059, "and" +263, 24, 7, 623, 38, 42, 3060, 3064, "MAGE" +263, 24, 8, 624, 43, 49, 3065, 3071, "values" +263, 24, 9, 625, 50, 54, 3072, 3076, "were" +263, 24, 10, 626, 55, 68, 3077, 3090, "significantly" +263, 24, 11, 627, 69, 74, 3091, 3096, "lower" +263, 24, 12, 628, 75, 77, 3097, 3099, "in" +263, 24, 13, 629, 78, 81, 3100, 3103, "the" +263, 24, 14, 630, 82, 90, 3104, 3112, "acarbose" +263, 24, 15, 631, 91, 96, 3113, 3118, "group" +263, 24, 16, 632, 97, 98, 3119, 3120, "." +263, 25, 1, 633, 0, 3, 3121, 3124, "The" +263, 25, 2, 634, 4, 8, 3125, 3129, "MODD" +263, 25, 3, 635, 9, 14, 3130, 3135, "value" +263, 25, 4, 636, 15, 18, 3136, 3139, "was" +263, 25, 5, 637, 19, 22, 3140, 3143, "not" +263, 25, 6, 638, 23, 36, 3144, 3157, "significantly" +263, 25, 7, 639, 37, 44, 3158, 3165, "changed" +263, 25, 8, 640, 45, 47, 3166, 3168, "in" +263, 25, 9, 641, 48, 54, 3169, 3175, "either" +263, 25, 10, 642, 55, 60, 3176, 3181, "group" +263, 25, 11, 643, 61, 62, 3182, 3183, "," +263, 25, 12, 644, 63, 66, 3184, 3187, "and" +263, 25, 13, 645, 67, 69, 3188, 3190, "no" +263, 25, 14, 646, 70, 81, 3191, 3202, "significant" +263, 25, 15, 647, 82, 93, 3203, 3214, "differences" +263, 25, 16, 648, 94, 98, 3215, 3219, "were" +263, 25, 17, 649, 99, 107, 3220, 3228, "recorded" +263, 25, 18, 650, 108, 115, 3229, 3236, "between" +263, 25, 19, 651, 116, 122, 3237, 3243, "groups" +263, 25, 20, 652, 123, 124, 3244, 3245, "." +263, 26, 1, 653, 0, 3, 3246, 3249, "All" +263, 26, 2, 654, 4, 11, 3250, 3257, "adverse" +263, 26, 3, 655, 12, 18, 3258, 3264, "events" +263, 26, 4, 656, 19, 23, 3265, 3269, "were" +263, 26, 5, 657, 24, 28, 3270, 3274, "mild" +263, 26, 6, 658, 29, 31, 3275, 3277, "in" +263, 26, 7, 659, 32, 36, 3278, 3282, "both" +263, 26, 8, 660, 37, 43, 3283, 3289, "groups" +263, 26, 9, 661, 44, 45, 3290, 3291, "," +263, 26, 10, 662, 46, 50, 3292, 3296, "with" +263, 26, 11, 663, 51, 55, 3297, 3301, "only" +263, 26, 12, 664, 56, 57, 3302, 3303, "a" +263, 26, 13, 665, 58, 71, 3304, 3317, "significantly" +263, 26, 14, 666, 72, 79, 3318, 3325, "greater" +263, 26, 15, 667, 80, 89, 3326, 3335, "frequency" +263, 26, 16, 668, 90, 92, 3336, 3338, "of" +263, 26, 17, 669, 93, 103, 3339, 3349, "flatulence" +263, 26, 18, 670, 104, 109, 3350, 3355, "noted" +263, 26, 19, 671, 110, 112, 3356, 3358, "in" +263, 26, 20, 672, 113, 116, 3359, 3362, "the" +263, 26, 21, 673, 117, 125, 3363, 3371, "acarbose" +263, 26, 22, 674, 126, 131, 3372, 3377, "group" +263, 26, 23, 675, 132, 133, 3378, 3379, "(" +263, 26, 24, 676, 134, 135, 3380, 3381, "5" +263, 26, 25, 677, 136, 137, 3382, 3383, "%" +263, 26, 26, 678, 138, 142, 3384, 3388, "with" +263, 26, 27, 679, 143, 151, 3389, 3397, "acarbose" +263, 26, 28, 680, 152, 154, 3398, 3400, "vs" +263, 26, 29, 681, 155, 156, 3401, 3402, "0" +263, 26, 30, 682, 157, 158, 3403, 3404, "." +263, 26, 31, 683, 159, 160, 3405, 3406, "5" +263, 26, 32, 684, 161, 162, 3407, 3408, "%" +263, 26, 33, 685, 163, 167, 3409, 3413, "with" +263, 26, 34, 686, 168, 175, 3414, 3421, "placebo" +263, 26, 35, 687, 176, 177, 3422, 3423, "," +263, 26, 36, 688, 178, 179, 3424, 3425, "p" +263, 26, 37, 689, 180, 181, 3426, 3427, "<" +263, 26, 38, 690, 182, 183, 3428, 3429, "0" +263, 26, 39, 691, 184, 185, 3430, 3431, "." +263, 26, 40, 692, 186, 188, 3432, 3434, "05" +263, 26, 41, 693, 189, 190, 3435, 3436, ")" +263, 26, 42, 694, 191, 192, 3437, 3438, "." +263, 27, 1, 695, 0, 10, 3439, 3449, "CONCLUSION" +263, 27, 2, 696, 11, 12, 3450, 3451, ":" +263, 27, 3, 697, 13, 16, 3452, 3455, "The" +263, 27, 4, 698, 17, 25, 3456, 3464, "addition" +263, 27, 5, 699, 26, 28, 3465, 3467, "of" +263, 27, 6, 700, 29, 37, 3468, 3476, "acarbose" +263, 27, 7, 701, 38, 40, 3477, 3479, "to" +263, 27, 8, 702, 41, 50, 3480, 3489, "metformin" +263, 27, 9, 703, 51, 54, 3490, 3493, "and" +263, 27, 10, 704, 55, 67, 3494, 3506, "vildagliptin" +263, 27, 11, 705, 68, 78, 3507, 3517, "background" +263, 27, 12, 706, 79, 86, 3518, 3525, "therapy" +263, 27, 13, 707, 87, 89, 3526, 3528, "in" +263, 27, 14, 708, 90, 98, 3529, 3537, "patients" +263, 27, 15, 709, 99, 103, 3538, 3542, "with" +263, 27, 16, 710, 104, 116, 3543, 3555, "inadequately" +263, 27, 17, 711, 117, 127, 3556, 3566, "controlled" +263, 27, 18, 712, 128, 132, 3567, 3571, "type" +263, 27, 19, 713, 133, 134, 3572, 3573, "2" +263, 27, 20, 714, 135, 143, 3574, 3582, "diabetes" +263, 27, 21, 715, 144, 153, 3583, 3592, "decreased" +263, 27, 22, 716, 154, 162, 3593, 3601, "intraday" +263, 27, 23, 717, 163, 171, 3602, 3610, "glycemic" +263, 27, 24, 718, 172, 183, 3611, 3622, "variability" +263, 27, 25, 719, 184, 185, 3623, 3624, "," +263, 27, 26, 720, 186, 196, 3625, 3635, "especially" +263, 27, 27, 721, 197, 209, 3636, 3648, "postprandial" +263, 27, 28, 722, 210, 221, 3649, 3660, "variability" +263, 27, 29, 723, 222, 223, 3661, 3662, "," +263, 27, 30, 724, 224, 227, 3663, 3666, "but" +263, 27, 31, 725, 228, 230, 3667, 3669, "it" +263, 27, 32, 726, 231, 234, 3670, 3673, "was" +263, 27, 33, 727, 235, 238, 3674, 3677, "not" +263, 27, 34, 728, 239, 249, 3678, 3688, "associated" +263, 27, 35, 729, 250, 254, 3689, 3693, "with" +263, 27, 36, 730, 255, 256, 3694, 3695, "a" +263, 27, 37, 731, 257, 268, 3696, 3707, "significant" +263, 27, 38, 732, 269, 275, 3708, 3714, "change" +263, 27, 39, 733, 276, 278, 3715, 3717, "in" +263, 27, 40, 734, 279, 287, 3718, 3726, "interday" +263, 27, 41, 735, 288, 296, 3727, 3735, "glycemic" +263, 27, 42, 736, 297, 308, 3736, 3747, "variability" +263, 27, 43, 737, 309, 310, 3748, 3749, "." +263, 28, 1, 738, 0, 1, 3750, 3751, "©" +263, 28, 2, 739, 2, 6, 3752, 3756, "2015" +263, 28, 3, 740, 7, 22, 3757, 3772, "Pharmacotherapy" +263, 28, 4, 741, 23, 35, 3773, 3785, "Publications" +263, 28, 5, 742, 36, 37, 3786, 3787, "," +263, 28, 6, 743, 38, 41, 3788, 3791, "Inc" +263, 28, 7, 744, 42, 43, 3792, 3793, "." +263, 28, 8, 745, 44, 47, 3794, 3797, "DOI" +263, 28, 9, 746, 48, 49, 3798, 3799, ":" +263, 28, 10, 747, 50, 52, 3800, 3802, "10" +263, 28, 11, 748, 53, 54, 3803, 3804, "." +263, 28, 12, 749, 55, 59, 3805, 3809, "1002" +263, 28, 13, 750, 60, 61, 3810, 3811, "/" +263, 28, 14, 751, 62, 66, 3812, 3816, "phar" +263, 28, 15, 752, 67, 68, 3817, 3818, "." +263, 28, 16, 753, 69, 73, 3819, 3823, "1648" +263, 28, 17, 754, 74, 78, 3824, 3828, "PMID" +263, 28, 18, 755, 79, 80, 3829, 3830, ":" +263, 28, 19, 756, 81, 89, 3831, 3839, "26598090" +263, 28, 20, 757, 90, 91, 3840, 3841, "[" +263, 28, 21, 758, 92, 99, 3842, 3849, "Indexed" +263, 28, 22, 759, 100, 103, 3850, 3853, "for" +263, 28, 23, 760, 104, 111, 3854, 3861, "MEDLINE" +263, 28, 24, 761, 112, 113, 3862, 3863, "]" diff --git a/data/dm2 26598090_kwoodley.annodb b/data/dm2 26598090_kwoodley.annodb new file mode 100644 index 0000000..b98fc2e --- /dev/null +++ b/data/dm2 26598090_kwoodley.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +55678, Journal, 0, 15, "Pharmacotherapy", "", +55679, PublicationYear, 18, 22, "2015", "", +55699, Title, 102, 273, "Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy : A Placebo - Controlled Trial .", "", +55680, Drug, 112, 120, "Acarbose", "", +55692, Precondition, 148, 240, "Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy", "", +55688, Type2Diabetes, 180, 204, "Type 2 Diabetes Mellitus", "", +55693, Placebo, 245, 252, "Placebo", "", +55700, Author, 274, 282, "Derosa G", "", +55701, Author, 303, 314, "Franzetti I", "", +55702, Author, 323, 331, "Querci F", "", +55703, Author, 340, 352, "D ' Angelo A", "", +55704, Author, 367, 377, "Maffioli P", "", +55705, Italy, 546, 551, "Italy", "", +55706, Italy, 676, 681, "Italy", "", +55707, Italy, 755, 760, "Italy", "", +55708, Italy, 836, 841, "Italy", "", +55709, Italy, 906, 911, "Italy", "", +55710, Italy, 988, 993, "Italy", "", +55718, ObjectiveDescription, 1014, 1255, "To evaluate the effect of acarbose on glycemic control and glycemic variability , using a continuous glucose - monitoring system , in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy .", "", +55681, Drug, 1040, 1048, "acarbose", "", +55717, Precondition, 1148, 1253, "patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy", "", +55689, Type2Diabetes, 1162, 1186, "type 2 diabetes mellitus", "", +55711, Metformin, 1219, 1228, "metformin", "", +55714, Vildagliptin, 1233, 1245, "vildagliptin", "", +55719, Multicenter, 1265, 1276, "Multicenter", "", +55720, Randomized, 1279, 1289, "randomized", "", +55721, DoubleBlind, 1292, 1306, "double - blind", "", +55694, Placebo, 1309, 1316, "placebo", "", +55722, Country, 1394, 1399, "Italy", "", +55723, NumberPatientsArm, 1413, 1426, "Fifty - three", "", +55733, Precondition, 1427, 1640, "patients with type 2 diabetes who were taking stable dosages of metformin 850 mg 3 times / day and vildagliptin 50 mg twice / day for at least 3 months and who were not adequately controlled with these therapies .", "", +55690, Type2Diabetes, 1441, 1456, "type 2 diabetes", "", +55724, Metformin, 1491, 1500, "metformin", "", +55726, DoseValue, 1501, 1504, "850", "", +55728, mg, 1505, 1507, "mg", "", +55730, Frequency, 1508, 1521, "3 times / day", "", +55725, Vildagliptin, 1526, 1538, "vildagliptin", "", +55727, DoseValue, 1539, 1541, "50", "", +55729, mg, 1542, 1544, "mg", "", +55731, Frequency, 1545, 1556, "twice / day", "", +55732, Duration, 1570, 1578, "3 months", "", +55734, Randomized, 1670, 1680, "randomized", "", +55695, Placebo, 1691, 1698, "placebo", "", +55682, Drug, 1702, 1710, "acarbose", "", +55735, DoseValue, 1711, 1714, "100", "", +55736, mg, 1715, 1717, "mg", "", +55737, Frequency, 1718, 1731, "3 times / day", "", +55712, Metformin, 1753, 1762, "metformin", "", +55715, Vildagliptin, 1765, 1777, "vildagliptin", "", +55738, MeasurementDevice, 1865, 1903, "continuous glucose - monitoring system", "", +55739, BloodGlucose, 1955, 1973, "mean blood glucose", "", +55740, BloodGlucose, 1976, 1979, "MBG", "", +55741, Mg_per_deciliter, 2073, 2080, "mg / dl", "", +55750, EndPointDescription, 2083, 2086, "AUC", "", +55771, SubGroupDescription, 2087, 2095, "above 70", "", +55742, Mg_per_deciliter, 2105, 2112, "mg / dl", "", +55751, EndPointDescription, 2115, 2118, "AUC", "", +55772, SubGroupDescription, 2119, 2128, "above 180", "", +55743, Mg_per_deciliter, 2196, 2203, "mg / dl", "", +55753, EndPointDescription, 2206, 2207, "T", "", +55773, SubGroupDescription, 2208, 2216, "above 70", "", +55744, Mg_per_deciliter, 2226, 2233, "mg / dl", "", +55754, EndPointDescription, 2236, 2237, "T", "", +55774, SubGroupDescription, 2238, 2247, "above 180", "", +55745, BloodGlucose, 2328, 2341, "blood glucose", "", +55757, EndPointDescription, 2354, 2391, "mean amplitude of glycemic excursions", "", +55756, EndPointDescription, 2394, 2398, "MAGE", "", +55758, EndPointDescription, 2407, 2414, "M value", "", +55762, EndPointDescription, 2522, 2546, "mean of daily difference", "", +55761, EndPointDescription, 2549, 2553, "MODD", "", +55746, EndPointDescription, 2562, 2565, "MBG", "", +55765, ObservedResult, 2572, 2703, "was ~ 20 mg / dl lower in the acarbose group than in the placebo group ( p < 0 . 05 ) , particularly during the postprandial period", "", +55764, Mg_per_deciliter, 2581, 2588, "mg / dl", "", +55683, Drug, 2602, 2610, "acarbose", "", +55696, Placebo, 2629, 2636, "placebo", "", +55769, PvalueDiff, 2645, 2657, "p < 0 . 05 )", "", +55748, EndPointDescription, 2710, 2713, "AUC", "", +55770, SubGroupDescription, 2714, 2722, "above 70", "", +55777, ObservedResult, 2723, 2774, "did not significantly differ between the two groups", "", +55749, EndPointDescription, 2789, 2792, "AUC", "", +55775, SubGroupDescription, 2793, 2802, "above 180", "", +55778, ObservedResult, 2803, 2886, "was ~ 40 % lower in the acarbose group than in the placebo group during the daytime", "", +55779, Percentage, 2812, 2813, "%", "", +55684, Drug, 2827, 2835, "acarbose", "", +55697, Placebo, 2854, 2861, "placebo", "", +55780, RelativeTime, 2879, 2886, "daytime", "", +55781, PvalueDiff, 2889, 2899, "p < 0 . 01", "", +55752, EndPointDescription, 2908, 2909, "T", "", +55776, SubGroupDescription, 2910, 2919, "above 180", "", +55698, Placebo, 2952, 2959, "placebo", "", +55685, Drug, 2978, 2986, "acarbose", "", +55782, ResultMeasuredValue, 2995, 2997, "31", "", +55785, Percentage, 2998, 2999, "%", "", +55784, ResultMeasuredValue, 3003, 3004, "8", "", +55786, Percentage, 3005, 3006, "%", "", +55787, PvalueDiff, 3009, 3019, "p < 0 . 01", "", +55767, ObservedResult, 3033, 3118, "the standard deviation and MAGE values were significantly lower in the acarbose group", "", +55755, EndPointDescription, 3060, 3064, "MAGE", "", +55766, ObservedResult, 3121, 3245, "The MODD value was not significantly changed in either group , and no significant differences were recorded between groups .", "", +55759, EndPointDescription, 3125, 3129, "MODD", "", +55768, ObservedResult, 3246, 3377, "All adverse events were mild in both groups , with only a significantly greater frequency of flatulence noted in the acarbose group", "", +55760, EndPointDescription, 3250, 3264, "adverse events", "", +55686, Drug, 3363, 3371, "acarbose", "", +55788, ResultMeasuredValue, 3380, 3381, "5", "", +55790, Percentage, 3382, 3383, "%", "", +55793, Drug, 3389, 3397, "acarbose", "", +55789, ResultMeasuredValue, 3401, 3406, "0 . 5", "", +55792, Percentage, 3407, 3408, "%", "", +55794, Placebo, 3414, 3421, "placebo", "", +55795, PvalueDiff, 3424, 3434, "p < 0 . 05", "", +55796, ConclusionComment, 3452, 3662, "The addition of acarbose to metformin and vildagliptin background therapy in patients with inadequately controlled type 2 diabetes decreased intraday glycemic variability , especially postprandial variability ,", "", +55687, Drug, 3468, 3476, "acarbose", "", +55713, Metformin, 3480, 3489, "metformin", "", +55716, Vildagliptin, 3494, 3506, "vildagliptin", "", +55691, Type2Diabetes, 3567, 3582, "type 2 diabetes", "", +55797, ConclusionComment, 3663, 3749, "but it was not associated with a significant change in interday glycemic variability .", "", +55798, PMID, 3831, 3839, "26598090", "", diff --git a/data/dm2 26598090_kwoodley.n-triples b/data/dm2 26598090_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26598090_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26950829_admin.annodb b/data/dm2 26950829_admin.annodb new file mode 100644 index 0000000..8a905e4 --- /dev/null +++ b/data/dm2 26950829_admin.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2016", "", " \"2016\"." +33, Title, 118, 301, "Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea .", "", " \"Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea .\"." +2, Vildagliptin, 129, 141, "vildagliptin", "", +10, Saxagliptin, 149, 160, "saxagliptin", "", +18, Ethnicity, 200, 207, "Chinese", "", " . ." +20, Type2Diabetes, 222, 226, "T2DM", "", +25, Metformin, 273, 282, "metformin", "", +29, Sulfonylureas, 287, 299, "sulfonylurea", "", +34, Author, 302, 311, "Xiaoyan C", "", " \"Xiaoyan C\"." +35, Author, 320, 326, "Jing W", "", " \"Jing W\"." +36, Author, 335, 345, "Xiaochun H", "", " \"Xiaochun H\"." +37, Author, 354, 360, "Yuyu T", "", " \"Yuyu T\"." +38, Author, 369, 378, "Shunyou D", "", " \"Shunyou D\"." +39, Author, 387, 395, "Yingyu F", "", " \"Yingyu F\"." +40, China, 536, 541, "China", "", +141, ObjectiveDescription, 554, 744, "The present study aimed to compare the effects of the dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors vildagliptin and saxagliptin on 24   hour acute glucose fluctuations in Chinese patients", "", " \"The present study aimed to compare the effects of the dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors vildagliptin and saxagliptin on 24   hour acute glucose fluctuations in Chinese patients\"." +3, Vildagliptin, 656, 668, "vildagliptin", "", +11, Saxagliptin, 673, 684, "saxagliptin", "", +41, Precondition, 728, 856, "Chinese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea", "", " \"Chinese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea\"." +19, Ethnicity, 728, 735, "Chinese", "", +142, ObjectiveDescription, 745, 858, "with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea .", "", " \"with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea .\"." +21, Type2Diabetes, 750, 774, "type 2 diabetes mellitus", "", " ." +22, Type2Diabetes, 777, 781, "T2DM", "", +26, Metformin, 830, 839, "metformin", "", +30, Sulfonylureas, 844, 856, "sulfonylurea", "", +44, Duration, 898, 905, "24 week", "", " \"24 week\"." +45, Prospective, 908, 919, "prospective", "", " ." +46, Randomized, 922, 932, "randomized", "", " ." +47, OpenLabel, 935, 947, "open - label", "", " ." +48, CTDesign, 950, 969, "active - controlled", "", " . ." +50, NumberPatientsCT, 995, 997, "73", "", " \"73\"." +49, Type2Diabetes, 1005, 1009, "T2DM", "", +51, HbA1c, 1048, 1053, "HbA1c", "", +53, Percentage, 1060, 1061, "%", "", " ." +54, Percentage, 1071, 1072, "%", "", +27, Metformin, 1099, 1108, "metformin", "", +55, Drug, 1114, 1124, "gliclazide", "", +154, Duration, 1139, 1147, "3 months", "", +57, Randomized, 1153, 1163, "randomized", "", +4, Vildagliptin, 1182, 1194, "vildagliptin", "", " ." +58, DoseValue, 1195, 1197, "50", "", " \"50\"." +60, mg, 1200, 1202, "mg", "", " ." +62, Frequency, 1203, 1214, "twice daily", "", " \"twice daily\"." +64, Frequency, 1217, 1220, "BID", "", +66, NumberPatientsArm, 1229, 1231, "37", "", " \"37\"." +12, Saxagliptin, 1237, 1248, "saxagliptin", "", " ." +59, DoseValue, 1249, 1250, "5", "", " \"5\"." +61, mg, 1253, 1255, "mg", "", " ." +63, Frequency, 1256, 1266, "once daily", "", " \"once daily\"." +65, Frequency, 1269, 1271, "QD", "", +67, NumberPatientsArm, 1280, 1282, "36", "", " \"36\"." +68, EndPointDescription, 1297, 1334, "mean amplitude of glycemic excursions", "", " . ." +69, EndPointDescription, 1337, 1341, "MAGE", "", +72, TimePoint, 1371, 1379, "24 weeks", "", +73, TimePoint, 1393, 1401, "baseline", "", +166, Mean, 1408, 1412, "mean", "", +77, AvgAge, 1430, 1436, "62 . 9", "", " \"62 . 9\"." +170, Year, 1448, 1453, "years", "", +171, Year, 1494, 1499, "years", "", +78, HbA1c, 1506, 1511, "HbA1c", "", +173, BaseLineValue, 1516, 1521, "8 . 4", "", " \"8 . 4\". \"8 . 4\"." +174, SdDevBL, 1526, 1532, "0 . 68", "", " \"0 . 68\". \"0 . 68\"." +79, Percentage, 1533, 1534, "%", "", +74, TimePoint, 1543, 1551, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +70, EndPointDescription, 1571, 1575, "MAGE", "", +81, BaseLineValue, 1591, 1597, "5 . 81", "", " \"5 . 81\"." +83, SdDevBL, 1602, 1608, "1 . 16", "", " \"1 . 16\"." +89, Millimoles_per_litre, 1611, 1619, "mmol / L", "", " ." +85, ResultMeasuredValue, 1623, 1629, "4 . 06", "", " \"4 . 06\"." +87, SdDevResValue, 1634, 1640, "0 . 86", "", " \"0 . 86\"." +90, Millimoles_per_litre, 1643, 1651, "mmol / L", "", +193, PValueChangeValue, 1654, 1665, "p < 0 . 001", "", " \"p < 0 . 001\"." +5, Vildagliptin, 1675, 1687, "vildagliptin", "", +82, BaseLineValue, 1703, 1709, "5 . 66", "", " \"5 . 66\"." +84, SdDevBL, 1714, 1720, "1 . 14", "", " \"1 . 14\"." +91, Millimoles_per_litre, 1723, 1731, "mmol / L", "", +86, ResultMeasuredValue, 1735, 1741, "4 . 79", "", " \"4 . 79\"." +88, SdDevResValue, 1746, 1752, "1 . 25", "", " \"1 . 25\"." +92, Millimoles_per_litre, 1755, 1763, "mmol / L", "", +194, PValueChangeValue, 1766, 1779, "p  =  0 . 003", "", " \"p  =  0 . 003\"." +13, Saxagliptin, 1789, 1800, "saxagliptin", "", +197, Mean, 1813, 1817, "mean", "", +71, EndPointDescription, 1828, 1832, "MAGE", "", +6, Vildagliptin, 1840, 1852, "vildagliptin", "", +14, Saxagliptin, 1902, 1913, "saxagliptin", "", +106365, Increment, 1922, 1928, "1 . 74", "", " \"1 . 74\"." +97, SdDevChangeValue, 1933, 1939, "0 . 48", "", " \"0 . 48\"." +99, Millimoles_per_litre, 1942, 1950, "mmol / L", "", +106366, Increment, 1956, 1962, "0 . 87", "", " \"0 . 87\"." +98, SdDevChangeValue, 1967, 1973, "0 . 40", "", " \"0 . 40\"." +100, Millimoles_per_litre, 1976, 1984, "mmol / L", "", +101, PvalueDiff, 1987, 1998, "p < 0 . 001", "", +207, Mean, 2007, 2011, "mean", "", " . . . ." +52, HbA1c, 2022, 2027, "HbA1c", "", " ." +75, TimePoint, 2035, 2043, "baseline", "", +76, TimePoint, 2051, 2065, "study endpoint", "", +7, Vildagliptin, 2075, 2087, "vildagliptin", "", +15, Saxagliptin, 2092, 2103, "saxagliptin", "", +106367, Increment, 2117, 2123, "1 . 22", "", " \"1 . 22\"." +104, SdDevChangeValue, 2128, 2134, "0 . 40", "", " \"0 . 40\"." +106, Percentage, 2135, 2136, "%", "", " ." +106368, Increment, 2141, 2147, "1 . 07", "", " \"1 . 07\"." +105, SdDevChangeValue, 2152, 2158, "0 . 36", "", " \"0 . 36\"." +107, Percentage, 2159, 2160, "%", "", +108, PvalueDiff, 2230, 2243, "p  =  0 . 091", "", " \"p  =  0 . 091\"." +8, Vildagliptin, 2287, 2299, "vildagliptin", "", +16, Saxagliptin, 2304, 2315, "saxagliptin", "", +109, OpenLabel, 2396, 2408, "open - label", "", +110, ConclusionComment, 2455, 2661, "Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM .", "", " \"Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM .\"." +9, Vildagliptin, 2455, 2467, "Vildagliptin", "", +17, Saxagliptin, 2555, 2566, "saxagliptin", "", +28, Metformin, 2603, 2612, "metformin", "", +31, Sulfonylureas, 2617, 2629, "sulfonylurea", "", +24, Ethnicity, 2633, 2640, "Chinese", "", +23, Type2Diabetes, 2655, 2659, "T2DM", "", +111, PMID, 2782, 2790, "26950829", "", " \"26950829\"." diff --git a/data/dm2 26950829_admin.n-triples b/data/dm2 26950829_admin.n-triples new file mode 100644 index 0000000..2262bf9 --- /dev/null +++ b/data/dm2 26950829_admin.n-triples @@ -0,0 +1,143 @@ +# RDF export of group: Publication + . + "Publication 69127" . + "Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea ." . + "Xiaoyan C" . + "2016" . + "Curr Med Res Opin ." . + "26950829" . + . + "Jing W" . + "Xiaochun H" . + "Yuyu T" . + "Shunyou D" . + "Yingyu F" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 69134" . + "The present study aimed to compare the effects of the dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors vildagliptin and saxagliptin on 24   hour acute glucose fluctuations in Chinese patients" . + "73" . + "24 week" . + . + . + . + "Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM ." . + . + . + . + . + . + "with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population 69150" . + "Chinese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea" . + . + . + . + "62 . 9" . + . +# RDF export of group: Endpoint + . + "mag" . + . + . + . + . + . + . + . + "hba" . + . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + "37" . + . + . + . + . + . + "sax" . + "36" . + . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + "twice daily" . + . + . + "sax" . + . + "once daily" . + . +# RDF export of group: Medication + . + "vil" . + . + "50" . + . + . + . + "sax" . + . + "5" . + . + . +# RDF export of group: Outcome + . + "mag 1" . + . + "5 . 81" . + "1 . 16" . + "4 . 06" . + "0 . 86" . + "1 . 74" . + "p < 0 . 001" . + "0 . 48" . + "24 weeks" . + . + "mag 2" . + . + "5 . 66" . + "1 . 14" . + "4 . 79" . + "1 . 25" . + "0 . 87" . + "p  =  0 . 003" . + "0 . 40" . + "24 weeks" . + . + "hba 1" . + . + "8 . 4" . + "0 . 68" . + "1 . 22" . + "0 . 40" . + . + "hba 2" . + . + "8 . 4" . + "0 . 68" . + "1 . 07" . + "0 . 36" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "p  =  0 . 091" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26950829_akramersunderbrink.annodb b/data/dm2 26950829_akramersunderbrink.annodb new file mode 100644 index 0000000..11b8394 --- /dev/null +++ b/data/dm2 26950829_akramersunderbrink.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +64577, Journal, 0, 17, "Curr Med Res Opin", "", +64597, PublicationYear, 20, 24, "2016", "", +64605, Title, 118, 301, "Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea .", "", +64598, Vildagliptin, 129, 141, "vildagliptin", "", +64599, Saxagliptin, 149, 160, "saxagliptin", "", +64600, Ethnicity, 200, 207, "Chinese", "", +64601, Type2Diabetes, 222, 226, "T2DM", "", +64604, Precondition, 227, 299, "inadequately controlled with a combination of metformin and sulfonylurea", "", +64602, Metformin, 273, 282, "metformin", "", +64603, Sulfonylureas, 287, 299, "sulfonylurea", "", +64606, Author, 302, 311, "Xiaoyan C", "", +64607, Author, 320, 326, "Jing W", "", +64608, Author, 335, 345, "Xiaochun H", "", +64609, Author, 354, 360, "Yuyu T", "", +64610, Author, 369, 378, "Shunyou D", "", +64611, Author, 387, 395, "Yingyu F", "", +64612, China, 536, 541, "China", "", +64627, ObjectiveDescription, 554, 744, "The present study aimed to compare the effects of the dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors vildagliptin and saxagliptin on 24   hour acute glucose fluctuations in Chinese patients", "", +64613, Vildagliptin, 656, 668, "vildagliptin", "", +64614, Saxagliptin, 673, 684, "saxagliptin", "", +64621, Ethnicity, 728, 735, "Chinese", "", +64628, ObjectiveDescription, 745, 858, "with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea .", "", +64615, Type2Diabetes, 750, 774, "type 2 diabetes mellitus", "", +64618, Type2Diabetes, 777, 781, "T2DM", "", +64622, Metformin, 830, 839, "metformin", "", +64623, Sulfonylureas, 844, 856, "sulfonylurea", "", +64624, Duration, 898, 905, "24 week", "", +64629, Prospective, 908, 919, "prospective", "", +64625, Randomized, 922, 932, "randomized", "", +64626, OpenLabel, 935, 947, "open - label", "", +64630, NumberPatientsCT, 995, 997, "73", "", +64619, Type2Diabetes, 1005, 1009, "T2DM", "", +64631, Precondition, 1018, 1147, "inadequate glycemic control ( HbA1c 7 . 0 % - 10 . 0 % ) with a stable dosage of metformin plus gliclazide for more than 3 months", "", +64632, HbA1c, 1048, 1053, "HbA1c", "", +64633, Percentage, 1060, 1061, "%", "", +64634, Percentage, 1071, 1072, "%", "", +64635, Metformin, 1099, 1108, "metformin", "", +64639, Drug, 1114, 1124, "gliclazide", "", +64640, Duration, 1139, 1147, "3 months", "", +64636, Randomized, 1153, 1163, "randomized", "", +64637, Vildagliptin, 1182, 1194, "vildagliptin", "", +64641, DoseValue, 1195, 1202, "50   mg", "", +64643, mg, 1200, 1202, "mg", "", +64645, Frequency, 1203, 1214, "twice daily", "", +64647, Frequency, 1217, 1220, "BID", "", +64649, NumberPatientsArm, 1229, 1231, "37", "", +64638, Saxagliptin, 1237, 1248, "saxagliptin", "", +64642, DoseValue, 1249, 1255, "5   mg", "", +64644, mg, 1253, 1255, "mg", "", +64646, Frequency, 1256, 1266, "once daily", "", +64648, Frequency, 1269, 1271, "QD", "", +64650, NumberPatientsArm, 1280, 1282, "36", "", +64651, Mean, 1297, 1301, "mean", "", +64662, EndPointDescription, 1297, 1334, "mean amplitude of glycemic excursions", "", +64663, EndPointDescription, 1337, 1341, "MAGE", "", +64666, TimePoint, 1371, 1379, "24 weeks", "", +64653, TimePoint, 1393, 1401, "baseline", "", +64652, Mean, 1408, 1412, "mean", "", +64655, AvgAge, 1430, 1436, "62 . 9", "", +64656, Year, 1448, 1453, "years", "", +64657, Year, 1494, 1499, "years", "", +64658, HbA1c, 1506, 1511, "HbA1c", "", +64659, BaseLineValue, 1516, 1521, "8 . 4", "", +64660, SdDevBL, 1526, 1532, "0 . 68", "", +64661, Percentage, 1533, 1534, "%", "", +64654, TimePoint, 1543, 1551, "24 weeks", "", +64664, EndPointDescription, 1571, 1575, "MAGE", "", +64667, BaseLineValue, 1591, 1597, "5 . 81", "", +64668, SdDevBL, 1602, 1608, "1 . 16", "", +64669, Millimoles_per_litre, 1611, 1619, "mmol / L", "", +64675, ResultMeasuredValue, 1623, 1629, "4 . 06", "", +64677, SdDevResValue, 1634, 1640, "0 . 86", "", +64670, Millimoles_per_litre, 1643, 1651, "mmol / L", "", +64679, PValueChangeValue, 1654, 1665, "p < 0 . 001", "", +64681, Vildagliptin, 1675, 1687, "vildagliptin", "", +64673, BaseLineValue, 1703, 1709, "5 . 66", "", +64674, SdDevBL, 1714, 1720, "1 . 14", "", +64671, Millimoles_per_litre, 1723, 1731, "mmol / L", "", +64676, ResultMeasuredValue, 1735, 1741, "4 . 79", "", +64678, SdDevResValue, 1746, 1752, "1 . 25", "", +64672, Millimoles_per_litre, 1755, 1763, "mmol / L", "", +64680, PValueChangeValue, 1766, 1779, "p  =  0 . 003", "", +64682, Saxagliptin, 1789, 1800, "saxagliptin", "", +64683, Mean, 1813, 1817, "mean", "", +64665, EndPointDescription, 1828, 1832, "MAGE", "", +64684, Vildagliptin, 1840, 1852, "vildagliptin", "", +64685, Saxagliptin, 1902, 1913, "saxagliptin", "", +64686, ChangeValue, 1922, 1928, "1 . 74", "", +64688, SdDevChangeValue, 1933, 1939, "0 . 48", "", +64690, Millimoles_per_litre, 1942, 1950, "mmol / L", "", +64687, ChangeValue, 1956, 1962, "0 . 87", "", +64689, SdDevChangeValue, 1967, 1973, "0 . 40", "", +64691, Millimoles_per_litre, 1976, 1984, "mmol / L", "", +64692, PvalueDiff, 1987, 1998, "p < 0 . 001", "", +64693, Mean, 2007, 2011, "mean", "", +64694, HbA1c, 2022, 2027, "HbA1c", "", +64695, TimePoint, 2035, 2043, "baseline", "", +64696, TimePoint, 2051, 2065, "study endpoint", "", +64697, Vildagliptin, 2075, 2087, "vildagliptin", "", +64698, Saxagliptin, 2092, 2103, "saxagliptin", "", +64699, ChangeValue, 2117, 2123, "1 . 22", "", +64701, SdDevChangeValue, 2128, 2134, "0 . 40", "", +64703, Percentage, 2135, 2136, "%", "", +64700, ChangeValue, 2141, 2147, "1 . 07", "", +64702, SdDevChangeValue, 2152, 2158, "0 . 36", "", +64704, Percentage, 2159, 2160, "%", "", +64705, PvalueDiff, 2230, 2243, "p  =  0 . 091", "", +64706, Vildagliptin, 2287, 2299, "vildagliptin", "", +64707, Saxagliptin, 2304, 2315, "saxagliptin", "", +64708, OpenLabel, 2396, 2408, "open - label", "", +64709, Vildagliptin, 2455, 2467, "Vildagliptin", "", +64714, ConclusionComment, 2455, 2661, "Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM .", "", +64710, Saxagliptin, 2555, 2566, "saxagliptin", "", +64711, Metformin, 2603, 2612, "metformin", "", +64712, Sulfonylureas, 2617, 2629, "sulfonylurea", "", +64713, Ethnicity, 2633, 2640, "Chinese", "", +64620, Type2Diabetes, 2655, 2659, "T2DM", "", +64715, PMID, 2782, 2790, "26950829", "", diff --git a/data/dm2 26950829_akramersunderbrink.n-triples b/data/dm2 26950829_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26950829_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 26950829_export.csv b/data/dm2 26950829_export.csv new file mode 100644 index 0000000..0812364 --- /dev/null +++ b/data/dm2 26950829_export.csv @@ -0,0 +1,610 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +262, 1, 1, 1, 0, 4, 0, 4, "Curr" +262, 1, 2, 2, 5, 8, 5, 8, "Med" +262, 1, 3, 3, 9, 12, 9, 12, "Res" +262, 1, 4, 4, 13, 17, 13, 17, "Opin" +262, 1, 5, 5, 18, 19, 18, 19, "." +262, 2, 1, 6, 0, 4, 20, 24, "2016" +262, 2, 2, 7, 5, 8, 25, 28, "Jun" +262, 2, 3, 8, 9, 10, 29, 30, ";" +262, 2, 4, 9, 11, 13, 31, 33, "32" +262, 2, 5, 10, 14, 15, 34, 35, "(" +262, 2, 6, 11, 16, 17, 36, 37, "6" +262, 2, 7, 12, 18, 19, 38, 39, ")" +262, 2, 8, 13, 20, 21, 40, 41, ":" +262, 2, 9, 14, 22, 26, 42, 46, "1131" +262, 2, 10, 15, 27, 28, 47, 48, "-" +262, 2, 11, 16, 29, 30, 49, 50, "6" +262, 2, 12, 17, 31, 32, 51, 52, "." +262, 2, 13, 18, 33, 36, 53, 56, "doi" +262, 2, 14, 19, 37, 38, 57, 58, ":" +262, 2, 15, 20, 39, 41, 59, 61, "10" +262, 2, 16, 21, 42, 43, 62, 63, "." +262, 2, 17, 22, 44, 48, 64, 68, "1185" +262, 2, 18, 23, 49, 50, 69, 70, "/" +262, 2, 19, 24, 51, 59, 71, 79, "03007995" +262, 2, 20, 25, 60, 61, 80, 81, "." +262, 2, 21, 26, 62, 66, 82, 86, "2016" +262, 2, 22, 27, 67, 68, 87, 88, "." +262, 2, 23, 28, 69, 76, 89, 96, "1162773" +262, 2, 24, 29, 77, 78, 97, 98, "." +262, 3, 1, 30, 0, 4, 99, 103, "Epub" +262, 3, 2, 31, 5, 9, 104, 108, "2016" +262, 3, 3, 32, 10, 13, 109, 112, "Mar" +262, 3, 4, 33, 14, 16, 113, 115, "23" +262, 3, 5, 34, 17, 18, 116, 117, "." +262, 4, 1, 35, 0, 7, 118, 125, "Effects" +262, 4, 2, 36, 8, 10, 126, 128, "of" +262, 4, 3, 37, 11, 23, 129, 141, "vildagliptin" +262, 4, 4, 38, 24, 30, 142, 148, "versus" +262, 4, 5, 39, 31, 42, 149, 160, "saxagliptin" +262, 4, 6, 40, 43, 45, 161, 163, "on" +262, 4, 7, 41, 46, 51, 164, 169, "daily" +262, 4, 8, 42, 52, 57, 170, 175, "acute" +262, 4, 9, 43, 58, 65, 176, 183, "glucose" +262, 4, 10, 44, 66, 78, 184, 196, "fluctuations" +262, 4, 11, 45, 79, 81, 197, 199, "in" +262, 4, 12, 46, 82, 89, 200, 207, "Chinese" +262, 4, 13, 47, 90, 98, 208, 216, "patients" +262, 4, 14, 48, 99, 103, 217, 221, "with" +262, 4, 15, 49, 104, 108, 222, 226, "T2DM" +262, 4, 16, 50, 109, 121, 227, 239, "inadequately" +262, 4, 17, 51, 122, 132, 240, 250, "controlled" +262, 4, 18, 52, 133, 137, 251, 255, "with" +262, 4, 19, 53, 138, 139, 256, 257, "a" +262, 4, 20, 54, 140, 151, 258, 269, "combination" +262, 4, 21, 55, 152, 154, 270, 272, "of" +262, 4, 22, 56, 155, 164, 273, 282, "metformin" +262, 4, 23, 57, 165, 168, 283, 286, "and" +262, 4, 24, 58, 169, 181, 287, 299, "sulfonylurea" +262, 4, 25, 59, 182, 183, 300, 301, "." +262, 5, 1, 60, 0, 7, 302, 309, "Xiaoyan" +262, 5, 2, 61, 8, 9, 310, 311, "C" +262, 5, 3, 62, 10, 11, 312, 313, "(" +262, 5, 4, 63, 12, 13, 314, 315, "1" +262, 5, 5, 64, 14, 15, 316, 317, ")" +262, 5, 6, 65, 16, 17, 318, 319, "," +262, 5, 7, 66, 18, 22, 320, 324, "Jing" +262, 5, 8, 67, 23, 24, 325, 326, "W" +262, 5, 9, 68, 25, 26, 327, 328, "(" +262, 5, 10, 69, 27, 28, 329, 330, "1" +262, 5, 11, 70, 29, 30, 331, 332, ")" +262, 5, 12, 71, 31, 32, 333, 334, "," +262, 5, 13, 72, 33, 41, 335, 343, "Xiaochun" +262, 5, 14, 73, 42, 43, 344, 345, "H" +262, 5, 15, 74, 44, 45, 346, 347, "(" +262, 5, 16, 75, 46, 47, 348, 349, "1" +262, 5, 17, 76, 48, 49, 350, 351, ")" +262, 5, 18, 77, 50, 51, 352, 353, "," +262, 5, 19, 78, 52, 56, 354, 358, "Yuyu" +262, 5, 20, 79, 57, 58, 359, 360, "T" +262, 5, 21, 80, 59, 60, 361, 362, "(" +262, 5, 22, 81, 61, 62, 363, 364, "1" +262, 5, 23, 82, 63, 64, 365, 366, ")" +262, 5, 24, 83, 65, 66, 367, 368, "," +262, 5, 25, 84, 67, 74, 369, 376, "Shunyou" +262, 5, 26, 85, 75, 76, 377, 378, "D" +262, 5, 27, 86, 77, 78, 379, 380, "(" +262, 5, 28, 87, 79, 80, 381, 382, "1" +262, 5, 29, 88, 81, 82, 383, 384, ")" +262, 5, 30, 89, 83, 84, 385, 386, "," +262, 5, 31, 90, 85, 91, 387, 393, "Yingyu" +262, 5, 32, 91, 92, 93, 394, 395, "F" +262, 5, 33, 92, 94, 95, 396, 397, "(" +262, 5, 34, 93, 96, 97, 398, 399, "1" +262, 5, 35, 94, 98, 99, 400, 401, ")" +262, 5, 36, 95, 100, 101, 402, 403, "." +262, 6, 1, 96, 0, 6, 404, 410, "Author" +262, 6, 2, 97, 7, 18, 411, 422, "information" +262, 6, 3, 98, 19, 20, 423, 424, ":" +262, 6, 4, 99, 21, 22, 425, 426, "(" +262, 6, 5, 100, 23, 24, 427, 428, "1" +262, 6, 6, 101, 25, 26, 429, 430, ")" +262, 6, 7, 102, 27, 28, 431, 432, "a" +262, 6, 8, 103, 29, 32, 433, 436, "The" +262, 6, 9, 104, 33, 38, 437, 442, "First" +262, 6, 10, 105, 39, 49, 443, 453, "Affiliated" +262, 6, 11, 106, 50, 58, 454, 462, "Hospital" +262, 6, 12, 107, 59, 61, 463, 465, "of" +262, 6, 13, 108, 62, 71, 466, 475, "Guangzhou" +262, 6, 14, 109, 72, 79, 476, 483, "Medical" +262, 6, 15, 110, 80, 90, 484, 494, "University" +262, 6, 16, 111, 91, 92, 495, 496, "," +262, 6, 17, 112, 93, 106, 497, 510, "Endocrinology" +262, 6, 18, 113, 107, 117, 511, 521, "Department" +262, 6, 19, 114, 118, 119, 522, 523, "," +262, 6, 20, 115, 120, 129, 524, 533, "Guangzhou" +262, 6, 21, 116, 130, 131, 534, 535, "," +262, 6, 22, 117, 132, 137, 536, 541, "China" +262, 6, 23, 118, 138, 139, 542, 543, "." +262, 7, 1, 119, 0, 9, 544, 553, "Objective" +262, 7, 2, 120, 10, 13, 554, 557, "The" +262, 7, 3, 121, 14, 21, 558, 565, "present" +262, 7, 4, 122, 22, 27, 566, 571, "study" +262, 7, 5, 123, 28, 33, 572, 577, "aimed" +262, 7, 6, 124, 34, 36, 578, 580, "to" +262, 7, 7, 125, 37, 44, 581, 588, "compare" +262, 7, 8, 126, 45, 48, 589, 592, "the" +262, 7, 9, 127, 49, 56, 593, 600, "effects" +262, 7, 10, 128, 57, 59, 601, 603, "of" +262, 7, 11, 129, 60, 63, 604, 607, "the" +262, 7, 12, 130, 64, 74, 608, 618, "dipeptidyl" +262, 7, 13, 131, 75, 84, 619, 628, "peptidase" +262, 7, 14, 132, 85, 86, 629, 630, "-" +262, 7, 15, 133, 87, 88, 631, 632, "4" +262, 7, 16, 134, 89, 90, 633, 634, "(" +262, 7, 17, 135, 91, 94, 635, 638, "DPP" +262, 7, 18, 136, 95, 96, 639, 640, "-" +262, 7, 19, 137, 97, 98, 641, 642, "4" +262, 7, 20, 138, 99, 100, 643, 644, ")" +262, 7, 21, 139, 101, 111, 645, 655, "inhibitors" +262, 7, 22, 140, 112, 124, 656, 668, "vildagliptin" +262, 7, 23, 141, 125, 128, 669, 672, "and" +262, 7, 24, 142, 129, 140, 673, 684, "saxagliptin" +262, 7, 25, 143, 141, 143, 685, 687, "on" +262, 7, 26, 144, 144, 146, 688, 690, "24" +262, 7, 27, 145, 147, 148, 691, 692, " " +262, 7, 28, 146, 149, 153, 693, 697, "hour" +262, 7, 29, 147, 154, 159, 698, 703, "acute" +262, 7, 30, 148, 160, 167, 704, 711, "glucose" +262, 7, 31, 149, 168, 180, 712, 724, "fluctuations" +262, 7, 32, 150, 181, 183, 725, 727, "in" +262, 7, 33, 151, 184, 191, 728, 735, "Chinese" +262, 7, 34, 152, 192, 200, 736, 744, "patients" +262, 7, 35, 153, 201, 205, 745, 749, "with" +262, 7, 36, 154, 206, 210, 750, 754, "type" +262, 7, 37, 155, 211, 212, 755, 756, "2" +262, 7, 38, 156, 213, 221, 757, 765, "diabetes" +262, 7, 39, 157, 222, 230, 766, 774, "mellitus" +262, 7, 40, 158, 231, 232, 775, 776, "(" +262, 7, 41, 159, 233, 237, 777, 781, "T2DM" +262, 7, 42, 160, 238, 239, 782, 783, ")" +262, 7, 43, 161, 240, 252, 784, 796, "inadequately" +262, 7, 44, 162, 253, 263, 797, 807, "controlled" +262, 7, 45, 163, 264, 268, 808, 812, "with" +262, 7, 46, 164, 269, 270, 813, 814, "a" +262, 7, 47, 165, 271, 282, 815, 826, "combination" +262, 7, 48, 166, 283, 285, 827, 829, "of" +262, 7, 49, 167, 286, 295, 830, 839, "metformin" +262, 7, 50, 168, 296, 299, 840, 843, "and" +262, 7, 51, 169, 300, 312, 844, 856, "sulfonylurea" +262, 7, 52, 170, 313, 314, 857, 858, "." +262, 8, 1, 171, 0, 8, 859, 867, "Research" +262, 8, 2, 172, 9, 15, 868, 874, "design" +262, 8, 3, 173, 16, 19, 875, 878, "and" +262, 8, 4, 174, 20, 27, 879, 886, "methods" +262, 8, 5, 175, 28, 32, 887, 891, "This" +262, 8, 6, 176, 33, 36, 892, 895, "was" +262, 8, 7, 177, 37, 38, 896, 897, "a" +262, 8, 8, 178, 39, 41, 898, 900, "24" +262, 8, 9, 179, 42, 46, 901, 905, "week" +262, 8, 10, 180, 47, 48, 906, 907, "," +262, 8, 11, 181, 49, 60, 908, 919, "prospective" +262, 8, 12, 182, 61, 62, 920, 921, "," +262, 8, 13, 183, 63, 73, 922, 932, "randomized" +262, 8, 14, 184, 74, 75, 933, 934, "," +262, 8, 15, 185, 76, 80, 935, 939, "open" +262, 8, 16, 186, 81, 82, 940, 941, "-" +262, 8, 17, 187, 83, 88, 942, 947, "label" +262, 8, 18, 188, 89, 90, 948, 949, "," +262, 8, 19, 189, 91, 97, 950, 956, "active" +262, 8, 20, 190, 98, 99, 957, 958, "-" +262, 8, 21, 191, 100, 110, 959, 969, "controlled" +262, 8, 22, 192, 111, 116, 970, 975, "study" +262, 8, 23, 193, 117, 118, 976, 977, "." +262, 9, 1, 194, 0, 8, 978, 986, "Patients" +262, 9, 2, 195, 9, 10, 987, 988, "(" +262, 9, 3, 196, 11, 12, 989, 990, "N" +262, 9, 4, 197, 13, 16, 991, 994, " = " +262, 9, 5, 198, 17, 19, 995, 997, "73" +262, 9, 6, 199, 20, 21, 998, 999, ")" +262, 9, 7, 200, 22, 26, 1000, 1004, "with" +262, 9, 8, 201, 27, 31, 1005, 1009, "T2DM" +262, 9, 9, 202, 32, 35, 1010, 1013, "who" +262, 9, 10, 203, 36, 39, 1014, 1017, "had" +262, 9, 11, 204, 40, 50, 1018, 1028, "inadequate" +262, 9, 12, 205, 51, 59, 1029, 1037, "glycemic" +262, 9, 13, 206, 60, 67, 1038, 1045, "control" +262, 9, 14, 207, 68, 69, 1046, 1047, "(" +262, 9, 15, 208, 70, 75, 1048, 1053, "HbA1c" +262, 9, 16, 209, 76, 77, 1054, 1055, "7" +262, 9, 17, 210, 78, 79, 1056, 1057, "." +262, 9, 18, 211, 80, 81, 1058, 1059, "0" +262, 9, 19, 212, 82, 83, 1060, 1061, "%" +262, 9, 20, 213, 84, 85, 1062, 1063, "-" +262, 9, 21, 214, 86, 88, 1064, 1066, "10" +262, 9, 22, 215, 89, 90, 1067, 1068, "." +262, 9, 23, 216, 91, 92, 1069, 1070, "0" +262, 9, 24, 217, 93, 94, 1071, 1072, "%" +262, 9, 25, 218, 95, 96, 1073, 1074, ")" +262, 9, 26, 219, 97, 101, 1075, 1079, "with" +262, 9, 27, 220, 102, 103, 1080, 1081, "a" +262, 9, 28, 221, 104, 110, 1082, 1088, "stable" +262, 9, 29, 222, 111, 117, 1089, 1095, "dosage" +262, 9, 30, 223, 118, 120, 1096, 1098, "of" +262, 9, 31, 224, 121, 130, 1099, 1108, "metformin" +262, 9, 32, 225, 131, 135, 1109, 1113, "plus" +262, 9, 33, 226, 136, 146, 1114, 1124, "gliclazide" +262, 9, 34, 227, 147, 150, 1125, 1128, "for" +262, 9, 35, 228, 151, 155, 1129, 1133, "more" +262, 9, 36, 229, 156, 160, 1134, 1138, "than" +262, 9, 37, 230, 161, 162, 1139, 1140, "3" +262, 9, 38, 231, 163, 169, 1141, 1147, "months" +262, 9, 39, 232, 170, 174, 1148, 1152, "were" +262, 9, 40, 233, 175, 185, 1153, 1163, "randomized" +262, 9, 41, 234, 186, 188, 1164, 1166, "to" +262, 9, 42, 235, 189, 196, 1167, 1174, "receive" +262, 9, 43, 236, 197, 203, 1175, 1181, "either" +262, 9, 44, 237, 204, 216, 1182, 1194, "vildagliptin" +262, 9, 45, 238, 217, 219, 1195, 1197, "50" +262, 9, 46, 239, 220, 221, 1198, 1199, " " +262, 9, 47, 240, 222, 224, 1200, 1202, "mg" +262, 9, 48, 241, 225, 230, 1203, 1208, "twice" +262, 9, 49, 242, 231, 236, 1209, 1214, "daily" +262, 9, 50, 243, 237, 238, 1215, 1216, "(" +262, 9, 51, 244, 239, 242, 1217, 1220, "BID" +262, 9, 52, 245, 243, 244, 1221, 1222, "," +262, 9, 53, 246, 245, 246, 1223, 1224, "n" +262, 9, 54, 247, 247, 250, 1225, 1228, " = " +262, 9, 55, 248, 251, 253, 1229, 1231, "37" +262, 9, 56, 249, 254, 255, 1232, 1233, ")" +262, 9, 57, 250, 256, 258, 1234, 1236, "or" +262, 9, 58, 251, 259, 270, 1237, 1248, "saxagliptin" +262, 9, 59, 252, 271, 272, 1249, 1250, "5" +262, 9, 60, 253, 273, 274, 1251, 1252, " " +262, 9, 61, 254, 275, 277, 1253, 1255, "mg" +262, 9, 62, 255, 278, 282, 1256, 1260, "once" +262, 9, 63, 256, 283, 288, 1261, 1266, "daily" +262, 9, 64, 257, 289, 290, 1267, 1268, "(" +262, 9, 65, 258, 291, 293, 1269, 1271, "QD" +262, 9, 66, 259, 294, 295, 1272, 1273, "," +262, 9, 67, 260, 296, 297, 1274, 1275, "n" +262, 9, 68, 261, 298, 301, 1276, 1279, " = " +262, 9, 69, 262, 302, 304, 1280, 1282, "36" +262, 9, 70, 263, 305, 306, 1283, 1284, ")" +262, 9, 71, 264, 307, 308, 1285, 1286, "." +262, 10, 1, 265, 0, 6, 1287, 1293, "Change" +262, 10, 2, 266, 7, 9, 1294, 1296, "in" +262, 10, 3, 267, 10, 14, 1297, 1301, "mean" +262, 10, 4, 268, 15, 24, 1302, 1311, "amplitude" +262, 10, 5, 269, 25, 27, 1312, 1314, "of" +262, 10, 6, 270, 28, 36, 1315, 1323, "glycemic" +262, 10, 7, 271, 37, 47, 1324, 1334, "excursions" +262, 10, 8, 272, 48, 49, 1335, 1336, "(" +262, 10, 9, 273, 50, 54, 1337, 1341, "MAGE" +262, 10, 10, 274, 55, 56, 1342, 1343, ")" +262, 10, 11, 275, 57, 60, 1344, 1347, "was" +262, 10, 12, 276, 61, 69, 1348, 1356, "assessed" +262, 10, 13, 277, 70, 72, 1357, 1359, "at" +262, 10, 14, 278, 73, 76, 1360, 1363, "the" +262, 10, 15, 279, 77, 80, 1364, 1367, "end" +262, 10, 16, 280, 81, 83, 1368, 1370, "of" +262, 10, 17, 281, 84, 86, 1371, 1373, "24" +262, 10, 18, 282, 87, 92, 1374, 1379, "weeks" +262, 10, 19, 283, 93, 94, 1380, 1381, "." +262, 11, 1, 284, 0, 7, 1382, 1389, "Results" +262, 11, 2, 285, 8, 10, 1390, 1392, "At" +262, 11, 3, 286, 11, 19, 1393, 1401, "baseline" +262, 11, 4, 287, 20, 21, 1402, 1403, "," +262, 11, 5, 288, 22, 25, 1404, 1407, "the" +262, 11, 6, 289, 26, 30, 1408, 1412, "mean" +262, 11, 7, 290, 31, 32, 1413, 1414, "(" +262, 11, 8, 291, 33, 34, 1415, 1416, "±" +262, 11, 9, 292, 35, 37, 1417, 1419, "SD" +262, 11, 10, 293, 38, 39, 1420, 1421, ")" +262, 11, 11, 294, 40, 43, 1422, 1425, "age" +262, 11, 12, 295, 44, 47, 1426, 1429, "was" +262, 11, 13, 296, 48, 50, 1430, 1432, "62" +262, 11, 14, 297, 51, 52, 1433, 1434, "." +262, 11, 15, 298, 53, 54, 1435, 1436, "9" +262, 11, 16, 299, 55, 58, 1437, 1440, " ± " +262, 11, 17, 300, 59, 60, 1441, 1442, "6" +262, 11, 18, 301, 61, 62, 1443, 1444, "." +262, 11, 19, 302, 63, 65, 1445, 1447, "55" +262, 11, 20, 303, 66, 71, 1448, 1453, "years" +262, 11, 21, 304, 72, 73, 1454, 1455, "," +262, 11, 22, 305, 74, 81, 1456, 1463, "disease" +262, 11, 23, 306, 82, 90, 1464, 1472, "duration" +262, 11, 24, 307, 91, 94, 1473, 1476, "was" +262, 11, 25, 308, 95, 96, 1477, 1478, "7" +262, 11, 26, 309, 97, 98, 1479, 1480, "." +262, 11, 27, 310, 99, 100, 1481, 1482, "0" +262, 11, 28, 311, 101, 104, 1483, 1486, " ± " +262, 11, 29, 312, 105, 106, 1487, 1488, "2" +262, 11, 30, 313, 107, 108, 1489, 1490, "." +262, 11, 31, 314, 109, 111, 1491, 1493, "33" +262, 11, 32, 315, 112, 117, 1494, 1499, "years" +262, 11, 33, 316, 118, 119, 1500, 1501, "," +262, 11, 34, 317, 120, 123, 1502, 1505, "and" +262, 11, 35, 318, 124, 129, 1506, 1511, "HbA1c" +262, 11, 36, 319, 130, 133, 1512, 1515, "was" +262, 11, 37, 320, 134, 135, 1516, 1517, "8" +262, 11, 38, 321, 136, 137, 1518, 1519, "." +262, 11, 39, 322, 138, 139, 1520, 1521, "4" +262, 11, 40, 323, 140, 143, 1522, 1525, " ± " +262, 11, 41, 324, 144, 145, 1526, 1527, "0" +262, 11, 42, 325, 146, 147, 1528, 1529, "." +262, 11, 43, 326, 148, 150, 1530, 1532, "68" +262, 11, 44, 327, 151, 152, 1533, 1534, "%" +262, 11, 45, 328, 153, 154, 1535, 1536, "." +262, 12, 1, 329, 0, 5, 1537, 1542, "After" +262, 12, 2, 330, 6, 8, 1543, 1545, "24" +262, 12, 3, 331, 9, 14, 1546, 1551, "weeks" +262, 12, 4, 332, 15, 17, 1552, 1554, "of" +262, 12, 5, 333, 18, 27, 1555, 1564, "treatment" +262, 12, 6, 334, 28, 29, 1565, 1566, "," +262, 12, 7, 335, 30, 33, 1567, 1570, "the" +262, 12, 8, 336, 34, 38, 1571, 1575, "MAGE" +262, 12, 9, 337, 39, 48, 1576, 1585, "decreased" +262, 12, 10, 338, 49, 53, 1586, 1590, "from" +262, 12, 11, 339, 54, 55, 1591, 1592, "5" +262, 12, 12, 340, 56, 57, 1593, 1594, "." +262, 12, 13, 341, 58, 60, 1595, 1597, "81" +262, 12, 14, 342, 61, 64, 1598, 1601, " ± " +262, 12, 15, 343, 65, 66, 1602, 1603, "1" +262, 12, 16, 344, 67, 68, 1604, 1605, "." +262, 12, 17, 345, 69, 71, 1606, 1608, "16" +262, 12, 18, 346, 72, 73, 1609, 1610, " " +262, 12, 19, 347, 74, 78, 1611, 1615, "mmol" +262, 12, 20, 348, 79, 80, 1616, 1617, "/" +262, 12, 21, 349, 81, 82, 1618, 1619, "L" +262, 12, 22, 350, 83, 85, 1620, 1622, "to" +262, 12, 23, 351, 86, 87, 1623, 1624, "4" +262, 12, 24, 352, 88, 89, 1625, 1626, "." +262, 12, 25, 353, 90, 92, 1627, 1629, "06" +262, 12, 26, 354, 93, 96, 1630, 1633, " ± " +262, 12, 27, 355, 97, 98, 1634, 1635, "0" +262, 12, 28, 356, 99, 100, 1636, 1637, "." +262, 12, 29, 357, 101, 103, 1638, 1640, "86" +262, 12, 30, 358, 104, 105, 1641, 1642, " " +262, 12, 31, 359, 106, 110, 1643, 1647, "mmol" +262, 12, 32, 360, 111, 112, 1648, 1649, "/" +262, 12, 33, 361, 113, 114, 1650, 1651, "L" +262, 12, 34, 362, 115, 116, 1652, 1653, "(" +262, 12, 35, 363, 117, 118, 1654, 1655, "p" +262, 12, 36, 364, 119, 120, 1656, 1657, "<" +262, 12, 37, 365, 121, 122, 1658, 1659, "0" +262, 12, 38, 366, 123, 124, 1660, 1661, "." +262, 12, 39, 367, 125, 128, 1662, 1665, "001" +262, 12, 40, 368, 129, 130, 1666, 1667, ")" +262, 12, 41, 369, 131, 133, 1668, 1670, "in" +262, 12, 42, 370, 134, 137, 1671, 1674, "the" +262, 12, 43, 371, 138, 150, 1675, 1687, "vildagliptin" +262, 12, 44, 372, 151, 156, 1688, 1693, "group" +262, 12, 45, 373, 157, 160, 1694, 1697, "and" +262, 12, 46, 374, 161, 165, 1698, 1702, "from" +262, 12, 47, 375, 166, 167, 1703, 1704, "5" +262, 12, 48, 376, 168, 169, 1705, 1706, "." +262, 12, 49, 377, 170, 172, 1707, 1709, "66" +262, 12, 50, 378, 173, 176, 1710, 1713, " ± " +262, 12, 51, 379, 177, 178, 1714, 1715, "1" +262, 12, 52, 380, 179, 180, 1716, 1717, "." +262, 12, 53, 381, 181, 183, 1718, 1720, "14" +262, 12, 54, 382, 184, 185, 1721, 1722, " " +262, 12, 55, 383, 186, 190, 1723, 1727, "mmol" +262, 12, 56, 384, 191, 192, 1728, 1729, "/" +262, 12, 57, 385, 193, 194, 1730, 1731, "L" +262, 12, 58, 386, 195, 197, 1732, 1734, "to" +262, 12, 59, 387, 198, 199, 1735, 1736, "4" +262, 12, 60, 388, 200, 201, 1737, 1738, "." +262, 12, 61, 389, 202, 204, 1739, 1741, "79" +262, 12, 62, 390, 205, 208, 1742, 1745, " ± " +262, 12, 63, 391, 209, 210, 1746, 1747, "1" +262, 12, 64, 392, 211, 212, 1748, 1749, "." +262, 12, 65, 393, 213, 215, 1750, 1752, "25" +262, 12, 66, 394, 216, 217, 1753, 1754, " " +262, 12, 67, 395, 218, 222, 1755, 1759, "mmol" +262, 12, 68, 396, 223, 224, 1760, 1761, "/" +262, 12, 69, 397, 225, 226, 1762, 1763, "L" +262, 12, 70, 398, 227, 228, 1764, 1765, "(" +262, 12, 71, 399, 229, 230, 1766, 1767, "p" +262, 12, 72, 400, 231, 234, 1768, 1771, " = " +262, 12, 73, 401, 235, 236, 1772, 1773, "0" +262, 12, 74, 402, 237, 238, 1774, 1775, "." +262, 12, 75, 403, 239, 242, 1776, 1779, "003" +262, 12, 76, 404, 243, 244, 1780, 1781, ")" +262, 12, 77, 405, 245, 247, 1782, 1784, "in" +262, 12, 78, 406, 248, 251, 1785, 1788, "the" +262, 12, 79, 407, 252, 263, 1789, 1800, "saxagliptin" +262, 12, 80, 408, 264, 269, 1801, 1806, "group" +262, 12, 81, 409, 270, 271, 1807, 1808, "." +262, 13, 1, 410, 0, 3, 1809, 1812, "The" +262, 13, 2, 411, 4, 8, 1813, 1817, "mean" +262, 13, 3, 412, 9, 15, 1818, 1824, "change" +262, 13, 4, 413, 16, 18, 1825, 1827, "in" +262, 13, 5, 414, 19, 23, 1828, 1832, "MAGE" +262, 13, 6, 415, 24, 26, 1833, 1835, "in" +262, 13, 7, 416, 27, 30, 1836, 1839, "the" +262, 13, 8, 417, 31, 43, 1840, 1852, "vildagliptin" +262, 13, 9, 418, 44, 49, 1853, 1858, "group" +262, 13, 10, 419, 50, 53, 1859, 1862, "was" +262, 13, 11, 420, 54, 67, 1863, 1876, "significantly" +262, 13, 12, 421, 68, 75, 1877, 1884, "greater" +262, 13, 13, 422, 76, 80, 1885, 1889, "than" +262, 13, 14, 423, 81, 85, 1890, 1894, "that" +262, 13, 15, 424, 86, 88, 1895, 1897, "in" +262, 13, 16, 425, 89, 92, 1898, 1901, "the" +262, 13, 17, 426, 93, 104, 1902, 1913, "saxagliptin" +262, 13, 18, 427, 105, 110, 1914, 1919, "group" +262, 13, 19, 428, 111, 112, 1920, 1921, "(" +262, 13, 20, 429, 113, 114, 1922, 1923, "1" +262, 13, 21, 430, 115, 116, 1924, 1925, "." +262, 13, 22, 431, 117, 119, 1926, 1928, "74" +262, 13, 23, 432, 120, 123, 1929, 1932, " ± " +262, 13, 24, 433, 124, 125, 1933, 1934, "0" +262, 13, 25, 434, 126, 127, 1935, 1936, "." +262, 13, 26, 435, 128, 130, 1937, 1939, "48" +262, 13, 27, 436, 131, 132, 1940, 1941, " " +262, 13, 28, 437, 133, 137, 1942, 1946, "mmol" +262, 13, 29, 438, 138, 139, 1947, 1948, "/" +262, 13, 30, 439, 140, 141, 1949, 1950, "L" +262, 13, 31, 440, 142, 144, 1951, 1953, "vs" +262, 13, 32, 441, 145, 146, 1954, 1955, "." +262, 13, 33, 442, 147, 148, 1956, 1957, "0" +262, 13, 34, 443, 149, 150, 1958, 1959, "." +262, 13, 35, 444, 151, 153, 1960, 1962, "87" +262, 13, 36, 445, 154, 157, 1963, 1966, " ± " +262, 13, 37, 446, 158, 159, 1967, 1968, "0" +262, 13, 38, 447, 160, 161, 1969, 1970, "." +262, 13, 39, 448, 162, 164, 1971, 1973, "40" +262, 13, 40, 449, 165, 166, 1974, 1975, " " +262, 13, 41, 450, 167, 171, 1976, 1980, "mmol" +262, 13, 42, 451, 172, 173, 1981, 1982, "/" +262, 13, 43, 452, 174, 175, 1983, 1984, "L" +262, 13, 44, 453, 176, 177, 1985, 1986, "," +262, 13, 45, 454, 178, 179, 1987, 1988, "p" +262, 13, 46, 455, 180, 181, 1989, 1990, "<" +262, 13, 47, 456, 182, 183, 1991, 1992, "0" +262, 13, 48, 457, 184, 185, 1993, 1994, "." +262, 13, 49, 458, 186, 189, 1995, 1998, "001" +262, 13, 50, 459, 190, 191, 1999, 2000, ")" +262, 13, 51, 460, 192, 193, 2001, 2002, "." +262, 14, 1, 461, 0, 3, 2003, 2006, "The" +262, 14, 2, 462, 4, 8, 2007, 2011, "mean" +262, 14, 3, 463, 9, 15, 2012, 2018, "change" +262, 14, 4, 464, 16, 18, 2019, 2021, "in" +262, 14, 5, 465, 19, 24, 2022, 2027, "HbA1c" +262, 14, 6, 466, 25, 26, 2028, 2029, "," +262, 14, 7, 467, 27, 31, 2030, 2034, "from" +262, 14, 8, 468, 32, 40, 2035, 2043, "baseline" +262, 14, 9, 469, 41, 43, 2044, 2046, "to" +262, 14, 10, 470, 44, 47, 2047, 2050, "the" +262, 14, 11, 471, 48, 53, 2051, 2056, "study" +262, 14, 12, 472, 54, 62, 2057, 2065, "endpoint" +262, 14, 13, 473, 63, 64, 2066, 2067, "," +262, 14, 14, 474, 65, 67, 2068, 2070, "in" +262, 14, 15, 475, 68, 71, 2071, 2074, "the" +262, 14, 16, 476, 72, 84, 2075, 2087, "vildagliptin" +262, 14, 17, 477, 85, 88, 2088, 2091, "and" +262, 14, 18, 478, 89, 100, 2092, 2103, "saxagliptin" +262, 14, 19, 479, 101, 107, 2104, 2110, "groups" +262, 14, 20, 480, 108, 109, 2111, 2112, "," +262, 14, 21, 481, 110, 113, 2113, 2116, "was" +262, 14, 22, 482, 114, 115, 2117, 2118, "1" +262, 14, 23, 483, 116, 117, 2119, 2120, "." +262, 14, 24, 484, 118, 120, 2121, 2123, "22" +262, 14, 25, 485, 121, 124, 2124, 2127, " ± " +262, 14, 26, 486, 125, 126, 2128, 2129, "0" +262, 14, 27, 487, 127, 128, 2130, 2131, "." +262, 14, 28, 488, 129, 131, 2132, 2134, "40" +262, 14, 29, 489, 132, 133, 2135, 2136, "%" +262, 14, 30, 490, 134, 137, 2137, 2140, "and" +262, 14, 31, 491, 138, 139, 2141, 2142, "1" +262, 14, 32, 492, 140, 141, 2143, 2144, "." +262, 14, 33, 493, 142, 144, 2145, 2147, "07" +262, 14, 34, 494, 145, 148, 2148, 2151, " ± " +262, 14, 35, 495, 149, 150, 2152, 2153, "0" +262, 14, 36, 496, 151, 152, 2154, 2155, "." +262, 14, 37, 497, 153, 155, 2156, 2158, "36" +262, 14, 38, 498, 156, 157, 2159, 2160, "%" +262, 14, 39, 499, 158, 159, 2161, 2162, "," +262, 14, 40, 500, 160, 172, 2163, 2175, "respectively" +262, 14, 41, 501, 173, 174, 2176, 2177, "," +262, 14, 42, 502, 175, 179, 2178, 2182, "with" +262, 14, 43, 503, 180, 182, 2183, 2185, "no" +262, 14, 44, 504, 183, 194, 2186, 2197, "significant" +262, 14, 45, 505, 195, 205, 2198, 2208, "difference" +262, 14, 46, 506, 206, 213, 2209, 2216, "between" +262, 14, 47, 507, 214, 217, 2217, 2220, "the" +262, 14, 48, 508, 218, 224, 2221, 2227, "groups" +262, 14, 49, 509, 225, 226, 2228, 2229, "(" +262, 14, 50, 510, 227, 228, 2230, 2231, "p" +262, 14, 51, 511, 229, 232, 2232, 2235, " = " +262, 14, 52, 512, 233, 234, 2236, 2237, "0" +262, 14, 53, 513, 235, 236, 2238, 2239, "." +262, 14, 54, 514, 237, 240, 2240, 2243, "091" +262, 14, 55, 515, 241, 242, 2244, 2245, ")" +262, 14, 56, 516, 243, 244, 2246, 2247, "." +262, 15, 1, 517, 0, 3, 2248, 2251, "The" +262, 15, 2, 518, 4, 11, 2252, 2259, "overall" +262, 15, 3, 519, 12, 18, 2260, 2266, "safety" +262, 15, 4, 520, 19, 22, 2267, 2270, "and" +262, 15, 5, 521, 23, 35, 2271, 2283, "tolerability" +262, 15, 6, 522, 36, 38, 2284, 2286, "of" +262, 15, 7, 523, 39, 51, 2287, 2299, "vildagliptin" +262, 15, 8, 524, 52, 55, 2300, 2303, "and" +262, 15, 9, 525, 56, 67, 2304, 2315, "saxagliptin" +262, 15, 10, 526, 68, 72, 2316, 2320, "were" +262, 15, 11, 527, 73, 80, 2321, 2328, "similar" +262, 15, 12, 528, 81, 82, 2329, 2330, "." +262, 16, 1, 529, 0, 3, 2331, 2334, "The" +262, 16, 2, 530, 4, 15, 2335, 2346, "limitations" +262, 16, 3, 531, 16, 18, 2347, 2349, "of" +262, 16, 4, 532, 19, 22, 2350, 2353, "the" +262, 16, 5, 533, 23, 28, 2354, 2359, "study" +262, 16, 6, 534, 29, 33, 2360, 2364, "were" +262, 16, 7, 535, 34, 35, 2365, 2366, "a" +262, 16, 8, 536, 36, 41, 2367, 2372, "small" +262, 16, 9, 537, 42, 48, 2373, 2379, "number" +262, 16, 10, 538, 49, 51, 2380, 2382, "of" +262, 16, 11, 539, 52, 60, 2383, 2391, "patients" +262, 16, 12, 540, 61, 64, 2392, 2395, "and" +262, 16, 13, 541, 65, 69, 2396, 2400, "open" +262, 16, 14, 542, 70, 71, 2401, 2402, "-" +262, 16, 15, 543, 72, 77, 2403, 2408, "label" +262, 16, 16, 544, 78, 92, 2409, 2423, "administration" +262, 16, 17, 545, 93, 95, 2424, 2426, "of" +262, 16, 18, 546, 96, 99, 2427, 2430, "the" +262, 16, 19, 547, 100, 105, 2431, 2436, "study" +262, 16, 20, 548, 106, 110, 2437, 2441, "drug" +262, 16, 21, 549, 111, 112, 2442, 2443, "." +262, 17, 1, 550, 0, 10, 2444, 2454, "Conclusion" +262, 17, 2, 551, 11, 23, 2455, 2467, "Vildagliptin" +262, 17, 3, 552, 24, 32, 2468, 2476, "produced" +262, 17, 4, 553, 33, 34, 2477, 2478, "a" +262, 17, 5, 554, 35, 48, 2479, 2492, "significantly" +262, 17, 6, 555, 49, 56, 2493, 2500, "greater" +262, 17, 7, 556, 57, 66, 2501, 2510, "reduction" +262, 17, 8, 557, 67, 69, 2511, 2513, "in" +262, 17, 9, 558, 70, 75, 2514, 2519, "acute" +262, 17, 10, 559, 76, 83, 2520, 2527, "glucose" +262, 17, 11, 560, 84, 96, 2528, 2540, "fluctuations" +262, 17, 12, 561, 97, 105, 2541, 2549, "compared" +262, 17, 13, 562, 106, 110, 2550, 2554, "with" +262, 17, 14, 563, 111, 122, 2555, 2566, "saxagliptin" +262, 17, 15, 564, 123, 127, 2567, 2571, "when" +262, 17, 16, 565, 128, 133, 2572, 2577, "added" +262, 17, 17, 566, 134, 136, 2578, 2580, "to" +262, 17, 18, 567, 137, 138, 2581, 2582, "a" +262, 17, 19, 568, 139, 143, 2583, 2587, "dual" +262, 17, 20, 569, 144, 155, 2588, 2599, "combination" +262, 17, 21, 570, 156, 158, 2600, 2602, "of" +262, 17, 22, 571, 159, 168, 2603, 2612, "metformin" +262, 17, 23, 572, 169, 172, 2613, 2616, "and" +262, 17, 24, 573, 173, 185, 2617, 2629, "sulfonylurea" +262, 17, 25, 574, 186, 188, 2630, 2632, "in" +262, 17, 26, 575, 189, 196, 2633, 2640, "Chinese" +262, 17, 27, 576, 197, 205, 2641, 2649, "patients" +262, 17, 28, 577, 206, 210, 2650, 2654, "with" +262, 17, 29, 578, 211, 215, 2655, 2659, "T2DM" +262, 17, 30, 579, 216, 217, 2660, 2661, "." +262, 18, 1, 580, 0, 7, 2662, 2669, "Chinese" +262, 18, 2, 581, 8, 16, 2670, 2678, "clinical" +262, 18, 3, 582, 17, 22, 2679, 2684, "trial" +262, 18, 4, 583, 23, 35, 2685, 2697, "registration" +262, 18, 5, 584, 36, 42, 2698, 2704, "number" +262, 18, 6, 585, 43, 49, 2705, 2711, "ChiCTR" +262, 18, 7, 586, 50, 51, 2712, 2713, "-" +262, 18, 8, 587, 52, 55, 2714, 2717, "TRC" +262, 18, 9, 588, 56, 57, 2718, 2719, "-" +262, 18, 10, 589, 58, 66, 2720, 2728, "13003858" +262, 18, 11, 590, 67, 68, 2729, 2730, "." +262, 19, 1, 591, 0, 3, 2731, 2734, "DOI" +262, 19, 2, 592, 4, 5, 2735, 2736, ":" +262, 19, 3, 593, 6, 8, 2737, 2739, "10" +262, 19, 4, 594, 9, 10, 2740, 2741, "." +262, 19, 5, 595, 11, 15, 2742, 2746, "1185" +262, 19, 6, 596, 16, 17, 2747, 2748, "/" +262, 19, 7, 597, 18, 26, 2749, 2757, "03007995" +262, 19, 8, 598, 27, 28, 2758, 2759, "." +262, 19, 9, 599, 29, 33, 2760, 2764, "2016" +262, 19, 10, 600, 34, 35, 2765, 2766, "." +262, 19, 11, 601, 36, 43, 2767, 2774, "1162773" +262, 19, 12, 602, 44, 48, 2775, 2779, "PMID" +262, 19, 13, 603, 49, 50, 2780, 2781, ":" +262, 19, 14, 604, 51, 59, 2782, 2790, "26950829" +262, 19, 15, 605, 60, 61, 2791, 2792, "[" +262, 19, 16, 606, 62, 69, 2793, 2800, "Indexed" +262, 19, 17, 607, 70, 73, 2801, 2804, "for" +262, 19, 18, 608, 74, 81, 2805, 2812, "MEDLINE" +262, 19, 19, 609, 82, 83, 2813, 2814, "]" diff --git a/data/dm2 26950829_kwoodley.annodb b/data/dm2 26950829_kwoodley.annodb new file mode 100644 index 0000000..1a68ffc --- /dev/null +++ b/data/dm2 26950829_kwoodley.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +62400, Journal, 0, 17, "Curr Med Res Opin", "", +62401, PublicationYear, 20, 24, "2016", "", +62433, Title, 118, 301, "Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea .", "", +62402, Vildagliptin, 129, 141, "vildagliptin", "", +62410, Saxagliptin, 149, 160, "saxagliptin", "", +62418, Ethnicity, 200, 207, "Chinese", "", +62432, Precondition, 200, 299, "Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea", "", +62420, Type2Diabetes, 222, 226, "T2DM", "", +62425, Metformin, 273, 282, "metformin", "", +62429, Sulfonylureas, 287, 299, "sulfonylurea", "", +62434, Author, 302, 311, "Xiaoyan C", "", +62435, Author, 320, 326, "Jing W", "", +62436, Author, 335, 345, "Xiaochun H", "", +62437, Author, 354, 360, "Yuyu T", "", +62438, Author, 369, 378, "Shunyou D", "", +62439, Author, 387, 395, "Yingyu F", "", +62440, China, 536, 541, "China", "", +62442, ObjectiveDescription, 554, 724, "The present study aimed to compare the effects of the dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors vildagliptin and saxagliptin on 24   hour acute glucose fluctuations", "", +62403, Vildagliptin, 656, 668, "vildagliptin", "", +62411, Saxagliptin, 673, 684, "saxagliptin", "", +62443, ObjectiveDescription, 725, 858, "in Chinese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea .", "", +62419, Ethnicity, 728, 735, "Chinese", "", +62441, Precondition, 728, 856, "Chinese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with a combination of metformin and sulfonylurea", "", +62421, Type2Diabetes, 750, 774, "type 2 diabetes mellitus", "", +62422, Type2Diabetes, 777, 781, "T2DM", "", +62426, Metformin, 830, 839, "metformin", "", +62430, Sulfonylureas, 844, 856, "sulfonylurea", "", +62444, Duration, 898, 905, "24 week", "", +62445, Prospective, 908, 919, "prospective", "", +62446, Randomized, 922, 932, "randomized", "", +62447, OpenLabel, 935, 947, "open - label", "", +62448, CTDesign, 950, 969, "active - controlled", "", +62456, Precondition, 978, 1147, "Patients ( N  =  73 ) with T2DM who had inadequate glycemic control ( HbA1c 7 . 0 % - 10 . 0 % ) with a stable dosage of metformin plus gliclazide for more than 3 months", "", +62450, NumberPatientsCT, 995, 997, "73", "", +62449, Type2Diabetes, 1005, 1009, "T2DM", "", +62451, HbA1c, 1048, 1053, "HbA1c", "", +62453, Percentage, 1060, 1061, "%", "", +62454, Percentage, 1071, 1072, "%", "", +62427, Metformin, 1099, 1108, "metformin", "", +62455, Drug, 1114, 1124, "gliclazide", "", +62457, Randomized, 1153, 1163, "randomized", "", +62404, Vildagliptin, 1182, 1194, "vildagliptin", "", +62458, DoseValue, 1195, 1197, "50", "", +62460, mg, 1200, 1202, "mg", "", +62462, Frequency, 1203, 1214, "twice daily", "", +62464, Frequency, 1217, 1220, "BID", "", +62466, NumberPatientsArm, 1229, 1231, "37", "", +62412, Saxagliptin, 1237, 1248, "saxagliptin", "", +62459, DoseValue, 1249, 1250, "5", "", +62461, mg, 1253, 1255, "mg", "", +62463, Frequency, 1256, 1266, "once daily", "", +62465, Frequency, 1269, 1271, "QD", "", +62467, NumberPatientsArm, 1280, 1282, "36", "", +62468, EndPointDescription, 1297, 1334, "mean amplitude of glycemic excursions", "", +62469, EndPointDescription, 1337, 1341, "MAGE", "", +62472, TimePoint, 1371, 1379, "24 weeks", "", +62473, TimePoint, 1393, 1401, "baseline", "", +62477, AvgAge, 1430, 1436, "62 . 9", "", +62480, Precondition, 1456, 1534, "disease duration was 7 . 0  ±  2 . 33 years , and HbA1c was 8 . 4  ±  0 . 68 %", "", +62478, HbA1c, 1506, 1511, "HbA1c", "", +62479, Percentage, 1533, 1534, "%", "", +62474, TimePoint, 1543, 1551, "24 weeks", "", +62470, EndPointDescription, 1571, 1575, "MAGE", "", +62481, BaseLineValue, 1591, 1597, "5 . 81", "", +62483, SdDevBL, 1602, 1608, "1 . 16", "", +62489, Millimoles_per_litre, 1611, 1619, "mmol / L", "", +62485, ResultMeasuredValue, 1623, 1629, "4 . 06", "", +62487, SdDevResValue, 1634, 1640, "0 . 86", "", +62490, Millimoles_per_litre, 1643, 1651, "mmol / L", "", +62493, PValueResValue, 1654, 1665, "p < 0 . 001", "", +62405, Vildagliptin, 1675, 1687, "vildagliptin", "", +62482, BaseLineValue, 1703, 1709, "5 . 66", "", +62484, SdDevBL, 1714, 1720, "1 . 14", "", +62491, Millimoles_per_litre, 1723, 1731, "mmol / L", "", +62486, ResultMeasuredValue, 1735, 1741, "4 . 79", "", +62488, SdDevResValue, 1746, 1752, "1 . 25", "", +62492, Millimoles_per_litre, 1755, 1763, "mmol / L", "", +62494, PValueResValue, 1766, 1779, "p  =  0 . 003", "", +62413, Saxagliptin, 1789, 1800, "saxagliptin", "", +62471, EndPointDescription, 1828, 1832, "MAGE", "", +62406, Vildagliptin, 1840, 1852, "vildagliptin", "", +62414, Saxagliptin, 1902, 1913, "saxagliptin", "", +62495, ChangeValue, 1922, 1928, "1 . 74", "", +62497, SdDevChangeValue, 1933, 1939, "0 . 48", "", +62499, Millimoles_per_litre, 1942, 1950, "mmol / L", "", +62496, ChangeValue, 1956, 1962, "0 . 87", "", +62498, SdDevChangeValue, 1967, 1973, "0 . 40", "", +62500, Millimoles_per_litre, 1976, 1984, "mmol / L", "", +62501, PvalueDiff, 1987, 1998, "p < 0 . 001", "", +62452, HbA1c, 2022, 2027, "HbA1c", "", +62475, TimePoint, 2035, 2043, "baseline", "", +62476, TimePoint, 2051, 2065, "study endpoint", "", +62407, Vildagliptin, 2075, 2087, "vildagliptin", "", +62415, Saxagliptin, 2092, 2103, "saxagliptin", "", +62502, ChangeValue, 2117, 2123, "1 . 22", "", +62504, SdDevChangeValue, 2128, 2134, "0 . 40", "", +62506, Percentage, 2135, 2136, "%", "", +62503, ChangeValue, 2141, 2147, "1 . 07", "", +62505, SdDevChangeValue, 2152, 2158, "0 . 36", "", +62507, Percentage, 2159, 2160, "%", "", +62508, PvalueDiff, 2230, 2243, "p  =  0 . 091", "", +62408, Vildagliptin, 2287, 2299, "vildagliptin", "", +62416, Saxagliptin, 2304, 2315, "saxagliptin", "", +62509, OpenLabel, 2396, 2408, "open - label", "", +62510, ConclusionComment, 2455, 2661, "Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM .", "", +62409, Vildagliptin, 2455, 2467, "Vildagliptin", "", +62417, Saxagliptin, 2555, 2566, "saxagliptin", "", +62428, Metformin, 2603, 2612, "metformin", "", +62431, Sulfonylureas, 2617, 2629, "sulfonylurea", "", +62424, Ethnicity, 2633, 2640, "Chinese", "", +62423, Type2Diabetes, 2655, 2659, "T2DM", "", +62512, PMID, 2782, 2790, "26950829", "", diff --git a/data/dm2 26950829_kwoodley.n-triples b/data/dm2 26950829_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 26950829_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27321385_admin.annodb b/data/dm2 27321385_admin.annodb new file mode 100644 index 0000000..b7cc3af --- /dev/null +++ b/data/dm2 27321385_admin.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "Endocr J .", "", " \"Endocr J .\"." +1, PublicationYear, 11, 15, "2016", "", " \"2016\"." +23, Title, 108, 247, "Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus .", "", " \"Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus .\"." +2, Vildagliptin, 131, 143, "vildagliptin", "", +10, Sitagliptin, 148, 159, "sitagliptin", "", +17, Type2Diabetes, 221, 245, "type 2 diabetes mellitus", "", " ." +24, Author, 248, 260, "Koyanagawa N", "", " \"Koyanagawa N\"." +25, Author, 269, 278, "Miyoshi H", "", " \"Miyoshi H\"." +26, Author, 281, 286, "Ono K", "", " \"Ono K\"." +27, Author, 289, 299, "Nakamura A", "", " \"Nakamura A\"." +28, Author, 302, 308, "Cho KY", "", " \"Cho KY\"." +29, Author, 311, 321, "Yamamoto K", "", " \"Yamamoto K\"." +30, Author, 324, 332, "Takano Y", "", " \"Takano Y\"." +31, Author, 335, 348, "Dan - Noura M", "", " \"Dan - Noura M\"." +32, Author, 351, 359, "Atsumi T", "", " \"Atsumi T\"." +33, Japan, 507, 512, "Japan", "", " ." +3, Vildagliptin, 555, 567, "vildagliptin", "", +11, Sitagliptin, 572, 583, "sitagliptin", "", +18, Type2Diabetes, 624, 648, "type 2 diabetes mellitus", "", +34, Sitagliptin, 688, 699, "sitagliptin", "", +35, Insulin, 705, 712, "insulin", "", +12, Sitagliptin, 744, 755, "sitagliptin", "", +4, Vildagliptin, 772, 784, "vildagliptin", "", +114, BloodGlucose, 796, 809, "blood glucose", "", +40, ObjectiveDescription, 820, 990, "This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin .", "", " \"This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin .\"." +38, Sitagliptin, 866, 877, "sitagliptin", "", +5, Vildagliptin, 895, 907, "vildagliptin", "", +19, Type2Diabetes, 911, 926, "type 2 diabetes", "", +39, Precondition, 911, 988, "type 2 diabetes patients receiving standard doses of sitagliptin plus insulin", "", +13, Sitagliptin, 964, 975, "sitagliptin", "", +37, Insulin, 981, 988, "insulin", "", +41, Prospective, 996, 1007, "prospective", "", " ." +42, Randomized, 1010, 1020, "randomized", "", " ." +43, Parallel, 1023, 1039, "parallel - group", "", " ." +44, NumberPatientsCT, 1066, 1068, "33", "", " \"33\"." +54, Precondition, 1069, 1145, "type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin", "", " \"type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin\"." +20, Type2Diabetes, 1069, 1084, "type 2 diabetes", "", +45, DoseValue, 1104, 1106, "50", "", " \"50\"." +48, mg, 1107, 1109, "mg", "", " ." +14, Sitagliptin, 1110, 1121, "sitagliptin", "", +51, Frequency, 1122, 1132, "once daily", "", +36, Insulin, 1138, 1145, "insulin", "", +55, NumberPatientsArm, 1148, 1157, "Seventeen", "", " \"Seventeen\"." +57, Randomized, 1172, 1182, "randomized", "", +46, DoseValue, 1186, 1188, "50", "", " \"50\"." +49, mg, 1189, 1191, "mg", "", " ." +6, Vildagliptin, 1192, 1204, "vildagliptin", "", " ." +52, Frequency, 1205, 1216, "twice daily", "", " \"twice daily\"." +56, NumberPatientsArm, 1223, 1225, "16", "", " \"16\"." +47, DoseValue, 1229, 1232, "100", "", +50, mg, 1233, 1235, "mg", "", +58, Sitagliptin, 1236, 1247, "sitagliptin", "", " ." +53, Frequency, 1248, 1258, "once daily", "", " \"twice daily\"." +59, TimePoint, 1311, 1319, "baseline", "", +145, TimePoint, 1324, 1337, "after 8 weeks", "", +60, TimePoint, 1330, 1337, "8 weeks", "", +64, EndPointDescription, 1382, 1419, "mean amplitude of glycemic excursions", "", " . ." +63, EndPointDescription, 1422, 1426, "MAGE", "", +65, EndPointDescription, 1431, 1435, "MAGE", "", +62, TimePoint, 1451, 1459, "baseline", "", +7, Vildagliptin, 1472, 1484, "vildagliptin", "", +67, Reduction, 1489, 1495, "13 . 4", "", " \"13 . 4\"." +69, SdDevChangeValue, 1498, 1504, "35 . 7", "", " \"35 . 7\"." +71, Mg_per_deciliter, 1505, 1512, "mg / dL", "", " ." +15, Sitagliptin, 1519, 1530, "sitagliptin", "", +68, Reduction, 1535, 1540, "8 . 4", "", " \"8 . 4\"." +70, SdDevChangeValue, 1543, 1549, "24 . 3", "", " \"24 . 3\"." +72, Mg_per_deciliter, 1550, 1557, "mg / dL", "", +74, BloodGlucose, 1693, 1706, "blood glucose", "", +76, BaseLineValue, 1714, 1719, "≥ 180", "", +75, Mg_per_deciliter, 1720, 1727, "mg / dL", "", +77, BaseLineValue, 1732, 1736, "< 70", "", +73, Mg_per_deciliter, 1737, 1744, "mg / dL", "", +78, ObservedResult, 1745, 1836, "tended to improve in both groups , but these differences were not statistically significant", "", +79, HbA1c, 1853, 1858, "HbA1c", "", " ." +8, Vildagliptin, 1897, 1909, "vildagliptin", "", +80, BaseLineValue, 1923, 1928, "7 . 1", "", " \"7 . 1\"." +82, SdDevBL, 1931, 1936, "0 . 6", "", " \"0 . 6\"." +83, Percentage, 1937, 1938, "%", "", " ." +81, TimePoint, 1942, 1950, "baseline", "", +85, ResultMeasuredValue, 1954, 1959, "6 . 8", "", " \"6 . 8\"." +86, SdDevResValue, 1962, 1967, "0 . 6", "", " \"0 . 6\"." +84, Percentage, 1968, 1969, "%", "", +61, TimePoint, 1973, 1980, "8 weeks", "", " \"8 weeks\"." +87, PValueChangeValue, 1983, 1994, "p = 0 . 006", "", " \"p = 0 . 006\"." +89, ConclusionComment, 1999, 2167, "Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin .", "", " \"Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin .\"." +16, Sitagliptin, 2010, 2021, "sitagliptin", "", +9, Vildagliptin, 2044, 2056, "vildagliptin", "", +66, EndPointDescription, 2090, 2094, "MAGE", "", +21, Type2Diabetes, 2098, 2113, "type 2 diabetic", "", +22, Sitagliptin, 2154, 2165, "sitagliptin", "", +90, PMID, 2215, 2223, "27321385", "", " \"27321385\"." diff --git a/data/dm2 27321385_admin.n-triples b/data/dm2 27321385_admin.n-triples new file mode 100644 index 0000000..ab458b4 --- /dev/null +++ b/data/dm2 27321385_admin.n-triples @@ -0,0 +1,115 @@ +# RDF export of group: Publication + . + "Publication 69425" . + "Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus ." . + "Koyanagawa N" . + "2016" . + "Endocr J ." . + "27321385" . + . + "Miyoshi H" . + "Ono K" . + "Nakamura A" . + "Cho KY" . + "Yamamoto K" . + "Takano Y" . + "Dan - Noura M" . + "Atsumi T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 69432" . + "This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin ." . + "33" . + . + . + . + "Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 69448" . + "type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin" . + . + . + . +# RDF export of group: Endpoint + . + "mag" . + . + . + . + . + . + . + "hba" . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + "Seventeen" . + . + . + . + . + . + "sit" . + "16" . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + "twice daily" . + . + . + "sit" . + . + "once daily" . + . +# RDF export of group: Medication + . + "vil" . + . + "50" . + . + . + . + "sit" . + . + "50" . + . + . +# RDF export of group: Outcome + . + "mag 1" . + . + "13 . 4" . + "35 . 7" . + . + "mag 2" . + . + "8 . 4" . + "24 . 3" . + . + "hba 1" . + . + "7 . 1" . + "0 . 6" . + "6 . 8" . + "0 . 6" . + "p = 0 . 006" . + "8 weeks" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27321385_akramersunderbrink.annodb b/data/dm2 27321385_akramersunderbrink.annodb new file mode 100644 index 0000000..37dca97 --- /dev/null +++ b/data/dm2 27321385_akramersunderbrink.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +64716, Journal, 0, 8, "Endocr J", "", +64717, PublicationYear, 11, 15, "2016", "", +64721, Title, 108, 247, "Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus .", "", +64718, Vildagliptin, 131, 143, "vildagliptin", "", +64719, Sitagliptin, 148, 159, "sitagliptin", "", +64720, Type2Diabetes, 221, 245, "type 2 diabetes mellitus", "", +64722, Author, 248, 260, "Koyanagawa N", "", +64723, Author, 269, 278, "Miyoshi H", "", +64724, Author, 281, 286, "Ono K", "", +64725, Author, 289, 299, "Nakamura A", "", +64726, Author, 302, 308, "Cho KY", "", +64727, Author, 311, 321, "Yamamoto K", "", +64728, Author, 324, 332, "Takano Y", "", +64729, Author, 335, 348, "Dan - Noura M", "", +64730, Author, 351, 359, "Atsumi T", "", +64731, Japan, 507, 512, "Japan", "", +64747, ObjectiveDescription, 515, 650, "The dipeptidyl peptidase - 4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus .", "", +64732, Vildagliptin, 555, 567, "vildagliptin", "", +64733, Sitagliptin, 572, 583, "sitagliptin", "", +64734, Type2Diabetes, 624, 648, "type 2 diabetes mellitus", "", +64746, ObjectiveDescription, 651, 819, "Patients receiving standard doses of sitagliptin plus insulin may require increased doses of sitagliptin or switching to vildagliptin to improve blood glucose control .", "", +64735, Sitagliptin, 688, 699, "sitagliptin", "", +64736, Insulin, 705, 712, "insulin", "", +64737, Sitagliptin, 744, 755, "sitagliptin", "", +64738, Vildagliptin, 772, 784, "vildagliptin", "", +64739, BloodGlucose, 796, 809, "blood glucose", "", +64745, ObjectiveDescription, 820, 990, "This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin .", "", +64740, Sitagliptin, 866, 877, "sitagliptin", "", +64741, Vildagliptin, 895, 907, "vildagliptin", "", +64742, Type2Diabetes, 911, 926, "type 2 diabetes", "", +64743, Sitagliptin, 964, 975, "sitagliptin", "", +64744, Insulin, 981, 988, "insulin", "", +64749, Prospective, 996, 1007, "prospective", "", +64748, Randomized, 1010, 1020, "randomized", "", +64750, Parallel, 1023, 1039, "parallel - group", "", +64751, NumberPatientsCT, 1066, 1068, "33", "", +64752, Type2Diabetes, 1069, 1084, "type 2 diabetes", "", +64753, DoseValue, 1104, 1109, "50 mg", "", +64754, mg, 1107, 1109, "mg", "", +64755, Sitagliptin, 1110, 1121, "sitagliptin", "", +64756, Frequency, 1122, 1132, "once daily", "", +64757, Insulin, 1138, 1145, "insulin", "", +64758, NumberPatientsArm, 1148, 1157, "Seventeen", "", +64760, Randomized, 1172, 1182, "randomized", "", +64761, DoseValue, 1186, 1191, "50 mg", "", +64763, mg, 1189, 1191, "mg", "", +64765, Vildagliptin, 1192, 1204, "vildagliptin", "", +64767, Frequency, 1205, 1216, "twice daily", "", +64759, NumberPatientsArm, 1223, 1225, "16", "", +64762, DoseValue, 1229, 1235, "100 mg", "", +64764, mg, 1233, 1235, "mg", "", +64766, Sitagliptin, 1236, 1247, "sitagliptin", "", +64768, Frequency, 1248, 1258, "once daily", "", +64769, TimePoint, 1311, 1319, "baseline", "", +64770, TimePoint, 1324, 1337, "after 8 weeks", "", +64771, Mean, 1382, 1386, "mean", "", +64772, EndPointDescription, 1382, 1419, "mean amplitude of glycemic excursions", "", +64773, EndPointDescription, 1422, 1426, "MAGE", "", +64774, EndPointDescription, 1431, 1435, "MAGE", "", +64776, TimePoint, 1451, 1459, "baseline", "", +64777, Vildagliptin, 1472, 1484, "vildagliptin", "", +64779, ChangeValue, 1487, 1495, "- 13 . 4", "", +64800, SdDevChangeValue, 1498, 1504, "35 . 7", "", +64781, Mg_per_deciliter, 1505, 1512, "mg / dL", "", +64778, Sitagliptin, 1519, 1530, "sitagliptin", "", +64780, ChangeValue, 1533, 1540, "- 8 . 4", "", +64801, SdDevChangeValue, 1543, 1549, "24 . 3", "", +64782, Mg_per_deciliter, 1550, 1557, "mg / dL", "", +64783, Mg_per_deciliter, 1720, 1727, "mg / dL", "", +64784, Mg_per_deciliter, 1737, 1744, "mg / dL", "", +64785, HbA1c, 1853, 1858, "HbA1c", "", +64786, Vildagliptin, 1897, 1909, "vildagliptin", "", +64789, BaseLineValue, 1923, 1928, "7 . 1", "", +64803, SdDevBL, 1929, 1936, "± 0 . 6", "", +64791, Percentage, 1937, 1938, "%", "", +64787, TimePoint, 1942, 1950, "baseline", "", +64790, ResultMeasuredValue, 1954, 1959, "6 . 8", "", +64802, SdDevResValue, 1960, 1967, "± 0 . 6", "", +64792, Percentage, 1968, 1969, "%", "", +64788, TimePoint, 1973, 1980, "8 weeks", "", +64793, PValueChangeValue, 1983, 1994, "p = 0 . 006", "", +64798, ConclusionComment, 1999, 2167, "Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin .", "", +64794, Sitagliptin, 2010, 2021, "sitagliptin", "", +64795, Vildagliptin, 2044, 2056, "vildagliptin", "", +64775, EndPointDescription, 2090, 2094, "MAGE", "", +64796, Type2Diabetes, 2098, 2113, "type 2 diabetic", "", +64797, Sitagliptin, 2154, 2165, "sitagliptin", "", +64799, PMID, 2215, 2223, "27321385", "", diff --git a/data/dm2 27321385_akramersunderbrink.n-triples b/data/dm2 27321385_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27321385_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27321385_export.csv b/data/dm2 27321385_export.csv new file mode 100644 index 0000000..fdb9cf2 --- /dev/null +++ b/data/dm2 27321385_export.csv @@ -0,0 +1,431 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +261, 1, 1, 1, 0, 6, 0, 6, "Endocr" +261, 1, 2, 2, 7, 8, 7, 8, "J" +261, 1, 3, 3, 9, 10, 9, 10, "." +261, 2, 1, 4, 0, 4, 11, 15, "2016" +261, 2, 2, 5, 5, 8, 16, 19, "Aug" +261, 2, 3, 6, 9, 11, 20, 22, "31" +261, 2, 4, 7, 12, 13, 23, 24, ";" +261, 2, 5, 8, 14, 16, 25, 27, "63" +261, 2, 6, 9, 17, 18, 28, 29, "(" +261, 2, 7, 10, 19, 20, 30, 31, "8" +261, 2, 8, 11, 21, 22, 32, 33, ")" +261, 2, 9, 12, 23, 24, 34, 35, ":" +261, 2, 10, 13, 25, 28, 36, 39, "747" +261, 2, 11, 14, 29, 30, 40, 41, "-" +261, 2, 12, 15, 31, 33, 42, 44, "53" +261, 2, 13, 16, 34, 35, 45, 46, "." +261, 2, 14, 17, 36, 39, 47, 50, "doi" +261, 2, 15, 18, 40, 41, 51, 52, ":" +261, 2, 16, 19, 42, 44, 53, 55, "10" +261, 2, 17, 20, 45, 46, 56, 57, "." +261, 2, 18, 21, 47, 51, 58, 62, "1507" +261, 2, 19, 22, 52, 53, 63, 64, "/" +261, 2, 20, 23, 54, 61, 65, 72, "endocrj" +261, 2, 21, 24, 62, 63, 73, 74, "." +261, 2, 22, 25, 64, 68, 75, 79, "EJ16" +261, 2, 23, 26, 69, 70, 80, 81, "-" +261, 2, 24, 27, 71, 75, 82, 86, "0266" +261, 2, 25, 28, 76, 77, 87, 88, "." +261, 3, 1, 29, 0, 4, 89, 93, "Epub" +261, 3, 2, 30, 5, 9, 94, 98, "2016" +261, 3, 3, 31, 10, 13, 99, 102, "Jun" +261, 3, 4, 32, 14, 16, 103, 105, "16" +261, 3, 5, 33, 17, 18, 106, 107, "." +261, 4, 1, 34, 0, 11, 108, 119, "Comparative" +261, 4, 2, 35, 12, 19, 120, 127, "effects" +261, 4, 3, 36, 20, 22, 128, 130, "of" +261, 4, 4, 37, 23, 35, 131, 143, "vildagliptin" +261, 4, 5, 38, 36, 39, 144, 147, "and" +261, 4, 6, 39, 40, 51, 148, 159, "sitagliptin" +261, 4, 7, 40, 52, 62, 160, 170, "determined" +261, 4, 8, 41, 63, 65, 171, 173, "by" +261, 4, 9, 42, 66, 76, 174, 184, "continuous" +261, 4, 10, 43, 77, 84, 185, 192, "glucose" +261, 4, 11, 44, 85, 95, 193, 203, "monitoring" +261, 4, 12, 45, 96, 98, 204, 206, "in" +261, 4, 13, 46, 99, 107, 207, 215, "patients" +261, 4, 14, 47, 108, 112, 216, 220, "with" +261, 4, 15, 48, 113, 117, 221, 225, "type" +261, 4, 16, 49, 118, 119, 226, 227, "2" +261, 4, 17, 50, 120, 128, 228, 236, "diabetes" +261, 4, 18, 51, 129, 137, 237, 245, "mellitus" +261, 4, 19, 52, 138, 139, 246, 247, "." +261, 5, 1, 53, 0, 10, 248, 258, "Koyanagawa" +261, 5, 2, 54, 11, 12, 259, 260, "N" +261, 5, 3, 55, 13, 14, 261, 262, "(" +261, 5, 4, 56, 15, 16, 263, 264, "1" +261, 5, 5, 57, 17, 18, 265, 266, ")" +261, 5, 6, 58, 19, 20, 267, 268, "," +261, 5, 7, 59, 21, 28, 269, 276, "Miyoshi" +261, 5, 8, 60, 29, 30, 277, 278, "H" +261, 5, 9, 61, 31, 32, 279, 280, "," +261, 5, 10, 62, 33, 36, 281, 284, "Ono" +261, 5, 11, 63, 37, 38, 285, 286, "K" +261, 5, 12, 64, 39, 40, 287, 288, "," +261, 5, 13, 65, 41, 49, 289, 297, "Nakamura" +261, 5, 14, 66, 50, 51, 298, 299, "A" +261, 5, 15, 67, 52, 53, 300, 301, "," +261, 5, 16, 68, 54, 57, 302, 305, "Cho" +261, 5, 17, 69, 58, 60, 306, 308, "KY" +261, 5, 18, 70, 61, 62, 309, 310, "," +261, 5, 19, 71, 63, 71, 311, 319, "Yamamoto" +261, 5, 20, 72, 72, 73, 320, 321, "K" +261, 5, 21, 73, 74, 75, 322, 323, "," +261, 5, 22, 74, 76, 82, 324, 330, "Takano" +261, 5, 23, 75, 83, 84, 331, 332, "Y" +261, 5, 24, 76, 85, 86, 333, 334, "," +261, 5, 25, 77, 87, 90, 335, 338, "Dan" +261, 5, 26, 78, 91, 92, 339, 340, "-" +261, 5, 27, 79, 93, 98, 341, 346, "Noura" +261, 5, 28, 80, 99, 100, 347, 348, "M" +261, 5, 29, 81, 101, 102, 349, 350, "," +261, 5, 30, 82, 103, 109, 351, 357, "Atsumi" +261, 5, 31, 83, 110, 111, 358, 359, "T" +261, 5, 32, 84, 112, 113, 360, 361, "." +261, 5, 33, 85, 114, 120, 362, 368, "Author" +261, 5, 34, 86, 121, 132, 369, 380, "information" +261, 5, 35, 87, 133, 134, 381, 382, ":" +261, 5, 36, 88, 135, 136, 383, 384, "(" +261, 5, 37, 89, 137, 138, 385, 386, "1" +261, 5, 38, 90, 139, 140, 387, 388, ")" +261, 5, 39, 91, 141, 149, 389, 397, "Division" +261, 5, 40, 92, 150, 152, 398, 400, "of" +261, 5, 41, 93, 153, 165, 401, 413, "Rheumatology" +261, 5, 42, 94, 166, 167, 414, 415, "," +261, 5, 43, 95, 168, 181, 416, 429, "Endocrinology" +261, 5, 44, 96, 182, 185, 430, 433, "and" +261, 5, 45, 97, 186, 196, 434, 444, "Nephrology" +261, 5, 46, 98, 197, 198, 445, 446, "," +261, 5, 47, 99, 199, 207, 447, 455, "Hokkaido" +261, 5, 48, 100, 208, 218, 456, 466, "University" +261, 5, 49, 101, 219, 227, 467, 475, "Graduate" +261, 5, 50, 102, 228, 234, 476, 482, "School" +261, 5, 51, 103, 235, 237, 483, 485, "of" +261, 5, 52, 104, 238, 246, 486, 494, "Medicine" +261, 5, 53, 105, 247, 248, 495, 496, "," +261, 5, 54, 106, 249, 256, 497, 504, "Sapporo" +261, 5, 55, 107, 257, 258, 505, 506, "," +261, 5, 56, 108, 259, 264, 507, 512, "Japan" +261, 5, 57, 109, 265, 266, 513, 514, "." +261, 6, 1, 110, 0, 3, 515, 518, "The" +261, 6, 2, 111, 4, 14, 519, 529, "dipeptidyl" +261, 6, 3, 112, 15, 24, 530, 539, "peptidase" +261, 6, 4, 113, 25, 26, 540, 541, "-" +261, 6, 5, 114, 27, 28, 542, 543, "4" +261, 6, 6, 115, 29, 39, 544, 554, "inhibitors" +261, 6, 7, 116, 40, 52, 555, 567, "vildagliptin" +261, 6, 8, 117, 53, 56, 568, 571, "and" +261, 6, 9, 118, 57, 68, 572, 583, "sitagliptin" +261, 6, 10, 119, 69, 72, 584, 587, "are" +261, 6, 11, 120, 73, 82, 588, 597, "effective" +261, 6, 12, 121, 83, 85, 598, 600, "in" +261, 6, 13, 122, 86, 94, 601, 609, "treating" +261, 6, 14, 123, 95, 103, 610, 618, "patients" +261, 6, 15, 124, 104, 108, 619, 623, "with" +261, 6, 16, 125, 109, 113, 624, 628, "type" +261, 6, 17, 126, 114, 115, 629, 630, "2" +261, 6, 18, 127, 116, 124, 631, 639, "diabetes" +261, 6, 19, 128, 125, 133, 640, 648, "mellitus" +261, 6, 20, 129, 134, 135, 649, 650, "." +261, 7, 1, 130, 0, 8, 651, 659, "Patients" +261, 7, 2, 131, 9, 18, 660, 669, "receiving" +261, 7, 3, 132, 19, 27, 670, 678, "standard" +261, 7, 4, 133, 28, 33, 679, 684, "doses" +261, 7, 5, 134, 34, 36, 685, 687, "of" +261, 7, 6, 135, 37, 48, 688, 699, "sitagliptin" +261, 7, 7, 136, 49, 53, 700, 704, "plus" +261, 7, 8, 137, 54, 61, 705, 712, "insulin" +261, 7, 9, 138, 62, 65, 713, 716, "may" +261, 7, 10, 139, 66, 73, 717, 724, "require" +261, 7, 11, 140, 74, 83, 725, 734, "increased" +261, 7, 12, 141, 84, 89, 735, 740, "doses" +261, 7, 13, 142, 90, 92, 741, 743, "of" +261, 7, 14, 143, 93, 104, 744, 755, "sitagliptin" +261, 7, 15, 144, 105, 107, 756, 758, "or" +261, 7, 16, 145, 108, 117, 759, 768, "switching" +261, 7, 17, 146, 118, 120, 769, 771, "to" +261, 7, 18, 147, 121, 133, 772, 784, "vildagliptin" +261, 7, 19, 148, 134, 136, 785, 787, "to" +261, 7, 20, 149, 137, 144, 788, 795, "improve" +261, 7, 21, 150, 145, 150, 796, 801, "blood" +261, 7, 22, 151, 151, 158, 802, 809, "glucose" +261, 7, 23, 152, 159, 166, 810, 817, "control" +261, 7, 24, 153, 167, 168, 818, 819, "." +261, 8, 1, 154, 0, 4, 820, 824, "This" +261, 8, 2, 155, 5, 10, 825, 830, "study" +261, 8, 3, 156, 11, 19, 831, 839, "compared" +261, 8, 4, 157, 20, 23, 840, 843, "the" +261, 8, 5, 158, 24, 31, 844, 851, "effects" +261, 8, 6, 159, 32, 34, 852, 854, "of" +261, 8, 7, 160, 35, 45, 855, 865, "increasing" +261, 8, 8, 161, 46, 57, 866, 877, "sitagliptin" +261, 8, 9, 162, 58, 61, 878, 881, "and" +261, 8, 10, 163, 62, 71, 882, 891, "switching" +261, 8, 11, 164, 72, 74, 892, 894, "to" +261, 8, 12, 165, 75, 87, 895, 907, "vildagliptin" +261, 8, 13, 166, 88, 90, 908, 910, "in" +261, 8, 14, 167, 91, 95, 911, 915, "type" +261, 8, 15, 168, 96, 97, 916, 917, "2" +261, 8, 16, 169, 98, 106, 918, 926, "diabetes" +261, 8, 17, 170, 107, 115, 927, 935, "patients" +261, 8, 18, 171, 116, 125, 936, 945, "receiving" +261, 8, 19, 172, 126, 134, 946, 954, "standard" +261, 8, 20, 173, 135, 140, 955, 960, "doses" +261, 8, 21, 174, 141, 143, 961, 963, "of" +261, 8, 22, 175, 144, 155, 964, 975, "sitagliptin" +261, 8, 23, 176, 156, 160, 976, 980, "plus" +261, 8, 24, 177, 161, 168, 981, 988, "insulin" +261, 8, 25, 178, 169, 170, 989, 990, "." +261, 9, 1, 179, 0, 4, 991, 995, "This" +261, 9, 2, 180, 5, 16, 996, 1007, "prospective" +261, 9, 3, 181, 17, 18, 1008, 1009, "," +261, 9, 4, 182, 19, 29, 1010, 1020, "randomized" +261, 9, 5, 183, 30, 31, 1021, 1022, "," +261, 9, 6, 184, 32, 40, 1023, 1031, "parallel" +261, 9, 7, 185, 41, 42, 1032, 1033, "-" +261, 9, 8, 186, 43, 48, 1034, 1039, "group" +261, 9, 9, 187, 49, 59, 1040, 1050, "comparison" +261, 9, 10, 188, 60, 65, 1051, 1056, "trial" +261, 9, 11, 189, 66, 74, 1057, 1065, "enrolled" +261, 9, 12, 190, 75, 77, 1066, 1068, "33" +261, 9, 13, 191, 78, 82, 1069, 1073, "type" +261, 9, 14, 192, 83, 84, 1074, 1075, "2" +261, 9, 15, 193, 85, 93, 1076, 1084, "diabetes" +261, 9, 16, 194, 94, 102, 1085, 1093, "patients" +261, 9, 17, 195, 103, 112, 1094, 1103, "receiving" +261, 9, 18, 196, 113, 115, 1104, 1106, "50" +261, 9, 19, 197, 116, 118, 1107, 1109, "mg" +261, 9, 20, 198, 119, 130, 1110, 1121, "sitagliptin" +261, 9, 21, 199, 131, 135, 1122, 1126, "once" +261, 9, 22, 200, 136, 141, 1127, 1132, "daily" +261, 9, 23, 201, 142, 146, 1133, 1137, "plus" +261, 9, 24, 202, 147, 154, 1138, 1145, "insulin" +261, 9, 25, 203, 155, 156, 1146, 1147, "." +261, 10, 1, 204, 0, 9, 1148, 1157, "Seventeen" +261, 10, 2, 205, 10, 18, 1158, 1166, "patients" +261, 10, 3, 206, 19, 23, 1167, 1171, "were" +261, 10, 4, 207, 24, 34, 1172, 1182, "randomized" +261, 10, 5, 208, 35, 37, 1183, 1185, "to" +261, 10, 6, 209, 38, 40, 1186, 1188, "50" +261, 10, 7, 210, 41, 43, 1189, 1191, "mg" +261, 10, 8, 211, 44, 56, 1192, 1204, "vildagliptin" +261, 10, 9, 212, 57, 62, 1205, 1210, "twice" +261, 10, 10, 213, 63, 68, 1211, 1216, "daily" +261, 10, 11, 214, 69, 70, 1217, 1218, "," +261, 10, 12, 215, 71, 74, 1219, 1222, "and" +261, 10, 13, 216, 75, 77, 1223, 1225, "16" +261, 10, 14, 217, 78, 80, 1226, 1228, "to" +261, 10, 15, 218, 81, 84, 1229, 1232, "100" +261, 10, 16, 219, 85, 87, 1233, 1235, "mg" +261, 10, 17, 220, 88, 99, 1236, 1247, "sitagliptin" +261, 10, 18, 221, 100, 104, 1248, 1252, "once" +261, 10, 19, 222, 105, 110, 1253, 1258, "daily" +261, 10, 20, 223, 111, 112, 1259, 1260, "," +261, 10, 21, 224, 113, 116, 1261, 1264, "and" +261, 10, 22, 225, 117, 126, 1265, 1274, "evaluated" +261, 10, 23, 226, 127, 129, 1275, 1277, "by" +261, 10, 24, 227, 130, 140, 1278, 1288, "continuous" +261, 10, 25, 228, 141, 148, 1289, 1296, "glucose" +261, 10, 26, 229, 149, 159, 1297, 1307, "monitoring" +261, 10, 27, 230, 160, 162, 1308, 1310, "at" +261, 10, 28, 231, 163, 171, 1311, 1319, "baseline" +261, 10, 29, 232, 172, 175, 1320, 1323, "and" +261, 10, 30, 233, 176, 181, 1324, 1329, "after" +261, 10, 31, 234, 182, 183, 1330, 1331, "8" +261, 10, 32, 235, 184, 189, 1332, 1337, "weeks" +261, 10, 33, 236, 190, 191, 1338, 1339, "." +261, 11, 1, 237, 0, 3, 1340, 1343, "The" +261, 11, 2, 238, 4, 11, 1344, 1351, "primary" +261, 11, 3, 239, 12, 15, 1352, 1355, "end" +261, 11, 4, 240, 16, 17, 1356, 1357, "-" +261, 11, 5, 241, 18, 23, 1358, 1363, "point" +261, 11, 6, 242, 24, 27, 1364, 1367, "was" +261, 11, 7, 243, 28, 31, 1368, 1371, "the" +261, 11, 8, 244, 32, 38, 1372, 1378, "change" +261, 11, 9, 245, 39, 41, 1379, 1381, "in" +261, 11, 10, 246, 42, 46, 1382, 1386, "mean" +261, 11, 11, 247, 47, 56, 1387, 1396, "amplitude" +261, 11, 12, 248, 57, 59, 1397, 1399, "of" +261, 11, 13, 249, 60, 68, 1400, 1408, "glycemic" +261, 11, 14, 250, 69, 79, 1409, 1419, "excursions" +261, 11, 15, 251, 80, 81, 1420, 1421, "(" +261, 11, 16, 252, 82, 86, 1422, 1426, "MAGE" +261, 11, 17, 253, 87, 88, 1427, 1428, ")" +261, 11, 18, 254, 89, 90, 1429, 1430, "." +261, 12, 1, 255, 0, 4, 1431, 1435, "MAGE" +261, 12, 2, 256, 5, 14, 1436, 1445, "decreased" +261, 12, 3, 257, 15, 19, 1446, 1450, "from" +261, 12, 4, 258, 20, 28, 1451, 1459, "baseline" +261, 12, 5, 259, 29, 31, 1460, 1462, "in" +261, 12, 6, 260, 32, 36, 1463, 1467, "both" +261, 12, 7, 261, 37, 40, 1468, 1471, "the" +261, 12, 8, 262, 41, 53, 1472, 1484, "vildagliptin" +261, 12, 9, 263, 54, 55, 1485, 1486, "(" +261, 12, 10, 264, 56, 57, 1487, 1488, "-" +261, 12, 11, 265, 58, 60, 1489, 1491, "13" +261, 12, 12, 266, 61, 62, 1492, 1493, "." +261, 12, 13, 267, 63, 64, 1494, 1495, "4" +261, 12, 14, 268, 65, 66, 1496, 1497, "±" +261, 12, 15, 269, 67, 69, 1498, 1500, "35" +261, 12, 16, 270, 70, 71, 1501, 1502, "." +261, 12, 17, 271, 72, 73, 1503, 1504, "7" +261, 12, 18, 272, 74, 76, 1505, 1507, "mg" +261, 12, 19, 273, 77, 78, 1508, 1509, "/" +261, 12, 20, 274, 79, 81, 1510, 1512, "dL" +261, 12, 21, 275, 82, 83, 1513, 1514, ")" +261, 12, 22, 276, 84, 87, 1515, 1518, "and" +261, 12, 23, 277, 88, 99, 1519, 1530, "sitagliptin" +261, 12, 24, 278, 100, 101, 1531, 1532, "(" +261, 12, 25, 279, 102, 103, 1533, 1534, "-" +261, 12, 26, 280, 104, 105, 1535, 1536, "8" +261, 12, 27, 281, 106, 107, 1537, 1538, "." +261, 12, 28, 282, 108, 109, 1539, 1540, "4" +261, 12, 29, 283, 110, 111, 1541, 1542, "±" +261, 12, 30, 284, 112, 114, 1543, 1545, "24" +261, 12, 31, 285, 115, 116, 1546, 1547, "." +261, 12, 32, 286, 117, 118, 1548, 1549, "3" +261, 12, 33, 287, 119, 121, 1550, 1552, "mg" +261, 12, 34, 288, 122, 123, 1553, 1554, "/" +261, 12, 35, 289, 124, 126, 1555, 1557, "dL" +261, 12, 36, 290, 127, 128, 1558, 1559, ")" +261, 12, 37, 291, 129, 135, 1560, 1566, "groups" +261, 12, 38, 292, 136, 137, 1567, 1568, "," +261, 12, 39, 293, 138, 141, 1569, 1572, "but" +261, 12, 40, 294, 142, 149, 1573, 1580, "neither" +261, 12, 41, 295, 150, 156, 1581, 1587, "within" +261, 12, 42, 296, 157, 158, 1588, 1589, "-" +261, 12, 43, 297, 159, 162, 1590, 1593, "nor" +261, 12, 44, 298, 163, 170, 1594, 1601, "between" +261, 12, 45, 299, 171, 172, 1602, 1603, "-" +261, 12, 46, 300, 173, 178, 1604, 1609, "group" +261, 12, 47, 301, 179, 186, 1610, 1617, "changes" +261, 12, 48, 302, 187, 191, 1618, 1622, "were" +261, 12, 49, 303, 192, 205, 1623, 1636, "statistically" +261, 12, 50, 304, 206, 217, 1637, 1648, "significant" +261, 12, 51, 305, 218, 219, 1649, 1650, "." +261, 13, 1, 306, 0, 9, 1651, 1660, "Similarly" +261, 13, 2, 307, 10, 11, 1661, 1662, "," +261, 13, 3, 308, 12, 15, 1663, 1666, "the" +261, 13, 4, 309, 16, 21, 1667, 1672, "areas" +261, 13, 5, 310, 22, 27, 1673, 1678, "under" +261, 13, 6, 311, 28, 31, 1679, 1682, "the" +261, 13, 7, 312, 32, 37, 1683, 1688, "curve" +261, 13, 8, 313, 38, 41, 1689, 1692, "for" +261, 13, 9, 314, 42, 47, 1693, 1698, "blood" +261, 13, 10, 315, 48, 55, 1699, 1706, "glucose" +261, 13, 11, 316, 56, 62, 1707, 1713, "levels" +261, 13, 12, 317, 63, 64, 1714, 1715, "≥" +261, 13, 13, 318, 65, 68, 1716, 1719, "180" +261, 13, 14, 319, 69, 71, 1720, 1722, "mg" +261, 13, 15, 320, 72, 73, 1723, 1724, "/" +261, 13, 16, 321, 74, 76, 1725, 1727, "dL" +261, 13, 17, 322, 77, 80, 1728, 1731, "and" +261, 13, 18, 323, 81, 82, 1732, 1733, "<" +261, 13, 19, 324, 83, 85, 1734, 1736, "70" +261, 13, 20, 325, 86, 88, 1737, 1739, "mg" +261, 13, 21, 326, 89, 90, 1740, 1741, "/" +261, 13, 22, 327, 91, 93, 1742, 1744, "dL" +261, 13, 23, 328, 94, 100, 1745, 1751, "tended" +261, 13, 24, 329, 101, 103, 1752, 1754, "to" +261, 13, 25, 330, 104, 111, 1755, 1762, "improve" +261, 13, 26, 331, 112, 114, 1763, 1765, "in" +261, 13, 27, 332, 115, 119, 1766, 1770, "both" +261, 13, 28, 333, 120, 126, 1771, 1777, "groups" +261, 13, 29, 334, 127, 128, 1778, 1779, "," +261, 13, 30, 335, 129, 132, 1780, 1783, "but" +261, 13, 31, 336, 133, 138, 1784, 1789, "these" +261, 13, 32, 337, 139, 150, 1790, 1801, "differences" +261, 13, 33, 338, 151, 155, 1802, 1806, "were" +261, 13, 34, 339, 156, 159, 1807, 1810, "not" +261, 13, 35, 340, 160, 173, 1811, 1824, "statistically" +261, 13, 36, 341, 174, 185, 1825, 1836, "significant" +261, 13, 37, 342, 186, 187, 1837, 1838, "." +261, 14, 1, 343, 0, 2, 1839, 1841, "In" +261, 14, 2, 344, 3, 11, 1842, 1850, "contrast" +261, 14, 3, 345, 12, 13, 1851, 1852, "," +261, 14, 4, 346, 14, 19, 1853, 1858, "HbA1c" +261, 14, 5, 347, 20, 23, 1859, 1862, "was" +261, 14, 6, 348, 24, 37, 1863, 1876, "significantly" +261, 14, 7, 349, 38, 45, 1877, 1884, "reduced" +261, 14, 8, 350, 46, 50, 1885, 1889, "only" +261, 14, 9, 351, 51, 53, 1890, 1892, "in" +261, 14, 10, 352, 54, 57, 1893, 1896, "the" +261, 14, 11, 353, 58, 70, 1897, 1909, "vildagliptin" +261, 14, 12, 354, 71, 76, 1910, 1915, "group" +261, 14, 13, 355, 77, 78, 1916, 1917, "," +261, 14, 14, 356, 79, 83, 1918, 1922, "from" +261, 14, 15, 357, 84, 85, 1923, 1924, "7" +261, 14, 16, 358, 86, 87, 1925, 1926, "." +261, 14, 17, 359, 88, 89, 1927, 1928, "1" +261, 14, 18, 360, 90, 91, 1929, 1930, "±" +261, 14, 19, 361, 92, 93, 1931, 1932, "0" +261, 14, 20, 362, 94, 95, 1933, 1934, "." +261, 14, 21, 363, 96, 97, 1935, 1936, "6" +261, 14, 22, 364, 98, 99, 1937, 1938, "%" +261, 14, 23, 365, 100, 102, 1939, 1941, "at" +261, 14, 24, 366, 103, 111, 1942, 1950, "baseline" +261, 14, 25, 367, 112, 114, 1951, 1953, "to" +261, 14, 26, 368, 115, 116, 1954, 1955, "6" +261, 14, 27, 369, 117, 118, 1956, 1957, "." +261, 14, 28, 370, 119, 120, 1958, 1959, "8" +261, 14, 29, 371, 121, 122, 1960, 1961, "±" +261, 14, 30, 372, 123, 124, 1962, 1963, "0" +261, 14, 31, 373, 125, 126, 1964, 1965, "." +261, 14, 32, 374, 127, 128, 1966, 1967, "6" +261, 14, 33, 375, 129, 130, 1968, 1969, "%" +261, 14, 34, 376, 131, 133, 1970, 1972, "at" +261, 14, 35, 377, 134, 135, 1973, 1974, "8" +261, 14, 36, 378, 136, 141, 1975, 1980, "weeks" +261, 14, 37, 379, 142, 143, 1981, 1982, "(" +261, 14, 38, 380, 144, 145, 1983, 1984, "p" +261, 14, 39, 381, 146, 147, 1985, 1986, "=" +261, 14, 40, 382, 148, 149, 1987, 1988, "0" +261, 14, 41, 383, 150, 151, 1989, 1990, "." +261, 14, 42, 384, 152, 155, 1991, 1994, "006" +261, 14, 43, 385, 156, 157, 1995, 1996, ")" +261, 14, 44, 386, 158, 159, 1997, 1998, "." +261, 15, 1, 387, 0, 10, 1999, 2009, "Increasing" +261, 15, 2, 388, 11, 22, 2010, 2021, "sitagliptin" +261, 15, 3, 389, 23, 27, 2022, 2026, "dose" +261, 15, 4, 390, 28, 31, 2027, 2030, "and" +261, 15, 5, 391, 32, 41, 2031, 2040, "switching" +261, 15, 6, 392, 42, 44, 2041, 2043, "to" +261, 15, 7, 393, 45, 57, 2044, 2056, "vildagliptin" +261, 15, 8, 394, 58, 61, 2057, 2060, "had" +261, 15, 9, 395, 62, 69, 2061, 2068, "limited" +261, 15, 10, 396, 70, 77, 2069, 2076, "effects" +261, 15, 11, 397, 78, 80, 2077, 2079, "in" +261, 15, 12, 398, 81, 90, 2080, 2089, "improving" +261, 15, 13, 399, 91, 95, 2090, 2094, "MAGE" +261, 15, 14, 400, 96, 98, 2095, 2097, "in" +261, 15, 15, 401, 99, 103, 2098, 2102, "type" +261, 15, 16, 402, 104, 105, 2103, 2104, "2" +261, 15, 17, 403, 106, 114, 2105, 2113, "diabetic" +261, 15, 18, 404, 115, 123, 2114, 2122, "patients" +261, 15, 19, 405, 124, 131, 2123, 2130, "treated" +261, 15, 20, 406, 132, 136, 2131, 2135, "with" +261, 15, 21, 407, 137, 145, 2136, 2144, "standard" +261, 15, 22, 408, 146, 151, 2145, 2150, "doses" +261, 15, 23, 409, 152, 154, 2151, 2153, "of" +261, 15, 24, 410, 155, 166, 2154, 2165, "sitagliptin" +261, 15, 25, 411, 167, 168, 2166, 2167, "." +261, 16, 1, 412, 0, 3, 2168, 2171, "DOI" +261, 16, 2, 413, 4, 5, 2172, 2173, ":" +261, 16, 3, 414, 6, 8, 2174, 2176, "10" +261, 16, 4, 415, 9, 10, 2177, 2178, "." +261, 16, 5, 416, 11, 15, 2179, 2183, "1507" +261, 16, 6, 417, 16, 17, 2184, 2185, "/" +261, 16, 7, 418, 18, 25, 2186, 2193, "endocrj" +261, 16, 8, 419, 26, 27, 2194, 2195, "." +261, 16, 9, 420, 28, 32, 2196, 2200, "EJ16" +261, 16, 10, 421, 33, 34, 2201, 2202, "-" +261, 16, 11, 422, 35, 39, 2203, 2207, "0266" +261, 16, 12, 423, 40, 44, 2208, 2212, "PMID" +261, 16, 13, 424, 45, 46, 2213, 2214, ":" +261, 16, 14, 425, 47, 55, 2215, 2223, "27321385" +261, 16, 15, 426, 56, 57, 2224, 2225, "[" +261, 16, 16, 427, 58, 65, 2226, 2233, "Indexed" +261, 16, 17, 428, 66, 69, 2234, 2237, "for" +261, 16, 18, 429, 70, 77, 2238, 2245, "MEDLINE" +261, 16, 19, 430, 78, 79, 2246, 2247, "]" diff --git a/data/dm2 27321385_kwoodley.annodb b/data/dm2 27321385_kwoodley.annodb new file mode 100644 index 0000000..aa5f89c --- /dev/null +++ b/data/dm2 27321385_kwoodley.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +64056, Journal, 0, 8, "Endocr J", "", +64057, PublicationYear, 11, 15, "2016", "", +64079, Title, 108, 247, "Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus .", "", +64058, Vildagliptin, 131, 143, "vildagliptin", "", +64066, Sitagliptin, 148, 159, "sitagliptin", "", +64073, Type2Diabetes, 221, 245, "type 2 diabetes mellitus", "", +64080, Author, 248, 260, "Koyanagawa N", "", +64081, Author, 269, 278, "Miyoshi H", "", +64082, Author, 281, 286, "Ono K", "", +64083, Author, 289, 299, "Nakamura A", "", +64084, Author, 302, 308, "Cho KY", "", +64085, Author, 311, 321, "Yamamoto K", "", +64086, Author, 324, 332, "Takano Y", "", +64087, Author, 335, 348, "Dan - Noura M", "", +64088, Author, 351, 359, "Atsumi T", "", +64089, Japan, 507, 512, "Japan", "", +64059, Vildagliptin, 555, 567, "vildagliptin", "", +64067, Sitagliptin, 572, 583, "sitagliptin", "", +64074, Type2Diabetes, 624, 648, "type 2 diabetes mellitus", "", +64090, Sitagliptin, 688, 699, "sitagliptin", "", +64091, Insulin, 705, 712, "insulin", "", +64068, Sitagliptin, 744, 755, "sitagliptin", "", +64060, Vildagliptin, 772, 784, "vildagliptin", "", +64096, ObjectiveDescription, 820, 990, "This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin .", "", +64094, Sitagliptin, 866, 877, "sitagliptin", "", +64061, Vildagliptin, 895, 907, "vildagliptin", "", +64075, Type2Diabetes, 911, 926, "type 2 diabetes", "", +64095, Precondition, 911, 988, "type 2 diabetes patients receiving standard doses of sitagliptin plus insulin", "", +64069, Sitagliptin, 964, 975, "sitagliptin", "", +64093, Insulin, 981, 988, "insulin", "", +64097, Prospective, 996, 1007, "prospective", "", +64098, Randomized, 1010, 1020, "randomized", "", +64099, Parallel, 1023, 1039, "parallel - group", "", +64100, NumberPatientsCT, 1066, 1068, "33", "", +64076, Type2Diabetes, 1069, 1084, "type 2 diabetes", "", +64110, Precondition, 1069, 1145, "type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin", "", +64101, DoseValue, 1104, 1106, "50", "", +64104, mg, 1107, 1109, "mg", "", +64070, Sitagliptin, 1110, 1121, "sitagliptin", "", +64107, Frequency, 1122, 1132, "once daily", "", +64092, Insulin, 1138, 1145, "insulin", "", +64111, NumberPatientsArm, 1148, 1157, "Seventeen", "", +64113, Randomized, 1172, 1182, "randomized", "", +64102, DoseValue, 1186, 1188, "50", "", +64105, mg, 1189, 1191, "mg", "", +64062, Vildagliptin, 1192, 1204, "vildagliptin", "", +64108, Frequency, 1205, 1216, "twice daily", "", +64112, NumberPatientsArm, 1223, 1225, "16", "", +64103, DoseValue, 1229, 1232, "100", "", +64106, mg, 1233, 1235, "mg", "", +64114, Sitagliptin, 1236, 1247, "sitagliptin", "", +64109, Frequency, 1248, 1258, "once daily", "", +64115, TimePoint, 1311, 1319, "baseline", "", +64116, TimePoint, 1330, 1337, "8 weeks", "", +64120, EndPointDescription, 1382, 1419, "mean amplitude of glycemic excursions", "", +64119, EndPointDescription, 1422, 1426, "MAGE", "", +64121, EndPointDescription, 1431, 1435, "MAGE", "", +64118, TimePoint, 1451, 1459, "baseline", "", +64063, Vildagliptin, 1472, 1484, "vildagliptin", "", +64123, Reduction, 1489, 1495, "13 . 4", "", +64125, SdDevChangeValue, 1498, 1504, "35 . 7", "", +64127, Mg_per_deciliter, 1505, 1512, "mg / dL", "", +64071, Sitagliptin, 1519, 1530, "sitagliptin", "", +64124, Reduction, 1535, 1540, "8 . 4", "", +64126, SdDevChangeValue, 1543, 1549, "24 . 3", "", +64128, Mg_per_deciliter, 1550, 1557, "mg / dL", "", +64130, BloodGlucose, 1693, 1706, "blood glucose", "", +64132, BaseLineValue, 1714, 1719, "≥ 180", "", +64131, Mg_per_deciliter, 1720, 1727, "mg / dL", "", +64133, BaseLineValue, 1732, 1736, "< 70", "", +64129, Mg_per_deciliter, 1737, 1744, "mg / dL", "", +64134, ObservedResult, 1745, 1836, "tended to improve in both groups , but these differences were not statistically significant", "", +64135, HbA1c, 1853, 1858, "HbA1c", "", +64064, Vildagliptin, 1897, 1909, "vildagliptin", "", +64136, BaseLineValue, 1923, 1928, "7 . 1", "", +64138, SdDevBL, 1931, 1936, "0 . 6", "", +64139, Percentage, 1937, 1938, "%", "", +64137, TimePoint, 1942, 1950, "baseline", "", +64141, ResultMeasuredValue, 1954, 1959, "6 . 8", "", +64142, SdDevResValue, 1962, 1967, "0 . 6", "", +64140, Percentage, 1968, 1969, "%", "", +64117, TimePoint, 1973, 1980, "8 weeks", "", +64143, PValueChangeValue, 1983, 1994, "p = 0 . 006", "", +64145, ConclusionComment, 1999, 2167, "Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin .", "", +64072, Sitagliptin, 2010, 2021, "sitagliptin", "", +64065, Vildagliptin, 2044, 2056, "vildagliptin", "", +64122, EndPointDescription, 2090, 2094, "MAGE", "", +64077, Type2Diabetes, 2098, 2113, "type 2 diabetic", "", +64144, Precondition, 2098, 2165, "type 2 diabetic patients treated with standard doses of sitagliptin", "", +64078, Sitagliptin, 2154, 2165, "sitagliptin", "", +64146, PMID, 2215, 2223, "27321385", "", diff --git a/data/dm2 27321385_kwoodley.n-triples b/data/dm2 27321385_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27321385_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27589252_admin.annodb b/data/dm2 27589252_admin.annodb new file mode 100644 index 0000000..4e23750 --- /dev/null +++ b/data/dm2 27589252_admin.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Diabet Med .", "", " \"Diabet Med .\"." +1, PublicationYear, 13, 17, "2017", "", " \"2017\"." +27, Title, 97, 297, "Safety and efficacy of insulin degludec / liraglutide ( IDegLira ) added to sulphonylurea alone or to sulphonylurea and metformin in insulin - na ï ve people with Type 2 diabetes : the DUAL IV trial .", "", " \"Safety and efficacy of insulin degludec / liraglutide ( IDegLira ) added to sulphonylurea alone or to sulphonylurea and metformin in insulin - na ï ve people with Type 2 diabetes : the DUAL IV trial .\"." +2, InsulinDegludec, 120, 136, "insulin degludec", "", +96037, FixedCombDrug, 128, 150, "degludec / liraglutide", "", +5, Liraglutide, 139, 150, "liraglutide", "", +8, FixedCombDrug, 153, 161, "IDegLira", "", +16, Sulfonylureas, 173, 186, "sulphonylurea", "", +19, Sulfonylureas, 199, 212, "sulphonylurea", "", +20, Metformin, 217, 226, "metformin", "", +26, Precondition, 230, 275, "insulin - na ï ve people with Type 2 diabetes", "", " \"insulin - na ï ve people with Type 2 diabetes\"." +22, Type2Diabetes, 260, 275, "Type 2 diabetes", "", " ." +28, Author, 298, 308, "Rodbard HW", "", " \"Rodbard HW\"." +29, Author, 317, 324, "Bode BW", "", " \"Bode BW\"." +30, Author, 333, 342, "Harris SB", "", " \"Harris SB\"." +31, Author, 351, 357, "Rose L", "", " \"Rose L\"." +32, Author, 366, 375, "Lehmann L", "", " \"Lehmann L\"." +33, Author, 384, 392, "Jarlov H", "", " \"Jarlov H\"." +34, Author, 401, 410, "Thurman J", "", " \"Thurman J\"." +35, Liraglutide, 434, 445, "Liraglutide", "", +36, InsulinDegludec, 450, 466, "insulin degludec", "", +37, USA, 583, 586, "USA", "", +38, USA, 640, 643, "USA", "", +40, Canada, 706, 712, "Canada", "", +41, Germany, 767, 774, "Germany", "", +42, Country, 815, 822, "Denmark", "", +39, USA, 871, 874, "USA", "", +45, ObjectiveDescription, 883, 1092, "To investigate the safety and efficacy of insulin degludec / liraglutide ( IDegLira ) , a novel combination product , as add - on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy .", "", " \"To investigate the safety and efficacy of insulin degludec / liraglutide ( IDegLira ) , a novel combination product , as add - on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy .\"." +3, InsulinDegludec, 925, 941, "insulin degludec", "", +6, Liraglutide, 944, 955, "liraglutide", "", +9, FixedCombDrug, 958, 966, "IDegLira", "", +44, Precondition, 1025, 1090, "people with Type 2 diabetes uncontrolled on sulphonylurea therapy", "", " \"people with Type 2 diabetes uncontrolled on sulphonylurea therapy\"." +23, Type2Diabetes, 1037, 1052, "Type 2 diabetes", "", +43, Sulfonylureas, 1069, 1082, "sulphonylurea", "", +46, Duration, 1111, 1120, "26 - week", "", " \"26 - week\"." +47, DoubleBlind, 1123, 1137, "double - blind", "", " ." +48, Type2Diabetes, 1158, 1173, "Type 2 diabetes", "", +49, HbA1c, 1176, 1181, "HbA1c", "", +151, ConcentrationUnit, 1190, 1200, "mmol / mol", "", +51, Percentage, 1217, 1218, "%", "", +52, Randomized, 1228, 1238, "randomized", "", " ." +18, FixedCombDrug, 1242, 1250, "IDegLira", "", +54, NumberPatientsArm, 1257, 1260, "289", "", " \"289\"." +56, Placebo, 1266, 1273, "placebo", "", " ." +55, NumberPatientsArm, 1280, 1283, "146", "", " \"146\"." +106271, Precondition, 1301, 1338, "pre - trial sulphonylurea ± metformin", "", " \"pre - trial sulphonylurea ± metformin\"." +17, Sulfonylureas, 1313, 1326, "sulphonylurea", "", +21, Metformin, 1329, 1338, "metformin", "", +63, FastingBloodGlucose_target, 1356, 1406, "fasting glycaemic target of 4 . 0 - 6 . 0 mmol / l", "", +159, Millimoles_per_litre, 1398, 1406, "mmol / l", "", +68, DoseDescription, 1409, 1487, "Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps", "", " \"Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps\". \"Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps\"." +64, DoseValue, 1490, 1492, "50", "", " \"50\"." +66, BioAndMedicalUnit, 1493, 1498, "units", "", " . ." +4, InsulinDegludec, 1499, 1515, "insulin degludec", "", " ." +65, DoseValue, 1518, 1523, "1 . 8", "", " \"1 . 8\"." +67, mg, 1524, 1526, "mg", "", " ." +7, Liraglutide, 1527, 1538, "liraglutide", "", " ." +163, Mean, 1557, 1561, "mean", "", " . ." +69, HbA1c, 1562, 1567, "HbA1c", "", " ." +70, BaseLineValue, 1583, 1585, "63", "", " \"63\". \"63\"." +165, ConcentrationUnit, 1586, 1596, "mmol / mol", "", " . ." +75, BaseLineValue, 1599, 1604, "7 . 9", "", +76, Percentage, 1605, 1606, "%", "", +80, ResultMeasuredValue, 1612, 1614, "46", "", " \"46\"." +171, ConcentrationUnit, 1615, 1625, "mmol / mol", "", +81, ResultMeasuredValue, 1628, 1633, "6 . 4", "", +77, Percentage, 1634, 1635, "%", "", +10, FixedCombDrug, 1643, 1651, "IDegLira", "", +82, ResultMeasuredValue, 1659, 1661, "57", "", " \"57\"." +172, ConcentrationUnit, 1662, 1672, "mmol / mol", "", +83, ResultMeasuredValue, 1675, 1680, "7 . 4", "", +78, Percentage, 1681, 1682, "%", "", +57, Placebo, 1690, 1697, "placebo", "", +181, DiffGroupAbsValue, 1731, 1735, "- 11", "", " \"- 11\"." +180, ConcentrationUnit, 1736, 1746, "mmol / mol", "", +85, ConfIntervalDiff, 1749, 1768, "95 % CI - 13 ; - 10", "", " \"95 % CI - 13 ; - 10\"." +100, DiffGroupAbsValue, 1774, 1782, "- 1 . 02", "", +79, Percentage, 1783, 1784, "%", "", +86, ConfIntervalDiff, 1787, 1814, "95 % CI - 1 . 18 ; - 0 . 87", "", +87, PvalueDiff, 1819, 1830, "P < 0 . 001", "", " \"P < 0 . 001\"." +88, HbA1c_target, 1839, 1878, "HbA1c target of 53 mmol / mol ( < 7 % )", "", " ." +188, ConcentrationUnit, 1858, 1868, "mmol / mol", "", +189, Percentage, 1875, 1876, "%", "", +89, PercentageAffected, 1895, 1901, "79 . 2", "", " \"79 . 2\"." +12, FixedCombDrug, 1927, 1935, "IDegLira", "", +90, PercentageAffected, 1945, 1951, "28 . 8", "", " \"28 . 8\"." +58, Placebo, 1961, 1968, "placebo", "", +92, PvalueDiff, 2037, 2048, "P < 0 . 001", "", " \"P < 0 . 001\"." +197, Mean, 2053, 2057, "Mean", "", " . ." +198, BodyWeight, 2058, 2064, "weight", "", " ." +94, Increment, 2078, 2083, "0 . 5", "", " \"0 . 5\"." +95, Kg, 2084, 2086, "kg", "", " ." +11, FixedCombDrug, 2092, 2100, "IDegLira", "", +98, Reduction, 2106, 2111, "1 . 0", "", " \"1 . 0\"." +96, Kg, 2112, 2114, "kg", "", +59, Placebo, 2120, 2127, "placebo", "", +99, DiffGroupAbsValue, 2161, 2167, "1 . 48", "", " \"1 . 48\"." +97, Kg, 2168, 2170, "kg", "", +101, ConfIntervalDiff, 2173, 2196, "95 % CI 0 . 90 ; 2 . 06", "", " \"95 % CI 0 . 90 ; 2 . 06\"." +102, PvalueDiff, 2201, 2212, "P < 0 . 001", "", " \"P < 0 . 001\"." +103, Hypoglycemia, 2227, 2240, "hypoglycaemia", "", " . ." +104, PercentageAffected, 2253, 2259, "41 . 7", "", " \"41 . 7\"." +105, PercentageAffected, 2264, 2270, "17 . 1", "", " \"17 . 1\"." +13, FixedCombDrug, 2276, 2284, "IDegLira", "", +60, Placebo, 2291, 2298, "placebo", "", +106172, ResultMeasuredValue, 2353, 2358, "3 . 5", "", " \"3 . 5\"." +106173, ResultMeasuredValue, 2362, 2367, "1 . 4", "", " \"1 . 4\"." +218, BioAndMedicalUnit, 2368, 2404, "events / patient - years of exposure", "", " . ." +106174, DiffGroupRelValue, 2428, 2434, "3 . 74", "", " \"3 . 74\"." +109, ConfIntervalDiff, 2437, 2460, "95 % CI 2 . 28 ; 6 . 13", "", " \"95 % CI 2 . 28 ; 6 . 13\"." +110, PvalueDiff, 2465, 2476, "P < 0 . 001", "", " \"P < 0 . 001\"." +62, FixedCombDrug, 2481, 2489, "IDegLira", "", +111, EndPointDescription, 2534, 2556, "serious adverse events", "", " . ." +112, ResultMeasuredValue, 2562, 2568, "20 . 3", "", " \"20 . 3\"." +113, ResultMeasuredValue, 2573, 2578, "8 . 0", "", " \"8 . 0\"." +222, BioAndMedicalUnit, 2579, 2614, "per 100 patient - years of exposure", "", " . ." +14, FixedCombDrug, 2620, 2628, "IDegLira", "", +61, Placebo, 2633, 2640, "placebo", "", +15, FixedCombDrug, 2721, 2729, "IDegLira", "", +115, ConclusionComment, 2721, 2873, "IDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials .", "", " \"IDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials .\"." +24, Sulfonylureas, 2770, 2783, "sulphonylurea", "", +25, Metformin, 2786, 2795, "metformin", "", +116, PMID, 2951, 2959, "27589252", "", " \"27589252\"." diff --git a/data/dm2 27589252_admin.n-triples b/data/dm2 27589252_admin.n-triples new file mode 100644 index 0000000..740f308 --- /dev/null +++ b/data/dm2 27589252_admin.n-triples @@ -0,0 +1,217 @@ +# RDF export of group: Publication + . + "Publication 70043" . + "Safety and efficacy of insulin degludec / liraglutide ( IDegLira ) added to sulphonylurea alone or to sulphonylurea and metformin in insulin - na ï ve people with Type 2 diabetes : the DUAL IV trial ." . + "Rodbard HW" . + "2017" . + "Diabet Med ." . + "27589252" . + . + "Bode BW" . + "Harris SB" . + "Rose L" . + "Lehmann L" . + "Jarlov H" . + "Thurman J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 70050" . + "To investigate the safety and efficacy of insulin degludec / liraglutide ( IDegLira ) , a novel combination product , as add - on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy ." . + "26 - week" . + . + . + . + "IDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 70066" . + "insulin - na ï ve people with Type 2 diabetes" . + . + . + . + "people with Type 2 diabetes uncontrolled on sulphonylurea therapy" . + "pre - trial sulphonylurea ± metformin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "hypr" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "id" . + "289" . + . + . + . + . + . + . + . + . + "pl" . + "146" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "id" . + . + . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "id" . + . + "50" . + . + . + . + "Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps" . + . + "pl" . + . + . + . + . + "id2" . + . + "1 . 8" . + . + . + "Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps" . +# RDF export of group: Outcome + . + "hba 1" . + . + "63" . + "46" . + . + "hba 2" . + . + "63" . + "57" . + . + . + . + "hbat 1" . + . + "79 . 2" . + . + "hbat 2" . + . + "28 . 8" . + . + "bw 1" . + . + "0 . 5" . + . + "bw 2" . + . + "1 . 0" . + . + "hyp 1" . + . + "41 . 7" . + . + "hyp 2" . + . + "17 . 1" . + . + "hypr 1" . + . + "3 . 5" . + . + "hypr 2" . + . + "1 . 4" . + . + "ae 1" . + . + "20 . 3" . + . + "ae 2" . + . + "8 . 0" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 11" . + "P < 0 . 001" . + "95 % CI - 13 ; - 10" . + . + "hbat" . + "P < 0 . 001" . + . + . + . + "bw" . + "1 . 48" . + "P < 0 . 001" . + "95 % CI 0 . 90 ; 2 . 06" . + . + . + . + "hypr" . + "3 . 74" . + "P < 0 . 001" . + "95 % CI 2 . 28 ; 6 . 13" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27589252_akramersunderbrink.annodb b/data/dm2 27589252_akramersunderbrink.annodb new file mode 100644 index 0000000..5f0cc42 --- /dev/null +++ b/data/dm2 27589252_akramersunderbrink.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +64804, Journal, 0, 10, "Diabet Med", "", +64805, PublicationYear, 13, 17, "2017", "", +64825, Title, 97, 297, "Safety and efficacy of insulin degludec / liraglutide ( IDegLira ) added to sulphonylurea alone or to sulphonylurea and metformin in insulin - na ï ve people with Type 2 diabetes : the DUAL IV trial .", "", +64832, InsulinDegludec, 120, 136, "insulin degludec", "", +64833, Liraglutide, 139, 150, "liraglutide", "", +64806, Sulfonylureas, 173, 186, "sulphonylurea", "", +64807, Sulfonylureas, 199, 212, "sulphonylurea", "", +64808, Metformin, 217, 226, "metformin", "", +64809, Precondition, 230, 247, "insulin - na ï ve", "", +64811, Type2Diabetes, 260, 275, "Type 2 diabetes", "", +64812, Author, 298, 308, "Rodbard HW", "", +64813, Author, 317, 324, "Bode BW", "", +64814, Author, 333, 342, "Harris SB", "", +64815, Author, 351, 357, "Rose L", "", +64816, Author, 366, 375, "Lehmann L", "", +64817, Author, 384, 392, "Jarlov H", "", +64818, Author, 401, 410, "Thurman J", "", +64819, USA, 583, 586, "USA", "", +64820, USA, 640, 643, "USA", "", +64822, Canada, 706, 712, "Canada", "", +64823, Germany, 767, 774, "Germany", "", +64824, Country, 815, 822, "Denmark", "", +64821, USA, 871, 874, "USA", "", +64831, ObjectiveDescription, 883, 1092, "To investigate the safety and efficacy of insulin degludec / liraglutide ( IDegLira ) , a novel combination product , as add - on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy .", "", +64826, InsulinDegludec, 925, 941, "insulin degludec", "", +64827, Liraglutide, 944, 955, "liraglutide", "", +64828, Type2Diabetes, 1037, 1052, "Type 2 diabetes", "", +64829, Precondition, 1053, 1090, "uncontrolled on sulphonylurea therapy", "", +64830, Sulfonylureas, 1069, 1082, "sulphonylurea", "", +64834, Duration, 1111, 1120, "26 - week", "", +64835, DoubleBlind, 1123, 1137, "double - blind", "", +64836, Type2Diabetes, 1158, 1173, "Type 2 diabetes", "", +64837, Precondition, 1176, 1220, "HbA1c 53 - 75 mmol / mol ( 7 . 0 - 9 . 0 % )", "", +64838, HbA1c, 1176, 1181, "HbA1c", "", +64839, ConcentrationUnit, 1190, 1200, "mmol / mol", "", +64840, Percentage, 1217, 1218, "%", "", +64841, Randomized, 1228, 1238, "randomized", "", +64842, NumberPatientsArm, 1257, 1260, "289", "", +64843, NumberPatientsArm, 1280, 1283, "146", "", +64844, Sulfonylureas, 1313, 1326, "sulphonylurea", "", +64845, Metformin, 1329, 1338, "metformin", "", +64846, FastingBloodGlucose_target, 1356, 1406, "fasting glycaemic target of 4 . 0 - 6 . 0 mmol / l", "", +64847, Millimoles_per_litre, 1398, 1406, "mmol / l", "", +64850, InsulinDegludec, 1499, 1515, "insulin degludec", "", +64848, mg, 1524, 1526, "mg", "", +64849, Liraglutide, 1527, 1538, "liraglutide", "", +64851, Mean, 1557, 1561, "mean", "", +64852, HbA1c, 1562, 1567, "HbA1c", "", +64862, BaseLineValue, 1583, 1585, "63", "", +64853, ConcentrationUnit, 1586, 1596, "mmol / mol", "", +64863, BaseLineValue, 1599, 1604, "7 . 9", "", +64854, Percentage, 1605, 1606, "%", "", +64864, ResultMeasuredValue, 1612, 1614, "46", "", +64859, ConcentrationUnit, 1615, 1625, "mmol / mol", "", +64865, ResultMeasuredValue, 1628, 1633, "6 . 4", "", +64855, Percentage, 1634, 1635, "%", "", +64866, ResultMeasuredValue, 1659, 1661, "57", "", +64860, ConcentrationUnit, 1662, 1672, "mmol / mol", "", +64867, ResultMeasuredValue, 1675, 1680, "7 . 4", "", +64856, Percentage, 1681, 1682, "%", "", +64861, Placebo, 1690, 1697, "placebo", "", +64869, DiffGroupAbsValue, 1731, 1735, "- 11", "", +64868, ConcentrationUnit, 1736, 1746, "mmol / mol", "", +64871, ConfIntervalDiff, 1749, 1768, "95 % CI - 13 ; - 10", "", +64857, Percentage, 1752, 1753, "%", "", +64870, DiffGroupAbsValue, 1774, 1782, "- 1 . 02", "", +64858, Percentage, 1783, 1784, "%", "", +64872, ConfIntervalDiff, 1787, 1814, "95 % CI - 1 . 18 ; - 0 . 87", "", +64873, Percentage, 1790, 1791, "%", "", +64874, PvalueDiff, 1819, 1830, "P < 0 . 001", "", +64875, HbA1c_target, 1839, 1878, "HbA1c target of 53 mmol / mol ( < 7 % )", "", +64876, ConcentrationUnit, 1858, 1868, "mmol / mol", "", +64877, Percentage, 1875, 1876, "%", "", +64881, PercentageAffected, 1895, 1901, "79 . 2", "", +64878, Percentage, 1902, 1903, "%", "", +64882, PercentageAffected, 1945, 1951, "28 . 8", "", +64879, Percentage, 1952, 1953, "%", "", +64883, Placebo, 1961, 1968, "placebo", "", +64880, Percentage, 2011, 2012, "%", "", +64884, PvalueDiff, 2037, 2048, "P < 0 . 001", "", +64885, Mean, 2053, 2057, "Mean", "", +64886, BodyWeight, 2058, 2064, "weight", "", +64887, ChangeValue, 2076, 2083, "+ 0 . 5", "", +64889, Kg, 2084, 2086, "kg", "", +64888, ChangeValue, 2104, 2111, "- 1 . 0", "", +64890, Kg, 2112, 2114, "kg", "", +64892, Placebo, 2120, 2127, "placebo", "", +64893, DiffGroupAbsValue, 2161, 2167, "1 . 48", "", +64891, Kg, 2168, 2170, "kg", "", +64894, ConfIntervalDiff, 2173, 2196, "95 % CI 0 . 90 ; 2 . 06", "", +64895, Percentage, 2176, 2177, "%", "", +64896, PvalueDiff, 2201, 2212, "P < 0 . 001", "", +64897, Hypoglycemia, 2217, 2240, "Confirmed hypoglycaemia", "", +64898, PercentageAffected, 2253, 2259, "41 . 7", "", +64899, PercentageAffected, 2264, 2270, "17 . 1", "", +64900, Percentage, 2271, 2272, "%", "", +64901, Placebo, 2291, 2298, "placebo", "", +64903, EndPointDescription, 2344, 2349, "rates", "", +64904, ResultMeasuredValue, 2353, 2358, "3 . 5", "", +64905, ResultMeasuredValue, 2362, 2367, "1 . 4", "", +64906, BioAndMedicalUnit, 2368, 2404, "events / patient - years of exposure", "", +64902, PvalueDiff, 2465, 2476, "P < 0 . 001", "", +64907, EndPointDescription, 2525, 2556, "rates of serious adverse events", "", +64908, ResultMeasuredValue, 2562, 2568, "20 . 3", "", +64909, ResultMeasuredValue, 2573, 2578, "8 . 0", "", +64910, BioAndMedicalUnit, 2579, 2614, "per 100 patient - years of exposure", "", +64911, Placebo, 2633, 2640, "placebo", "", +64914, ConclusionComment, 2721, 2873, "IDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials .", "", +64912, Sulfonylureas, 2770, 2783, "sulphonylurea", "", +64913, Metformin, 2786, 2795, "metformin", "", +64915, PMID, 2951, 2959, "27589252", "", diff --git a/data/dm2 27589252_akramersunderbrink.n-triples b/data/dm2 27589252_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27589252_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27589252_export.csv b/data/dm2 27589252_export.csv new file mode 100644 index 0000000..33823ba --- /dev/null +++ b/data/dm2 27589252_export.csv @@ -0,0 +1,726 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +260, 1, 1, 1, 0, 6, 0, 6, "Diabet" +260, 1, 2, 2, 7, 10, 7, 10, "Med" +260, 1, 3, 3, 11, 12, 11, 12, "." +260, 2, 1, 4, 0, 4, 13, 17, "2017" +260, 2, 2, 5, 5, 8, 18, 21, "Feb" +260, 2, 3, 6, 9, 10, 22, 23, ";" +260, 2, 4, 7, 11, 13, 24, 26, "34" +260, 2, 5, 8, 14, 15, 27, 28, "(" +260, 2, 6, 9, 16, 17, 29, 30, "2" +260, 2, 7, 10, 18, 19, 31, 32, ")" +260, 2, 8, 11, 20, 21, 33, 34, ":" +260, 2, 9, 12, 22, 25, 35, 38, "189" +260, 2, 10, 13, 26, 27, 39, 40, "-" +260, 2, 11, 14, 28, 31, 41, 44, "196" +260, 2, 12, 15, 32, 33, 45, 46, "." +260, 2, 13, 16, 34, 37, 47, 50, "doi" +260, 2, 14, 17, 38, 39, 51, 52, ":" +260, 2, 15, 18, 40, 42, 53, 55, "10" +260, 2, 16, 19, 43, 44, 56, 57, "." +260, 2, 17, 20, 45, 49, 58, 62, "1111" +260, 2, 18, 21, 50, 51, 63, 64, "/" +260, 2, 19, 22, 52, 55, 65, 68, "dme" +260, 2, 20, 23, 56, 57, 69, 70, "." +260, 2, 21, 24, 58, 63, 71, 76, "13256" +260, 2, 22, 25, 64, 65, 77, 78, "." +260, 3, 1, 26, 0, 4, 79, 83, "Epub" +260, 3, 2, 27, 5, 9, 84, 88, "2016" +260, 3, 3, 28, 10, 13, 89, 92, "Oct" +260, 3, 4, 29, 14, 15, 93, 94, "7" +260, 3, 5, 30, 16, 17, 95, 96, "." +260, 4, 1, 31, 0, 6, 97, 103, "Safety" +260, 4, 2, 32, 7, 10, 104, 107, "and" +260, 4, 3, 33, 11, 19, 108, 116, "efficacy" +260, 4, 4, 34, 20, 22, 117, 119, "of" +260, 4, 5, 35, 23, 30, 120, 127, "insulin" +260, 4, 6, 36, 31, 39, 128, 136, "degludec" +260, 4, 7, 37, 40, 41, 137, 138, "/" +260, 4, 8, 38, 42, 53, 139, 150, "liraglutide" +260, 4, 9, 39, 54, 55, 151, 152, "(" +260, 4, 10, 40, 56, 64, 153, 161, "IDegLira" +260, 4, 11, 41, 65, 66, 162, 163, ")" +260, 4, 12, 42, 67, 72, 164, 169, "added" +260, 4, 13, 43, 73, 75, 170, 172, "to" +260, 4, 14, 44, 76, 89, 173, 186, "sulphonylurea" +260, 4, 15, 45, 90, 95, 187, 192, "alone" +260, 4, 16, 46, 96, 98, 193, 195, "or" +260, 4, 17, 47, 99, 101, 196, 198, "to" +260, 4, 18, 48, 102, 115, 199, 212, "sulphonylurea" +260, 4, 19, 49, 116, 119, 213, 216, "and" +260, 4, 20, 50, 120, 129, 217, 226, "metformin" +260, 4, 21, 51, 130, 132, 227, 229, "in" +260, 4, 22, 52, 133, 140, 230, 237, "insulin" +260, 4, 23, 53, 141, 142, 238, 239, "-" +260, 4, 24, 54, 143, 145, 240, 242, "na" +260, 4, 25, 55, 146, 147, 243, 244, "ï" +260, 4, 26, 56, 148, 150, 245, 247, "ve" +260, 4, 27, 57, 151, 157, 248, 254, "people" +260, 4, 28, 58, 158, 162, 255, 259, "with" +260, 4, 29, 59, 163, 167, 260, 264, "Type" +260, 4, 30, 60, 168, 169, 265, 266, "2" +260, 4, 31, 61, 170, 178, 267, 275, "diabetes" +260, 4, 32, 62, 179, 180, 276, 277, ":" +260, 4, 33, 63, 181, 184, 278, 281, "the" +260, 4, 34, 64, 185, 189, 282, 286, "DUAL" +260, 4, 35, 65, 190, 192, 287, 289, "IV" +260, 4, 36, 66, 193, 198, 290, 295, "trial" +260, 4, 37, 67, 199, 200, 296, 297, "." +260, 5, 1, 68, 0, 7, 298, 305, "Rodbard" +260, 5, 2, 69, 8, 10, 306, 308, "HW" +260, 5, 3, 70, 11, 12, 309, 310, "(" +260, 5, 4, 71, 13, 14, 311, 312, "1" +260, 5, 5, 72, 15, 16, 313, 314, ")" +260, 5, 6, 73, 17, 18, 315, 316, "," +260, 5, 7, 74, 19, 23, 317, 321, "Bode" +260, 5, 8, 75, 24, 26, 322, 324, "BW" +260, 5, 9, 76, 27, 28, 325, 326, "(" +260, 5, 10, 77, 29, 30, 327, 328, "2" +260, 5, 11, 78, 31, 32, 329, 330, ")" +260, 5, 12, 79, 33, 34, 331, 332, "," +260, 5, 13, 80, 35, 41, 333, 339, "Harris" +260, 5, 14, 81, 42, 44, 340, 342, "SB" +260, 5, 15, 82, 45, 46, 343, 344, "(" +260, 5, 16, 83, 47, 48, 345, 346, "3" +260, 5, 17, 84, 49, 50, 347, 348, ")" +260, 5, 18, 85, 51, 52, 349, 350, "," +260, 5, 19, 86, 53, 57, 351, 355, "Rose" +260, 5, 20, 87, 58, 59, 356, 357, "L" +260, 5, 21, 88, 60, 61, 358, 359, "(" +260, 5, 22, 89, 62, 63, 360, 361, "4" +260, 5, 23, 90, 64, 65, 362, 363, ")" +260, 5, 24, 91, 66, 67, 364, 365, "," +260, 5, 25, 92, 68, 75, 366, 373, "Lehmann" +260, 5, 26, 93, 76, 77, 374, 375, "L" +260, 5, 27, 94, 78, 79, 376, 377, "(" +260, 5, 28, 95, 80, 81, 378, 379, "5" +260, 5, 29, 96, 82, 83, 380, 381, ")" +260, 5, 30, 97, 84, 85, 382, 383, "," +260, 5, 31, 98, 86, 92, 384, 390, "Jarlov" +260, 5, 32, 99, 93, 94, 391, 392, "H" +260, 5, 33, 100, 95, 96, 393, 394, "(" +260, 5, 34, 101, 97, 98, 395, 396, "5" +260, 5, 35, 102, 99, 100, 397, 398, ")" +260, 5, 36, 103, 101, 102, 399, 400, "," +260, 5, 37, 104, 103, 110, 401, 408, "Thurman" +260, 5, 38, 105, 111, 112, 409, 410, "J" +260, 5, 39, 106, 113, 114, 411, 412, "(" +260, 5, 40, 107, 115, 116, 413, 414, "6" +260, 5, 41, 108, 117, 118, 415, 416, ")" +260, 5, 42, 109, 119, 120, 417, 418, ";" +260, 5, 43, 110, 121, 125, 419, 423, "Dual" +260, 5, 44, 111, 126, 132, 424, 430, "Action" +260, 5, 45, 112, 133, 135, 431, 433, "of" +260, 5, 46, 113, 136, 147, 434, 445, "Liraglutide" +260, 5, 47, 114, 148, 151, 446, 449, "and" +260, 5, 48, 115, 152, 159, 450, 457, "insulin" +260, 5, 49, 116, 160, 168, 458, 466, "degludec" +260, 5, 50, 117, 169, 170, 467, 468, "(" +260, 5, 51, 118, 171, 175, 469, 473, "DUAL" +260, 5, 52, 119, 176, 177, 474, 475, ")" +260, 5, 53, 120, 178, 180, 476, 478, "IV" +260, 5, 54, 121, 181, 186, 479, 484, "trial" +260, 5, 55, 122, 187, 200, 485, 498, "investigators" +260, 5, 56, 123, 201, 202, 499, 500, "." +260, 6, 1, 124, 0, 6, 501, 507, "Author" +260, 6, 2, 125, 7, 18, 508, 519, "information" +260, 6, 3, 126, 19, 20, 520, 521, ":" +260, 6, 4, 127, 21, 22, 522, 523, "(" +260, 6, 5, 128, 23, 24, 524, 525, "1" +260, 6, 6, 129, 25, 26, 526, 527, ")" +260, 6, 7, 130, 27, 36, 528, 537, "Endocrine" +260, 6, 8, 131, 37, 40, 538, 541, "and" +260, 6, 9, 132, 41, 50, 542, 551, "Metabolic" +260, 6, 10, 133, 51, 62, 552, 563, "Consultants" +260, 6, 11, 134, 63, 64, 564, 565, "," +260, 6, 12, 135, 65, 74, 566, 575, "Rockville" +260, 6, 13, 136, 75, 76, 576, 577, "," +260, 6, 14, 137, 77, 79, 578, 580, "MD" +260, 6, 15, 138, 80, 81, 581, 582, "," +260, 6, 16, 139, 82, 85, 583, 586, "USA" +260, 6, 17, 140, 86, 87, 587, 588, "." +260, 7, 1, 141, 0, 1, 589, 590, "(" +260, 7, 2, 142, 2, 3, 591, 592, "2" +260, 7, 3, 143, 4, 5, 593, 594, ")" +260, 7, 4, 144, 6, 13, 595, 602, "Atlanta" +260, 7, 5, 145, 14, 22, 603, 611, "Diabetes" +260, 7, 6, 146, 23, 33, 612, 622, "Associates" +260, 7, 7, 147, 34, 35, 623, 624, "," +260, 7, 8, 148, 36, 43, 625, 632, "Atlanta" +260, 7, 9, 149, 44, 45, 633, 634, "," +260, 7, 10, 150, 46, 48, 635, 637, "GA" +260, 7, 11, 151, 49, 50, 638, 639, "," +260, 7, 12, 152, 51, 54, 640, 643, "USA" +260, 7, 13, 153, 55, 56, 644, 645, "." +260, 8, 1, 154, 0, 1, 646, 647, "(" +260, 8, 2, 155, 2, 3, 648, 649, "3" +260, 8, 3, 156, 4, 5, 650, 651, ")" +260, 8, 4, 157, 6, 12, 652, 658, "Centre" +260, 8, 5, 158, 13, 16, 659, 662, "for" +260, 8, 6, 159, 17, 24, 663, 670, "Studies" +260, 8, 7, 160, 25, 27, 671, 673, "in" +260, 8, 8, 161, 28, 34, 674, 680, "Family" +260, 8, 9, 162, 35, 43, 681, 689, "Medicine" +260, 8, 10, 163, 44, 45, 690, 691, "," +260, 8, 11, 164, 46, 52, 692, 698, "London" +260, 8, 12, 165, 53, 54, 699, 700, "," +260, 8, 13, 166, 55, 57, 701, 703, "ON" +260, 8, 14, 167, 58, 59, 704, 705, "," +260, 8, 15, 168, 60, 66, 706, 712, "Canada" +260, 8, 16, 169, 67, 68, 713, 714, "." +260, 9, 1, 170, 0, 1, 715, 716, "(" +260, 9, 2, 171, 2, 3, 717, 718, "4" +260, 9, 3, 172, 4, 5, 719, 720, ")" +260, 9, 4, 173, 6, 15, 721, 730, "Institute" +260, 9, 5, 174, 16, 19, 731, 734, "for" +260, 9, 6, 175, 20, 28, 735, 743, "Diabetes" +260, 9, 7, 176, 29, 37, 744, 752, "Research" +260, 9, 8, 177, 38, 39, 753, 754, "," +260, 9, 9, 178, 40, 41, 755, 756, "M" +260, 9, 10, 179, 42, 43, 757, 758, "ü" +260, 9, 11, 180, 44, 49, 759, 764, "nster" +260, 9, 12, 181, 50, 51, 765, 766, "," +260, 9, 13, 182, 52, 59, 767, 774, "Germany" +260, 9, 14, 183, 60, 61, 775, 776, "." +260, 10, 1, 184, 0, 1, 777, 778, "(" +260, 10, 2, 185, 2, 3, 779, 780, "5" +260, 10, 3, 186, 4, 5, 781, 782, ")" +260, 10, 4, 187, 6, 10, 783, 787, "Novo" +260, 10, 5, 188, 11, 18, 788, 795, "Nordisk" +260, 10, 6, 189, 19, 20, 796, 797, "A" +260, 10, 7, 190, 21, 22, 798, 799, "/" +260, 10, 8, 191, 23, 24, 800, 801, "S" +260, 10, 9, 192, 25, 26, 802, 803, "," +260, 10, 10, 193, 27, 28, 804, 805, "S" +260, 10, 11, 194, 29, 30, 806, 807, "ø" +260, 10, 12, 195, 31, 35, 808, 812, "borg" +260, 10, 13, 196, 36, 37, 813, 814, "," +260, 10, 14, 197, 38, 45, 815, 822, "Denmark" +260, 10, 15, 198, 46, 47, 823, 824, "." +260, 11, 1, 199, 0, 1, 825, 826, "(" +260, 11, 2, 200, 2, 3, 827, 828, "6" +260, 11, 3, 201, 4, 5, 829, 830, ")" +260, 11, 4, 202, 6, 9, 831, 834, "SSM" +260, 11, 5, 203, 10, 11, 835, 836, "-" +260, 11, 6, 204, 12, 19, 837, 844, "Medical" +260, 11, 7, 205, 20, 25, 845, 850, "Group" +260, 11, 8, 206, 26, 27, 851, 852, "," +260, 11, 9, 207, 28, 30, 853, 855, "St" +260, 11, 10, 208, 31, 32, 856, 857, "." +260, 11, 11, 209, 33, 38, 858, 863, "Louis" +260, 11, 12, 210, 39, 40, 864, 865, "," +260, 11, 13, 211, 41, 43, 866, 868, "MO" +260, 11, 14, 212, 44, 45, 869, 870, "," +260, 11, 15, 213, 46, 49, 871, 874, "USA" +260, 11, 16, 214, 50, 51, 875, 876, "." +260, 12, 1, 215, 0, 3, 877, 880, "AIM" +260, 12, 2, 216, 4, 5, 881, 882, ":" +260, 12, 3, 217, 6, 8, 883, 885, "To" +260, 12, 4, 218, 9, 20, 886, 897, "investigate" +260, 12, 5, 219, 21, 24, 898, 901, "the" +260, 12, 6, 220, 25, 31, 902, 908, "safety" +260, 12, 7, 221, 32, 35, 909, 912, "and" +260, 12, 8, 222, 36, 44, 913, 921, "efficacy" +260, 12, 9, 223, 45, 47, 922, 924, "of" +260, 12, 10, 224, 48, 55, 925, 932, "insulin" +260, 12, 11, 225, 56, 64, 933, 941, "degludec" +260, 12, 12, 226, 65, 66, 942, 943, "/" +260, 12, 13, 227, 67, 78, 944, 955, "liraglutide" +260, 12, 14, 228, 79, 80, 956, 957, "(" +260, 12, 15, 229, 81, 89, 958, 966, "IDegLira" +260, 12, 16, 230, 90, 91, 967, 968, ")" +260, 12, 17, 231, 92, 93, 969, 970, "," +260, 12, 18, 232, 94, 95, 971, 972, "a" +260, 12, 19, 233, 96, 101, 973, 978, "novel" +260, 12, 20, 234, 102, 113, 979, 990, "combination" +260, 12, 21, 235, 114, 121, 991, 998, "product" +260, 12, 22, 236, 122, 123, 999, 1000, "," +260, 12, 23, 237, 124, 126, 1001, 1003, "as" +260, 12, 24, 238, 127, 130, 1004, 1007, "add" +260, 12, 25, 239, 131, 132, 1008, 1009, "-" +260, 12, 26, 240, 133, 135, 1010, 1012, "on" +260, 12, 27, 241, 136, 143, 1013, 1020, "therapy" +260, 12, 28, 242, 144, 147, 1021, 1024, "for" +260, 12, 29, 243, 148, 154, 1025, 1031, "people" +260, 12, 30, 244, 155, 159, 1032, 1036, "with" +260, 12, 31, 245, 160, 164, 1037, 1041, "Type" +260, 12, 32, 246, 165, 166, 1042, 1043, "2" +260, 12, 33, 247, 167, 175, 1044, 1052, "diabetes" +260, 12, 34, 248, 176, 188, 1053, 1065, "uncontrolled" +260, 12, 35, 249, 189, 191, 1066, 1068, "on" +260, 12, 36, 250, 192, 205, 1069, 1082, "sulphonylurea" +260, 12, 37, 251, 206, 213, 1083, 1090, "therapy" +260, 12, 38, 252, 214, 215, 1091, 1092, "." +260, 13, 1, 253, 0, 7, 1093, 1100, "METHODS" +260, 13, 2, 254, 8, 9, 1101, 1102, ":" +260, 13, 3, 255, 10, 12, 1103, 1105, "In" +260, 13, 4, 256, 13, 17, 1106, 1110, "this" +260, 13, 5, 257, 18, 20, 1111, 1113, "26" +260, 13, 6, 258, 21, 22, 1114, 1115, "-" +260, 13, 7, 259, 23, 27, 1116, 1120, "week" +260, 13, 8, 260, 28, 29, 1121, 1122, "," +260, 13, 9, 261, 30, 36, 1123, 1129, "double" +260, 13, 10, 262, 37, 38, 1130, 1131, "-" +260, 13, 11, 263, 39, 44, 1132, 1137, "blind" +260, 13, 12, 264, 45, 50, 1138, 1143, "trial" +260, 13, 13, 265, 51, 52, 1144, 1145, "," +260, 13, 14, 266, 53, 59, 1146, 1152, "adults" +260, 13, 15, 267, 60, 64, 1153, 1157, "with" +260, 13, 16, 268, 65, 69, 1158, 1162, "Type" +260, 13, 17, 269, 70, 71, 1163, 1164, "2" +260, 13, 18, 270, 72, 80, 1165, 1173, "diabetes" +260, 13, 19, 271, 81, 82, 1174, 1175, "[" +260, 13, 20, 272, 83, 88, 1176, 1181, "HbA1c" +260, 13, 21, 273, 89, 91, 1182, 1184, "53" +260, 13, 22, 274, 92, 93, 1185, 1186, "-" +260, 13, 23, 275, 94, 96, 1187, 1189, "75" +260, 13, 24, 276, 97, 101, 1190, 1194, "mmol" +260, 13, 25, 277, 102, 103, 1195, 1196, "/" +260, 13, 26, 278, 104, 107, 1197, 1200, "mol" +260, 13, 27, 279, 108, 109, 1201, 1202, "(" +260, 13, 28, 280, 110, 111, 1203, 1204, "7" +260, 13, 29, 281, 112, 113, 1205, 1206, "." +260, 13, 30, 282, 114, 115, 1207, 1208, "0" +260, 13, 31, 283, 116, 117, 1209, 1210, "-" +260, 13, 32, 284, 118, 119, 1211, 1212, "9" +260, 13, 33, 285, 120, 121, 1213, 1214, "." +260, 13, 34, 286, 122, 123, 1215, 1216, "0" +260, 13, 35, 287, 124, 125, 1217, 1218, "%" +260, 13, 36, 288, 126, 127, 1219, 1220, ")" +260, 13, 37, 289, 128, 129, 1221, 1222, "]" +260, 13, 38, 290, 130, 134, 1223, 1227, "were" +260, 13, 39, 291, 135, 145, 1228, 1238, "randomized" +260, 13, 40, 292, 146, 148, 1239, 1241, "to" +260, 13, 41, 293, 149, 157, 1242, 1250, "IDegLira" +260, 13, 42, 294, 158, 159, 1251, 1252, "(" +260, 13, 43, 295, 160, 161, 1253, 1254, "n" +260, 13, 44, 296, 162, 163, 1255, 1256, "=" +260, 13, 45, 297, 164, 167, 1257, 1260, "289" +260, 13, 46, 298, 168, 169, 1261, 1262, ")" +260, 13, 47, 299, 170, 172, 1263, 1265, "or" +260, 13, 48, 300, 173, 180, 1266, 1273, "placebo" +260, 13, 49, 301, 181, 182, 1274, 1275, "(" +260, 13, 50, 302, 183, 184, 1276, 1277, "n" +260, 13, 51, 303, 185, 186, 1278, 1279, "=" +260, 13, 52, 304, 187, 190, 1280, 1283, "146" +260, 13, 53, 305, 191, 192, 1284, 1285, ")" +260, 13, 54, 306, 193, 195, 1286, 1288, "as" +260, 13, 55, 307, 196, 199, 1289, 1292, "add" +260, 13, 56, 308, 200, 201, 1293, 1294, "-" +260, 13, 57, 309, 202, 204, 1295, 1297, "on" +260, 13, 58, 310, 205, 207, 1298, 1300, "to" +260, 13, 59, 311, 208, 211, 1301, 1304, "pre" +260, 13, 60, 312, 212, 213, 1305, 1306, "-" +260, 13, 61, 313, 214, 219, 1307, 1312, "trial" +260, 13, 62, 314, 220, 233, 1313, 1326, "sulphonylurea" +260, 13, 63, 315, 234, 235, 1327, 1328, "±" +260, 13, 64, 316, 236, 245, 1329, 1338, "metformin" +260, 13, 65, 317, 246, 247, 1339, 1340, "," +260, 13, 66, 318, 248, 257, 1341, 1350, "titrating" +260, 13, 67, 319, 258, 260, 1351, 1353, "to" +260, 13, 68, 320, 261, 262, 1354, 1355, "a" +260, 13, 69, 321, 263, 270, 1356, 1363, "fasting" +260, 13, 70, 322, 271, 280, 1364, 1373, "glycaemic" +260, 13, 71, 323, 281, 287, 1374, 1380, "target" +260, 13, 72, 324, 288, 290, 1381, 1383, "of" +260, 13, 73, 325, 291, 292, 1384, 1385, "4" +260, 13, 74, 326, 293, 294, 1386, 1387, "." +260, 13, 75, 327, 295, 296, 1388, 1389, "0" +260, 13, 76, 328, 297, 298, 1390, 1391, "-" +260, 13, 77, 329, 299, 300, 1392, 1393, "6" +260, 13, 78, 330, 301, 302, 1394, 1395, "." +260, 13, 79, 331, 303, 304, 1396, 1397, "0" +260, 13, 80, 332, 305, 309, 1398, 1402, "mmol" +260, 13, 81, 333, 310, 311, 1403, 1404, "/" +260, 13, 82, 334, 312, 313, 1405, 1406, "l" +260, 13, 83, 335, 314, 315, 1407, 1408, "." +260, 14, 1, 336, 0, 9, 1409, 1418, "Treatment" +260, 14, 2, 337, 10, 20, 1419, 1429, "initiation" +260, 14, 3, 338, 21, 24, 1430, 1433, "was" +260, 14, 4, 339, 25, 27, 1434, 1436, "at" +260, 14, 5, 340, 28, 30, 1437, 1439, "10" +260, 14, 6, 341, 31, 35, 1440, 1444, "dose" +260, 14, 7, 342, 36, 41, 1445, 1450, "steps" +260, 14, 8, 343, 42, 43, 1451, 1452, "," +260, 14, 9, 344, 44, 47, 1453, 1456, "and" +260, 14, 10, 345, 48, 55, 1457, 1464, "maximum" +260, 14, 11, 346, 56, 60, 1465, 1469, "dose" +260, 14, 12, 347, 61, 64, 1470, 1473, "was" +260, 14, 13, 348, 65, 67, 1474, 1476, "50" +260, 14, 14, 349, 68, 72, 1477, 1481, "dose" +260, 14, 15, 350, 73, 78, 1482, 1487, "steps" +260, 14, 16, 351, 79, 80, 1488, 1489, "(" +260, 14, 17, 352, 81, 83, 1490, 1492, "50" +260, 14, 18, 353, 84, 89, 1493, 1498, "units" +260, 14, 19, 354, 90, 97, 1499, 1506, "insulin" +260, 14, 20, 355, 98, 106, 1507, 1515, "degludec" +260, 14, 21, 356, 107, 108, 1516, 1517, "/" +260, 14, 22, 357, 109, 110, 1518, 1519, "1" +260, 14, 23, 358, 111, 112, 1520, 1521, "." +260, 14, 24, 359, 113, 114, 1522, 1523, "8" +260, 14, 25, 360, 115, 117, 1524, 1526, "mg" +260, 14, 26, 361, 118, 129, 1527, 1538, "liraglutide" +260, 14, 27, 362, 130, 131, 1539, 1540, ")" +260, 14, 28, 363, 132, 133, 1541, 1542, "." +260, 15, 1, 364, 0, 7, 1543, 1550, "RESULTS" +260, 15, 2, 365, 8, 9, 1551, 1552, ":" +260, 15, 3, 366, 10, 13, 1553, 1556, "The" +260, 15, 4, 367, 14, 18, 1557, 1561, "mean" +260, 15, 5, 368, 19, 24, 1562, 1567, "HbA1c" +260, 15, 6, 369, 25, 34, 1568, 1577, "decreased" +260, 15, 7, 370, 35, 39, 1578, 1582, "from" +260, 15, 8, 371, 40, 42, 1583, 1585, "63" +260, 15, 9, 372, 43, 47, 1586, 1590, "mmol" +260, 15, 10, 373, 48, 49, 1591, 1592, "/" +260, 15, 11, 374, 50, 53, 1593, 1596, "mol" +260, 15, 12, 375, 54, 55, 1597, 1598, "(" +260, 15, 13, 376, 56, 57, 1599, 1600, "7" +260, 15, 14, 377, 58, 59, 1601, 1602, "." +260, 15, 15, 378, 60, 61, 1603, 1604, "9" +260, 15, 16, 379, 62, 63, 1605, 1606, "%" +260, 15, 17, 380, 64, 65, 1607, 1608, ")" +260, 15, 18, 381, 66, 68, 1609, 1611, "to" +260, 15, 19, 382, 69, 71, 1612, 1614, "46" +260, 15, 20, 383, 72, 76, 1615, 1619, "mmol" +260, 15, 21, 384, 77, 78, 1620, 1621, "/" +260, 15, 22, 385, 79, 82, 1622, 1625, "mol" +260, 15, 23, 386, 83, 84, 1626, 1627, "(" +260, 15, 24, 387, 85, 86, 1628, 1629, "6" +260, 15, 25, 388, 87, 88, 1630, 1631, "." +260, 15, 26, 389, 89, 90, 1632, 1633, "4" +260, 15, 27, 390, 91, 92, 1634, 1635, "%" +260, 15, 28, 391, 93, 94, 1636, 1637, ")" +260, 15, 29, 392, 95, 99, 1638, 1642, "with" +260, 15, 30, 393, 100, 108, 1643, 1651, "IDegLira" +260, 15, 31, 394, 109, 112, 1652, 1655, "and" +260, 15, 32, 395, 113, 115, 1656, 1658, "to" +260, 15, 33, 396, 116, 118, 1659, 1661, "57" +260, 15, 34, 397, 119, 123, 1662, 1666, "mmol" +260, 15, 35, 398, 124, 125, 1667, 1668, "/" +260, 15, 36, 399, 126, 129, 1669, 1672, "mol" +260, 15, 37, 400, 130, 131, 1673, 1674, "(" +260, 15, 38, 401, 132, 133, 1675, 1676, "7" +260, 15, 39, 402, 134, 135, 1677, 1678, "." +260, 15, 40, 403, 136, 137, 1679, 1680, "4" +260, 15, 41, 404, 138, 139, 1681, 1682, "%" +260, 15, 42, 405, 140, 141, 1683, 1684, ")" +260, 15, 43, 406, 142, 146, 1685, 1689, "with" +260, 15, 44, 407, 147, 154, 1690, 1697, "placebo" +260, 15, 45, 408, 155, 156, 1698, 1699, "[" +260, 15, 46, 409, 157, 166, 1700, 1709, "estimated" +260, 15, 47, 410, 167, 176, 1710, 1719, "treatment" +260, 15, 48, 411, 177, 187, 1720, 1730, "difference" +260, 15, 49, 412, 188, 189, 1731, 1732, "-" +260, 15, 50, 413, 190, 192, 1733, 1735, "11" +260, 15, 51, 414, 193, 197, 1736, 1740, "mmol" +260, 15, 52, 415, 198, 199, 1741, 1742, "/" +260, 15, 53, 416, 200, 203, 1743, 1746, "mol" +260, 15, 54, 417, 204, 205, 1747, 1748, "(" +260, 15, 55, 418, 206, 208, 1749, 1751, "95" +260, 15, 56, 419, 209, 210, 1752, 1753, "%" +260, 15, 57, 420, 211, 213, 1754, 1756, "CI" +260, 15, 58, 421, 214, 215, 1757, 1758, "-" +260, 15, 59, 422, 216, 218, 1759, 1761, "13" +260, 15, 60, 423, 219, 220, 1762, 1763, ";" +260, 15, 61, 424, 221, 222, 1764, 1765, "-" +260, 15, 62, 425, 223, 225, 1766, 1768, "10" +260, 15, 63, 426, 226, 227, 1769, 1770, ")" +260, 15, 64, 427, 228, 230, 1771, 1773, "or" +260, 15, 65, 428, 231, 232, 1774, 1775, "-" +260, 15, 66, 429, 233, 234, 1776, 1777, "1" +260, 15, 67, 430, 235, 236, 1778, 1779, "." +260, 15, 68, 431, 237, 239, 1780, 1782, "02" +260, 15, 69, 432, 240, 241, 1783, 1784, "%" +260, 15, 70, 433, 242, 243, 1785, 1786, "(" +260, 15, 71, 434, 244, 246, 1787, 1789, "95" +260, 15, 72, 435, 247, 248, 1790, 1791, "%" +260, 15, 73, 436, 249, 251, 1792, 1794, "CI" +260, 15, 74, 437, 252, 253, 1795, 1796, "-" +260, 15, 75, 438, 254, 255, 1797, 1798, "1" +260, 15, 76, 439, 256, 257, 1799, 1800, "." +260, 15, 77, 440, 258, 260, 1801, 1803, "18" +260, 15, 78, 441, 261, 262, 1804, 1805, ";" +260, 15, 79, 442, 263, 264, 1806, 1807, "-" +260, 15, 80, 443, 265, 266, 1808, 1809, "0" +260, 15, 81, 444, 267, 268, 1810, 1811, "." +260, 15, 82, 445, 269, 271, 1812, 1814, "87" +260, 15, 83, 446, 272, 273, 1815, 1816, ")" +260, 15, 84, 447, 274, 275, 1817, 1818, ";" +260, 15, 85, 448, 276, 277, 1819, 1820, "P" +260, 15, 86, 449, 278, 279, 1821, 1822, "<" +260, 15, 87, 450, 280, 281, 1823, 1824, "0" +260, 15, 88, 451, 282, 283, 1825, 1826, "." +260, 15, 89, 452, 284, 287, 1827, 1830, "001" +260, 15, 90, 453, 288, 289, 1831, 1832, "]" +260, 15, 91, 454, 290, 291, 1833, 1834, "." +260, 16, 1, 455, 0, 3, 1835, 1838, "The" +260, 16, 2, 456, 4, 9, 1839, 1844, "HbA1c" +260, 16, 3, 457, 10, 16, 1845, 1851, "target" +260, 16, 4, 458, 17, 19, 1852, 1854, "of" +260, 16, 5, 459, 20, 22, 1855, 1857, "53" +260, 16, 6, 460, 23, 27, 1858, 1862, "mmol" +260, 16, 7, 461, 28, 29, 1863, 1864, "/" +260, 16, 8, 462, 30, 33, 1865, 1868, "mol" +260, 16, 9, 463, 34, 35, 1869, 1870, "(" +260, 16, 10, 464, 36, 37, 1871, 1872, "<" +260, 16, 11, 465, 38, 39, 1873, 1874, "7" +260, 16, 12, 466, 40, 41, 1875, 1876, "%" +260, 16, 13, 467, 42, 43, 1877, 1878, ")" +260, 16, 14, 468, 44, 47, 1879, 1882, "was" +260, 16, 15, 469, 48, 56, 1883, 1891, "achieved" +260, 16, 16, 470, 57, 59, 1892, 1894, "by" +260, 16, 17, 471, 60, 62, 1895, 1897, "79" +260, 16, 18, 472, 63, 64, 1898, 1899, "." +260, 16, 19, 473, 65, 66, 1900, 1901, "2" +260, 16, 20, 474, 67, 68, 1902, 1903, "%" +260, 16, 21, 475, 69, 71, 1904, 1906, "of" +260, 16, 22, 476, 72, 84, 1907, 1919, "participants" +260, 16, 23, 477, 85, 87, 1920, 1922, "in" +260, 16, 24, 478, 88, 91, 1923, 1926, "the" +260, 16, 25, 479, 92, 100, 1927, 1935, "IDegLira" +260, 16, 26, 480, 101, 106, 1936, 1941, "group" +260, 16, 27, 481, 107, 109, 1942, 1944, "vs" +260, 16, 28, 482, 110, 112, 1945, 1947, "28" +260, 16, 29, 483, 113, 114, 1948, 1949, "." +260, 16, 30, 484, 115, 116, 1950, 1951, "8" +260, 16, 31, 485, 117, 118, 1952, 1953, "%" +260, 16, 32, 486, 119, 121, 1954, 1956, "in" +260, 16, 33, 487, 122, 125, 1957, 1960, "the" +260, 16, 34, 488, 126, 133, 1961, 1968, "placebo" +260, 16, 35, 489, 134, 139, 1969, 1974, "group" +260, 16, 36, 490, 140, 141, 1975, 1976, "[" +260, 16, 37, 491, 142, 151, 1977, 1986, "estimated" +260, 16, 38, 492, 152, 156, 1987, 1991, "odds" +260, 16, 39, 493, 157, 162, 1992, 1997, "ratio" +260, 16, 40, 494, 163, 165, 1998, 2000, "11" +260, 16, 41, 495, 166, 167, 2001, 2002, "." +260, 16, 42, 496, 168, 170, 2003, 2005, "95" +260, 16, 43, 497, 171, 172, 2006, 2007, "(" +260, 16, 44, 498, 173, 175, 2008, 2010, "95" +260, 16, 45, 499, 176, 177, 2011, 2012, "%" +260, 16, 46, 500, 178, 180, 2013, 2015, "CI" +260, 16, 47, 501, 181, 182, 2016, 2017, "7" +260, 16, 48, 502, 183, 184, 2018, 2019, "." +260, 16, 49, 503, 185, 187, 2020, 2022, "22" +260, 16, 50, 504, 188, 189, 2023, 2024, ";" +260, 16, 51, 505, 190, 192, 2025, 2027, "19" +260, 16, 52, 506, 193, 194, 2028, 2029, "." +260, 16, 53, 507, 195, 197, 2030, 2032, "77" +260, 16, 54, 508, 198, 199, 2033, 2034, ")" +260, 16, 55, 509, 200, 201, 2035, 2036, ";" +260, 16, 56, 510, 202, 203, 2037, 2038, "P" +260, 16, 57, 511, 204, 205, 2039, 2040, "<" +260, 16, 58, 512, 206, 207, 2041, 2042, "0" +260, 16, 59, 513, 208, 209, 2043, 2044, "." +260, 16, 60, 514, 210, 213, 2045, 2048, "001" +260, 16, 61, 515, 214, 215, 2049, 2050, "]" +260, 16, 62, 516, 216, 217, 2051, 2052, "." +260, 17, 1, 517, 0, 4, 2053, 2057, "Mean" +260, 17, 2, 518, 5, 11, 2058, 2064, "weight" +260, 17, 3, 519, 12, 18, 2065, 2071, "change" +260, 17, 4, 520, 19, 22, 2072, 2075, "was" +260, 17, 5, 521, 23, 24, 2076, 2077, "+" +260, 17, 6, 522, 25, 26, 2078, 2079, "0" +260, 17, 7, 523, 27, 28, 2080, 2081, "." +260, 17, 8, 524, 29, 30, 2082, 2083, "5" +260, 17, 9, 525, 31, 33, 2084, 2086, "kg" +260, 17, 10, 526, 34, 38, 2087, 2091, "with" +260, 17, 11, 527, 39, 47, 2092, 2100, "IDegLira" +260, 17, 12, 528, 48, 50, 2101, 2103, "vs" +260, 17, 13, 529, 51, 52, 2104, 2105, "-" +260, 17, 14, 530, 53, 54, 2106, 2107, "1" +260, 17, 15, 531, 55, 56, 2108, 2109, "." +260, 17, 16, 532, 57, 58, 2110, 2111, "0" +260, 17, 17, 533, 59, 61, 2112, 2114, "kg" +260, 17, 18, 534, 62, 66, 2115, 2119, "with" +260, 17, 19, 535, 67, 74, 2120, 2127, "placebo" +260, 17, 20, 536, 75, 76, 2128, 2129, "[" +260, 17, 21, 537, 77, 86, 2130, 2139, "estimated" +260, 17, 22, 538, 87, 96, 2140, 2149, "treatment" +260, 17, 23, 539, 97, 107, 2150, 2160, "difference" +260, 17, 24, 540, 108, 109, 2161, 2162, "1" +260, 17, 25, 541, 110, 111, 2163, 2164, "." +260, 17, 26, 542, 112, 114, 2165, 2167, "48" +260, 17, 27, 543, 115, 117, 2168, 2170, "kg" +260, 17, 28, 544, 118, 119, 2171, 2172, "(" +260, 17, 29, 545, 120, 122, 2173, 2175, "95" +260, 17, 30, 546, 123, 124, 2176, 2177, "%" +260, 17, 31, 547, 125, 127, 2178, 2180, "CI" +260, 17, 32, 548, 128, 129, 2181, 2182, "0" +260, 17, 33, 549, 130, 131, 2183, 2184, "." +260, 17, 34, 550, 132, 134, 2185, 2187, "90" +260, 17, 35, 551, 135, 136, 2188, 2189, ";" +260, 17, 36, 552, 137, 138, 2190, 2191, "2" +260, 17, 37, 553, 139, 140, 2192, 2193, "." +260, 17, 38, 554, 141, 143, 2194, 2196, "06" +260, 17, 39, 555, 144, 145, 2197, 2198, ")" +260, 17, 40, 556, 146, 147, 2199, 2200, ";" +260, 17, 41, 557, 148, 149, 2201, 2202, "P" +260, 17, 42, 558, 150, 151, 2203, 2204, "<" +260, 17, 43, 559, 152, 153, 2205, 2206, "0" +260, 17, 44, 560, 154, 155, 2207, 2208, "." +260, 17, 45, 561, 156, 159, 2209, 2212, "001" +260, 17, 46, 562, 160, 161, 2213, 2214, "]" +260, 17, 47, 563, 162, 163, 2215, 2216, "." +260, 18, 1, 564, 0, 9, 2217, 2226, "Confirmed" +260, 18, 2, 565, 10, 23, 2227, 2240, "hypoglycaemia" +260, 18, 3, 566, 24, 32, 2241, 2249, "occurred" +260, 18, 4, 567, 33, 35, 2250, 2252, "in" +260, 18, 5, 568, 36, 38, 2253, 2255, "41" +260, 18, 6, 569, 39, 40, 2256, 2257, "." +260, 18, 7, 570, 41, 42, 2258, 2259, "7" +260, 18, 8, 571, 43, 46, 2260, 2263, "and" +260, 18, 9, 572, 47, 49, 2264, 2266, "17" +260, 18, 10, 573, 50, 51, 2267, 2268, "." +260, 18, 11, 574, 52, 53, 2269, 2270, "1" +260, 18, 12, 575, 54, 55, 2271, 2272, "%" +260, 18, 13, 576, 56, 58, 2273, 2275, "of" +260, 18, 14, 577, 59, 67, 2276, 2284, "IDegLira" +260, 18, 15, 578, 68, 69, 2285, 2286, "-" +260, 18, 16, 579, 70, 73, 2287, 2290, "and" +260, 18, 17, 580, 74, 81, 2291, 2298, "placebo" +260, 18, 18, 581, 82, 83, 2299, 2300, "-" +260, 18, 19, 582, 84, 91, 2301, 2308, "treated" +260, 18, 20, 583, 92, 104, 2309, 2321, "participants" +260, 18, 21, 584, 105, 106, 2322, 2323, "," +260, 18, 22, 585, 107, 119, 2324, 2336, "respectively" +260, 18, 23, 586, 120, 121, 2337, 2338, "," +260, 18, 24, 587, 122, 126, 2339, 2343, "with" +260, 18, 25, 588, 127, 132, 2344, 2349, "rates" +260, 18, 26, 589, 133, 135, 2350, 2352, "of" +260, 18, 27, 590, 136, 137, 2353, 2354, "3" +260, 18, 28, 591, 138, 139, 2355, 2356, "." +260, 18, 29, 592, 140, 141, 2357, 2358, "5" +260, 18, 30, 593, 142, 144, 2359, 2361, "vs" +260, 18, 31, 594, 145, 146, 2362, 2363, "1" +260, 18, 32, 595, 147, 148, 2364, 2365, "." +260, 18, 33, 596, 149, 150, 2366, 2367, "4" +260, 18, 34, 597, 151, 157, 2368, 2374, "events" +260, 18, 35, 598, 158, 159, 2375, 2376, "/" +260, 18, 36, 599, 160, 167, 2377, 2384, "patient" +260, 18, 37, 600, 168, 169, 2385, 2386, "-" +260, 18, 38, 601, 170, 175, 2387, 2392, "years" +260, 18, 39, 602, 176, 178, 2393, 2395, "of" +260, 18, 40, 603, 179, 187, 2396, 2404, "exposure" +260, 18, 41, 604, 188, 189, 2405, 2406, "[" +260, 18, 42, 605, 190, 199, 2407, 2416, "estimated" +260, 18, 43, 606, 200, 204, 2417, 2421, "rate" +260, 18, 44, 607, 205, 210, 2422, 2427, "ratio" +260, 18, 45, 608, 211, 212, 2428, 2429, "3" +260, 18, 46, 609, 213, 214, 2430, 2431, "." +260, 18, 47, 610, 215, 217, 2432, 2434, "74" +260, 18, 48, 611, 218, 219, 2435, 2436, "(" +260, 18, 49, 612, 220, 222, 2437, 2439, "95" +260, 18, 50, 613, 223, 224, 2440, 2441, "%" +260, 18, 51, 614, 225, 227, 2442, 2444, "CI" +260, 18, 52, 615, 228, 229, 2445, 2446, "2" +260, 18, 53, 616, 230, 231, 2447, 2448, "." +260, 18, 54, 617, 232, 234, 2449, 2451, "28" +260, 18, 55, 618, 235, 236, 2452, 2453, ";" +260, 18, 56, 619, 237, 238, 2454, 2455, "6" +260, 18, 57, 620, 239, 240, 2456, 2457, "." +260, 18, 58, 621, 241, 243, 2458, 2460, "13" +260, 18, 59, 622, 244, 245, 2461, 2462, ")" +260, 18, 60, 623, 246, 247, 2463, 2464, ";" +260, 18, 61, 624, 248, 249, 2465, 2466, "P" +260, 18, 62, 625, 250, 251, 2467, 2468, "<" +260, 18, 63, 626, 252, 253, 2469, 2470, "0" +260, 18, 64, 627, 254, 255, 2471, 2472, "." +260, 18, 65, 628, 256, 259, 2473, 2476, "001" +260, 18, 66, 629, 260, 261, 2477, 2478, "]" +260, 18, 67, 630, 262, 263, 2479, 2480, "." +260, 19, 1, 631, 0, 8, 2481, 2489, "IDegLira" +260, 19, 2, 632, 9, 12, 2490, 2493, "was" +260, 19, 3, 633, 13, 22, 2494, 2503, "generally" +260, 19, 4, 634, 23, 27, 2504, 2508, "well" +260, 19, 5, 635, 28, 37, 2509, 2518, "tolerated" +260, 19, 6, 636, 38, 39, 2519, 2520, "." +260, 20, 1, 637, 0, 3, 2521, 2524, "The" +260, 20, 2, 638, 4, 9, 2525, 2530, "rates" +260, 20, 3, 639, 10, 12, 2531, 2533, "of" +260, 20, 4, 640, 13, 20, 2534, 2541, "serious" +260, 20, 5, 641, 21, 28, 2542, 2549, "adverse" +260, 20, 6, 642, 29, 35, 2550, 2556, "events" +260, 20, 7, 643, 36, 40, 2557, 2561, "were" +260, 20, 8, 644, 41, 43, 2562, 2564, "20" +260, 20, 9, 645, 44, 45, 2565, 2566, "." +260, 20, 10, 646, 46, 47, 2567, 2568, "3" +260, 20, 11, 647, 48, 51, 2569, 2572, "and" +260, 20, 12, 648, 52, 53, 2573, 2574, "8" +260, 20, 13, 649, 54, 55, 2575, 2576, "." +260, 20, 14, 650, 56, 57, 2577, 2578, "0" +260, 20, 15, 651, 58, 61, 2579, 2582, "per" +260, 20, 16, 652, 62, 65, 2583, 2586, "100" +260, 20, 17, 653, 66, 73, 2587, 2594, "patient" +260, 20, 18, 654, 74, 75, 2595, 2596, "-" +260, 20, 19, 655, 76, 81, 2597, 2602, "years" +260, 20, 20, 656, 82, 84, 2603, 2605, "of" +260, 20, 21, 657, 85, 93, 2606, 2614, "exposure" +260, 20, 22, 658, 94, 98, 2615, 2619, "with" +260, 20, 23, 659, 99, 107, 2620, 2628, "IDegLira" +260, 20, 24, 660, 108, 111, 2629, 2632, "and" +260, 20, 25, 661, 112, 119, 2633, 2640, "placebo" +260, 20, 26, 662, 120, 121, 2641, 2642, "," +260, 20, 27, 663, 122, 134, 2643, 2655, "respectively" +260, 20, 28, 664, 135, 136, 2656, 2657, "," +260, 20, 29, 665, 137, 144, 2658, 2665, "without" +260, 20, 30, 666, 145, 152, 2666, 2673, "obvious" +260, 20, 31, 667, 153, 161, 2674, 2682, "patterns" +260, 20, 32, 668, 162, 164, 2683, 2685, "in" +260, 20, 33, 669, 165, 168, 2686, 2689, "the" +260, 20, 34, 670, 169, 173, 2690, 2694, "type" +260, 20, 35, 671, 174, 176, 2695, 2697, "of" +260, 20, 36, 672, 177, 183, 2698, 2704, "events" +260, 20, 37, 673, 184, 185, 2705, 2706, "." +260, 21, 1, 674, 0, 11, 2707, 2718, "CONCLUSIONS" +260, 21, 2, 675, 12, 13, 2719, 2720, ":" +260, 21, 3, 676, 14, 22, 2721, 2729, "IDegLira" +260, 21, 4, 677, 23, 26, 2730, 2733, "can" +260, 21, 5, 678, 27, 29, 2734, 2736, "be" +260, 21, 6, 679, 30, 34, 2737, 2741, "used" +260, 21, 7, 680, 35, 37, 2742, 2744, "in" +260, 21, 8, 681, 38, 44, 2745, 2751, "people" +260, 21, 9, 682, 45, 57, 2752, 2764, "uncontrolled" +260, 21, 10, 683, 58, 62, 2765, 2769, "with" +260, 21, 11, 684, 63, 76, 2770, 2783, "sulphonylurea" +260, 21, 12, 685, 77, 78, 2784, 2785, "±" +260, 21, 13, 686, 79, 88, 2786, 2795, "metformin" +260, 21, 14, 687, 89, 91, 2796, 2798, "to" +260, 21, 15, 688, 92, 99, 2799, 2806, "improve" +260, 21, 16, 689, 100, 108, 2807, 2815, "efficacy" +260, 21, 17, 690, 109, 113, 2816, 2820, "with" +260, 21, 18, 691, 114, 115, 2821, 2822, "a" +260, 21, 19, 692, 116, 122, 2823, 2829, "safety" +260, 21, 20, 693, 123, 130, 2830, 2837, "profile" +260, 21, 21, 694, 131, 133, 2838, 2840, "in" +260, 21, 22, 695, 134, 138, 2841, 2845, "line" +260, 21, 23, 696, 139, 143, 2846, 2850, "with" +260, 21, 24, 697, 144, 152, 2851, 2859, "previous" +260, 21, 25, 698, 153, 157, 2860, 2864, "DUAL" +260, 21, 26, 699, 158, 164, 2865, 2871, "trials" +260, 21, 27, 700, 165, 166, 2872, 2873, "." +260, 22, 1, 701, 0, 1, 2874, 2875, "©" +260, 22, 2, 702, 2, 6, 2876, 2880, "2016" +260, 22, 3, 703, 7, 15, 2881, 2889, "Diabetes" +260, 22, 4, 704, 16, 18, 2890, 2892, "UK" +260, 22, 5, 705, 19, 20, 2893, 2894, "." +260, 23, 1, 706, 0, 3, 2895, 2898, "DOI" +260, 23, 2, 707, 4, 5, 2899, 2900, ":" +260, 23, 3, 708, 6, 8, 2901, 2903, "10" +260, 23, 4, 709, 9, 10, 2904, 2905, "." +260, 23, 5, 710, 11, 15, 2906, 2910, "1111" +260, 23, 6, 711, 16, 17, 2911, 2912, "/" +260, 23, 7, 712, 18, 21, 2913, 2916, "dme" +260, 23, 8, 713, 22, 23, 2917, 2918, "." +260, 23, 9, 714, 24, 29, 2919, 2924, "13256" +260, 23, 10, 715, 30, 35, 2925, 2930, "PMCID" +260, 23, 11, 716, 36, 37, 2931, 2932, ":" +260, 23, 12, 717, 38, 48, 2933, 2943, "PMC5811787" +260, 23, 13, 718, 49, 53, 2944, 2948, "PMID" +260, 23, 14, 719, 54, 55, 2949, 2950, ":" +260, 23, 15, 720, 56, 64, 2951, 2959, "27589252" +260, 23, 16, 721, 65, 66, 2960, 2961, "[" +260, 23, 17, 722, 67, 74, 2962, 2969, "Indexed" +260, 23, 18, 723, 75, 78, 2970, 2973, "for" +260, 23, 19, 724, 79, 86, 2974, 2981, "MEDLINE" +260, 23, 20, 725, 87, 88, 2982, 2983, "]" diff --git a/data/dm2 27589252_kwoodley.annodb b/data/dm2 27589252_kwoodley.annodb new file mode 100644 index 0000000..56ce383 --- /dev/null +++ b/data/dm2 27589252_kwoodley.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +64147, Journal, 0, 10, "Diabet Med", "", +64148, PublicationYear, 13, 17, "2017", "", +64174, Title, 97, 297, "Safety and efficacy of insulin degludec / liraglutide ( IDegLira ) added to sulphonylurea alone or to sulphonylurea and metformin in insulin - na ï ve people with Type 2 diabetes : the DUAL IV trial .", "", +64149, InsulinDegludec, 120, 136, "insulin degludec", "", +64152, Liraglutide, 139, 150, "liraglutide", "", +64155, FixedCombDrug, 153, 161, "IDegLira", "", +64163, Sulfonylureas, 173, 186, "sulphonylurea", "", +64166, Sulfonylureas, 199, 212, "sulphonylurea", "", +64167, Metformin, 217, 226, "metformin", "", +64173, Precondition, 230, 275, "insulin - na ï ve people with Type 2 diabetes", "", +64169, Type2Diabetes, 260, 275, "Type 2 diabetes", "", +64175, Author, 298, 308, "Rodbard HW", "", +64176, Author, 317, 324, "Bode BW", "", +64177, Author, 333, 342, "Harris SB", "", +64178, Author, 351, 357, "Rose L", "", +64179, Author, 366, 375, "Lehmann L", "", +64180, Author, 384, 392, "Jarlov H", "", +64181, Author, 401, 410, "Thurman J", "", +64182, Liraglutide, 434, 445, "Liraglutide", "", +64183, InsulinDegludec, 450, 466, "insulin degludec", "", +64184, USA, 583, 586, "USA", "", +64185, USA, 640, 643, "USA", "", +64187, Canada, 706, 712, "Canada", "", +64188, Germany, 767, 774, "Germany", "", +64189, Country, 815, 822, "Denmark", "", +64186, USA, 871, 874, "USA", "", +64192, ObjectiveDescription, 883, 1092, "To investigate the safety and efficacy of insulin degludec / liraglutide ( IDegLira ) , a novel combination product , as add - on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy .", "", +64150, InsulinDegludec, 925, 941, "insulin degludec", "", +64153, Liraglutide, 944, 955, "liraglutide", "", +64156, FixedCombDrug, 958, 966, "IDegLira", "", +64191, Precondition, 1025, 1090, "people with Type 2 diabetes uncontrolled on sulphonylurea therapy", "", +64170, Type2Diabetes, 1037, 1052, "Type 2 diabetes", "", +64190, Sulfonylureas, 1069, 1082, "sulphonylurea", "", +64193, Duration, 1111, 1120, "26 - week", "", +64194, DoubleBlind, 1123, 1137, "double - blind", "", +64200, Precondition, 1146, 1222, "adults with Type 2 diabetes [ HbA1c 53 - 75 mmol / mol ( 7 . 0 - 9 . 0 % ) ]", "", +64195, Type2Diabetes, 1158, 1173, "Type 2 diabetes", "", +64196, HbA1c, 1176, 1181, "HbA1c", "", +64197, BioAndMedicalUnit, 1190, 1200, "mmol / mol", "", +64198, Percentage, 1217, 1218, "%", "", +64199, Randomized, 1228, 1238, "randomized", "", +64165, FixedCombDrug, 1242, 1250, "IDegLira", "", +64201, NumberPatientsArm, 1257, 1260, "289", "", +64203, Placebo, 1266, 1273, "placebo", "", +64202, NumberPatientsArm, 1280, 1283, "146", "", +64164, Sulfonylureas, 1313, 1326, "sulphonylurea", "", +64168, Metformin, 1329, 1338, "metformin", "", +64210, FastingBloodGlucose_target, 1356, 1406, "fasting glycaemic target of 4 . 0 - 6 . 0 mmol / l", "", +64215, DoseDescription, 1409, 1487, "Treatment initiation was at 10 dose steps , and maximum dose was 50 dose steps", "", +64211, DoseValue, 1490, 1492, "50", "", +64213, BioAndMedicalUnit, 1493, 1498, "units", "", +64151, InsulinDegludec, 1499, 1515, "insulin degludec", "", +64212, DoseValue, 1518, 1523, "1 . 8", "", +64214, mg, 1524, 1526, "mg", "", +64154, Liraglutide, 1527, 1538, "liraglutide", "", +64216, HbA1c, 1562, 1567, "HbA1c", "", +64217, BaseLineValue, 1583, 1585, "63", "", +64218, BioAndMedicalUnit, 1586, 1596, "mmol / mol", "", +64222, BaseLineValue, 1599, 1604, "7 . 9", "", +64223, Percentage, 1605, 1606, "%", "", +64227, ResultMeasuredValue, 1612, 1614, "46", "", +64219, BioAndMedicalUnit, 1615, 1625, "mmol / mol", "", +64228, ResultMeasuredValue, 1628, 1633, "6 . 4", "", +64224, Percentage, 1634, 1635, "%", "", +64157, FixedCombDrug, 1643, 1651, "IDegLira", "", +64229, ResultMeasuredValue, 1659, 1661, "57", "", +64220, BioAndMedicalUnit, 1662, 1672, "mmol / mol", "", +64230, ResultMeasuredValue, 1675, 1680, "7 . 4", "", +64225, Percentage, 1681, 1682, "%", "", +64204, Placebo, 1690, 1697, "placebo", "", +64231, DiffGroupRelValue, 1731, 1735, "- 11", "", +64221, BioAndMedicalUnit, 1736, 1746, "mmol / mol", "", +64233, ConfIntervalDiff, 1749, 1768, "95 % CI - 13 ; - 10", "", +64248, DiffGroupAbsValue, 1774, 1782, "- 1 . 02", "", +64226, Percentage, 1783, 1784, "%", "", +64234, ConfIntervalDiff, 1787, 1814, "95 % CI - 1 . 18 ; - 0 . 87", "", +64235, PvalueDiff, 1819, 1830, "P < 0 . 001", "", +64236, HbA1c_target, 1839, 1878, "HbA1c target of 53 mmol / mol ( < 7 % )", "", +64237, PercentageAffected, 1895, 1901, "79 . 2", "", +64159, FixedCombDrug, 1927, 1935, "IDegLira", "", +64238, PercentageAffected, 1945, 1951, "28 . 8", "", +64205, Placebo, 1961, 1968, "placebo", "", +64239, ConfIntervalNumAffected, 2008, 2032, "95 % CI 7 . 22 ; 19 . 77", "", +64240, PvalueDiff, 2037, 2048, "P < 0 . 001", "", +64241, BodyWeight, 2058, 2071, "weight change", "", +64242, Increment, 2078, 2083, "0 . 5", "", +64243, Kg, 2084, 2086, "kg", "", +64158, FixedCombDrug, 2092, 2100, "IDegLira", "", +64246, Reduction, 2106, 2111, "1 . 0", "", +64244, Kg, 2112, 2114, "kg", "", +64206, Placebo, 2120, 2127, "placebo", "", +64247, DiffGroupAbsValue, 2161, 2167, "1 . 48", "", +64245, Kg, 2168, 2170, "kg", "", +64249, ConfIntervalDiff, 2173, 2196, "95 % CI 0 . 90 ; 2 . 06", "", +64250, PvalueDiff, 2201, 2212, "P < 0 . 001", "", +64251, Hypoglycemia, 2227, 2240, "hypoglycaemia", "", +64252, PercentageAffected, 2253, 2259, "41 . 7", "", +64253, PercentageAffected, 2264, 2270, "17 . 1", "", +64160, FixedCombDrug, 2276, 2284, "IDegLira", "", +64207, Placebo, 2291, 2298, "placebo", "", +64254, ResultMeasuredValue, 2353, 2358, "3 . 5", "", +64255, ResultMeasuredValue, 2362, 2367, "1 . 4", "", +64256, BioAndMedicalUnit, 2368, 2392, "events / patient - years", "", +64257, ConfIntervalDiff, 2437, 2460, "95 % CI 2 . 28 ; 6 . 13", "", +64258, PvalueDiff, 2465, 2476, "P < 0 . 001", "", +64209, FixedCombDrug, 2481, 2489, "IDegLira", "", +64259, EndPointDescription, 2534, 2556, "serious adverse events", "", +64260, ResultMeasuredValue, 2562, 2568, "20 . 3", "", +64261, ResultMeasuredValue, 2573, 2578, "8 . 0", "", +64262, BioAndMedicalUnit, 2583, 2602, "100 patient - years", "", +64161, FixedCombDrug, 2620, 2628, "IDegLira", "", +64208, Placebo, 2633, 2640, "placebo", "", +64263, ConclusionComment, 2721, 2873, "IDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials .", "", +64162, FixedCombDrug, 2721, 2729, "IDegLira", "", +64171, Sulfonylureas, 2770, 2783, "sulphonylurea", "", +64172, Metformin, 2786, 2795, "metformin", "", +64264, PMID, 2951, 2959, "27589252", "", diff --git a/data/dm2 27589252_kwoodley.n-triples b/data/dm2 27589252_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27589252_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27650977_admin.annodb b/data/dm2 27650977_admin.annodb new file mode 100644 index 0000000..0abdb03 --- /dev/null +++ b/data/dm2 27650977_admin.annodb @@ -0,0 +1,139 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2016", "", " \"2016\"." +154, Title, 72, 292, "Efficacy and Safety of LixiLan , a Titratable Fixed - Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin : The LixiLan - L Randomized Trial .", "", " \"Efficacy and Safety of LixiLan , a Titratable Fixed - Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin : The LixiLan - L Randomized Trial .\"." +25, FixedCombDrug, 95, 102, "LixiLan", "", +96789, FixedCombDrug, 147, 181, "Insulin Glargine Plus Lixisenatide", "", +24, InsulinGlargine, 147, 163, "Insulin Glargine", "", +96787, Lixisenatide, 169, 181, "Lixisenatide", "", +3, Type2Diabetes, 185, 200, "Type 2 Diabetes", "", " ." +155, Precondition, 185, 255, "Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin", "", " \"Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin\"." +5, Insulin, 228, 241, "Basal Insulin", "", +6, Metformin, 246, 255, "Metformin", "", +26, FixedCombDrug, 262, 269, "LixiLan", "", +7, Randomized, 274, 284, "Randomized", "", " ." +8, Author, 293, 301, "Aroda VR", "", " \"Aroda VR\"." +9, Author, 310, 322, "Rosenstock J", "", " \"Rosenstock J\"." +10, Author, 331, 339, "Wysham C", "", " \"Wysham C\"." +11, Author, 348, 355, "Unger J", "", " \"Unger J\"." +12, Author, 364, 373, "Bellido D", "", " \"Bellido D\"." +13, Author, 382, 405, "Gonz á lez - G á lvez G", "", " \"Gonz á lez - G á lvez G\"." +14, Author, 414, 422, "Takami A", "", " \"Takami A\"." +15, Author, 431, 436, "Guo H", "", " \"Guo H\"." +16, Author, 445, 457, "Niemoeller E", "", " \"Niemoeller E\"." +17, Author, 466, 475, "Souhami E", "", " \"Souhami E\"." +18, Author, 485, 498, "Bergenstal RM", "", " \"Bergenstal RM\"." +27, FixedCombDrug, 508, 515, "LixiLan", "", +167, USA, 720, 722, "TX", "", +168, USA, 759, 761, "WA", "", +169, USA, 808, 810, "CA", "", +19, Spain, 904, 909, "Spain", "", +20, Mexico, 1094, 1100, "Mexico", "", +21, Japan, 1126, 1131, "Japan", "", +175, UK, 1190, 1192, "NJ", "", +22, Germany, 1242, 1249, "Germany", "", +23, France, 1296, 1302, "France", "", +176, USA, 1390, 1392, "MN", "", +37, ObjectiveDescription, 1462, 1664, "This study was conducted to demonstrate the efficacy and safety of LixiLan ( iGlarLixi ) , a novel , titratable , fixed - ratio combination of insulin glargine ( iGlar ) ( 100 units ) and lixisenatide ,", "", " \"This study was conducted to demonstrate the efficacy and safety of LixiLan ( iGlarLixi ) , a novel , titratable , fixed - ratio combination of insulin glargine ( iGlar ) ( 100 units ) and lixisenatide ,\"." +28, FixedCombDrug, 1529, 1536, "LixiLan", "", +54, FixedCombDrug, 1539, 1548, "iGlarLixi", "", +29, InsulinGlargine, 1605, 1621, "insulin glargine", "", +31, InsulinGlargine, 1624, 1629, "iGlar", "", +177, DoseValue, 1634, 1637, "100", "", +178, BioAndMedicalUnit, 1638, 1643, "units", "", +96790, Lixisenatide, 1650, 1662, "lixisenatide", "", +38, ObjectiveDescription, 1665, 1817, "compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents .", "", " \"compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents .\"." +32, InsulinGlargine, 1679, 1684, "iGlar", "", +182, Precondition, 1688, 1815, "patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents", "", " \"patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents\"." +33, Type2Diabetes, 1702, 1717, "type 2 diabetes", "", +35, Insulin, 1745, 1758, "basal insulin", "", +36, OralAntidiabeticAgent, 1785, 1815, "oral glucose - lowering agents", "", +39, Duration, 1856, 1864, "6 - week", "", +40, InsulinGlargine, 1879, 1884, "iGlar", "", +41, OralAntidiabeticAgent, 1932, 1955, "oral antidiabetic drugs", "", +42, Metformin, 1967, 1976, "metformin", "", +44, NumberPatientsCT, 1992, 1995, "736", "", " \"736\"." +43, Insulin, 1996, 2009, "basal insulin", "", +45, Mean, 2031, 2035, "mean", "", +47, Year, 2057, 2062, "years", "", +48, BMI, 2065, 2068, "BMI", "", +49, Kg_per_squareMeter, 2072, 2079, "kg / m2", "", +51, Randomized, 2087, 2097, "randomized", "", +194, AllocationRatio, 2098, 2103, "1 : 1", "", " . ." +52, OpenLabel, 2107, 2119, "open - label", "", " ." +53, Frequency, 2122, 2134, "once - daily", "", " ." +55, FixedCombDrug, 2135, 2144, "iGlarLixi", "", " . ." +56, InsulinGlargine, 2148, 2153, "iGlar", "", " ." +124, DoseDescription, 2161, 2269, "titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day", "", " \"titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day\". \"titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day\"." +57, FastingPlasmaGlucose_target, 2173, 2230, "fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L )", "", +58, Mg_per_deciliter, 2202, 2209, "mg / dL", "", +200, Millimoles_per_litre, 2220, 2228, "mmol / L", "", +96791, Int_Unit, 2258, 2263, "units", "", " . ." +96792, Interval, 2266, 2269, "day", "", +61, HbA1c, 2306, 2311, "HbA1c", "", +96793, Duration, 2322, 2330, "30 weeks", "", " \"30 weeks\"." +63, HbA1c, 2343, 2348, "HbA1c", "", +208, BaseLineValue, 2364, 2369, "8 . 5", "", +64, Percentage, 2370, 2371, "%", "", " ." +209, BaseLineValue, 2374, 2376, "69", "", +66, ConcentrationUnit, 2377, 2387, "mmol / mol", "", +220, ResultMeasuredValue, 2393, 2398, "8 . 1", "", +65, Percentage, 2399, 2400, "%", "", +221, ResultMeasuredValue, 2403, 2405, "65", "", +67, ConcentrationUnit, 2406, 2416, "mmol / mol", "", +205, TimePoint, 2419, 2445, "during the run - in period", "", +70, Randomized, 2454, 2467, "randomization", "", +71, FixedCombDrug, 2470, 2479, "iGlarLixi", "", +72, HbA1c, 2509, 2514, "HbA1c", "", " ." +76, TimePoint, 2520, 2528, "baseline", "", +73, InsulinGlargine, 2543, 2548, "iGlar", "", +224, Reduction, 2553, 2558, "1 . 1", "", " \"1 . 1\"." +74, Percentage, 2559, 2560, "%", "", +225, Reduction, 2568, 2573, "0 . 6", "", " \"0 . 6\"." +75, Percentage, 2574, 2575, "%", "", +226, PvalueDiff, 2578, 2590, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +77, Mean, 2606, 2610, "mean", "", " . ." +78, HbA1c, 2617, 2622, "HbA1c", "", +228, ResultMeasuredValue, 2626, 2631, "6 . 9", "", " \"6 . 9\"." +79, Percentage, 2632, 2633, "%", "", +229, ResultMeasuredValue, 2636, 2638, "52", "", +85, ConcentrationUnit, 2639, 2649, "mmol / mol", "", +230, ResultMeasuredValue, 2666, 2671, "7 . 5", "", " \"7 . 5\"." +80, Percentage, 2672, 2673, "%", "", +231, ResultMeasuredValue, 2676, 2678, "58", "", +86, ConcentrationUnit, 2679, 2689, "mmol / mol", "", +81, InsulinGlargine, 2696, 2701, "iGlar", "", +91, HbA1c_target, 2704, 2737, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", " ." +92, Percentage, 2718, 2719, "%", "", +93, ConcentrationUnit, 2725, 2735, "mmol / mol", "", +99, PercentageAffected, 2754, 2756, "55", "", " \"55\"." +94, FixedCombDrug, 2762, 2771, "iGlarLixi", "", +98, PercentageAffected, 2795, 2797, "30", "", " \"30\"." +95, InsulinGlargine, 2803, 2808, "iGlar", "", +100, Mean, 2811, 2815, "Mean", "", " . ." +101, BodyWeight, 2816, 2827, "body weight", "", " ." +105, Reduction, 2841, 2846, "0 . 7", "", " \"0 . 7\"." +102, Kg, 2847, 2849, "kg", "", " ." +107, FixedCombDrug, 2855, 2864, "iGlarLixi", "", +106, Increment, 2882, 2887, "0 . 7", "", " \"0 . 7\"." +103, Kg, 2888, 2890, "kg", "", +108, InsulinGlargine, 2896, 2901, "iGlar", "", +109, DiffGroupAbsValue, 2904, 2909, "1 . 4", "", " \"1 . 4\"." +104, Kg, 2910, 2912, "kg", "", +110, PvalueDiff, 2926, 2938, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +245, ObservedResult, 2943, 3027, "Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups .", "", " \"Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups .\". \"Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups .\"." +243, SymptomaticHypoglycemia, 2954, 2978, "symptomatic hypoglycemia", "", " ." +112, Mg_per_deciliter, 2986, 2993, "mg / dL", "", +247, ObservedResult, 3028, 3114, "Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi .", "", " \"Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi .\"." +246, GastrointestinalProblem, 3033, 3065, "gastrointestinal adverse effects", "", " ." +113, FixedCombDrug, 3103, 3112, "iGlarLixi", "", +253, ConclusionComment, 3129, 3321, "Compared with iGlar , a substantially higher proportion of iGlarLixi - treated patients achieved glycemic targets with a beneficial effect on body weight , no additional risk of hypoglycemia ,", "", " \"Compared with iGlar , a substantially higher proportion of iGlarLixi - treated patients achieved glycemic targets with a beneficial effect on body weight , no additional risk of hypoglycemia ,\"." +115, InsulinGlargine, 3143, 3148, "iGlar", "", +114, FixedCombDrug, 3188, 3197, "iGlarLixi", "", +116, BodyWeight, 3271, 3282, "body weight", "", +117, Hypoglycemia, 3307, 3319, "hypoglycemia", "", +254, ConclusionComment, 3322, 3461, "and low levels of gastrointestinal adverse effects in inadequately controlled , basal insulin - treated , long - standing type 2 diabetes .", "", " \"and low levels of gastrointestinal adverse effects in inadequately controlled , basal insulin - treated , long - standing type 2 diabetes .\"." +250, GastrointestinalProblem, 3340, 3372, "gastrointestinal adverse effects", "", +119, Insulin, 3402, 3415, "basal insulin", "", +118, Type2Diabetes, 3444, 3459, "type 2 diabetes", "", +123, PMID, 3545, 3553, "27650977", "", " \"27650977\"." diff --git a/data/dm2 27650977_admin.n-triples b/data/dm2 27650977_admin.n-triples new file mode 100644 index 0000000..7e2339f --- /dev/null +++ b/data/dm2 27650977_admin.n-triples @@ -0,0 +1,174 @@ +# RDF export of group: Publication + . + "Publication 74641" . + "Efficacy and Safety of LixiLan , a Titratable Fixed - Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin : The LixiLan - L Randomized Trial ." . + "Aroda VR" . + "2016" . + "Diabetes Care" . + "27650977" . + . + "Rosenstock J" . + "Wysham C" . + "Unger J" . + "Bellido D" . + "Gonz á lez - G á lvez G" . + "Takami A" . + "Guo H" . + "Niemoeller E" . + "Souhami E" . + "Bergenstal RM" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 74648" . + "This study was conducted to demonstrate the efficacy and safety of LixiLan ( iGlarLixi ) , a novel , titratable , fixed - ratio combination of insulin glargine ( iGlar ) ( 100 units ) and lixisenatide ," . + "736" . + "30 weeks" . + . + . + . + . + "Compared with iGlar , a substantially higher proportion of iGlarLixi - treated patients achieved glycemic targets with a beneficial effect on body weight , no additional risk of hypoglycemia ," . + . + . + . + . + . + . + "and low levels of gastrointestinal adverse effects in inadequately controlled , basal insulin - treated , long - standing type 2 diabetes ." . + . + "compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents ." . + . +# RDF export of group: Population + . + "Population 74664" . + "Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin" . + . + . + . + "patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "gas" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + . + . + . + . + . + . + . + "gl" . + . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + "once - daily" . + . + . + "gla" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "lix" . + . + . + . + . + "titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day" . + . + "gla" . + . + . + . + "titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day" . +# RDF export of group: Outcome + . + "hba 1" . + . + "6 . 9" . + "1 . 1" . + . + "hba 2" . + . + "7 . 5" . + "0 . 6" . + . + "hbat 1" . + . + "55" . + . + "hbat 2" . + . + "30" . + . + "bw 1" . + . + "0 . 7" . + . + "bw 2" . + . + "0 . 7" . + . + "hyp 1" . + . + "Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups ." . + . + "hyp 2" . + . + "Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups ." . + . + "gas 1" . + . + "Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi ." . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "P < 0 . 0001" . + . + . + . + "bw" . + "1 . 4" . + "P < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27650977_akramersunderbrink.annodb b/data/dm2 27650977_akramersunderbrink.annodb new file mode 100644 index 0000000..020e764 --- /dev/null +++ b/data/dm2 27650977_akramersunderbrink.annodb @@ -0,0 +1,126 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66754, Journal, 0, 13, "Diabetes Care", "", +66755, PublicationYear, 16, 20, "2016", "", +66784, FixedCombDrug, 95, 102, "LixiLan", "", +66782, InsulinGlargine, 147, 163, "Insulin Glargine", "", +66758, Drug, 169, 181, "Lixisenatide", "", +66759, Type2Diabetes, 185, 200, "Type 2 Diabetes", "", +66760, Precondition, 201, 255, "Inadequately Controlled on Basal Insulin and Metformin", "", +66761, Insulin, 228, 241, "Basal Insulin", "", +66762, Metformin, 246, 255, "Metformin", "", +66785, FixedCombDrug, 262, 269, "LixiLan", "", +66764, Randomized, 274, 284, "Randomized", "", +66765, Author, 293, 301, "Aroda VR", "", +66766, Author, 310, 322, "Rosenstock J", "", +66767, Author, 331, 339, "Wysham C", "", +66768, Author, 348, 355, "Unger J", "", +66769, Author, 364, 373, "Bellido D", "", +66770, Author, 382, 405, "Gonz á lez - G á lvez G", "", +66771, Author, 414, 422, "Takami A", "", +66772, Author, 431, 436, "Guo H", "", +66773, Author, 445, 457, "Niemoeller E", "", +66774, Author, 466, 475, "Souhami E", "", +66775, Author, 485, 498, "Bergenstal RM", "", +66786, FixedCombDrug, 508, 515, "LixiLan", "", +66777, Spain, 904, 909, "Spain", "", +66778, Mexico, 1094, 1100, "Mexico", "", +66779, Japan, 1126, 1131, "Japan", "", +66780, Germany, 1242, 1249, "Germany", "", +66781, France, 1296, 1302, "France", "", +66796, ObjectiveDescription, 1462, 1664, "This study was conducted to demonstrate the efficacy and safety of LixiLan ( iGlarLixi ) , a novel , titratable , fixed - ratio combination of insulin glargine ( iGlar ) ( 100 units ) and lixisenatide ,", "", +66787, FixedCombDrug, 1529, 1536, "LixiLan", "", +66815, FixedCombDrug, 1539, 1548, "iGlarLixi", "", +66788, InsulinGlargine, 1605, 1621, "insulin glargine", "", +66790, InsulinGlargine, 1624, 1629, "iGlar", "", +66789, Drug, 1650, 1662, "lixisenatide", "", +66799, ObjectiveDescription, 1665, 1817, "compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents .", "", +66791, InsulinGlargine, 1679, 1684, "iGlar", "", +66792, Type2Diabetes, 1702, 1717, "type 2 diabetes", "", +66793, Precondition, 1718, 1815, "inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents", "", +66794, Insulin, 1745, 1758, "basal insulin", "", +66795, OralAntidiabeticAgent, 1785, 1815, "oral glucose - lowering agents", "", +66800, Duration, 1856, 1864, "6 - week", "", +66801, InsulinGlargine, 1879, 1884, "iGlar", "", +66802, OralAntidiabeticAgent, 1932, 1955, "oral antidiabetic drugs", "", +66803, Metformin, 1967, 1976, "metformin", "", +66805, NumberPatientsCT, 1992, 1995, "736", "", +66804, Insulin, 1996, 2009, "basal insulin", "", +66806, Mean, 2031, 2035, "mean", "", +66807, Precondition, 2031, 2062, "mean diabetes duration 12 years", "", +66808, Year, 2057, 2062, "years", "", +66809, BMI, 2065, 2068, "BMI", "", +66811, Precondition, 2065, 2079, "BMI 31 kg / m2", "", +66810, Kg_per_squareMeter, 2072, 2079, "kg / m2", "", +66812, Randomized, 2087, 2097, "randomized", "", +66813, OpenLabel, 2107, 2119, "open - label", "", +66814, Frequency, 2122, 2134, "once - daily", "", +66816, FixedCombDrug, 2135, 2144, "iGlarLixi", "", +66817, InsulinGlargine, 2148, 2153, "iGlar", "", +67011, DoseDescription, 2161, 2269, "titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day", "", +66818, FastingPlasmaGlucose_target, 2173, 2230, "fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L )", "", +66819, Mg_per_deciliter, 2202, 2209, "mg / dL", "", +66820, Millimoles_per_litre, 2220, 2230, "mmol / L )", "", +66822, BioAndMedicalUnit, 2258, 2269, "units / day", "", +66825, HbA1c, 2306, 2311, "HbA1c", "", +66826, TimePoint, 2322, 2330, "30 weeks", "", +66827, HbA1c, 2343, 2348, "HbA1c", "", +66828, Percentage, 2370, 2371, "%", "", +66830, ConcentrationUnit, 2377, 2387, "mmol / mol", "", +66832, BaseLineValue, 2393, 2398, "8 . 1", "", +66829, Percentage, 2399, 2400, "%", "", +66833, BaseLineValue, 2403, 2405, "65", "", +66831, ConcentrationUnit, 2406, 2416, "mmol / mol", "", +66834, Randomized, 2454, 2467, "randomization", "", +66835, FixedCombDrug, 2470, 2479, "iGlarLixi", "", +66836, HbA1c, 2509, 2514, "HbA1c", "", +66840, TimePoint, 2520, 2528, "baseline", "", +66837, InsulinGlargine, 2543, 2548, "iGlar", "", +66846, ChangeValue, 2551, 2558, "- 1 . 1", "", +66838, Percentage, 2559, 2560, "%", "", +66847, ChangeValue, 2566, 2573, "- 0 . 6", "", +66839, Percentage, 2574, 2575, "%", "", +66848, PValueChangeValue, 2578, 2590, "P < 0 . 0001", "", +66841, Mean, 2606, 2610, "mean", "", +66842, HbA1c, 2617, 2622, "HbA1c", "", +66851, EndPointDescription, 2626, 2631, "6 . 9", "", +66843, Percentage, 2632, 2633, "%", "", +66852, EndPointDescription, 2636, 2638, "52", "", +66849, ConcentrationUnit, 2639, 2649, "mmol / mol", "", +66853, EndPointDescription, 2666, 2671, "7 . 5", "", +66844, Percentage, 2672, 2673, "%", "", +66854, EndPointDescription, 2676, 2678, "58", "", +66850, ConcentrationUnit, 2679, 2689, "mmol / mol", "", +66845, InsulinGlargine, 2696, 2701, "iGlar", "", +66855, HbA1c_target, 2704, 2737, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", +66856, Percentage, 2718, 2719, "%", "", +66857, ConcentrationUnit, 2725, 2735, "mmol / mol", "", +66863, PercentageAffected, 2754, 2756, "55", "", +66860, Percentage, 2757, 2758, "%", "", +66858, FixedCombDrug, 2762, 2771, "iGlarLixi", "", +66862, PercentageAffected, 2795, 2797, "30", "", +66861, Percentage, 2798, 2799, "%", "", +66859, InsulinGlargine, 2803, 2808, "iGlar", "", +66864, Mean, 2811, 2815, "Mean", "", +66865, BodyWeight, 2816, 2827, "body weight", "", +66869, Reduction, 2841, 2846, "0 . 7", "", +66866, Kg, 2847, 2849, "kg", "", +66871, FixedCombDrug, 2855, 2864, "iGlarLixi", "", +66870, Increment, 2882, 2887, "0 . 7", "", +66867, Kg, 2888, 2890, "kg", "", +66872, InsulinGlargine, 2896, 2901, "iGlar", "", +66873, DiffGroupAbsValue, 2904, 2909, "1 . 4", "", +66868, Kg, 2910, 2912, "kg", "", +66874, PvalueDiff, 2926, 2938, "P < 0 . 0001", "", +66875, SymptomaticHypoglycemia, 2943, 2995, "Documented symptomatic hypoglycemia ( ≤ 70 mg / dL )", "", +66876, Mg_per_deciliter, 2986, 2993, "mg / dL", "", +66877, FixedCombDrug, 3103, 3112, "iGlarLixi", "", +66879, InsulinGlargine, 3143, 3148, "iGlar", "", +66878, FixedCombDrug, 3188, 3197, "iGlarLixi", "", +66880, BodyWeight, 3271, 3282, "body weight", "", +66881, Hypoglycemia, 3307, 3319, "hypoglycemia", "", +66884, Precondition, 3376, 3399, "inadequately controlled", "", +66883, Insulin, 3402, 3415, "basal insulin", "", +66885, Precondition, 3402, 3425, "basal insulin - treated", "", +66886, Precondition, 3428, 3459, "long - standing type 2 diabetes", "", +66882, Type2Diabetes, 3444, 3459, "type 2 diabetes", "", +66887, PMID, 3545, 3553, "27650977", "", diff --git a/data/dm2 27650977_akramersunderbrink.n-triples b/data/dm2 27650977_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27650977_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27650977_export.csv b/data/dm2 27650977_export.csv new file mode 100644 index 0000000..a29379e --- /dev/null +++ b/data/dm2 27650977_export.csv @@ -0,0 +1,776 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +259, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +259, 1, 2, 2, 9, 13, 9, 13, "Care" +259, 1, 3, 3, 14, 15, 14, 15, "." +259, 2, 1, 4, 0, 4, 16, 20, "2016" +259, 2, 2, 5, 5, 8, 21, 24, "Nov" +259, 2, 3, 6, 9, 10, 25, 26, ";" +259, 2, 4, 7, 11, 13, 27, 29, "39" +259, 2, 5, 8, 14, 15, 30, 31, "(" +259, 2, 6, 9, 16, 18, 32, 34, "11" +259, 2, 7, 10, 19, 20, 35, 36, ")" +259, 2, 8, 11, 21, 22, 37, 38, ":" +259, 2, 9, 12, 23, 27, 39, 43, "1972" +259, 2, 10, 13, 28, 29, 44, 45, "-" +259, 2, 11, 14, 30, 34, 46, 50, "1980" +259, 2, 12, 15, 35, 36, 51, 52, "." +259, 3, 1, 16, 0, 4, 53, 57, "Epub" +259, 3, 2, 17, 5, 9, 58, 62, "2016" +259, 3, 3, 18, 10, 13, 63, 66, "Sep" +259, 3, 4, 19, 14, 16, 67, 69, "20" +259, 3, 5, 20, 17, 18, 70, 71, "." +259, 4, 1, 21, 0, 8, 72, 80, "Efficacy" +259, 4, 2, 22, 9, 12, 81, 84, "and" +259, 4, 3, 23, 13, 19, 85, 91, "Safety" +259, 4, 4, 24, 20, 22, 92, 94, "of" +259, 4, 5, 25, 23, 30, 95, 102, "LixiLan" +259, 4, 6, 26, 31, 32, 103, 104, "," +259, 4, 7, 27, 33, 34, 105, 106, "a" +259, 4, 8, 28, 35, 45, 107, 117, "Titratable" +259, 4, 9, 29, 46, 51, 118, 123, "Fixed" +259, 4, 10, 30, 52, 53, 124, 125, "-" +259, 4, 11, 31, 54, 59, 126, 131, "Ratio" +259, 4, 12, 32, 60, 71, 132, 143, "Combination" +259, 4, 13, 33, 72, 74, 144, 146, "of" +259, 4, 14, 34, 75, 82, 147, 154, "Insulin" +259, 4, 15, 35, 83, 91, 155, 163, "Glargine" +259, 4, 16, 36, 92, 96, 164, 168, "Plus" +259, 4, 17, 37, 97, 109, 169, 181, "Lixisenatide" +259, 4, 18, 38, 110, 112, 182, 184, "in" +259, 4, 19, 39, 113, 117, 185, 189, "Type" +259, 4, 20, 40, 118, 119, 190, 191, "2" +259, 4, 21, 41, 120, 128, 192, 200, "Diabetes" +259, 4, 22, 42, 129, 141, 201, 213, "Inadequately" +259, 4, 23, 43, 142, 152, 214, 224, "Controlled" +259, 4, 24, 44, 153, 155, 225, 227, "on" +259, 4, 25, 45, 156, 161, 228, 233, "Basal" +259, 4, 26, 46, 162, 169, 234, 241, "Insulin" +259, 4, 27, 47, 170, 173, 242, 245, "and" +259, 4, 28, 48, 174, 183, 246, 255, "Metformin" +259, 4, 29, 49, 184, 185, 256, 257, ":" +259, 4, 30, 50, 186, 189, 258, 261, "The" +259, 4, 31, 51, 190, 197, 262, 269, "LixiLan" +259, 4, 32, 52, 198, 199, 270, 271, "-" +259, 4, 33, 53, 200, 201, 272, 273, "L" +259, 4, 34, 54, 202, 212, 274, 284, "Randomized" +259, 4, 35, 55, 213, 218, 285, 290, "Trial" +259, 4, 36, 56, 219, 220, 291, 292, "." +259, 5, 1, 57, 0, 5, 293, 298, "Aroda" +259, 5, 2, 58, 6, 8, 299, 301, "VR" +259, 5, 3, 59, 9, 10, 302, 303, "(" +259, 5, 4, 60, 11, 12, 304, 305, "1" +259, 5, 5, 61, 13, 14, 306, 307, ")" +259, 5, 6, 62, 15, 16, 308, 309, "," +259, 5, 7, 63, 17, 27, 310, 320, "Rosenstock" +259, 5, 8, 64, 28, 29, 321, 322, "J" +259, 5, 9, 65, 30, 31, 323, 324, "(" +259, 5, 10, 66, 32, 33, 325, 326, "2" +259, 5, 11, 67, 34, 35, 327, 328, ")" +259, 5, 12, 68, 36, 37, 329, 330, "," +259, 5, 13, 69, 38, 44, 331, 337, "Wysham" +259, 5, 14, 70, 45, 46, 338, 339, "C" +259, 5, 15, 71, 47, 48, 340, 341, "(" +259, 5, 16, 72, 49, 50, 342, 343, "3" +259, 5, 17, 73, 51, 52, 344, 345, ")" +259, 5, 18, 74, 53, 54, 346, 347, "," +259, 5, 19, 75, 55, 60, 348, 353, "Unger" +259, 5, 20, 76, 61, 62, 354, 355, "J" +259, 5, 21, 77, 63, 64, 356, 357, "(" +259, 5, 22, 78, 65, 66, 358, 359, "4" +259, 5, 23, 79, 67, 68, 360, 361, ")" +259, 5, 24, 80, 69, 70, 362, 363, "," +259, 5, 25, 81, 71, 78, 364, 371, "Bellido" +259, 5, 26, 82, 79, 80, 372, 373, "D" +259, 5, 27, 83, 81, 82, 374, 375, "(" +259, 5, 28, 84, 83, 84, 376, 377, "5" +259, 5, 29, 85, 85, 86, 378, 379, ")" +259, 5, 30, 86, 87, 88, 380, 381, "," +259, 5, 31, 87, 89, 93, 382, 386, "Gonz" +259, 5, 32, 88, 94, 95, 387, 388, "á" +259, 5, 33, 89, 96, 99, 389, 392, "lez" +259, 5, 34, 90, 100, 101, 393, 394, "-" +259, 5, 35, 91, 102, 103, 395, 396, "G" +259, 5, 36, 92, 104, 105, 397, 398, "á" +259, 5, 37, 93, 106, 110, 399, 403, "lvez" +259, 5, 38, 94, 111, 112, 404, 405, "G" +259, 5, 39, 95, 113, 114, 406, 407, "(" +259, 5, 40, 96, 115, 116, 408, 409, "6" +259, 5, 41, 97, 117, 118, 410, 411, ")" +259, 5, 42, 98, 119, 120, 412, 413, "," +259, 5, 43, 99, 121, 127, 414, 420, "Takami" +259, 5, 44, 100, 128, 129, 421, 422, "A" +259, 5, 45, 101, 130, 131, 423, 424, "(" +259, 5, 46, 102, 132, 133, 425, 426, "7" +259, 5, 47, 103, 134, 135, 427, 428, ")" +259, 5, 48, 104, 136, 137, 429, 430, "," +259, 5, 49, 105, 138, 141, 431, 434, "Guo" +259, 5, 50, 106, 142, 143, 435, 436, "H" +259, 5, 51, 107, 144, 145, 437, 438, "(" +259, 5, 52, 108, 146, 147, 439, 440, "8" +259, 5, 53, 109, 148, 149, 441, 442, ")" +259, 5, 54, 110, 150, 151, 443, 444, "," +259, 5, 55, 111, 152, 162, 445, 455, "Niemoeller" +259, 5, 56, 112, 163, 164, 456, 457, "E" +259, 5, 57, 113, 165, 166, 458, 459, "(" +259, 5, 58, 114, 167, 168, 460, 461, "9" +259, 5, 59, 115, 169, 170, 462, 463, ")" +259, 5, 60, 116, 171, 172, 464, 465, "," +259, 5, 61, 117, 173, 180, 466, 473, "Souhami" +259, 5, 62, 118, 181, 182, 474, 475, "E" +259, 5, 63, 119, 183, 184, 476, 477, "(" +259, 5, 64, 120, 185, 187, 478, 480, "10" +259, 5, 65, 121, 188, 189, 481, 482, ")" +259, 5, 66, 122, 190, 191, 483, 484, "," +259, 5, 67, 123, 192, 202, 485, 495, "Bergenstal" +259, 5, 68, 124, 203, 205, 496, 498, "RM" +259, 5, 69, 125, 206, 207, 499, 500, "(" +259, 5, 70, 126, 208, 210, 501, 503, "11" +259, 5, 71, 127, 211, 212, 504, 505, ")" +259, 5, 72, 128, 213, 214, 506, 507, ";" +259, 5, 73, 129, 215, 222, 508, 515, "LixiLan" +259, 5, 74, 130, 223, 224, 516, 517, "-" +259, 5, 75, 131, 225, 226, 518, 519, "L" +259, 5, 76, 132, 227, 232, 520, 525, "Trial" +259, 5, 77, 133, 233, 246, 526, 539, "Investigators" +259, 5, 78, 134, 247, 248, 540, 541, "." +259, 6, 1, 135, 0, 6, 542, 548, "Author" +259, 6, 2, 136, 7, 18, 549, 560, "information" +259, 6, 3, 137, 19, 20, 561, 562, ":" +259, 6, 4, 138, 21, 22, 563, 564, "(" +259, 6, 5, 139, 23, 24, 565, 566, "1" +259, 6, 6, 140, 25, 26, 567, 568, ")" +259, 6, 7, 141, 27, 34, 569, 576, "Medstar" +259, 6, 8, 142, 35, 41, 577, 583, "Health" +259, 6, 9, 143, 42, 50, 584, 592, "Research" +259, 6, 10, 144, 51, 60, 593, 602, "Institute" +259, 6, 11, 145, 61, 62, 603, 604, "," +259, 6, 12, 146, 63, 74, 605, 616, "Hyattsville" +259, 6, 13, 147, 75, 76, 617, 618, "," +259, 6, 14, 148, 77, 79, 619, 621, "MD" +259, 6, 15, 149, 80, 86, 622, 628, "vanita" +259, 6, 16, 150, 87, 88, 629, 630, "." +259, 6, 17, 151, 89, 94, 631, 636, "aroda" +259, 6, 18, 152, 95, 96, 637, 638, "@" +259, 6, 19, 153, 97, 104, 639, 646, "medstar" +259, 6, 20, 154, 105, 106, 647, 648, "." +259, 6, 21, 155, 107, 110, 649, 652, "net" +259, 6, 22, 156, 111, 112, 653, 654, "." +259, 7, 1, 157, 0, 1, 655, 656, "(" +259, 7, 2, 158, 2, 3, 657, 658, "2" +259, 7, 3, 159, 4, 5, 659, 660, ")" +259, 7, 4, 160, 6, 12, 661, 667, "Dallas" +259, 7, 5, 161, 13, 21, 668, 676, "Diabetes" +259, 7, 6, 162, 22, 30, 677, 685, "Research" +259, 7, 7, 163, 31, 37, 686, 692, "Center" +259, 7, 8, 164, 38, 40, 693, 695, "at" +259, 7, 9, 165, 41, 48, 696, 703, "Medical" +259, 7, 10, 166, 49, 53, 704, 708, "City" +259, 7, 11, 167, 54, 55, 709, 710, "," +259, 7, 12, 168, 56, 62, 711, 717, "Dallas" +259, 7, 13, 169, 63, 64, 718, 719, "," +259, 7, 14, 170, 65, 67, 720, 722, "TX" +259, 7, 15, 171, 68, 69, 723, 724, "." +259, 8, 1, 172, 0, 1, 725, 726, "(" +259, 8, 2, 173, 2, 3, 727, 728, "3" +259, 8, 3, 174, 4, 5, 729, 730, ")" +259, 8, 4, 175, 6, 14, 731, 739, "Rockwood" +259, 8, 5, 176, 15, 21, 740, 746, "Clinic" +259, 8, 6, 177, 22, 23, 747, 748, "," +259, 8, 7, 178, 24, 31, 749, 756, "Spokane" +259, 8, 8, 179, 32, 33, 757, 758, "," +259, 8, 9, 180, 34, 36, 759, 761, "WA" +259, 8, 10, 181, 37, 38, 762, 763, "." +259, 9, 1, 182, 0, 1, 764, 765, "(" +259, 9, 2, 183, 2, 3, 766, 767, "4" +259, 9, 3, 184, 4, 5, 768, 769, ")" +259, 9, 4, 185, 6, 14, 770, 778, "Catalina" +259, 9, 5, 186, 15, 23, 779, 787, "Research" +259, 9, 6, 187, 24, 33, 788, 797, "Institute" +259, 9, 7, 188, 34, 35, 798, 799, "," +259, 9, 8, 189, 36, 41, 800, 805, "Chino" +259, 9, 9, 190, 42, 43, 806, 807, "," +259, 9, 10, 191, 44, 46, 808, 810, "CA" +259, 9, 11, 192, 47, 48, 811, 812, "." +259, 10, 1, 193, 0, 1, 813, 814, "(" +259, 10, 2, 194, 2, 3, 815, 816, "5" +259, 10, 3, 195, 4, 5, 817, 818, ")" +259, 10, 4, 196, 6, 14, 819, 827, "Complejo" +259, 10, 5, 197, 15, 27, 828, 840, "Hospitalario" +259, 10, 6, 198, 28, 41, 841, 854, "Universitario" +259, 10, 7, 199, 42, 44, 855, 857, "de" +259, 10, 8, 200, 45, 51, 858, 864, "Ferrol" +259, 10, 9, 201, 52, 53, 865, 866, "," +259, 10, 10, 202, 54, 55, 867, 868, "A" +259, 10, 11, 203, 56, 60, 869, 873, "Coru" +259, 10, 12, 204, 61, 62, 874, 875, "ñ" +259, 10, 13, 205, 63, 64, 876, 877, "a" +259, 10, 14, 206, 65, 75, 878, 888, "University" +259, 10, 15, 207, 76, 77, 889, 890, "," +259, 10, 16, 208, 78, 79, 891, 892, "A" +259, 10, 17, 209, 80, 84, 893, 897, "Coru" +259, 10, 18, 210, 85, 86, 898, 899, "ñ" +259, 10, 19, 211, 87, 88, 900, 901, "a" +259, 10, 20, 212, 89, 90, 902, 903, "," +259, 10, 21, 213, 91, 96, 904, 909, "Spain" +259, 10, 22, 214, 97, 98, 910, 911, "." +259, 11, 1, 215, 0, 1, 912, 913, "(" +259, 11, 2, 216, 2, 3, 914, 915, "6" +259, 11, 3, 217, 4, 5, 916, 917, ")" +259, 11, 4, 218, 6, 15, 918, 927, "Instituto" +259, 11, 5, 219, 16, 27, 928, 939, "Jalisciense" +259, 11, 6, 220, 28, 30, 940, 942, "de" +259, 11, 7, 221, 31, 42, 943, 954, "Investigaci" +259, 11, 8, 222, 43, 44, 955, 956, "ó" +259, 11, 9, 223, 45, 46, 957, 958, "n" +259, 11, 10, 224, 47, 49, 959, 961, "en" +259, 11, 11, 225, 50, 58, 962, 970, "Diabetes" +259, 11, 12, 226, 59, 60, 971, 972, "y" +259, 11, 13, 227, 61, 69, 973, 981, "Obesidad" +259, 11, 14, 228, 70, 71, 982, 983, "S" +259, 11, 15, 229, 72, 73, 984, 985, "." +259, 11, 16, 230, 74, 75, 986, 987, "C" +259, 11, 17, 231, 76, 77, 988, 989, "." +259, 11, 18, 232, 78, 79, 990, 991, "," +259, 11, 19, 233, 80, 91, 992, 1003, "Universidad" +259, 11, 20, 234, 92, 94, 1004, 1006, "de" +259, 11, 21, 235, 95, 106, 1007, 1018, "Guadalajara" +259, 11, 22, 236, 107, 108, 1019, 1020, "," +259, 11, 23, 237, 109, 117, 1021, 1029, "Hospital" +259, 11, 24, 238, 118, 123, 1030, 1035, "Civil" +259, 11, 25, 239, 124, 126, 1036, 1038, "de" +259, 11, 26, 240, 127, 138, 1039, 1050, "Guadalajara" +259, 11, 28, 242, 141, 143, 1053, 1055, "Dr" +259, 11, 29, 243, 144, 145, 1056, 1057, "." +259, 11, 30, 244, 146, 150, 1058, 1062, "Juan" +259, 11, 31, 245, 151, 152, 1063, 1064, "I" +259, 11, 32, 246, 153, 154, 1065, 1066, "." +259, 11, 33, 247, 155, 163, 1067, 1075, "Menchaca" +259, 11, 34, 248, 164, 165, 1076, 1077, "," +259, 11, 36, 250, 168, 179, 1080, 1091, "Guadalajara" +259, 11, 37, 251, 180, 181, 1092, 1093, "," +259, 11, 38, 252, 182, 188, 1094, 1100, "Mexico" +259, 11, 39, 253, 189, 190, 1101, 1102, "." +259, 12, 1, 254, 0, 1, 1103, 1104, "(" +259, 12, 2, 255, 2, 3, 1105, 1106, "7" +259, 12, 3, 256, 4, 5, 1107, 1108, ")" +259, 12, 4, 257, 6, 12, 1109, 1115, "Sanofi" +259, 12, 5, 258, 13, 14, 1116, 1117, "," +259, 12, 6, 259, 15, 20, 1118, 1123, "Tokyo" +259, 12, 7, 260, 21, 22, 1124, 1125, "," +259, 12, 8, 261, 23, 28, 1126, 1131, "Japan" +259, 12, 9, 262, 29, 30, 1132, 1133, "." +259, 13, 1, 263, 0, 1, 1134, 1135, "(" +259, 13, 2, 264, 2, 3, 1136, 1137, "8" +259, 13, 3, 265, 4, 5, 1138, 1139, ")" +259, 13, 4, 266, 6, 19, 1140, 1153, "Biostatistics" +259, 13, 5, 267, 20, 21, 1154, 1155, "," +259, 13, 6, 268, 22, 25, 1156, 1159, "BMD" +259, 13, 7, 269, 26, 36, 1160, 1170, "Consulting" +259, 13, 8, 270, 37, 40, 1171, 1174, "Inc" +259, 13, 9, 271, 41, 42, 1175, 1176, "." +259, 13, 10, 272, 43, 44, 1177, 1178, "," +259, 13, 11, 273, 45, 53, 1179, 1187, "Somerset" +259, 13, 12, 274, 54, 55, 1188, 1189, "," +259, 13, 13, 275, 56, 58, 1190, 1192, "NJ" +259, 13, 14, 276, 59, 60, 1193, 1194, "." +259, 14, 1, 277, 0, 1, 1195, 1196, "(" +259, 14, 2, 278, 2, 3, 1197, 1198, "9" +259, 14, 3, 279, 4, 5, 1199, 1200, ")" +259, 14, 4, 280, 6, 14, 1201, 1209, "Diabetes" +259, 14, 5, 281, 15, 23, 1210, 1218, "Division" +259, 14, 6, 282, 24, 25, 1219, 1220, "," +259, 14, 7, 283, 26, 32, 1221, 1227, "Sanofi" +259, 14, 8, 284, 33, 34, 1228, 1229, "," +259, 14, 9, 285, 35, 44, 1230, 1239, "Frankfurt" +259, 14, 10, 286, 45, 46, 1240, 1241, "," +259, 14, 11, 287, 47, 54, 1242, 1249, "Germany" +259, 14, 12, 288, 55, 56, 1250, 1251, "." +259, 15, 1, 289, 0, 1, 1252, 1253, "(" +259, 15, 2, 290, 2, 4, 1254, 1256, "10" +259, 15, 3, 291, 5, 6, 1257, 1258, ")" +259, 15, 4, 292, 7, 15, 1259, 1267, "Diabetes" +259, 15, 5, 293, 16, 24, 1268, 1276, "Division" +259, 15, 6, 294, 25, 26, 1277, 1278, "," +259, 15, 7, 295, 27, 33, 1279, 1285, "Sanofi" +259, 15, 8, 296, 34, 35, 1286, 1287, "," +259, 15, 9, 297, 36, 41, 1288, 1293, "Paris" +259, 15, 10, 298, 42, 43, 1294, 1295, "," +259, 15, 11, 299, 44, 50, 1296, 1302, "France" +259, 15, 12, 300, 51, 52, 1303, 1304, "." +259, 16, 1, 301, 0, 1, 1305, 1306, "(" +259, 16, 2, 302, 2, 4, 1307, 1309, "11" +259, 16, 3, 303, 5, 6, 1310, 1311, ")" +259, 16, 4, 304, 7, 20, 1312, 1325, "International" +259, 16, 5, 305, 21, 29, 1326, 1334, "Diabetes" +259, 16, 6, 306, 30, 36, 1335, 1341, "Center" +259, 16, 7, 307, 37, 38, 1342, 1343, "," +259, 16, 8, 308, 39, 43, 1344, 1348, "Park" +259, 16, 9, 309, 44, 52, 1349, 1357, "Nicollet" +259, 16, 10, 310, 53, 59, 1358, 1364, "Health" +259, 16, 11, 311, 60, 68, 1365, 1373, "Services" +259, 16, 12, 312, 69, 70, 1374, 1375, "," +259, 16, 13, 313, 71, 82, 1376, 1387, "Minneapolis" +259, 16, 14, 314, 83, 84, 1388, 1389, "," +259, 16, 15, 315, 85, 87, 1390, 1392, "MN" +259, 16, 16, 316, 88, 89, 1393, 1394, "." +259, 17, 1, 317, 0, 7, 1395, 1402, "Erratum" +259, 17, 2, 318, 8, 10, 1403, 1405, "in" +259, 17, 3, 319, 11, 19, 1406, 1414, "Diabetes" +259, 17, 4, 320, 20, 24, 1415, 1419, "Care" +259, 17, 5, 321, 25, 26, 1420, 1421, "." +259, 18, 1, 322, 0, 4, 1422, 1426, "2017" +259, 18, 2, 323, 5, 8, 1427, 1430, "Jun" +259, 18, 3, 324, 9, 10, 1431, 1432, ";" +259, 18, 4, 325, 11, 13, 1433, 1435, "40" +259, 18, 5, 326, 14, 15, 1436, 1437, "(" +259, 18, 6, 327, 16, 17, 1438, 1439, "6" +259, 18, 7, 328, 18, 19, 1440, 1441, ")" +259, 18, 8, 329, 20, 21, 1442, 1443, ":" +259, 18, 9, 330, 22, 25, 1444, 1447, "809" +259, 18, 10, 331, 26, 27, 1448, 1449, "." +259, 19, 1, 332, 0, 9, 1450, 1459, "OBJECTIVE" +259, 19, 2, 333, 10, 11, 1460, 1461, ":" +259, 19, 3, 334, 12, 16, 1462, 1466, "This" +259, 19, 4, 335, 17, 22, 1467, 1472, "study" +259, 19, 5, 336, 23, 26, 1473, 1476, "was" +259, 19, 6, 337, 27, 36, 1477, 1486, "conducted" +259, 19, 7, 338, 37, 39, 1487, 1489, "to" +259, 19, 8, 339, 40, 51, 1490, 1501, "demonstrate" +259, 19, 9, 340, 52, 55, 1502, 1505, "the" +259, 19, 10, 341, 56, 64, 1506, 1514, "efficacy" +259, 19, 11, 342, 65, 68, 1515, 1518, "and" +259, 19, 12, 343, 69, 75, 1519, 1525, "safety" +259, 19, 13, 344, 76, 78, 1526, 1528, "of" +259, 19, 14, 345, 79, 86, 1529, 1536, "LixiLan" +259, 19, 15, 346, 87, 88, 1537, 1538, "(" +259, 19, 16, 347, 89, 98, 1539, 1548, "iGlarLixi" +259, 19, 17, 348, 99, 100, 1549, 1550, ")" +259, 19, 18, 349, 101, 102, 1551, 1552, "," +259, 19, 19, 350, 103, 104, 1553, 1554, "a" +259, 19, 20, 351, 105, 110, 1555, 1560, "novel" +259, 19, 21, 352, 111, 112, 1561, 1562, "," +259, 19, 22, 353, 113, 123, 1563, 1573, "titratable" +259, 19, 23, 354, 124, 125, 1574, 1575, "," +259, 19, 24, 355, 126, 131, 1576, 1581, "fixed" +259, 19, 25, 356, 132, 133, 1582, 1583, "-" +259, 19, 26, 357, 134, 139, 1584, 1589, "ratio" +259, 19, 27, 358, 140, 151, 1590, 1601, "combination" +259, 19, 28, 359, 152, 154, 1602, 1604, "of" +259, 19, 29, 360, 155, 162, 1605, 1612, "insulin" +259, 19, 30, 361, 163, 171, 1613, 1621, "glargine" +259, 19, 31, 362, 172, 173, 1622, 1623, "(" +259, 19, 32, 363, 174, 179, 1624, 1629, "iGlar" +259, 19, 33, 364, 180, 181, 1630, 1631, ")" +259, 19, 34, 365, 182, 183, 1632, 1633, "(" +259, 19, 35, 366, 184, 187, 1634, 1637, "100" +259, 19, 36, 367, 188, 193, 1638, 1643, "units" +259, 19, 37, 368, 194, 195, 1644, 1645, ")" +259, 19, 38, 369, 196, 199, 1646, 1649, "and" +259, 19, 39, 370, 200, 212, 1650, 1662, "lixisenatide" +259, 19, 40, 371, 213, 214, 1663, 1664, "," +259, 19, 41, 372, 215, 223, 1665, 1673, "compared" +259, 19, 42, 373, 224, 228, 1674, 1678, "with" +259, 19, 43, 374, 229, 234, 1679, 1684, "iGlar" +259, 19, 44, 375, 235, 237, 1685, 1687, "in" +259, 19, 45, 376, 238, 246, 1688, 1696, "patients" +259, 19, 46, 377, 247, 251, 1697, 1701, "with" +259, 19, 47, 378, 252, 256, 1702, 1706, "type" +259, 19, 48, 379, 257, 258, 1707, 1708, "2" +259, 19, 49, 380, 259, 267, 1709, 1717, "diabetes" +259, 19, 50, 381, 268, 280, 1718, 1730, "inadequately" +259, 19, 51, 382, 281, 291, 1731, 1741, "controlled" +259, 19, 52, 383, 292, 294, 1742, 1744, "on" +259, 19, 53, 384, 295, 300, 1745, 1750, "basal" +259, 19, 54, 385, 301, 308, 1751, 1758, "insulin" +259, 19, 55, 386, 309, 313, 1759, 1763, "with" +259, 19, 56, 387, 314, 316, 1764, 1766, "or" +259, 19, 57, 388, 317, 324, 1767, 1774, "without" +259, 19, 58, 389, 325, 327, 1775, 1777, "up" +259, 19, 59, 390, 328, 330, 1778, 1780, "to" +259, 19, 60, 391, 331, 334, 1781, 1784, "two" +259, 19, 61, 392, 335, 339, 1785, 1789, "oral" +259, 19, 62, 393, 340, 347, 1790, 1797, "glucose" +259, 19, 63, 394, 348, 349, 1798, 1799, "-" +259, 19, 64, 395, 350, 358, 1800, 1808, "lowering" +259, 19, 65, 396, 359, 365, 1809, 1815, "agents" +259, 19, 66, 397, 366, 367, 1816, 1817, "." +259, 20, 1, 398, 0, 8, 1818, 1826, "RESEARCH" +259, 20, 2, 399, 9, 15, 1827, 1833, "DESIGN" +259, 20, 3, 400, 16, 19, 1834, 1837, "AND" +259, 20, 4, 401, 20, 27, 1838, 1845, "METHODS" +259, 20, 5, 402, 28, 29, 1846, 1847, ":" +259, 20, 6, 403, 30, 35, 1848, 1853, "After" +259, 20, 7, 404, 36, 37, 1854, 1855, "a" +259, 20, 8, 405, 38, 39, 1856, 1857, "6" +259, 20, 9, 406, 40, 41, 1858, 1859, "-" +259, 20, 10, 407, 42, 46, 1860, 1864, "week" +259, 20, 11, 408, 47, 50, 1865, 1868, "run" +259, 20, 12, 409, 51, 52, 1869, 1870, "-" +259, 20, 13, 410, 53, 55, 1871, 1873, "in" +259, 20, 14, 411, 56, 60, 1874, 1878, "when" +259, 20, 15, 412, 61, 66, 1879, 1884, "iGlar" +259, 20, 16, 413, 67, 70, 1885, 1888, "was" +259, 20, 17, 414, 71, 81, 1889, 1899, "introduced" +259, 20, 18, 415, 82, 85, 1900, 1903, "and" +259, 20, 19, 416, 86, 87, 1904, 1905, "/" +259, 20, 20, 417, 88, 90, 1906, 1908, "or" +259, 20, 21, 418, 91, 98, 1909, 1916, "further" +259, 20, 22, 419, 99, 107, 1917, 1925, "titrated" +259, 20, 23, 420, 108, 109, 1926, 1927, "," +259, 20, 24, 421, 110, 113, 1928, 1931, "and" +259, 20, 25, 422, 114, 118, 1932, 1936, "oral" +259, 20, 26, 423, 119, 131, 1937, 1949, "antidiabetic" +259, 20, 27, 424, 132, 137, 1950, 1955, "drugs" +259, 20, 28, 425, 138, 143, 1956, 1961, "other" +259, 20, 29, 426, 144, 148, 1962, 1966, "than" +259, 20, 30, 427, 149, 158, 1967, 1976, "metformin" +259, 20, 31, 428, 159, 163, 1977, 1981, "were" +259, 20, 32, 429, 164, 171, 1982, 1989, "stopped" +259, 20, 33, 430, 172, 173, 1990, 1991, "," +259, 20, 34, 431, 174, 177, 1992, 1995, "736" +259, 20, 35, 432, 178, 183, 1996, 2001, "basal" +259, 20, 36, 433, 184, 191, 2002, 2009, "insulin" +259, 20, 37, 434, 192, 193, 2010, 2011, "-" +259, 20, 38, 435, 194, 201, 2012, 2019, "treated" +259, 20, 39, 436, 202, 210, 2020, 2028, "patients" +259, 20, 40, 437, 211, 212, 2029, 2030, "(" +259, 20, 41, 438, 213, 217, 2031, 2035, "mean" +259, 20, 42, 439, 218, 226, 2036, 2044, "diabetes" +259, 20, 43, 440, 227, 235, 2045, 2053, "duration" +259, 20, 44, 441, 236, 238, 2054, 2056, "12" +259, 20, 45, 442, 239, 244, 2057, 2062, "years" +259, 20, 46, 443, 245, 246, 2063, 2064, "," +259, 20, 47, 444, 247, 250, 2065, 2068, "BMI" +259, 20, 48, 445, 251, 253, 2069, 2071, "31" +259, 20, 49, 446, 254, 256, 2072, 2074, "kg" +259, 20, 50, 447, 257, 258, 2075, 2076, "/" +259, 20, 51, 448, 259, 261, 2077, 2079, "m2" +259, 20, 52, 449, 262, 263, 2080, 2081, ")" +259, 20, 53, 450, 264, 268, 2082, 2086, "were" +259, 20, 54, 451, 269, 279, 2087, 2097, "randomized" +259, 20, 55, 452, 280, 281, 2098, 2099, "1" +259, 20, 56, 453, 282, 283, 2100, 2101, ":" +259, 20, 57, 454, 284, 285, 2102, 2103, "1" +259, 20, 58, 455, 286, 288, 2104, 2106, "to" +259, 20, 59, 456, 289, 293, 2107, 2111, "open" +259, 20, 60, 457, 294, 295, 2112, 2113, "-" +259, 20, 61, 458, 296, 301, 2114, 2119, "label" +259, 20, 62, 459, 302, 303, 2120, 2121, "," +259, 20, 63, 460, 304, 308, 2122, 2126, "once" +259, 20, 64, 461, 309, 310, 2127, 2128, "-" +259, 20, 65, 462, 311, 316, 2129, 2134, "daily" +259, 20, 66, 463, 317, 326, 2135, 2144, "iGlarLixi" +259, 20, 67, 464, 327, 329, 2145, 2147, "or" +259, 20, 68, 465, 330, 335, 2148, 2153, "iGlar" +259, 20, 69, 466, 336, 337, 2154, 2155, "," +259, 20, 70, 467, 338, 342, 2156, 2160, "both" +259, 20, 71, 468, 343, 351, 2161, 2169, "titrated" +259, 20, 72, 469, 352, 354, 2170, 2172, "to" +259, 20, 73, 470, 355, 362, 2173, 2180, "fasting" +259, 20, 74, 471, 363, 369, 2181, 2187, "plasma" +259, 20, 75, 472, 370, 377, 2188, 2195, "glucose" +259, 20, 76, 473, 378, 379, 2196, 2197, "<" +259, 20, 77, 474, 380, 383, 2198, 2201, "100" +259, 20, 78, 475, 384, 386, 2202, 2204, "mg" +259, 20, 79, 476, 387, 388, 2205, 2206, "/" +259, 20, 80, 477, 389, 391, 2207, 2209, "dL" +259, 20, 81, 478, 392, 393, 2210, 2211, "(" +259, 20, 82, 479, 394, 395, 2212, 2213, "<" +259, 20, 83, 480, 396, 397, 2214, 2215, "5" +259, 20, 84, 481, 398, 399, 2216, 2217, "." +259, 20, 85, 482, 400, 401, 2218, 2219, "6" +259, 20, 86, 483, 402, 406, 2220, 2224, "mmol" +259, 20, 87, 484, 407, 408, 2225, 2226, "/" +259, 20, 88, 485, 409, 410, 2227, 2228, "L" +259, 20, 89, 486, 411, 412, 2229, 2230, ")" +259, 20, 90, 487, 413, 415, 2231, 2233, "up" +259, 20, 91, 488, 416, 418, 2234, 2236, "to" +259, 20, 92, 489, 419, 420, 2237, 2238, "a" +259, 20, 93, 490, 421, 428, 2239, 2246, "maximum" +259, 20, 94, 491, 429, 433, 2247, 2251, "dose" +259, 20, 95, 492, 434, 436, 2252, 2254, "of" +259, 20, 96, 493, 437, 439, 2255, 2257, "60" +259, 20, 97, 494, 440, 445, 2258, 2263, "units" +259, 20, 98, 495, 446, 447, 2264, 2265, "/" +259, 20, 99, 496, 448, 451, 2266, 2269, "day" +259, 20, 100, 497, 452, 453, 2270, 2271, "." +259, 21, 1, 498, 0, 3, 2272, 2275, "The" +259, 21, 2, 499, 4, 11, 2276, 2283, "primary" +259, 21, 3, 500, 12, 19, 2284, 2291, "outcome" +259, 21, 4, 501, 20, 23, 2292, 2295, "was" +259, 21, 5, 502, 24, 30, 2296, 2302, "change" +259, 21, 6, 503, 31, 33, 2303, 2305, "in" +259, 21, 7, 504, 34, 39, 2306, 2311, "HbA1c" +259, 21, 8, 505, 40, 46, 2312, 2318, "levels" +259, 21, 9, 506, 47, 49, 2319, 2321, "at" +259, 21, 10, 507, 50, 52, 2322, 2324, "30" +259, 21, 11, 508, 53, 58, 2325, 2330, "weeks" +259, 21, 12, 509, 59, 60, 2331, 2332, "." +259, 22, 1, 510, 0, 7, 2333, 2340, "RESULTS" +259, 22, 2, 511, 8, 9, 2341, 2342, ":" +259, 22, 3, 512, 10, 15, 2343, 2348, "HbA1c" +259, 22, 4, 513, 16, 25, 2349, 2358, "decreased" +259, 22, 5, 514, 26, 30, 2359, 2363, "from" +259, 22, 6, 515, 31, 32, 2364, 2365, "8" +259, 22, 7, 516, 33, 34, 2366, 2367, "." +259, 22, 8, 517, 35, 36, 2368, 2369, "5" +259, 22, 9, 518, 37, 38, 2370, 2371, "%" +259, 22, 10, 519, 39, 40, 2372, 2373, "(" +259, 22, 11, 520, 41, 43, 2374, 2376, "69" +259, 22, 12, 521, 44, 48, 2377, 2381, "mmol" +259, 22, 13, 522, 49, 50, 2382, 2383, "/" +259, 22, 14, 523, 51, 54, 2384, 2387, "mol" +259, 22, 15, 524, 55, 56, 2388, 2389, ")" +259, 22, 16, 525, 57, 59, 2390, 2392, "to" +259, 22, 17, 526, 60, 61, 2393, 2394, "8" +259, 22, 18, 527, 62, 63, 2395, 2396, "." +259, 22, 19, 528, 64, 65, 2397, 2398, "1" +259, 22, 20, 529, 66, 67, 2399, 2400, "%" +259, 22, 21, 530, 68, 69, 2401, 2402, "(" +259, 22, 22, 531, 70, 72, 2403, 2405, "65" +259, 22, 23, 532, 73, 77, 2406, 2410, "mmol" +259, 22, 24, 533, 78, 79, 2411, 2412, "/" +259, 22, 25, 534, 80, 83, 2413, 2416, "mol" +259, 22, 26, 535, 84, 85, 2417, 2418, ")" +259, 22, 27, 536, 86, 92, 2419, 2425, "during" +259, 22, 28, 537, 93, 96, 2426, 2429, "the" +259, 22, 29, 538, 97, 100, 2430, 2433, "run" +259, 22, 30, 539, 101, 102, 2434, 2435, "-" +259, 22, 31, 540, 103, 105, 2436, 2438, "in" +259, 22, 32, 541, 106, 112, 2439, 2445, "period" +259, 22, 33, 542, 113, 114, 2446, 2447, "." +259, 23, 1, 543, 0, 5, 2448, 2453, "After" +259, 23, 2, 544, 6, 19, 2454, 2467, "randomization" +259, 23, 3, 545, 20, 21, 2468, 2469, "," +259, 23, 4, 546, 22, 31, 2470, 2479, "iGlarLixi" +259, 23, 5, 547, 32, 38, 2480, 2486, "showed" +259, 23, 6, 548, 39, 46, 2487, 2494, "greater" +259, 23, 7, 549, 47, 57, 2495, 2505, "reductions" +259, 23, 8, 550, 58, 60, 2506, 2508, "in" +259, 23, 9, 551, 61, 66, 2509, 2514, "HbA1c" +259, 23, 10, 552, 67, 71, 2515, 2519, "from" +259, 23, 11, 553, 72, 80, 2520, 2528, "baseline" +259, 23, 12, 554, 81, 89, 2529, 2537, "compared" +259, 23, 13, 555, 90, 94, 2538, 2542, "with" +259, 23, 14, 556, 95, 100, 2543, 2548, "iGlar" +259, 23, 15, 557, 101, 102, 2549, 2550, "(" +259, 23, 16, 558, 103, 104, 2551, 2552, "-" +259, 23, 17, 559, 105, 106, 2553, 2554, "1" +259, 23, 18, 560, 107, 108, 2555, 2556, "." +259, 23, 19, 561, 109, 110, 2557, 2558, "1" +259, 23, 20, 562, 111, 112, 2559, 2560, "%" +259, 23, 21, 563, 113, 115, 2561, 2563, "vs" +259, 23, 22, 564, 116, 117, 2564, 2565, "." +259, 23, 23, 565, 118, 119, 2566, 2567, "-" +259, 23, 24, 566, 120, 121, 2568, 2569, "0" +259, 23, 25, 567, 122, 123, 2570, 2571, "." +259, 23, 26, 568, 124, 125, 2572, 2573, "6" +259, 23, 27, 569, 126, 127, 2574, 2575, "%" +259, 23, 28, 570, 128, 129, 2576, 2577, "," +259, 23, 29, 571, 130, 131, 2578, 2579, "P" +259, 23, 30, 572, 132, 133, 2580, 2581, "<" +259, 23, 31, 573, 134, 135, 2582, 2583, "0" +259, 23, 32, 574, 136, 137, 2584, 2585, "." +259, 23, 33, 575, 138, 142, 2586, 2590, "0001" +259, 23, 34, 576, 143, 144, 2591, 2592, ")" +259, 23, 35, 577, 145, 146, 2593, 2594, "," +259, 23, 36, 578, 147, 155, 2595, 2603, "reaching" +259, 23, 37, 579, 156, 157, 2604, 2605, "a" +259, 23, 38, 580, 158, 162, 2606, 2610, "mean" +259, 23, 39, 581, 163, 168, 2611, 2616, "final" +259, 23, 40, 582, 169, 174, 2617, 2622, "HbA1c" +259, 23, 41, 583, 175, 177, 2623, 2625, "of" +259, 23, 42, 584, 178, 179, 2626, 2627, "6" +259, 23, 43, 585, 180, 181, 2628, 2629, "." +259, 23, 44, 586, 182, 183, 2630, 2631, "9" +259, 23, 45, 587, 184, 185, 2632, 2633, "%" +259, 23, 46, 588, 186, 187, 2634, 2635, "(" +259, 23, 47, 589, 188, 190, 2636, 2638, "52" +259, 23, 48, 590, 191, 195, 2639, 2643, "mmol" +259, 23, 49, 591, 196, 197, 2644, 2645, "/" +259, 23, 50, 592, 198, 201, 2646, 2649, "mol" +259, 23, 51, 593, 202, 203, 2650, 2651, ")" +259, 23, 52, 594, 204, 212, 2652, 2660, "compared" +259, 23, 53, 595, 213, 217, 2661, 2665, "with" +259, 23, 54, 596, 218, 219, 2666, 2667, "7" +259, 23, 55, 597, 220, 221, 2668, 2669, "." +259, 23, 56, 598, 222, 223, 2670, 2671, "5" +259, 23, 57, 599, 224, 225, 2672, 2673, "%" +259, 23, 58, 600, 226, 227, 2674, 2675, "(" +259, 23, 59, 601, 228, 230, 2676, 2678, "58" +259, 23, 60, 602, 231, 235, 2679, 2683, "mmol" +259, 23, 61, 603, 236, 237, 2684, 2685, "/" +259, 23, 62, 604, 238, 241, 2686, 2689, "mol" +259, 23, 63, 605, 242, 243, 2690, 2691, ")" +259, 23, 64, 606, 244, 247, 2692, 2695, "for" +259, 23, 65, 607, 248, 253, 2696, 2701, "iGlar" +259, 23, 66, 608, 254, 255, 2702, 2703, "." +259, 24, 1, 609, 0, 5, 2704, 2709, "HbA1c" +259, 24, 2, 610, 6, 7, 2710, 2711, "<" +259, 24, 3, 611, 8, 9, 2712, 2713, "7" +259, 24, 4, 612, 10, 11, 2714, 2715, "." +259, 24, 5, 613, 12, 13, 2716, 2717, "0" +259, 24, 6, 614, 14, 15, 2718, 2719, "%" +259, 24, 7, 615, 16, 17, 2720, 2721, "(" +259, 24, 8, 616, 18, 20, 2722, 2724, "53" +259, 24, 9, 617, 21, 25, 2725, 2729, "mmol" +259, 24, 10, 618, 26, 27, 2730, 2731, "/" +259, 24, 11, 619, 28, 31, 2732, 2735, "mol" +259, 24, 12, 620, 32, 33, 2736, 2737, ")" +259, 24, 13, 621, 34, 37, 2738, 2741, "was" +259, 24, 14, 622, 38, 46, 2742, 2750, "achieved" +259, 24, 15, 623, 47, 49, 2751, 2753, "in" +259, 24, 16, 624, 50, 52, 2754, 2756, "55" +259, 24, 17, 625, 53, 54, 2757, 2758, "%" +259, 24, 18, 626, 55, 57, 2759, 2761, "of" +259, 24, 19, 627, 58, 67, 2762, 2771, "iGlarLixi" +259, 24, 20, 628, 68, 76, 2772, 2780, "patients" +259, 24, 21, 629, 77, 85, 2781, 2789, "compared" +259, 24, 22, 630, 86, 90, 2790, 2794, "with" +259, 24, 23, 631, 91, 93, 2795, 2797, "30" +259, 24, 24, 632, 94, 95, 2798, 2799, "%" +259, 24, 25, 633, 96, 98, 2800, 2802, "on" +259, 24, 26, 634, 99, 104, 2803, 2808, "iGlar" +259, 24, 27, 635, 105, 106, 2809, 2810, "." +259, 25, 1, 636, 0, 4, 2811, 2815, "Mean" +259, 25, 2, 637, 5, 9, 2816, 2820, "body" +259, 25, 3, 638, 10, 16, 2821, 2827, "weight" +259, 25, 4, 639, 17, 26, 2828, 2837, "decreased" +259, 25, 5, 640, 27, 29, 2838, 2840, "by" +259, 25, 6, 641, 30, 31, 2841, 2842, "0" +259, 25, 7, 642, 32, 33, 2843, 2844, "." +259, 25, 8, 643, 34, 35, 2845, 2846, "7" +259, 25, 9, 644, 36, 38, 2847, 2849, "kg" +259, 25, 10, 645, 39, 43, 2850, 2854, "with" +259, 25, 11, 646, 44, 53, 2855, 2864, "iGlarLixi" +259, 25, 12, 647, 54, 57, 2865, 2868, "and" +259, 25, 13, 648, 58, 67, 2869, 2878, "increased" +259, 25, 14, 649, 68, 70, 2879, 2881, "by" +259, 25, 15, 650, 71, 72, 2882, 2883, "0" +259, 25, 16, 651, 73, 74, 2884, 2885, "." +259, 25, 17, 652, 75, 76, 2886, 2887, "7" +259, 25, 18, 653, 77, 79, 2888, 2890, "kg" +259, 25, 19, 654, 80, 84, 2891, 2895, "with" +259, 25, 20, 655, 85, 90, 2896, 2901, "iGlar" +259, 25, 21, 656, 91, 92, 2902, 2903, "(" +259, 25, 22, 657, 93, 94, 2904, 2905, "1" +259, 25, 23, 658, 95, 96, 2906, 2907, "." +259, 25, 24, 659, 97, 98, 2908, 2909, "4" +259, 25, 25, 660, 99, 101, 2910, 2912, "kg" +259, 25, 26, 661, 102, 112, 2913, 2923, "difference" +259, 25, 27, 662, 113, 114, 2924, 2925, "," +259, 25, 28, 663, 115, 116, 2926, 2927, "P" +259, 25, 29, 664, 117, 118, 2928, 2929, "<" +259, 25, 30, 665, 119, 120, 2930, 2931, "0" +259, 25, 31, 666, 121, 122, 2932, 2933, "." +259, 25, 32, 667, 123, 127, 2934, 2938, "0001" +259, 25, 33, 668, 128, 129, 2939, 2940, ")" +259, 25, 34, 669, 130, 131, 2941, 2942, "." +259, 26, 1, 670, 0, 10, 2943, 2953, "Documented" +259, 26, 2, 671, 11, 22, 2954, 2965, "symptomatic" +259, 26, 3, 672, 23, 35, 2966, 2978, "hypoglycemia" +259, 26, 4, 673, 36, 37, 2979, 2980, "(" +259, 26, 5, 674, 38, 39, 2981, 2982, "≤" +259, 26, 6, 675, 40, 42, 2983, 2985, "70" +259, 26, 7, 676, 43, 45, 2986, 2988, "mg" +259, 26, 8, 677, 46, 47, 2989, 2990, "/" +259, 26, 9, 678, 48, 50, 2991, 2993, "dL" +259, 26, 10, 679, 51, 52, 2994, 2995, ")" +259, 26, 11, 680, 53, 56, 2996, 2999, "was" +259, 26, 12, 681, 57, 67, 3000, 3010, "comparable" +259, 26, 13, 682, 68, 75, 3011, 3018, "between" +259, 26, 14, 683, 76, 82, 3019, 3025, "groups" +259, 26, 15, 684, 83, 84, 3026, 3027, "." +259, 27, 1, 685, 0, 4, 3028, 3032, "Mild" +259, 27, 2, 686, 5, 21, 3033, 3049, "gastrointestinal" +259, 27, 3, 687, 22, 29, 3050, 3057, "adverse" +259, 27, 4, 688, 30, 37, 3058, 3065, "effects" +259, 27, 5, 689, 38, 42, 3066, 3070, "were" +259, 27, 6, 690, 43, 47, 3071, 3075, "very" +259, 27, 7, 691, 48, 51, 3076, 3079, "low" +259, 27, 8, 692, 52, 55, 3080, 3083, "but" +259, 27, 9, 693, 56, 60, 3084, 3088, "more" +259, 27, 10, 694, 61, 69, 3089, 3097, "frequent" +259, 27, 11, 695, 70, 74, 3098, 3102, "with" +259, 27, 12, 696, 75, 84, 3103, 3112, "iGlarLixi" +259, 27, 13, 697, 85, 86, 3113, 3114, "." +259, 28, 1, 698, 0, 11, 3115, 3126, "CONCLUSIONS" +259, 28, 2, 699, 12, 13, 3127, 3128, ":" +259, 28, 3, 700, 14, 22, 3129, 3137, "Compared" +259, 28, 4, 701, 23, 27, 3138, 3142, "with" +259, 28, 5, 702, 28, 33, 3143, 3148, "iGlar" +259, 28, 6, 703, 34, 35, 3149, 3150, "," +259, 28, 7, 704, 36, 37, 3151, 3152, "a" +259, 28, 8, 705, 38, 51, 3153, 3166, "substantially" +259, 28, 9, 706, 52, 58, 3167, 3173, "higher" +259, 28, 10, 707, 59, 69, 3174, 3184, "proportion" +259, 28, 11, 708, 70, 72, 3185, 3187, "of" +259, 28, 12, 709, 73, 82, 3188, 3197, "iGlarLixi" +259, 28, 13, 710, 83, 84, 3198, 3199, "-" +259, 28, 14, 711, 85, 92, 3200, 3207, "treated" +259, 28, 15, 712, 93, 101, 3208, 3216, "patients" +259, 28, 16, 713, 102, 110, 3217, 3225, "achieved" +259, 28, 17, 714, 111, 119, 3226, 3234, "glycemic" +259, 28, 18, 715, 120, 127, 3235, 3242, "targets" +259, 28, 19, 716, 128, 132, 3243, 3247, "with" +259, 28, 20, 717, 133, 134, 3248, 3249, "a" +259, 28, 21, 718, 135, 145, 3250, 3260, "beneficial" +259, 28, 22, 719, 146, 152, 3261, 3267, "effect" +259, 28, 23, 720, 153, 155, 3268, 3270, "on" +259, 28, 24, 721, 156, 160, 3271, 3275, "body" +259, 28, 25, 722, 161, 167, 3276, 3282, "weight" +259, 28, 26, 723, 168, 169, 3283, 3284, "," +259, 28, 27, 724, 170, 172, 3285, 3287, "no" +259, 28, 28, 725, 173, 183, 3288, 3298, "additional" +259, 28, 29, 726, 184, 188, 3299, 3303, "risk" +259, 28, 30, 727, 189, 191, 3304, 3306, "of" +259, 28, 31, 728, 192, 204, 3307, 3319, "hypoglycemia" +259, 28, 32, 729, 205, 206, 3320, 3321, "," +259, 28, 33, 730, 207, 210, 3322, 3325, "and" +259, 28, 34, 731, 211, 214, 3326, 3329, "low" +259, 28, 35, 732, 215, 221, 3330, 3336, "levels" +259, 28, 36, 733, 222, 224, 3337, 3339, "of" +259, 28, 37, 734, 225, 241, 3340, 3356, "gastrointestinal" +259, 28, 38, 735, 242, 249, 3357, 3364, "adverse" +259, 28, 39, 736, 250, 257, 3365, 3372, "effects" +259, 28, 40, 737, 258, 260, 3373, 3375, "in" +259, 28, 41, 738, 261, 273, 3376, 3388, "inadequately" +259, 28, 42, 739, 274, 284, 3389, 3399, "controlled" +259, 28, 43, 740, 285, 286, 3400, 3401, "," +259, 28, 44, 741, 287, 292, 3402, 3407, "basal" +259, 28, 45, 742, 293, 300, 3408, 3415, "insulin" +259, 28, 46, 743, 301, 302, 3416, 3417, "-" +259, 28, 47, 744, 303, 310, 3418, 3425, "treated" +259, 28, 48, 745, 311, 312, 3426, 3427, "," +259, 28, 49, 746, 313, 317, 3428, 3432, "long" +259, 28, 50, 747, 318, 319, 3433, 3434, "-" +259, 28, 51, 748, 320, 328, 3435, 3443, "standing" +259, 28, 52, 749, 329, 333, 3444, 3448, "type" +259, 28, 53, 750, 334, 335, 3449, 3450, "2" +259, 28, 54, 751, 336, 344, 3451, 3459, "diabetes" +259, 28, 55, 752, 345, 346, 3460, 3461, "." +259, 29, 1, 753, 0, 1, 3462, 3463, "©" +259, 29, 2, 754, 2, 6, 3464, 3468, "2016" +259, 29, 3, 755, 7, 9, 3469, 3471, "by" +259, 29, 4, 756, 10, 13, 3472, 3475, "the" +259, 29, 5, 757, 14, 22, 3476, 3484, "American" +259, 29, 6, 758, 23, 31, 3485, 3493, "Diabetes" +259, 29, 7, 759, 32, 43, 3494, 3505, "Association" +259, 29, 8, 760, 44, 45, 3506, 3507, "." +259, 30, 1, 761, 0, 3, 3508, 3511, "DOI" +259, 30, 2, 762, 4, 5, 3512, 3513, ":" +259, 30, 3, 763, 6, 8, 3514, 3516, "10" +259, 30, 4, 764, 9, 10, 3517, 3518, "." +259, 30, 5, 765, 11, 15, 3519, 3523, "2337" +259, 30, 6, 766, 16, 17, 3524, 3525, "/" +259, 30, 7, 767, 18, 22, 3526, 3530, "dc16" +259, 30, 8, 768, 23, 24, 3531, 3532, "-" +259, 30, 9, 769, 25, 29, 3533, 3537, "1495" +259, 30, 10, 770, 30, 34, 3538, 3542, "PMID" +259, 30, 11, 771, 35, 36, 3543, 3544, ":" +259, 30, 12, 772, 37, 45, 3545, 3553, "27650977" +259, 30, 13, 773, 46, 47, 3554, 3555, "[" +259, 30, 14, 774, 48, 55, 3556, 3563, "Indexed" +259, 30, 15, 775, 56, 59, 3564, 3567, "for" +259, 30, 16, 776, 60, 67, 3568, 3575, "MEDLINE" +259, 30, 17, 777, 68, 69, 3576, 3577, "]" diff --git a/data/dm2 27650977_kwoodley.annodb b/data/dm2 27650977_kwoodley.annodb new file mode 100644 index 0000000..685a0ec --- /dev/null +++ b/data/dm2 27650977_kwoodley.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +69066, Journal, 0, 13, "Diabetes Care", "", +69176, PublicationYear, 16, 20, "2016", "", +69206, Title, 72, 292, "Efficacy and Safety of LixiLan , a Titratable Fixed - Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin : The LixiLan - L Randomized Trial .", "", +69179, FixedCombDrug, 95, 102, "LixiLan", "", +69189, InsulinGlargine, 147, 163, "Insulin Glargine", "", +69178, Drug, 169, 181, "Lixisenatide", "", +69201, Type2Diabetes, 185, 200, "Type 2 Diabetes", "", +69207, Precondition, 185, 255, "Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin", "", +69204, Insulin, 228, 241, "Basal Insulin", "", +69205, Metformin, 246, 255, "Metformin", "", +69200, FixedCombDrug, 262, 269, "LixiLan", "", +69208, Author, 293, 301, "Aroda VR", "", +69209, Author, 310, 322, "Rosenstock J", "", +69210, Author, 331, 339, "Wysham C", "", +69211, Author, 348, 355, "Unger J", "", +69212, Author, 364, 373, "Bellido D", "", +69214, Author, 382, 405, "Gonz á lez - G á lvez G", "", +69213, Author, 414, 422, "Takami A", "", +69215, Author, 431, 436, "Guo H", "", +69216, Author, 445, 457, "Niemoeller E", "", +69217, Author, 466, 475, "Souhami E", "", +69218, Author, 485, 498, "Bergenstal RM", "", +69180, FixedCombDrug, 508, 515, "LixiLan", "", +69219, USA, 720, 722, "TX", "", +69220, USA, 759, 761, "WA", "", +69221, USA, 808, 810, "CA", "", +69222, Spain, 904, 909, "Spain", "", +69223, Mexico, 1094, 1100, "Mexico", "", +69224, Japan, 1126, 1131, "Japan", "", +69227, UK, 1190, 1192, "NJ", "", +69225, Germany, 1242, 1249, "Germany", "", +69226, France, 1296, 1302, "France", "", +69228, USA, 1390, 1392, "MN", "", +69235, ObjectiveDescription, 1462, 1664, "This study was conducted to demonstrate the efficacy and safety of LixiLan ( iGlarLixi ) , a novel , titratable , fixed - ratio combination of insulin glargine ( iGlar ) ( 100 units ) and lixisenatide ,", "", +69182, FixedCombDrug, 1529, 1536, "LixiLan", "", +69181, FixedCombDrug, 1539, 1548, "iGlarLixi", "", +69193, InsulinGlargine, 1605, 1621, "insulin glargine", "", +69190, InsulinGlargine, 1624, 1629, "iGlar", "", +69229, DoseValue, 1634, 1637, "100", "", +69230, BioAndMedicalUnit, 1638, 1643, "units", "", +69231, Drug, 1650, 1662, "lixisenatide", "", +69236, ObjectiveDescription, 1665, 1817, "compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents .", "", +69191, InsulinGlargine, 1679, 1684, "iGlar", "", +69234, Precondition, 1688, 1815, "patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose - lowering agents", "", +69202, Type2Diabetes, 1702, 1717, "type 2 diabetes", "", +69232, Insulin, 1745, 1758, "basal insulin", "", +69233, OralAntidiabeticAgent, 1785, 1815, "oral glucose - lowering agents", "", +70762, DoseDescription, 1854, 1989, "a 6 - week run - in when iGlar was introduced and / or further titrated , and oral antidiabetic drugs other than metformin were stopped", "", +69192, InsulinGlargine, 1879, 1884, "iGlar", "", +69237, OralAntidiabeticAgent, 1932, 1955, "oral antidiabetic drugs", "", +70756, Metformin, 1967, 1976, "metformin", "", +70757, NumberPatientsCT, 1992, 1995, "736", "", +70758, Insulin, 1996, 2009, "basal insulin", "", +70761, Precondition, 1996, 2081, "basal insulin - treated patients ( mean diabetes duration 12 years , BMI 31 kg / m2 )", "", +70759, BMI, 2065, 2068, "BMI", "", +70760, Kg_per_squareMeter, 2072, 2079, "kg / m2", "", +70763, Randomized, 2087, 2097, "randomized", "", +70764, AllocationRatio, 2098, 2103, "1 : 1", "", +70765, OpenLabel, 2107, 2119, "open - label", "", +70766, Frequency, 2122, 2134, "once - daily", "", +69183, FixedCombDrug, 2135, 2144, "iGlarLixi", "", +70767, InsulinGlargine, 2148, 2153, "iGlar", "", +70772, DoseDescription, 2156, 2269, "both titrated to fasting plasma glucose < 100 mg / dL ( < 5 . 6 mmol / L ) up to a maximum dose of 60 units / day", "", +70768, FastingPlasmaGlucose, 2173, 2195, "fasting plasma glucose", "", +70769, Mg_per_deciliter, 2202, 2209, "mg / dL", "", +70770, Millimoles_per_litre, 2220, 2228, "mmol / L", "", +70771, BioAndMedicalUnit, 2258, 2269, "units / day", "", +70773, HbA1c, 2306, 2311, "HbA1c", "", +70774, TimePoint, 2322, 2330, "30 weeks", "", +70776, HbA1c, 2343, 2348, "HbA1c", "", +70778, BaseLineValue, 2364, 2369, "8 . 5", "", +70780, Percentage, 2370, 2371, "%", "", +70779, BaseLineValue, 2374, 2376, "69", "", +70786, BioAndMedicalUnit, 2377, 2387, "mmol / mol", "", +70790, ResultMeasuredValue, 2393, 2398, "8 . 1", "", +70781, Percentage, 2399, 2400, "%", "", +70791, ResultMeasuredValue, 2403, 2405, "65", "", +70787, BioAndMedicalUnit, 2406, 2416, "mmol / mol", "", +70775, TimePoint, 2419, 2445, "during the run - in period", "", +70792, Randomized, 2454, 2467, "randomization", "", +69184, FixedCombDrug, 2470, 2479, "iGlarLixi", "", +70777, HbA1c, 2509, 2514, "HbA1c", "", +70793, TimePoint, 2520, 2528, "baseline", "", +69194, InsulinGlargine, 2543, 2548, "iGlar", "", +70794, Reduction, 2553, 2558, "1 . 1", "", +70782, Percentage, 2559, 2560, "%", "", +70795, Reduction, 2568, 2573, "0 . 6", "", +70783, Percentage, 2574, 2575, "%", "", +70796, PvalueDiff, 2578, 2590, "P < 0 . 0001", "", +70797, HbA1c, 2617, 2622, "HbA1c", "", +70798, ResultMeasuredValue, 2626, 2631, "6 . 9", "", +70784, Percentage, 2632, 2633, "%", "", +70799, ResultMeasuredValue, 2636, 2638, "52", "", +70788, BioAndMedicalUnit, 2639, 2649, "mmol / mol", "", +70800, ResultMeasuredValue, 2666, 2671, "7 . 5", "", +70785, Percentage, 2672, 2673, "%", "", +70801, ResultMeasuredValue, 2676, 2678, "58", "", +70789, BioAndMedicalUnit, 2679, 2689, "mmol / mol", "", +69197, InsulinGlargine, 2696, 2701, "iGlar", "", +70802, HbA1c_target, 2704, 2737, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", +70803, Percentage, 2754, 2756, "55", "", +69185, FixedCombDrug, 2762, 2771, "iGlarLixi", "", +70804, Percentage, 2795, 2797, "30", "", +69195, InsulinGlargine, 2803, 2808, "iGlar", "", +70805, BodyWeight, 2816, 2827, "body weight", "", +70806, Reduction, 2841, 2846, "0 . 7", "", +70807, Kg, 2847, 2849, "kg", "", +69187, FixedCombDrug, 2855, 2864, "iGlarLixi", "", +70810, Increment, 2882, 2887, "0 . 7", "", +70808, Kg, 2888, 2890, "kg", "", +69196, InsulinGlargine, 2896, 2901, "iGlar", "", +70811, DiffGroupAbsValue, 2904, 2909, "1 . 4", "", +70809, Kg, 2910, 2912, "kg", "", +70812, PvalueDiff, 2926, 2938, "P < 0 . 0001", "", +70815, ObservedResult, 2943, 3027, "Documented symptomatic hypoglycemia ( ≤ 70 mg / dL ) was comparable between groups .", "", +70813, SymptomaticHypoglycemia, 2954, 2978, "symptomatic hypoglycemia", "", +70814, Mg_per_deciliter, 2986, 2993, "mg / dL", "", +70817, ObservedResult, 3028, 3114, "Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi .", "", +70816, GastrointestinalProblem, 3033, 3065, "gastrointestinal adverse effects", "", +69199, FixedCombDrug, 3103, 3112, "iGlarLixi", "", +70823, ConclusionComment, 3129, 3321, "Compared with iGlar , a substantially higher proportion of iGlarLixi - treated patients achieved glycemic targets with a beneficial effect on body weight , no additional risk of hypoglycemia ,", "", +69198, InsulinGlargine, 3143, 3148, "iGlar", "", +69188, FixedCombDrug, 3188, 3197, "iGlarLixi", "", +70818, BodyWeight, 3271, 3282, "body weight", "", +70819, Hypoglycemia, 3307, 3319, "hypoglycemia", "", +70824, ConclusionComment, 3322, 3461, "and low levels of gastrointestinal adverse effects in inadequately controlled , basal insulin - treated , long - standing type 2 diabetes .", "", +70820, GastrointestinalProblem, 3340, 3372, "gastrointestinal adverse effects", "", +70822, Precondition, 3376, 3459, "inadequately controlled , basal insulin - treated , long - standing type 2 diabetes", "", +70821, Insulin, 3402, 3415, "basal insulin", "", +69203, Type2Diabetes, 3444, 3459, "type 2 diabetes", "", +70825, PMID, 3545, 3553, "27650977", "", diff --git a/data/dm2 27650977_kwoodley.n-triples b/data/dm2 27650977_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27650977_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27711199_admin.annodb b/data/dm2 27711199_admin.annodb new file mode 100644 index 0000000..9642c35 --- /dev/null +++ b/data/dm2 27711199_admin.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 8, "PLoS One", "", " \"PLoS One\"." +1, PublicationYear, 11, 15, "2016", "", " \"2016\"." +5, Title, 111, 290, "A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero - Incretin Study 1 ( SAIS1 ) .", "", " \"A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero - Incretin Study 1 ( SAIS1 ) .\"." +2, Randomized, 113, 123, "Randomized", "", " ." +3, Sitagliptin, 166, 177, "Sitagliptin", "", +4, Glimepiride, 182, 193, "Glimepiride", "", +6, Author, 291, 299, "Nomoto H", "", " \"Nomoto H\"." +7, Author, 308, 317, "Miyoshi H", "", " \"Miyoshi H\"." +8, Author, 326, 336, "Furumoto T", "", " \"Furumoto T\"." +9, Author, 351, 356, "Oba K", "", " \"Oba K\"." +10, Author, 371, 380, "Tsutsui H", "", " \"Tsutsui H\"." +11, Author, 389, 396, "Inoue A", "", " \"Inoue A\"." +12, Author, 405, 413, "Atsumi T", "", " \"Atsumi T\"." +13, Author, 422, 429, "Manda N", "", " \"Manda N\"." +14, Author, 438, 448, "Kurihara Y", "", " \"Kurihara Y\"." +15, Author, 457, 463, "Aoki S", "", " \"Aoki S\"." +16, Japan, 636, 641, "Japan", "", " ." +17, Japan, 734, 739, "Japan", "", +18, Japan, 848, 853, "Japan", "", +19, Japan, 982, 987, "Japan", "", +20, Japan, 1079, 1084, "Japan", "", +21, Japan, 1167, 1172, "Japan", "", +22, Japan, 1217, 1222, "Japan", "", +23, Japan, 1259, 1264, "Japan", "", +24, Japan, 1297, 1302, "Japan", "", +97271, Drug, 1322, 1340, "DPP - 4 inhibitors", "", +118, Hypoglycemia, 1383, 1396, "hyperglycemia", "", +97273, DisorderOrSyndrome, 1482, 1497, "atherosclerosis", "", +97274, Drug, 1551, 1569, "DPP - 4 inhibitors", "", +25, Type2Diabetes, 1628, 1643, "type 2 diabetes", "", " ." +123, ObjectiveDescription, 1658, 1824, "we investigated the efficacy of sitagliptin , a DPP - 4 inhibitor , on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride", "", " \"we investigated the efficacy of sitagliptin , a DPP - 4 inhibitor , on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride\"." +26, Sitagliptin, 1690, 1701, "sitagliptin", "", +97275, Drug, 1706, 1723, "DPP - 4 inhibitor", "", +27, Sulfonylureas, 1800, 1812, "sulfonylurea", "", +28, Glimepiride, 1813, 1824, "glimepiride", "", +32, Multicenter, 1859, 1870, "multicenter", "", " ." +33, Prospective, 1873, 1884, "prospective", "", " ." +34, Randomized, 1887, 1897, "randomized", "", +127, Parallel, 1898, 1914, "parallel - group", "", " ." +36, NumberPatientsCT, 1934, 1937, "103", "", " \"103\"." +134, Precondition, 1938, 2097, "outpatients with type 2 diabetes ( aged 59 . 9 ± 9 . 9 years with HbA1c levels of 7 . 5 ± 0 . 4 % ) with dietary cure only and / or current metformin treatment", "", " \"outpatients with type 2 diabetes ( aged 59 . 9 ± 9 . 9 years with HbA1c levels of 7 . 5 ± 0 . 4 % ) with dietary cure only and / or current metformin treatment\"." +37, Type2Diabetes, 1955, 1970, "type 2 diabetes", "", +129, AvgAge, 1978, 1984, "59 . 9", "", " \"59 . 9\"." +39, Year, 1993, 1998, "years", "", +40, HbA1c, 2004, 2009, "HbA1c", "", +42, Percentage, 2034, 2035, "%", "", +43, Metformin, 2078, 2087, "metformin", "", +44, Randomized, 2116, 2124, "randomly", "", +45, Sitagliptin, 2145, 2156, "sitagliptin", "", " ." +46, Glimepiride, 2160, 2171, "glimepiride", "", " ." +47, Frequency, 2180, 2190, "once daily", "", " \"once daily\". \"once daily\"." +48, Duration, 2195, 2203, "26 weeks", "", " \"26 weeks\"." +52, EndPointDescription, 2206, 2230, "Flow - mediated dilation", "", " . ." +53, EndPointDescription, 2233, 2236, "FMD", "", " . ." +49, Percentage, 2466, 2467, "%", "", +54, EndPointDescription, 2468, 2471, "FMD", "", +55, Sitagliptin, 2498, 2509, "sitagliptin", "", +57, BaseLineValue, 2512, 2517, "5 . 6", "", " \"5 . 6\"." +59, ResultMeasuredValue, 2521, 2526, "5 . 6", "", " \"5 . 6\"." +50, Percentage, 2527, 2528, "%", "", " ." +56, Glimepiride, 2531, 2542, "glimepiride", "", +58, BaseLineValue, 2545, 2550, "5 . 6", "", " \"5 . 6\"." +60, ResultMeasuredValue, 2554, 2559, "6 . 0", "", " \"6 . 0\"." +51, Percentage, 2560, 2561, "%", "", +66, EndPointDescription, 2566, 2610, "Secretory units of islets in transplantation", "", " . ." +67, EndPointDescription, 2613, 2620, "TNF", "", " . ." +68, EndPointDescription, 2621, 2632, "adiponectin", "", " . ." +69, EndPointDescription, 2637, 2669, "biological antioxidant potential", "", " . ." +70, ObservedResult, 2670, 2692, "significantly improved", "", " \"significantly improved\". \"significantly improved\". \"significantly improved\". \"significantly improved\"." +61, Sitagliptin, 2700, 2711, "sitagliptin", "", +71, EndPointDescription, 2724, 2744, "superoxide dismutase", "", " . ." +152, ObservedResult, 2750, 2767, "tended to improve", "", " \"tended to improve\"." +62, Sitagliptin, 2775, 2786, "sitagliptin", "", +153, ObservedResult, 2801, 2857, "improvements in HbA1c levels were similar between groups", "", " \"improvements in HbA1c levels were similar between groups\". \"improvements in HbA1c levels were similar between groups\"." +63, HbA1c, 2817, 2822, "HbA1c", "", " ." +64, EndPointDescription, 2860, 2873, "Cardiac index", "", " . ." +158, ObservedResult, 2860, 2947, "Cardiac index , blood pressure and most other metabolic parameters were not different .", "", " \"Cardiac index , blood pressure and most other metabolic parameters were not different .\". \"Cardiac index , blood pressure and most other metabolic parameters were not different .\". \"Cardiac index , blood pressure and most other metabolic parameters were not different .\". \"Cardiac index , blood pressure and most other metabolic parameters were not different .\"." +65, BloodPressure, 2876, 2890, "blood pressure", "", " . ." +74, ConclusionComment, 2962, 3138, "Regardless of glycemic improvement , early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta - cell function and on inflammatory", "", " \"Regardless of glycemic improvement , early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta - cell function and on inflammatory\". \"and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis .\"." +72, Sitagliptin, 3005, 3016, "sitagliptin", "", +74, ConclusionComment, 3139, 3227, "and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis .", "", " \"and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis .\"." +73, Type2Diabetes, 3177, 3192, "type 2 diabetes", "", +76, PMID, 3372, 3380, "27711199", "", " \"27711199\"." +77, ConflictInterest, 3438, 3624, "I have read the journal ' s policy and the authors of this manuscript have the following competing interests : H . Miyoshi has received honoraria for lectures from Astellas , AstraZeneca", "", +78, ConflictInterest, 3625, 3796, ", Dainippon Pharma , Eli Lilly , Kissei , Mitsubishi Tanabe Pharma , MSD , Novartis , Novo Nordisk and Sanofi ; and received scholarship grants from Astellas , AstraZeneca", "", +79, ConflictInterest, 3797, 3977, ", Daiichi Sankyo , Eli Lilly , Mitsubishi Tanabe Pharma , MSD , Novo Nordisk , Sanofi , Takeda and Taisho Pharmaceutical Co . , Ltd . T . Atsumi has received honoraria for lectures", "", +80, ConflictInterest, 3978, 4154, "from Takeda Pharmaceutical , Mitsubishi Tanabe Pharma , Pfizer , Eisai , Avvie , UCB Japan , Astellas Pharma and Chugai Pharmaceutical Co . , Ltd ; and received research grants", "", +81, ConflictInterest, 4155, 4291, "from Astellas , Chugai , Sanofi , Eisai , Alexion , Bristol - Myers Squibb , Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K . K .", "", +82, ConflictInterest, 4292, 4427, "; and received scholarship grants from Astellas , Takeda , Mitsubishi Tanabe Pharma , Chugai , Daiichi Sankyo , Eisai and Bayer , Ltd .", "", +83, ConflictInterest, 4428, 4514, "This does not alter our adherence to PLOS ONE policies on sharing data and materials .", "", diff --git a/data/dm2 27711199_admin.n-triples b/data/dm2 27711199_admin.n-triples new file mode 100644 index 0000000..1340762 --- /dev/null +++ b/data/dm2 27711199_admin.n-triples @@ -0,0 +1,210 @@ +# RDF export of group: Publication + . + "Publication 75038" . + "A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero - Incretin Study 1 ( SAIS1 ) ." . + "Nomoto H" . + "2016" . + "PLoS One" . + "27711199" . + . + "Miyoshi H" . + "Furumoto T" . + "Oba K" . + "Tsutsui H" . + "Inoue A" . + "Atsumi T" . + "Manda N" . + "Kurihara Y" . + "Aoki S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 75045" . + "we investigated the efficacy of sitagliptin , a DPP - 4 inhibitor , on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride" . + "103" . + "26 weeks" . + . + . + . + "Regardless of glycemic improvement , early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta - cell function and on inflammatory" . + "and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 75061" . + "outpatients with type 2 diabetes ( aged 59 . 9 ± 9 . 9 years with HbA1c levels of 7 . 5 ± 0 . 4 % ) with dietary cure only and / or current metformin treatment" . + . + . + "59 . 9" . + . +# RDF export of group: Endpoint + . + "fmd" . + . + . + . + . + . + . + "se" . + . + . + . + . + . + . + "tnf" . + . + . + . + . + . + . + "adi" . + . + . + . + . + . + . + "bio" . + . + . + . + . + . + . + "sup" . + . + . + . + . + . + . + "hba" . + . + . + . + . + . + "car" . + . + . + . + . + . + . + "bp" . + . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + . + . + . + . + . + . + . + . + . + . + . + . + "gli" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "once daily" . + . + . + "gli" . + . + "once daily" . + . +# RDF export of group: Medication + . + "sit" . + . + . + . + . + "gli" . + . + . + . +# RDF export of group: Outcome + . + "fmd 1" . + . + "5 . 6" . + "5 . 6" . + . + "fmd 2" . + . + "5 . 6" . + "6 . 0" . + . + "sec 1" . + . + "significantly improved" . + . + "tnf" . + . + "significantly improved" . + . + "adi" . + . + "significantly improved" . + . + "bio" . + . + "significantly improved" . + . + "sup" . + . + "tended to improve" . + . + "hba 1" . + . + "improvements in HbA1c levels were similar between groups" . + . + "hba 2" . + . + "improvements in HbA1c levels were similar between groups" . + . + "car 1" . + . + "Cardiac index , blood pressure and most other metabolic parameters were not different ." . + . + "car 2" . + . + "Cardiac index , blood pressure and most other metabolic parameters were not different ." . + . + "bp 1" . + . + "Cardiac index , blood pressure and most other metabolic parameters were not different ." . + . + "bp 2" . + . + "Cardiac index , blood pressure and most other metabolic parameters were not different ." . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27711199_akramersunderbrink.annodb b/data/dm2 27711199_akramersunderbrink.annodb new file mode 100644 index 0000000..5123742 --- /dev/null +++ b/data/dm2 27711199_akramersunderbrink.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66888, Journal, 0, 8, "PLoS One", "", +66889, PublicationYear, 11, 15, "2016", "", +66893, Title, 111, 290, "A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero - Incretin Study 1 ( SAIS1 ) .", "", +66890, Randomized, 113, 123, "Randomized", "", +66891, Sitagliptin, 166, 177, "Sitagliptin", "", +66892, Glimepiride, 182, 193, "Glimepiride", "", +66894, Author, 291, 299, "Nomoto H", "", +66895, Author, 308, 317, "Miyoshi H", "", +66896, Author, 326, 336, "Furumoto T", "", +66897, Author, 351, 356, "Oba K", "", +66898, Author, 371, 380, "Tsutsui H", "", +66899, Author, 389, 396, "Inoue A", "", +66900, Author, 405, 413, "Atsumi T", "", +66901, Author, 422, 429, "Manda N", "", +66902, Author, 438, 448, "Kurihara Y", "", +66903, Author, 457, 463, "Aoki S", "", +66904, Japan, 636, 641, "Japan", "", +66905, Japan, 734, 739, "Japan", "", +66906, Japan, 848, 853, "Japan", "", +66907, Japan, 982, 987, "Japan", "", +66908, Japan, 1079, 1084, "Japan", "", +66909, Japan, 1167, 1172, "Japan", "", +66910, Japan, 1217, 1222, "Japan", "", +66911, Japan, 1259, 1264, "Japan", "", +66912, Japan, 1297, 1302, "Japan", "", +66917, ObjectiveDescription, 1318, 1499, "The DPP - 4 inhibitors are incretin - related drugs that improve hyperglycemia in a glucose - dependent manner and have been reported to exert favorable effects on atherosclerosis .", "", +66918, ObjectiveDescription, 1500, 1645, "However , it has not been fully elucidated whether DPP - 4 inhibitors are able to improve endothelial function in patients with type 2 diabetes .", "", +66913, Type2Diabetes, 1628, 1643, "type 2 diabetes", "", +66919, ObjectiveDescription, 1646, 1826, "Therefore , we investigated the efficacy of sitagliptin , a DPP - 4 inhibitor , on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride .", "", +66914, Sitagliptin, 1690, 1701, "sitagliptin", "", +66915, Sulfonylureas, 1800, 1812, "sulfonylurea", "", +66916, Glimepiride, 1813, 1824, "glimepiride", "", +66920, Multicenter, 1859, 1870, "multicenter", "", +66921, Prospective, 1873, 1884, "prospective", "", +66922, Randomized, 1887, 1897, "randomized", "", +66923, Parallel, 1898, 1906, "parallel", "", +66924, NumberPatientsCT, 1934, 1937, "103", "", +66925, Type2Diabetes, 1955, 1970, "type 2 diabetes", "", +66926, AvgAge, 1978, 1980, "59", "", +66927, Year, 1993, 1998, "years", "", +66928, HbA1c, 2004, 2009, "HbA1c", "", +66929, Precondition, 2004, 2035, "HbA1c levels of 7 . 5 ± 0 . 4 %", "", +66930, Percentage, 2034, 2035, "%", "", +66931, Metformin, 2078, 2087, "metformin", "", +66932, Randomized, 2116, 2124, "randomly", "", +66933, Sitagliptin, 2145, 2156, "sitagliptin", "", +66934, Glimepiride, 2160, 2171, "glimepiride", "", +66935, Frequency, 2180, 2190, "once daily", "", +66936, Duration, 2195, 2203, "26 weeks", "", +66940, EndPointDescription, 2206, 2230, "Flow - mediated dilation", "", +66941, EndPointDescription, 2233, 2236, "FMD", "", +66937, Percentage, 2466, 2467, "%", "", +66942, EndPointDescription, 2468, 2471, "FMD", "", +66943, Sitagliptin, 2498, 2509, "sitagliptin", "", +66945, BaseLineValue, 2512, 2517, "5 . 6", "", +66947, ResultMeasuredValue, 2521, 2526, "5 . 6", "", +66938, Percentage, 2527, 2528, "%", "", +66944, Glimepiride, 2531, 2542, "glimepiride", "", +66946, BaseLineValue, 2545, 2550, "5 . 6", "", +66948, ResultMeasuredValue, 2554, 2559, "6 . 0", "", +66939, Percentage, 2560, 2561, "%", "", +66954, EndPointDescription, 2566, 2610, "Secretory units of islets in transplantation", "", +66955, EndPointDescription, 2613, 2620, "TNF -α,", "", +66956, EndPointDescription, 2621, 2632, "adiponectin", "", +66957, EndPointDescription, 2637, 2669, "biological antioxidant potential", "", +66958, ObservedResult, 2670, 2692, "significantly improved", "", +66949, Sitagliptin, 2700, 2711, "sitagliptin", "", +66959, EndPointDescription, 2724, 2744, "superoxide dismutase", "", +66950, Sitagliptin, 2775, 2786, "sitagliptin", "", +66951, HbA1c, 2817, 2822, "HbA1c", "", +66952, EndPointDescription, 2860, 2873, "Cardiac index", "", +66953, BloodPressure, 2876, 2890, "blood pressure", "", +66962, ConclusionComment, 2962, 3138, "Regardless of glycemic improvement , early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta - cell function and on inflammatory", "", +66960, Sitagliptin, 3005, 3016, "sitagliptin", "", +66963, ConclusionComment, 3139, 3227, "and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis .", "", +66961, Type2Diabetes, 3177, 3192, "type 2 diabetes", "", +66964, PMID, 3372, 3380, "27711199", "", +66965, ConflictInterest, 3438, 3624, "I have read the journal ' s policy and the authors of this manuscript have the following competing interests : H . Miyoshi has received honoraria for lectures from Astellas , AstraZeneca", "", +66966, ConflictInterest, 3625, 3796, ", Dainippon Pharma , Eli Lilly , Kissei , Mitsubishi Tanabe Pharma , MSD , Novartis , Novo Nordisk and Sanofi ; and received scholarship grants from Astellas , AstraZeneca", "", +66967, ConflictInterest, 3797, 3977, ", Daiichi Sankyo , Eli Lilly , Mitsubishi Tanabe Pharma , MSD , Novo Nordisk , Sanofi , Takeda and Taisho Pharmaceutical Co . , Ltd . T . Atsumi has received honoraria for lectures", "", +66968, ConflictInterest, 3978, 4154, "from Takeda Pharmaceutical , Mitsubishi Tanabe Pharma , Pfizer , Eisai , Avvie , UCB Japan , Astellas Pharma and Chugai Pharmaceutical Co . , Ltd ; and received research grants", "", +66969, ConflictInterest, 4155, 4291, "from Astellas , Chugai , Sanofi , Eisai , Alexion , Bristol - Myers Squibb , Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K . K .", "", +66970, ConflictInterest, 4292, 4427, "; and received scholarship grants from Astellas , Takeda , Mitsubishi Tanabe Pharma , Chugai , Daiichi Sankyo , Eisai and Bayer , Ltd .", "", +66971, ConflictInterest, 4428, 4514, "This does not alter our adherence to PLOS ONE policies on sharing data and materials .", "", diff --git a/data/dm2 27711199_akramersunderbrink.n-triples b/data/dm2 27711199_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27711199_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27711199_export.csv b/data/dm2 27711199_export.csv new file mode 100644 index 0000000..e34928c --- /dev/null +++ b/data/dm2 27711199_export.csv @@ -0,0 +1,847 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +258, 1, 1, 1, 0, 4, 0, 4, "PLoS" +258, 1, 2, 2, 5, 8, 5, 8, "One" +258, 1, 3, 3, 9, 10, 9, 10, "." +258, 2, 1, 4, 0, 4, 11, 15, "2016" +258, 2, 2, 5, 5, 8, 16, 19, "Oct" +258, 2, 3, 6, 9, 10, 20, 21, "6" +258, 2, 4, 7, 11, 12, 22, 23, ";" +258, 2, 5, 8, 13, 15, 24, 26, "11" +258, 2, 6, 9, 16, 17, 27, 28, "(" +258, 2, 7, 10, 18, 20, 29, 31, "10" +258, 2, 8, 11, 21, 22, 32, 33, ")" +258, 2, 9, 12, 23, 24, 34, 35, ":" +258, 2, 10, 13, 25, 33, 36, 44, "e0164255" +258, 2, 11, 14, 34, 35, 45, 46, "." +258, 3, 1, 15, 0, 3, 47, 50, "doi" +258, 3, 2, 16, 4, 5, 51, 52, ":" +258, 3, 3, 17, 6, 8, 53, 55, "10" +258, 3, 4, 18, 9, 10, 56, 57, "." +258, 3, 5, 19, 11, 15, 58, 62, "1371" +258, 3, 6, 20, 16, 17, 63, 64, "/" +258, 3, 7, 21, 18, 25, 65, 72, "journal" +258, 3, 8, 22, 26, 27, 73, 74, "." +258, 3, 9, 23, 28, 32, 75, 79, "pone" +258, 3, 10, 24, 33, 34, 80, 81, "." +258, 3, 11, 25, 35, 42, 82, 89, "0164255" +258, 3, 12, 26, 43, 44, 90, 91, "." +258, 4, 1, 27, 0, 11, 92, 103, "eCollection" +258, 4, 2, 28, 12, 16, 104, 108, "2016" +258, 4, 3, 29, 17, 18, 109, 110, "." +258, 5, 1, 30, 0, 1, 111, 112, "A" +258, 5, 2, 31, 2, 12, 113, 123, "Randomized" +258, 5, 3, 32, 13, 23, 124, 134, "Controlled" +258, 5, 4, 33, 24, 29, 135, 140, "Trial" +258, 5, 5, 34, 30, 39, 141, 150, "Comparing" +258, 5, 6, 35, 40, 43, 151, 154, "the" +258, 5, 7, 36, 44, 51, 155, 162, "Effects" +258, 5, 8, 37, 52, 54, 163, 165, "of" +258, 5, 9, 38, 55, 66, 166, 177, "Sitagliptin" +258, 5, 10, 39, 67, 70, 178, 181, "and" +258, 5, 11, 40, 71, 82, 182, 193, "Glimepiride" +258, 5, 12, 41, 83, 85, 194, 196, "on" +258, 5, 13, 42, 86, 97, 197, 208, "Endothelial" +258, 5, 14, 43, 98, 106, 209, 217, "Function" +258, 5, 15, 44, 107, 110, 218, 221, "and" +258, 5, 16, 45, 111, 120, 222, 231, "Metabolic" +258, 5, 17, 46, 121, 131, 232, 242, "Parameters" +258, 5, 18, 47, 132, 133, 243, 244, ":" +258, 5, 19, 48, 134, 141, 245, 252, "Sapporo" +258, 5, 20, 49, 142, 148, 253, 259, "Athero" +258, 5, 21, 50, 149, 150, 260, 261, "-" +258, 5, 22, 51, 151, 159, 262, 270, "Incretin" +258, 5, 23, 52, 160, 165, 271, 276, "Study" +258, 5, 24, 53, 166, 167, 277, 278, "1" +258, 5, 25, 54, 168, 169, 279, 280, "(" +258, 5, 26, 55, 170, 175, 281, 286, "SAIS1" +258, 5, 27, 56, 176, 177, 287, 288, ")" +258, 5, 28, 57, 178, 179, 289, 290, "." +258, 6, 1, 58, 0, 6, 291, 297, "Nomoto" +258, 6, 2, 59, 7, 8, 298, 299, "H" +258, 6, 3, 60, 9, 10, 300, 301, "(" +258, 6, 4, 61, 11, 12, 302, 303, "1" +258, 6, 5, 62, 13, 14, 304, 305, ")" +258, 6, 6, 63, 15, 16, 306, 307, "," +258, 6, 7, 64, 17, 24, 308, 315, "Miyoshi" +258, 6, 8, 65, 25, 26, 316, 317, "H" +258, 6, 9, 66, 27, 28, 318, 319, "(" +258, 6, 10, 67, 29, 30, 320, 321, "1" +258, 6, 11, 68, 31, 32, 322, 323, ")" +258, 6, 12, 69, 33, 34, 324, 325, "," +258, 6, 13, 70, 35, 43, 326, 334, "Furumoto" +258, 6, 14, 71, 44, 45, 335, 336, "T" +258, 6, 15, 72, 46, 47, 337, 338, "(" +258, 6, 16, 73, 48, 49, 339, 340, "2" +258, 6, 17, 74, 50, 51, 341, 342, ")" +258, 6, 18, 75, 52, 53, 343, 344, "(" +258, 6, 19, 76, 54, 55, 345, 346, "3" +258, 6, 20, 77, 56, 57, 347, 348, ")" +258, 6, 21, 78, 58, 59, 349, 350, "," +258, 6, 22, 79, 60, 63, 351, 354, "Oba" +258, 6, 23, 80, 64, 65, 355, 356, "K" +258, 6, 24, 81, 66, 67, 357, 358, "(" +258, 6, 25, 82, 68, 69, 359, 360, "4" +258, 6, 26, 83, 70, 71, 361, 362, ")" +258, 6, 27, 84, 72, 73, 363, 364, "(" +258, 6, 28, 85, 74, 75, 365, 366, "5" +258, 6, 29, 86, 76, 77, 367, 368, ")" +258, 6, 30, 87, 78, 79, 369, 370, "," +258, 6, 31, 88, 80, 87, 371, 378, "Tsutsui" +258, 6, 32, 89, 88, 89, 379, 380, "H" +258, 6, 33, 90, 90, 91, 381, 382, "(" +258, 6, 34, 91, 92, 93, 383, 384, "3" +258, 6, 35, 92, 94, 95, 385, 386, ")" +258, 6, 36, 93, 96, 97, 387, 388, "," +258, 6, 37, 94, 98, 103, 389, 394, "Inoue" +258, 6, 38, 95, 104, 105, 395, 396, "A" +258, 6, 39, 96, 106, 107, 397, 398, "(" +258, 6, 40, 97, 108, 109, 399, 400, "6" +258, 6, 41, 98, 110, 111, 401, 402, ")" +258, 6, 42, 99, 112, 113, 403, 404, "," +258, 6, 43, 100, 114, 120, 405, 411, "Atsumi" +258, 6, 44, 101, 121, 122, 412, 413, "T" +258, 6, 45, 102, 123, 124, 414, 415, "(" +258, 6, 46, 103, 125, 126, 416, 417, "1" +258, 6, 47, 104, 127, 128, 418, 419, ")" +258, 6, 48, 105, 129, 130, 420, 421, "," +258, 6, 49, 106, 131, 136, 422, 427, "Manda" +258, 6, 50, 107, 137, 138, 428, 429, "N" +258, 6, 51, 108, 139, 140, 430, 431, "(" +258, 6, 52, 109, 141, 142, 432, 433, "7" +258, 6, 53, 110, 143, 144, 434, 435, ")" +258, 6, 54, 111, 145, 146, 436, 437, "," +258, 6, 55, 112, 147, 155, 438, 446, "Kurihara" +258, 6, 56, 113, 156, 157, 447, 448, "Y" +258, 6, 57, 114, 158, 159, 449, 450, "(" +258, 6, 58, 115, 160, 161, 451, 452, "8" +258, 6, 59, 116, 162, 163, 453, 454, ")" +258, 6, 60, 117, 164, 165, 455, 456, "," +258, 6, 61, 118, 166, 170, 457, 461, "Aoki" +258, 6, 62, 119, 171, 172, 462, 463, "S" +258, 6, 63, 120, 173, 174, 464, 465, "(" +258, 6, 64, 121, 175, 176, 466, 467, "9" +258, 6, 65, 122, 177, 178, 468, 469, ")" +258, 6, 66, 123, 179, 180, 470, 471, ";" +258, 6, 67, 124, 181, 185, 472, 476, "SAIS" +258, 6, 68, 125, 186, 191, 477, 482, "Study" +258, 6, 69, 126, 192, 197, 483, 488, "Group" +258, 6, 70, 127, 198, 199, 489, 490, "." +258, 7, 1, 128, 0, 6, 491, 497, "Author" +258, 7, 2, 129, 7, 18, 498, 509, "information" +258, 7, 3, 130, 19, 20, 510, 511, ":" +258, 7, 4, 131, 21, 22, 512, 513, "(" +258, 7, 5, 132, 23, 24, 514, 515, "1" +258, 7, 6, 133, 25, 26, 516, 517, ")" +258, 7, 7, 134, 27, 35, 518, 526, "Division" +258, 7, 8, 135, 36, 38, 527, 529, "of" +258, 7, 9, 136, 39, 51, 530, 542, "Rheumatology" +258, 7, 10, 137, 52, 53, 543, 544, "," +258, 7, 11, 138, 54, 67, 545, 558, "Endocrinology" +258, 7, 12, 139, 68, 71, 559, 562, "and" +258, 7, 13, 140, 72, 82, 563, 573, "Nephrology" +258, 7, 14, 141, 83, 84, 574, 575, "," +258, 7, 15, 142, 85, 93, 576, 584, "Hokkaido" +258, 7, 16, 143, 94, 104, 585, 595, "University" +258, 7, 17, 144, 105, 113, 596, 604, "Graduate" +258, 7, 18, 145, 114, 120, 605, 611, "School" +258, 7, 19, 146, 121, 123, 612, 614, "of" +258, 7, 20, 147, 124, 132, 615, 623, "Medicine" +258, 7, 21, 148, 133, 134, 624, 625, "," +258, 7, 22, 149, 135, 142, 626, 633, "Sapporo" +258, 7, 23, 150, 143, 144, 634, 635, "," +258, 7, 24, 151, 145, 150, 636, 641, "Japan" +258, 7, 25, 152, 151, 152, 642, 643, "." +258, 8, 1, 153, 0, 1, 644, 645, "(" +258, 8, 2, 154, 2, 3, 646, 647, "2" +258, 8, 3, 155, 4, 5, 648, 649, ")" +258, 8, 4, 156, 6, 16, 650, 660, "Department" +258, 8, 5, 157, 17, 19, 661, 663, "of" +258, 8, 6, 158, 20, 34, 664, 678, "Cardiovascular" +258, 8, 7, 159, 35, 43, 679, 687, "Medicine" +258, 8, 8, 160, 44, 45, 688, 689, "," +258, 8, 9, 161, 46, 49, 690, 693, "NTT" +258, 8, 10, 162, 50, 54, 694, 698, "East" +258, 8, 11, 163, 55, 60, 699, 704, "Japan" +258, 8, 12, 164, 61, 68, 705, 712, "Sapporo" +258, 8, 13, 165, 69, 77, 713, 721, "Hospital" +258, 8, 14, 166, 78, 79, 722, 723, "," +258, 8, 15, 167, 80, 87, 724, 731, "Sapporo" +258, 8, 16, 168, 88, 89, 732, 733, "," +258, 8, 17, 169, 90, 95, 734, 739, "Japan" +258, 8, 18, 170, 96, 97, 740, 741, "." +258, 9, 1, 171, 0, 1, 742, 743, "(" +258, 9, 2, 172, 2, 3, 744, 745, "3" +258, 9, 3, 173, 4, 5, 746, 747, ")" +258, 9, 4, 174, 6, 16, 748, 758, "Department" +258, 9, 5, 175, 17, 19, 759, 761, "of" +258, 9, 6, 176, 20, 34, 762, 776, "Cardiovascular" +258, 9, 7, 177, 35, 43, 777, 785, "Medicine" +258, 9, 8, 178, 44, 45, 786, 787, "," +258, 9, 9, 179, 46, 54, 788, 796, "Hokkaido" +258, 9, 10, 180, 55, 65, 797, 807, "University" +258, 9, 11, 181, 66, 74, 808, 816, "Graduate" +258, 9, 12, 182, 75, 81, 817, 823, "School" +258, 9, 13, 183, 82, 84, 824, 826, "of" +258, 9, 14, 184, 85, 93, 827, 835, "Medicine" +258, 9, 15, 185, 94, 95, 836, 837, "," +258, 9, 16, 186, 96, 103, 838, 845, "Sapporo" +258, 9, 17, 187, 104, 105, 846, 847, "," +258, 9, 18, 188, 106, 111, 848, 853, "Japan" +258, 9, 19, 189, 112, 113, 854, 855, "." +258, 10, 1, 190, 0, 1, 856, 857, "(" +258, 10, 2, 191, 2, 3, 858, 859, "4" +258, 10, 3, 192, 4, 5, 860, 861, ")" +258, 10, 4, 193, 6, 16, 862, 872, "Department" +258, 10, 5, 194, 17, 19, 873, 875, "of" +258, 10, 6, 195, 20, 33, 876, 889, "Biostatistics" +258, 10, 7, 196, 34, 35, 890, 891, "," +258, 10, 8, 197, 36, 42, 892, 898, "School" +258, 10, 9, 198, 43, 45, 899, 901, "of" +258, 10, 10, 199, 46, 52, 902, 908, "Public" +258, 10, 11, 200, 53, 59, 909, 915, "Health" +258, 10, 12, 201, 60, 61, 916, 917, "," +258, 10, 13, 202, 62, 70, 918, 926, "Graduate" +258, 10, 14, 203, 71, 77, 927, 933, "School" +258, 10, 15, 204, 78, 80, 934, 936, "of" +258, 10, 16, 205, 81, 89, 937, 945, "Medicine" +258, 10, 17, 206, 90, 91, 946, 947, "," +258, 10, 18, 207, 92, 95, 948, 951, "The" +258, 10, 19, 208, 96, 106, 952, 962, "University" +258, 10, 20, 209, 107, 109, 963, 965, "of" +258, 10, 21, 210, 110, 115, 966, 971, "Tokyo" +258, 10, 22, 211, 116, 117, 972, 973, "," +258, 10, 23, 212, 118, 123, 974, 979, "Tokyo" +258, 10, 24, 213, 124, 125, 980, 981, "," +258, 10, 25, 214, 126, 131, 982, 987, "Japan" +258, 10, 26, 215, 132, 133, 988, 989, "." +258, 11, 1, 216, 0, 1, 990, 991, "(" +258, 11, 2, 217, 2, 3, 992, 993, "5" +258, 11, 3, 218, 4, 5, 994, 995, ")" +258, 11, 4, 219, 6, 18, 996, 1008, "Interfaculty" +258, 11, 5, 220, 19, 29, 1009, 1019, "Initiative" +258, 11, 6, 221, 30, 32, 1020, 1022, "in" +258, 11, 7, 222, 33, 44, 1023, 1034, "Information" +258, 11, 8, 223, 45, 52, 1035, 1042, "Studies" +258, 11, 9, 224, 53, 54, 1043, 1044, "," +258, 11, 10, 225, 55, 58, 1045, 1048, "The" +258, 11, 11, 226, 59, 69, 1049, 1059, "University" +258, 11, 12, 227, 70, 72, 1060, 1062, "of" +258, 11, 13, 228, 73, 78, 1063, 1068, "Tokyo" +258, 11, 14, 229, 79, 80, 1069, 1070, "," +258, 11, 15, 230, 81, 86, 1071, 1076, "Tokyo" +258, 11, 16, 231, 87, 88, 1077, 1078, "," +258, 11, 17, 232, 89, 94, 1079, 1084, "Japan" +258, 11, 18, 233, 95, 96, 1085, 1086, "." +258, 12, 1, 234, 0, 1, 1087, 1088, "(" +258, 12, 2, 235, 2, 3, 1089, 1090, "6" +258, 12, 3, 236, 4, 5, 1091, 1092, ")" +258, 12, 4, 237, 6, 11, 1093, 1098, "Japan" +258, 12, 5, 238, 12, 21, 1099, 1108, "Community" +258, 12, 6, 239, 22, 32, 1109, 1119, "Healthcare" +258, 12, 7, 240, 33, 36, 1120, 1123, "and" +258, 12, 8, 241, 37, 49, 1124, 1136, "Organization" +258, 12, 9, 242, 50, 58, 1137, 1145, "Hokkaido" +258, 12, 10, 243, 59, 67, 1146, 1154, "Hospital" +258, 12, 11, 244, 68, 69, 1155, 1156, "," +258, 12, 12, 245, 70, 77, 1157, 1164, "Sapporo" +258, 12, 13, 246, 78, 79, 1165, 1166, "," +258, 12, 14, 247, 80, 85, 1167, 1172, "Japan" +258, 12, 15, 248, 86, 87, 1173, 1174, "." +258, 13, 1, 249, 0, 1, 1175, 1176, "(" +258, 13, 2, 250, 2, 3, 1177, 1178, "7" +258, 13, 3, 251, 4, 5, 1179, 1180, ")" +258, 13, 4, 252, 6, 11, 1181, 1186, "Manda" +258, 13, 5, 253, 12, 20, 1187, 1195, "Memorial" +258, 13, 6, 254, 21, 29, 1196, 1204, "Hospital" +258, 13, 7, 255, 30, 31, 1205, 1206, "," +258, 13, 8, 256, 32, 39, 1207, 1214, "Sapporo" +258, 13, 9, 257, 40, 41, 1215, 1216, "," +258, 13, 10, 258, 42, 47, 1217, 1222, "Japan" +258, 13, 11, 259, 48, 49, 1223, 1224, "." +258, 14, 1, 260, 0, 1, 1225, 1226, "(" +258, 14, 2, 261, 2, 3, 1227, 1228, "8" +258, 14, 3, 262, 4, 5, 1229, 1230, ")" +258, 14, 4, 263, 6, 14, 1231, 1239, "Kurihara" +258, 14, 5, 264, 15, 21, 1240, 1246, "Clinic" +258, 14, 6, 265, 22, 23, 1247, 1248, "," +258, 14, 7, 266, 24, 31, 1249, 1256, "Sapporo" +258, 14, 8, 267, 32, 33, 1257, 1258, "," +258, 14, 9, 268, 34, 39, 1259, 1264, "Japan" +258, 14, 10, 269, 40, 41, 1265, 1266, "." +258, 15, 1, 270, 0, 1, 1267, 1268, "(" +258, 15, 2, 271, 2, 3, 1269, 1270, "9" +258, 15, 3, 272, 4, 5, 1271, 1272, ")" +258, 15, 4, 273, 6, 10, 1273, 1277, "Aoki" +258, 15, 5, 274, 11, 17, 1278, 1284, "Clinic" +258, 15, 6, 275, 18, 19, 1285, 1286, "," +258, 15, 7, 276, 20, 27, 1287, 1294, "Sapporo" +258, 15, 8, 277, 28, 29, 1295, 1296, "," +258, 15, 9, 278, 30, 35, 1297, 1302, "Japan" +258, 15, 10, 279, 36, 37, 1303, 1304, "." +258, 16, 1, 280, 0, 10, 1305, 1315, "OBJECTIVES" +258, 16, 2, 281, 11, 12, 1316, 1317, ":" +258, 16, 3, 282, 13, 16, 1318, 1321, "The" +258, 16, 4, 283, 17, 20, 1322, 1325, "DPP" +258, 16, 5, 284, 21, 22, 1326, 1327, "-" +258, 16, 6, 285, 23, 24, 1328, 1329, "4" +258, 16, 7, 286, 25, 35, 1330, 1340, "inhibitors" +258, 16, 8, 287, 36, 39, 1341, 1344, "are" +258, 16, 9, 288, 40, 48, 1345, 1353, "incretin" +258, 16, 10, 289, 49, 50, 1354, 1355, "-" +258, 16, 11, 290, 51, 58, 1356, 1363, "related" +258, 16, 12, 291, 59, 64, 1364, 1369, "drugs" +258, 16, 13, 292, 65, 69, 1370, 1374, "that" +258, 16, 14, 293, 70, 77, 1375, 1382, "improve" +258, 16, 15, 294, 78, 91, 1383, 1396, "hyperglycemia" +258, 16, 16, 295, 92, 94, 1397, 1399, "in" +258, 16, 17, 296, 95, 96, 1400, 1401, "a" +258, 16, 18, 297, 97, 104, 1402, 1409, "glucose" +258, 16, 19, 298, 105, 106, 1410, 1411, "-" +258, 16, 20, 299, 107, 116, 1412, 1421, "dependent" +258, 16, 21, 300, 117, 123, 1422, 1428, "manner" +258, 16, 22, 301, 124, 127, 1429, 1432, "and" +258, 16, 23, 302, 128, 132, 1433, 1437, "have" +258, 16, 24, 303, 133, 137, 1438, 1442, "been" +258, 16, 25, 304, 138, 146, 1443, 1451, "reported" +258, 16, 26, 305, 147, 149, 1452, 1454, "to" +258, 16, 27, 306, 150, 155, 1455, 1460, "exert" +258, 16, 28, 307, 156, 165, 1461, 1470, "favorable" +258, 16, 29, 308, 166, 173, 1471, 1478, "effects" +258, 16, 30, 309, 174, 176, 1479, 1481, "on" +258, 16, 31, 310, 177, 192, 1482, 1497, "atherosclerosis" +258, 16, 32, 311, 193, 194, 1498, 1499, "." +258, 17, 1, 312, 0, 7, 1500, 1507, "However" +258, 17, 2, 313, 8, 9, 1508, 1509, "," +258, 17, 3, 314, 10, 12, 1510, 1512, "it" +258, 17, 4, 315, 13, 16, 1513, 1516, "has" +258, 17, 5, 316, 17, 20, 1517, 1520, "not" +258, 17, 6, 317, 21, 25, 1521, 1525, "been" +258, 17, 7, 318, 26, 31, 1526, 1531, "fully" +258, 17, 8, 319, 32, 42, 1532, 1542, "elucidated" +258, 17, 9, 320, 43, 50, 1543, 1550, "whether" +258, 17, 10, 321, 51, 54, 1551, 1554, "DPP" +258, 17, 11, 322, 55, 56, 1555, 1556, "-" +258, 17, 12, 323, 57, 58, 1557, 1558, "4" +258, 17, 13, 324, 59, 69, 1559, 1569, "inhibitors" +258, 17, 14, 325, 70, 73, 1570, 1573, "are" +258, 17, 15, 326, 74, 78, 1574, 1578, "able" +258, 17, 16, 327, 79, 81, 1579, 1581, "to" +258, 17, 17, 328, 82, 89, 1582, 1589, "improve" +258, 17, 18, 329, 90, 101, 1590, 1601, "endothelial" +258, 17, 19, 330, 102, 110, 1602, 1610, "function" +258, 17, 20, 331, 111, 113, 1611, 1613, "in" +258, 17, 21, 332, 114, 122, 1614, 1622, "patients" +258, 17, 22, 333, 123, 127, 1623, 1627, "with" +258, 17, 23, 334, 128, 132, 1628, 1632, "type" +258, 17, 24, 335, 133, 134, 1633, 1634, "2" +258, 17, 25, 336, 135, 143, 1635, 1643, "diabetes" +258, 17, 26, 337, 144, 145, 1644, 1645, "." +258, 18, 1, 338, 0, 9, 1646, 1655, "Therefore" +258, 18, 2, 339, 10, 11, 1656, 1657, "," +258, 18, 3, 340, 12, 14, 1658, 1660, "we" +258, 18, 4, 341, 15, 27, 1661, 1673, "investigated" +258, 18, 5, 342, 28, 31, 1674, 1677, "the" +258, 18, 6, 343, 32, 40, 1678, 1686, "efficacy" +258, 18, 7, 344, 41, 43, 1687, 1689, "of" +258, 18, 8, 345, 44, 55, 1690, 1701, "sitagliptin" +258, 18, 9, 346, 56, 57, 1702, 1703, "," +258, 18, 10, 347, 58, 59, 1704, 1705, "a" +258, 18, 11, 348, 60, 63, 1706, 1709, "DPP" +258, 18, 12, 349, 64, 65, 1710, 1711, "-" +258, 18, 13, 350, 66, 67, 1712, 1713, "4" +258, 18, 14, 351, 68, 77, 1714, 1723, "inhibitor" +258, 18, 15, 352, 78, 79, 1724, 1725, "," +258, 18, 16, 353, 80, 82, 1726, 1728, "on" +258, 18, 17, 354, 83, 94, 1729, 1740, "endothelial" +258, 18, 18, 355, 95, 103, 1741, 1749, "function" +258, 18, 19, 356, 104, 107, 1750, 1753, "and" +258, 18, 20, 357, 108, 116, 1754, 1762, "glycemic" +258, 18, 21, 358, 117, 127, 1763, 1773, "metabolism" +258, 18, 22, 359, 128, 136, 1774, 1782, "compared" +258, 18, 23, 360, 137, 141, 1783, 1787, "with" +258, 18, 24, 361, 142, 146, 1788, 1792, "that" +258, 18, 25, 362, 147, 149, 1793, 1795, "of" +258, 18, 26, 363, 150, 153, 1796, 1799, "the" +258, 18, 27, 364, 154, 166, 1800, 1812, "sulfonylurea" +258, 18, 28, 365, 167, 178, 1813, 1824, "glimepiride" +258, 18, 29, 366, 179, 180, 1825, 1826, "." +258, 19, 1, 367, 0, 9, 1827, 1836, "MATERIALS" +258, 19, 2, 368, 10, 13, 1837, 1840, "AND" +258, 19, 3, 369, 14, 21, 1841, 1848, "METHODS" +258, 19, 4, 370, 22, 23, 1849, 1850, ":" +258, 19, 5, 371, 24, 26, 1851, 1853, "In" +258, 19, 6, 372, 27, 31, 1854, 1858, "this" +258, 19, 7, 373, 32, 43, 1859, 1870, "multicenter" +258, 19, 8, 374, 44, 45, 1871, 1872, "," +258, 19, 9, 375, 46, 57, 1873, 1884, "prospective" +258, 19, 10, 376, 58, 59, 1885, 1886, "," +258, 19, 11, 377, 60, 70, 1887, 1897, "randomized" +258, 19, 12, 378, 71, 79, 1898, 1906, "parallel" +258, 19, 13, 379, 80, 81, 1907, 1908, "-" +258, 19, 14, 380, 82, 87, 1909, 1914, "group" +258, 19, 15, 381, 88, 98, 1915, 1925, "comparison" +258, 19, 16, 382, 99, 104, 1926, 1931, "study" +258, 19, 17, 383, 105, 106, 1932, 1933, "," +258, 19, 18, 384, 107, 110, 1934, 1937, "103" +258, 19, 19, 385, 111, 122, 1938, 1949, "outpatients" +258, 19, 20, 386, 123, 127, 1950, 1954, "with" +258, 19, 21, 387, 128, 132, 1955, 1959, "type" +258, 19, 22, 388, 133, 134, 1960, 1961, "2" +258, 19, 23, 389, 135, 143, 1962, 1970, "diabetes" +258, 19, 24, 390, 144, 145, 1971, 1972, "(" +258, 19, 25, 391, 146, 150, 1973, 1977, "aged" +258, 19, 26, 392, 151, 153, 1978, 1980, "59" +258, 19, 27, 393, 154, 155, 1981, 1982, "." +258, 19, 28, 394, 156, 157, 1983, 1984, "9" +258, 19, 29, 395, 158, 159, 1985, 1986, "±" +258, 19, 30, 396, 160, 161, 1987, 1988, "9" +258, 19, 31, 397, 162, 163, 1989, 1990, "." +258, 19, 32, 398, 164, 165, 1991, 1992, "9" +258, 19, 33, 399, 166, 171, 1993, 1998, "years" +258, 19, 34, 400, 172, 176, 1999, 2003, "with" +258, 19, 35, 401, 177, 182, 2004, 2009, "HbA1c" +258, 19, 36, 402, 183, 189, 2010, 2016, "levels" +258, 19, 37, 403, 190, 192, 2017, 2019, "of" +258, 19, 38, 404, 193, 194, 2020, 2021, "7" +258, 19, 39, 405, 195, 196, 2022, 2023, "." +258, 19, 40, 406, 197, 198, 2024, 2025, "5" +258, 19, 41, 407, 199, 200, 2026, 2027, "±" +258, 19, 42, 408, 201, 202, 2028, 2029, "0" +258, 19, 43, 409, 203, 204, 2030, 2031, "." +258, 19, 44, 410, 205, 206, 2032, 2033, "4" +258, 19, 45, 411, 207, 208, 2034, 2035, "%" +258, 19, 46, 412, 209, 210, 2036, 2037, ")" +258, 19, 47, 413, 211, 215, 2038, 2042, "with" +258, 19, 48, 414, 216, 223, 2043, 2050, "dietary" +258, 19, 49, 415, 224, 228, 2051, 2055, "cure" +258, 19, 50, 416, 229, 233, 2056, 2060, "only" +258, 19, 51, 417, 234, 237, 2061, 2064, "and" +258, 19, 52, 418, 238, 239, 2065, 2066, "/" +258, 19, 53, 419, 240, 242, 2067, 2069, "or" +258, 19, 54, 420, 243, 250, 2070, 2077, "current" +258, 19, 55, 421, 251, 260, 2078, 2087, "metformin" +258, 19, 56, 422, 261, 270, 2088, 2097, "treatment" +258, 19, 57, 423, 271, 275, 2098, 2102, "were" +258, 19, 58, 424, 276, 284, 2103, 2111, "enrolled" +258, 19, 59, 425, 285, 288, 2112, 2115, "and" +258, 19, 60, 426, 289, 297, 2116, 2124, "randomly" +258, 19, 61, 427, 298, 306, 2125, 2133, "assigned" +258, 19, 62, 428, 307, 309, 2134, 2136, "to" +258, 19, 63, 429, 310, 317, 2137, 2144, "receive" +258, 19, 64, 430, 318, 329, 2145, 2156, "sitagliptin" +258, 19, 65, 431, 330, 332, 2157, 2159, "or" +258, 19, 66, 432, 333, 344, 2160, 2171, "glimepiride" +258, 19, 67, 433, 345, 352, 2172, 2179, "therapy" +258, 19, 68, 434, 353, 357, 2180, 2184, "once" +258, 19, 69, 435, 358, 363, 2185, 2190, "daily" +258, 19, 70, 436, 364, 367, 2191, 2194, "for" +258, 19, 71, 437, 368, 370, 2195, 2197, "26" +258, 19, 72, 438, 371, 376, 2198, 2203, "weeks" +258, 19, 73, 439, 377, 378, 2204, 2205, "." +258, 20, 1, 440, 0, 4, 2206, 2210, "Flow" +258, 20, 2, 441, 5, 6, 2211, 2212, "-" +258, 20, 3, 442, 7, 15, 2213, 2221, "mediated" +258, 20, 4, 443, 16, 24, 2222, 2230, "dilation" +258, 20, 5, 444, 25, 26, 2231, 2232, "(" +258, 20, 6, 445, 27, 30, 2233, 2236, "FMD" +258, 20, 7, 446, 31, 32, 2237, 2238, ")" +258, 20, 8, 447, 33, 34, 2239, 2240, "," +258, 20, 9, 448, 35, 36, 2241, 2242, "a" +258, 20, 10, 449, 37, 50, 2243, 2256, "comprehensive" +258, 20, 11, 450, 51, 56, 2257, 2262, "panel" +258, 20, 12, 451, 57, 59, 2263, 2265, "of" +258, 20, 13, 452, 60, 71, 2266, 2277, "hemodynamic" +258, 20, 14, 453, 72, 82, 2278, 2288, "parameters" +258, 20, 15, 454, 83, 84, 2289, 2290, "(" +258, 20, 16, 455, 85, 89, 2291, 2295, "Task" +258, 20, 17, 456, 90, 95, 2296, 2301, "Force" +258, 20, 18, 457, 96, 97, 2302, 2303, "®" +258, 20, 19, 458, 98, 105, 2304, 2311, "Monitor" +258, 20, 20, 459, 106, 107, 2312, 2313, ")" +258, 20, 21, 460, 108, 109, 2314, 2315, "," +258, 20, 22, 461, 110, 113, 2316, 2319, "and" +258, 20, 23, 462, 114, 119, 2320, 2325, "serum" +258, 20, 24, 463, 120, 129, 2326, 2335, "metabolic" +258, 20, 25, 464, 130, 137, 2336, 2343, "markers" +258, 20, 26, 465, 138, 142, 2344, 2348, "were" +258, 20, 27, 466, 143, 151, 2349, 2357, "assessed" +258, 20, 28, 467, 152, 158, 2358, 2364, "before" +258, 20, 29, 468, 159, 162, 2365, 2368, "and" +258, 20, 30, 469, 163, 168, 2369, 2374, "after" +258, 20, 31, 470, 169, 172, 2375, 2378, "the" +258, 20, 32, 471, 173, 182, 2379, 2388, "treatment" +258, 20, 33, 472, 183, 184, 2389, 2390, "." +258, 21, 1, 473, 0, 7, 2391, 2398, "RESULTS" +258, 21, 2, 474, 8, 9, 2399, 2400, ":" +258, 21, 3, 475, 10, 16, 2401, 2407, "During" +258, 21, 4, 476, 17, 20, 2408, 2411, "the" +258, 21, 5, 477, 21, 26, 2412, 2417, "study" +258, 21, 6, 478, 27, 33, 2418, 2424, "period" +258, 21, 7, 479, 34, 35, 2425, 2426, "," +258, 21, 8, 480, 36, 38, 2427, 2429, "no" +258, 21, 9, 481, 39, 52, 2430, 2443, "statistically" +258, 21, 10, 482, 53, 64, 2444, 2455, "significant" +258, 21, 11, 483, 65, 71, 2456, 2462, "change" +258, 21, 12, 484, 72, 74, 2463, 2465, "in" +258, 21, 13, 485, 75, 76, 2466, 2467, "%" +258, 21, 14, 486, 77, 80, 2468, 2471, "FMD" +258, 21, 15, 487, 81, 84, 2472, 2475, "was" +258, 21, 16, 488, 85, 89, 2476, 2480, "seen" +258, 21, 17, 489, 90, 92, 2481, 2483, "in" +258, 21, 18, 490, 93, 97, 2484, 2488, "both" +258, 21, 19, 491, 98, 104, 2489, 2495, "groups" +258, 21, 20, 492, 105, 106, 2496, 2497, "(" +258, 21, 21, 493, 107, 118, 2498, 2509, "sitagliptin" +258, 21, 22, 494, 119, 120, 2510, 2511, "," +258, 21, 23, 495, 121, 122, 2512, 2513, "5" +258, 21, 24, 496, 123, 124, 2514, 2515, "." +258, 21, 25, 497, 125, 126, 2516, 2517, "6" +258, 21, 26, 498, 127, 129, 2518, 2520, "to" +258, 21, 27, 499, 130, 131, 2521, 2522, "5" +258, 21, 28, 500, 132, 133, 2523, 2524, "." +258, 21, 29, 501, 134, 135, 2525, 2526, "6" +258, 21, 30, 502, 136, 137, 2527, 2528, "%" +258, 21, 31, 503, 138, 139, 2529, 2530, ";" +258, 21, 32, 504, 140, 151, 2531, 2542, "glimepiride" +258, 21, 33, 505, 152, 153, 2543, 2544, "," +258, 21, 34, 506, 154, 155, 2545, 2546, "5" +258, 21, 35, 507, 156, 157, 2547, 2548, "." +258, 21, 36, 508, 158, 159, 2549, 2550, "6" +258, 21, 37, 509, 160, 162, 2551, 2553, "to" +258, 21, 38, 510, 163, 164, 2554, 2555, "6" +258, 21, 39, 511, 165, 166, 2556, 2557, "." +258, 21, 40, 512, 167, 168, 2558, 2559, "0" +258, 21, 41, 513, 169, 170, 2560, 2561, "%" +258, 21, 42, 514, 171, 172, 2562, 2563, ")" +258, 21, 43, 515, 173, 174, 2564, 2565, "." +258, 22, 1, 516, 0, 9, 2566, 2575, "Secretory" +258, 22, 2, 517, 10, 15, 2576, 2581, "units" +258, 22, 3, 518, 16, 18, 2582, 2584, "of" +258, 22, 4, 519, 19, 25, 2585, 2591, "islets" +258, 22, 5, 520, 26, 28, 2592, 2594, "in" +258, 22, 6, 521, 29, 44, 2595, 2610, "transplantation" +258, 22, 7, 522, 45, 46, 2611, 2612, "," +258, 22, 8, 523, 47, 50, 2613, 2616, "TNF" +258, 22, 9, 524, 51, 54, 2617, 2620, "-α," +258, 22, 10, 525, 55, 66, 2621, 2632, "adiponectin" +258, 22, 11, 526, 67, 70, 2633, 2636, "and" +258, 22, 12, 527, 71, 81, 2637, 2647, "biological" +258, 22, 13, 528, 82, 93, 2648, 2659, "antioxidant" +258, 22, 14, 529, 94, 103, 2660, 2669, "potential" +258, 22, 15, 530, 104, 117, 2670, 2683, "significantly" +258, 22, 16, 531, 118, 126, 2684, 2692, "improved" +258, 22, 17, 532, 127, 129, 2693, 2695, "in" +258, 22, 18, 533, 130, 133, 2696, 2699, "the" +258, 22, 19, 534, 134, 145, 2700, 2711, "sitagliptin" +258, 22, 20, 535, 146, 151, 2712, 2717, "group" +258, 22, 21, 536, 152, 153, 2718, 2719, "," +258, 22, 22, 537, 154, 157, 2720, 2723, "and" +258, 22, 23, 538, 158, 168, 2724, 2734, "superoxide" +258, 22, 24, 539, 169, 178, 2735, 2744, "dismutase" +258, 22, 25, 540, 179, 183, 2745, 2749, "also" +258, 22, 26, 541, 184, 190, 2750, 2756, "tended" +258, 22, 27, 542, 191, 193, 2757, 2759, "to" +258, 22, 28, 543, 194, 201, 2760, 2767, "improve" +258, 22, 29, 544, 202, 204, 2768, 2770, "in" +258, 22, 30, 545, 205, 208, 2771, 2774, "the" +258, 22, 31, 546, 209, 220, 2775, 2786, "sitagliptin" +258, 22, 32, 547, 221, 226, 2787, 2792, "group" +258, 22, 33, 548, 227, 228, 2793, 2794, "," +258, 22, 34, 549, 229, 234, 2795, 2800, "while" +258, 22, 35, 550, 235, 247, 2801, 2813, "improvements" +258, 22, 36, 551, 248, 250, 2814, 2816, "in" +258, 22, 37, 552, 251, 256, 2817, 2822, "HbA1c" +258, 22, 38, 553, 257, 263, 2823, 2829, "levels" +258, 22, 39, 554, 264, 268, 2830, 2834, "were" +258, 22, 40, 555, 269, 276, 2835, 2842, "similar" +258, 22, 41, 556, 277, 284, 2843, 2850, "between" +258, 22, 42, 557, 285, 291, 2851, 2857, "groups" +258, 22, 43, 558, 292, 293, 2858, 2859, "." +258, 23, 1, 559, 0, 7, 2860, 2867, "Cardiac" +258, 23, 2, 560, 8, 13, 2868, 2873, "index" +258, 23, 3, 561, 14, 15, 2874, 2875, "," +258, 23, 4, 562, 16, 21, 2876, 2881, "blood" +258, 23, 5, 563, 22, 30, 2882, 2890, "pressure" +258, 23, 6, 564, 31, 34, 2891, 2894, "and" +258, 23, 7, 565, 35, 39, 2895, 2899, "most" +258, 23, 8, 566, 40, 45, 2900, 2905, "other" +258, 23, 9, 567, 46, 55, 2906, 2915, "metabolic" +258, 23, 10, 568, 56, 66, 2916, 2926, "parameters" +258, 23, 11, 569, 67, 71, 2927, 2931, "were" +258, 23, 12, 570, 72, 75, 2932, 2935, "not" +258, 23, 13, 571, 76, 85, 2936, 2945, "different" +258, 23, 14, 572, 86, 87, 2946, 2947, "." +258, 24, 1, 573, 0, 11, 2948, 2959, "CONCLUSIONS" +258, 24, 2, 574, 12, 13, 2960, 2961, ":" +258, 24, 3, 575, 14, 24, 2962, 2972, "Regardless" +258, 24, 4, 576, 25, 27, 2973, 2975, "of" +258, 24, 5, 577, 28, 36, 2976, 2984, "glycemic" +258, 24, 6, 578, 37, 48, 2985, 2996, "improvement" +258, 24, 7, 579, 49, 50, 2997, 2998, "," +258, 24, 8, 580, 51, 56, 2999, 3004, "early" +258, 24, 9, 581, 57, 68, 3005, 3016, "sitagliptin" +258, 24, 10, 582, 69, 76, 3017, 3024, "therapy" +258, 24, 11, 583, 77, 80, 3025, 3028, "did" +258, 24, 12, 584, 81, 84, 3029, 3032, "not" +258, 24, 13, 585, 85, 91, 3033, 3039, "affect" +258, 24, 14, 586, 92, 103, 3040, 3051, "endothelial" +258, 24, 15, 587, 104, 112, 3052, 3060, "function" +258, 24, 16, 588, 113, 116, 3061, 3064, "but" +258, 24, 17, 589, 117, 120, 3065, 3068, "may" +258, 24, 18, 590, 121, 128, 3069, 3076, "provide" +258, 24, 19, 591, 129, 138, 3077, 3086, "favorable" +258, 24, 20, 592, 139, 146, 3087, 3094, "effects" +258, 24, 21, 593, 147, 149, 3095, 3097, "on" +258, 24, 22, 594, 150, 154, 3098, 3102, "beta" +258, 24, 23, 595, 155, 156, 3103, 3104, "-" +258, 24, 24, 596, 157, 161, 3105, 3109, "cell" +258, 24, 25, 597, 162, 170, 3110, 3118, "function" +258, 24, 26, 598, 171, 174, 3119, 3122, "and" +258, 24, 27, 599, 175, 177, 3123, 3125, "on" +258, 24, 28, 600, 178, 190, 3126, 3138, "inflammatory" +258, 24, 29, 601, 191, 194, 3139, 3142, "and" +258, 24, 30, 602, 195, 204, 3143, 3152, "oxidative" +258, 24, 31, 603, 205, 211, 3153, 3159, "stress" +258, 24, 32, 604, 212, 214, 3160, 3162, "in" +258, 24, 33, 605, 215, 223, 3163, 3171, "patients" +258, 24, 34, 606, 224, 228, 3172, 3176, "with" +258, 24, 35, 607, 229, 233, 3177, 3181, "type" +258, 24, 36, 608, 234, 235, 3182, 3183, "2" +258, 24, 37, 609, 236, 244, 3184, 3192, "diabetes" +258, 24, 38, 610, 245, 252, 3193, 3200, "without" +258, 24, 39, 611, 253, 261, 3201, 3209, "advanced" +258, 24, 40, 612, 262, 277, 3210, 3225, "atherosclerosis" +258, 24, 41, 613, 278, 279, 3226, 3227, "." +258, 25, 1, 614, 0, 5, 3228, 3233, "TRIAL" +258, 25, 2, 615, 6, 18, 3234, 3246, "REGISTRATION" +258, 25, 3, 616, 19, 20, 3247, 3248, ":" +258, 25, 4, 617, 21, 25, 3249, 3253, "UMIN" +258, 25, 5, 618, 26, 34, 3254, 3262, "Clinical" +258, 25, 6, 619, 35, 41, 3263, 3269, "Trials" +258, 25, 7, 620, 42, 50, 3270, 3278, "Registry" +258, 25, 8, 621, 51, 57, 3279, 3285, "System" +258, 25, 9, 622, 58, 62, 3286, 3290, "UMIN" +258, 25, 10, 623, 63, 72, 3291, 3300, "000004955" +258, 25, 11, 624, 73, 74, 3301, 3302, "." +258, 26, 1, 625, 0, 3, 3303, 3306, "DOI" +258, 26, 2, 626, 4, 5, 3307, 3308, ":" +258, 26, 3, 627, 6, 8, 3309, 3311, "10" +258, 26, 4, 628, 9, 10, 3312, 3313, "." +258, 26, 5, 629, 11, 15, 3314, 3318, "1371" +258, 26, 6, 630, 16, 17, 3319, 3320, "/" +258, 26, 7, 631, 18, 25, 3321, 3328, "journal" +258, 26, 8, 632, 26, 27, 3329, 3330, "." +258, 26, 9, 633, 28, 32, 3331, 3335, "pone" +258, 26, 10, 634, 33, 34, 3336, 3337, "." +258, 26, 11, 635, 35, 42, 3338, 3345, "0164255" +258, 26, 12, 636, 43, 48, 3346, 3351, "PMCID" +258, 26, 13, 637, 49, 50, 3352, 3353, ":" +258, 26, 14, 638, 51, 61, 3354, 3364, "PMC5053511" +258, 26, 15, 639, 62, 66, 3365, 3369, "PMID" +258, 26, 16, 640, 67, 68, 3370, 3371, ":" +258, 26, 17, 641, 69, 77, 3372, 3380, "27711199" +258, 26, 18, 642, 78, 79, 3381, 3382, "[" +258, 26, 19, 643, 80, 87, 3383, 3390, "Indexed" +258, 26, 20, 644, 88, 91, 3391, 3394, "for" +258, 26, 21, 645, 92, 99, 3395, 3402, "MEDLINE" +258, 26, 22, 646, 100, 101, 3403, 3404, "]" +258, 26, 23, 647, 102, 110, 3405, 3413, "Conflict" +258, 26, 24, 648, 111, 113, 3414, 3416, "of" +258, 26, 25, 649, 114, 122, 3417, 3425, "interest" +258, 26, 26, 650, 123, 132, 3426, 3435, "statement" +258, 26, 27, 651, 133, 134, 3436, 3437, ":" +258, 26, 28, 652, 135, 136, 3438, 3439, "I" +258, 26, 29, 653, 137, 141, 3440, 3444, "have" +258, 26, 30, 654, 142, 146, 3445, 3449, "read" +258, 26, 31, 655, 147, 150, 3450, 3453, "the" +258, 26, 32, 656, 151, 158, 3454, 3461, "journal" +258, 26, 33, 657, 159, 160, 3462, 3463, "'" +258, 26, 34, 658, 161, 162, 3464, 3465, "s" +258, 26, 35, 659, 163, 169, 3466, 3472, "policy" +258, 26, 36, 660, 170, 173, 3473, 3476, "and" +258, 26, 37, 661, 174, 177, 3477, 3480, "the" +258, 26, 38, 662, 178, 185, 3481, 3488, "authors" +258, 26, 39, 663, 186, 188, 3489, 3491, "of" +258, 26, 40, 664, 189, 193, 3492, 3496, "this" +258, 26, 41, 665, 194, 204, 3497, 3507, "manuscript" +258, 26, 42, 666, 205, 209, 3508, 3512, "have" +258, 26, 43, 667, 210, 213, 3513, 3516, "the" +258, 26, 44, 668, 214, 223, 3517, 3526, "following" +258, 26, 45, 669, 224, 233, 3527, 3536, "competing" +258, 26, 46, 670, 234, 243, 3537, 3546, "interests" +258, 26, 47, 671, 244, 245, 3547, 3548, ":" +258, 26, 48, 672, 246, 247, 3549, 3550, "H" +258, 26, 49, 673, 248, 249, 3551, 3552, "." +258, 26, 50, 674, 250, 257, 3553, 3560, "Miyoshi" +258, 26, 51, 675, 258, 261, 3561, 3564, "has" +258, 26, 52, 676, 262, 270, 3565, 3573, "received" +258, 26, 53, 677, 271, 280, 3574, 3583, "honoraria" +258, 26, 54, 678, 281, 284, 3584, 3587, "for" +258, 26, 55, 679, 285, 293, 3588, 3596, "lectures" +258, 26, 56, 680, 294, 298, 3597, 3601, "from" +258, 26, 57, 681, 299, 307, 3602, 3610, "Astellas" +258, 26, 58, 682, 308, 309, 3611, 3612, "," +258, 26, 59, 683, 310, 321, 3613, 3624, "AstraZeneca" +258, 26, 60, 684, 322, 323, 3625, 3626, "," +258, 26, 61, 685, 324, 333, 3627, 3636, "Dainippon" +258, 26, 62, 686, 334, 340, 3637, 3643, "Pharma" +258, 26, 63, 687, 341, 342, 3644, 3645, "," +258, 26, 64, 688, 343, 346, 3646, 3649, "Eli" +258, 26, 65, 689, 347, 352, 3650, 3655, "Lilly" +258, 26, 66, 690, 353, 354, 3656, 3657, "," +258, 26, 67, 691, 355, 361, 3658, 3664, "Kissei" +258, 26, 68, 692, 362, 363, 3665, 3666, "," +258, 26, 69, 693, 364, 374, 3667, 3677, "Mitsubishi" +258, 26, 70, 694, 375, 381, 3678, 3684, "Tanabe" +258, 26, 71, 695, 382, 388, 3685, 3691, "Pharma" +258, 26, 72, 696, 389, 390, 3692, 3693, "," +258, 26, 73, 697, 391, 394, 3694, 3697, "MSD" +258, 26, 74, 698, 395, 396, 3698, 3699, "," +258, 26, 75, 699, 397, 405, 3700, 3708, "Novartis" +258, 26, 76, 700, 406, 407, 3709, 3710, "," +258, 26, 77, 701, 408, 412, 3711, 3715, "Novo" +258, 26, 78, 702, 413, 420, 3716, 3723, "Nordisk" +258, 26, 79, 703, 421, 424, 3724, 3727, "and" +258, 26, 80, 704, 425, 431, 3728, 3734, "Sanofi" +258, 26, 81, 705, 432, 433, 3735, 3736, ";" +258, 26, 82, 706, 434, 437, 3737, 3740, "and" +258, 26, 83, 707, 438, 446, 3741, 3749, "received" +258, 26, 84, 708, 447, 458, 3750, 3761, "scholarship" +258, 26, 85, 709, 459, 465, 3762, 3768, "grants" +258, 26, 86, 710, 466, 470, 3769, 3773, "from" +258, 26, 87, 711, 471, 479, 3774, 3782, "Astellas" +258, 26, 88, 712, 480, 481, 3783, 3784, "," +258, 26, 89, 713, 482, 493, 3785, 3796, "AstraZeneca" +258, 26, 90, 714, 494, 495, 3797, 3798, "," +258, 26, 91, 715, 496, 503, 3799, 3806, "Daiichi" +258, 26, 92, 716, 504, 510, 3807, 3813, "Sankyo" +258, 26, 93, 717, 511, 512, 3814, 3815, "," +258, 26, 94, 718, 513, 516, 3816, 3819, "Eli" +258, 26, 95, 719, 517, 522, 3820, 3825, "Lilly" +258, 26, 96, 720, 523, 524, 3826, 3827, "," +258, 26, 97, 721, 525, 535, 3828, 3838, "Mitsubishi" +258, 26, 98, 722, 536, 542, 3839, 3845, "Tanabe" +258, 26, 99, 723, 543, 549, 3846, 3852, "Pharma" +258, 26, 100, 724, 550, 551, 3853, 3854, "," +258, 26, 101, 725, 552, 555, 3855, 3858, "MSD" +258, 26, 102, 726, 556, 557, 3859, 3860, "," +258, 26, 103, 727, 558, 562, 3861, 3865, "Novo" +258, 26, 104, 728, 563, 570, 3866, 3873, "Nordisk" +258, 26, 105, 729, 571, 572, 3874, 3875, "," +258, 26, 106, 730, 573, 579, 3876, 3882, "Sanofi" +258, 26, 107, 731, 580, 581, 3883, 3884, "," +258, 26, 108, 732, 582, 588, 3885, 3891, "Takeda" +258, 26, 109, 733, 589, 592, 3892, 3895, "and" +258, 26, 110, 734, 593, 599, 3896, 3902, "Taisho" +258, 26, 111, 735, 600, 614, 3903, 3917, "Pharmaceutical" +258, 26, 112, 736, 615, 617, 3918, 3920, "Co" +258, 26, 113, 737, 618, 619, 3921, 3922, "." +258, 26, 114, 738, 620, 621, 3923, 3924, "," +258, 26, 115, 739, 622, 625, 3925, 3928, "Ltd" +258, 26, 116, 740, 626, 627, 3929, 3930, "." +258, 26, 117, 741, 628, 629, 3931, 3932, "T" +258, 26, 118, 742, 630, 631, 3933, 3934, "." +258, 26, 119, 743, 632, 638, 3935, 3941, "Atsumi" +258, 26, 120, 744, 639, 642, 3942, 3945, "has" +258, 26, 121, 745, 643, 651, 3946, 3954, "received" +258, 26, 122, 746, 652, 661, 3955, 3964, "honoraria" +258, 26, 123, 747, 662, 665, 3965, 3968, "for" +258, 26, 124, 748, 666, 674, 3969, 3977, "lectures" +258, 26, 125, 749, 675, 679, 3978, 3982, "from" +258, 26, 126, 750, 680, 686, 3983, 3989, "Takeda" +258, 26, 127, 751, 687, 701, 3990, 4004, "Pharmaceutical" +258, 26, 128, 752, 702, 703, 4005, 4006, "," +258, 26, 129, 753, 704, 714, 4007, 4017, "Mitsubishi" +258, 26, 130, 754, 715, 721, 4018, 4024, "Tanabe" +258, 26, 131, 755, 722, 728, 4025, 4031, "Pharma" +258, 26, 132, 756, 729, 730, 4032, 4033, "," +258, 26, 133, 757, 731, 737, 4034, 4040, "Pfizer" +258, 26, 134, 758, 738, 739, 4041, 4042, "," +258, 26, 135, 759, 740, 745, 4043, 4048, "Eisai" +258, 26, 136, 760, 746, 747, 4049, 4050, "," +258, 26, 137, 761, 748, 753, 4051, 4056, "Avvie" +258, 26, 138, 762, 754, 755, 4057, 4058, "," +258, 26, 139, 763, 756, 759, 4059, 4062, "UCB" +258, 26, 140, 764, 760, 765, 4063, 4068, "Japan" +258, 26, 141, 765, 766, 767, 4069, 4070, "," +258, 26, 142, 766, 768, 776, 4071, 4079, "Astellas" +258, 26, 143, 767, 777, 783, 4080, 4086, "Pharma" +258, 26, 144, 768, 784, 787, 4087, 4090, "and" +258, 26, 145, 769, 788, 794, 4091, 4097, "Chugai" +258, 26, 146, 770, 795, 809, 4098, 4112, "Pharmaceutical" +258, 26, 147, 771, 810, 812, 4113, 4115, "Co" +258, 26, 148, 772, 813, 814, 4116, 4117, "." +258, 26, 149, 773, 815, 816, 4118, 4119, "," +258, 26, 150, 774, 817, 820, 4120, 4123, "Ltd" +258, 26, 151, 775, 821, 822, 4124, 4125, ";" +258, 26, 152, 776, 823, 826, 4126, 4129, "and" +258, 26, 153, 777, 827, 835, 4130, 4138, "received" +258, 26, 154, 778, 836, 844, 4139, 4147, "research" +258, 26, 155, 779, 845, 851, 4148, 4154, "grants" +258, 26, 156, 780, 852, 856, 4155, 4159, "from" +258, 26, 157, 781, 857, 865, 4160, 4168, "Astellas" +258, 26, 158, 782, 866, 867, 4169, 4170, "," +258, 26, 159, 783, 868, 874, 4171, 4177, "Chugai" +258, 26, 160, 784, 875, 876, 4178, 4179, "," +258, 26, 161, 785, 877, 883, 4180, 4186, "Sanofi" +258, 26, 162, 786, 884, 885, 4187, 4188, "," +258, 26, 163, 787, 886, 891, 4189, 4194, "Eisai" +258, 26, 164, 788, 892, 893, 4195, 4196, "," +258, 26, 165, 789, 894, 901, 4197, 4204, "Alexion" +258, 26, 166, 790, 902, 903, 4205, 4206, "," +258, 26, 167, 791, 904, 911, 4207, 4214, "Bristol" +258, 26, 168, 792, 912, 913, 4215, 4216, "-" +258, 26, 169, 793, 914, 919, 4217, 4222, "Myers" +258, 26, 170, 794, 920, 926, 4223, 4229, "Squibb" +258, 26, 171, 795, 927, 928, 4230, 4231, "," +258, 26, 172, 796, 929, 939, 4232, 4242, "Mitsubishi" +258, 26, 173, 797, 940, 946, 4243, 4249, "Tanabe" +258, 26, 174, 798, 947, 953, 4250, 4256, "Pharma" +258, 26, 175, 799, 954, 957, 4257, 4260, "and" +258, 26, 176, 800, 958, 965, 4261, 4268, "Janssen" +258, 26, 177, 801, 966, 980, 4269, 4283, "Pharmaceutical" +258, 26, 178, 802, 981, 982, 4284, 4285, "K" +258, 26, 179, 803, 983, 984, 4286, 4287, "." +258, 26, 180, 804, 985, 986, 4288, 4289, "K" +258, 26, 181, 805, 987, 988, 4290, 4291, "." +258, 27, 1, 806, 0, 1, 4292, 4293, ";" +258, 27, 2, 807, 2, 5, 4294, 4297, "and" +258, 27, 3, 808, 6, 14, 4298, 4306, "received" +258, 27, 4, 809, 15, 26, 4307, 4318, "scholarship" +258, 27, 5, 810, 27, 33, 4319, 4325, "grants" +258, 27, 6, 811, 34, 38, 4326, 4330, "from" +258, 27, 7, 812, 39, 47, 4331, 4339, "Astellas" +258, 27, 8, 813, 48, 49, 4340, 4341, "," +258, 27, 9, 814, 50, 56, 4342, 4348, "Takeda" +258, 27, 10, 815, 57, 58, 4349, 4350, "," +258, 27, 11, 816, 59, 69, 4351, 4361, "Mitsubishi" +258, 27, 12, 817, 70, 76, 4362, 4368, "Tanabe" +258, 27, 13, 818, 77, 83, 4369, 4375, "Pharma" +258, 27, 14, 819, 84, 85, 4376, 4377, "," +258, 27, 15, 820, 86, 92, 4378, 4384, "Chugai" +258, 27, 16, 821, 93, 94, 4385, 4386, "," +258, 27, 17, 822, 95, 102, 4387, 4394, "Daiichi" +258, 27, 18, 823, 103, 109, 4395, 4401, "Sankyo" +258, 27, 19, 824, 110, 111, 4402, 4403, "," +258, 27, 20, 825, 112, 117, 4404, 4409, "Eisai" +258, 27, 21, 826, 118, 121, 4410, 4413, "and" +258, 27, 22, 827, 122, 127, 4414, 4419, "Bayer" +258, 27, 23, 828, 128, 129, 4420, 4421, "," +258, 27, 24, 829, 130, 133, 4422, 4425, "Ltd" +258, 27, 25, 830, 134, 135, 4426, 4427, "." +258, 28, 1, 831, 0, 4, 4428, 4432, "This" +258, 28, 2, 832, 5, 9, 4433, 4437, "does" +258, 28, 3, 833, 10, 13, 4438, 4441, "not" +258, 28, 4, 834, 14, 19, 4442, 4447, "alter" +258, 28, 5, 835, 20, 23, 4448, 4451, "our" +258, 28, 6, 836, 24, 33, 4452, 4461, "adherence" +258, 28, 7, 837, 34, 36, 4462, 4464, "to" +258, 28, 8, 838, 37, 41, 4465, 4469, "PLOS" +258, 28, 9, 839, 42, 45, 4470, 4473, "ONE" +258, 28, 10, 840, 46, 54, 4474, 4482, "policies" +258, 28, 11, 841, 55, 57, 4483, 4485, "on" +258, 28, 12, 842, 58, 65, 4486, 4493, "sharing" +258, 28, 13, 843, 66, 70, 4494, 4498, "data" +258, 28, 14, 844, 71, 74, 4499, 4502, "and" +258, 28, 15, 845, 75, 84, 4503, 4512, "materials" +258, 28, 16, 846, 85, 86, 4513, 4514, "." diff --git a/data/dm2 27711199_kwoodley.annodb b/data/dm2 27711199_kwoodley.annodb new file mode 100644 index 0000000..02c878b --- /dev/null +++ b/data/dm2 27711199_kwoodley.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70826, Journal, 0, 8, "PLoS One", "", +70827, PublicationYear, 11, 15, "2016", "", +80177, Title, 111, 290, "A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero - Incretin Study 1 ( SAIS1 ) .", "", +70829, Randomized, 113, 123, "Randomized", "", +70830, Sitagliptin, 166, 177, "Sitagliptin", "", +80173, Glimepiride, 182, 193, "Glimepiride", "", +80178, Author, 291, 299, "Nomoto H", "", +80179, Author, 308, 317, "Miyoshi H", "", +80180, Author, 326, 336, "Furumoto T", "", +80181, Author, 351, 356, "Oba K", "", +80182, Author, 371, 380, "Tsutsui H", "", +80183, Author, 389, 396, "Inoue A", "", +80184, Author, 405, 413, "Atsumi T", "", +80185, Author, 422, 429, "Manda N", "", +80186, Author, 438, 448, "Kurihara Y", "", +80187, Author, 457, 463, "Aoki S", "", +80188, Japan, 636, 641, "Japan", "", +80189, Japan, 734, 739, "Japan", "", +80190, Japan, 848, 853, "Japan", "", +80191, Japan, 982, 987, "Japan", "", +80192, Japan, 1079, 1084, "Japan", "", +80193, Japan, 1167, 1172, "Japan", "", +80194, Japan, 1217, 1222, "Japan", "", +80195, Japan, 1259, 1264, "Japan", "", +80196, Japan, 1297, 1302, "Japan", "", +80197, Hypoglycemia, 1383, 1396, "hyperglycemia", "", +80198, Type2Diabetes, 1628, 1643, "type 2 diabetes", "", +80202, ObjectiveDescription, 1658, 1824, "we investigated the efficacy of sitagliptin , a DPP - 4 inhibitor , on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride", "", +70831, Sitagliptin, 1690, 1701, "sitagliptin", "", +80201, Sulfonylureas, 1800, 1812, "sulfonylurea", "", +80174, Glimepiride, 1813, 1824, "glimepiride", "", +80203, Multicenter, 1859, 1870, "multicenter", "", +80204, Prospective, 1873, 1884, "prospective", "", +80205, Randomized, 1887, 1897, "randomized", "", +80206, Parallel, 1898, 1914, "parallel - group", "", +80207, NumberPatientsCT, 1934, 1937, "103", "", +80213, Precondition, 1938, 2097, "outpatients with type 2 diabetes ( aged 59 . 9 ± 9 . 9 years with HbA1c levels of 7 . 5 ± 0 . 4 % ) with dietary cure only and / or current metformin treatment", "", +80199, Type2Diabetes, 1955, 1970, "type 2 diabetes", "", +80208, AvgAge, 1978, 1984, "59 . 9", "", +80209, HbA1c, 2004, 2009, "HbA1c", "", +80210, Percentage, 2034, 2035, "%", "", +80211, Metformin, 2078, 2087, "metformin", "", +80212, Randomized, 2116, 2124, "randomly", "", +70832, Sitagliptin, 2145, 2156, "sitagliptin", "", +80175, Glimepiride, 2160, 2171, "glimepiride", "", +80214, Frequency, 2180, 2190, "once daily", "", +80215, Duration, 2195, 2203, "26 weeks", "", +80216, EndPointDescription, 2206, 2230, "Flow - mediated dilation", "", +80217, EndPointDescription, 2233, 2236, "FMD", "", +80223, Percentage, 2466, 2467, "%", "", +80218, EndPointDescription, 2468, 2471, "FMD", "", +70833, Sitagliptin, 2498, 2509, "sitagliptin", "", +80226, BaseLineValue, 2512, 2517, "5 . 6", "", +80228, ResultMeasuredValue, 2521, 2526, "5 . 6", "", +80224, Percentage, 2527, 2528, "%", "", +80176, Glimepiride, 2531, 2542, "glimepiride", "", +80227, BaseLineValue, 2545, 2550, "5 . 6", "", +80229, ResultMeasuredValue, 2554, 2559, "6 . 0", "", +80225, Percentage, 2560, 2561, "%", "", +80219, EndPointDescription, 2566, 2610, "Secretory units of islets in transplantation", "", +80220, EndPointDescription, 2613, 2620, "TNF -α,", "", +80221, EndPointDescription, 2621, 2632, "adiponectin", "", +80222, EndPointDescription, 2637, 2669, "biological antioxidant potential", "", +80230, ObservedResult, 2670, 2692, "significantly improved", "", +70834, Sitagliptin, 2700, 2711, "sitagliptin", "", +80233, EndPointDescription, 2724, 2744, "superoxide dismutase", "", +80231, ObservedResult, 2750, 2767, "tended to improve", "", +70835, Sitagliptin, 2775, 2786, "sitagliptin", "", +80232, ObservedResult, 2801, 2857, "improvements in HbA1c levels were similar between groups", "", +80234, HbA1c, 2817, 2822, "HbA1c", "", +80235, EndPointDescription, 2860, 2873, "Cardiac index", "", +80237, ObservedResult, 2860, 2947, "Cardiac index , blood pressure and most other metabolic parameters were not different .", "", +80236, BloodPressure, 2876, 2890, "blood pressure", "", +80238, ConclusionComment, 2962, 3162, "Regardless of glycemic improvement , early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta - cell function and on inflammatory and oxidative stress in", "", +70836, Sitagliptin, 3005, 3016, "sitagliptin", "", +80239, ConclusionComment, 3163, 3227, "patients with type 2 diabetes without advanced atherosclerosis .", "", +80200, Type2Diabetes, 3177, 3192, "type 2 diabetes", "", +80240, PMID, 3372, 3380, "27711199", "", diff --git a/data/dm2 27711199_kwoodley.n-triples b/data/dm2 27711199_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27711199_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27740719_admin.annodb b/data/dm2 27740719_admin.annodb new file mode 100644 index 0000000..fabf0d7 --- /dev/null +++ b/data/dm2 27740719_admin.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "J Diabetes Investig .", "", " \"J Diabetes Investig .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +6, Title, 105, 217, "Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes .", "", " \"Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes .\"." +2, Sitagliptin, 105, 116, "Sitagliptin", "", +113, Insulin, 133, 140, "insulin", "", +3, Metformin, 165, 174, "metformin", "", +4, Ethnicity, 178, 185, "Chinese", "", +120, Precondition, 178, 215, "Chinese patients with type 2 diabetes", "", +5, Type2Diabetes, 200, 215, "type 2 diabetes", "", +7, Author, 218, 228, "Shankar RR", "", " \"Shankar RR\"." +8, Author, 237, 242, "Bao Y", "", " \"Bao Y\"." +9, Author, 251, 256, "Han P", "", " \"Han P\"." +10, Author, 265, 269, "Hu J", "", " \"Hu J\"." +11, Author, 278, 282, "Ma J", "", " \"Ma J\"." +12, Author, 291, 297, "Peng Y", "", " \"Peng Y\"." +13, Author, 306, 310, "Wu F", "", " \"Wu F\"." +14, Author, 319, 323, "Xu L", "", " \"Xu L\"." +15, Author, 332, 340, "Engel SS", "", " \"Engel SS\"." +16, Author, 349, 354, "Jia W", "", " \"Jia W\"." +17, USA, 439, 442, "USA", "", " ." +19, China, 856, 861, "China", "", +18, China, 874, 879, "China", "", +25, ObjectiveDescription, 897, 1094, "We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin .", "", " \"We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin .\"." +20, Sitagliptin, 959, 970, "sitagliptin", "", +21, Ethnicity, 974, 981, "Chinese", "", " . ." +135, Precondition, 974, 1092, "Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin", "", " \"Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin\"." +22, Type2Diabetes, 996, 1020, "type 2 diabetes mellitus", "", " ." +23, Insulin, 1038, 1045, "insulin", "", +24, Metformin, 1083, 1092, "metformin", "", +26, NumberPatientsCT, 1130, 1133, "467", "", " \"467\"." +144, Precondition, 1134, 1241, "patients with inadequate glycemic control on insulin ( glycated hemoglobin [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", " \"patients with inadequate glycemic control on insulin ( glycated hemoglobin [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )\"." +138, Insulin, 1179, 1186, "insulin", "", +28, HbA1c, 1189, 1208, "glycated hemoglobin", "", +29, HbA1c, 1211, 1216, "HbA1c", "", +30, Percentage, 1227, 1228, "%", "", +31, Percentage, 1238, 1239, "%", "", +32, Randomized, 1247, 1257, "randomized", "", " ." +156, AllocationRatio, 1258, 1263, "1 : 1", "", " . ." +33, Sitagliptin, 1275, 1286, "sitagliptin", "", " ." +146, DoseValue, 1287, 1290, "100", "", " \"100\"." +37, mg, 1291, 1293, "mg", "", " ." +38, Frequency, 1294, 1304, "once daily", "", " \"once daily\"." +34, Placebo, 1319, 1326, "placebo", "", " ." +35, Duration, 1331, 1339, "24 weeks", "", " \"24 weeks\"." +39, Randomized, 1342, 1355, "Randomization", "", +40, Metformin, 1380, 1389, "metformin", "", +41, Metformin, 1409, 1418, "metformin", "", +42, Insulin, 1433, 1440, "insulin", "", +43, TimePoint, 1550, 1558, "baseline", "", +44, TimePoint, 1562, 1569, "week 24", "", +45, HbA1c, 1573, 1578, "HbA1c", "", +46, Sitagliptin, 1607, 1618, "sitagliptin", "", +56, PvalueDiff, 1644, 1655, "P < 0 . 001", "", " \"P < 0 . 001\"." +57, TimePoint, 1666, 1673, "week 24", "", +47, HbA1c, 1674, 1679, "HbA1c", "", " ." +58, Reduction, 1692, 1697, "0 . 7", "", " \"0 . 7\"." +49, Percentage, 1698, 1699, "%", "", " ." +59, Reduction, 1732, 1737, "0 . 3", "", " \"0 . 3\"." +50, Percentage, 1738, 1739, "%", "", +48, Placebo, 1747, 1754, "placebo", "", +66, PvalueDiff, 1775, 1786, "P = 0 . 013", "", " \"P = 0 . 013\"." +62, Sitagliptin, 1827, 1838, "sitagliptin", "", +63, PercentageAffected, 1841, 1843, "16", "", " \"16\"." +60, HbA1c_target, 1855, 1873, "HbA1c of < 7 . 0 %", "", " ." +52, Percentage, 1872, 1873, "%", "", +61, TimePoint, 1877, 1884, "week 24", "", " \"week 24\". \"week 24\"." +65, Placebo, 1899, 1906, "placebo", "", +64, PercentageAffected, 1909, 1910, "8", "", " \"8\"." +67, Sitagliptin, 1933, 1944, "sitagliptin", "", +68, PvalueDiff, 1961, 1972, "P < 0 . 001", "", " \"P < 0 . 001\"." +72, PostprandialBloodGlucose, 1983, 2008, "2 - h post - meal glucose", "", " ." +73, Reduction, 2012, 2018, "26 . 5", "", " \"26 . 5\"." +69, Mg_per_deciliter, 2019, 2026, "mg / dL", "", " ." +74, Reduction, 2029, 2034, "1 . 5", "", +70, Millimoles_per_litre, 2035, 2043, "mmol / L", "", +71, Placebo, 2058, 2065, "placebo", "", +75, TimePoint, 2084, 2092, "baseline", "", +76, FastingPlasmaGlucose, 2096, 2118, "fasting plasma glucose", "", " ." +77, Sitagliptin, 2145, 2156, "sitagliptin", "", +81, Reduction, 2159, 2165, "14 . 4", "", " \"14 . 4\"." +79, Mg_per_deciliter, 2166, 2173, "mg / dL", "", " ." +78, Placebo, 2190, 2197, "placebo", "", +82, Reduction, 2200, 2206, "10 . 7", "", " \"10 . 7\"." +80, Mg_per_deciliter, 2207, 2214, "mg / dL", "", +83, NumberAffected, 2300, 2302, "64", "", " \"64\"." +85, PercentageAffected, 2305, 2311, "27 . 4", "", " \"27 . 4\"." +87, Sitagliptin, 2332, 2343, "sitagliptin", "", +84, NumberAffected, 2348, 2350, "51", "", " \"51\"." +86, PercentageAffected, 2353, 2359, "21 . 9", "", " \"21 . 9\"." +88, Placebo, 2371, 2378, "placebo", "", +89, Hypoglycemia, 2409, 2453, "hypoglycemia ( symptomatic or asymptomatic )", "", " ." +197, ObservedResult, 2456, 2524, "Neither group had a significant change from baseline in bodyweight .", "", " \"Neither group had a significant change from baseline in bodyweight .\"." +111, Sitagliptin, 2476, 2487, "significant", "", +90, TimePoint, 2500, 2508, "baseline", "", +91, BodyWeight, 2512, 2522, "bodyweight", "", " ." +98, ConclusionComment, 2539, 2726, "After 24 weeks , sitagliptin added to stable insulin therapy ( ± metformin ) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus .", "", " \"After 24 weeks , sitagliptin added to stable insulin therapy ( ± metformin ) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus .\"." +92, Duration, 2545, 2553, "24 weeks", "", +93, Sitagliptin, 2556, 2567, "sitagliptin", "", +94, Insulin, 2584, 2591, "insulin", "", +95, Metformin, 2604, 2613, "metformin", "", +96, Ethnicity, 2678, 2685, "Chinese", "", +97, Type2Diabetes, 2700, 2724, "type 2 diabetes mellitus", "", +97475, DisorderOrSyndrome, 2843, 2851, "Diabetes", "", +100, Australia, 2883, 2892, "Australia", "", " ." +99, PMID, 2957, 2965, "27740719", "", " \"27740719\"." diff --git a/data/dm2 27740719_admin.n-triples b/data/dm2 27740719_admin.n-triples new file mode 100644 index 0000000..e06acd4 --- /dev/null +++ b/data/dm2 27740719_admin.n-triples @@ -0,0 +1,191 @@ +# RDF export of group: Publication + . + "Publication " . + "Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes ." . + "Shankar RR" . + "2017" . + "J Diabetes Investig ." . + "27740719" . + . + "Bao Y" . + "Han P" . + "Hu J" . + "Ma J" . + "Peng Y" . + "Wu F" . + "Xu L" . + "Engel SS" . + "Jia W" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin ." . + "467" . + "24 weeks" . + . + . + . + . + "After 24 weeks , sitagliptin added to stable insulin therapy ( ± metformin ) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin" . + . + . + . + . + "patients with inadequate glycemic control on insulin ( glycated hemoglobin [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )" . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint pbg" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm s" . + . + . + . + . + . + . + . + . + "Arm p" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s" . + . + "once daily" . + . + . + "Intervention p" . + . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s" . + . + "0 . 7" . + . + "Outcome hba1c p" . + . + "0 . 3" . + . + "Outcome hba1c target s" . + . + "16" . + "week 24" . + . + "Outcome hba1c target p" . + . + "8" . + "week 24" . + . + "Outcome pbg s" . + . + "26 . 5" . + . + "Outcome pbg p" . + . + . + "Outcome fpg s" . + . + "14 . 4" . + . + "Outcome fpg p " . + . + "10 . 7" . + . + "Outcome h s" . + . + "64" . + "27 . 4" . + . + "Outcome h p " . + . + "51" . + "21 . 9" . + . + "Outcome weight both drugs" . + . + "Neither group had a significant change from baseline in bodyweight ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups hba1c target" . + "P = 0 . 013" . + . + . + . + "DiffBetweenGroups pbg" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27740719_akramersunderbrink.annodb b/data/dm2 27740719_akramersunderbrink.annodb new file mode 100644 index 0000000..231248d --- /dev/null +++ b/data/dm2 27740719_akramersunderbrink.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66972, Journal, 0, 19, "J Diabetes Investig", "", +66973, PublicationYear, 22, 26, "2017", "", +66974, Sitagliptin, 105, 116, "Sitagliptin", "", +66978, Title, 105, 217, "Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes .", "", +66975, Metformin, 165, 174, "metformin", "", +66976, Ethnicity, 178, 185, "Chinese", "", +66977, Type2Diabetes, 200, 215, "type 2 diabetes", "", +66979, Author, 218, 228, "Shankar RR", "", +66980, Author, 237, 242, "Bao Y", "", +66981, Author, 251, 256, "Han P", "", +66982, Author, 265, 269, "Hu J", "", +66983, Author, 278, 282, "Ma J", "", +66984, Author, 291, 297, "Peng Y", "", +66985, Author, 306, 310, "Wu F", "", +66986, Author, 319, 323, "Xu L", "", +66987, Author, 332, 340, "Engel SS", "", +66988, Author, 349, 354, "Jia W", "", +66989, USA, 439, 442, "USA", "", +66991, China, 856, 861, "China", "", +66990, China, 874, 879, "China", "", +66997, ObjectiveDescription, 897, 1094, "We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin .", "", +66992, Sitagliptin, 959, 970, "sitagliptin", "", +66993, Ethnicity, 974, 981, "Chinese", "", +66994, Type2Diabetes, 996, 1020, "type 2 diabetes mellitus", "", +66995, Insulin, 1038, 1045, "insulin", "", +66996, Metformin, 1083, 1092, "metformin", "", +66998, NumberPatientsCT, 1130, 1133, "467", "", +66999, Precondition, 1143, 1241, "with inadequate glycemic control on insulin ( glycated hemoglobin [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", +67000, HbA1c, 1189, 1208, "glycated hemoglobin", "", +67001, HbA1c, 1211, 1216, "HbA1c", "", +67002, Percentage, 1227, 1228, "%", "", +67003, Percentage, 1238, 1239, "%", "", +67004, Randomized, 1247, 1257, "randomized", "", +67005, Sitagliptin, 1275, 1286, "sitagliptin", "", +67008, DoseValue, 1287, 1293, "100 mg", "", +67009, mg, 1291, 1293, "mg", "", +67010, Frequency, 1294, 1304, "once daily", "", +67006, Placebo, 1319, 1326, "placebo", "", +67007, Duration, 1331, 1339, "24 weeks", "", +67012, Randomized, 1342, 1355, "Randomization", "", +67013, Metformin, 1380, 1389, "metformin", "", +67014, Metformin, 1409, 1418, "metformin", "", +67015, Insulin, 1433, 1440, "insulin", "", +67016, TimePoint, 1550, 1558, "baseline", "", +67017, TimePoint, 1562, 1569, "week 24", "", +67018, HbA1c, 1573, 1578, "HbA1c", "", +67019, Sitagliptin, 1607, 1618, "sitagliptin", "", +67029, PvalueDiff, 1644, 1655, "P < 0 . 001", "", +67030, TimePoint, 1666, 1673, "week 24", "", +67020, HbA1c, 1674, 1679, "HbA1c", "", +67031, Reduction, 1692, 1697, "0 . 7", "", +67022, Percentage, 1698, 1699, "%", "", +67032, Reduction, 1732, 1737, "0 . 3", "", +67023, Percentage, 1738, 1739, "%", "", +67021, Placebo, 1747, 1754, "placebo", "", +67039, PvalueDiff, 1775, 1786, "P = 0 . 013", "", +67035, Sitagliptin, 1827, 1838, "sitagliptin", "", +67036, PercentageAffected, 1841, 1843, "16", "", +67024, Percentage, 1844, 1845, "%", "", +67033, HbA1c_target, 1855, 1873, "HbA1c of < 7 . 0 %", "", +67025, Percentage, 1872, 1873, "%", "", +67034, TimePoint, 1877, 1884, "week 24", "", +67038, Placebo, 1899, 1906, "placebo", "", +67037, PercentageAffected, 1909, 1910, "8", "", +67026, Percentage, 1911, 1912, "%", "", +67040, Sitagliptin, 1933, 1944, "sitagliptin", "", +67041, PvalueDiff, 1961, 1972, "P < 0 . 001", "", +67045, PostprandialBloodGlucose, 1983, 2008, "2 - h post - meal glucose", "", +67046, Reduction, 2012, 2018, "26 . 5", "", +67042, Mg_per_deciliter, 2019, 2026, "mg / dL", "", +67047, Reduction, 2029, 2034, "1 . 5", "", +67043, Millimoles_per_litre, 2035, 2043, "mmol / L", "", +67044, Placebo, 2058, 2065, "placebo", "", +67048, TimePoint, 2084, 2092, "baseline", "", +67049, FastingPlasmaGlucose, 2096, 2118, "fasting plasma glucose", "", +67050, Sitagliptin, 2145, 2156, "sitagliptin", "", +67054, Reduction, 2159, 2165, "14 . 4", "", +67052, Mg_per_deciliter, 2166, 2173, "mg / dL", "", +67051, Placebo, 2190, 2197, "placebo", "", +67055, Reduction, 2200, 2206, "10 . 7", "", +67053, Mg_per_deciliter, 2207, 2214, "mg / dL", "", +67056, NumberAffected, 2300, 2302, "64", "", +67058, PercentageAffected, 2305, 2311, "27 . 4", "", +67028, Percentage, 2312, 2313, "%", "", +67060, Sitagliptin, 2332, 2343, "sitagliptin", "", +67057, NumberAffected, 2348, 2350, "51", "", +67059, PercentageAffected, 2353, 2359, "21 . 9", "", +67027, Percentage, 2360, 2361, "%", "", +67061, Placebo, 2371, 2378, "placebo", "", +67062, Hypoglycemia, 2409, 2453, "hypoglycemia ( symptomatic or asymptomatic )", "", +67063, TimePoint, 2500, 2508, "baseline", "", +67064, BodyWeight, 2512, 2522, "bodyweight", "", +67071, ConclusionComment, 2539, 2726, "After 24 weeks , sitagliptin added to stable insulin therapy ( ± metformin ) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus .", "", +67065, Duration, 2545, 2553, "24 weeks", "", +67066, Sitagliptin, 2556, 2567, "sitagliptin", "", +67067, Insulin, 2584, 2591, "insulin", "", +67068, Metformin, 2604, 2613, "metformin", "", +67069, Ethnicity, 2678, 2685, "Chinese", "", +67070, Type2Diabetes, 2700, 2724, "type 2 diabetes mellitus", "", +67073, Australia, 2883, 2892, "Australia", "", +67072, PMID, 2957, 2965, "27740719", "", diff --git a/data/dm2 27740719_akramersunderbrink.n-triples b/data/dm2 27740719_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27740719_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 27740719_export.csv b/data/dm2 27740719_export.csv new file mode 100644 index 0000000..5a6e984 --- /dev/null +++ b/data/dm2 27740719_export.csv @@ -0,0 +1,639 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +257, 1, 1, 1, 0, 1, 0, 1, "J" +257, 1, 2, 2, 2, 10, 2, 10, "Diabetes" +257, 1, 3, 3, 11, 19, 11, 19, "Investig" +257, 1, 4, 4, 20, 21, 20, 21, "." +257, 2, 1, 5, 0, 4, 22, 26, "2017" +257, 2, 2, 6, 5, 8, 27, 30, "May" +257, 2, 3, 7, 9, 10, 31, 32, ";" +257, 2, 4, 8, 11, 12, 33, 34, "8" +257, 2, 5, 9, 13, 14, 35, 36, "(" +257, 2, 6, 10, 15, 16, 37, 38, "3" +257, 2, 7, 11, 17, 18, 39, 40, ")" +257, 2, 8, 12, 19, 20, 41, 42, ":" +257, 2, 9, 13, 21, 24, 43, 46, "321" +257, 2, 10, 14, 25, 26, 47, 48, "-" +257, 2, 11, 15, 27, 30, 49, 52, "329" +257, 2, 12, 16, 31, 32, 53, 54, "." +257, 2, 13, 17, 33, 36, 55, 58, "doi" +257, 2, 14, 18, 37, 38, 59, 60, ":" +257, 2, 15, 19, 39, 41, 61, 63, "10" +257, 2, 16, 20, 42, 43, 64, 65, "." +257, 2, 17, 21, 44, 48, 66, 70, "1111" +257, 2, 18, 22, 49, 50, 71, 72, "/" +257, 2, 19, 23, 51, 54, 73, 76, "jdi" +257, 2, 20, 24, 55, 56, 77, 78, "." +257, 2, 21, 25, 57, 62, 79, 84, "12585" +257, 2, 22, 26, 63, 64, 85, 86, "." +257, 3, 1, 27, 0, 4, 87, 91, "Epub" +257, 3, 2, 28, 5, 9, 92, 96, "2016" +257, 3, 3, 29, 10, 13, 97, 100, "Dec" +257, 3, 4, 30, 14, 15, 101, 102, "9" +257, 3, 5, 31, 16, 17, 103, 104, "." +257, 4, 1, 32, 0, 11, 105, 116, "Sitagliptin" +257, 4, 2, 33, 12, 17, 117, 122, "added" +257, 4, 3, 34, 18, 20, 123, 125, "to" +257, 4, 4, 35, 21, 27, 126, 132, "stable" +257, 4, 5, 36, 28, 35, 133, 140, "insulin" +257, 4, 6, 37, 36, 43, 141, 148, "therapy" +257, 4, 7, 38, 44, 48, 149, 153, "with" +257, 4, 8, 39, 49, 51, 154, 156, "or" +257, 4, 9, 40, 52, 59, 157, 164, "without" +257, 4, 10, 41, 60, 69, 165, 174, "metformin" +257, 4, 11, 42, 70, 72, 175, 177, "in" +257, 4, 12, 43, 73, 80, 178, 185, "Chinese" +257, 4, 13, 44, 81, 89, 186, 194, "patients" +257, 4, 14, 45, 90, 94, 195, 199, "with" +257, 4, 15, 46, 95, 99, 200, 204, "type" +257, 4, 16, 47, 100, 101, 205, 206, "2" +257, 4, 17, 48, 102, 110, 207, 215, "diabetes" +257, 4, 18, 49, 111, 112, 216, 217, "." +257, 5, 1, 50, 0, 7, 218, 225, "Shankar" +257, 5, 2, 51, 8, 10, 226, 228, "RR" +257, 5, 3, 52, 11, 12, 229, 230, "(" +257, 5, 4, 53, 13, 14, 231, 232, "1" +257, 5, 5, 54, 15, 16, 233, 234, ")" +257, 5, 6, 55, 17, 18, 235, 236, "," +257, 5, 7, 56, 19, 22, 237, 240, "Bao" +257, 5, 8, 57, 23, 24, 241, 242, "Y" +257, 5, 9, 58, 25, 26, 243, 244, "(" +257, 5, 10, 59, 27, 28, 245, 246, "2" +257, 5, 11, 60, 29, 30, 247, 248, ")" +257, 5, 12, 61, 31, 32, 249, 250, "," +257, 5, 13, 62, 33, 36, 251, 254, "Han" +257, 5, 14, 63, 37, 38, 255, 256, "P" +257, 5, 15, 64, 39, 40, 257, 258, "(" +257, 5, 16, 65, 41, 42, 259, 260, "3" +257, 5, 17, 66, 43, 44, 261, 262, ")" +257, 5, 18, 67, 45, 46, 263, 264, "," +257, 5, 19, 68, 47, 49, 265, 267, "Hu" +257, 5, 20, 69, 50, 51, 268, 269, "J" +257, 5, 21, 70, 52, 53, 270, 271, "(" +257, 5, 22, 71, 54, 55, 272, 273, "4" +257, 5, 23, 72, 56, 57, 274, 275, ")" +257, 5, 24, 73, 58, 59, 276, 277, "," +257, 5, 25, 74, 60, 62, 278, 280, "Ma" +257, 5, 26, 75, 63, 64, 281, 282, "J" +257, 5, 27, 76, 65, 66, 283, 284, "(" +257, 5, 28, 77, 67, 68, 285, 286, "5" +257, 5, 29, 78, 69, 70, 287, 288, ")" +257, 5, 30, 79, 71, 72, 289, 290, "," +257, 5, 31, 80, 73, 77, 291, 295, "Peng" +257, 5, 32, 81, 78, 79, 296, 297, "Y" +257, 5, 33, 82, 80, 81, 298, 299, "(" +257, 5, 34, 83, 82, 83, 300, 301, "6" +257, 5, 35, 84, 84, 85, 302, 303, ")" +257, 5, 36, 85, 86, 87, 304, 305, "," +257, 5, 37, 86, 88, 90, 306, 308, "Wu" +257, 5, 38, 87, 91, 92, 309, 310, "F" +257, 5, 39, 88, 93, 94, 311, 312, "(" +257, 5, 40, 89, 95, 96, 313, 314, "7" +257, 5, 41, 90, 97, 98, 315, 316, ")" +257, 5, 42, 91, 99, 100, 317, 318, "," +257, 5, 43, 92, 101, 103, 319, 321, "Xu" +257, 5, 44, 93, 104, 105, 322, 323, "L" +257, 5, 45, 94, 106, 107, 324, 325, "(" +257, 5, 46, 95, 108, 109, 326, 327, "1" +257, 5, 47, 96, 110, 111, 328, 329, ")" +257, 5, 48, 97, 112, 113, 330, 331, "," +257, 5, 49, 98, 114, 119, 332, 337, "Engel" +257, 5, 50, 99, 120, 122, 338, 340, "SS" +257, 5, 51, 100, 123, 124, 341, 342, "(" +257, 5, 52, 101, 125, 126, 343, 344, "1" +257, 5, 53, 102, 127, 128, 345, 346, ")" +257, 5, 54, 103, 129, 130, 347, 348, "," +257, 5, 55, 104, 131, 134, 349, 352, "Jia" +257, 5, 56, 105, 135, 136, 353, 354, "W" +257, 5, 57, 106, 137, 138, 355, 356, "(" +257, 5, 58, 107, 139, 140, 357, 358, "2" +257, 5, 59, 108, 141, 142, 359, 360, ")" +257, 5, 60, 109, 143, 144, 361, 362, "." +257, 6, 1, 110, 0, 6, 363, 369, "Author" +257, 6, 2, 111, 7, 18, 370, 381, "information" +257, 6, 3, 112, 19, 20, 382, 383, ":" +257, 6, 4, 113, 21, 22, 384, 385, "(" +257, 6, 5, 114, 23, 24, 386, 387, "1" +257, 6, 6, 115, 25, 26, 388, 389, ")" +257, 6, 7, 116, 27, 32, 390, 395, "Merck" +257, 6, 8, 117, 33, 34, 396, 397, "&" +257, 6, 9, 118, 35, 37, 398, 400, "Co" +257, 6, 10, 119, 38, 39, 401, 402, "." +257, 6, 11, 120, 40, 41, 403, 404, "," +257, 6, 12, 121, 42, 45, 405, 408, "Inc" +257, 6, 13, 122, 46, 47, 409, 410, "." +257, 6, 14, 123, 48, 49, 411, 412, "," +257, 6, 15, 124, 50, 60, 413, 423, "Kenilworth" +257, 6, 16, 125, 61, 62, 424, 425, "," +257, 6, 17, 126, 63, 66, 426, 429, "New" +257, 6, 18, 127, 67, 73, 430, 436, "Jersey" +257, 6, 19, 128, 74, 75, 437, 438, "," +257, 6, 20, 129, 76, 79, 439, 442, "USA" +257, 6, 21, 130, 80, 81, 443, 444, "." +257, 7, 1, 131, 0, 1, 445, 446, "(" +257, 7, 2, 132, 2, 3, 447, 448, "2" +257, 7, 3, 133, 4, 5, 449, 450, ")" +257, 7, 4, 134, 6, 14, 451, 459, "Shanghai" +257, 7, 5, 135, 15, 19, 460, 464, "Jiao" +257, 7, 6, 136, 20, 24, 465, 469, "Tong" +257, 7, 7, 137, 25, 35, 470, 480, "University" +257, 7, 8, 138, 36, 46, 481, 491, "Affiliated" +257, 7, 9, 139, 47, 52, 492, 497, "Sixth" +257, 7, 10, 140, 53, 59, 498, 504, "People" +257, 7, 11, 141, 60, 61, 505, 506, "'" +257, 7, 12, 142, 62, 63, 507, 508, "s" +257, 7, 13, 143, 64, 72, 509, 517, "Hospital" +257, 7, 14, 144, 73, 74, 518, 519, "," +257, 7, 15, 145, 75, 83, 520, 528, "Shanghai" +257, 7, 16, 146, 84, 85, 529, 530, "." +257, 8, 1, 147, 0, 1, 531, 532, "(" +257, 8, 2, 148, 2, 3, 533, 534, "3" +257, 8, 3, 149, 4, 5, 535, 536, ")" +257, 8, 4, 150, 6, 15, 537, 546, "Shengjing" +257, 8, 5, 151, 16, 24, 547, 555, "Hospital" +257, 8, 6, 152, 25, 27, 556, 558, "of" +257, 8, 7, 153, 28, 33, 559, 564, "China" +257, 8, 8, 154, 34, 41, 565, 572, "Medical" +257, 8, 9, 155, 42, 52, 573, 583, "University" +257, 8, 10, 156, 53, 54, 584, 585, "," +257, 8, 11, 157, 55, 63, 586, 594, "Shenyang" +257, 8, 12, 158, 64, 65, 595, 596, "." +257, 9, 1, 159, 0, 1, 597, 598, "(" +257, 9, 2, 160, 2, 3, 599, 600, "4" +257, 9, 3, 161, 4, 5, 601, 602, ")" +257, 9, 4, 162, 6, 9, 603, 606, "The" +257, 9, 5, 163, 10, 16, 607, 613, "Second" +257, 9, 6, 164, 17, 27, 614, 624, "Affiliated" +257, 9, 7, 165, 28, 36, 625, 633, "Hospital" +257, 9, 8, 166, 37, 39, 634, 636, "of" +257, 9, 9, 167, 40, 47, 637, 644, "Soochow" +257, 9, 10, 168, 48, 58, 645, 655, "University" +257, 9, 11, 169, 59, 60, 656, 657, "," +257, 9, 12, 170, 61, 67, 658, 664, "Suzhou" +257, 9, 13, 171, 68, 69, 665, 666, "." +257, 10, 1, 172, 0, 1, 667, 668, "(" +257, 10, 2, 173, 2, 3, 669, 670, "5" +257, 10, 3, 174, 4, 5, 671, 672, ")" +257, 10, 4, 175, 6, 13, 673, 680, "Nanjing" +257, 10, 5, 176, 14, 19, 681, 686, "First" +257, 10, 6, 177, 20, 28, 687, 695, "Hospital" +257, 10, 7, 178, 29, 39, 696, 706, "Affiliated" +257, 10, 8, 179, 40, 42, 707, 709, "to" +257, 10, 9, 180, 43, 50, 710, 717, "Nanjing" +257, 10, 10, 181, 51, 58, 718, 725, "Medical" +257, 10, 11, 182, 59, 69, 726, 736, "University" +257, 10, 12, 183, 70, 71, 737, 738, "," +257, 10, 13, 184, 72, 79, 739, 746, "Nanjing" +257, 10, 14, 185, 80, 81, 747, 748, "." +257, 11, 1, 186, 0, 1, 749, 750, "(" +257, 11, 2, 187, 2, 3, 751, 752, "6" +257, 11, 3, 188, 4, 5, 753, 754, ")" +257, 11, 4, 189, 6, 14, 755, 763, "Shanghai" +257, 11, 5, 190, 15, 20, 764, 769, "First" +257, 11, 6, 191, 21, 27, 770, 776, "People" +257, 11, 7, 192, 28, 29, 777, 778, "'" +257, 11, 8, 193, 30, 31, 779, 780, "s" +257, 11, 9, 194, 32, 40, 781, 789, "Hospital" +257, 11, 10, 195, 41, 51, 790, 800, "affiliated" +257, 11, 11, 196, 52, 54, 801, 803, "to" +257, 11, 12, 197, 55, 63, 804, 812, "Shanghai" +257, 11, 13, 198, 64, 72, 813, 821, "Jiaotong" +257, 11, 14, 199, 73, 83, 822, 832, "University" +257, 11, 15, 200, 84, 85, 833, 834, "," +257, 11, 16, 201, 86, 94, 835, 843, "Shanghai" +257, 11, 17, 202, 95, 96, 844, 845, "." +257, 12, 1, 203, 0, 1, 846, 847, "(" +257, 12, 2, 204, 2, 3, 848, 849, "7" +257, 12, 3, 205, 4, 5, 850, 851, ")" +257, 12, 4, 206, 6, 9, 852, 855, "MSD" +257, 12, 5, 207, 10, 15, 856, 861, "China" +257, 12, 6, 208, 16, 17, 862, 863, "," +257, 12, 7, 209, 18, 25, 864, 871, "Beijing" +257, 12, 8, 210, 26, 27, 872, 873, "," +257, 12, 9, 211, 28, 33, 874, 879, "China" +257, 12, 10, 212, 34, 35, 880, 881, "." +257, 13, 1, 213, 0, 12, 882, 894, "INTRODUCTION" +257, 13, 2, 214, 13, 14, 895, 896, ":" +257, 13, 3, 215, 15, 17, 897, 899, "We" +257, 13, 4, 216, 18, 27, 900, 909, "evaluated" +257, 13, 5, 217, 28, 31, 910, 913, "the" +257, 13, 6, 218, 32, 44, 914, 926, "tolerability" +257, 13, 7, 219, 45, 48, 927, 930, "and" +257, 13, 8, 220, 49, 57, 931, 939, "efficacy" +257, 13, 9, 221, 58, 60, 940, 942, "of" +257, 13, 10, 222, 61, 64, 943, 946, "the" +257, 13, 11, 223, 65, 73, 947, 955, "addition" +257, 13, 12, 224, 74, 76, 956, 958, "of" +257, 13, 13, 225, 77, 88, 959, 970, "sitagliptin" +257, 13, 14, 226, 89, 91, 971, 973, "in" +257, 13, 15, 227, 92, 99, 974, 981, "Chinese" +257, 13, 16, 228, 100, 108, 982, 990, "patients" +257, 13, 17, 229, 109, 113, 991, 995, "with" +257, 13, 18, 230, 114, 118, 996, 1000, "type" +257, 13, 19, 231, 119, 120, 1001, 1002, "2" +257, 13, 20, 232, 121, 129, 1003, 1011, "diabetes" +257, 13, 21, 233, 130, 138, 1012, 1020, "mellitus" +257, 13, 22, 234, 139, 148, 1021, 1030, "receiving" +257, 13, 23, 235, 149, 155, 1031, 1037, "stable" +257, 13, 24, 236, 156, 163, 1038, 1045, "insulin" +257, 13, 25, 237, 164, 171, 1046, 1053, "therapy" +257, 13, 26, 238, 172, 177, 1054, 1059, "alone" +257, 13, 27, 239, 178, 180, 1060, 1062, "or" +257, 13, 28, 240, 181, 183, 1063, 1065, "in" +257, 13, 29, 241, 184, 195, 1066, 1077, "combination" +257, 13, 30, 242, 196, 200, 1078, 1082, "with" +257, 13, 31, 243, 201, 210, 1083, 1092, "metformin" +257, 13, 32, 244, 211, 212, 1093, 1094, "." +257, 14, 1, 245, 0, 9, 1095, 1104, "MATERIALS" +257, 14, 2, 246, 10, 13, 1105, 1108, "AND" +257, 14, 3, 247, 14, 21, 1109, 1116, "METHODS" +257, 14, 4, 248, 22, 23, 1117, 1118, ":" +257, 14, 5, 249, 24, 25, 1119, 1120, "A" +257, 14, 6, 250, 26, 31, 1121, 1126, "total" +257, 14, 7, 251, 32, 34, 1127, 1129, "of" +257, 14, 8, 252, 35, 38, 1130, 1133, "467" +257, 14, 9, 253, 39, 47, 1134, 1142, "patients" +257, 14, 10, 254, 48, 52, 1143, 1147, "with" +257, 14, 11, 255, 53, 63, 1148, 1158, "inadequate" +257, 14, 12, 256, 64, 72, 1159, 1167, "glycemic" +257, 14, 13, 257, 73, 80, 1168, 1175, "control" +257, 14, 14, 258, 81, 83, 1176, 1178, "on" +257, 14, 15, 259, 84, 91, 1179, 1186, "insulin" +257, 14, 16, 260, 92, 93, 1187, 1188, "(" +257, 14, 17, 261, 94, 102, 1189, 1197, "glycated" +257, 14, 18, 262, 103, 113, 1198, 1208, "hemoglobin" +257, 14, 19, 263, 114, 115, 1209, 1210, "[" +257, 14, 20, 264, 116, 121, 1211, 1216, "HbA1c" +257, 14, 21, 265, 122, 123, 1217, 1218, "]" +257, 14, 22, 266, 124, 125, 1219, 1220, "≥" +257, 14, 23, 267, 126, 127, 1221, 1222, "7" +257, 14, 24, 268, 128, 129, 1223, 1224, "." +257, 14, 25, 269, 130, 131, 1225, 1226, "5" +257, 14, 26, 270, 132, 133, 1227, 1228, "%" +257, 14, 27, 271, 134, 137, 1229, 1232, "and" +257, 14, 28, 272, 138, 139, 1233, 1234, "≤" +257, 14, 29, 273, 140, 142, 1235, 1237, "11" +257, 14, 30, 274, 143, 144, 1238, 1239, "%" +257, 14, 31, 275, 145, 146, 1240, 1241, ")" +257, 14, 32, 276, 147, 151, 1242, 1246, "were" +257, 14, 33, 277, 152, 162, 1247, 1257, "randomized" +257, 14, 34, 278, 163, 164, 1258, 1259, "1" +257, 14, 35, 279, 165, 166, 1260, 1261, ":" +257, 14, 36, 280, 167, 168, 1262, 1263, "1" +257, 14, 37, 281, 169, 171, 1264, 1266, "to" +257, 14, 38, 282, 172, 179, 1267, 1274, "receive" +257, 14, 39, 283, 180, 191, 1275, 1286, "sitagliptin" +257, 14, 40, 284, 192, 195, 1287, 1290, "100" +257, 14, 41, 285, 196, 198, 1291, 1293, "mg" +257, 14, 42, 286, 199, 203, 1294, 1298, "once" +257, 14, 43, 287, 204, 209, 1299, 1304, "daily" +257, 14, 44, 288, 210, 212, 1305, 1307, "or" +257, 14, 45, 289, 213, 214, 1308, 1309, "a" +257, 14, 46, 290, 215, 223, 1310, 1318, "matching" +257, 14, 47, 291, 224, 231, 1319, 1326, "placebo" +257, 14, 48, 292, 232, 235, 1327, 1330, "for" +257, 14, 49, 293, 236, 238, 1331, 1333, "24" +257, 14, 50, 294, 239, 244, 1334, 1339, "weeks" +257, 14, 51, 295, 245, 246, 1340, 1341, "." +257, 15, 1, 296, 0, 13, 1342, 1355, "Randomization" +257, 15, 2, 297, 14, 17, 1356, 1359, "was" +257, 15, 3, 298, 18, 28, 1360, 1370, "stratified" +257, 15, 4, 299, 29, 34, 1371, 1376, "based" +257, 15, 5, 300, 35, 37, 1377, 1379, "on" +257, 15, 6, 301, 38, 47, 1380, 1389, "metformin" +257, 15, 7, 302, 48, 51, 1390, 1393, "use" +257, 15, 8, 303, 52, 53, 1394, 1395, "(" +257, 15, 9, 304, 54, 56, 1396, 1398, "on" +257, 15, 10, 305, 57, 59, 1399, 1401, "or" +257, 15, 11, 306, 60, 63, 1402, 1405, "not" +257, 15, 12, 307, 64, 66, 1406, 1408, "on" +257, 15, 13, 308, 67, 76, 1409, 1418, "metformin" +257, 15, 14, 309, 77, 78, 1419, 1420, ")" +257, 15, 15, 310, 79, 82, 1421, 1424, "and" +257, 15, 16, 311, 83, 87, 1425, 1429, "type" +257, 15, 17, 312, 88, 90, 1430, 1432, "of" +257, 15, 18, 313, 91, 98, 1433, 1440, "insulin" +257, 15, 19, 314, 99, 100, 1441, 1442, "(" +257, 15, 20, 315, 101, 104, 1443, 1446, "pre" +257, 15, 21, 316, 105, 106, 1447, 1448, "-" +257, 15, 22, 317, 107, 112, 1449, 1454, "mixed" +257, 15, 23, 318, 113, 115, 1455, 1457, "vs" +257, 15, 24, 319, 116, 128, 1458, 1470, "intermediate" +257, 15, 25, 320, 129, 130, 1471, 1472, "-" +257, 15, 26, 321, 131, 132, 1473, 1474, "/" +257, 15, 27, 322, 133, 137, 1475, 1479, "long" +257, 15, 28, 323, 138, 139, 1480, 1481, "-" +257, 15, 29, 324, 140, 146, 1482, 1488, "acting" +257, 15, 30, 325, 147, 148, 1489, 1490, ")" +257, 15, 31, 326, 149, 151, 1491, 1493, "at" +257, 15, 32, 327, 152, 161, 1494, 1503, "screening" +257, 15, 33, 328, 162, 163, 1504, 1505, "." +257, 16, 1, 329, 0, 3, 1506, 1509, "The" +257, 16, 2, 330, 4, 11, 1510, 1517, "primary" +257, 16, 3, 331, 12, 15, 1518, 1521, "end" +257, 16, 4, 332, 16, 17, 1522, 1523, "-" +257, 16, 5, 333, 18, 23, 1524, 1529, "point" +257, 16, 6, 334, 24, 27, 1530, 1533, "was" +257, 16, 7, 335, 28, 31, 1534, 1537, "the" +257, 16, 8, 336, 32, 38, 1538, 1544, "change" +257, 16, 9, 337, 39, 43, 1545, 1549, "from" +257, 16, 10, 338, 44, 52, 1550, 1558, "baseline" +257, 16, 11, 339, 53, 55, 1559, 1561, "at" +257, 16, 12, 340, 56, 60, 1562, 1566, "week" +257, 16, 13, 341, 61, 63, 1567, 1569, "24" +257, 16, 14, 342, 64, 66, 1570, 1572, "in" +257, 16, 15, 343, 67, 72, 1573, 1578, "HbA1c" +257, 16, 16, 344, 73, 74, 1579, 1580, "." +257, 17, 1, 345, 0, 7, 1581, 1588, "RESULTS" +257, 17, 2, 346, 8, 9, 1589, 1590, ":" +257, 17, 3, 347, 10, 13, 1591, 1594, "The" +257, 17, 4, 348, 14, 22, 1595, 1603, "addition" +257, 17, 5, 349, 23, 25, 1604, 1606, "of" +257, 17, 6, 350, 26, 37, 1607, 1618, "sitagliptin" +257, 17, 7, 351, 38, 41, 1619, 1622, "led" +257, 17, 8, 352, 42, 44, 1623, 1625, "to" +257, 17, 9, 353, 45, 46, 1626, 1627, "a" +257, 17, 10, 354, 47, 60, 1628, 1641, "significantly" +257, 17, 11, 355, 61, 62, 1642, 1643, "(" +257, 17, 12, 356, 63, 64, 1644, 1645, "P" +257, 17, 13, 357, 65, 66, 1646, 1647, "<" +257, 17, 14, 358, 67, 68, 1648, 1649, "0" +257, 17, 15, 359, 69, 70, 1650, 1651, "." +257, 17, 16, 360, 71, 74, 1652, 1655, "001" +257, 17, 17, 361, 75, 76, 1656, 1657, ")" +257, 17, 18, 362, 77, 84, 1658, 1665, "greater" +257, 17, 19, 363, 85, 89, 1666, 1670, "week" +257, 17, 20, 364, 90, 92, 1671, 1673, "24" +257, 17, 21, 365, 93, 98, 1674, 1679, "HbA1c" +257, 17, 22, 366, 99, 108, 1680, 1689, "reduction" +257, 17, 23, 367, 109, 110, 1690, 1691, "(" +257, 17, 24, 368, 111, 112, 1692, 1693, "0" +257, 17, 25, 369, 113, 114, 1694, 1695, "." +257, 17, 26, 370, 115, 116, 1696, 1697, "7" +257, 17, 27, 371, 117, 118, 1698, 1699, "%" +257, 17, 28, 372, 119, 120, 1700, 1701, ")" +257, 17, 29, 373, 121, 129, 1702, 1710, "compared" +257, 17, 30, 374, 130, 134, 1711, 1715, "with" +257, 17, 31, 375, 135, 138, 1716, 1719, "the" +257, 17, 32, 376, 139, 148, 1720, 1729, "reduction" +257, 17, 33, 377, 149, 150, 1730, 1731, "(" +257, 17, 34, 378, 151, 152, 1732, 1733, "0" +257, 17, 35, 379, 153, 154, 1734, 1735, "." +257, 17, 36, 380, 155, 156, 1736, 1737, "3" +257, 17, 37, 381, 157, 158, 1738, 1739, "%" +257, 17, 38, 382, 159, 160, 1740, 1741, ")" +257, 17, 39, 383, 161, 165, 1742, 1746, "with" +257, 17, 40, 384, 166, 173, 1747, 1754, "placebo" +257, 17, 41, 385, 174, 175, 1755, 1756, "." +257, 18, 1, 386, 0, 1, 1757, 1758, "A" +257, 18, 2, 387, 2, 15, 1759, 1772, "significantly" +257, 18, 3, 388, 16, 17, 1773, 1774, "(" +257, 18, 4, 389, 18, 19, 1775, 1776, "P" +257, 18, 5, 390, 20, 21, 1777, 1778, "=" +257, 18, 6, 391, 22, 23, 1779, 1780, "0" +257, 18, 7, 392, 24, 25, 1781, 1782, "." +257, 18, 8, 393, 26, 29, 1783, 1786, "013" +257, 18, 9, 394, 30, 31, 1787, 1788, ")" +257, 18, 10, 395, 32, 39, 1789, 1796, "greater" +257, 18, 11, 396, 40, 50, 1797, 1807, "proportion" +257, 18, 12, 397, 51, 53, 1808, 1810, "of" +257, 18, 13, 398, 54, 62, 1811, 1819, "patients" +257, 18, 14, 399, 63, 69, 1820, 1826, "taking" +257, 18, 15, 400, 70, 81, 1827, 1838, "sitagliptin" +257, 18, 16, 401, 82, 83, 1839, 1840, "(" +257, 18, 17, 402, 84, 86, 1841, 1843, "16" +257, 18, 18, 403, 87, 88, 1844, 1845, "%" +257, 18, 19, 404, 89, 90, 1846, 1847, ")" +257, 18, 20, 405, 91, 94, 1848, 1851, "had" +257, 18, 21, 406, 95, 97, 1852, 1854, "an" +257, 18, 22, 407, 98, 103, 1855, 1860, "HbA1c" +257, 18, 23, 408, 104, 106, 1861, 1863, "of" +257, 18, 24, 409, 107, 108, 1864, 1865, "<" +257, 18, 25, 410, 109, 110, 1866, 1867, "7" +257, 18, 26, 411, 111, 112, 1868, 1869, "." +257, 18, 27, 412, 113, 114, 1870, 1871, "0" +257, 18, 28, 413, 115, 116, 1872, 1873, "%" +257, 18, 29, 414, 117, 119, 1874, 1876, "at" +257, 18, 30, 415, 120, 124, 1877, 1881, "week" +257, 18, 31, 416, 125, 127, 1882, 1884, "24" +257, 18, 32, 417, 128, 136, 1885, 1893, "compared" +257, 18, 33, 418, 137, 141, 1894, 1898, "with" +257, 18, 34, 419, 142, 149, 1899, 1906, "placebo" +257, 18, 35, 420, 150, 151, 1907, 1908, "(" +257, 18, 36, 421, 152, 153, 1909, 1910, "8" +257, 18, 37, 422, 154, 155, 1911, 1912, "%" +257, 18, 38, 423, 156, 157, 1913, 1914, ")" +257, 18, 39, 424, 158, 159, 1915, 1916, "." +257, 19, 1, 425, 0, 3, 1917, 1920, "The" +257, 19, 2, 426, 4, 12, 1921, 1929, "addition" +257, 19, 3, 427, 13, 15, 1930, 1932, "of" +257, 19, 4, 428, 16, 27, 1933, 1944, "sitagliptin" +257, 19, 5, 429, 28, 41, 1945, 1958, "significantly" +257, 19, 6, 430, 42, 43, 1959, 1960, "(" +257, 19, 7, 431, 44, 45, 1961, 1962, "P" +257, 19, 8, 432, 46, 47, 1963, 1964, "<" +257, 19, 9, 433, 48, 49, 1965, 1966, "0" +257, 19, 10, 434, 50, 51, 1967, 1968, "." +257, 19, 11, 435, 52, 55, 1969, 1972, "001" +257, 19, 12, 436, 56, 57, 1973, 1974, ")" +257, 19, 13, 437, 58, 65, 1975, 1982, "reduced" +257, 19, 14, 438, 66, 67, 1983, 1984, "2" +257, 19, 15, 439, 68, 69, 1985, 1986, "-" +257, 19, 16, 440, 70, 71, 1987, 1988, "h" +257, 19, 17, 441, 72, 76, 1989, 1993, "post" +257, 19, 18, 442, 77, 78, 1994, 1995, "-" +257, 19, 19, 443, 79, 83, 1996, 2000, "meal" +257, 19, 20, 444, 84, 91, 2001, 2008, "glucose" +257, 19, 21, 445, 92, 94, 2009, 2011, "by" +257, 19, 22, 446, 95, 97, 2012, 2014, "26" +257, 19, 23, 447, 98, 99, 2015, 2016, "." +257, 19, 24, 448, 100, 101, 2017, 2018, "5" +257, 19, 25, 449, 102, 104, 2019, 2021, "mg" +257, 19, 26, 450, 105, 106, 2022, 2023, "/" +257, 19, 27, 451, 107, 109, 2024, 2026, "dL" +257, 19, 28, 452, 110, 111, 2027, 2028, "(" +257, 19, 29, 453, 112, 113, 2029, 2030, "1" +257, 19, 30, 454, 114, 115, 2031, 2032, "." +257, 19, 31, 455, 116, 117, 2033, 2034, "5" +257, 19, 32, 456, 118, 122, 2035, 2039, "mmol" +257, 19, 33, 457, 123, 124, 2040, 2041, "/" +257, 19, 34, 458, 125, 126, 2042, 2043, "L" +257, 19, 35, 459, 127, 128, 2044, 2045, ")" +257, 19, 36, 460, 129, 137, 2046, 2054, "relative" +257, 19, 37, 461, 138, 140, 2055, 2057, "to" +257, 19, 38, 462, 141, 148, 2058, 2065, "placebo" +257, 19, 39, 463, 149, 150, 2066, 2067, "." +257, 20, 1, 464, 0, 10, 2068, 2078, "Reductions" +257, 20, 2, 465, 11, 15, 2079, 2083, "from" +257, 20, 3, 466, 16, 24, 2084, 2092, "baseline" +257, 20, 4, 467, 25, 27, 2093, 2095, "in" +257, 20, 5, 468, 28, 35, 2096, 2103, "fasting" +257, 20, 6, 469, 36, 42, 2104, 2110, "plasma" +257, 20, 7, 470, 43, 50, 2111, 2118, "glucose" +257, 20, 8, 471, 51, 55, 2119, 2123, "were" +257, 20, 9, 472, 56, 64, 2124, 2132, "observed" +257, 20, 10, 473, 65, 67, 2133, 2135, "in" +257, 20, 11, 474, 68, 72, 2136, 2140, "both" +257, 20, 12, 475, 73, 76, 2141, 2144, "the" +257, 20, 13, 476, 77, 88, 2145, 2156, "sitagliptin" +257, 20, 14, 477, 89, 90, 2157, 2158, "(" +257, 20, 15, 478, 91, 93, 2159, 2161, "14" +257, 20, 16, 479, 94, 95, 2162, 2163, "." +257, 20, 17, 480, 96, 97, 2164, 2165, "4" +257, 20, 18, 481, 98, 100, 2166, 2168, "mg" +257, 20, 19, 482, 101, 102, 2169, 2170, "/" +257, 20, 20, 483, 103, 105, 2171, 2173, "dL" +257, 20, 21, 484, 106, 115, 2174, 2183, "reduction" +257, 20, 22, 485, 116, 117, 2184, 2185, ")" +257, 20, 23, 486, 118, 121, 2186, 2189, "and" +257, 20, 24, 487, 122, 129, 2190, 2197, "placebo" +257, 20, 25, 488, 130, 131, 2198, 2199, "(" +257, 20, 26, 489, 132, 134, 2200, 2202, "10" +257, 20, 27, 490, 135, 136, 2203, 2204, "." +257, 20, 28, 491, 137, 138, 2205, 2206, "7" +257, 20, 29, 492, 139, 141, 2207, 2209, "mg" +257, 20, 30, 493, 142, 143, 2210, 2211, "/" +257, 20, 31, 494, 144, 146, 2212, 2214, "dL" +257, 20, 32, 495, 147, 156, 2215, 2224, "reduction" +257, 20, 33, 496, 157, 158, 2225, 2226, ")" +257, 20, 34, 497, 159, 165, 2227, 2233, "groups" +257, 20, 35, 498, 166, 167, 2234, 2235, ";" +257, 20, 36, 499, 168, 171, 2236, 2239, "the" +257, 20, 37, 500, 172, 179, 2240, 2247, "between" +257, 20, 38, 501, 180, 181, 2248, 2249, "-" +257, 20, 39, 502, 182, 187, 2250, 2255, "group" +257, 20, 40, 503, 188, 198, 2256, 2266, "difference" +257, 20, 41, 504, 199, 202, 2267, 2270, "was" +257, 20, 42, 505, 203, 206, 2271, 2274, "not" +257, 20, 43, 506, 207, 218, 2275, 2286, "significant" +257, 20, 44, 507, 219, 220, 2287, 2288, "." +257, 21, 1, 508, 0, 1, 2289, 2290, "A" +257, 21, 2, 509, 2, 7, 2291, 2296, "total" +257, 21, 3, 510, 8, 10, 2297, 2299, "of" +257, 21, 4, 511, 11, 13, 2300, 2302, "64" +257, 21, 5, 512, 14, 15, 2303, 2304, "(" +257, 21, 6, 513, 16, 18, 2305, 2307, "27" +257, 21, 7, 514, 19, 20, 2308, 2309, "." +257, 21, 8, 515, 21, 22, 2310, 2311, "4" +257, 21, 9, 516, 23, 24, 2312, 2313, "%" +257, 21, 10, 517, 25, 26, 2314, 2315, ")" +257, 21, 11, 518, 27, 35, 2316, 2324, "patients" +257, 21, 12, 519, 36, 42, 2325, 2331, "taking" +257, 21, 13, 520, 43, 54, 2332, 2343, "sitagliptin" +257, 21, 14, 521, 55, 58, 2344, 2347, "and" +257, 21, 15, 522, 59, 61, 2348, 2350, "51" +257, 21, 16, 523, 62, 63, 2351, 2352, "(" +257, 21, 17, 524, 64, 66, 2353, 2355, "21" +257, 21, 18, 525, 67, 68, 2356, 2357, "." +257, 21, 19, 526, 69, 70, 2358, 2359, "9" +257, 21, 20, 527, 71, 72, 2360, 2361, "%" +257, 21, 21, 528, 73, 74, 2362, 2363, ")" +257, 21, 22, 529, 75, 81, 2364, 2370, "taking" +257, 21, 23, 530, 82, 89, 2371, 2378, "placebo" +257, 21, 24, 531, 90, 101, 2379, 2390, "experienced" +257, 21, 25, 532, 102, 109, 2391, 2398, "adverse" +257, 21, 26, 533, 110, 116, 2399, 2405, "events" +257, 21, 27, 534, 117, 119, 2406, 2408, "of" +257, 21, 28, 535, 120, 132, 2409, 2421, "hypoglycemia" +257, 21, 29, 536, 133, 134, 2422, 2423, "(" +257, 21, 30, 537, 135, 146, 2424, 2435, "symptomatic" +257, 21, 31, 538, 147, 149, 2436, 2438, "or" +257, 21, 32, 539, 150, 162, 2439, 2451, "asymptomatic" +257, 21, 33, 540, 163, 164, 2452, 2453, ")" +257, 21, 34, 541, 165, 166, 2454, 2455, "." +257, 22, 1, 542, 0, 7, 2456, 2463, "Neither" +257, 22, 2, 543, 8, 13, 2464, 2469, "group" +257, 22, 3, 544, 14, 17, 2470, 2473, "had" +257, 22, 4, 545, 18, 19, 2474, 2475, "a" +257, 22, 5, 546, 20, 31, 2476, 2487, "significant" +257, 22, 6, 547, 32, 38, 2488, 2494, "change" +257, 22, 7, 548, 39, 43, 2495, 2499, "from" +257, 22, 8, 549, 44, 52, 2500, 2508, "baseline" +257, 22, 9, 550, 53, 55, 2509, 2511, "in" +257, 22, 10, 551, 56, 66, 2512, 2522, "bodyweight" +257, 22, 11, 552, 67, 68, 2523, 2524, "." +257, 23, 1, 553, 0, 11, 2525, 2536, "CONCLUSIONS" +257, 23, 2, 554, 12, 13, 2537, 2538, ":" +257, 23, 3, 555, 14, 19, 2539, 2544, "After" +257, 23, 4, 556, 20, 22, 2545, 2547, "24" +257, 23, 5, 557, 23, 28, 2548, 2553, "weeks" +257, 23, 6, 558, 29, 30, 2554, 2555, "," +257, 23, 7, 559, 31, 42, 2556, 2567, "sitagliptin" +257, 23, 8, 560, 43, 48, 2568, 2573, "added" +257, 23, 9, 561, 49, 51, 2574, 2576, "to" +257, 23, 10, 562, 52, 58, 2577, 2583, "stable" +257, 23, 11, 563, 59, 66, 2584, 2591, "insulin" +257, 23, 12, 564, 67, 74, 2592, 2599, "therapy" +257, 23, 13, 565, 75, 76, 2600, 2601, "(" +257, 23, 14, 566, 77, 78, 2602, 2603, "±" +257, 23, 15, 567, 79, 88, 2604, 2613, "metformin" +257, 23, 16, 568, 89, 90, 2614, 2615, ")" +257, 23, 17, 569, 91, 94, 2616, 2619, "was" +257, 23, 18, 570, 95, 104, 2620, 2629, "generally" +257, 23, 19, 571, 105, 109, 2630, 2634, "well" +257, 23, 20, 572, 110, 119, 2635, 2644, "tolerated" +257, 23, 21, 573, 120, 123, 2645, 2648, "and" +257, 23, 22, 574, 124, 132, 2649, 2657, "improved" +257, 23, 23, 575, 133, 141, 2658, 2666, "glycemic" +257, 23, 24, 576, 142, 149, 2667, 2674, "control" +257, 23, 25, 577, 150, 152, 2675, 2677, "in" +257, 23, 26, 578, 153, 160, 2678, 2685, "Chinese" +257, 23, 27, 579, 161, 169, 2686, 2694, "patients" +257, 23, 28, 580, 170, 174, 2695, 2699, "with" +257, 23, 29, 581, 175, 179, 2700, 2704, "type" +257, 23, 30, 582, 180, 181, 2705, 2706, "2" +257, 23, 31, 583, 182, 190, 2707, 2715, "diabetes" +257, 23, 32, 584, 191, 199, 2716, 2724, "mellitus" +257, 23, 33, 585, 200, 201, 2725, 2726, "." +257, 24, 1, 586, 0, 1, 2727, 2728, "©" +257, 24, 2, 587, 2, 6, 2729, 2733, "2016" +257, 24, 3, 588, 7, 12, 2734, 2739, "Merck" +257, 24, 4, 589, 13, 18, 2740, 2745, "Sharp" +257, 24, 5, 590, 19, 20, 2746, 2747, "&" +257, 24, 6, 591, 21, 26, 2748, 2753, "Dohme" +257, 24, 7, 592, 27, 31, 2754, 2758, "Corp" +257, 24, 8, 593, 32, 33, 2759, 2760, "." +257, 24, 9, 594, 34, 41, 2761, 2768, "Journal" +257, 24, 10, 595, 42, 44, 2769, 2771, "of" +257, 24, 11, 596, 45, 53, 2772, 2780, "Diabetes" +257, 24, 12, 597, 54, 67, 2781, 2794, "Investigation" +257, 24, 13, 598, 68, 77, 2795, 2804, "published" +257, 24, 14, 599, 78, 80, 2805, 2807, "by" +257, 24, 15, 600, 81, 86, 2808, 2813, "Asian" +257, 24, 16, 601, 87, 98, 2814, 2825, "Association" +257, 24, 17, 602, 99, 102, 2826, 2829, "for" +257, 24, 18, 603, 103, 106, 2830, 2833, "the" +257, 24, 19, 604, 107, 112, 2834, 2839, "Study" +257, 24, 20, 605, 113, 115, 2840, 2842, "of" +257, 24, 21, 606, 116, 124, 2843, 2851, "Diabetes" +257, 24, 22, 607, 125, 126, 2852, 2853, "(" +257, 24, 23, 608, 127, 131, 2854, 2858, "AASD" +257, 24, 24, 609, 132, 133, 2859, 2860, ")" +257, 24, 25, 610, 134, 137, 2861, 2864, "and" +257, 24, 26, 611, 138, 142, 2865, 2869, "John" +257, 24, 27, 612, 143, 148, 2870, 2875, "Wiley" +257, 24, 28, 613, 149, 150, 2876, 2877, "&" +257, 24, 29, 614, 151, 155, 2878, 2882, "Sons" +257, 24, 30, 615, 156, 165, 2883, 2892, "Australia" +257, 24, 31, 616, 166, 167, 2893, 2894, "," +257, 24, 32, 617, 168, 171, 2895, 2898, "Ltd" +257, 24, 33, 618, 172, 173, 2899, 2900, "." +257, 24, 34, 619, 174, 177, 2901, 2904, "DOI" +257, 24, 35, 620, 178, 179, 2905, 2906, ":" +257, 24, 36, 621, 180, 182, 2907, 2909, "10" +257, 24, 37, 622, 183, 184, 2910, 2911, "." +257, 24, 38, 623, 185, 189, 2912, 2916, "1111" +257, 24, 39, 624, 190, 191, 2917, 2918, "/" +257, 24, 40, 625, 192, 195, 2919, 2922, "jdi" +257, 24, 41, 626, 196, 197, 2923, 2924, "." +257, 24, 42, 627, 198, 203, 2925, 2930, "12585" +257, 24, 43, 628, 204, 209, 2931, 2936, "PMCID" +257, 24, 44, 629, 210, 211, 2937, 2938, ":" +257, 24, 45, 630, 212, 222, 2939, 2949, "PMC5415484" +257, 24, 46, 631, 223, 227, 2950, 2954, "PMID" +257, 24, 47, 632, 228, 229, 2955, 2956, ":" +257, 24, 48, 633, 230, 238, 2957, 2965, "27740719" +257, 24, 49, 634, 239, 240, 2966, 2967, "[" +257, 24, 50, 635, 241, 248, 2968, 2975, "Indexed" +257, 24, 51, 636, 249, 252, 2976, 2979, "for" +257, 24, 52, 637, 253, 260, 2980, 2987, "MEDLINE" +257, 24, 53, 638, 261, 262, 2988, 2989, "]" diff --git a/data/dm2 27740719_kwoodley.annodb b/data/dm2 27740719_kwoodley.annodb new file mode 100644 index 0000000..e539a5f --- /dev/null +++ b/data/dm2 27740719_kwoodley.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70837, Journal, 0, 19, "J Diabetes Investig", "", +70838, PublicationYear, 22, 26, "2017", "", +70839, Sitagliptin, 105, 116, "Sitagliptin", "", +70858, Title, 105, 217, "Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes .", "", +70849, Insulin, 133, 140, "insulin", "", +70850, Metformin, 165, 174, "metformin", "", +70852, Ethnicity, 178, 185, "Chinese", "", +70856, Precondition, 178, 215, "Chinese patients with type 2 diabetes", "", +70853, Type2Diabetes, 200, 215, "type 2 diabetes", "", +70857, Author, 218, 228, "Shankar RR", "", +70859, Author, 237, 242, "Bao Y", "", +70860, Author, 251, 256, "Han P", "", +70861, Author, 265, 269, "Hu J", "", +70862, Author, 278, 282, "Ma J", "", +70863, Author, 291, 297, "Peng Y", "", +70864, Author, 306, 310, "Wu F", "", +70865, Author, 319, 323, "Xu L", "", +70866, Author, 332, 340, "Engel SS", "", +70867, Author, 349, 354, "Jia W", "", +70868, USA, 439, 442, "USA", "", +70949, China, 874, 879, "China", "", +70877, ObjectiveDescription, 897, 1094, "We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin .", "", +70840, Sitagliptin, 959, 970, "sitagliptin", "", +70874, Ethnicity, 974, 981, "Chinese", "", +70876, Precondition, 974, 1092, "Chinese patients with type 2 diabetes mellitus receiving stable insulin therapy alone or in combination with metformin", "", +70854, Type2Diabetes, 996, 1020, "type 2 diabetes mellitus", "", +70875, Insulin, 1038, 1045, "insulin", "", +70851, Metformin, 1083, 1092, "metformin", "", +70878, NumberPatientsCT, 1130, 1133, "467", "", +70885, Precondition, 1134, 1241, "patients with inadequate glycemic control on insulin ( glycated hemoglobin [ HbA1c ] ≥ 7 . 5 % and ≤ 11 % )", "", +70879, Insulin, 1179, 1186, "insulin", "", +70880, HbA1c, 1189, 1208, "glycated hemoglobin", "", +70881, HbA1c, 1211, 1216, "HbA1c", "", +70883, Percentage, 1227, 1228, "%", "", +70884, Percentage, 1238, 1239, "%", "", +70886, Randomized, 1247, 1257, "randomized", "", +70898, AllocationRatio, 1258, 1263, "1 : 1", "", +70841, Sitagliptin, 1275, 1286, "sitagliptin", "", +70888, DoseValue, 1287, 1290, "100", "", +70889, mg, 1291, 1293, "mg", "", +70890, Frequency, 1294, 1304, "once daily", "", +70891, Placebo, 1319, 1326, "placebo", "", +70896, Duration, 1331, 1339, "24 weeks", "", +70897, Randomized, 1342, 1355, "Randomization", "", +70899, Metformin, 1380, 1389, "metformin", "", +70900, Metformin, 1409, 1418, "metformin", "", +70902, Insulin, 1433, 1440, "insulin", "", +70903, TimePoint, 1550, 1558, "baseline", "", +70906, TimePoint, 1562, 1569, "week 24", "", +70882, HbA1c, 1573, 1578, "HbA1c", "", +70842, Sitagliptin, 1607, 1618, "sitagliptin", "", +70909, PValueChangeValue, 1644, 1655, "P < 0 . 001", "", +70907, TimePoint, 1666, 1673, "week 24", "", +70910, HbA1c, 1674, 1679, "HbA1c", "", +70912, Reduction, 1692, 1697, "0 . 7", "", +70913, Percentage, 1698, 1699, "%", "", +70911, Reduction, 1732, 1737, "0 . 3", "", +70914, Percentage, 1738, 1739, "%", "", +70892, Placebo, 1747, 1754, "placebo", "", +70915, PValueNumAffected, 1775, 1786, "P = 0 . 013", "", +70843, Sitagliptin, 1827, 1838, "sitagliptin", "", +70916, PercentageAffected, 1841, 1843, "16", "", +70919, HbA1c_target, 1855, 1873, "HbA1c of < 7 . 0 %", "", +70908, TimePoint, 1877, 1884, "week 24", "", +70893, Placebo, 1899, 1906, "placebo", "", +70917, PercentageAffected, 1909, 1910, "8", "", +70844, Sitagliptin, 1933, 1944, "sitagliptin", "", +70918, PValueChangeValue, 1961, 1972, "P < 0 . 001", "", +70920, PostprandialBloodGlucose, 1983, 2008, "2 - h post - meal glucose", "", +70922, Reduction, 2012, 2018, "26 . 5", "", +70923, Mg_per_deciliter, 2019, 2026, "mg / dL", "", +70921, Reduction, 2029, 2034, "1 . 5", "", +70925, Millimoles_per_litre, 2035, 2043, "mmol / L", "", +70894, Placebo, 2058, 2065, "placebo", "", +70926, TimePoint, 2084, 2092, "baseline", "", +70927, FastingPlasmaGlucose, 2096, 2118, "fasting plasma glucose", "", +70845, Sitagliptin, 2145, 2156, "sitagliptin", "", +70928, Reduction, 2159, 2165, "14 . 4", "", +70930, Mg_per_deciliter, 2166, 2173, "mg / dL", "", +70895, Placebo, 2190, 2197, "placebo", "", +70929, Reduction, 2200, 2206, "10 . 7", "", +70931, Mg_per_deciliter, 2207, 2214, "mg / dL", "", +70932, ObservedResult, 2236, 2286, "the between - group difference was not significant", "", +70938, NumberAffected, 2300, 2302, "64", "", +70940, PercentageAffected, 2305, 2311, "27 . 4", "", +70846, Sitagliptin, 2332, 2343, "sitagliptin", "", +70933, NumberPatientsArm, 2348, 2350, "51", "", +70939, NumberAffected, 2348, 2350, "51", "", +70941, PercentageAffected, 2353, 2359, "21 . 9", "", +70935, Placebo, 2371, 2378, "placebo", "", +70942, Hypoglycemia, 2391, 2453, "adverse events of hypoglycemia ( symptomatic or asymptomatic )", "", +70945, ObservedResult, 2456, 2524, "Neither group had a significant change from baseline in bodyweight .", "", +70847, Sitagliptin, 2476, 2487, "significant", "", +70943, TimePoint, 2500, 2508, "baseline", "", +70944, BodyWeight, 2512, 2522, "bodyweight", "", +70950, ConclusionComment, 2539, 2726, "After 24 weeks , sitagliptin added to stable insulin therapy ( ± metformin ) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus .", "", +70946, Duration, 2545, 2553, "24 weeks", "", +70848, Sitagliptin, 2556, 2567, "sitagliptin", "", +70947, Insulin, 2584, 2591, "insulin", "", +70901, Metformin, 2604, 2613, "metformin", "", +70948, Ethnicity, 2678, 2685, "Chinese", "", +70855, Type2Diabetes, 2700, 2724, "type 2 diabetes mellitus", "", +70951, PMID, 2957, 2965, "27740719", "", diff --git a/data/dm2 27740719_kwoodley.n-triples b/data/dm2 27740719_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 27740719_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28026912_admin.annodb b/data/dm2 28026912_admin.annodb new file mode 100644 index 0000000..6c394a6 --- /dev/null +++ b/data/dm2 28026912_admin.annodb @@ -0,0 +1,146 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +55, Title, 107, 336, "Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ,", "", " \"Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ,\"." +97778, Gemigliptin, 130, 141, "gemigliptin", "", +176, Precondition, 186, 306, "patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea", "", +3, Type2Diabetes, 200, 224, "type 2 diabetes mellitus", "", " ." +4, Metformin, 279, 288, "metformin", "", +5, Sulfonylureas, 293, 306, "sulphonylurea", "", +6, Duration, 311, 320, "24 - week", "", " \"24 - week\"." +7, Multicenter, 323, 334, "multicentre", "", " ." +8, Randomized, 337, 347, "randomized", "", " ." +55, Title, 337, 412, "randomized , double - blind , placebo - controlled study ( TROICA study ) .", "", " \"randomized , double - blind , placebo - controlled study ( TROICA study ) .\"." +9, DoubleBlind, 350, 364, "double - blind", "", " ." +10, Placebo, 367, 374, "placebo", "", +11, Author, 413, 419, "Ahn CH", "", " \"Ahn CH\"." +12, Author, 428, 434, "Han KA", "", " \"Han KA\"." +13, Author, 443, 448, "Yu JM", "", " \"Yu JM\"." +14, Author, 457, 463, "Nam JY", "", " \"Nam JY\"." +15, Author, 472, 478, "Ahn KJ", "", " \"Ahn KJ\"." +16, Author, 487, 492, "Oh TK", "", " \"Oh TK\"." +17, Author, 501, 507, "Lee HW", "", " \"Lee HW\"." +18, Author, 516, 522, "Lee DH", "", " \"Lee DH\"." +19, Author, 531, 536, "Kim J", "", " \"Kim J\"." +20, Author, 545, 553, "Chung CH", "", " \"Chung CH\"." +21, Author, 563, 570, "Park TS", "", " \"Park TS\"." +22, Author, 580, 586, "Kim BJ", "", " \"Kim BJ\"." +23, Author, 596, 603, "Park SW", "", " \"Park SW\"." +24, Author, 613, 620, "Park HK", "", " \"Park HK\"." +25, Author, 630, 636, "Lee KJ", "", " \"Lee KJ\"." +26, Author, 646, 652, "Kim SW", "", " \"Kim SW\"." +27, Author, 662, 669, "Park JH", "", " \"Park JH\"." +28, Author, 679, 684, "Ko KP", "", " \"Ko KP\"." +29, Author, 694, 700, "Kim CH", "", " \"Kim CH\"." +30, Author, 710, 715, "Lee H", "", " \"Lee H\"." +31, Author, 725, 732, "Jang HC", "", " \"Jang HC\"." +32, Author, 749, 756, "Park KS", "", " \"Park KS\"." +33, SouthKorea, 885, 890, "Korea", "", " ." +34, SouthKorea, 966, 971, "Korea", "", +35, SouthKorea, 1072, 1077, "Korea", "", +36, SouthKorea, 1180, 1185, "Korea", "", +37, SouthKorea, 1291, 1296, "Korea", "", +38, SouthKorea, 1390, 1395, "Korea", "", +39, SouthKorea, 1483, 1488, "Korea", "", +40, SouthKorea, 1593, 1598, "Korea", "", +41, SouthKorea, 1683, 1688, "Korea", "", +42, SouthKorea, 1795, 1800, "Korea", "", +42, SouthKorea, 1892, 1897, "Korea", "", +43, SouthKorea, 1990, 1995, "Korea", "", +44, SouthKorea, 2079, 2084, "Korea", "", +45, SouthKorea, 2172, 2177, "Korea", "", +46, SouthKorea, 2256, 2261, "Korea", "", +47, SouthKorea, 2356, 2361, "Korea", "", +48, SouthKorea, 2451, 2456, "Korea", "", +49, SouthKorea, 2543, 2548, "Korea", "", +50, SouthKorea, 2628, 2633, "Korea", "", +51, SouthKorea, 2670, 2675, "Korea", "", +52, SouthKorea, 2775, 2780, "Korea", "", +53, SouthKorea, 2880, 2885, "Korea", "", +54, SouthKorea, 3053, 3058, "Korea", "", +62, ObjectiveDescription, 3068, 3238, "To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .", "", " \"To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .\"." +97779, Gemigliptin, 3105, 3116, "gemigliptin", "", +58, Metformin, 3167, 3176, "metformin", "", +59, Sulfonylureas, 3181, 3194, "sulphonylurea", "", +60, Type2Diabetes, 3212, 3227, "type 2 diabetes", "", +61, Type2Diabetes, 3230, 3234, "T2DM", "", +63, Randomized, 3278, 3288, "randomized", "", +64, DoubleBlind, 3291, 3305, "double - blind", "", +65, Placebo, 3308, 3315, "placebo", "", +66, NumberPatientsCT, 3338, 3341, "219", "", " \"219\"." +67, Ethnicity, 3342, 3348, "Korean", "", " . ." +244, Precondition, 3342, 3412, "Korean patients inadequately controlled with metformin and glimepiride", "", " \"Korean patients inadequately controlled with metformin and glimepiride\"." +68, Metformin, 3387, 3396, "metformin", "", +69, Glimepiride, 3401, 3412, "glimepiride", "", +71, Randomized, 3433, 3443, "randomized", "", +97780, Gemigliptin, 3447, 3458, "gemigliptin", "", " ." +246, DoseValue, 3459, 3461, "50", "", " \"50\"." +74, mg, 3464, 3466, "mg", "", " ." +75, Frequency, 3467, 3477, "once daily", "", " \"once daily\"." +76, Placebo, 3481, 3488, "placebo", "", " ." +77, Metformin, 3498, 3507, "metformin", "", " ." +78, Glimepiride, 3512, 3523, "glimepiride", "", " ." +79, HbA1c, 3561, 3581, "glycated haemoglobin", "", +80, HbA1c, 3584, 3589, "HbA1c", "", +81, TimePoint, 3603, 3611, "baseline", "", +82, TimePoint, 3615, 3622, "week 24", "", +83, TimePoint, 3639, 3647, "baseline", "", +84, HbA1c, 3648, 3653, "HbA1c", "", " ." +85, BaseLineValue, 3658, 3663, "8 . 2", "", " \"8 . 2\". \"8 . 2\"." +86, Percentage, 3664, 3665, "%", "", " ." +97781, Gemigliptin, 3699, 3710, "gemigliptin", "", +88, Metformin, 3714, 3723, "metformin", "", +89, Glimepiride, 3728, 3739, "glimepiride", "", +252, HbA1c, 3762, 3767, "HbA1c", "", +91, TimePoint, 3778, 3785, "week 24", "", " \"week 24\". \"week 24\"." +92, Placebo, 3800, 3807, "placebo", "", +93, Mean, 3849, 3853, "mean", "", " . ." +150, DiffGroupAbsValue, 3861, 3869, "- 0 . 87", "", " \"- 0 . 87\"." +94, Percentage, 3870, 3871, "%", "", +98, ConfIntervalDiff, 3874, 3930, "95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %", "", " \"95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %\"." +96, Percentage, 3915, 3916, "%", "", +97, Percentage, 3929, 3930, "%", "", +264, FastingPlasmaGlucose, 3935, 3957, "Fasting plasma glucose", "", " ." +97782, Gemigliptin, 4000, 4011, "gemigliptin", "", +265, Reduction, 4016, 4022, "0 . 93", "", " \"0 . 93\"." +102, Millimoles_per_litre, 4025, 4033, "mmol / L", "", " ." +104, ConfIntervalChangeValue, 4036, 4075, "95 % CI - 1 . 50 to - 0 . 35   mmol / L", "", " \"95 % CI - 1 . 50 to - 0 . 35   mmol / L\"." +103, Millimoles_per_litre, 4067, 4075, "mmol / L", "", +111, HbA1c_target, 4132, 4152, "HbA1c level of < 7 %", "", " ." +106, Percentage, 4151, 4152, "%", "", +112, PercentageAffected, 4155, 4161, "39 . 3", "", " \"39 . 3\"." +113, PercentageAffected, 4167, 4172, "5 . 5", "", " \"5 . 5\"." +114, PvalueDiff, 4177, 4186, "P < . 001", "", " \"P < . 001\"." +97783, Gemigliptin, 4196, 4207, "gemigliptin", "", +110, Placebo, 4226, 4233, "placebo", "", +117, EndPointDescription, 4242, 4259, "Total cholesterol", "", " . ." +277, ObservedResult, 4242, 4376, "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group", "", " \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\"." +118, EndPointDescription, 4264, 4279, "LDL cholesterol", "", " . ." +97784, Gemigliptin, 4327, 4338, "gemigliptin", "", +116, Placebo, 4363, 4370, "placebo", "", +278, DiffGroupAbsValue, 4379, 4387, "- 0 . 21", "", " \"- 0 . 21\"." +123, Millimoles_per_litre, 4390, 4398, "mmol / L", "", " . ." +284, ConfIntervalDiff, 4401, 4440, "95 % CI - 0 . 38 to - 0 . 03   mmol / L", "", " \"95 % CI - 0 . 38 to - 0 . 03   mmol / L\"." +124, Millimoles_per_litre, 4432, 4440, "mmol / L", "", +119, EndPointDescription, 4445, 4462, "total cholesterol", "", +279, DiffGroupAbsValue, 4465, 4473, "- 0 . 18", "", " \"- 0 . 18\"." +125, Millimoles_per_litre, 4476, 4484, "mmol / L", "", +285, ConfIntervalDiff, 4487, 4526, "95 % CI - 0 . 34 to - 0 . 01   mmol / L", "", " \"95 % CI - 0 . 34 to - 0 . 01   mmol / L\"." +126, Millimoles_per_litre, 4518, 4526, "mmol / L", "", +120, EndPointDescription, 4531, 4546, "LDL cholesterol", "", +131, Hypoglycemia, 4568, 4581, "hypoglycaemia", "", " ." +134, PercentageAffected, 4586, 4591, "9 . 4", "", " \"9 . 4\"." +97787, Gemigliptin, 4601, 4612, "gemigliptin", "", +135, PercentageAffected, 4623, 4628, "2 . 7", "", " \"2 . 7\"." +133, Placebo, 4638, 4645, "placebo", "", +147, ConclusionComment, 4668, 4801, "Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .", "", " \"Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .\"." +97785, Gemigliptin, 4668, 4679, "Gemigliptin", "", +139, Type2Diabetes, 4738, 4742, "T2DM", "", +140, Metformin, 4772, 4781, "metformin", "", +141, Sulfonylureas, 4786, 4799, "sulphonylurea", "", +148, ConclusionComment, 4802, 4959, "The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .", "", " \"The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .\"." +143, Hypoglycemia, 4819, 4832, "hypoglycaemia", "", +97786, Gemigliptin, 4849, 4860, "gemigliptin", "", +145, Placebo, 4871, 4878, "placebo", "", +146, Sulfonylureas, 4944, 4957, "sulphonylurea", "", +149, PMID, 5028, 5036, "28026912", "", " \"28026912\"." diff --git a/data/dm2 28026912_admin.n-triples b/data/dm2 28026912_admin.n-triples new file mode 100644 index 0000000..37265a5 --- /dev/null +++ b/data/dm2 28026912_admin.n-triples @@ -0,0 +1,229 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ," . + "randomized , double - blind , placebo - controlled study ( TROICA study ) ." . + "Ahn CH" . + "2017" . + "Diabetes Obes Metab ." . + "28026912" . + . + "Han KA" . + "Yu JM" . + "Nam JY" . + "Ahn KJ" . + "Oh TK" . + "Lee HW" . + "Lee DH" . + "Kim J" . + "Chung CH" . + "Park TS" . + "Kim BJ" . + "Park SW" . + "Park HK" . + "Lee KJ" . + "Kim SW" . + "Park JH" . + "Ko KP" . + "Kim CH" . + "Lee H" . + "Jang HC" . + "Park KS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) ." . + "219" . + "24 - week" . + . + . + . + "Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea ." . + . + . + . + . + . + . + . + "The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . + . + "Korean patients inadequately controlled with metformin and glimepiride" . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint cholesterol" . + . + . + . + . + . + . + "Endpoint ldl cholesterol" . + . + . + . + . + . + . + "Endpoint h" . + . + . + . + . +# RDF export of group: Arm + . + "Arm g" . + . + . + . + . + . + . + . + . + "Arm p" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention g" . + . + "once daily" . + . + . + "Intervention p" . + . + . + . + "Intervention m+g" . + . + . + . +# RDF export of group: Medication + . + "Medication g" . + . + "50" . + . + . + . + "Medication p" . + . + . + . + . + "Medication metformin" . + . + . + . + . + "Medication glimepiride" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c g" . + . + "8 . 2" . + "week 24" . + . + "Outcome hba1c p" . + . + "8 . 2" . + "week 24" . + . + "Outcome hba1c target g" . + . + "39 . 3" . + . + "Outcome hba1c target p " . + . + "5 . 5" . + . + "Outcome fpg g" . + . + "0 . 93" . + "95 % CI - 1 . 50 to - 0 . 35   mmol / L" . + . + "Outcome total cholesterol g" . + . + "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group" . + . + "Outcome total cholesterol p" . + . + "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group" . + . + "Outcome ldl cholesterol g" . + . + "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group" . + . + "Outcome ldl cholesterol p" . + . + "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group" . + . + "Outcome h g " . + . + "9 . 4" . + . + "Outcome h p " . + . + "2 . 7" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 87" . + "95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %" . + . + . + . + "DiffBetweenGroups hba1c target" . + "P < . 001" . + . + . + . + "DiffBetweenGroups total cholesterol" . + "- 0 . 21" . + "95 % CI - 0 . 38 to - 0 . 03   mmol / L" . + . + . + . + "DiffBetweenGroups ldl cholesterol" . + "- 0 . 18" . + "95 % CI - 0 . 34 to - 0 . 01   mmol / L" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28026912_akramersunderbrink.annodb b/data/dm2 28026912_akramersunderbrink.annodb new file mode 100644 index 0000000..e815e3a --- /dev/null +++ b/data/dm2 28026912_akramersunderbrink.annodb @@ -0,0 +1,153 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +67701, Journal, 0, 19, "Diabetes Obes Metab", "", +67702, PublicationYear, 22, 26, "2017", "", +67758, Title, 107, 336, "Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ,", "", +67703, Drug, 130, 141, "gemigliptin", "", +67704, Type2Diabetes, 200, 224, "type 2 diabetes mellitus", "", +67705, Metformin, 279, 288, "metformin", "", +67706, Sulfonylureas, 293, 306, "sulphonylurea", "", +67707, Duration, 311, 320, "24 - week", "", +67708, Multicenter, 323, 334, "multicentre", "", +67709, Randomized, 337, 347, "randomized", "", +67759, Title, 337, 412, "randomized , double - blind , placebo - controlled study ( TROICA study ) .", "", +67710, DoubleBlind, 350, 364, "double - blind", "", +67711, Placebo, 367, 374, "placebo", "", +67712, Author, 413, 419, "Ahn CH", "", +67713, Author, 428, 434, "Han KA", "", +67714, Author, 443, 448, "Yu JM", "", +67715, Author, 457, 463, "Nam JY", "", +67716, Author, 472, 478, "Ahn KJ", "", +67717, Author, 487, 492, "Oh TK", "", +67718, Author, 501, 507, "Lee HW", "", +67719, Author, 516, 522, "Lee DH", "", +67720, Author, 531, 536, "Kim J", "", +67721, Author, 545, 553, "Chung CH", "", +67722, Author, 563, 570, "Park TS", "", +67723, Author, 580, 586, "Kim BJ", "", +67724, Author, 596, 603, "Park SW", "", +67725, Author, 613, 620, "Park HK", "", +67726, Author, 630, 636, "Lee KJ", "", +67727, Author, 646, 652, "Kim SW", "", +67728, Author, 662, 669, "Park JH", "", +67729, Author, 679, 684, "Ko KP", "", +67730, Author, 694, 700, "Kim CH", "", +67731, Author, 710, 715, "Lee H", "", +67732, Author, 725, 732, "Jang HC", "", +67733, Author, 749, 756, "Park KS", "", +67734, SouthKorea, 885, 890, "Korea", "", +67735, SouthKorea, 966, 971, "Korea", "", +67736, SouthKorea, 1072, 1077, "Korea", "", +67737, SouthKorea, 1180, 1185, "Korea", "", +67738, SouthKorea, 1291, 1296, "Korea", "", +67739, SouthKorea, 1390, 1395, "Korea", "", +67740, SouthKorea, 1483, 1488, "Korea", "", +67741, SouthKorea, 1593, 1598, "Korea", "", +67742, SouthKorea, 1683, 1688, "Korea", "", +67743, SouthKorea, 1795, 1800, "Korea", "", +67743, SouthKorea, 1892, 1897, "Korea", "", +67745, SouthKorea, 1990, 1995, "Korea", "", +67747, SouthKorea, 2079, 2084, "Korea", "", +67748, SouthKorea, 2172, 2177, "Korea", "", +67749, SouthKorea, 2256, 2261, "Korea", "", +67750, SouthKorea, 2356, 2361, "Korea", "", +67751, SouthKorea, 2451, 2456, "Korea", "", +67752, SouthKorea, 2543, 2548, "Korea", "", +67753, SouthKorea, 2628, 2633, "Korea", "", +67754, SouthKorea, 2670, 2675, "Korea", "", +67755, SouthKorea, 2775, 2780, "Korea", "", +67756, SouthKorea, 2880, 2885, "Korea", "", +67757, SouthKorea, 3053, 3058, "Korea", "", +67765, ObjectiveDescription, 3068, 3238, "To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .", "", +67760, Drug, 3105, 3116, "gemigliptin", "", +67761, Metformin, 3167, 3176, "metformin", "", +67762, Sulfonylureas, 3181, 3194, "sulphonylurea", "", +67763, Type2Diabetes, 3212, 3227, "type 2 diabetes", "", +67764, Type2Diabetes, 3230, 3234, "T2DM", "", +67766, Randomized, 3278, 3288, "randomized", "", +67767, DoubleBlind, 3291, 3305, "double - blind", "", +67768, Placebo, 3308, 3315, "placebo", "", +67769, NumberPatientsCT, 3338, 3341, "219", "", +67770, Ethnicity, 3342, 3348, "Korean", "", +67773, Precondition, 3358, 3412, "inadequately controlled with metformin and glimepiride", "", +67771, Metformin, 3387, 3396, "metformin", "", +67772, Glimepiride, 3401, 3412, "glimepiride", "", +67774, Randomized, 3433, 3443, "randomized", "", +67775, Drug, 3447, 3458, "gemigliptin", "", +67776, DoseValue, 3459, 3466, "50   mg", "", +67777, mg, 3464, 3466, "mg", "", +67778, Frequency, 3467, 3477, "once daily", "", +67779, Placebo, 3481, 3488, "placebo", "", +67780, Metformin, 3498, 3507, "metformin", "", +67781, Glimepiride, 3512, 3523, "glimepiride", "", +67782, HbA1c, 3561, 3581, "glycated haemoglobin", "", +67783, HbA1c, 3584, 3589, "HbA1c", "", +67784, TimePoint, 3603, 3611, "baseline", "", +67785, TimePoint, 3615, 3622, "week 24", "", +67786, TimePoint, 3639, 3647, "baseline", "", +67787, HbA1c, 3648, 3653, "HbA1c", "", +67788, BaseLineValue, 3658, 3663, "8 . 2", "", +67789, Percentage, 3664, 3665, "%", "", +67790, Drug, 3699, 3710, "gemigliptin", "", +67791, Metformin, 3714, 3723, "metformin", "", +67792, Glimepiride, 3728, 3739, "glimepiride", "", +67793, HbA1c, 3762, 3774, "HbA1c levels", "", +67794, TimePoint, 3778, 3785, "week 24", "", +67795, Placebo, 3800, 3807, "placebo", "", +67796, Mean, 3849, 3853, "mean", "", +68062, DiffGroupAbsValue, 3861, 3869, "- 0 . 87", "", +67798, Percentage, 3870, 3871, "%", "", +67802, ConfIntervalDiff, 3874, 3930, "95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %", "", +67799, Percentage, 3877, 3878, "%", "", +67800, Percentage, 3915, 3916, "%", "", +67801, Percentage, 3929, 3930, "%", "", +67803, FastingPlasmaGlucose, 3935, 3963, "Fasting plasma glucose level", "", +67804, Drug, 4000, 4011, "gemigliptin", "", +67806, ChangeValue, 4014, 4022, "- 0 . 93", "", +67807, Millimoles_per_litre, 4025, 4033, "mmol / L", "", +67809, ConfIntervalChangeValue, 4036, 4075, "95 % CI - 1 . 50 to - 0 . 35   mmol / L", "", +67810, Percentage, 4039, 4040, "%", "", +67808, Millimoles_per_litre, 4067, 4075, "mmol / L", "", +67816, HbA1c_target, 4132, 4152, "HbA1c level of < 7 %", "", +67811, Percentage, 4151, 4152, "%", "", +67817, PercentageAffected, 4155, 4161, "39 . 3", "", +67812, Percentage, 4162, 4163, "%", "", +67818, PercentageAffected, 4167, 4172, "5 . 5", "", +67813, Percentage, 4173, 4174, "%", "", +67819, PvalueDiff, 4177, 4186, "P < . 001", "", +67814, Drug, 4196, 4207, "gemigliptin", "", +67815, Placebo, 4226, 4233, "placebo", "", +67822, EndPointDescription, 4242, 4259, "Total cholesterol", "", +67823, EndPointDescription, 4264, 4279, "LDL cholesterol", "", +67820, Drug, 4327, 4338, "gemigliptin", "", +67821, Placebo, 4363, 4370, "placebo", "", +67828, ChangeValue, 4379, 4387, "- 0 . 21", "", +67829, Millimoles_per_litre, 4390, 4398, "mmol / L", "", +67835, ConfIntervalChangeValue, 4401, 4440, "95 % CI - 0 . 38 to - 0 . 03   mmol / L", "", +67833, Percentage, 4404, 4405, "%", "", +67830, Millimoles_per_litre, 4432, 4440, "mmol / L", "", +67824, EndPointDescription, 4445, 4462, "total cholesterol", "", +67826, ChangeValue, 4465, 4473, "- 0 . 18", "", +67831, Millimoles_per_litre, 4476, 4484, "mmol / L", "", +67836, ConfIntervalChangeValue, 4487, 4526, "95 % CI - 0 . 34 to - 0 . 01   mmol / L", "", +67834, Percentage, 4490, 4491, "%", "", +67832, Millimoles_per_litre, 4518, 4526, "mmol / L", "", +67825, EndPointDescription, 4531, 4546, "LDL cholesterol", "", +67837, Hypoglycemia, 4568, 4581, "hypoglycaemia", "", +67840, PercentageAffected, 4586, 4591, "9 . 4", "", +67842, Percentage, 4592, 4593, "%", "", +67838, Drug, 4601, 4612, "gemigliptin", "", +67841, PercentageAffected, 4623, 4628, "2 . 7", "", +67843, Percentage, 4629, 4630, "%", "", +67839, Placebo, 4638, 4645, "placebo", "", +67844, Drug, 4668, 4679, "Gemigliptin", "", +67853, ConclusionComment, 4668, 4801, "Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .", "", +67845, Type2Diabetes, 4738, 4742, "T2DM", "", +67848, Precondition, 4743, 4799, "inadequately controlled with metformin and sulphonylurea", "", +67846, Metformin, 4772, 4781, "metformin", "", +67847, Sulfonylureas, 4786, 4799, "sulphonylurea", "", +67854, ConclusionComment, 4802, 4959, "The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .", "", +67849, Hypoglycemia, 4819, 4832, "hypoglycaemia", "", +67850, Drug, 4849, 4860, "gemigliptin", "", +67851, Placebo, 4871, 4878, "placebo", "", +67852, Sulfonylureas, 4944, 4957, "sulphonylurea", "", +67855, PMID, 5028, 5036, "28026912", "", diff --git a/data/dm2 28026912_akramersunderbrink.n-triples b/data/dm2 28026912_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28026912_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28026912_export.csv b/data/dm2 28026912_export.csv new file mode 100644 index 0000000..cfbc7ac --- /dev/null +++ b/data/dm2 28026912_export.csv @@ -0,0 +1,1047 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +256, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +256, 1, 2, 2, 9, 13, 9, 13, "Obes" +256, 1, 3, 3, 14, 19, 14, 19, "Metab" +256, 1, 4, 4, 20, 21, 20, 21, "." +256, 2, 1, 5, 0, 4, 22, 26, "2017" +256, 2, 2, 6, 5, 8, 27, 30, "May" +256, 2, 3, 7, 9, 10, 31, 32, ";" +256, 2, 4, 8, 11, 13, 33, 35, "19" +256, 2, 5, 9, 14, 15, 36, 37, "(" +256, 2, 6, 10, 16, 17, 38, 39, "5" +256, 2, 7, 11, 18, 19, 40, 41, ")" +256, 2, 8, 12, 20, 21, 42, 43, ":" +256, 2, 9, 13, 22, 25, 44, 47, "635" +256, 2, 10, 14, 26, 27, 48, 49, "-" +256, 2, 11, 15, 28, 31, 50, 53, "643" +256, 2, 12, 16, 32, 33, 54, 55, "." +256, 2, 13, 17, 34, 37, 56, 59, "doi" +256, 2, 14, 18, 38, 39, 60, 61, ":" +256, 2, 15, 19, 40, 42, 62, 64, "10" +256, 2, 16, 20, 43, 44, 65, 66, "." +256, 2, 17, 21, 45, 49, 67, 71, "1111" +256, 2, 18, 22, 50, 51, 72, 73, "/" +256, 2, 19, 23, 52, 55, 74, 77, "dom" +256, 2, 20, 24, 56, 57, 78, 79, "." +256, 2, 21, 25, 58, 63, 80, 85, "12866" +256, 2, 22, 26, 64, 65, 86, 87, "." +256, 3, 1, 27, 0, 4, 88, 92, "Epub" +256, 3, 2, 28, 5, 9, 93, 97, "2017" +256, 3, 3, 29, 10, 13, 98, 101, "Feb" +256, 3, 4, 30, 14, 16, 102, 104, "17" +256, 3, 5, 31, 17, 18, 105, 106, "." +256, 4, 1, 32, 0, 8, 107, 115, "Efficacy" +256, 4, 2, 33, 9, 12, 116, 119, "and" +256, 4, 3, 34, 13, 19, 120, 126, "safety" +256, 4, 4, 35, 20, 22, 127, 129, "of" +256, 4, 5, 36, 23, 34, 130, 141, "gemigliptin" +256, 4, 6, 37, 35, 36, 142, 143, "," +256, 4, 7, 38, 37, 38, 144, 145, "a" +256, 4, 8, 39, 39, 49, 146, 156, "dipeptidyl" +256, 4, 9, 40, 50, 59, 157, 166, "peptidase" +256, 4, 10, 41, 60, 61, 167, 168, "-" +256, 4, 11, 42, 62, 63, 169, 170, "4" +256, 4, 12, 43, 64, 73, 171, 180, "inhibitor" +256, 4, 13, 44, 74, 75, 181, 182, "," +256, 4, 14, 45, 76, 78, 183, 185, "in" +256, 4, 15, 46, 79, 87, 186, 194, "patients" +256, 4, 16, 47, 88, 92, 195, 199, "with" +256, 4, 17, 48, 93, 97, 200, 204, "type" +256, 4, 18, 49, 98, 99, 205, 206, "2" +256, 4, 19, 50, 100, 108, 207, 215, "diabetes" +256, 4, 20, 51, 109, 117, 216, 224, "mellitus" +256, 4, 21, 52, 118, 130, 225, 237, "inadequately" +256, 4, 22, 53, 131, 141, 238, 248, "controlled" +256, 4, 23, 54, 142, 146, 249, 253, "with" +256, 4, 24, 55, 147, 158, 254, 265, "combination" +256, 4, 25, 56, 159, 168, 266, 275, "treatment" +256, 4, 26, 57, 169, 171, 276, 278, "of" +256, 4, 27, 58, 172, 181, 279, 288, "metformin" +256, 4, 28, 59, 182, 185, 289, 292, "and" +256, 4, 29, 60, 186, 199, 293, 306, "sulphonylurea" +256, 4, 30, 61, 200, 201, 307, 308, ":" +256, 4, 31, 62, 202, 203, 309, 310, "a" +256, 4, 32, 63, 204, 206, 311, 313, "24" +256, 4, 33, 64, 207, 208, 314, 315, "-" +256, 4, 34, 65, 209, 213, 316, 320, "week" +256, 4, 35, 66, 214, 215, 321, 322, "," +256, 4, 36, 67, 216, 227, 323, 334, "multicentre" +256, 4, 37, 68, 228, 229, 335, 336, "," +256, 4, 38, 69, 230, 240, 337, 347, "randomized" +256, 4, 39, 70, 241, 242, 348, 349, "," +256, 4, 40, 71, 243, 249, 350, 356, "double" +256, 4, 41, 72, 250, 251, 357, 358, "-" +256, 4, 42, 73, 252, 257, 359, 364, "blind" +256, 4, 43, 74, 258, 259, 365, 366, "," +256, 4, 44, 75, 260, 267, 367, 374, "placebo" +256, 4, 45, 76, 268, 269, 375, 376, "-" +256, 4, 46, 77, 270, 280, 377, 387, "controlled" +256, 4, 47, 78, 281, 286, 388, 393, "study" +256, 4, 48, 79, 287, 288, 394, 395, "(" +256, 4, 49, 80, 289, 295, 396, 402, "TROICA" +256, 4, 50, 81, 296, 301, 403, 408, "study" +256, 4, 51, 82, 302, 303, 409, 410, ")" +256, 4, 52, 83, 304, 305, 411, 412, "." +256, 5, 1, 84, 0, 3, 413, 416, "Ahn" +256, 5, 2, 85, 4, 6, 417, 419, "CH" +256, 5, 3, 86, 7, 8, 420, 421, "(" +256, 5, 4, 87, 9, 10, 422, 423, "1" +256, 5, 5, 88, 11, 12, 424, 425, ")" +256, 5, 6, 89, 13, 14, 426, 427, "," +256, 5, 7, 90, 15, 18, 428, 431, "Han" +256, 5, 8, 91, 19, 21, 432, 434, "KA" +256, 5, 9, 92, 22, 23, 435, 436, "(" +256, 5, 10, 93, 24, 25, 437, 438, "2" +256, 5, 11, 94, 26, 27, 439, 440, ")" +256, 5, 12, 95, 28, 29, 441, 442, "," +256, 5, 13, 96, 30, 32, 443, 445, "Yu" +256, 5, 14, 97, 33, 35, 446, 448, "JM" +256, 5, 15, 98, 36, 37, 449, 450, "(" +256, 5, 16, 99, 38, 39, 451, 452, "3" +256, 5, 17, 100, 40, 41, 453, 454, ")" +256, 5, 18, 101, 42, 43, 455, 456, "," +256, 5, 19, 102, 44, 47, 457, 460, "Nam" +256, 5, 20, 103, 48, 50, 461, 463, "JY" +256, 5, 21, 104, 51, 52, 464, 465, "(" +256, 5, 22, 105, 53, 54, 466, 467, "4" +256, 5, 23, 106, 55, 56, 468, 469, ")" +256, 5, 24, 107, 57, 58, 470, 471, "," +256, 5, 25, 108, 59, 62, 472, 475, "Ahn" +256, 5, 26, 109, 63, 65, 476, 478, "KJ" +256, 5, 27, 110, 66, 67, 479, 480, "(" +256, 5, 28, 111, 68, 69, 481, 482, "5" +256, 5, 29, 112, 70, 71, 483, 484, ")" +256, 5, 30, 113, 72, 73, 485, 486, "," +256, 5, 31, 114, 74, 76, 487, 489, "Oh" +256, 5, 32, 115, 77, 79, 490, 492, "TK" +256, 5, 33, 116, 80, 81, 493, 494, "(" +256, 5, 34, 117, 82, 83, 495, 496, "6" +256, 5, 35, 118, 84, 85, 497, 498, ")" +256, 5, 36, 119, 86, 87, 499, 500, "," +256, 5, 37, 120, 88, 91, 501, 504, "Lee" +256, 5, 38, 121, 92, 94, 505, 507, "HW" +256, 5, 39, 122, 95, 96, 508, 509, "(" +256, 5, 40, 123, 97, 98, 510, 511, "7" +256, 5, 41, 124, 99, 100, 512, 513, ")" +256, 5, 42, 125, 101, 102, 514, 515, "," +256, 5, 43, 126, 103, 106, 516, 519, "Lee" +256, 5, 44, 127, 107, 109, 520, 522, "DH" +256, 5, 45, 128, 110, 111, 523, 524, "(" +256, 5, 46, 129, 112, 113, 525, 526, "8" +256, 5, 47, 130, 114, 115, 527, 528, ")" +256, 5, 48, 131, 116, 117, 529, 530, "," +256, 5, 49, 132, 118, 121, 531, 534, "Kim" +256, 5, 50, 133, 122, 123, 535, 536, "J" +256, 5, 51, 134, 124, 125, 537, 538, "(" +256, 5, 52, 135, 126, 127, 539, 540, "9" +256, 5, 53, 136, 128, 129, 541, 542, ")" +256, 5, 54, 137, 130, 131, 543, 544, "," +256, 5, 55, 138, 132, 137, 545, 550, "Chung" +256, 5, 56, 139, 138, 140, 551, 553, "CH" +256, 5, 57, 140, 141, 142, 554, 555, "(" +256, 5, 58, 141, 143, 145, 556, 558, "10" +256, 5, 59, 142, 146, 147, 559, 560, ")" +256, 5, 60, 143, 148, 149, 561, 562, "," +256, 5, 61, 144, 150, 154, 563, 567, "Park" +256, 5, 62, 145, 155, 157, 568, 570, "TS" +256, 5, 63, 146, 158, 159, 571, 572, "(" +256, 5, 64, 147, 160, 162, 573, 575, "11" +256, 5, 65, 148, 163, 164, 576, 577, ")" +256, 5, 66, 149, 165, 166, 578, 579, "," +256, 5, 67, 150, 167, 170, 580, 583, "Kim" +256, 5, 68, 151, 171, 173, 584, 586, "BJ" +256, 5, 69, 152, 174, 175, 587, 588, "(" +256, 5, 70, 153, 176, 178, 589, 591, "12" +256, 5, 71, 154, 179, 180, 592, 593, ")" +256, 5, 72, 155, 181, 182, 594, 595, "," +256, 5, 73, 156, 183, 187, 596, 600, "Park" +256, 5, 74, 157, 188, 190, 601, 603, "SW" +256, 5, 75, 158, 191, 192, 604, 605, "(" +256, 5, 76, 159, 193, 195, 606, 608, "13" +256, 5, 77, 160, 196, 197, 609, 610, ")" +256, 5, 78, 161, 198, 199, 611, 612, "," +256, 5, 79, 162, 200, 204, 613, 617, "Park" +256, 5, 80, 163, 205, 207, 618, 620, "HK" +256, 5, 81, 164, 208, 209, 621, 622, "(" +256, 5, 82, 165, 210, 212, 623, 625, "14" +256, 5, 83, 166, 213, 214, 626, 627, ")" +256, 5, 84, 167, 215, 216, 628, 629, "," +256, 5, 85, 168, 217, 220, 630, 633, "Lee" +256, 5, 86, 169, 221, 223, 634, 636, "KJ" +256, 5, 87, 170, 224, 225, 637, 638, "(" +256, 5, 88, 171, 226, 228, 639, 641, "15" +256, 5, 89, 172, 229, 230, 642, 643, ")" +256, 5, 90, 173, 231, 232, 644, 645, "," +256, 5, 91, 174, 233, 236, 646, 649, "Kim" +256, 5, 92, 175, 237, 239, 650, 652, "SW" +256, 5, 93, 176, 240, 241, 653, 654, "(" +256, 5, 94, 177, 242, 244, 655, 657, "16" +256, 5, 95, 178, 245, 246, 658, 659, ")" +256, 5, 96, 179, 247, 248, 660, 661, "," +256, 5, 97, 180, 249, 253, 662, 666, "Park" +256, 5, 98, 181, 254, 256, 667, 669, "JH" +256, 5, 99, 182, 257, 258, 670, 671, "(" +256, 5, 100, 183, 259, 261, 672, 674, "17" +256, 5, 101, 184, 262, 263, 675, 676, ")" +256, 5, 102, 185, 264, 265, 677, 678, "," +256, 5, 103, 186, 266, 268, 679, 681, "Ko" +256, 5, 104, 187, 269, 271, 682, 684, "KP" +256, 5, 105, 188, 272, 273, 685, 686, "(" +256, 5, 106, 189, 274, 276, 687, 689, "18" +256, 5, 107, 190, 277, 278, 690, 691, ")" +256, 5, 108, 191, 279, 280, 692, 693, "," +256, 5, 109, 192, 281, 284, 694, 697, "Kim" +256, 5, 110, 193, 285, 287, 698, 700, "CH" +256, 5, 111, 194, 288, 289, 701, 702, "(" +256, 5, 112, 195, 290, 292, 703, 705, "19" +256, 5, 113, 196, 293, 294, 706, 707, ")" +256, 5, 114, 197, 295, 296, 708, 709, "," +256, 5, 115, 198, 297, 300, 710, 713, "Lee" +256, 5, 116, 199, 301, 302, 714, 715, "H" +256, 5, 117, 200, 303, 304, 716, 717, "(" +256, 5, 118, 201, 305, 307, 718, 720, "20" +256, 5, 119, 202, 308, 309, 721, 722, ")" +256, 5, 120, 203, 310, 311, 723, 724, "," +256, 5, 121, 204, 312, 316, 725, 729, "Jang" +256, 5, 122, 205, 317, 319, 730, 732, "HC" +256, 5, 123, 206, 320, 321, 733, 734, "(" +256, 5, 124, 207, 322, 324, 735, 737, "21" +256, 5, 125, 208, 325, 326, 738, 739, ")" +256, 5, 126, 209, 327, 328, 740, 741, "(" +256, 5, 127, 210, 329, 331, 742, 744, "22" +256, 5, 128, 211, 332, 333, 745, 746, ")" +256, 5, 129, 212, 334, 335, 747, 748, "," +256, 5, 130, 213, 336, 340, 749, 753, "Park" +256, 5, 131, 214, 341, 343, 754, 756, "KS" +256, 5, 132, 215, 344, 345, 757, 758, "(" +256, 5, 133, 216, 346, 347, 759, 760, "1" +256, 5, 134, 217, 348, 349, 761, 762, ")" +256, 5, 135, 218, 350, 351, 763, 764, "(" +256, 5, 136, 219, 352, 354, 765, 767, "22" +256, 5, 137, 220, 355, 356, 768, 769, ")" +256, 5, 138, 221, 357, 358, 770, 771, "(" +256, 5, 139, 222, 359, 361, 772, 774, "23" +256, 5, 140, 223, 362, 363, 775, 776, ")" +256, 5, 141, 224, 364, 365, 777, 778, "." +256, 6, 1, 225, 0, 6, 779, 785, "Author" +256, 6, 2, 226, 7, 18, 786, 797, "information" +256, 6, 3, 227, 19, 20, 798, 799, ":" +256, 6, 4, 228, 21, 22, 800, 801, "(" +256, 6, 5, 229, 23, 24, 802, 803, "1" +256, 6, 6, 230, 25, 26, 804, 805, ")" +256, 6, 7, 231, 27, 37, 806, 816, "Department" +256, 6, 8, 232, 38, 40, 817, 819, "of" +256, 6, 9, 233, 41, 49, 820, 828, "Internal" +256, 6, 10, 234, 50, 58, 829, 837, "Medicine" +256, 6, 11, 235, 59, 60, 838, 839, "," +256, 6, 12, 236, 61, 66, 840, 845, "Seoul" +256, 6, 13, 237, 67, 75, 846, 854, "National" +256, 6, 14, 238, 76, 86, 855, 865, "University" +256, 6, 15, 239, 87, 95, 866, 874, "Hospital" +256, 6, 16, 240, 96, 97, 875, 876, "," +256, 6, 17, 241, 98, 103, 877, 882, "Seoul" +256, 6, 18, 242, 104, 105, 883, 884, "," +256, 6, 19, 243, 106, 111, 885, 890, "Korea" +256, 6, 20, 244, 112, 113, 891, 892, "." +256, 7, 1, 245, 0, 1, 893, 894, "(" +256, 7, 2, 246, 2, 3, 895, 896, "2" +256, 7, 3, 247, 4, 5, 897, 898, ")" +256, 7, 4, 248, 6, 16, 899, 909, "Department" +256, 7, 5, 249, 17, 19, 910, 912, "of" +256, 7, 6, 250, 20, 28, 913, 921, "Internal" +256, 7, 7, 251, 29, 37, 922, 930, "Medicine" +256, 7, 8, 252, 38, 39, 931, 932, "," +256, 7, 9, 253, 40, 45, 933, 938, "Eulji" +256, 7, 10, 254, 46, 53, 939, 946, "General" +256, 7, 11, 255, 54, 62, 947, 955, "Hospital" +256, 7, 12, 256, 63, 64, 956, 957, "," +256, 7, 13, 257, 65, 70, 958, 963, "Seoul" +256, 7, 14, 258, 71, 72, 964, 965, "," +256, 7, 15, 259, 73, 78, 966, 971, "Korea" +256, 7, 16, 260, 79, 80, 972, 973, "." +256, 8, 1, 261, 0, 1, 974, 975, "(" +256, 8, 2, 262, 2, 3, 976, 977, "3" +256, 8, 3, 263, 4, 5, 978, 979, ")" +256, 8, 4, 264, 6, 16, 980, 990, "Department" +256, 8, 5, 265, 17, 19, 991, 993, "of" +256, 8, 6, 266, 20, 28, 994, 1002, "Internal" +256, 8, 7, 267, 29, 37, 1003, 1011, "Medicine" +256, 8, 8, 268, 38, 39, 1012, 1013, "," +256, 8, 9, 269, 40, 46, 1014, 1020, "Hallym" +256, 8, 10, 270, 47, 57, 1021, 1031, "University" +256, 8, 11, 271, 58, 65, 1032, 1039, "Kangnam" +256, 8, 12, 272, 66, 72, 1040, 1046, "Sacred" +256, 8, 13, 273, 73, 78, 1047, 1052, "Heart" +256, 8, 14, 274, 79, 87, 1053, 1061, "Hospital" +256, 8, 15, 275, 88, 89, 1062, 1063, "," +256, 8, 16, 276, 90, 95, 1064, 1069, "Seoul" +256, 8, 17, 277, 96, 97, 1070, 1071, "," +256, 8, 18, 278, 98, 103, 1072, 1077, "Korea" +256, 8, 19, 279, 104, 105, 1078, 1079, "." +256, 9, 1, 280, 0, 1, 1080, 1081, "(" +256, 9, 2, 281, 2, 3, 1082, 1083, "4" +256, 9, 3, 282, 4, 5, 1084, 1085, ")" +256, 9, 4, 283, 6, 16, 1086, 1096, "Department" +256, 9, 5, 284, 17, 19, 1097, 1099, "of" +256, 9, 6, 285, 20, 28, 1100, 1108, "Internal" +256, 9, 7, 286, 29, 37, 1109, 1117, "Medicine" +256, 9, 8, 287, 38, 39, 1118, 1119, "," +256, 9, 9, 288, 40, 48, 1120, 1128, "National" +256, 9, 10, 289, 49, 55, 1129, 1135, "Health" +256, 9, 11, 290, 56, 65, 1136, 1145, "Insurance" +256, 9, 12, 291, 66, 73, 1146, 1153, "Service" +256, 9, 13, 292, 74, 79, 1154, 1159, "Ilsan" +256, 9, 14, 293, 80, 88, 1160, 1168, "Hospital" +256, 9, 15, 294, 89, 90, 1169, 1170, "," +256, 9, 16, 295, 91, 97, 1171, 1177, "Goyang" +256, 9, 17, 296, 98, 99, 1178, 1179, "," +256, 9, 18, 297, 100, 105, 1180, 1185, "Korea" +256, 9, 19, 298, 106, 107, 1186, 1187, "." +256, 10, 1, 299, 0, 1, 1188, 1189, "(" +256, 10, 2, 300, 2, 3, 1190, 1191, "5" +256, 10, 3, 301, 4, 5, 1192, 1193, ")" +256, 10, 4, 302, 6, 16, 1194, 1204, "Department" +256, 10, 5, 303, 17, 19, 1205, 1207, "of" +256, 10, 6, 304, 20, 33, 1208, 1221, "Endocrinology" +256, 10, 7, 305, 34, 37, 1222, 1225, "and" +256, 10, 8, 306, 38, 48, 1226, 1236, "Metabolism" +256, 10, 9, 307, 49, 50, 1237, 1238, "," +256, 10, 10, 308, 51, 56, 1239, 1244, "Kyung" +256, 10, 11, 309, 57, 60, 1245, 1248, "Hee" +256, 10, 12, 310, 61, 71, 1249, 1259, "University" +256, 10, 13, 311, 72, 80, 1260, 1268, "Hospital" +256, 10, 14, 312, 81, 83, 1269, 1271, "at" +256, 10, 15, 313, 84, 92, 1272, 1280, "Gangdong" +256, 10, 16, 314, 93, 94, 1281, 1282, "," +256, 10, 17, 315, 95, 100, 1283, 1288, "Seoul" +256, 10, 18, 316, 101, 102, 1289, 1290, "," +256, 10, 19, 317, 103, 108, 1291, 1296, "Korea" +256, 10, 20, 318, 109, 110, 1297, 1298, "." +256, 11, 1, 319, 0, 1, 1299, 1300, "(" +256, 11, 2, 320, 2, 3, 1301, 1302, "6" +256, 11, 3, 321, 4, 5, 1303, 1304, ")" +256, 11, 4, 322, 6, 16, 1305, 1315, "Department" +256, 11, 5, 323, 17, 19, 1316, 1318, "of" +256, 11, 6, 324, 20, 28, 1319, 1327, "Internal" +256, 11, 7, 325, 29, 37, 1328, 1336, "Medicine" +256, 11, 8, 326, 38, 39, 1337, 1338, "," +256, 11, 9, 327, 40, 48, 1339, 1347, "Chungbuk" +256, 11, 10, 328, 49, 57, 1348, 1356, "National" +256, 11, 11, 329, 58, 68, 1357, 1367, "University" +256, 11, 12, 330, 69, 77, 1368, 1376, "Hospital" +256, 11, 13, 331, 78, 79, 1377, 1378, "," +256, 11, 14, 332, 80, 88, 1379, 1387, "Cheongju" +256, 11, 15, 333, 89, 90, 1388, 1389, "," +256, 11, 16, 334, 91, 96, 1390, 1395, "Korea" +256, 11, 17, 335, 97, 98, 1396, 1397, "." +256, 12, 1, 336, 0, 1, 1398, 1399, "(" +256, 12, 2, 337, 2, 3, 1400, 1401, "7" +256, 12, 3, 338, 4, 5, 1402, 1403, ")" +256, 12, 4, 339, 6, 16, 1404, 1414, "Department" +256, 12, 5, 340, 17, 19, 1415, 1417, "of" +256, 12, 6, 341, 20, 28, 1418, 1426, "Internal" +256, 12, 7, 342, 29, 37, 1427, 1435, "Medicine" +256, 12, 8, 343, 38, 39, 1436, 1437, "," +256, 12, 9, 344, 40, 48, 1438, 1446, "Yeungnam" +256, 12, 10, 345, 49, 59, 1447, 1457, "University" +256, 12, 11, 346, 60, 67, 1458, 1465, "Medical" +256, 12, 12, 347, 68, 74, 1466, 1472, "Centre" +256, 12, 13, 348, 75, 76, 1473, 1474, "," +256, 12, 14, 349, 77, 82, 1475, 1480, "Daegu" +256, 12, 15, 350, 83, 84, 1481, 1482, "," +256, 12, 16, 351, 85, 90, 1483, 1488, "Korea" +256, 12, 17, 352, 91, 92, 1489, 1490, "." +256, 13, 1, 353, 0, 1, 1491, 1492, "(" +256, 13, 2, 354, 2, 3, 1493, 1494, "8" +256, 13, 3, 355, 4, 5, 1495, 1496, ")" +256, 13, 4, 356, 6, 16, 1497, 1507, "Department" +256, 13, 5, 357, 17, 19, 1508, 1510, "of" +256, 13, 6, 358, 20, 28, 1511, 1519, "Internal" +256, 13, 7, 359, 29, 37, 1520, 1528, "Medicine" +256, 13, 8, 360, 38, 39, 1529, 1530, "," +256, 13, 9, 361, 40, 48, 1531, 1539, "Wonkwang" +256, 13, 10, 362, 49, 59, 1540, 1550, "University" +256, 13, 11, 363, 60, 66, 1551, 1557, "School" +256, 13, 12, 364, 67, 69, 1558, 1560, "of" +256, 13, 13, 365, 70, 78, 1561, 1569, "Medicine" +256, 13, 14, 366, 79, 82, 1570, 1573, "and" +256, 13, 15, 367, 83, 91, 1574, 1582, "Hospital" +256, 13, 16, 368, 92, 93, 1583, 1584, "," +256, 13, 17, 369, 94, 99, 1585, 1590, "Iksan" +256, 13, 18, 370, 100, 101, 1591, 1592, "," +256, 13, 19, 371, 102, 107, 1593, 1598, "Korea" +256, 13, 20, 372, 108, 109, 1599, 1600, "." +256, 14, 1, 373, 0, 1, 1601, 1602, "(" +256, 14, 2, 374, 2, 3, 1603, 1604, "9" +256, 14, 3, 375, 4, 5, 1605, 1606, ")" +256, 14, 4, 376, 6, 16, 1607, 1617, "Department" +256, 14, 5, 377, 17, 19, 1618, 1620, "of" +256, 14, 6, 378, 20, 28, 1621, 1629, "Internal" +256, 14, 7, 379, 29, 37, 1630, 1638, "Medicine" +256, 14, 8, 380, 38, 39, 1639, 1640, "," +256, 14, 9, 381, 40, 45, 1641, 1646, "Chung" +256, 14, 10, 382, 46, 47, 1647, 1648, "-" +256, 14, 11, 383, 48, 51, 1649, 1652, "Ang" +256, 14, 12, 384, 52, 62, 1653, 1663, "University" +256, 14, 13, 385, 63, 71, 1664, 1672, "Hospital" +256, 14, 14, 386, 72, 73, 1673, 1674, "," +256, 14, 15, 387, 74, 79, 1675, 1680, "Seoul" +256, 14, 16, 388, 80, 81, 1681, 1682, "," +256, 14, 17, 389, 82, 87, 1683, 1688, "Korea" +256, 14, 18, 390, 88, 89, 1689, 1690, "." +256, 15, 1, 391, 0, 1, 1691, 1692, "(" +256, 15, 2, 392, 2, 4, 1693, 1695, "10" +256, 15, 3, 393, 5, 6, 1696, 1697, ")" +256, 15, 4, 394, 7, 17, 1698, 1708, "Department" +256, 15, 5, 395, 18, 20, 1709, 1711, "of" +256, 15, 6, 396, 21, 29, 1712, 1720, "Internal" +256, 15, 7, 397, 30, 38, 1721, 1729, "Medicine" +256, 15, 8, 398, 39, 40, 1730, 1731, "," +256, 15, 9, 399, 41, 47, 1732, 1738, "Yonsei" +256, 15, 10, 400, 48, 58, 1739, 1749, "University" +256, 15, 11, 401, 59, 64, 1750, 1755, "Wonju" +256, 15, 12, 402, 65, 74, 1756, 1765, "Severance" +256, 15, 13, 403, 75, 84, 1766, 1775, "Christian" +256, 15, 14, 404, 85, 93, 1776, 1784, "Hospital" +256, 15, 15, 405, 94, 95, 1785, 1786, "," +256, 15, 16, 406, 96, 101, 1787, 1792, "Wonju" +256, 15, 17, 407, 102, 103, 1793, 1794, "," +256, 15, 18, 408, 104, 109, 1795, 1800, "Korea" +256, 15, 19, 409, 110, 111, 1801, 1802, "." +256, 16, 1, 410, 0, 1, 1803, 1804, "(" +256, 16, 2, 411, 2, 4, 1805, 1807, "11" +256, 16, 3, 412, 5, 6, 1808, 1809, ")" +256, 16, 4, 413, 7, 17, 1810, 1820, "Department" +256, 16, 5, 414, 18, 20, 1821, 1823, "of" +256, 16, 6, 415, 21, 29, 1824, 1832, "Internal" +256, 16, 7, 416, 30, 38, 1833, 1841, "Medicine" +256, 16, 8, 417, 39, 40, 1842, 1843, "," +256, 16, 9, 418, 41, 48, 1844, 1851, "Chonbuk" +256, 16, 10, 419, 49, 57, 1852, 1860, "National" +256, 16, 11, 420, 58, 68, 1861, 1871, "University" +256, 16, 12, 421, 69, 77, 1872, 1880, "Hospital" +256, 16, 13, 422, 78, 79, 1881, 1882, "," +256, 16, 14, 423, 80, 86, 1883, 1889, "Jeonju" +256, 16, 15, 424, 87, 88, 1890, 1891, "," +256, 16, 16, 425, 89, 94, 1892, 1897, "Korea" +256, 16, 17, 426, 95, 96, 1898, 1899, "." +256, 17, 1, 427, 0, 1, 1900, 1901, "(" +256, 17, 2, 428, 2, 4, 1902, 1904, "12" +256, 17, 3, 429, 5, 6, 1905, 1906, ")" +256, 17, 4, 430, 7, 17, 1907, 1917, "Department" +256, 17, 5, 431, 18, 20, 1918, 1920, "of" +256, 17, 6, 432, 21, 29, 1921, 1929, "Internal" +256, 17, 7, 433, 30, 38, 1930, 1938, "Medicine" +256, 17, 8, 434, 39, 40, 1939, 1940, "," +256, 17, 9, 435, 41, 47, 1941, 1947, "Gachon" +256, 17, 10, 436, 48, 58, 1948, 1958, "University" +256, 17, 11, 437, 59, 62, 1959, 1962, "Gil" +256, 17, 12, 438, 63, 70, 1963, 1970, "Medical" +256, 17, 13, 439, 71, 77, 1971, 1977, "Center" +256, 17, 14, 440, 78, 79, 1978, 1979, "," +256, 17, 15, 441, 80, 87, 1980, 1987, "Incheon" +256, 17, 16, 442, 88, 89, 1988, 1989, "," +256, 17, 17, 443, 90, 95, 1990, 1995, "Korea" +256, 17, 18, 444, 96, 97, 1996, 1997, "." +256, 18, 1, 445, 0, 1, 1998, 1999, "(" +256, 18, 2, 446, 2, 4, 2000, 2002, "13" +256, 18, 3, 447, 5, 6, 2003, 2004, ")" +256, 18, 4, 448, 7, 17, 2005, 2015, "Department" +256, 18, 5, 449, 18, 20, 2016, 2018, "of" +256, 18, 6, 450, 21, 29, 2019, 2027, "Internal" +256, 18, 7, 451, 30, 38, 2028, 2036, "Medicine" +256, 18, 8, 452, 39, 40, 2037, 2038, "," +256, 18, 9, 453, 41, 44, 2039, 2042, "CHA" +256, 18, 10, 454, 45, 52, 2043, 2050, "Bundang" +256, 18, 11, 455, 53, 60, 2051, 2058, "Medical" +256, 18, 12, 456, 61, 67, 2059, 2065, "Center" +256, 18, 13, 457, 68, 69, 2066, 2067, "," +256, 18, 14, 458, 70, 78, 2068, 2076, "Seongnam" +256, 18, 15, 459, 79, 80, 2077, 2078, "," +256, 18, 16, 460, 81, 86, 2079, 2084, "Korea" +256, 18, 17, 461, 87, 88, 2085, 2086, "." +256, 19, 1, 462, 0, 1, 2087, 2088, "(" +256, 19, 2, 463, 2, 4, 2089, 2091, "14" +256, 19, 3, 464, 5, 6, 2092, 2093, ")" +256, 19, 4, 465, 7, 17, 2094, 2104, "Department" +256, 19, 5, 466, 18, 20, 2105, 2107, "of" +256, 19, 6, 467, 21, 29, 2108, 2116, "Internal" +256, 19, 7, 468, 30, 38, 2117, 2125, "Medicine" +256, 19, 8, 469, 39, 40, 2126, 2127, "," +256, 19, 9, 470, 41, 54, 2128, 2141, "Soonchunhyang" +256, 19, 10, 471, 55, 65, 2142, 2152, "University" +256, 19, 11, 472, 66, 74, 2153, 2161, "Hospital" +256, 19, 12, 473, 75, 76, 2162, 2163, "," +256, 19, 13, 474, 77, 82, 2164, 2169, "Seoul" +256, 19, 14, 475, 83, 84, 2170, 2171, "," +256, 19, 15, 476, 85, 90, 2172, 2177, "Korea" +256, 19, 16, 477, 91, 92, 2178, 2179, "." +256, 20, 1, 478, 0, 1, 2180, 2181, "(" +256, 20, 2, 479, 2, 4, 2182, 2184, "15" +256, 20, 3, 480, 5, 6, 2185, 2186, ")" +256, 20, 4, 481, 7, 17, 2187, 2197, "Department" +256, 20, 5, 482, 18, 20, 2198, 2200, "of" +256, 20, 6, 483, 21, 29, 2201, 2209, "Internal" +256, 20, 7, 484, 30, 38, 2210, 2218, "Medicine" +256, 20, 8, 485, 39, 40, 2219, 2220, "," +256, 20, 9, 486, 41, 48, 2221, 2228, "Daedong" +256, 20, 10, 487, 49, 56, 2229, 2236, "General" +256, 20, 11, 488, 57, 65, 2237, 2245, "Hospital" +256, 20, 12, 489, 66, 67, 2246, 2247, "," +256, 20, 13, 490, 68, 73, 2248, 2253, "Busan" +256, 20, 14, 491, 74, 75, 2254, 2255, "," +256, 20, 15, 492, 76, 81, 2256, 2261, "Korea" +256, 20, 16, 493, 82, 83, 2262, 2263, "." +256, 21, 1, 494, 0, 1, 2264, 2265, "(" +256, 21, 2, 495, 2, 4, 2266, 2268, "16" +256, 21, 3, 496, 5, 6, 2269, 2270, ")" +256, 21, 4, 497, 7, 17, 2271, 2281, "Department" +256, 21, 5, 498, 18, 20, 2282, 2284, "of" +256, 21, 6, 499, 21, 29, 2285, 2293, "Internal" +256, 21, 7, 500, 30, 38, 2294, 2302, "Medicine" +256, 21, 8, 501, 39, 40, 2303, 2304, "," +256, 21, 9, 502, 41, 48, 2305, 2312, "Kangwon" +256, 21, 10, 503, 49, 57, 2313, 2321, "National" +256, 21, 11, 504, 58, 68, 2322, 2332, "University" +256, 21, 12, 505, 69, 77, 2333, 2341, "Hospital" +256, 21, 13, 506, 78, 79, 2342, 2343, "," +256, 21, 14, 507, 80, 89, 2344, 2353, "Chuncheon" +256, 21, 15, 508, 90, 91, 2354, 2355, "," +256, 21, 16, 509, 92, 97, 2356, 2361, "Korea" +256, 21, 17, 510, 98, 99, 2362, 2363, "." +256, 22, 1, 511, 0, 1, 2364, 2365, "(" +256, 22, 2, 512, 2, 4, 2366, 2368, "17" +256, 22, 3, 513, 5, 6, 2369, 2370, ")" +256, 22, 4, 514, 7, 17, 2371, 2381, "Department" +256, 22, 5, 515, 18, 20, 2382, 2384, "of" +256, 22, 6, 516, 21, 29, 2385, 2393, "Internal" +256, 22, 7, 517, 30, 38, 2394, 2402, "Medicine" +256, 22, 8, 518, 39, 40, 2403, 2404, "," +256, 22, 9, 519, 41, 45, 2405, 2409, "Inje" +256, 22, 10, 520, 46, 56, 2410, 2420, "University" +256, 22, 11, 521, 57, 62, 2421, 2426, "Busan" +256, 22, 12, 522, 63, 67, 2427, 2431, "Paik" +256, 22, 13, 523, 68, 76, 2432, 2440, "Hospital" +256, 22, 14, 524, 77, 78, 2441, 2442, "," +256, 22, 15, 525, 79, 84, 2443, 2448, "Busan" +256, 22, 16, 526, 85, 86, 2449, 2450, "," +256, 22, 17, 527, 87, 92, 2451, 2456, "Korea" +256, 22, 18, 528, 93, 94, 2457, 2458, "." +256, 23, 1, 529, 0, 1, 2459, 2460, "(" +256, 23, 2, 530, 2, 4, 2461, 2463, "18" +256, 23, 3, 531, 5, 6, 2464, 2465, ")" +256, 23, 4, 532, 7, 17, 2466, 2476, "Department" +256, 23, 5, 533, 18, 20, 2477, 2479, "of" +256, 23, 6, 534, 21, 29, 2480, 2488, "Internal" +256, 23, 7, 535, 30, 38, 2489, 2497, "Medicine" +256, 23, 8, 536, 39, 40, 2498, 2499, "," +256, 23, 9, 537, 41, 45, 2500, 2504, "Jeju" +256, 23, 10, 538, 46, 54, 2505, 2513, "National" +256, 23, 11, 539, 55, 65, 2514, 2524, "University" +256, 23, 12, 540, 66, 74, 2525, 2533, "Hospital" +256, 23, 13, 541, 75, 76, 2534, 2535, "," +256, 23, 14, 542, 77, 81, 2536, 2540, "Jeju" +256, 23, 15, 543, 82, 83, 2541, 2542, "," +256, 23, 16, 544, 84, 89, 2543, 2548, "Korea" +256, 23, 17, 545, 90, 91, 2549, 2550, "." +256, 24, 1, 546, 0, 1, 2551, 2552, "(" +256, 24, 2, 547, 2, 4, 2553, 2555, "19" +256, 24, 3, 548, 5, 6, 2556, 2557, ")" +256, 24, 4, 549, 7, 17, 2558, 2568, "Department" +256, 24, 5, 550, 18, 20, 2569, 2571, "of" +256, 24, 6, 551, 21, 29, 2572, 2580, "Internal" +256, 24, 7, 552, 30, 38, 2581, 2589, "Medicine" +256, 24, 8, 553, 39, 40, 2590, 2591, "," +256, 24, 9, 554, 41, 47, 2592, 2598, "Sejong" +256, 24, 10, 555, 48, 55, 2599, 2606, "General" +256, 24, 11, 556, 56, 64, 2607, 2615, "Hospital" +256, 24, 12, 557, 65, 66, 2616, 2617, "," +256, 24, 13, 558, 67, 74, 2618, 2625, "Bucheon" +256, 24, 14, 559, 75, 76, 2626, 2627, "," +256, 24, 15, 560, 77, 82, 2628, 2633, "Korea" +256, 24, 16, 561, 83, 84, 2634, 2635, "." +256, 25, 1, 562, 0, 1, 2636, 2637, "(" +256, 25, 2, 563, 2, 4, 2638, 2640, "20" +256, 25, 3, 564, 5, 6, 2641, 2642, ")" +256, 25, 4, 565, 7, 9, 2643, 2645, "LG" +256, 25, 5, 566, 10, 14, 2646, 2650, "Life" +256, 25, 6, 567, 15, 23, 2651, 2659, "Sciences" +256, 25, 7, 568, 24, 25, 2660, 2661, "," +256, 25, 8, 569, 26, 31, 2662, 2667, "Seoul" +256, 25, 9, 570, 32, 33, 2668, 2669, "," +256, 25, 10, 571, 34, 39, 2670, 2675, "Korea" +256, 25, 11, 572, 40, 41, 2676, 2677, "." +256, 26, 1, 573, 0, 1, 2678, 2679, "(" +256, 26, 2, 574, 2, 4, 2680, 2682, "21" +256, 26, 3, 575, 5, 6, 2683, 2684, ")" +256, 26, 4, 576, 7, 17, 2685, 2695, "Department" +256, 26, 5, 577, 18, 20, 2696, 2698, "of" +256, 26, 6, 578, 21, 29, 2699, 2707, "Internal" +256, 26, 7, 579, 30, 38, 2708, 2716, "Medicine" +256, 26, 8, 580, 39, 40, 2717, 2718, "," +256, 26, 9, 581, 41, 46, 2719, 2724, "Seoul" +256, 26, 10, 582, 47, 55, 2725, 2733, "National" +256, 26, 11, 583, 56, 66, 2734, 2744, "University" +256, 26, 12, 584, 67, 74, 2745, 2752, "Bundang" +256, 26, 13, 585, 75, 83, 2753, 2761, "Hospital" +256, 26, 14, 586, 84, 85, 2762, 2763, "," +256, 26, 15, 587, 86, 94, 2764, 2772, "Seongnam" +256, 26, 16, 588, 95, 96, 2773, 2774, "," +256, 26, 17, 589, 97, 102, 2775, 2780, "Korea" +256, 26, 18, 590, 103, 104, 2781, 2782, "." +256, 27, 1, 591, 0, 1, 2783, 2784, "(" +256, 27, 2, 592, 2, 4, 2785, 2787, "22" +256, 27, 3, 593, 5, 6, 2788, 2789, ")" +256, 27, 4, 594, 7, 17, 2790, 2800, "Department" +256, 27, 5, 595, 18, 20, 2801, 2803, "of" +256, 27, 6, 596, 21, 29, 2804, 2812, "Internal" +256, 27, 7, 597, 30, 38, 2813, 2821, "Medicine" +256, 27, 8, 598, 39, 40, 2822, 2823, "," +256, 27, 9, 599, 41, 46, 2824, 2829, "Seoul" +256, 27, 10, 600, 47, 55, 2830, 2838, "National" +256, 27, 11, 601, 56, 66, 2839, 2849, "University" +256, 27, 12, 602, 67, 74, 2850, 2857, "College" +256, 27, 13, 603, 75, 77, 2858, 2860, "of" +256, 27, 14, 604, 78, 86, 2861, 2869, "Medicine" +256, 27, 15, 605, 87, 88, 2870, 2871, "," +256, 27, 16, 606, 89, 94, 2872, 2877, "Seoul" +256, 27, 17, 607, 95, 96, 2878, 2879, "," +256, 27, 18, 608, 97, 102, 2880, 2885, "Korea" +256, 27, 19, 609, 103, 104, 2886, 2887, "." +256, 28, 1, 610, 0, 1, 2888, 2889, "(" +256, 28, 2, 611, 2, 4, 2890, 2892, "23" +256, 28, 3, 612, 5, 6, 2893, 2894, ")" +256, 28, 4, 613, 7, 17, 2895, 2905, "Department" +256, 28, 5, 614, 18, 20, 2906, 2908, "of" +256, 28, 6, 615, 21, 30, 2909, 2918, "Molecular" +256, 28, 7, 616, 31, 39, 2919, 2927, "Medicine" +256, 28, 8, 617, 40, 43, 2928, 2931, "and" +256, 28, 9, 618, 44, 61, 2932, 2949, "Biopharmaceutical" +256, 28, 10, 619, 62, 70, 2950, 2958, "Sciences" +256, 28, 11, 620, 71, 72, 2959, 2960, "," +256, 28, 12, 621, 73, 81, 2961, 2969, "Graduate" +256, 28, 13, 622, 82, 88, 2970, 2976, "School" +256, 28, 14, 623, 89, 91, 2977, 2979, "of" +256, 28, 15, 624, 92, 103, 2980, 2991, "Convergence" +256, 28, 16, 625, 104, 111, 2992, 2999, "Science" +256, 28, 17, 626, 112, 115, 3000, 3003, "and" +256, 28, 18, 627, 116, 126, 3004, 3014, "Technology" +256, 28, 19, 628, 127, 128, 3015, 3016, "," +256, 28, 20, 629, 129, 134, 3017, 3022, "Seoul" +256, 28, 21, 630, 135, 143, 3023, 3031, "National" +256, 28, 22, 631, 144, 154, 3032, 3042, "University" +256, 28, 23, 632, 155, 156, 3043, 3044, "," +256, 28, 24, 633, 157, 162, 3045, 3050, "Seoul" +256, 28, 25, 634, 163, 164, 3051, 3052, "," +256, 28, 26, 635, 165, 170, 3053, 3058, "Korea" +256, 28, 27, 636, 171, 172, 3059, 3060, "." +256, 29, 1, 637, 0, 4, 3061, 3065, "AIMS" +256, 29, 2, 638, 5, 6, 3066, 3067, ":" +256, 29, 3, 639, 7, 9, 3068, 3070, "To" +256, 29, 4, 640, 10, 16, 3071, 3077, "assess" +256, 29, 5, 641, 17, 20, 3078, 3081, "the" +256, 29, 6, 642, 21, 29, 3082, 3090, "efficacy" +256, 29, 7, 643, 30, 33, 3091, 3094, "and" +256, 29, 8, 644, 34, 40, 3095, 3101, "safety" +256, 29, 9, 645, 41, 43, 3102, 3104, "of" +256, 29, 10, 646, 44, 55, 3105, 3116, "gemigliptin" +256, 29, 11, 647, 56, 57, 3117, 3118, "," +256, 29, 12, 648, 58, 59, 3119, 3120, "a" +256, 29, 13, 649, 60, 70, 3121, 3131, "dipeptidyl" +256, 29, 14, 650, 71, 80, 3132, 3141, "peptidase" +256, 29, 15, 651, 81, 82, 3142, 3143, "-" +256, 29, 16, 652, 83, 84, 3144, 3145, "4" +256, 29, 17, 653, 85, 94, 3146, 3155, "inhibitor" +256, 29, 18, 654, 95, 96, 3156, 3157, "," +256, 29, 19, 655, 97, 102, 3158, 3163, "added" +256, 29, 20, 656, 103, 105, 3164, 3166, "to" +256, 29, 21, 657, 106, 115, 3167, 3176, "metformin" +256, 29, 22, 658, 116, 119, 3177, 3180, "and" +256, 29, 23, 659, 120, 133, 3181, 3194, "sulphonylurea" +256, 29, 24, 660, 134, 136, 3195, 3197, "in" +256, 29, 25, 661, 137, 145, 3198, 3206, "patients" +256, 29, 26, 662, 146, 150, 3207, 3211, "with" +256, 29, 27, 663, 151, 155, 3212, 3216, "type" +256, 29, 28, 664, 156, 157, 3217, 3218, "2" +256, 29, 29, 665, 158, 166, 3219, 3227, "diabetes" +256, 29, 30, 666, 167, 168, 3228, 3229, "(" +256, 29, 31, 667, 169, 173, 3230, 3234, "T2DM" +256, 29, 32, 668, 174, 175, 3235, 3236, ")" +256, 29, 33, 669, 176, 177, 3237, 3238, "." +256, 30, 1, 670, 0, 9, 3239, 3248, "MATERIALS" +256, 30, 2, 671, 10, 13, 3249, 3252, "AND" +256, 30, 3, 672, 14, 21, 3253, 3260, "METHODS" +256, 30, 4, 673, 22, 23, 3261, 3262, ":" +256, 30, 5, 674, 24, 26, 3263, 3265, "We" +256, 30, 6, 675, 27, 36, 3266, 3275, "conducted" +256, 30, 7, 676, 37, 38, 3276, 3277, "a" +256, 30, 8, 677, 39, 49, 3278, 3288, "randomized" +256, 30, 9, 678, 50, 51, 3289, 3290, "," +256, 30, 10, 679, 52, 58, 3291, 3297, "double" +256, 30, 11, 680, 59, 60, 3298, 3299, "-" +256, 30, 12, 681, 61, 66, 3300, 3305, "blind" +256, 30, 13, 682, 67, 68, 3306, 3307, "," +256, 30, 14, 683, 69, 76, 3308, 3315, "placebo" +256, 30, 15, 684, 77, 78, 3316, 3317, "-" +256, 30, 16, 685, 79, 89, 3318, 3328, "controlled" +256, 30, 17, 686, 90, 95, 3329, 3334, "trial" +256, 30, 18, 687, 96, 98, 3335, 3337, "in" +256, 30, 19, 688, 99, 102, 3338, 3341, "219" +256, 30, 20, 689, 103, 109, 3342, 3348, "Korean" +256, 30, 21, 690, 110, 118, 3349, 3357, "patients" +256, 30, 22, 691, 119, 131, 3358, 3370, "inadequately" +256, 30, 23, 692, 132, 142, 3371, 3381, "controlled" +256, 30, 24, 693, 143, 147, 3382, 3386, "with" +256, 30, 25, 694, 148, 157, 3387, 3396, "metformin" +256, 30, 26, 695, 158, 161, 3397, 3400, "and" +256, 30, 27, 696, 162, 173, 3401, 3412, "glimepiride" +256, 30, 28, 697, 174, 175, 3413, 3414, "." +256, 31, 1, 698, 0, 12, 3415, 3427, "Participants" +256, 31, 2, 699, 13, 17, 3428, 3432, "were" +256, 31, 3, 700, 18, 28, 3433, 3443, "randomized" +256, 31, 4, 701, 29, 31, 3444, 3446, "to" +256, 31, 5, 702, 32, 43, 3447, 3458, "gemigliptin" +256, 31, 6, 703, 44, 46, 3459, 3461, "50" +256, 31, 7, 704, 47, 48, 3462, 3463, " " +256, 31, 8, 705, 49, 51, 3464, 3466, "mg" +256, 31, 9, 706, 52, 56, 3467, 3471, "once" +256, 31, 10, 707, 57, 62, 3472, 3477, "daily" +256, 31, 11, 708, 63, 65, 3478, 3480, "or" +256, 31, 12, 709, 66, 73, 3481, 3488, "placebo" +256, 31, 13, 710, 74, 79, 3489, 3494, "added" +256, 31, 14, 711, 80, 82, 3495, 3497, "to" +256, 31, 15, 712, 83, 92, 3498, 3507, "metformin" +256, 31, 16, 713, 93, 96, 3508, 3511, "and" +256, 31, 17, 714, 97, 108, 3512, 3523, "glimepiride" +256, 31, 18, 715, 109, 110, 3524, 3525, "." +256, 32, 1, 716, 0, 3, 3526, 3529, "The" +256, 32, 2, 717, 4, 11, 3530, 3537, "primary" +256, 32, 3, 718, 12, 20, 3538, 3546, "endpoint" +256, 32, 4, 719, 21, 24, 3547, 3550, "was" +256, 32, 5, 720, 25, 31, 3551, 3557, "change" +256, 32, 6, 721, 32, 34, 3558, 3560, "in" +256, 32, 7, 722, 35, 43, 3561, 3569, "glycated" +256, 32, 8, 723, 44, 55, 3570, 3581, "haemoglobin" +256, 32, 9, 724, 56, 57, 3582, 3583, "(" +256, 32, 10, 725, 58, 63, 3584, 3589, "HbA1c" +256, 32, 11, 726, 64, 65, 3590, 3591, ")" +256, 32, 12, 727, 66, 71, 3592, 3597, "level" +256, 32, 13, 728, 72, 76, 3598, 3602, "from" +256, 32, 14, 729, 77, 85, 3603, 3611, "baseline" +256, 32, 15, 730, 86, 88, 3612, 3614, "to" +256, 32, 16, 731, 89, 93, 3615, 3619, "week" +256, 32, 17, 732, 94, 96, 3620, 3622, "24" +256, 32, 18, 733, 97, 98, 3623, 3624, "." +256, 33, 1, 734, 0, 7, 3625, 3632, "RESULTS" +256, 33, 2, 735, 8, 9, 3633, 3634, ":" +256, 33, 3, 736, 10, 13, 3635, 3638, "The" +256, 33, 4, 737, 14, 22, 3639, 3647, "baseline" +256, 33, 5, 738, 23, 28, 3648, 3653, "HbA1c" +256, 33, 6, 739, 29, 32, 3654, 3657, "was" +256, 33, 7, 740, 33, 34, 3658, 3659, "8" +256, 33, 8, 741, 35, 36, 3660, 3661, "." +256, 33, 9, 742, 37, 38, 3662, 3663, "2" +256, 33, 10, 743, 39, 40, 3664, 3665, "%" +256, 33, 11, 744, 41, 43, 3666, 3668, "in" +256, 33, 12, 745, 44, 48, 3669, 3673, "both" +256, 33, 13, 746, 49, 55, 3674, 3680, "groups" +256, 33, 14, 747, 56, 57, 3681, 3682, "." +256, 34, 1, 748, 0, 3, 3683, 3686, "The" +256, 34, 2, 749, 4, 12, 3687, 3695, "addition" +256, 34, 3, 750, 13, 15, 3696, 3698, "of" +256, 34, 4, 751, 16, 27, 3699, 3710, "gemigliptin" +256, 34, 5, 752, 28, 30, 3711, 3713, "to" +256, 34, 6, 753, 31, 40, 3714, 3723, "metformin" +256, 34, 7, 754, 41, 44, 3724, 3727, "and" +256, 34, 8, 755, 45, 56, 3728, 3739, "glimepiride" +256, 34, 9, 756, 57, 70, 3740, 3753, "significantly" +256, 34, 10, 757, 71, 78, 3754, 3761, "reduced" +256, 34, 11, 758, 79, 84, 3762, 3767, "HbA1c" +256, 34, 12, 759, 85, 91, 3768, 3774, "levels" +256, 34, 13, 760, 92, 94, 3775, 3777, "at" +256, 34, 14, 761, 95, 99, 3778, 3782, "week" +256, 34, 15, 762, 100, 102, 3783, 3785, "24" +256, 34, 16, 763, 103, 111, 3786, 3794, "compared" +256, 34, 17, 764, 112, 116, 3795, 3799, "with" +256, 34, 18, 765, 117, 124, 3800, 3807, "placebo" +256, 34, 19, 766, 125, 126, 3808, 3809, "(" +256, 34, 20, 767, 127, 134, 3810, 3817, "between" +256, 34, 21, 768, 135, 136, 3818, 3819, "-" +256, 34, 22, 769, 137, 142, 3820, 3825, "group" +256, 34, 23, 770, 143, 153, 3826, 3836, "difference" +256, 34, 24, 771, 154, 156, 3837, 3839, "in" +256, 34, 25, 772, 157, 165, 3840, 3848, "adjusted" +256, 34, 26, 773, 166, 170, 3849, 3853, "mean" +256, 34, 27, 774, 171, 177, 3854, 3860, "change" +256, 34, 28, 775, 178, 179, 3861, 3862, "-" +256, 34, 29, 776, 180, 181, 3863, 3864, "0" +256, 34, 30, 777, 182, 183, 3865, 3866, "." +256, 34, 31, 778, 184, 186, 3867, 3869, "87" +256, 34, 32, 779, 187, 188, 3870, 3871, "%" +256, 34, 33, 780, 189, 190, 3872, 3873, "," +256, 34, 34, 781, 191, 193, 3874, 3876, "95" +256, 34, 35, 782, 194, 195, 3877, 3878, "%" +256, 34, 36, 783, 196, 206, 3879, 3889, "confidence" +256, 34, 37, 784, 207, 215, 3890, 3898, "interval" +256, 34, 38, 785, 216, 217, 3899, 3900, "[" +256, 34, 39, 786, 218, 220, 3901, 3903, "CI" +256, 34, 40, 787, 221, 222, 3904, 3905, "]" +256, 34, 41, 788, 223, 224, 3906, 3907, "-" +256, 34, 42, 789, 225, 226, 3908, 3909, "1" +256, 34, 43, 790, 227, 228, 3910, 3911, "." +256, 34, 44, 791, 229, 231, 3912, 3914, "09" +256, 34, 45, 792, 232, 233, 3915, 3916, "%" +256, 34, 46, 793, 234, 236, 3917, 3919, "to" +256, 34, 47, 794, 237, 238, 3920, 3921, "-" +256, 34, 48, 795, 239, 240, 3922, 3923, "0" +256, 34, 49, 796, 241, 242, 3924, 3925, "." +256, 34, 50, 797, 243, 245, 3926, 3928, "64" +256, 34, 51, 798, 246, 247, 3929, 3930, "%" +256, 34, 52, 799, 248, 249, 3931, 3932, ")" +256, 34, 53, 800, 250, 251, 3933, 3934, "." +256, 35, 1, 801, 0, 7, 3935, 3942, "Fasting" +256, 35, 2, 802, 8, 14, 3943, 3949, "plasma" +256, 35, 3, 803, 15, 22, 3950, 3957, "glucose" +256, 35, 4, 804, 23, 28, 3958, 3963, "level" +256, 35, 5, 805, 29, 32, 3964, 3967, "was" +256, 35, 6, 806, 33, 37, 3968, 3972, "also" +256, 35, 7, 807, 38, 51, 3973, 3986, "significantly" +256, 35, 8, 808, 52, 59, 3987, 3994, "reduced" +256, 35, 9, 809, 60, 64, 3995, 3999, "with" +256, 35, 10, 810, 65, 76, 4000, 4011, "gemigliptin" +256, 35, 11, 811, 77, 78, 4012, 4013, "(" +256, 35, 12, 812, 79, 80, 4014, 4015, "-" +256, 35, 13, 813, 81, 82, 4016, 4017, "0" +256, 35, 14, 814, 83, 84, 4018, 4019, "." +256, 35, 15, 815, 85, 87, 4020, 4022, "93" +256, 35, 16, 816, 88, 89, 4023, 4024, " " +256, 35, 17, 817, 90, 94, 4025, 4029, "mmol" +256, 35, 18, 818, 95, 96, 4030, 4031, "/" +256, 35, 19, 819, 97, 98, 4032, 4033, "L" +256, 35, 20, 820, 99, 100, 4034, 4035, "," +256, 35, 21, 821, 101, 103, 4036, 4038, "95" +256, 35, 22, 822, 104, 105, 4039, 4040, "%" +256, 35, 23, 823, 106, 108, 4041, 4043, "CI" +256, 35, 24, 824, 109, 110, 4044, 4045, "-" +256, 35, 25, 825, 111, 112, 4046, 4047, "1" +256, 35, 26, 826, 113, 114, 4048, 4049, "." +256, 35, 27, 827, 115, 117, 4050, 4052, "50" +256, 35, 28, 828, 118, 120, 4053, 4055, "to" +256, 35, 29, 829, 121, 122, 4056, 4057, "-" +256, 35, 30, 830, 123, 124, 4058, 4059, "0" +256, 35, 31, 831, 125, 126, 4060, 4061, "." +256, 35, 32, 832, 127, 129, 4062, 4064, "35" +256, 35, 33, 833, 130, 131, 4065, 4066, " " +256, 35, 34, 834, 132, 136, 4067, 4071, "mmol" +256, 35, 35, 835, 137, 138, 4072, 4073, "/" +256, 35, 36, 836, 139, 140, 4074, 4075, "L" +256, 35, 37, 837, 141, 142, 4076, 4077, ")" +256, 35, 38, 838, 143, 144, 4078, 4079, "," +256, 35, 39, 839, 145, 148, 4080, 4083, "and" +256, 35, 40, 840, 149, 150, 4084, 4085, "a" +256, 35, 41, 841, 151, 157, 4086, 4092, "higher" +256, 35, 42, 842, 158, 168, 4093, 4103, "proportion" +256, 35, 43, 843, 169, 171, 4104, 4106, "of" +256, 35, 44, 844, 172, 184, 4107, 4119, "participants" +256, 35, 45, 845, 185, 193, 4120, 4128, "achieved" +256, 35, 46, 846, 194, 196, 4129, 4131, "an" +256, 35, 47, 847, 197, 202, 4132, 4137, "HbA1c" +256, 35, 48, 848, 203, 208, 4138, 4143, "level" +256, 35, 49, 849, 209, 211, 4144, 4146, "of" +256, 35, 50, 850, 212, 213, 4147, 4148, "<" +256, 35, 51, 851, 214, 215, 4149, 4150, "7" +256, 35, 52, 852, 216, 217, 4151, 4152, "%" +256, 35, 53, 853, 218, 219, 4153, 4154, "(" +256, 35, 54, 854, 220, 222, 4155, 4157, "39" +256, 35, 55, 855, 223, 224, 4158, 4159, "." +256, 35, 56, 856, 225, 226, 4160, 4161, "3" +256, 35, 57, 857, 227, 228, 4162, 4163, "%" +256, 35, 58, 858, 229, 231, 4164, 4166, "vs" +256, 35, 59, 859, 232, 233, 4167, 4168, "5" +256, 35, 60, 860, 234, 235, 4169, 4170, "." +256, 35, 61, 861, 236, 237, 4171, 4172, "5" +256, 35, 62, 862, 238, 239, 4173, 4174, "%" +256, 35, 63, 863, 240, 241, 4175, 4176, ";" +256, 35, 64, 864, 242, 243, 4177, 4178, "P" +256, 35, 65, 865, 244, 245, 4179, 4180, "<" +256, 35, 66, 866, 246, 247, 4181, 4182, "." +256, 35, 67, 867, 248, 251, 4183, 4186, "001" +256, 35, 68, 868, 252, 253, 4187, 4188, ")" +256, 35, 69, 869, 254, 256, 4189, 4191, "in" +256, 35, 70, 870, 257, 260, 4192, 4195, "the" +256, 35, 71, 871, 261, 272, 4196, 4207, "gemigliptin" +256, 35, 72, 872, 273, 278, 4208, 4213, "group" +256, 35, 73, 873, 279, 283, 4214, 4218, "than" +256, 35, 74, 874, 284, 286, 4219, 4221, "in" +256, 35, 75, 875, 287, 290, 4222, 4225, "the" +256, 35, 76, 876, 291, 298, 4226, 4233, "placebo" +256, 35, 77, 877, 299, 304, 4234, 4239, "group" +256, 35, 78, 878, 305, 306, 4240, 4241, "." +256, 36, 1, 879, 0, 5, 4242, 4247, "Total" +256, 36, 2, 880, 6, 17, 4248, 4259, "cholesterol" +256, 36, 3, 881, 18, 21, 4260, 4263, "and" +256, 36, 4, 882, 22, 25, 4264, 4267, "LDL" +256, 36, 5, 883, 26, 37, 4268, 4279, "cholesterol" +256, 36, 6, 884, 38, 42, 4280, 4284, "were" +256, 36, 7, 885, 43, 51, 4285, 4293, "modestly" +256, 36, 8, 886, 52, 55, 4294, 4297, "but" +256, 36, 9, 887, 56, 69, 4298, 4311, "significantly" +256, 36, 10, 888, 70, 77, 4312, 4319, "reduced" +256, 36, 11, 889, 78, 80, 4320, 4322, "in" +256, 36, 12, 890, 81, 84, 4323, 4326, "the" +256, 36, 13, 891, 85, 96, 4327, 4338, "gemigliptin" +256, 36, 14, 892, 97, 102, 4339, 4344, "group" +256, 36, 15, 893, 103, 111, 4345, 4353, "compared" +256, 36, 16, 894, 112, 116, 4354, 4358, "with" +256, 36, 17, 895, 117, 120, 4359, 4362, "the" +256, 36, 18, 896, 121, 128, 4363, 4370, "placebo" +256, 36, 19, 897, 129, 134, 4371, 4376, "group" +256, 36, 20, 898, 135, 136, 4377, 4378, "(" +256, 36, 21, 899, 137, 138, 4379, 4380, "-" +256, 36, 22, 900, 139, 140, 4381, 4382, "0" +256, 36, 23, 901, 141, 142, 4383, 4384, "." +256, 36, 24, 902, 143, 145, 4385, 4387, "21" +256, 36, 25, 903, 146, 147, 4388, 4389, " " +256, 36, 26, 904, 148, 152, 4390, 4394, "mmol" +256, 36, 27, 905, 153, 154, 4395, 4396, "/" +256, 36, 28, 906, 155, 156, 4397, 4398, "L" +256, 36, 29, 907, 157, 158, 4399, 4400, "," +256, 36, 30, 908, 159, 161, 4401, 4403, "95" +256, 36, 31, 909, 162, 163, 4404, 4405, "%" +256, 36, 32, 910, 164, 166, 4406, 4408, "CI" +256, 36, 33, 911, 167, 168, 4409, 4410, "-" +256, 36, 34, 912, 169, 170, 4411, 4412, "0" +256, 36, 35, 913, 171, 172, 4413, 4414, "." +256, 36, 36, 914, 173, 175, 4415, 4417, "38" +256, 36, 37, 915, 176, 178, 4418, 4420, "to" +256, 36, 38, 916, 179, 180, 4421, 4422, "-" +256, 36, 39, 917, 181, 182, 4423, 4424, "0" +256, 36, 40, 918, 183, 184, 4425, 4426, "." +256, 36, 41, 919, 185, 187, 4427, 4429, "03" +256, 36, 42, 920, 188, 189, 4430, 4431, " " +256, 36, 43, 921, 190, 194, 4432, 4436, "mmol" +256, 36, 44, 922, 195, 196, 4437, 4438, "/" +256, 36, 45, 923, 197, 198, 4439, 4440, "L" +256, 36, 46, 924, 199, 202, 4441, 4444, "for" +256, 36, 47, 925, 203, 208, 4445, 4450, "total" +256, 36, 48, 926, 209, 220, 4451, 4462, "cholesterol" +256, 36, 49, 927, 221, 222, 4463, 4464, "," +256, 36, 50, 928, 223, 224, 4465, 4466, "-" +256, 36, 51, 929, 225, 226, 4467, 4468, "0" +256, 36, 52, 930, 227, 228, 4469, 4470, "." +256, 36, 53, 931, 229, 231, 4471, 4473, "18" +256, 36, 54, 932, 232, 233, 4474, 4475, " " +256, 36, 55, 933, 234, 238, 4476, 4480, "mmol" +256, 36, 56, 934, 239, 240, 4481, 4482, "/" +256, 36, 57, 935, 241, 242, 4483, 4484, "L" +256, 36, 58, 936, 243, 244, 4485, 4486, "," +256, 36, 59, 937, 245, 247, 4487, 4489, "95" +256, 36, 60, 938, 248, 249, 4490, 4491, "%" +256, 36, 61, 939, 250, 252, 4492, 4494, "CI" +256, 36, 62, 940, 253, 254, 4495, 4496, "-" +256, 36, 63, 941, 255, 256, 4497, 4498, "0" +256, 36, 64, 942, 257, 258, 4499, 4500, "." +256, 36, 65, 943, 259, 261, 4501, 4503, "34" +256, 36, 66, 944, 262, 264, 4504, 4506, "to" +256, 36, 67, 945, 265, 266, 4507, 4508, "-" +256, 36, 68, 946, 267, 268, 4509, 4510, "0" +256, 36, 69, 947, 269, 270, 4511, 4512, "." +256, 36, 70, 948, 271, 273, 4513, 4515, "01" +256, 36, 71, 949, 274, 275, 4516, 4517, " " +256, 36, 72, 950, 276, 280, 4518, 4522, "mmol" +256, 36, 73, 951, 281, 282, 4523, 4524, "/" +256, 36, 74, 952, 283, 284, 4525, 4526, "L" +256, 36, 75, 953, 285, 288, 4527, 4530, "for" +256, 36, 76, 954, 289, 292, 4531, 4534, "LDL" +256, 36, 77, 955, 293, 304, 4535, 4546, "cholesterol" +256, 36, 78, 956, 305, 306, 4547, 4548, ")" +256, 36, 79, 957, 307, 308, 4549, 4550, "." +256, 37, 1, 958, 0, 3, 4551, 4554, "The" +256, 37, 2, 959, 4, 13, 4555, 4564, "incidence" +256, 37, 3, 960, 14, 16, 4565, 4567, "of" +256, 37, 4, 961, 17, 30, 4568, 4581, "hypoglycaemia" +256, 37, 5, 962, 31, 34, 4582, 4585, "was" +256, 37, 6, 963, 35, 36, 4586, 4587, "9" +256, 37, 7, 964, 37, 38, 4588, 4589, "." +256, 37, 8, 965, 39, 40, 4590, 4591, "4" +256, 37, 9, 966, 41, 42, 4592, 4593, "%" +256, 37, 10, 967, 43, 45, 4594, 4596, "in" +256, 37, 11, 968, 46, 49, 4597, 4600, "the" +256, 37, 12, 969, 50, 61, 4601, 4612, "gemigliptin" +256, 37, 13, 970, 62, 67, 4613, 4618, "group" +256, 37, 14, 971, 68, 71, 4619, 4622, "and" +256, 37, 15, 972, 72, 73, 4623, 4624, "2" +256, 37, 16, 973, 74, 75, 4625, 4626, "." +256, 37, 17, 974, 76, 77, 4627, 4628, "7" +256, 37, 18, 975, 78, 79, 4629, 4630, "%" +256, 37, 19, 976, 80, 82, 4631, 4633, "in" +256, 37, 20, 977, 83, 86, 4634, 4637, "the" +256, 37, 21, 978, 87, 94, 4638, 4645, "placebo" +256, 37, 22, 979, 95, 100, 4646, 4651, "group" +256, 37, 23, 980, 101, 102, 4652, 4653, "." +256, 38, 1, 981, 0, 11, 4654, 4665, "CONCLUSIONS" +256, 38, 2, 982, 12, 13, 4666, 4667, ":" +256, 38, 3, 983, 14, 25, 4668, 4679, "Gemigliptin" +256, 38, 4, 984, 26, 39, 4680, 4693, "significantly" +256, 38, 5, 985, 40, 48, 4694, 4702, "improved" +256, 38, 6, 986, 49, 58, 4703, 4712, "glycaemic" +256, 38, 7, 987, 59, 66, 4713, 4720, "control" +256, 38, 8, 988, 67, 69, 4721, 4723, "in" +256, 38, 9, 989, 70, 78, 4724, 4732, "patients" +256, 38, 10, 990, 79, 83, 4733, 4737, "with" +256, 38, 11, 991, 84, 88, 4738, 4742, "T2DM" +256, 38, 12, 992, 89, 101, 4743, 4755, "inadequately" +256, 38, 13, 993, 102, 112, 4756, 4766, "controlled" +256, 38, 14, 994, 113, 117, 4767, 4771, "with" +256, 38, 15, 995, 118, 127, 4772, 4781, "metformin" +256, 38, 16, 996, 128, 131, 4782, 4785, "and" +256, 38, 17, 997, 132, 145, 4786, 4799, "sulphonylurea" +256, 38, 18, 998, 146, 147, 4800, 4801, "." +256, 39, 1, 999, 0, 3, 4802, 4805, "The" +256, 39, 2, 1000, 4, 13, 4806, 4815, "incidence" +256, 39, 3, 1001, 14, 16, 4816, 4818, "of" +256, 39, 4, 1002, 17, 30, 4819, 4832, "hypoglycaemia" +256, 39, 5, 1003, 31, 34, 4833, 4836, "was" +256, 39, 6, 1004, 35, 41, 4837, 4843, "higher" +256, 39, 7, 1005, 42, 46, 4844, 4848, "with" +256, 39, 8, 1006, 47, 58, 4849, 4860, "gemigliptin" +256, 39, 9, 1007, 59, 63, 4861, 4865, "than" +256, 39, 10, 1008, 64, 68, 4866, 4870, "with" +256, 39, 11, 1009, 69, 76, 4871, 4878, "placebo" +256, 39, 12, 1010, 77, 78, 4879, 4880, "," +256, 39, 13, 1011, 79, 84, 4881, 4886, "which" +256, 39, 14, 1012, 85, 95, 4887, 4897, "highlights" +256, 39, 15, 1013, 96, 99, 4898, 4901, "the" +256, 39, 16, 1014, 100, 110, 4902, 4912, "importance" +256, 39, 17, 1015, 111, 113, 4913, 4915, "of" +256, 39, 18, 1016, 114, 121, 4916, 4923, "optimal" +256, 39, 19, 1017, 122, 126, 4924, 4928, "dose" +256, 39, 20, 1018, 127, 137, 4929, 4939, "adjustment" +256, 39, 21, 1019, 138, 141, 4940, 4943, "for" +256, 39, 22, 1020, 142, 155, 4944, 4957, "sulphonylurea" +256, 39, 23, 1021, 156, 157, 4958, 4959, "." +256, 40, 1, 1022, 0, 1, 4960, 4961, "©" +256, 40, 2, 1023, 2, 6, 4962, 4966, "2016" +256, 40, 3, 1024, 7, 11, 4967, 4971, "John" +256, 40, 4, 1025, 12, 17, 4972, 4977, "Wiley" +256, 40, 5, 1026, 18, 19, 4978, 4979, "&" +256, 40, 6, 1027, 20, 24, 4980, 4984, "Sons" +256, 40, 7, 1028, 25, 28, 4985, 4988, "Ltd" +256, 40, 8, 1029, 29, 30, 4989, 4990, "." +256, 40, 9, 1030, 31, 34, 4991, 4994, "DOI" +256, 40, 10, 1031, 35, 36, 4995, 4996, ":" +256, 40, 11, 1032, 37, 39, 4997, 4999, "10" +256, 40, 12, 1033, 40, 41, 5000, 5001, "." +256, 40, 13, 1034, 42, 46, 5002, 5006, "1111" +256, 40, 14, 1035, 47, 48, 5007, 5008, "/" +256, 40, 15, 1036, 49, 52, 5009, 5012, "dom" +256, 40, 16, 1037, 53, 54, 5013, 5014, "." +256, 40, 17, 1038, 55, 60, 5015, 5020, "12866" +256, 40, 18, 1039, 61, 65, 5021, 5025, "PMID" +256, 40, 19, 1040, 66, 67, 5026, 5027, ":" +256, 40, 20, 1041, 68, 76, 5028, 5036, "28026912" +256, 40, 21, 1042, 77, 78, 5037, 5038, "[" +256, 40, 22, 1043, 79, 86, 5039, 5046, "Indexed" +256, 40, 23, 1044, 87, 90, 5047, 5050, "for" +256, 40, 24, 1045, 91, 98, 5051, 5058, "MEDLINE" +256, 40, 25, 1046, 99, 100, 5059, 5060, "]" diff --git a/data/dm2 28026912_kwoodley.annodb b/data/dm2 28026912_kwoodley.annodb new file mode 100644 index 0000000..effeb88 --- /dev/null +++ b/data/dm2 28026912_kwoodley.annodb @@ -0,0 +1,144 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70952, Journal, 0, 19, "Diabetes Obes Metab", "", +70953, PublicationYear, 22, 26, "2017", "", +70989, Title, 107, 349, "Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre , randomized ,", "", +70954, Drug, 130, 141, "gemigliptin", "", +70977, Precondition, 186, 306, "patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea", "", +70963, Type2Diabetes, 200, 224, "type 2 diabetes mellitus", "", +70967, Metformin, 279, 288, "metformin", "", +70973, Sulfonylureas, 293, 306, "sulphonylurea", "", +70978, Duration, 311, 320, "24 - week", "", +70979, Multicenter, 323, 334, "multicentre", "", +70980, Randomized, 337, 347, "randomized", "", +70981, DoubleBlind, 350, 364, "double - blind", "", +70982, Placebo, 367, 374, "placebo", "", +70990, Title, 367, 412, "placebo - controlled study ( TROICA study ) .", "", +70991, Author, 413, 419, "Ahn CH", "", +70992, Author, 428, 434, "Han KA", "", +70994, Author, 443, 448, "Yu JM", "", +70993, Author, 457, 463, "Nam JY", "", +70995, Author, 472, 478, "Ahn KJ", "", +70996, Author, 487, 492, "Oh TK", "", +70997, Author, 501, 507, "Lee HW", "", +70998, Author, 516, 522, "Lee DH", "", +70999, Author, 531, 536, "Kim J", "", +71000, Author, 545, 553, "Chung CH", "", +71001, Author, 563, 570, "Park TS", "", +71002, Author, 580, 586, "Kim BJ", "", +71003, Author, 596, 603, "Park SW", "", +71004, Author, 613, 620, "Park HK", "", +71005, Author, 630, 636, "Lee KJ", "", +71006, Author, 646, 652, "Kim SW", "", +71007, Author, 662, 669, "Park JH", "", +71008, Author, 679, 684, "Ko KP", "", +71009, Author, 694, 700, "Kim CH", "", +71010, Author, 710, 715, "Lee H", "", +71011, Author, 725, 732, "Jang HC", "", +71012, Author, 749, 756, "Park KS", "", +71013, SouthKorea, 885, 890, "Korea", "", +71014, SouthKorea, 966, 971, "Korea", "", +71015, SouthKorea, 1072, 1077, "Korea", "", +71016, SouthKorea, 1180, 1185, "Korea", "", +71017, SouthKorea, 1291, 1296, "Korea", "", +71018, SouthKorea, 1390, 1395, "Korea", "", +71019, SouthKorea, 1483, 1488, "Korea", "", +71020, SouthKorea, 1593, 1598, "Korea", "", +71021, SouthKorea, 1683, 1688, "Korea", "", +71022, SouthKorea, 1795, 1800, "Korea", "", +71023, SouthKorea, 1892, 1897, "Korea", "", +71024, SouthKorea, 1990, 1995, "Korea", "", +71025, SouthKorea, 2079, 2084, "Korea", "", +71026, SouthKorea, 2172, 2177, "Korea", "", +71027, SouthKorea, 2256, 2261, "Korea", "", +71028, SouthKorea, 2356, 2361, "Korea", "", +71029, SouthKorea, 2451, 2456, "Korea", "", +71030, SouthKorea, 2543, 2548, "Korea", "", +71031, SouthKorea, 2628, 2633, "Korea", "", +71032, SouthKorea, 2670, 2675, "Korea", "", +71033, SouthKorea, 2775, 2780, "Korea", "", +71034, SouthKorea, 2880, 2885, "Korea", "", +71035, SouthKorea, 3053, 3058, "Korea", "", +71036, ObjectiveDescription, 3068, 3238, "To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .", "", +70955, Drug, 3105, 3116, "gemigliptin", "", +70968, Metformin, 3167, 3176, "metformin", "", +70974, Sulfonylureas, 3181, 3194, "sulphonylurea", "", +70964, Type2Diabetes, 3212, 3227, "type 2 diabetes", "", +70965, Type2Diabetes, 3230, 3234, "T2DM", "", +71037, Randomized, 3278, 3288, "randomized", "", +71038, DoubleBlind, 3291, 3305, "double - blind", "", +70983, Placebo, 3308, 3315, "placebo", "", +71039, NumberPatientsCT, 3338, 3341, "219", "", +71040, Ethnicity, 3342, 3348, "Korean", "", +71045, Precondition, 3342, 3412, "Korean patients inadequately controlled with metformin and glimepiride", "", +70969, Metformin, 3387, 3396, "metformin", "", +71041, Glimepiride, 3401, 3412, "glimepiride", "", +71046, Randomized, 3433, 3443, "randomized", "", +70956, Drug, 3447, 3458, "gemigliptin", "", +71047, DoseValue, 3459, 3461, "50", "", +71048, mg, 3464, 3466, "mg", "", +71049, Frequency, 3467, 3477, "once daily", "", +70984, Placebo, 3481, 3488, "placebo", "", +70970, Metformin, 3498, 3507, "metformin", "", +71042, Glimepiride, 3512, 3523, "glimepiride", "", +71050, HbA1c, 3561, 3581, "glycated haemoglobin", "", +71051, HbA1c, 3584, 3589, "HbA1c", "", +71054, TimePoint, 3603, 3611, "baseline", "", +71055, TimePoint, 3615, 3622, "week 24", "", +71056, TimePoint, 3639, 3647, "baseline", "", +71052, HbA1c, 3648, 3653, "HbA1c", "", +71058, BaseLineValue, 3658, 3663, "8 . 2", "", +71059, Percentage, 3664, 3665, "%", "", +70957, Drug, 3699, 3710, "gemigliptin", "", +70971, Metformin, 3714, 3723, "metformin", "", +71043, Glimepiride, 3728, 3739, "glimepiride", "", +71053, HbA1c, 3762, 3767, "HbA1c", "", +71057, TimePoint, 3778, 3785, "week 24", "", +70985, Placebo, 3800, 3807, "placebo", "", +71063, DiffGroupAbsValue, 3861, 3869, "- 0 . 87", "", +71060, Percentage, 3870, 3871, "%", "", +71064, ConfIntervalDiff, 3874, 3932, "95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 % )", "", +71061, Percentage, 3915, 3916, "%", "", +71062, Percentage, 3929, 3930, "%", "", +71065, FastingPlasmaGlucose, 3935, 3957, "Fasting plasma glucose", "", +70958, Drug, 4000, 4011, "gemigliptin", "", +71066, Reduction, 4016, 4022, "0 . 93", "", +71067, Millimoles_per_litre, 4025, 4033, "mmol / L", "", +71069, ConfIntervalChangeValue, 4036, 4075, "95 % CI - 1 . 50 to - 0 . 35   mmol / L", "", +71068, Millimoles_per_litre, 4067, 4075, "mmol / L", "", +71070, HbA1c_target, 4132, 4152, "HbA1c level of < 7 %", "", +71071, PercentageAffected, 4155, 4161, "39 . 3", "", +71072, PercentageAffected, 4167, 4172, "5 . 5", "", +71073, PvalueDiff, 4177, 4186, "P < . 001", "", +71044, Drug, 4196, 4207, "gemigliptin", "", +70986, Placebo, 4226, 4233, "placebo", "", +71074, EndPointDescription, 4242, 4259, "Total cholesterol", "", +71078, ObservedResult, 4242, 4376, "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group", "", +71075, EndPointDescription, 4264, 4279, "LDL cholesterol", "", +70959, Drug, 4327, 4338, "gemigliptin", "", +70987, Placebo, 4363, 4370, "placebo", "", +71080, DiffGroupAbsValue, 4379, 4387, "- 0 . 21", "", +71082, Millimoles_per_litre, 4390, 4398, "mmol / L", "", +71086, ConfIntervalDiff, 4401, 4440, "95 % CI - 0 . 38 to - 0 . 03   mmol / L", "", +71085, Millimoles_per_litre, 4432, 4440, "mmol / L", "", +71076, EndPointDescription, 4445, 4462, "total cholesterol", "", +71081, DiffGroupAbsValue, 4465, 4473, "- 0 . 18", "", +71083, Millimoles_per_litre, 4476, 4484, "mmol / L", "", +71087, ConfIntervalDiff, 4487, 4526, "95 % CI - 0 . 34 to - 0 . 01   mmol / L", "", +71084, Millimoles_per_litre, 4518, 4526, "mmol / L", "", +71077, EndPointDescription, 4531, 4546, "LDL cholesterol", "", +71088, Hypoglycemia, 4568, 4581, "hypoglycaemia", "", +71089, PercentageAffected, 4586, 4591, "9 . 4", "", +70960, Drug, 4601, 4612, "gemigliptin", "", +71090, PercentageAffected, 4623, 4628, "2 . 7", "", +70988, Placebo, 4638, 4645, "placebo", "", +70961, Drug, 4668, 4679, "Gemigliptin", "", +71091, ConclusionComment, 4668, 4801, "Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .", "", +70966, Type2Diabetes, 4738, 4742, "T2DM", "", +70972, Metformin, 4772, 4781, "metformin", "", +70975, Sulfonylureas, 4786, 4799, "sulphonylurea", "", +71092, ConclusionComment, 4802, 4959, "The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .", "", +71093, Hypoglycemia, 4819, 4832, "hypoglycaemia", "", +70962, Drug, 4849, 4860, "gemigliptin", "", +71094, Placebo, 4871, 4878, "placebo", "", +70976, Sulfonylureas, 4944, 4957, "sulphonylurea", "", +71095, PMID, 5028, 5036, "28026912", "", diff --git a/data/dm2 28026912_kwoodley.n-triples b/data/dm2 28026912_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28026912_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28035868_admin.annodb b/data/dm2 28035868_admin.annodb new file mode 100644 index 0000000..7d85a98 --- /dev/null +++ b/data/dm2 28035868_admin.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2017", "", " \"2017\"." +7, Title, 119, 274, "A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone .", "", " \"A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone .\"." +2, Randomized, 121, 131, "randomized", "", +3, Sitagliptin, 177, 188, "sitagliptin", "", +123, Precondition, 192, 272, "patients with type 2 diabetes mellitus inadequately controlled by acarbose alone", "", +4, Type2Diabetes, 206, 230, "type 2 diabetes mellitus", "", +97999, Acarbose, 258, 266, "acarbose", "", +8, Author, 275, 281, "Wang W", "", " \"Wang W\"." +9, Author, 290, 296, "Ning G", "", " \"Ning G\"." +10, Author, 305, 309, "Ma J", "", " \"Ma J\"." +11, Author, 318, 323, "Liu X", "", " \"Liu X\"." +12, Author, 332, 339, "Zheng S", "", " \"Zheng S\"." +13, Author, 348, 352, "Wu F", "", " \"Wu F\"." +14, Author, 367, 371, "Xu L", "", " \"Xu L\"." +15, Author, 380, 392, "O ' Neill EA", "", " \"O ' Neill EA\"." +16, Author, 401, 410, "Fujita KP", "", " \"Fujita KP\"." +17, Author, 425, 433, "Engel SS", "", " \"Engel SS\"." +18, Author, 442, 452, "Kaufman KD", "", " \"Kaufman KD\"." +19, Author, 461, 471, "Shankar RR", "", " \"Shankar RR\"." +20, China, 590, 595, "China", "", " ." +21, China, 682, 687, "China", "", +22, China, 774, 779, "China", "", +23, China, 852, 857, "China", "", +25, USA, 909, 912, "USA", "", +24, China, 983, 988, "China", "", +26, USA, 1060, 1063, "USA", "", +32, ObjectiveDescription, 1078, 1265, "To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy .", "", " \"To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy .\"." +27, Sitagliptin, 1117, 1128, "sitagliptin", "", +144, Precondition, 1160, 1263, "patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy", "", +28, Type2Diabetes, 1174, 1198, "type 2 diabetes mellitus", "", " ." +29, Type2Diabetes, 1201, 1205, "T2DM", "", +98085, Acarbose, 1243, 1251, "acarbose", "", +33, Multicenter, 1307, 1318, "multicenter", "", " ." +34, Randomized, 1321, 1331, "randomized", "", " ." +35, Placebo, 1334, 1341, "placebo", "", +36, DoubleBlind, 1357, 1371, "double - blind", "", " ." +163, Precondition, 1389, 1576, "Patients ( N  =  381 ) with T2DM and inadequate glycemic control ( glycated hemoglobin [ HbA1c ] ≥  7 . 0 % and ≤ 10 . 0 % ) on acarbose monotherapy ( at least 50   mg three times daily )", "", " \"Patients ( N  =  381 ) with T2DM and inadequate glycemic control ( glycated hemoglobin [ HbA1c ] ≥  7 . 0 % and ≤ 10 . 0 % ) on acarbose monotherapy ( at least 50   mg three times daily )\"." +37, NumberPatientsCT, 1406, 1409, "381", "", " \"381\"." +38, Type2Diabetes, 1417, 1421, "T2DM", "", +40, HbA1c, 1456, 1475, "glycated hemoglobin", "", +41, HbA1c, 1478, 1483, "HbA1c", "", +42, Percentage, 1495, 1496, "%", "", +43, Percentage, 1510, 1511, "%", "", +98086, Acarbose, 1517, 1525, "acarbose", "", +166, DoseDescription, 1540, 1574, "at least 50   mg three times daily", "", +164, mg, 1554, 1556, "mg", "", +46, Frequency, 1557, 1574, "three times daily", "", +47, Randomized, 1582, 1592, "randomized", "", +168, AllocationRatio, 1598, 1603, "1 : 1", "", " . ." +48, Sitagliptin, 1637, 1648, "sitagliptin", "", " ." +169, DoseValue, 1649, 1652, "100", "", " \"100\"." +170, mg, 1655, 1657, "mg", "", " ." +50, Placebo, 1670, 1677, "placebo", "", " ." +51, Frequency, 1678, 1688, "once daily", "", " \"once daily\". \"once daily\"." +52, Duration, 1693, 1701, "24 weeks", "", " \"24 weeks\"." +53, TimePoint, 1741, 1749, "baseline", "", " \"24 weeks\"." +55, HbA1c, 1753, 1758, "HbA1c", "", +56, FastingPlasmaGlucose, 1763, 1785, "fasting plasma glucose", "", +57, FastingPlasmaGlucose, 1788, 1791, "FPG", "", +54, TimePoint, 1797, 1804, "Week 24", "", +58, Mean, 1821, 1825, "mean", "", +59, TimePoint, 1826, 1834, "baseline", "", +60, HbA1c, 1835, 1840, "HbA1c", "", " ." +61, Randomized, 1844, 1854, "randomized", "", +62, BaseLineValue, 1868, 1873, "8 . 1", "", " \"8 . 1\". \"8 . 1\"." +63, Percentage, 1874, 1875, "%", "", " ." +71, TimePoint, 1881, 1888, "Week 24", "", " \"Week 24\"." +73, Placebo, 1895, 1902, "placebo", "", +77, LeastSquaresMean, 1918, 1936, "least squares mean", "", " . ." +78, TimePoint, 1950, 1958, "baseline", "", +185, ConfIntervalChangeValue, 1961, 1985, "95 % confidence interval", "", " \"95 % confidence interval\". \"95 % confidence interval\"." +79, HbA1c, 1991, 1996, "HbA1c", "", +80, FastingPlasmaGlucose, 2001, 2004, "FPG", "", " ." +81, Sitagliptin, 2012, 2023, "sitagliptin", "", +106292, DiffGroupAbsValue, 2035, 2043, "- 0 . 62", "", " \"- 0 . 62\"." +65, Percentage, 2044, 2045, "%", "", +106296, DiffGroupAbsValue, 2050, 2057, "- 0 . 8", "", " \"- 0 . 8\"." +89, Millimoles_per_litre, 2060, 2068, "mmol / L", "", +90, PvalueDiff, 2071, 2081, "p  < . 001", "", " \"p  < . 001\". \"p  < . 001\"." +72, TimePoint, 2104, 2111, "Week 24", "", " \"Week 24\". \"Week 24\"." +92, PercentageAffected, 2114, 2120, "37 . 8", "", " \"37 . 8\"." +82, Sitagliptin, 2142, 2153, "sitagliptin", "", +91, HbA1c_target, 2168, 2187, "HbA1c goal of < 7 %", "", " ." +67, Percentage, 2186, 2187, "%", "", +93, PercentageAffected, 2202, 2208, "17 . 2", "", " \"17 . 2\"." +74, Placebo, 2218, 2225, "placebo", "", +94, PvalueDiff, 2234, 2244, "p  < . 001", "", " \"p  < . 001\"." +83, Sitagliptin, 2249, 2260, "Sitagliptin", "", +195, ObservedResult, 2296, 2383, "there were no significant between - group differences in prespecified safety parameters", "", " \"there were no significant between - group differences in prespecified safety parameters\". \"there were no significant between - group differences in prespecified safety parameters\". \"there were no significant between - group differences in prespecified safety parameters\". \"there were no significant between - group differences in prespecified safety parameters\". \"there were no significant between - group differences in prespecified safety parameters\"." +196, SymptomaticHypoglycemia, 2386, 2410, "symptomatic hypoglycemia", "", " ." +197, EndPointDescription, 2413, 2421, "diarrhea", "", " . ." +198, EndPointDescription, 2424, 2438, "abdominal pain", "", " . ." +200, Nausea, 2441, 2447, "nausea", "", " ." +199, EndPointDescription, 2450, 2458, "vomiting", "", " . ." +95, EndPointDescription, 2485, 2507, "serious adverse events", "", " . ." +84, Sitagliptin, 2528, 2539, "sitagliptin", "", +96, PercentageAffected, 2548, 2553, "5 . 2", "", " \"5 . 2\"." +75, Placebo, 2570, 2577, "placebo", "", +97, PercentageAffected, 2580, 2585, "0 . 5", "", " \"0 . 5\"." +85, Sitagliptin, 2613, 2624, "sitagliptin", "", +86, Sitagliptin, 2685, 2696, "Sitagliptin", "", +209, ConclusionComment, 2685, 2868, "Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in glycemic control after 24 weeks of treatment compared to placebo", "", " \"Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in glycemic control after 24 weeks of treatment compared to placebo\"." +98, Duration, 2827, 2835, "24 weeks", "", +76, Placebo, 2861, 2868, "placebo", "", +210, ConclusionComment, 2869, 2963, "when added to treatment of patients with inadequate glycemic control on acarbose monotherapy .", "", " \"when added to treatment of patients with inadequate glycemic control on acarbose monotherapy .\"." +98087, Acarbose, 2941, 2949, "acarbose", "", +103, PMID, 3052, 3060, "28035868", "", " \"28035868\"." diff --git a/data/dm2 28035868_admin.n-triples b/data/dm2 28035868_admin.n-triples new file mode 100644 index 0000000..b8f065a --- /dev/null +++ b/data/dm2 28035868_admin.n-triples @@ -0,0 +1,226 @@ +# RDF export of group: Publication + . + "Publication " . + "A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone ." . + "Wang W" . + "2017" . + "Curr Med Res Opin ." . + "28035868" . + . + "Ning G" . + "Ma J" . + "Liu X" . + "Zheng S" . + "Wu F" . + "Xu L" . + "O ' Neill EA" . + "Fujita KP" . + "Engel SS" . + "Kaufman KD" . + "Shankar RR" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy ." . + "381" . + "24 weeks" . + . + . + . + . + "Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in glycemic control after 24 weeks of treatment compared to placebo" . + . + . + . + . + . + . + . + "when added to treatment of patients with inadequate glycemic control on acarbose monotherapy ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "Patients ( N  =  381 ) with T2DM and inadequate glycemic control ( glycated hemoglobin [ HbA1c ] ≥  7 . 0 % and ≤ 10 . 0 % ) on acarbose monotherapy ( at least 50   mg three times daily )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + "Endpoint d" . + . + . + . + . + . + . + "Endpoint ap" . + . + . + . + . + . + . + "Endpoint n" . + . + . + . + . + . + "Endpoint v" . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm s+a" . + . + . + . + . + . + . + . + . + . + . + . + "Arm s+p" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention s" . + . + "once daily" . + . + . + "Intervention p" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication s" . + . + "100" . + . + . + . + "Medication p" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c s" . + . + "8 . 1" . + "95 % confidence interval" . + "Week 24" . + . + "Outcome hba1c p" . + . + "8 . 1" . + . + "Outcome fpg s" . + . + "95 % confidence interval" . + . + "Outcome fpg p " . + . + . + "Outcome hba1c target s" . + . + "37 . 8" . + "Week 24" . + . + "Outcome hba1c target p " . + . + "17 . 2" . + "Week 24" . + . + "Outcome sh s" . + . + "there were no significant between - group differences in prespecified safety parameters" . + . + "Outcome d s" . + . + "there were no significant between - group differences in prespecified safety parameters" . + . + "Outcome ap s " . + . + "there were no significant between - group differences in prespecified safety parameters" . + . + "Outcome n s" . + . + "there were no significant between - group differences in prespecified safety parameters" . + . + "Outcome v s" . + . + "there were no significant between - group differences in prespecified safety parameters" . + . + "Outcome aes s" . + . + "5 . 2" . + . + "Outcome aes p " . + . + "0 . 5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 62" . + "p  < . 001" . + . + . + . + "DiffBetweenGroups fpg" . + "- 0 . 8" . + "p  < . 001" . + . + . + . + "DiffBetweenGroups hba1c target " . + "p  < . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28035868_akramersunderbrink.annodb b/data/dm2 28035868_akramersunderbrink.annodb new file mode 100644 index 0000000..a30545a --- /dev/null +++ b/data/dm2 28035868_akramersunderbrink.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +67856, Journal, 0, 17, "Curr Med Res Opin", "", +67857, PublicationYear, 20, 24, "2017", "", +67863, Title, 119, 274, "A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone .", "", +67858, Randomized, 121, 131, "randomized", "", +67859, Sitagliptin, 177, 188, "sitagliptin", "", +67860, Type2Diabetes, 206, 230, "type 2 diabetes mellitus", "", +67861, Precondition, 231, 272, "inadequately controlled by acarbose alone", "", +67862, Drug, 258, 266, "acarbose", "", +67864, Author, 275, 281, "Wang W", "", +67865, Author, 290, 296, "Ning G", "", +67866, Author, 305, 309, "Ma J", "", +67867, Author, 318, 323, "Liu X", "", +67868, Author, 332, 339, "Zheng S", "", +67869, Author, 348, 352, "Wu F", "", +67870, Author, 367, 371, "Xu L", "", +67871, Author, 380, 392, "O ' Neill EA", "", +67872, Author, 401, 410, "Fujita KP", "", +67873, Author, 425, 433, "Engel SS", "", +67874, Author, 442, 452, "Kaufman KD", "", +67875, Author, 461, 471, "Shankar RR", "", +67876, China, 590, 595, "China", "", +67877, China, 682, 687, "China", "", +67878, China, 774, 779, "China", "", +67879, China, 852, 857, "China", "", +67881, USA, 909, 912, "USA", "", +67880, China, 983, 988, "China", "", +67882, USA, 1060, 1063, "USA", "", +67888, ObjectiveDescription, 1078, 1265, "To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy .", "", +67883, Sitagliptin, 1117, 1128, "sitagliptin", "", +67884, Type2Diabetes, 1174, 1198, "type 2 diabetes mellitus", "", +67885, Type2Diabetes, 1201, 1205, "T2DM", "", +67886, Precondition, 1212, 1263, "inadequate glycemic control on acarbose monotherapy", "", +67887, Drug, 1243, 1251, "acarbose", "", +67889, Multicenter, 1307, 1318, "multicenter", "", +67890, Randomized, 1321, 1331, "randomized", "", +67891, Placebo, 1334, 1341, "placebo", "", +67892, DoubleBlind, 1357, 1371, "double - blind", "", +67893, NumberPatientsCT, 1406, 1409, "381", "", +67894, Type2Diabetes, 1417, 1421, "T2DM", "", +67895, Precondition, 1426, 1576, "inadequate glycemic control ( glycated hemoglobin [ HbA1c ] ≥  7 . 0 % and ≤ 10 . 0 % ) on acarbose monotherapy ( at least 50   mg three times daily )", "", +67896, HbA1c, 1456, 1475, "glycated hemoglobin", "", +67897, HbA1c, 1478, 1483, "HbA1c", "", +67898, Percentage, 1495, 1496, "%", "", +67899, Percentage, 1510, 1511, "%", "", +67900, Drug, 1517, 1525, "acarbose", "", +67901, DoseValue, 1540, 1556, "at least 50   mg", "", +67902, Frequency, 1557, 1574, "three times daily", "", +67903, Randomized, 1582, 1592, "randomized", "", +67904, Sitagliptin, 1637, 1648, "sitagliptin", "", +67905, DoseValue, 1649, 1657, "100   mg", "", +67906, Placebo, 1670, 1677, "placebo", "", +67907, Frequency, 1678, 1688, "once daily", "", +67908, Duration, 1693, 1701, "24 weeks", "", +67909, TimePoint, 1741, 1749, "baseline", "", +67911, HbA1c, 1753, 1758, "HbA1c", "", +67912, FastingPlasmaGlucose, 1763, 1785, "fasting plasma glucose", "", +67913, FastingPlasmaGlucose, 1788, 1791, "FPG", "", +67910, TimePoint, 1797, 1804, "Week 24", "", +67914, Mean, 1821, 1825, "mean", "", +67915, TimePoint, 1826, 1834, "baseline", "", +67916, HbA1c, 1835, 1840, "HbA1c", "", +67917, Randomized, 1844, 1854, "randomized", "", +67918, BaseLineValue, 1868, 1873, "8 . 1", "", +67919, Percentage, 1874, 1875, "%", "", +67927, TimePoint, 1881, 1888, "Week 24", "", +67929, Placebo, 1895, 1902, "placebo", "", +67933, LeastSquaresMean, 1918, 1936, "least squares mean", "", +67934, TimePoint, 1950, 1958, "baseline", "", +67920, Percentage, 1964, 1965, "%", "", +67935, HbA1c, 1991, 1996, "HbA1c", "", +67936, FastingPlasmaGlucose, 2001, 2004, "FPG", "", +67937, Sitagliptin, 2012, 2023, "sitagliptin", "", +67943, ChangeValue, 2035, 2043, "- 0 . 62", "", +67921, Percentage, 2044, 2045, "%", "", +67944, ChangeValue, 2050, 2057, "- 0 . 8", "", +67945, Millimoles_per_litre, 2060, 2068, "mmol / L", "", +67946, PvalueDiff, 2071, 2081, "p  < . 001", "", +67928, TimePoint, 2104, 2111, "Week 24", "", +67948, PercentageAffected, 2114, 2120, "37 . 8", "", +67922, Percentage, 2121, 2122, "%", "", +67938, Sitagliptin, 2142, 2153, "sitagliptin", "", +67947, HbA1c_target, 2168, 2187, "HbA1c goal of < 7 %", "", +67923, Percentage, 2186, 2187, "%", "", +67949, PercentageAffected, 2202, 2208, "17 . 2", "", +67924, Percentage, 2209, 2210, "%", "", +67930, Placebo, 2218, 2225, "placebo", "", +67950, PvalueDiff, 2234, 2244, "p  < . 001", "", +67939, Sitagliptin, 2249, 2260, "Sitagliptin", "", +67951, EndPointDescription, 2485, 2507, "serious adverse events", "", +67940, Sitagliptin, 2528, 2539, "sitagliptin", "", +67952, PercentageAffected, 2548, 2553, "5 . 2", "", +67925, Percentage, 2554, 2555, "%", "", +67931, Placebo, 2570, 2577, "placebo", "", +67953, PercentageAffected, 2580, 2585, "0 . 5", "", +67926, Percentage, 2586, 2587, "%", "", +67941, Sitagliptin, 2613, 2624, "sitagliptin", "", +67942, Sitagliptin, 2685, 2696, "Sitagliptin", "", +67957, ObjectiveDescription, 2685, 2860, "Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in glycemic control after 24 weeks of treatment compared to", "", +67954, Duration, 2827, 2835, "24 weeks", "", +67932, Placebo, 2861, 2868, "placebo", "", +67958, ObjectiveDescription, 2861, 2963, "placebo when added to treatment of patients with inadequate glycemic control on acarbose monotherapy .", "", +67955, Precondition, 2910, 2961, "inadequate glycemic control on acarbose monotherapy", "", +67956, Drug, 2941, 2949, "acarbose", "", +67959, PMID, 3052, 3060, "28035868", "", diff --git a/data/dm2 28035868_akramersunderbrink.n-triples b/data/dm2 28035868_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28035868_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28035868_export.csv b/data/dm2 28035868_export.csv new file mode 100644 index 0000000..584bc31 --- /dev/null +++ b/data/dm2 28035868_export.csv @@ -0,0 +1,657 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +255, 1, 1, 1, 0, 4, 0, 4, "Curr" +255, 1, 2, 2, 5, 8, 5, 8, "Med" +255, 1, 3, 3, 9, 12, 9, 12, "Res" +255, 1, 4, 4, 13, 17, 13, 17, "Opin" +255, 1, 5, 5, 18, 19, 18, 19, "." +255, 2, 1, 6, 0, 4, 20, 24, "2017" +255, 2, 2, 7, 5, 8, 25, 28, "Apr" +255, 2, 3, 8, 9, 10, 29, 30, ";" +255, 2, 4, 9, 11, 13, 31, 33, "33" +255, 2, 5, 10, 14, 15, 34, 35, "(" +255, 2, 6, 11, 16, 17, 36, 37, "4" +255, 2, 7, 12, 18, 19, 38, 39, ")" +255, 2, 8, 13, 20, 21, 40, 41, ":" +255, 2, 9, 14, 22, 25, 42, 45, "693" +255, 2, 10, 15, 26, 27, 46, 47, "-" +255, 2, 11, 16, 28, 31, 48, 51, "699" +255, 2, 12, 17, 32, 33, 52, 53, "." +255, 2, 13, 18, 34, 37, 54, 57, "doi" +255, 2, 14, 19, 38, 39, 58, 59, ":" +255, 2, 15, 20, 40, 42, 60, 62, "10" +255, 2, 16, 21, 43, 44, 63, 64, "." +255, 2, 17, 22, 45, 49, 65, 69, "1080" +255, 2, 18, 23, 50, 51, 70, 71, "/" +255, 2, 19, 24, 52, 60, 72, 80, "03007995" +255, 2, 20, 25, 61, 62, 81, 82, "." +255, 2, 21, 26, 63, 67, 83, 87, "2016" +255, 2, 22, 27, 68, 69, 88, 89, "." +255, 2, 23, 28, 70, 77, 90, 97, "1277200" +255, 2, 24, 29, 78, 79, 98, 99, "." +255, 3, 1, 30, 0, 4, 100, 104, "Epub" +255, 3, 2, 31, 5, 9, 105, 109, "2017" +255, 3, 3, 32, 10, 13, 110, 113, "Jan" +255, 3, 4, 33, 14, 16, 114, 116, "25" +255, 3, 5, 34, 17, 18, 117, 118, "." +255, 4, 1, 35, 0, 1, 119, 120, "A" +255, 4, 2, 36, 2, 12, 121, 131, "randomized" +255, 4, 3, 37, 13, 21, 132, 140, "clinical" +255, 4, 4, 38, 22, 27, 141, 146, "trial" +255, 4, 5, 39, 28, 30, 147, 149, "of" +255, 4, 6, 40, 31, 34, 150, 153, "the" +255, 4, 7, 41, 35, 41, 154, 160, "safety" +255, 4, 8, 42, 42, 45, 161, 164, "and" +255, 4, 9, 43, 46, 54, 165, 173, "efficacy" +255, 4, 10, 44, 55, 57, 174, 176, "of" +255, 4, 11, 45, 58, 69, 177, 188, "sitagliptin" +255, 4, 12, 46, 70, 72, 189, 191, "in" +255, 4, 13, 47, 73, 81, 192, 200, "patients" +255, 4, 14, 48, 82, 86, 201, 205, "with" +255, 4, 15, 49, 87, 91, 206, 210, "type" +255, 4, 16, 50, 92, 93, 211, 212, "2" +255, 4, 17, 51, 94, 102, 213, 221, "diabetes" +255, 4, 18, 52, 103, 111, 222, 230, "mellitus" +255, 4, 19, 53, 112, 124, 231, 243, "inadequately" +255, 4, 20, 54, 125, 135, 244, 254, "controlled" +255, 4, 21, 55, 136, 138, 255, 257, "by" +255, 4, 22, 56, 139, 147, 258, 266, "acarbose" +255, 4, 23, 57, 148, 153, 267, 272, "alone" +255, 4, 24, 58, 154, 155, 273, 274, "." +255, 5, 1, 59, 0, 4, 275, 279, "Wang" +255, 5, 2, 60, 5, 6, 280, 281, "W" +255, 5, 3, 61, 7, 8, 282, 283, "(" +255, 5, 4, 62, 9, 10, 284, 285, "1" +255, 5, 5, 63, 11, 12, 286, 287, ")" +255, 5, 6, 64, 13, 14, 288, 289, "," +255, 5, 7, 65, 15, 19, 290, 294, "Ning" +255, 5, 8, 66, 20, 21, 295, 296, "G" +255, 5, 9, 67, 22, 23, 297, 298, "(" +255, 5, 10, 68, 24, 25, 299, 300, "1" +255, 5, 11, 69, 26, 27, 301, 302, ")" +255, 5, 12, 70, 28, 29, 303, 304, "," +255, 5, 13, 71, 30, 32, 305, 307, "Ma" +255, 5, 14, 72, 33, 34, 308, 309, "J" +255, 5, 15, 73, 35, 36, 310, 311, "(" +255, 5, 16, 74, 37, 38, 312, 313, "2" +255, 5, 17, 75, 39, 40, 314, 315, ")" +255, 5, 18, 76, 41, 42, 316, 317, "," +255, 5, 19, 77, 43, 46, 318, 321, "Liu" +255, 5, 20, 78, 47, 48, 322, 323, "X" +255, 5, 21, 79, 49, 50, 324, 325, "(" +255, 5, 22, 80, 51, 52, 326, 327, "3" +255, 5, 23, 81, 53, 54, 328, 329, ")" +255, 5, 24, 82, 55, 56, 330, 331, "," +255, 5, 25, 83, 57, 62, 332, 337, "Zheng" +255, 5, 26, 84, 63, 64, 338, 339, "S" +255, 5, 27, 85, 65, 66, 340, 341, "(" +255, 5, 28, 86, 67, 68, 342, 343, "4" +255, 5, 29, 87, 69, 70, 344, 345, ")" +255, 5, 30, 88, 71, 72, 346, 347, "," +255, 5, 31, 89, 73, 75, 348, 350, "Wu" +255, 5, 32, 90, 76, 77, 351, 352, "F" +255, 5, 33, 91, 78, 79, 353, 354, "(" +255, 5, 34, 92, 80, 81, 355, 356, "5" +255, 5, 35, 93, 82, 83, 357, 358, ")" +255, 5, 36, 94, 84, 85, 359, 360, "(" +255, 5, 37, 95, 86, 87, 361, 362, "6" +255, 5, 38, 96, 88, 89, 363, 364, ")" +255, 5, 39, 97, 90, 91, 365, 366, "," +255, 5, 40, 98, 92, 94, 367, 369, "Xu" +255, 5, 41, 99, 95, 96, 370, 371, "L" +255, 5, 42, 100, 97, 98, 372, 373, "(" +255, 5, 43, 101, 99, 100, 374, 375, "5" +255, 5, 44, 102, 101, 102, 376, 377, ")" +255, 5, 45, 103, 103, 104, 378, 379, "," +255, 5, 46, 104, 105, 106, 380, 381, "O" +255, 5, 47, 105, 107, 108, 382, 383, "'" +255, 5, 48, 106, 109, 114, 384, 389, "Neill" +255, 5, 49, 107, 115, 117, 390, 392, "EA" +255, 5, 50, 108, 118, 119, 393, 394, "(" +255, 5, 51, 109, 120, 121, 395, 396, "5" +255, 5, 52, 110, 122, 123, 397, 398, ")" +255, 5, 53, 111, 124, 125, 399, 400, "," +255, 5, 54, 112, 126, 132, 401, 407, "Fujita" +255, 5, 55, 113, 133, 135, 408, 410, "KP" +255, 5, 56, 114, 136, 137, 411, 412, "(" +255, 5, 57, 115, 138, 139, 413, 414, "5" +255, 5, 58, 116, 140, 141, 415, 416, ")" +255, 5, 59, 117, 142, 143, 417, 418, "(" +255, 5, 60, 118, 144, 145, 419, 420, "7" +255, 5, 61, 119, 146, 147, 421, 422, ")" +255, 5, 62, 120, 148, 149, 423, 424, "," +255, 5, 63, 121, 150, 155, 425, 430, "Engel" +255, 5, 64, 122, 156, 158, 431, 433, "SS" +255, 5, 65, 123, 159, 160, 434, 435, "(" +255, 5, 66, 124, 161, 162, 436, 437, "5" +255, 5, 67, 125, 163, 164, 438, 439, ")" +255, 5, 68, 126, 165, 166, 440, 441, "," +255, 5, 69, 127, 167, 174, 442, 449, "Kaufman" +255, 5, 70, 128, 175, 177, 450, 452, "KD" +255, 5, 71, 129, 178, 179, 453, 454, "(" +255, 5, 72, 130, 180, 181, 455, 456, "5" +255, 5, 73, 131, 182, 183, 457, 458, ")" +255, 5, 74, 132, 184, 185, 459, 460, "," +255, 5, 75, 133, 186, 193, 461, 468, "Shankar" +255, 5, 76, 134, 194, 196, 469, 471, "RR" +255, 5, 77, 135, 197, 198, 472, 473, "(" +255, 5, 78, 136, 199, 200, 474, 475, "5" +255, 5, 79, 137, 201, 202, 476, 477, ")" +255, 5, 80, 138, 203, 204, 478, 479, "." +255, 6, 1, 139, 0, 6, 480, 486, "Author" +255, 6, 2, 140, 7, 18, 487, 498, "information" +255, 6, 3, 141, 19, 20, 499, 500, ":" +255, 6, 4, 142, 21, 22, 501, 502, "(" +255, 6, 5, 143, 23, 24, 503, 504, "1" +255, 6, 6, 144, 25, 26, 505, 506, ")" +255, 6, 7, 145, 27, 28, 507, 508, "a" +255, 6, 8, 146, 29, 35, 509, 515, "Ruijin" +255, 6, 9, 147, 36, 44, 516, 524, "Hospital" +255, 6, 10, 148, 45, 46, 525, 526, "," +255, 6, 11, 149, 47, 53, 527, 533, "School" +255, 6, 12, 150, 54, 56, 534, 536, "of" +255, 6, 13, 151, 57, 65, 537, 545, "Medicine" +255, 6, 14, 152, 66, 67, 546, 547, "," +255, 6, 15, 153, 68, 76, 548, 556, "Shanghai" +255, 6, 16, 154, 77, 85, 557, 565, "Jiaotong" +255, 6, 17, 155, 86, 96, 566, 576, "University" +255, 6, 18, 156, 97, 98, 577, 578, "," +255, 6, 19, 157, 99, 107, 579, 587, "Shanghai" +255, 6, 20, 158, 108, 109, 588, 589, "," +255, 6, 21, 159, 110, 115, 590, 595, "China" +255, 6, 22, 160, 116, 117, 596, 597, "." +255, 7, 1, 161, 0, 1, 598, 599, "(" +255, 7, 2, 162, 2, 3, 600, 601, "2" +255, 7, 3, 163, 4, 5, 602, 603, ")" +255, 7, 4, 164, 6, 7, 604, 605, "b" +255, 7, 5, 165, 8, 15, 606, 613, "Nanjing" +255, 7, 6, 166, 16, 21, 614, 619, "First" +255, 7, 7, 167, 22, 30, 620, 628, "Hospital" +255, 7, 8, 168, 31, 41, 629, 639, "Affiliated" +255, 7, 9, 169, 42, 44, 640, 642, "to" +255, 7, 10, 170, 45, 52, 643, 650, "Nanjing" +255, 7, 11, 171, 53, 60, 651, 658, "Medical" +255, 7, 12, 172, 61, 71, 659, 669, "University" +255, 7, 13, 173, 72, 73, 670, 671, "," +255, 7, 14, 174, 74, 81, 672, 679, "Nanjing" +255, 7, 15, 175, 82, 83, 680, 681, "," +255, 7, 16, 176, 84, 89, 682, 687, "China" +255, 7, 17, 177, 90, 91, 688, 689, "." +255, 8, 1, 178, 0, 1, 690, 691, "(" +255, 8, 2, 179, 2, 3, 692, 693, "3" +255, 8, 3, 180, 4, 5, 694, 695, ")" +255, 8, 4, 181, 6, 7, 696, 697, "c" +255, 8, 5, 182, 8, 11, 698, 701, "The" +255, 8, 6, 183, 12, 17, 702, 707, "First" +255, 8, 7, 184, 18, 28, 708, 718, "Affiliated" +255, 8, 8, 185, 29, 37, 719, 727, "Hospital" +255, 8, 9, 186, 38, 40, 728, 730, "of" +255, 8, 10, 187, 41, 47, 731, 737, "Harbin" +255, 8, 11, 188, 48, 55, 738, 745, "Medical" +255, 8, 12, 189, 56, 66, 746, 756, "University" +255, 8, 13, 190, 67, 68, 757, 758, "," +255, 8, 14, 191, 69, 81, 759, 771, "Heilongjiang" +255, 8, 15, 192, 82, 83, 772, 773, "," +255, 8, 16, 193, 84, 89, 774, 779, "China" +255, 8, 17, 194, 90, 91, 780, 781, "." +255, 9, 1, 195, 0, 1, 782, 783, "(" +255, 9, 2, 196, 2, 3, 784, 785, "4" +255, 9, 3, 197, 4, 5, 786, 787, ")" +255, 9, 4, 198, 6, 7, 788, 789, "d" +255, 9, 5, 199, 8, 11, 790, 793, "The" +255, 9, 6, 200, 12, 18, 794, 800, "Second" +255, 9, 7, 201, 19, 27, 801, 809, "Hospital" +255, 9, 8, 202, 28, 30, 810, 812, "of" +255, 9, 9, 203, 31, 38, 813, 820, "Tianjin" +255, 9, 10, 204, 39, 46, 821, 828, "Medical" +255, 9, 11, 205, 47, 57, 829, 839, "University" +255, 9, 12, 206, 58, 59, 840, 841, "," +255, 9, 13, 207, 60, 67, 842, 849, "Tianjin" +255, 9, 14, 208, 68, 69, 850, 851, "," +255, 9, 15, 209, 70, 75, 852, 857, "China" +255, 9, 16, 210, 76, 77, 858, 859, "." +255, 10, 1, 211, 0, 1, 860, 861, "(" +255, 10, 2, 212, 2, 3, 862, 863, "5" +255, 10, 3, 213, 4, 5, 864, 865, ")" +255, 10, 4, 214, 6, 7, 866, 867, "e" +255, 10, 5, 215, 8, 13, 868, 873, "Merck" +255, 10, 6, 216, 14, 15, 874, 875, "&" +255, 10, 7, 217, 16, 18, 876, 878, "Co" +255, 10, 8, 218, 19, 20, 879, 880, "." +255, 10, 9, 219, 21, 22, 881, 882, "," +255, 10, 10, 220, 23, 26, 883, 886, "Inc" +255, 10, 11, 221, 27, 28, 887, 888, "." +255, 10, 12, 222, 29, 30, 889, 890, "," +255, 10, 13, 223, 31, 41, 891, 901, "Kenilworth" +255, 10, 14, 224, 42, 43, 902, 903, "," +255, 10, 15, 225, 44, 46, 904, 906, "NJ" +255, 10, 16, 226, 47, 48, 907, 908, "," +255, 10, 17, 227, 49, 52, 909, 912, "USA" +255, 10, 18, 228, 53, 54, 913, 914, "." +255, 11, 1, 229, 0, 1, 915, 916, "(" +255, 11, 2, 230, 2, 3, 917, 918, "6" +255, 11, 3, 231, 4, 5, 919, 920, ")" +255, 11, 4, 232, 6, 7, 921, 922, "f" +255, 11, 5, 233, 8, 15, 923, 930, "Current" +255, 11, 6, 234, 16, 23, 931, 938, "address" +255, 11, 7, 235, 24, 25, 939, 940, ":" +255, 11, 8, 236, 26, 31, 941, 946, "Roche" +255, 11, 9, 237, 32, 33, 947, 948, "(" +255, 11, 10, 238, 34, 39, 949, 954, "China" +255, 11, 11, 239, 40, 41, 955, 956, ")" +255, 11, 12, 240, 42, 49, 957, 964, "Holding" +255, 11, 13, 241, 50, 53, 965, 968, "Ltd" +255, 11, 14, 242, 54, 55, 969, 970, "." +255, 11, 15, 243, 56, 57, 971, 972, "," +255, 11, 16, 244, 58, 65, 973, 980, "Beijing" +255, 11, 17, 245, 66, 67, 981, 982, "," +255, 11, 18, 246, 68, 73, 983, 988, "China" +255, 11, 19, 247, 74, 75, 989, 990, "." +255, 12, 1, 248, 0, 1, 991, 992, "(" +255, 12, 2, 249, 2, 3, 993, 994, "7" +255, 12, 3, 250, 4, 5, 995, 996, ")" +255, 12, 4, 251, 6, 7, 997, 998, "g" +255, 12, 5, 252, 8, 15, 999, 1006, "Current" +255, 12, 6, 253, 16, 23, 1007, 1014, "address" +255, 12, 7, 254, 24, 25, 1015, 1016, ":" +255, 12, 8, 255, 26, 33, 1017, 1024, "Alexion" +255, 12, 9, 256, 34, 49, 1025, 1040, "Pharmaceuticals" +255, 12, 10, 257, 50, 51, 1041, 1042, "," +255, 12, 11, 258, 52, 55, 1043, 1046, "New" +255, 12, 12, 259, 56, 61, 1047, 1052, "Haven" +255, 12, 13, 260, 62, 63, 1053, 1054, "," +255, 12, 14, 261, 64, 66, 1055, 1057, "CT" +255, 12, 15, 262, 67, 68, 1058, 1059, "," +255, 12, 16, 263, 69, 72, 1060, 1063, "USA" +255, 12, 17, 264, 73, 74, 1064, 1065, "." +255, 13, 1, 265, 0, 9, 1066, 1075, "OBJECTIVE" +255, 13, 2, 266, 10, 11, 1076, 1077, ":" +255, 13, 3, 267, 12, 14, 1078, 1080, "To" +255, 13, 4, 268, 15, 23, 1081, 1089, "evaluate" +255, 13, 5, 269, 24, 27, 1090, 1093, "the" +255, 13, 6, 270, 28, 34, 1094, 1100, "safety" +255, 13, 7, 271, 35, 38, 1101, 1104, "and" +255, 13, 8, 272, 39, 47, 1105, 1113, "efficacy" +255, 13, 9, 273, 48, 50, 1114, 1116, "of" +255, 13, 10, 274, 51, 62, 1117, 1128, "sitagliptin" +255, 13, 11, 275, 63, 67, 1129, 1133, "when" +255, 13, 12, 276, 68, 73, 1134, 1139, "added" +255, 13, 13, 277, 74, 76, 1140, 1142, "to" +255, 13, 14, 278, 77, 80, 1143, 1146, "the" +255, 13, 15, 279, 81, 90, 1147, 1156, "treatment" +255, 13, 16, 280, 91, 93, 1157, 1159, "of" +255, 13, 17, 281, 94, 102, 1160, 1168, "patients" +255, 13, 18, 282, 103, 107, 1169, 1173, "with" +255, 13, 19, 283, 108, 112, 1174, 1178, "type" +255, 13, 20, 284, 113, 114, 1179, 1180, "2" +255, 13, 21, 285, 115, 123, 1181, 1189, "diabetes" +255, 13, 22, 286, 124, 132, 1190, 1198, "mellitus" +255, 13, 23, 287, 133, 134, 1199, 1200, "(" +255, 13, 24, 288, 135, 139, 1201, 1205, "T2DM" +255, 13, 25, 289, 140, 141, 1206, 1207, ")" +255, 13, 26, 290, 142, 145, 1208, 1211, "and" +255, 13, 27, 291, 146, 156, 1212, 1222, "inadequate" +255, 13, 28, 292, 157, 165, 1223, 1231, "glycemic" +255, 13, 29, 293, 166, 173, 1232, 1239, "control" +255, 13, 30, 294, 174, 176, 1240, 1242, "on" +255, 13, 31, 295, 177, 185, 1243, 1251, "acarbose" +255, 13, 32, 296, 186, 197, 1252, 1263, "monotherapy" +255, 13, 33, 297, 198, 199, 1264, 1265, "." +255, 14, 1, 298, 0, 8, 1266, 1274, "RESEARCH" +255, 14, 2, 299, 9, 15, 1275, 1281, "DESIGN" +255, 14, 3, 300, 16, 19, 1282, 1285, "AND" +255, 14, 4, 301, 20, 27, 1286, 1293, "METHODS" +255, 14, 5, 302, 28, 29, 1294, 1295, ":" +255, 14, 6, 303, 30, 34, 1296, 1300, "This" +255, 14, 7, 304, 35, 38, 1301, 1304, "was" +255, 14, 8, 305, 39, 40, 1305, 1306, "a" +255, 14, 9, 306, 41, 52, 1307, 1318, "multicenter" +255, 14, 10, 307, 53, 54, 1319, 1320, "," +255, 14, 11, 308, 55, 65, 1321, 1331, "randomized" +255, 14, 12, 309, 66, 67, 1332, 1333, "," +255, 14, 13, 310, 68, 75, 1334, 1341, "placebo" +255, 14, 14, 311, 76, 77, 1342, 1343, "-" +255, 14, 15, 312, 78, 88, 1344, 1354, "controlled" +255, 14, 16, 313, 89, 90, 1355, 1356, "," +255, 14, 17, 314, 91, 97, 1357, 1363, "double" +255, 14, 18, 315, 98, 99, 1364, 1365, "-" +255, 14, 19, 316, 100, 105, 1366, 1371, "blind" +255, 14, 20, 317, 106, 114, 1372, 1380, "clinical" +255, 14, 21, 318, 115, 120, 1381, 1386, "trial" +255, 14, 22, 319, 121, 122, 1387, 1388, "." +255, 15, 1, 320, 0, 8, 1389, 1397, "Patients" +255, 15, 2, 321, 9, 10, 1398, 1399, "(" +255, 15, 3, 322, 11, 12, 1400, 1401, "N" +255, 15, 4, 323, 13, 16, 1402, 1405, " = " +255, 15, 5, 324, 17, 20, 1406, 1409, "381" +255, 15, 6, 325, 21, 22, 1410, 1411, ")" +255, 15, 7, 326, 23, 27, 1412, 1416, "with" +255, 15, 8, 327, 28, 32, 1417, 1421, "T2DM" +255, 15, 9, 328, 33, 36, 1422, 1425, "and" +255, 15, 10, 329, 37, 47, 1426, 1436, "inadequate" +255, 15, 11, 330, 48, 56, 1437, 1445, "glycemic" +255, 15, 12, 331, 57, 64, 1446, 1453, "control" +255, 15, 13, 332, 65, 66, 1454, 1455, "(" +255, 15, 14, 333, 67, 75, 1456, 1464, "glycated" +255, 15, 15, 334, 76, 86, 1465, 1475, "hemoglobin" +255, 15, 16, 335, 87, 88, 1476, 1477, "[" +255, 15, 17, 336, 89, 94, 1478, 1483, "HbA1c" +255, 15, 18, 337, 95, 96, 1484, 1485, "]" +255, 15, 19, 338, 97, 99, 1486, 1488, "≥ " +255, 15, 20, 339, 100, 101, 1489, 1490, "7" +255, 15, 21, 340, 102, 103, 1491, 1492, "." +255, 15, 22, 341, 104, 105, 1493, 1494, "0" +255, 15, 23, 342, 106, 107, 1495, 1496, "%" +255, 15, 24, 343, 108, 111, 1497, 1500, "and" +255, 15, 25, 344, 112, 113, 1501, 1502, "≤" +255, 15, 26, 345, 114, 116, 1503, 1505, "10" +255, 15, 27, 346, 117, 118, 1506, 1507, "." +255, 15, 28, 347, 119, 120, 1508, 1509, "0" +255, 15, 29, 348, 121, 122, 1510, 1511, "%" +255, 15, 30, 349, 123, 124, 1512, 1513, ")" +255, 15, 31, 350, 125, 127, 1514, 1516, "on" +255, 15, 32, 351, 128, 136, 1517, 1525, "acarbose" +255, 15, 33, 352, 137, 148, 1526, 1537, "monotherapy" +255, 15, 34, 353, 149, 150, 1538, 1539, "(" +255, 15, 35, 354, 151, 153, 1540, 1542, "at" +255, 15, 36, 355, 154, 159, 1543, 1548, "least" +255, 15, 37, 356, 160, 162, 1549, 1551, "50" +255, 15, 38, 357, 163, 164, 1552, 1553, " " +255, 15, 39, 358, 165, 167, 1554, 1556, "mg" +255, 15, 40, 359, 168, 173, 1557, 1562, "three" +255, 15, 41, 360, 174, 179, 1563, 1568, "times" +255, 15, 42, 361, 180, 185, 1569, 1574, "daily" +255, 15, 43, 362, 186, 187, 1575, 1576, ")" +255, 15, 44, 363, 188, 192, 1577, 1581, "were" +255, 15, 45, 364, 193, 203, 1582, 1592, "randomized" +255, 15, 46, 365, 204, 206, 1593, 1595, "in" +255, 15, 47, 366, 207, 208, 1596, 1597, "a" +255, 15, 48, 367, 209, 210, 1598, 1599, "1" +255, 15, 49, 368, 211, 212, 1600, 1601, ":" +255, 15, 50, 369, 213, 214, 1602, 1603, "1" +255, 15, 51, 370, 215, 220, 1604, 1609, "ratio" +255, 15, 52, 371, 221, 223, 1610, 1612, "to" +255, 15, 53, 372, 224, 231, 1613, 1620, "receive" +255, 15, 54, 373, 232, 235, 1621, 1624, "the" +255, 15, 55, 374, 236, 244, 1625, 1633, "addition" +255, 15, 56, 375, 245, 247, 1634, 1636, "of" +255, 15, 57, 376, 248, 259, 1637, 1648, "sitagliptin" +255, 15, 58, 377, 260, 263, 1649, 1652, "100" +255, 15, 59, 378, 264, 265, 1653, 1654, " " +255, 15, 60, 379, 266, 268, 1655, 1657, "mg" +255, 15, 61, 380, 269, 271, 1658, 1660, "or" +255, 15, 62, 381, 272, 280, 1661, 1669, "matching" +255, 15, 63, 382, 281, 288, 1670, 1677, "placebo" +255, 15, 64, 383, 289, 293, 1678, 1682, "once" +255, 15, 65, 384, 294, 299, 1683, 1688, "daily" +255, 15, 66, 385, 300, 303, 1689, 1692, "for" +255, 15, 67, 386, 304, 306, 1693, 1695, "24" +255, 15, 68, 387, 307, 312, 1696, 1701, "weeks" +255, 15, 69, 388, 313, 314, 1702, 1703, "." +255, 16, 1, 389, 0, 4, 1704, 1708, "MAIN" +255, 16, 2, 390, 5, 12, 1709, 1716, "OUTCOME" +255, 16, 3, 391, 13, 21, 1717, 1725, "MEASURES" +255, 16, 4, 392, 22, 23, 1726, 1727, ":" +255, 16, 5, 393, 24, 31, 1728, 1735, "Changes" +255, 16, 6, 394, 32, 36, 1736, 1740, "from" +255, 16, 7, 395, 37, 45, 1741, 1749, "baseline" +255, 16, 8, 396, 46, 48, 1750, 1752, "in" +255, 16, 9, 397, 49, 54, 1753, 1758, "HbA1c" +255, 16, 10, 398, 55, 58, 1759, 1762, "and" +255, 16, 11, 399, 59, 66, 1763, 1770, "fasting" +255, 16, 12, 400, 67, 73, 1771, 1777, "plasma" +255, 16, 13, 401, 74, 81, 1778, 1785, "glucose" +255, 16, 14, 402, 82, 83, 1786, 1787, "(" +255, 16, 15, 403, 84, 87, 1788, 1791, "FPG" +255, 16, 16, 404, 88, 89, 1792, 1793, ")" +255, 16, 17, 405, 90, 92, 1794, 1796, "at" +255, 16, 18, 406, 93, 97, 1797, 1801, "Week" +255, 16, 19, 407, 98, 100, 1802, 1804, "24" +255, 16, 20, 408, 101, 102, 1805, 1806, "." +255, 17, 1, 409, 0, 7, 1807, 1814, "RESULTS" +255, 17, 2, 410, 8, 9, 1815, 1816, ":" +255, 17, 3, 411, 10, 13, 1817, 1820, "The" +255, 17, 4, 412, 14, 18, 1821, 1825, "mean" +255, 17, 5, 413, 19, 27, 1826, 1834, "baseline" +255, 17, 6, 414, 28, 33, 1835, 1840, "HbA1c" +255, 17, 7, 415, 34, 36, 1841, 1843, "in" +255, 17, 8, 416, 37, 47, 1844, 1854, "randomized" +255, 17, 9, 417, 48, 56, 1855, 1863, "patients" +255, 17, 10, 418, 57, 60, 1864, 1867, "was" +255, 17, 11, 419, 61, 62, 1868, 1869, "8" +255, 17, 12, 420, 63, 64, 1870, 1871, "." +255, 17, 13, 421, 65, 66, 1872, 1873, "1" +255, 17, 14, 422, 67, 68, 1874, 1875, "%" +255, 17, 15, 423, 69, 70, 1876, 1877, "." +255, 18, 1, 424, 0, 2, 1878, 1880, "At" +255, 18, 2, 425, 3, 7, 1881, 1885, "Week" +255, 18, 3, 426, 8, 10, 1886, 1888, "24" +255, 18, 4, 427, 11, 12, 1889, 1890, "," +255, 18, 5, 428, 13, 16, 1891, 1894, "the" +255, 18, 6, 429, 17, 24, 1895, 1902, "placebo" +255, 18, 7, 430, 25, 26, 1903, 1904, "-" +255, 18, 8, 431, 27, 37, 1905, 1915, "controlled" +255, 18, 9, 432, 38, 39, 1916, 1917, "," +255, 18, 10, 433, 40, 45, 1918, 1923, "least" +255, 18, 11, 434, 46, 53, 1924, 1931, "squares" +255, 18, 12, 435, 54, 58, 1932, 1936, "mean" +255, 18, 13, 436, 59, 66, 1937, 1944, "changes" +255, 18, 14, 437, 67, 71, 1945, 1949, "from" +255, 18, 15, 438, 72, 80, 1950, 1958, "baseline" +255, 18, 16, 439, 81, 82, 1959, 1960, "(" +255, 18, 17, 440, 83, 85, 1961, 1963, "95" +255, 18, 18, 441, 86, 87, 1964, 1965, "%" +255, 18, 19, 442, 88, 98, 1966, 1976, "confidence" +255, 18, 20, 443, 99, 107, 1977, 1985, "interval" +255, 18, 21, 444, 108, 109, 1986, 1987, ")" +255, 18, 22, 445, 110, 112, 1988, 1990, "in" +255, 18, 23, 446, 113, 118, 1991, 1996, "HbA1c" +255, 18, 24, 447, 119, 122, 1997, 2000, "and" +255, 18, 25, 448, 123, 126, 2001, 2004, "FPG" +255, 18, 26, 449, 127, 129, 2005, 2007, "in" +255, 18, 27, 450, 130, 133, 2008, 2011, "the" +255, 18, 28, 451, 134, 145, 2012, 2023, "sitagliptin" +255, 18, 29, 452, 146, 151, 2024, 2029, "group" +255, 18, 30, 453, 152, 156, 2030, 2034, "were" +255, 18, 31, 454, 157, 158, 2035, 2036, "-" +255, 18, 32, 455, 159, 160, 2037, 2038, "0" +255, 18, 33, 456, 161, 162, 2039, 2040, "." +255, 18, 34, 457, 163, 165, 2041, 2043, "62" +255, 18, 35, 458, 166, 167, 2044, 2045, "%" +255, 18, 36, 459, 168, 171, 2046, 2049, "and" +255, 18, 37, 460, 172, 173, 2050, 2051, "-" +255, 18, 38, 461, 174, 175, 2052, 2053, "0" +255, 18, 39, 462, 176, 177, 2054, 2055, "." +255, 18, 40, 463, 178, 179, 2056, 2057, "8" +255, 18, 41, 464, 180, 181, 2058, 2059, " " +255, 18, 42, 465, 182, 186, 2060, 2064, "mmol" +255, 18, 43, 466, 187, 188, 2065, 2066, "/" +255, 18, 44, 467, 189, 190, 2067, 2068, "L" +255, 18, 45, 468, 191, 192, 2069, 2070, "(" +255, 18, 46, 469, 193, 194, 2071, 2072, "p" +255, 18, 47, 470, 195, 199, 2073, 2077, " < ." +255, 18, 48, 471, 200, 203, 2078, 2081, "001" +255, 18, 49, 472, 204, 205, 2082, 2083, ")" +255, 18, 50, 473, 206, 207, 2084, 2085, "," +255, 18, 51, 474, 208, 220, 2086, 2098, "respectively" +255, 18, 52, 475, 221, 222, 2099, 2100, "." +255, 19, 1, 476, 0, 2, 2101, 2103, "At" +255, 19, 2, 477, 3, 7, 2104, 2108, "Week" +255, 19, 3, 478, 8, 10, 2109, 2111, "24" +255, 19, 4, 479, 11, 12, 2112, 2113, "," +255, 19, 5, 480, 13, 15, 2114, 2116, "37" +255, 19, 6, 481, 16, 17, 2117, 2118, "." +255, 19, 7, 482, 18, 19, 2119, 2120, "8" +255, 19, 8, 483, 20, 21, 2121, 2122, "%" +255, 19, 9, 484, 22, 24, 2123, 2125, "of" +255, 19, 10, 485, 25, 33, 2126, 2134, "patients" +255, 19, 11, 486, 34, 36, 2135, 2137, "in" +255, 19, 12, 487, 37, 40, 2138, 2141, "the" +255, 19, 13, 488, 41, 52, 2142, 2153, "sitagliptin" +255, 19, 14, 489, 53, 58, 2154, 2159, "group" +255, 19, 15, 490, 59, 63, 2160, 2164, "were" +255, 19, 16, 491, 64, 66, 2165, 2167, "at" +255, 19, 17, 492, 67, 72, 2168, 2173, "HbA1c" +255, 19, 18, 493, 73, 77, 2174, 2178, "goal" +255, 19, 19, 494, 78, 80, 2179, 2181, "of" +255, 19, 20, 495, 81, 82, 2182, 2183, "<" +255, 19, 21, 496, 83, 84, 2184, 2185, "7" +255, 19, 22, 497, 85, 86, 2186, 2187, "%" +255, 19, 23, 498, 87, 95, 2188, 2196, "compared" +255, 19, 24, 499, 96, 100, 2197, 2201, "with" +255, 19, 25, 500, 101, 103, 2202, 2204, "17" +255, 19, 26, 501, 104, 105, 2205, 2206, "." +255, 19, 27, 502, 106, 107, 2207, 2208, "2" +255, 19, 28, 503, 108, 109, 2209, 2210, "%" +255, 19, 29, 504, 110, 112, 2211, 2213, "in" +255, 19, 30, 505, 113, 116, 2214, 2217, "the" +255, 19, 31, 506, 117, 124, 2218, 2225, "placebo" +255, 19, 32, 507, 125, 130, 2226, 2231, "group" +255, 19, 33, 508, 131, 132, 2232, 2233, "(" +255, 19, 34, 509, 133, 134, 2234, 2235, "p" +255, 19, 35, 510, 135, 139, 2236, 2240, " < ." +255, 19, 36, 511, 140, 143, 2241, 2244, "001" +255, 19, 37, 512, 144, 145, 2245, 2246, ")" +255, 19, 38, 513, 146, 147, 2247, 2248, "." +255, 20, 1, 514, 0, 11, 2249, 2260, "Sitagliptin" +255, 20, 2, 515, 12, 15, 2261, 2264, "was" +255, 20, 3, 516, 16, 25, 2265, 2274, "generally" +255, 20, 4, 517, 26, 30, 2275, 2279, "well" +255, 20, 5, 518, 31, 40, 2280, 2289, "tolerated" +255, 20, 6, 519, 41, 42, 2290, 2291, "," +255, 20, 7, 520, 43, 46, 2292, 2295, "and" +255, 20, 8, 521, 47, 52, 2296, 2301, "there" +255, 20, 9, 522, 53, 57, 2302, 2306, "were" +255, 20, 10, 523, 58, 60, 2307, 2309, "no" +255, 20, 11, 524, 61, 72, 2310, 2321, "significant" +255, 20, 12, 525, 73, 80, 2322, 2329, "between" +255, 20, 13, 526, 81, 82, 2330, 2331, "-" +255, 20, 14, 527, 83, 88, 2332, 2337, "group" +255, 20, 15, 528, 89, 100, 2338, 2349, "differences" +255, 20, 16, 529, 101, 103, 2350, 2352, "in" +255, 20, 17, 530, 104, 116, 2353, 2365, "prespecified" +255, 20, 18, 531, 117, 123, 2366, 2372, "safety" +255, 20, 19, 532, 124, 134, 2373, 2383, "parameters" +255, 20, 20, 533, 135, 136, 2384, 2385, "(" +255, 20, 21, 534, 137, 148, 2386, 2397, "symptomatic" +255, 20, 22, 535, 149, 161, 2398, 2410, "hypoglycemia" +255, 20, 23, 536, 162, 163, 2411, 2412, "," +255, 20, 24, 537, 164, 172, 2413, 2421, "diarrhea" +255, 20, 25, 538, 173, 174, 2422, 2423, "," +255, 20, 26, 539, 175, 184, 2424, 2433, "abdominal" +255, 20, 27, 540, 185, 189, 2434, 2438, "pain" +255, 20, 28, 541, 190, 191, 2439, 2440, "," +255, 20, 29, 542, 192, 198, 2441, 2447, "nausea" +255, 20, 30, 543, 199, 200, 2448, 2449, "," +255, 20, 31, 544, 201, 209, 2450, 2458, "vomiting" +255, 20, 32, 545, 210, 211, 2459, 2460, ")" +255, 20, 33, 546, 212, 213, 2461, 2462, "." +255, 21, 1, 547, 0, 1, 2463, 2464, "A" +255, 21, 2, 548, 2, 8, 2465, 2471, "higher" +255, 21, 3, 549, 9, 18, 2472, 2481, "incidence" +255, 21, 4, 550, 19, 21, 2482, 2484, "of" +255, 21, 5, 551, 22, 29, 2485, 2492, "serious" +255, 21, 6, 552, 30, 37, 2493, 2500, "adverse" +255, 21, 7, 553, 38, 44, 2501, 2507, "events" +255, 21, 8, 554, 45, 48, 2508, 2511, "was" +255, 21, 9, 555, 49, 57, 2512, 2520, "observed" +255, 21, 10, 556, 58, 60, 2521, 2523, "in" +255, 21, 11, 557, 61, 64, 2524, 2527, "the" +255, 21, 12, 558, 65, 76, 2528, 2539, "sitagliptin" +255, 21, 13, 559, 77, 82, 2540, 2545, "group" +255, 21, 14, 560, 83, 84, 2546, 2547, "(" +255, 21, 15, 561, 85, 86, 2548, 2549, "5" +255, 21, 16, 562, 87, 88, 2550, 2551, "." +255, 21, 17, 563, 89, 90, 2552, 2553, "2" +255, 21, 18, 564, 91, 92, 2554, 2555, "%" +255, 21, 19, 565, 93, 94, 2556, 2557, ")" +255, 21, 20, 566, 95, 103, 2558, 2566, "relative" +255, 21, 21, 567, 104, 106, 2567, 2569, "to" +255, 21, 22, 568, 107, 114, 2570, 2577, "placebo" +255, 21, 23, 569, 115, 116, 2578, 2579, "(" +255, 21, 24, 570, 117, 118, 2580, 2581, "0" +255, 21, 25, 571, 119, 120, 2582, 2583, "." +255, 21, 26, 572, 121, 122, 2584, 2585, "5" +255, 21, 27, 573, 123, 124, 2586, 2587, "%" +255, 21, 28, 574, 125, 126, 2588, 2589, ")" +255, 21, 29, 575, 127, 128, 2590, 2591, ";" +255, 21, 30, 576, 129, 132, 2592, 2595, "all" +255, 21, 31, 577, 133, 136, 2596, 2599, "but" +255, 21, 32, 578, 137, 140, 2600, 2603, "one" +255, 21, 33, 579, 141, 142, 2604, 2605, "," +255, 21, 34, 580, 143, 145, 2606, 2608, "in" +255, 21, 35, 581, 146, 149, 2609, 2612, "the" +255, 21, 36, 582, 150, 161, 2613, 2624, "sitagliptin" +255, 21, 37, 583, 162, 167, 2625, 2630, "group" +255, 21, 38, 584, 168, 169, 2631, 2632, "," +255, 21, 39, 585, 170, 174, 2633, 2637, "were" +255, 21, 40, 586, 175, 178, 2638, 2641, "not" +255, 21, 41, 587, 179, 189, 2642, 2652, "considered" +255, 21, 42, 588, 190, 197, 2653, 2660, "related" +255, 21, 43, 589, 198, 200, 2661, 2663, "to" +255, 21, 44, 590, 201, 205, 2664, 2668, "drug" +255, 21, 45, 591, 206, 207, 2669, 2670, "." +255, 22, 1, 592, 0, 11, 2671, 2682, "CONCLUSIONS" +255, 22, 2, 593, 12, 13, 2683, 2684, ":" +255, 22, 3, 594, 14, 25, 2685, 2696, "Sitagliptin" +255, 22, 4, 595, 26, 29, 2697, 2700, "was" +255, 22, 5, 596, 30, 39, 2701, 2710, "generally" +255, 22, 6, 597, 40, 44, 2711, 2715, "well" +255, 22, 7, 598, 45, 54, 2716, 2725, "tolerated" +255, 22, 8, 599, 55, 58, 2726, 2729, "and" +255, 22, 9, 600, 59, 67, 2730, 2738, "provided" +255, 22, 10, 601, 68, 81, 2739, 2752, "statistically" +255, 22, 11, 602, 82, 90, 2753, 2761, "superior" +255, 22, 12, 603, 91, 94, 2762, 2765, "and" +255, 22, 13, 604, 95, 105, 2766, 2776, "clinically" +255, 22, 14, 605, 106, 116, 2777, 2787, "meaningful" +255, 22, 15, 606, 117, 129, 2788, 2800, "improvements" +255, 22, 16, 607, 130, 132, 2801, 2803, "in" +255, 22, 17, 608, 133, 141, 2804, 2812, "glycemic" +255, 22, 18, 609, 142, 149, 2813, 2820, "control" +255, 22, 19, 610, 150, 155, 2821, 2826, "after" +255, 22, 20, 611, 156, 158, 2827, 2829, "24" +255, 22, 21, 612, 159, 164, 2830, 2835, "weeks" +255, 22, 22, 613, 165, 167, 2836, 2838, "of" +255, 22, 23, 614, 168, 177, 2839, 2848, "treatment" +255, 22, 24, 615, 178, 186, 2849, 2857, "compared" +255, 22, 25, 616, 187, 189, 2858, 2860, "to" +255, 22, 26, 617, 190, 197, 2861, 2868, "placebo" +255, 22, 27, 618, 198, 202, 2869, 2873, "when" +255, 22, 28, 619, 203, 208, 2874, 2879, "added" +255, 22, 29, 620, 209, 211, 2880, 2882, "to" +255, 22, 30, 621, 212, 221, 2883, 2892, "treatment" +255, 22, 31, 622, 222, 224, 2893, 2895, "of" +255, 22, 32, 623, 225, 233, 2896, 2904, "patients" +255, 22, 33, 624, 234, 238, 2905, 2909, "with" +255, 22, 34, 625, 239, 249, 2910, 2920, "inadequate" +255, 22, 35, 626, 250, 258, 2921, 2929, "glycemic" +255, 22, 36, 627, 259, 266, 2930, 2937, "control" +255, 22, 37, 628, 267, 269, 2938, 2940, "on" +255, 22, 38, 629, 270, 278, 2941, 2949, "acarbose" +255, 22, 39, 630, 279, 290, 2950, 2961, "monotherapy" +255, 22, 40, 631, 291, 292, 2962, 2963, "." +255, 23, 1, 632, 0, 14, 2964, 2978, "Clinicaltrials" +255, 23, 2, 633, 15, 16, 2979, 2980, "." +255, 23, 3, 634, 17, 20, 2981, 2984, "gov" +255, 23, 4, 635, 21, 22, 2985, 2986, ":" +255, 23, 5, 636, 23, 34, 2987, 2998, "NCT01177384" +255, 23, 6, 637, 35, 36, 2999, 3000, "." +255, 24, 1, 638, 0, 3, 3001, 3004, "DOI" +255, 24, 2, 639, 4, 5, 3005, 3006, ":" +255, 24, 3, 640, 6, 8, 3007, 3009, "10" +255, 24, 4, 641, 9, 10, 3010, 3011, "." +255, 24, 5, 642, 11, 15, 3012, 3016, "1080" +255, 24, 6, 643, 16, 17, 3017, 3018, "/" +255, 24, 7, 644, 18, 26, 3019, 3027, "03007995" +255, 24, 8, 645, 27, 28, 3028, 3029, "." +255, 24, 9, 646, 29, 33, 3030, 3034, "2016" +255, 24, 10, 647, 34, 35, 3035, 3036, "." +255, 24, 11, 648, 36, 43, 3037, 3044, "1277200" +255, 24, 12, 649, 44, 48, 3045, 3049, "PMID" +255, 24, 13, 650, 49, 50, 3050, 3051, ":" +255, 24, 14, 651, 51, 59, 3052, 3060, "28035868" +255, 24, 15, 652, 60, 61, 3061, 3062, "[" +255, 24, 16, 653, 62, 69, 3063, 3070, "Indexed" +255, 24, 17, 654, 70, 73, 3071, 3074, "for" +255, 24, 18, 655, 74, 81, 3075, 3082, "MEDLINE" +255, 24, 19, 656, 82, 83, 3083, 3084, "]" diff --git a/data/dm2 28035868_kwoodley.annodb b/data/dm2 28035868_kwoodley.annodb new file mode 100644 index 0000000..3b1037a --- /dev/null +++ b/data/dm2 28035868_kwoodley.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71096, Journal, 0, 17, "Curr Med Res Opin", "", +71097, PublicationYear, 20, 24, "2017", "", +71117, Title, 119, 274, "A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone .", "", +71098, Randomized, 121, 131, "randomized", "", +71099, Sitagliptin, 177, 188, "sitagliptin", "", +71116, Precondition, 192, 272, "patients with type 2 diabetes mellitus inadequately controlled by acarbose alone", "", +71111, Type2Diabetes, 206, 230, "type 2 diabetes mellitus", "", +71112, Drug, 258, 266, "acarbose", "", +71118, Author, 275, 281, "Wang W", "", +71119, Author, 290, 296, "Ning G", "", +71120, Author, 305, 309, "Ma J", "", +71121, Author, 318, 323, "Liu X", "", +71122, Author, 332, 339, "Zheng S", "", +71123, Author, 348, 352, "Wu F", "", +71124, Author, 367, 371, "Xu L", "", +71125, Author, 380, 392, "O ' Neill EA", "", +71126, Author, 401, 410, "Fujita KP", "", +71127, Author, 425, 433, "Engel SS", "", +71128, Author, 442, 452, "Kaufman KD", "", +71129, Author, 461, 471, "Shankar RR", "", +71130, China, 590, 595, "China", "", +71131, China, 682, 687, "China", "", +71132, China, 774, 779, "China", "", +71133, China, 852, 857, "China", "", +71135, USA, 909, 912, "USA", "", +71134, China, 983, 988, "China", "", +71136, USA, 1060, 1063, "USA", "", +71138, ObjectiveDescription, 1078, 1265, "To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy .", "", +71100, Sitagliptin, 1117, 1128, "sitagliptin", "", +71137, Precondition, 1160, 1263, "patients with type 2 diabetes mellitus ( T2DM ) and inadequate glycemic control on acarbose monotherapy", "", +71109, Type2Diabetes, 1174, 1198, "type 2 diabetes mellitus", "", +71108, Type2Diabetes, 1201, 1205, "T2DM", "", +71114, Drug, 1243, 1251, "acarbose", "", +71139, Multicenter, 1307, 1318, "multicenter", "", +71140, Randomized, 1321, 1331, "randomized", "", +71142, Placebo, 1334, 1341, "placebo", "", +71141, DoubleBlind, 1357, 1371, "double - blind", "", +71157, Precondition, 1389, 1576, "Patients ( N  =  381 ) with T2DM and inadequate glycemic control ( glycated hemoglobin [ HbA1c ] ≥  7 . 0 % and ≤ 10 . 0 % ) on acarbose monotherapy ( at least 50   mg three times daily )", "", +71148, NumberPatientsCT, 1406, 1409, "381", "", +71110, Type2Diabetes, 1417, 1421, "T2DM", "", +71149, HbA1c, 1456, 1475, "glycated hemoglobin", "", +71151, HbA1c, 1478, 1483, "HbA1c", "", +71155, Percentage, 1495, 1496, "%", "", +71156, Percentage, 1510, 1511, "%", "", +71113, Drug, 1517, 1525, "acarbose", "", +71160, DoseDescription, 1540, 1574, "at least 50   mg three times daily", "", +71158, mg, 1554, 1556, "mg", "", +71159, Frequency, 1557, 1574, "three times daily", "", +71161, Randomized, 1582, 1592, "randomized", "", +71162, AllocationRatio, 1598, 1603, "1 : 1", "", +71101, Sitagliptin, 1637, 1648, "sitagliptin", "", +71163, DoseValue, 1649, 1652, "100", "", +71164, mg, 1655, 1657, "mg", "", +71143, Placebo, 1670, 1677, "placebo", "", +71165, Frequency, 1678, 1688, "once daily", "", +71166, Duration, 1693, 1701, "24 weeks", "", +71167, TimePoint, 1741, 1749, "baseline", "", +71152, HbA1c, 1753, 1758, "HbA1c", "", +71172, FastingPlasmaGlucose, 1763, 1785, "fasting plasma glucose", "", +71173, FastingPlasmaGlucose, 1788, 1791, "FPG", "", +71168, TimePoint, 1797, 1804, "Week 24", "", +71153, HbA1c, 1835, 1840, "HbA1c", "", +71175, Randomized, 1844, 1854, "randomized", "", +71176, BaseLineValue, 1868, 1873, "8 . 1", "", +71177, Percentage, 1874, 1875, "%", "", +71170, TimePoint, 1881, 1888, "Week 24", "", +71144, Placebo, 1895, 1902, "placebo", "", +71178, LeastSquaresMean, 1918, 1936, "least squares mean", "", +71169, TimePoint, 1950, 1958, "baseline", "", +71179, ConfIntervalChangeValue, 1961, 1985, "95 % confidence interval", "", +71154, HbA1c, 1991, 1996, "HbA1c", "", +71174, FastingPlasmaGlucose, 2001, 2004, "FPG", "", +71102, Sitagliptin, 2012, 2023, "sitagliptin", "", +71180, Reduction, 2037, 2043, "0 . 62", "", +71182, Percentage, 2044, 2045, "%", "", +71181, Reduction, 2052, 2057, "0 . 8", "", +71183, Millimoles_per_litre, 2060, 2068, "mmol / L", "", +71184, PValueChangeValue, 2071, 2081, "p  < . 001", "", +71171, TimePoint, 2104, 2111, "Week 24", "", +71185, PercentageAffected, 2114, 2120, "37 . 8", "", +71104, Sitagliptin, 2142, 2153, "sitagliptin", "", +71187, HbA1c_target, 2168, 2187, "HbA1c goal of < 7 %", "", +71186, PercentageAffected, 2202, 2208, "17 . 2", "", +71145, Placebo, 2218, 2225, "placebo", "", +71188, PvalueDiff, 2234, 2244, "p  < . 001", "", +71103, Sitagliptin, 2249, 2260, "Sitagliptin", "", +71189, ObservedResult, 2296, 2383, "there were no significant between - group differences in prespecified safety parameters", "", +71190, SymptomaticHypoglycemia, 2386, 2410, "symptomatic hypoglycemia", "", +71191, EndPointDescription, 2413, 2421, "diarrhea", "", +71192, EndPointDescription, 2424, 2438, "abdominal pain", "", +71194, Nausea, 2441, 2447, "nausea", "", +71193, EndPointDescription, 2450, 2458, "vomiting", "", +71200, SubGroupDescription, 2485, 2507, "serious adverse events", "", +71195, EndPointDescription, 2493, 2507, "adverse events", "", +71196, Sitagliptin, 2528, 2539, "sitagliptin", "", +71197, PercentageAffected, 2548, 2553, "5 . 2", "", +71146, Placebo, 2570, 2577, "placebo", "", +71198, PercentageAffected, 2580, 2585, "0 . 5", "", +71199, ObservedResult, 2592, 2668, "all but one , in the sitagliptin group , were not considered related to drug", "", +71105, Sitagliptin, 2613, 2624, "sitagliptin", "", +71203, ConclusionComment, 2685, 2868, "Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in glycemic control after 24 weeks of treatment compared to placebo", "", +71106, Sitagliptin, 2685, 2696, "Sitagliptin", "", +71201, Duration, 2827, 2835, "24 weeks", "", +71147, Placebo, 2861, 2868, "placebo", "", +71204, ConclusionComment, 2869, 2963, "when added to treatment of patients with inadequate glycemic control on acarbose monotherapy .", "", +71202, Precondition, 2896, 2961, "patients with inadequate glycemic control on acarbose monotherapy", "", +71115, Drug, 2941, 2949, "acarbose", "", +71205, PMID, 3052, 3060, "28035868", "", diff --git a/data/dm2 28035868_kwoodley.n-triples b/data/dm2 28035868_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28035868_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28093853_admin.annodb b/data/dm2 28093853_admin.annodb new file mode 100644 index 0000000..5719b2b --- /dev/null +++ b/data/dm2 28093853_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +2, Randomized, 107, 117, "Randomized", "", +128, Title, 107, 312, "Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin", "", " \"Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin\"." +3, Frequency, 189, 202, "once - weekly", "", +4, Omarigliptin, 250, 262, "omarigliptin", "", +5, Frequency, 270, 282, "once - daily", "", +6, Sitagliptin, 301, 312, "sitagliptin", "", +128, Title, 313, 396, "in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", " \"in patients with type 2 diabetes inadequately controlled on metformin monotherapy .\"." +127, Precondition, 316, 394, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +7, Type2Diabetes, 330, 345, "type 2 diabetes", "", +9, Metformin, 373, 382, "metformin", "", +12, Author, 397, 409, "Goldenberg R", "", " \"Goldenberg R\"." +13, Author, 418, 425, "Gantz I", "", " \"Gantz I\"." +14, Author, 434, 444, "Andryuk PJ", "", " \"Andryuk PJ\"." +15, Author, 453, 465, "O ' Neill EA", "", " \"O ' Neill EA\"." +16, Author, 474, 484, "Kaufman KD", "", " \"Kaufman KD\"." +17, Author, 493, 498, "Lai E", "", " \"Lai E\"." +18, Author, 507, 514, "Wang YN", "", " \"Wang YN\"." +19, Author, 523, 536, "Suryawanshi S", "", " \"Suryawanshi S\"." +20, Author, 545, 553, "Engel SS", "", " \"Engel SS\"." +21, Canada, 640, 646, "Canada", "", " ." +147, ObjectiveDescription, 710, 876, "To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin", "", " \"To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin\"." +22, Frequency, 752, 765, "once - weekly", "", " \"once - weekly\"." +24, Omarigliptin, 818, 830, "omarigliptin", "", +23, Frequency, 834, 846, "once - daily", "", " \"once - daily\"." +25, Sitagliptin, 865, 876, "sitagliptin", "", +147, ObjectiveDescription, 877, 966, "in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .", "", " \"in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .\"." +146, Precondition, 880, 964, "patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin", "", +26, Type2Diabetes, 894, 909, "type 2 diabetes", "", " ." +27, Type2Diabetes, 912, 916, "T2DM", "", +29, Metformin, 955, 964, "metformin", "", +158, Precondition, 991, 1138, "Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )", "", " \"Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )\"." +32, Type2Diabetes, 1005, 1009, "T2DM", "", +33, HbA1c, 1017, 1037, "glycated haemoglobin", "", +34, HbA1c, 1040, 1045, "HbA1c", "", +35, Percentage, 1070, 1071, "%", "", +36, Percentage, 1083, 1084, "%", "", +37, Metformin, 1111, 1120, "metformin", "", +157, DoseValue, 1123, 1129, "≥ 1500", "", +155, mg, 1130, 1132, "mg", "", +98292, Interval, 1135, 1136, "d", "", +41, Randomized, 1144, 1154, "randomized", "", " ." +42, DoubleBlind, 1160, 1174, "double - blind", "", " ." +43, Omarigliptin, 1193, 1205, "omarigliptin", "", " ." +161, DoseValue, 1206, 1208, "25", "", " \"25\"." +46, mg, 1209, 1211, "mg", "", " ." +45, Frequency, 1212, 1223, "once weekly", "", +47, NumberPatientsArm, 1230, 1233, "322", "", " \"322\"." +49, Sitagliptin, 1239, 1250, "sitagliptin", "", " ." +162, DoseValue, 1251, 1254, "100", "", " \"100\"." +51, mg, 1255, 1257, "mg", "", " ." +52, Frequency, 1258, 1268, "once daily", "", +48, NumberPatientsArm, 1275, 1278, "320", "", " \"320\"." +53, Omarigliptin, 1321, 1333, "omarigliptin", "", +54, Sitagliptin, 1356, 1367, "sitagliptin", "", +55, HbA1c, 1380, 1385, "HbA1c", "", +56, TimePoint, 1389, 1396, "week 24", "", +57, Percentage, 1554, 1555, "%", "", +58, Mean, 1572, 1576, "mean", "", +60, HbA1c, 1586, 1591, "HbA1c", "", " ." +62, BaseLineValue, 1596, 1601, "7 . 5", "", " \"7 . 5\". \"7 . 5\"." +61, Percentage, 1602, 1603, "%", "", " ." +106245, TimePoint, 1627, 1635, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +64, LeastSquaresMean, 1642, 1667, "least squares ( LS ) mean", "", " ." +65, HbA1c, 1678, 1683, "HbA1c", "", +66, TimePoint, 1689, 1697, "baseline", "", +181, Reduction, 1704, 1710, "0 . 47", "", " \"0 . 47\"." +74, Percentage, 1711, 1712, "%", "", +69, Omarigliptin, 1720, 1732, "omarigliptin", "", +182, Reduction, 1745, 1751, "0 . 43", "", " \"0 . 43\"." +75, Percentage, 1752, 1753, "%", "", +70, Sitagliptin, 1761, 1772, "sitagliptin", "", +71, DiffGroupAbsValue, 1818, 1826, "- 0 . 03", "", " \"- 0 . 03\"." +72, Percentage, 1827, 1828, "%", "", +76, ConfIntervalDiff, 1831, 1856, "95 % CI - 0 . 15 , 0 . 08", "", " \"95 % CI - 0 . 15 , 0 . 08\"." +77, LeastSquaresMean, 1942, 1949, "LS mean", "", " . ." +78, TimePoint, 1962, 1970, "baseline", "", +79, FastingPlasmaGlucose, 1974, 1996, "fasting plasma glucose", "", " ." +188, HbA1c_target, 2033, 2061, "HbA1c < 7 . 0 % or < 6 . 5 %", "", " ." +83, Percentage, 2047, 2048, "%", "", +84, Percentage, 2060, 2061, "%", "", +82, TimePoint, 2065, 2072, "week 24", "", " \"week 24\". \"week 24\"." +189, ObservedResult, 2073, 2113, "were similar in the two treatment groups", "", " \"were similar in the two treatment groups\". \"were similar in the two treatment groups\"." +98295, ObservedResult, 2116, 2149, "There were no notable differences", "", " \"There were no notable differences\"." +190, EndPointDescription, 2153, 2167, "adverse events", "", " . ." +85, SymptomaticHypoglycemia, 2189, 2214, "symptomatic hypoglycaemia", "", " ." +98296, ObservedResult, 2215, 2248, "was low and similar in the groups", "", " \"was low and similar in the groups\"." +198, ConclusionComment, 2265, 2465, "In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .", "", " \"In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .\"." +86, Type2Diabetes, 2282, 2286, "T2DM", "", +88, Metformin, 2323, 2332, "metformin", "", +89, Omarigliptin, 2351, 2363, "omarigliptin", "", +194, DoseValue, 2364, 2366, "25", "", +95, mg, 2367, 2369, "mg", "", +91, Frequency, 2370, 2381, "once weekly", "", +92, Sitagliptin, 2385, 2396, "sitagliptin", "", +195, DoseValue, 2397, 2400, "100", "", +94, mg, 2401, 2403, "mg", "", +96, Frequency, 2404, 2414, "once daily", "", +199, ConclusionComment, 2466, 2547, "Both agents were generally well tolerated with a low incidence of hypoglycaemia .", "", " \"Both agents were generally well tolerated with a low incidence of hypoglycaemia .\"." +99, Hypoglycemia, 2532, 2545, "hypoglycaemia", "", +100, PMID, 2709, 2717, "28093853", "", " \"28093853\"." diff --git a/data/dm2 28093853_admin.n-triples b/data/dm2 28093853_admin.n-triples new file mode 100644 index 0000000..53c8dc4 --- /dev/null +++ b/data/dm2 28093853_admin.n-triples @@ -0,0 +1,156 @@ +# RDF export of group: Publication + . + "Publication " . + "Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin" . + "in patients with type 2 diabetes inadequately controlled on metformin monotherapy ." . + "Goldenberg R" . + "2017" . + "Diabetes Obes Metab ." . + "28093853" . + . + "Gantz I" . + "Andryuk PJ" . + "O ' Neill EA" . + "Kaufman KD" . + "Lai E" . + "Wang YN" . + "Suryawanshi S" . + "Engel SS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin" . + "in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin ." . + . + . + . + "In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control ." . + . + . + . + . + . + . + "Both agents were generally well tolerated with a low incidence of hypoglycaemia ." . + . +# RDF export of group: Population + . + "Population " . + "Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint hba1c target" . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . +# RDF export of group: Arm + . + "Arm o " . + "322" . + . + . + . + . + . + . + . + "Arm s" . + "320" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention o" . + . + "once - weekly" . + . + . + "Intervention s" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication o" . + . + "25" . + . + . + . + "Medication s" . + . + "100" . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c o" . + . + "7 . 5" . + "0 . 47" . + "24 weeks" . + . + "Outcome hba1c s" . + . + "7 . 5" . + "0 . 43" . + "24 weeks" . + . + "Outcome fpg both drugs" . + . + "were similar in the two treatment groups" . + "week 24" . + . + "Outcome hba1c target both drugs" . + . + "were similar in the two treatment groups" . + "week 24" . + . + "Outcome aes both drugs" . + . + "There were no notable differences" . + . + "Outcome sh both drugs" . + . + "was low and similar in the groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 03" . + "95 % CI - 0 . 15 , 0 . 08" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28093853_akramersunderbrink.annodb b/data/dm2 28093853_akramersunderbrink.annodb new file mode 100644 index 0000000..83773d3 --- /dev/null +++ b/data/dm2 28093853_akramersunderbrink.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +67960, Journal, 0, 19, "Diabetes Obes Metab", "", +67961, PublicationYear, 22, 26, "2017", "", +67962, Randomized, 107, 117, "Randomized", "", +67970, Title, 107, 329, "Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin in patients with", "", +67963, Frequency, 189, 202, "once - weekly", "", +67964, Omarigliptin, 250, 262, "omarigliptin", "", +67965, Frequency, 270, 282, "once - daily", "", +67966, Sitagliptin, 301, 312, "sitagliptin", "", +67967, Type2Diabetes, 330, 345, "type 2 diabetes", "", +67971, Title, 330, 396, "type 2 diabetes inadequately controlled on metformin monotherapy .", "", +67968, Precondition, 346, 394, "inadequately controlled on metformin monotherapy", "", +67969, Metformin, 373, 382, "metformin", "", +67972, Author, 397, 409, "Goldenberg R", "", +67973, Author, 418, 425, "Gantz I", "", +67974, Author, 434, 444, "Andryuk PJ", "", +67975, Author, 453, 465, "O ' Neill EA", "", +67976, Author, 474, 484, "Kaufman KD", "", +67977, Author, 493, 498, "Lai E", "", +67978, Author, 507, 514, "Wang YN", "", +67979, Author, 523, 536, "Suryawanshi S", "", +67980, Author, 545, 553, "Engel SS", "", +67981, Canada, 640, 646, "Canada", "", +67990, ObjectiveDescription, 710, 893, "To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin in patients with", "", +67982, Frequency, 752, 765, "once - weekly", "", +67984, Omarigliptin, 818, 830, "omarigliptin", "", +67983, Frequency, 834, 846, "once - daily", "", +67985, Sitagliptin, 865, 876, "sitagliptin", "", +67986, Type2Diabetes, 894, 909, "type 2 diabetes", "", +67991, ObjectiveDescription, 894, 966, "type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .", "", +67987, Type2Diabetes, 912, 916, "T2DM", "", +67988, Precondition, 923, 964, "inadequate glycaemic control on metformin", "", +67989, Metformin, 955, 964, "metformin", "", +67992, Type2Diabetes, 1005, 1009, "T2DM", "", +67993, HbA1c, 1017, 1037, "glycated haemoglobin", "", +68000, Precondition, 1017, 1138, "glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )", "", +67994, HbA1c, 1040, 1045, "HbA1c", "", +67995, Percentage, 1070, 1071, "%", "", +67996, Percentage, 1083, 1084, "%", "", +67997, Metformin, 1111, 1120, "metformin", "", +67998, DoseValue, 1125, 1136, "1500 mg / d", "", +67999, BioAndMedicalUnit, 1130, 1136, "mg / d", "", +68001, Randomized, 1144, 1154, "randomized", "", +68002, DoubleBlind, 1160, 1174, "double - blind", "", +68003, Omarigliptin, 1193, 1205, "omarigliptin", "", +68004, DoseValue, 1206, 1211, "25 mg", "", +68006, mg, 1209, 1211, "mg", "", +68005, Frequency, 1212, 1223, "once weekly", "", +68007, NumberPatientsArm, 1230, 1233, "322", "", +68010, Sitagliptin, 1239, 1250, "sitagliptin", "", +68011, DoseValue, 1251, 1257, "100 mg", "", +68012, mg, 1255, 1257, "mg", "", +68013, Frequency, 1258, 1268, "once daily", "", +68009, NumberPatientsArm, 1275, 1278, "320", "", +68014, Omarigliptin, 1321, 1333, "omarigliptin", "", +68015, Sitagliptin, 1356, 1367, "sitagliptin", "", +68016, HbA1c, 1380, 1385, "HbA1c", "", +68017, TimePoint, 1389, 1396, "week 24", "", +68018, Percentage, 1554, 1555, "%", "", +68019, Mean, 1572, 1576, "mean", "", +68020, TimePoint, 1577, 1585, "baseline", "", +68021, HbA1c, 1586, 1591, "HbA1c", "", +68023, BaseLineValue, 1596, 1601, "7 . 5", "", +68022, Percentage, 1602, 1603, "%", "", +68024, TimePoint, 1627, 1635, "24 weeks", "", +68025, LeastSquaresMean, 1642, 1667, "least squares ( LS ) mean", "", +68026, HbA1c, 1678, 1683, "HbA1c", "", +68027, TimePoint, 1689, 1697, "baseline", "", +68028, ChangeValue, 1702, 1710, "- 0 . 47", "", +68035, Percentage, 1711, 1712, "%", "", +68030, Omarigliptin, 1720, 1732, "omarigliptin", "", +68029, ChangeValue, 1743, 1751, "- 0 . 43", "", +68036, Percentage, 1752, 1753, "%", "", +68031, Sitagliptin, 1761, 1772, "sitagliptin", "", +68032, DiffGroupAbsValue, 1818, 1826, "- 0 . 03", "", +68033, Percentage, 1827, 1828, "%", "", +68037, ConfIntervalDiff, 1831, 1856, "95 % CI - 0 . 15 , 0 . 08", "", +68034, Percentage, 1834, 1835, "%", "", +68038, LeastSquaresMean, 1942, 1949, "LS mean", "", +68039, TimePoint, 1962, 1970, "baseline", "", +68040, FastingPlasmaGlucose, 1974, 1996, "fasting plasma glucose", "", +68041, EndPointDescription, 2033, 2061, "HbA1c < 7 . 0 % or < 6 . 5 %", "", +68042, EndPointDescription, 2033, 2048, "HbA1c < 7 . 0 %", "", +68044, Percentage, 2047, 2048, "%", "", +68045, Percentage, 2060, 2061, "%", "", +68043, TimePoint, 2065, 2072, "week 24", "", +68046, SymptomaticHypoglycemia, 2189, 2214, "symptomatic hypoglycaemia", "", +68058, ObjectiveDescription, 2265, 2465, "In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .", "", +68047, Type2Diabetes, 2282, 2286, "T2DM", "", +68048, Precondition, 2291, 2332, "inadequate glycaemic control on metformin", "", +68049, Metformin, 2323, 2332, "metformin", "", +68050, Omarigliptin, 2351, 2363, "omarigliptin", "", +68051, DoseValue, 2364, 2369, "25 mg", "", +68056, mg, 2367, 2369, "mg", "", +68052, Frequency, 2370, 2381, "once weekly", "", +68053, Sitagliptin, 2385, 2396, "sitagliptin", "", +68054, DoseValue, 2397, 2403, "100 mg", "", +68055, mg, 2401, 2403, "mg", "", +68057, Frequency, 2404, 2414, "once daily", "", +68059, ObjectiveDescription, 2466, 2547, "Both agents were generally well tolerated with a low incidence of hypoglycaemia .", "", +68060, Hypoglycemia, 2532, 2545, "hypoglycaemia", "", +68061, PMID, 2709, 2717, "28093853", "", diff --git a/data/dm2 28093853_akramersunderbrink.n-triples b/data/dm2 28093853_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28093853_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28093853_export.csv b/data/dm2 28093853_export.csv new file mode 100644 index 0000000..d3da35e --- /dev/null +++ b/data/dm2 28093853_export.csv @@ -0,0 +1,584 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +254, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +254, 1, 2, 2, 9, 13, 9, 13, "Obes" +254, 1, 3, 3, 14, 19, 14, 19, "Metab" +254, 1, 4, 4, 20, 21, 20, 21, "." +254, 2, 1, 5, 0, 4, 22, 26, "2017" +254, 2, 2, 6, 5, 8, 27, 30, "Mar" +254, 2, 3, 7, 9, 10, 31, 32, ";" +254, 2, 4, 8, 11, 13, 33, 35, "19" +254, 2, 5, 9, 14, 15, 36, 37, "(" +254, 2, 6, 10, 16, 17, 38, 39, "3" +254, 2, 7, 11, 18, 19, 40, 41, ")" +254, 2, 8, 12, 20, 21, 42, 43, ":" +254, 2, 9, 13, 22, 25, 44, 47, "394" +254, 2, 10, 14, 26, 27, 48, 49, "-" +254, 2, 11, 15, 28, 31, 50, 53, "400" +254, 2, 12, 16, 32, 33, 54, 55, "." +254, 2, 13, 17, 34, 37, 56, 59, "doi" +254, 2, 14, 18, 38, 39, 60, 61, ":" +254, 2, 15, 19, 40, 42, 62, 64, "10" +254, 2, 16, 20, 43, 44, 65, 66, "." +254, 2, 17, 21, 45, 49, 67, 71, "1111" +254, 2, 18, 22, 50, 51, 72, 73, "/" +254, 2, 19, 23, 52, 55, 74, 77, "dom" +254, 2, 20, 24, 56, 57, 78, 79, "." +254, 2, 21, 25, 58, 63, 80, 85, "12832" +254, 2, 22, 26, 64, 65, 86, 87, "." +254, 3, 1, 27, 0, 4, 88, 92, "Epub" +254, 3, 2, 28, 5, 9, 93, 97, "2017" +254, 3, 3, 29, 10, 13, 98, 101, "Jan" +254, 3, 4, 30, 14, 16, 102, 104, "17" +254, 3, 5, 31, 17, 18, 105, 106, "." +254, 4, 1, 32, 0, 10, 107, 117, "Randomized" +254, 4, 2, 33, 11, 19, 118, 126, "clinical" +254, 4, 3, 34, 20, 25, 127, 132, "trial" +254, 4, 4, 35, 26, 35, 133, 142, "comparing" +254, 4, 5, 36, 36, 39, 143, 146, "the" +254, 4, 6, 37, 40, 48, 147, 155, "efficacy" +254, 4, 7, 38, 49, 52, 156, 159, "and" +254, 4, 8, 39, 53, 59, 160, 166, "safety" +254, 4, 9, 40, 60, 62, 167, 169, "of" +254, 4, 10, 41, 63, 72, 170, 179, "treatment" +254, 4, 11, 42, 73, 77, 180, 184, "with" +254, 4, 12, 43, 78, 81, 185, 188, "the" +254, 4, 13, 44, 82, 86, 189, 193, "once" +254, 4, 14, 45, 87, 88, 194, 195, "-" +254, 4, 15, 46, 89, 95, 196, 202, "weekly" +254, 4, 16, 47, 96, 106, 203, 213, "dipeptidyl" +254, 4, 17, 48, 107, 116, 214, 223, "peptidase" +254, 4, 18, 49, 117, 118, 224, 225, "-" +254, 4, 19, 50, 119, 120, 226, 227, "4" +254, 4, 20, 51, 121, 122, 228, 229, "(" +254, 4, 21, 52, 123, 126, 230, 233, "DPP" +254, 4, 22, 53, 127, 128, 234, 235, "-" +254, 4, 23, 54, 129, 130, 236, 237, "4" +254, 4, 24, 55, 131, 132, 238, 239, ")" +254, 4, 25, 56, 133, 142, 240, 249, "inhibitor" +254, 4, 26, 57, 143, 155, 250, 262, "omarigliptin" +254, 4, 27, 58, 156, 158, 263, 265, "or" +254, 4, 28, 59, 159, 162, 266, 269, "the" +254, 4, 29, 60, 163, 167, 270, 274, "once" +254, 4, 30, 61, 168, 169, 275, 276, "-" +254, 4, 31, 62, 170, 175, 277, 282, "daily" +254, 4, 32, 63, 176, 179, 283, 286, "DPP" +254, 4, 33, 64, 180, 181, 287, 288, "-" +254, 4, 34, 65, 182, 183, 289, 290, "4" +254, 4, 35, 66, 184, 193, 291, 300, "inhibitor" +254, 4, 36, 67, 194, 205, 301, 312, "sitagliptin" +254, 4, 37, 68, 206, 208, 313, 315, "in" +254, 4, 38, 69, 209, 217, 316, 324, "patients" +254, 4, 39, 70, 218, 222, 325, 329, "with" +254, 4, 40, 71, 223, 227, 330, 334, "type" +254, 4, 41, 72, 228, 229, 335, 336, "2" +254, 4, 42, 73, 230, 238, 337, 345, "diabetes" +254, 4, 43, 74, 239, 251, 346, 358, "inadequately" +254, 4, 44, 75, 252, 262, 359, 369, "controlled" +254, 4, 45, 76, 263, 265, 370, 372, "on" +254, 4, 46, 77, 266, 275, 373, 382, "metformin" +254, 4, 47, 78, 276, 287, 383, 394, "monotherapy" +254, 4, 48, 79, 288, 289, 395, 396, "." +254, 5, 1, 80, 0, 10, 397, 407, "Goldenberg" +254, 5, 2, 81, 11, 12, 408, 409, "R" +254, 5, 3, 82, 13, 14, 410, 411, "(" +254, 5, 4, 83, 15, 16, 412, 413, "1" +254, 5, 5, 84, 17, 18, 414, 415, ")" +254, 5, 6, 85, 19, 20, 416, 417, "," +254, 5, 7, 86, 21, 26, 418, 423, "Gantz" +254, 5, 8, 87, 27, 28, 424, 425, "I" +254, 5, 9, 88, 29, 30, 426, 427, "(" +254, 5, 10, 89, 31, 32, 428, 429, "2" +254, 5, 11, 90, 33, 34, 430, 431, ")" +254, 5, 12, 91, 35, 36, 432, 433, "," +254, 5, 13, 92, 37, 44, 434, 441, "Andryuk" +254, 5, 14, 93, 45, 47, 442, 444, "PJ" +254, 5, 15, 94, 48, 49, 445, 446, "(" +254, 5, 16, 95, 50, 51, 447, 448, "2" +254, 5, 17, 96, 52, 53, 449, 450, ")" +254, 5, 18, 97, 54, 55, 451, 452, "," +254, 5, 19, 98, 56, 57, 453, 454, "O" +254, 5, 20, 99, 58, 59, 455, 456, "'" +254, 5, 21, 100, 60, 65, 457, 462, "Neill" +254, 5, 22, 101, 66, 68, 463, 465, "EA" +254, 5, 23, 102, 69, 70, 466, 467, "(" +254, 5, 24, 103, 71, 72, 468, 469, "2" +254, 5, 25, 104, 73, 74, 470, 471, ")" +254, 5, 26, 105, 75, 76, 472, 473, "," +254, 5, 27, 106, 77, 84, 474, 481, "Kaufman" +254, 5, 28, 107, 85, 87, 482, 484, "KD" +254, 5, 29, 108, 88, 89, 485, 486, "(" +254, 5, 30, 109, 90, 91, 487, 488, "2" +254, 5, 31, 110, 92, 93, 489, 490, ")" +254, 5, 32, 111, 94, 95, 491, 492, "," +254, 5, 33, 112, 96, 99, 493, 496, "Lai" +254, 5, 34, 113, 100, 101, 497, 498, "E" +254, 5, 35, 114, 102, 103, 499, 500, "(" +254, 5, 36, 115, 104, 105, 501, 502, "2" +254, 5, 37, 116, 106, 107, 503, 504, ")" +254, 5, 38, 117, 108, 109, 505, 506, "," +254, 5, 39, 118, 110, 114, 507, 511, "Wang" +254, 5, 40, 119, 115, 117, 512, 514, "YN" +254, 5, 41, 120, 118, 119, 515, 516, "(" +254, 5, 42, 121, 120, 121, 517, 518, "2" +254, 5, 43, 122, 122, 123, 519, 520, ")" +254, 5, 44, 123, 124, 125, 521, 522, "," +254, 5, 45, 124, 126, 137, 523, 534, "Suryawanshi" +254, 5, 46, 125, 138, 139, 535, 536, "S" +254, 5, 47, 126, 140, 141, 537, 538, "(" +254, 5, 48, 127, 142, 143, 539, 540, "2" +254, 5, 49, 128, 144, 145, 541, 542, ")" +254, 5, 50, 129, 146, 147, 543, 544, "," +254, 5, 51, 130, 148, 153, 545, 550, "Engel" +254, 5, 52, 131, 154, 156, 551, 553, "SS" +254, 5, 53, 132, 157, 158, 554, 555, "(" +254, 5, 54, 133, 159, 160, 556, 557, "2" +254, 5, 55, 134, 161, 162, 558, 559, ")" +254, 5, 56, 135, 163, 164, 560, 561, "." +254, 6, 1, 136, 0, 6, 562, 568, "Author" +254, 6, 2, 137, 7, 18, 569, 580, "information" +254, 6, 3, 138, 19, 20, 581, 582, ":" +254, 6, 4, 139, 21, 22, 583, 584, "(" +254, 6, 5, 140, 23, 24, 585, 586, "1" +254, 6, 6, 141, 25, 26, 587, 588, ")" +254, 6, 7, 142, 27, 30, 589, 592, "LMC" +254, 6, 8, 143, 31, 39, 593, 601, "Diabetes" +254, 6, 9, 144, 40, 41, 602, 603, "&" +254, 6, 10, 145, 42, 55, 604, 617, "Endocrinology" +254, 6, 11, 146, 56, 57, 618, 619, "," +254, 6, 12, 147, 58, 65, 620, 627, "Toronto" +254, 6, 13, 148, 66, 67, 628, 629, "," +254, 6, 14, 149, 68, 75, 630, 637, "Ontario" +254, 6, 15, 150, 76, 77, 638, 639, "," +254, 6, 16, 151, 78, 84, 640, 646, "Canada" +254, 6, 17, 152, 85, 86, 647, 648, "." +254, 7, 1, 153, 0, 1, 649, 650, "(" +254, 7, 2, 154, 2, 3, 651, 652, "2" +254, 7, 3, 155, 4, 5, 653, 654, ")" +254, 7, 4, 156, 6, 11, 655, 660, "Merck" +254, 7, 5, 157, 12, 13, 661, 662, "&" +254, 7, 6, 158, 14, 16, 663, 665, "Co" +254, 7, 7, 159, 17, 18, 666, 667, "." +254, 7, 8, 160, 19, 20, 668, 669, "," +254, 7, 9, 161, 21, 24, 670, 673, "Inc" +254, 7, 10, 162, 25, 26, 674, 675, "." +254, 7, 11, 163, 27, 28, 676, 677, "," +254, 7, 12, 164, 29, 39, 678, 688, "Kenilworth" +254, 7, 13, 165, 40, 41, 689, 690, "," +254, 7, 14, 166, 42, 45, 691, 694, "New" +254, 7, 15, 167, 46, 52, 695, 701, "Jersey" +254, 7, 16, 168, 53, 54, 702, 703, "." +254, 8, 1, 169, 0, 3, 704, 707, "AIM" +254, 8, 2, 170, 4, 5, 708, 709, ":" +254, 8, 3, 171, 6, 8, 710, 712, "To" +254, 8, 4, 172, 9, 16, 713, 720, "compare" +254, 8, 5, 173, 17, 20, 721, 724, "the" +254, 8, 6, 174, 21, 29, 725, 733, "efficacy" +254, 8, 7, 175, 30, 33, 734, 737, "and" +254, 8, 8, 176, 34, 40, 738, 744, "safety" +254, 8, 9, 177, 41, 43, 745, 747, "of" +254, 8, 10, 178, 44, 47, 748, 751, "the" +254, 8, 11, 179, 48, 52, 752, 756, "once" +254, 8, 12, 180, 53, 54, 757, 758, "-" +254, 8, 13, 181, 55, 61, 759, 765, "weekly" +254, 8, 14, 182, 62, 66, 766, 770, "oral" +254, 8, 15, 183, 67, 77, 771, 781, "dipeptidyl" +254, 8, 16, 184, 78, 87, 782, 791, "peptidase" +254, 8, 17, 185, 88, 89, 792, 793, "-" +254, 8, 18, 186, 90, 91, 794, 795, "4" +254, 8, 19, 187, 92, 93, 796, 797, "(" +254, 8, 20, 188, 94, 97, 798, 801, "DPP" +254, 8, 21, 189, 98, 99, 802, 803, "-" +254, 8, 22, 190, 100, 101, 804, 805, "4" +254, 8, 23, 191, 102, 103, 806, 807, ")" +254, 8, 24, 192, 104, 113, 808, 817, "inhibitor" +254, 8, 25, 193, 114, 126, 818, 830, "omarigliptin" +254, 8, 26, 194, 127, 129, 831, 833, "or" +254, 8, 27, 195, 130, 134, 834, 838, "once" +254, 8, 28, 196, 135, 136, 839, 840, "-" +254, 8, 29, 197, 137, 142, 841, 846, "daily" +254, 8, 30, 198, 143, 146, 847, 850, "DPP" +254, 8, 31, 199, 147, 148, 851, 852, "-" +254, 8, 32, 200, 149, 150, 853, 854, "4" +254, 8, 33, 201, 151, 160, 855, 864, "inhibitor" +254, 8, 34, 202, 161, 172, 865, 876, "sitagliptin" +254, 8, 35, 203, 173, 175, 877, 879, "in" +254, 8, 36, 204, 176, 184, 880, 888, "patients" +254, 8, 37, 205, 185, 189, 889, 893, "with" +254, 8, 38, 206, 190, 194, 894, 898, "type" +254, 8, 39, 207, 195, 196, 899, 900, "2" +254, 8, 40, 208, 197, 205, 901, 909, "diabetes" +254, 8, 41, 209, 206, 207, 910, 911, "(" +254, 8, 42, 210, 208, 212, 912, 916, "T2DM" +254, 8, 43, 211, 213, 214, 917, 918, ")" +254, 8, 44, 212, 215, 218, 919, 922, "and" +254, 8, 45, 213, 219, 229, 923, 933, "inadequate" +254, 8, 46, 214, 230, 239, 934, 943, "glycaemic" +254, 8, 47, 215, 240, 247, 944, 951, "control" +254, 8, 48, 216, 248, 250, 952, 954, "on" +254, 8, 49, 217, 251, 260, 955, 964, "metformin" +254, 8, 50, 218, 261, 262, 965, 966, "." +254, 9, 1, 219, 0, 9, 967, 976, "MATERIALS" +254, 9, 2, 220, 10, 13, 977, 980, "AND" +254, 9, 3, 221, 14, 21, 981, 988, "METHODS" +254, 9, 4, 222, 22, 23, 989, 990, ":" +254, 9, 5, 223, 24, 32, 991, 999, "Patients" +254, 9, 6, 224, 33, 37, 1000, 1004, "with" +254, 9, 7, 225, 38, 42, 1005, 1009, "T2DM" +254, 9, 8, 226, 43, 47, 1010, 1014, "with" +254, 9, 9, 227, 48, 49, 1015, 1016, "a" +254, 9, 10, 228, 50, 58, 1017, 1025, "glycated" +254, 9, 11, 229, 59, 70, 1026, 1037, "haemoglobin" +254, 9, 12, 230, 71, 72, 1038, 1039, "(" +254, 9, 13, 231, 73, 78, 1040, 1045, "HbA1c" +254, 9, 14, 232, 79, 80, 1046, 1047, ")" +254, 9, 15, 233, 81, 94, 1048, 1061, "concentration" +254, 9, 16, 234, 95, 96, 1062, 1063, "≥" +254, 9, 17, 235, 97, 98, 1064, 1065, "6" +254, 9, 18, 236, 99, 100, 1066, 1067, "." +254, 9, 19, 237, 101, 102, 1068, 1069, "5" +254, 9, 20, 238, 103, 104, 1070, 1071, "%" +254, 9, 21, 239, 105, 107, 1072, 1074, "to" +254, 9, 22, 240, 108, 109, 1075, 1076, "≤" +254, 9, 23, 241, 110, 111, 1077, 1078, "9" +254, 9, 24, 242, 112, 113, 1079, 1080, "." +254, 9, 25, 243, 114, 115, 1081, 1082, "0" +254, 9, 26, 244, 116, 117, 1083, 1084, "%" +254, 9, 27, 245, 118, 123, 1085, 1090, "while" +254, 9, 28, 246, 124, 126, 1091, 1093, "on" +254, 9, 29, 247, 127, 128, 1094, 1095, "a" +254, 9, 30, 248, 129, 135, 1096, 1102, "stable" +254, 9, 31, 249, 136, 140, 1103, 1107, "dose" +254, 9, 32, 250, 141, 143, 1108, 1110, "of" +254, 9, 33, 251, 144, 153, 1111, 1120, "metformin" +254, 9, 34, 252, 154, 155, 1121, 1122, "(" +254, 9, 35, 253, 156, 157, 1123, 1124, "≥" +254, 9, 36, 254, 158, 162, 1125, 1129, "1500" +254, 9, 37, 255, 163, 165, 1130, 1132, "mg" +254, 9, 38, 256, 166, 167, 1133, 1134, "/" +254, 9, 39, 257, 168, 169, 1135, 1136, "d" +254, 9, 40, 258, 170, 171, 1137, 1138, ")" +254, 9, 41, 259, 172, 176, 1139, 1143, "were" +254, 9, 42, 260, 177, 187, 1144, 1154, "randomized" +254, 9, 43, 261, 188, 190, 1155, 1157, "in" +254, 9, 44, 262, 191, 192, 1158, 1159, "a" +254, 9, 45, 263, 193, 199, 1160, 1166, "double" +254, 9, 46, 264, 200, 201, 1167, 1168, "-" +254, 9, 47, 265, 202, 207, 1169, 1174, "blind" +254, 9, 48, 266, 208, 214, 1175, 1181, "manner" +254, 9, 49, 267, 215, 217, 1182, 1184, "to" +254, 9, 50, 268, 218, 225, 1185, 1192, "receive" +254, 9, 51, 269, 226, 238, 1193, 1205, "omarigliptin" +254, 9, 52, 270, 239, 241, 1206, 1208, "25" +254, 9, 53, 271, 242, 244, 1209, 1211, "mg" +254, 9, 54, 272, 245, 249, 1212, 1216, "once" +254, 9, 55, 273, 250, 256, 1217, 1223, "weekly" +254, 9, 56, 274, 257, 258, 1224, 1225, "(" +254, 9, 57, 275, 259, 260, 1226, 1227, "n" +254, 9, 58, 276, 261, 262, 1228, 1229, "=" +254, 9, 59, 277, 263, 266, 1230, 1233, "322" +254, 9, 60, 278, 267, 268, 1234, 1235, ")" +254, 9, 61, 279, 269, 271, 1236, 1238, "or" +254, 9, 62, 280, 272, 283, 1239, 1250, "sitagliptin" +254, 9, 63, 281, 284, 287, 1251, 1254, "100" +254, 9, 64, 282, 288, 290, 1255, 1257, "mg" +254, 9, 65, 283, 291, 295, 1258, 1262, "once" +254, 9, 66, 284, 296, 301, 1263, 1268, "daily" +254, 9, 67, 285, 302, 303, 1269, 1270, "(" +254, 9, 68, 286, 304, 305, 1271, 1272, "n" +254, 9, 69, 287, 306, 307, 1273, 1274, "=" +254, 9, 70, 288, 308, 311, 1275, 1278, "320" +254, 9, 71, 289, 312, 313, 1279, 1280, ")" +254, 9, 72, 290, 314, 315, 1281, 1282, "." +254, 10, 1, 291, 0, 3, 1283, 1286, "The" +254, 10, 2, 292, 4, 11, 1287, 1294, "primary" +254, 10, 3, 293, 12, 20, 1295, 1303, "analysis" +254, 10, 4, 294, 21, 29, 1304, 1312, "assessed" +254, 10, 5, 295, 30, 37, 1313, 1320, "whether" +254, 10, 6, 296, 38, 50, 1321, 1333, "omarigliptin" +254, 10, 7, 297, 51, 54, 1334, 1337, "was" +254, 10, 8, 298, 55, 58, 1338, 1341, "non" +254, 10, 9, 299, 59, 60, 1342, 1343, "-" +254, 10, 10, 300, 61, 69, 1344, 1352, "inferior" +254, 10, 11, 301, 70, 72, 1353, 1355, "to" +254, 10, 12, 302, 73, 84, 1356, 1367, "sitagliptin" +254, 10, 13, 303, 85, 87, 1368, 1370, "in" +254, 10, 14, 304, 88, 96, 1371, 1379, "reducing" +254, 10, 15, 305, 97, 102, 1380, 1385, "HbA1c" +254, 10, 16, 306, 103, 105, 1386, 1388, "at" +254, 10, 17, 307, 106, 110, 1389, 1393, "week" +254, 10, 18, 308, 111, 113, 1394, 1396, "24" +254, 10, 19, 309, 114, 115, 1397, 1398, "," +254, 10, 20, 310, 116, 121, 1399, 1404, "based" +254, 10, 21, 311, 122, 124, 1405, 1407, "on" +254, 10, 22, 312, 125, 128, 1408, 1411, "the" +254, 10, 23, 313, 129, 138, 1412, 1421, "criterion" +254, 10, 24, 314, 139, 141, 1422, 1424, "of" +254, 10, 25, 315, 142, 148, 1425, 1431, "having" +254, 10, 26, 316, 149, 151, 1432, 1434, "an" +254, 10, 27, 317, 152, 157, 1435, 1440, "upper" +254, 10, 28, 318, 158, 163, 1441, 1446, "bound" +254, 10, 29, 319, 164, 166, 1447, 1449, "of" +254, 10, 30, 320, 167, 170, 1450, 1453, "the" +254, 10, 31, 321, 171, 173, 1454, 1456, "95" +254, 10, 32, 322, 174, 175, 1457, 1458, "%" +254, 10, 33, 323, 176, 186, 1459, 1469, "confidence" +254, 10, 34, 324, 187, 195, 1470, 1478, "interval" +254, 10, 35, 325, 196, 197, 1479, 1480, "(" +254, 10, 36, 326, 198, 200, 1481, 1483, "CI" +254, 10, 37, 327, 201, 202, 1484, 1485, ")" +254, 10, 38, 328, 203, 208, 1486, 1491, "about" +254, 10, 39, 329, 209, 212, 1492, 1495, "the" +254, 10, 40, 330, 213, 223, 1496, 1506, "difference" +254, 10, 41, 331, 224, 228, 1507, 1511, "less" +254, 10, 42, 332, 229, 233, 1512, 1516, "than" +254, 10, 43, 333, 234, 237, 1517, 1520, "the" +254, 10, 44, 334, 238, 241, 1521, 1524, "non" +254, 10, 45, 335, 242, 243, 1525, 1526, "-" +254, 10, 46, 336, 244, 255, 1527, 1538, "inferiority" +254, 10, 47, 337, 256, 261, 1539, 1544, "bound" +254, 10, 48, 338, 262, 264, 1545, 1547, "of" +254, 10, 49, 339, 265, 266, 1548, 1549, "0" +254, 10, 50, 340, 267, 268, 1550, 1551, "." +254, 10, 51, 341, 269, 270, 1552, 1553, "3" +254, 10, 52, 342, 271, 272, 1554, 1555, "%" +254, 10, 53, 343, 273, 274, 1556, 1557, "." +254, 11, 1, 344, 0, 7, 1558, 1565, "RESULTS" +254, 11, 2, 345, 8, 9, 1566, 1567, ":" +254, 11, 3, 346, 10, 13, 1568, 1571, "The" +254, 11, 4, 347, 14, 18, 1572, 1576, "mean" +254, 11, 5, 348, 19, 27, 1577, 1585, "baseline" +254, 11, 6, 349, 28, 33, 1586, 1591, "HbA1c" +254, 11, 7, 350, 34, 37, 1592, 1595, "was" +254, 11, 8, 351, 38, 39, 1596, 1597, "7" +254, 11, 9, 352, 40, 41, 1598, 1599, "." +254, 11, 10, 353, 42, 43, 1600, 1601, "5" +254, 11, 11, 354, 44, 45, 1602, 1603, "%" +254, 11, 12, 355, 46, 48, 1604, 1606, "in" +254, 11, 13, 356, 49, 53, 1607, 1611, "both" +254, 11, 14, 357, 54, 60, 1612, 1618, "groups" +254, 11, 15, 358, 61, 62, 1619, 1620, "." +254, 12, 1, 359, 0, 5, 1621, 1626, "After" +254, 12, 2, 360, 6, 8, 1627, 1629, "24" +254, 12, 3, 361, 9, 14, 1630, 1635, "weeks" +254, 12, 4, 362, 15, 16, 1636, 1637, "," +254, 12, 5, 363, 17, 20, 1638, 1641, "the" +254, 12, 6, 364, 21, 26, 1642, 1647, "least" +254, 12, 7, 365, 27, 34, 1648, 1655, "squares" +254, 12, 8, 366, 35, 36, 1656, 1657, "(" +254, 12, 9, 367, 37, 39, 1658, 1660, "LS" +254, 12, 10, 368, 40, 41, 1661, 1662, ")" +254, 12, 11, 369, 42, 46, 1663, 1667, "mean" +254, 12, 12, 370, 47, 53, 1668, 1674, "change" +254, 12, 13, 371, 54, 56, 1675, 1677, "in" +254, 12, 14, 372, 57, 62, 1678, 1683, "HbA1c" +254, 12, 15, 373, 63, 67, 1684, 1688, "from" +254, 12, 16, 374, 68, 76, 1689, 1697, "baseline" +254, 12, 17, 375, 77, 80, 1698, 1701, "was" +254, 12, 18, 376, 81, 82, 1702, 1703, "-" +254, 12, 19, 377, 83, 84, 1704, 1705, "0" +254, 12, 20, 378, 85, 86, 1706, 1707, "." +254, 12, 21, 379, 87, 89, 1708, 1710, "47" +254, 12, 22, 380, 90, 91, 1711, 1712, "%" +254, 12, 23, 381, 92, 94, 1713, 1715, "in" +254, 12, 24, 382, 95, 98, 1716, 1719, "the" +254, 12, 25, 383, 99, 111, 1720, 1732, "omarigliptin" +254, 12, 26, 384, 112, 117, 1733, 1738, "group" +254, 12, 27, 385, 118, 121, 1739, 1742, "and" +254, 12, 28, 386, 122, 123, 1743, 1744, "-" +254, 12, 29, 387, 124, 125, 1745, 1746, "0" +254, 12, 30, 388, 126, 127, 1747, 1748, "." +254, 12, 31, 389, 128, 130, 1749, 1751, "43" +254, 12, 32, 390, 131, 132, 1752, 1753, "%" +254, 12, 33, 391, 133, 135, 1754, 1756, "in" +254, 12, 34, 392, 136, 139, 1757, 1760, "the" +254, 12, 35, 393, 140, 151, 1761, 1772, "sitagliptin" +254, 12, 36, 394, 152, 157, 1773, 1778, "group" +254, 12, 37, 395, 158, 159, 1779, 1780, "," +254, 12, 38, 396, 160, 164, 1781, 1785, "with" +254, 12, 39, 397, 165, 166, 1786, 1787, "a" +254, 12, 40, 398, 167, 174, 1788, 1795, "between" +254, 12, 41, 399, 175, 176, 1796, 1797, "-" +254, 12, 42, 400, 177, 182, 1798, 1803, "group" +254, 12, 43, 401, 183, 193, 1804, 1814, "difference" +254, 12, 44, 402, 194, 196, 1815, 1817, "of" +254, 12, 45, 403, 197, 198, 1818, 1819, "-" +254, 12, 46, 404, 199, 200, 1820, 1821, "0" +254, 12, 47, 405, 201, 202, 1822, 1823, "." +254, 12, 48, 406, 203, 205, 1824, 1826, "03" +254, 12, 49, 407, 206, 207, 1827, 1828, "%" +254, 12, 50, 408, 208, 209, 1829, 1830, "(" +254, 12, 51, 409, 210, 212, 1831, 1833, "95" +254, 12, 52, 410, 213, 214, 1834, 1835, "%" +254, 12, 53, 411, 215, 217, 1836, 1838, "CI" +254, 12, 54, 412, 218, 219, 1839, 1840, "-" +254, 12, 55, 413, 220, 221, 1841, 1842, "0" +254, 12, 56, 414, 222, 223, 1843, 1844, "." +254, 12, 57, 415, 224, 226, 1845, 1847, "15" +254, 12, 58, 416, 227, 228, 1848, 1849, "," +254, 12, 59, 417, 229, 230, 1850, 1851, "0" +254, 12, 60, 418, 231, 232, 1852, 1853, "." +254, 12, 61, 419, 233, 235, 1854, 1856, "08" +254, 12, 62, 420, 236, 237, 1857, 1858, ")" +254, 12, 63, 421, 238, 239, 1859, 1860, "." +254, 13, 1, 422, 0, 4, 1861, 1865, "This" +254, 13, 2, 423, 5, 11, 1866, 1872, "result" +254, 13, 3, 424, 12, 15, 1873, 1876, "met" +254, 13, 4, 425, 16, 19, 1877, 1880, "the" +254, 13, 5, 426, 20, 32, 1881, 1893, "prespecified" +254, 13, 6, 427, 33, 42, 1894, 1903, "criterion" +254, 13, 7, 428, 43, 46, 1904, 1907, "for" +254, 13, 8, 429, 47, 56, 1908, 1917, "declaring" +254, 13, 9, 430, 57, 60, 1918, 1921, "non" +254, 13, 10, 431, 61, 62, 1922, 1923, "-" +254, 13, 11, 432, 63, 74, 1924, 1935, "inferiority" +254, 13, 12, 433, 75, 76, 1936, 1937, "." +254, 14, 1, 434, 0, 3, 1938, 1941, "The" +254, 14, 2, 435, 4, 6, 1942, 1944, "LS" +254, 14, 3, 436, 7, 11, 1945, 1949, "mean" +254, 14, 4, 437, 12, 18, 1950, 1956, "change" +254, 14, 5, 438, 19, 23, 1957, 1961, "from" +254, 14, 6, 439, 24, 32, 1962, 1970, "baseline" +254, 14, 7, 440, 33, 35, 1971, 1973, "in" +254, 14, 8, 441, 36, 43, 1974, 1981, "fasting" +254, 14, 9, 442, 44, 50, 1982, 1988, "plasma" +254, 14, 10, 443, 51, 58, 1989, 1996, "glucose" +254, 14, 11, 444, 59, 62, 1997, 2000, "and" +254, 14, 12, 445, 63, 66, 2001, 2004, "the" +254, 14, 13, 446, 67, 77, 2005, 2015, "percentage" +254, 14, 14, 447, 78, 80, 2016, 2018, "of" +254, 14, 15, 448, 81, 89, 2019, 2027, "patients" +254, 14, 16, 449, 90, 94, 2028, 2032, "with" +254, 14, 17, 450, 95, 100, 2033, 2038, "HbA1c" +254, 14, 18, 451, 101, 102, 2039, 2040, "<" +254, 14, 19, 452, 103, 104, 2041, 2042, "7" +254, 14, 20, 453, 105, 106, 2043, 2044, "." +254, 14, 21, 454, 107, 108, 2045, 2046, "0" +254, 14, 22, 455, 109, 110, 2047, 2048, "%" +254, 14, 23, 456, 111, 113, 2049, 2051, "or" +254, 14, 24, 457, 114, 115, 2052, 2053, "<" +254, 14, 25, 458, 116, 117, 2054, 2055, "6" +254, 14, 26, 459, 118, 119, 2056, 2057, "." +254, 14, 27, 460, 120, 121, 2058, 2059, "5" +254, 14, 28, 461, 122, 123, 2060, 2061, "%" +254, 14, 29, 462, 124, 126, 2062, 2064, "at" +254, 14, 30, 463, 127, 131, 2065, 2069, "week" +254, 14, 31, 464, 132, 134, 2070, 2072, "24" +254, 14, 32, 465, 135, 139, 2073, 2077, "were" +254, 14, 33, 466, 140, 147, 2078, 2085, "similar" +254, 14, 34, 467, 148, 150, 2086, 2088, "in" +254, 14, 35, 468, 151, 154, 2089, 2092, "the" +254, 14, 36, 469, 155, 158, 2093, 2096, "two" +254, 14, 37, 470, 159, 168, 2097, 2106, "treatment" +254, 14, 38, 471, 169, 175, 2107, 2113, "groups" +254, 14, 39, 472, 176, 177, 2114, 2115, "." +254, 15, 1, 473, 0, 5, 2116, 2121, "There" +254, 15, 2, 474, 6, 10, 2122, 2126, "were" +254, 15, 3, 475, 11, 13, 2127, 2129, "no" +254, 15, 4, 476, 14, 21, 2130, 2137, "notable" +254, 15, 5, 477, 22, 33, 2138, 2149, "differences" +254, 15, 6, 478, 34, 36, 2150, 2152, "in" +254, 15, 7, 479, 37, 44, 2153, 2160, "adverse" +254, 15, 8, 480, 45, 51, 2161, 2167, "events" +254, 15, 9, 481, 52, 55, 2168, 2171, "and" +254, 15, 10, 482, 56, 59, 2172, 2175, "the" +254, 15, 11, 483, 60, 69, 2176, 2185, "incidence" +254, 15, 12, 484, 70, 72, 2186, 2188, "of" +254, 15, 13, 485, 73, 84, 2189, 2200, "symptomatic" +254, 15, 14, 486, 85, 98, 2201, 2214, "hypoglycaemia" +254, 15, 15, 487, 99, 102, 2215, 2218, "was" +254, 15, 16, 488, 103, 106, 2219, 2222, "low" +254, 15, 17, 489, 107, 110, 2223, 2226, "and" +254, 15, 18, 490, 111, 118, 2227, 2234, "similar" +254, 15, 19, 491, 119, 121, 2235, 2237, "in" +254, 15, 20, 492, 122, 125, 2238, 2241, "the" +254, 15, 21, 493, 126, 132, 2242, 2248, "groups" +254, 15, 22, 494, 133, 134, 2249, 2250, "." +254, 16, 1, 495, 0, 11, 2251, 2262, "CONCLUSIONS" +254, 16, 2, 496, 12, 13, 2263, 2264, ":" +254, 16, 3, 497, 14, 16, 2265, 2267, "In" +254, 16, 4, 498, 17, 25, 2268, 2276, "patients" +254, 16, 5, 499, 26, 30, 2277, 2281, "with" +254, 16, 6, 500, 31, 35, 2282, 2286, "T2DM" +254, 16, 7, 501, 36, 39, 2287, 2290, "and" +254, 16, 8, 502, 40, 50, 2291, 2301, "inadequate" +254, 16, 9, 503, 51, 60, 2302, 2311, "glycaemic" +254, 16, 10, 504, 61, 68, 2312, 2319, "control" +254, 16, 11, 505, 69, 71, 2320, 2322, "on" +254, 16, 12, 506, 72, 81, 2323, 2332, "metformin" +254, 16, 13, 507, 82, 83, 2333, 2334, "," +254, 16, 14, 508, 84, 87, 2335, 2338, "the" +254, 16, 15, 509, 88, 96, 2339, 2347, "addition" +254, 16, 16, 510, 97, 99, 2348, 2350, "of" +254, 16, 17, 511, 100, 112, 2351, 2363, "omarigliptin" +254, 16, 18, 512, 113, 115, 2364, 2366, "25" +254, 16, 19, 513, 116, 118, 2367, 2369, "mg" +254, 16, 20, 514, 119, 123, 2370, 2374, "once" +254, 16, 21, 515, 124, 130, 2375, 2381, "weekly" +254, 16, 22, 516, 131, 133, 2382, 2384, "or" +254, 16, 23, 517, 134, 145, 2385, 2396, "sitagliptin" +254, 16, 24, 518, 146, 149, 2397, 2400, "100" +254, 16, 25, 519, 150, 152, 2401, 2403, "mg" +254, 16, 26, 520, 153, 157, 2404, 2408, "once" +254, 16, 27, 521, 158, 163, 2409, 2414, "daily" +254, 16, 28, 522, 164, 167, 2415, 2418, "led" +254, 16, 29, 523, 168, 170, 2419, 2421, "to" +254, 16, 30, 524, 171, 178, 2422, 2429, "similar" +254, 16, 31, 525, 179, 191, 2430, 2442, "improvements" +254, 16, 32, 526, 192, 194, 2443, 2445, "in" +254, 16, 33, 527, 195, 204, 2446, 2455, "glycaemic" +254, 16, 34, 528, 205, 212, 2456, 2463, "control" +254, 16, 35, 529, 213, 214, 2464, 2465, "." +254, 17, 1, 530, 0, 4, 2466, 2470, "Both" +254, 17, 2, 531, 5, 11, 2471, 2477, "agents" +254, 17, 3, 532, 12, 16, 2478, 2482, "were" +254, 17, 4, 533, 17, 26, 2483, 2492, "generally" +254, 17, 5, 534, 27, 31, 2493, 2497, "well" +254, 17, 6, 535, 32, 41, 2498, 2507, "tolerated" +254, 17, 7, 536, 42, 46, 2508, 2512, "with" +254, 17, 8, 537, 47, 48, 2513, 2514, "a" +254, 17, 9, 538, 49, 52, 2515, 2518, "low" +254, 17, 10, 539, 53, 62, 2519, 2528, "incidence" +254, 17, 11, 540, 63, 65, 2529, 2531, "of" +254, 17, 12, 541, 66, 79, 2532, 2545, "hypoglycaemia" +254, 17, 13, 542, 80, 81, 2546, 2547, "." +254, 18, 1, 543, 0, 1, 2548, 2549, "©" +254, 18, 2, 544, 2, 6, 2550, 2554, "2017" +254, 18, 3, 545, 7, 12, 2555, 2560, "Merck" +254, 18, 4, 546, 13, 18, 2561, 2566, "Sharp" +254, 18, 5, 547, 19, 20, 2567, 2568, "&" +254, 18, 6, 548, 21, 26, 2569, 2574, "Dohme" +254, 18, 7, 549, 27, 31, 2575, 2579, "Corp" +254, 18, 8, 550, 32, 33, 2580, 2581, "." +254, 18, 9, 551, 34, 42, 2582, 2590, "Diabetes" +254, 18, 10, 552, 43, 44, 2591, 2592, "," +254, 18, 11, 553, 45, 52, 2593, 2600, "Obesity" +254, 18, 12, 554, 53, 56, 2601, 2604, "and" +254, 18, 13, 555, 57, 67, 2605, 2615, "Metabolism" +254, 18, 14, 556, 68, 77, 2616, 2625, "published" +254, 18, 15, 557, 78, 80, 2626, 2628, "by" +254, 18, 16, 558, 81, 85, 2629, 2633, "John" +254, 18, 17, 559, 86, 91, 2634, 2639, "Wiley" +254, 18, 18, 560, 92, 93, 2640, 2641, "&" +254, 18, 19, 561, 94, 98, 2642, 2646, "Sons" +254, 18, 20, 562, 99, 102, 2647, 2650, "Ltd" +254, 18, 21, 563, 103, 104, 2651, 2652, "." +254, 18, 22, 564, 105, 108, 2653, 2656, "DOI" +254, 18, 23, 565, 109, 110, 2657, 2658, ":" +254, 18, 24, 566, 111, 113, 2659, 2661, "10" +254, 18, 25, 567, 114, 115, 2662, 2663, "." +254, 18, 26, 568, 116, 120, 2664, 2668, "1111" +254, 18, 27, 569, 121, 122, 2669, 2670, "/" +254, 18, 28, 570, 123, 126, 2671, 2674, "dom" +254, 18, 29, 571, 127, 128, 2675, 2676, "." +254, 18, 30, 572, 129, 134, 2677, 2682, "12832" +254, 18, 31, 573, 135, 140, 2683, 2688, "PMCID" +254, 18, 32, 574, 141, 142, 2689, 2690, ":" +254, 18, 33, 575, 143, 153, 2691, 2701, "PMC5347923" +254, 18, 34, 576, 154, 158, 2702, 2706, "PMID" +254, 18, 35, 577, 159, 160, 2707, 2708, ":" +254, 18, 36, 578, 161, 169, 2709, 2717, "28093853" +254, 18, 37, 579, 170, 171, 2718, 2719, "[" +254, 18, 38, 580, 172, 179, 2720, 2727, "Indexed" +254, 18, 39, 581, 180, 183, 2728, 2731, "for" +254, 18, 40, 582, 184, 191, 2732, 2739, "MEDLINE" +254, 18, 41, 583, 192, 193, 2740, 2741, "]" diff --git a/data/dm2 28093853_kwoodley.annodb b/data/dm2 28093853_kwoodley.annodb new file mode 100644 index 0000000..0326b88 --- /dev/null +++ b/data/dm2 28093853_kwoodley.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71206, Journal, 0, 19, "Diabetes Obes Metab", "", +71207, PublicationYear, 22, 26, "2017", "", +71209, Randomized, 107, 117, "Randomized", "", +71234, Title, 107, 312, "Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin", "", +71210, Frequency, 189, 202, "once - weekly", "", +71211, Omarigliptin, 250, 262, "omarigliptin", "", +71217, Frequency, 270, 282, "once - daily", "", +71218, Sitagliptin, 301, 312, "sitagliptin", "", +71235, Title, 313, 396, "in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", +71233, Precondition, 316, 394, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +71224, Type2Diabetes, 330, 345, "type 2 diabetes", "", +71228, Metformin, 373, 382, "metformin", "", +71236, Author, 397, 409, "Goldenberg R", "", +71237, Author, 418, 425, "Gantz I", "", +71238, Author, 434, 444, "Andryuk PJ", "", +71239, Author, 453, 465, "O ' Neill EA", "", +71240, Author, 474, 484, "Kaufman KD", "", +71241, Author, 493, 498, "Lai E", "", +71242, Author, 507, 514, "Wang YN", "", +71243, Author, 523, 536, "Suryawanshi S", "", +71244, Author, 545, 553, "Engel SS", "", +71245, Canada, 640, 646, "Canada", "", +71253, ObjectiveDescription, 710, 876, "To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin", "", +71246, Frequency, 752, 765, "once - weekly", "", +71212, Omarigliptin, 818, 830, "omarigliptin", "", +71247, Frequency, 834, 846, "once - daily", "", +71219, Sitagliptin, 865, 876, "sitagliptin", "", +71254, ObjectiveDescription, 877, 966, "in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .", "", +71252, Precondition, 880, 964, "patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin", "", +71225, Type2Diabetes, 894, 909, "type 2 diabetes", "", +71226, Type2Diabetes, 912, 916, "T2DM", "", +71229, Metformin, 955, 964, "metformin", "", +71264, Precondition, 991, 1138, "Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )", "", +71231, Type2Diabetes, 1005, 1009, "T2DM", "", +71255, HbA1c, 1017, 1037, "glycated haemoglobin", "", +71256, HbA1c, 1040, 1045, "HbA1c", "", +71259, Percentage, 1070, 1071, "%", "", +71260, Percentage, 1083, 1084, "%", "", +71230, Metformin, 1111, 1120, "metformin", "", +71263, DoseValue, 1123, 1129, "≥ 1500", "", +71261, mg, 1130, 1132, "mg", "", +71262, Frequency, 1135, 1136, "d", "", +71265, Randomized, 1144, 1154, "randomized", "", +71266, DoubleBlind, 1160, 1174, "double - blind", "", +71213, Omarigliptin, 1193, 1205, "omarigliptin", "", +71267, DoseValue, 1206, 1208, "25", "", +71269, mg, 1209, 1211, "mg", "", +71248, Frequency, 1212, 1223, "once weekly", "", +71271, NumberPatientsArm, 1230, 1233, "322", "", +71220, Sitagliptin, 1239, 1250, "sitagliptin", "", +71268, DoseValue, 1251, 1254, "100", "", +71270, mg, 1255, 1257, "mg", "", +71249, Frequency, 1258, 1268, "once daily", "", +71272, NumberPatientsArm, 1275, 1278, "320", "", +71214, Omarigliptin, 1321, 1333, "omarigliptin", "", +71221, Sitagliptin, 1356, 1367, "sitagliptin", "", +71257, HbA1c, 1380, 1385, "HbA1c", "", +71273, TimePoint, 1389, 1396, "week 24", "", +71278, ConfIntervalBL, 1454, 1485, "95 % confidence interval ( CI )", "", +71279, TimePoint, 1577, 1585, "baseline", "", +71280, HbA1c, 1586, 1591, "HbA1c", "", +71281, BaseLineValue, 1596, 1601, "7 . 5", "", +71282, Percentage, 1602, 1603, "%", "", +71274, TimePoint, 1627, 1635, "24 weeks", "", +71286, LeastSquaresMean, 1642, 1667, "least squares ( LS ) mean", "", +71258, HbA1c, 1678, 1683, "HbA1c", "", +71275, TimePoint, 1689, 1697, "baseline", "", +71287, Reduction, 1704, 1710, "0 . 47", "", +71283, Percentage, 1711, 1712, "%", "", +71215, Omarigliptin, 1720, 1732, "omarigliptin", "", +71288, Reduction, 1745, 1751, "0 . 43", "", +71284, Percentage, 1752, 1753, "%", "", +71222, Sitagliptin, 1761, 1772, "sitagliptin", "", +71289, DiffGroupAbsValue, 1818, 1826, "- 0 . 03", "", +71285, Percentage, 1827, 1828, "%", "", +71290, ConfIntervalDiff, 1831, 1856, "95 % CI - 0 . 15 , 0 . 08", "", +71291, LeastSquaresMean, 1942, 1949, "LS mean", "", +71276, TimePoint, 1962, 1970, "baseline", "", +71292, FastingPlasmaGlucose, 1974, 1996, "fasting plasma glucose", "", +71293, HbA1c_target, 2033, 2048, "HbA1c < 7 . 0 %", "", +71294, HbA1c_target, 2033, 2061, "HbA1c < 7 . 0 % or < 6 . 5 %", "", +71277, TimePoint, 2065, 2072, "week 24", "", +71295, ObservedResult, 2073, 2113, "were similar in the two treatment groups", "", +71298, ObservedResult, 2116, 2250, "There were no notable differences in adverse events and the incidence of symptomatic hypoglycaemia was low and similar in the groups .", "", +71296, EndPointDescription, 2153, 2167, "adverse events", "", +71297, SymptomaticHypoglycemia, 2189, 2214, "symptomatic hypoglycaemia", "", +71304, ConclusionComment, 2265, 2465, "In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .", "", +71299, Precondition, 2268, 2332, "patients with T2DM and inadequate glycaemic control on metformin", "", +71227, Type2Diabetes, 2282, 2286, "T2DM", "", +71232, Metformin, 2323, 2332, "metformin", "", +71216, Omarigliptin, 2351, 2363, "omarigliptin", "", +71300, DoseValue, 2364, 2366, "25", "", +71302, mg, 2367, 2369, "mg", "", +71250, Frequency, 2370, 2381, "once weekly", "", +71223, Sitagliptin, 2385, 2396, "sitagliptin", "", +71301, DoseValue, 2397, 2400, "100", "", +71303, mg, 2401, 2403, "mg", "", +71251, Frequency, 2404, 2414, "once daily", "", +71305, ConclusionComment, 2466, 2547, "Both agents were generally well tolerated with a low incidence of hypoglycaemia .", "", +71306, Hypoglycemia, 2532, 2545, "hypoglycaemia", "", +71307, PMID, 2709, 2717, "28093853", "", diff --git a/data/dm2 28093853_kwoodley.n-triples b/data/dm2 28093853_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28093853_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345162_admin.annodb b/data/dm2 28345162_admin.annodb new file mode 100644 index 0000000..459da6e --- /dev/null +++ b/data/dm2 28345162_admin.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +9, Title, 109, 306, "Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine : A randomized phase IV study ( NEXTAGE Study ) .", "", " \"Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine : A randomized phase IV study ( NEXTAGE Study ) .\"." +8, PostprandialBloodGlucose, 122, 142, "postprandial glucose", "", +98508, Lixisenatide, 146, 158, "lixisenatide", "", +3, Sitagliptin, 162, 173, "sitagliptin", "", +4, Ethnicity, 187, 195, "Japanese", "", " . ." +134, Precondition, 196, 256, "patients with type 2 diabetes on background insulin glargine", "", +5, Type2Diabetes, 210, 225, "type 2 diabetes", "", " ." +129, InsulinGlargine, 240, 256, "insulin glargine", "", +7, Randomized, 261, 271, "randomized", "", " ." +10, Author, 307, 315, "Yamada Y", "", " \"Yamada Y\"." +11, Author, 324, 331, "Senda M", "", " \"Senda M\"." +12, Author, 340, 347, "Naito Y", "", " \"Naito Y\"." +13, Author, 356, 364, "Tamura M", "", " \"Tamura M\"." +14, Author, 373, 383, "Watanabe D", "", " \"Watanabe D\"." +15, Author, 392, 399, "Shuto Y", "", " \"Shuto Y\"." +16, Author, 408, 415, "Urita Y", "", " \"Urita Y\"." +17, Japan, 594, 599, "Japan", "", " ." +18, Japan, 651, 656, "Japan", "", +19, Japan, 739, 744, "Japan", "", +20, Japan, 810, 815, "Japan", "", +21, Japan, 938, 943, "Japan", "", +28, ObjectiveDescription, 952, 1113, "To evaluate the pharmacodynamics of lixisenatide once daily vs sitagliptin once daily in Japanese patients with type 2 diabetes receiving insulin glargine U100 .", "", " \"To evaluate the pharmacodynamics of lixisenatide once daily vs sitagliptin once daily in Japanese patients with type 2 diabetes receiving insulin glargine U100 .\"." +98510, Lixisenatide, 988, 1000, "lixisenatide", "", +23, Frequency, 1001, 1011, "once daily", "", +152, Sitagliptin, 1015, 1026, "sitagliptin", "", +24, Frequency, 1027, 1037, "once daily", "", +25, Ethnicity, 1041, 1049, "Japanese", "", +153, Precondition, 1050, 1111, "patients with type 2 diabetes receiving insulin glargine U100", "", " \"patients with type 2 diabetes receiving insulin glargine U100\"." +26, Type2Diabetes, 1064, 1079, "type 2 diabetes", "", +27, InsulinGlargine, 1090, 1106, "insulin glargine", "", +29, Multicenter, 1143, 1154, "multicentre", "", " ." +30, OpenLabel, 1157, 1169, "open - label", "", " ." +31, Randomized, 1249, 1257, "randomly", "", +32, NumberPatientsCT, 1267, 1270, "136", "", " \"136\"." +98511, Lixisenatide, 1290, 1302, "lixisenatide", "", " ." +34, Frequency, 1303, 1313, "once daily", "", " \"once daily\"." +38, SubcutaneousInjection, 1318, 1340, "subcutaneous injection", "", " ." +39, DoseDescription, 1343, 1396, "10  µ g initially increased weekly by 5 up to 20  µ g", "", " \"10  µ g initially increased weekly by 5 up to 20  µ g\"." +41, Microgram, 1346, 1350, " µ g", "", " ." +42, Microgram, 1392, 1396, " µ g", "", +35, Frequency, 1402, 1414, "once - daily", "", " \"once - daily\"." +36, Oral, 1415, 1419, "oral", "", " ." +37, Sitagliptin, 1420, 1431, "sitagliptin", "", " ." +162, DoseValue, 1432, 1434, "50", "", " \"50\"." +43, mg, 1437, 1439, "mg", "", " ." +164, PostprandialBloodGlucose, 1481, 1501, "postprandial glucose", "", +165, PostprandialBloodGlucose, 1504, 1507, "PPG", "", +45, Hour, 1523, 1528, "hours", "", +166, PostprandialBloodGlucose, 1562, 1565, "PPG", "", +46, TimePoint, 1654, 1662, "baseline", "", +98518, Duration, 1666, 1672, "day 29", "", " \"day 29\"." +98512, Lixisenatide, 1685, 1697, "Lixisenatide", "", +169, PostprandialBloodGlucose, 1706, 1709, "PPG", "", " ." +50, Sitagliptin, 1772, 1783, "sitagliptin", "", +51, LeastSquaresMean, 1786, 1811, "least squares ( LS ) mean", "", " ." +52, TimePoint, 1824, 1832, "baseline", "", +172, PostprandialBloodGlucose, 1836, 1839, "PPG", "", +174, Reduction, 1866, 1873, "347 . 3", "", " \"347 . 3\"." +173, Mg_per_deciliter, 1878, 1885, "mg / dL", "", " ." +175, Reduction, 1890, 1896, "19 . 3", "", +176, Millimoles_per_litre, 1901, 1909, "mmol / L", "", +98517, Lixisenatide, 1919, 1931, "lixisenatide", "", +177, Reduction, 1944, 1951, "113 . 3", "", " \"113 . 3\"." +179, Mg_per_deciliter, 1956, 1963, "mg / dL", "", +178, Reduction, 1968, 1973, "6 . 3", "", +180, Millimoles_per_litre, 1978, 1986, "mmol / L", "", +74, Sitagliptin, 1996, 2007, "sitagliptin", "", +181, LeastSquaresMean, 2016, 2023, "LS mean", "", +58, DiffGroupAbsValue, 2051, 2060, "- 234 . 0", "", " \"- 234 . 0\"." +184, Mg_per_deciliter, 2065, 2072, "mg / dL", "", +59, DiffGroupAbsValue, 2075, 2083, "- 13 . 0", "", +186, Millimoles_per_litre, 2088, 2096, "mmol / L", "", +60, ConfIntervalDiff, 2101, 2200, "95 % confidence interval - 285 . 02 to - 183 . 00 h · mg / dL [ - 15 . 8 to - 10 . 2 h · mmol / L ]", "", " \"95 % confidence interval - 285 . 02 to - 183 . 00 h · mg / dL [ - 15 . 8 to - 10 . 2 h · mmol / L ]\"." +185, Mg_per_deciliter, 2155, 2162, "mg / dL", "", +187, Millimoles_per_litre, 2190, 2198, "mmol / L", "", +61, PvalueDiff, 2203, 2214, "P  < . 0001", "", " \"P  < . 0001\"." +98516, Lixisenatide, 2219, 2231, "Lixisenatide", "", +77, LeastSquaresMean, 2261, 2268, "LS mean", "", +191, PostprandialBloodGlucose, 2291, 2294, "PPG", "", +79, Sitagliptin, 2310, 2321, "sitagliptin", "", +192, Reduction, 2326, 2333, "122 . 4", "", +193, Reduction, 2339, 2345, "46 . 6", "", +81, Mg_per_deciliter, 2346, 2353, "mg / dL", "", +194, Reduction, 2358, 2363, "6 . 8", "", +195, Reduction, 2369, 2374, "2 . 6", "", +197, Millimoles_per_litre, 2379, 2387, "mmol / L", "", +87, PvalueDiff, 2392, 2403, "P  < . 0001", "", +203, ObservedResult, 2408, 2597, "Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group .", "", " \"Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group .\". \"Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group .\". \"Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group .\"." +88, TimePoint, 2424, 2432, "baseline", "", +200, EndPointDescription, 2459, 2470, "C - peptide", "", " . ." +201, EndPointDescription, 2473, 2493, "fasting glycoalbumin", "", " . ." +202, EndPointDescription, 2511, 2532, "gastric emptying rate", "", " . ." +98515, Lixisenatide, 2553, 2565, "lixisenatide", "", +89, Sitagliptin, 2578, 2589, "sitagliptin", "", +204, EndPointDescription, 2636, 2650, "adverse events", "", " . ." +98513, Lixisenatide, 2667, 2679, "lixisenatide", "", +96, PercentageAffected, 2682, 2688, "60 . 9", "", " \"60 . 9\"." +93, Sitagliptin, 2703, 2714, "sitagliptin", "", +97, PercentageAffected, 2717, 2723, "16 . 4", "", " \"16 . 4\"." +208, ObservedResult, 2730, 2785, "with no serious events or severe hypoglycaemia reported", "", " \"with no serious events or severe hypoglycaemia reported\"." +94, SevereHypoglycemia, 2756, 2776, "severe hypoglycaemia", "", " ." +210, ConclusionComment, 2801, 2950, "Lixisenatide reduced PPG significantly more than sitagliptin , when these agents were added to basal insulin glargine U100 , and was well tolerated .", "", " \"Lixisenatide reduced PPG significantly more than sitagliptin , when these agents were added to basal insulin glargine U100 , and was well tolerated .\"." +98514, Lixisenatide, 2801, 2813, "Lixisenatide", "", +209, PostprandialBloodGlucose, 2822, 2825, "PPG", "", +101, Sitagliptin, 2850, 2861, "sitagliptin", "", +102, InsulinGlargine, 2902, 2918, "insulin glargine", "", +104, PMID, 3099, 3107, "28345162", "", " \"28345162\"." diff --git a/data/dm2 28345162_admin.n-triples b/data/dm2 28345162_admin.n-triples new file mode 100644 index 0000000..1c1dab6 --- /dev/null +++ b/data/dm2 28345162_admin.n-triples @@ -0,0 +1,166 @@ +# RDF export of group: Publication + . + "Publication " . + "Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine : A randomized phase IV study ( NEXTAGE Study ) ." . + "Yamada Y" . + "2017" . + "28345162" . + . + "Senda M" . + "Naito Y" . + "Tamura M" . + "Watanabe D" . + "Shuto Y" . + "Urita Y" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the pharmacodynamics of lixisenatide once daily vs sitagliptin once daily in Japanese patients with type 2 diabetes receiving insulin glargine U100 ." . + "136" . + "day 29" . + . + . + . + "Lixisenatide reduced PPG significantly more than sitagliptin , when these agents were added to basal insulin glargine U100 , and was well tolerated ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with type 2 diabetes receiving insulin glargine U100" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint c peptide" . + . + . + . + . + . + . + "Endpoint fg" . + . + . + . + . + . + . + "Endpoint ge" . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + . + . + . + . + "Arm s" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "once daily" . + . + . + "Intervention s" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + "10  µ g initially increased weekly by 5 up to 20  µ g" . + . + "Medication s" . + . + "50" . + . + . +# RDF export of group: Outcome + . + "Outcome ppg l" . + . + "347 . 3" . + . + "Outcome ppg s" . + . + "113 . 3" . + . + "Outcome c peptide both drugs" . + . + "Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group ." . + . + "Outcome fg both drugs" . + . + "Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group ." . + . + "Outcome ge both drugs" . + . + "Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group ." . + . + "Outcome aes l" . + . + "60 . 9" . + . + "Outcome aes s" . + . + "16 . 4" . + . + "Outcome sh both drugs" . + . + "with no serious events or severe hypoglycaemia reported" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups ppg" . + "- 234 . 0" . + "P  < . 0001" . + "95 % confidence interval - 285 . 02 to - 183 . 00 h · mg / dL [ - 15 . 8 to - 10 . 2 h · mmol / L ]" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345162_akramersunderbrink.annodb b/data/dm2 28345162_akramersunderbrink.annodb new file mode 100644 index 0000000..251bfe6 --- /dev/null +++ b/data/dm2 28345162_akramersunderbrink.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +68063, Journal, 0, 19, "Diabetes Obes Metab", "", +68064, PublicationYear, 22, 26, "2017", "", +68072, Title, 109, 306, "Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine : A randomized phase IV study ( NEXTAGE Study ) .", "", +68071, PostprandialBloodGlucose, 122, 142, "postprandial glucose", "", +68065, Drug, 146, 158, "lixisenatide", "", +68066, Sitagliptin, 162, 173, "sitagliptin", "", +68067, Ethnicity, 187, 195, "Japanese", "", +68068, Type2Diabetes, 210, 225, "type 2 diabetes", "", +68069, InsulinGlargine, 248, 256, "glargine", "", +68070, Randomized, 261, 271, "randomized", "", +68073, Author, 307, 315, "Yamada Y", "", +68074, Author, 324, 331, "Senda M", "", +68075, Author, 340, 347, "Naito Y", "", +68076, Author, 356, 364, "Tamura M", "", +68077, Author, 373, 383, "Watanabe D", "", +68078, Author, 392, 399, "Shuto Y", "", +68079, Author, 408, 415, "Urita Y", "", +68080, Japan, 594, 599, "Japan", "", +68081, Japan, 651, 656, "Japan", "", +68082, Japan, 739, 744, "Japan", "", +68083, Japan, 810, 815, "Japan", "", +68084, Japan, 938, 943, "Japan", "", +68091, ObjectiveDescription, 952, 1113, "To evaluate the pharmacodynamics of lixisenatide once daily vs sitagliptin once daily in Japanese patients with type 2 diabetes receiving insulin glargine U100 .", "", +68085, Drug, 988, 1000, "lixisenatide", "", +68086, Frequency, 1001, 1011, "once daily", "", +68087, Frequency, 1027, 1037, "once daily", "", +68088, Ethnicity, 1041, 1049, "Japanese", "", +68089, Type2Diabetes, 1064, 1079, "type 2 diabetes", "", +68090, InsulinGlargine, 1090, 1106, "insulin glargine", "", +68092, Multicenter, 1143, 1154, "multicentre", "", +68093, OpenLabel, 1157, 1169, "open - label", "", +68094, Randomized, 1249, 1257, "randomly", "", +68095, NumberPatientsCT, 1267, 1270, "136", "", +68096, Drug, 1290, 1302, "lixisenatide", "", +68097, Frequency, 1303, 1313, "once daily", "", +68101, SubcutaneousInjection, 1318, 1340, "subcutaneous injection", "", +68103, DoseDescription, 1343, 1396, "10  µ g initially increased weekly by 5 up to 20  µ g", "", +68105, Microgram, 1346, 1350, " µ g", "", +68106, Microgram, 1392, 1396, " µ g", "", +68098, Frequency, 1402, 1414, "once - daily", "", +68099, Oral, 1415, 1419, "oral", "", +68100, Sitagliptin, 1420, 1431, "sitagliptin", "", +68104, DoseValue, 1432, 1439, "50   mg", "", +68107, mg, 1437, 1439, "mg", "", +68132, PostprandialPlasmaGlucose, 1481, 1648, "postprandial glucose ( PPG ) exposure 4   hours after a standardized breakfast ( PPG area under the plasma glucose concentration - time curve [ AUC0 : 00 - 4 : 00h ] )", "", +68133, PostprandialPlasmaGlucose, 1504, 1507, "PPG", "", +68112, Hour, 1523, 1528, "hours", "", +68111, PostprandialPlasmaGlucose, 1562, 1565, "PPG", "", +68114, TimePoint, 1654, 1662, "baseline", "", +68115, TimePoint, 1666, 1672, "day 29", "", +68116, Drug, 1685, 1697, "Lixisenatide", "", +68117, PostprandialPlasmaGlucose, 1706, 1709, "PPG", "", +68118, Sitagliptin, 1772, 1783, "sitagliptin", "", +68119, LeastSquaresMean, 1786, 1811, "least squares ( LS ) mean", "", +68120, TimePoint, 1824, 1832, "baseline", "", +68131, PostprandialPlasmaGlucose, 1836, 1859, "PPG AUC0 : 00 - 4 : 00h", "", +68122, ChangeValue, 1864, 1873, "- 347 . 3", "", +68134, BioAndMedicalUnit, 1874, 1885, "h · mg / dL", "", +68123, ChangeValue, 1888, 1896, "- 19 . 3", "", +68135, BioAndMedicalUnit, 1897, 1909, "h · mmol / L", "", +68144, Drug, 1919, 1931, "lixisenatide", "", +68124, ChangeValue, 1942, 1951, "- 113 . 3", "", +68136, BioAndMedicalUnit, 1952, 1963, "h · mg / dL", "", +68125, ChangeValue, 1966, 1973, "- 6 . 3", "", +68137, BioAndMedicalUnit, 1974, 1986, "h · mmol / L", "", +68143, Sitagliptin, 1996, 2007, "sitagliptin", "", +68121, LeastSquaresMean, 2016, 2031, "LS mean between", "", +68126, DiffGroupAbsValue, 2051, 2060, "- 234 . 0", "", +68138, BioAndMedicalUnit, 2061, 2072, "h · mg / dL", "", +68127, DiffGroupAbsValue, 2075, 2083, "- 13 . 0", "", +68139, BioAndMedicalUnit, 2084, 2096, "h · mmol / L", "", +68128, ConfIntervalDiff, 2101, 2200, "95 % confidence interval - 285 . 02 to - 183 . 00 h · mg / dL [ - 15 . 8 to - 10 . 2 h · mmol / L ]", "", +68142, Percentage, 2104, 2105, "%", "", +68140, BioAndMedicalUnit, 2151, 2162, "h · mg / dL", "", +68141, BioAndMedicalUnit, 2186, 2198, "h · mmol / L", "", +68129, PvalueDiff, 2203, 2214, "P  < . 0001", "", +68145, Drug, 2219, 2231, "Lixisenatide", "", +68146, LeastSquaresMean, 2261, 2268, "LS mean", "", +68149, PostprandialPlasmaGlucose, 2283, 2304, "maximum PPG excursion", "", +68147, PostprandialPlasmaGlucose, 2291, 2294, "PPG", "", +68148, Sitagliptin, 2310, 2321, "sitagliptin", "", +68152, ChangeValue, 2324, 2333, "- 122 . 4", "", +68153, ChangeValue, 2337, 2345, "- 46 . 6", "", +68150, Mg_per_deciliter, 2346, 2353, "mg / dL", "", +68154, ChangeValue, 2356, 2363, "- 6 . 8", "", +68155, ChangeValue, 2367, 2374, "- 2 . 6", "", +68151, BioAndMedicalUnit, 2375, 2387, "h · mmol / L", "", +68156, PvalueDiff, 2392, 2403, "P  < . 0001", "", +68157, TimePoint, 2424, 2432, "baseline", "", +68159, Drug, 2553, 2565, "lixisenatide", "", +68158, Sitagliptin, 2578, 2589, "sitagliptin", "", +68160, EndPointDescription, 2615, 2650, "treatment - emergent adverse events", "", +68161, Drug, 2667, 2679, "lixisenatide", "", +68165, PercentageAffected, 2682, 2688, "60 . 9", "", +68167, Percentage, 2689, 2690, "%", "", +68162, Sitagliptin, 2703, 2714, "sitagliptin", "", +68166, PercentageAffected, 2717, 2723, "16 . 4", "", +68168, Percentage, 2724, 2725, "%", "", +68164, NumberAffected, 2735, 2737, "no", "", +68163, SevereHypoglycemia, 2756, 2776, "severe hypoglycaemia", "", +68169, Drug, 2801, 2813, "Lixisenatide", "", +68172, PostprandialPlasmaGlucose, 2822, 2825, "PPG", "", +68170, Sitagliptin, 2850, 2861, "sitagliptin", "", +68171, InsulinGlargine, 2902, 2918, "insulin glargine", "", +68173, PMID, 3099, 3107, "28345162", "", diff --git a/data/dm2 28345162_akramersunderbrink.n-triples b/data/dm2 28345162_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28345162_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345162_export.csv b/data/dm2 28345162_export.csv new file mode 100644 index 0000000..ea09c76 --- /dev/null +++ b/data/dm2 28345162_export.csv @@ -0,0 +1,680 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +252, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +252, 1, 2, 2, 9, 13, 9, 13, "Obes" +252, 1, 3, 3, 14, 19, 14, 19, "Metab" +252, 1, 4, 4, 20, 21, 20, 21, "." +252, 2, 1, 5, 0, 4, 22, 26, "2017" +252, 2, 2, 6, 5, 8, 27, 30, "Sep" +252, 2, 3, 7, 9, 10, 31, 32, ";" +252, 2, 4, 8, 11, 13, 33, 35, "19" +252, 2, 5, 9, 14, 15, 36, 37, "(" +252, 2, 6, 10, 16, 17, 38, 39, "9" +252, 2, 7, 11, 18, 19, 40, 41, ")" +252, 2, 8, 12, 20, 21, 42, 43, ":" +252, 2, 9, 13, 22, 26, 44, 48, "1252" +252, 2, 10, 14, 27, 28, 49, 50, "-" +252, 2, 11, 15, 29, 33, 51, 55, "1259" +252, 2, 12, 16, 34, 35, 56, 57, "." +252, 2, 13, 17, 36, 39, 58, 61, "doi" +252, 2, 14, 18, 40, 41, 62, 63, ":" +252, 2, 15, 19, 42, 44, 64, 66, "10" +252, 2, 16, 20, 45, 46, 67, 68, "." +252, 2, 17, 21, 47, 51, 69, 73, "1111" +252, 2, 18, 22, 52, 53, 74, 75, "/" +252, 2, 19, 23, 54, 57, 76, 79, "dom" +252, 2, 20, 24, 58, 59, 80, 81, "." +252, 2, 21, 25, 60, 65, 82, 87, "12945" +252, 2, 22, 26, 66, 67, 88, 89, "." +252, 3, 1, 27, 0, 4, 90, 94, "Epub" +252, 3, 2, 28, 5, 9, 95, 99, "2017" +252, 3, 3, 29, 10, 13, 100, 103, "Apr" +252, 3, 4, 30, 14, 16, 104, 106, "27" +252, 3, 5, 31, 17, 18, 107, 108, "." +252, 4, 1, 32, 0, 9, 109, 118, "Reduction" +252, 4, 2, 33, 10, 12, 119, 121, "of" +252, 4, 3, 34, 13, 25, 122, 134, "postprandial" +252, 4, 4, 35, 26, 33, 135, 142, "glucose" +252, 4, 5, 36, 34, 36, 143, 145, "by" +252, 4, 6, 37, 37, 49, 146, 158, "lixisenatide" +252, 4, 7, 38, 50, 52, 159, 161, "vs" +252, 4, 8, 39, 53, 64, 162, 173, "sitagliptin" +252, 4, 9, 40, 65, 74, 174, 183, "treatment" +252, 4, 10, 41, 75, 77, 184, 186, "in" +252, 4, 11, 42, 78, 86, 187, 195, "Japanese" +252, 4, 12, 43, 87, 95, 196, 204, "patients" +252, 4, 13, 44, 96, 100, 205, 209, "with" +252, 4, 14, 45, 101, 105, 210, 214, "type" +252, 4, 15, 46, 106, 107, 215, 216, "2" +252, 4, 16, 47, 108, 116, 217, 225, "diabetes" +252, 4, 17, 48, 117, 119, 226, 228, "on" +252, 4, 18, 49, 120, 130, 229, 239, "background" +252, 4, 19, 50, 131, 138, 240, 247, "insulin" +252, 4, 20, 51, 139, 147, 248, 256, "glargine" +252, 4, 21, 52, 148, 149, 257, 258, ":" +252, 4, 22, 53, 150, 151, 259, 260, "A" +252, 4, 23, 54, 152, 162, 261, 271, "randomized" +252, 4, 24, 55, 163, 168, 272, 277, "phase" +252, 4, 25, 56, 169, 171, 278, 280, "IV" +252, 4, 26, 57, 172, 177, 281, 286, "study" +252, 4, 27, 58, 178, 179, 287, 288, "(" +252, 4, 28, 59, 180, 187, 289, 296, "NEXTAGE" +252, 4, 29, 60, 188, 193, 297, 302, "Study" +252, 4, 30, 61, 194, 195, 303, 304, ")" +252, 4, 31, 62, 196, 197, 305, 306, "." +252, 5, 1, 63, 0, 6, 307, 313, "Yamada" +252, 5, 2, 64, 7, 8, 314, 315, "Y" +252, 5, 3, 65, 9, 10, 316, 317, "(" +252, 5, 4, 66, 11, 12, 318, 319, "1" +252, 5, 5, 67, 13, 14, 320, 321, ")" +252, 5, 6, 68, 15, 16, 322, 323, "," +252, 5, 7, 69, 17, 22, 324, 329, "Senda" +252, 5, 8, 70, 23, 24, 330, 331, "M" +252, 5, 9, 71, 25, 26, 332, 333, "(" +252, 5, 10, 72, 27, 28, 334, 335, "2" +252, 5, 11, 73, 29, 30, 336, 337, ")" +252, 5, 12, 74, 31, 32, 338, 339, "," +252, 5, 13, 75, 33, 38, 340, 345, "Naito" +252, 5, 14, 76, 39, 40, 346, 347, "Y" +252, 5, 15, 77, 41, 42, 348, 349, "(" +252, 5, 16, 78, 43, 44, 350, 351, "3" +252, 5, 17, 79, 45, 46, 352, 353, ")" +252, 5, 18, 80, 47, 48, 354, 355, "," +252, 5, 19, 81, 49, 55, 356, 362, "Tamura" +252, 5, 20, 82, 56, 57, 363, 364, "M" +252, 5, 21, 83, 58, 59, 365, 366, "(" +252, 5, 22, 84, 60, 61, 367, 368, "3" +252, 5, 23, 85, 62, 63, 369, 370, ")" +252, 5, 24, 86, 64, 65, 371, 372, "," +252, 5, 25, 87, 66, 74, 373, 381, "Watanabe" +252, 5, 26, 88, 75, 76, 382, 383, "D" +252, 5, 27, 89, 77, 78, 384, 385, "(" +252, 5, 28, 90, 79, 80, 386, 387, "4" +252, 5, 29, 91, 81, 82, 388, 389, ")" +252, 5, 30, 92, 83, 84, 390, 391, "," +252, 5, 31, 93, 85, 90, 392, 397, "Shuto" +252, 5, 32, 94, 91, 92, 398, 399, "Y" +252, 5, 33, 95, 93, 94, 400, 401, "(" +252, 5, 34, 96, 95, 96, 402, 403, "3" +252, 5, 35, 97, 97, 98, 404, 405, ")" +252, 5, 36, 98, 99, 100, 406, 407, "," +252, 5, 37, 99, 101, 106, 408, 413, "Urita" +252, 5, 38, 100, 107, 108, 414, 415, "Y" +252, 5, 39, 101, 109, 110, 416, 417, "(" +252, 5, 40, 102, 111, 112, 418, 419, "5" +252, 5, 41, 103, 113, 114, 420, 421, ")" +252, 5, 42, 104, 115, 116, 422, 423, "." +252, 6, 1, 105, 0, 6, 424, 430, "Author" +252, 6, 2, 106, 7, 18, 431, 442, "information" +252, 6, 3, 107, 19, 20, 443, 444, ":" +252, 6, 4, 108, 21, 22, 445, 446, "(" +252, 6, 5, 109, 23, 24, 447, 448, "1" +252, 6, 6, 110, 25, 26, 449, 450, ")" +252, 6, 7, 111, 27, 37, 451, 461, "Department" +252, 6, 8, 112, 38, 40, 462, 464, "of" +252, 6, 9, 113, 41, 54, 465, 478, "Endocrinology" +252, 6, 10, 114, 55, 56, 479, 480, "," +252, 6, 11, 115, 57, 65, 481, 489, "Diabetes" +252, 6, 12, 116, 66, 69, 490, 493, "and" +252, 6, 13, 117, 70, 79, 494, 503, "Geriatric" +252, 6, 14, 118, 80, 88, 504, 512, "Medicine" +252, 6, 15, 119, 89, 90, 513, 514, "," +252, 6, 16, 120, 91, 96, 515, 520, "Akita" +252, 6, 17, 121, 97, 107, 521, 531, "University" +252, 6, 18, 122, 108, 116, 532, 540, "Graduate" +252, 6, 19, 123, 117, 123, 541, 547, "School" +252, 6, 20, 124, 124, 126, 548, 550, "of" +252, 6, 21, 125, 127, 135, 551, 559, "Medicine" +252, 6, 22, 126, 136, 139, 560, 563, "and" +252, 6, 23, 127, 140, 147, 564, 571, "Faculty" +252, 6, 24, 128, 148, 150, 572, 574, "of" +252, 6, 25, 129, 151, 159, 575, 583, "Medicine" +252, 6, 26, 130, 160, 161, 584, 585, "," +252, 6, 27, 131, 162, 167, 586, 591, "Akita" +252, 6, 28, 132, 168, 169, 592, 593, "," +252, 6, 29, 133, 170, 175, 594, 599, "Japan" +252, 6, 30, 134, 176, 177, 600, 601, "." +252, 7, 1, 135, 0, 1, 602, 603, "(" +252, 7, 2, 136, 2, 3, 604, 605, "2" +252, 7, 3, 137, 4, 5, 606, 607, ")" +252, 7, 4, 138, 6, 13, 608, 615, "Medical" +252, 7, 5, 139, 14, 21, 616, 623, "Affairs" +252, 7, 6, 140, 22, 23, 624, 625, "," +252, 7, 7, 141, 24, 30, 626, 632, "Sanofi" +252, 7, 8, 142, 31, 32, 633, 634, "K" +252, 7, 9, 143, 33, 34, 635, 636, "." +252, 7, 10, 144, 35, 36, 637, 638, "K" +252, 7, 11, 145, 37, 38, 639, 640, "." +252, 7, 12, 146, 39, 40, 641, 642, "," +252, 7, 13, 147, 41, 46, 643, 648, "Tokyo" +252, 7, 14, 148, 47, 48, 649, 650, "," +252, 7, 15, 149, 49, 54, 651, 656, "Japan" +252, 7, 16, 150, 55, 56, 657, 658, "." +252, 8, 1, 151, 0, 1, 659, 660, "(" +252, 8, 2, 152, 2, 3, 661, 662, "3" +252, 8, 3, 153, 4, 5, 663, 664, ")" +252, 8, 4, 154, 6, 14, 665, 673, "Diabetes" +252, 8, 5, 155, 15, 18, 674, 677, "and" +252, 8, 6, 156, 19, 33, 678, 692, "Cardiovascular" +252, 8, 7, 157, 34, 41, 693, 700, "Medical" +252, 8, 8, 158, 42, 52, 701, 711, "Operations" +252, 8, 9, 159, 53, 54, 712, 713, "," +252, 8, 10, 160, 55, 61, 714, 720, "Sanofi" +252, 8, 11, 161, 62, 63, 721, 722, "K" +252, 8, 12, 162, 64, 65, 723, 724, "." +252, 8, 13, 163, 66, 67, 725, 726, "K" +252, 8, 14, 164, 68, 69, 727, 728, "." +252, 8, 15, 165, 70, 71, 729, 730, "," +252, 8, 16, 166, 72, 77, 731, 736, "Tokyo" +252, 8, 17, 167, 78, 79, 737, 738, "," +252, 8, 18, 168, 80, 85, 739, 744, "Japan" +252, 8, 19, 169, 86, 87, 745, 746, "." +252, 9, 1, 170, 0, 1, 747, 748, "(" +252, 9, 2, 171, 2, 3, 749, 750, "4" +252, 9, 3, 172, 4, 5, 751, 752, ")" +252, 9, 4, 173, 6, 19, 753, 766, "Biostatistics" +252, 9, 5, 174, 20, 23, 767, 770, "and" +252, 9, 6, 175, 24, 35, 771, 782, "Programming" +252, 9, 7, 176, 36, 37, 783, 784, "," +252, 9, 8, 177, 38, 44, 785, 791, "Sanofi" +252, 9, 9, 178, 45, 46, 792, 793, "K" +252, 9, 10, 179, 47, 48, 794, 795, "." +252, 9, 11, 180, 49, 50, 796, 797, "K" +252, 9, 12, 181, 51, 52, 798, 799, "." +252, 9, 13, 182, 53, 54, 800, 801, "," +252, 9, 14, 183, 55, 60, 802, 807, "Tokyo" +252, 9, 15, 184, 61, 62, 808, 809, "," +252, 9, 16, 185, 63, 68, 810, 815, "Japan" +252, 9, 17, 186, 69, 70, 816, 817, "." +252, 10, 1, 187, 0, 1, 818, 819, "(" +252, 10, 2, 188, 2, 3, 820, 821, "5" +252, 10, 3, 189, 4, 5, 822, 823, ")" +252, 10, 4, 190, 6, 16, 824, 834, "Department" +252, 10, 5, 191, 17, 19, 835, 837, "of" +252, 10, 6, 192, 20, 27, 838, 845, "General" +252, 10, 7, 193, 28, 36, 846, 854, "Medicine" +252, 10, 8, 194, 37, 40, 855, 858, "and" +252, 10, 9, 195, 41, 50, 859, 868, "Emergency" +252, 10, 10, 196, 51, 55, 869, 873, "Care" +252, 10, 11, 197, 56, 57, 874, 875, "," +252, 10, 12, 198, 58, 62, 876, 880, "Toho" +252, 10, 13, 199, 63, 73, 881, 891, "University" +252, 10, 14, 200, 74, 80, 892, 898, "School" +252, 10, 15, 201, 81, 83, 899, 901, "of" +252, 10, 16, 202, 84, 92, 902, 910, "Medicine" +252, 10, 17, 203, 93, 94, 911, 912, "," +252, 10, 18, 204, 95, 100, 913, 918, "Omori" +252, 10, 19, 205, 101, 109, 919, 927, "Hospital" +252, 10, 20, 206, 110, 111, 928, 929, "," +252, 10, 21, 207, 112, 117, 930, 935, "Tokyo" +252, 10, 22, 208, 118, 119, 936, 937, "," +252, 10, 23, 209, 120, 125, 938, 943, "Japan" +252, 10, 24, 210, 126, 127, 944, 945, "." +252, 11, 1, 211, 0, 3, 946, 949, "AIM" +252, 11, 2, 212, 4, 5, 950, 951, ":" +252, 11, 3, 213, 6, 8, 952, 954, "To" +252, 11, 4, 214, 9, 17, 955, 963, "evaluate" +252, 11, 5, 215, 18, 21, 964, 967, "the" +252, 11, 6, 216, 22, 38, 968, 984, "pharmacodynamics" +252, 11, 7, 217, 39, 41, 985, 987, "of" +252, 11, 8, 218, 42, 54, 988, 1000, "lixisenatide" +252, 11, 9, 219, 55, 59, 1001, 1005, "once" +252, 11, 10, 220, 60, 65, 1006, 1011, "daily" +252, 11, 11, 221, 66, 68, 1012, 1014, "vs" +252, 11, 12, 222, 69, 80, 1015, 1026, "sitagliptin" +252, 11, 13, 223, 81, 85, 1027, 1031, "once" +252, 11, 14, 224, 86, 91, 1032, 1037, "daily" +252, 11, 15, 225, 92, 94, 1038, 1040, "in" +252, 11, 16, 226, 95, 103, 1041, 1049, "Japanese" +252, 11, 17, 227, 104, 112, 1050, 1058, "patients" +252, 11, 18, 228, 113, 117, 1059, 1063, "with" +252, 11, 19, 229, 118, 122, 1064, 1068, "type" +252, 11, 20, 230, 123, 124, 1069, 1070, "2" +252, 11, 21, 231, 125, 133, 1071, 1079, "diabetes" +252, 11, 22, 232, 134, 143, 1080, 1089, "receiving" +252, 11, 23, 233, 144, 151, 1090, 1097, "insulin" +252, 11, 24, 234, 152, 160, 1098, 1106, "glargine" +252, 11, 25, 235, 161, 165, 1107, 1111, "U100" +252, 11, 26, 236, 166, 167, 1112, 1113, "." +252, 12, 1, 237, 0, 9, 1114, 1123, "MATERIALS" +252, 12, 2, 238, 10, 13, 1124, 1127, "AND" +252, 12, 3, 239, 14, 21, 1128, 1135, "METHODS" +252, 12, 4, 240, 22, 23, 1136, 1137, ":" +252, 12, 5, 241, 24, 28, 1138, 1142, "This" +252, 12, 6, 242, 29, 40, 1143, 1154, "multicentre" +252, 12, 7, 243, 41, 42, 1155, 1156, "," +252, 12, 8, 244, 43, 47, 1157, 1161, "open" +252, 12, 9, 245, 48, 49, 1162, 1163, "-" +252, 12, 10, 246, 50, 55, 1164, 1169, "label" +252, 12, 11, 247, 56, 57, 1170, 1171, "," +252, 12, 12, 248, 58, 63, 1172, 1177, "phase" +252, 12, 13, 249, 64, 66, 1178, 1180, "IV" +252, 12, 14, 250, 67, 72, 1181, 1186, "study" +252, 12, 15, 251, 73, 74, 1187, 1188, "(" +252, 12, 16, 252, 75, 82, 1189, 1196, "NEXTAGE" +252, 12, 17, 253, 83, 88, 1197, 1202, "Study" +252, 12, 18, 254, 89, 90, 1203, 1204, ";" +252, 12, 19, 255, 91, 105, 1205, 1219, "ClinicalTrials" +252, 12, 20, 256, 106, 107, 1220, 1221, "." +252, 12, 21, 257, 108, 111, 1222, 1225, "gov" +252, 12, 22, 258, 112, 118, 1226, 1232, "number" +252, 12, 23, 259, 119, 120, 1233, 1234, "," +252, 12, 24, 260, 121, 132, 1235, 1246, "NCT02200991" +252, 12, 25, 261, 133, 134, 1247, 1248, ")" +252, 12, 26, 262, 135, 143, 1249, 1257, "randomly" +252, 12, 27, 263, 144, 152, 1258, 1266, "assigned" +252, 12, 28, 264, 153, 156, 1267, 1270, "136" +252, 12, 29, 265, 157, 165, 1271, 1279, "patients" +252, 12, 30, 266, 166, 168, 1280, 1282, "to" +252, 12, 31, 267, 169, 175, 1283, 1289, "either" +252, 12, 32, 268, 176, 188, 1290, 1302, "lixisenatide" +252, 12, 33, 269, 189, 193, 1303, 1307, "once" +252, 12, 34, 270, 194, 199, 1308, 1313, "daily" +252, 12, 35, 271, 200, 203, 1314, 1317, "via" +252, 12, 36, 272, 204, 216, 1318, 1330, "subcutaneous" +252, 12, 37, 273, 217, 226, 1331, 1340, "injection" +252, 12, 38, 274, 227, 228, 1341, 1342, "(" +252, 12, 39, 275, 229, 231, 1343, 1345, "10" +252, 12, 40, 276, 232, 234, 1346, 1348, " µ" +252, 12, 41, 277, 235, 236, 1349, 1350, "g" +252, 12, 42, 278, 237, 246, 1351, 1360, "initially" +252, 12, 43, 279, 247, 256, 1361, 1370, "increased" +252, 12, 44, 280, 257, 263, 1371, 1377, "weekly" +252, 12, 45, 281, 264, 266, 1378, 1380, "by" +252, 12, 46, 282, 267, 268, 1381, 1382, "5" +252, 12, 47, 283, 269, 271, 1383, 1385, "up" +252, 12, 48, 284, 272, 274, 1386, 1388, "to" +252, 12, 49, 285, 275, 277, 1389, 1391, "20" +252, 12, 50, 286, 278, 280, 1392, 1394, " µ" +252, 12, 51, 287, 281, 282, 1395, 1396, "g" +252, 12, 52, 288, 283, 284, 1397, 1398, ")" +252, 12, 53, 289, 285, 287, 1399, 1401, "or" +252, 12, 54, 290, 288, 292, 1402, 1406, "once" +252, 12, 55, 291, 293, 294, 1407, 1408, "-" +252, 12, 56, 292, 295, 300, 1409, 1414, "daily" +252, 12, 57, 293, 301, 305, 1415, 1419, "oral" +252, 12, 58, 294, 306, 317, 1420, 1431, "sitagliptin" +252, 12, 59, 295, 318, 320, 1432, 1434, "50" +252, 12, 60, 296, 321, 322, 1435, 1436, " " +252, 12, 61, 297, 323, 325, 1437, 1439, "mg" +252, 12, 62, 298, 326, 327, 1440, 1441, "." +252, 13, 1, 299, 0, 3, 1442, 1445, "The" +252, 13, 2, 300, 4, 11, 1446, 1453, "primary" +252, 13, 3, 301, 12, 20, 1454, 1462, "endpoint" +252, 13, 4, 302, 21, 24, 1463, 1466, "was" +252, 13, 5, 303, 25, 28, 1467, 1470, "the" +252, 13, 6, 304, 29, 35, 1471, 1477, "change" +252, 13, 7, 305, 36, 38, 1478, 1480, "in" +252, 13, 8, 306, 39, 51, 1481, 1493, "postprandial" +252, 13, 9, 307, 52, 59, 1494, 1501, "glucose" +252, 13, 10, 308, 60, 61, 1502, 1503, "(" +252, 13, 11, 309, 62, 65, 1504, 1507, "PPG" +252, 13, 12, 310, 66, 67, 1508, 1509, ")" +252, 13, 13, 311, 68, 76, 1510, 1518, "exposure" +252, 13, 14, 312, 77, 78, 1519, 1520, "4" +252, 13, 15, 313, 79, 80, 1521, 1522, " " +252, 13, 16, 314, 81, 86, 1523, 1528, "hours" +252, 13, 17, 315, 87, 92, 1529, 1534, "after" +252, 13, 18, 316, 93, 94, 1535, 1536, "a" +252, 13, 19, 317, 95, 107, 1537, 1549, "standardized" +252, 13, 20, 318, 108, 117, 1550, 1559, "breakfast" +252, 13, 21, 319, 118, 119, 1560, 1561, "(" +252, 13, 22, 320, 120, 123, 1562, 1565, "PPG" +252, 13, 23, 321, 124, 128, 1566, 1570, "area" +252, 13, 24, 322, 129, 134, 1571, 1576, "under" +252, 13, 25, 323, 135, 138, 1577, 1580, "the" +252, 13, 26, 324, 139, 145, 1581, 1587, "plasma" +252, 13, 27, 325, 146, 153, 1588, 1595, "glucose" +252, 13, 28, 326, 154, 167, 1596, 1609, "concentration" +252, 13, 29, 327, 168, 169, 1610, 1611, "-" +252, 13, 30, 328, 170, 174, 1612, 1616, "time" +252, 13, 31, 329, 175, 180, 1617, 1622, "curve" +252, 13, 32, 330, 181, 182, 1623, 1624, "[" +252, 13, 33, 331, 183, 187, 1625, 1629, "AUC0" +252, 13, 34, 332, 188, 189, 1630, 1631, ":" +252, 13, 35, 333, 190, 192, 1632, 1634, "00" +252, 13, 36, 334, 193, 194, 1635, 1636, "-" +252, 13, 37, 335, 195, 196, 1637, 1638, "4" +252, 13, 38, 336, 197, 198, 1639, 1640, ":" +252, 13, 39, 337, 199, 202, 1641, 1644, "00h" +252, 13, 40, 338, 203, 204, 1645, 1646, "]" +252, 13, 41, 339, 205, 206, 1647, 1648, ")" +252, 13, 42, 340, 207, 211, 1649, 1653, "from" +252, 13, 43, 341, 212, 220, 1654, 1662, "baseline" +252, 13, 44, 342, 221, 223, 1663, 1665, "to" +252, 13, 45, 343, 224, 227, 1666, 1669, "day" +252, 13, 46, 344, 228, 230, 1670, 1672, "29" +252, 13, 47, 345, 231, 232, 1673, 1674, "." +252, 14, 1, 346, 0, 7, 1675, 1682, "RESULTS" +252, 14, 2, 347, 8, 9, 1683, 1684, ":" +252, 14, 3, 348, 10, 22, 1685, 1697, "Lixisenatide" +252, 14, 4, 349, 23, 30, 1698, 1705, "reduced" +252, 14, 5, 350, 31, 34, 1706, 1709, "PPG" +252, 14, 6, 351, 35, 43, 1710, 1718, "exposure" +252, 14, 7, 352, 44, 46, 1719, 1721, "to" +252, 14, 8, 353, 47, 48, 1722, 1723, "a" +252, 14, 9, 354, 49, 62, 1724, 1737, "statistically" +252, 14, 10, 355, 63, 76, 1738, 1751, "significantly" +252, 14, 11, 356, 77, 84, 1752, 1759, "greater" +252, 14, 12, 357, 85, 91, 1760, 1766, "extent" +252, 14, 13, 358, 92, 96, 1767, 1771, "than" +252, 14, 14, 359, 97, 108, 1772, 1783, "sitagliptin" +252, 14, 15, 360, 109, 110, 1784, 1785, ":" +252, 14, 16, 361, 111, 116, 1786, 1791, "least" +252, 14, 17, 362, 117, 124, 1792, 1799, "squares" +252, 14, 18, 363, 125, 126, 1800, 1801, "(" +252, 14, 19, 364, 127, 129, 1802, 1804, "LS" +252, 14, 20, 365, 130, 131, 1805, 1806, ")" +252, 14, 21, 366, 132, 136, 1807, 1811, "mean" +252, 14, 22, 367, 137, 143, 1812, 1818, "change" +252, 14, 23, 368, 144, 148, 1819, 1823, "from" +252, 14, 24, 369, 149, 157, 1824, 1832, "baseline" +252, 14, 25, 370, 158, 160, 1833, 1835, "in" +252, 14, 26, 371, 161, 164, 1836, 1839, "PPG" +252, 14, 27, 372, 165, 169, 1840, 1844, "AUC0" +252, 14, 28, 373, 170, 171, 1845, 1846, ":" +252, 14, 29, 374, 172, 174, 1847, 1849, "00" +252, 14, 30, 375, 175, 176, 1850, 1851, "-" +252, 14, 31, 376, 177, 178, 1852, 1853, "4" +252, 14, 32, 377, 179, 180, 1854, 1855, ":" +252, 14, 33, 378, 181, 184, 1856, 1859, "00h" +252, 14, 34, 379, 185, 188, 1860, 1863, "was" +252, 14, 35, 380, 189, 190, 1864, 1865, "-" +252, 14, 36, 381, 191, 194, 1866, 1869, "347" +252, 14, 37, 382, 195, 196, 1870, 1871, "." +252, 14, 38, 383, 197, 198, 1872, 1873, "3" +252, 14, 39, 384, 199, 200, 1874, 1875, "h" +252, 14, 40, 385, 201, 202, 1876, 1877, "·" +252, 14, 41, 386, 203, 205, 1878, 1880, "mg" +252, 14, 42, 387, 206, 207, 1881, 1882, "/" +252, 14, 43, 388, 208, 210, 1883, 1885, "dL" +252, 14, 44, 389, 211, 212, 1886, 1887, "(" +252, 14, 45, 390, 213, 214, 1888, 1889, "-" +252, 14, 46, 391, 215, 217, 1890, 1892, "19" +252, 14, 47, 392, 218, 219, 1893, 1894, "." +252, 14, 48, 393, 220, 221, 1895, 1896, "3" +252, 14, 49, 394, 222, 223, 1897, 1898, "h" +252, 14, 50, 395, 224, 225, 1899, 1900, "·" +252, 14, 51, 396, 226, 230, 1901, 1905, "mmol" +252, 14, 52, 397, 231, 232, 1906, 1907, "/" +252, 14, 53, 398, 233, 234, 1908, 1909, "L" +252, 14, 54, 399, 235, 236, 1910, 1911, ")" +252, 14, 55, 400, 237, 239, 1912, 1914, "in" +252, 14, 56, 401, 240, 243, 1915, 1918, "the" +252, 14, 57, 402, 244, 256, 1919, 1931, "lixisenatide" +252, 14, 58, 403, 257, 262, 1932, 1937, "group" +252, 14, 59, 404, 263, 266, 1938, 1941, "and" +252, 14, 60, 405, 267, 268, 1942, 1943, "-" +252, 14, 61, 406, 269, 272, 1944, 1947, "113" +252, 14, 62, 407, 273, 274, 1948, 1949, "." +252, 14, 63, 408, 275, 276, 1950, 1951, "3" +252, 14, 64, 409, 277, 278, 1952, 1953, "h" +252, 14, 65, 410, 279, 280, 1954, 1955, "·" +252, 14, 66, 411, 281, 283, 1956, 1958, "mg" +252, 14, 67, 412, 284, 285, 1959, 1960, "/" +252, 14, 68, 413, 286, 288, 1961, 1963, "dL" +252, 14, 69, 414, 289, 290, 1964, 1965, "(" +252, 14, 70, 415, 291, 292, 1966, 1967, "-" +252, 14, 71, 416, 293, 294, 1968, 1969, "6" +252, 14, 72, 417, 295, 296, 1970, 1971, "." +252, 14, 73, 418, 297, 298, 1972, 1973, "3" +252, 14, 74, 419, 299, 300, 1974, 1975, "h" +252, 14, 75, 420, 301, 302, 1976, 1977, "·" +252, 14, 76, 421, 303, 307, 1978, 1982, "mmol" +252, 14, 77, 422, 308, 309, 1983, 1984, "/" +252, 14, 78, 423, 310, 311, 1985, 1986, "L" +252, 14, 79, 424, 312, 313, 1987, 1988, ")" +252, 14, 80, 425, 314, 316, 1989, 1991, "in" +252, 14, 81, 426, 317, 320, 1992, 1995, "the" +252, 14, 82, 427, 321, 332, 1996, 2007, "sitagliptin" +252, 14, 83, 428, 333, 338, 2008, 2013, "group" +252, 14, 84, 429, 339, 340, 2014, 2015, "(" +252, 14, 85, 430, 341, 343, 2016, 2018, "LS" +252, 14, 86, 431, 344, 348, 2019, 2023, "mean" +252, 14, 87, 432, 349, 356, 2024, 2031, "between" +252, 14, 88, 433, 357, 358, 2032, 2033, "-" +252, 14, 89, 434, 359, 364, 2034, 2039, "group" +252, 14, 90, 435, 365, 375, 2040, 2050, "difference" +252, 14, 91, 436, 376, 377, 2051, 2052, "-" +252, 14, 92, 437, 378, 381, 2053, 2056, "234" +252, 14, 93, 438, 382, 383, 2057, 2058, "." +252, 14, 94, 439, 384, 385, 2059, 2060, "0" +252, 14, 95, 440, 386, 387, 2061, 2062, "h" +252, 14, 96, 441, 388, 389, 2063, 2064, "·" +252, 14, 97, 442, 390, 392, 2065, 2067, "mg" +252, 14, 98, 443, 393, 394, 2068, 2069, "/" +252, 14, 99, 444, 395, 397, 2070, 2072, "dL" +252, 14, 100, 445, 398, 399, 2073, 2074, "[" +252, 14, 101, 446, 400, 401, 2075, 2076, "-" +252, 14, 102, 447, 402, 404, 2077, 2079, "13" +252, 14, 103, 448, 405, 406, 2080, 2081, "." +252, 14, 104, 449, 407, 408, 2082, 2083, "0" +252, 14, 105, 450, 409, 410, 2084, 2085, "h" +252, 14, 106, 451, 411, 412, 2086, 2087, "·" +252, 14, 107, 452, 413, 417, 2088, 2092, "mmol" +252, 14, 108, 453, 418, 419, 2093, 2094, "/" +252, 14, 109, 454, 420, 421, 2095, 2096, "L" +252, 14, 110, 455, 422, 423, 2097, 2098, "]" +252, 14, 111, 456, 424, 425, 2099, 2100, "," +252, 14, 112, 457, 426, 428, 2101, 2103, "95" +252, 14, 113, 458, 429, 430, 2104, 2105, "%" +252, 14, 114, 459, 431, 441, 2106, 2116, "confidence" +252, 14, 115, 460, 442, 450, 2117, 2125, "interval" +252, 14, 116, 461, 451, 452, 2126, 2127, "-" +252, 14, 117, 462, 453, 456, 2128, 2131, "285" +252, 14, 118, 463, 457, 458, 2132, 2133, "." +252, 14, 119, 464, 459, 461, 2134, 2136, "02" +252, 14, 120, 465, 462, 464, 2137, 2139, "to" +252, 14, 121, 466, 465, 466, 2140, 2141, "-" +252, 14, 122, 467, 467, 470, 2142, 2145, "183" +252, 14, 123, 468, 471, 472, 2146, 2147, "." +252, 14, 124, 469, 473, 475, 2148, 2150, "00" +252, 14, 125, 470, 476, 477, 2151, 2152, "h" +252, 14, 126, 471, 478, 479, 2153, 2154, "·" +252, 14, 127, 472, 480, 482, 2155, 2157, "mg" +252, 14, 128, 473, 483, 484, 2158, 2159, "/" +252, 14, 129, 474, 485, 487, 2160, 2162, "dL" +252, 14, 130, 475, 488, 489, 2163, 2164, "[" +252, 14, 131, 476, 490, 491, 2165, 2166, "-" +252, 14, 132, 477, 492, 494, 2167, 2169, "15" +252, 14, 133, 478, 495, 496, 2170, 2171, "." +252, 14, 134, 479, 497, 498, 2172, 2173, "8" +252, 14, 135, 480, 499, 501, 2174, 2176, "to" +252, 14, 136, 481, 502, 503, 2177, 2178, "-" +252, 14, 137, 482, 504, 506, 2179, 2181, "10" +252, 14, 138, 483, 507, 508, 2182, 2183, "." +252, 14, 139, 484, 509, 510, 2184, 2185, "2" +252, 14, 140, 485, 511, 512, 2186, 2187, "h" +252, 14, 141, 486, 513, 514, 2188, 2189, "·" +252, 14, 142, 487, 515, 519, 2190, 2194, "mmol" +252, 14, 143, 488, 520, 521, 2195, 2196, "/" +252, 14, 144, 489, 522, 523, 2197, 2198, "L" +252, 14, 145, 490, 524, 525, 2199, 2200, "]" +252, 14, 146, 491, 526, 527, 2201, 2202, ";" +252, 14, 147, 492, 528, 529, 2203, 2204, "P" +252, 14, 148, 493, 530, 534, 2205, 2209, " < ." +252, 14, 149, 494, 535, 539, 2210, 2214, "0001" +252, 14, 150, 495, 540, 541, 2215, 2216, ")" +252, 14, 151, 496, 542, 543, 2217, 2218, "." +252, 15, 1, 497, 0, 12, 2219, 2231, "Lixisenatide" +252, 15, 2, 498, 13, 16, 2232, 2235, "led" +252, 15, 3, 499, 17, 19, 2236, 2238, "to" +252, 15, 4, 500, 20, 33, 2239, 2252, "significantly" +252, 15, 5, 501, 34, 41, 2253, 2260, "greater" +252, 15, 6, 502, 42, 44, 2261, 2263, "LS" +252, 15, 7, 503, 45, 49, 2264, 2268, "mean" +252, 15, 8, 504, 50, 60, 2269, 2279, "reductions" +252, 15, 9, 505, 61, 63, 2280, 2282, "in" +252, 15, 10, 506, 64, 71, 2283, 2290, "maximum" +252, 15, 11, 507, 72, 75, 2291, 2294, "PPG" +252, 15, 12, 508, 76, 85, 2295, 2304, "excursion" +252, 15, 13, 509, 86, 90, 2305, 2309, "than" +252, 15, 14, 510, 91, 102, 2310, 2321, "sitagliptin" +252, 15, 15, 511, 103, 104, 2322, 2323, "(" +252, 15, 16, 512, 105, 106, 2324, 2325, "-" +252, 15, 17, 513, 107, 110, 2326, 2329, "122" +252, 15, 18, 514, 111, 112, 2330, 2331, "." +252, 15, 19, 515, 113, 114, 2332, 2333, "4" +252, 15, 20, 516, 115, 117, 2334, 2336, "vs" +252, 15, 21, 517, 118, 119, 2337, 2338, "-" +252, 15, 22, 518, 120, 122, 2339, 2341, "46" +252, 15, 23, 519, 123, 124, 2342, 2343, "." +252, 15, 24, 520, 125, 126, 2344, 2345, "6" +252, 15, 25, 521, 127, 129, 2346, 2348, "mg" +252, 15, 26, 522, 130, 131, 2349, 2350, "/" +252, 15, 27, 523, 132, 134, 2351, 2353, "dL" +252, 15, 28, 524, 135, 136, 2354, 2355, "[" +252, 15, 29, 525, 137, 138, 2356, 2357, "-" +252, 15, 30, 526, 139, 140, 2358, 2359, "6" +252, 15, 31, 527, 141, 142, 2360, 2361, "." +252, 15, 32, 528, 143, 144, 2362, 2363, "8" +252, 15, 33, 529, 145, 147, 2364, 2366, "vs" +252, 15, 34, 530, 148, 149, 2367, 2368, "-" +252, 15, 35, 531, 150, 151, 2369, 2370, "2" +252, 15, 36, 532, 152, 153, 2371, 2372, "." +252, 15, 37, 533, 154, 155, 2373, 2374, "6" +252, 15, 38, 534, 156, 157, 2375, 2376, "h" +252, 15, 39, 535, 158, 159, 2377, 2378, "·" +252, 15, 40, 536, 160, 164, 2379, 2383, "mmol" +252, 15, 41, 537, 165, 166, 2384, 2385, "/" +252, 15, 42, 538, 167, 168, 2386, 2387, "L" +252, 15, 43, 539, 169, 170, 2388, 2389, "]" +252, 15, 44, 540, 171, 172, 2390, 2391, ";" +252, 15, 45, 541, 173, 174, 2392, 2393, "P" +252, 15, 46, 542, 175, 179, 2394, 2398, " < ." +252, 15, 47, 543, 180, 184, 2399, 2403, "0001" +252, 15, 48, 544, 185, 186, 2404, 2405, ")" +252, 15, 49, 545, 187, 188, 2406, 2407, "." +252, 16, 1, 546, 0, 6, 2408, 2414, "Change" +252, 16, 2, 547, 7, 8, 2415, 2416, "-" +252, 16, 3, 548, 9, 13, 2417, 2421, "from" +252, 16, 4, 549, 14, 15, 2422, 2423, "-" +252, 16, 5, 550, 16, 24, 2424, 2432, "baseline" +252, 16, 6, 551, 25, 35, 2433, 2443, "reductions" +252, 16, 7, 552, 36, 38, 2444, 2446, "in" +252, 16, 8, 553, 39, 47, 2447, 2455, "exposure" +252, 16, 9, 554, 48, 50, 2456, 2458, "to" +252, 16, 10, 555, 51, 52, 2459, 2460, "C" +252, 16, 11, 556, 53, 54, 2461, 2462, "-" +252, 16, 12, 557, 55, 62, 2463, 2470, "peptide" +252, 16, 13, 558, 63, 64, 2471, 2472, "," +252, 16, 14, 559, 65, 72, 2473, 2480, "fasting" +252, 16, 15, 560, 73, 85, 2481, 2493, "glycoalbumin" +252, 16, 16, 561, 86, 92, 2494, 2500, "levels" +252, 16, 17, 562, 93, 94, 2501, 2502, "," +252, 16, 18, 563, 95, 98, 2503, 2506, "and" +252, 16, 19, 564, 99, 102, 2507, 2510, "the" +252, 16, 20, 565, 103, 110, 2511, 2518, "gastric" +252, 16, 21, 566, 111, 119, 2519, 2527, "emptying" +252, 16, 22, 567, 120, 124, 2528, 2532, "rate" +252, 16, 23, 568, 125, 129, 2533, 2537, "were" +252, 16, 24, 569, 130, 137, 2538, 2545, "greater" +252, 16, 25, 570, 138, 140, 2546, 2548, "in" +252, 16, 26, 571, 141, 144, 2549, 2552, "the" +252, 16, 27, 572, 145, 157, 2553, 2565, "lixisenatide" +252, 16, 28, 573, 158, 162, 2566, 2570, "than" +252, 16, 29, 574, 163, 165, 2571, 2573, "in" +252, 16, 30, 575, 166, 169, 2574, 2577, "the" +252, 16, 31, 576, 170, 181, 2578, 2589, "sitagliptin" +252, 16, 32, 577, 182, 187, 2590, 2595, "group" +252, 16, 33, 578, 188, 189, 2596, 2597, "." +252, 17, 1, 579, 0, 3, 2598, 2601, "The" +252, 17, 2, 580, 4, 13, 2602, 2611, "incidence" +252, 17, 3, 581, 14, 16, 2612, 2614, "of" +252, 17, 4, 582, 17, 26, 2615, 2624, "treatment" +252, 17, 5, 583, 27, 28, 2625, 2626, "-" +252, 17, 6, 584, 29, 37, 2627, 2635, "emergent" +252, 17, 7, 585, 38, 45, 2636, 2643, "adverse" +252, 17, 8, 586, 46, 52, 2644, 2650, "events" +252, 17, 9, 587, 53, 56, 2651, 2654, "was" +252, 17, 10, 588, 57, 63, 2655, 2661, "higher" +252, 17, 11, 589, 64, 68, 2662, 2666, "with" +252, 17, 12, 590, 69, 81, 2667, 2679, "lixisenatide" +252, 17, 13, 591, 82, 83, 2680, 2681, "(" +252, 17, 14, 592, 84, 86, 2682, 2684, "60" +252, 17, 15, 593, 87, 88, 2685, 2686, "." +252, 17, 16, 594, 89, 90, 2687, 2688, "9" +252, 17, 17, 595, 91, 92, 2689, 2690, "%" +252, 17, 18, 596, 93, 94, 2691, 2692, ")" +252, 17, 19, 597, 95, 99, 2693, 2697, "than" +252, 17, 20, 598, 100, 104, 2698, 2702, "with" +252, 17, 21, 599, 105, 116, 2703, 2714, "sitagliptin" +252, 17, 22, 600, 117, 118, 2715, 2716, "(" +252, 17, 23, 601, 119, 121, 2717, 2719, "16" +252, 17, 24, 602, 122, 123, 2720, 2721, "." +252, 17, 25, 603, 124, 125, 2722, 2723, "4" +252, 17, 26, 604, 126, 127, 2724, 2725, "%" +252, 17, 27, 605, 128, 129, 2726, 2727, ")" +252, 17, 28, 606, 130, 131, 2728, 2729, "," +252, 17, 29, 607, 132, 136, 2730, 2734, "with" +252, 17, 30, 608, 137, 139, 2735, 2737, "no" +252, 17, 31, 609, 140, 147, 2738, 2745, "serious" +252, 17, 32, 610, 148, 154, 2746, 2752, "events" +252, 17, 33, 611, 155, 157, 2753, 2755, "or" +252, 17, 34, 612, 158, 164, 2756, 2762, "severe" +252, 17, 35, 613, 165, 178, 2763, 2776, "hypoglycaemia" +252, 17, 36, 614, 179, 187, 2777, 2785, "reported" +252, 17, 37, 615, 188, 189, 2786, 2787, "." +252, 18, 1, 616, 0, 10, 2788, 2798, "CONCLUSION" +252, 18, 2, 617, 11, 12, 2799, 2800, ":" +252, 18, 3, 618, 13, 25, 2801, 2813, "Lixisenatide" +252, 18, 4, 619, 26, 33, 2814, 2821, "reduced" +252, 18, 5, 620, 34, 37, 2822, 2825, "PPG" +252, 18, 6, 621, 38, 51, 2826, 2839, "significantly" +252, 18, 7, 622, 52, 56, 2840, 2844, "more" +252, 18, 8, 623, 57, 61, 2845, 2849, "than" +252, 18, 9, 624, 62, 73, 2850, 2861, "sitagliptin" +252, 18, 10, 625, 74, 75, 2862, 2863, "," +252, 18, 11, 626, 76, 80, 2864, 2868, "when" +252, 18, 12, 627, 81, 86, 2869, 2874, "these" +252, 18, 13, 628, 87, 93, 2875, 2881, "agents" +252, 18, 14, 629, 94, 98, 2882, 2886, "were" +252, 18, 15, 630, 99, 104, 2887, 2892, "added" +252, 18, 16, 631, 105, 107, 2893, 2895, "to" +252, 18, 17, 632, 108, 113, 2896, 2901, "basal" +252, 18, 18, 633, 114, 121, 2902, 2909, "insulin" +252, 18, 19, 634, 122, 130, 2910, 2918, "glargine" +252, 18, 20, 635, 131, 135, 2919, 2923, "U100" +252, 18, 21, 636, 136, 137, 2924, 2925, "," +252, 18, 22, 637, 138, 141, 2926, 2929, "and" +252, 18, 23, 638, 142, 145, 2930, 2933, "was" +252, 18, 24, 639, 146, 150, 2934, 2938, "well" +252, 18, 25, 640, 151, 160, 2939, 2948, "tolerated" +252, 18, 26, 641, 161, 162, 2949, 2950, "." +252, 19, 1, 642, 0, 1, 2951, 2952, "©" +252, 19, 2, 643, 2, 6, 2953, 2957, "2017" +252, 19, 3, 644, 7, 10, 2958, 2961, "The" +252, 19, 4, 645, 11, 18, 2962, 2969, "Authors" +252, 19, 5, 646, 19, 20, 2970, 2971, "." +252, 20, 1, 647, 0, 8, 2972, 2980, "Diabetes" +252, 20, 2, 648, 9, 10, 2981, 2982, "," +252, 20, 3, 649, 11, 18, 2983, 2990, "Obesity" +252, 20, 4, 650, 19, 22, 2991, 2994, "and" +252, 20, 5, 651, 23, 33, 2995, 3005, "Metabolism" +252, 20, 6, 652, 34, 43, 3006, 3015, "published" +252, 20, 7, 653, 44, 46, 3016, 3018, "by" +252, 20, 8, 654, 47, 51, 3019, 3023, "John" +252, 20, 9, 655, 52, 57, 3024, 3029, "Wiley" +252, 20, 10, 656, 58, 59, 3030, 3031, "&" +252, 20, 11, 657, 60, 64, 3032, 3036, "Sons" +252, 20, 12, 658, 65, 68, 3037, 3040, "Ltd" +252, 20, 13, 659, 69, 70, 3041, 3042, "." +252, 20, 14, 660, 71, 74, 3043, 3046, "DOI" +252, 20, 15, 661, 75, 76, 3047, 3048, ":" +252, 20, 16, 662, 77, 79, 3049, 3051, "10" +252, 20, 17, 663, 80, 81, 3052, 3053, "." +252, 20, 18, 664, 82, 86, 3054, 3058, "1111" +252, 20, 19, 665, 87, 88, 3059, 3060, "/" +252, 20, 20, 666, 89, 92, 3061, 3064, "dom" +252, 20, 21, 667, 93, 94, 3065, 3066, "." +252, 20, 22, 668, 95, 100, 3067, 3072, "12945" +252, 20, 23, 669, 101, 106, 3073, 3078, "PMCID" +252, 20, 24, 670, 107, 108, 3079, 3080, ":" +252, 20, 25, 671, 109, 119, 3081, 3091, "PMC5573929" +252, 20, 26, 672, 120, 124, 3092, 3096, "PMID" +252, 20, 27, 673, 125, 126, 3097, 3098, ":" +252, 20, 28, 674, 127, 135, 3099, 3107, "28345162" +252, 20, 29, 675, 136, 137, 3108, 3109, "[" +252, 20, 30, 676, 138, 145, 3110, 3117, "Indexed" +252, 20, 31, 677, 146, 149, 3118, 3121, "for" +252, 20, 32, 678, 150, 157, 3122, 3129, "MEDLINE" +252, 20, 33, 679, 158, 159, 3130, 3131, "]" diff --git a/data/dm2 28345162_kwoodley.annodb b/data/dm2 28345162_kwoodley.annodb new file mode 100644 index 0000000..98f26e8 --- /dev/null +++ b/data/dm2 28345162_kwoodley.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71308, Journal, 0, 19, "Diabetes Obes Metab", "", +71309, PublicationYear, 22, 26, "2017", "", +71338, Title, 109, 306, "Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine : A randomized phase IV study ( NEXTAGE Study ) .", "", +71310, PostprandialBloodGlucose, 122, 142, "postprandial glucose", "", +71311, Drug, 146, 158, "lixisenatide", "", +71320, Sitagliptin, 162, 173, "sitagliptin", "", +71328, Ethnicity, 187, 195, "Japanese", "", +71337, Precondition, 196, 256, "patients with type 2 diabetes on background insulin glargine", "", +71330, Type2Diabetes, 210, 225, "type 2 diabetes", "", +71332, InsulinGlargine, 240, 256, "insulin glargine", "", +71335, Randomized, 261, 271, "randomized", "", +71339, Author, 307, 315, "Yamada Y", "", +71340, Author, 324, 331, "Senda M", "", +71341, Author, 340, 347, "Naito Y", "", +71342, Author, 356, 364, "Tamura M", "", +71343, Author, 373, 383, "Watanabe D", "", +71344, Author, 392, 399, "Shuto Y", "", +71345, Author, 408, 415, "Urita Y", "", +71346, Japan, 594, 599, "Japan", "", +71347, Japan, 651, 656, "Japan", "", +71348, Japan, 739, 744, "Japan", "", +71349, Japan, 810, 815, "Japan", "", +71350, Japan, 938, 943, "Japan", "", +71357, ObjectiveDescription, 952, 1113, "To evaluate the pharmacodynamics of lixisenatide once daily vs sitagliptin once daily in Japanese patients with type 2 diabetes receiving insulin glargine U100 .", "", +71312, Drug, 988, 1000, "lixisenatide", "", +71351, Frequency, 1001, 1011, "once daily", "", +71355, Sitagliptin, 1015, 1026, "sitagliptin", "", +71354, Frequency, 1027, 1037, "once daily", "", +71329, Ethnicity, 1041, 1049, "Japanese", "", +71356, Precondition, 1050, 1111, "patients with type 2 diabetes receiving insulin glargine U100", "", +71331, Type2Diabetes, 1064, 1079, "type 2 diabetes", "", +71333, InsulinGlargine, 1090, 1106, "insulin glargine", "", +71358, Multicenter, 1143, 1154, "multicentre", "", +71359, OpenLabel, 1157, 1169, "open - label", "", +71336, Randomized, 1249, 1257, "randomly", "", +71360, NumberPatientsCT, 1267, 1270, "136", "", +71313, Drug, 1290, 1302, "lixisenatide", "", +71352, Frequency, 1303, 1313, "once daily", "", +71364, DoseDescription, 1314, 1398, "via subcutaneous injection ( 10  µ g initially increased weekly by 5 up to 20  µ g )", "", +71362, Microgram, 1346, 1350, " µ g", "", +71363, Microgram, 1392, 1396, " µ g", "", +71353, Frequency, 1402, 1414, "once - daily", "", +71365, Oral, 1415, 1419, "oral", "", +71321, Sitagliptin, 1420, 1431, "sitagliptin", "", +71366, DoseValue, 1432, 1434, "50", "", +71367, mg, 1437, 1439, "mg", "", +71368, PostprandialBloodGlucose, 1481, 1501, "postprandial glucose", "", +71369, PostprandialBloodGlucose, 1504, 1507, "PPG", "", +71370, PostprandialBloodGlucose, 1562, 1565, "PPG", "", +71371, TimePoint, 1654, 1662, "baseline", "", +71372, TimePoint, 1666, 1672, "day 29", "", +71314, Drug, 1685, 1697, "Lixisenatide", "", +71373, PostprandialBloodGlucose, 1706, 1709, "PPG", "", +71322, Sitagliptin, 1772, 1783, "sitagliptin", "", +71374, LeastSquaresMean, 1786, 1811, "least squares ( LS ) mean", "", +71375, TimePoint, 1824, 1832, "baseline", "", +71376, PostprandialBloodGlucose, 1836, 1839, "PPG", "", +71378, Reduction, 1866, 1873, "347 . 3", "", +71377, Mg_per_deciliter, 1878, 1885, "mg / dL", "", +71379, Reduction, 1890, 1896, "19 . 3", "", +71380, Millimoles_per_litre, 1901, 1909, "mmol / L", "", +71315, Drug, 1919, 1931, "lixisenatide", "", +71381, Reduction, 1944, 1951, "113 . 3", "", +71383, Mg_per_deciliter, 1956, 1963, "mg / dL", "", +71382, Reduction, 1968, 1973, "6 . 3", "", +71384, Millimoles_per_litre, 1978, 1986, "mmol / L", "", +71323, Sitagliptin, 1996, 2007, "sitagliptin", "", +71385, LeastSquaresMean, 2016, 2023, "LS mean", "", +71386, DiffGroupAbsValue, 2051, 2060, "- 234 . 0", "", +71388, Mg_per_deciliter, 2065, 2072, "mg / dL", "", +71387, DiffGroupAbsValue, 2075, 2083, "- 13 . 0", "", +71390, Millimoles_per_litre, 2088, 2096, "mmol / L", "", +71392, ConfIntervalDiff, 2101, 2200, "95 % confidence interval - 285 . 02 to - 183 . 00 h · mg / dL [ - 15 . 8 to - 10 . 2 h · mmol / L ]", "", +71389, Mg_per_deciliter, 2155, 2162, "mg / dL", "", +71391, Millimoles_per_litre, 2190, 2198, "mmol / L", "", +71393, PvalueDiff, 2203, 2214, "P  < . 0001", "", +71316, Drug, 2219, 2231, "Lixisenatide", "", +71394, LeastSquaresMean, 2261, 2268, "LS mean", "", +71395, PostprandialBloodGlucose, 2291, 2294, "PPG", "", +71324, Sitagliptin, 2310, 2321, "sitagliptin", "", +71396, Reduction, 2326, 2333, "122 . 4", "", +71397, Reduction, 2339, 2345, "46 . 6", "", +71400, Mg_per_deciliter, 2346, 2353, "mg / dL", "", +71398, Reduction, 2358, 2363, "6 . 8", "", +71399, Reduction, 2369, 2374, "2 . 6", "", +71401, Millimoles_per_litre, 2379, 2387, "mmol / L", "", +71402, PvalueDiff, 2392, 2403, "P  < . 0001", "", +71407, ObservedResult, 2408, 2597, "Change - from - baseline reductions in exposure to C - peptide , fasting glycoalbumin levels , and the gastric emptying rate were greater in the lixisenatide than in the sitagliptin group .", "", +71403, TimePoint, 2424, 2432, "baseline", "", +71404, EndPointDescription, 2459, 2470, "C - peptide", "", +71405, EndPointDescription, 2473, 2493, "fasting glycoalbumin", "", +71406, EndPointDescription, 2511, 2532, "gastric emptying rate", "", +71317, Drug, 2553, 2565, "lixisenatide", "", +71325, Sitagliptin, 2578, 2589, "sitagliptin", "", +71408, EndPointDescription, 2636, 2650, "adverse events", "", +71318, Drug, 2667, 2679, "lixisenatide", "", +71409, PercentageAffected, 2682, 2688, "60 . 9", "", +71326, Sitagliptin, 2703, 2714, "sitagliptin", "", +71410, PercentageAffected, 2717, 2723, "16 . 4", "", +71412, ObservedResult, 2730, 2785, "with no serious events or severe hypoglycaemia reported", "", +71411, SevereHypoglycemia, 2756, 2776, "severe hypoglycaemia", "", +71319, Drug, 2801, 2813, "Lixisenatide", "", +71414, ConclusionComment, 2801, 2950, "Lixisenatide reduced PPG significantly more than sitagliptin , when these agents were added to basal insulin glargine U100 , and was well tolerated .", "", +71413, PostprandialBloodGlucose, 2822, 2825, "PPG", "", +71327, Sitagliptin, 2850, 2861, "sitagliptin", "", +71334, InsulinGlargine, 2902, 2918, "insulin glargine", "", +71415, PMID, 3099, 3107, "28345162", "", diff --git a/data/dm2 28345162_kwoodley.n-triples b/data/dm2 28345162_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28345162_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345792_admin.annodb b/data/dm2 28345792_admin.annodb new file mode 100644 index 0000000..0d27243 --- /dev/null +++ b/data/dm2 28345792_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +8, Title, 109, 307, "Adding fast - acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes : A randomized , 18 - week , open - label , phase 3 trial ( onset 3 ) .", "", " \"Adding fast - acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes : A randomized , 18 - week , open - label , phase 3 trial ( onset 3 ) .\"." +2, InsulinAspart, 130, 144, "insulin aspart", "", +3, Insulin, 148, 161, "basal insulin", "", +4, Type2Diabetes, 220, 235, "type 2 diabetes", "", +5, Randomized, 240, 250, "randomized", "", +6, Duration, 253, 262, "18 - week", "", +7, OpenLabel, 265, 277, "open - label", "", +9, Author, 308, 318, "Rodbard HW", "", " \"Rodbard HW\"." +10, Author, 327, 337, "Tripathy D", "", " \"Tripathy D\"." +11, Author, 352, 372, "Vidrio Vel á zquez M", "", " \"Vidrio Vel á zquez M\"." +12, Author, 381, 391, "Demissie M", "", " \"Demissie M\"." +13, Author, 400, 408, "Tamer SC", "", " \"Tamer SC\"." +14, Author, 417, 427, "Pileti č M", "", " \"Pileti č M\"." +127, USA, 513, 521, "Maryland", "", " ." +128, USA, 588, 593, "Texas", "", " ." +129, USA, 645, 650, "Texas", "", +15, Mexico, 705, 711, "Mexico", "", " ." +16, Country, 752, 759, "Denmark", "", " . ." +17, Country, 800, 808, "Slovenia", "", " . ." +37, ObjectiveDescription, 817, 976, "To confirm glycaemic control superiority of mealtime fast - acting insulin aspart ( faster aspart ) in a basal - bolus ( BB ) regimen vs basal - only insulin .", "", " \"To confirm glycaemic control superiority of mealtime fast - acting insulin aspart ( faster aspart ) in a basal - bolus ( BB ) regimen vs basal - only insulin .\"." +108, InsulinAspart, 870, 898, "fast - acting insulin aspart", "", " ." +19, InsulinAspart, 901, 914, "faster aspart", "", +20, Insulin, 954, 974, "basal - only insulin", "", " . ." +21, OpenLabel, 1009, 1021, "open - label", "", " ." +22, Randomized, 1024, 1034, "randomized", "", " ." +23, Duration, 1037, 1046, "18 - week", "", " \"18 - week\"." +24, Multicenter, 1055, 1077, "51 sites ; 6 countries", "", " ." +98740, Precondition, 1082, 1088, "adults", "", " \"adults\". \"with inadequately controlled type 2 diabetes\". \"receiving basal insulin and oral antidiabetic drugs\"." +25, NumberPatientsCT, 1097, 1100, "236", "", " \"236\"." +98740, Precondition, 1103, 1147, "with inadequately controlled type 2 diabetes", "", +27, Type2Diabetes, 1132, 1147, "type 2 diabetes", "", " ." +28, Type2Diabetes, 1150, 1153, "T2D", "", +30, Mean, 1156, 1160, "mean", "", +31, HbA1c, 1161, 1185, "glycosylated haemoglobin", "", +32, HbA1c, 1188, 1193, "HbA1c", "", +33, Percentage, 1221, 1222, "%", "", +35, ConcentrationUnit, 1244, 1254, "mmol / mol", "", +98740, Precondition, 1259, 1310, "receiving basal insulin and oral antidiabetic drugs", "", +36, Insulin, 1269, 1282, "basal insulin", "", +38, OralAntidiabeticAgent, 1287, 1310, "oral antidiabetic drugs", "", +39, Duration, 1321, 1329, "8 - week", "", +40, Frequency, 1352, 1364, "once - daily", "", +42, Insulin, 1365, 1378, "basal insulin", "", +43, Randomized, 1391, 1404, "randomization", "", +156, AllocationRatio, 1405, 1410, "1 : 1", "", " . ." +44, InsulinAspart, 1439, 1452, "faster aspart", "", +47, NumberPatientsArm, 1461, 1464, "116", "", " \"116\"." +41, Frequency, 1486, 1498, "once - daily", "", " \"once - daily\"." +45, Insulin, 1499, 1512, "basal insulin", "", +48, NumberPatientsArm, 1521, 1524, "120", "", " \"120\"." +46, Metformin, 1539, 1548, "metformin", "", " ." +49, HbA1c, 1572, 1577, "HbA1c", "", +50, TimePoint, 1590, 1598, "baseline", "", +51, TimePoint, 1605, 1615, "18   weeks", "", +52, PostprandialPlasmaGlucose, 1662, 1689, "postprandial plasma glucose", "", +53, PostprandialPlasmaGlucose, 1692, 1695, "PPG", "", +54, PostprandialPlasmaGlucose, 1709, 1720, "overall PPG", "", +55, BodyWeight, 1747, 1753, "weight", "", +172, EndPointDescription, 1777, 1791, "adverse events", "", +56, Hypoglycemia, 1794, 1816, "hypoglycaemic episodes", "", +57, HbA1c, 1829, 1834, "HbA1c", "", " ." +69, BaseLineValue, 1850, 1855, "7 . 9", "", " \"7 . 9\"." +58, Percentage, 1856, 1857, "%", "", " ." +71, BaseLineValue, 1860, 1866, "63 . 2", "", +64, ConcentrationUnit, 1869, 1879, "mmol / mol", "", +73, ResultMeasuredValue, 1885, 1890, "6 . 8", "", " \"6 . 8\"." +59, Percentage, 1891, 1892, "%", "", +74, ResultMeasuredValue, 1895, 1901, "50 . 7", "", +65, ConcentrationUnit, 1904, 1914, "mmol / mol", "", +70, BaseLineValue, 1937, 1942, "7 . 9", "", " \"7 . 9\"." +60, Percentage, 1943, 1944, "%", "", +72, BaseLineValue, 1947, 1953, "63 . 2", "", +66, ConcentrationUnit, 1956, 1966, "mmol / mol", "", +75, ResultMeasuredValue, 1972, 1977, "7 . 7", "", " \"7 . 7\"." +61, Percentage, 1978, 1979, "%", "", +76, ResultMeasuredValue, 1982, 1988, "60 . 7", "", +67, ConcentrationUnit, 1991, 2001, "mmol / mol", "", +193, Insulin, 2004, 2016, "basal - only", "", +77, DiffGroupAbsValue, 2087, 2095, "- 0 . 94", "", " \"- 0 . 94\"." +63, Percentage, 2096, 2097, "%", "", +78, ConfIntervalDiff, 2100, 2119, "- 1 . 17 ; - 0 . 72", "", " \"- 1 . 17 ; - 0 . 72\"." +80, DiffGroupAbsValue, 2124, 2132, "- 10 . 3", "", +68, ConcentrationUnit, 2135, 2145, "mmol / mol", "", +79, ConfIntervalDiff, 2148, 2166, "- 12 . 8 ; - 7 . 8", "", +81, PvalueDiff, 2171, 2182, "P  < . 0001", "", " \"P  < . 0001\"." +106250, ObservedResult, 2185, 2379, "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment", "", " \"Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment\". \"Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment\". \"Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment\". \"Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment\"." +82, TimePoint, 2201, 2209, "baseline", "", +83, Mean, 2221, 2225, "mean", "", " . . . ." +84, PostprandialPlasmaGlucose, 2226, 2238, "2 - hour PPG", "", " ." +85, PostprandialPlasmaGlucose, 2243, 2254, "overall PPG", "", " ." +86, PvalueDiff, 2382, 2393, "P  < . 0001", "", " \"P  < . 0001\". \"P  < . 0001\"." +87, SevereHypoglycemia, 2398, 2444, "Severe / blood glucose confirmed hypoglycaemia", "", " ." +90, ResultMeasuredValue, 2452, 2458, "12 . 8", "", " \"12 . 8\"." +91, ResultMeasuredValue, 2462, 2467, "2 . 0", "", " \"2 . 0\"." +96, BioAndMedicalUnit, 2468, 2508, "episodes per patient - years of exposure", "", " . ." +88, InsulinDose, 2513, 2532, "total daily insulin", "", " . ." +92, ResultMeasuredValue, 2535, 2540, "1 . 2", "", " \"1 . 2\"." +93, ResultMeasuredValue, 2544, 2549, "0 . 6", "", " \"0 . 6\"." +97, BioAndMedicalUnit, 2550, 2556, "U / kg", "", " . ." +98752, BodyWeight, 2563, 2569, "weight", "", " ." +214, Increment, 2577, 2582, "1 . 8", "", " \"1 . 8\"." +215, Increment, 2586, 2591, "0 . 2", "", " \"0 . 2\"." +98, Kg, 2594, 2596, "kg", "", " ." +167, FixedCombDrug, 2617, 2619, "BB", "", +217, Insulin, 2630, 2642, "basal - only", "", +103, ConclusionComment, 2669, 2863, "In T2D , faster aspart in a BB regimen provided superior glycaemic control as compared with basal - only insulin , but with an increase in the frequency of hypoglycaemia and modest weight gain .", "", " \"In T2D , faster aspart in a BB regimen provided superior glycaemic control as compared with basal - only insulin , but with an increase in the frequency of hypoglycaemia and modest weight gain .\"." +99, Type2Diabetes, 2672, 2675, "T2D", "", +111, InsulinAspart, 2678, 2691, "faster aspart", "", +102, Insulin, 2774, 2781, "insulin", "", +100, Hypoglycemia, 2825, 2838, "hypoglycaemia", "", +101, WeightGain, 2850, 2861, "weight gain", "", +104, PMID, 3012, 3020, "28345792", "", " \"28345792\"." diff --git a/data/dm2 28345792_admin.n-triples b/data/dm2 28345792_admin.n-triples new file mode 100644 index 0000000..c36ee3b --- /dev/null +++ b/data/dm2 28345792_admin.n-triples @@ -0,0 +1,211 @@ +# RDF export of group: Publication + . + "Publication " . + "Adding fast - acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes : A randomized , 18 - week , open - label , phase 3 trial ( onset 3 ) ." . + "Rodbard HW" . + "2017" . + "Diabetes Obes Metab ." . + "28345792" . + . + "Tripathy D" . + "Vidrio Vel á zquez M" . + "Demissie M" . + "Tamer SC" . + "Pileti č M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To confirm glycaemic control superiority of mealtime fast - acting insulin aspart ( faster aspart ) in a basal - bolus ( BB ) regimen vs basal - only insulin ." . + "236" . + "18 - week" . + . + . + . + . + "In T2D , faster aspart in a BB regimen provided superior glycaemic control as compared with basal - only insulin , but with an increase in the frequency of hypoglycaemia and modest weight gain ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "adults" . + "with inadequately controlled type 2 diabetes" . + "receiving basal insulin and oral antidiabetic drugs" . + . + . + . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c " . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + . + "Endpoint oppg" . + . + . + . + . + . + . + "Endpoint sh " . + . + . + . + . + . + . + "Endpoint id" . + . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . +# RDF export of group: Arm + . + "Arm a+m" . + "116" . + . + . + . + . + . + . + . + . + "Arm bi+m" . + "120" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention a+m" . + . + . + . + . + "Intervention bi+m" . + . + "once - daily" . + . + . +# RDF export of group: Medication + . + "Medication aspart" . + . + . + . + . + "Medication bi" . + . + . + . + . + . + "Medication m" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c a" . + . + "7 . 9" . + "6 . 8" . + . + "Outcome hba1c bi" . + . + "7 . 9" . + "7 . 7" . + . + "Outcome ppg a" . + . + "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment" . + . + "Outcome o ppg a" . + . + "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment" . + . + "Outcome sh a" . + . + "12 . 8" . + . + "Outcome sh bi" . + . + "2 . 0" . + . + "Outcome id a " . + . + "1 . 2" . + . + "Outcome id bi " . + . + "0 . 6" . + . + "Outcome weight a" . + . + "1 . 8" . + . + "Outcome weight bi" . + . + "0 . 2" . + . + "Outcome ppg bi" . + . + "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment" . + . + "Outcome o ppg bi" . + . + "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 94" . + "P  < . 0001" . + "- 1 . 17 ; - 0 . 72" . + . + . + . + "DiffBetweenGroups ppg " . + "P  < . 0001" . + . + . + . + "DiffBetweenGroups o ppg" . + "P  < . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345792_akramersunderbrink.annodb b/data/dm2 28345792_akramersunderbrink.annodb new file mode 100644 index 0000000..6a007ad --- /dev/null +++ b/data/dm2 28345792_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +68174, Journal, 0, 19, "Diabetes Obes Metab", "", +68175, PublicationYear, 22, 26, "2017", "", +68182, Title, 109, 307, "Adding fast - acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes : A randomized , 18 - week , open - label , phase 3 trial ( onset 3 ) .", "", +68176, InsulinAspart, 130, 144, "insulin aspart", "", +68177, Insulin, 148, 161, "basal insulin", "", +68178, Type2Diabetes, 220, 235, "type 2 diabetes", "", +68179, Randomized, 240, 250, "randomized", "", +68180, Duration, 253, 262, "18 - week", "", +68181, OpenLabel, 265, 277, "open - label", "", +68183, Author, 308, 318, "Rodbard HW", "", +68184, Author, 327, 337, "Tripathy D", "", +68185, Author, 352, 372, "Vidrio Vel á zquez M", "", +68186, Author, 381, 391, "Demissie M", "", +68187, Author, 400, 408, "Tamer SC", "", +68188, Author, 417, 427, "Pileti č M", "", +68189, Mexico, 705, 711, "Mexico", "", +68190, Country, 752, 759, "Denmark", "", +68191, Country, 800, 808, "Slovenia", "", +68212, ObjectiveDescription, 817, 976, "To confirm glycaemic control superiority of mealtime fast - acting insulin aspart ( faster aspart ) in a basal - bolus ( BB ) regimen vs basal - only insulin .", "", +68192, InsulinAspart, 870, 898, "fast - acting insulin aspart", "", +68193, InsulinAspart, 901, 914, "faster aspart", "", +68194, Insulin, 967, 974, "insulin", "", +68195, OpenLabel, 1009, 1021, "open - label", "", +68196, Randomized, 1024, 1034, "randomized", "", +68197, Duration, 1037, 1046, "18 - week", "", +68198, Multicenter, 1055, 1077, "51 sites ; 6 countries", "", +68199, NumberPatientsCT, 1097, 1100, "236", "", +68200, Precondition, 1108, 1131, "inadequately controlled", "", +68201, Type2Diabetes, 1132, 1147, "type 2 diabetes", "", +68202, Type2Diabetes, 1150, 1153, "T2D", "", +68203, Precondition, 1156, 1256, "mean glycosylated haemoglobin [ HbA1c ] ±  SD : 7 . 9 % ±  0 . 7 % [ 63 . 1  ±  7 . 5   mmol / mol ]", "", +68204, Mean, 1156, 1160, "mean", "", +68205, HbA1c, 1161, 1185, "glycosylated haemoglobin", "", +68206, HbA1c, 1188, 1193, "HbA1c", "", +68207, Percentage, 1210, 1209, "", "", +68209, Percentage, 1210, 1214, "% ± ", "", +68208, Percentage, 1221, 1222, "%", "", +68210, ConcentrationUnit, 1244, 1254, "mmol / mol", "", +68211, Insulin, 1269, 1282, "basal insulin", "", +68213, OralAntidiabeticAgent, 1287, 1310, "oral antidiabetic drugs", "", +68214, Duration, 1321, 1329, "8 - week", "", +68215, Frequency, 1352, 1364, "once - daily", "", +68217, Insulin, 1365, 1378, "basal insulin", "", +68218, Randomized, 1391, 1404, "randomization", "", +68219, InsulinAspart, 1439, 1452, "faster aspart", "", +68222, NumberPatientsArm, 1461, 1464, "116", "", +68216, Frequency, 1486, 1498, "once - daily", "", +68220, Insulin, 1505, 1512, "insulin", "", +68223, NumberPatientsArm, 1521, 1524, "120", "", +68221, Metformin, 1539, 1548, "metformin", "", +68224, HbA1c, 1572, 1577, "HbA1c", "", +68225, TimePoint, 1590, 1598, "baseline", "", +68226, TimePoint, 1605, 1615, "18   weeks", "", +68227, PostprandialPlasmaGlucose, 1662, 1689, "postprandial plasma glucose", "", +68228, PostprandialPlasmaGlucose, 1692, 1695, "PPG", "", +68229, PostprandialPlasmaGlucose, 1717, 1720, "PPG", "", +68230, BodyWeight, 1747, 1753, "weight", "", +68231, Hypoglycemia, 1794, 1816, "hypoglycaemic episodes", "", +68232, HbA1c, 1829, 1834, "HbA1c", "", +68244, BaseLineValue, 1850, 1855, "7 . 9", "", +68233, Percentage, 1856, 1857, "%", "", +68246, BaseLineValue, 1860, 1866, "63 . 2", "", +68239, ConcentrationUnit, 1869, 1879, "mmol / mol", "", +68248, ResultMeasuredValue, 1885, 1890, "6 . 8", "", +68234, Percentage, 1891, 1892, "%", "", +68249, ResultMeasuredValue, 1895, 1901, "50 . 7", "", +68240, ConcentrationUnit, 1904, 1914, "mmol / mol", "", +68245, BaseLineValue, 1937, 1942, "7 . 9", "", +68235, Percentage, 1943, 1944, "%", "", +68247, BaseLineValue, 1947, 1953, "63 . 2", "", +68241, ConcentrationUnit, 1956, 1966, "mmol / mol", "", +68250, ResultMeasuredValue, 1972, 1977, "7 . 7", "", +68236, Percentage, 1978, 1979, "%", "", +68251, ResultMeasuredValue, 1982, 1988, "60 . 7", "", +68242, ConcentrationUnit, 1991, 2001, "mmol / mol", "", +68237, Percentage, 2063, 2064, "%", "", +68252, DiffGroupAbsValue, 2087, 2095, "- 0 . 94", "", +68238, Percentage, 2096, 2097, "%", "", +68253, ConfIntervalDiff, 2100, 2119, "- 1 . 17 ; - 0 . 72", "", +68255, DiffGroupAbsValue, 2124, 2132, "- 10 . 3", "", +68243, ConcentrationUnit, 2135, 2145, "mmol / mol", "", +68254, ConfIntervalDiff, 2148, 2166, "- 12 . 8 ; - 7 . 8", "", +68256, PvalueDiff, 2171, 2182, "P  < . 0001", "", +68257, TimePoint, 2201, 2209, "baseline", "", +68258, Mean, 2221, 2225, "mean", "", +68259, PostprandialPlasmaGlucose, 2226, 2238, "2 - hour PPG", "", +68260, PostprandialPlasmaGlucose, 2251, 2254, "PPG", "", +68261, PvalueDiff, 2382, 2393, "P  < . 0001", "", +68262, SevereHypoglycemia, 2398, 2444, "Severe / blood glucose confirmed hypoglycaemia", "", +68265, ResultMeasuredValue, 2452, 2458, "12 . 8", "", +68266, ResultMeasuredValue, 2462, 2467, "2 . 0", "", +68271, BioAndMedicalUnit, 2468, 2508, "episodes per patient - years of exposure", "", +68263, InsulinDose, 2513, 2532, "total daily insulin", "", +68267, ResultMeasuredValue, 2535, 2540, "1 . 2", "", +68268, ResultMeasuredValue, 2544, 2549, "0 . 6", "", +68272, BioAndMedicalUnit, 2550, 2556, "U / kg", "", +68264, WeightGain, 2563, 2574, "weight gain", "", +68269, ResultMeasuredValue, 2577, 2582, "1 . 8", "", +68270, ResultMeasuredValue, 2586, 2591, "0 . 2", "", +68273, Kg, 2594, 2596, "kg", "", +68278, ConclusionComment, 2669, 2863, "In T2D , faster aspart in a BB regimen provided superior glycaemic control as compared with basal - only insulin , but with an increase in the frequency of hypoglycaemia and modest weight gain .", "", +68274, Type2Diabetes, 2672, 2675, "T2D", "", +68277, Insulin, 2774, 2781, "insulin", "", +68275, Hypoglycemia, 2825, 2838, "hypoglycaemia", "", +68276, WeightGain, 2850, 2861, "weight gain", "", +68279, PMID, 3012, 3020, "28345792", "", diff --git a/data/dm2 28345792_akramersunderbrink.n-triples b/data/dm2 28345792_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28345792_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28345792_export.csv b/data/dm2 28345792_export.csv new file mode 100644 index 0000000..8188767 --- /dev/null +++ b/data/dm2 28345792_export.csv @@ -0,0 +1,697 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +251, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +251, 1, 2, 2, 9, 13, 9, 13, "Obes" +251, 1, 3, 3, 14, 19, 14, 19, "Metab" +251, 1, 4, 4, 20, 21, 20, 21, "." +251, 2, 1, 5, 0, 4, 22, 26, "2017" +251, 2, 2, 6, 5, 8, 27, 30, "Oct" +251, 2, 3, 7, 9, 10, 31, 32, ";" +251, 2, 4, 8, 11, 13, 33, 35, "19" +251, 2, 5, 9, 14, 15, 36, 37, "(" +251, 2, 6, 10, 16, 18, 38, 40, "10" +251, 2, 7, 11, 19, 20, 41, 42, ")" +251, 2, 8, 12, 21, 22, 43, 44, ":" +251, 2, 9, 13, 23, 27, 45, 49, "1389" +251, 2, 10, 14, 28, 29, 50, 51, "-" +251, 2, 11, 15, 30, 34, 52, 56, "1396" +251, 2, 12, 16, 35, 36, 57, 58, "." +251, 2, 13, 17, 37, 40, 59, 62, "doi" +251, 2, 14, 18, 41, 42, 63, 64, ":" +251, 2, 15, 19, 43, 45, 65, 67, "10" +251, 2, 16, 20, 46, 47, 68, 69, "." +251, 2, 17, 21, 48, 52, 70, 74, "1111" +251, 2, 18, 22, 53, 54, 75, 76, "/" +251, 2, 19, 23, 55, 58, 77, 80, "dom" +251, 2, 20, 24, 59, 60, 81, 82, "." +251, 2, 21, 25, 61, 66, 83, 88, "12955" +251, 2, 22, 26, 67, 68, 89, 90, "." +251, 3, 1, 27, 0, 4, 91, 95, "Epub" +251, 3, 2, 28, 5, 9, 96, 100, "2017" +251, 3, 3, 29, 10, 13, 101, 104, "Jul" +251, 3, 4, 30, 14, 15, 105, 106, "6" +251, 3, 5, 31, 16, 17, 107, 108, "." +251, 4, 1, 32, 0, 6, 109, 115, "Adding" +251, 4, 2, 33, 7, 11, 116, 120, "fast" +251, 4, 3, 34, 12, 13, 121, 122, "-" +251, 4, 4, 35, 14, 20, 123, 129, "acting" +251, 4, 5, 36, 21, 28, 130, 137, "insulin" +251, 4, 6, 37, 29, 35, 138, 144, "aspart" +251, 4, 7, 38, 36, 38, 145, 147, "to" +251, 4, 8, 39, 39, 44, 148, 153, "basal" +251, 4, 9, 40, 45, 52, 154, 161, "insulin" +251, 4, 10, 41, 53, 66, 162, 175, "significantly" +251, 4, 11, 42, 67, 75, 176, 184, "improved" +251, 4, 12, 43, 76, 85, 185, 194, "glycaemic" +251, 4, 13, 44, 86, 93, 195, 202, "control" +251, 4, 14, 45, 94, 96, 203, 205, "in" +251, 4, 15, 46, 97, 105, 206, 214, "patients" +251, 4, 16, 47, 106, 110, 215, 219, "with" +251, 4, 17, 48, 111, 115, 220, 224, "type" +251, 4, 18, 49, 116, 117, 225, 226, "2" +251, 4, 19, 50, 118, 126, 227, 235, "diabetes" +251, 4, 20, 51, 127, 128, 236, 237, ":" +251, 4, 21, 52, 129, 130, 238, 239, "A" +251, 4, 22, 53, 131, 141, 240, 250, "randomized" +251, 4, 23, 54, 142, 143, 251, 252, "," +251, 4, 24, 55, 144, 146, 253, 255, "18" +251, 4, 25, 56, 147, 148, 256, 257, "-" +251, 4, 26, 57, 149, 153, 258, 262, "week" +251, 4, 27, 58, 154, 155, 263, 264, "," +251, 4, 28, 59, 156, 160, 265, 269, "open" +251, 4, 29, 60, 161, 162, 270, 271, "-" +251, 4, 30, 61, 163, 168, 272, 277, "label" +251, 4, 31, 62, 169, 170, 278, 279, "," +251, 4, 32, 63, 171, 176, 280, 285, "phase" +251, 4, 33, 64, 177, 178, 286, 287, "3" +251, 4, 34, 65, 179, 184, 288, 293, "trial" +251, 4, 35, 66, 185, 186, 294, 295, "(" +251, 4, 36, 67, 187, 192, 296, 301, "onset" +251, 4, 37, 68, 193, 194, 302, 303, "3" +251, 4, 38, 69, 195, 196, 304, 305, ")" +251, 4, 39, 70, 197, 198, 306, 307, "." +251, 5, 1, 71, 0, 7, 308, 315, "Rodbard" +251, 5, 2, 72, 8, 10, 316, 318, "HW" +251, 5, 3, 73, 11, 12, 319, 320, "(" +251, 5, 4, 74, 13, 14, 321, 322, "1" +251, 5, 5, 75, 15, 16, 323, 324, ")" +251, 5, 6, 76, 17, 18, 325, 326, "," +251, 5, 7, 77, 19, 27, 327, 335, "Tripathy" +251, 5, 8, 78, 28, 29, 336, 337, "D" +251, 5, 9, 79, 30, 31, 338, 339, "(" +251, 5, 10, 80, 32, 33, 340, 341, "2" +251, 5, 11, 81, 34, 35, 342, 343, ")" +251, 5, 12, 82, 36, 37, 344, 345, "(" +251, 5, 13, 83, 38, 39, 346, 347, "3" +251, 5, 14, 84, 40, 41, 348, 349, ")" +251, 5, 15, 85, 42, 43, 350, 351, "," +251, 5, 16, 86, 44, 50, 352, 358, "Vidrio" +251, 5, 17, 87, 51, 54, 359, 362, "Vel" +251, 5, 18, 88, 55, 56, 363, 364, "á" +251, 5, 19, 89, 57, 62, 365, 370, "zquez" +251, 5, 20, 90, 63, 64, 371, 372, "M" +251, 5, 21, 91, 65, 66, 373, 374, "(" +251, 5, 22, 92, 67, 68, 375, 376, "4" +251, 5, 23, 93, 69, 70, 377, 378, ")" +251, 5, 24, 94, 71, 72, 379, 380, "," +251, 5, 25, 95, 73, 81, 381, 389, "Demissie" +251, 5, 26, 96, 82, 83, 390, 391, "M" +251, 5, 27, 97, 84, 85, 392, 393, "(" +251, 5, 28, 98, 86, 87, 394, 395, "5" +251, 5, 29, 99, 88, 89, 396, 397, ")" +251, 5, 30, 100, 90, 91, 398, 399, "," +251, 5, 31, 101, 92, 97, 400, 405, "Tamer" +251, 5, 32, 102, 98, 100, 406, 408, "SC" +251, 5, 33, 103, 101, 102, 409, 410, "(" +251, 5, 34, 104, 103, 104, 411, 412, "5" +251, 5, 35, 105, 105, 106, 413, 414, ")" +251, 5, 36, 106, 107, 108, 415, 416, "," +251, 5, 37, 107, 109, 115, 417, 423, "Pileti" +251, 5, 38, 108, 116, 117, 424, 425, "č" +251, 5, 39, 109, 118, 119, 426, 427, "M" +251, 5, 40, 110, 120, 121, 428, 429, "(" +251, 5, 41, 111, 122, 123, 430, 431, "6" +251, 5, 42, 112, 124, 125, 432, 433, ")" +251, 5, 43, 113, 126, 127, 434, 435, "." +251, 6, 1, 114, 0, 6, 436, 442, "Author" +251, 6, 2, 115, 7, 18, 443, 454, "information" +251, 6, 3, 116, 19, 20, 455, 456, ":" +251, 6, 4, 117, 21, 22, 457, 458, "(" +251, 6, 5, 118, 23, 24, 459, 460, "1" +251, 6, 6, 119, 25, 26, 461, 462, ")" +251, 6, 7, 120, 27, 36, 463, 472, "Endocrine" +251, 6, 8, 121, 37, 40, 473, 476, "and" +251, 6, 9, 122, 41, 50, 477, 486, "Metabolic" +251, 6, 10, 123, 51, 62, 487, 498, "Consultants" +251, 6, 11, 124, 63, 64, 499, 500, "," +251, 6, 12, 125, 65, 74, 501, 510, "Rockville" +251, 6, 13, 126, 75, 76, 511, 512, "," +251, 6, 14, 127, 77, 85, 513, 521, "Maryland" +251, 6, 15, 128, 86, 87, 522, 523, "." +251, 7, 1, 129, 0, 1, 524, 525, "(" +251, 7, 2, 130, 2, 3, 526, 527, "2" +251, 7, 3, 131, 4, 5, 528, 529, ")" +251, 7, 4, 132, 6, 16, 530, 540, "University" +251, 7, 5, 133, 17, 19, 541, 543, "of" +251, 7, 6, 134, 20, 25, 544, 549, "Texas" +251, 7, 7, 135, 26, 32, 550, 556, "Health" +251, 7, 8, 136, 33, 40, 557, 564, "Science" +251, 7, 9, 137, 41, 47, 565, 571, "Center" +251, 7, 10, 138, 48, 49, 572, 573, "," +251, 7, 11, 139, 50, 53, 574, 577, "San" +251, 7, 12, 140, 54, 61, 578, 585, "Antonio" +251, 7, 13, 141, 62, 63, 586, 587, "," +251, 7, 14, 142, 64, 69, 588, 593, "Texas" +251, 7, 15, 143, 70, 71, 594, 595, "." +251, 8, 1, 144, 0, 1, 596, 597, "(" +251, 8, 2, 145, 2, 3, 598, 599, "3" +251, 8, 3, 146, 4, 5, 600, 601, ")" +251, 8, 4, 147, 6, 11, 602, 607, "Audie" +251, 8, 5, 148, 12, 13, 608, 609, "L" +251, 8, 6, 149, 14, 20, 610, 616, "Murphy" +251, 8, 7, 150, 21, 23, 617, 619, "VA" +251, 8, 8, 151, 24, 32, 620, 628, "Hospital" +251, 8, 9, 152, 33, 34, 629, 630, "," +251, 8, 10, 153, 35, 38, 631, 634, "San" +251, 8, 11, 154, 39, 46, 635, 642, "Antonio" +251, 8, 12, 155, 47, 48, 643, 644, "," +251, 8, 13, 156, 49, 54, 645, 650, "Texas" +251, 8, 14, 157, 55, 56, 651, 652, "." +251, 9, 1, 158, 0, 1, 653, 654, "(" +251, 9, 2, 159, 2, 3, 655, 656, "4" +251, 9, 3, 160, 4, 5, 657, 658, ")" +251, 9, 4, 161, 6, 14, 659, 667, "Hospital" +251, 9, 5, 162, 15, 22, 668, 675, "General" +251, 9, 6, 163, 23, 31, 676, 684, "Regional" +251, 9, 7, 164, 32, 35, 685, 688, "110" +251, 9, 8, 165, 36, 37, 689, 690, "," +251, 9, 9, 166, 38, 49, 691, 702, "Guadalajara" +251, 9, 10, 167, 50, 51, 703, 704, "," +251, 9, 11, 168, 52, 58, 705, 711, "Mexico" +251, 9, 12, 169, 59, 60, 712, 713, "." +251, 10, 1, 170, 0, 1, 714, 715, "(" +251, 10, 2, 171, 2, 3, 716, 717, "5" +251, 10, 3, 172, 4, 5, 718, 719, ")" +251, 10, 4, 173, 6, 10, 720, 724, "Novo" +251, 10, 5, 174, 11, 18, 725, 732, "Nordisk" +251, 10, 6, 175, 19, 20, 733, 734, "A" +251, 10, 7, 176, 21, 22, 735, 736, "/" +251, 10, 8, 177, 23, 24, 737, 738, "S" +251, 10, 9, 178, 25, 26, 739, 740, "," +251, 10, 10, 179, 27, 28, 741, 742, "S" +251, 10, 11, 180, 29, 30, 743, 744, "ø" +251, 10, 12, 181, 31, 35, 745, 749, "borg" +251, 10, 13, 182, 36, 37, 750, 751, "," +251, 10, 14, 183, 38, 45, 752, 759, "Denmark" +251, 10, 15, 184, 46, 47, 760, 761, "." +251, 11, 1, 185, 0, 1, 762, 763, "(" +251, 11, 2, 186, 2, 3, 764, 765, "6" +251, 11, 3, 187, 4, 5, 766, 767, ")" +251, 11, 4, 188, 6, 13, 768, 775, "General" +251, 11, 5, 189, 14, 22, 776, 784, "Hospital" +251, 11, 6, 190, 23, 24, 785, 786, "," +251, 11, 7, 191, 25, 29, 787, 791, "Novo" +251, 11, 8, 192, 30, 35, 792, 797, "Mesto" +251, 11, 9, 193, 36, 37, 798, 799, "," +251, 11, 10, 194, 38, 46, 800, 808, "Slovenia" +251, 11, 11, 195, 47, 48, 809, 810, "." +251, 12, 1, 196, 0, 3, 811, 814, "AIM" +251, 12, 2, 197, 4, 5, 815, 816, ":" +251, 12, 3, 198, 6, 8, 817, 819, "To" +251, 12, 4, 199, 9, 16, 820, 827, "confirm" +251, 12, 5, 200, 17, 26, 828, 837, "glycaemic" +251, 12, 6, 201, 27, 34, 838, 845, "control" +251, 12, 7, 202, 35, 46, 846, 857, "superiority" +251, 12, 8, 203, 47, 49, 858, 860, "of" +251, 12, 9, 204, 50, 58, 861, 869, "mealtime" +251, 12, 10, 205, 59, 63, 870, 874, "fast" +251, 12, 11, 206, 64, 65, 875, 876, "-" +251, 12, 12, 207, 66, 72, 877, 883, "acting" +251, 12, 13, 208, 73, 80, 884, 891, "insulin" +251, 12, 14, 209, 81, 87, 892, 898, "aspart" +251, 12, 15, 210, 88, 89, 899, 900, "(" +251, 12, 16, 211, 90, 96, 901, 907, "faster" +251, 12, 17, 212, 97, 103, 908, 914, "aspart" +251, 12, 18, 213, 104, 105, 915, 916, ")" +251, 12, 19, 214, 106, 108, 917, 919, "in" +251, 12, 20, 215, 109, 110, 920, 921, "a" +251, 12, 21, 216, 111, 116, 922, 927, "basal" +251, 12, 22, 217, 117, 118, 928, 929, "-" +251, 12, 23, 218, 119, 124, 930, 935, "bolus" +251, 12, 24, 219, 125, 126, 936, 937, "(" +251, 12, 25, 220, 127, 129, 938, 940, "BB" +251, 12, 26, 221, 130, 131, 941, 942, ")" +251, 12, 27, 222, 132, 139, 943, 950, "regimen" +251, 12, 28, 223, 140, 142, 951, 953, "vs" +251, 12, 29, 224, 143, 148, 954, 959, "basal" +251, 12, 30, 225, 149, 150, 960, 961, "-" +251, 12, 31, 226, 151, 155, 962, 966, "only" +251, 12, 32, 227, 156, 163, 967, 974, "insulin" +251, 12, 33, 228, 164, 165, 975, 976, "." +251, 13, 1, 229, 0, 9, 977, 986, "MATERIALS" +251, 13, 2, 230, 10, 13, 987, 990, "AND" +251, 13, 3, 231, 14, 21, 991, 998, "METHODS" +251, 13, 4, 232, 22, 23, 999, 1000, ":" +251, 13, 5, 233, 24, 26, 1001, 1003, "In" +251, 13, 6, 234, 27, 31, 1004, 1008, "this" +251, 13, 7, 235, 32, 36, 1009, 1013, "open" +251, 13, 8, 236, 37, 38, 1014, 1015, "-" +251, 13, 9, 237, 39, 44, 1016, 1021, "label" +251, 13, 10, 238, 45, 46, 1022, 1023, "," +251, 13, 11, 239, 47, 57, 1024, 1034, "randomized" +251, 13, 12, 240, 58, 59, 1035, 1036, "," +251, 13, 13, 241, 60, 62, 1037, 1039, "18" +251, 13, 14, 242, 63, 64, 1040, 1041, "-" +251, 13, 15, 243, 65, 69, 1042, 1046, "week" +251, 13, 16, 244, 70, 75, 1047, 1052, "trial" +251, 13, 17, 245, 76, 77, 1053, 1054, "(" +251, 13, 18, 246, 78, 80, 1055, 1057, "51" +251, 13, 19, 247, 81, 86, 1058, 1063, "sites" +251, 13, 20, 248, 87, 88, 1064, 1065, ";" +251, 13, 21, 249, 89, 90, 1066, 1067, "6" +251, 13, 22, 250, 91, 100, 1068, 1077, "countries" +251, 13, 23, 251, 101, 102, 1078, 1079, ")" +251, 13, 24, 252, 103, 104, 1080, 1081, "," +251, 13, 25, 253, 105, 111, 1082, 1088, "adults" +251, 13, 26, 254, 112, 113, 1089, 1090, "(" +251, 13, 27, 255, 114, 115, 1091, 1092, "n" +251, 13, 28, 256, 116, 119, 1093, 1096, " = " +251, 13, 29, 257, 120, 123, 1097, 1100, "236" +251, 13, 30, 258, 124, 125, 1101, 1102, ")" +251, 13, 31, 259, 126, 130, 1103, 1107, "with" +251, 13, 32, 260, 131, 143, 1108, 1120, "inadequately" +251, 13, 33, 261, 144, 154, 1121, 1131, "controlled" +251, 13, 34, 262, 155, 159, 1132, 1136, "type" +251, 13, 35, 263, 160, 161, 1137, 1138, "2" +251, 13, 36, 264, 162, 170, 1139, 1147, "diabetes" +251, 13, 37, 265, 171, 172, 1148, 1149, "(" +251, 13, 38, 266, 173, 176, 1150, 1153, "T2D" +251, 13, 39, 267, 177, 178, 1154, 1155, ";" +251, 13, 40, 268, 179, 183, 1156, 1160, "mean" +251, 13, 41, 269, 184, 196, 1161, 1173, "glycosylated" +251, 13, 42, 270, 197, 208, 1174, 1185, "haemoglobin" +251, 13, 43, 271, 209, 210, 1186, 1187, "[" +251, 13, 44, 272, 211, 216, 1188, 1193, "HbA1c" +251, 13, 45, 273, 217, 221, 1194, 1198, "] ± " +251, 13, 46, 274, 222, 224, 1199, 1201, "SD" +251, 13, 47, 275, 225, 226, 1202, 1203, ":" +251, 13, 48, 276, 227, 228, 1204, 1205, "7" +251, 13, 49, 277, 229, 230, 1206, 1207, "." +251, 13, 50, 278, 231, 232, 1208, 1209, "9" +251, 13, 51, 279, 233, 237, 1210, 1214, "% ± " +251, 13, 52, 280, 238, 239, 1215, 1216, "0" +251, 13, 53, 281, 240, 241, 1217, 1218, "." +251, 13, 54, 282, 242, 243, 1219, 1220, "7" +251, 13, 55, 283, 244, 245, 1221, 1222, "%" +251, 13, 56, 284, 246, 247, 1223, 1224, "[" +251, 13, 57, 285, 248, 250, 1225, 1227, "63" +251, 13, 58, 286, 251, 252, 1228, 1229, "." +251, 13, 59, 287, 253, 254, 1230, 1231, "1" +251, 13, 60, 288, 255, 258, 1232, 1235, " ± " +251, 13, 61, 289, 259, 260, 1236, 1237, "7" +251, 13, 62, 290, 261, 262, 1238, 1239, "." +251, 13, 63, 291, 263, 264, 1240, 1241, "5" +251, 13, 64, 292, 265, 266, 1242, 1243, " " +251, 13, 65, 293, 267, 271, 1244, 1248, "mmol" +251, 13, 66, 294, 272, 273, 1249, 1250, "/" +251, 13, 67, 295, 274, 277, 1251, 1254, "mol" +251, 13, 68, 296, 278, 279, 1255, 1256, "]" +251, 13, 69, 297, 280, 281, 1257, 1258, ")" +251, 13, 70, 298, 282, 291, 1259, 1268, "receiving" +251, 13, 71, 299, 292, 297, 1269, 1274, "basal" +251, 13, 72, 300, 298, 305, 1275, 1282, "insulin" +251, 13, 73, 301, 306, 309, 1283, 1286, "and" +251, 13, 74, 302, 310, 314, 1287, 1291, "oral" +251, 13, 75, 303, 315, 327, 1292, 1304, "antidiabetic" +251, 13, 76, 304, 328, 333, 1305, 1310, "drugs" +251, 13, 77, 305, 334, 343, 1311, 1320, "underwent" +251, 13, 78, 306, 344, 345, 1321, 1322, "8" +251, 13, 79, 307, 346, 347, 1323, 1324, "-" +251, 13, 80, 308, 348, 352, 1325, 1329, "week" +251, 13, 81, 309, 353, 365, 1330, 1342, "optimization" +251, 13, 82, 310, 366, 368, 1343, 1345, "of" +251, 13, 83, 311, 369, 374, 1346, 1351, "prior" +251, 13, 84, 312, 375, 379, 1352, 1356, "once" +251, 13, 85, 313, 380, 381, 1357, 1358, "-" +251, 13, 86, 314, 382, 387, 1359, 1364, "daily" +251, 13, 87, 315, 388, 393, 1365, 1370, "basal" +251, 13, 88, 316, 394, 401, 1371, 1378, "insulin" +251, 13, 89, 317, 402, 410, 1379, 1387, "followed" +251, 13, 90, 318, 411, 413, 1388, 1390, "by" +251, 13, 91, 319, 414, 427, 1391, 1404, "randomization" +251, 13, 92, 320, 428, 429, 1405, 1406, "1" +251, 13, 93, 321, 430, 431, 1407, 1408, ":" +251, 13, 94, 322, 432, 433, 1409, 1410, "1" +251, 13, 95, 323, 434, 436, 1411, 1413, "to" +251, 13, 96, 324, 437, 443, 1414, 1420, "either" +251, 13, 97, 325, 444, 445, 1421, 1422, "a" +251, 13, 98, 326, 446, 448, 1423, 1425, "BB" +251, 13, 99, 327, 449, 456, 1426, 1433, "regimen" +251, 13, 100, 328, 457, 461, 1434, 1438, "with" +251, 13, 101, 329, 462, 468, 1439, 1445, "faster" +251, 13, 102, 330, 469, 475, 1446, 1452, "aspart" +251, 13, 103, 331, 476, 477, 1453, 1454, "(" +251, 13, 104, 332, 478, 479, 1455, 1456, "n" +251, 13, 105, 333, 480, 483, 1457, 1460, " = " +251, 13, 106, 334, 484, 487, 1461, 1464, "116" +251, 13, 107, 335, 488, 489, 1465, 1466, ")" +251, 13, 108, 336, 490, 492, 1467, 1469, "or" +251, 13, 109, 337, 493, 505, 1470, 1482, "continuation" +251, 13, 110, 338, 506, 508, 1483, 1485, "of" +251, 13, 111, 339, 509, 513, 1486, 1490, "once" +251, 13, 112, 340, 514, 515, 1491, 1492, "-" +251, 13, 113, 341, 516, 521, 1493, 1498, "daily" +251, 13, 114, 342, 522, 527, 1499, 1504, "basal" +251, 13, 115, 343, 528, 535, 1505, 1512, "insulin" +251, 13, 116, 344, 536, 537, 1513, 1514, "(" +251, 13, 117, 345, 538, 539, 1515, 1516, "n" +251, 13, 118, 346, 540, 543, 1517, 1520, " = " +251, 13, 119, 347, 544, 547, 1521, 1524, "120" +251, 13, 120, 348, 548, 549, 1525, 1526, ")" +251, 13, 121, 349, 550, 551, 1527, 1528, "," +251, 13, 122, 350, 552, 556, 1529, 1533, "both" +251, 13, 123, 351, 557, 561, 1534, 1538, "with" +251, 13, 124, 352, 562, 571, 1539, 1548, "metformin" +251, 13, 125, 353, 572, 573, 1549, 1550, "." +251, 14, 1, 354, 0, 7, 1551, 1558, "Primary" +251, 14, 2, 355, 8, 16, 1559, 1567, "endpoint" +251, 14, 3, 356, 17, 20, 1568, 1571, "was" +251, 14, 4, 357, 21, 26, 1572, 1577, "HbA1c" +251, 14, 5, 358, 27, 33, 1578, 1584, "change" +251, 14, 6, 359, 34, 38, 1585, 1589, "from" +251, 14, 7, 360, 39, 47, 1590, 1598, "baseline" +251, 14, 8, 361, 48, 53, 1599, 1604, "after" +251, 14, 9, 362, 54, 56, 1605, 1607, "18" +251, 14, 10, 363, 57, 58, 1608, 1609, " " +251, 14, 11, 364, 59, 64, 1610, 1615, "weeks" +251, 14, 12, 365, 65, 67, 1616, 1618, "of" +251, 14, 13, 366, 68, 77, 1619, 1628, "treatment" +251, 14, 14, 367, 78, 79, 1629, 1630, "." +251, 15, 1, 368, 0, 9, 1631, 1640, "Secondary" +251, 15, 2, 369, 10, 19, 1641, 1650, "endpoints" +251, 15, 3, 370, 20, 28, 1651, 1659, "included" +251, 15, 4, 371, 29, 30, 1660, 1661, ":" +251, 15, 5, 372, 31, 43, 1662, 1674, "postprandial" +251, 15, 6, 373, 44, 50, 1675, 1681, "plasma" +251, 15, 7, 374, 51, 58, 1682, 1689, "glucose" +251, 15, 8, 375, 59, 60, 1690, 1691, "(" +251, 15, 9, 376, 61, 64, 1692, 1695, "PPG" +251, 15, 10, 377, 65, 66, 1696, 1697, ")" +251, 15, 11, 378, 67, 73, 1698, 1704, "change" +251, 15, 12, 379, 74, 77, 1705, 1708, "and" +251, 15, 13, 380, 78, 85, 1709, 1716, "overall" +251, 15, 14, 381, 86, 89, 1717, 1720, "PPG" +251, 15, 15, 382, 90, 99, 1721, 1730, "increment" +251, 15, 16, 383, 100, 101, 1731, 1732, "(" +251, 15, 17, 384, 102, 105, 1733, 1736, "all" +251, 15, 18, 385, 106, 111, 1737, 1742, "meals" +251, 15, 19, 386, 112, 113, 1743, 1744, ")" +251, 15, 20, 387, 114, 115, 1745, 1746, ";" +251, 15, 21, 388, 116, 122, 1747, 1753, "weight" +251, 15, 22, 389, 123, 124, 1754, 1755, ";" +251, 15, 23, 390, 125, 134, 1756, 1765, "treatment" +251, 15, 24, 391, 135, 136, 1766, 1767, "-" +251, 15, 25, 392, 137, 145, 1768, 1776, "emergent" +251, 15, 26, 393, 146, 153, 1777, 1784, "adverse" +251, 15, 27, 394, 154, 160, 1785, 1791, "events" +251, 15, 28, 395, 161, 162, 1792, 1793, ";" +251, 15, 29, 396, 163, 176, 1794, 1807, "hypoglycaemic" +251, 15, 30, 397, 177, 185, 1808, 1816, "episodes" +251, 15, 31, 398, 186, 187, 1817, 1818, "." +251, 16, 1, 399, 0, 7, 1819, 1826, "RESULTS" +251, 16, 2, 400, 8, 9, 1827, 1828, ":" +251, 16, 3, 401, 10, 15, 1829, 1834, "HbA1c" +251, 16, 4, 402, 16, 25, 1835, 1844, "decreased" +251, 16, 5, 403, 26, 30, 1845, 1849, "from" +251, 16, 6, 404, 31, 32, 1850, 1851, "7" +251, 16, 7, 405, 33, 34, 1852, 1853, "." +251, 16, 8, 406, 35, 36, 1854, 1855, "9" +251, 16, 9, 407, 37, 38, 1856, 1857, "%" +251, 16, 10, 408, 39, 40, 1858, 1859, "(" +251, 16, 11, 409, 41, 43, 1860, 1862, "63" +251, 16, 12, 410, 44, 45, 1863, 1864, "." +251, 16, 13, 411, 46, 47, 1865, 1866, "2" +251, 16, 14, 412, 48, 49, 1867, 1868, " " +251, 16, 15, 413, 50, 54, 1869, 1873, "mmol" +251, 16, 16, 414, 55, 56, 1874, 1875, "/" +251, 16, 17, 415, 57, 60, 1876, 1879, "mol" +251, 16, 18, 416, 61, 62, 1880, 1881, ")" +251, 16, 19, 417, 63, 65, 1882, 1884, "to" +251, 16, 20, 418, 66, 67, 1885, 1886, "6" +251, 16, 21, 419, 68, 69, 1887, 1888, "." +251, 16, 22, 420, 70, 71, 1889, 1890, "8" +251, 16, 23, 421, 72, 73, 1891, 1892, "%" +251, 16, 24, 422, 74, 75, 1893, 1894, "(" +251, 16, 25, 423, 76, 78, 1895, 1897, "50" +251, 16, 26, 424, 79, 80, 1898, 1899, "." +251, 16, 27, 425, 81, 82, 1900, 1901, "7" +251, 16, 28, 426, 83, 84, 1902, 1903, " " +251, 16, 29, 427, 85, 89, 1904, 1908, "mmol" +251, 16, 30, 428, 90, 91, 1909, 1910, "/" +251, 16, 31, 429, 92, 95, 1911, 1914, "mol" +251, 16, 32, 430, 96, 97, 1915, 1916, ";" +251, 16, 33, 431, 98, 100, 1917, 1919, "BB" +251, 16, 34, 432, 101, 106, 1920, 1925, "group" +251, 16, 35, 433, 107, 108, 1926, 1927, ")" +251, 16, 36, 434, 109, 112, 1928, 1931, "and" +251, 16, 37, 435, 113, 117, 1932, 1936, "from" +251, 16, 38, 436, 118, 119, 1937, 1938, "7" +251, 16, 39, 437, 120, 121, 1939, 1940, "." +251, 16, 40, 438, 122, 123, 1941, 1942, "9" +251, 16, 41, 439, 124, 125, 1943, 1944, "%" +251, 16, 42, 440, 126, 127, 1945, 1946, "(" +251, 16, 43, 441, 128, 130, 1947, 1949, "63" +251, 16, 44, 442, 131, 132, 1950, 1951, "." +251, 16, 45, 443, 133, 134, 1952, 1953, "2" +251, 16, 46, 444, 135, 136, 1954, 1955, " " +251, 16, 47, 445, 137, 141, 1956, 1960, "mmol" +251, 16, 48, 446, 142, 143, 1961, 1962, "/" +251, 16, 49, 447, 144, 147, 1963, 1966, "mol" +251, 16, 50, 448, 148, 149, 1967, 1968, ")" +251, 16, 51, 449, 150, 152, 1969, 1971, "to" +251, 16, 52, 450, 153, 154, 1972, 1973, "7" +251, 16, 53, 451, 155, 156, 1974, 1975, "." +251, 16, 54, 452, 157, 158, 1976, 1977, "7" +251, 16, 55, 453, 159, 160, 1978, 1979, "%" +251, 16, 56, 454, 161, 162, 1980, 1981, "(" +251, 16, 57, 455, 163, 165, 1982, 1984, "60" +251, 16, 58, 456, 166, 167, 1985, 1986, "." +251, 16, 59, 457, 168, 169, 1987, 1988, "7" +251, 16, 60, 458, 170, 171, 1989, 1990, " " +251, 16, 61, 459, 172, 176, 1991, 1995, "mmol" +251, 16, 62, 460, 177, 178, 1996, 1997, "/" +251, 16, 63, 461, 179, 182, 1998, 2001, "mol" +251, 16, 64, 462, 183, 184, 2002, 2003, ";" +251, 16, 65, 463, 185, 190, 2004, 2009, "basal" +251, 16, 66, 464, 191, 192, 2010, 2011, "-" +251, 16, 67, 465, 193, 197, 2012, 2016, "only" +251, 16, 68, 466, 198, 203, 2017, 2022, "group" +251, 16, 69, 467, 204, 205, 2023, 2024, ")" +251, 16, 70, 468, 206, 207, 2025, 2026, ";" +251, 16, 71, 469, 208, 217, 2027, 2036, "estimated" +251, 16, 72, 470, 218, 227, 2037, 2046, "treatment" +251, 16, 73, 471, 228, 238, 2047, 2057, "difference" +251, 16, 74, 472, 239, 240, 2058, 2059, "[" +251, 16, 75, 473, 241, 243, 2060, 2062, "95" +251, 16, 76, 474, 244, 245, 2063, 2064, "%" +251, 16, 77, 475, 246, 256, 2065, 2075, "confidence" +251, 16, 78, 476, 257, 265, 2076, 2084, "interval" +251, 16, 79, 477, 266, 267, 2085, 2086, "]" +251, 16, 80, 478, 268, 269, 2087, 2088, "-" +251, 16, 81, 479, 270, 271, 2089, 2090, "0" +251, 16, 82, 480, 272, 273, 2091, 2092, "." +251, 16, 83, 481, 274, 276, 2093, 2095, "94" +251, 16, 84, 482, 277, 278, 2096, 2097, "%" +251, 16, 85, 483, 279, 280, 2098, 2099, "[" +251, 16, 86, 484, 281, 282, 2100, 2101, "-" +251, 16, 87, 485, 283, 284, 2102, 2103, "1" +251, 16, 88, 486, 285, 286, 2104, 2105, "." +251, 16, 89, 487, 287, 289, 2106, 2108, "17" +251, 16, 90, 488, 290, 291, 2109, 2110, ";" +251, 16, 91, 489, 292, 293, 2111, 2112, "-" +251, 16, 92, 490, 294, 295, 2113, 2114, "0" +251, 16, 93, 491, 296, 297, 2115, 2116, "." +251, 16, 94, 492, 298, 300, 2117, 2119, "72" +251, 16, 95, 493, 301, 302, 2120, 2121, "]" +251, 16, 96, 494, 303, 304, 2122, 2123, ";" +251, 16, 97, 495, 305, 306, 2124, 2125, "-" +251, 16, 98, 496, 307, 309, 2126, 2128, "10" +251, 16, 99, 497, 310, 311, 2129, 2130, "." +251, 16, 100, 498, 312, 313, 2131, 2132, "3" +251, 16, 101, 499, 314, 315, 2133, 2134, " " +251, 16, 102, 500, 316, 320, 2135, 2139, "mmol" +251, 16, 103, 501, 321, 322, 2140, 2141, "/" +251, 16, 104, 502, 323, 326, 2142, 2145, "mol" +251, 16, 105, 503, 327, 328, 2146, 2147, "[" +251, 16, 106, 504, 329, 330, 2148, 2149, "-" +251, 16, 107, 505, 331, 333, 2150, 2152, "12" +251, 16, 108, 506, 334, 335, 2153, 2154, "." +251, 16, 109, 507, 336, 337, 2155, 2156, "8" +251, 16, 110, 508, 338, 339, 2157, 2158, ";" +251, 16, 111, 509, 340, 341, 2159, 2160, "-" +251, 16, 112, 510, 342, 343, 2161, 2162, "7" +251, 16, 113, 511, 344, 345, 2163, 2164, "." +251, 16, 114, 512, 346, 347, 2165, 2166, "8" +251, 16, 115, 513, 348, 349, 2167, 2168, "]" +251, 16, 116, 514, 350, 351, 2169, 2170, ";" +251, 16, 117, 515, 352, 353, 2171, 2172, "P" +251, 16, 118, 516, 354, 358, 2173, 2177, " < ." +251, 16, 119, 517, 359, 363, 2178, 2182, "0001" +251, 16, 120, 518, 364, 365, 2183, 2184, "." +251, 17, 1, 519, 0, 10, 2185, 2195, "Reductions" +251, 17, 2, 520, 11, 15, 2196, 2200, "from" +251, 17, 3, 521, 16, 24, 2201, 2209, "baseline" +251, 17, 4, 522, 25, 27, 2210, 2212, "in" +251, 17, 5, 523, 28, 35, 2213, 2220, "overall" +251, 17, 6, 524, 36, 40, 2221, 2225, "mean" +251, 17, 7, 525, 41, 42, 2226, 2227, "2" +251, 17, 8, 526, 43, 44, 2228, 2229, "-" +251, 17, 9, 527, 45, 49, 2230, 2234, "hour" +251, 17, 10, 528, 50, 53, 2235, 2238, "PPG" +251, 17, 11, 529, 54, 57, 2239, 2242, "and" +251, 17, 12, 530, 58, 65, 2243, 2250, "overall" +251, 17, 13, 531, 66, 69, 2251, 2254, "PPG" +251, 17, 14, 532, 70, 79, 2255, 2264, "increment" +251, 17, 15, 533, 80, 83, 2265, 2268, "for" +251, 17, 16, 534, 84, 87, 2269, 2272, "all" +251, 17, 17, 535, 88, 93, 2273, 2278, "meals" +251, 17, 18, 536, 94, 95, 2279, 2280, "(" +251, 17, 19, 537, 96, 100, 2281, 2285, "self" +251, 17, 20, 538, 101, 102, 2286, 2287, "-" +251, 17, 21, 539, 103, 111, 2288, 2296, "measured" +251, 17, 22, 540, 112, 118, 2297, 2303, "plasma" +251, 17, 23, 541, 119, 126, 2304, 2311, "glucose" +251, 17, 24, 542, 127, 135, 2312, 2320, "profiles" +251, 17, 25, 543, 136, 137, 2321, 2322, ")" +251, 17, 26, 544, 138, 142, 2323, 2327, "were" +251, 17, 27, 545, 143, 156, 2328, 2341, "statistically" +251, 17, 28, 546, 157, 168, 2342, 2353, "significant" +251, 17, 29, 547, 169, 171, 2354, 2356, "in" +251, 17, 30, 548, 172, 178, 2357, 2363, "favour" +251, 17, 31, 549, 179, 181, 2364, 2366, "of" +251, 17, 32, 550, 182, 184, 2367, 2369, "BB" +251, 17, 33, 551, 185, 194, 2370, 2379, "treatment" +251, 17, 34, 552, 195, 196, 2380, 2381, "(" +251, 17, 35, 553, 197, 198, 2382, 2383, "P" +251, 17, 36, 554, 199, 203, 2384, 2388, " < ." +251, 17, 37, 555, 204, 208, 2389, 2393, "0001" +251, 17, 38, 556, 209, 210, 2394, 2395, ")" +251, 17, 39, 557, 211, 212, 2396, 2397, "." +251, 18, 1, 558, 0, 6, 2398, 2404, "Severe" +251, 18, 2, 559, 7, 8, 2405, 2406, "/" +251, 18, 3, 560, 9, 14, 2407, 2412, "blood" +251, 18, 4, 561, 15, 22, 2413, 2420, "glucose" +251, 18, 5, 562, 23, 32, 2421, 2430, "confirmed" +251, 18, 6, 563, 33, 46, 2431, 2444, "hypoglycaemia" +251, 18, 7, 564, 47, 51, 2445, 2449, "rate" +251, 18, 8, 565, 52, 53, 2450, 2451, "(" +251, 18, 9, 566, 54, 56, 2452, 2454, "12" +251, 18, 10, 567, 57, 58, 2455, 2456, "." +251, 18, 11, 568, 59, 60, 2457, 2458, "8" +251, 18, 12, 569, 61, 63, 2459, 2461, "vs" +251, 18, 13, 570, 64, 65, 2462, 2463, "2" +251, 18, 14, 571, 66, 67, 2464, 2465, "." +251, 18, 15, 572, 68, 69, 2466, 2467, "0" +251, 18, 16, 573, 70, 78, 2468, 2476, "episodes" +251, 18, 17, 574, 79, 82, 2477, 2480, "per" +251, 18, 18, 575, 83, 90, 2481, 2488, "patient" +251, 18, 19, 576, 91, 92, 2489, 2490, "-" +251, 18, 20, 577, 93, 98, 2491, 2496, "years" +251, 18, 21, 578, 99, 101, 2497, 2499, "of" +251, 18, 22, 579, 102, 110, 2500, 2508, "exposure" +251, 18, 23, 580, 111, 112, 2509, 2510, ")" +251, 18, 24, 581, 113, 114, 2511, 2512, "," +251, 18, 25, 582, 115, 120, 2513, 2518, "total" +251, 18, 26, 583, 121, 126, 2519, 2524, "daily" +251, 18, 27, 584, 127, 134, 2525, 2532, "insulin" +251, 18, 28, 585, 135, 136, 2533, 2534, "(" +251, 18, 29, 586, 137, 138, 2535, 2536, "1" +251, 18, 30, 587, 139, 140, 2537, 2538, "." +251, 18, 31, 588, 141, 142, 2539, 2540, "2" +251, 18, 32, 589, 143, 145, 2541, 2543, "vs" +251, 18, 33, 590, 146, 147, 2544, 2545, "0" +251, 18, 34, 591, 148, 149, 2546, 2547, "." +251, 18, 35, 592, 150, 151, 2548, 2549, "6" +251, 18, 36, 593, 152, 153, 2550, 2551, "U" +251, 18, 37, 594, 154, 155, 2552, 2553, "/" +251, 18, 38, 595, 156, 158, 2554, 2556, "kg" +251, 18, 39, 596, 159, 160, 2557, 2558, ")" +251, 18, 40, 597, 161, 164, 2559, 2562, "and" +251, 18, 41, 598, 165, 171, 2563, 2569, "weight" +251, 18, 42, 599, 172, 176, 2570, 2574, "gain" +251, 18, 43, 600, 177, 178, 2575, 2576, "(" +251, 18, 44, 601, 179, 180, 2577, 2578, "1" +251, 18, 45, 602, 181, 182, 2579, 2580, "." +251, 18, 46, 603, 183, 184, 2581, 2582, "8" +251, 18, 47, 604, 185, 187, 2583, 2585, "vs" +251, 18, 48, 605, 188, 189, 2586, 2587, "0" +251, 18, 49, 606, 190, 191, 2588, 2589, "." +251, 18, 50, 607, 192, 193, 2590, 2591, "2" +251, 18, 51, 608, 194, 195, 2592, 2593, " " +251, 18, 52, 609, 196, 198, 2594, 2596, "kg" +251, 18, 53, 610, 199, 200, 2597, 2598, ")" +251, 18, 54, 611, 201, 205, 2599, 2603, "were" +251, 18, 55, 612, 206, 213, 2604, 2611, "greater" +251, 18, 56, 613, 214, 218, 2612, 2616, "with" +251, 18, 57, 614, 219, 221, 2617, 2619, "BB" +251, 18, 58, 615, 222, 226, 2620, 2624, "than" +251, 18, 59, 616, 227, 231, 2625, 2629, "with" +251, 18, 60, 617, 232, 237, 2630, 2635, "basal" +251, 18, 61, 618, 238, 239, 2636, 2637, "-" +251, 18, 62, 619, 240, 244, 2638, 2642, "only" +251, 18, 63, 620, 245, 254, 2643, 2652, "treatment" +251, 18, 64, 621, 255, 256, 2653, 2654, "." +251, 19, 1, 622, 0, 11, 2655, 2666, "CONCLUSIONS" +251, 19, 2, 623, 12, 13, 2667, 2668, ":" +251, 19, 3, 624, 14, 16, 2669, 2671, "In" +251, 19, 4, 625, 17, 20, 2672, 2675, "T2D" +251, 19, 5, 626, 21, 22, 2676, 2677, "," +251, 19, 6, 627, 23, 29, 2678, 2684, "faster" +251, 19, 7, 628, 30, 36, 2685, 2691, "aspart" +251, 19, 8, 629, 37, 39, 2692, 2694, "in" +251, 19, 9, 630, 40, 41, 2695, 2696, "a" +251, 19, 10, 631, 42, 44, 2697, 2699, "BB" +251, 19, 11, 632, 45, 52, 2700, 2707, "regimen" +251, 19, 12, 633, 53, 61, 2708, 2716, "provided" +251, 19, 13, 634, 62, 70, 2717, 2725, "superior" +251, 19, 14, 635, 71, 80, 2726, 2735, "glycaemic" +251, 19, 15, 636, 81, 88, 2736, 2743, "control" +251, 19, 16, 637, 89, 91, 2744, 2746, "as" +251, 19, 17, 638, 92, 100, 2747, 2755, "compared" +251, 19, 18, 639, 101, 105, 2756, 2760, "with" +251, 19, 19, 640, 106, 111, 2761, 2766, "basal" +251, 19, 20, 641, 112, 113, 2767, 2768, "-" +251, 19, 21, 642, 114, 118, 2769, 2773, "only" +251, 19, 22, 643, 119, 126, 2774, 2781, "insulin" +251, 19, 23, 644, 127, 128, 2782, 2783, "," +251, 19, 24, 645, 129, 132, 2784, 2787, "but" +251, 19, 25, 646, 133, 137, 2788, 2792, "with" +251, 19, 26, 647, 138, 140, 2793, 2795, "an" +251, 19, 27, 648, 141, 149, 2796, 2804, "increase" +251, 19, 28, 649, 150, 152, 2805, 2807, "in" +251, 19, 29, 650, 153, 156, 2808, 2811, "the" +251, 19, 30, 651, 157, 166, 2812, 2821, "frequency" +251, 19, 31, 652, 167, 169, 2822, 2824, "of" +251, 19, 32, 653, 170, 183, 2825, 2838, "hypoglycaemia" +251, 19, 33, 654, 184, 187, 2839, 2842, "and" +251, 19, 34, 655, 188, 194, 2843, 2849, "modest" +251, 19, 35, 656, 195, 201, 2850, 2856, "weight" +251, 19, 36, 657, 202, 206, 2857, 2861, "gain" +251, 19, 37, 658, 207, 208, 2862, 2863, "." +251, 20, 1, 659, 0, 1, 2864, 2865, "©" +251, 20, 2, 660, 2, 6, 2866, 2870, "2017" +251, 20, 3, 661, 7, 10, 2871, 2874, "The" +251, 20, 4, 662, 11, 18, 2875, 2882, "Authors" +251, 20, 5, 663, 19, 20, 2883, 2884, "." +251, 21, 1, 664, 0, 8, 2885, 2893, "Diabetes" +251, 21, 2, 665, 9, 10, 2894, 2895, "," +251, 21, 3, 666, 11, 18, 2896, 2903, "Obesity" +251, 21, 4, 667, 19, 22, 2904, 2907, "and" +251, 21, 5, 668, 23, 33, 2908, 2918, "Metabolism" +251, 21, 6, 669, 34, 43, 2919, 2928, "published" +251, 21, 7, 670, 44, 46, 2929, 2931, "by" +251, 21, 8, 671, 47, 51, 2932, 2936, "John" +251, 21, 9, 672, 52, 57, 2937, 2942, "Wiley" +251, 21, 10, 673, 58, 59, 2943, 2944, "&" +251, 21, 11, 674, 60, 64, 2945, 2949, "Sons" +251, 21, 12, 675, 65, 68, 2950, 2953, "Ltd" +251, 21, 13, 676, 69, 70, 2954, 2955, "." +251, 21, 14, 677, 71, 74, 2956, 2959, "DOI" +251, 21, 15, 678, 75, 76, 2960, 2961, ":" +251, 21, 16, 679, 77, 79, 2962, 2964, "10" +251, 21, 17, 680, 80, 81, 2965, 2966, "." +251, 21, 18, 681, 82, 86, 2967, 2971, "1111" +251, 21, 19, 682, 87, 88, 2972, 2973, "/" +251, 21, 20, 683, 89, 92, 2974, 2977, "dom" +251, 21, 21, 684, 93, 94, 2978, 2979, "." +251, 21, 22, 685, 95, 100, 2980, 2985, "12955" +251, 21, 23, 686, 101, 106, 2986, 2991, "PMCID" +251, 21, 24, 687, 107, 108, 2992, 2993, ":" +251, 21, 25, 688, 109, 119, 2994, 3004, "PMC5637905" +251, 21, 26, 689, 120, 124, 3005, 3009, "PMID" +251, 21, 27, 690, 125, 126, 3010, 3011, ":" +251, 21, 28, 691, 127, 135, 3012, 3020, "28345792" +251, 21, 29, 692, 136, 137, 3021, 3022, "[" +251, 21, 30, 693, 138, 145, 3023, 3030, "Indexed" +251, 21, 31, 694, 146, 149, 3031, 3034, "for" +251, 21, 32, 695, 150, 157, 3035, 3042, "MEDLINE" +251, 21, 33, 696, 158, 159, 3043, 3044, "]" diff --git a/data/dm2 28345792_kwoodley.annodb b/data/dm2 28345792_kwoodley.annodb new file mode 100644 index 0000000..4bb8478 --- /dev/null +++ b/data/dm2 28345792_kwoodley.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71416, Journal, 0, 19, "Diabetes Obes Metab", "", +71417, PublicationYear, 22, 26, "2017", "", +71431, Title, 109, 307, "Adding fast - acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes : A randomized , 18 - week , open - label , phase 3 trial ( onset 3 ) .", "", +71418, InsulinAspart, 130, 144, "insulin aspart", "", +71423, Insulin, 154, 161, "insulin", "", +71424, Type2Diabetes, 220, 235, "type 2 diabetes", "", +71428, Randomized, 240, 250, "randomized", "", +71429, Duration, 253, 262, "18 - week", "", +71430, OpenLabel, 265, 277, "open - label", "", +71432, Author, 308, 318, "Rodbard HW", "", +71433, Author, 327, 337, "Tripathy D", "", +71434, Author, 352, 372, "Vidrio Vel á zquez M", "", +71435, Author, 381, 391, "Demissie M", "", +71436, Author, 400, 408, "Tamer SC", "", +71437, Author, 417, 427, "Pileti č M", "", +71438, USA, 513, 521, "Maryland", "", +71439, USA, 588, 593, "Texas", "", +71440, USA, 645, 650, "Texas", "", +71441, Mexico, 705, 711, "Mexico", "", +71442, Country, 752, 759, "Denmark", "", +71443, Country, 800, 808, "Slovenia", "", +71449, ObjectiveDescription, 817, 976, "To confirm glycaemic control superiority of mealtime fast - acting insulin aspart ( faster aspart ) in a basal - bolus ( BB ) regimen vs basal - only insulin .", "", +71419, InsulinAspart, 884, 898, "insulin aspart", "", +71420, InsulinAspart, 901, 914, "faster aspart", "", +71445, FixedCombDrug, 922, 950, "basal - bolus ( BB ) regimen", "", +71444, Insulin, 967, 974, "insulin", "", +71450, OpenLabel, 1009, 1021, "open - label", "", +71451, Randomized, 1024, 1034, "randomized", "", +71452, Duration, 1037, 1046, "18 - week", "", +71453, Multicenter, 1055, 1077, "51 sites ; 6 countries", "", +71465, Precondition, 1082, 1310, "adults ( n  =  236 ) with inadequately controlled type 2 diabetes ( T2D ; mean glycosylated haemoglobin [ HbA1c ] ±  SD : 7 . 9 % ±  0 . 7 % [ 63 . 1  ±  7 . 5   mmol / mol ] ) receiving basal insulin and oral antidiabetic drugs", "", +71454, NumberPatientsCT, 1097, 1100, "236", "", +71425, Type2Diabetes, 1132, 1147, "type 2 diabetes", "", +71426, Type2Diabetes, 1150, 1153, "T2D", "", +71455, HbA1c, 1161, 1185, "glycosylated haemoglobin", "", +71456, HbA1c, 1188, 1193, "HbA1c", "", +71459, Percentage, 1210, 1214, "% ± ", "", +71460, Percentage, 1221, 1222, "%", "", +71461, BioAndMedicalUnit, 1244, 1254, "mmol / mol", "", +71462, Insulin, 1275, 1282, "insulin", "", +71464, OralAntidiabeticAgent, 1287, 1310, "oral antidiabetic drugs", "", +71475, DoseDescription, 1311, 1548, "underwent 8 - week optimization of prior once - daily basal insulin followed by randomization 1 : 1 to either a BB regimen with faster aspart ( n  =  116 ) or continuation of once - daily basal insulin ( n  =  120 ) , both with metformin", "", +71474, Frequency, 1352, 1364, "once - daily", "", +71466, Insulin, 1371, 1378, "insulin", "", +71467, Randomized, 1391, 1404, "randomization", "", +71468, AllocationRatio, 1405, 1410, "1 : 1", "", +71446, FixedCombDrug, 1423, 1425, "BB", "", +71421, InsulinAspart, 1439, 1452, "faster aspart", "", +71469, NumberPatientsArm, 1461, 1464, "116", "", +71472, Frequency, 1486, 1498, "once - daily", "", +71473, Insulin, 1505, 1512, "insulin", "", +71470, NumberPatientsArm, 1521, 1524, "120", "", +71471, Metformin, 1539, 1548, "metformin", "", +71457, HbA1c, 1572, 1577, "HbA1c", "", +71476, TimePoint, 1590, 1598, "baseline", "", +71477, TimePoint, 1605, 1615, "18   weeks", "", +71480, PostprandialPlasmaGlucose, 1662, 1689, "postprandial plasma glucose", "", +71481, PostprandialPlasmaGlucose, 1692, 1695, "PPG", "", +71482, PostprandialPlasmaGlucose, 1717, 1720, "PPG", "", +71483, BodyWeight, 1747, 1753, "weight", "", +71484, EndPointDescription, 1777, 1791, "adverse events", "", +71485, Hypoglycemia, 1794, 1816, "hypoglycaemic episodes", "", +71458, HbA1c, 1829, 1834, "HbA1c", "", +71486, BaseLineValue, 1850, 1855, "7 . 9", "", +71490, Percentage, 1856, 1857, "%", "", +71487, BaseLineValue, 1860, 1866, "63 . 2", "", +71495, BioAndMedicalUnit, 1869, 1879, "mmol / mol", "", +71500, ResultMeasuredValue, 1885, 1890, "6 . 8", "", +71491, Percentage, 1891, 1892, "%", "", +71501, ResultMeasuredValue, 1895, 1901, "50 . 7", "", +71496, BioAndMedicalUnit, 1904, 1914, "mmol / mol", "", +71502, FixedCombDrug, 1917, 1919, "BB", "", +71488, BaseLineValue, 1937, 1942, "7 . 9", "", +71492, Percentage, 1943, 1944, "%", "", +71489, BaseLineValue, 1947, 1953, "63 . 2", "", +71497, BioAndMedicalUnit, 1956, 1966, "mmol / mol", "", +71503, ResultMeasuredValue, 1972, 1977, "7 . 7", "", +71493, Percentage, 1978, 1979, "%", "", +71504, ResultMeasuredValue, 1982, 1988, "60 . 7", "", +71498, BioAndMedicalUnit, 1991, 2001, "mmol / mol", "", +71505, Insulin, 2004, 2016, "basal - only", "", +71506, ConfIntervalDiff, 2060, 2084, "95 % confidence interval", "", +71507, DiffGroupAbsValue, 2087, 2095, "- 0 . 94", "", +71494, Percentage, 2096, 2097, "%", "", +71508, ConfIntervalDiff, 2100, 2119, "- 1 . 17 ; - 0 . 72", "", +71510, DiffGroupAbsValue, 2124, 2132, "- 10 . 3", "", +71499, BioAndMedicalUnit, 2135, 2145, "mmol / mol", "", +71509, ConfIntervalDiff, 2148, 2166, "- 12 . 8 ; - 7 . 8", "", +71511, PvalueDiff, 2171, 2182, "P  < . 0001", "", +71516, ObservedResult, 2185, 2397, "Reductions from baseline in overall mean 2 - hour PPG and overall PPG increment for all meals ( self - measured plasma glucose profiles ) were statistically significant in favour of BB treatment ( P  < . 0001 ) .", "", +71478, TimePoint, 2201, 2209, "baseline", "", +71514, SubGroupDescription, 2213, 2238, "overall mean 2 - hour PPG", "", +71512, PostprandialPlasmaGlucose, 2235, 2238, "PPG", "", +71513, PostprandialPlasmaGlucose, 2251, 2254, "PPG", "", +71447, FixedCombDrug, 2367, 2369, "BB", "", +71515, PValueResValue, 2382, 2393, "P  < . 0001", "", +71517, SevereHypoglycemia, 2398, 2444, "Severe / blood glucose confirmed hypoglycaemia", "", +71518, ResultMeasuredValue, 2452, 2458, "12 . 8", "", +71519, ResultMeasuredValue, 2462, 2467, "2 . 0", "", +71520, BioAndMedicalUnit, 2468, 2508, "episodes per patient - years of exposure", "", +71521, InsulinDose, 2519, 2532, "daily insulin", "", +71523, ResultMeasuredValue, 2535, 2540, "1 . 2", "", +71524, ResultMeasuredValue, 2544, 2549, "0 . 6", "", +71525, BioAndMedicalUnit, 2550, 2556, "U / kg", "", +71522, BodyWeight, 2563, 2569, "weight", "", +71526, Increment, 2577, 2582, "1 . 8", "", +71527, Increment, 2586, 2591, "0 . 2", "", +71528, Kg, 2594, 2596, "kg", "", +71479, FixedCombDrug, 2617, 2619, "BB", "", +71529, Insulin, 2630, 2642, "basal - only", "", +71533, ConclusionComment, 2669, 2863, "In T2D , faster aspart in a BB regimen provided superior glycaemic control as compared with basal - only insulin , but with an increase in the frequency of hypoglycaemia and modest weight gain .", "", +71427, Type2Diabetes, 2672, 2675, "T2D", "", +71422, InsulinAspart, 2678, 2691, "faster aspart", "", +71448, FixedCombDrug, 2697, 2699, "BB", "", +71530, Insulin, 2774, 2781, "insulin", "", +71531, Hypoglycemia, 2825, 2838, "hypoglycaemia", "", +71532, BodyWeight, 2850, 2856, "weight", "", +71534, PMID, 3012, 3020, "28345792", "", diff --git a/data/dm2 28345792_kwoodley.n-triples b/data/dm2 28345792_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28345792_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28449402_admin.annodb b/data/dm2 28449402_admin.annodb new file mode 100644 index 0000000..41f1c24 --- /dev/null +++ b/data/dm2 28449402_admin.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +10, Title, 110, 305, "Postprandial renal haemodynamic effect of lixisenatide vs once - daily insulin - glulisine in patients with type 2 diabetes on insulin - glargine : An 8 - week , randomised , open - label trial .", "", " \"Postprandial renal haemodynamic effect of lixisenatide vs once - daily insulin - glulisine in patients with type 2 diabetes on insulin - glargine : An 8 - week , randomised , open - label trial .\"." +98984, Lixisenatide, 152, 164, "lixisenatide", "", +4, Frequency, 168, 180, "once - daily", "", +3, InsulinGlulisine, 181, 200, "insulin - glulisine", "", +5, Type2Diabetes, 218, 233, "type 2 diabetes", "", +6, InsulinGlargine, 237, 255, "insulin - glargine", "", +7, Duration, 261, 269, "8 - week", "", " \"8 - week\"." +8, Randomized, 272, 282, "randomised", "", " ." +9, OpenLabel, 285, 297, "open - label", "", " ." +11, Author, 306, 317, "Tonneijck L", "", " \"Tonneijck L\"." +12, Author, 326, 337, "Muskiet MHA", "", " \"Muskiet MHA\"." +13, Author, 346, 354, "Smits MM", "", " \"Smits MM\"." +14, Author, 363, 373, "Hoekstra T", "", " \"Hoekstra T\"." +15, Author, 388, 398, "Kramer MHH", "", " \"Kramer MHH\"." +16, Author, 407, 417, "Danser AHJ", "", " \"Danser AHJ\"." +17, Author, 426, 435, "Diamant M", "", " \"Diamant M\"." +18, Author, 444, 452, "Joles JA", "", " \"Joles JA\"." +19, Author, 461, 474, "van Raalte DH", "", " \"van Raalte DH\"." +20, Netherlands, 605, 620, "The Netherlands", "", " ." +21, Netherlands, 751, 766, "The Netherlands", "", +22, Netherlands, 865, 880, "The Netherlands", "", +23, Netherlands, 1020, 1035, "The Netherlands", "", +24, Netherlands, 1126, 1141, "The Netherlands", "", +30, ObjectiveDescription, 1150, 1371, "To determine whether lixisenatide , a prandial short - acting glucagon - like peptide receptor agonist ( GLP - 1RA ) , ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus ( T2DM )", "", " \"To determine whether lixisenatide , a prandial short - acting glucagon - like peptide receptor agonist ( GLP - 1RA ) , ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus ( T2DM )\"." +98989, Lixisenatide, 1171, 1183, "lixisenatide", "", +26, Type2Diabetes, 1338, 1362, "type 2 diabetes mellitus", "", " ." +27, Type2Diabetes, 1365, 1369, "T2DM", "", +31, ObjectiveDescription, 1372, 1416, "compared with insulin - glulisine ( iGlu ) .", "", " \"compared with insulin - glulisine ( iGlu ) .\"." +28, InsulinGlulisine, 1386, 1405, "insulin - glulisine", "", +29, InsulinGlulisine, 1408, 1412, "iGlu", "", +32, Duration, 1470, 1478, "8 - week", "", +98988, Lixisenatide, 1494, 1506, "lixisenatide", "", " ." +156, DoseValue, 1507, 1509, "20", "", " \"20\"." +35, Microgram, 1510, 1513, "µ g", "", " ." +36, Frequency, 1517, 1529, "once - daily", "", " \"once - daily\"." +37, InsulinGlulisine, 1539, 1543, "iGlu", "", " ." +38, NumberPatientsCT, 1561, 1563, "35", "", " \"35\"." +98996, Precondition, 1575, 1667, "patients with T2DM inadequately controlled on insulin - glargine , with or without metformin", "", " \"patients with T2DM inadequately controlled on insulin - glargine , with or without metformin\"." +40, Type2Diabetes, 1589, 1593, "T2DM", "", +132, InsulinGlargine, 1621, 1639, "insulin - glargine", "", +43, Metformin, 1658, 1667, "metformin", "", +44, Mean, 1670, 1674, "mean", "", +45, AvgAge, 1684, 1686, "62", "", " \"62\"." +46, HbA1c, 1699, 1704, "HbA1c", "", +49, BaseLineValue, 1705, 1710, "8 . 0", "", +47, Percentage, 1711, 1712, "%", "", +50, SdDevBL, 1715, 1720, "0 . 9", "", +48, Percentage, 1721, 1722, "%", "", +98997, EndPointDescription, 1735, 1761, "glomerular filtration rate", "", +98998, EndPointDescription, 1764, 1767, "GFR", "", +55, BaseLineValue, 1770, 1772, "85", "", " \"85\". \"85\"." +56, SdDevBL, 1775, 1777, "12", "", " \"12\". \"12\"." +165, BioAndMedicalUnit, 1778, 1798, "mL / min / 1 . 73 m2", "", +51, BioAndMedicalUnit, 1875, 1884, "mg / mmol", "", +58, EndPointDescription, 1922, 1925, "GFR", "", +171, EndPointDescription, 1951, 1978, "effective renal plasma flow", "", +172, EndPointDescription, 1981, 1985, "ERPF", "", +173, Insulin, 2007, 2013, "inulin", "", +174, MeasurementDevice, 2164, 2179, "Gomez equations", "", +59, InsulinGlulisine, 2206, 2210, "iGlu", "", +98990, Lixisenatide, 2213, 2225, "lixisenatide", "", +61, EndPointDescription, 2241, 2244, "GFR", "", " . ." +106262, DiffGroupAbsValue, 2247, 2254, "+ 0 . 1", "", " \"+ 0 . 1\"." +186, BioAndMedicalUnit, 2255, 2275, "mL / min / 1 . 73 m2", "", " . ." +99000, ConfIntervalDiff, 2278, 2294, "95 % CI - 9 to 9", "", " \"95 % CI - 9 to 9\"." +63, EndPointDescription, 2301, 2305, "ERPF", "", " . ." +106263, DiffGroupAbsValue, 2308, 2312, "- 17", "", " \"- 17\"." +187, BioAndMedicalUnit, 2313, 2333, "mL / min / 1 . 73 m2", "", " . ." +99002, ConfIntervalDiff, 2336, 2346, "- 61 to 26", "", " \"- 61 to 26\"." +179, EndPointDescription, 2353, 2414, "other ( intra - ) renal haemodynamics or renal damage markers", "", " . ." +74, EndPointDescription, 2431, 2458, "fractional sodium excretion", "", " . ." +106265, DiffGroupAbsValue, 2461, 2469, "+ 0 . 25", "", " \"+ 0 . 25\"." +73, Percentage, 2470, 2471, "%", "", " ." +99004, ConfIntervalDiff, 2474, 2489, "0 . 09 - 0 . 41", "", " \"0 . 09 - 0 . 41\"." +75, EndPointDescription, 2498, 2508, "urinary pH", "", " . ." +106264, DiffGroupAbsValue, 2511, 2518, "+ 0 . 7", "", " \"+ 0 . 7\"." +99005, ConfIntervalDiff, 2521, 2534, "0 . 3 - 1 . 2", "", " \"0 . 3 - 1 . 2\"." +197, EndPointDescription, 2541, 2553, "Plasma renin", "", " . ." +198, EndPointDescription, 2556, 2572, "angiotensin - II", "", " . ." +199, EndPointDescription, 2577, 2588, "aldosterone", "", " . ." +200, ObservedResult, 2589, 2603, "were unchanged", "", " \"were unchanged\". \"were unchanged\". \"were unchanged\"." +98991, Lixisenatide, 2606, 2618, "Lixisenatide", "", +81, InsulinGlulisine, 2623, 2627, "iGlu", "", +85, HbA1c, 2636, 2641, "HbA1c", "", " ." +86, Reduction, 2657, 2662, "0 . 8", "", " \"0 . 8\"." +88, Percentage, 2663, 2664, "%", "", +94, SdDevChangeValue, 2667, 2672, "0 . 1", "", " \"0 . 1\"." +89, Percentage, 2673, 2674, "%", "", " ." +87, Reduction, 2679, 2684, "0 . 6", "", " \"0 . 6\"." +90, Percentage, 2685, 2686, "%", "", +95, SdDevChangeValue, 2689, 2694, "0 . 1", "", " \"0 . 1\"." +91, Percentage, 2695, 2696, "%", "", +103, PostprandialBloodGlucose, 2720, 2740, "postprandial glucose", "", " ." +212, ObservedResult, 2741, 2750, "was lower", "", " \"was lower\"." +98992, Lixisenatide, 2756, 2768, "lixisenatide", "", +92, PvalueDiff, 2771, 2780, "P = . 002", "", " \"P = . 002\"." +82, InsulinGlulisine, 2799, 2803, "iGlu", "", +98993, Lixisenatide, 2806, 2818, "lixisenatide", "", +93, BodyWeight, 2827, 2837, "bodyweight", "", " ." +217, Reduction, 2842, 2847, "1 . 4", "", " \"1 . 4\"." +100, Kg, 2848, 2850, "kg", "", " ." +96, ConfIntervalChangeValue, 2853, 2871, "- 2 . 5 to - 0 . 2", "", " \"- 2 . 5 to - 0 . 2\"." +216, EndPointDescription, 2890, 2925, "postprandial mean arterial pressure", "", " . ." +218, Increment, 2930, 2931, "9", "", " \"9\"." +222, mmHg, 2932, 2937, "mm Hg", "", " ." +97, ConfIntervalChangeValue, 2940, 2946, "4 - 14", "", " \"4 - 14\"." +104, Duration, 2966, 2978, "Eight - week", "", +110, ConclusionComment, 2966, 3164, "Eight - week lixisenatide treatment does not affect postprandial ( intra - ) renal haemodynamics compared with iGlu when added to insulin - glargine in patients with T2DM without overt nephropathy .", "", " \"Eight - week lixisenatide treatment does not affect postprandial ( intra - ) renal haemodynamics compared with iGlu when added to insulin - glargine in patients with T2DM without overt nephropathy .\"." +98994, Lixisenatide, 2979, 2991, "lixisenatide", "", +83, InsulinGlulisine, 3077, 3081, "iGlu", "", +105, InsulinGlargine, 3096, 3114, "insulin - glargine", "", +106, Type2Diabetes, 3132, 3136, "T2DM", "", +111, ConclusionComment, 3165, 3387, "Prolonged lixisenatide treatment has a sustained natriuretic effect , which is in contrast to previous reports on long - acting GLP - 1RA , reduces body weight and increases postprandial blood pressure compared with iGlu .", "", " \"Prolonged lixisenatide treatment has a sustained natriuretic effect , which is in contrast to previous reports on long - acting GLP - 1RA , reduces body weight and increases postprandial blood pressure compared with iGlu .\"." +98995, Lixisenatide, 3175, 3187, "lixisenatide", "", +107, BodyWeight, 3313, 3324, "body weight", "", +108, BloodPressure, 3339, 3366, "postprandial blood pressure", "", +84, InsulinGlulisine, 3381, 3385, "iGlu", "", +112, PMID, 3523, 3531, "28449402", "", " \"28449402\"." diff --git a/data/dm2 28449402_admin.n-triples b/data/dm2 28449402_admin.n-triples new file mode 100644 index 0000000..e30bf58 --- /dev/null +++ b/data/dm2 28449402_admin.n-triples @@ -0,0 +1,280 @@ +# RDF export of group: Publication + . + "Publication " . + "Postprandial renal haemodynamic effect of lixisenatide vs once - daily insulin - glulisine in patients with type 2 diabetes on insulin - glargine : An 8 - week , randomised , open - label trial ." . + "Tonneijck L" . + "2017" . + "Diabetes Obes Metab ." . + "28449402" . + . + "Muskiet MHA" . + "Smits MM" . + "Hoekstra T" . + "Kramer MHH" . + "Danser AHJ" . + "Diamant M" . + "Joles JA" . + "van Raalte DH" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To determine whether lixisenatide , a prandial short - acting glucagon - like peptide receptor agonist ( GLP - 1RA ) , ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus ( T2DM )" . + "35" . + "8 - week" . + . + . + . + "Eight - week lixisenatide treatment does not affect postprandial ( intra - ) renal haemodynamics compared with iGlu when added to insulin - glargine in patients with T2DM without overt nephropathy ." . + . + . + . + . + . + "compared with insulin - glulisine ( iGlu ) ." . + . + "Prolonged lixisenatide treatment has a sustained natriuretic effect , which is in contrast to previous reports on long - acting GLP - 1RA , reduces body weight and increases postprandial blood pressure compared with iGlu ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with T2DM inadequately controlled on insulin - glargine , with or without metformin" . + . + . + "62" . + . +# RDF export of group: Endpoint + . + "Endpoint gfr" . + . + . + . + . + . + . + . + "Endpoint erpf" . + . + . + . + . + . + . + . + "Endpoint markers" . + . + . + . + . + . + . + "Endpoint fse" . + . + . + . + . + . + . + "Endpoint urinary ph" . + . + . + . + . + . + . + "Endpoint pr" . + . + . + . + . + . + . + "Endpoint a2" . + . + . + . + . + . + . + "Endpoint aldosterone" . + . + . + . + . + . + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint ppmap" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm lix" . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm iglu" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention lix" . + . + . + . + "Intervention iglu" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication lix" . + . + "20" . + . + . + . + "Medication iglu" . + . + . + . +# RDF export of group: Outcome + . + "Outcome gfr lix" . + . + "85" . + "12" . + . + "Outcome gfr iglu" . + . + "85" . + "12" . + . + "Outcome erpf lix" . + . + . + "Outcome erpf iglu" . + . + . + "Outcome fse lix" . + . + . + "Outcome fse iglu" . + . + . + "Outcome u ph lix" . + . + . + "Outcome u ph iglu" . + . + . + "Outcome pr both drugs" . + . + "were unchanged" . + . + "Outcome a2 both drugs" . + . + "were unchanged" . + . + "Outcome a both drugs" . + . + "were unchanged" . + . + "Outcome hba1c lix" . + . + "0 . 8" . + "0 . 1" . + . + "Outcome hba1c iglu" . + . + "0 . 6" . + "0 . 1" . + . + "Outcome ppg lix" . + . + "was lower" . + . + "Outcome ppg iglu" . + . + . + "Outcome weight lix" . + . + "1 . 4" . + "- 2 . 5 to - 0 . 2" . + . + "Outcome ppmap lix" . + . + "9" . + "4 - 14" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups gfr" . + "+ 0 . 1" . + "95 % CI - 9 to 9" . + . + . + . + "DiffBetweenGroups erpf" . + "- 17" . + "- 61 to 26" . + . + . + . + "DiffBetweenGroups fse" . + "+ 0 . 25" . + "0 . 09 - 0 . 41" . + . + . + . + "DiffBetweenGroups u ph" . + "+ 0 . 7" . + "0 . 3 - 1 . 2" . + . + . + . + "DiffBetweenGroups ppg" . + "P = . 002" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28449402_akramersunderbrink.annodb b/data/dm2 28449402_akramersunderbrink.annodb new file mode 100644 index 0000000..e8f926d --- /dev/null +++ b/data/dm2 28449402_akramersunderbrink.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +69646, Journal, 0, 19, "Diabetes Obes Metab", "", +69663, PublicationYear, 22, 26, "2017", "", +69672, Title, 110, 305, "Postprandial renal haemodynamic effect of lixisenatide vs once - daily insulin - glulisine in patients with type 2 diabetes on insulin - glargine : An 8 - week , randomised , open - label trial .", "", +69664, Drug, 152, 164, "lixisenatide", "", +69666, Frequency, 168, 180, "once - daily", "", +69665, InsulinGlulisine, 181, 200, "insulin - glulisine", "", +69667, Type2Diabetes, 218, 233, "type 2 diabetes", "", +69668, InsulinGlargine, 237, 255, "insulin - glargine", "", +69669, Duration, 261, 269, "8 - week", "", +69670, Randomized, 272, 282, "randomised", "", +69671, OpenLabel, 285, 297, "open - label", "", +69673, Author, 306, 317, "Tonneijck L", "", +69674, Author, 326, 337, "Muskiet MHA", "", +69675, Author, 346, 354, "Smits MM", "", +69676, Author, 363, 373, "Hoekstra T", "", +69677, Author, 388, 398, "Kramer MHH", "", +69678, Author, 407, 417, "Danser AHJ", "", +69679, Author, 426, 435, "Diamant M", "", +69680, Author, 444, 452, "Joles JA", "", +69681, Author, 461, 474, "van Raalte DH", "", +69682, Netherlands, 605, 620, "The Netherlands", "", +69683, Netherlands, 751, 766, "The Netherlands", "", +69684, Netherlands, 865, 880, "The Netherlands", "", +69685, Netherlands, 1020, 1035, "The Netherlands", "", +69686, Netherlands, 1126, 1141, "The Netherlands", "", +69692, ObjectiveDescription, 1150, 1371, "To determine whether lixisenatide , a prandial short - acting glucagon - like peptide receptor agonist ( GLP - 1RA ) , ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus ( T2DM )", "", +69687, Drug, 1171, 1183, "lixisenatide", "", +69688, Type2Diabetes, 1338, 1362, "type 2 diabetes mellitus", "", +69689, Type2Diabetes, 1365, 1369, "T2DM", "", +69693, ObjectiveDescription, 1372, 1416, "compared with insulin - glulisine ( iGlu ) .", "", +69690, InsulinGlulisine, 1386, 1405, "insulin - glulisine", "", +69691, InsulinGlulisine, 1408, 1412, "iGlu", "", +69694, Duration, 1470, 1478, "8 - week", "", +69695, Drug, 1494, 1506, "lixisenatide", "", +69696, DoseValue, 1507, 1513, "20 µ g", "", +69697, Microgram, 1510, 1513, "µ g", "", +69698, Frequency, 1517, 1529, "once - daily", "", +69699, InsulinGlulisine, 1539, 1543, "iGlu", "", +69700, NumberPatientsCT, 1561, 1563, "35", "", +69701, Precondition, 1564, 1574, "overweight", "", +69702, Type2Diabetes, 1589, 1593, "T2DM", "", +69703, Precondition, 1594, 1639, "inadequately controlled on insulin - glargine", "", +69704, InsulinGlargine, 1621, 1667, "insulin - glargine , with or without metformin", "", +69705, Metformin, 1658, 1667, "metformin", "", +69706, Mean, 1670, 1674, "mean", "", +69707, AvgAge, 1684, 1686, "62", "", +69708, HbA1c, 1699, 1704, "HbA1c", "", +69711, BaseLineValue, 1705, 1710, "8 . 0", "", +69709, Percentage, 1711, 1712, "%", "", +69712, SdDevBL, 1715, 1720, "0 . 9", "", +69710, Percentage, 1721, 1722, "%", "", +69715, EndPointDescription, 1725, 1761, "estimated glomerular filtration rate", "", +69716, EndPointDescription, 1764, 1767, "GFR", "", +69717, BaseLineValue, 1770, 1772, "85", "", +69718, SdDevBL, 1775, 1777, "12", "", +69714, BioAndMedicalUnit, 1778, 1798, "mL / min / 1 . 73 m2", "", +69719, Precondition, 1801, 1884, "median ( IQR ) urinary albumin / creatinine ratio 1 . 5 ( 0 . 9 - 3 . 0 ) mg / mmol", "", +69713, BioAndMedicalUnit, 1875, 1884, "mg / mmol", "", +69720, EndPointDescription, 1922, 1925, "GFR", "", +69721, InsulinGlulisine, 2206, 2210, "iGlu", "", +69722, Drug, 2213, 2225, "lixisenatide", "", +69723, EndPointDescription, 2241, 2244, "GFR", "", +69727, ChangeValue, 2247, 2254, "+ 0 . 1", "", +69724, BioAndMedicalUnit, 2255, 2275, "mL / min / 1 . 73 m2", "", +69731, ConfIntervalChangeValue, 2278, 2294, "95 % CI - 9 to 9", "", +69725, EndPointDescription, 2301, 2305, "ERPF", "", +69728, ChangeValue, 2308, 2312, "- 17", "", +69726, BioAndMedicalUnit, 2313, 2333, "mL / min / 1 . 73 m2", "", +69733, ConfIntervalChangeValue, 2336, 2346, "- 61 to 26", "", +69737, EndPointDescription, 2431, 2458, "fractional sodium excretion", "", +69729, ChangeValue, 2461, 2469, "+ 0 . 25", "", +69736, Percentage, 2470, 2471, "%", "", +69734, ConfIntervalChangeValue, 2474, 2489, "0 . 09 - 0 . 41", "", +69738, EndPointDescription, 2498, 2508, "urinary pH", "", +69730, ChangeValue, 2511, 2518, "+ 0 . 7", "", +69735, ConfIntervalChangeValue, 2521, 2534, "0 . 3 - 1 . 2", "", +69739, Drug, 2606, 2618, "Lixisenatide", "", +69744, InsulinGlulisine, 2623, 2627, "iGlu", "", +69748, HbA1c, 2636, 2641, "HbA1c", "", +69749, Reduction, 2657, 2662, "0 . 8", "", +69751, Percentage, 2663, 2664, "%", "", +69757, SdDevChangeValue, 2667, 2672, "0 . 1", "", +69752, Percentage, 2673, 2674, "%", "", +69750, Reduction, 2679, 2684, "0 . 6", "", +69753, Percentage, 2685, 2686, "%", "", +69758, SdDevChangeValue, 2689, 2694, "0 . 1", "", +69754, Percentage, 2695, 2696, "%", "", +69767, PostprandialBloodGlucose, 2720, 2740, "postprandial glucose", "", +69741, Drug, 2756, 2768, "lixisenatide", "", +69755, PvalueDiff, 2771, 2780, "P = . 002", "", +69745, InsulinGlulisine, 2799, 2803, "iGlu", "", +69740, Drug, 2806, 2818, "lixisenatide", "", +69756, BodyWeight, 2827, 2837, "bodyweight", "", +69761, ChangeValue, 2840, 2847, "- 1 . 4", "", +69763, Kg, 2848, 2850, "kg", "", +69759, ConfIntervalChangeValue, 2853, 2871, "- 2 . 5 to - 0 . 2", "", +69773, BloodPressure, 2890, 2925, "postprandial mean arterial pressure", "", +69765, Mean, 2903, 2907, "mean", "", +69762, ChangeValue, 2928, 2931, "+ 9", "", +69764, BioAndMedicalUnit, 2932, 2937, "mm Hg", "", +69760, ConfIntervalChangeValue, 2940, 2946, "4 - 14", "", +69768, Duration, 2966, 2978, "Eight - week", "", +69774, ConclusionComment, 2966, 3164, "Eight - week lixisenatide treatment does not affect postprandial ( intra - ) renal haemodynamics compared with iGlu when added to insulin - glargine in patients with T2DM without overt nephropathy .", "", +69742, Drug, 2979, 2991, "lixisenatide", "", +69746, InsulinGlulisine, 3077, 3081, "iGlu", "", +69769, InsulinGlargine, 3096, 3114, "insulin - glargine", "", +69770, Type2Diabetes, 3132, 3136, "T2DM", "", +69775, ConclusionComment, 3165, 3387, "Prolonged lixisenatide treatment has a sustained natriuretic effect , which is in contrast to previous reports on long - acting GLP - 1RA , reduces body weight and increases postprandial blood pressure compared with iGlu .", "", +69743, Drug, 3175, 3187, "lixisenatide", "", +69771, BodyWeight, 3313, 3324, "body weight", "", +69772, BloodPressure, 3339, 3366, "postprandial blood pressure", "", +69747, InsulinGlulisine, 3381, 3385, "iGlu", "", +69776, PMID, 3523, 3531, "28449402", "", diff --git a/data/dm2 28449402_akramersunderbrink.n-triples b/data/dm2 28449402_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28449402_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28449402_export.csv b/data/dm2 28449402_export.csv new file mode 100644 index 0000000..9a13a58 --- /dev/null +++ b/data/dm2 28449402_export.csv @@ -0,0 +1,748 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +399, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +399, 1, 2, 2, 9, 13, 9, 13, "Obes" +399, 1, 3, 3, 14, 19, 14, 19, "Metab" +399, 1, 4, 4, 20, 21, 20, 21, "." +399, 2, 1, 5, 0, 4, 22, 26, "2017" +399, 2, 2, 6, 5, 8, 27, 30, "Dec" +399, 2, 3, 7, 9, 10, 31, 32, ";" +399, 2, 4, 8, 11, 13, 33, 35, "19" +399, 2, 5, 9, 14, 15, 36, 37, "(" +399, 2, 6, 10, 16, 18, 38, 40, "12" +399, 2, 7, 11, 19, 20, 41, 42, ")" +399, 2, 8, 12, 21, 22, 43, 44, ":" +399, 2, 9, 13, 23, 27, 45, 49, "1669" +399, 2, 10, 14, 28, 29, 50, 51, "-" +399, 2, 11, 15, 30, 34, 52, 56, "1680" +399, 2, 12, 16, 35, 36, 57, 58, "." +399, 2, 13, 17, 37, 40, 59, 62, "doi" +399, 2, 14, 18, 41, 42, 63, 64, ":" +399, 2, 15, 19, 43, 45, 65, 67, "10" +399, 2, 16, 20, 46, 47, 68, 69, "." +399, 2, 17, 21, 48, 52, 70, 74, "1111" +399, 2, 18, 22, 53, 54, 75, 76, "/" +399, 2, 19, 23, 55, 58, 77, 80, "dom" +399, 2, 20, 24, 59, 60, 81, 82, "." +399, 2, 21, 25, 61, 66, 83, 88, "12985" +399, 2, 22, 26, 67, 68, 89, 90, "." +399, 3, 1, 27, 0, 4, 91, 95, "Epub" +399, 3, 2, 28, 5, 9, 96, 100, "2017" +399, 3, 3, 29, 10, 13, 101, 104, "Jul" +399, 3, 4, 30, 14, 16, 105, 107, "25" +399, 3, 5, 31, 17, 18, 108, 109, "." +399, 4, 1, 32, 0, 12, 110, 122, "Postprandial" +399, 4, 2, 33, 13, 18, 123, 128, "renal" +399, 4, 3, 34, 19, 31, 129, 141, "haemodynamic" +399, 4, 4, 35, 32, 38, 142, 148, "effect" +399, 4, 5, 36, 39, 41, 149, 151, "of" +399, 4, 6, 37, 42, 54, 152, 164, "lixisenatide" +399, 4, 7, 38, 55, 57, 165, 167, "vs" +399, 4, 8, 39, 58, 62, 168, 172, "once" +399, 4, 9, 40, 63, 64, 173, 174, "-" +399, 4, 10, 41, 65, 70, 175, 180, "daily" +399, 4, 11, 42, 71, 78, 181, 188, "insulin" +399, 4, 12, 43, 79, 80, 189, 190, "-" +399, 4, 13, 44, 81, 90, 191, 200, "glulisine" +399, 4, 14, 45, 91, 93, 201, 203, "in" +399, 4, 15, 46, 94, 102, 204, 212, "patients" +399, 4, 16, 47, 103, 107, 213, 217, "with" +399, 4, 17, 48, 108, 112, 218, 222, "type" +399, 4, 18, 49, 113, 114, 223, 224, "2" +399, 4, 19, 50, 115, 123, 225, 233, "diabetes" +399, 4, 20, 51, 124, 126, 234, 236, "on" +399, 4, 21, 52, 127, 134, 237, 244, "insulin" +399, 4, 22, 53, 135, 136, 245, 246, "-" +399, 4, 23, 54, 137, 145, 247, 255, "glargine" +399, 4, 24, 55, 146, 147, 256, 257, ":" +399, 4, 25, 56, 148, 150, 258, 260, "An" +399, 4, 26, 57, 151, 152, 261, 262, "8" +399, 4, 27, 58, 153, 154, 263, 264, "-" +399, 4, 28, 59, 155, 159, 265, 269, "week" +399, 4, 29, 60, 160, 161, 270, 271, "," +399, 4, 30, 61, 162, 172, 272, 282, "randomised" +399, 4, 31, 62, 173, 174, 283, 284, "," +399, 4, 32, 63, 175, 179, 285, 289, "open" +399, 4, 33, 64, 180, 181, 290, 291, "-" +399, 4, 34, 65, 182, 187, 292, 297, "label" +399, 4, 35, 66, 188, 193, 298, 303, "trial" +399, 4, 36, 67, 194, 195, 304, 305, "." +399, 5, 1, 68, 0, 9, 306, 315, "Tonneijck" +399, 5, 2, 69, 10, 11, 316, 317, "L" +399, 5, 3, 70, 12, 13, 318, 319, "(" +399, 5, 4, 71, 14, 15, 320, 321, "1" +399, 5, 5, 72, 16, 17, 322, 323, ")" +399, 5, 6, 73, 18, 19, 324, 325, "," +399, 5, 7, 74, 20, 27, 326, 333, "Muskiet" +399, 5, 8, 75, 28, 31, 334, 337, "MHA" +399, 5, 9, 76, 32, 33, 338, 339, "(" +399, 5, 10, 77, 34, 35, 340, 341, "1" +399, 5, 11, 78, 36, 37, 342, 343, ")" +399, 5, 12, 79, 38, 39, 344, 345, "," +399, 5, 13, 80, 40, 45, 346, 351, "Smits" +399, 5, 14, 81, 46, 48, 352, 354, "MM" +399, 5, 15, 82, 49, 50, 355, 356, "(" +399, 5, 16, 83, 51, 52, 357, 358, "1" +399, 5, 17, 84, 53, 54, 359, 360, ")" +399, 5, 18, 85, 55, 56, 361, 362, "," +399, 5, 19, 86, 57, 65, 363, 371, "Hoekstra" +399, 5, 20, 87, 66, 67, 372, 373, "T" +399, 5, 21, 88, 68, 69, 374, 375, "(" +399, 5, 22, 89, 70, 71, 376, 377, "2" +399, 5, 23, 90, 72, 73, 378, 379, ")" +399, 5, 24, 91, 74, 75, 380, 381, "(" +399, 5, 25, 92, 76, 77, 382, 383, "3" +399, 5, 26, 93, 78, 79, 384, 385, ")" +399, 5, 27, 94, 80, 81, 386, 387, "," +399, 5, 28, 95, 82, 88, 388, 394, "Kramer" +399, 5, 29, 96, 89, 92, 395, 398, "MHH" +399, 5, 30, 97, 93, 94, 399, 400, "(" +399, 5, 31, 98, 95, 96, 401, 402, "1" +399, 5, 32, 99, 97, 98, 403, 404, ")" +399, 5, 33, 100, 99, 100, 405, 406, "," +399, 5, 34, 101, 101, 107, 407, 413, "Danser" +399, 5, 35, 102, 108, 111, 414, 417, "AHJ" +399, 5, 36, 103, 112, 113, 418, 419, "(" +399, 5, 37, 104, 114, 115, 420, 421, "4" +399, 5, 38, 105, 116, 117, 422, 423, ")" +399, 5, 39, 106, 118, 119, 424, 425, "," +399, 5, 40, 107, 120, 127, 426, 433, "Diamant" +399, 5, 41, 108, 128, 129, 434, 435, "M" +399, 5, 42, 109, 130, 131, 436, 437, "(" +399, 5, 43, 110, 132, 133, 438, 439, "1" +399, 5, 44, 111, 134, 135, 440, 441, ")" +399, 5, 45, 112, 136, 137, 442, 443, "," +399, 5, 46, 113, 138, 143, 444, 449, "Joles" +399, 5, 47, 114, 144, 146, 450, 452, "JA" +399, 5, 48, 115, 147, 148, 453, 454, "(" +399, 5, 49, 116, 149, 150, 455, 456, "5" +399, 5, 50, 117, 151, 152, 457, 458, ")" +399, 5, 51, 118, 153, 154, 459, 460, "," +399, 5, 52, 119, 155, 158, 461, 464, "van" +399, 5, 53, 120, 159, 165, 465, 471, "Raalte" +399, 5, 54, 121, 166, 168, 472, 474, "DH" +399, 5, 55, 122, 169, 170, 475, 476, "(" +399, 5, 56, 123, 171, 172, 477, 478, "1" +399, 5, 57, 124, 173, 174, 479, 480, ")" +399, 5, 58, 125, 175, 176, 481, 482, "." +399, 6, 1, 126, 0, 6, 483, 489, "Author" +399, 6, 2, 127, 7, 18, 490, 501, "information" +399, 6, 3, 128, 19, 20, 502, 503, ":" +399, 6, 4, 129, 21, 22, 504, 505, "(" +399, 6, 5, 130, 23, 24, 506, 507, "1" +399, 6, 6, 131, 25, 26, 508, 509, ")" +399, 6, 7, 132, 27, 37, 510, 520, "Department" +399, 6, 8, 133, 38, 40, 521, 523, "of" +399, 6, 9, 134, 41, 49, 524, 532, "Internal" +399, 6, 10, 135, 50, 58, 533, 541, "Medicine" +399, 6, 11, 136, 59, 60, 542, 543, "," +399, 6, 12, 137, 61, 69, 544, 552, "Diabetes" +399, 6, 13, 138, 70, 76, 553, 559, "Center" +399, 6, 14, 139, 77, 78, 560, 561, "," +399, 6, 15, 140, 79, 81, 562, 564, "VU" +399, 6, 16, 141, 82, 92, 565, 575, "University" +399, 6, 17, 142, 93, 100, 576, 583, "Medical" +399, 6, 18, 143, 101, 107, 584, 590, "Center" +399, 6, 19, 144, 108, 109, 591, 592, "," +399, 6, 20, 145, 110, 119, 593, 602, "Amsterdam" +399, 6, 21, 146, 120, 121, 603, 604, "," +399, 6, 22, 147, 122, 125, 605, 608, "The" +399, 6, 23, 148, 126, 137, 609, 620, "Netherlands" +399, 6, 24, 149, 138, 139, 621, 622, "." +399, 7, 1, 150, 0, 1, 623, 624, "(" +399, 7, 2, 151, 2, 3, 625, 626, "2" +399, 7, 3, 152, 4, 5, 627, 628, ")" +399, 7, 4, 153, 6, 16, 629, 639, "Department" +399, 7, 5, 154, 17, 19, 640, 642, "of" +399, 7, 6, 155, 20, 26, 643, 649, "Health" +399, 7, 7, 156, 27, 35, 650, 658, "Sciences" +399, 7, 8, 157, 36, 39, 659, 662, "and" +399, 7, 9, 158, 40, 43, 663, 666, "the" +399, 7, 10, 159, 44, 48, 667, 671, "EMGO" +399, 7, 11, 160, 49, 58, 672, 681, "Institute" +399, 7, 12, 161, 59, 62, 682, 685, "for" +399, 7, 13, 162, 63, 69, 686, 692, "Health" +399, 7, 14, 163, 70, 73, 693, 696, "and" +399, 7, 15, 164, 74, 78, 697, 701, "Care" +399, 7, 16, 165, 79, 87, 702, 710, "Research" +399, 7, 17, 166, 88, 89, 711, 712, "," +399, 7, 18, 167, 90, 92, 713, 715, "VU" +399, 7, 19, 168, 93, 103, 716, 726, "University" +399, 7, 20, 169, 104, 113, 727, 736, "Amsterdam" +399, 7, 21, 170, 114, 115, 737, 738, "," +399, 7, 22, 171, 116, 125, 739, 748, "Amsterdam" +399, 7, 23, 172, 126, 127, 749, 750, "," +399, 7, 24, 173, 128, 131, 751, 754, "The" +399, 7, 25, 174, 132, 143, 755, 766, "Netherlands" +399, 7, 26, 175, 144, 145, 767, 768, "." +399, 8, 1, 176, 0, 1, 769, 770, "(" +399, 8, 2, 177, 2, 3, 771, 772, "3" +399, 8, 3, 178, 4, 5, 773, 774, ")" +399, 8, 4, 179, 6, 16, 775, 785, "Department" +399, 8, 5, 180, 17, 19, 786, 788, "of" +399, 8, 6, 181, 20, 32, 789, 801, "Epidemiology" +399, 8, 7, 182, 33, 36, 802, 805, "and" +399, 8, 8, 183, 37, 50, 806, 819, "Biostatistics" +399, 8, 9, 184, 51, 52, 820, 821, "," +399, 8, 10, 185, 53, 55, 822, 824, "VU" +399, 8, 11, 186, 56, 66, 825, 835, "University" +399, 8, 12, 187, 67, 74, 836, 843, "Medical" +399, 8, 13, 188, 75, 81, 844, 850, "Center" +399, 8, 14, 189, 82, 83, 851, 852, "," +399, 8, 15, 190, 84, 93, 853, 862, "Amsterdam" +399, 8, 16, 191, 94, 95, 863, 864, "," +399, 8, 17, 192, 96, 99, 865, 868, "The" +399, 8, 18, 193, 100, 111, 869, 880, "Netherlands" +399, 8, 19, 194, 112, 113, 881, 882, "." +399, 9, 1, 195, 0, 1, 883, 884, "(" +399, 9, 2, 196, 2, 3, 885, 886, "4" +399, 9, 3, 197, 4, 5, 887, 888, ")" +399, 9, 4, 198, 6, 14, 889, 897, "Division" +399, 9, 5, 199, 15, 17, 898, 900, "of" +399, 9, 6, 200, 18, 30, 901, 913, "Pharmacology" +399, 9, 7, 201, 31, 34, 914, 917, "and" +399, 9, 8, 202, 35, 43, 918, 926, "Vascular" +399, 9, 9, 203, 44, 52, 927, 935, "Medicine" +399, 9, 10, 204, 53, 54, 936, 937, "," +399, 9, 11, 205, 55, 65, 938, 948, "Department" +399, 9, 12, 206, 66, 68, 949, 951, "of" +399, 9, 13, 207, 69, 77, 952, 960, "Internal" +399, 9, 14, 208, 78, 86, 961, 969, "Medicine" +399, 9, 15, 209, 87, 88, 970, 971, "," +399, 9, 16, 210, 89, 96, 972, 979, "Erasmus" +399, 9, 17, 211, 97, 107, 980, 990, "University" +399, 9, 18, 212, 108, 115, 991, 998, "Medical" +399, 9, 19, 213, 116, 122, 999, 1005, "Center" +399, 9, 20, 214, 123, 124, 1006, 1007, "," +399, 9, 21, 215, 125, 134, 1008, 1017, "Rotterdam" +399, 9, 22, 216, 135, 136, 1018, 1019, "," +399, 9, 23, 217, 137, 140, 1020, 1023, "The" +399, 9, 24, 218, 141, 152, 1024, 1035, "Netherlands" +399, 9, 25, 219, 153, 154, 1036, 1037, "." +399, 10, 1, 220, 0, 1, 1038, 1039, "(" +399, 10, 2, 221, 2, 3, 1040, 1041, "5" +399, 10, 3, 222, 4, 5, 1042, 1043, ")" +399, 10, 4, 223, 6, 16, 1044, 1054, "Department" +399, 10, 5, 224, 17, 19, 1055, 1057, "of" +399, 10, 6, 225, 20, 30, 1058, 1068, "Nephrology" +399, 10, 7, 226, 31, 34, 1069, 1072, "and" +399, 10, 8, 227, 35, 47, 1073, 1085, "Hypertension" +399, 10, 9, 228, 48, 49, 1086, 1087, "," +399, 10, 10, 229, 50, 60, 1088, 1098, "University" +399, 10, 11, 230, 61, 68, 1099, 1106, "Medical" +399, 10, 12, 231, 69, 75, 1107, 1113, "Center" +399, 10, 13, 232, 76, 77, 1114, 1115, "," +399, 10, 14, 233, 78, 85, 1116, 1123, "Utrecht" +399, 10, 15, 234, 86, 87, 1124, 1125, "," +399, 10, 16, 235, 88, 91, 1126, 1129, "The" +399, 10, 17, 236, 92, 103, 1130, 1141, "Netherlands" +399, 10, 18, 237, 104, 105, 1142, 1143, "." +399, 11, 1, 238, 0, 3, 1144, 1147, "AIM" +399, 11, 2, 239, 4, 5, 1148, 1149, ":" +399, 11, 3, 240, 6, 8, 1150, 1152, "To" +399, 11, 4, 241, 9, 18, 1153, 1162, "determine" +399, 11, 5, 242, 19, 26, 1163, 1170, "whether" +399, 11, 6, 243, 27, 39, 1171, 1183, "lixisenatide" +399, 11, 7, 244, 40, 41, 1184, 1185, "," +399, 11, 8, 245, 42, 43, 1186, 1187, "a" +399, 11, 9, 246, 44, 52, 1188, 1196, "prandial" +399, 11, 10, 247, 53, 58, 1197, 1202, "short" +399, 11, 11, 248, 59, 60, 1203, 1204, "-" +399, 11, 12, 249, 61, 67, 1205, 1211, "acting" +399, 11, 13, 250, 68, 76, 1212, 1220, "glucagon" +399, 11, 14, 251, 77, 78, 1221, 1222, "-" +399, 11, 15, 252, 79, 83, 1223, 1227, "like" +399, 11, 16, 253, 84, 91, 1228, 1235, "peptide" +399, 11, 17, 254, 92, 100, 1236, 1244, "receptor" +399, 11, 18, 255, 101, 108, 1245, 1252, "agonist" +399, 11, 19, 256, 109, 110, 1253, 1254, "(" +399, 11, 20, 257, 111, 114, 1255, 1258, "GLP" +399, 11, 21, 258, 115, 116, 1259, 1260, "-" +399, 11, 22, 259, 117, 120, 1261, 1264, "1RA" +399, 11, 23, 260, 121, 122, 1265, 1266, ")" +399, 11, 24, 261, 123, 124, 1267, 1268, "," +399, 11, 25, 262, 125, 136, 1269, 1280, "ameliorates" +399, 11, 26, 263, 137, 149, 1281, 1293, "postprandial" +399, 11, 27, 264, 150, 160, 1294, 1304, "glomerular" +399, 11, 28, 265, 161, 176, 1305, 1320, "hyperfiltration" +399, 11, 29, 266, 177, 179, 1321, 1323, "in" +399, 11, 30, 267, 180, 188, 1324, 1332, "patients" +399, 11, 31, 268, 189, 193, 1333, 1337, "with" +399, 11, 32, 269, 194, 198, 1338, 1342, "type" +399, 11, 33, 270, 199, 200, 1343, 1344, "2" +399, 11, 34, 271, 201, 209, 1345, 1353, "diabetes" +399, 11, 35, 272, 210, 218, 1354, 1362, "mellitus" +399, 11, 36, 273, 219, 220, 1363, 1364, "(" +399, 11, 37, 274, 221, 225, 1365, 1369, "T2DM" +399, 11, 38, 275, 226, 227, 1370, 1371, ")" +399, 11, 39, 276, 228, 236, 1372, 1380, "compared" +399, 11, 40, 277, 237, 241, 1381, 1385, "with" +399, 11, 41, 278, 242, 249, 1386, 1393, "insulin" +399, 11, 42, 279, 250, 251, 1394, 1395, "-" +399, 11, 43, 280, 252, 261, 1396, 1405, "glulisine" +399, 11, 44, 281, 262, 263, 1406, 1407, "(" +399, 11, 45, 282, 264, 268, 1408, 1412, "iGlu" +399, 11, 46, 283, 269, 270, 1413, 1414, ")" +399, 11, 47, 284, 271, 272, 1415, 1416, "." +399, 12, 1, 285, 0, 7, 1417, 1424, "METHODS" +399, 12, 2, 286, 8, 9, 1425, 1426, ":" +399, 12, 3, 287, 10, 22, 1427, 1439, "Postprandial" +399, 12, 4, 288, 23, 28, 1440, 1445, "renal" +399, 12, 5, 289, 29, 41, 1446, 1458, "haemodynamic" +399, 12, 6, 290, 42, 49, 1459, 1466, "effects" +399, 12, 7, 291, 50, 52, 1467, 1469, "of" +399, 12, 8, 292, 53, 54, 1470, 1471, "8" +399, 12, 9, 293, 55, 56, 1472, 1473, "-" +399, 12, 10, 294, 57, 61, 1474, 1478, "week" +399, 12, 11, 295, 62, 71, 1479, 1488, "treatment" +399, 12, 12, 296, 72, 76, 1489, 1493, "with" +399, 12, 13, 297, 77, 89, 1494, 1506, "lixisenatide" +399, 12, 14, 298, 90, 92, 1507, 1509, "20" +399, 12, 15, 299, 93, 94, 1510, 1511, "µ" +399, 12, 16, 300, 95, 96, 1512, 1513, "g" +399, 12, 17, 301, 97, 99, 1514, 1516, "vs" +399, 12, 18, 302, 100, 104, 1517, 1521, "once" +399, 12, 19, 303, 105, 106, 1522, 1523, "-" +399, 12, 20, 304, 107, 112, 1524, 1529, "daily" +399, 12, 21, 305, 113, 121, 1530, 1538, "titrated" +399, 12, 22, 306, 122, 126, 1539, 1543, "iGlu" +399, 12, 23, 307, 127, 131, 1544, 1548, "were" +399, 12, 24, 308, 132, 140, 1549, 1557, "measured" +399, 12, 25, 309, 141, 143, 1558, 1560, "in" +399, 12, 26, 310, 144, 146, 1561, 1563, "35" +399, 12, 27, 311, 147, 157, 1564, 1574, "overweight" +399, 12, 28, 312, 158, 166, 1575, 1583, "patients" +399, 12, 29, 313, 167, 171, 1584, 1588, "with" +399, 12, 30, 314, 172, 176, 1589, 1593, "T2DM" +399, 12, 31, 315, 177, 189, 1594, 1606, "inadequately" +399, 12, 32, 316, 190, 200, 1607, 1617, "controlled" +399, 12, 33, 317, 201, 203, 1618, 1620, "on" +399, 12, 34, 318, 204, 211, 1621, 1628, "insulin" +399, 12, 35, 319, 212, 213, 1629, 1630, "-" +399, 12, 36, 320, 214, 222, 1631, 1639, "glargine" +399, 12, 37, 321, 223, 224, 1640, 1641, "," +399, 12, 38, 322, 225, 229, 1642, 1646, "with" +399, 12, 39, 323, 230, 232, 1647, 1649, "or" +399, 12, 40, 324, 233, 240, 1650, 1657, "without" +399, 12, 41, 325, 241, 250, 1658, 1667, "metformin" +399, 12, 42, 326, 251, 252, 1668, 1669, "[" +399, 12, 43, 327, 253, 257, 1670, 1674, "mean" +399, 12, 44, 328, 258, 259, 1675, 1676, "±" +399, 12, 45, 329, 260, 262, 1677, 1679, "SD" +399, 12, 46, 330, 263, 266, 1680, 1683, "age" +399, 12, 47, 331, 267, 269, 1684, 1686, "62" +399, 12, 48, 332, 270, 271, 1687, 1688, "±" +399, 12, 49, 333, 272, 273, 1689, 1690, "7" +399, 12, 50, 334, 274, 279, 1691, 1696, "years" +399, 12, 51, 335, 280, 281, 1697, 1698, "," +399, 12, 52, 336, 282, 287, 1699, 1704, "HbA1c" +399, 12, 53, 337, 288, 289, 1705, 1706, "8" +399, 12, 54, 338, 290, 291, 1707, 1708, "." +399, 12, 55, 339, 292, 293, 1709, 1710, "0" +399, 12, 56, 340, 294, 295, 1711, 1712, "%" +399, 12, 57, 341, 296, 297, 1713, 1714, "±" +399, 12, 58, 342, 298, 299, 1715, 1716, "0" +399, 12, 59, 343, 300, 301, 1717, 1718, "." +399, 12, 60, 344, 302, 303, 1719, 1720, "9" +399, 12, 61, 345, 304, 305, 1721, 1722, "%" +399, 12, 62, 346, 306, 307, 1723, 1724, "," +399, 12, 63, 347, 308, 317, 1725, 1734, "estimated" +399, 12, 64, 348, 318, 328, 1735, 1745, "glomerular" +399, 12, 65, 349, 329, 339, 1746, 1756, "filtration" +399, 12, 66, 350, 340, 344, 1757, 1761, "rate" +399, 12, 67, 351, 345, 346, 1762, 1763, "(" +399, 12, 68, 352, 347, 350, 1764, 1767, "GFR" +399, 12, 69, 353, 351, 352, 1768, 1769, ")" +399, 12, 70, 354, 353, 355, 1770, 1772, "85" +399, 12, 71, 355, 356, 357, 1773, 1774, "±" +399, 12, 72, 356, 358, 360, 1775, 1777, "12" +399, 12, 73, 357, 361, 363, 1778, 1780, "mL" +399, 12, 74, 358, 364, 365, 1781, 1782, "/" +399, 12, 75, 359, 366, 369, 1783, 1786, "min" +399, 12, 76, 360, 370, 371, 1787, 1788, "/" +399, 12, 77, 361, 372, 373, 1789, 1790, "1" +399, 12, 78, 362, 374, 375, 1791, 1792, "." +399, 12, 79, 363, 376, 378, 1793, 1795, "73" +399, 12, 80, 364, 379, 381, 1796, 1798, "m2" +399, 12, 81, 365, 382, 383, 1799, 1800, "," +399, 12, 82, 366, 384, 390, 1801, 1807, "median" +399, 12, 83, 367, 391, 392, 1808, 1809, "(" +399, 12, 84, 368, 393, 396, 1810, 1813, "IQR" +399, 12, 85, 369, 397, 398, 1814, 1815, ")" +399, 12, 86, 370, 399, 406, 1816, 1823, "urinary" +399, 12, 87, 371, 407, 414, 1824, 1831, "albumin" +399, 12, 88, 372, 415, 416, 1832, 1833, "/" +399, 12, 89, 373, 417, 427, 1834, 1844, "creatinine" +399, 12, 90, 374, 428, 433, 1845, 1850, "ratio" +399, 12, 91, 375, 434, 435, 1851, 1852, "1" +399, 12, 92, 376, 436, 437, 1853, 1854, "." +399, 12, 93, 377, 438, 439, 1855, 1856, "5" +399, 12, 94, 378, 440, 441, 1857, 1858, "(" +399, 12, 95, 379, 442, 443, 1859, 1860, "0" +399, 12, 96, 380, 444, 445, 1861, 1862, "." +399, 12, 97, 381, 446, 447, 1863, 1864, "9" +399, 12, 98, 382, 448, 449, 1865, 1866, "-" +399, 12, 99, 383, 450, 451, 1867, 1868, "3" +399, 12, 100, 384, 452, 453, 1869, 1870, "." +399, 12, 101, 385, 454, 455, 1871, 1872, "0" +399, 12, 102, 386, 456, 457, 1873, 1874, ")" +399, 12, 103, 387, 458, 460, 1875, 1877, "mg" +399, 12, 104, 388, 461, 462, 1878, 1879, "/" +399, 12, 105, 389, 463, 467, 1880, 1884, "mmol" +399, 12, 106, 390, 468, 469, 1885, 1886, "]" +399, 12, 107, 391, 470, 471, 1887, 1888, "." +399, 13, 1, 392, 0, 5, 1889, 1894, "After" +399, 13, 2, 393, 6, 7, 1895, 1896, "a" +399, 13, 3, 394, 8, 20, 1897, 1909, "standardised" +399, 13, 4, 395, 21, 30, 1910, 1919, "breakfast" +399, 13, 5, 396, 31, 32, 1920, 1921, "," +399, 13, 6, 397, 33, 36, 1922, 1925, "GFR" +399, 13, 7, 398, 37, 38, 1926, 1927, "(" +399, 13, 8, 399, 39, 46, 1928, 1935, "primary" +399, 13, 9, 400, 47, 55, 1936, 1944, "endpoint" +399, 13, 10, 401, 56, 57, 1945, 1946, ")" +399, 13, 11, 402, 58, 61, 1947, 1950, "and" +399, 13, 12, 403, 62, 71, 1951, 1960, "effective" +399, 13, 13, 404, 72, 77, 1961, 1966, "renal" +399, 13, 14, 405, 78, 84, 1967, 1973, "plasma" +399, 13, 15, 406, 85, 89, 1974, 1978, "flow" +399, 13, 16, 407, 90, 91, 1979, 1980, "(" +399, 13, 17, 408, 92, 96, 1981, 1985, "ERPF" +399, 13, 18, 409, 97, 98, 1986, 1987, ")" +399, 13, 19, 410, 99, 103, 1988, 1992, "were" +399, 13, 20, 411, 104, 114, 1993, 2003, "determined" +399, 13, 21, 412, 115, 117, 2004, 2006, "by" +399, 13, 22, 413, 118, 124, 2007, 2013, "inulin" +399, 13, 23, 414, 125, 128, 2014, 2017, "and" +399, 13, 24, 415, 129, 133, 2018, 2022, "para" +399, 13, 25, 416, 134, 135, 2023, 2024, "-" +399, 13, 26, 417, 136, 149, 2025, 2038, "aminohippuric" +399, 13, 27, 418, 150, 154, 2039, 2043, "acid" +399, 13, 28, 419, 155, 160, 2044, 2049, "renal" +399, 13, 29, 420, 161, 170, 2050, 2059, "clearance" +399, 13, 30, 421, 171, 172, 2060, 2061, "," +399, 13, 31, 422, 173, 185, 2062, 2074, "respectively" +399, 13, 32, 423, 186, 187, 2075, 2076, "," +399, 13, 33, 424, 188, 193, 2077, 2082, "based" +399, 13, 34, 425, 194, 196, 2083, 2085, "on" +399, 13, 35, 426, 197, 202, 2086, 2091, "timed" +399, 13, 36, 427, 203, 208, 2092, 2097, "urine" +399, 13, 37, 428, 209, 217, 2098, 2106, "sampling" +399, 13, 38, 429, 218, 219, 2107, 2108, "." +399, 14, 1, 430, 0, 10, 2109, 2119, "Intrarenal" +399, 14, 2, 431, 11, 23, 2120, 2132, "haemodynamic" +399, 14, 3, 432, 24, 33, 2133, 2142, "functions" +399, 14, 4, 433, 34, 38, 2143, 2147, "were" +399, 14, 5, 434, 39, 48, 2148, 2157, "estimated" +399, 14, 6, 435, 49, 54, 2158, 2163, "using" +399, 14, 7, 436, 55, 60, 2164, 2169, "Gomez" +399, 14, 8, 437, 61, 70, 2170, 2179, "equations" +399, 14, 9, 438, 71, 72, 2180, 2181, "." +399, 15, 1, 439, 0, 7, 2182, 2189, "RESULTS" +399, 15, 2, 440, 8, 9, 2190, 2191, ":" +399, 15, 3, 441, 10, 18, 2192, 2200, "Compared" +399, 15, 4, 442, 19, 23, 2201, 2205, "with" +399, 15, 5, 443, 24, 28, 2206, 2210, "iGlu" +399, 15, 6, 444, 29, 30, 2211, 2212, "," +399, 15, 7, 445, 31, 43, 2213, 2225, "lixisenatide" +399, 15, 8, 446, 44, 47, 2226, 2229, "did" +399, 15, 9, 447, 48, 51, 2230, 2233, "not" +399, 15, 10, 448, 52, 58, 2234, 2240, "affect" +399, 15, 11, 449, 59, 62, 2241, 2244, "GFR" +399, 15, 12, 450, 63, 64, 2245, 2246, "[" +399, 15, 13, 451, 65, 66, 2247, 2248, "+" +399, 15, 14, 452, 67, 68, 2249, 2250, "0" +399, 15, 15, 453, 69, 70, 2251, 2252, "." +399, 15, 16, 454, 71, 72, 2253, 2254, "1" +399, 15, 17, 455, 73, 75, 2255, 2257, "mL" +399, 15, 18, 456, 76, 77, 2258, 2259, "/" +399, 15, 19, 457, 78, 81, 2260, 2263, "min" +399, 15, 20, 458, 82, 83, 2264, 2265, "/" +399, 15, 21, 459, 84, 85, 2266, 2267, "1" +399, 15, 22, 460, 86, 87, 2268, 2269, "." +399, 15, 23, 461, 88, 90, 2270, 2272, "73" +399, 15, 24, 462, 91, 93, 2273, 2275, "m2" +399, 15, 25, 463, 94, 95, 2276, 2277, "(" +399, 15, 26, 464, 96, 98, 2278, 2280, "95" +399, 15, 27, 465, 99, 100, 2281, 2282, "%" +399, 15, 28, 466, 101, 103, 2283, 2285, "CI" +399, 15, 29, 467, 104, 105, 2286, 2287, "-" +399, 15, 30, 468, 106, 107, 2288, 2289, "9" +399, 15, 31, 469, 108, 110, 2290, 2292, "to" +399, 15, 32, 470, 111, 112, 2293, 2294, "9" +399, 15, 33, 471, 113, 114, 2295, 2296, ")" +399, 15, 34, 472, 115, 116, 2297, 2298, "]" +399, 15, 35, 473, 117, 118, 2299, 2300, "," +399, 15, 36, 474, 119, 123, 2301, 2305, "ERPF" +399, 15, 37, 475, 124, 125, 2306, 2307, "[" +399, 15, 38, 476, 126, 127, 2308, 2309, "-" +399, 15, 39, 477, 128, 130, 2310, 2312, "17" +399, 15, 40, 478, 131, 133, 2313, 2315, "mL" +399, 15, 41, 479, 134, 135, 2316, 2317, "/" +399, 15, 42, 480, 136, 139, 2318, 2321, "min" +399, 15, 43, 481, 140, 141, 2322, 2323, "/" +399, 15, 44, 482, 142, 143, 2324, 2325, "1" +399, 15, 45, 483, 144, 145, 2326, 2327, "." +399, 15, 46, 484, 146, 148, 2328, 2330, "73" +399, 15, 47, 485, 149, 151, 2331, 2333, "m2" +399, 15, 48, 486, 152, 153, 2334, 2335, "(" +399, 15, 49, 487, 154, 155, 2336, 2337, "-" +399, 15, 50, 488, 156, 158, 2338, 2340, "61" +399, 15, 51, 489, 159, 161, 2341, 2343, "to" +399, 15, 52, 490, 162, 164, 2344, 2346, "26" +399, 15, 53, 491, 165, 166, 2347, 2348, ")" +399, 15, 54, 492, 167, 168, 2349, 2350, "]" +399, 15, 55, 493, 169, 170, 2351, 2352, "," +399, 15, 56, 494, 171, 176, 2353, 2358, "other" +399, 15, 57, 495, 177, 178, 2359, 2360, "(" +399, 15, 58, 496, 179, 184, 2361, 2366, "intra" +399, 15, 59, 497, 185, 186, 2367, 2368, "-" +399, 15, 60, 498, 187, 188, 2369, 2370, ")" +399, 15, 61, 499, 189, 194, 2371, 2376, "renal" +399, 15, 62, 500, 195, 208, 2377, 2390, "haemodynamics" +399, 15, 63, 501, 209, 211, 2391, 2393, "or" +399, 15, 64, 502, 212, 217, 2394, 2399, "renal" +399, 15, 65, 503, 218, 224, 2400, 2406, "damage" +399, 15, 66, 504, 225, 232, 2407, 2414, "markers" +399, 15, 67, 505, 233, 234, 2415, 2416, "," +399, 15, 68, 506, 235, 238, 2417, 2420, "but" +399, 15, 69, 507, 239, 248, 2421, 2430, "increased" +399, 15, 70, 508, 249, 259, 2431, 2441, "fractional" +399, 15, 71, 509, 260, 266, 2442, 2448, "sodium" +399, 15, 72, 510, 267, 276, 2449, 2458, "excretion" +399, 15, 73, 511, 277, 278, 2459, 2460, "[" +399, 15, 74, 512, 279, 280, 2461, 2462, "+" +399, 15, 75, 513, 281, 282, 2463, 2464, "0" +399, 15, 76, 514, 283, 284, 2465, 2466, "." +399, 15, 77, 515, 285, 287, 2467, 2469, "25" +399, 15, 78, 516, 288, 289, 2470, 2471, "%" +399, 15, 79, 517, 290, 291, 2472, 2473, "(" +399, 15, 80, 518, 292, 293, 2474, 2475, "0" +399, 15, 81, 519, 294, 295, 2476, 2477, "." +399, 15, 82, 520, 296, 298, 2478, 2480, "09" +399, 15, 83, 521, 299, 300, 2481, 2482, "-" +399, 15, 84, 522, 301, 302, 2483, 2484, "0" +399, 15, 85, 523, 303, 304, 2485, 2486, "." +399, 15, 86, 524, 305, 307, 2487, 2489, "41" +399, 15, 87, 525, 308, 309, 2490, 2491, ")" +399, 15, 88, 526, 310, 311, 2492, 2493, "]" +399, 15, 89, 527, 312, 315, 2494, 2497, "and" +399, 15, 90, 528, 316, 323, 2498, 2505, "urinary" +399, 15, 91, 529, 324, 326, 2506, 2508, "pH" +399, 15, 92, 530, 327, 328, 2509, 2510, "[" +399, 15, 93, 531, 329, 330, 2511, 2512, "+" +399, 15, 94, 532, 331, 332, 2513, 2514, "0" +399, 15, 95, 533, 333, 334, 2515, 2516, "." +399, 15, 96, 534, 335, 336, 2517, 2518, "7" +399, 15, 97, 535, 337, 338, 2519, 2520, "(" +399, 15, 98, 536, 339, 340, 2521, 2522, "0" +399, 15, 99, 537, 341, 342, 2523, 2524, "." +399, 15, 100, 538, 343, 344, 2525, 2526, "3" +399, 15, 101, 539, 345, 346, 2527, 2528, "-" +399, 15, 102, 540, 347, 348, 2529, 2530, "1" +399, 15, 103, 541, 349, 350, 2531, 2532, "." +399, 15, 104, 542, 351, 352, 2533, 2534, "2" +399, 15, 105, 543, 353, 354, 2535, 2536, ")" +399, 15, 106, 544, 355, 356, 2537, 2538, "]" +399, 15, 107, 545, 357, 358, 2539, 2540, "." +399, 16, 1, 546, 0, 6, 2541, 2547, "Plasma" +399, 16, 2, 547, 7, 12, 2548, 2553, "renin" +399, 16, 3, 548, 13, 14, 2554, 2555, "," +399, 16, 4, 549, 15, 26, 2556, 2567, "angiotensin" +399, 16, 5, 550, 27, 28, 2568, 2569, "-" +399, 16, 6, 551, 29, 31, 2570, 2572, "II" +399, 16, 7, 552, 32, 35, 2573, 2576, "and" +399, 16, 8, 553, 36, 47, 2577, 2588, "aldosterone" +399, 16, 9, 554, 48, 52, 2589, 2593, "were" +399, 16, 10, 555, 53, 62, 2594, 2603, "unchanged" +399, 16, 11, 556, 63, 64, 2604, 2605, "." +399, 17, 1, 557, 0, 12, 2606, 2618, "Lixisenatide" +399, 17, 2, 558, 13, 16, 2619, 2622, "and" +399, 17, 3, 559, 17, 21, 2623, 2627, "iGlu" +399, 17, 4, 560, 22, 29, 2628, 2635, "reduced" +399, 17, 5, 561, 30, 35, 2636, 2641, "HbA1c" +399, 17, 6, 562, 36, 45, 2642, 2651, "similarly" +399, 17, 7, 563, 46, 47, 2652, 2653, "," +399, 17, 8, 564, 48, 50, 2654, 2656, "by" +399, 17, 9, 565, 51, 52, 2657, 2658, "0" +399, 17, 10, 566, 53, 54, 2659, 2660, "." +399, 17, 11, 567, 55, 56, 2661, 2662, "8" +399, 17, 12, 568, 57, 58, 2663, 2664, "%" +399, 17, 13, 569, 59, 60, 2665, 2666, "±" +399, 17, 14, 570, 61, 62, 2667, 2668, "0" +399, 17, 15, 571, 63, 64, 2669, 2670, "." +399, 17, 16, 572, 65, 66, 2671, 2672, "1" +399, 17, 17, 573, 67, 68, 2673, 2674, "%" +399, 17, 18, 574, 69, 72, 2675, 2678, "and" +399, 17, 19, 575, 73, 74, 2679, 2680, "0" +399, 17, 20, 576, 75, 76, 2681, 2682, "." +399, 17, 21, 577, 77, 78, 2683, 2684, "6" +399, 17, 22, 578, 79, 80, 2685, 2686, "%" +399, 17, 23, 579, 81, 82, 2687, 2688, "±" +399, 17, 24, 580, 83, 84, 2689, 2690, "0" +399, 17, 25, 581, 85, 86, 2691, 2692, "." +399, 17, 26, 582, 87, 88, 2693, 2694, "1" +399, 17, 27, 583, 89, 90, 2695, 2696, "%" +399, 17, 28, 584, 91, 92, 2697, 2698, "," +399, 17, 29, 585, 93, 105, 2699, 2711, "respectively" +399, 17, 30, 586, 106, 107, 2712, 2713, "," +399, 17, 31, 587, 108, 113, 2714, 2719, "while" +399, 17, 32, 588, 114, 126, 2720, 2732, "postprandial" +399, 17, 33, 589, 127, 134, 2733, 2740, "glucose" +399, 17, 34, 590, 135, 138, 2741, 2744, "was" +399, 17, 35, 591, 139, 144, 2745, 2750, "lower" +399, 17, 36, 592, 145, 149, 2751, 2755, "with" +399, 17, 37, 593, 150, 162, 2756, 2768, "lixisenatide" +399, 17, 38, 594, 163, 164, 2769, 2770, "(" +399, 17, 39, 595, 165, 166, 2771, 2772, "P" +399, 17, 40, 596, 167, 168, 2773, 2774, "=" +399, 17, 41, 597, 169, 170, 2775, 2776, "." +399, 17, 42, 598, 171, 174, 2777, 2780, "002" +399, 17, 43, 599, 175, 176, 2781, 2782, ")" +399, 17, 44, 600, 177, 178, 2783, 2784, "." +399, 18, 1, 601, 0, 8, 2785, 2793, "Compared" +399, 18, 2, 602, 9, 13, 2794, 2798, "with" +399, 18, 3, 603, 14, 18, 2799, 2803, "iGlu" +399, 18, 4, 604, 19, 20, 2804, 2805, "," +399, 18, 5, 605, 21, 33, 2806, 2818, "lixisenatide" +399, 18, 6, 606, 34, 41, 2819, 2826, "reduced" +399, 18, 7, 607, 42, 52, 2827, 2837, "bodyweight" +399, 18, 8, 608, 53, 54, 2838, 2839, "[" +399, 18, 9, 609, 55, 56, 2840, 2841, "-" +399, 18, 10, 610, 57, 58, 2842, 2843, "1" +399, 18, 11, 611, 59, 60, 2844, 2845, "." +399, 18, 12, 612, 61, 62, 2846, 2847, "4" +399, 18, 13, 613, 63, 65, 2848, 2850, "kg" +399, 18, 14, 614, 66, 67, 2851, 2852, "(" +399, 18, 15, 615, 68, 69, 2853, 2854, "-" +399, 18, 16, 616, 70, 71, 2855, 2856, "2" +399, 18, 17, 617, 72, 73, 2857, 2858, "." +399, 18, 18, 618, 74, 75, 2859, 2860, "5" +399, 18, 19, 619, 76, 78, 2861, 2863, "to" +399, 18, 20, 620, 79, 80, 2864, 2865, "-" +399, 18, 21, 621, 81, 82, 2866, 2867, "0" +399, 18, 22, 622, 83, 84, 2868, 2869, "." +399, 18, 23, 623, 85, 86, 2870, 2871, "2" +399, 18, 24, 624, 87, 88, 2872, 2873, ")" +399, 18, 25, 625, 89, 90, 2874, 2875, "]" +399, 18, 26, 626, 91, 94, 2876, 2879, "and" +399, 18, 27, 627, 95, 104, 2880, 2889, "increased" +399, 18, 28, 628, 105, 117, 2890, 2902, "postprandial" +399, 18, 29, 629, 118, 122, 2903, 2907, "mean" +399, 18, 30, 630, 123, 131, 2908, 2916, "arterial" +399, 18, 31, 631, 132, 140, 2917, 2925, "pressure" +399, 18, 32, 632, 141, 142, 2926, 2927, "[" +399, 18, 33, 633, 143, 144, 2928, 2929, "+" +399, 18, 34, 634, 145, 146, 2930, 2931, "9" +399, 18, 35, 635, 147, 149, 2932, 2934, "mm" +399, 18, 36, 636, 150, 152, 2935, 2937, "Hg" +399, 18, 37, 637, 153, 154, 2938, 2939, "(" +399, 18, 38, 638, 155, 156, 2940, 2941, "4" +399, 18, 39, 639, 157, 158, 2942, 2943, "-" +399, 18, 40, 640, 159, 161, 2944, 2946, "14" +399, 18, 41, 641, 162, 163, 2947, 2948, ")" +399, 18, 42, 642, 164, 165, 2949, 2950, "]" +399, 18, 43, 643, 166, 167, 2951, 2952, "." +399, 19, 1, 644, 0, 10, 2953, 2963, "CONCLUSION" +399, 19, 2, 645, 11, 12, 2964, 2965, ":" +399, 19, 3, 646, 13, 18, 2966, 2971, "Eight" +399, 19, 4, 647, 19, 20, 2972, 2973, "-" +399, 19, 5, 648, 21, 25, 2974, 2978, "week" +399, 19, 6, 649, 26, 38, 2979, 2991, "lixisenatide" +399, 19, 7, 650, 39, 48, 2992, 3001, "treatment" +399, 19, 8, 651, 49, 53, 3002, 3006, "does" +399, 19, 9, 652, 54, 57, 3007, 3010, "not" +399, 19, 10, 653, 58, 64, 3011, 3017, "affect" +399, 19, 11, 654, 65, 77, 3018, 3030, "postprandial" +399, 19, 12, 655, 78, 79, 3031, 3032, "(" +399, 19, 13, 656, 80, 85, 3033, 3038, "intra" +399, 19, 14, 657, 86, 87, 3039, 3040, "-" +399, 19, 15, 658, 88, 89, 3041, 3042, ")" +399, 19, 16, 659, 90, 95, 3043, 3048, "renal" +399, 19, 17, 660, 96, 109, 3049, 3062, "haemodynamics" +399, 19, 18, 661, 110, 118, 3063, 3071, "compared" +399, 19, 19, 662, 119, 123, 3072, 3076, "with" +399, 19, 20, 663, 124, 128, 3077, 3081, "iGlu" +399, 19, 21, 664, 129, 133, 3082, 3086, "when" +399, 19, 22, 665, 134, 139, 3087, 3092, "added" +399, 19, 23, 666, 140, 142, 3093, 3095, "to" +399, 19, 24, 667, 143, 150, 3096, 3103, "insulin" +399, 19, 25, 668, 151, 152, 3104, 3105, "-" +399, 19, 26, 669, 153, 161, 3106, 3114, "glargine" +399, 19, 27, 670, 162, 164, 3115, 3117, "in" +399, 19, 28, 671, 165, 173, 3118, 3126, "patients" +399, 19, 29, 672, 174, 178, 3127, 3131, "with" +399, 19, 30, 673, 179, 183, 3132, 3136, "T2DM" +399, 19, 31, 674, 184, 191, 3137, 3144, "without" +399, 19, 32, 675, 192, 197, 3145, 3150, "overt" +399, 19, 33, 676, 198, 209, 3151, 3162, "nephropathy" +399, 19, 34, 677, 210, 211, 3163, 3164, "." +399, 20, 1, 678, 0, 9, 3165, 3174, "Prolonged" +399, 20, 2, 679, 10, 22, 3175, 3187, "lixisenatide" +399, 20, 3, 680, 23, 32, 3188, 3197, "treatment" +399, 20, 4, 681, 33, 36, 3198, 3201, "has" +399, 20, 5, 682, 37, 38, 3202, 3203, "a" +399, 20, 6, 683, 39, 48, 3204, 3213, "sustained" +399, 20, 7, 684, 49, 60, 3214, 3225, "natriuretic" +399, 20, 8, 685, 61, 67, 3226, 3232, "effect" +399, 20, 9, 686, 68, 69, 3233, 3234, "," +399, 20, 10, 687, 70, 75, 3235, 3240, "which" +399, 20, 11, 688, 76, 78, 3241, 3243, "is" +399, 20, 12, 689, 79, 81, 3244, 3246, "in" +399, 20, 13, 690, 82, 90, 3247, 3255, "contrast" +399, 20, 14, 691, 91, 93, 3256, 3258, "to" +399, 20, 15, 692, 94, 102, 3259, 3267, "previous" +399, 20, 16, 693, 103, 110, 3268, 3275, "reports" +399, 20, 17, 694, 111, 113, 3276, 3278, "on" +399, 20, 18, 695, 114, 118, 3279, 3283, "long" +399, 20, 19, 696, 119, 120, 3284, 3285, "-" +399, 20, 20, 697, 121, 127, 3286, 3292, "acting" +399, 20, 21, 698, 128, 131, 3293, 3296, "GLP" +399, 20, 22, 699, 132, 133, 3297, 3298, "-" +399, 20, 23, 700, 134, 137, 3299, 3302, "1RA" +399, 20, 24, 701, 138, 139, 3303, 3304, "," +399, 20, 25, 702, 140, 147, 3305, 3312, "reduces" +399, 20, 26, 703, 148, 152, 3313, 3317, "body" +399, 20, 27, 704, 153, 159, 3318, 3324, "weight" +399, 20, 28, 705, 160, 163, 3325, 3328, "and" +399, 20, 29, 706, 164, 173, 3329, 3338, "increases" +399, 20, 30, 707, 174, 186, 3339, 3351, "postprandial" +399, 20, 31, 708, 187, 192, 3352, 3357, "blood" +399, 20, 32, 709, 193, 201, 3358, 3366, "pressure" +399, 20, 33, 710, 202, 210, 3367, 3375, "compared" +399, 20, 34, 711, 211, 215, 3376, 3380, "with" +399, 20, 35, 712, 216, 220, 3381, 3385, "iGlu" +399, 20, 36, 713, 221, 222, 3386, 3387, "." +399, 21, 1, 714, 0, 5, 3388, 3393, "TRIAL" +399, 21, 2, 715, 6, 18, 3394, 3406, "REGISTRATION" +399, 21, 3, 716, 19, 20, 3407, 3408, ":" +399, 21, 4, 717, 21, 35, 3409, 3423, "ClinicalTrials" +399, 21, 5, 718, 36, 37, 3424, 3425, "." +399, 21, 6, 719, 38, 41, 3426, 3429, "gov" +399, 21, 7, 720, 42, 52, 3430, 3440, "identifier" +399, 21, 8, 721, 53, 64, 3441, 3452, "NCT02276196" +399, 21, 9, 722, 65, 66, 3453, 3454, "." +399, 22, 1, 723, 0, 1, 3455, 3456, "©" +399, 22, 2, 724, 2, 6, 3457, 3461, "2017" +399, 22, 3, 725, 7, 11, 3462, 3466, "John" +399, 22, 4, 726, 12, 17, 3467, 3472, "Wiley" +399, 22, 5, 727, 18, 19, 3473, 3474, "&" +399, 22, 6, 728, 20, 24, 3475, 3479, "Sons" +399, 22, 7, 729, 25, 28, 3480, 3483, "Ltd" +399, 22, 8, 730, 29, 30, 3484, 3485, "." +399, 22, 9, 731, 31, 34, 3486, 3489, "DOI" +399, 22, 10, 732, 35, 36, 3490, 3491, ":" +399, 22, 11, 733, 37, 39, 3492, 3494, "10" +399, 22, 12, 734, 40, 41, 3495, 3496, "." +399, 22, 13, 735, 42, 46, 3497, 3501, "1111" +399, 22, 14, 736, 47, 48, 3502, 3503, "/" +399, 22, 15, 737, 49, 52, 3504, 3507, "dom" +399, 22, 16, 738, 53, 54, 3508, 3509, "." +399, 22, 17, 739, 55, 60, 3510, 3515, "12985" +399, 22, 18, 740, 61, 65, 3516, 3520, "PMID" +399, 22, 19, 741, 66, 67, 3521, 3522, ":" +399, 22, 20, 742, 68, 76, 3523, 3531, "28449402" +399, 22, 21, 743, 77, 78, 3532, 3533, "[" +399, 22, 22, 744, 79, 86, 3534, 3541, "Indexed" +399, 22, 23, 745, 87, 90, 3542, 3545, "for" +399, 22, 24, 746, 91, 98, 3546, 3553, "MEDLINE" +399, 22, 25, 747, 99, 100, 3554, 3555, "]" diff --git a/data/dm2 28449402_kwoodley.annodb b/data/dm2 28449402_kwoodley.annodb new file mode 100644 index 0000000..2440594 --- /dev/null +++ b/data/dm2 28449402_kwoodley.annodb @@ -0,0 +1,122 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71535, Journal, 0, 19, "Diabetes Obes Metab", "", +71536, PublicationYear, 22, 26, "2017", "", +71558, Title, 110, 305, "Postprandial renal haemodynamic effect of lixisenatide vs once - daily insulin - glulisine in patients with type 2 diabetes on insulin - glargine : An 8 - week , randomised , open - label trial .", "", +71537, Drug, 152, 164, "lixisenatide", "", +71547, Frequency, 168, 180, "once - daily", "", +71546, Drug, 181, 200, "insulin - glulisine", "", +71549, Type2Diabetes, 218, 233, "type 2 diabetes", "", +71553, InsulinGlargine, 237, 255, "insulin - glargine", "", +71555, Duration, 261, 269, "8 - week", "", +71556, Randomized, 272, 282, "randomised", "", +71557, OpenLabel, 285, 297, "open - label", "", +71559, Author, 306, 317, "Tonneijck L", "", +71560, Author, 326, 337, "Muskiet MHA", "", +71561, Author, 346, 354, "Smits MM", "", +71562, Author, 363, 373, "Hoekstra T", "", +71563, Author, 388, 398, "Kramer MHH", "", +71564, Author, 407, 417, "Danser AHJ", "", +71565, Author, 426, 435, "Diamant M", "", +71566, Author, 444, 452, "Joles JA", "", +71567, Author, 461, 474, "van Raalte DH", "", +71568, Netherlands, 605, 620, "The Netherlands", "", +71569, Netherlands, 751, 766, "The Netherlands", "", +71570, Netherlands, 865, 880, "The Netherlands", "", +71571, Netherlands, 1020, 1035, "The Netherlands", "", +71572, Netherlands, 1126, 1141, "The Netherlands", "", +71575, ObjectiveDescription, 1150, 1371, "To determine whether lixisenatide , a prandial short - acting glucagon - like peptide receptor agonist ( GLP - 1RA ) , ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus ( T2DM )", "", +71538, Drug, 1171, 1183, "lixisenatide", "", +71550, Type2Diabetes, 1338, 1362, "type 2 diabetes mellitus", "", +71551, Type2Diabetes, 1365, 1369, "T2DM", "", +71576, ObjectiveDescription, 1372, 1414, "compared with insulin - glulisine ( iGlu )", "", +71573, Drug, 1386, 1405, "insulin - glulisine", "", +71574, Drug, 1408, 1412, "iGlu", "", +71577, Duration, 1470, 1478, "8 - week", "", +71539, Drug, 1494, 1506, "lixisenatide", "", +71578, DoseValue, 1507, 1509, "20", "", +71579, Microgram, 1510, 1513, "µ g", "", +71548, Frequency, 1517, 1529, "once - daily", "", +71580, Drug, 1539, 1543, "iGlu", "", +71581, NumberPatientsCT, 1561, 1563, "35", "", +71590, Precondition, 1564, 1724, "overweight patients with T2DM inadequately controlled on insulin - glargine , with or without metformin [ mean ± SD age 62 ± 7 years , HbA1c 8 . 0 % ± 0 . 9 % ,", "", +71552, Type2Diabetes, 1589, 1593, "T2DM", "", +71554, InsulinGlargine, 1621, 1639, "insulin - glargine", "", +71582, Metformin, 1658, 1667, "metformin", "", +71583, AvgAge, 1684, 1686, "62", "", +71584, HbA1c, 1699, 1704, "HbA1c", "", +71585, Percentage, 1711, 1712, "%", "", +71586, Percentage, 1721, 1722, "%", "", +71591, Precondition, 1725, 1886, "estimated glomerular filtration rate ( GFR ) 85 ± 12 mL / min / 1 . 73 m2 , median ( IQR ) urinary albumin / creatinine ratio 1 . 5 ( 0 . 9 - 3 . 0 ) mg / mmol ]", "", +71587, BioAndMedicalUnit, 1778, 1786, "mL / min", "", +71588, BioAndMedicalUnit, 1796, 1798, "m2", "", +71589, BioAndMedicalUnit, 1875, 1884, "mg / mmol", "", +71592, EndPointDescription, 1922, 1925, "GFR", "", +71593, EndPointDescription, 1951, 1978, "effective renal plasma flow", "", +71594, EndPointDescription, 1981, 1985, "ERPF", "", +71595, Insulin, 2007, 2013, "inulin", "", +71596, MeasurementDevice, 2164, 2179, "Gomez equations", "", +71597, Drug, 2206, 2210, "iGlu", "", +71540, Drug, 2213, 2225, "lixisenatide", "", +71602, ObservedResult, 2226, 2240, "did not affect", "", +71598, EndPointDescription, 2241, 2244, "GFR", "", +71603, Increment, 2249, 2254, "0 . 1", "", +71610, BioAndMedicalUnit, 2255, 2263, "mL / min", "", +71612, ResultMeasuredValue, 2266, 2272, "1 . 73", "", +71607, BioAndMedicalUnit, 2273, 2275, "m2", "", +71614, ConfIntervalChangeValue, 2278, 2294, "95 % CI - 9 to 9", "", +71618, EndPointDescription, 2301, 2305, "ERPF", "", +71619, Reduction, 2310, 2312, "17", "", +71611, BioAndMedicalUnit, 2313, 2321, "mL / min", "", +71613, ResultMeasuredValue, 2324, 2330, "1 . 73", "", +71609, BioAndMedicalUnit, 2331, 2333, "m2", "", +71615, ConfIntervalChangeValue, 2336, 2346, "- 61 to 26", "", +71601, EndPointDescription, 2353, 2414, "other ( intra - ) renal haemodynamics or renal damage markers", "", +71599, EndPointDescription, 2431, 2458, "fractional sodium excretion", "", +71604, Increment, 2463, 2469, "0 . 25", "", +71620, Percentage, 2470, 2471, "%", "", +71616, ConfIntervalChangeValue, 2474, 2489, "0 . 09 - 0 . 41", "", +71600, EndPointDescription, 2498, 2508, "urinary pH", "", +71605, Increment, 2513, 2518, "0 . 7", "", +71617, ConfIntervalChangeValue, 2521, 2534, "0 . 3 - 1 . 2", "", +71621, EndPointDescription, 2541, 2553, "Plasma renin", "", +71622, EndPointDescription, 2556, 2572, "angiotensin - II", "", +71623, EndPointDescription, 2577, 2588, "aldosterone", "", +71624, ObservedResult, 2589, 2603, "were unchanged", "", +71541, Drug, 2606, 2618, "Lixisenatide", "", +71625, Drug, 2623, 2627, "iGlu", "", +71626, HbA1c, 2636, 2641, "HbA1c", "", +71627, Reduction, 2657, 2662, "0 . 8", "", +71629, Percentage, 2663, 2664, "%", "", +71633, SdDevChangeValue, 2667, 2672, "0 . 1", "", +71630, Percentage, 2673, 2674, "%", "", +71628, Reduction, 2679, 2684, "0 . 6", "", +71631, Percentage, 2685, 2686, "%", "", +71634, SdDevChangeValue, 2689, 2694, "0 . 1", "", +71632, Percentage, 2695, 2696, "%", "", +71635, PostprandialBloodGlucose, 2720, 2740, "postprandial glucose", "", +71636, ObservedResult, 2741, 2750, "was lower", "", +71542, Drug, 2756, 2768, "lixisenatide", "", +71637, PValueResValue, 2771, 2780, "P = . 002", "", +71638, Drug, 2799, 2803, "iGlu", "", +71543, Drug, 2806, 2818, "lixisenatide", "", +71639, BodyWeight, 2827, 2837, "bodyweight", "", +71641, Reduction, 2842, 2847, "1 . 4", "", +71643, Kg, 2848, 2850, "kg", "", +71644, ConfIntervalChangeValue, 2853, 2871, "- 2 . 5 to - 0 . 2", "", +71640, EndPointDescription, 2890, 2925, "postprandial mean arterial pressure", "", +71642, Increment, 2930, 2931, "9", "", +71646, mmHg, 2932, 2937, "mm Hg", "", +71645, ConfIntervalChangeValue, 2940, 2946, "4 - 14", "", +71647, Duration, 2966, 2978, "Eight - week", "", +71655, ConclusionComment, 2966, 3164, "Eight - week lixisenatide treatment does not affect postprandial ( intra - ) renal haemodynamics compared with iGlu when added to insulin - glargine in patients with T2DM without overt nephropathy .", "", +71544, Drug, 2979, 2991, "lixisenatide", "", +71648, Drug, 3077, 3081, "iGlu", "", +71649, InsulinGlargine, 3096, 3114, "insulin - glargine", "", +71651, Precondition, 3118, 3162, "patients with T2DM without overt nephropathy", "", +71650, Type2Diabetes, 3132, 3136, "T2DM", "", +71657, ConclusionComment, 3165, 3387, "Prolonged lixisenatide treatment has a sustained natriuretic effect , which is in contrast to previous reports on long - acting GLP - 1RA , reduces body weight and increases postprandial blood pressure compared with iGlu .", "", +71545, Drug, 3175, 3187, "lixisenatide", "", +71652, BodyWeight, 3313, 3324, "body weight", "", +71653, PostprandialBloodGlucose, 3339, 3366, "postprandial blood pressure", "", +71654, Drug, 3381, 3385, "iGlu", "", +71658, PMID, 3523, 3531, "28449402", "", diff --git a/data/dm2 28449402_kwoodley.n-triples b/data/dm2 28449402_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28449402_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28483786_admin.annodb b/data/dm2 28483786_admin.annodb new file mode 100644 index 0000000..8595ace --- /dev/null +++ b/data/dm2 28483786_admin.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2017", "", " \"2017\"." +4, Title, 100, 235, "Faster Aspart Versus Insulin Aspart as Part of a Basal - Bolus Regimen in Inadequately Controlled Type 2 Diabetes : The onset 2 Trial .", "", " \"Faster Aspart Versus Insulin Aspart as Part of a Basal - Bolus Regimen in Inadequately Controlled Type 2 Diabetes : The onset 2 Trial .\"." +29, InsulinAspart, 100, 113, "Faster Aspart", "", +2, InsulinAspart, 121, 135, "Insulin Aspart", "", +126, Precondition, 174, 213, "Inadequately Controlled Type 2 Diabetes", "", +3, Type2Diabetes, 198, 213, "Type 2 Diabetes", "", +5, Author, 236, 246, "Bowering K", "", " \"Bowering K\"." +6, Author, 255, 261, "Case C", "", " \"Case C\"." +7, Author, 270, 278, "Harvey J", "", " \"Harvey J\"." +8, Author, 287, 295, "Reeves M", "", " \"Reeves M\"." +9, Author, 304, 313, "Sampson M", "", " \"Sampson M\"." +10, Author, 322, 332, "Strzinek R", "", " \"Strzinek R\"." +11, Author, 341, 351, "Bretler DM", "", " \"Bretler DM\"." +12, Author, 360, 367, "Bang RB", "", " \"Bang RB\"." +13, Author, 376, 383, "Bode BW", "", " \"Bode BW\"." +14, Canada, 507, 513, "Canada", "", " ." +142, USA, 603, 605, "MO", "", " ." +16, UK, 681, 688, "U . K .", "", " ." +141, USA, 736, 738, "TN", "", " ." +15, UK, 869, 876, "U . K .", "", +138, USA, 921, 923, "TX", "", " ." +17, Country, 964, 971, "Denmark", "", " . ." +139, USA, 1020, 1022, "GA", "", " ." +149, ObjectiveDescription, 1148, 1334, "This multicenter , double - blind , treat - to - target , phase 3 trial evaluated the efficacy and safety of fast - acting insulin aspart ( faster aspart ) versus insulin aspart ( IAsp )", "", " \"This multicenter , double - blind , treat - to - target , phase 3 trial evaluated the efficacy and safety of fast - acting insulin aspart ( faster aspart ) versus insulin aspart ( IAsp )\"." +18, Multicenter, 1153, 1164, "multicenter", "", " ." +19, DoubleBlind, 1167, 1181, "double - blind", "", " ." +145, CTDesign, 1184, 1203, "treat - to - target", "", " . ." +27, InsulinAspart, 1257, 1285, "fast - acting insulin aspart", "", +28, InsulinAspart, 1288, 1301, "faster aspart", "", +20, InsulinAspart, 1311, 1325, "insulin aspart", "", +21, InsulinAspart, 1328, 1332, "IAsp", "", +150, ObjectiveDescription, 1335, 1420, "in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents .", "", " \"in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents .\"." +148, Precondition, 1338, 1418, "adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents", "", " \"adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents\"." +22, Type2Diabetes, 1350, 1365, "type 2 diabetes", "", " ." +23, Insulin, 1376, 1389, "basal insulin", "", +24, OralAntidiabeticAgent, 1394, 1418, "oral antidiabetic agents", "", +30, HbA1c, 1477, 1482, "HbA1c", "", +31, TimePoint, 1495, 1503, "baseline", "", +99222, Duration, 1510, 1518, "26 weeks", "", " \"26 weeks\"." +33, Duration, 1542, 1550, "8 - week", "", +34, Insulin, 1572, 1585, "basal insulin", "", +35, Randomized, 1602, 1612, "randomized", "", " ." +161, AllocationRatio, 1615, 1620, "1 : 1", "", " . ." +162, RelativeTime, 1626, 1634, "mealtime", "", " . ." +36, InsulinAspart, 1635, 1648, "faster aspart", "", " ." +39, NumberPatientsArm, 1655, 1658, "345", "", " \"345\"." +37, InsulinAspart, 1664, 1668, "IAsp", "", " ." +40, NumberPatientsArm, 1675, 1678, "344", "", " \"344\"." +38, DoseDescription, 1683, 1739, "titrated using a simple daily patient - driven algorithm", "", " \"titrated using a simple daily patient - driven algorithm\". \"titrated using a simple daily patient - driven algorithm\"." +166, InsulinGlargine, 1747, 1763, "insulin glargine", "", " ." +42, Metformin, 1773, 1782, "metformin", "", " ." +43, HbA1c, 1795, 1800, "HbA1c", "", " ." +171, Reduction, 1814, 1820, "1 . 38", "", " \"1 . 38\"." +44, Percentage, 1821, 1822, "%", "", " ." +57, InsulinAspart, 1825, 1838, "faster aspart", "", +172, Reduction, 1847, 1853, "1 . 36", "", " \"1 . 36\"." +45, Percentage, 1854, 1855, "%", "", +58, InsulinAspart, 1858, 1862, "IAsp", "", +54, Mean, 1867, 1871, "mean", "", " . ." +55, HbA1c, 1872, 1877, "HbA1c", "", +175, ResultMeasuredValue, 1882, 1887, "6 . 6", "", " \"6 . 6\". \"6 . 6\"." +46, Percentage, 1888, 1889, "%", "", +59, InsulinAspart, 1908, 1921, "Faster aspart", "", +60, InsulinAspart, 1957, 1961, "IAsp", "", +61, HbA1c, 1974, 1979, "HbA1c", "", +62, DiffGroupAbsValue, 2033, 2041, "- 0 . 02", "", " \"- 0 . 02\"." +48, Percentage, 2042, 2043, "%", "", +63, ConfIntervalDiff, 2046, 2063, "- 0 . 15 ; 0 . 10", "", " \"- 0 . 15 ; 0 . 10\"." +64, PostprandialPlasmaGlucose, 2095, 2122, "postprandial plasma glucose", "", " ." +65, PostprandialPlasmaGlucose, 2125, 2128, "PPG", "", +181, PostprandialPlasmaGlucose, 2145, 2148, "PPG", "", +184, ObservedResult, 2180, 2245, "was statistically significant in favor of faster aspart after 1 h", "", " \"was statistically significant in favor of faster aspart after 1 h\"." +69, InsulinAspart, 2222, 2235, "faster aspart", "", +70, DiffGroupAbsValue, 2264, 2272, "- 0 . 59", "", " \"- 0 . 59\"." +67, Millimoles_per_litre, 2273, 2281, "mmol / L", "", " ." +72, ConfIntervalDiff, 2284, 2303, "- 1 . 09 ; - 0 . 09", "", " \"- 1 . 09 ; - 0 . 09\"." +71, DiffGroupAbsValue, 2308, 2317, "- 10 . 63", "", +68, Mg_per_deciliter, 2318, 2325, "mg / dL", "", +73, ConfIntervalDiff, 2328, 2348, "- 19 . 56 ; - 1 . 69", "", +74, PvalueDiff, 2353, 2365, "P = 0 . 0198", "", " \"P = 0 . 0198\"." +185, ObservedResult, 2370, 2391, "but not after 2 - 4 h", "", " \"but not after 2 - 4 h\"." +75, TimePoint, 2406, 2414, "baseline", "", +76, FastingPlasmaGlucose, 2418, 2440, "fasting plasma glucose", "", " ." +77, BodyWeight, 2443, 2454, "body weight", "", " ." +78, BloodGlucose, 2478, 2491, "blood glucose", "", " ." +99227, Hypoglycemia, 2504, 2516, "hypoglycemia", "", " ." +106266, AggregationMethod, 2525, 2535, "rate ratio", "", " . ." +106267, AggregationMethod, 2538, 2540, "RR", "", +84, DiffGroupRelValue, 2555, 2561, "1 . 09", "", " \"1 . 09\"." +86, ConfIntervalDiff, 2564, 2579, "0 . 88 ; 1 . 36", "", " \"0 . 88 ; 1 . 36\"." +200, ObservedResult, 2584, 2615, "were similar between treatments", "", " \"were similar between treatments\". \"were similar between treatments\". \"were similar between treatments\". \"were similar between treatments\". \"were similar between treatments\"." +80, Hypoglycemia, 2618, 2651, "Postmeal hypoglycemia ( 0 - 2 h )", "", " ." +106268, SubGroupDescription, 2618, 2639, "Postmeal hypoglycemia", "", " \"Postmeal hypoglycemia\". \"Postmeal hypoglycemia\"." +99228, AggregationMethod, 2652, 2657, "rates", "", +82, ResultMeasuredValue, 2663, 2669, "2 . 27", "", " \"2 . 27\"." +88, InsulinAspart, 2672, 2685, "faster aspart", "", +83, ResultMeasuredValue, 2692, 2698, "1 . 49", "", " \"1 . 49\"." +89, InsulinAspart, 2701, 2705, "IAsp", "", +205, BioAndMedicalUnit, 2712, 2738, "patient - year of exposure", "", +85, DiffGroupRelValue, 2756, 2762, "1 . 60", "", " \"1 . 60\"." +87, ConfIntervalDiff, 2765, 2780, "1 . 13 ; 2 . 27", "", " \"1 . 13 ; 2 . 27\"." +90, InsulinAspart, 2801, 2814, "Faster aspart", "", +102, ConclusionComment, 2801, 2919, "Faster aspart and IAsp were confirmed noninferior in a basal - bolus regimen regarding change from baseline in HbA1c .", "", " \"Faster aspart and IAsp were confirmed noninferior in a basal - bolus regimen regarding change from baseline in HbA1c .\"." +91, InsulinAspart, 2819, 2823, "IAsp", "", +95, TimePoint, 2900, 2908, "baseline", "", +96, HbA1c, 2912, 2917, "HbA1c", "", +92, InsulinAspart, 2920, 2933, "Faster aspart", "", +103, ConclusionComment, 2920, 3003, "Faster aspart improved 1 - h PPG with no differences in 2 - 4 - h PPG versus IAsp .", "", " \"Faster aspart improved 1 - h PPG with no differences in 2 - 4 - h PPG versus IAsp .\"." +207, PostprandialPlasmaGlucose, 2943, 2952, "1 - h PPG", "", +98, PostprandialPlasmaGlucose, 2976, 2989, "2 - 4 - h PPG", "", +93, InsulinAspart, 2997, 3001, "IAsp", "", +99, Hypoglycemia, 3004, 3024, "Overall hypoglycemia", "", +104, ConclusionComment, 3004, 3122, "Overall hypoglycemia rates were similar except for an increase in 0 - 2 - h postmeal hypoglycemia with faster aspart .", "", " \"Overall hypoglycemia rates were similar except for an increase in 0 - 2 - h postmeal hypoglycemia with faster aspart .\"." +100, Hypoglycemia, 3070, 3101, "0 - 2 - h postmeal hypoglycemia", "", +94, InsulinAspart, 3107, 3120, "faster aspart", "", +101, PMID, 3206, 3214, "28483786", "", " \"28483786\"." diff --git a/data/dm2 28483786_admin.n-triples b/data/dm2 28483786_admin.n-triples new file mode 100644 index 0000000..1bddb2d --- /dev/null +++ b/data/dm2 28483786_admin.n-triples @@ -0,0 +1,231 @@ +# RDF export of group: Publication + . + "Publication " . + "Faster Aspart Versus Insulin Aspart as Part of a Basal - Bolus Regimen in Inadequately Controlled Type 2 Diabetes : The onset 2 Trial ." . + "Bowering K" . + "2017" . + "Diabetes Care" . + "28483786" . + . + "Case C" . + "Harvey J" . + "Reeves M" . + "Sampson M" . + "Strzinek R" . + "Bretler DM" . + "Bang RB" . + "Bode BW" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "This multicenter , double - blind , treat - to - target , phase 3 trial evaluated the efficacy and safety of fast - acting insulin aspart ( faster aspart ) versus insulin aspart ( IAsp )" . + "26 weeks" . + . + . + . + . + "Faster aspart and IAsp were confirmed noninferior in a basal - bolus regimen regarding change from baseline in HbA1c ." . + . + . + . + . + . + "in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents ." . + . + . + . + . + "Faster aspart improved 1 - h PPG with no differences in 2 - 4 - h PPG versus IAsp ." . + "Overall hypoglycemia rates were similar except for an increase in 0 - 2 - h postmeal hypoglycemia with faster aspart ." . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents" . + . + . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . + "Endpoint bg" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint postmeal h" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm fa" . + "345" . + . + . + . + . + . + . + . + . + . + "Arm iasp" . + "344" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention fa" . + . + . + . + . + "Intervention iasp" . + . + . +# RDF export of group: Medication + . + "Medication fa" . + . + . + . + "titrated using a simple daily patient - driven algorithm" . + . + "Medication iasp" . + . + . + . + "titrated using a simple daily patient - driven algorithm" . + . + "Medication ig" . + . + . + . + . + "Medication m" . + . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c fa" . + . + "6 . 6" . + "1 . 38" . + . + "Outcome hba1c iasp" . + . + "6 . 6" . + "1 . 36" . + . + "Outcome ppg fa" . + . + "was statistically significant in favor of faster aspart after 1 h" . + "but not after 2 - 4 h" . + . + "Outcome ppg iasp" . + . + . + "Outcome fpg both drugs" . + . + "were similar between treatments" . + . + "Outcome weight both drugs" . + . + "were similar between treatments" . + . + "Outcome h fa" . + . + "were similar between treatments" . + . + "Outcome h iasp" . + . + "were similar between treatments" . + . + "Outcome pm h fa" . + . + "2 . 27" . + "Postmeal hypoglycemia" . + . + "Outcome pm h iasp" . + . + "1 . 49" . + "Postmeal hypoglycemia" . + . + "Outcome bg both drugs" . + . + "were similar between treatments" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c" . + "- 0 . 02" . + "- 0 . 15 ; 0 . 10" . + . + . + . + "DiffBetweenGroups ppg" . + "- 0 . 59" . + "P = 0 . 0198" . + "- 1 . 09 ; - 0 . 09" . + . + . + . + "DiffBetweenGroups h" . + "1 . 09" . + "0 . 88 ; 1 . 36" . + . + . + . + "DiffBetweenGroups pm h " . + "1 . 60" . + "1 . 13 ; 2 . 27" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28483786_akramersunderbrink.annodb b/data/dm2 28483786_akramersunderbrink.annodb new file mode 100644 index 0000000..b5c5702 --- /dev/null +++ b/data/dm2 28483786_akramersunderbrink.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +69956, Journal, 0, 13, "Diabetes Care", "", +69963, PublicationYear, 16, 20, "2017", "", +69966, Title, 100, 235, "Faster Aspart Versus Insulin Aspart as Part of a Basal - Bolus Regimen in Inadequately Controlled Type 2 Diabetes : The onset 2 Trial .", "", +69993, InsulinAspart, 100, 113, "Faster Aspart", "", +69964, InsulinAspart, 121, 135, "Insulin Aspart", "", +69965, Type2Diabetes, 198, 213, "Type 2 Diabetes", "", +69967, Author, 236, 246, "Bowering K", "", +69968, Author, 255, 261, "Case C", "", +69969, Author, 270, 278, "Harvey J", "", +69970, Author, 287, 295, "Reeves M", "", +69971, Author, 304, 313, "Sampson M", "", +69972, Author, 322, 332, "Strzinek R", "", +69973, Author, 341, 351, "Bretler DM", "", +69974, Author, 360, 367, "Bang RB", "", +69975, Author, 376, 383, "Bode BW", "", +69976, Canada, 507, 513, "Canada", "", +69978, UK, 681, 688, "U . K .", "", +69977, UK, 869, 876, "U . K .", "", +69979, Country, 964, 971, "Denmark", "", +69987, ObjectiveDescription, 1148, 1344, "This multicenter , double - blind , treat - to - target , phase 3 trial evaluated the efficacy and safety of fast - acting insulin aspart ( faster aspart ) versus insulin aspart ( IAsp ) in adults", "", +69980, Multicenter, 1153, 1164, "multicenter", "", +69981, DoubleBlind, 1167, 1181, "double - blind", "", +69991, InsulinAspart, 1257, 1285, "fast - acting insulin aspart", "", +69992, InsulinAspart, 1288, 1301, "faster aspart", "", +69982, InsulinAspart, 1311, 1325, "insulin aspart", "", +69983, InsulinAspart, 1328, 1332, "IAsp", "", +69988, ObjectiveDescription, 1345, 1420, "with type 2 diabetes receiving basal insulin and oral antidiabetic agents .", "", +69984, Type2Diabetes, 1350, 1365, "type 2 diabetes", "", +69985, Insulin, 1376, 1389, "basal insulin", "", +69986, OralAntidiabeticAgent, 1394, 1418, "oral antidiabetic agents", "", +69994, HbA1c, 1477, 1482, "HbA1c", "", +69995, TimePoint, 1495, 1503, "baseline", "", +69996, TimePoint, 1510, 1518, "26 weeks", "", +69997, Duration, 1542, 1550, "8 - week", "", +69998, Insulin, 1572, 1585, "basal insulin", "", +69999, Randomized, 1602, 1612, "randomized", "", +70000, InsulinAspart, 1635, 1648, "faster aspart", "", +70003, NumberPatientsArm, 1655, 1658, "345", "", +70001, InsulinAspart, 1664, 1668, "IAsp", "", +70004, NumberPatientsArm, 1675, 1678, "344", "", +70002, DoseDescription, 1683, 1739, "titrated using a simple daily patient - driven algorithm", "", +70005, InsulinGlargine, 1747, 1768, "insulin glargine U100", "", +70006, Metformin, 1773, 1782, "metformin", "", +70007, HbA1c, 1795, 1800, "HbA1c", "", +70016, ChangeValue, 1812, 1820, "- 1 . 38", "", +70008, Percentage, 1821, 1822, "%", "", +70021, InsulinAspart, 1825, 1838, "faster aspart", "", +70017, ChangeValue, 1845, 1853, "- 1 . 36", "", +70009, Percentage, 1854, 1855, "%", "", +70022, InsulinAspart, 1858, 1862, "IAsp", "", +70018, Mean, 1867, 1871, "mean", "", +70019, HbA1c, 1872, 1877, "HbA1c", "", +70020, BaseLineValue, 1882, 1887, "6 . 6", "", +70010, Percentage, 1888, 1889, "%", "", +70023, InsulinAspart, 1908, 1921, "Faster aspart", "", +70024, InsulinAspart, 1957, 1961, "IAsp", "", +70025, HbA1c, 1974, 1979, "HbA1c", "", +70011, Percentage, 2026, 2027, "%", "", +70026, DiffGroupAbsValue, 2033, 2041, "- 0 . 02", "", +70012, Percentage, 2042, 2043, "%", "", +70027, ConfIntervalDiff, 2046, 2063, "- 0 . 15 ; 0 . 10", "", +70029, PostprandialPlasmaGlucose, 2095, 2122, "postprandial plasma glucose", "", +70030, PostprandialPlasmaGlucose, 2125, 2128, "PPG", "", +70031, PostprandialPlasmaGlucose, 2145, 2158, "PPG increment", "", +70036, InsulinAspart, 2222, 2235, "faster aspart", "", +70013, Percentage, 2257, 2258, "%", "", +70038, DiffGroupAbsValue, 2264, 2272, "- 0 . 59", "", +70033, Millimoles_per_litre, 2273, 2281, "mmol / L", "", +70040, ConfIntervalDiff, 2284, 2303, "- 1 . 09 ; - 0 . 09", "", +70039, DiffGroupAbsValue, 2308, 2317, "- 10 . 63", "", +70034, Mg_per_deciliter, 2318, 2325, "mg / dL", "", +70041, ConfIntervalDiff, 2328, 2348, "- 19 . 56 ; - 1 . 69", "", +70042, PvalueDiff, 2353, 2365, "P = 0 . 0198", "", +70043, TimePoint, 2406, 2414, "baseline", "", +70044, FastingPlasmaGlucose, 2418, 2440, "fasting plasma glucose", "", +70045, BodyWeight, 2443, 2454, "body weight", "", +70046, BloodGlucose, 2461, 2491, "overall severe / blood glucose", "", +70047, Hypoglycemia, 2504, 2522, "hypoglycemia rates", "", +70014, Percentage, 2548, 2549, "%", "", +70054, DiffGroupRelValue, 2555, 2561, "1 . 09", "", +70056, ConfIntervalDiff, 2564, 2579, "0 . 88 ; 1 . 36", "", +70050, Hypoglycemia, 2618, 2657, "Postmeal hypoglycemia ( 0 - 2 h ) rates", "", +70052, ResultMeasuredValue, 2663, 2669, "2 . 27", "", +70058, InsulinAspart, 2672, 2685, "faster aspart", "", +70053, ResultMeasuredValue, 2692, 2698, "1 . 49", "", +70059, InsulinAspart, 2701, 2705, "IAsp", "", +70051, BioAndMedicalUnit, 2708, 2738, "per patient - year of exposure", "", +70015, Percentage, 2749, 2750, "%", "", +70055, DiffGroupRelValue, 2756, 2762, "1 . 60", "", +70057, ConfIntervalDiff, 2765, 2780, "1 . 13 ; 2 . 27", "", +70060, InsulinAspart, 2801, 2814, "Faster aspart", "", +70072, ConclusionComment, 2801, 2919, "Faster aspart and IAsp were confirmed noninferior in a basal - bolus regimen regarding change from baseline in HbA1c .", "", +70061, InsulinAspart, 2819, 2823, "IAsp", "", +70065, TimePoint, 2900, 2908, "baseline", "", +70066, HbA1c, 2912, 2917, "HbA1c", "", +70062, InsulinAspart, 2920, 2933, "Faster aspart", "", +70073, ConclusionComment, 2920, 3003, "Faster aspart improved 1 - h PPG with no differences in 2 - 4 - h PPG versus IAsp .", "", +70067, PostprandialPlasmaGlucose, 2943, 2952, "1 - h PPG", "", +70068, PostprandialPlasmaGlucose, 2976, 2989, "2 - 4 - h PPG", "", +70063, InsulinAspart, 2997, 3001, "IAsp", "", +70074, ConclusionComment, 3004, 3122, "Overall hypoglycemia rates were similar except for an increase in 0 - 2 - h postmeal hypoglycemia with faster aspart .", "", +70069, Hypoglycemia, 3012, 3024, "hypoglycemia", "", +70070, Hypoglycemia, 3070, 3101, "0 - 2 - h postmeal hypoglycemia", "", +70064, InsulinAspart, 3107, 3120, "faster aspart", "", +70071, PMID, 3206, 3214, "28483786", "", diff --git a/data/dm2 28483786_akramersunderbrink.n-triples b/data/dm2 28483786_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28483786_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28483786_export.csv b/data/dm2 28483786_export.csv new file mode 100644 index 0000000..12f8ede --- /dev/null +++ b/data/dm2 28483786_export.csv @@ -0,0 +1,755 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +398, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +398, 1, 2, 2, 9, 13, 9, 13, "Care" +398, 1, 3, 3, 14, 15, 14, 15, "." +398, 2, 1, 4, 0, 4, 16, 20, "2017" +398, 2, 2, 5, 5, 8, 21, 24, "Jul" +398, 2, 3, 6, 9, 10, 25, 26, ";" +398, 2, 4, 7, 11, 13, 27, 29, "40" +398, 2, 5, 8, 14, 15, 30, 31, "(" +398, 2, 6, 9, 16, 17, 32, 33, "7" +398, 2, 7, 10, 18, 19, 34, 35, ")" +398, 2, 8, 11, 20, 21, 36, 37, ":" +398, 2, 9, 12, 22, 25, 38, 41, "951" +398, 2, 10, 13, 26, 27, 42, 43, "-" +398, 2, 11, 14, 28, 31, 44, 47, "957" +398, 2, 12, 15, 32, 33, 48, 49, "." +398, 2, 13, 16, 34, 37, 50, 53, "doi" +398, 2, 14, 17, 38, 39, 54, 55, ":" +398, 2, 15, 18, 40, 42, 56, 58, "10" +398, 2, 16, 19, 43, 44, 59, 60, "." +398, 2, 17, 20, 45, 49, 61, 65, "2337" +398, 2, 18, 21, 50, 51, 66, 67, "/" +398, 2, 19, 22, 52, 56, 68, 72, "dc16" +398, 2, 20, 23, 57, 58, 73, 74, "-" +398, 2, 21, 24, 59, 63, 75, 79, "1770" +398, 2, 22, 25, 64, 65, 80, 81, "." +398, 3, 1, 26, 0, 4, 82, 86, "Epub" +398, 3, 2, 27, 5, 9, 87, 91, "2017" +398, 3, 3, 28, 10, 13, 92, 95, "May" +398, 3, 4, 29, 14, 15, 96, 97, "8" +398, 3, 5, 30, 16, 17, 98, 99, "." +398, 4, 1, 31, 0, 6, 100, 106, "Faster" +398, 4, 2, 32, 7, 13, 107, 113, "Aspart" +398, 4, 3, 33, 14, 20, 114, 120, "Versus" +398, 4, 4, 34, 21, 28, 121, 128, "Insulin" +398, 4, 5, 35, 29, 35, 129, 135, "Aspart" +398, 4, 6, 36, 36, 38, 136, 138, "as" +398, 4, 7, 37, 39, 43, 139, 143, "Part" +398, 4, 8, 38, 44, 46, 144, 146, "of" +398, 4, 9, 39, 47, 48, 147, 148, "a" +398, 4, 10, 40, 49, 54, 149, 154, "Basal" +398, 4, 11, 41, 55, 56, 155, 156, "-" +398, 4, 12, 42, 57, 62, 157, 162, "Bolus" +398, 4, 13, 43, 63, 70, 163, 170, "Regimen" +398, 4, 14, 44, 71, 73, 171, 173, "in" +398, 4, 15, 45, 74, 86, 174, 186, "Inadequately" +398, 4, 16, 46, 87, 97, 187, 197, "Controlled" +398, 4, 17, 47, 98, 102, 198, 202, "Type" +398, 4, 18, 48, 103, 104, 203, 204, "2" +398, 4, 19, 49, 105, 113, 205, 213, "Diabetes" +398, 4, 20, 50, 114, 115, 214, 215, ":" +398, 4, 21, 51, 116, 119, 216, 219, "The" +398, 4, 22, 52, 120, 125, 220, 225, "onset" +398, 4, 23, 53, 126, 127, 226, 227, "2" +398, 4, 24, 54, 128, 133, 228, 233, "Trial" +398, 4, 25, 55, 134, 135, 234, 235, "." +398, 5, 1, 56, 0, 8, 236, 244, "Bowering" +398, 5, 2, 57, 9, 10, 245, 246, "K" +398, 5, 3, 58, 11, 12, 247, 248, "(" +398, 5, 4, 59, 13, 14, 249, 250, "1" +398, 5, 5, 60, 15, 16, 251, 252, ")" +398, 5, 6, 61, 17, 18, 253, 254, "," +398, 5, 7, 62, 19, 23, 255, 259, "Case" +398, 5, 8, 63, 24, 25, 260, 261, "C" +398, 5, 9, 64, 26, 27, 262, 263, "(" +398, 5, 10, 65, 28, 29, 264, 265, "2" +398, 5, 11, 66, 30, 31, 266, 267, ")" +398, 5, 12, 67, 32, 33, 268, 269, "," +398, 5, 13, 68, 34, 40, 270, 276, "Harvey" +398, 5, 14, 69, 41, 42, 277, 278, "J" +398, 5, 15, 70, 43, 44, 279, 280, "(" +398, 5, 16, 71, 45, 46, 281, 282, "3" +398, 5, 17, 72, 47, 48, 283, 284, ")" +398, 5, 18, 73, 49, 50, 285, 286, "," +398, 5, 19, 74, 51, 57, 287, 293, "Reeves" +398, 5, 20, 75, 58, 59, 294, 295, "M" +398, 5, 21, 76, 60, 61, 296, 297, "(" +398, 5, 22, 77, 62, 63, 298, 299, "4" +398, 5, 23, 78, 64, 65, 300, 301, ")" +398, 5, 24, 79, 66, 67, 302, 303, "," +398, 5, 25, 80, 68, 75, 304, 311, "Sampson" +398, 5, 26, 81, 76, 77, 312, 313, "M" +398, 5, 27, 82, 78, 79, 314, 315, "(" +398, 5, 28, 83, 80, 81, 316, 317, "5" +398, 5, 29, 84, 82, 83, 318, 319, ")" +398, 5, 30, 85, 84, 85, 320, 321, "," +398, 5, 31, 86, 86, 94, 322, 330, "Strzinek" +398, 5, 32, 87, 95, 96, 331, 332, "R" +398, 5, 33, 88, 97, 98, 333, 334, "(" +398, 5, 34, 89, 99, 100, 335, 336, "6" +398, 5, 35, 90, 101, 102, 337, 338, ")" +398, 5, 36, 91, 103, 104, 339, 340, "," +398, 5, 37, 92, 105, 112, 341, 348, "Bretler" +398, 5, 38, 93, 113, 115, 349, 351, "DM" +398, 5, 39, 94, 116, 117, 352, 353, "(" +398, 5, 40, 95, 118, 119, 354, 355, "7" +398, 5, 41, 96, 120, 121, 356, 357, ")" +398, 5, 42, 97, 122, 123, 358, 359, "," +398, 5, 43, 98, 124, 128, 360, 364, "Bang" +398, 5, 44, 99, 129, 131, 365, 367, "RB" +398, 5, 45, 100, 132, 133, 368, 369, "(" +398, 5, 46, 101, 134, 135, 370, 371, "7" +398, 5, 47, 102, 136, 137, 372, 373, ")" +398, 5, 48, 103, 138, 139, 374, 375, "," +398, 5, 49, 104, 140, 144, 376, 380, "Bode" +398, 5, 50, 105, 145, 147, 381, 383, "BW" +398, 5, 51, 106, 148, 149, 384, 385, "(" +398, 5, 52, 107, 150, 151, 386, 387, "8" +398, 5, 53, 108, 152, 153, 388, 389, ")" +398, 5, 54, 109, 154, 155, 390, 391, "." +398, 6, 1, 110, 0, 6, 392, 398, "Author" +398, 6, 2, 111, 7, 18, 399, 410, "information" +398, 6, 3, 112, 19, 20, 411, 412, ":" +398, 6, 4, 113, 21, 22, 413, 414, "(" +398, 6, 5, 114, 23, 24, 415, 416, "1" +398, 6, 6, 115, 25, 26, 417, 418, ")" +398, 6, 7, 116, 27, 35, 419, 427, "Division" +398, 6, 8, 117, 36, 38, 428, 430, "of" +398, 6, 9, 118, 39, 52, 431, 444, "Endocrinology" +398, 6, 10, 119, 53, 56, 445, 448, "and" +398, 6, 11, 120, 57, 67, 449, 459, "Metabolism" +398, 6, 12, 121, 68, 69, 460, 461, "," +398, 6, 13, 122, 70, 80, 462, 472, "University" +398, 6, 14, 123, 81, 83, 473, 475, "of" +398, 6, 15, 124, 84, 91, 476, 483, "Alberta" +398, 6, 16, 125, 92, 93, 484, 485, "," +398, 6, 17, 126, 94, 102, 486, 494, "Edmonton" +398, 6, 18, 127, 103, 104, 495, 496, "," +398, 6, 19, 128, 105, 112, 497, 504, "Alberta" +398, 6, 20, 129, 113, 114, 505, 506, "," +398, 6, 21, 130, 115, 121, 507, 513, "Canada" +398, 6, 22, 131, 122, 127, 514, 519, "keith" +398, 6, 23, 132, 128, 129, 520, 521, "." +398, 6, 24, 133, 130, 138, 522, 530, "bowering" +398, 6, 25, 134, 139, 140, 531, 532, "@" +398, 6, 26, 135, 141, 149, 533, 541, "ualberta" +398, 6, 27, 136, 150, 151, 542, 543, "." +398, 6, 28, 137, 152, 154, 544, 546, "ca" +398, 6, 29, 138, 155, 156, 547, 548, "." +398, 7, 1, 139, 0, 1, 549, 550, "(" +398, 7, 2, 140, 2, 3, 551, 552, "2" +398, 7, 3, 141, 4, 5, 553, 554, ")" +398, 7, 4, 142, 6, 15, 555, 564, "Jefferson" +398, 7, 5, 143, 16, 20, 565, 569, "City" +398, 7, 6, 144, 21, 28, 570, 577, "Medical" +398, 7, 7, 145, 29, 34, 578, 583, "Group" +398, 7, 8, 146, 35, 36, 584, 585, "," +398, 7, 9, 147, 37, 46, 586, 595, "Jefferson" +398, 7, 10, 148, 47, 51, 596, 600, "City" +398, 7, 11, 149, 52, 53, 601, 602, "," +398, 7, 12, 150, 54, 56, 603, 605, "MO" +398, 7, 13, 151, 57, 58, 606, 607, "." +398, 8, 1, 152, 0, 1, 608, 609, "(" +398, 8, 2, 153, 2, 3, 610, 611, "3" +398, 8, 3, 154, 4, 5, 612, 613, ")" +398, 8, 4, 155, 6, 15, 614, 623, "Gladstone" +398, 8, 5, 156, 16, 22, 624, 630, "Centre" +398, 8, 6, 157, 23, 24, 631, 632, "," +398, 8, 7, 158, 25, 31, 633, 639, "Maelor" +398, 8, 8, 159, 32, 40, 640, 648, "Hospital" +398, 8, 9, 160, 41, 42, 649, 650, "," +398, 8, 10, 161, 43, 49, 651, 657, "Bangor" +398, 8, 11, 162, 50, 60, 658, 668, "University" +398, 8, 12, 163, 61, 62, 669, 670, "," +398, 8, 13, 164, 63, 70, 671, 678, "Wrexham" +398, 8, 14, 165, 71, 72, 679, 680, "," +398, 8, 15, 166, 73, 74, 681, 682, "U" +398, 8, 16, 167, 75, 76, 683, 684, "." +398, 8, 17, 168, 77, 78, 685, 686, "K" +398, 8, 18, 169, 79, 80, 687, 688, "." +398, 8, 19, 170, 81, 82, 689, 690, "(" +398, 8, 20, 171, 83, 84, 691, 692, "4" +398, 8, 21, 172, 85, 86, 693, 694, ")" +398, 8, 22, 173, 87, 95, 695, 703, "Diabetes" +398, 8, 23, 174, 96, 104, 704, 712, "Clinical" +398, 8, 24, 175, 105, 111, 713, 719, "Trials" +398, 8, 25, 176, 112, 113, 720, 721, "," +398, 8, 26, 177, 114, 125, 722, 733, "Chattanooga" +398, 8, 27, 178, 126, 127, 734, 735, "," +398, 8, 28, 179, 128, 130, 736, 738, "TN" +398, 8, 29, 180, 131, 132, 739, 740, "." +398, 9, 1, 181, 0, 1, 741, 742, "(" +398, 9, 2, 182, 2, 3, 743, 744, "5" +398, 9, 3, 183, 4, 5, 745, 746, ")" +398, 9, 4, 184, 6, 14, 747, 755, "Diabetes" +398, 9, 5, 185, 15, 16, 756, 757, "," +398, 9, 6, 186, 17, 30, 758, 771, "Endocrinology" +398, 9, 7, 187, 31, 34, 772, 775, "and" +398, 9, 8, 188, 35, 42, 776, 783, "General" +398, 9, 9, 189, 43, 51, 784, 792, "Medicine" +398, 9, 10, 190, 52, 53, 793, 794, "," +398, 9, 11, 191, 54, 61, 795, 802, "Norfolk" +398, 9, 12, 192, 62, 65, 803, 806, "and" +398, 9, 13, 193, 66, 73, 807, 814, "Norwich" +398, 9, 14, 194, 74, 84, 815, 825, "University" +398, 9, 15, 195, 85, 94, 826, 835, "Hospitals" +398, 9, 16, 196, 95, 98, 836, 839, "NHS" +398, 9, 17, 197, 99, 109, 840, 850, "Foundation" +398, 9, 18, 198, 110, 115, 851, 856, "Trust" +398, 9, 19, 199, 116, 117, 857, 858, "," +398, 9, 20, 200, 118, 125, 859, 866, "Norwich" +398, 9, 21, 201, 126, 127, 867, 868, "," +398, 9, 22, 202, 128, 129, 869, 870, "U" +398, 9, 23, 203, 130, 131, 871, 872, "." +398, 9, 24, 204, 132, 133, 873, 874, "K" +398, 9, 25, 205, 134, 135, 875, 876, "." +398, 9, 26, 206, 136, 137, 877, 878, "(" +398, 9, 27, 207, 138, 139, 879, 880, "6" +398, 9, 28, 208, 140, 141, 881, 882, ")" +398, 9, 29, 209, 142, 151, 883, 892, "Protenium" +398, 9, 30, 210, 152, 160, 893, 901, "Clinical" +398, 9, 31, 211, 161, 169, 902, 910, "Research" +398, 9, 32, 212, 170, 171, 911, 912, "," +398, 9, 33, 213, 172, 177, 913, 918, "Hurst" +398, 9, 34, 214, 178, 179, 919, 920, "," +398, 9, 35, 215, 180, 182, 921, 923, "TX" +398, 9, 36, 216, 183, 184, 924, 925, "." +398, 10, 1, 217, 0, 1, 926, 927, "(" +398, 10, 2, 218, 2, 3, 928, 929, "7" +398, 10, 3, 219, 4, 5, 930, 931, ")" +398, 10, 4, 220, 6, 10, 932, 936, "Novo" +398, 10, 5, 221, 11, 18, 937, 944, "Nordisk" +398, 10, 6, 222, 19, 20, 945, 946, "A" +398, 10, 7, 223, 21, 22, 947, 948, "/" +398, 10, 8, 224, 23, 24, 949, 950, "S" +398, 10, 9, 225, 25, 26, 951, 952, "," +398, 10, 10, 226, 27, 28, 953, 954, "S" +398, 10, 11, 227, 29, 30, 955, 956, "ø" +398, 10, 12, 228, 31, 35, 957, 961, "borg" +398, 10, 13, 229, 36, 37, 962, 963, "," +398, 10, 14, 230, 38, 45, 964, 971, "Denmark" +398, 10, 15, 231, 46, 47, 972, 973, "." +398, 11, 1, 232, 0, 1, 974, 975, "(" +398, 11, 2, 233, 2, 3, 976, 977, "8" +398, 11, 3, 234, 4, 5, 978, 979, ")" +398, 11, 4, 235, 6, 13, 980, 987, "Atlanta" +398, 11, 5, 236, 14, 22, 988, 996, "Diabetes" +398, 11, 6, 237, 23, 33, 997, 1007, "Associates" +398, 11, 7, 238, 34, 35, 1008, 1009, "," +398, 11, 8, 239, 36, 43, 1010, 1017, "Atlanta" +398, 11, 9, 240, 44, 45, 1018, 1019, "," +398, 11, 10, 241, 46, 48, 1020, 1022, "GA" +398, 11, 11, 242, 49, 50, 1023, 1024, "." +398, 12, 1, 243, 0, 7, 1025, 1032, "Comment" +398, 12, 2, 244, 8, 10, 1033, 1035, "in" +398, 12, 3, 245, 11, 19, 1036, 1044, "Diabetes" +398, 12, 4, 246, 20, 24, 1045, 1049, "Care" +398, 12, 5, 247, 25, 26, 1050, 1051, "." +398, 13, 1, 248, 0, 4, 1052, 1056, "2018" +398, 13, 2, 249, 5, 8, 1057, 1060, "Mar" +398, 13, 3, 250, 9, 10, 1061, 1062, ";" +398, 13, 4, 251, 11, 13, 1063, 1065, "41" +398, 13, 5, 252, 14, 15, 1066, 1067, "(" +398, 13, 6, 253, 16, 17, 1068, 1069, "3" +398, 13, 7, 254, 18, 19, 1070, 1071, ")" +398, 13, 8, 255, 20, 21, 1072, 1073, ":" +398, 13, 9, 256, 22, 25, 1074, 1077, "e27" +398, 13, 10, 257, 26, 27, 1078, 1079, "-" +398, 13, 11, 258, 28, 31, 1080, 1083, "e28" +398, 13, 12, 259, 32, 33, 1084, 1085, "." +398, 14, 1, 260, 0, 8, 1086, 1094, "Diabetes" +398, 14, 2, 261, 9, 13, 1095, 1099, "Care" +398, 14, 3, 262, 14, 15, 1100, 1101, "." +398, 15, 1, 263, 0, 4, 1102, 1106, "2018" +398, 15, 2, 264, 5, 8, 1107, 1110, "Mar" +398, 15, 3, 265, 9, 10, 1111, 1112, ";" +398, 15, 4, 266, 11, 13, 1113, 1115, "41" +398, 15, 5, 267, 14, 15, 1116, 1117, "(" +398, 15, 6, 268, 16, 17, 1118, 1119, "3" +398, 15, 7, 269, 18, 19, 1120, 1121, ")" +398, 15, 8, 270, 20, 21, 1122, 1123, ":" +398, 15, 9, 271, 22, 25, 1124, 1127, "e29" +398, 15, 10, 272, 26, 27, 1128, 1129, "-" +398, 15, 11, 273, 28, 31, 1130, 1133, "e30" +398, 15, 12, 274, 32, 33, 1134, 1135, "." +398, 16, 1, 275, 0, 9, 1136, 1145, "OBJECTIVE" +398, 16, 2, 276, 10, 11, 1146, 1147, ":" +398, 16, 3, 277, 12, 16, 1148, 1152, "This" +398, 16, 4, 278, 17, 28, 1153, 1164, "multicenter" +398, 16, 5, 279, 29, 30, 1165, 1166, "," +398, 16, 6, 280, 31, 37, 1167, 1173, "double" +398, 16, 7, 281, 38, 39, 1174, 1175, "-" +398, 16, 8, 282, 40, 45, 1176, 1181, "blind" +398, 16, 9, 283, 46, 47, 1182, 1183, "," +398, 16, 10, 284, 48, 53, 1184, 1189, "treat" +398, 16, 11, 285, 54, 55, 1190, 1191, "-" +398, 16, 12, 286, 56, 58, 1192, 1194, "to" +398, 16, 13, 287, 59, 60, 1195, 1196, "-" +398, 16, 14, 288, 61, 67, 1197, 1203, "target" +398, 16, 15, 289, 68, 69, 1204, 1205, "," +398, 16, 16, 290, 70, 75, 1206, 1211, "phase" +398, 16, 17, 291, 76, 77, 1212, 1213, "3" +398, 16, 18, 292, 78, 83, 1214, 1219, "trial" +398, 16, 19, 293, 84, 93, 1220, 1229, "evaluated" +398, 16, 20, 294, 94, 97, 1230, 1233, "the" +398, 16, 21, 295, 98, 106, 1234, 1242, "efficacy" +398, 16, 22, 296, 107, 110, 1243, 1246, "and" +398, 16, 23, 297, 111, 117, 1247, 1253, "safety" +398, 16, 24, 298, 118, 120, 1254, 1256, "of" +398, 16, 25, 299, 121, 125, 1257, 1261, "fast" +398, 16, 26, 300, 126, 127, 1262, 1263, "-" +398, 16, 27, 301, 128, 134, 1264, 1270, "acting" +398, 16, 28, 302, 135, 142, 1271, 1278, "insulin" +398, 16, 29, 303, 143, 149, 1279, 1285, "aspart" +398, 16, 30, 304, 150, 151, 1286, 1287, "(" +398, 16, 31, 305, 152, 158, 1288, 1294, "faster" +398, 16, 32, 306, 159, 165, 1295, 1301, "aspart" +398, 16, 33, 307, 166, 167, 1302, 1303, ")" +398, 16, 34, 308, 168, 174, 1304, 1310, "versus" +398, 16, 35, 309, 175, 182, 1311, 1318, "insulin" +398, 16, 36, 310, 183, 189, 1319, 1325, "aspart" +398, 16, 37, 311, 190, 191, 1326, 1327, "(" +398, 16, 38, 312, 192, 196, 1328, 1332, "IAsp" +398, 16, 39, 313, 197, 198, 1333, 1334, ")" +398, 16, 40, 314, 199, 201, 1335, 1337, "in" +398, 16, 41, 315, 202, 208, 1338, 1344, "adults" +398, 16, 42, 316, 209, 213, 1345, 1349, "with" +398, 16, 43, 317, 214, 218, 1350, 1354, "type" +398, 16, 44, 318, 219, 220, 1355, 1356, "2" +398, 16, 45, 319, 221, 229, 1357, 1365, "diabetes" +398, 16, 46, 320, 230, 239, 1366, 1375, "receiving" +398, 16, 47, 321, 240, 245, 1376, 1381, "basal" +398, 16, 48, 322, 246, 253, 1382, 1389, "insulin" +398, 16, 49, 323, 254, 257, 1390, 1393, "and" +398, 16, 50, 324, 258, 262, 1394, 1398, "oral" +398, 16, 51, 325, 263, 275, 1399, 1411, "antidiabetic" +398, 16, 52, 326, 276, 282, 1412, 1418, "agents" +398, 16, 53, 327, 283, 284, 1419, 1420, "." +398, 17, 1, 328, 0, 8, 1421, 1429, "RESEARCH" +398, 17, 2, 329, 9, 15, 1430, 1436, "DESIGN" +398, 17, 3, 330, 16, 19, 1437, 1440, "AND" +398, 17, 4, 331, 20, 27, 1441, 1448, "METHODS" +398, 17, 5, 332, 28, 29, 1449, 1450, ":" +398, 17, 6, 333, 30, 33, 1451, 1454, "The" +398, 17, 7, 334, 34, 41, 1455, 1462, "primary" +398, 17, 8, 335, 42, 45, 1463, 1466, "end" +398, 17, 9, 336, 46, 51, 1467, 1472, "point" +398, 17, 10, 337, 52, 55, 1473, 1476, "was" +398, 17, 11, 338, 56, 61, 1477, 1482, "HbA1c" +398, 17, 12, 339, 62, 68, 1483, 1489, "change" +398, 17, 13, 340, 69, 73, 1490, 1494, "from" +398, 17, 14, 341, 74, 82, 1495, 1503, "baseline" +398, 17, 15, 342, 83, 88, 1504, 1509, "after" +398, 17, 16, 343, 89, 91, 1510, 1512, "26" +398, 17, 17, 344, 92, 97, 1513, 1518, "weeks" +398, 17, 18, 345, 98, 99, 1519, 1520, "'" +398, 17, 19, 346, 100, 109, 1521, 1530, "treatment" +398, 17, 20, 347, 110, 111, 1531, 1532, "." +398, 18, 1, 348, 0, 5, 1533, 1538, "After" +398, 18, 2, 349, 6, 8, 1539, 1541, "an" +398, 18, 3, 350, 9, 10, 1542, 1543, "8" +398, 18, 4, 351, 11, 12, 1544, 1545, "-" +398, 18, 5, 352, 13, 17, 1546, 1550, "week" +398, 18, 6, 353, 18, 21, 1551, 1554, "run" +398, 18, 7, 354, 22, 23, 1555, 1556, "-" +398, 18, 8, 355, 24, 26, 1557, 1559, "in" +398, 18, 9, 356, 27, 29, 1560, 1562, "to" +398, 18, 10, 357, 30, 38, 1563, 1571, "optimize" +398, 18, 11, 358, 39, 44, 1572, 1577, "basal" +398, 18, 12, 359, 45, 52, 1578, 1585, "insulin" +398, 18, 13, 360, 53, 54, 1586, 1587, "," +398, 18, 14, 361, 55, 63, 1588, 1596, "subjects" +398, 18, 15, 362, 64, 68, 1597, 1601, "were" +398, 18, 16, 363, 69, 79, 1602, 1612, "randomized" +398, 18, 17, 364, 80, 81, 1613, 1614, "(" +398, 18, 18, 365, 82, 83, 1615, 1616, "1" +398, 18, 19, 366, 84, 85, 1617, 1618, ":" +398, 18, 20, 367, 86, 87, 1619, 1620, "1" +398, 18, 21, 368, 88, 89, 1621, 1622, ")" +398, 18, 22, 369, 90, 92, 1623, 1625, "to" +398, 18, 23, 370, 93, 101, 1626, 1634, "mealtime" +398, 18, 24, 371, 102, 108, 1635, 1641, "faster" +398, 18, 25, 372, 109, 115, 1642, 1648, "aspart" +398, 18, 26, 373, 116, 117, 1649, 1650, "(" +398, 18, 27, 374, 118, 119, 1651, 1652, "n" +398, 18, 28, 375, 120, 121, 1653, 1654, "=" +398, 18, 29, 376, 122, 125, 1655, 1658, "345" +398, 18, 30, 377, 126, 127, 1659, 1660, ")" +398, 18, 31, 378, 128, 130, 1661, 1663, "or" +398, 18, 32, 379, 131, 135, 1664, 1668, "IAsp" +398, 18, 33, 380, 136, 137, 1669, 1670, "(" +398, 18, 34, 381, 138, 139, 1671, 1672, "n" +398, 18, 35, 382, 140, 141, 1673, 1674, "=" +398, 18, 36, 383, 142, 145, 1675, 1678, "344" +398, 18, 37, 384, 146, 147, 1679, 1680, ")" +398, 18, 38, 385, 148, 149, 1681, 1682, "," +398, 18, 39, 386, 150, 158, 1683, 1691, "titrated" +398, 18, 40, 387, 159, 164, 1692, 1697, "using" +398, 18, 41, 388, 165, 166, 1698, 1699, "a" +398, 18, 42, 389, 167, 173, 1700, 1706, "simple" +398, 18, 43, 390, 174, 179, 1707, 1712, "daily" +398, 18, 44, 391, 180, 187, 1713, 1720, "patient" +398, 18, 45, 392, 188, 189, 1721, 1722, "-" +398, 18, 46, 393, 190, 196, 1723, 1729, "driven" +398, 18, 47, 394, 197, 206, 1730, 1739, "algorithm" +398, 18, 48, 395, 207, 208, 1740, 1741, "," +398, 18, 49, 396, 209, 213, 1742, 1746, "plus" +398, 18, 50, 397, 214, 221, 1747, 1754, "insulin" +398, 18, 51, 398, 222, 230, 1755, 1763, "glargine" +398, 18, 52, 399, 231, 235, 1764, 1768, "U100" +398, 18, 53, 400, 236, 239, 1769, 1772, "and" +398, 18, 54, 401, 240, 249, 1773, 1782, "metformin" +398, 18, 55, 402, 250, 251, 1783, 1784, "." +398, 19, 1, 403, 0, 7, 1785, 1792, "RESULTS" +398, 19, 2, 404, 8, 9, 1793, 1794, ":" +398, 19, 3, 405, 10, 15, 1795, 1800, "HbA1c" +398, 19, 4, 406, 16, 22, 1801, 1807, "change" +398, 19, 5, 407, 23, 26, 1808, 1811, "was" +398, 19, 6, 408, 27, 28, 1812, 1813, "-" +398, 19, 7, 409, 29, 30, 1814, 1815, "1" +398, 19, 8, 410, 31, 32, 1816, 1817, "." +398, 19, 9, 411, 33, 35, 1818, 1820, "38" +398, 19, 10, 412, 36, 37, 1821, 1822, "%" +398, 19, 11, 413, 38, 39, 1823, 1824, "(" +398, 19, 12, 414, 40, 46, 1825, 1831, "faster" +398, 19, 13, 415, 47, 53, 1832, 1838, "aspart" +398, 19, 14, 416, 54, 55, 1839, 1840, ")" +398, 19, 15, 417, 56, 59, 1841, 1844, "and" +398, 19, 16, 418, 60, 61, 1845, 1846, "-" +398, 19, 17, 419, 62, 63, 1847, 1848, "1" +398, 19, 18, 420, 64, 65, 1849, 1850, "." +398, 19, 19, 421, 66, 68, 1851, 1853, "36" +398, 19, 20, 422, 69, 70, 1854, 1855, "%" +398, 19, 21, 423, 71, 72, 1856, 1857, "(" +398, 19, 22, 424, 73, 77, 1858, 1862, "IAsp" +398, 19, 23, 425, 78, 79, 1863, 1864, ")" +398, 19, 24, 426, 80, 81, 1865, 1866, ";" +398, 19, 25, 427, 82, 86, 1867, 1871, "mean" +398, 19, 26, 428, 87, 92, 1872, 1877, "HbA1c" +398, 19, 27, 429, 93, 96, 1878, 1881, "was" +398, 19, 28, 430, 97, 98, 1882, 1883, "6" +398, 19, 29, 431, 99, 100, 1884, 1885, "." +398, 19, 30, 432, 101, 102, 1886, 1887, "6" +398, 19, 31, 433, 103, 104, 1888, 1889, "%" +398, 19, 32, 434, 105, 108, 1890, 1893, "for" +398, 19, 33, 435, 109, 113, 1894, 1898, "both" +398, 19, 34, 436, 114, 120, 1899, 1905, "groups" +398, 19, 35, 437, 121, 122, 1906, 1907, "." +398, 20, 1, 438, 0, 6, 1908, 1914, "Faster" +398, 20, 2, 439, 7, 13, 1915, 1921, "aspart" +398, 20, 3, 440, 14, 26, 1922, 1934, "demonstrated" +398, 20, 4, 441, 27, 41, 1935, 1949, "noninferiority" +398, 20, 5, 442, 42, 48, 1950, 1956, "versus" +398, 20, 6, 443, 49, 53, 1957, 1961, "IAsp" +398, 20, 7, 444, 54, 56, 1962, 1964, "in" +398, 20, 8, 445, 57, 65, 1965, 1973, "reducing" +398, 20, 9, 446, 66, 71, 1974, 1979, "HbA1c" +398, 20, 10, 447, 72, 73, 1980, 1981, "(" +398, 20, 11, 448, 74, 83, 1982, 1991, "estimated" +398, 20, 12, 449, 84, 93, 1992, 2001, "treatment" +398, 20, 13, 450, 94, 104, 2002, 2012, "difference" +398, 20, 14, 451, 105, 106, 2013, 2014, "[" +398, 20, 15, 452, 107, 110, 2015, 2018, "ETD" +398, 20, 16, 453, 111, 112, 2019, 2020, "]" +398, 20, 17, 454, 113, 114, 2021, 2022, "[" +398, 20, 18, 455, 115, 117, 2023, 2025, "95" +398, 20, 19, 456, 118, 119, 2026, 2027, "%" +398, 20, 20, 457, 120, 122, 2028, 2030, "CI" +398, 20, 21, 458, 123, 124, 2031, 2032, "]" +398, 20, 22, 459, 125, 126, 2033, 2034, "-" +398, 20, 23, 460, 127, 128, 2035, 2036, "0" +398, 20, 24, 461, 129, 130, 2037, 2038, "." +398, 20, 25, 462, 131, 133, 2039, 2041, "02" +398, 20, 26, 463, 134, 135, 2042, 2043, "%" +398, 20, 27, 464, 136, 137, 2044, 2045, "[" +398, 20, 28, 465, 138, 139, 2046, 2047, "-" +398, 20, 29, 466, 140, 141, 2048, 2049, "0" +398, 20, 30, 467, 142, 143, 2050, 2051, "." +398, 20, 31, 468, 144, 146, 2052, 2054, "15" +398, 20, 32, 469, 147, 148, 2055, 2056, ";" +398, 20, 33, 470, 149, 150, 2057, 2058, "0" +398, 20, 34, 471, 151, 152, 2059, 2060, "." +398, 20, 35, 472, 153, 155, 2061, 2063, "10" +398, 20, 36, 473, 156, 157, 2064, 2065, "]" +398, 20, 37, 474, 158, 159, 2066, 2067, ")" +398, 20, 38, 475, 160, 161, 2068, 2069, "." +398, 21, 1, 476, 0, 4, 2070, 2074, "Both" +398, 21, 2, 477, 5, 15, 2075, 2085, "treatments" +398, 21, 3, 478, 16, 24, 2086, 2094, "improved" +398, 21, 4, 479, 25, 37, 2095, 2107, "postprandial" +398, 21, 5, 480, 38, 44, 2108, 2114, "plasma" +398, 21, 6, 481, 45, 52, 2115, 2122, "glucose" +398, 21, 7, 482, 53, 54, 2123, 2124, "(" +398, 21, 8, 483, 55, 58, 2125, 2128, "PPG" +398, 21, 9, 484, 59, 60, 2129, 2130, ")" +398, 21, 10, 485, 61, 68, 2131, 2138, "control" +398, 21, 11, 486, 69, 70, 2139, 2140, ";" +398, 21, 12, 487, 71, 74, 2141, 2144, "the" +398, 21, 13, 488, 75, 78, 2145, 2148, "PPG" +398, 21, 14, 489, 79, 88, 2149, 2158, "increment" +398, 21, 15, 490, 89, 90, 2159, 2160, "(" +398, 21, 16, 491, 91, 97, 2161, 2167, "liquid" +398, 21, 17, 492, 98, 102, 2168, 2172, "meal" +398, 21, 18, 493, 103, 107, 2173, 2177, "test" +398, 21, 19, 494, 108, 109, 2178, 2179, ")" +398, 21, 20, 495, 110, 113, 2180, 2183, "was" +398, 21, 21, 496, 114, 127, 2184, 2197, "statistically" +398, 21, 22, 497, 128, 139, 2198, 2209, "significant" +398, 21, 23, 498, 140, 142, 2210, 2212, "in" +398, 21, 24, 499, 143, 148, 2213, 2218, "favor" +398, 21, 25, 500, 149, 151, 2219, 2221, "of" +398, 21, 26, 501, 152, 158, 2222, 2228, "faster" +398, 21, 27, 502, 159, 165, 2229, 2235, "aspart" +398, 21, 28, 503, 166, 171, 2236, 2241, "after" +398, 21, 29, 504, 172, 173, 2242, 2243, "1" +398, 21, 30, 505, 174, 175, 2244, 2245, "h" +398, 21, 31, 506, 176, 177, 2246, 2247, "(" +398, 21, 32, 507, 178, 181, 2248, 2251, "ETD" +398, 21, 33, 508, 182, 183, 2252, 2253, "[" +398, 21, 34, 509, 184, 186, 2254, 2256, "95" +398, 21, 35, 510, 187, 188, 2257, 2258, "%" +398, 21, 36, 511, 189, 191, 2259, 2261, "CI" +398, 21, 37, 512, 192, 193, 2262, 2263, "]" +398, 21, 38, 513, 194, 195, 2264, 2265, "-" +398, 21, 39, 514, 196, 197, 2266, 2267, "0" +398, 21, 40, 515, 198, 199, 2268, 2269, "." +398, 21, 41, 516, 200, 202, 2270, 2272, "59" +398, 21, 42, 517, 203, 207, 2273, 2277, "mmol" +398, 21, 43, 518, 208, 209, 2278, 2279, "/" +398, 21, 44, 519, 210, 211, 2280, 2281, "L" +398, 21, 45, 520, 212, 213, 2282, 2283, "[" +398, 21, 46, 521, 214, 215, 2284, 2285, "-" +398, 21, 47, 522, 216, 217, 2286, 2287, "1" +398, 21, 48, 523, 218, 219, 2288, 2289, "." +398, 21, 49, 524, 220, 222, 2290, 2292, "09" +398, 21, 50, 525, 223, 224, 2293, 2294, ";" +398, 21, 51, 526, 225, 226, 2295, 2296, "-" +398, 21, 52, 527, 227, 228, 2297, 2298, "0" +398, 21, 53, 528, 229, 230, 2299, 2300, "." +398, 21, 54, 529, 231, 233, 2301, 2303, "09" +398, 21, 55, 530, 234, 235, 2304, 2305, "]" +398, 21, 56, 531, 236, 237, 2306, 2307, ";" +398, 21, 57, 532, 238, 239, 2308, 2309, "-" +398, 21, 58, 533, 240, 242, 2310, 2312, "10" +398, 21, 59, 534, 243, 244, 2313, 2314, "." +398, 21, 60, 535, 245, 247, 2315, 2317, "63" +398, 21, 61, 536, 248, 250, 2318, 2320, "mg" +398, 21, 62, 537, 251, 252, 2321, 2322, "/" +398, 21, 63, 538, 253, 255, 2323, 2325, "dL" +398, 21, 64, 539, 256, 257, 2326, 2327, "[" +398, 21, 65, 540, 258, 259, 2328, 2329, "-" +398, 21, 66, 541, 260, 262, 2330, 2332, "19" +398, 21, 67, 542, 263, 264, 2333, 2334, "." +398, 21, 68, 543, 265, 267, 2335, 2337, "56" +398, 21, 69, 544, 268, 269, 2338, 2339, ";" +398, 21, 70, 545, 270, 271, 2340, 2341, "-" +398, 21, 71, 546, 272, 273, 2342, 2343, "1" +398, 21, 72, 547, 274, 275, 2344, 2345, "." +398, 21, 73, 548, 276, 278, 2346, 2348, "69" +398, 21, 74, 549, 279, 280, 2349, 2350, "]" +398, 21, 75, 550, 281, 282, 2351, 2352, ";" +398, 21, 76, 551, 283, 284, 2353, 2354, "P" +398, 21, 77, 552, 285, 286, 2355, 2356, "=" +398, 21, 78, 553, 287, 288, 2357, 2358, "0" +398, 21, 79, 554, 289, 290, 2359, 2360, "." +398, 21, 80, 555, 291, 295, 2361, 2365, "0198" +398, 21, 81, 556, 296, 297, 2366, 2367, ")" +398, 21, 82, 557, 298, 299, 2368, 2369, "," +398, 21, 83, 558, 300, 303, 2370, 2373, "but" +398, 21, 84, 559, 304, 307, 2374, 2377, "not" +398, 21, 85, 560, 308, 313, 2378, 2383, "after" +398, 21, 86, 561, 314, 315, 2384, 2385, "2" +398, 21, 87, 562, 316, 317, 2386, 2387, "-" +398, 21, 88, 563, 318, 319, 2388, 2389, "4" +398, 21, 89, 564, 320, 321, 2390, 2391, "h" +398, 21, 90, 565, 322, 323, 2392, 2393, "." +398, 21, 91, 566, 324, 330, 2394, 2400, "Change" +398, 21, 92, 567, 331, 335, 2401, 2405, "from" +398, 21, 93, 568, 336, 344, 2406, 2414, "baseline" +398, 21, 94, 569, 345, 347, 2415, 2417, "in" +398, 21, 95, 570, 348, 355, 2418, 2425, "fasting" +398, 21, 96, 571, 356, 362, 2426, 2432, "plasma" +398, 21, 97, 572, 363, 370, 2433, 2440, "glucose" +398, 21, 98, 573, 371, 372, 2441, 2442, "," +398, 21, 99, 574, 373, 377, 2443, 2447, "body" +398, 21, 100, 575, 378, 384, 2448, 2454, "weight" +398, 21, 101, 576, 385, 386, 2455, 2456, "," +398, 21, 102, 577, 387, 390, 2457, 2460, "and" +398, 21, 103, 578, 391, 398, 2461, 2468, "overall" +398, 21, 104, 579, 399, 405, 2469, 2475, "severe" +398, 21, 105, 580, 406, 407, 2476, 2477, "/" +398, 21, 106, 581, 408, 413, 2478, 2483, "blood" +398, 21, 107, 582, 414, 421, 2484, 2491, "glucose" +398, 21, 108, 583, 422, 423, 2492, 2493, "-" +398, 21, 109, 584, 424, 433, 2494, 2503, "confirmed" +398, 21, 110, 585, 434, 446, 2504, 2516, "hypoglycemia" +398, 21, 111, 586, 447, 452, 2517, 2522, "rates" +398, 21, 112, 587, 453, 454, 2523, 2524, "(" +398, 21, 113, 588, 455, 459, 2525, 2529, "rate" +398, 21, 114, 589, 460, 465, 2530, 2535, "ratio" +398, 21, 115, 590, 466, 467, 2536, 2537, "[" +398, 21, 116, 591, 468, 470, 2538, 2540, "RR" +398, 21, 117, 592, 471, 472, 2541, 2542, "]" +398, 21, 118, 593, 473, 474, 2543, 2544, "[" +398, 21, 119, 594, 475, 477, 2545, 2547, "95" +398, 21, 120, 595, 478, 479, 2548, 2549, "%" +398, 21, 121, 596, 480, 482, 2550, 2552, "CI" +398, 21, 122, 597, 483, 484, 2553, 2554, "]" +398, 21, 123, 598, 485, 486, 2555, 2556, "1" +398, 21, 124, 599, 487, 488, 2557, 2558, "." +398, 21, 125, 600, 489, 491, 2559, 2561, "09" +398, 21, 126, 601, 492, 493, 2562, 2563, "[" +398, 21, 127, 602, 494, 495, 2564, 2565, "0" +398, 21, 128, 603, 496, 497, 2566, 2567, "." +398, 21, 129, 604, 498, 500, 2568, 2570, "88" +398, 21, 130, 605, 501, 502, 2571, 2572, ";" +398, 21, 131, 606, 503, 504, 2573, 2574, "1" +398, 21, 132, 607, 505, 506, 2575, 2576, "." +398, 21, 133, 608, 507, 509, 2577, 2579, "36" +398, 21, 134, 609, 510, 511, 2580, 2581, "]" +398, 21, 135, 610, 512, 513, 2582, 2583, ")" +398, 21, 136, 611, 514, 518, 2584, 2588, "were" +398, 21, 137, 612, 519, 526, 2589, 2596, "similar" +398, 21, 138, 613, 527, 534, 2597, 2604, "between" +398, 21, 139, 614, 535, 545, 2605, 2615, "treatments" +398, 21, 140, 615, 546, 547, 2616, 2617, "." +398, 22, 1, 616, 0, 8, 2618, 2626, "Postmeal" +398, 22, 2, 617, 9, 21, 2627, 2639, "hypoglycemia" +398, 22, 3, 618, 22, 23, 2640, 2641, "(" +398, 22, 4, 619, 24, 25, 2642, 2643, "0" +398, 22, 5, 620, 26, 27, 2644, 2645, "-" +398, 22, 6, 621, 28, 29, 2646, 2647, "2" +398, 22, 7, 622, 30, 31, 2648, 2649, "h" +398, 22, 8, 623, 32, 33, 2650, 2651, ")" +398, 22, 9, 624, 34, 39, 2652, 2657, "rates" +398, 22, 10, 625, 40, 44, 2658, 2662, "were" +398, 22, 11, 626, 45, 46, 2663, 2664, "2" +398, 22, 12, 627, 47, 48, 2665, 2666, "." +398, 22, 13, 628, 49, 51, 2667, 2669, "27" +398, 22, 14, 629, 52, 53, 2670, 2671, "(" +398, 22, 15, 630, 54, 60, 2672, 2678, "faster" +398, 22, 16, 631, 61, 67, 2679, 2685, "aspart" +398, 22, 17, 632, 68, 69, 2686, 2687, ")" +398, 22, 18, 633, 70, 73, 2688, 2691, "and" +398, 22, 19, 634, 74, 75, 2692, 2693, "1" +398, 22, 20, 635, 76, 77, 2694, 2695, "." +398, 22, 21, 636, 78, 80, 2696, 2698, "49" +398, 22, 22, 637, 81, 82, 2699, 2700, "(" +398, 22, 23, 638, 83, 87, 2701, 2705, "IAsp" +398, 22, 24, 639, 88, 89, 2706, 2707, ")" +398, 22, 25, 640, 90, 93, 2708, 2711, "per" +398, 22, 26, 641, 94, 101, 2712, 2719, "patient" +398, 22, 27, 642, 102, 103, 2720, 2721, "-" +398, 22, 28, 643, 104, 108, 2722, 2726, "year" +398, 22, 29, 644, 109, 111, 2727, 2729, "of" +398, 22, 30, 645, 112, 120, 2730, 2738, "exposure" +398, 22, 31, 646, 121, 122, 2739, 2740, "(" +398, 22, 32, 647, 123, 125, 2741, 2743, "RR" +398, 22, 33, 648, 126, 127, 2744, 2745, "[" +398, 22, 34, 649, 128, 130, 2746, 2748, "95" +398, 22, 35, 650, 131, 132, 2749, 2750, "%" +398, 22, 36, 651, 133, 135, 2751, 2753, "CI" +398, 22, 37, 652, 136, 137, 2754, 2755, "]" +398, 22, 38, 653, 138, 139, 2756, 2757, "1" +398, 22, 39, 654, 140, 141, 2758, 2759, "." +398, 22, 40, 655, 142, 144, 2760, 2762, "60" +398, 22, 41, 656, 145, 146, 2763, 2764, "[" +398, 22, 42, 657, 147, 148, 2765, 2766, "1" +398, 22, 43, 658, 149, 150, 2767, 2768, "." +398, 22, 44, 659, 151, 153, 2769, 2771, "13" +398, 22, 45, 660, 154, 155, 2772, 2773, ";" +398, 22, 46, 661, 156, 157, 2774, 2775, "2" +398, 22, 47, 662, 158, 159, 2776, 2777, "." +398, 22, 48, 663, 160, 162, 2778, 2780, "27" +398, 22, 49, 664, 163, 164, 2781, 2782, "]" +398, 22, 50, 665, 165, 166, 2783, 2784, ")" +398, 22, 51, 666, 167, 168, 2785, 2786, "." +398, 23, 1, 667, 0, 11, 2787, 2798, "CONCLUSIONS" +398, 23, 2, 668, 12, 13, 2799, 2800, ":" +398, 23, 3, 669, 14, 20, 2801, 2807, "Faster" +398, 23, 4, 670, 21, 27, 2808, 2814, "aspart" +398, 23, 5, 671, 28, 31, 2815, 2818, "and" +398, 23, 6, 672, 32, 36, 2819, 2823, "IAsp" +398, 23, 7, 673, 37, 41, 2824, 2828, "were" +398, 23, 8, 674, 42, 51, 2829, 2838, "confirmed" +398, 23, 9, 675, 52, 63, 2839, 2850, "noninferior" +398, 23, 10, 676, 64, 66, 2851, 2853, "in" +398, 23, 11, 677, 67, 68, 2854, 2855, "a" +398, 23, 12, 678, 69, 74, 2856, 2861, "basal" +398, 23, 13, 679, 75, 76, 2862, 2863, "-" +398, 23, 14, 680, 77, 82, 2864, 2869, "bolus" +398, 23, 15, 681, 83, 90, 2870, 2877, "regimen" +398, 23, 16, 682, 91, 100, 2878, 2887, "regarding" +398, 23, 17, 683, 101, 107, 2888, 2894, "change" +398, 23, 18, 684, 108, 112, 2895, 2899, "from" +398, 23, 19, 685, 113, 121, 2900, 2908, "baseline" +398, 23, 20, 686, 122, 124, 2909, 2911, "in" +398, 23, 21, 687, 125, 130, 2912, 2917, "HbA1c" +398, 23, 22, 688, 131, 132, 2918, 2919, "." +398, 24, 1, 689, 0, 6, 2920, 2926, "Faster" +398, 24, 2, 690, 7, 13, 2927, 2933, "aspart" +398, 24, 3, 691, 14, 22, 2934, 2942, "improved" +398, 24, 4, 692, 23, 24, 2943, 2944, "1" +398, 24, 5, 693, 25, 26, 2945, 2946, "-" +398, 24, 6, 694, 27, 28, 2947, 2948, "h" +398, 24, 7, 695, 29, 32, 2949, 2952, "PPG" +398, 24, 8, 696, 33, 37, 2953, 2957, "with" +398, 24, 9, 697, 38, 40, 2958, 2960, "no" +398, 24, 10, 698, 41, 52, 2961, 2972, "differences" +398, 24, 11, 699, 53, 55, 2973, 2975, "in" +398, 24, 12, 700, 56, 57, 2976, 2977, "2" +398, 24, 13, 701, 58, 59, 2978, 2979, "-" +398, 24, 14, 702, 60, 61, 2980, 2981, "4" +398, 24, 15, 703, 62, 63, 2982, 2983, "-" +398, 24, 16, 704, 64, 65, 2984, 2985, "h" +398, 24, 17, 705, 66, 69, 2986, 2989, "PPG" +398, 24, 18, 706, 70, 76, 2990, 2996, "versus" +398, 24, 19, 707, 77, 81, 2997, 3001, "IAsp" +398, 24, 20, 708, 82, 83, 3002, 3003, "." +398, 25, 1, 709, 0, 7, 3004, 3011, "Overall" +398, 25, 2, 710, 8, 20, 3012, 3024, "hypoglycemia" +398, 25, 3, 711, 21, 26, 3025, 3030, "rates" +398, 25, 4, 712, 27, 31, 3031, 3035, "were" +398, 25, 5, 713, 32, 39, 3036, 3043, "similar" +398, 25, 6, 714, 40, 46, 3044, 3050, "except" +398, 25, 7, 715, 47, 50, 3051, 3054, "for" +398, 25, 8, 716, 51, 53, 3055, 3057, "an" +398, 25, 9, 717, 54, 62, 3058, 3066, "increase" +398, 25, 10, 718, 63, 65, 3067, 3069, "in" +398, 25, 11, 719, 66, 67, 3070, 3071, "0" +398, 25, 12, 720, 68, 69, 3072, 3073, "-" +398, 25, 13, 721, 70, 71, 3074, 3075, "2" +398, 25, 14, 722, 72, 73, 3076, 3077, "-" +398, 25, 15, 723, 74, 75, 3078, 3079, "h" +398, 25, 16, 724, 76, 84, 3080, 3088, "postmeal" +398, 25, 17, 725, 85, 97, 3089, 3101, "hypoglycemia" +398, 25, 18, 726, 98, 102, 3102, 3106, "with" +398, 25, 19, 727, 103, 109, 3107, 3113, "faster" +398, 25, 20, 728, 110, 116, 3114, 3120, "aspart" +398, 25, 21, 729, 117, 118, 3121, 3122, "." +398, 26, 1, 730, 0, 1, 3123, 3124, "©" +398, 26, 2, 731, 2, 6, 3125, 3129, "2017" +398, 26, 3, 732, 7, 9, 3130, 3132, "by" +398, 26, 4, 733, 10, 13, 3133, 3136, "the" +398, 26, 5, 734, 14, 22, 3137, 3145, "American" +398, 26, 6, 735, 23, 31, 3146, 3154, "Diabetes" +398, 26, 7, 736, 32, 43, 3155, 3166, "Association" +398, 26, 8, 737, 44, 45, 3167, 3168, "." +398, 27, 1, 738, 0, 3, 3169, 3172, "DOI" +398, 27, 2, 739, 4, 5, 3173, 3174, ":" +398, 27, 3, 740, 6, 8, 3175, 3177, "10" +398, 27, 4, 741, 9, 10, 3178, 3179, "." +398, 27, 5, 742, 11, 15, 3180, 3184, "2337" +398, 27, 6, 743, 16, 17, 3185, 3186, "/" +398, 27, 7, 744, 18, 22, 3187, 3191, "dc16" +398, 27, 8, 745, 23, 24, 3192, 3193, "-" +398, 27, 9, 746, 25, 29, 3194, 3198, "1770" +398, 27, 10, 747, 30, 34, 3199, 3203, "PMID" +398, 27, 11, 748, 35, 36, 3204, 3205, ":" +398, 27, 12, 749, 37, 45, 3206, 3214, "28483786" +398, 27, 13, 750, 46, 47, 3215, 3216, "[" +398, 27, 14, 751, 48, 55, 3217, 3224, "Indexed" +398, 27, 15, 752, 56, 59, 3225, 3228, "for" +398, 27, 16, 753, 60, 67, 3229, 3236, "MEDLINE" +398, 27, 17, 754, 68, 69, 3237, 3238, "]" diff --git a/data/dm2 28483786_kwoodley.annodb b/data/dm2 28483786_kwoodley.annodb new file mode 100644 index 0000000..407d245 --- /dev/null +++ b/data/dm2 28483786_kwoodley.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71659, Journal, 0, 13, "Diabetes Care", "", +71660, PublicationYear, 16, 20, "2017", "", +71681, Title, 100, 235, "Faster Aspart Versus Insulin Aspart as Part of a Basal - Bolus Regimen in Inadequately Controlled Type 2 Diabetes : The onset 2 Trial .", "", +71661, InsulinAspart, 100, 113, "Faster Aspart", "", +71677, InsulinAspart, 121, 135, "Insulin Aspart", "", +71680, Precondition, 174, 213, "Inadequately Controlled Type 2 Diabetes", "", +71678, Type2Diabetes, 198, 213, "Type 2 Diabetes", "", +71682, Author, 236, 246, "Bowering K", "", +71683, Author, 255, 261, "Case C", "", +71684, Author, 270, 278, "Harvey J", "", +71685, Author, 287, 295, "Reeves M", "", +71686, Author, 304, 313, "Sampson M", "", +71687, Author, 322, 332, "Strzinek R", "", +71688, Author, 341, 351, "Bretler DM", "", +71689, Author, 360, 367, "Bang RB", "", +71690, Author, 376, 383, "Bode BW", "", +71691, Canada, 507, 513, "Canada", "", +71696, USA, 603, 605, "MO", "", +71695, USA, 736, 738, "TN", "", +71692, USA, 921, 923, "TX", "", +71694, Country, 964, 971, "Denmark", "", +71693, USA, 1020, 1022, "GA", "", +71703, ObjectiveDescription, 1148, 1334, "This multicenter , double - blind , treat - to - target , phase 3 trial evaluated the efficacy and safety of fast - acting insulin aspart ( faster aspart ) versus insulin aspart ( IAsp )", "", +71697, Multicenter, 1153, 1164, "multicenter", "", +71698, DoubleBlind, 1167, 1181, "double - blind", "", +71699, CTDesign, 1184, 1203, "treat - to - target", "", +71662, InsulinAspart, 1271, 1285, "insulin aspart", "", +71663, InsulinAspart, 1288, 1301, "faster aspart", "", +71664, InsulinAspart, 1311, 1325, "insulin aspart", "", +71665, InsulinAspart, 1328, 1332, "IAsp", "", +71704, ObjectiveDescription, 1335, 1420, "in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents .", "", +71702, Precondition, 1338, 1418, "adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents", "", +71679, Type2Diabetes, 1350, 1365, "type 2 diabetes", "", +71700, Insulin, 1382, 1389, "insulin", "", +71701, OralAntidiabeticAgent, 1394, 1418, "oral antidiabetic agents", "", +71705, HbA1c, 1477, 1482, "HbA1c", "", +71709, TimePoint, 1495, 1503, "baseline", "", +71710, TimePoint, 1510, 1518, "26 weeks", "", +71722, DoseDescription, 1533, 1784, "After an 8 - week run - in to optimize basal insulin , subjects were randomized ( 1 : 1 ) to mealtime faster aspart ( n = 345 ) or IAsp ( n = 344 ) , titrated using a simple daily patient - driven algorithm , plus insulin glargine U100 and metformin .", "", +71713, Insulin, 1578, 1585, "insulin", "", +71714, Randomized, 1602, 1612, "randomized", "", +71715, AllocationRatio, 1615, 1620, "1 : 1", "", +71716, RelativeTime, 1626, 1634, "mealtime", "", +71666, InsulinAspart, 1635, 1648, "faster aspart", "", +71717, NumberPatientsArm, 1655, 1658, "345", "", +71719, InsulinAspart, 1664, 1668, "IAsp", "", +71718, NumberPatientsArm, 1675, 1678, "344", "", +71720, InsulinGlargine, 1747, 1763, "insulin glargine", "", +71721, Metformin, 1773, 1782, "metformin", "", +71706, HbA1c, 1795, 1800, "HbA1c", "", +71725, Reduction, 1814, 1820, "1 . 38", "", +71727, Percentage, 1821, 1822, "%", "", +71723, InsulinAspart, 1825, 1838, "faster aspart", "", +71726, Reduction, 1847, 1853, "1 . 36", "", +71728, Percentage, 1854, 1855, "%", "", +71724, InsulinAspart, 1858, 1862, "IAsp", "", +71707, HbA1c, 1872, 1877, "HbA1c", "", +71729, ResultMeasuredValue, 1882, 1887, "6 . 6", "", +71730, Percentage, 1888, 1889, "%", "", +71667, InsulinAspart, 1908, 1921, "Faster aspart", "", +71668, InsulinAspart, 1957, 1961, "IAsp", "", +71708, HbA1c, 1974, 1979, "HbA1c", "", +71732, ConfIntervalDiff, 1982, 2065, "estimated treatment difference [ ETD ] [ 95 % CI ] - 0 . 02 % [ - 0 . 15 ; 0 . 10 ]", "", +71731, Percentage, 2042, 2043, "%", "", +71733, PostprandialPlasmaGlucose, 2095, 2122, "postprandial plasma glucose", "", +71734, PostprandialPlasmaGlucose, 2125, 2128, "PPG", "", +71735, PostprandialPlasmaGlucose, 2145, 2148, "PPG", "", +71745, Increment, 2149, 2158, "increment", "", +71738, ObservedResult, 2180, 2235, "was statistically significant in favor of faster aspart", "", +71669, InsulinAspart, 2222, 2235, "faster aspart", "", +71736, SubGroupDescription, 2236, 2245, "after 1 h", "", +71742, ConfIntervalDiff, 2248, 2263, "ETD [ 95 % CI ]", "", +71744, DiffGroupAbsValue, 2264, 2272, "- 0 . 59", "", +71746, Millimoles_per_litre, 2273, 2281, "mmol / L", "", +71747, ConfIntervalDiff, 2284, 2303, "- 1 . 09 ; - 0 . 09", "", +71748, DiffGroupAbsValue, 2308, 2317, "- 10 . 63", "", +71749, Mg_per_deciliter, 2318, 2325, "mg / dL", "", +71743, ConfIntervalDiff, 2328, 2348, "- 19 . 56 ; - 1 . 69", "", +71750, PvalueDiff, 2353, 2365, "P = 0 . 0198", "", +71739, ObservedResult, 2370, 2377, "but not", "", +71737, SubGroupDescription, 2378, 2391, "after 2 - 4 h", "", +71751, TimePoint, 2406, 2414, "baseline", "", +71752, FastingPlasmaGlucose, 2418, 2440, "fasting plasma glucose", "", +71753, BodyWeight, 2443, 2454, "body weight", "", +71754, SevereHypoglycemia, 2461, 2516, "overall severe / blood glucose - confirmed hypoglycemia", "", +71755, ConfIntervalDiff, 2525, 2581, "rate ratio [ RR ] [ 95 % CI ] 1 . 09 [ 0 . 88 ; 1 . 36 ]", "", +71756, ObservedResult, 2584, 2615, "were similar between treatments", "", +71759, SubGroupDescription, 2618, 2651, "Postmeal hypoglycemia ( 0 - 2 h )", "", +71757, Hypoglycemia, 2627, 2639, "hypoglycemia", "", +71760, ResultMeasuredValue, 2663, 2669, "2 . 27", "", +71670, InsulinAspart, 2672, 2685, "faster aspart", "", +71761, ResultMeasuredValue, 2692, 2698, "1 . 49", "", +71671, InsulinAspart, 2701, 2705, "IAsp", "", +71762, BioAndMedicalUnit, 2712, 2738, "patient - year of exposure", "", +71763, ConfIntervalDiff, 2741, 2782, "RR [ 95 % CI ] 1 . 60 [ 1 . 13 ; 2 . 27 ]", "", +71771, ConclusionComment, 2801, 2919, "Faster aspart and IAsp were confirmed noninferior in a basal - bolus regimen regarding change from baseline in HbA1c .", "", +71672, InsulinAspart, 2801, 2814, "Faster aspart", "", +71673, InsulinAspart, 2819, 2823, "IAsp", "", +71711, TimePoint, 2900, 2908, "baseline", "", +71712, HbA1c, 2912, 2917, "HbA1c", "", +71772, ConclusionComment, 2920, 3003, "Faster aspart improved 1 - h PPG with no differences in 2 - 4 - h PPG versus IAsp .", "", +71674, InsulinAspart, 2920, 2933, "Faster aspart", "", +71766, SubGroupDescription, 2943, 2952, "1 - h PPG", "", +71764, PostprandialPlasmaGlucose, 2949, 2952, "PPG", "", +71767, SubGroupDescription, 2976, 2989, "2 - 4 - h PPG", "", +71765, PostprandialPlasmaGlucose, 2986, 2989, "PPG", "", +71675, InsulinAspart, 2997, 3001, "IAsp", "", +71773, ConclusionComment, 3004, 3122, "Overall hypoglycemia rates were similar except for an increase in 0 - 2 - h postmeal hypoglycemia with faster aspart .", "", +71768, Hypoglycemia, 3012, 3024, "hypoglycemia", "", +71770, SubGroupDescription, 3070, 3101, "0 - 2 - h postmeal hypoglycemia", "", +71769, Hypoglycemia, 3089, 3101, "hypoglycemia", "", +71676, InsulinAspart, 3107, 3120, "faster aspart", "", +71774, PMID, 3206, 3214, "28483786", "", diff --git a/data/dm2 28483786_kwoodley.n-triples b/data/dm2 28483786_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28483786_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28547998_admin.annodb b/data/dm2 28547998_admin.annodb new file mode 100644 index 0000000..0ec9cf3 --- /dev/null +++ b/data/dm2 28547998_admin.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", +1, PublicationYear, 20, 24, "2017", "", " \"2017\"." +8, Title, 122, 337, "A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", " \"A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .\"." +2, Randomized, 124, 134, "randomized", "", +3, Frequency, 192, 205, "once - weekly", "", +4, Omarigliptin, 241, 253, "omarigliptin", "", +129, Precondition, 257, 335, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +5, Type2Diabetes, 271, 286, "type 2 diabetes", "", +7, Metformin, 314, 323, "metformin", "", +9, Author, 338, 348, "Shankar RR", "", " \"Shankar RR\"." +10, Author, 357, 368, "Inzucchi SE", "", " \"Inzucchi SE\"." +11, Author, 377, 389, "Scarabello V", "", " \"Scarabello V\"." +12, Author, 398, 405, "Gantz I", "", " \"Gantz I\"." +13, Author, 414, 424, "Kaufman KD", "", " \"Kaufman KD\"." +14, Author, 433, 438, "Lai E", "", " \"Lai E\"." +15, Author, 447, 455, "Ceesay P", "", " \"Ceesay P\"." +16, Author, 464, 477, "Suryawanshi S", "", " \"Suryawanshi S\"." +17, Author, 486, 494, "Engel SS", "", " \"Engel SS\"." +18, USA, 573, 576, "USA", "", " ." +19, USA, 708, 711, "USA", "", +27, ObjectiveDescription, 726, 793, "To examine the efficacy and safety of the once - weekly ( q . w . )", "", " \"To examine the efficacy and safety of the once - weekly ( q . w . )\"." +20, Frequency, 768, 781, "once - weekly", "", " \"once - weekly\". \"once - weekly\"." +21, Frequency, 784, 791, "q . w .", "", +28, ObjectiveDescription, 794, 946, "dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", " \"dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .\"." +22, Omarigliptin, 831, 843, "omarigliptin", "", +146, Precondition, 849, 944, "patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy", "", +23, Type2Diabetes, 863, 878, "type 2 diabetes", "", " ." +24, Type2Diabetes, 881, 885, "T2DM", "", +26, Metformin, 923, 932, "metformin", "", +29, Randomized, 962, 972, "randomized", "", " ." +30, DoubleBlind, 975, 989, "double - blind", "", " ." +156, Precondition, 998, 1135, "patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %", "", " \"patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %\"." +31, Type2Diabetes, 1012, 1016, "T2DM", "", +43, Precondition, 1017, 1080, "on a stable dose of metformin monotherapy ( ≥ 1500   mg / day )", "", +32, Metformin, 1037, 1046, "metformin", "", +151, DoseValue, 1061, 1067, "≥ 1500", "", +152, mg, 1070, 1072, "mg", "", +99456, Interval, 1075, 1078, "day", "", +35, HbA1c, 1086, 1105, "glycated hemoglobin", "", +36, HbA1c, 1108, 1113, "HbA1c", "", +99449, Percentage, 1134, 1135, "%", "", +38, Randomized, 1141, 1151, "randomized", "", +39, Omarigliptin, 1155, 1167, "omarigliptin", "", " ." +158, DoseValue, 1168, 1170, "25", "", " \"25\". \"25\"." +41, mg, 1173, 1175, "mg", "", " . ." +42, Frequency, 1176, 1183, "q . w .", "", +45, Placebo, 1196, 1203, "placebo", "", " ." +46, NumberPatientsArm, 1212, 1215, "201", "", " \"201\"." +47, Duration, 1230, 1238, "24 weeks", "", " \"24 weeks\"." +48, Duration, 1287, 1296, "80 - week", "", +49, TimePoint, 1329, 1336, "week 24", "", " \"week 24\". \"week 24\"." +51, Mean, 1346, 1350, "mean", "", +50, TimePoint, 1351, 1359, "baseline", "", +52, HbA1c, 1360, 1365, "HbA1c", "", " ." +66, BaseLineValue, 1369, 1382, "8 . 0 - 8 . 1", "", " \"8 . 0 - 8 . 1\". \"8 . 0 - 8 . 1\"." +54, Percentage, 1383, 1384, "%", "", " ." +67, LeastSquaresMean, 1391, 1416, "least squares ( LS ) mean", "", " ." +68, TimePoint, 1441, 1449, "baseline", "", +53, HbA1c, 1453, 1458, "HbA1c", "", " ." +176, Reduction, 1489, 1495, "0 . 54", "", " \"0 . 54\"." +64, Percentage, 1496, 1497, "%", "", +72, ConfIntervalChangeValue, 1500, 1523, "- 0 . 69 % , - 0 . 40 %", "", " \"- 0 . 69 % , - 0 . 40 %\"." +99458, Percentage, 1509, 1510, "%", "", +99459, Percentage, 1522, 1523, "%", "", +77, Omarigliptin, 1533, 1545, "omarigliptin", "", +99457, Reduction, 1556, 1562, "0 . 00", "", " \"0 . 00\"." +61, Percentage, 1563, 1564, "%", "", +73, ConfIntervalChangeValue, 1567, 1588, "- 0 . 14 % , 0 . 15 %", "", " \"- 0 . 14 % , 0 . 15 %\"." +99460, Percentage, 1576, 1577, "%", "", +59, Percentage, 1587, 1588, "%", "", +76, Placebo, 1598, 1605, "placebo", "", +71, DiffGroupAbsValue, 1650, 1658, "- 0 . 55", "", " \"- 0 . 55\"." +58, Percentage, 1659, 1660, "%", "", +74, ConfIntervalDiff, 1663, 1686, "- 0 . 75 % , - 0 . 34 %", "", " \"- 0 . 75 % , - 0 . 34 %\"." +57, Percentage, 1672, 1673, "%", "", +56, Percentage, 1685, 1686, "%", "", +75, PvalueDiff, 1691, 1701, "p  < . 001", "", " \"p  < . 001\"." +78, LeastSquaresMean, 1734, 1741, "LS mean", "", " . ." +197, PostprandialBloodGlucose, 1786, 1811, "2 - h post - meal glucose", "", " ." +80, FastingPlasmaGlucose, 1816, 1838, "fasting plasma glucose", "", " ." +81, Omarigliptin, 1841, 1853, "omarigliptin", "", +82, Placebo, 1857, 1864, "placebo", "", +83, DiffGroupAbsValue, 1872, 1879, "- 0 . 8", "", " \"- 0 . 8\"." +85, Millimoles_per_litre, 1882, 1890, "mmol / L", "", " ." +87, ConfIntervalDiff, 1893, 1910, "- 1 . 4 , - 0 . 2", "", " \"- 1 . 4 , - 0 . 2\"." +89, PvalueDiff, 1915, 1925, "p  = . 011", "", " \"p  = . 011\"." +84, DiffGroupAbsValue, 1932, 1939, "- 0 . 5", "", " \"- 0 . 5\"." +86, Millimoles_per_litre, 1940, 1948, "mmol / L", "", " ." +88, ConfIntervalDiff, 1951, 1968, "- 0 . 9 , - 0 . 1", "", " \"- 0 . 9 , - 0 . 1\"." +90, PvalueDiff, 1973, 1983, "p  = . 010", "", " \"p  = . 010\"." +91, TimePoint, 2006, 2013, "week 24", "", +92, SymptomaticHypoglycemia, 2034, 2058, "symptomatic hypoglycemia", "", " ." +210, EndPointDescription, 2089, 2102, "adverse event", "", " . ." +211, EndPointDescription, 2105, 2107, "AE", "", +212, EndPointDescription, 2112, 2123, "serious AEs", "", " . ." +99461, ObservedResult, 2160, 2211, "were similar in the omarigliptin and placebo groups", "", " \"were similar in the omarigliptin and placebo groups\". \"were similar in the omarigliptin and placebo groups\". \"were similar in the omarigliptin and placebo groups\"." +93, Omarigliptin, 2180, 2192, "omarigliptin", "", +94, Placebo, 2197, 2204, "placebo", "", +95, TimePoint, 2219, 2228, "104 weeks", "", +217, ObservedResult, 2231, 2305, "omarigliptin treatment provided a clinically meaningful reduction in HbA1c", "", +96, Omarigliptin, 2231, 2243, "omarigliptin", "", +97, HbA1c, 2300, 2305, "HbA1c", "", +106, ConclusionComment, 2322, 2381, "In patients with T2DM , adding omarigliptin 25   mg q . w .", "", " \"In patients with T2DM , adding omarigliptin 25   mg q . w .\"." +98, Type2Diabetes, 2339, 2343, "T2DM", "", +99, Omarigliptin, 2353, 2365, "omarigliptin", "", +218, DoseValue, 2366, 2368, "25", "", +101, mg, 2371, 2373, "mg", "", +102, Frequency, 2374, 2381, "q . w .", "", +107, ConclusionComment, 2382, 2513, "to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .", "", " \"to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .\"." +103, Metformin, 2385, 2394, "metformin", "", +104, Duration, 2438, 2447, "104 weeks", "", +105, Hypoglycemia, 2499, 2511, "hypoglycemia", "", +108, PMID, 2565, 2573, "28547998", "", " \"28547998\"." diff --git a/data/dm2 28547998_admin.n-triples b/data/dm2 28547998_admin.n-triples new file mode 100644 index 0000000..7bccdfc --- /dev/null +++ b/data/dm2 28547998_admin.n-triples @@ -0,0 +1,188 @@ +# RDF export of group: Publication + . + "Publication " . + "A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy ." . + "Shankar RR" . + "2017" . + "28547998" . + . + "Inzucchi SE" . + "Scarabello V" . + "Gantz I" . + "Kaufman KD" . + "Lai E" . + "Ceesay P" . + "Suryawanshi S" . + "Engel SS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To examine the efficacy and safety of the once - weekly ( q . w . )" . + "24 weeks" . + . + . + . + "In patients with T2DM , adding omarigliptin 25   mg q . w ." . + . + . + . + . + . + "dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy ." . + . + "to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint ppg" . + . + . + . + . + . + "Endpoint fpg" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint s aes" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm o" . + . + . + . + . + . + . + . + . + "Arm p" . + "201" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention o" . + . + "once - weekly" . + . + . + "Intervention p" . + . + "once - weekly" . + . +# RDF export of group: Medication + . + "Medication o" . + . + "25" . + . + . + . + "Medication p" . + . + "25" . + . + . +# RDF export of group: Outcome + . + "Outcome hba1c o " . + . + "8 . 0 - 8 . 1" . + "0 . 54" . + "- 0 . 69 % , - 0 . 40 %" . + "week 24" . + . + "Outcome hba1c p " . + . + "8 . 0 - 8 . 1" . + "0 . 00" . + "- 0 . 14 % , 0 . 15 %" . + "week 24" . + . + "Outcome ppg o " . + . + . + "Outcome ppg p" . + . + . + "Outcome fpg o " . + . + . + "Outcome fpg p " . + . + . + "Outcome sh both drugs" . + . + "were similar in the omarigliptin and placebo groups" . + . + "Outcome aes both drugs" . + . + "were similar in the omarigliptin and placebo groups" . + . + "Outcome s aes both drugs" . + . + "were similar in the omarigliptin and placebo groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c " . + "- 0 . 55" . + "p  < . 001" . + "- 0 . 75 % , - 0 . 34 %" . + . + . + . + "DiffBetweenGroups ppg " . + "- 0 . 8" . + "p  = . 011" . + "- 1 . 4 , - 0 . 2" . + . + . + . + "DiffBetweenGroups fpg" . + "- 0 . 5" . + "p  = . 010" . + "- 0 . 9 , - 0 . 1" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28547998_akramersunderbrink.annodb b/data/dm2 28547998_akramersunderbrink.annodb new file mode 100644 index 0000000..6e811f6 --- /dev/null +++ b/data/dm2 28547998_akramersunderbrink.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70075, Journal, 0, 17, "Curr Med Res Opin", "", +70076, PublicationYear, 20, 24, "2017", "", +70083, Title, 122, 337, "A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", +70077, Randomized, 124, 134, "randomized", "", +70078, Frequency, 192, 205, "once - weekly", "", +70079, Omarigliptin, 241, 253, "omarigliptin", "", +70080, Type2Diabetes, 271, 286, "type 2 diabetes", "", +70081, Precondition, 287, 335, "inadequately controlled on metformin monotherapy", "", +70082, Metformin, 314, 323, "metformin", "", +70084, Author, 338, 348, "Shankar RR", "", +70085, Author, 357, 368, "Inzucchi SE", "", +70086, Author, 377, 389, "Scarabello V", "", +70087, Author, 398, 405, "Gantz I", "", +70088, Author, 414, 424, "Kaufman KD", "", +70089, Author, 433, 438, "Lai E", "", +70090, Author, 447, 455, "Ceesay P", "", +70091, Author, 464, 477, "Suryawanshi S", "", +70092, Author, 486, 494, "Engel SS", "", +70093, USA, 573, 576, "USA", "", +70094, USA, 708, 711, "USA", "", +70102, ObjectiveDescription, 726, 793, "To examine the efficacy and safety of the once - weekly ( q . w . )", "", +70095, Frequency, 768, 781, "once - weekly", "", +70096, Frequency, 784, 791, "q . w .", "", +70103, ObjectiveDescription, 794, 946, "dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", +70097, Omarigliptin, 831, 843, "omarigliptin", "", +70098, Type2Diabetes, 863, 878, "type 2 diabetes", "", +70099, Type2Diabetes, 881, 885, "T2DM", "", +70100, Precondition, 892, 944, "inadequate glycemic control on metformin monotherapy", "", +70101, Metformin, 923, 932, "metformin", "", +70104, Randomized, 962, 972, "randomized", "", +70105, DoubleBlind, 975, 989, "double - blind", "", +70106, Type2Diabetes, 1012, 1016, "T2DM", "", +70118, Precondition, 1017, 1080, "on a stable dose of metformin monotherapy ( ≥ 1500   mg / day )", "", +70107, Metformin, 1037, 1046, "metformin", "", +70108, DoseValue, 1061, 1078, "≥ 1500   mg / day", "", +70109, BioAndMedicalUnit, 1070, 1078, "mg / day", "", +70110, HbA1c, 1086, 1105, "glycated hemoglobin", "", +70119, Precondition, 1086, 1135, "glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %", "", +70111, HbA1c, 1108, 1113, "HbA1c", "", +70112, Percentage, 1134, 1135, "%", "", +70113, Randomized, 1141, 1151, "randomized", "", +70114, Omarigliptin, 1155, 1167, "omarigliptin", "", +70115, DoseValue, 1168, 1175, "25   mg", "", +70116, mg, 1173, 1175, "mg", "", +70117, Frequency, 1176, 1183, "q . w .", "", +70120, Placebo, 1196, 1203, "placebo", "", +70121, NumberPatientsArm, 1212, 1215, "201", "", +70122, Duration, 1230, 1238, "24 weeks", "", +70123, Duration, 1287, 1296, "80 - week", "", +70124, TimePoint, 1329, 1336, "week 24", "", +70126, Mean, 1346, 1350, "mean", "", +70125, TimePoint, 1351, 1359, "baseline", "", +70127, HbA1c, 1360, 1365, "HbA1c", "", +70141, BaseLineValue, 1369, 1382, "8 . 0 - 8 . 1", "", +70129, Percentage, 1383, 1384, "%", "", +70142, LeastSquaresMean, 1391, 1416, "least squares ( LS ) mean", "", +70130, Percentage, 1422, 1423, "%", "", +70143, TimePoint, 1441, 1449, "baseline", "", +70128, HbA1c, 1453, 1458, "HbA1c", "", +70144, ChangeValue, 1487, 1495, "- 0 . 54", "", +70139, Percentage, 1496, 1497, "%", "", +70149, ConfIntervalChangeValue, 1500, 1523, "- 0 . 69 % , - 0 . 40 %", "", +70138, Percentage, 1509, 1510, "%", "", +70137, Percentage, 1522, 1523, "%", "", +70154, Omarigliptin, 1533, 1545, "omarigliptin", "", +70147, ChangeValue, 1556, 1562, "0 . 00", "", +70136, Percentage, 1563, 1564, "%", "", +70150, ConfIntervalChangeValue, 1567, 1588, "- 0 . 14 % , 0 . 15 %", "", +70135, Percentage, 1576, 1577, "%", "", +70134, Percentage, 1587, 1588, "%", "", +70153, Placebo, 1598, 1605, "placebo", "", +70148, DiffGroupAbsValue, 1650, 1658, "- 0 . 55", "", +70133, Percentage, 1659, 1660, "%", "", +70151, ConfIntervalDiff, 1663, 1686, "- 0 . 75 % , - 0 . 34 %", "", +70132, Percentage, 1672, 1673, "%", "", +70131, Percentage, 1685, 1686, "%", "", +70152, PvalueDiff, 1691, 1701, "p  < . 001", "", +70155, LeastSquaresMean, 1734, 1741, "LS mean", "", +70140, Percentage, 1745, 1746, "%", "", +70156, PostprandialPlasmaGlucose, 1786, 1811, "2 - h post - meal glucose", "", +70157, FastingPlasmaGlucose, 1816, 1838, "fasting plasma glucose", "", +70158, Omarigliptin, 1841, 1853, "omarigliptin", "", +70159, Placebo, 1857, 1864, "placebo", "", +70160, DiffGroupAbsValue, 1872, 1879, "- 0 . 8", "", +70163, Millimoles_per_litre, 1882, 1890, "mmol / L", "", +70165, ConfIntervalDiff, 1893, 1910, "- 1 . 4 , - 0 . 2", "", +70167, PvalueDiff, 1915, 1925, "p  = . 011", "", +70161, DiffGroupAbsValue, 1932, 1939, "- 0 . 5", "", +70164, Millimoles_per_litre, 1940, 1948, "mmol / L", "", +70166, ConfIntervalDiff, 1951, 1968, "- 0 . 9 , - 0 . 1", "", +70168, PvalueDiff, 1973, 1983, "p  = . 010", "", +70169, TimePoint, 2006, 2013, "week 24", "", +70170, SymptomaticHypoglycemia, 2034, 2058, "symptomatic hypoglycemia", "", +70171, Omarigliptin, 2180, 2192, "omarigliptin", "", +70172, Placebo, 2197, 2204, "placebo", "", +70173, TimePoint, 2219, 2228, "104 weeks", "", +70174, Omarigliptin, 2231, 2243, "omarigliptin", "", +70175, HbA1c, 2300, 2305, "HbA1c", "", +70185, ConclusionComment, 2322, 2381, "In patients with T2DM , adding omarigliptin 25   mg q . w .", "", +70176, Type2Diabetes, 2339, 2343, "T2DM", "", +70177, Omarigliptin, 2353, 2365, "omarigliptin", "", +70178, DoseValue, 2366, 2373, "25   mg", "", +70179, mg, 2371, 2373, "mg", "", +70180, Frequency, 2374, 2381, "q . w .", "", +70186, ConclusionComment, 2382, 2513, "to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .", "", +70181, Metformin, 2385, 2394, "metformin", "", +70182, Duration, 2438, 2447, "104 weeks", "", +70183, Hypoglycemia, 2499, 2511, "hypoglycemia", "", +70187, PMID, 2565, 2573, "28547998", "", diff --git a/data/dm2 28547998_akramersunderbrink.n-triples b/data/dm2 28547998_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28547998_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28547998_export.csv b/data/dm2 28547998_export.csv new file mode 100644 index 0000000..f77e2ad --- /dev/null +++ b/data/dm2 28547998_export.csv @@ -0,0 +1,608 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +397, 1, 1, 1, 0, 4, 0, 4, "Curr" +397, 1, 2, 2, 5, 8, 5, 8, "Med" +397, 1, 3, 3, 9, 12, 9, 12, "Res" +397, 1, 4, 4, 13, 17, 13, 17, "Opin" +397, 1, 5, 5, 18, 19, 18, 19, "." +397, 2, 1, 6, 0, 4, 20, 24, "2017" +397, 2, 2, 7, 5, 8, 25, 28, "Oct" +397, 2, 3, 8, 9, 10, 29, 30, ";" +397, 2, 4, 9, 11, 13, 31, 33, "33" +397, 2, 5, 10, 14, 15, 34, 35, "(" +397, 2, 6, 11, 16, 18, 36, 38, "10" +397, 2, 7, 12, 19, 20, 39, 40, ")" +397, 2, 8, 13, 21, 22, 41, 42, ":" +397, 2, 9, 14, 23, 27, 43, 47, "1853" +397, 2, 10, 15, 28, 29, 48, 49, "-" +397, 2, 11, 16, 30, 34, 50, 54, "1860" +397, 2, 12, 17, 35, 36, 55, 56, "." +397, 2, 13, 18, 37, 40, 57, 60, "doi" +397, 2, 14, 19, 41, 42, 61, 62, ":" +397, 2, 15, 20, 43, 45, 63, 65, "10" +397, 2, 16, 21, 46, 47, 66, 67, "." +397, 2, 17, 22, 48, 52, 68, 72, "1080" +397, 2, 18, 23, 53, 54, 73, 74, "/" +397, 2, 19, 24, 55, 63, 75, 83, "03007995" +397, 2, 20, 25, 64, 65, 84, 85, "." +397, 2, 21, 26, 66, 70, 86, 90, "2017" +397, 2, 22, 27, 71, 72, 91, 92, "." +397, 2, 23, 28, 73, 80, 93, 100, "1335637" +397, 2, 24, 29, 81, 82, 101, 102, "." +397, 3, 1, 30, 0, 4, 103, 107, "Epub" +397, 3, 2, 31, 5, 9, 108, 112, "2017" +397, 3, 3, 32, 10, 13, 113, 116, "Jun" +397, 3, 4, 33, 14, 16, 117, 119, "23" +397, 3, 5, 34, 17, 18, 120, 121, "." +397, 4, 1, 35, 0, 1, 122, 123, "A" +397, 4, 2, 36, 2, 12, 124, 134, "randomized" +397, 4, 3, 37, 13, 21, 135, 143, "clinical" +397, 4, 4, 38, 22, 27, 144, 149, "trial" +397, 4, 5, 39, 28, 38, 150, 160, "evaluating" +397, 4, 6, 40, 39, 42, 161, 164, "the" +397, 4, 7, 41, 43, 51, 165, 173, "efficacy" +397, 4, 8, 42, 52, 55, 174, 177, "and" +397, 4, 9, 43, 56, 62, 178, 184, "safety" +397, 4, 10, 44, 63, 65, 185, 187, "of" +397, 4, 11, 45, 66, 69, 188, 191, "the" +397, 4, 12, 46, 70, 74, 192, 196, "once" +397, 4, 13, 47, 75, 76, 197, 198, "-" +397, 4, 14, 48, 77, 83, 199, 205, "weekly" +397, 4, 15, 49, 84, 94, 206, 216, "dipeptidyl" +397, 4, 16, 50, 95, 104, 217, 226, "peptidase" +397, 4, 17, 51, 105, 106, 227, 228, "-" +397, 4, 18, 52, 107, 108, 229, 230, "4" +397, 4, 19, 53, 109, 118, 231, 240, "inhibitor" +397, 4, 20, 54, 119, 131, 241, 253, "omarigliptin" +397, 4, 21, 55, 132, 134, 254, 256, "in" +397, 4, 22, 56, 135, 143, 257, 265, "patients" +397, 4, 23, 57, 144, 148, 266, 270, "with" +397, 4, 24, 58, 149, 153, 271, 275, "type" +397, 4, 25, 59, 154, 155, 276, 277, "2" +397, 4, 26, 60, 156, 164, 278, 286, "diabetes" +397, 4, 27, 61, 165, 177, 287, 299, "inadequately" +397, 4, 28, 62, 178, 188, 300, 310, "controlled" +397, 4, 29, 63, 189, 191, 311, 313, "on" +397, 4, 30, 64, 192, 201, 314, 323, "metformin" +397, 4, 31, 65, 202, 213, 324, 335, "monotherapy" +397, 4, 32, 66, 214, 215, 336, 337, "." +397, 5, 1, 67, 0, 7, 338, 345, "Shankar" +397, 5, 2, 68, 8, 10, 346, 348, "RR" +397, 5, 3, 69, 11, 12, 349, 350, "(" +397, 5, 4, 70, 13, 14, 351, 352, "1" +397, 5, 5, 71, 15, 16, 353, 354, ")" +397, 5, 6, 72, 17, 18, 355, 356, "," +397, 5, 7, 73, 19, 27, 357, 365, "Inzucchi" +397, 5, 8, 74, 28, 30, 366, 368, "SE" +397, 5, 9, 75, 31, 32, 369, 370, "(" +397, 5, 10, 76, 33, 34, 371, 372, "2" +397, 5, 11, 77, 35, 36, 373, 374, ")" +397, 5, 12, 78, 37, 38, 375, 376, "," +397, 5, 13, 79, 39, 49, 377, 387, "Scarabello" +397, 5, 14, 80, 50, 51, 388, 389, "V" +397, 5, 15, 81, 52, 53, 390, 391, "(" +397, 5, 16, 82, 54, 55, 392, 393, "1" +397, 5, 17, 83, 56, 57, 394, 395, ")" +397, 5, 18, 84, 58, 59, 396, 397, "," +397, 5, 19, 85, 60, 65, 398, 403, "Gantz" +397, 5, 20, 86, 66, 67, 404, 405, "I" +397, 5, 21, 87, 68, 69, 406, 407, "(" +397, 5, 22, 88, 70, 71, 408, 409, "1" +397, 5, 23, 89, 72, 73, 410, 411, ")" +397, 5, 24, 90, 74, 75, 412, 413, "," +397, 5, 25, 91, 76, 83, 414, 421, "Kaufman" +397, 5, 26, 92, 84, 86, 422, 424, "KD" +397, 5, 27, 93, 87, 88, 425, 426, "(" +397, 5, 28, 94, 89, 90, 427, 428, "1" +397, 5, 29, 95, 91, 92, 429, 430, ")" +397, 5, 30, 96, 93, 94, 431, 432, "," +397, 5, 31, 97, 95, 98, 433, 436, "Lai" +397, 5, 32, 98, 99, 100, 437, 438, "E" +397, 5, 33, 99, 101, 102, 439, 440, "(" +397, 5, 34, 100, 103, 104, 441, 442, "1" +397, 5, 35, 101, 105, 106, 443, 444, ")" +397, 5, 36, 102, 107, 108, 445, 446, "," +397, 5, 37, 103, 109, 115, 447, 453, "Ceesay" +397, 5, 38, 104, 116, 117, 454, 455, "P" +397, 5, 39, 105, 118, 119, 456, 457, "(" +397, 5, 40, 106, 120, 121, 458, 459, "1" +397, 5, 41, 107, 122, 123, 460, 461, ")" +397, 5, 42, 108, 124, 125, 462, 463, "," +397, 5, 43, 109, 126, 137, 464, 475, "Suryawanshi" +397, 5, 44, 110, 138, 139, 476, 477, "S" +397, 5, 45, 111, 140, 141, 478, 479, "(" +397, 5, 46, 112, 142, 143, 480, 481, "1" +397, 5, 47, 113, 144, 145, 482, 483, ")" +397, 5, 48, 114, 146, 147, 484, 485, "," +397, 5, 49, 115, 148, 153, 486, 491, "Engel" +397, 5, 50, 116, 154, 156, 492, 494, "SS" +397, 5, 51, 117, 157, 158, 495, 496, "(" +397, 5, 52, 118, 159, 160, 497, 498, "1" +397, 5, 53, 119, 161, 162, 499, 500, ")" +397, 5, 54, 120, 163, 164, 501, 502, "." +397, 6, 1, 121, 0, 6, 503, 509, "Author" +397, 6, 2, 122, 7, 18, 510, 521, "information" +397, 6, 3, 123, 19, 20, 522, 523, ":" +397, 6, 4, 124, 21, 22, 524, 525, "(" +397, 6, 5, 125, 23, 24, 526, 527, "1" +397, 6, 6, 126, 25, 26, 528, 529, ")" +397, 6, 7, 127, 27, 28, 530, 531, "a" +397, 6, 8, 128, 29, 34, 532, 537, "Merck" +397, 6, 9, 129, 35, 36, 538, 539, "&" +397, 6, 10, 130, 37, 39, 540, 542, "Co" +397, 6, 11, 131, 40, 41, 543, 544, "." +397, 6, 12, 132, 42, 43, 545, 546, "," +397, 6, 13, 133, 44, 47, 547, 550, "Inc" +397, 6, 14, 134, 48, 49, 551, 552, "." +397, 6, 15, 135, 50, 51, 553, 554, "," +397, 6, 16, 136, 52, 62, 555, 565, "Kenilworth" +397, 6, 17, 137, 63, 64, 566, 567, "," +397, 6, 18, 138, 65, 67, 568, 570, "NJ" +397, 6, 19, 139, 68, 69, 571, 572, "," +397, 6, 20, 140, 70, 73, 573, 576, "USA" +397, 6, 21, 141, 74, 75, 577, 578, "." +397, 7, 1, 142, 0, 1, 579, 580, "(" +397, 7, 2, 143, 2, 3, 581, 582, "2" +397, 7, 3, 144, 4, 5, 583, 584, ")" +397, 7, 4, 145, 6, 7, 585, 586, "b" +397, 7, 5, 146, 8, 18, 587, 597, "Department" +397, 7, 6, 147, 19, 21, 598, 600, "of" +397, 7, 7, 148, 22, 30, 601, 609, "Medicine" +397, 7, 8, 149, 31, 32, 610, 611, "," +397, 7, 9, 150, 33, 40, 612, 619, "Section" +397, 7, 10, 151, 41, 43, 620, 622, "of" +397, 7, 11, 152, 44, 57, 623, 636, "Endocrinology" +397, 7, 12, 153, 58, 61, 637, 640, "and" +397, 7, 13, 154, 62, 72, 641, 651, "Metabolism" +397, 7, 14, 155, 73, 74, 652, 653, "," +397, 7, 15, 156, 75, 79, 654, 658, "Yale" +397, 7, 16, 157, 80, 90, 659, 669, "University" +397, 7, 17, 158, 91, 97, 670, 676, "School" +397, 7, 18, 159, 98, 100, 677, 679, "of" +397, 7, 19, 160, 101, 109, 680, 688, "Medicine" +397, 7, 20, 161, 110, 111, 689, 690, "," +397, 7, 21, 162, 112, 115, 691, 694, "New" +397, 7, 22, 163, 116, 121, 695, 700, "Haven" +397, 7, 23, 164, 122, 123, 701, 702, "," +397, 7, 24, 165, 124, 126, 703, 705, "CT" +397, 7, 25, 166, 127, 128, 706, 707, "," +397, 7, 26, 167, 129, 132, 708, 711, "USA" +397, 7, 27, 168, 133, 134, 712, 713, "." +397, 8, 1, 169, 0, 9, 714, 723, "OBJECTIVE" +397, 8, 2, 170, 10, 11, 724, 725, ":" +397, 8, 3, 171, 12, 14, 726, 728, "To" +397, 8, 4, 172, 15, 22, 729, 736, "examine" +397, 8, 5, 173, 23, 26, 737, 740, "the" +397, 8, 6, 174, 27, 35, 741, 749, "efficacy" +397, 8, 7, 175, 36, 39, 750, 753, "and" +397, 8, 8, 176, 40, 46, 754, 760, "safety" +397, 8, 9, 177, 47, 49, 761, 763, "of" +397, 8, 10, 178, 50, 53, 764, 767, "the" +397, 8, 11, 179, 54, 58, 768, 772, "once" +397, 8, 12, 180, 59, 60, 773, 774, "-" +397, 8, 13, 181, 61, 67, 775, 781, "weekly" +397, 8, 14, 182, 68, 69, 782, 783, "(" +397, 8, 15, 183, 70, 71, 784, 785, "q" +397, 8, 16, 184, 72, 73, 786, 787, "." +397, 8, 17, 185, 74, 75, 788, 789, "w" +397, 8, 18, 186, 76, 77, 790, 791, "." +397, 8, 19, 187, 78, 79, 792, 793, ")" +397, 9, 1, 188, 0, 10, 794, 804, "dipeptidyl" +397, 9, 2, 189, 11, 20, 805, 814, "peptidase" +397, 9, 3, 190, 21, 22, 815, 816, "-" +397, 9, 4, 191, 23, 24, 817, 818, "4" +397, 9, 5, 192, 25, 34, 819, 828, "inhibitor" +397, 9, 6, 193, 35, 36, 829, 830, "," +397, 9, 7, 194, 37, 49, 831, 843, "omarigliptin" +397, 9, 8, 195, 50, 51, 844, 845, "," +397, 9, 9, 196, 52, 54, 846, 848, "in" +397, 9, 10, 197, 55, 63, 849, 857, "patients" +397, 9, 11, 198, 64, 68, 858, 862, "with" +397, 9, 12, 199, 69, 73, 863, 867, "type" +397, 9, 13, 200, 74, 75, 868, 869, "2" +397, 9, 14, 201, 76, 84, 870, 878, "diabetes" +397, 9, 15, 202, 85, 86, 879, 880, "(" +397, 9, 16, 203, 87, 91, 881, 885, "T2DM" +397, 9, 17, 204, 92, 93, 886, 887, ")" +397, 9, 18, 205, 94, 97, 888, 891, "and" +397, 9, 19, 206, 98, 108, 892, 902, "inadequate" +397, 9, 20, 207, 109, 117, 903, 911, "glycemic" +397, 9, 21, 208, 118, 125, 912, 919, "control" +397, 9, 22, 209, 126, 128, 920, 922, "on" +397, 9, 23, 210, 129, 138, 923, 932, "metformin" +397, 9, 24, 211, 139, 150, 933, 944, "monotherapy" +397, 9, 25, 212, 151, 152, 945, 946, "." +397, 10, 1, 213, 0, 7, 947, 954, "METHODS" +397, 10, 2, 214, 8, 9, 955, 956, ":" +397, 10, 3, 215, 10, 12, 957, 959, "In" +397, 10, 4, 216, 13, 14, 960, 961, "a" +397, 10, 5, 217, 15, 25, 962, 972, "randomized" +397, 10, 6, 218, 26, 27, 973, 974, "," +397, 10, 7, 219, 28, 34, 975, 981, "double" +397, 10, 8, 220, 35, 36, 982, 983, "-" +397, 10, 9, 221, 37, 42, 984, 989, "blind" +397, 10, 10, 222, 43, 48, 990, 995, "trial" +397, 10, 11, 223, 49, 50, 996, 997, "," +397, 10, 12, 224, 51, 59, 998, 1006, "patients" +397, 10, 13, 225, 60, 64, 1007, 1011, "with" +397, 10, 14, 226, 65, 69, 1012, 1016, "T2DM" +397, 10, 15, 227, 70, 72, 1017, 1019, "on" +397, 10, 16, 228, 73, 74, 1020, 1021, "a" +397, 10, 17, 229, 75, 81, 1022, 1028, "stable" +397, 10, 18, 230, 82, 86, 1029, 1033, "dose" +397, 10, 19, 231, 87, 89, 1034, 1036, "of" +397, 10, 20, 232, 90, 99, 1037, 1046, "metformin" +397, 10, 21, 233, 100, 111, 1047, 1058, "monotherapy" +397, 10, 22, 234, 112, 113, 1059, 1060, "(" +397, 10, 23, 235, 114, 115, 1061, 1062, "≥" +397, 10, 24, 236, 116, 120, 1063, 1067, "1500" +397, 10, 25, 237, 121, 122, 1068, 1069, " " +397, 10, 26, 238, 123, 125, 1070, 1072, "mg" +397, 10, 27, 239, 126, 127, 1073, 1074, "/" +397, 10, 28, 240, 128, 131, 1075, 1078, "day" +397, 10, 29, 241, 132, 133, 1079, 1080, ")" +397, 10, 30, 242, 134, 138, 1081, 1085, "with" +397, 10, 31, 243, 139, 147, 1086, 1094, "glycated" +397, 10, 32, 244, 148, 158, 1095, 1105, "hemoglobin" +397, 10, 33, 245, 159, 160, 1106, 1107, "(" +397, 10, 34, 246, 161, 166, 1108, 1113, "HbA1c" +397, 10, 35, 247, 167, 168, 1114, 1115, ")" +397, 10, 36, 248, 169, 171, 1116, 1118, "of" +397, 10, 37, 249, 172, 173, 1119, 1120, "7" +397, 10, 38, 250, 174, 175, 1121, 1122, "." +397, 10, 39, 251, 176, 177, 1123, 1124, "0" +397, 10, 40, 252, 178, 179, 1125, 1126, "-" +397, 10, 41, 253, 180, 182, 1127, 1129, "10" +397, 10, 42, 254, 183, 184, 1130, 1131, "." +397, 10, 43, 255, 185, 186, 1132, 1133, "5" +397, 10, 44, 256, 187, 188, 1134, 1135, "%" +397, 10, 45, 257, 189, 193, 1136, 1140, "were" +397, 10, 46, 258, 194, 204, 1141, 1151, "randomized" +397, 10, 47, 259, 205, 207, 1152, 1154, "to" +397, 10, 48, 260, 208, 220, 1155, 1167, "omarigliptin" +397, 10, 49, 261, 221, 223, 1168, 1170, "25" +397, 10, 50, 262, 224, 225, 1171, 1172, " " +397, 10, 51, 263, 226, 228, 1173, 1175, "mg" +397, 10, 52, 264, 229, 230, 1176, 1177, "q" +397, 10, 53, 265, 231, 232, 1178, 1179, "." +397, 10, 54, 266, 233, 234, 1180, 1181, "w" +397, 10, 55, 267, 235, 236, 1182, 1183, "." +397, 11, 1, 268, 0, 2, 1184, 1186, "or" +397, 11, 2, 269, 3, 11, 1187, 1195, "matching" +397, 11, 3, 270, 12, 19, 1196, 1203, "placebo" +397, 11, 4, 271, 20, 21, 1204, 1205, "(" +397, 11, 5, 272, 22, 23, 1206, 1207, "n" +397, 11, 6, 273, 24, 27, 1208, 1211, " = " +397, 11, 7, 274, 28, 31, 1212, 1215, "201" +397, 11, 8, 275, 32, 34, 1216, 1218, "in" +397, 11, 9, 276, 35, 39, 1219, 1223, "both" +397, 11, 10, 277, 40, 41, 1224, 1225, ")" +397, 11, 11, 278, 42, 45, 1226, 1229, "for" +397, 11, 12, 279, 46, 48, 1230, 1232, "24" +397, 11, 13, 280, 49, 54, 1233, 1238, "weeks" +397, 11, 14, 281, 55, 56, 1239, 1240, "(" +397, 11, 15, 282, 57, 64, 1241, 1248, "primary" +397, 11, 16, 283, 65, 74, 1249, 1258, "timepoint" +397, 11, 17, 284, 75, 76, 1259, 1260, ")" +397, 11, 18, 285, 77, 85, 1261, 1269, "followed" +397, 11, 19, 286, 86, 88, 1270, 1272, "by" +397, 11, 20, 287, 89, 91, 1273, 1275, "an" +397, 11, 21, 288, 92, 102, 1276, 1286, "additional" +397, 11, 22, 289, 103, 105, 1287, 1289, "80" +397, 11, 23, 290, 106, 107, 1290, 1291, "-" +397, 11, 24, 291, 108, 112, 1292, 1296, "week" +397, 11, 25, 292, 113, 122, 1297, 1306, "treatment" +397, 11, 26, 293, 123, 129, 1307, 1313, "period" +397, 11, 27, 294, 130, 131, 1314, 1315, "." +397, 12, 1, 295, 0, 7, 1316, 1323, "RESULTS" +397, 12, 2, 296, 8, 9, 1324, 1325, ":" +397, 12, 3, 297, 10, 12, 1326, 1328, "At" +397, 12, 4, 298, 13, 17, 1329, 1333, "week" +397, 12, 5, 299, 18, 20, 1334, 1336, "24" +397, 12, 6, 300, 21, 22, 1337, 1338, "," +397, 12, 7, 301, 23, 27, 1339, 1343, "from" +397, 12, 8, 302, 28, 29, 1344, 1345, "a" +397, 12, 9, 303, 30, 34, 1346, 1350, "mean" +397, 12, 10, 304, 35, 43, 1351, 1359, "baseline" +397, 12, 11, 305, 44, 49, 1360, 1365, "HbA1c" +397, 12, 12, 306, 50, 52, 1366, 1368, "of" +397, 12, 13, 307, 53, 54, 1369, 1370, "8" +397, 12, 14, 308, 55, 56, 1371, 1372, "." +397, 12, 15, 309, 57, 58, 1373, 1374, "0" +397, 12, 16, 310, 59, 60, 1375, 1376, "-" +397, 12, 17, 311, 61, 62, 1377, 1378, "8" +397, 12, 18, 312, 63, 64, 1379, 1380, "." +397, 12, 19, 313, 65, 66, 1381, 1382, "1" +397, 12, 20, 314, 67, 68, 1383, 1384, "%" +397, 12, 21, 315, 69, 70, 1385, 1386, "," +397, 12, 22, 316, 71, 74, 1387, 1390, "the" +397, 12, 23, 317, 75, 80, 1391, 1396, "least" +397, 12, 24, 318, 81, 88, 1397, 1404, "squares" +397, 12, 25, 319, 89, 90, 1405, 1406, "(" +397, 12, 26, 320, 91, 93, 1407, 1409, "LS" +397, 12, 27, 321, 94, 95, 1410, 1411, ")" +397, 12, 28, 322, 96, 100, 1412, 1416, "mean" +397, 12, 29, 323, 101, 102, 1417, 1418, "(" +397, 12, 30, 324, 103, 105, 1419, 1421, "95" +397, 12, 31, 325, 106, 107, 1422, 1423, "%" +397, 12, 32, 326, 108, 110, 1424, 1426, "CI" +397, 12, 33, 327, 111, 112, 1427, 1428, ")" +397, 12, 34, 328, 113, 119, 1429, 1435, "change" +397, 12, 35, 329, 120, 124, 1436, 1440, "from" +397, 12, 36, 330, 125, 133, 1441, 1449, "baseline" +397, 12, 37, 331, 134, 136, 1450, 1452, "in" +397, 12, 38, 332, 137, 142, 1453, 1458, "HbA1c" +397, 12, 39, 333, 143, 144, 1459, 1460, "(" +397, 12, 40, 334, 145, 152, 1461, 1468, "primary" +397, 12, 41, 335, 153, 156, 1469, 1472, "end" +397, 12, 42, 336, 157, 158, 1473, 1474, "-" +397, 12, 43, 337, 159, 164, 1475, 1480, "point" +397, 12, 44, 338, 165, 166, 1481, 1482, ")" +397, 12, 45, 339, 167, 170, 1483, 1486, "was" +397, 12, 46, 340, 171, 172, 1487, 1488, "-" +397, 12, 47, 341, 173, 174, 1489, 1490, "0" +397, 12, 48, 342, 175, 176, 1491, 1492, "." +397, 12, 49, 343, 177, 179, 1493, 1495, "54" +397, 12, 50, 344, 180, 181, 1496, 1497, "%" +397, 12, 51, 345, 182, 183, 1498, 1499, "(" +397, 12, 52, 346, 184, 185, 1500, 1501, "-" +397, 12, 53, 347, 186, 187, 1502, 1503, "0" +397, 12, 54, 348, 188, 189, 1504, 1505, "." +397, 12, 55, 349, 190, 192, 1506, 1508, "69" +397, 12, 56, 350, 193, 194, 1509, 1510, "%" +397, 12, 57, 351, 195, 196, 1511, 1512, "," +397, 12, 58, 352, 197, 198, 1513, 1514, "-" +397, 12, 59, 353, 199, 200, 1515, 1516, "0" +397, 12, 60, 354, 201, 202, 1517, 1518, "." +397, 12, 61, 355, 203, 205, 1519, 1521, "40" +397, 12, 62, 356, 206, 207, 1522, 1523, "%" +397, 12, 63, 357, 208, 209, 1524, 1525, ")" +397, 12, 64, 358, 210, 212, 1526, 1528, "in" +397, 12, 65, 359, 213, 216, 1529, 1532, "the" +397, 12, 66, 360, 217, 229, 1533, 1545, "omarigliptin" +397, 12, 67, 361, 230, 235, 1546, 1551, "group" +397, 12, 68, 362, 236, 239, 1552, 1555, "and" +397, 12, 69, 363, 240, 241, 1556, 1557, "0" +397, 12, 70, 364, 242, 243, 1558, 1559, "." +397, 12, 71, 365, 244, 246, 1560, 1562, "00" +397, 12, 72, 366, 247, 248, 1563, 1564, "%" +397, 12, 73, 367, 249, 250, 1565, 1566, "(" +397, 12, 74, 368, 251, 252, 1567, 1568, "-" +397, 12, 75, 369, 253, 254, 1569, 1570, "0" +397, 12, 76, 370, 255, 256, 1571, 1572, "." +397, 12, 77, 371, 257, 259, 1573, 1575, "14" +397, 12, 78, 372, 260, 261, 1576, 1577, "%" +397, 12, 79, 373, 262, 263, 1578, 1579, "," +397, 12, 80, 374, 264, 265, 1580, 1581, "0" +397, 12, 81, 375, 266, 267, 1582, 1583, "." +397, 12, 82, 376, 268, 270, 1584, 1586, "15" +397, 12, 83, 377, 271, 272, 1587, 1588, "%" +397, 12, 84, 378, 273, 274, 1589, 1590, ")" +397, 12, 85, 379, 275, 277, 1591, 1593, "in" +397, 12, 86, 380, 278, 281, 1594, 1597, "the" +397, 12, 87, 381, 282, 289, 1598, 1605, "placebo" +397, 12, 88, 382, 290, 295, 1606, 1611, "group" +397, 12, 89, 383, 296, 297, 1612, 1613, "," +397, 12, 90, 384, 298, 301, 1614, 1617, "for" +397, 12, 91, 385, 302, 303, 1618, 1619, "a" +397, 12, 92, 386, 304, 311, 1620, 1627, "between" +397, 12, 93, 387, 312, 313, 1628, 1629, "-" +397, 12, 94, 388, 314, 319, 1630, 1635, "group" +397, 12, 95, 389, 320, 330, 1636, 1646, "difference" +397, 12, 96, 390, 331, 333, 1647, 1649, "of" +397, 12, 97, 391, 334, 335, 1650, 1651, "-" +397, 12, 98, 392, 336, 337, 1652, 1653, "0" +397, 12, 99, 393, 338, 339, 1654, 1655, "." +397, 12, 100, 394, 340, 342, 1656, 1658, "55" +397, 12, 101, 395, 343, 344, 1659, 1660, "%" +397, 12, 102, 396, 345, 346, 1661, 1662, "(" +397, 12, 103, 397, 347, 348, 1663, 1664, "-" +397, 12, 104, 398, 349, 350, 1665, 1666, "0" +397, 12, 105, 399, 351, 352, 1667, 1668, "." +397, 12, 106, 400, 353, 355, 1669, 1671, "75" +397, 12, 107, 401, 356, 357, 1672, 1673, "%" +397, 12, 108, 402, 358, 359, 1674, 1675, "," +397, 12, 109, 403, 360, 361, 1676, 1677, "-" +397, 12, 110, 404, 362, 363, 1678, 1679, "0" +397, 12, 111, 405, 364, 365, 1680, 1681, "." +397, 12, 112, 406, 366, 368, 1682, 1684, "34" +397, 12, 113, 407, 369, 370, 1685, 1686, "%" +397, 12, 114, 408, 371, 372, 1687, 1688, ")" +397, 12, 115, 409, 373, 374, 1689, 1690, ";" +397, 12, 116, 410, 375, 376, 1691, 1692, "p" +397, 12, 117, 411, 377, 381, 1693, 1697, " < ." +397, 12, 118, 412, 382, 385, 1698, 1701, "001" +397, 12, 119, 413, 386, 387, 1702, 1703, "." +397, 13, 1, 414, 0, 7, 1704, 1711, "Between" +397, 13, 2, 415, 8, 9, 1712, 1713, "-" +397, 13, 3, 416, 10, 15, 1714, 1719, "group" +397, 13, 4, 417, 16, 27, 1720, 1731, "differences" +397, 13, 5, 418, 28, 29, 1732, 1733, "(" +397, 13, 6, 419, 30, 32, 1734, 1736, "LS" +397, 13, 7, 420, 33, 37, 1737, 1741, "mean" +397, 13, 8, 421, 38, 40, 1742, 1744, "95" +397, 13, 9, 422, 41, 42, 1745, 1746, "%" +397, 13, 10, 423, 43, 45, 1747, 1749, "CI" +397, 13, 11, 424, 46, 47, 1750, 1751, ")" +397, 13, 12, 425, 48, 51, 1752, 1755, "for" +397, 13, 13, 426, 52, 55, 1756, 1759, "the" +397, 13, 14, 427, 56, 65, 1760, 1769, "secondary" +397, 13, 15, 428, 66, 69, 1770, 1773, "end" +397, 13, 16, 429, 70, 71, 1774, 1775, "-" +397, 13, 17, 430, 72, 78, 1776, 1782, "points" +397, 13, 18, 431, 79, 81, 1783, 1785, "of" +397, 13, 19, 432, 82, 83, 1786, 1787, "2" +397, 13, 20, 433, 84, 85, 1788, 1789, "-" +397, 13, 21, 434, 86, 87, 1790, 1791, "h" +397, 13, 22, 435, 88, 92, 1792, 1796, "post" +397, 13, 23, 436, 93, 94, 1797, 1798, "-" +397, 13, 24, 437, 95, 99, 1799, 1803, "meal" +397, 13, 25, 438, 100, 107, 1804, 1811, "glucose" +397, 13, 26, 439, 108, 111, 1812, 1815, "and" +397, 13, 27, 440, 112, 119, 1816, 1823, "fasting" +397, 13, 28, 441, 120, 126, 1824, 1830, "plasma" +397, 13, 29, 442, 127, 134, 1831, 1838, "glucose" +397, 13, 30, 443, 135, 136, 1839, 1840, "(" +397, 13, 31, 444, 137, 149, 1841, 1853, "omarigliptin" +397, 13, 32, 445, 150, 152, 1854, 1856, "vs" +397, 13, 33, 446, 153, 160, 1857, 1864, "placebo" +397, 13, 34, 447, 161, 162, 1865, 1866, ")" +397, 13, 35, 448, 163, 167, 1867, 1871, "were" +397, 13, 36, 449, 168, 169, 1872, 1873, "-" +397, 13, 37, 450, 170, 171, 1874, 1875, "0" +397, 13, 38, 451, 172, 173, 1876, 1877, "." +397, 13, 39, 452, 174, 175, 1878, 1879, "8" +397, 13, 40, 453, 176, 177, 1880, 1881, " " +397, 13, 41, 454, 178, 182, 1882, 1886, "mmol" +397, 13, 42, 455, 183, 184, 1887, 1888, "/" +397, 13, 43, 456, 185, 186, 1889, 1890, "L" +397, 13, 44, 457, 187, 188, 1891, 1892, "(" +397, 13, 45, 458, 189, 190, 1893, 1894, "-" +397, 13, 46, 459, 191, 192, 1895, 1896, "1" +397, 13, 47, 460, 193, 194, 1897, 1898, "." +397, 13, 48, 461, 195, 196, 1899, 1900, "4" +397, 13, 49, 462, 197, 198, 1901, 1902, "," +397, 13, 50, 463, 199, 200, 1903, 1904, "-" +397, 13, 51, 464, 201, 202, 1905, 1906, "0" +397, 13, 52, 465, 203, 204, 1907, 1908, "." +397, 13, 53, 466, 205, 206, 1909, 1910, "2" +397, 13, 54, 467, 207, 208, 1911, 1912, ")" +397, 13, 55, 468, 209, 210, 1913, 1914, "(" +397, 13, 56, 469, 211, 212, 1915, 1916, "p" +397, 13, 57, 470, 213, 217, 1917, 1921, " = ." +397, 13, 58, 471, 218, 221, 1922, 1925, "011" +397, 13, 59, 472, 222, 223, 1926, 1927, ")" +397, 13, 60, 473, 224, 227, 1928, 1931, "and" +397, 13, 61, 474, 228, 229, 1932, 1933, "-" +397, 13, 62, 475, 230, 231, 1934, 1935, "0" +397, 13, 63, 476, 232, 233, 1936, 1937, "." +397, 13, 64, 477, 234, 235, 1938, 1939, "5" +397, 13, 65, 478, 236, 240, 1940, 1944, "mmol" +397, 13, 66, 479, 241, 242, 1945, 1946, "/" +397, 13, 67, 480, 243, 244, 1947, 1948, "L" +397, 13, 68, 481, 245, 246, 1949, 1950, "(" +397, 13, 69, 482, 247, 248, 1951, 1952, "-" +397, 13, 70, 483, 249, 250, 1953, 1954, "0" +397, 13, 71, 484, 251, 252, 1955, 1956, "." +397, 13, 72, 485, 253, 254, 1957, 1958, "9" +397, 13, 73, 486, 255, 256, 1959, 1960, "," +397, 13, 74, 487, 257, 258, 1961, 1962, "-" +397, 13, 75, 488, 259, 260, 1963, 1964, "0" +397, 13, 76, 489, 261, 262, 1965, 1966, "." +397, 13, 77, 490, 263, 264, 1967, 1968, "1" +397, 13, 78, 491, 265, 266, 1969, 1970, ")" +397, 13, 79, 492, 267, 268, 1971, 1972, "(" +397, 13, 80, 493, 269, 270, 1973, 1974, "p" +397, 13, 81, 494, 271, 275, 1975, 1979, " = ." +397, 13, 82, 495, 276, 279, 1980, 1983, "010" +397, 13, 83, 496, 280, 281, 1984, 1985, ")" +397, 13, 84, 497, 282, 283, 1986, 1987, "," +397, 13, 85, 498, 284, 296, 1988, 2000, "respectively" +397, 13, 86, 499, 297, 298, 2001, 2002, "." +397, 14, 1, 500, 0, 2, 2003, 2005, "At" +397, 14, 2, 501, 3, 7, 2006, 2010, "week" +397, 14, 3, 502, 8, 10, 2011, 2013, "24" +397, 14, 4, 503, 11, 12, 2014, 2015, "," +397, 14, 5, 504, 13, 16, 2016, 2019, "the" +397, 14, 6, 505, 17, 27, 2020, 2030, "incidences" +397, 14, 7, 506, 28, 30, 2031, 2033, "of" +397, 14, 8, 507, 31, 42, 2034, 2045, "symptomatic" +397, 14, 9, 508, 43, 55, 2046, 2058, "hypoglycemia" +397, 14, 10, 509, 56, 59, 2059, 2062, "and" +397, 14, 11, 510, 60, 68, 2063, 2071, "subjects" +397, 14, 12, 511, 69, 73, 2072, 2076, "with" +397, 14, 13, 512, 74, 77, 2077, 2080, "one" +397, 14, 14, 513, 78, 80, 2081, 2083, "or" +397, 14, 15, 514, 81, 85, 2084, 2088, "more" +397, 14, 16, 515, 86, 93, 2089, 2096, "adverse" +397, 14, 17, 516, 94, 99, 2097, 2102, "event" +397, 14, 18, 517, 100, 101, 2103, 2104, "(" +397, 14, 19, 518, 102, 104, 2105, 2107, "AE" +397, 14, 20, 519, 105, 106, 2108, 2109, ")" +397, 14, 21, 520, 107, 108, 2110, 2111, "," +397, 14, 22, 521, 109, 116, 2112, 2119, "serious" +397, 14, 23, 522, 117, 120, 2120, 2123, "AEs" +397, 14, 24, 523, 121, 122, 2124, 2125, "," +397, 14, 25, 524, 123, 126, 2126, 2129, "and" +397, 14, 26, 525, 127, 143, 2130, 2146, "discontinuations" +397, 14, 27, 526, 144, 147, 2147, 2150, "due" +397, 14, 28, 527, 148, 150, 2151, 2153, "to" +397, 14, 29, 528, 151, 153, 2154, 2156, "an" +397, 14, 30, 529, 154, 156, 2157, 2159, "AE" +397, 14, 31, 530, 157, 161, 2160, 2164, "were" +397, 14, 32, 531, 162, 169, 2165, 2172, "similar" +397, 14, 33, 532, 170, 172, 2173, 2175, "in" +397, 14, 34, 533, 173, 176, 2176, 2179, "the" +397, 14, 35, 534, 177, 189, 2180, 2192, "omarigliptin" +397, 14, 36, 535, 190, 193, 2193, 2196, "and" +397, 14, 37, 536, 194, 201, 2197, 2204, "placebo" +397, 14, 38, 537, 202, 208, 2205, 2211, "groups" +397, 14, 39, 538, 209, 210, 2212, 2213, "." +397, 15, 1, 539, 0, 4, 2214, 2218, "Over" +397, 15, 2, 540, 5, 8, 2219, 2222, "104" +397, 15, 3, 541, 9, 14, 2223, 2228, "weeks" +397, 15, 4, 542, 15, 16, 2229, 2230, "," +397, 15, 5, 543, 17, 29, 2231, 2243, "omarigliptin" +397, 15, 6, 544, 30, 39, 2244, 2253, "treatment" +397, 15, 7, 545, 40, 48, 2254, 2262, "provided" +397, 15, 8, 546, 49, 50, 2263, 2264, "a" +397, 15, 9, 547, 51, 61, 2265, 2275, "clinically" +397, 15, 10, 548, 62, 72, 2276, 2286, "meaningful" +397, 15, 11, 549, 73, 82, 2287, 2296, "reduction" +397, 15, 12, 550, 83, 85, 2297, 2299, "in" +397, 15, 13, 551, 86, 91, 2300, 2305, "HbA1c" +397, 15, 14, 552, 92, 93, 2306, 2307, "." +397, 16, 1, 553, 0, 11, 2308, 2319, "CONCLUSIONS" +397, 16, 2, 554, 12, 13, 2320, 2321, ":" +397, 16, 3, 555, 14, 16, 2322, 2324, "In" +397, 16, 4, 556, 17, 25, 2325, 2333, "patients" +397, 16, 5, 557, 26, 30, 2334, 2338, "with" +397, 16, 6, 558, 31, 35, 2339, 2343, "T2DM" +397, 16, 7, 559, 36, 37, 2344, 2345, "," +397, 16, 8, 560, 38, 44, 2346, 2352, "adding" +397, 16, 9, 561, 45, 57, 2353, 2365, "omarigliptin" +397, 16, 10, 562, 58, 60, 2366, 2368, "25" +397, 16, 11, 563, 61, 62, 2369, 2370, " " +397, 16, 12, 564, 63, 65, 2371, 2373, "mg" +397, 16, 13, 565, 66, 67, 2374, 2375, "q" +397, 16, 14, 566, 68, 69, 2376, 2377, "." +397, 16, 15, 567, 70, 71, 2378, 2379, "w" +397, 16, 16, 568, 72, 73, 2380, 2381, "." +397, 17, 1, 569, 0, 2, 2382, 2384, "to" +397, 17, 2, 570, 3, 12, 2385, 2394, "metformin" +397, 17, 3, 571, 13, 24, 2395, 2406, "monotherapy" +397, 17, 4, 572, 25, 33, 2407, 2415, "improved" +397, 17, 5, 573, 34, 42, 2416, 2424, "glycemic" +397, 17, 6, 574, 43, 50, 2425, 2432, "control" +397, 17, 7, 575, 51, 55, 2433, 2437, "over" +397, 17, 8, 576, 56, 59, 2438, 2441, "104" +397, 17, 9, 577, 60, 65, 2442, 2447, "weeks" +397, 17, 10, 578, 66, 69, 2448, 2451, "and" +397, 17, 11, 579, 70, 73, 2452, 2455, "was" +397, 17, 12, 580, 74, 83, 2456, 2465, "generally" +397, 17, 13, 581, 84, 97, 2466, 2479, "welltolerated" +397, 17, 14, 582, 98, 102, 2480, 2484, "with" +397, 17, 15, 583, 103, 104, 2485, 2486, "a" +397, 17, 16, 584, 105, 108, 2487, 2490, "low" +397, 17, 17, 585, 109, 113, 2491, 2495, "risk" +397, 17, 18, 586, 114, 116, 2496, 2498, "of" +397, 17, 19, 587, 117, 129, 2499, 2511, "hypoglycemia" +397, 17, 20, 588, 130, 131, 2512, 2513, "." +397, 18, 1, 589, 0, 3, 2514, 2517, "DOI" +397, 18, 2, 590, 4, 5, 2518, 2519, ":" +397, 18, 3, 591, 6, 8, 2520, 2522, "10" +397, 18, 4, 592, 9, 10, 2523, 2524, "." +397, 18, 5, 593, 11, 15, 2525, 2529, "1080" +397, 18, 6, 594, 16, 17, 2530, 2531, "/" +397, 18, 7, 595, 18, 26, 2532, 2540, "03007995" +397, 18, 8, 596, 27, 28, 2541, 2542, "." +397, 18, 9, 597, 29, 33, 2543, 2547, "2017" +397, 18, 10, 598, 34, 35, 2548, 2549, "." +397, 18, 11, 599, 36, 43, 2550, 2557, "1335637" +397, 18, 12, 600, 44, 48, 2558, 2562, "PMID" +397, 18, 13, 601, 49, 50, 2563, 2564, ":" +397, 18, 14, 602, 51, 59, 2565, 2573, "28547998" +397, 18, 15, 603, 60, 61, 2574, 2575, "[" +397, 18, 16, 604, 62, 69, 2576, 2583, "Indexed" +397, 18, 17, 605, 70, 73, 2584, 2587, "for" +397, 18, 18, 606, 74, 81, 2588, 2595, "MEDLINE" +397, 18, 19, 607, 82, 83, 2596, 2597, "]" diff --git a/data/dm2 28547998_kwoodley.annodb b/data/dm2 28547998_kwoodley.annodb new file mode 100644 index 0000000..0dbd86c --- /dev/null +++ b/data/dm2 28547998_kwoodley.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71775, Journal, 0, 17, "Curr Med Res Opin", "", +71776, PublicationYear, 20, 24, "2017", "", +71796, Title, 122, 337, "A randomized clinical trial evaluating the efficacy and safety of the once - weekly dipeptidyl peptidase - 4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", +71777, Randomized, 124, 134, "randomized", "", +71778, Frequency, 192, 205, "once - weekly", "", +71779, Omarigliptin, 241, 253, "omarigliptin", "", +71795, Precondition, 257, 335, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +71786, Type2Diabetes, 271, 286, "type 2 diabetes", "", +71791, Metformin, 314, 323, "metformin", "", +71797, Author, 338, 348, "Shankar RR", "", +71798, Author, 357, 368, "Inzucchi SE", "", +71799, Author, 377, 389, "Scarabello V", "", +71800, Author, 398, 405, "Gantz I", "", +71801, Author, 414, 424, "Kaufman KD", "", +71802, Author, 433, 438, "Lai E", "", +71803, Author, 447, 455, "Ceesay P", "", +71804, Author, 464, 477, "Suryawanshi S", "", +71805, Author, 486, 494, "Engel SS", "", +71806, USA, 573, 576, "USA", "", +71807, USA, 708, 711, "USA", "", +71813, ObjectiveDescription, 726, 793, "To examine the efficacy and safety of the once - weekly ( q . w . )", "", +71808, Frequency, 768, 781, "once - weekly", "", +71809, Frequency, 784, 791, "q . w .", "", +71814, ObjectiveDescription, 794, 946, "dipeptidyl peptidase - 4 inhibitor , omarigliptin , in patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", +71780, Omarigliptin, 831, 843, "omarigliptin", "", +71812, Precondition, 849, 944, "patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy", "", +71787, Type2Diabetes, 863, 878, "type 2 diabetes", "", +71788, Type2Diabetes, 881, 885, "T2DM", "", +71792, Metformin, 923, 932, "metformin", "", +71815, Randomized, 962, 972, "randomized", "", +71816, DoubleBlind, 975, 989, "double - blind", "", +71822, Precondition, 998, 1135, "patients with T2DM on a stable dose of metformin monotherapy ( ≥ 1500   mg / day ) with glycated hemoglobin ( HbA1c ) of 7 . 0 - 10 . 5 %", "", +71789, Type2Diabetes, 1012, 1016, "T2DM", "", +71793, Metformin, 1037, 1046, "metformin", "", +71817, DoseValue, 1061, 1067, "≥ 1500", "", +71818, mg, 1070, 1072, "mg", "", +71819, Frequency, 1075, 1078, "day", "", +71820, HbA1c, 1108, 1113, "HbA1c", "", +71821, Percentage, 1134, 1135, "%", "", +71823, Randomized, 1141, 1151, "randomized", "", +71781, Omarigliptin, 1155, 1167, "omarigliptin", "", +71824, DoseValue, 1168, 1170, "25", "", +71825, mg, 1173, 1175, "mg", "", +71810, Frequency, 1176, 1183, "q . w .", "", +71826, Placebo, 1196, 1203, "placebo", "", +71829, NumberPatientsArm, 1212, 1215, "201", "", +71830, Duration, 1230, 1238, "24 weeks", "", +71831, TimePoint, 1329, 1336, "week 24", "", +71832, TimePoint, 1351, 1359, "baseline", "", +71836, HbA1c, 1360, 1365, "HbA1c", "", +71837, BaseLineValue, 1369, 1382, "8 . 0 - 8 . 1", "", +71838, Percentage, 1383, 1384, "%", "", +71839, LeastSquaresMean, 1391, 1416, "least squares ( LS ) mean", "", +71840, ConfIntervalBL, 1419, 1426, "95 % CI", "", +71833, TimePoint, 1441, 1449, "baseline", "", +71841, HbA1c, 1453, 1458, "HbA1c", "", +71842, Reduction, 1489, 1495, "0 . 54", "", +71846, Percentage, 1496, 1497, "%", "", +71843, Reduction, 1502, 1508, "0 . 69", "", +71847, Percentage, 1509, 1510, "%", "", +71844, Reduction, 1515, 1521, "0 . 40", "", +71848, Percentage, 1522, 1523, "%", "", +71782, Omarigliptin, 1533, 1545, "omarigliptin", "", +71855, ResultMeasuredValue, 1556, 1562, "0 . 00", "", +71849, Percentage, 1563, 1564, "%", "", +71845, Reduction, 1569, 1575, "0 . 14", "", +71850, Percentage, 1576, 1577, "%", "", +71856, Increment, 1580, 1586, "0 . 15", "", +71851, Percentage, 1587, 1588, "%", "", +71827, Placebo, 1598, 1605, "placebo", "", +71857, DiffGroupAbsValue, 1650, 1658, "- 0 . 55", "", +71852, Percentage, 1659, 1660, "%", "", +71858, DiffGroupAbsValue, 1663, 1671, "- 0 . 75", "", +71853, Percentage, 1672, 1673, "%", "", +71859, DiffGroupAbsValue, 1676, 1684, "- 0 . 34", "", +71854, Percentage, 1685, 1686, "%", "", +71860, PvalueDiff, 1691, 1701, "p  < . 001", "", +71861, LeastSquaresMean, 1734, 1741, "LS mean", "", +71862, ConfIntervalDiff, 1742, 1749, "95 % CI", "", +71863, PostprandialBloodGlucose, 1786, 1811, "2 - h post - meal glucose", "", +71864, FastingPlasmaGlucose, 1816, 1838, "fasting plasma glucose", "", +71865, Omarigliptin, 1841, 1853, "omarigliptin", "", +71866, Placebo, 1857, 1864, "placebo", "", +71867, DiffGroupAbsValue, 1872, 1879, "- 0 . 8", "", +71869, Millimoles_per_litre, 1882, 1890, "mmol / L", "", +71868, ConfIntervalDiff, 1893, 1910, "- 1 . 4 , - 0 . 2", "", +71871, PvalueDiff, 1915, 1925, "p  = . 011", "", +71873, DiffGroupAbsValue, 1932, 1939, "- 0 . 5", "", +71870, Millimoles_per_litre, 1940, 1948, "mmol / L", "", +71874, ConfIntervalDiff, 1951, 1968, "- 0 . 9 , - 0 . 1", "", +71872, PvalueDiff, 1973, 1983, "p  = . 010", "", +71834, TimePoint, 2006, 2013, "week 24", "", +71881, ObservedResult, 2016, 2211, "the incidences of symptomatic hypoglycemia and subjects with one or more adverse event ( AE ) , serious AEs , and discontinuations due to an AE were similar in the omarigliptin and placebo groups", "", +71875, SymptomaticHypoglycemia, 2034, 2058, "symptomatic hypoglycemia", "", +71880, SubGroupDescription, 2077, 2088, "one or more", "", +71876, EndPointDescription, 2089, 2102, "adverse event", "", +71877, EndPointDescription, 2105, 2107, "AE", "", +71878, EndPointDescription, 2112, 2123, "serious AEs", "", +71879, SubGroupDescription, 2130, 2159, "discontinuations due to an AE", "", +71783, Omarigliptin, 2180, 2192, "omarigliptin", "", +71828, Placebo, 2197, 2204, "placebo", "", +71835, TimePoint, 2219, 2228, "104 weeks", "", +71784, Omarigliptin, 2231, 2243, "omarigliptin", "", +71883, ObservedResult, 2231, 2305, "omarigliptin treatment provided a clinically meaningful reduction in HbA1c", "", +71882, HbA1c, 2300, 2305, "HbA1c", "", +71889, ConclusionComment, 2322, 2381, "In patients with T2DM , adding omarigliptin 25   mg q . w .", "", +71790, Type2Diabetes, 2339, 2343, "T2DM", "", +71785, Omarigliptin, 2353, 2365, "omarigliptin", "", +71884, DoseValue, 2366, 2368, "25", "", +71885, mg, 2371, 2373, "mg", "", +71811, Frequency, 2374, 2381, "q . w .", "", +71888, ConclusionComment, 2382, 2513, "to metformin monotherapy improved glycemic control over 104 weeks and was generally welltolerated with a low risk of hypoglycemia .", "", +71794, Metformin, 2385, 2394, "metformin", "", +71886, Duration, 2438, 2447, "104 weeks", "", +71887, Hypoglycemia, 2499, 2511, "hypoglycemia", "", +71890, PMID, 2565, 2573, "28547998", "", diff --git a/data/dm2 28547998_kwoodley.n-triples b/data/dm2 28547998_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28547998_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28548024_admin.annodb b/data/dm2 28548024_admin.annodb new file mode 100644 index 0000000..14b1013 --- /dev/null +++ b/data/dm2 28548024_admin.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2017", "", " \"2017\"." +10, Title, 122, 365, "A randomized , double - blind , non - inferiority trial evaluating the efficacy and safety of omarigliptin , a once - weekly DPP - 4 inhibitor , or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", " \"A randomized , double - blind , non - inferiority trial evaluating the efficacy and safety of omarigliptin , a once - weekly DPP - 4 inhibitor , or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy .\"." +2, Randomized, 124, 134, "randomized", "", " ." +3, DoubleBlind, 137, 151, "double - blind", "", " ." +110, CTDesign, 154, 171, "non - inferiority", "", " . ." +4, Omarigliptin, 216, 228, "omarigliptin", "", +5, Frequency, 233, 246, "once - weekly", "", +6, Glimepiride, 270, 281, "glimepiride", "", +141, Precondition, 285, 363, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +7, Type2Diabetes, 299, 314, "type 2 diabetes", "", +9, Metformin, 342, 351, "metformin", "", +11, Author, 366, 378, "Handelsman Y", "", " \"Handelsman Y\"." +12, Author, 387, 396, "Lauring B", "", " \"Lauring B\"." +13, Author, 405, 412, "Gantz I", "", " \"Gantz I\"." +14, Author, 421, 430, "Iredale C", "", " \"Iredale C\"." +15, Author, 439, 451, "O ' Neill EA", "", " \"O ' Neill EA\"." +16, Author, 460, 465, "Wei Z", "", " \"Wei Z\"." +17, Author, 474, 487, "Suryawanshi S", "", " \"Suryawanshi S\"." +18, Author, 496, 506, "Kaufman KD", "", " \"Kaufman KD\"." +19, Author, 515, 523, "Engel SS", "", " \"Engel SS\"." +20, Author, 532, 537, "Lai E", "", " \"Lai E\"." +21, USA, 623, 626, "USA", "", " ." +22, USA, 678, 681, "USA", "", +30, ObjectiveDescription, 814, 1066, "To evaluate the efficacy and safety of adding the once - weekly DPP - 4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", " \"To evaluate the efficacy and safety of adding the once - weekly DPP - 4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .\"." +23, Frequency, 864, 877, "once - weekly", "", +24, Omarigliptin, 896, 908, "omarigliptin", "", +156, Sulfonylureas, 916, 928, "sulfonylurea", "", +25, Glimepiride, 929, 940, "glimepiride", "", +157, Precondition, 969, 1064, "patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy", "", +26, Type2Diabetes, 983, 998, "type 2 diabetes", "", " ." +27, Type2Diabetes, 1001, 1005, "T2DM", "", +29, Metformin, 1043, 1052, "metformin", "", +169, Precondition, 1077, 1186, "Patients with T2DM and HbA1c ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500   mg / day )", "", " \"Patients with T2DM and HbA1c ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500   mg / day )\"." +31, Type2Diabetes, 1091, 1095, "T2DM", "", +33, HbA1c, 1100, 1105, "HbA1c", "", +34, Percentage, 1114, 1115, "%", "", +35, Percentage, 1127, 1128, "%", "", +44, Metformin, 1155, 1164, "metformin", "", +162, DoseValue, 1167, 1173, "≥ 1500", "", +165, mg, 1176, 1178, "mg", "", +168, Frequency, 1181, 1184, "day", "", +47, Randomized, 1192, 1202, "randomized", "", +48, Omarigliptin, 1206, 1218, "omarigliptin", "", " ." +163, DoseValue, 1219, 1221, "25", "", " \"25\"." +50, mg, 1224, 1226, "mg", "", " ." +51, Frequency, 1227, 1240, "once - weekly", "", " \"once - weekly\"." +57, NumberPatientsArm, 1249, 1252, "376", "", " \"376\"." +54, Glimepiride, 1258, 1269, "glimepiride", "", " ." +164, DoseDescription, 1270, 1293, "up to 6   mg once daily", "", " \"up to 6   mg once daily\"." +55, DoseValue, 1276, 1282, "6   mg", "", " \"6   mg\"." +53, mg, 1280, 1282, "mg", "", " \"once daily\"." +52, Frequency, 1283, 1293, "once daily", "", " \"once daily\"." +58, NumberPatientsArm, 1302, 1305, "375", "", " \"375\"." +56, Duration, 1312, 1320, "54 weeks", "", " \"54 weeks\"." +59, Omarigliptin, 1355, 1367, "omarigliptin", "", +60, Glimepiride, 1389, 1400, "glimepiride", "", +61, HbA1c, 1413, 1418, "HbA1c", "", +62, TimePoint, 1422, 1429, "week 54", "", +66, Mean, 1446, 1450, "mean", "", +63, TimePoint, 1451, 1459, "baseline", "", +67, HbA1c, 1460, 1465, "HbA1c", "", " ." +69, BaseLineValue, 1470, 1475, "7 . 5", "", " \"7 . 5\"." +36, Percentage, 1476, 1477, "%", "", " ." +71, Omarigliptin, 1485, 1497, "omarigliptin", "", +70, BaseLineValue, 1508, 1513, "7 . 4", "", " \"7 . 4\"." +37, Percentage, 1514, 1515, "%", "", +72, Glimepiride, 1523, 1534, "glimepiride", "", +64, TimePoint, 1549, 1557, "54 weeks", "", +65, LeastSquaresMean, 1564, 1589, "least squares ( LS ) mean", "", " ." +73, TimePoint, 1602, 1610, "baseline", "", +68, HbA1c, 1614, 1619, "HbA1c", "", +186, Reduction, 1626, 1632, "0 . 30", "", " \"0 . 30\"." +38, Percentage, 1633, 1634, "%", "", +76, Omarigliptin, 1642, 1654, "omarigliptin", "", +187, Reduction, 1667, 1673, "0 . 48", "", " \"0 . 48\"." +39, Percentage, 1674, 1675, "%", "", +77, Glimepiride, 1683, 1694, "glimepiride", "", +191, ConfIntervalDiff, 1739, 1746, "95 % CI", "", " \"95 % CI\"." +78, DiffGroupAbsValue, 1752, 1758, "0 . 18", "", " \"0 . 18\"." +41, Percentage, 1759, 1760, "%", "", +191, ConfIntervalDiff, 1763, 1778, "0 . 06 , 0 . 30", "", " \"0 . 06 , 0 . 30\"." +80, SymptomaticHypoglycemia, 1874, 1898, "symptomatic hypoglycemia", "", " ." +81, PercentageAffected, 1903, 1908, "5 . 3", "", " \"5 . 3\"." +83, Omarigliptin, 1918, 1930, "omarigliptin", "", +82, PercentageAffected, 1941, 1947, "26 . 7", "", " \"26 . 7\"." +84, Glimepiride, 1957, 1968, "glimepiride", "", +99676, ObservedResult, 1977, 2105, "With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups", "", " \"With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups\". \"With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups\"." +85, Hypoglycemia, 1999, 2011, "hypoglycemia", "", " ." +198, EndPointDescription, 2032, 2046, "adverse events", "", " . ." +86, TimePoint, 2120, 2128, "baseline", "", +87, Omarigliptin, 2131, 2143, "omarigliptin", "", +89, Mean, 2166, 2170, "mean", "", " . ." +201, BodyWeight, 2171, 2177, "weight", "", " ." +203, Reduction, 2187, 2192, "0 . 4", "", " \"0 . 4\"." +95, Kg, 2195, 2197, "kg", "", " ." +88, Glimepiride, 2204, 2215, "glimepiride", "", +90, Mean, 2218, 2222, "mean", "", +202, BodyWeight, 2223, 2229, "weight", "", +206, Increment, 2239, 2244, "1 . 5", "", " \"1 . 5\"." +96, Kg, 2247, 2249, "kg", "", +211, ConclusionComment, 2268, 2518, "After 54 weeks , as add - on therapy to metformin , once - weekly omarigliptin was generally well tolerated and non - inferior to glimepiride in improving glycemic control , with a lower incidence of hypoglycemia and with weight loss vs weight gain .", "", " \"After 54 weeks , as add - on therapy to metformin , once - weekly omarigliptin was generally well tolerated and non - inferior to glimepiride in improving glycemic control , with a lower incidence of hypoglycemia and with weight loss vs weight gain .\"." +97, Duration, 2274, 2282, "54 weeks", "", +98, Metformin, 2308, 2317, "metformin", "", +99, Frequency, 2320, 2333, "once - weekly", "", +100, Omarigliptin, 2334, 2346, "omarigliptin", "", +101, Glimepiride, 2398, 2409, "glimepiride", "", +102, Hypoglycemia, 2468, 2480, "hypoglycemia", "", +103, WeightReduction, 2490, 2501, "weight loss", "", +104, WeightGain, 2505, 2516, "weight gain", "", +105, PMID, 2570, 2578, "28548024", "", " \"28548024\"." diff --git a/data/dm2 28548024_admin.n-triples b/data/dm2 28548024_admin.n-triples new file mode 100644 index 0000000..58eb31f --- /dev/null +++ b/data/dm2 28548024_admin.n-triples @@ -0,0 +1,164 @@ +# RDF export of group: Publication + . + "Publication " . + "A randomized , double - blind , non - inferiority trial evaluating the efficacy and safety of omarigliptin , a once - weekly DPP - 4 inhibitor , or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy ." . + "Handelsman Y" . + "2017" . + "Curr Med Res Opin ." . + "28548024" . + . + "Lauring B" . + "Gantz I" . + "Iredale C" . + "O ' Neill EA" . + "Wei Z" . + "Suryawanshi S" . + "Kaufman KD" . + "Engel SS" . + "Lai E" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the efficacy and safety of adding the once - weekly DPP - 4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy ." . + "54 weeks" . + . + . + . + "After 54 weeks , as add - on therapy to metformin , once - weekly omarigliptin was generally well tolerated and non - inferior to glimepiride in improving glycemic control , with a lower incidence of hypoglycemia and with weight loss vs weight gain ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "Patients with T2DM and HbA1c ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500   mg / day )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint hba1c" . + . + . + . + . + . + "Endpoint sh" . + . + . + . + . + . + "Endpoint h" . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint weight" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm o " . + "376" . + . + . + . + . + . + . + . + "Arm g" . + "375" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention o " . + . + "once - weekly" . + . + . + "Intervention g" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication o" . + . + "25" . + . + . + . + "Medication g" . + . + "6   mg" . + . + . + "up to 6   mg once daily" . +# RDF export of group: Outcome + . + "Outcome hba1c o" . + . + "7 . 5" . + "0 . 30" . + . + "Outcome g" . + . + "7 . 4" . + "0 . 48" . + . + "Outcome sh o " . + . + "5 . 3" . + . + "Outcome sh g" . + . + "26 . 7" . + . + "Outcome h both drugs" . + . + "With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups" . + . + "Outcome aes both drugs" . + . + "With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups" . + . + "Outcome weight o " . + . + "0 . 4" . + . + "Outcome weight g" . + . + "1 . 5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups hba1c " . + "0 . 18" . + "95 % CI" . + "0 . 06 , 0 . 30" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28548024_akramersunderbrink.annodb b/data/dm2 28548024_akramersunderbrink.annodb new file mode 100644 index 0000000..b39014f --- /dev/null +++ b/data/dm2 28548024_akramersunderbrink.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70373, Journal, 0, 17, "Curr Med Res Opin", "", +70374, PublicationYear, 20, 24, "2017", "", +70383, Title, 122, 365, "A randomized , double - blind , non - inferiority trial evaluating the efficacy and safety of omarigliptin , a once - weekly DPP - 4 inhibitor , or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", +70375, Randomized, 124, 134, "randomized", "", +70376, DoubleBlind, 137, 151, "double - blind", "", +70377, Omarigliptin, 216, 228, "omarigliptin", "", +70378, Frequency, 233, 246, "once - weekly", "", +70379, Glimepiride, 270, 281, "glimepiride", "", +70380, Type2Diabetes, 299, 314, "type 2 diabetes", "", +70381, Precondition, 315, 363, "inadequately controlled on metformin monotherapy", "", +70382, Metformin, 342, 351, "metformin", "", +70384, Author, 366, 378, "Handelsman Y", "", +70385, Author, 387, 396, "Lauring B", "", +70386, Author, 405, 412, "Gantz I", "", +70387, Author, 421, 430, "Iredale C", "", +70388, Author, 439, 451, "O ' Neill EA", "", +70389, Author, 460, 465, "Wei Z", "", +70390, Author, 474, 487, "Suryawanshi S", "", +70391, Author, 496, 506, "Kaufman KD", "", +70392, Author, 515, 523, "Engel SS", "", +70393, Author, 532, 537, "Lai E", "", +70394, USA, 623, 626, "USA", "", +70395, USA, 678, 681, "USA", "", +70403, ObjectiveDescription, 814, 1066, "To evaluate the efficacy and safety of adding the once - weekly DPP - 4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", +70396, Frequency, 864, 877, "once - weekly", "", +70397, Omarigliptin, 896, 908, "omarigliptin", "", +70398, Glimepiride, 929, 940, "glimepiride", "", +70399, Type2Diabetes, 983, 998, "type 2 diabetes", "", +70400, Type2Diabetes, 1001, 1005, "T2DM", "", +70401, Precondition, 1012, 1064, "inadequate glycemic control on metformin monotherapy", "", +70402, Metformin, 1043, 1052, "metformin", "", +70404, Type2Diabetes, 1091, 1095, "T2DM", "", +70405, Precondition, 1100, 1186, "HbA1c ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500   mg / day )", "", +70406, HbA1c, 1100, 1105, "HbA1c", "", +70407, Percentage, 1114, 1115, "%", "", +70408, Percentage, 1127, 1128, "%", "", +70417, Metformin, 1155, 1164, "metformin", "", +70418, DoseValue, 1165, 1184, "( ≥ 1500   mg / day", "", +70419, BioAndMedicalUnit, 1176, 1184, "mg / day", "", +70420, Randomized, 1192, 1202, "randomized", "", +70421, Omarigliptin, 1206, 1218, "omarigliptin", "", +70422, DoseValue, 1219, 1226, "25   mg", "", +70423, mg, 1224, 1226, "mg", "", +70424, Frequency, 1227, 1240, "once - weekly", "", +70430, NumberPatientsArm, 1249, 1252, "376", "", +70427, Glimepiride, 1258, 1269, "glimepiride", "", +70428, DoseValue, 1276, 1282, "6   mg", "", +70426, mg, 1280, 1282, "mg", "", +70425, Frequency, 1283, 1293, "once daily", "", +70431, NumberPatientsArm, 1302, 1305, "375", "", +70429, Duration, 1312, 1320, "54 weeks", "", +70432, Omarigliptin, 1355, 1367, "omarigliptin", "", +70433, Glimepiride, 1389, 1400, "glimepiride", "", +70434, HbA1c, 1413, 1418, "HbA1c", "", +70435, TimePoint, 1422, 1429, "week 54", "", +70439, Mean, 1446, 1450, "mean", "", +70436, TimePoint, 1451, 1459, "baseline", "", +70440, HbA1c, 1460, 1465, "HbA1c", "", +70442, BaseLineValue, 1470, 1475, "7 . 5", "", +70409, Percentage, 1476, 1477, "%", "", +70444, Omarigliptin, 1485, 1497, "omarigliptin", "", +70443, BaseLineValue, 1508, 1513, "7 . 4", "", +70410, Percentage, 1514, 1515, "%", "", +70445, Glimepiride, 1523, 1534, "glimepiride", "", +70437, TimePoint, 1549, 1557, "54 weeks", "", +70438, LeastSquaresMean, 1564, 1589, "least squares ( LS ) mean", "", +70446, TimePoint, 1602, 1610, "baseline", "", +70441, HbA1c, 1614, 1619, "HbA1c", "", +70447, ChangeValue, 1624, 1632, "- 0 . 30", "", +70411, Percentage, 1633, 1634, "%", "", +70449, Omarigliptin, 1642, 1654, "omarigliptin", "", +70448, ChangeValue, 1665, 1673, "- 0 . 48", "", +70412, Percentage, 1674, 1675, "%", "", +70450, Glimepiride, 1683, 1694, "glimepiride", "", +70413, Percentage, 1742, 1743, "%", "", +70451, DiffGroupAbsValue, 1752, 1758, "0 . 18", "", +70414, Percentage, 1759, 1760, "%", "", +70452, ConfIntervalDiff, 1763, 1778, "0 . 06 , 0 . 30", "", +70453, SymptomaticHypoglycemia, 1874, 1898, "symptomatic hypoglycemia", "", +70454, PercentageAffected, 1903, 1908, "5 . 3", "", +70415, Percentage, 1909, 1910, "%", "", +70456, Omarigliptin, 1918, 1930, "omarigliptin", "", +70455, PercentageAffected, 1941, 1947, "26 . 7", "", +70416, Percentage, 1948, 1949, "%", "", +70457, Glimepiride, 1957, 1968, "glimepiride", "", +70458, Hypoglycemia, 1999, 2011, "hypoglycemia", "", +70459, TimePoint, 2120, 2128, "baseline", "", +70460, Omarigliptin, 2131, 2143, "omarigliptin", "", +70462, Mean, 2166, 2170, "mean", "", +70464, WeightReduction, 2171, 2182, "weight loss", "", +70466, ChangeValue, 2185, 2192, "- 0 . 4", "", +70468, Kg, 2195, 2197, "kg", "", +70461, Glimepiride, 2204, 2215, "glimepiride", "", +70463, Mean, 2218, 2222, "mean", "", +70465, WeightGain, 2223, 2234, "weight gain", "", +70467, ChangeValue, 2237, 2244, "+ 1 . 5", "", +70469, Kg, 2247, 2249, "kg", "", +70470, Duration, 2274, 2282, "54 weeks", "", +70471, Metformin, 2308, 2317, "metformin", "", +70472, Frequency, 2320, 2333, "once - weekly", "", +70473, Omarigliptin, 2334, 2346, "omarigliptin", "", +70474, Glimepiride, 2398, 2409, "glimepiride", "", +70475, Hypoglycemia, 2468, 2480, "hypoglycemia", "", +70476, WeightReduction, 2490, 2501, "weight loss", "", +70477, WeightGain, 2505, 2516, "weight gain", "", +70478, PMID, 2570, 2578, "28548024", "", diff --git a/data/dm2 28548024_akramersunderbrink.n-triples b/data/dm2 28548024_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28548024_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28548024_export.csv b/data/dm2 28548024_export.csv new file mode 100644 index 0000000..4381523 --- /dev/null +++ b/data/dm2 28548024_export.csv @@ -0,0 +1,583 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +396, 1, 1, 1, 0, 4, 0, 4, "Curr" +396, 1, 2, 2, 5, 8, 5, 8, "Med" +396, 1, 3, 3, 9, 12, 9, 12, "Res" +396, 1, 4, 4, 13, 17, 13, 17, "Opin" +396, 1, 5, 5, 18, 19, 18, 19, "." +396, 2, 1, 6, 0, 4, 20, 24, "2017" +396, 2, 2, 7, 5, 8, 25, 28, "Oct" +396, 2, 3, 8, 9, 10, 29, 30, ";" +396, 2, 4, 9, 11, 13, 31, 33, "33" +396, 2, 5, 10, 14, 15, 34, 35, "(" +396, 2, 6, 11, 16, 18, 36, 38, "10" +396, 2, 7, 12, 19, 20, 39, 40, ")" +396, 2, 8, 13, 21, 22, 41, 42, ":" +396, 2, 9, 14, 23, 27, 43, 47, "1861" +396, 2, 10, 15, 28, 29, 48, 49, "-" +396, 2, 11, 16, 30, 34, 50, 54, "1868" +396, 2, 12, 17, 35, 36, 55, 56, "." +396, 2, 13, 18, 37, 40, 57, 60, "doi" +396, 2, 14, 19, 41, 42, 61, 62, ":" +396, 2, 15, 20, 43, 45, 63, 65, "10" +396, 2, 16, 21, 46, 47, 66, 67, "." +396, 2, 17, 22, 48, 52, 68, 72, "1080" +396, 2, 18, 23, 53, 54, 73, 74, "/" +396, 2, 19, 24, 55, 63, 75, 83, "03007995" +396, 2, 20, 25, 64, 65, 84, 85, "." +396, 2, 21, 26, 66, 70, 86, 90, "2017" +396, 2, 22, 27, 71, 72, 91, 92, "." +396, 2, 23, 28, 73, 80, 93, 100, "1335638" +396, 2, 24, 29, 81, 82, 101, 102, "." +396, 3, 1, 30, 0, 4, 103, 107, "Epub" +396, 3, 2, 31, 5, 9, 108, 112, "2017" +396, 3, 3, 32, 10, 13, 113, 116, "Jun" +396, 3, 4, 33, 14, 16, 117, 119, "28" +396, 3, 5, 34, 17, 18, 120, 121, "." +396, 4, 1, 35, 0, 1, 122, 123, "A" +396, 4, 2, 36, 2, 12, 124, 134, "randomized" +396, 4, 3, 37, 13, 14, 135, 136, "," +396, 4, 4, 38, 15, 21, 137, 143, "double" +396, 4, 5, 39, 22, 23, 144, 145, "-" +396, 4, 6, 40, 24, 29, 146, 151, "blind" +396, 4, 7, 41, 30, 31, 152, 153, "," +396, 4, 8, 42, 32, 35, 154, 157, "non" +396, 4, 9, 43, 36, 37, 158, 159, "-" +396, 4, 10, 44, 38, 49, 160, 171, "inferiority" +396, 4, 11, 45, 50, 55, 172, 177, "trial" +396, 4, 12, 46, 56, 66, 178, 188, "evaluating" +396, 4, 13, 47, 67, 70, 189, 192, "the" +396, 4, 14, 48, 71, 79, 193, 201, "efficacy" +396, 4, 15, 49, 80, 83, 202, 205, "and" +396, 4, 16, 50, 84, 90, 206, 212, "safety" +396, 4, 17, 51, 91, 93, 213, 215, "of" +396, 4, 18, 52, 94, 106, 216, 228, "omarigliptin" +396, 4, 19, 53, 107, 108, 229, 230, "," +396, 4, 20, 54, 109, 110, 231, 232, "a" +396, 4, 21, 55, 111, 115, 233, 237, "once" +396, 4, 22, 56, 116, 117, 238, 239, "-" +396, 4, 23, 57, 118, 124, 240, 246, "weekly" +396, 4, 24, 58, 125, 128, 247, 250, "DPP" +396, 4, 25, 59, 129, 130, 251, 252, "-" +396, 4, 26, 60, 131, 132, 253, 254, "4" +396, 4, 27, 61, 133, 142, 255, 264, "inhibitor" +396, 4, 28, 62, 143, 144, 265, 266, "," +396, 4, 29, 63, 145, 147, 267, 269, "or" +396, 4, 30, 64, 148, 159, 270, 281, "glimepiride" +396, 4, 31, 65, 160, 162, 282, 284, "in" +396, 4, 32, 66, 163, 171, 285, 293, "patients" +396, 4, 33, 67, 172, 176, 294, 298, "with" +396, 4, 34, 68, 177, 181, 299, 303, "type" +396, 4, 35, 69, 182, 183, 304, 305, "2" +396, 4, 36, 70, 184, 192, 306, 314, "diabetes" +396, 4, 37, 71, 193, 205, 315, 327, "inadequately" +396, 4, 38, 72, 206, 216, 328, 338, "controlled" +396, 4, 39, 73, 217, 219, 339, 341, "on" +396, 4, 40, 74, 220, 229, 342, 351, "metformin" +396, 4, 41, 75, 230, 241, 352, 363, "monotherapy" +396, 4, 42, 76, 242, 243, 364, 365, "." +396, 5, 1, 77, 0, 10, 366, 376, "Handelsman" +396, 5, 2, 78, 11, 12, 377, 378, "Y" +396, 5, 3, 79, 13, 14, 379, 380, "(" +396, 5, 4, 80, 15, 16, 381, 382, "1" +396, 5, 5, 81, 17, 18, 383, 384, ")" +396, 5, 6, 82, 19, 20, 385, 386, "," +396, 5, 7, 83, 21, 28, 387, 394, "Lauring" +396, 5, 8, 84, 29, 30, 395, 396, "B" +396, 5, 9, 85, 31, 32, 397, 398, "(" +396, 5, 10, 86, 33, 34, 399, 400, "2" +396, 5, 11, 87, 35, 36, 401, 402, ")" +396, 5, 12, 88, 37, 38, 403, 404, "," +396, 5, 13, 89, 39, 44, 405, 410, "Gantz" +396, 5, 14, 90, 45, 46, 411, 412, "I" +396, 5, 15, 91, 47, 48, 413, 414, "(" +396, 5, 16, 92, 49, 50, 415, 416, "2" +396, 5, 17, 93, 51, 52, 417, 418, ")" +396, 5, 18, 94, 53, 54, 419, 420, "," +396, 5, 19, 95, 55, 62, 421, 428, "Iredale" +396, 5, 20, 96, 63, 64, 429, 430, "C" +396, 5, 21, 97, 65, 66, 431, 432, "(" +396, 5, 22, 98, 67, 68, 433, 434, "2" +396, 5, 23, 99, 69, 70, 435, 436, ")" +396, 5, 24, 100, 71, 72, 437, 438, "," +396, 5, 25, 101, 73, 74, 439, 440, "O" +396, 5, 26, 102, 75, 76, 441, 442, "'" +396, 5, 27, 103, 77, 82, 443, 448, "Neill" +396, 5, 28, 104, 83, 85, 449, 451, "EA" +396, 5, 29, 105, 86, 87, 452, 453, "(" +396, 5, 30, 106, 88, 89, 454, 455, "2" +396, 5, 31, 107, 90, 91, 456, 457, ")" +396, 5, 32, 108, 92, 93, 458, 459, "," +396, 5, 33, 109, 94, 97, 460, 463, "Wei" +396, 5, 34, 110, 98, 99, 464, 465, "Z" +396, 5, 35, 111, 100, 101, 466, 467, "(" +396, 5, 36, 112, 102, 103, 468, 469, "2" +396, 5, 37, 113, 104, 105, 470, 471, ")" +396, 5, 38, 114, 106, 107, 472, 473, "," +396, 5, 39, 115, 108, 119, 474, 485, "Suryawanshi" +396, 5, 40, 116, 120, 121, 486, 487, "S" +396, 5, 41, 117, 122, 123, 488, 489, "(" +396, 5, 42, 118, 124, 125, 490, 491, "2" +396, 5, 43, 119, 126, 127, 492, 493, ")" +396, 5, 44, 120, 128, 129, 494, 495, "," +396, 5, 45, 121, 130, 137, 496, 503, "Kaufman" +396, 5, 46, 122, 138, 140, 504, 506, "KD" +396, 5, 47, 123, 141, 142, 507, 508, "(" +396, 5, 48, 124, 143, 144, 509, 510, "2" +396, 5, 49, 125, 145, 146, 511, 512, ")" +396, 5, 50, 126, 147, 148, 513, 514, "," +396, 5, 51, 127, 149, 154, 515, 520, "Engel" +396, 5, 52, 128, 155, 157, 521, 523, "SS" +396, 5, 53, 129, 158, 159, 524, 525, "(" +396, 5, 54, 130, 160, 161, 526, 527, "2" +396, 5, 55, 131, 162, 163, 528, 529, ")" +396, 5, 56, 132, 164, 165, 530, 531, "," +396, 5, 57, 133, 166, 169, 532, 535, "Lai" +396, 5, 58, 134, 170, 171, 536, 537, "E" +396, 5, 59, 135, 172, 173, 538, 539, "(" +396, 5, 60, 136, 174, 175, 540, 541, "2" +396, 5, 61, 137, 176, 177, 542, 543, ")" +396, 5, 62, 138, 178, 179, 544, 545, "." +396, 6, 1, 139, 0, 6, 546, 552, "Author" +396, 6, 2, 140, 7, 18, 553, 564, "information" +396, 6, 3, 141, 19, 20, 565, 566, ":" +396, 6, 4, 142, 21, 22, 567, 568, "(" +396, 6, 5, 143, 23, 24, 569, 570, "1" +396, 6, 6, 144, 25, 26, 571, 572, ")" +396, 6, 7, 145, 27, 28, 573, 574, "a" +396, 6, 8, 146, 29, 38, 575, 584, "Metabolic" +396, 6, 9, 147, 39, 48, 585, 594, "Institute" +396, 6, 10, 148, 49, 51, 595, 597, "of" +396, 6, 11, 149, 52, 59, 598, 605, "America" +396, 6, 12, 150, 60, 61, 606, 607, "," +396, 6, 13, 151, 62, 69, 608, 615, "Tarzana" +396, 6, 14, 152, 70, 71, 616, 617, "," +396, 6, 15, 153, 72, 74, 618, 620, "CA" +396, 6, 16, 154, 75, 76, 621, 622, "," +396, 6, 17, 155, 77, 80, 623, 626, "USA" +396, 6, 18, 156, 81, 82, 627, 628, "." +396, 7, 1, 157, 0, 1, 629, 630, "(" +396, 7, 2, 158, 2, 3, 631, 632, "2" +396, 7, 3, 159, 4, 5, 633, 634, ")" +396, 7, 4, 160, 6, 7, 635, 636, "b" +396, 7, 5, 161, 8, 13, 637, 642, "Merck" +396, 7, 6, 162, 14, 15, 643, 644, "&" +396, 7, 7, 163, 16, 18, 645, 647, "Co" +396, 7, 8, 164, 19, 20, 648, 649, "." +396, 7, 9, 165, 21, 22, 650, 651, "," +396, 7, 10, 166, 23, 26, 652, 655, "Inc" +396, 7, 11, 167, 27, 28, 656, 657, "." +396, 7, 12, 168, 29, 30, 658, 659, "," +396, 7, 13, 169, 31, 41, 660, 670, "Kenilworth" +396, 7, 14, 170, 42, 43, 671, 672, "," +396, 7, 15, 171, 44, 46, 673, 675, "NJ" +396, 7, 16, 172, 47, 48, 676, 677, "," +396, 7, 17, 173, 49, 52, 678, 681, "USA" +396, 7, 18, 174, 53, 54, 682, 683, "." +396, 8, 1, 175, 0, 7, 684, 691, "Comment" +396, 8, 2, 176, 8, 10, 692, 694, "in" +396, 8, 3, 177, 11, 15, 695, 699, "Curr" +396, 8, 4, 178, 16, 19, 700, 703, "Med" +396, 8, 5, 179, 20, 23, 704, 707, "Res" +396, 8, 6, 180, 24, 28, 708, 712, "Opin" +396, 8, 7, 181, 29, 30, 713, 714, "." +396, 9, 1, 182, 0, 4, 715, 719, "2017" +396, 9, 2, 183, 5, 8, 720, 723, "Nov" +396, 9, 3, 184, 9, 10, 724, 725, ";" +396, 9, 4, 185, 11, 13, 726, 728, "33" +396, 9, 5, 186, 14, 15, 729, 730, "(" +396, 9, 6, 187, 16, 18, 731, 733, "11" +396, 9, 7, 188, 19, 20, 734, 735, ")" +396, 9, 8, 189, 21, 22, 736, 737, ":" +396, 9, 9, 190, 23, 27, 738, 742, "2095" +396, 9, 10, 191, 28, 29, 743, 744, "." +396, 10, 1, 192, 0, 4, 745, 749, "Curr" +396, 10, 2, 193, 5, 8, 750, 753, "Med" +396, 10, 3, 194, 9, 12, 754, 757, "Res" +396, 10, 4, 195, 13, 17, 758, 762, "Opin" +396, 10, 5, 196, 18, 19, 763, 764, "." +396, 11, 1, 197, 0, 4, 765, 769, "2017" +396, 11, 2, 198, 5, 8, 770, 773, "Nov" +396, 11, 3, 199, 9, 10, 774, 775, ";" +396, 11, 4, 200, 11, 13, 776, 778, "33" +396, 11, 5, 201, 14, 15, 779, 780, "(" +396, 11, 6, 202, 16, 18, 781, 783, "11" +396, 11, 7, 203, 19, 20, 784, 785, ")" +396, 11, 8, 204, 21, 22, 786, 787, ":" +396, 11, 9, 205, 23, 27, 788, 792, "2093" +396, 11, 10, 206, 28, 29, 793, 794, "-" +396, 11, 11, 207, 30, 34, 795, 799, "2094" +396, 11, 12, 208, 35, 36, 800, 801, "." +396, 12, 1, 209, 0, 9, 802, 811, "OBJECTIVE" +396, 12, 2, 210, 10, 11, 812, 813, ":" +396, 12, 3, 211, 12, 14, 814, 816, "To" +396, 12, 4, 212, 15, 23, 817, 825, "evaluate" +396, 12, 5, 213, 24, 27, 826, 829, "the" +396, 12, 6, 214, 28, 36, 830, 838, "efficacy" +396, 12, 7, 215, 37, 40, 839, 842, "and" +396, 12, 8, 216, 41, 47, 843, 849, "safety" +396, 12, 9, 217, 48, 50, 850, 852, "of" +396, 12, 10, 218, 51, 57, 853, 859, "adding" +396, 12, 11, 219, 58, 61, 860, 863, "the" +396, 12, 12, 220, 62, 66, 864, 868, "once" +396, 12, 13, 221, 67, 68, 869, 870, "-" +396, 12, 14, 222, 69, 75, 871, 877, "weekly" +396, 12, 15, 223, 76, 79, 878, 881, "DPP" +396, 12, 16, 224, 80, 81, 882, 883, "-" +396, 12, 17, 225, 82, 83, 884, 885, "4" +396, 12, 18, 226, 84, 93, 886, 895, "inhibitor" +396, 12, 19, 227, 94, 106, 896, 908, "omarigliptin" +396, 12, 20, 228, 107, 109, 909, 911, "or" +396, 12, 21, 229, 110, 113, 912, 915, "the" +396, 12, 22, 230, 114, 126, 916, 928, "sulfonylurea" +396, 12, 23, 231, 127, 138, 929, 940, "glimepiride" +396, 12, 24, 232, 139, 141, 941, 943, "to" +396, 12, 25, 233, 142, 145, 944, 947, "the" +396, 12, 26, 234, 146, 155, 948, 957, "treatment" +396, 12, 27, 235, 156, 163, 958, 965, "regimen" +396, 12, 28, 236, 164, 166, 966, 968, "of" +396, 12, 29, 237, 167, 175, 969, 977, "patients" +396, 12, 30, 238, 176, 180, 978, 982, "with" +396, 12, 31, 239, 181, 185, 983, 987, "type" +396, 12, 32, 240, 186, 187, 988, 989, "2" +396, 12, 33, 241, 188, 196, 990, 998, "diabetes" +396, 12, 34, 242, 197, 198, 999, 1000, "(" +396, 12, 35, 243, 199, 203, 1001, 1005, "T2DM" +396, 12, 36, 244, 204, 205, 1006, 1007, ")" +396, 12, 37, 245, 206, 209, 1008, 1011, "and" +396, 12, 38, 246, 210, 220, 1012, 1022, "inadequate" +396, 12, 39, 247, 221, 229, 1023, 1031, "glycemic" +396, 12, 40, 248, 230, 237, 1032, 1039, "control" +396, 12, 41, 249, 238, 240, 1040, 1042, "on" +396, 12, 42, 250, 241, 250, 1043, 1052, "metformin" +396, 12, 43, 251, 251, 262, 1053, 1064, "monotherapy" +396, 12, 44, 252, 263, 264, 1065, 1066, "." +396, 13, 1, 253, 0, 7, 1067, 1074, "METHODS" +396, 13, 2, 254, 8, 9, 1075, 1076, ":" +396, 13, 3, 255, 10, 18, 1077, 1085, "Patients" +396, 13, 4, 256, 19, 23, 1086, 1090, "with" +396, 13, 5, 257, 24, 28, 1091, 1095, "T2DM" +396, 13, 6, 258, 29, 32, 1096, 1099, "and" +396, 13, 7, 259, 33, 38, 1100, 1105, "HbA1c" +396, 13, 8, 260, 39, 40, 1106, 1107, "≥" +396, 13, 9, 261, 41, 42, 1108, 1109, "6" +396, 13, 10, 262, 43, 44, 1110, 1111, "." +396, 13, 11, 263, 45, 46, 1112, 1113, "5" +396, 13, 12, 264, 47, 48, 1114, 1115, "%" +396, 13, 13, 265, 49, 51, 1116, 1118, "to" +396, 13, 14, 266, 52, 53, 1119, 1120, "≤" +396, 13, 15, 267, 54, 55, 1121, 1122, "9" +396, 13, 16, 268, 56, 57, 1123, 1124, "." +396, 13, 17, 269, 58, 59, 1125, 1126, "0" +396, 13, 18, 270, 60, 61, 1127, 1128, "%" +396, 13, 19, 271, 62, 67, 1129, 1134, "while" +396, 13, 20, 272, 68, 70, 1135, 1137, "on" +396, 13, 21, 273, 71, 72, 1138, 1139, "a" +396, 13, 22, 274, 73, 79, 1140, 1146, "stable" +396, 13, 23, 275, 80, 84, 1147, 1151, "dose" +396, 13, 24, 276, 85, 87, 1152, 1154, "of" +396, 13, 25, 277, 88, 97, 1155, 1164, "metformin" +396, 13, 26, 278, 98, 99, 1165, 1166, "(" +396, 13, 27, 279, 100, 101, 1167, 1168, "≥" +396, 13, 28, 280, 102, 106, 1169, 1173, "1500" +396, 13, 29, 281, 107, 108, 1174, 1175, " " +396, 13, 30, 282, 109, 111, 1176, 1178, "mg" +396, 13, 31, 283, 112, 113, 1179, 1180, "/" +396, 13, 32, 284, 114, 117, 1181, 1184, "day" +396, 13, 33, 285, 118, 119, 1185, 1186, ")" +396, 13, 34, 286, 120, 124, 1187, 1191, "were" +396, 13, 35, 287, 125, 135, 1192, 1202, "randomized" +396, 13, 36, 288, 136, 138, 1203, 1205, "to" +396, 13, 37, 289, 139, 151, 1206, 1218, "omarigliptin" +396, 13, 38, 290, 152, 154, 1219, 1221, "25" +396, 13, 39, 291, 155, 156, 1222, 1223, " " +396, 13, 40, 292, 157, 159, 1224, 1226, "mg" +396, 13, 41, 293, 160, 164, 1227, 1231, "once" +396, 13, 42, 294, 165, 166, 1232, 1233, "-" +396, 13, 43, 295, 167, 173, 1234, 1240, "weekly" +396, 13, 44, 296, 174, 175, 1241, 1242, "(" +396, 13, 45, 297, 176, 177, 1243, 1244, "n" +396, 13, 46, 298, 178, 181, 1245, 1248, " = " +396, 13, 47, 299, 182, 185, 1249, 1252, "376" +396, 13, 48, 300, 186, 187, 1253, 1254, ")" +396, 13, 49, 301, 188, 190, 1255, 1257, "or" +396, 13, 50, 302, 191, 202, 1258, 1269, "glimepiride" +396, 13, 51, 303, 203, 205, 1270, 1272, "up" +396, 13, 52, 304, 206, 208, 1273, 1275, "to" +396, 13, 53, 305, 209, 210, 1276, 1277, "6" +396, 13, 54, 306, 211, 212, 1278, 1279, " " +396, 13, 55, 307, 213, 215, 1280, 1282, "mg" +396, 13, 56, 308, 216, 220, 1283, 1287, "once" +396, 13, 57, 309, 221, 226, 1288, 1293, "daily" +396, 13, 58, 310, 227, 228, 1294, 1295, "(" +396, 13, 59, 311, 229, 230, 1296, 1297, "n" +396, 13, 60, 312, 231, 234, 1298, 1301, " = " +396, 13, 61, 313, 235, 238, 1302, 1305, "375" +396, 13, 62, 314, 239, 240, 1306, 1307, ")" +396, 13, 63, 315, 241, 244, 1308, 1311, "for" +396, 13, 64, 316, 245, 247, 1312, 1314, "54" +396, 13, 65, 317, 248, 253, 1315, 1320, "weeks" +396, 13, 66, 318, 254, 255, 1321, 1322, "." +396, 14, 1, 319, 0, 3, 1323, 1326, "The" +396, 14, 2, 320, 4, 11, 1327, 1334, "primary" +396, 14, 3, 321, 12, 22, 1335, 1345, "hypothesis" +396, 14, 4, 322, 23, 26, 1346, 1349, "was" +396, 14, 5, 323, 27, 31, 1350, 1354, "that" +396, 14, 6, 324, 32, 44, 1355, 1367, "omarigliptin" +396, 14, 7, 325, 45, 47, 1368, 1370, "is" +396, 14, 8, 326, 48, 51, 1371, 1374, "non" +396, 14, 9, 327, 52, 53, 1375, 1376, "-" +396, 14, 10, 328, 54, 62, 1377, 1385, "inferior" +396, 14, 11, 329, 63, 65, 1386, 1388, "to" +396, 14, 12, 330, 66, 77, 1389, 1400, "glimepiride" +396, 14, 13, 331, 78, 80, 1401, 1403, "in" +396, 14, 14, 332, 81, 89, 1404, 1412, "reducing" +396, 14, 15, 333, 90, 95, 1413, 1418, "HbA1c" +396, 14, 16, 334, 96, 98, 1419, 1421, "at" +396, 14, 17, 335, 99, 103, 1422, 1426, "week" +396, 14, 18, 336, 104, 106, 1427, 1429, "54" +396, 14, 19, 337, 107, 108, 1430, 1431, "." +396, 15, 1, 338, 0, 7, 1432, 1439, "RESULTS" +396, 15, 2, 339, 8, 9, 1440, 1441, ":" +396, 15, 3, 340, 10, 13, 1442, 1445, "The" +396, 15, 4, 341, 14, 18, 1446, 1450, "mean" +396, 15, 5, 342, 19, 27, 1451, 1459, "baseline" +396, 15, 6, 343, 28, 33, 1460, 1465, "HbA1c" +396, 15, 7, 344, 34, 37, 1466, 1469, "was" +396, 15, 8, 345, 38, 39, 1470, 1471, "7" +396, 15, 9, 346, 40, 41, 1472, 1473, "." +396, 15, 10, 347, 42, 43, 1474, 1475, "5" +396, 15, 11, 348, 44, 45, 1476, 1477, "%" +396, 15, 12, 349, 46, 48, 1478, 1480, "in" +396, 15, 13, 350, 49, 52, 1481, 1484, "the" +396, 15, 14, 351, 53, 65, 1485, 1497, "omarigliptin" +396, 15, 15, 352, 66, 71, 1498, 1503, "group" +396, 15, 16, 353, 72, 75, 1504, 1507, "and" +396, 15, 17, 354, 76, 77, 1508, 1509, "7" +396, 15, 18, 355, 78, 79, 1510, 1511, "." +396, 15, 19, 356, 80, 81, 1512, 1513, "4" +396, 15, 20, 357, 82, 83, 1514, 1515, "%" +396, 15, 21, 358, 84, 86, 1516, 1518, "in" +396, 15, 22, 359, 87, 90, 1519, 1522, "the" +396, 15, 23, 360, 91, 102, 1523, 1534, "glimepiride" +396, 15, 24, 361, 103, 108, 1535, 1540, "group" +396, 15, 25, 362, 109, 110, 1541, 1542, "." +396, 16, 1, 363, 0, 5, 1543, 1548, "After" +396, 16, 2, 364, 6, 8, 1549, 1551, "54" +396, 16, 3, 365, 9, 14, 1552, 1557, "weeks" +396, 16, 4, 366, 15, 16, 1558, 1559, "," +396, 16, 5, 367, 17, 20, 1560, 1563, "the" +396, 16, 6, 368, 21, 26, 1564, 1569, "least" +396, 16, 7, 369, 27, 34, 1570, 1577, "squares" +396, 16, 8, 370, 35, 36, 1578, 1579, "(" +396, 16, 9, 371, 37, 39, 1580, 1582, "LS" +396, 16, 10, 372, 40, 41, 1583, 1584, ")" +396, 16, 11, 373, 42, 46, 1585, 1589, "mean" +396, 16, 12, 374, 47, 53, 1590, 1596, "change" +396, 16, 13, 375, 54, 58, 1597, 1601, "from" +396, 16, 14, 376, 59, 67, 1602, 1610, "baseline" +396, 16, 15, 377, 68, 70, 1611, 1613, "in" +396, 16, 16, 378, 71, 76, 1614, 1619, "HbA1c" +396, 16, 17, 379, 77, 80, 1620, 1623, "was" +396, 16, 18, 380, 81, 82, 1624, 1625, "-" +396, 16, 19, 381, 83, 84, 1626, 1627, "0" +396, 16, 20, 382, 85, 86, 1628, 1629, "." +396, 16, 21, 383, 87, 89, 1630, 1632, "30" +396, 16, 22, 384, 90, 91, 1633, 1634, "%" +396, 16, 23, 385, 92, 94, 1635, 1637, "in" +396, 16, 24, 386, 95, 98, 1638, 1641, "the" +396, 16, 25, 387, 99, 111, 1642, 1654, "omarigliptin" +396, 16, 26, 388, 112, 117, 1655, 1660, "group" +396, 16, 27, 389, 118, 121, 1661, 1664, "and" +396, 16, 28, 390, 122, 123, 1665, 1666, "-" +396, 16, 29, 391, 124, 125, 1667, 1668, "0" +396, 16, 30, 392, 126, 127, 1669, 1670, "." +396, 16, 31, 393, 128, 130, 1671, 1673, "48" +396, 16, 32, 394, 131, 132, 1674, 1675, "%" +396, 16, 33, 395, 133, 135, 1676, 1678, "in" +396, 16, 34, 396, 136, 139, 1679, 1682, "the" +396, 16, 35, 397, 140, 151, 1683, 1694, "glimepiride" +396, 16, 36, 398, 152, 157, 1695, 1700, "group" +396, 16, 37, 399, 158, 159, 1701, 1702, "," +396, 16, 38, 400, 160, 164, 1703, 1707, "with" +396, 16, 39, 401, 165, 166, 1708, 1709, "a" +396, 16, 40, 402, 167, 174, 1710, 1717, "between" +396, 16, 41, 403, 175, 176, 1718, 1719, "-" +396, 16, 42, 404, 177, 182, 1720, 1725, "group" +396, 16, 43, 405, 183, 193, 1726, 1736, "difference" +396, 16, 44, 406, 194, 195, 1737, 1738, "(" +396, 16, 45, 407, 196, 198, 1739, 1741, "95" +396, 16, 46, 408, 199, 200, 1742, 1743, "%" +396, 16, 47, 409, 201, 203, 1744, 1746, "CI" +396, 16, 48, 410, 204, 205, 1747, 1748, ")" +396, 16, 49, 411, 206, 208, 1749, 1751, "of" +396, 16, 50, 412, 209, 210, 1752, 1753, "0" +396, 16, 51, 413, 211, 212, 1754, 1755, "." +396, 16, 52, 414, 213, 215, 1756, 1758, "18" +396, 16, 53, 415, 216, 217, 1759, 1760, "%" +396, 16, 54, 416, 218, 219, 1761, 1762, "(" +396, 16, 55, 417, 220, 221, 1763, 1764, "0" +396, 16, 56, 418, 222, 223, 1765, 1766, "." +396, 16, 57, 419, 224, 226, 1767, 1769, "06" +396, 16, 58, 420, 227, 228, 1770, 1771, "," +396, 16, 59, 421, 229, 230, 1772, 1773, "0" +396, 16, 60, 422, 231, 232, 1774, 1775, "." +396, 16, 61, 423, 233, 235, 1776, 1778, "30" +396, 16, 62, 424, 236, 237, 1779, 1780, ")" +396, 16, 63, 425, 238, 239, 1781, 1782, "," +396, 16, 64, 426, 240, 245, 1783, 1788, "which" +396, 16, 65, 427, 246, 249, 1789, 1792, "met" +396, 16, 66, 428, 250, 253, 1793, 1796, "the" +396, 16, 67, 429, 254, 257, 1797, 1800, "pre" +396, 16, 68, 430, 258, 259, 1801, 1802, "-" +396, 16, 69, 431, 260, 269, 1803, 1812, "specified" +396, 16, 70, 432, 270, 279, 1813, 1822, "criterion" +396, 16, 71, 433, 280, 283, 1823, 1826, "for" +396, 16, 72, 434, 284, 293, 1827, 1836, "declaring" +396, 16, 73, 435, 294, 297, 1837, 1840, "non" +396, 16, 74, 436, 298, 299, 1841, 1842, "-" +396, 16, 75, 437, 300, 311, 1843, 1854, "inferiority" +396, 16, 76, 438, 312, 313, 1855, 1856, "." +396, 17, 1, 439, 0, 3, 1857, 1860, "The" +396, 17, 2, 440, 4, 13, 1861, 1870, "incidence" +396, 17, 3, 441, 14, 16, 1871, 1873, "of" +396, 17, 4, 442, 17, 28, 1874, 1885, "symptomatic" +396, 17, 5, 443, 29, 41, 1886, 1898, "hypoglycemia" +396, 17, 6, 444, 42, 45, 1899, 1902, "was" +396, 17, 7, 445, 46, 47, 1903, 1904, "5" +396, 17, 8, 446, 48, 49, 1905, 1906, "." +396, 17, 9, 447, 50, 51, 1907, 1908, "3" +396, 17, 10, 448, 52, 53, 1909, 1910, "%" +396, 17, 11, 449, 54, 56, 1911, 1913, "in" +396, 17, 12, 450, 57, 60, 1914, 1917, "the" +396, 17, 13, 451, 61, 73, 1918, 1930, "omarigliptin" +396, 17, 14, 452, 74, 79, 1931, 1936, "group" +396, 17, 15, 453, 80, 83, 1937, 1940, "and" +396, 17, 16, 454, 84, 86, 1941, 1943, "26" +396, 17, 17, 455, 87, 88, 1944, 1945, "." +396, 17, 18, 456, 89, 90, 1946, 1947, "7" +396, 17, 19, 457, 91, 92, 1948, 1949, "%" +396, 17, 20, 458, 93, 95, 1950, 1952, "in" +396, 17, 21, 459, 96, 99, 1953, 1956, "the" +396, 17, 22, 460, 100, 111, 1957, 1968, "glimepiride" +396, 17, 23, 461, 112, 117, 1969, 1974, "group" +396, 17, 24, 462, 118, 119, 1975, 1976, "." +396, 18, 1, 463, 0, 4, 1977, 1981, "With" +396, 18, 2, 464, 5, 8, 1982, 1985, "the" +396, 18, 3, 465, 9, 18, 1986, 1995, "exception" +396, 18, 4, 466, 19, 21, 1996, 1998, "of" +396, 18, 5, 467, 22, 34, 1999, 2011, "hypoglycemia" +396, 18, 6, 468, 35, 36, 2012, 2013, "," +396, 18, 7, 469, 37, 40, 2014, 2017, "the" +396, 18, 8, 470, 41, 51, 2018, 2028, "incidences" +396, 18, 9, 471, 52, 54, 2029, 2031, "of" +396, 18, 10, 472, 55, 62, 2032, 2039, "adverse" +396, 18, 11, 473, 63, 69, 2040, 2046, "events" +396, 18, 12, 474, 70, 73, 2047, 2050, "and" +396, 18, 13, 475, 74, 90, 2051, 2067, "discontinuations" +396, 18, 14, 476, 91, 95, 2068, 2072, "were" +396, 18, 15, 477, 96, 103, 2073, 2080, "similar" +396, 18, 16, 478, 104, 111, 2081, 2088, "between" +396, 18, 17, 479, 112, 121, 2089, 2098, "treatment" +396, 18, 18, 480, 122, 128, 2099, 2105, "groups" +396, 18, 19, 481, 129, 130, 2106, 2107, "." +396, 19, 1, 482, 0, 8, 2108, 2116, "Relative" +396, 19, 2, 483, 9, 11, 2117, 2119, "to" +396, 19, 3, 484, 12, 20, 2120, 2128, "baseline" +396, 19, 4, 485, 21, 22, 2129, 2130, "," +396, 19, 5, 486, 23, 35, 2131, 2143, "omarigliptin" +396, 19, 6, 487, 36, 39, 2144, 2147, "was" +396, 19, 7, 488, 40, 50, 2148, 2158, "associated" +396, 19, 8, 489, 51, 55, 2159, 2163, "with" +396, 19, 9, 490, 56, 57, 2164, 2165, "a" +396, 19, 10, 491, 58, 62, 2166, 2170, "mean" +396, 19, 11, 492, 63, 69, 2171, 2177, "weight" +396, 19, 12, 493, 70, 74, 2178, 2182, "loss" +396, 19, 13, 494, 75, 76, 2183, 2184, "(" +396, 19, 14, 495, 77, 78, 2185, 2186, "-" +396, 19, 15, 496, 79, 80, 2187, 2188, "0" +396, 19, 16, 497, 81, 82, 2189, 2190, "." +396, 19, 17, 498, 83, 84, 2191, 2192, "4" +396, 19, 18, 499, 85, 86, 2193, 2194, " " +396, 19, 19, 500, 87, 89, 2195, 2197, "kg" +396, 19, 20, 501, 90, 91, 2198, 2199, ")" +396, 19, 21, 502, 92, 95, 2200, 2203, "and" +396, 19, 22, 503, 96, 107, 2204, 2215, "glimepiride" +396, 19, 23, 504, 108, 109, 2216, 2217, "a" +396, 19, 24, 505, 110, 114, 2218, 2222, "mean" +396, 19, 25, 506, 115, 121, 2223, 2229, "weight" +396, 19, 26, 507, 122, 126, 2230, 2234, "gain" +396, 19, 27, 508, 127, 128, 2235, 2236, "(" +396, 19, 28, 509, 129, 130, 2237, 2238, "+" +396, 19, 29, 510, 131, 132, 2239, 2240, "1" +396, 19, 30, 511, 133, 134, 2241, 2242, "." +396, 19, 31, 512, 135, 136, 2243, 2244, "5" +396, 19, 32, 513, 137, 138, 2245, 2246, " " +396, 19, 33, 514, 139, 141, 2247, 2249, "kg" +396, 19, 34, 515, 142, 143, 2250, 2251, ")" +396, 19, 35, 516, 144, 145, 2252, 2253, "." +396, 20, 1, 517, 0, 11, 2254, 2265, "CONCLUSIONS" +396, 20, 2, 518, 12, 13, 2266, 2267, ":" +396, 20, 3, 519, 14, 19, 2268, 2273, "After" +396, 20, 4, 520, 20, 22, 2274, 2276, "54" +396, 20, 5, 521, 23, 28, 2277, 2282, "weeks" +396, 20, 6, 522, 29, 30, 2283, 2284, "," +396, 20, 7, 523, 31, 33, 2285, 2287, "as" +396, 20, 8, 524, 34, 37, 2288, 2291, "add" +396, 20, 9, 525, 38, 39, 2292, 2293, "-" +396, 20, 10, 526, 40, 42, 2294, 2296, "on" +396, 20, 11, 527, 43, 50, 2297, 2304, "therapy" +396, 20, 12, 528, 51, 53, 2305, 2307, "to" +396, 20, 13, 529, 54, 63, 2308, 2317, "metformin" +396, 20, 14, 530, 64, 65, 2318, 2319, "," +396, 20, 15, 531, 66, 70, 2320, 2324, "once" +396, 20, 16, 532, 71, 72, 2325, 2326, "-" +396, 20, 17, 533, 73, 79, 2327, 2333, "weekly" +396, 20, 18, 534, 80, 92, 2334, 2346, "omarigliptin" +396, 20, 19, 535, 93, 96, 2347, 2350, "was" +396, 20, 20, 536, 97, 106, 2351, 2360, "generally" +396, 20, 21, 537, 107, 111, 2361, 2365, "well" +396, 20, 22, 538, 112, 121, 2366, 2375, "tolerated" +396, 20, 23, 539, 122, 125, 2376, 2379, "and" +396, 20, 24, 540, 126, 129, 2380, 2383, "non" +396, 20, 25, 541, 130, 131, 2384, 2385, "-" +396, 20, 26, 542, 132, 140, 2386, 2394, "inferior" +396, 20, 27, 543, 141, 143, 2395, 2397, "to" +396, 20, 28, 544, 144, 155, 2398, 2409, "glimepiride" +396, 20, 29, 545, 156, 158, 2410, 2412, "in" +396, 20, 30, 546, 159, 168, 2413, 2422, "improving" +396, 20, 31, 547, 169, 177, 2423, 2431, "glycemic" +396, 20, 32, 548, 178, 185, 2432, 2439, "control" +396, 20, 33, 549, 186, 187, 2440, 2441, "," +396, 20, 34, 550, 188, 192, 2442, 2446, "with" +396, 20, 35, 551, 193, 194, 2447, 2448, "a" +396, 20, 36, 552, 195, 200, 2449, 2454, "lower" +396, 20, 37, 553, 201, 210, 2455, 2464, "incidence" +396, 20, 38, 554, 211, 213, 2465, 2467, "of" +396, 20, 39, 555, 214, 226, 2468, 2480, "hypoglycemia" +396, 20, 40, 556, 227, 230, 2481, 2484, "and" +396, 20, 41, 557, 231, 235, 2485, 2489, "with" +396, 20, 42, 558, 236, 242, 2490, 2496, "weight" +396, 20, 43, 559, 243, 247, 2497, 2501, "loss" +396, 20, 44, 560, 248, 250, 2502, 2504, "vs" +396, 20, 45, 561, 251, 257, 2505, 2511, "weight" +396, 20, 46, 562, 258, 262, 2512, 2516, "gain" +396, 20, 47, 563, 263, 264, 2517, 2518, "." +396, 21, 1, 564, 0, 3, 2519, 2522, "DOI" +396, 21, 2, 565, 4, 5, 2523, 2524, ":" +396, 21, 3, 566, 6, 8, 2525, 2527, "10" +396, 21, 4, 567, 9, 10, 2528, 2529, "." +396, 21, 5, 568, 11, 15, 2530, 2534, "1080" +396, 21, 6, 569, 16, 17, 2535, 2536, "/" +396, 21, 7, 570, 18, 26, 2537, 2545, "03007995" +396, 21, 8, 571, 27, 28, 2546, 2547, "." +396, 21, 9, 572, 29, 33, 2548, 2552, "2017" +396, 21, 10, 573, 34, 35, 2553, 2554, "." +396, 21, 11, 574, 36, 43, 2555, 2562, "1335638" +396, 21, 12, 575, 44, 48, 2563, 2567, "PMID" +396, 21, 13, 576, 49, 50, 2568, 2569, ":" +396, 21, 14, 577, 51, 59, 2570, 2578, "28548024" +396, 21, 15, 578, 60, 61, 2579, 2580, "[" +396, 21, 16, 579, 62, 69, 2581, 2588, "Indexed" +396, 21, 17, 580, 70, 73, 2589, 2592, "for" +396, 21, 18, 581, 74, 81, 2593, 2600, "MEDLINE" +396, 21, 19, 582, 82, 83, 2601, 2602, "]" diff --git a/data/dm2 28548024_kwoodley.annodb b/data/dm2 28548024_kwoodley.annodb new file mode 100644 index 0000000..31fdd39 --- /dev/null +++ b/data/dm2 28548024_kwoodley.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71891, Journal, 0, 17, "Curr Med Res Opin", "", +71892, PublicationYear, 20, 24, "2017", "", +71927, Title, 122, 365, "A randomized , double - blind , non - inferiority trial evaluating the efficacy and safety of omarigliptin , a once - weekly DPP - 4 inhibitor , or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", +71893, Randomized, 124, 134, "randomized", "", +71894, DoubleBlind, 137, 151, "double - blind", "", +71895, CTDesign, 154, 171, "non - inferiority", "", +71896, Omarigliptin, 216, 228, "omarigliptin", "", +71905, Frequency, 233, 246, "once - weekly", "", +71909, Glimepiride, 270, 281, "glimepiride", "", +71926, Precondition, 285, 363, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", +71918, Type2Diabetes, 299, 314, "type 2 diabetes", "", +71922, Metformin, 342, 351, "metformin", "", +71928, Author, 366, 378, "Handelsman Y", "", +71929, Author, 387, 396, "Lauring B", "", +71930, Author, 405, 412, "Gantz I", "", +71931, Author, 421, 430, "Iredale C", "", +71932, Author, 439, 451, "O ' Neill EA", "", +71933, Author, 460, 465, "Wei Z", "", +71934, Author, 474, 487, "Suryawanshi S", "", +71935, Author, 496, 506, "Kaufman KD", "", +71936, Author, 515, 523, "Engel SS", "", +71937, Author, 532, 537, "Lai E", "", +71938, USA, 623, 626, "USA", "", +71939, USA, 678, 681, "USA", "", +71943, ObjectiveDescription, 814, 1066, "To evaluate the efficacy and safety of adding the once - weekly DPP - 4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy .", "", +71940, Frequency, 864, 877, "once - weekly", "", +71897, Omarigliptin, 896, 908, "omarigliptin", "", +71941, Sulfonylureas, 916, 928, "sulfonylurea", "", +71910, Glimepiride, 929, 940, "glimepiride", "", +71942, Precondition, 969, 1064, "patients with type 2 diabetes ( T2DM ) and inadequate glycemic control on metformin monotherapy", "", +71919, Type2Diabetes, 983, 998, "type 2 diabetes", "", +71920, Type2Diabetes, 1001, 1005, "T2DM", "", +71923, Metformin, 1043, 1052, "metformin", "", +71954, Precondition, 1077, 1186, "Patients with T2DM and HbA1c ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500   mg / day )", "", +71921, Type2Diabetes, 1091, 1095, "T2DM", "", +71944, HbA1c, 1100, 1105, "HbA1c", "", +71945, Percentage, 1114, 1115, "%", "", +71946, Percentage, 1127, 1128, "%", "", +71924, Metformin, 1155, 1164, "metformin", "", +71947, DoseValue, 1167, 1173, "≥ 1500", "", +71950, mg, 1176, 1178, "mg", "", +71953, Frequency, 1181, 1184, "day", "", +71955, Randomized, 1192, 1202, "randomized", "", +71898, Omarigliptin, 1206, 1218, "omarigliptin", "", +71948, DoseValue, 1219, 1221, "25", "", +71951, mg, 1224, 1226, "mg", "", +71906, Frequency, 1227, 1240, "once - weekly", "", +71956, NumberPatientsArm, 1249, 1252, "376", "", +71911, Glimepiride, 1258, 1269, "glimepiride", "", +71949, DoseDescription, 1270, 1277, "up to 6", "", +71952, mg, 1280, 1282, "mg", "", +71907, Frequency, 1283, 1293, "once daily", "", +71957, NumberPatientsArm, 1302, 1305, "375", "", +71958, Duration, 1312, 1320, "54 weeks", "", +71899, Omarigliptin, 1355, 1367, "omarigliptin", "", +71912, Glimepiride, 1389, 1400, "glimepiride", "", +71959, HbA1c, 1413, 1418, "HbA1c", "", +71960, TimePoint, 1422, 1429, "week 54", "", +71963, HbA1c, 1460, 1465, "HbA1c", "", +71965, BaseLineValue, 1470, 1475, "7 . 5", "", +71967, Percentage, 1476, 1477, "%", "", +71901, Omarigliptin, 1485, 1497, "omarigliptin", "", +71966, BaseLineValue, 1508, 1513, "7 . 4", "", +71968, Percentage, 1514, 1515, "%", "", +71913, Glimepiride, 1523, 1534, "glimepiride", "", +71961, TimePoint, 1549, 1557, "54 weeks", "", +71969, LeastSquaresMean, 1564, 1589, "least squares ( LS ) mean", "", +71970, TimePoint, 1602, 1610, "baseline", "", +71964, HbA1c, 1614, 1619, "HbA1c", "", +71971, Reduction, 1626, 1632, "0 . 30", "", +71973, Percentage, 1633, 1634, "%", "", +71900, Omarigliptin, 1642, 1654, "omarigliptin", "", +71972, Reduction, 1667, 1673, "0 . 48", "", +71974, Percentage, 1674, 1675, "%", "", +71914, Glimepiride, 1683, 1694, "glimepiride", "", +71976, ConfIntervalDiff, 1739, 1746, "95 % CI", "", +71978, DiffGroupAbsValue, 1752, 1758, "0 . 18", "", +71975, Percentage, 1759, 1760, "%", "", +71979, ConfIntervalDiff, 1763, 1778, "0 . 06 , 0 . 30", "", +71980, SymptomaticHypoglycemia, 1874, 1898, "symptomatic hypoglycemia", "", +71981, PercentageAffected, 1903, 1908, "5 . 3", "", +71902, Omarigliptin, 1918, 1930, "omarigliptin", "", +71982, PercentageAffected, 1941, 1947, "26 . 7", "", +71915, Glimepiride, 1957, 1968, "glimepiride", "", +71986, ObservedResult, 1977, 2107, "With the exception of hypoglycemia , the incidences of adverse events and discontinuations were similar between treatment groups .", "", +71983, Hypoglycemia, 1999, 2011, "hypoglycemia", "", +71984, EndPointDescription, 2032, 2046, "adverse events", "", +71985, EndPointDescription, 2051, 2067, "discontinuations", "", +71962, TimePoint, 2120, 2128, "baseline", "", +71903, Omarigliptin, 2131, 2143, "omarigliptin", "", +71987, BodyWeight, 2171, 2177, "weight", "", +71989, Reduction, 2187, 2192, "0 . 4", "", +71990, Kg, 2195, 2197, "kg", "", +71916, Glimepiride, 2204, 2215, "glimepiride", "", +71988, BodyWeight, 2223, 2229, "weight", "", +71992, Increment, 2239, 2244, "1 . 5", "", +71991, Kg, 2247, 2249, "kg", "", +71997, ConclusionComment, 2268, 2518, "After 54 weeks , as add - on therapy to metformin , once - weekly omarigliptin was generally well tolerated and non - inferior to glimepiride in improving glycemic control , with a lower incidence of hypoglycemia and with weight loss vs weight gain .", "", +71993, Duration, 2274, 2282, "54 weeks", "", +71925, Metformin, 2308, 2317, "metformin", "", +71908, Frequency, 2320, 2333, "once - weekly", "", +71904, Omarigliptin, 2334, 2346, "omarigliptin", "", +71917, Glimepiride, 2398, 2409, "glimepiride", "", +71994, Hypoglycemia, 2468, 2480, "hypoglycemia", "", +71995, BodyWeight, 2490, 2496, "weight", "", +71996, BodyWeight, 2505, 2511, "weight", "", +71998, PMID, 2570, 2578, "28548024", "", diff --git a/data/dm2 28548024_kwoodley.n-triples b/data/dm2 28548024_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28548024_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28742225_admin.annodb b/data/dm2 28742225_admin.annodb new file mode 100644 index 0000000..34701f2 --- /dev/null +++ b/data/dm2 28742225_admin.annodb @@ -0,0 +1,136 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2018", "", " \"2018\"." +8, Title, 106, 284, "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .", "", " \"Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .\"." +99938, Lixisenatide, 129, 141, "lixisenatide", "", +140, Ethnicity, 145, 177, "a predominantly Asian population", "", " . ." +3, Ethnicity, 161, 166, "Asian", "", +4, Type2Diabetes, 183, 198, "type 2 diabetes", "", " ." +6, Precondition, 199, 243, "insufficiently controlled with basal insulin", "", " \"insufficiently controlled with basal insulin\"." +5, Insulin, 230, 243, "basal insulin", "", +146, Insulin, 236, 243, "insulin", "", +7, Randomized, 266, 276, "randomized", "", " ." +9, Author, 285, 291, "Yang W", "", " \"Yang W\"." +10, Author, 300, 305, "Min K", "", " \"Min K\"." +11, Author, 314, 320, "Zhou Z", "", " \"Zhou Z\"." +12, Author, 329, 333, "Li L", "", " \"Li L\"." +13, Author, 342, 346, "Xu X", "", " \"Xu X\"." +14, Author, 355, 360, "Zhu D", "", " \"Zhu D\"." +15, Author, 369, 387, "Venkateshwar Rao A", "", " \"Venkateshwar Rao A\"." +16, Author, 396, 405, "Murthy LS", "", " \"Murthy LS\"." +17, Author, 414, 421, "Zhang N", "", " \"Zhang N\"." +18, Author, 430, 434, "Li I", "", " \"Li I\"." +19, Author, 443, 455, "Niemoeller E", "", " \"Niemoeller E\"." +20, Author, 465, 472, "Shang S", "", " \"Shang S\"." +21, China, 508, 513, "China", "", " ." +29, Japan, 516, 521, "Japan", "", " ." +22, China, 554, 559, "China", "", " ." +30, SouthKorea, 601, 612, "South Korea", "", " ." +23, China, 690, 695, "China", "", +24, China, 726, 731, "China", "", +25, China, 764, 769, "China", "", +26, China, 813, 818, "China", "", +27, China, 862, 867, "China", "", +31, India, 907, 912, "India", "", " ." +32, India, 958, 963, "India", "", +28, China, 992, 997, "China", "", +33, Germany, 1048, 1055, "Germany", "", " ." +44, ObjectiveDescription, 1065, 1319, "To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .", "", " \"To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .\"." +99930, Lixisenatide, 1111, 1123, "lixisenatide", "", +35, Placebo, 1127, 1134, "placebo", "", +36, Insulin, 1160, 1173, "basal insulin", "", +37, Insulin, 1176, 1178, "BI", "", +38, Metformin, 1185, 1194, "metformin", "", +39, HbA1c, 1210, 1230, "glycated haemoglobin", "", +40, HbA1c, 1233, 1238, "HbA1c", "", +189, Precondition, 1254, 1317, "patients with insufficiently controlled type 2 diabetes ( T2D )", "", +41, Type2Diabetes, 1294, 1309, "type 2 diabetes", "", +42, Type2Diabetes, 1312, 1315, "T2D", "", +45, NumberPatientsCT, 1347, 1350, "448", "", " \"448\"." +47, Precondition, 1358, 1381, "inadequately controlled", "", +46, Type2Diabetes, 1382, 1385, "T2D", "", +48, Randomized, 1391, 1401, "randomized", "", +194, AllocationRatio, 1404, 1409, "1 : 1", "", " . ." +99932, Lixisenatide, 1415, 1427, "lixisenatide", "", " ." +50, Placebo, 1431, 1438, "placebo", "", " ." +51, Insulin, 1454, 1456, "BI", "", +52, Metformin, 1461, 1470, "metformin", "", +53, Duration, 1475, 1485, "24   weeks", "", " \"24   weeks\"." +54, Duration, 1495, 1503, "8 - week", "", +55, Insulin, 1534, 1536, "BI", "", +56, DoseDescription, 1541, 1629, "titrated to a target self - monitored plasma glucose ( SMPG ; 4 . 4 - 5 . 6   mmol / L )", "", +196, PlasmaGlucose, 1555, 1593, "target self - monitored plasma glucose", "", +99940, PlasmaGlucose, 1596, 1600, "SMPG", "", +58, Millimoles_per_litre, 1619, 1627, "mmol / L", "", +59, HbA1c, 1676, 1681, "HbA1c", "", +60, TimePoint, 1687, 1695, "baseline", "", +61, TimePoint, 1699, 1706, "week 24", "", +63, PostprandialPlasmaGlucose, 1787, 1823, "2 - hour postprandial plasma glucose", "", +64, PostprandialPlasmaGlucose, 1826, 1829, "PPG", "", +205, EndPointDescription, 1834, 1848, "7 - point SMPG", "", +65, BodyWeight, 1869, 1880, "body weight", "", +66, BodyWeight, 1883, 1885, "BW", "", +208, InsulinDose, 1902, 1909, "BI dose", "", +70, FastingPlasmaGlucose, 1912, 1934, "fasting plasma glucose", "", +210, EndPointDescription, 1941, 1959, "safety assessments", "", +71, TimePoint, 1972, 1980, "Baseline", "", +72, Insulin, 2043, 2050, "insulin", "", +99933, Lixisenatide, 2082, 2094, "lixisenatide", "", +74, Placebo, 2111, 2118, "placebo", "", +75, Mean, 2122, 2126, "mean", "", " . ." +62, TimePoint, 2139, 2147, "baseline", "", +84, BaseLineValue, 2150, 2155, "7 . 9", "", " \"7 . 9\"." +76, Percentage, 2156, 2157, "%", "", " ." +86, SdDevBL, 2193, 2199, "0 . 66", "", " \"0 . 66\"." +85, BaseLineValue, 2206, 2211, "7 . 9", "", " \"7 . 9\"." +77, Percentage, 2212, 2213, "%", "", +87, SdDevBL, 2216, 2222, "0 . 70", "", " \"0 . 70\"." +88, TimePoint, 2245, 2252, "week 24", "", " \"week 24\". \"week 24\"." +89, HbA1c, 2256, 2261, "HbA1c", "", " ." +90, LeastSquaresMean, 2264, 2282, "least squares mean", "", +219, Reduction, 2323, 2329, "0 . 62", "", " \"0 . 62\"." +78, Percentage, 2330, 2331, "%", "", +93, SdErrorChangeValue, 2334, 2340, "0 . 09", "", " \"0 . 09\"." +220, Reduction, 2348, 2354, "0 . 11", "", " \"0 . 11\"." +79, Percentage, 2355, 2356, "%", "", +94, SdErrorChangeValue, 2359, 2365, "0 . 09", "", " \"0 . 09\"." +95, PvalueDiff, 2370, 2381, "P  < . 0001", "", " \"P  < . 0001\"." +99939, HbA1c, 2443, 2448, "HbA1c", "", +97, PostprandialPlasmaGlucose, 2459, 2473, "Two - hour PPG", "", " ." +99941, Mean, 2482, 2486, "mean", "", " . ." +100, PlasmaGlucose, 2487, 2491, "SMPG", "", " . ." +99, Mean, 2496, 2500, "mean", "", " . ." +101, BodyWeight, 2501, 2503, "BW", "", " ." +232, ObservedResult, 2504, 2524, "were reduced further", "", " \"were reduced further\". \"were reduced further\". \"were reduced further\"." +231, InsulinDose, 2535, 2542, "BI dose", "", " . ." +233, ObservedResult, 2543, 2552, "was lower", "", " \"was lower\"." +99934, Lixisenatide, 2558, 2570, "lixisenatide", "", +104, Placebo, 2576, 2583, "placebo", "", +234, Reduction, 2588, 2594, "1 . 12", "", " \"1 . 12\"." +109, Kg, 2597, 2599, "kg", "", " ." +239, Increment, 2603, 2609, "0 . 04", "", " \"0 . 04\"." +110, Kg, 2612, 2614, "kg", "", +113, PvalueDiff, 2617, 2628, "P  < . 0001", "", " \"P  < . 0001\"." +235, Reduction, 2635, 2640, "3 . 0", "", " \"3 . 0\"." +111, Int_Unit, 2643, 2644, "U", "", " ." +236, Reduction, 2650, 2655, "1 . 9", "", " \"1 . 9\"." +112, Int_Unit, 2658, 2659, "U", "", +114, PvalueDiff, 2662, 2673, "P  = . 0033", "", " \"P  = . 0033\"." +244, EndPointDescription, 2716, 2730, "adverse events", "", " . ." +99935, Lixisenatide, 2749, 2761, "lixisenatide", "", +116, Placebo, 2767, 2774, "placebo", "", +117, PercentageAffected, 2777, 2783, "63 . 8", "", " \"63 . 8\"." +118, PercentageAffected, 2789, 2795, "40 . 8", "", " \"40 . 8\"." +119, SymptomaticHypoglycemia, 2834, 2859, "symptomatic hypoglycaemia", "", " ." +99936, Lixisenatide, 2874, 2886, "lixisenatide", "", +120, PercentageAffected, 2887, 2893, "15 . 6", "", " \"15 . 6\"." +123, Placebo, 2899, 2906, "placebo", "", +121, PercentageAffected, 2907, 2913, "13 . 5", "", " \"13 . 5\"." +251, ConclusionComment, 2934, 3154, "In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists .", "", " \"In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists .\"." +124, Ethnicity, 2937, 2942, "Asian", "", +106276, Precondition, 2943, 2997, "patients insufficiently controlled on BI  ±  metformin", "", " \"patients insufficiently controlled on BI  ±  metformin\"." +125, Insulin, 2981, 2983, "BI", "", +126, Metformin, 2988, 2997, "metformin", "", +99937, Lixisenatide, 3000, 3012, "lixisenatide", "", +128, Placebo, 3029, 3036, "placebo", "", +129, PMID, 3366, 3374, "28742225", "", " \"28742225\"." diff --git a/data/dm2 28742225_admin.n-triples b/data/dm2 28742225_admin.n-triples new file mode 100644 index 0000000..789b59f --- /dev/null +++ b/data/dm2 28742225_admin.n-triples @@ -0,0 +1,216 @@ +# RDF export of group: Publication + . + "Publication 75549" . + "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial ." . + "Yang W" . + "2018" . + "Diabetes Obes Metab ." . + "28742225" . + . + "Min K" . + "Zhou Z" . + "Li L" . + "Xu X" . + "Zhu D" . + "Venkateshwar Rao A" . + "Murthy LS" . + "Zhang N" . + "Li I" . + "Niemoeller E" . + "Shang S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 75556" . + "To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) ." . + "448" . + "24   weeks" . + . + . + . + . + "In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 75572" . + "insufficiently controlled with basal insulin" . + . + . + . + . + "patients insufficiently controlled on BI  ±  metformin" . + . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "ppg" . + . + . + . + . + . + "smpg" . + . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "in" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "lix" . + . + . + . + . + . + . + . + . + . + "pla" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lix" . + . + . + . + "pla" . + . + . +# RDF export of group: Medication + . + "lix" . + . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 9" . + "0 . 66" . + "0 . 62" . + "0 . 09" . + "week 24" . + . + "hba 2" . + . + "7 . 9" . + "0 . 70" . + "0 . 11" . + "0 . 09" . + "week 24" . + . + "ppg 1" . + . + "were reduced further" . + . + "smpg 1" . + . + "were reduced further" . + . + "bw 1" . + . + "1 . 12" . + "were reduced further" . + . + "bw 2" . + . + "0 . 04" . + . + "in 1" . + . + "3 . 0" . + "was lower" . + . + "in 2" . + . + "1 . 9" . + . + "ae 1" . + . + "63 . 8" . + . + "ae 2" . + . + "40 . 8" . + . + "hyp 1" . + . + "15 . 6" . + . + "hyp 2" . + . + "13 . 5" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "P  < . 0001" . + . + . + . + "bw" . + "P  < . 0001" . + . + . + . + "in" . + "P  = . 0033" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28742225_akramersunderbrink.annodb b/data/dm2 28742225_akramersunderbrink.annodb new file mode 100644 index 0000000..6b5eb3b --- /dev/null +++ b/data/dm2 28742225_akramersunderbrink.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70479, Journal, 0, 19, "Diabetes Obes Metab", "", +70480, PublicationYear, 22, 26, "2018", "", +70487, Title, 106, 284, "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .", "", +70481, Drug, 129, 141, "lixisenatide", "", +70482, Ethnicity, 161, 166, "Asian", "", +70483, Type2Diabetes, 183, 198, "type 2 diabetes", "", +70485, Precondition, 199, 243, "insufficiently controlled with basal insulin", "", +70484, Insulin, 230, 243, "basal insulin", "", +70486, Randomized, 266, 276, "randomized", "", +70488, Author, 285, 291, "Yang W", "", +70489, Author, 300, 305, "Min K", "", +70490, Author, 314, 320, "Zhou Z", "", +70491, Author, 329, 333, "Li L", "", +70492, Author, 342, 346, "Xu X", "", +70493, Author, 355, 360, "Zhu D", "", +70494, Author, 369, 387, "Venkateshwar Rao A", "", +70495, Author, 396, 405, "Murthy LS", "", +70496, Author, 414, 421, "Zhang N", "", +70497, Author, 430, 434, "Li I", "", +70498, Author, 443, 455, "Niemoeller E", "", +70499, Author, 465, 472, "Shang S", "", +70500, China, 508, 513, "China", "", +70508, Japan, 516, 521, "Japan", "", +70501, China, 554, 559, "China", "", +70509, SouthKorea, 601, 612, "South Korea", "", +70502, China, 690, 695, "China", "", +70503, China, 726, 731, "China", "", +70504, China, 764, 769, "China", "", +70505, China, 813, 818, "China", "", +70506, China, 862, 867, "China", "", +70510, India, 907, 912, "India", "", +70511, India, 958, 963, "India", "", +70507, China, 992, 997, "China", "", +70512, Germany, 1048, 1055, "Germany", "", +70523, ObjectiveDescription, 1065, 1319, "To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .", "", +70513, Drug, 1111, 1123, "lixisenatide", "", +70514, Placebo, 1127, 1134, "placebo", "", +70515, Insulin, 1160, 1173, "basal insulin", "", +70516, Insulin, 1176, 1178, "BI", "", +70517, Metformin, 1185, 1194, "metformin", "", +70518, HbA1c, 1210, 1230, "glycated haemoglobin", "", +70519, HbA1c, 1233, 1238, "HbA1c", "", +70522, Precondition, 1268, 1293, "insufficiently controlled", "", +70520, Type2Diabetes, 1294, 1309, "type 2 diabetes", "", +70521, Type2Diabetes, 1312, 1315, "T2D", "", +70524, NumberPatientsCT, 1347, 1350, "448", "", +70526, Precondition, 1358, 1381, "inadequately controlled", "", +70525, Type2Diabetes, 1382, 1385, "T2D", "", +70527, Randomized, 1391, 1401, "randomized", "", +70528, Drug, 1415, 1427, "lixisenatide", "", +70529, Placebo, 1431, 1438, "placebo", "", +70530, Insulin, 1454, 1456, "BI", "", +70531, Metformin, 1461, 1470, "metformin", "", +70532, Duration, 1475, 1485, "24   weeks", "", +70533, Duration, 1495, 1503, "8 - week", "", +70534, Insulin, 1534, 1536, "BI", "", +70535, DoseDescription, 1541, 1629, "titrated to a target self - monitored plasma glucose ( SMPG ; 4 . 4 - 5 . 6   mmol / L )", "", +70536, FastingPlasmaGlucose_target, 1555, 1629, "target self - monitored plasma glucose ( SMPG ; 4 . 4 - 5 . 6   mmol / L )", "", +70537, Millimoles_per_litre, 1619, 1627, "mmol / L", "", +70538, HbA1c, 1676, 1681, "HbA1c", "", +70539, TimePoint, 1687, 1695, "baseline", "", +70540, TimePoint, 1699, 1706, "week 24", "", +70542, PostprandialPlasmaGlucose, 1787, 1823, "2 - hour postprandial plasma glucose", "", +70543, PostprandialPlasmaGlucose, 1826, 1829, "PPG", "", +70546, PlasmaGlucose, 1834, 1866, "7 - point SMPG ( daily average )", "", +70544, BodyWeight, 1869, 1880, "body weight", "", +70545, BodyWeight, 1883, 1885, "BW", "", +70548, InsulinDose, 1890, 1909, "total daily BI dose", "", +70547, Insulin, 1902, 1904, "BI", "", +70549, FastingPlasmaGlucose, 1912, 1934, "fasting plasma glucose", "", +70550, TimePoint, 1972, 1980, "Baseline", "", +70551, Insulin, 2043, 2050, "insulin", "", +70552, Drug, 2082, 2094, "lixisenatide", "", +70553, Placebo, 2111, 2118, "placebo", "", +70554, Mean, 2122, 2126, "mean", "", +70541, TimePoint, 2139, 2147, "baseline", "", +70563, BaseLineValue, 2150, 2155, "7 . 9", "", +70555, Percentage, 2156, 2157, "%", "", +70565, SdDevBL, 2193, 2199, "0 . 66", "", +70564, BaseLineValue, 2206, 2211, "7 . 9", "", +70556, Percentage, 2212, 2213, "%", "", +70566, SdDevBL, 2216, 2222, "0 . 70", "", +70567, TimePoint, 2245, 2252, "week 24", "", +70568, HbA1c, 2256, 2261, "HbA1c", "", +70569, LeastSquaresMean, 2264, 2282, "least squares mean", "", +70570, ChangeValue, 2321, 2329, "- 0 . 62", "", +70557, Percentage, 2330, 2331, "%", "", +70572, SdErrorChangeValue, 2334, 2340, "0 . 09", "", +70571, ChangeValue, 2346, 2354, "- 0 . 11", "", +70558, Percentage, 2355, 2356, "%", "", +70573, SdErrorChangeValue, 2359, 2365, "0 . 09", "", +70574, PvalueDiff, 2370, 2381, "P  < . 0001", "", +70575, HbA1c_target, 2443, 2456, "HbA1c targets", "", +70577, PostprandialPlasmaGlucose, 2459, 2473, "Two - hour PPG", "", +70580, PlasmaGlucose, 2476, 2491, "daily mean SMPG", "", +70578, Mean, 2482, 2486, "mean", "", +70579, Mean, 2496, 2500, "mean", "", +70581, BodyWeight, 2501, 2503, "BW", "", +70582, InsulinDose, 2529, 2542, "daily BI dose", "", +70583, Drug, 2558, 2570, "lixisenatide", "", +70584, Placebo, 2576, 2583, "placebo", "", +70585, ChangeValue, 2586, 2594, "- 1 . 12", "", +70589, Kg, 2597, 2599, "kg", "", +70586, ChangeValue, 2603, 2609, "0 . 04", "", +70590, Kg, 2612, 2614, "kg", "", +70593, PvalueDiff, 2617, 2628, "P  < . 0001", "", +70587, ChangeValue, 2633, 2640, "- 3 . 0", "", +70591, Int_Unit, 2643, 2644, "U", "", +70588, ChangeValue, 2648, 2655, "- 1 . 9", "", +70592, Int_Unit, 2658, 2659, "U", "", +70594, PvalueDiff, 2662, 2673, "P  = . 0033", "", +70595, Drug, 2749, 2761, "lixisenatide", "", +70596, Placebo, 2767, 2774, "placebo", "", +70597, PercentageAffected, 2777, 2783, "63 . 8", "", +70559, Percentage, 2784, 2785, "%", "", +70598, PercentageAffected, 2789, 2795, "40 . 8", "", +70560, Percentage, 2796, 2797, "%", "", +70599, SymptomaticHypoglycemia, 2834, 2859, "symptomatic hypoglycaemia", "", +70602, Drug, 2874, 2886, "lixisenatide", "", +70600, PercentageAffected, 2887, 2893, "15 . 6", "", +70561, Percentage, 2894, 2895, "%", "", +70603, Placebo, 2899, 2906, "placebo", "", +70601, PercentageAffected, 2907, 2913, "13 . 5", "", +70562, Percentage, 2914, 2915, "%", "", +70604, Ethnicity, 2937, 2942, "Asian", "", +70605, Insulin, 2981, 2983, "BI", "", +70606, Metformin, 2988, 2997, "metformin", "", +70607, Drug, 3000, 3012, "lixisenatide", "", +70608, Placebo, 3029, 3036, "placebo", "", +70609, PMID, 3366, 3374, "28742225", "", diff --git a/data/dm2 28742225_akramersunderbrink.n-triples b/data/dm2 28742225_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28742225_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28742225_export.csv b/data/dm2 28742225_export.csv new file mode 100644 index 0000000..2abc65e --- /dev/null +++ b/data/dm2 28742225_export.csv @@ -0,0 +1,757 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +393, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +393, 1, 2, 2, 9, 13, 9, 13, "Obes" +393, 1, 3, 3, 14, 19, 14, 19, "Metab" +393, 1, 4, 4, 20, 21, 20, 21, "." +393, 2, 1, 5, 0, 4, 22, 26, "2018" +393, 2, 2, 6, 5, 8, 27, 30, "Feb" +393, 2, 3, 7, 9, 10, 31, 32, ";" +393, 2, 4, 8, 11, 13, 33, 35, "20" +393, 2, 5, 9, 14, 15, 36, 37, "(" +393, 2, 6, 10, 16, 17, 38, 39, "2" +393, 2, 7, 11, 18, 19, 40, 41, ")" +393, 2, 8, 12, 20, 21, 42, 43, ":" +393, 2, 9, 13, 22, 25, 44, 47, "335" +393, 2, 10, 14, 26, 27, 48, 49, "-" +393, 2, 11, 15, 28, 31, 50, 53, "343" +393, 2, 12, 16, 32, 33, 54, 55, "." +393, 2, 13, 17, 34, 37, 56, 59, "doi" +393, 2, 14, 18, 38, 39, 60, 61, ":" +393, 2, 15, 19, 40, 42, 62, 64, "10" +393, 2, 16, 20, 43, 44, 65, 66, "." +393, 2, 17, 21, 45, 49, 67, 71, "1111" +393, 2, 18, 22, 50, 51, 72, 73, "/" +393, 2, 19, 23, 52, 55, 74, 77, "dom" +393, 2, 20, 24, 56, 57, 78, 79, "." +393, 2, 21, 25, 58, 63, 80, 85, "13072" +393, 2, 22, 26, 64, 65, 86, 87, "." +393, 3, 1, 27, 0, 4, 88, 92, "Epub" +393, 3, 2, 28, 5, 9, 93, 97, "2017" +393, 3, 3, 29, 10, 13, 98, 101, "Oct" +393, 3, 4, 30, 14, 15, 102, 103, "5" +393, 3, 5, 31, 16, 17, 104, 105, "." +393, 4, 1, 32, 0, 8, 106, 114, "Efficacy" +393, 4, 2, 33, 9, 12, 115, 118, "and" +393, 4, 3, 34, 13, 19, 119, 125, "safety" +393, 4, 4, 35, 20, 22, 126, 128, "of" +393, 4, 5, 36, 23, 35, 129, 141, "lixisenatide" +393, 4, 6, 37, 36, 38, 142, 144, "in" +393, 4, 7, 38, 39, 40, 145, 146, "a" +393, 4, 8, 39, 41, 54, 147, 160, "predominantly" +393, 4, 9, 40, 55, 60, 161, 166, "Asian" +393, 4, 10, 41, 61, 71, 167, 177, "population" +393, 4, 11, 42, 72, 76, 178, 182, "with" +393, 4, 12, 43, 77, 81, 183, 187, "type" +393, 4, 13, 44, 82, 83, 188, 189, "2" +393, 4, 14, 45, 84, 92, 190, 198, "diabetes" +393, 4, 15, 46, 93, 107, 199, 213, "insufficiently" +393, 4, 16, 47, 108, 118, 214, 224, "controlled" +393, 4, 17, 48, 119, 123, 225, 229, "with" +393, 4, 18, 49, 124, 129, 230, 235, "basal" +393, 4, 19, 50, 130, 137, 236, 243, "insulin" +393, 4, 20, 51, 138, 139, 244, 245, ":" +393, 4, 21, 52, 140, 143, 246, 249, "The" +393, 4, 22, 53, 144, 151, 250, 257, "GetGoal" +393, 4, 23, 54, 152, 153, 258, 259, "-" +393, 4, 24, 55, 154, 155, 260, 261, "L" +393, 4, 25, 56, 156, 157, 262, 263, "-" +393, 4, 26, 57, 158, 159, 264, 265, "C" +393, 4, 27, 58, 160, 170, 266, 276, "randomized" +393, 4, 28, 59, 171, 176, 277, 282, "trial" +393, 4, 29, 60, 177, 178, 283, 284, "." +393, 5, 1, 61, 0, 4, 285, 289, "Yang" +393, 5, 2, 62, 5, 6, 290, 291, "W" +393, 5, 3, 63, 7, 8, 292, 293, "(" +393, 5, 4, 64, 9, 10, 294, 295, "1" +393, 5, 5, 65, 11, 12, 296, 297, ")" +393, 5, 6, 66, 13, 14, 298, 299, "," +393, 5, 7, 67, 15, 18, 300, 303, "Min" +393, 5, 8, 68, 19, 20, 304, 305, "K" +393, 5, 9, 69, 21, 22, 306, 307, "(" +393, 5, 10, 70, 23, 24, 308, 309, "2" +393, 5, 11, 71, 25, 26, 310, 311, ")" +393, 5, 12, 72, 27, 28, 312, 313, "," +393, 5, 13, 73, 29, 33, 314, 318, "Zhou" +393, 5, 14, 74, 34, 35, 319, 320, "Z" +393, 5, 15, 75, 36, 37, 321, 322, "(" +393, 5, 16, 76, 38, 39, 323, 324, "3" +393, 5, 17, 77, 40, 41, 325, 326, ")" +393, 5, 18, 78, 42, 43, 327, 328, "," +393, 5, 19, 79, 44, 46, 329, 331, "Li" +393, 5, 20, 80, 47, 48, 332, 333, "L" +393, 5, 21, 81, 49, 50, 334, 335, "(" +393, 5, 22, 82, 51, 52, 336, 337, "4" +393, 5, 23, 83, 53, 54, 338, 339, ")" +393, 5, 24, 84, 55, 56, 340, 341, "," +393, 5, 25, 85, 57, 59, 342, 344, "Xu" +393, 5, 26, 86, 60, 61, 345, 346, "X" +393, 5, 27, 87, 62, 63, 347, 348, "(" +393, 5, 28, 88, 64, 65, 349, 350, "5" +393, 5, 29, 89, 66, 67, 351, 352, ")" +393, 5, 30, 90, 68, 69, 353, 354, "," +393, 5, 31, 91, 70, 73, 355, 358, "Zhu" +393, 5, 32, 92, 74, 75, 359, 360, "D" +393, 5, 33, 93, 76, 77, 361, 362, "(" +393, 5, 34, 94, 78, 79, 363, 364, "6" +393, 5, 35, 95, 80, 81, 365, 366, ")" +393, 5, 36, 96, 82, 83, 367, 368, "," +393, 5, 37, 97, 84, 96, 369, 381, "Venkateshwar" +393, 5, 38, 98, 97, 100, 382, 385, "Rao" +393, 5, 39, 99, 101, 102, 386, 387, "A" +393, 5, 40, 100, 103, 104, 388, 389, "(" +393, 5, 41, 101, 105, 106, 390, 391, "7" +393, 5, 42, 102, 107, 108, 392, 393, ")" +393, 5, 43, 103, 109, 110, 394, 395, "," +393, 5, 44, 104, 111, 117, 396, 402, "Murthy" +393, 5, 45, 105, 118, 120, 403, 405, "LS" +393, 5, 46, 106, 121, 122, 406, 407, "(" +393, 5, 47, 107, 123, 124, 408, 409, "8" +393, 5, 48, 108, 125, 126, 410, 411, ")" +393, 5, 49, 109, 127, 128, 412, 413, "," +393, 5, 50, 110, 129, 134, 414, 419, "Zhang" +393, 5, 51, 111, 135, 136, 420, 421, "N" +393, 5, 52, 112, 137, 138, 422, 423, "(" +393, 5, 53, 113, 139, 140, 424, 425, "9" +393, 5, 54, 114, 141, 142, 426, 427, ")" +393, 5, 55, 115, 143, 144, 428, 429, "," +393, 5, 56, 116, 145, 147, 430, 432, "Li" +393, 5, 57, 117, 148, 149, 433, 434, "I" +393, 5, 58, 118, 150, 151, 435, 436, "(" +393, 5, 59, 119, 152, 153, 437, 438, "9" +393, 5, 60, 120, 154, 155, 439, 440, ")" +393, 5, 61, 121, 156, 157, 441, 442, "," +393, 5, 62, 122, 158, 168, 443, 453, "Niemoeller" +393, 5, 63, 123, 169, 170, 454, 455, "E" +393, 5, 64, 124, 171, 172, 456, 457, "(" +393, 5, 65, 125, 173, 175, 458, 460, "10" +393, 5, 66, 126, 176, 177, 461, 462, ")" +393, 5, 67, 127, 178, 179, 463, 464, "," +393, 5, 68, 128, 180, 185, 465, 470, "Shang" +393, 5, 69, 129, 186, 187, 471, 472, "S" +393, 5, 70, 130, 188, 189, 473, 474, "(" +393, 5, 71, 131, 190, 191, 475, 476, "9" +393, 5, 72, 132, 192, 193, 477, 478, ")" +393, 5, 73, 133, 194, 195, 479, 480, "." +393, 6, 1, 134, 0, 6, 481, 487, "Author" +393, 6, 2, 135, 7, 18, 488, 499, "information" +393, 6, 3, 136, 19, 20, 500, 501, ":" +393, 6, 4, 137, 21, 22, 502, 503, "(" +393, 6, 5, 138, 23, 24, 504, 505, "1" +393, 6, 6, 139, 25, 26, 506, 507, ")" +393, 6, 7, 140, 27, 32, 508, 513, "China" +393, 6, 8, 141, 33, 34, 514, 515, "-" +393, 6, 9, 142, 35, 40, 516, 521, "Japan" +393, 6, 10, 143, 41, 51, 522, 532, "Friendship" +393, 6, 11, 144, 52, 60, 533, 541, "Hospital" +393, 6, 12, 145, 61, 62, 542, 543, "," +393, 6, 13, 146, 63, 70, 544, 551, "Beijing" +393, 6, 14, 147, 71, 72, 552, 553, "," +393, 6, 15, 148, 73, 78, 554, 559, "China" +393, 6, 16, 149, 79, 80, 560, 561, "." +393, 7, 1, 150, 0, 1, 562, 563, "(" +393, 7, 2, 151, 2, 3, 564, 565, "2" +393, 7, 3, 152, 4, 5, 566, 567, ")" +393, 7, 4, 153, 6, 11, 568, 573, "Eulji" +393, 7, 5, 154, 12, 19, 574, 581, "General" +393, 7, 6, 155, 20, 28, 582, 590, "Hospital" +393, 7, 7, 156, 29, 30, 591, 592, "," +393, 7, 8, 157, 31, 36, 593, 598, "Seoul" +393, 7, 9, 158, 37, 38, 599, 600, "," +393, 7, 10, 159, 39, 44, 601, 606, "South" +393, 7, 11, 160, 45, 50, 607, 612, "Korea" +393, 7, 12, 161, 51, 52, 613, 614, "." +393, 8, 1, 162, 0, 1, 615, 616, "(" +393, 8, 2, 163, 2, 3, 617, 618, "3" +393, 8, 3, 164, 4, 5, 619, 620, ")" +393, 8, 4, 165, 6, 9, 621, 624, "The" +393, 8, 5, 166, 10, 16, 625, 631, "Second" +393, 8, 6, 167, 17, 24, 632, 639, "Xiangya" +393, 8, 7, 168, 25, 33, 640, 648, "Hospital" +393, 8, 8, 169, 34, 36, 649, 651, "of" +393, 8, 9, 170, 37, 44, 652, 659, "Central" +393, 8, 10, 171, 45, 50, 660, 665, "South" +393, 8, 11, 172, 51, 61, 666, 676, "University" +393, 8, 12, 173, 62, 63, 677, 678, "," +393, 8, 13, 174, 64, 72, 679, 687, "Changsha" +393, 8, 14, 175, 73, 74, 688, 689, "," +393, 8, 15, 176, 75, 80, 690, 695, "China" +393, 8, 16, 177, 81, 82, 696, 697, "." +393, 9, 1, 178, 0, 1, 698, 699, "(" +393, 9, 2, 179, 2, 3, 700, 701, "4" +393, 9, 3, 180, 4, 5, 702, 703, ")" +393, 9, 4, 181, 6, 15, 704, 713, "Shengjing" +393, 9, 5, 182, 16, 24, 714, 722, "Hospital" +393, 9, 6, 183, 25, 27, 723, 725, "of" +393, 9, 7, 184, 28, 33, 726, 731, "China" +393, 9, 8, 185, 34, 41, 732, 739, "Medical" +393, 9, 9, 186, 42, 52, 740, 750, "University" +393, 9, 10, 187, 53, 54, 751, 752, "," +393, 9, 11, 188, 55, 63, 753, 761, "Shenyang" +393, 9, 12, 189, 64, 65, 762, 763, "," +393, 9, 13, 190, 66, 71, 764, 769, "China" +393, 9, 14, 191, 72, 73, 770, 771, "." +393, 10, 1, 192, 0, 1, 772, 773, "(" +393, 10, 2, 193, 2, 3, 774, 775, "5" +393, 10, 3, 194, 4, 5, 776, 777, ")" +393, 10, 4, 195, 6, 12, 778, 784, "Fuzhou" +393, 10, 5, 196, 13, 20, 785, 792, "General" +393, 10, 6, 197, 21, 29, 793, 801, "Hospital" +393, 10, 7, 198, 30, 31, 802, 803, "," +393, 10, 8, 199, 32, 38, 804, 810, "Fuzhou" +393, 10, 9, 200, 39, 40, 811, 812, "," +393, 10, 10, 201, 41, 46, 813, 818, "China" +393, 10, 11, 202, 47, 48, 819, 820, "." +393, 11, 1, 203, 0, 1, 821, 822, "(" +393, 11, 2, 204, 2, 3, 823, 824, "6" +393, 11, 3, 205, 4, 5, 825, 826, ")" +393, 11, 4, 206, 6, 13, 827, 834, "Nanjing" +393, 11, 5, 207, 14, 19, 835, 840, "Gulou" +393, 11, 6, 208, 20, 28, 841, 849, "Hospital" +393, 11, 7, 209, 29, 30, 850, 851, "," +393, 11, 8, 210, 31, 38, 852, 859, "Nanjing" +393, 11, 9, 211, 39, 40, 860, 861, "," +393, 11, 10, 212, 41, 46, 862, 867, "China" +393, 11, 11, 213, 47, 48, 868, 869, "." +393, 12, 1, 214, 0, 1, 870, 871, "(" +393, 12, 2, 215, 2, 3, 872, 873, "7" +393, 12, 3, 216, 4, 5, 874, 875, ")" +393, 12, 4, 217, 6, 13, 876, 883, "MaxCure" +393, 12, 5, 218, 14, 22, 884, 892, "Hospital" +393, 12, 6, 219, 23, 24, 893, 894, "," +393, 12, 7, 220, 25, 34, 895, 904, "Hyderabad" +393, 12, 8, 221, 35, 36, 905, 906, "," +393, 12, 9, 222, 37, 42, 907, 912, "India" +393, 12, 10, 223, 43, 44, 913, 914, "." +393, 13, 1, 224, 0, 1, 915, 916, "(" +393, 13, 2, 225, 2, 3, 917, 918, "8" +393, 13, 3, 226, 4, 5, 919, 920, ")" +393, 13, 4, 227, 6, 13, 921, 928, "Cauvery" +393, 13, 5, 228, 14, 21, 929, 936, "Medical" +393, 13, 6, 229, 22, 28, 937, 943, "Centre" +393, 13, 7, 230, 29, 30, 944, 945, "," +393, 13, 8, 231, 31, 40, 946, 955, "Bengaluru" +393, 13, 9, 232, 41, 42, 956, 957, "," +393, 13, 10, 233, 43, 48, 958, 963, "India" +393, 13, 11, 234, 49, 50, 964, 965, "." +393, 14, 1, 235, 0, 1, 966, 967, "(" +393, 14, 2, 236, 2, 3, 968, 969, "9" +393, 14, 3, 237, 4, 5, 970, 971, ")" +393, 14, 4, 238, 6, 12, 972, 978, "Sanofi" +393, 14, 5, 239, 13, 14, 979, 980, "," +393, 14, 6, 240, 15, 23, 981, 989, "Shanghai" +393, 14, 7, 241, 24, 25, 990, 991, "," +393, 14, 8, 242, 26, 31, 992, 997, "China" +393, 14, 9, 243, 32, 33, 998, 999, "." +393, 15, 1, 244, 0, 1, 1000, 1001, "(" +393, 15, 2, 245, 2, 4, 1002, 1004, "10" +393, 15, 3, 246, 5, 6, 1005, 1006, ")" +393, 15, 4, 247, 7, 15, 1007, 1015, "Diabetes" +393, 15, 5, 248, 16, 24, 1016, 1024, "Division" +393, 15, 6, 249, 25, 26, 1025, 1026, "," +393, 15, 7, 250, 27, 33, 1027, 1033, "Sanofi" +393, 15, 8, 251, 34, 35, 1034, 1035, "," +393, 15, 9, 252, 36, 45, 1036, 1045, "Frankfurt" +393, 15, 10, 253, 46, 47, 1046, 1047, "," +393, 15, 11, 254, 48, 55, 1048, 1055, "Germany" +393, 15, 12, 255, 56, 57, 1056, 1057, "." +393, 16, 1, 256, 0, 4, 1058, 1062, "AIMS" +393, 16, 2, 257, 5, 6, 1063, 1064, ":" +393, 16, 3, 258, 7, 9, 1065, 1067, "To" +393, 16, 4, 259, 10, 16, 1068, 1074, "assess" +393, 16, 5, 260, 17, 20, 1075, 1078, "the" +393, 16, 6, 261, 21, 28, 1079, 1086, "effects" +393, 16, 7, 262, 29, 31, 1087, 1089, "on" +393, 16, 8, 263, 32, 41, 1090, 1099, "glycaemic" +393, 16, 9, 264, 42, 49, 1100, 1107, "control" +393, 16, 10, 265, 50, 52, 1108, 1110, "of" +393, 16, 11, 266, 53, 65, 1111, 1123, "lixisenatide" +393, 16, 12, 267, 66, 68, 1124, 1126, "vs" +393, 16, 13, 268, 69, 76, 1127, 1134, "placebo" +393, 16, 14, 269, 77, 79, 1135, 1137, "as" +393, 16, 15, 270, 80, 83, 1138, 1141, "add" +393, 16, 16, 271, 84, 85, 1142, 1143, "-" +393, 16, 17, 272, 86, 88, 1144, 1146, "on" +393, 16, 18, 273, 89, 98, 1147, 1156, "treatment" +393, 16, 19, 274, 99, 101, 1157, 1159, "to" +393, 16, 20, 275, 102, 107, 1160, 1165, "basal" +393, 16, 21, 276, 108, 115, 1166, 1173, "insulin" +393, 16, 22, 277, 116, 117, 1174, 1175, "(" +393, 16, 23, 278, 118, 120, 1176, 1178, "BI" +393, 16, 24, 279, 121, 122, 1179, 1180, ")" +393, 16, 25, 280, 123, 126, 1181, 1184, " ± " +393, 16, 26, 281, 127, 136, 1185, 1194, "metformin" +393, 16, 27, 282, 137, 140, 1195, 1198, "and" +393, 16, 28, 283, 141, 148, 1199, 1206, "effects" +393, 16, 29, 284, 149, 151, 1207, 1209, "on" +393, 16, 30, 285, 152, 160, 1210, 1218, "glycated" +393, 16, 31, 286, 161, 172, 1219, 1230, "haemoglobin" +393, 16, 32, 287, 173, 174, 1231, 1232, "(" +393, 16, 33, 288, 175, 180, 1233, 1238, "HbA1c" +393, 16, 34, 289, 181, 182, 1239, 1240, ")" +393, 16, 35, 290, 183, 192, 1241, 1250, "reduction" +393, 16, 36, 291, 193, 195, 1251, 1253, "in" +393, 16, 37, 292, 196, 204, 1254, 1262, "patients" +393, 16, 38, 293, 205, 209, 1263, 1267, "with" +393, 16, 39, 294, 210, 224, 1268, 1282, "insufficiently" +393, 16, 40, 295, 225, 235, 1283, 1293, "controlled" +393, 16, 41, 296, 236, 240, 1294, 1298, "type" +393, 16, 42, 297, 241, 242, 1299, 1300, "2" +393, 16, 43, 298, 243, 251, 1301, 1309, "diabetes" +393, 16, 44, 299, 252, 253, 1310, 1311, "(" +393, 16, 45, 300, 254, 257, 1312, 1315, "T2D" +393, 16, 46, 301, 258, 259, 1316, 1317, ")" +393, 16, 47, 302, 260, 261, 1318, 1319, "." +393, 17, 1, 303, 0, 7, 1320, 1327, "METHODS" +393, 17, 2, 304, 8, 9, 1328, 1329, ":" +393, 17, 3, 305, 10, 18, 1330, 1338, "Patients" +393, 17, 4, 306, 19, 20, 1339, 1340, "(" +393, 17, 5, 307, 21, 22, 1341, 1342, "n" +393, 17, 6, 308, 23, 26, 1343, 1346, " = " +393, 17, 7, 309, 27, 30, 1347, 1350, "448" +393, 17, 8, 310, 31, 32, 1351, 1352, ")" +393, 17, 9, 311, 33, 37, 1353, 1357, "with" +393, 17, 10, 312, 38, 50, 1358, 1370, "inadequately" +393, 17, 11, 313, 51, 61, 1371, 1381, "controlled" +393, 17, 12, 314, 62, 65, 1382, 1385, "T2D" +393, 17, 13, 315, 66, 70, 1386, 1390, "were" +393, 17, 14, 316, 71, 81, 1391, 1401, "randomized" +393, 17, 15, 317, 82, 83, 1402, 1403, "(" +393, 17, 16, 318, 84, 85, 1404, 1405, "1" +393, 17, 17, 319, 86, 87, 1406, 1407, ":" +393, 17, 18, 320, 88, 89, 1408, 1409, "1" +393, 17, 19, 321, 90, 91, 1410, 1411, ")" +393, 17, 20, 322, 92, 94, 1412, 1414, "to" +393, 17, 21, 323, 95, 107, 1415, 1427, "lixisenatide" +393, 17, 22, 324, 108, 110, 1428, 1430, "or" +393, 17, 23, 325, 111, 118, 1431, 1438, "placebo" +393, 17, 24, 326, 119, 121, 1439, 1441, "as" +393, 17, 25, 327, 122, 125, 1442, 1445, "add" +393, 17, 26, 328, 126, 127, 1446, 1447, "-" +393, 17, 27, 329, 128, 130, 1448, 1450, "on" +393, 17, 28, 330, 131, 133, 1451, 1453, "to" +393, 17, 29, 331, 134, 136, 1454, 1456, "BI" +393, 17, 30, 332, 137, 140, 1457, 1460, " ± " +393, 17, 31, 333, 141, 150, 1461, 1470, "metformin" +393, 17, 32, 334, 151, 154, 1471, 1474, "for" +393, 17, 33, 335, 155, 157, 1475, 1477, "24" +393, 17, 34, 336, 158, 159, 1478, 1479, " " +393, 17, 35, 337, 160, 165, 1480, 1485, "weeks" +393, 17, 36, 338, 166, 171, 1486, 1491, "after" +393, 17, 37, 339, 172, 174, 1492, 1494, "an" +393, 17, 38, 340, 175, 176, 1495, 1496, "8" +393, 17, 39, 341, 177, 178, 1497, 1498, "-" +393, 17, 40, 342, 179, 183, 1499, 1503, "week" +393, 17, 41, 343, 184, 187, 1504, 1507, "run" +393, 17, 42, 344, 188, 189, 1508, 1509, "-" +393, 17, 43, 345, 190, 192, 1510, 1512, "in" +393, 17, 44, 346, 193, 198, 1513, 1518, "phase" +393, 17, 45, 347, 199, 200, 1519, 1520, "," +393, 17, 46, 348, 201, 207, 1521, 1527, "during" +393, 17, 47, 349, 208, 213, 1528, 1533, "which" +393, 17, 48, 350, 214, 216, 1534, 1536, "BI" +393, 17, 49, 351, 217, 220, 1537, 1540, "was" +393, 17, 50, 352, 221, 229, 1541, 1549, "titrated" +393, 17, 51, 353, 230, 232, 1550, 1552, "to" +393, 17, 52, 354, 233, 234, 1553, 1554, "a" +393, 17, 53, 355, 235, 241, 1555, 1561, "target" +393, 17, 54, 356, 242, 246, 1562, 1566, "self" +393, 17, 55, 357, 247, 248, 1567, 1568, "-" +393, 17, 56, 358, 249, 258, 1569, 1578, "monitored" +393, 17, 57, 359, 259, 265, 1579, 1585, "plasma" +393, 17, 58, 360, 266, 273, 1586, 1593, "glucose" +393, 17, 59, 361, 274, 275, 1594, 1595, "(" +393, 17, 60, 362, 276, 280, 1596, 1600, "SMPG" +393, 17, 61, 363, 281, 282, 1601, 1602, ";" +393, 17, 62, 364, 283, 284, 1603, 1604, "4" +393, 17, 63, 365, 285, 286, 1605, 1606, "." +393, 17, 64, 366, 287, 288, 1607, 1608, "4" +393, 17, 65, 367, 289, 290, 1609, 1610, "-" +393, 17, 66, 368, 291, 292, 1611, 1612, "5" +393, 17, 67, 369, 293, 294, 1613, 1614, "." +393, 17, 68, 370, 295, 296, 1615, 1616, "6" +393, 17, 69, 371, 297, 298, 1617, 1618, " " +393, 17, 70, 372, 299, 303, 1619, 1623, "mmol" +393, 17, 71, 373, 304, 305, 1624, 1625, "/" +393, 17, 72, 374, 306, 307, 1626, 1627, "L" +393, 17, 73, 375, 308, 309, 1628, 1629, ")" +393, 17, 74, 376, 310, 311, 1630, 1631, "." +393, 18, 1, 377, 0, 3, 1632, 1635, "The" +393, 18, 2, 378, 4, 11, 1636, 1643, "primary" +393, 18, 3, 379, 12, 20, 1644, 1652, "endpoint" +393, 18, 4, 380, 21, 24, 1653, 1656, "was" +393, 18, 5, 381, 25, 33, 1657, 1665, "absolute" +393, 18, 6, 382, 34, 40, 1666, 1672, "change" +393, 18, 7, 383, 41, 43, 1673, 1675, "in" +393, 18, 8, 384, 44, 49, 1676, 1681, "HbA1c" +393, 18, 9, 385, 50, 54, 1682, 1686, "from" +393, 18, 10, 386, 55, 63, 1687, 1695, "baseline" +393, 18, 11, 387, 64, 66, 1696, 1698, "to" +393, 18, 12, 388, 67, 71, 1699, 1703, "week" +393, 18, 13, 389, 72, 74, 1704, 1706, "24" +393, 18, 14, 390, 75, 76, 1707, 1708, "." +393, 19, 1, 391, 0, 9, 1709, 1718, "Secondary" +393, 19, 2, 392, 10, 18, 1719, 1727, "efficacy" +393, 19, 3, 393, 19, 28, 1728, 1737, "endpoints" +393, 19, 4, 394, 29, 37, 1738, 1746, "included" +393, 19, 5, 395, 38, 39, 1747, 1748, ":" +393, 19, 6, 396, 40, 50, 1749, 1759, "percentage" +393, 19, 7, 397, 51, 53, 1760, 1762, "of" +393, 19, 8, 398, 54, 64, 1763, 1773, "responders" +393, 19, 9, 399, 65, 66, 1774, 1775, ";" +393, 19, 10, 400, 67, 74, 1776, 1783, "changes" +393, 19, 11, 401, 75, 77, 1784, 1786, "in" +393, 19, 12, 402, 78, 79, 1787, 1788, "2" +393, 19, 13, 403, 80, 81, 1789, 1790, "-" +393, 19, 14, 404, 82, 86, 1791, 1795, "hour" +393, 19, 15, 405, 87, 99, 1796, 1808, "postprandial" +393, 19, 16, 406, 100, 106, 1809, 1815, "plasma" +393, 19, 17, 407, 107, 114, 1816, 1823, "glucose" +393, 19, 18, 408, 115, 116, 1824, 1825, "(" +393, 19, 19, 409, 117, 120, 1826, 1829, "PPG" +393, 19, 20, 410, 121, 122, 1830, 1831, ")" +393, 19, 21, 411, 123, 124, 1832, 1833, ";" +393, 19, 22, 412, 125, 126, 1834, 1835, "7" +393, 19, 23, 413, 127, 128, 1836, 1837, "-" +393, 19, 24, 414, 129, 134, 1838, 1843, "point" +393, 19, 25, 415, 135, 139, 1844, 1848, "SMPG" +393, 19, 26, 416, 140, 141, 1849, 1850, "(" +393, 19, 27, 417, 142, 147, 1851, 1856, "daily" +393, 19, 28, 418, 148, 155, 1857, 1864, "average" +393, 19, 29, 419, 156, 157, 1865, 1866, ")" +393, 19, 30, 420, 158, 159, 1867, 1868, ";" +393, 19, 31, 421, 160, 164, 1869, 1873, "body" +393, 19, 32, 422, 165, 171, 1874, 1880, "weight" +393, 19, 33, 423, 172, 173, 1881, 1882, "(" +393, 19, 34, 424, 174, 176, 1883, 1885, "BW" +393, 19, 35, 425, 177, 178, 1886, 1887, ")" +393, 19, 36, 426, 179, 180, 1888, 1889, ";" +393, 19, 37, 427, 181, 186, 1890, 1895, "total" +393, 19, 38, 428, 187, 192, 1896, 1901, "daily" +393, 19, 39, 429, 193, 195, 1902, 1904, "BI" +393, 19, 40, 430, 196, 200, 1905, 1909, "dose" +393, 19, 41, 431, 201, 202, 1910, 1911, ";" +393, 19, 42, 432, 203, 210, 1912, 1919, "fasting" +393, 19, 43, 433, 211, 217, 1920, 1926, "plasma" +393, 19, 44, 434, 218, 225, 1927, 1934, "glucose" +393, 19, 45, 435, 226, 227, 1935, 1936, ";" +393, 19, 46, 436, 228, 231, 1937, 1940, "and" +393, 19, 47, 437, 232, 238, 1941, 1947, "safety" +393, 19, 48, 438, 239, 250, 1948, 1959, "assessments" +393, 19, 49, 439, 251, 252, 1960, 1961, "." +393, 20, 1, 440, 0, 7, 1962, 1969, "RESULTS" +393, 20, 2, 441, 8, 9, 1970, 1971, ":" +393, 20, 3, 442, 10, 18, 1972, 1980, "Baseline" +393, 20, 4, 443, 19, 31, 1981, 1993, "demographics" +393, 20, 5, 444, 32, 36, 1994, 1998, "were" +393, 20, 6, 445, 37, 44, 1999, 2006, "similar" +393, 20, 7, 446, 45, 47, 2007, 2009, "in" +393, 20, 8, 447, 48, 51, 2010, 2013, "the" +393, 20, 9, 448, 52, 55, 2014, 2017, "two" +393, 20, 10, 449, 56, 65, 2018, 2027, "treatment" +393, 20, 11, 450, 66, 72, 2028, 2034, "groups" +393, 20, 12, 451, 73, 74, 2035, 2036, "." +393, 21, 1, 452, 0, 5, 2037, 2042, "After" +393, 21, 2, 453, 6, 13, 2043, 2050, "insulin" +393, 21, 3, 454, 14, 26, 2051, 2063, "optimization" +393, 21, 4, 455, 27, 33, 2064, 2070, "during" +393, 21, 5, 456, 34, 37, 2071, 2074, "run" +393, 21, 6, 457, 38, 39, 2075, 2076, "-" +393, 21, 7, 458, 40, 42, 2077, 2079, "in" +393, 21, 8, 459, 43, 44, 2080, 2081, "," +393, 21, 9, 460, 45, 57, 2082, 2094, "lixisenatide" +393, 21, 10, 461, 58, 61, 2095, 2098, "was" +393, 21, 11, 462, 62, 70, 2099, 2107, "superior" +393, 21, 12, 463, 71, 73, 2108, 2110, "to" +393, 21, 13, 464, 74, 81, 2111, 2118, "placebo" +393, 21, 14, 465, 82, 84, 2119, 2121, "in" +393, 21, 15, 466, 85, 89, 2122, 2126, "mean" +393, 21, 16, 467, 90, 96, 2127, 2133, "change" +393, 21, 17, 468, 97, 101, 2134, 2138, "from" +393, 21, 18, 469, 102, 110, 2139, 2147, "baseline" +393, 21, 19, 470, 111, 112, 2148, 2149, "(" +393, 21, 20, 471, 113, 114, 2150, 2151, "7" +393, 21, 21, 472, 115, 116, 2152, 2153, "." +393, 21, 22, 473, 117, 118, 2154, 2155, "9" +393, 21, 23, 474, 119, 120, 2156, 2157, "%" +393, 21, 24, 475, 121, 122, 2158, 2159, "[" +393, 21, 25, 476, 123, 131, 2160, 2168, "standard" +393, 21, 26, 477, 132, 141, 2169, 2178, "deviation" +393, 21, 27, 478, 142, 143, 2179, 2180, "{" +393, 21, 28, 479, 144, 145, 2181, 2182, "s" +393, 21, 29, 480, 146, 147, 2183, 2184, "." +393, 21, 30, 481, 148, 149, 2185, 2186, "d" +393, 21, 31, 482, 150, 151, 2187, 2188, "." +393, 22, 1, 483, 0, 1, 2189, 2190, "}" +393, 22, 2, 484, 2, 3, 2191, 2192, "," +393, 22, 3, 485, 4, 5, 2193, 2194, "0" +393, 22, 4, 486, 6, 7, 2195, 2196, "." +393, 22, 5, 487, 8, 10, 2197, 2199, "66" +393, 22, 6, 488, 11, 12, 2200, 2201, "]" +393, 22, 7, 489, 13, 16, 2202, 2205, "and" +393, 22, 8, 490, 17, 18, 2206, 2207, "7" +393, 22, 9, 491, 19, 20, 2208, 2209, "." +393, 22, 10, 492, 21, 22, 2210, 2211, "9" +393, 22, 11, 493, 23, 24, 2212, 2213, "%" +393, 22, 12, 494, 25, 26, 2214, 2215, "[" +393, 22, 13, 495, 27, 28, 2216, 2217, "0" +393, 22, 14, 496, 29, 30, 2218, 2219, "." +393, 22, 15, 497, 31, 33, 2220, 2222, "70" +393, 22, 16, 498, 34, 35, 2223, 2224, "]" +393, 22, 17, 499, 36, 37, 2225, 2226, "," +393, 22, 18, 500, 38, 50, 2227, 2239, "respectively" +393, 22, 19, 501, 51, 52, 2240, 2241, ")" +393, 22, 20, 502, 53, 55, 2242, 2244, "to" +393, 22, 21, 503, 56, 60, 2245, 2249, "week" +393, 22, 22, 504, 61, 63, 2250, 2252, "24" +393, 22, 23, 505, 64, 66, 2253, 2255, "in" +393, 22, 24, 506, 67, 72, 2256, 2261, "HbA1c" +393, 22, 25, 507, 73, 74, 2262, 2263, "(" +393, 22, 26, 508, 75, 80, 2264, 2269, "least" +393, 22, 27, 509, 81, 88, 2270, 2277, "squares" +393, 22, 28, 510, 89, 93, 2278, 2282, "mean" +393, 22, 29, 511, 94, 95, 2283, 2284, "[" +393, 22, 30, 512, 96, 104, 2285, 2293, "standard" +393, 22, 31, 513, 105, 110, 2294, 2299, "error" +393, 22, 32, 514, 111, 112, 2300, 2301, "{" +393, 22, 33, 515, 113, 114, 2302, 2303, "s" +393, 22, 34, 516, 115, 116, 2304, 2305, "." +393, 22, 35, 517, 117, 118, 2306, 2307, "e" +393, 22, 36, 518, 119, 120, 2308, 2309, "." +393, 22, 37, 519, 121, 122, 2310, 2311, "}" +393, 22, 38, 520, 123, 124, 2312, 2313, "]" +393, 23, 1, 521, 0, 6, 2314, 2320, "change" +393, 23, 2, 522, 7, 8, 2321, 2322, "-" +393, 23, 3, 523, 9, 10, 2323, 2324, "0" +393, 23, 4, 524, 11, 12, 2325, 2326, "." +393, 23, 5, 525, 13, 15, 2327, 2329, "62" +393, 23, 6, 526, 16, 17, 2330, 2331, "%" +393, 23, 7, 527, 18, 19, 2332, 2333, "[" +393, 23, 8, 528, 20, 21, 2334, 2335, "0" +393, 23, 9, 529, 22, 23, 2336, 2337, "." +393, 23, 10, 530, 24, 26, 2338, 2340, "09" +393, 23, 11, 531, 27, 28, 2341, 2342, "]" +393, 23, 12, 532, 29, 31, 2343, 2345, "vs" +393, 23, 13, 533, 32, 33, 2346, 2347, "-" +393, 23, 14, 534, 34, 35, 2348, 2349, "0" +393, 23, 15, 535, 36, 37, 2350, 2351, "." +393, 23, 16, 536, 38, 40, 2352, 2354, "11" +393, 23, 17, 537, 41, 42, 2355, 2356, "%" +393, 23, 18, 538, 43, 44, 2357, 2358, "[" +393, 23, 19, 539, 45, 46, 2359, 2360, "0" +393, 23, 20, 540, 47, 48, 2361, 2362, "." +393, 23, 21, 541, 49, 51, 2363, 2365, "09" +393, 23, 22, 542, 52, 53, 2366, 2367, "]" +393, 23, 23, 543, 54, 55, 2368, 2369, ";" +393, 23, 24, 544, 56, 57, 2370, 2371, "P" +393, 23, 25, 545, 58, 62, 2372, 2376, " < ." +393, 23, 26, 546, 63, 67, 2377, 2381, "0001" +393, 23, 27, 547, 68, 69, 2382, 2383, "," +393, 23, 28, 548, 70, 82, 2384, 2396, "respectively" +393, 23, 29, 549, 83, 84, 2397, 2398, ")" +393, 23, 30, 550, 85, 88, 2399, 2402, "and" +393, 23, 31, 551, 89, 95, 2403, 2409, "higher" +393, 23, 32, 552, 96, 107, 2410, 2421, "proportions" +393, 23, 33, 553, 108, 110, 2422, 2424, "of" +393, 23, 34, 554, 111, 119, 2425, 2433, "patients" +393, 23, 35, 555, 120, 128, 2434, 2442, "achieved" +393, 23, 36, 556, 129, 134, 2443, 2448, "HbA1c" +393, 23, 37, 557, 135, 142, 2449, 2456, "targets" +393, 23, 38, 558, 143, 144, 2457, 2458, "." +393, 24, 1, 559, 0, 3, 2459, 2462, "Two" +393, 24, 2, 560, 4, 5, 2463, 2464, "-" +393, 24, 3, 561, 6, 10, 2465, 2469, "hour" +393, 24, 4, 562, 11, 14, 2470, 2473, "PPG" +393, 24, 5, 563, 15, 16, 2474, 2475, "," +393, 24, 6, 564, 17, 22, 2476, 2481, "daily" +393, 24, 7, 565, 23, 27, 2482, 2486, "mean" +393, 24, 8, 566, 28, 32, 2487, 2491, "SMPG" +393, 24, 9, 567, 33, 36, 2492, 2495, "and" +393, 24, 10, 568, 37, 41, 2496, 2500, "mean" +393, 24, 11, 569, 42, 44, 2501, 2503, "BW" +393, 24, 12, 570, 45, 49, 2504, 2508, "were" +393, 24, 13, 571, 50, 57, 2509, 2516, "reduced" +393, 24, 14, 572, 58, 65, 2517, 2524, "further" +393, 24, 15, 573, 66, 69, 2525, 2528, "and" +393, 24, 16, 574, 70, 75, 2529, 2534, "daily" +393, 24, 17, 575, 76, 78, 2535, 2537, "BI" +393, 24, 18, 576, 79, 83, 2538, 2542, "dose" +393, 24, 19, 577, 84, 87, 2543, 2546, "was" +393, 24, 20, 578, 88, 93, 2547, 2552, "lower" +393, 24, 21, 579, 94, 98, 2553, 2557, "with" +393, 24, 22, 580, 99, 111, 2558, 2570, "lixisenatide" +393, 24, 23, 581, 112, 116, 2571, 2575, "than" +393, 24, 24, 582, 117, 124, 2576, 2583, "placebo" +393, 24, 25, 583, 125, 126, 2584, 2585, "(" +393, 24, 26, 584, 127, 128, 2586, 2587, "-" +393, 24, 27, 585, 129, 130, 2588, 2589, "1" +393, 24, 28, 586, 131, 132, 2590, 2591, "." +393, 24, 29, 587, 133, 135, 2592, 2594, "12" +393, 24, 30, 588, 136, 137, 2595, 2596, " " +393, 24, 31, 589, 138, 140, 2597, 2599, "kg" +393, 24, 32, 590, 141, 143, 2600, 2602, "vs" +393, 24, 33, 591, 144, 145, 2603, 2604, "0" +393, 24, 34, 592, 146, 147, 2605, 2606, "." +393, 24, 35, 593, 148, 150, 2607, 2609, "04" +393, 24, 36, 594, 151, 152, 2610, 2611, " " +393, 24, 37, 595, 153, 155, 2612, 2614, "kg" +393, 24, 38, 596, 156, 157, 2615, 2616, "[" +393, 24, 39, 597, 158, 159, 2617, 2618, "P" +393, 24, 40, 598, 160, 164, 2619, 2623, " < ." +393, 24, 41, 599, 165, 169, 2624, 2628, "0001" +393, 24, 42, 600, 170, 171, 2629, 2630, "]" +393, 24, 43, 601, 172, 173, 2631, 2632, ";" +393, 24, 44, 602, 174, 175, 2633, 2634, "-" +393, 24, 45, 603, 176, 177, 2635, 2636, "3" +393, 24, 46, 604, 178, 179, 2637, 2638, "." +393, 24, 47, 605, 180, 181, 2639, 2640, "0" +393, 24, 48, 606, 182, 183, 2641, 2642, " " +393, 24, 49, 607, 184, 185, 2643, 2644, "U" +393, 24, 50, 608, 186, 188, 2645, 2647, "vs" +393, 24, 51, 609, 189, 190, 2648, 2649, "-" +393, 24, 52, 610, 191, 192, 2650, 2651, "1" +393, 24, 53, 611, 193, 194, 2652, 2653, "." +393, 24, 54, 612, 195, 196, 2654, 2655, "9" +393, 24, 55, 613, 197, 198, 2656, 2657, " " +393, 24, 56, 614, 199, 200, 2658, 2659, "U" +393, 24, 57, 615, 201, 202, 2660, 2661, "[" +393, 24, 58, 616, 203, 204, 2662, 2663, "P" +393, 24, 59, 617, 205, 209, 2664, 2668, " = ." +393, 24, 60, 618, 210, 214, 2669, 2673, "0033" +393, 24, 61, 619, 215, 216, 2674, 2675, "]" +393, 24, 62, 620, 217, 218, 2676, 2677, "," +393, 24, 63, 621, 219, 231, 2678, 2690, "respectively" +393, 24, 64, 622, 232, 233, 2691, 2692, ")" +393, 24, 65, 623, 234, 235, 2693, 2694, "." +393, 25, 1, 624, 0, 9, 2695, 2704, "Treatment" +393, 25, 2, 625, 10, 11, 2705, 2706, "-" +393, 25, 3, 626, 12, 20, 2707, 2715, "emergent" +393, 25, 4, 627, 21, 28, 2716, 2723, "adverse" +393, 25, 5, 628, 29, 35, 2724, 2730, "events" +393, 25, 6, 629, 36, 40, 2731, 2735, "were" +393, 25, 7, 630, 41, 48, 2736, 2743, "greater" +393, 25, 8, 631, 49, 53, 2744, 2748, "with" +393, 25, 9, 632, 54, 66, 2749, 2761, "lixisenatide" +393, 25, 10, 633, 67, 71, 2762, 2766, "than" +393, 25, 11, 634, 72, 79, 2767, 2774, "placebo" +393, 25, 12, 635, 80, 81, 2775, 2776, "(" +393, 25, 13, 636, 82, 84, 2777, 2779, "63" +393, 25, 14, 637, 85, 86, 2780, 2781, "." +393, 25, 15, 638, 87, 88, 2782, 2783, "8" +393, 25, 16, 639, 89, 90, 2784, 2785, "%" +393, 25, 17, 640, 91, 93, 2786, 2788, "vs" +393, 25, 18, 641, 94, 96, 2789, 2791, "40" +393, 25, 19, 642, 97, 98, 2792, 2793, "." +393, 25, 20, 643, 99, 100, 2794, 2795, "8" +393, 25, 21, 644, 101, 102, 2796, 2797, "%" +393, 25, 22, 645, 103, 104, 2798, 2799, "," +393, 25, 23, 646, 105, 117, 2800, 2812, "respectively" +393, 25, 24, 647, 118, 119, 2813, 2814, ")" +393, 25, 25, 648, 120, 121, 2815, 2816, "." +393, 26, 1, 649, 0, 3, 2817, 2820, "The" +393, 26, 2, 650, 4, 13, 2821, 2830, "incidence" +393, 26, 3, 651, 14, 16, 2831, 2833, "of" +393, 26, 4, 652, 17, 28, 2834, 2845, "symptomatic" +393, 26, 5, 653, 29, 42, 2846, 2859, "hypoglycaemia" +393, 26, 6, 654, 43, 46, 2860, 2863, "was" +393, 26, 7, 655, 47, 54, 2864, 2871, "similar" +393, 26, 8, 656, 55, 56, 2872, 2873, "(" +393, 26, 9, 657, 57, 69, 2874, 2886, "lixisenatide" +393, 26, 10, 658, 70, 72, 2887, 2889, "15" +393, 26, 11, 659, 73, 74, 2890, 2891, "." +393, 26, 12, 660, 75, 76, 2892, 2893, "6" +393, 26, 13, 661, 77, 78, 2894, 2895, "%" +393, 26, 14, 662, 79, 81, 2896, 2898, "vs" +393, 26, 15, 663, 82, 89, 2899, 2906, "placebo" +393, 26, 16, 664, 90, 92, 2907, 2909, "13" +393, 26, 17, 665, 93, 94, 2910, 2911, "." +393, 26, 18, 666, 95, 96, 2912, 2913, "5" +393, 26, 19, 667, 97, 98, 2914, 2915, "%" +393, 26, 20, 668, 99, 100, 2916, 2917, ")" +393, 26, 21, 669, 101, 102, 2918, 2919, "." +393, 27, 1, 670, 0, 11, 2920, 2931, "CONCLUSIONS" +393, 27, 2, 671, 12, 13, 2932, 2933, ":" +393, 27, 3, 672, 14, 16, 2934, 2936, "In" +393, 27, 4, 673, 17, 22, 2937, 2942, "Asian" +393, 27, 5, 674, 23, 31, 2943, 2951, "patients" +393, 27, 6, 675, 32, 46, 2952, 2966, "insufficiently" +393, 27, 7, 676, 47, 57, 2967, 2977, "controlled" +393, 27, 8, 677, 58, 60, 2978, 2980, "on" +393, 27, 9, 678, 61, 63, 2981, 2983, "BI" +393, 27, 10, 679, 64, 67, 2984, 2987, " ± " +393, 27, 11, 680, 68, 77, 2988, 2997, "metformin" +393, 27, 12, 681, 78, 79, 2998, 2999, "," +393, 27, 13, 682, 80, 92, 3000, 3012, "lixisenatide" +393, 27, 14, 683, 93, 96, 3013, 3016, "was" +393, 27, 15, 684, 97, 105, 3017, 3025, "superior" +393, 27, 16, 685, 106, 108, 3026, 3028, "to" +393, 27, 17, 686, 109, 116, 3029, 3036, "placebo" +393, 27, 18, 687, 117, 119, 3037, 3039, "in" +393, 27, 19, 688, 120, 129, 3040, 3049, "glycaemic" +393, 27, 20, 689, 130, 137, 3050, 3057, "control" +393, 27, 21, 690, 138, 139, 3058, 3059, "," +393, 27, 22, 691, 140, 144, 3060, 3064, "with" +393, 27, 23, 692, 145, 146, 3065, 3066, "a" +393, 27, 24, 693, 147, 159, 3067, 3079, "tolerability" +393, 27, 25, 694, 160, 167, 3080, 3087, "profile" +393, 27, 26, 695, 168, 170, 3088, 3090, "in" +393, 27, 27, 696, 171, 175, 3091, 3095, "line" +393, 27, 28, 697, 176, 180, 3096, 3100, "with" +393, 27, 29, 698, 181, 186, 3101, 3106, "other" +393, 27, 30, 699, 187, 195, 3107, 3115, "glucagon" +393, 27, 31, 700, 196, 197, 3116, 3117, "-" +393, 27, 32, 701, 198, 202, 3118, 3122, "like" +393, 27, 33, 702, 203, 210, 3123, 3130, "peptide" +393, 27, 34, 703, 211, 212, 3131, 3132, "-" +393, 27, 35, 704, 213, 214, 3133, 3134, "1" +393, 27, 36, 705, 215, 223, 3135, 3143, "receptor" +393, 27, 37, 706, 224, 232, 3144, 3152, "agonists" +393, 27, 38, 707, 233, 234, 3153, 3154, "." +393, 28, 1, 708, 0, 8, 3155, 3163, "CLINICAL" +393, 28, 2, 709, 9, 14, 3164, 3169, "TRIAL" +393, 28, 3, 710, 15, 21, 3170, 3176, "NUMBER" +393, 28, 4, 711, 22, 23, 3177, 3178, ":" +393, 28, 5, 712, 24, 35, 3179, 3190, "NCT01632163" +393, 28, 6, 713, 36, 37, 3191, 3192, "(" +393, 28, 7, 714, 38, 52, 3193, 3207, "clinicaltrials" +393, 28, 8, 715, 53, 54, 3208, 3209, "." +393, 28, 9, 716, 55, 58, 3210, 3213, "gov" +393, 28, 10, 717, 59, 60, 3214, 3215, ")" +393, 28, 11, 718, 61, 62, 3216, 3217, "." +393, 29, 1, 719, 0, 1, 3218, 3219, "©" +393, 29, 2, 720, 2, 6, 3220, 3224, "2017" +393, 29, 3, 721, 7, 10, 3225, 3228, "The" +393, 29, 4, 722, 11, 18, 3229, 3236, "Authors" +393, 29, 5, 723, 19, 20, 3237, 3238, "." +393, 30, 1, 724, 0, 8, 3239, 3247, "Diabetes" +393, 30, 2, 725, 9, 10, 3248, 3249, "," +393, 30, 3, 726, 11, 18, 3250, 3257, "Obesity" +393, 30, 4, 727, 19, 22, 3258, 3261, "and" +393, 30, 5, 728, 23, 33, 3262, 3272, "Metabolism" +393, 30, 6, 729, 34, 43, 3273, 3282, "published" +393, 30, 7, 730, 44, 46, 3283, 3285, "by" +393, 30, 8, 731, 47, 51, 3286, 3290, "John" +393, 30, 9, 732, 52, 57, 3291, 3296, "Wiley" +393, 30, 10, 733, 58, 59, 3297, 3298, "&" +393, 30, 11, 734, 60, 64, 3299, 3303, "Sons" +393, 30, 12, 735, 65, 68, 3304, 3307, "Ltd" +393, 30, 13, 736, 69, 70, 3308, 3309, "." +393, 30, 14, 737, 71, 74, 3310, 3313, "DOI" +393, 30, 15, 738, 75, 76, 3314, 3315, ":" +393, 30, 16, 739, 77, 79, 3316, 3318, "10" +393, 30, 17, 740, 80, 81, 3319, 3320, "." +393, 30, 18, 741, 82, 86, 3321, 3325, "1111" +393, 30, 19, 742, 87, 88, 3326, 3327, "/" +393, 30, 20, 743, 89, 92, 3328, 3331, "dom" +393, 30, 21, 744, 93, 94, 3332, 3333, "." +393, 30, 22, 745, 95, 100, 3334, 3339, "13072" +393, 30, 23, 746, 101, 106, 3340, 3345, "PMCID" +393, 30, 24, 747, 107, 108, 3346, 3347, ":" +393, 30, 25, 748, 109, 119, 3348, 3358, "PMC5813270" +393, 30, 26, 749, 120, 124, 3359, 3363, "PMID" +393, 30, 27, 750, 125, 126, 3364, 3365, ":" +393, 30, 28, 751, 127, 135, 3366, 3374, "28742225" +393, 30, 29, 752, 136, 137, 3375, 3376, "[" +393, 30, 30, 753, 138, 145, 3377, 3384, "Indexed" +393, 30, 31, 754, 146, 149, 3385, 3388, "for" +393, 30, 32, 755, 150, 157, 3389, 3396, "MEDLINE" +393, 30, 33, 756, 158, 159, 3397, 3398, "]" diff --git a/data/dm2 28742225_kwoodley.annodb b/data/dm2 28742225_kwoodley.annodb new file mode 100644 index 0000000..cad52a1 --- /dev/null +++ b/data/dm2 28742225_kwoodley.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +71999, Journal, 0, 19, "Diabetes Obes Metab", "", +72000, PublicationYear, 22, 26, "2018", "", +72018, Title, 106, 284, "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .", "", +72001, Drug, 129, 141, "lixisenatide", "", +72009, Ethnicity, 145, 177, "a predominantly Asian population", "", +72011, Type2Diabetes, 183, 198, "type 2 diabetes", "", +72015, Insulin, 236, 243, "insulin", "", +72019, Author, 285, 291, "Yang W", "", +72020, Author, 300, 305, "Min K", "", +72021, Author, 314, 320, "Zhou Z", "", +72022, Author, 329, 333, "Li L", "", +72023, Author, 342, 346, "Xu X", "", +72024, Author, 355, 360, "Zhu D", "", +72025, Author, 369, 387, "Venkateshwar Rao A", "", +72026, Author, 396, 405, "Murthy LS", "", +72027, Author, 414, 421, "Zhang N", "", +72028, Author, 430, 434, "Li I", "", +72029, Author, 443, 455, "Niemoeller E", "", +72030, Author, 465, 472, "Shang S", "", +72031, China, 554, 559, "China", "", +72035, SouthKorea, 601, 612, "South Korea", "", +72032, China, 690, 695, "China", "", +72033, China, 764, 769, "China", "", +72034, China, 813, 818, "China", "", +72038, China, 862, 867, "China", "", +72037, India, 907, 912, "India", "", +72039, India, 958, 963, "India", "", +72036, China, 992, 997, "China", "", +72040, Germany, 1048, 1055, "Germany", "", +72059, ObjectiveDescription, 1065, 1319, "To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .", "", +72002, Drug, 1111, 1123, "lixisenatide", "", +72041, Placebo, 1127, 1134, "placebo", "", +72016, Insulin, 1166, 1173, "insulin", "", +72017, Insulin, 1176, 1178, "BI", "", +72048, Metformin, 1185, 1194, "metformin", "", +72054, HbA1c, 1210, 1230, "glycated haemoglobin", "", +72055, HbA1c, 1233, 1238, "HbA1c", "", +72058, Precondition, 1254, 1317, "patients with insufficiently controlled type 2 diabetes ( T2D )", "", +72012, Type2Diabetes, 1294, 1309, "type 2 diabetes", "", +72013, Type2Diabetes, 1312, 1315, "T2D", "", +72061, Precondition, 1330, 1385, "Patients ( n  =  448 ) with inadequately controlled T2D", "", +72060, NumberPatientsCT, 1347, 1350, "448", "", +72014, Type2Diabetes, 1382, 1385, "T2D", "", +72062, Randomized, 1391, 1401, "randomized", "", +72063, AllocationRatio, 1404, 1409, "1 : 1", "", +72003, Drug, 1415, 1427, "lixisenatide", "", +72067, DoseDescription, 1415, 1629, "lixisenatide or placebo as add - on to BI  ±  metformin for 24   weeks after an 8 - week run - in phase , during which BI was titrated to a target self - monitored plasma glucose ( SMPG ; 4 . 4 - 5 . 6   mmol / L )", "", +72043, Placebo, 1431, 1438, "placebo", "", +72051, Insulin, 1454, 1456, "BI", "", +72049, Metformin, 1461, 1470, "metformin", "", +72064, Duration, 1475, 1485, "24   weeks", "", +72052, Insulin, 1534, 1536, "BI", "", +72065, PlasmaGlucose, 1579, 1593, "plasma glucose", "", +72066, Millimoles_per_litre, 1619, 1627, "mmol / L", "", +72056, HbA1c, 1676, 1681, "HbA1c", "", +72069, TimePoint, 1687, 1695, "baseline", "", +72070, TimePoint, 1699, 1706, "week 24", "", +72073, PostprandialPlasmaGlucose, 1787, 1823, "2 - hour postprandial plasma glucose", "", +72074, PostprandialPlasmaGlucose, 1826, 1829, "PPG", "", +72075, EndPointDescription, 1834, 1848, "7 - point SMPG", "", +72076, BodyWeight, 1869, 1880, "body weight", "", +72077, BodyWeight, 1883, 1885, "BW", "", +72078, InsulinDose, 1902, 1909, "BI dose", "", +72079, FastingPlasmaGlucose, 1912, 1934, "fasting plasma glucose", "", +72080, EndPointDescription, 1941, 1959, "safety assessments", "", +72081, Insulin, 2043, 2050, "insulin", "", +72004, Drug, 2082, 2094, "lixisenatide", "", +72042, Placebo, 2111, 2118, "placebo", "", +72071, TimePoint, 2139, 2147, "baseline", "", +72088, ResultMeasuredValue, 2150, 2155, "7 . 9", "", +72082, Percentage, 2156, 2157, "%", "", +72086, SdDevResValue, 2193, 2199, "0 . 66", "", +72089, ResultMeasuredValue, 2206, 2211, "7 . 9", "", +72090, Percentage, 2212, 2213, "%", "", +72087, SdDevResValue, 2216, 2222, "0 . 70", "", +72072, TimePoint, 2245, 2252, "week 24", "", +72057, HbA1c, 2256, 2261, "HbA1c", "", +72091, LeastSquaresMean, 2264, 2282, "least squares mean", "", +72092, Reduction, 2323, 2329, "0 . 62", "", +72094, Percentage, 2330, 2331, "%", "", +72096, SdErrorChangeValue, 2334, 2340, "0 . 09", "", +72093, Reduction, 2348, 2354, "0 . 11", "", +72095, Percentage, 2355, 2356, "%", "", +72097, SdErrorChangeValue, 2359, 2365, "0 . 09", "", +72098, PvalueDiff, 2370, 2381, "P  < . 0001", "", +72100, ObservedResult, 2403, 2456, "higher proportions of patients achieved HbA1c targets", "", +72099, HbA1c_target, 2443, 2456, "HbA1c targets", "", +72101, PostprandialPlasmaGlucose, 2459, 2473, "Two - hour PPG", "", +72102, EndPointDescription, 2487, 2491, "SMPG", "", +72103, BodyWeight, 2501, 2503, "BW", "", +72105, ObservedResult, 2504, 2524, "were reduced further", "", +72104, InsulinDose, 2535, 2542, "BI dose", "", +72106, ObservedResult, 2543, 2552, "was lower", "", +72005, Drug, 2558, 2570, "lixisenatide", "", +72044, Placebo, 2576, 2583, "placebo", "", +72107, Reduction, 2588, 2594, "1 . 12", "", +72110, Kg, 2597, 2599, "kg", "", +72112, Increment, 2603, 2609, "0 . 04", "", +72111, Kg, 2612, 2614, "kg", "", +72113, PvalueDiff, 2617, 2628, "P  < . 0001", "", +72108, Reduction, 2635, 2640, "3 . 0", "", +72114, BioAndMedicalUnit, 2643, 2644, "U", "", +72109, Reduction, 2650, 2655, "1 . 9", "", +72115, BioAndMedicalUnit, 2658, 2659, "U", "", +72116, PvalueDiff, 2662, 2673, "P  = . 0033", "", +72117, EndPointDescription, 2716, 2730, "adverse events", "", +72006, Drug, 2749, 2761, "lixisenatide", "", +72045, Placebo, 2767, 2774, "placebo", "", +72118, PercentageAffected, 2777, 2783, "63 . 8", "", +72119, PercentageAffected, 2789, 2795, "40 . 8", "", +72120, SymptomaticHypoglycemia, 2834, 2859, "symptomatic hypoglycaemia", "", +72007, Drug, 2874, 2886, "lixisenatide", "", +72121, PercentageAffected, 2887, 2893, "15 . 6", "", +72046, Placebo, 2899, 2906, "placebo", "", +72122, PercentageAffected, 2907, 2913, "13 . 5", "", +72124, ConclusionComment, 2934, 3154, "In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists .", "", +72010, Ethnicity, 2937, 2942, "Asian", "", +72123, Precondition, 2943, 2997, "patients insufficiently controlled on BI  ±  metformin", "", +72053, Insulin, 2981, 2983, "BI", "", +72050, Metformin, 2988, 2997, "metformin", "", +72008, Drug, 3000, 3012, "lixisenatide", "", +72047, Placebo, 3029, 3036, "placebo", "", +72125, PMID, 3366, 3374, "28742225", "", diff --git a/data/dm2 28742225_kwoodley.n-triples b/data/dm2 28742225_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28742225_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28923291_admin.annodb b/data/dm2 28923291_admin.annodb new file mode 100644 index 0000000..3fe2b02 --- /dev/null +++ b/data/dm2 28923291_admin.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2017", "", " \"2017\"." +6, Title, 120, 304, "Use of Prohibited Medication , a Potentially Overlooked Confounder in Clinical Trials : Omarigliptin ( Once - weekly DPP - 4 Inhibitor ) Monotherapy Trial in 18 - to 45 - year - olds .", "", " \"Use of Prohibited Medication , a Potentially Overlooked Confounder in Clinical Trials : Omarigliptin ( Once - weekly DPP - 4 Inhibitor ) Monotherapy Trial in 18 - to 45 - year - olds .\"." +2, Omarigliptin, 208, 220, "Omarigliptin", "", +3, Frequency, 223, 236, "Once - weekly", "", +4, MinAge, 278, 280, "18", "", " \"18\"." +5, MaxAge, 286, 288, "45", "", " \"45\"." +7, Author, 305, 312, "Gantz I", "", " \"Gantz I\"." +8, Author, 321, 331, "Sokolova L", "", " \"Sokolova L\"." +9, Author, 340, 346, "Jain L", "", " \"Jain L\"." +10, Author, 355, 364, "Iredale C", "", " \"Iredale C\"." +11, Author, 373, 385, "O ' Neill EA", "", " \"O ' Neill EA\"." +12, Author, 394, 399, "Wei Z", "", " \"Wei Z\"." +13, Author, 408, 413, "Lam R", "", " \"Lam R\"." +14, Author, 422, 435, "Suryawanshi S", "", " \"Suryawanshi S\"." +15, Author, 444, 454, "Kaufman KD", "", " \"Kaufman KD\"." +16, Author, 463, 471, "Engel SS", "", " \"Engel SS\"." +17, Author, 480, 485, "Lai E", "", " \"Lai E\"." +141, USA, 553, 563, "New Jersey", "", +18, Country, 733, 740, "Ukraine", "", +143, USA, 781, 791, "New Jersey", "", +22, ObjectiveDescription, 804, 971, "The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus ( T2DM ) .", "", " \"The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus ( T2DM ) .\"." +19, Omarigliptin, 882, 894, "omarigliptin", "", +20, Type2Diabetes, 936, 960, "type 2 diabetes mellitus", "", " ." +21, Type2Diabetes, 963, 967, "T2DM", "", +150, Precondition, 1151, 1313, "Patients with T2DM who were ≥ 18 to < 45 years of age and either drug - naive or not on an antihyperglycemic agent for ≥ 12 weeks with inadequate glycemic control", "", " \"Patients with T2DM who were ≥ 18 to < 45 years of age and either drug - naive or not on an antihyperglycemic agent for ≥ 12 weeks with inadequate glycemic control\"." +24, Type2Diabetes, 1165, 1169, "T2DM", "", +25, MinAge, 1181, 1183, "18", "", +26, MaxAge, 1189, 1191, "45", "", +27, Year, 1192, 1197, "years", "", +29, Duration, 1272, 1280, "12 weeks", "", +30, Randomized, 1319, 1329, "randomized", "", " ." +31, DoubleBlind, 1335, 1349, "double - blind", "", " ." +32, Omarigliptin, 1368, 1380, "omarigliptin", "", " ." +153, DoseValue, 1381, 1383, "25", "", " \"25\"." +34, mg, 1384, 1386, "mg", "", " ." +35, Frequency, 1387, 1398, "once weekly", "", " \"once weekly\"." +37, NumberPatientsArm, 1405, 1408, "102", "", " \"102\"." +39, Placebo, 1414, 1421, "placebo", "", " ." +36, Frequency, 1422, 1433, "once weekly", "", " \"once weekly\"." +38, NumberPatientsArm, 1440, 1443, "101", "", " \"101\"." +40, Duration, 1450, 1458, "24 weeks", "", " \"24 weeks\"." +165, ObjectiveDescription, 1461, 1683, "The objectives of the trial were to assess the effect of treatment with omarigliptin on glycemic parameters , including levels of glycosylated hemoglobin ( HbA1c ) , 2 - hour postmeal glucose , and fasting plasma glucose ,", "", " \"The objectives of the trial were to assess the effect of treatment with omarigliptin on glycemic parameters , including levels of glycosylated hemoglobin ( HbA1c ) , 2 - hour postmeal glucose , and fasting plasma glucose ,\". \"and to assess the safety and tolerability of omarigliptin .\"." +41, Omarigliptin, 1533, 1545, "omarigliptin", "", +42, HbA1c, 1591, 1614, "glycosylated hemoglobin", "", +43, HbA1c, 1617, 1622, "HbA1c", "", +44, PostprandialBloodGlucose, 1627, 1652, "2 - hour postmeal glucose", "", +45, FastingPlasmaGlucose, 1659, 1681, "fasting plasma glucose", "", +165, ObjectiveDescription, 1684, 1743, "and to assess the safety and tolerability of omarigliptin .", "", " \"and to assess the safety and tolerability of omarigliptin .\"." +46, Omarigliptin, 1729, 1741, "omarigliptin", "", +47, Omarigliptin, 1833, 1845, "omarigliptin", "", +48, Metformin, 1850, 1859, "metformin", "", +49, Mean, 1990, 1994, "mean", "", +50, AvgAge, 2025, 2031, "39 . 2", "", " \"39 . 2\"." +51, Year, 2032, 2037, "years", "", +100159, Male, 2064, 2068, "male", "", " ." +54, Mean, 2071, 2075, "mean", "", +55, BMI, 2076, 2091, "body mass index", "", +172, BaseLineValue, 2096, 2102, "32 . 5", "", +56, Kg_per_squareMeter, 2103, 2110, "kg / m2", "", +57, Mean, 2117, 2121, "mean", "", +60, Type2Diabetes, 2134, 2142, "diabetes", "", +100161, Duration, 2147, 2158, "3 . 1 years", "", +61, Year, 2153, 2158, "years", "", +62, Mean, 2165, 2169, "mean", "", +63, TimePoint, 2170, 2178, "baseline", "", +64, HbA1c, 2179, 2184, "HbA1c", "", +74, BaseLineValue, 2195, 2200, "7 . 9", "", " \"7 . 9\"." +65, Percentage, 2201, 2202, "%", "", +76, Omarigliptin, 2210, 2222, "omarigliptin", "", +75, BaseLineValue, 2233, 2238, "8 . 1", "", " \"8 . 1\"." +66, Percentage, 2239, 2240, "%", "", +77, Placebo, 2248, 2255, "placebo", "", +78, TimePoint, 2270, 2278, "24 weeks", "", " \"24 weeks\". \"24 weeks\"." +79, LeastSquaresMean, 2285, 2305, "least squares   mean", "", " ." +80, HbA1c, 2328, 2333, "HbA1c", "", " ." +81, TimePoint, 2345, 2353, "baseline", "", +186, Reduction, 2360, 2366, "0 . 33", "", " \"0 . 33\"." +68, Percentage, 2367, 2368, "%", "", " ." +85, ConfIntervalChangeValue, 2371, 2391, "- 0 . 60 to - 0 . 06", "", " \"- 0 . 60 to - 0 . 06\"." +87, Omarigliptin, 2401, 2413, "omarigliptin", "", +187, Reduction, 2426, 2432, "0 . 45", "", " \"0 . 45\"." +69, Percentage, 2433, 2434, "%", "", +86, ConfIntervalChangeValue, 2437, 2457, "- 0 . 72 to - 0 . 18", "", " \"- 0 . 72 to - 0 . 18\"." +88, Placebo, 2467, 2474, "placebo", "", +84, DiffGroupAbsValue, 2520, 2526, "0 . 12", "", " \"0 . 12\"." +70, Percentage, 2527, 2528, "%", "", +89, ConfIntervalDiff, 2531, 2549, "- 0 . 26 to 0 . 49", "", " \"- 0 . 26 to 0 . 49\"." +90, PvalueDiff, 2552, 2563, "P = 0 . 535", "", " \"P = 0 . 535\"." +198, ObservedResult, 2580, 2622, "no between - group difference was observed", "", +91, PostprandialBloodGlucose, 2659, 2684, "2 - hour postmeal glucose", "", +197, FastingPlasmaGlucose, 2689, 2711, "fasting plasma glucose", "", +93, Metformin, 3119, 3128, "metformin", "", +94, PercentageAffected, 3134, 3140, "42 . 4", "", +96, NumberAffected, 3145, 3147, "39", "", +100162, FinalNumPatientsCT, 3151, 3153, "92", "", " \"92\"." +97, Metformin, 3170, 3179, "Metformin", "", +106224, EndPointDescription, 3170, 3188, "Metformin was used", "", " . ." +98, Placebo, 3213, 3220, "placebo", "", +100, PercentageAffected, 3229, 3231, "57", "", " \"57\"." +102, NumberAffected, 3236, 3238, "25", "", " \"25\"." +104, FinalNumPatientsArm, 3242, 3244, "44", "", " \"44\"." +99, Omarigliptin, 3261, 3273, "omarigliptin", "", +101, PercentageAffected, 3282, 3284, "29", "", " \"29\"." +103, NumberAffected, 3289, 3291, "14", "", " \"14\"." +105, FinalNumPatientsArm, 3295, 3297, "48", "", " \"48\"." +110, ConclusionComment, 3319, 3496, "The use of prohibited metformin in a trial of a dipeptidyl peptidase - 4   inhibitor , omarigliptin , introduced a confounding factor that invalidated the results of the trial .", "", " \"The use of prohibited metformin in a trial of a dipeptidyl peptidase - 4   inhibitor , omarigliptin , introduced a confounding factor that invalidated the results of the trial .\"." +107, Metformin, 3341, 3350, "metformin", "", +108, Omarigliptin, 3406, 3418, "omarigliptin", "", +111, ConclusionComment, 3497, 3616, "This behavior may have been encouraged in the trial by protocol - specified self - monitoring of blood glucose levels .", "", " \"This behavior may have been encouraged in the trial by protocol - specified self - monitoring of blood glucose levels .\"." +209, BloodGlucose, 3594, 3607, "blood glucose", "", +112, ConclusionComment, 3617, 3712, "Use of prohibited medication may be an underappreciated confounder in clinical trial research .", "", " \"Use of prohibited medication may be an underappreciated confounder in clinical trial research .\"." +113, PMID, 3991, 3999, "28923291", "", " \"28923291\"." diff --git a/data/dm2 28923291_admin.n-triples b/data/dm2 28923291_admin.n-triples new file mode 100644 index 0000000..7e2b502 --- /dev/null +++ b/data/dm2 28923291_admin.n-triples @@ -0,0 +1,138 @@ +# RDF export of group: Publication + . + "Publication 76062" . + "Use of Prohibited Medication , a Potentially Overlooked Confounder in Clinical Trials : Omarigliptin ( Once - weekly DPP - 4 Inhibitor ) Monotherapy Trial in 18 - to 45 - year - olds ." . + "Gantz I" . + "2017" . + "Clin Ther ." . + "28923291" . + . + "Sokolova L" . + "Jain L" . + "Iredale C" . + "O ' Neill EA" . + "Wei Z" . + "Lam R" . + "Suryawanshi S" . + "Kaufman KD" . + "Engel SS" . + "Lai E" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 76069" . + "The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus ( T2DM ) ." . + "24 weeks" . + . + . + . + "The use of prohibited metformin in a trial of a dipeptidyl peptidase - 4   inhibitor , omarigliptin , introduced a confounding factor that invalidated the results of the trial ." . + . + . + . + . + . + "92" . + . + "This behavior may have been encouraged in the trial by protocol - specified self - monitoring of blood glucose levels ." . + "Use of prohibited medication may be an underappreciated confounder in clinical trial research ." . + . + "The objectives of the trial were to assess the effect of treatment with omarigliptin on glycemic parameters , including levels of glycosylated hemoglobin ( HbA1c ) , 2 - hour postmeal glucose , and fasting plasma glucose ," . + "and to assess the safety and tolerability of omarigliptin ." . +# RDF export of group: Population + . + "Population 76085" . + "Patients with T2DM who were ≥ 18 to < 45 years of age and either drug - naive or not on an antihyperglycemic agent for ≥ 12 weeks with inadequate glycemic control" . + . + . + "18" . + "45" . + "39 . 2" . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "met" . + . + . + . + . + . +# RDF export of group: Arm + . + "om" . + "102" . + "48" . + . + . + . + . + . + "pla" . + "101" . + "44" . + . + . + . + . +# RDF export of group: Intervention + . + "om" . + . + "once weekly" . + . + . + "pl" . + . + "once weekly" . + . +# RDF export of group: Medication + . + "om" . + . + "25" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 9" . + "0 . 33" . + "- 0 . 60 to - 0 . 06" . + "24 weeks" . + . + "hba 2" . + . + "8 . 1" . + "0 . 45" . + "- 0 . 72 to - 0 . 18" . + "24 weeks" . + . + "met 1" . + . + "14" . + "29" . + . + "met 2" . + . + "25" . + "57" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "0 . 12" . + "P = 0 . 535" . + "- 0 . 26 to 0 . 49" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28923291_akramersunderbrink.annodb b/data/dm2 28923291_akramersunderbrink.annodb new file mode 100644 index 0000000..5ae5338 --- /dev/null +++ b/data/dm2 28923291_akramersunderbrink.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +70638, Journal, 0, 9, "Clin Ther", "", +70639, PublicationYear, 12, 16, "2017", "", +70644, Title, 120, 304, "Use of Prohibited Medication , a Potentially Overlooked Confounder in Clinical Trials : Omarigliptin ( Once - weekly DPP - 4 Inhibitor ) Monotherapy Trial in 18 - to 45 - year - olds .", "", +70640, Omarigliptin, 208, 220, "Omarigliptin", "", +70641, Frequency, 223, 236, "Once - weekly", "", +70642, MinAge, 278, 280, "18", "", +70643, MaxAge, 286, 288, "45", "", +70645, Author, 305, 312, "Gantz I", "", +70646, Author, 321, 331, "Sokolova L", "", +70647, Author, 340, 346, "Jain L", "", +70648, Author, 355, 364, "Iredale C", "", +70649, Author, 373, 385, "O ' Neill EA", "", +70650, Author, 394, 399, "Wei Z", "", +70651, Author, 408, 413, "Lam R", "", +70652, Author, 422, 435, "Suryawanshi S", "", +70653, Author, 444, 454, "Kaufman KD", "", +70654, Author, 463, 471, "Engel SS", "", +70655, Author, 480, 485, "Lai E", "", +70656, Country, 733, 740, "Ukraine", "", +70660, ObjectiveDescription, 804, 971, "The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus ( T2DM ) .", "", +70657, Omarigliptin, 882, 894, "omarigliptin", "", +70658, Type2Diabetes, 936, 960, "type 2 diabetes mellitus", "", +70659, Type2Diabetes, 963, 967, "T2DM", "", +70661, ObjectiveDescription, 972, 1140, "Unexpected efficacy results in this trial led to a series of investigations that identified the use of prohibited medication by a substantial number of trial patients .", "", +70662, Type2Diabetes, 1165, 1169, "T2DM", "", +70663, MinAge, 1181, 1183, "18", "", +70664, MaxAge, 1189, 1191, "45", "", +70665, Year, 1192, 1197, "years", "", +70666, Precondition, 1209, 1313, "either drug - naive or not on an antihyperglycemic agent for ≥ 12 weeks with inadequate glycemic control", "", +70667, Duration, 1272, 1280, "12 weeks", "", +70668, Randomized, 1319, 1329, "randomized", "", +70669, DoubleBlind, 1335, 1349, "double - blind", "", +70670, Omarigliptin, 1368, 1380, "omarigliptin", "", +70671, DoseValue, 1381, 1386, "25 mg", "", +70672, mg, 1384, 1386, "mg", "", +70673, Frequency, 1387, 1398, "once weekly", "", +70675, NumberPatientsArm, 1405, 1408, "102", "", +70677, Placebo, 1414, 1421, "placebo", "", +70674, Frequency, 1422, 1433, "once weekly", "", +70676, NumberPatientsArm, 1440, 1443, "101", "", +70678, Duration, 1450, 1458, "24 weeks", "", +70679, Omarigliptin, 1533, 1545, "omarigliptin", "", +70680, HbA1c, 1591, 1614, "glycosylated hemoglobin", "", +70681, HbA1c, 1617, 1622, "HbA1c", "", +70682, PostprandialBloodGlucose, 1627, 1652, "2 - hour postmeal glucose", "", +70683, FastingPlasmaGlucose, 1659, 1681, "fasting plasma glucose", "", +70684, Omarigliptin, 1729, 1741, "omarigliptin", "", +70685, Omarigliptin, 1833, 1845, "omarigliptin", "", +70686, Metformin, 1850, 1859, "metformin", "", +70687, Mean, 1990, 1994, "mean", "", +70688, AvgAge, 2025, 2031, "39 . 2", "", +70689, Year, 2032, 2037, "years", "", +70691, AnyGender, 2054, 2068, "60 % were male", "", +70690, Percentage, 2057, 2058, "%", "", +70692, Mean, 2071, 2075, "mean", "", +70696, Precondition, 2071, 2110, "mean body mass index was 32 . 5 kg / m2", "", +70693, BMI, 2076, 2091, "body mass index", "", +70694, Kg_per_squareMeter, 2103, 2110, "kg / m2", "", +70695, Mean, 2117, 2121, "mean", "", +70697, Precondition, 2117, 2158, "mean duration of diabetes was 3 . 1 years", "", +70698, Type2Diabetes, 2134, 2142, "diabetes", "", +70700, Year, 2153, 2158, "years", "", +70701, Mean, 2165, 2169, "mean", "", +70702, TimePoint, 2170, 2178, "baseline", "", +70703, HbA1c, 2179, 2184, "HbA1c", "", +70713, BaseLineValue, 2195, 2200, "7 . 9", "", +70704, Percentage, 2201, 2202, "%", "", +70715, Omarigliptin, 2210, 2222, "omarigliptin", "", +70714, BaseLineValue, 2233, 2238, "8 . 1", "", +70705, Percentage, 2239, 2240, "%", "", +70716, Placebo, 2248, 2255, "placebo", "", +70717, TimePoint, 2270, 2278, "24 weeks", "", +70718, LeastSquaresMean, 2285, 2305, "least squares   mean", "", +70706, Percentage, 2318, 2319, "%", "", +70719, HbA1c, 2328, 2333, "HbA1c", "", +70721, TimePoint, 2345, 2353, "baseline", "", +70722, ChangeValue, 2358, 2366, "- 0 . 33", "", +70707, Percentage, 2367, 2368, "%", "", +70725, ConfIntervalChangeValue, 2371, 2391, "- 0 . 60 to - 0 . 06", "", +70727, Omarigliptin, 2401, 2413, "omarigliptin", "", +70723, ChangeValue, 2424, 2432, "- 0 . 45", "", +70708, Percentage, 2433, 2434, "%", "", +70726, ConfIntervalChangeValue, 2437, 2457, "- 0 . 72 to - 0 . 18", "", +70728, Placebo, 2467, 2474, "placebo", "", +70724, DiffGroupAbsValue, 2520, 2526, "0 . 12", "", +70709, Percentage, 2527, 2528, "%", "", +70729, ConfIntervalDiff, 2531, 2549, "- 0 . 26 to 0 . 49", "", +70731, PvalueDiff, 2552, 2563, "P = 0 . 535", "", +70732, PostprandialBloodGlucose, 2659, 2684, "2 - hour postmeal glucose", "", +70733, FastingPlasmaGlucose, 2689, 2718, "fasting plasma glucose levels", "", +70737, EndPointDescription, 2926, 3111, "Measurement of drug levels from future biomedical research samples uncovered the use , with no investigator knowledge , of an antihyperglycemic agent that was prohibited by the protocol", "", +70734, Metformin, 3119, 3128, "metformin", "", +70736, PercentageAffected, 3134, 3140, "42 . 4", "", +70710, Percentage, 3141, 3142, "%", "", +70738, NumberAffected, 3145, 3147, "39", "", +70748, FinalNumPatientsCT, 3151, 3153, "92", "", +70739, Metformin, 3170, 3179, "Metformin", "", +70740, Placebo, 3213, 3220, "placebo", "", +70742, PercentageAffected, 3229, 3231, "57", "", +70711, Percentage, 3232, 3233, "%", "", +70744, NumberAffected, 3236, 3238, "25", "", +70746, FinalNumPatientsArm, 3242, 3244, "44", "", +70741, Omarigliptin, 3261, 3273, "omarigliptin", "", +70743, PercentageAffected, 3282, 3284, "29", "", +70712, Percentage, 3285, 3286, "%", "", +70745, NumberAffected, 3289, 3291, "14", "", +70747, FinalNumPatientsArm, 3295, 3297, "48", "", +70752, ConclusionComment, 3319, 3496, "The use of prohibited metformin in a trial of a dipeptidyl peptidase - 4   inhibitor , omarigliptin , introduced a confounding factor that invalidated the results of the trial .", "", +70749, Metformin, 3341, 3350, "metformin", "", +70750, Omarigliptin, 3406, 3418, "omarigliptin", "", +70753, ConclusionComment, 3497, 3616, "This behavior may have been encouraged in the trial by protocol - specified self - monitoring of blood glucose levels .", "", +70751, BloodGlucose, 3594, 3614, "blood glucose levels", "", +70754, ConclusionComment, 3617, 3712, "Use of prohibited medication may be an underappreciated confounder in clinical trial research .", "", +70755, PMID, 3991, 3999, "28923291", "", diff --git a/data/dm2 28923291_akramersunderbrink.n-triples b/data/dm2 28923291_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28923291_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 28923291_export.csv b/data/dm2 28923291_export.csv new file mode 100644 index 0000000..34624aa --- /dev/null +++ b/data/dm2 28923291_export.csv @@ -0,0 +1,848 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +391, 1, 1, 1, 0, 4, 0, 4, "Clin" +391, 1, 2, 2, 5, 9, 5, 9, "Ther" +391, 1, 3, 3, 10, 11, 10, 11, "." +391, 2, 1, 4, 0, 4, 12, 16, "2017" +391, 2, 2, 5, 5, 8, 17, 20, "Oct" +391, 2, 3, 6, 9, 10, 21, 22, ";" +391, 2, 4, 7, 11, 13, 23, 25, "39" +391, 2, 5, 8, 14, 15, 26, 27, "(" +391, 2, 6, 9, 16, 18, 28, 30, "10" +391, 2, 7, 10, 19, 20, 31, 32, ")" +391, 2, 8, 11, 21, 22, 33, 34, ":" +391, 2, 9, 12, 23, 27, 35, 39, "2024" +391, 2, 10, 13, 28, 29, 40, 41, "-" +391, 2, 11, 14, 30, 34, 42, 46, "2037" +391, 2, 12, 15, 35, 36, 47, 48, "." +391, 2, 13, 16, 37, 40, 49, 52, "doi" +391, 2, 14, 17, 41, 42, 53, 54, ":" +391, 2, 15, 18, 43, 45, 55, 57, "10" +391, 2, 16, 19, 46, 47, 58, 59, "." +391, 2, 17, 20, 48, 52, 60, 64, "1016" +391, 2, 18, 21, 53, 54, 65, 66, "/" +391, 2, 19, 22, 55, 56, 67, 68, "j" +391, 2, 20, 23, 57, 58, 69, 70, "." +391, 2, 21, 24, 59, 68, 71, 80, "clinthera" +391, 2, 22, 25, 69, 70, 81, 82, "." +391, 2, 23, 26, 71, 75, 83, 87, "2017" +391, 2, 24, 27, 76, 77, 88, 89, "." +391, 2, 25, 28, 78, 80, 90, 92, "08" +391, 2, 26, 29, 81, 82, 93, 94, "." +391, 2, 27, 30, 83, 86, 95, 98, "009" +391, 2, 28, 31, 87, 88, 99, 100, "." +391, 3, 1, 32, 0, 4, 101, 105, "Epub" +391, 3, 2, 33, 5, 9, 106, 110, "2017" +391, 3, 3, 34, 10, 13, 111, 114, "Sep" +391, 3, 4, 35, 14, 16, 115, 117, "18" +391, 3, 5, 36, 17, 18, 118, 119, "." +391, 4, 1, 37, 0, 3, 120, 123, "Use" +391, 4, 2, 38, 4, 6, 124, 126, "of" +391, 4, 3, 39, 7, 17, 127, 137, "Prohibited" +391, 4, 4, 40, 18, 28, 138, 148, "Medication" +391, 4, 5, 41, 29, 30, 149, 150, "," +391, 4, 6, 42, 31, 32, 151, 152, "a" +391, 4, 7, 43, 33, 44, 153, 164, "Potentially" +391, 4, 8, 44, 45, 55, 165, 175, "Overlooked" +391, 4, 9, 45, 56, 66, 176, 186, "Confounder" +391, 4, 10, 46, 67, 69, 187, 189, "in" +391, 4, 11, 47, 70, 78, 190, 198, "Clinical" +391, 4, 12, 48, 79, 85, 199, 205, "Trials" +391, 4, 13, 49, 86, 87, 206, 207, ":" +391, 4, 14, 50, 88, 100, 208, 220, "Omarigliptin" +391, 4, 15, 51, 101, 102, 221, 222, "(" +391, 4, 16, 52, 103, 107, 223, 227, "Once" +391, 4, 17, 53, 108, 109, 228, 229, "-" +391, 4, 18, 54, 110, 116, 230, 236, "weekly" +391, 4, 19, 55, 117, 120, 237, 240, "DPP" +391, 4, 20, 56, 121, 122, 241, 242, "-" +391, 4, 21, 57, 123, 124, 243, 244, "4" +391, 4, 22, 58, 125, 134, 245, 254, "Inhibitor" +391, 4, 23, 59, 135, 136, 255, 256, ")" +391, 4, 24, 60, 137, 148, 257, 268, "Monotherapy" +391, 4, 25, 61, 149, 154, 269, 274, "Trial" +391, 4, 26, 62, 155, 157, 275, 277, "in" +391, 4, 27, 63, 158, 160, 278, 280, "18" +391, 4, 28, 64, 161, 162, 281, 282, "-" +391, 4, 29, 65, 163, 165, 283, 285, "to" +391, 4, 30, 66, 166, 168, 286, 288, "45" +391, 4, 31, 67, 169, 170, 289, 290, "-" +391, 4, 32, 68, 171, 175, 291, 295, "year" +391, 4, 33, 69, 176, 177, 296, 297, "-" +391, 4, 34, 70, 178, 182, 298, 302, "olds" +391, 4, 35, 71, 183, 184, 303, 304, "." +391, 5, 1, 72, 0, 5, 305, 310, "Gantz" +391, 5, 2, 73, 6, 7, 311, 312, "I" +391, 5, 3, 74, 8, 9, 313, 314, "(" +391, 5, 4, 75, 10, 11, 315, 316, "1" +391, 5, 5, 76, 12, 13, 317, 318, ")" +391, 5, 6, 77, 14, 15, 319, 320, "," +391, 5, 7, 78, 16, 24, 321, 329, "Sokolova" +391, 5, 8, 79, 25, 26, 330, 331, "L" +391, 5, 9, 80, 27, 28, 332, 333, "(" +391, 5, 10, 81, 29, 30, 334, 335, "2" +391, 5, 11, 82, 31, 32, 336, 337, ")" +391, 5, 12, 83, 33, 34, 338, 339, "," +391, 5, 13, 84, 35, 39, 340, 344, "Jain" +391, 5, 14, 85, 40, 41, 345, 346, "L" +391, 5, 15, 86, 42, 43, 347, 348, "(" +391, 5, 16, 87, 44, 45, 349, 350, "3" +391, 5, 17, 88, 46, 47, 351, 352, ")" +391, 5, 18, 89, 48, 49, 353, 354, "," +391, 5, 19, 90, 50, 57, 355, 362, "Iredale" +391, 5, 20, 91, 58, 59, 363, 364, "C" +391, 5, 21, 92, 60, 61, 365, 366, "(" +391, 5, 22, 93, 62, 63, 367, 368, "3" +391, 5, 23, 94, 64, 65, 369, 370, ")" +391, 5, 24, 95, 66, 67, 371, 372, "," +391, 5, 25, 96, 68, 69, 373, 374, "O" +391, 5, 26, 97, 70, 71, 375, 376, "'" +391, 5, 27, 98, 72, 77, 377, 382, "Neill" +391, 5, 28, 99, 78, 80, 383, 385, "EA" +391, 5, 29, 100, 81, 82, 386, 387, "(" +391, 5, 30, 101, 83, 84, 388, 389, "3" +391, 5, 31, 102, 85, 86, 390, 391, ")" +391, 5, 32, 103, 87, 88, 392, 393, "," +391, 5, 33, 104, 89, 92, 394, 397, "Wei" +391, 5, 34, 105, 93, 94, 398, 399, "Z" +391, 5, 35, 106, 95, 96, 400, 401, "(" +391, 5, 36, 107, 97, 98, 402, 403, "3" +391, 5, 37, 108, 99, 100, 404, 405, ")" +391, 5, 38, 109, 101, 102, 406, 407, "," +391, 5, 39, 110, 103, 106, 408, 411, "Lam" +391, 5, 40, 111, 107, 108, 412, 413, "R" +391, 5, 41, 112, 109, 110, 414, 415, "(" +391, 5, 42, 113, 111, 112, 416, 417, "3" +391, 5, 43, 114, 113, 114, 418, 419, ")" +391, 5, 44, 115, 115, 116, 420, 421, "," +391, 5, 45, 116, 117, 128, 422, 433, "Suryawanshi" +391, 5, 46, 117, 129, 130, 434, 435, "S" +391, 5, 47, 118, 131, 132, 436, 437, "(" +391, 5, 48, 119, 133, 134, 438, 439, "3" +391, 5, 49, 120, 135, 136, 440, 441, ")" +391, 5, 50, 121, 137, 138, 442, 443, "," +391, 5, 51, 122, 139, 146, 444, 451, "Kaufman" +391, 5, 52, 123, 147, 149, 452, 454, "KD" +391, 5, 53, 124, 150, 151, 455, 456, "(" +391, 5, 54, 125, 152, 153, 457, 458, "3" +391, 5, 55, 126, 154, 155, 459, 460, ")" +391, 5, 56, 127, 156, 157, 461, 462, "," +391, 5, 57, 128, 158, 163, 463, 468, "Engel" +391, 5, 58, 129, 164, 166, 469, 471, "SS" +391, 5, 59, 130, 167, 168, 472, 473, "(" +391, 5, 60, 131, 169, 170, 474, 475, "3" +391, 5, 61, 132, 171, 172, 476, 477, ")" +391, 5, 62, 133, 173, 174, 478, 479, "," +391, 5, 63, 134, 175, 178, 480, 483, "Lai" +391, 5, 64, 135, 179, 180, 484, 485, "E" +391, 5, 65, 136, 181, 182, 486, 487, "(" +391, 5, 66, 137, 183, 184, 488, 489, "3" +391, 5, 67, 138, 185, 186, 490, 491, ")" +391, 5, 68, 139, 187, 188, 492, 493, "." +391, 6, 1, 140, 0, 6, 494, 500, "Author" +391, 6, 2, 141, 7, 18, 501, 512, "information" +391, 6, 3, 142, 19, 20, 513, 514, ":" +391, 6, 4, 143, 21, 22, 515, 516, "(" +391, 6, 5, 144, 23, 24, 517, 518, "1" +391, 6, 6, 145, 25, 26, 519, 520, ")" +391, 6, 7, 146, 27, 32, 521, 526, "Merck" +391, 6, 8, 147, 33, 34, 527, 528, "&" +391, 6, 9, 148, 35, 37, 529, 531, "Co" +391, 6, 10, 149, 38, 39, 532, 533, "," +391, 6, 11, 150, 40, 43, 534, 537, "Inc" +391, 6, 12, 151, 44, 45, 538, 539, "," +391, 6, 13, 152, 46, 56, 540, 550, "Kenilworth" +391, 6, 14, 153, 57, 58, 551, 552, "," +391, 6, 15, 154, 59, 62, 553, 556, "New" +391, 6, 16, 155, 63, 69, 557, 563, "Jersey" +391, 6, 17, 156, 70, 71, 564, 565, "." +391, 7, 1, 157, 0, 10, 566, 576, "Electronic" +391, 7, 2, 158, 11, 18, 577, 584, "address" +391, 7, 3, 159, 19, 20, 585, 586, ":" +391, 7, 4, 160, 21, 24, 587, 590, "ira" +391, 7, 5, 161, 25, 26, 591, 592, "." +391, 7, 6, 162, 27, 32, 593, 598, "gantz" +391, 7, 7, 163, 33, 34, 599, 600, "@" +391, 7, 8, 164, 35, 40, 601, 606, "merck" +391, 7, 9, 165, 41, 42, 607, 608, "." +391, 7, 10, 166, 43, 46, 609, 612, "com" +391, 7, 11, 167, 47, 48, 613, 614, "." +391, 8, 1, 168, 0, 1, 615, 616, "(" +391, 8, 2, 169, 2, 3, 617, 618, "2" +391, 8, 3, 170, 4, 5, 619, 620, ")" +391, 8, 4, 171, 6, 7, 621, 622, "V" +391, 8, 5, 172, 8, 9, 623, 624, "." +391, 8, 6, 173, 10, 11, 625, 626, "P" +391, 8, 7, 174, 12, 13, 627, 628, "." +391, 9, 1, 175, 0, 11, 629, 640, "Komisarenko" +391, 9, 2, 176, 12, 21, 641, 650, "Institute" +391, 9, 3, 177, 22, 24, 651, 653, "of" +391, 9, 4, 178, 25, 38, 654, 667, "Endocrinology" +391, 9, 5, 179, 39, 42, 668, 671, "and" +391, 9, 6, 180, 43, 53, 672, 682, "Metabolism" +391, 9, 7, 181, 54, 55, 683, 684, "," +391, 9, 8, 182, 56, 63, 685, 692, "Academy" +391, 9, 9, 183, 64, 66, 693, 695, "of" +391, 9, 10, 184, 67, 74, 696, 703, "Medical" +391, 9, 11, 185, 75, 83, 704, 712, "Sciences" +391, 9, 12, 186, 84, 86, 713, 715, "of" +391, 9, 13, 187, 87, 94, 716, 723, "Ukraine" +391, 9, 14, 188, 95, 96, 724, 725, "," +391, 9, 15, 189, 97, 101, 726, 730, "Kiev" +391, 9, 16, 190, 102, 103, 731, 732, "," +391, 9, 17, 191, 104, 111, 733, 740, "Ukraine" +391, 9, 18, 192, 112, 113, 741, 742, "." +391, 10, 1, 193, 0, 1, 743, 744, "(" +391, 10, 2, 194, 2, 3, 745, 746, "3" +391, 10, 3, 195, 4, 5, 747, 748, ")" +391, 10, 4, 196, 6, 11, 749, 754, "Merck" +391, 10, 5, 197, 12, 13, 755, 756, "&" +391, 10, 6, 198, 14, 16, 757, 759, "Co" +391, 10, 7, 199, 17, 18, 760, 761, "," +391, 10, 8, 200, 19, 22, 762, 765, "Inc" +391, 10, 9, 201, 23, 24, 766, 767, "," +391, 10, 10, 202, 25, 35, 768, 778, "Kenilworth" +391, 10, 11, 203, 36, 37, 779, 780, "," +391, 10, 12, 204, 38, 41, 781, 784, "New" +391, 10, 13, 205, 42, 48, 785, 791, "Jersey" +391, 10, 14, 206, 49, 50, 792, 793, "." +391, 11, 1, 207, 0, 7, 794, 801, "PURPOSE" +391, 11, 2, 208, 8, 9, 802, 803, ":" +391, 11, 3, 209, 10, 13, 804, 807, "The" +391, 11, 4, 210, 14, 23, 808, 817, "objective" +391, 11, 5, 211, 24, 26, 818, 820, "of" +391, 11, 6, 212, 27, 31, 821, 825, "this" +391, 11, 7, 213, 32, 40, 826, 834, "clinical" +391, 11, 8, 214, 41, 46, 835, 840, "trial" +391, 11, 9, 215, 47, 50, 841, 844, "was" +391, 11, 10, 216, 51, 53, 845, 847, "to" +391, 11, 11, 217, 54, 60, 848, 854, "assess" +391, 11, 12, 218, 61, 64, 855, 858, "the" +391, 11, 13, 219, 65, 73, 859, 867, "efficacy" +391, 11, 14, 220, 74, 77, 868, 871, "and" +391, 11, 15, 221, 78, 84, 872, 878, "safety" +391, 11, 16, 222, 85, 87, 879, 881, "of" +391, 11, 17, 223, 88, 100, 882, 894, "omarigliptin" +391, 11, 18, 224, 101, 112, 895, 906, "monotherapy" +391, 11, 19, 225, 113, 115, 907, 909, "in" +391, 11, 20, 226, 116, 121, 910, 915, "young" +391, 11, 21, 227, 122, 127, 916, 921, "adult" +391, 11, 22, 228, 128, 136, 922, 930, "patients" +391, 11, 23, 229, 137, 141, 931, 935, "with" +391, 11, 24, 230, 142, 146, 936, 940, "type" +391, 11, 25, 231, 147, 148, 941, 942, "2" +391, 11, 26, 232, 149, 157, 943, 951, "diabetes" +391, 11, 27, 233, 158, 166, 952, 960, "mellitus" +391, 11, 28, 234, 167, 168, 961, 962, "(" +391, 11, 29, 235, 169, 173, 963, 967, "T2DM" +391, 11, 30, 236, 174, 175, 968, 969, ")" +391, 11, 31, 237, 176, 177, 970, 971, "." +391, 12, 1, 238, 0, 10, 972, 982, "Unexpected" +391, 12, 2, 239, 11, 19, 983, 991, "efficacy" +391, 12, 3, 240, 20, 27, 992, 999, "results" +391, 12, 4, 241, 28, 30, 1000, 1002, "in" +391, 12, 5, 242, 31, 35, 1003, 1007, "this" +391, 12, 6, 243, 36, 41, 1008, 1013, "trial" +391, 12, 7, 244, 42, 45, 1014, 1017, "led" +391, 12, 8, 245, 46, 48, 1018, 1020, "to" +391, 12, 9, 246, 49, 50, 1021, 1022, "a" +391, 12, 10, 247, 51, 57, 1023, 1029, "series" +391, 12, 11, 248, 58, 60, 1030, 1032, "of" +391, 12, 12, 249, 61, 75, 1033, 1047, "investigations" +391, 12, 13, 250, 76, 80, 1048, 1052, "that" +391, 12, 14, 251, 81, 91, 1053, 1063, "identified" +391, 12, 15, 252, 92, 95, 1064, 1067, "the" +391, 12, 16, 253, 96, 99, 1068, 1071, "use" +391, 12, 17, 254, 100, 102, 1072, 1074, "of" +391, 12, 18, 255, 103, 113, 1075, 1085, "prohibited" +391, 12, 19, 256, 114, 124, 1086, 1096, "medication" +391, 12, 20, 257, 125, 127, 1097, 1099, "by" +391, 12, 21, 258, 128, 129, 1100, 1101, "a" +391, 12, 22, 259, 130, 141, 1102, 1113, "substantial" +391, 12, 23, 260, 142, 148, 1114, 1120, "number" +391, 12, 24, 261, 149, 151, 1121, 1123, "of" +391, 12, 25, 262, 152, 157, 1124, 1129, "trial" +391, 12, 26, 263, 158, 166, 1130, 1138, "patients" +391, 12, 27, 264, 167, 168, 1139, 1140, "." +391, 13, 1, 265, 0, 7, 1141, 1148, "METHODS" +391, 13, 2, 266, 8, 9, 1149, 1150, ":" +391, 13, 3, 267, 10, 18, 1151, 1159, "Patients" +391, 13, 4, 268, 19, 23, 1160, 1164, "with" +391, 13, 5, 269, 24, 28, 1165, 1169, "T2DM" +391, 13, 6, 270, 29, 32, 1170, 1173, "who" +391, 13, 7, 271, 33, 37, 1174, 1178, "were" +391, 13, 8, 272, 38, 39, 1179, 1180, "≥" +391, 13, 9, 273, 40, 42, 1181, 1183, "18" +391, 13, 10, 274, 43, 45, 1184, 1186, "to" +391, 13, 11, 275, 46, 47, 1187, 1188, "<" +391, 13, 12, 276, 48, 50, 1189, 1191, "45" +391, 13, 13, 277, 51, 56, 1192, 1197, "years" +391, 13, 14, 278, 57, 59, 1198, 1200, "of" +391, 13, 15, 279, 60, 63, 1201, 1204, "age" +391, 13, 16, 280, 64, 67, 1205, 1208, "and" +391, 13, 17, 281, 68, 74, 1209, 1215, "either" +391, 13, 18, 282, 75, 79, 1216, 1220, "drug" +391, 13, 19, 283, 80, 81, 1221, 1222, "-" +391, 13, 20, 284, 82, 87, 1223, 1228, "naive" +391, 13, 21, 285, 88, 90, 1229, 1231, "or" +391, 13, 22, 286, 91, 94, 1232, 1235, "not" +391, 13, 23, 287, 95, 97, 1236, 1238, "on" +391, 13, 24, 288, 98, 100, 1239, 1241, "an" +391, 13, 25, 289, 101, 118, 1242, 1259, "antihyperglycemic" +391, 13, 26, 290, 119, 124, 1260, 1265, "agent" +391, 13, 27, 291, 125, 128, 1266, 1269, "for" +391, 13, 28, 292, 129, 130, 1270, 1271, "≥" +391, 13, 29, 293, 131, 133, 1272, 1274, "12" +391, 13, 30, 294, 134, 139, 1275, 1280, "weeks" +391, 13, 31, 295, 140, 144, 1281, 1285, "with" +391, 13, 32, 296, 145, 155, 1286, 1296, "inadequate" +391, 13, 33, 297, 156, 164, 1297, 1305, "glycemic" +391, 13, 34, 298, 165, 172, 1306, 1313, "control" +391, 13, 35, 299, 173, 177, 1314, 1318, "were" +391, 13, 36, 300, 178, 188, 1319, 1329, "randomized" +391, 13, 37, 301, 189, 191, 1330, 1332, "in" +391, 13, 38, 302, 192, 193, 1333, 1334, "a" +391, 13, 39, 303, 194, 200, 1335, 1341, "double" +391, 13, 40, 304, 201, 202, 1342, 1343, "-" +391, 13, 41, 305, 203, 208, 1344, 1349, "blind" +391, 13, 42, 306, 209, 215, 1350, 1356, "manner" +391, 13, 43, 307, 216, 218, 1357, 1359, "to" +391, 13, 44, 308, 219, 226, 1360, 1367, "receive" +391, 13, 45, 309, 227, 239, 1368, 1380, "omarigliptin" +391, 13, 46, 310, 240, 242, 1381, 1383, "25" +391, 13, 47, 311, 243, 245, 1384, 1386, "mg" +391, 13, 48, 312, 246, 250, 1387, 1391, "once" +391, 13, 49, 313, 251, 257, 1392, 1398, "weekly" +391, 13, 50, 314, 258, 259, 1399, 1400, "(" +391, 13, 51, 315, 260, 261, 1401, 1402, "n" +391, 13, 52, 316, 262, 263, 1403, 1404, "=" +391, 13, 53, 317, 264, 267, 1405, 1408, "102" +391, 13, 54, 318, 268, 269, 1409, 1410, ")" +391, 13, 55, 319, 270, 272, 1411, 1413, "or" +391, 13, 56, 320, 273, 280, 1414, 1421, "placebo" +391, 13, 57, 321, 281, 285, 1422, 1426, "once" +391, 13, 58, 322, 286, 292, 1427, 1433, "weekly" +391, 13, 59, 323, 293, 294, 1434, 1435, "(" +391, 13, 60, 324, 295, 296, 1436, 1437, "n" +391, 13, 61, 325, 297, 298, 1438, 1439, "=" +391, 13, 62, 326, 299, 302, 1440, 1443, "101" +391, 13, 63, 327, 303, 304, 1444, 1445, ")" +391, 13, 64, 328, 305, 308, 1446, 1449, "for" +391, 13, 65, 329, 309, 311, 1450, 1452, "24" +391, 13, 66, 330, 312, 317, 1453, 1458, "weeks" +391, 13, 67, 331, 318, 319, 1459, 1460, "." +391, 14, 1, 332, 0, 3, 1461, 1464, "The" +391, 14, 2, 333, 4, 14, 1465, 1475, "objectives" +391, 14, 3, 334, 15, 17, 1476, 1478, "of" +391, 14, 4, 335, 18, 21, 1479, 1482, "the" +391, 14, 5, 336, 22, 27, 1483, 1488, "trial" +391, 14, 6, 337, 28, 32, 1489, 1493, "were" +391, 14, 7, 338, 33, 35, 1494, 1496, "to" +391, 14, 8, 339, 36, 42, 1497, 1503, "assess" +391, 14, 9, 340, 43, 46, 1504, 1507, "the" +391, 14, 10, 341, 47, 53, 1508, 1514, "effect" +391, 14, 11, 342, 54, 56, 1515, 1517, "of" +391, 14, 12, 343, 57, 66, 1518, 1527, "treatment" +391, 14, 13, 344, 67, 71, 1528, 1532, "with" +391, 14, 14, 345, 72, 84, 1533, 1545, "omarigliptin" +391, 14, 15, 346, 85, 87, 1546, 1548, "on" +391, 14, 16, 347, 88, 96, 1549, 1557, "glycemic" +391, 14, 17, 348, 97, 107, 1558, 1568, "parameters" +391, 14, 18, 349, 108, 109, 1569, 1570, "," +391, 14, 19, 350, 110, 119, 1571, 1580, "including" +391, 14, 20, 351, 120, 126, 1581, 1587, "levels" +391, 14, 21, 352, 127, 129, 1588, 1590, "of" +391, 14, 22, 353, 130, 142, 1591, 1603, "glycosylated" +391, 14, 23, 354, 143, 153, 1604, 1614, "hemoglobin" +391, 14, 24, 355, 154, 155, 1615, 1616, "(" +391, 14, 25, 356, 156, 161, 1617, 1622, "HbA1c" +391, 14, 26, 357, 162, 163, 1623, 1624, ")" +391, 14, 27, 358, 164, 165, 1625, 1626, "," +391, 14, 28, 359, 166, 167, 1627, 1628, "2" +391, 14, 29, 360, 168, 169, 1629, 1630, "-" +391, 14, 30, 361, 170, 174, 1631, 1635, "hour" +391, 14, 31, 362, 175, 183, 1636, 1644, "postmeal" +391, 14, 32, 363, 184, 191, 1645, 1652, "glucose" +391, 14, 33, 364, 192, 193, 1653, 1654, "," +391, 14, 34, 365, 194, 197, 1655, 1658, "and" +391, 14, 35, 366, 198, 205, 1659, 1666, "fasting" +391, 14, 36, 367, 206, 212, 1667, 1673, "plasma" +391, 14, 37, 368, 213, 220, 1674, 1681, "glucose" +391, 14, 38, 369, 221, 222, 1682, 1683, "," +391, 14, 39, 370, 223, 226, 1684, 1687, "and" +391, 14, 40, 371, 227, 229, 1688, 1690, "to" +391, 14, 41, 372, 230, 236, 1691, 1697, "assess" +391, 14, 42, 373, 237, 240, 1698, 1701, "the" +391, 14, 43, 374, 241, 247, 1702, 1708, "safety" +391, 14, 44, 375, 248, 251, 1709, 1712, "and" +391, 14, 45, 376, 252, 264, 1713, 1725, "tolerability" +391, 14, 46, 377, 265, 267, 1726, 1728, "of" +391, 14, 47, 378, 268, 280, 1729, 1741, "omarigliptin" +391, 14, 48, 379, 281, 282, 1742, 1743, "." +391, 15, 1, 380, 0, 10, 1744, 1754, "Additional" +391, 15, 2, 381, 11, 25, 1755, 1769, "investigations" +391, 15, 3, 382, 26, 30, 1770, 1774, "into" +391, 15, 4, 383, 31, 36, 1775, 1780, "trial" +391, 15, 5, 384, 37, 44, 1781, 1788, "conduct" +391, 15, 6, 385, 45, 53, 1789, 1797, "included" +391, 15, 7, 386, 54, 57, 1798, 1801, "the" +391, 15, 8, 387, 58, 69, 1802, 1813, "measurement" +391, 15, 9, 388, 70, 72, 1814, 1816, "of" +391, 15, 10, 389, 73, 77, 1817, 1821, "drug" +391, 15, 11, 390, 78, 84, 1822, 1828, "levels" +391, 15, 12, 391, 85, 88, 1829, 1832, "for" +391, 15, 13, 392, 89, 101, 1833, 1845, "omarigliptin" +391, 15, 14, 393, 102, 105, 1846, 1849, "and" +391, 15, 15, 394, 106, 115, 1850, 1859, "metformin" +391, 15, 16, 395, 116, 118, 1860, 1862, "in" +391, 15, 17, 396, 119, 124, 1863, 1868, "blood" +391, 15, 18, 397, 125, 132, 1869, 1876, "samples" +391, 15, 19, 398, 133, 142, 1877, 1886, "collected" +391, 15, 20, 399, 143, 146, 1887, 1890, "for" +391, 15, 21, 400, 147, 153, 1891, 1897, "future" +391, 15, 22, 401, 154, 164, 1898, 1908, "biomedical" +391, 15, 23, 402, 165, 173, 1909, 1917, "research" +391, 15, 24, 403, 174, 175, 1918, 1919, "," +391, 15, 25, 404, 176, 185, 1920, 1929, "available" +391, 15, 26, 405, 186, 189, 1930, 1933, "for" +391, 15, 27, 406, 190, 203, 1934, 1947, "approximately" +391, 15, 28, 407, 204, 207, 1948, 1951, "one" +391, 15, 29, 408, 208, 212, 1952, 1956, "half" +391, 15, 30, 409, 213, 215, 1957, 1959, "of" +391, 15, 31, 410, 216, 219, 1960, 1963, "the" +391, 15, 32, 411, 220, 228, 1964, 1972, "patients" +391, 15, 33, 412, 229, 230, 1973, 1974, "." +391, 16, 1, 413, 0, 8, 1975, 1983, "FINDINGS" +391, 16, 2, 414, 9, 10, 1984, 1985, ":" +391, 16, 3, 415, 11, 14, 1986, 1989, "The" +391, 16, 4, 416, 15, 19, 1990, 1994, "mean" +391, 16, 5, 417, 20, 23, 1995, 1998, "age" +391, 16, 6, 418, 24, 26, 1999, 2001, "of" +391, 16, 7, 419, 27, 32, 2002, 2007, "trial" +391, 16, 8, 420, 33, 45, 2008, 2020, "participants" +391, 16, 9, 421, 46, 49, 2021, 2024, "was" +391, 16, 10, 422, 50, 52, 2025, 2027, "39" +391, 16, 11, 423, 53, 54, 2028, 2029, "." +391, 16, 12, 424, 55, 56, 2030, 2031, "2" +391, 16, 13, 425, 57, 62, 2032, 2037, "years" +391, 16, 14, 426, 63, 64, 2038, 2039, "," +391, 16, 15, 427, 65, 78, 2040, 2053, "approximately" +391, 16, 16, 428, 79, 81, 2054, 2056, "60" +391, 16, 17, 429, 82, 83, 2057, 2058, "%" +391, 16, 18, 430, 84, 88, 2059, 2063, "were" +391, 16, 19, 431, 89, 93, 2064, 2068, "male" +391, 16, 20, 432, 94, 95, 2069, 2070, "," +391, 16, 21, 433, 96, 100, 2071, 2075, "mean" +391, 16, 22, 434, 101, 105, 2076, 2080, "body" +391, 16, 23, 435, 106, 110, 2081, 2085, "mass" +391, 16, 24, 436, 111, 116, 2086, 2091, "index" +391, 16, 25, 437, 117, 120, 2092, 2095, "was" +391, 16, 26, 438, 121, 123, 2096, 2098, "32" +391, 16, 27, 439, 124, 125, 2099, 2100, "." +391, 16, 28, 440, 126, 127, 2101, 2102, "5" +391, 16, 29, 441, 128, 130, 2103, 2105, "kg" +391, 16, 30, 442, 131, 132, 2106, 2107, "/" +391, 16, 31, 443, 133, 135, 2108, 2110, "m2" +391, 16, 32, 444, 136, 137, 2111, 2112, "," +391, 16, 33, 445, 138, 141, 2113, 2116, "and" +391, 16, 34, 446, 142, 146, 2117, 2121, "mean" +391, 16, 35, 447, 147, 155, 2122, 2130, "duration" +391, 16, 36, 448, 156, 158, 2131, 2133, "of" +391, 16, 37, 449, 159, 167, 2134, 2142, "diabetes" +391, 16, 38, 450, 168, 171, 2143, 2146, "was" +391, 16, 39, 451, 172, 173, 2147, 2148, "3" +391, 16, 40, 452, 174, 175, 2149, 2150, "." +391, 16, 41, 453, 176, 177, 2151, 2152, "1" +391, 16, 42, 454, 178, 183, 2153, 2158, "years" +391, 16, 43, 455, 184, 185, 2159, 2160, "." +391, 17, 1, 456, 0, 3, 2161, 2164, "The" +391, 17, 2, 457, 4, 8, 2165, 2169, "mean" +391, 17, 3, 458, 9, 17, 2170, 2178, "baseline" +391, 17, 4, 459, 18, 23, 2179, 2184, "HbA1c" +391, 17, 5, 460, 24, 29, 2185, 2190, "value" +391, 17, 6, 461, 30, 33, 2191, 2194, "was" +391, 17, 7, 462, 34, 35, 2195, 2196, "7" +391, 17, 8, 463, 36, 37, 2197, 2198, "." +391, 17, 9, 464, 38, 39, 2199, 2200, "9" +391, 17, 10, 465, 40, 41, 2201, 2202, "%" +391, 17, 11, 466, 42, 44, 2203, 2205, "in" +391, 17, 12, 467, 45, 48, 2206, 2209, "the" +391, 17, 13, 468, 49, 61, 2210, 2222, "omarigliptin" +391, 17, 14, 469, 62, 67, 2223, 2228, "group" +391, 17, 15, 470, 68, 71, 2229, 2232, "and" +391, 17, 16, 471, 72, 73, 2233, 2234, "8" +391, 17, 17, 472, 74, 75, 2235, 2236, "." +391, 17, 18, 473, 76, 77, 2237, 2238, "1" +391, 17, 19, 474, 78, 79, 2239, 2240, "%" +391, 17, 20, 475, 80, 82, 2241, 2243, "in" +391, 17, 21, 476, 83, 86, 2244, 2247, "the" +391, 17, 22, 477, 87, 94, 2248, 2255, "placebo" +391, 17, 23, 478, 95, 100, 2256, 2261, "group" +391, 17, 24, 479, 101, 102, 2262, 2263, "." +391, 18, 1, 480, 0, 5, 2264, 2269, "After" +391, 18, 2, 481, 6, 8, 2270, 2272, "24" +391, 18, 3, 482, 9, 14, 2273, 2278, "weeks" +391, 18, 4, 483, 15, 16, 2279, 2280, "," +391, 18, 5, 484, 17, 20, 2281, 2284, "the" +391, 18, 6, 485, 21, 26, 2285, 2290, "least" +391, 18, 7, 486, 27, 34, 2291, 2298, "squares" +391, 18, 8, 487, 35, 36, 2299, 2300, " " +391, 18, 9, 488, 37, 41, 2301, 2305, "mean" +391, 18, 10, 489, 42, 48, 2306, 2312, "change" +391, 18, 11, 490, 49, 50, 2313, 2314, "(" +391, 18, 12, 491, 51, 53, 2315, 2317, "95" +391, 18, 13, 492, 54, 55, 2318, 2319, "%" +391, 18, 14, 493, 56, 58, 2320, 2322, "CI" +391, 18, 15, 494, 59, 60, 2323, 2324, ")" +391, 18, 16, 495, 61, 63, 2325, 2327, "in" +391, 18, 17, 496, 64, 69, 2328, 2333, "HbA1c" +391, 18, 18, 497, 70, 75, 2334, 2339, "value" +391, 18, 19, 498, 76, 80, 2340, 2344, "from" +391, 18, 20, 499, 81, 89, 2345, 2353, "baseline" +391, 18, 21, 500, 90, 93, 2354, 2357, "was" +391, 18, 22, 501, 94, 95, 2358, 2359, "-" +391, 18, 23, 502, 96, 97, 2360, 2361, "0" +391, 18, 24, 503, 98, 99, 2362, 2363, "." +391, 18, 25, 504, 100, 102, 2364, 2366, "33" +391, 18, 26, 505, 103, 104, 2367, 2368, "%" +391, 18, 27, 506, 105, 106, 2369, 2370, "(" +391, 18, 28, 507, 107, 108, 2371, 2372, "-" +391, 18, 29, 508, 109, 110, 2373, 2374, "0" +391, 18, 30, 509, 111, 112, 2375, 2376, "." +391, 18, 31, 510, 113, 115, 2377, 2379, "60" +391, 18, 32, 511, 116, 118, 2380, 2382, "to" +391, 18, 33, 512, 119, 120, 2383, 2384, "-" +391, 18, 34, 513, 121, 122, 2385, 2386, "0" +391, 18, 35, 514, 123, 124, 2387, 2388, "." +391, 18, 36, 515, 125, 127, 2389, 2391, "06" +391, 18, 37, 516, 128, 129, 2392, 2393, ")" +391, 18, 38, 517, 130, 132, 2394, 2396, "in" +391, 18, 39, 518, 133, 136, 2397, 2400, "the" +391, 18, 40, 519, 137, 149, 2401, 2413, "omarigliptin" +391, 18, 41, 520, 150, 155, 2414, 2419, "group" +391, 18, 42, 521, 156, 159, 2420, 2423, "and" +391, 18, 43, 522, 160, 161, 2424, 2425, "-" +391, 18, 44, 523, 162, 163, 2426, 2427, "0" +391, 18, 45, 524, 164, 165, 2428, 2429, "." +391, 18, 46, 525, 166, 168, 2430, 2432, "45" +391, 18, 47, 526, 169, 170, 2433, 2434, "%" +391, 18, 48, 527, 171, 172, 2435, 2436, "(" +391, 18, 49, 528, 173, 174, 2437, 2438, "-" +391, 18, 50, 529, 175, 176, 2439, 2440, "0" +391, 18, 51, 530, 177, 178, 2441, 2442, "." +391, 18, 52, 531, 179, 181, 2443, 2445, "72" +391, 18, 53, 532, 182, 184, 2446, 2448, "to" +391, 18, 54, 533, 185, 186, 2449, 2450, "-" +391, 18, 55, 534, 187, 188, 2451, 2452, "0" +391, 18, 56, 535, 189, 190, 2453, 2454, "." +391, 18, 57, 536, 191, 193, 2455, 2457, "18" +391, 18, 58, 537, 194, 195, 2458, 2459, ")" +391, 18, 59, 538, 196, 198, 2460, 2462, "in" +391, 18, 60, 539, 199, 202, 2463, 2466, "the" +391, 18, 61, 540, 203, 210, 2467, 2474, "placebo" +391, 18, 62, 541, 211, 216, 2475, 2480, "group" +391, 18, 63, 542, 217, 218, 2481, 2482, "," +391, 18, 64, 543, 219, 223, 2483, 2487, "with" +391, 18, 65, 544, 224, 225, 2488, 2489, "a" +391, 18, 66, 545, 226, 233, 2490, 2497, "between" +391, 18, 67, 546, 234, 235, 2498, 2499, "-" +391, 18, 68, 547, 236, 241, 2500, 2505, "group" +391, 18, 69, 548, 242, 252, 2506, 2516, "difference" +391, 18, 70, 549, 253, 255, 2517, 2519, "of" +391, 18, 71, 550, 256, 257, 2520, 2521, "0" +391, 18, 72, 551, 258, 259, 2522, 2523, "." +391, 18, 73, 552, 260, 262, 2524, 2526, "12" +391, 18, 74, 553, 263, 264, 2527, 2528, "%" +391, 18, 75, 554, 265, 266, 2529, 2530, "(" +391, 18, 76, 555, 267, 268, 2531, 2532, "-" +391, 18, 77, 556, 269, 270, 2533, 2534, "0" +391, 18, 78, 557, 271, 272, 2535, 2536, "." +391, 18, 79, 558, 273, 275, 2537, 2539, "26" +391, 18, 80, 559, 276, 278, 2540, 2542, "to" +391, 18, 81, 560, 279, 280, 2543, 2544, "0" +391, 18, 82, 561, 281, 282, 2545, 2546, "." +391, 18, 83, 562, 283, 285, 2547, 2549, "49" +391, 18, 84, 563, 286, 287, 2550, 2551, ";" +391, 18, 85, 564, 288, 289, 2552, 2553, "P" +391, 18, 86, 565, 290, 291, 2554, 2555, "=" +391, 18, 87, 566, 292, 293, 2556, 2557, "0" +391, 18, 88, 567, 294, 295, 2558, 2559, "." +391, 18, 89, 568, 296, 299, 2560, 2563, "535" +391, 18, 90, 569, 300, 301, 2564, 2565, ")" +391, 18, 91, 570, 302, 303, 2566, 2567, "." +391, 19, 1, 571, 0, 9, 2568, 2577, "Similarly" +391, 19, 2, 572, 10, 11, 2578, 2579, "," +391, 19, 3, 573, 12, 14, 2580, 2582, "no" +391, 19, 4, 574, 15, 22, 2583, 2590, "between" +391, 19, 5, 575, 23, 24, 2591, 2592, "-" +391, 19, 6, 576, 25, 30, 2593, 2598, "group" +391, 19, 7, 577, 31, 41, 2599, 2609, "difference" +391, 19, 8, 578, 42, 45, 2610, 2613, "was" +391, 19, 9, 579, 46, 54, 2614, 2622, "observed" +391, 19, 10, 580, 55, 58, 2623, 2626, "for" +391, 19, 11, 581, 59, 62, 2627, 2630, "the" +391, 19, 12, 582, 63, 68, 2631, 2636, "other" +391, 19, 13, 583, 69, 77, 2637, 2645, "glycemic" +391, 19, 14, 584, 78, 88, 2646, 2656, "parameters" +391, 19, 15, 585, 89, 90, 2657, 2658, "(" +391, 19, 16, 586, 91, 92, 2659, 2660, "2" +391, 19, 17, 587, 93, 94, 2661, 2662, "-" +391, 19, 18, 588, 95, 99, 2663, 2667, "hour" +391, 19, 19, 589, 100, 108, 2668, 2676, "postmeal" +391, 19, 20, 590, 109, 116, 2677, 2684, "glucose" +391, 19, 21, 591, 117, 120, 2685, 2688, "and" +391, 19, 22, 592, 121, 128, 2689, 2696, "fasting" +391, 19, 23, 593, 129, 135, 2697, 2703, "plasma" +391, 19, 24, 594, 136, 143, 2704, 2711, "glucose" +391, 19, 25, 595, 144, 150, 2712, 2718, "levels" +391, 19, 26, 596, 151, 152, 2719, 2720, ")" +391, 19, 27, 597, 153, 154, 2721, 2722, "." +391, 20, 1, 598, 0, 2, 2723, 2725, "No" +391, 20, 2, 599, 3, 9, 2726, 2732, "issues" +391, 20, 3, 600, 10, 14, 2733, 2737, "were" +391, 20, 4, 601, 15, 25, 2738, 2748, "identified" +391, 20, 5, 602, 26, 28, 2749, 2751, "in" +391, 20, 6, 603, 29, 33, 2752, 2756, "drug" +391, 20, 7, 604, 34, 44, 2757, 2767, "allocation" +391, 20, 8, 605, 45, 46, 2768, 2769, "," +391, 20, 9, 606, 47, 57, 2770, 2780, "dispensing" +391, 20, 10, 607, 58, 60, 2781, 2783, "or" +391, 20, 11, 608, 61, 67, 2784, 2790, "supply" +391, 20, 12, 609, 68, 69, 2791, 2792, "," +391, 20, 13, 610, 70, 77, 2793, 2800, "patient" +391, 20, 14, 611, 78, 88, 2801, 2811, "compliance" +391, 20, 15, 612, 89, 93, 2812, 2816, "with" +391, 20, 16, 613, 94, 99, 2817, 2822, "trial" +391, 20, 17, 614, 100, 110, 2823, 2833, "medication" +391, 20, 18, 615, 111, 112, 2834, 2835, "," +391, 20, 19, 616, 113, 119, 2836, 2842, "sample" +391, 20, 20, 617, 120, 128, 2843, 2851, "handling" +391, 20, 21, 618, 129, 131, 2852, 2854, "or" +391, 20, 22, 619, 132, 140, 2855, 2863, "analysis" +391, 20, 23, 620, 141, 142, 2864, 2865, "," +391, 20, 24, 621, 143, 145, 2866, 2868, "or" +391, 20, 25, 622, 146, 150, 2869, 2873, "site" +391, 20, 26, 623, 151, 156, 2874, 2879, "trial" +391, 20, 27, 624, 157, 164, 2880, 2887, "conduct" +391, 20, 28, 625, 165, 169, 2888, 2892, "that" +391, 20, 29, 626, 170, 179, 2893, 2902, "explained" +391, 20, 30, 627, 180, 183, 2903, 2906, "the" +391, 20, 31, 628, 184, 192, 2907, 2915, "observed" +391, 20, 32, 629, 193, 200, 2916, 2923, "results" +391, 20, 33, 630, 201, 202, 2924, 2925, "." +391, 21, 1, 631, 0, 11, 2926, 2937, "Measurement" +391, 21, 2, 632, 12, 14, 2938, 2940, "of" +391, 21, 3, 633, 15, 19, 2941, 2945, "drug" +391, 21, 4, 634, 20, 26, 2946, 2952, "levels" +391, 21, 5, 635, 27, 31, 2953, 2957, "from" +391, 21, 6, 636, 32, 38, 2958, 2964, "future" +391, 21, 7, 637, 39, 49, 2965, 2975, "biomedical" +391, 21, 8, 638, 50, 58, 2976, 2984, "research" +391, 21, 9, 639, 59, 66, 2985, 2992, "samples" +391, 21, 10, 640, 67, 76, 2993, 3002, "uncovered" +391, 21, 11, 641, 77, 80, 3003, 3006, "the" +391, 21, 12, 642, 81, 84, 3007, 3010, "use" +391, 21, 13, 643, 85, 86, 3011, 3012, "," +391, 21, 14, 644, 87, 91, 3013, 3017, "with" +391, 21, 15, 645, 92, 94, 3018, 3020, "no" +391, 21, 16, 646, 95, 107, 3021, 3033, "investigator" +391, 21, 17, 647, 108, 117, 3034, 3043, "knowledge" +391, 21, 18, 648, 118, 119, 3044, 3045, "," +391, 21, 19, 649, 120, 122, 3046, 3048, "of" +391, 21, 20, 650, 123, 125, 3049, 3051, "an" +391, 21, 21, 651, 126, 143, 3052, 3069, "antihyperglycemic" +391, 21, 22, 652, 144, 149, 3070, 3075, "agent" +391, 21, 23, 653, 150, 154, 3076, 3080, "that" +391, 21, 24, 654, 155, 158, 3081, 3084, "was" +391, 21, 25, 655, 159, 169, 3085, 3095, "prohibited" +391, 21, 26, 656, 170, 172, 3096, 3098, "by" +391, 21, 27, 657, 173, 176, 3099, 3102, "the" +391, 21, 28, 658, 177, 185, 3103, 3111, "protocol" +391, 21, 29, 659, 186, 187, 3112, 3113, "(" +391, 21, 30, 660, 188, 190, 3114, 3116, "ie" +391, 21, 31, 661, 191, 192, 3117, 3118, "," +391, 21, 32, 662, 193, 202, 3119, 3128, "metformin" +391, 21, 33, 663, 203, 204, 3129, 3130, ")" +391, 21, 34, 664, 205, 207, 3131, 3133, "by" +391, 21, 35, 665, 208, 210, 3134, 3136, "42" +391, 21, 36, 666, 211, 212, 3137, 3138, "." +391, 21, 37, 667, 213, 214, 3139, 3140, "4" +391, 21, 38, 668, 215, 216, 3141, 3142, "%" +391, 21, 39, 669, 217, 218, 3143, 3144, "(" +391, 21, 40, 670, 219, 221, 3145, 3147, "39" +391, 21, 41, 671, 222, 224, 3148, 3150, "of" +391, 21, 42, 672, 225, 227, 3151, 3153, "92" +391, 21, 43, 673, 228, 229, 3154, 3155, ")" +391, 21, 44, 674, 230, 232, 3156, 3158, "of" +391, 21, 45, 675, 233, 241, 3159, 3167, "patients" +391, 21, 46, 676, 242, 243, 3168, 3169, "." +391, 22, 1, 677, 0, 9, 3170, 3179, "Metformin" +391, 22, 2, 678, 10, 13, 3180, 3183, "was" +391, 22, 3, 679, 14, 18, 3184, 3188, "used" +391, 22, 4, 680, 19, 21, 3189, 3191, "by" +391, 22, 5, 681, 22, 26, 3192, 3196, "more" +391, 22, 6, 682, 27, 35, 3197, 3205, "patients" +391, 22, 7, 683, 36, 38, 3206, 3208, "in" +391, 22, 8, 684, 39, 42, 3209, 3212, "the" +391, 22, 9, 685, 43, 50, 3213, 3220, "placebo" +391, 22, 10, 686, 51, 56, 3221, 3226, "group" +391, 22, 11, 687, 57, 58, 3227, 3228, "(" +391, 22, 12, 688, 59, 61, 3229, 3231, "57" +391, 22, 13, 689, 62, 63, 3232, 3233, "%" +391, 22, 14, 690, 64, 65, 3234, 3235, "[" +391, 22, 15, 691, 66, 68, 3236, 3238, "25" +391, 22, 16, 692, 69, 71, 3239, 3241, "of" +391, 22, 17, 693, 72, 74, 3242, 3244, "44" +391, 22, 18, 694, 75, 76, 3245, 3246, "]" +391, 22, 19, 695, 77, 78, 3247, 3248, ")" +391, 22, 20, 696, 79, 83, 3249, 3253, "than" +391, 22, 21, 697, 84, 86, 3254, 3256, "in" +391, 22, 22, 698, 87, 90, 3257, 3260, "the" +391, 22, 23, 699, 91, 103, 3261, 3273, "omarigliptin" +391, 22, 24, 700, 104, 109, 3274, 3279, "group" +391, 22, 25, 701, 110, 111, 3280, 3281, "(" +391, 22, 26, 702, 112, 114, 3282, 3284, "29" +391, 22, 27, 703, 115, 116, 3285, 3286, "%" +391, 22, 28, 704, 117, 118, 3287, 3288, "[" +391, 22, 29, 705, 119, 121, 3289, 3291, "14" +391, 22, 30, 706, 122, 124, 3292, 3294, "of" +391, 22, 31, 707, 125, 127, 3295, 3297, "48" +391, 22, 32, 708, 128, 129, 3298, 3299, "]" +391, 22, 33, 709, 130, 131, 3300, 3301, ")" +391, 22, 34, 710, 132, 133, 3302, 3303, "." +391, 23, 1, 711, 0, 12, 3304, 3316, "IMPLICATIONS" +391, 23, 2, 712, 13, 14, 3317, 3318, ":" +391, 23, 3, 713, 15, 18, 3319, 3322, "The" +391, 23, 4, 714, 19, 22, 3323, 3326, "use" +391, 23, 5, 715, 23, 25, 3327, 3329, "of" +391, 23, 6, 716, 26, 36, 3330, 3340, "prohibited" +391, 23, 7, 717, 37, 46, 3341, 3350, "metformin" +391, 23, 8, 718, 47, 49, 3351, 3353, "in" +391, 23, 9, 719, 50, 51, 3354, 3355, "a" +391, 23, 10, 720, 52, 57, 3356, 3361, "trial" +391, 23, 11, 721, 58, 60, 3362, 3364, "of" +391, 23, 12, 722, 61, 62, 3365, 3366, "a" +391, 23, 13, 723, 63, 73, 3367, 3377, "dipeptidyl" +391, 23, 14, 724, 74, 83, 3378, 3387, "peptidase" +391, 23, 15, 725, 84, 85, 3388, 3389, "-" +391, 23, 16, 726, 86, 87, 3390, 3391, "4" +391, 23, 17, 727, 88, 89, 3392, 3393, " " +391, 23, 18, 728, 90, 99, 3394, 3403, "inhibitor" +391, 23, 19, 729, 100, 101, 3404, 3405, "," +391, 23, 20, 730, 102, 114, 3406, 3418, "omarigliptin" +391, 23, 21, 731, 115, 116, 3419, 3420, "," +391, 23, 22, 732, 117, 127, 3421, 3431, "introduced" +391, 23, 23, 733, 128, 129, 3432, 3433, "a" +391, 23, 24, 734, 130, 141, 3434, 3445, "confounding" +391, 23, 25, 735, 142, 148, 3446, 3452, "factor" +391, 23, 26, 736, 149, 153, 3453, 3457, "that" +391, 23, 27, 737, 154, 165, 3458, 3469, "invalidated" +391, 23, 28, 738, 166, 169, 3470, 3473, "the" +391, 23, 29, 739, 170, 177, 3474, 3481, "results" +391, 23, 30, 740, 178, 180, 3482, 3484, "of" +391, 23, 31, 741, 181, 184, 3485, 3488, "the" +391, 23, 32, 742, 185, 190, 3489, 3494, "trial" +391, 23, 33, 743, 191, 192, 3495, 3496, "." +391, 24, 1, 744, 0, 4, 3497, 3501, "This" +391, 24, 2, 745, 5, 13, 3502, 3510, "behavior" +391, 24, 3, 746, 14, 17, 3511, 3514, "may" +391, 24, 4, 747, 18, 22, 3515, 3519, "have" +391, 24, 5, 748, 23, 27, 3520, 3524, "been" +391, 24, 6, 749, 28, 38, 3525, 3535, "encouraged" +391, 24, 7, 750, 39, 41, 3536, 3538, "in" +391, 24, 8, 751, 42, 45, 3539, 3542, "the" +391, 24, 9, 752, 46, 51, 3543, 3548, "trial" +391, 24, 10, 753, 52, 54, 3549, 3551, "by" +391, 24, 11, 754, 55, 63, 3552, 3560, "protocol" +391, 24, 12, 755, 64, 65, 3561, 3562, "-" +391, 24, 13, 756, 66, 75, 3563, 3572, "specified" +391, 24, 14, 757, 76, 80, 3573, 3577, "self" +391, 24, 15, 758, 81, 82, 3578, 3579, "-" +391, 24, 16, 759, 83, 93, 3580, 3590, "monitoring" +391, 24, 17, 760, 94, 96, 3591, 3593, "of" +391, 24, 18, 761, 97, 102, 3594, 3599, "blood" +391, 24, 19, 762, 103, 110, 3600, 3607, "glucose" +391, 24, 20, 763, 111, 117, 3608, 3614, "levels" +391, 24, 21, 764, 118, 119, 3615, 3616, "." +391, 25, 1, 765, 0, 3, 3617, 3620, "Use" +391, 25, 2, 766, 4, 6, 3621, 3623, "of" +391, 25, 3, 767, 7, 17, 3624, 3634, "prohibited" +391, 25, 4, 768, 18, 28, 3635, 3645, "medication" +391, 25, 5, 769, 29, 32, 3646, 3649, "may" +391, 25, 6, 770, 33, 35, 3650, 3652, "be" +391, 25, 7, 771, 36, 38, 3653, 3655, "an" +391, 25, 8, 772, 39, 55, 3656, 3672, "underappreciated" +391, 25, 9, 773, 56, 66, 3673, 3683, "confounder" +391, 25, 10, 774, 67, 69, 3684, 3686, "in" +391, 25, 11, 775, 70, 78, 3687, 3695, "clinical" +391, 25, 12, 776, 79, 84, 3696, 3701, "trial" +391, 25, 13, 777, 85, 93, 3702, 3710, "research" +391, 25, 14, 778, 94, 95, 3711, 3712, "." +391, 26, 1, 779, 0, 5, 3713, 3718, "TRIAL" +391, 26, 2, 780, 6, 19, 3719, 3732, "REGISTRATIONS" +391, 26, 3, 781, 20, 21, 3733, 3734, ":" +391, 26, 4, 782, 22, 24, 3735, 3737, "MK" +391, 26, 5, 783, 25, 26, 3738, 3739, "-" +391, 26, 6, 784, 27, 31, 3740, 3744, "3102" +391, 26, 7, 785, 32, 33, 3745, 3746, "-" +391, 26, 8, 786, 34, 37, 3747, 3750, "028" +391, 26, 9, 787, 38, 39, 3751, 3752, "(" +391, 26, 10, 788, 40, 42, 3753, 3755, "US" +391, 26, 11, 789, 43, 44, 3756, 3757, ")" +391, 26, 12, 790, 45, 46, 3758, 3759, ";" +391, 26, 13, 791, 47, 61, 3760, 3774, "ClinicalTrials" +391, 26, 14, 792, 62, 63, 3775, 3776, "." +391, 26, 15, 793, 64, 67, 3777, 3780, "gov" +391, 26, 16, 794, 68, 78, 3781, 3791, "identifier" +391, 26, 17, 795, 79, 80, 3792, 3793, "," +391, 26, 18, 796, 81, 92, 3794, 3805, "NCT01814748" +391, 26, 19, 797, 93, 94, 3806, 3807, ";" +391, 26, 20, 798, 95, 102, 3808, 3815, "EudraCT" +391, 26, 21, 799, 103, 109, 3816, 3822, "number" +391, 26, 22, 800, 110, 111, 3823, 3824, "," +391, 26, 23, 801, 112, 116, 3825, 3829, "2012" +391, 26, 24, 802, 117, 118, 3830, 3831, "-" +391, 26, 25, 803, 119, 125, 3832, 3838, "004303" +391, 26, 26, 804, 126, 127, 3839, 3840, "-" +391, 26, 27, 805, 128, 130, 3841, 3843, "12" +391, 26, 28, 806, 131, 132, 3844, 3845, "(" +391, 26, 29, 807, 133, 135, 3846, 3848, "EU" +391, 26, 30, 808, 136, 137, 3849, 3850, ")" +391, 26, 31, 809, 138, 139, 3851, 3852, "." +391, 27, 1, 810, 0, 9, 3853, 3862, "Copyright" +391, 27, 2, 811, 10, 11, 3863, 3864, "©" +391, 27, 3, 812, 12, 16, 3865, 3869, "2017" +391, 27, 4, 813, 17, 20, 3870, 3873, "The" +391, 27, 5, 814, 21, 28, 3874, 3881, "Authors" +391, 27, 6, 815, 29, 30, 3882, 3883, "." +391, 28, 1, 816, 0, 9, 3884, 3893, "Published" +391, 28, 2, 817, 10, 12, 3894, 3896, "by" +391, 28, 3, 818, 13, 21, 3897, 3905, "Elsevier" +391, 28, 4, 819, 22, 25, 3906, 3909, "Inc" +391, 28, 5, 820, 26, 27, 3910, 3911, "." +391, 28, 6, 821, 28, 31, 3912, 3915, "All" +391, 28, 7, 822, 32, 38, 3916, 3922, "rights" +391, 28, 8, 823, 39, 47, 3923, 3931, "reserved" +391, 28, 9, 824, 48, 49, 3932, 3933, "." +391, 29, 1, 825, 0, 3, 3934, 3937, "DOI" +391, 29, 2, 826, 4, 5, 3938, 3939, ":" +391, 29, 3, 827, 6, 8, 3940, 3942, "10" +391, 29, 4, 828, 9, 10, 3943, 3944, "." +391, 29, 5, 829, 11, 15, 3945, 3949, "1016" +391, 29, 6, 830, 16, 17, 3950, 3951, "/" +391, 29, 7, 831, 18, 19, 3952, 3953, "j" +391, 29, 8, 832, 20, 21, 3954, 3955, "." +391, 29, 9, 833, 22, 31, 3956, 3965, "clinthera" +391, 29, 10, 834, 32, 33, 3966, 3967, "." +391, 29, 11, 835, 34, 38, 3968, 3972, "2017" +391, 29, 12, 836, 39, 40, 3973, 3974, "." +391, 29, 13, 837, 41, 43, 3975, 3977, "08" +391, 29, 14, 838, 44, 45, 3978, 3979, "." +391, 29, 15, 839, 46, 49, 3980, 3983, "009" +391, 29, 16, 840, 50, 54, 3984, 3988, "PMID" +391, 29, 17, 841, 55, 56, 3989, 3990, ":" +391, 29, 18, 842, 57, 65, 3991, 3999, "28923291" +391, 29, 19, 843, 66, 67, 4000, 4001, "[" +391, 29, 20, 844, 68, 75, 4002, 4009, "Indexed" +391, 29, 21, 845, 76, 79, 4010, 4013, "for" +391, 29, 22, 846, 80, 87, 4014, 4021, "MEDLINE" +391, 29, 23, 847, 88, 89, 4022, 4023, "]" diff --git a/data/dm2 28923291_kwoodley.annodb b/data/dm2 28923291_kwoodley.annodb new file mode 100644 index 0000000..2d362b6 --- /dev/null +++ b/data/dm2 28923291_kwoodley.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72126, Journal, 0, 9, "Clin Ther", "", +72127, PublicationYear, 12, 16, "2017", "", +72141, Title, 120, 304, "Use of Prohibited Medication , a Potentially Overlooked Confounder in Clinical Trials : Omarigliptin ( Once - weekly DPP - 4 Inhibitor ) Monotherapy Trial in 18 - to 45 - year - olds .", "", +72128, Omarigliptin, 208, 220, "Omarigliptin", "", +72138, Frequency, 223, 236, "Once - weekly", "", +72142, Author, 305, 312, "Gantz I", "", +72143, Author, 321, 331, "Sokolova L", "", +72144, Author, 340, 346, "Jain L", "", +72145, Author, 355, 364, "Iredale C", "", +72146, Author, 373, 385, "O ' Neill EA", "", +72147, Author, 394, 399, "Wei Z", "", +72148, Author, 408, 413, "Lam R", "", +72149, Author, 422, 435, "Suryawanshi S", "", +72150, Author, 444, 454, "Kaufman KD", "", +72151, Author, 463, 471, "Engel SS", "", +72152, Author, 480, 485, "Lai E", "", +72153, USA, 553, 563, "New Jersey", "", +72154, Country, 733, 740, "Ukraine", "", +72155, USA, 781, 791, "New Jersey", "", +72158, ObjectiveDescription, 804, 971, "The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus ( T2DM ) .", "", +72129, Omarigliptin, 882, 894, "omarigliptin", "", +72156, Type2Diabetes, 936, 960, "type 2 diabetes mellitus", "", +72157, Type2Diabetes, 963, 967, "T2DM", "", +72162, Precondition, 1151, 1313, "Patients with T2DM who were ≥ 18 to < 45 years of age and either drug - naive or not on an antihyperglycemic agent for ≥ 12 weeks with inadequate glycemic control", "", +72159, Type2Diabetes, 1165, 1169, "T2DM", "", +72160, MinAge, 1181, 1183, "18", "", +72161, MaxAge, 1189, 1191, "45", "", +72163, Randomized, 1319, 1329, "randomized", "", +72164, DoubleBlind, 1335, 1349, "double - blind", "", +72130, Omarigliptin, 1368, 1380, "omarigliptin", "", +72165, DoseValue, 1381, 1383, "25", "", +72166, mg, 1384, 1386, "mg", "", +72139, Frequency, 1387, 1398, "once weekly", "", +72167, NumberPatientsArm, 1405, 1408, "102", "", +72170, Placebo, 1414, 1421, "placebo", "", +72140, Frequency, 1422, 1433, "once weekly", "", +72168, NumberPatientsArm, 1440, 1443, "101", "", +72169, Duration, 1450, 1458, "24 weeks", "", +72177, ObjectiveDescription, 1461, 1683, "The objectives of the trial were to assess the effect of treatment with omarigliptin on glycemic parameters , including levels of glycosylated hemoglobin ( HbA1c ) , 2 - hour postmeal glucose , and fasting plasma glucose ,", "", +72131, Omarigliptin, 1533, 1545, "omarigliptin", "", +72173, HbA1c, 1591, 1614, "glycosylated hemoglobin", "", +72174, HbA1c, 1617, 1622, "HbA1c", "", +72175, PostprandialPlasmaGlucose, 1627, 1652, "2 - hour postmeal glucose", "", +72176, FastingPlasmaGlucose, 1659, 1681, "fasting plasma glucose", "", +72178, ObjectiveDescription, 1684, 1743, "and to assess the safety and tolerability of omarigliptin .", "", +72132, Omarigliptin, 1729, 1741, "omarigliptin", "", +72133, Omarigliptin, 1833, 1845, "omarigliptin", "", +72179, Metformin, 1850, 1859, "metformin", "", +72181, AvgAge, 2025, 2031, "39 . 2", "", +72182, Male, 2054, 2058, "60 %", "", +72186, Precondition, 2071, 2158, "mean body mass index was 32 . 5 kg / m2 , and mean duration of diabetes was 3 . 1 years", "", +72183, BMI, 2076, 2091, "body mass index", "", +72184, BaseLineValue, 2096, 2102, "32 . 5", "", +72185, Kg_per_squareMeter, 2103, 2110, "kg / m2", "", +72187, HbA1c, 2179, 2184, "HbA1c", "", +72188, BaseLineValue, 2195, 2200, "7 . 9", "", +72191, Percentage, 2201, 2202, "%", "", +72134, Omarigliptin, 2210, 2222, "omarigliptin", "", +72189, BaseLineValue, 2233, 2238, "8 . 1", "", +72190, Percentage, 2239, 2240, "%", "", +72192, Placebo, 2248, 2255, "placebo", "", +72193, TimePoint, 2270, 2278, "24 weeks", "", +72195, LeastSquaresMean, 2285, 2305, "least squares   mean", "", +72196, ConfIntervalChangeValue, 2315, 2322, "95 % CI", "", +72197, HbA1c, 2328, 2333, "HbA1c", "", +72194, TimePoint, 2345, 2353, "baseline", "", +72198, Reduction, 2360, 2366, "0 . 33", "", +72200, Percentage, 2367, 2368, "%", "", +72202, ConfIntervalChangeValue, 2371, 2391, "- 0 . 60 to - 0 . 06", "", +72135, Omarigliptin, 2401, 2413, "omarigliptin", "", +72199, Reduction, 2426, 2432, "0 . 45", "", +72201, Percentage, 2433, 2434, "%", "", +72203, ConfIntervalChangeValue, 2437, 2457, "- 0 . 72 to - 0 . 18", "", +72171, Placebo, 2467, 2474, "placebo", "", +72204, DiffGroupAbsValue, 2520, 2526, "0 . 12", "", +72205, Percentage, 2527, 2528, "%", "", +72206, ConfIntervalDiff, 2531, 2549, "- 0 . 26 to 0 . 49", "", +72207, PvalueDiff, 2552, 2563, "P = 0 . 535", "", +72210, ObservedResult, 2580, 2622, "no between - group difference was observed", "", +72208, PostprandialPlasmaGlucose, 2659, 2684, "2 - hour postmeal glucose", "", +72209, FastingPlasmaGlucose, 2689, 2711, "fasting plasma glucose", "", +72211, Metformin, 3119, 3128, "metformin", "", +72213, PercentageAffected, 3134, 3140, "42 . 4", "", +72212, NumberAffected, 3145, 3147, "39", "", +72214, NumberPatientsCT, 3151, 3153, "92", "", +72230, Metformin, 3170, 3179, "Metformin", "used as an endpoint here", +72172, Placebo, 3213, 3220, "placebo", "", +72216, PercentageAffected, 3229, 3231, "57", "", +72218, NumberAffected, 3236, 3238, "25", "", +72220, NumberPatientsArm, 3242, 3244, "44", "", +72136, Omarigliptin, 3261, 3273, "omarigliptin", "", +72217, PercentageAffected, 3282, 3284, "29", "", +72219, NumberAffected, 3289, 3291, "14", "", +72221, NumberPatientsArm, 3295, 3297, "48", "", +72228, ConclusionComment, 3319, 3496, "The use of prohibited metformin in a trial of a dipeptidyl peptidase - 4   inhibitor , omarigliptin , introduced a confounding factor that invalidated the results of the trial .", "", +72180, Metformin, 3341, 3350, "metformin", "", +72137, Omarigliptin, 3406, 3418, "omarigliptin", "", +72229, ConclusionComment, 3497, 3616, "This behavior may have been encouraged in the trial by protocol - specified self - monitoring of blood glucose levels .", "", +72226, BloodGlucose, 3594, 3607, "blood glucose", "", +72233, ConclusionComment, 3617, 3712, "Use of prohibited medication may be an underappreciated confounder in clinical trial research .", "", +72232, PMID, 3991, 3999, "28923291", "", diff --git a/data/dm2 28923291_kwoodley.n-triples b/data/dm2 28923291_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 28923291_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29017497_admin.annodb b/data/dm2 29017497_admin.annodb new file mode 100644 index 0000000..ed1d6ce --- /dev/null +++ b/data/dm2 29017497_admin.annodb @@ -0,0 +1,150 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Cardiovasc Diabetol .", "", " \"Cardiovasc Diabetol .\"." +1, PublicationYear, 22, 26, "2017", "", " \"2017\"." +16, Title, 97, 280, "The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters : a randomized , controlled trial ( Sapporo Athero - Incretin Study 3 ) .", "", " \"The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters : a randomized , controlled trial ( Sapporo Athero - Incretin Study 3 ) .\"." +2, Vildagliptin, 112, 124, "vildagliptin", "", +8, Metformin, 139, 148, "metformin", "", +15, Randomized, 211, 221, "randomized", "", " ." +17, Author, 281, 288, "Kitao N", "", " \"Kitao N\"." +18, Author, 297, 306, "Miyoshi H", "", " \"Miyoshi H\"." +19, Author, 315, 325, "Furumoto T", "", " \"Furumoto T\"." +20, Author, 340, 345, "Ono K", "", " \"Ono K\"." +21, Author, 354, 362, "Nomoto H", "", " \"Nomoto H\"." +22, Author, 371, 377, "Miya A", "", " \"Miya A\"." +23, Author, 386, 396, "Yamamoto C", "", " \"Yamamoto C\"." +24, Author, 405, 412, "Inoue A", "", " \"Inoue A\"." +25, Author, 421, 431, "Tsuchida K", "", " \"Tsuchida K\"." +26, Author, 440, 447, "Manda N", "", " \"Manda N\"." +27, Author, 456, 466, "Kurihara Y", "", " \"Kurihara Y\"." +158, Author, 475, 481, "Aoki S", "", " \"Aoki S\"." +29, Author, 490, 500, "Nakamura A", "", " \"Nakamura A\"." +30, Author, 509, 517, "Atsumi T", "", " \"Atsumi T\"." +63, Author, 561, 570, "Edagawa Y", "", +31, Author, 573, 579, "Oita M", "", +32, Author, 582, 589, "Kondo A", "", +33, Author, 592, 603, "Takahashi K", "", +34, Author, 606, 616, "Sugawara H", "", +35, Author, 619, 632, "Dan - Noura M", "", +36, Author, 635, 643, "Takano Y", "", +37, Author, 646, 653, "Kitao N", "", +38, Author, 656, 668, "Koyanagawa N", "", +39, Author, 671, 677, "Miya A", "", +40, Author, 680, 690, "Yamamoto K", "", +41, Author, 693, 703, "Yamamoto C", "", +42, Author, 706, 714, "Nomoto H", "", +43, Author, 717, 725, "Kameda Y", "", +44, Author, 728, 734, "Cho KY", "", +45, Author, 737, 747, "Nakamura A", "", +46, Author, 750, 759, "Miyoshi H", "", +47, Author, 762, 770, "Atsumi T", "", +48, Author, 773, 783, "Watanabe T", "", +49, Author, 786, 797, "Takahashi K", "", +50, Author, 800, 812, "Koyanagawa N", "", +51, Author, 815, 821, "Kito K", "", +52, Author, 824, 834, "Yamamoto C", "", +53, Author, 837, 843, "Endo M", "", +54, Author, 846, 856, "Takeuchi J", "", +55, Author, 859, 866, "Nagai S", "", +56, Author, 869, 877, "Masuda H", "", +57, Author, 880, 887, "Inoue A", "", +58, Author, 890, 895, "Ono Y", "", +59, Author, 898, 908, "Tsuchida K", "", +60, Author, 911, 918, "Manda N", "", +61, Author, 921, 931, "Kurihara Y", "", +62, Author, 934, 940, "Aoki S", "", +64, Japan, 1146, 1151, "Japan", "", +65, Japan, 1336, 1341, "Japan", "", +66, Japan, 1471, 1476, "Japan", "", +67, Japan, 1585, 1590, "Japan", "", +68, Japan, 1690, 1695, "Japan", "", +69, Japan, 1778, 1783, "Japan", "", +70, Japan, 1828, 1833, "Japan", "", +71, Japan, 1870, 1875, "Japan", "", +72, Japan, 1908, 1913, "Japan", "", +175, ObjectiveDescription, 1929, 2135, "Dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes , although similar effects in advanced atherosclerosis were", "", " \"Dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes , although similar effects in advanced atherosclerosis were\"." +73, Type2Diabetes, 2060, 2075, "type 2 diabetes", "", " ." +83462, DisorderOrSyndrome, 2115, 2130, "atherosclerosis", "", +176, ObjectiveDescription, 2136, 2197, "not shown in recent randomized placebo - controlled studies .", "", " \"not shown in recent randomized placebo - controlled studies .\"." +75, Randomized, 2156, 2166, "randomized", "", +76, Placebo, 2167, 2174, "placebo", "", +174, ObjectiveDescription, 2198, 2345, "Therefore , we investigated the efficacy of DPP - 4 inhibitor on endothelial function and glycemic metabolism compared with high - dose metformin .", "", " \"Therefore , we investigated the efficacy of DPP - 4 inhibitor on endothelial function and glycemic metabolism compared with high - dose metformin .\"." +77, Metformin, 2334, 2343, "metformin", "", +79, Multicenter, 2364, 2375, "multicenter", "", " ." +80, OpenLabel, 2378, 2392, "open - labeled", "", " ." +81, Prospective, 2395, 2406, "prospective", "", " ." +82, Randomized, 2409, 2419, "randomized", "", +83, Parallel, 2422, 2438, "parallel - group", "", " ." +88, Precondition, 2458, 2546, "patients with type 2 diabetes treated with low - dose metformin ( 500 - 750   mg / day )", "", " \"patients with type 2 diabetes treated with low - dose metformin ( 500 - 750   mg / day )\"." +74, Type2Diabetes, 2472, 2487, "type 2 diabetes", "", +84, Metformin, 2512, 2521, "metformin", "", " . ." +85, DoseValue, 2524, 2533, "500 - 750", "", " \"500 - 750\". \"500 - 750\"." +86, mg, 2536, 2538, "mg", "", " . ." +83469, Interval, 2541, 2544, "day", "", " \"day\". \"day\"." +89, Randomized, 2565, 2573, "randomly", "", +3, Vildagliptin, 2588, 2600, "vildagliptin", "", " ." +14, Vildagliptin, 2642, 2647, "Vilda", "", +214, DoseDescription, 2655, 2666, "double dose", "", " \"double dose\"." +9, Metformin, 2670, 2679, "metformin", "", +189, Metformin, 2693, 2696, "Met", "", +90, Duration, 2703, 2713, "12   weeks", "", " \"12   weeks\"." +201, EndPointDescription, 2716, 2740, "Flow - mediated dilation", "", +202, EndPointDescription, 2743, 2746, "FMD", "", +92, NumberPatientsCT, 2907, 2921, "Ninety - seven", "", " \"Ninety - seven\"." +93, AvgAge, 2938, 2944, "58 . 7", "", " \"58 . 7\"." +194, Year, 2958, 2963, "years", "", +94, BMI, 2966, 2981, "body mass index", "", +95, BaseLineValue, 2984, 2990, "25 . 9", "", +96, SdDevBL, 2995, 3000, "4 . 4", "", +97, Kg_per_squareMeter, 3003, 3010, "kg / m2", "", +98, HbA1c, 3013, 3018, "HbA1c", "", +99, BaseLineValue, 3021, 3026, "7 . 3", "", " \"7 . 3\". \"7 . 3\"." +100, SdDevBL, 3031, 3036, "0 . 5", "", " \"0 . 5\". \"0 . 5\"." +101, Percentage, 3037, 3038, "%", "", +102, EndPointDescription, 3041, 3044, "FMD", "", " . ." +103, BaseLineValue, 3047, 3052, "5 . 8", "", " \"5 . 8\". \"5 . 8\"." +104, SdDevBL, 3057, 3062, "2 . 6", "", " \"2 . 6\". \"2 . 6\"." +105, Percentage, 3063, 3064, "%", "", " ." +106, NumPatientsLeftCT, 3083, 3088, "Eight", "", " \"Eight\"." +242, TimePoint, 3200, 3208, "baseline", "", +107, TimePoint, 3233, 3243, "12   weeks", "", +108, HbA1c, 3246, 3251, "HbA1c", "", " ." +5, Vildagliptin, 3286, 3291, "Vilda", "", +212, Metformin, 3321, 3324, "Met", "", +109, Reduction, 3336, 3342, "0 . 80", "", " \"0 . 80\"." +111, SdDevChangeValue, 3347, 3353, "0 . 38", "", " \"0 . 38\"." +113, Percentage, 3354, 3355, "%", "", " ." +110, Reduction, 3364, 3370, "0 . 40", "", " \"0 . 40\"." +112, SdDevChangeValue, 3375, 3381, "0 . 47", "", " \"0 . 47\"." +114, Percentage, 3382, 3383, "%", "", +115, PvalueDiff, 3401, 3413, "p  <  0 . 01", "", " \"p  <  0 . 01\"." +116, EndPointDescription, 3469, 3472, "FMD", "", +117, Reduction, 3478, 3484, "0 . 51", "", " \"0 . 51\"." +119, ConfIntervalChangeValue, 3485, 3504, "[-  1 . 08 - 0 . 06", "", " \"[-  1 . 08 - 0 . 06\"." +121, Percentage, 3507, 3508, "%", "", +118, Reduction, 3517, 3523, "0 . 58", "", " \"0 . 58\"." +120, ConfIntervalChangeValue, 3524, 3543, "[-  1 . 20 - 0 . 04", "", " \"[-  1 . 20 - 0 . 04\"." +122, Percentage, 3546, 3547, "%", "", +123, EndPointDescription, 3565, 3607, "apolipoprotein B / apolipoprotein A1 ratio", "", " . ." +125, ObservedResult, 3608, 3675, "was significantly reduced in the Vilda group compared with baseline", "", +4, Vildagliptin, 3641, 3646, "Vilda", "", +124, TimePoint, 3667, 3675, "baseline", "", +227, BaseLineValue, 3678, 3684, "0 . 66", "", " \"0 . 66\"." +228, ResultMeasuredValue, 3687, 3693, "0 . 62", "", " \"0 . 62\"." +127, PValueChangeValue, 3696, 3708, "p  <  0 . 01", "", " \"p  <  0 . 01\"." +128, Reduction, 3781, 3787, "0 . 04", "", " \"0 . 04\"." +129, NoChange, 3793, 3799, "0 . 00", "", " \"0 . 00\"." +130, PvalueDiff, 3802, 3814, "p  =  0 . 27", "", " \"p  =  0 . 27\"." +131, EndPointDescription, 3819, 3830, "Adiponectin", "", " . ." +6, Vildagliptin, 3874, 3879, "Vilda", "", +234, Metformin, 3909, 3912, "Met", "", +132, Increment, 3921, 3927, "0 . 75", "", " \"0 . 75\"." +134, BioAndMedicalUnit, 3928, 3937, " μ g / mL", "", " . ." +133, Increment, 3943, 3949, "0 . 01", "", " \"0 . 01\"." +135, BioAndMedicalUnit, 3950, 3959, " μ g / mL", "", +136, PvalueDiff, 3962, 3974, "p  <  0 . 01", "", " \"p  <  0 . 01\"." +138, ConclusionComment, 3993, 4185, "Regardless of glycemic improvement , combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile", "", " \"Regardless of glycemic improvement , combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile\"." +7, Vildagliptin, 4053, 4065, "vildagliptin", "", +13, Metformin, 4070, 4079, "metformin", "", +139, ConclusionComment, 4186, 4253, "in patients with type 2 diabetes without advanced atherosclerosis .", "", " \"in patients with type 2 diabetes without advanced atherosclerosis .\"." +137, Type2Diabetes, 4203, 4218, "type 2 diabetes", "", +140, PMID, 4322, 4330, "29017497", "", " \"29017497\"." diff --git a/data/dm2 29017497_admin.n-triples b/data/dm2 29017497_admin.n-triples new file mode 100644 index 0000000..6f62180 --- /dev/null +++ b/data/dm2 29017497_admin.n-triples @@ -0,0 +1,201 @@ +# RDF export of group: Publication + . + "Publication 76341" . + "The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters : a randomized , controlled trial ( Sapporo Athero - Incretin Study 3 ) ." . + "Kitao N" . + "2017" . + "Cardiovasc Diabetol ." . + "29017497" . + . + "Miyoshi H" . + "Furumoto T" . + "Ono K" . + "Nomoto H" . + "Miya A" . + "Yamamoto C" . + "Inoue A" . + "Tsuchida K" . + "Manda N" . + "Kurihara Y" . + "Aoki S" . + "Nakamura A" . + "Atsumi T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 76348" . + "Dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes , although similar effects in advanced atherosclerosis were" . + "Ninety - seven" . + "12   weeks" . + . + . + . + "Regardless of glycemic improvement , combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile" . + . + . + . + . + . + "Eight" . + . + "in patients with type 2 diabetes without advanced atherosclerosis ." . + . + . + . + . + "not shown in recent randomized placebo - controlled studies ." . + "Therefore , we investigated the efficacy of DPP - 4 inhibitor on endothelial function and glycemic metabolism compared with high - dose metformin ." . + . + . +# RDF export of group: Population + . + "Population 76364" . + "patients with type 2 diabetes treated with low - dose metformin ( 500 - 750   mg / day )" . + . + . + "58 . 7" . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fmd" . + . + . + . + . + . + . + "apo" . + . + . + . + . + . + . + "adi" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "vil" . + . + . + . + . + . + . + . + . + "met" . + . + . + . + . + . +# RDF export of group: Intervention + . + "vil" . + . + . + . + "met" . + . + "day" . + . + . + "met2" . + . + "day" . + . +# RDF export of group: Medication + . + "vil" . + . + . + . + . + "met" . + . + "500 - 750" . + . + . + . + "met2" . + . + "500 - 750" . + . + . + "double dose" . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 3" . + "0 . 5" . + "0 . 80" . + "0 . 38" . + . + "hba 2" . + . + "7 . 3" . + "0 . 5" . + "0 . 40" . + "0 . 47" . + . + "fmd 1" . + . + "5 . 8" . + "2 . 6" . + "0 . 51" . + "[-  1 . 08 - 0 . 06" . + . + "fmd 2" . + . + "5 . 8" . + "2 . 6" . + "0 . 58" . + "[-  1 . 20 - 0 . 04" . + . + "apo 1" . + . + "0 . 66" . + "0 . 62" . + "0 . 04" . + "p  <  0 . 01" . + . + "apo 2" . + . + "0 . 00" . + . + "adi 1" . + . + "0 . 75" . + . + "adi 2" . + . + "0 . 01" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "p  <  0 . 01" . + . + . + . + "apo" . + "p  =  0 . 27" . + . + . + . + "adi" . + "p  <  0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29017497_akramersunderbrink.annodb b/data/dm2 29017497_akramersunderbrink.annodb new file mode 100644 index 0000000..10fb1c3 --- /dev/null +++ b/data/dm2 29017497_akramersunderbrink.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72997, Journal, 0, 19, "Cardiovasc Diabetol", "", +72998, PublicationYear, 22, 26, "2017", "", +73002, Title, 97, 280, "The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters : a randomized , controlled trial ( Sapporo Athero - Incretin Study 3 ) .", "", +72999, Vildagliptin, 112, 124, "vildagliptin", "", +73000, Metformin, 139, 148, "metformin", "", +73001, Randomized, 211, 221, "randomized", "", +73003, Author, 281, 288, "Kitao N", "", +73004, Author, 297, 306, "Miyoshi H", "", +73005, Author, 315, 325, "Furumoto T", "", +73006, Author, 340, 345, "Ono K", "", +73007, Author, 354, 362, "Nomoto H", "", +73008, Author, 371, 377, "Miya A", "", +73009, Author, 386, 396, "Yamamoto C", "", +73010, Author, 405, 412, "Inoue A", "", +73011, Author, 421, 431, "Tsuchida K", "", +73012, Author, 440, 447, "Manda N", "", +73013, Author, 456, 466, "Kurihara Y", "", +73014, Author, 475, 481, "Aoki S", "", +73015, Author, 490, 500, "Nakamura A", "", +73016, Author, 509, 517, "Atsumi T", "", +73017, Japan, 1146, 1151, "Japan", "", +73018, Japan, 1336, 1341, "Japan", "", +73019, Japan, 1471, 1476, "Japan", "", +73020, Japan, 1585, 1590, "Japan", "", +73021, Japan, 1690, 1695, "Japan", "", +73022, Japan, 1778, 1783, "Japan", "", +73023, Japan, 1828, 1833, "Japan", "", +73024, Japan, 1870, 1875, "Japan", "", +73025, Japan, 1908, 1913, "Japan", "", +73031, ObjectiveDescription, 1929, 2135, "Dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes , although similar effects in advanced atherosclerosis were", "", +73026, Type2Diabetes, 2060, 2075, "type 2 diabetes", "", +73032, ObjectiveDescription, 2136, 2197, "not shown in recent randomized placebo - controlled studies .", "", +73027, Randomized, 2156, 2166, "randomized", "", +73028, Placebo, 2167, 2174, "placebo", "", +73030, ObjectiveDescription, 2198, 2345, "Therefore , we investigated the efficacy of DPP - 4 inhibitor on endothelial function and glycemic metabolism compared with high - dose metformin .", "", +73029, Metformin, 2334, 2343, "metformin", "", +73033, Multicenter, 2364, 2375, "multicenter", "", +73034, OpenLabel, 2378, 2392, "open - labeled", "", +73035, Prospective, 2395, 2406, "prospective", "", +73036, Randomized, 2409, 2419, "randomized", "", +73037, Parallel, 2422, 2438, "parallel - group", "", +73038, Type2Diabetes, 2472, 2487, "type 2 diabetes", "", +73039, Metformin, 2512, 2521, "metformin", "", +73040, DoseValue, 2524, 2544, "500 - 750   mg / day", "", +73041, BioAndMedicalUnit, 2536, 2544, "mg / day", "", +73042, Randomized, 2565, 2573, "randomly", "", +73043, Vildagliptin, 2588, 2600, "vildagliptin", "", +73046, Vildagliptin, 2642, 2647, "Vilda", "", +73070, DoseDescription, 2655, 2666, "double dose", "", +73044, Metformin, 2670, 2679, "metformin", "", +73045, Metformin, 2693, 2696, "Met", "", +73047, Duration, 2703, 2713, "12   weeks", "", +73057, EndPointDescription, 2716, 2740, "Flow - mediated dilation", "", +73058, EndPointDescription, 2743, 2746, "FMD", "", +73048, NumberPatientsCT, 2907, 2921, "Ninety - seven", "", +73049, AvgAge, 2938, 2944, "58 . 7", "", +73050, Year, 2958, 2963, "years", "", +73051, BMI, 2966, 2981, "body mass index", "", +73052, Kg_per_squareMeter, 3003, 3010, "kg / m2", "", +73053, HbA1c, 3013, 3018, "HbA1c", "", +73054, BaseLineValue, 3021, 3026, "7 . 3", "", +73162, SdDevBL, 3031, 3036, "0 . 5", "", +73055, Percentage, 3037, 3038, "%", "", +73059, EndPointDescription, 3041, 3044, "FMD", "", +73061, BaseLineValue, 3047, 3052, "5 . 8", "", +73165, SdDevBL, 3057, 3062, "2 . 6", "", +73056, Percentage, 3063, 3064, "%", "", +73133, TimePoint, 3200, 3208, "baseline", "", +73062, TimePoint, 3233, 3243, "12   weeks", "", +73063, HbA1c, 3246, 3251, "HbA1c", "", +73064, Vildagliptin, 3286, 3291, "Vilda", "", +73068, Metformin, 3321, 3324, "Met", "", +73071, ChangeValue, 3333, 3342, "-  0 . 80", "", +73190, SdDevChangeValue, 3347, 3353, "0 . 38", "", +73075, Percentage, 3354, 3355, "%", "", +73072, ChangeValue, 3361, 3370, "-  0 . 40", "", +73191, SdDevChangeValue, 3375, 3381, "0 . 47", "", +73076, Percentage, 3382, 3383, "%", "", +73079, PvalueDiff, 3401, 3413, "p  <  0 . 01", "", +73060, EndPointDescription, 3469, 3472, "FMD", "", +73073, ChangeValue, 3475, 3484, "-  0 . 51", "", +73176, ConfIntervalChangeValue, 3485, 3504, "[-  1 . 08 - 0 . 06", "", +73077, Percentage, 3507, 3508, "%", "", +73074, ChangeValue, 3514, 3523, "-  0 . 58", "", +73179, ConfIntervalChangeValue, 3524, 3543, "[-  1 . 20 - 0 . 04", "", +73078, Percentage, 3546, 3547, "%", "", +73081, EndPointDescription, 3565, 3607, "apolipoprotein B / apolipoprotein A1 ratio", "", +73065, Vildagliptin, 3641, 3646, "Vilda", "", +73082, TimePoint, 3667, 3675, "baseline", "", +73083, BaseLineValue, 3678, 3684, "0 . 66", "", +73084, ResultMeasuredValue, 3687, 3693, "0 . 62", "", +73085, PValueChangeValue, 3696, 3708, "p  <  0 . 01", "", +73086, ChangeValue, 3778, 3787, "-  0 . 04", "", +73088, ChangeValue, 3793, 3799, "0 . 00", "", +73090, PvalueDiff, 3802, 3814, "p  =  0 . 27", "", +73096, EndPointDescription, 3819, 3837, "Adiponectin levels", "", +73066, Vildagliptin, 3874, 3879, "Vilda", "", +73098, Metformin, 3909, 3912, "Met", "", +73103, ChangeValue, 3921, 3927, "0 . 75", "", +73118, ConcentrationUnit, 3928, 3937, " μ g / mL", "", +73105, ChangeValue, 3943, 3949, "0 . 01", "", +73116, ConcentrationUnit, 3950, 3959, " μ g / mL", "", +73080, PvalueDiff, 3962, 3974, "p  <  0 . 01", "", +73067, Vildagliptin, 4053, 4065, "vildagliptin", "", +73069, Metformin, 4070, 4079, "metformin", "", +73125, Type2Diabetes, 4203, 4218, "type 2 diabetes", "", +73127, Precondition, 4219, 4251, "without advanced atherosclerosis", "", +73129, PMID, 4322, 4330, "29017497", "", diff --git a/data/dm2 29017497_akramersunderbrink.n-triples b/data/dm2 29017497_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29017497_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29017497_export.csv b/data/dm2 29017497_export.csv new file mode 100644 index 0000000..8d6c7e8 --- /dev/null +++ b/data/dm2 29017497_export.csv @@ -0,0 +1,962 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +390, 1, 1, 1, 0, 10, 0, 10, "Cardiovasc" +390, 1, 2, 2, 11, 19, 11, 19, "Diabetol" +390, 1, 3, 3, 20, 21, 20, 21, "." +390, 2, 1, 4, 0, 4, 22, 26, "2017" +390, 2, 2, 5, 5, 8, 27, 30, "Oct" +390, 2, 3, 6, 9, 11, 31, 33, "10" +390, 2, 4, 7, 12, 13, 34, 35, ";" +390, 2, 5, 8, 14, 16, 36, 38, "16" +390, 2, 6, 9, 17, 18, 39, 40, "(" +390, 2, 7, 10, 19, 20, 41, 42, "1" +390, 2, 8, 11, 21, 22, 43, 44, ")" +390, 2, 9, 12, 23, 24, 45, 46, ":" +390, 2, 10, 13, 25, 28, 47, 50, "125" +390, 2, 11, 14, 29, 30, 51, 52, "." +390, 2, 12, 15, 31, 34, 53, 56, "doi" +390, 2, 13, 16, 35, 36, 57, 58, ":" +390, 2, 14, 17, 37, 39, 59, 61, "10" +390, 2, 15, 18, 40, 41, 62, 63, "." +390, 2, 16, 19, 42, 46, 64, 68, "1186" +390, 2, 17, 20, 47, 48, 69, 70, "/" +390, 2, 18, 21, 49, 55, 71, 77, "s12933" +390, 2, 19, 22, 56, 57, 78, 79, "-" +390, 2, 20, 23, 58, 61, 80, 83, "017" +390, 2, 21, 24, 62, 63, 84, 85, "-" +390, 2, 22, 25, 64, 68, 86, 90, "0607" +390, 2, 23, 26, 69, 70, 91, 92, "-" +390, 2, 24, 27, 71, 72, 93, 94, "6" +390, 2, 25, 28, 73, 74, 95, 96, "." +390, 3, 1, 29, 0, 3, 97, 100, "The" +390, 3, 2, 30, 4, 11, 101, 108, "effects" +390, 3, 3, 31, 12, 14, 109, 111, "of" +390, 3, 4, 32, 15, 27, 112, 124, "vildagliptin" +390, 3, 5, 33, 28, 36, 125, 133, "compared" +390, 3, 6, 34, 37, 41, 134, 138, "with" +390, 3, 7, 35, 42, 51, 139, 148, "metformin" +390, 3, 8, 36, 52, 54, 149, 151, "on" +390, 3, 9, 37, 55, 63, 152, 160, "vascular" +390, 3, 10, 38, 64, 75, 161, 172, "endothelial" +390, 3, 11, 39, 76, 84, 173, 181, "function" +390, 3, 12, 40, 85, 88, 182, 185, "and" +390, 3, 13, 41, 89, 98, 186, 195, "metabolic" +390, 3, 14, 42, 99, 109, 196, 206, "parameters" +390, 3, 15, 43, 110, 111, 207, 208, ":" +390, 3, 16, 44, 112, 113, 209, 210, "a" +390, 3, 17, 45, 114, 124, 211, 221, "randomized" +390, 3, 18, 46, 125, 126, 222, 223, "," +390, 3, 19, 47, 127, 137, 224, 234, "controlled" +390, 3, 20, 48, 138, 143, 235, 240, "trial" +390, 3, 21, 49, 144, 145, 241, 242, "(" +390, 3, 22, 50, 146, 153, 243, 250, "Sapporo" +390, 3, 23, 51, 154, 160, 251, 257, "Athero" +390, 3, 24, 52, 161, 162, 258, 259, "-" +390, 3, 25, 53, 163, 171, 260, 268, "Incretin" +390, 3, 26, 54, 172, 177, 269, 274, "Study" +390, 3, 27, 55, 178, 179, 275, 276, "3" +390, 3, 28, 56, 180, 181, 277, 278, ")" +390, 3, 29, 57, 182, 183, 279, 280, "." +390, 4, 1, 58, 0, 5, 281, 286, "Kitao" +390, 4, 2, 59, 6, 7, 287, 288, "N" +390, 4, 3, 60, 8, 9, 289, 290, "(" +390, 4, 4, 61, 10, 11, 291, 292, "1" +390, 4, 5, 62, 12, 13, 293, 294, ")" +390, 4, 6, 63, 14, 15, 295, 296, "," +390, 4, 7, 64, 16, 23, 297, 304, "Miyoshi" +390, 4, 8, 65, 24, 25, 305, 306, "H" +390, 4, 9, 66, 26, 27, 307, 308, "(" +390, 4, 10, 67, 28, 29, 309, 310, "2" +390, 4, 11, 68, 30, 31, 311, 312, ")" +390, 4, 12, 69, 32, 33, 313, 314, "," +390, 4, 13, 70, 34, 42, 315, 323, "Furumoto" +390, 4, 14, 71, 43, 44, 324, 325, "T" +390, 4, 15, 72, 45, 46, 326, 327, "(" +390, 4, 16, 73, 47, 48, 328, 329, "3" +390, 4, 17, 74, 49, 50, 330, 331, ")" +390, 4, 18, 75, 51, 52, 332, 333, "(" +390, 4, 19, 76, 53, 54, 334, 335, "4" +390, 4, 20, 77, 55, 56, 336, 337, ")" +390, 4, 21, 78, 57, 58, 338, 339, "," +390, 4, 22, 79, 59, 62, 340, 343, "Ono" +390, 4, 23, 80, 63, 64, 344, 345, "K" +390, 4, 24, 81, 65, 66, 346, 347, "(" +390, 4, 25, 82, 67, 68, 348, 349, "5" +390, 4, 26, 83, 69, 70, 350, 351, ")" +390, 4, 27, 84, 71, 72, 352, 353, "," +390, 4, 28, 85, 73, 79, 354, 360, "Nomoto" +390, 4, 29, 86, 80, 81, 361, 362, "H" +390, 4, 30, 87, 82, 83, 363, 364, "(" +390, 4, 31, 88, 84, 85, 365, 366, "1" +390, 4, 32, 89, 86, 87, 367, 368, ")" +390, 4, 33, 90, 88, 89, 369, 370, "," +390, 4, 34, 91, 90, 94, 371, 375, "Miya" +390, 4, 35, 92, 95, 96, 376, 377, "A" +390, 4, 36, 93, 97, 98, 378, 379, "(" +390, 4, 37, 94, 99, 100, 380, 381, "1" +390, 4, 38, 95, 101, 102, 382, 383, ")" +390, 4, 39, 96, 103, 104, 384, 385, "," +390, 4, 40, 97, 105, 113, 386, 394, "Yamamoto" +390, 4, 41, 98, 114, 115, 395, 396, "C" +390, 4, 42, 99, 116, 117, 397, 398, "(" +390, 4, 43, 100, 118, 119, 399, 400, "1" +390, 4, 44, 101, 120, 121, 401, 402, ")" +390, 4, 45, 102, 122, 123, 403, 404, "," +390, 4, 46, 103, 124, 129, 405, 410, "Inoue" +390, 4, 47, 104, 130, 131, 411, 412, "A" +390, 4, 48, 105, 132, 133, 413, 414, "(" +390, 4, 49, 106, 134, 135, 415, 416, "6" +390, 4, 50, 107, 136, 137, 417, 418, ")" +390, 4, 51, 108, 138, 139, 419, 420, "," +390, 4, 52, 109, 140, 148, 421, 429, "Tsuchida" +390, 4, 53, 110, 149, 150, 430, 431, "K" +390, 4, 54, 111, 151, 152, 432, 433, "(" +390, 4, 55, 112, 153, 154, 434, 435, "7" +390, 4, 56, 113, 155, 156, 436, 437, ")" +390, 4, 57, 114, 157, 158, 438, 439, "," +390, 4, 58, 115, 159, 164, 440, 445, "Manda" +390, 4, 59, 116, 165, 166, 446, 447, "N" +390, 4, 60, 117, 167, 168, 448, 449, "(" +390, 4, 61, 118, 169, 170, 450, 451, "7" +390, 4, 62, 119, 171, 172, 452, 453, ")" +390, 4, 63, 120, 173, 174, 454, 455, "," +390, 4, 64, 121, 175, 183, 456, 464, "Kurihara" +390, 4, 65, 122, 184, 185, 465, 466, "Y" +390, 4, 66, 123, 186, 187, 467, 468, "(" +390, 4, 67, 124, 188, 189, 469, 470, "8" +390, 4, 68, 125, 190, 191, 471, 472, ")" +390, 4, 69, 126, 192, 193, 473, 474, "," +390, 4, 70, 127, 194, 198, 475, 479, "Aoki" +390, 4, 71, 128, 199, 200, 480, 481, "S" +390, 4, 72, 129, 201, 202, 482, 483, "(" +390, 4, 73, 130, 203, 204, 484, 485, "9" +390, 4, 74, 131, 205, 206, 486, 487, ")" +390, 4, 75, 132, 207, 208, 488, 489, "," +390, 4, 76, 133, 209, 217, 490, 498, "Nakamura" +390, 4, 77, 134, 218, 219, 499, 500, "A" +390, 4, 78, 135, 220, 221, 501, 502, "(" +390, 4, 79, 136, 222, 223, 503, 504, "1" +390, 4, 80, 137, 224, 225, 505, 506, ")" +390, 4, 81, 138, 226, 227, 507, 508, "," +390, 4, 82, 139, 228, 234, 509, 515, "Atsumi" +390, 4, 83, 140, 235, 236, 516, 517, "T" +390, 4, 84, 141, 237, 238, 518, 519, "(" +390, 4, 85, 142, 239, 240, 520, 521, "1" +390, 4, 86, 143, 241, 242, 522, 523, ")" +390, 4, 87, 144, 243, 244, 524, 525, ";" +390, 4, 88, 145, 245, 249, 526, 530, "SAIS" +390, 4, 89, 146, 250, 255, 531, 536, "Study" +390, 4, 90, 147, 256, 261, 537, 542, "Group" +390, 4, 91, 148, 262, 263, 543, 544, "." +390, 5, 1, 149, 0, 13, 545, 558, "Collaborators" +390, 5, 2, 150, 14, 15, 559, 560, ":" +390, 5, 3, 151, 16, 23, 561, 568, "Edagawa" +390, 5, 4, 152, 24, 25, 569, 570, "Y" +390, 5, 5, 153, 26, 27, 571, 572, "," +390, 5, 6, 154, 28, 32, 573, 577, "Oita" +390, 5, 7, 155, 33, 34, 578, 579, "M" +390, 5, 8, 156, 35, 36, 580, 581, "," +390, 5, 9, 157, 37, 42, 582, 587, "Kondo" +390, 5, 10, 158, 43, 44, 588, 589, "A" +390, 5, 11, 159, 45, 46, 590, 591, "," +390, 5, 12, 160, 47, 56, 592, 601, "Takahashi" +390, 5, 13, 161, 57, 58, 602, 603, "K" +390, 5, 14, 162, 59, 60, 604, 605, "," +390, 5, 15, 163, 61, 69, 606, 614, "Sugawara" +390, 5, 16, 164, 70, 71, 615, 616, "H" +390, 5, 17, 165, 72, 73, 617, 618, "," +390, 5, 18, 166, 74, 77, 619, 622, "Dan" +390, 5, 19, 167, 78, 79, 623, 624, "-" +390, 5, 20, 168, 80, 85, 625, 630, "Noura" +390, 5, 21, 169, 86, 87, 631, 632, "M" +390, 5, 22, 170, 88, 89, 633, 634, "," +390, 5, 23, 171, 90, 96, 635, 641, "Takano" +390, 5, 24, 172, 97, 98, 642, 643, "Y" +390, 5, 25, 173, 99, 100, 644, 645, "," +390, 5, 26, 174, 101, 106, 646, 651, "Kitao" +390, 5, 27, 175, 107, 108, 652, 653, "N" +390, 5, 28, 176, 109, 110, 654, 655, "," +390, 5, 29, 177, 111, 121, 656, 666, "Koyanagawa" +390, 5, 30, 178, 122, 123, 667, 668, "N" +390, 5, 31, 179, 124, 125, 669, 670, "," +390, 5, 32, 180, 126, 130, 671, 675, "Miya" +390, 5, 33, 181, 131, 132, 676, 677, "A" +390, 5, 34, 182, 133, 134, 678, 679, "," +390, 5, 35, 183, 135, 143, 680, 688, "Yamamoto" +390, 5, 36, 184, 144, 145, 689, 690, "K" +390, 5, 37, 185, 146, 147, 691, 692, "," +390, 5, 38, 186, 148, 156, 693, 701, "Yamamoto" +390, 5, 39, 187, 157, 158, 702, 703, "C" +390, 5, 40, 188, 159, 160, 704, 705, "," +390, 5, 41, 189, 161, 167, 706, 712, "Nomoto" +390, 5, 42, 190, 168, 169, 713, 714, "H" +390, 5, 43, 191, 170, 171, 715, 716, "," +390, 5, 44, 192, 172, 178, 717, 723, "Kameda" +390, 5, 45, 193, 179, 180, 724, 725, "Y" +390, 5, 46, 194, 181, 182, 726, 727, "," +390, 5, 47, 195, 183, 186, 728, 731, "Cho" +390, 5, 48, 196, 187, 189, 732, 734, "KY" +390, 5, 49, 197, 190, 191, 735, 736, "," +390, 5, 50, 198, 192, 200, 737, 745, "Nakamura" +390, 5, 51, 199, 201, 202, 746, 747, "A" +390, 5, 52, 200, 203, 204, 748, 749, "," +390, 5, 53, 201, 205, 212, 750, 757, "Miyoshi" +390, 5, 54, 202, 213, 214, 758, 759, "H" +390, 5, 55, 203, 215, 216, 760, 761, "," +390, 5, 56, 204, 217, 223, 762, 768, "Atsumi" +390, 5, 57, 205, 224, 225, 769, 770, "T" +390, 5, 58, 206, 226, 227, 771, 772, "," +390, 5, 59, 207, 228, 236, 773, 781, "Watanabe" +390, 5, 60, 208, 237, 238, 782, 783, "T" +390, 5, 61, 209, 239, 240, 784, 785, "," +390, 5, 62, 210, 241, 250, 786, 795, "Takahashi" +390, 5, 63, 211, 251, 252, 796, 797, "K" +390, 5, 64, 212, 253, 254, 798, 799, "," +390, 5, 65, 213, 255, 265, 800, 810, "Koyanagawa" +390, 5, 66, 214, 266, 267, 811, 812, "N" +390, 5, 67, 215, 268, 269, 813, 814, "," +390, 5, 68, 216, 270, 274, 815, 819, "Kito" +390, 5, 69, 217, 275, 276, 820, 821, "K" +390, 5, 70, 218, 277, 278, 822, 823, "," +390, 5, 71, 219, 279, 287, 824, 832, "Yamamoto" +390, 5, 72, 220, 288, 289, 833, 834, "C" +390, 5, 73, 221, 290, 291, 835, 836, "," +390, 5, 74, 222, 292, 296, 837, 841, "Endo" +390, 5, 75, 223, 297, 298, 842, 843, "M" +390, 5, 76, 224, 299, 300, 844, 845, "," +390, 5, 77, 225, 301, 309, 846, 854, "Takeuchi" +390, 5, 78, 226, 310, 311, 855, 856, "J" +390, 5, 79, 227, 312, 313, 857, 858, "," +390, 5, 80, 228, 314, 319, 859, 864, "Nagai" +390, 5, 81, 229, 320, 321, 865, 866, "S" +390, 5, 82, 230, 322, 323, 867, 868, "," +390, 5, 83, 231, 324, 330, 869, 875, "Masuda" +390, 5, 84, 232, 331, 332, 876, 877, "H" +390, 5, 85, 233, 333, 334, 878, 879, "," +390, 5, 86, 234, 335, 340, 880, 885, "Inoue" +390, 5, 87, 235, 341, 342, 886, 887, "A" +390, 5, 88, 236, 343, 344, 888, 889, "," +390, 5, 89, 237, 345, 348, 890, 893, "Ono" +390, 5, 90, 238, 349, 350, 894, 895, "Y" +390, 5, 91, 239, 351, 352, 896, 897, "," +390, 5, 92, 240, 353, 361, 898, 906, "Tsuchida" +390, 5, 93, 241, 362, 363, 907, 908, "K" +390, 5, 94, 242, 364, 365, 909, 910, "," +390, 5, 95, 243, 366, 371, 911, 916, "Manda" +390, 5, 96, 244, 372, 373, 917, 918, "N" +390, 5, 97, 245, 374, 375, 919, 920, "," +390, 5, 98, 246, 376, 384, 921, 929, "Kurihara" +390, 5, 99, 247, 385, 386, 930, 931, "Y" +390, 5, 100, 248, 387, 388, 932, 933, "," +390, 5, 101, 249, 389, 393, 934, 938, "Aoki" +390, 5, 102, 250, 394, 395, 939, 940, "S" +390, 5, 103, 251, 396, 397, 941, 942, "." +390, 5, 104, 252, 398, 404, 943, 949, "Author" +390, 5, 105, 253, 405, 416, 950, 961, "information" +390, 5, 106, 254, 417, 418, 962, 963, ":" +390, 5, 107, 255, 419, 420, 964, 965, "(" +390, 5, 108, 256, 421, 422, 966, 967, "1" +390, 5, 109, 257, 423, 424, 968, 969, ")" +390, 5, 110, 258, 425, 433, 970, 978, "Division" +390, 5, 111, 259, 434, 436, 979, 981, "of" +390, 5, 112, 260, 437, 449, 982, 994, "Rheumatology" +390, 5, 113, 261, 450, 451, 995, 996, "," +390, 5, 114, 262, 452, 465, 997, 1010, "Endocrinology" +390, 5, 115, 263, 466, 469, 1011, 1014, "and" +390, 5, 116, 264, 470, 480, 1015, 1025, "Nephrology" +390, 5, 117, 265, 481, 482, 1026, 1027, "," +390, 5, 118, 266, 483, 491, 1028, 1036, "Hokkaido" +390, 5, 119, 267, 492, 502, 1037, 1047, "University" +390, 5, 120, 268, 503, 511, 1048, 1056, "Graduate" +390, 5, 121, 269, 512, 518, 1057, 1063, "School" +390, 5, 122, 270, 519, 521, 1064, 1066, "of" +390, 5, 123, 271, 522, 530, 1067, 1075, "Medicine" +390, 5, 124, 272, 531, 532, 1076, 1077, "," +390, 5, 125, 273, 533, 537, 1078, 1082, "Kita" +390, 5, 126, 274, 538, 539, 1083, 1084, "-" +390, 5, 127, 275, 540, 542, 1085, 1087, "15" +390, 5, 128, 276, 543, 548, 1088, 1093, "Nishi" +390, 5, 129, 277, 549, 550, 1094, 1095, "-" +390, 5, 130, 278, 551, 552, 1096, 1097, "7" +390, 5, 131, 279, 553, 554, 1098, 1099, "," +390, 5, 132, 280, 555, 559, 1100, 1104, "Kita" +390, 5, 133, 281, 560, 561, 1105, 1106, "-" +390, 5, 134, 282, 562, 564, 1107, 1109, "ku" +390, 5, 135, 283, 565, 566, 1110, 1111, "," +390, 5, 136, 284, 567, 574, 1112, 1119, "Sapporo" +390, 5, 137, 285, 575, 576, 1120, 1121, "," +390, 5, 138, 286, 577, 585, 1122, 1130, "Hokkaido" +390, 5, 139, 287, 586, 587, 1131, 1132, "," +390, 5, 140, 288, 588, 591, 1133, 1136, "060" +390, 5, 141, 289, 592, 593, 1137, 1138, "-" +390, 5, 142, 290, 594, 598, 1139, 1143, "8638" +390, 5, 143, 291, 599, 600, 1144, 1145, "," +390, 5, 144, 292, 601, 606, 1146, 1151, "Japan" +390, 5, 145, 293, 607, 608, 1152, 1153, "." +390, 6, 1, 294, 0, 1, 1154, 1155, "(" +390, 6, 2, 295, 2, 3, 1156, 1157, "2" +390, 6, 3, 296, 4, 5, 1158, 1159, ")" +390, 6, 4, 297, 6, 14, 1160, 1168, "Division" +390, 6, 5, 298, 15, 17, 1169, 1171, "of" +390, 6, 6, 299, 18, 30, 1172, 1184, "Rheumatology" +390, 6, 7, 300, 31, 32, 1185, 1186, "," +390, 6, 8, 301, 33, 46, 1187, 1200, "Endocrinology" +390, 6, 9, 302, 47, 50, 1201, 1204, "and" +390, 6, 10, 303, 51, 61, 1205, 1215, "Nephrology" +390, 6, 11, 304, 62, 63, 1216, 1217, "," +390, 6, 12, 305, 64, 72, 1218, 1226, "Hokkaido" +390, 6, 13, 306, 73, 83, 1227, 1237, "University" +390, 6, 14, 307, 84, 92, 1238, 1246, "Graduate" +390, 6, 15, 308, 93, 99, 1247, 1253, "School" +390, 6, 16, 309, 100, 102, 1254, 1256, "of" +390, 6, 17, 310, 103, 111, 1257, 1265, "Medicine" +390, 6, 18, 311, 112, 113, 1266, 1267, "," +390, 6, 19, 312, 114, 118, 1268, 1272, "Kita" +390, 6, 20, 313, 119, 120, 1273, 1274, "-" +390, 6, 21, 314, 121, 123, 1275, 1277, "15" +390, 6, 22, 315, 124, 129, 1278, 1283, "Nishi" +390, 6, 23, 316, 130, 131, 1284, 1285, "-" +390, 6, 24, 317, 132, 133, 1286, 1287, "7" +390, 6, 25, 318, 134, 135, 1288, 1289, "," +390, 6, 26, 319, 136, 140, 1290, 1294, "Kita" +390, 6, 27, 320, 141, 142, 1295, 1296, "-" +390, 6, 28, 321, 143, 145, 1297, 1299, "ku" +390, 6, 29, 322, 146, 147, 1300, 1301, "," +390, 6, 30, 323, 148, 155, 1302, 1309, "Sapporo" +390, 6, 31, 324, 156, 157, 1310, 1311, "," +390, 6, 32, 325, 158, 166, 1312, 1320, "Hokkaido" +390, 6, 33, 326, 167, 168, 1321, 1322, "," +390, 6, 34, 327, 169, 172, 1323, 1326, "060" +390, 6, 35, 328, 173, 174, 1327, 1328, "-" +390, 6, 36, 329, 175, 179, 1329, 1333, "8638" +390, 6, 37, 330, 180, 181, 1334, 1335, "," +390, 6, 38, 331, 182, 187, 1336, 1341, "Japan" +390, 6, 39, 332, 188, 189, 1342, 1343, "." +390, 7, 1, 333, 0, 8, 1344, 1352, "hmiyoshi" +390, 7, 2, 334, 9, 10, 1353, 1354, "@" +390, 7, 3, 335, 11, 14, 1355, 1358, "med" +390, 7, 4, 336, 15, 16, 1359, 1360, "." +390, 7, 5, 337, 17, 24, 1361, 1368, "hokudai" +390, 7, 6, 338, 25, 26, 1369, 1370, "." +390, 7, 7, 339, 27, 29, 1371, 1373, "ac" +390, 7, 8, 340, 30, 31, 1374, 1375, "." +390, 7, 9, 341, 32, 34, 1376, 1378, "jp" +390, 7, 10, 342, 35, 36, 1379, 1380, "." +390, 8, 1, 343, 0, 1, 1381, 1382, "(" +390, 8, 2, 344, 2, 3, 1383, 1384, "3" +390, 8, 3, 345, 4, 5, 1385, 1386, ")" +390, 8, 4, 346, 6, 16, 1387, 1397, "Department" +390, 8, 5, 347, 17, 19, 1398, 1400, "of" +390, 8, 6, 348, 20, 34, 1401, 1415, "Cardiovascular" +390, 8, 7, 349, 35, 43, 1416, 1424, "Medicine" +390, 8, 8, 350, 44, 45, 1425, 1426, "," +390, 8, 9, 351, 46, 49, 1427, 1430, "NTT" +390, 8, 10, 352, 50, 54, 1431, 1435, "East" +390, 8, 11, 353, 55, 60, 1436, 1441, "Japan" +390, 8, 12, 354, 61, 68, 1442, 1449, "Sapporo" +390, 8, 13, 355, 69, 77, 1450, 1458, "Hospital" +390, 8, 14, 356, 78, 79, 1459, 1460, "," +390, 8, 15, 357, 80, 87, 1461, 1468, "Sapporo" +390, 8, 16, 358, 88, 89, 1469, 1470, "," +390, 8, 17, 359, 90, 95, 1471, 1476, "Japan" +390, 8, 18, 360, 96, 97, 1477, 1478, "." +390, 9, 1, 361, 0, 1, 1479, 1480, "(" +390, 9, 2, 362, 2, 3, 1481, 1482, "4" +390, 9, 3, 363, 4, 5, 1483, 1484, ")" +390, 9, 4, 364, 6, 16, 1485, 1495, "Department" +390, 9, 5, 365, 17, 19, 1496, 1498, "of" +390, 9, 6, 366, 20, 34, 1499, 1513, "Cardiovascular" +390, 9, 7, 367, 35, 43, 1514, 1522, "Medicine" +390, 9, 8, 368, 44, 45, 1523, 1524, "," +390, 9, 9, 369, 46, 54, 1525, 1533, "Hokkaido" +390, 9, 10, 370, 55, 65, 1534, 1544, "University" +390, 9, 11, 371, 66, 74, 1545, 1553, "Graduate" +390, 9, 12, 372, 75, 81, 1554, 1560, "School" +390, 9, 13, 373, 82, 84, 1561, 1563, "of" +390, 9, 14, 374, 85, 93, 1564, 1572, "Medicine" +390, 9, 15, 375, 94, 95, 1573, 1574, "," +390, 9, 16, 376, 96, 103, 1575, 1582, "Sapporo" +390, 9, 17, 377, 104, 105, 1583, 1584, "," +390, 9, 18, 378, 106, 111, 1585, 1590, "Japan" +390, 9, 19, 379, 112, 113, 1591, 1592, "." +390, 10, 1, 380, 0, 1, 1593, 1594, "(" +390, 10, 2, 381, 2, 3, 1595, 1596, "5" +390, 10, 3, 382, 4, 5, 1597, 1598, ")" +390, 10, 4, 383, 6, 14, 1599, 1607, "Clinical" +390, 10, 5, 384, 15, 23, 1608, 1616, "Research" +390, 10, 6, 385, 24, 27, 1617, 1620, "and" +390, 10, 7, 386, 28, 35, 1621, 1628, "Medical" +390, 10, 8, 387, 36, 46, 1629, 1639, "Innovation" +390, 10, 9, 388, 47, 53, 1640, 1646, "Center" +390, 10, 10, 389, 54, 55, 1647, 1648, "," +390, 10, 11, 390, 56, 64, 1649, 1657, "Hokkaido" +390, 10, 12, 391, 65, 75, 1658, 1668, "University" +390, 10, 13, 392, 76, 84, 1669, 1677, "Hospital" +390, 10, 14, 393, 85, 86, 1678, 1679, "," +390, 10, 15, 394, 87, 94, 1680, 1687, "Sapporo" +390, 10, 16, 395, 95, 96, 1688, 1689, "," +390, 10, 17, 396, 97, 102, 1690, 1695, "Japan" +390, 10, 18, 397, 103, 104, 1696, 1697, "." +390, 11, 1, 398, 0, 1, 1698, 1699, "(" +390, 11, 2, 399, 2, 3, 1700, 1701, "6" +390, 11, 3, 400, 4, 5, 1702, 1703, ")" +390, 11, 4, 401, 6, 11, 1704, 1709, "Japan" +390, 11, 5, 402, 12, 21, 1710, 1719, "Community" +390, 11, 6, 403, 22, 32, 1720, 1730, "Healthcare" +390, 11, 7, 404, 33, 36, 1731, 1734, "and" +390, 11, 8, 405, 37, 49, 1735, 1747, "Organization" +390, 11, 9, 406, 50, 58, 1748, 1756, "Hokkaido" +390, 11, 10, 407, 59, 67, 1757, 1765, "Hospital" +390, 11, 11, 408, 68, 69, 1766, 1767, "," +390, 11, 12, 409, 70, 77, 1768, 1775, "Sapporo" +390, 11, 13, 410, 78, 79, 1776, 1777, "," +390, 11, 14, 411, 80, 85, 1778, 1783, "Japan" +390, 11, 15, 412, 86, 87, 1784, 1785, "." +390, 12, 1, 413, 0, 1, 1786, 1787, "(" +390, 12, 2, 414, 2, 3, 1788, 1789, "7" +390, 12, 3, 415, 4, 5, 1790, 1791, ")" +390, 12, 4, 416, 6, 11, 1792, 1797, "Manda" +390, 12, 5, 417, 12, 20, 1798, 1806, "Memorial" +390, 12, 6, 418, 21, 29, 1807, 1815, "Hospital" +390, 12, 7, 419, 30, 31, 1816, 1817, "," +390, 12, 8, 420, 32, 39, 1818, 1825, "Sapporo" +390, 12, 9, 421, 40, 41, 1826, 1827, "," +390, 12, 10, 422, 42, 47, 1828, 1833, "Japan" +390, 12, 11, 423, 48, 49, 1834, 1835, "." +390, 13, 1, 424, 0, 1, 1836, 1837, "(" +390, 13, 2, 425, 2, 3, 1838, 1839, "8" +390, 13, 3, 426, 4, 5, 1840, 1841, ")" +390, 13, 4, 427, 6, 14, 1842, 1850, "Kurihara" +390, 13, 5, 428, 15, 21, 1851, 1857, "Clinic" +390, 13, 6, 429, 22, 23, 1858, 1859, "," +390, 13, 7, 430, 24, 31, 1860, 1867, "Sapporo" +390, 13, 8, 431, 32, 33, 1868, 1869, "," +390, 13, 9, 432, 34, 39, 1870, 1875, "Japan" +390, 13, 10, 433, 40, 41, 1876, 1877, "." +390, 14, 1, 434, 0, 1, 1878, 1879, "(" +390, 14, 2, 435, 2, 3, 1880, 1881, "9" +390, 14, 3, 436, 4, 5, 1882, 1883, ")" +390, 14, 4, 437, 6, 10, 1884, 1888, "Aoki" +390, 14, 5, 438, 11, 17, 1889, 1895, "Clinic" +390, 14, 6, 439, 18, 19, 1896, 1897, "," +390, 14, 7, 440, 20, 27, 1898, 1905, "Sapporo" +390, 14, 8, 441, 28, 29, 1906, 1907, "," +390, 14, 9, 442, 30, 35, 1908, 1913, "Japan" +390, 14, 10, 443, 36, 37, 1914, 1915, "." +390, 15, 1, 444, 0, 10, 1916, 1926, "BACKGROUND" +390, 15, 2, 445, 11, 12, 1927, 1928, ":" +390, 15, 3, 446, 13, 23, 1929, 1939, "Dipeptidyl" +390, 15, 4, 447, 24, 33, 1940, 1949, "peptidase" +390, 15, 5, 448, 34, 35, 1950, 1951, "-" +390, 15, 6, 449, 36, 37, 1952, 1953, "4" +390, 15, 7, 450, 38, 39, 1954, 1955, "(" +390, 15, 8, 451, 40, 43, 1956, 1959, "DPP" +390, 15, 9, 452, 44, 45, 1960, 1961, "-" +390, 15, 10, 453, 46, 47, 1962, 1963, "4" +390, 15, 11, 454, 48, 49, 1964, 1965, ")" +390, 15, 12, 455, 50, 60, 1966, 1976, "inhibitors" +390, 15, 13, 456, 61, 64, 1977, 1980, "may" +390, 15, 14, 457, 65, 69, 1981, 1985, "have" +390, 15, 15, 458, 70, 80, 1986, 1996, "protective" +390, 15, 16, 459, 81, 88, 1997, 2004, "effects" +390, 15, 17, 460, 89, 91, 2005, 2007, "in" +390, 15, 18, 461, 92, 95, 2008, 2011, "the" +390, 15, 19, 462, 96, 101, 2012, 2017, "early" +390, 15, 20, 463, 102, 107, 2018, 2023, "stage" +390, 15, 21, 464, 108, 110, 2024, 2026, "of" +390, 15, 22, 465, 111, 126, 2027, 2042, "atherosclerosis" +390, 15, 23, 466, 127, 129, 2043, 2045, "in" +390, 15, 24, 467, 130, 138, 2046, 2054, "patients" +390, 15, 25, 468, 139, 143, 2055, 2059, "with" +390, 15, 26, 469, 144, 148, 2060, 2064, "type" +390, 15, 27, 470, 149, 150, 2065, 2066, "2" +390, 15, 28, 471, 151, 159, 2067, 2075, "diabetes" +390, 15, 29, 472, 160, 161, 2076, 2077, "," +390, 15, 30, 473, 162, 170, 2078, 2086, "although" +390, 15, 31, 474, 171, 178, 2087, 2094, "similar" +390, 15, 32, 475, 179, 186, 2095, 2102, "effects" +390, 15, 33, 476, 187, 189, 2103, 2105, "in" +390, 15, 34, 477, 190, 198, 2106, 2114, "advanced" +390, 15, 35, 478, 199, 214, 2115, 2130, "atherosclerosis" +390, 15, 36, 479, 215, 219, 2131, 2135, "were" +390, 15, 37, 480, 220, 223, 2136, 2139, "not" +390, 15, 38, 481, 224, 229, 2140, 2145, "shown" +390, 15, 39, 482, 230, 232, 2146, 2148, "in" +390, 15, 40, 483, 233, 239, 2149, 2155, "recent" +390, 15, 41, 484, 240, 250, 2156, 2166, "randomized" +390, 15, 42, 485, 251, 258, 2167, 2174, "placebo" +390, 15, 43, 486, 259, 260, 2175, 2176, "-" +390, 15, 44, 487, 261, 271, 2177, 2187, "controlled" +390, 15, 45, 488, 272, 279, 2188, 2195, "studies" +390, 15, 46, 489, 280, 281, 2196, 2197, "." +390, 16, 1, 490, 0, 9, 2198, 2207, "Therefore" +390, 16, 2, 491, 10, 11, 2208, 2209, "," +390, 16, 3, 492, 12, 14, 2210, 2212, "we" +390, 16, 4, 493, 15, 27, 2213, 2225, "investigated" +390, 16, 5, 494, 28, 31, 2226, 2229, "the" +390, 16, 6, 495, 32, 40, 2230, 2238, "efficacy" +390, 16, 7, 496, 41, 43, 2239, 2241, "of" +390, 16, 8, 497, 44, 47, 2242, 2245, "DPP" +390, 16, 9, 498, 48, 49, 2246, 2247, "-" +390, 16, 10, 499, 50, 51, 2248, 2249, "4" +390, 16, 11, 500, 52, 61, 2250, 2259, "inhibitor" +390, 16, 12, 501, 62, 64, 2260, 2262, "on" +390, 16, 13, 502, 65, 76, 2263, 2274, "endothelial" +390, 16, 14, 503, 77, 85, 2275, 2283, "function" +390, 16, 15, 504, 86, 89, 2284, 2287, "and" +390, 16, 16, 505, 90, 98, 2288, 2296, "glycemic" +390, 16, 17, 506, 99, 109, 2297, 2307, "metabolism" +390, 16, 18, 507, 110, 118, 2308, 2316, "compared" +390, 16, 19, 508, 119, 123, 2317, 2321, "with" +390, 16, 20, 509, 124, 128, 2322, 2326, "high" +390, 16, 21, 510, 129, 130, 2327, 2328, "-" +390, 16, 22, 511, 131, 135, 2329, 2333, "dose" +390, 16, 23, 512, 136, 145, 2334, 2343, "metformin" +390, 16, 24, 513, 146, 147, 2344, 2345, "." +390, 17, 1, 514, 0, 7, 2346, 2353, "METHODS" +390, 17, 2, 515, 8, 9, 2354, 2355, ":" +390, 17, 3, 516, 10, 12, 2356, 2358, "In" +390, 17, 4, 517, 13, 17, 2359, 2363, "this" +390, 17, 5, 518, 18, 29, 2364, 2375, "multicenter" +390, 17, 6, 519, 30, 31, 2376, 2377, "," +390, 17, 7, 520, 32, 36, 2378, 2382, "open" +390, 17, 8, 521, 37, 38, 2383, 2384, "-" +390, 17, 9, 522, 39, 46, 2385, 2392, "labeled" +390, 17, 10, 523, 47, 48, 2393, 2394, "," +390, 17, 11, 524, 49, 60, 2395, 2406, "prospective" +390, 17, 12, 525, 61, 62, 2407, 2408, "," +390, 17, 13, 526, 63, 73, 2409, 2419, "randomized" +390, 17, 14, 527, 74, 75, 2420, 2421, "," +390, 17, 15, 528, 76, 84, 2422, 2430, "parallel" +390, 17, 16, 529, 85, 86, 2431, 2432, "-" +390, 17, 17, 530, 87, 92, 2433, 2438, "group" +390, 17, 18, 531, 93, 103, 2439, 2449, "comparison" +390, 17, 19, 532, 104, 109, 2450, 2455, "study" +390, 17, 20, 533, 110, 111, 2456, 2457, "," +390, 17, 21, 534, 112, 120, 2458, 2466, "patients" +390, 17, 22, 535, 121, 125, 2467, 2471, "with" +390, 17, 23, 536, 126, 130, 2472, 2476, "type" +390, 17, 24, 537, 131, 132, 2477, 2478, "2" +390, 17, 25, 538, 133, 141, 2479, 2487, "diabetes" +390, 17, 26, 539, 142, 149, 2488, 2495, "treated" +390, 17, 27, 540, 150, 154, 2496, 2500, "with" +390, 17, 28, 541, 155, 158, 2501, 2504, "low" +390, 17, 29, 542, 159, 160, 2505, 2506, "-" +390, 17, 30, 543, 161, 165, 2507, 2511, "dose" +390, 17, 31, 544, 166, 175, 2512, 2521, "metformin" +390, 17, 32, 545, 176, 177, 2522, 2523, "(" +390, 17, 33, 546, 178, 181, 2524, 2527, "500" +390, 17, 34, 547, 182, 183, 2528, 2529, "-" +390, 17, 35, 548, 184, 187, 2530, 2533, "750" +390, 17, 36, 549, 188, 189, 2534, 2535, " " +390, 17, 37, 550, 190, 192, 2536, 2538, "mg" +390, 17, 38, 551, 193, 194, 2539, 2540, "/" +390, 17, 39, 552, 195, 198, 2541, 2544, "day" +390, 17, 40, 553, 199, 200, 2545, 2546, ")" +390, 17, 41, 554, 201, 205, 2547, 2551, "were" +390, 17, 42, 555, 206, 214, 2552, 2560, "enrolled" +390, 17, 43, 556, 215, 218, 2561, 2564, "and" +390, 17, 44, 557, 219, 227, 2565, 2573, "randomly" +390, 17, 45, 558, 228, 236, 2574, 2582, "assigned" +390, 17, 46, 559, 237, 239, 2583, 2585, "to" +390, 17, 47, 560, 240, 241, 2586, 2587, "a" +390, 17, 48, 561, 242, 254, 2588, 2600, "vildagliptin" +390, 17, 49, 562, 255, 256, 2601, 2602, "," +390, 17, 50, 563, 257, 258, 2603, 2604, "a" +390, 17, 51, 564, 259, 262, 2605, 2608, "DPP" +390, 17, 52, 565, 263, 264, 2609, 2610, "-" +390, 17, 53, 566, 265, 266, 2611, 2612, "4" +390, 17, 54, 567, 267, 276, 2613, 2622, "inhibitor" +390, 17, 55, 568, 277, 278, 2623, 2624, "," +390, 17, 56, 569, 279, 282, 2625, 2628, "add" +390, 17, 57, 570, 283, 284, 2629, 2630, "-" +390, 17, 58, 571, 285, 287, 2631, 2633, "on" +390, 17, 59, 572, 288, 293, 2634, 2639, "group" +390, 17, 60, 573, 294, 295, 2640, 2641, "(" +390, 17, 61, 574, 296, 301, 2642, 2647, "Vilda" +390, 17, 62, 575, 302, 303, 2648, 2649, ")" +390, 17, 63, 576, 304, 306, 2650, 2652, "or" +390, 17, 64, 577, 307, 308, 2653, 2654, "a" +390, 17, 65, 578, 309, 315, 2655, 2661, "double" +390, 17, 66, 579, 316, 320, 2662, 2666, "dose" +390, 17, 67, 580, 321, 323, 2667, 2669, "of" +390, 17, 68, 581, 324, 333, 2670, 2679, "metformin" +390, 17, 69, 582, 334, 339, 2680, 2685, "group" +390, 17, 70, 583, 340, 341, 2686, 2687, "(" +390, 17, 71, 584, 342, 346, 2688, 2692, "high" +390, 17, 72, 585, 347, 350, 2693, 2696, "Met" +390, 17, 73, 586, 351, 352, 2697, 2698, ")" +390, 17, 74, 587, 353, 356, 2699, 2702, "for" +390, 17, 75, 588, 357, 359, 2703, 2705, "12" +390, 17, 76, 589, 360, 361, 2706, 2707, " " +390, 17, 77, 590, 362, 367, 2708, 2713, "weeks" +390, 17, 78, 591, 368, 369, 2714, 2715, "." +390, 18, 1, 592, 0, 4, 2716, 2720, "Flow" +390, 18, 2, 593, 5, 6, 2721, 2722, "-" +390, 18, 3, 594, 7, 15, 2723, 2731, "mediated" +390, 18, 4, 595, 16, 24, 2732, 2740, "dilation" +390, 18, 5, 596, 25, 26, 2741, 2742, "(" +390, 18, 6, 597, 27, 30, 2743, 2746, "FMD" +390, 18, 7, 598, 31, 32, 2747, 2748, ")" +390, 18, 8, 599, 33, 36, 2749, 2752, "and" +390, 18, 9, 600, 37, 42, 2753, 2758, "serum" +390, 18, 10, 601, 43, 52, 2759, 2768, "metabolic" +390, 18, 11, 602, 53, 60, 2769, 2776, "markers" +390, 18, 12, 603, 61, 65, 2777, 2781, "were" +390, 18, 13, 604, 66, 74, 2782, 2790, "assessed" +390, 18, 14, 605, 75, 81, 2791, 2797, "before" +390, 18, 15, 606, 82, 85, 2798, 2801, "and" +390, 18, 16, 607, 86, 91, 2802, 2807, "after" +390, 18, 17, 608, 92, 101, 2808, 2817, "treatment" +390, 18, 18, 609, 102, 103, 2818, 2819, "." +390, 19, 1, 610, 0, 2, 2820, 2822, "In" +390, 19, 2, 611, 3, 11, 2823, 2831, "addition" +390, 19, 3, 612, 12, 13, 2832, 2833, "," +390, 19, 4, 613, 14, 22, 2834, 2842, "glycemic" +390, 19, 5, 614, 23, 30, 2843, 2850, "control" +390, 19, 6, 615, 31, 34, 2851, 2854, "and" +390, 19, 7, 616, 35, 44, 2855, 2864, "metabolic" +390, 19, 8, 617, 45, 55, 2865, 2875, "parameters" +390, 19, 9, 618, 56, 60, 2876, 2880, "were" +390, 19, 10, 619, 61, 65, 2881, 2885, "also" +390, 19, 11, 620, 66, 74, 2886, 2894, "assessed" +390, 19, 12, 621, 75, 76, 2895, 2896, "." +390, 20, 1, 622, 0, 7, 2897, 2904, "RESULTS" +390, 20, 2, 623, 8, 9, 2905, 2906, ":" +390, 20, 3, 624, 10, 16, 2907, 2913, "Ninety" +390, 20, 4, 625, 17, 18, 2914, 2915, "-" +390, 20, 5, 626, 19, 24, 2916, 2921, "seven" +390, 20, 6, 627, 25, 33, 2922, 2930, "subjects" +390, 20, 7, 628, 34, 35, 2931, 2932, "(" +390, 20, 8, 629, 36, 40, 2933, 2937, "aged" +390, 20, 9, 630, 41, 43, 2938, 2940, "58" +390, 20, 10, 631, 44, 45, 2941, 2942, "." +390, 20, 11, 632, 46, 47, 2943, 2944, "7" +390, 20, 12, 633, 48, 51, 2945, 2948, " ± " +390, 20, 13, 634, 52, 54, 2949, 2951, "11" +390, 20, 14, 635, 55, 56, 2952, 2953, "." +390, 20, 15, 636, 57, 58, 2954, 2955, "0" +390, 20, 16, 637, 59, 60, 2956, 2957, " " +390, 20, 17, 638, 61, 66, 2958, 2963, "years" +390, 20, 18, 639, 67, 68, 2964, 2965, ";" +390, 20, 19, 640, 69, 73, 2966, 2970, "body" +390, 20, 20, 641, 74, 78, 2971, 2975, "mass" +390, 20, 21, 642, 79, 84, 2976, 2981, "index" +390, 20, 22, 643, 85, 86, 2982, 2983, "," +390, 20, 23, 644, 87, 89, 2984, 2986, "25" +390, 20, 24, 645, 90, 91, 2987, 2988, "." +390, 20, 25, 646, 92, 93, 2989, 2990, "9" +390, 20, 26, 647, 94, 97, 2991, 2994, " ± " +390, 20, 27, 648, 98, 99, 2995, 2996, "4" +390, 20, 28, 649, 100, 101, 2997, 2998, "." +390, 20, 29, 650, 102, 103, 2999, 3000, "4" +390, 20, 30, 651, 104, 105, 3001, 3002, " " +390, 20, 31, 652, 106, 108, 3003, 3005, "kg" +390, 20, 32, 653, 109, 110, 3006, 3007, "/" +390, 20, 33, 654, 111, 113, 3008, 3010, "m2" +390, 20, 34, 655, 114, 115, 3011, 3012, ";" +390, 20, 35, 656, 116, 121, 3013, 3018, "HbA1c" +390, 20, 36, 657, 122, 123, 3019, 3020, "," +390, 20, 37, 658, 124, 125, 3021, 3022, "7" +390, 20, 38, 659, 126, 127, 3023, 3024, "." +390, 20, 39, 660, 128, 129, 3025, 3026, "3" +390, 20, 40, 661, 130, 133, 3027, 3030, " ± " +390, 20, 41, 662, 134, 135, 3031, 3032, "0" +390, 20, 42, 663, 136, 137, 3033, 3034, "." +390, 20, 43, 664, 138, 139, 3035, 3036, "5" +390, 20, 44, 665, 140, 141, 3037, 3038, "%" +390, 20, 45, 666, 142, 143, 3039, 3040, ";" +390, 20, 46, 667, 144, 147, 3041, 3044, "FMD" +390, 20, 47, 668, 148, 149, 3045, 3046, "," +390, 20, 48, 669, 150, 151, 3047, 3048, "5" +390, 20, 49, 670, 152, 153, 3049, 3050, "." +390, 20, 50, 671, 154, 155, 3051, 3052, "8" +390, 20, 51, 672, 156, 159, 3053, 3056, " ± " +390, 20, 52, 673, 160, 161, 3057, 3058, "2" +390, 20, 53, 674, 162, 163, 3059, 3060, "." +390, 20, 54, 675, 164, 165, 3061, 3062, "6" +390, 20, 55, 676, 166, 167, 3063, 3064, "%" +390, 20, 56, 677, 168, 169, 3065, 3066, ")" +390, 20, 57, 678, 170, 174, 3067, 3071, "were" +390, 20, 58, 679, 175, 183, 3072, 3080, "enrolled" +390, 20, 59, 680, 184, 185, 3081, 3082, "." +390, 21, 1, 681, 0, 5, 3083, 3088, "Eight" +390, 21, 2, 682, 6, 14, 3089, 3097, "subjects" +390, 21, 3, 683, 15, 22, 3098, 3105, "dropped" +390, 21, 4, 684, 23, 26, 3106, 3109, "out" +390, 21, 5, 685, 27, 29, 3110, 3112, "by" +390, 21, 6, 686, 30, 33, 3113, 3116, "the" +390, 21, 7, 687, 34, 37, 3117, 3120, "end" +390, 21, 8, 688, 38, 40, 3121, 3123, "of" +390, 21, 9, 689, 41, 44, 3124, 3127, "the" +390, 21, 10, 690, 45, 50, 3128, 3133, "study" +390, 21, 11, 691, 51, 52, 3134, 3135, "." +390, 22, 1, 692, 0, 5, 3136, 3141, "There" +390, 22, 2, 693, 6, 10, 3142, 3146, "were" +390, 22, 3, 694, 11, 13, 3147, 3149, "no" +390, 22, 4, 695, 14, 25, 3150, 3161, "significant" +390, 22, 5, 696, 26, 37, 3162, 3173, "differences" +390, 22, 6, 697, 38, 45, 3174, 3181, "between" +390, 22, 7, 698, 46, 49, 3182, 3185, "the" +390, 22, 8, 699, 50, 53, 3186, 3189, "two" +390, 22, 9, 700, 54, 60, 3190, 3196, "groups" +390, 22, 10, 701, 61, 63, 3197, 3199, "in" +390, 22, 11, 702, 64, 72, 3200, 3208, "baseline" +390, 22, 12, 703, 73, 88, 3209, 3224, "characteristics" +390, 22, 13, 704, 89, 90, 3225, 3226, "." +390, 23, 1, 705, 0, 5, 3227, 3232, "After" +390, 23, 2, 706, 6, 8, 3233, 3235, "12" +390, 23, 3, 707, 9, 10, 3236, 3237, " " +390, 23, 4, 708, 11, 16, 3238, 3243, "weeks" +390, 23, 5, 709, 17, 18, 3244, 3245, "," +390, 23, 6, 710, 19, 24, 3246, 3251, "HbA1c" +390, 23, 7, 711, 25, 28, 3252, 3255, "was" +390, 23, 8, 712, 29, 42, 3256, 3269, "significantly" +390, 23, 9, 713, 43, 51, 3270, 3278, "improved" +390, 23, 10, 714, 52, 54, 3279, 3281, "in" +390, 23, 11, 715, 55, 58, 3282, 3285, "the" +390, 23, 12, 716, 59, 64, 3286, 3291, "Vilda" +390, 23, 13, 717, 65, 70, 3292, 3297, "group" +390, 23, 14, 718, 71, 79, 3298, 3306, "compared" +390, 23, 15, 719, 80, 84, 3307, 3311, "with" +390, 23, 16, 720, 85, 88, 3312, 3315, "the" +390, 23, 17, 721, 89, 93, 3316, 3320, "high" +390, 23, 18, 722, 94, 97, 3321, 3324, "Met" +390, 23, 19, 723, 98, 103, 3325, 3330, "group" +390, 23, 20, 724, 104, 105, 3331, 3332, "(" +390, 23, 21, 725, 106, 108, 3333, 3335, "- " +390, 23, 22, 726, 109, 110, 3336, 3337, "0" +390, 23, 23, 727, 111, 112, 3338, 3339, "." +390, 23, 24, 728, 113, 115, 3340, 3342, "80" +390, 23, 25, 729, 116, 119, 3343, 3346, " ± " +390, 23, 26, 730, 120, 121, 3347, 3348, "0" +390, 23, 27, 731, 122, 123, 3349, 3350, "." +390, 23, 28, 732, 124, 126, 3351, 3353, "38" +390, 23, 29, 733, 127, 128, 3354, 3355, "%" +390, 23, 30, 734, 129, 131, 3356, 3358, "vs" +390, 23, 31, 735, 132, 133, 3359, 3360, "." +390, 23, 32, 736, 134, 136, 3361, 3363, "- " +390, 23, 33, 737, 137, 138, 3364, 3365, "0" +390, 23, 34, 738, 139, 140, 3366, 3367, "." +390, 23, 35, 739, 141, 143, 3368, 3370, "40" +390, 23, 36, 740, 144, 147, 3371, 3374, " ± " +390, 23, 37, 741, 148, 149, 3375, 3376, "0" +390, 23, 38, 742, 150, 151, 3377, 3378, "." +390, 23, 39, 743, 152, 154, 3379, 3381, "47" +390, 23, 40, 744, 155, 156, 3382, 3383, "%" +390, 23, 41, 745, 157, 158, 3384, 3385, "," +390, 23, 42, 746, 159, 171, 3386, 3398, "respectively" +390, 23, 43, 747, 172, 173, 3399, 3400, ";" +390, 23, 44, 748, 174, 175, 3401, 3402, "p" +390, 23, 45, 749, 176, 179, 3403, 3406, " < " +390, 23, 46, 750, 180, 181, 3407, 3408, "0" +390, 23, 47, 751, 182, 183, 3409, 3410, "." +390, 23, 48, 752, 184, 186, 3411, 3413, "01" +390, 23, 49, 753, 187, 188, 3414, 3415, ")" +390, 23, 50, 754, 189, 190, 3416, 3417, "." +390, 24, 1, 755, 0, 7, 3418, 3425, "However" +390, 24, 2, 756, 8, 9, 3426, 3427, "," +390, 24, 3, 757, 10, 15, 3428, 3433, "there" +390, 24, 4, 758, 16, 20, 3434, 3438, "were" +390, 24, 5, 759, 21, 23, 3439, 3441, "no" +390, 24, 6, 760, 24, 35, 3442, 3453, "significant" +390, 24, 7, 761, 36, 47, 3454, 3465, "differences" +390, 24, 8, 762, 48, 50, 3466, 3468, "in" +390, 24, 9, 763, 51, 54, 3469, 3472, "FMD" +390, 24, 10, 764, 55, 56, 3473, 3474, "(" +390, 24, 11, 765, 57, 59, 3475, 3477, "- " +390, 24, 12, 766, 60, 61, 3478, 3479, "0" +390, 24, 13, 767, 62, 63, 3480, 3481, "." +390, 24, 14, 768, 64, 66, 3482, 3484, "51" +390, 24, 15, 769, 67, 70, 3485, 3488, "[- " +390, 24, 16, 770, 71, 72, 3489, 3490, "1" +390, 24, 17, 771, 73, 74, 3491, 3492, "." +390, 24, 18, 772, 75, 77, 3493, 3495, "08" +390, 24, 19, 773, 78, 79, 3496, 3497, "-" +390, 24, 20, 774, 80, 81, 3498, 3499, "0" +390, 24, 21, 775, 82, 83, 3500, 3501, "." +390, 24, 22, 776, 84, 86, 3502, 3504, "06" +390, 24, 23, 777, 87, 88, 3505, 3506, "]" +390, 24, 24, 778, 89, 90, 3507, 3508, "%" +390, 24, 25, 779, 91, 93, 3509, 3511, "vs" +390, 24, 26, 780, 94, 95, 3512, 3513, "." +390, 24, 27, 781, 96, 98, 3514, 3516, "- " +390, 24, 28, 782, 99, 100, 3517, 3518, "0" +390, 24, 29, 783, 101, 102, 3519, 3520, "." +390, 24, 30, 784, 103, 105, 3521, 3523, "58" +390, 24, 31, 785, 106, 109, 3524, 3527, "[- " +390, 24, 32, 786, 110, 111, 3528, 3529, "1" +390, 24, 33, 787, 112, 113, 3530, 3531, "." +390, 24, 34, 788, 114, 116, 3532, 3534, "20" +390, 24, 35, 789, 117, 118, 3535, 3536, "-" +390, 24, 36, 790, 119, 120, 3537, 3538, "0" +390, 24, 37, 791, 121, 122, 3539, 3540, "." +390, 24, 38, 792, 123, 125, 3541, 3543, "04" +390, 24, 39, 793, 126, 127, 3544, 3545, "]" +390, 24, 40, 794, 128, 129, 3546, 3547, "%" +390, 24, 41, 795, 130, 131, 3548, 3549, ")" +390, 24, 42, 796, 132, 133, 3550, 3551, "." +390, 25, 1, 797, 0, 8, 3552, 3560, "Although" +390, 25, 2, 798, 9, 12, 3561, 3564, "the" +390, 25, 3, 799, 13, 27, 3565, 3579, "apolipoprotein" +390, 25, 4, 800, 28, 29, 3580, 3581, "B" +390, 25, 5, 801, 30, 31, 3582, 3583, "/" +390, 25, 6, 802, 32, 46, 3584, 3598, "apolipoprotein" +390, 25, 7, 803, 47, 49, 3599, 3601, "A1" +390, 25, 8, 804, 50, 55, 3602, 3607, "ratio" +390, 25, 9, 805, 56, 59, 3608, 3611, "was" +390, 25, 10, 806, 60, 73, 3612, 3625, "significantly" +390, 25, 11, 807, 74, 81, 3626, 3633, "reduced" +390, 25, 12, 808, 82, 84, 3634, 3636, "in" +390, 25, 13, 809, 85, 88, 3637, 3640, "the" +390, 25, 14, 810, 89, 94, 3641, 3646, "Vilda" +390, 25, 15, 811, 95, 100, 3647, 3652, "group" +390, 25, 16, 812, 101, 109, 3653, 3661, "compared" +390, 25, 17, 813, 110, 114, 3662, 3666, "with" +390, 25, 18, 814, 115, 123, 3667, 3675, "baseline" +390, 25, 19, 815, 124, 125, 3676, 3677, "(" +390, 25, 20, 816, 126, 127, 3678, 3679, "0" +390, 25, 21, 817, 128, 129, 3680, 3681, "." +390, 25, 22, 818, 130, 132, 3682, 3684, "66" +390, 25, 23, 819, 133, 134, 3685, 3686, "-" +390, 25, 24, 820, 135, 136, 3687, 3688, "0" +390, 25, 25, 821, 137, 138, 3689, 3690, "." +390, 25, 26, 822, 139, 141, 3691, 3693, "62" +390, 25, 27, 823, 142, 143, 3694, 3695, ";" +390, 25, 28, 824, 144, 145, 3696, 3697, "p" +390, 25, 29, 825, 146, 149, 3698, 3701, " < " +390, 25, 30, 826, 150, 151, 3702, 3703, "0" +390, 25, 31, 827, 152, 153, 3704, 3705, "." +390, 25, 32, 828, 154, 156, 3706, 3708, "01" +390, 25, 33, 829, 157, 158, 3709, 3710, ")" +390, 25, 34, 830, 159, 160, 3711, 3712, "," +390, 25, 35, 831, 161, 164, 3713, 3716, "the" +390, 25, 36, 832, 165, 171, 3717, 3723, "change" +390, 25, 37, 833, 172, 175, 3724, 3727, "did" +390, 25, 38, 834, 176, 179, 3728, 3731, "not" +390, 25, 39, 835, 180, 186, 3732, 3738, "differ" +390, 25, 40, 836, 187, 200, 3739, 3752, "significantly" +390, 25, 41, 837, 201, 208, 3753, 3760, "between" +390, 25, 42, 838, 209, 212, 3761, 3764, "the" +390, 25, 43, 839, 213, 216, 3765, 3768, "two" +390, 25, 44, 840, 217, 223, 3769, 3775, "groups" +390, 25, 45, 841, 224, 225, 3776, 3777, "(" +390, 25, 46, 842, 226, 228, 3778, 3780, "- " +390, 25, 47, 843, 229, 230, 3781, 3782, "0" +390, 25, 48, 844, 231, 232, 3783, 3784, "." +390, 25, 49, 845, 233, 235, 3785, 3787, "04" +390, 25, 50, 846, 236, 238, 3788, 3790, "vs" +390, 25, 51, 847, 239, 240, 3791, 3792, "." +390, 25, 52, 848, 241, 242, 3793, 3794, "0" +390, 25, 53, 849, 243, 244, 3795, 3796, "." +390, 25, 54, 850, 245, 247, 3797, 3799, "00" +390, 25, 55, 851, 248, 249, 3800, 3801, ";" +390, 25, 56, 852, 250, 251, 3802, 3803, "p" +390, 25, 57, 853, 252, 255, 3804, 3807, " = " +390, 25, 58, 854, 256, 257, 3808, 3809, "0" +390, 25, 59, 855, 258, 259, 3810, 3811, "." +390, 25, 60, 856, 260, 262, 3812, 3814, "27" +390, 25, 61, 857, 263, 264, 3815, 3816, ")" +390, 25, 62, 858, 265, 266, 3817, 3818, "." +390, 26, 1, 859, 0, 11, 3819, 3830, "Adiponectin" +390, 26, 2, 860, 12, 18, 3831, 3837, "levels" +390, 26, 3, 861, 19, 23, 3838, 3842, "were" +390, 26, 4, 862, 24, 37, 3843, 3856, "significantly" +390, 26, 5, 863, 38, 47, 3857, 3866, "increased" +390, 26, 6, 864, 48, 50, 3867, 3869, "in" +390, 26, 7, 865, 51, 54, 3870, 3873, "the" +390, 26, 8, 866, 55, 60, 3874, 3879, "Vilda" +390, 26, 9, 867, 61, 66, 3880, 3885, "group" +390, 26, 10, 868, 67, 75, 3886, 3894, "compared" +390, 26, 11, 869, 76, 80, 3895, 3899, "with" +390, 26, 12, 870, 81, 84, 3900, 3903, "the" +390, 26, 13, 871, 85, 89, 3904, 3908, "high" +390, 26, 14, 872, 90, 93, 3909, 3912, "Met" +390, 26, 15, 873, 94, 99, 3913, 3918, "group" +390, 26, 16, 874, 100, 101, 3919, 3920, "(" +390, 26, 17, 875, 102, 103, 3921, 3922, "0" +390, 26, 18, 876, 104, 105, 3923, 3924, "." +390, 26, 19, 877, 106, 108, 3925, 3927, "75" +390, 26, 20, 878, 109, 111, 3928, 3930, " μ" +390, 26, 21, 879, 112, 113, 3931, 3932, "g" +390, 26, 22, 880, 114, 115, 3933, 3934, "/" +390, 26, 23, 881, 116, 118, 3935, 3937, "mL" +390, 26, 24, 882, 119, 121, 3938, 3940, "vs" +390, 26, 25, 883, 122, 123, 3941, 3942, "." +390, 26, 26, 884, 124, 125, 3943, 3944, "0" +390, 26, 27, 885, 126, 127, 3945, 3946, "." +390, 26, 28, 886, 128, 130, 3947, 3949, "01" +390, 26, 29, 887, 131, 133, 3950, 3952, " μ" +390, 26, 30, 888, 134, 135, 3953, 3954, "g" +390, 26, 31, 889, 136, 137, 3955, 3956, "/" +390, 26, 32, 890, 138, 140, 3957, 3959, "mL" +390, 26, 33, 891, 141, 142, 3960, 3961, ";" +390, 26, 34, 892, 143, 144, 3962, 3963, "p" +390, 26, 35, 893, 145, 148, 3964, 3967, " < " +390, 26, 36, 894, 149, 150, 3968, 3969, "0" +390, 26, 37, 895, 151, 152, 3970, 3971, "." +390, 26, 38, 896, 153, 155, 3972, 3974, "01" +390, 26, 39, 897, 156, 157, 3975, 3976, ")" +390, 26, 40, 898, 158, 159, 3977, 3978, "." +390, 27, 1, 899, 0, 11, 3979, 3990, "CONCLUSIONS" +390, 27, 2, 900, 12, 13, 3991, 3992, ":" +390, 27, 3, 901, 14, 24, 3993, 4003, "Regardless" +390, 27, 4, 902, 25, 27, 4004, 4006, "of" +390, 27, 5, 903, 28, 36, 4007, 4015, "glycemic" +390, 27, 6, 904, 37, 48, 4016, 4027, "improvement" +390, 27, 7, 905, 49, 50, 4028, 4029, "," +390, 27, 8, 906, 51, 62, 4030, 4041, "combination" +390, 27, 9, 907, 63, 70, 4042, 4049, "therapy" +390, 27, 10, 908, 71, 73, 4050, 4052, "of" +390, 27, 11, 909, 74, 86, 4053, 4065, "vildagliptin" +390, 27, 12, 910, 87, 90, 4066, 4069, "and" +390, 27, 13, 911, 91, 100, 4070, 4079, "metformin" +390, 27, 14, 912, 101, 104, 4080, 4083, "did" +390, 27, 15, 913, 105, 108, 4084, 4087, "not" +390, 27, 16, 914, 109, 115, 4088, 4094, "affect" +390, 27, 17, 915, 116, 127, 4095, 4106, "endothelial" +390, 27, 18, 916, 128, 136, 4107, 4115, "function" +390, 27, 19, 917, 137, 140, 4116, 4119, "but" +390, 27, 20, 918, 141, 144, 4120, 4123, "may" +390, 27, 21, 919, 145, 150, 4124, 4129, "exert" +390, 27, 22, 920, 151, 160, 4130, 4139, "favorable" +390, 27, 23, 921, 161, 168, 4140, 4147, "effects" +390, 27, 24, 922, 169, 171, 4148, 4150, "on" +390, 27, 25, 923, 172, 181, 4151, 4160, "adipokine" +390, 27, 26, 924, 182, 188, 4161, 4167, "levels" +390, 27, 27, 925, 189, 192, 4168, 4171, "and" +390, 27, 28, 926, 193, 198, 4172, 4177, "lipid" +390, 27, 29, 927, 199, 206, 4178, 4185, "profile" +390, 27, 30, 928, 207, 209, 4186, 4188, "in" +390, 27, 31, 929, 210, 218, 4189, 4197, "patients" +390, 27, 32, 930, 219, 223, 4198, 4202, "with" +390, 27, 33, 931, 224, 228, 4203, 4207, "type" +390, 27, 34, 932, 229, 230, 4208, 4209, "2" +390, 27, 35, 933, 231, 239, 4210, 4218, "diabetes" +390, 27, 36, 934, 240, 247, 4219, 4226, "without" +390, 27, 37, 935, 248, 256, 4227, 4235, "advanced" +390, 27, 38, 936, 257, 272, 4236, 4251, "atherosclerosis" +390, 27, 39, 937, 273, 274, 4252, 4253, "." +390, 28, 1, 938, 0, 3, 4254, 4257, "DOI" +390, 28, 2, 939, 4, 5, 4258, 4259, ":" +390, 28, 3, 940, 6, 8, 4260, 4262, "10" +390, 28, 4, 941, 9, 10, 4263, 4264, "." +390, 28, 5, 942, 11, 15, 4265, 4269, "1186" +390, 28, 6, 943, 16, 17, 4270, 4271, "/" +390, 28, 7, 944, 18, 24, 4272, 4278, "s12933" +390, 28, 8, 945, 25, 26, 4279, 4280, "-" +390, 28, 9, 946, 27, 30, 4281, 4284, "017" +390, 28, 10, 947, 31, 32, 4285, 4286, "-" +390, 28, 11, 948, 33, 37, 4287, 4291, "0607" +390, 28, 12, 949, 38, 39, 4292, 4293, "-" +390, 28, 13, 950, 40, 41, 4294, 4295, "6" +390, 28, 14, 951, 42, 47, 4296, 4301, "PMCID" +390, 28, 15, 952, 48, 49, 4302, 4303, ":" +390, 28, 16, 953, 50, 60, 4304, 4314, "PMC5634845" +390, 28, 17, 954, 61, 65, 4315, 4319, "PMID" +390, 28, 18, 955, 66, 67, 4320, 4321, ":" +390, 28, 19, 956, 68, 76, 4322, 4330, "29017497" +390, 28, 20, 957, 77, 78, 4331, 4332, "[" +390, 28, 21, 958, 79, 86, 4333, 4340, "Indexed" +390, 28, 22, 959, 87, 90, 4341, 4344, "for" +390, 28, 23, 960, 91, 98, 4345, 4352, "MEDLINE" +390, 28, 24, 961, 99, 100, 4353, 4354, "]" diff --git a/data/dm2 29017497_kwoodley.annodb b/data/dm2 29017497_kwoodley.annodb new file mode 100644 index 0000000..590d295 --- /dev/null +++ b/data/dm2 29017497_kwoodley.annodb @@ -0,0 +1,142 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72234, Journal, 0, 19, "Cardiovasc Diabetol", "", +72235, PublicationYear, 22, 26, "2017", "", +72252, Title, 97, 280, "The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters : a randomized , controlled trial ( Sapporo Athero - Incretin Study 3 ) .", "", +72236, Vildagliptin, 112, 124, "vildagliptin", "", +72244, Metformin, 139, 148, "metformin", "", +72251, Randomized, 211, 221, "randomized", "", +72253, Author, 281, 288, "Kitao N", "", +72254, Author, 297, 306, "Miyoshi H", "", +72255, Author, 315, 325, "Furumoto T", "", +72256, Author, 340, 345, "Ono K", "", +72257, Author, 354, 362, "Nomoto H", "", +72258, Author, 371, 377, "Miya A", "", +72259, Author, 386, 396, "Yamamoto C", "", +72260, Author, 405, 412, "Inoue A", "", +72261, Author, 421, 431, "Tsuchida K", "", +72262, Author, 440, 447, "Manda N", "", +72263, Author, 456, 466, "Kurihara Y", "", +72264, Author, 475, 479, "Aoki", "", +72265, Author, 490, 500, "Nakamura A", "", +72266, Author, 509, 517, "Atsumi T", "", +72300, Author, 561, 570, "Edagawa Y", "not sure for all collaborations", +72268, Author, 573, 579, "Oita M", "", +72269, Author, 582, 589, "Kondo A", "", +72270, Author, 592, 603, "Takahashi K", "", +72271, Author, 606, 616, "Sugawara H", "", +72272, Author, 619, 632, "Dan - Noura M", "", +72273, Author, 635, 643, "Takano Y", "", +72274, Author, 646, 653, "Kitao N", "", +72275, Author, 656, 668, "Koyanagawa N", "", +72276, Author, 671, 677, "Miya A", "", +72277, Author, 680, 690, "Yamamoto K", "", +72278, Author, 693, 703, "Yamamoto C", "", +72279, Author, 706, 714, "Nomoto H", "", +72280, Author, 717, 725, "Kameda Y", "", +72281, Author, 728, 734, "Cho KY", "", +72282, Author, 737, 747, "Nakamura A", "", +72283, Author, 750, 759, "Miyoshi H", "", +72284, Author, 762, 770, "Atsumi T", "", +72285, Author, 773, 783, "Watanabe T", "", +72286, Author, 786, 797, "Takahashi K", "", +72287, Author, 800, 812, "Koyanagawa N", "", +72288, Author, 815, 821, "Kito K", "", +72289, Author, 824, 834, "Yamamoto C", "", +72290, Author, 837, 843, "Endo M", "", +72291, Author, 846, 856, "Takeuchi J", "", +72292, Author, 859, 866, "Nagai S", "", +72293, Author, 869, 877, "Masuda H", "", +72294, Author, 880, 887, "Inoue A", "", +72295, Author, 890, 895, "Ono Y", "", +72296, Author, 898, 908, "Tsuchida K", "", +72297, Author, 911, 918, "Manda N", "", +72298, Author, 921, 931, "Kurihara Y", "", +72299, Author, 934, 940, "Aoki S", "", +72301, Japan, 1146, 1151, "Japan", "", +72302, Japan, 1336, 1341, "Japan", "", +72303, Japan, 1471, 1476, "Japan", "", +72304, Japan, 1585, 1590, "Japan", "", +72305, Japan, 1690, 1695, "Japan", "", +72306, Japan, 1778, 1783, "Japan", "", +72307, Japan, 1828, 1833, "Japan", "", +72309, Japan, 1870, 1875, "Japan", "", +72310, Japan, 1908, 1913, "Japan", "", +72311, Type2Diabetes, 2060, 2075, "type 2 diabetes", "", +72313, Randomized, 2156, 2166, "randomized", "", +72314, Placebo, 2167, 2174, "placebo", "", +72316, ObjectiveDescription, 2210, 2345, "we investigated the efficacy of DPP - 4 inhibitor on endothelial function and glycemic metabolism compared with high - dose metformin .", "", +72315, Metformin, 2334, 2343, "metformin", "", +72317, Multicenter, 2364, 2375, "multicenter", "", +72318, OpenLabel, 2378, 2392, "open - labeled", "", +72319, Prospective, 2395, 2406, "prospective", "", +72320, Randomized, 2409, 2419, "randomized", "", +72321, Parallel, 2422, 2438, "parallel - group", "", +72326, Precondition, 2458, 2546, "patients with type 2 diabetes treated with low - dose metformin ( 500 - 750   mg / day )", "", +72312, Type2Diabetes, 2472, 2487, "type 2 diabetes", "", +72322, Metformin, 2512, 2521, "metformin", "", +72323, DoseValue, 2524, 2533, "500 - 750", "", +72324, mg, 2536, 2538, "mg", "", +72325, Frequency, 2541, 2544, "day", "", +72327, Randomized, 2565, 2573, "randomly", "", +72329, DoseDescription, 2574, 2698, "assigned to a vildagliptin , a DPP - 4 inhibitor , add - on group ( Vilda ) or a double dose of metformin group ( high Met )", "", +72237, Vildagliptin, 2588, 2600, "vildagliptin", "", +72250, Vildagliptin, 2642, 2647, "Vilda", "", +72245, Metformin, 2670, 2679, "metformin", "", +72246, Metformin, 2688, 2696, "high Met", "", +72328, Duration, 2703, 2713, "12   weeks", "", +72330, NumberPatientsCT, 2907, 2921, "Ninety - seven", "", +72331, AvgAge, 2938, 2944, "58 . 7", "", +72332, BMI, 2966, 2981, "body mass index", "", +72333, BaseLineValue, 2984, 2990, "25 . 9", "", +72334, SdDevBL, 2995, 3000, "4 . 4", "", +72335, Kg_per_squareMeter, 3003, 3010, "kg / m2", "", +72336, HbA1c, 3013, 3018, "HbA1c", "", +72337, BaseLineValue, 3021, 3026, "7 . 3", "", +72338, SdDevBL, 3031, 3036, "0 . 5", "", +72339, Percentage, 3037, 3038, "%", "", +72340, EndPointDescription, 3041, 3044, "FMD", "", +72341, BaseLineValue, 3047, 3052, "5 . 8", "", +72342, SdDevBL, 3057, 3062, "2 . 6", "", +72343, Percentage, 3063, 3064, "%", "", +72344, NumPatientsLeftCT, 3083, 3088, "Eight", "", +72345, TimePoint, 3233, 3243, "12   weeks", "", +72346, HbA1c, 3246, 3251, "HbA1c", "", +72239, Vildagliptin, 3286, 3291, "Vilda", "", +72247, Metformin, 3316, 3324, "high Met", "", +72347, Reduction, 3336, 3342, "0 . 80", "", +72349, SdDevChangeValue, 3347, 3353, "0 . 38", "", +72351, Percentage, 3354, 3355, "%", "", +72348, Reduction, 3364, 3370, "0 . 40", "", +72350, SdDevChangeValue, 3375, 3381, "0 . 47", "", +72352, Percentage, 3382, 3383, "%", "", +72353, PvalueDiff, 3401, 3413, "p  <  0 . 01", "", +72354, EndPointDescription, 3469, 3472, "FMD", "", +72355, Reduction, 3478, 3484, "0 . 51", "", +72357, ConfIntervalChangeValue, 3485, 3504, "[-  1 . 08 - 0 . 06", "", +72359, Percentage, 3507, 3508, "%", "", +72356, Reduction, 3517, 3523, "0 . 58", "", +72358, ConfIntervalChangeValue, 3524, 3543, "[-  1 . 20 - 0 . 04", "", +72360, Percentage, 3546, 3547, "%", "", +72361, EndPointDescription, 3565, 3607, "apolipoprotein B / apolipoprotein A1 ratio", "", +72363, ObservedResult, 3608, 3675, "was significantly reduced in the Vilda group compared with baseline", "", +72238, Vildagliptin, 3641, 3646, "Vilda", "", +72362, TimePoint, 3667, 3675, "baseline", "", +72365, ConfIntervalChangeValue, 3678, 3693, "0 . 66 - 0 . 62", "", +72366, PValueChangeValue, 3696, 3708, "p  <  0 . 01", "", +72367, Reduction, 3781, 3787, "0 . 04", "", +72368, NoChange, 3793, 3799, "0 . 00", "", +72369, PvalueDiff, 3802, 3814, "p  =  0 . 27", "", +72370, EndPointDescription, 3819, 3830, "Adiponectin", "", +72240, Vildagliptin, 3874, 3879, "Vilda", "", +72248, Metformin, 3904, 3912, "high Met", "", +72371, Increment, 3921, 3927, "0 . 75", "", +72373, BioAndMedicalUnit, 3928, 3937, " μ g / mL", "", +72372, Increment, 3943, 3949, "0 . 01", "", +72374, BioAndMedicalUnit, 3950, 3959, " μ g / mL", "", +72375, PvalueDiff, 3962, 3974, "p  <  0 . 01", "", +72377, ConclusionComment, 3993, 4185, "Regardless of glycemic improvement , combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile", "", +72243, Vildagliptin, 4053, 4065, "vildagliptin", "", +72249, Metformin, 4070, 4079, "metformin", "", +72378, ConclusionComment, 4186, 4253, "in patients with type 2 diabetes without advanced atherosclerosis .", "", +72376, Type2Diabetes, 4203, 4218, "type 2 diabetes", "", +72379, PMID, 4322, 4330, "29017497", "", diff --git a/data/dm2 29017497_kwoodley.n-triples b/data/dm2 29017497_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29017497_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29110647_admin.annodb b/data/dm2 29110647_admin.annodb new file mode 100644 index 0000000..ae92c29 --- /dev/null +++ b/data/dm2 29110647_admin.annodb @@ -0,0 +1,136 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "BMC Endocr Disord .", "", " \"BMC Endocr Disord .\"." +1, PublicationYear, 20, 24, "2017", "", " \"2017\"." +47, Title, 93, 327, "A randomized , placebo - controlled clinical trial evaluating the safety and efficacy of the once - weekly DPP - 4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin .", "", " \"A randomized , placebo - controlled clinical trial evaluating the safety and efficacy of the once - weekly DPP - 4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin .\"." +2, Randomized, 95, 105, "randomized", "", " ." +3, Placebo, 108, 115, "placebo", "", +12, Frequency, 186, 199, "once - weekly", "", +18, Omarigliptin, 218, 230, "omarigliptin", "", +46, Precondition, 234, 325, "patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin", "", " \"patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin\"." +28, Type2Diabetes, 248, 272, "type 2 diabetes mellitus", "", " ." +34, Glimepiride, 300, 311, "glimepiride", "", +42, Metformin, 316, 325, "metformin", "", +48, Author, 328, 334, "Lee SH", "", " \"Lee SH\"." +49, Author, 343, 350, "Gantz I", "", " \"Gantz I\"." +50, Author, 359, 366, "Round E", "", " \"Round E\"." +51, Author, 375, 383, "Latham M", "", " \"Latham M\"." +52, Author, 392, 404, "O ' Neill EA", "", " \"O ' Neill EA\"." +53, Author, 413, 421, "Ceesay P", "", " \"O ' Neill EA\"." +54, Author, 430, 443, "Suryawanshi S", "", " \"Suryawanshi S\"." +55, Author, 452, 462, "Kaufman KD", "", " \"Kaufman KD\"." +56, Author, 471, 479, "Engel SS", "", " \"Engel SS\"." +57, Author, 488, 493, "Lai E", "", " \"Lai E\"." +152, SouthKorea, 686, 691, "Korea", "", " ." +58, SouthKorea, 714, 719, "Korea", "", +59, USA, 804, 807, "USA", "", +60, USA, 920, 923, "USA", "", +30, Type2Diabetes, 939, 954, "Type 2 diabetes", "", +29, Type2Diabetes, 957, 960, "T2D", "", +158, OralAntidiabeticAgent, 1034, 1058, "antihyperglycemic agents", "", +19, Omarigliptin, 1114, 1126, "Omarigliptin", "", +14, Frequency, 1132, 1145, "once - weekly", "", +62, ObjectiveDescription, 1183, 1388, "The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride .", "", " \"The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride .\"." +20, Omarigliptin, 1257, 1269, "omarigliptin", "", +61, Precondition, 1298, 1386, "patients with T2D inadequately controlled by dual therapy with metformin and glimepiride", "", +31, Type2Diabetes, 1312, 1315, "T2D", "", +43, Metformin, 1361, 1370, "metformin", "", +35, Glimepiride, 1375, 1386, "glimepiride", "", +32, Type2Diabetes, 1413, 1416, "T2D", "", +63, HbA1c, 1421, 1426, "HbA1c", "", +64, Percentage, 1435, 1436, "%", "", +65, Percentage, 1450, 1451, "%", "", +44, Metformin, 1461, 1470, "metformin", "", +66, DoseValue, 1473, 1479, "≥ 1500", "", +69, mg, 1482, 1484, "mg", "", +83921, Interval, 1487, 1490, "day", "", +36, Glimepiride, 1497, 1508, "glimepiride", "", +67, DoseValue, 1511, 1514, "≥ 4", "", +70, mg, 1517, 1519, "mg", "", +83922, Interval, 1522, 1525, "day", "", +73, Randomized, 1533, 1543, "randomized", "", +21, Omarigliptin, 1547, 1559, "omarigliptin", "", " ." +68, DoseValue, 1560, 1562, "25", "", " \"25\"." +71, mg, 1565, 1567, "mg", "", " ." +13, Frequency, 1568, 1581, "once - weekly", "", " \"once - weekly\"." +74, NumberPatientsArm, 1590, 1593, "154", "", " \"154\"." +4, Placebo, 1599, 1606, "placebo", "", " ." +75, NumberPatientsArm, 1615, 1618, "153", "", " \"153\"." +76, Duration, 1625, 1635, "24   weeks", "", " \"24   weeks\"." +38, Omarigliptin, 1682, 1694, "omarigliptin", "", +40, Placebo, 1711, 1718, "placebo", "", +77, HbA1c, 1731, 1736, "HbA1c", "", +80, TimePoint, 1740, 1747, "Week 24", "", +39, Omarigliptin, 1801, 1813, "omarigliptin", "", +41, Placebo, 1819, 1826, "placebo", "", +84, FastingPlasmaGlucose, 1830, 1833, "FPG", "", +86, HbA1c_target, 1890, 1895, "< 7 %", "", +175, Percentage, 1894, 1895, "%", "", +87, HbA1c_target, 1900, 1909, "< 6 . 5 %", "", +176, Percentage, 1908, 1909, "%", "", +205, Mean, 1929, 1933, "mean", "", +81, TimePoint, 1934, 1942, "baseline", "", +78, HbA1c, 1943, 1948, "HbA1c", "", " ." +88, BaseLineValue, 1952, 1957, "8 . 5", "", " \"8 . 5\"." +90, Percentage, 1958, 1959, "%", "", " ." +95, Omarigliptin, 1962, 1974, "omarigliptin", "", +89, BaseLineValue, 1981, 1986, "8 . 6", "", " \"8 . 6\"." +91, Percentage, 1987, 1988, "%", "", +5, Placebo, 1991, 1998, "placebo", "", +96, LeastSquaresMean, 2007, 2032, "least squares ( LS ) mean", "", " ." +82, TimePoint, 2045, 2053, "baseline", "", +79, HbA1c, 2057, 2062, "HbA1c", "", +83, TimePoint, 2066, 2073, "Week 24", "", +97, Reduction, 2080, 2086, "0 . 67", "", " \"0 . 67\"." +92, Percentage, 2087, 2088, "%", "", +22, Omarigliptin, 2096, 2108, "omarigliptin", "", +98, Reduction, 2121, 2127, "0 . 06", "", " \"0 . 06\"." +93, Percentage, 2128, 2129, "%", "", +6, Placebo, 2137, 2144, "placebo", "", +99, ConfIntervalDiff, 2189, 2196, "95 % CI", "", +101, DiffGroupAbsValue, 2202, 2210, "- 0 . 61", "", " \"- 0 . 61\"." +94, Percentage, 2211, 2212, "%", "", +100, ConfIntervalDiff, 2215, 2234, "- 0 . 85 , - 0 . 38", "", +23, Omarigliptin, 2254, 2266, "omarigliptin", "", +85, FastingPlasmaGlucose, 2316, 2319, "FPG", "", " ." +7, Placebo, 2332, 2339, "placebo", "", +102, LeastSquaresMean, 2342, 2349, "LS mean", "", " ." +103, ConfIntervalDiff, 2363, 2370, "95 % CI", "", +105, DiffGroupAbsValue, 2373, 2380, "- 0 . 9", "", " \"- 0 . 9\"." +106, Millimoles_per_litre, 2383, 2391, "mmol / L", "", " ." +104, ConfIntervalDiff, 2394, 2411, "- 1 . 4 , - 0 . 4", "", " \"- 1 . 4 , - 0 . 4\"." +107, PvalueDiff, 2416, 2429, "p  <  0 . 001", "", " \"p  <  0 . 001\"." +110, ObservedResult, 2434, 2485, "The proportion of patients achieving glycemic goals", "", " \"The proportion of patients achieving glycemic goals\". \"The proportion of patients achieving glycemic goals\". \"The proportion of patients achieving glycemic goals\". \"The proportion of patients achieving glycemic goals\"." +108, HbA1c_target, 2489, 2498, "< 7 . 0 %", "", " ." +184, Percentage, 2497, 2498, "%", "", +109, HbA1c_target, 2503, 2512, "< 6 . 5 %", "", " ." +182, Percentage, 2511, 2512, "%", "", +110, ObservedResult, 2513, 2579, "was higher in the omarigliptin group relative to the placebo group", "", " \"was higher in the omarigliptin group relative to the placebo group\". \"was higher in the omarigliptin group relative to the placebo group\". \"was higher in the omarigliptin group relative to the placebo group\". \"was higher in the omarigliptin group relative to the placebo group\"." +24, Omarigliptin, 2531, 2543, "omarigliptin", "", +8, Placebo, 2566, 2573, "placebo", "", +111, EndPointDescription, 2608, 2622, "adverse events", "", +112, EndPointDescription, 2625, 2628, "AEs", "", +113, EndPointDescription, 2641, 2644, "AEs", "", +114, EndPointDescription, 2662, 2665, "AEs", "", +118, ObservedResult, 2687, 2734, "were generally similar between treatment groups", "", +119, SymptomaticHypoglycemia, 2754, 2778, "symptomatic hypoglycemia", "", " ." +120, PercentageAffected, 2783, 2789, "10 . 5", "", " \"10 . 5\"." +25, Omarigliptin, 2799, 2811, "omarigliptin", "", +121, PercentageAffected, 2822, 2827, "8 . 5", "", " \"8 . 5\"." +9, Placebo, 2837, 2844, "placebo", "", +122, TimePoint, 2865, 2873, "baseline", "", " \"8 . 5\"." +26, Omarigliptin, 2876, 2888, "omarigliptin", "", +10, Placebo, 2893, 2900, "placebo", "", +123, LeastSquaresMean, 2933, 2940, "LS mean", "", " ." +124, BodyWeight, 2952, 2963, "body weight", "", " ." +125, Reduction, 2969, 2974, "0 . 1", "", " \"0 . 1\"." +127, Kg, 2977, 2979, "kg", "", " ." +126, Reduction, 2986, 2991, "0 . 9", "", " \"0 . 9\"." +128, Kg, 2994, 2996, "kg", "", +129, ConclusionComment, 3027, 3263, "In patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride , compared with placebo , once - weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated .", "", " \"In patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride , compared with placebo , once - weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated .\"." +33, Type2Diabetes, 3044, 3047, "T2D", "", +45, Metformin, 3101, 3110, "metformin", "", +37, Glimepiride, 3115, 3126, "glimepiride", "", +11, Placebo, 3143, 3150, "placebo", "", +17, Frequency, 3153, 3166, "once - weekly", "", +27, Omarigliptin, 3167, 3179, "omarigliptin", "", +130, PMID, 3473, 3481, "29110647", "", " \"29110647\"." diff --git a/data/dm2 29110647_admin.n-triples b/data/dm2 29110647_admin.n-triples new file mode 100644 index 0000000..5362fcd --- /dev/null +++ b/data/dm2 29110647_admin.n-triples @@ -0,0 +1,188 @@ +# RDF export of group: Publication + . + "Publication 76748" . + "A randomized , placebo - controlled clinical trial evaluating the safety and efficacy of the once - weekly DPP - 4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin ." . + "Lee SH" . + "2017" . + "BMC Endocr Disord ." . + "29110647" . + . + "Gantz I" . + "Round E" . + "Latham M" . + "O ' Neill EA" . + "Ceesay P" . + "Suryawanshi S" . + "Kaufman KD" . + "Engel SS" . + "Lai E" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 76755" . + "The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride ." . + "24   weeks" . + . + . + . + "In patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride , compared with placebo , once - weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 76771" . + "patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + "tar" . + . + . + . + . + . + "tar2" . + . + . + . + . + . + "hyp" . + . + . + . + . + . + "bw" . + . + . + . + . +# RDF export of group: Arm + . + "om" . + "154" . + . + . + . + . + . + . + . + . + "pl" . + "153" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "om" . + . + "once - weekly" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "om" . + . + "25" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 5" . + "0 . 67" . + . + "hba 2" . + . + "8 . 6" . + "0 . 06" . + . + "fpg 1" . + . + . + "fpg 2" . + . + . + "tar 1" . + . + "The proportion of patients achieving glycemic goals" . + "was higher in the omarigliptin group relative to the placebo group" . + . + "tar 2" . + . + "The proportion of patients achieving glycemic goals" . + "was higher in the omarigliptin group relative to the placebo group" . + . + "tar2 1" . + . + "The proportion of patients achieving glycemic goals" . + "was higher in the omarigliptin group relative to the placebo group" . + . + "tar2 2" . + . + "The proportion of patients achieving glycemic goals" . + "was higher in the omarigliptin group relative to the placebo group" . + . + "hyp 1" . + . + "10 . 5" . + . + "hyp 2" . + . + "8 . 5" . + . + "bw 1" . + . + "0 . 1" . + . + "bw 2" . + . + "0 . 9" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 61" . + . + . + . + "fpg" . + "- 0 . 9" . + "p  <  0 . 001" . + "- 1 . 4 , - 0 . 4" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29110647_akramersunderbrink.annodb b/data/dm2 29110647_akramersunderbrink.annodb new file mode 100644 index 0000000..1dc1185 --- /dev/null +++ b/data/dm2 29110647_akramersunderbrink.annodb @@ -0,0 +1,126 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73194, Journal, 0, 17, "BMC Endocr Disord", "", +73195, PublicationYear, 20, 24, "2017", "", +73298, Title, 93, 327, "A randomized , placebo - controlled clinical trial evaluating the safety and efficacy of the once - weekly DPP - 4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin .", "", +73196, Randomized, 95, 105, "randomized", "", +73197, Placebo, 108, 115, "placebo", "", +73198, Frequency, 186, 199, "once - weekly", "", +73199, Omarigliptin, 218, 230, "omarigliptin", "", +73200, Type2Diabetes, 248, 272, "type 2 diabetes mellitus", "", +73201, Precondition, 273, 325, "inadequately controlled by glimepiride and metformin", "", +73202, Glimepiride, 300, 311, "glimepiride", "", +73203, Metformin, 316, 325, "metformin", "", +73299, Author, 328, 334, "Lee SH", "", +73300, Author, 343, 350, "Gantz I", "", +73301, Author, 359, 366, "Round E", "", +73303, Author, 375, 383, "Latham M", "", +73305, Author, 392, 404, "O ' Neill EA", "", +73306, Author, 413, 421, "Ceesay P", "", +73307, Author, 430, 443, "Suryawanshi S", "", +73308, Author, 452, 462, "Kaufman KD", "", +73310, Author, 471, 479, "Engel SS", "", +73312, Author, 488, 493, "Lai E", "", +73315, SouthKorea, 686, 691, "Korea", "", +73317, SouthKorea, 714, 719, "Korea", "", +73320, USA, 804, 807, "USA", "", +73322, USA, 920, 923, "USA", "", +73325, Type2Diabetes, 939, 954, "Type 2 diabetes", "", +73352, ObjectiveDescription, 939, 1113, "Type 2 diabetes ( T2D ) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression .", "", +73326, Type2Diabetes, 957, 960, "T2D", "", +73335, OralAntidiabeticAgent, 1034, 1058, "antihyperglycemic agents", "", +73337, Omarigliptin, 1114, 1126, "Omarigliptin", "", +73354, ObjectiveDescription, 1114, 1182, "Omarigliptin is a once - weekly dipeptidyl peptidase - 4 inhibitor .", "", +73339, Frequency, 1132, 1145, "once - weekly", "", +73355, ObjectiveDescription, 1183, 1388, "The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride .", "", +73341, Omarigliptin, 1257, 1269, "omarigliptin", "", +73344, Type2Diabetes, 1312, 1315, "T2D", "", +73347, Precondition, 1316, 1386, "inadequately controlled by dual therapy with metformin and glimepiride", "", +73348, Metformin, 1361, 1370, "metformin", "", +73350, Glimepiride, 1375, 1386, "glimepiride", "", +73357, Type2Diabetes, 1413, 1416, "T2D", "", +73359, HbA1c, 1421, 1426, "HbA1c", "", +73389, Precondition, 1421, 1527, "HbA1c ≥ 7 . 5 % and ≤ 10 . 5 % while on metformin ( ≥ 1500   mg / day ) and glimepiride ( ≥ 4   mg / day )", "", +73361, Percentage, 1435, 1436, "%", "", +73362, Percentage, 1450, 1451, "%", "", +73390, Metformin, 1461, 1470, "metformin", "", +73392, DoseValue, 1473, 1490, "≥ 1500   mg / day", "", +73394, BioAndMedicalUnit, 1482, 1490, "mg / day", "", +73391, Glimepiride, 1497, 1508, "glimepiride", "", +73393, DoseValue, 1511, 1525, "≥ 4   mg / day", "", +73396, BioAndMedicalUnit, 1517, 1525, "mg / day", "", +73398, Randomized, 1533, 1543, "randomized", "", +73399, Omarigliptin, 1547, 1559, "omarigliptin", "", +73400, DoseValue, 1560, 1567, "25   mg", "", +73401, mg, 1565, 1567, "mg", "", +73402, Frequency, 1568, 1581, "once - weekly", "", +73404, NumberPatientsArm, 1590, 1593, "154", "", +73403, Placebo, 1599, 1606, "placebo", "", +73405, NumberPatientsArm, 1615, 1618, "153", "", +73406, Duration, 1625, 1635, "24   weeks", "", +73407, Omarigliptin, 1801, 1813, "omarigliptin", "", +73408, Placebo, 1819, 1826, "placebo", "", +73409, FastingPlasmaGlucose, 1830, 1833, "FPG", "", +73410, HbA1c_target, 1875, 1909, "HbA1c goals of < 7 % and < 6 . 5 %", "", +73368, Percentage, 1894, 1895, "%", "", +73369, Percentage, 1908, 1909, "%", "", +73411, Mean, 1929, 1933, "mean", "", +73412, TimePoint, 1934, 1942, "baseline", "", +73414, HbA1c, 1943, 1948, "HbA1c", "", +73415, BaseLineValue, 1952, 1957, "8 . 5", "", +73364, Percentage, 1958, 1959, "%", "", +73417, Omarigliptin, 1962, 1974, "omarigliptin", "", +73416, BaseLineValue, 1981, 1986, "8 . 6", "", +73365, Percentage, 1987, 1988, "%", "", +73418, Placebo, 1991, 1998, "placebo", "", +73419, LeastSquaresMean, 2007, 2032, "least squares ( LS ) mean", "", +73420, TimePoint, 2045, 2053, "baseline", "", +73421, HbA1c, 2057, 2062, "HbA1c", "", +73413, TimePoint, 2066, 2073, "Week 24", "", +73422, ChangeValue, 2078, 2086, "- 0 . 67", "", +73371, Percentage, 2087, 2088, "%", "", +73424, Omarigliptin, 2096, 2108, "omarigliptin", "", +73423, ChangeValue, 2119, 2127, "- 0 . 06", "", +73372, Percentage, 2128, 2129, "%", "", +73425, Placebo, 2137, 2144, "placebo", "", +73374, Percentage, 2192, 2193, "%", "", +73426, DiffGroupAbsValue, 2202, 2210, "- 0 . 61", "", +73375, Percentage, 2211, 2212, "%", "", +73427, ConfIntervalDiff, 2215, 2234, "- 0 . 85 , - 0 . 38", "", +73428, Omarigliptin, 2254, 2266, "omarigliptin", "", +73433, FastingPlasmaGlucose, 2316, 2319, "FPG", "", +73435, Placebo, 2332, 2339, "placebo", "", +73437, LeastSquaresMean, 2342, 2349, "LS mean", "", +73377, Percentage, 2366, 2367, "%", "", +73439, DiffGroupAbsValue, 2373, 2380, "- 0 . 9", "", +73442, Millimoles_per_litre, 2383, 2391, "mmol / L", "", +73445, ConfIntervalDiff, 2394, 2411, "- 1 . 4 , - 0 . 4", "", +73447, PvalueDiff, 2416, 2429, "p  <  0 . 001", "", +73453, HbA1c_target, 2438, 2512, "proportion of patients achieving glycemic goals of < 7 . 0 % and < 6 . 5 %", "", +73388, Percentage, 2497, 2498, "%", "", +73378, Percentage, 2511, 2512, "%", "", +73455, Omarigliptin, 2531, 2543, "omarigliptin", "", +73457, Placebo, 2566, 2573, "placebo", "", +73460, SymptomaticHypoglycemia, 2754, 2778, "symptomatic hypoglycemia", "", +73462, PercentageAffected, 2783, 2789, "10 . 5", "", +73380, Percentage, 2790, 2791, "%", "", +73465, Omarigliptin, 2799, 2811, "omarigliptin", "", +73464, PercentageAffected, 2822, 2827, "8 . 5", "", +73469, Percentage, 2828, 2829, "%", "", +73467, Placebo, 2837, 2844, "placebo", "", +73472, TimePoint, 2865, 2873, "baseline", "", +73473, Omarigliptin, 2876, 2888, "omarigliptin", "", +73478, Placebo, 2893, 2900, "placebo", "", +73480, LeastSquaresMean, 2933, 2940, "LS mean", "", +73481, BodyWeight, 2952, 2963, "body weight", "", +73483, ChangeValue, 2967, 2974, "- 0 . 1", "", +73486, Kg, 2977, 2979, "kg", "", +73485, ChangeValue, 2984, 2991, "- 0 . 9", "", +73487, Kg, 2994, 2996, "kg", "", +73811, ConclusionComment, 3027, 3261, "In patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride , compared with placebo , once - weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated", "", +73489, Type2Diabetes, 3044, 3047, "T2D", "", +73492, Metformin, 3101, 3110, "metformin", "", +73493, Glimepiride, 3115, 3126, "glimepiride", "", +73495, Placebo, 3143, 3150, "placebo", "", +73497, Frequency, 3153, 3166, "once - weekly", "", +73498, Omarigliptin, 3167, 3179, "omarigliptin", "", +73499, PMID, 3473, 3481, "29110647", "", diff --git a/data/dm2 29110647_akramersunderbrink.n-triples b/data/dm2 29110647_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29110647_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29110647_export.csv b/data/dm2 29110647_export.csv new file mode 100644 index 0000000..b0b6a6c --- /dev/null +++ b/data/dm2 29110647_export.csv @@ -0,0 +1,762 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +389, 1, 1, 1, 0, 3, 0, 3, "BMC" +389, 1, 2, 2, 4, 10, 4, 10, "Endocr" +389, 1, 3, 3, 11, 17, 11, 17, "Disord" +389, 1, 4, 4, 18, 19, 18, 19, "." +389, 2, 1, 5, 0, 4, 20, 24, "2017" +389, 2, 2, 6, 5, 8, 25, 28, "Nov" +389, 2, 3, 7, 9, 10, 29, 30, "6" +389, 2, 4, 8, 11, 12, 31, 32, ";" +389, 2, 5, 9, 13, 15, 33, 35, "17" +389, 2, 6, 10, 16, 17, 36, 37, "(" +389, 2, 7, 11, 18, 19, 38, 39, "1" +389, 2, 8, 12, 20, 21, 40, 41, ")" +389, 2, 9, 13, 22, 23, 42, 43, ":" +389, 2, 10, 14, 24, 26, 44, 46, "70" +389, 2, 11, 15, 27, 28, 47, 48, "." +389, 2, 12, 16, 29, 32, 49, 52, "doi" +389, 2, 13, 17, 33, 34, 53, 54, ":" +389, 2, 14, 18, 35, 37, 55, 57, "10" +389, 2, 15, 19, 38, 39, 58, 59, "." +389, 2, 16, 20, 40, 44, 60, 64, "1186" +389, 2, 17, 21, 45, 46, 65, 66, "/" +389, 2, 18, 22, 47, 53, 67, 73, "s12902" +389, 2, 19, 23, 54, 55, 74, 75, "-" +389, 2, 20, 24, 56, 59, 76, 79, "017" +389, 2, 21, 25, 60, 61, 80, 81, "-" +389, 2, 22, 26, 62, 66, 82, 86, "0219" +389, 2, 23, 27, 67, 68, 87, 88, "-" +389, 2, 24, 28, 69, 70, 89, 90, "x" +389, 2, 25, 29, 71, 72, 91, 92, "." +389, 3, 1, 30, 0, 1, 93, 94, "A" +389, 3, 2, 31, 2, 12, 95, 105, "randomized" +389, 3, 3, 32, 13, 14, 106, 107, "," +389, 3, 4, 33, 15, 22, 108, 115, "placebo" +389, 3, 5, 34, 23, 24, 116, 117, "-" +389, 3, 6, 35, 25, 35, 118, 128, "controlled" +389, 3, 7, 36, 36, 44, 129, 137, "clinical" +389, 3, 8, 37, 45, 50, 138, 143, "trial" +389, 3, 9, 38, 51, 61, 144, 154, "evaluating" +389, 3, 10, 39, 62, 65, 155, 158, "the" +389, 3, 11, 40, 66, 72, 159, 165, "safety" +389, 3, 12, 41, 73, 76, 166, 169, "and" +389, 3, 13, 42, 77, 85, 170, 178, "efficacy" +389, 3, 14, 43, 86, 88, 179, 181, "of" +389, 3, 15, 44, 89, 92, 182, 185, "the" +389, 3, 16, 45, 93, 97, 186, 190, "once" +389, 3, 17, 46, 98, 99, 191, 192, "-" +389, 3, 18, 47, 100, 106, 193, 199, "weekly" +389, 3, 19, 48, 107, 110, 200, 203, "DPP" +389, 3, 20, 49, 111, 112, 204, 205, "-" +389, 3, 21, 50, 113, 114, 206, 207, "4" +389, 3, 22, 51, 115, 124, 208, 217, "inhibitor" +389, 3, 23, 52, 125, 137, 218, 230, "omarigliptin" +389, 3, 24, 53, 138, 140, 231, 233, "in" +389, 3, 25, 54, 141, 149, 234, 242, "patients" +389, 3, 26, 55, 150, 154, 243, 247, "with" +389, 3, 27, 56, 155, 159, 248, 252, "type" +389, 3, 28, 57, 160, 161, 253, 254, "2" +389, 3, 29, 58, 162, 170, 255, 263, "diabetes" +389, 3, 30, 59, 171, 179, 264, 272, "mellitus" +389, 3, 31, 60, 180, 192, 273, 285, "inadequately" +389, 3, 32, 61, 193, 203, 286, 296, "controlled" +389, 3, 33, 62, 204, 206, 297, 299, "by" +389, 3, 34, 63, 207, 218, 300, 311, "glimepiride" +389, 3, 35, 64, 219, 222, 312, 315, "and" +389, 3, 36, 65, 223, 232, 316, 325, "metformin" +389, 3, 37, 66, 233, 234, 326, 327, "." +389, 4, 1, 67, 0, 3, 328, 331, "Lee" +389, 4, 2, 68, 4, 6, 332, 334, "SH" +389, 4, 3, 69, 7, 8, 335, 336, "(" +389, 4, 4, 70, 9, 10, 337, 338, "1" +389, 4, 5, 71, 11, 12, 339, 340, ")" +389, 4, 6, 72, 13, 14, 341, 342, "," +389, 4, 7, 73, 15, 20, 343, 348, "Gantz" +389, 4, 8, 74, 21, 22, 349, 350, "I" +389, 4, 9, 75, 23, 24, 351, 352, "(" +389, 4, 10, 76, 25, 26, 353, 354, "2" +389, 4, 11, 77, 27, 28, 355, 356, ")" +389, 4, 12, 78, 29, 30, 357, 358, "," +389, 4, 13, 79, 31, 36, 359, 364, "Round" +389, 4, 14, 80, 37, 38, 365, 366, "E" +389, 4, 15, 81, 39, 40, 367, 368, "(" +389, 4, 16, 82, 41, 42, 369, 370, "3" +389, 4, 17, 83, 43, 44, 371, 372, ")" +389, 4, 18, 84, 45, 46, 373, 374, "," +389, 4, 19, 85, 47, 53, 375, 381, "Latham" +389, 4, 20, 86, 54, 55, 382, 383, "M" +389, 4, 21, 87, 56, 57, 384, 385, "(" +389, 4, 22, 88, 58, 59, 386, 387, "3" +389, 4, 23, 89, 60, 61, 388, 389, ")" +389, 4, 24, 90, 62, 63, 390, 391, "," +389, 4, 25, 91, 64, 65, 392, 393, "O" +389, 4, 26, 92, 66, 67, 394, 395, "'" +389, 4, 27, 93, 68, 73, 396, 401, "Neill" +389, 4, 28, 94, 74, 76, 402, 404, "EA" +389, 4, 29, 95, 77, 78, 405, 406, "(" +389, 4, 30, 96, 79, 80, 407, 408, "3" +389, 4, 31, 97, 81, 82, 409, 410, ")" +389, 4, 32, 98, 83, 84, 411, 412, "," +389, 4, 33, 99, 85, 91, 413, 419, "Ceesay" +389, 4, 34, 100, 92, 93, 420, 421, "P" +389, 4, 35, 101, 94, 95, 422, 423, "(" +389, 4, 36, 102, 96, 97, 424, 425, "3" +389, 4, 37, 103, 98, 99, 426, 427, ")" +389, 4, 38, 104, 100, 101, 428, 429, "," +389, 4, 39, 105, 102, 113, 430, 441, "Suryawanshi" +389, 4, 40, 106, 114, 115, 442, 443, "S" +389, 4, 41, 107, 116, 117, 444, 445, "(" +389, 4, 42, 108, 118, 119, 446, 447, "3" +389, 4, 43, 109, 120, 121, 448, 449, ")" +389, 4, 44, 110, 122, 123, 450, 451, "," +389, 4, 45, 111, 124, 131, 452, 459, "Kaufman" +389, 4, 46, 112, 132, 134, 460, 462, "KD" +389, 4, 47, 113, 135, 136, 463, 464, "(" +389, 4, 48, 114, 137, 138, 465, 466, "3" +389, 4, 49, 115, 139, 140, 467, 468, ")" +389, 4, 50, 116, 141, 142, 469, 470, "," +389, 4, 51, 117, 143, 148, 471, 476, "Engel" +389, 4, 52, 118, 149, 151, 477, 479, "SS" +389, 4, 53, 119, 152, 153, 480, 481, "(" +389, 4, 54, 120, 154, 155, 482, 483, "3" +389, 4, 55, 121, 156, 157, 484, 485, ")" +389, 4, 56, 122, 158, 159, 486, 487, "," +389, 4, 57, 123, 160, 163, 488, 491, "Lai" +389, 4, 58, 124, 164, 165, 492, 493, "E" +389, 4, 59, 125, 166, 167, 494, 495, "(" +389, 4, 60, 126, 168, 169, 496, 497, "3" +389, 4, 61, 127, 170, 171, 498, 499, ")" +389, 4, 62, 128, 172, 173, 500, 501, "." +389, 5, 1, 129, 0, 6, 502, 508, "Author" +389, 5, 2, 130, 7, 18, 509, 520, "information" +389, 5, 3, 131, 19, 20, 521, 522, ":" +389, 5, 4, 132, 21, 22, 523, 524, "(" +389, 5, 5, 133, 23, 24, 525, 526, "1" +389, 5, 6, 134, 25, 26, 527, 528, ")" +389, 5, 7, 135, 27, 37, 529, 539, "Department" +389, 5, 8, 136, 38, 40, 540, 542, "of" +389, 5, 9, 137, 41, 49, 543, 551, "Internal" +389, 5, 10, 138, 50, 58, 552, 560, "Medicine" +389, 5, 11, 139, 59, 60, 561, 562, "," +389, 5, 12, 140, 61, 69, 563, 571, "Division" +389, 5, 13, 141, 70, 72, 572, 574, "of" +389, 5, 14, 142, 73, 86, 575, 588, "Endocrinology" +389, 5, 15, 143, 87, 90, 589, 592, "and" +389, 5, 16, 144, 91, 101, 593, 603, "Metabolism" +389, 5, 17, 145, 102, 103, 604, 605, "," +389, 5, 18, 146, 104, 109, 606, 611, "Seoul" +389, 5, 19, 147, 110, 112, 612, 614, "St" +389, 5, 20, 148, 113, 114, 615, 616, "." +389, 5, 21, 149, 115, 119, 617, 621, "Mary" +389, 5, 22, 150, 120, 121, 622, 623, "'" +389, 5, 23, 151, 122, 123, 624, 625, "s" +389, 5, 24, 152, 124, 132, 626, 634, "Hospital" +389, 5, 25, 153, 133, 134, 635, 636, "," +389, 5, 26, 154, 135, 142, 637, 644, "College" +389, 5, 27, 155, 143, 145, 645, 647, "of" +389, 5, 28, 156, 146, 154, 648, 656, "Medicine" +389, 5, 29, 157, 155, 156, 657, 658, "," +389, 5, 30, 158, 157, 160, 659, 662, "The" +389, 5, 31, 159, 161, 169, 663, 671, "Catholic" +389, 5, 32, 160, 170, 180, 672, 682, "University" +389, 5, 33, 161, 181, 183, 683, 685, "of" +389, 5, 34, 162, 184, 189, 686, 691, "Korea" +389, 5, 35, 163, 190, 191, 692, 693, "," +389, 5, 36, 164, 192, 197, 694, 699, "Seoul" +389, 5, 37, 165, 198, 199, 700, 701, "," +389, 5, 38, 166, 200, 208, 702, 710, "Republic" +389, 5, 39, 167, 209, 211, 711, 713, "of" +389, 5, 40, 168, 212, 217, 714, 719, "Korea" +389, 5, 41, 169, 218, 219, 720, 721, "." +389, 6, 1, 170, 0, 1, 722, 723, "(" +389, 6, 2, 171, 2, 3, 724, 725, "2" +389, 6, 3, 172, 4, 5, 726, 727, ")" +389, 6, 4, 173, 6, 11, 728, 733, "Merck" +389, 6, 5, 174, 12, 13, 734, 735, "&" +389, 6, 6, 175, 14, 16, 736, 738, "Co" +389, 6, 7, 176, 17, 18, 739, 740, "." +389, 6, 8, 177, 19, 20, 741, 742, "," +389, 6, 9, 178, 21, 24, 743, 746, "Inc" +389, 6, 10, 179, 25, 26, 747, 748, "." +389, 6, 11, 180, 27, 28, 749, 750, "," +389, 6, 12, 181, 29, 33, 751, 755, "2000" +389, 6, 13, 182, 34, 43, 756, 765, "Galloping" +389, 6, 14, 183, 44, 48, 766, 770, "Hill" +389, 6, 15, 184, 49, 53, 771, 775, "Road" +389, 6, 16, 185, 54, 55, 776, 777, "," +389, 6, 17, 186, 56, 66, 778, 788, "Kenilworth" +389, 6, 18, 187, 67, 68, 789, 790, "," +389, 6, 19, 188, 69, 71, 791, 793, "NJ" +389, 6, 20, 189, 72, 73, 794, 795, "," +389, 6, 21, 190, 74, 79, 796, 801, "07033" +389, 6, 22, 191, 80, 81, 802, 803, "," +389, 6, 23, 192, 82, 85, 804, 807, "USA" +389, 6, 24, 193, 86, 87, 808, 809, "." +389, 7, 1, 194, 0, 3, 810, 813, "ira" +389, 7, 2, 195, 4, 5, 814, 815, "." +389, 7, 3, 196, 6, 11, 816, 821, "gantz" +389, 7, 4, 197, 12, 13, 822, 823, "@" +389, 7, 5, 198, 14, 19, 824, 829, "merck" +389, 7, 6, 199, 20, 21, 830, 831, "." +389, 7, 7, 200, 22, 25, 832, 835, "com" +389, 7, 8, 201, 26, 27, 836, 837, "." +389, 8, 1, 202, 0, 1, 838, 839, "(" +389, 8, 2, 203, 2, 3, 840, 841, "3" +389, 8, 3, 204, 4, 5, 842, 843, ")" +389, 8, 4, 205, 6, 11, 844, 849, "Merck" +389, 8, 5, 206, 12, 13, 850, 851, "&" +389, 8, 6, 207, 14, 16, 852, 854, "Co" +389, 8, 7, 208, 17, 18, 855, 856, "." +389, 8, 8, 209, 19, 20, 857, 858, "," +389, 8, 9, 210, 21, 24, 859, 862, "Inc" +389, 8, 10, 211, 25, 26, 863, 864, "." +389, 8, 11, 212, 27, 28, 865, 866, "," +389, 8, 12, 213, 29, 33, 867, 871, "2000" +389, 8, 13, 214, 34, 43, 872, 881, "Galloping" +389, 8, 14, 215, 44, 48, 882, 886, "Hill" +389, 8, 15, 216, 49, 53, 887, 891, "Road" +389, 8, 16, 217, 54, 55, 892, 893, "," +389, 8, 17, 218, 56, 66, 894, 904, "Kenilworth" +389, 8, 18, 219, 67, 68, 905, 906, "," +389, 8, 19, 220, 69, 71, 907, 909, "NJ" +389, 8, 20, 221, 72, 73, 910, 911, "," +389, 8, 21, 222, 74, 79, 912, 917, "07033" +389, 8, 22, 223, 80, 81, 918, 919, "," +389, 8, 23, 224, 82, 85, 920, 923, "USA" +389, 8, 24, 225, 86, 87, 924, 925, "." +389, 9, 1, 226, 0, 10, 926, 936, "BACKGROUND" +389, 9, 2, 227, 11, 12, 937, 938, ":" +389, 9, 3, 228, 13, 17, 939, 943, "Type" +389, 9, 4, 229, 18, 19, 944, 945, "2" +389, 9, 5, 230, 20, 28, 946, 954, "diabetes" +389, 9, 6, 231, 29, 30, 955, 956, "(" +389, 9, 7, 232, 31, 34, 957, 960, "T2D" +389, 9, 8, 233, 35, 36, 961, 962, ")" +389, 9, 9, 234, 37, 39, 963, 965, "is" +389, 9, 10, 235, 40, 41, 966, 967, "a" +389, 9, 11, 236, 42, 53, 968, 979, "progressive" +389, 9, 12, 237, 54, 61, 980, 987, "disease" +389, 9, 13, 238, 62, 66, 988, 992, "that" +389, 9, 14, 239, 67, 72, 993, 998, "often" +389, 9, 15, 240, 73, 81, 999, 1007, "requires" +389, 9, 16, 241, 82, 83, 1008, 1009, "a" +389, 9, 17, 242, 84, 91, 1010, 1017, "patient" +389, 9, 18, 243, 92, 94, 1018, 1020, "to" +389, 9, 19, 244, 95, 98, 1021, 1024, "use" +389, 9, 20, 245, 99, 107, 1025, 1033, "multiple" +389, 9, 21, 246, 108, 125, 1034, 1051, "antihyperglycemic" +389, 9, 22, 247, 126, 132, 1052, 1058, "agents" +389, 9, 23, 248, 133, 135, 1059, 1061, "to" +389, 9, 24, 249, 136, 143, 1062, 1069, "achieve" +389, 9, 25, 250, 144, 152, 1070, 1078, "glycemic" +389, 9, 26, 251, 153, 160, 1079, 1086, "control" +389, 9, 27, 252, 161, 165, 1087, 1091, "with" +389, 9, 28, 253, 166, 173, 1092, 1099, "disease" +389, 9, 29, 254, 174, 185, 1100, 1111, "progression" +389, 9, 30, 255, 186, 187, 1112, 1113, "." +389, 10, 1, 256, 0, 12, 1114, 1126, "Omarigliptin" +389, 10, 2, 257, 13, 15, 1127, 1129, "is" +389, 10, 3, 258, 16, 17, 1130, 1131, "a" +389, 10, 4, 259, 18, 22, 1132, 1136, "once" +389, 10, 5, 260, 23, 24, 1137, 1138, "-" +389, 10, 6, 261, 25, 31, 1139, 1145, "weekly" +389, 10, 7, 262, 32, 42, 1146, 1156, "dipeptidyl" +389, 10, 8, 263, 43, 52, 1157, 1166, "peptidase" +389, 10, 9, 264, 53, 54, 1167, 1168, "-" +389, 10, 10, 265, 55, 56, 1169, 1170, "4" +389, 10, 11, 266, 57, 66, 1171, 1180, "inhibitor" +389, 10, 12, 267, 67, 68, 1181, 1182, "." +389, 11, 1, 268, 0, 3, 1183, 1186, "The" +389, 11, 2, 269, 4, 11, 1187, 1194, "purpose" +389, 11, 3, 270, 12, 14, 1195, 1197, "of" +389, 11, 4, 271, 15, 19, 1198, 1202, "this" +389, 11, 5, 272, 20, 25, 1203, 1208, "trial" +389, 11, 6, 273, 26, 29, 1209, 1212, "was" +389, 11, 7, 274, 30, 32, 1213, 1215, "to" +389, 11, 8, 275, 33, 39, 1216, 1222, "assess" +389, 11, 9, 276, 40, 43, 1223, 1226, "the" +389, 11, 10, 277, 44, 52, 1227, 1235, "efficacy" +389, 11, 11, 278, 53, 56, 1236, 1239, "and" +389, 11, 12, 279, 57, 63, 1240, 1246, "safety" +389, 11, 13, 280, 64, 66, 1247, 1249, "of" +389, 11, 14, 281, 67, 73, 1250, 1256, "adding" +389, 11, 15, 282, 74, 86, 1257, 1269, "omarigliptin" +389, 11, 16, 283, 87, 89, 1270, 1272, "to" +389, 11, 17, 284, 90, 93, 1273, 1276, "the" +389, 11, 18, 285, 94, 103, 1277, 1286, "treatment" +389, 11, 19, 286, 104, 111, 1287, 1294, "regimen" +389, 11, 20, 287, 112, 114, 1295, 1297, "of" +389, 11, 21, 288, 115, 123, 1298, 1306, "patients" +389, 11, 22, 289, 124, 128, 1307, 1311, "with" +389, 11, 23, 290, 129, 132, 1312, 1315, "T2D" +389, 11, 24, 291, 133, 145, 1316, 1328, "inadequately" +389, 11, 25, 292, 146, 156, 1329, 1339, "controlled" +389, 11, 26, 293, 157, 159, 1340, 1342, "by" +389, 11, 27, 294, 160, 164, 1343, 1347, "dual" +389, 11, 28, 295, 165, 172, 1348, 1355, "therapy" +389, 11, 29, 296, 173, 177, 1356, 1360, "with" +389, 11, 30, 297, 178, 187, 1361, 1370, "metformin" +389, 11, 31, 298, 188, 191, 1371, 1374, "and" +389, 11, 32, 299, 192, 203, 1375, 1386, "glimepiride" +389, 11, 33, 300, 204, 205, 1387, 1388, "." +389, 12, 1, 301, 0, 7, 1389, 1396, "METHODS" +389, 12, 2, 302, 8, 9, 1397, 1398, ":" +389, 12, 3, 303, 10, 18, 1399, 1407, "Patients" +389, 12, 4, 304, 19, 23, 1408, 1412, "with" +389, 12, 5, 305, 24, 27, 1413, 1416, "T2D" +389, 12, 6, 306, 28, 31, 1417, 1420, "and" +389, 12, 7, 307, 32, 37, 1421, 1426, "HbA1c" +389, 12, 8, 308, 38, 39, 1427, 1428, "≥" +389, 12, 9, 309, 40, 41, 1429, 1430, "7" +389, 12, 10, 310, 42, 43, 1431, 1432, "." +389, 12, 11, 311, 44, 45, 1433, 1434, "5" +389, 12, 12, 312, 46, 47, 1435, 1436, "%" +389, 12, 13, 313, 48, 51, 1437, 1440, "and" +389, 12, 14, 314, 52, 53, 1441, 1442, "≤" +389, 12, 15, 315, 54, 56, 1443, 1445, "10" +389, 12, 16, 316, 57, 58, 1446, 1447, "." +389, 12, 17, 317, 59, 60, 1448, 1449, "5" +389, 12, 18, 318, 61, 62, 1450, 1451, "%" +389, 12, 19, 319, 63, 68, 1452, 1457, "while" +389, 12, 20, 320, 69, 71, 1458, 1460, "on" +389, 12, 21, 321, 72, 81, 1461, 1470, "metformin" +389, 12, 22, 322, 82, 83, 1471, 1472, "(" +389, 12, 23, 323, 84, 85, 1473, 1474, "≥" +389, 12, 24, 324, 86, 90, 1475, 1479, "1500" +389, 12, 25, 325, 91, 92, 1480, 1481, " " +389, 12, 26, 326, 93, 95, 1482, 1484, "mg" +389, 12, 27, 327, 96, 97, 1485, 1486, "/" +389, 12, 28, 328, 98, 101, 1487, 1490, "day" +389, 12, 29, 329, 102, 103, 1491, 1492, ")" +389, 12, 30, 330, 104, 107, 1493, 1496, "and" +389, 12, 31, 331, 108, 119, 1497, 1508, "glimepiride" +389, 12, 32, 332, 120, 121, 1509, 1510, "(" +389, 12, 33, 333, 122, 123, 1511, 1512, "≥" +389, 12, 34, 334, 124, 125, 1513, 1514, "4" +389, 12, 35, 335, 126, 127, 1515, 1516, " " +389, 12, 36, 336, 128, 130, 1517, 1519, "mg" +389, 12, 37, 337, 131, 132, 1520, 1521, "/" +389, 12, 38, 338, 133, 136, 1522, 1525, "day" +389, 12, 39, 339, 137, 138, 1526, 1527, ")" +389, 12, 40, 340, 139, 143, 1528, 1532, "were" +389, 12, 41, 341, 144, 154, 1533, 1543, "randomized" +389, 12, 42, 342, 155, 157, 1544, 1546, "to" +389, 12, 43, 343, 158, 170, 1547, 1559, "omarigliptin" +389, 12, 44, 344, 171, 173, 1560, 1562, "25" +389, 12, 45, 345, 174, 175, 1563, 1564, " " +389, 12, 46, 346, 176, 178, 1565, 1567, "mg" +389, 12, 47, 347, 179, 183, 1568, 1572, "once" +389, 12, 48, 348, 184, 185, 1573, 1574, "-" +389, 12, 49, 349, 186, 192, 1575, 1581, "weekly" +389, 12, 50, 350, 193, 194, 1582, 1583, "(" +389, 12, 51, 351, 195, 196, 1584, 1585, "N" +389, 12, 52, 352, 197, 200, 1586, 1589, " = " +389, 12, 53, 353, 201, 204, 1590, 1593, "154" +389, 12, 54, 354, 205, 206, 1594, 1595, ")" +389, 12, 55, 355, 207, 209, 1596, 1598, "or" +389, 12, 56, 356, 210, 217, 1599, 1606, "placebo" +389, 12, 57, 357, 218, 219, 1607, 1608, "(" +389, 12, 58, 358, 220, 221, 1609, 1610, "N" +389, 12, 59, 359, 222, 225, 1611, 1614, " = " +389, 12, 60, 360, 226, 229, 1615, 1618, "153" +389, 12, 61, 361, 230, 231, 1619, 1620, ")" +389, 12, 62, 362, 232, 235, 1621, 1624, "for" +389, 12, 63, 363, 236, 238, 1625, 1627, "24" +389, 12, 64, 364, 239, 240, 1628, 1629, " " +389, 12, 65, 365, 241, 246, 1630, 1635, "weeks" +389, 12, 66, 366, 247, 248, 1636, 1637, "." +389, 13, 1, 367, 0, 3, 1638, 1641, "The" +389, 13, 2, 368, 4, 11, 1642, 1649, "primary" +389, 13, 3, 369, 12, 21, 1650, 1659, "objective" +389, 13, 4, 370, 22, 25, 1660, 1663, "was" +389, 13, 5, 371, 26, 28, 1664, 1666, "to" +389, 13, 6, 372, 29, 35, 1667, 1673, "assess" +389, 13, 7, 373, 36, 43, 1674, 1681, "whether" +389, 13, 8, 374, 44, 56, 1682, 1694, "omarigliptin" +389, 13, 9, 375, 57, 60, 1695, 1698, "was" +389, 13, 10, 376, 61, 69, 1699, 1707, "superior" +389, 13, 11, 377, 70, 72, 1708, 1710, "to" +389, 13, 12, 378, 73, 80, 1711, 1718, "placebo" +389, 13, 13, 379, 81, 83, 1719, 1721, "in" +389, 13, 14, 380, 84, 92, 1722, 1730, "reducing" +389, 13, 15, 381, 93, 98, 1731, 1736, "HbA1c" +389, 13, 16, 382, 99, 101, 1737, 1739, "at" +389, 13, 17, 383, 102, 106, 1740, 1744, "Week" +389, 13, 18, 384, 107, 109, 1745, 1747, "24" +389, 13, 19, 385, 110, 111, 1748, 1749, "." +389, 14, 1, 386, 0, 9, 1750, 1759, "Secondary" +389, 14, 2, 387, 10, 20, 1760, 1770, "objectives" +389, 14, 3, 388, 21, 25, 1771, 1775, "were" +389, 14, 4, 389, 26, 28, 1776, 1778, "to" +389, 14, 5, 390, 29, 35, 1779, 1785, "assess" +389, 14, 6, 391, 36, 39, 1786, 1789, "the" +389, 14, 7, 392, 40, 47, 1790, 1797, "effects" +389, 14, 8, 393, 48, 50, 1798, 1800, "of" +389, 14, 9, 394, 51, 63, 1801, 1813, "omarigliptin" +389, 14, 10, 395, 64, 66, 1814, 1816, "vs" +389, 14, 11, 396, 67, 68, 1817, 1818, "." +389, 14, 12, 397, 69, 76, 1819, 1826, "placebo" +389, 14, 13, 398, 77, 79, 1827, 1829, "on" +389, 14, 14, 399, 80, 83, 1830, 1833, "FPG" +389, 14, 15, 400, 84, 87, 1834, 1837, "and" +389, 14, 16, 401, 88, 91, 1838, 1841, "the" +389, 14, 17, 402, 92, 102, 1842, 1852, "proportion" +389, 14, 18, 403, 103, 105, 1853, 1855, "of" +389, 14, 19, 404, 106, 114, 1856, 1864, "subjects" +389, 14, 20, 405, 115, 124, 1865, 1874, "attaining" +389, 14, 21, 406, 125, 130, 1875, 1880, "HbA1c" +389, 14, 22, 407, 131, 136, 1881, 1886, "goals" +389, 14, 23, 408, 137, 139, 1887, 1889, "of" +389, 14, 24, 409, 140, 141, 1890, 1891, "<" +389, 14, 25, 410, 142, 143, 1892, 1893, "7" +389, 14, 26, 411, 144, 145, 1894, 1895, "%" +389, 14, 27, 412, 146, 149, 1896, 1899, "and" +389, 14, 28, 413, 150, 151, 1900, 1901, "<" +389, 14, 29, 414, 152, 153, 1902, 1903, "6" +389, 14, 30, 415, 154, 155, 1904, 1905, "." +389, 14, 31, 416, 156, 157, 1906, 1907, "5" +389, 14, 32, 417, 158, 159, 1908, 1909, "%" +389, 14, 33, 418, 160, 161, 1910, 1911, "." +389, 15, 1, 419, 0, 7, 1912, 1919, "RESULTS" +389, 15, 2, 420, 8, 9, 1920, 1921, ":" +389, 15, 3, 421, 10, 14, 1922, 1926, "From" +389, 15, 4, 422, 15, 16, 1927, 1928, "a" +389, 15, 5, 423, 17, 21, 1929, 1933, "mean" +389, 15, 6, 424, 22, 30, 1934, 1942, "baseline" +389, 15, 7, 425, 31, 36, 1943, 1948, "HbA1c" +389, 15, 8, 426, 37, 39, 1949, 1951, "of" +389, 15, 9, 427, 40, 41, 1952, 1953, "8" +389, 15, 10, 428, 42, 43, 1954, 1955, "." +389, 15, 11, 429, 44, 45, 1956, 1957, "5" +389, 15, 12, 430, 46, 47, 1958, 1959, "%" +389, 15, 13, 431, 48, 49, 1960, 1961, "(" +389, 15, 14, 432, 50, 62, 1962, 1974, "omarigliptin" +389, 15, 15, 433, 63, 64, 1975, 1976, ")" +389, 15, 16, 434, 65, 68, 1977, 1980, "and" +389, 15, 17, 435, 69, 70, 1981, 1982, "8" +389, 15, 18, 436, 71, 72, 1983, 1984, "." +389, 15, 19, 437, 73, 74, 1985, 1986, "6" +389, 15, 20, 438, 75, 76, 1987, 1988, "%" +389, 15, 21, 439, 77, 78, 1989, 1990, "(" +389, 15, 22, 440, 79, 86, 1991, 1998, "placebo" +389, 15, 23, 441, 87, 88, 1999, 2000, ")" +389, 15, 24, 442, 89, 90, 2001, 2002, "," +389, 15, 25, 443, 91, 94, 2003, 2006, "the" +389, 15, 26, 444, 95, 100, 2007, 2012, "least" +389, 15, 27, 445, 101, 108, 2013, 2020, "squares" +389, 15, 28, 446, 109, 110, 2021, 2022, "(" +389, 15, 29, 447, 111, 113, 2023, 2025, "LS" +389, 15, 30, 448, 114, 115, 2026, 2027, ")" +389, 15, 31, 449, 116, 120, 2028, 2032, "mean" +389, 15, 32, 450, 121, 127, 2033, 2039, "change" +389, 15, 33, 451, 128, 132, 2040, 2044, "from" +389, 15, 34, 452, 133, 141, 2045, 2053, "baseline" +389, 15, 35, 453, 142, 144, 2054, 2056, "in" +389, 15, 36, 454, 145, 150, 2057, 2062, "HbA1c" +389, 15, 37, 455, 151, 153, 2063, 2065, "at" +389, 15, 38, 456, 154, 158, 2066, 2070, "Week" +389, 15, 39, 457, 159, 161, 2071, 2073, "24" +389, 15, 40, 458, 162, 165, 2074, 2077, "was" +389, 15, 41, 459, 166, 167, 2078, 2079, "-" +389, 15, 42, 460, 168, 169, 2080, 2081, "0" +389, 15, 43, 461, 170, 171, 2082, 2083, "." +389, 15, 44, 462, 172, 174, 2084, 2086, "67" +389, 15, 45, 463, 175, 176, 2087, 2088, "%" +389, 15, 46, 464, 177, 179, 2089, 2091, "in" +389, 15, 47, 465, 180, 183, 2092, 2095, "the" +389, 15, 48, 466, 184, 196, 2096, 2108, "omarigliptin" +389, 15, 49, 467, 197, 202, 2109, 2114, "group" +389, 15, 50, 468, 203, 206, 2115, 2118, "and" +389, 15, 51, 469, 207, 208, 2119, 2120, "-" +389, 15, 52, 470, 209, 210, 2121, 2122, "0" +389, 15, 53, 471, 211, 212, 2123, 2124, "." +389, 15, 54, 472, 213, 215, 2125, 2127, "06" +389, 15, 55, 473, 216, 217, 2128, 2129, "%" +389, 15, 56, 474, 218, 220, 2130, 2132, "in" +389, 15, 57, 475, 221, 224, 2133, 2136, "the" +389, 15, 58, 476, 225, 232, 2137, 2144, "placebo" +389, 15, 59, 477, 233, 238, 2145, 2150, "group" +389, 15, 60, 478, 239, 240, 2151, 2152, "," +389, 15, 61, 479, 241, 245, 2153, 2157, "with" +389, 15, 62, 480, 246, 247, 2158, 2159, "a" +389, 15, 63, 481, 248, 255, 2160, 2167, "between" +389, 15, 64, 482, 256, 257, 2168, 2169, "-" +389, 15, 65, 483, 258, 263, 2170, 2175, "group" +389, 15, 66, 484, 264, 274, 2176, 2186, "difference" +389, 15, 67, 485, 275, 276, 2187, 2188, "(" +389, 15, 68, 486, 277, 279, 2189, 2191, "95" +389, 15, 69, 487, 280, 281, 2192, 2193, "%" +389, 15, 70, 488, 282, 284, 2194, 2196, "CI" +389, 15, 71, 489, 285, 286, 2197, 2198, ")" +389, 15, 72, 490, 287, 289, 2199, 2201, "of" +389, 15, 73, 491, 290, 291, 2202, 2203, "-" +389, 15, 74, 492, 292, 293, 2204, 2205, "0" +389, 15, 75, 493, 294, 295, 2206, 2207, "." +389, 15, 76, 494, 296, 298, 2208, 2210, "61" +389, 15, 77, 495, 299, 300, 2211, 2212, "%" +389, 15, 78, 496, 301, 302, 2213, 2214, "(" +389, 15, 79, 497, 303, 304, 2215, 2216, "-" +389, 15, 80, 498, 305, 306, 2217, 2218, "0" +389, 15, 81, 499, 307, 308, 2219, 2220, "." +389, 15, 82, 500, 309, 311, 2221, 2223, "85" +389, 15, 83, 501, 312, 313, 2224, 2225, "," +389, 15, 84, 502, 314, 315, 2226, 2227, "-" +389, 15, 85, 503, 316, 317, 2228, 2229, "0" +389, 15, 86, 504, 318, 319, 2230, 2231, "." +389, 15, 87, 505, 320, 322, 2232, 2234, "38" +389, 15, 88, 506, 323, 324, 2235, 2236, ")" +389, 15, 89, 507, 325, 326, 2237, 2238, "." +389, 16, 1, 508, 0, 9, 2239, 2248, "Treatment" +389, 16, 2, 509, 10, 14, 2249, 2253, "with" +389, 16, 3, 510, 15, 27, 2254, 2266, "omarigliptin" +389, 16, 4, 511, 28, 36, 2267, 2275, "resulted" +389, 16, 5, 512, 37, 39, 2276, 2278, "in" +389, 16, 6, 513, 40, 41, 2279, 2280, "a" +389, 16, 7, 514, 42, 55, 2281, 2294, "significantly" +389, 16, 8, 515, 56, 63, 2295, 2302, "greater" +389, 16, 9, 516, 64, 73, 2303, 2312, "reduction" +389, 16, 10, 517, 74, 76, 2313, 2315, "in" +389, 16, 11, 518, 77, 80, 2316, 2319, "FPG" +389, 16, 12, 519, 81, 89, 2320, 2328, "relative" +389, 16, 13, 520, 90, 92, 2329, 2331, "to" +389, 16, 14, 521, 93, 100, 2332, 2339, "placebo" +389, 16, 15, 522, 101, 102, 2340, 2341, "(" +389, 16, 16, 523, 103, 105, 2342, 2344, "LS" +389, 16, 17, 524, 106, 110, 2345, 2349, "mean" +389, 16, 18, 525, 111, 121, 2350, 2360, "difference" +389, 16, 19, 526, 122, 123, 2361, 2362, "[" +389, 16, 20, 527, 124, 126, 2363, 2365, "95" +389, 16, 21, 528, 127, 128, 2366, 2367, "%" +389, 16, 22, 529, 129, 131, 2368, 2370, "CI" +389, 16, 23, 530, 132, 133, 2371, 2372, "]" +389, 16, 24, 531, 134, 135, 2373, 2374, "-" +389, 16, 25, 532, 136, 137, 2375, 2376, "0" +389, 16, 26, 533, 138, 139, 2377, 2378, "." +389, 16, 27, 534, 140, 141, 2379, 2380, "9" +389, 16, 28, 535, 142, 143, 2381, 2382, " " +389, 16, 29, 536, 144, 148, 2383, 2387, "mmol" +389, 16, 30, 537, 149, 150, 2388, 2389, "/" +389, 16, 31, 538, 151, 152, 2390, 2391, "L" +389, 16, 32, 539, 153, 154, 2392, 2393, "[" +389, 16, 33, 540, 155, 156, 2394, 2395, "-" +389, 16, 34, 541, 157, 158, 2396, 2397, "1" +389, 16, 35, 542, 159, 160, 2398, 2399, "." +389, 16, 36, 543, 161, 162, 2400, 2401, "4" +389, 16, 37, 544, 163, 164, 2402, 2403, "," +389, 16, 38, 545, 165, 166, 2404, 2405, "-" +389, 16, 39, 546, 167, 168, 2406, 2407, "0" +389, 16, 40, 547, 169, 170, 2408, 2409, "." +389, 16, 41, 548, 171, 172, 2410, 2411, "4" +389, 16, 42, 549, 173, 174, 2412, 2413, "]" +389, 16, 43, 550, 175, 176, 2414, 2415, ";" +389, 16, 44, 551, 177, 178, 2416, 2417, "p" +389, 16, 45, 552, 179, 182, 2418, 2421, " < " +389, 16, 46, 553, 183, 184, 2422, 2423, "0" +389, 16, 47, 554, 185, 186, 2424, 2425, "." +389, 16, 48, 555, 187, 190, 2426, 2429, "001" +389, 16, 49, 556, 191, 192, 2430, 2431, ")" +389, 16, 50, 557, 193, 194, 2432, 2433, "." +389, 17, 1, 558, 0, 3, 2434, 2437, "The" +389, 17, 2, 559, 4, 14, 2438, 2448, "proportion" +389, 17, 3, 560, 15, 17, 2449, 2451, "of" +389, 17, 4, 561, 18, 26, 2452, 2460, "patients" +389, 17, 5, 562, 27, 36, 2461, 2470, "achieving" +389, 17, 6, 563, 37, 45, 2471, 2479, "glycemic" +389, 17, 7, 564, 46, 51, 2480, 2485, "goals" +389, 17, 8, 565, 52, 54, 2486, 2488, "of" +389, 17, 9, 566, 55, 56, 2489, 2490, "<" +389, 17, 10, 567, 57, 58, 2491, 2492, "7" +389, 17, 11, 568, 59, 60, 2493, 2494, "." +389, 17, 12, 569, 61, 62, 2495, 2496, "0" +389, 17, 13, 570, 63, 64, 2497, 2498, "%" +389, 17, 14, 571, 65, 68, 2499, 2502, "and" +389, 17, 15, 572, 69, 70, 2503, 2504, "<" +389, 17, 16, 573, 71, 72, 2505, 2506, "6" +389, 17, 17, 574, 73, 74, 2507, 2508, "." +389, 17, 18, 575, 75, 76, 2509, 2510, "5" +389, 17, 19, 576, 77, 78, 2511, 2512, "%" +389, 17, 20, 577, 79, 82, 2513, 2516, "was" +389, 17, 21, 578, 83, 89, 2517, 2523, "higher" +389, 17, 22, 579, 90, 92, 2524, 2526, "in" +389, 17, 23, 580, 93, 96, 2527, 2530, "the" +389, 17, 24, 581, 97, 109, 2531, 2543, "omarigliptin" +389, 17, 25, 582, 110, 115, 2544, 2549, "group" +389, 17, 26, 583, 116, 124, 2550, 2558, "relative" +389, 17, 27, 584, 125, 127, 2559, 2561, "to" +389, 17, 28, 585, 128, 131, 2562, 2565, "the" +389, 17, 29, 586, 132, 139, 2566, 2573, "placebo" +389, 17, 30, 587, 140, 145, 2574, 2579, "group" +389, 17, 31, 588, 146, 147, 2580, 2581, "." +389, 18, 1, 589, 0, 3, 2582, 2585, "The" +389, 18, 2, 590, 4, 11, 2586, 2593, "overall" +389, 18, 3, 591, 12, 22, 2594, 2604, "incidences" +389, 18, 4, 592, 23, 25, 2605, 2607, "of" +389, 18, 5, 593, 26, 33, 2608, 2615, "adverse" +389, 18, 6, 594, 34, 40, 2616, 2622, "events" +389, 18, 7, 595, 41, 42, 2623, 2624, "(" +389, 18, 8, 596, 43, 46, 2625, 2628, "AEs" +389, 18, 9, 597, 47, 48, 2629, 2630, ")" +389, 18, 10, 598, 49, 50, 2631, 2632, "," +389, 18, 11, 599, 51, 58, 2633, 2640, "serious" +389, 18, 12, 600, 59, 62, 2641, 2644, "AEs" +389, 18, 13, 601, 63, 64, 2645, 2646, "," +389, 18, 14, 602, 65, 69, 2647, 2651, "drug" +389, 18, 15, 603, 70, 71, 2652, 2653, "-" +389, 18, 16, 604, 72, 79, 2654, 2661, "related" +389, 18, 17, 605, 80, 83, 2662, 2665, "AEs" +389, 18, 18, 606, 84, 87, 2666, 2669, "and" +389, 18, 19, 607, 88, 104, 2670, 2686, "discontinuations" +389, 18, 20, 608, 105, 109, 2687, 2691, "were" +389, 18, 21, 609, 110, 119, 2692, 2701, "generally" +389, 18, 22, 610, 120, 127, 2702, 2709, "similar" +389, 18, 23, 611, 128, 135, 2710, 2717, "between" +389, 18, 24, 612, 136, 145, 2718, 2727, "treatment" +389, 18, 25, 613, 146, 152, 2728, 2734, "groups" +389, 18, 26, 614, 153, 154, 2735, 2736, "." +389, 19, 1, 615, 0, 3, 2737, 2740, "The" +389, 19, 2, 616, 4, 13, 2741, 2750, "incidence" +389, 19, 3, 617, 14, 16, 2751, 2753, "of" +389, 19, 4, 618, 17, 28, 2754, 2765, "symptomatic" +389, 19, 5, 619, 29, 41, 2766, 2778, "hypoglycemia" +389, 19, 6, 620, 42, 45, 2779, 2782, "was" +389, 19, 7, 621, 46, 48, 2783, 2785, "10" +389, 19, 8, 622, 49, 50, 2786, 2787, "." +389, 19, 9, 623, 51, 52, 2788, 2789, "5" +389, 19, 10, 624, 53, 54, 2790, 2791, "%" +389, 19, 11, 625, 55, 57, 2792, 2794, "in" +389, 19, 12, 626, 58, 61, 2795, 2798, "the" +389, 19, 13, 627, 62, 74, 2799, 2811, "omarigliptin" +389, 19, 14, 628, 75, 80, 2812, 2817, "group" +389, 19, 15, 629, 81, 84, 2818, 2821, "and" +389, 19, 16, 630, 85, 86, 2822, 2823, "8" +389, 19, 17, 631, 87, 88, 2824, 2825, "." +389, 19, 18, 632, 89, 90, 2826, 2827, "5" +389, 19, 19, 633, 91, 92, 2828, 2829, "%" +389, 19, 20, 634, 93, 95, 2830, 2832, "in" +389, 19, 21, 635, 96, 99, 2833, 2836, "the" +389, 19, 22, 636, 100, 107, 2837, 2844, "placebo" +389, 19, 23, 637, 108, 113, 2845, 2850, "group" +389, 19, 24, 638, 114, 115, 2851, 2852, "." +389, 20, 1, 639, 0, 8, 2853, 2861, "Relative" +389, 20, 2, 640, 9, 11, 2862, 2864, "to" +389, 20, 3, 641, 12, 20, 2865, 2873, "baseline" +389, 20, 4, 642, 21, 22, 2874, 2875, "," +389, 20, 5, 643, 23, 35, 2876, 2888, "omarigliptin" +389, 20, 6, 644, 36, 39, 2889, 2892, "and" +389, 20, 7, 645, 40, 47, 2893, 2900, "placebo" +389, 20, 8, 646, 48, 58, 2901, 2911, "treatments" +389, 20, 9, 647, 59, 63, 2912, 2916, "were" +389, 20, 10, 648, 64, 74, 2917, 2927, "associated" +389, 20, 11, 649, 75, 79, 2928, 2932, "with" +389, 20, 12, 650, 80, 82, 2933, 2935, "LS" +389, 20, 13, 651, 83, 87, 2936, 2940, "mean" +389, 20, 14, 652, 88, 95, 2941, 2948, "changes" +389, 20, 15, 653, 96, 98, 2949, 2951, "in" +389, 20, 16, 654, 99, 103, 2952, 2956, "body" +389, 20, 17, 655, 104, 110, 2957, 2963, "weight" +389, 20, 18, 656, 111, 113, 2964, 2966, "of" +389, 20, 19, 657, 114, 115, 2967, 2968, "-" +389, 20, 20, 658, 116, 117, 2969, 2970, "0" +389, 20, 21, 659, 118, 119, 2971, 2972, "." +389, 20, 22, 660, 120, 121, 2973, 2974, "1" +389, 20, 23, 661, 122, 123, 2975, 2976, " " +389, 20, 24, 662, 124, 126, 2977, 2979, "kg" +389, 20, 25, 663, 127, 130, 2980, 2983, "and" +389, 20, 26, 664, 131, 132, 2984, 2985, "-" +389, 20, 27, 665, 133, 134, 2986, 2987, "0" +389, 20, 28, 666, 135, 136, 2988, 2989, "." +389, 20, 29, 667, 137, 138, 2990, 2991, "9" +389, 20, 30, 668, 139, 140, 2992, 2993, " " +389, 20, 31, 669, 141, 143, 2994, 2996, "kg" +389, 20, 32, 670, 144, 145, 2997, 2998, "," +389, 20, 33, 671, 146, 158, 2999, 3011, "respectively" +389, 20, 34, 672, 159, 160, 3012, 3013, "." +389, 21, 1, 673, 0, 10, 3014, 3024, "CONCLUSION" +389, 21, 2, 674, 11, 12, 3025, 3026, ":" +389, 21, 3, 675, 13, 15, 3027, 3029, "In" +389, 21, 4, 676, 16, 24, 3030, 3038, "patients" +389, 21, 5, 677, 25, 29, 3039, 3043, "with" +389, 21, 6, 678, 30, 33, 3044, 3047, "T2D" +389, 21, 7, 679, 34, 37, 3048, 3051, "and" +389, 21, 8, 680, 38, 48, 3052, 3062, "inadequate" +389, 21, 9, 681, 49, 57, 3063, 3071, "glycemic" +389, 21, 10, 682, 58, 65, 3072, 3079, "control" +389, 21, 11, 683, 66, 68, 3080, 3082, "on" +389, 21, 12, 684, 69, 73, 3083, 3087, "dual" +389, 21, 13, 685, 74, 81, 3088, 3095, "therapy" +389, 21, 14, 686, 82, 86, 3096, 3100, "with" +389, 21, 15, 687, 87, 96, 3101, 3110, "metformin" +389, 21, 16, 688, 97, 100, 3111, 3114, "and" +389, 21, 17, 689, 101, 112, 3115, 3126, "glimepiride" +389, 21, 18, 690, 113, 114, 3127, 3128, "," +389, 21, 19, 691, 115, 123, 3129, 3137, "compared" +389, 21, 20, 692, 124, 128, 3138, 3142, "with" +389, 21, 21, 693, 129, 136, 3143, 3150, "placebo" +389, 21, 22, 694, 137, 138, 3151, 3152, "," +389, 21, 23, 695, 139, 143, 3153, 3157, "once" +389, 21, 24, 696, 144, 145, 3158, 3159, "-" +389, 21, 25, 697, 146, 152, 3160, 3166, "weekly" +389, 21, 26, 698, 153, 165, 3167, 3179, "omarigliptin" +389, 21, 27, 699, 166, 174, 3180, 3188, "provided" +389, 21, 28, 700, 175, 182, 3189, 3196, "greater" +389, 21, 29, 701, 183, 194, 3197, 3208, "improvement" +389, 21, 30, 702, 195, 197, 3209, 3211, "in" +389, 21, 31, 703, 198, 206, 3212, 3220, "glycemic" +389, 21, 32, 704, 207, 214, 3221, 3228, "control" +389, 21, 33, 705, 215, 218, 3229, 3232, "and" +389, 21, 34, 706, 219, 222, 3233, 3236, "was" +389, 21, 35, 707, 223, 232, 3237, 3246, "generally" +389, 21, 36, 708, 233, 237, 3247, 3251, "well" +389, 21, 37, 709, 238, 247, 3252, 3261, "tolerated" +389, 21, 38, 710, 248, 249, 3262, 3263, "." +389, 22, 1, 711, 0, 5, 3264, 3269, "TRIAL" +389, 22, 2, 712, 6, 18, 3270, 3282, "REGISTRATION" +389, 22, 3, 713, 19, 20, 3283, 3284, ":" +389, 22, 4, 714, 21, 35, 3285, 3299, "ClinicalTrials" +389, 22, 5, 715, 36, 37, 3300, 3301, "." +389, 22, 6, 716, 38, 41, 3302, 3305, "gov" +389, 22, 7, 717, 42, 43, 3306, 3307, ":" +389, 22, 8, 718, 44, 55, 3308, 3319, "NCT01704261" +389, 22, 9, 719, 56, 57, 3320, 3321, "," +389, 22, 10, 720, 58, 65, 3322, 3329, "EudraCT" +389, 22, 11, 721, 66, 72, 3330, 3336, "Number" +389, 22, 12, 722, 73, 74, 3337, 3338, ":" +389, 22, 13, 723, 75, 79, 3339, 3343, "2012" +389, 22, 14, 724, 80, 81, 3344, 3345, "-" +389, 22, 15, 725, 82, 88, 3346, 3352, "002612" +389, 22, 16, 726, 89, 90, 3353, 3354, "-" +389, 22, 17, 727, 91, 93, 3355, 3357, "10" +389, 22, 18, 728, 94, 95, 3358, 3359, "." +389, 23, 1, 729, 0, 5, 3360, 3365, "Trial" +389, 23, 2, 730, 6, 18, 3366, 3378, "Registration" +389, 23, 3, 731, 19, 23, 3379, 3383, "Date" +389, 23, 4, 732, 24, 25, 3384, 3385, ":" +389, 23, 5, 733, 26, 33, 3386, 3393, "October" +389, 23, 6, 734, 34, 35, 3394, 3395, "8" +389, 23, 7, 735, 36, 37, 3396, 3397, "," +389, 23, 8, 736, 38, 42, 3398, 3402, "2012" +389, 23, 9, 737, 43, 44, 3403, 3404, "." +389, 24, 1, 738, 0, 3, 3405, 3408, "DOI" +389, 24, 2, 739, 4, 5, 3409, 3410, ":" +389, 24, 3, 740, 6, 8, 3411, 3413, "10" +389, 24, 4, 741, 9, 10, 3414, 3415, "." +389, 24, 5, 742, 11, 15, 3416, 3420, "1186" +389, 24, 6, 743, 16, 17, 3421, 3422, "/" +389, 24, 7, 744, 18, 24, 3423, 3429, "s12902" +389, 24, 8, 745, 25, 26, 3430, 3431, "-" +389, 24, 9, 746, 27, 30, 3432, 3435, "017" +389, 24, 10, 747, 31, 32, 3436, 3437, "-" +389, 24, 11, 748, 33, 37, 3438, 3442, "0219" +389, 24, 12, 749, 38, 39, 3443, 3444, "-" +389, 24, 13, 750, 40, 41, 3445, 3446, "x" +389, 24, 14, 751, 42, 47, 3447, 3452, "PMCID" +389, 24, 15, 752, 48, 49, 3453, 3454, ":" +389, 24, 16, 753, 50, 60, 3455, 3465, "PMC5674832" +389, 24, 17, 754, 61, 65, 3466, 3470, "PMID" +389, 24, 18, 755, 66, 67, 3471, 3472, ":" +389, 24, 19, 756, 68, 76, 3473, 3481, "29110647" +389, 24, 20, 757, 77, 78, 3482, 3483, "[" +389, 24, 21, 758, 79, 86, 3484, 3491, "Indexed" +389, 24, 22, 759, 87, 90, 3492, 3495, "for" +389, 24, 23, 760, 91, 98, 3496, 3503, "MEDLINE" +389, 24, 24, 761, 99, 100, 3504, 3505, "]" diff --git a/data/dm2 29110647_kwoodley.annodb b/data/dm2 29110647_kwoodley.annodb new file mode 100644 index 0000000..3d6b68c --- /dev/null +++ b/data/dm2 29110647_kwoodley.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72380, Journal, 0, 17, "BMC Endocr Disord", "", +72381, PublicationYear, 20, 24, "2017", "", +72427, Title, 93, 327, "A randomized , placebo - controlled clinical trial evaluating the safety and efficacy of the once - weekly DPP - 4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin .", "", +72382, Randomized, 95, 105, "randomized", "", +72383, Placebo, 108, 115, "placebo", "", +72392, Frequency, 186, 199, "once - weekly", "", +72398, Omarigliptin, 218, 230, "omarigliptin", "", +72426, Precondition, 234, 325, "patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin", "", +72408, Type2Diabetes, 248, 272, "type 2 diabetes mellitus", "", +72414, Glimepiride, 300, 311, "glimepiride", "", +72422, Metformin, 316, 325, "metformin", "", +72428, Author, 328, 334, "Lee SH", "", +72429, Author, 343, 350, "Gantz I", "", +72430, Author, 359, 366, "Round E", "", +72431, Author, 375, 383, "Latham M", "", +72432, Author, 392, 404, "O ' Neill EA", "", +72433, Author, 413, 421, "Ceesay P", "", +72434, Author, 430, 443, "Suryawanshi S", "", +72435, Author, 452, 462, "Kaufman KD", "", +72436, Author, 471, 479, "Engel SS", "", +72437, Author, 488, 493, "Lai E", "", +72438, SouthKorea, 714, 719, "Korea", "", +72439, USA, 804, 807, "USA", "", +72440, USA, 920, 923, "USA", "", +72410, Type2Diabetes, 939, 954, "Type 2 diabetes", "", +72409, Type2Diabetes, 957, 960, "T2D", "", +72399, Omarigliptin, 1114, 1126, "Omarigliptin", "", +72394, Frequency, 1132, 1145, "once - weekly", "", +72442, ObjectiveDescription, 1183, 1388, "The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride .", "", +72400, Omarigliptin, 1257, 1269, "omarigliptin", "", +72441, Precondition, 1298, 1386, "patients with T2D inadequately controlled by dual therapy with metformin and glimepiride", "", +72411, Type2Diabetes, 1312, 1315, "T2D", "", +72423, Metformin, 1361, 1370, "metformin", "", +72415, Glimepiride, 1375, 1386, "glimepiride", "", +72452, Precondition, 1399, 1527, "Patients with T2D and HbA1c ≥ 7 . 5 % and ≤ 10 . 5 % while on metformin ( ≥ 1500   mg / day ) and glimepiride ( ≥ 4   mg / day )", "", +72412, Type2Diabetes, 1413, 1416, "T2D", "", +72443, HbA1c, 1421, 1426, "HbA1c", "", +72444, Percentage, 1435, 1436, "%", "", +72445, Percentage, 1450, 1451, "%", "", +72424, Metformin, 1461, 1470, "metformin", "", +72446, DoseValue, 1473, 1479, "≥ 1500", "", +72449, mg, 1482, 1484, "mg", "", +72395, Frequency, 1487, 1490, "day", "", +72416, Glimepiride, 1497, 1508, "glimepiride", "", +72447, DoseValue, 1511, 1514, "≥ 4", "", +72450, mg, 1517, 1519, "mg", "", +72396, Frequency, 1522, 1525, "day", "", +72453, Randomized, 1533, 1543, "randomized", "", +72401, Omarigliptin, 1547, 1559, "omarigliptin", "", +72448, DoseValue, 1560, 1562, "25", "", +72451, mg, 1565, 1567, "mg", "", +72393, Frequency, 1568, 1581, "once - weekly", "", +72454, NumberPatientsArm, 1590, 1593, "154", "", +72384, Placebo, 1599, 1606, "placebo", "", +72455, NumberPatientsArm, 1615, 1618, "153", "", +72456, Duration, 1625, 1635, "24   weeks", "", +72418, Omarigliptin, 1682, 1694, "omarigliptin", "", +72420, Placebo, 1711, 1718, "placebo", "", +72457, HbA1c, 1731, 1736, "HbA1c", "", +72460, TimePoint, 1740, 1747, "Week 24", "", +72419, Omarigliptin, 1801, 1813, "omarigliptin", "", +72421, Placebo, 1819, 1826, "placebo", "", +72464, FastingPlasmaGlucose, 1830, 1833, "FPG", "", +72466, HbA1c_target, 1875, 1895, "HbA1c goals of < 7 %", "", +72467, HbA1c_target, 1875, 1909, "HbA1c goals of < 7 % and < 6 . 5 %", "", +72461, TimePoint, 1934, 1942, "baseline", "", +72458, HbA1c, 1943, 1948, "HbA1c", "", +72468, BaseLineValue, 1952, 1957, "8 . 5", "", +72470, Percentage, 1958, 1959, "%", "", +72475, Omarigliptin, 1962, 1974, "omarigliptin", "", +72469, BaseLineValue, 1981, 1986, "8 . 6", "", +72471, Percentage, 1987, 1988, "%", "", +72385, Placebo, 1991, 1998, "placebo", "", +72476, LeastSquaresMean, 2007, 2032, "least squares ( LS ) mean", "", +72462, TimePoint, 2045, 2053, "baseline", "", +72459, HbA1c, 2057, 2062, "HbA1c", "", +72463, TimePoint, 2066, 2073, "Week 24", "", +72477, Reduction, 2080, 2086, "0 . 67", "", +72472, Percentage, 2087, 2088, "%", "", +72402, Omarigliptin, 2096, 2108, "omarigliptin", "", +72478, Reduction, 2121, 2127, "0 . 06", "", +72473, Percentage, 2128, 2129, "%", "", +72386, Placebo, 2137, 2144, "placebo", "", +72479, ConfIntervalDiff, 2189, 2196, "95 % CI", "", +72481, DiffGroupAbsValue, 2202, 2210, "- 0 . 61", "", +72474, Percentage, 2211, 2212, "%", "", +72480, ConfIntervalDiff, 2215, 2234, "- 0 . 85 , - 0 . 38", "", +72403, Omarigliptin, 2254, 2266, "omarigliptin", "", +72465, FastingPlasmaGlucose, 2316, 2319, "FPG", "", +72387, Placebo, 2332, 2339, "placebo", "", +72482, LeastSquaresMean, 2342, 2349, "LS mean", "", +72483, ConfIntervalDiff, 2363, 2370, "95 % CI", "", +72485, DiffGroupAbsValue, 2373, 2380, "- 0 . 9", "", +72486, Millimoles_per_litre, 2383, 2391, "mmol / L", "", +72484, ConfIntervalDiff, 2394, 2411, "- 1 . 4 , - 0 . 4", "", +72487, PvalueDiff, 2416, 2429, "p  <  0 . 001", "", +72490, ObservedResult, 2434, 2581, "The proportion of patients achieving glycemic goals of < 7 . 0 % and < 6 . 5 % was higher in the omarigliptin group relative to the placebo group .", "", +72488, HbA1c_target, 2489, 2498, "< 7 . 0 %", "", +72489, HbA1c_target, 2503, 2512, "< 6 . 5 %", "", +72404, Omarigliptin, 2531, 2543, "omarigliptin", "", +72388, Placebo, 2566, 2573, "placebo", "", +72491, EndPointDescription, 2608, 2622, "adverse events", "", +72492, EndPointDescription, 2625, 2628, "AEs", "", +72496, SubGroupDescription, 2633, 2644, "serious AEs", "", +72494, EndPointDescription, 2641, 2644, "AEs", "", +72497, SubGroupDescription, 2647, 2665, "drug - related AEs", "", +72495, EndPointDescription, 2662, 2665, "AEs", "", +72498, EndPointDescription, 2670, 2686, "discontinuations", "", +72499, ObservedResult, 2687, 2734, "were generally similar between treatment groups", "", +72500, SymptomaticHypoglycemia, 2754, 2778, "symptomatic hypoglycemia", "", +72501, PercentageAffected, 2783, 2789, "10 . 5", "", +72405, Omarigliptin, 2799, 2811, "omarigliptin", "", +72502, PercentageAffected, 2822, 2827, "8 . 5", "", +72389, Placebo, 2837, 2844, "placebo", "", +72503, TimePoint, 2865, 2873, "baseline", "", +72406, Omarigliptin, 2876, 2888, "omarigliptin", "", +72390, Placebo, 2893, 2900, "placebo", "", +72504, LeastSquaresMean, 2933, 2940, "LS mean", "", +72505, BodyWeight, 2952, 2963, "body weight", "", +72506, Reduction, 2969, 2974, "0 . 1", "", +72508, Kg, 2977, 2979, "kg", "", +72507, Reduction, 2986, 2991, "0 . 9", "", +72509, Kg, 2994, 2996, "kg", "", +72510, ConclusionComment, 3027, 3263, "In patients with T2D and inadequate glycemic control on dual therapy with metformin and glimepiride , compared with placebo , once - weekly omarigliptin provided greater improvement in glycemic control and was generally well tolerated .", "", +72413, Type2Diabetes, 3044, 3047, "T2D", "", +72425, Metformin, 3101, 3110, "metformin", "", +72417, Glimepiride, 3115, 3126, "glimepiride", "", +72391, Placebo, 3143, 3150, "placebo", "", +72397, Frequency, 3153, 3166, "once - weekly", "", +72407, Omarigliptin, 3167, 3179, "omarigliptin", "", +72511, PMID, 3473, 3481, "29110647", "", diff --git a/data/dm2 29110647_kwoodley.n-triples b/data/dm2 29110647_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29110647_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29144061_admin.annodb b/data/dm2 29144061_admin.annodb new file mode 100644 index 0000000..558a575 --- /dev/null +++ b/data/dm2 29144061_admin.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2018", "", " \"2018\"." +2, Saxagliptin, 109, 120, "Saxagliptin", "", +27, Title, 109, 333, "Saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin : Results from the SUPER study , a randomized , double - blind , placebo - controlled trial .", "", " \"Saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin : Results from the SUPER study , a randomized , double - blind , placebo - controlled trial .\"." +8, Ethnicity, 141, 148, "Chinese", "", +22, Precondition, 149, 239, "patients with type 2 diabetes inadequately controlled by insulin with or without metformin", "", " \"patients with type 2 diabetes inadequately controlled by insulin with or without metformin\"." +11, Type2Diabetes, 163, 178, "type 2 diabetes", "", " ." +112, Precondition, 179, 239, "inadequately controlled by insulin with or without metformin", "", +14, Insulin, 206, 213, "insulin", "", +17, Metformin, 230, 239, "metformin", "", +20, Randomized, 275, 285, "randomized", "", " ." +21, DoubleBlind, 288, 302, "double - blind", "", " ." +23, Placebo, 305, 312, "placebo", "", +28, Author, 334, 340, "Chen Y", "", " \"Chen Y\"." +29, Author, 349, 354, "Liu X", "", " \"Liu X\"." +30, Author, 363, 367, "Li Q", "", " \"Li Q\"." +31, Author, 376, 380, "Ma J", "", " \"Ma J\"." +32, Author, 389, 393, "Lv X", "", " \"Lv X\"." +33, Author, 402, 407, "Guo L", "", " \"Guo L\"." +34, Author, 416, 422, "Wang C", "", " \"Wang C\"." +35, Author, 431, 436, "Shi Y", "", " \"Shi Y\"." +36, Author, 445, 449, "Li Y", "", " \"Li Y\"." +37, Author, 458, 468, "Johnsson E", "", " \"Johnsson E\"." +38, Author, 478, 484, "Wang M", "", " \"Wang M\"." +39, Author, 494, 500, "Zhao J", "", " \"Zhao J\"." +40, Author, 510, 514, "Ji L", "", " \"Ji L\"." +41, China, 645, 650, "China", "", +42, China, 755, 760, "China", "", +43, China, 856, 861, "China", "", +44, China, 935, 940, "China", "", +45, China, 1009, 1014, "China", "", +46, China, 1115, 1120, "China", "", +47, China, 1223, 1228, "China", "", +48, China, 1309, 1314, "China", "", +49, China, 1421, 1426, "China", "", " ." +51, Sweden, 1473, 1479, "Sweden", "", +50, China, 1538, 1543, "China", "", +52, USA, 1582, 1590, "Maryland", "", +56, ObjectiveDescription, 1593, 1815, "This prospective , multicentre , phase III study ( NCT02104804 ) evaluated the efficacy and safety of saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin  ±  metformin .", "", " \"This prospective , multicentre , phase III study ( NCT02104804 ) evaluated the efficacy and safety of saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin  ±  metformin .\"." +53, Prospective, 1598, 1609, "prospective", "", " ." +54, Multicenter, 1612, 1623, "multicentre", "", " ." +3, Saxagliptin, 1695, 1706, "saxagliptin", "", +9, Ethnicity, 1727, 1734, "Chinese", "", " . ." +55, Precondition, 1735, 1813, "patients with type 2 diabetes inadequately controlled by insulin  ±  metformin", "", +12, Type2Diabetes, 1749, 1764, "type 2 diabetes", "", +15, Insulin, 1792, 1799, "insulin", "", +18, Metformin, 1804, 1813, "metformin", "", +57, HbA1c, 1830, 1850, "glycated haemoglobin", "", +58, HbA1c, 1853, 1858, "HbA1c", "", +61, Percentage, 1867, 1868, "%", "", +62, Percentage, 1879, 1880, "%", "", +63, FastingPlasmaGlucose, 1885, 1907, "fasting plasma glucose", "", +64, FastingPlasmaGlucose, 1910, 1913, "FPG", "", +65, Millimoles_per_litre, 1921, 1929, "mmol / L", "", +66, Mg_per_deciliter, 1938, 1945, "mg / dL", "", +67, Insulin, 1958, 1965, "insulin", "", +68, DoseValue, 1976, 1984, "20 - 150", "", +85184, Int_Unit, 1987, 1988, "U", "", +106234, Frequency, 1991, 1992, "d", "", +71, Randomized, 2000, 2010, "randomized", "", +72, AllocationRatio, 2013, 2018, "1 : 1", "", " . ." +4, Saxagliptin, 2024, 2035, "saxagliptin", "", " ." +74, DoseValue, 2036, 2037, "5", "", " \"5\"." +75, mg, 2038, 2040, "mg", "", " ." +76, Frequency, 2041, 2051, "once daily", "", " \"once daily\"." +77, NumberPatientsArm, 2060, 2063, "232", "", " \"232\"." +24, Placebo, 2069, 2076, "placebo", "", " ." +78, NumberPatientsArm, 2085, 2088, "230", "", " \"230\"." +79, Duration, 2095, 2105, "24   weeks", "", " \"24   weeks\"." +80, Metformin, 2122, 2131, "metformin", "", +59, HbA1c, 2181, 2186, "HbA1c", "", +5, Saxagliptin, 2189, 2200, "Saxagliptin", "", +181, Mean, 2242, 2246, "mean", "", " . ." +60, HbA1c, 2257, 2262, "HbA1c", "", " ." +81, TimePoint, 2268, 2276, "baseline", "", +82, TimePoint, 2280, 2287, "week 24", "", +25, Placebo, 2293, 2300, "placebo", "", +83, DiffGroupAbsValue, 2303, 2311, "- 0 . 58", "", " \"- 0 . 58\"." +84, Percentage, 2312, 2313, "%", "", " ." +85, PvalueDiff, 2316, 2326, "P  < . 001", "", " \"P  < . 001\"." +87, Metformin, 2347, 2356, "metformin", "", +187, Mean, 2377, 2381, "mean", "", " . ." +88, FastingPlasmaGlucose, 2392, 2395, "FPG", "", " ." +89, DiffGroupAbsValue, 2398, 2403, "0 . 9", "", " \"0 . 9\"." +91, Millimoles_per_litre, 2404, 2412, "mmol / L", "", " ." +90, DiffGroupAbsValue, 2415, 2423, "- 15 . 9", "", +92, Mg_per_deciliter, 2424, 2431, "mg / dL", "", +86, PvalueDiff, 2436, 2446, "P  < . 001", "", " \"P  < . 001\"." +93, HbA1c_target, 2474, 2485, "HbA1c < 7 %", "", " ." +162, Percentage, 2484, 2485, "%", "", +6, Saxagliptin, 2491, 2502, "saxagliptin", "", +94, PercentageAffected, 2505, 2511, "11 . 4", "", " \"11 . 4\"." +26, Placebo, 2526, 2533, "placebo", "", +95, PercentageAffected, 2536, 2541, "3 . 5", "", " \"3 . 5\"." +96, PvalueDiff, 2546, 2556, "P  = . 002", "", " \"P  = . 002\"." +97, EndPointDescription, 2561, 2575, "Adverse events", "", +99, ObservedResult, 2561, 2636, "Adverse events and incidence of hypoglycaemia were similar in both groups .", "", +98, Hypoglycemia, 2593, 2606, "hypoglycaemia", "", +105, ConclusionComment, 2637, 2879, "Overall , add - on saxagliptin 5 mg once daily significantly improved glycaemic control without increasing hypoglycaemia risk and was well tolerated in Chinese patients with type 2 diabetes inadequately controlled by insulin ( ± metformin ) .", "", " \"Overall , add - on saxagliptin 5 mg once daily significantly improved glycaemic control without increasing hypoglycaemia risk and was well tolerated in Chinese patients with type 2 diabetes inadequately controlled by insulin ( ± metformin ) .\"." +7, Saxagliptin, 2656, 2667, "saxagliptin", "", +100, DoseValue, 2668, 2669, "5", "", +101, mg, 2670, 2672, "mg", "", +102, Frequency, 2673, 2683, "once daily", "", +103, Hypoglycemia, 2744, 2757, "hypoglycaemia", "", +10, Ethnicity, 2789, 2796, "Chinese", "", +13, Type2Diabetes, 2811, 2826, "type 2 diabetes", "", +16, Insulin, 2854, 2861, "insulin", "", +19, Metformin, 2866, 2875, "metformin", "", +106, PMID, 2948, 2956, "29144061", "", " \"29144061\"." diff --git a/data/dm2 29144061_admin.n-triples b/data/dm2 29144061_admin.n-triples new file mode 100644 index 0000000..c508afb --- /dev/null +++ b/data/dm2 29144061_admin.n-triples @@ -0,0 +1,150 @@ +# RDF export of group: Publication + . + "Publication 78000" . + "Saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin : Results from the SUPER study , a randomized , double - blind , placebo - controlled trial ." . + "Chen Y" . + "2018" . + "Diabetes Obes Metab ." . + "29144061" . + . + "Liu X" . + "Li Q" . + "Ma J" . + "Lv X" . + "Guo L" . + "Wang C" . + "Shi Y" . + "Li Y" . + "Johnsson E" . + "Wang M" . + "Zhao J" . + "Ji L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 78007" . + "This prospective , multicentre , phase III study ( NCT02104804 ) evaluated the efficacy and safety of saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin  ±  metformin ." . + "24   weeks" . + . + . + . + . + "Overall , add - on saxagliptin 5 mg once daily significantly improved glycaemic control without increasing hypoglycaemia risk and was well tolerated in Chinese patients with type 2 diabetes inadequately controlled by insulin ( ± metformin ) ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 78023" . + "patients with type 2 diabetes inadequately controlled by insulin with or without metformin" . + . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "hbat" . + . + . + . + . +# RDF export of group: Arm + . + "sax" . + "232" . + . + . + . + . + . + . + "pla" . + "230" . + . + . + . + . + . +# RDF export of group: Intervention + . + "sax" . + . + "once daily" . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "sax" . + . + "5" . + . + . + . + "pla" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + . + "hba 2" . + . + . + "fpg 1" . + . + . + "fpg 2" . + . + . + "hbat 1" . + . + "11 . 4" . + . + "hbat2" . + . + "3 . 5" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 58" . + "P  < . 001" . + . + . + . + "fpg" . + "0 . 9" . + "P  < . 001" . + . + . + . + "hbat" . + "P  = . 002" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29144061_akramersunderbrink.annodb b/data/dm2 29144061_akramersunderbrink.annodb new file mode 100644 index 0000000..202cbab --- /dev/null +++ b/data/dm2 29144061_akramersunderbrink.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73700, Journal, 0, 19, "Diabetes Obes Metab", "", +73701, PublicationYear, 22, 26, "2018", "", +73702, Saxagliptin, 109, 120, "Saxagliptin", "", +73711, Title, 109, 333, "Saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin : Results from the SUPER study , a randomized , double - blind , placebo - controlled trial .", "", +73703, Ethnicity, 141, 148, "Chinese", "", +73704, Type2Diabetes, 163, 178, "type 2 diabetes", "", +73705, Precondition, 179, 239, "inadequately controlled by insulin with or without metformin", "", +73706, Insulin, 206, 213, "insulin", "", +73707, Metformin, 230, 239, "metformin", "", +73708, Randomized, 275, 285, "randomized", "", +73709, DoubleBlind, 288, 302, "double - blind", "", +73710, Placebo, 305, 312, "placebo", "", +73712, Author, 334, 340, "Chen Y", "", +73713, Author, 349, 354, "Liu X", "", +73714, Author, 363, 367, "Li Q", "", +73715, Author, 376, 380, "Ma J", "", +73716, Author, 389, 393, "Lv X", "", +73717, Author, 402, 407, "Guo L", "", +73718, Author, 416, 422, "Wang C", "", +73719, Author, 431, 436, "Shi Y", "", +73720, Author, 445, 449, "Li Y", "", +73721, Author, 458, 468, "Johnsson E", "", +73722, Author, 478, 484, "Wang M", "", +73723, Author, 494, 500, "Zhao J", "", +73724, Author, 510, 514, "Ji L", "", +73725, China, 645, 650, "China", "", +73726, China, 755, 760, "China", "", +73727, China, 856, 861, "China", "", +73728, China, 935, 940, "China", "", +73729, China, 1009, 1014, "China", "", +73730, China, 1115, 1120, "China", "", +73731, China, 1223, 1228, "China", "", +73732, China, 1309, 1314, "China", "", +73733, China, 1421, 1426, "China", "", +73735, Sweden, 1473, 1479, "Sweden", "", +73734, China, 1538, 1543, "China", "", +73758, ObjectiveDescription, 1593, 1815, "This prospective , multicentre , phase III study ( NCT02104804 ) evaluated the efficacy and safety of saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin  ±  metformin .", "", +73736, Multicenter, 1612, 1623, "multicentre", "", +73737, Saxagliptin, 1695, 1706, "saxagliptin", "", +73738, Ethnicity, 1727, 1734, "Chinese", "", +73739, Type2Diabetes, 1749, 1764, "type 2 diabetes", "", +73740, Precondition, 1765, 1813, "inadequately controlled by insulin  ±  metformin", "", +73741, Insulin, 1792, 1799, "insulin", "", +73742, Metformin, 1804, 1813, "metformin", "", +73743, HbA1c, 1830, 1850, "glycated haemoglobin", "", +73769, Precondition, 1830, 1880, "glycated haemoglobin ( HbA1c ) 7 . 5 % to 10 . 5 %", "", +73744, HbA1c, 1853, 1858, "HbA1c", "", +73752, Percentage, 1867, 1868, "%", "", +73753, Percentage, 1879, 1880, "%", "", +73745, FastingPlasmaGlucose, 1885, 1907, "fasting plasma glucose", "", +73770, Precondition, 1885, 1947, "fasting plasma glucose ( FPG ) < 15 mmol / L ( 270   mg / dL )", "", +73746, FastingPlasmaGlucose, 1910, 1913, "FPG", "", +73759, Millimoles_per_litre, 1921, 1929, "mmol / L", "", +73760, Mg_per_deciliter, 1938, 1945, "mg / dL", "", +73771, Precondition, 1948, 1994, "on stable insulin therapy ( 20 - 150   U / d )", "", +73747, Insulin, 1958, 1965, "insulin", "", +73761, BioAndMedicalUnit, 1987, 1992, "U / d", "", +73748, Randomized, 2000, 2010, "randomized", "", +73749, Saxagliptin, 2024, 2035, "saxagliptin", "", +73762, DoseValue, 2036, 2040, "5 mg", "", +73763, mg, 2038, 2040, "mg", "", +73764, Frequency, 2041, 2051, "once daily", "", +73766, NumberPatientsArm, 2060, 2063, "232", "", +73750, Placebo, 2069, 2076, "placebo", "", +73767, NumberPatientsArm, 2085, 2088, "230", "", +73765, Duration, 2095, 2105, "24   weeks", "", +73751, Metformin, 2122, 2131, "metformin", "", +73768, HbA1c, 2181, 2186, "HbA1c", "", +73772, Saxagliptin, 2189, 2200, "Saxagliptin", "", +73774, Mean, 2242, 2246, "mean", "", +73773, HbA1c, 2257, 2262, "HbA1c", "", +73775, TimePoint, 2268, 2276, "baseline", "", +73776, TimePoint, 2280, 2287, "week 24", "", +73777, Placebo, 2293, 2300, "placebo", "", +73778, ChangeValue, 2303, 2311, "- 0 . 58", "", +73754, Percentage, 2312, 2313, "%", "", +73796, PValueChangeValue, 2316, 2326, "P  < . 001", "", +73780, Metformin, 2347, 2356, "metformin", "", +73781, Mean, 2377, 2381, "mean", "", +73782, FastingPlasmaGlucose, 2392, 2395, "FPG", "", +73783, ChangeValue, 2398, 2403, "0 . 9", "", +73785, Millimoles_per_litre, 2404, 2412, "mmol / L", "", +73784, ChangeValue, 2415, 2423, "- 15 . 9", "", +73786, Mg_per_deciliter, 2424, 2431, "mg / dL", "", +73795, PValueChangeValue, 2436, 2446, "P  < . 001", "", +73791, HbA1c_target, 2474, 2485, "HbA1c < 7 %", "", +73755, Percentage, 2484, 2485, "%", "", +73789, Saxagliptin, 2491, 2502, "saxagliptin", "", +73792, PercentageAffected, 2505, 2511, "11 . 4", "", +73756, Percentage, 2512, 2513, "%", "", +73790, Placebo, 2526, 2533, "placebo", "", +73793, PercentageAffected, 2536, 2541, "3 . 5", "", +73757, Percentage, 2542, 2543, "%", "", +73794, PvalueDiff, 2546, 2556, "P  = . 002", "", +73797, Hypoglycemia, 2593, 2606, "hypoglycaemia", "", +73808, ConclusionComment, 2637, 2879, "Overall , add - on saxagliptin 5 mg once daily significantly improved glycaemic control without increasing hypoglycaemia risk and was well tolerated in Chinese patients with type 2 diabetes inadequately controlled by insulin ( ± metformin ) .", "", +73798, Saxagliptin, 2656, 2667, "saxagliptin", "", +73799, DoseValue, 2668, 2672, "5 mg", "", +73800, mg, 2670, 2672, "mg", "", +73801, Frequency, 2673, 2683, "once daily", "", +73802, Hypoglycemia, 2744, 2757, "hypoglycaemia", "", +73803, Ethnicity, 2789, 2796, "Chinese", "", +73804, Type2Diabetes, 2811, 2826, "type 2 diabetes", "", +73805, Precondition, 2827, 2877, "inadequately controlled by insulin ( ± metformin )", "", +73806, Insulin, 2854, 2861, "insulin", "", +73807, Metformin, 2866, 2875, "metformin", "", +73809, PMID, 2948, 2956, "29144061", "", diff --git a/data/dm2 29144061_akramersunderbrink.n-triples b/data/dm2 29144061_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29144061_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29144061_export.csv b/data/dm2 29144061_export.csv new file mode 100644 index 0000000..6f4a495 --- /dev/null +++ b/data/dm2 29144061_export.csv @@ -0,0 +1,645 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +388, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +388, 1, 2, 2, 9, 13, 9, 13, "Obes" +388, 1, 3, 3, 14, 19, 14, 19, "Metab" +388, 1, 4, 4, 20, 21, 20, 21, "." +388, 2, 1, 5, 0, 4, 22, 26, "2018" +388, 2, 2, 6, 5, 8, 27, 30, "Apr" +388, 2, 3, 7, 9, 10, 31, 32, ";" +388, 2, 4, 8, 11, 13, 33, 35, "20" +388, 2, 5, 9, 14, 15, 36, 37, "(" +388, 2, 6, 10, 16, 17, 38, 39, "4" +388, 2, 7, 11, 18, 19, 40, 41, ")" +388, 2, 8, 12, 20, 21, 42, 43, ":" +388, 2, 9, 13, 22, 26, 44, 48, "1044" +388, 2, 10, 14, 27, 28, 49, 50, "-" +388, 2, 11, 15, 29, 33, 51, 55, "1049" +388, 2, 12, 16, 34, 35, 56, 57, "." +388, 2, 13, 17, 36, 39, 58, 61, "doi" +388, 2, 14, 18, 40, 41, 62, 63, ":" +388, 2, 15, 19, 42, 44, 64, 66, "10" +388, 2, 16, 20, 45, 46, 67, 68, "." +388, 2, 17, 21, 47, 51, 69, 73, "1111" +388, 2, 18, 22, 52, 53, 74, 75, "/" +388, 2, 19, 23, 54, 57, 76, 79, "dom" +388, 2, 20, 24, 58, 59, 80, 81, "." +388, 2, 21, 25, 60, 65, 82, 87, "13161" +388, 2, 22, 26, 66, 67, 88, 89, "." +388, 3, 1, 27, 0, 4, 90, 94, "Epub" +388, 3, 2, 28, 5, 9, 95, 99, "2017" +388, 3, 3, 29, 10, 13, 100, 103, "Dec" +388, 3, 4, 30, 14, 16, 104, 106, "18" +388, 3, 5, 31, 17, 18, 107, 108, "." +388, 4, 1, 32, 0, 11, 109, 120, "Saxagliptin" +388, 4, 2, 33, 12, 15, 121, 124, "add" +388, 4, 3, 34, 16, 17, 125, 126, "-" +388, 4, 4, 35, 18, 20, 127, 129, "on" +388, 4, 5, 36, 21, 28, 130, 137, "therapy" +388, 4, 6, 37, 29, 31, 138, 140, "in" +388, 4, 7, 38, 32, 39, 141, 148, "Chinese" +388, 4, 8, 39, 40, 48, 149, 157, "patients" +388, 4, 9, 40, 49, 53, 158, 162, "with" +388, 4, 10, 41, 54, 58, 163, 167, "type" +388, 4, 11, 42, 59, 60, 168, 169, "2" +388, 4, 12, 43, 61, 69, 170, 178, "diabetes" +388, 4, 13, 44, 70, 82, 179, 191, "inadequately" +388, 4, 14, 45, 83, 93, 192, 202, "controlled" +388, 4, 15, 46, 94, 96, 203, 205, "by" +388, 4, 16, 47, 97, 104, 206, 213, "insulin" +388, 4, 17, 48, 105, 109, 214, 218, "with" +388, 4, 18, 49, 110, 112, 219, 221, "or" +388, 4, 19, 50, 113, 120, 222, 229, "without" +388, 4, 20, 51, 121, 130, 230, 239, "metformin" +388, 4, 21, 52, 131, 132, 240, 241, ":" +388, 4, 22, 53, 133, 140, 242, 249, "Results" +388, 4, 23, 54, 141, 145, 250, 254, "from" +388, 4, 24, 55, 146, 149, 255, 258, "the" +388, 4, 25, 56, 150, 155, 259, 264, "SUPER" +388, 4, 26, 57, 156, 161, 265, 270, "study" +388, 4, 27, 58, 162, 163, 271, 272, "," +388, 4, 28, 59, 164, 165, 273, 274, "a" +388, 4, 29, 60, 166, 176, 275, 285, "randomized" +388, 4, 30, 61, 177, 178, 286, 287, "," +388, 4, 31, 62, 179, 185, 288, 294, "double" +388, 4, 32, 63, 186, 187, 295, 296, "-" +388, 4, 33, 64, 188, 193, 297, 302, "blind" +388, 4, 34, 65, 194, 195, 303, 304, "," +388, 4, 35, 66, 196, 203, 305, 312, "placebo" +388, 4, 36, 67, 204, 205, 313, 314, "-" +388, 4, 37, 68, 206, 216, 315, 325, "controlled" +388, 4, 38, 69, 217, 222, 326, 331, "trial" +388, 4, 39, 70, 223, 224, 332, 333, "." +388, 5, 1, 71, 0, 4, 334, 338, "Chen" +388, 5, 2, 72, 5, 6, 339, 340, "Y" +388, 5, 3, 73, 7, 8, 341, 342, "(" +388, 5, 4, 74, 9, 10, 343, 344, "1" +388, 5, 5, 75, 11, 12, 345, 346, ")" +388, 5, 6, 76, 13, 14, 347, 348, "," +388, 5, 7, 77, 15, 18, 349, 352, "Liu" +388, 5, 8, 78, 19, 20, 353, 354, "X" +388, 5, 9, 79, 21, 22, 355, 356, "(" +388, 5, 10, 80, 23, 24, 357, 358, "2" +388, 5, 11, 81, 25, 26, 359, 360, ")" +388, 5, 12, 82, 27, 28, 361, 362, "," +388, 5, 13, 83, 29, 31, 363, 365, "Li" +388, 5, 14, 84, 32, 33, 366, 367, "Q" +388, 5, 15, 85, 34, 35, 368, 369, "(" +388, 5, 16, 86, 36, 37, 370, 371, "3" +388, 5, 17, 87, 38, 39, 372, 373, ")" +388, 5, 18, 88, 40, 41, 374, 375, "," +388, 5, 19, 89, 42, 44, 376, 378, "Ma" +388, 5, 20, 90, 45, 46, 379, 380, "J" +388, 5, 21, 91, 47, 48, 381, 382, "(" +388, 5, 22, 92, 49, 50, 383, 384, "4" +388, 5, 23, 93, 51, 52, 385, 386, ")" +388, 5, 24, 94, 53, 54, 387, 388, "," +388, 5, 25, 95, 55, 57, 389, 391, "Lv" +388, 5, 26, 96, 58, 59, 392, 393, "X" +388, 5, 27, 97, 60, 61, 394, 395, "(" +388, 5, 28, 98, 62, 63, 396, 397, "5" +388, 5, 29, 99, 64, 65, 398, 399, ")" +388, 5, 30, 100, 66, 67, 400, 401, "," +388, 5, 31, 101, 68, 71, 402, 405, "Guo" +388, 5, 32, 102, 72, 73, 406, 407, "L" +388, 5, 33, 103, 74, 75, 408, 409, "(" +388, 5, 34, 104, 76, 77, 410, 411, "6" +388, 5, 35, 105, 78, 79, 412, 413, ")" +388, 5, 36, 106, 80, 81, 414, 415, "," +388, 5, 37, 107, 82, 86, 416, 420, "Wang" +388, 5, 38, 108, 87, 88, 421, 422, "C" +388, 5, 39, 109, 89, 90, 423, 424, "(" +388, 5, 40, 110, 91, 92, 425, 426, "7" +388, 5, 41, 111, 93, 94, 427, 428, ")" +388, 5, 42, 112, 95, 96, 429, 430, "," +388, 5, 43, 113, 97, 100, 431, 434, "Shi" +388, 5, 44, 114, 101, 102, 435, 436, "Y" +388, 5, 45, 115, 103, 104, 437, 438, "(" +388, 5, 46, 116, 105, 106, 439, 440, "8" +388, 5, 47, 117, 107, 108, 441, 442, ")" +388, 5, 48, 118, 109, 110, 443, 444, "," +388, 5, 49, 119, 111, 113, 445, 447, "Li" +388, 5, 50, 120, 114, 115, 448, 449, "Y" +388, 5, 51, 121, 116, 117, 450, 451, "(" +388, 5, 52, 122, 118, 119, 452, 453, "9" +388, 5, 53, 123, 120, 121, 454, 455, ")" +388, 5, 54, 124, 122, 123, 456, 457, "," +388, 5, 55, 125, 124, 132, 458, 466, "Johnsson" +388, 5, 56, 126, 133, 134, 467, 468, "E" +388, 5, 57, 127, 135, 136, 469, 470, "(" +388, 5, 58, 128, 137, 139, 471, 473, "10" +388, 5, 59, 129, 140, 141, 474, 475, ")" +388, 5, 60, 130, 142, 143, 476, 477, "," +388, 5, 61, 131, 144, 148, 478, 482, "Wang" +388, 5, 62, 132, 149, 150, 483, 484, "M" +388, 5, 63, 133, 151, 152, 485, 486, "(" +388, 5, 64, 134, 153, 155, 487, 489, "11" +388, 5, 65, 135, 156, 157, 490, 491, ")" +388, 5, 66, 136, 158, 159, 492, 493, "," +388, 5, 67, 137, 160, 164, 494, 498, "Zhao" +388, 5, 68, 138, 165, 166, 499, 500, "J" +388, 5, 69, 139, 167, 168, 501, 502, "(" +388, 5, 70, 140, 169, 171, 503, 505, "12" +388, 5, 71, 141, 172, 173, 506, 507, ")" +388, 5, 72, 142, 174, 175, 508, 509, "," +388, 5, 73, 143, 176, 178, 510, 512, "Ji" +388, 5, 74, 144, 179, 180, 513, 514, "L" +388, 5, 75, 145, 181, 182, 515, 516, "(" +388, 5, 76, 146, 183, 184, 517, 518, "1" +388, 5, 77, 147, 185, 186, 519, 520, ")" +388, 5, 78, 148, 187, 188, 521, 522, "." +388, 6, 1, 149, 0, 6, 523, 529, "Author" +388, 6, 2, 150, 7, 18, 530, 541, "information" +388, 6, 3, 151, 19, 20, 542, 543, ":" +388, 6, 4, 152, 21, 22, 544, 545, "(" +388, 6, 5, 153, 23, 24, 546, 547, "1" +388, 6, 6, 154, 25, 26, 548, 549, ")" +388, 6, 7, 155, 27, 37, 550, 560, "Department" +388, 6, 8, 156, 38, 40, 561, 563, "of" +388, 6, 9, 157, 41, 54, 564, 577, "Endocrinology" +388, 6, 10, 158, 55, 58, 578, 581, "and" +388, 6, 11, 159, 59, 69, 582, 592, "Metabolism" +388, 6, 12, 160, 70, 71, 593, 594, "," +388, 6, 13, 161, 72, 78, 595, 601, "Peking" +388, 6, 14, 162, 79, 89, 602, 612, "University" +388, 6, 15, 163, 90, 96, 613, 619, "People" +388, 6, 16, 164, 97, 98, 620, 621, "'" +388, 6, 17, 165, 99, 100, 622, 623, "s" +388, 6, 18, 166, 101, 109, 624, 632, "Hospital" +388, 6, 19, 167, 110, 111, 633, 634, "," +388, 6, 20, 168, 112, 119, 635, 642, "Beijing" +388, 6, 21, 169, 120, 121, 643, 644, "," +388, 6, 22, 170, 122, 127, 645, 650, "China" +388, 6, 23, 171, 128, 129, 651, 652, "." +388, 7, 1, 172, 0, 1, 653, 654, "(" +388, 7, 2, 173, 2, 3, 655, 656, "2" +388, 7, 3, 174, 4, 5, 657, 658, ")" +388, 7, 4, 175, 6, 16, 659, 669, "Department" +388, 7, 5, 176, 17, 19, 670, 672, "of" +388, 7, 6, 177, 20, 33, 673, 686, "Endocrinology" +388, 7, 7, 178, 34, 35, 687, 688, "," +388, 7, 8, 179, 36, 41, 689, 694, "First" +388, 7, 9, 180, 42, 52, 695, 705, "Affiliated" +388, 7, 10, 181, 53, 61, 706, 714, "Hospital" +388, 7, 11, 182, 62, 64, 715, 717, "of" +388, 7, 12, 183, 65, 71, 718, 724, "Harbin" +388, 7, 13, 184, 72, 79, 725, 732, "Medical" +388, 7, 14, 185, 80, 90, 733, 743, "University" +388, 7, 15, 186, 91, 92, 744, 745, "," +388, 7, 16, 187, 93, 99, 746, 752, "Harbin" +388, 7, 17, 188, 100, 101, 753, 754, "," +388, 7, 18, 189, 102, 107, 755, 760, "China" +388, 7, 19, 190, 108, 109, 761, 762, "." +388, 8, 1, 191, 0, 1, 763, 764, "(" +388, 8, 2, 192, 2, 3, 765, 766, "3" +388, 8, 3, 193, 4, 5, 767, 768, ")" +388, 8, 4, 194, 6, 16, 769, 779, "Department" +388, 8, 5, 195, 17, 19, 780, 782, "of" +388, 8, 6, 196, 20, 33, 783, 796, "Endocrinology" +388, 8, 7, 197, 34, 35, 797, 798, "," +388, 8, 8, 198, 36, 39, 799, 802, "The" +388, 8, 9, 199, 40, 47, 803, 810, "General" +388, 8, 10, 200, 48, 56, 811, 819, "Hospital" +388, 8, 11, 201, 57, 59, 820, 822, "of" +388, 8, 12, 202, 60, 63, 823, 826, "the" +388, 8, 13, 203, 64, 67, 827, 830, "PLA" +388, 8, 14, 204, 68, 74, 831, 837, "Rocket" +388, 8, 15, 205, 75, 80, 838, 843, "Force" +388, 8, 16, 206, 81, 82, 844, 845, "," +388, 8, 17, 207, 83, 90, 846, 853, "Beijing" +388, 8, 18, 208, 91, 92, 854, 855, "," +388, 8, 19, 209, 93, 98, 856, 861, "China" +388, 8, 20, 210, 99, 100, 862, 863, "." +388, 9, 1, 211, 0, 1, 864, 865, "(" +388, 9, 2, 212, 2, 3, 866, 867, "4" +388, 9, 3, 213, 4, 5, 868, 869, ")" +388, 9, 4, 214, 6, 16, 870, 880, "Department" +388, 9, 5, 215, 17, 19, 881, 883, "of" +388, 9, 6, 216, 20, 33, 884, 897, "Endocrinology" +388, 9, 7, 217, 34, 35, 898, 899, "," +388, 9, 8, 218, 36, 43, 900, 907, "Nanjing" +388, 9, 9, 219, 44, 49, 908, 913, "First" +388, 9, 10, 220, 50, 58, 914, 922, "Hospital" +388, 9, 11, 221, 59, 60, 923, 924, "," +388, 9, 12, 222, 61, 68, 925, 932, "Nanjing" +388, 9, 13, 223, 69, 70, 933, 934, "," +388, 9, 14, 224, 71, 76, 935, 940, "China" +388, 9, 15, 225, 77, 78, 941, 942, "." +388, 10, 1, 226, 0, 1, 943, 944, "(" +388, 10, 2, 227, 2, 3, 945, 946, "5" +388, 10, 3, 228, 4, 5, 947, 948, ")" +388, 10, 4, 229, 6, 9, 949, 952, "PLA" +388, 10, 5, 230, 10, 17, 953, 960, "General" +388, 10, 6, 231, 18, 26, 961, 969, "Hospital" +388, 10, 7, 232, 27, 29, 970, 972, "of" +388, 10, 8, 233, 30, 37, 973, 980, "Beijing" +388, 10, 9, 234, 38, 46, 981, 989, "Military" +388, 10, 10, 235, 47, 53, 990, 996, "Region" +388, 10, 11, 236, 54, 55, 997, 998, "," +388, 10, 12, 237, 56, 63, 999, 1006, "Beijing" +388, 10, 13, 238, 64, 65, 1007, 1008, "," +388, 10, 14, 239, 66, 71, 1009, 1014, "China" +388, 10, 15, 240, 72, 73, 1015, 1016, "." +388, 11, 1, 241, 0, 1, 1017, 1018, "(" +388, 11, 2, 242, 2, 3, 1019, 1020, "6" +388, 11, 3, 243, 4, 5, 1021, 1022, ")" +388, 11, 4, 244, 6, 16, 1023, 1033, "Department" +388, 11, 5, 245, 17, 19, 1034, 1036, "of" +388, 11, 6, 246, 20, 33, 1037, 1050, "Endocrinology" +388, 11, 7, 247, 34, 35, 1051, 1052, "," +388, 11, 8, 248, 36, 43, 1053, 1060, "Beijing" +388, 11, 9, 249, 44, 52, 1061, 1069, "Hospital" +388, 11, 10, 250, 53, 54, 1070, 1071, "," +388, 11, 11, 251, 55, 63, 1072, 1080, "National" +388, 11, 12, 252, 64, 70, 1081, 1087, "Center" +388, 11, 13, 253, 71, 73, 1088, 1090, "of" +388, 11, 14, 254, 74, 85, 1091, 1102, "Gerontology" +388, 11, 15, 255, 86, 87, 1103, 1104, "," +388, 11, 16, 256, 88, 95, 1105, 1112, "Beijing" +388, 11, 17, 257, 96, 97, 1113, 1114, "," +388, 11, 18, 258, 98, 103, 1115, 1120, "China" +388, 11, 19, 259, 104, 105, 1121, 1122, "." +388, 12, 1, 260, 0, 1, 1123, 1124, "(" +388, 12, 2, 261, 2, 3, 1125, 1126, "7" +388, 12, 3, 262, 4, 5, 1127, 1128, ")" +388, 12, 4, 263, 6, 16, 1129, 1139, "Department" +388, 12, 5, 264, 17, 19, 1140, 1142, "of" +388, 12, 6, 265, 20, 33, 1143, 1156, "Endocrinology" +388, 12, 7, 266, 34, 35, 1157, 1158, "," +388, 12, 8, 267, 36, 41, 1159, 1164, "First" +388, 12, 9, 268, 42, 52, 1165, 1175, "Affiliated" +388, 12, 10, 269, 53, 61, 1176, 1184, "Hospital" +388, 12, 11, 270, 62, 64, 1185, 1187, "of" +388, 12, 12, 271, 65, 70, 1188, 1193, "Anhui" +388, 12, 13, 272, 71, 78, 1194, 1201, "Medical" +388, 12, 14, 273, 79, 89, 1202, 1212, "University" +388, 12, 15, 274, 90, 91, 1213, 1214, "," +388, 12, 16, 275, 92, 97, 1215, 1220, "Hefei" +388, 12, 17, 276, 98, 99, 1221, 1222, "," +388, 12, 18, 277, 100, 105, 1223, 1228, "China" +388, 12, 19, 278, 106, 107, 1229, 1230, "." +388, 13, 1, 279, 0, 1, 1231, 1232, "(" +388, 13, 2, 280, 2, 3, 1233, 1234, "8" +388, 13, 3, 281, 4, 5, 1235, 1236, ")" +388, 13, 4, 282, 6, 16, 1237, 1247, "Department" +388, 13, 5, 283, 17, 19, 1248, 1250, "of" +388, 13, 6, 284, 20, 33, 1251, 1264, "Endocrinology" +388, 13, 7, 285, 34, 35, 1265, 1266, "," +388, 13, 8, 286, 36, 44, 1267, 1275, "Shanghai" +388, 13, 9, 287, 45, 55, 1276, 1286, "Changzheng" +388, 13, 10, 288, 56, 64, 1287, 1295, "Hospital" +388, 13, 11, 289, 65, 66, 1296, 1297, "," +388, 13, 12, 290, 67, 75, 1298, 1306, "Shanghai" +388, 13, 13, 291, 76, 77, 1307, 1308, "," +388, 13, 14, 292, 78, 83, 1309, 1314, "China" +388, 13, 15, 293, 84, 85, 1315, 1316, "." +388, 14, 1, 294, 0, 1, 1317, 1318, "(" +388, 14, 2, 295, 2, 3, 1319, 1320, "9" +388, 14, 3, 296, 4, 5, 1321, 1322, ")" +388, 14, 4, 297, 6, 16, 1323, 1333, "Department" +388, 14, 5, 298, 17, 19, 1334, 1336, "of" +388, 14, 6, 299, 20, 33, 1337, 1350, "Endocrinology" +388, 14, 7, 300, 34, 35, 1351, 1352, "," +388, 14, 8, 301, 36, 41, 1353, 1358, "First" +388, 14, 9, 302, 42, 52, 1359, 1369, "Affiliated" +388, 14, 10, 303, 53, 61, 1370, 1378, "Hospital" +388, 14, 11, 304, 62, 64, 1379, 1381, "of" +388, 14, 12, 305, 65, 68, 1382, 1385, "Sun" +388, 14, 13, 306, 69, 72, 1386, 1389, "Yat" +388, 14, 14, 307, 73, 74, 1390, 1391, "-" +388, 14, 15, 308, 75, 78, 1392, 1395, "sen" +388, 14, 16, 309, 79, 89, 1396, 1406, "University" +388, 14, 17, 310, 90, 91, 1407, 1408, "," +388, 14, 18, 311, 92, 101, 1409, 1418, "Guangzhou" +388, 14, 19, 312, 102, 103, 1419, 1420, "," +388, 14, 20, 313, 104, 109, 1421, 1426, "China" +388, 14, 21, 314, 110, 111, 1427, 1428, "." +388, 15, 1, 315, 0, 1, 1429, 1430, "(" +388, 15, 2, 316, 2, 4, 1431, 1433, "10" +388, 15, 3, 317, 5, 6, 1434, 1435, ")" +388, 15, 4, 318, 7, 18, 1436, 1447, "AstraZeneca" +388, 15, 5, 319, 19, 29, 1448, 1458, "Gothenburg" +388, 15, 6, 320, 30, 31, 1459, 1460, "," +388, 15, 7, 321, 32, 33, 1461, 1462, "M" +388, 15, 8, 322, 34, 35, 1463, 1464, "ö" +388, 15, 9, 323, 36, 41, 1465, 1470, "lndal" +388, 15, 10, 324, 42, 43, 1471, 1472, "," +388, 15, 11, 325, 44, 50, 1473, 1479, "Sweden" +388, 15, 12, 326, 51, 52, 1480, 1481, "." +388, 16, 1, 327, 0, 1, 1482, 1483, "(" +388, 16, 2, 328, 2, 4, 1484, 1486, "11" +388, 16, 3, 329, 5, 6, 1487, 1488, ")" +388, 16, 4, 330, 7, 12, 1489, 1494, "China" +388, 16, 5, 331, 13, 24, 1495, 1506, "Development" +388, 16, 6, 332, 25, 29, 1507, 1511, "Unit" +388, 16, 7, 333, 30, 31, 1512, 1513, "," +388, 16, 8, 334, 32, 43, 1514, 1525, "AstraZeneca" +388, 16, 9, 335, 44, 45, 1526, 1527, "," +388, 16, 10, 336, 46, 53, 1528, 1535, "Beijing" +388, 16, 11, 337, 54, 55, 1536, 1537, "," +388, 16, 12, 338, 56, 61, 1538, 1543, "China" +388, 16, 13, 339, 62, 63, 1544, 1545, "." +388, 17, 1, 340, 0, 1, 1546, 1547, "(" +388, 17, 2, 341, 2, 4, 1548, 1550, "12" +388, 17, 3, 342, 5, 6, 1551, 1552, ")" +388, 17, 4, 343, 7, 18, 1553, 1564, "AstraZeneca" +388, 17, 5, 344, 19, 20, 1565, 1566, "," +388, 17, 6, 345, 21, 33, 1567, 1579, "Gaithersburg" +388, 17, 7, 346, 34, 35, 1580, 1581, "," +388, 17, 8, 347, 36, 44, 1582, 1590, "Maryland" +388, 17, 9, 348, 45, 46, 1591, 1592, "." +388, 18, 1, 349, 0, 4, 1593, 1597, "This" +388, 18, 2, 350, 5, 16, 1598, 1609, "prospective" +388, 18, 3, 351, 17, 18, 1610, 1611, "," +388, 18, 4, 352, 19, 30, 1612, 1623, "multicentre" +388, 18, 5, 353, 31, 32, 1624, 1625, "," +388, 18, 6, 354, 33, 38, 1626, 1631, "phase" +388, 18, 7, 355, 39, 42, 1632, 1635, "III" +388, 18, 8, 356, 43, 48, 1636, 1641, "study" +388, 18, 9, 357, 49, 50, 1642, 1643, "(" +388, 18, 10, 358, 51, 62, 1644, 1655, "NCT02104804" +388, 18, 11, 359, 63, 64, 1656, 1657, ")" +388, 18, 12, 360, 65, 74, 1658, 1667, "evaluated" +388, 18, 13, 361, 75, 78, 1668, 1671, "the" +388, 18, 14, 362, 79, 87, 1672, 1680, "efficacy" +388, 18, 15, 363, 88, 91, 1681, 1684, "and" +388, 18, 16, 364, 92, 98, 1685, 1691, "safety" +388, 18, 17, 365, 99, 101, 1692, 1694, "of" +388, 18, 18, 366, 102, 113, 1695, 1706, "saxagliptin" +388, 18, 19, 367, 114, 117, 1707, 1710, "add" +388, 18, 20, 368, 118, 119, 1711, 1712, "-" +388, 18, 21, 369, 120, 122, 1713, 1715, "on" +388, 18, 22, 370, 123, 130, 1716, 1723, "therapy" +388, 18, 23, 371, 131, 133, 1724, 1726, "in" +388, 18, 24, 372, 134, 141, 1727, 1734, "Chinese" +388, 18, 25, 373, 142, 150, 1735, 1743, "patients" +388, 18, 26, 374, 151, 155, 1744, 1748, "with" +388, 18, 27, 375, 156, 160, 1749, 1753, "type" +388, 18, 28, 376, 161, 162, 1754, 1755, "2" +388, 18, 29, 377, 163, 171, 1756, 1764, "diabetes" +388, 18, 30, 378, 172, 184, 1765, 1777, "inadequately" +388, 18, 31, 379, 185, 195, 1778, 1788, "controlled" +388, 18, 32, 380, 196, 198, 1789, 1791, "by" +388, 18, 33, 381, 199, 206, 1792, 1799, "insulin" +388, 18, 34, 382, 207, 210, 1800, 1803, " ± " +388, 18, 35, 383, 211, 220, 1804, 1813, "metformin" +388, 18, 36, 384, 221, 222, 1814, 1815, "." +388, 19, 1, 385, 0, 8, 1816, 1824, "Patients" +388, 19, 2, 386, 9, 13, 1825, 1829, "with" +388, 19, 3, 387, 14, 22, 1830, 1838, "glycated" +388, 19, 4, 388, 23, 34, 1839, 1850, "haemoglobin" +388, 19, 5, 389, 35, 36, 1851, 1852, "(" +388, 19, 6, 390, 37, 42, 1853, 1858, "HbA1c" +388, 19, 7, 391, 43, 44, 1859, 1860, ")" +388, 19, 8, 392, 45, 46, 1861, 1862, "7" +388, 19, 9, 393, 47, 48, 1863, 1864, "." +388, 19, 10, 394, 49, 50, 1865, 1866, "5" +388, 19, 11, 395, 51, 52, 1867, 1868, "%" +388, 19, 12, 396, 53, 55, 1869, 1871, "to" +388, 19, 13, 397, 56, 58, 1872, 1874, "10" +388, 19, 14, 398, 59, 60, 1875, 1876, "." +388, 19, 15, 399, 61, 62, 1877, 1878, "5" +388, 19, 16, 400, 63, 64, 1879, 1880, "%" +388, 19, 17, 401, 65, 68, 1881, 1884, "and" +388, 19, 18, 402, 69, 76, 1885, 1892, "fasting" +388, 19, 19, 403, 77, 83, 1893, 1899, "plasma" +388, 19, 20, 404, 84, 91, 1900, 1907, "glucose" +388, 19, 21, 405, 92, 93, 1908, 1909, "(" +388, 19, 22, 406, 94, 97, 1910, 1913, "FPG" +388, 19, 23, 407, 98, 99, 1914, 1915, ")" +388, 19, 24, 408, 100, 101, 1916, 1917, "<" +388, 19, 25, 409, 102, 104, 1918, 1920, "15" +388, 19, 26, 410, 105, 109, 1921, 1925, "mmol" +388, 19, 27, 411, 110, 111, 1926, 1927, "/" +388, 19, 28, 412, 112, 113, 1928, 1929, "L" +388, 19, 29, 413, 114, 115, 1930, 1931, "(" +388, 19, 30, 414, 116, 119, 1932, 1935, "270" +388, 19, 31, 415, 120, 121, 1936, 1937, " " +388, 19, 32, 416, 122, 124, 1938, 1940, "mg" +388, 19, 33, 417, 125, 126, 1941, 1942, "/" +388, 19, 34, 418, 127, 129, 1943, 1945, "dL" +388, 19, 35, 419, 130, 131, 1946, 1947, ")" +388, 19, 36, 420, 132, 134, 1948, 1950, "on" +388, 19, 37, 421, 135, 141, 1951, 1957, "stable" +388, 19, 38, 422, 142, 149, 1958, 1965, "insulin" +388, 19, 39, 423, 150, 157, 1966, 1973, "therapy" +388, 19, 40, 424, 158, 159, 1974, 1975, "(" +388, 19, 41, 425, 160, 162, 1976, 1978, "20" +388, 19, 42, 426, 163, 164, 1979, 1980, "-" +388, 19, 43, 427, 165, 168, 1981, 1984, "150" +388, 19, 44, 428, 169, 170, 1985, 1986, " " +388, 19, 45, 429, 171, 172, 1987, 1988, "U" +388, 19, 46, 430, 173, 174, 1989, 1990, "/" +388, 19, 47, 431, 175, 176, 1991, 1992, "d" +388, 19, 48, 432, 177, 178, 1993, 1994, ")" +388, 19, 49, 433, 179, 183, 1995, 1999, "were" +388, 19, 50, 434, 184, 194, 2000, 2010, "randomized" +388, 19, 51, 435, 195, 196, 2011, 2012, "(" +388, 19, 52, 436, 197, 198, 2013, 2014, "1" +388, 19, 53, 437, 199, 200, 2015, 2016, ":" +388, 19, 54, 438, 201, 202, 2017, 2018, "1" +388, 19, 55, 439, 203, 204, 2019, 2020, ")" +388, 19, 56, 440, 205, 207, 2021, 2023, "to" +388, 19, 57, 441, 208, 219, 2024, 2035, "saxagliptin" +388, 19, 58, 442, 220, 221, 2036, 2037, "5" +388, 19, 59, 443, 222, 224, 2038, 2040, "mg" +388, 19, 60, 444, 225, 229, 2041, 2045, "once" +388, 19, 61, 445, 230, 235, 2046, 2051, "daily" +388, 19, 62, 446, 236, 237, 2052, 2053, "(" +388, 19, 63, 447, 238, 239, 2054, 2055, "N" +388, 19, 64, 448, 240, 243, 2056, 2059, " = " +388, 19, 65, 449, 244, 247, 2060, 2063, "232" +388, 19, 66, 450, 248, 249, 2064, 2065, ")" +388, 19, 67, 451, 250, 252, 2066, 2068, "or" +388, 19, 68, 452, 253, 260, 2069, 2076, "placebo" +388, 19, 69, 453, 261, 262, 2077, 2078, "(" +388, 19, 70, 454, 263, 264, 2079, 2080, "N" +388, 19, 71, 455, 265, 268, 2081, 2084, " = " +388, 19, 72, 456, 269, 272, 2085, 2088, "230" +388, 19, 73, 457, 273, 274, 2089, 2090, ")" +388, 19, 74, 458, 275, 278, 2091, 2094, "for" +388, 19, 75, 459, 279, 281, 2095, 2097, "24" +388, 19, 76, 460, 282, 283, 2098, 2099, " " +388, 19, 77, 461, 284, 289, 2100, 2105, "weeks" +388, 19, 78, 462, 290, 291, 2106, 2107, "," +388, 19, 79, 463, 292, 302, 2108, 2118, "stratified" +388, 19, 80, 464, 303, 305, 2119, 2121, "by" +388, 19, 81, 465, 306, 315, 2122, 2131, "metformin" +388, 19, 82, 466, 316, 319, 2132, 2135, "use" +388, 19, 83, 467, 320, 321, 2136, 2137, "." +388, 20, 1, 468, 0, 3, 2138, 2141, "The" +388, 20, 2, 469, 4, 11, 2142, 2149, "primary" +388, 20, 3, 470, 12, 20, 2150, 2158, "efficacy" +388, 20, 4, 471, 21, 28, 2159, 2166, "measure" +388, 20, 5, 472, 29, 32, 2167, 2170, "was" +388, 20, 6, 473, 33, 39, 2171, 2177, "change" +388, 20, 7, 474, 40, 42, 2178, 2180, "in" +388, 20, 8, 475, 43, 48, 2181, 2186, "HbA1c" +388, 20, 9, 476, 49, 50, 2187, 2188, "." +388, 21, 1, 477, 0, 11, 2189, 2200, "Saxagliptin" +388, 21, 2, 478, 12, 21, 2201, 2210, "treatment" +388, 21, 3, 479, 22, 30, 2211, 2219, "resulted" +388, 21, 4, 480, 31, 33, 2220, 2222, "in" +388, 21, 5, 481, 34, 35, 2223, 2224, "a" +388, 21, 6, 482, 36, 43, 2225, 2232, "greater" +388, 21, 7, 483, 44, 52, 2233, 2241, "adjusted" +388, 21, 8, 484, 53, 57, 2242, 2246, "mean" +388, 21, 9, 485, 58, 64, 2247, 2253, "change" +388, 21, 10, 486, 65, 67, 2254, 2256, "in" +388, 21, 11, 487, 68, 73, 2257, 2262, "HbA1c" +388, 21, 12, 488, 74, 78, 2263, 2267, "from" +388, 21, 13, 489, 79, 87, 2268, 2276, "baseline" +388, 21, 14, 490, 88, 90, 2277, 2279, "to" +388, 21, 15, 491, 91, 95, 2280, 2284, "week" +388, 21, 16, 492, 96, 98, 2285, 2287, "24" +388, 21, 17, 493, 99, 103, 2288, 2292, "than" +388, 21, 18, 494, 104, 111, 2293, 2300, "placebo" +388, 21, 19, 495, 112, 113, 2301, 2302, "(" +388, 21, 20, 496, 114, 115, 2303, 2304, "-" +388, 21, 21, 497, 116, 117, 2305, 2306, "0" +388, 21, 22, 498, 118, 119, 2307, 2308, "." +388, 21, 23, 499, 120, 122, 2309, 2311, "58" +388, 21, 24, 500, 123, 124, 2312, 2313, "%" +388, 21, 25, 501, 125, 126, 2314, 2315, ";" +388, 21, 26, 502, 127, 128, 2316, 2317, "P" +388, 21, 27, 503, 129, 133, 2318, 2322, " < ." +388, 21, 28, 504, 134, 137, 2323, 2326, "001" +388, 21, 29, 505, 138, 139, 2327, 2328, ")" +388, 21, 30, 506, 140, 141, 2329, 2330, "," +388, 21, 31, 507, 142, 154, 2331, 2343, "irrespective" +388, 21, 32, 508, 155, 157, 2344, 2346, "of" +388, 21, 33, 509, 158, 167, 2347, 2356, "metformin" +388, 21, 34, 510, 168, 171, 2357, 2360, "use" +388, 21, 35, 511, 172, 173, 2361, 2362, "," +388, 21, 36, 512, 174, 177, 2363, 2366, "and" +388, 21, 37, 513, 178, 179, 2367, 2368, "a" +388, 21, 38, 514, 180, 187, 2369, 2376, "greater" +388, 21, 39, 515, 188, 192, 2377, 2381, "mean" +388, 21, 40, 516, 193, 199, 2382, 2388, "change" +388, 21, 41, 517, 200, 202, 2389, 2391, "in" +388, 21, 42, 518, 203, 206, 2392, 2395, "FPG" +388, 21, 43, 519, 207, 208, 2396, 2397, "(" +388, 21, 44, 520, 209, 210, 2398, 2399, "0" +388, 21, 45, 521, 211, 212, 2400, 2401, "." +388, 21, 46, 522, 213, 214, 2402, 2403, "9" +388, 21, 47, 523, 215, 219, 2404, 2408, "mmol" +388, 21, 48, 524, 220, 221, 2409, 2410, "/" +388, 21, 49, 525, 222, 223, 2411, 2412, "L" +388, 21, 50, 526, 224, 225, 2413, 2414, "[" +388, 21, 51, 527, 226, 227, 2415, 2416, "-" +388, 21, 52, 528, 228, 230, 2417, 2419, "15" +388, 21, 53, 529, 231, 232, 2420, 2421, "." +388, 21, 54, 530, 233, 234, 2422, 2423, "9" +388, 21, 55, 531, 235, 237, 2424, 2426, "mg" +388, 21, 56, 532, 238, 239, 2427, 2428, "/" +388, 21, 57, 533, 240, 242, 2429, 2431, "dL" +388, 21, 58, 534, 243, 244, 2432, 2433, "]" +388, 21, 59, 535, 245, 246, 2434, 2435, ";" +388, 21, 60, 536, 247, 248, 2436, 2437, "P" +388, 21, 61, 537, 249, 253, 2438, 2442, " < ." +388, 21, 62, 538, 254, 257, 2443, 2446, "001" +388, 21, 63, 539, 258, 259, 2447, 2448, ")" +388, 21, 64, 540, 260, 261, 2449, 2450, "." +388, 22, 1, 541, 0, 4, 2451, 2455, "More" +388, 22, 2, 542, 5, 13, 2456, 2464, "patients" +388, 22, 3, 543, 14, 22, 2465, 2473, "achieved" +388, 22, 4, 544, 23, 28, 2474, 2479, "HbA1c" +388, 22, 5, 545, 29, 30, 2480, 2481, "<" +388, 22, 6, 546, 31, 32, 2482, 2483, "7" +388, 22, 7, 547, 33, 34, 2484, 2485, "%" +388, 22, 8, 548, 35, 39, 2486, 2490, "with" +388, 22, 9, 549, 40, 51, 2491, 2502, "saxagliptin" +388, 22, 10, 550, 52, 53, 2503, 2504, "(" +388, 22, 11, 551, 54, 56, 2505, 2507, "11" +388, 22, 12, 552, 57, 58, 2508, 2509, "." +388, 22, 13, 553, 59, 60, 2510, 2511, "4" +388, 22, 14, 554, 61, 62, 2512, 2513, "%" +388, 22, 15, 555, 63, 64, 2514, 2515, ")" +388, 22, 16, 556, 65, 69, 2516, 2520, "than" +388, 22, 17, 557, 70, 74, 2521, 2525, "with" +388, 22, 18, 558, 75, 82, 2526, 2533, "placebo" +388, 22, 19, 559, 83, 84, 2534, 2535, "(" +388, 22, 20, 560, 85, 86, 2536, 2537, "3" +388, 22, 21, 561, 87, 88, 2538, 2539, "." +388, 22, 22, 562, 89, 90, 2540, 2541, "5" +388, 22, 23, 563, 91, 92, 2542, 2543, "%" +388, 22, 24, 564, 93, 94, 2544, 2545, "," +388, 22, 25, 565, 95, 96, 2546, 2547, "P" +388, 22, 26, 566, 97, 101, 2548, 2552, " = ." +388, 22, 27, 567, 102, 105, 2553, 2556, "002" +388, 22, 28, 568, 106, 107, 2557, 2558, ")" +388, 22, 29, 569, 108, 109, 2559, 2560, "." +388, 23, 1, 570, 0, 7, 2561, 2568, "Adverse" +388, 23, 2, 571, 8, 14, 2569, 2575, "events" +388, 23, 3, 572, 15, 18, 2576, 2579, "and" +388, 23, 4, 573, 19, 28, 2580, 2589, "incidence" +388, 23, 5, 574, 29, 31, 2590, 2592, "of" +388, 23, 6, 575, 32, 45, 2593, 2606, "hypoglycaemia" +388, 23, 7, 576, 46, 50, 2607, 2611, "were" +388, 23, 8, 577, 51, 58, 2612, 2619, "similar" +388, 23, 9, 578, 59, 61, 2620, 2622, "in" +388, 23, 10, 579, 62, 66, 2623, 2627, "both" +388, 23, 11, 580, 67, 73, 2628, 2634, "groups" +388, 23, 12, 581, 74, 75, 2635, 2636, "." +388, 24, 1, 582, 0, 7, 2637, 2644, "Overall" +388, 24, 2, 583, 8, 9, 2645, 2646, "," +388, 24, 3, 584, 10, 13, 2647, 2650, "add" +388, 24, 4, 585, 14, 15, 2651, 2652, "-" +388, 24, 5, 586, 16, 18, 2653, 2655, "on" +388, 24, 6, 587, 19, 30, 2656, 2667, "saxagliptin" +388, 24, 7, 588, 31, 32, 2668, 2669, "5" +388, 24, 8, 589, 33, 35, 2670, 2672, "mg" +388, 24, 9, 590, 36, 40, 2673, 2677, "once" +388, 24, 10, 591, 41, 46, 2678, 2683, "daily" +388, 24, 11, 592, 47, 60, 2684, 2697, "significantly" +388, 24, 12, 593, 61, 69, 2698, 2706, "improved" +388, 24, 13, 594, 70, 79, 2707, 2716, "glycaemic" +388, 24, 14, 595, 80, 87, 2717, 2724, "control" +388, 24, 15, 596, 88, 95, 2725, 2732, "without" +388, 24, 16, 597, 96, 106, 2733, 2743, "increasing" +388, 24, 17, 598, 107, 120, 2744, 2757, "hypoglycaemia" +388, 24, 18, 599, 121, 125, 2758, 2762, "risk" +388, 24, 19, 600, 126, 129, 2763, 2766, "and" +388, 24, 20, 601, 130, 133, 2767, 2770, "was" +388, 24, 21, 602, 134, 138, 2771, 2775, "well" +388, 24, 22, 603, 139, 148, 2776, 2785, "tolerated" +388, 24, 23, 604, 149, 151, 2786, 2788, "in" +388, 24, 24, 605, 152, 159, 2789, 2796, "Chinese" +388, 24, 25, 606, 160, 168, 2797, 2805, "patients" +388, 24, 26, 607, 169, 173, 2806, 2810, "with" +388, 24, 27, 608, 174, 178, 2811, 2815, "type" +388, 24, 28, 609, 179, 180, 2816, 2817, "2" +388, 24, 29, 610, 181, 189, 2818, 2826, "diabetes" +388, 24, 30, 611, 190, 202, 2827, 2839, "inadequately" +388, 24, 31, 612, 203, 213, 2840, 2850, "controlled" +388, 24, 32, 613, 214, 216, 2851, 2853, "by" +388, 24, 33, 614, 217, 224, 2854, 2861, "insulin" +388, 24, 34, 615, 225, 226, 2862, 2863, "(" +388, 24, 35, 616, 227, 228, 2864, 2865, "±" +388, 24, 36, 617, 229, 238, 2866, 2875, "metformin" +388, 24, 37, 618, 239, 240, 2876, 2877, ")" +388, 24, 38, 619, 241, 242, 2878, 2879, "." +388, 25, 1, 620, 0, 1, 2880, 2881, "©" +388, 25, 2, 621, 2, 6, 2882, 2886, "2017" +388, 25, 3, 622, 7, 11, 2887, 2891, "John" +388, 25, 4, 623, 12, 17, 2892, 2897, "Wiley" +388, 25, 5, 624, 18, 19, 2898, 2899, "&" +388, 25, 6, 625, 20, 24, 2900, 2904, "Sons" +388, 25, 7, 626, 25, 28, 2905, 2908, "Ltd" +388, 25, 8, 627, 29, 30, 2909, 2910, "." +388, 25, 9, 628, 31, 34, 2911, 2914, "DOI" +388, 25, 10, 629, 35, 36, 2915, 2916, ":" +388, 25, 11, 630, 37, 39, 2917, 2919, "10" +388, 25, 12, 631, 40, 41, 2920, 2921, "." +388, 25, 13, 632, 42, 46, 2922, 2926, "1111" +388, 25, 14, 633, 47, 48, 2927, 2928, "/" +388, 25, 15, 634, 49, 52, 2929, 2932, "dom" +388, 25, 16, 635, 53, 54, 2933, 2934, "." +388, 25, 17, 636, 55, 60, 2935, 2940, "13161" +388, 25, 18, 637, 61, 65, 2941, 2945, "PMID" +388, 25, 19, 638, 66, 67, 2946, 2947, ":" +388, 25, 20, 639, 68, 76, 2948, 2956, "29144061" +388, 25, 21, 640, 77, 78, 2957, 2958, "[" +388, 25, 22, 641, 79, 86, 2959, 2966, "Indexed" +388, 25, 23, 642, 87, 90, 2967, 2970, "for" +388, 25, 24, 643, 91, 98, 2971, 2978, "MEDLINE" +388, 25, 25, 644, 99, 100, 2979, 2980, "]" diff --git a/data/dm2 29144061_kwoodley.annodb b/data/dm2 29144061_kwoodley.annodb new file mode 100644 index 0000000..4c6ba93 --- /dev/null +++ b/data/dm2 29144061_kwoodley.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72749, Journal, 0, 19, "Diabetes Obes Metab", "", +72750, PublicationYear, 22, 26, "2018", "", +72751, Saxagliptin, 109, 120, "Saxagliptin", "", +72776, Title, 109, 333, "Saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin : Results from the SUPER study , a randomized , double - blind , placebo - controlled trial .", "", +72757, Ethnicity, 141, 148, "Chinese", "", +72771, Precondition, 149, 239, "patients with type 2 diabetes inadequately controlled by insulin with or without metformin", "", +72760, Type2Diabetes, 163, 178, "type 2 diabetes", "", +72763, Insulin, 206, 213, "insulin", "", +72766, Metformin, 230, 239, "metformin", "", +72769, Randomized, 275, 285, "randomized", "", +72770, DoubleBlind, 288, 302, "double - blind", "", +72772, Placebo, 305, 312, "placebo", "", +72777, Author, 334, 340, "Chen Y", "", +72778, Author, 349, 354, "Liu X", "", +72779, Author, 363, 367, "Li Q", "", +72780, Author, 376, 380, "Ma J", "", +72781, Author, 389, 393, "Lv X", "", +72782, Author, 402, 407, "Guo L", "", +72783, Author, 416, 422, "Wang C", "", +72784, Author, 431, 436, "Shi Y", "", +72785, Author, 445, 449, "Li Y", "", +72786, Author, 458, 468, "Johnsson E", "", +72787, Author, 478, 484, "Wang M", "", +72788, Author, 494, 500, "Zhao J", "", +72789, Author, 510, 514, "Ji L", "", +72790, China, 645, 650, "China", "", +72791, China, 755, 760, "China", "", +72792, China, 856, 861, "China", "", +72793, China, 935, 940, "China", "", +72794, China, 1009, 1014, "China", "", +72795, China, 1115, 1120, "China", "", +72796, China, 1223, 1228, "China", "", +72797, China, 1309, 1314, "China", "", +72798, China, 1421, 1426, "China", "", +72800, Sweden, 1473, 1479, "Sweden", "", +72799, China, 1538, 1543, "China", "", +72801, USA, 1582, 1590, "Maryland", "", +72805, ObjectiveDescription, 1593, 1815, "This prospective , multicentre , phase III study ( NCT02104804 ) evaluated the efficacy and safety of saxagliptin add - on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin  ±  metformin .", "", +72802, Prospective, 1598, 1609, "prospective", "", +72803, Multicenter, 1612, 1623, "multicentre", "", +72752, Saxagliptin, 1695, 1706, "saxagliptin", "", +72758, Ethnicity, 1727, 1734, "Chinese", "", +72804, Precondition, 1735, 1813, "patients with type 2 diabetes inadequately controlled by insulin  ±  metformin", "", +72761, Type2Diabetes, 1749, 1764, "type 2 diabetes", "", +72764, Insulin, 1792, 1799, "insulin", "", +72767, Metformin, 1804, 1813, "metformin", "", +72822, Precondition, 1816, 1994, "Patients with glycated haemoglobin ( HbA1c ) 7 . 5 % to 10 . 5 % and fasting plasma glucose ( FPG ) < 15 mmol / L ( 270   mg / dL ) on stable insulin therapy ( 20 - 150   U / d )", "", +72806, HbA1c, 1830, 1850, "glycated haemoglobin", "", +72807, HbA1c, 1853, 1858, "HbA1c", "", +72810, Percentage, 1867, 1868, "%", "", +72811, Percentage, 1879, 1880, "%", "", +72812, FastingPlasmaGlucose, 1885, 1907, "fasting plasma glucose", "", +72813, FastingPlasmaGlucose, 1910, 1913, "FPG", "", +72814, Millimoles_per_litre, 1921, 1929, "mmol / L", "", +72815, Mg_per_deciliter, 1938, 1945, "mg / dL", "", +72816, Insulin, 1958, 1965, "insulin", "", +72817, DoseValue, 1976, 1984, "20 - 150", "", +72818, BioAndMedicalUnit, 1987, 1988, "U", "", +72819, Frequency, 1991, 1992, "d", "", +72820, Randomized, 2000, 2010, "randomized", "", +72821, AllocationRatio, 2013, 2018, "1 : 1", "", +72753, Saxagliptin, 2024, 2035, "saxagliptin", "", +72823, DoseValue, 2036, 2037, "5", "", +72824, mg, 2038, 2040, "mg", "", +72825, Frequency, 2041, 2051, "once daily", "", +72826, NumberPatientsArm, 2060, 2063, "232", "", +72773, Placebo, 2069, 2076, "placebo", "", +72827, NumberPatientsArm, 2085, 2088, "230", "", +72828, Duration, 2095, 2105, "24   weeks", "", +72829, Metformin, 2122, 2131, "metformin", "", +72808, HbA1c, 2181, 2186, "HbA1c", "", +72754, Saxagliptin, 2189, 2200, "Saxagliptin", "", +72809, HbA1c, 2257, 2262, "HbA1c", "", +72830, TimePoint, 2268, 2276, "baseline", "", +72831, TimePoint, 2280, 2287, "week 24", "", +72774, Placebo, 2293, 2300, "placebo", "", +72832, DiffGroupAbsValue, 2303, 2311, "- 0 . 58", "", +72833, Percentage, 2312, 2313, "%", "", +72834, PvalueDiff, 2316, 2326, "P  < . 001", "", +72836, Metformin, 2347, 2356, "metformin", "", +72837, FastingPlasmaGlucose, 2392, 2395, "FPG", "", +72838, DiffGroupAbsValue, 2398, 2403, "0 . 9", "", +72840, Millimoles_per_litre, 2404, 2412, "mmol / L", "", +72839, DiffGroupAbsValue, 2415, 2423, "- 15 . 9", "", +72841, Mg_per_deciliter, 2424, 2431, "mg / dL", "", +72835, PvalueDiff, 2436, 2446, "P  < . 001", "", +72842, HbA1c_target, 2474, 2485, "HbA1c < 7 %", "", +72755, Saxagliptin, 2491, 2502, "saxagliptin", "", +72843, PercentageAffected, 2505, 2511, "11 . 4", "", +72775, Placebo, 2526, 2533, "placebo", "", +72844, PercentageAffected, 2536, 2541, "3 . 5", "", +72845, PvalueDiff, 2546, 2556, "P  = . 002", "", +72846, EndPointDescription, 2561, 2575, "Adverse events", "", +72848, ObservedResult, 2561, 2636, "Adverse events and incidence of hypoglycaemia were similar in both groups .", "", +72847, Hypoglycemia, 2593, 2606, "hypoglycaemia", "", +72854, ConclusionComment, 2637, 2879, "Overall , add - on saxagliptin 5 mg once daily significantly improved glycaemic control without increasing hypoglycaemia risk and was well tolerated in Chinese patients with type 2 diabetes inadequately controlled by insulin ( ± metformin ) .", "", +72756, Saxagliptin, 2656, 2667, "saxagliptin", "", +72849, DoseValue, 2668, 2669, "5", "", +72850, mg, 2670, 2672, "mg", "", +72851, Frequency, 2673, 2683, "once daily", "", +72852, Hypoglycemia, 2744, 2757, "hypoglycaemia", "", +72759, Ethnicity, 2789, 2796, "Chinese", "", +72853, Precondition, 2797, 2877, "patients with type 2 diabetes inadequately controlled by insulin ( ± metformin )", "", +72762, Type2Diabetes, 2811, 2826, "type 2 diabetes", "", +72765, Insulin, 2854, 2861, "insulin", "", +72768, Metformin, 2866, 2875, "metformin", "", +72855, PMID, 2948, 2956, "29144061", "", diff --git a/data/dm2 29144061_kwoodley.n-triples b/data/dm2 29144061_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29144061_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29246950_admin.annodb b/data/dm2 29246950_admin.annodb new file mode 100644 index 0000000..f514284 --- /dev/null +++ b/data/dm2 29246950_admin.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Diabetes Care", "", " \"Diabetes Care\"." +1, PublicationYear, 16, 20, "2018", "", " \"2018\"." +32, Title, 101, 275, "Efficacy and Safety of Once - Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes ( SUSTAIN 3 ) : A 56 - Week , Open - Label , Randomized Clinical Trial .", "", " \"Efficacy and Safety of Once - Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes ( SUSTAIN 3 ) : A 56 - Week , Open - Label , Randomized Clinical Trial .\"." +2, Frequency, 124, 137, "Once - Weekly", "", " \"Once - Weekly\". \"Once - Weekly\"." +4, Semaglutide, 138, 149, "Semaglutide", "", +129, Exenatide, 157, 169, "Exenatide ER", "", +14, Type2Diabetes, 187, 202, "Type 2 Diabetes", "", " ." +28, Duration, 221, 230, "56 - Week", "", " \"56 - Week\"." +29, OpenLabel, 233, 245, "Open - Label", "", " ." +30, Randomized, 248, 258, "Randomized", "", " ." +33, Author, 276, 285, "Ahmann AJ", "", " \"Ahmann AJ\"." +34, Author, 294, 304, "Capehorn M", "", " \"Capehorn M\"." +35, Author, 313, 326, "Charpentier G", "", " \"Charpentier G\"." +36, Author, 335, 342, "Dotta F", "", " \"Dotta F\"." +37, Author, 351, 359, "Henkel E", "", " \"Henkel E\"." +38, Author, 368, 377, "Lingvay I", "", " \"Lingvay I\"." +39, Author, 386, 394, "Holst AG", "", " \"Holst AG\"." +40, Author, 403, 412, "Annett MP", "", " \"Annett MP\"." +41, Author, 421, 429, "Aroda VR", "", " \"Aroda VR\"." +42, USA, 544, 552, "Portland", "", +44, France, 729, 735, "France", "", +45, Italy, 826, 831, "Italy", "", +46, Germany, 899, 906, "Germany", "", +43, USA, 1031, 1033, "TX", "", +47, Country, 1074, 1081, "Denmark", "", +48, USA, 1124, 1126, "NJ", "", +49, USA, 1185, 1187, "MD", "", +64, ObjectiveDescription, 1202, 1373, "To compare the efficacy and safety of once - weekly semaglutide 1 . 0 mg s . c . with exenatide extended release ( ER ) 2 . 0 mg s . c . in subjects with type 2 diabetes .", "", " \"To compare the efficacy and safety of once - weekly semaglutide 1 . 0 mg s . c . with exenatide extended release ( ER ) 2 . 0 mg s . c . in subjects with type 2 diabetes .\"." +3, Frequency, 1240, 1253, "once - weekly", "", +5, Semaglutide, 1254, 1265, "semaglutide", "", +50, DoseValue, 1266, 1271, "1 . 0", "", +56, mg, 1272, 1274, "mg", "", +86252, Subcutaneous, 1275, 1282, "s . c .", "", " ." +17, Exenatide, 1288, 1314, "exenatide extended release", "", +18, Exenatide, 1317, 1319, "ER", "", +51, DoseValue, 1322, 1327, "2 . 0", "", +57, mg, 1328, 1330, "mg", "", +86257, Subcutaneous, 1331, 1338, "s . c .", "", " ." +15, Type2Diabetes, 1356, 1371, "type 2 diabetes", "", +65, OpenLabel, 1423, 1435, "open - label", "", +66, Parallel, 1438, 1454, "parallel - group", "", " ." +67, Randomized, 1457, 1467, "randomized", "", +68, NumberPatientsCT, 1487, 1490, "813", "", " \"813\"." +70, Precondition, 1491, 1551, "subjects with type 2 diabetes taking oral antidiabetic drugs", "", " \"subjects with type 2 diabetes taking oral antidiabetic drugs\"." +16, Type2Diabetes, 1505, 1520, "type 2 diabetes", "", +69, OralAntidiabeticAgent, 1528, 1551, "oral antidiabetic drugs", "", +71, Randomized, 1557, 1567, "randomized", "", +72, AllocationRatio, 1570, 1575, "1 : 1", "", " . ." +6, Semaglutide, 1581, 1592, "semaglutide", "", " ." +52, DoseValue, 1593, 1598, "1 . 0", "", " \"1 . 0\"." +59, mg, 1599, 1601, "mg", "", " ." +19, Exenatide, 1605, 1617, "exenatide ER", "", " ." +53, DoseValue, 1618, 1623, "2 . 0", "", " \"1 . 0\"." +58, mg, 1624, 1626, "mg", "", " ." +73, Duration, 1631, 1639, "56 weeks", "", +74, TimePoint, 1680, 1688, "baseline", "", +76, HbA1c, 1692, 1697, "HbA1c", "", +75, TimePoint, 1701, 1708, "week 56", "", +178, Mean, 1721, 1725, "Mean", "", " . ." +77, HbA1c, 1726, 1731, "HbA1c", "", " ." +78, BaseLineValue, 1734, 1739, "8 . 3", "", " \"8 . 3\". \"8 . 3\"." +80, Percentage, 1740, 1741, "%", "", " ." +79, BaseLineValue, 1744, 1750, "67 . 7", "", +86258, Millimoles_per_mole, 1751, 1761, "mmol / mol", "", +88, TimePoint, 1767, 1775, "baseline", "", +89, Reduction, 1793, 1798, "1 . 5", "", " \"1 . 5\"." +81, Percentage, 1799, 1800, "%", "", +90, Reduction, 1803, 1809, "16 . 8", "", +86259, Millimoles_per_mole, 1810, 1820, "mmol / mol", "", +7, Semaglutide, 1828, 1839, "semaglutide", "", +91, Reduction, 1844, 1849, "0 . 9", "", " \"0 . 9\"." +82, Percentage, 1850, 1851, "%", "", +92, Reduction, 1854, 1860, "10 . 0", "", +86260, Millimoles_per_mole, 1861, 1871, "mmol / mol", "", +26, Exenatide, 1879, 1891, "exenatide ER", "", +20, Exenatide, 1930, 1942, "exenatide ER", "", +93, DiffGroupAbsValue, 1951, 1959, "- 0 . 62", "", " \"- 0 . 62\"." +83, Percentage, 1960, 1961, "%", "", +95, ConfIntervalDiff, 1964, 1991, "95 % CI - 0 . 80 , - 0 . 44", "", " \"95 % CI - 0 . 80 , - 0 . 44\"." +94, DiffGroupAbsValue, 1996, 2004, "- 6 . 78", "", +86261, Millimoles_per_mole, 2005, 2015, "mmol / mol", "", +96, ConfIntervalDiff, 2018, 2045, "95 % CI - 8 . 70 , - 4 . 86", "", +97, PvalueDiff, 2052, 2064, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +214, Mean, 2104, 2108, "Mean", "", " . ." +98, BodyWeight, 2109, 2120, "body weight", "", " ." +100, BaseLineValue, 2123, 2129, "95 . 8", "", " \"95 . 8\". \"95 . 8\"." +101, Kg, 2130, 2132, "kg", "", " ." +105, TimePoint, 2136, 2144, "baseline", "", +106, Reduction, 2162, 2167, "5 . 6", "", " \"5 . 6\"." +102, Kg, 2168, 2170, "kg", "", +8, Semaglutide, 2176, 2187, "semaglutide", "", +107, Reduction, 2192, 2197, "1 . 9", "", " \"1 . 9\"." +103, Kg, 2198, 2200, "kg", "", +24, Exenatide, 2206, 2218, "exenatide ER", "", +108, DiffGroupAbsValue, 2225, 2233, "- 3 . 78", "", " \"- 3 . 78\"." +104, Kg, 2234, 2236, "kg", "", +109, ConfIntervalDiff, 2239, 2266, "95 % CI - 4 . 58 , - 2 . 98", "", " \"95 % CI - 4 . 58 , - 2 . 98\"." +110, PvalueDiff, 2271, 2283, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +9, Semaglutide, 2329, 2340, "semaglutide", "", +111, PercentageAffected, 2343, 2345, "67", "", " \"67\"." +113, HbA1c_target, 2359, 2394, "HbA1c < 7 . 0 % ( < 53 mmol / mol )", "", " ." +191, Percentage, 2373, 2374, "%", "", +86262, Millimoles_per_mole, 2382, 2392, "mmol / mol", "", +23, Exenatide, 2415, 2427, "exenatide ER", "", +112, PercentageAffected, 2430, 2432, "40", "", " \"40\"." +114, GastrointestinalProblem, 2489, 2520, "gastrointestinal adverse events", "", " ." +10, Semaglutide, 2541, 2552, "semaglutide", "", +115, PercentageAffected, 2574, 2580, "41 . 8", "", " \"41 . 8\"." +22, Exenatide, 2593, 2605, "exenatide ER", "", +116, PercentageAffected, 2627, 2633, "33 . 3", "", " \"33 . 3\"." +117, EndPointDescription, 2640, 2666, "injection - site reactions", "", " . ." +21, Exenatide, 2691, 2703, "exenatide ER", "", +118, PercentageAffected, 2706, 2712, "22 . 0", "", " \"22 . 0\"." +11, Semaglutide, 2727, 2738, "semaglutide", "", +119, PercentageAffected, 2741, 2746, "1 . 2", "", " \"1 . 2\"." +123, ConclusionComment, 2767, 2953, "Semaglutide 1 . 0 mg was superior to exenatide ER 2 . 0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment ; the drugs had comparable safety profiles .", "", " \"Semaglutide 1 . 0 mg was superior to exenatide ER 2 . 0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment ; the drugs had comparable safety profiles .\"." +12, Semaglutide, 2767, 2778, "Semaglutide", "", +54, DoseValue, 2779, 2784, "1 . 0", "", +60, mg, 2785, 2787, "mg", "", +25, Exenatide, 2804, 2816, "exenatide ER", "", +55, DoseValue, 2817, 2822, "2 . 0", "", +61, mg, 2823, 2825, "mg", "", +99, BodyWeight, 2869, 2880, "body weight", "", +120, Duration, 2887, 2895, "56 weeks", "", +124, ConclusionComment, 2954, 3118, "These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs .", "", " \"These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs .\"." +13, Semaglutide, 2982, 2993, "semaglutide", "", +27, Type2Diabetes, 3042, 3057, "type 2 diabetes", "", +121, OralAntidiabeticAgent, 3093, 3116, "oral antidiabetic drugs", "", +125, PMID, 3202, 3210, "29246950", "", " \"29246950\"." diff --git a/data/dm2 29246950_admin.n-triples b/data/dm2 29246950_admin.n-triples new file mode 100644 index 0000000..6cd6ed0 --- /dev/null +++ b/data/dm2 29246950_admin.n-triples @@ -0,0 +1,181 @@ +# RDF export of group: Publication + . + "Publication 78333" . + "Efficacy and Safety of Once - Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes ( SUSTAIN 3 ) : A 56 - Week , Open - Label , Randomized Clinical Trial ." . + "Ahmann AJ" . + "2018" . + "Diabetes Care" . + "29246950" . + . + "Capehorn M" . + "Charpentier G" . + "Dotta F" . + "Henkel E" . + "Lingvay I" . + "Holst AG" . + "Annett MP" . + "Aroda VR" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 78340" . + "To compare the efficacy and safety of once - weekly semaglutide 1 . 0 mg s . c . with exenatide extended release ( ER ) 2 . 0 mg s . c . in subjects with type 2 diabetes ." . + "813" . + "56 - Week" . + . + . + . + . + "Semaglutide 1 . 0 mg was superior to exenatide ER 2 . 0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment ; the drugs had comparable safety profiles ." . + . + . + . + . + . + . + "These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs ." . + . + . + . +# RDF export of group: Population + . + "Population 78356" . + "subjects with type 2 diabetes taking oral antidiabetic drugs" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "gas" . + . + . + . + . + . + "in" . + . + . + . + . + . +# RDF export of group: Arm + . + "sem" . + . + . + . + . + . + . + . + "ex" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sem" . + . + "Once - Weekly" . + . + . + "ex" . + . + "Once - Weekly" . + . +# RDF export of group: Medication + . + "sem" . + . + "1 . 0" . + . + . + . + "ex" . + "2 . 0" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "8 . 3" . + "1 . 5" . + . + "hba 2" . + . + "8 . 3" . + "0 . 9" . + . + "bw 1" . + . + "95 . 8" . + "5 . 6" . + . + "bw 2" . + . + "95 . 8" . + "1 . 9" . + . + "hbat 1" . + . + "67" . + . + "hbat 2" . + . + "40" . + . + "gas 1" . + . + "41 . 8" . + . + "gas 2" . + . + "33 . 3" . + . + "in 1" . + . + "1 . 2" . + . + "in 2" . + . + "22 . 0" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 62" . + "P < 0 . 0001" . + "95 % CI - 0 . 80 , - 0 . 44" . + . + . + . + "bw" . + "- 3 . 78" . + "P < 0 . 0001" . + "95 % CI - 4 . 58 , - 2 . 98" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29246950_akramersunderbrink.annodb b/data/dm2 29246950_akramersunderbrink.annodb new file mode 100644 index 0000000..4683d55 --- /dev/null +++ b/data/dm2 29246950_akramersunderbrink.annodb @@ -0,0 +1,133 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73812, Journal, 0, 13, "Diabetes Care", "", +73813, PublicationYear, 16, 20, "2018", "", +73821, Title, 101, 275, "Efficacy and Safety of Once - Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes ( SUSTAIN 3 ) : A 56 - Week , Open - Label , Randomized Clinical Trial .", "", +73816, Frequency, 124, 137, "Once - Weekly", "", +73814, Semaglutide, 138, 149, "Semaglutide", "", +73815, Exenatide, 157, 166, "Exenatide", "", +73817, Type2Diabetes, 187, 202, "Type 2 Diabetes", "", +73818, Duration, 221, 230, "56 - Week", "", +73819, OpenLabel, 233, 245, "Open - Label", "", +73820, Randomized, 248, 258, "Randomized", "", +73822, Author, 276, 285, "Ahmann AJ", "", +73823, Author, 294, 304, "Capehorn M", "", +73824, Author, 313, 326, "Charpentier G", "", +73825, Author, 335, 342, "Dotta F", "", +73826, Author, 351, 359, "Henkel E", "", +73827, Author, 368, 377, "Lingvay I", "", +73828, Author, 386, 394, "Holst AG", "", +73829, Author, 403, 412, "Annett MP", "", +73830, Author, 421, 429, "Aroda VR", "", +73831, France, 729, 735, "France", "", +73832, Italy, 826, 831, "Italy", "", +73833, Germany, 899, 906, "Germany", "", +73834, Country, 1074, 1081, "Denmark", "", +73835, Frequency, 1240, 1253, "once - weekly", "", +73836, Semaglutide, 1254, 1265, "semaglutide", "", +73838, DoseValue, 1266, 1274, "1 . 0 mg", "", +73840, mg, 1272, 1274, "mg", "", +73842, Frequency, 1275, 1282, "s . c .", "", +73837, Exenatide, 1288, 1314, "exenatide extended release", "", +73839, DoseValue, 1322, 1330, "2 . 0 mg", "", +73841, mg, 1328, 1330, "mg", "", +73843, Frequency, 1331, 1338, "s . c .", "", +73844, Type2Diabetes, 1356, 1371, "type 2 diabetes", "", +73845, OpenLabel, 1423, 1435, "open - label", "", +73846, Parallel, 1438, 1454, "parallel - group", "", +73847, Randomized, 1457, 1467, "randomized", "", +73848, NumberPatientsCT, 1487, 1490, "813", "", +73849, Type2Diabetes, 1505, 1520, "type 2 diabetes", "", +73859, Precondition, 1521, 1551, "taking oral antidiabetic drugs", "", +73850, OralAntidiabeticAgent, 1528, 1551, "oral antidiabetic drugs", "", +73851, Randomized, 1557, 1567, "randomized", "", +73852, Semaglutide, 1581, 1592, "semaglutide", "", +73854, DoseValue, 1593, 1601, "1 . 0 mg", "", +73856, mg, 1599, 1601, "mg", "", +73853, Exenatide, 1605, 1617, "exenatide ER", "", +73855, DoseValue, 1618, 1626, "2 . 0 mg", "", +73857, mg, 1624, 1626, "mg", "", +73858, Duration, 1631, 1639, "56 weeks", "", +73860, TimePoint, 1680, 1688, "baseline", "", +73862, HbA1c, 1692, 1697, "HbA1c", "", +73861, TimePoint, 1701, 1708, "week 56", "", +73864, Mean, 1721, 1725, "Mean", "", +73863, HbA1c, 1726, 1731, "HbA1c", "", +73867, BaseLineValue, 1734, 1739, "8 . 3", "", +73869, Percentage, 1740, 1741, "%", "", +73868, BaseLineValue, 1744, 1750, "67 . 7", "", +73883, ConcentrationUnit, 1751, 1761, "mmol / mol", "", +73865, TimePoint, 1767, 1775, "baseline", "", +73887, ChangeValue, 1793, 1798, "1 . 5", "", +73870, Percentage, 1799, 1800, "%", "", +73888, ChangeValue, 1803, 1809, "16 . 8", "", +73891, ConcentrationUnit, 1810, 1820, "mmol / mol", "", +73892, Semaglutide, 1828, 1839, "semaglutide", "", +73889, ChangeValue, 1844, 1849, "0 . 9", "", +73873, Percentage, 1850, 1851, "%", "", +73890, ChangeValue, 1854, 1860, "10 . 0", "", +73886, ConcentrationUnit, 1861, 1871, "mmol / mol", "", +73893, Exenatide, 1879, 1891, "exenatide ER", "", +73894, Exenatide, 1930, 1942, "exenatide ER", "", +73895, DiffGroupAbsValue, 1951, 1959, "- 0 . 62", "", +73872, Percentage, 1960, 1961, "%", "", +73897, ConfIntervalDiff, 1964, 1991, "95 % CI - 0 . 80 , - 0 . 44", "", +73871, Percentage, 1967, 1968, "%", "", +73896, DiffGroupAbsValue, 1996, 2004, "- 6 . 78", "", +73885, ConcentrationUnit, 2005, 2015, "mmol / mol", "", +73898, ConfIntervalDiff, 2018, 2045, "95 % CI - 8 . 70 , - 4 . 86", "", +73874, Percentage, 2021, 2022, "%", "", +73899, PvalueDiff, 2052, 2064, "P < 0 . 0001", "", +73900, Mean, 2104, 2108, "Mean", "", +73901, BodyWeight, 2109, 2120, "body weight", "", +73902, BaseLineValue, 2123, 2129, "95 . 8", "", +73903, Kg, 2130, 2132, "kg", "", +73866, TimePoint, 2136, 2144, "baseline", "", +73909, Reduction, 2162, 2167, "5 . 6", "", +73904, Kg, 2168, 2170, "kg", "", +73907, Semaglutide, 2176, 2187, "semaglutide", "", +73910, Reduction, 2192, 2197, "1 . 9", "", +73905, Kg, 2198, 2200, "kg", "", +73908, Exenatide, 2206, 2218, "exenatide ER", "", +73911, DiffGroupAbsValue, 2225, 2233, "- 3 . 78", "", +73906, Kg, 2234, 2236, "kg", "", +73912, ConfIntervalDiff, 2239, 2266, "95 % CI - 4 . 58 , - 2 . 98", "", +73875, Percentage, 2242, 2243, "%", "", +73913, PvalueDiff, 2271, 2283, "P < 0 . 0001", "", +73914, Semaglutide, 2329, 2340, "semaglutide", "", +73917, PercentageAffected, 2343, 2345, "67", "", +73876, Percentage, 2346, 2347, "%", "", +73915, HbA1c_target, 2359, 2394, "HbA1c < 7 . 0 % ( < 53 mmol / mol )", "", +73877, Percentage, 2373, 2374, "%", "", +73884, ConcentrationUnit, 2382, 2392, "mmol / mol", "", +73916, Exenatide, 2415, 2427, "exenatide ER", "", +73918, PercentageAffected, 2430, 2432, "40", "", +73878, Percentage, 2433, 2434, "%", "", +73921, EndPointDescription, 2489, 2520, "gastrointestinal adverse events", "", +73919, Semaglutide, 2541, 2552, "semaglutide", "", +73922, PercentageAffected, 2574, 2580, "41 . 8", "", +73880, Percentage, 2581, 2582, "%", "", +73920, Exenatide, 2593, 2605, "exenatide ER", "", +73923, PercentageAffected, 2627, 2633, "33 . 3", "", +73879, Percentage, 2634, 2635, "%", "", +73924, EndPointDescription, 2640, 2666, "injection - site reactions", "", +73925, Exenatide, 2691, 2703, "exenatide ER", "", +73927, PercentageAffected, 2706, 2712, "22 . 0", "", +73881, Percentage, 2713, 2714, "%", "", +73926, Semaglutide, 2727, 2738, "semaglutide", "", +73928, PercentageAffected, 2741, 2746, "1 . 2", "", +73882, Percentage, 2747, 2748, "%", "", +73929, Semaglutide, 2767, 2778, "Semaglutide", "", +73941, ConclusionComment, 2767, 2953, "Semaglutide 1 . 0 mg was superior to exenatide ER 2 . 0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment ; the drugs had comparable safety profiles .", "", +73931, DoseValue, 2779, 2787, "1 . 0 mg", "", +73933, mg, 2785, 2787, "mg", "", +73930, Exenatide, 2804, 2816, "exenatide ER", "", +73932, DoseValue, 2817, 2825, "2 . 0 mg", "", +73934, mg, 2823, 2825, "mg", "", +73935, BodyWeight, 2869, 2880, "body weight", "", +73936, Duration, 2887, 2895, "56 weeks", "", +73942, ConclusionComment, 2954, 3118, "These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs .", "", +73937, Semaglutide, 2982, 2993, "semaglutide", "", +73938, Type2Diabetes, 3042, 3057, "type 2 diabetes", "", +73939, Precondition, 3066, 3116, "inadequately controlled on oral antidiabetic drugs", "", +73940, OralAntidiabeticAgent, 3093, 3116, "oral antidiabetic drugs", "", +73943, PMID, 3202, 3210, "29246950", "", diff --git a/data/dm2 29246950_akramersunderbrink.n-triples b/data/dm2 29246950_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29246950_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29246950_export.csv b/data/dm2 29246950_export.csv new file mode 100644 index 0000000..1c58ffb --- /dev/null +++ b/data/dm2 29246950_export.csv @@ -0,0 +1,749 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +386, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +386, 1, 2, 2, 9, 13, 9, 13, "Care" +386, 1, 3, 3, 14, 15, 14, 15, "." +386, 2, 1, 4, 0, 4, 16, 20, "2018" +386, 2, 2, 5, 5, 8, 21, 24, "Feb" +386, 2, 3, 6, 9, 10, 25, 26, ";" +386, 2, 4, 7, 11, 13, 27, 29, "41" +386, 2, 5, 8, 14, 15, 30, 31, "(" +386, 2, 6, 9, 16, 17, 32, 33, "2" +386, 2, 7, 10, 18, 19, 34, 35, ")" +386, 2, 8, 11, 20, 21, 36, 37, ":" +386, 2, 9, 12, 22, 25, 38, 41, "258" +386, 2, 10, 13, 26, 27, 42, 43, "-" +386, 2, 11, 14, 28, 31, 44, 47, "266" +386, 2, 12, 15, 32, 33, 48, 49, "." +386, 2, 13, 16, 34, 37, 50, 53, "doi" +386, 2, 14, 17, 38, 39, 54, 55, ":" +386, 2, 15, 18, 40, 42, 56, 58, "10" +386, 2, 16, 19, 43, 44, 59, 60, "." +386, 2, 17, 20, 45, 49, 61, 65, "2337" +386, 2, 18, 21, 50, 51, 66, 67, "/" +386, 2, 19, 22, 52, 56, 68, 72, "dc17" +386, 2, 20, 23, 57, 58, 73, 74, "-" +386, 2, 21, 24, 59, 63, 75, 79, "0417" +386, 2, 22, 25, 64, 65, 80, 81, "." +386, 3, 1, 26, 0, 4, 82, 86, "Epub" +386, 3, 2, 27, 5, 9, 87, 91, "2017" +386, 3, 3, 28, 10, 13, 92, 95, "Dec" +386, 3, 4, 29, 14, 16, 96, 98, "15" +386, 3, 5, 30, 17, 18, 99, 100, "." +386, 4, 1, 31, 0, 8, 101, 109, "Efficacy" +386, 4, 2, 32, 9, 12, 110, 113, "and" +386, 4, 3, 33, 13, 19, 114, 120, "Safety" +386, 4, 4, 34, 20, 22, 121, 123, "of" +386, 4, 5, 35, 23, 27, 124, 128, "Once" +386, 4, 6, 36, 28, 29, 129, 130, "-" +386, 4, 7, 37, 30, 36, 131, 137, "Weekly" +386, 4, 8, 38, 37, 48, 138, 149, "Semaglutide" +386, 4, 9, 39, 49, 55, 150, 156, "Versus" +386, 4, 10, 40, 56, 65, 157, 166, "Exenatide" +386, 4, 11, 41, 66, 68, 167, 169, "ER" +386, 4, 12, 42, 69, 71, 170, 172, "in" +386, 4, 13, 43, 72, 80, 173, 181, "Subjects" +386, 4, 14, 44, 81, 85, 182, 186, "With" +386, 4, 15, 45, 86, 90, 187, 191, "Type" +386, 4, 16, 46, 91, 92, 192, 193, "2" +386, 4, 17, 47, 93, 101, 194, 202, "Diabetes" +386, 4, 18, 48, 102, 103, 203, 204, "(" +386, 4, 19, 49, 104, 111, 205, 212, "SUSTAIN" +386, 4, 20, 50, 112, 113, 213, 214, "3" +386, 4, 21, 51, 114, 115, 215, 216, ")" +386, 4, 22, 52, 116, 117, 217, 218, ":" +386, 4, 23, 53, 118, 119, 219, 220, "A" +386, 4, 24, 54, 120, 122, 221, 223, "56" +386, 4, 25, 55, 123, 124, 224, 225, "-" +386, 4, 26, 56, 125, 129, 226, 230, "Week" +386, 4, 27, 57, 130, 131, 231, 232, "," +386, 4, 28, 58, 132, 136, 233, 237, "Open" +386, 4, 29, 59, 137, 138, 238, 239, "-" +386, 4, 30, 60, 139, 144, 240, 245, "Label" +386, 4, 31, 61, 145, 146, 246, 247, "," +386, 4, 32, 62, 147, 157, 248, 258, "Randomized" +386, 4, 33, 63, 158, 166, 259, 267, "Clinical" +386, 4, 34, 64, 167, 172, 268, 273, "Trial" +386, 4, 35, 65, 173, 174, 274, 275, "." +386, 5, 1, 66, 0, 6, 276, 282, "Ahmann" +386, 5, 2, 67, 7, 9, 283, 285, "AJ" +386, 5, 3, 68, 10, 11, 286, 287, "(" +386, 5, 4, 69, 12, 13, 288, 289, "1" +386, 5, 5, 70, 14, 15, 290, 291, ")" +386, 5, 6, 71, 16, 17, 292, 293, "," +386, 5, 7, 72, 18, 26, 294, 302, "Capehorn" +386, 5, 8, 73, 27, 28, 303, 304, "M" +386, 5, 9, 74, 29, 30, 305, 306, "(" +386, 5, 10, 75, 31, 32, 307, 308, "2" +386, 5, 11, 76, 33, 34, 309, 310, ")" +386, 5, 12, 77, 35, 36, 311, 312, "," +386, 5, 13, 78, 37, 48, 313, 324, "Charpentier" +386, 5, 14, 79, 49, 50, 325, 326, "G" +386, 5, 15, 80, 51, 52, 327, 328, "(" +386, 5, 16, 81, 53, 54, 329, 330, "3" +386, 5, 17, 82, 55, 56, 331, 332, ")" +386, 5, 18, 83, 57, 58, 333, 334, "," +386, 5, 19, 84, 59, 64, 335, 340, "Dotta" +386, 5, 20, 85, 65, 66, 341, 342, "F" +386, 5, 21, 86, 67, 68, 343, 344, "(" +386, 5, 22, 87, 69, 70, 345, 346, "4" +386, 5, 23, 88, 71, 72, 347, 348, ")" +386, 5, 24, 89, 73, 74, 349, 350, "," +386, 5, 25, 90, 75, 81, 351, 357, "Henkel" +386, 5, 26, 91, 82, 83, 358, 359, "E" +386, 5, 27, 92, 84, 85, 360, 361, "(" +386, 5, 28, 93, 86, 87, 362, 363, "5" +386, 5, 29, 94, 88, 89, 364, 365, ")" +386, 5, 30, 95, 90, 91, 366, 367, "," +386, 5, 31, 96, 92, 99, 368, 375, "Lingvay" +386, 5, 32, 97, 100, 101, 376, 377, "I" +386, 5, 33, 98, 102, 103, 378, 379, "(" +386, 5, 34, 99, 104, 105, 380, 381, "6" +386, 5, 35, 100, 106, 107, 382, 383, ")" +386, 5, 36, 101, 108, 109, 384, 385, "," +386, 5, 37, 102, 110, 115, 386, 391, "Holst" +386, 5, 38, 103, 116, 118, 392, 394, "AG" +386, 5, 39, 104, 119, 120, 395, 396, "(" +386, 5, 40, 105, 121, 122, 397, 398, "7" +386, 5, 41, 106, 123, 124, 399, 400, ")" +386, 5, 42, 107, 125, 126, 401, 402, "," +386, 5, 43, 108, 127, 133, 403, 409, "Annett" +386, 5, 44, 109, 134, 136, 410, 412, "MP" +386, 5, 45, 110, 137, 138, 413, 414, "(" +386, 5, 46, 111, 139, 140, 415, 416, "8" +386, 5, 47, 112, 141, 142, 417, 418, ")" +386, 5, 48, 113, 143, 144, 419, 420, "," +386, 5, 49, 114, 145, 150, 421, 426, "Aroda" +386, 5, 50, 115, 151, 153, 427, 429, "VR" +386, 5, 51, 116, 154, 155, 430, 431, "(" +386, 5, 52, 117, 156, 157, 432, 433, "9" +386, 5, 53, 118, 158, 159, 434, 435, ")" +386, 5, 54, 119, 160, 161, 436, 437, "." +386, 6, 1, 120, 0, 6, 438, 444, "Author" +386, 6, 2, 121, 7, 18, 445, 456, "information" +386, 6, 3, 122, 19, 20, 457, 458, ":" +386, 6, 4, 123, 21, 22, 459, 460, "(" +386, 6, 5, 124, 23, 24, 461, 462, "1" +386, 6, 6, 125, 25, 26, 463, 464, ")" +386, 6, 7, 126, 27, 33, 465, 471, "Harold" +386, 6, 8, 127, 34, 43, 472, 481, "Schnitzer" +386, 6, 9, 128, 44, 52, 482, 490, "Diabetes" +386, 6, 10, 129, 53, 59, 491, 497, "Health" +386, 6, 11, 130, 60, 66, 498, 504, "Center" +386, 6, 12, 131, 67, 68, 505, 506, "," +386, 6, 13, 132, 69, 75, 507, 513, "Oregon" +386, 6, 14, 133, 76, 82, 514, 520, "Health" +386, 6, 15, 134, 83, 84, 521, 522, "&" +386, 6, 16, 135, 85, 92, 523, 530, "Science" +386, 6, 17, 136, 93, 103, 531, 541, "University" +386, 6, 18, 137, 104, 105, 542, 543, "," +386, 6, 19, 138, 106, 114, 544, 552, "Portland" +386, 6, 20, 139, 115, 116, 553, 554, "," +386, 6, 21, 140, 117, 119, 555, 557, "OR" +386, 6, 22, 141, 120, 127, 558, 565, "ahmanna" +386, 6, 23, 142, 128, 129, 566, 567, "@" +386, 6, 24, 143, 130, 134, 568, 572, "ohsu" +386, 6, 25, 144, 135, 136, 573, 574, "." +386, 6, 26, 145, 137, 140, 575, 578, "edu" +386, 6, 27, 146, 141, 142, 579, 580, "." +386, 7, 1, 147, 0, 1, 581, 582, "(" +386, 7, 2, 148, 2, 3, 583, 584, "2" +386, 7, 3, 149, 4, 5, 585, 586, ")" +386, 7, 4, 150, 6, 15, 587, 596, "Rotherham" +386, 7, 5, 151, 16, 25, 597, 606, "Institute" +386, 7, 6, 152, 26, 29, 607, 610, "for" +386, 7, 7, 153, 30, 37, 611, 618, "Obesity" +386, 7, 8, 154, 38, 39, 619, 620, "," +386, 7, 9, 155, 40, 47, 621, 628, "Clifton" +386, 7, 10, 156, 48, 55, 629, 636, "Medical" +386, 7, 11, 157, 56, 62, 637, 643, "Centre" +386, 7, 12, 158, 63, 64, 644, 645, "," +386, 7, 13, 159, 65, 74, 646, 655, "Rotherham" +386, 7, 14, 160, 75, 76, 656, 657, "," +386, 7, 15, 161, 77, 78, 658, 659, "U" +386, 7, 16, 162, 79, 80, 660, 661, "." +386, 7, 17, 163, 81, 82, 662, 663, "K" +386, 7, 18, 164, 83, 84, 664, 665, "." +386, 7, 19, 165, 85, 86, 666, 667, "(" +386, 7, 20, 166, 87, 88, 668, 669, "3" +386, 7, 21, 167, 89, 90, 670, 671, ")" +386, 7, 22, 168, 91, 97, 672, 678, "Centre" +386, 7, 23, 169, 98, 109, 679, 690, "Hospitalier" +386, 7, 24, 170, 110, 113, 691, 694, "Sud" +386, 7, 25, 171, 114, 124, 695, 705, "Francilien" +386, 7, 26, 172, 125, 126, 706, 707, "," +386, 7, 27, 173, 127, 134, 708, 715, "Corbeil" +386, 7, 28, 174, 135, 136, 716, 717, "-" +386, 7, 29, 175, 137, 145, 718, 726, "Essonnes" +386, 7, 30, 176, 146, 147, 727, 728, "," +386, 7, 31, 177, 148, 154, 729, 735, "France" +386, 7, 32, 178, 155, 156, 736, 737, "." +386, 8, 1, 179, 0, 1, 738, 739, "(" +386, 8, 2, 180, 2, 3, 740, 741, "4" +386, 8, 3, 181, 4, 5, 742, 743, ")" +386, 8, 4, 182, 6, 16, 744, 754, "Department" +386, 8, 5, 183, 17, 19, 755, 757, "of" +386, 8, 6, 184, 20, 28, 758, 766, "Medicine" +386, 8, 7, 185, 29, 30, 767, 768, "," +386, 8, 8, 186, 31, 38, 769, 776, "Surgery" +386, 8, 9, 187, 39, 42, 777, 780, "and" +386, 8, 10, 188, 43, 55, 781, 793, "Neuroscience" +386, 8, 11, 189, 56, 57, 794, 795, "," +386, 8, 12, 190, 58, 68, 796, 806, "University" +386, 8, 13, 191, 69, 71, 807, 809, "of" +386, 8, 14, 192, 72, 77, 810, 815, "Siena" +386, 8, 15, 193, 78, 79, 816, 817, "," +386, 8, 16, 194, 80, 85, 818, 823, "Siena" +386, 8, 17, 195, 86, 87, 824, 825, "," +386, 8, 18, 196, 88, 93, 826, 831, "Italy" +386, 8, 19, 197, 94, 95, 832, 833, "." +386, 9, 1, 198, 0, 1, 834, 835, "(" +386, 9, 2, 199, 2, 3, 836, 837, "5" +386, 9, 3, 200, 4, 5, 838, 839, ")" +386, 9, 4, 201, 6, 12, 840, 846, "Center" +386, 9, 5, 202, 13, 16, 847, 850, "for" +386, 9, 6, 203, 17, 25, 851, 859, "Clinical" +386, 9, 7, 204, 26, 33, 860, 867, "Studies" +386, 9, 8, 205, 34, 35, 868, 869, "," +386, 9, 9, 206, 36, 39, 870, 873, "GWT" +386, 9, 10, 207, 40, 41, 874, 875, "-" +386, 9, 11, 208, 42, 44, 876, 878, "TU" +386, 9, 12, 209, 45, 52, 879, 886, "Dresden" +386, 9, 13, 210, 53, 54, 887, 888, "," +386, 9, 14, 211, 55, 62, 889, 896, "Dresden" +386, 9, 15, 212, 63, 64, 897, 898, "," +386, 9, 16, 213, 65, 72, 899, 906, "Germany" +386, 9, 17, 214, 73, 74, 907, 908, "." +386, 10, 1, 215, 0, 1, 909, 910, "(" +386, 10, 2, 216, 2, 3, 911, 912, "6" +386, 10, 3, 217, 4, 5, 913, 914, ")" +386, 10, 4, 218, 6, 17, 915, 926, "Departments" +386, 10, 5, 219, 18, 20, 927, 929, "of" +386, 10, 6, 220, 21, 29, 930, 938, "Internal" +386, 10, 7, 221, 30, 38, 939, 947, "Medicine" +386, 10, 8, 222, 39, 42, 948, 951, "and" +386, 10, 9, 223, 43, 51, 952, 960, "Clinical" +386, 10, 10, 224, 52, 60, 961, 969, "Sciences" +386, 10, 11, 225, 61, 62, 970, 971, "," +386, 10, 12, 226, 63, 73, 972, 982, "University" +386, 10, 13, 227, 74, 76, 983, 985, "of" +386, 10, 14, 228, 77, 82, 986, 991, "Texas" +386, 10, 15, 229, 83, 95, 992, 1004, "Southwestern" +386, 10, 16, 230, 96, 103, 1005, 1012, "Medical" +386, 10, 17, 231, 104, 110, 1013, 1019, "Center" +386, 10, 18, 232, 111, 112, 1020, 1021, "," +386, 10, 19, 233, 113, 119, 1022, 1028, "Dallas" +386, 10, 20, 234, 120, 121, 1029, 1030, "," +386, 10, 21, 235, 122, 124, 1031, 1033, "TX" +386, 10, 22, 236, 125, 126, 1034, 1035, "." +386, 11, 1, 237, 0, 1, 1036, 1037, "(" +386, 11, 2, 238, 2, 3, 1038, 1039, "7" +386, 11, 3, 239, 4, 5, 1040, 1041, ")" +386, 11, 4, 240, 6, 10, 1042, 1046, "Novo" +386, 11, 5, 241, 11, 18, 1047, 1054, "Nordisk" +386, 11, 6, 242, 19, 20, 1055, 1056, "A" +386, 11, 7, 243, 21, 22, 1057, 1058, "/" +386, 11, 8, 244, 23, 24, 1059, 1060, "S" +386, 11, 9, 245, 25, 26, 1061, 1062, "," +386, 11, 10, 246, 27, 28, 1063, 1064, "S" +386, 11, 11, 247, 29, 30, 1065, 1066, "ø" +386, 11, 12, 248, 31, 35, 1067, 1071, "borg" +386, 11, 13, 249, 36, 37, 1072, 1073, "," +386, 11, 14, 250, 38, 45, 1074, 1081, "Denmark" +386, 11, 15, 251, 46, 47, 1082, 1083, "." +386, 12, 1, 252, 0, 1, 1084, 1085, "(" +386, 12, 2, 253, 2, 3, 1086, 1087, "8" +386, 12, 3, 254, 4, 5, 1088, 1089, ")" +386, 12, 4, 255, 6, 10, 1090, 1094, "Novo" +386, 12, 5, 256, 11, 18, 1095, 1102, "Nordisk" +386, 12, 6, 257, 19, 22, 1103, 1106, "Inc" +386, 12, 7, 258, 23, 24, 1107, 1108, "." +386, 12, 8, 259, 25, 26, 1109, 1110, "," +386, 12, 9, 260, 27, 37, 1111, 1121, "Plainsboro" +386, 12, 10, 261, 38, 39, 1122, 1123, "," +386, 12, 11, 262, 40, 42, 1124, 1126, "NJ" +386, 12, 12, 263, 43, 44, 1127, 1128, "." +386, 13, 1, 264, 0, 1, 1129, 1130, "(" +386, 13, 2, 265, 2, 3, 1131, 1132, "9" +386, 13, 3, 266, 4, 5, 1133, 1134, ")" +386, 13, 4, 267, 6, 13, 1135, 1142, "MedStar" +386, 13, 5, 268, 14, 20, 1143, 1149, "Health" +386, 13, 6, 269, 21, 29, 1150, 1158, "Research" +386, 13, 7, 270, 30, 39, 1159, 1168, "Institute" +386, 13, 8, 271, 40, 41, 1169, 1170, "," +386, 13, 9, 272, 42, 53, 1171, 1182, "Hyattsville" +386, 13, 10, 273, 54, 55, 1183, 1184, "," +386, 13, 11, 274, 56, 58, 1185, 1187, "MD" +386, 13, 12, 275, 59, 60, 1188, 1189, "." +386, 14, 1, 276, 0, 9, 1190, 1199, "OBJECTIVE" +386, 14, 2, 277, 10, 11, 1200, 1201, ":" +386, 14, 3, 278, 12, 14, 1202, 1204, "To" +386, 14, 4, 279, 15, 22, 1205, 1212, "compare" +386, 14, 5, 280, 23, 26, 1213, 1216, "the" +386, 14, 6, 281, 27, 35, 1217, 1225, "efficacy" +386, 14, 7, 282, 36, 39, 1226, 1229, "and" +386, 14, 8, 283, 40, 46, 1230, 1236, "safety" +386, 14, 9, 284, 47, 49, 1237, 1239, "of" +386, 14, 10, 285, 50, 54, 1240, 1244, "once" +386, 14, 11, 286, 55, 56, 1245, 1246, "-" +386, 14, 12, 287, 57, 63, 1247, 1253, "weekly" +386, 14, 13, 288, 64, 75, 1254, 1265, "semaglutide" +386, 14, 14, 289, 76, 77, 1266, 1267, "1" +386, 14, 15, 290, 78, 79, 1268, 1269, "." +386, 14, 16, 291, 80, 81, 1270, 1271, "0" +386, 14, 17, 292, 82, 84, 1272, 1274, "mg" +386, 14, 18, 293, 85, 86, 1275, 1276, "s" +386, 14, 19, 294, 87, 88, 1277, 1278, "." +386, 14, 20, 295, 89, 90, 1279, 1280, "c" +386, 14, 21, 296, 91, 92, 1281, 1282, "." +386, 14, 22, 297, 93, 97, 1283, 1287, "with" +386, 14, 23, 298, 98, 107, 1288, 1297, "exenatide" +386, 14, 24, 299, 108, 116, 1298, 1306, "extended" +386, 14, 25, 300, 117, 124, 1307, 1314, "release" +386, 14, 26, 301, 125, 126, 1315, 1316, "(" +386, 14, 27, 302, 127, 129, 1317, 1319, "ER" +386, 14, 28, 303, 130, 131, 1320, 1321, ")" +386, 14, 29, 304, 132, 133, 1322, 1323, "2" +386, 14, 30, 305, 134, 135, 1324, 1325, "." +386, 14, 31, 306, 136, 137, 1326, 1327, "0" +386, 14, 32, 307, 138, 140, 1328, 1330, "mg" +386, 14, 33, 308, 141, 142, 1331, 1332, "s" +386, 14, 34, 309, 143, 144, 1333, 1334, "." +386, 14, 35, 310, 145, 146, 1335, 1336, "c" +386, 14, 36, 311, 147, 148, 1337, 1338, "." +386, 14, 37, 312, 149, 151, 1339, 1341, "in" +386, 14, 38, 313, 152, 160, 1342, 1350, "subjects" +386, 14, 39, 314, 161, 165, 1351, 1355, "with" +386, 14, 40, 315, 166, 170, 1356, 1360, "type" +386, 14, 41, 316, 171, 172, 1361, 1362, "2" +386, 14, 42, 317, 173, 181, 1363, 1371, "diabetes" +386, 14, 43, 318, 182, 183, 1372, 1373, "." +386, 15, 1, 319, 0, 8, 1374, 1382, "RESEARCH" +386, 15, 2, 320, 9, 15, 1383, 1389, "DESIGN" +386, 15, 3, 321, 16, 19, 1390, 1393, "AND" +386, 15, 4, 322, 20, 27, 1394, 1401, "METHODS" +386, 15, 5, 323, 28, 29, 1402, 1403, ":" +386, 15, 6, 324, 30, 32, 1404, 1406, "In" +386, 15, 7, 325, 33, 37, 1407, 1411, "this" +386, 15, 8, 326, 38, 43, 1412, 1417, "phase" +386, 15, 9, 327, 44, 46, 1418, 1420, "3a" +386, 15, 10, 328, 47, 48, 1421, 1422, "," +386, 15, 11, 329, 49, 53, 1423, 1427, "open" +386, 15, 12, 330, 54, 55, 1428, 1429, "-" +386, 15, 13, 331, 56, 61, 1430, 1435, "label" +386, 15, 14, 332, 62, 63, 1436, 1437, "," +386, 15, 15, 333, 64, 72, 1438, 1446, "parallel" +386, 15, 16, 334, 73, 74, 1447, 1448, "-" +386, 15, 17, 335, 75, 80, 1449, 1454, "group" +386, 15, 18, 336, 81, 82, 1455, 1456, "," +386, 15, 19, 337, 83, 93, 1457, 1467, "randomized" +386, 15, 20, 338, 94, 104, 1468, 1478, "controlled" +386, 15, 21, 339, 105, 110, 1479, 1484, "trial" +386, 15, 22, 340, 111, 112, 1485, 1486, "," +386, 15, 23, 341, 113, 116, 1487, 1490, "813" +386, 15, 24, 342, 117, 125, 1491, 1499, "subjects" +386, 15, 25, 343, 126, 130, 1500, 1504, "with" +386, 15, 26, 344, 131, 135, 1505, 1509, "type" +386, 15, 27, 345, 136, 137, 1510, 1511, "2" +386, 15, 28, 346, 138, 146, 1512, 1520, "diabetes" +386, 15, 29, 347, 147, 153, 1521, 1527, "taking" +386, 15, 30, 348, 154, 158, 1528, 1532, "oral" +386, 15, 31, 349, 159, 171, 1533, 1545, "antidiabetic" +386, 15, 32, 350, 172, 177, 1546, 1551, "drugs" +386, 15, 33, 351, 178, 182, 1552, 1556, "were" +386, 15, 34, 352, 183, 193, 1557, 1567, "randomized" +386, 15, 35, 353, 194, 195, 1568, 1569, "(" +386, 15, 36, 354, 196, 197, 1570, 1571, "1" +386, 15, 37, 355, 198, 199, 1572, 1573, ":" +386, 15, 38, 356, 200, 201, 1574, 1575, "1" +386, 15, 39, 357, 202, 203, 1576, 1577, ")" +386, 15, 40, 358, 204, 206, 1578, 1580, "to" +386, 15, 41, 359, 207, 218, 1581, 1592, "semaglutide" +386, 15, 42, 360, 219, 220, 1593, 1594, "1" +386, 15, 43, 361, 221, 222, 1595, 1596, "." +386, 15, 44, 362, 223, 224, 1597, 1598, "0" +386, 15, 45, 363, 225, 227, 1599, 1601, "mg" +386, 15, 46, 364, 228, 230, 1602, 1604, "or" +386, 15, 47, 365, 231, 240, 1605, 1614, "exenatide" +386, 15, 48, 366, 241, 243, 1615, 1617, "ER" +386, 15, 49, 367, 244, 245, 1618, 1619, "2" +386, 15, 50, 368, 246, 247, 1620, 1621, "." +386, 15, 51, 369, 248, 249, 1622, 1623, "0" +386, 15, 52, 370, 250, 252, 1624, 1626, "mg" +386, 15, 53, 371, 253, 256, 1627, 1630, "for" +386, 15, 54, 372, 257, 259, 1631, 1633, "56" +386, 15, 55, 373, 260, 265, 1634, 1639, "weeks" +386, 15, 56, 374, 266, 267, 1640, 1641, "." +386, 16, 1, 375, 0, 3, 1642, 1645, "The" +386, 16, 2, 376, 4, 11, 1646, 1653, "primary" +386, 16, 3, 377, 12, 15, 1654, 1657, "end" +386, 16, 4, 378, 16, 21, 1658, 1663, "point" +386, 16, 5, 379, 22, 25, 1664, 1667, "was" +386, 16, 6, 380, 26, 32, 1668, 1674, "change" +386, 16, 7, 381, 33, 37, 1675, 1679, "from" +386, 16, 8, 382, 38, 46, 1680, 1688, "baseline" +386, 16, 9, 383, 47, 49, 1689, 1691, "in" +386, 16, 10, 384, 50, 55, 1692, 1697, "HbA1c" +386, 16, 11, 385, 56, 58, 1698, 1700, "at" +386, 16, 12, 386, 59, 63, 1701, 1705, "week" +386, 16, 13, 387, 64, 66, 1706, 1708, "56" +386, 16, 14, 388, 67, 68, 1709, 1710, "." +386, 17, 1, 389, 0, 7, 1711, 1718, "RESULTS" +386, 17, 2, 390, 8, 9, 1719, 1720, ":" +386, 17, 3, 391, 10, 14, 1721, 1725, "Mean" +386, 17, 4, 392, 15, 20, 1726, 1731, "HbA1c" +386, 17, 5, 393, 21, 22, 1732, 1733, "(" +386, 17, 6, 394, 23, 24, 1734, 1735, "8" +386, 17, 7, 395, 25, 26, 1736, 1737, "." +386, 17, 8, 396, 27, 28, 1738, 1739, "3" +386, 17, 9, 397, 29, 30, 1740, 1741, "%" +386, 17, 10, 398, 31, 32, 1742, 1743, "[" +386, 17, 11, 399, 33, 35, 1744, 1746, "67" +386, 17, 12, 400, 36, 37, 1747, 1748, "." +386, 17, 13, 401, 38, 39, 1749, 1750, "7" +386, 17, 14, 402, 40, 44, 1751, 1755, "mmol" +386, 17, 15, 403, 45, 46, 1756, 1757, "/" +386, 17, 16, 404, 47, 50, 1758, 1761, "mol" +386, 17, 17, 405, 51, 52, 1762, 1763, "]" +386, 17, 18, 406, 53, 55, 1764, 1766, "at" +386, 17, 19, 407, 56, 64, 1767, 1775, "baseline" +386, 17, 20, 408, 65, 66, 1776, 1777, ")" +386, 17, 21, 409, 67, 70, 1778, 1781, "was" +386, 17, 22, 410, 71, 78, 1782, 1789, "reduced" +386, 17, 23, 411, 79, 81, 1790, 1792, "by" +386, 17, 24, 412, 82, 83, 1793, 1794, "1" +386, 17, 25, 413, 84, 85, 1795, 1796, "." +386, 17, 26, 414, 86, 87, 1797, 1798, "5" +386, 17, 27, 415, 88, 89, 1799, 1800, "%" +386, 17, 28, 416, 90, 91, 1801, 1802, "(" +386, 17, 29, 417, 92, 94, 1803, 1805, "16" +386, 17, 30, 418, 95, 96, 1806, 1807, "." +386, 17, 31, 419, 97, 98, 1808, 1809, "8" +386, 17, 32, 420, 99, 103, 1810, 1814, "mmol" +386, 17, 33, 421, 104, 105, 1815, 1816, "/" +386, 17, 34, 422, 106, 109, 1817, 1820, "mol" +386, 17, 35, 423, 110, 111, 1821, 1822, ")" +386, 17, 36, 424, 112, 116, 1823, 1827, "with" +386, 17, 37, 425, 117, 128, 1828, 1839, "semaglutide" +386, 17, 38, 426, 129, 132, 1840, 1843, "and" +386, 17, 39, 427, 133, 134, 1844, 1845, "0" +386, 17, 40, 428, 135, 136, 1846, 1847, "." +386, 17, 41, 429, 137, 138, 1848, 1849, "9" +386, 17, 42, 430, 139, 140, 1850, 1851, "%" +386, 17, 43, 431, 141, 142, 1852, 1853, "(" +386, 17, 44, 432, 143, 145, 1854, 1856, "10" +386, 17, 45, 433, 146, 147, 1857, 1858, "." +386, 17, 46, 434, 148, 149, 1859, 1860, "0" +386, 17, 47, 435, 150, 154, 1861, 1865, "mmol" +386, 17, 48, 436, 155, 156, 1866, 1867, "/" +386, 17, 49, 437, 157, 160, 1868, 1871, "mol" +386, 17, 50, 438, 161, 162, 1872, 1873, ")" +386, 17, 51, 439, 163, 167, 1874, 1878, "with" +386, 17, 52, 440, 168, 177, 1879, 1888, "exenatide" +386, 17, 53, 441, 178, 180, 1889, 1891, "ER" +386, 17, 54, 442, 181, 182, 1892, 1893, "(" +386, 17, 55, 443, 183, 192, 1894, 1903, "estimated" +386, 17, 56, 444, 193, 202, 1904, 1913, "treatment" +386, 17, 57, 445, 203, 213, 1914, 1924, "difference" +386, 17, 58, 446, 214, 216, 1925, 1927, "vs" +386, 17, 59, 447, 217, 218, 1928, 1929, "." +386, 17, 60, 448, 219, 228, 1930, 1939, "exenatide" +386, 17, 61, 449, 229, 231, 1940, 1942, "ER" +386, 17, 62, 450, 232, 233, 1943, 1944, "[" +386, 17, 63, 451, 234, 237, 1945, 1948, "ETD" +386, 17, 64, 452, 238, 239, 1949, 1950, "]" +386, 17, 65, 453, 240, 241, 1951, 1952, "-" +386, 17, 66, 454, 242, 243, 1953, 1954, "0" +386, 17, 67, 455, 244, 245, 1955, 1956, "." +386, 17, 68, 456, 246, 248, 1957, 1959, "62" +386, 17, 69, 457, 249, 250, 1960, 1961, "%" +386, 17, 70, 458, 251, 252, 1962, 1963, "[" +386, 17, 71, 459, 253, 255, 1964, 1966, "95" +386, 17, 72, 460, 256, 257, 1967, 1968, "%" +386, 17, 73, 461, 258, 260, 1969, 1971, "CI" +386, 17, 74, 462, 261, 262, 1972, 1973, "-" +386, 17, 75, 463, 263, 264, 1974, 1975, "0" +386, 17, 76, 464, 265, 266, 1976, 1977, "." +386, 17, 77, 465, 267, 269, 1978, 1980, "80" +386, 17, 78, 466, 270, 271, 1981, 1982, "," +386, 17, 79, 467, 272, 273, 1983, 1984, "-" +386, 17, 80, 468, 274, 275, 1985, 1986, "0" +386, 17, 81, 469, 276, 277, 1987, 1988, "." +386, 17, 82, 470, 278, 280, 1989, 1991, "44" +386, 17, 83, 471, 281, 282, 1992, 1993, "]" +386, 17, 84, 472, 283, 284, 1994, 1995, "[" +386, 17, 85, 473, 285, 286, 1996, 1997, "-" +386, 17, 86, 474, 287, 288, 1998, 1999, "6" +386, 17, 87, 475, 289, 290, 2000, 2001, "." +386, 17, 88, 476, 291, 293, 2002, 2004, "78" +386, 17, 89, 477, 294, 298, 2005, 2009, "mmol" +386, 17, 90, 478, 299, 300, 2010, 2011, "/" +386, 17, 91, 479, 301, 304, 2012, 2015, "mol" +386, 17, 92, 480, 305, 306, 2016, 2017, "(" +386, 17, 93, 481, 307, 309, 2018, 2020, "95" +386, 17, 94, 482, 310, 311, 2021, 2022, "%" +386, 17, 95, 483, 312, 314, 2023, 2025, "CI" +386, 17, 96, 484, 315, 316, 2026, 2027, "-" +386, 17, 97, 485, 317, 318, 2028, 2029, "8" +386, 17, 98, 486, 319, 320, 2030, 2031, "." +386, 17, 99, 487, 321, 323, 2032, 2034, "70" +386, 17, 100, 488, 324, 325, 2035, 2036, "," +386, 17, 101, 489, 326, 327, 2037, 2038, "-" +386, 17, 102, 490, 328, 329, 2039, 2040, "4" +386, 17, 103, 491, 330, 331, 2041, 2042, "." +386, 17, 104, 492, 332, 334, 2043, 2045, "86" +386, 17, 105, 493, 335, 336, 2046, 2047, ")" +386, 17, 106, 494, 337, 338, 2048, 2049, "]" +386, 17, 107, 495, 339, 340, 2050, 2051, ";" +386, 17, 108, 496, 341, 342, 2052, 2053, "P" +386, 17, 109, 497, 343, 344, 2054, 2055, "<" +386, 17, 110, 498, 345, 346, 2056, 2057, "0" +386, 17, 111, 499, 347, 348, 2058, 2059, "." +386, 17, 112, 500, 349, 353, 2060, 2064, "0001" +386, 17, 113, 501, 354, 357, 2065, 2068, "for" +386, 17, 114, 502, 358, 372, 2069, 2083, "noninferiority" +386, 17, 115, 503, 373, 376, 2084, 2087, "and" +386, 17, 116, 504, 377, 388, 2088, 2099, "superiority" +386, 17, 117, 505, 389, 390, 2100, 2101, ")" +386, 17, 118, 506, 391, 392, 2102, 2103, "." +386, 18, 1, 507, 0, 4, 2104, 2108, "Mean" +386, 18, 2, 508, 5, 9, 2109, 2113, "body" +386, 18, 3, 509, 10, 16, 2114, 2120, "weight" +386, 18, 4, 510, 17, 18, 2121, 2122, "(" +386, 18, 5, 511, 19, 21, 2123, 2125, "95" +386, 18, 6, 512, 22, 23, 2126, 2127, "." +386, 18, 7, 513, 24, 25, 2128, 2129, "8" +386, 18, 8, 514, 26, 28, 2130, 2132, "kg" +386, 18, 9, 515, 29, 31, 2133, 2135, "at" +386, 18, 10, 516, 32, 40, 2136, 2144, "baseline" +386, 18, 11, 517, 41, 42, 2145, 2146, ")" +386, 18, 12, 518, 43, 46, 2147, 2150, "was" +386, 18, 13, 519, 47, 54, 2151, 2158, "reduced" +386, 18, 14, 520, 55, 57, 2159, 2161, "by" +386, 18, 15, 521, 58, 59, 2162, 2163, "5" +386, 18, 16, 522, 60, 61, 2164, 2165, "." +386, 18, 17, 523, 62, 63, 2166, 2167, "6" +386, 18, 18, 524, 64, 66, 2168, 2170, "kg" +386, 18, 19, 525, 67, 71, 2171, 2175, "with" +386, 18, 20, 526, 72, 83, 2176, 2187, "semaglutide" +386, 18, 21, 527, 84, 87, 2188, 2191, "and" +386, 18, 22, 528, 88, 89, 2192, 2193, "1" +386, 18, 23, 529, 90, 91, 2194, 2195, "." +386, 18, 24, 530, 92, 93, 2196, 2197, "9" +386, 18, 25, 531, 94, 96, 2198, 2200, "kg" +386, 18, 26, 532, 97, 101, 2201, 2205, "with" +386, 18, 27, 533, 102, 111, 2206, 2215, "exenatide" +386, 18, 28, 534, 112, 114, 2216, 2218, "ER" +386, 18, 29, 535, 115, 116, 2219, 2220, "(" +386, 18, 30, 536, 117, 120, 2221, 2224, "ETD" +386, 18, 31, 537, 121, 122, 2225, 2226, "-" +386, 18, 32, 538, 123, 124, 2227, 2228, "3" +386, 18, 33, 539, 125, 126, 2229, 2230, "." +386, 18, 34, 540, 127, 129, 2231, 2233, "78" +386, 18, 35, 541, 130, 132, 2234, 2236, "kg" +386, 18, 36, 542, 133, 134, 2237, 2238, "[" +386, 18, 37, 543, 135, 137, 2239, 2241, "95" +386, 18, 38, 544, 138, 139, 2242, 2243, "%" +386, 18, 39, 545, 140, 142, 2244, 2246, "CI" +386, 18, 40, 546, 143, 144, 2247, 2248, "-" +386, 18, 41, 547, 145, 146, 2249, 2250, "4" +386, 18, 42, 548, 147, 148, 2251, 2252, "." +386, 18, 43, 549, 149, 151, 2253, 2255, "58" +386, 18, 44, 550, 152, 153, 2256, 2257, "," +386, 18, 45, 551, 154, 155, 2258, 2259, "-" +386, 18, 46, 552, 156, 157, 2260, 2261, "2" +386, 18, 47, 553, 158, 159, 2262, 2263, "." +386, 18, 48, 554, 160, 162, 2264, 2266, "98" +386, 18, 49, 555, 163, 164, 2267, 2268, "]" +386, 18, 50, 556, 165, 166, 2269, 2270, ";" +386, 18, 51, 557, 167, 168, 2271, 2272, "P" +386, 18, 52, 558, 169, 170, 2273, 2274, "<" +386, 18, 53, 559, 171, 172, 2275, 2276, "0" +386, 18, 54, 560, 173, 174, 2277, 2278, "." +386, 18, 55, 561, 175, 179, 2279, 2283, "0001" +386, 18, 56, 562, 180, 181, 2284, 2285, ")" +386, 18, 57, 563, 182, 183, 2286, 2287, "." +386, 19, 1, 564, 0, 13, 2288, 2301, "Significantly" +386, 19, 2, 565, 14, 18, 2302, 2306, "more" +386, 19, 3, 566, 19, 27, 2307, 2315, "subjects" +386, 19, 4, 567, 28, 35, 2316, 2323, "treated" +386, 19, 5, 568, 36, 40, 2324, 2328, "with" +386, 19, 6, 569, 41, 52, 2329, 2340, "semaglutide" +386, 19, 7, 570, 53, 54, 2341, 2342, "(" +386, 19, 8, 571, 55, 57, 2343, 2345, "67" +386, 19, 9, 572, 58, 59, 2346, 2347, "%" +386, 19, 10, 573, 60, 61, 2348, 2349, ")" +386, 19, 11, 574, 62, 70, 2350, 2358, "achieved" +386, 19, 12, 575, 71, 76, 2359, 2364, "HbA1c" +386, 19, 13, 576, 77, 78, 2365, 2366, "<" +386, 19, 14, 577, 79, 80, 2367, 2368, "7" +386, 19, 15, 578, 81, 82, 2369, 2370, "." +386, 19, 16, 579, 83, 84, 2371, 2372, "0" +386, 19, 17, 580, 85, 86, 2373, 2374, "%" +386, 19, 18, 581, 87, 88, 2375, 2376, "(" +386, 19, 19, 582, 89, 90, 2377, 2378, "<" +386, 19, 20, 583, 91, 93, 2379, 2381, "53" +386, 19, 21, 584, 94, 98, 2382, 2386, "mmol" +386, 19, 22, 585, 99, 100, 2387, 2388, "/" +386, 19, 23, 586, 101, 104, 2389, 2392, "mol" +386, 19, 24, 587, 105, 106, 2393, 2394, ")" +386, 19, 25, 588, 107, 113, 2395, 2401, "versus" +386, 19, 26, 589, 114, 119, 2402, 2407, "those" +386, 19, 27, 590, 120, 126, 2408, 2414, "taking" +386, 19, 28, 591, 127, 136, 2415, 2424, "exenatide" +386, 19, 29, 592, 137, 139, 2425, 2427, "ER" +386, 19, 30, 593, 140, 141, 2428, 2429, "(" +386, 19, 31, 594, 142, 144, 2430, 2432, "40" +386, 19, 32, 595, 145, 146, 2433, 2434, "%" +386, 19, 33, 596, 147, 148, 2435, 2436, ")" +386, 19, 34, 597, 149, 150, 2437, 2438, "." +386, 20, 1, 598, 0, 4, 2439, 2443, "Both" +386, 20, 2, 599, 5, 15, 2444, 2454, "treatments" +386, 20, 3, 600, 16, 19, 2455, 2458, "had" +386, 20, 4, 601, 20, 27, 2459, 2466, "similar" +386, 20, 5, 602, 28, 34, 2467, 2473, "safety" +386, 20, 6, 603, 35, 43, 2474, 2482, "profiles" +386, 20, 7, 604, 44, 45, 2483, 2484, "," +386, 20, 8, 605, 46, 49, 2485, 2488, "but" +386, 20, 9, 606, 50, 66, 2489, 2505, "gastrointestinal" +386, 20, 10, 607, 67, 74, 2506, 2513, "adverse" +386, 20, 11, 608, 75, 81, 2514, 2520, "events" +386, 20, 12, 609, 82, 86, 2521, 2525, "were" +386, 20, 13, 610, 87, 91, 2526, 2530, "more" +386, 20, 14, 611, 92, 98, 2531, 2537, "common" +386, 20, 15, 612, 99, 101, 2538, 2540, "in" +386, 20, 16, 613, 102, 113, 2541, 2552, "semaglutide" +386, 20, 17, 614, 114, 115, 2553, 2554, "-" +386, 20, 18, 615, 116, 123, 2555, 2562, "treated" +386, 20, 19, 616, 124, 132, 2563, 2571, "subjects" +386, 20, 20, 617, 133, 134, 2572, 2573, "(" +386, 20, 21, 618, 135, 137, 2574, 2576, "41" +386, 20, 22, 619, 138, 139, 2577, 2578, "." +386, 20, 23, 620, 140, 141, 2579, 2580, "8" +386, 20, 24, 621, 142, 143, 2581, 2582, "%" +386, 20, 25, 622, 144, 145, 2583, 2584, ")" +386, 20, 26, 623, 146, 150, 2585, 2589, "than" +386, 20, 27, 624, 151, 153, 2590, 2592, "in" +386, 20, 28, 625, 154, 163, 2593, 2602, "exenatide" +386, 20, 29, 626, 164, 166, 2603, 2605, "ER" +386, 20, 30, 627, 167, 168, 2606, 2607, "-" +386, 20, 31, 628, 169, 176, 2608, 2615, "treated" +386, 20, 32, 629, 177, 185, 2616, 2624, "subjects" +386, 20, 33, 630, 186, 187, 2625, 2626, "(" +386, 20, 34, 631, 188, 190, 2627, 2629, "33" +386, 20, 35, 632, 191, 192, 2630, 2631, "." +386, 20, 36, 633, 193, 194, 2632, 2633, "3" +386, 20, 37, 634, 195, 196, 2634, 2635, "%" +386, 20, 38, 635, 197, 198, 2636, 2637, ")" +386, 20, 39, 636, 199, 200, 2638, 2639, ";" +386, 20, 40, 637, 201, 210, 2640, 2649, "injection" +386, 20, 41, 638, 211, 212, 2650, 2651, "-" +386, 20, 42, 639, 213, 217, 2652, 2656, "site" +386, 20, 43, 640, 218, 227, 2657, 2666, "reactions" +386, 20, 44, 641, 228, 232, 2667, 2671, "were" +386, 20, 45, 642, 233, 237, 2672, 2676, "more" +386, 20, 46, 643, 238, 246, 2677, 2685, "frequent" +386, 20, 47, 644, 247, 251, 2686, 2690, "with" +386, 20, 48, 645, 252, 261, 2691, 2700, "exenatide" +386, 20, 49, 646, 262, 264, 2701, 2703, "ER" +386, 20, 50, 647, 265, 266, 2704, 2705, "(" +386, 20, 51, 648, 267, 269, 2706, 2708, "22" +386, 20, 52, 649, 270, 271, 2709, 2710, "." +386, 20, 53, 650, 272, 273, 2711, 2712, "0" +386, 20, 54, 651, 274, 275, 2713, 2714, "%" +386, 20, 55, 652, 276, 277, 2715, 2716, ")" +386, 20, 56, 653, 278, 282, 2717, 2721, "than" +386, 20, 57, 654, 283, 287, 2722, 2726, "with" +386, 20, 58, 655, 288, 299, 2727, 2738, "semaglutide" +386, 20, 59, 656, 300, 301, 2739, 2740, "(" +386, 20, 60, 657, 302, 303, 2741, 2742, "1" +386, 20, 61, 658, 304, 305, 2743, 2744, "." +386, 20, 62, 659, 306, 307, 2745, 2746, "2" +386, 20, 63, 660, 308, 309, 2747, 2748, "%" +386, 20, 64, 661, 310, 311, 2749, 2750, ")" +386, 20, 65, 662, 312, 313, 2751, 2752, "." +386, 21, 1, 663, 0, 11, 2753, 2764, "CONCLUSIONS" +386, 21, 2, 664, 12, 13, 2765, 2766, ":" +386, 21, 3, 665, 14, 25, 2767, 2778, "Semaglutide" +386, 21, 4, 666, 26, 27, 2779, 2780, "1" +386, 21, 5, 667, 28, 29, 2781, 2782, "." +386, 21, 6, 668, 30, 31, 2783, 2784, "0" +386, 21, 7, 669, 32, 34, 2785, 2787, "mg" +386, 21, 8, 670, 35, 38, 2788, 2791, "was" +386, 21, 9, 671, 39, 47, 2792, 2800, "superior" +386, 21, 10, 672, 48, 50, 2801, 2803, "to" +386, 21, 11, 673, 51, 60, 2804, 2813, "exenatide" +386, 21, 12, 674, 61, 63, 2814, 2816, "ER" +386, 21, 13, 675, 64, 65, 2817, 2818, "2" +386, 21, 14, 676, 66, 67, 2819, 2820, "." +386, 21, 15, 677, 68, 69, 2821, 2822, "0" +386, 21, 16, 678, 70, 72, 2823, 2825, "mg" +386, 21, 17, 679, 73, 75, 2826, 2828, "in" +386, 21, 18, 680, 76, 85, 2829, 2838, "improving" +386, 21, 19, 681, 86, 94, 2839, 2847, "glycemic" +386, 21, 20, 682, 95, 102, 2848, 2855, "control" +386, 21, 21, 683, 103, 106, 2856, 2859, "and" +386, 21, 22, 684, 107, 115, 2860, 2868, "reducing" +386, 21, 23, 685, 116, 120, 2869, 2873, "body" +386, 21, 24, 686, 121, 127, 2874, 2880, "weight" +386, 21, 25, 687, 128, 133, 2881, 2886, "after" +386, 21, 26, 688, 134, 136, 2887, 2889, "56" +386, 21, 27, 689, 137, 142, 2890, 2895, "weeks" +386, 21, 28, 690, 143, 145, 2896, 2898, "of" +386, 21, 29, 691, 146, 155, 2899, 2908, "treatment" +386, 21, 30, 692, 156, 157, 2909, 2910, ";" +386, 21, 31, 693, 158, 161, 2911, 2914, "the" +386, 21, 32, 694, 162, 167, 2915, 2920, "drugs" +386, 21, 33, 695, 168, 171, 2921, 2924, "had" +386, 21, 34, 696, 172, 182, 2925, 2935, "comparable" +386, 21, 35, 697, 183, 189, 2936, 2942, "safety" +386, 21, 36, 698, 190, 198, 2943, 2951, "profiles" +386, 21, 37, 699, 199, 200, 2952, 2953, "." +386, 22, 1, 700, 0, 5, 2954, 2959, "These" +386, 22, 2, 701, 6, 13, 2960, 2967, "results" +386, 22, 3, 702, 14, 22, 2968, 2976, "indicate" +386, 22, 4, 703, 23, 27, 2977, 2981, "that" +386, 22, 5, 704, 28, 39, 2982, 2993, "semaglutide" +386, 22, 6, 705, 40, 49, 2994, 3003, "treatment" +386, 22, 7, 706, 50, 52, 3004, 3006, "is" +386, 22, 8, 707, 53, 59, 3007, 3013, "highly" +386, 22, 9, 708, 60, 69, 3014, 3023, "effective" +386, 22, 10, 709, 70, 73, 3024, 3027, "for" +386, 22, 11, 710, 74, 82, 3028, 3036, "subjects" +386, 22, 12, 711, 83, 87, 3037, 3041, "with" +386, 22, 13, 712, 88, 92, 3042, 3046, "type" +386, 22, 14, 713, 93, 94, 3047, 3048, "2" +386, 22, 15, 714, 95, 103, 3049, 3057, "diabetes" +386, 22, 16, 715, 104, 107, 3058, 3061, "who" +386, 22, 17, 716, 108, 111, 3062, 3065, "are" +386, 22, 18, 717, 112, 124, 3066, 3078, "inadequately" +386, 22, 19, 718, 125, 135, 3079, 3089, "controlled" +386, 22, 20, 719, 136, 138, 3090, 3092, "on" +386, 22, 21, 720, 139, 143, 3093, 3097, "oral" +386, 22, 22, 721, 144, 156, 3098, 3110, "antidiabetic" +386, 22, 23, 722, 157, 162, 3111, 3116, "drugs" +386, 22, 24, 723, 163, 164, 3117, 3118, "." +386, 23, 1, 724, 0, 1, 3119, 3120, "©" +386, 23, 2, 725, 2, 6, 3121, 3125, "2017" +386, 23, 3, 726, 7, 9, 3126, 3128, "by" +386, 23, 4, 727, 10, 13, 3129, 3132, "the" +386, 23, 5, 728, 14, 22, 3133, 3141, "American" +386, 23, 6, 729, 23, 31, 3142, 3150, "Diabetes" +386, 23, 7, 730, 32, 43, 3151, 3162, "Association" +386, 23, 8, 731, 44, 45, 3163, 3164, "." +386, 24, 1, 732, 0, 3, 3165, 3168, "DOI" +386, 24, 2, 733, 4, 5, 3169, 3170, ":" +386, 24, 3, 734, 6, 8, 3171, 3173, "10" +386, 24, 4, 735, 9, 10, 3174, 3175, "." +386, 24, 5, 736, 11, 15, 3176, 3180, "2337" +386, 24, 6, 737, 16, 17, 3181, 3182, "/" +386, 24, 7, 738, 18, 22, 3183, 3187, "dc17" +386, 24, 8, 739, 23, 24, 3188, 3189, "-" +386, 24, 9, 740, 25, 29, 3190, 3194, "0417" +386, 24, 10, 741, 30, 34, 3195, 3199, "PMID" +386, 24, 11, 742, 35, 36, 3200, 3201, ":" +386, 24, 12, 743, 37, 45, 3202, 3210, "29246950" +386, 24, 13, 744, 46, 47, 3211, 3212, "[" +386, 24, 14, 745, 48, 55, 3213, 3220, "Indexed" +386, 24, 15, 746, 56, 59, 3221, 3224, "for" +386, 24, 16, 747, 60, 67, 3225, 3232, "MEDLINE" +386, 24, 17, 748, 68, 69, 3233, 3234, "]" diff --git a/data/dm2 29246950_kwoodley.annodb b/data/dm2 29246950_kwoodley.annodb new file mode 100644 index 0000000..e1d4db8 --- /dev/null +++ b/data/dm2 29246950_kwoodley.annodb @@ -0,0 +1,127 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72856, Journal, 0, 13, "Diabetes Care", "", +72857, PublicationYear, 16, 20, "2018", "", +72900, Title, 101, 275, "Efficacy and Safety of Once - Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes ( SUSTAIN 3 ) : A 56 - Week , Open - Label , Randomized Clinical Trial .", "", +72858, Frequency, 124, 137, "Once - Weekly", "", +72860, Semaglutide, 138, 149, "Semaglutide", "", +72899, Exenatide, 157, 169, "Exenatide ER", "", +72880, Type2Diabetes, 187, 202, "Type 2 Diabetes", "", +72896, Duration, 221, 230, "56 - Week", "", +72897, OpenLabel, 233, 245, "Open - Label", "", +72898, Randomized, 248, 258, "Randomized", "", +72901, Author, 276, 285, "Ahmann AJ", "", +72902, Author, 294, 304, "Capehorn M", "", +72903, Author, 313, 326, "Charpentier G", "", +72904, Author, 335, 342, "Dotta F", "", +72905, Author, 351, 359, "Henkel E", "", +72906, Author, 368, 377, "Lingvay I", "", +72907, Author, 386, 394, "Holst AG", "", +72908, Author, 403, 412, "Annett MP", "", +72909, Author, 421, 429, "Aroda VR", "", +72910, USA, 544, 552, "Portland", "", +72912, France, 729, 735, "France", "", +72913, Italy, 826, 831, "Italy", "", +72914, Germany, 899, 906, "Germany", "", +72911, USA, 1031, 1033, "TX", "", +72915, Country, 1074, 1081, "Denmark", "", +72916, USA, 1124, 1126, "NJ", "", +72917, USA, 1185, 1187, "MD", "", +72933, ObjectiveDescription, 1202, 1371, "To compare the efficacy and safety of once - weekly semaglutide 1 . 0 mg s . c . with exenatide extended release ( ER ) 2 . 0 mg s . c . in subjects with type 2 diabetes", "", +72859, Frequency, 1240, 1253, "once - weekly", "", +72861, Semaglutide, 1254, 1265, "semaglutide", "", +72918, DoseValue, 1266, 1271, "1 . 0", "", +72924, mg, 1272, 1274, "mg", "", +72932, DeliveryMethod, 1275, 1282, "s . c .", "short for subcutaneous? ", +72883, Exenatide, 1288, 1314, "exenatide extended release", "", +72884, Exenatide, 1317, 1319, "ER", "", +72919, DoseValue, 1322, 1327, "2 . 0", "", +72925, mg, 1328, 1330, "mg", "", +72931, DeliveryMethod, 1331, 1336, "s . c", "", +72881, Type2Diabetes, 1356, 1371, "type 2 diabetes", "", +72934, OpenLabel, 1423, 1435, "open - label", "", +72935, Parallel, 1438, 1454, "parallel - group", "", +72936, Randomized, 1457, 1467, "randomized", "", +72937, NumberPatientsCT, 1487, 1490, "813", "", +72939, Precondition, 1491, 1551, "subjects with type 2 diabetes taking oral antidiabetic drugs", "", +72882, Type2Diabetes, 1505, 1520, "type 2 diabetes", "", +72938, OralAntidiabeticAgent, 1528, 1551, "oral antidiabetic drugs", "", +72940, Randomized, 1557, 1567, "randomized", "", +72941, AllocationRatio, 1570, 1575, "1 : 1", "", +72862, Semaglutide, 1581, 1592, "semaglutide", "", +72920, DoseValue, 1593, 1598, "1 . 0", "", +72927, mg, 1599, 1601, "mg", "", +72887, Exenatide, 1605, 1617, "exenatide ER", "", +72921, DoseValue, 1618, 1623, "2 . 0", "", +72926, mg, 1624, 1626, "mg", "", +72942, Duration, 1631, 1639, "56 weeks", "", +72943, TimePoint, 1680, 1688, "baseline", "", +72945, HbA1c, 1692, 1697, "HbA1c", "", +72944, TimePoint, 1701, 1708, "week 56", "", +72946, HbA1c, 1726, 1731, "HbA1c", "", +72947, BaseLineValue, 1734, 1739, "8 . 3", "", +72949, Percentage, 1740, 1741, "%", "", +72948, BaseLineValue, 1744, 1750, "67 . 7", "", +72953, BioAndMedicalUnit, 1751, 1761, "mmol / mol", "", +72957, TimePoint, 1767, 1775, "baseline", "", +72958, Reduction, 1793, 1798, "1 . 5", "", +72950, Percentage, 1799, 1800, "%", "", +72959, Reduction, 1803, 1809, "16 . 8", "", +72955, BioAndMedicalUnit, 1810, 1820, "mmol / mol", "", +72863, Semaglutide, 1828, 1839, "semaglutide", "", +72960, Reduction, 1844, 1849, "0 . 9", "", +72951, Percentage, 1850, 1851, "%", "", +72961, Reduction, 1854, 1860, "10 . 0", "", +72954, BioAndMedicalUnit, 1861, 1871, "mmol / mol", "", +72894, Exenatide, 1879, 1891, "exenatide ER", "", +72888, Exenatide, 1930, 1942, "exenatide ER", "", +72962, DiffGroupAbsValue, 1951, 1959, "- 0 . 62", "", +72952, Percentage, 1960, 1961, "%", "", +72964, ConfIntervalDiff, 1964, 1991, "95 % CI - 0 . 80 , - 0 . 44", "", +72963, DiffGroupAbsValue, 1996, 2004, "- 6 . 78", "", +72956, BioAndMedicalUnit, 2005, 2015, "mmol / mol", "", +72965, ConfIntervalDiff, 2018, 2045, "95 % CI - 8 . 70 , - 4 . 86", "", +72966, PvalueDiff, 2052, 2064, "P < 0 . 0001", "", +72967, BodyWeight, 2109, 2120, "body weight", "", +72969, BaseLineValue, 2123, 2129, "95 . 8", "", +72970, Kg, 2130, 2132, "kg", "", +72975, TimePoint, 2136, 2144, "baseline", "", +72976, Reduction, 2162, 2167, "5 . 6", "", +72972, Kg, 2168, 2170, "kg", "", +72864, Semaglutide, 2176, 2187, "semaglutide", "", +72977, Reduction, 2192, 2197, "1 . 9", "", +72973, Kg, 2198, 2200, "kg", "", +72892, Exenatide, 2206, 2218, "exenatide ER", "", +72978, DiffGroupAbsValue, 2225, 2233, "- 3 . 78", "", +72974, Kg, 2234, 2236, "kg", "", +72979, ConfIntervalDiff, 2239, 2266, "95 % CI - 4 . 58 , - 2 . 98", "", +72980, PvalueDiff, 2271, 2283, "P < 0 . 0001", "", +72865, Semaglutide, 2329, 2340, "semaglutide", "", +72981, PercentageAffected, 2343, 2345, "67", "", +72983, HbA1c_target, 2359, 2394, "HbA1c < 7 . 0 % ( < 53 mmol / mol )", "", +72891, Exenatide, 2415, 2427, "exenatide ER", "", +72982, PercentageAffected, 2430, 2432, "40", "", +72984, GastrointestinalProblem, 2489, 2520, "gastrointestinal adverse events", "", +72866, Semaglutide, 2541, 2552, "semaglutide", "", +72985, PercentageAffected, 2574, 2580, "41 . 8", "", +72890, Exenatide, 2593, 2605, "exenatide ER", "", +72986, PercentageAffected, 2627, 2633, "33 . 3", "", +72987, EndPointDescription, 2640, 2666, "injection - site reactions", "", +72889, Exenatide, 2691, 2703, "exenatide ER", "", +72988, PercentageAffected, 2706, 2712, "22 . 0", "", +72867, Semaglutide, 2727, 2738, "semaglutide", "", +72989, PercentageAffected, 2741, 2746, "1 . 2", "", +72993, ConclusionComment, 2767, 2953, "Semaglutide 1 . 0 mg was superior to exenatide ER 2 . 0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment ; the drugs had comparable safety profiles .", "", +72868, Semaglutide, 2767, 2778, "Semaglutide", "", +72922, DoseValue, 2779, 2784, "1 . 0", "", +72928, mg, 2785, 2787, "mg", "", +72893, Exenatide, 2804, 2816, "exenatide ER", "", +72923, DoseValue, 2817, 2822, "2 . 0", "", +72929, mg, 2823, 2825, "mg", "", +72968, BodyWeight, 2869, 2880, "body weight", "", +72990, Duration, 2887, 2895, "56 weeks", "", +72994, ConclusionComment, 2954, 3118, "These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs .", "", +72869, Semaglutide, 2982, 2993, "semaglutide", "", +72992, Precondition, 3028, 3116, "subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs", "", +72895, Type2Diabetes, 3042, 3057, "type 2 diabetes", "", +72991, OralAntidiabeticAgent, 3093, 3116, "oral antidiabetic drugs", "", +72995, PMID, 3202, 3210, "29246950", "", diff --git a/data/dm2 29246950_kwoodley.n-triples b/data/dm2 29246950_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29246950_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29362626_admin.annodb b/data/dm2 29362626_admin.annodb new file mode 100644 index 0000000..fbfff02 --- /dev/null +++ b/data/dm2 29362626_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 29, "Open Access Maced J Med Sci .", "", " \"Open Access Maced J Med Sci .\"." +1, PublicationYear, 30, 34, "2017", "", " \"2017\"." +31, Title, 132, 272, "Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin .", "", " \"Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin .\"." +2, Pioglitazone, 160, 172, "Pioglitazone", "", +11, Sitagliptin, 176, 187, "Sitagliptin", "", +28, Precondition, 191, 270, "Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin", "", " \"Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin\"." +20, Type2Diabetes, 205, 229, "Type 2 Diabetes Mellitus", "", " ." +24, Metformin, 261, 270, "Metformin", "", +32, Author, 273, 286, "Jameshorani M", "", " \"Jameshorani M\"." +33, Author, 295, 303, "Sayari S", "", " \"Sayari S\"." +34, Author, 312, 324, "Kiahashemi N", "", " \"Kiahashemi N\"." +35, Author, 333, 342, "Motamed N", "", " \"Motamed N\"." +36, Iran, 513, 517, "Iran", "", " ." +37, Iran, 612, 616, "Iran", "", +38, Type2Diabetes, 632, 649, "Diabetes mellitus", "", +40, ObjectiveDescription, 724, 879, "This study aimed to compare and study of add - on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin .", "", " \"This study aimed to compare and study of add - on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin .\"." +12, Sitagliptin, 774, 785, "sitagliptin", "", +3, Pioglitazone, 793, 805, "pioglitazone", "", +39, Precondition, 809, 877, "patients with type 2 diabetes inadequately controlled with metformin", "", +21, Type2Diabetes, 823, 838, "type 2 diabetes", "", +25, Metformin, 868, 877, "metformin", "", +41, Duration, 895, 904, "12 - week", "", " \"12 - week\"." +42, Randomized, 907, 917, "randomised", "", " ." +43, OpenLabel, 920, 932, "open - label", "", " ." +44, SingleCenter, 937, 950, "single centre", "", " ." +13, Sitagliptin, 966, 977, "sitagliptin", "", " ." +45, DoseValue, 980, 983, "100", "", " \"100\"." +47, mg, 984, 986, "mg", "", " ." +49, Frequency, 987, 992, "daily", "", " \"daily\"." +51, NumberPatientsArm, 999, 1001, "80", "", " \"80\"." +4, Pioglitazone, 1008, 1020, "pioglitazone", "", " ." +46, DoseValue, 1023, 1025, "30", "", " \"30\"." +48, mg, 1026, 1028, "mg", "", " ." +50, Frequency, 1029, 1034, "daily", "", " \"daily\"." +52, NumberPatientsArm, 1041, 1043, "80", "", " \"80\"." +22, Type2Diabetes, 1049, 1064, "type 2 diabetic", "", +29, Precondition, 1049, 1132, "type 2 diabetic patients whose disease was not adequately controlled with metformin", "", +26, Metformin, 1123, 1132, "metformin", "", +124, Mean, 1149, 1153, "mean", "", " . ." +53, HbA1c, 1164, 1169, "HbA1c", "", " \"80\"." +54, TimePoint, 1175, 1183, "baseline", "", +55, Reduction, 1190, 1197, "1 . 001", "", " \"1 . 001\"." +57, SdDevChangeValue, 1200, 1206, "0 . 83", "", " \"0 . 83\"." +14, Sitagliptin, 1212, 1223, "sitagliptin", "", +56, Reduction, 1230, 1236, "0 . 75", "", " \"0 . 75\"." +58, SdDevChangeValue, 1239, 1245, "1 . 20", "", " \"1 . 20\"." +5, Pioglitazone, 1251, 1263, "pioglitazone", "", +59, PvalueDiff, 1324, 1335, "P = 0 . 132", "", " \"P = 0 . 132\"." +132, Mean, 1344, 1348, "mean", "", " . ." +60, FastingBloodGlucose, 1359, 1378, "fasting blood sugar", "", " ." +61, FastingBloodGlucose, 1381, 1384, "FBS", "", +62, Reduction, 1393, 1400, "18 . 48", "", " \"18 . 48\"." +64, SdDevChangeValue, 1403, 1410, "33 . 32", "", " \"33 . 32\"." +66, Mg_per_deciliter, 1411, 1418, "mg / dl", "", " ." +15, Sitagliptin, 1424, 1435, "sitagliptin", "", +63, Reduction, 1442, 1449, "20 . 53", "", " \"20 . 53\"." +65, SdDevChangeValue, 1452, 1459, "53 . 97", "", " \"53 . 97\"." +67, Mg_per_deciliter, 1460, 1467, "mg / dl", "", +6, Pioglitazone, 1473, 1485, "pioglitazone", "", +68, PvalueDiff, 1546, 1557, "P = 0 . 773", "", " \"P = 0 . 773\"." +16, Sitagliptin, 1562, 1573, "Sitagliptin", "", +69, Reduction, 1581, 1587, "1 . 08", "", " \"1 . 08\"." +71, SdDevChangeValue, 1590, 1596, "2 . 39", "", " \"2 . 39\"." +73, Kg, 1597, 1599, "kg", "", " ." +76, BodyWeight, 1612, 1618, "weight", "", " ." +7, Pioglitazone, 1629, 1641, "pioglitazone", "", +70, Increment, 1649, 1655, "0 . 27", "", " \"0 . 27\"." +72, SdDevChangeValue, 1658, 1664, "2 . 42", "", " \"2 . 42\"." +74, Kg, 1665, 1667, "kg", "", +77, BodyWeight, 1680, 1686, "weight", "", +78, DiffGroupAbsValue, 1726, 1732, "0 . 81", "", " \"0 . 81\"." +75, Kg, 1733, 1735, "kg", "", +79, PvalueDiff, 1738, 1749, "P < 0 . 001", "", " \"P < 0 . 001\"." +81, ObservedResult, 1774, 1867, "in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group", "", " \"in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group\". \"in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group\"." +17, Sitagliptin, 1777, 1788, "sitagliptin", "", +80, EndPointDescription, 1830, 1843, "lipid profile", "", " . ." +8, Pioglitazone, 1849, 1861, "pioglitazone", "", +84, ConclusionComment, 1883, 2067, "Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin .", "", " \"Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin .\"." +18, Sitagliptin, 1883, 1894, "Sitagliptin", "", +9, Pioglitazone, 1899, 1911, "Pioglitazone", "", +23, Type2Diabetes, 1969, 1993, "type 2 diabetes mellitus", "", +27, Metformin, 2056, 2065, "metformin", "", +85, ConclusionComment, 2068, 2172, "Nevertheless , sitagliptin was more effective than pioglitazone regarding lipid and body weight change .", "", " \"Nevertheless , sitagliptin was more effective than pioglitazone regarding lipid and body weight change .\"." +19, Sitagliptin, 2083, 2094, "sitagliptin", "", +10, Pioglitazone, 2119, 2131, "pioglitazone", "", +82, EndPointDescription, 2142, 2147, "lipid", "", +83, BodyWeight, 2152, 2163, "body weight", "", +86, PMID, 2237, 2245, "29362626", "", " \"29362626\"." diff --git a/data/dm2 29362626_admin.n-triples b/data/dm2 29362626_admin.n-triples new file mode 100644 index 0000000..cce5b21 --- /dev/null +++ b/data/dm2 29362626_admin.n-triples @@ -0,0 +1,167 @@ +# RDF export of group: Publication + . + "Publication 78756" . + "Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin ." . + "Jameshorani M" . + "2017" . + "Open Access Maced J Med Sci ." . + "29362626" . + . + "Sayari S" . + "Kiahashemi N" . + "Motamed N" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 78763" . + "This study aimed to compare and study of add - on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin ." . + "12 - week" . + . + . + . + "Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin ." . + . + . + . + . + . + . + "Nevertheless , sitagliptin was more effective than pioglitazone regarding lipid and body weight change ." . + . + . + . + . +# RDF export of group: Population + . + "Population 78779" . + "Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin" . + . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "fbs" . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + "lip" . + . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + "80" . + . + . + . + . + . + . + . + "pio" . + "80" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "daily" . + . + . + "pio" . + . + "daily" . + . +# RDF export of group: Medication + . + "sit" . + . + "100" . + . + . + . + "pio" . + . + "30" . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "1 . 001" . + "0 . 83" . + . + "hba 2" . + . + "0 . 75" . + "1 . 20" . + . + "fbs 1" . + . + "18 . 48" . + "33 . 32" . + . + "fbs 2" . + . + "20 . 53" . + "53 . 97" . + . + "bw 1" . + . + "1 . 08" . + "2 . 39" . + . + "bw 2" . + . + "0 . 27" . + "2 . 42" . + . + "lip 1" . + . + "in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group" . + . + "lip 2" . + . + "in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "P = 0 . 132" . + . + . + . + "fbs" . + "P = 0 . 773" . + . + . + . + "bw" . + "0 . 81" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29362626_akramersunderbrink.annodb b/data/dm2 29362626_akramersunderbrink.annodb new file mode 100644 index 0000000..4a37a34 --- /dev/null +++ b/data/dm2 29362626_akramersunderbrink.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73944, Journal, 0, 27, "Open Access Maced J Med Sci", "", +73945, PublicationYear, 30, 34, "2017", "", +73951, Title, 132, 272, "Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin .", "", +73946, Pioglitazone, 160, 172, "Pioglitazone", "", +73947, Sitagliptin, 176, 187, "Sitagliptin", "", +73948, Type2Diabetes, 205, 229, "Type 2 Diabetes Mellitus", "", +73950, Precondition, 230, 270, "Insufficiently Controlled With Metformin", "", +73949, Metformin, 261, 270, "Metformin", "", +73952, Author, 273, 286, "Jameshorani M", "", +73953, Author, 295, 303, "Sayari S", "", +73954, Author, 312, 324, "Kiahashemi N", "", +73955, Author, 333, 342, "Motamed N", "", +73956, Iran, 513, 517, "Iran", "", +73957, Iran, 612, 616, "Iran", "", +73958, Type2Diabetes, 632, 649, "Diabetes mellitus", "", +73964, ObjectiveDescription, 724, 879, "This study aimed to compare and study of add - on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin .", "", +73959, Sitagliptin, 774, 785, "sitagliptin", "", +73960, Pioglitazone, 793, 805, "pioglitazone", "", +73961, Type2Diabetes, 823, 838, "type 2 diabetes", "", +73962, Precondition, 839, 877, "inadequately controlled with metformin", "", +73963, Metformin, 868, 877, "metformin", "", +73965, Duration, 895, 904, "12 - week", "", +73966, Randomized, 907, 917, "randomised", "", +73967, OpenLabel, 920, 932, "open - label", "", +73968, SingleCenter, 937, 950, "single centre", "", +73969, Sitagliptin, 966, 977, "sitagliptin", "", +73972, DoseValue, 980, 986, "100 mg", "", +73974, mg, 984, 986, "mg", "", +73976, Frequency, 987, 992, "daily", "", +73978, NumberPatientsArm, 999, 1001, "80", "", +73970, Pioglitazone, 1008, 1020, "pioglitazone", "", +73973, DoseValue, 1023, 1028, "30 mg", "", +73975, mg, 1026, 1028, "mg", "", +73977, Frequency, 1029, 1034, "daily", "", +73979, NumberPatientsArm, 1041, 1043, "80", "", +73971, Type2Diabetes, 1049, 1064, "type 2 diabetic", "", +73980, Metformin, 1123, 1132, "metformin", "", +73981, Mean, 1149, 1153, "mean", "", +73982, HbA1c, 1164, 1169, "HbA1c", "", +73983, TimePoint, 1175, 1183, "baseline", "", +73984, ChangeValue, 1188, 1197, "- 1 . 001", "", +74023, SdDevChangeValue, 1200, 1206, "0 . 83", "", +73986, Sitagliptin, 1212, 1223, "sitagliptin", "", +73985, ChangeValue, 1228, 1236, "- 0 . 75", "", +74024, SdDevChangeValue, 1239, 1245, "1 . 20", "", +73987, Pioglitazone, 1251, 1263, "pioglitazone", "", +73988, PvalueDiff, 1324, 1335, "P = 0 . 132", "", +73989, Mean, 1344, 1348, "mean", "", +73990, FastingBloodGlucose, 1359, 1378, "fasting blood sugar", "", +73991, FastingBloodGlucose, 1381, 1384, "FBS", "", +73992, ChangeValue, 1391, 1400, "- 18 . 48", "", +74025, SdDevChangeValue, 1403, 1410, "33 . 32", "", +73994, Mg_per_deciliter, 1411, 1418, "mg / dl", "", +73998, Sitagliptin, 1424, 1435, "sitagliptin", "", +73993, ChangeValue, 1440, 1449, "- 20 . 53", "", +74026, SdDevChangeValue, 1452, 1459, "53 . 97", "", +73995, Mg_per_deciliter, 1460, 1467, "mg / dl", "", +73996, Pioglitazone, 1473, 1485, "pioglitazone", "", +73997, PvalueDiff, 1546, 1557, "P = 0 . 773", "", +73999, Sitagliptin, 1562, 1573, "Sitagliptin", "", +74003, Reduction, 1581, 1587, "1 . 08", "", +74027, SdDevChangeValue, 1590, 1596, "2 . 39", "", +74000, Kg, 1597, 1599, "kg", "", +74007, BodyWeight, 1612, 1618, "weight", "", +74008, Pioglitazone, 1629, 1641, "pioglitazone", "", +74004, Reduction, 1649, 1655, "0 . 27", "", +74028, SdDevChangeValue, 1658, 1664, "2 . 42", "", +74001, Kg, 1665, 1667, "kg", "", +74005, BodyWeight, 1680, 1686, "weight", "", +74006, DiffGroupAbsValue, 1726, 1732, "0 . 81", "", +74002, Kg, 1733, 1735, "kg", "", +74009, PvalueDiff, 1738, 1749, "P < 0 . 001", "", +74010, Sitagliptin, 1777, 1788, "sitagliptin", "", +74011, Pioglitazone, 1849, 1861, "pioglitazone", "", +74013, Sitagliptin, 1883, 1894, "Sitagliptin", "", +74017, ConclusionComment, 1883, 2067, "Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin .", "", +74012, Pioglitazone, 1899, 1911, "Pioglitazone", "", +74014, Type2Diabetes, 1969, 1993, "type 2 diabetes mellitus", "", +74015, Precondition, 2003, 2065, "whose diabetes had been inadequately controlled with metformin", "", +74016, Metformin, 2056, 2065, "metformin", "", +74018, ConclusionComment, 2068, 2172, "Nevertheless , sitagliptin was more effective than pioglitazone regarding lipid and body weight change .", "", +74019, Sitagliptin, 2083, 2094, "sitagliptin", "", +74020, Pioglitazone, 2119, 2131, "pioglitazone", "", +74021, BodyWeight, 2152, 2163, "body weight", "", +74022, PMID, 2237, 2245, "29362626", "", diff --git a/data/dm2 29362626_akramersunderbrink.n-triples b/data/dm2 29362626_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29362626_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29362626_export.csv b/data/dm2 29362626_export.csv new file mode 100644 index 0000000..f778d11 --- /dev/null +++ b/data/dm2 29362626_export.csv @@ -0,0 +1,458 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +385, 1, 1, 1, 0, 4, 0, 4, "Open" +385, 1, 2, 2, 5, 11, 5, 11, "Access" +385, 1, 3, 3, 12, 17, 12, 17, "Maced" +385, 1, 4, 4, 18, 19, 18, 19, "J" +385, 1, 5, 5, 20, 23, 20, 23, "Med" +385, 1, 6, 6, 24, 27, 24, 27, "Sci" +385, 1, 7, 7, 28, 29, 28, 29, "." +385, 2, 1, 8, 0, 4, 30, 34, "2017" +385, 2, 2, 9, 5, 8, 35, 38, "Dec" +385, 2, 3, 10, 9, 11, 39, 41, "12" +385, 2, 4, 11, 12, 13, 42, 43, ";" +385, 2, 5, 12, 14, 15, 44, 45, "5" +385, 2, 6, 13, 16, 17, 46, 47, "(" +385, 2, 7, 14, 18, 19, 48, 49, "7" +385, 2, 8, 15, 20, 21, 50, 51, ")" +385, 2, 9, 16, 22, 23, 52, 53, ":" +385, 2, 10, 17, 24, 27, 54, 57, "955" +385, 2, 11, 18, 28, 29, 58, 59, "-" +385, 2, 12, 19, 30, 33, 60, 63, "962" +385, 2, 13, 20, 34, 35, 64, 65, "." +385, 2, 14, 21, 36, 39, 66, 69, "doi" +385, 2, 15, 22, 40, 41, 70, 71, ":" +385, 2, 16, 23, 42, 44, 72, 74, "10" +385, 2, 17, 24, 45, 46, 75, 76, "." +385, 2, 18, 25, 47, 51, 77, 81, "3889" +385, 2, 19, 26, 52, 53, 82, 83, "/" +385, 2, 20, 27, 54, 60, 84, 90, "oamjms" +385, 2, 21, 28, 61, 62, 91, 92, "." +385, 2, 22, 29, 63, 67, 93, 97, "2017" +385, 2, 23, 30, 68, 69, 98, 99, "." +385, 2, 24, 31, 70, 73, 100, 103, "193" +385, 2, 25, 32, 74, 75, 104, 105, "." +385, 3, 1, 33, 0, 11, 106, 117, "eCollection" +385, 3, 2, 34, 12, 16, 118, 122, "2017" +385, 3, 3, 35, 17, 20, 123, 126, "Dec" +385, 3, 4, 36, 21, 23, 127, 129, "15" +385, 3, 5, 37, 24, 25, 130, 131, "." +385, 4, 1, 38, 0, 11, 132, 143, "Comparative" +385, 4, 2, 39, 12, 17, 144, 149, "Study" +385, 4, 3, 40, 18, 20, 150, 152, "on" +385, 4, 4, 41, 21, 27, 153, 159, "Adding" +385, 4, 5, 42, 28, 40, 160, 172, "Pioglitazone" +385, 4, 6, 43, 41, 43, 173, 175, "or" +385, 4, 7, 44, 44, 55, 176, 187, "Sitagliptin" +385, 4, 8, 45, 56, 58, 188, 190, "to" +385, 4, 9, 46, 59, 67, 191, 199, "Patients" +385, 4, 10, 47, 68, 72, 200, 204, "with" +385, 4, 11, 48, 73, 77, 205, 209, "Type" +385, 4, 12, 49, 78, 79, 210, 211, "2" +385, 4, 13, 50, 80, 88, 212, 220, "Diabetes" +385, 4, 14, 51, 89, 97, 221, 229, "Mellitus" +385, 4, 15, 52, 98, 112, 230, 244, "Insufficiently" +385, 4, 16, 53, 113, 123, 245, 255, "Controlled" +385, 4, 17, 54, 124, 128, 256, 260, "With" +385, 4, 18, 55, 129, 138, 261, 270, "Metformin" +385, 4, 19, 56, 139, 140, 271, 272, "." +385, 5, 1, 57, 0, 11, 273, 284, "Jameshorani" +385, 5, 2, 58, 12, 13, 285, 286, "M" +385, 5, 3, 59, 14, 15, 287, 288, "(" +385, 5, 4, 60, 16, 17, 289, 290, "1" +385, 5, 5, 61, 18, 19, 291, 292, ")" +385, 5, 6, 62, 20, 21, 293, 294, "," +385, 5, 7, 63, 22, 28, 295, 301, "Sayari" +385, 5, 8, 64, 29, 30, 302, 303, "S" +385, 5, 9, 65, 31, 32, 304, 305, "(" +385, 5, 10, 66, 33, 34, 306, 307, "1" +385, 5, 11, 67, 35, 36, 308, 309, ")" +385, 5, 12, 68, 37, 38, 310, 311, "," +385, 5, 13, 69, 39, 49, 312, 322, "Kiahashemi" +385, 5, 14, 70, 50, 51, 323, 324, "N" +385, 5, 15, 71, 52, 53, 325, 326, "(" +385, 5, 16, 72, 54, 55, 327, 328, "1" +385, 5, 17, 73, 56, 57, 329, 330, ")" +385, 5, 18, 74, 58, 59, 331, 332, "," +385, 5, 19, 75, 60, 67, 333, 340, "Motamed" +385, 5, 20, 76, 68, 69, 341, 342, "N" +385, 5, 21, 77, 70, 71, 343, 344, "(" +385, 5, 22, 78, 72, 73, 345, 346, "2" +385, 5, 23, 79, 74, 75, 347, 348, ")" +385, 5, 24, 80, 76, 77, 349, 350, "." +385, 6, 1, 81, 0, 6, 351, 357, "Author" +385, 6, 2, 82, 7, 18, 358, 369, "information" +385, 6, 3, 83, 19, 20, 370, 371, ":" +385, 6, 4, 84, 21, 22, 372, 373, "(" +385, 6, 5, 85, 23, 24, 374, 375, "1" +385, 6, 6, 86, 25, 26, 376, 377, ")" +385, 6, 7, 87, 27, 33, 378, 384, "Zanjan" +385, 6, 8, 88, 34, 43, 385, 394, "Metabolic" +385, 6, 9, 89, 44, 51, 395, 402, "Disease" +385, 6, 10, 90, 52, 60, 403, 411, "Research" +385, 6, 11, 91, 61, 67, 412, 418, "Center" +385, 6, 12, 92, 68, 69, 419, 420, "(" +385, 6, 13, 93, 70, 74, 421, 425, "ZMDR" +385, 6, 14, 94, 75, 76, 426, 427, ")" +385, 6, 15, 95, 77, 78, 428, 429, "," +385, 6, 16, 96, 79, 83, 430, 434, "Vali" +385, 6, 17, 97, 84, 85, 435, 436, "-" +385, 6, 18, 98, 86, 87, 437, 438, "e" +385, 6, 19, 99, 88, 89, 439, 440, "-" +385, 6, 20, 100, 90, 93, 441, 444, "asr" +385, 6, 21, 101, 94, 102, 445, 453, "Hospital" +385, 6, 22, 102, 103, 104, 454, 455, "," +385, 6, 23, 103, 105, 111, 456, 462, "Zanjan" +385, 6, 24, 104, 112, 122, 463, 473, "University" +385, 6, 25, 105, 123, 125, 474, 476, "of" +385, 6, 26, 106, 126, 133, 477, 484, "Medical" +385, 6, 27, 107, 134, 141, 485, 492, "Science" +385, 6, 28, 108, 142, 143, 493, 494, "(" +385, 6, 29, 109, 144, 148, 495, 499, "ZUMS" +385, 6, 30, 110, 149, 150, 500, 501, ")" +385, 6, 31, 111, 151, 152, 502, 503, "," +385, 6, 32, 112, 153, 159, 504, 510, "Zanjan" +385, 6, 33, 113, 160, 161, 511, 512, "," +385, 6, 34, 114, 162, 166, 513, 517, "Iran" +385, 6, 35, 115, 167, 168, 518, 519, "." +385, 7, 1, 116, 0, 1, 520, 521, "(" +385, 7, 2, 117, 2, 3, 522, 523, "2" +385, 7, 3, 118, 4, 5, 524, 525, ")" +385, 7, 4, 119, 6, 16, 526, 536, "Department" +385, 7, 5, 120, 17, 19, 537, 539, "of" +385, 7, 6, 121, 20, 32, 540, 552, "Epidemiology" +385, 7, 7, 122, 33, 34, 553, 554, "," +385, 7, 8, 123, 35, 41, 555, 561, "Zanjan" +385, 7, 9, 124, 42, 52, 562, 572, "University" +385, 7, 10, 125, 53, 55, 573, 575, "of" +385, 7, 11, 126, 56, 63, 576, 583, "Medical" +385, 7, 12, 127, 64, 71, 584, 591, "Science" +385, 7, 13, 128, 72, 73, 592, 593, "(" +385, 7, 14, 129, 74, 78, 594, 598, "ZUMS" +385, 7, 15, 130, 79, 80, 599, 600, ")" +385, 7, 16, 131, 81, 82, 601, 602, "," +385, 7, 17, 132, 83, 89, 603, 609, "Zanjan" +385, 7, 18, 133, 90, 91, 610, 611, "," +385, 7, 19, 134, 92, 96, 612, 616, "Iran" +385, 7, 20, 135, 97, 98, 617, 618, "." +385, 8, 1, 136, 0, 10, 619, 629, "BACKGROUND" +385, 8, 2, 137, 11, 12, 630, 631, ":" +385, 8, 3, 138, 13, 21, 632, 640, "Diabetes" +385, 8, 4, 139, 22, 30, 641, 649, "mellitus" +385, 8, 5, 140, 31, 33, 650, 652, "is" +385, 8, 6, 141, 34, 35, 653, 654, "a" +385, 8, 7, 142, 36, 47, 655, 666, "progressive" +385, 8, 8, 143, 48, 56, 667, 675, "disorder" +385, 8, 9, 144, 57, 61, 676, 680, "that" +385, 8, 10, 145, 62, 67, 681, 686, "often" +385, 8, 11, 146, 68, 76, 687, 695, "requires" +385, 8, 12, 147, 77, 88, 696, 707, "combination" +385, 8, 13, 148, 89, 96, 708, 715, "therapy" +385, 8, 14, 149, 97, 98, 716, 717, "." +385, 9, 1, 150, 0, 3, 718, 721, "AIM" +385, 9, 2, 151, 4, 5, 722, 723, ":" +385, 9, 3, 152, 6, 10, 724, 728, "This" +385, 9, 4, 153, 11, 16, 729, 734, "study" +385, 9, 5, 154, 17, 22, 735, 740, "aimed" +385, 9, 6, 155, 23, 25, 741, 743, "to" +385, 9, 7, 156, 26, 33, 744, 751, "compare" +385, 9, 8, 157, 34, 37, 752, 755, "and" +385, 9, 9, 158, 38, 43, 756, 761, "study" +385, 9, 10, 159, 44, 46, 762, 764, "of" +385, 9, 11, 160, 47, 50, 765, 768, "add" +385, 9, 12, 161, 51, 52, 769, 770, "-" +385, 9, 13, 162, 53, 55, 771, 773, "on" +385, 9, 14, 163, 56, 67, 774, 785, "sitagliptin" +385, 9, 15, 164, 68, 74, 786, 792, "versus" +385, 9, 16, 165, 75, 87, 793, 805, "pioglitazone" +385, 9, 17, 166, 88, 90, 806, 808, "in" +385, 9, 18, 167, 91, 99, 809, 817, "patients" +385, 9, 19, 168, 100, 104, 818, 822, "with" +385, 9, 20, 169, 105, 109, 823, 827, "type" +385, 9, 21, 170, 110, 111, 828, 829, "2" +385, 9, 22, 171, 112, 120, 830, 838, "diabetes" +385, 9, 23, 172, 121, 133, 839, 851, "inadequately" +385, 9, 24, 173, 134, 144, 852, 862, "controlled" +385, 9, 25, 174, 145, 149, 863, 867, "with" +385, 9, 26, 175, 150, 159, 868, 877, "metformin" +385, 9, 27, 176, 160, 161, 878, 879, "." +385, 10, 1, 177, 0, 7, 880, 887, "METHODS" +385, 10, 2, 178, 8, 9, 888, 889, ":" +385, 10, 3, 179, 10, 14, 890, 894, "This" +385, 10, 4, 180, 15, 17, 895, 897, "12" +385, 10, 5, 181, 18, 19, 898, 899, "-" +385, 10, 6, 182, 20, 24, 900, 904, "week" +385, 10, 7, 183, 25, 26, 905, 906, "," +385, 10, 8, 184, 27, 37, 907, 917, "randomised" +385, 10, 9, 185, 38, 39, 918, 919, "," +385, 10, 10, 186, 40, 44, 920, 924, "open" +385, 10, 11, 187, 45, 46, 925, 926, "-" +385, 10, 12, 188, 47, 52, 927, 932, "label" +385, 10, 13, 189, 53, 56, 933, 936, "and" +385, 10, 14, 190, 57, 63, 937, 943, "single" +385, 10, 15, 191, 64, 70, 944, 950, "centre" +385, 10, 16, 192, 71, 76, 951, 956, "study" +385, 10, 17, 193, 77, 85, 957, 965, "compared" +385, 10, 18, 194, 86, 97, 966, 977, "sitagliptin" +385, 10, 19, 195, 98, 99, 978, 979, "(" +385, 10, 20, 196, 100, 103, 980, 983, "100" +385, 10, 21, 197, 104, 106, 984, 986, "mg" +385, 10, 22, 198, 107, 112, 987, 992, "daily" +385, 10, 23, 199, 113, 114, 993, 994, "," +385, 10, 24, 200, 115, 116, 995, 996, "n" +385, 10, 25, 201, 117, 118, 997, 998, "=" +385, 10, 26, 202, 119, 121, 999, 1001, "80" +385, 10, 27, 203, 122, 123, 1002, 1003, ")" +385, 10, 28, 204, 124, 127, 1004, 1007, "and" +385, 10, 29, 205, 128, 140, 1008, 1020, "pioglitazone" +385, 10, 30, 206, 141, 142, 1021, 1022, "(" +385, 10, 31, 207, 143, 145, 1023, 1025, "30" +385, 10, 32, 208, 146, 148, 1026, 1028, "mg" +385, 10, 33, 209, 149, 154, 1029, 1034, "daily" +385, 10, 34, 210, 155, 156, 1035, 1036, "," +385, 10, 35, 211, 157, 158, 1037, 1038, "n" +385, 10, 36, 212, 159, 160, 1039, 1040, "=" +385, 10, 37, 213, 161, 163, 1041, 1043, "80" +385, 10, 38, 214, 164, 165, 1044, 1045, ")" +385, 10, 39, 215, 166, 168, 1046, 1048, "in" +385, 10, 40, 216, 169, 173, 1049, 1053, "type" +385, 10, 41, 217, 174, 175, 1054, 1055, "2" +385, 10, 42, 218, 176, 184, 1056, 1064, "diabetic" +385, 10, 43, 219, 185, 193, 1065, 1073, "patients" +385, 10, 44, 220, 194, 199, 1074, 1079, "whose" +385, 10, 45, 221, 200, 207, 1080, 1087, "disease" +385, 10, 46, 222, 208, 211, 1088, 1091, "was" +385, 10, 47, 223, 212, 215, 1092, 1095, "not" +385, 10, 48, 224, 216, 226, 1096, 1106, "adequately" +385, 10, 49, 225, 227, 237, 1107, 1117, "controlled" +385, 10, 50, 226, 238, 242, 1118, 1122, "with" +385, 10, 51, 227, 243, 252, 1123, 1132, "metformin" +385, 10, 52, 228, 253, 254, 1133, 1134, "." +385, 11, 1, 229, 0, 7, 1135, 1142, "RESULTS" +385, 11, 2, 230, 8, 9, 1143, 1144, ":" +385, 11, 3, 231, 10, 13, 1145, 1148, "The" +385, 11, 4, 232, 14, 18, 1149, 1153, "mean" +385, 11, 5, 233, 19, 25, 1154, 1160, "change" +385, 11, 6, 234, 26, 28, 1161, 1163, "in" +385, 11, 7, 235, 29, 34, 1164, 1169, "HbA1c" +385, 11, 8, 236, 35, 39, 1170, 1174, "from" +385, 11, 9, 237, 40, 48, 1175, 1183, "baseline" +385, 11, 10, 238, 49, 52, 1184, 1187, "was" +385, 11, 11, 239, 53, 54, 1188, 1189, "-" +385, 11, 12, 240, 55, 56, 1190, 1191, "1" +385, 11, 13, 241, 57, 58, 1192, 1193, "." +385, 11, 14, 242, 59, 62, 1194, 1197, "001" +385, 11, 15, 243, 63, 64, 1198, 1199, "±" +385, 11, 16, 244, 65, 66, 1200, 1201, "0" +385, 11, 17, 245, 67, 68, 1202, 1203, "." +385, 11, 18, 246, 69, 71, 1204, 1206, "83" +385, 11, 19, 247, 72, 76, 1207, 1211, "with" +385, 11, 20, 248, 77, 88, 1212, 1223, "sitagliptin" +385, 11, 21, 249, 89, 92, 1224, 1227, "and" +385, 11, 22, 250, 93, 94, 1228, 1229, "-" +385, 11, 23, 251, 95, 96, 1230, 1231, "0" +385, 11, 24, 252, 97, 98, 1232, 1233, "." +385, 11, 25, 253, 99, 101, 1234, 1236, "75" +385, 11, 26, 254, 102, 103, 1237, 1238, "±" +385, 11, 27, 255, 104, 105, 1239, 1240, "1" +385, 11, 28, 256, 106, 107, 1241, 1242, "." +385, 11, 29, 257, 108, 110, 1243, 1245, "20" +385, 11, 30, 258, 111, 115, 1246, 1250, "with" +385, 11, 31, 259, 116, 128, 1251, 1263, "pioglitazone" +385, 11, 32, 260, 129, 130, 1264, 1265, "," +385, 11, 33, 261, 131, 134, 1266, 1269, "and" +385, 11, 34, 262, 135, 140, 1270, 1275, "there" +385, 11, 35, 263, 141, 145, 1276, 1280, "were" +385, 11, 36, 264, 146, 148, 1281, 1283, "no" +385, 11, 37, 265, 149, 160, 1284, 1295, "significant" +385, 11, 38, 266, 161, 171, 1296, 1306, "difference" +385, 11, 39, 267, 172, 179, 1307, 1314, "between" +385, 11, 40, 268, 180, 186, 1315, 1321, "groups" +385, 11, 41, 269, 187, 188, 1322, 1323, "(" +385, 11, 42, 270, 189, 190, 1324, 1325, "P" +385, 11, 43, 271, 191, 192, 1326, 1327, "=" +385, 11, 44, 272, 193, 194, 1328, 1329, "0" +385, 11, 45, 273, 195, 196, 1330, 1331, "." +385, 11, 46, 274, 197, 200, 1332, 1335, "132" +385, 11, 47, 275, 201, 202, 1336, 1337, ")" +385, 11, 48, 276, 203, 204, 1338, 1339, "." +385, 12, 1, 277, 0, 3, 1340, 1343, "The" +385, 12, 2, 278, 4, 8, 1344, 1348, "mean" +385, 12, 3, 279, 9, 15, 1349, 1355, "change" +385, 12, 4, 280, 16, 18, 1356, 1358, "in" +385, 12, 5, 281, 19, 26, 1359, 1366, "fasting" +385, 12, 6, 282, 27, 32, 1367, 1372, "blood" +385, 12, 7, 283, 33, 38, 1373, 1378, "sugar" +385, 12, 8, 284, 39, 40, 1379, 1380, "(" +385, 12, 9, 285, 41, 44, 1381, 1384, "FBS" +385, 12, 10, 286, 45, 46, 1385, 1386, ")" +385, 12, 11, 287, 47, 50, 1387, 1390, "was" +385, 12, 12, 288, 51, 52, 1391, 1392, "-" +385, 12, 13, 289, 53, 55, 1393, 1395, "18" +385, 12, 14, 290, 56, 57, 1396, 1397, "." +385, 12, 15, 291, 58, 60, 1398, 1400, "48" +385, 12, 16, 292, 61, 62, 1401, 1402, "±" +385, 12, 17, 293, 63, 65, 1403, 1405, "33" +385, 12, 18, 294, 66, 67, 1406, 1407, "." +385, 12, 19, 295, 68, 70, 1408, 1410, "32" +385, 12, 20, 296, 71, 73, 1411, 1413, "mg" +385, 12, 21, 297, 74, 75, 1414, 1415, "/" +385, 12, 22, 298, 76, 78, 1416, 1418, "dl" +385, 12, 23, 299, 79, 83, 1419, 1423, "with" +385, 12, 24, 300, 84, 95, 1424, 1435, "sitagliptin" +385, 12, 25, 301, 96, 99, 1436, 1439, "and" +385, 12, 26, 302, 100, 101, 1440, 1441, "-" +385, 12, 27, 303, 102, 104, 1442, 1444, "20" +385, 12, 28, 304, 105, 106, 1445, 1446, "." +385, 12, 29, 305, 107, 109, 1447, 1449, "53" +385, 12, 30, 306, 110, 111, 1450, 1451, "±" +385, 12, 31, 307, 112, 114, 1452, 1454, "53" +385, 12, 32, 308, 115, 116, 1455, 1456, "." +385, 12, 33, 309, 117, 119, 1457, 1459, "97" +385, 12, 34, 310, 120, 122, 1460, 1462, "mg" +385, 12, 35, 311, 123, 124, 1463, 1464, "/" +385, 12, 36, 312, 125, 127, 1465, 1467, "dl" +385, 12, 37, 313, 128, 132, 1468, 1472, "with" +385, 12, 38, 314, 133, 145, 1473, 1485, "pioglitazone" +385, 12, 39, 315, 146, 147, 1486, 1487, "," +385, 12, 40, 316, 148, 151, 1488, 1491, "and" +385, 12, 41, 317, 152, 157, 1492, 1497, "there" +385, 12, 42, 318, 158, 162, 1498, 1502, "were" +385, 12, 43, 319, 163, 165, 1503, 1505, "no" +385, 12, 44, 320, 166, 177, 1506, 1517, "significant" +385, 12, 45, 321, 178, 188, 1518, 1528, "difference" +385, 12, 46, 322, 189, 196, 1529, 1536, "between" +385, 12, 47, 323, 197, 203, 1537, 1543, "groups" +385, 12, 48, 324, 204, 205, 1544, 1545, "(" +385, 12, 49, 325, 206, 207, 1546, 1547, "P" +385, 12, 50, 326, 208, 209, 1548, 1549, "=" +385, 12, 51, 327, 210, 211, 1550, 1551, "0" +385, 12, 52, 328, 212, 213, 1552, 1553, "." +385, 12, 53, 329, 214, 217, 1554, 1557, "773" +385, 12, 54, 330, 218, 219, 1558, 1559, ")" +385, 12, 55, 331, 220, 221, 1560, 1561, "." +385, 13, 1, 332, 0, 11, 1562, 1573, "Sitagliptin" +385, 13, 2, 333, 12, 18, 1574, 1580, "caused" +385, 13, 3, 334, 19, 20, 1581, 1582, "1" +385, 13, 4, 335, 21, 22, 1583, 1584, "." +385, 13, 5, 336, 23, 25, 1585, 1587, "08" +385, 13, 6, 337, 26, 27, 1588, 1589, "±" +385, 13, 7, 338, 28, 29, 1590, 1591, "2" +385, 13, 8, 339, 30, 31, 1592, 1593, "." +385, 13, 9, 340, 32, 34, 1594, 1596, "39" +385, 13, 10, 341, 35, 37, 1597, 1599, "kg" +385, 13, 11, 342, 38, 46, 1600, 1608, "decrease" +385, 13, 12, 343, 47, 49, 1609, 1611, "in" +385, 13, 13, 344, 50, 56, 1612, 1618, "weight" +385, 13, 14, 345, 57, 58, 1619, 1620, "," +385, 13, 15, 346, 59, 66, 1621, 1628, "whereas" +385, 13, 16, 347, 67, 79, 1629, 1641, "pioglitazone" +385, 13, 17, 348, 80, 86, 1642, 1648, "caused" +385, 13, 18, 349, 87, 88, 1649, 1650, "0" +385, 13, 19, 350, 89, 90, 1651, 1652, "." +385, 13, 20, 351, 91, 93, 1653, 1655, "27" +385, 13, 21, 352, 94, 95, 1656, 1657, "±" +385, 13, 22, 353, 96, 97, 1658, 1659, "2" +385, 13, 23, 354, 98, 99, 1660, 1661, "." +385, 13, 24, 355, 100, 102, 1662, 1664, "42" +385, 13, 25, 356, 103, 105, 1665, 1667, "kg" +385, 13, 26, 357, 106, 114, 1668, 1676, "increase" +385, 13, 27, 358, 115, 117, 1677, 1679, "in" +385, 13, 28, 359, 118, 124, 1680, 1686, "weight" +385, 13, 29, 360, 125, 126, 1687, 1688, "," +385, 13, 30, 361, 127, 131, 1689, 1693, "with" +385, 13, 31, 362, 132, 133, 1694, 1695, "a" +385, 13, 32, 363, 134, 141, 1696, 1703, "between" +385, 13, 33, 364, 142, 143, 1704, 1705, "-" +385, 13, 34, 365, 144, 149, 1706, 1711, "group" +385, 13, 35, 366, 150, 160, 1712, 1722, "difference" +385, 13, 36, 367, 161, 163, 1723, 1725, "of" +385, 13, 37, 368, 164, 165, 1726, 1727, "0" +385, 13, 38, 369, 166, 167, 1728, 1729, "." +385, 13, 39, 370, 168, 170, 1730, 1732, "81" +385, 13, 40, 371, 171, 173, 1733, 1735, "kg" +385, 13, 41, 372, 174, 175, 1736, 1737, "(" +385, 13, 42, 373, 176, 177, 1738, 1739, "P" +385, 13, 43, 374, 178, 179, 1740, 1741, "<" +385, 13, 44, 375, 180, 181, 1742, 1743, "0" +385, 13, 45, 376, 182, 183, 1744, 1745, "." +385, 13, 46, 377, 184, 187, 1746, 1749, "001" +385, 13, 47, 378, 188, 189, 1750, 1751, ")" +385, 13, 48, 379, 190, 191, 1752, 1753, "." +385, 14, 1, 380, 0, 2, 1754, 1756, "On" +385, 14, 2, 381, 3, 6, 1757, 1760, "the" +385, 14, 3, 382, 7, 12, 1761, 1766, "other" +385, 14, 4, 383, 13, 17, 1767, 1771, "hand" +385, 14, 5, 384, 18, 19, 1772, 1773, "," +385, 14, 6, 385, 20, 22, 1774, 1776, "in" +385, 14, 7, 386, 23, 34, 1777, 1788, "sitagliptin" +385, 14, 8, 387, 35, 40, 1789, 1794, "group" +385, 14, 9, 388, 41, 42, 1795, 1796, "," +385, 14, 10, 389, 43, 48, 1797, 1802, "there" +385, 14, 11, 390, 49, 52, 1803, 1806, "was" +385, 14, 12, 391, 53, 60, 1807, 1814, "greater" +385, 14, 13, 392, 61, 72, 1815, 1826, "improvement" +385, 14, 14, 393, 73, 75, 1827, 1829, "in" +385, 14, 15, 394, 76, 81, 1830, 1835, "lipid" +385, 14, 16, 395, 82, 89, 1836, 1843, "profile" +385, 14, 17, 396, 90, 94, 1844, 1848, "than" +385, 14, 18, 397, 95, 107, 1849, 1861, "pioglitazone" +385, 14, 19, 398, 108, 113, 1862, 1867, "group" +385, 14, 20, 399, 114, 115, 1868, 1869, "." +385, 15, 1, 400, 0, 10, 1870, 1880, "CONCLUSION" +385, 15, 2, 401, 11, 12, 1881, 1882, ":" +385, 15, 3, 402, 13, 24, 1883, 1894, "Sitagliptin" +385, 15, 4, 403, 25, 28, 1895, 1898, "and" +385, 15, 5, 404, 29, 41, 1899, 1911, "Pioglitazone" +385, 15, 6, 405, 42, 54, 1912, 1924, "demonstrated" +385, 15, 7, 406, 55, 62, 1925, 1932, "similar" +385, 15, 8, 407, 63, 75, 1933, 1945, "improvements" +385, 15, 9, 408, 76, 78, 1946, 1948, "in" +385, 15, 10, 409, 79, 87, 1949, 1957, "glycemic" +385, 15, 11, 410, 88, 95, 1958, 1965, "control" +385, 15, 12, 411, 96, 98, 1966, 1968, "in" +385, 15, 13, 412, 99, 103, 1969, 1973, "type" +385, 15, 14, 413, 104, 105, 1974, 1975, "2" +385, 15, 15, 414, 106, 114, 1976, 1984, "diabetes" +385, 15, 16, 415, 115, 123, 1985, 1993, "mellitus" +385, 15, 17, 416, 124, 132, 1994, 2002, "patients" +385, 15, 18, 417, 133, 138, 2003, 2008, "whose" +385, 15, 19, 418, 139, 147, 2009, 2017, "diabetes" +385, 15, 20, 419, 148, 151, 2018, 2021, "had" +385, 15, 21, 420, 152, 156, 2022, 2026, "been" +385, 15, 22, 421, 157, 169, 2027, 2039, "inadequately" +385, 15, 23, 422, 170, 180, 2040, 2050, "controlled" +385, 15, 24, 423, 181, 185, 2051, 2055, "with" +385, 15, 25, 424, 186, 195, 2056, 2065, "metformin" +385, 15, 26, 425, 196, 197, 2066, 2067, "." +385, 16, 1, 426, 0, 12, 2068, 2080, "Nevertheless" +385, 16, 2, 427, 13, 14, 2081, 2082, "," +385, 16, 3, 428, 15, 26, 2083, 2094, "sitagliptin" +385, 16, 4, 429, 27, 30, 2095, 2098, "was" +385, 16, 5, 430, 31, 35, 2099, 2103, "more" +385, 16, 6, 431, 36, 45, 2104, 2113, "effective" +385, 16, 7, 432, 46, 50, 2114, 2118, "than" +385, 16, 8, 433, 51, 63, 2119, 2131, "pioglitazone" +385, 16, 9, 434, 64, 73, 2132, 2141, "regarding" +385, 16, 10, 435, 74, 79, 2142, 2147, "lipid" +385, 16, 11, 436, 80, 83, 2148, 2151, "and" +385, 16, 12, 437, 84, 88, 2152, 2156, "body" +385, 16, 13, 438, 89, 95, 2157, 2163, "weight" +385, 16, 14, 439, 96, 102, 2164, 2170, "change" +385, 16, 15, 440, 103, 104, 2171, 2172, "." +385, 17, 1, 441, 0, 3, 2173, 2176, "DOI" +385, 17, 2, 442, 4, 5, 2177, 2178, ":" +385, 17, 3, 443, 6, 8, 2179, 2181, "10" +385, 17, 4, 444, 9, 10, 2182, 2183, "." +385, 17, 5, 445, 11, 15, 2184, 2188, "3889" +385, 17, 6, 446, 16, 17, 2189, 2190, "/" +385, 17, 7, 447, 18, 24, 2191, 2197, "oamjms" +385, 17, 8, 448, 25, 26, 2198, 2199, "." +385, 17, 9, 449, 27, 31, 2200, 2204, "2017" +385, 17, 10, 450, 32, 33, 2205, 2206, "." +385, 17, 11, 451, 34, 37, 2207, 2210, "193" +385, 17, 12, 452, 38, 43, 2211, 2216, "PMCID" +385, 17, 13, 453, 44, 45, 2217, 2218, ":" +385, 17, 14, 454, 46, 56, 2219, 2229, "PMC5771302" +385, 17, 15, 455, 57, 61, 2230, 2234, "PMID" +385, 17, 16, 456, 62, 63, 2235, 2236, ":" +385, 17, 17, 457, 64, 72, 2237, 2245, "29362626" diff --git a/data/dm2 29362626_kwoodley.annodb b/data/dm2 29362626_kwoodley.annodb new file mode 100644 index 0000000..7ad421d --- /dev/null +++ b/data/dm2 29362626_kwoodley.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72996, Journal, 0, 27, "Open Access Maced J Med Sci", "", +73087, PublicationYear, 30, 34, "2017", "", +73128, Title, 132, 272, "Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin .", "", +73089, Pioglitazone, 160, 172, "Pioglitazone", "", +73101, Sitagliptin, 176, 187, "Sitagliptin", "", +73123, Precondition, 191, 270, "Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin", "", +73112, Type2Diabetes, 205, 229, "Type 2 Diabetes Mellitus", "", +73119, Metformin, 261, 270, "Metformin", "", +73130, Author, 273, 286, "Jameshorani M", "", +73131, Author, 295, 303, "Sayari S", "", +73132, Author, 312, 324, "Kiahashemi N", "", +73134, Author, 333, 342, "Motamed N", "", +73135, Iran, 513, 517, "Iran", "", +73136, Iran, 612, 616, "Iran", "", +73137, Type2Diabetes, 632, 649, "Diabetes mellitus", "", +73139, ObjectiveDescription, 724, 879, "This study aimed to compare and study of add - on sitagliptin versus pioglitazone in patients with type 2 diabetes inadequately controlled with metformin .", "", +73102, Sitagliptin, 774, 785, "sitagliptin", "", +73091, Pioglitazone, 793, 805, "pioglitazone", "", +73138, Precondition, 809, 877, "patients with type 2 diabetes inadequately controlled with metformin", "", +73114, Type2Diabetes, 823, 838, "type 2 diabetes", "", +73120, Metformin, 868, 877, "metformin", "", +73140, Duration, 895, 904, "12 - week", "", +73141, Randomized, 907, 917, "randomised", "", +73142, OpenLabel, 920, 932, "open - label", "", +73143, SingleCenter, 937, 950, "single centre", "", +73104, Sitagliptin, 966, 977, "sitagliptin", "", +73144, DoseValue, 980, 983, "100", "", +73146, mg, 984, 986, "mg", "", +73148, Frequency, 987, 992, "daily", "", +73150, NumberPatientsArm, 999, 1001, "80", "", +73092, Pioglitazone, 1008, 1020, "pioglitazone", "", +73145, DoseValue, 1023, 1025, "30", "", +73147, mg, 1026, 1028, "mg", "", +73149, Frequency, 1029, 1034, "daily", "", +73151, NumberPatientsArm, 1041, 1043, "80", "", +73115, Type2Diabetes, 1049, 1064, "type 2 diabetic", "", +73124, Precondition, 1049, 1132, "type 2 diabetic patients whose disease was not adequately controlled with metformin", "", +73121, Metformin, 1123, 1132, "metformin", "", +73152, HbA1c, 1164, 1169, "HbA1c", "", +73153, TimePoint, 1175, 1183, "baseline", "", +73154, Reduction, 1190, 1197, "1 . 001", "", +73156, SdDevChangeValue, 1200, 1206, "0 . 83", "", +73106, Sitagliptin, 1212, 1223, "sitagliptin", "", +73155, Reduction, 1230, 1236, "0 . 75", "", +73157, SdDevChangeValue, 1239, 1245, "1 . 20", "", +73093, Pioglitazone, 1251, 1263, "pioglitazone", "", +73158, PvalueDiff, 1324, 1335, "P = 0 . 132", "", +73159, FastingBloodGlucose, 1359, 1378, "fasting blood sugar", "", +73160, FastingBloodGlucose, 1381, 1384, "FBS", "", +73161, Reduction, 1393, 1400, "18 . 48", "", +73164, SdDevChangeValue, 1403, 1410, "33 . 32", "", +73167, Mg_per_deciliter, 1411, 1418, "mg / dl", "", +73107, Sitagliptin, 1424, 1435, "sitagliptin", "", +73163, Reduction, 1442, 1449, "20 . 53", "", +73166, SdDevChangeValue, 1452, 1459, "53 . 97", "", +73168, Mg_per_deciliter, 1460, 1467, "mg / dl", "", +73094, Pioglitazone, 1473, 1485, "pioglitazone", "", +73169, PvalueDiff, 1546, 1557, "P = 0 . 773", "", +73108, Sitagliptin, 1562, 1573, "Sitagliptin", "", +73170, Reduction, 1581, 1587, "1 . 08", "", +73172, SdDevChangeValue, 1590, 1596, "2 . 39", "", +73174, Kg, 1597, 1599, "kg", "", +73178, BodyWeight, 1612, 1618, "weight", "", +73095, Pioglitazone, 1629, 1641, "pioglitazone", "", +73171, Increment, 1649, 1655, "0 . 27", "", +73173, SdDevChangeValue, 1658, 1664, "2 . 42", "", +73175, Kg, 1665, 1667, "kg", "", +73180, BodyWeight, 1680, 1686, "weight", "", +73181, DiffGroupAbsValue, 1726, 1732, "0 . 81", "", +73177, Kg, 1733, 1735, "kg", "", +73182, PvalueDiff, 1738, 1749, "P < 0 . 001", "", +73184, ObservedResult, 1774, 1867, "in sitagliptin group , there was greater improvement in lipid profile than pioglitazone group", "", +73109, Sitagliptin, 1777, 1788, "sitagliptin", "", +73183, EndPointDescription, 1830, 1843, "lipid profile", "", +73097, Pioglitazone, 1849, 1861, "pioglitazone", "", +73110, Sitagliptin, 1883, 1894, "Sitagliptin", "", +73187, ConclusionComment, 1883, 2067, "Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin .", "", +73099, Pioglitazone, 1899, 1911, "Pioglitazone", "", +73117, Type2Diabetes, 1969, 1993, "type 2 diabetes mellitus", "", +73126, Precondition, 1969, 2065, "type 2 diabetes mellitus patients whose diabetes had been inadequately controlled with metformin", "", +73122, Metformin, 2056, 2065, "metformin", "", +73188, ConclusionComment, 2068, 2172, "Nevertheless , sitagliptin was more effective than pioglitazone regarding lipid and body weight change .", "", +73111, Sitagliptin, 2083, 2094, "sitagliptin", "", +73100, Pioglitazone, 2119, 2131, "pioglitazone", "", +73185, EndPointDescription, 2142, 2147, "lipid", "", +73186, BodyWeight, 2152, 2163, "body weight", "", +73189, PMID, 2237, 2245, "29362626", "", diff --git a/data/dm2 29362626_kwoodley.n-triples b/data/dm2 29362626_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29362626_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29862619_admin.annodb b/data/dm2 29862619_admin.annodb new file mode 100644 index 0000000..971f7b6 --- /dev/null +++ b/data/dm2 29862619_admin.annodb @@ -0,0 +1,141 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2018", "", " \"2018\"." +30, Title, 110, 305, "Efficacy and safety of ipragliflozin as an add - on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus : A randomized controlled trial .", "", " \"Efficacy and safety of ipragliflozin as an add - on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus : A randomized controlled trial .\"." +2, Drug, 133, 146, "ipragliflozin", "", +11, Sitagliptin, 173, 184, "sitagliptin", "", +15, Metformin, 189, 198, "metformin", "", +19, Ethnicity, 202, 208, "Korean", "", +28, Precondition, 209, 271, "patients with inadequately controlled type 2 diabetes mellitus", "", " \"patients with inadequately controlled type 2 diabetes mellitus\"." +22, Type2Diabetes, 247, 271, "type 2 diabetes mellitus", "", " ." +26, Randomized, 276, 286, "randomized", "", " ." +31, Author, 306, 312, "Han KA", "", " \"Han KA\"." +32, Author, 321, 327, "Chon S", "", " \"Chon S\"." +33, Author, 336, 344, "Chung CH", "", " \"Chung CH\"." +34, Author, 353, 358, "Lim S", "", " \"Lim S\"." +35, Author, 367, 373, "Lee KW", "", " \"Lee KW\"." +36, Author, 382, 388, "Baik S", "", " \"Baik S\"." +37, Author, 397, 404, "Jung CH", "", " \"Jung CH\"." +38, Author, 413, 419, "Kim DS", "", " \"Kim DS\"." +39, Author, 428, 435, "Park KS", "", " \"Park KS\"." +40, Author, 444, 451, "Yoon KH", "", " \"Yoon KH\"." +41, Author, 461, 467, "Lee IK", "", " \"Lee IK\"." +42, Author, 477, 483, "Cha BS", "", " \"Cha BS\"." +43, Author, 493, 503, "Sakatani T", "", " \"Sakatani T\"." +44, Author, 513, 519, "Park S", "", " \"Park S\"." +45, Author, 529, 535, "Lee MK", "", " \"Lee MK\"." +46, SouthKorea, 628, 633, "Korea", "", +47, SouthKorea, 682, 687, "Korea", "", +48, SouthKorea, 761, 766, "Korea", "", +49, SouthKorea, 881, 886, "Korea", "", +50, SouthKorea, 935, 940, "Korea", "", +51, SouthKorea, 990, 995, "Korea", "", +52, SouthKorea, 1121, 1126, "Korea", "", +53, SouthKorea, 1218, 1223, "Korea", "", +54, SouthKorea, 1322, 1327, "Korea", "", +55, SouthKorea, 1459, 1464, "Korea", "", +56, SouthKorea, 1557, 1562, "Korea", "", +57, SouthKorea, 1653, 1658, "Korea", "", +60, Japan, 1764, 1769, "Japan", "", +58, SouthKorea, 1869, 1874, "Korea", "", +59, SouthKorea, 1987, 1992, "Korea", "", +68, ObjectiveDescription, 2001, 2173, "To evaluate the efficacy and safety of ipragliflozin vs placebo as add - on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus ( T2DM ) .", "", " \"To evaluate the efficacy and safety of ipragliflozin vs placebo as add - on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus ( T2DM ) .\"." +3, Drug, 2040, 2053, "ipragliflozin", "", +61, Placebo, 2057, 2064, "placebo", "", +16, Metformin, 2088, 2097, "metformin", "", +12, Sitagliptin, 2102, 2113, "sitagliptin", "", +20, Ethnicity, 2117, 2123, "Korean", "", " . ." +23, Type2Diabetes, 2138, 2162, "type 2 diabetes mellitus", "", +24, Type2Diabetes, 2165, 2169, "T2DM", "", +69, DoubleBlind, 2189, 2203, "double - blind", "", " ." +70, Placebo, 2206, 2213, "placebo", "", +71, Multicenter, 2229, 2243, "multi - centre", "", " ." +72, SouthKorea, 2279, 2284, "Korea", "", " ." +73, Duration, 2288, 2300, "2015 to 2017", "", +27, Randomized, 2317, 2327, "randomized", "", +4, Drug, 2346, 2359, "ipragliflozin", "", " . ." +74, DoseValue, 2360, 2362, "50", "", " \"50\"." +75, mg, 2363, 2365, "mg", "", " ." +76, Frequency, 2368, 2371, "day", "", " \"day\"." +62, Placebo, 2375, 2382, "placebo", "", " ." +77, Frequency, 2383, 2393, "once daily", "", " \"once daily\"." +78, Duration, 2398, 2406, "24 weeks", "", " \"24 weeks\"." +106278, Precondition, 2410, 2447, "addition to metformin and sitagliptin", "", " \"addition to metformin and sitagliptin\"." +17, Metformin, 2422, 2431, "metformin", "", +13, Sitagliptin, 2436, 2447, "sitagliptin", "", +79, HbA1c, 2489, 2509, "glycated haemoglobin", "", +80, HbA1c, 2512, 2517, "HbA1c", "", +81, TimePoint, 2525, 2533, "baseline", "", +82, TimePoint, 2537, 2553, "end of treatment", "", +83, TimePoint, 2556, 2559, "EOT", "", +88, NumberPatientsCT, 2585, 2588, "143", "", " \"143\"." +89, Randomized, 2603, 2613, "randomized", "", +90, FinalNumPatientsCT, 2618, 2621, "139", "", " \"139\"." +5, Drug, 2659, 2672, "ipragliflozin", "", +91, FinalNumPatientsArm, 2675, 2677, "73", "", " \"73\"." +63, Placebo, 2680, 2687, "placebo", "", +92, FinalNumPatientsArm, 2690, 2692, "66", "", " \"66\"." +208, TimePoint, 2697, 2705, "Baseline", "", +212, Mean, 2706, 2710, "mean", "", " . ." +94, HbA1c, 2718, 2723, "HbA1c", "", " ." +95, BaseLineValue, 2736, 2742, "7 . 90", "", " \"7 . 90\"." +216, SdDevBL, 2745, 2751, "0 . 69", "", " \"0 . 69\"." +99, Percentage, 2754, 2755, "%", "", " ." +6, Drug, 2760, 2773, "ipragliflozin", "", +97, BaseLineValue, 2787, 2793, "7 . 92", "", " \"7 . 92\"." +217, SdDevBL, 2796, 2802, "0 . 79", "", " \"0 . 79\"." +100, Percentage, 2805, 2806, "%", "", +64, Placebo, 2811, 2818, "placebo", "", +222, Mean, 2839, 2843, "mean", "", +84, TimePoint, 2864, 2872, "baseline", "", +85, TimePoint, 2876, 2879, "EOT", "", " \"EOT\". \"EOT\"." +102, Reduction, 2887, 2893, "0 . 79", "", " \"0 . 79\"." +225, SdDevChangeValue, 2896, 2902, "0 . 59", "", " \"0 . 59\"." +106, Percentage, 2905, 2906, "%", "", +104, Increment, 2911, 2917, "0 . 03", "", " \"0 . 03\"." +226, SdDevChangeValue, 2920, 2926, "0 . 84", "", " \"0 . 84\"." +107, Percentage, 2929, 2930, "%", "", +7, Drug, 2961, 2974, "ipragliflozin", "", +240, Mean, 2986, 2990, "mean", "", +109, DiffGroupAbsValue, 3002, 3010, "- 0 . 83", "", " \"- 0 . 83\"." +108, Percentage, 3011, 3012, "%", "", +110, ConfIntervalDiff, 3015, 3043, "95 % CI - 1 . 07 to - 0 . 59", "", " \"95 % CI - 1 . 07 to - 0 . 59\"." +111, PvalueDiff, 3048, 3058, "P < . 0001", "", " \"P < . 0001\"." +8, Drug, 3068, 3081, "ipragliflozin", "", +65, Placebo, 3106, 3113, "placebo", "", +112, HbA1c_target, 3142, 3174, "HbA1c target levels of < 7 . 0 %", "", " ." +231, Percentage, 3173, 3174, "%", "", +114, PercentageAffected, 3177, 3183, "44 . 4", "", " \"44 . 4\"." +115, PercentageAffected, 3189, 3195, "12 . 1", "", " \"12 . 1\"." +113, HbA1c_target, 3204, 3213, "< 6 . 5 %", "", " ." +116, PercentageAffected, 3216, 3222, "12 . 5", "", " \"12 . 5\"." +117, PercentageAffected, 3228, 3233, "1 . 5", "", " \"1 . 5\"." +86, TimePoint, 3241, 3244, "EOT", "", " \"EOT\". \"EOT\". \"EOT\". \"EOT\"." +262, PvalueDiff, 3247, 3255, "P < . 05", "", " \"P < . 05\". \"P < . 05\"." +119, FastingPlasmaGlucose, 3269, 3291, "Fasting plasma glucose", "", " ." +120, EndPointDescription, 3294, 3315, "fasting serum insulin", "", " . ." +122, BodyWeight, 3318, 3329, "body weight", "", " . ." +121, EndPointDescription, 3334, 3384, "homeostatic model assessment of insulin resistance", "", " . ." +87, TimePoint, 3412, 3415, "EOT", "", " \"EOT\". \"EOT\". \"EOT\". \"EOT\". \"EOT\". \"EOT\". \"EOT\". \"EOT\"." +9, Drug, 3431, 3444, "ipragliflozin", "", +256, Mean, 3456, 3460, "mean", "", " . . . . . . . ." +123, DiffGroupAbsValue, 3472, 3480, "- 1 . 64", "", " \"- 1 . 64\"." +127, Millimoles_per_litre, 3481, 3489, "mmol / L", "", " ." +124, DiffGroupAbsValue, 3492, 3500, "- 1 . 50", "", " \"- 1 . 50\"." +128, MicroUnits_per_milliliter, 3501, 3509, "μ U / mL", "", " ." +125, DiffGroupAbsValue, 3512, 3520, "- 1 . 72", "", " \"- 1 . 72\"." +129, Kg, 3521, 3523, "kg", "", " ." +126, DiffGroupAbsValue, 3530, 3538, "- 0 . 99", "", " \"- 0 . 99\"." +130, PvalueDiff, 3556, 3564, "P < . 05", "", " \"P < . 05\". \"P < . 05\". \"P < . 05\". \"P < . 05\"." +131, EndPointDescription, 3577, 3590, "Adverse event", "", " . ." +67, Drug, 3627, 3640, "ipragliflozin", "", +96321, NumberAffected, 3643, 3649, "51 . 4", "", " \"51 . 4\"." +66, Placebo, 3654, 3661, "placebo", "", +96325, NumberAffected, 3664, 3670, "50 . 0", "", " \"50 . 0\"." +10, Drug, 3745, 3758, "Ipragliflozin", "", +134, ConclusionComment, 3745, 3936, "Ipragliflozin as add - on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM .", "", " \"Ipragliflozin as add - on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM .\"." +18, Metformin, 3774, 3783, "metformin", "", +14, Sitagliptin, 3788, 3799, "sitagliptin", "", +21, Ethnicity, 3885, 3891, "Korean", "", +25, Type2Diabetes, 3930, 3934, "T2DM", "", +135, PMID, 4085, 4093, "29862619", "", " \"29862619\"." diff --git a/data/dm2 29862619_admin.n-triples b/data/dm2 29862619_admin.n-triples new file mode 100644 index 0000000..e8f3bd3 --- /dev/null +++ b/data/dm2 29862619_admin.n-triples @@ -0,0 +1,283 @@ +# RDF export of group: Publication + . + "Publication 81801" . + "Efficacy and safety of ipragliflozin as an add - on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus : A randomized controlled trial ." . + "Han KA" . + "2018" . + "Diabetes Obes Metab ." . + "29862619" . + . + "Chon S" . + "Chung CH" . + "Lim S" . + "Lee KW" . + "Baik S" . + "Jung CH" . + "Kim DS" . + "Park KS" . + "Yoon KH" . + "Lee IK" . + "Cha BS" . + "Sakatani T" . + "Park S" . + "Lee MK" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 81808" . + "To evaluate the efficacy and safety of ipragliflozin vs placebo as add - on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus ( T2DM ) ." . + "143" . + "24 weeks" . + . + . + . + "Ipragliflozin as add - on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM ." . + . + . + . + . + . + "139" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 81824" . + "patients with inadequately controlled type 2 diabetes mellitus" . + . + . + . + . + "addition to metformin and sitagliptin" . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "hbat2" . + . + . + . + . + . + "fpg" . + . + . + . + . + . + . + "fsi" . + . + . + . + . + . + . + . + "bw" . + . + . + . + . + . + . + "hom" . + . + . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "ip" . + "73" . + . + . + . + . + . + . + . + . + . + . + "pla" . + "66" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "ip" . + . + "day" . + . + . + "pl" . + . + "once daily" . + . +# RDF export of group: Medication + . + "ip" . + . + . + "50" . + . + . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 90" . + "0 . 69" . + "0 . 79" . + "0 . 59" . + "EOT" . + . + "hba 2" . + . + "7 . 92" . + "0 . 79" . + "0 . 03" . + "0 . 84" . + "EOT" . + . + "hbat 1" . + . + "44 . 4" . + "EOT" . + . + "hbat 2" . + . + "12 . 1" . + "EOT" . + . + "hbat2 1" . + . + "12 . 5" . + "EOT" . + . + "hbat2 2" . + . + "1 . 5" . + "EOT" . + . + "fpg 1" . + . + "EOT" . + . + "fpg 2" . + . + "EOT" . + . + "fsi 1" . + . + "EOT" . + . + "fsi 2" . + . + "EOT" . + . + "bw 1" . + . + "EOT" . + . + "bw 2" . + . + "EOT" . + . + "hom 1" . + . + "EOT" . + . + "hom 2" . + . + "EOT" . + . + "ae 1" . + . + "51 . 4" . + . + "are 2" . + . + "50 . 0" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 83" . + "P < . 0001" . + "95 % CI - 1 . 07 to - 0 . 59" . + . + . + . + "hbat1" . + "P < . 05" . + . + . + . + "hbat2" . + "P < . 05" . + . + . + . + "fpg" . + "- 1 . 64" . + "P < . 05" . + . + . + . + "fsi" . + "- 1 . 50" . + "P < . 05" . + . + . + . + "bw" . + "- 1 . 72" . + "P < . 05" . + . + . + . + "hom" . + "- 0 . 99" . + "P < . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29862619_akramersunderbrink.annodb b/data/dm2 29862619_akramersunderbrink.annodb new file mode 100644 index 0000000..b7cf0f3 --- /dev/null +++ b/data/dm2 29862619_akramersunderbrink.annodb @@ -0,0 +1,146 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +74031, Journal, 0, 19, "Diabetes Obes Metab", "", +74032, PublicationYear, 22, 26, "2018", "", +74039, Title, 110, 305, "Efficacy and safety of ipragliflozin as an add - on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus : A randomized controlled trial .", "", +74033, Drug, 133, 146, "ipragliflozin", "", +74034, Sitagliptin, 173, 184, "sitagliptin", "", +74035, Metformin, 189, 198, "metformin", "", +74036, Ethnicity, 202, 208, "Korean", "", +74037, Type2Diabetes, 247, 271, "type 2 diabetes mellitus", "", +74038, Randomized, 276, 286, "randomized", "", +74040, Author, 306, 312, "Han KA", "", +74041, Author, 321, 327, "Chon S", "", +74042, Author, 336, 344, "Chung CH", "", +74043, Author, 353, 358, "Lim S", "", +74044, Author, 367, 373, "Lee KW", "", +74045, Author, 382, 388, "Baik S", "", +74046, Author, 397, 404, "Jung CH", "", +74047, Author, 413, 419, "Kim DS", "", +74048, Author, 428, 435, "Park KS", "", +74049, Author, 444, 451, "Yoon KH", "", +74051, Author, 461, 467, "Lee IK", "", +74050, Author, 477, 483, "Cha BS", "", +74052, Author, 493, 503, "Sakatani T", "", +74053, Author, 513, 519, "Park S", "", +74054, Author, 529, 535, "Lee MK", "", +74055, SouthKorea, 628, 633, "Korea", "", +74056, SouthKorea, 682, 687, "Korea", "", +74057, SouthKorea, 761, 766, "Korea", "", +74058, SouthKorea, 881, 886, "Korea", "", +74059, SouthKorea, 935, 940, "Korea", "", +74060, SouthKorea, 990, 995, "Korea", "", +74061, SouthKorea, 1121, 1126, "Korea", "", +74062, SouthKorea, 1218, 1223, "Korea", "", +74063, SouthKorea, 1322, 1327, "Korea", "", +74065, SouthKorea, 1459, 1464, "Korea", "", +74066, SouthKorea, 1557, 1562, "Korea", "", +74067, SouthKorea, 1653, 1658, "Korea", "", +74070, Japan, 1764, 1769, "Japan", "", +74068, SouthKorea, 1869, 1874, "Korea", "", +74069, SouthKorea, 1987, 1992, "Korea", "", +74078, ObjectiveDescription, 2001, 2173, "To evaluate the efficacy and safety of ipragliflozin vs placebo as add - on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus ( T2DM ) .", "", +74071, Drug, 2040, 2053, "ipragliflozin", "", +74072, Placebo, 2057, 2064, "placebo", "", +74073, Metformin, 2088, 2097, "metformin", "", +74074, Sitagliptin, 2102, 2113, "sitagliptin", "", +74075, Ethnicity, 2117, 2123, "Korean", "", +74076, Type2Diabetes, 2138, 2162, "type 2 diabetes mellitus", "", +74077, Type2Diabetes, 2165, 2169, "T2DM", "", +74079, DoubleBlind, 2189, 2203, "double - blind", "", +74080, Placebo, 2206, 2213, "placebo", "", +74081, Multicenter, 2229, 2243, "multi - centre", "", +74082, SouthKorea, 2279, 2284, "Korea", "", +74083, Randomized, 2317, 2327, "randomized", "", +74084, Drug, 2346, 2359, "ipragliflozin", "", +74088, DoseValue, 2360, 2371, "50 mg / day", "", +74089, BioAndMedicalUnit, 2363, 2371, "mg / day", "", +74085, Placebo, 2375, 2382, "placebo", "", +74090, Frequency, 2383, 2393, "once daily", "", +74091, Duration, 2398, 2406, "24 weeks", "", +74086, Metformin, 2422, 2431, "metformin", "", +74087, Sitagliptin, 2436, 2447, "sitagliptin", "", +74092, HbA1c, 2489, 2509, "glycated haemoglobin", "", +74093, HbA1c, 2512, 2517, "HbA1c", "", +74094, TimePoint, 2525, 2533, "baseline", "", +74095, TimePoint, 2537, 2553, "end of treatment", "", +74096, TimePoint, 2556, 2559, "EOT", "", +74097, NumberPatientsCT, 2585, 2588, "143", "", +74099, Randomized, 2603, 2613, "randomized", "", +74098, FinalNumPatientsCT, 2618, 2621, "139", "", +74100, Drug, 2659, 2672, "ipragliflozin", "", +74102, FinalNumPatientsArm, 2675, 2677, "73", "", +74101, Placebo, 2680, 2687, "placebo", "", +74103, FinalNumPatientsArm, 2690, 2692, "66", "", +74104, TimePoint, 2697, 2705, "Baseline", "", +74108, Mean, 2706, 2710, "mean", "", +74109, HbA1c, 2718, 2723, "HbA1c", "", +74110, BaseLineValue, 2736, 2742, "7 . 90", "", +74112, SdDevBL, 2745, 2751, "0 . 69", "", +74114, Percentage, 2754, 2755, "%", "", +74116, Drug, 2760, 2773, "ipragliflozin", "", +74111, BaseLineValue, 2787, 2793, "7 . 92", "", +74113, SdDevBL, 2796, 2802, "0 . 79", "", +74115, Percentage, 2805, 2806, "%", "", +74117, Placebo, 2811, 2818, "placebo", "", +74118, Mean, 2839, 2843, "mean", "", +74106, TimePoint, 2864, 2872, "baseline", "", +74105, TimePoint, 2876, 2879, "EOT", "", +74119, ChangeValue, 2885, 2893, "- 0 . 79", "", +74121, SdDevChangeValue, 2896, 2902, "0 . 59", "", +74123, Percentage, 2905, 2906, "%", "", +74120, ChangeValue, 2911, 2917, "0 . 03", "", +74122, SdDevChangeValue, 2920, 2926, "0 . 84", "", +74124, Percentage, 2929, 2930, "%", "", +74135, Drug, 2961, 2974, "ipragliflozin", "", +74136, Mean, 2986, 2990, "mean", "", +74137, DiffGroupAbsValue, 3002, 3010, "- 0 . 83", "", +74125, Percentage, 3011, 3012, "%", "", +74138, ConfIntervalDiff, 3015, 3043, "95 % CI - 1 . 07 to - 0 . 59", "", +74126, Percentage, 3018, 3019, "%", "", +74139, PvalueDiff, 3048, 3058, "P < . 0001", "", +74140, Drug, 3068, 3081, "ipragliflozin", "", +74141, Placebo, 3106, 3113, "placebo", "", +74142, HbA1c_target, 3142, 3174, "HbA1c target levels of < 7 . 0 %", "", +74127, Percentage, 3173, 3174, "%", "", +74143, PercentageAffected, 3177, 3183, "44 . 4", "", +74128, Percentage, 3184, 3185, "%", "", +74144, PercentageAffected, 3189, 3195, "12 . 1", "", +74129, Percentage, 3196, 3197, "%", "", +74145, HbA1c_target, 3204, 3213, "< 6 . 5 %", "", +74130, Percentage, 3212, 3213, "%", "", +74146, PercentageAffected, 3216, 3222, "12 . 5", "", +74131, Percentage, 3223, 3224, "%", "", +74147, PercentageAffected, 3228, 3233, "1 . 5", "", +74132, Percentage, 3234, 3235, "%", "", +74148, TimePoint, 3241, 3244, "EOT", "", +74159, PvalueDiff, 3247, 3255, "P < . 05", "", +74150, FastingPlasmaGlucose, 3269, 3291, "Fasting plasma glucose", "", +74160, EndPointDescription, 3294, 3315, "fasting serum insulin", "", +74151, BodyWeight, 3318, 3329, "body weight", "", +74161, EndPointDescription, 3334, 3384, "homeostatic model assessment of insulin resistance", "", +74107, TimePoint, 3412, 3415, "EOT", "", +74152, Drug, 3431, 3444, "ipragliflozin", "", +74153, Mean, 3456, 3460, "mean", "", +74154, ChangeValue, 3472, 3480, "- 1 . 64", "", +74162, Millimoles_per_litre, 3481, 3489, "mmol / L", "", +74155, ChangeValue, 3492, 3500, "- 1 . 50", "", +74163, MicroUnits_per_milliliter, 3501, 3509, "μ U / mL", "", +74156, ChangeValue, 3512, 3520, "- 1 . 72", "", +74164, Kg, 3521, 3523, "kg", "", +74157, ChangeValue, 3530, 3538, "- 0 . 99", "", +74158, PvalueDiff, 3556, 3564, "P < . 05", "", +74165, EndPointDescription, 3577, 3596, "Adverse event rates", "", +74166, Drug, 3627, 3640, "ipragliflozin", "", +74168, ResultMeasuredValue, 3643, 3649, "51 . 4", "", +74133, Percentage, 3650, 3651, "%", "", +74167, Placebo, 3654, 3661, "placebo", "", +74169, ResultMeasuredValue, 3664, 3670, "50 . 0", "", +74134, Percentage, 3671, 3672, "%", "", +74170, Drug, 3745, 3758, "Ipragliflozin", "", +74176, ConclusionComment, 3745, 3936, "Ipragliflozin as add - on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM .", "", +74171, Metformin, 3774, 3783, "metformin", "", +74172, Sitagliptin, 3788, 3799, "sitagliptin", "", +74173, Ethnicity, 3885, 3891, "Korean", "", +74174, Precondition, 3906, 3929, "inadequately controlled", "", +74175, Type2Diabetes, 3930, 3934, "T2DM", "", +74177, PMID, 4085, 4093, "29862619", "", diff --git a/data/dm2 29862619_akramersunderbrink.n-triples b/data/dm2 29862619_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29862619_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 29862619_export.csv b/data/dm2 29862619_export.csv new file mode 100644 index 0000000..e8978e3 --- /dev/null +++ b/data/dm2 29862619_export.csv @@ -0,0 +1,890 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +381, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +381, 1, 2, 2, 9, 13, 9, 13, "Obes" +381, 1, 3, 3, 14, 19, 14, 19, "Metab" +381, 1, 4, 4, 20, 21, 20, 21, "." +381, 2, 1, 5, 0, 4, 22, 26, "2018" +381, 2, 2, 6, 5, 8, 27, 30, "Oct" +381, 2, 3, 7, 9, 10, 31, 32, ";" +381, 2, 4, 8, 11, 13, 33, 35, "20" +381, 2, 5, 9, 14, 15, 36, 37, "(" +381, 2, 6, 10, 16, 18, 38, 40, "10" +381, 2, 7, 11, 19, 20, 41, 42, ")" +381, 2, 8, 12, 21, 22, 43, 44, ":" +381, 2, 9, 13, 23, 27, 45, 49, "2408" +381, 2, 10, 14, 28, 29, 50, 51, "-" +381, 2, 11, 15, 30, 34, 52, 56, "2415" +381, 2, 12, 16, 35, 36, 57, 58, "." +381, 2, 13, 17, 37, 40, 59, 62, "doi" +381, 2, 14, 18, 41, 42, 63, 64, ":" +381, 2, 15, 19, 43, 45, 65, 67, "10" +381, 2, 16, 20, 46, 47, 68, 69, "." +381, 2, 17, 21, 48, 52, 70, 74, "1111" +381, 2, 18, 22, 53, 54, 75, 76, "/" +381, 2, 19, 23, 55, 58, 77, 80, "dom" +381, 2, 20, 24, 59, 60, 81, 82, "." +381, 2, 21, 25, 61, 66, 83, 88, "13394" +381, 2, 22, 26, 67, 68, 89, 90, "." +381, 3, 1, 27, 0, 4, 91, 95, "Epub" +381, 3, 2, 28, 5, 9, 96, 100, "2018" +381, 3, 3, 29, 10, 13, 101, 104, "Jul" +381, 3, 4, 30, 14, 16, 105, 107, "16" +381, 3, 5, 31, 17, 18, 108, 109, "." +381, 4, 1, 32, 0, 8, 110, 118, "Efficacy" +381, 4, 2, 33, 9, 12, 119, 122, "and" +381, 4, 3, 34, 13, 19, 123, 129, "safety" +381, 4, 4, 35, 20, 22, 130, 132, "of" +381, 4, 5, 36, 23, 36, 133, 146, "ipragliflozin" +381, 4, 6, 37, 37, 39, 147, 149, "as" +381, 4, 7, 38, 40, 42, 150, 152, "an" +381, 4, 8, 39, 43, 46, 153, 156, "add" +381, 4, 9, 40, 47, 48, 157, 158, "-" +381, 4, 10, 41, 49, 51, 159, 161, "on" +381, 4, 11, 42, 52, 59, 162, 169, "therapy" +381, 4, 12, 43, 60, 62, 170, 172, "to" +381, 4, 13, 44, 63, 74, 173, 184, "sitagliptin" +381, 4, 14, 45, 75, 78, 185, 188, "and" +381, 4, 15, 46, 79, 88, 189, 198, "metformin" +381, 4, 16, 47, 89, 91, 199, 201, "in" +381, 4, 17, 48, 92, 98, 202, 208, "Korean" +381, 4, 18, 49, 99, 107, 209, 217, "patients" +381, 4, 19, 50, 108, 112, 218, 222, "with" +381, 4, 20, 51, 113, 125, 223, 235, "inadequately" +381, 4, 21, 52, 126, 136, 236, 246, "controlled" +381, 4, 22, 53, 137, 141, 247, 251, "type" +381, 4, 23, 54, 142, 143, 252, 253, "2" +381, 4, 24, 55, 144, 152, 254, 262, "diabetes" +381, 4, 25, 56, 153, 161, 263, 271, "mellitus" +381, 4, 26, 57, 162, 163, 272, 273, ":" +381, 4, 27, 58, 164, 165, 274, 275, "A" +381, 4, 28, 59, 166, 176, 276, 286, "randomized" +381, 4, 29, 60, 177, 187, 287, 297, "controlled" +381, 4, 30, 61, 188, 193, 298, 303, "trial" +381, 4, 31, 62, 194, 195, 304, 305, "." +381, 5, 1, 63, 0, 3, 306, 309, "Han" +381, 5, 2, 64, 4, 6, 310, 312, "KA" +381, 5, 3, 65, 7, 8, 313, 314, "(" +381, 5, 4, 66, 9, 10, 315, 316, "1" +381, 5, 5, 67, 11, 12, 317, 318, ")" +381, 5, 6, 68, 13, 14, 319, 320, "," +381, 5, 7, 69, 15, 19, 321, 325, "Chon" +381, 5, 8, 70, 20, 21, 326, 327, "S" +381, 5, 9, 71, 22, 23, 328, 329, "(" +381, 5, 10, 72, 24, 25, 330, 331, "2" +381, 5, 11, 73, 26, 27, 332, 333, ")" +381, 5, 12, 74, 28, 29, 334, 335, "," +381, 5, 13, 75, 30, 35, 336, 341, "Chung" +381, 5, 14, 76, 36, 38, 342, 344, "CH" +381, 5, 15, 77, 39, 40, 345, 346, "(" +381, 5, 16, 78, 41, 42, 347, 348, "3" +381, 5, 17, 79, 43, 44, 349, 350, ")" +381, 5, 18, 80, 45, 46, 351, 352, "," +381, 5, 19, 81, 47, 50, 353, 356, "Lim" +381, 5, 20, 82, 51, 52, 357, 358, "S" +381, 5, 21, 83, 53, 54, 359, 360, "(" +381, 5, 22, 84, 55, 56, 361, 362, "4" +381, 5, 23, 85, 57, 58, 363, 364, ")" +381, 5, 24, 86, 59, 60, 365, 366, "," +381, 5, 25, 87, 61, 64, 367, 370, "Lee" +381, 5, 26, 88, 65, 67, 371, 373, "KW" +381, 5, 27, 89, 68, 69, 374, 375, "(" +381, 5, 28, 90, 70, 71, 376, 377, "5" +381, 5, 29, 91, 72, 73, 378, 379, ")" +381, 5, 30, 92, 74, 75, 380, 381, "," +381, 5, 31, 93, 76, 80, 382, 386, "Baik" +381, 5, 32, 94, 81, 82, 387, 388, "S" +381, 5, 33, 95, 83, 84, 389, 390, "(" +381, 5, 34, 96, 85, 86, 391, 392, "6" +381, 5, 35, 97, 87, 88, 393, 394, ")" +381, 5, 36, 98, 89, 90, 395, 396, "," +381, 5, 37, 99, 91, 95, 397, 401, "Jung" +381, 5, 38, 100, 96, 98, 402, 404, "CH" +381, 5, 39, 101, 99, 100, 405, 406, "(" +381, 5, 40, 102, 101, 102, 407, 408, "7" +381, 5, 41, 103, 103, 104, 409, 410, ")" +381, 5, 42, 104, 105, 106, 411, 412, "," +381, 5, 43, 105, 107, 110, 413, 416, "Kim" +381, 5, 44, 106, 111, 113, 417, 419, "DS" +381, 5, 45, 107, 114, 115, 420, 421, "(" +381, 5, 46, 108, 116, 117, 422, 423, "8" +381, 5, 47, 109, 118, 119, 424, 425, ")" +381, 5, 48, 110, 120, 121, 426, 427, "," +381, 5, 49, 111, 122, 126, 428, 432, "Park" +381, 5, 50, 112, 127, 129, 433, 435, "KS" +381, 5, 51, 113, 130, 131, 436, 437, "(" +381, 5, 52, 114, 132, 133, 438, 439, "9" +381, 5, 53, 115, 134, 135, 440, 441, ")" +381, 5, 54, 116, 136, 137, 442, 443, "," +381, 5, 55, 117, 138, 142, 444, 448, "Yoon" +381, 5, 56, 118, 143, 145, 449, 451, "KH" +381, 5, 57, 119, 146, 147, 452, 453, "(" +381, 5, 58, 120, 148, 150, 454, 456, "10" +381, 5, 59, 121, 151, 152, 457, 458, ")" +381, 5, 60, 122, 153, 154, 459, 460, "," +381, 5, 61, 123, 155, 158, 461, 464, "Lee" +381, 5, 62, 124, 159, 161, 465, 467, "IK" +381, 5, 63, 125, 162, 163, 468, 469, "(" +381, 5, 64, 126, 164, 166, 470, 472, "11" +381, 5, 65, 127, 167, 168, 473, 474, ")" +381, 5, 66, 128, 169, 170, 475, 476, "," +381, 5, 67, 129, 171, 174, 477, 480, "Cha" +381, 5, 68, 130, 175, 177, 481, 483, "BS" +381, 5, 69, 131, 178, 179, 484, 485, "(" +381, 5, 70, 132, 180, 182, 486, 488, "12" +381, 5, 71, 133, 183, 184, 489, 490, ")" +381, 5, 72, 134, 185, 186, 491, 492, "," +381, 5, 73, 135, 187, 195, 493, 501, "Sakatani" +381, 5, 74, 136, 196, 197, 502, 503, "T" +381, 5, 75, 137, 198, 199, 504, 505, "(" +381, 5, 76, 138, 200, 202, 506, 508, "13" +381, 5, 77, 139, 203, 204, 509, 510, ")" +381, 5, 78, 140, 205, 206, 511, 512, "," +381, 5, 79, 141, 207, 211, 513, 517, "Park" +381, 5, 80, 142, 212, 213, 518, 519, "S" +381, 5, 81, 143, 214, 215, 520, 521, "(" +381, 5, 82, 144, 216, 218, 522, 524, "14" +381, 5, 83, 145, 219, 220, 525, 526, ")" +381, 5, 84, 146, 221, 222, 527, 528, "," +381, 5, 85, 147, 223, 226, 529, 532, "Lee" +381, 5, 86, 148, 227, 229, 533, 535, "MK" +381, 5, 87, 149, 230, 231, 536, 537, "(" +381, 5, 88, 150, 232, 234, 538, 540, "15" +381, 5, 89, 151, 235, 236, 541, 542, ")" +381, 5, 90, 152, 237, 238, 543, 544, "." +381, 6, 1, 153, 0, 6, 545, 551, "Author" +381, 6, 2, 154, 7, 18, 552, 563, "information" +381, 6, 3, 155, 19, 20, 564, 565, ":" +381, 6, 4, 156, 21, 22, 566, 567, "(" +381, 6, 5, 157, 23, 24, 568, 569, "1" +381, 6, 6, 158, 25, 26, 570, 571, ")" +381, 6, 7, 159, 27, 32, 572, 577, "Nowon" +381, 6, 8, 160, 33, 38, 578, 583, "Eulji" +381, 6, 9, 161, 39, 46, 584, 591, "Medical" +381, 6, 10, 162, 47, 53, 592, 598, "Center" +381, 6, 11, 163, 54, 55, 599, 600, "," +381, 6, 12, 164, 56, 61, 601, 606, "Eulji" +381, 6, 13, 165, 62, 72, 607, 617, "University" +381, 6, 14, 166, 73, 74, 618, 619, "," +381, 6, 15, 167, 75, 80, 620, 625, "Seoul" +381, 6, 16, 168, 81, 82, 626, 627, "," +381, 6, 17, 169, 83, 88, 628, 633, "Korea" +381, 6, 18, 170, 89, 90, 634, 635, "." +381, 7, 1, 171, 0, 1, 636, 637, "(" +381, 7, 2, 172, 2, 3, 638, 639, "2" +381, 7, 3, 173, 4, 5, 640, 641, ")" +381, 7, 4, 174, 6, 11, 642, 647, "Kyung" +381, 7, 5, 175, 12, 15, 648, 651, "Hee" +381, 7, 6, 176, 16, 26, 652, 662, "University" +381, 7, 7, 177, 27, 35, 663, 671, "Hospital" +381, 7, 8, 178, 36, 37, 672, 673, "," +381, 7, 9, 179, 38, 43, 674, 679, "Seoul" +381, 7, 10, 180, 44, 45, 680, 681, "," +381, 7, 11, 181, 46, 51, 682, 687, "Korea" +381, 7, 12, 182, 52, 53, 688, 689, "." +381, 8, 1, 183, 0, 1, 690, 691, "(" +381, 8, 2, 184, 2, 3, 692, 693, "3" +381, 8, 3, 185, 4, 5, 694, 695, ")" +381, 8, 4, 186, 6, 12, 696, 702, "Yonsei" +381, 8, 5, 187, 13, 23, 703, 713, "University" +381, 8, 6, 188, 24, 29, 714, 719, "Wonju" +381, 8, 7, 189, 30, 39, 720, 729, "Severance" +381, 8, 8, 190, 40, 49, 730, 739, "Christian" +381, 8, 9, 191, 50, 58, 740, 748, "Hospital" +381, 8, 10, 192, 59, 60, 749, 750, "," +381, 8, 11, 193, 61, 68, 751, 758, "Gangwon" +381, 8, 12, 194, 69, 70, 759, 760, "," +381, 8, 13, 195, 71, 76, 761, 766, "Korea" +381, 8, 14, 196, 77, 78, 767, 768, "." +381, 9, 1, 197, 0, 1, 769, 770, "(" +381, 9, 2, 198, 2, 3, 771, 772, "4" +381, 9, 3, 199, 4, 5, 773, 774, ")" +381, 9, 4, 200, 6, 11, 775, 780, "Seoul" +381, 9, 5, 201, 12, 20, 781, 789, "National" +381, 9, 6, 202, 21, 31, 790, 800, "University" +381, 9, 7, 203, 32, 39, 801, 808, "College" +381, 9, 8, 204, 40, 42, 809, 811, "of" +381, 9, 9, 205, 43, 51, 812, 820, "Medicine" +381, 9, 10, 206, 52, 55, 821, 824, "and" +381, 9, 11, 207, 56, 61, 825, 830, "Seoul" +381, 9, 12, 208, 62, 70, 831, 839, "National" +381, 9, 13, 209, 71, 81, 840, 850, "University" +381, 9, 14, 210, 82, 89, 851, 858, "Bundang" +381, 9, 15, 211, 90, 98, 859, 867, "Hospital" +381, 9, 16, 212, 99, 100, 868, 869, "," +381, 9, 17, 213, 101, 109, 870, 878, "Seongnam" +381, 9, 18, 214, 110, 111, 879, 880, "," +381, 9, 19, 215, 112, 117, 881, 886, "Korea" +381, 9, 20, 216, 118, 119, 887, 888, "." +381, 10, 1, 217, 0, 1, 889, 890, "(" +381, 10, 2, 218, 2, 3, 891, 892, "5" +381, 10, 3, 219, 4, 5, 893, 894, ")" +381, 10, 4, 220, 6, 10, 895, 899, "Ajou" +381, 10, 5, 221, 11, 21, 900, 910, "University" +381, 10, 6, 222, 22, 30, 911, 919, "Hospital" +381, 10, 7, 223, 31, 32, 920, 921, "," +381, 10, 8, 224, 33, 38, 922, 927, "Suwon" +381, 10, 9, 225, 39, 40, 928, 929, "-" +381, 10, 10, 226, 41, 43, 930, 932, "si" +381, 10, 11, 227, 44, 45, 933, 934, "," +381, 10, 12, 228, 46, 51, 935, 940, "Korea" +381, 10, 13, 229, 52, 53, 941, 942, "." +381, 11, 1, 230, 0, 1, 943, 944, "(" +381, 11, 2, 231, 2, 3, 945, 946, "6" +381, 11, 3, 232, 4, 5, 947, 948, ")" +381, 11, 4, 233, 6, 11, 949, 954, "Korea" +381, 11, 5, 234, 12, 22, 955, 965, "University" +381, 11, 6, 235, 23, 27, 966, 970, "Guro" +381, 11, 7, 236, 28, 36, 971, 979, "Hospital" +381, 11, 8, 237, 37, 38, 980, 981, "," +381, 11, 9, 238, 39, 44, 982, 987, "Seoul" +381, 11, 10, 239, 45, 46, 988, 989, "," +381, 11, 11, 240, 47, 52, 990, 995, "Korea" +381, 11, 12, 241, 53, 54, 996, 997, "." +381, 12, 1, 242, 0, 1, 998, 999, "(" +381, 12, 2, 243, 2, 3, 1000, 1001, "7" +381, 12, 3, 244, 4, 5, 1002, 1003, ")" +381, 12, 4, 245, 6, 16, 1004, 1014, "Department" +381, 12, 5, 246, 17, 19, 1015, 1017, "of" +381, 12, 6, 247, 20, 33, 1018, 1031, "Endocrinology" +381, 12, 7, 248, 34, 37, 1032, 1035, "and" +381, 12, 8, 249, 38, 48, 1036, 1046, "Metabolism" +381, 12, 9, 250, 49, 50, 1047, 1048, "," +381, 12, 10, 251, 51, 55, 1049, 1053, "Asan" +381, 12, 11, 252, 56, 63, 1054, 1061, "Medical" +381, 12, 12, 253, 64, 70, 1062, 1068, "Center" +381, 12, 13, 254, 71, 72, 1069, 1070, "," +381, 12, 14, 255, 73, 83, 1071, 1081, "University" +381, 12, 15, 256, 84, 86, 1082, 1084, "of" +381, 12, 16, 257, 87, 92, 1085, 1090, "Ulsan" +381, 12, 17, 258, 93, 100, 1091, 1098, "College" +381, 12, 18, 259, 101, 103, 1099, 1101, "of" +381, 12, 19, 260, 104, 112, 1102, 1110, "Medicine" +381, 12, 20, 261, 113, 114, 1111, 1112, "," +381, 12, 21, 262, 115, 120, 1113, 1118, "Seoul" +381, 12, 22, 263, 121, 122, 1119, 1120, "," +381, 12, 23, 264, 123, 128, 1121, 1126, "Korea" +381, 12, 24, 265, 129, 130, 1127, 1128, "." +381, 13, 1, 266, 0, 1, 1129, 1130, "(" +381, 13, 2, 267, 2, 3, 1131, 1132, "8" +381, 13, 3, 268, 4, 5, 1133, 1134, ")" +381, 13, 4, 269, 6, 16, 1135, 1145, "Department" +381, 13, 5, 270, 17, 19, 1146, 1148, "of" +381, 13, 6, 271, 20, 33, 1149, 1162, "Endocrinology" +381, 13, 7, 272, 34, 37, 1163, 1166, "and" +381, 13, 8, 273, 38, 48, 1167, 1177, "Metabolism" +381, 13, 9, 274, 49, 50, 1178, 1179, "," +381, 13, 10, 275, 51, 58, 1180, 1187, "Hanyang" +381, 13, 11, 276, 59, 69, 1188, 1198, "University" +381, 13, 12, 277, 70, 78, 1199, 1207, "Hospital" +381, 13, 13, 278, 79, 80, 1208, 1209, "," +381, 13, 14, 279, 81, 86, 1210, 1215, "Seoul" +381, 13, 15, 280, 87, 88, 1216, 1217, "," +381, 13, 16, 281, 89, 94, 1218, 1223, "Korea" +381, 13, 17, 282, 95, 96, 1224, 1225, "." +381, 14, 1, 283, 0, 1, 1226, 1227, "(" +381, 14, 2, 284, 2, 3, 1228, 1229, "9" +381, 14, 3, 285, 4, 5, 1230, 1231, ")" +381, 14, 4, 286, 6, 16, 1232, 1242, "Department" +381, 14, 5, 287, 17, 19, 1243, 1245, "of" +381, 14, 6, 288, 20, 28, 1246, 1254, "Internal" +381, 14, 7, 289, 29, 37, 1255, 1263, "Medicine" +381, 14, 8, 290, 38, 39, 1264, 1265, "," +381, 14, 9, 291, 40, 45, 1266, 1271, "Seoul" +381, 14, 10, 292, 46, 54, 1272, 1280, "National" +381, 14, 11, 293, 55, 65, 1281, 1291, "University" +381, 14, 12, 294, 66, 73, 1292, 1299, "College" +381, 14, 13, 295, 74, 76, 1300, 1302, "of" +381, 14, 14, 296, 77, 85, 1303, 1311, "Medicine" +381, 14, 15, 297, 86, 87, 1312, 1313, "," +381, 14, 16, 298, 88, 93, 1314, 1319, "Seoul" +381, 14, 17, 299, 94, 95, 1320, 1321, "," +381, 14, 18, 300, 96, 101, 1322, 1327, "Korea" +381, 14, 19, 301, 102, 103, 1328, 1329, "." +381, 15, 1, 302, 0, 1, 1330, 1331, "(" +381, 15, 2, 303, 2, 4, 1332, 1334, "10" +381, 15, 3, 304, 5, 6, 1335, 1336, ")" +381, 15, 4, 305, 7, 17, 1337, 1347, "Department" +381, 15, 5, 306, 18, 20, 1348, 1350, "of" +381, 15, 6, 307, 21, 34, 1351, 1364, "Endocrinology" +381, 15, 7, 308, 35, 38, 1365, 1368, "and" +381, 15, 8, 309, 39, 49, 1369, 1379, "Metabolism" +381, 15, 9, 310, 50, 51, 1380, 1381, "," +381, 15, 10, 311, 52, 57, 1382, 1387, "Seoul" +381, 15, 11, 312, 58, 60, 1388, 1390, "St" +381, 15, 12, 313, 61, 62, 1391, 1392, "." +381, 15, 13, 314, 63, 67, 1393, 1397, "Mary" +381, 15, 14, 315, 68, 69, 1398, 1399, "'" +381, 15, 15, 316, 70, 71, 1400, 1401, "s" +381, 15, 16, 317, 72, 80, 1402, 1410, "Hospital" +381, 15, 17, 318, 81, 82, 1411, 1412, "," +381, 15, 18, 319, 83, 91, 1413, 1421, "Catholic" +381, 15, 19, 320, 92, 102, 1422, 1432, "University" +381, 15, 20, 321, 103, 110, 1433, 1440, "Medical" +381, 15, 21, 322, 111, 118, 1441, 1448, "College" +381, 15, 22, 323, 119, 120, 1449, 1450, "," +381, 15, 23, 324, 121, 126, 1451, 1456, "Seoul" +381, 15, 24, 325, 127, 128, 1457, 1458, "," +381, 15, 25, 326, 129, 134, 1459, 1464, "Korea" +381, 15, 26, 327, 135, 136, 1465, 1466, "." +381, 16, 1, 328, 0, 1, 1467, 1468, "(" +381, 16, 2, 329, 2, 4, 1469, 1471, "11" +381, 16, 3, 330, 5, 6, 1472, 1473, ")" +381, 16, 4, 331, 7, 17, 1474, 1484, "Department" +381, 16, 5, 332, 18, 20, 1485, 1487, "of" +381, 16, 6, 333, 21, 29, 1488, 1496, "Internal" +381, 16, 7, 334, 30, 38, 1497, 1505, "Medicine" +381, 16, 8, 335, 39, 40, 1506, 1507, "," +381, 16, 9, 336, 41, 50, 1508, 1517, "Kyungpook" +381, 16, 10, 337, 51, 59, 1518, 1526, "National" +381, 16, 11, 338, 60, 70, 1527, 1537, "University" +381, 16, 12, 339, 71, 79, 1538, 1546, "Hospital" +381, 16, 13, 340, 80, 81, 1547, 1548, "," +381, 16, 14, 341, 82, 87, 1549, 1554, "Daegu" +381, 16, 15, 342, 88, 89, 1555, 1556, "," +381, 16, 16, 343, 90, 95, 1557, 1562, "Korea" +381, 16, 17, 344, 96, 97, 1563, 1564, "." +381, 17, 1, 345, 0, 1, 1565, 1566, "(" +381, 17, 2, 346, 2, 4, 1567, 1569, "12" +381, 17, 3, 347, 5, 6, 1570, 1571, ")" +381, 17, 4, 348, 7, 17, 1572, 1582, "Department" +381, 17, 5, 349, 18, 20, 1583, 1585, "of" +381, 17, 6, 350, 21, 29, 1586, 1594, "Internal" +381, 17, 7, 351, 30, 38, 1595, 1603, "Medicine" +381, 17, 8, 352, 39, 40, 1604, 1605, "," +381, 17, 9, 353, 41, 47, 1606, 1612, "Yonsei" +381, 17, 10, 354, 48, 58, 1613, 1623, "University" +381, 17, 11, 355, 59, 68, 1624, 1633, "Severance" +381, 17, 12, 356, 69, 77, 1634, 1642, "Hospital" +381, 17, 13, 357, 78, 79, 1643, 1644, "," +381, 17, 14, 358, 80, 85, 1645, 1650, "Seoul" +381, 17, 15, 359, 86, 87, 1651, 1652, "," +381, 17, 16, 360, 88, 93, 1653, 1658, "Korea" +381, 17, 17, 361, 94, 95, 1659, 1660, "." +381, 18, 1, 362, 0, 1, 1661, 1662, "(" +381, 18, 2, 363, 2, 4, 1663, 1665, "13" +381, 18, 3, 364, 5, 6, 1666, 1667, ")" +381, 18, 4, 365, 7, 20, 1668, 1681, "Biostatistics" +381, 18, 5, 366, 21, 26, 1682, 1687, "Group" +381, 18, 6, 367, 27, 28, 1688, 1689, "," +381, 18, 7, 368, 29, 34, 1690, 1695, "Japan" +381, 18, 8, 369, 35, 36, 1696, 1697, "-" +381, 18, 9, 370, 37, 41, 1698, 1702, "Asia" +381, 18, 10, 371, 42, 46, 1703, 1707, "Data" +381, 18, 11, 372, 47, 54, 1708, 1715, "Science" +381, 18, 12, 373, 55, 56, 1716, 1717, "," +381, 18, 13, 374, 57, 68, 1718, 1729, "Development" +381, 18, 14, 375, 69, 70, 1730, 1731, "," +381, 18, 15, 376, 71, 79, 1732, 1740, "Astellas" +381, 18, 16, 377, 80, 86, 1741, 1747, "Pharma" +381, 18, 17, 378, 87, 90, 1748, 1751, "Inc" +381, 18, 18, 379, 91, 92, 1752, 1753, "." +381, 18, 19, 380, 93, 94, 1754, 1755, "," +381, 18, 20, 381, 95, 100, 1756, 1761, "Tokyo" +381, 18, 21, 382, 101, 102, 1762, 1763, "," +381, 18, 22, 383, 103, 108, 1764, 1769, "Japan" +381, 18, 23, 384, 109, 110, 1770, 1771, "." +381, 19, 1, 385, 0, 1, 1772, 1773, "(" +381, 19, 2, 386, 2, 4, 1774, 1776, "14" +381, 19, 3, 387, 5, 6, 1777, 1778, ")" +381, 19, 4, 388, 7, 15, 1779, 1787, "Clinical" +381, 19, 5, 389, 16, 24, 1788, 1796, "Research" +381, 19, 6, 390, 25, 29, 1797, 1801, "Team" +381, 19, 7, 391, 30, 31, 1802, 1803, "," +381, 19, 8, 392, 32, 43, 1804, 1815, "Development" +381, 19, 9, 393, 44, 54, 1816, 1826, "Department" +381, 19, 10, 394, 55, 56, 1827, 1828, "," +381, 19, 11, 395, 57, 65, 1829, 1837, "Astellas" +381, 19, 12, 396, 66, 72, 1838, 1844, "Pharma" +381, 19, 13, 397, 73, 78, 1845, 1850, "Korea" +381, 19, 14, 398, 79, 80, 1851, 1852, "," +381, 19, 15, 399, 81, 84, 1853, 1856, "Inc" +381, 19, 16, 400, 85, 86, 1857, 1858, "." +381, 19, 17, 401, 87, 88, 1859, 1860, "," +381, 19, 18, 402, 89, 94, 1861, 1866, "Seoul" +381, 19, 19, 403, 95, 96, 1867, 1868, "," +381, 19, 20, 404, 97, 102, 1869, 1874, "Korea" +381, 19, 21, 405, 103, 104, 1875, 1876, "." +381, 20, 1, 406, 0, 1, 1877, 1878, "(" +381, 20, 2, 407, 2, 4, 1879, 1881, "15" +381, 20, 3, 408, 5, 6, 1882, 1883, ")" +381, 20, 4, 409, 7, 17, 1884, 1894, "Department" +381, 20, 5, 410, 18, 20, 1895, 1897, "of" +381, 20, 6, 411, 21, 29, 1898, 1906, "Medicine" +381, 20, 7, 412, 30, 31, 1907, 1908, "," +381, 20, 8, 413, 32, 39, 1909, 1916, "Samsung" +381, 20, 9, 414, 40, 47, 1917, 1924, "Medical" +381, 20, 10, 415, 48, 54, 1925, 1931, "Center" +381, 20, 11, 416, 55, 56, 1932, 1933, "," +381, 20, 12, 417, 57, 69, 1934, 1946, "Sungkyunkwan" +381, 20, 13, 418, 70, 80, 1947, 1957, "University" +381, 20, 14, 419, 81, 87, 1958, 1964, "School" +381, 20, 15, 420, 88, 90, 1965, 1967, "of" +381, 20, 16, 421, 91, 99, 1968, 1976, "Medicine" +381, 20, 17, 422, 100, 101, 1977, 1978, "," +381, 20, 18, 423, 102, 107, 1979, 1984, "Seoul" +381, 20, 19, 424, 108, 109, 1985, 1986, "," +381, 20, 20, 425, 110, 115, 1987, 1992, "Korea" +381, 20, 21, 426, 116, 117, 1993, 1994, "." +381, 21, 1, 427, 0, 3, 1995, 1998, "AIM" +381, 21, 2, 428, 4, 5, 1999, 2000, ":" +381, 21, 3, 429, 6, 8, 2001, 2003, "To" +381, 21, 4, 430, 9, 17, 2004, 2012, "evaluate" +381, 21, 5, 431, 18, 21, 2013, 2016, "the" +381, 21, 6, 432, 22, 30, 2017, 2025, "efficacy" +381, 21, 7, 433, 31, 34, 2026, 2029, "and" +381, 21, 8, 434, 35, 41, 2030, 2036, "safety" +381, 21, 9, 435, 42, 44, 2037, 2039, "of" +381, 21, 10, 436, 45, 58, 2040, 2053, "ipragliflozin" +381, 21, 11, 437, 59, 61, 2054, 2056, "vs" +381, 21, 12, 438, 62, 69, 2057, 2064, "placebo" +381, 21, 13, 439, 70, 72, 2065, 2067, "as" +381, 21, 14, 440, 73, 76, 2068, 2071, "add" +381, 21, 15, 441, 77, 78, 2072, 2073, "-" +381, 21, 16, 442, 79, 81, 2074, 2076, "on" +381, 21, 17, 443, 82, 89, 2077, 2084, "therapy" +381, 21, 18, 444, 90, 92, 2085, 2087, "to" +381, 21, 19, 445, 93, 102, 2088, 2097, "metformin" +381, 21, 20, 446, 103, 106, 2098, 2101, "and" +381, 21, 21, 447, 107, 118, 2102, 2113, "sitagliptin" +381, 21, 22, 448, 119, 121, 2114, 2116, "in" +381, 21, 23, 449, 122, 128, 2117, 2123, "Korean" +381, 21, 24, 450, 129, 137, 2124, 2132, "patients" +381, 21, 25, 451, 138, 142, 2133, 2137, "with" +381, 21, 26, 452, 143, 147, 2138, 2142, "type" +381, 21, 27, 453, 148, 149, 2143, 2144, "2" +381, 21, 28, 454, 150, 158, 2145, 2153, "diabetes" +381, 21, 29, 455, 159, 167, 2154, 2162, "mellitus" +381, 21, 30, 456, 168, 169, 2163, 2164, "(" +381, 21, 31, 457, 170, 174, 2165, 2169, "T2DM" +381, 21, 32, 458, 175, 176, 2170, 2171, ")" +381, 21, 33, 459, 177, 178, 2172, 2173, "." +381, 22, 1, 460, 0, 7, 2174, 2181, "METHODS" +381, 22, 2, 461, 8, 9, 2182, 2183, ":" +381, 22, 3, 462, 10, 14, 2184, 2188, "This" +381, 22, 4, 463, 15, 21, 2189, 2195, "double" +381, 22, 5, 464, 22, 23, 2196, 2197, "-" +381, 22, 6, 465, 24, 29, 2198, 2203, "blind" +381, 22, 7, 466, 30, 31, 2204, 2205, "," +381, 22, 8, 467, 32, 39, 2206, 2213, "placebo" +381, 22, 9, 468, 40, 41, 2214, 2215, "-" +381, 22, 10, 469, 42, 52, 2216, 2226, "controlled" +381, 22, 11, 470, 53, 54, 2227, 2228, "," +381, 22, 12, 471, 55, 60, 2229, 2234, "multi" +381, 22, 13, 472, 61, 62, 2235, 2236, "-" +381, 22, 14, 473, 63, 69, 2237, 2243, "centre" +381, 22, 15, 474, 70, 71, 2244, 2245, "," +381, 22, 16, 475, 72, 77, 2246, 2251, "phase" +381, 22, 17, 476, 78, 81, 2252, 2255, "III" +381, 22, 18, 477, 82, 87, 2256, 2261, "study" +381, 22, 19, 478, 88, 91, 2262, 2265, "was" +381, 22, 20, 479, 92, 101, 2266, 2275, "conducted" +381, 22, 21, 480, 102, 104, 2276, 2278, "in" +381, 22, 22, 481, 105, 110, 2279, 2284, "Korea" +381, 22, 23, 482, 111, 113, 2285, 2287, "in" +381, 22, 24, 483, 114, 118, 2288, 2292, "2015" +381, 22, 25, 484, 119, 121, 2293, 2295, "to" +381, 22, 26, 485, 122, 126, 2296, 2300, "2017" +381, 22, 27, 486, 127, 128, 2301, 2302, "." +381, 23, 1, 487, 0, 8, 2303, 2311, "Patients" +381, 23, 2, 488, 9, 13, 2312, 2316, "were" +381, 23, 3, 489, 14, 24, 2317, 2327, "randomized" +381, 23, 4, 490, 25, 27, 2328, 2330, "to" +381, 23, 5, 491, 28, 35, 2331, 2338, "receive" +381, 23, 6, 492, 36, 42, 2339, 2345, "either" +381, 23, 7, 493, 43, 56, 2346, 2359, "ipragliflozin" +381, 23, 8, 494, 57, 59, 2360, 2362, "50" +381, 23, 9, 495, 60, 62, 2363, 2365, "mg" +381, 23, 10, 496, 63, 64, 2366, 2367, "/" +381, 23, 11, 497, 65, 68, 2368, 2371, "day" +381, 23, 12, 498, 69, 71, 2372, 2374, "or" +381, 23, 13, 499, 72, 79, 2375, 2382, "placebo" +381, 23, 14, 500, 80, 84, 2383, 2387, "once" +381, 23, 15, 501, 85, 90, 2388, 2393, "daily" +381, 23, 16, 502, 91, 94, 2394, 2397, "for" +381, 23, 17, 503, 95, 97, 2398, 2400, "24" +381, 23, 18, 504, 98, 103, 2401, 2406, "weeks" +381, 23, 19, 505, 104, 106, 2407, 2409, "in" +381, 23, 20, 506, 107, 115, 2410, 2418, "addition" +381, 23, 21, 507, 116, 118, 2419, 2421, "to" +381, 23, 22, 508, 119, 128, 2422, 2431, "metformin" +381, 23, 23, 509, 129, 132, 2432, 2435, "and" +381, 23, 24, 510, 133, 144, 2436, 2447, "sitagliptin" +381, 23, 25, 511, 145, 146, 2448, 2449, "." +381, 24, 1, 512, 0, 3, 2450, 2453, "The" +381, 24, 2, 513, 4, 11, 2454, 2461, "primary" +381, 24, 3, 514, 12, 20, 2462, 2470, "endpoint" +381, 24, 4, 515, 21, 24, 2471, 2474, "was" +381, 24, 5, 516, 25, 28, 2475, 2478, "the" +381, 24, 6, 517, 29, 35, 2479, 2485, "change" +381, 24, 7, 518, 36, 38, 2486, 2488, "in" +381, 24, 8, 519, 39, 47, 2489, 2497, "glycated" +381, 24, 9, 520, 48, 59, 2498, 2509, "haemoglobin" +381, 24, 10, 521, 60, 61, 2510, 2511, "(" +381, 24, 11, 522, 62, 67, 2512, 2517, "HbA1c" +381, 24, 12, 523, 68, 69, 2518, 2519, ")" +381, 24, 13, 524, 70, 74, 2520, 2524, "from" +381, 24, 14, 525, 75, 83, 2525, 2533, "baseline" +381, 24, 15, 526, 84, 86, 2534, 2536, "to" +381, 24, 16, 527, 87, 90, 2537, 2540, "end" +381, 24, 17, 528, 91, 93, 2541, 2543, "of" +381, 24, 18, 529, 94, 103, 2544, 2553, "treatment" +381, 24, 19, 530, 104, 105, 2554, 2555, "(" +381, 24, 20, 531, 106, 109, 2556, 2559, "EOT" +381, 24, 21, 532, 110, 111, 2560, 2561, ")" +381, 24, 22, 533, 112, 113, 2562, 2563, "." +381, 25, 1, 534, 0, 7, 2564, 2571, "RESULTS" +381, 25, 2, 535, 8, 9, 2572, 2573, ":" +381, 25, 3, 536, 10, 12, 2574, 2576, "In" +381, 25, 4, 537, 13, 18, 2577, 2582, "total" +381, 25, 5, 538, 19, 20, 2583, 2584, "," +381, 25, 6, 539, 21, 24, 2585, 2588, "143" +381, 25, 7, 540, 25, 33, 2589, 2597, "patients" +381, 25, 8, 541, 34, 38, 2598, 2602, "were" +381, 25, 9, 542, 39, 49, 2603, 2613, "randomized" +381, 25, 10, 543, 50, 53, 2614, 2617, "and" +381, 25, 11, 544, 54, 57, 2618, 2621, "139" +381, 25, 12, 545, 58, 62, 2622, 2626, "were" +381, 25, 13, 546, 63, 71, 2627, 2635, "included" +381, 25, 14, 547, 72, 74, 2636, 2638, "in" +381, 25, 15, 548, 75, 83, 2639, 2647, "efficacy" +381, 25, 16, 549, 84, 92, 2648, 2656, "analyses" +381, 25, 17, 550, 93, 94, 2657, 2658, "(" +381, 25, 18, 551, 95, 108, 2659, 2672, "ipragliflozin" +381, 25, 19, 552, 109, 110, 2673, 2674, ":" +381, 25, 20, 553, 111, 113, 2675, 2677, "73" +381, 25, 21, 554, 114, 115, 2678, 2679, "," +381, 25, 22, 555, 116, 123, 2680, 2687, "placebo" +381, 25, 23, 556, 124, 125, 2688, 2689, ":" +381, 25, 24, 557, 126, 128, 2690, 2692, "66" +381, 25, 25, 558, 129, 130, 2693, 2694, ")" +381, 25, 26, 559, 131, 132, 2695, 2696, "." +381, 26, 1, 560, 0, 8, 2697, 2705, "Baseline" +381, 26, 2, 561, 9, 13, 2706, 2710, "mean" +381, 26, 3, 562, 14, 15, 2711, 2712, "(" +381, 26, 4, 563, 16, 18, 2713, 2715, "SD" +381, 26, 5, 564, 19, 20, 2716, 2717, ")" +381, 26, 6, 565, 21, 26, 2718, 2723, "HbA1c" +381, 26, 7, 566, 27, 33, 2724, 2730, "levels" +381, 26, 8, 567, 34, 38, 2731, 2735, "were" +381, 26, 9, 568, 39, 40, 2736, 2737, "7" +381, 26, 10, 569, 41, 42, 2738, 2739, "." +381, 26, 11, 570, 43, 45, 2740, 2742, "90" +381, 26, 12, 571, 46, 47, 2743, 2744, "(" +381, 26, 13, 572, 48, 49, 2745, 2746, "0" +381, 26, 14, 573, 50, 51, 2747, 2748, "." +381, 26, 15, 574, 52, 54, 2749, 2751, "69" +381, 26, 16, 575, 55, 56, 2752, 2753, ")" +381, 26, 17, 576, 57, 58, 2754, 2755, "%" +381, 26, 18, 577, 59, 62, 2756, 2759, "for" +381, 26, 19, 578, 63, 76, 2760, 2773, "ipragliflozin" +381, 26, 20, 579, 77, 80, 2774, 2777, "add" +381, 26, 21, 580, 81, 82, 2778, 2779, "-" +381, 26, 22, 581, 83, 85, 2780, 2782, "on" +381, 26, 23, 582, 86, 89, 2783, 2786, "and" +381, 26, 24, 583, 90, 91, 2787, 2788, "7" +381, 26, 25, 584, 92, 93, 2789, 2790, "." +381, 26, 26, 585, 94, 96, 2791, 2793, "92" +381, 26, 27, 586, 97, 98, 2794, 2795, "(" +381, 26, 28, 587, 99, 100, 2796, 2797, "0" +381, 26, 29, 588, 101, 102, 2798, 2799, "." +381, 26, 30, 589, 103, 105, 2800, 2802, "79" +381, 26, 31, 590, 106, 107, 2803, 2804, ")" +381, 26, 32, 591, 108, 109, 2805, 2806, "%" +381, 26, 33, 592, 110, 113, 2807, 2810, "for" +381, 26, 34, 593, 114, 121, 2811, 2818, "placebo" +381, 26, 35, 594, 122, 123, 2819, 2820, "." +381, 27, 1, 595, 0, 3, 2821, 2824, "The" +381, 27, 2, 596, 4, 17, 2825, 2838, "corresponding" +381, 27, 3, 597, 18, 22, 2839, 2843, "mean" +381, 27, 4, 598, 23, 24, 2844, 2845, "(" +381, 27, 5, 599, 25, 27, 2846, 2848, "SD" +381, 27, 6, 600, 28, 29, 2849, 2850, ")" +381, 27, 7, 601, 30, 37, 2851, 2858, "changes" +381, 27, 8, 602, 38, 42, 2859, 2863, "from" +381, 27, 9, 603, 43, 51, 2864, 2872, "baseline" +381, 27, 10, 604, 52, 54, 2873, 2875, "to" +381, 27, 11, 605, 55, 58, 2876, 2879, "EOT" +381, 27, 12, 606, 59, 63, 2880, 2884, "were" +381, 27, 13, 607, 64, 65, 2885, 2886, "-" +381, 27, 14, 608, 66, 67, 2887, 2888, "0" +381, 27, 15, 609, 68, 69, 2889, 2890, "." +381, 27, 16, 610, 70, 72, 2891, 2893, "79" +381, 27, 17, 611, 73, 74, 2894, 2895, "(" +381, 27, 18, 612, 75, 76, 2896, 2897, "0" +381, 27, 19, 613, 77, 78, 2898, 2899, "." +381, 27, 20, 614, 79, 81, 2900, 2902, "59" +381, 27, 21, 615, 82, 83, 2903, 2904, ")" +381, 27, 22, 616, 84, 85, 2905, 2906, "%" +381, 27, 23, 617, 86, 89, 2907, 2910, "and" +381, 27, 24, 618, 90, 91, 2911, 2912, "0" +381, 27, 25, 619, 92, 93, 2913, 2914, "." +381, 27, 26, 620, 94, 96, 2915, 2917, "03" +381, 27, 27, 621, 97, 98, 2918, 2919, "(" +381, 27, 28, 622, 99, 100, 2920, 2921, "0" +381, 27, 29, 623, 101, 102, 2922, 2923, "." +381, 27, 30, 624, 103, 105, 2924, 2926, "84" +381, 27, 31, 625, 106, 107, 2927, 2928, ")" +381, 27, 32, 626, 108, 109, 2929, 2930, "%" +381, 27, 33, 627, 110, 111, 2931, 2932, "," +381, 27, 34, 628, 112, 124, 2933, 2945, "respectively" +381, 27, 35, 629, 125, 126, 2946, 2947, "," +381, 27, 36, 630, 127, 129, 2948, 2950, "in" +381, 27, 37, 631, 130, 136, 2951, 2957, "favour" +381, 27, 38, 632, 137, 139, 2958, 2960, "of" +381, 27, 39, 633, 140, 153, 2961, 2974, "ipragliflozin" +381, 27, 40, 634, 154, 155, 2975, 2976, "(" +381, 27, 41, 635, 156, 164, 2977, 2985, "adjusted" +381, 27, 42, 636, 165, 169, 2986, 2990, "mean" +381, 27, 43, 637, 170, 180, 2991, 3001, "difference" +381, 27, 44, 638, 181, 182, 3002, 3003, "-" +381, 27, 45, 639, 183, 184, 3004, 3005, "0" +381, 27, 46, 640, 185, 186, 3006, 3007, "." +381, 27, 47, 641, 187, 189, 3008, 3010, "83" +381, 27, 48, 642, 190, 191, 3011, 3012, "%" +381, 27, 49, 643, 192, 193, 3013, 3014, "[" +381, 27, 50, 644, 194, 196, 3015, 3017, "95" +381, 27, 51, 645, 197, 198, 3018, 3019, "%" +381, 27, 52, 646, 199, 201, 3020, 3022, "CI" +381, 27, 53, 647, 202, 203, 3023, 3024, "-" +381, 27, 54, 648, 204, 205, 3025, 3026, "1" +381, 27, 55, 649, 206, 207, 3027, 3028, "." +381, 27, 56, 650, 208, 210, 3029, 3031, "07" +381, 27, 57, 651, 211, 213, 3032, 3034, "to" +381, 27, 58, 652, 214, 215, 3035, 3036, "-" +381, 27, 59, 653, 216, 217, 3037, 3038, "0" +381, 27, 60, 654, 218, 219, 3039, 3040, "." +381, 27, 61, 655, 220, 222, 3041, 3043, "59" +381, 27, 62, 656, 223, 224, 3044, 3045, "]" +381, 27, 63, 657, 225, 226, 3046, 3047, ";" +381, 27, 64, 658, 227, 228, 3048, 3049, "P" +381, 27, 65, 659, 229, 230, 3050, 3051, "<" +381, 27, 66, 660, 231, 232, 3052, 3053, "." +381, 27, 67, 661, 233, 237, 3054, 3058, "0001" +381, 27, 68, 662, 238, 239, 3059, 3060, ")" +381, 27, 69, 663, 240, 241, 3061, 3062, "." +381, 28, 1, 664, 0, 4, 3063, 3067, "More" +381, 28, 2, 665, 5, 18, 3068, 3081, "ipragliflozin" +381, 28, 3, 666, 19, 20, 3082, 3083, "-" +381, 28, 4, 667, 21, 28, 3084, 3091, "treated" +381, 28, 5, 668, 29, 37, 3092, 3100, "patients" +381, 28, 6, 669, 38, 42, 3101, 3105, "than" +381, 28, 7, 670, 43, 50, 3106, 3113, "placebo" +381, 28, 8, 671, 51, 52, 3114, 3115, "-" +381, 28, 9, 672, 53, 60, 3116, 3123, "treated" +381, 28, 10, 673, 61, 69, 3124, 3132, "patients" +381, 28, 11, 674, 70, 78, 3133, 3141, "achieved" +381, 28, 12, 675, 79, 84, 3142, 3147, "HbA1c" +381, 28, 13, 676, 85, 91, 3148, 3154, "target" +381, 28, 14, 677, 92, 98, 3155, 3161, "levels" +381, 28, 15, 678, 99, 101, 3162, 3164, "of" +381, 28, 16, 679, 102, 103, 3165, 3166, "<" +381, 28, 17, 680, 104, 105, 3167, 3168, "7" +381, 28, 18, 681, 106, 107, 3169, 3170, "." +381, 28, 19, 682, 108, 109, 3171, 3172, "0" +381, 28, 20, 683, 110, 111, 3173, 3174, "%" +381, 28, 21, 684, 112, 113, 3175, 3176, "(" +381, 28, 22, 685, 114, 116, 3177, 3179, "44" +381, 28, 23, 686, 117, 118, 3180, 3181, "." +381, 28, 24, 687, 119, 120, 3182, 3183, "4" +381, 28, 25, 688, 121, 122, 3184, 3185, "%" +381, 28, 26, 689, 123, 125, 3186, 3188, "vs" +381, 28, 27, 690, 126, 128, 3189, 3191, "12" +381, 28, 28, 691, 129, 130, 3192, 3193, "." +381, 28, 29, 692, 131, 132, 3194, 3195, "1" +381, 28, 30, 693, 133, 134, 3196, 3197, "%" +381, 28, 31, 694, 135, 136, 3198, 3199, ")" +381, 28, 32, 695, 137, 140, 3200, 3203, "and" +381, 28, 33, 696, 141, 142, 3204, 3205, "<" +381, 28, 34, 697, 143, 144, 3206, 3207, "6" +381, 28, 35, 698, 145, 146, 3208, 3209, "." +381, 28, 36, 699, 147, 148, 3210, 3211, "5" +381, 28, 37, 700, 149, 150, 3212, 3213, "%" +381, 28, 38, 701, 151, 152, 3214, 3215, "(" +381, 28, 39, 702, 153, 155, 3216, 3218, "12" +381, 28, 40, 703, 156, 157, 3219, 3220, "." +381, 28, 41, 704, 158, 159, 3221, 3222, "5" +381, 28, 42, 705, 160, 161, 3223, 3224, "%" +381, 28, 43, 706, 162, 164, 3225, 3227, "vs" +381, 28, 44, 707, 165, 166, 3228, 3229, "1" +381, 28, 45, 708, 167, 168, 3230, 3231, "." +381, 28, 46, 709, 169, 170, 3232, 3233, "5" +381, 28, 47, 710, 171, 172, 3234, 3235, "%" +381, 28, 48, 711, 173, 174, 3236, 3237, ")" +381, 28, 49, 712, 175, 177, 3238, 3240, "at" +381, 28, 50, 713, 178, 181, 3241, 3244, "EOT" +381, 28, 51, 714, 182, 183, 3245, 3246, "(" +381, 28, 52, 715, 184, 185, 3247, 3248, "P" +381, 28, 53, 716, 186, 187, 3249, 3250, "<" +381, 28, 54, 717, 188, 189, 3251, 3252, "." +381, 28, 55, 718, 190, 192, 3253, 3255, "05" +381, 28, 56, 719, 193, 196, 3256, 3259, "for" +381, 28, 57, 720, 197, 201, 3260, 3264, "both" +381, 28, 58, 721, 202, 203, 3265, 3266, ")" +381, 28, 59, 722, 204, 205, 3267, 3268, "." +381, 29, 1, 723, 0, 7, 3269, 3276, "Fasting" +381, 29, 2, 724, 8, 14, 3277, 3283, "plasma" +381, 29, 3, 725, 15, 22, 3284, 3291, "glucose" +381, 29, 4, 726, 23, 24, 3292, 3293, "," +381, 29, 5, 727, 25, 32, 3294, 3301, "fasting" +381, 29, 6, 728, 33, 38, 3302, 3307, "serum" +381, 29, 7, 729, 39, 46, 3308, 3315, "insulin" +381, 29, 8, 730, 47, 48, 3316, 3317, "," +381, 29, 9, 731, 49, 53, 3318, 3322, "body" +381, 29, 10, 732, 54, 60, 3323, 3329, "weight" +381, 29, 11, 733, 61, 64, 3330, 3333, "and" +381, 29, 12, 734, 65, 76, 3334, 3345, "homeostatic" +381, 29, 13, 735, 77, 82, 3346, 3351, "model" +381, 29, 14, 736, 83, 93, 3352, 3362, "assessment" +381, 29, 15, 737, 94, 96, 3363, 3365, "of" +381, 29, 16, 738, 97, 104, 3366, 3373, "insulin" +381, 29, 17, 739, 105, 115, 3374, 3384, "resistance" +381, 29, 18, 740, 116, 125, 3385, 3394, "decreased" +381, 29, 19, 741, 126, 139, 3395, 3408, "significantly" +381, 29, 20, 742, 140, 142, 3409, 3411, "at" +381, 29, 21, 743, 143, 146, 3412, 3415, "EOT" +381, 29, 22, 744, 147, 148, 3416, 3417, "," +381, 29, 23, 745, 149, 151, 3418, 3420, "in" +381, 29, 24, 746, 152, 158, 3421, 3427, "favour" +381, 29, 25, 747, 159, 161, 3428, 3430, "of" +381, 29, 26, 748, 162, 175, 3431, 3444, "ipragliflozin" +381, 29, 27, 749, 176, 177, 3445, 3446, "(" +381, 29, 28, 750, 178, 186, 3447, 3455, "adjusted" +381, 29, 29, 751, 187, 191, 3456, 3460, "mean" +381, 29, 30, 752, 192, 202, 3461, 3471, "difference" +381, 29, 31, 753, 203, 204, 3472, 3473, "-" +381, 29, 32, 754, 205, 206, 3474, 3475, "1" +381, 29, 33, 755, 207, 208, 3476, 3477, "." +381, 29, 34, 756, 209, 211, 3478, 3480, "64" +381, 29, 35, 757, 212, 216, 3481, 3485, "mmol" +381, 29, 36, 758, 217, 218, 3486, 3487, "/" +381, 29, 37, 759, 219, 220, 3488, 3489, "L" +381, 29, 38, 760, 221, 222, 3490, 3491, "," +381, 29, 39, 761, 223, 224, 3492, 3493, "-" +381, 29, 40, 762, 225, 226, 3494, 3495, "1" +381, 29, 41, 763, 227, 228, 3496, 3497, "." +381, 29, 42, 764, 229, 231, 3498, 3500, "50" +381, 29, 43, 765, 232, 233, 3501, 3502, "μ" +381, 29, 44, 766, 234, 235, 3503, 3504, "U" +381, 29, 45, 767, 236, 237, 3505, 3506, "/" +381, 29, 46, 768, 238, 240, 3507, 3509, "mL" +381, 29, 47, 769, 241, 242, 3510, 3511, "," +381, 29, 48, 770, 243, 244, 3512, 3513, "-" +381, 29, 49, 771, 245, 246, 3514, 3515, "1" +381, 29, 50, 772, 247, 248, 3516, 3517, "." +381, 29, 51, 773, 249, 251, 3518, 3520, "72" +381, 29, 52, 774, 252, 254, 3521, 3523, "kg" +381, 29, 53, 775, 255, 256, 3524, 3525, "," +381, 29, 54, 776, 257, 260, 3526, 3529, "and" +381, 29, 55, 777, 261, 262, 3530, 3531, "-" +381, 29, 56, 778, 263, 264, 3532, 3533, "0" +381, 29, 57, 779, 265, 266, 3534, 3535, "." +381, 29, 58, 780, 267, 269, 3536, 3538, "99" +381, 29, 59, 781, 270, 271, 3539, 3540, "," +381, 29, 60, 782, 272, 284, 3541, 3553, "respectively" +381, 29, 61, 783, 285, 286, 3554, 3555, ";" +381, 29, 62, 784, 287, 288, 3556, 3557, "P" +381, 29, 63, 785, 289, 290, 3558, 3559, "<" +381, 29, 64, 786, 291, 292, 3560, 3561, "." +381, 29, 65, 787, 293, 295, 3562, 3564, "05" +381, 29, 66, 788, 296, 299, 3565, 3568, "for" +381, 29, 67, 789, 300, 303, 3569, 3572, "all" +381, 29, 68, 790, 304, 305, 3573, 3574, ")" +381, 29, 69, 791, 306, 307, 3575, 3576, "." +381, 30, 1, 792, 0, 7, 3577, 3584, "Adverse" +381, 30, 2, 793, 8, 13, 3585, 3590, "event" +381, 30, 3, 794, 14, 19, 3591, 3596, "rates" +381, 30, 4, 795, 20, 24, 3597, 3601, "were" +381, 30, 5, 796, 25, 32, 3602, 3609, "similar" +381, 30, 6, 797, 33, 40, 3610, 3617, "between" +381, 30, 7, 798, 41, 47, 3618, 3624, "groups" +381, 30, 8, 799, 48, 49, 3625, 3626, "(" +381, 30, 9, 800, 50, 63, 3627, 3640, "ipragliflozin" +381, 30, 10, 801, 64, 65, 3641, 3642, ":" +381, 30, 11, 802, 66, 68, 3643, 3645, "51" +381, 30, 12, 803, 69, 70, 3646, 3647, "." +381, 30, 13, 804, 71, 72, 3648, 3649, "4" +381, 30, 14, 805, 73, 74, 3650, 3651, "%" +381, 30, 15, 806, 75, 76, 3652, 3653, ";" +381, 30, 16, 807, 77, 84, 3654, 3661, "placebo" +381, 30, 17, 808, 85, 86, 3662, 3663, ":" +381, 30, 18, 809, 87, 89, 3664, 3666, "50" +381, 30, 19, 810, 90, 91, 3667, 3668, "." +381, 30, 20, 811, 92, 93, 3669, 3670, "0" +381, 30, 21, 812, 94, 95, 3671, 3672, "%" +381, 30, 22, 813, 96, 97, 3673, 3674, ")" +381, 30, 23, 814, 98, 99, 3675, 3676, "." +381, 31, 1, 815, 0, 2, 3677, 3679, "No" +381, 31, 2, 816, 3, 13, 3680, 3690, "previously" +381, 31, 3, 817, 14, 24, 3691, 3701, "unreported" +381, 31, 4, 818, 25, 31, 3702, 3708, "safety" +381, 31, 5, 819, 32, 40, 3709, 3717, "concerns" +381, 31, 6, 820, 41, 45, 3718, 3722, "were" +381, 31, 7, 821, 46, 51, 3723, 3728, "noted" +381, 31, 8, 822, 52, 53, 3729, 3730, "." +381, 32, 1, 823, 0, 11, 3731, 3742, "CONCLUSIONS" +381, 32, 2, 824, 12, 13, 3743, 3744, ":" +381, 32, 3, 825, 14, 27, 3745, 3758, "Ipragliflozin" +381, 32, 4, 826, 28, 30, 3759, 3761, "as" +381, 32, 5, 827, 31, 34, 3762, 3765, "add" +381, 32, 6, 828, 35, 36, 3766, 3767, "-" +381, 32, 7, 829, 37, 39, 3768, 3770, "on" +381, 32, 8, 830, 40, 42, 3771, 3773, "to" +381, 32, 9, 831, 43, 52, 3774, 3783, "metformin" +381, 32, 10, 832, 53, 56, 3784, 3787, "and" +381, 32, 11, 833, 57, 68, 3788, 3799, "sitagliptin" +381, 32, 12, 834, 69, 82, 3800, 3813, "significantly" +381, 32, 13, 835, 83, 91, 3814, 3822, "improved" +381, 32, 14, 836, 92, 101, 3823, 3832, "glycaemic" +381, 32, 15, 837, 102, 111, 3833, 3842, "variables" +381, 32, 16, 838, 112, 115, 3843, 3846, "and" +381, 32, 17, 839, 116, 128, 3847, 3859, "demonstrated" +381, 32, 18, 840, 129, 130, 3860, 3861, "a" +381, 32, 19, 841, 131, 135, 3862, 3866, "good" +381, 32, 20, 842, 136, 142, 3867, 3873, "safety" +381, 32, 21, 843, 143, 150, 3874, 3881, "profile" +381, 32, 22, 844, 151, 153, 3882, 3884, "in" +381, 32, 23, 845, 154, 160, 3885, 3891, "Korean" +381, 32, 24, 846, 161, 169, 3892, 3900, "patients" +381, 32, 25, 847, 170, 174, 3901, 3905, "with" +381, 32, 26, 848, 175, 187, 3906, 3918, "inadequately" +381, 32, 27, 849, 188, 198, 3919, 3929, "controlled" +381, 32, 28, 850, 199, 203, 3930, 3934, "T2DM" +381, 32, 29, 851, 204, 205, 3935, 3936, "." +381, 33, 1, 852, 0, 1, 3937, 3938, "©" +381, 33, 2, 853, 2, 6, 3939, 3943, "2018" +381, 33, 3, 854, 7, 10, 3944, 3947, "The" +381, 33, 4, 855, 11, 18, 3948, 3955, "Authors" +381, 33, 5, 856, 19, 20, 3956, 3957, "." +381, 34, 1, 857, 0, 8, 3958, 3966, "Diabetes" +381, 34, 2, 858, 9, 10, 3967, 3968, "," +381, 34, 3, 859, 11, 18, 3969, 3976, "Obesity" +381, 34, 4, 860, 19, 22, 3977, 3980, "and" +381, 34, 5, 861, 23, 33, 3981, 3991, "Metabolism" +381, 34, 6, 862, 34, 43, 3992, 4001, "published" +381, 34, 7, 863, 44, 46, 4002, 4004, "by" +381, 34, 8, 864, 47, 51, 4005, 4009, "John" +381, 34, 9, 865, 52, 57, 4010, 4015, "Wiley" +381, 34, 10, 866, 58, 59, 4016, 4017, "&" +381, 34, 11, 867, 60, 64, 4018, 4022, "Sons" +381, 34, 12, 868, 65, 68, 4023, 4026, "Ltd" +381, 34, 13, 869, 69, 70, 4027, 4028, "." +381, 34, 14, 870, 71, 74, 4029, 4032, "DOI" +381, 34, 15, 871, 75, 76, 4033, 4034, ":" +381, 34, 16, 872, 77, 79, 4035, 4037, "10" +381, 34, 17, 873, 80, 81, 4038, 4039, "." +381, 34, 18, 874, 82, 86, 4040, 4044, "1111" +381, 34, 19, 875, 87, 88, 4045, 4046, "/" +381, 34, 20, 876, 89, 92, 4047, 4050, "dom" +381, 34, 21, 877, 93, 94, 4051, 4052, "." +381, 34, 22, 878, 95, 100, 4053, 4058, "13394" +381, 34, 23, 879, 101, 106, 4059, 4064, "PMCID" +381, 34, 24, 880, 107, 108, 4065, 4066, ":" +381, 34, 25, 881, 109, 119, 4067, 4077, "PMC6175352" +381, 34, 26, 882, 120, 124, 4078, 4082, "PMID" +381, 34, 27, 883, 125, 126, 4083, 4084, ":" +381, 34, 28, 884, 127, 135, 4085, 4093, "29862619" +381, 34, 29, 885, 136, 137, 4094, 4095, "[" +381, 34, 30, 886, 138, 145, 4096, 4103, "Indexed" +381, 34, 31, 887, 146, 149, 4104, 4107, "for" +381, 34, 32, 888, 150, 157, 4108, 4115, "MEDLINE" +381, 34, 33, 889, 158, 159, 4116, 4117, "]" diff --git a/data/dm2 29862619_kwoodley.annodb b/data/dm2 29862619_kwoodley.annodb new file mode 100644 index 0000000..745dc78 --- /dev/null +++ b/data/dm2 29862619_kwoodley.annodb @@ -0,0 +1,137 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73206, Journal, 0, 19, "Diabetes Obes Metab", "", +73207, PublicationYear, 22, 26, "2018", "", +73236, Title, 110, 305, "Efficacy and safety of ipragliflozin as an add - on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus : A randomized controlled trial .", "", +73208, Drug, 133, 146, "ipragliflozin", "", +73217, Sitagliptin, 173, 184, "sitagliptin", "", +73221, Metformin, 189, 198, "metformin", "", +73225, Ethnicity, 202, 208, "Korean", "", +73234, Precondition, 209, 271, "patients with inadequately controlled type 2 diabetes mellitus", "", +73228, Type2Diabetes, 247, 271, "type 2 diabetes mellitus", "", +73232, Randomized, 276, 286, "randomized", "", +73237, Author, 306, 312, "Han KA", "", +73238, Author, 321, 327, "Chon S", "", +73239, Author, 336, 344, "Chung CH", "", +73240, Author, 353, 358, "Lim S", "", +73241, Author, 367, 373, "Lee KW", "", +73242, Author, 382, 388, "Baik S", "", +73243, Author, 397, 404, "Jung CH", "", +73244, Author, 413, 419, "Kim DS", "", +73245, Author, 428, 435, "Park KS", "", +73246, Author, 444, 451, "Yoon KH", "", +73247, Author, 461, 467, "Lee IK", "", +73248, Author, 477, 483, "Cha BS", "", +73249, Author, 493, 503, "Sakatani T", "", +73250, Author, 513, 519, "Park S", "", +73251, Author, 529, 535, "Lee MK", "", +73252, SouthKorea, 628, 633, "Korea", "", +73253, SouthKorea, 682, 687, "Korea", "", +73254, SouthKorea, 761, 766, "Korea", "", +73255, SouthKorea, 881, 886, "Korea", "", +73256, SouthKorea, 935, 940, "Korea", "", +73257, SouthKorea, 990, 995, "Korea", "", +73258, SouthKorea, 1121, 1126, "Korea", "", +73259, SouthKorea, 1218, 1223, "Korea", "", +73260, SouthKorea, 1322, 1327, "Korea", "", +73261, SouthKorea, 1459, 1464, "Korea", "", +73262, SouthKorea, 1557, 1562, "Korea", "", +73263, SouthKorea, 1653, 1658, "Korea", "", +73266, Japan, 1764, 1769, "Japan", "", +73264, SouthKorea, 1869, 1874, "Korea", "", +73265, SouthKorea, 1987, 1992, "Korea", "", +73274, ObjectiveDescription, 2001, 2173, "To evaluate the efficacy and safety of ipragliflozin vs placebo as add - on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus ( T2DM ) .", "", +73209, Drug, 2040, 2053, "ipragliflozin", "", +73267, Placebo, 2057, 2064, "placebo", "", +73222, Metformin, 2088, 2097, "metformin", "", +73218, Sitagliptin, 2102, 2113, "sitagliptin", "", +73226, Ethnicity, 2117, 2123, "Korean", "", +73229, Type2Diabetes, 2138, 2162, "type 2 diabetes mellitus", "", +73230, Type2Diabetes, 2165, 2169, "T2DM", "", +73275, DoubleBlind, 2189, 2203, "double - blind", "", +73276, Placebo, 2206, 2213, "placebo", "", +73277, Multicenter, 2229, 2243, "multi - centre", "", +73278, SouthKorea, 2279, 2284, "Korea", "", +73279, Duration, 2288, 2300, "2015 to 2017", "", +73233, Randomized, 2317, 2327, "randomized", "", +73210, Drug, 2346, 2359, "ipragliflozin", "", +73280, DoseValue, 2360, 2362, "50", "", +73281, mg, 2363, 2365, "mg", "", +73282, Frequency, 2368, 2371, "day", "", +73268, Placebo, 2375, 2382, "placebo", "", +73283, Frequency, 2383, 2393, "once daily", "", +73284, Duration, 2398, 2406, "24 weeks", "", +73223, Metformin, 2422, 2431, "metformin", "", +73219, Sitagliptin, 2436, 2447, "sitagliptin", "", +73285, HbA1c, 2489, 2509, "glycated haemoglobin", "", +73286, HbA1c, 2512, 2517, "HbA1c", "", +73287, TimePoint, 2525, 2533, "baseline", "", +73288, TimePoint, 2537, 2553, "end of treatment", "", +73289, TimePoint, 2556, 2559, "EOT", "", +73294, NumberPatientsCT, 2585, 2588, "143", "", +73295, Randomized, 2603, 2613, "randomized", "", +73296, FinalNumPatientsCT, 2618, 2621, "139", "", +73211, Drug, 2659, 2672, "ipragliflozin", "", +73302, FinalNumPatientsArm, 2675, 2677, "73", "", +73269, Placebo, 2680, 2687, "placebo", "", +73304, FinalNumPatientsArm, 2690, 2692, "66", "", +73309, Mean, 2706, 2717, "mean ( SD )", "", +73311, HbA1c, 2718, 2723, "HbA1c", "", +73313, BaseLineValue, 2736, 2742, "7 . 90", "", +73314, BaseLineValue, 2745, 2751, "0 . 69", "", +73319, Percentage, 2754, 2755, "%", "", +73212, Drug, 2760, 2773, "ipragliflozin", "", +73316, BaseLineValue, 2787, 2793, "7 . 92", "", +73318, BaseLineValue, 2796, 2802, "0 . 79", "", +73321, Percentage, 2805, 2806, "%", "", +73270, Placebo, 2811, 2818, "placebo", "", +73323, Mean, 2839, 2850, "mean ( SD )", "", +73290, TimePoint, 2864, 2872, "baseline", "", +73291, TimePoint, 2876, 2879, "EOT", "", +73324, Reduction, 2887, 2893, "0 . 79", "", +73327, Reduction, 2896, 2902, "0 . 59", "", +73330, Percentage, 2905, 2906, "%", "", +73328, Increment, 2911, 2917, "0 . 03", "", +73329, Increment, 2920, 2926, "0 . 84", "", +73331, Percentage, 2929, 2930, "%", "", +73213, Drug, 2961, 2974, "ipragliflozin", "", +73333, DiffGroupAbsValue, 3002, 3010, "- 0 . 83", "", +73332, Percentage, 3011, 3012, "%", "", +73334, ConfIntervalDiff, 3015, 3043, "95 % CI - 1 . 07 to - 0 . 59", "", +73336, PvalueDiff, 3048, 3058, "P < . 0001", "", +73214, Drug, 3068, 3081, "ipragliflozin", "", +73271, Placebo, 3106, 3113, "placebo", "", +73338, HbA1c_target, 3142, 3174, "HbA1c target levels of < 7 . 0 %", "", +73342, PercentageAffected, 3177, 3183, "44 . 4", "", +73343, PercentageAffected, 3189, 3195, "12 . 1", "", +73340, HbA1c_target, 3204, 3213, "< 6 . 5 %", "", +73345, PercentageAffected, 3216, 3222, "12 . 5", "", +73346, PercentageAffected, 3228, 3233, "1 . 5", "", +73292, TimePoint, 3241, 3244, "EOT", "", +73349, PValueResValue, 3247, 3255, "P < . 05", "", +73351, FastingPlasmaGlucose, 3269, 3291, "Fasting plasma glucose", "", +73353, EndPointDescription, 3294, 3315, "fasting serum insulin", "", +73358, BodyWeight, 3318, 3329, "body weight", "", +73356, EndPointDescription, 3334, 3384, "homeostatic model assessment of insulin resistance", "", +73293, TimePoint, 3412, 3415, "EOT", "", +73215, Drug, 3431, 3444, "ipragliflozin", "", +73360, DiffGroupAbsValue, 3472, 3480, "- 1 . 64", "", +73370, Millimoles_per_litre, 3481, 3489, "mmol / L", "", +73363, DiffGroupAbsValue, 3492, 3500, "- 1 . 50", "", +73373, MicroUnits_per_milliliter, 3501, 3509, "μ U / mL", "", +73366, DiffGroupAbsValue, 3512, 3520, "- 1 . 72", "", +73376, Kg, 3521, 3523, "kg", "", +73367, DiffGroupAbsValue, 3530, 3538, "- 0 . 99", "", +73381, PvalueDiff, 3556, 3564, "P < . 05", "", +73382, EndPointDescription, 3577, 3590, "Adverse event", "", +73273, Drug, 3627, 3640, "ipragliflozin", "", +73383, PercentageAffected, 3643, 3649, "51 . 4", "", +73272, Placebo, 3654, 3661, "placebo", "", +73384, PercentageAffected, 3664, 3670, "50 . 0", "", +73216, Drug, 3745, 3758, "Ipragliflozin", "", +73386, ConclusionComment, 3745, 3936, "Ipragliflozin as add - on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM .", "", +73224, Metformin, 3774, 3783, "metformin", "", +73220, Sitagliptin, 3788, 3799, "sitagliptin", "", +73227, Ethnicity, 3885, 3891, "Korean", "", +73235, Precondition, 3892, 3934, "patients with inadequately controlled T2DM", "", +73231, Type2Diabetes, 3930, 3934, "T2DM", "", +73387, PMID, 4085, 4093, "29862619", "", diff --git a/data/dm2 29862619_kwoodley.n-triples b/data/dm2 29862619_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 29862619_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 30019498_admin.annodb b/data/dm2 30019498_admin.annodb new file mode 100644 index 0000000..0139c53 --- /dev/null +++ b/data/dm2 30019498_admin.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Diabetes Obes Metab .", "", " \"Diabetes Obes Metab .\"." +1, PublicationYear, 22, 26, "2018", "", " \"2018\"." +24, Title, 110, 305, "A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency : The CompoSIT - R study .", "", " \"A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency : The CompoSIT - R study .\"." +2, Randomized, 112, 122, "randomized", "", " ." +3, Sitagliptin, 168, 179, "sitagliptin", "", +11, Dapagliflozin, 194, 207, "dapagliflozin", "", +21, Type2Diabetes, 225, 249, "type 2 diabetes mellitus", "", " ." +96529, DisorderOrSyndrome, 259, 278, "renal insufficiency", "", " . ." +25, Author, 306, 313, "Scott R", "", " \"Scott R\"." +26, Author, 322, 330, "Morgan J", "", " \"Morgan J\"." +27, Author, 339, 347, "Zimmer Z", "", " \"Zimmer Z\"." +28, Author, 356, 363, "Lam RLH", "", " \"Lam RLH\"." +29, Author, 372, 384, "O ' Neill EA", "", " \"O ' Neill EA\"." +30, Author, 393, 403, "Kaufman KD", "", " \"Kaufman KD\"." +31, Author, 412, 420, "Engel SS", "", " \"Engel SS\"." +32, Author, 429, 435, "Raji A", "", " \"Raji A\"." +33, Country, 556, 567, "New Zealand", "", " . ." +34, USA, 612, 622, "New Jersey", "", " ." +36, ObjectiveDescription, 631, 849, "To compare the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin with the sodium - glucose transporter - 2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency .", "", " \"To compare the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin with the sodium - glucose transporter - 2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency .\"." +4, Sitagliptin, 708, 719, "sitagliptin", "", +13, Dapagliflozin, 772, 785, "dapagliflozin", "", +35, Precondition, 789, 847, "patients with type 2 diabetes and mild renal insufficiency", "", " \"patients with type 2 diabetes and mild renal insufficiency\"." +22, Type2Diabetes, 803, 818, "type 2 diabetes", "", +96528, DisorderOrSyndrome, 828, 847, "renal insufficiency", "", +106274, Precondition, 874, 1070, "Patients with HbA1c ≥ 7 . 0 to ≤ 9 . 5 % ( ≥ 53 to ≤ 80   mmol / mol ) and estimated glomerular filtration rate ≥ 60 to < 90   mL / min / 1 . 73m2 on metformin ( ≥ 1500   mg / d )  ±  sulfonylurea", "", " \"Patients with HbA1c ≥ 7 . 0 to ≤ 9 . 5 % ( ≥ 53 to ≤ 80   mmol / mol ) and estimated glomerular filtration rate ≥ 60 to < 90   mL / min / 1 . 73m2 on metformin ( ≥ 1500   mg / d )  ±  sulfonylurea\"." +37, HbA1c, 888, 893, "HbA1c", "", +38, Percentage, 913, 914, "%", "", +135, Millimoles_per_litre, 932, 942, "mmol / mol", "", +73, EndPointDescription, 949, 985, "estimated glomerular filtration rate", "", +74, BioAndMedicalUnit, 1001, 1020, "mL / min / 1 . 73m2", "", +40, Metformin, 1024, 1033, "metformin", "", +42, DoseValue, 1036, 1042, "≥ 1500", "", +45, mg, 1045, 1047, "mg", "", +50, Frequency, 1050, 1051, "d", "", +52, Sulfonylureas, 1058, 1070, "sulfonylurea", "", +55, Randomized, 1076, 1086, "randomized", "", +5, Sitagliptin, 1090, 1101, "sitagliptin", "", " ." +43, DoseValue, 1102, 1105, "100", "", " \"100\"." +46, mg, 1108, 1110, "mg", "", " ." +56, NumberPatientsArm, 1119, 1122, "307", "", " \"307\"." +12, Dapagliflozin, 1128, 1141, "dapagliflozin", "", " ." +44, DoseValue, 1142, 1143, "5", "", +58, DoseDescription, 1142, 1164, "5 mg titrated to 10 mg", "", " \"5 mg titrated to 10 mg\"." +47, mg, 1144, 1146, "mg", "", +49, DoseValue, 1159, 1161, "10", "", +48, mg, 1162, 1164, "mg", "", +57, NumberPatientsArm, 1173, 1176, "306", "", " \"306\"." +51, Frequency, 1179, 1189, "once daily", "", " \"once daily\". \"once daily\"." +59, Duration, 1194, 1204, "24   weeks", "", " \"24   weeks\"." +60, MeasurementDevice, 1209, 1241, "longitudinal data analysis model", "", +20, Sitagliptin, 1287, 1298, "sitagliptin", "", +14, Dapagliflozin, 1320, 1333, "dapagliflozin", "", +61, HbA1c, 1346, 1351, "HbA1c", "", +62, TimePoint, 1355, 1362, "Week 24", "", +162, TimePoint, 1470, 1478, "Baseline", "", +163, Mean, 1479, 1483, "mean", "", +65, HbA1c, 1484, 1489, "HbA1c", "", " ." +66, Percentage, 1492, 1493, "%", "", " ." +136, Millimoles_per_litre, 1496, 1506, "mmol / mol", "", +68, BaseLineValue, 1515, 1520, "7 . 7", "", " \"7 . 7\"." +69, BaseLineValue, 1523, 1529, "60 . 9", "", +70, BaseLineValue, 1536, 1541, "7 . 8", "", " \"7 . 8\"." +71, BaseLineValue, 1544, 1550, "61 . 2", "", +169, Mean, 1559, 1563, "mean", "", +72, EndPointDescription, 1564, 1568, "eGFR", "", " . ." +75, BioAndMedicalUnit, 1571, 1590, "mL / min / 1 . 73m2", "", " . ." +76, BaseLineValue, 1597, 1603, "79 . 4", "", +77, BaseLineValue, 1608, 1614, "76 . 9", "", " \"76 . 9\"." +6, Sitagliptin, 1623, 1634, "sitagliptin", "", +15, Dapagliflozin, 1639, 1652, "dapagliflozin", "", +63, TimePoint, 1683, 1693, "24   weeks", "", " \"24   weeks\". \"24   weeks\"." +78, LeastSquaresMean, 1730, 1748, "least squares mean", "", " ." +79, ConfIntervalChangeValue, 1751, 1758, "95 % CI", "", +64, TimePoint, 1774, 1782, "baseline", "", +80, HbA1c, 1786, 1791, "HbA1c", "", +181, DiffGroupAbsValue, 1796, 1804, "- 0 . 15", "", " \"- 0 . 15\"." +83, Percentage, 1805, 1806, "%", "", +183, ConfIntervalDiff, 1809, 1828, "- 0 . 26 , - 0 . 04", "", " \"- 0 . 26 , - 0 . 04\"." +182, DiffGroupAbsValue, 1833, 1841, "- 1 . 67", "", +137, Millimoles_per_litre, 1844, 1854, "mmol / mol", "", +184, ConfIntervalDiff, 1857, 1876, "- 2 . 86 , - 0 . 48", "", +185, PvalueDiff, 1883, 1896, "P  =  0 . 006", "", " \"P  =  0 . 006\"." +7, Sitagliptin, 1989, 2000, "sitagliptin", "", +16, Dapagliflozin, 2008, 2021, "dapagliflozin", "", +88, HbA1c_target, 2028, 2069, "HbA1c goal of < 7 % ( < 53   mmol / mol )", "", " ." +129, Percentage, 2046, 2047, "%", "", +138, Millimoles_per_litre, 2057, 2067, "mmol / mol", "", +89, PercentageAffected, 2081, 2083, "43", "", " \"43\"." +8, Sitagliptin, 2088, 2099, "sitagliptin", "", +90, PercentageAffected, 2106, 2108, "27", "", " \"27\"." +17, Dapagliflozin, 2113, 2126, "dapagliflozin", "", +92, ObservedResult, 2143, 2283, "No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion .", "", " \"No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion .\". \"No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion .\"." +91, PostprandialBloodGlucose, 2230, 2281, "2 - hour incremental postprandial glucose excursion", "", " ." +93, EndPointDescription, 2296, 2310, "adverse events", "", " . ." +94, EndPointDescription, 2313, 2316, "AEs", "", +97, ObservedResult, 2317, 2419, ") was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin", "", " \") was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin\". \") was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin\"." +95, EndPointDescription, 2371, 2374, "AEs", "", +9, Sitagliptin, 2380, 2391, "sitagliptin", "", +18, Dapagliflozin, 2406, 2419, "dapagliflozin", "", +99, ConclusionComment, 2436, 2635, "In patients with type 2 diabetes , mild renal insufficiency and inadequate glycaemic control on metformin  ±  sulfonylurea , sitagliptin treatment resulted in greater improvement in glycaemic control", "", " \"In patients with type 2 diabetes , mild renal insufficiency and inadequate glycaemic control on metformin  ±  sulfonylurea , sitagliptin treatment resulted in greater improvement in glycaemic control\"." +23, Type2Diabetes, 2453, 2468, "type 2 diabetes", "", +96512, DisorderOrSyndrome, 2476, 2495, "renal insufficiency", "", +41, Metformin, 2532, 2541, "metformin", "", +53, Sulfonylureas, 2546, 2558, "sulfonylurea", "", +10, Sitagliptin, 2561, 2572, "sitagliptin", "", +100, ConclusionComment, 2636, 2698, "compared with dapagliflozin and was generally well tolerated .", "", " \"compared with dapagliflozin and was generally well tolerated .\"." +19, Dapagliflozin, 2650, 2663, "dapagliflozin", "", +101, PMID, 2847, 2855, "30019498", "", " \"30019498\"." diff --git a/data/dm2 30019498_admin.n-triples b/data/dm2 30019498_admin.n-triples new file mode 100644 index 0000000..ac9f3ce --- /dev/null +++ b/data/dm2 30019498_admin.n-triples @@ -0,0 +1,172 @@ +# RDF export of group: Publication + . + "Publication 82476" . + "A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency : The CompoSIT - R study ." . + "Scott R" . + "2018" . + "Diabetes Obes Metab ." . + "30019498" . + . + "Morgan J" . + "Zimmer Z" . + "Lam RLH" . + "O ' Neill EA" . + "Kaufman KD" . + "Engel SS" . + "Raji A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 82483" . + "To compare the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin with the sodium - glucose transporter - 2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency ." . + "24   weeks" . + . + . + . + "In patients with type 2 diabetes , mild renal insufficiency and inadequate glycaemic control on metformin  ±  sulfonylurea , sitagliptin treatment resulted in greater improvement in glycaemic control" . + . + . + . + . + . + . + . + . + "compared with dapagliflozin and was generally well tolerated ." . +# RDF export of group: Population + . + "Population 82499" . + "patients with type 2 diabetes and mild renal insufficiency" . + . + . + . + "Patients with HbA1c ≥ 7 . 0 to ≤ 9 . 5 % ( ≥ 53 to ≤ 80   mmol / mol ) and estimated glomerular filtration rate ≥ 60 to < 90   mL / min / 1 . 73m2 on metformin ( ≥ 1500   mg / d )  ±  sulfonylurea" . + . + . +# RDF export of group: Endpoint + . + "hba" . + . + . + . + . + . + "egfr" . + . + . + . + . + . + . + . + "hbat" . + . + . + . + . + . + "pbg" . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "sit" . + "307" . + . + . + . + . + . + . + . + "dap" . + "306" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "sit" . + . + "once daily" . + . + . + "dap" . + . + "once daily" . + . +# RDF export of group: Medication + . + "sit" . + . + "100" . + . + . + . + "dap" . + . + . + "5 mg titrated to 10 mg" . + . +# RDF export of group: Outcome + . + "hba 1" . + . + "7 . 7" . + "24   weeks" . + . + "hba 2" . + . + "7 . 8" . + "24   weeks" . + . + "egfr 1" . + . + "76 . 9" . + . + "egfr 2" . + . + . + "hbat 1" . + . + "43" . + . + "hbat 2" . + . + "27" . + . + "pbg 1" . + . + "No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion ." . + . + "pbg 2" . + . + "No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion ." . + . + "ae 1" . + . + ") was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin" . + . + "ae 2" . + . + ") was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin" . +# RDF export of group: DiffBetweenGroups + . + "hba" . + "- 0 . 15" . + "P  =  0 . 006" . + "- 0 . 26 , - 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 30019498_akramersunderbrink.annodb b/data/dm2 30019498_akramersunderbrink.annodb new file mode 100644 index 0000000..0c5e248 --- /dev/null +++ b/data/dm2 30019498_akramersunderbrink.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +74178, Journal, 0, 19, "Diabetes Obes Metab", "", +74179, PublicationYear, 22, 26, "2018", "", +74185, Title, 110, 305, "A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency : The CompoSIT - R study .", "", +74180, Randomized, 112, 122, "randomized", "", +74181, Sitagliptin, 168, 179, "sitagliptin", "", +74182, Dapagliflozin, 194, 207, "dapagliflozin", "", +74183, Type2Diabetes, 225, 249, "type 2 diabetes mellitus", "", +74184, Precondition, 254, 278, "mild renal insufficiency", "", +74186, Author, 306, 313, "Scott R", "", +74187, Author, 322, 330, "Morgan J", "", +74188, Author, 339, 347, "Zimmer Z", "", +74189, Author, 356, 363, "Lam RLH", "", +74190, Author, 372, 384, "O ' Neill EA", "", +74191, Author, 393, 403, "Kaufman KD", "", +74192, Author, 412, 420, "Engel SS", "", +74193, Author, 429, 435, "Raji A", "", +74194, Country, 556, 567, "New Zealand", "", +74199, ObjectiveDescription, 631, 849, "To compare the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin with the sodium - glucose transporter - 2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency .", "", +74195, Sitagliptin, 708, 719, "sitagliptin", "", +74196, Dapagliflozin, 772, 785, "dapagliflozin", "", +74197, Type2Diabetes, 803, 818, "type 2 diabetes", "", +74198, Precondition, 823, 847, "mild renal insufficiency", "", +74200, HbA1c, 888, 893, "HbA1c", "", +74208, Precondition, 888, 944, "HbA1c ≥ 7 . 0 to ≤ 9 . 5 % ( ≥ 53 to ≤ 80   mmol / mol )", "", +74201, Percentage, 913, 914, "%", "", +74211, Millimoles_per_litre, 932, 942, "mmol / mol", "", +74246, EndPointDescription, 949, 985, "estimated glomerular filtration rate", "", +74209, Precondition, 949, 1020, "estimated glomerular filtration rate ≥ 60 to < 90   mL / min / 1 . 73m2", "", +74215, BioAndMedicalUnit, 1001, 1020, "mL / min / 1 . 73m2", "", +74210, Precondition, 1021, 1070, "on metformin ( ≥ 1500   mg / d )  ±  sulfonylurea", "", +74216, Metformin, 1024, 1033, "metformin", "", +74218, DoseValue, 1036, 1051, "≥ 1500   mg / d", "", +74219, BioAndMedicalUnit, 1045, 1051, "mg / d", "", +74217, Sulfonylureas, 1058, 1070, "sulfonylurea", "", +74220, Randomized, 1076, 1086, "randomized", "", +74221, Sitagliptin, 1090, 1101, "sitagliptin", "", +74222, DoseValue, 1102, 1110, "100   mg", "", +74225, mg, 1108, 1110, "mg", "", +74228, NumberPatientsArm, 1119, 1122, "307", "", +74230, Dapagliflozin, 1128, 1141, "dapagliflozin", "", +74223, DoseValue, 1142, 1146, "5 mg", "", +74233, DoseDescription, 1142, 1164, "5 mg titrated to 10 mg", "", +74226, mg, 1144, 1146, "mg", "", +74224, DoseValue, 1159, 1164, "10 mg", "", +74227, mg, 1162, 1164, "mg", "", +74229, NumberPatientsArm, 1173, 1176, "306", "", +74231, Frequency, 1179, 1189, "once daily", "", +74232, Duration, 1194, 1204, "24   weeks", "", +74234, Sitagliptin, 1287, 1298, "sitagliptin", "", +74235, Dapagliflozin, 1320, 1333, "dapagliflozin", "", +74236, HbA1c, 1346, 1351, "HbA1c", "", +74237, TimePoint, 1355, 1362, "Week 24", "", +74238, TimePoint, 1470, 1478, "Baseline", "", +74239, Mean, 1479, 1483, "mean", "", +74240, HbA1c, 1484, 1489, "HbA1c", "", +74202, Percentage, 1492, 1493, "%", "", +74212, Millimoles_per_litre, 1496, 1506, "mmol / mol", "", +74241, BaseLineValue, 1515, 1520, "7 . 7", "", +74242, BaseLineValue, 1523, 1529, "60 . 9", "", +74243, BaseLineValue, 1536, 1541, "7 . 8", "", +74244, BaseLineValue, 1544, 1550, "61 . 2", "", +74245, Mean, 1559, 1563, "mean", "", +74247, EndPointDescription, 1564, 1568, "eGFR", "", +74248, BioAndMedicalUnit, 1571, 1590, "mL / min / 1 . 73m2", "", +74249, BaseLineValue, 1597, 1603, "79 . 4", "", +74250, BaseLineValue, 1608, 1614, "76 . 9", "", +74251, Sitagliptin, 1623, 1634, "sitagliptin", "", +74252, Dapagliflozin, 1639, 1652, "dapagliflozin", "", +74253, TimePoint, 1683, 1693, "24   weeks", "", +74254, LeastSquaresMean, 1730, 1748, "least squares mean", "", +74203, Percentage, 1754, 1755, "%", "", +74255, TimePoint, 1774, 1782, "baseline", "", +74256, HbA1c, 1786, 1791, "HbA1c", "", +74257, DiffGroupAbsValue, 1796, 1804, "- 0 . 15", "", +74204, Percentage, 1805, 1806, "%", "", +74261, ConfIntervalDiff, 1809, 1828, "- 0 . 26 , - 0 . 04", "", +74260, DiffGroupAbsValue, 1833, 1841, "- 1 . 67", "", +74213, Millimoles_per_litre, 1844, 1854, "mmol / mol", "", +74262, ConfIntervalDiff, 1857, 1876, "- 2 . 86 , - 0 . 48", "", +74263, PvalueDiff, 1883, 1896, "P  =  0 . 006", "", +74264, Sitagliptin, 1989, 2000, "sitagliptin", "", +74265, Dapagliflozin, 2008, 2021, "dapagliflozin", "", +74266, HbA1c_target, 2028, 2069, "HbA1c goal of < 7 % ( < 53   mmol / mol )", "", +74205, Percentage, 2046, 2047, "%", "", +74214, Millimoles_per_litre, 2057, 2067, "mmol / mol", "", +74268, PercentageAffected, 2081, 2083, "43", "", +74206, Percentage, 2084, 2085, "%", "", +74270, Sitagliptin, 2088, 2099, "sitagliptin", "", +74269, PercentageAffected, 2106, 2108, "27", "", +74207, Percentage, 2109, 2110, "%", "", +74271, Dapagliflozin, 2113, 2126, "dapagliflozin", "", +74272, Sitagliptin, 2380, 2391, "sitagliptin", "", +74273, Dapagliflozin, 2406, 2419, "dapagliflozin", "", +74274, Type2Diabetes, 2453, 2468, "type 2 diabetes", "", +74275, Metformin, 2532, 2541, "metformin", "", +74276, Sulfonylureas, 2546, 2558, "sulfonylurea", "", +74277, Sitagliptin, 2561, 2572, "sitagliptin", "", +74278, Dapagliflozin, 2650, 2663, "dapagliflozin", "", +74279, PMID, 2847, 2855, "30019498", "", diff --git a/data/dm2 30019498_akramersunderbrink.n-triples b/data/dm2 30019498_akramersunderbrink.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 30019498_akramersunderbrink.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/dm2 30019498_export.csv b/data/dm2 30019498_export.csv new file mode 100644 index 0000000..acbbd8c --- /dev/null +++ b/data/dm2 30019498_export.csv @@ -0,0 +1,627 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +380, 1, 1, 1, 0, 8, 0, 8, "Diabetes" +380, 1, 2, 2, 9, 13, 9, 13, "Obes" +380, 1, 3, 3, 14, 19, 14, 19, "Metab" +380, 1, 4, 4, 20, 21, 20, 21, "." +380, 2, 1, 5, 0, 4, 22, 26, "2018" +380, 2, 2, 6, 5, 8, 27, 30, "Dec" +380, 2, 3, 7, 9, 10, 31, 32, ";" +380, 2, 4, 8, 11, 13, 33, 35, "20" +380, 2, 5, 9, 14, 15, 36, 37, "(" +380, 2, 6, 10, 16, 18, 38, 40, "12" +380, 2, 7, 11, 19, 20, 41, 42, ")" +380, 2, 8, 12, 21, 22, 43, 44, ":" +380, 2, 9, 13, 23, 27, 45, 49, "2876" +380, 2, 10, 14, 28, 29, 50, 51, "-" +380, 2, 11, 15, 30, 34, 52, 56, "2884" +380, 2, 12, 16, 35, 36, 57, 58, "." +380, 2, 13, 17, 37, 40, 59, 62, "doi" +380, 2, 14, 18, 41, 42, 63, 64, ":" +380, 2, 15, 19, 43, 45, 65, 67, "10" +380, 2, 16, 20, 46, 47, 68, 69, "." +380, 2, 17, 21, 48, 52, 70, 74, "1111" +380, 2, 18, 22, 53, 54, 75, 76, "/" +380, 2, 19, 23, 55, 58, 77, 80, "dom" +380, 2, 20, 24, 59, 60, 81, 82, "." +380, 2, 21, 25, 61, 66, 83, 88, "13473" +380, 2, 22, 26, 67, 68, 89, 90, "." +380, 3, 1, 27, 0, 4, 91, 95, "Epub" +380, 3, 2, 28, 5, 9, 96, 100, "2018" +380, 3, 3, 29, 10, 13, 101, 104, "Aug" +380, 3, 4, 30, 14, 16, 105, 107, "16" +380, 3, 5, 31, 17, 18, 108, 109, "." +380, 4, 1, 32, 0, 1, 110, 111, "A" +380, 4, 2, 33, 2, 12, 112, 122, "randomized" +380, 4, 3, 34, 13, 21, 123, 131, "clinical" +380, 4, 4, 35, 22, 27, 132, 137, "trial" +380, 4, 5, 36, 28, 30, 138, 140, "of" +380, 4, 6, 37, 31, 34, 141, 144, "the" +380, 4, 7, 38, 35, 43, 145, 153, "efficacy" +380, 4, 8, 39, 44, 47, 154, 157, "and" +380, 4, 9, 40, 48, 54, 158, 164, "safety" +380, 4, 10, 41, 55, 57, 165, 167, "of" +380, 4, 11, 42, 58, 69, 168, 179, "sitagliptin" +380, 4, 12, 43, 70, 78, 180, 188, "compared" +380, 4, 13, 44, 79, 83, 189, 193, "with" +380, 4, 14, 45, 84, 97, 194, 207, "dapagliflozin" +380, 4, 15, 46, 98, 100, 208, 210, "in" +380, 4, 16, 47, 101, 109, 211, 219, "patients" +380, 4, 17, 48, 110, 114, 220, 224, "with" +380, 4, 18, 49, 115, 119, 225, 229, "type" +380, 4, 19, 50, 120, 121, 230, 231, "2" +380, 4, 20, 51, 122, 130, 232, 240, "diabetes" +380, 4, 21, 52, 131, 139, 241, 249, "mellitus" +380, 4, 22, 53, 140, 143, 250, 253, "and" +380, 4, 23, 54, 144, 148, 254, 258, "mild" +380, 4, 24, 55, 149, 154, 259, 264, "renal" +380, 4, 25, 56, 155, 168, 265, 278, "insufficiency" +380, 4, 26, 57, 169, 170, 279, 280, ":" +380, 4, 27, 58, 171, 174, 281, 284, "The" +380, 4, 28, 59, 175, 183, 285, 293, "CompoSIT" +380, 4, 29, 60, 184, 185, 294, 295, "-" +380, 4, 30, 61, 186, 187, 296, 297, "R" +380, 4, 31, 62, 188, 193, 298, 303, "study" +380, 4, 32, 63, 194, 195, 304, 305, "." +380, 5, 1, 64, 0, 5, 306, 311, "Scott" +380, 5, 2, 65, 6, 7, 312, 313, "R" +380, 5, 3, 66, 8, 9, 314, 315, "(" +380, 5, 4, 67, 10, 11, 316, 317, "1" +380, 5, 5, 68, 12, 13, 318, 319, ")" +380, 5, 6, 69, 14, 15, 320, 321, "," +380, 5, 7, 70, 16, 22, 322, 328, "Morgan" +380, 5, 8, 71, 23, 24, 329, 330, "J" +380, 5, 9, 72, 25, 26, 331, 332, "(" +380, 5, 10, 73, 27, 28, 333, 334, "2" +380, 5, 11, 74, 29, 30, 335, 336, ")" +380, 5, 12, 75, 31, 32, 337, 338, "," +380, 5, 13, 76, 33, 39, 339, 345, "Zimmer" +380, 5, 14, 77, 40, 41, 346, 347, "Z" +380, 5, 15, 78, 42, 43, 348, 349, "(" +380, 5, 16, 79, 44, 45, 350, 351, "2" +380, 5, 17, 80, 46, 47, 352, 353, ")" +380, 5, 18, 81, 48, 49, 354, 355, "," +380, 5, 19, 82, 50, 53, 356, 359, "Lam" +380, 5, 20, 83, 54, 57, 360, 363, "RLH" +380, 5, 21, 84, 58, 59, 364, 365, "(" +380, 5, 22, 85, 60, 61, 366, 367, "2" +380, 5, 23, 86, 62, 63, 368, 369, ")" +380, 5, 24, 87, 64, 65, 370, 371, "," +380, 5, 25, 88, 66, 67, 372, 373, "O" +380, 5, 26, 89, 68, 69, 374, 375, "'" +380, 5, 27, 90, 70, 75, 376, 381, "Neill" +380, 5, 28, 91, 76, 78, 382, 384, "EA" +380, 5, 29, 92, 79, 80, 385, 386, "(" +380, 5, 30, 93, 81, 82, 387, 388, "2" +380, 5, 31, 94, 83, 84, 389, 390, ")" +380, 5, 32, 95, 85, 86, 391, 392, "," +380, 5, 33, 96, 87, 94, 393, 400, "Kaufman" +380, 5, 34, 97, 95, 97, 401, 403, "KD" +380, 5, 35, 98, 98, 99, 404, 405, "(" +380, 5, 36, 99, 100, 101, 406, 407, "2" +380, 5, 37, 100, 102, 103, 408, 409, ")" +380, 5, 38, 101, 104, 105, 410, 411, "," +380, 5, 39, 102, 106, 111, 412, 417, "Engel" +380, 5, 40, 103, 112, 114, 418, 420, "SS" +380, 5, 41, 104, 115, 116, 421, 422, "(" +380, 5, 42, 105, 117, 118, 423, 424, "2" +380, 5, 43, 106, 119, 120, 425, 426, ")" +380, 5, 44, 107, 121, 122, 427, 428, "," +380, 5, 45, 108, 123, 127, 429, 433, "Raji" +380, 5, 46, 109, 128, 129, 434, 435, "A" +380, 5, 47, 110, 130, 131, 436, 437, "(" +380, 5, 48, 111, 132, 133, 438, 439, "2" +380, 5, 49, 112, 134, 135, 440, 441, ")" +380, 5, 50, 113, 136, 137, 442, 443, "." +380, 6, 1, 114, 0, 6, 444, 450, "Author" +380, 6, 2, 115, 7, 18, 451, 462, "information" +380, 6, 3, 116, 19, 20, 463, 464, ":" +380, 6, 4, 117, 21, 22, 465, 466, "(" +380, 6, 5, 118, 23, 24, 467, 468, "1" +380, 6, 6, 119, 25, 26, 469, 470, ")" +380, 6, 7, 120, 27, 32, 471, 476, "Lipid" +380, 6, 8, 121, 33, 36, 477, 480, "and" +380, 6, 9, 122, 37, 45, 481, 489, "Diabetes" +380, 6, 10, 123, 46, 54, 490, 498, "Research" +380, 6, 11, 124, 55, 60, 499, 504, "Group" +380, 6, 12, 125, 61, 62, 505, 506, "," +380, 6, 13, 126, 63, 75, 507, 519, "Christchurch" +380, 6, 14, 127, 76, 82, 520, 526, "School" +380, 6, 15, 128, 83, 85, 527, 529, "of" +380, 6, 16, 129, 86, 94, 530, 538, "Medicine" +380, 6, 17, 130, 95, 96, 539, 540, "," +380, 6, 18, 131, 97, 109, 541, 553, "Christchurch" +380, 6, 19, 132, 110, 111, 554, 555, "," +380, 6, 20, 133, 112, 115, 556, 559, "New" +380, 6, 21, 134, 116, 123, 560, 567, "Zealand" +380, 6, 22, 135, 124, 125, 568, 569, "." +380, 7, 1, 136, 0, 1, 570, 571, "(" +380, 7, 2, 137, 2, 3, 572, 573, "2" +380, 7, 3, 138, 4, 5, 574, 575, ")" +380, 7, 4, 139, 6, 11, 576, 581, "Merck" +380, 7, 5, 140, 12, 13, 582, 583, "&" +380, 7, 6, 141, 14, 16, 584, 586, "Co" +380, 7, 7, 142, 17, 18, 587, 588, "." +380, 7, 8, 143, 19, 20, 589, 590, "," +380, 7, 9, 144, 21, 24, 591, 594, "Inc" +380, 7, 10, 145, 25, 26, 595, 596, "." +380, 7, 11, 146, 27, 28, 597, 598, "," +380, 7, 12, 147, 29, 39, 599, 609, "Kenilworth" +380, 7, 13, 148, 40, 41, 610, 611, "," +380, 7, 14, 149, 42, 45, 612, 615, "New" +380, 7, 15, 150, 46, 52, 616, 622, "Jersey" +380, 7, 16, 151, 53, 54, 623, 624, "." +380, 8, 1, 152, 0, 3, 625, 628, "AIM" +380, 8, 2, 153, 4, 5, 629, 630, ":" +380, 8, 3, 154, 6, 8, 631, 633, "To" +380, 8, 4, 155, 9, 16, 634, 641, "compare" +380, 8, 5, 156, 17, 20, 642, 645, "the" +380, 8, 6, 157, 21, 29, 646, 654, "efficacy" +380, 8, 7, 158, 30, 33, 655, 658, "and" +380, 8, 8, 159, 34, 40, 659, 665, "safety" +380, 8, 9, 160, 41, 43, 666, 668, "of" +380, 8, 10, 161, 44, 47, 669, 672, "the" +380, 8, 11, 162, 48, 58, 673, 683, "dipeptidyl" +380, 8, 12, 163, 59, 68, 684, 693, "peptidase" +380, 8, 13, 164, 69, 70, 694, 695, "-" +380, 8, 14, 165, 71, 72, 696, 697, "4" +380, 8, 15, 166, 73, 82, 698, 707, "inhibitor" +380, 8, 16, 167, 83, 94, 708, 719, "sitagliptin" +380, 8, 17, 168, 95, 99, 720, 724, "with" +380, 8, 18, 169, 100, 103, 725, 728, "the" +380, 8, 19, 170, 104, 110, 729, 735, "sodium" +380, 8, 20, 171, 111, 112, 736, 737, "-" +380, 8, 21, 172, 113, 120, 738, 745, "glucose" +380, 8, 22, 173, 121, 132, 746, 757, "transporter" +380, 8, 23, 174, 133, 134, 758, 759, "-" +380, 8, 24, 175, 135, 136, 760, 761, "2" +380, 8, 25, 176, 137, 146, 762, 771, "inhibitor" +380, 8, 26, 177, 147, 160, 772, 785, "dapagliflozin" +380, 8, 27, 178, 161, 163, 786, 788, "in" +380, 8, 28, 179, 164, 172, 789, 797, "patients" +380, 8, 29, 180, 173, 177, 798, 802, "with" +380, 8, 30, 181, 178, 182, 803, 807, "type" +380, 8, 31, 182, 183, 184, 808, 809, "2" +380, 8, 32, 183, 185, 193, 810, 818, "diabetes" +380, 8, 33, 184, 194, 197, 819, 822, "and" +380, 8, 34, 185, 198, 202, 823, 827, "mild" +380, 8, 35, 186, 203, 208, 828, 833, "renal" +380, 8, 36, 187, 209, 222, 834, 847, "insufficiency" +380, 8, 37, 188, 223, 224, 848, 849, "." +380, 9, 1, 189, 0, 9, 850, 859, "MATERIALS" +380, 9, 2, 190, 10, 13, 860, 863, "AND" +380, 9, 3, 191, 14, 21, 864, 871, "METHODS" +380, 9, 4, 192, 22, 23, 872, 873, ":" +380, 9, 5, 193, 24, 32, 874, 882, "Patients" +380, 9, 6, 194, 33, 37, 883, 887, "with" +380, 9, 7, 195, 38, 43, 888, 893, "HbA1c" +380, 9, 8, 196, 44, 45, 894, 895, "≥" +380, 9, 9, 197, 46, 47, 896, 897, "7" +380, 9, 10, 198, 48, 49, 898, 899, "." +380, 9, 11, 199, 50, 51, 900, 901, "0" +380, 9, 12, 200, 52, 54, 902, 904, "to" +380, 9, 13, 201, 55, 56, 905, 906, "≤" +380, 9, 14, 202, 57, 58, 907, 908, "9" +380, 9, 15, 203, 59, 60, 909, 910, "." +380, 9, 16, 204, 61, 62, 911, 912, "5" +380, 9, 17, 205, 63, 64, 913, 914, "%" +380, 9, 18, 206, 65, 66, 915, 916, "(" +380, 9, 19, 207, 67, 68, 917, 918, "≥" +380, 9, 20, 208, 69, 71, 919, 921, "53" +380, 9, 21, 209, 72, 74, 922, 924, "to" +380, 9, 22, 210, 75, 76, 925, 926, "≤" +380, 9, 23, 211, 77, 79, 927, 929, "80" +380, 9, 24, 212, 80, 81, 930, 931, " " +380, 9, 25, 213, 82, 86, 932, 936, "mmol" +380, 9, 26, 214, 87, 88, 937, 938, "/" +380, 9, 27, 215, 89, 92, 939, 942, "mol" +380, 9, 28, 216, 93, 94, 943, 944, ")" +380, 9, 29, 217, 95, 98, 945, 948, "and" +380, 9, 30, 218, 99, 108, 949, 958, "estimated" +380, 9, 31, 219, 109, 119, 959, 969, "glomerular" +380, 9, 32, 220, 120, 130, 970, 980, "filtration" +380, 9, 33, 221, 131, 135, 981, 985, "rate" +380, 9, 34, 222, 136, 137, 986, 987, "≥" +380, 9, 35, 223, 138, 140, 988, 990, "60" +380, 9, 36, 224, 141, 143, 991, 993, "to" +380, 9, 37, 225, 144, 145, 994, 995, "<" +380, 9, 38, 226, 146, 148, 996, 998, "90" +380, 9, 39, 227, 149, 150, 999, 1000, " " +380, 9, 40, 228, 151, 153, 1001, 1003, "mL" +380, 9, 41, 229, 154, 155, 1004, 1005, "/" +380, 9, 42, 230, 156, 159, 1006, 1009, "min" +380, 9, 43, 231, 160, 161, 1010, 1011, "/" +380, 9, 44, 232, 162, 163, 1012, 1013, "1" +380, 9, 45, 233, 164, 165, 1014, 1015, "." +380, 9, 46, 234, 166, 170, 1016, 1020, "73m2" +380, 9, 47, 235, 171, 173, 1021, 1023, "on" +380, 9, 48, 236, 174, 183, 1024, 1033, "metformin" +380, 9, 49, 237, 184, 185, 1034, 1035, "(" +380, 9, 50, 238, 186, 187, 1036, 1037, "≥" +380, 9, 51, 239, 188, 192, 1038, 1042, "1500" +380, 9, 52, 240, 193, 194, 1043, 1044, " " +380, 9, 53, 241, 195, 197, 1045, 1047, "mg" +380, 9, 54, 242, 198, 199, 1048, 1049, "/" +380, 9, 55, 243, 200, 201, 1050, 1051, "d" +380, 9, 56, 244, 202, 203, 1052, 1053, ")" +380, 9, 57, 245, 204, 207, 1054, 1057, " ± " +380, 9, 58, 246, 208, 220, 1058, 1070, "sulfonylurea" +380, 9, 59, 247, 221, 225, 1071, 1075, "were" +380, 9, 60, 248, 226, 236, 1076, 1086, "randomized" +380, 9, 61, 249, 237, 239, 1087, 1089, "to" +380, 9, 62, 250, 240, 251, 1090, 1101, "sitagliptin" +380, 9, 63, 251, 252, 255, 1102, 1105, "100" +380, 9, 64, 252, 256, 257, 1106, 1107, " " +380, 9, 65, 253, 258, 260, 1108, 1110, "mg" +380, 9, 66, 254, 261, 262, 1111, 1112, "(" +380, 9, 67, 255, 263, 264, 1113, 1114, "n" +380, 9, 68, 256, 265, 268, 1115, 1118, " = " +380, 9, 69, 257, 269, 272, 1119, 1122, "307" +380, 9, 70, 258, 273, 274, 1123, 1124, ")" +380, 9, 71, 259, 275, 277, 1125, 1127, "or" +380, 9, 72, 260, 278, 291, 1128, 1141, "dapagliflozin" +380, 9, 73, 261, 292, 293, 1142, 1143, "5" +380, 9, 74, 262, 294, 296, 1144, 1146, "mg" +380, 9, 75, 263, 297, 305, 1147, 1155, "titrated" +380, 9, 76, 264, 306, 308, 1156, 1158, "to" +380, 9, 77, 265, 309, 311, 1159, 1161, "10" +380, 9, 78, 266, 312, 314, 1162, 1164, "mg" +380, 9, 79, 267, 315, 316, 1165, 1166, "(" +380, 9, 80, 268, 317, 318, 1167, 1168, "n" +380, 9, 81, 269, 319, 322, 1169, 1172, " = " +380, 9, 82, 270, 323, 326, 1173, 1176, "306" +380, 9, 83, 271, 327, 328, 1177, 1178, ")" +380, 9, 84, 272, 329, 333, 1179, 1183, "once" +380, 9, 85, 273, 334, 339, 1184, 1189, "daily" +380, 9, 86, 274, 340, 343, 1190, 1193, "for" +380, 9, 87, 275, 344, 346, 1194, 1196, "24" +380, 9, 88, 276, 347, 348, 1197, 1198, " " +380, 9, 89, 277, 349, 354, 1199, 1204, "weeks" +380, 9, 90, 278, 355, 356, 1205, 1206, "." +380, 10, 1, 279, 0, 1, 1207, 1208, "A" +380, 10, 2, 280, 2, 14, 1209, 1221, "longitudinal" +380, 10, 3, 281, 15, 19, 1222, 1226, "data" +380, 10, 4, 282, 20, 28, 1227, 1235, "analysis" +380, 10, 5, 283, 29, 34, 1236, 1241, "model" +380, 10, 6, 284, 35, 38, 1242, 1245, "was" +380, 10, 7, 285, 39, 43, 1246, 1250, "used" +380, 10, 8, 286, 44, 46, 1251, 1253, "to" +380, 10, 9, 287, 47, 51, 1254, 1258, "test" +380, 10, 10, 288, 52, 55, 1259, 1262, "the" +380, 10, 11, 289, 56, 63, 1263, 1270, "primary" +380, 10, 12, 290, 64, 74, 1271, 1281, "hypothesis" +380, 10, 13, 291, 75, 79, 1282, 1286, "that" +380, 10, 14, 292, 80, 91, 1287, 1298, "sitagliptin" +380, 10, 15, 293, 92, 94, 1299, 1301, "is" +380, 10, 16, 294, 95, 98, 1302, 1305, "non" +380, 10, 17, 295, 99, 100, 1306, 1307, "-" +380, 10, 18, 296, 101, 109, 1308, 1316, "inferior" +380, 10, 19, 297, 110, 112, 1317, 1319, "to" +380, 10, 20, 298, 113, 126, 1320, 1333, "dapagliflozin" +380, 10, 21, 299, 127, 129, 1334, 1336, "in" +380, 10, 22, 300, 130, 138, 1337, 1345, "reducing" +380, 10, 23, 301, 139, 144, 1346, 1351, "HbA1c" +380, 10, 24, 302, 145, 147, 1352, 1354, "at" +380, 10, 25, 303, 148, 152, 1355, 1359, "Week" +380, 10, 26, 304, 153, 155, 1360, 1362, "24" +380, 10, 27, 305, 156, 157, 1363, 1364, "," +380, 10, 28, 306, 158, 162, 1365, 1369, "with" +380, 10, 29, 307, 163, 174, 1370, 1381, "superiority" +380, 10, 30, 308, 175, 177, 1382, 1384, "to" +380, 10, 31, 309, 178, 180, 1385, 1387, "be" +380, 10, 32, 310, 181, 187, 1388, 1394, "tested" +380, 10, 33, 311, 188, 190, 1395, 1397, "if" +380, 10, 34, 312, 191, 194, 1398, 1401, "non" +380, 10, 35, 313, 195, 196, 1402, 1403, "-" +380, 10, 36, 314, 197, 208, 1404, 1415, "inferiority" +380, 10, 37, 315, 209, 211, 1416, 1418, "is" +380, 10, 38, 316, 212, 215, 1419, 1422, "met" +380, 10, 39, 317, 216, 217, 1423, 1424, "." +380, 11, 1, 318, 0, 14, 1425, 1439, "ClinicalTrials" +380, 11, 2, 319, 15, 16, 1440, 1441, "." +380, 11, 3, 320, 17, 20, 1442, 1445, "gov" +380, 11, 4, 321, 21, 32, 1446, 1457, "NCT02532855" +380, 11, 5, 322, 33, 34, 1458, 1459, "." +380, 12, 1, 323, 0, 7, 1460, 1467, "RESULTS" +380, 12, 2, 324, 8, 9, 1468, 1469, ":" +380, 12, 3, 325, 10, 18, 1470, 1478, "Baseline" +380, 12, 4, 326, 19, 23, 1479, 1483, "mean" +380, 12, 5, 327, 24, 29, 1484, 1489, "HbA1c" +380, 12, 6, 328, 30, 31, 1490, 1491, "(" +380, 12, 7, 329, 32, 33, 1492, 1493, "%" +380, 12, 8, 330, 34, 35, 1494, 1495, "[" +380, 12, 9, 331, 36, 40, 1496, 1500, "mmol" +380, 12, 10, 332, 41, 42, 1501, 1502, "/" +380, 12, 11, 333, 43, 46, 1503, 1506, "mol" +380, 12, 12, 334, 47, 48, 1507, 1508, "]" +380, 12, 13, 335, 49, 50, 1509, 1510, ")" +380, 12, 14, 336, 51, 54, 1511, 1514, "was" +380, 12, 15, 337, 55, 56, 1515, 1516, "7" +380, 12, 16, 338, 57, 58, 1517, 1518, "." +380, 12, 17, 339, 59, 60, 1519, 1520, "7" +380, 12, 18, 340, 61, 62, 1521, 1522, "(" +380, 12, 19, 341, 63, 65, 1523, 1525, "60" +380, 12, 20, 342, 66, 67, 1526, 1527, "." +380, 12, 21, 343, 68, 69, 1528, 1529, "9" +380, 12, 22, 344, 70, 71, 1530, 1531, ")" +380, 12, 23, 345, 72, 75, 1532, 1535, "and" +380, 12, 24, 346, 76, 77, 1536, 1537, "7" +380, 12, 25, 347, 78, 79, 1538, 1539, "." +380, 12, 26, 348, 80, 81, 1540, 1541, "8" +380, 12, 27, 349, 82, 83, 1542, 1543, "(" +380, 12, 28, 350, 84, 86, 1544, 1546, "61" +380, 12, 29, 351, 87, 88, 1547, 1548, "." +380, 12, 30, 352, 89, 90, 1549, 1550, "2" +380, 12, 31, 353, 91, 92, 1551, 1552, ")" +380, 12, 32, 354, 93, 94, 1553, 1554, "," +380, 12, 33, 355, 95, 98, 1555, 1558, "and" +380, 12, 34, 356, 99, 103, 1559, 1563, "mean" +380, 12, 35, 357, 104, 108, 1564, 1568, "eGFR" +380, 12, 36, 358, 109, 110, 1569, 1570, "(" +380, 12, 37, 359, 111, 113, 1571, 1573, "mL" +380, 12, 38, 360, 114, 115, 1574, 1575, "/" +380, 12, 39, 361, 116, 119, 1576, 1579, "min" +380, 12, 40, 362, 120, 121, 1580, 1581, "/" +380, 12, 41, 363, 122, 123, 1582, 1583, "1" +380, 12, 42, 364, 124, 125, 1584, 1585, "." +380, 12, 43, 365, 126, 130, 1586, 1590, "73m2" +380, 12, 44, 366, 131, 132, 1591, 1592, ")" +380, 12, 45, 367, 133, 136, 1593, 1596, "was" +380, 12, 46, 368, 137, 139, 1597, 1599, "79" +380, 12, 47, 369, 140, 141, 1600, 1601, "." +380, 12, 48, 370, 142, 143, 1602, 1603, "4" +380, 12, 49, 371, 144, 147, 1604, 1607, "and" +380, 12, 50, 372, 148, 150, 1608, 1610, "76" +380, 12, 51, 373, 151, 152, 1611, 1612, "." +380, 12, 52, 374, 153, 154, 1613, 1614, "9" +380, 12, 53, 375, 155, 158, 1615, 1618, "for" +380, 12, 54, 376, 159, 162, 1619, 1622, "the" +380, 12, 55, 377, 163, 174, 1623, 1634, "sitagliptin" +380, 12, 56, 378, 175, 178, 1635, 1638, "and" +380, 12, 57, 379, 179, 192, 1639, 1652, "dapagliflozin" +380, 12, 58, 380, 193, 199, 1653, 1659, "groups" +380, 12, 59, 381, 200, 201, 1660, 1661, "," +380, 12, 60, 382, 202, 214, 1662, 1674, "respectively" +380, 12, 61, 383, 215, 216, 1675, 1676, "." +380, 13, 1, 384, 0, 5, 1677, 1682, "After" +380, 13, 2, 385, 6, 8, 1683, 1685, "24" +380, 13, 3, 386, 9, 10, 1686, 1687, " " +380, 13, 4, 387, 11, 16, 1688, 1693, "weeks" +380, 13, 5, 388, 17, 18, 1694, 1695, "," +380, 13, 6, 389, 19, 22, 1696, 1699, "the" +380, 13, 7, 390, 23, 30, 1700, 1707, "between" +380, 13, 8, 391, 31, 32, 1708, 1709, "-" +380, 13, 9, 392, 33, 38, 1710, 1715, "group" +380, 13, 10, 393, 39, 49, 1716, 1726, "difference" +380, 13, 11, 394, 50, 52, 1727, 1729, "in" +380, 13, 12, 395, 53, 58, 1730, 1735, "least" +380, 13, 13, 396, 59, 66, 1736, 1743, "squares" +380, 13, 14, 397, 67, 71, 1744, 1748, "mean" +380, 13, 15, 398, 72, 73, 1749, 1750, "(" +380, 13, 16, 399, 74, 76, 1751, 1753, "95" +380, 13, 17, 400, 77, 78, 1754, 1755, "%" +380, 13, 18, 401, 79, 81, 1756, 1758, "CI" +380, 13, 19, 402, 82, 83, 1759, 1760, ")" +380, 13, 20, 403, 84, 91, 1761, 1768, "changes" +380, 13, 21, 404, 92, 96, 1769, 1773, "from" +380, 13, 22, 405, 97, 105, 1774, 1782, "baseline" +380, 13, 23, 406, 106, 108, 1783, 1785, "in" +380, 13, 24, 407, 109, 114, 1786, 1791, "HbA1c" +380, 13, 25, 408, 115, 118, 1792, 1795, "was" +380, 13, 26, 409, 119, 120, 1796, 1797, "-" +380, 13, 27, 410, 121, 122, 1798, 1799, "0" +380, 13, 28, 411, 123, 124, 1800, 1801, "." +380, 13, 29, 412, 125, 127, 1802, 1804, "15" +380, 13, 30, 413, 128, 129, 1805, 1806, "%" +380, 13, 31, 414, 130, 131, 1807, 1808, "(" +380, 13, 32, 415, 132, 133, 1809, 1810, "-" +380, 13, 33, 416, 134, 135, 1811, 1812, "0" +380, 13, 34, 417, 136, 137, 1813, 1814, "." +380, 13, 35, 418, 138, 140, 1815, 1817, "26" +380, 13, 36, 419, 141, 142, 1818, 1819, "," +380, 13, 37, 420, 143, 144, 1820, 1821, "-" +380, 13, 38, 421, 145, 146, 1822, 1823, "0" +380, 13, 39, 422, 147, 148, 1824, 1825, "." +380, 13, 40, 423, 149, 151, 1826, 1828, "04" +380, 13, 41, 424, 152, 153, 1829, 1830, ")" +380, 13, 42, 425, 154, 155, 1831, 1832, "(" +380, 13, 43, 426, 156, 157, 1833, 1834, "-" +380, 13, 44, 427, 158, 159, 1835, 1836, "1" +380, 13, 45, 428, 160, 161, 1837, 1838, "." +380, 13, 46, 429, 162, 164, 1839, 1841, "67" +380, 13, 47, 430, 165, 166, 1842, 1843, " " +380, 13, 48, 431, 167, 171, 1844, 1848, "mmol" +380, 13, 49, 432, 172, 173, 1849, 1850, "/" +380, 13, 50, 433, 174, 177, 1851, 1854, "mol" +380, 13, 51, 434, 178, 179, 1855, 1856, "[" +380, 13, 52, 435, 180, 181, 1857, 1858, "-" +380, 13, 53, 436, 182, 183, 1859, 1860, "2" +380, 13, 54, 437, 184, 185, 1861, 1862, "." +380, 13, 55, 438, 186, 188, 1863, 1865, "86" +380, 13, 56, 439, 189, 190, 1866, 1867, "," +380, 13, 57, 440, 191, 192, 1868, 1869, "-" +380, 13, 58, 441, 193, 194, 1870, 1871, "0" +380, 13, 59, 442, 195, 196, 1872, 1873, "." +380, 13, 60, 443, 197, 199, 1874, 1876, "48" +380, 13, 61, 444, 200, 201, 1877, 1878, "]" +380, 13, 62, 445, 202, 203, 1879, 1880, ")" +380, 13, 63, 446, 204, 205, 1881, 1882, "," +380, 13, 64, 447, 206, 207, 1883, 1884, "P" +380, 13, 65, 448, 208, 211, 1885, 1888, " = " +380, 13, 66, 449, 212, 213, 1889, 1890, "0" +380, 13, 67, 450, 214, 215, 1891, 1892, "." +380, 13, 68, 451, 216, 219, 1893, 1896, "006" +380, 13, 69, 452, 220, 221, 1897, 1898, "," +380, 13, 70, 453, 222, 229, 1899, 1906, "meeting" +380, 13, 71, 454, 230, 233, 1907, 1910, "the" +380, 13, 72, 455, 234, 246, 1911, 1923, "prespecified" +380, 13, 73, 456, 247, 255, 1924, 1932, "criteria" +380, 13, 74, 457, 256, 259, 1933, 1936, "for" +380, 13, 75, 458, 260, 269, 1937, 1946, "declaring" +380, 13, 76, 459, 270, 274, 1947, 1951, "both" +380, 13, 77, 460, 275, 278, 1952, 1955, "non" +380, 13, 78, 461, 279, 280, 1956, 1957, "-" +380, 13, 79, 462, 281, 292, 1958, 1969, "inferiority" +380, 13, 80, 463, 293, 296, 1970, 1973, "and" +380, 13, 81, 464, 297, 308, 1974, 1985, "superiority" +380, 13, 82, 465, 309, 311, 1986, 1988, "of" +380, 13, 83, 466, 312, 323, 1989, 2000, "sitagliptin" +380, 13, 84, 467, 324, 330, 2001, 2007, "versus" +380, 13, 85, 468, 331, 344, 2008, 2021, "dapagliflozin" +380, 13, 86, 469, 345, 346, 2022, 2023, "." +380, 14, 1, 470, 0, 3, 2024, 2027, "The" +380, 14, 2, 471, 4, 9, 2028, 2033, "HbA1c" +380, 14, 3, 472, 10, 14, 2034, 2038, "goal" +380, 14, 4, 473, 15, 17, 2039, 2041, "of" +380, 14, 5, 474, 18, 19, 2042, 2043, "<" +380, 14, 6, 475, 20, 21, 2044, 2045, "7" +380, 14, 7, 476, 22, 23, 2046, 2047, "%" +380, 14, 8, 477, 24, 25, 2048, 2049, "(" +380, 14, 9, 478, 26, 27, 2050, 2051, "<" +380, 14, 10, 479, 28, 30, 2052, 2054, "53" +380, 14, 11, 480, 31, 32, 2055, 2056, " " +380, 14, 12, 481, 33, 37, 2057, 2061, "mmol" +380, 14, 13, 482, 38, 39, 2062, 2063, "/" +380, 14, 14, 483, 40, 43, 2064, 2067, "mol" +380, 14, 15, 484, 44, 45, 2068, 2069, ")" +380, 14, 16, 485, 46, 49, 2070, 2073, "was" +380, 14, 17, 486, 50, 53, 2074, 2077, "met" +380, 14, 18, 487, 54, 56, 2078, 2080, "by" +380, 14, 19, 488, 57, 59, 2081, 2083, "43" +380, 14, 20, 489, 60, 61, 2084, 2085, "%" +380, 14, 21, 490, 62, 63, 2086, 2087, "(" +380, 14, 22, 491, 64, 75, 2088, 2099, "sitagliptin" +380, 14, 23, 492, 76, 77, 2100, 2101, ")" +380, 14, 24, 493, 78, 81, 2102, 2105, "and" +380, 14, 25, 494, 82, 84, 2106, 2108, "27" +380, 14, 26, 495, 85, 86, 2109, 2110, "%" +380, 14, 27, 496, 87, 88, 2111, 2112, "(" +380, 14, 28, 497, 89, 102, 2113, 2126, "dapagliflozin" +380, 14, 29, 498, 103, 104, 2127, 2128, ")" +380, 14, 30, 499, 105, 107, 2129, 2131, "of" +380, 14, 31, 500, 108, 116, 2132, 2140, "patients" +380, 14, 32, 501, 117, 118, 2141, 2142, "." +380, 15, 1, 502, 0, 2, 2143, 2145, "No" +380, 15, 2, 503, 3, 13, 2146, 2156, "meaningful" +380, 15, 3, 504, 14, 21, 2157, 2164, "between" +380, 15, 4, 505, 22, 23, 2165, 2166, "-" +380, 15, 5, 506, 24, 29, 2167, 2172, "group" +380, 15, 6, 507, 30, 40, 2173, 2183, "difference" +380, 15, 7, 508, 41, 44, 2184, 2187, "was" +380, 15, 8, 509, 45, 53, 2188, 2196, "observed" +380, 15, 9, 510, 54, 56, 2197, 2199, "in" +380, 15, 10, 511, 57, 58, 2200, 2201, "a" +380, 15, 11, 512, 59, 62, 2202, 2205, "pre" +380, 15, 12, 513, 63, 64, 2206, 2207, "-" +380, 15, 13, 514, 65, 74, 2208, 2217, "specified" +380, 15, 14, 515, 75, 83, 2218, 2226, "analysis" +380, 15, 15, 516, 84, 86, 2227, 2229, "of" +380, 15, 16, 517, 87, 88, 2230, 2231, "2" +380, 15, 17, 518, 89, 90, 2232, 2233, "-" +380, 15, 18, 519, 91, 95, 2234, 2238, "hour" +380, 15, 19, 520, 96, 107, 2239, 2250, "incremental" +380, 15, 20, 521, 108, 120, 2251, 2263, "postprandial" +380, 15, 21, 522, 121, 128, 2264, 2271, "glucose" +380, 15, 22, 523, 129, 138, 2272, 2281, "excursion" +380, 15, 23, 524, 139, 140, 2282, 2283, "." +380, 16, 1, 525, 0, 1, 2284, 2285, "A" +380, 16, 2, 526, 2, 8, 2286, 2292, "review" +380, 16, 3, 527, 9, 11, 2293, 2295, "of" +380, 16, 4, 528, 12, 19, 2296, 2303, "adverse" +380, 16, 5, 529, 20, 26, 2304, 2310, "events" +380, 16, 6, 530, 27, 28, 2311, 2312, "(" +380, 16, 7, 531, 29, 32, 2313, 2316, "AEs" +380, 16, 8, 532, 33, 34, 2317, 2318, ")" +380, 16, 9, 533, 35, 38, 2319, 2322, "was" +380, 16, 10, 534, 39, 46, 2323, 2330, "notable" +380, 16, 11, 535, 47, 50, 2331, 2334, "for" +380, 16, 12, 536, 51, 52, 2335, 2336, "a" +380, 16, 13, 537, 53, 58, 2337, 2342, "lower" +380, 16, 14, 538, 59, 68, 2343, 2352, "incidence" +380, 16, 15, 539, 69, 71, 2353, 2355, "of" +380, 16, 16, 540, 72, 76, 2356, 2360, "drug" +380, 16, 17, 541, 77, 78, 2361, 2362, "-" +380, 16, 18, 542, 79, 86, 2363, 2370, "related" +380, 16, 19, 543, 87, 90, 2371, 2374, "AEs" +380, 16, 20, 544, 91, 95, 2375, 2379, "with" +380, 16, 21, 545, 96, 107, 2380, 2391, "sitagliptin" +380, 16, 22, 546, 108, 116, 2392, 2400, "compared" +380, 16, 23, 547, 117, 121, 2401, 2405, "with" +380, 16, 24, 548, 122, 135, 2406, 2419, "dapagliflozin" +380, 16, 25, 549, 136, 137, 2420, 2421, "." +380, 17, 1, 550, 0, 11, 2422, 2433, "CONCLUSIONS" +380, 17, 2, 551, 12, 13, 2434, 2435, ":" +380, 17, 3, 552, 14, 16, 2436, 2438, "In" +380, 17, 4, 553, 17, 25, 2439, 2447, "patients" +380, 17, 5, 554, 26, 30, 2448, 2452, "with" +380, 17, 6, 555, 31, 35, 2453, 2457, "type" +380, 17, 7, 556, 36, 37, 2458, 2459, "2" +380, 17, 8, 557, 38, 46, 2460, 2468, "diabetes" +380, 17, 9, 558, 47, 48, 2469, 2470, "," +380, 17, 10, 559, 49, 53, 2471, 2475, "mild" +380, 17, 11, 560, 54, 59, 2476, 2481, "renal" +380, 17, 12, 561, 60, 73, 2482, 2495, "insufficiency" +380, 17, 13, 562, 74, 77, 2496, 2499, "and" +380, 17, 14, 563, 78, 88, 2500, 2510, "inadequate" +380, 17, 15, 564, 89, 98, 2511, 2520, "glycaemic" +380, 17, 16, 565, 99, 106, 2521, 2528, "control" +380, 17, 17, 566, 107, 109, 2529, 2531, "on" +380, 17, 18, 567, 110, 119, 2532, 2541, "metformin" +380, 17, 19, 568, 120, 123, 2542, 2545, " ± " +380, 17, 20, 569, 124, 136, 2546, 2558, "sulfonylurea" +380, 17, 21, 570, 137, 138, 2559, 2560, "," +380, 17, 22, 571, 139, 150, 2561, 2572, "sitagliptin" +380, 17, 23, 572, 151, 160, 2573, 2582, "treatment" +380, 17, 24, 573, 161, 169, 2583, 2591, "resulted" +380, 17, 25, 574, 170, 172, 2592, 2594, "in" +380, 17, 26, 575, 173, 180, 2595, 2602, "greater" +380, 17, 27, 576, 181, 192, 2603, 2614, "improvement" +380, 17, 28, 577, 193, 195, 2615, 2617, "in" +380, 17, 29, 578, 196, 205, 2618, 2627, "glycaemic" +380, 17, 30, 579, 206, 213, 2628, 2635, "control" +380, 17, 31, 580, 214, 222, 2636, 2644, "compared" +380, 17, 32, 581, 223, 227, 2645, 2649, "with" +380, 17, 33, 582, 228, 241, 2650, 2663, "dapagliflozin" +380, 17, 34, 583, 242, 245, 2664, 2667, "and" +380, 17, 35, 584, 246, 249, 2668, 2671, "was" +380, 17, 36, 585, 250, 259, 2672, 2681, "generally" +380, 17, 37, 586, 260, 264, 2682, 2686, "well" +380, 17, 38, 587, 265, 274, 2687, 2696, "tolerated" +380, 17, 39, 588, 275, 276, 2697, 2698, "." +380, 18, 1, 589, 0, 1, 2699, 2700, "©" +380, 18, 2, 590, 2, 6, 2701, 2705, "2018" +380, 18, 3, 591, 7, 10, 2706, 2709, "The" +380, 18, 4, 592, 11, 18, 2710, 2717, "Authors" +380, 18, 5, 593, 19, 20, 2718, 2719, "." +380, 19, 1, 594, 0, 8, 2720, 2728, "Diabetes" +380, 19, 2, 595, 9, 10, 2729, 2730, "," +380, 19, 3, 596, 11, 18, 2731, 2738, "Obesity" +380, 19, 4, 597, 19, 22, 2739, 2742, "and" +380, 19, 5, 598, 23, 33, 2743, 2753, "Metabolism" +380, 19, 6, 599, 34, 43, 2754, 2763, "published" +380, 19, 7, 600, 44, 46, 2764, 2766, "by" +380, 19, 8, 601, 47, 51, 2767, 2771, "John" +380, 19, 9, 602, 52, 57, 2772, 2777, "Wiley" +380, 19, 10, 603, 58, 59, 2778, 2779, "&" +380, 19, 11, 604, 60, 64, 2780, 2784, "Sons" +380, 19, 12, 605, 65, 68, 2785, 2788, "Ltd" +380, 19, 13, 606, 69, 70, 2789, 2790, "." +380, 19, 14, 607, 71, 74, 2791, 2794, "DOI" +380, 19, 15, 608, 75, 76, 2795, 2796, ":" +380, 19, 16, 609, 77, 79, 2797, 2799, "10" +380, 19, 17, 610, 80, 81, 2800, 2801, "." +380, 19, 18, 611, 82, 86, 2802, 2806, "1111" +380, 19, 19, 612, 87, 88, 2807, 2808, "/" +380, 19, 20, 613, 89, 92, 2809, 2812, "dom" +380, 19, 21, 614, 93, 94, 2813, 2814, "." +380, 19, 22, 615, 95, 100, 2815, 2820, "13473" +380, 19, 23, 616, 101, 106, 2821, 2826, "PMCID" +380, 19, 24, 617, 107, 108, 2827, 2828, ":" +380, 19, 25, 618, 109, 119, 2829, 2839, "PMC6283039" +380, 19, 26, 619, 120, 124, 2840, 2844, "PMID" +380, 19, 27, 620, 125, 126, 2845, 2846, ":" +380, 19, 28, 621, 127, 135, 2847, 2855, "30019498" +380, 19, 29, 622, 136, 137, 2856, 2857, "[" +380, 19, 30, 623, 138, 145, 2858, 2865, "Indexed" +380, 19, 31, 624, 146, 149, 2866, 2869, "for" +380, 19, 32, 625, 150, 157, 2870, 2877, "MEDLINE" +380, 19, 33, 626, 158, 159, 2878, 2879, "]" diff --git a/data/dm2 30019498_kwoodley.annodb b/data/dm2 30019498_kwoodley.annodb new file mode 100644 index 0000000..c789aaa --- /dev/null +++ b/data/dm2 30019498_kwoodley.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +73395, Journal, 0, 19, "Diabetes Obes Metab", "", +73397, PublicationYear, 22, 26, "2018", "", +73466, Title, 110, 305, "A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency : The CompoSIT - R study .", "", +73429, Randomized, 112, 122, "randomized", "", +73430, Sitagliptin, 168, 179, "sitagliptin", "", +73444, Dapagliflozin, 194, 207, "dapagliflozin", "", +73459, Type2Diabetes, 225, 249, "type 2 diabetes mellitus", "", +73468, Author, 306, 313, "Scott R", "", +73470, Author, 322, 330, "Morgan J", "", +73471, Author, 339, 347, "Zimmer Z", "", +73474, Author, 356, 363, "Lam RLH", "", +73475, Author, 372, 384, "O ' Neill EA", "", +73476, Author, 393, 403, "Kaufman KD", "", +73477, Author, 412, 420, "Engel SS", "", +73479, Author, 429, 435, "Raji A", "", +73482, Country, 556, 567, "New Zealand", "", +73484, USA, 612, 622, "New Jersey", "", +73490, ObjectiveDescription, 631, 849, "To compare the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin with the sodium - glucose transporter - 2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency .", "", +73432, Sitagliptin, 708, 719, "sitagliptin", "", +73448, Dapagliflozin, 772, 785, "dapagliflozin", "", +73488, Precondition, 789, 847, "patients with type 2 diabetes and mild renal insufficiency", "", +73461, Type2Diabetes, 803, 818, "type 2 diabetes", "", +73525, Precondition, 874, 1070, "Patients with HbA1c ≥ 7 . 0 to ≤ 9 . 5 % ( ≥ 53 to ≤ 80   mmol / mol ) and estimated glomerular filtration rate ≥ 60 to < 90   mL / min / 1 . 73m2 on metformin ( ≥ 1500   mg / d )  ±  sulfonylurea", "", +73491, HbA1c, 888, 893, "HbA1c", "", +73494, Percentage, 913, 914, "%", "", +73496, BioAndMedicalUnit, 932, 942, "mmol / mol", "", +73573, EndPointDescription, 949, 985, "estimated glomerular filtration rate", "", +73579, BioAndMedicalUnit, 1001, 1020, "mL / min / 1 . 73m2", "", +73502, Metformin, 1024, 1033, "metformin", "", +73504, DoseValue, 1036, 1042, "≥ 1500", "", +73507, mg, 1045, 1047, "mg", "", +73514, Frequency, 1050, 1051, "d", "", +73518, Sulfonylureas, 1058, 1070, "sulfonylurea", "", +73528, Randomized, 1076, 1086, "randomized", "", +73434, Sitagliptin, 1090, 1101, "sitagliptin", "", +73505, DoseValue, 1102, 1105, "100", "", +73508, mg, 1108, 1110, "mg", "", +73530, NumberPatientsArm, 1119, 1122, "307", "", +73446, Dapagliflozin, 1128, 1141, "dapagliflozin", "", +73506, DoseValue, 1142, 1143, "5", "", +73535, DoseDescription, 1142, 1164, "5 mg titrated to 10 mg", "", +73509, mg, 1144, 1146, "mg", "", +73512, DoseValue, 1159, 1161, "10", "", +73511, mg, 1162, 1164, "mg", "", +73532, NumberPatientsArm, 1173, 1176, "306", "", +73516, Frequency, 1179, 1189, "once daily", "", +73538, Duration, 1194, 1204, "24   weeks", "", +73545, MeasurementDevice, 1209, 1241, "longitudinal data analysis model", "", +73458, Sitagliptin, 1287, 1298, "sitagliptin", "", +73449, Dapagliflozin, 1320, 1333, "dapagliflozin", "", +73548, HbA1c, 1346, 1351, "HbA1c", "", +73550, TimePoint, 1355, 1362, "Week 24", "", +73558, HbA1c, 1484, 1489, "HbA1c", "", +73560, Percentage, 1492, 1493, "%", "", +73561, BioAndMedicalUnit, 1496, 1506, "mmol / mol", "", +73563, BaseLineValue, 1515, 1520, "7 . 7", "", +73566, BaseLineValue, 1523, 1529, "60 . 9", "", +73569, BaseLineValue, 1536, 1541, "7 . 8", "", +73571, BaseLineValue, 1544, 1550, "61 . 2", "", +73572, EndPointDescription, 1564, 1568, "eGFR", "", +73582, BioAndMedicalUnit, 1571, 1590, "mL / min / 1 . 73m2", "", +73585, BaseLineValue, 1597, 1603, "79 . 4", "", +73586, BaseLineValue, 1608, 1614, "76 . 9", "", +73436, Sitagliptin, 1623, 1634, "sitagliptin", "", +73450, Dapagliflozin, 1639, 1652, "dapagliflozin", "", +73553, TimePoint, 1683, 1693, "24   weeks", "", +73588, LeastSquaresMean, 1730, 1748, "least squares mean", "", +73590, ConfIntervalChangeValue, 1751, 1758, "95 % CI", "", +73554, TimePoint, 1774, 1782, "baseline", "", +73591, HbA1c, 1786, 1791, "HbA1c", "", +73594, Reduction, 1798, 1804, "0 . 15", "", +73600, Percentage, 1805, 1806, "%", "", +73601, ConfIntervalChangeValue, 1809, 1828, "- 0 . 26 , - 0 . 04", "", +73598, Reduction, 1835, 1841, "1 . 67", "", +73603, BioAndMedicalUnit, 1844, 1854, "mmol / mol", "", +73605, ConfIntervalChangeValue, 1857, 1876, "- 2 . 86 , - 0 . 48", "", +73607, PValueChangeValue, 1883, 1896, "P  =  0 . 006", "", +73438, Sitagliptin, 1989, 2000, "sitagliptin", "", +73451, Dapagliflozin, 2008, 2021, "dapagliflozin", "", +73611, HbA1c_target, 2028, 2069, "HbA1c goal of < 7 % ( < 53   mmol / mol )", "", +73612, PercentageAffected, 2081, 2083, "43", "", +73440, Sitagliptin, 2088, 2099, "sitagliptin", "", +73613, PercentageAffected, 2106, 2108, "27", "", +73452, Dapagliflozin, 2113, 2126, "dapagliflozin", "", +73617, ObservedResult, 2143, 2283, "No meaningful between - group difference was observed in a pre - specified analysis of 2 - hour incremental postprandial glucose excursion .", "", +73615, PostprandialBloodGlucose, 2230, 2281, "2 - hour incremental postprandial glucose excursion", "", +73625, ObservedResult, 2284, 2421, "A review of adverse events ( AEs ) was notable for a lower incidence of drug - related AEs with sitagliptin compared with dapagliflozin .", "", +73619, EndPointDescription, 2296, 2310, "adverse events", "", +73620, EndPointDescription, 2313, 2316, "AEs", "", +73623, SubGroupDescription, 2356, 2374, "drug - related AEs", "", +73621, EndPointDescription, 2371, 2374, "AEs", "", +73441, Sitagliptin, 2380, 2391, "sitagliptin", "", +73454, Dapagliflozin, 2406, 2419, "dapagliflozin", "", +73631, ConclusionComment, 2436, 2635, "In patients with type 2 diabetes , mild renal insufficiency and inadequate glycaemic control on metformin  ±  sulfonylurea , sitagliptin treatment resulted in greater improvement in glycaemic control", "", +73627, Precondition, 2439, 2558, "patients with type 2 diabetes , mild renal insufficiency and inadequate glycaemic control on metformin  ±  sulfonylurea", "", +73463, Type2Diabetes, 2453, 2468, "type 2 diabetes", "", +73503, Metformin, 2532, 2541, "metformin", "", +73520, Sulfonylureas, 2546, 2558, "sulfonylurea", "", +73443, Sitagliptin, 2561, 2572, "sitagliptin", "", +73633, ConclusionComment, 2636, 2698, "compared with dapagliflozin and was generally well tolerated .", "", +73456, Dapagliflozin, 2650, 2663, "dapagliflozin", "", +73634, PMID, 2847, 2855, "30019498", "", diff --git a/data/dm2 30019498_kwoodley.n-triples b/data/dm2 30019498_kwoodley.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/dm2 30019498_kwoodley.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10080213_admin.annodb b/data/gl 10080213_admin.annodb new file mode 100644 index 0000000..6901ab0 --- /dev/null +++ b/data/gl 10080213_admin.annodb @@ -0,0 +1,133 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +27025, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "1999", "", " \"1999\"." +77, Title, 49, 158, "A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma .", "", " \"A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma .\"." +25340, Duration, 51, 61, "12 - month", "", " \"12 - month\"." +3, Randomized, 64, 74, "randomized", "", " ." +4, DoubleBlind, 77, 92, "double - masked", "", " ." +5, Latanoprost, 109, 120, "latanoprost", "", +6, Timolol, 126, 133, "timolol", "", +25342, PigmentaryGlaucoma, 137, 156, "pigmentary glaucoma", "", " ." +8, Author, 159, 173, "Mastropasqua L", "", " \"Mastropasqua L\"." +9, Author, 182, 193, "Carpineto P", "", " \"Carpineto P\"." +10, Author, 196, 209, "Ciancaglini M", "", " \"Ciancaglini M\"." +11, Author, 212, 223, "Gallenga PE", "", " \"Gallenga PE\"." +12, Italy, 338, 343, "Italy", "", " ." +13, ObjectiveDescription, 358, 585, "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma .", "", " \"To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma .\"." +27038, DoseValue, 443, 450, "0 . 005", "", " \"0 . 005\"." +119896, Percentage, 451, 452, "%", "", " ." +27052, Latanoprost, 453, 464, "latanoprost", "", +27054, Topic, 473, 482, "topically", "", " ." +27048, Frequency, 483, 493, "once daily", "", +27050, DoseValue, 499, 504, "0 . 5", "", +25338, Percentage, 505, 506, "%", "", +21, Timolol, 507, 514, "timolol", "", +27049, Frequency, 521, 532, "twice daily", "", +25341, Duration, 537, 546, "12 months", "", +195, Precondition, 550, 583, "patients with pigmentary glaucoma", "", " \"patients with pigmentary glaucoma\"." +25347, PigmentaryGlaucoma, 564, 583, "pigmentary glaucoma", "", +36927, Prospective, 595, 606, "Prospective", "", " ." +23, Randomized, 609, 619, "randomized", "", +24, DoubleBlind, 622, 637, "double - masked", "", +25, NumberPatientsCT, 672, 684, "Thirty - six", "", " \"Thirty - six\"." +4145, Precondition, 708, 798, "bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication", "", +25346, PigmentaryGlaucoma, 718, 737, "pigmentary glaucoma", "", +36928, Randomized, 869, 877, "randomly", "", +36931, NumberPatientsArm, 935, 937, "18", "", " \"18\". \"18\"." +119898, DoseValue, 966, 973, "0 . 005", "", +119897, Percentage, 974, 975, "%", "", +27, Latanoprost, 976, 987, "latanoprost", "", " . ." +28, Eyedrops, 988, 996, "eyedrops", "", " . ." +33209, Frequency, 997, 1007, "once daily", "", " \"once daily\"." +92842, Vehicle, 1016, 1023, "vehicle", "", +29, Placebo, 1026, 1033, "placebo", "", " ." +30, Frequency, 1036, 1046, "once daily", "", " \"once daily\"." +31, Timolol, 1073, 1080, "timolol", "", " ." +27030, DoseValue, 1081, 1086, "0 . 5", "", " \"0 . 5\"." +25337, Percentage, 1087, 1088, "%", "", " ." +32, Eyedrops, 1089, 1097, "eyedrops", "", " ." +27035, Frequency, 1098, 1109, "twice daily", "", " \"twice daily\"." +18006, IOP, 1154, 1174, "intraocular pressure", "", " . ." +121, IOP, 1177, 1180, "IOP", "", +36932, TimePoint, 1205, 1213, "baseline", "", +36926, TimePoint, 1228, 1257, "0 . 5 , 3 , 6 , and 12 months", "", +36925, TimePoint, 1236, 1257, "3 , 6 , and 12 months", "", +36924, TimePoint, 1240, 1257, "6 , and 12 months", "", +4445, TimePoint, 1248, 1257, "12 months", "", +129, IOP, 1277, 1280, "IOP", "", +19522, TimePoint, 1312, 1321, "8 : 00 AM", "", +19523, TimePoint, 1324, 1336, "12 : 00 noon", "", +19524, TimePoint, 1339, 1348, "4 : 00 PM", "", +19525, TimePoint, 1355, 1364, "8 : 00 PM", "", +4273, Outflow_Facility_C, 1367, 1383, "Outflow facility", "", " ." +4274, Outflow_Facility_C, 1388, 1389, "C", "", +37, MeasurementDevice, 1467, 1495, "Schiotz electronic tonometer", "", " . ." +146, Latanoprost, 1664, 1675, "latanoprost", "", +147, Timolol, 1680, 1687, "timolol", "", +38, Diurnal_IOP, 1696, 1707, "Diurnal IOP", "", +135, IOP, 1778, 1781, "IOP", "", +4275, Outflow_Facility_C, 1788, 1789, "C", "", +148, Latanoprost, 1870, 1881, "latanoprost", "", +149, Timolol, 1886, 1893, "timolol", "", +150, IOP, 1944, 1947, "IOP", "", +152, IOP, 2028, 2031, "IOP", "", +79, Reduction, 2036, 2041, "6 . 0", "", " \"6 . 0\"." +83, SdErrorChangeValue, 2048, 2053, "4 . 5", "", " \"4 . 5\"." +80, Reduction, 2058, 2063, "5 . 9", "", " \"5 . 9\"." +84, SdErrorChangeValue, 2070, 2075, "4 . 6", "", " \"4 . 6\"." +42, Latanoprost, 2081, 2092, "latanoprost", "", +81, Reduction, 2097, 2102, "4 . 8", "", " \"4 . 8\"." +85, SdErrorChangeValue, 2109, 2114, "3 . 0", "", " \"3 . 0\"." +82, Reduction, 2119, 2124, "4 . 6", "", " \"4 . 6\"." +86, SdErrorChangeValue, 2131, 2136, "3 . 1", "", " \"3 . 1\"." +43, Timolol, 2142, 2149, "timolol", "", +36929, TimePoint, 2156, 2171, "6 and 12 months", "", " \"6 and 12 months\". \"6 and 12 months\"." +36930, TimePoint, 2162, 2171, "12 months", "", " \"12 months\". \"12 months\"." +44, Latanoprost, 2234, 2245, "latanoprost", "", +45, Timolol, 2250, 2257, "timolol", "", +161, PvalueDiff, 2293, 2304, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\"." +27015, TimePoint, 2321, 2342, "3 , 6 , and 12 months", "", +36922, TimePoint, 2325, 2342, "6 , and 12 months", "", +36923, TimePoint, 2333, 2342, "12 months", "", +50, Mean, 2345, 2349, "Mean", "", " . . . ." +18004, Outflow_Facility_C, 2352, 2353, "C", "", +51, RelativeIncrement, 2399, 2401, "30", "", " \"30\"." +78, Percentage, 2402, 2403, "%", "", " ." +52, Latanoprost, 2418, 2429, "latanoprost", "", +53, PValueChangeValue, 2475, 2486, "P = 0 . 017", "", " \"P = 0 . 017\"." +54, Mean, 2491, 2495, "Mean", "", +55, ConjunctivalHyperemia, 2496, 2518, "conjunctival hyperemia", "", " ." +56, ResultMeasuredValue, 2533, 2538, "0 . 3", "", " \"0 . 3\"." +57, Latanoprost, 2542, 2553, "latanoprost", "", +58, ResultMeasuredValue, 2573, 2578, "0 . 2", "", " \"0 . 2\"." +59, Timolol, 2582, 2589, "timolol", "", +27016, IrisPigmentation, 2620, 2640, "change in iris color", "", " . ." +61, NumberAffected, 2670, 2671, "1", "", " \"1\"." +27018, NumberPatientsArm, 2679, 2681, "18", "", +62, Latanoprost, 2704, 2715, "latanoprost", "", +92905, NumberAffected, 2720, 2724, "none", "", " \"none\"." +27019, NumberPatientsArm, 2732, 2734, "18", "", +63, Timolol, 2757, 2764, "timolol", "", +27020, EndPointDescription, 2767, 2806, "Darkening of the peripheral iris stroma", "Adverse effect", +19516, NumberAffected, 2824, 2827, "two", "", +181, Latanoprost, 2850, 2861, "latanoprost", "", +64, Timolol, 2871, 2878, "timolol", "", +183, HeartRate, 2887, 2897, "heart rate", "", " . ." +65, BaseLineValue, 2929, 2931, "72", "", " \"72\"." +66, SdErrorBL, 2938, 2939, "9", "", " \"9\"." +67, ResultMeasuredValue, 2955, 2957, "67", "", " \"67\"." +68, SdErrorResValue, 2964, 2966, "10", "", " \"10\"." +69, BioAndMedicalUnit, 2967, 2983, "beats per minute", "", " . ." +70, TimePoint, 2987, 2996, "12 months", "", " \"12 months\"." +27027, ConclusionComment, 3013, 3261, "Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was", "", " \"Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was\"." +71, PigmentaryGlaucoma, 3197, 3216, "pigmentary glaucoma", "", +27037, DoseValue, 3219, 3226, "0 . 005", "", +25336, Percentage, 3227, 3228, "%", "", +72, Latanoprost, 3229, 3240, "latanoprost", "", +27036, Frequency, 3247, 3257, "once daily", "", +27028, ConclusionComment, 3262, 3352, "well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .", "", " \"well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .\"." +27029, DoseValue, 3317, 3322, "0 . 5", "", +25339, Percentage, 3323, 3324, "%", "", +74, Timolol, 3325, 3332, "timolol", "", +1, Frequency, 3339, 3350, "twice daily", "", " \"twice daily\"." +75, PMID, 3408, 3416, "10080213", "", " \"10080213\"." diff --git a/data/gl 10080213_admin.n-triples b/data/gl 10080213_admin.n-triples new file mode 100644 index 0000000..fd0614c --- /dev/null +++ b/data/gl 10080213_admin.n-triples @@ -0,0 +1,202 @@ +# RDF export of group: Publication + . + "Publication" . + "A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma ." . + "Mastropasqua L" . + "twice daily" . + "1999" . + "Ophthalmology" . + "10080213" . + . + "Carpineto P" . + "Ciancaglini M" . + "Gallenga PE" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma ." . + "Thirty - six" . + "12 - month" . + . + . + . + "Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was" . + . + . + . + . + . + . + . + "well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily ." . + . + . +# RDF export of group: Population + . + "Population" . + "patients with pigmentary glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_IOP" . + . + . + . + . + . + . + . + "Endpoint_C" . + . + . + . + . + . + . + . + "Endpoint_H" . + . + . + . + . + . + . + "Endpoint_Iris" . + . + . + . + . + . + . + "Endpoint_HR" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + "18" . + . + . + . + . + . + . + . + . + "Arm_tim" . + "18" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + . + "Intervention_tim" . + . + "twice daily" . + . + . + "Intervention_Pla" . + . + . + "once daily" . +# RDF export of group: Medication + . + "Medication_Lat" . + . + . + "0 . 005" . + . + . + . + . + "Medication_Pla" . + . + . + . + . + "Medication_tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_lat_IOP_6" . + . + "6 . 0" . + "4 . 5" . + "6 and 12 months" . + . + "Outcome_lat_IOP_12" . + . + "5 . 9" . + "4 . 6" . + "12 months" . + . + "Outcome_tim_IOP_6" . + . + "4 . 8" . + "3 . 0" . + "6 and 12 months" . + . + "Outcome_tim_IOP_12" . + . + "4 . 6" . + "3 . 1" . + "12 months" . + . + "Outcome_lat_C" . + . + "30" . + "P = 0 . 017" . + . + "Outcome_lat_H" . + . + "0 . 3" . + . + "Outcome_tim_H" . + . + "0 . 2" . + . + "Outcome_lat_Iris" . + . + "1" . + . + "Outcome_tim_Iris" . + . + "none" . + . + "Outcome_tim_HR" . + . + "72" . + "9" . + "67" . + "10" . + "12 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_IOP" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_IOP_12" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10080213_export.csv b/data/gl 10080213_export.csv new file mode 100644 index 0000000..7674e7d --- /dev/null +++ b/data/gl 10080213_export.csv @@ -0,0 +1,696 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +497, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +497, 1, 2, 2, 14, 15, 14, 15, "." +497, 2, 1, 3, 0, 4, 16, 20, "1999" +497, 2, 2, 4, 5, 8, 21, 24, "Mar" +497, 2, 3, 5, 9, 10, 25, 26, ";" +497, 2, 4, 6, 11, 14, 27, 30, "106" +497, 2, 5, 7, 15, 16, 31, 32, "(" +497, 2, 6, 8, 17, 18, 33, 34, "3" +497, 2, 7, 9, 19, 20, 35, 36, ")" +497, 2, 8, 10, 21, 22, 37, 38, ":" +497, 2, 9, 11, 23, 26, 39, 42, "550" +497, 2, 10, 12, 27, 28, 43, 44, "-" +497, 2, 11, 13, 29, 30, 45, 46, "5" +497, 2, 12, 14, 31, 32, 47, 48, "." +497, 3, 1, 15, 0, 1, 49, 50, "A" +497, 3, 2, 16, 2, 4, 51, 53, "12" +497, 3, 3, 17, 5, 6, 54, 55, "-" +497, 3, 4, 18, 7, 12, 56, 61, "month" +497, 3, 5, 19, 13, 14, 62, 63, "," +497, 3, 6, 20, 15, 25, 64, 74, "randomized" +497, 3, 7, 21, 26, 27, 75, 76, "," +497, 3, 8, 22, 28, 34, 77, 83, "double" +497, 3, 9, 23, 35, 36, 84, 85, "-" +497, 3, 10, 24, 37, 43, 86, 92, "masked" +497, 3, 11, 25, 44, 49, 93, 98, "study" +497, 3, 12, 26, 50, 59, 99, 108, "comparing" +497, 3, 13, 27, 60, 71, 109, 120, "latanoprost" +497, 3, 14, 28, 72, 76, 121, 125, "with" +497, 3, 15, 29, 77, 84, 126, 133, "timolol" +497, 3, 16, 30, 85, 87, 134, 136, "in" +497, 3, 17, 31, 88, 98, 137, 147, "pigmentary" +497, 3, 18, 32, 99, 107, 148, 156, "glaucoma" +497, 3, 19, 33, 108, 109, 157, 158, "." +497, 4, 1, 34, 0, 12, 159, 171, "Mastropasqua" +497, 4, 2, 35, 13, 14, 172, 173, "L" +497, 4, 3, 36, 15, 16, 174, 175, "(" +497, 4, 4, 37, 17, 18, 176, 177, "1" +497, 4, 5, 38, 19, 20, 178, 179, ")" +497, 4, 6, 39, 21, 22, 180, 181, "," +497, 4, 7, 40, 23, 32, 182, 191, "Carpineto" +497, 4, 8, 41, 33, 34, 192, 193, "P" +497, 4, 9, 42, 35, 36, 194, 195, "," +497, 4, 10, 43, 37, 48, 196, 207, "Ciancaglini" +497, 4, 11, 44, 49, 50, 208, 209, "M" +497, 4, 12, 45, 51, 52, 210, 211, "," +497, 4, 13, 46, 53, 61, 212, 220, "Gallenga" +497, 4, 14, 47, 62, 64, 221, 223, "PE" +497, 4, 15, 48, 65, 66, 224, 225, "." +497, 5, 1, 49, 0, 6, 226, 232, "Author" +497, 5, 2, 50, 7, 18, 233, 244, "information" +497, 5, 3, 51, 19, 20, 245, 246, ":" +497, 5, 4, 52, 21, 22, 247, 248, "(" +497, 5, 5, 53, 23, 24, 249, 250, "1" +497, 5, 6, 54, 25, 26, 251, 252, ")" +497, 5, 7, 55, 27, 36, 253, 262, "Institute" +497, 5, 8, 56, 37, 39, 263, 265, "of" +497, 5, 9, 57, 40, 53, 266, 279, "Ophthalmology" +497, 5, 10, 58, 54, 57, 280, 283, "and" +497, 5, 11, 59, 58, 63, 284, 289, "Legal" +497, 5, 12, 60, 64, 72, 290, 298, "Medicine" +497, 5, 13, 61, 73, 83, 299, 309, "University" +497, 5, 14, 62, 84, 85, 310, 311, "G" +497, 5, 15, 63, 86, 87, 312, 313, "." +497, 5, 16, 64, 88, 89, 314, 315, "D" +497, 5, 17, 65, 90, 91, 316, 317, "'" +497, 5, 18, 66, 92, 100, 318, 326, "Annunzio" +497, 5, 19, 67, 101, 102, 327, 328, "," +497, 5, 20, 68, 103, 109, 329, 335, "Chieti" +497, 5, 21, 69, 110, 111, 336, 337, "," +497, 5, 22, 70, 112, 117, 338, 343, "Italy" +497, 5, 23, 71, 118, 119, 344, 345, "." +497, 6, 1, 72, 0, 9, 346, 355, "OBJECTIVE" +497, 6, 2, 73, 10, 11, 356, 357, ":" +497, 6, 3, 74, 12, 14, 358, 360, "To" +497, 6, 4, 75, 15, 22, 361, 368, "compare" +497, 6, 5, 76, 23, 26, 369, 372, "the" +497, 6, 6, 77, 27, 35, 373, 381, "efficacy" +497, 6, 7, 78, 36, 39, 382, 385, "and" +497, 6, 8, 79, 40, 44, 386, 390, "side" +497, 6, 9, 80, 45, 52, 391, 398, "effects" +497, 6, 10, 81, 53, 56, 399, 402, "and" +497, 6, 11, 82, 57, 60, 403, 406, "the" +497, 6, 12, 83, 61, 67, 407, 413, "effect" +497, 6, 13, 84, 68, 70, 414, 416, "on" +497, 6, 14, 85, 71, 78, 417, 424, "aqueous" +497, 6, 15, 86, 79, 84, 425, 430, "humor" +497, 6, 16, 87, 85, 93, 431, 439, "dynamics" +497, 6, 17, 88, 94, 96, 440, 442, "of" +497, 6, 18, 89, 97, 98, 443, 444, "0" +497, 6, 19, 90, 99, 100, 445, 446, "." +497, 6, 20, 91, 101, 104, 447, 450, "005" +497, 6, 21, 92, 105, 106, 451, 452, "%" +497, 6, 22, 93, 107, 118, 453, 464, "latanoprost" +497, 6, 23, 94, 119, 126, 465, 472, "applied" +497, 6, 24, 95, 127, 136, 473, 482, "topically" +497, 6, 25, 96, 137, 141, 483, 487, "once" +497, 6, 26, 97, 142, 147, 488, 493, "daily" +497, 6, 27, 98, 148, 152, 494, 498, "with" +497, 6, 28, 99, 153, 154, 499, 500, "0" +497, 6, 29, 100, 155, 156, 501, 502, "." +497, 6, 30, 101, 157, 158, 503, 504, "5" +497, 6, 31, 102, 159, 160, 505, 506, "%" +497, 6, 32, 103, 161, 168, 507, 514, "timolol" +497, 6, 33, 104, 169, 174, 515, 520, "given" +497, 6, 34, 105, 175, 180, 521, 526, "twice" +497, 6, 35, 106, 181, 186, 527, 532, "daily" +497, 6, 36, 107, 187, 190, 533, 536, "for" +497, 6, 37, 108, 191, 193, 537, 539, "12" +497, 6, 38, 109, 194, 200, 540, 546, "months" +497, 6, 39, 110, 201, 203, 547, 549, "to" +497, 6, 40, 111, 204, 212, 550, 558, "patients" +497, 6, 41, 112, 213, 217, 559, 563, "with" +497, 6, 42, 113, 218, 228, 564, 574, "pigmentary" +497, 6, 43, 114, 229, 237, 575, 583, "glaucoma" +497, 6, 44, 115, 238, 239, 584, 585, "." +497, 7, 1, 116, 0, 6, 586, 592, "DESIGN" +497, 7, 2, 117, 7, 8, 593, 594, ":" +497, 7, 3, 118, 9, 20, 595, 606, "Prospective" +497, 7, 4, 119, 21, 22, 607, 608, "," +497, 7, 5, 120, 23, 33, 609, 619, "randomized" +497, 7, 6, 121, 34, 35, 620, 621, "," +497, 7, 7, 122, 36, 42, 622, 628, "double" +497, 7, 8, 123, 43, 44, 629, 630, "-" +497, 7, 9, 124, 45, 51, 631, 637, "masked" +497, 7, 10, 125, 52, 53, 638, 639, "," +497, 7, 11, 126, 54, 62, 640, 648, "clinical" +497, 7, 12, 127, 63, 68, 649, 654, "study" +497, 7, 13, 128, 69, 70, 655, 656, "." +497, 8, 1, 129, 0, 12, 657, 669, "PARTICIPANTS" +497, 8, 2, 130, 13, 14, 670, 671, ":" +497, 8, 3, 131, 15, 21, 672, 678, "Thirty" +497, 8, 4, 132, 22, 23, 679, 680, "-" +497, 8, 5, 133, 24, 27, 681, 684, "six" +497, 8, 6, 134, 28, 36, 685, 693, "patients" +497, 8, 7, 135, 37, 45, 694, 702, "affected" +497, 8, 8, 136, 46, 50, 703, 707, "with" +497, 8, 9, 137, 51, 60, 708, 717, "bilateral" +497, 8, 10, 138, 61, 71, 718, 728, "pigmentary" +497, 8, 11, 139, 72, 80, 729, 737, "glaucoma" +497, 8, 12, 140, 81, 91, 738, 748, "controlled" +497, 8, 13, 141, 92, 96, 749, 753, "with" +497, 8, 14, 142, 97, 99, 754, 756, "no" +497, 8, 15, 143, 100, 104, 757, 761, "more" +497, 8, 16, 144, 105, 109, 762, 766, "than" +497, 8, 17, 145, 110, 111, 767, 768, "a" +497, 8, 18, 146, 112, 118, 769, 775, "single" +497, 8, 19, 147, 119, 130, 776, 787, "hypotensive" +497, 8, 20, 148, 131, 141, 788, 798, "medication" +497, 8, 21, 149, 142, 146, 799, 803, "were" +497, 8, 22, 150, 147, 155, 804, 812, "enrolled" +497, 8, 23, 151, 156, 158, 813, 815, "in" +497, 8, 24, 152, 159, 162, 816, 819, "the" +497, 8, 25, 153, 163, 168, 820, 825, "study" +497, 8, 26, 154, 169, 170, 826, 827, "." +497, 9, 1, 155, 0, 12, 828, 840, "INTERVENTION" +497, 9, 2, 156, 13, 14, 841, 842, ":" +497, 9, 3, 157, 15, 18, 843, 846, "The" +497, 9, 4, 158, 19, 25, 847, 853, "sample" +497, 9, 5, 159, 26, 36, 854, 864, "population" +497, 9, 6, 160, 37, 40, 865, 868, "was" +497, 9, 7, 161, 41, 49, 869, 877, "randomly" +497, 9, 8, 162, 50, 57, 878, 885, "divided" +497, 9, 9, 163, 58, 62, 886, 890, "into" +497, 9, 10, 164, 63, 64, 891, 892, "2" +497, 9, 11, 165, 65, 68, 893, 896, "age" +497, 9, 12, 166, 69, 70, 897, 898, "-" +497, 9, 13, 167, 71, 74, 899, 902, "and" +497, 9, 14, 168, 75, 81, 903, 909, "gender" +497, 9, 15, 169, 82, 83, 910, 911, "-" +497, 9, 16, 170, 84, 91, 912, 919, "matched" +497, 9, 17, 171, 92, 98, 920, 926, "groups" +497, 9, 18, 172, 99, 103, 927, 931, "each" +497, 9, 19, 173, 104, 106, 932, 934, "of" +497, 9, 20, 174, 107, 109, 935, 937, "18" +497, 9, 21, 175, 110, 118, 938, 946, "patients" +497, 9, 22, 176, 119, 120, 947, 948, "." +497, 10, 1, 177, 0, 5, 949, 954, "Group" +497, 10, 2, 178, 6, 7, 955, 956, "1" +497, 10, 3, 179, 8, 16, 957, 965, "received" +497, 10, 4, 180, 17, 18, 966, 967, "0" +497, 10, 5, 181, 19, 20, 968, 969, "." +497, 10, 6, 182, 21, 24, 970, 973, "005" +497, 10, 7, 183, 25, 26, 974, 975, "%" +497, 10, 8, 184, 27, 38, 976, 987, "latanoprost" +497, 10, 9, 185, 39, 47, 988, 996, "eyedrops" +497, 10, 10, 186, 48, 52, 997, 1001, "once" +497, 10, 11, 187, 53, 58, 1002, 1007, "daily" +497, 10, 12, 188, 59, 62, 1008, 1011, "and" +497, 10, 13, 189, 63, 66, 1012, 1015, "the" +497, 10, 14, 190, 67, 74, 1016, 1023, "vehicle" +497, 10, 15, 191, 75, 76, 1024, 1025, "(" +497, 10, 16, 192, 77, 84, 1026, 1033, "placebo" +497, 10, 17, 193, 85, 86, 1034, 1035, ")" +497, 10, 18, 194, 87, 91, 1036, 1040, "once" +497, 10, 19, 195, 92, 97, 1041, 1046, "daily" +497, 10, 20, 196, 98, 99, 1047, 1048, ";" +497, 10, 21, 197, 100, 105, 1049, 1054, "group" +497, 10, 22, 198, 106, 107, 1055, 1056, "2" +497, 10, 23, 199, 108, 111, 1057, 1060, "was" +497, 10, 24, 200, 112, 120, 1061, 1069, "assigned" +497, 10, 25, 201, 121, 123, 1070, 1072, "to" +497, 10, 26, 202, 124, 131, 1073, 1080, "timolol" +497, 10, 27, 203, 132, 133, 1081, 1082, "0" +497, 10, 28, 204, 134, 135, 1083, 1084, "." +497, 10, 29, 205, 136, 137, 1085, 1086, "5" +497, 10, 30, 206, 138, 139, 1087, 1088, "%" +497, 10, 31, 207, 140, 148, 1089, 1097, "eyedrops" +497, 10, 32, 208, 149, 154, 1098, 1103, "twice" +497, 10, 33, 209, 155, 160, 1104, 1109, "daily" +497, 10, 34, 210, 161, 162, 1110, 1111, "." +497, 11, 1, 211, 0, 4, 1112, 1116, "MAIN" +497, 11, 2, 212, 5, 12, 1117, 1124, "OUTCOME" +497, 11, 3, 213, 13, 21, 1125, 1133, "MEASURES" +497, 11, 4, 214, 22, 23, 1134, 1135, ":" +497, 11, 5, 215, 24, 31, 1136, 1143, "Diurnal" +497, 11, 6, 216, 32, 38, 1144, 1150, "curves" +497, 11, 7, 217, 39, 41, 1151, 1153, "of" +497, 11, 8, 218, 42, 53, 1154, 1165, "intraocular" +497, 11, 9, 219, 54, 62, 1166, 1174, "pressure" +497, 11, 10, 220, 63, 64, 1175, 1176, "(" +497, 11, 11, 221, 65, 68, 1177, 1180, "IOP" +497, 11, 12, 222, 69, 70, 1181, 1182, ")" +497, 11, 13, 223, 71, 75, 1183, 1187, "were" +497, 11, 14, 224, 76, 85, 1188, 1197, "performed" +497, 11, 15, 225, 86, 88, 1198, 1200, "on" +497, 11, 16, 226, 89, 92, 1201, 1204, "the" +497, 11, 17, 227, 93, 101, 1205, 1213, "baseline" +497, 11, 18, 228, 102, 105, 1214, 1217, "day" +497, 11, 19, 229, 106, 109, 1218, 1221, "and" +497, 11, 20, 230, 110, 115, 1222, 1227, "after" +497, 11, 21, 231, 116, 117, 1228, 1229, "0" +497, 11, 22, 232, 118, 119, 1230, 1231, "." +497, 11, 23, 233, 120, 121, 1232, 1233, "5" +497, 11, 24, 234, 122, 123, 1234, 1235, "," +497, 11, 25, 235, 124, 125, 1236, 1237, "3" +497, 11, 26, 236, 126, 127, 1238, 1239, "," +497, 11, 27, 237, 128, 129, 1240, 1241, "6" +497, 11, 28, 238, 130, 131, 1242, 1243, "," +497, 11, 29, 239, 132, 135, 1244, 1247, "and" +497, 11, 30, 240, 136, 138, 1248, 1250, "12" +497, 11, 31, 241, 139, 145, 1251, 1257, "months" +497, 11, 32, 242, 146, 148, 1258, 1260, "of" +497, 11, 33, 243, 149, 158, 1261, 1270, "treatment" +497, 11, 34, 244, 159, 160, 1271, 1272, "." +497, 12, 1, 245, 0, 3, 1273, 1276, "The" +497, 12, 2, 246, 4, 7, 1277, 1280, "IOP" +497, 12, 3, 247, 8, 20, 1281, 1293, "measurements" +497, 12, 4, 248, 21, 25, 1294, 1298, "were" +497, 12, 5, 249, 26, 35, 1299, 1308, "performed" +497, 12, 6, 250, 36, 38, 1309, 1311, "at" +497, 12, 7, 251, 39, 40, 1312, 1313, "8" +497, 12, 8, 252, 41, 42, 1314, 1315, ":" +497, 12, 9, 253, 43, 45, 1316, 1318, "00" +497, 12, 10, 254, 46, 48, 1319, 1321, "AM" +497, 12, 11, 255, 49, 50, 1322, 1323, "," +497, 12, 12, 256, 51, 53, 1324, 1326, "12" +497, 12, 13, 257, 54, 55, 1327, 1328, ":" +497, 12, 14, 258, 56, 58, 1329, 1331, "00" +497, 12, 15, 259, 59, 63, 1332, 1336, "noon" +497, 12, 16, 260, 64, 65, 1337, 1338, "," +497, 12, 17, 261, 66, 67, 1339, 1340, "4" +497, 12, 18, 262, 68, 69, 1341, 1342, ":" +497, 12, 19, 263, 70, 72, 1343, 1345, "00" +497, 12, 20, 264, 73, 75, 1346, 1348, "PM" +497, 12, 21, 265, 76, 77, 1349, 1350, "," +497, 12, 22, 266, 78, 81, 1351, 1354, "and" +497, 12, 23, 267, 82, 83, 1355, 1356, "8" +497, 12, 24, 268, 84, 85, 1357, 1358, ":" +497, 12, 25, 269, 86, 88, 1359, 1361, "00" +497, 12, 26, 270, 89, 91, 1362, 1364, "PM" +497, 12, 27, 271, 92, 93, 1365, 1366, "." +497, 13, 1, 272, 0, 7, 1367, 1374, "Outflow" +497, 13, 2, 273, 8, 16, 1375, 1383, "facility" +497, 13, 3, 274, 17, 18, 1384, 1385, "(" +497, 13, 5, 276, 21, 22, 1388, 1389, "C" +497, 13, 7, 278, 25, 26, 1392, 1393, ")" +497, 13, 8, 279, 27, 30, 1394, 1397, "was" +497, 13, 9, 280, 31, 39, 1398, 1406, "measured" +497, 13, 10, 281, 40, 42, 1407, 1409, "on" +497, 13, 11, 282, 43, 46, 1410, 1413, "the" +497, 13, 12, 283, 47, 55, 1414, 1422, "baseline" +497, 13, 13, 284, 56, 59, 1423, 1426, "day" +497, 13, 14, 285, 60, 63, 1427, 1430, "and" +497, 13, 15, 286, 64, 66, 1431, 1433, "on" +497, 13, 16, 287, 67, 70, 1434, 1437, "the" +497, 13, 17, 288, 71, 75, 1438, 1442, "last" +497, 13, 18, 289, 76, 79, 1443, 1446, "day" +497, 13, 19, 290, 80, 82, 1447, 1449, "of" +497, 13, 20, 291, 83, 86, 1450, 1453, "the" +497, 13, 21, 292, 87, 92, 1454, 1459, "study" +497, 13, 22, 293, 93, 97, 1460, 1464, "with" +497, 13, 23, 294, 98, 99, 1465, 1466, "a" +497, 13, 24, 295, 100, 107, 1467, 1474, "Schiotz" +497, 13, 25, 296, 108, 118, 1475, 1485, "electronic" +497, 13, 26, 297, 119, 128, 1486, 1495, "tonometer" +497, 13, 27, 298, 129, 130, 1496, 1497, "." +497, 14, 1, 299, 0, 1, 1498, 1499, "A" +497, 14, 2, 300, 2, 5, 1500, 1503, "two" +497, 14, 3, 301, 6, 7, 1504, 1505, "-" +497, 14, 4, 302, 8, 14, 1506, 1512, "tailed" +497, 14, 5, 303, 15, 22, 1513, 1520, "Student" +497, 14, 6, 304, 23, 24, 1521, 1522, "'" +497, 14, 7, 305, 25, 26, 1523, 1524, "s" +497, 14, 8, 306, 27, 28, 1525, 1526, "t" +497, 14, 9, 307, 29, 33, 1527, 1531, "test" +497, 14, 10, 308, 34, 37, 1532, 1535, "for" +497, 14, 11, 309, 38, 44, 1536, 1542, "paired" +497, 14, 12, 310, 45, 47, 1543, 1545, "or" +497, 14, 13, 311, 48, 56, 1546, 1554, "unpaired" +497, 14, 14, 312, 57, 61, 1555, 1559, "data" +497, 14, 15, 313, 62, 65, 1560, 1563, "was" +497, 14, 16, 314, 66, 70, 1564, 1568, "used" +497, 14, 17, 315, 71, 74, 1569, 1572, "for" +497, 14, 18, 316, 75, 86, 1573, 1584, "statistical" +497, 14, 19, 317, 87, 97, 1585, 1595, "evaluation" +497, 14, 20, 318, 98, 100, 1596, 1598, "of" +497, 14, 21, 319, 101, 112, 1599, 1610, "differences" +497, 14, 22, 320, 113, 120, 1611, 1618, "between" +497, 14, 23, 321, 121, 130, 1619, 1628, "treatment" +497, 14, 24, 322, 131, 134, 1629, 1632, "and" +497, 14, 25, 323, 135, 143, 1633, 1641, "baseline" +497, 14, 26, 324, 144, 150, 1642, 1648, "values" +497, 14, 27, 325, 151, 153, 1649, 1651, "or" +497, 14, 28, 326, 154, 161, 1652, 1659, "between" +497, 14, 29, 327, 162, 165, 1660, 1663, "the" +497, 14, 30, 328, 166, 177, 1664, 1675, "latanoprost" +497, 14, 31, 329, 178, 181, 1676, 1679, "and" +497, 14, 32, 330, 182, 189, 1680, 1687, "timolol" +497, 14, 33, 331, 190, 195, 1688, 1693, "group" +497, 14, 34, 332, 196, 197, 1694, 1695, "." +497, 15, 1, 333, 0, 7, 1696, 1703, "Diurnal" +497, 15, 2, 334, 8, 11, 1704, 1707, "IOP" +497, 15, 3, 335, 12, 24, 1708, 1720, "measurements" +497, 15, 4, 336, 25, 29, 1721, 1725, "were" +497, 15, 5, 337, 30, 38, 1726, 1734, "compared" +497, 15, 6, 338, 39, 43, 1735, 1739, "hour" +497, 15, 7, 339, 44, 46, 1740, 1742, "by" +497, 15, 8, 340, 47, 51, 1743, 1747, "hour" +497, 15, 9, 341, 52, 53, 1748, 1749, "." +497, 16, 1, 342, 0, 4, 1750, 1754, "Mean" +497, 16, 2, 343, 5, 11, 1755, 1761, "values" +497, 16, 3, 344, 12, 14, 1762, 1764, "of" +497, 16, 4, 345, 15, 18, 1765, 1768, "the" +497, 16, 5, 346, 19, 22, 1769, 1772, "two" +497, 16, 6, 347, 23, 27, 1773, 1777, "eyes" +497, 16, 7, 348, 28, 31, 1778, 1781, "IOP" +497, 16, 8, 349, 32, 35, 1782, 1785, "and" +497, 16, 10, 351, 38, 39, 1788, 1789, "C" +497, 16, 12, 353, 42, 46, 1792, 1796, "were" +497, 16, 13, 354, 47, 51, 1797, 1801, "used" +497, 16, 14, 355, 52, 55, 1802, 1805, "for" +497, 16, 15, 356, 56, 64, 1806, 1814, "analysis" +497, 16, 16, 357, 65, 66, 1815, 1816, "." +497, 17, 1, 358, 0, 7, 1817, 1824, "RESULTS" +497, 17, 2, 359, 8, 9, 1825, 1826, ":" +497, 17, 3, 360, 10, 18, 1827, 1835, "Compared" +497, 17, 4, 361, 19, 23, 1836, 1840, "with" +497, 17, 5, 362, 24, 32, 1841, 1849, "baseline" +497, 17, 6, 363, 33, 45, 1850, 1862, "measurements" +497, 17, 7, 364, 46, 47, 1863, 1864, "," +497, 17, 8, 365, 48, 52, 1865, 1869, "both" +497, 17, 9, 366, 53, 64, 1870, 1881, "latanoprost" +497, 17, 10, 367, 65, 68, 1882, 1885, "and" +497, 17, 11, 368, 69, 76, 1886, 1893, "timolol" +497, 17, 12, 369, 77, 83, 1894, 1900, "caused" +497, 17, 13, 370, 84, 85, 1901, 1902, "a" +497, 17, 14, 371, 86, 97, 1903, 1914, "significant" +497, 17, 15, 372, 98, 99, 1915, 1916, "(" +497, 17, 16, 373, 100, 101, 1917, 1918, "P" +497, 17, 17, 374, 102, 103, 1919, 1920, "<" +497, 17, 18, 375, 104, 105, 1921, 1922, "0" +497, 17, 19, 376, 106, 107, 1923, 1924, "." +497, 17, 20, 377, 108, 111, 1925, 1928, "001" +497, 17, 21, 378, 112, 113, 1929, 1930, ")" +497, 17, 22, 379, 114, 123, 1931, 1940, "reduction" +497, 17, 23, 380, 124, 126, 1941, 1943, "of" +497, 17, 24, 381, 127, 130, 1944, 1947, "IOP" +497, 17, 25, 382, 131, 133, 1948, 1950, "at" +497, 17, 26, 383, 134, 138, 1951, 1955, "each" +497, 17, 27, 384, 139, 143, 1956, 1960, "hour" +497, 17, 28, 385, 144, 146, 1961, 1963, "of" +497, 17, 29, 386, 147, 154, 1964, 1971, "diurnal" +497, 17, 30, 387, 155, 160, 1972, 1977, "curve" +497, 17, 31, 388, 161, 171, 1978, 1988, "throughout" +497, 17, 32, 389, 172, 175, 1989, 1992, "the" +497, 17, 33, 390, 176, 184, 1993, 2001, "duration" +497, 17, 34, 391, 185, 187, 2002, 2004, "of" +497, 17, 35, 392, 188, 195, 2005, 2012, "therapy" +497, 17, 36, 393, 196, 197, 2013, 2014, "." +497, 18, 1, 394, 0, 9, 2015, 2024, "Reduction" +497, 18, 2, 395, 10, 12, 2025, 2027, "of" +497, 18, 3, 396, 13, 16, 2028, 2031, "IOP" +497, 18, 4, 397, 17, 20, 2032, 2035, "was" +497, 18, 5, 398, 21, 22, 2036, 2037, "6" +497, 18, 6, 399, 23, 24, 2038, 2039, "." +497, 18, 7, 400, 25, 26, 2040, 2041, "0" +497, 18, 8, 401, 27, 28, 2042, 2043, "+" +497, 18, 9, 402, 29, 30, 2044, 2045, "/" +497, 18, 10, 403, 31, 32, 2046, 2047, "-" +497, 18, 11, 404, 33, 34, 2048, 2049, "4" +497, 18, 12, 405, 35, 36, 2050, 2051, "." +497, 18, 13, 406, 37, 38, 2052, 2053, "5" +497, 18, 14, 407, 39, 42, 2054, 2057, "and" +497, 18, 15, 408, 43, 44, 2058, 2059, "5" +497, 18, 16, 409, 45, 46, 2060, 2061, "." +497, 18, 17, 410, 47, 48, 2062, 2063, "9" +497, 18, 18, 411, 49, 50, 2064, 2065, "+" +497, 18, 19, 412, 51, 52, 2066, 2067, "/" +497, 18, 20, 413, 53, 54, 2068, 2069, "-" +497, 18, 21, 414, 55, 56, 2070, 2071, "4" +497, 18, 22, 415, 57, 58, 2072, 2073, "." +497, 18, 23, 416, 59, 60, 2074, 2075, "6" +497, 18, 24, 417, 61, 65, 2076, 2080, "with" +497, 18, 25, 418, 66, 77, 2081, 2092, "latanoprost" +497, 18, 26, 419, 78, 81, 2093, 2096, "and" +497, 18, 27, 420, 82, 83, 2097, 2098, "4" +497, 18, 28, 421, 84, 85, 2099, 2100, "." +497, 18, 29, 422, 86, 87, 2101, 2102, "8" +497, 18, 30, 423, 88, 89, 2103, 2104, "+" +497, 18, 31, 424, 90, 91, 2105, 2106, "/" +497, 18, 32, 425, 92, 93, 2107, 2108, "-" +497, 18, 33, 426, 94, 95, 2109, 2110, "3" +497, 18, 34, 427, 96, 97, 2111, 2112, "." +497, 18, 35, 428, 98, 99, 2113, 2114, "0" +497, 18, 36, 429, 100, 103, 2115, 2118, "and" +497, 18, 37, 430, 104, 105, 2119, 2120, "4" +497, 18, 38, 431, 106, 107, 2121, 2122, "." +497, 18, 39, 432, 108, 109, 2123, 2124, "6" +497, 18, 40, 433, 110, 111, 2125, 2126, "+" +497, 18, 41, 434, 112, 113, 2127, 2128, "/" +497, 18, 42, 435, 114, 115, 2129, 2130, "-" +497, 18, 43, 436, 116, 117, 2131, 2132, "3" +497, 18, 44, 437, 118, 119, 2133, 2134, "." +497, 18, 45, 438, 120, 121, 2135, 2136, "1" +497, 18, 46, 439, 122, 126, 2137, 2141, "with" +497, 18, 47, 440, 127, 134, 2142, 2149, "timolol" +497, 18, 48, 441, 135, 140, 2150, 2155, "after" +497, 18, 49, 442, 141, 142, 2156, 2157, "6" +497, 18, 50, 443, 143, 146, 2158, 2161, "and" +497, 18, 51, 444, 147, 149, 2162, 2164, "12" +497, 18, 52, 445, 150, 156, 2165, 2171, "months" +497, 18, 53, 446, 157, 158, 2172, 2173, "," +497, 18, 54, 447, 159, 171, 2174, 2186, "respectively" +497, 18, 55, 448, 172, 173, 2187, 2188, "." +497, 19, 1, 449, 0, 10, 2189, 2199, "Comparison" +497, 19, 2, 450, 11, 13, 2200, 2202, "of" +497, 19, 3, 451, 14, 18, 2203, 2207, "mean" +497, 19, 4, 452, 19, 26, 2208, 2215, "diurnal" +497, 19, 5, 453, 27, 39, 2216, 2228, "measurements" +497, 19, 6, 454, 40, 44, 2229, 2233, "with" +497, 19, 7, 455, 45, 56, 2234, 2245, "latanoprost" +497, 19, 8, 456, 57, 60, 2246, 2249, "and" +497, 19, 9, 457, 61, 68, 2250, 2257, "timolol" +497, 19, 10, 458, 69, 75, 2258, 2264, "showed" +497, 19, 11, 459, 76, 77, 2265, 2266, "a" +497, 19, 12, 460, 78, 89, 2267, 2278, "statistical" +497, 19, 13, 461, 90, 101, 2279, 2290, "significant" +497, 19, 14, 462, 102, 103, 2291, 2292, "(" +497, 19, 15, 463, 104, 105, 2293, 2294, "P" +497, 19, 16, 464, 106, 107, 2295, 2296, "<" +497, 19, 17, 465, 108, 109, 2297, 2298, "0" +497, 19, 18, 466, 110, 111, 2299, 2300, "." +497, 19, 19, 467, 112, 115, 2301, 2304, "001" +497, 19, 20, 468, 116, 117, 2305, 2306, ")" +497, 19, 21, 469, 118, 128, 2307, 2317, "difference" +497, 19, 22, 470, 129, 131, 2318, 2320, "at" +497, 19, 23, 471, 132, 133, 2321, 2322, "3" +497, 19, 24, 472, 134, 135, 2323, 2324, "," +497, 19, 25, 473, 136, 137, 2325, 2326, "6" +497, 19, 26, 474, 138, 139, 2327, 2328, "," +497, 19, 27, 475, 140, 143, 2329, 2332, "and" +497, 19, 28, 476, 144, 146, 2333, 2335, "12" +497, 19, 29, 477, 147, 153, 2336, 2342, "months" +497, 19, 30, 478, 154, 155, 2343, 2344, "." +497, 20, 1, 479, 0, 4, 2345, 2349, "Mean" +497, 20, 3, 481, 7, 8, 2352, 2353, "C" +497, 20, 5, 483, 11, 14, 2356, 2359, "was" +497, 20, 6, 484, 15, 20, 2360, 2365, "found" +497, 20, 7, 485, 21, 23, 2366, 2368, "to" +497, 20, 8, 486, 24, 26, 2369, 2371, "be" +497, 20, 9, 487, 27, 40, 2372, 2385, "significantly" +497, 20, 10, 488, 41, 49, 2386, 2394, "enhanced" +497, 20, 11, 489, 50, 51, 2395, 2396, "(" +497, 20, 12, 490, 52, 53, 2397, 2398, "+" +497, 20, 13, 491, 54, 56, 2399, 2401, "30" +497, 20, 14, 492, 57, 58, 2402, 2403, "%" +497, 20, 15, 493, 59, 60, 2404, 2405, ")" +497, 20, 16, 494, 61, 65, 2406, 2410, "only" +497, 20, 17, 495, 66, 68, 2411, 2413, "in" +497, 20, 18, 496, 69, 72, 2414, 2417, "the" +497, 20, 19, 497, 73, 84, 2418, 2429, "latanoprost" +497, 20, 20, 498, 85, 86, 2430, 2431, "-" +497, 20, 21, 499, 87, 94, 2432, 2439, "treated" +497, 20, 22, 500, 95, 100, 2440, 2445, "group" +497, 20, 23, 501, 101, 109, 2446, 2454, "compared" +497, 20, 24, 502, 110, 114, 2455, 2459, "with" +497, 20, 25, 503, 115, 118, 2460, 2463, "the" +497, 20, 26, 504, 119, 127, 2464, 2472, "baseline" +497, 20, 27, 505, 128, 129, 2473, 2474, "(" +497, 20, 28, 506, 130, 131, 2475, 2476, "P" +497, 20, 29, 507, 132, 133, 2477, 2478, "=" +497, 20, 30, 508, 134, 135, 2479, 2480, "0" +497, 20, 31, 509, 136, 137, 2481, 2482, "." +497, 20, 32, 510, 138, 141, 2483, 2486, "017" +497, 20, 33, 511, 142, 143, 2487, 2488, ")" +497, 20, 34, 512, 144, 145, 2489, 2490, "." +497, 21, 1, 513, 0, 4, 2491, 2495, "Mean" +497, 21, 2, 514, 5, 17, 2496, 2508, "conjunctival" +497, 21, 3, 515, 18, 27, 2509, 2518, "hyperemia" +497, 21, 4, 516, 28, 31, 2519, 2522, "was" +497, 21, 5, 517, 32, 38, 2523, 2529, "graded" +497, 21, 6, 518, 39, 41, 2530, 2532, "at" +497, 21, 7, 519, 42, 43, 2533, 2534, "0" +497, 21, 8, 520, 44, 45, 2535, 2536, "." +497, 21, 9, 521, 46, 47, 2537, 2538, "3" +497, 21, 10, 522, 48, 50, 2539, 2541, "in" +497, 21, 11, 523, 51, 62, 2542, 2553, "latanoprost" +497, 21, 12, 524, 63, 64, 2554, 2555, "-" +497, 21, 13, 525, 65, 72, 2556, 2563, "treated" +497, 21, 14, 526, 73, 77, 2564, 2568, "eyes" +497, 21, 15, 527, 78, 81, 2569, 2572, "and" +497, 21, 16, 528, 82, 83, 2573, 2574, "0" +497, 21, 17, 529, 84, 85, 2575, 2576, "." +497, 21, 18, 530, 86, 87, 2577, 2578, "2" +497, 21, 19, 531, 88, 90, 2579, 2581, "in" +497, 21, 20, 532, 91, 98, 2582, 2589, "timolol" +497, 21, 21, 533, 99, 100, 2590, 2591, "-" +497, 21, 22, 534, 101, 108, 2592, 2599, "treated" +497, 21, 23, 535, 109, 113, 2600, 2604, "eyes" +497, 21, 24, 536, 114, 115, 2605, 2606, "." +497, 22, 1, 537, 0, 1, 2607, 2608, "A" +497, 22, 2, 538, 2, 12, 2609, 2619, "remarkable" +497, 22, 3, 539, 13, 19, 2620, 2626, "change" +497, 22, 4, 540, 20, 22, 2627, 2629, "in" +497, 22, 5, 541, 23, 27, 2630, 2634, "iris" +497, 22, 6, 542, 28, 33, 2635, 2640, "color" +497, 22, 7, 543, 34, 37, 2641, 2644, "was" +497, 22, 8, 544, 38, 46, 2645, 2653, "observed" +497, 22, 9, 545, 47, 49, 2654, 2656, "in" +497, 22, 10, 546, 50, 54, 2657, 2661, "both" +497, 22, 11, 547, 55, 59, 2662, 2666, "eyes" +497, 22, 12, 548, 60, 62, 2667, 2669, "of" +497, 22, 13, 549, 63, 64, 2670, 2671, "1" +497, 22, 14, 550, 65, 67, 2672, 2674, "of" +497, 22, 15, 551, 68, 71, 2675, 2678, "the" +497, 22, 16, 552, 72, 74, 2679, 2681, "18" +497, 22, 17, 553, 75, 83, 2682, 2690, "patients" +497, 22, 18, 554, 84, 91, 2691, 2698, "treated" +497, 22, 19, 555, 92, 96, 2699, 2703, "with" +497, 22, 20, 556, 97, 108, 2704, 2715, "latanoprost" +497, 22, 21, 557, 109, 112, 2716, 2719, "and" +497, 22, 22, 558, 113, 117, 2720, 2724, "none" +497, 22, 23, 559, 118, 120, 2725, 2727, "of" +497, 22, 24, 560, 121, 124, 2728, 2731, "the" +497, 22, 25, 561, 125, 127, 2732, 2734, "18" +497, 22, 26, 562, 128, 136, 2735, 2743, "patients" +497, 22, 27, 563, 137, 140, 2744, 2747, "who" +497, 22, 28, 564, 141, 149, 2748, 2756, "received" +497, 22, 29, 565, 150, 157, 2757, 2764, "timolol" +497, 22, 30, 566, 158, 159, 2765, 2766, "." +497, 23, 1, 567, 0, 9, 2767, 2776, "Darkening" +497, 23, 2, 568, 10, 12, 2777, 2779, "of" +497, 23, 3, 569, 13, 16, 2780, 2783, "the" +497, 23, 4, 570, 17, 27, 2784, 2794, "peripheral" +497, 23, 5, 571, 28, 32, 2795, 2799, "iris" +497, 23, 6, 572, 33, 39, 2800, 2806, "stroma" +497, 23, 7, 573, 40, 43, 2807, 2810, "was" +497, 23, 8, 574, 44, 53, 2811, 2820, "suspected" +497, 23, 9, 575, 54, 56, 2821, 2823, "in" +497, 23, 10, 576, 57, 60, 2824, 2827, "two" +497, 23, 11, 577, 61, 69, 2828, 2836, "patients" +497, 23, 12, 578, 70, 77, 2837, 2844, "treated" +497, 23, 13, 579, 78, 82, 2845, 2849, "with" +497, 23, 14, 580, 83, 94, 2850, 2861, "latanoprost" +497, 23, 15, 581, 95, 96, 2862, 2863, "." +497, 24, 1, 582, 0, 2, 2864, 2866, "In" +497, 24, 2, 583, 3, 6, 2867, 2870, "the" +497, 24, 3, 584, 7, 14, 2871, 2878, "timolol" +497, 24, 4, 585, 15, 20, 2879, 2884, "group" +497, 24, 5, 586, 21, 22, 2885, 2886, "," +497, 24, 6, 587, 23, 28, 2887, 2892, "heart" +497, 24, 7, 588, 29, 33, 2893, 2897, "rate" +497, 24, 8, 589, 34, 37, 2898, 2901, "was" +497, 24, 9, 590, 38, 51, 2902, 2915, "significantly" +497, 24, 10, 591, 52, 59, 2916, 2923, "reduced" +497, 24, 11, 592, 60, 64, 2924, 2928, "from" +497, 24, 12, 593, 65, 67, 2929, 2931, "72" +497, 24, 13, 594, 68, 69, 2932, 2933, "+" +497, 24, 14, 595, 70, 71, 2934, 2935, "/" +497, 24, 15, 596, 72, 73, 2936, 2937, "-" +497, 24, 16, 597, 74, 75, 2938, 2939, "9" +497, 24, 17, 598, 76, 78, 2940, 2942, "at" +497, 24, 18, 599, 79, 87, 2943, 2951, "baseline" +497, 24, 19, 600, 88, 90, 2952, 2954, "to" +497, 24, 20, 601, 91, 93, 2955, 2957, "67" +497, 24, 21, 602, 94, 95, 2958, 2959, "+" +497, 24, 22, 603, 96, 97, 2960, 2961, "/" +497, 24, 23, 604, 98, 99, 2962, 2963, "-" +497, 24, 24, 605, 100, 102, 2964, 2966, "10" +497, 24, 25, 606, 103, 108, 2967, 2972, "beats" +497, 24, 26, 607, 109, 112, 2973, 2976, "per" +497, 24, 27, 608, 113, 119, 2977, 2983, "minute" +497, 24, 28, 609, 120, 122, 2984, 2986, "at" +497, 24, 29, 610, 123, 125, 2987, 2989, "12" +497, 24, 30, 611, 126, 132, 2990, 2996, "months" +497, 24, 31, 612, 133, 134, 2997, 2998, "." +497, 25, 1, 613, 0, 11, 2999, 3010, "CONCLUSIONS" +497, 25, 2, 614, 12, 13, 3011, 3012, ":" +497, 25, 3, 615, 14, 22, 3013, 3021, "Although" +497, 25, 4, 616, 23, 30, 3022, 3029, "further" +497, 25, 5, 617, 31, 38, 3030, 3037, "studies" +497, 25, 6, 618, 39, 42, 3038, 3041, "may" +497, 25, 7, 619, 43, 47, 3042, 3046, "need" +497, 25, 8, 620, 48, 50, 3047, 3049, "to" +497, 25, 9, 621, 51, 58, 3050, 3057, "confirm" +497, 25, 10, 622, 59, 64, 3058, 3063, "these" +497, 25, 11, 623, 65, 69, 3064, 3068, "data" +497, 25, 12, 624, 70, 72, 3069, 3071, "on" +497, 25, 13, 625, 73, 74, 3072, 3073, "a" +497, 25, 14, 626, 75, 81, 3074, 3080, "larger" +497, 25, 15, 627, 82, 88, 3081, 3087, "sample" +497, 25, 16, 628, 89, 92, 3088, 3091, "and" +497, 25, 17, 629, 93, 95, 3092, 3094, "to" +497, 25, 18, 630, 96, 104, 3095, 3103, "evaluate" +497, 25, 19, 631, 105, 108, 3104, 3107, "the" +497, 25, 20, 632, 109, 113, 3108, 3112, "side" +497, 25, 21, 633, 114, 120, 3113, 3119, "effect" +497, 25, 22, 634, 121, 123, 3120, 3122, "of" +497, 25, 23, 635, 124, 133, 3123, 3132, "increased" +497, 25, 24, 636, 134, 138, 3133, 3137, "iris" +497, 25, 25, 637, 139, 151, 3138, 3150, "pigmentation" +497, 25, 26, 638, 152, 154, 3151, 3153, "on" +497, 25, 27, 639, 155, 159, 3154, 3158, "long" +497, 25, 28, 640, 160, 161, 3159, 3160, "-" +497, 25, 29, 641, 162, 166, 3161, 3165, "term" +497, 25, 30, 642, 167, 173, 3166, 3172, "follow" +497, 25, 31, 643, 174, 175, 3173, 3174, "-" +497, 25, 32, 644, 176, 178, 3175, 3177, "up" +497, 25, 33, 645, 179, 180, 3178, 3179, "," +497, 25, 34, 646, 181, 183, 3180, 3182, "in" +497, 25, 35, 647, 184, 192, 3183, 3191, "patients" +497, 25, 36, 648, 193, 197, 3192, 3196, "with" +497, 25, 37, 649, 198, 208, 3197, 3207, "pigmentary" +497, 25, 38, 650, 209, 217, 3208, 3216, "glaucoma" +497, 25, 39, 651, 218, 219, 3217, 3218, "," +497, 25, 40, 652, 220, 221, 3219, 3220, "0" +497, 25, 41, 653, 222, 223, 3221, 3222, "." +497, 25, 42, 654, 224, 227, 3223, 3226, "005" +497, 25, 43, 655, 228, 229, 3227, 3228, "%" +497, 25, 44, 656, 230, 241, 3229, 3240, "latanoprost" +497, 25, 45, 657, 242, 247, 3241, 3246, "taken" +497, 25, 46, 658, 248, 252, 3247, 3251, "once" +497, 25, 47, 659, 253, 258, 3252, 3257, "daily" +497, 25, 48, 660, 259, 262, 3258, 3261, "was" +497, 25, 49, 661, 263, 267, 3262, 3266, "well" +497, 25, 50, 662, 268, 277, 3267, 3276, "tolerated" +497, 25, 51, 663, 278, 281, 3277, 3280, "and" +497, 25, 52, 664, 282, 286, 3281, 3285, "more" +497, 25, 53, 665, 287, 296, 3286, 3295, "effective" +497, 25, 54, 666, 297, 299, 3296, 3298, "in" +497, 25, 55, 667, 300, 308, 3299, 3307, "reducing" +497, 25, 56, 668, 309, 312, 3308, 3311, "IOP" +497, 25, 57, 669, 313, 317, 3312, 3316, "than" +497, 25, 58, 670, 318, 319, 3317, 3318, "0" +497, 25, 59, 671, 320, 321, 3319, 3320, "." +497, 25, 60, 672, 322, 323, 3321, 3322, "5" +497, 25, 61, 673, 324, 325, 3323, 3324, "%" +497, 25, 62, 674, 326, 333, 3325, 3332, "timolol" +497, 25, 63, 675, 334, 339, 3333, 3338, "taken" +497, 25, 64, 676, 340, 345, 3339, 3344, "twice" +497, 25, 65, 677, 346, 351, 3345, 3350, "daily" +497, 25, 66, 678, 352, 353, 3351, 3352, "." +497, 26, 1, 679, 0, 3, 3353, 3356, "DOI" +497, 26, 2, 680, 4, 5, 3357, 3358, ":" +497, 26, 3, 681, 6, 8, 3359, 3361, "10" +497, 26, 4, 682, 9, 10, 3362, 3363, "." +497, 26, 5, 683, 11, 15, 3364, 3368, "1016" +497, 26, 6, 684, 16, 17, 3369, 3370, "/" +497, 26, 7, 685, 18, 23, 3371, 3376, "S0161" +497, 26, 8, 686, 24, 25, 3377, 3378, "-" +497, 26, 9, 687, 26, 30, 3379, 3383, "6420" +497, 26, 10, 688, 31, 32, 3384, 3385, "(" +497, 26, 11, 689, 33, 35, 3386, 3388, "99" +497, 26, 12, 690, 36, 37, 3389, 3390, ")" +497, 26, 13, 691, 38, 43, 3391, 3396, "90115" +497, 26, 14, 692, 44, 45, 3397, 3398, "-" +497, 26, 15, 693, 46, 47, 3399, 3400, "X" +497, 26, 16, 694, 48, 52, 3401, 3405, "PMID" +497, 26, 17, 695, 53, 54, 3406, 3407, ":" +497, 26, 18, 696, 55, 63, 3408, 3416, "10080213" +497, 26, 19, 697, 64, 65, 3417, 3418, "[" +497, 26, 20, 698, 66, 73, 3419, 3426, "Indexed" +497, 26, 21, 699, 74, 77, 3427, 3430, "for" +497, 26, 22, 700, 78, 85, 3431, 3438, "MEDLINE" +497, 26, 23, 701, 86, 87, 3439, 3440, "]" diff --git a/data/gl 10080213_jshahinitiran.annodb b/data/gl 10080213_jshahinitiran.annodb new file mode 100644 index 0000000000000000000000000000000000000000..7b14e66cfe4772b776fe82fde3a8c9da125b5246 GIT binary patch literal 13115 zcmd^GYmeK;747Hzih+UvEg;*Pp&n$B8d&c-$rg4kINJgR0vNPJNlYkGAt|qwU*B^s zUqg}HU3a%Zi++%trH1$3xsP)nGx=Iw#Bq}Qd6>l4S7UV<`B`>zIs{{Nm8>pze)=xX zg8YwRyo&zRJlkyeF!(GFZ-USHSiKE$f2^+KEcfG8kbR{mb2Csk0=6ITBQCN_$lO=kClNuBkg(K<3%{5PfEa?(27zTNG$!t^*BT9aHgzv6|_z zn&UHSG&sD$%P5TDMbS+f`VswTI^;)}H|vsx*srz@gy?a+>o^b6PtY`?24uA!B3sG* z?+`VU0iPcvDjq)@tM|1(L08kUTHrHkoa|}zbrodcHtrL#VgIrSLd4sZc=apTV-0y= zQ4ioSI`j4av|yGHrDPD~O%qQD&k18xz`=^MVY#fA=?7-f=;QYG_W7;zJW01N2nR1F z=7llO()H$9c0!1Leimn6=K$K~jRyTJvM>Am?`^Pdz)_od9}R%xReId^{bZ3Zr7r9Q zXu2uDgi3(bv_r@)0cKbWZE+l@kLMlYlsst?ggY&;ta0r762>SCjHPFgYSaUB!@@lf z1AJtuQx;@D1b&q7E|Yj2GP?V=(v`08rUi1!#WCL{%rP@M(t_%H>t{%72S5Au=&Luw zf?9cmP&JtH3Km3^HsvzqEdY+S6fUAndz9kRPY+=nL(|Ny@q+Q28!U!Da(gS)CNphswgWJOPDF9+WHaw@PB=|9T9PW2Sb;eUhs6Dfai_ zDpScuP1JKWnatETtxCl|9HJ1_Or9K=kfRfbtOB+6L;R*8iMK`k-UR6x79 zp~(#Vs@5l#893X_p|e?FG_107n+=xnH4oa%B3-GDiK8m@DFH>EQgJl~+I~ho_f$VausL6%sXP=Z121{7)LblOJs;lp!}0X;X1I5-SQR1XV%tqaL5bkI zbB(WVM}vmn6;EdeUG^GtnsZL&4RjlP3Do{}+he;2Y>4cvCzsHrC8iDepp8SD)^Xioiv0K z=?D+SQ)?-9XHnJ@2RqdhfvYARaXnteKco&%tN~e1XdFZ$ONuTeGu$n6VjThl-&Cia z!34e;Ggh&HWwK2gz%nRAwC#gc;8E=Pi!C&qpuW^XY*Si#^dPl{SX4_>3fGE9fIu^$ z%ve8Mzgu$g44$gB%zQ$03VyOeTal_m8f4iq4a#?WX0ET}^&!D4jN*mv^Ctuz79~rr zvYLv%rIt_v zbIE9_zAYzJde}L!FC3u-Ft(l!xlD%oB$xxKAN&OR6IYHvN5Ld z?Jt#CDp8J2igLx961Kc4VW{m{L=RbGCN!CuIA`9c9gZ;G2kRrIoE&Xp34G2>rd&AZ z9Fn$$L(TbbH(yv*7__hDLbR+Oynp5(Zx*U+!5^0XLWEU=&Pkb_CE%FPbs*xzCfG%ooO)e&h$rhu>Zxm ztwYT1Zc79Jf*Kq#LktHmh)+LGj4mIlPl#8}1fI4oG&?Yyq)>?3h!Em_XBx(e9%Yo) zbJ)Ijg`@<;0DL3NMP32#N6OJzzKL(*Irm22AQaVPDIZnUQ#D$UHt2;NIs(ZC`>B8726=tQXdWkaCXRPw=^%X6 zz;#eq02U1dYllp@? zuvdPD(M%jX@bo}C5VD<4rX0bVDJ|UZCL9@b3N60EOlYPuyIQKh6ji8RP_^65CrOGC)uK@mJ{(f6qqB9jc1IsO@l_qV1qV;^M{6$C#(qe)I!w$G}fQTq}eM zSlP{}^wG*%qjuGz(l>ilV|&D)#19>d^a@zY57$JTAEO+`;J9O5h5Sq+ZpIjp`Bfdo zFgDPp?O8L)FEa_CUI1cH4)Ea=6*tX?yB_+6WOR?90G;KrPrAmw|M(dL2g(uueO7r)Aj;Wb(Ij}JK)K0BXH0SG(n@p%M>+;%M?|lpV}=g$GTC!NiP^FohdNr$Yc6mf zEIDp>YI96+2_}^rxnYpug6>Jhfm~`q1jL&#-SZwz#%nFPFSlfH2PWO}6@P!grC!de zac?C6xE*0NxpiY*wBhv`T(nMs9-u0bRUPj!21zkWa0U38!dP^#Hc5oRG5$IpFbC)L zU*Eb9Q+jg`9)7_|?YU}Lxc!gnLuz@(E1ao|ZfH3Wl#ZawsH6D?85qql zxa;5_Eb68_mPGd6917$(%&Pr|pgikbzUBYE;^4f8-x7v6+IA-x77QcdL$BPDxb& . + "Publication" . + "A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma ." . + "Mastropasqua L" . + "1999" . + "Ophthalmology" . + "10080213" . + . + "Carpineto P" . + "Ciancaglini M" . + "Gallenga PE" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma ." . + "Thirty - six" . + "12 - month" . + . + . + . + "Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long - term follow - up , in patients with" . + . + . + . + . + . + . + . + "pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily ." . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_IOP" . + . + . + . + . + . + . + "Endpoint_C" . + . + . + . + . + . + . + . + "Endpoint_H" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_Lat" . + "18" . + . + . + . + . + "Arm_Tim" . + "18" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_Lat" . + . + "once daily" . + "12 - month" . + . + . + "Intervention_Tim" . + . + "twice daily" . + "12 - month" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_lat_IOP_6" . + . + "6 . 0" . + "P < 0 . 001" . + "4 . 5" . + "6" . + . + "Outcome_lat_IOP_12" . + . + "5 . 9" . + "P < 0 . 001" . + "4 . 6" . + "12 months" . + . + "Outcome_tim_IOP_6" . + . + "4 . 8" . + "P < 0 . 001" . + "3 . 0" . + "6" . + . + "Outcome_tim_IOP_12" . + . + "4 . 6" . + "P < 0 . 001" . + "3 . 1" . + "12 months" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10080213_tstrakeljahn.annodb b/data/gl 10080213_tstrakeljahn.annodb new file mode 100644 index 0000000..63d2ad5 --- /dev/null +++ b/data/gl 10080213_tstrakeljahn.annodb @@ -0,0 +1,137 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +1650, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1663, PublicationYear, 16, 20, "1999", "", " \"1999\"." +1670, Title, 49, 158, "A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma .", "", " \"A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma .\"." +1665, Duration, 51, 61, "12 - month", "", " \"12 - month\"." +1652, Randomized, 64, 74, "randomized", "", " ." +1653, DoubleBlind, 77, 92, "double - masked", "", " ." +1666, Latanoprost, 109, 120, "latanoprost", "", +1667, Timolol, 126, 133, "timolol", "", +1668, PigmentaryGlaucoma, 137, 156, "pigmentary glaucoma", "", " ." +1658, Author, 159, 173, "Mastropasqua L", "", " \"Mastropasqua L\"." +1660, Author, 182, 191, "Carpineto", "", " \"Carpineto\"." +1656, Author, 196, 209, "Ciancaglini M", "", " \"Ciancaglini M\"." +1657, Author, 212, 223, "Gallenga PE", "", " \"Gallenga PE\"." +1664, Country, 338, 343, "Italy", "", +1669, ObjectiveDescription, 358, 585, "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma .", "", " \"To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma .\"." +1799, DoseValue, 443, 450, "0 . 005", "", +1800, Percentage, 451, 452, "%", "", +1790, Latanoprost, 453, 464, "latanoprost", "", +1792, Frequency, 483, 487, "once", "", +1791, Interval, 488, 493, "daily", "", +1802, DoseValue, 499, 504, "0 . 5", "", +1801, Percentage, 505, 506, "%", "", +1793, Timolol, 507, 514, "timolol", "", +1794, Frequency, 521, 526, "twice", "", +1795, Interval, 527, 532, "daily", "", +1796, Duration, 537, 546, "12 months", "", " \"12 months\". \"12 months\"." +1798, Precondition, 550, 583, "patients with pigmentary glaucoma", "", +1797, PigmentaryGlaucoma, 564, 583, "pigmentary glaucoma", "", +1671, Randomized, 609, 619, "randomized", "", +1672, DoubleBlind, 622, 637, "double - masked", "", +1701, ClinicalTrial, 640, 654, "clinical study", "", +1821, NumberPatientsCT, 672, 684, "Thirty - six", "", " \"Thirty - six\"." +1675, Precondition, 694, 798, "affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication", "", " \"affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication\"." +1674, PigmentaryGlaucoma, 718, 737, "pigmentary glaucoma", "", +1702, Randomized, 869, 877, "randomly", "", +1682, NumberPatientsArm, 935, 937, "18", "", " \"18\". \"18\"." +1687, DoseValue, 966, 973, "0 . 005", "", " \"0 . 005\"." +1690, Percentage, 974, 975, "%", "", " ." +1685, Latanoprost, 976, 987, "latanoprost", "", " . ." +1707, Eyedrops, 988, 996, "eyedrops", "", " ." +1695, Frequency, 997, 1001, "once", "", " \"once\"." +1692, Interval, 1002, 1007, "daily", "", " \"daily\"." +1676, Placebo, 1016, 1023, "vehicle", "", +1681, Placebo, 1026, 1033, "placebo", "", +1705, Frequency, 1036, 1040, "once", "", +1706, Interval, 1041, 1046, "daily", "", +1686, Timolol, 1073, 1080, "timolol", "", " ." +1688, DoseValue, 1081, 1086, "0 . 5", "", " \"0 . 5\"." +1691, Percentage, 1087, 1088, "%", "", " ." +1708, Eyedrops, 1089, 1097, "eyedrops", "", " ." +1694, Frequency, 1098, 1103, "twice", "", " \"twice\"." +1693, Interval, 1104, 1109, "daily", "", " \"daily\"." +1696, Diurnal_IOP, 1136, 1174, "Diurnal curves of intraocular pressure", "", " ." +1699, IOP, 1177, 1180, "IOP", "", +1710, Interval, 1198, 1257, "on the baseline day and after 0 . 5 , 3 , 6 , and 12 months", "", +1709, IOP, 1277, 1280, "IOP", "", +1711, Frequency, 1312, 1364, "8 : 00 AM , 12 : 00 noon , 4 : 00 PM , and 8 : 00 PM", "", +1766, EndPointDescription, 1367, 1383, "Outflow facility", "", " . ." +1767, EndPointDescription, 1388, 1389, "C", "", +1728, TimePoint, 1414, 1426, "baseline day", "", +1722, TimePoint, 1434, 1459, "the last day of the study", "", +1700, MeasurementDevice, 1467, 1495, "Schiotz electronic tonometer", "", " . ." +1730, CTAnalysisApproach, 1498, 1695, "A two - tailed Student ' s t test for paired or unpaired data was used for statistical evaluation of differences between treatment and baseline values or between the latanoprost and timolol group .", "", +1741, Latanoprost, 1664, 1675, "latanoprost", "", +1742, Timolol, 1680, 1687, "timolol", "", +1723, Diurnal_IOP, 1696, 1707, "Diurnal IOP", "", +1727, CTAnalysisApproach, 1696, 1749, "Diurnal IOP measurements were compared hour by hour .", "", " . ." +1835, Mean, 1750, 1754, "Mean", "", " . ." +1724, CTAnalysisApproach, 1750, 1814, "Mean values of the two eyes IOP and C were used for analysis", "", " . ." +1726, IOP, 1778, 1781, "IOP", "", +1808, EndPointDescription, 1788, 1789, "C", "", +1743, Latanoprost, 1870, 1881, "latanoprost", "", +1745, Timolol, 1886, 1893, "timolol", "", +1747, PValueBL, 1917, 1928, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\". \"P < 0 . 001\". \"P < 0 . 001\"." +1746, IOP, 1944, 1947, "IOP", "", +1750, IOP, 2028, 2031, "IOP", "", +1751, Reduction, 2036, 2041, "6 . 0", "", " \"6 . 0\"." +1838, SdErrorChangeValue, 2042, 2053, "+ / - 4 . 5", "", " \"+ / - 4 . 5\"." +1752, Reduction, 2058, 2063, "5 . 9", "", " \"5 . 9\"." +1839, SdErrorChangeValue, 2064, 2075, "+ / - 4 . 6", "", " \"+ / - 4 . 6\"." +1753, Latanoprost, 2081, 2092, "latanoprost", "", +1754, Reduction, 2097, 2102, "4 . 8", "", " \"4 . 8\"." +1840, SdErrorChangeValue, 2103, 2114, "+ / - 3 . 0", "", " \"+ / - 3 . 0\"." +1755, Reduction, 2119, 2124, "4 . 6", "", " \"4 . 6\"." +1841, SdErrorChangeValue, 2125, 2136, "+ / - 3 . 1", "", " \"+ / - 3 . 1\"." +1756, Timolol, 2142, 2149, "timolol", "", +1758, TimePoint, 2156, 2157, "6", "", +1757, TimePoint, 2162, 2171, "12 months", "", +1758, TimePoint, 2165, 2171, "months", "", +1761, Latanoprost, 2234, 2245, "latanoprost", "", +1762, Timolol, 2250, 2257, "timolol", "", +1760, PvalueDiff, 2293, 2304, "P < 0 . 001", "", " \"P < 0 . 001\"." +1763, TimePoint, 2321, 2322, "3", "", +1764, TimePoint, 2325, 2326, "6", "", +1765, TimePoint, 2333, 2335, "12", "", +1833, Mean, 2345, 2349, "Mean", "", " . ." +1768, EndPointDescription, 2352, 2353, "C", "", +1809, RelativeIncrement, 2399, 2401, "30", "", " \"30\"." +1770, Latanoprost, 2418, 2429, "latanoprost", "", +1769, PValueBL, 2475, 2486, "P = 0 . 017", "", " \"P = 0 . 017\"." +1834, Mean, 2491, 2495, "Mean", "", +1771, ConjunctivalHyperemia, 2496, 2518, "conjunctival hyperemia", "", +1810, PercentageAffected, 2533, 2538, "0 . 3", "", " \"0 . 3\"." +1772, Latanoprost, 2542, 2553, "latanoprost", "", +1811, PercentageAffected, 2573, 2578, "0 . 2", "", " \"0 . 2\"." +1773, Timolol, 2582, 2589, "timolol", "", +1836, ObservedResult, 2620, 2640, "change in iris color", "", " \"change in iris color\"." +1774, IrisPigmentation, 2620, 2640, "change in iris color", "", +1812, NumberAffected, 2670, 2671, "1", "", " \"1\"." +1778, FinalNumPatientsArm, 2679, 2681, "18", "", " \"18\"." +1776, Latanoprost, 2704, 2715, "latanoprost", "", +1779, FinalNumPatientsArm, 2732, 2734, "18", "", " \"18\"." +1777, Timolol, 2757, 2764, "timolol", "", +1780, IrisPigmentation, 2767, 2806, "Darkening of the peripheral iris stroma", "", +1781, Latanoprost, 2850, 2861, "latanoprost", "", +1782, Timolol, 2871, 2878, "timolol", "", +1783, HeartRate, 2887, 2897, "heart rate", "", +1785, BaseLineValue, 2929, 2931, "72", "", " \"72\"." +1813, SdErrorBL, 2932, 2939, "+ / - 9", "", " \"+ / - 9\"." +1837, SdErrorResValue, 2958, 2966, "+ / - 10", "", " \"+ / - 10\"." +1788, PulseRate, 2967, 2983, "beats per minute", "", +1786, TimePoint, 2987, 2989, "12", "", " \"12\"." +1820, ConclusionComment, 3013, 3103, "Although further studies may need to confirm these data on a larger sample and to evaluate", "", " \"Although further studies may need to confirm these data on a larger sample and to evaluate\"." +1818, ConclusionComment, 3104, 3352, "the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .", "", " \"the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .\"." +1815, PigmentaryGlaucoma, 3197, 3216, "pigmentary glaucoma", "", +1734, DoseValue, 3219, 3226, "0 . 005", "", +1733, Percentage, 3227, 3228, "%", "", +1732, Latanoprost, 3229, 3240, "latanoprost", "", +3000, Frequency, 3247, 3257, "once daily", "", +1737, IOP, 3308, 3311, "IOP", "", +1739, DoseValue, 3317, 3322, "0 . 5", "", +1740, Percentage, 3323, 3324, "%", "", +1738, Timolol, 3325, 3332, "timolol", "", +1816, Frequency, 3339, 3344, "twice", "", +1817, Interval, 3345, 3350, "daily", "", +1684, PMID, 3408, 3416, "10080213", "", " \"10080213\"." diff --git a/data/gl 10080213_tstrakeljahn.n-triples b/data/gl 10080213_tstrakeljahn.n-triples new file mode 100644 index 0000000..1461a8c --- /dev/null +++ b/data/gl 10080213_tstrakeljahn.n-triples @@ -0,0 +1,165 @@ +# RDF export of group: Publication + . + "Publication 3702" . + "A 12 - month , randomized , double - masked study comparing latanoprost with timolol in pigmentary glaucoma ." . + "Mastropasqua L" . + "1999" . + "Ophthalmology" . + "10080213" . + . + "Carpineto" . + "Ciancaglini M" . + "Gallenga PE" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 3712" . + "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0 . 005 % latanoprost applied topically once daily with 0 . 5 % timolol given twice daily for 12 months to patients with pigmentary glaucoma ." . + "12 - month" . + . + . + . + "Although further studies may need to confirm these data on a larger sample and to evaluate" . + . + . + . + . + . + "Thirty - six" . + . + . + . + . + . + "the side effect of increased iris pigmentation on long - term follow - up , in patients with pigmentary glaucoma , 0 . 005 % latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily ." . + . + . +# RDF export of group: Population + . + "Population 3743" . + "affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint C" . + . + . + . + . + . + . + . + . + "Endpoint IOP" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 1" . + "18" . + "18" . + . + . + . + . + . + . + . + "Arm 2" . + "18" . + "18" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 1" . + . + "once" . + "daily" . + "12 months" . + . + . + "Intervention 2" . + . + "twice" . + "daily" . + "12 months" . + . +# RDF export of group: Medication + . + "Medication Latanoprost" . + . + . + "0 . 005" . + . + . + . + "Medication Timolol" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + . + . + "Outcome lat 6 month" . + . + "P < 0 . 001" . + "6 . 0" . + "+ / - 4 . 5" . + . + "Outcome lat 12 month" . + . + "P < 0 . 001" . + "5 . 9" . + "+ / - 4 . 6" . + . + "Outcome tim 6 month" . + . + "P < 0 . 001" . + "4 . 8" . + "+ / - 3 . 0" . + . + "Outcome tim 12 month" . + "P < 0 . 001" . + "4 . 6" . + "+ / - 3 . 1" . + . + "Outcome lat C" . + . + "P = 0 . 017" . + "30" . + . + "Outcome lat CH" . + "0 . 3" . + . + "Outcome tim CH" . + "0 . 2" . + . + "Outcome lat pigment" . + "1" . + "change in iris color" . + . + "Outcome tim Heart Rate" . + "72" . + "+ / - 9" . + "+ / - 10" . + "12" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 3752" . + "P < 0 . 001" . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10664047_admin.annodb b/data/gl 10664047_admin.annodb new file mode 100644 index 0000000..b9483da --- /dev/null +++ b/data/gl 10664047_admin.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 34, "Graefes Arch Clin Exp Ophthalmol .", "", " \"Graefes Arch Clin Exp Ophthalmol .\"." +1, PublicationYear, 35, 39, "2000", "", " \"2000\"." +2, Title, 68, 225, "Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension . A 3 - month randomised study .", "", " \"Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension . A 3 - month randomised study .\"." +3, Latanoprost, 82, 93, "latanoprost", "", +4, Dorzolamide, 109, 120, "dorzolamide", "", +5, Timolol, 135, 142, "timolol", "", +6, Glaucoma, 160, 168, "glaucoma", "", " . ." +7, OcularHypertension, 173, 192, "ocular hypertension", "", " ." +8, Duration, 197, 206, "3 - month", "", " \"3 - month\"." +9, Randomized, 207, 217, "randomised", "", +10, Author, 226, 237, "Emmerich KH", "", " \"Emmerich KH\"." +11, Germany, 340, 347, "Germany", "", " ." +12, ObjectiveDescription, 363, 593, "The purpose of the study was to compare the effects on intraocular pressure ( IOP ) of adding dorzolamide to timolol or of switching from timolol to latanoprost monotherapy in glaucoma patients inadequately controlled on timolol .", "", " \"The purpose of the study was to compare the effects on intraocular pressure ( IOP ) of adding dorzolamide to timolol or of switching from timolol to latanoprost monotherapy in glaucoma patients inadequately controlled on timolol .\"." +13, IOP, 418, 438, "intraocular pressure", "", +14, IOP, 441, 444, "IOP", "", +15, Dorzolamide, 457, 468, "dorzolamide", "", +16, Timolol, 472, 479, "timolol", "", +17, Timolol, 501, 508, "timolol", "", +18, Latanoprost, 512, 523, "latanoprost", "", +19, Glaucoma, 539, 547, "glaucoma", "", +21, Precondition, 539, 591, "glaucoma patients inadequately controlled on timolol", "", " \"glaucoma patients inadequately controlled on timolol\"." +20, Timolol, 584, 591, "timolol", "", +22, Duration, 632, 641, "3 - month", "", +23, Randomized, 642, 652, "randomised", "", " ." +24, OpenLabel, 655, 667, "open - label", "", " ." +25, Multicenter, 670, 681, "multicentre", "", " ." +26, NumberPatientsCT, 699, 702, "183", "", " \"183\"." +112, Precondition, 703, 746, "patients with primary open - angle glaucoma", "", " \"patients with primary open - angle glaucoma\"." +27, Primary_OpenAngleGlaucoma, 717, 746, "primary open - angle glaucoma", "", +111, Precondition, 749, 843, "capsular glaucoma with IOP above 22 mmHg on treatment with one or two ocular hypotensive drugs", "", " \"capsular glaucoma with IOP above 22 mmHg on treatment with one or two ocular hypotensive drugs\"." +28, Glaucoma, 749, 766, "capsular glaucoma", "", +29, IOP, 772, 775, "IOP", "", +30, mmHg, 785, 789, "mmHg", "", +110, Precondition, 849, 891, "ocular hypertension with IOP above 27 mmHg", "", " \"ocular hypertension with IOP above 27 mmHg\"." +34, OcularHypertension, 849, 868, "ocular hypertension", "", +32, IOP, 874, 877, "IOP", "", +33, mmHg, 887, 891, "mmHg", "", +36, Timolol, 937, 944, "timolol", "", +37, DoseValue, 947, 952, "0 . 5", "", +124, Percentage, 953, 954, "%", "", +42, Frequency, 955, 966, "twice daily", "", +43, Randomized, 987, 997, "randomised", "", +44, Latanoprost, 1023, 1034, "latanoprost", "", " . ." +39, DoseValue, 1037, 1040, "0 .", "", " \"0 .\". \"005\"." +39, DoseValue, 1041, 1044, "005", "", " \"005\"." +125, Percentage, 1045, 1046, "%", "", " ." +45, Frequency, 1047, 1057, "once daily", "", " \"once daily\"." +46, Timolol, 1082, 1089, "timolol", "", " ." +38, DoseValue, 1092, 1097, "0 . 5", "", " \"0 . 5\"." +126, Percentage, 1098, 1099, "%", "", " ." +47, Frequency, 1100, 1111, "twice daily", "", " \"twice daily\"." +48, Dorzolamide, 1118, 1129, "dorzolamide", "", " ." +41, DoseValue, 1132, 1133, "2", "", " \"2\"." +127, Percentage, 1134, 1135, "%", "", " ." +49, Frequency, 1136, 1147, "twice daily", "", " \"twice daily\"." +50, Mean, 1154, 1158, "mean", "", +51, Diurnal_IOP, 1159, 1170, "diurnal IOP", "", +52, Duration, 1177, 1185, "3 months", "", +53, Timolol, 1253, 1260, "timolol", "", +54, Latanoprost, 1264, 1275, "latanoprost", "", +55, Mean, 1284, 1288, "mean", "", " . ." +56, Diurnal_IOP, 1289, 1300, "diurnal IOP", "", " ." +57, Reduction, 1304, 1309, "4 . 5", "", " \"4 . 5\"." +58, SdErrorChangeValue, 1316, 1321, "0 . 2", "", " \"0 . 2\"." +59, mmHg, 1322, 1326, "mmHg", "", " ." +60, Dorzolamide, 1375, 1386, "dorzolamide", "", +61, Timolol, 1390, 1397, "timolol", "", +62, Mean, 1406, 1410, "mean", "", +63, Diurnal_IOP, 1411, 1418, "diurnal", "", +64, Reduction, 1422, 1427, "4 . 4", "", " \"4 . 4\"." +65, SdErrorChangeValue, 1434, 1439, "0 . 2", "", " \"0 . 2\"." +66, mmHg, 1440, 1444, "mmHg", "", +146, ObservedResult, 1482, 1543, "No serious side effects were observed with either treatment .", "", " \"No serious side effects were observed with either treatment .\". \"No serious side effects were observed with either treatment .\"." +92903, EndPointDescription, 1493, 1505, "side effects", "", " . ." +67, ConclusionComment, 1557, 1728, "Latanoprost monotherapy can be an alternative to combined treatment with two aqueous flow suppressors in patients whose IOP is insufficiently controlled by timolol alone .", "", " \"Latanoprost monotherapy can be an alternative to combined treatment with two aqueous flow suppressors in patients whose IOP is insufficiently controlled by timolol alone .\"." +68, Latanoprost, 1557, 1568, "Latanoprost", "", +69, IOP, 1677, 1680, "IOP", "", +70, Timolol, 1713, 1720, "timolol", "", +71, PMID, 1768, 1776, "10664047", "", " \"10664047\"." diff --git a/data/gl 10664047_admin.n-triples b/data/gl 10664047_admin.n-triples new file mode 100644 index 0000000..d43e67a --- /dev/null +++ b/data/gl 10664047_admin.n-triples @@ -0,0 +1,121 @@ +# RDF export of group: Publication + . + "Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension . A 3 - month randomised study ." . + "Emmerich KH" . + "2000" . + "Graefes Arch Clin Exp Ophthalmol ." . + "10664047" . + . +# RDF export of group: ClinicalTrial + . + "The purpose of the study was to compare the effects on intraocular pressure ( IOP ) of adding dorzolamide to timolol or of switching from timolol to latanoprost monotherapy in glaucoma patients inadequately controlled on timolol ." . + "183" . + "3 - month" . + . + . + "Latanoprost monotherapy can be an alternative to combined treatment with two aqueous flow suppressors in patients whose IOP is insufficiently controlled by timolol alone ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "glaucoma patients inadequately controlled on timolol" . + . + . + "patients with primary open - angle glaucoma" . + "capsular glaucoma with IOP above 22 mmHg on treatment with one or two ocular hypotensive drugs" . + "ocular hypertension with IOP above 27 mmHg" . + . +# RDF export of group: Endpoint + . + "Endpoint_IOP" . + . + . + . + . + . + . + "Endpoint_SideEffects" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + "Arm_TimDor" . + . + . + . + . +# RDF export of group: Intervention + . + "Interv_lat" . + . + "once daily" . + . + . + "Intervention_tim" . + . + "twice daily" . + . + . + "Intervention_Dor" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_Lat" . + . + . + "0 ." . + "005" . + . + . + . + "Medication_Tim" . + . + "0 . 5" . + . + . + . + "Medication_Dor" . + . + "2" . + . + . +# RDF export of group: Outcome + . + "Outcome_lat_IOP" . + . + "4 . 5" . + "0 . 2" . + . + "Outcome_TimDor_IOP" . + . + "4 . 4" . + "0 . 2" . + . + "Outcome_LAt_SE" . + . + "No serious side effects were observed with either treatment ." . + . + "Outcome_TimDor_SE" . + . + "No serious side effects were observed with either treatment ." . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10664047_export.csv b/data/gl 10664047_export.csv new file mode 100644 index 0000000..9680f6b --- /dev/null +++ b/data/gl 10664047_export.csv @@ -0,0 +1,356 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +558, 1, 1, 1, 0, 7, 0, 7, "Graefes" +558, 1, 2, 2, 8, 12, 8, 12, "Arch" +558, 1, 3, 3, 13, 17, 13, 17, "Clin" +558, 1, 4, 4, 18, 21, 18, 21, "Exp" +558, 1, 5, 5, 22, 32, 22, 32, "Ophthalmol" +558, 1, 6, 6, 33, 34, 33, 34, "." +558, 2, 1, 7, 0, 4, 35, 39, "2000" +558, 2, 2, 8, 5, 8, 40, 43, "Jan" +558, 2, 3, 9, 9, 10, 44, 45, ";" +558, 2, 4, 10, 11, 14, 46, 49, "238" +558, 2, 5, 11, 15, 16, 50, 51, "(" +558, 2, 6, 12, 17, 18, 52, 53, "1" +558, 2, 7, 13, 19, 20, 54, 55, ")" +558, 2, 8, 14, 21, 22, 56, 57, ":" +558, 2, 9, 15, 23, 25, 58, 60, "19" +558, 2, 10, 16, 26, 27, 61, 62, "-" +558, 2, 11, 17, 28, 30, 63, 65, "23" +558, 2, 12, 18, 31, 32, 66, 67, "." +558, 3, 1, 19, 0, 10, 68, 78, "Comparison" +558, 3, 2, 20, 11, 13, 79, 81, "of" +558, 3, 3, 21, 14, 25, 82, 93, "latanoprost" +558, 3, 4, 22, 26, 37, 94, 105, "monotherapy" +558, 3, 5, 23, 38, 40, 106, 108, "to" +558, 3, 6, 24, 41, 52, 109, 120, "dorzolamide" +558, 3, 7, 25, 53, 61, 121, 129, "combined" +558, 3, 8, 26, 62, 66, 130, 134, "with" +558, 3, 9, 27, 67, 74, 135, 142, "timolol" +558, 3, 10, 28, 75, 77, 143, 145, "in" +558, 3, 11, 29, 78, 86, 146, 154, "patients" +558, 3, 12, 30, 87, 91, 155, 159, "with" +558, 3, 13, 31, 92, 100, 160, 168, "glaucoma" +558, 3, 14, 32, 101, 104, 169, 172, "and" +558, 3, 15, 33, 105, 111, 173, 179, "ocular" +558, 3, 16, 34, 112, 124, 180, 192, "hypertension" +558, 3, 17, 35, 125, 126, 193, 194, "." +558, 3, 18, 36, 127, 128, 195, 196, "A" +558, 3, 19, 37, 129, 130, 197, 198, "3" +558, 3, 20, 38, 131, 132, 199, 200, "-" +558, 3, 21, 39, 133, 138, 201, 206, "month" +558, 3, 22, 40, 139, 149, 207, 217, "randomised" +558, 3, 23, 41, 150, 155, 218, 223, "study" +558, 3, 24, 42, 156, 157, 224, 225, "." +558, 4, 1, 43, 0, 8, 226, 234, "Emmerich" +558, 4, 2, 44, 9, 11, 235, 237, "KH" +558, 4, 3, 45, 12, 13, 238, 239, "(" +558, 4, 4, 46, 14, 15, 240, 241, "1" +558, 4, 5, 47, 16, 17, 242, 243, ")" +558, 4, 6, 48, 18, 19, 244, 245, "." +558, 5, 1, 49, 0, 6, 246, 252, "Author" +558, 5, 2, 50, 7, 18, 253, 264, "information" +558, 5, 3, 51, 19, 20, 265, 266, ":" +558, 5, 4, 52, 21, 22, 267, 268, "(" +558, 5, 5, 53, 23, 24, 269, 270, "1" +558, 5, 6, 54, 25, 26, 271, 272, ")" +558, 5, 7, 55, 27, 30, 273, 276, "Eye" +558, 5, 8, 56, 31, 37, 277, 283, "Clinic" +558, 5, 9, 57, 38, 39, 284, 285, "," +558, 5, 10, 58, 40, 49, 286, 295, "Darmstadt" +558, 5, 11, 59, 50, 59, 296, 305, "Municipal" +558, 5, 12, 60, 60, 69, 306, 315, "Hospitals" +558, 5, 13, 61, 70, 71, 316, 317, "," +558, 5, 14, 62, 72, 73, 318, 319, "D" +558, 5, 15, 63, 74, 75, 320, 321, "-" +558, 5, 16, 64, 76, 81, 322, 327, "64297" +558, 5, 17, 65, 82, 91, 328, 337, "Darmstadt" +558, 5, 18, 66, 92, 93, 338, 339, "," +558, 5, 19, 67, 94, 101, 340, 347, "Germany" +558, 5, 20, 68, 102, 103, 348, 349, "." +558, 6, 1, 69, 0, 10, 350, 360, "BACKGROUND" +558, 6, 2, 70, 11, 12, 361, 362, ":" +558, 6, 3, 71, 13, 16, 363, 366, "The" +558, 6, 4, 72, 17, 24, 367, 374, "purpose" +558, 6, 5, 73, 25, 27, 375, 377, "of" +558, 6, 6, 74, 28, 31, 378, 381, "the" +558, 6, 7, 75, 32, 37, 382, 387, "study" +558, 6, 8, 76, 38, 41, 388, 391, "was" +558, 6, 9, 77, 42, 44, 392, 394, "to" +558, 6, 10, 78, 45, 52, 395, 402, "compare" +558, 6, 11, 79, 53, 56, 403, 406, "the" +558, 6, 12, 80, 57, 64, 407, 414, "effects" +558, 6, 13, 81, 65, 67, 415, 417, "on" +558, 6, 14, 82, 68, 79, 418, 429, "intraocular" +558, 6, 15, 83, 80, 88, 430, 438, "pressure" +558, 6, 16, 84, 89, 90, 439, 440, "(" +558, 6, 17, 85, 91, 94, 441, 444, "IOP" +558, 6, 18, 86, 95, 96, 445, 446, ")" +558, 6, 19, 87, 97, 99, 447, 449, "of" +558, 6, 20, 88, 100, 106, 450, 456, "adding" +558, 6, 21, 89, 107, 118, 457, 468, "dorzolamide" +558, 6, 22, 90, 119, 121, 469, 471, "to" +558, 6, 23, 91, 122, 129, 472, 479, "timolol" +558, 6, 24, 92, 130, 132, 480, 482, "or" +558, 6, 25, 93, 133, 135, 483, 485, "of" +558, 6, 26, 94, 136, 145, 486, 495, "switching" +558, 6, 27, 95, 146, 150, 496, 500, "from" +558, 6, 28, 96, 151, 158, 501, 508, "timolol" +558, 6, 29, 97, 159, 161, 509, 511, "to" +558, 6, 30, 98, 162, 173, 512, 523, "latanoprost" +558, 6, 31, 99, 174, 185, 524, 535, "monotherapy" +558, 6, 32, 100, 186, 188, 536, 538, "in" +558, 6, 33, 101, 189, 197, 539, 547, "glaucoma" +558, 6, 34, 102, 198, 206, 548, 556, "patients" +558, 6, 35, 103, 207, 219, 557, 569, "inadequately" +558, 6, 36, 104, 220, 230, 570, 580, "controlled" +558, 6, 37, 105, 231, 233, 581, 583, "on" +558, 6, 38, 106, 234, 241, 584, 591, "timolol" +558, 6, 39, 107, 242, 243, 592, 593, "." +558, 7, 1, 108, 0, 7, 594, 601, "METHODS" +558, 7, 2, 109, 8, 9, 602, 603, ":" +558, 7, 3, 110, 10, 13, 604, 607, "The" +558, 7, 4, 111, 14, 19, 608, 613, "study" +558, 7, 5, 112, 20, 23, 614, 617, "was" +558, 7, 6, 113, 24, 32, 618, 626, "designed" +558, 7, 7, 114, 33, 35, 627, 629, "as" +558, 7, 8, 115, 36, 37, 630, 631, "a" +558, 7, 9, 116, 38, 39, 632, 633, "3" +558, 7, 10, 117, 40, 41, 634, 635, "-" +558, 7, 11, 118, 42, 47, 636, 641, "month" +558, 7, 12, 119, 48, 58, 642, 652, "randomised" +558, 7, 13, 120, 59, 60, 653, 654, "," +558, 7, 14, 121, 61, 65, 655, 659, "open" +558, 7, 15, 122, 66, 67, 660, 661, "-" +558, 7, 16, 123, 68, 73, 662, 667, "label" +558, 7, 17, 124, 74, 75, 668, 669, "," +558, 7, 18, 125, 76, 87, 670, 681, "multicentre" +558, 7, 19, 126, 88, 93, 682, 687, "study" +558, 7, 20, 127, 94, 104, 688, 698, "comprising" +558, 7, 21, 128, 105, 108, 699, 702, "183" +558, 7, 22, 129, 109, 117, 703, 711, "patients" +558, 7, 23, 130, 118, 122, 712, 716, "with" +558, 7, 24, 131, 123, 130, 717, 724, "primary" +558, 7, 25, 132, 131, 135, 725, 729, "open" +558, 7, 26, 133, 136, 137, 730, 731, "-" +558, 7, 27, 134, 138, 143, 732, 737, "angle" +558, 7, 28, 135, 144, 152, 738, 746, "glaucoma" +558, 7, 29, 136, 153, 154, 747, 748, "," +558, 7, 30, 137, 155, 163, 749, 757, "capsular" +558, 7, 31, 138, 164, 172, 758, 766, "glaucoma" +558, 7, 32, 139, 173, 177, 767, 771, "with" +558, 7, 33, 140, 178, 181, 772, 775, "IOP" +558, 7, 34, 141, 182, 187, 776, 781, "above" +558, 7, 35, 142, 188, 190, 782, 784, "22" +558, 7, 36, 143, 191, 195, 785, 789, "mmHg" +558, 7, 37, 144, 196, 198, 790, 792, "on" +558, 7, 38, 145, 199, 208, 793, 802, "treatment" +558, 7, 39, 146, 209, 213, 803, 807, "with" +558, 7, 40, 147, 214, 217, 808, 811, "one" +558, 7, 41, 148, 218, 220, 812, 814, "or" +558, 7, 42, 149, 221, 224, 815, 818, "two" +558, 7, 43, 150, 225, 231, 819, 825, "ocular" +558, 7, 44, 151, 232, 243, 826, 837, "hypotensive" +558, 7, 45, 152, 244, 249, 838, 843, "drugs" +558, 7, 46, 153, 250, 251, 844, 845, "," +558, 7, 47, 154, 252, 254, 846, 848, "or" +558, 7, 48, 155, 255, 261, 849, 855, "ocular" +558, 7, 49, 156, 262, 274, 856, 868, "hypertension" +558, 7, 50, 157, 275, 279, 869, 873, "with" +558, 7, 51, 158, 280, 283, 874, 877, "IOP" +558, 7, 52, 159, 284, 289, 878, 883, "above" +558, 7, 53, 160, 290, 292, 884, 886, "27" +558, 7, 54, 161, 293, 297, 887, 891, "mmHg" +558, 7, 55, 162, 298, 299, 892, 893, "." +558, 8, 1, 163, 0, 5, 894, 899, "After" +558, 8, 2, 164, 6, 7, 900, 901, "a" +558, 8, 3, 165, 8, 9, 902, 903, "2" +558, 8, 4, 166, 10, 11, 904, 905, "-" +558, 8, 5, 167, 12, 14, 906, 908, "to" +558, 8, 6, 168, 15, 16, 909, 910, "4" +558, 8, 7, 169, 17, 18, 911, 912, "-" +558, 8, 8, 170, 19, 23, 913, 917, "week" +558, 8, 9, 171, 24, 27, 918, 921, "run" +558, 8, 10, 172, 28, 29, 922, 923, "-" +558, 8, 11, 173, 30, 32, 924, 926, "in" +558, 8, 12, 174, 33, 39, 927, 933, "period" +558, 8, 13, 175, 40, 42, 934, 936, "on" +558, 8, 14, 176, 43, 50, 937, 944, "timolol" +558, 8, 15, 177, 51, 52, 945, 946, "," +558, 8, 16, 178, 53, 54, 947, 948, "0" +558, 8, 17, 179, 55, 56, 949, 950, "." +558, 8, 18, 180, 57, 58, 951, 952, "5" +558, 8, 19, 181, 59, 60, 953, 954, "%" +558, 8, 20, 182, 61, 66, 955, 960, "twice" +558, 8, 21, 183, 67, 72, 961, 966, "daily" +558, 8, 22, 184, 73, 74, 967, 968, "," +558, 8, 23, 185, 75, 78, 969, 972, "the" +558, 8, 24, 186, 79, 87, 973, 981, "patients" +558, 8, 25, 187, 88, 92, 982, 986, "were" +558, 8, 26, 188, 93, 103, 987, 997, "randomised" +558, 8, 27, 189, 104, 106, 998, 1000, "to" +558, 8, 28, 190, 107, 116, 1001, 1010, "treatment" +558, 8, 29, 191, 117, 121, 1011, 1015, "with" +558, 8, 30, 192, 122, 128, 1016, 1022, "either" +558, 8, 31, 193, 129, 140, 1023, 1034, "latanoprost" +558, 8, 32, 194, 141, 142, 1035, 1036, "," +558, 8, 33, 195, 143, 144, 1037, 1038, "0" +558, 8, 34, 196, 145, 146, 1039, 1040, "." +558, 9, 1, 197, 0, 3, 1041, 1044, "005" +558, 9, 2, 198, 4, 5, 1045, 1046, "%" +558, 9, 3, 199, 6, 10, 1047, 1051, "once" +558, 9, 4, 200, 11, 16, 1052, 1057, "daily" +558, 9, 5, 201, 17, 18, 1058, 1059, "," +558, 9, 6, 202, 19, 21, 1060, 1062, "or" +558, 9, 7, 203, 22, 25, 1063, 1066, "the" +558, 9, 8, 204, 26, 37, 1067, 1078, "combination" +558, 9, 9, 205, 38, 40, 1079, 1081, "of" +558, 9, 10, 206, 41, 48, 1082, 1089, "timolol" +558, 9, 11, 207, 49, 50, 1090, 1091, "," +558, 9, 12, 208, 51, 52, 1092, 1093, "0" +558, 9, 13, 209, 53, 54, 1094, 1095, "." +558, 9, 14, 210, 55, 56, 1096, 1097, "5" +558, 9, 15, 211, 57, 58, 1098, 1099, "%" +558, 9, 16, 212, 59, 64, 1100, 1105, "twice" +558, 9, 17, 213, 65, 70, 1106, 1111, "daily" +558, 9, 18, 214, 71, 72, 1112, 1113, "," +558, 9, 19, 215, 73, 76, 1114, 1117, "and" +558, 9, 20, 216, 77, 88, 1118, 1129, "dorzolamide" +558, 9, 21, 217, 89, 90, 1130, 1131, "," +558, 9, 22, 218, 91, 92, 1132, 1133, "2" +558, 9, 23, 219, 93, 94, 1134, 1135, "%" +558, 9, 24, 220, 95, 100, 1136, 1141, "twice" +558, 9, 25, 221, 101, 106, 1142, 1147, "daily" +558, 9, 26, 222, 107, 108, 1148, 1149, "." +558, 10, 1, 223, 0, 3, 1150, 1153, "The" +558, 10, 2, 224, 4, 8, 1154, 1158, "mean" +558, 10, 3, 225, 9, 16, 1159, 1166, "diurnal" +558, 10, 4, 226, 17, 20, 1167, 1170, "IOP" +558, 10, 5, 227, 21, 26, 1171, 1176, "after" +558, 10, 6, 228, 27, 28, 1177, 1178, "3" +558, 10, 7, 229, 29, 35, 1179, 1185, "months" +558, 10, 8, 230, 36, 38, 1186, 1188, "of" +558, 10, 9, 231, 39, 48, 1189, 1198, "treatment" +558, 10, 10, 232, 49, 52, 1199, 1202, "was" +558, 10, 11, 233, 53, 61, 1203, 1211, "compared" +558, 10, 12, 234, 62, 66, 1212, 1216, "with" +558, 10, 13, 235, 67, 75, 1217, 1225, "baseline" +558, 10, 14, 236, 76, 77, 1226, 1227, "." +558, 11, 1, 237, 0, 7, 1228, 1235, "RESULTS" +558, 11, 2, 238, 8, 9, 1236, 1237, ":" +558, 11, 3, 239, 10, 19, 1238, 1247, "Switching" +558, 11, 4, 240, 20, 24, 1248, 1252, "from" +558, 11, 5, 241, 25, 32, 1253, 1260, "timolol" +558, 11, 6, 242, 33, 35, 1261, 1263, "to" +558, 11, 7, 243, 36, 47, 1264, 1275, "latanoprost" +558, 11, 8, 244, 48, 55, 1276, 1283, "reduced" +558, 11, 9, 245, 56, 60, 1284, 1288, "mean" +558, 11, 10, 246, 61, 68, 1289, 1296, "diurnal" +558, 11, 11, 247, 69, 72, 1297, 1300, "IOP" +558, 11, 12, 248, 73, 75, 1301, 1303, "by" +558, 11, 13, 249, 76, 77, 1304, 1305, "4" +558, 11, 14, 250, 78, 79, 1306, 1307, "." +558, 11, 15, 251, 80, 81, 1308, 1309, "5" +558, 11, 16, 252, 82, 83, 1310, 1311, "+" +558, 11, 17, 253, 84, 85, 1312, 1313, "/" +558, 11, 18, 254, 86, 87, 1314, 1315, "-" +558, 11, 19, 255, 88, 89, 1316, 1317, "0" +558, 11, 20, 256, 90, 91, 1318, 1319, "." +558, 11, 21, 257, 92, 93, 1320, 1321, "2" +558, 11, 22, 258, 94, 98, 1322, 1326, "mmHg" +558, 11, 23, 259, 99, 100, 1327, 1328, "(" +558, 11, 24, 260, 101, 105, 1329, 1333, "mean" +558, 11, 25, 261, 106, 107, 1334, 1335, "+" +558, 11, 26, 262, 108, 109, 1336, 1337, "/" +558, 11, 27, 263, 110, 111, 1338, 1339, "-" +558, 11, 28, 264, 112, 115, 1340, 1343, "SEM" +558, 11, 29, 265, 116, 117, 1344, 1345, "," +558, 11, 30, 266, 118, 124, 1346, 1352, "ANCOVA" +558, 11, 31, 267, 125, 126, 1353, 1354, ";" +558, 11, 32, 268, 127, 129, 1355, 1357, "20" +558, 11, 33, 269, 130, 131, 1358, 1359, "%" +558, 11, 34, 270, 132, 133, 1360, 1361, ")" +558, 11, 35, 271, 134, 135, 1362, 1363, "," +558, 11, 36, 272, 136, 139, 1364, 1367, "and" +558, 11, 37, 273, 140, 146, 1368, 1374, "adding" +558, 11, 38, 274, 147, 158, 1375, 1386, "dorzolamide" +558, 11, 39, 275, 159, 161, 1387, 1389, "to" +558, 11, 40, 276, 162, 169, 1390, 1397, "timolol" +558, 11, 41, 277, 170, 177, 1398, 1405, "reduced" +558, 11, 42, 278, 178, 182, 1406, 1410, "mean" +558, 11, 43, 279, 183, 190, 1411, 1418, "diurnal" +558, 11, 44, 280, 191, 193, 1419, 1421, "by" +558, 11, 45, 281, 194, 195, 1422, 1423, "4" +558, 11, 46, 282, 196, 197, 1424, 1425, "." +558, 11, 47, 283, 198, 199, 1426, 1427, "4" +558, 11, 48, 284, 200, 201, 1428, 1429, "+" +558, 11, 49, 285, 202, 203, 1430, 1431, "/" +558, 11, 50, 286, 204, 205, 1432, 1433, "-" +558, 11, 51, 287, 206, 207, 1434, 1435, "0" +558, 11, 52, 288, 208, 209, 1436, 1437, "." +558, 11, 53, 289, 210, 211, 1438, 1439, "2" +558, 11, 54, 290, 212, 216, 1440, 1444, "mmHg" +558, 11, 55, 291, 217, 218, 1445, 1446, "(" +558, 11, 56, 292, 219, 223, 1447, 1451, "mean" +558, 11, 57, 293, 224, 225, 1452, 1453, "+" +558, 11, 58, 294, 226, 227, 1454, 1455, "/" +558, 11, 59, 295, 228, 229, 1456, 1457, "-" +558, 11, 60, 296, 230, 233, 1458, 1461, "SEM" +558, 11, 61, 297, 234, 235, 1462, 1463, "," +558, 11, 62, 298, 236, 242, 1464, 1470, "ANCOVA" +558, 11, 63, 299, 243, 244, 1471, 1472, ";" +558, 11, 64, 300, 245, 247, 1473, 1475, "20" +558, 11, 65, 301, 248, 249, 1476, 1477, "%" +558, 11, 66, 302, 250, 251, 1478, 1479, ")" +558, 11, 67, 303, 252, 253, 1480, 1481, "." +558, 12, 1, 304, 0, 2, 1482, 1484, "No" +558, 12, 2, 305, 3, 10, 1485, 1492, "serious" +558, 12, 3, 306, 11, 15, 1493, 1497, "side" +558, 12, 4, 307, 16, 23, 1498, 1505, "effects" +558, 12, 5, 308, 24, 28, 1506, 1510, "were" +558, 12, 6, 309, 29, 37, 1511, 1519, "observed" +558, 12, 7, 310, 38, 42, 1520, 1524, "with" +558, 12, 8, 311, 43, 49, 1525, 1531, "either" +558, 12, 9, 312, 50, 59, 1532, 1541, "treatment" +558, 12, 10, 313, 60, 61, 1542, 1543, "." +558, 13, 1, 314, 0, 10, 1544, 1554, "CONCLUSION" +558, 13, 2, 315, 11, 12, 1555, 1556, ":" +558, 13, 3, 316, 13, 24, 1557, 1568, "Latanoprost" +558, 13, 4, 317, 25, 36, 1569, 1580, "monotherapy" +558, 13, 5, 318, 37, 40, 1581, 1584, "can" +558, 13, 6, 319, 41, 43, 1585, 1587, "be" +558, 13, 7, 320, 44, 46, 1588, 1590, "an" +558, 13, 8, 321, 47, 58, 1591, 1602, "alternative" +558, 13, 9, 322, 59, 61, 1603, 1605, "to" +558, 13, 10, 323, 62, 70, 1606, 1614, "combined" +558, 13, 11, 324, 71, 80, 1615, 1624, "treatment" +558, 13, 12, 325, 81, 85, 1625, 1629, "with" +558, 13, 13, 326, 86, 89, 1630, 1633, "two" +558, 13, 14, 327, 90, 97, 1634, 1641, "aqueous" +558, 13, 15, 328, 98, 102, 1642, 1646, "flow" +558, 13, 16, 329, 103, 114, 1647, 1658, "suppressors" +558, 13, 17, 330, 115, 117, 1659, 1661, "in" +558, 13, 18, 331, 118, 126, 1662, 1670, "patients" +558, 13, 19, 332, 127, 132, 1671, 1676, "whose" +558, 13, 20, 333, 133, 136, 1677, 1680, "IOP" +558, 13, 21, 334, 137, 139, 1681, 1683, "is" +558, 13, 22, 335, 140, 154, 1684, 1698, "insufficiently" +558, 13, 23, 336, 155, 165, 1699, 1709, "controlled" +558, 13, 24, 337, 166, 168, 1710, 1712, "by" +558, 13, 25, 338, 169, 176, 1713, 1720, "timolol" +558, 13, 26, 339, 177, 182, 1721, 1726, "alone" +558, 13, 27, 340, 183, 184, 1727, 1728, "." +558, 14, 1, 341, 0, 3, 1729, 1732, "DOI" +558, 14, 2, 342, 4, 5, 1733, 1734, ":" +558, 14, 3, 343, 6, 8, 1735, 1737, "10" +558, 14, 4, 344, 9, 10, 1738, 1739, "." +558, 14, 5, 345, 11, 15, 1740, 1744, "1007" +558, 14, 6, 346, 16, 17, 1745, 1746, "/" +558, 14, 7, 347, 18, 31, 1747, 1760, "s004170050003" +558, 14, 8, 348, 32, 36, 1761, 1765, "PMID" +558, 14, 9, 349, 37, 38, 1766, 1767, ":" +558, 14, 10, 350, 39, 47, 1768, 1776, "10664047" +558, 14, 11, 351, 48, 49, 1777, 1778, "[" +558, 14, 12, 352, 50, 57, 1779, 1786, "Indexed" +558, 14, 13, 353, 58, 61, 1787, 1790, "for" +558, 14, 14, 354, 62, 69, 1791, 1798, "MEDLINE" +558, 14, 15, 355, 70, 71, 1799, 1800, "]" diff --git a/data/gl 10664047_jshahinitiran.annodb b/data/gl 10664047_jshahinitiran.annodb new file mode 100644 index 0000000..0ad8ab4 --- /dev/null +++ b/data/gl 10664047_jshahinitiran.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80913, Journal, 0, 34, "Graefes Arch Clin Exp Ophthalmol .", "", +80914, PublicationYear, 35, 39, "2000", "", +80915, Title, 68, 225, "Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension . A 3 - month randomised study .", "", +80916, Latanoprost, 82, 93, "latanoprost", "", +80917, Dorzolamide, 109, 120, "dorzolamide", "", +80918, Timolol, 135, 142, "timolol", "", +80919, Glaucoma, 160, 168, "glaucoma", "", +80920, OcularHypertension, 173, 192, "ocular hypertension", "", +80921, Duration, 197, 206, "3 - month", "", +80922, Randomized, 207, 217, "randomised", "", +80923, Author, 226, 237, "Emmerich KH", "", +80924, Germany, 340, 347, "Germany", "", +80925, ObjectiveDescription, 363, 593, "The purpose of the study was to compare the effects on intraocular pressure ( IOP ) of adding dorzolamide to timolol or of switching from timolol to latanoprost monotherapy in glaucoma patients inadequately controlled on timolol .", "", +80926, IOP, 418, 438, "intraocular pressure", "", +80927, IOP, 441, 444, "IOP", "", +80928, Dorzolamide, 457, 468, "dorzolamide", "", +80929, Timolol, 472, 479, "timolol", "", +80930, Timolol, 501, 508, "timolol", "", +80931, Latanoprost, 512, 523, "latanoprost", "", +80932, Glaucoma, 539, 547, "glaucoma", "", +80934, Precondition, 539, 591, "glaucoma patients inadequately controlled on timolol", "", +80933, Timolol, 584, 591, "timolol", "", +80935, Duration, 632, 641, "3 - month", "", +80936, Randomized, 642, 652, "randomised", "", +80937, OpenLabel, 655, 667, "open - label", "", +80938, Multicenter, 670, 681, "multicentre", "", +80939, NumberPatientsCT, 699, 702, "183", "", +80940, Primary_OpenAngleGlaucoma, 717, 746, "primary open - angle glaucoma", "", +80941, Glaucoma, 749, 766, "capsular glaucoma", "", +80944, Precondition, 767, 789, "with IOP above 22 mmHg", "", +80942, IOP, 772, 775, "IOP", "", +80943, mmHg, 785, 789, "mmHg", "", +80947, OcularHypertension, 849, 868, "ocular hypertension", "", +80948, Precondition, 869, 891, "with IOP above 27 mmHg", "", +80945, IOP, 874, 877, "IOP", "", +80946, mmHg, 887, 891, "mmHg", "", +80949, Timolol, 937, 944, "timolol", "", +80950, DoseValue, 947, 952, "0 . 5", "", +80955, Frequency, 955, 966, "twice daily", "", +80956, Randomized, 987, 997, "randomised", "", +80957, Latanoprost, 1023, 1034, "latanoprost", "", +80953, DoseValue, 1037, 1040, "0 .", "", +80952, DoseValue, 1041, 1044, "005", "", +80958, Frequency, 1047, 1057, "once daily", "", +80959, Timolol, 1082, 1089, "timolol", "", +80951, DoseValue, 1092, 1097, "0 . 5", "", +80960, Frequency, 1100, 1111, "twice daily", "", +80961, Dorzolamide, 1118, 1129, "dorzolamide", "", +80954, DoseValue, 1132, 1133, "2", "", +80962, Frequency, 1136, 1147, "twice daily", "", +80963, Mean, 1154, 1158, "mean", "", +80964, Diurnal_IOP, 1159, 1170, "diurnal IOP", "", +80965, Duration, 1177, 1185, "3 months", "", +80966, Timolol, 1253, 1260, "timolol", "", +80967, Latanoprost, 1264, 1275, "latanoprost", "", +80968, Mean, 1284, 1288, "mean", "", +80969, Diurnal_IOP, 1289, 1300, "diurnal IOP", "", +80970, Reduction, 1304, 1309, "4 . 5", "", +80971, SdErrorChangeValue, 1316, 1321, "0 . 2", "", +80972, mmHg, 1322, 1326, "mmHg", "", +80973, Dorzolamide, 1375, 1386, "dorzolamide", "", +80974, Timolol, 1390, 1397, "timolol", "", +80976, Mean, 1406, 1410, "mean", "", +80977, Diurnal_IOP, 1411, 1418, "diurnal", "", +80978, Reduction, 1422, 1427, "4 . 4", "", +80979, SdErrorChangeValue, 1434, 1439, "0 . 2", "", +80980, mmHg, 1440, 1444, "mmHg", "", +80981, ConclusionComment, 1557, 1728, "Latanoprost monotherapy can be an alternative to combined treatment with two aqueous flow suppressors in patients whose IOP is insufficiently controlled by timolol alone .", "", +80982, Latanoprost, 1557, 1568, "Latanoprost", "", +80983, IOP, 1677, 1680, "IOP", "", +80984, Timolol, 1713, 1720, "timolol", "", +80985, PMID, 1768, 1776, "10664047", "", diff --git a/data/gl 10664047_jshahinitiran.n-triples b/data/gl 10664047_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10664047_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10664047_tstrakeljahn.annodb b/data/gl 10664047_tstrakeljahn.annodb new file mode 100644 index 0000000..557652f --- /dev/null +++ b/data/gl 10664047_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81625, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +81626, PublicationYear, 35, 39, "2000", "", +81637, Title, 68, 225, "Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension . A 3 - month randomised study .", "", +81627, Latanoprost, 82, 93, "latanoprost", "", +81628, Dorzolamide, 109, 120, "dorzolamide", "", +81635, Dorz/TimFC, 109, 142, "dorzolamide combined with timolol", "", +81629, Timolol, 135, 142, "timolol", "", +81630, Glaucoma, 160, 168, "glaucoma", "", +81631, OcularHypertension, 173, 192, "ocular hypertension", "", +81632, Duration, 197, 206, "3 - month", "", +81633, Randomized, 207, 217, "randomised", "", +81634, Author, 226, 237, "Emmerich KH", "", +81636, Germany, 340, 347, "Germany", "", +81647, ObjectiveDescription, 363, 593, "The purpose of the study was to compare the effects on intraocular pressure ( IOP ) of adding dorzolamide to timolol or of switching from timolol to latanoprost monotherapy in glaucoma patients inadequately controlled on timolol .", "", +81638, IOP, 418, 438, "intraocular pressure", "", +81639, IOP, 441, 444, "IOP", "", +81640, Dorzolamide, 457, 468, "dorzolamide", "", +81641, Timolol, 472, 479, "timolol", "", +81642, Timolol, 501, 508, "timolol", "", +81643, Latanoprost, 512, 523, "latanoprost", "", +81644, Glaucoma, 539, 547, "glaucoma", "", +81646, Precondition, 539, 591, "glaucoma patients inadequately controlled on timolol", "", +81645, Timolol, 584, 591, "timolol", "", +81648, Duration, 632, 641, "3 - month", "", +81649, Randomized, 642, 652, "randomised", "", +81650, OpenLabel, 655, 667, "open - label", "", +81651, Multicenter, 670, 681, "multicentre", "", +81652, NumberPatientsCT, 699, 702, "183", "", +81665, Precondition, 703, 746, "patients with primary open - angle glaucoma", "", +81656, SubGroupDescription, 703, 746, "patients with primary open - angle glaucoma", "", +81653, Primary_OpenAngleGlaucoma, 717, 746, "primary open - angle glaucoma", "", +81664, Precondition, 749, 843, "capsular glaucoma with IOP above 22 mmHg on treatment with one or two ocular hypotensive drugs", "", +81658, SubGroupDescription, 749, 843, "capsular glaucoma with IOP above 22 mmHg on treatment with one or two ocular hypotensive drugs", "", +81654, Glaucoma, 758, 766, "glaucoma", "", +81655, IOP, 772, 775, "IOP", "", +81657, mmHg, 785, 789, "mmHg", "", +81659, OcularHypertension, 849, 868, "ocular hypertension", "", +81662, SubGroupDescription, 849, 891, "ocular hypertension with IOP above 27 mmHg", "", +81663, Precondition, 849, 891, "ocular hypertension with IOP above 27 mmHg", "", +81660, IOP, 874, 877, "IOP", "", +81661, mmHg, 887, 891, "mmHg", "", +81666, Timolol, 937, 944, "timolol", "", +81667, DoseValue, 947, 952, "0 . 5", "", +81677, Percentage, 953, 954, "%", "", +81670, Frequency, 955, 966, "twice daily", "", +81674, Latanoprost, 1023, 1034, "latanoprost", "", +81678, Percentage, 1045, 1046, "%", "", +81671, Frequency, 1047, 1057, "once daily", "", +81675, Timolol, 1082, 1089, "timolol", "", +81681, Dorz/TimFC, 1082, 1135, "timolol , 0 . 5 % twice daily , and dorzolamide , 2 %", "", +81668, DoseValue, 1092, 1097, "0 . 5", "", +81679, Percentage, 1098, 1099, "%", "", +81672, Frequency, 1100, 1111, "twice daily", "", +81676, Dorzolamide, 1118, 1129, "dorzolamide", "", +81669, DoseValue, 1132, 1133, "2", "", +81680, Percentage, 1134, 1135, "%", "", +81673, Frequency, 1136, 1147, "twice daily", "", +81682, Mean, 1154, 1158, "mean", "", +81683, Diurnal_IOP, 1159, 1170, "diurnal IOP", "", +81684, TimePoint, 1171, 1185, "after 3 months", "", +81685, Timolol, 1253, 1260, "timolol", "", +81686, Latanoprost, 1264, 1275, "latanoprost", "", +81687, Mean, 1284, 1288, "mean", "", +81688, Diurnal_IOP, 1289, 1300, "diurnal IOP", "", +81689, Reduction, 1304, 1309, "4 . 5", "", +81691, SdErrorChangeValue, 1316, 1321, "0 . 2", "", +81693, mmHg, 1322, 1326, "mmHg", "", +81695, Dorzolamide, 1375, 1386, "dorzolamide", "", +81696, Timolol, 1390, 1397, "timolol", "", +81697, Mean, 1406, 1410, "mean", "", +81698, Diurnal_IOP, 1411, 1418, "diurnal", "", +81690, Reduction, 1422, 1427, "4 . 4", "", +81692, SdErrorChangeValue, 1434, 1439, "0 . 2", "", +81694, mmHg, 1440, 1444, "mmHg", "", +81699, ObservedResult, 1482, 1543, "No serious side effects were observed with either treatment .", "", +81700, Latanoprost, 1557, 1568, "Latanoprost", "", +81703, ConclusionComment, 1557, 1728, "Latanoprost monotherapy can be an alternative to combined treatment with two aqueous flow suppressors in patients whose IOP is insufficiently controlled by timolol alone .", "", +81701, IOP, 1677, 1680, "IOP", "", +81702, Timolol, 1713, 1720, "timolol", "", +81704, PMID, 1768, 1776, "10664047", "", diff --git a/data/gl 10664047_tstrakeljahn.n-triples b/data/gl 10664047_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10664047_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10837379_admin.annodb b/data/gl 10837379_admin.annodb new file mode 100644 index 0000000..ade6172 --- /dev/null +++ b/data/gl 10837379_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +20239, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2000", "", " \"2000\"." +2, Title, 51, 177, "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study .", "", " \"A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study .\"." +7, Latanoprost, 67, 78, "latanoprost", "", " . ." +8, Dorzolamide, 83, 94, "dorzolamide", "", " ." +9, Glaucoma, 112, 120, "glaucoma", "", " . ." +64, OcularHypertension, 125, 144, "ocular hypertension", "", " ." +25348, Duration, 149, 156, "3 month", "", " \"3 month\"." +11, Randomized, 159, 169, "randomised", "", " ." +67, Ireland, 178, 185, "Ireland", "", " ." +18307, Latanoprost, 186, 197, "Latanoprost", "", +106183, Author, 212, 227, "O ' Donoghue EP", "", " \"O ' Donoghue EP\"." +12, Ireland, 332, 339, "Ireland", "", +4, ObjectiveDescription, 366, 542, "To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension .", "", " \"To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension .\"." +71, IOP, 392, 412, "intraocular pressure", "", +70, IOP, 415, 418, "IOP", "", +72, Latanoprost, 465, 476, "latanoprost", "", +73, Dorzolamide, 480, 491, "dorzolamide", "", +74, Glaucoma, 509, 517, "glaucoma", "", +75, OcularHypertension, 521, 540, "ocular hypertension", "", +14, OpenAngleGlaucoma, 571, 590, "open angle glaucoma", "", +15, OcularHypertension, 594, 613, "ocular hypertension", "", +25349, Duration, 634, 641, "3 month", "", +16, OpenLabel, 642, 655, "open labelled", "", " ." +82, Precondition, 664, 709, "Previous glaucoma medications were washed out", "", " \"Previous glaucoma medications were washed out\"." +162, Glaucoma, 673, 681, "glaucoma", "", +83, Randomized, 732, 742, "randomised", "", +17, Latanoprost, 761, 772, "latanoprost", "", +18, DoseValue, 773, 780, "0 . 005", "", " \"0 . 005\"." +19, Percentage, 781, 782, "%", "", " . ." +20, Frequency, 783, 793, "once daily", "", " \"once daily\"." +21, Dorzolamide, 797, 808, "dorzolamide", "", +22, DoseValue, 809, 810, "2", "", " \"2\"." +23, Percentage, 811, 812, "%", "", +24, Frequency, 813, 830, "three times daily", "", " \"three times daily\"." +17542, FinalNumPatientsCT, 859, 862, "213", "", " \"213\"." +36933, TimePoint, 913, 921, "3 months", "", " \"3 months\". \"3 months\". \"3 months\". \"3 months\". \"3 months\". \"3 months\"." +25, Latanoprost, 924, 935, "latanoprost", "", +26, Mean, 944, 948, "mean", "", " . ." +27, Diurnal_IOP, 958, 969, "diurnal IOP", "", " ." +28, BaseLineValue, 975, 981, "27 . 2", "", " \"27 . 2\"." +29, SdDevBL, 987, 992, "3 . 0", "", " \"3 . 0\"." +30, mmHg, 995, 1000, "mm Hg", "", +31, Reduction, 1004, 1009, "8 . 5", "", " \"8 . 5\"." +32, SdDevChangeValue, 1012, 1017, "3 . 3", "", " \"3 . 3\"." +33, mmHg, 1020, 1025, "mm Hg", "", " ." +34, Dorzolamide, 1058, 1069, "dorzolamide", "", +35, BaseLineValue, 1075, 1081, "27 . 2", "", " \"27 . 2\"." +36, SdDevBL, 1084, 1089, "3 . 4", "", " \"3 . 4\"." +37, Reduction, 1096, 1101, "5 . 6", "", " \"5 . 6\"." +38, SdDevChangeValue, 1104, 1109, "2 . 6", "", " \"2 . 6\"." +39, mmHg, 1112, 1117, "mm Hg", "", +40, DiffGroupAbsValue, 1138, 1143, "2 . 9", "", " \"2 . 9\"." +41, mmHg, 1144, 1149, "mm Hg", "", +42, ConfIntervalDiff, 1152, 1175, "95 % CI : 2 . 3 - 3 . 6", "", " \"95 % CI : 2 . 3 - 3 . 6\"." +43, PvalueDiff, 1203, 1214, "p < 0 . 001", "", " \"p < 0 . 001\"." +44, Latanoprost, 1228, 1239, "Latanoprost", "", +20419, Peak_IOP, 1248, 1259, "IOP at peak", "", " ." +46, Reduction, 1263, 1268, "8 . 6", "", " \"8 . 6\"." +47, mmHg, 1269, 1274, "mm Hg", "", " ." +118, RelativeReduction, 1277, 1279, "32", "", " \"32\"." +48, Reduction, 1298, 1303, "6 . 2", "", " \"6 . 2\"." +49, mmHg, 1304, 1309, "mm Hg", "", +121, RelativeReduction, 1312, 1314, "23", "", " \"23\"." +50, Dorzolamide, 1323, 1334, "dorzolamide", "", +51, DiffGroupAbsValue, 1359, 1364, "2 . 4", "", " \"2 . 4\"." +52, mmHg, 1365, 1370, "mm Hg", "", +53, PvalueDiff, 1389, 1400, "p < 0 . 001", "", " \"p < 0 . 001\"." +150, Trough_IOP, 1443, 1449, "trough", "", " ." +127, Reduction, 1455, 1460, "8 . 1", "", " \"8 . 1\"." +128, mmHg, 1461, 1466, "mm Hg", "", " ." +129, RelativeReduction, 1469, 1471, "31", "", " \"31\"." +130, Latanoprost, 1480, 1491, "latanoprost", "", +131, Reduction, 1496, 1501, "4 . 7", "", " \"4 . 7\"." +132, mmHg, 1502, 1507, "mm Hg", "", +133, RelativeReduction, 1510, 1512, "17", "", " \"17\"." +134, Dorzolamide, 1521, 1532, "dorzolamide", "", +158, DiffGroupAbsValue, 1563, 1568, "3 . 4", "", " \"3 . 4\"." +136, mmHg, 1569, 1574, "mm Hg", "", +137, PvalueDiff, 1577, 1588, "p < 0 . 001", "", " \"p < 0 . 001\"." +5, ConclusionComment, 1673, 1823, "Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP .", "", " \"Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP .\"." +54, Latanoprost, 1673, 1684, "Latanoprost", "", +55, Dorzolamide, 1701, 1712, "dorzolamide", "", +56, IOP, 1729, 1732, "IOP", "", +17577, Peak_IOP, 1766, 1777, "IOP at peak", "", +58, Diurnal_IOP, 1810, 1821, "diurnal IOP", "", +6, PMID, 1887, 1895, "10837379", "", " \"10837379\"." diff --git a/data/gl 10837379_admin.n-triples b/data/gl 10837379_admin.n-triples new file mode 100644 index 0000000..b138102 --- /dev/null +++ b/data/gl 10837379_admin.n-triples @@ -0,0 +1,159 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study ." . + "2000" . + "Br J Ophthalmol ." . + "10837379" . + . + "O ' Donoghue EP" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension ." . + "3 month" . + . + . + . + "Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP ." . + . + . + . + . + . + . + "213" . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Previous glaucoma medications were washed out" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_diurnal" . + . + . + . + . + . + . + "Endpoint_peak" . + . + . + . + . + . + "Endpoint_trough" . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + . + . + . + . + . + "Arm-dor" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-dor" . + . + "three times daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-dor" . + . + "2" . + . + . +# RDF export of group: Outcome + . + "Outcome-diurnal-lat" . + . + "27 . 2" . + "3 . 0" . + "8 . 5" . + "3 . 3" . + "3 months" . + . + "Outcome-diurnal-dor" . + . + "27 . 2" . + "3 . 4" . + "5 . 6" . + "2 . 6" . + "3 months" . + . + "Outcome-peak-lat" . + . + "8 . 6" . + "32" . + "3 months" . + . + "Outcome-peak-dor" . + . + "6 . 2" . + "23" . + "3 months" . + . + "Outcome-trough-lat" . + . + "8 . 1" . + "31" . + "3 months" . + . + "Outcome-trough-dor" . + . + "4 . 7" . + "17" . + "3 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-diurnal" . + "2 . 9" . + "p < 0 . 001" . + "95 % CI : 2 . 3 - 3 . 6" . + . + . + . + "DiffBetweenGroups-peak" . + "2 . 4" . + "p < 0 . 001" . + . + . + . + "DiffBetweenGroups-trough" . + "3 . 4" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10837379_export.csv b/data/gl 10837379_export.csv new file mode 100644 index 0000000..dddcc81 --- /dev/null +++ b/data/gl 10837379_export.csv @@ -0,0 +1,425 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +495, 1, 1, 1, 0, 2, 0, 2, "Br" +495, 1, 2, 2, 3, 4, 3, 4, "J" +495, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +495, 1, 4, 4, 16, 17, 16, 17, "." +495, 2, 1, 5, 0, 4, 18, 22, "2000" +495, 2, 2, 6, 5, 8, 23, 26, "Jun" +495, 2, 3, 7, 9, 10, 27, 28, ";" +495, 2, 4, 8, 11, 13, 29, 31, "84" +495, 2, 5, 9, 14, 15, 32, 33, "(" +495, 2, 6, 10, 16, 17, 34, 35, "6" +495, 2, 7, 11, 18, 19, 36, 37, ")" +495, 2, 8, 12, 20, 21, 38, 39, ":" +495, 2, 9, 13, 22, 25, 40, 43, "579" +495, 2, 10, 14, 26, 27, 44, 45, "-" +495, 2, 11, 15, 28, 30, 46, 48, "82" +495, 2, 12, 16, 31, 32, 49, 50, "." +495, 3, 1, 17, 0, 1, 51, 52, "A" +495, 3, 2, 18, 2, 12, 53, 63, "comparison" +495, 3, 3, 19, 13, 15, 64, 66, "of" +495, 3, 4, 20, 16, 27, 67, 78, "latanoprost" +495, 3, 5, 21, 28, 31, 79, 82, "and" +495, 3, 6, 22, 32, 43, 83, 94, "dorzolamide" +495, 3, 7, 23, 44, 46, 95, 97, "in" +495, 3, 8, 24, 47, 55, 98, 106, "patients" +495, 3, 9, 25, 56, 60, 107, 111, "with" +495, 3, 10, 26, 61, 69, 112, 120, "glaucoma" +495, 3, 11, 27, 70, 73, 121, 124, "and" +495, 3, 12, 28, 74, 80, 125, 131, "ocular" +495, 3, 13, 29, 81, 93, 132, 144, "hypertension" +495, 3, 14, 30, 94, 95, 145, 146, ":" +495, 3, 15, 31, 96, 97, 147, 148, "a" +495, 3, 16, 32, 98, 99, 149, 150, "3" +495, 3, 17, 33, 100, 105, 151, 156, "month" +495, 3, 18, 34, 106, 107, 157, 158, "," +495, 3, 19, 35, 108, 118, 159, 169, "randomised" +495, 3, 20, 36, 119, 124, 170, 175, "study" +495, 3, 21, 37, 125, 126, 176, 177, "." +495, 4, 1, 38, 0, 7, 178, 185, "Ireland" +495, 4, 2, 39, 8, 19, 186, 197, "Latanoprost" +495, 4, 3, 40, 20, 25, 198, 203, "Study" +495, 4, 4, 41, 26, 31, 204, 209, "Group" +495, 4, 5, 42, 32, 33, 210, 211, "." +495, 5, 1, 43, 0, 1, 212, 213, "O" +495, 5, 2, 44, 2, 3, 214, 215, "'" +495, 5, 3, 45, 4, 12, 216, 224, "Donoghue" +495, 5, 4, 46, 13, 15, 225, 227, "EP" +495, 5, 5, 47, 16, 17, 228, 229, "(" +495, 5, 6, 48, 18, 19, 230, 231, "1" +495, 5, 7, 49, 20, 21, 232, 233, ")" +495, 5, 8, 50, 22, 23, 234, 235, "." +495, 6, 1, 51, 0, 6, 236, 242, "Author" +495, 6, 2, 52, 7, 18, 243, 254, "information" +495, 6, 3, 53, 19, 20, 255, 256, ":" +495, 6, 4, 54, 21, 22, 257, 258, "(" +495, 6, 5, 55, 23, 24, 259, 260, "1" +495, 6, 6, 56, 25, 26, 261, 262, ")" +495, 6, 7, 57, 27, 37, 263, 273, "Department" +495, 6, 8, 58, 38, 40, 274, 276, "of" +495, 6, 9, 59, 41, 54, 277, 290, "Ophthalmology" +495, 6, 10, 60, 55, 56, 291, 292, "," +495, 6, 11, 61, 57, 67, 293, 303, "University" +495, 6, 12, 62, 68, 75, 304, 311, "College" +495, 6, 13, 63, 76, 84, 312, 320, "Hospital" +495, 6, 14, 64, 85, 86, 321, 322, "," +495, 6, 15, 65, 87, 93, 323, 329, "Galway" +495, 6, 16, 66, 94, 95, 330, 331, "," +495, 6, 17, 67, 96, 103, 332, 339, "Ireland" +495, 6, 18, 68, 104, 105, 340, 341, "." +495, 7, 1, 69, 0, 5, 342, 347, "eyeod" +495, 7, 2, 70, 6, 7, 348, 349, "@" +495, 7, 3, 71, 8, 11, 350, 353, "iol" +495, 7, 4, 72, 12, 13, 354, 355, "." +495, 7, 5, 73, 14, 16, 356, 358, "ie" +495, 7, 6, 74, 17, 21, 359, 363, "AIMS" +495, 7, 7, 75, 22, 23, 364, 365, ":" +495, 7, 8, 76, 24, 26, 366, 368, "To" +495, 7, 9, 77, 27, 34, 369, 376, "compare" +495, 7, 10, 78, 35, 38, 377, 380, "the" +495, 7, 11, 79, 39, 46, 381, 388, "effects" +495, 7, 12, 80, 47, 49, 389, 391, "on" +495, 7, 13, 81, 50, 61, 392, 403, "intraocular" +495, 7, 14, 82, 62, 70, 404, 412, "pressure" +495, 7, 15, 83, 71, 72, 413, 414, "(" +495, 7, 16, 84, 73, 76, 415, 418, "IOP" +495, 7, 17, 85, 77, 78, 419, 420, ")" +495, 7, 18, 86, 79, 82, 421, 424, "and" +495, 7, 19, 87, 83, 87, 425, 429, "side" +495, 7, 20, 88, 88, 95, 430, 437, "effects" +495, 7, 21, 89, 96, 98, 438, 440, "of" +495, 7, 22, 90, 99, 110, 441, 452, "monotherapy" +495, 7, 23, 91, 111, 115, 453, 457, "with" +495, 7, 24, 92, 116, 122, 458, 464, "either" +495, 7, 25, 93, 123, 134, 465, 476, "latanoprost" +495, 7, 26, 94, 135, 137, 477, 479, "or" +495, 7, 27, 95, 138, 149, 480, 491, "dorzolamide" +495, 7, 28, 96, 150, 152, 492, 494, "in" +495, 7, 29, 97, 153, 161, 495, 503, "patients" +495, 7, 30, 98, 162, 166, 504, 508, "with" +495, 7, 31, 99, 167, 175, 509, 517, "glaucoma" +495, 7, 32, 100, 176, 178, 518, 520, "or" +495, 7, 33, 101, 179, 185, 521, 527, "ocular" +495, 7, 34, 102, 186, 198, 528, 540, "hypertension" +495, 7, 35, 103, 199, 200, 541, 542, "." +495, 8, 1, 104, 0, 7, 543, 550, "METHODS" +495, 8, 2, 105, 8, 9, 551, 552, ":" +495, 8, 3, 106, 10, 13, 553, 556, "224" +495, 8, 4, 107, 14, 22, 557, 565, "patients" +495, 8, 5, 108, 23, 27, 566, 570, "with" +495, 8, 6, 109, 28, 32, 571, 575, "open" +495, 8, 7, 110, 33, 38, 576, 581, "angle" +495, 8, 8, 111, 39, 47, 582, 590, "glaucoma" +495, 8, 9, 112, 48, 50, 591, 593, "or" +495, 8, 10, 113, 51, 57, 594, 600, "ocular" +495, 8, 11, 114, 58, 70, 601, 613, "hypertension" +495, 8, 12, 115, 71, 75, 614, 618, "were" +495, 8, 13, 116, 76, 85, 619, 628, "recruited" +495, 8, 14, 117, 86, 88, 629, 631, "to" +495, 8, 15, 118, 89, 90, 632, 633, "a" +495, 8, 16, 119, 91, 92, 634, 635, "3" +495, 8, 17, 120, 93, 98, 636, 641, "month" +495, 8, 18, 121, 99, 103, 642, 646, "open" +495, 8, 19, 122, 104, 112, 647, 655, "labelled" +495, 8, 20, 123, 113, 118, 656, 661, "study" +495, 8, 21, 124, 119, 120, 662, 663, "." +495, 9, 1, 125, 0, 8, 664, 672, "Previous" +495, 9, 2, 126, 9, 17, 673, 681, "glaucoma" +495, 9, 3, 127, 18, 29, 682, 693, "medications" +495, 9, 4, 128, 30, 34, 694, 698, "were" +495, 9, 5, 129, 35, 41, 699, 705, "washed" +495, 9, 6, 130, 42, 45, 706, 709, "out" +495, 9, 7, 131, 46, 49, 710, 713, "and" +495, 9, 8, 132, 50, 53, 714, 717, "the" +495, 9, 9, 133, 54, 62, 718, 726, "patients" +495, 9, 10, 134, 63, 67, 727, 731, "were" +495, 9, 11, 135, 68, 78, 732, 742, "randomised" +495, 9, 12, 136, 79, 81, 743, 745, "to" +495, 9, 13, 137, 82, 89, 746, 753, "receive" +495, 9, 14, 138, 90, 96, 754, 760, "either" +495, 9, 15, 139, 97, 108, 761, 772, "latanoprost" +495, 9, 16, 140, 109, 110, 773, 774, "0" +495, 9, 17, 141, 111, 112, 775, 776, "." +495, 9, 18, 142, 113, 116, 777, 780, "005" +495, 9, 19, 143, 117, 118, 781, 782, "%" +495, 9, 20, 144, 119, 123, 783, 787, "once" +495, 9, 21, 145, 124, 129, 788, 793, "daily" +495, 9, 22, 146, 130, 132, 794, 796, "or" +495, 9, 23, 147, 133, 144, 797, 808, "dorzolamide" +495, 9, 24, 148, 145, 146, 809, 810, "2" +495, 9, 25, 149, 147, 148, 811, 812, "%" +495, 9, 26, 150, 149, 154, 813, 818, "three" +495, 9, 27, 151, 155, 160, 819, 824, "times" +495, 9, 28, 152, 161, 166, 825, 830, "daily" +495, 9, 29, 153, 167, 168, 831, 832, "." +495, 10, 1, 154, 0, 7, 833, 840, "RESULTS" +495, 10, 2, 155, 8, 9, 841, 842, ":" +495, 10, 3, 156, 10, 12, 843, 845, "Of" +495, 10, 4, 157, 13, 16, 846, 849, "224" +495, 10, 5, 158, 17, 25, 850, 858, "patients" +495, 10, 6, 159, 26, 29, 859, 862, "213" +495, 10, 7, 160, 30, 34, 863, 867, "were" +495, 10, 8, 161, 35, 43, 868, 876, "included" +495, 10, 9, 162, 44, 46, 877, 879, "in" +495, 10, 10, 163, 47, 50, 880, 883, "the" +495, 10, 11, 164, 51, 59, 884, 892, "analysis" +495, 10, 12, 165, 60, 62, 893, 895, "of" +495, 10, 13, 166, 63, 71, 896, 904, "efficacy" +495, 10, 14, 167, 72, 73, 905, 906, "." +495, 11, 1, 168, 0, 5, 907, 912, "After" +495, 11, 2, 169, 6, 7, 913, 914, "3" +495, 11, 3, 170, 8, 14, 915, 921, "months" +495, 11, 4, 171, 15, 16, 922, 923, "," +495, 11, 5, 172, 17, 28, 924, 935, "latanoprost" +495, 11, 6, 173, 29, 36, 936, 943, "reduced" +495, 11, 7, 174, 37, 41, 944, 948, "mean" +495, 11, 8, 175, 42, 50, 949, 957, "baseline" +495, 11, 9, 176, 51, 58, 958, 965, "diurnal" +495, 11, 10, 177, 59, 62, 966, 969, "IOP" +495, 11, 11, 178, 63, 67, 970, 974, "from" +495, 11, 12, 179, 68, 70, 975, 977, "27" +495, 11, 13, 180, 71, 72, 978, 979, "." +495, 11, 14, 181, 73, 74, 980, 981, "2" +495, 11, 15, 182, 75, 76, 982, 983, "(" +495, 11, 16, 183, 77, 79, 984, 986, "SD" +495, 11, 17, 184, 80, 81, 987, 988, "3" +495, 11, 18, 185, 82, 83, 989, 990, "." +495, 11, 19, 186, 84, 85, 991, 992, "0" +495, 11, 20, 187, 86, 87, 993, 994, ")" +495, 11, 21, 188, 88, 90, 995, 997, "mm" +495, 11, 22, 189, 91, 93, 998, 1000, "Hg" +495, 11, 23, 190, 94, 96, 1001, 1003, "by" +495, 11, 24, 191, 97, 98, 1004, 1005, "8" +495, 11, 25, 192, 99, 100, 1006, 1007, "." +495, 11, 26, 193, 101, 102, 1008, 1009, "5" +495, 11, 27, 194, 103, 104, 1010, 1011, "(" +495, 11, 28, 195, 105, 106, 1012, 1013, "3" +495, 11, 29, 196, 107, 108, 1014, 1015, "." +495, 11, 30, 197, 109, 110, 1016, 1017, "3" +495, 11, 31, 198, 111, 112, 1018, 1019, ")" +495, 11, 32, 199, 113, 115, 1020, 1022, "mm" +495, 11, 33, 200, 116, 118, 1023, 1025, "Hg" +495, 11, 34, 201, 119, 120, 1026, 1027, "." +495, 12, 1, 202, 0, 3, 1028, 1031, "The" +495, 12, 2, 203, 4, 17, 1032, 1045, "corresponding" +495, 12, 3, 204, 18, 25, 1046, 1053, "figures" +495, 12, 4, 205, 26, 29, 1054, 1057, "for" +495, 12, 5, 206, 30, 41, 1058, 1069, "dorzolamide" +495, 12, 6, 207, 42, 46, 1070, 1074, "were" +495, 12, 7, 208, 47, 49, 1075, 1077, "27" +495, 12, 8, 209, 50, 51, 1078, 1079, "." +495, 12, 9, 210, 52, 53, 1080, 1081, "2" +495, 12, 10, 211, 54, 55, 1082, 1083, "(" +495, 12, 11, 212, 56, 57, 1084, 1085, "3" +495, 12, 12, 213, 58, 59, 1086, 1087, "." +495, 12, 13, 214, 60, 61, 1088, 1089, "4" +495, 12, 14, 215, 62, 63, 1090, 1091, ")" +495, 12, 15, 216, 64, 67, 1092, 1095, "and" +495, 12, 16, 217, 68, 69, 1096, 1097, "5" +495, 12, 17, 218, 70, 71, 1098, 1099, "." +495, 12, 18, 219, 72, 73, 1100, 1101, "6" +495, 12, 19, 220, 74, 75, 1102, 1103, "(" +495, 12, 20, 221, 76, 77, 1104, 1105, "2" +495, 12, 21, 222, 78, 79, 1106, 1107, "." +495, 12, 22, 223, 80, 81, 1108, 1109, "6" +495, 12, 23, 224, 82, 83, 1110, 1111, ")" +495, 12, 24, 225, 84, 86, 1112, 1114, "mm" +495, 12, 25, 226, 87, 89, 1115, 1117, "Hg" +495, 12, 26, 227, 90, 91, 1118, 1119, "." +495, 13, 1, 228, 0, 3, 1120, 1123, "The" +495, 13, 2, 229, 4, 14, 1124, 1134, "difference" +495, 13, 3, 230, 15, 17, 1135, 1137, "of" +495, 13, 4, 231, 18, 19, 1138, 1139, "2" +495, 13, 5, 232, 20, 21, 1140, 1141, "." +495, 13, 6, 233, 22, 23, 1142, 1143, "9" +495, 13, 7, 234, 24, 26, 1144, 1146, "mm" +495, 13, 8, 235, 27, 29, 1147, 1149, "Hg" +495, 13, 9, 236, 30, 31, 1150, 1151, "(" +495, 13, 10, 237, 32, 34, 1152, 1154, "95" +495, 13, 11, 238, 35, 36, 1155, 1156, "%" +495, 13, 12, 239, 37, 39, 1157, 1159, "CI" +495, 13, 13, 240, 40, 41, 1160, 1161, ":" +495, 13, 14, 241, 42, 43, 1162, 1163, "2" +495, 13, 15, 242, 44, 45, 1164, 1165, "." +495, 13, 16, 243, 46, 47, 1166, 1167, "3" +495, 13, 17, 244, 48, 49, 1168, 1169, "-" +495, 13, 18, 245, 50, 51, 1170, 1171, "3" +495, 13, 19, 246, 52, 53, 1172, 1173, "." +495, 13, 20, 247, 54, 55, 1174, 1175, "6" +495, 13, 21, 248, 56, 57, 1176, 1177, ")" +495, 13, 22, 249, 58, 61, 1178, 1181, "was" +495, 13, 23, 250, 62, 68, 1182, 1188, "highly" +495, 13, 24, 251, 69, 80, 1189, 1200, "significant" +495, 13, 25, 252, 81, 82, 1201, 1202, "(" +495, 13, 26, 253, 83, 84, 1203, 1204, "p" +495, 13, 27, 254, 85, 86, 1205, 1206, "<" +495, 13, 28, 255, 87, 88, 1207, 1208, "0" +495, 13, 29, 256, 89, 90, 1209, 1210, "." +495, 13, 30, 257, 91, 94, 1211, 1214, "001" +495, 13, 31, 258, 95, 96, 1215, 1216, "," +495, 13, 32, 259, 97, 103, 1217, 1223, "ANCOVA" +495, 13, 33, 260, 104, 105, 1224, 1225, ")" +495, 13, 34, 261, 106, 107, 1226, 1227, "." +495, 14, 1, 262, 0, 11, 1228, 1239, "Latanoprost" +495, 14, 2, 263, 12, 19, 1240, 1247, "reduced" +495, 14, 3, 264, 20, 23, 1248, 1251, "IOP" +495, 14, 4, 265, 24, 26, 1252, 1254, "at" +495, 14, 5, 266, 27, 31, 1255, 1259, "peak" +495, 14, 6, 267, 32, 34, 1260, 1262, "by" +495, 14, 7, 268, 35, 36, 1263, 1264, "8" +495, 14, 8, 269, 37, 38, 1265, 1266, "." +495, 14, 9, 270, 39, 40, 1267, 1268, "6" +495, 14, 10, 271, 41, 43, 1269, 1271, "mm" +495, 14, 11, 272, 44, 46, 1272, 1274, "Hg" +495, 14, 12, 273, 47, 48, 1275, 1276, "(" +495, 14, 13, 274, 49, 51, 1277, 1279, "32" +495, 14, 14, 275, 52, 53, 1280, 1281, "%" +495, 14, 15, 276, 54, 55, 1282, 1283, ")" +495, 14, 16, 277, 56, 64, 1284, 1292, "compared" +495, 14, 17, 278, 65, 69, 1293, 1297, "with" +495, 14, 18, 279, 70, 71, 1298, 1299, "6" +495, 14, 19, 280, 72, 73, 1300, 1301, "." +495, 14, 20, 281, 74, 75, 1302, 1303, "2" +495, 14, 21, 282, 76, 78, 1304, 1306, "mm" +495, 14, 22, 283, 79, 81, 1307, 1309, "Hg" +495, 14, 23, 284, 82, 83, 1310, 1311, "(" +495, 14, 24, 285, 84, 86, 1312, 1314, "23" +495, 14, 25, 286, 87, 88, 1315, 1316, "%" +495, 14, 26, 287, 89, 90, 1317, 1318, ")" +495, 14, 27, 288, 91, 94, 1319, 1322, "for" +495, 14, 28, 289, 95, 106, 1323, 1334, "dorzolamide" +495, 14, 29, 290, 107, 108, 1335, 1336, "," +495, 14, 30, 291, 109, 112, 1337, 1340, "and" +495, 14, 31, 292, 113, 116, 1341, 1344, "the" +495, 14, 32, 293, 117, 127, 1345, 1355, "difference" +495, 14, 33, 294, 128, 130, 1356, 1358, "of" +495, 14, 34, 295, 131, 132, 1359, 1360, "2" +495, 14, 35, 296, 133, 134, 1361, 1362, "." +495, 14, 36, 297, 135, 136, 1363, 1364, "4" +495, 14, 37, 298, 137, 139, 1365, 1367, "mm" +495, 14, 38, 299, 140, 142, 1368, 1370, "Hg" +495, 14, 39, 300, 143, 146, 1371, 1374, "was" +495, 14, 40, 301, 147, 158, 1375, 1386, "significant" +495, 14, 41, 302, 159, 160, 1387, 1388, "(" +495, 14, 42, 303, 161, 162, 1389, 1390, "p" +495, 14, 43, 304, 163, 164, 1391, 1392, "<" +495, 14, 44, 305, 165, 166, 1393, 1394, "0" +495, 14, 45, 306, 167, 168, 1395, 1396, "." +495, 14, 46, 307, 169, 172, 1397, 1400, "001" +495, 14, 47, 308, 173, 174, 1401, 1402, "," +495, 14, 48, 309, 175, 181, 1403, 1409, "ANCOVA" +495, 14, 49, 310, 182, 183, 1410, 1411, ")" +495, 14, 50, 311, 184, 185, 1412, 1413, "." +495, 15, 1, 312, 0, 3, 1414, 1417, "The" +495, 15, 2, 313, 4, 17, 1418, 1431, "corresponding" +495, 15, 3, 314, 18, 25, 1432, 1439, "figures" +495, 15, 4, 315, 26, 28, 1440, 1442, "at" +495, 15, 5, 316, 29, 35, 1443, 1449, "trough" +495, 15, 6, 317, 36, 40, 1450, 1454, "were" +495, 15, 7, 318, 41, 42, 1455, 1456, "8" +495, 15, 8, 319, 43, 44, 1457, 1458, "." +495, 15, 9, 320, 45, 46, 1459, 1460, "1" +495, 15, 10, 321, 47, 49, 1461, 1463, "mm" +495, 15, 11, 322, 50, 52, 1464, 1466, "Hg" +495, 15, 12, 323, 53, 54, 1467, 1468, "(" +495, 15, 13, 324, 55, 57, 1469, 1471, "31" +495, 15, 14, 325, 58, 59, 1472, 1473, "%" +495, 15, 15, 326, 60, 61, 1474, 1475, ")" +495, 15, 16, 327, 62, 65, 1476, 1479, "for" +495, 15, 17, 328, 66, 77, 1480, 1491, "latanoprost" +495, 15, 18, 329, 78, 81, 1492, 1495, "and" +495, 15, 19, 330, 82, 83, 1496, 1497, "4" +495, 15, 20, 331, 84, 85, 1498, 1499, "." +495, 15, 21, 332, 86, 87, 1500, 1501, "7" +495, 15, 22, 333, 88, 90, 1502, 1504, "mm" +495, 15, 23, 334, 91, 93, 1505, 1507, "Hg" +495, 15, 24, 335, 94, 95, 1508, 1509, "(" +495, 15, 25, 336, 96, 98, 1510, 1512, "17" +495, 15, 26, 337, 99, 100, 1513, 1514, "%" +495, 15, 27, 338, 101, 102, 1515, 1516, ")" +495, 15, 28, 339, 103, 106, 1517, 1520, "for" +495, 15, 29, 340, 107, 118, 1521, 1532, "dorzolamide" +495, 15, 30, 341, 119, 120, 1533, 1534, "," +495, 15, 31, 342, 121, 122, 1535, 1536, "a" +495, 15, 32, 343, 123, 134, 1537, 1548, "significant" +495, 15, 33, 344, 135, 145, 1549, 1559, "difference" +495, 15, 34, 345, 146, 148, 1560, 1562, "of" +495, 15, 35, 346, 149, 150, 1563, 1564, "3" +495, 15, 36, 347, 151, 152, 1565, 1566, "." +495, 15, 37, 348, 153, 154, 1567, 1568, "4" +495, 15, 38, 349, 155, 157, 1569, 1571, "mm" +495, 15, 39, 350, 158, 160, 1572, 1574, "Hg" +495, 15, 40, 351, 161, 162, 1575, 1576, "(" +495, 15, 41, 352, 163, 164, 1577, 1578, "p" +495, 15, 42, 353, 165, 166, 1579, 1580, "<" +495, 15, 43, 354, 167, 168, 1581, 1582, "0" +495, 15, 44, 355, 169, 170, 1583, 1584, "." +495, 15, 45, 356, 171, 174, 1585, 1588, "001" +495, 15, 46, 357, 175, 176, 1589, 1590, "," +495, 15, 47, 358, 177, 183, 1591, 1597, "ANCOVA" +495, 15, 48, 359, 184, 185, 1598, 1599, ")" +495, 15, 49, 360, 186, 187, 1600, 1601, "." +495, 16, 1, 361, 0, 4, 1602, 1606, "Both" +495, 16, 2, 362, 5, 10, 1607, 1612, "drugs" +495, 16, 3, 363, 11, 15, 1613, 1617, "were" +495, 16, 4, 364, 16, 20, 1618, 1622, "well" +495, 16, 5, 365, 21, 30, 1623, 1632, "tolerated" +495, 16, 6, 366, 31, 43, 1633, 1645, "systemically" +495, 16, 7, 367, 44, 47, 1646, 1649, "and" +495, 16, 8, 368, 48, 55, 1650, 1657, "locally" +495, 16, 9, 369, 56, 57, 1658, 1659, "." +495, 17, 1, 370, 0, 10, 1660, 1670, "CONCLUSION" +495, 17, 2, 371, 11, 12, 1671, 1672, ":" +495, 17, 3, 372, 13, 24, 1673, 1684, "Latanoprost" +495, 17, 4, 373, 25, 28, 1685, 1688, "was" +495, 17, 5, 374, 29, 37, 1689, 1697, "superior" +495, 17, 6, 375, 38, 40, 1698, 1700, "to" +495, 17, 7, 376, 41, 52, 1701, 1712, "dorzolamide" +495, 17, 8, 377, 53, 55, 1713, 1715, "in" +495, 17, 9, 378, 56, 64, 1716, 1724, "reducing" +495, 17, 10, 379, 65, 68, 1725, 1728, "the" +495, 17, 11, 380, 69, 72, 1729, 1732, "IOP" +495, 17, 12, 381, 73, 74, 1733, 1734, "," +495, 17, 13, 382, 75, 81, 1735, 1741, "judged" +495, 17, 14, 383, 82, 86, 1742, 1746, "both" +495, 17, 15, 384, 87, 91, 1747, 1751, "from" +495, 17, 16, 385, 92, 95, 1752, 1755, "the" +495, 17, 17, 386, 96, 102, 1756, 1762, "effect" +495, 17, 18, 387, 103, 105, 1763, 1765, "on" +495, 17, 19, 388, 106, 109, 1766, 1769, "IOP" +495, 17, 20, 389, 110, 112, 1770, 1772, "at" +495, 17, 21, 390, 113, 117, 1773, 1777, "peak" +495, 17, 22, 391, 118, 121, 1778, 1781, "and" +495, 17, 23, 392, 122, 128, 1782, 1788, "trough" +495, 17, 24, 393, 129, 132, 1789, 1792, "and" +495, 17, 25, 394, 133, 135, 1793, 1795, "by" +495, 17, 26, 395, 136, 139, 1796, 1799, "the" +495, 17, 27, 396, 140, 146, 1800, 1806, "effect" +495, 17, 28, 397, 147, 149, 1807, 1809, "on" +495, 17, 29, 398, 150, 157, 1810, 1817, "diurnal" +495, 17, 30, 399, 158, 161, 1818, 1821, "IOP" +495, 17, 31, 400, 162, 163, 1822, 1823, "." +495, 18, 1, 401, 0, 3, 1824, 1827, "DOI" +495, 18, 2, 402, 4, 5, 1828, 1829, ":" +495, 18, 3, 403, 6, 8, 1830, 1832, "10" +495, 18, 4, 404, 9, 10, 1833, 1834, "." +495, 18, 5, 405, 11, 15, 1835, 1839, "1136" +495, 18, 6, 406, 16, 17, 1840, 1841, "/" +495, 18, 7, 407, 18, 21, 1842, 1845, "bjo" +495, 18, 8, 408, 22, 23, 1846, 1847, "." +495, 18, 9, 409, 24, 26, 1848, 1850, "84" +495, 18, 10, 410, 27, 28, 1851, 1852, "." +495, 18, 11, 411, 29, 30, 1853, 1854, "6" +495, 18, 12, 412, 31, 32, 1855, 1856, "." +495, 18, 13, 413, 33, 36, 1857, 1860, "579" +495, 18, 14, 414, 37, 42, 1861, 1866, "PMCID" +495, 18, 15, 415, 43, 44, 1867, 1868, ":" +495, 18, 16, 416, 45, 55, 1869, 1879, "PMC1723499" +495, 18, 17, 417, 56, 60, 1880, 1884, "PMID" +495, 18, 18, 418, 61, 62, 1885, 1886, ":" +495, 18, 19, 419, 63, 71, 1887, 1895, "10837379" +495, 18, 20, 420, 72, 73, 1896, 1897, "[" +495, 18, 21, 421, 74, 81, 1898, 1905, "Indexed" +495, 18, 22, 422, 82, 85, 1906, 1909, "for" +495, 18, 23, 423, 86, 93, 1910, 1917, "MEDLINE" +495, 18, 24, 424, 94, 95, 1918, 1919, "]" diff --git a/data/gl 10837379_jshahinitiran.annodb b/data/gl 10837379_jshahinitiran.annodb new file mode 100644 index 0000000..111517f --- /dev/null +++ b/data/gl 10837379_jshahinitiran.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +1403, Journal, 0, 15, "Br J Ophthalmol", "", +1404, PublicationYear, 18, 22, "2000", "", +1405, Title, 51, 177, "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study .", "", +1410, Latanoprost, 67, 78, "latanoprost", "", +1411, Dorzolamide, 83, 94, "dorzolamide", "", +1412, Glaucoma, 112, 120, "glaucoma", "", +10331, OcularHypertension, 125, 144, "ocular hypertension", "", +25864, Duration, 149, 156, "3 month", "", +1416, Randomized, 159, 169, "randomised", "", +25870, Latanoprost, 186, 197, "Latanoprost", "", +1406, Author, 212, 227, "O ' Donoghue EP", "", +1417, Ireland, 332, 339, "Ireland", "", +1407, ObjectiveDescription, 366, 542, "To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension .", "", +26397, IOP, 392, 412, "intraocular pressure", "", +26398, IOP, 415, 418, "IOP", "", +26399, Latanoprost, 465, 476, "latanoprost", "", +26400, Dorzolamide, 480, 491, "dorzolamide", "", +26401, Glaucoma, 509, 517, "glaucoma", "", +26402, OcularHypertension, 521, 540, "ocular hypertension", "", +25867, NumberPatientsCT, 553, 556, "224", "", +1419, OpenAngleGlaucoma, 571, 590, "open angle glaucoma", "", +1421, OcularHypertension, 594, 613, "ocular hypertension", "", +25865, Duration, 634, 641, "3 month", "", +1423, OpenLabel, 642, 655, "open labelled", "", +10332, Glaucoma, 673, 681, "glaucoma", "", +25869, Randomized, 732, 742, "randomised", "", +1424, Latanoprost, 761, 772, "latanoprost", "", +1425, DoseValue, 773, 780, "0 . 005", "lat", +1426, Percentage, 781, 782, "%", "lat", +1427, Frequency, 783, 793, "once daily", "lat", +1428, Dorzolamide, 797, 808, "dorzolamide", "", +1429, DoseValue, 809, 810, "2", "dor", +1431, Percentage, 811, 812, "%", "dor", +1432, Frequency, 813, 830, "three times daily", "dor", +25868, NumberPatientsCT, 846, 849, "224", "", +31624, TimePoint, 913, 921, "3 months", "", +1435, Latanoprost, 924, 935, "latanoprost", "", +1436, Mean, 944, 948, "mean", "", +1437, Diurnal_IOP, 958, 969, "diurnal IOP", "", +1438, BaseLineValue, 975, 981, "27 . 2", "lat", +1439, SdDevBL, 987, 992, "3 . 0", "lat", +1440, mmHg, 995, 1000, "mm Hg", "lat", +1441, Reduction, 1004, 1009, "8 . 5", "lat", +1442, SdDevChangeValue, 1012, 1017, "3 . 3", "lat", +1443, mmHg, 1020, 1025, "mm Hg", "lat", +1444, Dorzolamide, 1058, 1069, "dorzolamide", "", +1445, BaseLineValue, 1075, 1081, "27 . 2", "dor", +1446, SdDevBL, 1084, 1089, "3 . 4", "dor", +1447, Reduction, 1096, 1101, "5 . 6", "dor", +1448, SdDevChangeValue, 1104, 1109, "2 . 6", "dor", +1449, mmHg, 1112, 1117, "mm Hg", "dor", +1450, DiffGroupAbsValue, 1138, 1143, "2 . 9", "", +1451, mmHg, 1144, 1149, "mm Hg", "Diff", +1452, ConfIntervalDiff, 1152, 1175, "95 % CI : 2 . 3 - 3 . 6", "Diff", +1453, PvalueDiff, 1203, 1214, "p < 0 . 001", "Diff", +1454, Latanoprost, 1228, 1239, "Latanoprost", "", +1455, Peak_IOP, 1248, 1251, "IOP", "", +1457, Reduction, 1263, 1268, "8 . 6", "Peak_lat", +1459, mmHg, 1269, 1274, "mm Hg", "Peak_lat", +10317, RelativeReduction, 1277, 1279, "32", "", +1460, Reduction, 1298, 1303, "6 . 2", "Peak_dor", +1461, mmHg, 1304, 1309, "mm Hg", "Peak_dor", +10318, RelativeReduction, 1312, 1314, "23", "", +1462, Dorzolamide, 1323, 1334, "dorzolamide", "", +1463, DiffGroupAbsValue, 1359, 1364, "2 . 4", "Peak", +1464, mmHg, 1365, 1370, "mm Hg", "Peak", +1465, PvalueDiff, 1389, 1400, "p < 0 . 001", "Peak", +10319, Trough_IOP, 1443, 1449, "trough", "", +10320, Reduction, 1455, 1460, "8 . 1", "", +10323, mmHg, 1461, 1466, "mm Hg", "", +10325, RelativeReduction, 1469, 1471, "31", "", +39018, Latanoprost, 1480, 1491, "latanoprost", "", +10322, Reduction, 1496, 1501, "4 . 7", "", +10324, mmHg, 1502, 1507, "mm Hg", "", +10326, RelativeReduction, 1510, 1512, "17", "", +10327, Dorzolamide, 1521, 1532, "dorzolamide", "", +10328, DiffGroupAbsValue, 1563, 1568, "3 . 4", "", +10329, mmHg, 1569, 1574, "mm Hg", "", +10330, PvalueDiff, 1577, 1588, "p < 0 . 001", "", +1408, ConclusionComment, 1673, 1823, "Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP .", "", +1467, Latanoprost, 1673, 1684, "Latanoprost", "", +1468, Dorzolamide, 1701, 1712, "dorzolamide", "", +1469, IOP, 1729, 1732, "IOP", "", +1471, IOP, 1766, 1769, "IOP", "", +1472, Diurnal_IOP, 1810, 1821, "diurnal IOP", "", +1409, PMID, 1887, 1895, "10837379", "", diff --git a/data/gl 10837379_jshahinitiran.n-triples b/data/gl 10837379_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10837379_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10837379_tstrakeljahn.annodb b/data/gl 10837379_tstrakeljahn.annodb new file mode 100644 index 0000000..4f439f6 --- /dev/null +++ b/data/gl 10837379_tstrakeljahn.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +3003, Journal, 3, 15, "J Ophthalmol", "", " \"J Ophthalmol\"." +3004, PublicationYear, 18, 22, "2000", "", " \"2000\"." +3013, Title, 51, 177, "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study .", "", " \"A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study .\"." +3005, Latanoprost, 67, 78, "latanoprost", "", +3006, Dorzolamide, 83, 94, "dorzolamide", "", +3007, Glaucoma, 112, 120, "glaucoma", "", " . ." +3008, OcularHypertension, 125, 144, "ocular hypertension", "", " ." +3009, Duration, 149, 156, "3 month", "", " \"3 month\"." +3010, Randomized, 159, 169, "randomised", "", " ." +3011, Ireland, 178, 185, "Ireland", "", +3012, Author, 212, 224, "O ' Donoghue", "", " \"O ' Donoghue\"." +3065, Ireland, 332, 339, "Ireland", "", +3023, ObjectiveDescription, 366, 540, "To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension", "", " \"To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension\"." +3015, IOP, 392, 412, "intraocular pressure", "", +3014, IOP, 415, 418, "IOP", "", +3016, Latanoprost, 465, 476, "latanoprost", "", +3017, Dorzolamide, 480, 491, "dorzolamide", "", +3018, Glaucoma, 509, 517, "glaucoma", "", +3019, OcularHypertension, 521, 540, "ocular hypertension", "", +3020, NumberPatientsCT, 553, 556, "224", "", " \"224\"." +3641, OpenAngleGlaucoma, 571, 590, "open angle glaucoma", "", +3026, OcularHypertension, 594, 613, "ocular hypertension", "", +3025, Duration, 634, 641, "3 month", "", +3024, OpenLabel, 642, 655, "open labelled", "", " ." +3028, Precondition, 664, 709, "Previous glaucoma medications were washed out", "", " \"Previous glaucoma medications were washed out\"." +3029, Randomized, 732, 742, "randomised", "", +3030, Latanoprost, 761, 772, "latanoprost", "", +3031, DoseValue, 773, 780, "0 . 005", "", +3032, Percentage, 781, 782, "%", "", +3033, Frequency, 783, 793, "once daily", "", +3034, Dorzolamide, 797, 808, "dorzolamide", "", +3035, DoseValue, 809, 810, "2", "", +3036, Percentage, 811, 812, "%", "", +3037, Frequency, 813, 830, "three times daily", "", +3022, NumberPatientsCT, 846, 849, "224", "", +3269, NumberPatientsCT, 859, 862, "213", "final", +3038, Duration, 913, 921, "3 months", "", +3039, Latanoprost, 924, 935, "latanoprost", "", +3040, Mean, 944, 948, "mean", "", +3041, Diurnal_IOP, 958, 969, "diurnal IOP", "", +3042, BaseLineValue, 975, 981, "27 . 2", "", +3043, SdDevBL, 984, 992, "SD 3 . 0", "", +3044, mmHg, 995, 1000, "mm Hg", "", +3045, Reduction, 1004, 1009, "8 . 5", "", +3046, SdDevChangeValue, 1012, 1017, "3 . 3", "", +3047, mmHg, 1020, 1025, "mm Hg", "", +3048, Dorzolamide, 1058, 1069, "dorzolamide", "", +3049, BaseLineValue, 1075, 1081, "27 . 2", "", +3050, SdDevBL, 1084, 1089, "3 . 4", "", +3051, Reduction, 1096, 1101, "5 . 6", "", +3052, SdDevChangeValue, 1104, 1109, "2 . 6", "", +3053, mmHg, 1112, 1117, "mm Hg", "", +3056, DiffBetweenGroups, 1138, 1143, "2 . 9", "", +3058, mmHg, 1144, 1149, "mm Hg", "", +3059, ConfIntervalDiff, 1152, 1175, "95 % CI : 2 . 3 - 3 . 6", "", +3060, PvalueDiff, 1203, 1214, "p < 0 . 001", "", +3062, Latanoprost, 1228, 1239, "Latanoprost", "", +3063, IOP, 1248, 1251, "IOP", "", +3067, Peak_IOP, 1252, 1274, "at peak by 8 . 6 mm Hg", "", +3068, Reduction, 1263, 1268, "8 . 6", "", +3069, mmHg, 1269, 1274, "mm Hg", "", +3070, RelativeReduction, 1277, 1279, "32", "", +3071, Reduction, 1298, 1303, "6 . 2", "", +3072, mmHg, 1304, 1311, "mm Hg (", "", +3073, RelativeReduction, 1312, 1314, "23", "", +3074, Dorzolamide, 1323, 1334, "dorzolamide", "", +3075, DiffBetweenGroups, 1359, 1364, "2 . 4", "", +3076, mmHg, 1365, 1370, "mm Hg", "", +3077, PvalueDiff, 1389, 1400, "p < 0 . 001", "", +3078, TimePoint, 1443, 1449, "trough", "", +3079, Reduction, 1455, 1460, "8 . 1", "", +3080, mmHg, 1461, 1466, "mm Hg", "", +3081, RelativeReduction, 1469, 1471, "31", "", +3082, Latanoprost, 1480, 1491, "latanoprost", "", +3083, Reduction, 1496, 1501, "4 . 7", "", +3084, mmHg, 1502, 1507, "mm Hg", "", +3085, RelativeReduction, 1510, 1512, "17", "", +3086, Dorzolamide, 1521, 1532, "dorzolamide", "", +3087, DiffBetweenGroups, 1563, 1568, "3 . 4", "", +3088, mmHg, 1569, 1574, "mm Hg", "", +3089, PvalueDiff, 1577, 1588, "p < 0 . 001", "", +3090, ObservedResult, 1602, 1657, "Both drugs were well tolerated systemically and locally", "", +3094, Latanoprost, 1673, 1684, "Latanoprost", "", +3096, ConclusionComment, 1673, 1821, "Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP", "", " \"Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP\"." +3095, Dorzolamide, 1701, 1712, "dorzolamide", "", +3092, IOP, 1729, 1732, "IOP", "", +3093, Peak_IOP, 1766, 1769, "IOP", "", +3091, Diurnal_IOP, 1810, 1821, "diurnal IOP", "", +3097, PMID, 1887, 1895, "10837379", "", " \"10837379\"." diff --git a/data/gl 10837379_tstrakeljahn.n-triples b/data/gl 10837379_tstrakeljahn.n-triples new file mode 100644 index 0000000..8aada34 --- /dev/null +++ b/data/gl 10837379_tstrakeljahn.n-triples @@ -0,0 +1,41 @@ +# RDF export of group: Publication + . + "Publication 8462" . + "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension : a 3 month , randomised study ." . + "O ' Donoghue" . + "2000" . + "J Ophthalmol" . + "10837379" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 8469" . + "To compare the effects on intraocular pressure ( IOP ) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension" . + "224" . + "3 month" . + . + . + . + "Latanoprost was superior to dorzolamide in reducing the IOP , judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 8484" . + "Previous glaucoma medications were washed out" . + . + . + . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10877373_admin.annodb b/data/gl 10877373_admin.annodb new file mode 100644 index 0000000..b03e614 --- /dev/null +++ b/data/gl 10877373_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\". \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2000", "", " \"2000\"." +36936, EndPointDescription, 45, 61, "Clinical success", "", +0, Title, 45, 211, "Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial .", "", " \"Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial .\". \"Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial .\"." +36935, EndPointDescription, 66, 81, "quality of life", "", +64, Brimonidine, 87, 98, "brimonidine", "", +69, DoseValue, 99, 104, "0 . 2", "", +71, Percentage, 105, 106, "%", "", +65, Timolol, 110, 117, "timolol", "", +70, DoseValue, 118, 123, "0 . 5", "", +72, Percentage, 124, 125, "%", "", +73, Frequency, 131, 142, "twice daily", "", +66, Glaucoma, 146, 154, "glaucoma", "", " . ." +67, OcularHypertension, 158, 179, "ocular t hypertension", "", " ." +68, Randomized, 184, 194, "randomized", "", " ." +20562, Brimonidine, 212, 223, "Brimonidine", "", +3, Author, 249, 258, "Javitt JC", "", " \"Javitt JC\"." +4, Author, 267, 279, "Schiffman RM", "", " \"Schiffman RM\"." +61, USA, 396, 399, "USA", "", " ." +5, ObjectiveDescription, 412, 576, "To compare the clinical success rates and quality of life impact of brimonidine 0 . 2 % with timolol 0 . 5 % in newly diagnosed patients naive to glaucoma therapy .", "", " \"To compare the clinical success rates and quality of life impact of brimonidine 0 . 2 % with timolol 0 . 5 % in newly diagnosed patients naive to glaucoma therapy .\"." +36937, EndPointDescription, 427, 443, "clinical success", "", " . ." +36938, EndPointDescription, 454, 469, "quality of life", "", " . ." +27, Brimonidine, 480, 491, "brimonidine", "", +28, DoseValue, 492, 497, "0 . 2", "", +29, Percentage, 498, 499, "%", "", +30, Timolol, 505, 512, "timolol", "", +31, DoseValue, 513, 518, "0 . 5", "", +32, Percentage, 519, 520, "%", "", +33, Precondition, 524, 574, "newly diagnosed patients naive to glaucoma therapy", "", " \"newly diagnosed patients naive to glaucoma therapy\"." +20563, Glaucoma, 558, 566, "glaucoma", "", +36934, Prospective, 589, 600, "prospective", "", " ." +7, Multicenter, 603, 614, "multicenter", "", " ." +8, Randomized, 617, 627, "randomized", "", +9, DoubleBlind, 630, 645, "double - masked", "", +10, Frequency, 711, 722, "twice daily", "", " \"twice daily\". \"twice daily\"." +11, Brimonidine, 723, 743, "brimonidine tartrate", "", " ." +12, DoseValue, 744, 749, "0 . 2", "", " \"0 . 2\"." +13, Percentage, 750, 751, "%", "", " ." +14, Timolol, 780, 795, "timolol maleate", "", " ." +15, DoseValue, 796, 801, "0 . 5", "", +16, Percentage, 802, 803, "%", "", " ." +17, Glaucoma, 821, 829, "glaucoma", "", +18, OcularHypertension, 836, 855, "ocular hypertension", "", +19, NumberPatientsCT, 872, 892, "Two hundred nineteen", "", +20, NumberPatientsArm, 920, 923, "111", "", +22, Brimonidine, 931, 942, "brimonidine", "", +21, NumberPatientsArm, 953, 956, "108", "", +23, Timolol, 964, 971, "timolol", "", +24, Frequency, 1023, 1034, "twice daily", "", +25, Duration, 1039, 1047, "4 months", "", " \"4 months\"." +36939, EndPointDescription, 1074, 1090, "clinical success", "", +25351, IOP, 1109, 1129, "intraocular pressure", "", +25352, IOP, 1132, 1135, "IOP", "", +20572, EndPointDescription, 1170, 1185, "Quality of life", "", +109, MeasurementDevice, 1217, 1283, "SF - 36 Health Survey and Glaucoma Disability Index questionnaires", "", +60, EndPointDescription, 1296, 1312, "Clinical success", "", +135, PercentageAffected, 1317, 1319, "71", "", " \"71\"." +137, NumberAffected, 1324, 1326, "75", "", " \"75\"." +110, FinalNumPatientsArm, 1329, 1332, "106", "", " \"106\"." +36, Brimonidine, 1340, 1351, "brimonidine", "", +136, PercentageAffected, 1356, 1358, "70", "", " \"70\"." +138, NumberAffected, 1363, 1365, "73", "", " \"73\"." +111, FinalNumPatientsArm, 1368, 1371, "105", "", " \"105\"." +37, Timolol, 1379, 1386, "timolol", "", +38, Mean, 1422, 1426, "mean", "", +39, IOP, 1439, 1442, "IOP", "", " . ." +116, Reduction, 1447, 1452, "6 . 5", "", " \"6 . 5\"." +41, mmHg, 1453, 1458, "mm Hg", "", " ." +42, Brimonidine, 1464, 1475, "brimonidine", "", +117, Reduction, 1480, 1485, "6 . 2", "", " \"6 . 2\"." +44, mmHg, 1486, 1491, "mm Hg", "", +45, Timolol, 1497, 1504, "timolol", "", +92910, ObservedResult, 1584, 1635, "slightly higher rate of ocular burning and stinging", "", +20565, EndPointDescription, 1608, 1622, "ocular burning", "", " . ." +20564, Smarting, 1627, 1635, "stinging", "", " ." +46, Brimonidine, 1643, 1654, "brimonidine", "", +92908, ObservedResult, 1719, 1777, "No significant chronotropic effects on the heart were seen", "", " \"No significant chronotropic effects on the heart were seen\"." +20567, EndPointDescription, 1734, 1767, "chronotropic effects on the heart", "", " . ." +47, Brimonidine, 1783, 1794, "brimonidine", "", +92909, ObservedResult, 1803, 1881, "small but significant mean decreases in heart rate were seen at months 1 and 4", "", " \"small but significant mean decreases in heart rate were seen at months 1 and 4\"." +126, Mean, 1825, 1829, "mean", "", " . ." +20569, HeartRate, 1843, 1853, "heart rate", "", " . ." +123, TimePoint, 1867, 1875, "months 1", "", +124, TimePoint, 1880, 1881, "4", "", +48, Timolol, 1887, 1894, "timolol", "", +20570, ObservedResult, 1984, 2067, "Quality of life remained stable , with no significant between - group differences .", "", " \"Quality of life remained stable , with no significant between - group differences .\"." +20571, EndPointDescription, 1984, 1999, "Quality of life", "", +49, ConclusionComment, 2082, 2273, "As a first - line agent for the treatment of glaucoma and ocular hypertension , brimonidine has clinical effectiveness equivalent to timolol , but with less chronotropic effect on the heart .", "", " \"As a first - line agent for the treatment of glaucoma and ocular hypertension , brimonidine has clinical effectiveness equivalent to timolol , but with less chronotropic effect on the heart .\"." +50, Glaucoma, 2127, 2135, "glaucoma", "", +51, OcularHypertension, 2140, 2159, "ocular hypertension", "", +52, Brimonidine, 2162, 2173, "brimonidine", "", +53, Timolol, 2215, 2222, "timolol", "", +54, ConclusionComment, 2274, 2383, "Brimonidine is a viable alternative to timolol for first - line therapy in glaucoma and ocular hypertension .", "", +55, Brimonidine, 2274, 2285, "Brimonidine", "", +56, Timolol, 2313, 2320, "timolol", "", +57, Glaucoma, 2349, 2357, "glaucoma", "", +58, OcularHypertension, 2362, 2381, "ocular hypertension", "", +59, PMID, 2391, 2399, "10877373", "", " \"10877373\"." diff --git a/data/gl 10877373_admin.n-triples b/data/gl 10877373_admin.n-triples new file mode 100644 index 0000000..f3966d2 --- /dev/null +++ b/data/gl 10877373_admin.n-triples @@ -0,0 +1,171 @@ +# RDF export of group: Publication + . + "Publication" . + "J Glaucoma" . + "Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial ." . + "Javitt JC" . + "2000" . + "J Glaucoma" . + "Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial ." . + "10877373" . + . + "Schiffman RM" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the clinical success rates and quality of life impact of brimonidine 0 . 2 % with timolol 0 . 5 % in newly diagnosed patients naive to glaucoma therapy ." . + "4 months" . + . + . + . + "As a first - line agent for the treatment of glaucoma and ocular hypertension , brimonidine has clinical effectiveness equivalent to timolol , but with less chronotropic effect on the heart ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "newly diagnosed patients naive to glaucoma therapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-CS" . + . + . + . + . + . + . + "Endpoint-QL" . + . + . + . + . + . + . + "Endpoint-IOP" . + . + . + . + . + . + . + . + "Endpoint-burning" . + . + . + . + . + . + . + "Endpoint-stinging" . + . + . + . + . + . + "Endpoint-CH" . + . + . + . + . + . + . + "Endpoint-HR" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-tim" . + "105" . + . + . + . + . + . + . + "Arm-bri" . + "106" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-tim" . + . + "twice daily" . + . + . + "Intervention-bri" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication-tim" . + . + . + . + . + "Medication-bri" . + . + "0 . 2" . + . + . +# RDF export of group: Outcome + . + "Outcome-CS-tim" . + . + "73" . + "70" . + . + "Outcome-CS-bri" . + . + "75" . + "71" . + . + "Outcome-IOP-bri" . + . + "6 . 5" . + . + "Outcome-IOP-tim" . + . + "6 . 2" . + . + "Outcome-Burning-bri" . + . + . + "Outcome-Stinging-bri" . + . + . + "Outcome-CH-bri" . + . + "No significant chronotropic effects on the heart were seen" . + . + "Outcome-HR-tim" . + . + "small but significant mean decreases in heart rate were seen at months 1 and 4" . + . + "Outcome-QL" . + . + "Quality of life remained stable , with no significant between - group differences ." . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10877373_export.csv b/data/gl 10877373_export.csv new file mode 100644 index 0000000..d297864 --- /dev/null +++ b/data/gl 10877373_export.csv @@ -0,0 +1,446 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +494, 1, 1, 1, 0, 1, 0, 1, "J" +494, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +494, 1, 3, 3, 11, 12, 11, 12, "." +494, 2, 1, 4, 0, 4, 13, 17, "2000" +494, 2, 2, 5, 5, 8, 18, 21, "Jun" +494, 2, 3, 6, 9, 10, 22, 23, ";" +494, 2, 4, 7, 11, 12, 24, 25, "9" +494, 2, 5, 8, 13, 14, 26, 27, "(" +494, 2, 6, 9, 15, 16, 28, 29, "3" +494, 2, 7, 10, 17, 18, 30, 31, ")" +494, 2, 8, 11, 19, 20, 32, 33, ":" +494, 2, 9, 12, 21, 24, 34, 37, "224" +494, 2, 10, 13, 25, 26, 38, 39, "-" +494, 2, 11, 14, 27, 29, 40, 42, "34" +494, 2, 12, 15, 30, 31, 43, 44, "." +494, 3, 1, 16, 0, 8, 45, 53, "Clinical" +494, 3, 2, 17, 9, 16, 54, 61, "success" +494, 3, 3, 18, 17, 20, 62, 65, "and" +494, 3, 4, 19, 21, 28, 66, 73, "quality" +494, 3, 5, 20, 29, 31, 74, 76, "of" +494, 3, 6, 21, 32, 36, 77, 81, "life" +494, 3, 7, 22, 37, 41, 82, 86, "with" +494, 3, 8, 23, 42, 53, 87, 98, "brimonidine" +494, 3, 9, 24, 54, 55, 99, 100, "0" +494, 3, 10, 25, 56, 57, 101, 102, "." +494, 3, 11, 26, 58, 59, 103, 104, "2" +494, 3, 12, 27, 60, 61, 105, 106, "%" +494, 3, 13, 28, 62, 64, 107, 109, "or" +494, 3, 14, 29, 65, 72, 110, 117, "timolol" +494, 3, 15, 30, 73, 74, 118, 119, "0" +494, 3, 16, 31, 75, 76, 120, 121, "." +494, 3, 17, 32, 77, 78, 122, 123, "5" +494, 3, 18, 33, 79, 80, 124, 125, "%" +494, 3, 19, 34, 81, 85, 126, 130, "used" +494, 3, 20, 35, 86, 91, 131, 136, "twice" +494, 3, 21, 36, 92, 97, 137, 142, "daily" +494, 3, 22, 37, 98, 100, 143, 145, "in" +494, 3, 23, 38, 101, 109, 146, 154, "glaucoma" +494, 3, 24, 39, 110, 112, 155, 157, "or" +494, 3, 25, 40, 113, 119, 158, 164, "ocular" +494, 3, 26, 41, 120, 121, 165, 166, "t" +494, 3, 27, 42, 122, 134, 167, 179, "hypertension" +494, 3, 28, 43, 135, 136, 180, 181, ":" +494, 3, 29, 44, 137, 138, 182, 183, "a" +494, 3, 30, 45, 139, 149, 184, 194, "randomized" +494, 3, 31, 46, 150, 158, 195, 203, "clinical" +494, 3, 32, 47, 159, 164, 204, 209, "trial" +494, 3, 33, 48, 165, 166, 210, 211, "." +494, 4, 1, 49, 0, 11, 212, 223, "Brimonidine" +494, 4, 2, 50, 12, 20, 224, 232, "Outcomes" +494, 4, 3, 51, 21, 26, 233, 238, "Study" +494, 4, 4, 52, 27, 32, 239, 244, "Group" +494, 4, 5, 53, 33, 34, 245, 246, "I" +494, 4, 6, 54, 35, 36, 247, 248, "." +494, 4, 7, 55, 37, 43, 249, 255, "Javitt" +494, 4, 8, 56, 44, 46, 256, 258, "JC" +494, 4, 9, 57, 47, 48, 259, 260, "(" +494, 4, 10, 58, 49, 50, 261, 262, "1" +494, 4, 11, 59, 51, 52, 263, 264, ")" +494, 4, 12, 60, 53, 54, 265, 266, "," +494, 4, 13, 61, 55, 64, 267, 276, "Schiffman" +494, 4, 14, 62, 65, 67, 277, 279, "RM" +494, 4, 15, 63, 68, 69, 280, 281, "." +494, 5, 1, 64, 0, 6, 282, 288, "Author" +494, 5, 2, 65, 7, 18, 289, 300, "information" +494, 5, 3, 66, 19, 20, 301, 302, ":" +494, 5, 4, 67, 21, 22, 303, 304, "(" +494, 5, 5, 68, 23, 24, 305, 306, "1" +494, 5, 6, 69, 25, 26, 307, 308, ")" +494, 5, 7, 70, 27, 37, 309, 319, "Department" +494, 5, 8, 71, 38, 40, 320, 322, "of" +494, 5, 9, 72, 41, 54, 323, 336, "Ophthalmology" +494, 5, 10, 73, 55, 56, 337, 338, "," +494, 5, 11, 74, 57, 67, 339, 349, "Georgetown" +494, 5, 12, 75, 68, 78, 350, 360, "University" +494, 5, 13, 76, 79, 86, 361, 368, "Medical" +494, 5, 14, 77, 87, 93, 369, 375, "Center" +494, 5, 15, 78, 94, 95, 376, 377, "," +494, 5, 16, 79, 96, 106, 378, 388, "Washington" +494, 5, 17, 80, 107, 108, 389, 390, "," +494, 5, 18, 81, 109, 111, 391, 393, "DC" +494, 5, 19, 82, 112, 113, 394, 395, "," +494, 5, 20, 83, 114, 117, 396, 399, "USA" +494, 5, 21, 84, 118, 119, 400, 401, "." +494, 6, 1, 85, 0, 7, 402, 409, "PURPOSE" +494, 6, 2, 86, 8, 9, 410, 411, ":" +494, 6, 3, 87, 10, 12, 412, 414, "To" +494, 6, 4, 88, 13, 20, 415, 422, "compare" +494, 6, 5, 89, 21, 24, 423, 426, "the" +494, 6, 6, 90, 25, 33, 427, 435, "clinical" +494, 6, 7, 91, 34, 41, 436, 443, "success" +494, 6, 8, 92, 42, 47, 444, 449, "rates" +494, 6, 9, 93, 48, 51, 450, 453, "and" +494, 6, 10, 94, 52, 59, 454, 461, "quality" +494, 6, 11, 95, 60, 62, 462, 464, "of" +494, 6, 12, 96, 63, 67, 465, 469, "life" +494, 6, 13, 97, 68, 74, 470, 476, "impact" +494, 6, 14, 98, 75, 77, 477, 479, "of" +494, 6, 15, 99, 78, 89, 480, 491, "brimonidine" +494, 6, 16, 100, 90, 91, 492, 493, "0" +494, 6, 17, 101, 92, 93, 494, 495, "." +494, 6, 18, 102, 94, 95, 496, 497, "2" +494, 6, 19, 103, 96, 97, 498, 499, "%" +494, 6, 20, 104, 98, 102, 500, 504, "with" +494, 6, 21, 105, 103, 110, 505, 512, "timolol" +494, 6, 22, 106, 111, 112, 513, 514, "0" +494, 6, 23, 107, 113, 114, 515, 516, "." +494, 6, 24, 108, 115, 116, 517, 518, "5" +494, 6, 25, 109, 117, 118, 519, 520, "%" +494, 6, 26, 110, 119, 121, 521, 523, "in" +494, 6, 27, 111, 122, 127, 524, 529, "newly" +494, 6, 28, 112, 128, 137, 530, 539, "diagnosed" +494, 6, 29, 113, 138, 146, 540, 548, "patients" +494, 6, 30, 114, 147, 152, 549, 554, "naive" +494, 6, 31, 115, 153, 155, 555, 557, "to" +494, 6, 32, 116, 156, 164, 558, 566, "glaucoma" +494, 6, 33, 117, 165, 172, 567, 574, "therapy" +494, 6, 34, 118, 173, 174, 575, 576, "." +494, 7, 1, 119, 0, 7, 577, 584, "METHODS" +494, 7, 2, 120, 8, 9, 585, 586, ":" +494, 7, 3, 121, 10, 11, 587, 588, "A" +494, 7, 4, 122, 12, 23, 589, 600, "prospective" +494, 7, 5, 123, 24, 25, 601, 602, "," +494, 7, 6, 124, 26, 37, 603, 614, "multicenter" +494, 7, 7, 125, 38, 39, 615, 616, "," +494, 7, 8, 126, 40, 50, 617, 627, "randomized" +494, 7, 9, 127, 51, 52, 628, 629, "," +494, 7, 10, 128, 53, 59, 630, 636, "double" +494, 7, 11, 129, 60, 61, 637, 638, "-" +494, 7, 12, 130, 62, 68, 639, 645, "masked" +494, 7, 13, 131, 69, 70, 646, 647, "," +494, 7, 14, 132, 71, 79, 648, 656, "clinical" +494, 7, 15, 133, 80, 93, 657, 670, "effectiveness" +494, 7, 16, 134, 94, 99, 671, 676, "trial" +494, 7, 17, 135, 100, 102, 677, 679, "in" +494, 7, 18, 136, 103, 108, 680, 685, "which" +494, 7, 19, 137, 109, 112, 686, 689, "the" +494, 7, 20, 138, 113, 121, 690, 698, "clinical" +494, 7, 21, 139, 122, 130, 699, 707, "outcomes" +494, 7, 22, 140, 131, 133, 708, 710, "of" +494, 7, 23, 141, 134, 139, 711, 716, "twice" +494, 7, 24, 142, 140, 145, 717, 722, "daily" +494, 7, 25, 143, 146, 157, 723, 734, "brimonidine" +494, 7, 26, 144, 158, 166, 735, 743, "tartrate" +494, 7, 27, 145, 167, 168, 744, 745, "0" +494, 7, 28, 146, 169, 170, 746, 747, "." +494, 7, 29, 147, 171, 172, 748, 749, "2" +494, 7, 30, 148, 173, 174, 750, 751, "%" +494, 7, 31, 149, 175, 179, 752, 756, "were" +494, 7, 32, 150, 180, 188, 757, 765, "compared" +494, 7, 33, 151, 189, 193, 766, 770, "with" +494, 7, 34, 152, 194, 199, 771, 776, "those" +494, 7, 35, 153, 200, 202, 777, 779, "of" +494, 7, 36, 154, 203, 210, 780, 787, "timolol" +494, 7, 37, 155, 211, 218, 788, 795, "maleate" +494, 7, 38, 156, 219, 220, 796, 797, "0" +494, 7, 39, 157, 221, 222, 798, 799, "." +494, 7, 40, 158, 223, 224, 800, 801, "5" +494, 7, 41, 159, 225, 226, 802, 803, "%" +494, 7, 42, 160, 227, 229, 804, 806, "in" +494, 7, 43, 161, 230, 238, 807, 815, "patients" +494, 7, 44, 162, 239, 243, 816, 820, "with" +494, 7, 45, 163, 244, 252, 821, 829, "glaucoma" +494, 7, 46, 164, 253, 256, 830, 833, "and" +494, 7, 47, 165, 257, 258, 834, 835, "'" +494, 7, 48, 166, 259, 265, 836, 842, "ocular" +494, 7, 49, 167, 266, 278, 843, 855, "hypertension" +494, 7, 50, 168, 279, 282, 856, 859, "was" +494, 7, 51, 169, 283, 292, 860, 869, "conducted" +494, 7, 52, 170, 293, 294, 870, 871, "." +494, 8, 1, 171, 0, 3, 872, 875, "Two" +494, 8, 2, 172, 4, 11, 876, 883, "hundred" +494, 8, 3, 173, 12, 20, 884, 892, "nineteen" +494, 8, 4, 174, 21, 29, 893, 901, "patients" +494, 8, 5, 175, 30, 34, 902, 906, "were" +494, 8, 6, 176, 35, 43, 907, 915, "enrolled" +494, 8, 7, 177, 44, 45, 916, 917, "-" +494, 8, 8, 178, 46, 47, 918, 919, "-" +494, 8, 9, 179, 48, 51, 920, 923, "111" +494, 8, 10, 180, 52, 54, 924, 926, "in" +494, 8, 11, 181, 55, 58, 927, 930, "the" +494, 8, 12, 182, 59, 70, 931, 942, "brimonidine" +494, 8, 13, 183, 71, 76, 943, 948, "group" +494, 8, 14, 184, 77, 80, 949, 952, "and" +494, 8, 15, 185, 81, 84, 953, 956, "108" +494, 8, 16, 186, 85, 87, 957, 959, "in" +494, 8, 17, 187, 88, 91, 960, 963, "the" +494, 8, 18, 188, 92, 99, 964, 971, "timolol" +494, 8, 19, 189, 100, 105, 972, 977, "group" +494, 8, 20, 190, 106, 107, 978, 979, "." +494, 9, 1, 191, 0, 8, 980, 988, "Patients" +494, 9, 2, 192, 9, 18, 989, 998, "instilled" +494, 9, 3, 193, 19, 24, 999, 1004, "their" +494, 9, 4, 194, 25, 30, 1005, 1010, "study" +494, 9, 5, 195, 31, 42, 1011, 1022, "medications" +494, 9, 6, 196, 43, 48, 1023, 1028, "twice" +494, 9, 7, 197, 49, 54, 1029, 1034, "daily" +494, 9, 8, 198, 55, 58, 1035, 1038, "for" +494, 9, 9, 199, 59, 60, 1039, 1040, "4" +494, 9, 10, 200, 61, 67, 1041, 1047, "months" +494, 9, 11, 201, 68, 69, 1048, 1049, "." +494, 10, 1, 202, 0, 7, 1050, 1057, "Factors" +494, 10, 2, 203, 8, 11, 1058, 1061, "for" +494, 10, 3, 204, 12, 23, 1062, 1073, "determining" +494, 10, 4, 205, 24, 32, 1074, 1082, "clinical" +494, 10, 5, 206, 33, 40, 1083, 1090, "success" +494, 10, 6, 207, 41, 45, 1091, 1095, "were" +494, 10, 7, 208, 46, 55, 1096, 1105, "reduction" +494, 10, 8, 209, 56, 58, 1106, 1108, "of" +494, 10, 9, 210, 59, 70, 1109, 1120, "intraocular" +494, 10, 10, 211, 71, 79, 1121, 1129, "pressure" +494, 10, 11, 212, 80, 81, 1130, 1131, "(" +494, 10, 12, 213, 82, 85, 1132, 1135, "IOP" +494, 10, 13, 214, 86, 87, 1136, 1137, ")" +494, 10, 14, 215, 88, 89, 1138, 1139, "," +494, 10, 15, 216, 90, 96, 1140, 1146, "safety" +494, 10, 16, 217, 97, 98, 1147, 1148, "," +494, 10, 17, 218, 99, 102, 1149, 1152, "and" +494, 10, 18, 219, 103, 110, 1153, 1160, "adverse" +494, 10, 19, 220, 111, 117, 1161, 1167, "events" +494, 10, 20, 221, 118, 119, 1168, 1169, "." +494, 11, 1, 222, 0, 7, 1170, 1177, "Quality" +494, 11, 2, 223, 8, 10, 1178, 1180, "of" +494, 11, 3, 224, 11, 15, 1181, 1185, "life" +494, 11, 4, 225, 16, 23, 1186, 1193, "effects" +494, 11, 5, 226, 24, 28, 1194, 1198, "were" +494, 11, 6, 227, 29, 37, 1199, 1207, "assessed" +494, 11, 7, 228, 38, 42, 1208, 1212, "with" +494, 11, 8, 229, 43, 46, 1213, 1216, "the" +494, 11, 9, 230, 47, 49, 1217, 1219, "SF" +494, 11, 10, 231, 50, 51, 1220, 1221, "-" +494, 11, 11, 232, 52, 54, 1222, 1224, "36" +494, 11, 12, 233, 55, 61, 1225, 1231, "Health" +494, 11, 13, 234, 62, 68, 1232, 1238, "Survey" +494, 11, 14, 235, 69, 72, 1239, 1242, "and" +494, 11, 15, 236, 73, 81, 1243, 1251, "Glaucoma" +494, 11, 16, 237, 82, 92, 1252, 1262, "Disability" +494, 11, 17, 238, 93, 98, 1263, 1268, "Index" +494, 11, 18, 239, 99, 113, 1269, 1283, "questionnaires" +494, 11, 19, 240, 114, 115, 1284, 1285, "." +494, 12, 1, 241, 0, 7, 1286, 1293, "RESULTS" +494, 12, 2, 242, 8, 9, 1294, 1295, ":" +494, 12, 3, 243, 10, 18, 1296, 1304, "Clinical" +494, 12, 4, 244, 19, 26, 1305, 1312, "success" +494, 12, 5, 245, 27, 30, 1313, 1316, "was" +494, 12, 6, 246, 31, 33, 1317, 1319, "71" +494, 12, 7, 247, 34, 35, 1320, 1321, "%" +494, 12, 8, 248, 36, 37, 1322, 1323, "(" +494, 12, 9, 249, 38, 40, 1324, 1326, "75" +494, 12, 10, 250, 41, 42, 1327, 1328, "/" +494, 12, 11, 251, 43, 46, 1329, 1332, "106" +494, 12, 12, 252, 47, 48, 1333, 1334, ")" +494, 12, 13, 253, 49, 53, 1335, 1339, "with" +494, 12, 14, 254, 54, 65, 1340, 1351, "brimonidine" +494, 12, 15, 255, 66, 69, 1352, 1355, "and" +494, 12, 16, 256, 70, 72, 1356, 1358, "70" +494, 12, 17, 257, 73, 74, 1359, 1360, "%" +494, 12, 18, 258, 75, 76, 1361, 1362, "(" +494, 12, 19, 259, 77, 79, 1363, 1365, "73" +494, 12, 20, 260, 80, 81, 1366, 1367, "/" +494, 12, 21, 261, 82, 85, 1368, 1371, "105" +494, 12, 22, 262, 86, 87, 1372, 1373, ")" +494, 12, 23, 263, 88, 92, 1374, 1378, "with" +494, 12, 24, 264, 93, 100, 1379, 1386, "timolol" +494, 12, 25, 265, 101, 103, 1387, 1389, "as" +494, 12, 26, 266, 104, 111, 1390, 1397, "initial" +494, 12, 27, 267, 112, 121, 1398, 1407, "treatment" +494, 12, 28, 268, 122, 123, 1408, 1409, "." +494, 13, 1, 269, 0, 3, 1410, 1413, "The" +494, 13, 2, 270, 4, 11, 1414, 1421, "overall" +494, 13, 3, 271, 12, 16, 1422, 1426, "mean" +494, 13, 4, 272, 17, 25, 1427, 1435, "decrease" +494, 13, 5, 273, 26, 28, 1436, 1438, "in" +494, 13, 6, 274, 29, 32, 1439, 1442, "IOP" +494, 13, 7, 275, 33, 36, 1443, 1446, "was" +494, 13, 8, 276, 37, 38, 1447, 1448, "6" +494, 13, 9, 277, 39, 40, 1449, 1450, "." +494, 13, 10, 278, 41, 42, 1451, 1452, "5" +494, 13, 11, 279, 43, 45, 1453, 1455, "mm" +494, 13, 12, 280, 46, 48, 1456, 1458, "Hg" +494, 13, 13, 281, 49, 53, 1459, 1463, "with" +494, 13, 14, 282, 54, 65, 1464, 1475, "brimonidine" +494, 13, 15, 283, 66, 69, 1476, 1479, "and" +494, 13, 16, 284, 70, 71, 1480, 1481, "6" +494, 13, 17, 285, 72, 73, 1482, 1483, "." +494, 13, 18, 286, 74, 75, 1484, 1485, "2" +494, 13, 19, 287, 76, 78, 1486, 1488, "mm" +494, 13, 20, 288, 79, 81, 1489, 1491, "Hg" +494, 13, 21, 289, 82, 86, 1492, 1496, "with" +494, 13, 22, 290, 87, 94, 1497, 1504, "timolol" +494, 13, 23, 291, 95, 96, 1505, 1506, "." +494, 14, 1, 292, 0, 3, 1507, 1510, "Few" +494, 14, 2, 293, 4, 12, 1511, 1519, "patients" +494, 14, 3, 294, 13, 21, 1520, 1528, "reported" +494, 14, 4, 295, 22, 23, 1529, 1530, "a" +494, 14, 5, 296, 24, 32, 1531, 1539, "specific" +494, 14, 6, 297, 33, 40, 1540, 1547, "adverse" +494, 14, 7, 298, 41, 46, 1548, 1553, "event" +494, 14, 8, 299, 47, 50, 1554, 1557, "and" +494, 14, 9, 300, 51, 52, 1558, 1559, "," +494, 14, 10, 301, 53, 57, 1560, 1564, "with" +494, 14, 11, 302, 58, 61, 1565, 1568, "the" +494, 14, 12, 303, 62, 71, 1569, 1578, "exception" +494, 14, 13, 304, 72, 74, 1579, 1581, "of" +494, 14, 14, 305, 75, 76, 1582, 1583, "a" +494, 14, 15, 306, 77, 85, 1584, 1592, "slightly" +494, 14, 16, 307, 86, 92, 1593, 1599, "higher" +494, 14, 17, 308, 93, 97, 1600, 1604, "rate" +494, 14, 18, 309, 98, 100, 1605, 1607, "of" +494, 14, 19, 310, 101, 107, 1608, 1614, "ocular" +494, 14, 20, 311, 108, 115, 1615, 1622, "burning" +494, 14, 21, 312, 116, 119, 1623, 1626, "and" +494, 14, 22, 313, 120, 128, 1627, 1635, "stinging" +494, 14, 23, 314, 129, 131, 1636, 1638, "in" +494, 14, 24, 315, 132, 135, 1639, 1642, "the" +494, 14, 25, 316, 136, 147, 1643, 1654, "brimonidine" +494, 14, 26, 317, 148, 153, 1655, 1660, "group" +494, 14, 27, 318, 154, 155, 1661, 1662, "," +494, 14, 28, 319, 156, 161, 1663, 1668, "there" +494, 14, 29, 320, 162, 166, 1669, 1673, "were" +494, 14, 30, 321, 167, 169, 1674, 1676, "no" +494, 14, 31, 322, 170, 181, 1677, 1688, "significant" +494, 14, 32, 323, 182, 189, 1689, 1696, "between" +494, 14, 33, 324, 190, 191, 1697, 1698, "-" +494, 14, 34, 325, 192, 197, 1699, 1704, "group" +494, 14, 35, 326, 198, 209, 1705, 1716, "differences" +494, 14, 36, 327, 210, 211, 1717, 1718, "." +494, 15, 1, 328, 0, 2, 1719, 1721, "No" +494, 15, 2, 329, 3, 14, 1722, 1733, "significant" +494, 15, 3, 330, 15, 27, 1734, 1746, "chronotropic" +494, 15, 4, 331, 28, 35, 1747, 1754, "effects" +494, 15, 5, 332, 36, 38, 1755, 1757, "on" +494, 15, 6, 333, 39, 42, 1758, 1761, "the" +494, 15, 7, 334, 43, 48, 1762, 1767, "heart" +494, 15, 8, 335, 49, 53, 1768, 1772, "were" +494, 15, 9, 336, 54, 58, 1773, 1777, "seen" +494, 15, 10, 337, 59, 63, 1778, 1782, "with" +494, 15, 11, 338, 64, 75, 1783, 1794, "brimonidine" +494, 15, 12, 339, 76, 77, 1795, 1796, "," +494, 15, 13, 340, 78, 83, 1797, 1802, "while" +494, 15, 14, 341, 84, 89, 1803, 1808, "small" +494, 15, 15, 342, 90, 93, 1809, 1812, "but" +494, 15, 16, 343, 94, 105, 1813, 1824, "significant" +494, 15, 17, 344, 106, 110, 1825, 1829, "mean" +494, 15, 18, 345, 111, 120, 1830, 1839, "decreases" +494, 15, 19, 346, 121, 123, 1840, 1842, "in" +494, 15, 20, 347, 124, 129, 1843, 1848, "heart" +494, 15, 21, 348, 130, 134, 1849, 1853, "rate" +494, 15, 22, 349, 135, 139, 1854, 1858, "were" +494, 15, 23, 350, 140, 144, 1859, 1863, "seen" +494, 15, 24, 351, 145, 147, 1864, 1866, "at" +494, 15, 25, 352, 148, 154, 1867, 1873, "months" +494, 15, 26, 353, 155, 156, 1874, 1875, "1" +494, 15, 27, 354, 157, 160, 1876, 1879, "and" +494, 15, 28, 355, 161, 162, 1880, 1881, "4" +494, 15, 29, 356, 163, 167, 1882, 1886, "with" +494, 15, 30, 357, 168, 175, 1887, 1894, "timolol" +494, 15, 31, 358, 176, 177, 1895, 1896, "." +494, 16, 1, 359, 0, 4, 1897, 1901, "Mean" +494, 16, 2, 360, 5, 13, 1902, 1910, "systolic" +494, 16, 3, 361, 14, 17, 1911, 1914, "and" +494, 16, 4, 362, 18, 27, 1915, 1924, "diastolic" +494, 16, 5, 363, 28, 33, 1925, 1930, "blood" +494, 16, 6, 364, 34, 42, 1931, 1939, "pressure" +494, 16, 7, 365, 43, 51, 1940, 1948, "remained" +494, 16, 8, 366, 52, 62, 1949, 1959, "relatively" +494, 16, 9, 367, 63, 69, 1960, 1966, "stable" +494, 16, 10, 368, 70, 72, 1967, 1969, "in" +494, 16, 11, 369, 73, 77, 1970, 1974, "both" +494, 16, 12, 370, 78, 84, 1975, 1981, "groups" +494, 16, 13, 371, 85, 86, 1982, 1983, "." +494, 17, 1, 372, 0, 7, 1984, 1991, "Quality" +494, 17, 2, 373, 8, 10, 1992, 1994, "of" +494, 17, 3, 374, 11, 15, 1995, 1999, "life" +494, 17, 4, 375, 16, 24, 2000, 2008, "remained" +494, 17, 5, 376, 25, 31, 2009, 2015, "stable" +494, 17, 6, 377, 32, 33, 2016, 2017, "," +494, 17, 7, 378, 34, 38, 2018, 2022, "with" +494, 17, 8, 379, 39, 41, 2023, 2025, "no" +494, 17, 9, 380, 42, 53, 2026, 2037, "significant" +494, 17, 10, 381, 54, 61, 2038, 2045, "between" +494, 17, 11, 382, 62, 63, 2046, 2047, "-" +494, 17, 12, 383, 64, 69, 2048, 2053, "group" +494, 17, 13, 384, 70, 81, 2054, 2065, "differences" +494, 17, 14, 385, 82, 83, 2066, 2067, "." +494, 18, 1, 386, 0, 11, 2068, 2079, "CONCLUSIONS" +494, 18, 2, 387, 12, 13, 2080, 2081, ":" +494, 18, 3, 388, 14, 16, 2082, 2084, "As" +494, 18, 4, 389, 17, 18, 2085, 2086, "a" +494, 18, 5, 390, 19, 24, 2087, 2092, "first" +494, 18, 6, 391, 25, 26, 2093, 2094, "-" +494, 18, 7, 392, 27, 31, 2095, 2099, "line" +494, 18, 8, 393, 32, 37, 2100, 2105, "agent" +494, 18, 9, 394, 38, 41, 2106, 2109, "for" +494, 18, 10, 395, 42, 45, 2110, 2113, "the" +494, 18, 11, 396, 46, 55, 2114, 2123, "treatment" +494, 18, 12, 397, 56, 58, 2124, 2126, "of" +494, 18, 13, 398, 59, 67, 2127, 2135, "glaucoma" +494, 18, 14, 399, 68, 71, 2136, 2139, "and" +494, 18, 15, 400, 72, 78, 2140, 2146, "ocular" +494, 18, 16, 401, 79, 91, 2147, 2159, "hypertension" +494, 18, 17, 402, 92, 93, 2160, 2161, "," +494, 18, 18, 403, 94, 105, 2162, 2173, "brimonidine" +494, 18, 19, 404, 106, 109, 2174, 2177, "has" +494, 18, 20, 405, 110, 118, 2178, 2186, "clinical" +494, 18, 21, 406, 119, 132, 2187, 2200, "effectiveness" +494, 18, 22, 407, 133, 143, 2201, 2211, "equivalent" +494, 18, 23, 408, 144, 146, 2212, 2214, "to" +494, 18, 24, 409, 147, 154, 2215, 2222, "timolol" +494, 18, 25, 410, 155, 156, 2223, 2224, "," +494, 18, 26, 411, 157, 160, 2225, 2228, "but" +494, 18, 27, 412, 161, 165, 2229, 2233, "with" +494, 18, 28, 413, 166, 170, 2234, 2238, "less" +494, 18, 29, 414, 171, 183, 2239, 2251, "chronotropic" +494, 18, 30, 415, 184, 190, 2252, 2258, "effect" +494, 18, 31, 416, 191, 193, 2259, 2261, "on" +494, 18, 32, 417, 194, 197, 2262, 2265, "the" +494, 18, 33, 418, 198, 203, 2266, 2271, "heart" +494, 18, 34, 419, 204, 205, 2272, 2273, "." +494, 19, 1, 420, 0, 11, 2274, 2285, "Brimonidine" +494, 19, 2, 421, 12, 14, 2286, 2288, "is" +494, 19, 3, 422, 15, 16, 2289, 2290, "a" +494, 19, 4, 423, 17, 23, 2291, 2297, "viable" +494, 19, 5, 424, 24, 35, 2298, 2309, "alternative" +494, 19, 6, 425, 36, 38, 2310, 2312, "to" +494, 19, 7, 426, 39, 46, 2313, 2320, "timolol" +494, 19, 8, 427, 47, 50, 2321, 2324, "for" +494, 19, 9, 428, 51, 56, 2325, 2330, "first" +494, 19, 10, 429, 57, 58, 2331, 2332, "-" +494, 19, 11, 430, 59, 63, 2333, 2337, "line" +494, 19, 12, 431, 64, 71, 2338, 2345, "therapy" +494, 19, 13, 432, 72, 74, 2346, 2348, "in" +494, 19, 14, 433, 75, 83, 2349, 2357, "glaucoma" +494, 19, 15, 434, 84, 87, 2358, 2361, "and" +494, 19, 16, 435, 88, 94, 2362, 2368, "ocular" +494, 19, 17, 436, 95, 107, 2369, 2381, "hypertension" +494, 19, 18, 437, 108, 109, 2382, 2383, "." +494, 20, 1, 438, 0, 4, 2384, 2388, "PMID" +494, 20, 2, 439, 5, 6, 2389, 2390, ":" +494, 20, 3, 440, 7, 15, 2391, 2399, "10877373" +494, 20, 4, 441, 16, 17, 2400, 2401, "[" +494, 20, 5, 442, 18, 25, 2402, 2409, "Indexed" +494, 20, 6, 443, 26, 29, 2410, 2413, "for" +494, 20, 7, 444, 30, 37, 2414, 2421, "MEDLINE" +494, 20, 8, 445, 38, 39, 2422, 2423, "]" diff --git a/data/gl 10877373_jshahinitiran.annodb b/data/gl 10877373_jshahinitiran.annodb new file mode 100644 index 0000000..a2982f2 --- /dev/null +++ b/data/gl 10877373_jshahinitiran.annodb @@ -0,0 +1,77 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +1473, Journal, 0, 10, "J Glaucoma", "", +1474, PublicationYear, 13, 17, "2000", "", +25871, Title, 45, 211, "Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial .", "", +25873, Brimonidine, 87, 98, "brimonidine", "", +25874, DoseValue, 99, 104, "0 . 2", "", +25876, Percentage, 105, 106, "%", "", +25878, Timolol, 110, 117, "timolol", "", +25875, DoseValue, 118, 123, "0 . 5", "", +25877, Percentage, 124, 125, "%", "", +25879, Frequency, 131, 142, "twice daily", "", +25880, Glaucoma, 146, 154, "glaucoma", "", +25881, OcularHypertension, 158, 179, "ocular t hypertension", "", +25882, Randomized, 184, 194, "randomized", "", +25883, Brimonidine, 212, 223, "Brimonidine", "", +1476, Author, 249, 258, "Javitt JC", "", +1477, Author, 267, 279, "Schiffman RM", "", +1544, USA, 396, 399, "USA", "", +1478, ObjectiveDescription, 412, 576, "To compare the clinical success rates and quality of life impact of brimonidine 0 . 2 % with timolol 0 . 5 % in newly diagnosed patients naive to glaucoma therapy .", "", +1502, Brimonidine, 480, 491, "brimonidine", "", +1503, DoseValue, 492, 497, "0 . 2", "bri", +1504, Percentage, 498, 499, "%", "bri", +1506, Timolol, 505, 512, "timolol", "", +1507, DoseValue, 513, 518, "0 . 5", "tim", +1508, Percentage, 519, 520, "%", "tim", +1509, Precondition, 524, 574, "newly diagnosed patients naive to glaucoma therapy", "", +26403, Glaucoma, 558, 566, "glaucoma", "", +39019, Prospective, 589, 600, "prospective", "", +1480, Multicenter, 603, 614, "multicenter", "", +1481, Randomized, 617, 627, "randomized", "", +1482, DoubleBlind, 630, 645, "double - masked", "", +1483, Frequency, 711, 722, "twice daily", "bri", +1484, Brimonidine, 723, 743, "brimonidine tartrate", "", +1485, DoseValue, 744, 749, "0 . 2", "bri", +1486, Percentage, 750, 751, "%", "bri", +1487, Timolol, 780, 795, "timolol maleate", "", +1488, DoseValue, 796, 801, "0 . 5", "tim", +1490, Percentage, 802, 803, "%", "tim", +1491, Glaucoma, 821, 829, "glaucoma", "", +1492, OcularHypertension, 836, 855, "ocular hypertension", "", +1493, NumberPatientsCT, 872, 892, "Two hundred nineteen", "", +1494, NumberPatientsArm, 920, 923, "111", "bri", +1496, Brimonidine, 931, 942, "brimonidine", "", +1495, NumberPatientsArm, 953, 956, "108", "tim", +1497, Timolol, 964, 971, "timolol", "", +1498, Frequency, 1023, 1034, "twice daily", "", +1499, Duration, 1039, 1047, "4 months", "", +25884, IOP, 1109, 1129, "intraocular pressure", "", +25885, IOP, 1132, 1135, "IOP", "", +26404, Glaucoma, 1243, 1251, "Glaucoma", "", +1541, EndPointDescription, 1296, 1312, "Clinical success", "CS", +1511, ResultMeasuredValue, 1317, 1319, "71", "Clinical Success_bri", +1513, Brimonidine, 1340, 1351, "brimonidine", "", +1512, ResultMeasuredValue, 1356, 1358, "70", "Clinical Success_tim", +1514, Timolol, 1379, 1386, "timolol", "", +1515, Mean, 1422, 1426, "mean", "", +1516, IOP, 1439, 1442, "IOP", "", +1517, ResultMeasuredValue, 1447, 1452, "6 . 5", "bri", +1518, mmHg, 1453, 1458, "mm Hg", "bri", +1519, Brimonidine, 1464, 1475, "brimonidine", "", +1520, ResultMeasuredValue, 1480, 1485, "6 . 2", "tim", +1522, mmHg, 1486, 1491, "mm Hg", "tim", +1523, Timolol, 1497, 1504, "timolol", "", +1526, Brimonidine, 1643, 1654, "brimonidine", "", +1528, Brimonidine, 1783, 1794, "brimonidine", "", +1529, Timolol, 1887, 1894, "timolol", "", +1530, ConclusionComment, 2082, 2273, "As a first - line agent for the treatment of glaucoma and ocular hypertension , brimonidine has clinical effectiveness equivalent to timolol , but with less chronotropic effect on the heart .", "", +1531, Glaucoma, 2127, 2135, "glaucoma", "", +1532, OcularHypertension, 2140, 2159, "ocular hypertension", "", +1533, Brimonidine, 2162, 2173, "brimonidine", "", +1534, Timolol, 2215, 2222, "timolol", "", +1536, Brimonidine, 2274, 2285, "Brimonidine", "", +1535, ConclusionComment, 2274, 2383, "Brimonidine is a viable alternative to timolol for first - line therapy in glaucoma and ocular hypertension .", "", +1537, Timolol, 2313, 2320, "timolol", "", +1538, Glaucoma, 2349, 2357, "glaucoma", "", +1539, OcularHypertension, 2362, 2381, "ocular hypertension", "", +1540, PMID, 2391, 2399, "10877373", "", diff --git a/data/gl 10877373_jshahinitiran.n-triples b/data/gl 10877373_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10877373_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10877373_tstrakeljahn.annodb b/data/gl 10877373_tstrakeljahn.annodb new file mode 100644 index 0000000..5f21476 --- /dev/null +++ b/data/gl 10877373_tstrakeljahn.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +3271, Journal, 0, 10, "J Glaucoma", "", +3272, PublicationYear, 13, 17, "2000", "", +3283, Title, 45, 209, "Clinical success and quality of life with brimonidine 0 . 2 % or timolol 0 . 5 % used twice daily in glaucoma or ocular t hypertension : a randomized clinical trial", "", +3273, Brimonidine, 87, 98, "brimonidine", "", +3278, DoseValue, 99, 104, "0 . 2", "", +3280, Percentage, 105, 106, "%", "", +3274, Timolol, 110, 117, "timolol", "", +3279, DoseValue, 118, 123, "0 . 5", "", +3281, Percentage, 124, 125, "%", "", +3282, Frequency, 131, 142, "twice daily", "", +3275, Glaucoma, 146, 154, "glaucoma", "", +3276, OcularHypertension, 158, 179, "ocular t hypertension", "", +3277, Randomized, 184, 194, "randomized", "", +3284, Author, 249, 258, "Javitt JC", "", +3285, Author, 267, 279, "Schiffman RM", "", +3352, USA, 396, 399, "USA", "", +3294, ObjectiveDescription, 412, 574, "To compare the clinical success rates and quality of life impact of brimonidine 0 . 2 % with timolol 0 . 5 % in newly diagnosed patients naive to glaucoma therapy", "", +3287, Brimonidine, 480, 491, "brimonidine", "", +3289, DoseValue, 492, 497, "0 . 2", "", +3291, Percentage, 498, 499, "%", "", +3288, Timolol, 505, 512, "timolol", "", +3290, DoseValue, 513, 518, "0 . 5", "", +3292, Percentage, 519, 520, "%", "", +3293, Precondition, 524, 574, "newly diagnosed patients naive to glaucoma therapy", "", +3295, Multicenter, 603, 614, "multicenter", "", +3296, Randomized, 617, 627, "randomized", "", +3297, DoubleBlind, 630, 645, "double - masked", "", +3298, ClinicalTrial, 648, 656, "clinical", "", +3298, ClinicalTrial, 671, 676, "trial", "", +3300, Frequency, 711, 722, "twice daily", "", +3301, Brimonidine, 723, 743, "brimonidine tartrate", "", +3306, DoseValue, 744, 749, "0 . 2", "", +3307, Percentage, 750, 751, "%", "", +3302, Timolol, 780, 795, "timolol maleate", "", +3305, DoseValue, 796, 801, "0 . 5", "", +3308, Percentage, 802, 803, "%", "", +3303, Glaucoma, 821, 829, "glaucoma", "", +3304, OcularHypertension, 836, 855, "ocular hypertension", "", +3309, NumberPatientsCT, 872, 892, "Two hundred nineteen", "", +3310, NumberPatientsArm, 920, 923, "111", "", +3312, Brimonidine, 931, 942, "brimonidine", "", +3311, NumberPatientsArm, 953, 956, "108", "", +3313, Timolol, 964, 971, "timolol", "", +3315, Frequency, 1023, 1034, "twice daily", "", +3314, Duration, 1039, 1047, "4 months", "", +3316, EndPointDescription, 1096, 1129, "reduction of intraocular pressure", "", +3321, IOP, 1109, 1129, "intraocular pressure", "", +3322, IOP, 1132, 1135, "IOP", "", +3323, EndPointDescription, 1170, 1193, "Quality of life effects", "", +3324, MeasurementDevice, 1217, 1283, "SF - 36 Health Survey and Glaucoma Disability Index questionnaires", "", +7332, PercentageAffected, 1317, 1319, "71", "", +7334, NumberAffected, 1324, 1326, "75", "", +3325, FinalNumPatientsArm, 1329, 1332, "106", "", +3328, Brimonidine, 1340, 1351, "brimonidine", "", +7333, PercentageAffected, 1356, 1358, "70", "", +7335, NumberAffected, 1363, 1365, "73", "", +3326, FinalNumPatientsArm, 1368, 1371, "105", "", +3327, Timolol, 1379, 1386, "timolol", "", +3329, Mean, 1422, 1426, "mean", "", +3330, IOP, 1439, 1442, "IOP", "", +3331, Reduction, 1447, 1452, "6 . 5", "", +3333, mmHg, 1453, 1458, "mm Hg", "", +3335, Brimonidine, 1464, 1475, "brimonidine", "", +3332, Reduction, 1480, 1485, "6 . 2", "", +3334, mmHg, 1486, 1491, "mm Hg", "", +3336, Timolol, 1497, 1504, "timolol", "", +3337, ObservedResult, 1507, 1553, "Few patients reported a specific adverse event", "", +7336, ObservedResult, 1803, 1894, "small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol", "", +3344, Mean, 1825, 1829, "mean", "", +3339, TimePoint, 1867, 1875, "months 1", "", +3340, TimePoint, 1880, 1881, "4", "", +3341, Timolol, 1887, 1894, "timolol", "", +3345, ConclusionComment, 2082, 2273, "As a first - line agent for the treatment of glaucoma and ocular hypertension , brimonidine has clinical effectiveness equivalent to timolol , but with less chronotropic effect on the heart .", "", +3346, ConclusionComment, 2274, 2383, "Brimonidine is a viable alternative to timolol for first - line therapy in glaucoma and ocular hypertension .", "", +3347, Brimonidine, 2274, 2285, "Brimonidine", "", +3348, Timolol, 2313, 2320, "timolol", "", +3349, Glaucoma, 2349, 2357, "glaucoma", "", +3350, OcularHypertension, 2362, 2381, "ocular hypertension", "", +3351, PMID, 2391, 2399, "10877373", "", diff --git a/data/gl 10877373_tstrakeljahn.n-triples b/data/gl 10877373_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10877373_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10901475_admin.annodb b/data/gl 10901475_admin.annodb new file mode 100644 index 0000000..8c257f6 --- /dev/null +++ b/data/gl 10901475_admin.annodb @@ -0,0 +1,144 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +20802, Journal, 0, 34, "Graefes Arch Clin Exp Ophthalmol .", "", " \"Graefes Arch Clin Exp Ophthalmol .\"." +1, PublicationYear, 35, 39, "2000", "", " \"2000\"." +2, Title, 68, 187, "The additive intraocular pressure - lowering effect of latanoprost 0 . 005 % daily once and pilocarpine 2 % t . i . d .", "", " \"The additive intraocular pressure - lowering effect of latanoprost 0 . 005 % daily once and pilocarpine 2 % t . i . d .\"." +3, IOP, 81, 101, "intraocular pressure", "", +4, Latanoprost, 123, 134, "latanoprost", "", " . ." +20814, DoseValue, 135, 142, "0 . 005", "", +27234, Percentage, 143, 144, "%", "", +20825, Frequency, 145, 155, "daily once", "", " \"daily once\"." +27224, Pilocarpine, 160, 171, "pilocarpine", "", +20847, DoseValue, 172, 173, "2", "", +20827, Percentage, 174, 175, "%", "", +66, Frequency, 176, 187, "t . i . d .", "", " \"t . i . d .\"." +12, OpenAngleGlaucoma, 205, 226, "open - angle glaucoma", "", " ." +13, OcularHypertension, 230, 249, "ocular hypertension", "", " ." +27231, Duration, 254, 263, "6 - month", "", " \"6 - month\"." +61, Randomized, 266, 276, "randomized", "", " ." +62, Multicenter, 279, 290, "multicenter", "", " ." +77, Latanoprost, 306, 317, "Latanoprost", "", +58, Author, 332, 346, "Diestelhorst M", "", " \"Diestelhorst M\"." +27233, Germany, 436, 443, "Germany", "", " ." +27225, ObjectiveDescription, 456, 646, "To compare the additional intraocular pressure - lowering effect of latanoprost 0 . 005 % administered once daily with that of pilocarpine 2 % administered three times daily in patients with", "", " \"To compare the additional intraocular pressure - lowering effect of latanoprost 0 . 005 % administered once daily with that of pilocarpine 2 % administered three times daily in patients with\"." +80, IOP, 482, 502, "intraocular pressure", "", +26, Latanoprost, 524, 535, "latanoprost", "", +20815, DoseValue, 536, 543, "0 . 005", "", " \"0 . 005\"." +73, Percentage, 544, 545, "%", "", " ." +20821, Frequency, 559, 569, "once daily", "", +27, Pilocarpine, 583, 594, "pilocarpine", "", " ." +20850, DoseValue, 595, 596, "2", "", " \"2\"." +20828, Percentage, 597, 598, "%", "", " ." +20822, Frequency, 612, 629, "three times daily", "", +94, Precondition, 633, 757, "patients with primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily", "", " \"patients with primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily\"." +20824, Primary_OpenAngleGlaucoma, 647, 676, "primary open - angle glaucoma", "", " ." +27226, ObjectiveDescription, 647, 759, "primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily .", "", " \"primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily .\"." +29, OcularHypertension, 680, 699, "ocular hypertension", "", +30, Timolol, 730, 737, "timolol", "", +20845, DoseValue, 738, 743, "0 . 5", "", +20829, Percentage, 744, 745, "%", "", +20860, Frequency, 746, 757, "twice daily", "", +84, Duration, 775, 784, "6 - month", "", +85, Multicenter, 787, 798, "multicenter", "", +86, Randomized, 801, 811, "randomized", "", +18, OpenLabel, 814, 826, "open - label", "", +20809, Precondition, 837, 923, "patients with POAG or OH whose IOP was not controlled with timolol 0 . 5 % b . i . d .", "", " \"patients with POAG or OH whose IOP was not controlled with timolol 0 . 5 % b . i . d .\"." +243, Primary_OpenAngleGlaucoma, 851, 855, "POAG", "", +20, OcularHypertension, 859, 861, "OH", "", +21, IOP, 868, 871, "IOP", "", +22, Timolol, 896, 903, "timolol", "", +20844, DoseValue, 904, 909, "0 . 5", "", +20833, Percentage, 910, 911, "%", "", +20862, Frequency, 912, 923, "b . i . d .", "", +31, Precondition, 940, 1021, "Eyes had not been treated with pilocarpine and latanoprost for at least 2 years .", "", " \"Eyes had not been treated with pilocarpine and latanoprost for at least 2 years .\"." +112, Pilocarpine, 971, 982, "pilocarpine", "", +113, Latanoprost, 987, 998, "latanoprost", "", +27227, Duration, 1012, 1019, "2 years", "", +27238, Diurnal_IOP, 1053, 1064, "diurnal IOP", "", " ." +36940, TimePoint, 1077, 1085, "baseline", "", +222, TimePoint, 1089, 1096, "month 6", "", +189, NumPatientsLeftArm, 1138, 1142, "Four", "", " \"Four\"." +46, Latanoprost, 1155, 1166, "latanoprost", "", +20826, DoseValue, 1167, 1174, "0 . 005", "", +20838, Percentage, 1175, 1176, "%", "", +190, NumPatientsLeftArm, 1181, 1183, "35", "", " \"35\"." +27237, Pilocarpine, 1187, 1198, "pilocarpine", "", +20853, DoseValue, 1199, 1200, "2", "", +20830, Percentage, 1201, 1202, "%", "", +34, NumberPatientsCT, 1248, 1269, "Two hundred and forty", "", " \"Two hundred and forty\"." +33, IntentionToTreat, 1300, 1319, "intent - to - treat", "", " ." +27239, Diurnal_IOP, 1355, 1366, "diurnal IOP", "", +33211, TimePoint, 1383, 1391, "6 months", "", " \"6 months\". \"6 months\"." +35, PValueChangeValue, 1424, 1435, "P < 0 . 001", "", +36, IOP, 1440, 1443, "IOP", "", +37, Mean, 1446, 1450, "mean", "", +38, BaseLineValue, 1479, 1485, "23 . 3", "", +130, SdDevBL, 1492, 1497, "2 . 8", "", " \"2 . 8\"." +39, ResultMeasuredValue, 1501, 1507, "17 . 8", "", " \"17 . 8\"." +133, SdDevResValue, 1514, 1519, "2 . 8", "", " \"2 . 8\"." +132, Reduction, 1524, 1529, "5 . 6", "", " \"5 . 6\"." +40, mmHg, 1532, 1536, "mmHg", "", " ." +41, Latanoprost, 1544, 1555, "latanoprost", "", +20817, DoseValue, 1556, 1563, "0 . 005", "", +20841, Percentage, 1564, 1565, "%", "", +42, BaseLineValue, 1581, 1587, "23 . 0", "", " \"23 . 0\"." +138, SdDevBL, 1594, 1599, "3 . 2", "", " \"3 . 2\"." +43, ResultMeasuredValue, 1603, 1609, "18 . 5", "", " \"18 . 5\"." +141, SdDevResValue, 1616, 1621, "2 . 4", "", " \"2 . 4\"." +140, Reduction, 1626, 1631, "4 . 8", "", " \"4 . 8\"." +44, mmHg, 1634, 1638, "mmHg", "", +27240, Pilocarpine, 1642, 1653, "pilocarpine", "", +20857, DoseValue, 1654, 1655, "2", "", +20856, Percentage, 1656, 1657, "%", "", +146, Frequency, 1658, 1667, "t . i . d", "", +147, Mean, 1691, 1695, "mean", "", +148, DiffGroupAbsValue, 1710, 1717, "- 0 . 8", "", " \"- 0 . 8\"." +151, mmHg, 1718, 1722, "mmHg", "", +194, PerProtocol, 1725, 1737, "per protocol", "", " ." +20834, PerProtocol, 1740, 1742, "PP", "", +149, DiffGroupAbsValue, 1749, 1756, "- 1 . 6", "", " \"- 1 . 6\"." +150, mmHg, 1757, 1761, "mmHg", "", +17771, IntentionToTreat, 1764, 1783, "intend - to - treat", "", +17772, IntentionToTreat, 1786, 1789, "ITT", "", +152, PvalueDiff, 1824, 1834, "P < 0 . 04", "", " \"P < 0 . 04\"." +17781, PerProtocol, 1837, 1839, "PP", "", +153, PvalueDiff, 1842, 1853, "P < 0 . 001", "", " \"P < 0 . 001\"." +17780, IntentionToTreat, 1856, 1859, "ITT", "", +154, Latanoprost, 1874, 1885, "latanoprost", "", +155, DoseValue, 1886, 1893, "0 . 005", "", +156, Percentage, 1894, 1895, "%", "", +17784, NumberAffected, 1898, 1901, "Two", "", " \"Two\"." +49, Latanoprost, 1920, 1931, "latanoprost", "", +48, IrisPigmentation, 1942, 1959, "iris color change", "", " . ." +17792, NumberAffected, 1962, 1974, "Thirty - six", "", " \"Thirty - six\"." +161, Latanoprost, 1991, 2002, "latanoprost", "", +162, NumberAffected, 2013, 2016, "106", "", " \"106\"." +27236, Pilocarpine, 2024, 2035, "pilocarpine", "", +164, DoseValue, 2036, 2037, "2", "", +165, Percentage, 2038, 2039, "%", "", +27228, EndPointDescription, 2055, 2076, "ocular adverse events", "Adverse Effect", " . ." +167, PValueNumAffected, 2079, 2090, "P < 0 . 001", "", +27241, ConclusionComment, 2108, 2203, "From the data we conclude that the additivity of latanoprost 0 . 005 % is at least as effective", "", " \"From the data we conclude that the additivity of latanoprost 0 . 005 % is at least as effective\"." +50, Latanoprost, 2157, 2168, "latanoprost", "", +20842, DoseValue, 2169, 2176, "0 . 005", "", +20843, Percentage, 2177, 2178, "%", "", +27242, ConclusionComment, 2204, 2234, "as pilocarpine 2 % t . i . d .", "", " \"as pilocarpine 2 % t . i . d .\"." +51, Pilocarpine, 2207, 2218, "pilocarpine", "", +20858, DoseValue, 2219, 2220, "2", "", +20835, Percentage, 2221, 2222, "%", "", +20812, Frequency, 2223, 2234, "t . i . d .", "", +27243, ConclusionComment, 2235, 2294, "in reducing IOP when added to eyes currently on monotherapy", "", " \"in reducing IOP when added to eyes currently on monotherapy\"." +55, IOP, 2247, 2250, "IOP", "", +27244, ConclusionComment, 2295, 2327, "with timolol 0 . 5 % b . i . d .", "", " \"with timolol 0 . 5 % b . i . d .\"." +52, Timolol, 2300, 2307, "timolol", "", +20844, DoseValue, 2308, 2313, "0 . 5", "", +20836, Percentage, 2314, 2315, "%", "", +20861, Frequency, 2316, 2327, "b . i . d .", "", +20810, ConclusionComment, 2328, 2407, "Latanoprost was better tolerated than pilocarpine 2 % eye drops in this study .", "", " \"Latanoprost was better tolerated than pilocarpine 2 % eye drops in this study .\"." +53, Latanoprost, 2328, 2339, "Latanoprost", "", +54, Pilocarpine, 2366, 2377, "pilocarpine", "", +20859, DoseValue, 2378, 2379, "2", "", +20837, Percentage, 2380, 2381, "%", "", +27235, Eyedrops, 2382, 2391, "eye drops", "", +20811, ConclusionComment, 2408, 2474, "The increase in iris pigmentation requires further investigation .", "", " \"The increase in iris pigmentation requires further investigation .\"." +251, IrisPigmentation, 2424, 2441, "iris pigmentation", "", +57, PMID, 2482, 2490, "10901475", "", " \"10901475\"." diff --git a/data/gl 10901475_admin.n-triples b/data/gl 10901475_admin.n-triples new file mode 100644 index 0000000..d802c8d --- /dev/null +++ b/data/gl 10901475_admin.n-triples @@ -0,0 +1,151 @@ +# RDF export of group: Publication + . + "Publication" . + "The additive intraocular pressure - lowering effect of latanoprost 0 . 005 % daily once and pilocarpine 2 % t . i . d ." . + "Diestelhorst M" . + "2000" . + "Graefes Arch Clin Exp Ophthalmol ." . + "10901475" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the additional intraocular pressure - lowering effect of latanoprost 0 . 005 % administered once daily with that of pilocarpine 2 % administered three times daily in patients with" . + "Two hundred and forty" . + "6 - month" . + . + . + . + "From the data we conclude that the additivity of latanoprost 0 . 005 % is at least as effective" . + . + . + . + . + . + "primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily ." . + . + . + "as pilocarpine 2 % t . i . d ." . + "in reducing IOP when added to eyes currently on monotherapy" . + "with timolol 0 . 5 % b . i . d ." . + "Latanoprost was better tolerated than pilocarpine 2 % eye drops in this study ." . + "The increase in iris pigmentation requires further investigation ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma or ocular hypertension currently on monotherapy with timolol 0 . 5 % twice daily" . + . + . + . + "patients with POAG or OH whose IOP was not controlled with timolol 0 . 5 % b . i . d ." . + "Eyes had not been treated with pilocarpine and latanoprost for at least 2 years ." . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + "Endpoint-iris" . + . + . + . + . + . + . + "Endpoint-oc" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + "Four" . + . + . + . + . + "Arm-pil" . + . + . + "35" . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "daily once" . + . + . + "Intervention-pil" . + . + "t . i . d ." . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-pil" . + . + "2" . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-lat" . + . + "2 . 8" . + "17 . 8" . + "2 . 8" . + "5 . 6" . + "6 months" . + . + "Outcome-iop-pil" . + . + "23 . 0" . + "3 . 2" . + "18 . 5" . + "2 . 4" . + "4 . 8" . + "6 months" . + . + "Outcome-iris-lat" . + . + "Two" . + . + "Outcome-oc-lat" . + . + "Thirty - six" . + . + "Outcome-oc-pil" . + . + "106" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-ITT" . + "- 1 . 6" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups-PP" . + "- 0 . 8" . + "P < 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10901475_export.csv b/data/gl 10901475_export.csv new file mode 100644 index 0000000..eac893d --- /dev/null +++ b/data/gl 10901475_export.csv @@ -0,0 +1,556 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +493, 1, 1, 1, 0, 7, 0, 7, "Graefes" +493, 1, 2, 2, 8, 12, 8, 12, "Arch" +493, 1, 3, 3, 13, 17, 13, 17, "Clin" +493, 1, 4, 4, 18, 21, 18, 21, "Exp" +493, 1, 5, 5, 22, 32, 22, 32, "Ophthalmol" +493, 1, 6, 6, 33, 34, 33, 34, "." +493, 2, 1, 7, 0, 4, 35, 39, "2000" +493, 2, 2, 8, 5, 8, 40, 43, "May" +493, 2, 3, 9, 9, 10, 44, 45, ";" +493, 2, 4, 10, 11, 14, 46, 49, "238" +493, 2, 5, 11, 15, 16, 50, 51, "(" +493, 2, 6, 12, 17, 18, 52, 53, "5" +493, 2, 7, 13, 19, 20, 54, 55, ")" +493, 2, 8, 14, 21, 22, 56, 57, ":" +493, 2, 9, 15, 23, 26, 58, 61, "433" +493, 2, 10, 16, 27, 28, 62, 63, "-" +493, 2, 11, 17, 29, 30, 64, 65, "9" +493, 2, 12, 18, 31, 32, 66, 67, "." +493, 3, 1, 19, 0, 3, 68, 71, "The" +493, 3, 2, 20, 4, 12, 72, 80, "additive" +493, 3, 3, 21, 13, 24, 81, 92, "intraocular" +493, 3, 4, 22, 25, 33, 93, 101, "pressure" +493, 3, 5, 23, 34, 35, 102, 103, "-" +493, 3, 6, 24, 36, 44, 104, 112, "lowering" +493, 3, 7, 25, 45, 51, 113, 119, "effect" +493, 3, 8, 26, 52, 54, 120, 122, "of" +493, 3, 9, 27, 55, 66, 123, 134, "latanoprost" +493, 3, 10, 28, 67, 68, 135, 136, "0" +493, 3, 11, 29, 69, 70, 137, 138, "." +493, 3, 12, 30, 71, 74, 139, 142, "005" +493, 3, 13, 31, 75, 76, 143, 144, "%" +493, 3, 14, 32, 77, 82, 145, 150, "daily" +493, 3, 15, 33, 83, 87, 151, 155, "once" +493, 3, 16, 34, 88, 91, 156, 159, "and" +493, 3, 17, 35, 92, 103, 160, 171, "pilocarpine" +493, 3, 18, 36, 104, 105, 172, 173, "2" +493, 3, 19, 37, 106, 107, 174, 175, "%" +493, 3, 20, 38, 108, 109, 176, 177, "t" +493, 3, 21, 39, 110, 111, 178, 179, "." +493, 3, 22, 40, 112, 113, 180, 181, "i" +493, 3, 23, 41, 114, 115, 182, 183, "." +493, 3, 24, 42, 116, 117, 184, 185, "d" +493, 3, 25, 43, 118, 119, 186, 187, "." +493, 4, 1, 44, 0, 2, 188, 190, "in" +493, 4, 2, 45, 3, 11, 191, 199, "patients" +493, 4, 3, 46, 12, 16, 200, 204, "with" +493, 4, 4, 47, 17, 21, 205, 209, "open" +493, 4, 5, 48, 22, 23, 210, 211, "-" +493, 4, 6, 49, 24, 29, 212, 217, "angle" +493, 4, 7, 50, 30, 38, 218, 226, "glaucoma" +493, 4, 8, 51, 39, 41, 227, 229, "or" +493, 4, 9, 52, 42, 48, 230, 236, "ocular" +493, 4, 10, 53, 49, 61, 237, 249, "hypertension" +493, 4, 11, 54, 62, 63, 250, 251, "." +493, 5, 1, 55, 0, 1, 252, 253, "a" +493, 5, 2, 56, 2, 3, 254, 255, "6" +493, 5, 3, 57, 4, 5, 256, 257, "-" +493, 5, 4, 58, 6, 11, 258, 263, "month" +493, 5, 5, 59, 12, 13, 264, 265, "," +493, 5, 6, 60, 14, 24, 266, 276, "randomized" +493, 5, 7, 61, 25, 26, 277, 278, "," +493, 5, 8, 62, 27, 38, 279, 290, "multicenter" +493, 5, 9, 63, 39, 44, 291, 296, "study" +493, 5, 10, 64, 45, 46, 297, 298, "." +493, 6, 1, 65, 0, 6, 299, 305, "German" +493, 6, 2, 66, 7, 18, 306, 317, "Latanoprost" +493, 6, 3, 67, 19, 24, 318, 323, "Study" +493, 6, 4, 68, 25, 30, 324, 329, "Group" +493, 6, 5, 69, 31, 32, 330, 331, "." +493, 7, 1, 70, 0, 12, 332, 344, "Diestelhorst" +493, 7, 2, 71, 13, 14, 345, 346, "M" +493, 7, 3, 72, 15, 16, 347, 348, "(" +493, 7, 4, 73, 17, 18, 349, 350, "1" +493, 7, 5, 74, 19, 20, 351, 352, ")" +493, 7, 6, 75, 21, 22, 353, 354, "." +493, 8, 1, 76, 0, 6, 355, 361, "Author" +493, 8, 2, 77, 7, 18, 362, 373, "information" +493, 8, 3, 78, 19, 20, 374, 375, ":" +493, 8, 4, 79, 21, 22, 376, 377, "(" +493, 8, 5, 80, 23, 24, 378, 379, "1" +493, 8, 6, 81, 25, 26, 380, 381, ")" +493, 8, 7, 82, 27, 37, 382, 392, "Department" +493, 8, 8, 83, 38, 40, 393, 395, "of" +493, 8, 9, 84, 41, 54, 396, 409, "Ophthalmology" +493, 8, 10, 85, 55, 56, 410, 411, "," +493, 8, 11, 86, 57, 67, 412, 422, "University" +493, 8, 12, 87, 68, 70, 423, 425, "of" +493, 8, 13, 88, 71, 78, 426, 433, "Cologne" +493, 8, 14, 89, 79, 80, 434, 435, "," +493, 8, 15, 90, 81, 88, 436, 443, "Germany" +493, 8, 16, 91, 89, 90, 444, 445, "." +493, 9, 1, 92, 0, 7, 446, 453, "PURPOSE" +493, 9, 2, 93, 8, 9, 454, 455, ":" +493, 9, 3, 94, 10, 12, 456, 458, "To" +493, 9, 4, 95, 13, 20, 459, 466, "compare" +493, 9, 5, 96, 21, 24, 467, 470, "the" +493, 9, 6, 97, 25, 35, 471, 481, "additional" +493, 9, 7, 98, 36, 47, 482, 493, "intraocular" +493, 9, 8, 99, 48, 56, 494, 502, "pressure" +493, 9, 9, 100, 57, 58, 503, 504, "-" +493, 9, 10, 101, 59, 67, 505, 513, "lowering" +493, 9, 11, 102, 68, 74, 514, 520, "effect" +493, 9, 12, 103, 75, 77, 521, 523, "of" +493, 9, 13, 104, 78, 89, 524, 535, "latanoprost" +493, 9, 14, 105, 90, 91, 536, 537, "0" +493, 9, 15, 106, 92, 93, 538, 539, "." +493, 9, 16, 107, 94, 97, 540, 543, "005" +493, 9, 17, 108, 98, 99, 544, 545, "%" +493, 9, 18, 109, 100, 112, 546, 558, "administered" +493, 9, 19, 110, 113, 117, 559, 563, "once" +493, 9, 20, 111, 118, 123, 564, 569, "daily" +493, 9, 21, 112, 124, 128, 570, 574, "with" +493, 9, 22, 113, 129, 133, 575, 579, "that" +493, 9, 23, 114, 134, 136, 580, 582, "of" +493, 9, 24, 115, 137, 148, 583, 594, "pilocarpine" +493, 9, 25, 116, 149, 150, 595, 596, "2" +493, 9, 26, 117, 151, 152, 597, 598, "%" +493, 9, 27, 118, 153, 165, 599, 611, "administered" +493, 9, 28, 119, 166, 171, 612, 617, "three" +493, 9, 29, 120, 172, 177, 618, 623, "times" +493, 9, 30, 121, 178, 183, 624, 629, "daily" +493, 9, 31, 122, 184, 186, 630, 632, "in" +493, 9, 32, 123, 187, 195, 633, 641, "patients" +493, 9, 33, 124, 196, 200, 642, 646, "with" +493, 9, 34, 125, 201, 208, 647, 654, "primary" +493, 9, 35, 126, 209, 213, 655, 659, "open" +493, 9, 36, 127, 214, 215, 660, 661, "-" +493, 9, 37, 128, 216, 221, 662, 667, "angle" +493, 9, 38, 129, 222, 230, 668, 676, "glaucoma" +493, 9, 39, 130, 231, 233, 677, 679, "or" +493, 9, 40, 131, 234, 240, 680, 686, "ocular" +493, 9, 41, 132, 241, 253, 687, 699, "hypertension" +493, 9, 42, 133, 254, 263, 700, 709, "currently" +493, 9, 43, 134, 264, 266, 710, 712, "on" +493, 9, 44, 135, 267, 278, 713, 724, "monotherapy" +493, 9, 45, 136, 279, 283, 725, 729, "with" +493, 9, 46, 137, 284, 291, 730, 737, "timolol" +493, 9, 47, 138, 292, 293, 738, 739, "0" +493, 9, 48, 139, 294, 295, 740, 741, "." +493, 9, 49, 140, 296, 297, 742, 743, "5" +493, 9, 50, 141, 298, 299, 744, 745, "%" +493, 9, 51, 142, 300, 305, 746, 751, "twice" +493, 9, 52, 143, 306, 311, 752, 757, "daily" +493, 9, 53, 144, 312, 313, 758, 759, "." +493, 10, 1, 145, 0, 7, 760, 767, "METHODS" +493, 10, 2, 146, 8, 9, 768, 769, ":" +493, 10, 3, 147, 10, 12, 770, 772, "In" +493, 10, 4, 148, 13, 14, 773, 774, "a" +493, 10, 5, 149, 15, 16, 775, 776, "6" +493, 10, 6, 150, 17, 18, 777, 778, "-" +493, 10, 7, 151, 19, 24, 779, 784, "month" +493, 10, 8, 152, 25, 26, 785, 786, "," +493, 10, 9, 153, 27, 38, 787, 798, "multicenter" +493, 10, 10, 154, 39, 40, 799, 800, "," +493, 10, 11, 155, 41, 51, 801, 811, "randomized" +493, 10, 12, 156, 52, 53, 812, 813, "," +493, 10, 13, 157, 54, 58, 814, 818, "open" +493, 10, 14, 158, 59, 60, 819, 820, "-" +493, 10, 15, 159, 61, 66, 821, 826, "label" +493, 10, 16, 160, 67, 72, 827, 832, "study" +493, 10, 17, 161, 73, 76, 833, 836, "242" +493, 10, 18, 162, 77, 85, 837, 845, "patients" +493, 10, 19, 163, 86, 90, 846, 850, "with" +493, 10, 20, 164, 91, 95, 851, 855, "POAG" +493, 10, 21, 165, 96, 98, 856, 858, "or" +493, 10, 22, 166, 99, 101, 859, 861, "OH" +493, 10, 23, 167, 102, 107, 862, 867, "whose" +493, 10, 24, 168, 108, 111, 868, 871, "IOP" +493, 10, 25, 169, 112, 115, 872, 875, "was" +493, 10, 26, 170, 116, 119, 876, 879, "not" +493, 10, 27, 171, 120, 130, 880, 890, "controlled" +493, 10, 28, 172, 131, 135, 891, 895, "with" +493, 10, 29, 173, 136, 143, 896, 903, "timolol" +493, 10, 30, 174, 144, 145, 904, 905, "0" +493, 10, 31, 175, 146, 147, 906, 907, "." +493, 10, 32, 176, 148, 149, 908, 909, "5" +493, 10, 33, 177, 150, 151, 910, 911, "%" +493, 10, 34, 178, 152, 153, 912, 913, "b" +493, 10, 35, 179, 154, 155, 914, 915, "." +493, 10, 36, 180, 156, 157, 916, 917, "i" +493, 10, 37, 181, 158, 159, 918, 919, "." +493, 10, 38, 182, 160, 161, 920, 921, "d" +493, 10, 39, 183, 162, 163, 922, 923, "." +493, 11, 1, 184, 0, 4, 924, 928, "were" +493, 11, 2, 185, 5, 13, 929, 937, "enrolled" +493, 11, 3, 186, 14, 15, 938, 939, "." +493, 12, 1, 187, 0, 4, 940, 944, "Eyes" +493, 12, 2, 188, 5, 8, 945, 948, "had" +493, 12, 3, 189, 9, 12, 949, 952, "not" +493, 12, 4, 190, 13, 17, 953, 957, "been" +493, 12, 5, 191, 18, 25, 958, 965, "treated" +493, 12, 6, 192, 26, 30, 966, 970, "with" +493, 12, 7, 193, 31, 42, 971, 982, "pilocarpine" +493, 12, 8, 194, 43, 46, 983, 986, "and" +493, 12, 9, 195, 47, 58, 987, 998, "latanoprost" +493, 12, 10, 196, 59, 62, 999, 1002, "for" +493, 12, 11, 197, 63, 65, 1003, 1005, "at" +493, 12, 12, 198, 66, 71, 1006, 1011, "least" +493, 12, 13, 199, 72, 73, 1012, 1013, "2" +493, 12, 14, 200, 74, 79, 1014, 1019, "years" +493, 12, 15, 201, 80, 81, 1020, 1021, "." +493, 13, 1, 202, 0, 2, 1022, 1024, "An" +493, 13, 2, 203, 3, 11, 1025, 1033, "analysis" +493, 13, 3, 204, 12, 14, 1034, 1036, "of" +493, 13, 4, 205, 15, 25, 1037, 1047, "covariance" +493, 13, 5, 206, 26, 30, 1048, 1052, "with" +493, 13, 6, 207, 31, 38, 1053, 1060, "diurnal" +493, 13, 7, 208, 39, 42, 1061, 1064, "IOP" +493, 13, 8, 209, 43, 49, 1065, 1071, "change" +493, 13, 9, 210, 50, 54, 1072, 1076, "from" +493, 13, 10, 211, 55, 63, 1077, 1085, "baseline" +493, 13, 11, 212, 64, 66, 1086, 1088, "to" +493, 13, 12, 213, 67, 72, 1089, 1094, "month" +493, 13, 13, 214, 73, 74, 1095, 1096, "6" +493, 13, 14, 215, 75, 78, 1097, 1100, "for" +493, 13, 15, 216, 79, 84, 1101, 1106, "study" +493, 13, 16, 217, 85, 89, 1107, 1111, "eyes" +493, 13, 17, 218, 90, 93, 1112, 1115, "was" +493, 13, 18, 219, 94, 103, 1116, 1125, "performed" +493, 13, 19, 220, 104, 105, 1126, 1127, "." +493, 14, 1, 221, 0, 7, 1128, 1135, "RESULTS" +493, 14, 2, 222, 8, 9, 1136, 1137, ":" +493, 14, 3, 223, 10, 14, 1138, 1142, "Four" +493, 14, 4, 224, 15, 23, 1143, 1151, "patients" +493, 14, 5, 225, 24, 26, 1152, 1154, "on" +493, 14, 6, 226, 27, 38, 1155, 1166, "latanoprost" +493, 14, 7, 227, 39, 40, 1167, 1168, "0" +493, 14, 8, 228, 41, 42, 1169, 1170, "." +493, 14, 9, 229, 43, 46, 1171, 1174, "005" +493, 14, 10, 230, 47, 48, 1175, 1176, "%" +493, 14, 11, 231, 49, 52, 1177, 1180, "and" +493, 14, 12, 232, 53, 55, 1181, 1183, "35" +493, 14, 13, 233, 56, 58, 1184, 1186, "on" +493, 14, 14, 234, 59, 70, 1187, 1198, "pilocarpine" +493, 14, 15, 235, 71, 72, 1199, 1200, "2" +493, 14, 16, 236, 73, 74, 1201, 1202, "%" +493, 14, 17, 237, 75, 78, 1203, 1206, "did" +493, 14, 18, 238, 79, 82, 1207, 1210, "not" +493, 14, 19, 239, 83, 91, 1211, 1219, "complete" +493, 14, 20, 240, 92, 95, 1220, 1223, "the" +493, 14, 21, 241, 96, 101, 1224, 1229, "study" +493, 14, 22, 242, 102, 103, 1230, 1231, "(" +493, 14, 23, 243, 104, 105, 1232, 1233, "P" +493, 14, 24, 244, 106, 107, 1234, 1235, "<" +493, 14, 25, 245, 108, 109, 1236, 1237, "0" +493, 14, 26, 246, 110, 111, 1238, 1239, "." +493, 14, 27, 247, 112, 115, 1240, 1243, "001" +493, 14, 28, 248, 116, 117, 1244, 1245, ")" +493, 14, 29, 249, 118, 119, 1246, 1247, "." +493, 15, 1, 250, 0, 3, 1248, 1251, "Two" +493, 15, 2, 251, 4, 11, 1252, 1259, "hundred" +493, 15, 3, 252, 12, 15, 1260, 1263, "and" +493, 15, 4, 253, 16, 21, 1264, 1269, "forty" +493, 15, 5, 254, 22, 30, 1270, 1278, "patients" +493, 15, 6, 255, 31, 35, 1279, 1283, "were" +493, 15, 7, 256, 36, 44, 1284, 1292, "included" +493, 15, 8, 257, 45, 47, 1293, 1295, "in" +493, 15, 9, 258, 48, 51, 1296, 1299, "the" +493, 15, 10, 259, 52, 58, 1300, 1306, "intent" +493, 15, 11, 260, 59, 60, 1307, 1308, "-" +493, 15, 12, 261, 61, 63, 1309, 1311, "to" +493, 15, 13, 262, 64, 65, 1312, 1313, "-" +493, 15, 14, 263, 66, 71, 1314, 1319, "treat" +493, 15, 15, 264, 72, 80, 1320, 1328, "analysis" +493, 15, 16, 265, 81, 82, 1329, 1330, "." +493, 16, 1, 266, 0, 3, 1331, 1334, "For" +493, 16, 2, 267, 4, 8, 1335, 1339, "both" +493, 16, 3, 268, 9, 19, 1340, 1350, "treatments" +493, 16, 4, 269, 20, 23, 1351, 1354, "the" +493, 16, 5, 270, 24, 31, 1355, 1362, "diurnal" +493, 16, 6, 271, 32, 35, 1363, 1366, "IOP" +493, 16, 7, 272, 36, 45, 1367, 1376, "reduction" +493, 16, 8, 273, 46, 51, 1377, 1382, "after" +493, 16, 9, 274, 52, 53, 1383, 1384, "6" +493, 16, 10, 275, 54, 60, 1385, 1391, "months" +493, 16, 11, 276, 61, 64, 1392, 1395, "was" +493, 16, 12, 277, 65, 78, 1396, 1409, "statistically" +493, 16, 13, 278, 79, 90, 1410, 1421, "significant" +493, 16, 14, 279, 91, 92, 1422, 1423, "(" +493, 16, 15, 280, 93, 94, 1424, 1425, "P" +493, 16, 16, 281, 95, 96, 1426, 1427, "<" +493, 16, 17, 282, 97, 98, 1428, 1429, "0" +493, 16, 18, 283, 99, 100, 1430, 1431, "." +493, 16, 19, 284, 101, 104, 1432, 1435, "001" +493, 16, 20, 285, 105, 106, 1436, 1437, ")" +493, 16, 21, 286, 107, 108, 1438, 1439, "." +493, 17, 1, 287, 0, 3, 1440, 1443, "IOP" +493, 17, 2, 288, 4, 5, 1444, 1445, "(" +493, 17, 3, 289, 6, 10, 1446, 1450, "mean" +493, 17, 4, 290, 11, 12, 1451, 1452, "+" +493, 17, 5, 291, 13, 14, 1453, 1454, "/" +493, 17, 6, 292, 15, 16, 1455, 1456, "-" +493, 17, 7, 293, 17, 19, 1457, 1459, "SD" +493, 17, 8, 294, 20, 21, 1460, 1461, ")" +493, 17, 9, 295, 22, 25, 1462, 1465, "was" +493, 17, 10, 296, 26, 33, 1466, 1473, "reduced" +493, 17, 11, 297, 34, 38, 1474, 1478, "from" +493, 17, 12, 298, 39, 41, 1479, 1481, "23" +493, 17, 13, 299, 42, 43, 1482, 1483, "." +493, 17, 14, 300, 44, 45, 1484, 1485, "3" +493, 17, 15, 301, 46, 47, 1486, 1487, "+" +493, 17, 16, 302, 48, 49, 1488, 1489, "/" +493, 17, 17, 303, 50, 51, 1490, 1491, "-" +493, 17, 18, 304, 52, 53, 1492, 1493, "2" +493, 17, 19, 305, 54, 55, 1494, 1495, "." +493, 17, 20, 306, 56, 57, 1496, 1497, "8" +493, 17, 21, 307, 58, 60, 1498, 1500, "to" +493, 17, 22, 308, 61, 63, 1501, 1503, "17" +493, 17, 23, 309, 64, 65, 1504, 1505, "." +493, 17, 24, 310, 66, 67, 1506, 1507, "8" +493, 17, 25, 311, 68, 69, 1508, 1509, "+" +493, 17, 26, 312, 70, 71, 1510, 1511, "/" +493, 17, 27, 313, 72, 73, 1512, 1513, "-" +493, 17, 28, 314, 74, 75, 1514, 1515, "2" +493, 17, 29, 315, 76, 77, 1516, 1517, "." +493, 17, 30, 316, 78, 79, 1518, 1519, "8" +493, 17, 31, 317, 80, 81, 1520, 1521, "(" +493, 17, 32, 318, 82, 83, 1522, 1523, "-" +493, 17, 33, 319, 84, 85, 1524, 1525, "5" +493, 17, 34, 320, 86, 87, 1526, 1527, "." +493, 17, 35, 321, 88, 89, 1528, 1529, "6" +493, 17, 36, 322, 90, 91, 1530, 1531, ")" +493, 17, 37, 323, 92, 96, 1532, 1536, "mmHg" +493, 17, 38, 324, 97, 99, 1537, 1539, "in" +493, 17, 39, 325, 100, 103, 1540, 1543, "the" +493, 17, 40, 326, 104, 115, 1544, 1555, "latanoprost" +493, 17, 41, 327, 116, 117, 1556, 1557, "0" +493, 17, 42, 328, 118, 119, 1558, 1559, "." +493, 17, 43, 329, 120, 123, 1560, 1563, "005" +493, 17, 44, 330, 124, 125, 1564, 1565, "%" +493, 17, 45, 331, 126, 131, 1566, 1571, "group" +493, 17, 46, 332, 132, 135, 1572, 1575, "and" +493, 17, 47, 333, 136, 140, 1576, 1580, "from" +493, 17, 48, 334, 141, 143, 1581, 1583, "23" +493, 17, 49, 335, 144, 145, 1584, 1585, "." +493, 17, 50, 336, 146, 147, 1586, 1587, "0" +493, 17, 51, 337, 148, 149, 1588, 1589, "+" +493, 17, 52, 338, 150, 151, 1590, 1591, "/" +493, 17, 53, 339, 152, 153, 1592, 1593, "-" +493, 17, 54, 340, 154, 155, 1594, 1595, "3" +493, 17, 55, 341, 156, 157, 1596, 1597, "." +493, 17, 56, 342, 158, 159, 1598, 1599, "2" +493, 17, 57, 343, 160, 162, 1600, 1602, "to" +493, 17, 58, 344, 163, 165, 1603, 1605, "18" +493, 17, 59, 345, 166, 167, 1606, 1607, "." +493, 17, 60, 346, 168, 169, 1608, 1609, "5" +493, 17, 61, 347, 170, 171, 1610, 1611, "+" +493, 17, 62, 348, 172, 173, 1612, 1613, "/" +493, 17, 63, 349, 174, 175, 1614, 1615, "-" +493, 17, 64, 350, 176, 177, 1616, 1617, "2" +493, 17, 65, 351, 178, 179, 1618, 1619, "." +493, 17, 66, 352, 180, 181, 1620, 1621, "4" +493, 17, 67, 353, 182, 183, 1622, 1623, "(" +493, 17, 68, 354, 184, 185, 1624, 1625, "-" +493, 17, 69, 355, 186, 187, 1626, 1627, "4" +493, 17, 70, 356, 188, 189, 1628, 1629, "." +493, 17, 71, 357, 190, 191, 1630, 1631, "8" +493, 17, 72, 358, 192, 193, 1632, 1633, ")" +493, 17, 73, 359, 194, 198, 1634, 1638, "mmHg" +493, 17, 74, 360, 199, 201, 1639, 1641, "in" +493, 17, 75, 361, 202, 213, 1642, 1653, "pilocarpine" +493, 17, 76, 362, 214, 215, 1654, 1655, "2" +493, 17, 77, 363, 216, 217, 1656, 1657, "%" +493, 17, 78, 364, 218, 219, 1658, 1659, "t" +493, 17, 79, 365, 220, 221, 1660, 1661, "." +493, 17, 80, 366, 222, 223, 1662, 1663, "i" +493, 17, 81, 367, 224, 225, 1664, 1665, "." +493, 17, 82, 368, 226, 227, 1666, 1667, "d" +493, 17, 83, 369, 228, 229, 1668, 1669, "." +493, 17, 84, 370, 230, 231, 1670, 1671, "-" +493, 17, 85, 371, 232, 239, 1672, 1679, "treated" +493, 17, 86, 372, 240, 244, 1680, 1684, "eyes" +493, 17, 87, 373, 245, 246, 1685, 1686, "." +493, 18, 1, 374, 0, 3, 1687, 1690, "The" +493, 18, 2, 375, 4, 8, 1691, 1695, "mean" +493, 18, 3, 376, 9, 19, 1696, 1706, "difference" +493, 18, 4, 377, 20, 22, 1707, 1709, "of" +493, 18, 5, 378, 23, 24, 1710, 1711, "-" +493, 18, 6, 379, 25, 26, 1712, 1713, "0" +493, 18, 7, 380, 27, 28, 1714, 1715, "." +493, 18, 8, 381, 29, 30, 1716, 1717, "8" +493, 18, 9, 382, 31, 35, 1718, 1722, "mmHg" +493, 18, 10, 383, 36, 37, 1723, 1724, "(" +493, 18, 11, 384, 38, 41, 1725, 1728, "per" +493, 18, 12, 385, 42, 50, 1729, 1737, "protocol" +493, 18, 13, 386, 51, 52, 1738, 1739, "," +493, 18, 14, 387, 53, 55, 1740, 1742, "PP" +493, 18, 15, 388, 56, 57, 1743, 1744, ")" +493, 18, 16, 389, 58, 61, 1745, 1748, "and" +493, 18, 17, 390, 62, 63, 1749, 1750, "-" +493, 18, 18, 391, 64, 65, 1751, 1752, "1" +493, 18, 19, 392, 66, 67, 1753, 1754, "." +493, 18, 20, 393, 68, 69, 1755, 1756, "6" +493, 18, 21, 394, 70, 74, 1757, 1761, "mmHg" +493, 18, 22, 395, 75, 76, 1762, 1763, "(" +493, 18, 23, 396, 77, 83, 1764, 1770, "intend" +493, 18, 24, 397, 84, 85, 1771, 1772, "-" +493, 18, 25, 398, 86, 88, 1773, 1775, "to" +493, 18, 26, 399, 89, 90, 1776, 1777, "-" +493, 18, 27, 400, 91, 96, 1778, 1783, "treat" +493, 18, 28, 401, 97, 98, 1784, 1785, "," +493, 18, 29, 402, 99, 102, 1786, 1789, "ITT" +493, 18, 30, 403, 103, 104, 1790, 1791, ")" +493, 18, 31, 404, 105, 108, 1792, 1795, "was" +493, 18, 32, 405, 109, 122, 1796, 1809, "statistically" +493, 18, 33, 406, 123, 134, 1810, 1821, "significant" +493, 18, 34, 407, 135, 136, 1822, 1823, "(" +493, 18, 35, 408, 137, 138, 1824, 1825, "P" +493, 18, 36, 409, 139, 140, 1826, 1827, "<" +493, 18, 37, 410, 141, 142, 1828, 1829, "0" +493, 18, 38, 411, 143, 144, 1830, 1831, "." +493, 18, 39, 412, 145, 147, 1832, 1834, "04" +493, 18, 40, 413, 148, 149, 1835, 1836, "," +493, 18, 41, 414, 150, 152, 1837, 1839, "PP" +493, 18, 42, 415, 153, 154, 1840, 1841, ";" +493, 18, 43, 416, 155, 156, 1842, 1843, "P" +493, 18, 44, 417, 157, 158, 1844, 1845, "<" +493, 18, 45, 418, 159, 160, 1846, 1847, "0" +493, 18, 46, 419, 161, 162, 1848, 1849, "." +493, 18, 47, 420, 163, 166, 1850, 1853, "001" +493, 18, 48, 421, 167, 168, 1854, 1855, "," +493, 18, 49, 422, 169, 172, 1856, 1859, "ITT" +493, 18, 50, 423, 173, 174, 1860, 1861, ")" +493, 18, 51, 424, 175, 177, 1862, 1864, "in" +493, 18, 52, 425, 178, 183, 1865, 1870, "favor" +493, 18, 53, 426, 184, 186, 1871, 1873, "of" +493, 18, 54, 427, 187, 198, 1874, 1885, "latanoprost" +493, 18, 55, 428, 199, 200, 1886, 1887, "0" +493, 18, 56, 429, 201, 202, 1888, 1889, "." +493, 18, 57, 430, 203, 206, 1890, 1893, "005" +493, 18, 58, 431, 207, 208, 1894, 1895, "%" +493, 18, 59, 432, 209, 210, 1896, 1897, "." +493, 19, 1, 433, 0, 3, 1898, 1901, "Two" +493, 19, 2, 434, 4, 8, 1902, 1906, "eyes" +493, 19, 3, 435, 9, 16, 1907, 1914, "treated" +493, 19, 4, 436, 17, 21, 1915, 1919, "with" +493, 19, 5, 437, 22, 33, 1920, 1931, "latanoprost" +493, 19, 6, 438, 34, 40, 1932, 1938, "showed" +493, 19, 7, 439, 41, 43, 1939, 1941, "an" +493, 19, 8, 440, 44, 48, 1942, 1946, "iris" +493, 19, 9, 441, 49, 54, 1947, 1952, "color" +493, 19, 10, 442, 55, 61, 1953, 1959, "change" +493, 19, 11, 443, 62, 63, 1960, 1961, "." +493, 20, 1, 444, 0, 6, 1962, 1968, "Thirty" +493, 20, 2, 445, 7, 8, 1969, 1970, "-" +493, 20, 3, 446, 9, 12, 1971, 1974, "six" +493, 20, 4, 447, 13, 21, 1975, 1983, "patients" +493, 20, 5, 448, 22, 24, 1984, 1986, "in" +493, 20, 6, 449, 25, 28, 1987, 1990, "the" +493, 20, 7, 450, 29, 40, 1991, 2002, "latanoprost" +493, 20, 8, 451, 41, 46, 2003, 2008, "group" +493, 20, 9, 452, 47, 50, 2009, 2012, "and" +493, 20, 10, 453, 51, 54, 2013, 2016, "106" +493, 20, 11, 454, 55, 57, 2017, 2019, "in" +493, 20, 12, 455, 58, 61, 2020, 2023, "the" +493, 20, 13, 456, 62, 73, 2024, 2035, "pilocarpine" +493, 20, 14, 457, 74, 75, 2036, 2037, "2" +493, 20, 15, 458, 76, 77, 2038, 2039, "%" +493, 20, 16, 459, 78, 83, 2040, 2045, "group" +493, 20, 17, 460, 84, 92, 2046, 2054, "reported" +493, 20, 18, 461, 93, 99, 2055, 2061, "ocular" +493, 20, 19, 462, 100, 107, 2062, 2069, "adverse" +493, 20, 20, 463, 108, 114, 2070, 2076, "events" +493, 20, 21, 464, 115, 116, 2077, 2078, "(" +493, 20, 22, 465, 117, 118, 2079, 2080, "P" +493, 20, 23, 466, 119, 120, 2081, 2082, "<" +493, 20, 24, 467, 121, 122, 2083, 2084, "0" +493, 20, 25, 468, 123, 124, 2085, 2086, "." +493, 20, 26, 469, 125, 128, 2087, 2090, "001" +493, 20, 27, 470, 129, 130, 2091, 2092, ")" +493, 20, 28, 471, 131, 132, 2093, 2094, "." +493, 21, 1, 472, 0, 10, 2095, 2105, "CONCLUSION" +493, 21, 2, 473, 11, 12, 2106, 2107, ":" +493, 21, 3, 474, 13, 17, 2108, 2112, "From" +493, 21, 4, 475, 18, 21, 2113, 2116, "the" +493, 21, 5, 476, 22, 26, 2117, 2121, "data" +493, 21, 6, 477, 27, 29, 2122, 2124, "we" +493, 21, 7, 478, 30, 38, 2125, 2133, "conclude" +493, 21, 8, 479, 39, 43, 2134, 2138, "that" +493, 21, 9, 480, 44, 47, 2139, 2142, "the" +493, 21, 10, 481, 48, 58, 2143, 2153, "additivity" +493, 21, 11, 482, 59, 61, 2154, 2156, "of" +493, 21, 12, 483, 62, 73, 2157, 2168, "latanoprost" +493, 21, 13, 484, 74, 75, 2169, 2170, "0" +493, 21, 14, 485, 76, 77, 2171, 2172, "." +493, 21, 15, 486, 78, 81, 2173, 2176, "005" +493, 21, 16, 487, 82, 83, 2177, 2178, "%" +493, 21, 17, 488, 84, 86, 2179, 2181, "is" +493, 21, 18, 489, 87, 89, 2182, 2184, "at" +493, 21, 19, 490, 90, 95, 2185, 2190, "least" +493, 21, 20, 491, 96, 98, 2191, 2193, "as" +493, 21, 21, 492, 99, 108, 2194, 2203, "effective" +493, 21, 22, 493, 109, 111, 2204, 2206, "as" +493, 21, 23, 494, 112, 123, 2207, 2218, "pilocarpine" +493, 21, 24, 495, 124, 125, 2219, 2220, "2" +493, 21, 25, 496, 126, 127, 2221, 2222, "%" +493, 21, 26, 497, 128, 129, 2223, 2224, "t" +493, 21, 27, 498, 130, 131, 2225, 2226, "." +493, 21, 28, 499, 132, 133, 2227, 2228, "i" +493, 21, 29, 500, 134, 135, 2229, 2230, "." +493, 21, 30, 501, 136, 137, 2231, 2232, "d" +493, 21, 31, 502, 138, 139, 2233, 2234, "." +493, 22, 1, 503, 0, 2, 2235, 2237, "in" +493, 22, 2, 504, 3, 11, 2238, 2246, "reducing" +493, 22, 3, 505, 12, 15, 2247, 2250, "IOP" +493, 22, 4, 506, 16, 20, 2251, 2255, "when" +493, 22, 5, 507, 21, 26, 2256, 2261, "added" +493, 22, 6, 508, 27, 29, 2262, 2264, "to" +493, 22, 7, 509, 30, 34, 2265, 2269, "eyes" +493, 22, 8, 510, 35, 44, 2270, 2279, "currently" +493, 22, 9, 511, 45, 47, 2280, 2282, "on" +493, 22, 10, 512, 48, 59, 2283, 2294, "monotherapy" +493, 22, 11, 513, 60, 64, 2295, 2299, "with" +493, 22, 12, 514, 65, 72, 2300, 2307, "timolol" +493, 22, 13, 515, 73, 74, 2308, 2309, "0" +493, 22, 14, 516, 75, 76, 2310, 2311, "." +493, 22, 15, 517, 77, 78, 2312, 2313, "5" +493, 22, 16, 518, 79, 80, 2314, 2315, "%" +493, 22, 17, 519, 81, 82, 2316, 2317, "b" +493, 22, 18, 520, 83, 84, 2318, 2319, "." +493, 22, 19, 521, 85, 86, 2320, 2321, "i" +493, 22, 20, 522, 87, 88, 2322, 2323, "." +493, 22, 21, 523, 89, 90, 2324, 2325, "d" +493, 22, 22, 524, 91, 92, 2326, 2327, "." +493, 23, 1, 525, 0, 11, 2328, 2339, "Latanoprost" +493, 23, 2, 526, 12, 15, 2340, 2343, "was" +493, 23, 3, 527, 16, 22, 2344, 2350, "better" +493, 23, 4, 528, 23, 32, 2351, 2360, "tolerated" +493, 23, 5, 529, 33, 37, 2361, 2365, "than" +493, 23, 6, 530, 38, 49, 2366, 2377, "pilocarpine" +493, 23, 7, 531, 50, 51, 2378, 2379, "2" +493, 23, 8, 532, 52, 53, 2380, 2381, "%" +493, 23, 9, 533, 54, 57, 2382, 2385, "eye" +493, 23, 10, 534, 58, 63, 2386, 2391, "drops" +493, 23, 11, 535, 64, 66, 2392, 2394, "in" +493, 23, 12, 536, 67, 71, 2395, 2399, "this" +493, 23, 13, 537, 72, 77, 2400, 2405, "study" +493, 23, 14, 538, 78, 79, 2406, 2407, "." +493, 24, 1, 539, 0, 3, 2408, 2411, "The" +493, 24, 2, 540, 4, 12, 2412, 2420, "increase" +493, 24, 3, 541, 13, 15, 2421, 2423, "in" +493, 24, 4, 542, 16, 20, 2424, 2428, "iris" +493, 24, 5, 543, 21, 33, 2429, 2441, "pigmentation" +493, 24, 6, 544, 34, 42, 2442, 2450, "requires" +493, 24, 7, 545, 43, 50, 2451, 2458, "further" +493, 24, 8, 546, 51, 64, 2459, 2472, "investigation" +493, 24, 9, 547, 65, 66, 2473, 2474, "." +493, 25, 1, 548, 0, 4, 2475, 2479, "PMID" +493, 25, 2, 549, 5, 6, 2480, 2481, ":" +493, 25, 3, 550, 7, 15, 2482, 2490, "10901475" +493, 25, 4, 551, 16, 17, 2491, 2492, "[" +493, 25, 5, 552, 18, 25, 2493, 2500, "Indexed" +493, 25, 6, 553, 26, 29, 2501, 2504, "for" +493, 25, 7, 554, 30, 37, 2505, 2512, "MEDLINE" +493, 25, 8, 555, 38, 39, 2513, 2514, "]" diff --git a/data/gl 10901475_jshahinitiran.annodb b/data/gl 10901475_jshahinitiran.annodb new file mode 100644 index 0000000..3d8f601 --- /dev/null +++ b/data/gl 10901475_jshahinitiran.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +1545, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +1546, PublicationYear, 35, 39, "2000", "", +1547, Title, 68, 187, "The additive intraocular pressure - lowering effect of latanoprost 0 . 005 % daily once and pilocarpine 2 % t . i . d .", "", +1548, IOP, 81, 101, "intraocular pressure", "", +1549, Latanoprost, 123, 134, "latanoprost", "", +25886, DoseValue, 135, 142, "0 . 005", "", +25891, Percentage, 143, 144, "%", "", +25902, Frequency, 145, 155, "daily once", "", +1554, Pilocarpine, 160, 171, "pilocarpine", "", +25903, DoseValue, 172, 173, "2", "", +25904, Percentage, 174, 175, "%", "", +25905, Frequency, 176, 185, "t . i . d", "", +1558, OpenAngleGlaucoma, 205, 226, "open - angle glaucoma", "", +1559, OcularHypertension, 230, 249, "ocular hypertension", "", +25906, Duration, 254, 263, "6 - month", "", +25943, Randomized, 266, 276, "randomized", "", +25907, Multicenter, 279, 290, "multicenter", "", +1646, Author, 332, 346, "Diestelhorst M", "", +1648, Germany, 436, 443, "Germany", "", +1563, ObjectiveDescription, 456, 709, "To compare the additional intraocular pressure - lowering effect of latanoprost 0 . 005 % administered once daily with that of pilocarpine 2 % administered three times daily in patients with primary open - angle glaucoma or ocular hypertension currently", "", +25915, IOP, 482, 502, "intraocular pressure", "", +1576, Latanoprost, 524, 535, "latanoprost", "", +25887, DoseValue, 536, 543, "0 . 005", "", +25892, Percentage, 544, 545, "%", "", +25908, Frequency, 559, 569, "once daily", "", +1580, Pilocarpine, 583, 594, "pilocarpine", "", +25909, DoseValue, 595, 596, "2", "", +25910, Percentage, 597, 598, "%", "", +25911, Frequency, 612, 629, "three times daily", "", +26405, Primary_OpenAngleGlaucoma, 647, 676, "primary open - angle glaucoma", "", +1585, OcularHypertension, 680, 699, "ocular hypertension", "", +39020, ObjectiveDescription, 710, 759, "on monotherapy with timolol 0 . 5 % twice daily .", "", +1588, Timolol, 730, 737, "timolol", "", +25912, DoseValue, 738, 743, "0 . 5", "", +25913, Percentage, 744, 745, "%", "", +25914, Frequency, 746, 757, "twice daily", "", +25916, Duration, 775, 784, "6 - month", "", +25917, Multicenter, 787, 798, "multicenter", "", +25942, Randomized, 801, 811, "randomized", "", +1567, OpenLabel, 814, 826, "open - label", "", +25918, NumberPatientsCT, 833, 836, "242", "", +26406, Primary_OpenAngleGlaucoma, 851, 855, "POAG", "", +1570, OcularHypertension, 859, 861, "OH", "", +1571, IOP, 868, 871, "IOP", "", +1572, Timolol, 896, 903, "timolol", "", +25919, DoseValue, 904, 909, "0 . 5", "", +25920, Percentage, 910, 911, "%", "", +25921, Frequency, 912, 921, "b . i . d", "", +1592, Precondition, 940, 1021, "Eyes had not been treated with pilocarpine and latanoprost for at least 2 years .", "", +25922, Pilocarpine, 971, 982, "pilocarpine", "", +25923, Latanoprost, 987, 998, "latanoprost", "", +1593, Diurnal_IOP, 1053, 1064, "diurnal IOP", "", +31626, TimePoint, 1077, 1085, "baseline", "", +25924, TimePoint, 1089, 1096, "month 6", "", +10333, NumPatientsLeftArm, 1138, 1142, "Four", "", +1620, Latanoprost, 1155, 1166, "latanoprost", "", +25888, DoseValue, 1167, 1174, "0 . 005", "", +25893, Percentage, 1175, 1176, "%", "", +10334, NumPatientsLeftArm, 1181, 1183, "35", "", +1621, Pilocarpine, 1187, 1198, "pilocarpine", "", +25925, DoseValue, 1199, 1200, "2", "", +25901, Percentage, 1201, 1202, "%", "", +1596, NumberPatientsCT, 1248, 1269, "Two hundred and forty", "", +1595, IntentionToTreat, 1300, 1319, "intent - to - treat", "", +1593, Diurnal_IOP, 1355, 1366, "diurnal IOP", "", +31625, TimePoint, 1383, 1391, "6 months", "", +1599, PValueChangeValue, 1424, 1435, "P < 0 . 001", "", +1600, IOP, 1440, 1443, "IOP", "", +1601, Mean, 1446, 1450, "mean", "", +1602, BaseLineValue, 1479, 1485, "23 . 3", "lat", +10339, SdDevBL, 1492, 1497, "2 . 8", "", +1605, ResultMeasuredValue, 1501, 1507, "17 . 8", "lat", +10340, SdDevResValue, 1514, 1519, "2 . 8", "", +10341, Reduction, 1524, 1529, "5 . 6", "", +1607, mmHg, 1532, 1536, "mmHg", "lat", +1608, Latanoprost, 1544, 1555, "latanoprost", "", +25890, DoseValue, 1556, 1563, "0 . 005", "", +25899, Percentage, 1564, 1565, "%", "", +1611, BaseLineValue, 1581, 1587, "23 . 0", "pil", +10342, SdDevBL, 1594, 1599, "3 . 2", "", +1613, ResultMeasuredValue, 1603, 1609, "18 . 5", "pil", +10343, SdDevResValue, 1616, 1621, "2 . 4", "", +10344, Reduction, 1626, 1631, "4 . 8", "", +1615, mmHg, 1634, 1638, "mmHg", "pil", +1616, Pilocarpine, 1642, 1653, "pilocarpine", "", +25927, DoseValue, 1654, 1655, "2", "", +25928, Percentage, 1656, 1657, "%", "", +25929, Frequency, 1658, 1667, "t . i . d", "", +10335, Mean, 1691, 1695, "mean", "", +10336, DiffGroupAbsValue, 1712, 1717, "0 . 8", "", +10337, mmHg, 1718, 1722, "mmHg", "", +10338, PerProtocol, 1725, 1737, "per protocol", "", +25930, PerProtocol, 1740, 1742, "PP", "", +39022, DiffGroupAbsValue, 1751, 1756, "1 . 6", "", +39021, mmHg, 1757, 1761, "mmHg", "", +25931, IntentionToTreat, 1764, 1783, "intend - to - treat", "", +25932, IntentionToTreat, 1786, 1789, "ITT", "", +25933, Latanoprost, 1874, 1885, "latanoprost", "", +25934, DoseValue, 1886, 1893, "0 . 005", "", +25935, Percentage, 1894, 1895, "%", "", +1649, NumberAffected, 1898, 1906, "Two eyes", "", +1627, Latanoprost, 1920, 1931, "latanoprost", "", +1626, IrisPigmentation, 1942, 1959, "iris color change", "", +26409, NumberAffected, 1962, 1974, "Thirty - six", "", +26407, Latanoprost, 1991, 2002, "latanoprost", "", +26410, NumberAffected, 2013, 2016, "106", "", +26408, Pilocarpine, 2024, 2035, "pilocarpine", "", +26411, DoseValue, 2036, 2037, "2", "", +26412, Percentage, 2038, 2039, "%", "", +26413, PValueNumAffected, 2079, 2090, "P < 0 . 001", "", +1647, ConclusionComment, 2108, 2234, "From the data we conclude that the additivity of latanoprost 0 . 005 % is at least as effective as pilocarpine 2 % t . i . d .", "", +1628, Latanoprost, 2157, 2168, "latanoprost", "", +25889, DoseValue, 2169, 2176, "0 . 005", "", +25896, Percentage, 2177, 2178, "%", "", +1629, Pilocarpine, 2207, 2218, "pilocarpine", "", +25936, DoseValue, 2219, 2220, "2", "", +25898, Percentage, 2221, 2222, "%", "", +25937, Frequency, 2223, 2232, "t . i . d", "", +1638, IOP, 2247, 2250, "IOP", "", +1630, Timolol, 2300, 2307, "timolol", "", +25938, DoseValue, 2308, 2313, "0 . 5", "", +25939, Percentage, 2314, 2315, "%", "", +25940, Frequency, 2316, 2325, "b . i . d", "", +1631, Latanoprost, 2328, 2339, "Latanoprost", "", +1632, Pilocarpine, 2366, 2377, "pilocarpine", "", +25941, DoseValue, 2378, 2379, "2", "", +25897, Percentage, 2380, 2381, "%", "", +1644, Eyedrops, 2382, 2391, "eye drops", "", +26414, IrisPigmentation, 2424, 2441, "iris pigmentation", "", +1645, PMID, 2482, 2490, "10901475", "", diff --git a/data/gl 10901475_jshahinitiran.n-triples b/data/gl 10901475_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10901475_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 10901475_tstrakeljahn.annodb b/data/gl 10901475_tstrakeljahn.annodb new file mode 100644 index 0000000..54bc1c8 --- /dev/null +++ b/data/gl 10901475_tstrakeljahn.annodb @@ -0,0 +1,127 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +3353, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +3354, PublicationYear, 35, 39, "2000", "", +3355, IOP, 81, 101, "intraocular pressure", "", +3356, Latanoprost, 123, 134, "latanoprost", "", +3359, DoseValue, 135, 142, "0 . 005", "", +3361, Percentage, 143, 144, "%", "", +3358, Frequency, 145, 155, "daily once", "", +7337, Pilocarpine, 160, 171, "pilocarpine", "", +3360, DoseValue, 172, 173, "2", "", +3362, Percentage, 174, 175, "%", "", +3357, Frequency, 176, 187, "t . i . d .", "'ter in die' three times daily", +3363, OpenAngleGlaucoma, 205, 226, "open - angle glaucoma", "", +3364, OcularHypertension, 230, 249, "ocular hypertension", "", +3365, Duration, 254, 263, "6 - month", "", +3366, Randomized, 266, 276, "randomized", "", +3367, Multicenter, 279, 290, "multicenter", "", +3368, Latanoprost, 306, 317, "Latanoprost", "", +3369, Author, 332, 346, "Diestelhorst M", "", +3370, Germany, 436, 443, "Germany", "", +3387, ObjectiveDescription, 456, 699, "To compare the additional intraocular pressure - lowering effect of latanoprost 0 . 005 % administered once daily with that of pilocarpine 2 % administered three times daily in patients with primary open - angle glaucoma or ocular hypertension", "", +3371, IOP, 482, 502, "intraocular pressure", "", +3372, Latanoprost, 524, 535, "latanoprost", "", +3376, DoseValue, 536, 543, "0 . 005", "", +3378, Percentage, 544, 545, "%", "", +3374, Frequency, 559, 569, "once daily", "", +3373, Pilocarpine, 583, 594, "pilocarpine", "", +3377, DoseValue, 595, 596, "2", "", +3379, Percentage, 597, 598, "%", "", +3375, Frequency, 612, 629, "three times daily", "", +3381, OpenAngleGlaucoma, 655, 676, "open - angle glaucoma", "", +3382, OcularHypertension, 680, 699, "ocular hypertension", "", +3388, ObjectiveDescription, 700, 757, "currently on monotherapy with timolol 0 . 5 % twice daily", "", +3385, Precondition, 713, 757, "monotherapy with timolol 0 . 5 % twice daily", "", +3383, Timolol, 730, 737, "timolol", "", +3384, DoseValue, 738, 743, "0 . 5", "", +3380, Percentage, 744, 745, "%", "", +3386, Frequency, 746, 757, "twice daily", "", +3389, Duration, 775, 784, "6 - month", "", +3390, Multicenter, 787, 798, "multicenter", "", +3391, Randomized, 801, 811, "randomized", "", +3392, OpenLabel, 814, 826, "open - label", "", +3393, NumberPatientsCT, 833, 836, "242", "", +3394, OpenAngleGlaucoma, 851, 855, "POAG", "", +3395, OcularHypertension, 859, 861, "OH", "", +3396, IOP, 868, 871, "IOP", "", +3401, Precondition, 876, 921, "not controlled with timolol 0 . 5 % b . i . d", "", +3398, Timolol, 896, 903, "timolol", "", +3399, DoseValue, 904, 909, "0 . 5", "", +3400, Percentage, 910, 911, "%", "", +3397, Frequency, 912, 921, "b . i . d", "'bis in die' twice daily", +3402, Precondition, 940, 1019, "Eyes had not been treated with pilocarpine and latanoprost for at least 2 years", "", +3403, Pilocarpine, 971, 982, "pilocarpine", "", +3404, Latanoprost, 987, 998, "latanoprost", "", +3406, CTAnalysisApproach, 1022, 1125, "An analysis of covariance with diurnal IOP change from baseline to month 6 for study eyes was performed", "", +3405, Diurnal_IOP, 1053, 1064, "diurnal IOP", "", +3408, Latanoprost, 1155, 1166, "latanoprost", "", +3410, DoseValue, 1167, 1174, "0 . 005", "", +3411, Percentage, 1175, 1176, "%", "", +3409, Pilocarpine, 1187, 1198, "pilocarpine", "", +3413, DoseValue, 1199, 1200, "2", "", +3412, Percentage, 1201, 1202, "%", "", +3407, NumberPatientsCT, 1248, 1278, "Two hundred and forty patients", "final", +3414, Diurnal_IOP, 1355, 1366, "diurnal IOP", "", +3415, TimePoint, 1383, 1391, "6 months", "", +3416, PValueChangeValue, 1424, 1435, "P < 0 . 001", "", +3417, IOP, 1440, 1443, "IOP", "", +3418, Mean, 1446, 1450, "mean", "", +3419, BaseLineValue, 1479, 1485, "23 . 3", "", +3421, SdDevBL, 1492, 1497, "2 . 8", "", +3422, ResultMeasuredValue, 1501, 1507, "17 . 8", "", +3424, SdDevResValue, 1514, 1519, "2 . 8", "", +3423, Reduction, 1524, 1529, "5 . 6", "", +3425, mmHg, 1532, 1536, "mmHg", "", +3426, Latanoprost, 1544, 1555, "latanoprost", "", +3427, DoseValue, 1556, 1563, "0 . 005", "", +3428, Percentage, 1564, 1565, "%", "", +3420, BaseLineValue, 1581, 1587, "23 . 0", "", +3429, SdDevBL, 1594, 1599, "3 . 2", "", +3430, ResultMeasuredValue, 1603, 1609, "18 . 5", "", +3432, SdDevResValue, 1616, 1621, "2 . 4", "", +3431, Reduction, 1626, 1631, "4 . 8", "", +3433, mmHg, 1634, 1638, "mmHg", "", +3434, Pilocarpine, 1642, 1653, "pilocarpine", "", +3435, DoseValue, 1654, 1655, "2", "", +3436, Percentage, 1656, 1657, "%", "", +3437, Frequency, 1658, 1667, "t . i . d", "'ter in die' three times daily", +3439, Mean, 1691, 1695, "mean", "", +3440, DiffGroupAbsValue, 1710, 1717, "- 0 . 8", "PP", +3444, mmHg, 1718, 1722, "mmHg", "", +3441, DiffGroupAbsValue, 1749, 1756, "- 1 . 6", "ITT", +3443, mmHg, 1757, 1761, "mmHg", "", +3445, PvalueDiff, 1824, 1834, "P < 0 . 04", "PP", +3446, PvalueDiff, 1842, 1853, "P < 0 . 001", "ITT", +3447, Latanoprost, 1874, 1885, "latanoprost", "", +3448, DoseValue, 1886, 1893, "0 . 005", "", +3449, Percentage, 1894, 1895, "%", "", +3451, NumberAffected, 1898, 1906, "Two eyes", "", +3452, Latanoprost, 1920, 1931, "latanoprost", "", +3450, IrisPigmentation, 1942, 1959, "iris color change", "", +3453, NumberAffected, 1962, 1983, "Thirty - six patients", "", +3454, Latanoprost, 1991, 2002, "latanoprost", "", +3455, NumberAffected, 2013, 2016, "106", "", +3456, Pilocarpine, 2024, 2035, "pilocarpine", "", +3457, DoseValue, 2036, 2037, "2", "", +3458, Percentage, 2038, 2039, "%", "", +3460, PValueNumAffected, 2079, 2090, "P < 0 . 001", "", +3471, ConclusionComment, 2108, 2234, "From the data we conclude that the additivity of latanoprost 0 . 005 % is at least as effective as pilocarpine 2 % t . i . d .", "", +3463, Latanoprost, 2157, 2168, "latanoprost", "", +3461, DoseValue, 2169, 2176, "0 . 005", "", +3464, Pilocarpine, 2207, 2218, "pilocarpine", "", +3462, DoseValue, 2219, 2220, "2", "", +3465, Frequency, 2223, 2232, "t . i . d", "'ter in die' three times daily", +3472, ConclusionComment, 2235, 2325, "in reducing IOP when added to eyes currently on monotherapy with timolol 0 . 5 % b . i . d", "", +3466, IOP, 2247, 2250, "IOP", "", +3467, Timolol, 2300, 2307, "timolol", "", +3468, DoseValue, 2308, 2313, "0 . 5", "", +3469, Percentage, 2314, 2315, "%", "", +3470, Frequency, 2316, 2325, "b . i . d", "'bis in die' twice daily", +3473, ConclusionComment, 2328, 2405, "Latanoprost was better tolerated than pilocarpine 2 % eye drops in this study", "", +3475, Latanoprost, 2328, 2339, "Latanoprost", "", +3474, Pilocarpine, 2366, 2377, "pilocarpine", "", +3476, DoseValue, 2378, 2379, "2", "", +3477, Percentage, 2380, 2381, "%", "", +3478, Eyedrops, 2382, 2391, "eye drops", "", +3480, ConclusionComment, 2408, 2472, "The increase in iris pigmentation requires further investigation", "", +3481, PMID, 2482, 2490, "10901475", "", diff --git a/data/gl 10901475_tstrakeljahn.n-triples b/data/gl 10901475_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 10901475_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11039742_admin.annodb b/data/gl 11039742_admin.annodb new file mode 100644 index 0000000..c38cad0 --- /dev/null +++ b/data/gl 11039742_admin.annodb @@ -0,0 +1,74 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +27346, PublicationYear, 13, 17, "2000", "", " \"2000\"." +2, Title, 46, 245, "Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0 . 2 % and betaxolol 0 . 25 % suspension in patients with open - angle glaucoma and ocular hypertension .", "", " \"Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0 . 2 % and betaxolol 0 . 25 % suspension in patients with open - angle glaucoma and ocular hypertension .\"." +36943, EndPointDescription, 64, 80, "clinical success", "", " . ." +24602, Brimonidine, 118, 138, "brimonidine tartrate", "", +76, DoseValue, 139, 144, "0 . 2", "", +80, Percentage, 145, 146, "%", "", +25, Betaxolol, 151, 160, "betaxolol", "", " ." +77, DoseValue, 161, 167, "0 . 25", "", +81, Percentage, 168, 169, "%", "", +23, OpenAngleGlaucoma, 198, 219, "open - angle glaucoma", "", " ." +39, OcularHypertension, 224, 243, "ocular hypertension", "", " ." +40, Brimonidine, 246, 257, "Brimonidine", "", +41, Author, 284, 292, "Javitt J", "", " \"Javitt J\"." +4, Author, 301, 311, "Goldberg I", "", " \"Goldberg I\"." +27348, USA, 428, 431, "USA", "", " ." +6, ObjectiveDescription, 444, 650, "To compare the clinical effectiveness and the impact on quality of life of twice - daily brimonidine 0 . 2 % with those of twice - daily betaxolol 0 . 25 % in patients with glaucoma or ocular hypertension .", "", " \"To compare the clinical effectiveness and the impact on quality of life of twice - daily brimonidine 0 . 2 % with those of twice - daily betaxolol 0 . 25 % in patients with glaucoma or ocular hypertension .\"." +44, Frequency, 519, 532, "twice - daily", "", " \"twice - daily\"." +34, Brimonidine, 533, 544, "brimonidine", "", " ." +102, DoseValue, 545, 550, "0 . 2", "", " \"0 . 2\"." +82, Percentage, 551, 552, "%", "", " ." +45, Frequency, 567, 580, "twice - daily", "", " \"twice - daily\"." +27347, Betaxolol, 581, 590, "betaxolol", "", +79, DoseValue, 591, 597, "0 . 25", "", " \"0 . 25\"." +27358, Percentage, 598, 599, "%", "", " ." +36, Glaucoma, 617, 625, "glaucoma", "", " . ." +24603, OcularHypertension, 629, 648, "ocular hypertension", "", +36941, Prospective, 663, 674, "prospective", "", " ." +8, DoubleBlind, 677, 692, "double - masked", "", " ." +51, Randomized, 695, 705, "randomized", "", " ." +27341, CTDesign, 708, 719, "comparative", "", " . ." +11, Multicenter, 722, 733, "multicenter", "", " ." +12, Duration, 736, 745, "4 - month", "", " \"4 - month\"." +54, NumberPatientsCT, 787, 790, "188", "", " \"188\"." +27349, Frequency, 829, 840, "twice daily", "", +46, IOP, 890, 910, "intraocular pressure", "", " . ." +96, Glaucoma, 1012, 1020, "Glaucoma", "", +16, HeartRate, 1042, 1052, "heart rate", "", " . ." +60, BloodPressure, 1059, 1073, "blood pressure", "", " . ." +49, IOP, 1116, 1136, "intraocular pressure", "", +111, TimePoint, 1143, 1150, "1 month", "", +36942, TimePoint, 1210, 1221, "first month", "", +27342, Duration, 1327, 1335, "4 months", "", +27343, EndPointDescription, 1385, 1401, "clinical success", "", +101, EndPointDescription, 1650, 1666, "clinical success", "", +27357, PercentageAffected, 1683, 1685, "74", "", " \"74\"." +63, Brimonidine, 1713, 1724, "brimonidine", "", +84, PercentageAffected, 1744, 1746, "57", "", " \"57\"." +27350, Betaxolol, 1774, 1783, "betaxolol", "", +50, PvalueDiff, 1786, 1797, "P = 0 . 027", "", " \"P = 0 . 027\"." +65, Mean, 1814, 1818, "mean", "", " . ." +26, IOP, 1831, 1851, "intraocular pressure", "", +27353, Reduction, 1870, 1875, "5 . 9", "", " \"5 . 9\"." +57, mmHg, 1876, 1881, "mm Hg", "", " ." +71, Brimonidine, 1887, 1898, "brimonidine", "", +27354, Reduction, 1903, 1908, "3 . 8", "", " \"3 . 8\"." +58, mmHg, 1909, 1914, "mm Hg", "", +72, Betaxolol, 1920, 1929, "betaxolol", "", +92990, ObservedResult, 1932, 2062, "Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events", "", " \"Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events\". \"Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events\"." +92991, EndPointDescription, 2048, 2062, "adverse events", "", " . ." +31, ConclusionComment, 2120, 2274, "Twice - daily brimonidine 0 . 2 % and betaxolol 0 . 25 % suspension were safe and effective as first - line therapy for glaucoma and ocular hypertension .", "", " \"Twice - daily brimonidine 0 . 2 % and betaxolol 0 . 25 % suspension were safe and effective as first - line therapy for glaucoma and ocular hypertension .\"." +27351, Frequency, 2120, 2133, "Twice - daily", "", +27352, Brimonidine, 2134, 2145, "brimonidine", "", +27356, DoseValue, 2146, 2151, "0 . 2", "", +69, Percentage, 2152, 2153, "%", "", +24590, Betaxolol, 2158, 2167, "betaxolol", "", +27355, DoseValue, 2168, 2174, "0 . 25", "", +70, Percentage, 2175, 2176, "%", "", +124, Glaucoma, 2240, 2248, "glaucoma", "", +24604, OcularHypertension, 2253, 2272, "ocular hypertension", "", +27345, ConclusionComment, 2275, 2364, "In this study , brimonidine showed clinical effectiveness superior to that of betaxolol .", "", " \"In this study , brimonidine showed clinical effectiveness superior to that of betaxolol .\"." +27344, Brimonidine, 2291, 2302, "brimonidine", "", +92975, PMID, 2372, 2380, "11039742", "", " \"11039742\"." diff --git a/data/gl 11039742_admin.n-triples b/data/gl 11039742_admin.n-triples new file mode 100644 index 0000000..1fa5565 --- /dev/null +++ b/data/gl 11039742_admin.n-triples @@ -0,0 +1,147 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0 . 2 % and betaxolol 0 . 25 % suspension in patients with open - angle glaucoma and ocular hypertension ." . + "Javitt J" . + "2000" . + "J Glaucoma" . + "11039742" . + . + "Goldberg I" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the clinical effectiveness and the impact on quality of life of twice - daily brimonidine 0 . 2 % with those of twice - daily betaxolol 0 . 25 % in patients with glaucoma or ocular hypertension ." . + "188" . + "4 - month" . + . + . + . + "Twice - daily brimonidine 0 . 2 % and betaxolol 0 . 25 % suspension were safe and effective as first - line therapy for glaucoma and ocular hypertension ." . + . + . + . + . + . + . + . + . + . + . + "In this study , brimonidine showed clinical effectiveness superior to that of betaxolol ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + . + "Endpoint-hr" . + . + . + . + . + . + . + "Endpoint-bp" . + . + . + . + . + . + . + "Endpoint-cs" . + . + . + . + . + . + . + "Endpoint-ad" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-bri" . + . + . + . + . + . + "Arm-bet" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-bri" . + . + "twice - daily" . + . + . + "Intervention-bet" . + . + "twice - daily" . + . +# RDF export of group: Medication + . + "Medication-bri" . + . + "0 . 2" . + . + . + . + "Medication-bet" . + . + "0 . 25" . + . + . +# RDF export of group: Outcome + . + "Outcome-cs-bri" . + . + "74" . + . + "Outcome-cs-bet" . + . + "57" . + . + "Outcome-iop-bri" . + . + "5 . 9" . + . + "Outcome-iop-bet" . + . + "3 . 8" . + . + "Outcome-ad-bri" . + . + "Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events" . + . + "Outcome-ad-bet" . + . + "Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-cs" . + "P = 0 . 027" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11039742_export.csv b/data/gl 11039742_export.csv new file mode 100644 index 0000000..a9b8e4a --- /dev/null +++ b/data/gl 11039742_export.csv @@ -0,0 +1,439 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +492, 1, 1, 1, 0, 1, 0, 1, "J" +492, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +492, 1, 3, 3, 11, 12, 11, 12, "." +492, 2, 1, 4, 0, 4, 13, 17, "2000" +492, 2, 2, 5, 5, 8, 18, 21, "Oct" +492, 2, 3, 6, 9, 10, 22, 23, ";" +492, 2, 4, 7, 11, 12, 24, 25, "9" +492, 2, 5, 8, 13, 14, 26, 27, "(" +492, 2, 6, 9, 15, 16, 28, 29, "5" +492, 2, 7, 10, 17, 18, 30, 31, ")" +492, 2, 8, 11, 19, 20, 32, 33, ":" +492, 2, 9, 12, 21, 24, 34, 37, "398" +492, 2, 10, 13, 25, 26, 38, 39, "-" +492, 2, 11, 14, 27, 30, 40, 43, "408" +492, 2, 12, 15, 31, 32, 44, 45, "." +492, 3, 1, 16, 0, 10, 46, 56, "Comparison" +492, 3, 2, 17, 11, 13, 57, 59, "of" +492, 3, 3, 18, 14, 17, 60, 63, "the" +492, 3, 4, 19, 18, 26, 64, 72, "clinical" +492, 3, 5, 20, 27, 34, 73, 80, "success" +492, 3, 6, 21, 35, 40, 81, 86, "rates" +492, 3, 7, 22, 41, 44, 87, 90, "and" +492, 3, 8, 23, 45, 52, 91, 98, "quality" +492, 3, 9, 24, 53, 55, 99, 101, "of" +492, 3, 10, 25, 56, 60, 102, 106, "life" +492, 3, 11, 26, 61, 68, 107, 114, "effects" +492, 3, 12, 27, 69, 71, 115, 117, "of" +492, 3, 13, 28, 72, 83, 118, 129, "brimonidine" +492, 3, 14, 29, 84, 92, 130, 138, "tartrate" +492, 3, 15, 30, 93, 94, 139, 140, "0" +492, 3, 16, 31, 95, 96, 141, 142, "." +492, 3, 17, 32, 97, 98, 143, 144, "2" +492, 3, 18, 33, 99, 100, 145, 146, "%" +492, 3, 19, 34, 101, 104, 147, 150, "and" +492, 3, 20, 35, 105, 114, 151, 160, "betaxolol" +492, 3, 21, 36, 115, 116, 161, 162, "0" +492, 3, 22, 37, 117, 118, 163, 164, "." +492, 3, 23, 38, 119, 121, 165, 167, "25" +492, 3, 24, 39, 122, 123, 168, 169, "%" +492, 3, 25, 40, 124, 134, 170, 180, "suspension" +492, 3, 26, 41, 135, 137, 181, 183, "in" +492, 3, 27, 42, 138, 146, 184, 192, "patients" +492, 3, 28, 43, 147, 151, 193, 197, "with" +492, 3, 29, 44, 152, 156, 198, 202, "open" +492, 3, 30, 45, 157, 158, 203, 204, "-" +492, 3, 31, 46, 159, 164, 205, 210, "angle" +492, 3, 32, 47, 165, 173, 211, 219, "glaucoma" +492, 3, 33, 48, 174, 177, 220, 223, "and" +492, 3, 34, 49, 178, 184, 224, 230, "ocular" +492, 3, 35, 50, 185, 197, 231, 243, "hypertension" +492, 3, 36, 51, 198, 199, 244, 245, "." +492, 4, 1, 52, 0, 11, 246, 257, "Brimonidine" +492, 4, 2, 53, 12, 20, 258, 266, "Outcomes" +492, 4, 3, 54, 21, 26, 267, 272, "Study" +492, 4, 4, 55, 27, 32, 273, 278, "Group" +492, 4, 5, 56, 33, 35, 279, 281, "II" +492, 4, 6, 57, 36, 37, 282, 283, "." +492, 5, 1, 58, 0, 6, 284, 290, "Javitt" +492, 5, 2, 59, 7, 8, 291, 292, "J" +492, 5, 3, 60, 9, 10, 293, 294, "(" +492, 5, 4, 61, 11, 12, 295, 296, "1" +492, 5, 5, 62, 13, 14, 297, 298, ")" +492, 5, 6, 63, 15, 16, 299, 300, "," +492, 5, 7, 64, 17, 25, 301, 309, "Goldberg" +492, 5, 8, 65, 26, 27, 310, 311, "I" +492, 5, 9, 66, 28, 29, 312, 313, "." +492, 6, 1, 67, 0, 6, 314, 320, "Author" +492, 6, 2, 68, 7, 18, 321, 332, "information" +492, 6, 3, 69, 19, 20, 333, 334, ":" +492, 6, 4, 70, 21, 22, 335, 336, "(" +492, 6, 5, 71, 23, 24, 337, 338, "1" +492, 6, 6, 72, 25, 26, 339, 340, ")" +492, 6, 7, 73, 27, 37, 341, 351, "Department" +492, 6, 8, 74, 38, 40, 352, 354, "of" +492, 6, 9, 75, 41, 54, 355, 368, "Ophthalmology" +492, 6, 10, 76, 55, 56, 369, 370, "," +492, 6, 11, 77, 57, 67, 371, 381, "Georgetown" +492, 6, 12, 78, 68, 78, 382, 392, "University" +492, 6, 13, 79, 79, 86, 393, 400, "Medical" +492, 6, 14, 80, 87, 93, 401, 407, "Center" +492, 6, 15, 81, 94, 95, 408, 409, "," +492, 6, 16, 82, 96, 106, 410, 420, "Washington" +492, 6, 17, 83, 107, 108, 421, 422, "," +492, 6, 18, 84, 109, 111, 423, 425, "DC" +492, 6, 19, 85, 112, 113, 426, 427, "," +492, 6, 20, 86, 114, 117, 428, 431, "USA" +492, 6, 21, 87, 118, 119, 432, 433, "." +492, 7, 1, 88, 0, 7, 434, 441, "PURPOSE" +492, 7, 2, 89, 8, 9, 442, 443, ":" +492, 7, 3, 90, 10, 12, 444, 446, "To" +492, 7, 4, 91, 13, 20, 447, 454, "compare" +492, 7, 5, 92, 21, 24, 455, 458, "the" +492, 7, 6, 93, 25, 33, 459, 467, "clinical" +492, 7, 7, 94, 34, 47, 468, 481, "effectiveness" +492, 7, 8, 95, 48, 51, 482, 485, "and" +492, 7, 9, 96, 52, 55, 486, 489, "the" +492, 7, 10, 97, 56, 62, 490, 496, "impact" +492, 7, 11, 98, 63, 65, 497, 499, "on" +492, 7, 12, 99, 66, 73, 500, 507, "quality" +492, 7, 13, 100, 74, 76, 508, 510, "of" +492, 7, 14, 101, 77, 81, 511, 515, "life" +492, 7, 15, 102, 82, 84, 516, 518, "of" +492, 7, 16, 103, 85, 90, 519, 524, "twice" +492, 7, 17, 104, 91, 92, 525, 526, "-" +492, 7, 18, 105, 93, 98, 527, 532, "daily" +492, 7, 19, 106, 99, 110, 533, 544, "brimonidine" +492, 7, 20, 107, 111, 112, 545, 546, "0" +492, 7, 21, 108, 113, 114, 547, 548, "." +492, 7, 22, 109, 115, 116, 549, 550, "2" +492, 7, 23, 110, 117, 118, 551, 552, "%" +492, 7, 24, 111, 119, 123, 553, 557, "with" +492, 7, 25, 112, 124, 129, 558, 563, "those" +492, 7, 26, 113, 130, 132, 564, 566, "of" +492, 7, 27, 114, 133, 138, 567, 572, "twice" +492, 7, 28, 115, 139, 140, 573, 574, "-" +492, 7, 29, 116, 141, 146, 575, 580, "daily" +492, 7, 30, 117, 147, 156, 581, 590, "betaxolol" +492, 7, 31, 118, 157, 158, 591, 592, "0" +492, 7, 32, 119, 159, 160, 593, 594, "." +492, 7, 33, 120, 161, 163, 595, 597, "25" +492, 7, 34, 121, 164, 165, 598, 599, "%" +492, 7, 35, 122, 166, 168, 600, 602, "in" +492, 7, 36, 123, 169, 177, 603, 611, "patients" +492, 7, 37, 124, 178, 182, 612, 616, "with" +492, 7, 38, 125, 183, 191, 617, 625, "glaucoma" +492, 7, 39, 126, 192, 194, 626, 628, "or" +492, 7, 40, 127, 195, 201, 629, 635, "ocular" +492, 7, 41, 128, 202, 214, 636, 648, "hypertension" +492, 7, 42, 129, 215, 216, 649, 650, "." +492, 8, 1, 130, 0, 7, 651, 658, "METHODS" +492, 8, 2, 131, 8, 9, 659, 660, ":" +492, 8, 3, 132, 10, 11, 661, 662, "A" +492, 8, 4, 133, 12, 23, 663, 674, "prospective" +492, 8, 5, 134, 24, 25, 675, 676, "," +492, 8, 6, 135, 26, 32, 677, 683, "double" +492, 8, 7, 136, 33, 34, 684, 685, "-" +492, 8, 8, 137, 35, 41, 686, 692, "masked" +492, 8, 9, 138, 42, 43, 693, 694, "," +492, 8, 10, 139, 44, 54, 695, 705, "randomized" +492, 8, 11, 140, 55, 56, 706, 707, "," +492, 8, 12, 141, 57, 68, 708, 719, "comparative" +492, 8, 13, 142, 69, 70, 720, 721, "," +492, 8, 14, 143, 71, 82, 722, 733, "multicenter" +492, 8, 15, 144, 83, 84, 734, 735, "," +492, 8, 16, 145, 85, 86, 736, 737, "4" +492, 8, 17, 146, 87, 88, 738, 739, "-" +492, 8, 18, 147, 89, 94, 740, 745, "month" +492, 8, 19, 148, 95, 96, 746, 747, "---" +492, 8, 20, 149, 97, 101, 748, 752, "real" +492, 8, 21, 150, 102, 103, 753, 754, "-" +492, 8, 22, 151, 104, 108, 755, 759, "life" +492, 8, 23, 152, 109, 110, 760, 761, "---" +492, 8, 24, 153, 111, 119, 762, 770, "clinical" +492, 8, 25, 154, 120, 125, 771, 776, "trial" +492, 8, 26, 155, 126, 135, 777, 786, "involving" +492, 8, 27, 156, 136, 139, 787, 790, "188" +492, 8, 28, 157, 140, 148, 791, 799, "patients" +492, 8, 29, 158, 149, 150, 800, 801, "." +492, 9, 1, 159, 0, 11, 802, 813, "Medications" +492, 9, 2, 160, 12, 16, 814, 818, "were" +492, 9, 3, 161, 17, 26, 819, 828, "instilled" +492, 9, 4, 162, 27, 32, 829, 834, "twice" +492, 9, 5, 163, 33, 38, 835, 840, "daily" +492, 9, 6, 164, 39, 40, 841, 842, "." +492, 10, 1, 165, 0, 8, 843, 851, "Efficacy" +492, 10, 2, 166, 9, 12, 852, 855, "was" +492, 10, 3, 167, 13, 23, 856, 866, "determined" +492, 10, 4, 168, 24, 31, 867, 874, "through" +492, 10, 5, 169, 32, 43, 875, 886, "measurement" +492, 10, 6, 170, 44, 46, 887, 889, "of" +492, 10, 7, 171, 47, 58, 890, 901, "intraocular" +492, 10, 8, 172, 59, 67, 902, 910, "pressure" +492, 10, 9, 173, 68, 69, 911, 912, ";" +492, 10, 10, 174, 70, 76, 913, 919, "safety" +492, 10, 11, 175, 77, 80, 920, 923, "and" +492, 10, 12, 176, 81, 93, 924, 936, "tolerability" +492, 10, 13, 177, 94, 98, 937, 941, "were" +492, 10, 14, 178, 99, 107, 942, 950, "measured" +492, 10, 15, 179, 108, 113, 951, 956, "using" +492, 10, 16, 180, 114, 121, 957, 964, "reports" +492, 10, 17, 181, 122, 124, 965, 967, "of" +492, 10, 18, 182, 125, 132, 968, 975, "adverse" +492, 10, 19, 183, 133, 139, 976, 982, "events" +492, 10, 20, 184, 140, 141, 983, 984, "," +492, 10, 21, 185, 142, 143, 985, 986, "a" +492, 10, 22, 186, 144, 151, 987, 994, "quality" +492, 10, 23, 187, 152, 154, 995, 997, "of" +492, 10, 24, 188, 155, 159, 998, 1002, "life" +492, 10, 25, 189, 160, 166, 1003, 1009, "survey" +492, 10, 26, 190, 167, 168, 1010, 1011, "(" +492, 10, 27, 191, 169, 177, 1012, 1020, "Glaucoma" +492, 10, 28, 192, 178, 188, 1021, 1031, "Disability" +492, 10, 29, 193, 189, 194, 1032, 1037, "Index" +492, 10, 30, 194, 195, 196, 1038, 1039, ")" +492, 10, 31, 195, 197, 198, 1040, 1041, "," +492, 10, 32, 196, 199, 204, 1042, 1047, "heart" +492, 10, 33, 197, 205, 209, 1048, 1052, "rate" +492, 10, 34, 198, 210, 211, 1053, 1054, "," +492, 10, 35, 199, 212, 215, 1055, 1058, "and" +492, 10, 36, 200, 216, 221, 1059, 1064, "blood" +492, 10, 37, 201, 222, 230, 1065, 1073, "pressure" +492, 10, 38, 202, 231, 232, 1074, 1075, "." +492, 11, 1, 203, 0, 8, 1076, 1084, "Patients" +492, 11, 2, 204, 9, 13, 1085, 1089, "with" +492, 11, 3, 205, 14, 16, 1090, 1092, "an" +492, 11, 4, 206, 17, 27, 1093, 1103, "inadequate" +492, 11, 5, 207, 28, 36, 1104, 1112, "response" +492, 11, 6, 208, 37, 39, 1113, 1115, "in" +492, 11, 7, 209, 40, 51, 1116, 1127, "intraocular" +492, 11, 8, 210, 52, 60, 1128, 1136, "pressure" +492, 11, 9, 211, 61, 66, 1137, 1142, "after" +492, 11, 10, 212, 67, 68, 1143, 1144, "1" +492, 11, 11, 213, 69, 74, 1145, 1150, "month" +492, 11, 12, 214, 75, 77, 1151, 1153, "or" +492, 11, 13, 215, 78, 83, 1154, 1159, "those" +492, 11, 14, 216, 84, 87, 1160, 1163, "who" +492, 11, 15, 217, 88, 99, 1164, 1175, "experienced" +492, 11, 16, 218, 100, 111, 1176, 1187, "significant" +492, 11, 17, 219, 112, 119, 1188, 1195, "adverse" +492, 11, 18, 220, 120, 126, 1196, 1202, "events" +492, 11, 19, 221, 127, 129, 1203, 1205, "in" +492, 11, 20, 222, 130, 133, 1206, 1209, "the" +492, 11, 21, 223, 134, 139, 1210, 1215, "first" +492, 11, 22, 224, 140, 145, 1216, 1221, "month" +492, 11, 23, 225, 146, 150, 1222, 1226, "were" +492, 11, 24, 226, 151, 159, 1227, 1235, "switched" +492, 11, 25, 227, 160, 162, 1236, 1238, "to" +492, 11, 26, 228, 163, 166, 1239, 1242, "the" +492, 11, 27, 229, 167, 178, 1243, 1254, "alternative" +492, 11, 28, 230, 179, 184, 1255, 1260, "study" +492, 11, 29, 231, 185, 188, 1261, 1264, "arm" +492, 11, 30, 232, 189, 192, 1265, 1268, "and" +492, 11, 31, 233, 193, 201, 1269, 1277, "remained" +492, 11, 32, 234, 202, 208, 1278, 1284, "taking" +492, 11, 33, 235, 209, 212, 1285, 1288, "the" +492, 11, 34, 236, 213, 224, 1289, 1300, "alternative" +492, 11, 35, 237, 225, 235, 1301, 1311, "medication" +492, 11, 36, 238, 236, 239, 1312, 1315, "for" +492, 11, 37, 239, 240, 241, 1316, 1317, "a" +492, 11, 38, 240, 242, 247, 1318, 1323, "total" +492, 11, 39, 241, 248, 250, 1324, 1326, "of" +492, 11, 40, 242, 251, 252, 1327, 1328, "4" +492, 11, 41, 243, 253, 259, 1329, 1335, "months" +492, 11, 42, 244, 260, 262, 1336, 1338, "or" +492, 11, 43, 245, 263, 267, 1339, 1343, "left" +492, 11, 44, 246, 268, 271, 1344, 1347, "the" +492, 11, 45, 247, 272, 277, 1348, 1353, "study" +492, 11, 46, 248, 278, 279, 1354, 1355, "." +492, 12, 1, 249, 0, 3, 1356, 1359, "The" +492, 12, 2, 250, 4, 8, 1360, 1364, "main" +492, 12, 3, 251, 9, 16, 1365, 1372, "outcome" +492, 12, 4, 252, 17, 24, 1373, 1380, "measure" +492, 12, 5, 253, 25, 28, 1381, 1384, "was" +492, 12, 6, 254, 29, 37, 1385, 1393, "clinical" +492, 12, 7, 255, 38, 45, 1394, 1401, "success" +492, 12, 8, 256, 46, 47, 1402, 1403, "," +492, 12, 9, 257, 48, 50, 1404, 1406, "as" +492, 12, 10, 258, 51, 61, 1407, 1417, "determined" +492, 12, 11, 259, 62, 64, 1418, 1420, "by" +492, 12, 12, 260, 65, 75, 1421, 1431, "evaluation" +492, 12, 13, 261, 76, 78, 1432, 1434, "of" +492, 12, 14, 262, 79, 82, 1435, 1438, "the" +492, 12, 15, 263, 83, 91, 1439, 1447, "efficacy" +492, 12, 16, 264, 92, 93, 1448, 1449, "," +492, 12, 17, 265, 94, 100, 1450, 1456, "safety" +492, 12, 18, 266, 101, 102, 1457, 1458, "," +492, 12, 19, 267, 103, 106, 1459, 1462, "and" +492, 12, 20, 268, 107, 119, 1463, 1475, "tolerability" +492, 12, 21, 269, 120, 122, 1476, 1478, "of" +492, 12, 22, 270, 123, 127, 1479, 1483, "drug" +492, 12, 23, 271, 128, 137, 1484, 1493, "treatment" +492, 12, 24, 272, 138, 139, 1494, 1495, "," +492, 12, 25, 273, 140, 143, 1496, 1499, "and" +492, 12, 26, 274, 144, 147, 1500, 1503, "was" +492, 12, 27, 275, 148, 156, 1504, 1512, "achieved" +492, 12, 28, 276, 157, 161, 1513, 1517, "when" +492, 12, 29, 277, 162, 165, 1518, 1521, "the" +492, 12, 30, 278, 166, 178, 1522, 1534, "investigator" +492, 12, 31, 279, 179, 190, 1535, 1546, "recommended" +492, 12, 32, 280, 191, 195, 1547, 1551, "that" +492, 12, 33, 281, 196, 199, 1552, 1555, "the" +492, 12, 34, 282, 200, 207, 1556, 1563, "patient" +492, 12, 35, 283, 208, 216, 1564, 1572, "continue" +492, 12, 36, 284, 217, 220, 1573, 1576, "the" +492, 12, 37, 285, 221, 230, 1577, 1586, "treatment" +492, 12, 38, 286, 231, 236, 1587, 1592, "after" +492, 12, 39, 287, 237, 247, 1593, 1603, "completion" +492, 12, 40, 288, 248, 250, 1604, 1606, "of" +492, 12, 41, 289, 251, 254, 1607, 1610, "the" +492, 12, 42, 290, 255, 260, 1611, 1616, "study" +492, 12, 43, 291, 261, 262, 1617, 1618, "." +492, 13, 1, 292, 0, 7, 1619, 1626, "RESULTS" +492, 13, 2, 293, 8, 9, 1627, 1628, ":" +492, 13, 3, 294, 10, 12, 1629, 1631, "As" +492, 13, 4, 295, 13, 20, 1632, 1639, "initial" +492, 13, 5, 296, 21, 28, 1640, 1647, "therapy" +492, 13, 6, 297, 29, 30, 1648, 1649, "," +492, 13, 7, 298, 31, 39, 1650, 1658, "clinical" +492, 13, 8, 299, 40, 47, 1659, 1666, "success" +492, 13, 9, 300, 48, 51, 1667, 1670, "was" +492, 13, 10, 301, 52, 60, 1671, 1679, "achieved" +492, 13, 11, 302, 61, 63, 1680, 1682, "in" +492, 13, 12, 303, 64, 66, 1683, 1685, "74" +492, 13, 13, 304, 67, 68, 1686, 1687, "%" +492, 13, 14, 305, 69, 71, 1688, 1690, "of" +492, 13, 15, 306, 72, 80, 1691, 1699, "patients" +492, 13, 16, 307, 81, 88, 1700, 1707, "treated" +492, 13, 17, 308, 89, 93, 1708, 1712, "with" +492, 13, 18, 309, 94, 105, 1713, 1724, "brimonidine" +492, 13, 19, 310, 106, 107, 1725, 1726, "," +492, 13, 20, 311, 108, 110, 1727, 1729, "as" +492, 13, 21, 312, 111, 119, 1730, 1738, "compared" +492, 13, 22, 313, 120, 124, 1739, 1743, "with" +492, 13, 23, 314, 125, 127, 1744, 1746, "57" +492, 13, 24, 315, 128, 129, 1747, 1748, "%" +492, 13, 25, 316, 130, 132, 1749, 1751, "of" +492, 13, 26, 317, 133, 141, 1752, 1760, "patients" +492, 13, 27, 318, 142, 149, 1761, 1768, "treated" +492, 13, 28, 319, 150, 154, 1769, 1773, "with" +492, 13, 29, 320, 155, 164, 1774, 1783, "betaxolol" +492, 13, 30, 321, 165, 166, 1784, 1785, "(" +492, 13, 31, 322, 167, 168, 1786, 1787, "P" +492, 13, 32, 323, 169, 170, 1788, 1789, "=" +492, 13, 33, 324, 171, 172, 1790, 1791, "0" +492, 13, 34, 325, 173, 174, 1792, 1793, "." +492, 13, 35, 326, 175, 178, 1794, 1797, "027" +492, 13, 36, 327, 179, 180, 1798, 1799, ")" +492, 13, 37, 328, 181, 182, 1800, 1801, "." +492, 14, 1, 329, 0, 3, 1802, 1805, "The" +492, 14, 2, 330, 4, 11, 1806, 1813, "overall" +492, 14, 3, 331, 12, 16, 1814, 1818, "mean" +492, 14, 4, 332, 17, 25, 1819, 1827, "decrease" +492, 14, 5, 333, 26, 28, 1828, 1830, "in" +492, 14, 6, 334, 29, 40, 1831, 1842, "intraocular" +492, 14, 7, 335, 41, 49, 1843, 1851, "pressure" +492, 14, 8, 336, 50, 54, 1852, 1856, "from" +492, 14, 9, 337, 55, 63, 1857, 1865, "baseline" +492, 14, 10, 338, 64, 67, 1866, 1869, "was" +492, 14, 11, 339, 68, 69, 1870, 1871, "5" +492, 14, 12, 340, 70, 71, 1872, 1873, "." +492, 14, 13, 341, 72, 73, 1874, 1875, "9" +492, 14, 14, 342, 74, 76, 1876, 1878, "mm" +492, 14, 15, 343, 77, 79, 1879, 1881, "Hg" +492, 14, 16, 344, 80, 84, 1882, 1886, "with" +492, 14, 17, 345, 85, 96, 1887, 1898, "brimonidine" +492, 14, 18, 346, 97, 100, 1899, 1902, "and" +492, 14, 19, 347, 101, 102, 1903, 1904, "3" +492, 14, 20, 348, 103, 104, 1905, 1906, "." +492, 14, 21, 349, 105, 106, 1907, 1908, "8" +492, 14, 22, 350, 107, 109, 1909, 1911, "mm" +492, 14, 23, 351, 110, 112, 1912, 1914, "Hg" +492, 14, 24, 352, 113, 117, 1915, 1919, "with" +492, 14, 25, 353, 118, 127, 1920, 1929, "betaxolol" +492, 14, 26, 354, 128, 129, 1930, 1931, "." +492, 15, 1, 355, 0, 4, 1932, 1936, "Both" +492, 15, 2, 356, 5, 15, 1937, 1947, "treatments" +492, 15, 3, 357, 16, 20, 1948, 1952, "were" +492, 15, 4, 358, 21, 25, 1953, 1957, "well" +492, 15, 5, 359, 26, 35, 1958, 1967, "tolerated" +492, 15, 6, 360, 36, 37, 1968, 1969, "," +492, 15, 7, 361, 38, 41, 1970, 1973, "and" +492, 15, 8, 362, 42, 47, 1974, 1979, "there" +492, 15, 9, 363, 48, 52, 1980, 1984, "were" +492, 15, 10, 364, 53, 55, 1985, 1987, "no" +492, 15, 11, 365, 56, 67, 1988, 1999, "significant" +492, 15, 12, 366, 68, 75, 2000, 2007, "between" +492, 15, 13, 367, 76, 77, 2008, 2009, "-" +492, 15, 14, 368, 78, 83, 2010, 2015, "group" +492, 15, 15, 369, 84, 95, 2016, 2027, "differences" +492, 15, 16, 370, 96, 98, 2028, 2030, "in" +492, 15, 17, 371, 99, 102, 2031, 2034, "the" +492, 15, 18, 372, 103, 112, 2035, 2044, "incidence" +492, 15, 19, 373, 113, 115, 2045, 2047, "of" +492, 15, 20, 374, 116, 123, 2048, 2055, "adverse" +492, 15, 21, 375, 124, 130, 2056, 2062, "events" +492, 15, 22, 376, 131, 133, 2063, 2065, "or" +492, 15, 23, 377, 134, 136, 2066, 2068, "in" +492, 15, 24, 378, 137, 140, 2069, 2072, "the" +492, 15, 25, 379, 141, 148, 2073, 2080, "quality" +492, 15, 26, 380, 149, 151, 2081, 2083, "of" +492, 15, 27, 381, 152, 156, 2084, 2088, "life" +492, 15, 28, 382, 157, 164, 2089, 2096, "summary" +492, 15, 29, 383, 165, 171, 2097, 2103, "scores" +492, 15, 30, 384, 172, 173, 2104, 2105, "." +492, 16, 1, 385, 0, 11, 2106, 2117, "CONCLUSIONS" +492, 16, 2, 386, 12, 13, 2118, 2119, ":" +492, 16, 3, 387, 14, 19, 2120, 2125, "Twice" +492, 16, 4, 388, 20, 21, 2126, 2127, "-" +492, 16, 5, 389, 22, 27, 2128, 2133, "daily" +492, 16, 6, 390, 28, 39, 2134, 2145, "brimonidine" +492, 16, 7, 391, 40, 41, 2146, 2147, "0" +492, 16, 8, 392, 42, 43, 2148, 2149, "." +492, 16, 9, 393, 44, 45, 2150, 2151, "2" +492, 16, 10, 394, 46, 47, 2152, 2153, "%" +492, 16, 11, 395, 48, 51, 2154, 2157, "and" +492, 16, 12, 396, 52, 61, 2158, 2167, "betaxolol" +492, 16, 13, 397, 62, 63, 2168, 2169, "0" +492, 16, 14, 398, 64, 65, 2170, 2171, "." +492, 16, 15, 399, 66, 68, 2172, 2174, "25" +492, 16, 16, 400, 69, 70, 2175, 2176, "%" +492, 16, 17, 401, 71, 81, 2177, 2187, "suspension" +492, 16, 18, 402, 82, 86, 2188, 2192, "were" +492, 16, 19, 403, 87, 91, 2193, 2197, "safe" +492, 16, 20, 404, 92, 95, 2198, 2201, "and" +492, 16, 21, 405, 96, 105, 2202, 2211, "effective" +492, 16, 22, 406, 106, 108, 2212, 2214, "as" +492, 16, 23, 407, 109, 114, 2215, 2220, "first" +492, 16, 24, 408, 115, 116, 2221, 2222, "-" +492, 16, 25, 409, 117, 121, 2223, 2227, "line" +492, 16, 26, 410, 122, 129, 2228, 2235, "therapy" +492, 16, 27, 411, 130, 133, 2236, 2239, "for" +492, 16, 28, 412, 134, 142, 2240, 2248, "glaucoma" +492, 16, 29, 413, 143, 146, 2249, 2252, "and" +492, 16, 30, 414, 147, 153, 2253, 2259, "ocular" +492, 16, 31, 415, 154, 166, 2260, 2272, "hypertension" +492, 16, 32, 416, 167, 168, 2273, 2274, "." +492, 17, 1, 417, 0, 2, 2275, 2277, "In" +492, 17, 2, 418, 3, 7, 2278, 2282, "this" +492, 17, 3, 419, 8, 13, 2283, 2288, "study" +492, 17, 4, 420, 14, 15, 2289, 2290, "," +492, 17, 5, 421, 16, 27, 2291, 2302, "brimonidine" +492, 17, 6, 422, 28, 34, 2303, 2309, "showed" +492, 17, 7, 423, 35, 43, 2310, 2318, "clinical" +492, 17, 8, 424, 44, 57, 2319, 2332, "effectiveness" +492, 17, 9, 425, 58, 66, 2333, 2341, "superior" +492, 17, 10, 426, 67, 69, 2342, 2344, "to" +492, 17, 11, 427, 70, 74, 2345, 2349, "that" +492, 17, 12, 428, 75, 77, 2350, 2352, "of" +492, 17, 13, 429, 78, 87, 2353, 2362, "betaxolol" +492, 17, 14, 430, 88, 89, 2363, 2364, "." +492, 18, 1, 431, 0, 4, 2365, 2369, "PMID" +492, 18, 2, 432, 5, 6, 2370, 2371, ":" +492, 18, 3, 433, 7, 15, 2372, 2380, "11039742" +492, 18, 4, 434, 16, 17, 2381, 2382, "[" +492, 18, 5, 435, 18, 25, 2383, 2390, "Indexed" +492, 18, 6, 436, 26, 29, 2391, 2394, "for" +492, 18, 7, 437, 30, 37, 2395, 2402, "MEDLINE" +492, 18, 8, 438, 38, 39, 2403, 2404, "]" diff --git a/data/gl 11039742_jshahinitiran.annodb b/data/gl 11039742_jshahinitiran.annodb new file mode 100644 index 0000000..ed0bfd6 --- /dev/null +++ b/data/gl 11039742_jshahinitiran.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2288, Journal, 0, 10, "J Glaucoma", "", +2289, PublicationYear, 13, 21, "2000 Oct", "", +2290, Title, 46, 245, "Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0 . 2 % and betaxolol 0 . 25 % suspension in patients with open - angle glaucoma and ocular hypertension .", "", +25944, Brimonidine, 118, 138, "brimonidine tartrate", "", +25946, DoseValue, 139, 144, "0 . 2", "", +25947, Percentage, 145, 146, "%", "", +25948, Betaxolol, 151, 160, "betaxolol", "", +25949, DoseValue, 161, 167, "0 . 25", "", +25950, Percentage, 168, 169, "%", "", +2319, OpenAngleGlaucoma, 198, 219, "open - angle glaucoma", "", +25951, OcularHypertension, 224, 243, "ocular hypertension", "", +25952, Brimonidine, 246, 257, "Brimonidine", "", +2291, Author, 284, 294, "Javitt J (", "", +2292, Author, 301, 311, "Goldberg I", "", +2293, USA, 428, 433, "USA .", "", +2294, ObjectiveDescription, 444, 650, "To compare the clinical effectiveness and the impact on quality of life of twice - daily brimonidine 0 . 2 % with those of twice - daily betaxolol 0 . 25 % in patients with glaucoma or ocular hypertension .", "", +25953, Frequency, 519, 532, "twice - daily", "", +25955, Brimonidine, 533, 544, "brimonidine", "", +25957, DoseValue, 545, 550, "0 . 2", "", +25959, Percentage, 551, 552, "%", "", +25954, Frequency, 567, 580, "twice - daily", "", +25956, Betaxolol, 581, 590, "betaxolol", "", +25958, DoseValue, 591, 597, "0 . 25", "", +25960, Percentage, 598, 599, "%", "", +25961, Glaucoma, 617, 625, "glaucoma", "", +25962, OcularHypertension, 629, 648, "ocular hypertension", "", +39023, Prospective, 663, 674, "prospective", "", +2296, DoubleBlind, 677, 692, "double - masked", "", +2298, Randomized, 695, 707, "randomized ,", "", +2299, CTDesign, 708, 721, "comparative ,", "comparative", +2300, Multicenter, 722, 733, "multicenter", "", +2303, Duration, 736, 745, "4 - month", "ct", +2304, NumberPatientsCT, 787, 799, "188 patients", "", +39024, Frequency, 829, 840, "twice daily", "", +25963, IOP, 890, 910, "intraocular pressure", "", +10345, Glaucoma, 1012, 1020, "Glaucoma", "", +2307, HeartRate, 1042, 1052, "heart rate", "", +25964, BloodPressure, 1059, 1073, "blood pressure", "", +25965, IOP, 1116, 1136, "intraocular pressure", "", +25966, TimePoint, 1143, 1150, "1 month", "", +10350, EndPointDescription, 1650, 1666, "clinical success", "", +10348, PercentageAffected, 1683, 1685, "74", "", +10346, Brimonidine, 1713, 1724, "brimonidine", "", +10349, PercentageAffected, 1744, 1746, "57", "", +10347, Betaxolol, 1774, 1783, "betaxolol", "", +25967, PValueNumAffected, 1786, 1797, "P = 0 . 027", "", +2332, Mean, 1814, 1818, "mean", "", +2331, IOP, 1831, 1851, "intraocular pressure", "", +2333, ResultMeasuredValue, 1870, 1875, "5 . 9", "", +25968, mmHg, 1876, 1881, "mm Hg", "", +25970, Brimonidine, 1887, 1898, "brimonidine", "", +2336, ResultMeasuredValue, 1903, 1908, "3 . 8", "", +25969, mmHg, 1909, 1914, "mm Hg", "", +25971, Betaxolol, 1920, 1929, "betaxolol", "", +2340, ConclusionComment, 2120, 2274, "Twice - daily brimonidine 0 . 2 % and betaxolol 0 . 25 % suspension were safe and effective as first - line therapy for glaucoma and ocular hypertension .", "", +25972, Frequency, 2120, 2133, "Twice - daily", "", +25973, Brimonidine, 2134, 2145, "brimonidine", "", +25975, DoseValue, 2146, 2151, "0 . 2", "", +25977, Percentage, 2152, 2153, "%", "", +25974, Betaxolol, 2158, 2167, "betaxolol", "", +25976, DoseValue, 2168, 2174, "0 . 25", "", +25978, Percentage, 2175, 2176, "%", "", +25979, Glaucoma, 2240, 2248, "glaucoma", "", +25980, OcularHypertension, 2253, 2272, "ocular hypertension", "", +2352, ConclusionComment, 2275, 2364, "In this study , brimonidine showed clinical effectiveness superior to that of betaxolol .", "", +25981, Brimonidine, 2291, 2302, "brimonidine", "", +25982, Betaxolol, 2353, 2362, "betaxolol", "", +25983, PMID, 2372, 2380, "11039742", "", diff --git a/data/gl 11039742_jshahinitiran.n-triples b/data/gl 11039742_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11039742_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11039742_tstrakeljahn.annodb b/data/gl 11039742_tstrakeljahn.annodb new file mode 100644 index 0000000..9d26ce3 --- /dev/null +++ b/data/gl 11039742_tstrakeljahn.annodb @@ -0,0 +1,63 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +3545, Journal, 0, 10, "J Glaucoma", "", +3546, PublicationYear, 13, 17, "2000", "", +3555, Title, 46, 243, "Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0 . 2 % and betaxolol 0 . 25 % suspension in patients with open - angle glaucoma and ocular hypertension", "", +3547, Brimonidine, 118, 138, "brimonidine tartrate", "", +3603, DoseValue, 139, 144, "0 . 2", "", +3607, Percentage, 145, 146, "%", "", +3548, Betaxolol, 151, 160, "betaxolol", "", +3604, DoseValue, 161, 167, "0 . 25", "", +3608, Percentage, 168, 169, "%", "", +3549, OpenAngleGlaucoma, 198, 219, "open - angle glaucoma", "", +3550, OcularHypertension, 224, 243, "ocular hypertension", "", +3551, Brimonidine, 246, 257, "Brimonidine", "", +3552, Author, 284, 292, "Javitt J", "", +3553, Author, 301, 311, "Goldberg I", "", +3554, USA, 428, 431, "USA", "", +3556, ObjectiveDescription, 444, 648, "To compare the clinical effectiveness and the impact on quality of life of twice - daily brimonidine 0 . 2 % with those of twice - daily betaxolol 0 . 25 % in patients with glaucoma or ocular hypertension", "", +3568, Frequency, 519, 532, "twice - daily", "", +3605, DoseValue, 533, 550, "brimonidine 0 . 2", "", +3557, Brimonidine, 533, 544, "brimonidine", "", +3609, Percentage, 551, 552, "%", "", +3569, Frequency, 567, 580, "twice - daily", "", +3558, Betaxolol, 581, 590, "betaxolol", "", +3606, DoseValue, 591, 597, "0 . 25", "", +3610, Percentage, 598, 599, "%", "", +3559, Glaucoma, 617, 625, "glaucoma", "", +3560, OcularHypertension, 629, 648, "ocular hypertension", "", +3561, DoubleBlind, 677, 692, "double - masked", "", +3562, Randomized, 695, 705, "randomized", "", +3563, Multicenter, 722, 733, "multicenter", "", +3564, Duration, 736, 745, "4 - month", "", +3566, NumberPatientsCT, 787, 790, "188", "", +3567, Frequency, 829, 840, "twice daily", "", +3570, IOP, 890, 910, "intraocular pressure", "", +3571, HeartRate, 1042, 1052, "heart rate", "", +3572, BloodPressure, 1059, 1073, "blood pressure", "", +3574, IOP, 1116, 1136, "intraocular pressure", "", +3598, PercentageAffected, 1683, 1685, "74", "", +3577, Brimonidine, 1713, 1724, "brimonidine", "", +3599, PercentageAffected, 1744, 1746, "57", "", +3578, Betaxolol, 1774, 1783, "betaxolol", "", +3575, PvalueDiff, 1786, 1797, "P = 0 . 027", "", +3579, Mean, 1814, 1818, "mean", "", +3581, IOP, 1831, 1851, "intraocular pressure", "", +3582, Reduction, 1870, 1875, "5 . 9", "", +3584, mmHg, 1876, 1881, "mm Hg", "", +3586, Brimonidine, 1887, 1898, "brimonidine", "", +3583, Reduction, 1903, 1908, "3 . 8", "", +3585, mmHg, 1909, 1914, "mm Hg", "", +3587, Betaxolol, 1920, 1929, "betaxolol", "", +3602, ObservedResult, 1932, 2103, "Both treatments were well tolerated , and there were no significant between - group differences in the incidence of adverse events or in the quality of life summary scores", "", +3591, Frequency, 2120, 2133, "Twice - daily", "", +3600, ConclusionComment, 2120, 2272, "Twice - daily brimonidine 0 . 2 % and betaxolol 0 . 25 % suspension were safe and effective as first - line therapy for glaucoma and ocular hypertension", "", +3592, Brimonidine, 2134, 2145, "brimonidine", "", +3594, DoseValue, 2146, 2151, "0 . 2", "", +3596, Percentage, 2152, 2153, "%", "", +3593, Betaxolol, 2158, 2167, "betaxolol", "", +3595, DoseValue, 2168, 2174, "0 . 25", "", +3597, Percentage, 2175, 2176, "%", "", +3601, ConclusionComment, 2275, 2362, "In this study , brimonidine showed clinical effectiveness superior to that of betaxolol", "", +3589, Brimonidine, 2291, 2302, "brimonidine", "", +3590, Betaxolol, 2353, 2362, "betaxolol", "", +3588, PMID, 2372, 2380, "11039742", "", diff --git a/data/gl 11039742_tstrakeljahn.n-triples b/data/gl 11039742_tstrakeljahn.n-triples new file mode 100644 index 0000000..f26af2b --- /dev/null +++ b/data/gl 11039742_tstrakeljahn.n-triples @@ -0,0 +1,13 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint + . +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome + . + "Outcome 9877" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11158796_admin.annodb b/data/gl 11158796_admin.annodb new file mode 100644 index 0000000..2c0bb1b --- /dev/null +++ b/data/gl 11158796_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +25523, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +0, PublicationYear, 16, 20, "2001", "", " \"2001\"." +6, Title, 50, 198, "A double - masked , randomized clinical trial comparing latanoprost with unoprostone in patients with open - angle glaucoma or ocular hypertension .", "", " \"A double - masked , randomized clinical trial comparing latanoprost with unoprostone in patients with open - angle glaucoma or ocular hypertension .\"." +36948, DoubleBlind, 52, 67, "double - masked", "", " ." +2, Randomized, 70, 80, "randomized", "", " ." +3, Latanoprost, 106, 117, "latanoprost", "", " . ." +4, Unoprostone, 123, 134, "unoprostone", "", +36947, OpenAngleGlaucoma, 152, 173, "open - angle glaucoma", "", " ." +25522, OcularHypertension, 177, 196, "ocular hypertension", "", " ." +7, Author, 199, 211, "Susanna R Jr", "", " \"Susanna R Jr\"." +8, Author, 220, 233, "Giampani J Jr", "", " \"Giampani J Jr\"." +9, Author, 236, 245, "Borges AS", "", " \"Borges AS\"." +10, Author, 248, 258, "Vessani RM", "", " \"Vessani RM\"." +11, Author, 261, 270, "Jordao ML", "", " \"Jordao ML\"." +73, Brazil, 432, 438, "Brazil", "", " ." +12, ObjectiveDescription, 451, 683, "To compare the intraocular pressure ( IOP ) reducing effect and safety of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", " \"To compare the intraocular pressure ( IOP ) reducing effect and safety of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .\"." +74, IOP, 466, 486, "intraocular pressure", "", " . ." +75, IOP, 489, 492, "IOP", "", +76, Latanoprost, 525, 536, "latanoprost", "", +77, DoseValue, 537, 544, "0 . 005", "", " \"0 . 005\"." +78, Percentage, 545, 546, "%", "", " ." +79, Frequency, 547, 557, "once daily", "", " \"once daily\"." +80, Unoprostone, 563, 574, "unoprostone", "", " ." +81, DoseValue, 575, 581, "0 . 12", "", " \"0 . 12\"." +82, Percentage, 582, 583, "%", "", " ." +83, Frequency, 584, 595, "twice daily", "", +106384, Precondition, 599, 681, "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +25511, Primary_OpenAngleGlaucoma, 613, 642, "primary open - angle glaucoma", "", " ." +25513, Primary_OpenAngleGlaucoma, 645, 649, "POAG", "", +85, OcularHypertension, 655, 674, "ocular hypertension", "", +86, OcularHypertension, 677, 679, "OH", "", +14, Duration, 696, 704, "8 - week", "", " \"8 - week\"." +15, DoubleBlind, 707, 722, "double - masked", "", +25516, Randomized, 725, 735, "randomized", "", +18, Parallel, 738, 754, "parallel - group", "", +17, SingleCenter, 757, 772, "single - center", "", " ." +19, NumberPatientsCT, 816, 819, "108", "", " \"108\"." +25514, Primary_OpenAngleGlaucoma, 834, 838, "POAG", "", +36949, OcularHypertension, 842, 844, "OH", "", +25, Latanoprost, 986, 997, "latanoprost", "", +25519, Frequency, 998, 1008, "once daily", "", +27, Bedtime, 1016, 1023, "evening", "", " ." +28, Placebo, 1029, 1036, "placebo", "", " ." +29, Frequency, 1037, 1047, "once daily", "", " \"once daily\"." +30, Morning, 1055, 1062, "morning", "", " ." +31, Unoprostone, 1068, 1079, "unoprostone", "", +25517, Frequency, 1080, 1091, "twice daily", "", " \"twice daily\"." +33, Morning, 1094, 1101, "morning", "", " ." +34, Bedtime, 1106, 1113, "evening", "", " ." +35, IOP, 1142, 1145, "IOP", "", +36946, TimePoint, 1162, 1201, "10 : 00 AM and at 5 : 00 PM at baseline", "", +36944, TimePoint, 1180, 1201, "5 : 00 PM at baseline", "", +99, TimePoint, 1209, 1215, "week 8", "", +100, TimePoint, 1222, 1251, "before 12 : 00 noon at week 2", "", +36, BaseLineValue, 1348, 1354, "24 . 1", "", " \"24 . 1\". \"24 . 1\"." +37, mmHg, 1355, 1359, "mmHg", "", " ." +38, Latanoprost, 1362, 1373, "latanoprost", "", +39, IOP, 1382, 1385, "IOP", "", +108, Reduction, 1389, 1394, "6 . 7", "", " \"6 . 7\"." +40, mmHg, 1395, 1399, "mmHg", "", +109, RelativeReduction, 1402, 1404, "28", "", " \"28\"." +41, Unoprostone, 1413, 1424, "unoprostone", "", +42, IOP, 1433, 1436, "IOP", "", +111, Reduction, 1440, 1445, "3 . 3", "", " \"3 . 3\"." +43, mmHg, 1446, 1450, "mmHg", "", +110, RelativeReduction, 1453, 1455, "14", "", " \"14\"." +114, DiffGroupAbsValue, 1499, 1504, "3 . 4", "", " \"3 . 4\"." +45, mmHg, 1505, 1509, "mmHg", "", +46, PvalueDiff, 1528, 1541, "P : < 0 . 001", "", " \"P : < 0 . 001\"." +47, ConfIntervalDiff, 1569, 1621, "95 % confidence interval [ CI ] : - 4 . 7 to - 2 . 1", "", " \"95 % confidence interval [ CI ] : - 4 . 7 to - 2 . 1\"." +48, Latanoprost, 1636, 1647, "latanoprost", "", +93013, IOP_target, 1652, 1684, "> / = 30 % reduction in mean IOP", "", +49, PercentageAffected, 1715, 1717, "44", "", " \"44\"." +122, Latanoprost, 1723, 1734, "latanoprost", "", +50, PercentageAffected, 1768, 1769, "8", "", " \"8\"." +124, Unoprostone, 1775, 1786, "unoprostone", "", +125, ObservedResult, 1808, 1881, "The incidence of adverse events was low and comparable between the groups", "", " \"The incidence of adverse events was low and comparable between the groups\"." +92992, EndPointDescription, 1825, 1839, "adverse events", "", " . ." +23, ConclusionComment, 1898, 2064, "Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH .", "", " \"Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH .\"." +54, Latanoprost, 1898, 1909, "Latanoprost", "", +25520, Frequency, 1923, 1933, "once daily", "", +55, IOP, 1979, 1982, "IOP", "", +56, Unoprostone, 1997, 2008, "unoprostone", "", +25518, Frequency, 2022, 2033, "twice daily", "", +25515, Primary_OpenAngleGlaucoma, 2051, 2055, "POAG", "", +25521, OcularHypertension, 2060, 2062, "OH", "", +24, PMID, 2072, 2080, "11158796", "", " \"11158796\"." diff --git a/data/gl 11158796_admin.n-triples b/data/gl 11158796_admin.n-triples new file mode 100644 index 0000000..97e14d6 --- /dev/null +++ b/data/gl 11158796_admin.n-triples @@ -0,0 +1,146 @@ +# RDF export of group: Publication + . + "Publication" . + "A double - masked , randomized clinical trial comparing latanoprost with unoprostone in patients with open - angle glaucoma or ocular hypertension ." . + "Susanna R Jr" . + "2001" . + "Ophthalmology" . + "11158796" . + . + "Giampani J Jr" . + "Borges AS" . + "Vessani RM" . + "Jordao ML" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ( IOP ) reducing effect and safety of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) ." . + "108" . + "8 - week" . + . + . + . + "Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + . + "Endpoint-ad" . + . + . + . + . + . + . + "Endpoint-30" . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + . + . + . + . + . + "Arm-uno" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-uno" . + . + "twice daily" . + . + . + . + "Intervention-pla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-pla" . + . + . + . + . + "Medication-uno" . + . + "0 . 12" . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-lat" . + . + "24 . 1" . + "6 . 7" . + "28" . + . + "Outcome-iop-uno" . + . + "24 . 1" . + "3 . 3" . + "14" . + . + "Outcome-ad" . + . + "The incidence of adverse events was low and comparable between the groups" . + . + "Outcome-30-lat" . + . + "44" . + . + "Outcome-30-uno" . + . + "8" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop" . + "3 . 4" . + "P : < 0 . 001" . + "95 % confidence interval [ CI ] : - 4 . 7 to - 2 . 1" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11158796_export.csv b/data/gl 11158796_export.csv new file mode 100644 index 0000000..5d77b10 --- /dev/null +++ b/data/gl 11158796_export.csv @@ -0,0 +1,426 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +489, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +489, 1, 2, 2, 14, 15, 14, 15, "." +489, 2, 1, 3, 0, 4, 16, 20, "2001" +489, 2, 2, 4, 5, 8, 21, 24, "Feb" +489, 2, 3, 5, 9, 10, 25, 26, ";" +489, 2, 4, 6, 11, 14, 27, 30, "108" +489, 2, 5, 7, 15, 16, 31, 32, "(" +489, 2, 6, 8, 17, 18, 33, 34, "2" +489, 2, 7, 9, 19, 20, 35, 36, ")" +489, 2, 8, 10, 21, 22, 37, 38, ":" +489, 2, 9, 11, 23, 26, 39, 42, "259" +489, 2, 10, 12, 27, 28, 43, 44, "-" +489, 2, 11, 13, 29, 31, 45, 47, "63" +489, 2, 12, 14, 32, 33, 48, 49, "." +489, 3, 1, 15, 0, 1, 50, 51, "A" +489, 3, 2, 16, 2, 8, 52, 58, "double" +489, 3, 3, 17, 9, 10, 59, 60, "-" +489, 3, 4, 18, 11, 17, 61, 67, "masked" +489, 3, 5, 19, 18, 19, 68, 69, "," +489, 3, 6, 20, 20, 30, 70, 80, "randomized" +489, 3, 7, 21, 31, 39, 81, 89, "clinical" +489, 3, 8, 22, 40, 45, 90, 95, "trial" +489, 3, 9, 23, 46, 55, 96, 105, "comparing" +489, 3, 10, 24, 56, 67, 106, 117, "latanoprost" +489, 3, 11, 25, 68, 72, 118, 122, "with" +489, 3, 12, 26, 73, 84, 123, 134, "unoprostone" +489, 3, 13, 27, 85, 87, 135, 137, "in" +489, 3, 14, 28, 88, 96, 138, 146, "patients" +489, 3, 15, 29, 97, 101, 147, 151, "with" +489, 3, 16, 30, 102, 106, 152, 156, "open" +489, 3, 17, 31, 107, 108, 157, 158, "-" +489, 3, 18, 32, 109, 114, 159, 164, "angle" +489, 3, 19, 33, 115, 123, 165, 173, "glaucoma" +489, 3, 20, 34, 124, 126, 174, 176, "or" +489, 3, 21, 35, 127, 133, 177, 183, "ocular" +489, 3, 22, 36, 134, 146, 184, 196, "hypertension" +489, 3, 23, 37, 147, 148, 197, 198, "." +489, 4, 1, 38, 0, 7, 199, 206, "Susanna" +489, 4, 2, 39, 8, 9, 207, 208, "R" +489, 4, 3, 40, 10, 12, 209, 211, "Jr" +489, 4, 4, 41, 13, 14, 212, 213, "(" +489, 4, 5, 42, 15, 16, 214, 215, "1" +489, 4, 6, 43, 17, 18, 216, 217, ")" +489, 4, 7, 44, 19, 20, 218, 219, "," +489, 4, 8, 45, 21, 29, 220, 228, "Giampani" +489, 4, 9, 46, 30, 31, 229, 230, "J" +489, 4, 10, 47, 32, 34, 231, 233, "Jr" +489, 4, 11, 48, 35, 36, 234, 235, "," +489, 4, 12, 49, 37, 43, 236, 242, "Borges" +489, 4, 13, 50, 44, 46, 243, 245, "AS" +489, 4, 14, 51, 47, 48, 246, 247, "," +489, 4, 15, 52, 49, 56, 248, 255, "Vessani" +489, 4, 16, 53, 57, 59, 256, 258, "RM" +489, 4, 17, 54, 60, 61, 259, 260, "," +489, 4, 18, 55, 62, 68, 261, 267, "Jordao" +489, 4, 19, 56, 69, 71, 268, 270, "ML" +489, 4, 20, 57, 72, 73, 271, 272, "." +489, 5, 1, 58, 0, 6, 273, 279, "Author" +489, 5, 2, 59, 7, 18, 280, 291, "information" +489, 5, 3, 60, 19, 20, 292, 293, ":" +489, 5, 4, 61, 21, 22, 294, 295, "(" +489, 5, 5, 62, 23, 24, 296, 297, "1" +489, 5, 6, 63, 25, 26, 298, 299, ")" +489, 5, 7, 64, 27, 35, 300, 308, "Glaucoma" +489, 5, 8, 65, 36, 43, 309, 316, "Service" +489, 5, 9, 66, 44, 45, 317, 318, "," +489, 5, 10, 67, 46, 56, 319, 329, "Department" +489, 5, 11, 68, 57, 59, 330, 332, "of" +489, 5, 12, 69, 60, 73, 333, 346, "Ophthalmology" +489, 5, 13, 70, 74, 77, 347, 350, "and" +489, 5, 14, 71, 78, 92, 351, 365, "Otolaringology" +489, 5, 15, 72, 93, 94, 366, 367, "," +489, 5, 16, 73, 95, 102, 368, 375, "Faculty" +489, 5, 17, 74, 103, 105, 376, 378, "of" +489, 5, 18, 75, 106, 114, 379, 387, "Medicine" +489, 5, 19, 76, 115, 116, 388, 389, "," +489, 5, 20, 77, 117, 127, 390, 400, "University" +489, 5, 21, 78, 128, 130, 401, 403, "of" +489, 5, 22, 79, 131, 132, 404, 405, "S" +489, 5, 23, 80, 133, 134, 406, 407, "ã" +489, 5, 24, 81, 135, 136, 408, 409, "o" +489, 5, 25, 82, 137, 142, 410, 415, "Paulo" +489, 5, 26, 83, 143, 144, 416, 417, "," +489, 5, 27, 84, 145, 146, 418, 419, "S" +489, 5, 28, 85, 147, 148, 420, 421, "ã" +489, 5, 29, 86, 149, 150, 422, 423, "o" +489, 5, 30, 87, 151, 156, 424, 429, "Paulo" +489, 5, 31, 88, 157, 158, 430, 431, "," +489, 5, 32, 89, 159, 165, 432, 438, "Brazil" +489, 5, 33, 90, 166, 167, 439, 440, "." +489, 6, 1, 91, 0, 7, 441, 448, "PURPOSE" +489, 6, 2, 92, 8, 9, 449, 450, ":" +489, 6, 3, 93, 10, 12, 451, 453, "To" +489, 6, 4, 94, 13, 20, 454, 461, "compare" +489, 6, 5, 95, 21, 24, 462, 465, "the" +489, 6, 6, 96, 25, 36, 466, 477, "intraocular" +489, 6, 7, 97, 37, 45, 478, 486, "pressure" +489, 6, 8, 98, 46, 47, 487, 488, "(" +489, 6, 9, 99, 48, 51, 489, 492, "IOP" +489, 6, 10, 100, 52, 53, 493, 494, ")" +489, 6, 11, 101, 54, 62, 495, 503, "reducing" +489, 6, 12, 102, 63, 69, 504, 510, "effect" +489, 6, 13, 103, 70, 73, 511, 514, "and" +489, 6, 14, 104, 74, 80, 515, 521, "safety" +489, 6, 15, 105, 81, 83, 522, 524, "of" +489, 6, 16, 106, 84, 95, 525, 536, "latanoprost" +489, 6, 17, 107, 96, 97, 537, 538, "0" +489, 6, 18, 108, 98, 99, 539, 540, "." +489, 6, 19, 109, 100, 103, 541, 544, "005" +489, 6, 20, 110, 104, 105, 545, 546, "%" +489, 6, 21, 111, 106, 110, 547, 551, "once" +489, 6, 22, 112, 111, 116, 552, 557, "daily" +489, 6, 23, 113, 117, 121, 558, 562, "with" +489, 6, 24, 114, 122, 133, 563, 574, "unoprostone" +489, 6, 25, 115, 134, 135, 575, 576, "0" +489, 6, 26, 116, 136, 137, 577, 578, "." +489, 6, 27, 117, 138, 140, 579, 581, "12" +489, 6, 28, 118, 141, 142, 582, 583, "%" +489, 6, 29, 119, 143, 148, 584, 589, "twice" +489, 6, 30, 120, 149, 154, 590, 595, "daily" +489, 6, 31, 121, 155, 157, 596, 598, "in" +489, 6, 32, 122, 158, 166, 599, 607, "patients" +489, 6, 33, 123, 167, 171, 608, 612, "with" +489, 6, 34, 124, 172, 179, 613, 620, "primary" +489, 6, 35, 125, 180, 184, 621, 625, "open" +489, 6, 36, 126, 185, 186, 626, 627, "-" +489, 6, 37, 127, 187, 192, 628, 633, "angle" +489, 6, 38, 128, 193, 201, 634, 642, "glaucoma" +489, 6, 39, 129, 202, 203, 643, 644, "(" +489, 6, 40, 130, 204, 208, 645, 649, "POAG" +489, 6, 41, 131, 209, 210, 650, 651, ")" +489, 6, 42, 132, 211, 213, 652, 654, "or" +489, 6, 43, 133, 214, 220, 655, 661, "ocular" +489, 6, 44, 134, 221, 233, 662, 674, "hypertension" +489, 6, 45, 135, 234, 235, 675, 676, "(" +489, 6, 46, 136, 236, 238, 677, 679, "OH" +489, 6, 47, 137, 239, 240, 680, 681, ")" +489, 6, 48, 138, 241, 242, 682, 683, "." +489, 7, 1, 139, 0, 6, 684, 690, "DESIGN" +489, 7, 2, 140, 7, 8, 691, 692, ":" +489, 7, 3, 141, 9, 11, 693, 695, "An" +489, 7, 4, 142, 12, 13, 696, 697, "8" +489, 7, 5, 143, 14, 15, 698, 699, "-" +489, 7, 6, 144, 16, 20, 700, 704, "week" +489, 7, 7, 145, 21, 22, 705, 706, "," +489, 7, 8, 146, 23, 29, 707, 713, "double" +489, 7, 9, 147, 30, 31, 714, 715, "-" +489, 7, 10, 148, 32, 38, 716, 722, "masked" +489, 7, 11, 149, 39, 40, 723, 724, "," +489, 7, 12, 150, 41, 51, 725, 735, "randomized" +489, 7, 13, 151, 52, 53, 736, 737, "," +489, 7, 14, 152, 54, 62, 738, 746, "parallel" +489, 7, 15, 153, 63, 64, 747, 748, "-" +489, 7, 16, 154, 65, 70, 749, 754, "group" +489, 7, 17, 155, 71, 72, 755, 756, "," +489, 7, 18, 156, 73, 79, 757, 763, "single" +489, 7, 19, 157, 80, 81, 764, 765, "-" +489, 7, 20, 158, 82, 88, 766, 772, "center" +489, 7, 21, 159, 89, 97, 773, 781, "clinical" +489, 7, 22, 160, 98, 103, 782, 787, "trial" +489, 7, 23, 161, 104, 105, 788, 789, "." +489, 8, 1, 162, 0, 12, 790, 802, "PARTICIPANTS" +489, 8, 2, 163, 13, 14, 803, 804, ":" +489, 8, 3, 164, 15, 16, 805, 806, "A" +489, 8, 4, 165, 17, 22, 807, 812, "total" +489, 8, 5, 166, 23, 25, 813, 815, "of" +489, 8, 6, 167, 26, 29, 816, 819, "108" +489, 8, 7, 168, 30, 38, 820, 828, "patients" +489, 8, 8, 169, 39, 43, 829, 833, "with" +489, 8, 9, 170, 44, 48, 834, 838, "POAG" +489, 8, 10, 171, 49, 51, 839, 841, "or" +489, 8, 11, 172, 52, 54, 842, 844, "OH" +489, 8, 12, 173, 55, 59, 845, 849, "were" +489, 8, 13, 174, 60, 68, 850, 858, "enrolled" +489, 8, 14, 175, 69, 70, 859, 860, "." +489, 9, 1, 176, 0, 13, 861, 874, "INTERVENTIONS" +489, 9, 2, 177, 14, 15, 875, 876, ":" +489, 9, 3, 178, 16, 21, 877, 882, "After" +489, 9, 4, 179, 22, 32, 883, 893, "completing" +489, 9, 5, 180, 33, 34, 894, 895, "a" +489, 9, 6, 181, 35, 39, 896, 900, "wash" +489, 9, 7, 182, 40, 41, 901, 902, "-" +489, 9, 8, 183, 42, 45, 903, 906, "out" +489, 9, 9, 184, 46, 48, 907, 909, "of" +489, 9, 10, 185, 49, 55, 910, 916, "ocular" +489, 9, 11, 186, 56, 67, 917, 928, "hypotensive" +489, 9, 12, 187, 68, 79, 929, 940, "medications" +489, 9, 13, 188, 80, 81, 941, 942, "," +489, 9, 14, 189, 82, 90, 943, 951, "patients" +489, 9, 15, 190, 91, 95, 952, 956, "were" +489, 9, 16, 191, 96, 106, 957, 967, "randomized" +489, 9, 17, 192, 107, 109, 968, 970, "to" +489, 9, 18, 193, 110, 117, 971, 978, "receive" +489, 9, 19, 194, 118, 124, 979, 985, "either" +489, 9, 20, 195, 125, 136, 986, 997, "latanoprost" +489, 9, 21, 196, 137, 141, 998, 1002, "once" +489, 9, 22, 197, 142, 147, 1003, 1008, "daily" +489, 9, 23, 198, 148, 150, 1009, 1011, "in" +489, 9, 24, 199, 151, 154, 1012, 1015, "the" +489, 9, 25, 200, 155, 162, 1016, 1023, "evening" +489, 9, 26, 201, 163, 167, 1024, 1028, "plus" +489, 9, 27, 202, 168, 175, 1029, 1036, "placebo" +489, 9, 28, 203, 176, 180, 1037, 1041, "once" +489, 9, 29, 204, 181, 186, 1042, 1047, "daily" +489, 9, 30, 205, 187, 189, 1048, 1050, "in" +489, 9, 31, 206, 190, 193, 1051, 1054, "the" +489, 9, 32, 207, 194, 201, 1055, 1062, "morning" +489, 9, 33, 208, 202, 203, 1063, 1064, "," +489, 9, 34, 209, 204, 206, 1065, 1067, "or" +489, 9, 35, 210, 207, 218, 1068, 1079, "unoprostone" +489, 9, 36, 211, 219, 224, 1080, 1085, "twice" +489, 9, 37, 212, 225, 230, 1086, 1091, "daily" +489, 9, 38, 213, 231, 232, 1092, 1093, "(" +489, 9, 39, 214, 233, 240, 1094, 1101, "morning" +489, 9, 40, 215, 241, 244, 1102, 1105, "and" +489, 9, 41, 216, 245, 252, 1106, 1113, "evening" +489, 9, 42, 217, 253, 254, 1114, 1115, ")" +489, 9, 43, 218, 255, 256, 1116, 1117, "." +489, 10, 1, 219, 0, 4, 1118, 1122, "MAIN" +489, 10, 2, 220, 5, 12, 1123, 1130, "OUTCOME" +489, 10, 3, 221, 13, 21, 1131, 1139, "MEASURES" +489, 10, 4, 222, 22, 23, 1140, 1141, ":" +489, 10, 5, 223, 24, 27, 1142, 1145, "IOP" +489, 10, 6, 224, 28, 31, 1146, 1149, "was" +489, 10, 7, 225, 32, 40, 1150, 1158, "measured" +489, 10, 8, 226, 41, 43, 1159, 1161, "at" +489, 10, 9, 227, 44, 46, 1162, 1164, "10" +489, 10, 10, 228, 47, 48, 1165, 1166, ":" +489, 10, 11, 229, 49, 51, 1167, 1169, "00" +489, 10, 12, 230, 52, 54, 1170, 1172, "AM" +489, 10, 13, 231, 55, 58, 1173, 1176, "and" +489, 10, 14, 232, 59, 61, 1177, 1179, "at" +489, 10, 15, 233, 62, 63, 1180, 1181, "5" +489, 10, 16, 234, 64, 65, 1182, 1183, ":" +489, 10, 17, 235, 66, 68, 1184, 1186, "00" +489, 10, 18, 236, 69, 71, 1187, 1189, "PM" +489, 10, 19, 237, 72, 74, 1190, 1192, "at" +489, 10, 20, 238, 75, 83, 1193, 1201, "baseline" +489, 10, 21, 239, 84, 87, 1202, 1205, "and" +489, 10, 22, 240, 88, 90, 1206, 1208, "at" +489, 10, 23, 241, 91, 95, 1209, 1213, "week" +489, 10, 24, 242, 96, 97, 1214, 1215, "8" +489, 10, 25, 243, 98, 99, 1216, 1217, "," +489, 10, 26, 244, 100, 103, 1218, 1221, "and" +489, 10, 27, 245, 104, 110, 1222, 1228, "before" +489, 10, 28, 246, 111, 113, 1229, 1231, "12" +489, 10, 29, 247, 114, 115, 1232, 1233, ":" +489, 10, 30, 248, 116, 118, 1234, 1236, "00" +489, 10, 31, 249, 119, 123, 1237, 1241, "noon" +489, 10, 32, 250, 124, 126, 1242, 1244, "at" +489, 10, 33, 251, 127, 131, 1245, 1249, "week" +489, 10, 34, 252, 132, 133, 1250, 1251, "2" +489, 10, 35, 253, 134, 135, 1252, 1253, "." +489, 11, 1, 254, 0, 6, 1254, 1260, "Ocular" +489, 11, 2, 255, 7, 10, 1261, 1264, "and" +489, 11, 3, 256, 11, 19, 1265, 1273, "systemic" +489, 11, 4, 257, 20, 26, 1274, 1280, "safety" +489, 11, 5, 258, 27, 38, 1281, 1292, "assessments" +489, 11, 6, 259, 39, 43, 1293, 1297, "were" +489, 11, 7, 260, 44, 53, 1298, 1307, "performed" +489, 11, 8, 261, 54, 55, 1308, 1309, "." +489, 12, 1, 262, 0, 7, 1310, 1317, "RESULTS" +489, 12, 2, 263, 8, 9, 1318, 1319, ":" +489, 12, 3, 264, 10, 14, 1320, 1324, "From" +489, 12, 4, 265, 15, 17, 1325, 1327, "an" +489, 12, 5, 266, 18, 25, 1328, 1335, "overall" +489, 12, 6, 267, 26, 34, 1336, 1344, "baseline" +489, 12, 7, 268, 35, 37, 1345, 1347, "of" +489, 12, 8, 269, 38, 40, 1348, 1350, "24" +489, 12, 9, 270, 41, 42, 1351, 1352, "." +489, 12, 10, 271, 43, 44, 1353, 1354, "1" +489, 12, 11, 272, 45, 49, 1355, 1359, "mmHg" +489, 12, 12, 273, 50, 51, 1360, 1361, "," +489, 12, 13, 274, 52, 63, 1362, 1373, "latanoprost" +489, 12, 14, 275, 64, 71, 1374, 1381, "reduced" +489, 12, 15, 276, 72, 75, 1382, 1385, "IOP" +489, 12, 16, 277, 76, 78, 1386, 1388, "by" +489, 12, 17, 278, 79, 80, 1389, 1390, "6" +489, 12, 18, 279, 81, 82, 1391, 1392, "." +489, 12, 19, 280, 83, 84, 1393, 1394, "7" +489, 12, 20, 281, 85, 89, 1395, 1399, "mmHg" +489, 12, 21, 282, 90, 91, 1400, 1401, "(" +489, 12, 22, 283, 92, 94, 1402, 1404, "28" +489, 12, 23, 284, 95, 96, 1405, 1406, "%" +489, 12, 24, 285, 97, 98, 1407, 1408, ")" +489, 12, 25, 286, 99, 102, 1409, 1412, "and" +489, 12, 26, 287, 103, 114, 1413, 1424, "unoprostone" +489, 12, 27, 288, 115, 122, 1425, 1432, "reduced" +489, 12, 28, 289, 123, 126, 1433, 1436, "IOP" +489, 12, 29, 290, 127, 129, 1437, 1439, "by" +489, 12, 30, 291, 130, 131, 1440, 1441, "3" +489, 12, 31, 292, 132, 133, 1442, 1443, "." +489, 12, 32, 293, 134, 135, 1444, 1445, "3" +489, 12, 33, 294, 136, 140, 1446, 1450, "mmHg" +489, 12, 34, 295, 141, 142, 1451, 1452, "(" +489, 12, 35, 296, 143, 145, 1453, 1455, "14" +489, 12, 36, 297, 146, 147, 1456, 1457, "%" +489, 12, 37, 298, 148, 149, 1458, 1459, ")" +489, 12, 38, 299, 150, 151, 1460, 1461, "." +489, 13, 1, 300, 0, 3, 1462, 1465, "The" +489, 13, 2, 301, 4, 14, 1466, 1476, "difference" +489, 13, 3, 302, 15, 22, 1477, 1484, "between" +489, 13, 4, 303, 23, 26, 1485, 1488, "the" +489, 13, 5, 304, 27, 33, 1489, 1495, "groups" +489, 13, 6, 305, 34, 36, 1496, 1498, "of" +489, 13, 7, 306, 37, 38, 1499, 1500, "3" +489, 13, 8, 307, 39, 40, 1501, 1502, "." +489, 13, 9, 308, 41, 42, 1503, 1504, "4" +489, 13, 10, 309, 43, 47, 1505, 1509, "mmHg" +489, 13, 11, 310, 48, 51, 1510, 1513, "was" +489, 13, 12, 311, 52, 63, 1514, 1525, "significant" +489, 13, 13, 312, 64, 65, 1526, 1527, "(" +489, 13, 14, 313, 66, 67, 1528, 1529, "P" +489, 13, 15, 314, 68, 69, 1530, 1531, ":" +489, 13, 16, 315, 70, 71, 1532, 1533, "<" +489, 13, 17, 316, 72, 73, 1534, 1535, "0" +489, 13, 18, 317, 74, 75, 1536, 1537, "." +489, 13, 19, 318, 76, 79, 1538, 1541, "001" +489, 13, 20, 319, 80, 81, 1542, 1543, "," +489, 13, 21, 320, 82, 90, 1544, 1552, "analysis" +489, 13, 22, 321, 91, 93, 1553, 1555, "of" +489, 13, 23, 322, 94, 104, 1556, 1566, "covariance" +489, 13, 24, 323, 105, 106, 1567, 1568, ";" +489, 13, 25, 324, 107, 109, 1569, 1571, "95" +489, 13, 26, 325, 110, 111, 1572, 1573, "%" +489, 13, 27, 326, 112, 122, 1574, 1584, "confidence" +489, 13, 28, 327, 123, 131, 1585, 1593, "interval" +489, 13, 29, 328, 132, 133, 1594, 1595, "[" +489, 13, 30, 329, 134, 136, 1596, 1598, "CI" +489, 13, 31, 330, 137, 138, 1599, 1600, "]" +489, 13, 32, 331, 139, 140, 1601, 1602, ":" +489, 13, 33, 332, 141, 142, 1603, 1604, "-" +489, 13, 34, 333, 143, 144, 1605, 1606, "4" +489, 13, 35, 334, 145, 146, 1607, 1608, "." +489, 13, 36, 335, 147, 148, 1609, 1610, "7" +489, 13, 37, 336, 149, 151, 1611, 1613, "to" +489, 13, 38, 337, 152, 153, 1614, 1615, "-" +489, 13, 39, 338, 154, 155, 1616, 1617, "2" +489, 13, 40, 339, 156, 157, 1618, 1619, "." +489, 13, 41, 340, 158, 159, 1620, 1621, "1" +489, 13, 42, 341, 160, 161, 1622, 1623, ")" +489, 13, 43, 342, 162, 164, 1624, 1626, "in" +489, 13, 44, 343, 165, 170, 1627, 1632, "favor" +489, 13, 45, 344, 171, 173, 1633, 1635, "of" +489, 13, 46, 345, 174, 185, 1636, 1647, "latanoprost" +489, 13, 47, 346, 186, 187, 1648, 1649, "." +489, 14, 1, 347, 0, 1, 1650, 1651, "A" +489, 14, 2, 348, 2, 3, 1652, 1653, ">" +489, 14, 3, 349, 4, 5, 1654, 1655, "/" +489, 14, 4, 350, 6, 7, 1656, 1657, "=" +489, 14, 5, 351, 8, 10, 1658, 1660, "30" +489, 14, 6, 352, 11, 12, 1661, 1662, "%" +489, 14, 7, 353, 13, 22, 1663, 1672, "reduction" +489, 14, 8, 354, 23, 25, 1673, 1675, "in" +489, 14, 9, 355, 26, 30, 1676, 1680, "mean" +489, 14, 10, 356, 31, 34, 1681, 1684, "IOP" +489, 14, 11, 357, 35, 39, 1685, 1689, "from" +489, 14, 12, 358, 40, 48, 1690, 1698, "baseline" +489, 14, 13, 359, 49, 52, 1699, 1702, "was" +489, 14, 14, 360, 53, 61, 1703, 1711, "achieved" +489, 14, 15, 361, 62, 64, 1712, 1714, "by" +489, 14, 16, 362, 65, 67, 1715, 1717, "44" +489, 14, 17, 363, 68, 69, 1718, 1719, "%" +489, 14, 18, 364, 70, 72, 1720, 1722, "of" +489, 14, 19, 365, 73, 84, 1723, 1734, "latanoprost" +489, 14, 20, 366, 85, 86, 1735, 1736, "-" +489, 14, 21, 367, 87, 94, 1737, 1744, "treated" +489, 14, 22, 368, 95, 103, 1745, 1753, "patients" +489, 14, 23, 369, 104, 112, 1754, 1762, "compared" +489, 14, 24, 370, 113, 117, 1763, 1767, "with" +489, 14, 25, 371, 118, 119, 1768, 1769, "8" +489, 14, 26, 372, 120, 121, 1770, 1771, "%" +489, 14, 27, 373, 122, 124, 1772, 1774, "of" +489, 14, 28, 374, 125, 136, 1775, 1786, "unoprostone" +489, 14, 29, 375, 137, 138, 1787, 1788, "-" +489, 14, 30, 376, 139, 146, 1789, 1796, "treated" +489, 14, 31, 377, 147, 155, 1797, 1805, "patients" +489, 14, 32, 378, 156, 157, 1806, 1807, "." +489, 15, 1, 379, 0, 3, 1808, 1811, "The" +489, 15, 2, 380, 4, 13, 1812, 1821, "incidence" +489, 15, 3, 381, 14, 16, 1822, 1824, "of" +489, 15, 4, 382, 17, 24, 1825, 1832, "adverse" +489, 15, 5, 383, 25, 31, 1833, 1839, "events" +489, 15, 6, 384, 32, 35, 1840, 1843, "was" +489, 15, 7, 385, 36, 39, 1844, 1847, "low" +489, 15, 8, 386, 40, 43, 1848, 1851, "and" +489, 15, 9, 387, 44, 54, 1852, 1862, "comparable" +489, 15, 10, 388, 55, 62, 1863, 1870, "between" +489, 15, 11, 389, 63, 66, 1871, 1874, "the" +489, 15, 12, 390, 67, 73, 1875, 1881, "groups" +489, 15, 13, 391, 74, 75, 1882, 1883, "." +489, 16, 1, 392, 0, 11, 1884, 1895, "CONCLUSIONS" +489, 16, 2, 393, 12, 13, 1896, 1897, ":" +489, 16, 3, 394, 14, 25, 1898, 1909, "Latanoprost" +489, 16, 4, 395, 26, 38, 1910, 1922, "administered" +489, 16, 5, 396, 39, 43, 1923, 1927, "once" +489, 16, 6, 397, 44, 49, 1928, 1933, "daily" +489, 16, 7, 398, 50, 53, 1934, 1937, "was" +489, 16, 8, 399, 54, 67, 1938, 1951, "significantly" +489, 16, 9, 400, 68, 72, 1952, 1956, "more" +489, 16, 10, 401, 73, 82, 1957, 1966, "effective" +489, 16, 11, 402, 83, 85, 1967, 1969, "in" +489, 16, 12, 403, 86, 94, 1970, 1978, "reducing" +489, 16, 13, 404, 95, 98, 1979, 1982, "IOP" +489, 16, 14, 405, 99, 107, 1983, 1991, "compared" +489, 16, 15, 406, 108, 112, 1992, 1996, "with" +489, 16, 16, 407, 113, 124, 1997, 2008, "unoprostone" +489, 16, 17, 408, 125, 137, 2009, 2021, "administered" +489, 16, 18, 409, 138, 143, 2022, 2027, "twice" +489, 16, 19, 410, 144, 149, 2028, 2033, "daily" +489, 16, 20, 411, 150, 152, 2034, 2036, "in" +489, 16, 21, 412, 153, 161, 2037, 2045, "patients" +489, 16, 22, 413, 162, 166, 2046, 2050, "with" +489, 16, 23, 414, 167, 171, 2051, 2055, "POAG" +489, 16, 24, 415, 172, 175, 2056, 2059, "and" +489, 16, 25, 416, 176, 178, 2060, 2062, "OH" +489, 16, 26, 417, 179, 180, 2063, 2064, "." +489, 17, 1, 418, 0, 4, 2065, 2069, "PMID" +489, 17, 2, 419, 5, 6, 2070, 2071, ":" +489, 17, 3, 420, 7, 15, 2072, 2080, "11158796" +489, 17, 4, 421, 16, 17, 2081, 2082, "[" +489, 17, 5, 422, 18, 25, 2083, 2090, "Indexed" +489, 17, 6, 423, 26, 29, 2091, 2094, "for" +489, 17, 7, 424, 30, 37, 2095, 2102, "MEDLINE" +489, 17, 8, 425, 38, 39, 2103, 2104, "]" diff --git a/data/gl 11158796_jshahinitiran.annodb b/data/gl 11158796_jshahinitiran.annodb new file mode 100644 index 0000000..ebb4323 --- /dev/null +++ b/data/gl 11158796_jshahinitiran.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2608, Journal, 0, 13, "Ophthalmology", "", +2414, PublicationYear, 16, 20, "2001", "", +2421, Title, 50, 198, "A double - masked , randomized clinical trial comparing latanoprost with unoprostone in patients with open - angle glaucoma or ocular hypertension .", "", +2415, DoubleBlind, 52, 67, "double - masked", "", +2416, Randomized, 70, 80, "randomized", "", +2417, Latanoprost, 106, 117, "latanoprost", "", +2418, Unoprostone, 123, 134, "unoprostone", "", +2456, OcularHypertension, 177, 196, "ocular hypertension", "", +2422, Author, 199, 211, "Susanna R Jr", "", +2423, Author, 220, 233, "Giampani J Jr", "", +2424, Author, 236, 245, "Borges AS", "", +2425, Author, 248, 258, "Vessani RM", "", +2430, Author, 261, 270, "Jordao ML", "", +26415, Glaucoma, 300, 308, "Glaucoma", "", +2434, Brazil, 432, 440, "Brazil .", "", +2432, ObjectiveDescription, 451, 683, "To compare the intraocular pressure ( IOP ) reducing effect and safety of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", +5782, IOP, 466, 486, "intraocular pressure", "", +5783, IOP, 489, 492, "IOP", "", +5784, Latanoprost, 525, 536, "latanoprost", "", +5785, DoseValue, 537, 544, "0 . 005", "", +5786, Percentage, 545, 546, "%", "", +5787, Frequency, 547, 557, "once daily", "", +5788, Unoprostone, 563, 574, "unoprostone", "", +5789, DoseValue, 575, 581, "0 . 12", "", +5790, Percentage, 582, 583, "%", "", +26417, Frequency, 584, 595, "twice daily", "", +26418, Primary_OpenAngleGlaucoma, 613, 642, "primary open - angle glaucoma", "", +26419, Primary_OpenAngleGlaucoma, 645, 649, "POAG", "", +5794, OcularHypertension, 655, 674, "ocular hypertension", "", +5795, OcularHypertension, 677, 679, "OH", "", +2438, Duration, 696, 704, "8 - week", "", +2440, DoubleBlind, 707, 722, "double - masked", "", +25984, Randomized, 725, 735, "randomized", "", +2450, Parallel, 738, 754, "parallel - group", "", +2446, SingleCenter, 757, 772, "single - center", "", +2452, NumberPatientsCT, 816, 819, "108", "", +26420, Primary_OpenAngleGlaucoma, 834, 838, "POAG", "", +25985, OcularHypertension, 842, 844, "OH", "", +25987, Randomized, 957, 967, "randomized", "", +2483, Latanoprost, 986, 997, "latanoprost", "", +25988, Frequency, 998, 1008, "once daily", "", +2487, Bedtime, 1016, 1023, "evening", "lat", +2489, Placebo, 1029, 1036, "placebo", "", +2494, Frequency, 1037, 1047, "once daily", "pla", +2497, Morning, 1055, 1062, "morning", "pla", +2499, Unoprostone, 1068, 1079, "unoprostone", "", +25991, Frequency, 1080, 1091, "twice daily", "", +2503, Morning, 1094, 1101, "morning", "uno", +2504, Bedtime, 1106, 1113, "evening", "uno", +2508, IOP, 1142, 1145, "IOP", "", +39025, TimePoint, 1193, 1201, "baseline", "", +39026, TimePoint, 1209, 1215, "week 8", "", +39027, TimePoint, 1245, 1251, "week 2", "", +2518, BaseLineValue, 1348, 1354, "24 . 1", "", +2520, mmHg, 1355, 1359, "mmHg", "", +2521, Latanoprost, 1362, 1373, "latanoprost", "", +2523, IOP, 1382, 1385, "IOP", "", +5796, Reduction, 1389, 1394, "6 . 7", "", +2528, mmHg, 1395, 1399, "mmHg", "", +5797, RelativeReduction, 1402, 1404, "28", "", +2530, Unoprostone, 1413, 1424, "unoprostone", "", +2532, IOP, 1433, 1436, "IOP", "", +5798, Reduction, 1440, 1445, "3 . 3", "", +2536, mmHg, 1446, 1450, "mmHg", "", +5799, RelativeReduction, 1453, 1455, "14", "", +2539, DiffGroupRelValue, 1499, 1504, "3 . 4", "", +2540, mmHg, 1505, 1509, "mmHg", "", +2543, PvalueDiff, 1528, 1541, "P : < 0 . 001", "", +2545, ConfIntervalDiff, 1569, 1621, "95 % confidence interval [ CI ] : - 4 . 7 to - 2 . 1", "", +2547, Latanoprost, 1636, 1647, "latanoprost", "", +2587, RelativeReduction, 1658, 1660, "30", "", +2570, Mean, 1676, 1680, "mean", "", +2572, IOP, 1681, 1684, "IOP", "", +2562, PercentageAffected, 1715, 1717, "44", "lat", +5800, Latanoprost, 1723, 1736, "latanoprost -", "", +2564, PercentageAffected, 1768, 1769, "8", "uno", +5801, Unoprostone, 1775, 1786, "unoprostone", "", +2590, Latanoprost, 1898, 1909, "Latanoprost", "", +2476, ConclusionComment, 1898, 2064, "Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH .", "", +25989, Frequency, 1923, 1933, "once daily", "", +2592, IOP, 1979, 1982, "IOP", "", +2594, Unoprostone, 1997, 2008, "unoprostone", "", +25990, Frequency, 2022, 2033, "twice daily", "", +26421, Primary_OpenAngleGlaucoma, 2051, 2055, "POAG", "", +2456, OcularHypertension, 2060, 2062, "OH", "", +2477, PMID, 2072, 2080, "11158796", "", diff --git a/data/gl 11158796_jshahinitiran.n-triples b/data/gl 11158796_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11158796_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11158796_tstrakeljahn.annodb b/data/gl 11158796_tstrakeljahn.annodb new file mode 100644 index 0000000..b0a1c33 --- /dev/null +++ b/data/gl 11158796_tstrakeljahn.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5464, Journal, 0, 13, "Ophthalmology", "", +5465, PublicationYear, 16, 20, "2001", "", +5473, Title, 50, 198, "A double - masked , randomized clinical trial comparing latanoprost with unoprostone in patients with open - angle glaucoma or ocular hypertension .", "", +5466, DoubleBlind, 52, 67, "double - masked", "", +5467, Randomized, 70, 80, "randomized", "", +5468, ClinicalTrial, 81, 95, "clinical trial", "", +5469, Latanoprost, 106, 117, "latanoprost", "", +5470, Unoprostone, 123, 134, "unoprostone", "", +5471, OpenAngleGlaucoma, 152, 173, "open - angle glaucoma", "", +5472, OcularHypertension, 177, 196, "ocular hypertension", "", +5474, Author, 199, 211, "Susanna R Jr", "", +5475, Author, 220, 233, "Giampani J Jr", "", +5476, Author, 236, 245, "Borges AS", "", +5477, Author, 248, 258, "Vessani RM", "", +5478, Author, 261, 270, "Jordao ML", "", +5479, Brazil, 432, 438, "Brazil", "", +5560, ObjectiveDescription, 451, 681, "To compare the intraocular pressure ( IOP ) reducing effect and safety of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", +5480, IOP, 466, 486, "intraocular pressure", "", +5481, IOP, 489, 492, "IOP", "", +5482, Latanoprost, 525, 536, "latanoprost", "", +5483, DoseValue, 537, 544, "0 . 005", "", +5484, Percentage, 545, 546, "%", "", +5485, Frequency, 547, 557, "once daily", "", +5486, Unoprostone, 563, 574, "unoprostone", "", +5487, DoseValue, 575, 581, "0 . 12", "", +5488, Percentage, 582, 583, "%", "", +5489, Frequency, 584, 595, "twice daily", "", +5490, OpenAngleGlaucoma, 621, 642, "open - angle glaucoma", "", +5491, OcularHypertension, 655, 674, "ocular hypertension", "", +5492, OcularHypertension, 677, 679, "OH", "", +5493, Duration, 696, 704, "8 - week", "", +5494, DoubleBlind, 707, 722, "double - masked", "", +5495, Randomized, 725, 735, "randomized", "", +5498, Parallel, 738, 754, "parallel - group", "", +5496, SingleCenter, 757, 772, "single - center", "", +5497, ClinicalTrial, 773, 787, "clinical trial", "", +5499, NumberPatientsCT, 816, 819, "108", "", +5500, OpenAngleGlaucoma, 834, 838, "POAG", "", +5501, OcularHypertension, 842, 844, "OH", "", +5502, IOP, 1142, 1145, "IOP", "", +5503, TimePoint, 1162, 1172, "10 : 00 AM", "", +5504, TimePoint, 1180, 1189, "5 : 00 PM", "", +5505, TimePoint, 1209, 1215, "week 8", "", +5506, TimePoint, 1222, 1251, "before 12 : 00 noon at week 2", "", +5507, BaseLineValue, 1348, 1354, "24 . 1", "", +5508, mmHg, 1355, 1359, "mmHg", "", +5512, Latanoprost, 1362, 1373, "latanoprost", "", +5513, IOP, 1382, 1385, "IOP", "", +5514, Reduction, 1389, 1394, "6 . 7", "", +5509, mmHg, 1395, 1399, "mmHg", "", +5515, RelativeReduction, 1402, 1404, "28", "", +5519, Unoprostone, 1413, 1424, "unoprostone", "", +5518, IOP, 1433, 1436, "IOP", "", +5517, Reduction, 1440, 1445, "3 . 3", "", +5510, mmHg, 1446, 1450, "mmHg", "", +5516, RelativeReduction, 1453, 1455, "14", "", +5520, DiffGroupAbsValue, 1499, 1504, "3 . 4", "", +5511, mmHg, 1505, 1509, "mmHg", "", +5521, PvalueDiff, 1528, 1541, "P : < 0 . 001", "", +5522, ConfIntervalDiff, 1569, 1621, "95 % confidence interval [ CI ] : - 4 . 7 to - 2 . 1", "", +5523, Latanoprost, 1636, 1647, "latanoprost", "", +5525, RelativeReduction, 1658, 1660, "30", "", +5527, Mean, 1676, 1680, "mean", "", +5526, IOP, 1681, 1684, "IOP", "", +5524, PercentageAffected, 1715, 1717, "44", "", +5528, Latanoprost, 1723, 1734, "latanoprost", "", +5529, PercentageAffected, 1768, 1769, "8", "", +5530, Unoprostone, 1775, 1786, "unoprostone", "", +5531, ObservedResult, 1808, 1881, "The incidence of adverse events was low and comparable between the groups", "", +5532, Latanoprost, 1898, 1909, "Latanoprost", "", +5533, Frequency, 1923, 1933, "once daily", "", +5534, IOP, 1979, 1982, "IOP", "", +5535, Unoprostone, 1997, 2008, "unoprostone", "", +5536, Frequency, 2022, 2033, "twice daily", "", +5537, OpenAngleGlaucoma, 2051, 2055, "POAG", "", +5538, OcularHypertension, 2060, 2062, "OH", "", +5539, PMID, 2072, 2080, "11158796", "", diff --git a/data/gl 11158796_tstrakeljahn.n-triples b/data/gl 11158796_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11158796_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11167277_admin.annodb b/data/gl 11167277_admin.annodb new file mode 100644 index 0000000..25f9f13 --- /dev/null +++ b/data/gl 11167277_admin.annodb @@ -0,0 +1,63 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Acta Ophthalmol Scand", "", " \"Acta Ophthalmol Scand\"." +59, PublicationYear, 24, 28, "2001", "", " \"2001\"." +5, Title, 54, 170, "Latanoprost versus combined therapy with timolol plus dorzolamide : IOP - lowering effect in open - angle glaucoma .", "", " \"Latanoprost versus combined therapy with timolol plus dorzolamide : IOP - lowering effect in open - angle glaucoma .\"." +6, Latanoprost, 54, 65, "Latanoprost", "", +2, Timolol, 95, 102, "timolol", "", " ." +3, Dorzolamide, 108, 119, "dorzolamide", "", " ." +13, IOP, 122, 125, "IOP", "", " . ." +4, OpenAngleGlaucoma, 147, 168, "open - angle glaucoma", "", " ." +7, Author, 171, 177, "Polo V", "", " \"Polo V\"." +8, Author, 186, 196, "Larrosa JM", "", " \"Larrosa JM\"." +9, Author, 199, 207, "Gomez ML", "", " \"Gomez ML\"." +10, Author, 210, 217, "Pablo L", "", " \"Pablo L\"." +11, Author, 220, 231, "Honrubia FM", "", " \"Honrubia FM\"." +35, Spain, 327, 332, "Spain", "", " ." +12, ObjectiveDescription, 345, 464, "To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open - angle glaucoma .", "", " \"To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open - angle glaucoma .\"." +14, IOP, 370, 390, "intraocular pressure", "", +15, Latanoprost, 394, 405, "latanoprost", "", +16, Timolol, 413, 420, "timolol", "", +17, Dorzolamide, 426, 437, "dorzolamide", "", +18, OpenAngleGlaucoma, 441, 462, "open - angle glaucoma", "", +19, NumberPatientsCT, 475, 488, "Thirty - five", "", +20, OpenAngleGlaucoma, 503, 524, "open - angle glaucoma", "", +21, Randomized, 530, 540, "randomized", "", " ." +22, NumberPatientsArm, 543, 545, "18", "", " \"18\"." +23, Latanoprost, 549, 560, "latanoprost", "", " . ." +24, Frequency, 561, 571, "once daily", "", " \"once daily\"." +25, NumberPatientsArm, 576, 578, "17", "", " \"17\"." +26, Timolol, 582, 589, "timolol", "", +27, Dorzolamide, 595, 606, "dorzolamide", "", +28, Frequency, 607, 618, "twice daily", "", " \"twice daily\"." +29, IOP, 621, 641, "Intraocular pressure", "", +36950, TimePoint, 683, 691, "baseline", "", +36951, TimePoint, 704, 711, "2 weeks", "", " \"2 weeks\"." +36952, TimePoint, 716, 724, "3 months", "", +33, Latanoprost, 750, 761, "Latanoprost", "", +34, IOP, 774, 794, "intraocular pressure", "", +91, DiffGroupAbsValue, 795, 801, "1 . 09", "", " \"1 . 09\"." +92, DiffGroupAbsValue, 806, 812, "1 . 58", "", " \"1 . 58\"." +38, mmHg, 813, 818, "mm Hg", "", " ." +39, Timolol, 829, 836, "timolol", "", +40, Dorzolamide, 842, 853, "dorzolamide", "", +36953, TimePoint, 860, 867, "2 weeks", "", " \"2 weeks\"." +36954, TimePoint, 872, 880, "3 months", "", " \"3 months\". \"3 months\"." +41, PvalueDiff, 962, 972, "p < 0 . 05", "", " \"p < 0 . 05\". \"p < 0 . 05\"." +36955, TimePoint, 1007, 1015, "3 months", "", " \"3 months\". \"3 months\"." +42, PercentageAffected, 1031, 1037, "32 . 3", "", " \"32 . 3\"." +43, Latanoprost, 1059, 1070, "latanoprost", "", +92994, EndPointDescription, 1089, 1125, "intraocular pressure in 30 % or more", "", " . ." +44, IOP, 1089, 1109, "intraocular pressure", "", +45, RelativeReduction, 1113, 1115, "30", "", +46, PercentageAffected, 1159, 1165, "15 . 6", "", " \"15 . 6\"." +47, Timolol, 1187, 1194, "timolol", "", +48, Dorzolamide, 1200, 1211, "dorzolamide", "", +49, ConclusionComment, 1258, 1424, "Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open - angle glaucoma .", "", " \"Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open - angle glaucoma .\"." +50, Latanoprost, 1258, 1269, "Latanoprost", "", +51, Frequency, 1283, 1293, "once daily", "", +52, IOP, 1306, 1326, "intraocular pressure", "", +53, Timolol, 1347, 1354, "timolol", "", +54, Dorzolamide, 1360, 1371, "dorzolamide", "", +55, Frequency, 1372, 1383, "twice daily", "", +56, OpenAngleGlaucoma, 1401, 1422, "open - angle glaucoma", "", +57, PMID, 1432, 1440, "11167277", "", " \"11167277\"." diff --git a/data/gl 11167277_admin.n-triples b/data/gl 11167277_admin.n-triples new file mode 100644 index 0000000..e0904cd --- /dev/null +++ b/data/gl 11167277_admin.n-triples @@ -0,0 +1,136 @@ +# RDF export of group: Publication + . + "Publication" . + "Latanoprost versus combined therapy with timolol plus dorzolamide : IOP - lowering effect in open - angle glaucoma ." . + "Polo V" . + "2001" . + "Acta Ophthalmol Scand" . + "11167277" . + . + "Larrosa JM" . + "Gomez ML" . + "Pablo L" . + "Honrubia FM" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open - angle glaucoma ." . + . + . + . + "Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open - angle glaucoma ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + "Endpoint-30" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + "18" . + . + . + . + . + . + . + "Arm-tim-dor" . + "17" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-tim-dor" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + . + . + . + "Medication-tim" . + . + . + . + . + "Medication-dor" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-lat-2weeks" . + . + "2 weeks" . + . + "Outcome-iop-lat-3months" . + . + "3 months" . + . + "Outcome-iop-tim-dor-2weeks" . + . + "2 weeks" . + . + "Outcome-iop-tim-dor-3months" . + . + "3 months" . + . + "Outcome-30-lat" . + . + "32 . 3" . + "3 months" . + . + "Outcome-30-tim-dor" . + . + "15 . 6" . + "3 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop-2weeks" . + "1 . 09" . + "p < 0 . 05" . + . + . + . + "DiffBetweenGroups-iop-3months" . + "1 . 58" . + "p < 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11167277_export.csv b/data/gl 11167277_export.csv new file mode 100644 index 0000000..aa2f236 --- /dev/null +++ b/data/gl 11167277_export.csv @@ -0,0 +1,278 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +488, 1, 1, 1, 0, 4, 0, 4, "Acta" +488, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +488, 1, 3, 3, 16, 21, 16, 21, "Scand" +488, 1, 4, 4, 22, 23, 22, 23, "." +488, 2, 1, 5, 0, 4, 24, 28, "2001" +488, 2, 2, 6, 5, 8, 29, 32, "Feb" +488, 2, 3, 7, 9, 10, 33, 34, ";" +488, 2, 4, 8, 11, 13, 35, 37, "79" +488, 2, 5, 9, 14, 15, 38, 39, "(" +488, 2, 6, 10, 16, 17, 40, 41, "1" +488, 2, 7, 11, 18, 19, 42, 43, ")" +488, 2, 8, 12, 20, 21, 44, 45, ":" +488, 2, 9, 13, 22, 23, 46, 47, "6" +488, 2, 10, 14, 24, 25, 48, 49, "-" +488, 2, 11, 15, 26, 27, 50, 51, "9" +488, 2, 12, 16, 28, 29, 52, 53, "." +488, 3, 1, 17, 0, 11, 54, 65, "Latanoprost" +488, 3, 2, 18, 12, 18, 66, 72, "versus" +488, 3, 3, 19, 19, 27, 73, 81, "combined" +488, 3, 4, 20, 28, 35, 82, 89, "therapy" +488, 3, 5, 21, 36, 40, 90, 94, "with" +488, 3, 6, 22, 41, 48, 95, 102, "timolol" +488, 3, 7, 23, 49, 53, 103, 107, "plus" +488, 3, 8, 24, 54, 65, 108, 119, "dorzolamide" +488, 3, 9, 25, 66, 67, 120, 121, ":" +488, 3, 10, 26, 68, 71, 122, 125, "IOP" +488, 3, 11, 27, 72, 73, 126, 127, "-" +488, 3, 12, 28, 74, 82, 128, 136, "lowering" +488, 3, 13, 29, 83, 89, 137, 143, "effect" +488, 3, 14, 30, 90, 92, 144, 146, "in" +488, 3, 15, 31, 93, 97, 147, 151, "open" +488, 3, 16, 32, 98, 99, 152, 153, "-" +488, 3, 17, 33, 100, 105, 154, 159, "angle" +488, 3, 18, 34, 106, 114, 160, 168, "glaucoma" +488, 3, 19, 35, 115, 116, 169, 170, "." +488, 4, 1, 36, 0, 4, 171, 175, "Polo" +488, 4, 2, 37, 5, 6, 176, 177, "V" +488, 4, 3, 38, 7, 8, 178, 179, "(" +488, 4, 4, 39, 9, 10, 180, 181, "1" +488, 4, 5, 40, 11, 12, 182, 183, ")" +488, 4, 6, 41, 13, 14, 184, 185, "," +488, 4, 7, 42, 15, 22, 186, 193, "Larrosa" +488, 4, 8, 43, 23, 25, 194, 196, "JM" +488, 4, 9, 44, 26, 27, 197, 198, "," +488, 4, 10, 45, 28, 33, 199, 204, "Gomez" +488, 4, 11, 46, 34, 36, 205, 207, "ML" +488, 4, 12, 47, 37, 38, 208, 209, "," +488, 4, 13, 48, 39, 44, 210, 215, "Pablo" +488, 4, 14, 49, 45, 46, 216, 217, "L" +488, 4, 15, 50, 47, 48, 218, 219, "," +488, 4, 16, 51, 49, 57, 220, 228, "Honrubia" +488, 4, 17, 52, 58, 60, 229, 231, "FM" +488, 4, 18, 53, 61, 62, 232, 233, "." +488, 5, 1, 54, 0, 6, 234, 240, "Author" +488, 5, 2, 55, 7, 18, 241, 252, "information" +488, 5, 3, 56, 19, 20, 253, 254, ":" +488, 5, 4, 57, 21, 22, 255, 256, "(" +488, 5, 5, 58, 23, 24, 257, 258, "1" +488, 5, 6, 59, 25, 26, 259, 260, ")" +488, 5, 7, 60, 27, 33, 261, 267, "Miguel" +488, 5, 8, 61, 34, 40, 268, 274, "Servet" +488, 5, 9, 62, 41, 49, 275, 283, "Hospital" +488, 5, 10, 63, 50, 51, 284, 285, "," +488, 5, 11, 64, 52, 62, 286, 296, "Department" +488, 5, 12, 65, 63, 65, 297, 299, "of" +488, 5, 13, 66, 66, 79, 300, 313, "Ophthalmology" +488, 5, 14, 67, 80, 81, 314, 315, "," +488, 5, 15, 68, 82, 90, 316, 324, "Zaragoza" +488, 5, 16, 69, 91, 92, 325, 326, "," +488, 5, 17, 70, 93, 98, 327, 332, "Spain" +488, 5, 18, 71, 99, 100, 333, 334, "." +488, 6, 1, 72, 0, 7, 335, 342, "PURPOSE" +488, 6, 2, 73, 8, 9, 343, 344, ":" +488, 6, 3, 74, 10, 12, 345, 347, "To" +488, 6, 4, 75, 13, 20, 348, 355, "compare" +488, 6, 5, 76, 21, 24, 356, 359, "the" +488, 6, 6, 77, 25, 31, 360, 366, "effect" +488, 6, 7, 78, 32, 34, 367, 369, "on" +488, 6, 8, 79, 35, 46, 370, 381, "intraocular" +488, 6, 9, 80, 47, 55, 382, 390, "pressure" +488, 6, 10, 81, 56, 58, 391, 393, "of" +488, 6, 11, 82, 59, 70, 394, 405, "latanoprost" +488, 6, 12, 83, 71, 77, 406, 412, "versus" +488, 6, 13, 84, 78, 85, 413, 420, "timolol" +488, 6, 14, 85, 86, 90, 421, 425, "plus" +488, 6, 15, 86, 91, 102, 426, 437, "dorzolamide" +488, 6, 16, 87, 103, 105, 438, 440, "in" +488, 6, 17, 88, 106, 110, 441, 445, "open" +488, 6, 18, 89, 111, 112, 446, 447, "-" +488, 6, 19, 90, 113, 118, 448, 453, "angle" +488, 6, 20, 91, 119, 127, 454, 462, "glaucoma" +488, 6, 21, 92, 128, 129, 463, 464, "." +488, 7, 1, 93, 0, 7, 465, 472, "METHODS" +488, 7, 2, 94, 8, 9, 473, 474, ":" +488, 7, 3, 95, 10, 16, 475, 481, "Thirty" +488, 7, 4, 96, 17, 18, 482, 483, "-" +488, 7, 5, 97, 19, 23, 484, 488, "five" +488, 7, 6, 98, 24, 32, 489, 497, "patients" +488, 7, 7, 99, 33, 37, 498, 502, "with" +488, 7, 8, 100, 38, 42, 503, 507, "open" +488, 7, 9, 101, 43, 44, 508, 509, "-" +488, 7, 10, 102, 45, 50, 510, 515, "angle" +488, 7, 11, 103, 51, 59, 516, 524, "glaucoma" +488, 7, 12, 104, 60, 64, 525, 529, "were" +488, 7, 13, 105, 65, 75, 530, 540, "randomized" +488, 7, 14, 106, 76, 77, 541, 542, "," +488, 7, 15, 107, 78, 80, 543, 545, "18" +488, 7, 16, 108, 81, 83, 546, 548, "to" +488, 7, 17, 109, 84, 95, 549, 560, "latanoprost" +488, 7, 18, 110, 96, 100, 561, 565, "once" +488, 7, 19, 111, 101, 106, 566, 571, "daily" +488, 7, 20, 112, 107, 110, 572, 575, "and" +488, 7, 21, 113, 111, 113, 576, 578, "17" +488, 7, 22, 114, 114, 116, 579, 581, "to" +488, 7, 23, 115, 117, 124, 582, 589, "timolol" +488, 7, 24, 116, 125, 129, 590, 594, "plus" +488, 7, 25, 117, 130, 141, 595, 606, "dorzolamide" +488, 7, 26, 118, 142, 147, 607, 612, "twice" +488, 7, 27, 119, 148, 153, 613, 618, "daily" +488, 7, 28, 120, 154, 155, 619, 620, "." +488, 8, 1, 121, 0, 11, 621, 632, "Intraocular" +488, 8, 2, 122, 12, 20, 633, 641, "pressure" +488, 8, 3, 123, 21, 24, 642, 645, "and" +488, 8, 4, 124, 25, 31, 646, 652, "ocular" +488, 8, 5, 125, 32, 36, 653, 657, "side" +488, 8, 6, 126, 37, 44, 658, 665, "effects" +488, 8, 7, 127, 45, 49, 666, 670, "were" +488, 8, 8, 128, 50, 58, 671, 679, "recorded" +488, 8, 9, 129, 59, 61, 680, 682, "at" +488, 8, 10, 130, 62, 70, 683, 691, "baseline" +488, 8, 11, 131, 71, 72, 692, 693, "," +488, 8, 12, 132, 73, 76, 694, 697, "and" +488, 8, 13, 133, 77, 82, 698, 703, "after" +488, 8, 14, 134, 83, 84, 704, 705, "2" +488, 8, 15, 135, 85, 90, 706, 711, "weeks" +488, 8, 16, 136, 91, 94, 712, 715, "and" +488, 8, 17, 137, 95, 96, 716, 717, "3" +488, 8, 18, 138, 97, 103, 718, 724, "months" +488, 8, 19, 139, 104, 106, 725, 727, "of" +488, 8, 20, 140, 107, 116, 728, 737, "treatment" +488, 8, 21, 141, 117, 118, 738, 739, "." +488, 9, 1, 142, 0, 7, 740, 747, "RESULTS" +488, 9, 2, 143, 8, 9, 748, 749, ":" +488, 9, 3, 144, 10, 21, 750, 761, "Latanoprost" +488, 9, 4, 145, 22, 29, 762, 769, "reduced" +488, 9, 5, 146, 30, 33, 770, 773, "the" +488, 9, 6, 147, 34, 45, 774, 785, "intraocular" +488, 9, 7, 148, 46, 54, 786, 794, "pressure" +488, 9, 8, 149, 55, 56, 795, 796, "1" +488, 9, 9, 150, 57, 58, 797, 798, "." +488, 9, 10, 151, 59, 61, 799, 801, "09" +488, 9, 11, 152, 62, 65, 802, 805, "and" +488, 9, 12, 153, 66, 67, 806, 807, "1" +488, 9, 13, 154, 68, 69, 808, 809, "." +488, 9, 14, 155, 70, 72, 810, 812, "58" +488, 9, 15, 156, 73, 75, 813, 815, "mm" +488, 9, 16, 157, 76, 78, 816, 818, "Hg" +488, 9, 17, 158, 79, 83, 819, 823, "more" +488, 9, 18, 159, 84, 88, 824, 828, "than" +488, 9, 19, 160, 89, 96, 829, 836, "timolol" +488, 9, 20, 161, 97, 101, 837, 841, "plus" +488, 9, 21, 162, 102, 113, 842, 853, "dorzolamide" +488, 9, 22, 163, 114, 119, 854, 859, "after" +488, 9, 23, 164, 120, 121, 860, 861, "2" +488, 9, 24, 165, 122, 127, 862, 867, "weeks" +488, 9, 25, 166, 128, 131, 868, 871, "and" +488, 9, 26, 167, 132, 133, 872, 873, "3" +488, 9, 27, 168, 134, 140, 874, 880, "months" +488, 9, 28, 169, 141, 143, 881, 883, "of" +488, 9, 29, 170, 144, 153, 884, 893, "treatment" +488, 9, 30, 171, 154, 155, 894, 895, "," +488, 9, 31, 172, 156, 168, 896, 908, "respectively" +488, 9, 32, 173, 169, 170, 909, 910, "." +488, 10, 1, 174, 0, 5, 911, 916, "These" +488, 10, 2, 175, 6, 17, 917, 928, "differences" +488, 10, 3, 176, 18, 22, 929, 933, "were" +488, 10, 4, 177, 23, 36, 934, 947, "statistically" +488, 10, 5, 178, 37, 48, 948, 959, "significant" +488, 10, 6, 179, 49, 50, 960, 961, "(" +488, 10, 7, 180, 51, 52, 962, 963, "p" +488, 10, 8, 181, 53, 54, 964, 965, "<" +488, 10, 9, 182, 55, 56, 966, 967, "0" +488, 10, 10, 183, 57, 58, 968, 969, "." +488, 10, 11, 184, 59, 61, 970, 972, "05" +488, 10, 12, 185, 62, 63, 973, 974, ")" +488, 10, 13, 186, 64, 66, 975, 977, "at" +488, 10, 14, 187, 67, 70, 978, 981, "the" +488, 10, 15, 188, 71, 74, 982, 985, "end" +488, 10, 16, 189, 75, 77, 986, 988, "of" +488, 10, 17, 190, 78, 81, 989, 992, "the" +488, 10, 18, 191, 82, 87, 993, 998, "study" +488, 10, 19, 192, 88, 89, 999, 1000, "." +488, 11, 1, 193, 0, 5, 1001, 1006, "After" +488, 11, 2, 194, 6, 7, 1007, 1008, "3" +488, 11, 3, 195, 8, 14, 1009, 1015, "months" +488, 11, 4, 196, 15, 17, 1016, 1018, "of" +488, 11, 5, 197, 18, 27, 1019, 1028, "treatment" +488, 11, 6, 198, 28, 29, 1029, 1030, "," +488, 11, 7, 199, 30, 32, 1031, 1033, "32" +488, 11, 8, 200, 33, 34, 1034, 1035, "." +488, 11, 9, 201, 35, 36, 1036, 1037, "3" +488, 11, 10, 202, 37, 38, 1038, 1039, "%" +488, 11, 11, 203, 39, 41, 1040, 1042, "of" +488, 11, 12, 204, 42, 45, 1043, 1046, "the" +488, 11, 13, 205, 46, 50, 1047, 1051, "eyes" +488, 11, 14, 206, 51, 53, 1052, 1054, "in" +488, 11, 15, 207, 54, 57, 1055, 1058, "the" +488, 11, 16, 208, 58, 69, 1059, 1070, "latanoprost" +488, 11, 17, 209, 70, 75, 1071, 1076, "group" +488, 11, 18, 210, 76, 83, 1077, 1084, "reduced" +488, 11, 19, 211, 84, 87, 1085, 1088, "the" +488, 11, 20, 212, 88, 99, 1089, 1100, "intraocular" +488, 11, 21, 213, 100, 108, 1101, 1109, "pressure" +488, 11, 22, 214, 109, 111, 1110, 1112, "in" +488, 11, 23, 215, 112, 114, 1113, 1115, "30" +488, 11, 24, 216, 115, 116, 1116, 1117, "%" +488, 11, 25, 217, 117, 119, 1118, 1120, "or" +488, 11, 26, 218, 120, 124, 1121, 1125, "more" +488, 11, 27, 219, 125, 129, 1126, 1130, "with" +488, 11, 28, 220, 130, 137, 1131, 1138, "respect" +488, 11, 29, 221, 138, 140, 1139, 1141, "to" +488, 11, 30, 222, 141, 149, 1142, 1150, "baseline" +488, 11, 31, 223, 150, 151, 1151, 1152, "," +488, 11, 32, 224, 152, 157, 1153, 1158, "while" +488, 11, 33, 225, 158, 160, 1159, 1161, "15" +488, 11, 34, 226, 161, 162, 1162, 1163, "." +488, 11, 35, 227, 163, 164, 1164, 1165, "6" +488, 11, 36, 228, 165, 166, 1166, 1167, "%" +488, 11, 37, 229, 167, 169, 1168, 1170, "of" +488, 11, 38, 230, 170, 173, 1171, 1174, "the" +488, 11, 39, 231, 174, 178, 1175, 1179, "eyes" +488, 11, 40, 232, 179, 181, 1180, 1182, "in" +488, 11, 41, 233, 182, 185, 1183, 1186, "the" +488, 11, 42, 234, 186, 193, 1187, 1194, "timolol" +488, 11, 43, 235, 194, 198, 1195, 1199, "plus" +488, 11, 44, 236, 199, 210, 1200, 1211, "dorzolamide" +488, 11, 45, 237, 211, 216, 1212, 1217, "group" +488, 11, 46, 238, 217, 225, 1218, 1226, "achieved" +488, 11, 47, 239, 226, 230, 1227, 1231, "this" +488, 11, 48, 240, 231, 240, 1232, 1241, "reduction" +488, 11, 49, 241, 241, 242, 1242, 1243, "." +488, 12, 1, 242, 0, 11, 1244, 1255, "CONCLUSIONS" +488, 12, 2, 243, 12, 13, 1256, 1257, ":" +488, 12, 3, 244, 14, 25, 1258, 1269, "Latanoprost" +488, 12, 4, 245, 26, 38, 1270, 1282, "administered" +488, 12, 5, 246, 39, 43, 1283, 1287, "once" +488, 12, 6, 247, 44, 49, 1288, 1293, "daily" +488, 12, 7, 248, 50, 57, 1294, 1301, "reduced" +488, 12, 8, 249, 58, 61, 1302, 1305, "the" +488, 12, 9, 250, 62, 73, 1306, 1317, "intraocular" +488, 12, 10, 251, 74, 82, 1318, 1326, "pressure" +488, 12, 11, 252, 83, 85, 1327, 1329, "at" +488, 12, 12, 253, 86, 91, 1330, 1335, "least" +488, 12, 13, 254, 92, 94, 1336, 1338, "as" +488, 12, 14, 255, 95, 99, 1339, 1343, "well" +488, 12, 15, 256, 100, 102, 1344, 1346, "as" +488, 12, 16, 257, 103, 110, 1347, 1354, "timolol" +488, 12, 17, 258, 111, 115, 1355, 1359, "plus" +488, 12, 18, 259, 116, 127, 1360, 1371, "dorzolamide" +488, 12, 19, 260, 128, 133, 1372, 1377, "twice" +488, 12, 20, 261, 134, 139, 1378, 1383, "daily" +488, 12, 21, 262, 140, 142, 1384, 1386, "in" +488, 12, 22, 263, 143, 151, 1387, 1395, "patients" +488, 12, 23, 264, 152, 156, 1396, 1400, "with" +488, 12, 24, 265, 157, 161, 1401, 1405, "open" +488, 12, 25, 266, 162, 163, 1406, 1407, "-" +488, 12, 26, 267, 164, 169, 1408, 1413, "angle" +488, 12, 27, 268, 170, 178, 1414, 1422, "glaucoma" +488, 12, 28, 269, 179, 180, 1423, 1424, "." +488, 13, 1, 270, 0, 4, 1425, 1429, "PMID" +488, 13, 2, 271, 5, 6, 1430, 1431, ":" +488, 13, 3, 272, 7, 15, 1432, 1440, "11167277" +488, 13, 4, 273, 16, 17, 1441, 1442, "[" +488, 13, 5, 274, 18, 25, 1443, 1450, "Indexed" +488, 13, 6, 275, 26, 29, 1451, 1454, "for" +488, 13, 7, 276, 30, 37, 1455, 1462, "MEDLINE" +488, 13, 8, 277, 38, 39, 1463, 1464, "]" diff --git a/data/gl 11167277_jshahinitiran.annodb b/data/gl 11167277_jshahinitiran.annodb new file mode 100644 index 0000000..d6368b3 --- /dev/null +++ b/data/gl 11167277_jshahinitiran.annodb @@ -0,0 +1,62 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2665, Journal, 0, 21, "Acta Ophthalmol Scand", "", +2666, PublicationYear, 24, 32, "2001 Feb", "", +2671, Title, 54, 170, "Latanoprost versus combined therapy with timolol plus dorzolamide : IOP - lowering effect in open - angle glaucoma .", "", +2672, Latanoprost, 54, 65, "Latanoprost", "", +2667, Timolol, 95, 102, "timolol", "", +2668, Dorzolamide, 108, 119, "dorzolamide", "", +2680, IOP, 122, 125, "IOP", "", +2670, OpenAngleGlaucoma, 147, 168, "open - angle glaucoma", "", +2674, Author, 171, 177, "Polo V", "", +2675, Author, 186, 196, "Larrosa JM", "", +2676, Author, 199, 207, "Gomez ML", "", +2677, Author, 210, 217, "Pablo L", "", +2678, Author, 220, 231, "Honrubia FM", "", +2705, Spain, 327, 332, "Spain", "", +2679, ObjectiveDescription, 345, 464, "To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open - angle glaucoma .", "", +2683, IOP, 370, 390, "intraocular pressure", "", +2684, Latanoprost, 394, 405, "latanoprost", "", +2685, Timolol, 413, 420, "timolol", "", +2686, Dorzolamide, 426, 437, "dorzolamide", "", +2687, OpenAngleGlaucoma, 441, 462, "open - angle glaucoma", "", +2688, NumberPatientsCT, 475, 488, "Thirty - five", "", +2689, OpenAngleGlaucoma, 503, 524, "open - angle glaucoma", "", +2690, Randomized, 530, 540, "randomized", "", +2691, NumberPatientsArm, 543, 545, "18", "lat", +2692, Latanoprost, 549, 560, "latanoprost", "", +2693, Frequency, 561, 571, "once daily", "lat", +2694, NumberPatientsArm, 576, 578, "17", "tim", +2695, Timolol, 582, 589, "timolol", "", +2696, Dorzolamide, 595, 606, "dorzolamide", "", +2697, Frequency, 607, 618, "twice daily", "tim", +2698, IOP, 621, 641, "Intraocular pressure", "", +2700, TimePoint, 683, 691, "baseline", "", +25992, TimePoint, 704, 711, "2 weeks", "", +25993, TimePoint, 716, 724, "3 months", "", +2703, Latanoprost, 750, 761, "Latanoprost", "", +2704, IOP, 774, 794, "intraocular pressure", "", +2706, DiffBetweenGroups, 795, 801, "1 . 09", "tp1", +2707, DiffBetweenGroups, 806, 812, "1 . 58", "tp2", +2708, mmHg, 813, 818, "mm Hg", "", +2709, Timolol, 829, 836, "timolol", "", +2710, Dorzolamide, 842, 853, "dorzolamide", "", +25994, TimePoint, 860, 867, "2 weeks", "", +25995, TimePoint, 872, 880, "3 months", "", +2713, PvalueDiff, 962, 972, "p < 0 . 05", "", +25996, TimePoint, 1007, 1015, "3 months", "", +2715, PercentageAffected, 1031, 1037, "32 . 3", "", +2716, Latanoprost, 1059, 1070, "latanoprost", "", +2717, IOP, 1089, 1109, "intraocular pressure", "", +2718, RelativeReduction, 1113, 1115, "30", "", +2719, PercentageAffected, 1159, 1165, "15 . 6", "", +2720, Timolol, 1187, 1194, "timolol", "", +2721, Dorzolamide, 1200, 1211, "dorzolamide", "", +2722, ConclusionComment, 1258, 1424, "Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open - angle glaucoma .", "", +2723, Latanoprost, 1258, 1269, "Latanoprost", "", +2724, Frequency, 1283, 1293, "once daily", "lat", +2725, IOP, 1306, 1326, "intraocular pressure", "", +2726, Timolol, 1347, 1354, "timolol", "", +2727, Dorzolamide, 1360, 1371, "dorzolamide", "", +2728, Frequency, 1372, 1383, "twice daily", "tim", +2729, OpenAngleGlaucoma, 1401, 1422, "open - angle glaucoma", "", +2730, PMID, 1432, 1440, "11167277", "", diff --git a/data/gl 11167277_jshahinitiran.n-triples b/data/gl 11167277_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11167277_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11167277_tstrakeljahn.annodb b/data/gl 11167277_tstrakeljahn.annodb new file mode 100644 index 0000000..7176cc3 --- /dev/null +++ b/data/gl 11167277_tstrakeljahn.annodb @@ -0,0 +1,59 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5540, Journal, 0, 21, "Acta Ophthalmol Scand", "", +5541, PublicationYear, 24, 28, "2001", "", +5542, Latanoprost, 54, 65, "Latanoprost", "", +5547, Title, 54, 168, "Latanoprost versus combined therapy with timolol plus dorzolamide : IOP - lowering effect in open - angle glaucoma", "", +5543, Timolol, 95, 102, "timolol", "", +5544, Dorzolamide, 108, 119, "dorzolamide", "", +5545, IOP, 122, 125, "IOP", "", +5546, OpenAngleGlaucoma, 147, 168, "open - angle glaucoma", "", +5548, Author, 171, 177, "Polo V", "", +5549, Author, 186, 196, "Larrosa JM", "", +5550, Author, 199, 207, "Gomez ML", "", +5551, Author, 210, 217, "Pablo L", "", +5552, Author, 220, 231, "Honrubia FM", "", +5553, Spain, 327, 332, "Spain", "", +5559, ObjectiveDescription, 345, 462, "To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open - angle glaucoma", "", +5554, IOP, 370, 390, "intraocular pressure", "", +5555, Latanoprost, 394, 405, "latanoprost", "", +5556, Timolol, 413, 420, "timolol", "", +5557, Dorzolamide, 426, 437, "dorzolamide", "", +5558, OpenAngleGlaucoma, 441, 462, "open - angle glaucoma", "", +5561, NumberPatientsCT, 475, 488, "Thirty - five", "", +5562, OpenAngleGlaucoma, 503, 524, "open - angle glaucoma", "", +5563, Randomized, 530, 540, "randomized", "", +5564, NumberPatientsArm, 543, 545, "18", "", +5566, Latanoprost, 549, 560, "latanoprost", "", +5567, Frequency, 561, 571, "once daily", "", +5565, NumberPatientsArm, 576, 578, "17", "", +5568, Timolol, 582, 589, "timolol", "", +5569, Dorzolamide, 595, 606, "dorzolamide", "", +5570, Frequency, 607, 618, "twice daily", "", +5571, IOP, 621, 641, "Intraocular pressure", "", +5572, Latanoprost, 750, 761, "Latanoprost", "", +5573, IOP, 774, 794, "intraocular pressure", "", +5574, DiffGroupAbsValue, 795, 801, "1 . 09", "", +5575, DiffGroupAbsValue, 806, 812, "1 . 58", "", +5576, mmHg, 813, 818, "mm Hg", "", +5577, Timolol, 829, 836, "timolol", "", +5578, Dorzolamide, 842, 853, "dorzolamide", "", +5579, TimePoint, 860, 867, "2 weeks", "", +5580, TimePoint, 872, 880, "3 months", "", +5581, PvalueDiff, 962, 972, "p < 0 . 05", "", +5582, TimePoint, 1007, 1015, "3 months", "", +5585, PercentageAffected, 1031, 1037, "32 . 3", "", +5587, Latanoprost, 1059, 1070, "latanoprost", "", +5588, IOP, 1089, 1109, "intraocular pressure", "", +5586, RelativeReduction, 1113, 1115, "30", "", +5584, PercentageAffected, 1159, 1165, "15 . 6", "", +5589, Timolol, 1187, 1194, "timolol", "", +5590, Dorzolamide, 1200, 1211, "dorzolamide", "", +5591, Latanoprost, 1258, 1269, "Latanoprost", "", +5599, ConclusionComment, 1258, 1422, "Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open - angle glaucoma", "", +5592, Frequency, 1283, 1293, "once daily", "", +5593, IOP, 1306, 1326, "intraocular pressure", "", +5594, Timolol, 1347, 1354, "timolol", "", +5595, Dorzolamide, 1360, 1371, "dorzolamide", "", +5596, Frequency, 1372, 1383, "twice daily", "", +5597, OpenAngleGlaucoma, 1401, 1422, "open - angle glaucoma", "", +5598, PMID, 1432, 1440, "11167277", "", diff --git a/data/gl 11167277_tstrakeljahn.n-triples b/data/gl 11167277_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11167277_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11336940_admin.annodb b/data/gl 11336940_admin.annodb new file mode 100644 index 0000000..a8f02bd --- /dev/null +++ b/data/gl 11336940_admin.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Am J Ophthalmol .", "", " \"Am J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2001", "", " \"2001\"." +2, Title, 52, 227, "A randomized double - masked crossover study comparing latanoprost 0 . 005 % with unoprostone 0 . 12 % in patients with primary open - angle glaucoma and ocular hypertension .", "", " \"A randomized double - masked crossover study comparing latanoprost 0 . 005 % with unoprostone 0 . 12 % in patients with primary open - angle glaucoma and ocular hypertension .\"." +57, Randomized, 54, 64, "randomized", "", " ." +59, DoubleBlind, 65, 80, "double - masked", "", " ." +60, Crossover, 81, 90, "crossover", "", " ." +61, Latanoprost, 107, 118, "latanoprost", "", +65, DoseValue, 119, 126, "0 . 005", "", +67, Percentage, 127, 128, "%", "", +62, Unoprostone, 134, 145, "unoprostone", "", +66, DoseValue, 146, 152, "0 . 12", "", +68, Percentage, 153, 154, "%", "", +94, Primary_OpenAngleGlaucoma, 172, 201, "primary open - angle glaucoma", "", " ." +63, OcularHypertension, 206, 225, "ocular hypertension", "", " ." +3, Author, 228, 234, "Aung T", "", " \"Aung T\"." +4, Author, 243, 250, "Chew PT", "", " \"Chew PT\"." +5, Author, 253, 259, "Yip CC", "", " \"Yip CC\"." +6, Author, 262, 269, "Chan YH", "", " \"Chan YH\"." +7, Author, 272, 278, "See JL", "", " \"See JL\"." +8, Author, 281, 288, "Khng CG", "", " \"Khng CG\"." +9, Author, 291, 297, "Hoh ST", "", " \"Hoh ST\"." +10, Author, 300, 305, "Ng LH", "", " \"Ng LH\"." +11, Author, 308, 314, "Lee HM", "", " \"Lee HM\"." +12, Singapore, 376, 385, "Singapore", "", " ." +13, ObjectiveDescription, 398, 546, "To compare the intraocular pressure ) - lowering effect and side effects of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily .", "", " \"To compare the intraocular pressure ) - lowering effect and side effects of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily .\"." +14, IOP, 413, 433, "intraocular pressure", "", +69, Latanoprost, 474, 485, "latanoprost", "", " . ." +71, DoseValue, 486, 493, "0 . 005", "", " \"0 . 005\"." +73, Percentage, 494, 495, "%", "", " ." +75, Frequency, 496, 506, "once daily", "", +70, Unoprostone, 512, 523, "unoprostone", "", " ." +72, DoseValue, 524, 530, "0 . 12", "", " \"0 . 12\"." +74, Percentage, 531, 532, "%", "", " ." +76, Frequency, 533, 544, "twice daily", "", +15, NumberPatientsCT, 557, 562, "Sixty", "", " \"Sixty\"." +80086, Precondition, 563, 629, "patients with primary open - angle glaucoma or ocular hypertension", "", " \"patients with primary open - angle glaucoma or ocular hypertension\"." +95, Primary_OpenAngleGlaucoma, 577, 606, "primary open - angle glaucoma", "", +77, OcularHypertension, 610, 629, "ocular hypertension", "", +78, Randomized, 635, 645, "randomized", "", +79, Latanoprost, 664, 675, "latanoprost", "", +80, Frequency, 676, 686, "once daily", "", +16, Bedtime, 694, 701, "evening", "", " ." +18, Placebo, 706, 713, "placebo", "", " ." +17, Frequency, 714, 724, "once daily", "", " \"once daily\". \"once daily\"." +19, Morning, 732, 739, "morning", "", " ." +81, Unoprostone, 745, 756, "unoprostone", "", +82, Frequency, 757, 768, "twice daily", "", " \"twice daily\"." +20, Morning, 776, 783, "morning", "", " ." +146, Evening, 788, 795, "evening", "", " ." +83, DoubleBlind, 812, 825, "double masked", "", +84, Crossover, 841, 850, "crossover", "", +93749, Duration, 888, 895, "1 month", "", " \"1 month\"." +85, IOP, 941, 961, "intraocular pressure", "", +151, Morning, 978, 982, "9 AM", "", +152, Evening, 987, 991, "5 PM", "", +97, TimePoint, 999, 1007, "baseline", "", +98, TimePoint, 1012, 1018, "day 28", "", +156, Morning, 1035, 1039, "9 AM", "", +99, TimePoint, 1043, 1048, "day 2", "", +100, TimePoint, 1053, 1059, "day 14", "", +157, Morning, 1098, 1102, "9 AM", "", +101, Unoprostone, 1169, 1180, "unoprostone", "", +102, Latanoprost, 1185, 1196, "latanoprost", "", +160, Evening, 1207, 1211, "5 PM", "", +86, Mean, 1268, 1272, "mean", "", +87, FinalNumPatientsCT, 1359, 1370, "Fifty - six", "", " \"Fifty - six\"." +22, IOP, 1421, 1441, "intraocular pressure", "", +23, TimePoint, 1480, 1487, "1 month", "", " \"1 month\". \"1 month\"." +24, Latanoprost, 1503, 1514, "latanoprost", "", +25, IOP, 1537, 1557, "intraocular pressure", "", " . ." +88, Mean, 1560, 1564, "mean", "", " . ." +168, Reduction, 1580, 1585, "6 . 1", "", " \"6 . 1\"." +27, SdErrorChangeValue, 1592, 1597, "0 . 5", "", " \"0 . 5\"." +28, mmHg, 1598, 1603, "mm Hg", "", " ." +175, PValueChangeValue, 1608, 1615, "< . 001", "", " \"< . 001\"." +34, Unoprostone, 1622, 1633, "unoprostone", "", +169, Reduction, 1637, 1642, "4 . 2", "", " \"4 . 2\"." +35, SdErrorChangeValue, 1649, 1654, "0 . 4", "", " \"0 . 4\"." +36, mmHg, 1655, 1660, "mm Hg", "", +37, PValueChangeValue, 1663, 1672, "P < . 001", "", " \"P < . 001\"." +30, BaseLineValue, 1712, 1718, "22 . 3", "", " \"22 . 3\"." +31, SdErrorBL, 1725, 1730, "0 . 5", "", " \"0 . 5\"." +32, mmHg, 1731, 1736, "mm Hg", "", +38, BaseLineValue, 1741, 1747, "23 . 2", "", " \"23 . 2\"." +39, SdErrorBL, 1754, 1759, "0 . 4", "", " \"0 . 4\"." +40, mmHg, 1760, 1765, "mm Hg", "", +106398, DiffGroupAbsValue, 1801, 1806, "1 . 9", "", " \"1 . 9\"." +42, mmHg, 1807, 1812, "mm Hg", "", +44, Latanoprost, 1874, 1885, "latanoprost", "", +43, PvalueDiff, 1888, 1897, "P = . 003", "", " \"P = . 003\"." +45, IOP, 2005, 2025, "intraocular pressure", "", +46, Latanoprost, 2074, 2085, "latanoprost", "", +47, Unoprostone, 2126, 2137, "unoprostone", "", +193, ObservedResult, 2230, 2304, "Eye redness and ocular irritation were the most frequently reported events", "", " \"Eye redness and ocular irritation were the most frequently reported events\". \"Eye redness and ocular irritation were the most frequently reported events\"." +80092, EndPointDescription, 2230, 2241, "Eye redness", "", " . ." +80093, EndPointDescription, 2246, 2263, "ocular irritation", "", " . ." +48, ConclusionComment, 2321, 2547, "Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open - angle glaucoma and ocular hypertension .", "", " \"Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open - angle glaucoma and ocular hypertension .\"." +49, Latanoprost, 2321, 2332, "Latanoprost", "", +91, Frequency, 2333, 2343, "once daily", "", +50, IOP, 2389, 2409, "intraocular pressure", "", +54, Unoprostone, 2424, 2435, "unoprostone", "", +92, Frequency, 2436, 2447, "twice daily", "", +93, TimePoint, 2454, 2461, "1 month", "", +96, Primary_OpenAngleGlaucoma, 2492, 2521, "primary open - angle glaucoma", "", +51, OcularHypertension, 2526, 2545, "ocular hypertension", "", +53, ConclusionComment, 2548, 2611, "Both drugs were well tolerated with few ocular adverse events .", "", " \"11336940\"." +52, PMID, 2667, 2675, "11336940", "", " \"11336940\"." diff --git a/data/gl 11336940_admin.n-triples b/data/gl 11336940_admin.n-triples new file mode 100644 index 0000000..6ae796f --- /dev/null +++ b/data/gl 11336940_admin.n-triples @@ -0,0 +1,153 @@ +# RDF export of group: Publication + . + "Publication" . + "A randomized double - masked crossover study comparing latanoprost 0 . 005 % with unoprostone 0 . 12 % in patients with primary open - angle glaucoma and ocular hypertension ." . + "Aung T" . + "2001" . + "Am J Ophthalmol ." . + "11336940" . + . + "Chew PT" . + "Yip CC" . + "Chan YH" . + "See JL" . + "Khng CG" . + "Hoh ST" . + "Ng LH" . + "Lee HM" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ) - lowering effect and side effects of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily ." . + "Sixty" . + "1 month" . + . + . + . + "Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open - angle glaucoma and ocular hypertension ." . + . + . + . + . + . + "Fifty - six" . + . + . + "Both drugs were well tolerated with few ocular adverse events ." . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_ER" . + . + . + . + . + . + . + "Endpoint_OI" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + . + "Arm_uno" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_uno" . + . + "twice daily" . + . + . + . + "Intervention_pla" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_uno" . + . + "0 . 12" . + . + . + . + "Medication_pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat" . + . + "22 . 3" . + "0 . 5" . + "6 . 1" . + "< . 001" . + "0 . 5" . + "1 month" . + . + "Outcome_iop_uno" . + . + "23 . 2" . + "0 . 4" . + "4 . 2" . + "P < . 001" . + "0 . 4" . + "1 month" . + . + "Outcome_ER" . + . + "Eye redness and ocular irritation were the most frequently reported events" . + . + "Outcome_OI" . + . + "Eye redness and ocular irritation were the most frequently reported events" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "1 . 9" . + "P = . 003" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11336940_export.csv b/data/gl 11336940_export.csv new file mode 100644 index 0000000..a7729d6 --- /dev/null +++ b/data/gl 11336940_export.csv @@ -0,0 +1,537 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +487, 1, 1, 1, 0, 2, 0, 2, "Am" +487, 1, 2, 2, 3, 4, 3, 4, "J" +487, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +487, 1, 4, 4, 16, 17, 16, 17, "." +487, 2, 1, 5, 0, 4, 18, 22, "2001" +487, 2, 2, 6, 5, 8, 23, 26, "May" +487, 2, 3, 7, 9, 10, 27, 28, ";" +487, 2, 4, 8, 11, 14, 29, 32, "131" +487, 2, 5, 9, 15, 16, 33, 34, "(" +487, 2, 6, 10, 17, 18, 35, 36, "5" +487, 2, 7, 11, 19, 20, 37, 38, ")" +487, 2, 8, 12, 21, 22, 39, 40, ":" +487, 2, 9, 13, 23, 26, 41, 44, "636" +487, 2, 10, 14, 27, 28, 45, 46, "-" +487, 2, 11, 15, 29, 31, 47, 49, "42" +487, 2, 12, 16, 32, 33, 50, 51, "." +487, 3, 1, 17, 0, 1, 52, 53, "A" +487, 3, 2, 18, 2, 12, 54, 64, "randomized" +487, 3, 3, 19, 13, 19, 65, 71, "double" +487, 3, 4, 20, 20, 21, 72, 73, "-" +487, 3, 5, 21, 22, 28, 74, 80, "masked" +487, 3, 6, 22, 29, 38, 81, 90, "crossover" +487, 3, 7, 23, 39, 44, 91, 96, "study" +487, 3, 8, 24, 45, 54, 97, 106, "comparing" +487, 3, 9, 25, 55, 66, 107, 118, "latanoprost" +487, 3, 10, 26, 67, 68, 119, 120, "0" +487, 3, 11, 27, 69, 70, 121, 122, "." +487, 3, 12, 28, 71, 74, 123, 126, "005" +487, 3, 13, 29, 75, 76, 127, 128, "%" +487, 3, 14, 30, 77, 81, 129, 133, "with" +487, 3, 15, 31, 82, 93, 134, 145, "unoprostone" +487, 3, 16, 32, 94, 95, 146, 147, "0" +487, 3, 17, 33, 96, 97, 148, 149, "." +487, 3, 18, 34, 98, 100, 150, 152, "12" +487, 3, 19, 35, 101, 102, 153, 154, "%" +487, 3, 20, 36, 103, 105, 155, 157, "in" +487, 3, 21, 37, 106, 114, 158, 166, "patients" +487, 3, 22, 38, 115, 119, 167, 171, "with" +487, 3, 23, 39, 120, 127, 172, 179, "primary" +487, 3, 24, 40, 128, 132, 180, 184, "open" +487, 3, 25, 41, 133, 134, 185, 186, "-" +487, 3, 26, 42, 135, 140, 187, 192, "angle" +487, 3, 27, 43, 141, 149, 193, 201, "glaucoma" +487, 3, 28, 44, 150, 153, 202, 205, "and" +487, 3, 29, 45, 154, 160, 206, 212, "ocular" +487, 3, 30, 46, 161, 173, 213, 225, "hypertension" +487, 3, 31, 47, 174, 175, 226, 227, "." +487, 4, 1, 48, 0, 4, 228, 232, "Aung" +487, 4, 2, 49, 5, 6, 233, 234, "T" +487, 4, 3, 50, 7, 8, 235, 236, "(" +487, 4, 4, 51, 9, 10, 237, 238, "1" +487, 4, 5, 52, 11, 12, 239, 240, ")" +487, 4, 6, 53, 13, 14, 241, 242, "," +487, 4, 7, 54, 15, 19, 243, 247, "Chew" +487, 4, 8, 55, 20, 22, 248, 250, "PT" +487, 4, 9, 56, 23, 24, 251, 252, "," +487, 4, 10, 57, 25, 28, 253, 256, "Yip" +487, 4, 11, 58, 29, 31, 257, 259, "CC" +487, 4, 12, 59, 32, 33, 260, 261, "," +487, 4, 13, 60, 34, 38, 262, 266, "Chan" +487, 4, 14, 61, 39, 41, 267, 269, "YH" +487, 4, 15, 62, 42, 43, 270, 271, "," +487, 4, 16, 63, 44, 47, 272, 275, "See" +487, 4, 17, 64, 48, 50, 276, 278, "JL" +487, 4, 18, 65, 51, 52, 279, 280, "," +487, 4, 19, 66, 53, 57, 281, 285, "Khng" +487, 4, 20, 67, 58, 60, 286, 288, "CG" +487, 4, 21, 68, 61, 62, 289, 290, "," +487, 4, 22, 69, 63, 66, 291, 294, "Hoh" +487, 4, 23, 70, 67, 69, 295, 297, "ST" +487, 4, 24, 71, 70, 71, 298, 299, "," +487, 4, 25, 72, 72, 74, 300, 302, "Ng" +487, 4, 26, 73, 75, 77, 303, 305, "LH" +487, 4, 27, 74, 78, 79, 306, 307, "," +487, 4, 28, 75, 80, 83, 308, 311, "Lee" +487, 4, 29, 76, 84, 86, 312, 314, "HM" +487, 4, 30, 77, 87, 88, 315, 316, "." +487, 5, 1, 78, 0, 6, 317, 323, "Author" +487, 5, 2, 79, 7, 18, 324, 335, "information" +487, 5, 3, 80, 19, 20, 336, 337, ":" +487, 5, 4, 81, 21, 22, 338, 339, "(" +487, 5, 5, 82, 23, 24, 340, 341, "1" +487, 5, 6, 83, 25, 26, 342, 343, ")" +487, 5, 7, 84, 27, 36, 344, 353, "Singapore" +487, 5, 8, 85, 37, 45, 354, 362, "National" +487, 5, 9, 86, 46, 49, 363, 366, "Eye" +487, 5, 10, 87, 50, 56, 367, 373, "Centre" +487, 5, 11, 88, 57, 58, 374, 375, "," +487, 5, 12, 89, 59, 68, 376, 385, "Singapore" +487, 5, 13, 90, 69, 70, 386, 387, "." +487, 6, 1, 91, 0, 7, 388, 395, "PURPOSE" +487, 6, 2, 92, 8, 9, 396, 397, ":" +487, 6, 3, 93, 10, 12, 398, 400, "To" +487, 6, 4, 94, 13, 20, 401, 408, "compare" +487, 6, 5, 95, 21, 24, 409, 412, "the" +487, 6, 6, 96, 25, 36, 413, 424, "intraocular" +487, 6, 7, 97, 37, 45, 425, 433, "pressure" +487, 6, 8, 98, 46, 47, 434, 435, ")" +487, 6, 9, 99, 48, 49, 436, 437, "-" +487, 6, 10, 100, 50, 58, 438, 446, "lowering" +487, 6, 11, 101, 59, 65, 447, 453, "effect" +487, 6, 12, 102, 66, 69, 454, 457, "and" +487, 6, 13, 103, 70, 74, 458, 462, "side" +487, 6, 14, 104, 75, 82, 463, 470, "effects" +487, 6, 15, 105, 83, 85, 471, 473, "of" +487, 6, 16, 106, 86, 97, 474, 485, "latanoprost" +487, 6, 17, 107, 98, 99, 486, 487, "0" +487, 6, 18, 108, 100, 101, 488, 489, "." +487, 6, 19, 109, 102, 105, 490, 493, "005" +487, 6, 20, 110, 106, 107, 494, 495, "%" +487, 6, 21, 111, 108, 112, 496, 500, "once" +487, 6, 22, 112, 113, 118, 501, 506, "daily" +487, 6, 23, 113, 119, 123, 507, 511, "with" +487, 6, 24, 114, 124, 135, 512, 523, "unoprostone" +487, 6, 25, 115, 136, 137, 524, 525, "0" +487, 6, 26, 116, 138, 139, 526, 527, "." +487, 6, 27, 117, 140, 142, 528, 530, "12" +487, 6, 28, 118, 143, 144, 531, 532, "%" +487, 6, 29, 119, 145, 150, 533, 538, "twice" +487, 6, 30, 120, 151, 156, 539, 544, "daily" +487, 6, 31, 121, 157, 158, 545, 546, "." +487, 7, 1, 122, 0, 7, 547, 554, "METHODS" +487, 7, 2, 123, 8, 9, 555, 556, ":" +487, 7, 3, 124, 10, 15, 557, 562, "Sixty" +487, 7, 4, 125, 16, 24, 563, 571, "patients" +487, 7, 5, 126, 25, 29, 572, 576, "with" +487, 7, 6, 127, 30, 37, 577, 584, "primary" +487, 7, 7, 128, 38, 42, 585, 589, "open" +487, 7, 8, 129, 43, 44, 590, 591, "-" +487, 7, 9, 130, 45, 50, 592, 597, "angle" +487, 7, 10, 131, 51, 59, 598, 606, "glaucoma" +487, 7, 11, 132, 60, 62, 607, 609, "or" +487, 7, 12, 133, 63, 69, 610, 616, "ocular" +487, 7, 13, 134, 70, 82, 617, 629, "hypertension" +487, 7, 14, 135, 83, 87, 630, 634, "were" +487, 7, 15, 136, 88, 98, 635, 645, "randomized" +487, 7, 16, 137, 99, 101, 646, 648, "to" +487, 7, 17, 138, 102, 109, 649, 656, "receive" +487, 7, 18, 139, 110, 116, 657, 663, "either" +487, 7, 19, 140, 117, 128, 664, 675, "latanoprost" +487, 7, 20, 141, 129, 133, 676, 680, "once" +487, 7, 21, 142, 134, 139, 681, 686, "daily" +487, 7, 22, 143, 140, 142, 687, 689, "in" +487, 7, 23, 144, 143, 146, 690, 693, "the" +487, 7, 24, 145, 147, 154, 694, 701, "evening" +487, 7, 25, 146, 155, 158, 702, 705, "and" +487, 7, 26, 147, 159, 166, 706, 713, "placebo" +487, 7, 27, 148, 167, 171, 714, 718, "once" +487, 7, 28, 149, 172, 177, 719, 724, "daily" +487, 7, 29, 150, 178, 180, 725, 727, "in" +487, 7, 30, 151, 181, 184, 728, 731, "the" +487, 7, 31, 152, 185, 192, 732, 739, "morning" +487, 7, 32, 153, 193, 194, 740, 741, "," +487, 7, 33, 154, 195, 197, 742, 744, "or" +487, 7, 34, 155, 198, 209, 745, 756, "unoprostone" +487, 7, 35, 156, 210, 215, 757, 762, "twice" +487, 7, 36, 157, 216, 221, 763, 768, "daily" +487, 7, 37, 158, 222, 224, 769, 771, "in" +487, 7, 38, 159, 225, 228, 772, 775, "the" +487, 7, 39, 160, 229, 236, 776, 783, "morning" +487, 7, 40, 161, 237, 240, 784, 787, "and" +487, 7, 41, 162, 241, 248, 788, 795, "evening" +487, 7, 42, 163, 249, 250, 796, 797, "." +487, 8, 1, 164, 0, 3, 798, 801, "The" +487, 8, 2, 165, 4, 9, 802, 807, "study" +487, 8, 3, 166, 10, 13, 808, 811, "was" +487, 8, 4, 167, 14, 20, 812, 818, "double" +487, 8, 5, 168, 21, 27, 819, 825, "masked" +487, 8, 6, 169, 28, 31, 826, 829, "and" +487, 8, 7, 170, 32, 40, 830, 838, "followed" +487, 8, 8, 171, 41, 42, 839, 840, "a" +487, 8, 9, 172, 43, 52, 841, 850, "crossover" +487, 8, 10, 173, 53, 59, 851, 857, "design" +487, 8, 11, 174, 60, 64, 858, 862, "with" +487, 8, 12, 175, 65, 68, 863, 866, "two" +487, 8, 13, 176, 69, 78, 867, 876, "treatment" +487, 8, 14, 177, 79, 86, 877, 884, "periods" +487, 8, 15, 178, 87, 89, 885, 887, "of" +487, 8, 16, 179, 90, 91, 888, 889, "1" +487, 8, 17, 180, 92, 97, 890, 895, "month" +487, 8, 18, 181, 98, 107, 896, 905, "separated" +487, 8, 19, 182, 108, 110, 906, 908, "by" +487, 8, 20, 183, 111, 112, 909, 910, "a" +487, 8, 21, 184, 113, 114, 911, 912, "3" +487, 8, 22, 185, 115, 116, 913, 914, "-" +487, 8, 23, 186, 117, 121, 915, 919, "week" +487, 8, 24, 187, 122, 129, 920, 927, "washout" +487, 8, 25, 188, 130, 136, 928, 934, "period" +487, 8, 26, 189, 137, 138, 935, 936, "." +487, 9, 1, 190, 0, 3, 937, 940, "The" +487, 9, 2, 191, 4, 15, 941, 952, "intraocular" +487, 9, 3, 192, 16, 24, 953, 961, "pressure" +487, 9, 4, 193, 25, 28, 962, 965, "was" +487, 9, 5, 194, 29, 37, 966, 974, "measured" +487, 9, 6, 195, 38, 40, 975, 977, "at" +487, 9, 7, 196, 41, 42, 978, 979, "9" +487, 9, 8, 197, 43, 45, 980, 982, "AM" +487, 9, 9, 198, 46, 49, 983, 986, "and" +487, 9, 10, 199, 50, 51, 987, 988, "5" +487, 9, 11, 200, 52, 54, 989, 991, "PM" +487, 9, 12, 201, 55, 57, 992, 994, "on" +487, 9, 13, 202, 58, 61, 995, 998, "the" +487, 9, 14, 203, 62, 70, 999, 1007, "baseline" +487, 9, 15, 204, 71, 74, 1008, 1011, "and" +487, 9, 16, 205, 75, 78, 1012, 1015, "day" +487, 9, 17, 206, 79, 81, 1016, 1018, "28" +487, 9, 18, 207, 82, 88, 1019, 1025, "visits" +487, 9, 19, 208, 89, 90, 1026, 1027, "," +487, 9, 20, 209, 91, 94, 1028, 1031, "and" +487, 9, 21, 210, 95, 97, 1032, 1034, "at" +487, 9, 22, 211, 98, 99, 1035, 1036, "9" +487, 9, 23, 212, 100, 102, 1037, 1039, "AM" +487, 9, 24, 213, 103, 105, 1040, 1042, "on" +487, 9, 25, 214, 106, 109, 1043, 1046, "day" +487, 9, 26, 215, 110, 111, 1047, 1048, "2" +487, 9, 27, 216, 112, 115, 1049, 1052, "and" +487, 9, 28, 217, 116, 119, 1053, 1056, "day" +487, 9, 29, 218, 120, 122, 1057, 1059, "14" +487, 9, 30, 219, 123, 129, 1060, 1066, "visits" +487, 9, 31, 220, 130, 132, 1067, 1069, "of" +487, 9, 32, 221, 133, 137, 1070, 1074, "each" +487, 9, 33, 222, 138, 147, 1075, 1084, "treatment" +487, 9, 34, 223, 148, 154, 1085, 1091, "period" +487, 9, 35, 224, 155, 156, 1092, 1093, "." +487, 10, 1, 225, 0, 3, 1094, 1097, "The" +487, 10, 2, 226, 4, 5, 1098, 1099, "9" +487, 10, 3, 227, 6, 8, 1100, 1102, "AM" +487, 10, 4, 228, 9, 20, 1103, 1114, "measurement" +487, 10, 5, 229, 21, 24, 1115, 1118, "was" +487, 10, 6, 230, 25, 30, 1119, 1124, "taken" +487, 10, 7, 231, 31, 32, 1125, 1126, "2" +487, 10, 8, 232, 33, 38, 1127, 1132, "hours" +487, 10, 9, 233, 39, 42, 1133, 1136, "and" +487, 10, 10, 234, 43, 45, 1137, 1139, "13" +487, 10, 11, 235, 46, 51, 1140, 1145, "hours" +487, 10, 12, 236, 52, 57, 1146, 1151, "after" +487, 10, 13, 237, 58, 61, 1152, 1155, "the" +487, 10, 14, 238, 62, 66, 1156, 1160, "last" +487, 10, 15, 239, 67, 71, 1161, 1165, "drop" +487, 10, 16, 240, 72, 74, 1166, 1168, "of" +487, 10, 17, 241, 75, 86, 1169, 1180, "unoprostone" +487, 10, 18, 242, 87, 90, 1181, 1184, "and" +487, 10, 19, 243, 91, 102, 1185, 1196, "latanoprost" +487, 10, 20, 244, 103, 104, 1197, 1198, "," +487, 10, 21, 245, 105, 108, 1199, 1202, "and" +487, 10, 22, 246, 109, 112, 1203, 1206, "the" +487, 10, 23, 247, 113, 114, 1207, 1208, "5" +487, 10, 24, 248, 115, 117, 1209, 1211, "PM" +487, 10, 25, 249, 118, 129, 1212, 1223, "measurement" +487, 10, 26, 250, 130, 133, 1224, 1227, "was" +487, 10, 27, 251, 134, 136, 1228, 1230, "at" +487, 10, 28, 252, 137, 139, 1231, 1233, "10" +487, 10, 29, 253, 140, 143, 1234, 1237, "and" +487, 10, 30, 254, 144, 146, 1238, 1240, "21" +487, 10, 31, 255, 147, 152, 1241, 1246, "hours" +487, 10, 32, 256, 153, 154, 1247, 1248, "," +487, 10, 33, 257, 155, 167, 1249, 1261, "respectively" +487, 10, 34, 258, 168, 169, 1262, 1263, "." +487, 11, 1, 259, 0, 3, 1264, 1267, "The" +487, 11, 2, 260, 4, 8, 1268, 1272, "mean" +487, 11, 3, 261, 9, 11, 1273, 1275, "of" +487, 11, 4, 262, 12, 15, 1276, 1279, "the" +487, 11, 5, 263, 16, 28, 1280, 1292, "measurements" +487, 11, 6, 264, 29, 32, 1293, 1296, "was" +487, 11, 7, 265, 33, 43, 1297, 1307, "calculated" +487, 11, 8, 266, 44, 45, 1308, 1309, "." +487, 12, 1, 267, 0, 6, 1310, 1316, "Safety" +487, 12, 2, 268, 7, 17, 1317, 1327, "parameters" +487, 12, 3, 269, 18, 22, 1328, 1332, "were" +487, 12, 4, 270, 23, 27, 1333, 1337, "also" +487, 12, 5, 271, 28, 36, 1338, 1346, "recorded" +487, 12, 6, 272, 37, 38, 1347, 1348, "." +487, 13, 1, 273, 0, 7, 1349, 1356, "RESULTS" +487, 13, 2, 274, 8, 9, 1357, 1358, ":" +487, 13, 3, 275, 10, 15, 1359, 1364, "Fifty" +487, 13, 4, 276, 16, 17, 1365, 1366, "-" +487, 13, 5, 277, 18, 21, 1367, 1370, "six" +487, 13, 6, 278, 22, 30, 1371, 1379, "patients" +487, 13, 7, 279, 31, 40, 1380, 1389, "completed" +487, 13, 8, 280, 41, 45, 1390, 1394, "both" +487, 13, 9, 281, 46, 55, 1395, 1404, "treatment" +487, 13, 10, 282, 56, 63, 1405, 1412, "periods" +487, 13, 11, 283, 64, 67, 1413, 1416, "and" +487, 13, 12, 284, 68, 71, 1417, 1420, "had" +487, 13, 13, 285, 72, 83, 1421, 1432, "intraocular" +487, 13, 14, 286, 84, 92, 1433, 1441, "pressure" +487, 13, 15, 287, 93, 97, 1442, 1446, "data" +487, 13, 16, 288, 98, 107, 1447, 1456, "available" +487, 13, 17, 289, 108, 111, 1457, 1460, "for" +487, 13, 18, 290, 112, 122, 1461, 1471, "evaluation" +487, 13, 19, 291, 123, 124, 1472, 1473, "." +487, 14, 1, 292, 0, 5, 1474, 1479, "After" +487, 14, 2, 293, 6, 7, 1480, 1481, "1" +487, 14, 3, 294, 8, 13, 1482, 1487, "month" +487, 14, 4, 295, 14, 16, 1488, 1490, "of" +487, 14, 5, 296, 17, 26, 1491, 1500, "treatment" +487, 14, 6, 297, 27, 28, 1501, 1502, "," +487, 14, 7, 298, 29, 40, 1503, 1514, "latanoprost" +487, 14, 8, 299, 41, 54, 1515, 1528, "significantly" +487, 14, 9, 300, 55, 62, 1529, 1536, "reduced" +487, 14, 10, 301, 63, 74, 1537, 1548, "intraocular" +487, 14, 11, 302, 75, 83, 1549, 1557, "pressure" +487, 14, 12, 303, 84, 85, 1558, 1559, "(" +487, 14, 13, 304, 86, 90, 1560, 1564, "mean" +487, 14, 14, 305, 91, 92, 1565, 1566, "+" +487, 14, 15, 306, 93, 94, 1567, 1568, "/" +487, 14, 16, 307, 95, 96, 1569, 1570, "-" +487, 14, 17, 308, 97, 100, 1571, 1574, "SEM" +487, 14, 18, 309, 101, 102, 1575, 1576, ")" +487, 14, 19, 310, 103, 105, 1577, 1579, "by" +487, 14, 20, 311, 106, 107, 1580, 1581, "6" +487, 14, 21, 312, 108, 109, 1582, 1583, "." +487, 14, 22, 313, 110, 111, 1584, 1585, "1" +487, 14, 23, 314, 112, 113, 1586, 1587, "+" +487, 14, 24, 315, 114, 115, 1588, 1589, "/" +487, 14, 25, 316, 116, 117, 1590, 1591, "-" +487, 14, 26, 317, 118, 119, 1592, 1593, "0" +487, 14, 27, 318, 120, 121, 1594, 1595, "." +487, 14, 28, 319, 122, 123, 1596, 1597, "5" +487, 14, 29, 320, 124, 126, 1598, 1600, "mm" +487, 14, 30, 321, 127, 129, 1601, 1603, "Hg" +487, 14, 31, 322, 130, 131, 1604, 1605, "(" +487, 14, 32, 323, 132, 133, 1606, 1607, "P" +487, 14, 33, 324, 134, 135, 1608, 1609, "<" +487, 14, 34, 325, 136, 137, 1610, 1611, "." +487, 14, 35, 326, 138, 141, 1612, 1615, "001" +487, 14, 36, 327, 142, 143, 1616, 1617, ")" +487, 14, 37, 328, 144, 147, 1618, 1621, "and" +487, 14, 38, 329, 148, 159, 1622, 1633, "unoprostone" +487, 14, 39, 330, 160, 162, 1634, 1636, "by" +487, 14, 40, 331, 163, 164, 1637, 1638, "4" +487, 14, 41, 332, 165, 166, 1639, 1640, "." +487, 14, 42, 333, 167, 168, 1641, 1642, "2" +487, 14, 43, 334, 169, 170, 1643, 1644, "+" +487, 14, 44, 335, 171, 172, 1645, 1646, "/" +487, 14, 45, 336, 173, 174, 1647, 1648, "-" +487, 14, 46, 337, 175, 176, 1649, 1650, "0" +487, 14, 47, 338, 177, 178, 1651, 1652, "." +487, 14, 48, 339, 179, 180, 1653, 1654, "4" +487, 14, 49, 340, 181, 183, 1655, 1657, "mm" +487, 14, 50, 341, 184, 186, 1658, 1660, "Hg" +487, 14, 51, 342, 187, 188, 1661, 1662, "(" +487, 14, 52, 343, 189, 190, 1663, 1664, "P" +487, 14, 53, 344, 191, 192, 1665, 1666, "<" +487, 14, 54, 345, 193, 194, 1667, 1668, "." +487, 14, 55, 346, 195, 198, 1669, 1672, "001" +487, 14, 56, 347, 199, 200, 1673, 1674, ")" +487, 14, 57, 348, 201, 209, 1675, 1683, "adjusted" +487, 14, 58, 349, 210, 214, 1684, 1688, "from" +487, 14, 59, 350, 215, 217, 1689, 1691, "an" +487, 14, 60, 351, 218, 225, 1692, 1699, "overall" +487, 14, 61, 352, 226, 234, 1700, 1708, "baseline" +487, 14, 62, 353, 235, 237, 1709, 1711, "of" +487, 14, 63, 354, 238, 240, 1712, 1714, "22" +487, 14, 64, 355, 241, 242, 1715, 1716, "." +487, 14, 65, 356, 243, 244, 1717, 1718, "3" +487, 14, 66, 357, 245, 246, 1719, 1720, "+" +487, 14, 67, 358, 247, 248, 1721, 1722, "/" +487, 14, 68, 359, 249, 250, 1723, 1724, "-" +487, 14, 69, 360, 251, 252, 1725, 1726, "0" +487, 14, 70, 361, 253, 254, 1727, 1728, "." +487, 14, 71, 362, 255, 256, 1729, 1730, "5" +487, 14, 72, 363, 257, 259, 1731, 1733, "mm" +487, 14, 73, 364, 260, 262, 1734, 1736, "Hg" +487, 14, 74, 365, 263, 266, 1737, 1740, "and" +487, 14, 75, 366, 267, 269, 1741, 1743, "23" +487, 14, 76, 367, 270, 271, 1744, 1745, "." +487, 14, 77, 368, 272, 273, 1746, 1747, "2" +487, 14, 78, 369, 274, 275, 1748, 1749, "+" +487, 14, 79, 370, 276, 277, 1750, 1751, "/" +487, 14, 80, 371, 278, 279, 1752, 1753, "-" +487, 14, 81, 372, 280, 281, 1754, 1755, "0" +487, 14, 82, 373, 282, 283, 1756, 1757, "." +487, 14, 83, 374, 284, 285, 1758, 1759, "4" +487, 14, 84, 375, 286, 288, 1760, 1762, "mm" +487, 14, 85, 376, 289, 291, 1763, 1765, "Hg" +487, 14, 86, 377, 292, 293, 1766, 1767, "," +487, 14, 87, 378, 294, 306, 1768, 1780, "respectively" +487, 14, 88, 379, 307, 308, 1781, 1782, "." +487, 15, 1, 380, 0, 3, 1783, 1786, "The" +487, 15, 2, 381, 4, 14, 1787, 1797, "difference" +487, 15, 3, 382, 15, 17, 1798, 1800, "of" +487, 15, 4, 383, 18, 19, 1801, 1802, "1" +487, 15, 5, 384, 20, 21, 1803, 1804, "." +487, 15, 6, 385, 22, 23, 1805, 1806, "9" +487, 15, 7, 386, 24, 26, 1807, 1809, "mm" +487, 15, 8, 387, 27, 29, 1810, 1812, "Hg" +487, 15, 9, 388, 30, 37, 1813, 1820, "between" +487, 15, 10, 389, 38, 48, 1821, 1831, "treatments" +487, 15, 11, 390, 49, 52, 1832, 1835, "was" +487, 15, 12, 391, 53, 66, 1836, 1849, "statistically" +487, 15, 13, 392, 67, 78, 1850, 1861, "significant" +487, 15, 14, 393, 79, 81, 1862, 1864, "in" +487, 15, 15, 394, 82, 87, 1865, 1870, "favor" +487, 15, 16, 395, 88, 90, 1871, 1873, "of" +487, 15, 17, 396, 91, 102, 1874, 1885, "latanoprost" +487, 15, 18, 397, 103, 104, 1886, 1887, "[" +487, 15, 19, 398, 105, 106, 1888, 1889, "P" +487, 15, 20, 399, 107, 108, 1890, 1891, "=" +487, 15, 21, 400, 109, 110, 1892, 1893, "." +487, 15, 22, 401, 111, 114, 1894, 1897, "003" +487, 15, 23, 402, 115, 116, 1898, 1899, "," +487, 15, 24, 403, 117, 125, 1900, 1908, "analysis" +487, 15, 25, 404, 126, 128, 1909, 1911, "of" +487, 15, 26, 405, 129, 139, 1912, 1922, "covariance" +487, 15, 27, 406, 140, 141, 1923, 1924, "(" +487, 15, 28, 407, 142, 148, 1925, 1931, "ANCOVA" +487, 15, 29, 408, 149, 150, 1932, 1933, ")" +487, 15, 30, 409, 151, 152, 1934, 1935, "]" +487, 15, 31, 410, 153, 154, 1936, 1937, "." +487, 16, 1, 411, 0, 10, 1938, 1948, "Unadjusted" +487, 16, 2, 412, 11, 19, 1949, 1957, "analysis" +487, 16, 3, 413, 20, 22, 1958, 1960, "of" +487, 16, 4, 414, 23, 33, 1961, 1971, "responders" +487, 16, 5, 415, 34, 39, 1972, 1977, "using" +487, 16, 6, 416, 40, 43, 1978, 1981, "the" +487, 16, 7, 417, 44, 54, 1982, 1992, "percentage" +487, 16, 8, 418, 55, 63, 1993, 2001, "decrease" +487, 16, 9, 419, 64, 66, 2002, 2004, "in" +487, 16, 10, 420, 67, 78, 2005, 2016, "intraocular" +487, 16, 11, 421, 79, 87, 2017, 2025, "pressure" +487, 16, 12, 422, 88, 94, 2026, 2032, "showed" +487, 16, 13, 423, 95, 99, 2033, 2037, "that" +487, 16, 14, 424, 100, 103, 2038, 2041, "the" +487, 16, 15, 425, 104, 114, 2042, 2052, "proportion" +487, 16, 16, 426, 115, 117, 2053, 2055, "of" +487, 16, 17, 427, 118, 128, 2056, 2066, "responders" +487, 16, 18, 428, 129, 131, 2067, 2069, "in" +487, 16, 19, 429, 132, 135, 2070, 2073, "the" +487, 16, 20, 430, 136, 147, 2074, 2085, "latanoprost" +487, 16, 21, 431, 148, 149, 2086, 2087, "-" +487, 16, 22, 432, 150, 157, 2088, 2095, "treated" +487, 16, 23, 433, 158, 163, 2096, 2101, "group" +487, 16, 24, 434, 164, 167, 2102, 2105, "was" +487, 16, 25, 435, 168, 175, 2106, 2113, "greater" +487, 16, 26, 436, 176, 180, 2114, 2118, "than" +487, 16, 27, 437, 181, 183, 2119, 2121, "in" +487, 16, 28, 438, 184, 187, 2122, 2125, "the" +487, 16, 29, 439, 188, 199, 2126, 2137, "unoprostone" +487, 16, 30, 440, 200, 201, 2138, 2139, "-" +487, 16, 31, 441, 202, 209, 2140, 2147, "treated" +487, 16, 32, 442, 210, 215, 2148, 2153, "group" +487, 16, 33, 443, 216, 217, 2154, 2155, "." +487, 17, 1, 444, 0, 7, 2156, 2163, "Adverse" +487, 17, 2, 445, 8, 14, 2164, 2170, "ocular" +487, 17, 3, 446, 15, 23, 2171, 2179, "symptoms" +487, 17, 4, 447, 24, 27, 2180, 2183, "and" +487, 17, 5, 448, 28, 36, 2184, 2192, "findings" +487, 17, 6, 449, 37, 41, 2193, 2197, "were" +487, 17, 7, 450, 42, 46, 2198, 2202, "mild" +487, 17, 8, 451, 47, 49, 2203, 2205, "in" +487, 17, 9, 452, 50, 54, 2206, 2210, "both" +487, 17, 10, 453, 55, 64, 2211, 2220, "treatment" +487, 17, 11, 454, 65, 71, 2221, 2227, "groups" +487, 17, 12, 455, 72, 73, 2228, 2229, "." +487, 18, 1, 456, 0, 3, 2230, 2233, "Eye" +487, 18, 2, 457, 4, 11, 2234, 2241, "redness" +487, 18, 3, 458, 12, 15, 2242, 2245, "and" +487, 18, 4, 459, 16, 22, 2246, 2252, "ocular" +487, 18, 5, 460, 23, 33, 2253, 2263, "irritation" +487, 18, 6, 461, 34, 38, 2264, 2268, "were" +487, 18, 7, 462, 39, 42, 2269, 2272, "the" +487, 18, 8, 463, 43, 47, 2273, 2277, "most" +487, 18, 9, 464, 48, 58, 2278, 2288, "frequently" +487, 18, 10, 465, 59, 67, 2289, 2297, "reported" +487, 18, 11, 466, 68, 74, 2298, 2304, "events" +487, 18, 12, 467, 75, 76, 2305, 2306, "." +487, 19, 1, 468, 0, 11, 2307, 2318, "CONCLUSIONS" +487, 19, 2, 469, 12, 13, 2319, 2320, ":" +487, 19, 3, 470, 14, 25, 2321, 2332, "Latanoprost" +487, 19, 4, 471, 26, 30, 2333, 2337, "once" +487, 19, 5, 472, 31, 36, 2338, 2343, "daily" +487, 19, 6, 473, 37, 40, 2344, 2347, "was" +487, 19, 7, 474, 41, 54, 2348, 2361, "significantly" +487, 19, 8, 475, 55, 59, 2362, 2366, "more" +487, 19, 9, 476, 60, 69, 2367, 2376, "effective" +487, 19, 10, 477, 70, 72, 2377, 2379, "in" +487, 19, 11, 478, 73, 81, 2380, 2388, "reducing" +487, 19, 12, 479, 82, 93, 2389, 2400, "intraocular" +487, 19, 13, 480, 94, 102, 2401, 2409, "pressure" +487, 19, 14, 481, 103, 111, 2410, 2418, "compared" +487, 19, 15, 482, 112, 116, 2419, 2423, "with" +487, 19, 16, 483, 117, 128, 2424, 2435, "unoprostone" +487, 19, 17, 484, 129, 134, 2436, 2441, "twice" +487, 19, 18, 485, 135, 140, 2442, 2447, "daily" +487, 19, 19, 486, 141, 146, 2448, 2453, "after" +487, 19, 20, 487, 147, 148, 2454, 2455, "1" +487, 19, 21, 488, 149, 154, 2456, 2461, "month" +487, 19, 22, 489, 155, 157, 2462, 2464, "of" +487, 19, 23, 490, 158, 167, 2465, 2474, "treatment" +487, 19, 24, 491, 168, 170, 2475, 2477, "in" +487, 19, 25, 492, 171, 179, 2478, 2486, "patients" +487, 19, 26, 493, 180, 184, 2487, 2491, "with" +487, 19, 27, 494, 185, 192, 2492, 2499, "primary" +487, 19, 28, 495, 193, 197, 2500, 2504, "open" +487, 19, 29, 496, 198, 199, 2505, 2506, "-" +487, 19, 30, 497, 200, 205, 2507, 2512, "angle" +487, 19, 31, 498, 206, 214, 2513, 2521, "glaucoma" +487, 19, 32, 499, 215, 218, 2522, 2525, "and" +487, 19, 33, 500, 219, 225, 2526, 2532, "ocular" +487, 19, 34, 501, 226, 238, 2533, 2545, "hypertension" +487, 19, 35, 502, 239, 240, 2546, 2547, "." +487, 20, 1, 503, 0, 4, 2548, 2552, "Both" +487, 20, 2, 504, 5, 10, 2553, 2558, "drugs" +487, 20, 3, 505, 11, 15, 2559, 2563, "were" +487, 20, 4, 506, 16, 20, 2564, 2568, "well" +487, 20, 5, 507, 21, 30, 2569, 2578, "tolerated" +487, 20, 6, 508, 31, 35, 2579, 2583, "with" +487, 20, 7, 509, 36, 39, 2584, 2587, "few" +487, 20, 8, 510, 40, 46, 2588, 2594, "ocular" +487, 20, 9, 511, 47, 54, 2595, 2602, "adverse" +487, 20, 10, 512, 55, 61, 2603, 2609, "events" +487, 20, 11, 513, 62, 63, 2610, 2611, "." +487, 21, 1, 514, 0, 3, 2612, 2615, "DOI" +487, 21, 2, 515, 4, 5, 2616, 2617, ":" +487, 21, 3, 516, 6, 8, 2618, 2620, "10" +487, 21, 4, 517, 9, 10, 2621, 2622, "." +487, 21, 5, 518, 11, 15, 2623, 2627, "1016" +487, 21, 6, 519, 16, 17, 2628, 2629, "/" +487, 21, 7, 520, 18, 23, 2630, 2635, "s0002" +487, 21, 8, 521, 24, 25, 2636, 2637, "-" +487, 21, 9, 522, 26, 30, 2638, 2642, "9394" +487, 21, 10, 523, 31, 32, 2643, 2644, "(" +487, 21, 11, 524, 33, 35, 2645, 2647, "00" +487, 21, 12, 525, 36, 37, 2648, 2649, ")" +487, 21, 13, 526, 38, 43, 2650, 2655, "00943" +487, 21, 14, 527, 44, 45, 2656, 2657, "-" +487, 21, 15, 528, 46, 47, 2658, 2659, "0" +487, 21, 16, 529, 48, 52, 2660, 2664, "PMID" +487, 21, 17, 530, 53, 54, 2665, 2666, ":" +487, 21, 18, 531, 55, 63, 2667, 2675, "11336940" +487, 21, 19, 532, 64, 65, 2676, 2677, "[" +487, 21, 20, 533, 66, 73, 2678, 2685, "Indexed" +487, 21, 21, 534, 74, 77, 2686, 2689, "for" +487, 21, 22, 535, 78, 85, 2690, 2697, "MEDLINE" +487, 21, 23, 536, 86, 87, 2698, 2699, "]" diff --git a/data/gl 11336940_jshahinitiran.annodb b/data/gl 11336940_jshahinitiran.annodb new file mode 100644 index 0000000..9d571f2 --- /dev/null +++ b/data/gl 11336940_jshahinitiran.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2731, Journal, 0, 15, "Am J Ophthalmol", "", +2732, PublicationYear, 18, 22, "2001", "", +2733, Title, 52, 227, "A randomized double - masked crossover study comparing latanoprost 0 . 005 % with unoprostone 0 . 12 % in patients with primary open - angle glaucoma and ocular hypertension .", "", +25997, Randomized, 54, 64, "randomized", "", +25998, DoubleBlind, 65, 80, "double - masked", "", +25999, Crossover, 81, 90, "crossover", "", +26000, Latanoprost, 107, 118, "latanoprost", "", +26004, DoseValue, 107, 126, "latanoprost 0 . 005", "", +26005, DoseValue, 119, 126, "0 . 005", "", +26007, Percentage, 127, 128, "%", "", +26001, Unoprostone, 134, 145, "unoprostone", "", +26006, DoseValue, 146, 152, "0 . 12", "", +26008, Percentage, 153, 154, "%", "", +26422, Primary_OpenAngleGlaucoma, 172, 201, "primary open - angle glaucoma", "", +26003, OcularHypertension, 206, 225, "ocular hypertension", "", +2745, Author, 228, 234, "Aung T", "", +2746, Author, 243, 250, "Chew PT", "", +2747, Author, 253, 259, "Yip CC", "", +2748, Author, 262, 269, "Chan YH", "", +2749, Author, 272, 278, "See JL", "", +2750, Author, 281, 288, "Khng CG", "", +2751, Author, 291, 297, "Hoh ST", "", +2752, Author, 300, 305, "Ng LH", "", +2753, Author, 308, 314, "Lee HM", "", +2754, Singapore, 376, 385, "Singapore", "", +2755, ObjectiveDescription, 398, 546, "To compare the intraocular pressure ) - lowering effect and side effects of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily .", "", +2756, IOP, 413, 433, "intraocular pressure", "", +26009, Latanoprost, 474, 485, "latanoprost", "", +26011, DoseValue, 486, 493, "0 . 005", "", +26013, Percentage, 494, 495, "%", "", +26015, Frequency, 496, 506, "once daily", "", +26010, Unoprostone, 512, 523, "unoprostone", "", +26012, DoseValue, 524, 530, "0 . 12", "", +26014, Percentage, 531, 532, "%", "", +26016, Frequency, 533, 544, "twice daily", "", +2765, NumberPatientsCT, 557, 562, "Sixty", "uno", +26423, Primary_OpenAngleGlaucoma, 577, 606, "primary open - angle glaucoma", "", +26018, OcularHypertension, 610, 629, "ocular hypertension", "", +26019, Randomized, 635, 645, "randomized", "", +26020, Latanoprost, 664, 675, "latanoprost", "", +26021, Frequency, 676, 686, "once daily", "", +2771, Bedtime, 694, 701, "evening", "lat", +2774, Placebo, 706, 713, "placebo", "", +2773, Frequency, 714, 724, "once daily", "pla", +2775, Morning, 732, 739, "morning", "pla", +26022, Unoprostone, 745, 756, "unoprostone", "", +26023, Frequency, 757, 768, "twice daily", "", +2778, Morning, 776, 783, "morning", "uno", +2779, Bedtime, 788, 795, "evening", "uno", +26024, DoubleBlind, 812, 825, "double masked", "", +26025, Crossover, 841, 850, "crossover", "", +26026, IOP, 941, 961, "intraocular pressure", "", +39028, TimePoint, 999, 1007, "baseline", "", +39029, TimePoint, 1012, 1018, "day 28", "", +39030, TimePoint, 1043, 1048, "day 2", "", +39031, TimePoint, 1053, 1059, "day 14", "", +39032, Unoprostone, 1169, 1180, "unoprostone", "", +39033, Latanoprost, 1185, 1196, "latanoprost", "", +26028, Mean, 1268, 1272, "mean", "", +26029, FinalNumPatientsCT, 1359, 1370, "Fifty - six", "", +2785, IOP, 1421, 1441, "intraocular pressure", "", +2786, TimePoint, 1480, 1487, "1 month", "", +2787, Latanoprost, 1503, 1514, "latanoprost", "", +2788, IOP, 1537, 1557, "intraocular pressure", "", +26030, Mean, 1560, 1564, "mean", "", +2790, RelativeReduction, 1580, 1585, "6 . 1", "lat", +2792, SdErrorChangeValue, 1592, 1597, "0 . 5", "lat", +2793, mmHg, 1598, 1603, "mm Hg", "lat", +2794, PValueChangeValue, 1604, 1615, "( P < . 001", "lat", +2799, Unoprostone, 1622, 1633, "unoprostone", "uno", +2798, RelativeReduction, 1637, 1642, "4 . 2", "uno", +2800, SdErrorChangeValue, 1649, 1654, "0 . 4", "uno", +2801, mmHg, 1655, 1660, "mm Hg", "uno", +2802, PValueChangeValue, 1663, 1672, "P < . 001", "uno", +2795, BaseLineValue, 1712, 1718, "22 . 3", "lat", +2796, SdErrorBL, 1725, 1730, "0 . 5", "lat", +2797, mmHg, 1731, 1736, "mm Hg", "lat", +2803, BaseLineValue, 1741, 1747, "23 . 2", "uno", +2804, SdErrorBL, 1754, 1759, "0 . 4", "uno", +2805, mmHg, 1760, 1765, "mm Hg", "uno", +2807, DiffBetweenGroups, 1801, 1806, "1 . 9", "", +2832, mmHg, 1807, 1812, "mm Hg", "", +2853, Latanoprost, 1874, 1885, "latanoprost", "", +2835, PvalueDiff, 1888, 1897, "P = . 003", "", +2854, IOP, 2005, 2025, "intraocular pressure", "", +2855, Latanoprost, 2074, 2085, "latanoprost", "", +2856, Unoprostone, 2126, 2137, "unoprostone", "", +2857, ConclusionComment, 2321, 2547, "Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open - angle glaucoma and ocular hypertension .", "", +2858, Latanoprost, 2321, 2332, "Latanoprost", "", +26033, Frequency, 2333, 2343, "once daily", "", +2861, IOP, 2389, 2409, "intraocular pressure", "", +3482, Unoprostone, 2424, 2435, "unoprostone", "", +26034, Frequency, 2436, 2447, "twice daily", "", +26035, TimePoint, 2454, 2461, "1 month", "", +26424, Primary_OpenAngleGlaucoma, 2492, 2521, "primary open - angle glaucoma", "", +2866, OcularHypertension, 2526, 2545, "ocular hypertension", "", +2868, ConclusionComment, 2548, 2611, "Both drugs were well tolerated with few ocular adverse events .", "", +2867, PMID, 2667, 2675, "11336940", "", diff --git a/data/gl 11336940_jshahinitiran.n-triples b/data/gl 11336940_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11336940_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11336940_tstrakeljahn.annodb b/data/gl 11336940_tstrakeljahn.annodb new file mode 100644 index 0000000..b9645f2 --- /dev/null +++ b/data/gl 11336940_tstrakeljahn.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5600, Journal, 0, 15, "Am J Ophthalmol", "", +5601, PublicationYear, 18, 22, "2001", "", +79467, Title, 52, 227, "A randomized double - masked crossover study comparing latanoprost 0 . 005 % with unoprostone 0 . 12 % in patients with primary open - angle glaucoma and ocular hypertension .", "", +5602, Randomized, 54, 64, "randomized", "", +79454, DoubleBlind, 65, 80, "double - masked", "", +55500, Crossover, 81, 90, "crossover", "", +79456, Latanoprost, 107, 118, "latanoprost", "", +79462, DoseValue, 119, 126, "0 . 005", "", +79464, Percentage, 127, 128, "%", "", +79457, Unoprostone, 134, 145, "unoprostone", "", +79463, DoseValue, 146, 152, "0 . 12", "", +79465, Percentage, 153, 154, "%", "", +79458, Primary_OpenAngleGlaucoma, 172, 201, "primary open - angle glaucoma", "", +79459, OcularHypertension, 206, 225, "ocular hypertension", "", +79469, Author, 228, 234, "Aung T", "", +79471, Author, 243, 250, "Chew PT", "", +79473, Author, 253, 259, "Yip CC", "", +79474, Author, 262, 269, "Chan YH", "", +79476, Author, 272, 278, "See JL", "", +79478, Author, 281, 288, "Khng CG", "", +79479, Author, 291, 297, "Hoh ST", "", +79480, Author, 300, 305, "Ng LH", "", +79481, Author, 308, 314, "Lee HM", "", +79482, Singapore, 376, 385, "Singapore", "", +79495, ObjectiveDescription, 398, 546, "To compare the intraocular pressure ) - lowering effect and side effects of latanoprost 0 . 005 % once daily with unoprostone 0 . 12 % twice daily .", "", +79483, IOP, 413, 433, "intraocular pressure", "", +79485, Latanoprost, 474, 485, "latanoprost", "", +79489, DoseValue, 486, 493, "0 . 005", "", +79491, Percentage, 494, 495, "%", "", +79487, Frequency, 496, 506, "once daily", "", +79486, Unoprostone, 512, 523, "unoprostone", "", +79490, DoseValue, 524, 530, "0 . 12", "", +79493, Percentage, 531, 532, "%", "", +79488, Frequency, 533, 544, "twice daily", "", +79497, NumberPatientsCT, 557, 562, "Sixty", "", +79499, Primary_OpenAngleGlaucoma, 577, 606, "primary open - angle glaucoma", "", +79501, OcularHypertension, 610, 629, "ocular hypertension", "", +79504, Randomized, 635, 645, "randomized", "", +79506, Latanoprost, 664, 675, "latanoprost", "", +79510, Frequency, 676, 686, "once daily", "", +79508, Placebo, 706, 713, "placebo", "", +79511, Frequency, 714, 724, "once daily", "", +79512, Morning, 725, 739, "in the morning", "", +79509, Unoprostone, 745, 756, "unoprostone", "", +79514, Frequency, 757, 768, "twice daily", "", +79516, Morning, 769, 783, "in the morning", "", +79518, Evening, 788, 795, "evening", "", +79520, DoubleBlind, 812, 825, "double masked", "", +79521, Crossover, 841, 850, "crossover", "", +79522, Duration, 863, 934, "two treatment periods of 1 month separated by a 3 - week washout period", "", +79523, IOP, 941, 961, "intraocular pressure", "", +79524, Morning, 978, 982, "9 AM", "", +79525, Evening, 987, 991, "5 PM", "", +79526, TimePoint, 1012, 1018, "day 28", "", +79529, Morning, 1035, 1039, "9 AM", "", +79527, TimePoint, 1043, 1048, "day 2", "", +79528, TimePoint, 1053, 1059, "day 14", "", +79531, Morning, 1098, 1102, "9 AM", "", +79532, Unoprostone, 1169, 1180, "unoprostone", "", +79533, Latanoprost, 1185, 1196, "latanoprost", "", +79534, Evening, 1207, 1211, "5 PM", "", +79536, Mean, 1268, 1272, "mean", "", +79537, FinalNumPatientsCT, 1359, 1379, "Fifty - six patients", "", +79538, IOP, 1421, 1441, "intraocular pressure", "", +79539, TimePoint, 1474, 1487, "After 1 month", "", +79540, Latanoprost, 1503, 1514, "latanoprost", "", +79541, IOP, 1537, 1557, "intraocular pressure", "", +79542, Mean, 1560, 1564, "mean", "", +79543, Reduction, 1580, 1585, "6 . 1", "", +79545, SdErrorChangeValue, 1592, 1597, "0 . 5", "", +79547, mmHg, 1598, 1603, "mm Hg", "", +79558, PValueChangeValue, 1608, 1615, "< . 001", "", +79553, Unoprostone, 1622, 1633, "unoprostone", "", +79544, Reduction, 1637, 1642, "4 . 2", "", +79546, SdErrorChangeValue, 1649, 1654, "0 . 4", "", +79548, mmHg, 1655, 1660, "mm Hg", "", +79561, PValueChangeValue, 1665, 1672, "< . 001", "", +79563, BaseLineValue, 1712, 1718, "22 . 3", "", +79566, SdErrorBL, 1725, 1730, "0 . 5", "", +79570, mmHg, 1731, 1736, "mm Hg", "", +79565, BaseLineValue, 1741, 1747, "23 . 2", "", +79567, SdErrorBL, 1754, 1759, "0 . 4", "", +79572, mmHg, 1760, 1765, "mm Hg", "", +79577, DiffBetweenGroups, 1801, 1806, "1 . 9", "", +79579, mmHg, 1807, 1812, "mm Hg", "", +79581, Latanoprost, 1874, 1885, "latanoprost", "", +79583, PvalueDiff, 1890, 1897, "= . 003", "", +79585, IOP, 2005, 2025, "intraocular pressure", "", +79586, Latanoprost, 2074, 2085, "latanoprost", "", +79587, Unoprostone, 2126, 2137, "unoprostone", "", +79588, ObservedResult, 2156, 2229, "Adverse ocular symptoms and findings were mild in both treatment groups .", "", +79591, ObservedResult, 2230, 2306, "Eye redness and ocular irritation were the most frequently reported events .", "", +79592, Latanoprost, 2321, 2332, "Latanoprost", "", +79604, ConclusionComment, 2321, 2547, "Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open - angle glaucoma and ocular hypertension .", "", +79594, Frequency, 2333, 2343, "once daily", "", +79593, Unoprostone, 2424, 2435, "unoprostone", "", +79595, Frequency, 2436, 2447, "twice daily", "", +79596, TimePoint, 2448, 2474, "after 1 month of treatment", "", +79597, Primary_OpenAngleGlaucoma, 2492, 2521, "primary open - angle glaucoma", "", +79599, OcularHypertension, 2526, 2545, "ocular hypertension", "", +79606, ConclusionComment, 2548, 2611, "Both drugs were well tolerated with few ocular adverse events .", "", +79608, PMID, 2667, 2675, "11336940", "", diff --git a/data/gl 11336940_tstrakeljahn.n-triples b/data/gl 11336940_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11336940_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11558817_admin.annodb b/data/gl 11558817_admin.annodb new file mode 100644 index 0000000..464abc7 --- /dev/null +++ b/data/gl 11558817_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2001", "", " \"2001\"." +2, Title, 46, 288, "Comparison of the additive intraocular pressure - lowering effect of latanoprost and dorzolamide when added to timolol in patients with open - angle glaucoma or ocular hypertension : a randomized , open - label , multicenter study in Greece .", "", " \"Comparison of the additive intraocular pressure - lowering effect of latanoprost and dorzolamide when added to timolol in patients with open - angle glaucoma or ocular hypertension : a randomized , open - label , multicenter study in Greece .\"." +6, IOP, 73, 93, "intraocular pressure", "", +7, Latanoprost, 115, 126, "latanoprost", "", " . ." +8, Dorzolamide, 131, 142, "dorzolamide", "", +9, Timolol, 157, 164, "timolol", "", +10, OpenAngleGlaucoma, 182, 203, "open - angle glaucoma", "", " ." +11, OcularHypertension, 207, 226, "ocular hypertension", "", " ." +75, Randomized, 231, 241, "randomized", "", +12, OpenLabel, 244, 256, "open - label", "", " ." +13, Multicenter, 259, 270, "multicenter", "", " ." +78, Greece, 280, 286, "Greece", "", " ." +14, Author, 289, 299, "Petounis A", "", " \"Petounis A\"." +15, Author, 308, 320, "Mylopoulos N", "", " \"Mylopoulos N\"." +16, Author, 323, 335, "Kandarakis A", "", " \"Kandarakis A\"." +17, Author, 338, 349, "Andreanos D", "", " \"Andreanos D\"." +18, Author, 352, 368, "Dimitrakoulias N", "", " \"Dimitrakoulias N\"." +84, Greece, 465, 471, "Greece", "", +3, ObjectiveDescription, 515, 632, "To compare the intraocular pressure - lowering effect of latanoprost with that of dorzolamide when added to timolol .", "", " \"To compare the intraocular pressure - lowering effect of latanoprost with that of dorzolamide when added to timolol .\"." +86, IOP, 530, 550, "intraocular pressure", "", +87, Latanoprost, 572, 583, "latanoprost", "", +88, Dorzolamide, 597, 608, "dorzolamide", "", +89, Timolol, 623, 630, "timolol", "", +105, Randomized, 661, 671, "randomized", "", " ." +4, OpenLabel, 674, 686, "open - label", "", +5, Parallel, 702, 710, "parallel", "", " ." +36962, Multicenter, 735, 747, "five centers", "", +109, Greece, 751, 757, "Greece", "", +19, NumberPatientsCT, 779, 782, "148", "", +113, Precondition, 783, 978, "patients with inadequately controlled open - angle or pseudoexfoliation glaucoma ( intraocular pressure of at least 22 mm Hg ) or ocular hypertension ( intraocular pressure of at least 27 mm Hg )", "", " \"patients with inadequately controlled open - angle or pseudoexfoliation glaucoma ( intraocular pressure of at least 22 mm Hg ) or ocular hypertension ( intraocular pressure of at least 27 mm Hg )\"." +20, OpenAngleGlaucoma, 821, 863, "open - angle or pseudoexfoliation glaucoma", "", " ." +148, IOP, 866, 886, "intraocular pressure", "", +150, mmHg, 902, 907, "mm Hg", "", " ." +151, OcularHypertension, 913, 932, "ocular hypertension", "", +152, IOP, 935, 955, "intraocular pressure", "", +153, mmHg, 971, 976, "mm Hg", "", +36956, Precondition, 979, 1097, "who were receiving monotherapy with a beta - blocker or dual therapy in which one of the agents was a beta - blocker .", "", " \"who were receiving monotherapy with a beta - blocker or dual therapy in which one of the agents was a beta - blocker .\"." +23, Timolol, 1128, 1135, "timolol", "", " ." +24, DoseValue, 1136, 1141, "0 . 5", "", " \"0 . 5\"." +25, Percentage, 1142, 1143, "%", "", " ." +26, Frequency, 1144, 1155, "twice daily", "", " \"twice daily\"." +36958, Duration, 1160, 1172, "2 to 4 weeks", "", +36959, TimePoint, 1241, 1249, "baseline", "", +36960, Randomized, 1270, 1280, "randomized", "", +27, Latanoprost, 1292, 1303, "latanoprost", "", +29, DoseValue, 1304, 1311, "0 . 005", "", " \"0 . 005\"." +28, Percentage, 1312, 1313, "%", "", " ." +30, Frequency, 1314, 1324, "once daily", "", " \"once daily\"." +31, Dorzolamide, 1328, 1339, "dorzolamide", "", " ." +32, DoseValue, 1340, 1341, "2", "", " \"2\"." +33, Percentage, 1342, 1343, "%", "", " ." +34, Frequency, 1344, 1355, "twice daily", "", " \"twice daily\"." +35, Timolol, 1379, 1386, "timolol", "", +36, IOP, 1393, 1413, "intraocular pressure", "", +36961, TimePoint, 1472, 1480, "baseline", "", +26587, Duration, 1488, 1496, "3 months", "", +39, Diurnal_IOP, 1556, 1584, "diurnal intraocular pressure", "", " ." +40, PValueChangeValue, 1628, 1639, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\"." +41, Mean, 1648, 1652, "mean", "", +42, IOP, 1653, 1673, "intraocular pressure", "", +43, RelativeReduction, 1702, 1704, "32", "", " \"32\"." +44, Latanoprost, 1715, 1726, "latanoprost", "", +45, Timolol, 1732, 1739, "timolol", "", +46, RelativeReduction, 1750, 1752, "20", "", " \"20\"." +47, Dorzolamide, 1763, 1774, "dorzolamide", "", +48, Timolol, 1780, 1787, "timolol", "", +49, LeastSquaresMean, 1800, 1833, "least square estimate of the mean", "", " ." +125, Mean, 1829, 1833, "mean", "", +50, Diurnal_IOP, 1834, 1862, "diurnal intraocular pressure", "", +26594, Duration, 1879, 1887, "3 months", "", " \"3 months\"." +52, Reduction, 1894, 1900, "7 . 06", "", " \"7 . 06\"." +53, mmHg, 1901, 1906, "mm Hg", "", " \"7 . 06\"." +54, Latanoprost, 1914, 1925, "latanoprost", "", +55, Timolol, 1931, 1938, "timolol", "", +56, Reduction, 1951, 1957, "4 . 44", "", " \"4 . 44\"." +57, mmHg, 1958, 1963, "mm Hg", "", +58, Dorzolamide, 1971, 1982, "dorzolamide", "", +59, Timolol, 1988, 1995, "timolol", "", +60, PValueChangeValue, 2004, 2015, "P < 0 . 001", "", +61, ConclusionComment, 2099, 2274, "This study clearly showed that the additive diurnal intraocular pressure - lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol .", "", " \"This study clearly showed that the additive diurnal intraocular pressure - lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol .\"." +62, Diurnal_IOP, 2143, 2171, "diurnal intraocular pressure", "", +63, Latanoprost, 2193, 2204, "latanoprost", "", +64, Dorzolamide, 2228, 2239, "dorzolamide", "", +65, Timolol, 2265, 2272, "timolol", "", +66, PMID, 2282, 2290, "11558817", "", " \"11558817\"." diff --git a/data/gl 11558817_admin.n-triples b/data/gl 11558817_admin.n-triples new file mode 100644 index 0000000..154b466 --- /dev/null +++ b/data/gl 11558817_admin.n-triples @@ -0,0 +1,111 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the additive intraocular pressure - lowering effect of latanoprost and dorzolamide when added to timolol in patients with open - angle glaucoma or ocular hypertension : a randomized , open - label , multicenter study in Greece ." . + "Petounis A" . + "2001" . + "J Glaucoma" . + "11558817" . + . + "Mylopoulos N" . + "Kandarakis A" . + "Andreanos D" . + "Dimitrakoulias N" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure - lowering effect of latanoprost with that of dorzolamide when added to timolol ." . + "3 months" . + . + . + . + "This study clearly showed that the additive diurnal intraocular pressure - lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with inadequately controlled open - angle or pseudoexfoliation glaucoma ( intraocular pressure of at least 22 mm Hg ) or ocular hypertension ( intraocular pressure of at least 27 mm Hg )" . + . + . + . + "who were receiving monotherapy with a beta - blocker or dual therapy in which one of the agents was a beta - blocker ." . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + . + . + . + . + "Arm-dor" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-dor" . + . + "twice daily" . + . + . + "Intervention-tim" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-dor" . + . + "2" . + . + . + . + "Medication-tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome-lat" . + . + "7 . 06" . + "32" . + "P < 0 . 001" . + . + "Outcome-dor" . + . + "4 . 44" . + "20" . + "P < 0 . 001" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11558817_export.csv b/data/gl 11558817_export.csv new file mode 100644 index 0000000..e8a6d3f --- /dev/null +++ b/data/gl 11558817_export.csv @@ -0,0 +1,441 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +485, 1, 1, 1, 0, 1, 0, 1, "J" +485, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +485, 1, 3, 3, 11, 12, 11, 12, "." +485, 2, 1, 4, 0, 4, 13, 17, "2001" +485, 2, 2, 5, 5, 8, 18, 21, "Aug" +485, 2, 3, 6, 9, 10, 22, 23, ";" +485, 2, 4, 7, 11, 13, 24, 26, "10" +485, 2, 5, 8, 14, 15, 27, 28, "(" +485, 2, 6, 9, 16, 17, 29, 30, "4" +485, 2, 7, 10, 18, 19, 31, 32, ")" +485, 2, 8, 11, 20, 21, 33, 34, ":" +485, 2, 9, 12, 22, 25, 35, 38, "316" +485, 2, 10, 13, 26, 27, 39, 40, "-" +485, 2, 11, 14, 28, 30, 41, 43, "24" +485, 2, 12, 15, 31, 32, 44, 45, "." +485, 3, 1, 16, 0, 10, 46, 56, "Comparison" +485, 3, 2, 17, 11, 13, 57, 59, "of" +485, 3, 3, 18, 14, 17, 60, 63, "the" +485, 3, 4, 19, 18, 26, 64, 72, "additive" +485, 3, 5, 20, 27, 38, 73, 84, "intraocular" +485, 3, 6, 21, 39, 47, 85, 93, "pressure" +485, 3, 7, 22, 48, 49, 94, 95, "-" +485, 3, 8, 23, 50, 58, 96, 104, "lowering" +485, 3, 9, 24, 59, 65, 105, 111, "effect" +485, 3, 10, 25, 66, 68, 112, 114, "of" +485, 3, 11, 26, 69, 80, 115, 126, "latanoprost" +485, 3, 12, 27, 81, 84, 127, 130, "and" +485, 3, 13, 28, 85, 96, 131, 142, "dorzolamide" +485, 3, 14, 29, 97, 101, 143, 147, "when" +485, 3, 15, 30, 102, 107, 148, 153, "added" +485, 3, 16, 31, 108, 110, 154, 156, "to" +485, 3, 17, 32, 111, 118, 157, 164, "timolol" +485, 3, 18, 33, 119, 121, 165, 167, "in" +485, 3, 19, 34, 122, 130, 168, 176, "patients" +485, 3, 20, 35, 131, 135, 177, 181, "with" +485, 3, 21, 36, 136, 140, 182, 186, "open" +485, 3, 22, 37, 141, 142, 187, 188, "-" +485, 3, 23, 38, 143, 148, 189, 194, "angle" +485, 3, 24, 39, 149, 157, 195, 203, "glaucoma" +485, 3, 25, 40, 158, 160, 204, 206, "or" +485, 3, 26, 41, 161, 167, 207, 213, "ocular" +485, 3, 27, 42, 168, 180, 214, 226, "hypertension" +485, 3, 28, 43, 181, 182, 227, 228, ":" +485, 3, 29, 44, 183, 184, 229, 230, "a" +485, 3, 30, 45, 185, 195, 231, 241, "randomized" +485, 3, 31, 46, 196, 197, 242, 243, "," +485, 3, 32, 47, 198, 202, 244, 248, "open" +485, 3, 33, 48, 203, 204, 249, 250, "-" +485, 3, 34, 49, 205, 210, 251, 256, "label" +485, 3, 35, 50, 211, 212, 257, 258, "," +485, 3, 36, 51, 213, 224, 259, 270, "multicenter" +485, 3, 37, 52, 225, 230, 271, 276, "study" +485, 3, 38, 53, 231, 233, 277, 279, "in" +485, 3, 39, 54, 234, 240, 280, 286, "Greece" +485, 3, 40, 55, 241, 242, 287, 288, "." +485, 4, 1, 56, 0, 8, 289, 297, "Petounis" +485, 4, 2, 57, 9, 10, 298, 299, "A" +485, 4, 3, 58, 11, 12, 300, 301, "(" +485, 4, 4, 59, 13, 14, 302, 303, "1" +485, 4, 5, 60, 15, 16, 304, 305, ")" +485, 4, 6, 61, 17, 18, 306, 307, "," +485, 4, 7, 62, 19, 29, 308, 318, "Mylopoulos" +485, 4, 8, 63, 30, 31, 319, 320, "N" +485, 4, 9, 64, 32, 33, 321, 322, "," +485, 4, 10, 65, 34, 44, 323, 333, "Kandarakis" +485, 4, 11, 66, 45, 46, 334, 335, "A" +485, 4, 12, 67, 47, 48, 336, 337, "," +485, 4, 13, 68, 49, 58, 338, 347, "Andreanos" +485, 4, 14, 69, 59, 60, 348, 349, "D" +485, 4, 15, 70, 61, 62, 350, 351, "," +485, 4, 16, 71, 63, 77, 352, 366, "Dimitrakoulias" +485, 4, 17, 72, 78, 79, 367, 368, "N" +485, 4, 18, 73, 80, 81, 369, 370, "." +485, 4, 19, 74, 82, 88, 371, 377, "Author" +485, 4, 20, 75, 89, 100, 378, 389, "information" +485, 4, 21, 76, 101, 102, 390, 391, ":" +485, 4, 22, 77, 103, 104, 392, 393, "(" +485, 4, 23, 78, 105, 106, 394, 395, "1" +485, 4, 24, 79, 107, 108, 396, 397, ")" +485, 4, 25, 80, 109, 119, 398, 408, "Department" +485, 4, 26, 81, 120, 122, 409, 411, "of" +485, 4, 27, 82, 123, 136, 412, 425, "Ophthalmology" +485, 4, 28, 83, 137, 138, 426, 427, "," +485, 4, 29, 84, 139, 147, 428, 436, "Patissia" +485, 4, 30, 85, 148, 155, 437, 444, "General" +485, 4, 31, 86, 156, 164, 445, 453, "Hospital" +485, 4, 32, 87, 165, 166, 454, 455, "," +485, 4, 33, 88, 167, 173, 456, 462, "Athens" +485, 4, 34, 89, 174, 175, 463, 464, "," +485, 4, 35, 90, 176, 182, 465, 471, "Greece" +485, 4, 36, 91, 183, 184, 472, 473, "." +485, 5, 1, 92, 0, 14, 474, 488, "andre_petounis" +485, 5, 2, 93, 15, 16, 489, 490, "@" +485, 5, 3, 94, 17, 24, 491, 498, "hotmail" +485, 5, 4, 95, 25, 26, 499, 500, "." +485, 5, 5, 96, 27, 30, 501, 504, "com" +485, 5, 6, 97, 31, 38, 505, 512, "PURPOSE" +485, 5, 7, 98, 39, 40, 513, 514, ":" +485, 5, 8, 99, 41, 43, 515, 517, "To" +485, 5, 9, 100, 44, 51, 518, 525, "compare" +485, 5, 10, 101, 52, 55, 526, 529, "the" +485, 5, 11, 102, 56, 67, 530, 541, "intraocular" +485, 5, 12, 103, 68, 76, 542, 550, "pressure" +485, 5, 13, 104, 77, 78, 551, 552, "-" +485, 5, 14, 105, 79, 87, 553, 561, "lowering" +485, 5, 15, 106, 88, 94, 562, 568, "effect" +485, 5, 16, 107, 95, 97, 569, 571, "of" +485, 5, 17, 108, 98, 109, 572, 583, "latanoprost" +485, 5, 18, 109, 110, 114, 584, 588, "with" +485, 5, 19, 110, 115, 119, 589, 593, "that" +485, 5, 20, 111, 120, 122, 594, 596, "of" +485, 5, 21, 112, 123, 134, 597, 608, "dorzolamide" +485, 5, 22, 113, 135, 139, 609, 613, "when" +485, 5, 23, 114, 140, 145, 614, 619, "added" +485, 5, 24, 115, 146, 148, 620, 622, "to" +485, 5, 25, 116, 149, 156, 623, 630, "timolol" +485, 5, 26, 117, 157, 158, 631, 632, "." +485, 6, 1, 118, 0, 8, 633, 641, "PATIENTS" +485, 6, 2, 119, 9, 12, 642, 645, "AND" +485, 6, 3, 120, 13, 20, 646, 653, "METHODS" +485, 6, 4, 121, 21, 22, 654, 655, ":" +485, 6, 5, 122, 23, 27, 656, 660, "This" +485, 6, 6, 123, 28, 38, 661, 671, "randomized" +485, 6, 7, 124, 39, 40, 672, 673, "," +485, 6, 8, 125, 41, 45, 674, 678, "open" +485, 6, 9, 126, 46, 47, 679, 680, "-" +485, 6, 10, 127, 48, 53, 681, 686, "label" +485, 6, 11, 128, 54, 59, 687, 692, "study" +485, 6, 12, 129, 60, 64, 693, 697, "with" +485, 6, 13, 130, 65, 68, 698, 701, "two" +485, 6, 14, 131, 69, 77, 702, 710, "parallel" +485, 6, 15, 132, 78, 84, 711, 717, "groups" +485, 6, 16, 133, 85, 88, 718, 721, "was" +485, 6, 17, 134, 89, 98, 722, 731, "conducted" +485, 6, 18, 135, 99, 101, 732, 734, "in" +485, 6, 19, 136, 102, 106, 735, 739, "five" +485, 6, 20, 137, 107, 114, 740, 747, "centers" +485, 6, 21, 138, 115, 117, 748, 750, "in" +485, 6, 22, 139, 118, 124, 751, 757, "Greece" +485, 6, 23, 140, 125, 126, 758, 759, "." +485, 7, 1, 141, 0, 3, 760, 763, "The" +485, 7, 2, 142, 4, 9, 764, 769, "study" +485, 7, 3, 143, 10, 18, 770, 778, "enrolled" +485, 7, 4, 144, 19, 22, 779, 782, "148" +485, 7, 5, 145, 23, 31, 783, 791, "patients" +485, 7, 6, 146, 32, 36, 792, 796, "with" +485, 7, 7, 147, 37, 49, 797, 809, "inadequately" +485, 7, 8, 148, 50, 60, 810, 820, "controlled" +485, 7, 9, 149, 61, 65, 821, 825, "open" +485, 7, 10, 150, 66, 67, 826, 827, "-" +485, 7, 11, 151, 68, 73, 828, 833, "angle" +485, 7, 12, 152, 74, 76, 834, 836, "or" +485, 7, 13, 153, 77, 94, 837, 854, "pseudoexfoliation" +485, 7, 14, 154, 95, 103, 855, 863, "glaucoma" +485, 7, 15, 155, 104, 105, 864, 865, "(" +485, 7, 16, 156, 106, 117, 866, 877, "intraocular" +485, 7, 17, 157, 118, 126, 878, 886, "pressure" +485, 7, 18, 158, 127, 129, 887, 889, "of" +485, 7, 19, 159, 130, 132, 890, 892, "at" +485, 7, 20, 160, 133, 138, 893, 898, "least" +485, 7, 21, 161, 139, 141, 899, 901, "22" +485, 7, 22, 162, 142, 144, 902, 904, "mm" +485, 7, 23, 163, 145, 147, 905, 907, "Hg" +485, 7, 24, 164, 148, 149, 908, 909, ")" +485, 7, 25, 165, 150, 152, 910, 912, "or" +485, 7, 26, 166, 153, 159, 913, 919, "ocular" +485, 7, 27, 167, 160, 172, 920, 932, "hypertension" +485, 7, 28, 168, 173, 174, 933, 934, "(" +485, 7, 29, 169, 175, 186, 935, 946, "intraocular" +485, 7, 30, 170, 187, 195, 947, 955, "pressure" +485, 7, 31, 171, 196, 198, 956, 958, "of" +485, 7, 32, 172, 199, 201, 959, 961, "at" +485, 7, 33, 173, 202, 207, 962, 967, "least" +485, 7, 34, 174, 208, 210, 968, 970, "27" +485, 7, 35, 175, 211, 213, 971, 973, "mm" +485, 7, 36, 176, 214, 216, 974, 976, "Hg" +485, 7, 37, 177, 217, 218, 977, 978, ")" +485, 7, 38, 178, 219, 222, 979, 982, "who" +485, 7, 39, 179, 223, 227, 983, 987, "were" +485, 7, 40, 180, 228, 237, 988, 997, "receiving" +485, 7, 41, 181, 238, 249, 998, 1009, "monotherapy" +485, 7, 42, 182, 250, 254, 1010, 1014, "with" +485, 7, 43, 183, 255, 256, 1015, 1016, "a" +485, 7, 44, 184, 257, 261, 1017, 1021, "beta" +485, 7, 45, 185, 262, 263, 1022, 1023, "-" +485, 7, 46, 186, 264, 271, 1024, 1031, "blocker" +485, 7, 47, 187, 272, 274, 1032, 1034, "or" +485, 7, 48, 188, 275, 279, 1035, 1039, "dual" +485, 7, 49, 189, 280, 287, 1040, 1047, "therapy" +485, 7, 50, 190, 288, 290, 1048, 1050, "in" +485, 7, 51, 191, 291, 296, 1051, 1056, "which" +485, 7, 52, 192, 297, 300, 1057, 1060, "one" +485, 7, 53, 193, 301, 303, 1061, 1063, "of" +485, 7, 54, 194, 304, 307, 1064, 1067, "the" +485, 7, 55, 195, 308, 314, 1068, 1074, "agents" +485, 7, 56, 196, 315, 318, 1075, 1078, "was" +485, 7, 57, 197, 319, 320, 1079, 1080, "a" +485, 7, 58, 198, 321, 325, 1081, 1085, "beta" +485, 7, 59, 199, 326, 327, 1086, 1087, "-" +485, 7, 60, 200, 328, 335, 1088, 1095, "blocker" +485, 7, 61, 201, 336, 337, 1096, 1097, "." +485, 8, 1, 202, 0, 3, 1098, 1101, "The" +485, 8, 2, 203, 4, 12, 1102, 1110, "patients" +485, 8, 3, 204, 13, 17, 1111, 1115, "were" +485, 8, 4, 205, 18, 26, 1116, 1124, "switched" +485, 8, 5, 206, 27, 29, 1125, 1127, "to" +485, 8, 6, 207, 30, 37, 1128, 1135, "timolol" +485, 8, 7, 208, 38, 39, 1136, 1137, "0" +485, 8, 8, 209, 40, 41, 1138, 1139, "." +485, 8, 9, 210, 42, 43, 1140, 1141, "5" +485, 8, 10, 211, 44, 45, 1142, 1143, "%" +485, 8, 11, 212, 46, 51, 1144, 1149, "twice" +485, 8, 12, 213, 52, 57, 1150, 1155, "daily" +485, 8, 13, 214, 58, 61, 1156, 1159, "for" +485, 8, 14, 215, 62, 63, 1160, 1161, "2" +485, 8, 15, 216, 64, 66, 1162, 1164, "to" +485, 8, 16, 217, 67, 68, 1165, 1166, "4" +485, 8, 17, 218, 69, 74, 1167, 1172, "weeks" +485, 8, 18, 219, 75, 76, 1173, 1174, "(" +485, 8, 19, 220, 77, 80, 1175, 1178, "run" +485, 8, 20, 221, 81, 82, 1179, 1180, "-" +485, 8, 21, 222, 83, 85, 1181, 1183, "in" +485, 8, 22, 223, 86, 92, 1184, 1190, "period" +485, 8, 23, 224, 93, 94, 1191, 1192, ")" +485, 8, 24, 225, 95, 101, 1193, 1199, "before" +485, 8, 25, 226, 102, 105, 1200, 1203, "the" +485, 8, 26, 227, 106, 111, 1204, 1209, "start" +485, 8, 27, 228, 112, 114, 1210, 1212, "of" +485, 8, 28, 229, 115, 118, 1213, 1216, "the" +485, 8, 29, 230, 119, 124, 1217, 1222, "study" +485, 8, 30, 231, 125, 126, 1223, 1224, "(" +485, 8, 31, 232, 127, 135, 1225, 1233, "baseline" +485, 8, 32, 233, 136, 137, 1234, 1235, ")" +485, 8, 33, 234, 138, 139, 1236, 1237, "." +485, 9, 1, 235, 0, 2, 1238, 1240, "At" +485, 9, 2, 236, 3, 11, 1241, 1249, "baseline" +485, 9, 3, 237, 12, 13, 1250, 1251, "," +485, 9, 4, 238, 14, 17, 1252, 1255, "the" +485, 9, 5, 239, 18, 26, 1256, 1264, "patients" +485, 9, 6, 240, 27, 31, 1265, 1269, "were" +485, 9, 7, 241, 32, 42, 1270, 1280, "randomized" +485, 9, 8, 242, 43, 45, 1281, 1283, "to" +485, 9, 9, 243, 46, 53, 1284, 1291, "receive" +485, 9, 10, 244, 54, 65, 1292, 1303, "latanoprost" +485, 9, 11, 245, 66, 67, 1304, 1305, "0" +485, 9, 12, 246, 68, 69, 1306, 1307, "." +485, 9, 13, 247, 70, 73, 1308, 1311, "005" +485, 9, 14, 248, 74, 75, 1312, 1313, "%" +485, 9, 15, 249, 76, 80, 1314, 1318, "once" +485, 9, 16, 250, 81, 86, 1319, 1324, "daily" +485, 9, 17, 251, 87, 89, 1325, 1327, "or" +485, 9, 18, 252, 90, 101, 1328, 1339, "dorzolamide" +485, 9, 19, 253, 102, 103, 1340, 1341, "2" +485, 9, 20, 254, 104, 105, 1342, 1343, "%" +485, 9, 21, 255, 106, 111, 1344, 1349, "twice" +485, 9, 22, 256, 112, 117, 1350, 1355, "daily" +485, 9, 23, 257, 118, 120, 1356, 1358, "as" +485, 9, 24, 258, 121, 124, 1359, 1362, "add" +485, 9, 25, 259, 125, 126, 1363, 1364, "-" +485, 9, 26, 260, 127, 129, 1365, 1367, "on" +485, 9, 27, 261, 130, 137, 1368, 1375, "therapy" +485, 9, 28, 262, 138, 140, 1376, 1378, "to" +485, 9, 29, 263, 141, 148, 1379, 1386, "timolol" +485, 9, 30, 264, 149, 150, 1387, 1388, "." +485, 10, 1, 265, 0, 3, 1389, 1392, "The" +485, 10, 2, 266, 4, 15, 1393, 1404, "intraocular" +485, 10, 3, 267, 16, 24, 1405, 1413, "pressure" +485, 10, 4, 268, 25, 28, 1414, 1417, "was" +485, 10, 5, 269, 29, 37, 1418, 1426, "recorded" +485, 10, 6, 270, 38, 40, 1427, 1429, "at" +485, 10, 7, 271, 41, 42, 1430, 1431, "9" +485, 10, 8, 272, 43, 44, 1432, 1433, ":" +485, 10, 9, 273, 45, 47, 1434, 1436, "30" +485, 10, 10, 274, 48, 50, 1437, 1439, "AM" +485, 10, 11, 275, 51, 52, 1440, 1441, "," +485, 10, 12, 276, 53, 55, 1442, 1444, "12" +485, 10, 13, 277, 56, 57, 1445, 1446, ":" +485, 10, 14, 278, 58, 60, 1447, 1449, "30" +485, 10, 15, 279, 61, 63, 1450, 1452, "PM" +485, 10, 16, 280, 64, 65, 1453, 1454, "," +485, 10, 17, 281, 66, 69, 1455, 1458, "and" +485, 10, 18, 282, 70, 71, 1459, 1460, "3" +485, 10, 19, 283, 72, 73, 1461, 1462, ":" +485, 10, 20, 284, 74, 76, 1463, 1465, "30" +485, 10, 21, 285, 77, 79, 1466, 1468, "PM" +485, 10, 22, 286, 80, 82, 1469, 1471, "at" +485, 10, 23, 287, 83, 91, 1472, 1480, "baseline" +485, 10, 24, 288, 92, 95, 1481, 1484, "and" +485, 10, 25, 289, 96, 98, 1485, 1487, "at" +485, 10, 26, 290, 99, 100, 1488, 1489, "3" +485, 10, 27, 291, 101, 107, 1490, 1496, "months" +485, 10, 28, 292, 108, 109, 1497, 1498, "." +485, 11, 1, 293, 0, 6, 1499, 1505, "Safety" +485, 11, 2, 294, 7, 10, 1506, 1509, "was" +485, 11, 3, 295, 11, 19, 1510, 1518, "followed" +485, 11, 4, 296, 20, 30, 1519, 1529, "throughout" +485, 11, 5, 297, 31, 34, 1530, 1533, "the" +485, 11, 6, 298, 35, 40, 1534, 1539, "study" +485, 11, 7, 299, 41, 42, 1540, 1541, "." +485, 12, 1, 300, 0, 7, 1542, 1549, "RESULTS" +485, 12, 2, 301, 8, 9, 1550, 1551, ":" +485, 12, 3, 302, 10, 13, 1552, 1555, "The" +485, 12, 4, 303, 14, 21, 1556, 1563, "diurnal" +485, 12, 5, 304, 22, 33, 1564, 1575, "intraocular" +485, 12, 6, 305, 34, 42, 1576, 1584, "pressure" +485, 12, 7, 306, 43, 52, 1585, 1594, "reduction" +485, 12, 8, 307, 53, 56, 1595, 1598, "was" +485, 12, 9, 308, 57, 68, 1599, 1610, "significant" +485, 12, 10, 309, 69, 71, 1611, 1613, "in" +485, 12, 11, 310, 72, 76, 1614, 1618, "both" +485, 12, 12, 311, 77, 83, 1619, 1625, "groups" +485, 12, 13, 312, 84, 85, 1626, 1627, "(" +485, 12, 14, 313, 86, 87, 1628, 1629, "P" +485, 12, 15, 314, 88, 89, 1630, 1631, "<" +485, 12, 16, 315, 90, 91, 1632, 1633, "0" +485, 12, 17, 316, 92, 93, 1634, 1635, "." +485, 12, 18, 317, 94, 97, 1636, 1639, "001" +485, 12, 19, 318, 98, 99, 1640, 1641, ")" +485, 12, 20, 319, 100, 101, 1642, 1643, "." +485, 13, 1, 320, 0, 3, 1644, 1647, "The" +485, 13, 2, 321, 4, 8, 1648, 1652, "mean" +485, 13, 3, 322, 9, 20, 1653, 1664, "intraocular" +485, 13, 4, 323, 21, 29, 1665, 1673, "pressure" +485, 13, 5, 324, 30, 39, 1674, 1683, "reduction" +485, 13, 6, 325, 40, 44, 1684, 1688, "from" +485, 13, 7, 326, 45, 53, 1689, 1697, "baseline" +485, 13, 8, 327, 54, 57, 1698, 1701, "was" +485, 13, 9, 328, 58, 60, 1702, 1704, "32" +485, 13, 10, 329, 61, 62, 1705, 1706, "%" +485, 13, 11, 330, 63, 66, 1707, 1710, "for" +485, 13, 12, 331, 67, 70, 1711, 1714, "the" +485, 13, 13, 332, 71, 82, 1715, 1726, "latanoprost" +485, 13, 14, 333, 83, 87, 1727, 1731, "plus" +485, 13, 15, 334, 88, 95, 1732, 1739, "timolol" +485, 13, 16, 335, 96, 101, 1740, 1745, "group" +485, 13, 17, 336, 102, 105, 1746, 1749, "and" +485, 13, 18, 337, 106, 108, 1750, 1752, "20" +485, 13, 19, 338, 109, 110, 1753, 1754, "%" +485, 13, 20, 339, 111, 114, 1755, 1758, "for" +485, 13, 21, 340, 115, 118, 1759, 1762, "the" +485, 13, 22, 341, 119, 130, 1763, 1774, "dorzolamide" +485, 13, 23, 342, 131, 135, 1775, 1779, "plus" +485, 13, 24, 343, 136, 143, 1780, 1787, "timolol" +485, 13, 25, 344, 144, 149, 1788, 1793, "group" +485, 13, 26, 345, 150, 151, 1794, 1795, "." +485, 14, 1, 346, 0, 3, 1796, 1799, "The" +485, 14, 2, 347, 4, 9, 1800, 1805, "least" +485, 14, 3, 348, 10, 16, 1806, 1812, "square" +485, 14, 4, 349, 17, 25, 1813, 1821, "estimate" +485, 14, 5, 350, 26, 28, 1822, 1824, "of" +485, 14, 6, 351, 29, 32, 1825, 1828, "the" +485, 14, 7, 352, 33, 37, 1829, 1833, "mean" +485, 14, 8, 353, 38, 45, 1834, 1841, "diurnal" +485, 14, 9, 354, 46, 57, 1842, 1853, "intraocular" +485, 14, 10, 355, 58, 66, 1854, 1862, "pressure" +485, 14, 11, 356, 67, 76, 1863, 1872, "reduction" +485, 14, 12, 357, 77, 82, 1873, 1878, "after" +485, 14, 13, 358, 83, 84, 1879, 1880, "3" +485, 14, 14, 359, 85, 91, 1881, 1887, "months" +485, 14, 15, 360, 92, 95, 1888, 1891, "was" +485, 14, 16, 361, 96, 97, 1892, 1893, "-" +485, 14, 17, 362, 98, 99, 1894, 1895, "7" +485, 14, 18, 363, 100, 101, 1896, 1897, "." +485, 14, 19, 364, 102, 104, 1898, 1900, "06" +485, 14, 20, 365, 105, 107, 1901, 1903, "mm" +485, 14, 21, 366, 108, 110, 1904, 1906, "Hg" +485, 14, 22, 367, 111, 113, 1907, 1909, "in" +485, 14, 23, 368, 114, 117, 1910, 1913, "the" +485, 14, 24, 369, 118, 129, 1914, 1925, "latanoprost" +485, 14, 25, 370, 130, 134, 1926, 1930, "plus" +485, 14, 26, 371, 135, 142, 1931, 1938, "timolol" +485, 14, 27, 372, 143, 148, 1939, 1944, "group" +485, 14, 28, 373, 149, 152, 1945, 1948, "and" +485, 14, 29, 374, 153, 154, 1949, 1950, "-" +485, 14, 30, 375, 155, 156, 1951, 1952, "4" +485, 14, 31, 376, 157, 158, 1953, 1954, "." +485, 14, 32, 377, 159, 161, 1955, 1957, "44" +485, 14, 33, 378, 162, 164, 1958, 1960, "mm" +485, 14, 34, 379, 165, 167, 1961, 1963, "Hg" +485, 14, 35, 380, 168, 170, 1964, 1966, "in" +485, 14, 36, 381, 171, 174, 1967, 1970, "the" +485, 14, 37, 382, 175, 186, 1971, 1982, "dorzolamide" +485, 14, 38, 383, 187, 191, 1983, 1987, "plus" +485, 14, 39, 384, 192, 199, 1988, 1995, "timolol" +485, 14, 40, 385, 200, 205, 1996, 2001, "group" +485, 14, 41, 386, 206, 207, 2002, 2003, "(" +485, 14, 42, 387, 208, 209, 2004, 2005, "P" +485, 14, 43, 388, 210, 211, 2006, 2007, "<" +485, 14, 44, 389, 212, 213, 2008, 2009, "0" +485, 14, 45, 390, 214, 215, 2010, 2011, "." +485, 14, 46, 391, 216, 219, 2012, 2015, "001" +485, 14, 47, 392, 220, 221, 2016, 2017, ")" +485, 14, 48, 393, 222, 223, 2018, 2019, "." +485, 15, 1, 394, 0, 5, 2020, 2025, "Drugs" +485, 15, 2, 395, 6, 18, 2026, 2038, "administered" +485, 15, 3, 396, 19, 21, 2039, 2041, "in" +485, 15, 4, 397, 22, 26, 2042, 2046, "both" +485, 15, 5, 398, 27, 36, 2047, 2056, "treatment" +485, 15, 6, 399, 37, 43, 2057, 2063, "groups" +485, 15, 7, 400, 44, 48, 2064, 2068, "were" +485, 15, 8, 401, 49, 53, 2069, 2073, "well" +485, 15, 9, 402, 54, 63, 2074, 2083, "tolerated" +485, 15, 10, 403, 64, 65, 2084, 2085, "." +485, 16, 1, 404, 0, 10, 2086, 2096, "CONCLUSION" +485, 16, 2, 405, 11, 12, 2097, 2098, ":" +485, 16, 3, 406, 13, 17, 2099, 2103, "This" +485, 16, 4, 407, 18, 23, 2104, 2109, "study" +485, 16, 5, 408, 24, 31, 2110, 2117, "clearly" +485, 16, 6, 409, 32, 38, 2118, 2124, "showed" +485, 16, 7, 410, 39, 43, 2125, 2129, "that" +485, 16, 8, 411, 44, 47, 2130, 2133, "the" +485, 16, 9, 412, 48, 56, 2134, 2142, "additive" +485, 16, 10, 413, 57, 64, 2143, 2150, "diurnal" +485, 16, 11, 414, 65, 76, 2151, 2162, "intraocular" +485, 16, 12, 415, 77, 85, 2163, 2171, "pressure" +485, 16, 13, 416, 86, 87, 2172, 2173, "-" +485, 16, 14, 417, 88, 96, 2174, 2182, "lowering" +485, 16, 15, 418, 97, 103, 2183, 2189, "effect" +485, 16, 16, 419, 104, 106, 2190, 2192, "of" +485, 16, 17, 420, 107, 118, 2193, 2204, "latanoprost" +485, 16, 18, 421, 119, 121, 2205, 2207, "is" +485, 16, 19, 422, 122, 130, 2208, 2216, "superior" +485, 16, 20, 423, 131, 133, 2217, 2219, "to" +485, 16, 21, 424, 134, 138, 2220, 2224, "that" +485, 16, 22, 425, 139, 141, 2225, 2227, "of" +485, 16, 23, 426, 142, 153, 2228, 2239, "dorzolamide" +485, 16, 24, 427, 154, 156, 2240, 2242, "in" +485, 16, 25, 428, 157, 165, 2243, 2251, "patients" +485, 16, 26, 429, 166, 173, 2252, 2259, "treated" +485, 16, 27, 430, 174, 178, 2260, 2264, "with" +485, 16, 28, 431, 179, 186, 2265, 2272, "timolol" +485, 16, 29, 432, 187, 188, 2273, 2274, "." +485, 17, 1, 433, 0, 4, 2275, 2279, "PMID" +485, 17, 2, 434, 5, 6, 2280, 2281, ":" +485, 17, 3, 435, 7, 15, 2282, 2290, "11558817" +485, 17, 4, 436, 16, 17, 2291, 2292, "[" +485, 17, 5, 437, 18, 25, 2293, 2300, "Indexed" +485, 17, 6, 438, 26, 29, 2301, 2304, "for" +485, 17, 7, 439, 30, 37, 2305, 2312, "MEDLINE" +485, 17, 8, 440, 38, 39, 2313, 2314, "]" diff --git a/data/gl 11558817_jshahinitiran.annodb b/data/gl 11558817_jshahinitiran.annodb new file mode 100644 index 0000000..26825ed --- /dev/null +++ b/data/gl 11558817_jshahinitiran.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4324, Journal, 0, 10, "J Glaucoma", "", +4325, PublicationYear, 13, 17, "2001", "", +4326, Title, 46, 288, "Comparison of the additive intraocular pressure - lowering effect of latanoprost and dorzolamide when added to timolol in patients with open - angle glaucoma or ocular hypertension : a randomized , open - label , multicenter study in Greece .", "", +4332, IOP, 73, 93, "intraocular pressure", "", +4333, Latanoprost, 115, 126, "latanoprost", "", +4334, Dorzolamide, 131, 142, "dorzolamide", "", +4335, Timolol, 157, 164, "timolol", "", +4336, OpenAngleGlaucoma, 182, 203, "open - angle glaucoma", "", +4337, OcularHypertension, 207, 226, "ocular hypertension", "", +26036, Randomized, 231, 241, "randomized", "", +4339, OpenLabel, 244, 256, "open - label", "", +4340, Multicenter, 259, 270, "multicenter", "", +26037, Greece, 280, 286, "Greece", "", +4342, Author, 289, 299, "Petounis A", "", +4343, Author, 308, 320, "Mylopoulos N", "", +4344, Author, 323, 335, "Kandarakis A", "", +4345, Author, 338, 349, "Andreanos D", "", +4346, Author, 352, 368, "Dimitrakoulias N", "", +5802, Greece, 465, 471, "Greece", "", +4327, ObjectiveDescription, 515, 632, "To compare the intraocular pressure - lowering effect of latanoprost with that of dorzolamide when added to timolol .", "", +5803, IOP, 526, 550, "the intraocular pressure", "", +5804, Latanoprost, 572, 583, "latanoprost", "", +5805, Dorzolamide, 597, 608, "dorzolamide", "", +5806, Timolol, 623, 630, "timolol", "", +26039, Randomized, 661, 671, "randomized", "", +4329, OpenLabel, 674, 686, "open - label", "", +4330, Parallel, 702, 710, "parallel", "", +26038, Greece, 751, 757, "Greece", "", +4347, NumberPatientsCT, 779, 782, "148", "", +4349, Precondition, 797, 909, "inadequately controlled open - angle or pseudoexfoliation glaucoma ( intraocular pressure of at least 22 mm Hg )", "", +4348, OpenAngleGlaucoma, 821, 863, "open - angle or pseudoexfoliation glaucoma", "", +5807, IOP, 866, 886, "intraocular pressure", "", +5808, Precondition, 866, 907, "intraocular pressure of at least 22 mm Hg", "", +5809, mmHg, 902, 907, "mm Hg", "", +5810, OcularHypertension, 913, 932, "ocular hypertension", "", +5811, IOP, 935, 955, "intraocular pressure", "", +5813, Precondition, 935, 976, "intraocular pressure of at least 27 mm Hg", "", +5812, mmHg, 971, 976, "mm Hg", "", +4351, Precondition, 988, 1097, "receiving monotherapy with a beta - blocker or dual therapy in which one of the agents was a beta - blocker .", "", +4352, Timolol, 1128, 1135, "timolol", "", +4353, DoseValue, 1136, 1141, "0 . 5", "tim", +4354, Percentage, 1142, 1143, "%", "tim", +4355, Frequency, 1144, 1155, "twice daily", "tim", +39034, Randomized, 1270, 1280, "randomized", "", +4357, Latanoprost, 1292, 1303, "latanoprost", "", +4360, DoseValue, 1304, 1311, "0 . 005", "lat", +4359, Percentage, 1312, 1313, "%", "lat", +4361, Frequency, 1314, 1324, "once daily", "lat", +4362, Dorzolamide, 1328, 1339, "dorzolamide", "", +4363, DoseValue, 1340, 1341, "2", "dor", +4364, Percentage, 1342, 1343, "%", "dor", +4365, Frequency, 1344, 1355, "twice daily", "dor", +4366, Timolol, 1379, 1386, "timolol", "dor", +4367, IOP, 1393, 1413, "intraocular pressure", "", +4368, TimePoint, 1472, 1480, "baseline", "", +4369, TimePoint, 1488, 1496, "3 months", "", +4370, Diurnal_IOP, 1556, 1584, "diurnal intraocular pressure", "", +4371, PValueChangeValue, 1628, 1639, "P < 0 . 001", "", +4372, Mean, 1648, 1652, "mean", "", +4373, IOP, 1653, 1673, "intraocular pressure", "", +4374, RelativeReduction, 1702, 1704, "32", "", +4375, Latanoprost, 1715, 1726, "latanoprost", "", +4376, Timolol, 1732, 1739, "timolol", "", +4377, RelativeReduction, 1750, 1752, "20", "", +4378, Dorzolamide, 1763, 1774, "dorzolamide", "", +4379, Timolol, 1780, 1787, "timolol", "", +4384, LeastSquaresMean, 1800, 1833, "least square estimate of the mean", "", +5814, Mean, 1829, 1833, "mean", "", +4387, Diurnal_IOP, 1834, 1862, "diurnal intraocular pressure", "", +4389, TimePoint, 1879, 1887, "3 months", "", +4396, Reduction, 1894, 1900, "7 . 06", "", +4397, mmHg, 1901, 1906, "mm Hg", "", +4399, Latanoprost, 1914, 1925, "latanoprost", "", +4400, Timolol, 1931, 1938, "timolol", "", +4401, Reduction, 1951, 1957, "4 . 44", "", +4402, mmHg, 1958, 1963, "mm Hg", "", +4403, Dorzolamide, 1971, 1982, "dorzolamide", "", +4404, Timolol, 1988, 1995, "timolol", "", +4411, PValueChangeValue, 2004, 2015, "P < 0 . 001", "", +4412, ConclusionComment, 2099, 2274, "This study clearly showed that the additive diurnal intraocular pressure - lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol .", "", +4413, Diurnal_IOP, 2143, 2171, "diurnal intraocular pressure", "", +4414, Latanoprost, 2193, 2204, "latanoprost", "", +4415, Dorzolamide, 2228, 2239, "dorzolamide", "", +4416, Timolol, 2265, 2272, "timolol", "", +4417, PMID, 2282, 2290, "11558817", "", diff --git a/data/gl 11558817_jshahinitiran.n-triples b/data/gl 11558817_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11558817_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11558817_tstrakeljahn.annodb b/data/gl 11558817_tstrakeljahn.annodb new file mode 100644 index 0000000..891be5f --- /dev/null +++ b/data/gl 11558817_tstrakeljahn.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5603, Journal, 0, 10, "J Glaucoma", "", +5604, PublicationYear, 13, 17, "2001", "", +5621, Title, 46, 288, "Comparison of the additive intraocular pressure - lowering effect of latanoprost and dorzolamide when added to timolol in patients with open - angle glaucoma or ocular hypertension : a randomized , open - label , multicenter study in Greece .", "", +5605, IOP, 73, 93, "intraocular pressure", "", +5606, Latanoprost, 115, 126, "latanoprost", "", +5607, Dorzolamide, 131, 142, "dorzolamide", "", +5608, Timolol, 157, 164, "timolol", "", +5609, OpenAngleGlaucoma, 182, 203, "open - angle glaucoma", "", +5610, OcularHypertension, 207, 226, "ocular hypertension", "", +5611, Randomized, 231, 241, "randomized", "", +5612, OpenLabel, 244, 256, "open - label", "", +5613, Multicenter, 259, 270, "multicenter", "", +5614, Greece, 280, 286, "Greece", "", +5615, Author, 289, 299, "Petounis A", "", +5616, Author, 308, 320, "Mylopoulos N", "", +5617, Author, 323, 335, "Kandarakis A", "", +5618, Author, 338, 349, "Andreanos D", "", +5619, Author, 352, 368, "Dimitrakoulias N", "", +5620, Greece, 465, 471, "Greece", "", +5622, IOP, 530, 550, "intraocular pressure", "", +5623, Latanoprost, 572, 583, "latanoprost", "", +5624, Dorzolamide, 597, 608, "dorzolamide", "", +5625, Timolol, 623, 630, "timolol", "", +5641, Randomized, 661, 671, "randomized", "", +5642, OpenLabel, 674, 686, "open - label", "", +5643, Parallel, 698, 717, "two parallel groups", "", +5644, Multicenter, 722, 747, "conducted in five centers", "", +5645, Greece, 751, 757, "Greece", "", +5646, NumberPatientsCT, 779, 782, "148", "", +5651, Precondition, 783, 978, "patients with inadequately controlled open - angle or pseudoexfoliation glaucoma ( intraocular pressure of at least 22 mm Hg ) or ocular hypertension ( intraocular pressure of at least 27 mm Hg )", "", +5648, OpenAngleGlaucoma, 821, 833, "open - angle", "", +5648, OpenAngleGlaucoma, 855, 863, "glaucoma", "", +5650, Glaucoma, 855, 863, "glaucoma", "", +5652, Precondition, 979, 1095, "who were receiving monotherapy with a beta - blocker or dual therapy in which one of the agents was a beta - blocker", "", +5630, Precondition, 1102, 1222, "patients were switched to timolol 0 . 5 % twice daily for 2 to 4 weeks ( run - in period ) before the start of the study", "", +5626, Timolol, 1128, 1135, "timolol", "", +5629, DoseValue, 1136, 1141, "0 . 5", "", +5628, Percentage, 1142, 1143, "%", "", +5627, Frequency, 1144, 1155, "twice daily", "", +5631, Latanoprost, 1292, 1303, "latanoprost", "", +5632, DoseValue, 1304, 1311, "0 . 005", "", +5633, Percentage, 1312, 1313, "%", "", +5634, Frequency, 1314, 1324, "once daily", "", +5635, Dorzolamide, 1328, 1339, "dorzolamide", "", +5636, DoseValue, 1340, 1341, "2", "", +5637, Percentage, 1342, 1343, "%", "", +5638, Frequency, 1344, 1355, "twice daily", "", +5639, Timolol, 1379, 1386, "timolol", "", +5640, IOP, 1393, 1413, "intraocular pressure", "", +5653, Diurnal_IOP, 1556, 1584, "diurnal intraocular pressure", "", +5654, PValueChangeValue, 1628, 1639, "P < 0 . 001", "", +5655, Mean, 1648, 1652, "mean", "", +5656, IOP, 1653, 1673, "intraocular pressure", "", +5657, RelativeReduction, 1702, 1704, "32", "", +5658, Latanoprost, 1715, 1726, "latanoprost", "", +5659, Timolol, 1732, 1739, "timolol", "", +5660, RelativeReduction, 1750, 1752, "20", "", +5661, Dorzolamide, 1763, 1774, "dorzolamide", "", +5662, Timolol, 1780, 1787, "timolol", "", +5663, Mean, 1829, 1833, "mean", "", +5664, Diurnal_IOP, 1834, 1862, "diurnal intraocular pressure", "", +5665, TimePoint, 1879, 1887, "3 months", "", +5666, Reduction, 1894, 1900, "7 . 06", "", +5668, mmHg, 1901, 1906, "mm Hg", "", +5670, Latanoprost, 1914, 1925, "latanoprost", "", +5671, Timolol, 1931, 1938, "timolol", "", +5667, Reduction, 1951, 1957, "4 . 44", "", +5669, mmHg, 1958, 1963, "mm Hg", "", +5672, Dorzolamide, 1971, 1982, "dorzolamide", "", +5673, Timolol, 1988, 1995, "timolol", "", +5674, PValueChangeValue, 2004, 2015, "P < 0 . 001", "", +5680, ConclusionComment, 2099, 2274, "This study clearly showed that the additive diurnal intraocular pressure - lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol .", "", +5676, Diurnal_IOP, 2143, 2171, "diurnal intraocular pressure", "", +5677, Latanoprost, 2193, 2204, "latanoprost", "", +5678, Dorzolamide, 2228, 2239, "dorzolamide", "", +5679, Timolol, 2265, 2272, "timolol", "", +5675, PMID, 2282, 2290, "11558817", "", diff --git a/data/gl 11558817_tstrakeljahn.n-triples b/data/gl 11558817_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11558817_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11813932 copy_admin.annodb b/data/gl 11813932 copy_admin.annodb new file mode 100644 index 0000000..f7584fe --- /dev/null +++ b/data/gl 11813932 copy_admin.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2001", "", " \"2001\"." +2, Title, 47, 273, "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial .", "", " \"A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial .\"." +52, Brimonidine, 96, 107, "brimonidine", "", +53, Latanoprost, 112, 123, "latanoprost", "", +54, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", " ." +55, OcularHypertension, 164, 183, "ocular hypertension", "", " ." +56, Duration, 188, 201, "three - month", "", " \"three - month\"." +57, Multicenter, 204, 215, "multicenter", "", " ." +58, Randomized, 218, 228, "randomized", "", " ." +128, DoubleBlind, 231, 246, "double - masked", "", " ." +129, Parallel, 249, 257, "parallel", "", " ." +3, Author, 274, 284, "DuBiner HB", "", " \"DuBiner HB\"." +4, Author, 293, 299, "Mroz M", "", " \"Mroz M\"." +5, Author, 302, 312, "Shapiro AM", "", " \"Shapiro AM\"." +6, Author, 315, 323, "Dirks MS", "", " \"Dirks MS\"." +135, Brimonidine, 326, 337, "Brimonidine", "", +136, Latanoprost, 343, 354, "Latanoprost", "", +8, USA, 442, 445, "USA", "", +61, Brimonidine, 494, 505, "brimonidine", "", +62, Latanoprost, 509, 520, "latanoprost", "", +63, OpenAngleGlaucoma, 554, 575, "open - angle glaucoma", "", +64, OcularHypertension, 579, 598, "ocular hypertension", "", +9, ObjectiveDescription, 754, 973, "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension .", "", " \"This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension .\"." +65, Brimonidine, 816, 827, "brimonidine", "", " ." +10, DoseValue, 828, 833, "0 . 2", "", " \"0 . 2\"." +11, Percentage, 834, 835, "%", "", " ." +12, Frequency, 836, 847, "twice daily", "", " \"twice daily\"." +66, Latanoprost, 862, 873, "latanoprost", "", " . ." +13, DoseValue, 874, 881, "0 . 005", "", " \"0 . 005\"." +14, Percentage, 882, 883, "%", "", " ." +15, Frequency, 884, 894, "once daily", "", " \"once daily\"." +67, OpenAngleGlaucoma, 927, 948, "open - angle glaucoma", "", +68, OcularHypertension, 952, 971, "ocular hypertension", "", +69, Duration, 992, 1001, "3 - month", "", +70, Multicenter, 1004, 1015, "multicenter", "", +71, DoubleBlind, 1018, 1033, "double - masked", "", +174, Parallel, 1036, 1044, "parallel", "", +175, Precondition, 1073, 1256, "treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg", "", " \"treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg\"." +73, OpenAngleGlaucoma, 1128, 1149, "open - angle glaucoma", "", +74, OcularHypertension, 1153, 1172, "ocular hypertension", "", +18, IOP, 1187, 1207, "intraocular pressure", "", +19, IOP, 1210, 1213, "IOP", "", +49, mmHg, 1251, 1256, "mm Hg", "", +76, Randomized, 1262, 1272, "randomized", "", +77, Brimonidine, 1291, 1302, "brimonidine", "", +78, Latanoprost, 1306, 1317, "latanoprost", "", +93009, IOP_target, 1515, 1543, "> or = 20 % reduction in IOP", "", +225, TimePoint, 1549, 1557, "baseline", "", +80, TimePoint, 1561, 1568, "month 3", "", +184, Mean, 1603, 1607, "mean", "", +21, IOP, 1608, 1611, "IOP", "", +81, TimePoint, 1639, 1646, "month 3", "", +22, NumberPatientsCT, 1802, 1805, "127", "", " \"127\"." +23, NumberPatientsArm, 1854, 1856, "66", "", " \"66\"." +82, Brimonidine, 1864, 1875, "brimonidine", "", +24, NumberPatientsArm, 1886, 1888, "61", "", " \"61\"." +83, Latanoprost, 1896, 1907, "latanoprost", "", +89, TimePoint, 1922, 1930, "3 months", "", +25, PercentageAffected, 1946, 1948, "80", "", +84, Brimonidine, 1970, 1981, "brimonidine", "", +26, PercentageAffected, 1992, 1994, "74", "", +85, Latanoprost, 2016, 2027, "latanoprost", "", +93012, IOP_target, 2047, 2075, "> or = 20 % reduction in IOP", "", +87, Mean, 2096, 2100, "mean", "", " . ." +27, IOP, 2114, 2117, "IOP", "", " . ." +88, TimePoint, 2135, 2142, "month 3", "", " \"month 3\". \"month 3\"." +28, Reduction, 2147, 2152, "6 . 8", "", " \"6 . 8\"." +50, mmHg, 2153, 2158, "mm Hg", "", " ." +90, Brimonidine, 2164, 2175, "brimonidine", "", +29, Reduction, 2180, 2185, "6 . 5", "", " \"6 . 5\"." +51, mmHg, 2186, 2191, "mm Hg", "", +91, Latanoprost, 2197, 2208, "latanoprost", "", +30, RelativeReduction, 2211, 2217, "27 . 8", "", " \"27 . 8\"." +31, RelativeReduction, 2223, 2229, "27 . 0", "", " \"27 . 0\"." +198, SubGroupDescription, 2257, 2283, "treatment - naive patients", "", " \"treatment - naive patients\". \"treatment - naive patients\"." +92, Brimonidine, 2323, 2334, "brimonidine", "", +93011, IOP_target, 2363, 2390, "> or = 20 % decrease in IOP", "", " ." +94, Latanoprost, 2405, 2416, "latanoprost", "", +200, PercentageAffected, 2438, 2440, "88", "", " \"88\"." +201, PercentageAffected, 2446, 2448, "59", "", " \"59\"." +202, PvalueDiff, 2468, 2478, "P = 0 . 01", "", " \"P = 0 . 01\"." +35, SubGroupDescription, 2486, 2504, "previously treated", "", " \"previously treated\". \"previously treated\"." +95, Latanoprost, 2543, 2554, "latanoprost", "", +93010, IOP_target, 2570, 2598, "> or = 20 % reduction in IOP", "", +97, Brimonidine, 2617, 2628, "brimonidine", "", +209, PercentageAffected, 2637, 2639, "88", "", " \"88\"." +210, PercentageAffected, 2645, 2647, "74", "", " \"74\"." +100, Brimonidine, 2765, 2776, "brimonidine", "", +40989, EndPointDescription, 2792, 2808, "clinical success", "", " . ." +98, TimePoint, 2812, 2819, "month 3", "", " \"month 3\". \"month 3\"." +99, Latanoprost, 2850, 2861, "latanoprost", "", +101, PercentageAffected, 2870, 2872, "91", "", " \"91\"." +102, PercentageAffected, 2878, 2880, "74", "", " \"74\"." +206, PvalueDiff, 2885, 2895, "P = 0 . 01", "", " \"P = 0 . 01\"." +38, ConclusionComment, 2914, 3015, "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .", "", " \"At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .\"." +104, Brimonidine, 2931, 2942, "brimonidine", "", +105, Frequency, 2943, 2954, "twice daily", "", +106, Latanoprost, 2975, 2986, "latanoprost", "", +107, Frequency, 2987, 2997, "once daily", "", +108, IOP, 3010, 3013, "IOP", "", +39, ConclusionComment, 3016, 3178, "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .", "", " \"In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .\"." +109, Latanoprost, 3048, 3059, "latanoprost", "", +110, TimePoint, 3129, 3137, "3 months", "", +111, Brimonidine, 3165, 3176, "brimonidine", "", +40, ConclusionComment, 3179, 3332, "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .", "", " \"This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .\"." +112, Brimonidine, 3198, 3209, "brimonidine", "", +113, OpenAngleGlaucoma, 3286, 3307, "open - angle glaucoma", "", +114, OcularHypertension, 3311, 3330, "ocular hypertension", "", +41, ConclusionComment, 3333, 3446, "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .", "", " \"In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .\"." +115, Latanoprost, 3376, 3387, "latanoprost", "", +43, Mean, 3405, 3409, "mean", "", +44, IOP, 3410, 3413, "IOP", "", +116, Brimonidine, 3433, 3444, "brimonidine", "", +42, ConclusionComment, 3447, 3565, "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .", "", " \"Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .\"." +117, Brimonidine, 3506, 3517, "brimonidine", "", +118, Latanoprost, 3540, 3551, "latanoprost", "", +45, PMID, 3573, 3581, "11813932", "", " \"11813932\"." diff --git a/data/gl 11813932 copy_admin.n-triples b/data/gl 11813932 copy_admin.n-triples new file mode 100644 index 0000000..2e922e6 --- /dev/null +++ b/data/gl 11813932 copy_admin.n-triples @@ -0,0 +1,165 @@ +# RDF export of group: Publication + . + "Publication 105239#" . + "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial ." . + "DuBiner HB" . + "2001" . + "Clin Ther ." . + "11813932" . + . + "Mroz M" . + "Shapiro AM" . + "Dirks MS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 105246" . + "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension ." . + "127" . + "three - month" . + . + . + . + "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP ." . + . + . + . + . + . + . + . + "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine ." . + "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension ." . + "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine ." . + "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy ." . + . + . + . + . +# RDF export of group: Population + . + "Population 105262" . + "treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + . + "iopt" . + . + . + . + . + . + "succ" . + . + . + . + . + . +# RDF export of group: Arm + . + "brim" . + "66" . + . + . + . + . + . + . + . + "lat" . + "61" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "brim" . + . + "twice daily" . + . + . + "lat" . + . + "once daily" . + . +# RDF export of group: Medication + . + "brim" . + . + "0 . 2" . + . + . + . + "lat" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "6 . 8" . + "27 . 8" . + "month 3" . + . + "iop2" . + . + "6 . 5" . + "27 . 0" . + "month 3" . + . + "iopt1" . + . + "88" . + "treatment - naive patients" . + . + "iopt2" . + . + "59" . + "treatment - naive patients" . + . + "usc1" . + . + "91" . + "month 3" . + . + "suc2" . + . + "74" . + "month 3" . + . + "iopt21" . + . + "74" . + "previously treated" . + . + "iopt22" . + . + "88" . + "previously treated" . +# RDF export of group: DiffBetweenGroups + . + "iopt" . + "P = 0 . 01" . + . + . + . + "succ" . + "P = 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11813932 copy_export.csv b/data/gl 11813932 copy_export.csv new file mode 100644 index 0000000..7dfab0c --- /dev/null +++ b/data/gl 11813932 copy_export.csv @@ -0,0 +1,664 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +828, 1, 1, 1, 0, 4, 0, 4, "Clin" +828, 1, 2, 2, 5, 9, 5, 9, "Ther" +828, 1, 3, 3, 10, 11, 10, 11, "." +828, 2, 1, 4, 0, 4, 12, 16, "2001" +828, 2, 2, 5, 5, 8, 17, 20, "Dec" +828, 2, 3, 6, 9, 10, 21, 22, ";" +828, 2, 4, 7, 11, 13, 23, 25, "23" +828, 2, 5, 8, 14, 15, 26, 27, "(" +828, 2, 6, 9, 16, 18, 28, 30, "12" +828, 2, 7, 10, 19, 20, 31, 32, ")" +828, 2, 8, 11, 21, 22, 33, 34, ":" +828, 2, 9, 12, 23, 27, 35, 39, "1969" +828, 2, 10, 13, 28, 29, 40, 41, "-" +828, 2, 11, 14, 30, 32, 42, 44, "83" +828, 2, 12, 15, 33, 34, 45, 46, "." +828, 3, 1, 16, 0, 1, 47, 48, "A" +828, 3, 2, 17, 2, 12, 49, 59, "comparison" +828, 3, 3, 18, 13, 15, 60, 62, "of" +828, 3, 4, 19, 16, 19, 63, 66, "the" +828, 3, 5, 20, 20, 28, 67, 75, "efficacy" +828, 3, 6, 21, 29, 32, 76, 79, "and" +828, 3, 7, 22, 33, 45, 80, 92, "tolerability" +828, 3, 8, 23, 46, 48, 93, 95, "of" +828, 3, 9, 24, 49, 60, 96, 107, "brimonidine" +828, 3, 10, 25, 61, 64, 108, 111, "and" +828, 3, 11, 26, 65, 76, 112, 123, "latanoprost" +828, 3, 12, 27, 77, 79, 124, 126, "in" +828, 3, 13, 28, 80, 86, 127, 133, "adults" +828, 3, 14, 29, 87, 91, 134, 138, "with" +828, 3, 15, 30, 92, 96, 139, 143, "open" +828, 3, 16, 31, 97, 98, 144, 145, "-" +828, 3, 17, 32, 99, 104, 146, 151, "angle" +828, 3, 18, 33, 105, 113, 152, 160, "glaucoma" +828, 3, 19, 34, 114, 116, 161, 163, "or" +828, 3, 20, 35, 117, 123, 164, 170, "ocular" +828, 3, 21, 36, 124, 136, 171, 183, "hypertension" +828, 3, 22, 37, 137, 138, 184, 185, ":" +828, 3, 23, 38, 139, 140, 186, 187, "a" +828, 3, 24, 39, 141, 146, 188, 193, "three" +828, 3, 25, 40, 147, 148, 194, 195, "-" +828, 3, 26, 41, 149, 154, 196, 201, "month" +828, 3, 27, 42, 155, 156, 202, 203, "," +828, 3, 28, 43, 157, 168, 204, 215, "multicenter" +828, 3, 29, 44, 169, 170, 216, 217, "," +828, 3, 30, 45, 171, 181, 218, 228, "randomized" +828, 3, 31, 46, 182, 183, 229, 230, "," +828, 3, 32, 47, 184, 190, 231, 237, "double" +828, 3, 33, 48, 191, 192, 238, 239, "-" +828, 3, 34, 49, 193, 199, 240, 246, "masked" +828, 3, 35, 50, 200, 201, 247, 248, "," +828, 3, 36, 51, 202, 210, 249, 257, "parallel" +828, 3, 37, 52, 211, 212, 258, 259, "-" +828, 3, 38, 53, 213, 218, 260, 265, "group" +828, 3, 39, 54, 219, 224, 266, 271, "trial" +828, 3, 40, 55, 225, 226, 272, 273, "." +828, 4, 1, 56, 0, 7, 274, 281, "DuBiner" +828, 4, 2, 57, 8, 10, 282, 284, "HB" +828, 4, 3, 58, 11, 12, 285, 286, "(" +828, 4, 4, 59, 13, 14, 287, 288, "1" +828, 4, 5, 60, 15, 16, 289, 290, ")" +828, 4, 6, 61, 17, 18, 291, 292, "," +828, 4, 7, 62, 19, 23, 293, 297, "Mroz" +828, 4, 8, 63, 24, 25, 298, 299, "M" +828, 4, 9, 64, 26, 27, 300, 301, "," +828, 4, 10, 65, 28, 35, 302, 309, "Shapiro" +828, 4, 11, 66, 36, 38, 310, 312, "AM" +828, 4, 12, 67, 39, 40, 313, 314, "," +828, 4, 13, 68, 41, 46, 315, 320, "Dirks" +828, 4, 14, 69, 47, 49, 321, 323, "MS" +828, 4, 15, 70, 50, 51, 324, 325, ";" +828, 4, 16, 71, 52, 63, 326, 337, "Brimonidine" +828, 4, 17, 72, 64, 66, 338, 340, "vs" +828, 4, 18, 73, 67, 68, 341, 342, "." +828, 4, 19, 74, 69, 80, 343, 354, "Latanoprost" +828, 4, 20, 75, 81, 86, 355, 360, "Study" +828, 4, 21, 76, 87, 92, 361, 366, "Group" +828, 4, 22, 77, 93, 94, 367, 368, "." +828, 5, 1, 78, 0, 6, 369, 375, "Author" +828, 5, 2, 79, 7, 18, 376, 387, "information" +828, 5, 3, 80, 19, 20, 388, 389, ":" +828, 5, 4, 81, 21, 22, 390, 391, "(" +828, 5, 5, 82, 23, 24, 392, 393, "1" +828, 5, 6, 83, 25, 26, 394, 395, ")" +828, 5, 7, 84, 27, 34, 396, 403, "Clayton" +828, 5, 8, 85, 35, 38, 404, 407, "Eye" +828, 5, 9, 86, 39, 45, 408, 414, "Center" +828, 5, 10, 87, 46, 47, 415, 416, "," +828, 5, 11, 88, 48, 54, 417, 423, "Morrow" +828, 5, 12, 89, 55, 56, 424, 425, "," +828, 5, 13, 90, 57, 64, 426, 433, "Georgia" +828, 5, 14, 91, 65, 70, 434, 439, "30260" +828, 5, 15, 92, 71, 72, 440, 441, "," +828, 5, 16, 93, 73, 76, 442, 445, "USA" +828, 5, 17, 94, 77, 78, 446, 447, "." +828, 6, 1, 95, 0, 10, 448, 458, "BACKGROUND" +828, 6, 2, 96, 11, 12, 459, 460, ":" +828, 6, 3, 97, 13, 17, 461, 465, "Many" +828, 6, 4, 98, 18, 28, 466, 476, "physicians" +828, 6, 5, 99, 29, 38, 477, 486, "recommend" +828, 6, 6, 100, 39, 45, 487, 493, "either" +828, 6, 7, 101, 46, 57, 494, 505, "brimonidine" +828, 6, 8, 102, 58, 60, 506, 508, "or" +828, 6, 9, 103, 61, 72, 509, 520, "latanoprost" +828, 6, 10, 104, 73, 75, 521, 523, "as" +828, 6, 11, 105, 76, 85, 524, 533, "firstline" +828, 6, 12, 106, 86, 93, 534, 541, "therapy" +828, 6, 13, 107, 94, 97, 542, 545, "for" +828, 6, 14, 108, 98, 105, 546, 553, "chronic" +828, 6, 15, 109, 106, 110, 554, 558, "open" +828, 6, 16, 110, 111, 112, 559, 560, "-" +828, 6, 17, 111, 113, 118, 561, 566, "angle" +828, 6, 18, 112, 119, 127, 567, 575, "glaucoma" +828, 6, 19, 113, 128, 130, 576, 578, "or" +828, 6, 20, 114, 131, 137, 579, 585, "ocular" +828, 6, 21, 115, 138, 150, 586, 598, "hypertension" +828, 6, 22, 116, 151, 152, 599, 600, "." +828, 7, 1, 117, 0, 7, 601, 608, "However" +828, 7, 2, 118, 8, 9, 609, 610, "," +828, 7, 3, 119, 10, 11, 611, 612, "a" +828, 7, 4, 120, 12, 18, 613, 619, "search" +828, 7, 5, 121, 19, 21, 620, 622, "of" +828, 7, 6, 122, 22, 29, 623, 630, "MEDLINE" +828, 7, 7, 123, 30, 39, 631, 640, "indicates" +828, 7, 8, 124, 40, 44, 641, 645, "that" +828, 7, 9, 125, 45, 50, 646, 651, "there" +828, 7, 10, 126, 51, 55, 652, 656, "have" +828, 7, 11, 127, 56, 60, 657, 661, "been" +828, 7, 12, 128, 61, 64, 662, 665, "few" +828, 7, 13, 129, 65, 69, 666, 670, "head" +828, 7, 14, 130, 70, 71, 671, 672, "-" +828, 7, 15, 131, 72, 74, 673, 675, "to" +828, 7, 16, 132, 75, 76, 676, 677, "-" +828, 7, 17, 133, 77, 81, 678, 682, "head" +828, 7, 18, 134, 82, 93, 683, 694, "comparisons" +828, 7, 19, 135, 94, 96, 695, 697, "of" +828, 7, 20, 136, 97, 100, 698, 701, "the" +828, 7, 21, 137, 101, 102, 702, 703, "2" +828, 7, 22, 138, 103, 116, 704, 717, "monotherapies" +828, 7, 23, 139, 117, 119, 718, 720, "in" +828, 7, 24, 140, 120, 121, 721, 722, "a" +828, 7, 25, 141, 122, 130, 723, 731, "clinical" +828, 7, 26, 142, 131, 138, 732, 739, "setting" +828, 7, 27, 143, 139, 140, 740, 741, "." +828, 8, 1, 144, 0, 9, 742, 751, "OBJECTIVE" +828, 8, 2, 145, 10, 11, 752, 753, ":" +828, 8, 3, 146, 12, 16, 754, 758, "This" +828, 8, 4, 147, 17, 22, 759, 764, "study" +828, 8, 5, 148, 23, 31, 765, 773, "compared" +828, 8, 6, 149, 32, 35, 774, 777, "the" +828, 8, 7, 150, 36, 44, 778, 786, "clinical" +828, 8, 8, 151, 45, 53, 787, 795, "efficacy" +828, 8, 9, 152, 54, 57, 796, 799, "and" +828, 8, 10, 153, 58, 70, 800, 812, "tolerability" +828, 8, 11, 154, 71, 73, 813, 815, "of" +828, 8, 12, 155, 74, 85, 816, 827, "brimonidine" +828, 8, 13, 156, 86, 87, 828, 829, "0" +828, 8, 14, 157, 88, 89, 830, 831, "." +828, 8, 15, 158, 90, 91, 832, 833, "2" +828, 8, 16, 159, 92, 93, 834, 835, "%" +828, 8, 17, 160, 94, 99, 836, 841, "twice" +828, 8, 18, 161, 100, 105, 842, 847, "daily" +828, 8, 19, 162, 106, 110, 848, 852, "with" +828, 8, 20, 163, 111, 116, 853, 858, "those" +828, 8, 21, 164, 117, 119, 859, 861, "of" +828, 8, 22, 165, 120, 131, 862, 873, "latanoprost" +828, 8, 23, 166, 132, 133, 874, 875, "0" +828, 8, 24, 167, 134, 135, 876, 877, "." +828, 8, 25, 168, 136, 139, 878, 881, "005" +828, 8, 26, 169, 140, 141, 882, 883, "%" +828, 8, 27, 170, 142, 146, 884, 888, "once" +828, 8, 28, 171, 147, 152, 889, 894, "daily" +828, 8, 29, 172, 153, 155, 895, 897, "as" +828, 8, 30, 173, 156, 167, 898, 909, "monotherapy" +828, 8, 31, 174, 168, 170, 910, 912, "in" +828, 8, 32, 175, 171, 179, 913, 921, "patients" +828, 8, 33, 176, 180, 184, 922, 926, "with" +828, 8, 34, 177, 185, 189, 927, 931, "open" +828, 8, 35, 178, 190, 191, 932, 933, "-" +828, 8, 36, 179, 192, 197, 934, 939, "angle" +828, 8, 37, 180, 198, 206, 940, 948, "glaucoma" +828, 8, 38, 181, 207, 209, 949, 951, "or" +828, 8, 39, 182, 210, 216, 952, 958, "ocular" +828, 8, 40, 183, 217, 229, 959, 971, "hypertension" +828, 8, 41, 184, 230, 231, 972, 973, "." +828, 9, 1, 185, 0, 7, 974, 981, "METHODS" +828, 9, 2, 186, 8, 9, 982, 983, ":" +828, 9, 3, 187, 10, 12, 984, 986, "In" +828, 9, 4, 188, 13, 17, 987, 991, "this" +828, 9, 5, 189, 18, 19, 992, 993, "3" +828, 9, 6, 190, 20, 21, 994, 995, "-" +828, 9, 7, 191, 22, 27, 996, 1001, "month" +828, 9, 8, 192, 28, 29, 1002, 1003, "," +828, 9, 9, 193, 30, 41, 1004, 1015, "multicenter" +828, 9, 10, 194, 42, 43, 1016, 1017, "," +828, 9, 11, 195, 44, 50, 1018, 1024, "double" +828, 9, 12, 196, 51, 52, 1025, 1026, "-" +828, 9, 13, 197, 53, 59, 1027, 1033, "masked" +828, 9, 14, 198, 60, 61, 1034, 1035, "," +828, 9, 15, 199, 62, 70, 1036, 1044, "parallel" +828, 9, 16, 200, 71, 72, 1045, 1046, "-" +828, 9, 17, 201, 73, 78, 1047, 1052, "group" +828, 9, 18, 202, 79, 80, 1053, 1054, "," +828, 9, 19, 203, 81, 82, 1055, 1056, "4" +828, 9, 20, 204, 83, 84, 1057, 1058, "-" +828, 9, 21, 205, 85, 90, 1059, 1064, "visit" +828, 9, 22, 206, 91, 96, 1065, 1070, "study" +828, 9, 23, 207, 97, 98, 1071, 1072, "," +828, 9, 24, 208, 99, 108, 1073, 1082, "treatment" +828, 9, 25, 209, 109, 110, 1083, 1084, "-" +828, 9, 26, 210, 111, 116, 1085, 1090, "naive" +828, 9, 27, 211, 117, 120, 1091, 1094, "and" +828, 9, 28, 212, 121, 131, 1095, 1105, "previously" +828, 9, 29, 213, 132, 139, 1106, 1113, "treated" +828, 9, 30, 214, 140, 148, 1114, 1122, "patients" +828, 9, 31, 215, 149, 153, 1123, 1127, "with" +828, 9, 32, 216, 154, 158, 1128, 1132, "open" +828, 9, 33, 217, 159, 160, 1133, 1134, "-" +828, 9, 34, 218, 161, 166, 1135, 1140, "angle" +828, 9, 35, 219, 167, 175, 1141, 1149, "glaucoma" +828, 9, 36, 220, 176, 178, 1150, 1152, "or" +828, 9, 37, 221, 179, 185, 1153, 1159, "ocular" +828, 9, 38, 222, 186, 198, 1160, 1172, "hypertension" +828, 9, 39, 223, 199, 202, 1173, 1176, "and" +828, 9, 40, 224, 203, 212, 1177, 1186, "bilateral" +828, 9, 41, 225, 213, 224, 1187, 1198, "intraocular" +828, 9, 42, 226, 225, 233, 1199, 1207, "pressure" +828, 9, 43, 227, 234, 235, 1208, 1209, "(" +828, 9, 44, 228, 236, 239, 1210, 1213, "IOP" +828, 9, 45, 229, 240, 241, 1214, 1215, ")" +828, 9, 46, 230, 242, 247, 1216, 1221, "after" +828, 9, 47, 231, 248, 255, 1222, 1229, "washout" +828, 9, 48, 232, 256, 258, 1230, 1232, "of" +828, 9, 49, 233, 259, 266, 1233, 1240, "between" +828, 9, 50, 234, 267, 269, 1241, 1243, "22" +828, 9, 51, 235, 270, 273, 1244, 1247, "and" +828, 9, 52, 236, 274, 276, 1248, 1250, "34" +828, 9, 53, 237, 277, 279, 1251, 1253, "mm" +828, 9, 54, 238, 280, 282, 1254, 1256, "Hg" +828, 9, 55, 239, 283, 287, 1257, 1261, "were" +828, 9, 56, 240, 288, 298, 1262, 1272, "randomized" +828, 9, 57, 241, 299, 301, 1273, 1275, "to" +828, 9, 58, 242, 302, 309, 1276, 1283, "receive" +828, 9, 59, 243, 310, 316, 1284, 1290, "either" +828, 9, 60, 244, 317, 328, 1291, 1302, "brimonidine" +828, 9, 61, 245, 329, 331, 1303, 1305, "or" +828, 9, 62, 246, 332, 343, 1306, 1317, "latanoprost" +828, 9, 63, 247, 344, 345, 1318, 1319, "." +828, 10, 1, 248, 0, 8, 1320, 1328, "Patients" +828, 10, 2, 249, 9, 12, 1329, 1332, "who" +828, 10, 3, 250, 13, 16, 1333, 1336, "had" +828, 10, 4, 251, 17, 25, 1337, 1345, "received" +828, 10, 5, 252, 26, 34, 1346, 1354, "previous" +828, 10, 6, 253, 35, 44, 1355, 1364, "treatment" +828, 10, 7, 254, 45, 49, 1365, 1369, "with" +828, 10, 8, 255, 50, 56, 1370, 1376, "either" +828, 10, 9, 256, 57, 62, 1377, 1382, "study" +828, 10, 10, 257, 63, 67, 1383, 1387, "drug" +828, 10, 11, 258, 68, 72, 1388, 1392, "were" +828, 10, 12, 259, 73, 81, 1393, 1401, "excluded" +828, 10, 13, 260, 82, 86, 1402, 1406, "from" +828, 10, 14, 261, 87, 90, 1407, 1410, "the" +828, 10, 15, 262, 91, 96, 1411, 1416, "study" +828, 10, 16, 263, 97, 98, 1417, 1418, "." +828, 11, 1, 264, 0, 3, 1419, 1422, "The" +828, 11, 2, 265, 4, 11, 1423, 1430, "primary" +828, 11, 3, 266, 12, 19, 1431, 1438, "outcome" +828, 11, 4, 267, 20, 27, 1439, 1446, "measure" +828, 11, 5, 268, 28, 31, 1447, 1450, "was" +828, 11, 6, 269, 32, 40, 1451, 1459, "response" +828, 11, 7, 270, 41, 45, 1460, 1464, "rate" +828, 11, 8, 271, 46, 47, 1465, 1466, "," +828, 11, 9, 272, 48, 55, 1467, 1474, "defined" +828, 11, 10, 273, 56, 58, 1475, 1477, "as" +828, 11, 11, 274, 59, 62, 1478, 1481, "the" +828, 11, 12, 275, 63, 73, 1482, 1492, "percentage" +828, 11, 13, 276, 74, 76, 1493, 1495, "of" +828, 11, 14, 277, 77, 85, 1496, 1504, "patients" +828, 11, 15, 278, 86, 95, 1505, 1514, "achieving" +828, 11, 16, 279, 96, 97, 1515, 1516, ">" +828, 11, 17, 280, 98, 100, 1517, 1519, "or" +828, 11, 18, 281, 101, 102, 1520, 1521, "=" +828, 11, 19, 282, 103, 105, 1522, 1524, "20" +828, 11, 20, 283, 106, 107, 1525, 1526, "%" +828, 11, 21, 284, 108, 117, 1527, 1536, "reduction" +828, 11, 22, 285, 118, 120, 1537, 1539, "in" +828, 11, 23, 286, 121, 124, 1540, 1543, "IOP" +828, 11, 24, 287, 125, 129, 1544, 1548, "from" +828, 11, 25, 288, 130, 138, 1549, 1557, "baseline" +828, 11, 26, 289, 139, 141, 1558, 1560, "to" +828, 11, 27, 290, 142, 147, 1561, 1566, "month" +828, 11, 28, 291, 148, 149, 1567, 1568, "3" +828, 11, 29, 292, 150, 151, 1569, 1570, "." +828, 12, 1, 293, 0, 9, 1571, 1580, "Secondary" +828, 12, 2, 294, 10, 17, 1581, 1588, "outcome" +828, 12, 3, 295, 18, 26, 1589, 1597, "measures" +828, 12, 4, 296, 27, 31, 1598, 1602, "were" +828, 12, 5, 297, 32, 36, 1603, 1607, "mean" +828, 12, 6, 298, 37, 40, 1608, 1611, "IOP" +828, 12, 7, 299, 41, 50, 1612, 1621, "reduction" +828, 12, 8, 300, 51, 55, 1622, 1626, "from" +828, 12, 9, 301, 56, 64, 1627, 1635, "baseline" +828, 12, 10, 302, 65, 67, 1636, 1638, "to" +828, 12, 11, 303, 68, 73, 1639, 1644, "month" +828, 12, 12, 304, 74, 75, 1645, 1646, "3" +828, 12, 13, 305, 76, 79, 1647, 1650, "and" +828, 12, 14, 306, 80, 88, 1651, 1659, "clinical" +828, 12, 15, 307, 89, 96, 1660, 1667, "success" +828, 12, 16, 308, 97, 98, 1668, 1669, "," +828, 12, 17, 309, 99, 106, 1670, 1677, "defined" +828, 12, 18, 310, 107, 109, 1678, 1680, "as" +828, 12, 19, 311, 110, 113, 1681, 1684, "the" +828, 12, 20, 312, 114, 126, 1685, 1697, "investigator" +828, 12, 21, 313, 127, 128, 1698, 1699, "'" +828, 12, 22, 314, 129, 130, 1700, 1701, "s" +828, 12, 23, 315, 131, 145, 1702, 1716, "recommendation" +828, 12, 24, 316, 146, 150, 1717, 1721, "that" +828, 12, 25, 317, 151, 154, 1722, 1725, "the" +828, 12, 26, 318, 155, 162, 1726, 1733, "patient" +828, 12, 27, 319, 163, 171, 1734, 1742, "continue" +828, 12, 28, 320, 172, 177, 1743, 1748, "using" +828, 12, 29, 321, 178, 181, 1749, 1752, "the" +828, 12, 30, 322, 182, 190, 1753, 1761, "assigned" +828, 12, 31, 323, 191, 196, 1762, 1767, "study" +828, 12, 32, 324, 197, 207, 1768, 1778, "medication" +828, 12, 33, 325, 208, 209, 1779, 1780, "." +828, 13, 1, 326, 0, 7, 1781, 1788, "RESULTS" +828, 13, 2, 327, 8, 9, 1789, 1790, ":" +828, 13, 3, 328, 10, 11, 1791, 1792, "A" +828, 13, 4, 329, 12, 17, 1793, 1798, "total" +828, 13, 5, 330, 18, 20, 1799, 1801, "of" +828, 13, 6, 331, 21, 24, 1802, 1805, "127" +828, 13, 7, 332, 25, 33, 1806, 1814, "patients" +828, 13, 8, 333, 34, 35, 1815, 1816, "(" +828, 13, 9, 334, 36, 38, 1817, 1819, "55" +828, 13, 10, 335, 39, 48, 1820, 1829, "treatment" +828, 13, 11, 336, 49, 54, 1830, 1835, "naive" +828, 13, 12, 337, 55, 56, 1836, 1837, ")" +828, 13, 13, 338, 57, 61, 1838, 1842, "were" +828, 13, 14, 339, 62, 70, 1843, 1851, "enrolled" +828, 13, 15, 340, 71, 72, 1852, 1853, "," +828, 13, 16, 341, 73, 75, 1854, 1856, "66" +828, 13, 17, 342, 76, 78, 1857, 1859, "in" +828, 13, 18, 343, 79, 82, 1860, 1863, "the" +828, 13, 19, 344, 83, 94, 1864, 1875, "brimonidine" +828, 13, 20, 345, 95, 100, 1876, 1881, "group" +828, 13, 21, 346, 101, 104, 1882, 1885, "and" +828, 13, 22, 347, 105, 107, 1886, 1888, "61" +828, 13, 23, 348, 108, 110, 1889, 1891, "in" +828, 13, 24, 349, 111, 114, 1892, 1895, "the" +828, 13, 25, 350, 115, 126, 1896, 1907, "latanoprost" +828, 13, 26, 351, 127, 132, 1908, 1913, "group" +828, 13, 27, 352, 133, 134, 1914, 1915, "." +828, 14, 1, 353, 0, 5, 1916, 1921, "After" +828, 14, 2, 354, 6, 7, 1922, 1923, "3" +828, 14, 3, 355, 8, 14, 1924, 1930, "months" +828, 14, 4, 356, 15, 17, 1931, 1933, "of" +828, 14, 5, 357, 18, 27, 1934, 1943, "treatment" +828, 14, 6, 358, 28, 29, 1944, 1945, "," +828, 14, 7, 359, 30, 32, 1946, 1948, "80" +828, 14, 8, 360, 33, 34, 1949, 1950, "%" +828, 14, 9, 361, 35, 37, 1951, 1953, "of" +828, 14, 10, 362, 38, 46, 1954, 1962, "patients" +828, 14, 11, 363, 47, 49, 1963, 1965, "in" +828, 14, 12, 364, 50, 53, 1966, 1969, "the" +828, 14, 13, 365, 54, 65, 1970, 1981, "brimonidine" +828, 14, 14, 366, 66, 71, 1982, 1987, "group" +828, 14, 15, 367, 72, 75, 1988, 1991, "and" +828, 14, 16, 368, 76, 78, 1992, 1994, "74" +828, 14, 17, 369, 79, 80, 1995, 1996, "%" +828, 14, 18, 370, 81, 83, 1997, 1999, "of" +828, 14, 19, 371, 84, 92, 2000, 2008, "patients" +828, 14, 20, 372, 93, 95, 2009, 2011, "in" +828, 14, 21, 373, 96, 99, 2012, 2015, "the" +828, 14, 22, 374, 100, 111, 2016, 2027, "latanoprost" +828, 14, 23, 375, 112, 117, 2028, 2033, "group" +828, 14, 24, 376, 118, 121, 2034, 2037, "had" +828, 14, 25, 377, 122, 130, 2038, 2046, "achieved" +828, 14, 26, 378, 131, 132, 2047, 2048, ">" +828, 14, 27, 379, 133, 135, 2049, 2051, "or" +828, 14, 28, 380, 136, 137, 2052, 2053, "=" +828, 14, 29, 381, 138, 140, 2054, 2056, "20" +828, 14, 30, 382, 141, 142, 2057, 2058, "%" +828, 14, 31, 383, 143, 152, 2059, 2068, "reduction" +828, 14, 32, 384, 153, 155, 2069, 2071, "in" +828, 14, 33, 385, 156, 159, 2072, 2075, "IOP" +828, 14, 34, 386, 160, 164, 2076, 2080, "from" +828, 14, 35, 387, 165, 173, 2081, 2089, "baseline" +828, 14, 36, 388, 174, 175, 2090, 2091, "." +828, 15, 1, 389, 0, 3, 2092, 2095, "The" +828, 15, 2, 390, 4, 8, 2096, 2100, "mean" +828, 15, 3, 391, 9, 18, 2101, 2110, "reduction" +828, 15, 4, 392, 19, 21, 2111, 2113, "in" +828, 15, 5, 393, 22, 25, 2114, 2117, "IOP" +828, 15, 6, 394, 26, 30, 2118, 2122, "from" +828, 15, 7, 395, 31, 39, 2123, 2131, "baseline" +828, 15, 8, 396, 40, 42, 2132, 2134, "at" +828, 15, 9, 397, 43, 48, 2135, 2140, "month" +828, 15, 10, 398, 49, 50, 2141, 2142, "3" +828, 15, 11, 399, 51, 54, 2143, 2146, "was" +828, 15, 12, 400, 55, 56, 2147, 2148, "6" +828, 15, 13, 401, 57, 58, 2149, 2150, "." +828, 15, 14, 402, 59, 60, 2151, 2152, "8" +828, 15, 15, 403, 61, 63, 2153, 2155, "mm" +828, 15, 16, 404, 64, 66, 2156, 2158, "Hg" +828, 15, 17, 405, 67, 71, 2159, 2163, "with" +828, 15, 18, 406, 72, 83, 2164, 2175, "brimonidine" +828, 15, 19, 407, 84, 87, 2176, 2179, "and" +828, 15, 20, 408, 88, 89, 2180, 2181, "6" +828, 15, 21, 409, 90, 91, 2182, 2183, "." +828, 15, 22, 410, 92, 93, 2184, 2185, "5" +828, 15, 23, 411, 94, 96, 2186, 2188, "mm" +828, 15, 24, 412, 97, 99, 2189, 2191, "Hg" +828, 15, 25, 413, 100, 104, 2192, 2196, "with" +828, 15, 26, 414, 105, 116, 2197, 2208, "latanoprost" +828, 15, 27, 415, 117, 118, 2209, 2210, "(" +828, 15, 28, 416, 119, 121, 2211, 2213, "27" +828, 15, 29, 417, 122, 123, 2214, 2215, "." +828, 15, 30, 418, 124, 125, 2216, 2217, "8" +828, 15, 31, 419, 126, 127, 2218, 2219, "%" +828, 15, 32, 420, 128, 130, 2220, 2222, "vs" +828, 15, 33, 421, 131, 133, 2223, 2225, "27" +828, 15, 34, 422, 134, 135, 2226, 2227, "." +828, 15, 35, 423, 136, 137, 2228, 2229, "0" +828, 15, 36, 424, 138, 139, 2230, 2231, "%" +828, 15, 37, 425, 140, 141, 2232, 2233, "," +828, 15, 38, 426, 142, 154, 2234, 2246, "respectively" +828, 15, 39, 427, 155, 156, 2247, 2248, ")" +828, 15, 40, 428, 157, 158, 2249, 2250, "." +828, 16, 1, 429, 0, 5, 2251, 2256, "Among" +828, 16, 2, 430, 6, 15, 2257, 2266, "treatment" +828, 16, 3, 431, 16, 17, 2267, 2268, "-" +828, 16, 4, 432, 18, 23, 2269, 2274, "naive" +828, 16, 5, 433, 24, 32, 2275, 2283, "patients" +828, 16, 6, 434, 33, 34, 2284, 2285, "," +828, 16, 7, 435, 35, 36, 2286, 2287, "a" +828, 16, 8, 436, 37, 50, 2288, 2301, "significantly" +828, 16, 9, 437, 51, 57, 2302, 2308, "higher" +828, 16, 10, 438, 58, 68, 2309, 2319, "percentage" +828, 16, 11, 439, 69, 71, 2320, 2322, "of" +828, 16, 12, 440, 72, 83, 2323, 2334, "brimonidine" +828, 16, 13, 441, 84, 85, 2335, 2336, "-" +828, 16, 14, 442, 86, 93, 2337, 2344, "treated" +828, 16, 15, 443, 94, 102, 2345, 2353, "patients" +828, 16, 16, 444, 103, 111, 2354, 2362, "achieved" +828, 16, 17, 445, 112, 113, 2363, 2364, ">" +828, 16, 18, 446, 114, 116, 2365, 2367, "or" +828, 16, 19, 447, 117, 118, 2368, 2369, "=" +828, 16, 20, 448, 119, 121, 2370, 2372, "20" +828, 16, 21, 449, 122, 123, 2373, 2374, "%" +828, 16, 22, 450, 124, 132, 2375, 2383, "decrease" +828, 16, 23, 451, 133, 135, 2384, 2386, "in" +828, 16, 24, 452, 136, 139, 2387, 2390, "IOP" +828, 16, 25, 453, 140, 148, 2391, 2399, "compared" +828, 16, 26, 454, 149, 153, 2400, 2404, "with" +828, 16, 27, 455, 154, 165, 2405, 2416, "latanoprost" +828, 16, 28, 456, 166, 167, 2417, 2418, "-" +828, 16, 29, 457, 168, 175, 2419, 2426, "treated" +828, 16, 30, 458, 176, 184, 2427, 2435, "patients" +828, 16, 31, 459, 185, 186, 2436, 2437, "(" +828, 16, 32, 460, 187, 189, 2438, 2440, "88" +828, 16, 33, 461, 190, 191, 2441, 2442, "%" +828, 16, 34, 462, 192, 194, 2443, 2445, "vs" +828, 16, 35, 463, 195, 197, 2446, 2448, "59" +828, 16, 36, 464, 198, 199, 2449, 2450, "%" +828, 16, 37, 465, 200, 201, 2451, 2452, "," +828, 16, 38, 466, 202, 214, 2453, 2465, "respectively" +828, 16, 39, 467, 215, 216, 2466, 2467, ";" +828, 16, 40, 468, 217, 218, 2468, 2469, "P" +828, 16, 41, 469, 219, 220, 2470, 2471, "=" +828, 16, 42, 470, 221, 222, 2472, 2473, "0" +828, 16, 43, 471, 223, 224, 2474, 2475, "." +828, 16, 44, 472, 225, 227, 2476, 2478, "01" +828, 16, 45, 473, 228, 229, 2479, 2480, ")" +828, 16, 46, 474, 230, 231, 2481, 2482, "." +828, 17, 1, 475, 0, 2, 2483, 2485, "In" +828, 17, 2, 476, 3, 13, 2486, 2496, "previously" +828, 17, 3, 477, 14, 21, 2497, 2504, "treated" +828, 17, 4, 478, 22, 30, 2505, 2513, "patients" +828, 17, 5, 479, 31, 32, 2514, 2515, "," +828, 17, 6, 480, 33, 34, 2516, 2517, "a" +828, 17, 7, 481, 35, 41, 2518, 2524, "higher" +828, 17, 8, 482, 42, 52, 2525, 2535, "percentage" +828, 17, 9, 483, 53, 55, 2536, 2538, "of" +828, 17, 10, 484, 56, 59, 2539, 2542, "the" +828, 17, 11, 485, 60, 71, 2543, 2554, "latanoprost" +828, 17, 12, 486, 72, 77, 2555, 2560, "group" +828, 17, 13, 487, 78, 86, 2561, 2569, "achieved" +828, 17, 14, 488, 87, 88, 2570, 2571, ">" +828, 17, 15, 489, 89, 91, 2572, 2574, "or" +828, 17, 16, 490, 92, 93, 2575, 2576, "=" +828, 17, 17, 491, 94, 96, 2577, 2579, "20" +828, 17, 18, 492, 97, 98, 2580, 2581, "%" +828, 17, 19, 493, 99, 108, 2582, 2591, "reduction" +828, 17, 20, 494, 109, 111, 2592, 2594, "in" +828, 17, 21, 495, 112, 115, 2595, 2598, "IOP" +828, 17, 22, 496, 116, 124, 2599, 2607, "compared" +828, 17, 23, 497, 125, 129, 2608, 2612, "with" +828, 17, 24, 498, 130, 133, 2613, 2616, "the" +828, 17, 25, 499, 134, 145, 2617, 2628, "brimonidine" +828, 17, 26, 500, 146, 151, 2629, 2634, "group" +828, 17, 27, 501, 152, 153, 2635, 2636, "(" +828, 17, 28, 502, 154, 156, 2637, 2639, "88" +828, 17, 29, 503, 157, 158, 2640, 2641, "%" +828, 17, 30, 504, 159, 161, 2642, 2644, "vs" +828, 17, 31, 505, 162, 164, 2645, 2647, "74" +828, 17, 32, 506, 165, 166, 2648, 2649, "%" +828, 17, 33, 507, 167, 168, 2650, 2651, "," +828, 17, 34, 508, 169, 181, 2652, 2664, "respectively" +828, 17, 35, 509, 182, 183, 2665, 2666, ")" +828, 17, 36, 510, 184, 185, 2667, 2668, ";" +828, 17, 37, 511, 186, 193, 2669, 2676, "however" +828, 17, 38, 512, 194, 195, 2677, 2678, "," +828, 17, 39, 513, 196, 199, 2679, 2682, "the" +828, 17, 40, 514, 200, 210, 2683, 2693, "difference" +828, 17, 41, 515, 211, 214, 2694, 2697, "was" +828, 17, 42, 516, 215, 218, 2698, 2701, "not" +828, 17, 43, 517, 219, 232, 2702, 2715, "statistically" +828, 17, 44, 518, 233, 244, 2716, 2727, "significant" +828, 17, 45, 519, 245, 246, 2728, 2729, "." +828, 18, 1, 520, 0, 13, 2730, 2743, "Significantly" +828, 18, 2, 521, 14, 18, 2744, 2748, "more" +828, 18, 3, 522, 19, 27, 2749, 2757, "patients" +828, 18, 4, 523, 28, 30, 2758, 2760, "in" +828, 18, 5, 524, 31, 34, 2761, 2764, "the" +828, 18, 6, 525, 35, 46, 2765, 2776, "brimonidine" +828, 18, 7, 526, 47, 52, 2777, 2782, "group" +828, 18, 8, 527, 53, 61, 2783, 2791, "achieved" +828, 18, 9, 528, 62, 70, 2792, 2800, "clinical" +828, 18, 10, 529, 71, 78, 2801, 2808, "success" +828, 18, 11, 530, 79, 81, 2809, 2811, "at" +828, 18, 12, 531, 82, 87, 2812, 2817, "month" +828, 18, 13, 532, 88, 89, 2818, 2819, "3" +828, 18, 14, 533, 90, 98, 2820, 2828, "compared" +828, 18, 15, 534, 99, 103, 2829, 2833, "with" +828, 18, 16, 535, 104, 112, 2834, 2842, "patients" +828, 18, 17, 536, 113, 115, 2843, 2845, "in" +828, 18, 18, 537, 116, 119, 2846, 2849, "the" +828, 18, 19, 538, 120, 131, 2850, 2861, "latanoprost" +828, 18, 20, 539, 132, 137, 2862, 2867, "group" +828, 18, 21, 540, 138, 139, 2868, 2869, "(" +828, 18, 22, 541, 140, 142, 2870, 2872, "91" +828, 18, 23, 542, 143, 144, 2873, 2874, "%" +828, 18, 24, 543, 145, 147, 2875, 2877, "vs" +828, 18, 25, 544, 148, 150, 2878, 2880, "74" +828, 18, 26, 545, 151, 152, 2881, 2882, "%" +828, 18, 27, 546, 153, 154, 2883, 2884, ";" +828, 18, 28, 547, 155, 156, 2885, 2886, "P" +828, 18, 29, 548, 157, 158, 2887, 2888, "=" +828, 18, 30, 549, 159, 160, 2889, 2890, "0" +828, 18, 31, 550, 161, 162, 2891, 2892, "." +828, 18, 32, 551, 163, 165, 2893, 2895, "01" +828, 18, 33, 552, 166, 167, 2896, 2897, ")" +828, 18, 34, 553, 168, 169, 2898, 2899, "." +828, 19, 1, 554, 0, 11, 2900, 2911, "CONCLUSIONS" +828, 19, 2, 555, 12, 13, 2912, 2913, ":" +828, 19, 3, 556, 14, 16, 2914, 2916, "At" +828, 19, 4, 557, 17, 21, 2917, 2921, "peak" +828, 19, 5, 558, 22, 28, 2922, 2928, "effect" +828, 19, 6, 559, 29, 30, 2929, 2930, "," +828, 19, 7, 560, 31, 42, 2931, 2942, "brimonidine" +828, 19, 8, 561, 43, 48, 2943, 2948, "twice" +828, 19, 9, 562, 49, 54, 2949, 2954, "daily" +828, 19, 10, 563, 55, 58, 2955, 2958, "was" +828, 19, 11, 564, 59, 61, 2959, 2961, "as" +828, 19, 12, 565, 62, 71, 2962, 2971, "effective" +828, 19, 13, 566, 72, 74, 2972, 2974, "as" +828, 19, 14, 567, 75, 86, 2975, 2986, "latanoprost" +828, 19, 15, 568, 87, 91, 2987, 2991, "once" +828, 19, 16, 569, 92, 97, 2992, 2997, "daily" +828, 19, 17, 570, 98, 100, 2998, 3000, "in" +828, 19, 18, 571, 101, 109, 3001, 3009, "lowering" +828, 19, 19, 572, 110, 113, 3010, 3013, "IOP" +828, 19, 20, 573, 114, 115, 3014, 3015, "." +828, 20, 1, 574, 0, 2, 3016, 3018, "In" +828, 20, 2, 575, 3, 12, 3019, 3028, "treatment" +828, 20, 3, 576, 13, 14, 3029, 3030, "-" +828, 20, 4, 577, 15, 20, 3031, 3036, "naive" +828, 20, 5, 578, 21, 29, 3037, 3045, "patients" +828, 20, 6, 579, 30, 31, 3046, 3047, "," +828, 20, 7, 580, 32, 43, 3048, 3059, "latanoprost" +828, 20, 8, 581, 44, 47, 3060, 3063, "was" +828, 20, 9, 582, 48, 58, 3064, 3074, "associated" +828, 20, 10, 583, 59, 63, 3075, 3079, "with" +828, 20, 11, 584, 64, 65, 3080, 3081, "a" +828, 20, 12, 585, 66, 79, 3082, 3095, "significantly" +828, 20, 13, 586, 80, 86, 3096, 3102, "higher" +828, 20, 14, 587, 87, 91, 3103, 3107, "rate" +828, 20, 15, 588, 92, 94, 3108, 3110, "of" +828, 20, 16, 589, 95, 106, 3111, 3122, "nonresponse" +828, 20, 17, 590, 107, 112, 3123, 3128, "after" +828, 20, 18, 591, 113, 114, 3129, 3130, "3" +828, 20, 19, 592, 115, 121, 3131, 3137, "months" +828, 20, 20, 593, 122, 124, 3138, 3140, "of" +828, 20, 21, 594, 125, 134, 3141, 3150, "treatment" +828, 20, 22, 595, 135, 143, 3151, 3159, "compared" +828, 20, 23, 596, 144, 148, 3160, 3164, "with" +828, 20, 24, 597, 149, 160, 3165, 3176, "brimonidine" +828, 20, 25, 598, 161, 162, 3177, 3178, "." +828, 21, 1, 599, 0, 4, 3179, 3183, "This" +828, 21, 2, 600, 5, 13, 3184, 3192, "suggests" +828, 21, 3, 601, 14, 18, 3193, 3197, "that" +828, 21, 4, 602, 19, 30, 3198, 3209, "brimonidine" +828, 21, 5, 603, 31, 34, 3210, 3213, "may" +828, 21, 6, 604, 35, 37, 3214, 3216, "be" +828, 21, 7, 605, 38, 41, 3217, 3220, "the" +828, 21, 8, 606, 42, 46, 3221, 3225, "more" +828, 21, 9, 607, 47, 55, 3226, 3234, "reliable" +828, 21, 10, 608, 56, 62, 3235, 3241, "choice" +828, 21, 11, 609, 63, 66, 3242, 3245, "for" +828, 21, 12, 610, 67, 72, 3246, 3251, "first" +828, 21, 13, 611, 73, 74, 3252, 3253, "-" +828, 21, 14, 612, 75, 79, 3254, 3258, "line" +828, 21, 15, 613, 80, 87, 3259, 3266, "therapy" +828, 21, 16, 614, 88, 90, 3267, 3269, "of" +828, 21, 17, 615, 91, 96, 3270, 3275, "newly" +828, 21, 18, 616, 97, 106, 3276, 3285, "diagnosed" +828, 21, 19, 617, 107, 111, 3286, 3290, "open" +828, 21, 20, 618, 112, 113, 3291, 3292, "-" +828, 21, 21, 619, 114, 119, 3293, 3298, "angle" +828, 21, 22, 620, 120, 128, 3299, 3307, "glaucoma" +828, 21, 23, 621, 129, 131, 3308, 3310, "or" +828, 21, 24, 622, 132, 138, 3311, 3317, "ocular" +828, 21, 25, 623, 139, 151, 3318, 3330, "hypertension" +828, 21, 26, 624, 152, 153, 3331, 3332, "." +828, 22, 1, 625, 0, 2, 3333, 3335, "In" +828, 22, 2, 626, 3, 13, 3336, 3346, "previously" +828, 22, 3, 627, 14, 21, 3347, 3354, "treated" +828, 22, 4, 628, 22, 30, 3355, 3363, "patients" +828, 22, 5, 629, 31, 32, 3364, 3365, "," +828, 22, 6, 630, 33, 40, 3366, 3373, "however" +828, 22, 7, 631, 41, 42, 3374, 3375, "," +828, 22, 8, 632, 43, 54, 3376, 3387, "latanoprost" +828, 22, 9, 633, 55, 63, 3388, 3396, "provided" +828, 22, 10, 634, 64, 71, 3397, 3404, "greater" +828, 22, 11, 635, 72, 76, 3405, 3409, "mean" +828, 22, 12, 636, 77, 80, 3410, 3413, "IOP" +828, 22, 13, 637, 81, 90, 3414, 3423, "reduction" +828, 22, 14, 638, 91, 95, 3424, 3428, "than" +828, 22, 15, 639, 96, 99, 3429, 3432, "did" +828, 22, 16, 640, 100, 111, 3433, 3444, "brimonidine" +828, 22, 17, 641, 112, 113, 3445, 3446, "." +828, 23, 1, 642, 0, 13, 3447, 3460, "Significantly" +828, 23, 2, 643, 14, 18, 3461, 3465, "more" +828, 23, 3, 644, 19, 27, 3466, 3474, "patients" +828, 23, 4, 645, 28, 36, 3475, 3483, "achieved" +828, 23, 5, 646, 37, 45, 3484, 3492, "clinical" +828, 23, 6, 647, 46, 53, 3493, 3500, "success" +828, 23, 7, 648, 54, 58, 3501, 3505, "with" +828, 23, 8, 649, 59, 70, 3506, 3517, "brimonidine" +828, 23, 9, 650, 71, 82, 3518, 3529, "monotherapy" +828, 23, 10, 651, 83, 87, 3530, 3534, "than" +828, 23, 11, 652, 88, 92, 3535, 3539, "with" +828, 23, 12, 653, 93, 104, 3540, 3551, "latanoprost" +828, 23, 13, 654, 105, 116, 3552, 3563, "monotherapy" +828, 23, 14, 655, 117, 118, 3564, 3565, "." +828, 24, 1, 656, 0, 4, 3566, 3570, "PMID" +828, 24, 2, 657, 5, 6, 3571, 3572, ":" +828, 24, 3, 658, 7, 15, 3573, 3581, "11813932" +828, 24, 4, 659, 16, 17, 3582, 3583, "[" +828, 24, 5, 660, 18, 25, 3584, 3591, "Indexed" +828, 24, 6, 661, 26, 29, 3592, 3595, "for" +828, 24, 7, 662, 30, 37, 3596, 3603, "MEDLINE" +828, 24, 8, 663, 38, 39, 3604, 3605, "]" diff --git a/data/gl 11813932_admin.annodb b/data/gl 11813932_admin.annodb new file mode 100644 index 0000000..275d0c5 --- /dev/null +++ b/data/gl 11813932_admin.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2001", "", " \"2001\"." +2, Title, 47, 273, "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial .", "", " \"A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial .\"." +52, Brimonidine, 96, 107, "brimonidine", "", +53, Latanoprost, 112, 123, "latanoprost", "", +54, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", " ." +55, OcularHypertension, 164, 183, "ocular hypertension", "", " ." +56, Duration, 188, 201, "three - month", "", " \"three - month\"." +57, Multicenter, 204, 215, "multicenter", "", " ." +58, Randomized, 218, 228, "randomized", "", " ." +128, DoubleBlind, 231, 246, "double - masked", "", " ." +129, Parallel, 249, 257, "parallel", "", " ." +3, Author, 274, 284, "DuBiner HB", "", " \"DuBiner HB\"." +4, Author, 293, 299, "Mroz M", "", " \"Mroz M\"." +5, Author, 302, 312, "Shapiro AM", "", " \"Shapiro AM\"." +6, Author, 315, 323, "Dirks MS", "", " \"Dirks MS\"." +135, Brimonidine, 326, 337, "Brimonidine", "", +136, Latanoprost, 343, 354, "Latanoprost", "", +8, USA, 442, 445, "USA", "", " ." +61, Brimonidine, 494, 505, "brimonidine", "", +62, Latanoprost, 509, 520, "latanoprost", "", +63, OpenAngleGlaucoma, 554, 575, "open - angle glaucoma", "", +64, OcularHypertension, 579, 598, "ocular hypertension", "", +9, ObjectiveDescription, 754, 973, "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension .", "", " \"This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension .\"." +65, Brimonidine, 816, 827, "brimonidine", "", " ." +10, DoseValue, 828, 833, "0 . 2", "", " \"0 . 2\"." +11, Percentage, 834, 835, "%", "", " ." +12, Frequency, 836, 847, "twice daily", "", " \"twice daily\"." +66, Latanoprost, 862, 873, "latanoprost", "", " . ." +13, DoseValue, 874, 881, "0 . 005", "", " \"0 . 005\"." +14, Percentage, 882, 883, "%", "", " ." +15, Frequency, 884, 894, "once daily", "", " \"once daily\"." +67, OpenAngleGlaucoma, 927, 948, "open - angle glaucoma", "", +68, OcularHypertension, 952, 971, "ocular hypertension", "", +69, Duration, 992, 1001, "3 - month", "", +70, Multicenter, 1004, 1015, "multicenter", "", +71, DoubleBlind, 1018, 1033, "double - masked", "", +174, Parallel, 1036, 1044, "parallel", "", +175, Precondition, 1073, 1256, "treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg", "", " \"treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg\"." +73, OpenAngleGlaucoma, 1128, 1149, "open - angle glaucoma", "", +74, OcularHypertension, 1153, 1172, "ocular hypertension", "", +18, IOP, 1187, 1207, "intraocular pressure", "", +19, IOP, 1210, 1213, "IOP", "", +49, mmHg, 1251, 1256, "mm Hg", "", " ." +76, Randomized, 1262, 1272, "randomized", "", +77, Brimonidine, 1291, 1302, "brimonidine", "", +78, Latanoprost, 1306, 1317, "latanoprost", "", +93009, IOP_target, 1515, 1543, "> or = 20 % reduction in IOP", "", " ." +225, TimePoint, 1549, 1557, "baseline", "", +80, TimePoint, 1561, 1568, "month 3", "", +184, Mean, 1603, 1607, "mean", "", " . ." +21, IOP, 1608, 1611, "IOP", "", +81, TimePoint, 1639, 1646, "month 3", "", +22, NumberPatientsCT, 1802, 1805, "127", "", " \"127\"." +23, NumberPatientsArm, 1854, 1856, "66", "", " \"66\"." +82, Brimonidine, 1864, 1875, "brimonidine", "", +24, NumberPatientsArm, 1886, 1888, "61", "", " \"61\"." +83, Latanoprost, 1896, 1907, "latanoprost", "", +89, TimePoint, 1922, 1930, "3 months", "", " \"3 months\". \"3 months\"." +25, PercentageAffected, 1946, 1948, "80", "", " \"80\"." +84, Brimonidine, 1970, 1981, "brimonidine", "", +26, PercentageAffected, 1992, 1994, "74", "", " \"74\"." +85, Latanoprost, 2016, 2027, "latanoprost", "", +93012, IOP_target, 2047, 2075, "> or = 20 % reduction in IOP", "", +87, Mean, 2096, 2100, "mean", "", +27, IOP, 2114, 2117, "IOP", "", +88, TimePoint, 2135, 2142, "month 3", "", " \"month 3\". \"month 3\"." +28, Reduction, 2147, 2152, "6 . 8", "", " \"6 . 8\"." +50, mmHg, 2153, 2158, "mm Hg", "", " ." +90, Brimonidine, 2164, 2175, "brimonidine", "", +29, Reduction, 2180, 2185, "6 . 5", "", " \"6 . 5\"." +51, mmHg, 2186, 2191, "mm Hg", "", +91, Latanoprost, 2197, 2208, "latanoprost", "", +30, RelativeReduction, 2211, 2217, "27 . 8", "", " \"27 . 8\"." +31, RelativeReduction, 2223, 2229, "27 . 0", "", " \"27 . 0\"." +198, SubGroupDescription, 2257, 2283, "treatment - naive patients", "", " \"treatment - naive patients\". \"treatment - naive patients\"." +92, Brimonidine, 2323, 2334, "brimonidine", "", +93011, IOP_target, 2363, 2390, "> or = 20 % decrease in IOP", "", +94, Latanoprost, 2405, 2416, "latanoprost", "", +200, PercentageAffected, 2438, 2440, "88", "", " \"88\"." +201, PercentageAffected, 2446, 2448, "59", "", +202, PvalueDiff, 2468, 2478, "P = 0 . 01", "", +35, SubGroupDescription, 2486, 2504, "previously treated", "", " \"previously treated\". \"previously treated\"." +95, Latanoprost, 2543, 2554, "latanoprost", "", +93010, IOP_target, 2570, 2598, "> or = 20 % reduction in IOP", "", +97, Brimonidine, 2617, 2628, "brimonidine", "", +209, PercentageAffected, 2637, 2639, "88", "", " \"88\"." +210, PercentageAffected, 2645, 2647, "74", "", " \"74\"." +100, Brimonidine, 2765, 2776, "brimonidine", "", +40989, EndPointDescription, 2792, 2808, "clinical success", "", " . ." +98, TimePoint, 2812, 2819, "month 3", "", " \"month 3\". \"month 3\"." +99, Latanoprost, 2850, 2861, "latanoprost", "", +101, PercentageAffected, 2870, 2872, "91", "", " \"91\"." +102, PercentageAffected, 2878, 2880, "74", "", " \"74\"." +206, PvalueDiff, 2885, 2895, "P = 0 . 01", "", " \"P = 0 . 01\"." +38, ConclusionComment, 2914, 3015, "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .", "", " \"At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .\"." +104, Brimonidine, 2931, 2942, "brimonidine", "", +105, Frequency, 2943, 2954, "twice daily", "", +106, Latanoprost, 2975, 2986, "latanoprost", "", +107, Frequency, 2987, 2997, "once daily", "", +108, IOP, 3010, 3013, "IOP", "", +39, ConclusionComment, 3016, 3178, "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .", "", " \"In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .\"." +109, Latanoprost, 3048, 3059, "latanoprost", "", +110, TimePoint, 3129, 3137, "3 months", "", +111, Brimonidine, 3165, 3176, "brimonidine", "", +40, ConclusionComment, 3179, 3332, "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .", "", " \"This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .\"." +112, Brimonidine, 3198, 3209, "brimonidine", "", +113, OpenAngleGlaucoma, 3286, 3307, "open - angle glaucoma", "", +114, OcularHypertension, 3311, 3330, "ocular hypertension", "", +41, ConclusionComment, 3333, 3446, "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .", "", " \"In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .\"." +115, Latanoprost, 3376, 3387, "latanoprost", "", +43, Mean, 3405, 3409, "mean", "", +44, IOP, 3410, 3413, "IOP", "", +116, Brimonidine, 3433, 3444, "brimonidine", "", +42, ConclusionComment, 3447, 3565, "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .", "", " \"Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .\"." +117, Brimonidine, 3506, 3517, "brimonidine", "", +118, Latanoprost, 3540, 3551, "latanoprost", "", +45, PMID, 3573, 3581, "11813932", "", " \"11813932\"." diff --git a/data/gl 11813932_admin.n-triples b/data/gl 11813932_admin.n-triples new file mode 100644 index 0000000..623a45b --- /dev/null +++ b/data/gl 11813932_admin.n-triples @@ -0,0 +1,175 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial ." . + "DuBiner HB" . + "2001" . + "Clin Ther ." . + "11813932" . + . + "Mroz M" . + "Shapiro AM" . + "Dirks MS" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension ." . + "127" . + "three - month" . + . + . + . + "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP ." . + . + . + . + . + . + . + . + . + "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine ." . + "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension ." . + "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine ." . + "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + . + "Endpoint-20" . + . + . + . + . + . + "Endpoint-cs" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-bri" . + "66" . + . + . + . + . + . + . + . + . + "Arm-lat" . + "61" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-bri" . + . + "twice daily" . + . + . + "Intervention-lat" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication-bri" . + . + "0 . 2" . + . + . + . + "Medication-lat" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "Outcome-bri-iop" . + . + "6 . 8" . + "27 . 8" . + "month 3" . + . + "Outcome-lat-iop" . + . + "6 . 5" . + "27 . 0" . + "month 3" . + . + "Outcome-bri-20" . + . + "80" . + "3 months" . + . + "Outcome-lat-20" . + . + "74" . + "3 months" . + . + "Outcome-bri-20-s" . + . + "88" . + "treatment - naive patients" . + . + "Outcome-lat-20-s" . + . + "treatment - naive patients" . + . + "Outcome-bri-20-s2" . + . + "74" . + "previously treated" . + . + "Outcome-lat-20-s2" . + . + "88" . + "previously treated" . + . + "Outcome-bri-cs" . + . + "91" . + "month 3" . + . + "Outcome-lat-cs" . + . + "74" . + "month 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-20-s" . + . + . + . + "DiffBetweenGroups-cs" . + "P = 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11813932_export.csv b/data/gl 11813932_export.csv new file mode 100644 index 0000000..6645316 --- /dev/null +++ b/data/gl 11813932_export.csv @@ -0,0 +1,664 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +482, 1, 1, 1, 0, 4, 0, 4, "Clin" +482, 1, 2, 2, 5, 9, 5, 9, "Ther" +482, 1, 3, 3, 10, 11, 10, 11, "." +482, 2, 1, 4, 0, 4, 12, 16, "2001" +482, 2, 2, 5, 5, 8, 17, 20, "Dec" +482, 2, 3, 6, 9, 10, 21, 22, ";" +482, 2, 4, 7, 11, 13, 23, 25, "23" +482, 2, 5, 8, 14, 15, 26, 27, "(" +482, 2, 6, 9, 16, 18, 28, 30, "12" +482, 2, 7, 10, 19, 20, 31, 32, ")" +482, 2, 8, 11, 21, 22, 33, 34, ":" +482, 2, 9, 12, 23, 27, 35, 39, "1969" +482, 2, 10, 13, 28, 29, 40, 41, "-" +482, 2, 11, 14, 30, 32, 42, 44, "83" +482, 2, 12, 15, 33, 34, 45, 46, "." +482, 3, 1, 16, 0, 1, 47, 48, "A" +482, 3, 2, 17, 2, 12, 49, 59, "comparison" +482, 3, 3, 18, 13, 15, 60, 62, "of" +482, 3, 4, 19, 16, 19, 63, 66, "the" +482, 3, 5, 20, 20, 28, 67, 75, "efficacy" +482, 3, 6, 21, 29, 32, 76, 79, "and" +482, 3, 7, 22, 33, 45, 80, 92, "tolerability" +482, 3, 8, 23, 46, 48, 93, 95, "of" +482, 3, 9, 24, 49, 60, 96, 107, "brimonidine" +482, 3, 10, 25, 61, 64, 108, 111, "and" +482, 3, 11, 26, 65, 76, 112, 123, "latanoprost" +482, 3, 12, 27, 77, 79, 124, 126, "in" +482, 3, 13, 28, 80, 86, 127, 133, "adults" +482, 3, 14, 29, 87, 91, 134, 138, "with" +482, 3, 15, 30, 92, 96, 139, 143, "open" +482, 3, 16, 31, 97, 98, 144, 145, "-" +482, 3, 17, 32, 99, 104, 146, 151, "angle" +482, 3, 18, 33, 105, 113, 152, 160, "glaucoma" +482, 3, 19, 34, 114, 116, 161, 163, "or" +482, 3, 20, 35, 117, 123, 164, 170, "ocular" +482, 3, 21, 36, 124, 136, 171, 183, "hypertension" +482, 3, 22, 37, 137, 138, 184, 185, ":" +482, 3, 23, 38, 139, 140, 186, 187, "a" +482, 3, 24, 39, 141, 146, 188, 193, "three" +482, 3, 25, 40, 147, 148, 194, 195, "-" +482, 3, 26, 41, 149, 154, 196, 201, "month" +482, 3, 27, 42, 155, 156, 202, 203, "," +482, 3, 28, 43, 157, 168, 204, 215, "multicenter" +482, 3, 29, 44, 169, 170, 216, 217, "," +482, 3, 30, 45, 171, 181, 218, 228, "randomized" +482, 3, 31, 46, 182, 183, 229, 230, "," +482, 3, 32, 47, 184, 190, 231, 237, "double" +482, 3, 33, 48, 191, 192, 238, 239, "-" +482, 3, 34, 49, 193, 199, 240, 246, "masked" +482, 3, 35, 50, 200, 201, 247, 248, "," +482, 3, 36, 51, 202, 210, 249, 257, "parallel" +482, 3, 37, 52, 211, 212, 258, 259, "-" +482, 3, 38, 53, 213, 218, 260, 265, "group" +482, 3, 39, 54, 219, 224, 266, 271, "trial" +482, 3, 40, 55, 225, 226, 272, 273, "." +482, 4, 1, 56, 0, 7, 274, 281, "DuBiner" +482, 4, 2, 57, 8, 10, 282, 284, "HB" +482, 4, 3, 58, 11, 12, 285, 286, "(" +482, 4, 4, 59, 13, 14, 287, 288, "1" +482, 4, 5, 60, 15, 16, 289, 290, ")" +482, 4, 6, 61, 17, 18, 291, 292, "," +482, 4, 7, 62, 19, 23, 293, 297, "Mroz" +482, 4, 8, 63, 24, 25, 298, 299, "M" +482, 4, 9, 64, 26, 27, 300, 301, "," +482, 4, 10, 65, 28, 35, 302, 309, "Shapiro" +482, 4, 11, 66, 36, 38, 310, 312, "AM" +482, 4, 12, 67, 39, 40, 313, 314, "," +482, 4, 13, 68, 41, 46, 315, 320, "Dirks" +482, 4, 14, 69, 47, 49, 321, 323, "MS" +482, 4, 15, 70, 50, 51, 324, 325, ";" +482, 4, 16, 71, 52, 63, 326, 337, "Brimonidine" +482, 4, 17, 72, 64, 66, 338, 340, "vs" +482, 4, 18, 73, 67, 68, 341, 342, "." +482, 4, 19, 74, 69, 80, 343, 354, "Latanoprost" +482, 4, 20, 75, 81, 86, 355, 360, "Study" +482, 4, 21, 76, 87, 92, 361, 366, "Group" +482, 4, 22, 77, 93, 94, 367, 368, "." +482, 5, 1, 78, 0, 6, 369, 375, "Author" +482, 5, 2, 79, 7, 18, 376, 387, "information" +482, 5, 3, 80, 19, 20, 388, 389, ":" +482, 5, 4, 81, 21, 22, 390, 391, "(" +482, 5, 5, 82, 23, 24, 392, 393, "1" +482, 5, 6, 83, 25, 26, 394, 395, ")" +482, 5, 7, 84, 27, 34, 396, 403, "Clayton" +482, 5, 8, 85, 35, 38, 404, 407, "Eye" +482, 5, 9, 86, 39, 45, 408, 414, "Center" +482, 5, 10, 87, 46, 47, 415, 416, "," +482, 5, 11, 88, 48, 54, 417, 423, "Morrow" +482, 5, 12, 89, 55, 56, 424, 425, "," +482, 5, 13, 90, 57, 64, 426, 433, "Georgia" +482, 5, 14, 91, 65, 70, 434, 439, "30260" +482, 5, 15, 92, 71, 72, 440, 441, "," +482, 5, 16, 93, 73, 76, 442, 445, "USA" +482, 5, 17, 94, 77, 78, 446, 447, "." +482, 6, 1, 95, 0, 10, 448, 458, "BACKGROUND" +482, 6, 2, 96, 11, 12, 459, 460, ":" +482, 6, 3, 97, 13, 17, 461, 465, "Many" +482, 6, 4, 98, 18, 28, 466, 476, "physicians" +482, 6, 5, 99, 29, 38, 477, 486, "recommend" +482, 6, 6, 100, 39, 45, 487, 493, "either" +482, 6, 7, 101, 46, 57, 494, 505, "brimonidine" +482, 6, 8, 102, 58, 60, 506, 508, "or" +482, 6, 9, 103, 61, 72, 509, 520, "latanoprost" +482, 6, 10, 104, 73, 75, 521, 523, "as" +482, 6, 11, 105, 76, 85, 524, 533, "firstline" +482, 6, 12, 106, 86, 93, 534, 541, "therapy" +482, 6, 13, 107, 94, 97, 542, 545, "for" +482, 6, 14, 108, 98, 105, 546, 553, "chronic" +482, 6, 15, 109, 106, 110, 554, 558, "open" +482, 6, 16, 110, 111, 112, 559, 560, "-" +482, 6, 17, 111, 113, 118, 561, 566, "angle" +482, 6, 18, 112, 119, 127, 567, 575, "glaucoma" +482, 6, 19, 113, 128, 130, 576, 578, "or" +482, 6, 20, 114, 131, 137, 579, 585, "ocular" +482, 6, 21, 115, 138, 150, 586, 598, "hypertension" +482, 6, 22, 116, 151, 152, 599, 600, "." +482, 7, 1, 117, 0, 7, 601, 608, "However" +482, 7, 2, 118, 8, 9, 609, 610, "," +482, 7, 3, 119, 10, 11, 611, 612, "a" +482, 7, 4, 120, 12, 18, 613, 619, "search" +482, 7, 5, 121, 19, 21, 620, 622, "of" +482, 7, 6, 122, 22, 29, 623, 630, "MEDLINE" +482, 7, 7, 123, 30, 39, 631, 640, "indicates" +482, 7, 8, 124, 40, 44, 641, 645, "that" +482, 7, 9, 125, 45, 50, 646, 651, "there" +482, 7, 10, 126, 51, 55, 652, 656, "have" +482, 7, 11, 127, 56, 60, 657, 661, "been" +482, 7, 12, 128, 61, 64, 662, 665, "few" +482, 7, 13, 129, 65, 69, 666, 670, "head" +482, 7, 14, 130, 70, 71, 671, 672, "-" +482, 7, 15, 131, 72, 74, 673, 675, "to" +482, 7, 16, 132, 75, 76, 676, 677, "-" +482, 7, 17, 133, 77, 81, 678, 682, "head" +482, 7, 18, 134, 82, 93, 683, 694, "comparisons" +482, 7, 19, 135, 94, 96, 695, 697, "of" +482, 7, 20, 136, 97, 100, 698, 701, "the" +482, 7, 21, 137, 101, 102, 702, 703, "2" +482, 7, 22, 138, 103, 116, 704, 717, "monotherapies" +482, 7, 23, 139, 117, 119, 718, 720, "in" +482, 7, 24, 140, 120, 121, 721, 722, "a" +482, 7, 25, 141, 122, 130, 723, 731, "clinical" +482, 7, 26, 142, 131, 138, 732, 739, "setting" +482, 7, 27, 143, 139, 140, 740, 741, "." +482, 8, 1, 144, 0, 9, 742, 751, "OBJECTIVE" +482, 8, 2, 145, 10, 11, 752, 753, ":" +482, 8, 3, 146, 12, 16, 754, 758, "This" +482, 8, 4, 147, 17, 22, 759, 764, "study" +482, 8, 5, 148, 23, 31, 765, 773, "compared" +482, 8, 6, 149, 32, 35, 774, 777, "the" +482, 8, 7, 150, 36, 44, 778, 786, "clinical" +482, 8, 8, 151, 45, 53, 787, 795, "efficacy" +482, 8, 9, 152, 54, 57, 796, 799, "and" +482, 8, 10, 153, 58, 70, 800, 812, "tolerability" +482, 8, 11, 154, 71, 73, 813, 815, "of" +482, 8, 12, 155, 74, 85, 816, 827, "brimonidine" +482, 8, 13, 156, 86, 87, 828, 829, "0" +482, 8, 14, 157, 88, 89, 830, 831, "." +482, 8, 15, 158, 90, 91, 832, 833, "2" +482, 8, 16, 159, 92, 93, 834, 835, "%" +482, 8, 17, 160, 94, 99, 836, 841, "twice" +482, 8, 18, 161, 100, 105, 842, 847, "daily" +482, 8, 19, 162, 106, 110, 848, 852, "with" +482, 8, 20, 163, 111, 116, 853, 858, "those" +482, 8, 21, 164, 117, 119, 859, 861, "of" +482, 8, 22, 165, 120, 131, 862, 873, "latanoprost" +482, 8, 23, 166, 132, 133, 874, 875, "0" +482, 8, 24, 167, 134, 135, 876, 877, "." +482, 8, 25, 168, 136, 139, 878, 881, "005" +482, 8, 26, 169, 140, 141, 882, 883, "%" +482, 8, 27, 170, 142, 146, 884, 888, "once" +482, 8, 28, 171, 147, 152, 889, 894, "daily" +482, 8, 29, 172, 153, 155, 895, 897, "as" +482, 8, 30, 173, 156, 167, 898, 909, "monotherapy" +482, 8, 31, 174, 168, 170, 910, 912, "in" +482, 8, 32, 175, 171, 179, 913, 921, "patients" +482, 8, 33, 176, 180, 184, 922, 926, "with" +482, 8, 34, 177, 185, 189, 927, 931, "open" +482, 8, 35, 178, 190, 191, 932, 933, "-" +482, 8, 36, 179, 192, 197, 934, 939, "angle" +482, 8, 37, 180, 198, 206, 940, 948, "glaucoma" +482, 8, 38, 181, 207, 209, 949, 951, "or" +482, 8, 39, 182, 210, 216, 952, 958, "ocular" +482, 8, 40, 183, 217, 229, 959, 971, "hypertension" +482, 8, 41, 184, 230, 231, 972, 973, "." +482, 9, 1, 185, 0, 7, 974, 981, "METHODS" +482, 9, 2, 186, 8, 9, 982, 983, ":" +482, 9, 3, 187, 10, 12, 984, 986, "In" +482, 9, 4, 188, 13, 17, 987, 991, "this" +482, 9, 5, 189, 18, 19, 992, 993, "3" +482, 9, 6, 190, 20, 21, 994, 995, "-" +482, 9, 7, 191, 22, 27, 996, 1001, "month" +482, 9, 8, 192, 28, 29, 1002, 1003, "," +482, 9, 9, 193, 30, 41, 1004, 1015, "multicenter" +482, 9, 10, 194, 42, 43, 1016, 1017, "," +482, 9, 11, 195, 44, 50, 1018, 1024, "double" +482, 9, 12, 196, 51, 52, 1025, 1026, "-" +482, 9, 13, 197, 53, 59, 1027, 1033, "masked" +482, 9, 14, 198, 60, 61, 1034, 1035, "," +482, 9, 15, 199, 62, 70, 1036, 1044, "parallel" +482, 9, 16, 200, 71, 72, 1045, 1046, "-" +482, 9, 17, 201, 73, 78, 1047, 1052, "group" +482, 9, 18, 202, 79, 80, 1053, 1054, "," +482, 9, 19, 203, 81, 82, 1055, 1056, "4" +482, 9, 20, 204, 83, 84, 1057, 1058, "-" +482, 9, 21, 205, 85, 90, 1059, 1064, "visit" +482, 9, 22, 206, 91, 96, 1065, 1070, "study" +482, 9, 23, 207, 97, 98, 1071, 1072, "," +482, 9, 24, 208, 99, 108, 1073, 1082, "treatment" +482, 9, 25, 209, 109, 110, 1083, 1084, "-" +482, 9, 26, 210, 111, 116, 1085, 1090, "naive" +482, 9, 27, 211, 117, 120, 1091, 1094, "and" +482, 9, 28, 212, 121, 131, 1095, 1105, "previously" +482, 9, 29, 213, 132, 139, 1106, 1113, "treated" +482, 9, 30, 214, 140, 148, 1114, 1122, "patients" +482, 9, 31, 215, 149, 153, 1123, 1127, "with" +482, 9, 32, 216, 154, 158, 1128, 1132, "open" +482, 9, 33, 217, 159, 160, 1133, 1134, "-" +482, 9, 34, 218, 161, 166, 1135, 1140, "angle" +482, 9, 35, 219, 167, 175, 1141, 1149, "glaucoma" +482, 9, 36, 220, 176, 178, 1150, 1152, "or" +482, 9, 37, 221, 179, 185, 1153, 1159, "ocular" +482, 9, 38, 222, 186, 198, 1160, 1172, "hypertension" +482, 9, 39, 223, 199, 202, 1173, 1176, "and" +482, 9, 40, 224, 203, 212, 1177, 1186, "bilateral" +482, 9, 41, 225, 213, 224, 1187, 1198, "intraocular" +482, 9, 42, 226, 225, 233, 1199, 1207, "pressure" +482, 9, 43, 227, 234, 235, 1208, 1209, "(" +482, 9, 44, 228, 236, 239, 1210, 1213, "IOP" +482, 9, 45, 229, 240, 241, 1214, 1215, ")" +482, 9, 46, 230, 242, 247, 1216, 1221, "after" +482, 9, 47, 231, 248, 255, 1222, 1229, "washout" +482, 9, 48, 232, 256, 258, 1230, 1232, "of" +482, 9, 49, 233, 259, 266, 1233, 1240, "between" +482, 9, 50, 234, 267, 269, 1241, 1243, "22" +482, 9, 51, 235, 270, 273, 1244, 1247, "and" +482, 9, 52, 236, 274, 276, 1248, 1250, "34" +482, 9, 53, 237, 277, 279, 1251, 1253, "mm" +482, 9, 54, 238, 280, 282, 1254, 1256, "Hg" +482, 9, 55, 239, 283, 287, 1257, 1261, "were" +482, 9, 56, 240, 288, 298, 1262, 1272, "randomized" +482, 9, 57, 241, 299, 301, 1273, 1275, "to" +482, 9, 58, 242, 302, 309, 1276, 1283, "receive" +482, 9, 59, 243, 310, 316, 1284, 1290, "either" +482, 9, 60, 244, 317, 328, 1291, 1302, "brimonidine" +482, 9, 61, 245, 329, 331, 1303, 1305, "or" +482, 9, 62, 246, 332, 343, 1306, 1317, "latanoprost" +482, 9, 63, 247, 344, 345, 1318, 1319, "." +482, 10, 1, 248, 0, 8, 1320, 1328, "Patients" +482, 10, 2, 249, 9, 12, 1329, 1332, "who" +482, 10, 3, 250, 13, 16, 1333, 1336, "had" +482, 10, 4, 251, 17, 25, 1337, 1345, "received" +482, 10, 5, 252, 26, 34, 1346, 1354, "previous" +482, 10, 6, 253, 35, 44, 1355, 1364, "treatment" +482, 10, 7, 254, 45, 49, 1365, 1369, "with" +482, 10, 8, 255, 50, 56, 1370, 1376, "either" +482, 10, 9, 256, 57, 62, 1377, 1382, "study" +482, 10, 10, 257, 63, 67, 1383, 1387, "drug" +482, 10, 11, 258, 68, 72, 1388, 1392, "were" +482, 10, 12, 259, 73, 81, 1393, 1401, "excluded" +482, 10, 13, 260, 82, 86, 1402, 1406, "from" +482, 10, 14, 261, 87, 90, 1407, 1410, "the" +482, 10, 15, 262, 91, 96, 1411, 1416, "study" +482, 10, 16, 263, 97, 98, 1417, 1418, "." +482, 11, 1, 264, 0, 3, 1419, 1422, "The" +482, 11, 2, 265, 4, 11, 1423, 1430, "primary" +482, 11, 3, 266, 12, 19, 1431, 1438, "outcome" +482, 11, 4, 267, 20, 27, 1439, 1446, "measure" +482, 11, 5, 268, 28, 31, 1447, 1450, "was" +482, 11, 6, 269, 32, 40, 1451, 1459, "response" +482, 11, 7, 270, 41, 45, 1460, 1464, "rate" +482, 11, 8, 271, 46, 47, 1465, 1466, "," +482, 11, 9, 272, 48, 55, 1467, 1474, "defined" +482, 11, 10, 273, 56, 58, 1475, 1477, "as" +482, 11, 11, 274, 59, 62, 1478, 1481, "the" +482, 11, 12, 275, 63, 73, 1482, 1492, "percentage" +482, 11, 13, 276, 74, 76, 1493, 1495, "of" +482, 11, 14, 277, 77, 85, 1496, 1504, "patients" +482, 11, 15, 278, 86, 95, 1505, 1514, "achieving" +482, 11, 16, 279, 96, 97, 1515, 1516, ">" +482, 11, 17, 280, 98, 100, 1517, 1519, "or" +482, 11, 18, 281, 101, 102, 1520, 1521, "=" +482, 11, 19, 282, 103, 105, 1522, 1524, "20" +482, 11, 20, 283, 106, 107, 1525, 1526, "%" +482, 11, 21, 284, 108, 117, 1527, 1536, "reduction" +482, 11, 22, 285, 118, 120, 1537, 1539, "in" +482, 11, 23, 286, 121, 124, 1540, 1543, "IOP" +482, 11, 24, 287, 125, 129, 1544, 1548, "from" +482, 11, 25, 288, 130, 138, 1549, 1557, "baseline" +482, 11, 26, 289, 139, 141, 1558, 1560, "to" +482, 11, 27, 290, 142, 147, 1561, 1566, "month" +482, 11, 28, 291, 148, 149, 1567, 1568, "3" +482, 11, 29, 292, 150, 151, 1569, 1570, "." +482, 12, 1, 293, 0, 9, 1571, 1580, "Secondary" +482, 12, 2, 294, 10, 17, 1581, 1588, "outcome" +482, 12, 3, 295, 18, 26, 1589, 1597, "measures" +482, 12, 4, 296, 27, 31, 1598, 1602, "were" +482, 12, 5, 297, 32, 36, 1603, 1607, "mean" +482, 12, 6, 298, 37, 40, 1608, 1611, "IOP" +482, 12, 7, 299, 41, 50, 1612, 1621, "reduction" +482, 12, 8, 300, 51, 55, 1622, 1626, "from" +482, 12, 9, 301, 56, 64, 1627, 1635, "baseline" +482, 12, 10, 302, 65, 67, 1636, 1638, "to" +482, 12, 11, 303, 68, 73, 1639, 1644, "month" +482, 12, 12, 304, 74, 75, 1645, 1646, "3" +482, 12, 13, 305, 76, 79, 1647, 1650, "and" +482, 12, 14, 306, 80, 88, 1651, 1659, "clinical" +482, 12, 15, 307, 89, 96, 1660, 1667, "success" +482, 12, 16, 308, 97, 98, 1668, 1669, "," +482, 12, 17, 309, 99, 106, 1670, 1677, "defined" +482, 12, 18, 310, 107, 109, 1678, 1680, "as" +482, 12, 19, 311, 110, 113, 1681, 1684, "the" +482, 12, 20, 312, 114, 126, 1685, 1697, "investigator" +482, 12, 21, 313, 127, 128, 1698, 1699, "'" +482, 12, 22, 314, 129, 130, 1700, 1701, "s" +482, 12, 23, 315, 131, 145, 1702, 1716, "recommendation" +482, 12, 24, 316, 146, 150, 1717, 1721, "that" +482, 12, 25, 317, 151, 154, 1722, 1725, "the" +482, 12, 26, 318, 155, 162, 1726, 1733, "patient" +482, 12, 27, 319, 163, 171, 1734, 1742, "continue" +482, 12, 28, 320, 172, 177, 1743, 1748, "using" +482, 12, 29, 321, 178, 181, 1749, 1752, "the" +482, 12, 30, 322, 182, 190, 1753, 1761, "assigned" +482, 12, 31, 323, 191, 196, 1762, 1767, "study" +482, 12, 32, 324, 197, 207, 1768, 1778, "medication" +482, 12, 33, 325, 208, 209, 1779, 1780, "." +482, 13, 1, 326, 0, 7, 1781, 1788, "RESULTS" +482, 13, 2, 327, 8, 9, 1789, 1790, ":" +482, 13, 3, 328, 10, 11, 1791, 1792, "A" +482, 13, 4, 329, 12, 17, 1793, 1798, "total" +482, 13, 5, 330, 18, 20, 1799, 1801, "of" +482, 13, 6, 331, 21, 24, 1802, 1805, "127" +482, 13, 7, 332, 25, 33, 1806, 1814, "patients" +482, 13, 8, 333, 34, 35, 1815, 1816, "(" +482, 13, 9, 334, 36, 38, 1817, 1819, "55" +482, 13, 10, 335, 39, 48, 1820, 1829, "treatment" +482, 13, 11, 336, 49, 54, 1830, 1835, "naive" +482, 13, 12, 337, 55, 56, 1836, 1837, ")" +482, 13, 13, 338, 57, 61, 1838, 1842, "were" +482, 13, 14, 339, 62, 70, 1843, 1851, "enrolled" +482, 13, 15, 340, 71, 72, 1852, 1853, "," +482, 13, 16, 341, 73, 75, 1854, 1856, "66" +482, 13, 17, 342, 76, 78, 1857, 1859, "in" +482, 13, 18, 343, 79, 82, 1860, 1863, "the" +482, 13, 19, 344, 83, 94, 1864, 1875, "brimonidine" +482, 13, 20, 345, 95, 100, 1876, 1881, "group" +482, 13, 21, 346, 101, 104, 1882, 1885, "and" +482, 13, 22, 347, 105, 107, 1886, 1888, "61" +482, 13, 23, 348, 108, 110, 1889, 1891, "in" +482, 13, 24, 349, 111, 114, 1892, 1895, "the" +482, 13, 25, 350, 115, 126, 1896, 1907, "latanoprost" +482, 13, 26, 351, 127, 132, 1908, 1913, "group" +482, 13, 27, 352, 133, 134, 1914, 1915, "." +482, 14, 1, 353, 0, 5, 1916, 1921, "After" +482, 14, 2, 354, 6, 7, 1922, 1923, "3" +482, 14, 3, 355, 8, 14, 1924, 1930, "months" +482, 14, 4, 356, 15, 17, 1931, 1933, "of" +482, 14, 5, 357, 18, 27, 1934, 1943, "treatment" +482, 14, 6, 358, 28, 29, 1944, 1945, "," +482, 14, 7, 359, 30, 32, 1946, 1948, "80" +482, 14, 8, 360, 33, 34, 1949, 1950, "%" +482, 14, 9, 361, 35, 37, 1951, 1953, "of" +482, 14, 10, 362, 38, 46, 1954, 1962, "patients" +482, 14, 11, 363, 47, 49, 1963, 1965, "in" +482, 14, 12, 364, 50, 53, 1966, 1969, "the" +482, 14, 13, 365, 54, 65, 1970, 1981, "brimonidine" +482, 14, 14, 366, 66, 71, 1982, 1987, "group" +482, 14, 15, 367, 72, 75, 1988, 1991, "and" +482, 14, 16, 368, 76, 78, 1992, 1994, "74" +482, 14, 17, 369, 79, 80, 1995, 1996, "%" +482, 14, 18, 370, 81, 83, 1997, 1999, "of" +482, 14, 19, 371, 84, 92, 2000, 2008, "patients" +482, 14, 20, 372, 93, 95, 2009, 2011, "in" +482, 14, 21, 373, 96, 99, 2012, 2015, "the" +482, 14, 22, 374, 100, 111, 2016, 2027, "latanoprost" +482, 14, 23, 375, 112, 117, 2028, 2033, "group" +482, 14, 24, 376, 118, 121, 2034, 2037, "had" +482, 14, 25, 377, 122, 130, 2038, 2046, "achieved" +482, 14, 26, 378, 131, 132, 2047, 2048, ">" +482, 14, 27, 379, 133, 135, 2049, 2051, "or" +482, 14, 28, 380, 136, 137, 2052, 2053, "=" +482, 14, 29, 381, 138, 140, 2054, 2056, "20" +482, 14, 30, 382, 141, 142, 2057, 2058, "%" +482, 14, 31, 383, 143, 152, 2059, 2068, "reduction" +482, 14, 32, 384, 153, 155, 2069, 2071, "in" +482, 14, 33, 385, 156, 159, 2072, 2075, "IOP" +482, 14, 34, 386, 160, 164, 2076, 2080, "from" +482, 14, 35, 387, 165, 173, 2081, 2089, "baseline" +482, 14, 36, 388, 174, 175, 2090, 2091, "." +482, 15, 1, 389, 0, 3, 2092, 2095, "The" +482, 15, 2, 390, 4, 8, 2096, 2100, "mean" +482, 15, 3, 391, 9, 18, 2101, 2110, "reduction" +482, 15, 4, 392, 19, 21, 2111, 2113, "in" +482, 15, 5, 393, 22, 25, 2114, 2117, "IOP" +482, 15, 6, 394, 26, 30, 2118, 2122, "from" +482, 15, 7, 395, 31, 39, 2123, 2131, "baseline" +482, 15, 8, 396, 40, 42, 2132, 2134, "at" +482, 15, 9, 397, 43, 48, 2135, 2140, "month" +482, 15, 10, 398, 49, 50, 2141, 2142, "3" +482, 15, 11, 399, 51, 54, 2143, 2146, "was" +482, 15, 12, 400, 55, 56, 2147, 2148, "6" +482, 15, 13, 401, 57, 58, 2149, 2150, "." +482, 15, 14, 402, 59, 60, 2151, 2152, "8" +482, 15, 15, 403, 61, 63, 2153, 2155, "mm" +482, 15, 16, 404, 64, 66, 2156, 2158, "Hg" +482, 15, 17, 405, 67, 71, 2159, 2163, "with" +482, 15, 18, 406, 72, 83, 2164, 2175, "brimonidine" +482, 15, 19, 407, 84, 87, 2176, 2179, "and" +482, 15, 20, 408, 88, 89, 2180, 2181, "6" +482, 15, 21, 409, 90, 91, 2182, 2183, "." +482, 15, 22, 410, 92, 93, 2184, 2185, "5" +482, 15, 23, 411, 94, 96, 2186, 2188, "mm" +482, 15, 24, 412, 97, 99, 2189, 2191, "Hg" +482, 15, 25, 413, 100, 104, 2192, 2196, "with" +482, 15, 26, 414, 105, 116, 2197, 2208, "latanoprost" +482, 15, 27, 415, 117, 118, 2209, 2210, "(" +482, 15, 28, 416, 119, 121, 2211, 2213, "27" +482, 15, 29, 417, 122, 123, 2214, 2215, "." +482, 15, 30, 418, 124, 125, 2216, 2217, "8" +482, 15, 31, 419, 126, 127, 2218, 2219, "%" +482, 15, 32, 420, 128, 130, 2220, 2222, "vs" +482, 15, 33, 421, 131, 133, 2223, 2225, "27" +482, 15, 34, 422, 134, 135, 2226, 2227, "." +482, 15, 35, 423, 136, 137, 2228, 2229, "0" +482, 15, 36, 424, 138, 139, 2230, 2231, "%" +482, 15, 37, 425, 140, 141, 2232, 2233, "," +482, 15, 38, 426, 142, 154, 2234, 2246, "respectively" +482, 15, 39, 427, 155, 156, 2247, 2248, ")" +482, 15, 40, 428, 157, 158, 2249, 2250, "." +482, 16, 1, 429, 0, 5, 2251, 2256, "Among" +482, 16, 2, 430, 6, 15, 2257, 2266, "treatment" +482, 16, 3, 431, 16, 17, 2267, 2268, "-" +482, 16, 4, 432, 18, 23, 2269, 2274, "naive" +482, 16, 5, 433, 24, 32, 2275, 2283, "patients" +482, 16, 6, 434, 33, 34, 2284, 2285, "," +482, 16, 7, 435, 35, 36, 2286, 2287, "a" +482, 16, 8, 436, 37, 50, 2288, 2301, "significantly" +482, 16, 9, 437, 51, 57, 2302, 2308, "higher" +482, 16, 10, 438, 58, 68, 2309, 2319, "percentage" +482, 16, 11, 439, 69, 71, 2320, 2322, "of" +482, 16, 12, 440, 72, 83, 2323, 2334, "brimonidine" +482, 16, 13, 441, 84, 85, 2335, 2336, "-" +482, 16, 14, 442, 86, 93, 2337, 2344, "treated" +482, 16, 15, 443, 94, 102, 2345, 2353, "patients" +482, 16, 16, 444, 103, 111, 2354, 2362, "achieved" +482, 16, 17, 445, 112, 113, 2363, 2364, ">" +482, 16, 18, 446, 114, 116, 2365, 2367, "or" +482, 16, 19, 447, 117, 118, 2368, 2369, "=" +482, 16, 20, 448, 119, 121, 2370, 2372, "20" +482, 16, 21, 449, 122, 123, 2373, 2374, "%" +482, 16, 22, 450, 124, 132, 2375, 2383, "decrease" +482, 16, 23, 451, 133, 135, 2384, 2386, "in" +482, 16, 24, 452, 136, 139, 2387, 2390, "IOP" +482, 16, 25, 453, 140, 148, 2391, 2399, "compared" +482, 16, 26, 454, 149, 153, 2400, 2404, "with" +482, 16, 27, 455, 154, 165, 2405, 2416, "latanoprost" +482, 16, 28, 456, 166, 167, 2417, 2418, "-" +482, 16, 29, 457, 168, 175, 2419, 2426, "treated" +482, 16, 30, 458, 176, 184, 2427, 2435, "patients" +482, 16, 31, 459, 185, 186, 2436, 2437, "(" +482, 16, 32, 460, 187, 189, 2438, 2440, "88" +482, 16, 33, 461, 190, 191, 2441, 2442, "%" +482, 16, 34, 462, 192, 194, 2443, 2445, "vs" +482, 16, 35, 463, 195, 197, 2446, 2448, "59" +482, 16, 36, 464, 198, 199, 2449, 2450, "%" +482, 16, 37, 465, 200, 201, 2451, 2452, "," +482, 16, 38, 466, 202, 214, 2453, 2465, "respectively" +482, 16, 39, 467, 215, 216, 2466, 2467, ";" +482, 16, 40, 468, 217, 218, 2468, 2469, "P" +482, 16, 41, 469, 219, 220, 2470, 2471, "=" +482, 16, 42, 470, 221, 222, 2472, 2473, "0" +482, 16, 43, 471, 223, 224, 2474, 2475, "." +482, 16, 44, 472, 225, 227, 2476, 2478, "01" +482, 16, 45, 473, 228, 229, 2479, 2480, ")" +482, 16, 46, 474, 230, 231, 2481, 2482, "." +482, 17, 1, 475, 0, 2, 2483, 2485, "In" +482, 17, 2, 476, 3, 13, 2486, 2496, "previously" +482, 17, 3, 477, 14, 21, 2497, 2504, "treated" +482, 17, 4, 478, 22, 30, 2505, 2513, "patients" +482, 17, 5, 479, 31, 32, 2514, 2515, "," +482, 17, 6, 480, 33, 34, 2516, 2517, "a" +482, 17, 7, 481, 35, 41, 2518, 2524, "higher" +482, 17, 8, 482, 42, 52, 2525, 2535, "percentage" +482, 17, 9, 483, 53, 55, 2536, 2538, "of" +482, 17, 10, 484, 56, 59, 2539, 2542, "the" +482, 17, 11, 485, 60, 71, 2543, 2554, "latanoprost" +482, 17, 12, 486, 72, 77, 2555, 2560, "group" +482, 17, 13, 487, 78, 86, 2561, 2569, "achieved" +482, 17, 14, 488, 87, 88, 2570, 2571, ">" +482, 17, 15, 489, 89, 91, 2572, 2574, "or" +482, 17, 16, 490, 92, 93, 2575, 2576, "=" +482, 17, 17, 491, 94, 96, 2577, 2579, "20" +482, 17, 18, 492, 97, 98, 2580, 2581, "%" +482, 17, 19, 493, 99, 108, 2582, 2591, "reduction" +482, 17, 20, 494, 109, 111, 2592, 2594, "in" +482, 17, 21, 495, 112, 115, 2595, 2598, "IOP" +482, 17, 22, 496, 116, 124, 2599, 2607, "compared" +482, 17, 23, 497, 125, 129, 2608, 2612, "with" +482, 17, 24, 498, 130, 133, 2613, 2616, "the" +482, 17, 25, 499, 134, 145, 2617, 2628, "brimonidine" +482, 17, 26, 500, 146, 151, 2629, 2634, "group" +482, 17, 27, 501, 152, 153, 2635, 2636, "(" +482, 17, 28, 502, 154, 156, 2637, 2639, "88" +482, 17, 29, 503, 157, 158, 2640, 2641, "%" +482, 17, 30, 504, 159, 161, 2642, 2644, "vs" +482, 17, 31, 505, 162, 164, 2645, 2647, "74" +482, 17, 32, 506, 165, 166, 2648, 2649, "%" +482, 17, 33, 507, 167, 168, 2650, 2651, "," +482, 17, 34, 508, 169, 181, 2652, 2664, "respectively" +482, 17, 35, 509, 182, 183, 2665, 2666, ")" +482, 17, 36, 510, 184, 185, 2667, 2668, ";" +482, 17, 37, 511, 186, 193, 2669, 2676, "however" +482, 17, 38, 512, 194, 195, 2677, 2678, "," +482, 17, 39, 513, 196, 199, 2679, 2682, "the" +482, 17, 40, 514, 200, 210, 2683, 2693, "difference" +482, 17, 41, 515, 211, 214, 2694, 2697, "was" +482, 17, 42, 516, 215, 218, 2698, 2701, "not" +482, 17, 43, 517, 219, 232, 2702, 2715, "statistically" +482, 17, 44, 518, 233, 244, 2716, 2727, "significant" +482, 17, 45, 519, 245, 246, 2728, 2729, "." +482, 18, 1, 520, 0, 13, 2730, 2743, "Significantly" +482, 18, 2, 521, 14, 18, 2744, 2748, "more" +482, 18, 3, 522, 19, 27, 2749, 2757, "patients" +482, 18, 4, 523, 28, 30, 2758, 2760, "in" +482, 18, 5, 524, 31, 34, 2761, 2764, "the" +482, 18, 6, 525, 35, 46, 2765, 2776, "brimonidine" +482, 18, 7, 526, 47, 52, 2777, 2782, "group" +482, 18, 8, 527, 53, 61, 2783, 2791, "achieved" +482, 18, 9, 528, 62, 70, 2792, 2800, "clinical" +482, 18, 10, 529, 71, 78, 2801, 2808, "success" +482, 18, 11, 530, 79, 81, 2809, 2811, "at" +482, 18, 12, 531, 82, 87, 2812, 2817, "month" +482, 18, 13, 532, 88, 89, 2818, 2819, "3" +482, 18, 14, 533, 90, 98, 2820, 2828, "compared" +482, 18, 15, 534, 99, 103, 2829, 2833, "with" +482, 18, 16, 535, 104, 112, 2834, 2842, "patients" +482, 18, 17, 536, 113, 115, 2843, 2845, "in" +482, 18, 18, 537, 116, 119, 2846, 2849, "the" +482, 18, 19, 538, 120, 131, 2850, 2861, "latanoprost" +482, 18, 20, 539, 132, 137, 2862, 2867, "group" +482, 18, 21, 540, 138, 139, 2868, 2869, "(" +482, 18, 22, 541, 140, 142, 2870, 2872, "91" +482, 18, 23, 542, 143, 144, 2873, 2874, "%" +482, 18, 24, 543, 145, 147, 2875, 2877, "vs" +482, 18, 25, 544, 148, 150, 2878, 2880, "74" +482, 18, 26, 545, 151, 152, 2881, 2882, "%" +482, 18, 27, 546, 153, 154, 2883, 2884, ";" +482, 18, 28, 547, 155, 156, 2885, 2886, "P" +482, 18, 29, 548, 157, 158, 2887, 2888, "=" +482, 18, 30, 549, 159, 160, 2889, 2890, "0" +482, 18, 31, 550, 161, 162, 2891, 2892, "." +482, 18, 32, 551, 163, 165, 2893, 2895, "01" +482, 18, 33, 552, 166, 167, 2896, 2897, ")" +482, 18, 34, 553, 168, 169, 2898, 2899, "." +482, 19, 1, 554, 0, 11, 2900, 2911, "CONCLUSIONS" +482, 19, 2, 555, 12, 13, 2912, 2913, ":" +482, 19, 3, 556, 14, 16, 2914, 2916, "At" +482, 19, 4, 557, 17, 21, 2917, 2921, "peak" +482, 19, 5, 558, 22, 28, 2922, 2928, "effect" +482, 19, 6, 559, 29, 30, 2929, 2930, "," +482, 19, 7, 560, 31, 42, 2931, 2942, "brimonidine" +482, 19, 8, 561, 43, 48, 2943, 2948, "twice" +482, 19, 9, 562, 49, 54, 2949, 2954, "daily" +482, 19, 10, 563, 55, 58, 2955, 2958, "was" +482, 19, 11, 564, 59, 61, 2959, 2961, "as" +482, 19, 12, 565, 62, 71, 2962, 2971, "effective" +482, 19, 13, 566, 72, 74, 2972, 2974, "as" +482, 19, 14, 567, 75, 86, 2975, 2986, "latanoprost" +482, 19, 15, 568, 87, 91, 2987, 2991, "once" +482, 19, 16, 569, 92, 97, 2992, 2997, "daily" +482, 19, 17, 570, 98, 100, 2998, 3000, "in" +482, 19, 18, 571, 101, 109, 3001, 3009, "lowering" +482, 19, 19, 572, 110, 113, 3010, 3013, "IOP" +482, 19, 20, 573, 114, 115, 3014, 3015, "." +482, 20, 1, 574, 0, 2, 3016, 3018, "In" +482, 20, 2, 575, 3, 12, 3019, 3028, "treatment" +482, 20, 3, 576, 13, 14, 3029, 3030, "-" +482, 20, 4, 577, 15, 20, 3031, 3036, "naive" +482, 20, 5, 578, 21, 29, 3037, 3045, "patients" +482, 20, 6, 579, 30, 31, 3046, 3047, "," +482, 20, 7, 580, 32, 43, 3048, 3059, "latanoprost" +482, 20, 8, 581, 44, 47, 3060, 3063, "was" +482, 20, 9, 582, 48, 58, 3064, 3074, "associated" +482, 20, 10, 583, 59, 63, 3075, 3079, "with" +482, 20, 11, 584, 64, 65, 3080, 3081, "a" +482, 20, 12, 585, 66, 79, 3082, 3095, "significantly" +482, 20, 13, 586, 80, 86, 3096, 3102, "higher" +482, 20, 14, 587, 87, 91, 3103, 3107, "rate" +482, 20, 15, 588, 92, 94, 3108, 3110, "of" +482, 20, 16, 589, 95, 106, 3111, 3122, "nonresponse" +482, 20, 17, 590, 107, 112, 3123, 3128, "after" +482, 20, 18, 591, 113, 114, 3129, 3130, "3" +482, 20, 19, 592, 115, 121, 3131, 3137, "months" +482, 20, 20, 593, 122, 124, 3138, 3140, "of" +482, 20, 21, 594, 125, 134, 3141, 3150, "treatment" +482, 20, 22, 595, 135, 143, 3151, 3159, "compared" +482, 20, 23, 596, 144, 148, 3160, 3164, "with" +482, 20, 24, 597, 149, 160, 3165, 3176, "brimonidine" +482, 20, 25, 598, 161, 162, 3177, 3178, "." +482, 21, 1, 599, 0, 4, 3179, 3183, "This" +482, 21, 2, 600, 5, 13, 3184, 3192, "suggests" +482, 21, 3, 601, 14, 18, 3193, 3197, "that" +482, 21, 4, 602, 19, 30, 3198, 3209, "brimonidine" +482, 21, 5, 603, 31, 34, 3210, 3213, "may" +482, 21, 6, 604, 35, 37, 3214, 3216, "be" +482, 21, 7, 605, 38, 41, 3217, 3220, "the" +482, 21, 8, 606, 42, 46, 3221, 3225, "more" +482, 21, 9, 607, 47, 55, 3226, 3234, "reliable" +482, 21, 10, 608, 56, 62, 3235, 3241, "choice" +482, 21, 11, 609, 63, 66, 3242, 3245, "for" +482, 21, 12, 610, 67, 72, 3246, 3251, "first" +482, 21, 13, 611, 73, 74, 3252, 3253, "-" +482, 21, 14, 612, 75, 79, 3254, 3258, "line" +482, 21, 15, 613, 80, 87, 3259, 3266, "therapy" +482, 21, 16, 614, 88, 90, 3267, 3269, "of" +482, 21, 17, 615, 91, 96, 3270, 3275, "newly" +482, 21, 18, 616, 97, 106, 3276, 3285, "diagnosed" +482, 21, 19, 617, 107, 111, 3286, 3290, "open" +482, 21, 20, 618, 112, 113, 3291, 3292, "-" +482, 21, 21, 619, 114, 119, 3293, 3298, "angle" +482, 21, 22, 620, 120, 128, 3299, 3307, "glaucoma" +482, 21, 23, 621, 129, 131, 3308, 3310, "or" +482, 21, 24, 622, 132, 138, 3311, 3317, "ocular" +482, 21, 25, 623, 139, 151, 3318, 3330, "hypertension" +482, 21, 26, 624, 152, 153, 3331, 3332, "." +482, 22, 1, 625, 0, 2, 3333, 3335, "In" +482, 22, 2, 626, 3, 13, 3336, 3346, "previously" +482, 22, 3, 627, 14, 21, 3347, 3354, "treated" +482, 22, 4, 628, 22, 30, 3355, 3363, "patients" +482, 22, 5, 629, 31, 32, 3364, 3365, "," +482, 22, 6, 630, 33, 40, 3366, 3373, "however" +482, 22, 7, 631, 41, 42, 3374, 3375, "," +482, 22, 8, 632, 43, 54, 3376, 3387, "latanoprost" +482, 22, 9, 633, 55, 63, 3388, 3396, "provided" +482, 22, 10, 634, 64, 71, 3397, 3404, "greater" +482, 22, 11, 635, 72, 76, 3405, 3409, "mean" +482, 22, 12, 636, 77, 80, 3410, 3413, "IOP" +482, 22, 13, 637, 81, 90, 3414, 3423, "reduction" +482, 22, 14, 638, 91, 95, 3424, 3428, "than" +482, 22, 15, 639, 96, 99, 3429, 3432, "did" +482, 22, 16, 640, 100, 111, 3433, 3444, "brimonidine" +482, 22, 17, 641, 112, 113, 3445, 3446, "." +482, 23, 1, 642, 0, 13, 3447, 3460, "Significantly" +482, 23, 2, 643, 14, 18, 3461, 3465, "more" +482, 23, 3, 644, 19, 27, 3466, 3474, "patients" +482, 23, 4, 645, 28, 36, 3475, 3483, "achieved" +482, 23, 5, 646, 37, 45, 3484, 3492, "clinical" +482, 23, 6, 647, 46, 53, 3493, 3500, "success" +482, 23, 7, 648, 54, 58, 3501, 3505, "with" +482, 23, 8, 649, 59, 70, 3506, 3517, "brimonidine" +482, 23, 9, 650, 71, 82, 3518, 3529, "monotherapy" +482, 23, 10, 651, 83, 87, 3530, 3534, "than" +482, 23, 11, 652, 88, 92, 3535, 3539, "with" +482, 23, 12, 653, 93, 104, 3540, 3551, "latanoprost" +482, 23, 13, 654, 105, 116, 3552, 3563, "monotherapy" +482, 23, 14, 655, 117, 118, 3564, 3565, "." +482, 24, 1, 656, 0, 4, 3566, 3570, "PMID" +482, 24, 2, 657, 5, 6, 3571, 3572, ":" +482, 24, 3, 658, 7, 15, 3573, 3581, "11813932" +482, 24, 4, 659, 16, 17, 3582, 3583, "[" +482, 24, 5, 660, 18, 25, 3584, 3591, "Indexed" +482, 24, 6, 661, 26, 29, 3592, 3595, "for" +482, 24, 7, 662, 30, 37, 3596, 3603, "MEDLINE" +482, 24, 8, 663, 38, 39, 3604, 3605, "]" diff --git a/data/gl 11813932_jshahinitiran.annodb b/data/gl 11813932_jshahinitiran.annodb new file mode 100644 index 0000000..45a5647 --- /dev/null +++ b/data/gl 11813932_jshahinitiran.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4677, Journal, 0, 9, "Clin Ther", "", +4678, PublicationYear, 12, 16, "2001", "", +4679, Title, 47, 273, "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial .", "", +26052, Brimonidine, 96, 107, "brimonidine", "", +26053, Latanoprost, 112, 123, "latanoprost", "", +26054, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", +26055, OcularHypertension, 164, 183, "ocular hypertension", "", +26056, Duration, 188, 201, "three - month", "", +26057, Multicenter, 204, 215, "multicenter", "", +26058, Randomized, 218, 228, "randomized", "", +26059, DoubleBlind, 229, 246, ", double - masked", "", +26060, Parallel, 249, 265, "parallel - group", "", +4689, Author, 274, 284, "DuBiner HB", "", +4690, Author, 293, 299, "Mroz M", "", +4691, Author, 302, 312, "Shapiro AM", "", +4692, Author, 315, 323, "Dirks MS", "", +4693, Author, 326, 340, "Brimonidine vs", "", +4694, USA, 442, 445, "USA", "", +26061, Brimonidine, 494, 505, "brimonidine", "", +26062, Latanoprost, 509, 520, "latanoprost", "", +26063, OpenAngleGlaucoma, 554, 575, "open - angle glaucoma", "", +26064, OcularHypertension, 579, 598, "ocular hypertension", "", +4699, ObjectiveDescription, 754, 973, "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension .", "", +26065, Brimonidine, 816, 827, "brimonidine", "", +4702, DoseValue, 828, 833, "0 . 2", "bri", +4703, Percentage, 834, 835, "%", "bri", +4704, Frequency, 836, 847, "twice daily", "bri", +26066, Latanoprost, 862, 873, "latanoprost", "", +4705, DoseValue, 874, 881, "0 . 005", "lat", +4706, Percentage, 882, 883, "%", "lat", +4707, Frequency, 884, 894, "once daily", "lat", +26067, OpenAngleGlaucoma, 927, 948, "open - angle glaucoma", "", +26068, OcularHypertension, 952, 971, "ocular hypertension", "", +26069, Duration, 992, 1001, "3 - month", "", +26070, Multicenter, 1004, 1015, "multicenter", "", +26071, DoubleBlind, 1018, 1033, "double - masked", "", +26072, Parallel, 1036, 1052, "parallel - group", "", +4714, Precondition, 1073, 1090, "treatment - naive", "", +4715, Precondition, 1095, 1122, "previously treated patients", "", +26073, OpenAngleGlaucoma, 1128, 1149, "open - angle glaucoma", "", +26074, OcularHypertension, 1153, 1172, "ocular hypertension", "", +26075, Precondition, 1177, 1256, "bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg", "", +4718, IOP, 1187, 1207, "intraocular pressure", "", +4719, IOP, 1210, 1213, "IOP", "", +4788, mmHg, 1251, 1256, "mm Hg", "", +26076, Randomized, 1262, 1272, "randomized", "", +26077, Brimonidine, 1291, 1302, "brimonidine", "", +26078, Latanoprost, 1306, 1317, "latanoprost", "", +26081, EndPointDescription, 1478, 1568, "the percentage of patients achieving > or = 20 % reduction in IOP from baseline to month 3", "", +4723, IOP, 1540, 1543, "IOP", "", +39037, TimePoint, 1549, 1557, "baseline", "", +26082, TimePoint, 1561, 1568, "month 3", "", +4726, IOP, 1608, 1611, "IOP", "", +26083, TimePoint, 1639, 1646, "month 3", "", +4727, NumberPatientsCT, 1802, 1805, "127", "", +4728, NumberPatientsArm, 1854, 1856, "66", "bri", +26084, Brimonidine, 1864, 1875, "brimonidine", "", +4730, NumberPatientsArm, 1886, 1888, "61", "lat", +26085, Latanoprost, 1896, 1907, "latanoprost", "", +26092, TimePoint, 1922, 1930, "3 months", "", +4733, PercentageAffected, 1946, 1948, "80", "bri", +26087, Brimonidine, 1970, 1981, "brimonidine", "", +4735, PercentageAffected, 1992, 1994, "74", "lat", +26088, Latanoprost, 2016, 2027, "latanoprost", "", +26089, EndPointDescription, 2047, 2089, "> or = 20 % reduction in IOP from baseline", "", +4785, IOP, 2072, 2075, "IOP", "", +26090, Mean, 2096, 2100, "mean", "", +4739, IOP, 2114, 2117, "IOP", "", +26091, TimePoint, 2135, 2142, "month 3", "", +4741, Reduction, 2147, 2152, "6 . 8", "bri", +4789, mmHg, 2153, 2158, "mm Hg", "", +26093, Brimonidine, 2164, 2175, "brimonidine", "", +4743, Reduction, 2180, 2185, "6 . 5", "lat", +4790, mmHg, 2186, 2191, "mm Hg", "", +26094, Latanoprost, 2197, 2208, "latanoprost", "", +4745, RelativeReduction, 2211, 2217, "27 . 8", "bri", +4746, RelativeReduction, 2223, 2229, "27 . 0", "lat", +26095, Brimonidine, 2323, 2334, "brimonidine", "", +26096, EndPointDescription, 2363, 2390, "> or = 20 % decrease in IOP", "", +4786, IOP, 2387, 2390, "IOP", "", +26097, Latanoprost, 2405, 2416, "latanoprost", "", +4751, RelativeReduction, 2438, 2440, "88", "bri_sub", +4752, RelativeReduction, 2446, 2448, "59", "lat_sub", +4753, PValueChangeValue, 2468, 2478, "P = 0 . 01", "sub", +4754, SubGroupDescription, 2486, 2504, "previously treated", "", +26098, Latanoprost, 2543, 2554, "latanoprost", "", +26099, EndPointDescription, 2570, 2598, "> or = 20 % reduction in IOP", "", +4787, IOP, 2595, 2598, "IOP", "", +26100, Brimonidine, 2617, 2628, "brimonidine", "", +4758, RelativeReduction, 2637, 2639, "88", "lat_sub2", +4759, RelativeReduction, 2645, 2647, "74", "bri_sub2", +26103, Brimonidine, 2765, 2776, "brimonidine", "", +26101, TimePoint, 2812, 2819, "month 3", "", +26102, Latanoprost, 2850, 2861, "latanoprost", "", +26104, PercentageAffected, 2870, 2872, "91", "", +26105, PercentageAffected, 2878, 2880, "74", "", +26106, PValueNumAffected, 2885, 2895, "P = 0 . 01", "", +4762, ConclusionComment, 2914, 3015, "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .", "", +26107, Brimonidine, 2931, 2942, "brimonidine", "", +26108, Frequency, 2943, 2954, "twice daily", "", +26109, Latanoprost, 2975, 2986, "latanoprost", "", +26110, Frequency, 2987, 2997, "once daily", "", +26111, IOP, 3010, 3013, "IOP", "", +4763, ConclusionComment, 3016, 3178, "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .", "", +26112, Latanoprost, 3048, 3059, "latanoprost", "", +26113, TimePoint, 3129, 3137, "3 months", "", +26114, Brimonidine, 3165, 3176, "brimonidine", "", +4764, ConclusionComment, 3179, 3332, "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .", "", +26115, Brimonidine, 3198, 3209, "brimonidine", "", +26116, OpenAngleGlaucoma, 3286, 3307, "open - angle glaucoma", "", +26117, OcularHypertension, 3311, 3330, "ocular hypertension", "", +4765, ConclusionComment, 3333, 3446, "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .", "", +26118, Latanoprost, 3376, 3387, "latanoprost", "", +4774, Mean, 3405, 3409, "mean", "", +4775, IOP, 3410, 3413, "IOP", "", +26119, Brimonidine, 3433, 3444, "brimonidine", "", +4766, ConclusionComment, 3447, 3565, "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .", "", +26120, Brimonidine, 3506, 3517, "brimonidine", "", +26121, Latanoprost, 3540, 3551, "latanoprost", "", +4779, PMID, 3573, 3581, "11813932", "", diff --git a/data/gl 11813932_jshahinitiran.n-triples b/data/gl 11813932_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11813932_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11813932_tstrakeljahn.annodb b/data/gl 11813932_tstrakeljahn.annodb new file mode 100644 index 0000000..26774b6 --- /dev/null +++ b/data/gl 11813932_tstrakeljahn.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +36467, Journal, 0, 9, "Clin Ther", "", +36468, PublicationYear, 12, 16, "2001", "", +36478, Title, 47, 271, "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open - angle glaucoma or ocular hypertension : a three - month , multicenter , randomized , double - masked , parallel - group trial", "", +36469, Brimonidine, 96, 107, "brimonidine", "", +36470, Latanoprost, 112, 123, "latanoprost", "", +36471, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", +36472, OcularHypertension, 164, 183, "ocular hypertension", "", +36473, Duration, 188, 201, "three - month", "", +36474, Multicenter, 204, 215, "multicenter", "", +36475, Randomized, 218, 228, "randomized", "", +36476, DoubleBlind, 231, 246, "double - masked", "", +36477, Parallel, 249, 257, "parallel", "", +36479, Author, 274, 284, "DuBiner HB", "", +36480, Author, 293, 299, "Mroz M", "", +36481, Author, 302, 312, "Shapiro AM", "", +36482, Author, 315, 323, "Dirks MS", "", +36483, Brimonidine, 326, 337, "Brimonidine", "", +36484, Latanoprost, 343, 354, "Latanoprost", "", +36485, USA, 442, 445, "USA", "", +36486, Brimonidine, 494, 505, "brimonidine", "", +36499, Latanoprost, 509, 520, "latanoprost", "", +36518, ObjectiveDescription, 754, 971, "This study compared the clinical efficacy and tolerability of brimonidine 0 . 2 % twice daily with those of latanoprost 0 . 005 % once daily as monotherapy in patients with open - angle glaucoma or ocular hypertension", "", +36487, Brimonidine, 816, 827, "brimonidine", "", +36510, DoseValue, 828, 833, "0 . 2", "", +36512, Percentage, 834, 835, "%", "", +36514, Frequency, 836, 847, "twice daily", "", +36500, Latanoprost, 862, 873, "latanoprost", "", +36511, DoseValue, 874, 881, "0 . 005", "", +36513, Percentage, 882, 883, "%", "", +36515, Frequency, 884, 894, "once daily", "", +36516, OpenAngleGlaucoma, 927, 948, "open - angle glaucoma", "", +36517, OcularHypertension, 952, 971, "ocular hypertension", "", +36519, Duration, 992, 1001, "3 - month", "", +36520, Multicenter, 1004, 1015, "multicenter", "", +36521, DoubleBlind, 1018, 1033, "double - masked", "", +36522, Parallel, 1036, 1044, "parallel", "", +36523, Precondition, 1073, 1256, "treatment - naive and previously treated patients with open - angle glaucoma or ocular hypertension and bilateral intraocular pressure ( IOP ) after washout of between 22 and 34 mm Hg", "", +36524, OpenAngleGlaucoma, 1128, 1149, "open - angle glaucoma", "", +36525, OcularHypertension, 1153, 1172, "ocular hypertension", "", +36526, IOP, 1187, 1207, "intraocular pressure", "", +36527, IOP, 1210, 1213, "IOP", "", +36528, mmHg, 1251, 1256, "mm Hg", "", +36529, Randomized, 1262, 1272, "randomized", "", +36488, Brimonidine, 1291, 1302, "brimonidine", "", +36501, Latanoprost, 1306, 1317, "latanoprost", "", +36530, EndPointDescription, 1505, 1543, "achieving > or = 20 % reduction in IOP", "", +36531, IOP, 1540, 1543, "IOP", "", +36532, Mean, 1603, 1607, "mean", "", +36533, IOP, 1608, 1611, "IOP", "", +36534, NumberPatientsCT, 1802, 1805, "127", "", +36535, NumberPatientsArm, 1854, 1856, "66", "", +36498, Brimonidine, 1864, 1875, "brimonidine", "", +36536, NumberPatientsArm, 1886, 1888, "61", "", +36502, Latanoprost, 1896, 1907, "latanoprost", "", +36537, Mean, 2096, 2100, "mean", "", +36538, IOP, 2114, 2117, "IOP", "", +36539, TimePoint, 2135, 2142, "month 3", "", +36540, Reduction, 2147, 2152, "6 . 8", "", +36542, mmHg, 2153, 2158, "mm Hg", "", +36497, Brimonidine, 2164, 2175, "brimonidine", "", +36541, Reduction, 2180, 2185, "6 . 5", "", +36543, mmHg, 2186, 2191, "mm Hg", "", +36503, Latanoprost, 2197, 2208, "latanoprost", "", +36544, RelativeReduction, 2211, 2217, "27 . 8", "", +36545, RelativeReduction, 2223, 2229, "27 . 0", "", +36546, SubGroupDescription, 2257, 2283, "treatment - naive patients", "", +36496, Brimonidine, 2323, 2334, "brimonidine", "", +36556, EndPointDescription, 2354, 2383, "achieved > or = 20 % decrease", "", +36547, IOP, 2387, 2390, "IOP", "", +36504, Latanoprost, 2405, 2416, "latanoprost", "", +36548, PercentageAffected, 2438, 2440, "88", "", +36549, PercentageAffected, 2446, 2448, "59", "", +36550, PvalueDiff, 2468, 2478, "P = 0 . 01", "", +36505, Latanoprost, 2543, 2554, "latanoprost", "", +36557, EndPointDescription, 2561, 2591, "achieved > or = 20 % reduction", "", +36552, IOP, 2595, 2598, "IOP", "", +36495, Brimonidine, 2617, 2628, "brimonidine", "", +36558, PercentageAffected, 2637, 2639, "88", "", +36559, PercentageAffected, 2645, 2647, "74", "", +36494, Brimonidine, 2765, 2776, "brimonidine", "", +36506, Latanoprost, 2850, 2861, "latanoprost", "", +36553, PercentageAffected, 2870, 2872, "91", "", +36554, PercentageAffected, 2878, 2880, "74", "", +36555, PvalueDiff, 2885, 2895, "P = 0 . 01", "", +36570, ConclusionComment, 2914, 3015, "At peak effect , brimonidine twice daily was as effective as latanoprost once daily in lowering IOP .", "", +36493, Brimonidine, 2931, 2942, "brimonidine", "", +36560, Frequency, 2943, 2954, "twice daily", "", +36507, Latanoprost, 2975, 2986, "latanoprost", "", +36561, Frequency, 2987, 2997, "once daily", "", +36562, IOP, 3010, 3013, "IOP", "", +36571, ConclusionComment, 3016, 3178, "In treatment - naive patients , latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine .", "", +36563, Latanoprost, 3048, 3059, "latanoprost", "", +36492, Brimonidine, 3165, 3176, "brimonidine", "", +36572, ConclusionComment, 3179, 3332, "This suggests that brimonidine may be the more reliable choice for first - line therapy of newly diagnosed open - angle glaucoma or ocular hypertension .", "", +36491, Brimonidine, 3198, 3209, "brimonidine", "", +36564, OpenAngleGlaucoma, 3286, 3307, "open - angle glaucoma", "", +36565, OcularHypertension, 3311, 3330, "ocular hypertension", "", +36573, ConclusionComment, 3333, 3446, "In previously treated patients , however , latanoprost provided greater mean IOP reduction than did brimonidine .", "", +36508, Latanoprost, 3376, 3387, "latanoprost", "", +36567, Mean, 3405, 3409, "mean", "", +36568, IOP, 3410, 3413, "IOP", "", +36490, Brimonidine, 3433, 3444, "brimonidine", "", +36574, ConclusionComment, 3447, 3565, "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy .", "", +36489, Brimonidine, 3506, 3517, "brimonidine", "", +36509, Latanoprost, 3540, 3551, "latanoprost", "", +36569, PMID, 3573, 3581, "11813932", "", diff --git a/data/gl 11813932_tstrakeljahn.n-triples b/data/gl 11813932_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11813932_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11825814_admin.annodb b/data/gl 11825814_admin.annodb new file mode 100644 index 0000000..0892463 --- /dev/null +++ b/data/gl 11825814_admin.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2002", "", " \"2002\"." +2, Title, 71, 278, "Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .", "", " \"Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .\"." +71, Duration, 71, 84, "Three - month", "", " \"Three - month\"." +72, Brimonidine, 99, 110, "brimonidine", "", +73, Latanoprost, 115, 126, "latanoprost", "", +3, Glaucoma, 152, 160, "glaucoma", "", " . ." +4, OcularHypertension, 165, 184, "ocular hypertension", "", " ." +5, Peak_IOP, 242, 267, "peak intraocular pressure", "", +6, Author, 279, 289, "Simmons ST", "", " \"Simmons ST\"." +7, Author, 298, 305, "Earl ML", "", " \"Earl ML\"." +136, Drug, 308, 316, "Alphagan", "", +135, Drug, 319, 326, "Xalatan", "", +67, USA, 433, 436, "USA", "", " ." +8, ObjectiveDescription, 528, 746, "To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .", "", " \"To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .\"." +9, Peak_IOP, 557, 582, "peak intraocular pressure", "", +10, IOP, 585, 588, "IOP", "", +74, Brimonidine, 614, 625, "brimonidine", "", +75, Latanoprost, 630, 641, "latanoprost", "", +11, OcularHypertension, 681, 700, "ocular hypertension", "", +12, Glaucoma, 704, 712, "glaucoma", "", +145, Precondition, 713, 744, "uncontrolled on beta - blockers", "", " \"uncontrolled on beta - blockers\"." +123, Prospective, 758, 769, "prospective", "", " ." +13, Multicenter, 772, 783, "multicenter", "", " ." +14, DoubleBlind, 786, 801, "double - masked", "", " ." +15, Parallel, 804, 812, "parallel", "", " ." +16, NumberPatientsCT, 854, 873, "One hundred fifteen", "", " \"One hundred fifteen\"." +17, IOP, 888, 891, "IOP", "", +154, Precondition, 892, 953, "inadequately controlled on topical beta - blocker monotherapy", "", " \"inadequately controlled on topical beta - blocker monotherapy\"." +18, Randomized, 980, 988, "randomly", "", " ." +155, Brimonidine, 1009, 1020, "brimonidine", "", " ." +19, DoseValue, 1023, 1028, "0 . 2", "", " \"0 . 2\"." +76, Percentage, 1029, 1030, "%", "", " ." +77, Frequency, 1033, 1044, "twice a day", "", " \"twice a day\"." +78, Latanoprost, 1048, 1059, "latanoprost", "", " . ." +20, DoseValue, 1062, 1069, "0 . 005", "", " \"0 . 005\"." +21, Percentage, 1070, 1071, "%", "", " ." +79, Frequency, 1074, 1083, "every day", "", " \"every day\"." +80, Duration, 1110, 1118, "3 months", "", +81, TimePoint, 1127, 1134, "1 month", "", +69, Peak_IOP, 1216, 1227, "IOP at peak", "", +83, Crossover, 1245, 1257, "crossed over", "", " ." +22, DiffGroupAbsValue, 1376, 1377, "1", "", +23, mmHg, 1378, 1382, "mmHg", "", +24, Mean, 1386, 1390, "mean", "", +25, IOP, 1391, 1394, "IOP", "", +94023, Peak_IOP, 1493, 1518, "IOP from baseline at peak", "", +27, Mean, 1629, 1633, "Mean", "", " . ." +28, IOP, 1668, 1671, "IOP", "", " . ." +29, BaseLineValue, 1728, 1734, "21 . 3", "", " \"21 . 3\". \"21 . 3\". \"21 . 3\". \"21 . 3\"." +30, mmHg, 1735, 1740, "mm Hg", "", " ." +68, TimePoint, 1751, 1758, "1 month", "", " \"1 month\". \"1 month\"." +84, Brimonidine, 1783, 1794, "brimonidine", "", +85, Latanoprost, 1799, 1810, "latanoprost", "", +31, IOP, 1831, 1834, "IOP", "", +32, Reduction, 1846, 1852, "4 . 88", "", " \"4 . 88\"." +33, mmHg, 1853, 1857, "mmHg", "", +34, RelativeReduction, 1860, 1866, "22 . 8", "", " \"22 . 8\"." +86, Brimonidine, 1876, 1887, "brimonidine", "", +35, Reduction, 1892, 1898, "5 . 01", "", " \"5 . 01\"." +36, mmHg, 1899, 1903, "mmHg", "", +37, RelativeReduction, 1906, 1912, "23 . 5", "", " \"23 . 5\"." +87, Latanoprost, 1922, 1933, "latanoprost", "", +186, PvalueDiff, 1938, 1947, "= 0 . 798", "", " \"= 0 . 798\"." +40, NumberAffected, 2002, 2004, "44", "", " \"44\"." +88, NumberPatientsArm, 2008, 2010, "54", "", " \"54\"." +89, Brimonidine, 2011, 2022, "brimonidine", "", +41, NumberAffected, 2036, 2038, "43", "", " \"43\"." +90, NumberPatientsArm, 2042, 2044, "53", "", " \"53\"." +91, Latanoprost, 2045, 2056, "latanoprost", "", +92, EndPointDescription, 2095, 2121, "15 % IOP reduction at peak", "", " . ." +39, TimePoint, 2137, 2144, "month 1", "", " \"month 1\". \"month 1\"." +196, PvalueDiff, 2149, 2158, "= 0 . 963", "", " \"= 0 . 963\"." +197, TimePoint, 2201, 2208, "month 1", "", +44, Mean, 2257, 2261, "mean", "", +45, IOP, 2262, 2265, "IOP", "", +46, Reduction, 2282, 2288, "4 . 55", "", " \"4 . 55\"." +47, mmHg, 2289, 2293, "mmHg", "", +94, Brimonidine, 2299, 2310, "brimonidine", "", +48, Reduction, 2315, 2321, "5 . 49", "", " \"5 . 49\"." +49, mmHg, 2322, 2326, "mmHg", "", +95, Latanoprost, 2332, 2343, "latanoprost", "", +207, PvalueDiff, 2348, 2357, "= 0 . 149", "", " \"= 0 . 149\"." +51, TimePoint, 2363, 2370, "month 3", "", " \"month 3\". \"month 3\"." +96, Brimonidine, 2427, 2438, "brimonidine", "", +97, Latanoprost, 2443, 2454, "latanoprost", "", +104, EndPointDescription, 2467, 2523, "at least a 15 % additional reduction in IOP for 3 months", "", +53, IOP, 2507, 2510, "IOP", "", +98, Duration, 2515, 2523, "3 months", "", +54, NumberAffected, 2526, 2528, "28", "", " \"28\"." +94032, NumberPatientsArm, 2532, 2534, "38", "", +99, Brimonidine, 2547, 2558, "brimonidine", "", +55, NumberAffected, 2564, 2566, "30", "", " \"30\"." +94033, NumberPatientsArm, 2570, 2572, "36", "", +100, Latanoprost, 2585, 2596, "latanoprost", "", +101, EndPointDescription, 2606, 2631, "> or = 15 % IOP reduction", "", +103, TimePoint, 2635, 2642, "month 3", "", " \"month 3\". \"month 3\"." +221, PvalueDiff, 2647, 2656, "= 0 . 314", "", " \"= 0 . 314\"." +105, Latanoprost, 2677, 2688, "latanoprost", "", +106, Brimonidine, 2782, 2793, "brimonidine", "", +107, Latanoprost, 2821, 2832, "latanoprost", "", +94034, EndPointDescription, 2851, 2871, "watery or teary eyes", "", " . ." +56, NumberAffected, 2874, 2876, "34", "", " \"34\"." +109, NumberPatientsArm, 2880, 2882, "53", "", +58, PercentageAffected, 2885, 2891, "64 . 2", "", " \"64 . 2\"." +57, NumberAffected, 2899, 2901, "23", "", " \"23\"." +110, NumberPatientsArm, 2905, 2907, "54", "", +59, PercentageAffected, 2910, 2916, "42 . 6", "", " \"42 . 6\"." +111, Brimonidine, 2924, 2935, "brimonidine", "", +236, PvalueDiff, 2940, 2949, "= 0 . 025", "", " \"= 0 . 025\"." +106400, EndPointDescription, 2956, 2994, "hands and feet that became cold easily", "", " . ." +61, NumberAffected, 2997, 2999, "24", "", " \"24\"." +113, NumberPatientsArm, 3003, 3005, "53", "", +62, PercentageAffected, 3008, 3014, "45 . 3", "", " \"45 . 3\"." +63, NumberAffected, 3022, 3024, "12", "", " \"12\"." +114, NumberPatientsArm, 3028, 3030, "54", "", +64, PercentageAffected, 3033, 3039, "22 . 2", "", " \"22 . 2\"." +115, Brimonidine, 3047, 3058, "brimonidine", "", +245, PvalueDiff, 3063, 3072, "= 0 . 012", "", " \"= 0 . 012\"." +66, ConclusionComment, 3091, 3330, "As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .", "", " \"As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .\"." +116, Brimonidine, 3133, 3144, "brimonidine", "", +117, Frequency, 3145, 3156, "twice daily", "", +118, Latanoprost, 3161, 3172, "latanoprost", "", +119, Frequency, 3173, 3182, "every day", "", +120, Peak_IOP, 3211, 3222, "IOP at peak", "", +121, Brimonidine, 3236, 3247, "brimonidine", "", +122, PMID, 3338, 3346, "11825814", "", " \"11825814\"." diff --git a/data/gl 11825814_admin.n-triples b/data/gl 11825814_admin.n-triples new file mode 100644 index 0000000..1203bc5 --- /dev/null +++ b/data/gl 11825814_admin.n-triples @@ -0,0 +1,221 @@ +# RDF export of group: Publication + . + "Publication" . + "Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering ." . + "Simmons ST" . + "2002" . + "Ophthalmology" . + "11825814" . + . + "Earl ML" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers ." . + "One hundred fifteen" . + "Three - month" . + . + . + . + "As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects ." . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "uncontrolled on beta - blockers" . + . + . + . + "inadequately controlled on topical beta - blocker monotherapy" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_15" . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . + . + "Endpoint_AE2" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bri" . + "54" . + . + . + . + . + . + . + . + . + "Arm_lat" . + "53" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_bri" . + . + "twice a day" . + . + . + "Intervention_lat" . + . + "every day" . + . +# RDF export of group: Medication + . + "Medication_bri" . + . + "0 . 2" . + . + . + . + "Medication_lat" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_1m_bri" . + . + "21 . 3" . + "4 . 88" . + "22 . 8" . + "1 month" . + . + "Outcome_iop_1m_lat" . + . + "21 . 3" . + "5 . 01" . + "23 . 5" . + "1 month" . + . + "Outcome_15_1m_bri" . + . + "44" . + "month 1" . + . + "Outcome_15_1m_lat" . + . + "43" . + "month 1" . + . + "Outcome_iop_3m_bri" . + . + "21 . 3" . + "4 . 55" . + "month 3" . + . + "Outcome_iop_3m_lat" . + . + "21 . 3" . + "5 . 49" . + "month 3" . + . + "Outcome_15_3m_bri" . + . + "28" . + "month 3" . + . + "Outcome_15_3m_lat" . + . + "30" . + "month 3" . + . + "Outcome_AE_bri" . + . + "23" . + "42 . 6" . + . + "Outcome_AE_lat" . + . + "34" . + "64 . 2" . + . + "Outcome_AE2_bri" . + . + "12" . + "22 . 2" . + . + "Outcome_AE2_lat" . + . + "24" . + "45 . 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop_1m" . + "= 0 . 798" . + . + . + . + "DiffBetweenGroups_15_1m" . + "= 0 . 963" . + . + . + . + "DiffBetweenGroups_iop_3m" . + "= 0 . 149" . + . + . + . + "DiffBetweenGroups_15_3m" . + "= 0 . 314" . + . + . + . + "DiffBetweenGroups_AE" . + "= 0 . 025" . + . + . + . + "DiffBetweenGroups_AE2" . + "= 0 . 012" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11825814_export.csv b/data/gl 11825814_export.csv new file mode 100644 index 0000000..a51c65a --- /dev/null +++ b/data/gl 11825814_export.csv @@ -0,0 +1,676 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +481, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +481, 1, 2, 2, 14, 15, 14, 15, "." +481, 2, 1, 3, 0, 4, 16, 20, "2002" +481, 2, 2, 4, 5, 8, 21, 24, "Feb" +481, 2, 3, 5, 9, 10, 25, 26, ";" +481, 2, 4, 6, 11, 14, 27, 30, "109" +481, 2, 5, 7, 15, 16, 31, 32, "(" +481, 2, 6, 8, 17, 18, 33, 34, "2" +481, 2, 7, 9, 19, 20, 35, 36, ")" +481, 2, 8, 10, 21, 22, 37, 38, ":" +481, 2, 9, 11, 23, 26, 39, 42, "307" +481, 2, 10, 12, 27, 28, 43, 44, "-" +481, 2, 11, 13, 29, 31, 45, 47, "14" +481, 2, 12, 14, 32, 33, 48, 49, ";" +481, 2, 13, 15, 34, 44, 50, 60, "discussion" +481, 2, 14, 16, 45, 48, 61, 64, "314" +481, 2, 15, 17, 49, 50, 65, 66, "-" +481, 2, 16, 18, 51, 52, 67, 68, "5" +481, 2, 17, 19, 53, 54, 69, 70, "." +481, 3, 1, 20, 0, 5, 71, 76, "Three" +481, 3, 2, 21, 6, 7, 77, 78, "-" +481, 3, 3, 22, 8, 13, 79, 84, "month" +481, 3, 4, 23, 14, 24, 85, 95, "comparison" +481, 3, 5, 24, 25, 27, 96, 98, "of" +481, 3, 6, 25, 28, 39, 99, 110, "brimonidine" +481, 3, 7, 26, 40, 43, 111, 114, "and" +481, 3, 8, 27, 44, 55, 115, 126, "latanoprost" +481, 3, 9, 28, 56, 58, 127, 129, "as" +481, 3, 10, 29, 59, 69, 130, 140, "adjunctive" +481, 3, 11, 30, 70, 77, 141, 148, "therapy" +481, 3, 12, 31, 78, 80, 149, 151, "in" +481, 3, 13, 32, 81, 89, 152, 160, "glaucoma" +481, 3, 14, 33, 90, 93, 161, 164, "and" +481, 3, 15, 34, 94, 100, 165, 171, "ocular" +481, 3, 16, 35, 101, 113, 172, 184, "hypertension" +481, 3, 17, 36, 114, 122, 185, 193, "patients" +481, 3, 18, 37, 123, 135, 194, 206, "uncontrolled" +481, 3, 19, 38, 136, 138, 207, 209, "on" +481, 3, 20, 39, 139, 143, 210, 214, "beta" +481, 3, 21, 40, 144, 145, 215, 216, "-" +481, 3, 22, 41, 146, 154, 217, 225, "blockers" +481, 3, 23, 42, 155, 156, 226, 227, ":" +481, 3, 24, 43, 157, 166, 228, 237, "tolerance" +481, 3, 25, 44, 167, 170, 238, 241, "and" +481, 3, 26, 45, 171, 175, 242, 246, "peak" +481, 3, 27, 46, 176, 187, 247, 258, "intraocular" +481, 3, 28, 47, 188, 196, 259, 267, "pressure" +481, 3, 29, 48, 197, 205, 268, 276, "lowering" +481, 3, 30, 49, 206, 207, 277, 278, "." +481, 4, 1, 50, 0, 7, 279, 286, "Simmons" +481, 4, 2, 51, 8, 10, 287, 289, "ST" +481, 4, 3, 52, 11, 12, 290, 291, "(" +481, 4, 4, 53, 13, 14, 292, 293, "1" +481, 4, 5, 54, 15, 16, 294, 295, ")" +481, 4, 6, 55, 17, 18, 296, 297, "," +481, 4, 7, 56, 19, 23, 298, 302, "Earl" +481, 4, 8, 57, 24, 26, 303, 305, "ML" +481, 4, 9, 58, 27, 28, 306, 307, ";" +481, 4, 10, 59, 29, 37, 308, 316, "Alphagan" +481, 4, 11, 60, 38, 39, 317, 318, "/" +481, 4, 12, 61, 40, 47, 319, 326, "Xalatan" +481, 4, 13, 62, 48, 53, 327, 332, "Study" +481, 4, 14, 63, 54, 59, 333, 338, "Group" +481, 4, 15, 64, 60, 61, 339, 340, "." +481, 5, 1, 65, 0, 6, 341, 347, "Author" +481, 5, 2, 66, 7, 18, 348, 359, "information" +481, 5, 3, 67, 19, 20, 360, 361, ":" +481, 5, 4, 68, 21, 22, 362, 363, "(" +481, 5, 5, 69, 23, 24, 364, 365, "1" +481, 5, 6, 70, 25, 26, 366, 367, ")" +481, 5, 7, 71, 27, 35, 368, 376, "Glaucoma" +481, 5, 8, 72, 36, 47, 377, 388, "Consultants" +481, 5, 9, 73, 48, 50, 389, 391, "of" +481, 5, 10, 74, 51, 54, 392, 395, "the" +481, 5, 11, 75, 55, 62, 396, 403, "Capital" +481, 5, 12, 76, 63, 69, 404, 410, "Region" +481, 5, 13, 77, 70, 71, 411, 412, "," +481, 5, 14, 78, 72, 78, 413, 419, "Albany" +481, 5, 15, 79, 79, 80, 420, 421, "," +481, 5, 16, 80, 81, 84, 422, 425, "New" +481, 5, 17, 81, 85, 89, 426, 430, "York" +481, 5, 18, 82, 90, 91, 431, 432, "," +481, 5, 19, 83, 92, 95, 433, 436, "USA" +481, 5, 20, 84, 96, 97, 437, 438, "." +481, 6, 1, 85, 0, 7, 439, 446, "Comment" +481, 6, 2, 86, 8, 10, 447, 449, "in" +481, 6, 3, 87, 11, 24, 450, 463, "Ophthalmology" +481, 6, 4, 88, 25, 26, 464, 465, "." +481, 7, 1, 89, 0, 4, 466, 470, "2003" +481, 7, 2, 90, 5, 8, 471, 474, "Jan" +481, 7, 3, 91, 9, 10, 475, 476, ";" +481, 7, 4, 92, 11, 14, 477, 480, "110" +481, 7, 5, 93, 15, 16, 481, 482, "(" +481, 7, 6, 94, 17, 18, 483, 484, "1" +481, 7, 7, 95, 19, 20, 485, 486, ")" +481, 7, 8, 96, 21, 22, 487, 488, ":" +481, 7, 9, 97, 23, 24, 489, 490, "6" +481, 7, 10, 98, 25, 26, 491, 492, "-" +481, 7, 11, 99, 27, 28, 493, 494, "8" +481, 7, 12, 100, 29, 30, 495, 496, ";" +481, 7, 13, 101, 31, 37, 497, 503, "author" +481, 7, 14, 102, 38, 43, 504, 509, "reply" +481, 7, 15, 103, 44, 45, 510, 511, "8" +481, 7, 16, 104, 46, 47, 512, 513, "-" +481, 7, 17, 105, 48, 49, 514, 515, "9" +481, 7, 18, 106, 50, 51, 516, 517, "." +481, 8, 1, 107, 0, 7, 518, 525, "PURPOSE" +481, 8, 2, 108, 8, 9, 526, 527, ":" +481, 8, 3, 109, 10, 12, 528, 530, "To" +481, 8, 4, 110, 13, 20, 531, 538, "compare" +481, 8, 5, 111, 21, 24, 539, 542, "the" +481, 8, 6, 112, 25, 34, 543, 552, "tolerance" +481, 8, 7, 113, 35, 38, 553, 556, "and" +481, 8, 8, 114, 39, 43, 557, 561, "peak" +481, 8, 9, 115, 44, 55, 562, 573, "intraocular" +481, 8, 10, 116, 56, 64, 574, 582, "pressure" +481, 8, 11, 117, 65, 66, 583, 584, "(" +481, 8, 12, 118, 67, 70, 585, 588, "IOP" +481, 8, 13, 119, 71, 72, 589, 590, ")" +481, 8, 14, 120, 73, 74, 591, 592, "-" +481, 8, 15, 121, 75, 83, 593, 601, "lowering" +481, 8, 16, 122, 84, 92, 602, 610, "efficacy" +481, 8, 17, 123, 93, 95, 611, 613, "of" +481, 8, 18, 124, 96, 107, 614, 625, "brimonidine" +481, 8, 19, 125, 108, 111, 626, 629, "and" +481, 8, 20, 126, 112, 123, 630, 641, "latanoprost" +481, 8, 21, 127, 124, 126, 642, 644, "as" +481, 8, 22, 128, 127, 137, 645, 655, "adjunctive" +481, 8, 23, 129, 138, 145, 656, 663, "therapy" +481, 8, 24, 130, 146, 148, 664, 666, "in" +481, 8, 25, 131, 149, 157, 667, 675, "patients" +481, 8, 26, 132, 158, 162, 676, 680, "with" +481, 8, 27, 133, 163, 169, 681, 687, "ocular" +481, 8, 28, 134, 170, 182, 688, 700, "hypertension" +481, 8, 29, 135, 183, 185, 701, 703, "or" +481, 8, 30, 136, 186, 194, 704, 712, "glaucoma" +481, 8, 31, 137, 195, 207, 713, 725, "uncontrolled" +481, 8, 32, 138, 208, 210, 726, 728, "on" +481, 8, 33, 139, 211, 215, 729, 733, "beta" +481, 8, 34, 140, 216, 217, 734, 735, "-" +481, 8, 35, 141, 218, 226, 736, 744, "blockers" +481, 8, 36, 142, 227, 228, 745, 746, "." +481, 9, 1, 143, 0, 6, 747, 753, "DESIGN" +481, 9, 2, 144, 7, 8, 754, 755, ":" +481, 9, 3, 145, 9, 10, 756, 757, "A" +481, 9, 4, 146, 11, 22, 758, 769, "prospective" +481, 9, 5, 147, 23, 24, 770, 771, "," +481, 9, 6, 148, 25, 36, 772, 783, "multicenter" +481, 9, 7, 149, 37, 38, 784, 785, "," +481, 9, 8, 150, 39, 45, 786, 792, "double" +481, 9, 9, 151, 46, 47, 793, 794, "-" +481, 9, 10, 152, 48, 54, 795, 801, "masked" +481, 9, 11, 153, 55, 56, 802, 803, "," +481, 9, 12, 154, 57, 65, 804, 812, "parallel" +481, 9, 13, 155, 66, 67, 813, 814, "-" +481, 9, 14, 156, 68, 74, 815, 821, "design" +481, 9, 15, 157, 75, 83, 822, 830, "clinical" +481, 9, 16, 158, 84, 89, 831, 836, "trial" +481, 9, 17, 159, 90, 91, 837, 838, "." +481, 10, 1, 160, 0, 12, 839, 851, "PARTICIPANTS" +481, 10, 2, 161, 13, 14, 852, 853, ":" +481, 10, 3, 162, 15, 18, 854, 857, "One" +481, 10, 4, 163, 19, 26, 858, 865, "hundred" +481, 10, 5, 164, 27, 34, 866, 873, "fifteen" +481, 10, 6, 165, 35, 43, 874, 882, "patients" +481, 10, 7, 166, 44, 48, 883, 887, "with" +481, 10, 8, 167, 49, 52, 888, 891, "IOP" +481, 10, 9, 168, 53, 65, 892, 904, "inadequately" +481, 10, 10, 169, 66, 76, 905, 915, "controlled" +481, 10, 11, 170, 77, 79, 916, 918, "on" +481, 10, 12, 171, 80, 87, 919, 926, "topical" +481, 10, 13, 172, 88, 92, 927, 931, "beta" +481, 10, 14, 173, 93, 94, 932, 933, "-" +481, 10, 15, 174, 95, 102, 934, 941, "blocker" +481, 10, 16, 175, 103, 114, 942, 953, "monotherapy" +481, 10, 17, 176, 115, 116, 954, 955, "." +481, 11, 1, 177, 0, 7, 956, 963, "METHODS" +481, 11, 2, 178, 8, 9, 964, 965, ":" +481, 11, 3, 179, 10, 18, 966, 974, "Patients" +481, 11, 4, 180, 19, 23, 975, 979, "were" +481, 11, 5, 181, 24, 32, 980, 988, "randomly" +481, 11, 6, 182, 33, 41, 989, 997, "assigned" +481, 11, 7, 183, 42, 44, 998, 1000, "to" +481, 11, 8, 184, 45, 52, 1001, 1008, "receive" +481, 11, 9, 185, 53, 64, 1009, 1020, "brimonidine" +481, 11, 10, 186, 65, 66, 1021, 1022, "," +481, 11, 11, 187, 67, 68, 1023, 1024, "0" +481, 11, 12, 188, 69, 70, 1025, 1026, "." +481, 11, 13, 189, 71, 72, 1027, 1028, "2" +481, 11, 14, 190, 73, 74, 1029, 1030, "%" +481, 11, 15, 191, 75, 76, 1031, 1032, "," +481, 11, 16, 192, 77, 82, 1033, 1038, "twice" +481, 11, 17, 193, 83, 84, 1039, 1040, "a" +481, 11, 18, 194, 85, 88, 1041, 1044, "day" +481, 11, 19, 195, 89, 91, 1045, 1047, "or" +481, 11, 20, 196, 92, 103, 1048, 1059, "latanoprost" +481, 11, 21, 197, 104, 105, 1060, 1061, "," +481, 11, 22, 198, 106, 107, 1062, 1063, "0" +481, 11, 23, 199, 108, 109, 1064, 1065, "." +481, 11, 24, 200, 110, 113, 1066, 1069, "005" +481, 11, 25, 201, 114, 115, 1070, 1071, "%" +481, 11, 26, 202, 116, 117, 1072, 1073, "," +481, 11, 27, 203, 118, 123, 1074, 1079, "every" +481, 11, 28, 204, 124, 127, 1080, 1083, "day" +481, 11, 29, 205, 128, 130, 1084, 1086, "as" +481, 11, 30, 206, 131, 141, 1087, 1097, "adjunctive" +481, 11, 31, 207, 142, 149, 1098, 1105, "therapy" +481, 11, 32, 208, 150, 153, 1106, 1109, "for" +481, 11, 33, 209, 154, 155, 1110, 1111, "3" +481, 11, 34, 210, 156, 162, 1112, 1118, "months" +481, 11, 35, 211, 163, 164, 1119, 1120, "." +481, 12, 1, 212, 0, 5, 1121, 1126, "After" +481, 12, 2, 213, 6, 7, 1127, 1128, "1" +481, 12, 3, 214, 8, 13, 1129, 1134, "month" +481, 12, 4, 215, 14, 16, 1135, 1137, "of" +481, 12, 5, 216, 17, 27, 1138, 1148, "adjunctive" +481, 12, 6, 217, 28, 37, 1149, 1158, "treatment" +481, 12, 7, 218, 38, 39, 1159, 1160, "," +481, 12, 8, 219, 40, 48, 1161, 1169, "patients" +481, 12, 9, 220, 49, 52, 1170, 1173, "who" +481, 12, 10, 221, 53, 59, 1174, 1180, "failed" +481, 12, 11, 222, 60, 62, 1181, 1183, "to" +481, 12, 12, 223, 63, 67, 1184, 1188, "meet" +481, 12, 13, 224, 68, 69, 1189, 1190, "a" +481, 12, 14, 225, 70, 76, 1191, 1197, "target" +481, 12, 15, 226, 77, 79, 1198, 1200, "15" +481, 12, 16, 227, 80, 81, 1201, 1202, "%" +481, 12, 17, 228, 82, 91, 1203, 1212, "reduction" +481, 12, 18, 229, 92, 94, 1213, 1215, "in" +481, 12, 19, 230, 95, 98, 1216, 1219, "IOP" +481, 12, 20, 231, 99, 101, 1220, 1222, "at" +481, 12, 21, 232, 102, 106, 1223, 1227, "peak" +481, 12, 22, 233, 107, 111, 1228, 1232, "drug" +481, 12, 23, 234, 112, 118, 1233, 1239, "effect" +481, 12, 24, 235, 119, 123, 1240, 1244, "were" +481, 12, 25, 236, 124, 131, 1245, 1252, "crossed" +481, 12, 26, 237, 132, 136, 1253, 1257, "over" +481, 12, 27, 238, 137, 139, 1258, 1260, "to" +481, 12, 28, 239, 140, 143, 1261, 1264, "the" +481, 12, 29, 240, 144, 149, 1265, 1270, "other" +481, 12, 30, 241, 150, 155, 1271, 1276, "study" +481, 12, 31, 242, 156, 166, 1277, 1287, "medication" +481, 12, 32, 243, 167, 168, 1288, 1289, "." +481, 13, 1, 244, 0, 3, 1290, 1293, "The" +481, 13, 2, 245, 4, 10, 1294, 1300, "target" +481, 13, 3, 246, 11, 17, 1301, 1307, "sample" +481, 13, 4, 247, 18, 22, 1308, 1312, "size" +481, 13, 5, 248, 23, 25, 1313, 1315, "of" +481, 13, 6, 249, 26, 28, 1316, 1318, "51" +481, 13, 7, 250, 29, 30, 1319, 1320, "/" +481, 13, 8, 251, 31, 36, 1321, 1326, "group" +481, 13, 9, 252, 37, 41, 1327, 1331, "gave" +481, 13, 10, 253, 42, 43, 1332, 1333, "a" +481, 13, 11, 254, 44, 49, 1334, 1339, "power" +481, 13, 12, 255, 50, 52, 1340, 1342, "of" +481, 13, 13, 256, 53, 54, 1343, 1344, "0" +481, 13, 14, 257, 55, 56, 1345, 1346, "." +481, 13, 15, 258, 57, 59, 1347, 1349, "80" +481, 13, 16, 259, 60, 62, 1350, 1352, "to" +481, 13, 17, 260, 63, 69, 1353, 1359, "detect" +481, 13, 18, 261, 70, 71, 1360, 1361, "a" +481, 13, 19, 262, 72, 82, 1362, 1372, "difference" +481, 13, 20, 263, 83, 85, 1373, 1375, "of" +481, 13, 21, 264, 86, 87, 1376, 1377, "1" +481, 13, 22, 265, 88, 92, 1378, 1382, "mmHg" +481, 13, 23, 266, 93, 95, 1383, 1385, "in" +481, 13, 24, 267, 96, 100, 1386, 1390, "mean" +481, 13, 25, 268, 101, 104, 1391, 1394, "IOP" +481, 13, 26, 269, 105, 113, 1395, 1403, "lowering" +481, 13, 27, 270, 114, 121, 1404, 1411, "between" +481, 13, 28, 271, 122, 128, 1412, 1418, "groups" +481, 13, 29, 272, 129, 130, 1419, 1420, "." +481, 14, 1, 273, 0, 4, 1421, 1425, "MAIN" +481, 14, 2, 274, 5, 12, 1426, 1433, "OUTCOME" +481, 14, 3, 275, 13, 21, 1434, 1442, "MEASURES" +481, 14, 4, 276, 22, 23, 1443, 1444, ":" +481, 14, 5, 277, 24, 27, 1445, 1448, "The" +481, 14, 6, 278, 28, 35, 1449, 1456, "primary" +481, 14, 7, 279, 36, 43, 1457, 1464, "outcome" +481, 14, 8, 280, 44, 53, 1465, 1474, "variables" +481, 14, 9, 281, 54, 58, 1475, 1479, "were" +481, 14, 10, 282, 59, 68, 1480, 1489, "reduction" +481, 14, 11, 283, 69, 71, 1490, 1492, "in" +481, 14, 12, 284, 72, 75, 1493, 1496, "IOP" +481, 14, 13, 285, 76, 80, 1497, 1501, "from" +481, 14, 14, 286, 81, 89, 1502, 1510, "baseline" +481, 14, 15, 287, 90, 92, 1511, 1513, "at" +481, 14, 16, 288, 93, 97, 1514, 1518, "peak" +481, 14, 17, 289, 98, 102, 1519, 1523, "drug" +481, 14, 18, 290, 103, 109, 1524, 1530, "effect" +481, 14, 19, 291, 110, 111, 1531, 1532, "," +481, 14, 20, 292, 112, 120, 1533, 1541, "response" +481, 14, 21, 293, 121, 125, 1542, 1546, "rate" +481, 14, 22, 294, 126, 127, 1547, 1548, "," +481, 14, 23, 295, 128, 131, 1549, 1552, "and" +481, 14, 24, 296, 132, 139, 1553, 1560, "quality" +481, 14, 25, 297, 140, 142, 1561, 1563, "of" +481, 14, 26, 298, 143, 147, 1564, 1568, "life" +481, 14, 27, 299, 148, 150, 1569, 1571, "as" +481, 14, 28, 300, 151, 159, 1572, 1580, "measured" +481, 14, 29, 301, 160, 165, 1581, 1586, "using" +481, 14, 30, 302, 166, 169, 1587, 1590, "the" +481, 14, 31, 303, 170, 178, 1591, 1599, "Glaucoma" +481, 14, 32, 304, 179, 189, 1600, 1610, "Disability" +481, 14, 33, 305, 190, 195, 1611, 1616, "Index" +481, 14, 34, 306, 196, 197, 1617, 1618, "." +481, 15, 1, 307, 0, 7, 1619, 1626, "RESULTS" +481, 15, 2, 308, 8, 9, 1627, 1628, ":" +481, 15, 3, 309, 10, 14, 1629, 1633, "Mean" +481, 15, 4, 310, 15, 19, 1634, 1638, "beta" +481, 15, 5, 311, 20, 21, 1639, 1640, "-" +481, 15, 6, 312, 22, 29, 1641, 1648, "blocker" +481, 15, 7, 313, 30, 31, 1649, 1650, "-" +481, 15, 8, 314, 32, 39, 1651, 1658, "treated" +481, 15, 9, 315, 40, 48, 1659, 1667, "baseline" +481, 15, 10, 316, 49, 52, 1668, 1671, "IOP" +481, 15, 11, 317, 53, 56, 1672, 1675, "was" +481, 15, 12, 318, 57, 67, 1676, 1686, "comparable" +481, 15, 13, 319, 68, 75, 1687, 1694, "between" +481, 15, 14, 320, 76, 85, 1695, 1704, "treatment" +481, 15, 15, 321, 86, 92, 1705, 1711, "groups" +481, 15, 16, 322, 93, 94, 1712, 1713, "(" +481, 15, 17, 323, 95, 108, 1714, 1727, "approximately" +481, 15, 18, 324, 109, 111, 1728, 1730, "21" +481, 15, 19, 325, 112, 113, 1731, 1732, "." +481, 15, 20, 326, 114, 115, 1733, 1734, "3" +481, 15, 21, 327, 116, 118, 1735, 1737, "mm" +481, 15, 22, 328, 119, 121, 1738, 1740, "Hg" +481, 15, 23, 329, 122, 123, 1741, 1742, ")" +481, 15, 24, 330, 124, 125, 1743, 1744, "." +481, 16, 1, 331, 0, 5, 1745, 1750, "After" +481, 16, 2, 332, 6, 7, 1751, 1752, "1" +481, 16, 3, 333, 8, 13, 1753, 1758, "month" +481, 16, 4, 334, 14, 16, 1759, 1761, "of" +481, 16, 5, 335, 17, 27, 1762, 1772, "adjunctive" +481, 16, 6, 336, 28, 35, 1773, 1780, "therapy" +481, 16, 7, 337, 36, 37, 1781, 1782, "," +481, 16, 8, 338, 38, 49, 1783, 1794, "brimonidine" +481, 16, 9, 339, 50, 53, 1795, 1798, "and" +481, 16, 10, 340, 54, 65, 1799, 1810, "latanoprost" +481, 16, 11, 341, 66, 74, 1811, 1819, "provided" +481, 16, 12, 342, 75, 85, 1820, 1830, "comparable" +481, 16, 13, 343, 86, 89, 1831, 1834, "IOP" +481, 16, 14, 344, 90, 98, 1835, 1843, "lowering" +481, 16, 15, 345, 99, 100, 1844, 1845, "(" +481, 16, 16, 346, 101, 102, 1846, 1847, "4" +481, 16, 17, 347, 103, 104, 1848, 1849, "." +481, 16, 18, 348, 105, 107, 1850, 1852, "88" +481, 16, 19, 349, 108, 112, 1853, 1857, "mmHg" +481, 16, 20, 350, 113, 114, 1858, 1859, "[" +481, 16, 21, 351, 115, 117, 1860, 1862, "22" +481, 16, 22, 352, 118, 119, 1863, 1864, "." +481, 16, 23, 353, 120, 121, 1865, 1866, "8" +481, 16, 24, 354, 122, 123, 1867, 1868, "%" +481, 16, 25, 355, 124, 125, 1869, 1870, "]" +481, 16, 26, 356, 126, 130, 1871, 1875, "with" +481, 16, 27, 357, 131, 142, 1876, 1887, "brimonidine" +481, 16, 28, 358, 143, 146, 1888, 1891, "and" +481, 16, 29, 359, 147, 148, 1892, 1893, "5" +481, 16, 30, 360, 149, 150, 1894, 1895, "." +481, 16, 31, 361, 151, 153, 1896, 1898, "01" +481, 16, 32, 362, 154, 158, 1899, 1903, "mmHg" +481, 16, 33, 363, 159, 160, 1904, 1905, "[" +481, 16, 34, 364, 161, 163, 1906, 1908, "23" +481, 16, 35, 365, 164, 165, 1909, 1910, "." +481, 16, 36, 366, 166, 167, 1911, 1912, "5" +481, 16, 37, 367, 168, 169, 1913, 1914, "%" +481, 16, 38, 368, 170, 171, 1915, 1916, "]" +481, 16, 39, 369, 172, 176, 1917, 1921, "with" +481, 16, 40, 370, 177, 188, 1922, 1933, "latanoprost" +481, 16, 41, 371, 189, 190, 1934, 1935, "," +481, 16, 42, 372, 191, 192, 1936, 1937, "P" +481, 16, 43, 373, 193, 194, 1938, 1939, "=" +481, 16, 44, 374, 195, 196, 1940, 1941, "0" +481, 16, 45, 375, 197, 198, 1942, 1943, "." +481, 16, 46, 376, 199, 202, 1944, 1947, "798" +481, 16, 47, 377, 203, 204, 1948, 1949, ")" +481, 16, 48, 378, 205, 206, 1950, 1951, "." +481, 17, 1, 379, 0, 8, 1952, 1960, "Response" +481, 17, 2, 380, 9, 14, 1961, 1966, "rates" +481, 17, 3, 381, 15, 19, 1967, 1971, "were" +481, 17, 4, 382, 20, 27, 1972, 1979, "similar" +481, 17, 5, 383, 28, 30, 1980, 1982, "in" +481, 17, 6, 384, 31, 35, 1983, 1987, "both" +481, 17, 7, 385, 36, 42, 1988, 1994, "groups" +481, 17, 8, 386, 43, 44, 1995, 1996, "," +481, 17, 9, 387, 45, 49, 1997, 2001, "with" +481, 17, 10, 388, 50, 52, 2002, 2004, "44" +481, 17, 11, 389, 53, 55, 2005, 2007, "of" +481, 17, 12, 390, 56, 58, 2008, 2010, "54" +481, 17, 13, 391, 59, 70, 2011, 2022, "brimonidine" +481, 17, 14, 392, 71, 79, 2023, 2031, "patients" +481, 17, 15, 393, 80, 83, 2032, 2035, "and" +481, 17, 16, 394, 84, 86, 2036, 2038, "43" +481, 17, 17, 395, 87, 89, 2039, 2041, "of" +481, 17, 18, 396, 90, 92, 2042, 2044, "53" +481, 17, 19, 397, 93, 104, 2045, 2056, "latanoprost" +481, 17, 20, 398, 105, 113, 2057, 2065, "patients" +481, 17, 21, 399, 114, 123, 2066, 2075, "achieving" +481, 17, 22, 400, 124, 127, 2076, 2079, "the" +481, 17, 23, 401, 128, 135, 2080, 2087, "minimum" +481, 17, 24, 402, 136, 142, 2088, 2094, "target" +481, 17, 25, 403, 143, 145, 2095, 2097, "15" +481, 17, 26, 404, 146, 147, 2098, 2099, "%" +481, 17, 27, 405, 148, 151, 2100, 2103, "IOP" +481, 17, 28, 406, 152, 161, 2104, 2113, "reduction" +481, 17, 29, 407, 162, 164, 2114, 2116, "at" +481, 17, 30, 408, 165, 169, 2117, 2121, "peak" +481, 17, 31, 409, 170, 174, 2122, 2126, "drug" +481, 17, 32, 410, 175, 181, 2127, 2133, "effect" +481, 17, 33, 411, 182, 184, 2134, 2136, "at" +481, 17, 34, 412, 185, 190, 2137, 2142, "month" +481, 17, 35, 413, 191, 192, 2143, 2144, "1" +481, 17, 36, 414, 193, 194, 2145, 2146, "(" +481, 17, 37, 415, 195, 196, 2147, 2148, "P" +481, 17, 38, 416, 197, 198, 2149, 2150, "=" +481, 17, 39, 417, 199, 200, 2151, 2152, "0" +481, 17, 40, 418, 201, 202, 2153, 2154, "." +481, 17, 41, 419, 203, 206, 2155, 2158, "963" +481, 17, 42, 420, 207, 208, 2159, 2160, ")" +481, 17, 43, 421, 209, 210, 2161, 2162, "." +481, 18, 1, 422, 0, 5, 2163, 2168, "Among" +481, 18, 2, 423, 6, 14, 2169, 2177, "patients" +481, 18, 3, 424, 15, 18, 2178, 2181, "who" +481, 18, 4, 425, 19, 23, 2182, 2186, "were" +481, 18, 5, 426, 24, 34, 2187, 2197, "successful" +481, 18, 6, 427, 35, 37, 2198, 2200, "at" +481, 18, 7, 428, 38, 43, 2201, 2206, "month" +481, 18, 8, 429, 44, 45, 2207, 2208, "1" +481, 18, 9, 430, 46, 49, 2209, 2212, "and" +481, 18, 10, 431, 50, 59, 2213, 2222, "continued" +481, 18, 11, 432, 60, 62, 2223, 2225, "on" +481, 18, 12, 433, 63, 66, 2226, 2229, "the" +481, 18, 13, 434, 67, 74, 2230, 2237, "initial" +481, 18, 14, 435, 75, 80, 2238, 2243, "study" +481, 18, 15, 436, 81, 91, 2244, 2254, "medication" +481, 18, 16, 437, 92, 93, 2255, 2256, "," +481, 18, 17, 438, 94, 98, 2257, 2261, "mean" +481, 18, 18, 439, 99, 102, 2262, 2265, "IOP" +481, 18, 19, 440, 103, 113, 2266, 2276, "reductions" +481, 18, 20, 441, 114, 118, 2277, 2281, "were" +481, 18, 21, 442, 119, 120, 2282, 2283, "4" +481, 18, 22, 443, 121, 122, 2284, 2285, "." +481, 18, 23, 444, 123, 125, 2286, 2288, "55" +481, 18, 24, 445, 126, 130, 2289, 2293, "mmHg" +481, 18, 25, 446, 131, 135, 2294, 2298, "with" +481, 18, 26, 447, 136, 147, 2299, 2310, "brimonidine" +481, 18, 27, 448, 148, 151, 2311, 2314, "and" +481, 18, 28, 449, 152, 153, 2315, 2316, "5" +481, 18, 29, 450, 154, 155, 2317, 2318, "." +481, 18, 30, 451, 156, 158, 2319, 2321, "49" +481, 18, 31, 452, 159, 163, 2322, 2326, "mmHg" +481, 18, 32, 453, 164, 168, 2327, 2331, "with" +481, 18, 33, 454, 169, 180, 2332, 2343, "latanoprost" +481, 18, 34, 455, 181, 182, 2344, 2345, "(" +481, 18, 35, 456, 183, 184, 2346, 2347, "P" +481, 18, 36, 457, 185, 186, 2348, 2349, "=" +481, 18, 37, 458, 187, 188, 2350, 2351, "0" +481, 18, 38, 459, 189, 190, 2352, 2353, "." +481, 18, 39, 460, 191, 194, 2354, 2357, "149" +481, 18, 40, 461, 195, 196, 2358, 2359, ")" +481, 18, 41, 462, 197, 199, 2360, 2362, "at" +481, 18, 42, 463, 200, 205, 2363, 2368, "month" +481, 18, 43, 464, 206, 207, 2369, 2370, "3" +481, 18, 44, 465, 208, 209, 2371, 2372, "." +481, 19, 1, 466, 0, 5, 2373, 2378, "There" +481, 19, 2, 467, 6, 9, 2379, 2382, "was" +481, 19, 3, 468, 10, 12, 2383, 2385, "no" +481, 19, 4, 469, 13, 24, 2386, 2397, "significant" +481, 19, 5, 470, 25, 35, 2398, 2408, "difference" +481, 19, 6, 471, 36, 38, 2409, 2411, "in" +481, 19, 7, 472, 39, 42, 2412, 2415, "the" +481, 19, 8, 473, 43, 50, 2416, 2423, "ability" +481, 19, 9, 474, 51, 53, 2424, 2426, "of" +481, 19, 10, 475, 54, 65, 2427, 2438, "brimonidine" +481, 19, 11, 476, 66, 69, 2439, 2442, "and" +481, 19, 12, 477, 70, 81, 2443, 2454, "latanoprost" +481, 19, 13, 478, 82, 84, 2455, 2457, "to" +481, 19, 14, 479, 85, 93, 2458, 2466, "maintain" +481, 19, 15, 480, 94, 96, 2467, 2469, "at" +481, 19, 16, 481, 97, 102, 2470, 2475, "least" +481, 19, 17, 482, 103, 104, 2476, 2477, "a" +481, 19, 18, 483, 105, 107, 2478, 2480, "15" +481, 19, 19, 484, 108, 109, 2481, 2482, "%" +481, 19, 20, 485, 110, 120, 2483, 2493, "additional" +481, 19, 21, 486, 121, 130, 2494, 2503, "reduction" +481, 19, 22, 487, 131, 133, 2504, 2506, "in" +481, 19, 23, 488, 134, 137, 2507, 2510, "IOP" +481, 19, 24, 489, 138, 141, 2511, 2514, "for" +481, 19, 25, 490, 142, 143, 2515, 2516, "3" +481, 19, 26, 491, 144, 150, 2517, 2523, "months" +481, 19, 27, 492, 151, 152, 2524, 2525, "(" +481, 19, 28, 493, 153, 155, 2526, 2528, "28" +481, 19, 29, 494, 156, 158, 2529, 2531, "of" +481, 19, 30, 495, 159, 161, 2532, 2534, "38" +481, 19, 31, 496, 162, 170, 2535, 2543, "patients" +481, 19, 32, 497, 171, 173, 2544, 2546, "on" +481, 19, 33, 498, 174, 185, 2547, 2558, "brimonidine" +481, 19, 34, 499, 186, 188, 2559, 2561, "vs" +481, 19, 35, 500, 189, 190, 2562, 2563, "." +481, 19, 36, 501, 191, 193, 2564, 2566, "30" +481, 19, 37, 502, 194, 196, 2567, 2569, "of" +481, 19, 38, 503, 197, 199, 2570, 2572, "36" +481, 19, 39, 504, 200, 208, 2573, 2581, "patients" +481, 19, 40, 505, 209, 211, 2582, 2584, "on" +481, 19, 41, 506, 212, 223, 2585, 2596, "latanoprost" +481, 19, 42, 507, 224, 232, 2597, 2605, "achieved" +481, 19, 43, 508, 233, 234, 2606, 2607, ">" +481, 19, 44, 509, 235, 237, 2608, 2610, "or" +481, 19, 45, 510, 238, 239, 2611, 2612, "=" +481, 19, 46, 511, 240, 242, 2613, 2615, "15" +481, 19, 47, 512, 243, 244, 2616, 2617, "%" +481, 19, 48, 513, 245, 248, 2618, 2621, "IOP" +481, 19, 49, 514, 249, 258, 2622, 2631, "reduction" +481, 19, 50, 515, 259, 261, 2632, 2634, "at" +481, 19, 51, 516, 262, 267, 2635, 2640, "month" +481, 19, 52, 517, 268, 269, 2641, 2642, "3" +481, 19, 53, 518, 270, 271, 2643, 2644, ";" +481, 19, 54, 519, 272, 273, 2645, 2646, "P" +481, 19, 55, 520, 274, 275, 2647, 2648, "=" +481, 19, 56, 521, 276, 277, 2649, 2650, "0" +481, 19, 57, 522, 278, 279, 2651, 2652, "." +481, 19, 58, 523, 280, 283, 2653, 2656, "314" +481, 19, 59, 524, 284, 285, 2657, 2658, ")" +481, 19, 60, 525, 286, 287, 2659, 2660, "." +481, 20, 1, 526, 0, 8, 2661, 2669, "Patients" +481, 20, 2, 527, 9, 11, 2670, 2672, "in" +481, 20, 3, 528, 12, 15, 2673, 2676, "the" +481, 20, 4, 529, 16, 27, 2677, 2688, "latanoprost" +481, 20, 5, 530, 28, 33, 2689, 2694, "group" +481, 20, 6, 531, 34, 38, 2695, 2699, "were" +481, 20, 7, 532, 39, 43, 2700, 2704, "more" +481, 20, 8, 533, 44, 50, 2705, 2711, "likely" +481, 20, 9, 534, 51, 53, 2712, 2714, "to" +481, 20, 10, 535, 54, 60, 2715, 2721, "report" +481, 20, 11, 536, 61, 69, 2722, 2730, "negative" +481, 20, 12, 537, 70, 77, 2731, 2738, "quality" +481, 20, 13, 538, 78, 79, 2739, 2740, "-" +481, 20, 14, 539, 80, 82, 2741, 2743, "of" +481, 20, 15, 540, 83, 84, 2744, 2745, "-" +481, 20, 16, 541, 85, 89, 2746, 2750, "life" +481, 20, 17, 542, 90, 99, 2751, 2760, "variables" +481, 20, 18, 543, 100, 104, 2761, 2765, "than" +481, 20, 19, 544, 105, 113, 2766, 2774, "patients" +481, 20, 20, 545, 114, 116, 2775, 2777, "in" +481, 20, 21, 546, 117, 120, 2778, 2781, "the" +481, 20, 22, 547, 121, 132, 2782, 2793, "brimonidine" +481, 20, 23, 548, 133, 138, 2794, 2799, "group" +481, 20, 24, 549, 139, 140, 2800, 2801, "." +481, 21, 1, 550, 0, 13, 2802, 2815, "Significantly" +481, 21, 2, 551, 14, 18, 2816, 2820, "more" +481, 21, 3, 552, 19, 30, 2821, 2832, "latanoprost" +481, 21, 4, 553, 31, 39, 2833, 2841, "patients" +481, 21, 5, 554, 40, 48, 2842, 2850, "reported" +481, 21, 6, 555, 49, 55, 2851, 2857, "watery" +481, 21, 7, 556, 56, 58, 2858, 2860, "or" +481, 21, 8, 557, 59, 64, 2861, 2866, "teary" +481, 21, 9, 558, 65, 69, 2867, 2871, "eyes" +481, 21, 10, 559, 70, 71, 2872, 2873, "(" +481, 21, 11, 560, 72, 74, 2874, 2876, "34" +481, 21, 12, 561, 75, 77, 2877, 2879, "of" +481, 21, 13, 562, 78, 80, 2880, 2882, "53" +481, 21, 14, 563, 81, 82, 2883, 2884, "," +481, 21, 15, 564, 83, 85, 2885, 2887, "64" +481, 21, 16, 565, 86, 87, 2888, 2889, "." +481, 21, 17, 566, 88, 89, 2890, 2891, "2" +481, 21, 18, 567, 90, 91, 2892, 2893, "%" +481, 21, 19, 568, 92, 94, 2894, 2896, "vs" +481, 21, 20, 569, 95, 96, 2897, 2898, "." +481, 21, 21, 570, 97, 99, 2899, 2901, "23" +481, 21, 22, 571, 100, 102, 2902, 2904, "of" +481, 21, 23, 572, 103, 105, 2905, 2907, "54" +481, 21, 24, 573, 106, 107, 2908, 2909, "," +481, 21, 25, 574, 108, 110, 2910, 2912, "42" +481, 21, 26, 575, 111, 112, 2913, 2914, "." +481, 21, 27, 576, 113, 114, 2915, 2916, "6" +481, 21, 28, 577, 115, 116, 2917, 2918, "%" +481, 21, 29, 578, 117, 121, 2919, 2923, "with" +481, 21, 30, 579, 122, 133, 2924, 2935, "brimonidine" +481, 21, 31, 580, 134, 135, 2936, 2937, ";" +481, 21, 32, 581, 136, 137, 2938, 2939, "P" +481, 21, 33, 582, 138, 139, 2940, 2941, "=" +481, 21, 34, 583, 140, 141, 2942, 2943, "0" +481, 21, 35, 584, 142, 143, 2944, 2945, "." +481, 21, 36, 585, 144, 147, 2946, 2949, "025" +481, 21, 37, 586, 148, 149, 2950, 2951, ")" +481, 21, 38, 587, 150, 153, 2952, 2955, "and" +481, 21, 39, 588, 154, 159, 2956, 2961, "hands" +481, 21, 40, 589, 160, 163, 2962, 2965, "and" +481, 21, 41, 590, 164, 168, 2966, 2970, "feet" +481, 21, 42, 591, 169, 173, 2971, 2975, "that" +481, 21, 43, 592, 174, 180, 2976, 2982, "became" +481, 21, 44, 593, 181, 185, 2983, 2987, "cold" +481, 21, 45, 594, 186, 192, 2988, 2994, "easily" +481, 21, 46, 595, 193, 194, 2995, 2996, "(" +481, 21, 47, 596, 195, 197, 2997, 2999, "24" +481, 21, 48, 597, 198, 200, 3000, 3002, "of" +481, 21, 49, 598, 201, 203, 3003, 3005, "53" +481, 21, 50, 599, 204, 205, 3006, 3007, "," +481, 21, 51, 600, 206, 208, 3008, 3010, "45" +481, 21, 52, 601, 209, 210, 3011, 3012, "." +481, 21, 53, 602, 211, 212, 3013, 3014, "3" +481, 21, 54, 603, 213, 214, 3015, 3016, "%" +481, 21, 55, 604, 215, 217, 3017, 3019, "vs" +481, 21, 56, 605, 218, 219, 3020, 3021, "." +481, 21, 57, 606, 220, 222, 3022, 3024, "12" +481, 21, 58, 607, 223, 225, 3025, 3027, "of" +481, 21, 59, 608, 226, 228, 3028, 3030, "54" +481, 21, 60, 609, 229, 230, 3031, 3032, "," +481, 21, 61, 610, 231, 233, 3033, 3035, "22" +481, 21, 62, 611, 234, 235, 3036, 3037, "." +481, 21, 63, 612, 236, 237, 3038, 3039, "2" +481, 21, 64, 613, 238, 239, 3040, 3041, "%" +481, 21, 65, 614, 240, 244, 3042, 3046, "with" +481, 21, 66, 615, 245, 256, 3047, 3058, "brimonidine" +481, 21, 67, 616, 257, 258, 3059, 3060, ";" +481, 21, 68, 617, 259, 260, 3061, 3062, "P" +481, 21, 69, 618, 261, 262, 3063, 3064, "=" +481, 21, 70, 619, 263, 264, 3065, 3066, "0" +481, 21, 71, 620, 265, 266, 3067, 3068, "." +481, 21, 72, 621, 267, 270, 3069, 3072, "012" +481, 21, 73, 622, 271, 272, 3073, 3074, ")" +481, 21, 74, 623, 273, 274, 3075, 3076, "." +481, 22, 1, 624, 0, 11, 3077, 3088, "CONCLUSIONS" +481, 22, 2, 625, 12, 13, 3089, 3090, ":" +481, 22, 3, 626, 14, 16, 3091, 3093, "As" +481, 22, 4, 627, 17, 24, 3094, 3101, "adjunct" +481, 22, 5, 628, 25, 32, 3102, 3109, "therapy" +481, 22, 6, 629, 33, 37, 3110, 3114, "with" +481, 22, 7, 630, 38, 42, 3115, 3119, "beta" +481, 22, 8, 631, 43, 44, 3120, 3121, "-" +481, 22, 9, 632, 45, 53, 3122, 3130, "blockers" +481, 22, 10, 633, 54, 55, 3131, 3132, "," +481, 22, 11, 634, 56, 67, 3133, 3144, "brimonidine" +481, 22, 12, 635, 68, 73, 3145, 3150, "twice" +481, 22, 13, 636, 74, 79, 3151, 3156, "daily" +481, 22, 14, 637, 80, 83, 3157, 3160, "and" +481, 22, 15, 638, 84, 95, 3161, 3172, "latanoprost" +481, 22, 16, 639, 96, 101, 3173, 3178, "every" +481, 22, 17, 640, 102, 105, 3179, 3182, "day" +481, 22, 18, 641, 106, 110, 3183, 3187, "were" +481, 22, 19, 642, 111, 121, 3188, 3198, "comparable" +481, 22, 20, 643, 122, 124, 3199, 3201, "in" +481, 22, 21, 644, 125, 133, 3202, 3210, "lowering" +481, 22, 22, 645, 134, 137, 3211, 3214, "IOP" +481, 22, 23, 646, 138, 140, 3215, 3217, "at" +481, 22, 24, 647, 141, 145, 3218, 3222, "peak" +481, 22, 25, 648, 146, 152, 3223, 3229, "effect" +481, 22, 26, 649, 153, 154, 3230, 3231, "," +481, 22, 27, 650, 155, 158, 3232, 3235, "but" +481, 22, 28, 651, 159, 170, 3236, 3247, "brimonidine" +481, 22, 29, 652, 171, 174, 3248, 3251, "was" +481, 22, 30, 653, 175, 181, 3252, 3258, "better" +481, 22, 31, 654, 182, 191, 3259, 3268, "tolerated" +481, 22, 32, 655, 192, 193, 3269, 3270, "," +481, 22, 33, 656, 194, 198, 3271, 3275, "with" +481, 22, 34, 657, 199, 204, 3276, 3281, "fewer" +481, 22, 35, 658, 205, 212, 3282, 3289, "reports" +481, 22, 36, 659, 213, 215, 3290, 3292, "of" +481, 22, 37, 660, 216, 223, 3293, 3300, "adverse" +481, 22, 38, 661, 224, 231, 3301, 3308, "quality" +481, 22, 39, 662, 232, 233, 3309, 3310, "-" +481, 22, 40, 663, 234, 236, 3311, 3313, "of" +481, 22, 41, 664, 237, 238, 3314, 3315, "-" +481, 22, 42, 665, 239, 243, 3316, 3320, "life" +481, 22, 43, 666, 244, 251, 3321, 3328, "effects" +481, 22, 44, 667, 252, 253, 3329, 3330, "." +481, 23, 1, 668, 0, 4, 3331, 3335, "PMID" +481, 23, 2, 669, 5, 6, 3336, 3337, ":" +481, 23, 3, 670, 7, 15, 3338, 3346, "11825814" +481, 23, 4, 671, 16, 17, 3347, 3348, "[" +481, 23, 5, 672, 18, 25, 3349, 3356, "Indexed" +481, 23, 6, 673, 26, 29, 3357, 3360, "for" +481, 23, 7, 674, 30, 37, 3361, 3368, "MEDLINE" +481, 23, 8, 675, 38, 39, 3369, 3370, "]" diff --git a/data/gl 11825814_jshahinitiran.annodb b/data/gl 11825814_jshahinitiran.annodb new file mode 100644 index 0000000..59ffb5d --- /dev/null +++ b/data/gl 11825814_jshahinitiran.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4797, Journal, 0, 13, "Ophthalmology", "", +4798, PublicationYear, 16, 20, "2002", "", +26122, Duration, 71, 84, "Three - month", "", +4799, Title, 71, 278, "Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .", "", +26127, Brimonidine, 99, 110, "brimonidine", "", +26128, Latanoprost, 115, 126, "latanoprost", "", +4803, Glaucoma, 152, 160, "glaucoma", "", +4804, OcularHypertension, 165, 184, "ocular hypertension", "", +4806, Peak_IOP, 242, 267, "peak intraocular pressure", "", +4807, Author, 279, 289, "Simmons ST", "", +4808, Author, 298, 305, "Earl ML", "", +4920, USA, 433, 436, "USA", "", +4809, ObjectiveDescription, 528, 746, "To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .", "", +4810, Peak_IOP, 557, 582, "peak intraocular pressure", "", +4811, IOP, 585, 588, "IOP", "", +26129, Brimonidine, 614, 625, "brimonidine", "", +26130, Latanoprost, 630, 641, "latanoprost", "", +4814, OcularHypertension, 681, 700, "ocular hypertension", "", +4815, Glaucoma, 704, 712, "glaucoma", "", +39038, Prospective, 758, 769, "prospective", "", +4820, Multicenter, 772, 783, "multicenter", "", +4821, DoubleBlind, 786, 801, "double - masked", "", +4822, Parallel, 804, 812, "parallel", "", +4823, NumberPatientsCT, 854, 873, "One hundred fifteen", "", +4824, IOP, 888, 891, "IOP", "", +4827, Randomized, 980, 988, "randomly", "", +4829, DoseValue, 1023, 1028, "0 . 2", "bri", +26131, Percentage, 1029, 1030, "%", "", +26133, Frequency, 1033, 1044, "twice a day", "", +26134, Latanoprost, 1048, 1059, "latanoprost", "", +4838, DoseValue, 1062, 1069, "0 . 005", "lat", +4839, Percentage, 1070, 1071, "%", "lat", +26135, Frequency, 1074, 1083, "every day", "", +26136, Duration, 1110, 1118, "3 months", "", +26137, TimePoint, 1127, 1134, "1 month", "", +26138, EndPointDescription, 1198, 1227, "15 % reduction in IOP at peak", "", +10360, Peak_IOP, 1216, 1227, "IOP at peak", "", +26139, Crossover, 1245, 1257, "crossed over", "", +10361, NumberPatientsArm, 1316, 1318, "51", "", +4842, DiffGroupAbsValue, 1376, 1377, "1", "", +4843, mmHg, 1378, 1382, "mmHg", "", +4844, Mean, 1386, 1390, "mean", "", +4845, IOP, 1391, 1394, "IOP", "", +4846, IOP, 1493, 1496, "IOP", "", +4847, Mean, 1629, 1633, "Mean", "", +4848, IOP, 1668, 1671, "IOP", "", +4849, BaseLineValue, 1728, 1734, "21 . 3", "", +4850, mmHg, 1735, 1740, "mm Hg", "bl", +4921, TimePoint, 1751, 1758, "1 month", "", +26140, Brimonidine, 1783, 1794, "brimonidine", "", +26141, Latanoprost, 1799, 1810, "latanoprost", "", +4853, IOP, 1831, 1834, "IOP", "", +4854, Reduction, 1846, 1852, "4 . 88", "bri", +4855, mmHg, 1853, 1857, "mmHg", "bri", +4856, RelativeReduction, 1860, 1866, "22 . 8", "bri", +26142, Brimonidine, 1876, 1887, "brimonidine", "", +4858, Reduction, 1892, 1898, "5 . 01", "lat", +4859, mmHg, 1899, 1903, "mmHg", "lat", +4860, RelativeReduction, 1906, 1912, "23 . 5", "lat", +26143, Latanoprost, 1922, 1933, "latanoprost", "", +4862, PValueChangeValue, 1936, 1947, "P = 0 . 798", "", +4867, NumberAffected, 2002, 2004, "44", "bri", +26144, NumberPatientsArm, 2008, 2010, "54", "", +26145, Brimonidine, 2011, 2022, "brimonidine", "", +4868, NumberAffected, 2036, 2038, "43", "lat", +26146, NumberPatientsArm, 2042, 2044, "53", "", +26147, Latanoprost, 2045, 2056, "latanoprost", "", +26148, EndPointDescription, 2095, 2121, "15 % IOP reduction at peak", "", +26149, IOP, 2100, 2103, "IOP", "", +4863, TimePoint, 2137, 2144, "month 1", "", +4869, PValueNumAffected, 2147, 2158, "P = 0 . 963", "", +4870, SubGroupDescription, 2169, 2254, "patients who were successful at month 1 and continued on the initial study medication", "", +4871, Mean, 2257, 2261, "mean", "", +4872, IOP, 2262, 2265, "IOP", "", +4873, Reduction, 2282, 2288, "4 . 55", "bri", +4874, mmHg, 2289, 2293, "mmHg", "bri", +26150, Brimonidine, 2299, 2310, "brimonidine", "", +4876, Reduction, 2315, 2321, "5 . 49", "lat", +4877, mmHg, 2322, 2326, "mmHg", "lat", +26151, Latanoprost, 2332, 2343, "latanoprost", "", +4879, PValueChangeValue, 2346, 2357, "P = 0 . 149", "", +4880, TimePoint, 2363, 2370, "month 3", "", +26152, Brimonidine, 2427, 2438, "brimonidine", "", +26153, Latanoprost, 2443, 2454, "latanoprost", "", +26160, EndPointDescription, 2467, 2523, "at least a 15 % additional reduction in IOP for 3 months", "", +4886, IOP, 2507, 2510, "IOP", "", +26154, Duration, 2515, 2523, "3 months", "", +4887, NumberAffected, 2526, 2528, "28", "bri", +26155, Brimonidine, 2547, 2558, "brimonidine", "", +4888, NumberAffected, 2564, 2566, "30", "lat", +26156, Latanoprost, 2585, 2596, "latanoprost", "", +26157, EndPointDescription, 2606, 2642, "> or = 15 % IOP reduction at month 3", "", +26158, IOP, 2618, 2621, "IOP", "", +26159, TimePoint, 2635, 2642, "month 3", "", +4885, PValueNumAffected, 2645, 2656, "P = 0 . 314", "", +26161, Latanoprost, 2677, 2688, "latanoprost", "", +26162, Brimonidine, 2782, 2793, "brimonidine", "", +26163, Latanoprost, 2821, 2832, "latanoprost", "", +4895, NumberAffected, 2874, 2876, "34", "lat", +26165, NumberPatientsArm, 2880, 2882, "53", "", +4899, PercentageAffected, 2885, 2891, "64 . 2", "lat", +4896, NumberAffected, 2899, 2901, "23", "bri", +26166, NumberPatientsArm, 2905, 2907, "54", "", +4900, PercentageAffected, 2910, 2916, "42 . 6", "bri", +26167, Brimonidine, 2924, 2935, "brimonidine", "", +4902, PValueNumAffected, 2938, 2949, "P = 0 . 025", "", +4906, NumberAffected, 2997, 2999, "24", "lat", +26169, NumberPatientsArm, 3003, 3005, "53", "", +4907, PercentageAffected, 3008, 3014, "45 . 3", "lat", +4908, NumberAffected, 3022, 3024, "12", "bri", +26170, NumberPatientsArm, 3028, 3030, "54", "", +4909, PercentageAffected, 3033, 3039, "22 . 2", "bri", +26171, Brimonidine, 3047, 3058, "brimonidine", "", +4911, PValueNumAffected, 3061, 3072, "P = 0 . 012", "", +4912, ConclusionComment, 3091, 3330, "As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .", "", +26172, Brimonidine, 3133, 3144, "brimonidine", "", +26173, Frequency, 3145, 3156, "twice daily", "", +26174, Latanoprost, 3161, 3172, "latanoprost", "", +26175, Frequency, 3173, 3182, "every day", "", +26176, Peak_IOP, 3211, 3222, "IOP at peak", "", +26177, Brimonidine, 3236, 3247, "brimonidine", "", +26178, PMID, 3338, 3346, "11825814", "", diff --git a/data/gl 11825814_jshahinitiran.n-triples b/data/gl 11825814_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11825814_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11825814_tstrakeljahn.annodb b/data/gl 11825814_tstrakeljahn.annodb new file mode 100644 index 0000000..5b66a00 --- /dev/null +++ b/data/gl 11825814_tstrakeljahn.annodb @@ -0,0 +1,129 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +79318, Journal, 0, 13, "Ophthalmology", "", +79336, PublicationYear, 16, 20, "2002", "", +79323, Duration, 71, 84, "Three - month", "", +79330, Title, 71, 278, "Three - month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta - blockers : tolerance and peak intraocular pressure lowering .", "", +79324, Brimonidine, 99, 110, "brimonidine", "", +79325, Latanoprost, 115, 126, "latanoprost", "", +79326, Glaucoma, 152, 160, "glaucoma", "", +79327, OcularHypertension, 165, 184, "ocular hypertension", "", +79329, Precondition, 194, 225, "uncontrolled on beta - blockers", "", +79328, Peak_IOP, 242, 267, "peak intraocular pressure", "", +79331, Author, 279, 289, "Simmons ST", "", +79332, Author, 298, 305, "Earl ML", "", +79334, Drug, 308, 316, "Alphagan", "", +79333, Drug, 319, 326, "Xalatan", "", +79335, USA, 433, 436, "USA", "", +79344, ObjectiveDescription, 528, 746, "To compare the tolerance and peak intraocular pressure ( IOP ) - lowering efficacy of brimonidine and latanoprost as adjunctive therapy in patients with ocular hypertension or glaucoma uncontrolled on beta - blockers .", "", +79337, Peak_IOP, 557, 582, "peak intraocular pressure", "", +79338, IOP, 585, 588, "IOP", "", +79339, Brimonidine, 614, 625, "brimonidine", "", +79340, Latanoprost, 630, 641, "latanoprost", "", +79341, OcularHypertension, 681, 700, "ocular hypertension", "", +79342, Glaucoma, 704, 712, "glaucoma", "", +79343, Precondition, 713, 744, "uncontrolled on beta - blockers", "", +79345, Prospective, 758, 769, "prospective", "", +79346, Multicenter, 772, 783, "multicenter", "", +79347, DoubleBlind, 786, 801, "double - masked", "", +79348, Parallel, 804, 812, "parallel", "", +79349, ClinicalTrial, 822, 836, "clinical trial", "", +79350, NumberPatientsCT, 854, 873, "One hundred fifteen", "", +79351, IOP, 888, 891, "IOP", "", +79352, Precondition, 892, 953, "inadequately controlled on topical beta - blocker monotherapy", "", +79353, Brimonidine, 1009, 1020, "brimonidine", "", +79355, DoseValue, 1023, 1028, "0 . 2", "", +79357, Percentage, 1029, 1030, "%", "", +79359, Frequency, 1033, 1044, "twice a day", "", +79354, Latanoprost, 1048, 1059, "latanoprost", "", +79356, DoseValue, 1062, 1069, "0 . 005", "", +79358, Percentage, 1070, 1071, "%", "", +79360, Frequency, 1074, 1083, "every day", "", +79361, Duration, 1110, 1118, "3 months", "", +79373, TimePoint, 1121, 1134, "After 1 month", "", +79364, SubGroupDescription, 1161, 1239, "patients who failed to meet a target 15 % reduction in IOP at peak drug effect", "", +79362, Peak_IOP, 1216, 1239, "IOP at peak drug effect", "", +79365, Mean, 1386, 1390, "mean", "", +79366, IOP, 1391, 1394, "IOP", "", +79367, IOP, 1493, 1496, "IOP", "", +79368, Mean, 1629, 1633, "Mean", "", +79369, IOP, 1668, 1671, "IOP", "", +79370, BaseLineValue, 1728, 1734, "21 . 3", "", +79371, mmHg, 1735, 1740, "mm Hg", "", +79372, TimePoint, 1745, 1758, "After 1 month", "", +79374, Brimonidine, 1783, 1794, "brimonidine", "", +79375, Latanoprost, 1799, 1810, "latanoprost", "", +79376, IOP, 1831, 1834, "IOP", "", +79377, Reduction, 1846, 1852, "4 . 88", "", +79384, mmHg, 1853, 1857, "mmHg", "", +79379, RelativeReduction, 1860, 1866, "22 . 8", "", +79381, Brimonidine, 1876, 1887, "brimonidine", "", +79378, Reduction, 1892, 1898, "5 . 01", "", +79383, mmHg, 1899, 1903, "mmHg", "", +79380, RelativeReduction, 1906, 1912, "23 . 5", "", +79382, Latanoprost, 1922, 1933, "latanoprost", "", +79385, PvalueDiff, 1938, 1947, "= 0 . 798", "", +79386, NumberAffected, 2002, 2004, "44", "", +79388, NumberPatientsArm, 2008, 2010, "54", "", +79390, Brimonidine, 2011, 2022, "brimonidine", "", +79387, NumberAffected, 2036, 2038, "43", "", +79389, NumberPatientsArm, 2042, 2044, "53", "", +79391, Latanoprost, 2045, 2056, "latanoprost", "", +79393, SubGroupDescription, 2066, 2133, "achieving the minimum target 15 % IOP reduction at peak drug effect", "", +79392, IOP, 2100, 2103, "IOP", "", +79394, TimePoint, 2137, 2144, "month 1", "", +79395, PvalueDiff, 2149, 2158, "= 0 . 963", "", +79398, SubGroupDescription, 2169, 2254, "patients who were successful at month 1 and continued on the initial study medication", "", +79397, TimePoint, 2201, 2208, "month 1", "", +79399, Mean, 2257, 2261, "mean", "", +79400, IOP, 2262, 2265, "IOP", "", +79401, Reduction, 2282, 2288, "4 . 55", "", +79405, mmHg, 2289, 2293, "mmHg", "", +79403, Brimonidine, 2299, 2310, "brimonidine", "", +79402, Reduction, 2315, 2321, "5 . 49", "", +79406, mmHg, 2322, 2326, "mmHg", "", +79404, Latanoprost, 2332, 2343, "latanoprost", "", +79407, PvalueDiff, 2348, 2357, "= 0 . 149", "", +79408, TimePoint, 2363, 2370, "month 3", "", +79422, ObservedResult, 2373, 2621, "There was no significant difference in the ability of brimonidine and latanoprost to maintain at least a 15 % additional reduction in IOP for 3 months ( 28 of 38 patients on brimonidine vs . 30 of 36 patients on latanoprost achieved > or = 15 % IOP", "", +79409, Brimonidine, 2427, 2438, "brimonidine", "", +79410, Latanoprost, 2443, 2454, "latanoprost", "", +79413, SubGroupDescription, 2458, 2523, "maintain at least a 15 % additional reduction in IOP for 3 months", "", +79411, IOP, 2507, 2510, "IOP", "", +79412, Duration, 2515, 2523, "3 months", "", +79414, NumberAffected, 2526, 2528, "28", "", +79416, NumberAffected, 2532, 2534, "38", "", +79415, NumberAffected, 2564, 2566, "30", "", +79417, NumberAffected, 2570, 2572, "36", "", +79418, Latanoprost, 2585, 2596, "latanoprost", "", +79419, IOP, 2618, 2621, "IOP", "", +79423, ObservedResult, 2622, 2660, "reduction at month 3 ; P = 0 . 314 ) .", "", +79420, TimePoint, 2635, 2642, "month 3", "", +79421, PvalueDiff, 2647, 2656, "= 0 . 314", "", +79427, ObservedResult, 2661, 2801, "Patients in the latanoprost group were more likely to report negative quality - of - life variables than patients in the brimonidine group .", "", +79424, Latanoprost, 2677, 2688, "latanoprost", "", +79425, Brimonidine, 2782, 2793, "brimonidine", "", +79426, Latanoprost, 2821, 2832, "latanoprost", "", +79429, NumberAffected, 2874, 2876, "34", "", +79433, FinalNumPatientsArm, 2880, 2882, "53", "", +79431, PercentageAffected, 2885, 2891, "64 . 2", "", +79430, NumberAffected, 2899, 2901, "23", "", +79434, FinalNumPatientsArm, 2905, 2907, "54", "", +79432, PercentageAffected, 2910, 2916, "42 . 6", "", +79435, Brimonidine, 2924, 2935, "brimonidine", "", +79436, PvalueDiff, 2940, 2949, "= 0 . 025", "", +79439, NumberAffected, 2997, 2999, "24", "", +79443, FinalNumPatientsArm, 3003, 3005, "53", "", +79441, PercentageAffected, 3008, 3014, "45 . 3", "", +79440, NumberAffected, 3022, 3024, "12", "", +79444, FinalNumPatientsArm, 3028, 3030, "54", "", +79442, PercentageAffected, 3033, 3039, "22 . 2", "", +79438, Brimonidine, 3047, 3058, "brimonidine", "", +79445, PvalueDiff, 3063, 3072, "= 0 . 012", "", +79452, ConclusionComment, 3091, 3330, "As adjunct therapy with beta - blockers , brimonidine twice daily and latanoprost every day were comparable in lowering IOP at peak effect , but brimonidine was better tolerated , with fewer reports of adverse quality - of - life effects .", "", +79446, Brimonidine, 3133, 3144, "brimonidine", "", +79448, Frequency, 3145, 3156, "twice daily", "", +79447, Latanoprost, 3161, 3172, "latanoprost", "", +79449, Frequency, 3173, 3182, "every day", "", +79450, IOP, 3211, 3214, "IOP", "", +79451, Brimonidine, 3236, 3247, "brimonidine", "", +79453, PMID, 3338, 3346, "11825814", "", diff --git a/data/gl 11825814_tstrakeljahn.n-triples b/data/gl 11825814_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11825814_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11912355_admin.annodb b/data/gl 11912355_admin.annodb new file mode 100644 index 0000000..0c040e2 --- /dev/null +++ b/data/gl 11912355_admin.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2002", "", " \"2002\"." +40, Title, 44, 237, "Intraocular pressure - lowering effects of latanoprost and brimonidine therapy in patients with open - angle glaucoma or ocular hypertension : a randomized observer - masked multicenter study .", "", " \"Intraocular pressure - lowering effects of latanoprost and brimonidine therapy in patients with open - angle glaucoma or ocular hypertension : a randomized observer - masked multicenter study .\"." +41, IOP, 44, 64, "Intraocular pressure", "", +42, Latanoprost, 87, 98, "latanoprost", "", +43, Brimonidine, 103, 114, "brimonidine", "", +8, OpenAngleGlaucoma, 140, 161, "open - angle glaucoma", "", " ." +9, OcularHypertension, 165, 184, "ocular hypertension", "", " ." +10, Randomized, 189, 199, "randomized", "", " ." +44, Blind, 200, 217, "observer - masked", "", " ." +45, Multicenter, 218, 229, "multicenter", "", " ." +2, Author, 238, 246, "Kampik A", "", " \"Kampik A\"." +3, Author, 255, 271, "Arias - Puente A", "", " \"Arias - Puente A\"." +4, Author, 274, 286, "O ' Brart DP", "", " \"O ' Brart DP\"." +5, Author, 289, 297, "Vuori ML", "", " \"Vuori ML\"." +105, Latanoprost, 309, 320, "Latanoprost", "", +6, Germany, 436, 443, "Germany", "", " ." +7, ObjectiveDescription, 456, 677, "To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy .", "", " \"To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy .\"." +46, Latanoprost, 496, 507, "latanoprost", "", +47, Brimonidine, 511, 522, "brimonidine", "", +11, IOP, 526, 546, "intraocular pressure", "", +121, Precondition, 550, 675, "patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy", "", " \"patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy\"." +12, Glaucoma, 564, 572, "glaucoma", "", " . ." +13, OcularHypertension, 576, 595, "ocular hypertension", "", +14, IOP, 600, 620, "intraocular pressure", "", +49, NumberPatientsCT, 701, 729, "Three hundred seventy - nine", "", " \"Three hundred seventy - nine\"." +89, Primary_OpenAngleGlaucoma, 744, 773, "primary open - angle glaucoma", "", " ." +15, OcularHypertension, 777, 796, "ocular hypertension", "", +50, Duration, 821, 830, "6 - month", "", " \"6 - month\"." +176, Prospective, 831, 842, "prospective", "", " ." +51, Randomized, 845, 855, "randomized", "", +52, Blind, 858, 875, "observer - masked", "", +53, Multicenter, 876, 887, "multicenter", "", +122, Precondition, 921, 1029, "All patients were receiving monotherapy or dual therapy that did not adequately control intraocular pressure", "", " \"patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy\"." +16, IOP, 1009, 1029, "intraocular pressure", "", +54, Randomized, 1082, 1092, "randomized", "", +55, Latanoprost, 1111, 1122, "latanoprost", "", " . ." +56, Frequency, 1123, 1133, "once daily", "", " \"once daily\"." +57, Brimonidine, 1137, 1148, "brimonidine", "", " ." +58, Frequency, 1149, 1160, "twice daily", "", " \"twice daily\"." +59, Mean, 1202, 1206, "mean", "", +60, Diurnal_IOP, 1207, 1235, "diurnal intraocular pressure", "", +61, Duration, 1242, 1250, "6 months", "", +62, NumberPatientsCT, 1306, 1309, "379", "", +63, Randomized, 1310, 1320, "randomized", "", +18, FinalNumPatientsCT, 1332, 1335, "375", "", " \"375\"." +17, IntentionToTreat, 1357, 1376, "intent - to - treat", "", " ." +19, Mean, 1413, 1417, "mean", "", " . ." +20, IOP, 1418, 1438, "intraocular pressure", "", " . ." +21, BaseLineValue, 1442, 1448, "25 . 0", "", " \"25 . 0\". \"25 . 0\"." +22, mmHg, 1449, 1454, "mm Hg", "", " ." +64, Latanoprost, 1457, 1468, "latanoprost", "", +65, Mean, 1489, 1493, "mean", "", +141, Diurnal_IOP, 1494, 1522, "diurnal intraocular pressure", "", +23, Reduction, 1526, 1531, "7 . 1", "", " \"7 . 1\"." +24, SdDevChangeValue, 1538, 1543, "3 . 3", "", " \"3 . 3\"." +25, mmHg, 1544, 1549, "mm Hg", "", +70, Mean, 1552, 1556, "mean", "", +26, PValueChangeValue, 1568, 1579, "P < 0 . 001", "", " \"P < 0 . 001\"." +67, Brimonidine, 1592, 1603, "brimonidine", "", +68, IOP, 1627, 1649, "intraocular - pressure", "", +27, Reduction, 1663, 1668, "5 . 2", "", " \"5 . 2\"." +28, SdDevChangeValue, 1675, 1680, "3 . 5", "", " \"3 . 5\"." +69, mmHg, 1681, 1686, "mm Hg", "", +29, PValueChangeValue, 1689, 1700, "P < 0 . 001", "", " \"P < 0 . 001\"." +30, DiffGroupAbsValue, 1710, 1715, "1 . 9", "", " \"1 . 9\"." +31, mmHg, 1716, 1721, "mm Hg", "", +71, IOP, 1736, 1758, "intraocular - pressure", "", +72, Latanoprost, 1799, 1810, "latanoprost", "", +32, PvalueDiff, 1813, 1824, "P < 0 . 001", "", " \"P < 0 . 001\"." +41188, EndPointDescription, 1829, 1843, "Ocular allergy", "", " . ." +74, PValueNumAffected, 1846, 1857, "P < 0 . 001", "", " \"P < 0 . 001\"." +41191, EndPointDescription, 1864, 1885, "systemic side effects", "", " . ." +75, PValueNumAffected, 1888, 1899, "P = 0 . 005", "", " \"P = 0 . 005\"." +41197, ObservedResult, 1902, 2024, "were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients", "", " \"were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients\". \"were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients\"." +76, Latanoprost, 1949, 1960, "latanoprost", "", +77, Brimonidine, 1994, 2005, "brimonidine", "", +34, ConclusionComment, 2041, 2181, "Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment .", "", " \"Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment .\"." +78, Latanoprost, 2046, 2057, "latanoprost", "", +79, Brimonidine, 2062, 2073, "brimonidine", "", +80, IOP, 2082, 2102, "intraocular pressure", "", +37, Glaucoma, 2120, 2128, "glaucoma", "", +38, OcularHypertension, 2132, 2151, "ocular hypertension", "", +81, Duration, 2158, 2166, "6 months", "", +35, ConclusionComment, 2182, 2324, "However , latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure .", "", " \"However , latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure .\"." +82, Latanoprost, 2192, 2203, "latanoprost", "", +83, Frequency, 2204, 2214, "once daily", "", +84, Brimonidine, 2253, 2264, "brimonidine", "", +85, Frequency, 2265, 2276, "twice daily", "", +86, Mean, 2289, 2293, "mean", "", +168, Diurnal_IOP, 2294, 2322, "diurnal intraocular pressure", "", +36, ConclusionComment, 2325, 2431, "Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects .", "", " \"Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects .\"." +88, Latanoprost, 2325, 2336, "Latanoprost", "", +105206, Ocular_Allergy, 2389, 2403, "ocular allergy", "", +41205, EndPointDescription, 2408, 2429, "systemic side effects", "", +39, PMID, 2439, 2447, "11912355", "", " \"11912355\"." diff --git a/data/gl 11912355_admin.n-triples b/data/gl 11912355_admin.n-triples new file mode 100644 index 0000000..a613019 --- /dev/null +++ b/data/gl 11912355_admin.n-triples @@ -0,0 +1,138 @@ +# RDF export of group: Publication + . + "Publication" . + "Intraocular pressure - lowering effects of latanoprost and brimonidine therapy in patients with open - angle glaucoma or ocular hypertension : a randomized observer - masked multicenter study ." . + "Kampik A" . + "2002" . + "J Glaucoma" . + "11912355" . + . + "Arias - Puente A" . + "O ' Brart DP" . + "Vuori ML" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy ." . + "Three hundred seventy - nine" . + "6 - month" . + . + . + . + "Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment ." . + . + . + . + . + . + "375" . + . + . + . + "However , latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure ." . + "Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy" . + . + . + . + "All patients were receiving monotherapy or dual therapy that did not adequately control intraocular pressure" . +# RDF export of group: Endpoint + . + "Endpoint" . + . + . + . + . + . + . + . + "Endpoint_AE_O" . + . + . + . + . + . + . + "Endpoint_AE_S" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + "Arm_bri" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_bri" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + . + . + . + "Medication_bri" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_lat" . + . + "25 . 0" . + "7 . 1" . + "P < 0 . 001" . + "3 . 3" . + . + "Outcome_bri" . + . + "25 . 0" . + "5 . 2" . + "P < 0 . 001" . + "3 . 5" . + . + "AE_O" . + . + "P < 0 . 001" . + "were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients" . + . + "AE_S" . + . + "P = 0 . 005" . + "were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "1 . 9" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11912355_export.csv b/data/gl 11912355_export.csv new file mode 100644 index 0000000..a26b105 --- /dev/null +++ b/data/gl 11912355_export.csv @@ -0,0 +1,440 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +480, 1, 1, 1, 0, 1, 0, 1, "J" +480, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +480, 1, 3, 3, 11, 12, 11, 12, "." +480, 2, 1, 4, 0, 4, 13, 17, "2002" +480, 2, 2, 5, 5, 8, 18, 21, "Apr" +480, 2, 3, 6, 9, 10, 22, 23, ";" +480, 2, 4, 7, 11, 13, 24, 26, "11" +480, 2, 5, 8, 14, 15, 27, 28, "(" +480, 2, 6, 9, 16, 17, 29, 30, "2" +480, 2, 7, 10, 18, 19, 31, 32, ")" +480, 2, 8, 11, 20, 21, 33, 34, ":" +480, 2, 9, 12, 22, 24, 35, 37, "90" +480, 2, 10, 13, 25, 26, 38, 39, "-" +480, 2, 11, 14, 27, 28, 40, 41, "6" +480, 2, 12, 15, 29, 30, 42, 43, "." +480, 3, 1, 16, 0, 11, 44, 55, "Intraocular" +480, 3, 2, 17, 12, 20, 56, 64, "pressure" +480, 3, 3, 18, 21, 22, 65, 66, "-" +480, 3, 4, 19, 23, 31, 67, 75, "lowering" +480, 3, 5, 20, 32, 39, 76, 83, "effects" +480, 3, 6, 21, 40, 42, 84, 86, "of" +480, 3, 7, 22, 43, 54, 87, 98, "latanoprost" +480, 3, 8, 23, 55, 58, 99, 102, "and" +480, 3, 9, 24, 59, 70, 103, 114, "brimonidine" +480, 3, 10, 25, 71, 78, 115, 122, "therapy" +480, 3, 11, 26, 79, 81, 123, 125, "in" +480, 3, 12, 27, 82, 90, 126, 134, "patients" +480, 3, 13, 28, 91, 95, 135, 139, "with" +480, 3, 14, 29, 96, 100, 140, 144, "open" +480, 3, 15, 30, 101, 102, 145, 146, "-" +480, 3, 16, 31, 103, 108, 147, 152, "angle" +480, 3, 17, 32, 109, 117, 153, 161, "glaucoma" +480, 3, 18, 33, 118, 120, 162, 164, "or" +480, 3, 19, 34, 121, 127, 165, 171, "ocular" +480, 3, 20, 35, 128, 140, 172, 184, "hypertension" +480, 3, 21, 36, 141, 142, 185, 186, ":" +480, 3, 22, 37, 143, 144, 187, 188, "a" +480, 3, 23, 38, 145, 155, 189, 199, "randomized" +480, 3, 24, 39, 156, 164, 200, 208, "observer" +480, 3, 25, 40, 165, 166, 209, 210, "-" +480, 3, 26, 41, 167, 173, 211, 217, "masked" +480, 3, 27, 42, 174, 185, 218, 229, "multicenter" +480, 3, 28, 43, 186, 191, 230, 235, "study" +480, 3, 29, 44, 192, 193, 236, 237, "." +480, 4, 1, 45, 0, 6, 238, 244, "Kampik" +480, 4, 2, 46, 7, 8, 245, 246, "A" +480, 4, 3, 47, 9, 10, 247, 248, "(" +480, 4, 4, 48, 11, 12, 249, 250, "1" +480, 4, 5, 49, 13, 14, 251, 252, ")" +480, 4, 6, 50, 15, 16, 253, 254, "," +480, 4, 7, 51, 17, 22, 255, 260, "Arias" +480, 4, 8, 52, 23, 24, 261, 262, "-" +480, 4, 9, 53, 25, 31, 263, 269, "Puente" +480, 4, 10, 54, 32, 33, 270, 271, "A" +480, 4, 11, 55, 34, 35, 272, 273, "," +480, 4, 12, 56, 36, 37, 274, 275, "O" +480, 4, 13, 57, 38, 39, 276, 277, "'" +480, 4, 14, 58, 40, 45, 278, 283, "Brart" +480, 4, 15, 59, 46, 48, 284, 286, "DP" +480, 4, 16, 60, 49, 50, 287, 288, "," +480, 4, 17, 61, 51, 56, 289, 294, "Vuori" +480, 4, 18, 62, 57, 59, 295, 297, "ML" +480, 4, 19, 63, 60, 61, 298, 299, ";" +480, 4, 20, 64, 62, 70, 300, 308, "European" +480, 4, 21, 65, 71, 82, 309, 320, "Latanoprost" +480, 4, 22, 66, 83, 88, 321, 326, "Study" +480, 4, 23, 67, 89, 94, 327, 332, "Group" +480, 4, 24, 68, 95, 96, 333, 334, "." +480, 5, 1, 69, 0, 6, 335, 341, "Author" +480, 5, 2, 70, 7, 18, 342, 353, "information" +480, 5, 3, 71, 19, 20, 354, 355, ":" +480, 5, 4, 72, 21, 22, 356, 357, "(" +480, 5, 5, 73, 23, 24, 358, 359, "1" +480, 5, 6, 74, 25, 26, 360, 361, ")" +480, 5, 7, 75, 27, 37, 362, 372, "Department" +480, 5, 8, 76, 38, 40, 373, 375, "of" +480, 5, 9, 77, 41, 54, 376, 389, "Ophthalmology" +480, 5, 10, 78, 55, 56, 390, 391, "," +480, 5, 11, 79, 57, 64, 392, 399, "Ludwigs" +480, 5, 12, 80, 65, 66, 400, 401, "-" +480, 5, 13, 81, 67, 78, 402, 413, "Maximilians" +480, 5, 14, 82, 79, 89, 414, 424, "University" +480, 5, 15, 83, 90, 91, 425, 426, "," +480, 5, 16, 84, 92, 98, 427, 433, "Munich" +480, 5, 17, 85, 99, 100, 434, 435, "," +480, 5, 18, 86, 101, 108, 436, 443, "Germany" +480, 5, 19, 87, 109, 110, 444, 445, "." +480, 6, 1, 88, 0, 7, 446, 453, "PURPOSE" +480, 6, 2, 89, 8, 9, 454, 455, ":" +480, 6, 3, 90, 10, 12, 456, 458, "To" +480, 6, 4, 91, 13, 20, 459, 466, "compare" +480, 6, 5, 92, 21, 24, 467, 470, "the" +480, 6, 6, 93, 25, 31, 471, 477, "effect" +480, 6, 7, 94, 32, 34, 478, 480, "of" +480, 6, 8, 95, 35, 44, 481, 490, "treatment" +480, 6, 9, 96, 45, 49, 491, 495, "with" +480, 6, 10, 97, 50, 61, 496, 507, "latanoprost" +480, 6, 11, 98, 62, 64, 508, 510, "or" +480, 6, 12, 99, 65, 76, 511, 522, "brimonidine" +480, 6, 13, 100, 77, 79, 523, 525, "on" +480, 6, 14, 101, 80, 91, 526, 537, "intraocular" +480, 6, 15, 102, 92, 100, 538, 546, "pressure" +480, 6, 16, 103, 101, 103, 547, 549, "in" +480, 6, 17, 104, 104, 112, 550, 558, "patients" +480, 6, 18, 105, 113, 117, 559, 563, "with" +480, 6, 19, 106, 118, 126, 564, 572, "glaucoma" +480, 6, 20, 107, 127, 129, 573, 575, "or" +480, 6, 21, 108, 130, 136, 576, 582, "ocular" +480, 6, 22, 109, 137, 149, 583, 595, "hypertension" +480, 6, 23, 110, 150, 153, 596, 599, "and" +480, 6, 24, 111, 154, 165, 600, 611, "intraocular" +480, 6, 25, 112, 166, 174, 612, 620, "pressure" +480, 6, 26, 113, 175, 187, 621, 633, "inadequately" +480, 6, 27, 114, 188, 198, 634, 644, "controlled" +480, 6, 28, 115, 199, 201, 645, 647, "by" +480, 6, 29, 116, 202, 213, 648, 659, "monotherapy" +480, 6, 30, 117, 214, 216, 660, 662, "or" +480, 6, 31, 118, 217, 221, 663, 667, "dual" +480, 6, 32, 119, 222, 229, 668, 675, "therapy" +480, 6, 33, 120, 230, 231, 676, 677, "." +480, 7, 1, 121, 0, 8, 678, 686, "PATIENTS" +480, 7, 2, 122, 9, 12, 687, 690, "AND" +480, 7, 3, 123, 13, 20, 691, 698, "METHODS" +480, 7, 4, 124, 21, 22, 699, 700, ":" +480, 7, 5, 125, 23, 28, 701, 706, "Three" +480, 7, 6, 126, 29, 36, 707, 714, "hundred" +480, 7, 7, 127, 37, 44, 715, 722, "seventy" +480, 7, 8, 128, 45, 46, 723, 724, "-" +480, 7, 9, 129, 47, 51, 725, 729, "nine" +480, 7, 10, 130, 52, 60, 730, 738, "patients" +480, 7, 11, 131, 61, 65, 739, 743, "with" +480, 7, 12, 132, 66, 73, 744, 751, "primary" +480, 7, 13, 133, 74, 78, 752, 756, "open" +480, 7, 14, 134, 79, 80, 757, 758, "-" +480, 7, 15, 135, 81, 86, 759, 764, "angle" +480, 7, 16, 136, 87, 95, 765, 773, "glaucoma" +480, 7, 17, 137, 96, 98, 774, 776, "or" +480, 7, 18, 138, 99, 105, 777, 783, "ocular" +480, 7, 19, 139, 106, 118, 784, 796, "hypertension" +480, 7, 20, 140, 119, 123, 797, 801, "were" +480, 7, 21, 141, 124, 133, 802, 811, "recruited" +480, 7, 22, 142, 134, 137, 812, 815, "for" +480, 7, 23, 143, 138, 142, 816, 820, "this" +480, 7, 24, 144, 143, 144, 821, 822, "6" +480, 7, 25, 145, 145, 146, 823, 824, "-" +480, 7, 26, 146, 147, 152, 825, 830, "month" +480, 7, 27, 147, 153, 164, 831, 842, "prospective" +480, 7, 28, 148, 165, 166, 843, 844, "," +480, 7, 29, 149, 167, 177, 845, 855, "randomized" +480, 7, 30, 150, 178, 179, 856, 857, "," +480, 7, 31, 151, 180, 188, 858, 866, "observer" +480, 7, 32, 152, 189, 190, 867, 868, "-" +480, 7, 33, 153, 191, 197, 869, 875, "masked" +480, 7, 34, 154, 198, 209, 876, 887, "multicenter" +480, 7, 35, 155, 210, 215, 888, 893, "study" +480, 7, 36, 156, 216, 225, 894, 903, "involving" +480, 7, 37, 157, 226, 228, 904, 906, "30" +480, 7, 38, 158, 229, 232, 907, 910, "eye" +480, 7, 39, 159, 233, 240, 911, 918, "clinics" +480, 7, 40, 160, 241, 242, 919, 920, "." +480, 8, 1, 161, 0, 3, 921, 924, "All" +480, 8, 2, 162, 4, 12, 925, 933, "patients" +480, 8, 3, 163, 13, 17, 934, 938, "were" +480, 8, 4, 164, 18, 27, 939, 948, "receiving" +480, 8, 5, 165, 28, 39, 949, 960, "monotherapy" +480, 8, 6, 166, 40, 42, 961, 963, "or" +480, 8, 7, 167, 43, 47, 964, 968, "dual" +480, 8, 8, 168, 48, 55, 969, 976, "therapy" +480, 8, 9, 169, 56, 60, 977, 981, "that" +480, 8, 10, 170, 61, 64, 982, 985, "did" +480, 8, 11, 171, 65, 68, 986, 989, "not" +480, 8, 12, 172, 69, 79, 990, 1000, "adequately" +480, 8, 13, 173, 80, 87, 1001, 1008, "control" +480, 8, 14, 174, 88, 99, 1009, 1020, "intraocular" +480, 8, 15, 175, 100, 108, 1021, 1029, "pressure" +480, 8, 16, 176, 109, 110, 1030, 1031, "." +480, 9, 1, 177, 0, 5, 1032, 1037, "After" +480, 9, 2, 178, 6, 17, 1038, 1049, "appropriate" +480, 9, 3, 179, 18, 25, 1050, 1057, "washout" +480, 9, 4, 180, 26, 33, 1058, 1065, "periods" +480, 9, 5, 181, 34, 35, 1066, 1067, "," +480, 9, 6, 182, 36, 44, 1068, 1076, "patients" +480, 9, 7, 183, 45, 49, 1077, 1081, "were" +480, 9, 8, 184, 50, 60, 1082, 1092, "randomized" +480, 9, 9, 185, 61, 63, 1093, 1095, "to" +480, 9, 10, 186, 64, 73, 1096, 1105, "treatment" +480, 9, 11, 187, 74, 78, 1106, 1110, "with" +480, 9, 12, 188, 79, 90, 1111, 1122, "latanoprost" +480, 9, 13, 189, 91, 95, 1123, 1127, "once" +480, 9, 14, 190, 96, 101, 1128, 1133, "daily" +480, 9, 15, 191, 102, 104, 1134, 1136, "or" +480, 9, 16, 192, 105, 116, 1137, 1148, "brimonidine" +480, 9, 17, 193, 117, 122, 1149, 1154, "twice" +480, 9, 18, 194, 123, 128, 1155, 1160, "daily" +480, 9, 19, 195, 129, 130, 1161, 1162, "." +480, 10, 1, 196, 0, 3, 1163, 1166, "The" +480, 10, 2, 197, 4, 8, 1167, 1171, "main" +480, 10, 3, 198, 9, 16, 1172, 1179, "outcome" +480, 10, 4, 199, 17, 24, 1180, 1187, "measure" +480, 10, 5, 200, 25, 28, 1188, 1191, "was" +480, 10, 6, 201, 29, 35, 1192, 1198, "change" +480, 10, 7, 202, 36, 38, 1199, 1201, "in" +480, 10, 8, 203, 39, 43, 1202, 1206, "mean" +480, 10, 9, 204, 44, 51, 1207, 1214, "diurnal" +480, 10, 10, 205, 52, 63, 1215, 1226, "intraocular" +480, 10, 11, 206, 64, 72, 1227, 1235, "pressure" +480, 10, 12, 207, 73, 78, 1236, 1241, "after" +480, 10, 13, 208, 79, 80, 1242, 1243, "6" +480, 10, 14, 209, 81, 87, 1244, 1250, "months" +480, 10, 15, 210, 88, 90, 1251, 1253, "of" +480, 10, 16, 211, 91, 100, 1254, 1263, "treatment" +480, 10, 17, 212, 101, 109, 1264, 1272, "compared" +480, 10, 18, 213, 110, 114, 1273, 1277, "with" +480, 10, 19, 214, 115, 123, 1278, 1286, "baseline" +480, 10, 20, 215, 124, 125, 1287, 1288, "." +480, 11, 1, 216, 0, 7, 1289, 1296, "RESULTS" +480, 11, 2, 217, 8, 9, 1297, 1298, ":" +480, 11, 3, 218, 10, 12, 1299, 1301, "Of" +480, 11, 4, 219, 13, 16, 1302, 1305, "the" +480, 11, 5, 220, 17, 20, 1306, 1309, "379" +480, 11, 6, 221, 21, 31, 1310, 1320, "randomized" +480, 11, 7, 222, 32, 40, 1321, 1329, "patients" +480, 11, 8, 223, 41, 42, 1330, 1331, "," +480, 11, 9, 224, 43, 46, 1332, 1335, "375" +480, 11, 10, 225, 47, 51, 1336, 1340, "were" +480, 11, 11, 226, 52, 60, 1341, 1349, "included" +480, 11, 12, 227, 61, 63, 1350, 1352, "in" +480, 11, 13, 228, 64, 67, 1353, 1356, "the" +480, 11, 14, 229, 68, 74, 1357, 1363, "intent" +480, 11, 15, 230, 75, 76, 1364, 1365, "-" +480, 11, 16, 231, 77, 79, 1366, 1368, "to" +480, 11, 17, 232, 80, 81, 1369, 1370, "-" +480, 11, 18, 233, 82, 87, 1371, 1376, "treat" +480, 11, 19, 234, 88, 96, 1377, 1385, "analysis" +480, 11, 20, 235, 97, 98, 1386, 1387, "." +480, 12, 1, 236, 0, 4, 1388, 1392, "From" +480, 12, 2, 237, 5, 7, 1393, 1395, "an" +480, 12, 3, 238, 8, 15, 1396, 1403, "overall" +480, 12, 4, 239, 16, 24, 1404, 1412, "baseline" +480, 12, 5, 240, 25, 29, 1413, 1417, "mean" +480, 12, 6, 241, 30, 41, 1418, 1429, "intraocular" +480, 12, 7, 242, 42, 50, 1430, 1438, "pressure" +480, 12, 8, 243, 51, 53, 1439, 1441, "of" +480, 12, 9, 244, 54, 56, 1442, 1444, "25" +480, 12, 10, 245, 57, 58, 1445, 1446, "." +480, 12, 11, 246, 59, 60, 1447, 1448, "0" +480, 12, 12, 247, 61, 63, 1449, 1451, "mm" +480, 12, 13, 248, 64, 66, 1452, 1454, "Hg" +480, 12, 14, 249, 67, 68, 1455, 1456, "," +480, 12, 15, 250, 69, 80, 1457, 1468, "latanoprost" +480, 12, 16, 251, 81, 92, 1469, 1480, "monotherapy" +480, 12, 17, 252, 93, 100, 1481, 1488, "reduced" +480, 12, 18, 253, 101, 105, 1489, 1493, "mean" +480, 12, 19, 254, 106, 113, 1494, 1501, "diurnal" +480, 12, 20, 255, 114, 125, 1502, 1513, "intraocular" +480, 12, 21, 256, 126, 134, 1514, 1522, "pressure" +480, 12, 22, 257, 135, 137, 1523, 1525, "by" +480, 12, 23, 258, 138, 139, 1526, 1527, "7" +480, 12, 24, 259, 140, 141, 1528, 1529, "." +480, 12, 25, 260, 142, 143, 1530, 1531, "1" +480, 12, 26, 261, 144, 145, 1532, 1533, "+" +480, 12, 27, 262, 146, 147, 1534, 1535, "/" +480, 12, 28, 263, 148, 149, 1536, 1537, "-" +480, 12, 29, 264, 150, 151, 1538, 1539, "3" +480, 12, 30, 265, 152, 153, 1540, 1541, "." +480, 12, 31, 266, 154, 155, 1542, 1543, "3" +480, 12, 32, 267, 156, 158, 1544, 1546, "mm" +480, 12, 33, 268, 159, 161, 1547, 1549, "Hg" +480, 12, 34, 269, 162, 163, 1550, 1551, "(" +480, 12, 35, 270, 164, 168, 1552, 1556, "mean" +480, 12, 36, 271, 169, 170, 1557, 1558, "+" +480, 12, 37, 272, 171, 172, 1559, 1560, "/" +480, 12, 38, 273, 173, 174, 1561, 1562, "-" +480, 12, 39, 274, 175, 177, 1563, 1565, "SD" +480, 12, 40, 275, 178, 179, 1566, 1567, "," +480, 12, 41, 276, 180, 181, 1568, 1569, "P" +480, 12, 42, 277, 182, 183, 1570, 1571, "<" +480, 12, 43, 278, 184, 185, 1572, 1573, "0" +480, 12, 44, 279, 186, 187, 1574, 1575, "." +480, 12, 45, 280, 188, 191, 1576, 1579, "001" +480, 12, 46, 281, 192, 193, 1580, 1581, ")" +480, 12, 47, 282, 194, 195, 1582, 1583, "," +480, 12, 48, 283, 196, 203, 1584, 1591, "whereas" +480, 12, 49, 284, 204, 215, 1592, 1603, "brimonidine" +480, 12, 50, 285, 216, 227, 1604, 1615, "monotherapy" +480, 12, 51, 286, 228, 235, 1616, 1623, "yielded" +480, 12, 52, 287, 236, 238, 1624, 1626, "an" +480, 12, 53, 288, 239, 250, 1627, 1638, "intraocular" +480, 12, 54, 289, 251, 252, 1639, 1640, "-" +480, 12, 55, 290, 253, 261, 1641, 1649, "pressure" +480, 12, 56, 291, 262, 271, 1650, 1659, "reduction" +480, 12, 57, 292, 272, 274, 1660, 1662, "of" +480, 12, 58, 293, 275, 276, 1663, 1664, "5" +480, 12, 59, 294, 277, 278, 1665, 1666, "." +480, 12, 60, 295, 279, 280, 1667, 1668, "2" +480, 12, 61, 296, 281, 282, 1669, 1670, "+" +480, 12, 62, 297, 283, 284, 1671, 1672, "/" +480, 12, 63, 298, 285, 286, 1673, 1674, "-" +480, 12, 64, 299, 287, 288, 1675, 1676, "3" +480, 12, 65, 300, 289, 290, 1677, 1678, "." +480, 12, 66, 301, 291, 292, 1679, 1680, "5" +480, 12, 67, 302, 293, 295, 1681, 1683, "mm" +480, 12, 68, 303, 296, 298, 1684, 1686, "Hg" +480, 12, 69, 304, 299, 300, 1687, 1688, "(" +480, 12, 70, 305, 301, 302, 1689, 1690, "P" +480, 12, 71, 306, 303, 304, 1691, 1692, "<" +480, 12, 72, 307, 305, 306, 1693, 1694, "0" +480, 12, 73, 308, 307, 308, 1695, 1696, "." +480, 12, 74, 309, 309, 312, 1697, 1700, "001" +480, 12, 75, 310, 313, 314, 1701, 1702, ")" +480, 12, 76, 311, 315, 316, 1703, 1704, "." +480, 13, 1, 312, 0, 4, 1705, 1709, "This" +480, 13, 2, 313, 5, 6, 1710, 1711, "1" +480, 13, 3, 314, 7, 8, 1712, 1713, "." +480, 13, 4, 315, 9, 10, 1714, 1715, "9" +480, 13, 5, 316, 11, 13, 1716, 1718, "mm" +480, 13, 6, 317, 14, 16, 1719, 1721, "Hg" +480, 13, 7, 318, 17, 27, 1722, 1732, "difference" +480, 13, 8, 319, 28, 30, 1733, 1735, "in" +480, 13, 9, 320, 31, 42, 1736, 1747, "intraocular" +480, 13, 10, 321, 43, 44, 1748, 1749, "-" +480, 13, 11, 322, 45, 53, 1750, 1758, "pressure" +480, 13, 12, 323, 54, 63, 1759, 1768, "reduction" +480, 13, 13, 324, 64, 67, 1769, 1772, "was" +480, 13, 14, 325, 68, 81, 1773, 1786, "significantly" +480, 13, 15, 326, 82, 84, 1787, 1789, "in" +480, 13, 16, 327, 85, 90, 1790, 1795, "favor" +480, 13, 17, 328, 91, 93, 1796, 1798, "of" +480, 13, 18, 329, 94, 105, 1799, 1810, "latanoprost" +480, 13, 19, 330, 106, 107, 1811, 1812, "(" +480, 13, 20, 331, 108, 109, 1813, 1814, "P" +480, 13, 21, 332, 110, 111, 1815, 1816, "<" +480, 13, 22, 333, 112, 113, 1817, 1818, "0" +480, 13, 23, 334, 114, 115, 1819, 1820, "." +480, 13, 24, 335, 116, 119, 1821, 1824, "001" +480, 13, 25, 336, 120, 121, 1825, 1826, ")" +480, 13, 26, 337, 122, 123, 1827, 1828, "." +480, 14, 1, 338, 0, 6, 1829, 1835, "Ocular" +480, 14, 2, 339, 7, 14, 1836, 1843, "allergy" +480, 14, 3, 340, 15, 16, 1844, 1845, "(" +480, 14, 4, 341, 17, 18, 1846, 1847, "P" +480, 14, 5, 342, 19, 20, 1848, 1849, "<" +480, 14, 6, 343, 21, 22, 1850, 1851, "0" +480, 14, 7, 344, 23, 24, 1852, 1853, "." +480, 14, 8, 345, 25, 28, 1854, 1857, "001" +480, 14, 9, 346, 29, 30, 1858, 1859, ")" +480, 14, 10, 347, 31, 34, 1860, 1863, "and" +480, 14, 11, 348, 35, 43, 1864, 1872, "systemic" +480, 14, 12, 349, 44, 48, 1873, 1877, "side" +480, 14, 13, 350, 49, 56, 1878, 1885, "effects" +480, 14, 14, 351, 57, 58, 1886, 1887, "(" +480, 14, 15, 352, 59, 60, 1888, 1889, "P" +480, 14, 16, 353, 61, 62, 1890, 1891, "=" +480, 14, 17, 354, 63, 64, 1892, 1893, "0" +480, 14, 18, 355, 65, 66, 1894, 1895, "." +480, 14, 19, 356, 67, 70, 1896, 1899, "005" +480, 14, 20, 357, 71, 72, 1900, 1901, ")" +480, 14, 21, 358, 73, 77, 1902, 1906, "were" +480, 14, 22, 359, 78, 86, 1907, 1915, "reported" +480, 14, 23, 360, 87, 100, 1916, 1929, "significantly" +480, 14, 24, 361, 101, 105, 1930, 1934, "less" +480, 14, 25, 362, 106, 116, 1935, 1945, "frequently" +480, 14, 26, 363, 117, 119, 1946, 1948, "by" +480, 14, 27, 364, 120, 131, 1949, 1960, "latanoprost" +480, 14, 28, 365, 132, 133, 1961, 1962, "-" +480, 14, 29, 366, 134, 141, 1963, 1970, "treated" +480, 14, 30, 367, 142, 150, 1971, 1979, "patients" +480, 14, 31, 368, 151, 159, 1980, 1988, "compared" +480, 14, 32, 369, 160, 164, 1989, 1993, "with" +480, 14, 33, 370, 165, 176, 1994, 2005, "brimonidine" +480, 14, 34, 371, 177, 178, 2006, 2007, "-" +480, 14, 35, 372, 179, 186, 2008, 2015, "treated" +480, 14, 36, 373, 187, 195, 2016, 2024, "patients" +480, 14, 37, 374, 196, 197, 2025, 2026, "." +480, 15, 1, 375, 0, 11, 2027, 2038, "CONCLUSIONS" +480, 15, 2, 376, 12, 13, 2039, 2040, ":" +480, 15, 3, 377, 14, 18, 2041, 2045, "Both" +480, 15, 4, 378, 19, 30, 2046, 2057, "latanoprost" +480, 15, 5, 379, 31, 34, 2058, 2061, "and" +480, 15, 6, 380, 35, 46, 2062, 2073, "brimonidine" +480, 15, 7, 381, 47, 54, 2074, 2081, "reduced" +480, 15, 8, 382, 55, 66, 2082, 2093, "intraocular" +480, 15, 9, 383, 67, 75, 2094, 2102, "pressure" +480, 15, 10, 384, 76, 78, 2103, 2105, "in" +480, 15, 11, 385, 79, 87, 2106, 2114, "patients" +480, 15, 12, 386, 88, 92, 2115, 2119, "with" +480, 15, 13, 387, 93, 101, 2120, 2128, "glaucoma" +480, 15, 14, 388, 102, 104, 2129, 2131, "or" +480, 15, 15, 389, 105, 111, 2132, 2138, "ocular" +480, 15, 16, 390, 112, 124, 2139, 2151, "hypertension" +480, 15, 17, 391, 125, 130, 2152, 2157, "after" +480, 15, 18, 392, 131, 132, 2158, 2159, "6" +480, 15, 19, 393, 133, 139, 2160, 2166, "months" +480, 15, 20, 394, 140, 142, 2167, 2169, "of" +480, 15, 21, 395, 143, 152, 2170, 2179, "treatment" +480, 15, 22, 396, 153, 154, 2180, 2181, "." +480, 16, 1, 397, 0, 7, 2182, 2189, "However" +480, 16, 2, 398, 8, 9, 2190, 2191, "," +480, 16, 3, 399, 10, 21, 2192, 2203, "latanoprost" +480, 16, 4, 400, 22, 26, 2204, 2208, "once" +480, 16, 5, 401, 27, 32, 2209, 2214, "daily" +480, 16, 6, 402, 33, 36, 2215, 2218, "was" +480, 16, 7, 403, 37, 50, 2219, 2232, "significantly" +480, 16, 8, 404, 51, 55, 2233, 2237, "more" +480, 16, 9, 405, 56, 65, 2238, 2247, "effective" +480, 16, 10, 406, 66, 70, 2248, 2252, "than" +480, 16, 11, 407, 71, 82, 2253, 2264, "brimonidine" +480, 16, 12, 408, 83, 88, 2265, 2270, "twice" +480, 16, 13, 409, 89, 94, 2271, 2276, "daily" +480, 16, 14, 410, 95, 97, 2277, 2279, "in" +480, 16, 15, 411, 98, 106, 2280, 2288, "reducing" +480, 16, 16, 412, 107, 111, 2289, 2293, "mean" +480, 16, 17, 413, 112, 119, 2294, 2301, "diurnal" +480, 16, 18, 414, 120, 131, 2302, 2313, "intraocular" +480, 16, 19, 415, 132, 140, 2314, 2322, "pressure" +480, 16, 20, 416, 141, 142, 2323, 2324, "." +480, 17, 1, 417, 0, 11, 2325, 2336, "Latanoprost" +480, 17, 2, 418, 12, 15, 2337, 2340, "was" +480, 17, 3, 419, 16, 22, 2341, 2347, "better" +480, 17, 4, 420, 23, 32, 2348, 2357, "tolerated" +480, 17, 5, 421, 33, 37, 2358, 2362, "with" +480, 17, 6, 422, 38, 42, 2363, 2367, "less" +480, 17, 7, 423, 43, 53, 2368, 2378, "frequently" +480, 17, 8, 424, 54, 63, 2379, 2388, "occurring" +480, 17, 9, 425, 64, 70, 2389, 2395, "ocular" +480, 17, 10, 426, 71, 78, 2396, 2403, "allergy" +480, 17, 11, 427, 79, 82, 2404, 2407, "and" +480, 17, 12, 428, 83, 91, 2408, 2416, "systemic" +480, 17, 13, 429, 92, 96, 2417, 2421, "side" +480, 17, 14, 430, 97, 104, 2422, 2429, "effects" +480, 17, 15, 431, 105, 106, 2430, 2431, "." +480, 18, 1, 432, 0, 4, 2432, 2436, "PMID" +480, 18, 2, 433, 5, 6, 2437, 2438, ":" +480, 18, 3, 434, 7, 15, 2439, 2447, "11912355" +480, 18, 4, 435, 16, 17, 2448, 2449, "[" +480, 18, 5, 436, 18, 25, 2450, 2457, "Indexed" +480, 18, 6, 437, 26, 29, 2458, 2461, "for" +480, 18, 7, 438, 30, 37, 2462, 2469, "MEDLINE" +480, 18, 8, 439, 38, 39, 2470, 2471, "]" diff --git a/data/gl 11912355_jshahinitiran.annodb b/data/gl 11912355_jshahinitiran.annodb new file mode 100644 index 0000000..6cf4837 --- /dev/null +++ b/data/gl 11912355_jshahinitiran.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4923, Journal, 0, 10, "J Glaucoma", "", +4924, PublicationYear, 13, 17, "2002", "", +26179, IOP, 44, 64, "Intraocular pressure", "", +5012, Title, 44, 237, "Intraocular pressure - lowering effects of latanoprost and brimonidine therapy in patients with open - angle glaucoma or ocular hypertension : a randomized observer - masked multicenter study .", "", +26180, Latanoprost, 87, 98, "latanoprost", "", +26181, Brimonidine, 103, 114, "brimonidine", "", +4934, OpenAngleGlaucoma, 140, 161, "open - angle glaucoma", "", +4935, OcularHypertension, 165, 184, "ocular hypertension", "", +4936, Randomized, 189, 199, "randomized", "", +26182, Blind, 200, 217, "observer - masked", "", +26183, Multicenter, 218, 229, "multicenter", "", +4926, Author, 238, 246, "Kampik A", "", +4927, Author, 255, 271, "Arias - Puente A", "", +4928, Author, 274, 286, "O ' Brart DP", "", +4929, Author, 289, 297, "Vuori ML", "", +4930, Germany, 436, 443, "Germany", "", +4931, ObjectiveDescription, 456, 675, "To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy", "", +26184, Latanoprost, 496, 507, "latanoprost", "", +26185, Brimonidine, 511, 522, "brimonidine", "", +4941, IOP, 526, 546, "intraocular pressure", "", +4942, Glaucoma, 564, 572, "glaucoma", "", +4943, OcularHypertension, 576, 595, "ocular hypertension", "", +26186, Precondition, 600, 675, "intraocular pressure inadequately controlled by monotherapy or dual therapy", "", +4944, IOP, 600, 620, "intraocular pressure", "", +26187, NumberPatientsCT, 701, 729, "Three hundred seventy - nine", "", +26427, Primary_OpenAngleGlaucoma, 744, 773, "primary open - angle glaucoma", "", +4948, OcularHypertension, 777, 796, "ocular hypertension", "", +26188, Duration, 821, 830, "6 - month", "", +39039, Prospective, 831, 842, "prospective", "", +26189, Randomized, 845, 855, "randomized", "", +26190, Blind, 858, 875, "observer - masked", "", +26191, Multicenter, 876, 887, "multicenter", "", +4954, IOP, 1009, 1029, "intraocular pressure", "", +26192, Randomized, 1082, 1092, "randomized", "", +26193, Latanoprost, 1111, 1122, "latanoprost", "", +26194, Frequency, 1123, 1133, "once daily", "", +26195, Brimonidine, 1137, 1148, "brimonidine", "", +26196, Frequency, 1149, 1160, "twice daily", "", +26197, Mean, 1202, 1206, "mean", "", +26198, Diurnal_IOP, 1207, 1235, "diurnal intraocular pressure", "", +26199, Duration, 1242, 1250, "6 months", "", +26200, NumberPatientsCT, 1306, 1309, "379", "", +26201, Randomized, 1310, 1320, "randomized", "", +4969, FinalNumPatientsCT, 1332, 1335, "375", "", +4968, IntentionToTreat, 1357, 1376, "intent - to - treat", "", +4970, Mean, 1413, 1417, "mean", "", +4971, IOP, 1418, 1438, "intraocular pressure", "", +4972, BaseLineValue, 1442, 1448, "25 . 0", "", +4973, mmHg, 1449, 1454, "mm Hg", "bl", +26202, Latanoprost, 1457, 1468, "latanoprost", "", +26203, Mean, 1489, 1493, "mean", "", +26204, Diurnal_IOP, 1494, 1513, "diurnal intraocular", "", +4977, Reduction, 1526, 1531, "7 . 1", "lat", +4979, SdDevChangeValue, 1538, 1543, "3 . 3", "lat", +4981, mmHg, 1544, 1549, "mm Hg", "lat", +26208, Mean, 1552, 1556, "mean", "", +4983, PValueChangeValue, 1568, 1579, "P < 0 . 001", "lat", +26205, Brimonidine, 1592, 1603, "brimonidine", "", +26206, IOP, 1627, 1649, "intraocular - pressure", "", +4986, Reduction, 1663, 1668, "5 . 2", "bri", +4987, SdDevChangeValue, 1675, 1680, "3 . 5", "bri", +26207, mmHg, 1681, 1686, "mm Hg", "", +4988, PValueChangeValue, 1689, 1700, "P < 0 . 001", "bri", +4989, DiffGroupAbsValue, 1710, 1715, "1 . 9", "", +4990, mmHg, 1716, 1721, "mm Hg", "", +26209, IOP, 1736, 1758, "intraocular - pressure", "", +26210, Latanoprost, 1799, 1810, "latanoprost", "", +4993, PvalueDiff, 1813, 1824, "P < 0 . 001", "", +4994, ObservedResult, 1829, 2026, "Ocular allergy ( P < 0 . 001 ) and systemic side effects ( P = 0 . 005 ) were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients .", "", +26212, PValueNumAffected, 1846, 1857, "P < 0 . 001", "", +26213, PValueNumAffected, 1888, 1899, "P = 0 . 005", "", +26214, Latanoprost, 1949, 1960, "latanoprost", "", +26215, Brimonidine, 1994, 2005, "brimonidine", "", +4995, ConclusionComment, 2041, 2181, "Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment .", "", +26216, Latanoprost, 2046, 2057, "latanoprost", "", +26217, Brimonidine, 2062, 2073, "brimonidine", "", +26218, IOP, 2082, 2102, "intraocular pressure", "", +5001, Glaucoma, 2120, 2128, "glaucoma", "", +5002, OcularHypertension, 2132, 2151, "ocular hypertension", "", +26219, Duration, 2158, 2166, "6 months", "", +4996, ConclusionComment, 2182, 2324, "However , latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure .", "", +26220, Latanoprost, 2192, 2203, "latanoprost", "", +26221, Frequency, 2204, 2214, "once daily", "", +26222, Brimonidine, 2253, 2264, "brimonidine", "", +26223, Frequency, 2265, 2276, "twice daily", "", +26224, Mean, 2289, 2293, "mean", "", +26225, Diurnal_IOP, 2294, 2313, "diurnal intraocular", "", +26226, Latanoprost, 2325, 2336, "Latanoprost", "", +4997, ConclusionComment, 2325, 2431, "Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects .", "", +5011, PMID, 2439, 2447, "11912355", "", diff --git a/data/gl 11912355_jshahinitiran.n-triples b/data/gl 11912355_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11912355_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11912355_tstrakeljahn.annodb b/data/gl 11912355_tstrakeljahn.annodb new file mode 100644 index 0000000..ff01f9e --- /dev/null +++ b/data/gl 11912355_tstrakeljahn.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +36363, Journal, 0, 10, "J Glaucoma", "", +36365, PublicationYear, 13, 17, "2002", "", +36366, IOP, 44, 64, "Intraocular pressure", "", +36374, Title, 44, 235, "Intraocular pressure - lowering effects of latanoprost and brimonidine therapy in patients with open - angle glaucoma or ocular hypertension : a randomized observer - masked multicenter study", "", +36367, Latanoprost, 87, 98, "latanoprost", "", +36368, Brimonidine, 103, 114, "brimonidine", "", +36369, OpenAngleGlaucoma, 140, 161, "open - angle glaucoma", "", +36370, OcularHypertension, 165, 184, "ocular hypertension", "", +36371, Randomized, 189, 199, "randomized", "", +36372, Blind, 200, 217, "observer - masked", "", +36373, Multicenter, 218, 229, "multicenter", "", +36375, Author, 238, 246, "Kampik A", "", +36376, Author, 255, 271, "Arias - Puente A", "", +36377, Author, 274, 286, "O ' Brart DP", "", +36378, Author, 289, 297, "Vuori ML", "", +36379, Latanoprost, 309, 320, "Latanoprost", "", +36380, Germany, 436, 443, "Germany", "", +36387, ObjectiveDescription, 456, 675, "To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy", "", +36381, Latanoprost, 496, 507, "latanoprost", "", +36382, Brimonidine, 511, 522, "brimonidine", "", +36383, IOP, 526, 546, "intraocular pressure", "", +36395, Precondition, 550, 675, "patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy", "", +36384, Glaucoma, 564, 572, "glaucoma", "", +36385, OcularHypertension, 576, 595, "ocular hypertension", "", +36386, IOP, 600, 620, "intraocular pressure", "", +36388, NumberPatientsCT, 701, 729, "Three hundred seventy - nine", "", +36389, Primary_OpenAngleGlaucoma, 744, 773, "primary open - angle glaucoma", "", +36390, OcularHypertension, 777, 796, "ocular hypertension", "", +36391, Duration, 821, 830, "6 - month", "", +36392, Randomized, 845, 855, "randomized", "", +36393, Blind, 858, 875, "observer - masked", "", +36394, Multicenter, 876, 887, "multicenter", "", +36396, Precondition, 921, 1029, "All patients were receiving monotherapy or dual therapy that did not adequately control intraocular pressure", "", +36397, IOP, 1009, 1029, "intraocular pressure", "", +36398, Randomized, 1082, 1092, "randomized", "", +36399, Latanoprost, 1111, 1122, "latanoprost", "", +36401, Frequency, 1123, 1133, "once daily", "", +36400, Brimonidine, 1137, 1148, "brimonidine", "", +36402, Frequency, 1149, 1160, "twice daily", "", +36403, Mean, 1202, 1206, "mean", "", +36404, Diurnal_IOP, 1207, 1235, "diurnal intraocular pressure", "", +36405, NumberPatientsCT, 1306, 1309, "379", "", +36407, Randomized, 1310, 1320, "randomized", "", +36406, FinalNumPatientsCT, 1332, 1335, "375", "", +36408, Mean, 1413, 1417, "mean", "", +36409, IOP, 1418, 1438, "intraocular pressure", "", +36410, BaseLineValue, 1442, 1448, "25 . 0", "", +36411, mmHg, 1449, 1454, "mm Hg", "", +36413, Latanoprost, 1457, 1468, "latanoprost", "", +36414, Mean, 1489, 1493, "mean", "", +36415, Diurnal_IOP, 1494, 1522, "diurnal intraocular pressure", "", +36416, Reduction, 1526, 1531, "7 . 1", "", +36451, SdDevChangeValue, 1532, 1543, "+ / - 3 . 3", "", +36420, mmHg, 1544, 1549, "mm Hg", "", +36421, Mean, 1552, 1556, "mean", "", +36422, PValueChangeValue, 1568, 1579, "P < 0 . 001", "", +36424, Brimonidine, 1592, 1603, "brimonidine", "", +36425, IOP, 1627, 1649, "intraocular - pressure", "", +36417, Reduction, 1663, 1668, "5 . 2", "", +36452, SdDevChangeValue, 1669, 1680, "+ / - 3 . 5", "", +36412, mmHg, 1681, 1686, "mm Hg", "", +36423, PValueChangeValue, 1689, 1700, "P < 0 . 001", "", +36426, DiffGroupAbsValue, 1710, 1715, "1 . 9", "", +36427, mmHg, 1716, 1721, "mm Hg", "", +36428, IOP, 1736, 1758, "intraocular - pressure", "", +36429, Latanoprost, 1799, 1810, "latanoprost", "", +36430, PValueChangeValue, 1813, 1824, "P < 0 . 001", "", +36433, ObservedResult, 1829, 2024, "Ocular allergy ( P < 0 . 001 ) and systemic side effects ( P = 0 . 005 ) were reported significantly less frequently by latanoprost - treated patients compared with brimonidine - treated patients", "", +36431, Latanoprost, 1949, 1960, "latanoprost", "", +36432, Brimonidine, 1994, 2005, "brimonidine", "", +36449, ConclusionComment, 2041, 2181, "Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment .", "", +36434, Latanoprost, 2046, 2057, "latanoprost", "", +36437, Brimonidine, 2062, 2073, "brimonidine", "", +36438, IOP, 2082, 2102, "intraocular pressure", "", +36439, Glaucoma, 2120, 2128, "glaucoma", "", +36440, OcularHypertension, 2132, 2151, "ocular hypertension", "", +36448, ConclusionComment, 2182, 2324, "However , latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure .", "", +36435, Latanoprost, 2192, 2203, "latanoprost", "", +36441, Frequency, 2204, 2214, "once daily", "", +36436, Brimonidine, 2253, 2264, "brimonidine", "", +36442, Frequency, 2265, 2276, "twice daily", "", +36443, Mean, 2289, 2293, "mean", "", +36444, Diurnal_IOP, 2294, 2322, "diurnal intraocular pressure", "", +36445, Latanoprost, 2325, 2336, "Latanoprost", "", +36446, ConclusionComment, 2325, 2431, "Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects .", "", +36450, PMID, 2439, 2447, "11912355", "", diff --git a/data/gl 11912355_tstrakeljahn.n-triples b/data/gl 11912355_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11912355_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11952485_admin.annodb b/data/gl 11952485_admin.annodb new file mode 100644 index 0000000..34fdc11 --- /dev/null +++ b/data/gl 11952485_admin.annodb @@ -0,0 +1,53 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "Acta Ophthalmol Scand .", "", " \"Acta Ophthalmol Scand .\"." +1, PublicationYear, 24, 28, "2002", "", " \"2002\"." +2, Title, 57, 171, "Dorzolamide and ocular blood flow in previously untreated glaucoma patients : a controlled double - masked study .", "", " \"Dorzolamide and ocular blood flow in previously untreated glaucoma patients : a controlled double - masked study .\"." +31, Dorzolamide, 57, 68, "Dorzolamide", "", " ." +41378, OcularBloodFlow, 73, 90, "ocular blood flow", "", +3, Precondition, 94, 114, "previously untreated", "", " \"previously untreated\"." +4, Glaucoma, 115, 123, "glaucoma", "", " . ." +5, DoubleBlind, 148, 163, "double - masked", "", " ." +7, Author, 172, 185, "Bergstrand IC", "", " \"Bergstrand IC\"." +8, Author, 194, 201, "Heijl A", "", " \"Heijl A\"." +9, Author, 204, 212, "Harris A", "", " \"Harris A\"." +6, Sweden, 309, 315, "Sweden", "", " ." +10, ObjectiveDescription, 442, 604, "The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma .", "", " \"The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma .\"." +32, Dorzolamide, 519, 530, "dorzolamide", "", +54, Precondition, 554, 602, "newly detected and previously untreated glaucoma", "", " \"newly detected and previously untreated glaucoma\"." +34, Glaucoma, 594, 602, "glaucoma", "", +12, NumberPatientsCT, 615, 628, "Forty - seven", "", " \"Forty - seven\"." +13, OpenAngleGlaucoma, 643, 662, "open angle glaucoma", "", " ." +14, Randomized, 682, 692, "randomized", "", " ." +35, Dorzolamide, 696, 707, "dorzolamide", "", +15, Placebo, 715, 722, "placebo", "", " ." +16, Frequency, 723, 726, "TID", "", " \"TID\". \"TID\"." +17, Duration, 736, 744, "6 - week", "", " \"6 - week\"." +18, DoubleBlind, 745, 760, "double - masked", "", +41381, OcularBloodFlow, 779, 796, "Ocular blood flow", "", +41393, TimePoint, 817, 825, "baseline", "", +41394, MeasurementDevice, 847, 869, "colour Doppler imaging", "", " . ." +41395, MeasurementDevice, 901, 930, "scanning laser ophthalmoscope", "", +41426, ObservedResult, 993, 1138, "None of the flow parameters , retrobulbar or retinal , changed significantly on therapy when the results were analysed with the Bonferroni method", "", " \"None of the flow parameters , retrobulbar or retinal , changed significantly on therapy when the results were analysed with the Bonferroni method\"." +41422, EndPointDescription, 1005, 1045, "flow parameters , retrobulbar or retinal", "", " . ." +41396, MeasurementDevice, 1121, 1138, "Bonferroni method", "", " . ." +41399, MeasurementDevice, 1155, 1179, "non - simultaneous tests", "", +40, Mean, 1439, 1443, "mean", "", +41403, EndPointDescription, 1497, 1535, "capillary velocities at the optic disc", "", " . ." +39, Dorzolamide, 1567, 1578, "dorzolamide", "", +41, PValueChangeValue, 1587, 1597, "P = 0 . 03", "", " \"P = 0 . 03\"." +19, IOP, 1602, 1622, "Intraocular pressure", "", +36, Dorzolamide, 1674, 1685, "dorzolamide", "", +23, PvalueDiff, 1694, 1705, "P = 0 . 002", "", " \"P = 0 . 002\"." +20, Reduction, 1717, 1722, "4 . 8", "", " \"4 . 8\"." +21, SdErrorChangeValue, 1729, 1734, "2 . 9", "", " \"2 . 9\"." +22, mmHg, 1735, 1739, "mmHg", "", +24, PValueChangeValue, 1742, 1754, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +25, Reduction, 1766, 1771, "1 . 8", "", " \"1 . 8\"." +26, SdErrorChangeValue, 1778, 1783, "3 . 0", "", " \"3 . 0\"." +27, mmHg, 1784, 1788, "mmHg", "", +38, Placebo, 1796, 1803, "placebo", "", +28, PValueChangeValue, 1812, 1823, "P = 0 . 006", "", " \"P = 0 . 006\"." +29, ConclusionComment, 1842, 1975, "The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes .", "", " \"The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes .\"." +82, Dorzolamide, 1914, 1925, "dorzolamide", "", +37, Glaucoma, 1960, 1968, "glaucoma", "", +30, PMID, 1983, 1991, "11952485", "", " \"11952485\"." diff --git a/data/gl 11952485_admin.n-triples b/data/gl 11952485_admin.n-triples new file mode 100644 index 0000000..cb4b415 --- /dev/null +++ b/data/gl 11952485_admin.n-triples @@ -0,0 +1,131 @@ +# RDF export of group: Publication + . + "Publication" . + "Dorzolamide and ocular blood flow in previously untreated glaucoma patients : a controlled double - masked study ." . + "Bergstrand IC" . + "2002" . + "Acta Ophthalmol Scand ." . + "11952485" . + . + "Heijl A" . + "Harris A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma ." . + "Forty - seven" . + "6 - week" . + . + . + . + "The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "previously untreated" . + . + . + . + "newly detected and previously untreated glaucoma" . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + "Endpoint-of" . + . + . + . + . + . + . + "Endpoint-fp" . + . + . + . + . + . + . + . + "Endpoint-cv" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-dor" . + . + . + . + . + . + . + "Arm-pla" . + . + . + . +# RDF export of group: Intervention + . + "Intervention-dor" . + . + "TID" . + . + . + "Intervention-pla" . + . + "TID" . + . +# RDF export of group: Medication + . + "Medication-dor" . + . + . + . + . + "Medication-pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-dor-iop" . + . + "4 . 8" . + "P < 0 . 0001" . + "2 . 9" . + . + "Outcome-pla-iop" . + . + "1 . 8" . + "P = 0 . 006" . + "3 . 0" . + . + "Outcome-cv-dor" . + . + "P = 0 . 03" . + . + "Outcome-fp-dor" . + . + "None of the flow parameters , retrobulbar or retinal , changed significantly on therapy when the results were analysed with the Bonferroni method" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop" . + "P = 0 . 002" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11952485_export.csv b/data/gl 11952485_export.csv new file mode 100644 index 0000000..2f7376d --- /dev/null +++ b/data/gl 11952485_export.csv @@ -0,0 +1,377 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +479, 1, 1, 1, 0, 4, 0, 4, "Acta" +479, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +479, 1, 3, 3, 16, 21, 16, 21, "Scand" +479, 1, 4, 4, 22, 23, 22, 23, "." +479, 2, 1, 5, 0, 4, 24, 28, "2002" +479, 2, 2, 6, 5, 8, 29, 32, "Apr" +479, 2, 3, 7, 9, 10, 33, 34, ";" +479, 2, 4, 8, 11, 13, 35, 37, "80" +479, 2, 5, 9, 14, 15, 38, 39, "(" +479, 2, 6, 10, 16, 17, 40, 41, "2" +479, 2, 7, 11, 18, 19, 42, 43, ")" +479, 2, 8, 12, 20, 21, 44, 45, ":" +479, 2, 9, 13, 22, 25, 46, 49, "176" +479, 2, 10, 14, 26, 27, 50, 51, "-" +479, 2, 11, 15, 28, 30, 52, 54, "82" +479, 2, 12, 16, 31, 32, 55, 56, "." +479, 3, 1, 17, 0, 11, 57, 68, "Dorzolamide" +479, 3, 2, 18, 12, 15, 69, 72, "and" +479, 3, 3, 19, 16, 22, 73, 79, "ocular" +479, 3, 4, 20, 23, 28, 80, 85, "blood" +479, 3, 5, 21, 29, 33, 86, 90, "flow" +479, 3, 6, 22, 34, 36, 91, 93, "in" +479, 3, 7, 23, 37, 47, 94, 104, "previously" +479, 3, 8, 24, 48, 57, 105, 114, "untreated" +479, 3, 9, 25, 58, 66, 115, 123, "glaucoma" +479, 3, 10, 26, 67, 75, 124, 132, "patients" +479, 3, 11, 27, 76, 77, 133, 134, ":" +479, 3, 12, 28, 78, 79, 135, 136, "a" +479, 3, 13, 29, 80, 90, 137, 147, "controlled" +479, 3, 14, 30, 91, 97, 148, 154, "double" +479, 3, 15, 31, 98, 99, 155, 156, "-" +479, 3, 16, 32, 100, 106, 157, 163, "masked" +479, 3, 17, 33, 107, 112, 164, 169, "study" +479, 3, 18, 34, 113, 114, 170, 171, "." +479, 4, 1, 35, 0, 10, 172, 182, "Bergstrand" +479, 4, 2, 36, 11, 13, 183, 185, "IC" +479, 4, 3, 37, 14, 15, 186, 187, "(" +479, 4, 4, 38, 16, 17, 188, 189, "1" +479, 4, 5, 39, 18, 19, 190, 191, ")" +479, 4, 6, 40, 20, 21, 192, 193, "," +479, 4, 7, 41, 22, 27, 194, 199, "Heijl" +479, 4, 8, 42, 28, 29, 200, 201, "A" +479, 4, 9, 43, 30, 31, 202, 203, "," +479, 4, 10, 44, 32, 38, 204, 210, "Harris" +479, 4, 11, 45, 39, 40, 211, 212, "A" +479, 4, 12, 46, 41, 42, 213, 214, "." +479, 5, 1, 47, 0, 6, 215, 221, "Author" +479, 5, 2, 48, 7, 18, 222, 233, "information" +479, 5, 3, 49, 19, 20, 234, 235, ":" +479, 5, 4, 50, 21, 22, 236, 237, "(" +479, 5, 5, 51, 23, 24, 238, 239, "1" +479, 5, 6, 52, 25, 26, 240, 241, ")" +479, 5, 7, 53, 27, 37, 242, 252, "Department" +479, 5, 8, 54, 38, 40, 253, 255, "of" +479, 5, 9, 55, 41, 54, 256, 269, "Ophthalmology" +479, 5, 10, 56, 55, 56, 270, 271, "," +479, 5, 11, 57, 57, 61, 272, 276, "Malm" +479, 5, 12, 58, 62, 63, 277, 278, "ö" +479, 5, 13, 59, 64, 74, 279, 289, "University" +479, 5, 14, 60, 75, 83, 290, 298, "Hospital" +479, 5, 15, 61, 84, 85, 299, 300, "," +479, 5, 16, 62, 86, 90, 301, 305, "Malm" +479, 5, 17, 63, 91, 93, 306, 308, "ö," +479, 5, 18, 64, 94, 100, 309, 315, "Sweden" +479, 5, 19, 65, 101, 102, 316, 317, "." +479, 6, 1, 66, 0, 5, 318, 323, "ingar" +479, 6, 2, 67, 6, 7, 324, 325, "." +479, 6, 3, 68, 8, 9, 326, 327, "c" +479, 6, 4, 69, 10, 11, 328, 329, "-" +479, 6, 5, 70, 12, 22, 330, 340, "bergstrand" +479, 6, 6, 71, 23, 24, 341, 342, "@" +479, 6, 7, 72, 25, 30, 343, 348, "oftal" +479, 6, 8, 73, 31, 32, 349, 350, "." +479, 6, 9, 74, 33, 36, 351, 354, "mas" +479, 6, 10, 75, 37, 38, 355, 356, "." +479, 6, 11, 76, 39, 41, 357, 359, "lu" +479, 6, 12, 77, 42, 43, 360, 361, "." +479, 6, 13, 78, 44, 46, 362, 364, "se" +479, 6, 14, 79, 47, 54, 365, 372, "Comment" +479, 6, 15, 80, 55, 57, 373, 375, "in" +479, 6, 16, 81, 58, 62, 376, 380, "Acta" +479, 6, 17, 82, 63, 73, 381, 391, "Ophthalmol" +479, 6, 18, 83, 74, 79, 392, 397, "Scand" +479, 6, 19, 84, 80, 81, 398, 399, "." +479, 7, 1, 85, 0, 4, 400, 404, "2002" +479, 7, 2, 86, 5, 8, 405, 408, "Apr" +479, 7, 3, 87, 9, 10, 409, 410, ";" +479, 7, 4, 88, 11, 13, 411, 413, "80" +479, 7, 5, 89, 14, 15, 414, 415, "(" +479, 7, 6, 90, 16, 17, 416, 417, "2" +479, 7, 7, 91, 18, 19, 418, 419, ")" +479, 7, 8, 92, 20, 21, 420, 421, ":" +479, 7, 9, 93, 22, 25, 422, 425, "123" +479, 7, 10, 94, 26, 27, 426, 427, "-" +479, 7, 11, 95, 28, 29, 428, 429, "4" +479, 7, 12, 96, 30, 31, 430, 431, "." +479, 8, 1, 97, 0, 7, 432, 439, "PURPOSE" +479, 8, 2, 98, 8, 9, 440, 441, ":" +479, 8, 3, 99, 10, 13, 442, 445, "The" +479, 8, 4, 100, 14, 17, 446, 449, "aim" +479, 8, 5, 101, 18, 20, 450, 452, "of" +479, 8, 6, 102, 21, 25, 453, 457, "this" +479, 8, 7, 103, 26, 31, 458, 463, "study" +479, 8, 8, 104, 32, 35, 464, 467, "was" +479, 8, 9, 105, 36, 38, 468, 470, "to" +479, 8, 10, 106, 39, 50, 471, 482, "investigate" +479, 8, 11, 107, 51, 54, 483, 486, "the" +479, 8, 12, 108, 55, 67, 487, 499, "haemodynamic" +479, 8, 13, 109, 68, 75, 500, 507, "effects" +479, 8, 14, 110, 76, 78, 508, 510, "of" +479, 8, 15, 111, 79, 86, 511, 518, "topical" +479, 8, 16, 112, 87, 98, 519, 530, "dorzolamide" +479, 8, 17, 113, 99, 108, 531, 540, "treatment" +479, 8, 18, 114, 109, 111, 541, 543, "in" +479, 8, 19, 115, 112, 116, 544, 548, "eyes" +479, 8, 20, 116, 117, 121, 549, 553, "with" +479, 8, 21, 117, 122, 127, 554, 559, "newly" +479, 8, 22, 118, 128, 136, 560, 568, "detected" +479, 8, 23, 119, 137, 140, 569, 572, "and" +479, 8, 24, 120, 141, 151, 573, 583, "previously" +479, 8, 25, 121, 152, 161, 584, 593, "untreated" +479, 8, 26, 122, 162, 170, 594, 602, "glaucoma" +479, 8, 27, 123, 171, 172, 603, 604, "." +479, 9, 1, 124, 0, 7, 605, 612, "METHODS" +479, 9, 2, 125, 8, 9, 613, 614, ":" +479, 9, 3, 126, 10, 15, 615, 620, "Forty" +479, 9, 4, 127, 16, 17, 621, 622, "-" +479, 9, 5, 128, 18, 23, 623, 628, "seven" +479, 9, 6, 129, 24, 32, 629, 637, "patients" +479, 9, 7, 130, 33, 37, 638, 642, "with" +479, 9, 8, 131, 38, 42, 643, 647, "open" +479, 9, 9, 132, 43, 48, 648, 653, "angle" +479, 9, 10, 133, 49, 57, 654, 662, "glaucoma" +479, 9, 11, 134, 58, 62, 663, 667, "were" +479, 9, 12, 135, 63, 76, 668, 681, "consecutively" +479, 9, 13, 136, 77, 87, 682, 692, "randomized" +479, 9, 14, 137, 88, 90, 693, 695, "to" +479, 9, 15, 138, 91, 102, 696, 707, "dorzolamide" +479, 9, 16, 139, 103, 109, 708, 714, "versus" +479, 9, 17, 140, 110, 117, 715, 722, "placebo" +479, 9, 18, 141, 118, 121, 723, 726, "TID" +479, 9, 19, 142, 122, 128, 727, 733, "during" +479, 9, 20, 143, 129, 130, 734, 735, "a" +479, 9, 21, 144, 131, 132, 736, 737, "6" +479, 9, 22, 145, 133, 134, 738, 739, "-" +479, 9, 23, 146, 135, 139, 740, 744, "week" +479, 9, 24, 147, 140, 146, 745, 751, "double" +479, 9, 25, 148, 147, 148, 752, 753, "-" +479, 9, 26, 149, 149, 155, 754, 760, "masked" +479, 9, 27, 150, 156, 165, 761, 770, "treatment" +479, 9, 28, 151, 166, 171, 771, 776, "trial" +479, 9, 29, 152, 172, 173, 777, 778, "." +479, 10, 1, 153, 0, 6, 779, 785, "Ocular" +479, 10, 2, 154, 7, 12, 786, 791, "blood" +479, 10, 3, 155, 13, 17, 792, 796, "flow" +479, 10, 4, 156, 18, 21, 797, 800, "was" +479, 10, 5, 157, 22, 34, 801, 813, "investigated" +479, 10, 6, 158, 35, 37, 814, 816, "at" +479, 10, 7, 159, 38, 46, 817, 825, "baseline" +479, 10, 8, 160, 47, 50, 826, 829, "and" +479, 10, 9, 161, 51, 53, 830, 832, "on" +479, 10, 10, 162, 54, 61, 833, 840, "therapy" +479, 10, 11, 163, 62, 67, 841, 846, "using" +479, 10, 12, 164, 68, 74, 847, 853, "colour" +479, 10, 13, 165, 75, 82, 854, 861, "Doppler" +479, 10, 14, 166, 83, 90, 862, 869, "imaging" +479, 10, 15, 167, 91, 93, 870, 872, "of" +479, 10, 16, 168, 94, 97, 873, 876, "the" +479, 10, 17, 169, 98, 109, 877, 888, "retrobulbar" +479, 10, 18, 170, 110, 117, 889, 896, "vessels" +479, 10, 19, 171, 118, 121, 897, 900, "and" +479, 10, 20, 172, 122, 130, 901, 909, "scanning" +479, 10, 21, 173, 131, 136, 910, 915, "laser" +479, 10, 22, 174, 137, 151, 916, 930, "ophthalmoscope" +479, 10, 23, 175, 152, 163, 931, 942, "fluorescein" +479, 10, 24, 176, 164, 174, 943, 953, "angiograms" +479, 10, 25, 177, 175, 177, 954, 956, "of" +479, 10, 26, 178, 178, 181, 957, 960, "the" +479, 10, 27, 179, 182, 189, 961, 968, "retinal" +479, 10, 28, 180, 190, 201, 969, 980, "circulation" +479, 10, 29, 181, 202, 203, 981, 982, "." +479, 11, 1, 182, 0, 7, 983, 990, "RESULTS" +479, 11, 2, 183, 8, 9, 991, 992, ":" +479, 11, 3, 184, 10, 14, 993, 997, "None" +479, 11, 4, 185, 15, 17, 998, 1000, "of" +479, 11, 5, 186, 18, 21, 1001, 1004, "the" +479, 11, 6, 187, 22, 26, 1005, 1009, "flow" +479, 11, 7, 188, 27, 37, 1010, 1020, "parameters" +479, 11, 8, 189, 38, 39, 1021, 1022, "," +479, 11, 9, 190, 40, 51, 1023, 1034, "retrobulbar" +479, 11, 10, 191, 52, 54, 1035, 1037, "or" +479, 11, 11, 192, 55, 62, 1038, 1045, "retinal" +479, 11, 12, 193, 63, 64, 1046, 1047, "," +479, 11, 13, 194, 65, 72, 1048, 1055, "changed" +479, 11, 14, 195, 73, 86, 1056, 1069, "significantly" +479, 11, 15, 196, 87, 89, 1070, 1072, "on" +479, 11, 16, 197, 90, 97, 1073, 1080, "therapy" +479, 11, 17, 198, 98, 102, 1081, 1085, "when" +479, 11, 18, 199, 103, 106, 1086, 1089, "the" +479, 11, 19, 200, 107, 114, 1090, 1097, "results" +479, 11, 20, 201, 115, 119, 1098, 1102, "were" +479, 11, 21, 202, 120, 128, 1103, 1111, "analysed" +479, 11, 22, 203, 129, 133, 1112, 1116, "with" +479, 11, 23, 204, 134, 137, 1117, 1120, "the" +479, 11, 24, 205, 138, 148, 1121, 1131, "Bonferroni" +479, 11, 25, 206, 149, 155, 1132, 1138, "method" +479, 11, 26, 207, 156, 157, 1139, 1140, "." +479, 12, 1, 208, 0, 8, 1141, 1149, "Analysis" +479, 12, 2, 209, 9, 13, 1150, 1154, "with" +479, 12, 3, 210, 14, 17, 1155, 1158, "non" +479, 12, 4, 211, 18, 19, 1159, 1160, "-" +479, 12, 5, 212, 20, 32, 1161, 1173, "simultaneous" +479, 12, 6, 213, 33, 38, 1174, 1179, "tests" +479, 12, 7, 214, 39, 43, 1180, 1184, "also" +479, 12, 8, 215, 44, 50, 1185, 1191, "failed" +479, 12, 9, 216, 51, 53, 1192, 1194, "to" +479, 12, 10, 217, 54, 60, 1195, 1201, "reveal" +479, 12, 11, 218, 61, 64, 1202, 1205, "any" +479, 12, 12, 219, 65, 76, 1206, 1217, "significant" +479, 12, 13, 220, 77, 84, 1218, 1225, "changes" +479, 12, 14, 221, 85, 91, 1226, 1232, "either" +479, 12, 15, 222, 92, 94, 1233, 1235, "in" +479, 12, 16, 223, 95, 106, 1236, 1247, "retrobulbar" +479, 12, 17, 224, 107, 111, 1248, 1252, "flow" +479, 12, 18, 225, 112, 122, 1253, 1263, "velocities" +479, 12, 19, 226, 123, 125, 1264, 1266, "in" +479, 12, 20, 227, 126, 129, 1267, 1270, "the" +479, 12, 21, 228, 130, 137, 1271, 1278, "central" +479, 12, 22, 229, 138, 145, 1279, 1286, "retinal" +479, 12, 23, 230, 146, 152, 1287, 1293, "artery" +479, 12, 24, 231, 153, 154, 1294, 1295, "," +479, 12, 25, 232, 155, 165, 1296, 1306, "ophthalmic" +479, 12, 26, 233, 166, 172, 1307, 1313, "artery" +479, 12, 27, 234, 173, 175, 1314, 1316, "or" +479, 12, 28, 235, 176, 178, 1317, 1319, "in" +479, 12, 29, 236, 179, 182, 1320, 1323, "the" +479, 12, 30, 237, 183, 188, 1324, 1329, "short" +479, 12, 31, 238, 189, 198, 1330, 1339, "posterior" +479, 12, 32, 239, 199, 206, 1340, 1347, "ciliary" +479, 12, 33, 240, 207, 215, 1348, 1356, "arteries" +479, 12, 34, 241, 216, 217, 1357, 1358, "," +479, 12, 35, 242, 218, 220, 1359, 1361, "or" +479, 12, 36, 243, 221, 223, 1362, 1364, "in" +479, 12, 37, 244, 224, 227, 1365, 1368, "the" +479, 12, 38, 245, 228, 235, 1369, 1376, "retinal" +479, 12, 39, 246, 236, 246, 1377, 1387, "parameters" +479, 12, 40, 247, 247, 248, 1388, 1389, "(" +479, 12, 41, 248, 249, 252, 1390, 1393, "arm" +479, 12, 42, 249, 253, 254, 1394, 1395, "-" +479, 12, 43, 250, 255, 261, 1396, 1402, "retina" +479, 12, 44, 251, 262, 266, 1403, 1407, "time" +479, 12, 45, 252, 267, 268, 1408, 1409, "," +479, 12, 46, 253, 269, 282, 1410, 1423, "arteriovenous" +479, 12, 47, 254, 283, 290, 1424, 1431, "passage" +479, 12, 48, 255, 291, 295, 1432, 1436, "time" +479, 12, 49, 256, 296, 297, 1437, 1438, "," +479, 12, 50, 257, 298, 302, 1439, 1443, "mean" +479, 12, 51, 258, 303, 306, 1444, 1447, "dye" +479, 12, 52, 259, 307, 315, 1448, 1456, "velocity" +479, 12, 53, 260, 316, 318, 1457, 1459, "or" +479, 12, 54, 261, 319, 326, 1460, 1467, "macular" +479, 12, 55, 262, 327, 336, 1468, 1477, "capillary" +479, 12, 56, 263, 337, 345, 1478, 1486, "velocity" +479, 12, 57, 264, 346, 347, 1487, 1488, ")" +479, 12, 58, 265, 348, 349, 1489, 1490, "," +479, 12, 59, 266, 350, 355, 1491, 1496, "while" +479, 12, 60, 267, 356, 365, 1497, 1506, "capillary" +479, 12, 61, 268, 366, 376, 1507, 1517, "velocities" +479, 12, 62, 269, 377, 379, 1518, 1520, "at" +479, 12, 63, 270, 380, 383, 1521, 1524, "the" +479, 12, 64, 271, 384, 389, 1525, 1530, "optic" +479, 12, 65, 272, 390, 394, 1531, 1535, "disc" +479, 12, 66, 273, 395, 404, 1536, 1545, "decreased" +479, 12, 67, 274, 405, 418, 1546, 1559, "significantly" +479, 12, 68, 275, 419, 421, 1560, 1562, "in" +479, 12, 69, 276, 422, 425, 1563, 1566, "the" +479, 12, 70, 277, 426, 437, 1567, 1578, "dorzolamide" +479, 12, 71, 278, 438, 443, 1579, 1584, "group" +479, 12, 72, 279, 444, 445, 1585, 1586, "(" +479, 12, 73, 280, 446, 447, 1587, 1588, "P" +479, 12, 74, 281, 448, 449, 1589, 1590, "=" +479, 12, 75, 282, 450, 451, 1591, 1592, "0" +479, 12, 76, 283, 452, 453, 1593, 1594, "." +479, 12, 77, 284, 454, 456, 1595, 1597, "03" +479, 12, 78, 285, 457, 458, 1598, 1599, ")" +479, 12, 79, 286, 459, 460, 1600, 1601, "." +479, 13, 1, 287, 0, 11, 1602, 1613, "Intraocular" +479, 13, 2, 288, 12, 20, 1614, 1622, "pressure" +479, 13, 3, 289, 21, 30, 1623, 1632, "reduction" +479, 13, 4, 290, 31, 34, 1633, 1636, "was" +479, 13, 5, 291, 35, 48, 1637, 1650, "significantly" +479, 13, 6, 292, 49, 53, 1651, 1655, "more" +479, 13, 7, 293, 54, 64, 1656, 1666, "pronounced" +479, 13, 8, 294, 65, 67, 1667, 1669, "in" +479, 13, 9, 295, 68, 71, 1670, 1673, "the" +479, 13, 10, 296, 72, 83, 1674, 1685, "dorzolamide" +479, 13, 11, 297, 84, 89, 1686, 1691, "group" +479, 13, 12, 298, 90, 91, 1692, 1693, "(" +479, 13, 13, 299, 92, 93, 1694, 1695, "P" +479, 13, 14, 300, 94, 95, 1696, 1697, "=" +479, 13, 15, 301, 96, 97, 1698, 1699, "0" +479, 13, 16, 302, 98, 99, 1700, 1701, "." +479, 13, 17, 303, 100, 103, 1702, 1705, "002" +479, 13, 18, 304, 104, 105, 1706, 1707, ")" +479, 13, 19, 305, 106, 107, 1708, 1709, "," +479, 13, 20, 306, 108, 112, 1710, 1714, "with" +479, 13, 21, 307, 113, 114, 1715, 1716, "-" +479, 13, 22, 308, 115, 116, 1717, 1718, "4" +479, 13, 23, 309, 117, 118, 1719, 1720, "." +479, 13, 24, 310, 119, 120, 1721, 1722, "8" +479, 13, 25, 311, 121, 122, 1723, 1724, "+" +479, 13, 26, 312, 123, 124, 1725, 1726, "/" +479, 13, 27, 313, 125, 126, 1727, 1728, "-" +479, 13, 28, 314, 127, 128, 1729, 1730, "2" +479, 13, 29, 315, 129, 130, 1731, 1732, "." +479, 13, 30, 316, 131, 132, 1733, 1734, "9" +479, 13, 31, 317, 133, 137, 1735, 1739, "mmHg" +479, 13, 32, 318, 138, 139, 1740, 1741, "(" +479, 13, 33, 319, 140, 141, 1742, 1743, "P" +479, 13, 34, 320, 142, 143, 1744, 1745, "<" +479, 13, 35, 321, 144, 145, 1746, 1747, "0" +479, 13, 36, 322, 146, 147, 1748, 1749, "." +479, 13, 37, 323, 148, 152, 1750, 1754, "0001" +479, 13, 38, 324, 153, 154, 1755, 1756, ")" +479, 13, 39, 325, 155, 161, 1757, 1763, "versus" +479, 13, 40, 326, 162, 163, 1764, 1765, "-" +479, 13, 41, 327, 164, 165, 1766, 1767, "1" +479, 13, 42, 328, 166, 167, 1768, 1769, "." +479, 13, 43, 329, 168, 169, 1770, 1771, "8" +479, 13, 44, 330, 170, 171, 1772, 1773, "+" +479, 13, 45, 331, 172, 173, 1774, 1775, "/" +479, 13, 46, 332, 174, 175, 1776, 1777, "-" +479, 13, 47, 333, 176, 177, 1778, 1779, "3" +479, 13, 48, 334, 178, 179, 1780, 1781, "." +479, 13, 49, 335, 180, 181, 1782, 1783, "0" +479, 13, 50, 336, 182, 186, 1784, 1788, "mmHg" +479, 13, 51, 337, 187, 189, 1789, 1791, "in" +479, 13, 52, 338, 190, 193, 1792, 1795, "the" +479, 13, 53, 339, 194, 201, 1796, 1803, "placebo" +479, 13, 54, 340, 202, 207, 1804, 1809, "group" +479, 13, 55, 341, 208, 209, 1810, 1811, "(" +479, 13, 56, 342, 210, 211, 1812, 1813, "P" +479, 13, 57, 343, 212, 213, 1814, 1815, "=" +479, 13, 58, 344, 214, 215, 1816, 1817, "0" +479, 13, 59, 345, 216, 217, 1818, 1819, "." +479, 13, 60, 346, 218, 221, 1820, 1823, "006" +479, 13, 61, 347, 222, 223, 1824, 1825, ")" +479, 13, 62, 348, 224, 225, 1826, 1827, "." +479, 14, 1, 349, 0, 11, 1828, 1839, "CONCLUSIONS" +479, 14, 2, 350, 12, 13, 1840, 1841, ":" +479, 14, 3, 351, 14, 17, 1842, 1845, "The" +479, 14, 4, 352, 18, 25, 1846, 1853, "present" +479, 14, 5, 353, 26, 31, 1854, 1859, "study" +479, 14, 6, 354, 32, 41, 1860, 1869, "indicated" +479, 14, 7, 355, 42, 44, 1870, 1872, "no" +479, 14, 8, 356, 45, 55, 1873, 1883, "measurable" +479, 14, 9, 357, 56, 64, 1884, 1892, "vascular" +479, 14, 10, 358, 65, 72, 1893, 1900, "effects" +479, 14, 11, 359, 73, 77, 1901, 1905, "from" +479, 14, 12, 360, 78, 85, 1906, 1913, "topical" +479, 14, 13, 361, 86, 97, 1914, 1925, "dorzolamide" +479, 14, 14, 362, 98, 107, 1926, 1935, "treatment" +479, 14, 15, 363, 108, 110, 1936, 1938, "in" +479, 14, 16, 364, 111, 121, 1939, 1949, "previously" +479, 14, 17, 365, 122, 131, 1950, 1959, "untreated" +479, 14, 18, 366, 132, 140, 1960, 1968, "glaucoma" +479, 14, 19, 367, 141, 145, 1969, 1973, "eyes" +479, 14, 20, 368, 146, 147, 1974, 1975, "." +479, 15, 1, 369, 0, 4, 1976, 1980, "PMID" +479, 15, 2, 370, 5, 6, 1981, 1982, ":" +479, 15, 3, 371, 7, 15, 1983, 1991, "11952485" +479, 15, 4, 372, 16, 17, 1992, 1993, "[" +479, 15, 5, 373, 18, 25, 1994, 2001, "Indexed" +479, 15, 6, 374, 26, 29, 2002, 2005, "for" +479, 15, 7, 375, 30, 37, 2006, 2013, "MEDLINE" +479, 15, 8, 376, 38, 39, 2014, 2015, "]" diff --git a/data/gl 11952485_jshahinitiran.annodb b/data/gl 11952485_jshahinitiran.annodb new file mode 100644 index 0000000..89d98c4 --- /dev/null +++ b/data/gl 11952485_jshahinitiran.annodb @@ -0,0 +1,43 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +5013, Journal, 0, 21, "Acta Ophthalmol Scand", "", +5014, PublicationYear, 24, 28, "2002", "", +26227, Dorzolamide, 57, 68, "Dorzolamide", "", +5015, Title, 57, 171, "Dorzolamide and ocular blood flow in previously untreated glaucoma patients : a controlled double - masked study .", "", +5017, Precondition, 94, 114, "previously untreated", "", +5018, Glaucoma, 115, 123, "glaucoma", "", +5019, DoubleBlind, 148, 163, "double - masked", "", +5021, Author, 172, 185, "Bergstrand IC", "", +5022, Author, 194, 201, "Heijl A", "", +5023, Author, 204, 212, "Harris A", "", +5020, Sweden, 309, 315, "Sweden", "", +5024, ObjectiveDescription, 442, 604, "The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma .", "", +26228, Dorzolamide, 519, 530, "dorzolamide", "", +5026, Precondition, 554, 568, "newly detected", "", +26229, Precondition, 573, 593, "previously untreated", "", +26230, Glaucoma, 594, 602, "glaucoma", "", +5029, NumberPatientsCT, 615, 628, "Forty - seven", "", +5030, OpenAngleGlaucoma, 643, 662, "open angle glaucoma", "", +5031, Randomized, 682, 692, "randomized", "", +26231, Dorzolamide, 696, 707, "dorzolamide", "", +5033, Placebo, 715, 722, "placebo", "", +5034, Frequency, 723, 726, "TID", "", +5035, Duration, 736, 744, "6 - week", "", +5036, DoubleBlind, 745, 760, "double - masked", "", +26236, Mean, 1439, 1443, "mean", "", +26235, Dorzolamide, 1567, 1578, "dorzolamide", "", +26238, PValueChangeValue, 1587, 1597, "P = 0 . 03", "", +5037, IOP, 1602, 1622, "Intraocular pressure", "", +26232, Dorzolamide, 1674, 1685, "dorzolamide", "", +5043, PvalueDiff, 1694, 1705, "P = 0 . 002", "", +5040, Reduction, 1717, 1722, "4 . 8", "", +5041, SdErrorChangeValue, 1729, 1734, "2 . 9", "", +5042, mmHg, 1735, 1739, "mmHg", "", +5044, PValueChangeValue, 1742, 1754, "P < 0 . 0001", "", +5045, Reduction, 1766, 1771, "1 . 8", "", +5046, SdErrorChangeValue, 1778, 1783, "3 . 0", "", +5047, mmHg, 1784, 1788, "mmHg", "", +26234, Placebo, 1796, 1803, "placebo", "", +5048, PValueChangeValue, 1812, 1823, "P = 0 . 006", "", +5049, ConclusionComment, 1842, 1975, "The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes .", "", +26233, Glaucoma, 1960, 1968, "glaucoma", "", +5050, PMID, 1983, 1991, "11952485", "", diff --git a/data/gl 11952485_jshahinitiran.n-triples b/data/gl 11952485_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11952485_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 11952485_tstrakeljahn.annodb b/data/gl 11952485_tstrakeljahn.annodb new file mode 100644 index 0000000..1939a7f --- /dev/null +++ b/data/gl 11952485_tstrakeljahn.annodb @@ -0,0 +1,42 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +36320, Journal, 0, 21, "Acta Ophthalmol Scand", "", +36321, PublicationYear, 24, 28, "2002", "", +36322, Dorzolamide, 57, 68, "Dorzolamide", "", +36329, Title, 57, 169, "Dorzolamide and ocular blood flow in previously untreated glaucoma patients : a controlled double - masked study", "", +36345, BloodVelocity, 80, 90, "blood flow", "", +36324, Glaucoma, 115, 123, "glaucoma", "", +36325, DoubleBlind, 148, 163, "double - masked", "", +36326, Author, 172, 185, "Bergstrand IC", "", +36327, Author, 194, 201, "Heijl A", "", +36328, Author, 204, 212, "Harris A", "", +36330, Sweden, 309, 315, "Sweden", "", +36342, ObjectiveDescription, 442, 604, "The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma .", "", +36331, Dorzolamide, 519, 530, "dorzolamide", "", +36333, Precondition, 554, 602, "newly detected and previously untreated glaucoma", "", +36332, Glaucoma, 594, 602, "glaucoma", "", +36334, NumberPatientsCT, 615, 628, "Forty - seven", "", +36335, OpenAngleGlaucoma, 643, 662, "open angle glaucoma", "", +36336, Randomized, 682, 692, "randomized", "", +36337, Dorzolamide, 696, 707, "dorzolamide", "", +36338, Placebo, 715, 722, "placebo", "", +36339, Frequency, 723, 726, "TID", "", +36340, Duration, 736, 744, "6 - week", "", +36341, DoubleBlind, 745, 760, "double - masked", "", +36343, Dorzolamide, 1567, 1578, "dorzolamide", "", +36344, PvalueDiff, 1587, 1597, "P = 0 . 03", "", +36346, IOP, 1602, 1622, "Intraocular pressure", "", +36347, Dorzolamide, 1674, 1685, "dorzolamide", "", +36348, PvalueDiff, 1694, 1705, "P = 0 . 002", "", +36349, Reduction, 1717, 1722, "4 . 8", "", +36351, SdDevChangeValue, 1723, 1734, "+ / - 2 . 9", "", +36353, mmHg, 1735, 1739, "mmHg", "", +36356, PValueChangeValue, 1742, 1754, "P < 0 . 0001", "", +36350, Reduction, 1766, 1771, "1 . 8", "", +36352, SdDevChangeValue, 1772, 1783, "+ / - 3 . 0", "", +36354, mmHg, 1784, 1788, "mmHg", "", +36355, Placebo, 1796, 1803, "placebo", "", +36357, PValueChangeValue, 1812, 1823, "P = 0 . 006", "", +36359, ConclusionComment, 1842, 1975, "The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes .", "", +36362, Dorzolamide, 1914, 1925, "dorzolamide", "", +36358, Glaucoma, 1960, 1968, "glaucoma", "", +36361, PMID, 1983, 1991, "11952485", "", diff --git a/data/gl 11952485_tstrakeljahn.n-triples b/data/gl 11952485_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 11952485_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12383812_admin.annodb b/data/gl 12383812_admin.annodb new file mode 100644 index 0000000..3d1b15e --- /dev/null +++ b/data/gl 12383812_admin.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +122, Journal, 0, 17, "Am J Ophthalmol .", "", " \"12383812\"." +1, PublicationYear, 18, 22, "2002", "", " \"2002\"." +8, Title, 51, 189, "Comparative effects of latanoprost ( Xalatan ) and unoprostone ( Rescula ) in patients with open - angle glaucoma and suspected glaucoma .", "", " \"Comparative effects of latanoprost ( Xalatan ) and unoprostone ( Rescula ) in patients with open - angle glaucoma and suspected glaucoma .\"." +2, Latanoprost, 74, 85, "latanoprost", "", +3, Latanoprost, 88, 95, "Xalatan", "", +4, Unoprostone, 102, 113, "unoprostone", "", +5, Unoprostone, 116, 123, "Rescula", "", +106415, Precondition, 129, 187, "patients with open - angle glaucoma and suspected glaucoma", "", " \"patients with open - angle glaucoma and suspected glaucoma\"." +6, OpenAngleGlaucoma, 143, 164, "open - angle glaucoma", "", " ." +7, Glaucoma, 179, 187, "glaucoma", "", " . ." +9, Author, 190, 200, "Sponsel WE", "", " \"Sponsel WE\"." +10, Author, 209, 216, "Paris G", "", " \"Paris G\"." +11, Author, 219, 226, "Trigo Y", "", " \"Trigo Y\"." +12, Author, 229, 235, "Pena M", "", " \"Pena M\"." +13, USA, 359, 362, "USA", "", " ." +19, ObjectiveDescription, 399, 595, "To compare , in paired eyes of open - angle glaucoma patients and glaucoma suspects , hydrodynamic and visual changes after 1 month of topical latanoprost in one eye and unoprostone in the other .", "", " \"To compare , in paired eyes of open - angle glaucoma patients and glaucoma suspects , hydrodynamic and visual changes after 1 month of topical latanoprost in one eye and unoprostone in the other .\"." +14, OpenAngleGlaucoma, 430, 451, "open - angle glaucoma", "", +15, Glaucoma, 465, 473, "glaucoma", "", +95059, EndPointDescription, 485, 516, "hydrodynamic and visual changes", "", +16, Duration, 523, 530, "1 month", "", " \"1 month\"." +95166, DeliveryMethod, 534, 541, "topical", "", " . . . ." +17, Latanoprost, 542, 553, "latanoprost", "", +18, Unoprostone, 569, 580, "unoprostone", "", +20, SingleCenter, 605, 620, "Single - center", "", " ." +21, Randomized, 637, 647, "randomized", "", " ." +95167, DeliveryMethod, 717, 724, "topical", "", +23, NumberPatientsCT, 738, 740, "25", "", " \"25\"." +142, Mean, 750, 754, "mean", "", +24, AvgAge, 759, 761, "54", "", " \"54\"." +144, OpenAngleGlaucoma, 787, 818, "bilateral open - angle glaucoma", "", " ." +26, Glaucoma, 822, 830, "glaucoma", "", +27, Morning, 856, 863, "morning", "", +28, Afternoon, 883, 892, "afternoon", "", +29, IOP, 923, 943, "intraocular pressure", "", " . ." +30, IOP, 946, 949, "IOP", "", +148, OcularBloodFlow, 954, 981, "pulsatile ocular blood flow", "", +149, OcularBloodFlow, 984, 988, "POBF", "", +31, Unoprostone, 1125, 1136, "unoprostone", "", " ." +33, DoseValue, 1137, 1143, "0 . 15", "", " \"0 . 15\"." +34, Percentage, 1144, 1145, "%", "", " ." +32, Unoprostone, 1148, 1155, "Rescula", "", +152, Randomized, 1165, 1173, "randomly", "", +35, Latanoprost, 1191, 1202, "latanoprost", "", " . ." +36, DoseValue, 1203, 1210, "0 . 005", "", " \"0 . 005\"." +106401, Percentage, 1211, 1212, "%", "", " ." +37, Latanoprost, 1215, 1222, "Xalatan", "", +38, Unoprostone, 1240, 1251, "Unoprostone", "", +106427, Morning, 1272, 1276, "8 AM", "", " ." +106428, Evening, 1281, 1285, "8 PM", "", " ." +156, Latanoprost, 1290, 1301, "latanoprost", "", +106425, Evening, 1305, 1309, "8 PM", "", " ." +43, Placebo, 1315, 1322, "placebo", "", " ." +106426, Morning, 1326, 1330, "8 AM", "", " ." +44, Duration, 1366, 1373, "28 days", "", +45, IOP, 1504, 1507, "IOP", "", +106418, Duration, 1523, 1530, "1 month", "", +47, Mean, 1550, 1554, "mean", "", " . ." +106419, TimePoint, 1555, 1562, "morning", "", " \"morning\". \"morning\"." +49, IOP, 1563, 1566, "IOP", "", +106416, DeliveryMethod, 1600, 1607, "topical", "", +50, ResultMeasuredValue, 1625, 1631, "16 . 2", "", " \"16 . 2\"." +52, SdErrorResValue, 1642, 1647, "0 . 6", "", " \"0 . 6\"." +57, mmHg, 1648, 1653, "mm Hg", "", " ." +56, Latanoprost, 1658, 1669, "latanoprost", "", +51, ResultMeasuredValue, 1673, 1679, "17 . 9", "", " \"17 . 9\"." +53, SdErrorResValue, 1686, 1691, "0 . 7", "", " \"0 . 6\"." +58, mmHg, 1692, 1697, "mm Hg", "", +55, Unoprostone, 1702, 1713, "unoprostone", "", +106417, DiffBetweenGroups, 1716, 1725, "P = . 001", "", +106424, TimePoint, 1736, 1743, "morning", "", +60, Reduction, 1759, 1764, "2 . 6", "", " \"2 . 6\"." +62, mmHg, 1765, 1770, "mm Hg", "", +64, Latanoprost, 1813, 1824, "latanoprost", "", +175, PValueChangeValue, 1827, 1837, "P < . 0001", "", " \"P < . 0001\"." +61, Reduction, 1846, 1851, "1 . 6", "", " \"1 . 6\"." +63, mmHg, 1852, 1857, "mm Hg", "", +65, Unoprostone, 1867, 1878, "unoprostone", "", +179, PValueChangeValue, 1896, 1904, "P = . 02", "", " \"P = . 02\"." +106420, TimePoint, 1909, 1918, "Afternoon", "", " \"Afternoon\". \"Afternoon\"." +69, Reduction, 1931, 1936, "3 . 1", "", " \"3 . 1\"." +71, SdErrorChangeValue, 1947, 1952, "0 . 6", "", " \"0 . 6\"." +73, Latanoprost, 2005, 2016, "latanoprost", "", +70, Reduction, 2023, 2028, "2 . 4", "", " \"2 . 4\"." +72, SdErrorChangeValue, 2039, 2044, "0 . 6", "", " \"0 . 6\"." +74, mmHg, 2045, 2050, "mm Hg", "", +76, Unoprostone, 2054, 2065, "unoprostone", "", +186, PValueChangeValue, 2083, 2093, "P < . 0001", "", +77, Mean, 2141, 2145, "mean", "", +78, IOP, 2146, 2149, "IOP", "", +189, PvalueDiff, 2163, 2171, "P = . 04", "", " \"P = . 04\"." +80, Unoprostone, 2191, 2202, "unoprostone", "", +81, Mean, 2257, 2261, "mean", "", +192, PValueChangeValue, 2274, 2282, "P = . 03", "", +193, OcularBloodFlow, 2342, 2369, "Pulsatile ocular blood flow", "", " ." +84, RelativeIncrement, 2380, 2382, "30", "", " \"30\"." +86, Latanoprost, 2424, 2435, "latanoprost", "", +196, PValueChangeValue, 2440, 2450, "P < . 0001", "", " \"P < . 0001\"." +85, RelativeIncrement, 2457, 2459, "16", "", " \"16\"." +87, Unoprostone, 2480, 2491, "unoprostone", "", +199, PValueChangeValue, 2494, 2502, "P = . 05", "", " \"P = . 05\"." +106422, TimePoint, 2512, 2519, "morning", "", " \"morning\". \"morning\"." +91, TimePoint, 2523, 2529, "day 28", "", +106421, TimePoint, 2537, 2546, "afternoon", "", " \"afternoon\". \"afternoon\"." +97, Mean, 2549, 2553, "mean", "", " . ." +93, OcularBloodFlow, 2554, 2558, "POBF", "", +94, RelativeIncrement, 2573, 2575, "30", "", " \"30\"." +204, PValueChangeValue, 2580, 2590, "P < . 0001", "", " \"P < . 0001\"." +106423, TimePoint, 2605, 2614, "afternoon", "", +100, Latanoprost, 2652, 2663, "latanoprost", "", +95, RelativeIncrement, 2668, 2670, "18", "", " \"18\"." +207, PValueChangeValue, 2675, 2683, "P = . 03", "", " \"P = . 03\"." +101, Unoprostone, 2708, 2719, "unoprostone", "", +209, PvalueDiff, 2752, 2760, "P = . 05", "", " \"P = . 05\"." +118, ConclusionComment, 2863, 3012, "Both latanoprost and unoprostone produced significant reductions in IOP and increases in POBF , with stable central and perimacular visual function .", "", " \"Both latanoprost and unoprostone produced significant reductions in IOP and increases in POBF , with stable central and perimacular visual function .\"." +103, Latanoprost, 2868, 2879, "latanoprost", "", +105, Unoprostone, 2884, 2895, "unoprostone", "", +107, IOP, 2931, 2934, "IOP", "", +108, OcularBloodFlow, 2952, 2956, "POBF", "", +109, Latanoprost, 3013, 3024, "Latanoprost", "", +119, ConclusionComment, 3013, 3151, "Latanoprost once daily produced IOP reduction and POBF increases nearly twofold greater than those obtained with unoprostone twice daily .", "", " \"Latanoprost once daily produced IOP reduction and POBF increases nearly twofold greater than those obtained with unoprostone twice daily .\"." +110, Frequency, 3025, 3035, "once daily", "", " \"once daily\"." +112, IOP, 3045, 3048, "IOP", "", +113, OcularBloodFlow, 3063, 3067, "POBF", "", +114, Unoprostone, 3126, 3137, "unoprostone", "", +111, Frequency, 3138, 3149, "twice daily", "", " \"twice daily\"." +120, ConclusionComment, 3152, 3261, "These differences in IOP and POBF change between unoprostone and latanoprost were statistically significant .", "", " \"These differences in IOP and POBF change between unoprostone and latanoprost were statistically significant .\"." +115, IOP, 3173, 3176, "IOP", "", +116, OcularBloodFlow, 3181, 3185, "POBF", "", +106, Unoprostone, 3201, 3212, "unoprostone", "", +104, Latanoprost, 3217, 3228, "latanoprost", "", +121, PMID, 3317, 3325, "12383812", "", " \"12383812\"." diff --git a/data/gl 12383812_admin.n-triples b/data/gl 12383812_admin.n-triples new file mode 100644 index 0000000..c7d6f23 --- /dev/null +++ b/data/gl 12383812_admin.n-triples @@ -0,0 +1,176 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparative effects of latanoprost ( Xalatan ) and unoprostone ( Rescula ) in patients with open - angle glaucoma and suspected glaucoma ." . + "Sponsel WE" . + "2002" . + "Am J Ophthalmol ." . + "12383812" . + . + "Paris G" . + "Trigo Y" . + "Pena M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare , in paired eyes of open - angle glaucoma patients and glaucoma suspects , hydrodynamic and visual changes after 1 month of topical latanoprost in one eye and unoprostone in the other ." . + "25" . + "1 month" . + . + . + . + "Both latanoprost and unoprostone produced significant reductions in IOP and increases in POBF , with stable central and perimacular visual function ." . + . + . + . + . + . + . + "Latanoprost once daily produced IOP reduction and POBF increases nearly twofold greater than those obtained with unoprostone twice daily ." . + "These differences in IOP and POBF change between unoprostone and latanoprost were statistically significant ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with open - angle glaucoma and suspected glaucoma" . + . + . + "54" . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_ocularFlow" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + . + . + "Arm_uno" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_uno" . + . + "twice daily" . + . + . + . + "Intervention_pla" . + . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + . + "Medication_uno" . + . + "0 . 15" . + . + . + . + . + "Medication_pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat_morning" . + . + "16 . 2" . + "0 . 6" . + "2 . 6" . + "P < . 0001" . + "morning" . + . + "Outcome_iop_uno_morning" . + . + "17 . 9" . + "0 . 7" . + "1 . 6" . + "P = . 02" . + "morning" . + . + "Outcome_iop_lat_afternoon" . + . + "3 . 1" . + "0 . 6" . + "Afternoon" . + . + "Outcome_iop_uno_afternoon" . + . + "2 . 4" . + "0 . 6" . + "Afternoon" . + . + "Outcome_OBF_lat_morning" . + . + "30" . + "P < . 0001" . + "morning" . + . + "Outcome_OBF_uno_morning" . + . + "16" . + "P = . 05" . + "morning" . + . + "Outcome_OBF_lat_afternoon" . + . + "30" . + "P < . 0001" . + "afternoon" . + . + "Outcome_OBF_uno_afternoon" . + . + "18" . + "P = . 03" . + "afternoon" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_OBF_afternoon" . + "P = . 05" . + . + . + . + "DiffBetweenGroups_IOP_afternoo" . + "P = . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12383812_export.csv b/data/gl 12383812_export.csv new file mode 100644 index 0000000..17be39c --- /dev/null +++ b/data/gl 12383812_export.csv @@ -0,0 +1,674 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +523, 1, 1, 1, 0, 2, 0, 2, "Am" +523, 1, 2, 2, 3, 4, 3, 4, "J" +523, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +523, 1, 4, 4, 16, 17, 16, 17, "." +523, 2, 1, 5, 0, 4, 18, 22, "2002" +523, 2, 2, 6, 5, 8, 23, 26, "Oct" +523, 2, 3, 7, 9, 10, 27, 28, ";" +523, 2, 4, 8, 11, 14, 29, 32, "134" +523, 2, 5, 9, 15, 16, 33, 34, "(" +523, 2, 6, 10, 17, 18, 35, 36, "4" +523, 2, 7, 11, 19, 20, 37, 38, ")" +523, 2, 8, 12, 21, 22, 39, 40, ":" +523, 2, 9, 13, 23, 26, 41, 44, "552" +523, 2, 10, 14, 27, 28, 45, 46, "-" +523, 2, 11, 15, 29, 30, 47, 48, "9" +523, 2, 12, 16, 31, 32, 49, 50, "." +523, 3, 1, 17, 0, 11, 51, 62, "Comparative" +523, 3, 2, 18, 12, 19, 63, 70, "effects" +523, 3, 3, 19, 20, 22, 71, 73, "of" +523, 3, 4, 20, 23, 34, 74, 85, "latanoprost" +523, 3, 5, 21, 35, 36, 86, 87, "(" +523, 3, 6, 22, 37, 44, 88, 95, "Xalatan" +523, 3, 7, 23, 45, 46, 96, 97, ")" +523, 3, 8, 24, 47, 50, 98, 101, "and" +523, 3, 9, 25, 51, 62, 102, 113, "unoprostone" +523, 3, 10, 26, 63, 64, 114, 115, "(" +523, 3, 11, 27, 65, 72, 116, 123, "Rescula" +523, 3, 12, 28, 73, 74, 124, 125, ")" +523, 3, 13, 29, 75, 77, 126, 128, "in" +523, 3, 14, 30, 78, 86, 129, 137, "patients" +523, 3, 15, 31, 87, 91, 138, 142, "with" +523, 3, 16, 32, 92, 96, 143, 147, "open" +523, 3, 17, 33, 97, 98, 148, 149, "-" +523, 3, 18, 34, 99, 104, 150, 155, "angle" +523, 3, 19, 35, 105, 113, 156, 164, "glaucoma" +523, 3, 20, 36, 114, 117, 165, 168, "and" +523, 3, 21, 37, 118, 127, 169, 178, "suspected" +523, 3, 22, 38, 128, 136, 179, 187, "glaucoma" +523, 3, 23, 39, 137, 138, 188, 189, "." +523, 4, 1, 40, 0, 7, 190, 197, "Sponsel" +523, 4, 2, 41, 8, 10, 198, 200, "WE" +523, 4, 3, 42, 11, 12, 201, 202, "(" +523, 4, 4, 43, 13, 14, 203, 204, "1" +523, 4, 5, 44, 15, 16, 205, 206, ")" +523, 4, 6, 45, 17, 18, 207, 208, "," +523, 4, 7, 46, 19, 24, 209, 214, "Paris" +523, 4, 8, 47, 25, 26, 215, 216, "G" +523, 4, 9, 48, 27, 28, 217, 218, "," +523, 4, 10, 49, 29, 34, 219, 224, "Trigo" +523, 4, 11, 50, 35, 36, 225, 226, "Y" +523, 4, 12, 51, 37, 38, 227, 228, "," +523, 4, 13, 52, 39, 43, 229, 233, "Pena" +523, 4, 14, 53, 44, 45, 234, 235, "M" +523, 4, 15, 54, 46, 47, 236, 237, "." +523, 4, 16, 55, 48, 54, 238, 244, "Author" +523, 4, 17, 56, 55, 66, 245, 256, "information" +523, 4, 18, 57, 67, 68, 257, 258, ":" +523, 4, 19, 58, 69, 70, 259, 260, "(" +523, 4, 20, 59, 71, 72, 261, 262, "1" +523, 4, 21, 60, 73, 74, 263, 264, ")" +523, 4, 22, 61, 75, 85, 265, 275, "Department" +523, 4, 23, 62, 86, 88, 276, 278, "of" +523, 4, 24, 63, 89, 102, 279, 292, "Ophthalmology" +523, 4, 25, 64, 103, 104, 293, 294, "," +523, 4, 26, 65, 105, 115, 295, 305, "University" +523, 4, 27, 66, 116, 118, 306, 308, "of" +523, 4, 28, 67, 119, 124, 309, 314, "Texas" +523, 4, 29, 68, 125, 131, 315, 321, "Health" +523, 4, 30, 69, 132, 139, 322, 329, "Science" +523, 4, 31, 70, 140, 146, 330, 336, "Center" +523, 4, 32, 71, 147, 148, 337, 338, "," +523, 4, 33, 72, 149, 152, 339, 342, "San" +523, 4, 34, 73, 153, 160, 343, 350, "Antonio" +523, 4, 35, 74, 161, 166, 351, 356, "78229" +523, 4, 36, 75, 167, 168, 357, 358, "," +523, 4, 37, 76, 169, 172, 359, 362, "USA" +523, 4, 38, 77, 173, 174, 363, 364, "." +523, 5, 1, 78, 0, 7, 365, 372, "sponsel" +523, 5, 2, 79, 8, 9, 373, 374, "@" +523, 5, 3, 80, 10, 17, 375, 382, "uthscsa" +523, 5, 4, 81, 18, 19, 383, 384, "." +523, 5, 5, 82, 20, 23, 385, 388, "edu" +523, 5, 6, 83, 24, 31, 389, 396, "PURPOSE" +523, 5, 7, 84, 32, 33, 397, 398, ":" +523, 5, 8, 85, 34, 36, 399, 401, "To" +523, 5, 9, 86, 37, 44, 402, 409, "compare" +523, 5, 10, 87, 45, 46, 410, 411, "," +523, 5, 11, 88, 47, 49, 412, 414, "in" +523, 5, 12, 89, 50, 56, 415, 421, "paired" +523, 5, 13, 90, 57, 61, 422, 426, "eyes" +523, 5, 14, 91, 62, 64, 427, 429, "of" +523, 5, 15, 92, 65, 69, 430, 434, "open" +523, 5, 16, 93, 70, 71, 435, 436, "-" +523, 5, 17, 94, 72, 77, 437, 442, "angle" +523, 5, 18, 95, 78, 86, 443, 451, "glaucoma" +523, 5, 19, 96, 87, 95, 452, 460, "patients" +523, 5, 20, 97, 96, 99, 461, 464, "and" +523, 5, 21, 98, 100, 108, 465, 473, "glaucoma" +523, 5, 22, 99, 109, 117, 474, 482, "suspects" +523, 5, 23, 100, 118, 119, 483, 484, "," +523, 5, 24, 101, 120, 132, 485, 497, "hydrodynamic" +523, 5, 25, 102, 133, 136, 498, 501, "and" +523, 5, 26, 103, 137, 143, 502, 508, "visual" +523, 5, 27, 104, 144, 151, 509, 516, "changes" +523, 5, 28, 105, 152, 157, 517, 522, "after" +523, 5, 29, 106, 158, 159, 523, 524, "1" +523, 5, 30, 107, 160, 165, 525, 530, "month" +523, 5, 31, 108, 166, 168, 531, 533, "of" +523, 5, 32, 109, 169, 176, 534, 541, "topical" +523, 5, 33, 110, 177, 188, 542, 553, "latanoprost" +523, 5, 34, 111, 189, 191, 554, 556, "in" +523, 5, 35, 112, 192, 195, 557, 560, "one" +523, 5, 36, 113, 196, 199, 561, 564, "eye" +523, 5, 37, 114, 200, 203, 565, 568, "and" +523, 5, 38, 115, 204, 215, 569, 580, "unoprostone" +523, 5, 39, 116, 216, 218, 581, 583, "in" +523, 5, 40, 117, 219, 222, 584, 587, "the" +523, 5, 41, 118, 223, 228, 588, 593, "other" +523, 5, 42, 119, 229, 230, 594, 595, "." +523, 6, 1, 120, 0, 6, 596, 602, "DESIGN" +523, 6, 2, 121, 7, 8, 603, 604, ":" +523, 6, 3, 122, 9, 15, 605, 611, "Single" +523, 6, 4, 123, 16, 17, 612, 613, "-" +523, 6, 5, 124, 18, 24, 614, 620, "center" +523, 6, 6, 125, 25, 26, 621, 622, "," +523, 6, 7, 126, 27, 40, 623, 636, "institutional" +523, 6, 8, 127, 41, 51, 637, 647, "randomized" +523, 6, 9, 128, 52, 60, 648, 656, "clinical" +523, 6, 10, 129, 61, 66, 657, 662, "trial" +523, 6, 11, 130, 67, 68, 663, 664, "." +523, 7, 1, 131, 0, 7, 665, 672, "METHODS" +523, 7, 2, 132, 8, 9, 673, 674, ":" +523, 7, 3, 133, 10, 15, 675, 680, "After" +523, 7, 4, 134, 16, 26, 681, 691, "completing" +523, 7, 5, 135, 27, 28, 692, 693, "a" +523, 7, 6, 136, 29, 36, 694, 701, "washout" +523, 7, 7, 137, 37, 43, 702, 708, "period" +523, 7, 8, 138, 44, 47, 709, 712, "off" +523, 7, 9, 139, 48, 51, 713, 716, "all" +523, 7, 10, 140, 52, 59, 717, 724, "topical" +523, 7, 11, 141, 60, 70, 725, 735, "medication" +523, 7, 12, 142, 71, 72, 736, 737, "," +523, 7, 13, 143, 73, 75, 738, 740, "25" +523, 7, 14, 144, 76, 82, 741, 747, "adults" +523, 7, 15, 145, 83, 84, 748, 749, "(" +523, 7, 16, 146, 85, 89, 750, 754, "mean" +523, 7, 17, 147, 90, 93, 755, 758, "age" +523, 7, 18, 148, 94, 96, 759, 761, "54" +523, 7, 19, 149, 97, 98, 762, 763, "+" +523, 7, 20, 150, 99, 100, 764, 765, "/" +523, 7, 21, 151, 101, 102, 766, 767, "-" +523, 7, 22, 152, 103, 106, 768, 771, "SEM" +523, 7, 23, 153, 107, 108, 772, 773, "2" +523, 7, 24, 154, 109, 114, 774, 779, "years" +523, 7, 25, 155, 115, 116, 780, 781, ")" +523, 7, 26, 156, 117, 121, 782, 786, "with" +523, 7, 27, 157, 122, 131, 787, 796, "bilateral" +523, 7, 28, 158, 132, 136, 797, 801, "open" +523, 7, 29, 159, 137, 138, 802, 803, "-" +523, 7, 30, 160, 139, 144, 804, 809, "angle" +523, 7, 31, 161, 145, 153, 810, 818, "glaucoma" +523, 7, 32, 162, 154, 156, 819, 821, "or" +523, 7, 33, 163, 157, 165, 822, 830, "glaucoma" +523, 7, 34, 164, 166, 173, 831, 838, "suspect" +523, 7, 35, 165, 174, 180, 839, 845, "status" +523, 7, 36, 166, 181, 190, 846, 855, "underwent" +523, 7, 37, 167, 191, 198, 856, 863, "morning" +523, 7, 38, 168, 199, 200, 864, 865, "(" +523, 7, 39, 169, 201, 202, 866, 867, "8" +523, 7, 40, 170, 203, 205, 868, 870, "to" +523, 7, 41, 171, 206, 208, 871, 873, "10" +523, 7, 42, 172, 209, 211, 874, 876, "AM" +523, 7, 43, 173, 212, 213, 877, 878, ")" +523, 7, 44, 174, 214, 217, 879, 882, "and" +523, 7, 45, 175, 218, 227, 883, 892, "afternoon" +523, 7, 46, 176, 228, 229, 893, 894, "(" +523, 7, 47, 177, 230, 231, 895, 896, "1" +523, 7, 48, 178, 232, 234, 897, 899, "to" +523, 7, 49, 179, 235, 236, 900, 901, "3" +523, 7, 50, 180, 237, 239, 902, 904, "PM" +523, 7, 51, 181, 240, 241, 905, 906, ")" +523, 7, 52, 182, 242, 254, 907, 919, "measurements" +523, 7, 53, 183, 255, 257, 920, 922, "of" +523, 7, 54, 184, 258, 269, 923, 934, "intraocular" +523, 7, 55, 185, 270, 278, 935, 943, "pressure" +523, 7, 56, 186, 279, 280, 944, 945, "(" +523, 7, 57, 187, 281, 284, 946, 949, "IOP" +523, 7, 58, 188, 285, 286, 950, 951, ")" +523, 7, 59, 189, 287, 288, 952, 953, "," +523, 7, 60, 190, 289, 298, 954, 963, "pulsatile" +523, 7, 61, 191, 299, 305, 964, 970, "ocular" +523, 7, 62, 192, 306, 311, 971, 976, "blood" +523, 7, 63, 193, 312, 316, 977, 981, "flow" +523, 7, 64, 194, 317, 318, 982, 983, "(" +523, 7, 65, 195, 319, 323, 984, 988, "POBF" +523, 7, 66, 196, 324, 325, 989, 990, ")" +523, 7, 67, 197, 326, 327, 991, 992, "," +523, 7, 68, 198, 328, 336, 993, 1001, "contrast" +523, 7, 69, 199, 337, 338, 1002, 1003, "," +523, 7, 70, 200, 339, 350, 1004, 1015, "sensitivity" +523, 7, 71, 201, 351, 352, 1016, 1017, "," +523, 7, 72, 202, 353, 362, 1018, 1027, "frequency" +523, 7, 73, 203, 363, 371, 1028, 1036, "doubling" +523, 7, 74, 204, 372, 382, 1037, 1047, "technology" +523, 7, 75, 205, 383, 384, 1048, 1049, "," +523, 7, 76, 206, 385, 388, 1050, 1053, "and" +523, 7, 77, 207, 389, 397, 1054, 1062, "Humphrey" +523, 7, 78, 208, 398, 400, 1063, 1065, "10" +523, 7, 79, 209, 401, 402, 1066, 1067, "-" +523, 7, 80, 210, 403, 404, 1068, 1069, "2" +523, 7, 81, 211, 405, 414, 1070, 1079, "perimetry" +523, 7, 82, 212, 415, 416, 1080, 1081, "(" +523, 7, 83, 213, 417, 421, 1082, 1086, "HVFA" +523, 7, 84, 214, 422, 424, 1087, 1089, "II" +523, 7, 85, 215, 425, 426, 1090, 1091, ")" +523, 7, 86, 216, 427, 429, 1092, 1094, "in" +523, 7, 87, 217, 430, 434, 1095, 1099, "both" +523, 7, 88, 218, 435, 439, 1100, 1104, "eyes" +523, 7, 89, 219, 440, 441, 1105, 1106, "." +523, 8, 1, 220, 0, 4, 1107, 1111, "Each" +523, 8, 2, 221, 5, 9, 1112, 1116, "then" +523, 8, 3, 222, 10, 17, 1117, 1124, "started" +523, 8, 4, 223, 18, 29, 1125, 1136, "unoprostone" +523, 8, 5, 224, 30, 31, 1137, 1138, "0" +523, 8, 6, 225, 32, 33, 1139, 1140, "." +523, 8, 7, 226, 34, 36, 1141, 1143, "15" +523, 8, 8, 227, 37, 38, 1144, 1145, "%" +523, 8, 9, 228, 39, 40, 1146, 1147, "(" +523, 8, 10, 229, 41, 48, 1148, 1155, "Rescula" +523, 8, 11, 230, 49, 50, 1156, 1157, ")" +523, 8, 12, 231, 51, 53, 1158, 1160, "in" +523, 8, 13, 232, 54, 57, 1161, 1164, "one" +523, 8, 14, 233, 58, 66, 1165, 1173, "randomly" +523, 8, 15, 234, 67, 75, 1174, 1182, "assigned" +523, 8, 16, 235, 76, 79, 1183, 1186, "eye" +523, 8, 17, 236, 80, 83, 1187, 1190, "and" +523, 8, 18, 237, 84, 95, 1191, 1202, "latanoprost" +523, 8, 19, 238, 96, 97, 1203, 1204, "0" +523, 8, 20, 239, 98, 99, 1205, 1206, "." +523, 8, 21, 240, 100, 103, 1207, 1210, "005" +523, 8, 22, 241, 104, 105, 1211, 1212, "%" +523, 8, 23, 242, 106, 107, 1213, 1214, "(" +523, 8, 24, 243, 108, 115, 1215, 1222, "Xalatan" +523, 8, 25, 244, 116, 117, 1223, 1224, ")" +523, 8, 26, 245, 118, 120, 1225, 1227, "in" +523, 8, 27, 246, 121, 124, 1228, 1231, "the" +523, 8, 28, 247, 125, 130, 1232, 1237, "other" +523, 8, 29, 248, 131, 132, 1238, 1239, "." +523, 9, 1, 249, 0, 11, 1240, 1251, "Unoprostone" +523, 9, 2, 250, 12, 15, 1252, 1255, "was" +523, 9, 3, 251, 16, 28, 1256, 1268, "administered" +523, 9, 4, 252, 29, 31, 1269, 1271, "at" +523, 9, 5, 253, 32, 33, 1272, 1273, "8" +523, 9, 6, 254, 34, 36, 1274, 1276, "AM" +523, 9, 7, 255, 37, 40, 1277, 1280, "and" +523, 9, 8, 256, 41, 42, 1281, 1282, "8" +523, 9, 9, 257, 43, 45, 1283, 1285, "PM" +523, 9, 10, 258, 46, 49, 1286, 1289, "and" +523, 9, 11, 259, 50, 61, 1290, 1301, "latanoprost" +523, 9, 12, 260, 62, 64, 1302, 1304, "at" +523, 9, 13, 261, 65, 66, 1305, 1306, "8" +523, 9, 14, 262, 67, 69, 1307, 1309, "PM" +523, 9, 15, 263, 70, 74, 1310, 1314, "with" +523, 9, 16, 264, 75, 82, 1315, 1322, "placebo" +523, 9, 17, 265, 83, 85, 1323, 1325, "at" +523, 9, 18, 266, 86, 87, 1326, 1327, "8" +523, 9, 19, 267, 88, 90, 1328, 1330, "AM" +523, 9, 20, 268, 91, 92, 1331, 1332, "," +523, 9, 21, 269, 93, 97, 1333, 1337, "both" +523, 9, 22, 270, 98, 102, 1338, 1342, "from" +523, 9, 23, 271, 103, 109, 1343, 1349, "masked" +523, 9, 24, 272, 110, 117, 1350, 1357, "bottles" +523, 9, 25, 273, 118, 119, 1358, 1359, "." +523, 10, 1, 274, 0, 5, 1360, 1365, "After" +523, 10, 2, 275, 6, 8, 1366, 1368, "28" +523, 10, 3, 276, 9, 13, 1369, 1373, "days" +523, 10, 4, 277, 14, 15, 1374, 1375, "," +523, 10, 5, 278, 16, 27, 1376, 1387, "differences" +523, 10, 6, 279, 28, 32, 1388, 1392, "were" +523, 10, 7, 280, 33, 43, 1393, 1403, "determined" +523, 10, 8, 281, 44, 47, 1404, 1407, "for" +523, 10, 9, 282, 48, 52, 1408, 1412, "each" +523, 10, 10, 283, 53, 61, 1413, 1421, "measured" +523, 10, 11, 284, 62, 70, 1422, 1430, "variable" +523, 10, 12, 285, 71, 73, 1431, 1433, "by" +523, 10, 13, 286, 74, 77, 1434, 1437, "two" +523, 10, 14, 287, 78, 79, 1438, 1439, "-" +523, 10, 15, 288, 80, 86, 1440, 1446, "tailed" +523, 10, 16, 289, 87, 93, 1447, 1453, "paired" +523, 10, 17, 290, 94, 95, 1454, 1455, "t" +523, 10, 18, 291, 96, 100, 1456, 1460, "test" +523, 10, 19, 292, 101, 102, 1461, 1462, "." +523, 11, 1, 293, 0, 7, 1463, 1470, "RESULTS" +523, 11, 2, 294, 8, 9, 1471, 1472, ":" +523, 11, 3, 295, 10, 18, 1473, 1481, "Starting" +523, 11, 4, 296, 19, 23, 1482, 1486, "from" +523, 11, 5, 297, 24, 31, 1487, 1494, "similar" +523, 11, 6, 298, 32, 40, 1495, 1503, "baseline" +523, 11, 7, 299, 41, 44, 1504, 1507, "IOP" +523, 11, 8, 300, 45, 51, 1508, 1514, "levels" +523, 11, 9, 301, 52, 53, 1515, 1516, "," +523, 11, 10, 302, 54, 59, 1517, 1522, "after" +523, 11, 11, 303, 60, 61, 1523, 1524, "1" +523, 11, 12, 304, 62, 67, 1525, 1530, "month" +523, 11, 13, 305, 68, 70, 1531, 1533, "of" +523, 11, 14, 306, 71, 80, 1534, 1543, "treatment" +523, 11, 15, 307, 81, 82, 1544, 1545, "," +523, 11, 16, 308, 83, 86, 1546, 1549, "the" +523, 11, 17, 309, 87, 91, 1550, 1554, "mean" +523, 11, 18, 310, 92, 99, 1555, 1562, "morning" +523, 11, 19, 311, 100, 103, 1563, 1566, "IOP" +523, 11, 20, 312, 104, 110, 1567, 1573, "values" +523, 11, 21, 313, 111, 119, 1574, 1582, "differed" +523, 11, 22, 314, 120, 129, 1583, 1592, "according" +523, 11, 23, 315, 130, 132, 1593, 1595, "to" +523, 11, 24, 316, 133, 136, 1596, 1599, "the" +523, 11, 25, 317, 137, 144, 1600, 1607, "topical" +523, 11, 26, 318, 145, 150, 1608, 1613, "agent" +523, 11, 27, 319, 151, 159, 1614, 1622, "received" +523, 11, 28, 320, 160, 161, 1623, 1624, "(" +523, 11, 29, 321, 162, 164, 1625, 1627, "16" +523, 11, 30, 322, 165, 166, 1628, 1629, "." +523, 11, 31, 323, 167, 168, 1630, 1631, "2" +523, 11, 32, 324, 169, 170, 1632, 1633, "+" +523, 11, 33, 325, 171, 172, 1634, 1635, "/" +523, 11, 34, 326, 173, 174, 1636, 1637, "-" +523, 11, 35, 327, 175, 178, 1638, 1641, "SEM" +523, 11, 36, 328, 179, 180, 1642, 1643, "0" +523, 11, 37, 329, 181, 182, 1644, 1645, "." +523, 11, 38, 330, 183, 184, 1646, 1647, "6" +523, 11, 39, 331, 185, 187, 1648, 1650, "mm" +523, 11, 40, 332, 188, 190, 1651, 1653, "Hg" +523, 11, 41, 333, 191, 194, 1654, 1657, "for" +523, 11, 42, 334, 195, 206, 1658, 1669, "latanoprost" +523, 11, 43, 335, 207, 209, 1670, 1672, "vs" +523, 11, 44, 336, 210, 212, 1673, 1675, "17" +523, 11, 45, 337, 213, 214, 1676, 1677, "." +523, 11, 46, 338, 215, 216, 1678, 1679, "9" +523, 11, 47, 339, 217, 218, 1680, 1681, "+" +523, 11, 48, 340, 219, 220, 1682, 1683, "/" +523, 11, 49, 341, 221, 222, 1684, 1685, "-" +523, 11, 50, 342, 223, 224, 1686, 1687, "0" +523, 11, 51, 343, 225, 226, 1688, 1689, "." +523, 11, 52, 344, 227, 228, 1690, 1691, "7" +523, 11, 53, 345, 229, 231, 1692, 1694, "mm" +523, 11, 54, 346, 232, 234, 1695, 1697, "Hg" +523, 11, 55, 347, 235, 238, 1698, 1701, "for" +523, 11, 56, 348, 239, 250, 1702, 1713, "unoprostone" +523, 11, 57, 349, 251, 252, 1714, 1715, ";" +523, 11, 58, 350, 253, 254, 1716, 1717, "P" +523, 11, 59, 351, 255, 256, 1718, 1719, "=" +523, 11, 60, 352, 257, 258, 1720, 1721, "." +523, 11, 61, 353, 259, 262, 1722, 1725, "001" +523, 11, 62, 354, 263, 264, 1726, 1727, ")" +523, 11, 63, 355, 265, 266, 1728, 1729, "." +523, 12, 1, 356, 0, 5, 1730, 1735, "These" +523, 12, 2, 357, 6, 13, 1736, 1743, "morning" +523, 12, 3, 358, 14, 23, 1744, 1753, "pressures" +523, 12, 4, 359, 24, 28, 1754, 1758, "were" +523, 12, 5, 360, 29, 30, 1759, 1760, "2" +523, 12, 6, 361, 31, 32, 1761, 1762, "." +523, 12, 7, 362, 33, 34, 1763, 1764, "6" +523, 12, 8, 363, 35, 37, 1765, 1767, "mm" +523, 12, 9, 364, 38, 40, 1768, 1770, "Hg" +523, 12, 10, 365, 41, 46, 1771, 1776, "lower" +523, 12, 11, 366, 47, 51, 1777, 1781, "than" +523, 12, 12, 367, 52, 60, 1782, 1790, "baseline" +523, 12, 13, 368, 61, 63, 1791, 1793, "in" +523, 12, 14, 369, 64, 67, 1794, 1797, "the" +523, 12, 15, 370, 68, 72, 1798, 1802, "eyes" +523, 12, 16, 371, 73, 82, 1803, 1812, "receiving" +523, 12, 17, 372, 83, 94, 1813, 1824, "latanoprost" +523, 12, 18, 373, 95, 96, 1825, 1826, "(" +523, 12, 19, 374, 97, 98, 1827, 1828, "P" +523, 12, 20, 375, 99, 100, 1829, 1830, "<" +523, 12, 21, 376, 101, 102, 1831, 1832, "." +523, 12, 22, 377, 103, 107, 1833, 1837, "0001" +523, 12, 23, 378, 108, 109, 1838, 1839, ")" +523, 12, 24, 379, 110, 111, 1840, 1841, "," +523, 12, 25, 380, 112, 115, 1842, 1845, "and" +523, 12, 26, 381, 116, 117, 1846, 1847, "1" +523, 12, 27, 382, 118, 119, 1848, 1849, "." +523, 12, 28, 383, 120, 121, 1850, 1851, "6" +523, 12, 29, 384, 122, 124, 1852, 1854, "mm" +523, 12, 30, 385, 125, 127, 1855, 1857, "Hg" +523, 12, 31, 386, 128, 133, 1858, 1863, "lower" +523, 12, 32, 387, 134, 136, 1864, 1866, "in" +523, 12, 33, 388, 137, 148, 1867, 1878, "unoprostone" +523, 12, 34, 389, 149, 150, 1879, 1880, "-" +523, 12, 35, 390, 151, 158, 1881, 1888, "treated" +523, 12, 36, 391, 159, 163, 1889, 1893, "eyes" +523, 12, 37, 392, 164, 165, 1894, 1895, "(" +523, 12, 38, 393, 166, 167, 1896, 1897, "P" +523, 12, 39, 394, 168, 169, 1898, 1899, "=" +523, 12, 40, 395, 170, 171, 1900, 1901, "." +523, 12, 41, 396, 172, 174, 1902, 1904, "02" +523, 12, 42, 397, 175, 176, 1905, 1906, ")" +523, 12, 43, 398, 177, 178, 1907, 1908, "." +523, 13, 1, 399, 0, 9, 1909, 1918, "Afternoon" +523, 13, 2, 400, 10, 16, 1919, 1925, "values" +523, 13, 3, 401, 17, 21, 1926, 1930, "were" +523, 13, 4, 402, 22, 23, 1931, 1932, "3" +523, 13, 5, 403, 24, 25, 1933, 1934, "." +523, 13, 6, 404, 26, 27, 1935, 1936, "1" +523, 13, 7, 405, 28, 29, 1937, 1938, "+" +523, 13, 8, 406, 30, 31, 1939, 1940, "/" +523, 13, 9, 407, 32, 33, 1941, 1942, "-" +523, 13, 10, 408, 34, 37, 1943, 1946, "SEM" +523, 13, 11, 409, 38, 39, 1947, 1948, "0" +523, 13, 12, 410, 40, 41, 1949, 1950, "." +523, 13, 13, 411, 42, 43, 1951, 1952, "6" +523, 13, 14, 412, 44, 49, 1953, 1958, "lower" +523, 13, 15, 413, 50, 54, 1959, 1963, "than" +523, 13, 16, 414, 55, 68, 1964, 1977, "corresponding" +523, 13, 17, 415, 69, 77, 1978, 1986, "baseline" +523, 13, 18, 416, 78, 80, 1987, 1989, "in" +523, 13, 19, 417, 81, 85, 1990, 1994, "eyes" +523, 13, 20, 418, 86, 95, 1995, 2004, "receiving" +523, 13, 21, 419, 96, 107, 2005, 2016, "latanoprost" +523, 13, 22, 420, 108, 109, 2017, 2018, "," +523, 13, 23, 421, 110, 113, 2019, 2022, "and" +523, 13, 24, 422, 114, 115, 2023, 2024, "2" +523, 13, 25, 423, 116, 117, 2025, 2026, "." +523, 13, 26, 424, 118, 119, 2027, 2028, "4" +523, 13, 27, 425, 120, 121, 2029, 2030, "+" +523, 13, 28, 426, 122, 123, 2031, 2032, "/" +523, 13, 29, 427, 124, 125, 2033, 2034, "-" +523, 13, 30, 428, 126, 129, 2035, 2038, "SEM" +523, 13, 31, 429, 130, 131, 2039, 2040, "0" +523, 13, 32, 430, 132, 133, 2041, 2042, "." +523, 13, 33, 431, 134, 135, 2043, 2044, "6" +523, 13, 34, 432, 136, 138, 2045, 2047, "mm" +523, 13, 35, 433, 139, 141, 2048, 2050, "Hg" +523, 13, 36, 434, 142, 144, 2051, 2053, "in" +523, 13, 37, 435, 145, 156, 2054, 2065, "unoprostone" +523, 13, 38, 436, 157, 158, 2066, 2067, "-" +523, 13, 39, 437, 159, 166, 2068, 2075, "treated" +523, 13, 40, 438, 167, 171, 2076, 2080, "eyes" +523, 13, 41, 439, 172, 173, 2081, 2082, "(" +523, 13, 42, 440, 174, 175, 2083, 2084, "P" +523, 13, 43, 441, 176, 177, 2085, 2086, "<" +523, 13, 44, 442, 178, 179, 2087, 2088, "." +523, 13, 45, 443, 180, 184, 2089, 2093, "0001" +523, 13, 46, 444, 185, 189, 2094, 2098, "from" +523, 13, 47, 445, 190, 198, 2099, 2107, "baseline" +523, 13, 48, 446, 199, 202, 2108, 2111, "for" +523, 13, 49, 447, 203, 207, 2112, 2116, "both" +523, 13, 50, 448, 208, 219, 2117, 2128, "medications" +523, 13, 51, 449, 220, 221, 2129, 2130, ";" +523, 13, 52, 450, 222, 231, 2131, 2140, "interdrug" +523, 13, 53, 451, 232, 236, 2141, 2145, "mean" +523, 13, 54, 452, 237, 240, 2146, 2149, "IOP" +523, 13, 55, 453, 241, 251, 2150, 2160, "difference" +523, 13, 56, 454, 252, 253, 2161, 2162, ";" +523, 13, 57, 455, 254, 255, 2163, 2164, "P" +523, 13, 58, 456, 256, 257, 2165, 2166, "=" +523, 13, 59, 457, 258, 259, 2167, 2168, "." +523, 13, 60, 458, 260, 262, 2169, 2171, "04" +523, 13, 61, 459, 263, 264, 2172, 2173, ")" +523, 13, 62, 460, 265, 266, 2174, 2175, "." +523, 14, 1, 461, 0, 4, 2176, 2180, "Eyes" +523, 14, 2, 462, 5, 14, 2181, 2190, "receiving" +523, 14, 3, 463, 15, 26, 2191, 2202, "unoprostone" +523, 14, 4, 464, 27, 33, 2203, 2209, "showed" +523, 14, 5, 465, 34, 35, 2210, 2211, "a" +523, 14, 6, 466, 36, 37, 2212, 2213, "1" +523, 14, 7, 467, 38, 39, 2214, 2215, "." +523, 14, 8, 468, 40, 41, 2216, 2217, "7" +523, 14, 9, 469, 42, 43, 2218, 2219, "-" +523, 14, 10, 470, 44, 46, 2220, 2222, "db" +523, 14, 11, 471, 47, 58, 2223, 2234, "improvement" +523, 14, 12, 472, 59, 61, 2235, 2237, "in" +523, 14, 13, 473, 62, 71, 2238, 2247, "frequency" +523, 14, 14, 474, 72, 80, 2248, 2256, "doubling" +523, 14, 15, 475, 81, 85, 2257, 2261, "mean" +523, 14, 16, 476, 86, 95, 2262, 2271, "deviation" +523, 14, 17, 477, 96, 97, 2272, 2273, "(" +523, 14, 18, 478, 98, 99, 2274, 2275, "P" +523, 14, 19, 479, 100, 101, 2276, 2277, "=" +523, 14, 20, 480, 102, 103, 2278, 2279, "." +523, 14, 21, 481, 104, 106, 2280, 2282, "03" +523, 14, 22, 482, 107, 108, 2283, 2284, ")" +523, 14, 23, 483, 109, 110, 2285, 2286, "," +523, 14, 24, 484, 111, 114, 2287, 2290, "the" +523, 14, 25, 485, 115, 119, 2291, 2295, "only" +523, 14, 26, 486, 120, 131, 2296, 2307, "significant" +523, 14, 27, 487, 132, 138, 2308, 2314, "visual" +523, 14, 28, 488, 139, 147, 2315, 2323, "function" +523, 14, 29, 489, 148, 154, 2324, 2330, "change" +523, 14, 30, 490, 155, 163, 2331, 2339, "observed" +523, 14, 31, 491, 164, 165, 2340, 2341, "." +523, 15, 1, 492, 0, 9, 2342, 2351, "Pulsatile" +523, 15, 2, 493, 10, 16, 2352, 2358, "ocular" +523, 15, 3, 494, 17, 22, 2359, 2364, "blood" +523, 15, 4, 495, 23, 27, 2365, 2369, "flow" +523, 15, 5, 496, 28, 37, 2370, 2379, "increased" +523, 15, 6, 497, 38, 40, 2380, 2382, "30" +523, 15, 7, 498, 41, 42, 2383, 2384, "%" +523, 15, 8, 499, 43, 51, 2385, 2393, "relative" +523, 15, 9, 500, 52, 54, 2394, 2396, "to" +523, 15, 10, 501, 55, 63, 2397, 2405, "baseline" +523, 15, 11, 502, 64, 66, 2406, 2408, "in" +523, 15, 12, 503, 67, 71, 2409, 2413, "eyes" +523, 15, 13, 504, 72, 81, 2414, 2423, "receiving" +523, 15, 14, 505, 82, 93, 2424, 2435, "latanoprost" +523, 15, 15, 506, 94, 95, 2436, 2437, "," +523, 15, 16, 507, 96, 97, 2438, 2439, "(" +523, 15, 17, 508, 98, 99, 2440, 2441, "P" +523, 15, 18, 509, 100, 101, 2442, 2443, "<" +523, 15, 19, 510, 102, 103, 2444, 2445, "." +523, 15, 20, 511, 104, 108, 2446, 2450, "0001" +523, 15, 21, 512, 109, 110, 2451, 2452, ")" +523, 15, 22, 513, 111, 114, 2453, 2456, "and" +523, 15, 23, 514, 115, 117, 2457, 2459, "16" +523, 15, 24, 515, 118, 119, 2460, 2461, "%" +523, 15, 25, 516, 120, 122, 2462, 2464, "in" +523, 15, 26, 517, 123, 127, 2465, 2469, "eyes" +523, 15, 27, 518, 128, 137, 2470, 2479, "receiving" +523, 15, 28, 519, 138, 149, 2480, 2491, "unoprostone" +523, 15, 29, 520, 150, 151, 2492, 2493, "(" +523, 15, 30, 521, 152, 153, 2494, 2495, "P" +523, 15, 31, 522, 154, 155, 2496, 2497, "=" +523, 15, 32, 523, 156, 157, 2498, 2499, "." +523, 15, 33, 524, 158, 160, 2500, 2502, "05" +523, 15, 34, 525, 161, 162, 2503, 2504, ")" +523, 15, 35, 526, 163, 165, 2505, 2507, "by" +523, 15, 36, 527, 166, 169, 2508, 2511, "the" +523, 15, 37, 528, 170, 177, 2512, 2519, "morning" +523, 15, 38, 529, 178, 180, 2520, 2522, "of" +523, 15, 39, 530, 181, 184, 2523, 2526, "day" +523, 15, 40, 531, 185, 187, 2527, 2529, "28" +523, 15, 41, 532, 188, 189, 2530, 2531, "." +523, 16, 1, 533, 0, 4, 2532, 2536, "That" +523, 16, 2, 534, 5, 14, 2537, 2546, "afternoon" +523, 16, 3, 535, 15, 16, 2547, 2548, "," +523, 16, 4, 536, 17, 21, 2549, 2553, "mean" +523, 16, 5, 537, 22, 26, 2554, 2558, "POBF" +523, 16, 6, 538, 27, 30, 2559, 2562, "had" +523, 16, 7, 539, 31, 40, 2563, 2572, "increased" +523, 16, 8, 540, 41, 43, 2573, 2575, "30" +523, 16, 9, 541, 44, 45, 2576, 2577, "%" +523, 16, 10, 542, 46, 47, 2578, 2579, "(" +523, 16, 11, 543, 48, 49, 2580, 2581, "P" +523, 16, 12, 544, 50, 51, 2582, 2583, "<" +523, 16, 13, 545, 52, 53, 2584, 2585, "." +523, 16, 14, 546, 54, 58, 2586, 2590, "0001" +523, 16, 15, 547, 59, 60, 2591, 2592, ")" +523, 16, 16, 548, 61, 69, 2593, 2601, "relative" +523, 16, 17, 549, 70, 72, 2602, 2604, "to" +523, 16, 18, 550, 73, 82, 2605, 2614, "afternoon" +523, 16, 19, 551, 83, 91, 2615, 2623, "baseline" +523, 16, 20, 552, 92, 98, 2624, 2630, "values" +523, 16, 21, 553, 99, 104, 2631, 2636, "among" +523, 16, 22, 554, 105, 109, 2637, 2641, "eyes" +523, 16, 23, 555, 110, 119, 2642, 2651, "receiving" +523, 16, 24, 556, 120, 131, 2652, 2663, "latanoprost" +523, 16, 25, 557, 132, 135, 2664, 2667, "and" +523, 16, 26, 558, 136, 138, 2668, 2670, "18" +523, 16, 27, 559, 139, 140, 2671, 2672, "%" +523, 16, 28, 560, 141, 142, 2673, 2674, "(" +523, 16, 29, 561, 143, 144, 2675, 2676, "P" +523, 16, 30, 562, 145, 146, 2677, 2678, "=" +523, 16, 31, 563, 147, 148, 2679, 2680, "." +523, 16, 32, 564, 149, 151, 2681, 2683, "03" +523, 16, 33, 565, 152, 153, 2684, 2685, ")" +523, 16, 34, 566, 154, 159, 2686, 2691, "among" +523, 16, 35, 567, 160, 165, 2692, 2697, "those" +523, 16, 36, 568, 166, 175, 2698, 2707, "receiving" +523, 16, 37, 569, 176, 187, 2708, 2719, "unoprostone" +523, 16, 38, 570, 188, 189, 2720, 2721, "(" +523, 16, 39, 571, 190, 199, 2722, 2731, "interdrug" +523, 16, 40, 572, 200, 206, 2732, 2738, "change" +523, 16, 41, 573, 207, 217, 2739, 2749, "difference" +523, 16, 42, 574, 218, 219, 2750, 2751, "," +523, 16, 43, 575, 220, 221, 2752, 2753, "P" +523, 16, 44, 576, 222, 223, 2754, 2755, "=" +523, 16, 45, 577, 224, 225, 2756, 2757, "." +523, 16, 46, 578, 226, 228, 2758, 2760, "05" +523, 16, 47, 579, 229, 230, 2761, 2762, ")" +523, 16, 48, 580, 231, 232, 2763, 2764, "." +523, 17, 1, 581, 0, 8, 2765, 2773, "Humphrey" +523, 17, 2, 582, 9, 18, 2774, 2783, "perimetry" +523, 17, 3, 583, 19, 22, 2784, 2787, "and" +523, 17, 4, 584, 23, 31, 2788, 2796, "contrast" +523, 17, 5, 585, 32, 43, 2797, 2808, "sensitivity" +523, 17, 6, 586, 44, 52, 2809, 2817, "remained" +523, 17, 7, 587, 53, 59, 2818, 2824, "stable" +523, 17, 8, 588, 60, 64, 2825, 2829, "with" +523, 17, 9, 589, 65, 69, 2830, 2834, "both" +523, 17, 10, 590, 70, 81, 2835, 2846, "prostanoids" +523, 17, 11, 591, 82, 83, 2847, 2848, "." +523, 18, 1, 592, 0, 11, 2849, 2860, "CONCLUSIONS" +523, 18, 2, 593, 12, 13, 2861, 2862, ":" +523, 18, 3, 594, 14, 18, 2863, 2867, "Both" +523, 18, 4, 595, 19, 30, 2868, 2879, "latanoprost" +523, 18, 5, 596, 31, 34, 2880, 2883, "and" +523, 18, 6, 597, 35, 46, 2884, 2895, "unoprostone" +523, 18, 7, 598, 47, 55, 2896, 2904, "produced" +523, 18, 8, 599, 56, 67, 2905, 2916, "significant" +523, 18, 9, 600, 68, 78, 2917, 2927, "reductions" +523, 18, 10, 601, 79, 81, 2928, 2930, "in" +523, 18, 11, 602, 82, 85, 2931, 2934, "IOP" +523, 18, 12, 603, 86, 89, 2935, 2938, "and" +523, 18, 13, 604, 90, 99, 2939, 2948, "increases" +523, 18, 14, 605, 100, 102, 2949, 2951, "in" +523, 18, 15, 606, 103, 107, 2952, 2956, "POBF" +523, 18, 16, 607, 108, 109, 2957, 2958, "," +523, 18, 17, 608, 110, 114, 2959, 2963, "with" +523, 18, 18, 609, 115, 121, 2964, 2970, "stable" +523, 18, 19, 610, 122, 129, 2971, 2978, "central" +523, 18, 20, 611, 130, 133, 2979, 2982, "and" +523, 18, 21, 612, 134, 145, 2983, 2994, "perimacular" +523, 18, 22, 613, 146, 152, 2995, 3001, "visual" +523, 18, 23, 614, 153, 161, 3002, 3010, "function" +523, 18, 24, 615, 162, 163, 3011, 3012, "." +523, 19, 1, 616, 0, 11, 3013, 3024, "Latanoprost" +523, 19, 2, 617, 12, 16, 3025, 3029, "once" +523, 19, 3, 618, 17, 22, 3030, 3035, "daily" +523, 19, 4, 619, 23, 31, 3036, 3044, "produced" +523, 19, 5, 620, 32, 35, 3045, 3048, "IOP" +523, 19, 6, 621, 36, 45, 3049, 3058, "reduction" +523, 19, 7, 622, 46, 49, 3059, 3062, "and" +523, 19, 8, 623, 50, 54, 3063, 3067, "POBF" +523, 19, 9, 624, 55, 64, 3068, 3077, "increases" +523, 19, 10, 625, 65, 71, 3078, 3084, "nearly" +523, 19, 11, 626, 72, 79, 3085, 3092, "twofold" +523, 19, 12, 627, 80, 87, 3093, 3100, "greater" +523, 19, 13, 628, 88, 92, 3101, 3105, "than" +523, 19, 14, 629, 93, 98, 3106, 3111, "those" +523, 19, 15, 630, 99, 107, 3112, 3120, "obtained" +523, 19, 16, 631, 108, 112, 3121, 3125, "with" +523, 19, 17, 632, 113, 124, 3126, 3137, "unoprostone" +523, 19, 18, 633, 125, 130, 3138, 3143, "twice" +523, 19, 19, 634, 131, 136, 3144, 3149, "daily" +523, 19, 20, 635, 137, 138, 3150, 3151, "." +523, 20, 1, 636, 0, 5, 3152, 3157, "These" +523, 20, 2, 637, 6, 17, 3158, 3169, "differences" +523, 20, 3, 638, 18, 20, 3170, 3172, "in" +523, 20, 4, 639, 21, 24, 3173, 3176, "IOP" +523, 20, 5, 640, 25, 28, 3177, 3180, "and" +523, 20, 6, 641, 29, 33, 3181, 3185, "POBF" +523, 20, 7, 642, 34, 40, 3186, 3192, "change" +523, 20, 8, 643, 41, 48, 3193, 3200, "between" +523, 20, 9, 644, 49, 60, 3201, 3212, "unoprostone" +523, 20, 10, 645, 61, 64, 3213, 3216, "and" +523, 20, 11, 646, 65, 76, 3217, 3228, "latanoprost" +523, 20, 12, 647, 77, 81, 3229, 3233, "were" +523, 20, 13, 648, 82, 95, 3234, 3247, "statistically" +523, 20, 14, 649, 96, 107, 3248, 3259, "significant" +523, 20, 15, 650, 108, 109, 3260, 3261, "." +523, 21, 1, 651, 0, 3, 3262, 3265, "DOI" +523, 21, 2, 652, 4, 5, 3266, 3267, ":" +523, 21, 3, 653, 6, 8, 3268, 3270, "10" +523, 21, 4, 654, 9, 10, 3271, 3272, "." +523, 21, 5, 655, 11, 15, 3273, 3277, "1016" +523, 21, 6, 656, 16, 17, 3278, 3279, "/" +523, 21, 7, 657, 18, 23, 3280, 3285, "s0002" +523, 21, 8, 658, 24, 25, 3286, 3287, "-" +523, 21, 9, 659, 26, 30, 3288, 3292, "9394" +523, 21, 10, 660, 31, 32, 3293, 3294, "(" +523, 21, 11, 661, 33, 35, 3295, 3297, "02" +523, 21, 12, 662, 36, 37, 3298, 3299, ")" +523, 21, 13, 663, 38, 43, 3300, 3305, "01643" +523, 21, 14, 664, 44, 45, 3306, 3307, "-" +523, 21, 15, 665, 46, 47, 3308, 3309, "4" +523, 21, 16, 666, 48, 52, 3310, 3314, "PMID" +523, 21, 17, 667, 53, 54, 3315, 3316, ":" +523, 21, 18, 668, 55, 63, 3317, 3325, "12383812" +523, 21, 19, 669, 64, 65, 3326, 3327, "[" +523, 21, 20, 670, 66, 73, 3328, 3335, "Indexed" +523, 21, 21, 671, 74, 77, 3336, 3339, "for" +523, 21, 22, 672, 78, 85, 3340, 3347, "MEDLINE" +523, 21, 23, 673, 86, 87, 3348, 3349, "]" diff --git a/data/gl 12383812_jshahinitiran.annodb b/data/gl 12383812_jshahinitiran.annodb new file mode 100644 index 0000000..3a6a0ed --- /dev/null +++ b/data/gl 12383812_jshahinitiran.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81338, Journal, 0, 17, "Am J Ophthalmol .", "", +81340, PublicationYear, 18, 22, "2002", "", +81341, Title, 51, 189, "Comparative effects of latanoprost ( Xalatan ) and unoprostone ( Rescula ) in patients with open - angle glaucoma and suspected glaucoma .", "", +81342, Latanoprost, 74, 85, "latanoprost", "", +81343, Unoprostone, 102, 113, "unoprostone", "", +81344, OpenAngleGlaucoma, 143, 164, "open - angle glaucoma", "", +81345, Glaucoma, 179, 187, "glaucoma", "", +81346, Author, 190, 200, "Sponsel WE", "", +81347, Author, 209, 216, "Paris G", "", +81348, Author, 219, 226, "Trigo Y", "", +81349, Author, 229, 235, "Pena M", "", +81350, USA, 359, 362, "USA", "", +81351, ObjectiveDescription, 399, 595, "To compare , in paired eyes of open - angle glaucoma patients and glaucoma suspects , hydrodynamic and visual changes after 1 month of topical latanoprost in one eye and unoprostone in the other .", "", +81352, OpenAngleGlaucoma, 430, 451, "open - angle glaucoma", "", +81353, Glaucoma, 465, 473, "glaucoma", "", +81354, Latanoprost, 542, 553, "latanoprost", "", +81355, Unoprostone, 569, 580, "unoprostone", "", +81356, SingleCenter, 605, 620, "Single - center", "", +81357, Randomized, 637, 647, "randomized", "", +81358, NumberPatientsCT, 738, 740, "25", "", +81359, Mean, 750, 754, "mean", "", +81360, AvgAge, 759, 761, "54", "", +81361, OpenAngleGlaucoma, 787, 818, "bilateral open - angle glaucoma", "", +81362, Glaucoma, 822, 830, "glaucoma", "", +81363, IOP, 923, 943, "intraocular pressure", "", +81364, IOP, 946, 949, "IOP", "", +81365, OcularBloodFlow, 954, 981, "pulsatile ocular blood flow", "", +81366, OcularBloodFlow, 984, 988, "POBF", "", +81367, Unoprostone, 1125, 1136, "unoprostone", "", +81368, DoseValue, 1137, 1143, "0 . 15", "", +81369, Randomized, 1165, 1173, "randomly", "", +81370, Latanoprost, 1191, 1202, "latanoprost", "", +81371, DoseValue, 1203, 1210, "0 . 005", "", +81372, Unoprostone, 1240, 1251, "Unoprostone", "", +81373, Latanoprost, 1290, 1301, "latanoprost", "", +81374, Placebo, 1315, 1322, "placebo", "", +81375, Duration, 1366, 1373, "28 days", "", +81376, IOP, 1504, 1507, "IOP", "", +81377, TimePoint, 1523, 1530, "1 month", "", +81378, Mean, 1550, 1554, "mean", "", +81379, IOP, 1563, 1566, "IOP", "", +81380, ResultMeasuredValue, 1625, 1631, "16 . 2", "", +81382, SdErrorResValue, 1642, 1647, "0 . 6", "", +81384, mmHg, 1648, 1653, "mm Hg", "", +81386, Latanoprost, 1658, 1669, "latanoprost", "", +81381, ResultMeasuredValue, 1673, 1679, "17 . 9", "", +81383, SdErrorResValue, 1686, 1691, "0 . 7", "", +81385, mmHg, 1692, 1697, "mm Hg", "", +81387, Unoprostone, 1702, 1713, "unoprostone", "", +81388, PValueResValue, 1716, 1725, "P = . 001", "", +81389, Reduction, 1759, 1764, "2 . 6", "", +81390, mmHg, 1765, 1770, "mm Hg", "", +81391, Latanoprost, 1813, 1824, "latanoprost", "", +81392, PValueChangeValue, 1827, 1837, "P < . 0001", "", +81393, Reduction, 1846, 1851, "1 . 6", "", +81394, mmHg, 1852, 1857, "mm Hg", "", +81395, Unoprostone, 1867, 1878, "unoprostone", "", +81396, PValueChangeValue, 1896, 1904, "P = . 02", "", +81397, Reduction, 1931, 1936, "3 . 1", "", +81399, SdErrorChangeValue, 1947, 1952, "0 . 6", "", +81398, Reduction, 2023, 2028, "2 . 4", "", +81400, SdErrorChangeValue, 2039, 2044, "0 . 6", "", +81401, mmHg, 2045, 2050, "mm Hg", "", +81402, Unoprostone, 2054, 2065, "unoprostone", "", +81403, PValueChangeValue, 2083, 2093, "P < . 0001", "", +81404, Mean, 2141, 2145, "mean", "", +81405, IOP, 2146, 2149, "IOP", "", +81406, PvalueDiff, 2163, 2171, "P = . 04", "", +81407, Unoprostone, 2191, 2202, "unoprostone", "", +81408, Mean, 2257, 2261, "mean", "", +81409, PValueChangeValue, 2274, 2282, "P = . 03", "", +81410, OcularBloodFlow, 2342, 2369, "Pulsatile ocular blood flow", "", +81411, RelativeIncrement, 2380, 2382, "30", "", +81412, Latanoprost, 2424, 2435, "latanoprost", "", +81413, PValueChangeValue, 2440, 2450, "P < . 0001", "", +81414, RelativeIncrement, 2457, 2459, "16", "", +81415, Unoprostone, 2480, 2491, "unoprostone", "", +81416, PValueChangeValue, 2494, 2502, "P = . 05", "", +81417, TimePoint, 2523, 2529, "day 28", "", +81418, Mean, 2549, 2553, "mean", "", +81419, OcularBloodFlow, 2554, 2558, "POBF", "", +81420, RelativeIncrement, 2573, 2575, "30", "", +81421, PValueChangeValue, 2580, 2590, "P < . 0001", "", +81422, Latanoprost, 2652, 2663, "latanoprost", "", +81423, RelativeIncrement, 2668, 2670, "18", "", +81424, PValueChangeValue, 2675, 2683, "P = . 03", "", +81425, Unoprostone, 2708, 2719, "unoprostone", "", +81426, PvalueDiff, 2752, 2760, "P = . 05", "", +81427, ObservedResult, 2765, 2848, "Humphrey perimetry and contrast sensitivity remained stable with both prostanoids .", "", +81428, ConclusionComment, 2863, 3012, "Both latanoprost and unoprostone produced significant reductions in IOP and increases in POBF , with stable central and perimacular visual function .", "", +81431, Latanoprost, 2868, 2879, "latanoprost", "", +81432, Unoprostone, 2884, 2895, "unoprostone", "", +81433, IOP, 2931, 2934, "IOP", "", +81434, OcularBloodFlow, 2952, 2956, "POBF", "", +81429, ConclusionComment, 3013, 3151, "Latanoprost once daily produced IOP reduction and POBF increases nearly twofold greater than those obtained with unoprostone twice daily .", "", +81435, Latanoprost, 3013, 3024, "Latanoprost", "", +81436, Frequency, 3025, 3035, "once daily", "", +81437, IOP, 3045, 3048, "IOP", "", +81438, OcularBloodFlow, 3063, 3067, "POBF", "", +81439, Unoprostone, 3126, 3137, "unoprostone", "", +81440, Frequency, 3138, 3149, "twice daily", "", +81430, ConclusionComment, 3152, 3261, "These differences in IOP and POBF change between unoprostone and latanoprost were statistically significant .", "", +81441, IOP, 3173, 3176, "IOP", "", +81442, OcularBloodFlow, 3181, 3185, "POBF", "", +81443, Unoprostone, 3201, 3212, "unoprostone", "", +81444, Latanoprost, 3217, 3228, "latanoprost", "", +81445, PMID, 3317, 3325, "12383812", "", diff --git a/data/gl 12383812_jshahinitiran.n-triples b/data/gl 12383812_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12383812_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12383812_tstrakeljahn.annodb b/data/gl 12383812_tstrakeljahn.annodb new file mode 100644 index 0000000..9bf9375 --- /dev/null +++ b/data/gl 12383812_tstrakeljahn.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81088, Journal, 0, 15, "Am J Ophthalmol", "", +81089, PublicationYear, 18, 22, "2002", "", +81096, Title, 51, 189, "Comparative effects of latanoprost ( Xalatan ) and unoprostone ( Rescula ) in patients with open - angle glaucoma and suspected glaucoma .", "", +81090, Latanoprost, 74, 85, "latanoprost", "", +81091, Latanoprost, 88, 95, "Xalatan", "", +81092, Unoprostone, 102, 113, "unoprostone", "", +81093, Unoprostone, 116, 123, "Rescula", "", +81094, OpenAngleGlaucoma, 143, 164, "open - angle glaucoma", "", +81095, Glaucoma, 179, 187, "glaucoma", "", +81097, Author, 190, 200, "Sponsel WE", "", +81098, Author, 209, 216, "Paris G", "", +81099, Author, 219, 226, "Trigo Y", "", +81100, Author, 229, 235, "Pena M", "", +81101, USA, 359, 362, "USA", "", +81107, ObjectiveDescription, 399, 595, "To compare , in paired eyes of open - angle glaucoma patients and glaucoma suspects , hydrodynamic and visual changes after 1 month of topical latanoprost in one eye and unoprostone in the other .", "", +81102, OpenAngleGlaucoma, 430, 451, "open - angle glaucoma", "", +81103, Glaucoma, 465, 473, "glaucoma", "", +81104, Duration, 523, 530, "1 month", "", +81105, Latanoprost, 542, 553, "latanoprost", "", +81106, Unoprostone, 569, 580, "unoprostone", "", +81108, SingleCenter, 605, 620, "Single - center", "", +81109, Randomized, 637, 647, "randomized", "", +81110, ClinicalTrial, 648, 662, "clinical trial", "", +81111, NumberPatientsCT, 738, 740, "25", "", +81112, AvgAge, 759, 761, "54", "", +81113, OpenAngleGlaucoma, 797, 818, "open - angle glaucoma", "", +81114, Glaucoma, 822, 830, "glaucoma", "", +81115, Morning, 856, 863, "morning", "", +81116, Afternoon, 883, 892, "afternoon", "", +81117, IOP, 923, 943, "intraocular pressure", "", +81118, IOP, 946, 949, "IOP", "", +81119, Unoprostone, 1125, 1136, "unoprostone", "", +81121, DoseValue, 1137, 1143, "0 . 15", "", +81122, Percentage, 1144, 1145, "%", "", +81120, Unoprostone, 1148, 1155, "Rescula", "", +81123, Latanoprost, 1191, 1202, "latanoprost", "", +81124, DoseValue, 1203, 1210, "0 . 005", "", +81125, Latanoprost, 1215, 1222, "Xalatan", "", +81126, Unoprostone, 1240, 1251, "Unoprostone", "", +81127, TimePoint, 1272, 1276, "8 AM", "", +81128, TimePoint, 1281, 1285, "8 PM", "", +81129, TimePoint, 1305, 1309, "8 PM", "", +81131, Placebo, 1315, 1322, "placebo", "", +81130, TimePoint, 1326, 1330, "8 AM", "", +81132, Duration, 1366, 1373, "28 days", "", +81133, IOP, 1504, 1507, "IOP", "", +81134, Duration, 1523, 1530, "1 month", "", +81135, Mean, 1550, 1554, "mean", "", +81136, Morning, 1555, 1562, "morning", "", +81137, IOP, 1563, 1566, "IOP", "", +81138, ResultMeasuredValue, 1625, 1631, "16 . 2", "", +81140, SdErrorResValue, 1642, 1647, "0 . 6", "", +81145, mmHg, 1648, 1653, "mm Hg", "", +81144, Latanoprost, 1658, 1669, "latanoprost", "", +81139, ResultMeasuredValue, 1673, 1679, "17 . 9", "", +81141, SdErrorResValue, 1686, 1691, "0 . 7", "", +81146, mmHg, 1692, 1697, "mm Hg", "", +81143, Unoprostone, 1702, 1713, "unoprostone", "", +81142, PvalueDiff, 1718, 1725, "= . 001", "", +81147, Morning, 1736, 1743, "morning", "", +81148, Reduction, 1759, 1764, "2 . 6", "", +81150, mmHg, 1765, 1770, "mm Hg", "", +81152, Latanoprost, 1813, 1824, "latanoprost", "", +81154, PValueChangeValue, 1829, 1837, "< . 0001", "", +81149, Reduction, 1846, 1851, "1 . 6", "", +81151, mmHg, 1852, 1857, "mm Hg", "", +81153, Unoprostone, 1867, 1878, "unoprostone", "", +81155, PValueChangeValue, 1898, 1904, "= . 02", "", +81156, Afternoon, 1909, 1918, "Afternoon", "", +81157, Reduction, 1931, 1936, "3 . 1", "", +81159, SdErrorChangeValue, 1947, 1952, "0 . 6", "", +81161, Latanoprost, 2005, 2016, "latanoprost", "", +81158, Reduction, 2023, 2028, "2 . 4", "", +81160, SdErrorChangeValue, 2039, 2044, "0 . 6", "", +81162, mmHg, 2045, 2050, "mm Hg", "", +81166, Unoprostone, 2054, 2065, "unoprostone", "", +81163, PValueChangeValue, 2085, 2093, "< . 0001", "", +81167, Mean, 2141, 2145, "mean", "", +81168, IOP, 2146, 2149, "IOP", "", +81169, PvalueDiff, 2165, 2171, "= . 04", "", +81170, Unoprostone, 2191, 2202, "unoprostone", "", +81171, Mean, 2257, 2261, "mean", "", +81172, PValueChangeValue, 2276, 2282, "= . 03", "", +81173, OcularBloodFlow, 2352, 2369, "ocular blood flow", "", +81174, RelativeIncrement, 2380, 2382, "30", "", +81177, Latanoprost, 2424, 2435, "latanoprost", "", +81179, PValueChangeValue, 2442, 2450, "< . 0001", "", +81176, RelativeIncrement, 2457, 2459, "16", "", +81178, Unoprostone, 2480, 2491, "unoprostone", "", +81180, PValueChangeValue, 2496, 2502, "= . 05", "", +81181, Morning, 2512, 2519, "morning", "", +81182, TimePoint, 2523, 2529, "day 28", "", +81183, Afternoon, 2537, 2546, "afternoon", "", +81188, Mean, 2549, 2553, "mean", "", +81184, OcularBloodFlow, 2554, 2558, "POBF", "", +81185, RelativeIncrement, 2573, 2575, "30", "", +81187, PValueChangeValue, 2582, 2590, "< . 0001", "", +81190, Afternoon, 2605, 2614, "afternoon", "", +81191, Latanoprost, 2652, 2663, "latanoprost", "", +81186, RelativeIncrement, 2668, 2670, "18", "", +81189, PValueChangeValue, 2677, 2683, "= . 03", "", +81192, Unoprostone, 2708, 2719, "unoprostone", "", +81193, DiffBetweenGroups, 2754, 2760, "= . 05", "", +81208, ObservedResult, 2765, 2848, "Humphrey perimetry and contrast sensitivity remained stable with both prostanoids .", "", +81209, ConclusionComment, 2863, 3012, "Both latanoprost and unoprostone produced significant reductions in IOP and increases in POBF , with stable central and perimacular visual function .", "", +81194, Latanoprost, 2868, 2879, "latanoprost", "", +81196, Unoprostone, 2884, 2895, "unoprostone", "", +81198, IOP, 2931, 2934, "IOP", "", +81199, OcularBloodFlow, 2952, 2956, "POBF", "", +81200, Latanoprost, 3013, 3024, "Latanoprost", "", +81210, ConclusionComment, 3013, 3151, "Latanoprost once daily produced IOP reduction and POBF increases nearly twofold greater than those obtained with unoprostone twice daily .", "", +81201, Frequency, 3025, 3035, "once daily", "", +81203, IOP, 3045, 3048, "IOP", "", +81204, OcularBloodFlow, 3063, 3067, "POBF", "", +81205, Unoprostone, 3126, 3137, "unoprostone", "", +81202, Frequency, 3138, 3149, "twice daily", "", +81211, ConclusionComment, 3152, 3261, "These differences in IOP and POBF change between unoprostone and latanoprost were statistically significant .", "", +81206, IOP, 3173, 3176, "IOP", "", +81207, OcularBloodFlow, 3181, 3185, "POBF", "", +81197, Unoprostone, 3201, 3212, "unoprostone", "", +81195, Latanoprost, 3217, 3228, "latanoprost", "", +81212, PMID, 3317, 3325, "12383812", "", diff --git a/data/gl 12383812_tstrakeljahn.n-triples b/data/gl 12383812_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12383812_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12466165_admin.annodb b/data/gl 12466165_admin.annodb new file mode 100644 index 0000000..707e713 --- /dev/null +++ b/data/gl 12466165_admin.annodb @@ -0,0 +1,142 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2002", "", " \"2002\"." +147, Title, 51, 212, "Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0 . 005 % or brimonidine tartrate 0 . 2 % in normal - tension glaucoma patients .", "", " \"Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0 . 005 % or brimonidine tartrate 0 . 2 % in normal - tension glaucoma patients .\"." +3, IOP, 62, 82, "intraocular pressure", "", +95, Latanoprost, 119, 130, "latanoprost", "", " . ." +119, DoseValue, 131, 138, "0 . 005", "", " \"0 . 005\"." +123, Percentage, 139, 140, "%", "", " ." +108, Brimonidine, 144, 164, "brimonidine tartrate", "", " ." +120, DoseValue, 165, 170, "0 . 2", "", " \"0 . 2\"." +124, Percentage, 171, 172, "%", "", " ." +129, NormalTensionGlaucoma, 176, 201, "normal - tension glaucoma", "", " ." +4, Author, 213, 219, "Liu CJ", "", " \"Liu CJ\"." +5, Author, 228, 233, "Ko YC", "", " \"Ko YC\"." +6, Author, 236, 244, "Cheng CY", "", " \"Cheng CY\"." +7, Author, 247, 254, "Chiu AW", "", " \"Chiu AW\"." +8, Author, 257, 264, "Chou JC", "", " \"Chou JC\"." +9, Author, 267, 273, "Hsu WM", "", " \"Hsu WM\"." +10, Author, 276, 282, "Liu JH", "", " \"Liu JH\"." +11, Taiwan, 386, 392, "Taiwan", "", " ." +12, ObjectiveDescription, 407, 576, "To evaluate and compare the effects of latanoprost 0 . 005 % once daily and brimonidine tartrate 0 . 2 % twice daily in patients with normal - tension glaucoma ( NTG ) .", "", " \"To evaluate and compare the effects of latanoprost 0 . 005 % once daily and brimonidine tartrate 0 . 2 % twice daily in patients with normal - tension glaucoma ( NTG ) .\"." +96, Latanoprost, 446, 457, "latanoprost", "", +121, DoseValue, 458, 465, "0 . 005", "", +125, Percentage, 466, 467, "%", "", +13, Frequency, 468, 478, "once daily", "", " \"once daily\"." +109, Brimonidine, 483, 503, "brimonidine tartrate", "", +122, DoseValue, 504, 509, "0 . 2", "", +126, Percentage, 510, 511, "%", "", +14, Frequency, 512, 523, "twice daily", "", " \"twice daily\"." +130, NormalTensionGlaucoma, 541, 566, "normal - tension glaucoma", "", +131, NormalTensionGlaucoma, 569, 572, "NTG", "", " ." +127, Randomized, 588, 598, "randomized", "", " ." +15, OpenLabel, 601, 613, "open - label", "", " ." +16, Crossover, 616, 625, "crossover", "", " ." +17, NumberPatientsCT, 649, 663, "Twenty - eight", "", " \"Twenty - eight\"." +132, NormalTensionGlaucoma, 664, 667, "NTG", "", +95582, Precondition, 668, 804, "patients with progressive visual field defects / optic disc excavation , new disc hemorrhage , or field defects that threatened fixation", "", " \"patients with progressive visual field defects / optic disc excavation , new disc hemorrhage , or field defects that threatened fixation\"." +128, Randomized, 836, 844, "randomly", "", +97, Latanoprost, 916, 927, "latanoprost", "", +165, Drug, 930, 939, "lubricant", "", +110, Brimonidine, 946, 957, "brimonidine", "", +25, Duration, 962, 969, "4 weeks", "", " \"4 weeks\"." +111, Brimonidine, 1023, 1034, "brimonidine", "", +168, Drug, 1037, 1046, "lubricant", "", +98, Latanoprost, 1053, 1064, "latanoprost", "", +26, Duration, 1069, 1076, "4 weeks", "", +21, IOP, 1108, 1128, "Intraocular pressure", "", +22, IOP, 1131, 1134, "IOP", "", +23, PulseRate, 1139, 1149, "pulse rate", "", +24, BloodPressure, 1156, 1170, "blood pressure", "", +95598, TimePoint, 1188, 1192, "8 am", "", +95599, TimePoint, 1195, 1202, "12 noon", "", +95600, TimePoint, 1209, 1213, "4 pm", "", +27, Duration, 1225, 1233, "4 - week", "", +95601, EndPointDescription, 1246, 1271, "Ocular perfusion pressure", "", +95602, EndPointDescription, 1274, 1277, "OPP", "", +99, Latanoprost, 1307, 1318, "Latanoprost", "", +112, Brimonidine, 1323, 1334, "brimonidine", "", +106404, Mean, 1347, 1354, "average", "", " . ." +28, IOP, 1355, 1358, "IOP", "", +29, Reduction, 1362, 1367, "3 . 6", "", " \"3 . 6\"." +183, SdDevChangeValue, 1374, 1379, "1 . 9", "", " \"1 . 9\"." +31, mmHg, 1380, 1384, "mmHg", "", +32, PValueChangeValue, 1387, 1398, "P < 0 . 001", "", " \"P < 0 . 001\"." +33, Reduction, 1405, 1410, "2 . 5", "", " \"2 . 5\"." +184, SdDevChangeValue, 1417, 1422, "1 . 3", "", " \"1 . 3\"." +35, mmHg, 1423, 1427, "mmHg", "", +36, PValueChangeValue, 1430, 1441, "P < 0 . 001", "", " \"P < 0 . 001\"." +37, PvalueDiff, 1518, 1529, "P = 0 . 009", "", " \"P = 0 . 009\"." +38, IOP, 1567, 1570, "IOP", "", +100, Latanoprost, 1592, 1603, "Latanoprost", "", +39, IOP, 1614, 1617, "IOP", "", " . ." +113, Brimonidine, 1646, 1657, "brimonidine", "", +41, TimePoint, 1661, 1665, "8 am", "", " \"8 am\". \"8 am\"." +44, Reduction, 1668, 1674, "11 . 7", "", " \"11 . 7\"." +203, SdDevChangeValue, 1681, 1686, "2 . 2", "", " \"2 . 2\"." +56, mmHg, 1687, 1691, "mmHg", "", " ." +45, Reduction, 1697, 1703, "13 . 7", "", " \"13 . 7\"." +204, SdDevChangeValue, 1710, 1715, "2 . 1", "", " \"2 . 1\"." +57, mmHg, 1716, 1720, "mmHg", "", +62, PValueChangeValue, 1723, 1734, "P = 0 . 004", "", " \"P = 0 . 004\". \"P = 0 . 004\"." +42, TimePoint, 1741, 1745, "4 pm", "", " \"4 pm\". \"4 pm\"." +46, Reduction, 1748, 1754, "11 . 4", "", " \"11 . 4\"." +205, SdDevChangeValue, 1761, 1766, "2 . 1", "", " \"2 . 1\"." +58, mmHg, 1767, 1771, "mmHg", "", +47, Reduction, 1777, 1783, "13 . 2", "", " \"13 . 2\"." +206, SdDevChangeValue, 1790, 1795, "2 . 9", "", " \"2 . 9\"." +59, mmHg, 1796, 1800, "mmHg", "", +63, PValueChangeValue, 1803, 1814, "P = 0 . 004", "", " \"P = 0 . 004\". \"P = 0 . 004\"." +40, IOP, 1823, 1826, "IOP", "", +43, TimePoint, 1863, 1870, "12 noon", "", " \"12 noon\". \"12 noon\"." +48, Reduction, 1873, 1879, "11 . 5", "", " \"11 . 5\"." +207, SdDevChangeValue, 1886, 1891, "2 . 6", "", " \"2 . 6\"." +60, mmHg, 1892, 1896, "mmHg", "", +49, Reduction, 1902, 1908, "11 . 5", "", " \"11 . 5\"." +208, SdDevChangeValue, 1915, 1920, "2 . 3", "", " \"2 . 3\"." +61, mmHg, 1921, 1925, "mmHg", "", +64, PValueChangeValue, 1928, 1939, "P = 0 . 967", "", " \"P = 0 . 967\". \"P = 0 . 967\"." +95606, IOP, 1944, 1947, "IOP", "", +106402, EndPointDescription, 1944, 1982, "IOP was maintained at 12 mmHg or lower", "", " . ." +66, mmHg, 1969, 1973, "mmHg", "", +67, NumberAffected, 1986, 1988, "18", "", " \"18\"." +68, PercentageAffected, 1991, 1997, "66 . 7", "", " \"66 . 7\"." +95605, FinalNumPatientsArm, 2005, 2007, "27", "", " \"27\"." +101, Latanoprost, 2038, 2049, "latanoprost", "", +70, NumberAffected, 2057, 2058, "9", "", " \"9\"." +71, PercentageAffected, 2061, 2067, "33 . 3", "", " \"33 . 3\"." +95604, FinalNumPatientsArm, 2075, 2077, "27", "", " \"27\"." +114, Brimonidine, 2108, 2119, "brimonidine", "", +102, Latanoprost, 2122, 2133, "Latanoprost", "", +106403, EndPointDescription, 2146, 2165, "reduced IOP by 30 %", "", " . ." +73, IOP, 2154, 2157, "IOP", "", +74, RelativeReduction, 2161, 2163, "30", "", +75, NumberAffected, 2169, 2170, "8", "", " \"8\"." +76, PercentageAffected, 2182, 2188, "29 . 6", "", " \"29 . 6\"." +115, Brimonidine, 2199, 2210, "brimonidine", "", +77, IOP, 2238, 2241, "IOP", "", +80, ObservedResult, 2280, 2404, "OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) .", "", " \"OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) .\". \"OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) .\"." +91, EndPointDescription, 2280, 2283, "OPP", "", " . ." +103, Latanoprost, 2300, 2311, "latanoprost", "", +78, PValueChangeValue, 2324, 2335, "P < 0 . 001", "", " \"P < 0 . 001\"." +116, Brimonidine, 2365, 2376, "brimonidine", "", +79, PValueChangeValue, 2389, 2400, "P = 0 . 355", "", " \"P = 0 . 355\"." +81, ObservedResult, 2405, 2468, "There was no significant change in pulse rate or blood pressure", "", +93, PulseRate, 2440, 2450, "pulse rate", "", +240, BloodPressure, 2454, 2468, "blood pressure", "", +82, ConclusionComment, 2485, 2546, "Both latanoprost and brimonidine reduce IOP in NTG patients .", "", " \"Both latanoprost and brimonidine reduce IOP in NTG patients .\"." +104, Latanoprost, 2490, 2501, "latanoprost", "", +117, Brimonidine, 2506, 2517, "brimonidine", "", +86, IOP, 2525, 2528, "IOP", "", +133, NormalTensionGlaucoma, 2532, 2535, "NTG", "", +83, ConclusionComment, 2547, 2713, "Brimonidine has a peak IOP - lowering effect equal to that of latanoprost but produces a higher mean diurnal IOP than does latanoprost because of its shorter effect .", "", " \"Brimonidine has a peak IOP - lowering effect equal to that of latanoprost but produces a higher mean diurnal IOP than does latanoprost because of its shorter effect .\"." +118, Brimonidine, 2547, 2558, "Brimonidine", "", +87, Peak_IOP, 2565, 2573, "peak IOP", "", +105, Latanoprost, 2609, 2620, "latanoprost", "", +88, Mean, 2643, 2647, "mean", "", +89, Diurnal_IOP, 2648, 2659, "diurnal IOP", "", +106, Latanoprost, 2670, 2681, "latanoprost", "", +84, ConclusionComment, 2714, 2794, "Latanoprost might favorably alter optic disc blood perfusion by increasing OPP .", "", " \"Latanoprost might favorably alter optic disc blood perfusion by increasing OPP .\"." +107, Latanoprost, 2714, 2725, "Latanoprost", "", +92, EndPointDescription, 2789, 2792, "OPP", "", +85, PMID, 2802, 2810, "12466165", "", " \"12466165\"." diff --git a/data/gl 12466165_admin.n-triples b/data/gl 12466165_admin.n-triples new file mode 100644 index 0000000..a828c6a --- /dev/null +++ b/data/gl 12466165_admin.n-triples @@ -0,0 +1,208 @@ +# RDF export of group: Publication + . + "Publication" . + "Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0 . 005 % or brimonidine tartrate 0 . 2 % in normal - tension glaucoma patients ." . + "Liu CJ" . + "2002" . + "Ophthalmology" . + "12466165" . + . + "Ko YC" . + "Cheng CY" . + "Chiu AW" . + "Chou JC" . + "Hsu WM" . + "Liu JH" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate and compare the effects of latanoprost 0 . 005 % once daily and brimonidine tartrate 0 . 2 % twice daily in patients with normal - tension glaucoma ( NTG ) ." . + "Twenty - eight" . + "4 weeks" . + . + . + . + "Both latanoprost and brimonidine reduce IOP in NTG patients ." . + . + . + . + . + . + . + . + "Brimonidine has a peak IOP - lowering effect equal to that of latanoprost but produces a higher mean diurnal IOP than does latanoprost because of its shorter effect ." . + "Latanoprost might favorably alter optic disc blood perfusion by increasing OPP ." . + . +# RDF export of group: Population + . + "Population" . + "patients with progressive visual field defects / optic disc excavation , new disc hemorrhage , or field defects that threatened fixation" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_12" . + . + . + . + . + . + . + "Endpoint_30" . + . + . + . + . + . + . + "Endpoint_OPP" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + "27" . + . + . + . + . + . + . + . + . + . + . + "Arm_bri" . + "27" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_bri" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_bri" . + . + "0 . 2" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat" . + . + "3 . 6" . + "P < 0 . 001" . + "1 . 9" . + . + "Outcome_ipo_bri" . + . + "2 . 5" . + "P < 0 . 001" . + "1 . 3" . + . + "Outcome_iop_8am_lat" . + . + "11 . 7" . + "P = 0 . 004" . + "2 . 2" . + "8 am" . + . + "Outcome_iop_8am_bri" . + . + "13 . 7" . + "P = 0 . 004" . + "2 . 1" . + "8 am" . + . + "Outcome_iop_4pm_lat" . + . + "11 . 4" . + "P = 0 . 004" . + "2 . 1" . + "4 pm" . + . + "Outcome_iop_4pm_bri" . + . + "13 . 2" . + "P = 0 . 004" . + "2 . 9" . + "4 pm" . + . + "Outcome_iop_12_lat" . + . + "11 . 5" . + "P = 0 . 967" . + "2 . 6" . + "12 noon" . + . + "Outcome_iop_12_bri" . + . + "11 . 5" . + "P = 0 . 967" . + "2 . 3" . + "12 noon" . + . + "Outcome_12_lat" . + . + "18" . + "66 . 7" . + . + "Outcome_12_bri" . + . + "9" . + "33 . 3" . + . + "Outcome_30_lat" . + . + "8" . + "29 . 6" . + . + "Outcome_OPP_lat" . + . + "P < 0 . 001" . + "OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) ." . + . + "Outcome_OPP_bri" . + . + "P = 0 . 355" . + "OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "P = 0 . 009" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12466165_export.csv b/data/gl 12466165_export.csv new file mode 100644 index 0000000..4a23fb5 --- /dev/null +++ b/data/gl 12466165_export.csv @@ -0,0 +1,619 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +475, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +475, 1, 2, 2, 14, 15, 14, 15, "." +475, 2, 1, 3, 0, 4, 16, 20, "2002" +475, 2, 2, 4, 5, 8, 21, 24, "Dec" +475, 2, 3, 5, 9, 10, 25, 26, ";" +475, 2, 4, 6, 11, 14, 27, 30, "109" +475, 2, 5, 7, 15, 16, 31, 32, "(" +475, 2, 6, 8, 17, 19, 33, 35, "12" +475, 2, 7, 9, 20, 21, 36, 37, ")" +475, 2, 8, 10, 22, 23, 38, 39, ":" +475, 2, 9, 11, 24, 28, 40, 44, "2241" +475, 2, 10, 12, 29, 30, 45, 46, "-" +475, 2, 11, 13, 31, 32, 47, 48, "7" +475, 2, 12, 14, 33, 34, 49, 50, "." +475, 3, 1, 15, 0, 7, 51, 58, "Changes" +475, 3, 2, 16, 8, 10, 59, 61, "in" +475, 3, 3, 17, 11, 22, 62, 73, "intraocular" +475, 3, 4, 18, 23, 31, 74, 82, "pressure" +475, 3, 5, 19, 32, 35, 83, 86, "and" +475, 3, 6, 20, 36, 42, 87, 93, "ocular" +475, 3, 7, 21, 43, 52, 94, 103, "perfusion" +475, 3, 8, 22, 53, 61, 104, 112, "pressure" +475, 3, 9, 23, 62, 67, 113, 118, "after" +475, 3, 10, 24, 68, 79, 119, 130, "latanoprost" +475, 3, 11, 25, 80, 81, 131, 132, "0" +475, 3, 12, 26, 82, 83, 133, 134, "." +475, 3, 13, 27, 84, 87, 135, 138, "005" +475, 3, 14, 28, 88, 89, 139, 140, "%" +475, 3, 15, 29, 90, 92, 141, 143, "or" +475, 3, 16, 30, 93, 104, 144, 155, "brimonidine" +475, 3, 17, 31, 105, 113, 156, 164, "tartrate" +475, 3, 18, 32, 114, 115, 165, 166, "0" +475, 3, 19, 33, 116, 117, 167, 168, "." +475, 3, 20, 34, 118, 119, 169, 170, "2" +475, 3, 21, 35, 120, 121, 171, 172, "%" +475, 3, 22, 36, 122, 124, 173, 175, "in" +475, 3, 23, 37, 125, 131, 176, 182, "normal" +475, 3, 24, 38, 132, 133, 183, 184, "-" +475, 3, 25, 39, 134, 141, 185, 192, "tension" +475, 3, 26, 40, 142, 150, 193, 201, "glaucoma" +475, 3, 27, 41, 151, 159, 202, 210, "patients" +475, 3, 28, 42, 160, 161, 211, 212, "." +475, 4, 1, 43, 0, 3, 213, 216, "Liu" +475, 4, 2, 44, 4, 6, 217, 219, "CJ" +475, 4, 3, 45, 7, 8, 220, 221, "(" +475, 4, 4, 46, 9, 10, 222, 223, "1" +475, 4, 5, 47, 11, 12, 224, 225, ")" +475, 4, 6, 48, 13, 14, 226, 227, "," +475, 4, 7, 49, 15, 17, 228, 230, "Ko" +475, 4, 8, 50, 18, 20, 231, 233, "YC" +475, 4, 9, 51, 21, 22, 234, 235, "," +475, 4, 10, 52, 23, 28, 236, 241, "Cheng" +475, 4, 11, 53, 29, 31, 242, 244, "CY" +475, 4, 12, 54, 32, 33, 245, 246, "," +475, 4, 13, 55, 34, 38, 247, 251, "Chiu" +475, 4, 14, 56, 39, 41, 252, 254, "AW" +475, 4, 15, 57, 42, 43, 255, 256, "," +475, 4, 16, 58, 44, 48, 257, 261, "Chou" +475, 4, 17, 59, 49, 51, 262, 264, "JC" +475, 4, 18, 60, 52, 53, 265, 266, "," +475, 4, 19, 61, 54, 57, 267, 270, "Hsu" +475, 4, 20, 62, 58, 60, 271, 273, "WM" +475, 4, 21, 63, 61, 62, 274, 275, "," +475, 4, 22, 64, 63, 66, 276, 279, "Liu" +475, 4, 23, 65, 67, 69, 280, 282, "JH" +475, 4, 24, 66, 70, 71, 283, 284, "." +475, 5, 1, 67, 0, 6, 285, 291, "Author" +475, 5, 2, 68, 7, 18, 292, 303, "information" +475, 5, 3, 69, 19, 20, 304, 305, ":" +475, 5, 4, 70, 21, 22, 306, 307, "(" +475, 5, 5, 71, 23, 24, 308, 309, "1" +475, 5, 6, 72, 25, 26, 310, 311, ")" +475, 5, 7, 73, 27, 37, 312, 322, "Department" +475, 5, 8, 74, 38, 40, 323, 325, "of" +475, 5, 9, 75, 41, 54, 326, 339, "Ophthalmology" +475, 5, 10, 76, 55, 56, 340, 341, "," +475, 5, 11, 77, 57, 63, 342, 348, "Taipei" +475, 5, 12, 78, 64, 72, 349, 357, "Veterans" +475, 5, 13, 79, 73, 80, 358, 365, "General" +475, 5, 14, 80, 81, 89, 366, 374, "Hospital" +475, 5, 15, 81, 90, 91, 375, 376, "," +475, 5, 16, 82, 92, 98, 377, 383, "Taipei" +475, 5, 17, 83, 99, 100, 384, 385, "," +475, 5, 18, 84, 101, 107, 386, 392, "Taiwan" +475, 5, 19, 85, 108, 109, 393, 394, "." +475, 6, 1, 86, 0, 9, 395, 404, "OBJECTIVE" +475, 6, 2, 87, 10, 11, 405, 406, ":" +475, 6, 3, 88, 12, 14, 407, 409, "To" +475, 6, 4, 89, 15, 23, 410, 418, "evaluate" +475, 6, 5, 90, 24, 27, 419, 422, "and" +475, 6, 6, 91, 28, 35, 423, 430, "compare" +475, 6, 7, 92, 36, 39, 431, 434, "the" +475, 6, 8, 93, 40, 47, 435, 442, "effects" +475, 6, 9, 94, 48, 50, 443, 445, "of" +475, 6, 10, 95, 51, 62, 446, 457, "latanoprost" +475, 6, 11, 96, 63, 64, 458, 459, "0" +475, 6, 12, 97, 65, 66, 460, 461, "." +475, 6, 13, 98, 67, 70, 462, 465, "005" +475, 6, 14, 99, 71, 72, 466, 467, "%" +475, 6, 15, 100, 73, 77, 468, 472, "once" +475, 6, 16, 101, 78, 83, 473, 478, "daily" +475, 6, 17, 102, 84, 87, 479, 482, "and" +475, 6, 18, 103, 88, 99, 483, 494, "brimonidine" +475, 6, 19, 104, 100, 108, 495, 503, "tartrate" +475, 6, 20, 105, 109, 110, 504, 505, "0" +475, 6, 21, 106, 111, 112, 506, 507, "." +475, 6, 22, 107, 113, 114, 508, 509, "2" +475, 6, 23, 108, 115, 116, 510, 511, "%" +475, 6, 24, 109, 117, 122, 512, 517, "twice" +475, 6, 25, 110, 123, 128, 518, 523, "daily" +475, 6, 26, 111, 129, 131, 524, 526, "in" +475, 6, 27, 112, 132, 140, 527, 535, "patients" +475, 6, 28, 113, 141, 145, 536, 540, "with" +475, 6, 29, 114, 146, 152, 541, 547, "normal" +475, 6, 30, 115, 153, 154, 548, 549, "-" +475, 6, 31, 116, 155, 162, 550, 557, "tension" +475, 6, 32, 117, 163, 171, 558, 566, "glaucoma" +475, 6, 33, 118, 172, 173, 567, 568, "(" +475, 6, 34, 119, 174, 177, 569, 572, "NTG" +475, 6, 35, 120, 178, 179, 573, 574, ")" +475, 6, 36, 121, 180, 181, 575, 576, "." +475, 7, 1, 122, 0, 6, 577, 583, "DESIGN" +475, 7, 2, 123, 7, 8, 584, 585, ":" +475, 7, 3, 124, 9, 10, 586, 587, "A" +475, 7, 4, 125, 11, 21, 588, 598, "randomized" +475, 7, 5, 126, 22, 23, 599, 600, "," +475, 7, 6, 127, 24, 28, 601, 605, "open" +475, 7, 7, 128, 29, 30, 606, 607, "-" +475, 7, 8, 129, 31, 36, 608, 613, "label" +475, 7, 9, 130, 37, 38, 614, 615, "," +475, 7, 10, 131, 39, 48, 616, 625, "crossover" +475, 7, 11, 132, 49, 54, 626, 631, "study" +475, 7, 12, 133, 55, 56, 632, 633, "." +475, 8, 1, 134, 0, 12, 634, 646, "PARTICIPANTS" +475, 8, 2, 135, 13, 14, 647, 648, ":" +475, 8, 3, 136, 15, 21, 649, 655, "Twenty" +475, 8, 4, 137, 22, 23, 656, 657, "-" +475, 8, 5, 138, 24, 29, 658, 663, "eight" +475, 8, 6, 139, 30, 33, 664, 667, "NTG" +475, 8, 7, 140, 34, 42, 668, 676, "patients" +475, 8, 8, 141, 43, 47, 677, 681, "with" +475, 8, 9, 142, 48, 59, 682, 693, "progressive" +475, 8, 10, 143, 60, 66, 694, 700, "visual" +475, 8, 11, 144, 67, 72, 701, 706, "field" +475, 8, 12, 145, 73, 80, 707, 714, "defects" +475, 8, 13, 146, 81, 82, 715, 716, "/" +475, 8, 14, 147, 83, 88, 717, 722, "optic" +475, 8, 15, 148, 89, 93, 723, 727, "disc" +475, 8, 16, 149, 94, 104, 728, 738, "excavation" +475, 8, 17, 150, 105, 106, 739, 740, "," +475, 8, 18, 151, 107, 110, 741, 744, "new" +475, 8, 19, 152, 111, 115, 745, 749, "disc" +475, 8, 20, 153, 116, 126, 750, 760, "hemorrhage" +475, 8, 21, 154, 127, 128, 761, 762, "," +475, 8, 22, 155, 129, 131, 763, 765, "or" +475, 8, 23, 156, 132, 137, 766, 771, "field" +475, 8, 24, 157, 138, 145, 772, 779, "defects" +475, 8, 25, 158, 146, 150, 780, 784, "that" +475, 8, 26, 159, 151, 161, 785, 795, "threatened" +475, 8, 27, 160, 162, 170, 796, 804, "fixation" +475, 8, 28, 161, 171, 172, 805, 806, "." +475, 9, 1, 162, 0, 12, 807, 819, "INTERVENTION" +475, 9, 2, 163, 13, 14, 820, 821, ":" +475, 9, 3, 164, 15, 23, 822, 830, "Patients" +475, 9, 4, 165, 24, 28, 831, 835, "were" +475, 9, 5, 166, 29, 37, 836, 844, "randomly" +475, 9, 6, 167, 38, 47, 845, 854, "allocated" +475, 9, 7, 168, 48, 50, 855, 857, "to" +475, 9, 8, 169, 51, 54, 858, 861, "one" +475, 9, 9, 170, 55, 57, 862, 864, "of" +475, 9, 10, 171, 58, 61, 865, 868, "two" +475, 9, 11, 172, 62, 68, 869, 875, "groups" +475, 9, 12, 173, 69, 70, 876, 877, "." +475, 10, 1, 174, 0, 8, 878, 886, "Patients" +475, 10, 2, 175, 9, 11, 887, 889, "in" +475, 10, 3, 176, 12, 17, 890, 895, "group" +475, 10, 4, 177, 18, 19, 896, 897, "1" +475, 10, 5, 178, 20, 24, 898, 902, "were" +475, 10, 6, 179, 25, 32, 903, 910, "treated" +475, 10, 7, 180, 33, 37, 911, 915, "with" +475, 10, 8, 181, 38, 49, 916, 927, "latanoprost" +475, 10, 9, 182, 50, 51, 928, 929, "," +475, 10, 10, 183, 52, 61, 930, 939, "lubricant" +475, 10, 11, 184, 62, 63, 940, 941, "," +475, 10, 12, 185, 64, 67, 942, 945, "and" +475, 10, 13, 186, 68, 79, 946, 957, "brimonidine" +475, 10, 14, 187, 80, 83, 958, 961, "for" +475, 10, 15, 188, 84, 85, 962, 963, "4" +475, 10, 16, 189, 86, 91, 964, 969, "weeks" +475, 10, 17, 190, 92, 96, 970, 974, "each" +475, 10, 18, 191, 97, 98, 975, 976, "," +475, 10, 19, 192, 99, 106, 977, 984, "whereas" +475, 10, 20, 193, 107, 115, 985, 993, "patients" +475, 10, 21, 194, 116, 118, 994, 996, "in" +475, 10, 22, 195, 119, 124, 997, 1002, "group" +475, 10, 23, 196, 125, 126, 1003, 1004, "2" +475, 10, 24, 197, 127, 131, 1005, 1009, "were" +475, 10, 25, 198, 132, 139, 1010, 1017, "treated" +475, 10, 26, 199, 140, 144, 1018, 1022, "with" +475, 10, 27, 200, 145, 156, 1023, 1034, "brimonidine" +475, 10, 28, 201, 157, 158, 1035, 1036, "," +475, 10, 29, 202, 159, 168, 1037, 1046, "lubricant" +475, 10, 30, 203, 169, 170, 1047, 1048, "," +475, 10, 31, 204, 171, 174, 1049, 1052, "and" +475, 10, 32, 205, 175, 186, 1053, 1064, "latanoprost" +475, 10, 33, 206, 187, 190, 1065, 1068, "for" +475, 10, 34, 207, 191, 192, 1069, 1070, "4" +475, 10, 35, 208, 193, 198, 1071, 1076, "weeks" +475, 10, 36, 209, 199, 203, 1077, 1081, "each" +475, 10, 37, 210, 204, 205, 1082, 1083, "." +475, 11, 1, 211, 0, 4, 1084, 1088, "MAIN" +475, 11, 2, 212, 5, 12, 1089, 1096, "OUTCOME" +475, 11, 3, 213, 13, 21, 1097, 1105, "MEASURES" +475, 11, 4, 214, 22, 23, 1106, 1107, ":" +475, 11, 5, 215, 24, 35, 1108, 1119, "Intraocular" +475, 11, 6, 216, 36, 44, 1120, 1128, "pressure" +475, 11, 7, 217, 45, 46, 1129, 1130, "(" +475, 11, 8, 218, 47, 50, 1131, 1134, "IOP" +475, 11, 9, 219, 51, 52, 1135, 1136, ")" +475, 11, 10, 220, 53, 54, 1137, 1138, "," +475, 11, 11, 221, 55, 60, 1139, 1144, "pulse" +475, 11, 12, 222, 61, 65, 1145, 1149, "rate" +475, 11, 13, 223, 66, 67, 1150, 1151, "," +475, 11, 14, 224, 68, 71, 1152, 1155, "and" +475, 11, 15, 225, 72, 77, 1156, 1161, "blood" +475, 11, 16, 226, 78, 86, 1162, 1170, "pressure" +475, 11, 17, 227, 87, 91, 1171, 1175, "were" +475, 11, 18, 228, 92, 100, 1176, 1184, "measured" +475, 11, 19, 229, 101, 103, 1185, 1187, "at" +475, 11, 20, 230, 104, 105, 1188, 1189, "8" +475, 11, 21, 231, 106, 108, 1190, 1192, "am" +475, 11, 22, 232, 109, 110, 1193, 1194, "," +475, 11, 23, 233, 111, 113, 1195, 1197, "12" +475, 11, 24, 234, 114, 118, 1198, 1202, "noon" +475, 11, 25, 235, 119, 120, 1203, 1204, "," +475, 11, 26, 236, 121, 124, 1205, 1208, "and" +475, 11, 27, 237, 125, 126, 1209, 1210, "4" +475, 11, 28, 238, 127, 129, 1211, 1213, "pm" +475, 11, 29, 239, 130, 135, 1214, 1219, "after" +475, 11, 30, 240, 136, 140, 1220, 1224, "each" +475, 11, 31, 241, 141, 142, 1225, 1226, "4" +475, 11, 32, 242, 143, 144, 1227, 1228, "-" +475, 11, 33, 243, 145, 149, 1229, 1233, "week" +475, 11, 34, 244, 150, 159, 1234, 1243, "treatment" +475, 11, 35, 245, 160, 161, 1244, 1245, "." +475, 12, 1, 246, 0, 6, 1246, 1252, "Ocular" +475, 12, 2, 247, 7, 16, 1253, 1262, "perfusion" +475, 12, 3, 248, 17, 25, 1263, 1271, "pressure" +475, 12, 4, 249, 26, 27, 1272, 1273, "(" +475, 12, 5, 250, 28, 31, 1274, 1277, "OPP" +475, 12, 6, 251, 32, 33, 1278, 1279, ")" +475, 12, 7, 252, 34, 37, 1280, 1283, "was" +475, 12, 8, 253, 38, 48, 1284, 1294, "calculated" +475, 12, 9, 254, 49, 50, 1295, 1296, "." +475, 13, 1, 255, 0, 7, 1297, 1304, "RESULTS" +475, 13, 2, 256, 8, 9, 1305, 1306, ":" +475, 13, 3, 257, 10, 21, 1307, 1318, "Latanoprost" +475, 13, 4, 258, 22, 25, 1319, 1322, "and" +475, 13, 5, 259, 26, 37, 1323, 1334, "brimonidine" +475, 13, 6, 260, 38, 45, 1335, 1342, "reduced" +475, 13, 7, 261, 46, 49, 1343, 1346, "the" +475, 13, 8, 262, 50, 57, 1347, 1354, "average" +475, 13, 9, 263, 58, 61, 1355, 1358, "IOP" +475, 13, 10, 264, 62, 64, 1359, 1361, "by" +475, 13, 11, 265, 65, 66, 1362, 1363, "3" +475, 13, 12, 266, 67, 68, 1364, 1365, "." +475, 13, 13, 267, 69, 70, 1366, 1367, "6" +475, 13, 14, 268, 71, 72, 1368, 1369, "+" +475, 13, 15, 269, 73, 74, 1370, 1371, "/" +475, 13, 16, 270, 75, 76, 1372, 1373, "-" +475, 13, 17, 271, 77, 78, 1374, 1375, "1" +475, 13, 18, 272, 79, 80, 1376, 1377, "." +475, 13, 19, 273, 81, 82, 1378, 1379, "9" +475, 13, 20, 274, 83, 87, 1380, 1384, "mmHg" +475, 13, 21, 275, 88, 89, 1385, 1386, "(" +475, 13, 22, 276, 90, 91, 1387, 1388, "P" +475, 13, 23, 277, 92, 93, 1389, 1390, "<" +475, 13, 24, 278, 94, 95, 1391, 1392, "0" +475, 13, 25, 279, 96, 97, 1393, 1394, "." +475, 13, 26, 280, 98, 101, 1395, 1398, "001" +475, 13, 27, 281, 102, 103, 1399, 1400, ")" +475, 13, 28, 282, 104, 107, 1401, 1404, "and" +475, 13, 29, 283, 108, 109, 1405, 1406, "2" +475, 13, 30, 284, 110, 111, 1407, 1408, "." +475, 13, 31, 285, 112, 113, 1409, 1410, "5" +475, 13, 32, 286, 114, 115, 1411, 1412, "+" +475, 13, 33, 287, 116, 117, 1413, 1414, "/" +475, 13, 34, 288, 118, 119, 1415, 1416, "-" +475, 13, 35, 289, 120, 121, 1417, 1418, "1" +475, 13, 36, 290, 122, 123, 1419, 1420, "." +475, 13, 37, 291, 124, 125, 1421, 1422, "3" +475, 13, 38, 292, 126, 130, 1423, 1427, "mmHg" +475, 13, 39, 293, 131, 132, 1428, 1429, "(" +475, 13, 40, 294, 133, 134, 1430, 1431, "P" +475, 13, 41, 295, 135, 136, 1432, 1433, "<" +475, 13, 42, 296, 137, 138, 1434, 1435, "0" +475, 13, 43, 297, 139, 140, 1436, 1437, "." +475, 13, 44, 298, 141, 144, 1438, 1441, "001" +475, 13, 45, 299, 145, 146, 1442, 1443, ")" +475, 13, 46, 300, 147, 148, 1444, 1445, "," +475, 13, 47, 301, 149, 161, 1446, 1458, "respectively" +475, 13, 48, 302, 162, 163, 1459, 1460, "," +475, 13, 49, 303, 164, 168, 1461, 1465, "with" +475, 13, 50, 304, 169, 170, 1466, 1467, "a" +475, 13, 51, 305, 171, 182, 1468, 1479, "significant" +475, 13, 52, 306, 183, 193, 1480, 1490, "difference" +475, 13, 53, 307, 194, 201, 1491, 1498, "between" +475, 13, 54, 308, 202, 205, 1499, 1502, "the" +475, 13, 55, 309, 206, 209, 1503, 1506, "two" +475, 13, 56, 310, 210, 218, 1507, 1515, "regimens" +475, 13, 57, 311, 219, 220, 1516, 1517, "(" +475, 13, 58, 312, 221, 222, 1518, 1519, "P" +475, 13, 59, 313, 223, 224, 1520, 1521, "=" +475, 13, 60, 314, 225, 226, 1522, 1523, "0" +475, 13, 61, 315, 227, 228, 1524, 1525, "." +475, 13, 62, 316, 229, 232, 1526, 1529, "009" +475, 13, 63, 317, 233, 234, 1530, 1531, ")" +475, 13, 64, 318, 235, 236, 1532, 1533, "." +475, 14, 1, 319, 0, 4, 1534, 1538, "Both" +475, 14, 2, 320, 5, 10, 1539, 1544, "drugs" +475, 14, 3, 321, 11, 24, 1545, 1558, "significantly" +475, 14, 4, 322, 25, 32, 1559, 1566, "reduced" +475, 14, 5, 323, 33, 36, 1567, 1570, "IOP" +475, 14, 6, 324, 37, 39, 1571, 1573, "at" +475, 14, 7, 325, 40, 44, 1574, 1578, "each" +475, 14, 8, 326, 45, 49, 1579, 1583, "time" +475, 14, 9, 327, 50, 55, 1584, 1589, "point" +475, 14, 10, 328, 56, 57, 1590, 1591, "." +475, 15, 1, 329, 0, 11, 1592, 1603, "Latanoprost" +475, 15, 2, 330, 12, 21, 1604, 1613, "decreased" +475, 15, 3, 331, 22, 25, 1614, 1617, "IOP" +475, 15, 4, 332, 26, 39, 1618, 1631, "significantly" +475, 15, 5, 333, 40, 44, 1632, 1636, "more" +475, 15, 6, 334, 45, 49, 1637, 1641, "than" +475, 15, 7, 335, 50, 53, 1642, 1645, "did" +475, 15, 8, 336, 54, 65, 1646, 1657, "brimonidine" +475, 15, 9, 337, 66, 68, 1658, 1660, "at" +475, 15, 10, 338, 69, 70, 1661, 1662, "8" +475, 15, 11, 339, 71, 73, 1663, 1665, "am" +475, 15, 12, 340, 74, 75, 1666, 1667, "(" +475, 15, 13, 341, 76, 78, 1668, 1670, "11" +475, 15, 14, 342, 79, 80, 1671, 1672, "." +475, 15, 15, 343, 81, 82, 1673, 1674, "7" +475, 15, 16, 344, 83, 84, 1675, 1676, "+" +475, 15, 17, 345, 85, 86, 1677, 1678, "/" +475, 15, 18, 346, 87, 88, 1679, 1680, "-" +475, 15, 19, 347, 89, 90, 1681, 1682, "2" +475, 15, 20, 348, 91, 92, 1683, 1684, "." +475, 15, 21, 349, 93, 94, 1685, 1686, "2" +475, 15, 22, 350, 95, 99, 1687, 1691, "mmHg" +475, 15, 23, 351, 100, 102, 1692, 1694, "vs" +475, 15, 24, 352, 103, 104, 1695, 1696, "." +475, 15, 25, 353, 105, 107, 1697, 1699, "13" +475, 15, 26, 354, 108, 109, 1700, 1701, "." +475, 15, 27, 355, 110, 111, 1702, 1703, "7" +475, 15, 28, 356, 112, 113, 1704, 1705, "+" +475, 15, 29, 357, 114, 115, 1706, 1707, "/" +475, 15, 30, 358, 116, 117, 1708, 1709, "-" +475, 15, 31, 359, 118, 119, 1710, 1711, "2" +475, 15, 32, 360, 120, 121, 1712, 1713, "." +475, 15, 33, 361, 122, 123, 1714, 1715, "1" +475, 15, 34, 362, 124, 128, 1716, 1720, "mmHg" +475, 15, 35, 363, 129, 130, 1721, 1722, "," +475, 15, 36, 364, 131, 132, 1723, 1724, "P" +475, 15, 37, 365, 133, 134, 1725, 1726, "=" +475, 15, 38, 366, 135, 136, 1727, 1728, "0" +475, 15, 39, 367, 137, 138, 1729, 1730, "." +475, 15, 40, 368, 139, 142, 1731, 1734, "004" +475, 15, 41, 369, 143, 144, 1735, 1736, ")" +475, 15, 42, 370, 145, 148, 1737, 1740, "and" +475, 15, 43, 371, 149, 150, 1741, 1742, "4" +475, 15, 44, 372, 151, 153, 1743, 1745, "pm" +475, 15, 45, 373, 154, 155, 1746, 1747, "(" +475, 15, 46, 374, 156, 158, 1748, 1750, "11" +475, 15, 47, 375, 159, 160, 1751, 1752, "." +475, 15, 48, 376, 161, 162, 1753, 1754, "4" +475, 15, 49, 377, 163, 164, 1755, 1756, "+" +475, 15, 50, 378, 165, 166, 1757, 1758, "/" +475, 15, 51, 379, 167, 168, 1759, 1760, "-" +475, 15, 52, 380, 169, 170, 1761, 1762, "2" +475, 15, 53, 381, 171, 172, 1763, 1764, "." +475, 15, 54, 382, 173, 174, 1765, 1766, "1" +475, 15, 55, 383, 175, 179, 1767, 1771, "mmHg" +475, 15, 56, 384, 180, 182, 1772, 1774, "vs" +475, 15, 57, 385, 183, 184, 1775, 1776, "." +475, 15, 58, 386, 185, 187, 1777, 1779, "13" +475, 15, 59, 387, 188, 189, 1780, 1781, "." +475, 15, 60, 388, 190, 191, 1782, 1783, "2" +475, 15, 61, 389, 192, 193, 1784, 1785, "+" +475, 15, 62, 390, 194, 195, 1786, 1787, "/" +475, 15, 63, 391, 196, 197, 1788, 1789, "-" +475, 15, 64, 392, 198, 199, 1790, 1791, "2" +475, 15, 65, 393, 200, 201, 1792, 1793, "." +475, 15, 66, 394, 202, 203, 1794, 1795, "9" +475, 15, 67, 395, 204, 208, 1796, 1800, "mmHg" +475, 15, 68, 396, 209, 210, 1801, 1802, "," +475, 15, 69, 397, 211, 212, 1803, 1804, "P" +475, 15, 70, 398, 213, 214, 1805, 1806, "=" +475, 15, 71, 399, 215, 216, 1807, 1808, "0" +475, 15, 72, 400, 217, 218, 1809, 1810, "." +475, 15, 73, 401, 219, 222, 1811, 1814, "004" +475, 15, 74, 402, 223, 224, 1815, 1816, ")" +475, 15, 75, 403, 225, 226, 1817, 1818, "," +475, 15, 76, 404, 227, 230, 1819, 1822, "but" +475, 15, 77, 405, 231, 234, 1823, 1826, "IOP" +475, 15, 78, 406, 235, 238, 1827, 1830, "was" +475, 15, 79, 407, 239, 244, 1831, 1836, "equal" +475, 15, 80, 408, 245, 252, 1837, 1844, "between" +475, 15, 81, 409, 253, 256, 1845, 1848, "the" +475, 15, 82, 410, 257, 260, 1849, 1852, "two" +475, 15, 83, 411, 261, 267, 1853, 1859, "agents" +475, 15, 84, 412, 268, 270, 1860, 1862, "at" +475, 15, 85, 413, 271, 273, 1863, 1865, "12" +475, 15, 86, 414, 274, 278, 1866, 1870, "noon" +475, 15, 87, 415, 279, 280, 1871, 1872, "(" +475, 15, 88, 416, 281, 283, 1873, 1875, "11" +475, 15, 89, 417, 284, 285, 1876, 1877, "." +475, 15, 90, 418, 286, 287, 1878, 1879, "5" +475, 15, 91, 419, 288, 289, 1880, 1881, "+" +475, 15, 92, 420, 290, 291, 1882, 1883, "/" +475, 15, 93, 421, 292, 293, 1884, 1885, "-" +475, 15, 94, 422, 294, 295, 1886, 1887, "2" +475, 15, 95, 423, 296, 297, 1888, 1889, "." +475, 15, 96, 424, 298, 299, 1890, 1891, "6" +475, 15, 97, 425, 300, 304, 1892, 1896, "mmHg" +475, 15, 98, 426, 305, 307, 1897, 1899, "vs" +475, 15, 99, 427, 308, 309, 1900, 1901, "." +475, 15, 100, 428, 310, 312, 1902, 1904, "11" +475, 15, 101, 429, 313, 314, 1905, 1906, "." +475, 15, 102, 430, 315, 316, 1907, 1908, "5" +475, 15, 103, 431, 317, 318, 1909, 1910, "+" +475, 15, 104, 432, 319, 320, 1911, 1912, "/" +475, 15, 105, 433, 321, 322, 1913, 1914, "-" +475, 15, 106, 434, 323, 324, 1915, 1916, "2" +475, 15, 107, 435, 325, 326, 1917, 1918, "." +475, 15, 108, 436, 327, 328, 1919, 1920, "3" +475, 15, 109, 437, 329, 333, 1921, 1925, "mmHg" +475, 15, 110, 438, 334, 335, 1926, 1927, "," +475, 15, 111, 439, 336, 337, 1928, 1929, "P" +475, 15, 112, 440, 338, 339, 1930, 1931, "=" +475, 15, 113, 441, 340, 341, 1932, 1933, "0" +475, 15, 114, 442, 342, 343, 1934, 1935, "." +475, 15, 115, 443, 344, 347, 1936, 1939, "967" +475, 15, 116, 444, 348, 349, 1940, 1941, ")" +475, 15, 117, 445, 350, 351, 1942, 1943, "." +475, 16, 1, 446, 0, 3, 1944, 1947, "IOP" +475, 16, 2, 447, 4, 7, 1948, 1951, "was" +475, 16, 3, 448, 8, 18, 1952, 1962, "maintained" +475, 16, 4, 449, 19, 21, 1963, 1965, "at" +475, 16, 5, 450, 22, 24, 1966, 1968, "12" +475, 16, 6, 451, 25, 29, 1969, 1973, "mmHg" +475, 16, 7, 452, 30, 32, 1974, 1976, "or" +475, 16, 8, 453, 33, 38, 1977, 1982, "lower" +475, 16, 9, 454, 39, 41, 1983, 1985, "in" +475, 16, 10, 455, 42, 44, 1986, 1988, "18" +475, 16, 11, 456, 45, 46, 1989, 1990, "(" +475, 16, 12, 457, 47, 49, 1991, 1993, "66" +475, 16, 13, 458, 50, 51, 1994, 1995, "." +475, 16, 14, 459, 52, 53, 1996, 1997, "7" +475, 16, 15, 460, 54, 55, 1998, 1999, "%" +475, 16, 16, 461, 56, 57, 2000, 2001, ")" +475, 16, 17, 462, 58, 60, 2002, 2004, "of" +475, 16, 18, 463, 61, 63, 2005, 2007, "27" +475, 16, 19, 464, 64, 72, 2008, 2016, "patients" +475, 16, 20, 465, 73, 78, 2017, 2022, "after" +475, 16, 21, 466, 79, 88, 2023, 2032, "treatment" +475, 16, 22, 467, 89, 93, 2033, 2037, "with" +475, 16, 23, 468, 94, 105, 2038, 2049, "latanoprost" +475, 16, 24, 469, 106, 109, 2050, 2053, "and" +475, 16, 25, 470, 110, 112, 2054, 2056, "in" +475, 16, 26, 471, 113, 114, 2057, 2058, "9" +475, 16, 27, 472, 115, 116, 2059, 2060, "(" +475, 16, 28, 473, 117, 119, 2061, 2063, "33" +475, 16, 29, 474, 120, 121, 2064, 2065, "." +475, 16, 30, 475, 122, 123, 2066, 2067, "3" +475, 16, 31, 476, 124, 125, 2068, 2069, "%" +475, 16, 32, 477, 126, 127, 2070, 2071, ")" +475, 16, 33, 478, 128, 130, 2072, 2074, "of" +475, 16, 34, 479, 131, 133, 2075, 2077, "27" +475, 16, 35, 480, 134, 142, 2078, 2086, "patients" +475, 16, 36, 481, 143, 148, 2087, 2092, "after" +475, 16, 37, 482, 149, 158, 2093, 2102, "treatment" +475, 16, 38, 483, 159, 163, 2103, 2107, "with" +475, 16, 39, 484, 164, 175, 2108, 2119, "brimonidine" +475, 16, 40, 485, 176, 177, 2120, 2121, "." +475, 17, 1, 486, 0, 11, 2122, 2133, "Latanoprost" +475, 17, 2, 487, 12, 23, 2134, 2145, "monotherapy" +475, 17, 3, 488, 24, 31, 2146, 2153, "reduced" +475, 17, 4, 489, 32, 35, 2154, 2157, "IOP" +475, 17, 5, 490, 36, 38, 2158, 2160, "by" +475, 17, 6, 491, 39, 41, 2161, 2163, "30" +475, 17, 7, 492, 42, 43, 2164, 2165, "%" +475, 17, 8, 493, 44, 46, 2166, 2168, "in" +475, 17, 9, 494, 47, 48, 2169, 2170, "8" +475, 17, 10, 495, 49, 57, 2171, 2179, "patients" +475, 17, 11, 496, 58, 59, 2180, 2181, "(" +475, 17, 12, 497, 60, 62, 2182, 2184, "29" +475, 17, 13, 498, 63, 64, 2185, 2186, "." +475, 17, 14, 499, 65, 66, 2187, 2188, "6" +475, 17, 15, 500, 67, 68, 2189, 2190, "%" +475, 17, 16, 501, 69, 70, 2191, 2192, ")" +475, 17, 17, 502, 71, 72, 2193, 2194, "," +475, 17, 18, 503, 73, 76, 2195, 2198, "but" +475, 17, 19, 504, 77, 88, 2199, 2210, "brimonidine" +475, 17, 20, 505, 89, 100, 2211, 2222, "monotherapy" +475, 17, 21, 506, 101, 104, 2223, 2226, "did" +475, 17, 22, 507, 105, 108, 2227, 2230, "not" +475, 17, 23, 508, 109, 115, 2231, 2237, "reduce" +475, 17, 24, 509, 116, 119, 2238, 2241, "IOP" +475, 17, 25, 510, 120, 122, 2242, 2244, "by" +475, 17, 26, 511, 123, 127, 2245, 2249, "that" +475, 17, 27, 512, 128, 132, 2250, 2254, "much" +475, 17, 28, 513, 133, 135, 2255, 2257, "in" +475, 17, 29, 514, 136, 139, 2258, 2261, "any" +475, 17, 30, 515, 140, 142, 2262, 2264, "of" +475, 17, 31, 516, 143, 146, 2265, 2268, "the" +475, 17, 32, 517, 147, 155, 2269, 2277, "patients" +475, 17, 33, 518, 156, 157, 2278, 2279, "." +475, 18, 1, 519, 0, 3, 2280, 2283, "OPP" +475, 18, 2, 520, 4, 13, 2284, 2293, "increased" +475, 18, 3, 521, 14, 19, 2294, 2299, "after" +475, 18, 4, 522, 20, 31, 2300, 2311, "latanoprost" +475, 18, 5, 523, 32, 41, 2312, 2321, "treatment" +475, 18, 6, 524, 42, 43, 2322, 2323, "(" +475, 18, 7, 525, 44, 45, 2324, 2325, "P" +475, 18, 8, 526, 46, 47, 2326, 2327, "<" +475, 18, 9, 527, 48, 49, 2328, 2329, "0" +475, 18, 10, 528, 50, 51, 2330, 2331, "." +475, 18, 11, 529, 52, 55, 2332, 2335, "001" +475, 18, 12, 530, 56, 57, 2336, 2337, ")" +475, 18, 13, 531, 58, 61, 2338, 2341, "but" +475, 18, 14, 532, 62, 65, 2342, 2345, "did" +475, 18, 15, 533, 66, 69, 2346, 2349, "not" +475, 18, 16, 534, 70, 78, 2350, 2358, "increase" +475, 18, 17, 535, 79, 84, 2359, 2364, "after" +475, 18, 18, 536, 85, 96, 2365, 2376, "brimonidine" +475, 18, 19, 537, 97, 106, 2377, 2386, "treatment" +475, 18, 20, 538, 107, 108, 2387, 2388, "(" +475, 18, 21, 539, 109, 110, 2389, 2390, "P" +475, 18, 22, 540, 111, 112, 2391, 2392, "=" +475, 18, 23, 541, 113, 114, 2393, 2394, "0" +475, 18, 24, 542, 115, 116, 2395, 2396, "." +475, 18, 25, 543, 117, 120, 2397, 2400, "355" +475, 18, 26, 544, 121, 122, 2401, 2402, ")" +475, 18, 27, 545, 123, 124, 2403, 2404, "." +475, 19, 1, 546, 0, 5, 2405, 2410, "There" +475, 19, 2, 547, 6, 9, 2411, 2414, "was" +475, 19, 3, 548, 10, 12, 2415, 2417, "no" +475, 19, 4, 549, 13, 24, 2418, 2429, "significant" +475, 19, 5, 550, 25, 31, 2430, 2436, "change" +475, 19, 6, 551, 32, 34, 2437, 2439, "in" +475, 19, 7, 552, 35, 40, 2440, 2445, "pulse" +475, 19, 8, 553, 41, 45, 2446, 2450, "rate" +475, 19, 9, 554, 46, 48, 2451, 2453, "or" +475, 19, 10, 555, 49, 54, 2454, 2459, "blood" +475, 19, 11, 556, 55, 63, 2460, 2468, "pressure" +475, 19, 12, 557, 64, 65, 2469, 2470, "." +475, 20, 1, 558, 0, 11, 2471, 2482, "CONCLUSIONS" +475, 20, 2, 559, 12, 13, 2483, 2484, ":" +475, 20, 3, 560, 14, 18, 2485, 2489, "Both" +475, 20, 4, 561, 19, 30, 2490, 2501, "latanoprost" +475, 20, 5, 562, 31, 34, 2502, 2505, "and" +475, 20, 6, 563, 35, 46, 2506, 2517, "brimonidine" +475, 20, 7, 564, 47, 53, 2518, 2524, "reduce" +475, 20, 8, 565, 54, 57, 2525, 2528, "IOP" +475, 20, 9, 566, 58, 60, 2529, 2531, "in" +475, 20, 10, 567, 61, 64, 2532, 2535, "NTG" +475, 20, 11, 568, 65, 73, 2536, 2544, "patients" +475, 20, 12, 569, 74, 75, 2545, 2546, "." +475, 21, 1, 570, 0, 11, 2547, 2558, "Brimonidine" +475, 21, 2, 571, 12, 15, 2559, 2562, "has" +475, 21, 3, 572, 16, 17, 2563, 2564, "a" +475, 21, 4, 573, 18, 22, 2565, 2569, "peak" +475, 21, 5, 574, 23, 26, 2570, 2573, "IOP" +475, 21, 6, 575, 27, 28, 2574, 2575, "-" +475, 21, 7, 576, 29, 37, 2576, 2584, "lowering" +475, 21, 8, 577, 38, 44, 2585, 2591, "effect" +475, 21, 9, 578, 45, 50, 2592, 2597, "equal" +475, 21, 10, 579, 51, 53, 2598, 2600, "to" +475, 21, 11, 580, 54, 58, 2601, 2605, "that" +475, 21, 12, 581, 59, 61, 2606, 2608, "of" +475, 21, 13, 582, 62, 73, 2609, 2620, "latanoprost" +475, 21, 14, 583, 74, 77, 2621, 2624, "but" +475, 21, 15, 584, 78, 86, 2625, 2633, "produces" +475, 21, 16, 585, 87, 88, 2634, 2635, "a" +475, 21, 17, 586, 89, 95, 2636, 2642, "higher" +475, 21, 18, 587, 96, 100, 2643, 2647, "mean" +475, 21, 19, 588, 101, 108, 2648, 2655, "diurnal" +475, 21, 20, 589, 109, 112, 2656, 2659, "IOP" +475, 21, 21, 590, 113, 117, 2660, 2664, "than" +475, 21, 22, 591, 118, 122, 2665, 2669, "does" +475, 21, 23, 592, 123, 134, 2670, 2681, "latanoprost" +475, 21, 24, 593, 135, 142, 2682, 2689, "because" +475, 21, 25, 594, 143, 145, 2690, 2692, "of" +475, 21, 26, 595, 146, 149, 2693, 2696, "its" +475, 21, 27, 596, 150, 157, 2697, 2704, "shorter" +475, 21, 28, 597, 158, 164, 2705, 2711, "effect" +475, 21, 29, 598, 165, 166, 2712, 2713, "." +475, 22, 1, 599, 0, 11, 2714, 2725, "Latanoprost" +475, 22, 2, 600, 12, 17, 2726, 2731, "might" +475, 22, 3, 601, 18, 27, 2732, 2741, "favorably" +475, 22, 4, 602, 28, 33, 2742, 2747, "alter" +475, 22, 5, 603, 34, 39, 2748, 2753, "optic" +475, 22, 6, 604, 40, 44, 2754, 2758, "disc" +475, 22, 7, 605, 45, 50, 2759, 2764, "blood" +475, 22, 8, 606, 51, 60, 2765, 2774, "perfusion" +475, 22, 9, 607, 61, 63, 2775, 2777, "by" +475, 22, 10, 608, 64, 74, 2778, 2788, "increasing" +475, 22, 11, 609, 75, 78, 2789, 2792, "OPP" +475, 22, 12, 610, 79, 80, 2793, 2794, "." +475, 23, 1, 611, 0, 4, 2795, 2799, "PMID" +475, 23, 2, 612, 5, 6, 2800, 2801, ":" +475, 23, 3, 613, 7, 15, 2802, 2810, "12466165" +475, 23, 4, 614, 16, 17, 2811, 2812, "[" +475, 23, 5, 615, 18, 25, 2813, 2820, "Indexed" +475, 23, 6, 616, 26, 29, 2821, 2824, "for" +475, 23, 7, 617, 30, 37, 2825, 2832, "MEDLINE" +475, 23, 8, 618, 38, 39, 2833, 2834, "]" diff --git a/data/gl 12466165_jshahinitiran.annodb b/data/gl 12466165_jshahinitiran.annodb new file mode 100644 index 0000000..efa2c19 --- /dev/null +++ b/data/gl 12466165_jshahinitiran.annodb @@ -0,0 +1,135 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +6871, Journal, 0, 13, "Ophthalmology", "", +6872, PublicationYear, 16, 20, "2002", "", +6873, Title, 51, 210, "Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0 . 005 % or brimonidine tartrate 0 . 2 % in normal - tension glaucoma patients", "", +6874, IOP, 62, 82, "intraocular pressure", "", +26244, Latanoprost, 119, 130, "latanoprost", "", +26268, DoseValue, 131, 138, "0 . 005", "", +26272, Percentage, 139, 140, "%", "", +26257, Brimonidine, 144, 164, "brimonidine tartrate", "", +26269, DoseValue, 165, 170, "0 . 2", "", +26273, Percentage, 171, 172, "%", "", +39040, NormalTensionGlaucoma, 176, 201, "normal - tension glaucoma", "", +6884, Author, 213, 219, "Liu CJ", "", +6885, Author, 228, 233, "Ko YC", "", +6886, Author, 236, 244, "Cheng CY", "", +6887, Author, 247, 254, "Chiu AW", "", +6888, Author, 257, 264, "Chou JC", "", +6889, Author, 267, 273, "Hsu WM", "", +6890, Author, 276, 282, "Liu JH", "", +6891, Taiwan, 386, 392, "Taiwan", "", +6892, ObjectiveDescription, 407, 576, "To evaluate and compare the effects of latanoprost 0 . 005 % once daily and brimonidine tartrate 0 . 2 % twice daily in patients with normal - tension glaucoma ( NTG ) .", "", +26245, Latanoprost, 446, 457, "latanoprost", "", +26270, DoseValue, 458, 465, "0 . 005", "", +26282, Percentage, 466, 467, "%", "", +6896, Frequency, 468, 478, "once daily", "", +26258, Brimonidine, 483, 503, "brimonidine tartrate", "", +26271, DoseValue, 504, 509, "0 . 2", "", +26283, Percentage, 510, 511, "%", "", +6900, Frequency, 512, 523, "twice daily", "", +39041, NormalTensionGlaucoma, 541, 566, "normal - tension glaucoma", "", +39042, NormalTensionGlaucoma, 569, 572, "NTG", "", +26284, Randomized, 588, 598, "randomized", "", +6905, OpenLabel, 601, 613, "open - label", "", +6906, Crossover, 616, 625, "crossover", "", +6907, NumberPatientsCT, 649, 663, "Twenty - eight", "", +39043, NormalTensionGlaucoma, 664, 667, "NTG", "", +6909, Precondition, 682, 738, "progressive visual field defects / optic disc excavation", "", +6910, Precondition, 741, 760, "new disc hemorrhage", "", +6911, Precondition, 766, 804, "field defects that threatened fixation", "", +26285, Randomized, 836, 844, "randomly", "", +26246, Latanoprost, 916, 927, "latanoprost", "", +26259, Brimonidine, 946, 957, "brimonidine", "", +6921, Duration, 962, 969, "4 weeks", "intervention", +26260, Brimonidine, 1023, 1034, "brimonidine", "", +26247, Latanoprost, 1053, 1064, "latanoprost", "", +6922, Duration, 1069, 1076, "4 weeks", "intervention", +6914, IOP, 1108, 1128, "Intraocular pressure", "", +6915, IOP, 1131, 1134, "IOP", "", +6916, PulseRate, 1139, 1149, "pulse rate", "", +6917, BloodPressure, 1156, 1170, "blood pressure", "", +6923, Duration, 1225, 1233, "4 - week", "intervention", +26248, Latanoprost, 1307, 1318, "Latanoprost", "", +26261, Brimonidine, 1323, 1334, "brimonidine", "", +6929, IOP, 1355, 1358, "IOP", "", +6930, Reduction, 1362, 1367, "3 . 6", "", +6931, SdErrorChangeValue, 1374, 1379, "1 . 9", "", +6932, mmHg, 1380, 1384, "mmHg", "", +6933, PValueChangeValue, 1387, 1398, "P < 0 . 001", "", +6934, Reduction, 1405, 1410, "2 . 5", "", +6935, SdErrorChangeValue, 1417, 1422, "1 . 3", "", +6936, mmHg, 1423, 1427, "mmHg", "", +6937, PValueChangeValue, 1430, 1441, "P < 0 . 001", "", +6938, PvalueDiff, 1518, 1529, "P = 0 . 009", "", +6939, IOP, 1567, 1570, "IOP", "", +26249, Latanoprost, 1592, 1603, "Latanoprost", "", +6941, IOP, 1614, 1617, "IOP", "", +26262, Brimonidine, 1646, 1657, "brimonidine", "", +6944, TimePoint, 1661, 1665, "8 am", "", +6947, Reduction, 1668, 1674, "11 . 7", "", +6953, SdErrorChangeValue, 1681, 1686, "2 . 2", "", +6959, mmHg, 1687, 1691, "mmHg", "", +6948, Reduction, 1697, 1703, "13 . 7", "", +6954, SdErrorChangeValue, 1710, 1715, "2 . 1", "", +6960, mmHg, 1716, 1720, "mmHg", "", +6965, PValueChangeValue, 1723, 1734, "P = 0 . 004", "", +6945, TimePoint, 1741, 1745, "4 pm", "", +6949, Reduction, 1748, 1754, "11 . 4", "", +6955, SdErrorChangeValue, 1761, 1766, "2 . 1", "", +6961, mmHg, 1767, 1771, "mmHg", "", +6950, Reduction, 1777, 1783, "13 . 2", "", +6956, SdErrorChangeValue, 1790, 1795, "2 . 9", "", +6962, mmHg, 1796, 1800, "mmHg", "", +6966, PValueChangeValue, 1803, 1814, "P = 0 . 004", "", +6943, IOP, 1823, 1826, "IOP", "", +6946, TimePoint, 1863, 1870, "12 noon", "", +6951, Reduction, 1873, 1879, "11 . 5", "", +6957, SdErrorChangeValue, 1886, 1891, "2 . 6", "", +6963, mmHg, 1892, 1896, "mmHg", "", +6952, Reduction, 1902, 1908, "11 . 5", "", +6958, SdErrorChangeValue, 1915, 1920, "2 . 3", "", +6964, mmHg, 1921, 1925, "mmHg", "", +6967, PValueChangeValue, 1928, 1939, "P = 0 . 967", "", +6968, IOP, 1944, 1947, "IOP", "", +10378, EndPointDescription, 1944, 1982, "IOP was maintained at 12 mmHg or lower", "", +6969, mmHg, 1969, 1973, "mmHg", "", +6970, NumberAffected, 1986, 1988, "18", "", +6971, PercentageAffected, 1991, 1997, "66 . 7", "", +6973, NumberPatientsArm, 2005, 2007, "27", "", +26250, Latanoprost, 2038, 2049, "latanoprost", "", +6975, NumberAffected, 2057, 2058, "9", "", +6976, PercentageAffected, 2061, 2067, "33 . 3", "", +6977, NumberPatientsArm, 2075, 2077, "27", "", +26263, Brimonidine, 2108, 2119, "brimonidine", "", +26251, Latanoprost, 2122, 2133, "Latanoprost", "", +6980, IOP, 2154, 2157, "IOP", "", +6981, RelativeReduction, 2161, 2163, "30", "", +6982, NumberAffected, 2169, 2170, "8", "", +6983, PercentageAffected, 2182, 2188, "29 . 6", "", +26264, Brimonidine, 2199, 2210, "brimonidine", "", +6985, IOP, 2238, 2241, "IOP", "", +6991, ObservedResult, 2280, 2404, "OPP increased after latanoprost treatment ( P < 0 . 001 ) but did not increase after brimonidine treatment ( P = 0 . 355 ) .", "", +10379, EndPointDescription, 2280, 2283, "OPP", "", +26252, Latanoprost, 2300, 2311, "latanoprost", "", +6988, PValueChangeValue, 2324, 2335, "P < 0 . 001", "", +26265, Brimonidine, 2365, 2376, "brimonidine", "", +6990, PValueChangeValue, 2389, 2400, "P = 0 . 355", "", +6992, ObservedResult, 2405, 2468, "There was no significant change in pulse rate or blood pressure", "", +10381, PulseRate, 2440, 2450, "pulse rate", "", +10382, BloodPressure, 2451, 2468, "or blood pressure", "", +6993, ConclusionComment, 2485, 2546, "Both latanoprost and brimonidine reduce IOP in NTG patients .", "", +26253, Latanoprost, 2490, 2501, "latanoprost", "", +26266, Brimonidine, 2506, 2517, "brimonidine", "", +6999, IOP, 2525, 2528, "IOP", "", +39044, NormalTensionGlaucoma, 2532, 2535, "NTG", "", +6994, ConclusionComment, 2547, 2713, "Brimonidine has a peak IOP - lowering effect equal to that of latanoprost but produces a higher mean diurnal IOP than does latanoprost because of its shorter effect .", "", +26267, Brimonidine, 2547, 2558, "Brimonidine", "", +7002, Peak_IOP, 2565, 2573, "peak IOP", "", +26254, Latanoprost, 2609, 2620, "latanoprost", "", +7004, Mean, 2643, 2647, "mean", "", +7005, Diurnal_IOP, 2648, 2659, "diurnal IOP", "", +26255, Latanoprost, 2670, 2681, "latanoprost", "", +6995, ConclusionComment, 2714, 2794, "Latanoprost might favorably alter optic disc blood perfusion by increasing OPP .", "", +26256, Latanoprost, 2714, 2725, "Latanoprost", "", +10380, EndPointDescription, 2789, 2792, "OPP", "", +6996, PMID, 2802, 2810, "12466165", "", diff --git a/data/gl 12466165_jshahinitiran.n-triples b/data/gl 12466165_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12466165_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12466165_tstrakeljahn.annodb b/data/gl 12466165_tstrakeljahn.annodb new file mode 100644 index 0000000..299ce41 --- /dev/null +++ b/data/gl 12466165_tstrakeljahn.annodb @@ -0,0 +1,124 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +78846, Journal, 0, 13, "Ophthalmology", "", +78847, PublicationYear, 16, 20, "2002", "", +78859, Title, 51, 212, "Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0 . 005 % or brimonidine tartrate 0 . 2 % in normal - tension glaucoma patients .", "", +78848, IOP, 62, 82, "intraocular pressure", "", +78849, Latanoprost, 119, 130, "latanoprost", "", +78850, Brimonidine, 144, 164, "brimonidine tartrate", "", +78851, NormalTensionGlaucoma, 176, 201, "normal - tension glaucoma", "", +78852, Author, 213, 219, "Liu CJ", "", +78853, Author, 228, 233, "Ko YC", "", +78854, Author, 236, 244, "Cheng CY", "", +78855, Author, 247, 254, "Chiu AW", "", +78856, Author, 257, 264, "Chou JC", "", +78857, Author, 267, 273, "Hsu WM", "", +78858, Author, 276, 282, "Liu JH", "", +78860, Taiwan, 386, 392, "Taiwan", "", +78869, ObjectiveDescription, 407, 576, "To evaluate and compare the effects of latanoprost 0 . 005 % once daily and brimonidine tartrate 0 . 2 % twice daily in patients with normal - tension glaucoma ( NTG ) .", "", +78861, Latanoprost, 446, 457, "latanoprost", "", +78865, DoseValue, 458, 465, "0 . 005", "", +78867, Percentage, 466, 467, "%", "", +78862, Brimonidine, 483, 503, "brimonidine tartrate", "", +78866, DoseValue, 504, 509, "0 . 2", "", +78868, Percentage, 510, 511, "%", "", +78863, NormalTensionGlaucoma, 541, 566, "normal - tension glaucoma", "", +78864, NormalTensionGlaucoma, 569, 572, "NTG", "", +78870, Randomized, 588, 598, "randomized", "", +78871, OpenLabel, 601, 613, "open - label", "", +78872, Crossover, 616, 625, "crossover", "", +78873, NumberPatientsCT, 649, 663, "Twenty - eight", "", +78874, NormalTensionGlaucoma, 664, 667, "NTG", "", +78875, Precondition, 677, 804, "with progressive visual field defects / optic disc excavation , new disc hemorrhage , or field defects that threatened fixation", "", +78876, Latanoprost, 916, 927, "latanoprost", "", +78877, Drug, 930, 939, "lubricant", "", +78878, Brimonidine, 946, 957, "brimonidine", "", +78879, Brimonidine, 1023, 1034, "brimonidine", "", +78880, Drug, 1037, 1046, "lubricant", "", +78881, Latanoprost, 1053, 1064, "latanoprost", "", +78882, IOP, 1108, 1128, "Intraocular pressure", "", +78883, IOP, 1131, 1134, "IOP", "", +78884, PulseRate, 1139, 1149, "pulse rate", "", +78885, BloodPressure, 1156, 1170, "blood pressure", "", +78886, RelativeTime, 1188, 1192, "8 am", "", +78887, RelativeTime, 1195, 1202, "12 noon", "", +78888, RelativeTime, 1209, 1213, "4 pm", "", +78889, TimePoint, 1214, 1243, "after each 4 - week treatment", "", +78890, Latanoprost, 1307, 1318, "Latanoprost", "", +78891, Brimonidine, 1323, 1334, "brimonidine", "", +78892, IOP, 1355, 1358, "IOP", "", +78893, Reduction, 1362, 1367, "3 . 6", "", +78895, SdDevChangeValue, 1374, 1379, "1 . 9", "", +78899, mmHg, 1380, 1384, "mmHg", "", +78897, PValueChangeValue, 1389, 1398, "< 0 . 001", "", +78894, Reduction, 1405, 1410, "2 . 5", "", +78896, SdDevChangeValue, 1417, 1422, "1 . 3", "", +78900, mmHg, 1423, 1427, "mmHg", "", +78898, PValueChangeValue, 1432, 1441, "< 0 . 001", "", +78901, PvalueDiff, 1520, 1529, "= 0 . 009", "", +78902, ObservedResult, 1534, 1591, "Both drugs significantly reduced IOP at each time point .", "", +78903, Latanoprost, 1592, 1603, "Latanoprost", "", +78904, IOP, 1614, 1617, "IOP", "", +78905, Brimonidine, 1646, 1657, "brimonidine", "", +78906, Morning, 1661, 1665, "8 am", "", +78909, Reduction, 1668, 1674, "11 . 7", "", +78915, SdDevChangeValue, 1681, 1686, "2 . 2", "", +78921, mmHg, 1687, 1691, "mmHg", "", +78910, Reduction, 1697, 1703, "13 . 7", "", +78916, SdDevChangeValue, 1710, 1715, "2 . 1", "", +78922, mmHg, 1716, 1720, "mmHg", "", +78926, PvalueDiff, 1725, 1734, "= 0 . 004", "", +78907, Afternoon, 1741, 1745, "4 pm", "", +78911, Reduction, 1748, 1754, "11 . 4", "", +78917, SdDevChangeValue, 1761, 1766, "2 . 1", "", +78923, mmHg, 1767, 1771, "mmHg", "", +78912, Reduction, 1777, 1783, "13 . 2", "", +78918, SdDevChangeValue, 1790, 1795, "2 . 9", "", +78924, mmHg, 1796, 1800, "mmHg", "", +78927, PvalueDiff, 1805, 1814, "= 0 . 004", "", +78928, IOP, 1823, 1826, "IOP", "", +78908, RelativeTime, 1863, 1870, "12 noon", "", +78913, Reduction, 1873, 1879, "11 . 5", "", +78919, SdDevChangeValue, 1886, 1891, "2 . 6", "", +78925, mmHg, 1892, 1896, "mmHg", "", +78914, Reduction, 1902, 1908, "11 . 5", "", +78920, SdDevChangeValue, 1915, 1920, "2 . 3", "", +78929, IOP, 1921, 1925, "mmHg", "", +78930, PvalueDiff, 1930, 1939, "= 0 . 967", "", +78931, IOP, 1944, 1947, "IOP", "", +78933, SubGroupDescription, 1944, 1982, "IOP was maintained at 12 mmHg or lower", "", +78932, mmHg, 1969, 1973, "mmHg", "", +78937, NumberAffected, 1986, 1988, "18", "", +78934, PercentageAffected, 1991, 1997, "66 . 7", "", +78939, FinalNumPatientsCT, 2005, 2007, "27", "", +78935, Latanoprost, 2038, 2049, "latanoprost", "", +78938, NumberAffected, 2057, 2058, "9", "", +78936, PercentageAffected, 2061, 2067, "33 . 3", "", +78940, FinalNumPatientsCT, 2075, 2077, "27", "", +78941, Brimonidine, 2108, 2119, "brimonidine", "", +78942, Latanoprost, 2122, 2133, "Latanoprost", "", +78944, SubGroupDescription, 2146, 2163, "reduced IOP by 30", "", +78943, IOP, 2154, 2157, "IOP", "", +78945, NumberAffected, 2169, 2170, "8", "", +78946, PercentageAffected, 2182, 2188, "29 . 6", "", +78947, Brimonidine, 2199, 2210, "brimonidine", "", +78948, IOP, 2238, 2241, "IOP", "", +78949, Latanoprost, 2300, 2311, "latanoprost", "", +78950, Brimonidine, 2365, 2376, "brimonidine", "", +79112, ObservedResult, 2405, 2470, "There was no significant change in pulse rate or blood pressure .", "", +79110, PulseRate, 2440, 2450, "pulse rate", "", +79111, BloodPressure, 2454, 2468, "blood pressure", "", +79117, ConclusionComment, 2485, 2546, "Both latanoprost and brimonidine reduce IOP in NTG patients .", "", +79113, Latanoprost, 2490, 2501, "latanoprost", "", +79114, Brimonidine, 2506, 2517, "brimonidine", "", +79115, IOP, 2525, 2528, "IOP", "", +79116, NormalTensionGlaucoma, 2532, 2535, "NTG", "", +79118, Brimonidine, 2547, 2558, "Brimonidine", "", +79126, ConclusionComment, 2547, 2713, "Brimonidine has a peak IOP - lowering effect equal to that of latanoprost but produces a higher mean diurnal IOP than does latanoprost because of its shorter effect .", "", +79119, Peak_IOP, 2565, 2573, "peak IOP", "", +79120, Latanoprost, 2609, 2620, "latanoprost", "", +79121, Mean, 2643, 2647, "mean", "", +79123, Diurnal_IOP, 2648, 2659, "diurnal IOP", "", +79124, Latanoprost, 2670, 2681, "latanoprost", "", +79127, Latanoprost, 2714, 2725, "Latanoprost", "", +79128, ConclusionComment, 2714, 2794, "Latanoprost might favorably alter optic disc blood perfusion by increasing OPP .", "", +79129, PMID, 2802, 2810, "12466165", "", diff --git a/data/gl 12466165_tstrakeljahn.n-triples b/data/gl 12466165_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12466165_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12470755 copy_admin.annodb b/data/gl 12470755 copy_admin.annodb new file mode 100644 index 0000000..1786244 --- /dev/null +++ b/data/gl 12470755 copy_admin.annodb @@ -0,0 +1,98 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Am J Ophthalmol .", "", " \"Am J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2002", "", " \"2002\"." +3, Randomized, 52, 62, "Randomized", "", " ." +2, Title, 52, 157, "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure .", "", " \"Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure .\"." +4, Latanoprost, 81, 92, "latanoprost", "", +5, Unoprostone, 97, 108, "unoprostone", "", +6, IOP, 135, 155, "intraocular pressure", "", +7, Author, 158, 167, "Jampel HD", "", " \"Jampel HD\"." +8, Author, 176, 187, "Bacharach J", "", " \"Bacharach J\"." +9, Author, 190, 197, "Sheu WP", "", " \"Sheu WP\"." +10, Author, 200, 207, "Wohl LG", "", " \"Wohl LG\"." +11, Author, 210, 219, "Solish AM", "", " \"Solish AM\"." +12, Author, 222, 232, "Christie W", "", " \"Christie W\"." +86, Latanoprost, 235, 246, "Latanoprost", "", +87, Unoprostone, 249, 260, "Unoprostone", "", +52, USA, 418, 421, "USA", "", +13, ObjectiveDescription, 455, 682, "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .", "", " \"To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .\"." +14, IOP, 470, 490, "intraocular pressure", "", +15, IOP, 493, 496, "IOP", "", +54, Latanoprost, 531, 542, "latanoprost", "", +56, DoseValue, 543, 550, "0 . 005", "", +59, Percentage, 551, 552, "%", "", +60, Frequency, 553, 563, "once daily", "", +55, Unoprostone, 577, 588, "unoprostone", "", +57, DoseValue, 589, 595, "0 . 15", "", +58, Percentage, 596, 597, "%", "", +61, Frequency, 598, 609, "twice daily", "", +89, Primary_OpenAngleGlaucoma, 628, 657, "primary open - angle glaucoma", "", " ." +16, OcularHypertension, 661, 680, "ocular hypertension", "", " ." +62, Randomized, 692, 702, "Randomized", "", +41657, Prospective, 735, 746, "prospective", "", " ." +63, Duration, 749, 757, "8 - week", "", " \"8 - week\"." +18, Blind, 760, 781, "investigator - masked", "", " ." +19, Parallel, 784, 792, "parallel", "", " ." +20, Multicenter, 820, 836, "numerous centers", "", " ." +53, USA, 844, 857, "United States", "", " ." +21, NumberPatientsCT, 860, 863, "165", "", " \"165\"." +22, Precondition, 864, 950, "previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout", "", " \"previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout\"." +64, mmHg, 911, 916, "mm Hg", "", +65, Randomized, 956, 964, "randomly", "", +66, Latanoprost, 992, 1003, "latanoprost", "", " . ." +68, DoseValue, 1004, 1011, "0 . 005", "", " \"0 . 005\"." +70, Percentage, 1012, 1013, "%", "", " ." +72, Frequency, 1014, 1024, "once daily", "", " \"once daily\"." +23, Bedtime, 1032, 1039, "evening", "", " ." +67, Unoprostone, 1043, 1054, "unoprostone", "", " ." +69, DoseValue, 1055, 1061, "0 . 15", "", " \"0 . 15\"." +71, Percentage, 1062, 1063, "%", "", " ." +73, Frequency, 1064, 1075, "twice daily", "", " \"twice daily\"." +88, Mean, 1263, 1267, "mean", "", +24, IOP, 1275, 1279, "IOPs", "", +181, TimePoint, 1336, 1344, "baseline", "", +182, TimePoint, 1376, 1383, "8 weeks", "", +74, Mean, 1427, 1431, "mean", "", " . ." +46, IOP, 1448, 1452, "IOPs", "", " . ." +25, Reduction, 1507, 1512, "7 . 2", "", " \"7 . 2\"." +26, SdDevChangeValue, 1519, 1524, "3 . 2", "", " \"3 . 2\"." +27, mmHg, 1525, 1530, "mm Hg", "", " ." +28, RelativeReduction, 1533, 1535, "28", "", " \"28\"." +75, Latanoprost, 1544, 1555, "latanoprost", "", +29, BaseLineValue, 1558, 1564, "25 . 3", "", " \"25 . 3\"." +30, SdDevBL, 1571, 1576, "2 . 8", "", " \"2 . 8\"." +31, mmHg, 1577, 1582, "mm Hg", "", +183, TimePoint, 1586, 1594, "baseline", "", +32, ResultMeasuredValue, 1598, 1604, "18 . 2", "", " \"18 . 2\"." +33, SdDevResValue, 1611, 1616, "2 . 8", "", " \"2 . 8\"." +34, mmHg, 1617, 1622, "mm Hg", "", +161, TimePoint, 1626, 1633, "8 weeks", "", " \"8 weeks\"." +35, Reduction, 1642, 1647, "3 . 9", "", " \"3 . 9\"." +36, SdDevChangeValue, 1654, 1659, "2 . 6", "", " \"2 . 6\"." +37, mmHg, 1660, 1665, "mm Hg", "", +38, RelativeReduction, 1668, 1670, "15", "", " \"15\"." +76, Unoprostone, 1679, 1690, "unoprostone", "", +39, BaseLineValue, 1693, 1699, "25 . 5", "", " \"25 . 5\"." +40, SdDevBL, 1706, 1711, "3 . 3", "", " \"3 . 3\"." +41, mmHg, 1712, 1717, "mm Hg", "", +41687, TimePoint, 1721, 1729, "baseline", "", +42, ResultMeasuredValue, 1733, 1739, "21 . 6", "", " \"21 . 6\"." +43, SdDevResValue, 1746, 1751, "4 . 0", "", " \"4 . 0\"." +44, mmHg, 1752, 1757, "mm Hg", "", +163, PvalueDiff, 1760, 1774, "P < or = . 001", "", " \"P < or = . 001\"." +164, ObservedResult, 1777, 1843, "No serious adverse event related to either medication was reported", "", " \"No serious adverse event related to either medication was reported\". \"No serious adverse event related to either medication was reported\"." +41709, EndPointDescription, 1788, 1801, "adverse event", "", " . ." +47, ConclusionComment, 1860, 2005, "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .", "", " \"Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .\"." +77, Duration, 1868, 1876, "8 - week", "", +78, Latanoprost, 1886, 1897, "latanoprost", "", +80, DoseValue, 1898, 1905, "0 . 005", "", +82, Percentage, 1906, 1907, "%", "", +84, Frequency, 1908, 1918, "once daily", "", +49, IOP, 1927, 1930, "IOP", "", +79, Unoprostone, 1941, 1952, "unoprostone", "", +81, DoseValue, 1953, 1959, "0 . 15", "", +83, Percentage, 1960, 1961, "%", "", +85, Frequency, 1962, 1973, "twice daily", "", +50, IOP, 2000, 2003, "IOP", "", +48, ConclusionComment, 2006, 2048, "Both agents were safe and well tolerated .", "", " \"Both agents were safe and well tolerated .\"." +51, PMID, 2104, 2112, "12470755", "", " \"12470755\"." diff --git a/data/gl 12470755 copy_admin.n-triples b/data/gl 12470755 copy_admin.n-triples new file mode 100644 index 0000000..4ca1dad --- /dev/null +++ b/data/gl 12470755 copy_admin.n-triples @@ -0,0 +1,132 @@ +# RDF export of group: Publication + . + "Publication 103776" . + "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure ." . + "Jampel HD" . + "2002" . + "Am J Ophthalmol ." . + "12470755" . + . + "Bacharach J" . + "Sheu WP" . + "Wohl LG" . + "Solish AM" . + "Christie W" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 106988" . + "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension ." . + "165" . + "8 - week" . + . + . + . + "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP ." . + . + . + . + . + . + . + . + "Both agents were safe and well tolerated ." . + . + . + . + . +# RDF export of group: Population + . + "Population 107004" . + "previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "lat" . + . + . + . + . + "uno" . + . + . + . +# RDF export of group: Intervention + . + "lat" . + . + "once daily" . + . + . + "uno" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "lat" . + . + . + "0 . 005" . + . + . + . + "uno" . + . + "0 . 15" . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "25 . 3" . + "2 . 8" . + "18 . 2" . + "2 . 8" . + "7 . 2" . + "28" . + "3 . 2" . + "8 weeks" . + . + "iop2" . + . + "25 . 5" . + "3 . 3" . + "21 . 6" . + "4 . 0" . + "3 . 9" . + "15" . + "2 . 6" . + . + "ae1" . + . + "No serious adverse event related to either medication was reported" . + . + "ae2" . + . + "No serious adverse event related to either medication was reported" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "P < or = . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12470755 copy_export.csv b/data/gl 12470755 copy_export.csv new file mode 100644 index 0000000..2f129ef --- /dev/null +++ b/data/gl 12470755 copy_export.csv @@ -0,0 +1,478 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +833, 1, 1, 1, 0, 2, 0, 2, "Am" +833, 1, 2, 2, 3, 4, 3, 4, "J" +833, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +833, 1, 4, 4, 16, 17, 16, 17, "." +833, 2, 1, 5, 0, 4, 18, 22, "2002" +833, 2, 2, 6, 5, 8, 23, 26, "Dec" +833, 2, 3, 7, 9, 10, 27, 28, ";" +833, 2, 4, 8, 11, 14, 29, 32, "134" +833, 2, 5, 9, 15, 16, 33, 34, "(" +833, 2, 6, 10, 17, 18, 35, 36, "6" +833, 2, 7, 11, 19, 20, 37, 38, ")" +833, 2, 8, 12, 21, 22, 39, 40, ":" +833, 2, 9, 13, 23, 26, 41, 44, "863" +833, 2, 10, 14, 27, 28, 45, 46, "-" +833, 2, 11, 15, 29, 31, 47, 49, "71" +833, 2, 12, 16, 32, 33, 50, 51, "." +833, 3, 1, 17, 0, 10, 52, 62, "Randomized" +833, 3, 2, 18, 11, 19, 63, 71, "clinical" +833, 3, 3, 19, 20, 25, 72, 77, "trial" +833, 3, 4, 20, 26, 28, 78, 80, "of" +833, 3, 5, 21, 29, 40, 81, 92, "latanoprost" +833, 3, 6, 22, 41, 44, 93, 96, "and" +833, 3, 7, 23, 45, 56, 97, 108, "unoprostone" +833, 3, 8, 24, 57, 59, 109, 111, "in" +833, 3, 9, 25, 60, 68, 112, 120, "patients" +833, 3, 10, 26, 69, 73, 121, 125, "with" +833, 3, 11, 27, 74, 82, 126, 134, "elevated" +833, 3, 12, 28, 83, 94, 135, 146, "intraocular" +833, 3, 13, 29, 95, 103, 147, 155, "pressure" +833, 3, 14, 30, 104, 105, 156, 157, "." +833, 4, 1, 31, 0, 6, 158, 164, "Jampel" +833, 4, 2, 32, 7, 9, 165, 167, "HD" +833, 4, 3, 33, 10, 11, 168, 169, "(" +833, 4, 4, 34, 12, 13, 170, 171, "1" +833, 4, 5, 35, 14, 15, 172, 173, ")" +833, 4, 6, 36, 16, 17, 174, 175, "," +833, 4, 7, 37, 18, 27, 176, 185, "Bacharach" +833, 4, 8, 38, 28, 29, 186, 187, "J" +833, 4, 9, 39, 30, 31, 188, 189, "," +833, 4, 10, 40, 32, 36, 190, 194, "Sheu" +833, 4, 11, 41, 37, 39, 195, 197, "WP" +833, 4, 12, 42, 40, 41, 198, 199, "," +833, 4, 13, 43, 42, 46, 200, 204, "Wohl" +833, 4, 14, 44, 47, 49, 205, 207, "LG" +833, 4, 15, 45, 50, 51, 208, 209, "," +833, 4, 16, 46, 52, 58, 210, 216, "Solish" +833, 4, 17, 47, 59, 61, 217, 219, "AM" +833, 4, 18, 48, 62, 63, 220, 221, "," +833, 4, 19, 49, 64, 72, 222, 230, "Christie" +833, 4, 20, 50, 73, 74, 231, 232, "W" +833, 4, 21, 51, 75, 76, 233, 234, ";" +833, 4, 22, 52, 77, 88, 235, 246, "Latanoprost" +833, 4, 23, 53, 89, 90, 247, 248, "/" +833, 4, 24, 54, 91, 102, 249, 260, "Unoprostone" +833, 4, 25, 55, 103, 108, 261, 266, "Study" +833, 4, 26, 56, 109, 114, 267, 272, "Group" +833, 4, 27, 57, 115, 116, 273, 274, "." +833, 5, 1, 58, 0, 6, 275, 281, "Author" +833, 5, 2, 59, 7, 18, 282, 293, "information" +833, 5, 3, 60, 19, 20, 294, 295, ":" +833, 5, 4, 61, 21, 22, 296, 297, "(" +833, 5, 5, 62, 23, 24, 298, 299, "1" +833, 5, 6, 63, 25, 26, 300, 301, ")" +833, 5, 7, 64, 27, 37, 302, 312, "Department" +833, 5, 8, 65, 38, 40, 313, 315, "of" +833, 5, 9, 66, 41, 54, 316, 329, "Ophthalmology" +833, 5, 10, 67, 55, 56, 330, 331, "," +833, 5, 11, 68, 57, 60, 332, 335, "The" +833, 5, 12, 69, 61, 66, 336, 341, "Johns" +833, 5, 13, 70, 67, 74, 342, 349, "Hopkins" +833, 5, 14, 71, 75, 85, 350, 360, "University" +833, 5, 15, 72, 86, 92, 361, 367, "School" +833, 5, 16, 73, 93, 95, 368, 370, "of" +833, 5, 17, 74, 96, 104, 371, 379, "Medicine" +833, 5, 18, 75, 105, 106, 380, 381, "," +833, 5, 19, 76, 107, 116, 382, 391, "Baltimore" +833, 5, 20, 77, 117, 118, 392, 393, "," +833, 5, 21, 78, 119, 127, 394, 402, "Maryland" +833, 5, 22, 79, 128, 133, 403, 408, "21287" +833, 5, 23, 80, 134, 135, 409, 410, "-" +833, 5, 24, 81, 136, 140, 411, 415, "9205" +833, 5, 25, 82, 141, 142, 416, 417, "," +833, 5, 26, 83, 143, 146, 418, 421, "USA" +833, 5, 27, 84, 147, 148, 422, 423, "." +833, 6, 1, 85, 0, 7, 424, 431, "hjampel" +833, 6, 2, 86, 8, 9, 432, 433, "@" +833, 6, 3, 87, 10, 14, 434, 438, "jhmi" +833, 6, 4, 88, 15, 16, 439, 440, "." +833, 6, 5, 89, 17, 20, 441, 444, "edu" +833, 6, 6, 90, 21, 28, 445, 452, "PURPOSE" +833, 6, 7, 91, 29, 30, 453, 454, ":" +833, 6, 8, 92, 31, 33, 455, 457, "To" +833, 6, 9, 93, 34, 41, 458, 465, "compare" +833, 6, 10, 94, 42, 45, 466, 469, "the" +833, 6, 11, 95, 46, 57, 470, 481, "intraocular" +833, 6, 12, 96, 58, 66, 482, 490, "pressure" +833, 6, 13, 97, 67, 68, 491, 492, "(" +833, 6, 14, 98, 69, 72, 493, 496, "IOP" +833, 6, 15, 99, 73, 74, 497, 498, ")" +833, 6, 16, 100, 75, 76, 499, 500, "-" +833, 6, 17, 101, 77, 85, 501, 509, "lowering" +833, 6, 18, 102, 86, 92, 510, 516, "effect" +833, 6, 19, 103, 93, 96, 517, 520, "and" +833, 6, 20, 104, 97, 103, 521, 527, "safety" +833, 6, 21, 105, 104, 106, 528, 530, "of" +833, 6, 22, 106, 107, 118, 531, 542, "latanoprost" +833, 6, 23, 107, 119, 120, 543, 544, "0" +833, 6, 24, 108, 121, 122, 545, 546, "." +833, 6, 25, 109, 123, 126, 547, 550, "005" +833, 6, 26, 110, 127, 128, 551, 552, "%" +833, 6, 27, 111, 129, 133, 553, 557, "once" +833, 6, 28, 112, 134, 139, 558, 563, "daily" +833, 6, 29, 113, 140, 144, 564, 568, "with" +833, 6, 30, 114, 145, 149, 569, 573, "that" +833, 6, 31, 115, 150, 152, 574, 576, "of" +833, 6, 32, 116, 153, 164, 577, 588, "unoprostone" +833, 6, 33, 117, 165, 166, 589, 590, "0" +833, 6, 34, 118, 167, 168, 591, 592, "." +833, 6, 35, 119, 169, 171, 593, 595, "15" +833, 6, 36, 120, 172, 173, 596, 597, "%" +833, 6, 37, 121, 174, 179, 598, 603, "twice" +833, 6, 38, 122, 180, 185, 604, 609, "daily" +833, 6, 39, 123, 186, 189, 610, 613, "for" +833, 6, 40, 124, 190, 198, 614, 622, "patients" +833, 6, 41, 125, 199, 203, 623, 627, "with" +833, 6, 42, 126, 204, 211, 628, 635, "primary" +833, 6, 43, 127, 212, 216, 636, 640, "open" +833, 6, 44, 128, 217, 218, 641, 642, "-" +833, 6, 45, 129, 219, 224, 643, 648, "angle" +833, 6, 46, 130, 225, 233, 649, 657, "glaucoma" +833, 6, 47, 131, 234, 236, 658, 660, "or" +833, 6, 48, 132, 237, 243, 661, 667, "ocular" +833, 6, 49, 133, 244, 256, 668, 680, "hypertension" +833, 6, 50, 134, 257, 258, 681, 682, "." +833, 7, 1, 135, 0, 6, 683, 689, "DESIGN" +833, 7, 2, 136, 7, 8, 690, 691, ":" +833, 7, 3, 137, 9, 19, 692, 702, "Randomized" +833, 7, 4, 138, 20, 28, 703, 711, "clinical" +833, 7, 5, 139, 29, 34, 712, 717, "trial" +833, 7, 6, 140, 35, 36, 718, 719, "." +833, 8, 1, 141, 0, 7, 720, 727, "METHODS" +833, 8, 2, 142, 8, 9, 728, 729, ":" +833, 8, 3, 143, 10, 12, 730, 732, "In" +833, 8, 4, 144, 13, 14, 733, 734, "a" +833, 8, 5, 145, 15, 26, 735, 746, "prospective" +833, 8, 6, 146, 27, 28, 747, 748, "," +833, 8, 7, 147, 29, 30, 749, 750, "8" +833, 8, 8, 148, 31, 32, 751, 752, "-" +833, 8, 9, 149, 33, 37, 753, 757, "week" +833, 8, 10, 150, 38, 39, 758, 759, "," +833, 8, 11, 151, 40, 52, 760, 772, "investigator" +833, 8, 12, 152, 53, 54, 773, 774, "-" +833, 8, 13, 153, 55, 61, 775, 781, "masked" +833, 8, 14, 154, 62, 63, 782, 783, "," +833, 8, 15, 155, 64, 72, 784, 792, "parallel" +833, 8, 16, 156, 73, 74, 793, 794, "-" +833, 8, 17, 157, 75, 80, 795, 800, "group" +833, 8, 18, 158, 81, 86, 801, 806, "study" +833, 8, 19, 159, 87, 96, 807, 816, "conducted" +833, 8, 20, 160, 97, 99, 817, 819, "at" +833, 8, 21, 161, 100, 108, 820, 828, "numerous" +833, 8, 22, 162, 109, 116, 829, 836, "centers" +833, 8, 23, 163, 117, 119, 837, 839, "in" +833, 8, 24, 164, 120, 123, 840, 843, "the" +833, 8, 25, 165, 124, 130, 844, 850, "United" +833, 8, 26, 166, 131, 137, 851, 857, "States" +833, 8, 27, 167, 138, 139, 858, 859, "," +833, 8, 28, 168, 140, 143, 860, 863, "165" +833, 8, 29, 169, 144, 154, 864, 874, "previously" +833, 8, 30, 170, 155, 162, 875, 882, "treated" +833, 8, 31, 171, 163, 171, 883, 891, "patients" +833, 8, 32, 172, 172, 176, 892, 896, "with" +833, 8, 33, 173, 177, 180, 897, 900, "IOP" +833, 8, 34, 174, 181, 182, 901, 902, ">" +833, 8, 35, 175, 183, 185, 903, 905, "or" +833, 8, 36, 176, 186, 187, 906, 907, "=" +833, 8, 37, 177, 188, 190, 908, 910, "25" +833, 8, 38, 178, 191, 193, 911, 913, "mm" +833, 8, 39, 179, 194, 196, 914, 916, "Hg" +833, 8, 40, 180, 197, 199, 917, 919, "in" +833, 8, 41, 181, 200, 203, 920, 923, "one" +833, 8, 42, 182, 204, 206, 924, 926, "or" +833, 8, 43, 183, 207, 211, 927, 931, "both" +833, 8, 44, 184, 212, 216, 932, 936, "eyes" +833, 8, 45, 185, 217, 222, 937, 942, "after" +833, 8, 46, 186, 223, 230, 943, 950, "washout" +833, 8, 47, 187, 231, 235, 951, 955, "were" +833, 8, 48, 188, 236, 244, 956, 964, "randomly" +833, 8, 49, 189, 245, 253, 965, 973, "assigned" +833, 8, 50, 190, 254, 256, 974, 976, "to" +833, 8, 51, 191, 257, 264, 977, 984, "receive" +833, 8, 52, 192, 265, 271, 985, 991, "either" +833, 8, 53, 193, 272, 283, 992, 1003, "latanoprost" +833, 8, 54, 194, 284, 285, 1004, 1005, "0" +833, 8, 55, 195, 286, 287, 1006, 1007, "." +833, 8, 56, 196, 288, 291, 1008, 1011, "005" +833, 8, 57, 197, 292, 293, 1012, 1013, "%" +833, 8, 58, 198, 294, 298, 1014, 1018, "once" +833, 8, 59, 199, 299, 304, 1019, 1024, "daily" +833, 8, 60, 200, 305, 307, 1025, 1027, "in" +833, 8, 61, 201, 308, 311, 1028, 1031, "the" +833, 8, 62, 202, 312, 319, 1032, 1039, "evening" +833, 8, 63, 203, 320, 322, 1040, 1042, "or" +833, 8, 64, 204, 323, 334, 1043, 1054, "unoprostone" +833, 8, 65, 205, 335, 336, 1055, 1056, "0" +833, 8, 66, 206, 337, 338, 1057, 1058, "." +833, 8, 67, 207, 339, 341, 1059, 1061, "15" +833, 8, 68, 208, 342, 343, 1062, 1063, "%" +833, 8, 69, 209, 344, 349, 1064, 1069, "twice" +833, 8, 70, 210, 350, 355, 1070, 1075, "daily" +833, 8, 71, 211, 356, 357, 1076, 1077, "." +833, 9, 1, 212, 0, 12, 1078, 1090, "Observations" +833, 9, 2, 213, 13, 23, 1091, 1101, "procedures" +833, 9, 3, 214, 24, 28, 1102, 1106, "were" +833, 9, 4, 215, 29, 37, 1107, 1115, "Goldmann" +833, 9, 5, 216, 38, 49, 1116, 1127, "applanation" +833, 9, 6, 217, 50, 59, 1128, 1137, "tonometry" +833, 9, 7, 218, 60, 61, 1138, 1139, "," +833, 9, 8, 219, 62, 66, 1140, 1144, "best" +833, 9, 9, 220, 67, 68, 1145, 1146, "-" +833, 9, 10, 221, 69, 78, 1147, 1156, "corrected" +833, 9, 11, 222, 79, 85, 1157, 1163, "visual" +833, 9, 12, 223, 86, 92, 1164, 1170, "acuity" +833, 9, 13, 224, 93, 94, 1171, 1172, "," +833, 9, 14, 225, 95, 99, 1173, 1177, "slit" +833, 9, 15, 226, 100, 104, 1178, 1182, "lamp" +833, 9, 16, 227, 105, 118, 1183, 1196, "biomicroscopy" +833, 9, 17, 228, 119, 120, 1197, 1198, "," +833, 9, 18, 229, 121, 124, 1199, 1202, "and" +833, 9, 19, 230, 125, 139, 1203, 1217, "ophthalmoscopy" +833, 9, 20, 231, 140, 141, 1218, 1219, "." +833, 10, 1, 232, 0, 3, 1220, 1223, "The" +833, 10, 2, 233, 4, 8, 1224, 1228, "main" +833, 10, 3, 234, 9, 16, 1229, 1236, "outcome" +833, 10, 4, 235, 17, 24, 1237, 1244, "measure" +833, 10, 5, 236, 25, 28, 1245, 1248, "was" +833, 10, 6, 237, 29, 35, 1249, 1255, "change" +833, 10, 7, 238, 36, 38, 1256, 1258, "in" +833, 10, 8, 239, 39, 42, 1259, 1262, "the" +833, 10, 9, 240, 43, 47, 1263, 1267, "mean" +833, 10, 10, 241, 48, 50, 1268, 1270, "of" +833, 10, 11, 242, 51, 54, 1271, 1274, "the" +833, 10, 12, 243, 55, 59, 1275, 1279, "IOPs" +833, 10, 13, 244, 60, 68, 1280, 1288, "measured" +833, 10, 14, 245, 69, 71, 1289, 1291, "at" +833, 10, 15, 246, 72, 73, 1292, 1293, "8" +833, 10, 16, 247, 74, 75, 1294, 1295, ":" +833, 10, 17, 248, 76, 78, 1296, 1298, "00" +833, 10, 18, 249, 79, 81, 1299, 1301, "AM" +833, 10, 19, 250, 82, 83, 1302, 1303, "," +833, 10, 20, 251, 84, 86, 1304, 1306, "12" +833, 10, 21, 252, 87, 91, 1307, 1311, "noon" +833, 10, 22, 253, 92, 93, 1312, 1313, "," +833, 10, 23, 254, 94, 97, 1314, 1317, "and" +833, 10, 24, 255, 98, 99, 1318, 1319, "4" +833, 10, 25, 256, 100, 101, 1320, 1321, ":" +833, 10, 26, 257, 102, 104, 1322, 1324, "00" +833, 10, 27, 258, 105, 107, 1325, 1327, "PM" +833, 10, 28, 259, 108, 115, 1328, 1335, "between" +833, 10, 29, 260, 116, 124, 1336, 1344, "baseline" +833, 10, 30, 261, 125, 126, 1345, 1346, "(" +833, 10, 31, 262, 127, 133, 1347, 1353, "before" +833, 10, 32, 263, 134, 143, 1354, 1363, "treatment" +833, 10, 33, 264, 144, 145, 1364, 1365, ")" +833, 10, 34, 265, 146, 149, 1366, 1369, "and" +833, 10, 35, 266, 150, 155, 1370, 1375, "after" +833, 10, 36, 267, 156, 157, 1376, 1377, "8" +833, 10, 37, 268, 158, 163, 1378, 1383, "weeks" +833, 10, 38, 269, 164, 166, 1384, 1386, "of" +833, 10, 39, 270, 167, 176, 1387, 1396, "treatment" +833, 10, 40, 271, 177, 178, 1397, 1398, "." +833, 11, 1, 272, 0, 7, 1399, 1406, "RESULTS" +833, 11, 2, 273, 8, 9, 1407, 1408, ":" +833, 11, 3, 274, 10, 13, 1409, 1412, "The" +833, 11, 4, 275, 14, 20, 1413, 1419, "change" +833, 11, 5, 276, 21, 23, 1420, 1422, "in" +833, 11, 6, 277, 24, 27, 1423, 1426, "the" +833, 11, 7, 278, 28, 32, 1427, 1431, "mean" +833, 11, 8, 279, 33, 34, 1432, 1433, "+" +833, 11, 9, 280, 35, 36, 1434, 1435, "/" +833, 11, 10, 281, 37, 38, 1436, 1437, "-" +833, 11, 11, 282, 39, 41, 1438, 1440, "SD" +833, 11, 12, 283, 42, 44, 1441, 1443, "of" +833, 11, 13, 284, 45, 48, 1444, 1447, "the" +833, 11, 14, 285, 49, 53, 1448, 1452, "IOPs" +833, 11, 15, 286, 54, 62, 1453, 1461, "measured" +833, 11, 16, 287, 63, 65, 1462, 1464, "at" +833, 11, 17, 288, 66, 67, 1465, 1466, "8" +833, 11, 18, 289, 68, 69, 1467, 1468, ":" +833, 11, 19, 290, 70, 72, 1469, 1471, "00" +833, 11, 20, 291, 73, 75, 1472, 1474, "AM" +833, 11, 21, 292, 76, 77, 1475, 1476, "," +833, 11, 22, 293, 78, 80, 1477, 1479, "12" +833, 11, 23, 294, 81, 85, 1480, 1484, "noon" +833, 11, 24, 295, 86, 87, 1485, 1486, "," +833, 11, 25, 296, 88, 91, 1487, 1490, "and" +833, 11, 26, 297, 92, 93, 1491, 1492, "4" +833, 11, 27, 298, 94, 95, 1493, 1494, ":" +833, 11, 28, 299, 96, 98, 1495, 1497, "00" +833, 11, 29, 300, 99, 101, 1498, 1500, "PM" +833, 11, 30, 301, 102, 105, 1501, 1504, "was" +833, 11, 31, 302, 106, 107, 1505, 1506, "-" +833, 11, 32, 303, 108, 109, 1507, 1508, "7" +833, 11, 33, 304, 110, 111, 1509, 1510, "." +833, 11, 34, 305, 112, 113, 1511, 1512, "2" +833, 11, 35, 306, 114, 115, 1513, 1514, "+" +833, 11, 36, 307, 116, 117, 1515, 1516, "/" +833, 11, 37, 308, 118, 119, 1517, 1518, "-" +833, 11, 38, 309, 120, 121, 1519, 1520, "3" +833, 11, 39, 310, 122, 123, 1521, 1522, "." +833, 11, 40, 311, 124, 125, 1523, 1524, "2" +833, 11, 41, 312, 126, 128, 1525, 1527, "mm" +833, 11, 42, 313, 129, 131, 1528, 1530, "Hg" +833, 11, 43, 314, 132, 133, 1531, 1532, "(" +833, 11, 44, 315, 134, 136, 1533, 1535, "28" +833, 11, 45, 316, 137, 138, 1536, 1537, "%" +833, 11, 46, 317, 139, 140, 1538, 1539, ")" +833, 11, 47, 318, 141, 144, 1540, 1543, "for" +833, 11, 48, 319, 145, 156, 1544, 1555, "latanoprost" +833, 11, 49, 320, 157, 158, 1556, 1557, "(" +833, 11, 50, 321, 159, 161, 1558, 1560, "25" +833, 11, 51, 322, 162, 163, 1561, 1562, "." +833, 11, 52, 323, 164, 165, 1563, 1564, "3" +833, 11, 53, 324, 166, 167, 1565, 1566, "+" +833, 11, 54, 325, 168, 169, 1567, 1568, "/" +833, 11, 55, 326, 170, 171, 1569, 1570, "-" +833, 11, 56, 327, 172, 173, 1571, 1572, "2" +833, 11, 57, 328, 174, 175, 1573, 1574, "." +833, 11, 58, 329, 176, 177, 1575, 1576, "8" +833, 11, 59, 330, 178, 180, 1577, 1579, "mm" +833, 11, 60, 331, 181, 183, 1580, 1582, "Hg" +833, 11, 61, 332, 184, 186, 1583, 1585, "at" +833, 11, 62, 333, 187, 195, 1586, 1594, "baseline" +833, 11, 63, 334, 196, 198, 1595, 1597, "to" +833, 11, 64, 335, 199, 201, 1598, 1600, "18" +833, 11, 65, 336, 202, 203, 1601, 1602, "." +833, 11, 66, 337, 204, 205, 1603, 1604, "2" +833, 11, 67, 338, 206, 207, 1605, 1606, "+" +833, 11, 68, 339, 208, 209, 1607, 1608, "/" +833, 11, 69, 340, 210, 211, 1609, 1610, "-" +833, 11, 70, 341, 212, 213, 1611, 1612, "2" +833, 11, 71, 342, 214, 215, 1613, 1614, "." +833, 11, 72, 343, 216, 217, 1615, 1616, "8" +833, 11, 73, 344, 218, 220, 1617, 1619, "mm" +833, 11, 74, 345, 221, 223, 1620, 1622, "Hg" +833, 11, 75, 346, 224, 226, 1623, 1625, "at" +833, 11, 76, 347, 227, 228, 1626, 1627, "8" +833, 11, 77, 348, 229, 234, 1628, 1633, "weeks" +833, 11, 78, 349, 235, 236, 1634, 1635, ")" +833, 11, 79, 350, 237, 240, 1636, 1639, "and" +833, 11, 80, 351, 241, 242, 1640, 1641, "-" +833, 11, 81, 352, 243, 244, 1642, 1643, "3" +833, 11, 82, 353, 245, 246, 1644, 1645, "." +833, 11, 83, 354, 247, 248, 1646, 1647, "9" +833, 11, 84, 355, 249, 250, 1648, 1649, "+" +833, 11, 85, 356, 251, 252, 1650, 1651, "/" +833, 11, 86, 357, 253, 254, 1652, 1653, "-" +833, 11, 87, 358, 255, 256, 1654, 1655, "2" +833, 11, 88, 359, 257, 258, 1656, 1657, "." +833, 11, 89, 360, 259, 260, 1658, 1659, "6" +833, 11, 90, 361, 261, 263, 1660, 1662, "mm" +833, 11, 91, 362, 264, 266, 1663, 1665, "Hg" +833, 11, 92, 363, 267, 268, 1666, 1667, "(" +833, 11, 93, 364, 269, 271, 1668, 1670, "15" +833, 11, 94, 365, 272, 273, 1671, 1672, "%" +833, 11, 95, 366, 274, 275, 1673, 1674, ")" +833, 11, 96, 367, 276, 279, 1675, 1678, "for" +833, 11, 97, 368, 280, 291, 1679, 1690, "unoprostone" +833, 11, 98, 369, 292, 293, 1691, 1692, "(" +833, 11, 99, 370, 294, 296, 1693, 1695, "25" +833, 11, 100, 371, 297, 298, 1696, 1697, "." +833, 11, 101, 372, 299, 300, 1698, 1699, "5" +833, 11, 102, 373, 301, 302, 1700, 1701, "+" +833, 11, 103, 374, 303, 304, 1702, 1703, "/" +833, 11, 104, 375, 305, 306, 1704, 1705, "-" +833, 11, 105, 376, 307, 308, 1706, 1707, "3" +833, 11, 106, 377, 309, 310, 1708, 1709, "." +833, 11, 107, 378, 311, 312, 1710, 1711, "3" +833, 11, 108, 379, 313, 315, 1712, 1714, "mm" +833, 11, 109, 380, 316, 318, 1715, 1717, "Hg" +833, 11, 110, 381, 319, 321, 1718, 1720, "at" +833, 11, 111, 382, 322, 330, 1721, 1729, "baseline" +833, 11, 112, 383, 331, 333, 1730, 1732, "to" +833, 11, 113, 384, 334, 336, 1733, 1735, "21" +833, 11, 114, 385, 337, 338, 1736, 1737, "." +833, 11, 115, 386, 339, 340, 1738, 1739, "6" +833, 11, 116, 387, 341, 342, 1740, 1741, "+" +833, 11, 117, 388, 343, 344, 1742, 1743, "/" +833, 11, 118, 389, 345, 346, 1744, 1745, "-" +833, 11, 119, 390, 347, 348, 1746, 1747, "4" +833, 11, 120, 391, 349, 350, 1748, 1749, "." +833, 11, 121, 392, 351, 352, 1750, 1751, "0" +833, 11, 122, 393, 353, 355, 1752, 1754, "mm" +833, 11, 123, 394, 356, 358, 1755, 1757, "Hg" +833, 11, 124, 395, 359, 360, 1758, 1759, ";" +833, 11, 125, 396, 361, 362, 1760, 1761, "P" +833, 11, 126, 397, 363, 364, 1762, 1763, "<" +833, 11, 127, 398, 365, 367, 1764, 1766, "or" +833, 11, 128, 399, 368, 369, 1767, 1768, "=" +833, 11, 129, 400, 370, 371, 1769, 1770, "." +833, 11, 130, 401, 372, 375, 1771, 1774, "001" +833, 11, 131, 402, 376, 377, 1775, 1776, "." +833, 12, 1, 403, 0, 2, 1777, 1779, "No" +833, 12, 2, 404, 3, 10, 1780, 1787, "serious" +833, 12, 3, 405, 11, 18, 1788, 1795, "adverse" +833, 12, 4, 406, 19, 24, 1796, 1801, "event" +833, 12, 5, 407, 25, 32, 1802, 1809, "related" +833, 12, 6, 408, 33, 35, 1810, 1812, "to" +833, 12, 7, 409, 36, 42, 1813, 1819, "either" +833, 12, 8, 410, 43, 53, 1820, 1830, "medication" +833, 12, 9, 411, 54, 57, 1831, 1834, "was" +833, 12, 10, 412, 58, 66, 1835, 1843, "reported" +833, 12, 11, 413, 67, 68, 1844, 1845, "." +833, 13, 1, 414, 0, 11, 1846, 1857, "CONCLUSIONS" +833, 13, 2, 415, 12, 13, 1858, 1859, ":" +833, 13, 3, 416, 14, 18, 1860, 1864, "Over" +833, 13, 4, 417, 19, 21, 1865, 1867, "an" +833, 13, 5, 418, 22, 23, 1868, 1869, "8" +833, 13, 6, 419, 24, 25, 1870, 1871, "-" +833, 13, 7, 420, 26, 30, 1872, 1876, "week" +833, 13, 8, 421, 31, 37, 1877, 1883, "period" +833, 13, 9, 422, 38, 39, 1884, 1885, "," +833, 13, 10, 423, 40, 51, 1886, 1897, "latanoprost" +833, 13, 11, 424, 52, 53, 1898, 1899, "0" +833, 13, 12, 425, 54, 55, 1900, 1901, "." +833, 13, 13, 426, 56, 59, 1902, 1905, "005" +833, 13, 14, 427, 60, 61, 1906, 1907, "%" +833, 13, 15, 428, 62, 66, 1908, 1912, "once" +833, 13, 16, 429, 67, 72, 1913, 1918, "daily" +833, 13, 17, 430, 73, 80, 1919, 1926, "lowered" +833, 13, 18, 431, 81, 84, 1927, 1930, "IOP" +833, 13, 19, 432, 85, 89, 1931, 1935, "more" +833, 13, 20, 433, 90, 94, 1936, 1940, "than" +833, 13, 21, 434, 95, 106, 1941, 1952, "unoprostone" +833, 13, 22, 435, 107, 108, 1953, 1954, "0" +833, 13, 23, 436, 109, 110, 1955, 1956, "." +833, 13, 24, 437, 111, 113, 1957, 1959, "15" +833, 13, 25, 438, 114, 115, 1960, 1961, "%" +833, 13, 26, 439, 116, 121, 1962, 1967, "twice" +833, 13, 27, 440, 122, 127, 1968, 1973, "daily" +833, 13, 28, 441, 128, 130, 1974, 1976, "in" +833, 13, 29, 442, 131, 139, 1977, 1985, "patients" +833, 13, 30, 443, 140, 144, 1986, 1990, "with" +833, 13, 31, 444, 145, 153, 1991, 1999, "elevated" +833, 13, 32, 445, 154, 157, 2000, 2003, "IOP" +833, 13, 33, 446, 158, 159, 2004, 2005, "." +833, 14, 1, 447, 0, 4, 2006, 2010, "Both" +833, 14, 2, 448, 5, 11, 2011, 2017, "agents" +833, 14, 3, 449, 12, 16, 2018, 2022, "were" +833, 14, 4, 450, 17, 21, 2023, 2027, "safe" +833, 14, 5, 451, 22, 25, 2028, 2031, "and" +833, 14, 6, 452, 26, 30, 2032, 2036, "well" +833, 14, 7, 453, 31, 40, 2037, 2046, "tolerated" +833, 14, 8, 454, 41, 42, 2047, 2048, "." +833, 15, 1, 455, 0, 3, 2049, 2052, "DOI" +833, 15, 2, 456, 4, 5, 2053, 2054, ":" +833, 15, 3, 457, 6, 8, 2055, 2057, "10" +833, 15, 4, 458, 9, 10, 2058, 2059, "." +833, 15, 5, 459, 11, 15, 2060, 2064, "1016" +833, 15, 6, 460, 16, 17, 2065, 2066, "/" +833, 15, 7, 461, 18, 23, 2067, 2072, "s0002" +833, 15, 8, 462, 24, 25, 2073, 2074, "-" +833, 15, 9, 463, 26, 30, 2075, 2079, "9394" +833, 15, 10, 464, 31, 32, 2080, 2081, "(" +833, 15, 11, 465, 33, 35, 2082, 2084, "02" +833, 15, 12, 466, 36, 37, 2085, 2086, ")" +833, 15, 13, 467, 38, 43, 2087, 2092, "01820" +833, 15, 14, 468, 44, 45, 2093, 2094, "-" +833, 15, 15, 469, 46, 47, 2095, 2096, "2" +833, 15, 16, 470, 48, 52, 2097, 2101, "PMID" +833, 15, 17, 471, 53, 54, 2102, 2103, ":" +833, 15, 18, 472, 55, 63, 2104, 2112, "12470755" +833, 15, 19, 473, 64, 65, 2113, 2114, "[" +833, 15, 20, 474, 66, 73, 2115, 2122, "Indexed" +833, 15, 21, 475, 74, 77, 2123, 2126, "for" +833, 15, 22, 476, 78, 85, 2127, 2134, "MEDLINE" +833, 15, 23, 477, 86, 87, 2135, 2136, "]" diff --git a/data/gl 12470755_admin.annodb b/data/gl 12470755_admin.annodb new file mode 100644 index 0000000..54cd3b9 --- /dev/null +++ b/data/gl 12470755_admin.annodb @@ -0,0 +1,98 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Am J Ophthalmol .", "", " \"Am J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2002", "", " \"2002\"." +2, Title, 52, 157, "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure .", "", " \"Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure .\"." +3, Randomized, 52, 62, "Randomized", "", +4, Latanoprost, 81, 92, "latanoprost", "", +5, Unoprostone, 97, 108, "unoprostone", "", +6, IOP, 135, 155, "intraocular pressure", "", +7, Author, 158, 167, "Jampel HD", "", " \"Jampel HD\"." +8, Author, 176, 187, "Bacharach J", "", " \"Bacharach J\"." +9, Author, 190, 197, "Sheu WP", "", " \"Sheu WP\"." +10, Author, 200, 207, "Wohl LG", "", " \"Wohl LG\"." +11, Author, 210, 219, "Solish AM", "", " \"Solish AM\"." +12, Author, 222, 232, "Christie W", "", " \"Christie W\"." +86, Latanoprost, 235, 246, "Latanoprost", "", +87, Unoprostone, 249, 260, "Unoprostone", "", +52, USA, 418, 421, "USA", "", +13, ObjectiveDescription, 455, 682, "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .", "", " \"To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .\"." +14, IOP, 470, 490, "intraocular pressure", "", +15, IOP, 493, 496, "IOP", "", +54, Latanoprost, 531, 542, "latanoprost", "", " . ." +56, DoseValue, 543, 550, "0 . 005", "", " \"0 . 005\"." +59, Percentage, 551, 552, "%", "", " ." +60, Frequency, 553, 563, "once daily", "", +55, Unoprostone, 577, 588, "unoprostone", "", " ." +57, DoseValue, 589, 595, "0 . 15", "", " \"0 . 15\"." +58, Percentage, 596, 597, "%", "", " ." +61, Frequency, 598, 609, "twice daily", "", " \"twice daily\"." +89, Primary_OpenAngleGlaucoma, 628, 657, "primary open - angle glaucoma", "", " ." +16, OcularHypertension, 661, 680, "ocular hypertension", "", " ." +62, Randomized, 692, 702, "Randomized", "", " ." +41657, Prospective, 735, 746, "prospective", "", " ." +63, Duration, 749, 757, "8 - week", "", " \"8 - week\"." +18, Blind, 760, 781, "investigator - masked", "", " ." +19, Parallel, 784, 792, "parallel", "", " ." +20, Multicenter, 820, 836, "numerous centers", "", " ." +53, USA, 844, 857, "United States", "", " ." +21, NumberPatientsCT, 860, 863, "165", "", " \"165\"." +22, Precondition, 864, 950, "previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout", "", " \"previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout\"." +64, mmHg, 911, 916, "mm Hg", "", +65, Randomized, 956, 964, "randomly", "", +66, Latanoprost, 992, 1003, "latanoprost", "", +68, DoseValue, 1004, 1011, "0 . 005", "", +70, Percentage, 1012, 1013, "%", "", +72, Frequency, 1014, 1024, "once daily", "", " \"once daily\"." +23, Bedtime, 1032, 1039, "evening", "", " ." +67, Unoprostone, 1043, 1054, "unoprostone", "", +69, DoseValue, 1055, 1061, "0 . 15", "", +71, Percentage, 1062, 1063, "%", "", +73, Frequency, 1064, 1075, "twice daily", "", +88, Mean, 1263, 1267, "mean", "", " . ." +24, IOP, 1275, 1279, "IOPs", "", +181, TimePoint, 1336, 1344, "baseline", "", +182, TimePoint, 1376, 1383, "8 weeks", "", +74, Mean, 1427, 1431, "mean", "", +46, IOP, 1448, 1452, "IOPs", "", +25, Reduction, 1507, 1512, "7 . 2", "", " \"7 . 2\"." +26, SdDevChangeValue, 1519, 1524, "3 . 2", "", " \"3 . 2\"." +27, mmHg, 1525, 1530, "mm Hg", "", " ." +28, RelativeReduction, 1533, 1535, "28", "", " \"28\"." +75, Latanoprost, 1544, 1555, "latanoprost", "", +29, BaseLineValue, 1558, 1564, "25 . 3", "", " \"25 . 3\"." +30, SdDevBL, 1571, 1576, "2 . 8", "", " \"2 . 8\"." +31, mmHg, 1577, 1582, "mm Hg", "", +183, TimePoint, 1586, 1594, "baseline", "", +32, ResultMeasuredValue, 1598, 1604, "18 . 2", "", " \"18 . 2\"." +33, SdDevResValue, 1611, 1616, "2 . 8", "", " \"2 . 8\"." +34, mmHg, 1617, 1622, "mm Hg", "", +161, TimePoint, 1626, 1633, "8 weeks", "", " \"8 weeks\". \"8 weeks\"." +35, Reduction, 1642, 1647, "3 . 9", "", " \"3 . 9\"." +36, SdDevChangeValue, 1654, 1659, "2 . 6", "", " \"2 . 6\"." +37, mmHg, 1660, 1665, "mm Hg", "", +38, RelativeReduction, 1668, 1670, "15", "", " \"15\"." +76, Unoprostone, 1679, 1690, "unoprostone", "", +39, BaseLineValue, 1693, 1699, "25 . 5", "", " \"25 . 5\"." +40, SdDevBL, 1706, 1711, "3 . 3", "", " \"3 . 3\"." +41, mmHg, 1712, 1717, "mm Hg", "", +41687, TimePoint, 1721, 1729, "baseline", "", +42, ResultMeasuredValue, 1733, 1739, "21 . 6", "", " \"21 . 6\"." +43, SdDevResValue, 1746, 1751, "4 . 0", "", " \"4 . 0\"." +44, mmHg, 1752, 1757, "mm Hg", "", +163, PvalueDiff, 1760, 1774, "P < or = . 001", "", " \"P < or = . 001\"." +164, ObservedResult, 1777, 1843, "No serious adverse event related to either medication was reported", "", " \"No serious adverse event related to either medication was reported\"." +41709, EndPointDescription, 1788, 1801, "adverse event", "", " . ." +47, ConclusionComment, 1860, 2005, "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .", "", " \"Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .\"." +77, Duration, 1868, 1876, "8 - week", "", +78, Latanoprost, 1886, 1897, "latanoprost", "", +80, DoseValue, 1898, 1905, "0 . 005", "", +82, Percentage, 1906, 1907, "%", "", +84, Frequency, 1908, 1918, "once daily", "", +49, IOP, 1927, 1930, "IOP", "", +79, Unoprostone, 1941, 1952, "unoprostone", "", +81, DoseValue, 1953, 1959, "0 . 15", "", +83, Percentage, 1960, 1961, "%", "", +85, Frequency, 1962, 1973, "twice daily", "", +50, IOP, 2000, 2003, "IOP", "", +48, ConclusionComment, 2006, 2048, "Both agents were safe and well tolerated .", "", " \"Both agents were safe and well tolerated .\"." +51, PMID, 2104, 2112, "12470755", "", " \"12470755\"." diff --git a/data/gl 12470755_admin.n-triples b/data/gl 12470755_admin.n-triples new file mode 100644 index 0000000..66df34b --- /dev/null +++ b/data/gl 12470755_admin.n-triples @@ -0,0 +1,128 @@ +# RDF export of group: Publication + . + "Publication" . + "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure ." . + "Jampel HD" . + "2002" . + "Am J Ophthalmol ." . + "12470755" . + . + "Bacharach J" . + "Sheu WP" . + "Wohl LG" . + "Solish AM" . + "Christie W" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension ." . + "165" . + "8 - week" . + . + . + . + "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP ." . + . + . + . + . + . + . + . + . + . + "Both agents were safe and well tolerated ." . + . + . +# RDF export of group: Population + . + "Population" . + "previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + "Endpoint-ad" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + . + . + . + "Arm-uno" . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-uno" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-uno" . + . + "0 . 15" . + . + . +# RDF export of group: Outcome + . + "Outcome-lat-iop" . + . + "25 . 3" . + "2 . 8" . + "18 . 2" . + "2 . 8" . + "7 . 2" . + "28" . + "3 . 2" . + "8 weeks" . + . + "Outcome-uno-iop" . + . + "25 . 5" . + "3 . 3" . + "21 . 6" . + "4 . 0" . + "3 . 9" . + "15" . + "2 . 6" . + "8 weeks" . + . + "Outcome-ad" . + . + "No serious adverse event related to either medication was reported" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop" . + "P < or = . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12470755_export.csv b/data/gl 12470755_export.csv new file mode 100644 index 0000000..2fa770c --- /dev/null +++ b/data/gl 12470755_export.csv @@ -0,0 +1,478 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +474, 1, 1, 1, 0, 2, 0, 2, "Am" +474, 1, 2, 2, 3, 4, 3, 4, "J" +474, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +474, 1, 4, 4, 16, 17, 16, 17, "." +474, 2, 1, 5, 0, 4, 18, 22, "2002" +474, 2, 2, 6, 5, 8, 23, 26, "Dec" +474, 2, 3, 7, 9, 10, 27, 28, ";" +474, 2, 4, 8, 11, 14, 29, 32, "134" +474, 2, 5, 9, 15, 16, 33, 34, "(" +474, 2, 6, 10, 17, 18, 35, 36, "6" +474, 2, 7, 11, 19, 20, 37, 38, ")" +474, 2, 8, 12, 21, 22, 39, 40, ":" +474, 2, 9, 13, 23, 26, 41, 44, "863" +474, 2, 10, 14, 27, 28, 45, 46, "-" +474, 2, 11, 15, 29, 31, 47, 49, "71" +474, 2, 12, 16, 32, 33, 50, 51, "." +474, 3, 1, 17, 0, 10, 52, 62, "Randomized" +474, 3, 2, 18, 11, 19, 63, 71, "clinical" +474, 3, 3, 19, 20, 25, 72, 77, "trial" +474, 3, 4, 20, 26, 28, 78, 80, "of" +474, 3, 5, 21, 29, 40, 81, 92, "latanoprost" +474, 3, 6, 22, 41, 44, 93, 96, "and" +474, 3, 7, 23, 45, 56, 97, 108, "unoprostone" +474, 3, 8, 24, 57, 59, 109, 111, "in" +474, 3, 9, 25, 60, 68, 112, 120, "patients" +474, 3, 10, 26, 69, 73, 121, 125, "with" +474, 3, 11, 27, 74, 82, 126, 134, "elevated" +474, 3, 12, 28, 83, 94, 135, 146, "intraocular" +474, 3, 13, 29, 95, 103, 147, 155, "pressure" +474, 3, 14, 30, 104, 105, 156, 157, "." +474, 4, 1, 31, 0, 6, 158, 164, "Jampel" +474, 4, 2, 32, 7, 9, 165, 167, "HD" +474, 4, 3, 33, 10, 11, 168, 169, "(" +474, 4, 4, 34, 12, 13, 170, 171, "1" +474, 4, 5, 35, 14, 15, 172, 173, ")" +474, 4, 6, 36, 16, 17, 174, 175, "," +474, 4, 7, 37, 18, 27, 176, 185, "Bacharach" +474, 4, 8, 38, 28, 29, 186, 187, "J" +474, 4, 9, 39, 30, 31, 188, 189, "," +474, 4, 10, 40, 32, 36, 190, 194, "Sheu" +474, 4, 11, 41, 37, 39, 195, 197, "WP" +474, 4, 12, 42, 40, 41, 198, 199, "," +474, 4, 13, 43, 42, 46, 200, 204, "Wohl" +474, 4, 14, 44, 47, 49, 205, 207, "LG" +474, 4, 15, 45, 50, 51, 208, 209, "," +474, 4, 16, 46, 52, 58, 210, 216, "Solish" +474, 4, 17, 47, 59, 61, 217, 219, "AM" +474, 4, 18, 48, 62, 63, 220, 221, "," +474, 4, 19, 49, 64, 72, 222, 230, "Christie" +474, 4, 20, 50, 73, 74, 231, 232, "W" +474, 4, 21, 51, 75, 76, 233, 234, ";" +474, 4, 22, 52, 77, 88, 235, 246, "Latanoprost" +474, 4, 23, 53, 89, 90, 247, 248, "/" +474, 4, 24, 54, 91, 102, 249, 260, "Unoprostone" +474, 4, 25, 55, 103, 108, 261, 266, "Study" +474, 4, 26, 56, 109, 114, 267, 272, "Group" +474, 4, 27, 57, 115, 116, 273, 274, "." +474, 5, 1, 58, 0, 6, 275, 281, "Author" +474, 5, 2, 59, 7, 18, 282, 293, "information" +474, 5, 3, 60, 19, 20, 294, 295, ":" +474, 5, 4, 61, 21, 22, 296, 297, "(" +474, 5, 5, 62, 23, 24, 298, 299, "1" +474, 5, 6, 63, 25, 26, 300, 301, ")" +474, 5, 7, 64, 27, 37, 302, 312, "Department" +474, 5, 8, 65, 38, 40, 313, 315, "of" +474, 5, 9, 66, 41, 54, 316, 329, "Ophthalmology" +474, 5, 10, 67, 55, 56, 330, 331, "," +474, 5, 11, 68, 57, 60, 332, 335, "The" +474, 5, 12, 69, 61, 66, 336, 341, "Johns" +474, 5, 13, 70, 67, 74, 342, 349, "Hopkins" +474, 5, 14, 71, 75, 85, 350, 360, "University" +474, 5, 15, 72, 86, 92, 361, 367, "School" +474, 5, 16, 73, 93, 95, 368, 370, "of" +474, 5, 17, 74, 96, 104, 371, 379, "Medicine" +474, 5, 18, 75, 105, 106, 380, 381, "," +474, 5, 19, 76, 107, 116, 382, 391, "Baltimore" +474, 5, 20, 77, 117, 118, 392, 393, "," +474, 5, 21, 78, 119, 127, 394, 402, "Maryland" +474, 5, 22, 79, 128, 133, 403, 408, "21287" +474, 5, 23, 80, 134, 135, 409, 410, "-" +474, 5, 24, 81, 136, 140, 411, 415, "9205" +474, 5, 25, 82, 141, 142, 416, 417, "," +474, 5, 26, 83, 143, 146, 418, 421, "USA" +474, 5, 27, 84, 147, 148, 422, 423, "." +474, 6, 1, 85, 0, 7, 424, 431, "hjampel" +474, 6, 2, 86, 8, 9, 432, 433, "@" +474, 6, 3, 87, 10, 14, 434, 438, "jhmi" +474, 6, 4, 88, 15, 16, 439, 440, "." +474, 6, 5, 89, 17, 20, 441, 444, "edu" +474, 6, 6, 90, 21, 28, 445, 452, "PURPOSE" +474, 6, 7, 91, 29, 30, 453, 454, ":" +474, 6, 8, 92, 31, 33, 455, 457, "To" +474, 6, 9, 93, 34, 41, 458, 465, "compare" +474, 6, 10, 94, 42, 45, 466, 469, "the" +474, 6, 11, 95, 46, 57, 470, 481, "intraocular" +474, 6, 12, 96, 58, 66, 482, 490, "pressure" +474, 6, 13, 97, 67, 68, 491, 492, "(" +474, 6, 14, 98, 69, 72, 493, 496, "IOP" +474, 6, 15, 99, 73, 74, 497, 498, ")" +474, 6, 16, 100, 75, 76, 499, 500, "-" +474, 6, 17, 101, 77, 85, 501, 509, "lowering" +474, 6, 18, 102, 86, 92, 510, 516, "effect" +474, 6, 19, 103, 93, 96, 517, 520, "and" +474, 6, 20, 104, 97, 103, 521, 527, "safety" +474, 6, 21, 105, 104, 106, 528, 530, "of" +474, 6, 22, 106, 107, 118, 531, 542, "latanoprost" +474, 6, 23, 107, 119, 120, 543, 544, "0" +474, 6, 24, 108, 121, 122, 545, 546, "." +474, 6, 25, 109, 123, 126, 547, 550, "005" +474, 6, 26, 110, 127, 128, 551, 552, "%" +474, 6, 27, 111, 129, 133, 553, 557, "once" +474, 6, 28, 112, 134, 139, 558, 563, "daily" +474, 6, 29, 113, 140, 144, 564, 568, "with" +474, 6, 30, 114, 145, 149, 569, 573, "that" +474, 6, 31, 115, 150, 152, 574, 576, "of" +474, 6, 32, 116, 153, 164, 577, 588, "unoprostone" +474, 6, 33, 117, 165, 166, 589, 590, "0" +474, 6, 34, 118, 167, 168, 591, 592, "." +474, 6, 35, 119, 169, 171, 593, 595, "15" +474, 6, 36, 120, 172, 173, 596, 597, "%" +474, 6, 37, 121, 174, 179, 598, 603, "twice" +474, 6, 38, 122, 180, 185, 604, 609, "daily" +474, 6, 39, 123, 186, 189, 610, 613, "for" +474, 6, 40, 124, 190, 198, 614, 622, "patients" +474, 6, 41, 125, 199, 203, 623, 627, "with" +474, 6, 42, 126, 204, 211, 628, 635, "primary" +474, 6, 43, 127, 212, 216, 636, 640, "open" +474, 6, 44, 128, 217, 218, 641, 642, "-" +474, 6, 45, 129, 219, 224, 643, 648, "angle" +474, 6, 46, 130, 225, 233, 649, 657, "glaucoma" +474, 6, 47, 131, 234, 236, 658, 660, "or" +474, 6, 48, 132, 237, 243, 661, 667, "ocular" +474, 6, 49, 133, 244, 256, 668, 680, "hypertension" +474, 6, 50, 134, 257, 258, 681, 682, "." +474, 7, 1, 135, 0, 6, 683, 689, "DESIGN" +474, 7, 2, 136, 7, 8, 690, 691, ":" +474, 7, 3, 137, 9, 19, 692, 702, "Randomized" +474, 7, 4, 138, 20, 28, 703, 711, "clinical" +474, 7, 5, 139, 29, 34, 712, 717, "trial" +474, 7, 6, 140, 35, 36, 718, 719, "." +474, 8, 1, 141, 0, 7, 720, 727, "METHODS" +474, 8, 2, 142, 8, 9, 728, 729, ":" +474, 8, 3, 143, 10, 12, 730, 732, "In" +474, 8, 4, 144, 13, 14, 733, 734, "a" +474, 8, 5, 145, 15, 26, 735, 746, "prospective" +474, 8, 6, 146, 27, 28, 747, 748, "," +474, 8, 7, 147, 29, 30, 749, 750, "8" +474, 8, 8, 148, 31, 32, 751, 752, "-" +474, 8, 9, 149, 33, 37, 753, 757, "week" +474, 8, 10, 150, 38, 39, 758, 759, "," +474, 8, 11, 151, 40, 52, 760, 772, "investigator" +474, 8, 12, 152, 53, 54, 773, 774, "-" +474, 8, 13, 153, 55, 61, 775, 781, "masked" +474, 8, 14, 154, 62, 63, 782, 783, "," +474, 8, 15, 155, 64, 72, 784, 792, "parallel" +474, 8, 16, 156, 73, 74, 793, 794, "-" +474, 8, 17, 157, 75, 80, 795, 800, "group" +474, 8, 18, 158, 81, 86, 801, 806, "study" +474, 8, 19, 159, 87, 96, 807, 816, "conducted" +474, 8, 20, 160, 97, 99, 817, 819, "at" +474, 8, 21, 161, 100, 108, 820, 828, "numerous" +474, 8, 22, 162, 109, 116, 829, 836, "centers" +474, 8, 23, 163, 117, 119, 837, 839, "in" +474, 8, 24, 164, 120, 123, 840, 843, "the" +474, 8, 25, 165, 124, 130, 844, 850, "United" +474, 8, 26, 166, 131, 137, 851, 857, "States" +474, 8, 27, 167, 138, 139, 858, 859, "," +474, 8, 28, 168, 140, 143, 860, 863, "165" +474, 8, 29, 169, 144, 154, 864, 874, "previously" +474, 8, 30, 170, 155, 162, 875, 882, "treated" +474, 8, 31, 171, 163, 171, 883, 891, "patients" +474, 8, 32, 172, 172, 176, 892, 896, "with" +474, 8, 33, 173, 177, 180, 897, 900, "IOP" +474, 8, 34, 174, 181, 182, 901, 902, ">" +474, 8, 35, 175, 183, 185, 903, 905, "or" +474, 8, 36, 176, 186, 187, 906, 907, "=" +474, 8, 37, 177, 188, 190, 908, 910, "25" +474, 8, 38, 178, 191, 193, 911, 913, "mm" +474, 8, 39, 179, 194, 196, 914, 916, "Hg" +474, 8, 40, 180, 197, 199, 917, 919, "in" +474, 8, 41, 181, 200, 203, 920, 923, "one" +474, 8, 42, 182, 204, 206, 924, 926, "or" +474, 8, 43, 183, 207, 211, 927, 931, "both" +474, 8, 44, 184, 212, 216, 932, 936, "eyes" +474, 8, 45, 185, 217, 222, 937, 942, "after" +474, 8, 46, 186, 223, 230, 943, 950, "washout" +474, 8, 47, 187, 231, 235, 951, 955, "were" +474, 8, 48, 188, 236, 244, 956, 964, "randomly" +474, 8, 49, 189, 245, 253, 965, 973, "assigned" +474, 8, 50, 190, 254, 256, 974, 976, "to" +474, 8, 51, 191, 257, 264, 977, 984, "receive" +474, 8, 52, 192, 265, 271, 985, 991, "either" +474, 8, 53, 193, 272, 283, 992, 1003, "latanoprost" +474, 8, 54, 194, 284, 285, 1004, 1005, "0" +474, 8, 55, 195, 286, 287, 1006, 1007, "." +474, 8, 56, 196, 288, 291, 1008, 1011, "005" +474, 8, 57, 197, 292, 293, 1012, 1013, "%" +474, 8, 58, 198, 294, 298, 1014, 1018, "once" +474, 8, 59, 199, 299, 304, 1019, 1024, "daily" +474, 8, 60, 200, 305, 307, 1025, 1027, "in" +474, 8, 61, 201, 308, 311, 1028, 1031, "the" +474, 8, 62, 202, 312, 319, 1032, 1039, "evening" +474, 8, 63, 203, 320, 322, 1040, 1042, "or" +474, 8, 64, 204, 323, 334, 1043, 1054, "unoprostone" +474, 8, 65, 205, 335, 336, 1055, 1056, "0" +474, 8, 66, 206, 337, 338, 1057, 1058, "." +474, 8, 67, 207, 339, 341, 1059, 1061, "15" +474, 8, 68, 208, 342, 343, 1062, 1063, "%" +474, 8, 69, 209, 344, 349, 1064, 1069, "twice" +474, 8, 70, 210, 350, 355, 1070, 1075, "daily" +474, 8, 71, 211, 356, 357, 1076, 1077, "." +474, 9, 1, 212, 0, 12, 1078, 1090, "Observations" +474, 9, 2, 213, 13, 23, 1091, 1101, "procedures" +474, 9, 3, 214, 24, 28, 1102, 1106, "were" +474, 9, 4, 215, 29, 37, 1107, 1115, "Goldmann" +474, 9, 5, 216, 38, 49, 1116, 1127, "applanation" +474, 9, 6, 217, 50, 59, 1128, 1137, "tonometry" +474, 9, 7, 218, 60, 61, 1138, 1139, "," +474, 9, 8, 219, 62, 66, 1140, 1144, "best" +474, 9, 9, 220, 67, 68, 1145, 1146, "-" +474, 9, 10, 221, 69, 78, 1147, 1156, "corrected" +474, 9, 11, 222, 79, 85, 1157, 1163, "visual" +474, 9, 12, 223, 86, 92, 1164, 1170, "acuity" +474, 9, 13, 224, 93, 94, 1171, 1172, "," +474, 9, 14, 225, 95, 99, 1173, 1177, "slit" +474, 9, 15, 226, 100, 104, 1178, 1182, "lamp" +474, 9, 16, 227, 105, 118, 1183, 1196, "biomicroscopy" +474, 9, 17, 228, 119, 120, 1197, 1198, "," +474, 9, 18, 229, 121, 124, 1199, 1202, "and" +474, 9, 19, 230, 125, 139, 1203, 1217, "ophthalmoscopy" +474, 9, 20, 231, 140, 141, 1218, 1219, "." +474, 10, 1, 232, 0, 3, 1220, 1223, "The" +474, 10, 2, 233, 4, 8, 1224, 1228, "main" +474, 10, 3, 234, 9, 16, 1229, 1236, "outcome" +474, 10, 4, 235, 17, 24, 1237, 1244, "measure" +474, 10, 5, 236, 25, 28, 1245, 1248, "was" +474, 10, 6, 237, 29, 35, 1249, 1255, "change" +474, 10, 7, 238, 36, 38, 1256, 1258, "in" +474, 10, 8, 239, 39, 42, 1259, 1262, "the" +474, 10, 9, 240, 43, 47, 1263, 1267, "mean" +474, 10, 10, 241, 48, 50, 1268, 1270, "of" +474, 10, 11, 242, 51, 54, 1271, 1274, "the" +474, 10, 12, 243, 55, 59, 1275, 1279, "IOPs" +474, 10, 13, 244, 60, 68, 1280, 1288, "measured" +474, 10, 14, 245, 69, 71, 1289, 1291, "at" +474, 10, 15, 246, 72, 73, 1292, 1293, "8" +474, 10, 16, 247, 74, 75, 1294, 1295, ":" +474, 10, 17, 248, 76, 78, 1296, 1298, "00" +474, 10, 18, 249, 79, 81, 1299, 1301, "AM" +474, 10, 19, 250, 82, 83, 1302, 1303, "," +474, 10, 20, 251, 84, 86, 1304, 1306, "12" +474, 10, 21, 252, 87, 91, 1307, 1311, "noon" +474, 10, 22, 253, 92, 93, 1312, 1313, "," +474, 10, 23, 254, 94, 97, 1314, 1317, "and" +474, 10, 24, 255, 98, 99, 1318, 1319, "4" +474, 10, 25, 256, 100, 101, 1320, 1321, ":" +474, 10, 26, 257, 102, 104, 1322, 1324, "00" +474, 10, 27, 258, 105, 107, 1325, 1327, "PM" +474, 10, 28, 259, 108, 115, 1328, 1335, "between" +474, 10, 29, 260, 116, 124, 1336, 1344, "baseline" +474, 10, 30, 261, 125, 126, 1345, 1346, "(" +474, 10, 31, 262, 127, 133, 1347, 1353, "before" +474, 10, 32, 263, 134, 143, 1354, 1363, "treatment" +474, 10, 33, 264, 144, 145, 1364, 1365, ")" +474, 10, 34, 265, 146, 149, 1366, 1369, "and" +474, 10, 35, 266, 150, 155, 1370, 1375, "after" +474, 10, 36, 267, 156, 157, 1376, 1377, "8" +474, 10, 37, 268, 158, 163, 1378, 1383, "weeks" +474, 10, 38, 269, 164, 166, 1384, 1386, "of" +474, 10, 39, 270, 167, 176, 1387, 1396, "treatment" +474, 10, 40, 271, 177, 178, 1397, 1398, "." +474, 11, 1, 272, 0, 7, 1399, 1406, "RESULTS" +474, 11, 2, 273, 8, 9, 1407, 1408, ":" +474, 11, 3, 274, 10, 13, 1409, 1412, "The" +474, 11, 4, 275, 14, 20, 1413, 1419, "change" +474, 11, 5, 276, 21, 23, 1420, 1422, "in" +474, 11, 6, 277, 24, 27, 1423, 1426, "the" +474, 11, 7, 278, 28, 32, 1427, 1431, "mean" +474, 11, 8, 279, 33, 34, 1432, 1433, "+" +474, 11, 9, 280, 35, 36, 1434, 1435, "/" +474, 11, 10, 281, 37, 38, 1436, 1437, "-" +474, 11, 11, 282, 39, 41, 1438, 1440, "SD" +474, 11, 12, 283, 42, 44, 1441, 1443, "of" +474, 11, 13, 284, 45, 48, 1444, 1447, "the" +474, 11, 14, 285, 49, 53, 1448, 1452, "IOPs" +474, 11, 15, 286, 54, 62, 1453, 1461, "measured" +474, 11, 16, 287, 63, 65, 1462, 1464, "at" +474, 11, 17, 288, 66, 67, 1465, 1466, "8" +474, 11, 18, 289, 68, 69, 1467, 1468, ":" +474, 11, 19, 290, 70, 72, 1469, 1471, "00" +474, 11, 20, 291, 73, 75, 1472, 1474, "AM" +474, 11, 21, 292, 76, 77, 1475, 1476, "," +474, 11, 22, 293, 78, 80, 1477, 1479, "12" +474, 11, 23, 294, 81, 85, 1480, 1484, "noon" +474, 11, 24, 295, 86, 87, 1485, 1486, "," +474, 11, 25, 296, 88, 91, 1487, 1490, "and" +474, 11, 26, 297, 92, 93, 1491, 1492, "4" +474, 11, 27, 298, 94, 95, 1493, 1494, ":" +474, 11, 28, 299, 96, 98, 1495, 1497, "00" +474, 11, 29, 300, 99, 101, 1498, 1500, "PM" +474, 11, 30, 301, 102, 105, 1501, 1504, "was" +474, 11, 31, 302, 106, 107, 1505, 1506, "-" +474, 11, 32, 303, 108, 109, 1507, 1508, "7" +474, 11, 33, 304, 110, 111, 1509, 1510, "." +474, 11, 34, 305, 112, 113, 1511, 1512, "2" +474, 11, 35, 306, 114, 115, 1513, 1514, "+" +474, 11, 36, 307, 116, 117, 1515, 1516, "/" +474, 11, 37, 308, 118, 119, 1517, 1518, "-" +474, 11, 38, 309, 120, 121, 1519, 1520, "3" +474, 11, 39, 310, 122, 123, 1521, 1522, "." +474, 11, 40, 311, 124, 125, 1523, 1524, "2" +474, 11, 41, 312, 126, 128, 1525, 1527, "mm" +474, 11, 42, 313, 129, 131, 1528, 1530, "Hg" +474, 11, 43, 314, 132, 133, 1531, 1532, "(" +474, 11, 44, 315, 134, 136, 1533, 1535, "28" +474, 11, 45, 316, 137, 138, 1536, 1537, "%" +474, 11, 46, 317, 139, 140, 1538, 1539, ")" +474, 11, 47, 318, 141, 144, 1540, 1543, "for" +474, 11, 48, 319, 145, 156, 1544, 1555, "latanoprost" +474, 11, 49, 320, 157, 158, 1556, 1557, "(" +474, 11, 50, 321, 159, 161, 1558, 1560, "25" +474, 11, 51, 322, 162, 163, 1561, 1562, "." +474, 11, 52, 323, 164, 165, 1563, 1564, "3" +474, 11, 53, 324, 166, 167, 1565, 1566, "+" +474, 11, 54, 325, 168, 169, 1567, 1568, "/" +474, 11, 55, 326, 170, 171, 1569, 1570, "-" +474, 11, 56, 327, 172, 173, 1571, 1572, "2" +474, 11, 57, 328, 174, 175, 1573, 1574, "." +474, 11, 58, 329, 176, 177, 1575, 1576, "8" +474, 11, 59, 330, 178, 180, 1577, 1579, "mm" +474, 11, 60, 331, 181, 183, 1580, 1582, "Hg" +474, 11, 61, 332, 184, 186, 1583, 1585, "at" +474, 11, 62, 333, 187, 195, 1586, 1594, "baseline" +474, 11, 63, 334, 196, 198, 1595, 1597, "to" +474, 11, 64, 335, 199, 201, 1598, 1600, "18" +474, 11, 65, 336, 202, 203, 1601, 1602, "." +474, 11, 66, 337, 204, 205, 1603, 1604, "2" +474, 11, 67, 338, 206, 207, 1605, 1606, "+" +474, 11, 68, 339, 208, 209, 1607, 1608, "/" +474, 11, 69, 340, 210, 211, 1609, 1610, "-" +474, 11, 70, 341, 212, 213, 1611, 1612, "2" +474, 11, 71, 342, 214, 215, 1613, 1614, "." +474, 11, 72, 343, 216, 217, 1615, 1616, "8" +474, 11, 73, 344, 218, 220, 1617, 1619, "mm" +474, 11, 74, 345, 221, 223, 1620, 1622, "Hg" +474, 11, 75, 346, 224, 226, 1623, 1625, "at" +474, 11, 76, 347, 227, 228, 1626, 1627, "8" +474, 11, 77, 348, 229, 234, 1628, 1633, "weeks" +474, 11, 78, 349, 235, 236, 1634, 1635, ")" +474, 11, 79, 350, 237, 240, 1636, 1639, "and" +474, 11, 80, 351, 241, 242, 1640, 1641, "-" +474, 11, 81, 352, 243, 244, 1642, 1643, "3" +474, 11, 82, 353, 245, 246, 1644, 1645, "." +474, 11, 83, 354, 247, 248, 1646, 1647, "9" +474, 11, 84, 355, 249, 250, 1648, 1649, "+" +474, 11, 85, 356, 251, 252, 1650, 1651, "/" +474, 11, 86, 357, 253, 254, 1652, 1653, "-" +474, 11, 87, 358, 255, 256, 1654, 1655, "2" +474, 11, 88, 359, 257, 258, 1656, 1657, "." +474, 11, 89, 360, 259, 260, 1658, 1659, "6" +474, 11, 90, 361, 261, 263, 1660, 1662, "mm" +474, 11, 91, 362, 264, 266, 1663, 1665, "Hg" +474, 11, 92, 363, 267, 268, 1666, 1667, "(" +474, 11, 93, 364, 269, 271, 1668, 1670, "15" +474, 11, 94, 365, 272, 273, 1671, 1672, "%" +474, 11, 95, 366, 274, 275, 1673, 1674, ")" +474, 11, 96, 367, 276, 279, 1675, 1678, "for" +474, 11, 97, 368, 280, 291, 1679, 1690, "unoprostone" +474, 11, 98, 369, 292, 293, 1691, 1692, "(" +474, 11, 99, 370, 294, 296, 1693, 1695, "25" +474, 11, 100, 371, 297, 298, 1696, 1697, "." +474, 11, 101, 372, 299, 300, 1698, 1699, "5" +474, 11, 102, 373, 301, 302, 1700, 1701, "+" +474, 11, 103, 374, 303, 304, 1702, 1703, "/" +474, 11, 104, 375, 305, 306, 1704, 1705, "-" +474, 11, 105, 376, 307, 308, 1706, 1707, "3" +474, 11, 106, 377, 309, 310, 1708, 1709, "." +474, 11, 107, 378, 311, 312, 1710, 1711, "3" +474, 11, 108, 379, 313, 315, 1712, 1714, "mm" +474, 11, 109, 380, 316, 318, 1715, 1717, "Hg" +474, 11, 110, 381, 319, 321, 1718, 1720, "at" +474, 11, 111, 382, 322, 330, 1721, 1729, "baseline" +474, 11, 112, 383, 331, 333, 1730, 1732, "to" +474, 11, 113, 384, 334, 336, 1733, 1735, "21" +474, 11, 114, 385, 337, 338, 1736, 1737, "." +474, 11, 115, 386, 339, 340, 1738, 1739, "6" +474, 11, 116, 387, 341, 342, 1740, 1741, "+" +474, 11, 117, 388, 343, 344, 1742, 1743, "/" +474, 11, 118, 389, 345, 346, 1744, 1745, "-" +474, 11, 119, 390, 347, 348, 1746, 1747, "4" +474, 11, 120, 391, 349, 350, 1748, 1749, "." +474, 11, 121, 392, 351, 352, 1750, 1751, "0" +474, 11, 122, 393, 353, 355, 1752, 1754, "mm" +474, 11, 123, 394, 356, 358, 1755, 1757, "Hg" +474, 11, 124, 395, 359, 360, 1758, 1759, ";" +474, 11, 125, 396, 361, 362, 1760, 1761, "P" +474, 11, 126, 397, 363, 364, 1762, 1763, "<" +474, 11, 127, 398, 365, 367, 1764, 1766, "or" +474, 11, 128, 399, 368, 369, 1767, 1768, "=" +474, 11, 129, 400, 370, 371, 1769, 1770, "." +474, 11, 130, 401, 372, 375, 1771, 1774, "001" +474, 11, 131, 402, 376, 377, 1775, 1776, "." +474, 12, 1, 403, 0, 2, 1777, 1779, "No" +474, 12, 2, 404, 3, 10, 1780, 1787, "serious" +474, 12, 3, 405, 11, 18, 1788, 1795, "adverse" +474, 12, 4, 406, 19, 24, 1796, 1801, "event" +474, 12, 5, 407, 25, 32, 1802, 1809, "related" +474, 12, 6, 408, 33, 35, 1810, 1812, "to" +474, 12, 7, 409, 36, 42, 1813, 1819, "either" +474, 12, 8, 410, 43, 53, 1820, 1830, "medication" +474, 12, 9, 411, 54, 57, 1831, 1834, "was" +474, 12, 10, 412, 58, 66, 1835, 1843, "reported" +474, 12, 11, 413, 67, 68, 1844, 1845, "." +474, 13, 1, 414, 0, 11, 1846, 1857, "CONCLUSIONS" +474, 13, 2, 415, 12, 13, 1858, 1859, ":" +474, 13, 3, 416, 14, 18, 1860, 1864, "Over" +474, 13, 4, 417, 19, 21, 1865, 1867, "an" +474, 13, 5, 418, 22, 23, 1868, 1869, "8" +474, 13, 6, 419, 24, 25, 1870, 1871, "-" +474, 13, 7, 420, 26, 30, 1872, 1876, "week" +474, 13, 8, 421, 31, 37, 1877, 1883, "period" +474, 13, 9, 422, 38, 39, 1884, 1885, "," +474, 13, 10, 423, 40, 51, 1886, 1897, "latanoprost" +474, 13, 11, 424, 52, 53, 1898, 1899, "0" +474, 13, 12, 425, 54, 55, 1900, 1901, "." +474, 13, 13, 426, 56, 59, 1902, 1905, "005" +474, 13, 14, 427, 60, 61, 1906, 1907, "%" +474, 13, 15, 428, 62, 66, 1908, 1912, "once" +474, 13, 16, 429, 67, 72, 1913, 1918, "daily" +474, 13, 17, 430, 73, 80, 1919, 1926, "lowered" +474, 13, 18, 431, 81, 84, 1927, 1930, "IOP" +474, 13, 19, 432, 85, 89, 1931, 1935, "more" +474, 13, 20, 433, 90, 94, 1936, 1940, "than" +474, 13, 21, 434, 95, 106, 1941, 1952, "unoprostone" +474, 13, 22, 435, 107, 108, 1953, 1954, "0" +474, 13, 23, 436, 109, 110, 1955, 1956, "." +474, 13, 24, 437, 111, 113, 1957, 1959, "15" +474, 13, 25, 438, 114, 115, 1960, 1961, "%" +474, 13, 26, 439, 116, 121, 1962, 1967, "twice" +474, 13, 27, 440, 122, 127, 1968, 1973, "daily" +474, 13, 28, 441, 128, 130, 1974, 1976, "in" +474, 13, 29, 442, 131, 139, 1977, 1985, "patients" +474, 13, 30, 443, 140, 144, 1986, 1990, "with" +474, 13, 31, 444, 145, 153, 1991, 1999, "elevated" +474, 13, 32, 445, 154, 157, 2000, 2003, "IOP" +474, 13, 33, 446, 158, 159, 2004, 2005, "." +474, 14, 1, 447, 0, 4, 2006, 2010, "Both" +474, 14, 2, 448, 5, 11, 2011, 2017, "agents" +474, 14, 3, 449, 12, 16, 2018, 2022, "were" +474, 14, 4, 450, 17, 21, 2023, 2027, "safe" +474, 14, 5, 451, 22, 25, 2028, 2031, "and" +474, 14, 6, 452, 26, 30, 2032, 2036, "well" +474, 14, 7, 453, 31, 40, 2037, 2046, "tolerated" +474, 14, 8, 454, 41, 42, 2047, 2048, "." +474, 15, 1, 455, 0, 3, 2049, 2052, "DOI" +474, 15, 2, 456, 4, 5, 2053, 2054, ":" +474, 15, 3, 457, 6, 8, 2055, 2057, "10" +474, 15, 4, 458, 9, 10, 2058, 2059, "." +474, 15, 5, 459, 11, 15, 2060, 2064, "1016" +474, 15, 6, 460, 16, 17, 2065, 2066, "/" +474, 15, 7, 461, 18, 23, 2067, 2072, "s0002" +474, 15, 8, 462, 24, 25, 2073, 2074, "-" +474, 15, 9, 463, 26, 30, 2075, 2079, "9394" +474, 15, 10, 464, 31, 32, 2080, 2081, "(" +474, 15, 11, 465, 33, 35, 2082, 2084, "02" +474, 15, 12, 466, 36, 37, 2085, 2086, ")" +474, 15, 13, 467, 38, 43, 2087, 2092, "01820" +474, 15, 14, 468, 44, 45, 2093, 2094, "-" +474, 15, 15, 469, 46, 47, 2095, 2096, "2" +474, 15, 16, 470, 48, 52, 2097, 2101, "PMID" +474, 15, 17, 471, 53, 54, 2102, 2103, ":" +474, 15, 18, 472, 55, 63, 2104, 2112, "12470755" +474, 15, 19, 473, 64, 65, 2113, 2114, "[" +474, 15, 20, 474, 66, 73, 2115, 2122, "Indexed" +474, 15, 21, 475, 74, 77, 2123, 2126, "for" +474, 15, 22, 476, 78, 85, 2127, 2134, "MEDLINE" +474, 15, 23, 477, 86, 87, 2135, 2136, "]" diff --git a/data/gl 12470755_jshahinitiran.annodb b/data/gl 12470755_jshahinitiran.annodb new file mode 100644 index 0000000..38e515a --- /dev/null +++ b/data/gl 12470755_jshahinitiran.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7009, Journal, 0, 15, "Am J Ophthalmol", "", +7010, PublicationYear, 18, 22, "2002", "", +7011, Title, 52, 157, "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure .", "", +7012, Randomized, 52, 62, "Randomized", "", +7013, Latanoprost, 81, 92, "latanoprost", "", +7014, Unoprostone, 97, 108, "unoprostone", "", +7015, IOP, 135, 155, "intraocular pressure", "", +7016, Author, 158, 167, "Jampel HD", "", +7017, Author, 176, 187, "Bacharach J", "", +7018, Author, 190, 197, "Sheu WP", "", +7019, Author, 200, 207, "Wohl LG", "", +7020, Author, 210, 219, "Solish AM", "", +7021, Author, 222, 232, "Christie W", "", +26321, Latanoprost, 235, 246, "Latanoprost", "", +26322, Unoprostone, 249, 260, "Unoprostone", "", +26286, USA, 418, 421, "USA", "", +7023, ObjectiveDescription, 455, 682, "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .", "", +7024, IOP, 470, 490, "intraocular pressure", "", +7025, IOP, 493, 496, "IOP", "", +26289, Latanoprost, 531, 542, "latanoprost", "", +26291, DoseValue, 543, 550, "0 . 005", "", +26294, Percentage, 551, 552, "%", "", +26295, Frequency, 553, 563, "once daily", "", +26290, Unoprostone, 577, 588, "unoprostone", "", +26292, DoseValue, 589, 595, "0 . 15", "", +26293, Percentage, 596, 597, "%", "", +26296, Frequency, 598, 609, "twice daily", "", +26431, Primary_OpenAngleGlaucoma, 628, 657, "primary open - angle glaucoma", "", +7035, OcularHypertension, 661, 680, "ocular hypertension", "", +26297, Randomized, 692, 702, "Randomized", "", +7037, CTDesign, 735, 746, "prospective", "prospective", +26298, Duration, 749, 757, "8 - week", "", +7039, Blind, 760, 781, "investigator - masked", "", +7040, Parallel, 784, 792, "parallel", "", +7041, Multicenter, 820, 836, "numerous centers", "", +26288, USA, 844, 857, "United States", "", +7043, NumberPatientsCT, 860, 863, "165", "", +7044, Precondition, 864, 950, "previously treated patients with IOP > or = 25 mm Hg in one or both eyes after washout", "", +26299, mmHg, 911, 916, "mm Hg", "", +26300, Randomized, 956, 964, "randomly", "", +26301, Latanoprost, 992, 1003, "latanoprost", "", +26303, DoseValue, 1004, 1011, "0 . 005", "", +26305, Percentage, 1012, 1013, "%", "", +26307, Frequency, 1014, 1024, "once daily", "", +7050, Bedtime, 1032, 1039, "evening", "", +26302, Unoprostone, 1043, 1054, "unoprostone", "", +26304, DoseValue, 1055, 1061, "0 . 15", "", +26306, Percentage, 1062, 1063, "%", "", +26308, Frequency, 1064, 1075, "twice daily", "", +26323, Mean, 1263, 1267, "mean", "", +7056, IOP, 1275, 1279, "IOPs", "", +39045, TimePoint, 1336, 1344, "baseline", "", +39046, TimePoint, 1376, 1383, "8 weeks", "", +26309, Mean, 1427, 1431, "mean", "", +7083, IOP, 1448, 1452, "IOPs", "", +7059, Reduction, 1507, 1512, "7 . 2", "", +7060, SdDevChangeValue, 1519, 1524, "3 . 2", "", +7061, mmHg, 1525, 1530, "mm Hg", "", +7062, RelativeReduction, 1533, 1535, "28", "", +26310, Latanoprost, 1544, 1555, "latanoprost", "", +7064, BaseLineValue, 1558, 1564, "25 . 3", "", +7065, SdDevBL, 1571, 1576, "2 . 8", "", +7066, mmHg, 1577, 1582, "mm Hg", "BL", +39047, TimePoint, 1586, 1594, "baseline", "", +7067, ResultMeasuredValue, 1598, 1604, "18 . 2", "", +7068, SdDevResValue, 1611, 1616, "2 . 8", "", +7069, mmHg, 1617, 1622, "mm Hg", "", +39048, TimePoint, 1626, 1633, "8 weeks", "", +7071, Reduction, 1642, 1647, "3 . 9", "", +7072, SdDevChangeValue, 1654, 1659, "2 . 6", "", +7073, mmHg, 1660, 1665, "mm Hg", "", +7074, RelativeReduction, 1668, 1670, "15", "", +26311, Unoprostone, 1679, 1690, "unoprostone", "", +7076, BaseLineValue, 1693, 1699, "25 . 5", "", +7077, SdDevBL, 1706, 1711, "3 . 3", "", +7078, mmHg, 1712, 1717, "mm Hg", "", +7079, ResultMeasuredValue, 1733, 1739, "21 . 6", "", +7080, SdDevResValue, 1746, 1751, "4 . 0", "", +7081, mmHg, 1752, 1757, "mm Hg", "", +7082, PValueChangeValue, 1760, 1774, "P < or = . 001", "", +7084, ConclusionComment, 1860, 2005, "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .", "", +26312, Duration, 1868, 1876, "8 - week", "", +26313, Latanoprost, 1886, 1897, "latanoprost", "", +26315, DoseValue, 1898, 1905, "0 . 005", "", +26317, Percentage, 1906, 1907, "%", "", +26319, Frequency, 1908, 1918, "once daily", "", +7092, IOP, 1927, 1930, "IOP", "", +26314, Unoprostone, 1941, 1952, "unoprostone", "", +26316, DoseValue, 1953, 1959, "0 . 15", "", +26318, Percentage, 1960, 1961, "%", "", +26320, Frequency, 1962, 1973, "twice daily", "", +7097, IOP, 2000, 2003, "IOP", "", +7085, ConclusionComment, 2006, 2048, "Both agents were safe and well tolerated .", "", +7098, PMID, 2104, 2112, "12470755", "", diff --git a/data/gl 12470755_jshahinitiran.n-triples b/data/gl 12470755_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12470755_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12470755_tstrakeljahn.annodb b/data/gl 12470755_tstrakeljahn.annodb new file mode 100644 index 0000000..80e22b2 --- /dev/null +++ b/data/gl 12470755_tstrakeljahn.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +36228, Journal, 0, 15, "Am J Ophthalmol", "", +36229, PublicationYear, 18, 22, "2002", "", +36230, Randomized, 52, 62, "Randomized", "", +36323, Title, 52, 155, "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure", "", +36231, Latanoprost, 81, 92, "latanoprost", "", +36232, Unoprostone, 97, 108, "unoprostone", "", +36233, IOP, 135, 155, "intraocular pressure", "", +36234, Author, 158, 167, "Jampel HD", "", +36235, Author, 176, 187, "Bacharach J", "", +36236, Author, 190, 197, "Sheu WP", "", +36237, Author, 200, 207, "Wohl LG", "", +36238, Author, 210, 219, "Solish AM", "", +36239, Author, 222, 232, "Christie W", "", +36240, Latanoprost, 235, 246, "Latanoprost", "", +36241, Unoprostone, 249, 260, "Unoprostone", "", +36242, USA, 418, 421, "USA", "", +36304, ObjectiveDescription, 455, 682, "To compare the intraocular pressure ( IOP ) - lowering effect and safety of latanoprost 0 . 005 % once daily with that of unoprostone 0 . 15 % twice daily for patients with primary open - angle glaucoma or ocular hypertension .", "", +36243, IOP, 470, 490, "intraocular pressure", "", +36244, IOP, 493, 496, "IOP", "", +36245, Latanoprost, 531, 542, "latanoprost", "", +36247, DoseValue, 543, 550, "0 . 005", "", +36249, Percentage, 551, 552, "%", "", +36251, Frequency, 553, 563, "once daily", "", +36246, Unoprostone, 577, 588, "unoprostone", "", +36248, DoseValue, 589, 595, "0 . 15", "", +36250, Percentage, 596, 597, "%", "", +36252, Frequency, 598, 609, "twice daily", "", +36253, Primary_OpenAngleGlaucoma, 628, 657, "primary open - angle glaucoma", "", +36254, OcularHypertension, 661, 680, "ocular hypertension", "", +36255, Randomized, 692, 702, "Randomized", "", +36256, ClinicalTrial, 703, 717, "clinical trial", "", +36257, Duration, 749, 757, "8 - week", "", +36258, Blind, 760, 781, "investigator - masked", "", +36259, Parallel, 784, 792, "parallel", "", +36260, Multicenter, 820, 836, "numerous centers", "", +36261, USA, 844, 857, "United States", "", +36262, NumberPatientsCT, 860, 863, "165", "", +36264, Precondition, 897, 916, "IOP > or = 25 mm Hg", "", +36263, mmHg, 911, 916, "mm Hg", "", +36265, Randomized, 956, 964, "randomly", "", +36266, Latanoprost, 992, 1003, "latanoprost", "", +36268, DoseValue, 1004, 1011, "0 . 005", "", +36270, Percentage, 1012, 1013, "%", "", +36273, Frequency, 1014, 1024, "once daily", "", +36267, Unoprostone, 1043, 1054, "unoprostone", "", +36269, DoseValue, 1055, 1061, "0 . 15", "", +36271, Percentage, 1062, 1063, "%", "", +36272, Frequency, 1064, 1075, "twice daily", "", +36274, Mean, 1263, 1267, "mean", "", +36275, IOP, 1275, 1279, "IOPs", "", +36276, Mean, 1427, 1431, "mean", "", +36278, IOP, 1448, 1452, "IOPs", "", +36279, Reduction, 1507, 1512, "7 . 2", "", +36280, SdDevChangeValue, 1513, 1524, "+ / - 3 . 2", "", +36282, mmHg, 1525, 1530, "mm Hg", "", +36284, RelativeReduction, 1533, 1535, "28", "", +36288, Latanoprost, 1544, 1555, "latanoprost", "", +36290, BaseLineValue, 1558, 1564, "25 . 3", "", +36293, SdDevBL, 1565, 1576, "+ / - 2 . 8", "", +36294, mmHg, 1577, 1582, "mm Hg", "", +36296, ResultMeasuredValue, 1598, 1604, "18 . 2", "", +36299, SdDevResValue, 1605, 1616, "+ / - 2 . 8", "", +36283, mmHg, 1617, 1622, "mm Hg", "", +36300, TimePoint, 1626, 1633, "8 weeks", "", +36301, Reduction, 1642, 1647, "3 . 9", "", +36281, SdDevChangeValue, 1648, 1659, "+ / - 2 . 6", "", +36286, mmHg, 1660, 1665, "mm Hg", "", +36285, RelativeReduction, 1668, 1670, "15", "", +36289, Unoprostone, 1679, 1690, "unoprostone", "", +36291, BaseLineValue, 1693, 1699, "25 . 5", "", +36292, SdDevBL, 1700, 1711, "+ / - 3 . 3", "", +36287, mmHg, 1712, 1717, "mm Hg", "", +36297, ResultMeasuredValue, 1733, 1739, "21 . 6", "", +36298, SdDevResValue, 1740, 1751, "+ / - 4 . 0", "", +36295, mmHg, 1752, 1757, "mm Hg", "", +36302, PvalueDiff, 1760, 1774, "P < or = . 001", "", +36303, ObservedResult, 1777, 1843, "No serious adverse event related to either medication was reported", "", +36316, ConclusionComment, 1860, 2005, "Over an 8 - week period , latanoprost 0 . 005 % once daily lowered IOP more than unoprostone 0 . 15 % twice daily in patients with elevated IOP .", "", +36305, Duration, 1868, 1876, "8 - week", "", +36306, Latanoprost, 1886, 1897, "latanoprost", "", +36308, DoseValue, 1898, 1905, "0 . 005", "", +36310, Percentage, 1906, 1907, "%", "", +36312, Frequency, 1908, 1918, "once daily", "", +36315, IOP, 1927, 1930, "IOP", "", +36307, Unoprostone, 1941, 1952, "unoprostone", "", +36309, DoseValue, 1953, 1959, "0 . 15", "", +36311, Percentage, 1960, 1961, "%", "", +36313, Frequency, 1962, 1973, "twice daily", "", +36314, IOP, 2000, 2003, "IOP", "", +36317, ConclusionComment, 2006, 2048, "Both agents were safe and well tolerated .", "", +36318, PMID, 2104, 2112, "12470755", "", diff --git a/data/gl 12470755_tstrakeljahn.n-triples b/data/gl 12470755_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12470755_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12483094_admin.annodb b/data/gl 12483094_admin.annodb new file mode 100644 index 0000000..80e7b78 --- /dev/null +++ b/data/gl 12483094_admin.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +102, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2002", "", " \"2002\"." +2, Title, 47, 198, "A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open - angle glaucoma and ocular hypertension .", "", " \"A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open - angle glaucoma and ocular hypertension .\"." +3, Latanoprost, 79, 90, "latanoprost", "", +4, Unoprostone, 95, 116, "isopropyl unoprostone", "", +5, Ethnicity, 120, 128, "Japanese", "", " . ." +6, Primary_OpenAngleGlaucoma, 143, 172, "primary open - angle glaucoma", "", " ." +7, OcularHypertension, 177, 196, "ocular hypertension", "", " ." +8, Author, 199, 210, "Tsukamoto H", "", " \"Tsukamoto H\"." +9, Author, 219, 229, "Mishima HK", "", " \"Mishima HK\"." +10, Author, 232, 242, "Kitazawa Y", "", " \"Kitazawa Y\"." +11, Author, 245, 252, "Araie M", "", " \"Araie M\"." +12, Author, 255, 260, "Abe H", "", " \"Abe H\"." +13, Author, 263, 269, "Negi A", "", " \"Negi A\"." +14, Glaucoma, 272, 280, "Glaucoma", "", " . ." +15, Japan, 444, 449, "Japan", "", " ." +16, ObjectiveDescription, 462, 653, "To compare the efficacy and safety of latanoprost versus isopropyl unoprostone ( unoprostone ) in Japanese patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", " \"To compare the efficacy and safety of latanoprost versus isopropyl unoprostone ( unoprostone ) in Japanese patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .\"." +17, Latanoprost, 500, 511, "latanoprost", "", +18, Unoprostone, 519, 540, "isopropyl unoprostone", "", +19, Unoprostone, 543, 554, "unoprostone", "", +20, Ethnicity, 560, 568, "Japanese", "", +21, Primary_OpenAngleGlaucoma, 583, 612, "primary open - angle glaucoma", "", +22, Primary_OpenAngleGlaucoma, 615, 619, "POAG", "", +24, OcularHypertension, 625, 644, "ocular hypertension", "", +25, OcularHypertension, 647, 649, "OH", "", +27, Duration, 667, 675, "8 - week", "", " \"8 - week\"." +28, Multicenter, 678, 689, "multicenter", "", " ." +29, Randomized, 692, 702, "randomized", "", " ." +30, NumberPatientsCT, 740, 742, "48", "", " \"48\"." +131, Ethnicity, 743, 751, "Japanese", "", +23, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +26, OcularHypertension, 774, 776, "OH", "", +31, NumPatientsLeftCT, 779, 783, "Four", "", " \"Four\"." +32, NumPatientsLeftArm, 795, 798, "two", "", " \"two\". \"two\"." +33, IOP, 910, 930, "intraocular pressure", "", " . ." +34, IOP, 933, 936, "IOP", "", +35, Randomized, 970, 978, "randomly", "", +36, Latanoprost, 992, 1003, "latanoprost", "", " . ." +38, DoseValue, 1004, 1011, "0 . 005", "", " \"0 . 005\"." +144, Percentage, 1012, 1013, "%", "", " ." +40, Frequency, 1014, 1024, "once daily", "", " \"once daily\"." +37, Unoprostone, 1028, 1039, "unoprostone", "", " ." +39, DoseValue, 1040, 1046, "0 . 12", "", " \"0 . 12\"." +145, Percentage, 1047, 1048, "%", "", " ." +41, Frequency, 1049, 1060, "twice daily", "", " \"twice daily\"." +146, Duration, 1065, 1072, "8 weeks", "", +43, IOP, 1075, 1078, "IOP", "", +44, TimePoint, 1095, 1103, "baseline", "", +151, TimePoint, 1108, 1143, "2 , 4 , and 8 weeks after treatment", "", +150, TimePoint, 1112, 1143, "4 , and 8 weeks after treatment", "", +149, TimePoint, 1120, 1143, "8 weeks after treatment", "", +48, IOP, 1234, 1238, "IOPs", "", +49, Latanoprost, 1264, 1275, "latanoprost", "", +186, FinalNumPatientsArm, 1282, 1284, "25", "", " \"25\"." +51, Unoprostone, 1291, 1302, "unoprostone", "", +187, FinalNumPatientsArm, 1309, 1311, "19", "", " \"19\"." +53, BaseLineValue, 1323, 1329, "24 . 3", "", +157, SdDevBL, 1336, 1341, "2 . 4", "", +58, mmHg, 1342, 1347, "mm Hg", "", +54, BaseLineValue, 1351, 1357, "23 . 3", "", +158, SdDevBL, 1364, 1369, "2 . 1", "", +57, mmHg, 1370, 1375, "mm Hg", "", " ." +59, PValueBL, 1393, 1401, "= 0 . 18", "", +60, IOP, 1410, 1413, "IOP", "", +164, TimePoint, 1442, 1477, "2 , 4 , and 8 weeks after treatment", "", " \"2 , 4 , and 8 weeks after treatment\". \"2 , 4 , and 8 weeks after treatment\"." +163, TimePoint, 1446, 1477, "4 , and 8 weeks after treatment", "", " \"4 , and 8 weeks after treatment\". \"4 , and 8 weeks after treatment\"." +162, TimePoint, 1454, 1477, "8 weeks after treatment", "", " \"8 weeks after treatment\". \"8 weeks after treatment\"." +64, Reduction, 1483, 1488, "5 . 8", "", " \"5 . 8\"." +171, SdDevChangeValue, 1495, 1500, "2 . 4", "", " \"2 . 4\"." +65, Reduction, 1503, 1508, "6 . 6", "", " \"6 . 6\"." +172, SdDevChangeValue, 1515, 1520, "2 . 5", "", " \"2 . 5\"." +66, Reduction, 1527, 1532, "6 . 7", "", " \"6 . 7\"." +173, SdDevChangeValue, 1539, 1544, "2 . 0", "", " \"2 . 0\"." +70, mmHg, 1545, 1550, "mm Hg", "", +71, Latanoprost, 1558, 1569, "latanoprost", "", +72, Reduction, 1582, 1587, "3 . 8", "", " \"3 . 8\"." +174, SdDevChangeValue, 1594, 1599, "2 . 0", "", " \"2 . 0\"." +73, Reduction, 1602, 1607, "3 . 5", "", " \"3 . 5\"." +175, SdDevChangeValue, 1614, 1619, "2 . 3", "", " \"2 . 3\"." +74, Reduction, 1626, 1631, "3 . 3", "", " \"3 . 3\"." +176, SdDevChangeValue, 1638, 1643, "3 . 0", "", " \"3 . 0\"." +78, mmHg, 1644, 1649, "mm Hg", "", +79, Unoprostone, 1657, 1668, "unoprostone", "", +80, IOP, 1696, 1699, "IOP", "", +81, Latanoprost, 1717, 1728, "latanoprost", "", +82, TimePoint, 1738, 1745, "8 weeks", "", +83, Unoprostone, 1774, 1785, "unoprostone", "", +84, PvalueDiff, 1794, 1803, "< 0 . 001", "", " \"< 0 . 001\"." +106405, EndPointDescription, 1838, 1852, "adverse events", "", " . ." +85, NumberAffected, 1870, 1871, "4", "", " \"4\"." +87, PercentageAffected, 1874, 1876, "15", "", " \"15\"." +89, NumberPatientsArm, 1884, 1886, "27", "", " \"27\"." +91, Latanoprost, 1903, 1914, "latanoprost", "", +86, NumberAffected, 1964, 1965, "4", "", " \"4\"." +88, PercentageAffected, 1968, 1970, "20", "", " \"20\"." +90, NumberPatientsArm, 1978, 1980, "21", "", " \"21\"." +92, Unoprostone, 1997, 2008, "unoprostone", "", +198, ObservedResult, 2017, 2105, "There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) .", "", " \"There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) .\". \"There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) .\"." +197, PvalueDiff, 2093, 2101, "= 0 . 71", "", " \"= 0 . 71\"." +94, ConclusionComment, 2119, 2236, "Latanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH .", "", " \"Latanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH .\"." +95, Latanoprost, 2119, 2130, "Latanoprost", "", +96, IOP, 2177, 2180, "IOP", "", +97, Unoprostone, 2186, 2197, "unoprostone", "", +98, Ethnicity, 2201, 2209, "Japanese", "", +99, Primary_OpenAngleGlaucoma, 2224, 2228, "POAG", "", +100, OcularHypertension, 2232, 2234, "OH", "", +101, PMID, 2291, 2299, "12483094", "", " \"12483094\"." diff --git a/data/gl 12483094_admin.n-triples b/data/gl 12483094_admin.n-triples new file mode 100644 index 0000000..7339d96 --- /dev/null +++ b/data/gl 12483094_admin.n-triples @@ -0,0 +1,165 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open - angle glaucoma and ocular hypertension ." . + "Tsukamoto H" . + "2002" . + "J Glaucoma" . + "12483094" . + . + "Mishima HK" . + "Kitazawa Y" . + "Araie M" . + "Abe H" . + "Negi A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and safety of latanoprost versus isopropyl unoprostone ( unoprostone ) in Japanese patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) ." . + "48" . + "8 - week" . + . + . + . + "Latanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH ." . + . + . + . + . + . + "Four" . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + "27" . + "25" . + . + . + . + "two" . + . + . + . + "Arm_uno" . + "21" . + "19" . + . + . + . + "two" . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_uno" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_uno" . + . + "0 . 12" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_2w_lat" . + . + "5 . 8" . + "2 . 4" . + "2 , 4 , and 8 weeks after treatment" . + . + "Outcome_iop_4w_lat" . + . + "6 . 6" . + "2 . 5" . + "4 , and 8 weeks after treatment" . + . + "Outcome_iop_8w_lat" . + . + "6 . 7" . + "2 . 0" . + "8 weeks after treatment" . + . + "Outcome_iop_2w_uno" . + . + "3 . 8" . + "2 . 0" . + "2 , 4 , and 8 weeks after treatment" . + . + "Outcome_iop_4w_uno" . + . + "3 . 5" . + "2 . 3" . + "4 , and 8 weeks after treatment" . + . + "Outcome_iop_8w_uno" . + . + "3 . 3" . + "3 . 0" . + "8 weeks after treatment" . + . + "Outcome_AE_lat" . + . + "4" . + "15" . + "There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) ." . + . + "Outcome_AE_uno" . + . + "4" . + "20" . + "There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop_8w" . + "< 0 . 001" . + . + . + . + "DiffBetweenGroups_AE" . + "= 0 . 71" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12483094_export.csv b/data/gl 12483094_export.csv new file mode 100644 index 0000000..3097459 --- /dev/null +++ b/data/gl 12483094_export.csv @@ -0,0 +1,507 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +524, 1, 1, 1, 0, 1, 0, 1, "J" +524, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +524, 1, 3, 3, 11, 12, 11, 12, "." +524, 2, 1, 4, 0, 4, 13, 17, "2002" +524, 2, 2, 5, 5, 8, 18, 21, "Dec" +524, 2, 3, 6, 9, 10, 22, 23, ";" +524, 2, 4, 7, 11, 13, 24, 26, "11" +524, 2, 5, 8, 14, 15, 27, 28, "(" +524, 2, 6, 9, 16, 17, 29, 30, "6" +524, 2, 7, 10, 18, 19, 31, 32, ")" +524, 2, 8, 11, 20, 21, 33, 34, ":" +524, 2, 9, 12, 22, 25, 35, 38, "497" +524, 2, 10, 13, 26, 27, 39, 40, "-" +524, 2, 11, 14, 28, 31, 41, 44, "501" +524, 2, 12, 15, 32, 33, 45, 46, "." +524, 3, 1, 16, 0, 1, 47, 48, "A" +524, 3, 2, 17, 2, 13, 49, 60, "comparative" +524, 3, 3, 18, 14, 22, 61, 69, "clinical" +524, 3, 4, 19, 23, 28, 70, 75, "study" +524, 3, 5, 20, 29, 31, 76, 78, "of" +524, 3, 6, 21, 32, 43, 79, 90, "latanoprost" +524, 3, 7, 22, 44, 47, 91, 94, "and" +524, 3, 8, 23, 48, 57, 95, 104, "isopropyl" +524, 3, 9, 24, 58, 69, 105, 116, "unoprostone" +524, 3, 10, 25, 70, 72, 117, 119, "in" +524, 3, 11, 26, 73, 81, 120, 128, "Japanese" +524, 3, 12, 27, 82, 90, 129, 137, "patients" +524, 3, 13, 28, 91, 95, 138, 142, "with" +524, 3, 14, 29, 96, 103, 143, 150, "primary" +524, 3, 15, 30, 104, 108, 151, 155, "open" +524, 3, 16, 31, 109, 110, 156, 157, "-" +524, 3, 17, 32, 111, 116, 158, 163, "angle" +524, 3, 18, 33, 117, 125, 164, 172, "glaucoma" +524, 3, 19, 34, 126, 129, 173, 176, "and" +524, 3, 20, 35, 130, 136, 177, 183, "ocular" +524, 3, 21, 36, 137, 149, 184, 196, "hypertension" +524, 3, 22, 37, 150, 151, 197, 198, "." +524, 4, 1, 38, 0, 9, 199, 208, "Tsukamoto" +524, 4, 2, 39, 10, 11, 209, 210, "H" +524, 4, 3, 40, 12, 13, 211, 212, "(" +524, 4, 4, 41, 14, 15, 213, 214, "1" +524, 4, 5, 42, 16, 17, 215, 216, ")" +524, 4, 6, 43, 18, 19, 217, 218, "," +524, 4, 7, 44, 20, 27, 219, 226, "Mishima" +524, 4, 8, 45, 28, 30, 227, 229, "HK" +524, 4, 9, 46, 31, 32, 230, 231, "," +524, 4, 10, 47, 33, 41, 232, 240, "Kitazawa" +524, 4, 11, 48, 42, 43, 241, 242, "Y" +524, 4, 12, 49, 44, 45, 243, 244, "," +524, 4, 13, 50, 46, 51, 245, 250, "Araie" +524, 4, 14, 51, 52, 53, 251, 252, "M" +524, 4, 15, 52, 54, 55, 253, 254, "," +524, 4, 16, 53, 56, 59, 255, 258, "Abe" +524, 4, 17, 54, 60, 61, 259, 260, "H" +524, 4, 18, 55, 62, 63, 261, 262, "," +524, 4, 19, 56, 64, 68, 263, 267, "Negi" +524, 4, 20, 57, 69, 70, 268, 269, "A" +524, 4, 21, 58, 71, 72, 270, 271, ";" +524, 4, 22, 59, 73, 81, 272, 280, "Glaucoma" +524, 4, 23, 60, 82, 87, 281, 286, "Study" +524, 4, 24, 61, 88, 93, 287, 292, "Group" +524, 4, 25, 62, 94, 95, 293, 294, "." +524, 5, 1, 63, 0, 6, 295, 301, "Author" +524, 5, 2, 64, 7, 18, 302, 313, "information" +524, 5, 3, 65, 19, 20, 314, 315, ":" +524, 5, 4, 66, 21, 22, 316, 317, "(" +524, 5, 5, 67, 23, 24, 318, 319, "1" +524, 5, 6, 68, 25, 26, 320, 321, ")" +524, 5, 7, 69, 27, 37, 322, 332, "Department" +524, 5, 8, 70, 38, 40, 333, 335, "of" +524, 5, 9, 71, 41, 53, 336, 348, "Opthalmology" +524, 5, 10, 72, 54, 57, 349, 352, "and" +524, 5, 11, 73, 58, 64, 353, 359, "Visual" +524, 5, 12, 74, 65, 72, 360, 367, "Science" +524, 5, 13, 75, 73, 74, 368, 369, "," +524, 5, 14, 76, 75, 84, 370, 379, "Hiroshima" +524, 5, 15, 77, 85, 95, 380, 390, "University" +524, 5, 16, 78, 96, 104, 391, 399, "Graduate" +524, 5, 17, 79, 105, 111, 400, 406, "School" +524, 5, 18, 80, 112, 114, 407, 409, "of" +524, 5, 19, 81, 115, 125, 410, 420, "Biomedical" +524, 5, 20, 82, 126, 134, 421, 429, "Sciences" +524, 5, 21, 83, 135, 136, 430, 431, "," +524, 5, 22, 84, 137, 146, 432, 441, "Hiroshima" +524, 5, 23, 85, 147, 148, 442, 443, "," +524, 5, 24, 86, 149, 154, 444, 449, "Japan" +524, 5, 25, 87, 155, 156, 450, 451, "." +524, 6, 1, 88, 0, 7, 452, 459, "PURPOSE" +524, 6, 2, 89, 8, 9, 460, 461, ":" +524, 6, 3, 90, 10, 12, 462, 464, "To" +524, 6, 4, 91, 13, 20, 465, 472, "compare" +524, 6, 5, 92, 21, 24, 473, 476, "the" +524, 6, 6, 93, 25, 33, 477, 485, "efficacy" +524, 6, 7, 94, 34, 37, 486, 489, "and" +524, 6, 8, 95, 38, 44, 490, 496, "safety" +524, 6, 9, 96, 45, 47, 497, 499, "of" +524, 6, 10, 97, 48, 59, 500, 511, "latanoprost" +524, 6, 11, 98, 60, 66, 512, 518, "versus" +524, 6, 12, 99, 67, 76, 519, 528, "isopropyl" +524, 6, 13, 100, 77, 88, 529, 540, "unoprostone" +524, 6, 14, 101, 89, 90, 541, 542, "(" +524, 6, 15, 102, 91, 102, 543, 554, "unoprostone" +524, 6, 16, 103, 103, 104, 555, 556, ")" +524, 6, 17, 104, 105, 107, 557, 559, "in" +524, 6, 18, 105, 108, 116, 560, 568, "Japanese" +524, 6, 19, 106, 117, 125, 569, 577, "patients" +524, 6, 20, 107, 126, 130, 578, 582, "with" +524, 6, 21, 108, 131, 138, 583, 590, "primary" +524, 6, 22, 109, 139, 143, 591, 595, "open" +524, 6, 23, 110, 144, 145, 596, 597, "-" +524, 6, 24, 111, 146, 151, 598, 603, "angle" +524, 6, 25, 112, 152, 160, 604, 612, "glaucoma" +524, 6, 26, 113, 161, 162, 613, 614, "(" +524, 6, 27, 114, 163, 167, 615, 619, "POAG" +524, 6, 28, 115, 168, 169, 620, 621, ")" +524, 6, 29, 116, 170, 172, 622, 624, "or" +524, 6, 30, 117, 173, 179, 625, 631, "ocular" +524, 6, 31, 118, 180, 192, 632, 644, "hypertension" +524, 6, 32, 119, 193, 194, 645, 646, "(" +524, 6, 33, 120, 195, 197, 647, 649, "OH" +524, 6, 34, 121, 198, 199, 650, 651, ")" +524, 6, 35, 122, 200, 201, 652, 653, "." +524, 7, 1, 123, 0, 7, 654, 661, "METHODS" +524, 7, 2, 124, 8, 9, 662, 663, ":" +524, 7, 3, 125, 10, 12, 664, 666, "An" +524, 7, 4, 126, 13, 14, 667, 668, "8" +524, 7, 5, 127, 15, 16, 669, 670, "-" +524, 7, 6, 128, 17, 21, 671, 675, "week" +524, 7, 7, 129, 22, 23, 676, 677, "," +524, 7, 8, 130, 24, 35, 678, 689, "multicenter" +524, 7, 9, 131, 36, 37, 690, 691, "," +524, 7, 10, 132, 38, 48, 692, 702, "randomized" +524, 7, 11, 133, 49, 50, 703, 704, "," +524, 7, 12, 134, 51, 62, 705, 716, "comparative" +524, 7, 13, 135, 63, 68, 717, 722, "study" +524, 7, 14, 136, 69, 72, 723, 726, "was" +524, 7, 15, 137, 73, 82, 727, 736, "performed" +524, 7, 16, 138, 83, 85, 737, 739, "in" +524, 7, 17, 139, 86, 88, 740, 742, "48" +524, 7, 18, 140, 89, 97, 743, 751, "Japanese" +524, 7, 19, 141, 98, 106, 752, 760, "patients" +524, 7, 20, 142, 107, 111, 761, 765, "with" +524, 7, 21, 143, 112, 116, 766, 770, "POAG" +524, 7, 22, 144, 117, 119, 771, 773, "or" +524, 7, 23, 145, 120, 122, 774, 776, "OH" +524, 7, 24, 146, 123, 124, 777, 778, "." +524, 8, 1, 147, 0, 4, 779, 783, "Four" +524, 8, 2, 148, 5, 13, 784, 792, "patients" +524, 8, 3, 149, 14, 15, 793, 794, "(" +524, 8, 4, 150, 16, 19, 795, 798, "two" +524, 8, 5, 151, 20, 22, 799, 801, "in" +524, 8, 6, 152, 23, 27, 802, 806, "each" +524, 8, 7, 153, 28, 33, 807, 812, "group" +524, 8, 8, 154, 34, 35, 813, 814, ")" +524, 8, 9, 155, 36, 44, 815, 823, "withdrew" +524, 8, 10, 156, 45, 49, 824, 828, "from" +524, 8, 11, 157, 50, 53, 829, 832, "the" +524, 8, 12, 158, 54, 59, 833, 838, "study" +524, 8, 13, 159, 60, 61, 839, 840, "," +524, 8, 14, 160, 62, 65, 841, 844, "but" +524, 8, 15, 161, 66, 71, 845, 850, "their" +524, 8, 16, 162, 72, 76, 851, 855, "data" +524, 8, 17, 163, 77, 81, 856, 860, "were" +524, 8, 18, 164, 82, 90, 861, 869, "included" +524, 8, 19, 165, 91, 93, 870, 872, "in" +524, 8, 20, 166, 94, 97, 873, 876, "the" +524, 8, 21, 167, 98, 104, 877, 883, "safety" +524, 8, 22, 168, 105, 115, 884, 894, "assessment" +524, 8, 23, 169, 116, 119, 895, 898, "but" +524, 8, 24, 170, 120, 123, 899, 902, "not" +524, 8, 25, 171, 124, 126, 903, 905, "in" +524, 8, 26, 172, 127, 130, 906, 909, "the" +524, 8, 27, 173, 131, 142, 910, 921, "intraocular" +524, 8, 28, 174, 143, 151, 922, 930, "pressure" +524, 8, 29, 175, 152, 153, 931, 932, "(" +524, 8, 30, 176, 154, 157, 933, 936, "IOP" +524, 8, 31, 177, 158, 159, 937, 938, ")" +524, 8, 32, 178, 160, 170, 939, 949, "evaluation" +524, 8, 33, 179, 171, 172, 950, 951, "." +524, 9, 1, 180, 0, 3, 952, 955, "The" +524, 9, 2, 181, 4, 12, 956, 964, "patients" +524, 9, 3, 182, 13, 17, 965, 969, "were" +524, 9, 4, 183, 18, 26, 970, 978, "randomly" +524, 9, 5, 184, 27, 34, 979, 986, "treated" +524, 9, 6, 185, 35, 39, 987, 991, "with" +524, 9, 7, 186, 40, 51, 992, 1003, "latanoprost" +524, 9, 8, 187, 52, 53, 1004, 1005, "0" +524, 9, 9, 188, 54, 55, 1006, 1007, "." +524, 9, 10, 189, 56, 59, 1008, 1011, "005" +524, 9, 11, 190, 60, 61, 1012, 1013, "%" +524, 9, 12, 191, 62, 66, 1014, 1018, "once" +524, 9, 13, 192, 67, 72, 1019, 1024, "daily" +524, 9, 14, 193, 73, 75, 1025, 1027, "or" +524, 9, 15, 194, 76, 87, 1028, 1039, "unoprostone" +524, 9, 16, 195, 88, 89, 1040, 1041, "0" +524, 9, 17, 196, 90, 91, 1042, 1043, "." +524, 9, 18, 197, 92, 94, 1044, 1046, "12" +524, 9, 19, 198, 95, 96, 1047, 1048, "%" +524, 9, 20, 199, 97, 102, 1049, 1054, "twice" +524, 9, 21, 200, 103, 108, 1055, 1060, "daily" +524, 9, 22, 201, 109, 112, 1061, 1064, "for" +524, 9, 23, 202, 113, 114, 1065, 1066, "8" +524, 9, 24, 203, 115, 120, 1067, 1072, "weeks" +524, 9, 25, 204, 121, 122, 1073, 1074, "." +524, 10, 1, 205, 0, 3, 1075, 1078, "IOP" +524, 10, 2, 206, 4, 7, 1079, 1082, "was" +524, 10, 3, 207, 8, 16, 1083, 1091, "measured" +524, 10, 4, 208, 17, 19, 1092, 1094, "at" +524, 10, 5, 209, 20, 28, 1095, 1103, "baseline" +524, 10, 6, 210, 29, 32, 1104, 1107, "and" +524, 10, 7, 211, 33, 34, 1108, 1109, "2" +524, 10, 8, 212, 35, 36, 1110, 1111, "," +524, 10, 9, 213, 37, 38, 1112, 1113, "4" +524, 10, 10, 214, 39, 40, 1114, 1115, "," +524, 10, 11, 215, 41, 44, 1116, 1119, "and" +524, 10, 12, 216, 45, 46, 1120, 1121, "8" +524, 10, 13, 217, 47, 52, 1122, 1127, "weeks" +524, 10, 14, 218, 53, 58, 1128, 1133, "after" +524, 10, 15, 219, 59, 68, 1134, 1143, "treatment" +524, 10, 16, 220, 69, 70, 1144, 1145, "." +524, 11, 1, 221, 0, 2, 1146, 1148, "In" +524, 11, 2, 222, 3, 11, 1149, 1157, "addition" +524, 11, 3, 223, 12, 13, 1158, 1159, "," +524, 11, 4, 224, 14, 20, 1160, 1166, "ocular" +524, 11, 5, 225, 21, 24, 1167, 1170, "and" +524, 11, 6, 226, 25, 33, 1171, 1179, "systemic" +524, 11, 7, 227, 34, 41, 1180, 1187, "adverse" +524, 11, 8, 228, 42, 48, 1188, 1194, "events" +524, 11, 9, 229, 49, 53, 1195, 1199, "were" +524, 11, 10, 230, 54, 62, 1200, 1208, "recorded" +524, 11, 11, 231, 63, 64, 1209, 1210, "." +524, 12, 1, 232, 0, 7, 1211, 1218, "RESULTS" +524, 12, 2, 233, 8, 9, 1219, 1220, ":" +524, 12, 3, 234, 10, 13, 1221, 1224, "The" +524, 12, 4, 235, 14, 22, 1225, 1233, "baseline" +524, 12, 5, 236, 23, 27, 1234, 1238, "IOPs" +524, 12, 6, 237, 28, 32, 1239, 1243, "were" +524, 12, 7, 238, 33, 40, 1244, 1251, "similar" +524, 12, 8, 239, 41, 48, 1252, 1259, "between" +524, 12, 9, 240, 49, 52, 1260, 1263, "the" +524, 12, 10, 241, 53, 64, 1264, 1275, "latanoprost" +524, 12, 11, 242, 65, 66, 1276, 1277, "(" +524, 12, 12, 243, 67, 68, 1278, 1279, "n" +524, 12, 13, 244, 69, 70, 1280, 1281, "=" +524, 12, 14, 245, 71, 73, 1282, 1284, "25" +524, 12, 15, 246, 74, 75, 1285, 1286, ")" +524, 12, 16, 247, 76, 79, 1287, 1290, "and" +524, 12, 17, 248, 80, 91, 1291, 1302, "unoprostone" +524, 12, 18, 249, 92, 93, 1303, 1304, "(" +524, 12, 19, 250, 94, 95, 1305, 1306, "n" +524, 12, 20, 251, 96, 97, 1307, 1308, "=" +524, 12, 21, 252, 98, 100, 1309, 1311, "19" +524, 12, 22, 253, 101, 102, 1312, 1313, ")" +524, 12, 23, 254, 103, 109, 1314, 1320, "groups" +524, 12, 24, 255, 110, 111, 1321, 1322, "(" +524, 12, 25, 256, 112, 114, 1323, 1325, "24" +524, 12, 26, 257, 115, 116, 1326, 1327, "." +524, 12, 27, 258, 117, 118, 1328, 1329, "3" +524, 12, 28, 259, 119, 120, 1330, 1331, "+" +524, 12, 29, 260, 121, 122, 1332, 1333, "/" +524, 12, 30, 261, 123, 124, 1334, 1335, "-" +524, 12, 31, 262, 125, 126, 1336, 1337, "2" +524, 12, 32, 263, 127, 128, 1338, 1339, "." +524, 12, 33, 264, 129, 130, 1340, 1341, "4" +524, 12, 34, 265, 131, 133, 1342, 1344, "mm" +524, 12, 35, 266, 134, 136, 1345, 1347, "Hg" +524, 12, 36, 267, 137, 139, 1348, 1350, "vs" +524, 12, 37, 268, 140, 142, 1351, 1353, "23" +524, 12, 38, 269, 143, 144, 1354, 1355, "." +524, 12, 39, 270, 145, 146, 1356, 1357, "3" +524, 12, 40, 271, 147, 148, 1358, 1359, "+" +524, 12, 41, 272, 149, 150, 1360, 1361, "/" +524, 12, 42, 273, 151, 152, 1362, 1363, "-" +524, 12, 43, 274, 153, 154, 1364, 1365, "2" +524, 12, 44, 275, 155, 156, 1366, 1367, "." +524, 12, 45, 276, 157, 158, 1368, 1369, "1" +524, 12, 46, 277, 159, 161, 1370, 1372, "mm" +524, 12, 47, 278, 162, 164, 1373, 1375, "Hg" +524, 12, 48, 279, 165, 166, 1376, 1377, "," +524, 12, 49, 280, 167, 179, 1378, 1390, "respectively" +524, 12, 50, 281, 180, 181, 1391, 1392, "," +524, 12, 51, 282, 182, 183, 1393, 1394, "=" +524, 12, 52, 283, 184, 185, 1395, 1396, "0" +524, 12, 53, 284, 186, 187, 1397, 1398, "." +524, 12, 54, 285, 188, 190, 1399, 1401, "18" +524, 12, 55, 286, 191, 192, 1402, 1403, ")" +524, 12, 56, 287, 193, 194, 1404, 1405, "." +524, 13, 1, 288, 0, 3, 1406, 1409, "The" +524, 13, 2, 289, 4, 7, 1410, 1413, "IOP" +524, 13, 3, 290, 8, 18, 1414, 1424, "reductions" +524, 13, 4, 291, 19, 23, 1425, 1429, "from" +524, 13, 5, 292, 24, 32, 1430, 1438, "baseline" +524, 13, 6, 293, 33, 35, 1439, 1441, "at" +524, 13, 7, 294, 36, 37, 1442, 1443, "2" +524, 13, 8, 295, 38, 39, 1444, 1445, "," +524, 13, 9, 296, 40, 41, 1446, 1447, "4" +524, 13, 10, 297, 42, 43, 1448, 1449, "," +524, 13, 11, 298, 44, 47, 1450, 1453, "and" +524, 13, 12, 299, 48, 49, 1454, 1455, "8" +524, 13, 13, 300, 50, 55, 1456, 1461, "weeks" +524, 13, 14, 301, 56, 61, 1462, 1467, "after" +524, 13, 15, 302, 62, 71, 1468, 1477, "treatment" +524, 13, 16, 303, 72, 76, 1478, 1482, "were" +524, 13, 17, 304, 77, 78, 1483, 1484, "5" +524, 13, 18, 305, 79, 80, 1485, 1486, "." +524, 13, 19, 306, 81, 82, 1487, 1488, "8" +524, 13, 20, 307, 83, 84, 1489, 1490, "+" +524, 13, 21, 308, 85, 86, 1491, 1492, "/" +524, 13, 22, 309, 87, 88, 1493, 1494, "-" +524, 13, 23, 310, 89, 90, 1495, 1496, "2" +524, 13, 24, 311, 91, 92, 1497, 1498, "." +524, 13, 25, 312, 93, 94, 1499, 1500, "4" +524, 13, 26, 313, 95, 96, 1501, 1502, "," +524, 13, 27, 314, 97, 98, 1503, 1504, "6" +524, 13, 28, 315, 99, 100, 1505, 1506, "." +524, 13, 29, 316, 101, 102, 1507, 1508, "6" +524, 13, 30, 317, 103, 104, 1509, 1510, "+" +524, 13, 31, 318, 105, 106, 1511, 1512, "/" +524, 13, 32, 319, 107, 108, 1513, 1514, "-" +524, 13, 33, 320, 109, 110, 1515, 1516, "2" +524, 13, 34, 321, 111, 112, 1517, 1518, "." +524, 13, 35, 322, 113, 114, 1519, 1520, "5" +524, 13, 36, 323, 115, 116, 1521, 1522, "," +524, 13, 37, 324, 117, 120, 1523, 1526, "and" +524, 13, 38, 325, 121, 122, 1527, 1528, "6" +524, 13, 39, 326, 123, 124, 1529, 1530, "." +524, 13, 40, 327, 125, 126, 1531, 1532, "7" +524, 13, 41, 328, 127, 128, 1533, 1534, "+" +524, 13, 42, 329, 129, 130, 1535, 1536, "/" +524, 13, 43, 330, 131, 132, 1537, 1538, "-" +524, 13, 44, 331, 133, 134, 1539, 1540, "2" +524, 13, 45, 332, 135, 136, 1541, 1542, "." +524, 13, 46, 333, 137, 138, 1543, 1544, "0" +524, 13, 47, 334, 139, 141, 1545, 1547, "mm" +524, 13, 48, 335, 142, 144, 1548, 1550, "Hg" +524, 13, 49, 336, 145, 147, 1551, 1553, "in" +524, 13, 50, 337, 148, 151, 1554, 1557, "the" +524, 13, 51, 338, 152, 163, 1558, 1569, "latanoprost" +524, 13, 52, 339, 164, 169, 1570, 1575, "group" +524, 13, 53, 340, 170, 171, 1576, 1577, "," +524, 13, 54, 341, 172, 175, 1578, 1581, "and" +524, 13, 55, 342, 176, 177, 1582, 1583, "3" +524, 13, 56, 343, 178, 179, 1584, 1585, "." +524, 13, 57, 344, 180, 181, 1586, 1587, "8" +524, 13, 58, 345, 182, 183, 1588, 1589, "+" +524, 13, 59, 346, 184, 185, 1590, 1591, "/" +524, 13, 60, 347, 186, 187, 1592, 1593, "-" +524, 13, 61, 348, 188, 189, 1594, 1595, "2" +524, 13, 62, 349, 190, 191, 1596, 1597, "." +524, 13, 63, 350, 192, 193, 1598, 1599, "0" +524, 13, 64, 351, 194, 195, 1600, 1601, "," +524, 13, 65, 352, 196, 197, 1602, 1603, "3" +524, 13, 66, 353, 198, 199, 1604, 1605, "." +524, 13, 67, 354, 200, 201, 1606, 1607, "5" +524, 13, 68, 355, 202, 203, 1608, 1609, "+" +524, 13, 69, 356, 204, 205, 1610, 1611, "/" +524, 13, 70, 357, 206, 207, 1612, 1613, "-" +524, 13, 71, 358, 208, 209, 1614, 1615, "2" +524, 13, 72, 359, 210, 211, 1616, 1617, "." +524, 13, 73, 360, 212, 213, 1618, 1619, "3" +524, 13, 74, 361, 214, 215, 1620, 1621, "," +524, 13, 75, 362, 216, 219, 1622, 1625, "and" +524, 13, 76, 363, 220, 221, 1626, 1627, "3" +524, 13, 77, 364, 222, 223, 1628, 1629, "." +524, 13, 78, 365, 224, 225, 1630, 1631, "3" +524, 13, 79, 366, 226, 227, 1632, 1633, "+" +524, 13, 80, 367, 228, 229, 1634, 1635, "/" +524, 13, 81, 368, 230, 231, 1636, 1637, "-" +524, 13, 82, 369, 232, 233, 1638, 1639, "3" +524, 13, 83, 370, 234, 235, 1640, 1641, "." +524, 13, 84, 371, 236, 237, 1642, 1643, "0" +524, 13, 85, 372, 238, 240, 1644, 1646, "mm" +524, 13, 86, 373, 241, 243, 1647, 1649, "Hg" +524, 13, 87, 374, 244, 246, 1650, 1652, "in" +524, 13, 88, 375, 247, 250, 1653, 1656, "the" +524, 13, 89, 376, 251, 262, 1657, 1668, "unoprostone" +524, 13, 90, 377, 263, 268, 1669, 1674, "group" +524, 13, 91, 378, 269, 270, 1675, 1676, "," +524, 13, 92, 379, 271, 283, 1677, 1689, "respectively" +524, 13, 93, 380, 284, 285, 1690, 1691, "." +524, 14, 1, 381, 0, 3, 1692, 1695, "The" +524, 14, 2, 382, 4, 7, 1696, 1699, "IOP" +524, 14, 3, 383, 8, 17, 1700, 1709, "reduction" +524, 14, 4, 384, 18, 20, 1710, 1712, "in" +524, 14, 5, 385, 21, 24, 1713, 1716, "the" +524, 14, 6, 386, 25, 36, 1717, 1728, "latanoprost" +524, 14, 7, 387, 37, 42, 1729, 1734, "group" +524, 14, 8, 388, 43, 45, 1735, 1737, "at" +524, 14, 9, 389, 46, 47, 1738, 1739, "8" +524, 14, 10, 390, 48, 53, 1740, 1745, "weeks" +524, 14, 11, 391, 54, 57, 1746, 1749, "was" +524, 14, 12, 392, 58, 64, 1750, 1756, "larger" +524, 14, 13, 393, 65, 69, 1757, 1761, "than" +524, 14, 14, 394, 70, 74, 1762, 1766, "that" +524, 14, 15, 395, 75, 77, 1767, 1769, "in" +524, 14, 16, 396, 78, 81, 1770, 1773, "the" +524, 14, 17, 397, 82, 93, 1774, 1785, "unoprostone" +524, 14, 18, 398, 94, 99, 1786, 1791, "group" +524, 14, 19, 399, 100, 101, 1792, 1793, "(" +524, 14, 20, 400, 102, 103, 1794, 1795, "<" +524, 14, 21, 401, 104, 105, 1796, 1797, "0" +524, 14, 22, 402, 106, 107, 1798, 1799, "." +524, 14, 23, 403, 108, 111, 1800, 1803, "001" +524, 14, 24, 404, 112, 113, 1804, 1805, "," +524, 14, 25, 405, 114, 122, 1806, 1814, "analysis" +524, 14, 26, 406, 123, 125, 1815, 1817, "of" +524, 14, 27, 407, 126, 136, 1818, 1828, "covariance" +524, 14, 28, 408, 137, 138, 1829, 1830, ")" +524, 14, 29, 409, 139, 140, 1831, 1832, "." +524, 15, 1, 410, 0, 4, 1833, 1837, "Five" +524, 15, 2, 411, 5, 12, 1838, 1845, "adverse" +524, 15, 3, 412, 13, 19, 1846, 1852, "events" +524, 15, 4, 413, 20, 24, 1853, 1857, "were" +524, 15, 5, 414, 25, 33, 1858, 1866, "observed" +524, 15, 6, 415, 34, 36, 1867, 1869, "in" +524, 15, 7, 416, 37, 38, 1870, 1871, "4" +524, 15, 8, 417, 39, 40, 1872, 1873, "(" +524, 15, 9, 418, 41, 43, 1874, 1876, "15" +524, 15, 10, 419, 44, 45, 1877, 1878, "%" +524, 15, 11, 420, 46, 47, 1879, 1880, ")" +524, 15, 12, 421, 48, 50, 1881, 1883, "of" +524, 15, 13, 422, 51, 53, 1884, 1886, "27" +524, 15, 14, 423, 54, 62, 1887, 1895, "patients" +524, 15, 15, 424, 63, 65, 1896, 1898, "in" +524, 15, 16, 425, 66, 69, 1899, 1902, "the" +524, 15, 17, 426, 70, 81, 1903, 1914, "latanoprost" +524, 15, 18, 427, 82, 87, 1915, 1920, "group" +524, 15, 19, 428, 88, 89, 1921, 1922, "," +524, 15, 20, 429, 90, 93, 1923, 1926, "and" +524, 15, 21, 430, 94, 98, 1927, 1931, "five" +524, 15, 22, 431, 99, 106, 1932, 1939, "adverse" +524, 15, 23, 432, 107, 113, 1940, 1946, "events" +524, 15, 24, 433, 114, 118, 1947, 1951, "were" +524, 15, 25, 434, 119, 127, 1952, 1960, "observed" +524, 15, 26, 435, 128, 130, 1961, 1963, "in" +524, 15, 27, 436, 131, 132, 1964, 1965, "4" +524, 15, 28, 437, 133, 134, 1966, 1967, "(" +524, 15, 29, 438, 135, 137, 1968, 1970, "20" +524, 15, 30, 439, 138, 139, 1971, 1972, "%" +524, 15, 31, 440, 140, 141, 1973, 1974, ")" +524, 15, 32, 441, 142, 144, 1975, 1977, "of" +524, 15, 33, 442, 145, 147, 1978, 1980, "21" +524, 15, 34, 443, 148, 156, 1981, 1989, "patients" +524, 15, 35, 444, 157, 159, 1990, 1992, "in" +524, 15, 36, 445, 160, 163, 1993, 1996, "the" +524, 15, 37, 446, 164, 175, 1997, 2008, "unoprostone" +524, 15, 38, 447, 176, 181, 2009, 2014, "group" +524, 15, 39, 448, 182, 183, 2015, 2016, "." +524, 16, 1, 449, 0, 5, 2017, 2022, "There" +524, 16, 2, 450, 6, 9, 2023, 2026, "was" +524, 16, 3, 451, 10, 12, 2027, 2029, "no" +524, 16, 4, 452, 13, 23, 2030, 2040, "difference" +524, 16, 5, 453, 24, 26, 2041, 2043, "in" +524, 16, 6, 454, 27, 30, 2044, 2047, "the" +524, 16, 7, 455, 31, 40, 2048, 2057, "incidence" +524, 16, 8, 456, 41, 43, 2058, 2060, "of" +524, 16, 9, 457, 44, 51, 2061, 2068, "adverse" +524, 16, 10, 458, 52, 58, 2069, 2075, "events" +524, 16, 11, 459, 59, 66, 2076, 2083, "between" +524, 16, 12, 460, 67, 73, 2084, 2090, "groups" +524, 16, 13, 461, 74, 75, 2091, 2092, "(" +524, 16, 14, 462, 76, 77, 2093, 2094, "=" +524, 16, 15, 463, 78, 79, 2095, 2096, "0" +524, 16, 16, 464, 80, 81, 2097, 2098, "." +524, 16, 17, 465, 82, 84, 2099, 2101, "71" +524, 16, 18, 466, 85, 86, 2102, 2103, ")" +524, 16, 19, 467, 87, 88, 2104, 2105, "." +524, 17, 1, 468, 0, 10, 2106, 2116, "CONCLUSION" +524, 17, 2, 469, 11, 12, 2117, 2118, ":" +524, 17, 3, 470, 13, 24, 2119, 2130, "Latanoprost" +524, 17, 4, 471, 25, 33, 2131, 2139, "produced" +524, 17, 5, 472, 34, 35, 2140, 2141, "a" +524, 17, 6, 473, 36, 49, 2142, 2155, "statistically" +524, 17, 7, 474, 50, 57, 2156, 2163, "greater" +524, 17, 8, 475, 58, 67, 2164, 2173, "reduction" +524, 17, 9, 476, 68, 70, 2174, 2176, "in" +524, 17, 10, 477, 71, 74, 2177, 2180, "IOP" +524, 17, 11, 478, 75, 79, 2181, 2185, "than" +524, 17, 12, 479, 80, 91, 2186, 2197, "unoprostone" +524, 17, 13, 480, 92, 94, 2198, 2200, "in" +524, 17, 14, 481, 95, 103, 2201, 2209, "Japanese" +524, 17, 15, 482, 104, 112, 2210, 2218, "patients" +524, 17, 16, 483, 113, 117, 2219, 2223, "with" +524, 17, 17, 484, 118, 122, 2224, 2228, "POAG" +524, 17, 18, 485, 123, 125, 2229, 2231, "or" +524, 17, 19, 486, 126, 128, 2232, 2234, "OH" +524, 17, 20, 487, 129, 130, 2235, 2236, "." +524, 18, 1, 488, 0, 3, 2237, 2240, "DOI" +524, 18, 2, 489, 4, 5, 2241, 2242, ":" +524, 18, 3, 490, 6, 8, 2243, 2245, "10" +524, 18, 4, 491, 9, 10, 2246, 2247, "." +524, 18, 5, 492, 11, 15, 2248, 2252, "1097" +524, 18, 6, 493, 16, 17, 2253, 2254, "/" +524, 18, 7, 494, 18, 26, 2255, 2263, "00061198" +524, 18, 8, 495, 27, 28, 2264, 2265, "-" +524, 18, 9, 496, 29, 38, 2266, 2275, "200212000" +524, 18, 10, 497, 39, 40, 2276, 2277, "-" +524, 18, 11, 498, 41, 46, 2278, 2283, "00008" +524, 18, 12, 499, 47, 51, 2284, 2288, "PMID" +524, 18, 13, 500, 52, 53, 2289, 2290, ":" +524, 18, 14, 501, 54, 62, 2291, 2299, "12483094" +524, 18, 15, 502, 63, 64, 2300, 2301, "[" +524, 18, 16, 503, 65, 72, 2302, 2309, "Indexed" +524, 18, 17, 504, 73, 76, 2310, 2313, "for" +524, 18, 18, 505, 77, 84, 2314, 2321, "MEDLINE" +524, 18, 19, 506, 85, 86, 2322, 2323, "]" diff --git a/data/gl 12483094_jshahinitiran.annodb b/data/gl 12483094_jshahinitiran.annodb new file mode 100644 index 0000000..f08fc37 --- /dev/null +++ b/data/gl 12483094_jshahinitiran.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81446, Journal, 0, 12, "J Glaucoma .", "", +81449, PublicationYear, 13, 17, "2002", "", +81450, Title, 47, 198, "A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open - angle glaucoma and ocular hypertension .", "", +81451, Latanoprost, 79, 90, "latanoprost", "", +81452, Unoprostone, 95, 116, "isopropyl unoprostone", "", +81453, Ethnicity, 120, 128, "Japanese", "", +81454, Primary_OpenAngleGlaucoma, 143, 172, "primary open - angle glaucoma", "", +81455, OcularHypertension, 177, 196, "ocular hypertension", "", +81456, Author, 199, 210, "Tsukamoto H", "", +81457, Author, 219, 229, "Mishima HK", "", +81458, Author, 232, 242, "Kitazawa Y", "", +81459, Author, 245, 252, "Araie M", "", +81460, Author, 255, 260, "Abe H", "", +81461, Author, 263, 269, "Negi A", "", +81462, Glaucoma, 272, 280, "Glaucoma", "", +81463, Japan, 444, 449, "Japan", "", +81464, ObjectiveDescription, 462, 653, "To compare the efficacy and safety of latanoprost versus isopropyl unoprostone ( unoprostone ) in Japanese patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", +81465, Latanoprost, 500, 511, "latanoprost", "", +81466, Unoprostone, 519, 540, "isopropyl unoprostone", "", +81467, Unoprostone, 543, 554, "unoprostone", "", +81468, Ethnicity, 560, 568, "Japanese", "", +81469, Primary_OpenAngleGlaucoma, 583, 612, "primary open - angle glaucoma", "", +81470, Primary_OpenAngleGlaucoma, 615, 619, "POAG", "", +81472, OcularHypertension, 625, 644, "ocular hypertension", "", +81473, OcularHypertension, 647, 649, "OH", "", +81475, Duration, 667, 675, "8 - week", "", +81476, Multicenter, 678, 689, "multicenter", "", +81477, Randomized, 692, 702, "randomized", "", +81478, NumberPatientsCT, 740, 742, "48", "", +81471, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +81474, OcularHypertension, 774, 776, "OH", "", +81479, NumPatientsLeftCT, 779, 783, "Four", "", +81480, NumPatientsLeftArm, 795, 798, "two", "", +81481, IOP, 910, 930, "intraocular pressure", "", +81482, IOP, 933, 936, "IOP", "", +81483, Randomized, 970, 978, "randomly", "", +81484, Latanoprost, 992, 1003, "latanoprost", "", +81486, DoseValue, 1004, 1011, "0 . 005", "", +81488, Frequency, 1014, 1024, "once daily", "", +81485, Unoprostone, 1028, 1039, "unoprostone", "", +81487, DoseValue, 1040, 1046, "0 . 12", "", +81489, Frequency, 1049, 1060, "twice daily", "", +81490, Duration, 1065, 1074, "8 weeks .", "", +81491, IOP, 1075, 1078, "IOP", "", +81492, TimePoint, 1095, 1103, "baseline", "", +81493, TimePoint, 1108, 1127, "2 , 4 , and 8 weeks", "", +81494, TimePoint, 1112, 1127, "4 , and 8 weeks", "", +81495, TimePoint, 1120, 1127, "8 weeks", "", +81496, IOP, 1234, 1238, "IOPs", "", +81497, Latanoprost, 1264, 1275, "latanoprost", "", +81498, NumberPatientsArm, 1282, 1284, "25", "", +81499, Unoprostone, 1291, 1302, "unoprostone", "", +81500, NumberPatientsArm, 1309, 1311, "19", "", +81501, BaseLineValue, 1323, 1329, "24 . 3", "", +81503, SdErrorBL, 1336, 1341, "2 . 4", "", +81506, mmHg, 1342, 1347, "mm Hg", "", +81502, BaseLineValue, 1351, 1357, "23 . 3", "", +81504, SdErrorBL, 1364, 1369, "2 . 1", "", +81505, mmHg, 1370, 1375, "mm Hg", "", +81507, PValueBL, 1393, 1401, "= 0 . 18", "", +81508, IOP, 1410, 1413, "IOP", "", +81509, TimePoint, 1442, 1461, "2 , 4 , and 8 weeks", "", +81510, TimePoint, 1446, 1461, "4 , and 8 weeks", "", +81511, TimePoint, 1454, 1461, "8 weeks", "", +81512, Reduction, 1483, 1488, "5 . 8", "", +81515, SdErrorChangeValue, 1495, 1500, "2 . 4", "", +81513, Reduction, 1503, 1508, "6 . 6", "", +81516, SdErrorChangeValue, 1515, 1520, "2 . 5", "", +81514, Reduction, 1527, 1532, "6 . 7", "", +81517, SdErrorChangeValue, 1539, 1544, "2 . 0", "", +81518, mmHg, 1545, 1550, "mm Hg", "", +81519, Latanoprost, 1558, 1569, "latanoprost", "", +81520, Reduction, 1582, 1587, "3 . 8", "", +81523, SdErrorChangeValue, 1594, 1599, "2 . 0", "", +81521, Reduction, 1602, 1607, "3 . 5", "", +81524, SdErrorChangeValue, 1614, 1619, "2 . 3", "", +81522, Reduction, 1626, 1631, "3 . 3", "", +81525, SdErrorChangeValue, 1638, 1643, "3 . 0", "", +81526, mmHg, 1644, 1649, "mm Hg", "", +81527, Unoprostone, 1657, 1668, "unoprostone", "", +81528, IOP, 1696, 1699, "IOP", "", +81529, Latanoprost, 1717, 1728, "latanoprost", "", +81530, TimePoint, 1738, 1745, "8 weeks", "", +81531, Unoprostone, 1774, 1785, "unoprostone", "", +81532, PvalueDiff, 1794, 1803, "< 0 . 001", "", +81533, NumberAffected, 1870, 1871, "4", "", +81535, PercentageAffected, 1874, 1876, "15", "", +81537, NumberPatientsArm, 1884, 1886, "27", "", +81539, Latanoprost, 1903, 1914, "latanoprost", "", +81534, NumberAffected, 1964, 1965, "4", "", +81536, PercentageAffected, 1968, 1970, "20", "", +81538, NumberPatientsArm, 1978, 1980, "21", "", +81540, Unoprostone, 1997, 2008, "unoprostone", "", +81541, PValueNumAffected, 2093, 2101, "= 0 . 71", "", +81542, ConclusionComment, 2119, 2236, "Latanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH .", "", +81543, Latanoprost, 2119, 2130, "Latanoprost", "", +81544, IOP, 2177, 2180, "IOP", "", +81545, Unoprostone, 2186, 2197, "unoprostone", "", +81546, Ethnicity, 2201, 2209, "Japanese", "", +81547, Primary_OpenAngleGlaucoma, 2224, 2228, "POAG", "", +81548, OcularHypertension, 2232, 2234, "OH", "", +81549, PMID, 2291, 2299, "12483094", "", diff --git a/data/gl 12483094_jshahinitiran.n-triples b/data/gl 12483094_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12483094_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12483094_tstrakeljahn.annodb b/data/gl 12483094_tstrakeljahn.annodb new file mode 100644 index 0000000..9696fa7 --- /dev/null +++ b/data/gl 12483094_tstrakeljahn.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81902, Journal, 0, 10, "J Glaucoma", "", +81903, PublicationYear, 13, 17, "2002", "", +81917, Title, 47, 198, "A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open - angle glaucoma and ocular hypertension .", "", +81904, ClinicalTrial, 61, 75, "clinical study", "", +81905, Latanoprost, 79, 90, "latanoprost", "", +81906, Unoprostone, 105, 116, "unoprostone", "", +81907, Ethnicity, 120, 128, "Japanese", "", +81908, Primary_OpenAngleGlaucoma, 143, 172, "primary open - angle glaucoma", "", +81909, OcularHypertension, 177, 196, "ocular hypertension", "", +81910, Author, 199, 210, "Tsukamoto H", "", +81911, Author, 219, 229, "Mishima HK", "", +81912, Author, 232, 242, "Kitazawa Y", "", +81913, Author, 245, 252, "Araie M", "", +81914, Author, 255, 260, "Abe H", "", +81915, Author, 263, 269, "Negi A", "", +81916, Japan, 444, 449, "Japan", "", +81926, ObjectiveDescription, 462, 653, "To compare the efficacy and safety of latanoprost versus isopropyl unoprostone ( unoprostone ) in Japanese patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", +81918, Latanoprost, 500, 511, "latanoprost", "", +81919, Unoprostone, 529, 540, "unoprostone", "", +81920, Unoprostone, 543, 554, "unoprostone", "", +81921, Ethnicity, 560, 568, "Japanese", "", +81922, Primary_OpenAngleGlaucoma, 583, 612, "primary open - angle glaucoma", "", +81923, Primary_OpenAngleGlaucoma, 615, 619, "POAG", "", +81924, OcularHypertension, 625, 644, "ocular hypertension", "", +81925, OcularHypertension, 647, 649, "OH", "", +81927, Duration, 667, 675, "8 - week", "", +81928, Multicenter, 678, 689, "multicenter", "", +81929, Randomized, 692, 702, "randomized", "", +81930, NumberPatientsCT, 740, 742, "48", "", +81931, Ethnicity, 743, 751, "Japanese", "", +81932, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +81933, OcularHypertension, 774, 776, "OH", "", +81935, NumPatientsLeftCT, 779, 783, "Four", "", +81934, NumPatientsLeftArm, 795, 798, "two", "", +81936, IOP, 910, 930, "intraocular pressure", "", +81937, IOP, 933, 936, "IOP", "", +81938, Latanoprost, 992, 1003, "latanoprost", "", +81942, DoseValue, 1004, 1011, "0 . 005", "", +81944, Percentage, 1012, 1013, "%", "", +81941, Frequency, 1014, 1024, "once daily", "", +81939, Unoprostone, 1028, 1039, "unoprostone", "", +81943, DoseValue, 1040, 1046, "0 . 12", "", +81945, Percentage, 1047, 1048, "%", "", +81940, Frequency, 1049, 1060, "twice daily", "", +81946, Duration, 1065, 1072, "8 weeks", "", +81947, IOP, 1075, 1078, "IOP", "", +81948, TimePoint, 1092, 1103, "at baseline", "", +81951, TimePoint, 1108, 1143, "2 , 4 , and 8 weeks after treatment", "", +81950, TimePoint, 1112, 1143, "4 , and 8 weeks after treatment", "", +81949, TimePoint, 1120, 1143, "8 weeks after treatment", "", +81952, IOP, 1234, 1238, "IOPs", "", +81953, Latanoprost, 1264, 1275, "latanoprost", "", +81988, FinalNumPatientsArm, 1282, 1284, "25", "", +81954, Unoprostone, 1291, 1302, "unoprostone", "", +81989, FinalNumPatientsArm, 1309, 1311, "19", "", +81957, BaseLineValue, 1323, 1329, "24 . 3", "", +81959, SdDevBL, 1336, 1341, "2 . 4", "", +81961, mmHg, 1342, 1347, "mm Hg", "", +81958, BaseLineValue, 1351, 1357, "23 . 3", "", +81960, SdDevBL, 1364, 1369, "2 . 1", "", +81962, mmHg, 1370, 1375, "mm Hg", "", +81963, IOP, 1410, 1413, "IOP", "", +81966, TimePoint, 1442, 1477, "2 , 4 , and 8 weeks after treatment", "", +81965, TimePoint, 1446, 1477, "4 , and 8 weeks after treatment", "", +81964, TimePoint, 1454, 1477, "8 weeks after treatment", "", +81967, Reduction, 1483, 1488, "5 . 8", "", +81973, SdDevChangeValue, 1495, 1500, "2 . 4", "", +81968, Reduction, 1503, 1508, "6 . 6", "", +81974, SdDevChangeValue, 1515, 1520, "2 . 5", "", +81969, Reduction, 1527, 1532, "6 . 7", "", +81975, SdDevChangeValue, 1539, 1544, "2 . 0", "", +81979, mmHg, 1545, 1550, "mm Hg", "", +81981, Latanoprost, 1558, 1569, "latanoprost", "", +81970, Reduction, 1582, 1587, "3 . 8", "", +81976, SdDevChangeValue, 1594, 1599, "2 . 0", "", +81971, Reduction, 1602, 1607, "3 . 5", "", +81977, SdDevChangeValue, 1614, 1619, "2 . 3", "", +81972, Reduction, 1626, 1631, "3 . 3", "", +81978, SdDevChangeValue, 1638, 1643, "3 . 0", "", +81980, mmHg, 1644, 1649, "mm Hg", "", +81982, Unoprostone, 1657, 1668, "unoprostone", "", +81983, IOP, 1696, 1699, "IOP", "", +81984, Latanoprost, 1717, 1728, "latanoprost", "", +81985, TimePoint, 1735, 1745, "at 8 weeks", "", +81986, Unoprostone, 1774, 1785, "unoprostone", "", +81987, PvalueDiff, 1794, 1803, "< 0 . 001", "", +81998, ObservedResult, 1833, 2016, "Five adverse events were observed in 4 ( 15 % ) of 27 patients in the latanoprost group , and five adverse events were observed in 4 ( 20 % ) of 21 patients in the unoprostone group .", "", +81994, NumberAffected, 1870, 1871, "4", "", +81992, PercentageAffected, 1874, 1876, "15", "", +81990, NumberPatientsArm, 1884, 1886, "27", "", +81996, Latanoprost, 1903, 1914, "latanoprost", "", +81995, NumberAffected, 1964, 1965, "4", "", +81993, PercentageAffected, 1968, 1970, "20", "", +81991, NumberPatientsArm, 1978, 1980, "21", "", +81997, Unoprostone, 1997, 2008, "unoprostone", "", +82000, ObservedResult, 2017, 2105, "There was no difference in the incidence of adverse events between groups ( = 0 . 71 ) .", "", +81999, PvalueDiff, 2093, 2101, "= 0 . 71", "", +82001, Latanoprost, 2119, 2130, "Latanoprost", "", +82008, ConclusionComment, 2119, 2236, "Latanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH .", "", +82002, IOP, 2177, 2180, "IOP", "", +82003, Unoprostone, 2186, 2197, "unoprostone", "", +82004, Ethnicity, 2201, 2209, "Japanese", "", +82005, Primary_OpenAngleGlaucoma, 2224, 2228, "POAG", "", +82006, OcularHypertension, 2232, 2234, "OH", "", +82007, PMID, 2291, 2299, "12483094", "", diff --git a/data/gl 12483094_tstrakeljahn.n-triples b/data/gl 12483094_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12483094_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12485286_admin.annodb b/data/gl 12485286_admin.annodb new file mode 100644 index 0000000..ee1da90 --- /dev/null +++ b/data/gl 12485286_admin.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "Acta Ophthalmol Scand .", "", " \"Acta Ophthalmol Scand .\"." +1, PublicationYear, 24, 28, "2002", "", " \"2002\"." +2, Title, 57, 239, "A comparison of the effects on intraocular pressure of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % in patients with open - angle glaucoma .", "", " \"A comparison of the effects on intraocular pressure of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % in patients with open - angle glaucoma .\"." +3, IOP, 88, 108, "intraocular pressure", "", +4, Latanoprost, 112, 123, "latanoprost", "", +8, DoseValue, 124, 131, "0 . 005", "", +83, Percentage, 132, 133, "%", "", +7, Dorz/TimFC, 142, 198, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", " ." +5, Dorzolamide, 163, 174, "dorzolamide", "", +9, DoseValue, 175, 176, "2", "", +84, Percentage, 177, 178, "%", "", +78, Timolol, 183, 190, "timolol", "", +10, DoseValue, 191, 196, "0 . 5", "", +85, Percentage, 197, 198, "%", "", +11, OpenAngleGlaucoma, 216, 237, "open - angle glaucoma", "", " ." +12, Author, 240, 251, "Honrubia FM", "", " \"Honrubia FM\"." +13, Author, 260, 270, "Larsson LI", "", " \"Larsson LI\"." +14, Author, 273, 282, "Spiegel D", "", " \"Spiegel D\"." +15, Latanoprost, 294, 305, "latanoprost", "", +16, Spain, 411, 416, "Spain", "", +17, ObjectiveDescription, 469, 615, "To compare the effects on intraocular pressure ( IOP ) of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % .", "", " \"To compare the effects on intraocular pressure ( IOP ) of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % .\"." +18, IOP, 495, 515, "intraocular pressure", "", +19, IOP, 518, 521, "IOP", "", +20, Latanoprost, 527, 538, "latanoprost", "", " . ." +23, DoseValue, 539, 546, "0 . 005", "", " \"0 . 005\"." +100, Percentage, 547, 548, "%", "", " ." +26, Dorz/TimFC, 557, 613, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", +21, Dorzolamide, 578, 589, "dorzolamide", "", +24, DoseValue, 590, 591, "2", "", +101, Percentage, 592, 593, "%", "", +22, Timolol, 598, 605, "timolol", "", +25, DoseValue, 606, 611, "0 . 5", "", +102, Percentage, 612, 613, "%", "", +27, NumberPatientsCT, 636, 639, "226", "", " \"226\"." +30, Precondition, 640, 705, "patients whose IOP was insufficiently controlled by timolol alone", "", " \"patients whose IOP was insufficiently controlled by timolol alone\"." +106, IOP, 655, 658, "IOP", "", +29, Timolol, 692, 699, "timolol", "", +31, Randomized, 711, 721, "randomized", "", " ." +32, Latanoprost, 740, 751, "latanoprost", "", +33, Frequency, 752, 762, "once daily", "", " \"once daily\"." +114, Dorz/TimFC, 770, 815, "fixed combination of dorzolamide plus timolol", "", +34, Dorzolamide, 791, 802, "dorzolamide", "", +35, Timolol, 808, 815, "timolol", "", +37, Frequency, 816, 827, "twice daily", "", " \"twice daily\"." +38, IOP, 830, 850, "Intraocular pressure", "", +116, TimePoint, 867, 877, "10 : 00 am", "", +117, TimePoint, 882, 891, "5 : 00 pm", "", +39, TimePoint, 895, 903, "baseline", "", +40, TimePoint, 914, 922, "3 months", "", " \"3 months\". \"3 months\"." +41, Mean, 948, 952, "Mean", "", " . ." +42, IOP, 953, 956, "IOP", "", " . ." +96939, TimePoint, 974, 982, "baseline", "", +43, PValueChangeValue, 1000, 1016, "p & lt ; 0 . 001", "", " \"p & lt ; 0 . 001\". \"p & lt ; 0 . 001\"." +122, Mean, 1028, 1032, "mean", "", +44, Reduction, 1058, 1063, "4 . 3", "", " \"4 . 3\"." +46, SdErrorChangeValue, 1070, 1075, "0 . 3", "", " \"0 . 3\"." +49, mmHg, 1076, 1080, "mmHg", "", " ." +50, RelativeReduction, 1083, 1085, "19", "", " \"19\"." +52, Latanoprost, 1098, 1109, "latanoprost", "", +45, Reduction, 1132, 1137, "4 . 0", "", " \"4 . 0\"." +47, SdErrorChangeValue, 1144, 1149, "0 . 3", "", " \"0 . 3\"." +48, mmHg, 1150, 1154, "mmHg", "", +51, RelativeReduction, 1157, 1159, "17", "", " \"17\"." +53, Dorzolamide, 1172, 1183, "dorzolamide", "", +133, Dorz/TimFC, 1172, 1196, "dorzolamide plus timolol", "", +54, Timolol, 1189, 1196, "timolol", "", +55, IOP, 1270, 1273, "IOP", "", +56, Mean, 1283, 1287, "mean", "", +57, DiffGroupAbsValue, 1314, 1321, "- 0 . 4", "", " \"- 0 . 4\"." +58, SdErrorDiff, 1328, 1333, "0 . 4", "", " \"0 . 4\"." +59, ConfIntervalDiff, 1336, 1378, "95 % confidence interval : - 1 . 1 , 0 . 4", "", " \"95 % confidence interval : - 1 . 1 , 0 . 4\"." +60, ConclusionComment, 1397, 1605, "Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone .", "", " \"Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone .\"." +61, Latanoprost, 1414, 1425, "latanoprost", "", +62, Frequency, 1426, 1436, "once daily", "", +64, Mean, 1466, 1470, "mean", "", +65, IOP, 1471, 1474, "IOP", "", +68, Dorz/TimFC, 1482, 1527, "fixed combination of dorzolamide plus timolol", "", +66, Dorzolamide, 1503, 1514, "dorzolamide", "", +67, Timolol, 1520, 1527, "timolol", "", +63, Frequency, 1528, 1539, "twice daily", "", +69, IOP, 1557, 1560, "IOP", "", +70, Timolol, 1590, 1597, "timolol", "", +72, PMID, 1667, 1675, "12485286", "", " \"12485286\"." diff --git a/data/gl 12485286_admin.n-triples b/data/gl 12485286_admin.n-triples new file mode 100644 index 0000000..05060b2 --- /dev/null +++ b/data/gl 12485286_admin.n-triples @@ -0,0 +1,103 @@ +# RDF export of group: Publication + . + "Publication 82905" . + "A comparison of the effects on intraocular pressure of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % in patients with open - angle glaucoma ." . + "Honrubia FM" . + "2002" . + "Acta Ophthalmol Scand ." . + "12485286" . + . + "Larsson LI" . + "Spiegel D" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 82912" . + "To compare the effects on intraocular pressure ( IOP ) of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % ." . + "226" . + . + . + . + "Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone ." . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 82928" . + "patients whose IOP was insufficiently controlled by timolol alone" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "la" . + . + . + . + . + "com" . + . + . + . +# RDF export of group: Intervention + . + "la" . + . + "once daily" . + . + . + "comb" . + "twice daily" . + . + . +# RDF export of group: Medication + . + "la" . + . + . + "0 . 005" . + . + . + . + "comb" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "4 . 3" . + "19" . + "p & lt ; 0 . 001" . + "0 . 3" . + "3 months" . + . + "iop 2" . + . + "4 . 0" . + "17" . + "p & lt ; 0 . 001" . + "0 . 3" . + "3 months" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "- 0 . 4" . + "95 % confidence interval : - 1 . 1 , 0 . 4" . + "0 . 4" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12485286_export.csv b/data/gl 12485286_export.csv new file mode 100644 index 0000000..33cf9e3 --- /dev/null +++ b/data/gl 12485286_export.csv @@ -0,0 +1,361 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +557, 1, 1, 1, 0, 4, 0, 4, "Acta" +557, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +557, 1, 3, 3, 16, 21, 16, 21, "Scand" +557, 1, 4, 4, 22, 23, 22, 23, "." +557, 2, 1, 5, 0, 4, 24, 28, "2002" +557, 2, 2, 6, 5, 8, 29, 32, "Dec" +557, 2, 3, 7, 9, 10, 33, 34, ";" +557, 2, 4, 8, 11, 13, 35, 37, "80" +557, 2, 5, 9, 14, 15, 38, 39, "(" +557, 2, 6, 10, 16, 17, 40, 41, "6" +557, 2, 7, 11, 18, 19, 42, 43, ")" +557, 2, 8, 12, 20, 21, 44, 45, ":" +557, 2, 9, 13, 22, 25, 46, 49, "635" +557, 2, 10, 14, 26, 27, 50, 51, "-" +557, 2, 11, 15, 28, 30, 52, 54, "41" +557, 2, 12, 16, 31, 32, 55, 56, "." +557, 3, 1, 17, 0, 1, 57, 58, "A" +557, 3, 2, 18, 2, 12, 59, 69, "comparison" +557, 3, 3, 19, 13, 15, 70, 72, "of" +557, 3, 4, 20, 16, 19, 73, 76, "the" +557, 3, 5, 21, 20, 27, 77, 84, "effects" +557, 3, 6, 22, 28, 30, 85, 87, "on" +557, 3, 7, 23, 31, 42, 88, 99, "intraocular" +557, 3, 8, 24, 43, 51, 100, 108, "pressure" +557, 3, 9, 25, 52, 54, 109, 111, "of" +557, 3, 10, 26, 55, 66, 112, 123, "latanoprost" +557, 3, 11, 27, 67, 68, 124, 125, "0" +557, 3, 12, 28, 69, 70, 126, 127, "." +557, 3, 13, 29, 71, 74, 128, 131, "005" +557, 3, 14, 30, 75, 76, 132, 133, "%" +557, 3, 15, 31, 77, 80, 134, 137, "and" +557, 3, 16, 32, 81, 84, 138, 141, "the" +557, 3, 17, 33, 85, 90, 142, 147, "fixed" +557, 3, 18, 34, 91, 102, 148, 159, "combination" +557, 3, 19, 35, 103, 105, 160, 162, "of" +557, 3, 20, 36, 106, 117, 163, 174, "dorzolamide" +557, 3, 21, 37, 118, 119, 175, 176, "2" +557, 3, 22, 38, 120, 121, 177, 178, "%" +557, 3, 23, 39, 122, 125, 179, 182, "and" +557, 3, 24, 40, 126, 133, 183, 190, "timolol" +557, 3, 25, 41, 134, 135, 191, 192, "0" +557, 3, 26, 42, 136, 137, 193, 194, "." +557, 3, 27, 43, 138, 139, 195, 196, "5" +557, 3, 28, 44, 140, 141, 197, 198, "%" +557, 3, 29, 45, 142, 144, 199, 201, "in" +557, 3, 30, 46, 145, 153, 202, 210, "patients" +557, 3, 31, 47, 154, 158, 211, 215, "with" +557, 3, 32, 48, 159, 163, 216, 220, "open" +557, 3, 33, 49, 164, 165, 221, 222, "-" +557, 3, 34, 50, 166, 171, 223, 228, "angle" +557, 3, 35, 51, 172, 180, 229, 237, "glaucoma" +557, 3, 36, 52, 181, 182, 238, 239, "." +557, 4, 1, 53, 0, 8, 240, 248, "Honrubia" +557, 4, 2, 54, 9, 11, 249, 251, "FM" +557, 4, 3, 55, 12, 13, 252, 253, "(" +557, 4, 4, 56, 14, 15, 254, 255, "1" +557, 4, 5, 57, 16, 17, 256, 257, ")" +557, 4, 6, 58, 18, 19, 258, 259, "," +557, 4, 7, 59, 20, 27, 260, 267, "Larsson" +557, 4, 8, 60, 28, 30, 268, 270, "LI" +557, 4, 9, 61, 31, 32, 271, 272, "," +557, 4, 10, 62, 33, 40, 273, 280, "Spiegel" +557, 4, 11, 63, 41, 42, 281, 282, "D" +557, 4, 12, 64, 43, 44, 283, 284, ";" +557, 4, 13, 65, 45, 53, 285, 293, "European" +557, 4, 14, 66, 54, 65, 294, 305, "latanoprost" +557, 4, 15, 67, 66, 71, 306, 311, "study" +557, 4, 16, 68, 72, 77, 312, 317, "group" +557, 4, 17, 69, 78, 79, 318, 319, "." +557, 5, 1, 70, 0, 6, 320, 326, "Author" +557, 5, 2, 71, 7, 18, 327, 338, "information" +557, 5, 3, 72, 19, 20, 339, 340, ":" +557, 5, 4, 73, 21, 22, 341, 342, "(" +557, 5, 5, 74, 23, 24, 343, 344, "1" +557, 5, 6, 75, 25, 26, 345, 346, ")" +557, 5, 7, 76, 27, 35, 347, 355, "Hospital" +557, 5, 8, 77, 36, 42, 356, 362, "Miguel" +557, 5, 9, 78, 43, 49, 363, 369, "Servet" +557, 5, 10, 79, 50, 51, 370, 371, "," +557, 5, 11, 80, 52, 59, 372, 379, "Servico" +557, 5, 12, 81, 60, 62, 380, 382, "de" +557, 5, 13, 82, 63, 73, 383, 393, "Oftalmolog" +557, 5, 14, 83, 74, 75, 394, 395, "í" +557, 5, 15, 84, 76, 77, 396, 397, "a" +557, 5, 16, 85, 78, 79, 398, 399, "," +557, 5, 17, 86, 80, 88, 400, 408, "Zaragoza" +557, 5, 18, 87, 89, 90, 409, 410, "," +557, 5, 19, 88, 91, 96, 411, 416, "Spain" +557, 5, 20, 89, 97, 98, 417, 418, "." +557, 6, 1, 90, 0, 9, 419, 428, "instituto" +557, 6, 2, 91, 10, 11, 429, 430, "@" +557, 6, 3, 92, 12, 24, 431, 443, "oftalmologia" +557, 6, 4, 93, 25, 26, 444, 445, "-" +557, 6, 5, 94, 27, 33, 446, 452, "aragon" +557, 6, 6, 95, 34, 35, 453, 454, "." +557, 6, 7, 96, 36, 39, 455, 458, "com" +557, 6, 8, 97, 40, 47, 459, 466, "PURPOSE" +557, 6, 9, 98, 48, 49, 467, 468, ":" +557, 6, 10, 99, 50, 52, 469, 471, "To" +557, 6, 11, 100, 53, 60, 472, 479, "compare" +557, 6, 12, 101, 61, 64, 480, 483, "the" +557, 6, 13, 102, 65, 72, 484, 491, "effects" +557, 6, 14, 103, 73, 75, 492, 494, "on" +557, 6, 15, 104, 76, 87, 495, 506, "intraocular" +557, 6, 16, 105, 88, 96, 507, 515, "pressure" +557, 6, 17, 106, 97, 98, 516, 517, "(" +557, 6, 18, 107, 99, 102, 518, 521, "IOP" +557, 6, 19, 108, 103, 104, 522, 523, ")" +557, 6, 20, 109, 105, 107, 524, 526, "of" +557, 6, 21, 110, 108, 119, 527, 538, "latanoprost" +557, 6, 22, 111, 120, 121, 539, 540, "0" +557, 6, 23, 112, 122, 123, 541, 542, "." +557, 6, 24, 113, 124, 127, 543, 546, "005" +557, 6, 25, 114, 128, 129, 547, 548, "%" +557, 6, 26, 115, 130, 133, 549, 552, "and" +557, 6, 27, 116, 134, 137, 553, 556, "the" +557, 6, 28, 117, 138, 143, 557, 562, "fixed" +557, 6, 29, 118, 144, 155, 563, 574, "combination" +557, 6, 30, 119, 156, 158, 575, 577, "of" +557, 6, 31, 120, 159, 170, 578, 589, "dorzolamide" +557, 6, 32, 121, 171, 172, 590, 591, "2" +557, 6, 33, 122, 173, 174, 592, 593, "%" +557, 6, 34, 123, 175, 178, 594, 597, "and" +557, 6, 35, 124, 179, 186, 598, 605, "timolol" +557, 6, 36, 125, 187, 188, 606, 607, "0" +557, 6, 37, 126, 189, 190, 608, 609, "." +557, 6, 38, 127, 191, 192, 610, 611, "5" +557, 6, 39, 128, 193, 194, 612, 613, "%" +557, 6, 40, 129, 195, 196, 614, 615, "." +557, 7, 1, 130, 0, 7, 616, 623, "METHODS" +557, 7, 2, 131, 8, 9, 624, 625, ":" +557, 7, 3, 132, 10, 17, 626, 633, "Overall" +557, 7, 4, 133, 18, 19, 634, 635, "," +557, 7, 5, 134, 20, 23, 636, 639, "226" +557, 7, 6, 135, 24, 32, 640, 648, "patients" +557, 7, 7, 136, 33, 38, 649, 654, "whose" +557, 7, 8, 137, 39, 42, 655, 658, "IOP" +557, 7, 9, 138, 43, 46, 659, 662, "was" +557, 7, 10, 139, 47, 61, 663, 677, "insufficiently" +557, 7, 11, 140, 62, 72, 678, 688, "controlled" +557, 7, 12, 141, 73, 75, 689, 691, "by" +557, 7, 13, 142, 76, 83, 692, 699, "timolol" +557, 7, 14, 143, 84, 89, 700, 705, "alone" +557, 7, 15, 144, 90, 94, 706, 710, "were" +557, 7, 16, 145, 95, 105, 711, 721, "randomized" +557, 7, 17, 146, 106, 108, 722, 724, "to" +557, 7, 18, 147, 109, 116, 725, 732, "receive" +557, 7, 19, 148, 117, 123, 733, 739, "either" +557, 7, 20, 149, 124, 135, 740, 751, "latanoprost" +557, 7, 21, 150, 136, 140, 752, 756, "once" +557, 7, 22, 151, 141, 146, 757, 762, "daily" +557, 7, 23, 152, 147, 149, 763, 765, "or" +557, 7, 24, 153, 150, 153, 766, 769, "the" +557, 7, 25, 154, 154, 159, 770, 775, "fixed" +557, 7, 26, 155, 160, 171, 776, 787, "combination" +557, 7, 27, 156, 172, 174, 788, 790, "of" +557, 7, 28, 157, 175, 186, 791, 802, "dorzolamide" +557, 7, 29, 158, 187, 191, 803, 807, "plus" +557, 7, 30, 159, 192, 199, 808, 815, "timolol" +557, 7, 31, 160, 200, 205, 816, 821, "twice" +557, 7, 32, 161, 206, 211, 822, 827, "daily" +557, 7, 33, 162, 212, 213, 828, 829, "." +557, 8, 1, 163, 0, 11, 830, 841, "Intraocular" +557, 8, 2, 164, 12, 20, 842, 850, "pressure" +557, 8, 3, 165, 21, 24, 851, 854, "was" +557, 8, 4, 166, 25, 33, 855, 863, "measured" +557, 8, 5, 167, 34, 36, 864, 866, "at" +557, 8, 6, 168, 37, 39, 867, 869, "10" +557, 8, 7, 169, 40, 41, 870, 871, ":" +557, 8, 8, 170, 42, 44, 872, 874, "00" +557, 8, 9, 171, 45, 47, 875, 877, "am" +557, 8, 10, 172, 48, 51, 878, 881, "and" +557, 8, 11, 173, 52, 53, 882, 883, "5" +557, 8, 12, 174, 54, 55, 884, 885, ":" +557, 8, 13, 175, 56, 58, 886, 888, "00" +557, 8, 14, 176, 59, 61, 889, 891, "pm" +557, 8, 15, 177, 62, 64, 892, 894, "at" +557, 8, 16, 178, 65, 73, 895, 903, "baseline" +557, 8, 17, 179, 74, 77, 904, 907, "and" +557, 8, 18, 180, 78, 83, 908, 913, "after" +557, 8, 19, 181, 84, 85, 914, 915, "3" +557, 8, 20, 182, 86, 92, 916, 922, "months" +557, 8, 21, 183, 93, 95, 923, 925, "of" +557, 8, 22, 184, 96, 105, 926, 935, "treatment" +557, 8, 23, 185, 106, 107, 936, 937, "." +557, 9, 1, 186, 0, 7, 938, 945, "RESULTS" +557, 9, 2, 187, 8, 9, 946, 947, ":" +557, 9, 3, 188, 10, 14, 948, 952, "Mean" +557, 9, 4, 189, 15, 18, 953, 956, "IOP" +557, 9, 5, 190, 19, 22, 957, 960, "was" +557, 9, 6, 191, 23, 30, 961, 968, "reduced" +557, 9, 7, 192, 31, 35, 969, 973, "from" +557, 9, 8, 193, 36, 44, 974, 982, "baseline" +557, 9, 9, 194, 45, 47, 983, 985, "in" +557, 9, 10, 195, 48, 52, 986, 990, "both" +557, 9, 11, 196, 53, 59, 991, 997, "groups" +557, 9, 12, 197, 60, 61, 998, 999, "(" +557, 9, 13, 198, 62, 63, 1000, 1001, "p" +557, 9, 14, 199, 64, 65, 1002, 1003, "&" +557, 9, 15, 200, 66, 68, 1004, 1006, "lt" +557, 9, 16, 201, 69, 70, 1007, 1008, ";" +557, 9, 17, 202, 71, 72, 1009, 1010, "0" +557, 9, 18, 203, 73, 74, 1011, 1012, "." +557, 9, 19, 204, 75, 78, 1013, 1016, "001" +557, 9, 20, 205, 79, 80, 1017, 1018, ")" +557, 9, 21, 206, 81, 82, 1019, 1020, "," +557, 9, 22, 207, 83, 87, 1021, 1025, "with" +557, 9, 23, 208, 88, 89, 1026, 1027, "a" +557, 9, 24, 209, 90, 94, 1028, 1032, "mean" +557, 9, 25, 210, 95, 96, 1033, 1034, "+" +557, 9, 26, 211, 97, 98, 1035, 1036, "/" +557, 9, 27, 212, 99, 100, 1037, 1038, "-" +557, 9, 28, 213, 101, 104, 1039, 1042, "SEM" +557, 9, 29, 214, 105, 114, 1043, 1052, "reduction" +557, 9, 30, 215, 115, 117, 1053, 1055, "of" +557, 9, 31, 216, 118, 119, 1056, 1057, "-" +557, 9, 32, 217, 120, 121, 1058, 1059, "4" +557, 9, 33, 218, 122, 123, 1060, 1061, "." +557, 9, 34, 219, 124, 125, 1062, 1063, "3" +557, 9, 35, 220, 126, 127, 1064, 1065, "+" +557, 9, 36, 221, 128, 129, 1066, 1067, "/" +557, 9, 37, 222, 130, 131, 1068, 1069, "-" +557, 9, 38, 223, 132, 133, 1070, 1071, "0" +557, 9, 39, 224, 134, 135, 1072, 1073, "." +557, 9, 40, 225, 136, 137, 1074, 1075, "3" +557, 9, 41, 226, 138, 142, 1076, 1080, "mmHg" +557, 9, 42, 227, 143, 144, 1081, 1082, "(" +557, 9, 43, 228, 145, 147, 1083, 1085, "19" +557, 9, 44, 229, 148, 149, 1086, 1087, "%" +557, 9, 45, 230, 150, 151, 1088, 1089, ")" +557, 9, 46, 231, 152, 155, 1090, 1093, "for" +557, 9, 47, 232, 156, 159, 1094, 1097, "the" +557, 9, 48, 233, 160, 171, 1098, 1109, "latanoprost" +557, 9, 49, 234, 172, 181, 1110, 1119, "treatment" +557, 9, 50, 235, 182, 187, 1120, 1125, "group" +557, 9, 51, 236, 188, 191, 1126, 1129, "and" +557, 9, 52, 237, 192, 193, 1130, 1131, "-" +557, 9, 53, 238, 194, 195, 1132, 1133, "4" +557, 9, 54, 239, 196, 197, 1134, 1135, "." +557, 9, 55, 240, 198, 199, 1136, 1137, "0" +557, 9, 56, 241, 200, 201, 1138, 1139, "+" +557, 9, 57, 242, 202, 203, 1140, 1141, "/" +557, 9, 58, 243, 204, 205, 1142, 1143, "-" +557, 9, 59, 244, 206, 207, 1144, 1145, "0" +557, 9, 60, 245, 208, 209, 1146, 1147, "." +557, 9, 61, 246, 210, 211, 1148, 1149, "3" +557, 9, 62, 247, 212, 216, 1150, 1154, "mmHg" +557, 9, 63, 248, 217, 218, 1155, 1156, "(" +557, 9, 64, 249, 219, 221, 1157, 1159, "17" +557, 9, 65, 250, 222, 223, 1160, 1161, "%" +557, 9, 66, 251, 224, 225, 1162, 1163, ")" +557, 9, 67, 252, 226, 229, 1164, 1167, "for" +557, 9, 68, 253, 230, 233, 1168, 1171, "the" +557, 9, 69, 254, 234, 245, 1172, 1183, "dorzolamide" +557, 9, 70, 255, 246, 250, 1184, 1188, "plus" +557, 9, 71, 256, 251, 258, 1189, 1196, "timolol" +557, 9, 72, 257, 259, 268, 1197, 1206, "treatment" +557, 9, 73, 258, 269, 274, 1207, 1212, "group" +557, 9, 74, 259, 275, 276, 1213, 1214, "." +557, 10, 1, 260, 0, 3, 1215, 1218, "The" +557, 10, 2, 261, 4, 7, 1219, 1222, "two" +557, 10, 3, 262, 8, 17, 1223, 1232, "therapies" +557, 10, 4, 263, 18, 22, 1233, 1237, "were" +557, 10, 5, 264, 23, 32, 1238, 1247, "similarly" +557, 10, 6, 265, 33, 42, 1248, 1257, "effective" +557, 10, 7, 266, 43, 45, 1258, 1260, "in" +557, 10, 8, 267, 46, 54, 1261, 1269, "lowering" +557, 10, 9, 268, 55, 58, 1270, 1273, "IOP" +557, 10, 10, 269, 59, 65, 1274, 1280, "levels" +557, 10, 11, 270, 66, 67, 1281, 1282, "(" +557, 10, 12, 271, 68, 72, 1283, 1287, "mean" +557, 10, 13, 272, 73, 83, 1288, 1298, "difference" +557, 10, 14, 273, 84, 86, 1299, 1301, "in" +557, 10, 15, 274, 87, 96, 1302, 1311, "reduction" +557, 10, 16, 275, 97, 98, 1312, 1313, ":" +557, 10, 17, 276, 99, 100, 1314, 1315, "-" +557, 10, 18, 277, 101, 102, 1316, 1317, "0" +557, 10, 19, 278, 103, 104, 1318, 1319, "." +557, 10, 20, 279, 105, 106, 1320, 1321, "4" +557, 10, 21, 280, 107, 108, 1322, 1323, "+" +557, 10, 22, 281, 109, 110, 1324, 1325, "/" +557, 10, 23, 282, 111, 112, 1326, 1327, "-" +557, 10, 24, 283, 113, 114, 1328, 1329, "0" +557, 10, 25, 284, 115, 116, 1330, 1331, "." +557, 10, 26, 285, 117, 118, 1332, 1333, "4" +557, 10, 27, 286, 119, 120, 1334, 1335, ";" +557, 10, 28, 287, 121, 123, 1336, 1338, "95" +557, 10, 29, 288, 124, 125, 1339, 1340, "%" +557, 10, 30, 289, 126, 136, 1341, 1351, "confidence" +557, 10, 31, 290, 137, 145, 1352, 1360, "interval" +557, 10, 32, 291, 146, 147, 1361, 1362, ":" +557, 10, 33, 292, 148, 149, 1363, 1364, "-" +557, 10, 34, 293, 150, 151, 1365, 1366, "1" +557, 10, 35, 294, 152, 153, 1367, 1368, "." +557, 10, 36, 295, 154, 155, 1369, 1370, "1" +557, 10, 37, 296, 156, 157, 1371, 1372, "," +557, 10, 38, 297, 158, 159, 1373, 1374, "0" +557, 10, 39, 298, 160, 161, 1375, 1376, "." +557, 10, 40, 299, 162, 163, 1377, 1378, "4" +557, 10, 41, 300, 164, 165, 1379, 1380, ")" +557, 10, 42, 301, 166, 167, 1381, 1382, "." +557, 11, 1, 302, 0, 11, 1383, 1394, "CONCLUSIONS" +557, 11, 2, 303, 12, 13, 1395, 1396, ":" +557, 11, 3, 304, 14, 25, 1397, 1408, "Monotherapy" +557, 11, 4, 305, 26, 30, 1409, 1413, "with" +557, 11, 5, 306, 31, 42, 1414, 1425, "latanoprost" +557, 11, 6, 307, 43, 47, 1426, 1430, "once" +557, 11, 7, 308, 48, 53, 1431, 1436, "daily" +557, 11, 8, 309, 54, 57, 1437, 1440, "was" +557, 11, 9, 310, 58, 60, 1441, 1443, "as" +557, 11, 10, 311, 61, 70, 1444, 1453, "effective" +557, 11, 11, 312, 71, 73, 1454, 1456, "in" +557, 11, 12, 313, 74, 82, 1457, 1465, "reducing" +557, 11, 13, 314, 83, 87, 1466, 1470, "mean" +557, 11, 14, 315, 88, 91, 1471, 1474, "IOP" +557, 11, 15, 316, 92, 94, 1475, 1477, "as" +557, 11, 16, 317, 95, 98, 1478, 1481, "the" +557, 11, 17, 318, 99, 104, 1482, 1487, "fixed" +557, 11, 18, 319, 105, 116, 1488, 1499, "combination" +557, 11, 19, 320, 117, 119, 1500, 1502, "of" +557, 11, 20, 321, 120, 131, 1503, 1514, "dorzolamide" +557, 11, 21, 322, 132, 136, 1515, 1519, "plus" +557, 11, 22, 323, 137, 144, 1520, 1527, "timolol" +557, 11, 23, 324, 145, 150, 1528, 1533, "twice" +557, 11, 24, 325, 151, 156, 1534, 1539, "daily" +557, 11, 25, 326, 157, 159, 1540, 1542, "in" +557, 11, 26, 327, 160, 168, 1543, 1551, "patients" +557, 11, 27, 328, 169, 173, 1552, 1556, "with" +557, 11, 28, 329, 174, 177, 1557, 1560, "IOP" +557, 11, 29, 330, 178, 192, 1561, 1575, "insufficiently" +557, 11, 30, 331, 193, 203, 1576, 1586, "controlled" +557, 11, 31, 332, 204, 206, 1587, 1589, "by" +557, 11, 32, 333, 207, 214, 1590, 1597, "timolol" +557, 11, 33, 334, 215, 220, 1598, 1603, "alone" +557, 11, 34, 335, 221, 222, 1604, 1605, "." +557, 12, 1, 336, 0, 3, 1606, 1609, "DOI" +557, 12, 2, 337, 4, 5, 1610, 1611, ":" +557, 12, 3, 338, 6, 8, 1612, 1614, "10" +557, 12, 4, 339, 9, 10, 1615, 1616, "." +557, 12, 5, 340, 11, 15, 1617, 1621, "1034" +557, 12, 6, 341, 16, 17, 1622, 1623, "/" +557, 12, 7, 342, 18, 19, 1624, 1625, "j" +557, 12, 8, 343, 20, 21, 1626, 1627, "." +557, 12, 9, 344, 22, 26, 1628, 1632, "1600" +557, 12, 10, 345, 27, 28, 1633, 1634, "-" +557, 12, 11, 346, 29, 33, 1635, 1639, "0420" +557, 12, 12, 347, 34, 35, 1640, 1641, "." +557, 12, 13, 348, 36, 40, 1642, 1646, "2002" +557, 12, 14, 349, 41, 42, 1647, 1648, "." +557, 12, 15, 350, 43, 49, 1649, 1655, "800615" +557, 12, 16, 351, 50, 51, 1656, 1657, "." +557, 12, 17, 352, 52, 53, 1658, 1659, "x" +557, 12, 18, 353, 54, 58, 1660, 1664, "PMID" +557, 12, 19, 354, 59, 60, 1665, 1666, ":" +557, 12, 20, 355, 61, 69, 1667, 1675, "12485286" +557, 12, 21, 356, 70, 71, 1676, 1677, "[" +557, 12, 22, 357, 72, 79, 1678, 1685, "Indexed" +557, 12, 23, 358, 80, 83, 1686, 1689, "for" +557, 12, 24, 359, 84, 91, 1690, 1697, "MEDLINE" +557, 12, 25, 360, 92, 93, 1698, 1699, "]" diff --git a/data/gl 12485286_jshahinitiran.annodb b/data/gl 12485286_jshahinitiran.annodb new file mode 100644 index 0000000..db85dcb --- /dev/null +++ b/data/gl 12485286_jshahinitiran.annodb @@ -0,0 +1,74 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81550, Journal, 0, 23, "Acta Ophthalmol Scand .", "", +81551, PublicationYear, 24, 28, "2002", "", +81552, Title, 57, 239, "A comparison of the effects on intraocular pressure of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % in patients with open - angle glaucoma .", "", +81553, IOP, 88, 108, "intraocular pressure", "", +81554, Latanoprost, 112, 123, "latanoprost", "", +81558, DoseValue, 124, 131, "0 . 005", "", +81557, Dorz/TimFC, 142, 198, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", +81555, Dorzolamide, 163, 174, "dorzolamide", "", +81559, DoseValue, 175, 176, "2", "", +81556, Dorzolamide, 183, 190, "timolol", "", +81560, DoseValue, 191, 196, "0 . 5", "", +81561, OpenAngleGlaucoma, 216, 237, "open - angle glaucoma", "", +81562, Author, 240, 251, "Honrubia FM", "", +81563, Author, 260, 270, "Larsson LI", "", +81564, Author, 273, 282, "Spiegel D", "", +81565, Latanoprost, 294, 305, "latanoprost", "", +81566, Spain, 411, 416, "Spain", "", +81567, ObjectiveDescription, 469, 615, "To compare the effects on intraocular pressure ( IOP ) of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % .", "", +81568, IOP, 495, 515, "intraocular pressure", "", +81569, IOP, 518, 521, "IOP", "", +81570, Latanoprost, 527, 538, "latanoprost", "", +81573, DoseValue, 539, 546, "0 . 005", "", +81577, Dorz/TimFC, 557, 613, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", +81571, Dorzolamide, 578, 589, "dorzolamide", "", +81575, DoseValue, 590, 591, "2", "", +81572, Timolol, 598, 605, "timolol", "", +81576, DoseValue, 606, 611, "0 . 5", "", +81578, NumberPatientsCT, 636, 639, "226", "", +81581, Precondition, 649, 699, "whose IOP was insufficiently controlled by timolol", "", +81579, Diurnal_IOP, 655, 658, "IOP", "", +81580, Timolol, 692, 699, "timolol", "", +81582, Randomized, 711, 721, "randomized", "", +81583, Latanoprost, 740, 751, "latanoprost", "", +81584, Frequency, 752, 762, "once daily", "", +81587, Dorzolamide, 770, 815, "fixed combination of dorzolamide plus timolol", "", +81585, Dorzolamide, 791, 802, "dorzolamide", "", +81586, Timolol, 808, 815, "timolol", "", +81588, Frequency, 816, 827, "twice daily", "", +81589, IOP, 830, 850, "Intraocular pressure", "", +81590, TimePoint, 895, 903, "baseline", "", +81592, TimePoint, 914, 922, "3 months", "", +81593, Mean, 948, 952, "Mean", "", +81594, IOP, 953, 956, "IOP", "", +81595, PValueChangeValue, 1000, 1016, "p & lt ; 0 . 001", "", +81596, Reduction, 1058, 1063, "4 . 3", "", +81598, SdErrorChangeValue, 1070, 1075, "0 . 3", "", +81601, mmHg, 1076, 1080, "mmHg", "", +81602, RelativeReduction, 1083, 1085, "19", "", +81604, Latanoprost, 1098, 1109, "latanoprost", "", +81597, Reduction, 1132, 1137, "4 . 0", "", +81599, SdErrorChangeValue, 1144, 1149, "0 . 3", "", +81600, mmHg, 1150, 1154, "mmHg", "", +81603, RelativeReduction, 1157, 1159, "17", "", +81605, Dorzolamide, 1172, 1183, "dorzolamide", "", +81606, Timolol, 1189, 1196, "timolol", "", +81607, IOP, 1270, 1273, "IOP", "", +81608, Mean, 1283, 1287, "mean", "", +81609, DiffGroupAbsValue, 1316, 1321, "0 . 4", "", +81610, SdErrorDiff, 1328, 1333, "0 . 4", "", +81611, ConfIntervalDiff, 1336, 1378, "95 % confidence interval : - 1 . 1 , 0 . 4", "", +81612, ConclusionComment, 1397, 1605, "Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone .", "", +81613, Latanoprost, 1414, 1425, "latanoprost", "", +81614, Frequency, 1426, 1436, "once daily", "", +81616, Mean, 1466, 1470, "mean", "", +81617, IOP, 1471, 1474, "IOP", "", +81620, Dorz/TimFC, 1482, 1527, "fixed combination of dorzolamide plus timolol", "", +81618, Dorzolamide, 1503, 1514, "dorzolamide", "", +81619, Timolol, 1520, 1527, "timolol", "", +81615, Frequency, 1528, 1539, "twice daily", "", +81623, Precondition, 1552, 1605, "with IOP insufficiently controlled by timolol alone .", "", +81621, IOP, 1557, 1560, "IOP", "", +81622, Timolol, 1590, 1597, "timolol", "", +81624, PMID, 1667, 1675, "12485286", "", diff --git a/data/gl 12485286_jshahinitiran.n-triples b/data/gl 12485286_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12485286_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12485286_tstrakeljahn.annodb b/data/gl 12485286_tstrakeljahn.annodb new file mode 100644 index 0000000..95d68a3 --- /dev/null +++ b/data/gl 12485286_tstrakeljahn.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82009, Journal, 0, 21, "Acta Ophthalmol Scand", "", +82010, PublicationYear, 24, 28, "2002", "", +82022, Title, 57, 239, "A comparison of the effects on intraocular pressure of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % in patients with open - angle glaucoma .", "", +82011, IOP, 88, 108, "intraocular pressure", "", +82012, Latanoprost, 112, 123, "latanoprost", "", +82016, DoseValue, 124, 131, "0 . 005", "", +82019, Percentage, 132, 133, "%", "", +82013, Dorzolamide, 163, 174, "dorzolamide", "", +82017, DoseValue, 175, 176, "2", "", +82020, Percentage, 177, 178, "%", "", +82014, Timolol, 183, 190, "timolol", "", +82018, DoseValue, 191, 196, "0 . 5", "", +82021, Percentage, 197, 198, "%", "", +82015, OpenAngleGlaucoma, 216, 237, "open - angle glaucoma", "", +82023, Author, 240, 251, "Honrubia FM", "", +82024, Author, 260, 270, "Larsson LI", "", +82025, Author, 273, 282, "Spiegel D", "", +82026, Latanoprost, 294, 305, "latanoprost", "", +82027, Spain, 411, 416, "Spain", "", +82039, ObjectiveDescription, 469, 615, "To compare the effects on intraocular pressure ( IOP ) of latanoprost 0 . 005 % and the fixed combination of dorzolamide 2 % and timolol 0 . 5 % .", "", +82028, IOP, 495, 515, "intraocular pressure", "", +82029, IOP, 518, 521, "IOP", "", +82030, Latanoprost, 527, 538, "latanoprost", "", +82034, DoseValue, 539, 546, "0 . 005", "", +82036, Percentage, 547, 548, "%", "", +82031, Dorzolamide, 578, 589, "dorzolamide", "", +82040, Dorz/TimFC, 578, 613, "dorzolamide 2 % and timolol 0 . 5 %", "", +82033, DoseValue, 590, 591, "2", "", +82037, Percentage, 592, 593, "%", "", +82032, Timolol, 598, 605, "timolol", "", +82035, DoseValue, 606, 611, "0 . 5", "", +82038, Percentage, 612, 613, "%", "", +82041, NumberPatientsCT, 636, 639, "226", "", +82042, IOP, 655, 658, "IOP", "", +82043, Timolol, 692, 699, "timolol", "", +82044, Randomized, 711, 721, "randomized", "", +82045, Latanoprost, 740, 751, "latanoprost", "", +82046, Frequency, 752, 762, "once daily", "", +82048, Dorzolamide, 791, 802, "dorzolamide", "", +82050, Dorz/TimFC, 791, 815, "dorzolamide plus timolol", "", +82049, Timolol, 808, 815, "timolol", "", +82047, Frequency, 816, 827, "twice daily", "", +82051, IOP, 830, 850, "Intraocular pressure", "", +82052, TimePoint, 867, 877, "10 : 00 am", "", +82053, TimePoint, 882, 891, "5 : 00 pm", "", +82054, TimePoint, 892, 903, "at baseline", "", +82055, TimePoint, 908, 935, "after 3 months of treatment", "", +82056, Mean, 948, 952, "Mean", "", +82057, IOP, 953, 956, "IOP", "", +82058, Mean, 1028, 1032, "mean", "", +82059, Reduction, 1058, 1063, "4 . 3", "", +82065, SdErrorChangeValue, 1070, 1075, "0 . 3", "", +82063, mmHg, 1076, 1080, "mmHg", "", +82061, RelativeReduction, 1083, 1085, "19", "", +82060, Reduction, 1132, 1137, "4 . 0", "", +82066, SdErrorChangeValue, 1144, 1149, "0 . 3", "", +82064, mmHg, 1150, 1154, "mmHg", "", +82062, RelativeReduction, 1157, 1159, "17", "", +82067, Dorzolamide, 1172, 1183, "dorzolamide", "", +82069, Dorz/TimFC, 1172, 1196, "dorzolamide plus timolol", "", +82068, Timolol, 1189, 1196, "timolol", "", +82070, IOP, 1270, 1273, "IOP", "", +82071, Mean, 1283, 1287, "mean", "", +82072, DiffGroupAbsValue, 1316, 1321, "0 . 4", "", +82076, SdErrorChangeValue, 1328, 1333, "0 . 4", "", +82075, ConfIntervalChangeValue, 1363, 1378, "- 1 . 1 , 0 . 4", "", +82087, ConclusionComment, 1397, 1605, "Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone .", "", +82077, Latanoprost, 1414, 1425, "latanoprost", "", +82085, Frequency, 1426, 1436, "once daily", "", +82078, Mean, 1466, 1470, "mean", "", +82079, IOP, 1471, 1474, "IOP", "", +82080, Dorzolamide, 1503, 1514, "dorzolamide", "", +82082, Dorz/TimFC, 1503, 1527, "dorzolamide plus timolol", "", +82081, Timolol, 1520, 1527, "timolol", "", +82086, Frequency, 1528, 1539, "twice daily", "", +82083, IOP, 1557, 1560, "IOP", "", +82084, Timolol, 1590, 1597, "timolol", "", +82088, PMID, 1667, 1675, "12485286", "", diff --git a/data/gl 12485286_tstrakeljahn.n-triples b/data/gl 12485286_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12485286_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12486510_admin.annodb b/data/gl 12486510_admin.annodb new file mode 100644 index 0000000..f69415f --- /dev/null +++ b/data/gl 12486510_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 34, "Graefes Arch Clin Exp Ophthalmol .", "", " \"Graefes Arch Clin Exp Ophthalmol .\"." +1, PublicationYear, 35, 39, "2002", "", " \"2002\"." +5, Title, 87, 184, "A comparison of the fixed combination of latanoprost and timolol with its individual components .", "", " \"A comparison of the fixed combination of latanoprost and timolol with its individual components .\"." +80, Lat/TimFC, 107, 151, "fixed combination of latanoprost and timolol", "", +2, Latanoprost, 128, 139, "latanoprost", "", +3, Timolol, 144, 151, "timolol", "", +6, Author, 185, 195, "Pfeiffer N", "", " \"Pfeiffer N\"." +7, Germany, 347, 354, "Germany", "", +17, ObjectiveDescription, 412, 589, "To evaluate the intraocular pressure ( IOP ) - reducing effect of the fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol compared with the individual monotherapies .", "", +8, IOP, 428, 448, "intraocular pressure", "", +9, IOP, 451, 454, "IOP", "", +90, Lat/TimFC, 482, 544, "fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol", "", " ." +10, DoseValue, 503, 510, "0 . 005", "", +12, Percentage, 511, 512, "%", "", +14, Latanoprost, 513, 524, "latanoprost", "", " . ." +11, DoseValue, 529, 534, "0 . 5", "", +13, Percentage, 535, 536, "%", "", +15, Timolol, 537, 544, "timolol", "", " ." +91, Duration, 602, 611, "6 - month", "", +19, Randomized, 614, 624, "randomised", "", " ." +20, DoubleBlind, 627, 642, "double - masked", "", " ." +21, Multicenter, 656, 667, "multicentre", "", " ." +95, Duration, 686, 694, "6 months", "", +22, OpenLabel, 698, 710, "open - label", "", " ." +101, Precondition, 754, 852, "glaucoma or ocular hypertension with pre - enrolment IOP & gt ; / = 25 mmHg on glaucoma medication", "", " \"glaucoma or ocular hypertension with pre - enrolment IOP & gt ; / = 25 mmHg on glaucoma medication\"." +23, Glaucoma, 754, 762, "glaucoma", "", " . ." +24, OcularHypertension, 766, 785, "ocular hypertension", "", " ." +25, IOP, 807, 810, "IOP", "", +26, mmHg, 825, 829, "mmHg", "", +27, Glaucoma, 833, 841, "glaucoma", "", +28, mmHg, 870, 874, "mmHg", "", +97098, Duration, 902, 917, "2 - to 4 - week", "", +30, Timolol, 937, 944, "timolol", "", +43, Frequency, 945, 956, "twice daily", "", +33, NumberPatientsCT, 959, 962, "436", "", +34, Randomized, 977, 987, "randomised", "", +35, NumberPatientsArm, 990, 993, "140", "", " \"140\"." +121, Lat/TimFC, 997, 1022, "fixed combination therapy", "", +36, Frequency, 1023, 1033, "once daily", "", " \"once daily\"." +111, Morning, 1041, 1048, "morning", "", " ." +39, NumberPatientsArm, 1051, 1054, "147", "", " \"147\"." +31, Latanoprost, 1058, 1069, "latanoprost", "", +38, Frequency, 1070, 1080, "once daily", "", " \"once daily\"." +115, Morning, 1088, 1095, "morning", "", " ." +41, NumberPatientsArm, 1100, 1103, "149", "", " \"149\"." +32, Timolol, 1107, 1114, "timolol", "", +42, Frequency, 1115, 1126, "twice daily", "", " \"twice daily\"." +44, OpenLabel, 1140, 1152, "open - label", "", +47, Lat/TimFC, 1183, 1205, "fixed combination drug", "", +45, Frequency, 1206, 1216, "once daily", "", +123, Morning, 1224, 1231, "morning", "", +48, Mean, 1262, 1266, "mean", "", " . ." +97102, TimePoint, 1279, 1287, "baseline", "", +49, Diurnal_IOP, 1291, 1302, "diurnal IOP", "", " ." +50, TimePoint, 1308, 1314, "week 2", "", +51, TimePoint, 1318, 1325, "week 26", "", " \"week 26\". \"week 26\". \"week 26\"." +57, DiffGroupAbsValue, 1330, 1337, "- 1 . 2", "", " \"- 1 . 2\"." +52, mmHg, 1338, 1342, "mmHg", "", " ." +130, Lat/TimFC, 1351, 1368, "fixed combination", "", +53, Latanoprost, 1373, 1384, "latanoprost", "", " ." +132, ConfIntervalDiff, 1387, 1413, "95 % confidence interval .", "", " \"95 % confidence interval .\"." +132, ConfIntervalDiff, 1414, 1437, "CI : - 1 . 8 to - 0 . 5", "", " \"CI : - 1 . 8 to - 0 . 5\"." +134, PvalueDiff, 1440, 1456, "P & lt ; 0 . 001", "", " \"P & lt ; 0 . 001\"." +55, Timolol, 1565, 1572, "timolol", "", +56, DiffGroupAbsValue, 1577, 1584, "- 1 . 9", "", " \"- 1 . 9\"." +138, mmHg, 1585, 1589, "mmHg", "", +139, ConfIntervalDiff, 1592, 1618, "95 % CI - 2 . 5 to - 1 . 2", "", " \"95 % CI - 2 . 5 to - 1 . 2\"." +140, PvalueDiff, 1621, 1637, "P & lt ; 0 . 001", "", " \"P & lt ; 0 . 001\"." +59, IOP, 1666, 1669, "IOP", "", +60, Duration, 1707, 1716, "12 months", "", " \"12 months\"." +62, ObservedResult, 1742, 1872, "All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events .", "", " \"All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events .\". \"All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events .\". \"All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events .\"." +97104, EndPointDescription, 1856, 1870, "adverse events", "", " . ." +74, ConclusionComment, 1886, 2111, "The fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol administered once daily in the morning for 6 months was more effective in reducing IOP than the individual components alone and was effective over 12 months .", "", " \"The fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol administered once daily in the morning for 6 months was more effective in reducing IOP than the individual components alone and was effective over 12 months .\"." +145, Lat/TimFC, 1890, 1952, "fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol", "", +63, DoseValue, 1911, 1918, "0 . 005", "", +67, Percentage, 1919, 1920, "%", "", +65, Latanoprost, 1921, 1932, "latanoprost", "", +64, DoseValue, 1937, 1942, "0 . 5", "", +68, Percentage, 1943, 1944, "%", "", +66, Timolol, 1945, 1952, "timolol", "", +69, Frequency, 1966, 1976, "once daily", "", +151, Morning, 1984, 1991, "morning", "", +71, Duration, 1996, 2004, "6 months", "", +72, IOP, 2036, 2039, "IOP", "", +73, Duration, 2100, 2109, "12 months", "", +97105, PMID, 2161, 2169, "12486510", "", " \"12486510\"." diff --git a/data/gl 12486510_admin.n-triples b/data/gl 12486510_admin.n-triples new file mode 100644 index 0000000..8ae6a43 --- /dev/null +++ b/data/gl 12486510_admin.n-triples @@ -0,0 +1,146 @@ +# RDF export of group: Publication + . + "Publication 83079" . + "A comparison of the fixed combination of latanoprost and timolol with its individual components ." . + "Pfeiffer N" . + "2002" . + "Graefes Arch Clin Exp Ophthalmol ." . + "12486510" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 83086" . + "12 months" . + . + . + . + "The fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol administered once daily in the morning for 6 months was more effective in reducing IOP than the individual components alone and was effective over 12 months ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 83102" . + "glaucoma or ocular hypertension with pre - enrolment IOP & gt ; / = 25 mmHg on glaucoma medication" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "lat" . + "147" . + . + . + . + . + "tim" . + "149" . + . + . + . + . + "com" . + "140" . + . + . + . +# RDF export of group: Intervention + . + "lat" . + . + "once daily" . + . + . + "tim" . + . + "twice daily" . + . + . + "com" . + "once daily" . + . + . +# RDF export of group: Medication + . + "lat" . + . + . + . + . + . + "tim" . + . + . + . + . + "com" . + . + . + . +# RDF export of group: Outcome + . + "iop lat" . + . + "week 26" . + . + "iop tim" . + . + "week 26" . + . + "iop com" . + . + "week 26" . + . + "ae 1" . + . + "All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events ." . + . + "ae 2" . + . + "All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events ." . + . + "ae 3" . + . + "All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events ." . +# RDF export of group: DiffBetweenGroups + . + "iop comlat" . + "- 1 . 2" . + "P & lt ; 0 . 001" . + "95 % confidence interval ." . + "CI : - 1 . 8 to - 0 . 5" . + . + . + . + "iop comtim" . + "- 1 . 9" . + "P & lt ; 0 . 001" . + "95 % CI - 2 . 5 to - 1 . 2" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12486510_export.csv b/data/gl 12486510_export.csv new file mode 100644 index 0000000..d564a4e --- /dev/null +++ b/data/gl 12486510_export.csv @@ -0,0 +1,447 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +533, 1, 1, 1, 0, 7, 0, 7, "Graefes" +533, 1, 2, 2, 8, 12, 8, 12, "Arch" +533, 1, 3, 3, 13, 17, 13, 17, "Clin" +533, 1, 4, 4, 18, 21, 18, 21, "Exp" +533, 1, 5, 5, 22, 32, 22, 32, "Ophthalmol" +533, 1, 6, 6, 33, 34, 33, 34, "." +533, 2, 1, 7, 0, 4, 35, 39, "2002" +533, 2, 2, 8, 5, 8, 40, 43, "Nov" +533, 2, 3, 9, 9, 10, 44, 45, ";" +533, 2, 4, 10, 11, 14, 46, 49, "240" +533, 2, 5, 11, 15, 16, 50, 51, "(" +533, 2, 6, 12, 17, 19, 52, 54, "11" +533, 2, 7, 13, 20, 21, 55, 56, ")" +533, 2, 8, 14, 22, 23, 57, 58, ":" +533, 2, 9, 15, 24, 27, 59, 62, "893" +533, 2, 10, 16, 28, 29, 63, 64, "-" +533, 2, 11, 17, 30, 31, 65, 66, "9" +533, 2, 12, 18, 32, 33, 67, 68, "." +533, 3, 1, 19, 0, 4, 69, 73, "Epub" +533, 3, 2, 20, 5, 9, 74, 78, "2002" +533, 3, 3, 21, 10, 13, 79, 82, "Nov" +533, 3, 4, 22, 14, 15, 83, 84, "1" +533, 3, 5, 23, 16, 17, 85, 86, "." +533, 4, 1, 24, 0, 1, 87, 88, "A" +533, 4, 2, 25, 2, 12, 89, 99, "comparison" +533, 4, 3, 26, 13, 15, 100, 102, "of" +533, 4, 4, 27, 16, 19, 103, 106, "the" +533, 4, 5, 28, 20, 25, 107, 112, "fixed" +533, 4, 6, 29, 26, 37, 113, 124, "combination" +533, 4, 7, 30, 38, 40, 125, 127, "of" +533, 4, 8, 31, 41, 52, 128, 139, "latanoprost" +533, 4, 9, 32, 53, 56, 140, 143, "and" +533, 4, 10, 33, 57, 64, 144, 151, "timolol" +533, 4, 11, 34, 65, 69, 152, 156, "with" +533, 4, 12, 35, 70, 73, 157, 160, "its" +533, 4, 13, 36, 74, 84, 161, 171, "individual" +533, 4, 14, 37, 85, 95, 172, 182, "components" +533, 4, 15, 38, 96, 97, 183, 184, "." +533, 5, 1, 39, 0, 8, 185, 193, "Pfeiffer" +533, 5, 2, 40, 9, 10, 194, 195, "N" +533, 5, 3, 41, 11, 12, 196, 197, "(" +533, 5, 4, 42, 13, 14, 198, 199, "1" +533, 5, 5, 43, 15, 16, 200, 201, ")" +533, 5, 6, 44, 17, 18, 202, 203, ";" +533, 5, 7, 45, 19, 27, 204, 212, "European" +533, 5, 8, 46, 28, 39, 213, 224, "Latanoprost" +533, 5, 9, 47, 40, 45, 225, 230, "Fixed" +533, 5, 10, 48, 46, 57, 231, 242, "Combination" +533, 5, 11, 49, 58, 63, 243, 248, "Study" +533, 5, 12, 50, 64, 69, 249, 254, "Group" +533, 5, 13, 51, 70, 71, 255, 256, "." +533, 6, 1, 52, 0, 6, 257, 263, "Author" +533, 6, 2, 53, 7, 18, 264, 275, "information" +533, 6, 3, 54, 19, 20, 276, 277, ":" +533, 6, 4, 55, 21, 22, 278, 279, "(" +533, 6, 5, 56, 23, 24, 280, 281, "1" +533, 6, 6, 57, 25, 26, 282, 283, ")" +533, 6, 7, 58, 27, 37, 284, 294, "Department" +533, 6, 8, 59, 38, 40, 295, 297, "of" +533, 6, 9, 60, 41, 54, 298, 311, "Ophthalmology" +533, 6, 10, 61, 55, 56, 312, 313, "," +533, 6, 11, 62, 57, 62, 314, 319, "Mainz" +533, 6, 12, 63, 63, 73, 320, 330, "University" +533, 6, 13, 64, 74, 75, 331, 332, "," +533, 6, 14, 65, 76, 81, 333, 338, "55101" +533, 6, 15, 66, 82, 87, 339, 344, "Mainz" +533, 6, 16, 67, 88, 89, 345, 346, "," +533, 6, 17, 68, 90, 97, 347, 354, "Germany" +533, 6, 18, 69, 98, 99, 355, 356, "." +533, 7, 1, 70, 0, 8, 357, 365, "pfeiffer" +533, 7, 2, 71, 9, 10, 366, 367, "@" +533, 7, 3, 72, 11, 16, 368, 373, "augen" +533, 7, 4, 73, 17, 18, 374, 375, "." +533, 7, 5, 74, 19, 25, 376, 382, "klinik" +533, 7, 6, 75, 26, 27, 383, 384, "." +533, 7, 7, 76, 28, 31, 385, 388, "uni" +533, 7, 8, 77, 32, 33, 389, 390, "-" +533, 7, 9, 78, 34, 39, 391, 396, "mainz" +533, 7, 10, 79, 40, 41, 397, 398, "." +533, 7, 11, 80, 42, 44, 399, 401, "de" +533, 7, 12, 81, 45, 52, 402, 409, "PURPOSE" +533, 7, 13, 82, 53, 54, 410, 411, ":" +533, 7, 14, 83, 55, 57, 412, 414, "To" +533, 7, 15, 84, 58, 66, 415, 423, "evaluate" +533, 7, 16, 85, 67, 70, 424, 427, "the" +533, 7, 17, 86, 71, 82, 428, 439, "intraocular" +533, 7, 18, 87, 83, 91, 440, 448, "pressure" +533, 7, 19, 88, 92, 93, 449, 450, "(" +533, 7, 20, 89, 94, 97, 451, 454, "IOP" +533, 7, 21, 90, 98, 99, 455, 456, ")" +533, 7, 22, 91, 100, 101, 457, 458, "-" +533, 7, 23, 92, 102, 110, 459, 467, "reducing" +533, 7, 24, 93, 111, 117, 468, 474, "effect" +533, 7, 25, 94, 118, 120, 475, 477, "of" +533, 7, 26, 95, 121, 124, 478, 481, "the" +533, 7, 27, 96, 125, 130, 482, 487, "fixed" +533, 7, 28, 97, 131, 142, 488, 499, "combination" +533, 7, 29, 98, 143, 145, 500, 502, "of" +533, 7, 30, 99, 146, 147, 503, 504, "0" +533, 7, 31, 100, 148, 149, 505, 506, "." +533, 7, 32, 101, 150, 153, 507, 510, "005" +533, 7, 33, 102, 154, 155, 511, 512, "%" +533, 7, 34, 103, 156, 167, 513, 524, "latanoprost" +533, 7, 35, 104, 168, 171, 525, 528, "and" +533, 7, 36, 105, 172, 173, 529, 530, "0" +533, 7, 37, 106, 174, 175, 531, 532, "." +533, 7, 38, 107, 176, 177, 533, 534, "5" +533, 7, 39, 108, 178, 179, 535, 536, "%" +533, 7, 40, 109, 180, 187, 537, 544, "timolol" +533, 7, 41, 110, 188, 196, 545, 553, "compared" +533, 7, 42, 111, 197, 201, 554, 558, "with" +533, 7, 43, 112, 202, 205, 559, 562, "the" +533, 7, 44, 113, 206, 216, 563, 573, "individual" +533, 7, 45, 114, 217, 230, 574, 587, "monotherapies" +533, 7, 46, 115, 231, 232, 588, 589, "." +533, 8, 1, 116, 0, 7, 590, 597, "METHODS" +533, 8, 2, 117, 8, 9, 598, 599, ":" +533, 8, 3, 118, 10, 11, 600, 601, "A" +533, 8, 4, 119, 12, 13, 602, 603, "6" +533, 8, 5, 120, 14, 15, 604, 605, "-" +533, 8, 6, 121, 16, 21, 606, 611, "month" +533, 8, 7, 122, 22, 23, 612, 613, "," +533, 8, 8, 123, 24, 34, 614, 624, "randomised" +533, 8, 9, 124, 35, 36, 625, 626, "," +533, 8, 10, 125, 37, 43, 627, 633, "double" +533, 8, 11, 126, 44, 45, 634, 635, "-" +533, 8, 12, 127, 46, 52, 636, 642, "masked" +533, 8, 13, 128, 53, 54, 643, 644, "," +533, 8, 14, 129, 55, 65, 645, 655, "controlled" +533, 8, 15, 130, 66, 77, 656, 667, "multicentre" +533, 8, 16, 131, 78, 83, 668, 673, "study" +533, 8, 17, 132, 84, 92, 674, 682, "followed" +533, 8, 18, 133, 93, 95, 683, 685, "by" +533, 8, 19, 134, 96, 97, 686, 687, "6" +533, 8, 20, 135, 98, 104, 688, 694, "months" +533, 8, 21, 136, 105, 107, 695, 697, "of" +533, 8, 22, 137, 108, 112, 698, 702, "open" +533, 8, 23, 138, 113, 114, 703, 704, "-" +533, 8, 24, 139, 115, 120, 705, 710, "label" +533, 8, 25, 140, 121, 130, 711, 720, "treatment" +533, 8, 26, 141, 131, 134, 721, 724, "was" +533, 8, 27, 142, 135, 142, 725, 732, "carried" +533, 8, 28, 143, 143, 146, 733, 736, "out" +533, 8, 29, 144, 147, 149, 737, 739, "in" +533, 8, 30, 145, 150, 158, 740, 748, "patients" +533, 8, 31, 146, 159, 163, 749, 753, "with" +533, 8, 32, 147, 164, 172, 754, 762, "glaucoma" +533, 8, 33, 148, 173, 175, 763, 765, "or" +533, 8, 34, 149, 176, 182, 766, 772, "ocular" +533, 8, 35, 150, 183, 195, 773, 785, "hypertension" +533, 8, 36, 151, 196, 200, 786, 790, "with" +533, 8, 37, 152, 201, 204, 791, 794, "pre" +533, 8, 38, 153, 205, 206, 795, 796, "-" +533, 8, 39, 154, 207, 216, 797, 806, "enrolment" +533, 8, 40, 155, 217, 220, 807, 810, "IOP" +533, 8, 41, 156, 221, 222, 811, 812, "&" +533, 8, 42, 157, 223, 225, 813, 815, "gt" +533, 8, 43, 158, 226, 227, 816, 817, ";" +533, 8, 44, 159, 228, 229, 818, 819, "/" +533, 8, 45, 160, 230, 231, 820, 821, "=" +533, 8, 46, 161, 232, 234, 822, 824, "25" +533, 8, 47, 162, 235, 239, 825, 829, "mmHg" +533, 8, 48, 163, 240, 242, 830, 832, "on" +533, 8, 49, 164, 243, 251, 833, 841, "glaucoma" +533, 8, 50, 165, 252, 262, 842, 852, "medication" +533, 8, 51, 166, 263, 265, 853, 855, "or" +533, 8, 52, 167, 266, 267, 856, 857, "&" +533, 8, 53, 168, 268, 270, 858, 860, "gt" +533, 8, 54, 169, 271, 272, 861, 862, ";" +533, 8, 55, 170, 273, 274, 863, 864, "/" +533, 8, 56, 171, 275, 276, 865, 866, "=" +533, 8, 57, 172, 277, 279, 867, 869, "30" +533, 8, 58, 173, 280, 284, 870, 874, "mmHg" +533, 8, 59, 174, 285, 287, 875, 877, "if" +533, 8, 60, 175, 288, 297, 878, 887, "untreated" +533, 8, 61, 176, 298, 299, 888, 889, "." +533, 9, 1, 177, 0, 9, 890, 899, "Following" +533, 9, 2, 178, 10, 11, 900, 901, "a" +533, 9, 3, 179, 12, 13, 902, 903, "2" +533, 9, 4, 180, 14, 15, 904, 905, "-" +533, 9, 5, 181, 16, 18, 906, 908, "to" +533, 9, 6, 182, 19, 20, 909, 910, "4" +533, 9, 7, 183, 21, 22, 911, 912, "-" +533, 9, 8, 184, 23, 27, 913, 917, "week" +533, 9, 9, 185, 28, 31, 918, 921, "run" +533, 9, 10, 186, 32, 33, 922, 923, "-" +533, 9, 11, 187, 34, 36, 924, 926, "in" +533, 9, 12, 188, 37, 43, 927, 933, "period" +533, 9, 13, 189, 44, 46, 934, 936, "on" +533, 9, 14, 190, 47, 54, 937, 944, "timolol" +533, 9, 15, 191, 55, 60, 945, 950, "twice" +533, 9, 16, 192, 61, 66, 951, 956, "daily" +533, 9, 17, 193, 67, 68, 957, 958, "," +533, 9, 18, 194, 69, 72, 959, 962, "436" +533, 9, 19, 195, 73, 81, 963, 971, "patients" +533, 9, 20, 196, 82, 86, 972, 976, "were" +533, 9, 21, 197, 87, 97, 977, 987, "randomised" +533, 9, 22, 198, 98, 99, 988, 989, ":" +533, 9, 23, 199, 100, 103, 990, 993, "140" +533, 9, 24, 200, 104, 106, 994, 996, "to" +533, 9, 25, 201, 107, 112, 997, 1002, "fixed" +533, 9, 26, 202, 113, 124, 1003, 1014, "combination" +533, 9, 27, 203, 125, 132, 1015, 1022, "therapy" +533, 9, 28, 204, 133, 137, 1023, 1027, "once" +533, 9, 29, 205, 138, 143, 1028, 1033, "daily" +533, 9, 30, 206, 144, 146, 1034, 1036, "in" +533, 9, 31, 207, 147, 150, 1037, 1040, "the" +533, 9, 32, 208, 151, 158, 1041, 1048, "morning" +533, 9, 33, 209, 159, 160, 1049, 1050, "," +533, 9, 34, 210, 161, 164, 1051, 1054, "147" +533, 9, 35, 211, 165, 167, 1055, 1057, "to" +533, 9, 36, 212, 168, 179, 1058, 1069, "latanoprost" +533, 9, 37, 213, 180, 184, 1070, 1074, "once" +533, 9, 38, 214, 185, 190, 1075, 1080, "daily" +533, 9, 39, 215, 191, 193, 1081, 1083, "in" +533, 9, 40, 216, 194, 197, 1084, 1087, "the" +533, 9, 41, 217, 198, 205, 1088, 1095, "morning" +533, 9, 42, 218, 206, 209, 1096, 1099, "and" +533, 9, 43, 219, 210, 213, 1100, 1103, "149" +533, 9, 44, 220, 214, 216, 1104, 1106, "to" +533, 9, 45, 221, 217, 224, 1107, 1114, "timolol" +533, 9, 46, 222, 225, 230, 1115, 1120, "twice" +533, 9, 47, 223, 231, 236, 1121, 1126, "daily" +533, 9, 48, 224, 237, 238, 1127, 1128, "." +533, 10, 1, 225, 0, 6, 1129, 1135, "During" +533, 10, 2, 226, 7, 10, 1136, 1139, "the" +533, 10, 3, 227, 11, 15, 1140, 1144, "open" +533, 10, 4, 228, 16, 17, 1145, 1146, "-" +533, 10, 5, 229, 18, 23, 1147, 1152, "label" +533, 10, 6, 230, 24, 33, 1153, 1162, "extension" +533, 10, 7, 231, 34, 35, 1163, 1164, "," +533, 10, 8, 232, 36, 44, 1165, 1173, "patients" +533, 10, 9, 233, 45, 53, 1174, 1182, "received" +533, 10, 10, 234, 54, 59, 1183, 1188, "fixed" +533, 10, 11, 235, 60, 71, 1189, 1200, "combination" +533, 10, 12, 236, 72, 76, 1201, 1205, "drug" +533, 10, 13, 237, 77, 81, 1206, 1210, "once" +533, 10, 14, 238, 82, 87, 1211, 1216, "daily" +533, 10, 15, 239, 88, 90, 1217, 1219, "in" +533, 10, 16, 240, 91, 94, 1220, 1223, "the" +533, 10, 17, 241, 95, 102, 1224, 1231, "morning" +533, 10, 18, 242, 103, 104, 1232, 1233, "." +533, 11, 1, 243, 0, 7, 1234, 1241, "RESULTS" +533, 11, 2, 244, 8, 9, 1242, 1243, ":" +533, 11, 3, 245, 10, 13, 1244, 1247, "The" +533, 11, 4, 246, 14, 24, 1248, 1258, "difference" +533, 11, 5, 247, 25, 27, 1259, 1261, "in" +533, 11, 6, 248, 28, 32, 1262, 1266, "mean" +533, 11, 7, 249, 33, 39, 1267, 1273, "change" +533, 11, 8, 250, 40, 44, 1274, 1278, "from" +533, 11, 9, 251, 45, 53, 1279, 1287, "baseline" +533, 11, 10, 252, 54, 56, 1288, 1290, "in" +533, 11, 11, 253, 57, 64, 1291, 1298, "diurnal" +533, 11, 12, 254, 65, 68, 1299, 1302, "IOP" +533, 11, 13, 255, 69, 73, 1303, 1307, "from" +533, 11, 14, 256, 74, 78, 1308, 1312, "week" +533, 11, 15, 257, 79, 80, 1313, 1314, "2" +533, 11, 16, 258, 81, 83, 1315, 1317, "to" +533, 11, 17, 259, 84, 88, 1318, 1322, "week" +533, 11, 18, 260, 89, 91, 1323, 1325, "26" +533, 11, 19, 261, 92, 95, 1326, 1329, "was" +533, 11, 20, 262, 96, 97, 1330, 1331, "-" +533, 11, 21, 263, 98, 99, 1332, 1333, "1" +533, 11, 22, 264, 100, 101, 1334, 1335, "." +533, 11, 23, 265, 102, 103, 1336, 1337, "2" +533, 11, 24, 266, 104, 108, 1338, 1342, "mmHg" +533, 11, 25, 267, 109, 116, 1343, 1350, "between" +533, 11, 26, 268, 117, 122, 1351, 1356, "fixed" +533, 11, 27, 269, 123, 134, 1357, 1368, "combination" +533, 11, 28, 270, 135, 138, 1369, 1372, "and" +533, 11, 29, 271, 139, 150, 1373, 1384, "latanoprost" +533, 11, 30, 272, 151, 152, 1385, 1386, "(" +533, 11, 31, 273, 153, 155, 1387, 1389, "95" +533, 11, 32, 274, 156, 157, 1390, 1391, "%" +533, 11, 33, 275, 158, 168, 1392, 1402, "confidence" +533, 11, 34, 276, 169, 177, 1403, 1411, "interval" +533, 11, 35, 277, 178, 179, 1412, 1413, "." +533, 12, 1, 278, 0, 2, 1414, 1416, "CI" +533, 12, 2, 279, 3, 4, 1417, 1418, ":" +533, 12, 3, 280, 5, 6, 1419, 1420, "-" +533, 12, 4, 281, 7, 8, 1421, 1422, "1" +533, 12, 5, 282, 9, 10, 1423, 1424, "." +533, 12, 6, 283, 11, 12, 1425, 1426, "8" +533, 12, 7, 284, 13, 15, 1427, 1429, "to" +533, 12, 8, 285, 16, 17, 1430, 1431, "-" +533, 12, 9, 286, 18, 19, 1432, 1433, "0" +533, 12, 10, 287, 20, 21, 1434, 1435, "." +533, 12, 11, 288, 22, 23, 1436, 1437, "5" +533, 12, 12, 289, 24, 25, 1438, 1439, ";" +533, 12, 13, 290, 26, 27, 1440, 1441, "P" +533, 12, 14, 291, 28, 29, 1442, 1443, "&" +533, 12, 15, 292, 30, 32, 1444, 1446, "lt" +533, 12, 16, 293, 33, 34, 1447, 1448, ";" +533, 12, 17, 294, 35, 36, 1449, 1450, "0" +533, 12, 18, 295, 37, 38, 1451, 1452, "." +533, 12, 19, 296, 39, 42, 1453, 1456, "001" +533, 12, 20, 297, 43, 44, 1457, 1458, ";" +533, 12, 21, 298, 45, 53, 1459, 1467, "repeated" +533, 12, 22, 299, 54, 55, 1468, 1469, "-" +533, 12, 23, 300, 56, 64, 1470, 1478, "measures" +533, 12, 24, 301, 65, 73, 1479, 1487, "analysis" +533, 12, 25, 302, 74, 76, 1488, 1490, "of" +533, 12, 26, 303, 77, 87, 1491, 1501, "covariance" +533, 12, 27, 304, 88, 89, 1502, 1503, ")" +533, 12, 28, 305, 90, 91, 1504, 1505, "." +533, 13, 1, 306, 0, 3, 1506, 1509, "The" +533, 13, 2, 307, 4, 17, 1510, 1523, "corresponding" +533, 13, 3, 308, 18, 28, 1524, 1534, "difference" +533, 13, 4, 309, 29, 36, 1535, 1542, "between" +533, 13, 5, 310, 37, 42, 1543, 1548, "fixed" +533, 13, 6, 311, 43, 54, 1549, 1560, "combination" +533, 13, 7, 312, 55, 58, 1561, 1564, "and" +533, 13, 8, 313, 59, 66, 1565, 1572, "timolol" +533, 13, 9, 314, 67, 70, 1573, 1576, "was" +533, 13, 10, 315, 71, 72, 1577, 1578, "-" +533, 13, 11, 316, 73, 74, 1579, 1580, "1" +533, 13, 12, 317, 75, 76, 1581, 1582, "." +533, 13, 13, 318, 77, 78, 1583, 1584, "9" +533, 13, 14, 319, 79, 83, 1585, 1589, "mmHg" +533, 13, 15, 320, 84, 85, 1590, 1591, "(" +533, 13, 16, 321, 86, 88, 1592, 1594, "95" +533, 13, 17, 322, 89, 90, 1595, 1596, "%" +533, 13, 18, 323, 91, 93, 1597, 1599, "CI" +533, 13, 19, 324, 94, 95, 1600, 1601, "-" +533, 13, 20, 325, 96, 97, 1602, 1603, "2" +533, 13, 21, 326, 98, 99, 1604, 1605, "." +533, 13, 22, 327, 100, 101, 1606, 1607, "5" +533, 13, 23, 328, 102, 104, 1608, 1610, "to" +533, 13, 24, 329, 105, 106, 1611, 1612, "-" +533, 13, 25, 330, 107, 108, 1613, 1614, "1" +533, 13, 26, 331, 109, 110, 1615, 1616, "." +533, 13, 27, 332, 111, 112, 1617, 1618, "2" +533, 13, 28, 333, 113, 114, 1619, 1620, ";" +533, 13, 29, 334, 115, 116, 1621, 1622, "P" +533, 13, 30, 335, 117, 118, 1623, 1624, "&" +533, 13, 31, 336, 119, 121, 1625, 1627, "lt" +533, 13, 32, 337, 122, 123, 1628, 1629, ";" +533, 13, 33, 338, 124, 125, 1630, 1631, "0" +533, 13, 34, 339, 126, 127, 1632, 1633, "." +533, 13, 35, 340, 128, 131, 1634, 1637, "001" +533, 13, 36, 341, 132, 133, 1638, 1639, ")" +533, 13, 37, 342, 134, 135, 1640, 1641, "." +533, 14, 1, 343, 0, 2, 1642, 1644, "No" +533, 14, 2, 344, 3, 7, 1645, 1649, "long" +533, 14, 3, 345, 8, 9, 1650, 1651, "-" +533, 14, 4, 346, 10, 14, 1652, 1656, "term" +533, 14, 5, 347, 15, 20, 1657, 1662, "drift" +533, 14, 6, 348, 21, 23, 1663, 1665, "in" +533, 14, 7, 349, 24, 27, 1666, 1669, "IOP" +533, 14, 8, 350, 28, 31, 1670, 1673, "was" +533, 14, 9, 351, 32, 40, 1674, 1682, "detected" +533, 14, 10, 352, 41, 43, 1683, 1685, "in" +533, 14, 11, 353, 44, 52, 1686, 1694, "patients" +533, 14, 12, 354, 53, 60, 1695, 1702, "treated" +533, 14, 13, 355, 61, 64, 1703, 1706, "for" +533, 14, 14, 356, 65, 67, 1707, 1709, "12" +533, 14, 15, 357, 68, 74, 1710, 1716, "months" +533, 14, 16, 358, 75, 79, 1717, 1721, "with" +533, 14, 17, 359, 80, 85, 1722, 1727, "fixed" +533, 14, 18, 360, 86, 97, 1728, 1739, "combination" +533, 14, 19, 361, 98, 99, 1740, 1741, "." +533, 15, 1, 362, 0, 3, 1742, 1745, "All" +533, 15, 2, 363, 4, 14, 1746, 1756, "treatments" +533, 15, 3, 364, 15, 19, 1757, 1761, "were" +533, 15, 4, 365, 20, 24, 1762, 1766, "well" +533, 15, 5, 366, 25, 34, 1767, 1776, "tolerated" +533, 15, 6, 367, 35, 39, 1777, 1781, "with" +533, 15, 7, 368, 40, 42, 1782, 1784, "no" +533, 15, 8, 369, 43, 48, 1785, 1790, "major" +533, 15, 9, 370, 49, 60, 1791, 1802, "differences" +533, 15, 10, 371, 61, 66, 1803, 1808, "among" +533, 15, 11, 372, 67, 73, 1809, 1815, "groups" +533, 15, 12, 373, 74, 76, 1816, 1818, "in" +533, 15, 13, 374, 77, 80, 1819, 1822, "the" +533, 15, 14, 375, 81, 90, 1823, 1832, "incidence" +533, 15, 15, 376, 91, 93, 1833, 1835, "of" +533, 15, 16, 377, 94, 104, 1836, 1846, "clinically" +533, 15, 17, 378, 105, 113, 1847, 1855, "relevant" +533, 15, 18, 379, 114, 121, 1856, 1863, "adverse" +533, 15, 19, 380, 122, 128, 1864, 1870, "events" +533, 15, 20, 381, 129, 130, 1871, 1872, "." +533, 16, 1, 382, 0, 10, 1873, 1883, "CONCLUSION" +533, 16, 2, 383, 11, 12, 1884, 1885, ":" +533, 16, 3, 384, 13, 16, 1886, 1889, "The" +533, 16, 4, 385, 17, 22, 1890, 1895, "fixed" +533, 16, 5, 386, 23, 34, 1896, 1907, "combination" +533, 16, 6, 387, 35, 37, 1908, 1910, "of" +533, 16, 7, 388, 38, 39, 1911, 1912, "0" +533, 16, 8, 389, 40, 41, 1913, 1914, "." +533, 16, 9, 390, 42, 45, 1915, 1918, "005" +533, 16, 10, 391, 46, 47, 1919, 1920, "%" +533, 16, 11, 392, 48, 59, 1921, 1932, "latanoprost" +533, 16, 12, 393, 60, 63, 1933, 1936, "and" +533, 16, 13, 394, 64, 65, 1937, 1938, "0" +533, 16, 14, 395, 66, 67, 1939, 1940, "." +533, 16, 15, 396, 68, 69, 1941, 1942, "5" +533, 16, 16, 397, 70, 71, 1943, 1944, "%" +533, 16, 17, 398, 72, 79, 1945, 1952, "timolol" +533, 16, 18, 399, 80, 92, 1953, 1965, "administered" +533, 16, 19, 400, 93, 97, 1966, 1970, "once" +533, 16, 20, 401, 98, 103, 1971, 1976, "daily" +533, 16, 21, 402, 104, 106, 1977, 1979, "in" +533, 16, 22, 403, 107, 110, 1980, 1983, "the" +533, 16, 23, 404, 111, 118, 1984, 1991, "morning" +533, 16, 24, 405, 119, 122, 1992, 1995, "for" +533, 16, 25, 406, 123, 124, 1996, 1997, "6" +533, 16, 26, 407, 125, 131, 1998, 2004, "months" +533, 16, 27, 408, 132, 135, 2005, 2008, "was" +533, 16, 28, 409, 136, 140, 2009, 2013, "more" +533, 16, 29, 410, 141, 150, 2014, 2023, "effective" +533, 16, 30, 411, 151, 153, 2024, 2026, "in" +533, 16, 31, 412, 154, 162, 2027, 2035, "reducing" +533, 16, 32, 413, 163, 166, 2036, 2039, "IOP" +533, 16, 33, 414, 167, 171, 2040, 2044, "than" +533, 16, 34, 415, 172, 175, 2045, 2048, "the" +533, 16, 35, 416, 176, 186, 2049, 2059, "individual" +533, 16, 36, 417, 187, 197, 2060, 2070, "components" +533, 16, 37, 418, 198, 203, 2071, 2076, "alone" +533, 16, 38, 419, 204, 207, 2077, 2080, "and" +533, 16, 39, 420, 208, 211, 2081, 2084, "was" +533, 16, 40, 421, 212, 221, 2085, 2094, "effective" +533, 16, 41, 422, 222, 226, 2095, 2099, "over" +533, 16, 42, 423, 227, 229, 2100, 2102, "12" +533, 16, 43, 424, 230, 236, 2103, 2109, "months" +533, 16, 44, 425, 237, 238, 2110, 2111, "." +533, 17, 1, 426, 0, 3, 2112, 2115, "DOI" +533, 17, 2, 427, 4, 5, 2116, 2117, ":" +533, 17, 3, 428, 6, 8, 2118, 2120, "10" +533, 17, 4, 429, 9, 10, 2121, 2122, "." +533, 17, 5, 430, 11, 15, 2123, 2127, "1007" +533, 17, 6, 431, 16, 17, 2128, 2129, "/" +533, 17, 7, 432, 18, 24, 2130, 2136, "s00417" +533, 17, 8, 433, 25, 26, 2137, 2138, "-" +533, 17, 9, 434, 27, 30, 2139, 2142, "002" +533, 17, 10, 435, 31, 32, 2143, 2144, "-" +533, 17, 11, 436, 33, 37, 2145, 2149, "0553" +533, 17, 12, 437, 38, 39, 2150, 2151, "-" +533, 17, 13, 438, 40, 41, 2152, 2153, "0" +533, 17, 14, 439, 42, 46, 2154, 2158, "PMID" +533, 17, 15, 440, 47, 48, 2159, 2160, ":" +533, 17, 16, 441, 49, 57, 2161, 2169, "12486510" +533, 17, 17, 442, 58, 59, 2170, 2171, "[" +533, 17, 18, 443, 60, 67, 2172, 2179, "Indexed" +533, 17, 19, 444, 68, 71, 2180, 2183, "for" +533, 17, 20, 445, 72, 79, 2184, 2191, "MEDLINE" +533, 17, 21, 446, 80, 81, 2192, 2193, "]" diff --git a/data/gl 12486510_jshahinitiran.annodb b/data/gl 12486510_jshahinitiran.annodb new file mode 100644 index 0000000..43961b1 --- /dev/null +++ b/data/gl 12486510_jshahinitiran.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82334, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +82335, PublicationYear, 35, 39, "2002", "", +82336, Title, 87, 184, "A comparison of the fixed combination of latanoprost and timolol with its individual components .", "", +82339, Lat/TimFC, 107, 151, "fixed combination of latanoprost and timolol", "", +82337, Latanoprost, 128, 139, "latanoprost", "", +82338, Timolol, 144, 151, "timolol", "", +82340, Author, 185, 195, "Pfeiffer N", "", +82341, Germany, 347, 354, "Germany", "", +82342, ObjectiveDescription, 412, 589, "To evaluate the intraocular pressure ( IOP ) - reducing effect of the fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol compared with the individual monotherapies .", "", +82343, IOP, 428, 448, "intraocular pressure", "", +82344, IOP, 451, 454, "IOP", "", +82349, Lat/TimFC, 482, 544, "fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol", "", +82347, DoseValue, 503, 510, "0 . 005", "", +82345, Latanoprost, 513, 524, "latanoprost", "", +82348, DoseValue, 529, 534, "0 . 5", "", +82346, Timolol, 537, 544, "timolol", "", +82350, Duration, 602, 611, "6 - month", "", +82351, Randomized, 614, 624, "randomised", "", +82352, DoubleBlind, 627, 642, "double - masked", "", +82353, Multicenter, 656, 667, "multicentre", "", +82354, Duration, 686, 694, "6 months", "", +82355, OpenLabel, 698, 710, "open - label", "", +82356, Glaucoma, 754, 762, "glaucoma", "", +82357, OcularHypertension, 766, 785, "ocular hypertension", "", +82360, Precondition, 791, 852, "pre - enrolment IOP & gt ; / = 25 mmHg on glaucoma medication", "", +82358, IOP, 807, 810, "IOP", "", +82359, mmHg, 825, 829, "mmHg", "", +82361, Glaucoma, 833, 841, "glaucoma", "", +82362, Precondition, 856, 887, "& gt ; / = 30 mmHg if untreated", "", +82363, mmHg, 870, 874, "mmHg", "", +82364, Timolol, 937, 944, "timolol", "", +82365, Frequency, 945, 956, "twice daily", "", +82366, NumberPatientsCT, 959, 962, "436", "", +82367, Randomized, 977, 987, "randomised", "", +82368, NumberPatientsArm, 990, 993, "140", "", +82380, Lat/TimFC, 997, 1022, "fixed combination therapy", "", +82369, Frequency, 1023, 1033, "once daily", "", +82370, Morning, 1041, 1048, "morning", "", +82371, NumberPatientsArm, 1051, 1054, "147", "", +82372, Latanoprost, 1058, 1069, "latanoprost", "", +82373, Frequency, 1070, 1080, "once daily", "", +82374, Morning, 1088, 1095, "morning", "", +82375, NumberPatientsArm, 1100, 1103, "149", "", +82376, Timolol, 1107, 1114, "timolol", "", +82377, Frequency, 1115, 1126, "twice daily", "", +82378, OpenLabel, 1140, 1152, "open - label", "", +82379, Lat/TimFC, 1183, 1205, "fixed combination drug", "", +82381, Frequency, 1206, 1216, "once daily", "", +82382, Morning, 1224, 1231, "morning", "", +82383, Mean, 1262, 1266, "mean", "", +82384, Diurnal_IOP, 1291, 1302, "diurnal IOP", "", +82385, TimePoint, 1308, 1314, "week 2", "", +82386, TimePoint, 1318, 1325, "week 26", "", +82387, DiffGroupAbsValue, 1332, 1337, "1 . 2", "", +82389, mmHg, 1338, 1342, "mmHg", "", +82390, Lat/TimFC, 1351, 1368, "fixed combination", "", +82391, Latanoprost, 1373, 1384, "latanoprost", "", +82392, ConfIntervalDiff, 1387, 1411, "95 % confidence interval", "", +82393, ConfIntervalDiff, 1414, 1437, "CI : - 1 . 8 to - 0 . 5", "", +82394, PvalueDiff, 1440, 1456, "P & lt ; 0 . 001", "", +82395, Lat/TimFC, 1543, 1560, "fixed combination", "", +82396, Timolol, 1565, 1572, "timolol", "", +82397, DiffGroupAbsValue, 1579, 1584, "1 . 9", "", +82398, mmHg, 1585, 1589, "mmHg", "", +82399, ConfIntervalDiff, 1592, 1618, "95 % CI - 2 . 5 to - 1 . 2", "", +82400, PvalueDiff, 1621, 1637, "P & lt ; 0 . 001", "", +82401, Diurnal_IOP, 1666, 1669, "IOP", "", +82402, Duration, 1707, 1716, "12 months", "", +82403, Lat/TimFC, 1722, 1739, "fixed combination", "", +82404, ConclusionComment, 1886, 2111, "The fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol administered once daily in the morning for 6 months was more effective in reducing IOP than the individual components alone and was effective over 12 months .", "", +82405, Lat/TimFC, 1890, 1952, "fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol", "", +82406, DoseValue, 1911, 1918, "0 . 005", "", +82408, Latanoprost, 1921, 1932, "latanoprost", "", +82407, DoseValue, 1937, 1942, "0 . 5", "", +82409, Timolol, 1945, 1952, "timolol", "", +82410, Frequency, 1966, 1976, "once daily", "", +82411, Morning, 1984, 1991, "morning", "", +82412, Duration, 1996, 2004, "6 months", "", +82413, IOP, 2036, 2039, "IOP", "", +82414, Duration, 2100, 2109, "12 months", "", diff --git a/data/gl 12486510_jshahinitiran.n-triples b/data/gl 12486510_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12486510_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12486510_tstrakeljahn.annodb b/data/gl 12486510_tstrakeljahn.annodb new file mode 100644 index 0000000..dd70be4 --- /dev/null +++ b/data/gl 12486510_tstrakeljahn.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82089, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +82090, PublicationYear, 35, 39, "2002", "", +82094, Title, 87, 184, "A comparison of the fixed combination of latanoprost and timolol with its individual components .", "", +82091, Latanoprost, 128, 139, "latanoprost", "", +82093, Lat/TimFC, 128, 151, "latanoprost and timolol", "", +82092, Timolol, 144, 151, "timolol", "", +82095, Author, 185, 195, "Pfeiffer N", "", +82096, Germany, 347, 354, "Germany", "", +82106, ObjectiveDescription, 412, 589, "To evaluate the intraocular pressure ( IOP ) - reducing effect of the fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol compared with the individual monotherapies .", "", +82097, IOP, 428, 448, "intraocular pressure", "", +82098, IOP, 451, 454, "IOP", "", +82099, DoseValue, 503, 510, "0 . 005", "", +82105, Lat/TimFC, 503, 544, "0 . 005 % latanoprost and 0 . 5 % timolol", "", +82101, Percentage, 511, 512, "%", "", +82103, Latanoprost, 513, 524, "latanoprost", "", +82100, DoseValue, 529, 534, "0 . 5", "", +82102, Percentage, 535, 536, "%", "", +82104, Timolol, 537, 544, "timolol", "", +82107, Duration, 600, 611, "A 6 - month", "", +82108, Randomized, 614, 624, "randomised", "", +82109, DoubleBlind, 627, 642, "double - masked", "", +82110, Multicenter, 656, 667, "multicentre", "", +82111, OpenLabel, 698, 710, "open - label", "", +82112, Glaucoma, 754, 762, "glaucoma", "", +82113, OcularHypertension, 766, 785, "ocular hypertension", "", +82114, IOP, 807, 810, "IOP", "", +82118, Precondition, 807, 887, "IOP & gt ; / = 25 mmHg on glaucoma medication or & gt ; / = 30 mmHg if untreated", "", +82115, mmHg, 825, 829, "mmHg", "", +82116, Glaucoma, 833, 841, "glaucoma", "", +82117, mmHg, 870, 874, "mmHg", "", +82119, Timolol, 937, 944, "timolol", "", +82132, Frequency, 945, 956, "twice daily", "", +82122, NumberPatientsCT, 959, 962, "436", "", +82123, Randomized, 977, 987, "randomised", "", +82124, NumberPatientsArm, 990, 993, "140", "", +82125, Frequency, 1023, 1033, "once daily", "", +82126, Morning, 1034, 1048, "in the morning", "", +82128, NumberPatientsArm, 1051, 1054, "147", "", +82120, Latanoprost, 1058, 1069, "latanoprost", "", +82127, Frequency, 1070, 1080, "once daily", "", +82129, Morning, 1081, 1095, "in the morning", "", +82130, NumberPatientsArm, 1100, 1103, "149", "", +82121, Timolol, 1107, 1114, "timolol", "", +82131, Frequency, 1115, 1126, "twice daily", "", +82133, OpenLabel, 1140, 1152, "open - label", "", +82136, Lat/TimFC, 1183, 1205, "fixed combination drug", "", +82134, Frequency, 1206, 1216, "once daily", "", +82135, Morning, 1217, 1231, "in the morning", "", +82137, Mean, 1262, 1266, "mean", "", +82138, Diurnal_IOP, 1291, 1302, "diurnal IOP", "", +82139, TimePoint, 1308, 1314, "week 2", "", +82140, TimePoint, 1318, 1325, "week 26", "", +82147, DiffGroupAbsValue, 1332, 1337, "1 . 2", "", +82142, mmHg, 1338, 1342, "mmHg", "", +82143, Latanoprost, 1373, 1384, "latanoprost", "", +82144, ConfIntervalDiff, 1419, 1437, "- 1 . 8 to - 0 . 5", "", +82145, Timolol, 1565, 1572, "timolol", "", +82146, DiffGroupAbsValue, 1579, 1584, "1 . 9", "", +82148, ConfIntervalDiff, 1600, 1618, "- 2 . 5 to - 1 . 2", "", +82151, ObservedResult, 1642, 1741, "No long - term drift in IOP was detected in patients treated for 12 months with fixed combination .", "", +82149, IOP, 1666, 1669, "IOP", "", +82150, Duration, 1707, 1716, "12 months", "", +82152, ObservedResult, 1742, 1872, "All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events .", "", +82164, ConclusionComment, 1886, 2111, "The fixed combination of 0 . 005 % latanoprost and 0 . 5 % timolol administered once daily in the morning for 6 months was more effective in reducing IOP than the individual components alone and was effective over 12 months .", "", +82153, DoseValue, 1911, 1918, "0 . 005", "", +82157, Percentage, 1919, 1920, "%", "", +82155, Latanoprost, 1921, 1932, "latanoprost", "", +82154, DoseValue, 1937, 1942, "0 . 5", "", +82158, Percentage, 1943, 1944, "%", "", +82156, Timolol, 1945, 1952, "timolol", "", +82159, Frequency, 1966, 1976, "once daily", "", +82160, Morning, 1977, 1991, "in the morning", "", +82161, Duration, 1996, 2004, "6 months", "", +82162, IOP, 2036, 2039, "IOP", "", +82163, Duration, 2100, 2109, "12 months", "", diff --git a/data/gl 12486510_tstrakeljahn.n-triples b/data/gl 12486510_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12486510_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12586182_admin.annodb b/data/gl 12586182_admin.annodb new file mode 100644 index 0000000..cb6fd68 --- /dev/null +++ b/data/gl 12586182_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Jpn J Ophthalmol", "", " \"Jpn J Ophthalmol\"." +1, PublicationYear, 19, 23, "2003", "", " \"2003\"." +2, Title, 56, 195, "Comparison of the intraocular pressure lowering effect of latanoprost and carteolol - pilocarpine combination in newly diagnosed glaucoma .", "", " \"Comparison of the intraocular pressure lowering effect of latanoprost and carteolol - pilocarpine combination in newly diagnosed glaucoma .\"." +3, IOP, 74, 94, "intraocular pressure", "", +60, Latanoprost, 114, 125, "latanoprost", "", +61, Carteolol, 130, 139, "carteolol", "", +62, Pilocarpine, 142, 153, "pilocarpine", "", +33783, Precondition, 169, 193, "newly diagnosed glaucoma", "", " \"newly diagnosed glaucoma\"." +63, Glaucoma, 185, 193, "glaucoma", "", " . ." +4, Author, 196, 205, "Ozdemir M", "", " \"Ozdemir M\"." +5, Author, 214, 223, "Ozdemir G", "", " \"Ozdemir G\"." +6, Turkey, 323, 329, "Turkey", "", " ." +108, ObjectiveDescription, 342, 499, "To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma .", "", " \"To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma .\"." +65, Latanoprost, 382, 393, "latanoprost", "", +66, Carteolol, 422, 431, "carteolol", "", +67, Pilocarpine, 436, 447, "pilocarpine", "", +33793, Precondition, 473, 497, "newly diagnosed glaucoma", "", +69, Glaucoma, 489, 497, "glaucoma", "", +8, Blind, 510, 516, "Masked", "", " ." +70, Randomized, 517, 527, "randomized", "", " ." +10, NumberPatientsCT, 568, 570, "51", "", " \"51\"." +33794, Precondition, 597, 644, "newly diagnosed glaucoma or ocular hypertension", "", " \"newly diagnosed glaucoma or ocular hypertension\"." +72, Glaucoma, 613, 621, "glaucoma", "", +11, OcularHypertension, 625, 644, "ocular hypertension", "", " ." +74, Latanoprost, 727, 738, "latanoprost", "", " . ." +12, DoseValue, 739, 746, "0 . 005", "", " \"0 . 005\"." +13, Percentage, 747, 748, "%", "", " ." +14, Frequency, 749, 759, "once daily", "", " \"once daily\"." +75, Carteolol, 768, 777, "carteolol", "", " ." +15, DoseValue, 778, 779, "2", "", " \"2\"." +16, Percentage, 780, 781, "%", "", " ." +17, Frequency, 782, 793, "twice daily", "", " \"twice daily\"." +76, Pilocarpine, 798, 809, "pilocarpine", "", " ." +18, DoseValue, 810, 811, "2", "", +19, Percentage, 812, 813, "%", "", +20, Frequency, 814, 825, "twice daily", "", " \"twice daily\"." +21, Mean, 828, 832, "Mean", "", " . ." +22, Diurnal_IOP, 833, 861, "diurnal intraocular pressure", "", " ." +23, IOP, 864, 867, "IOP", "", +33795, TimePoint, 886, 894, "baseline", "", +33796, TimePoint, 897, 903, "week 2", "", +33797, TimePoint, 906, 912, "week 4", "", +33798, TimePoint, 919, 926, "month 3", "", +24, Mean, 973, 977, "mean", "", +25, IOP, 978, 981, "IOP", "", +77, Duration, 1003, 1012, "3 - month", "", " \"3 - month\"." +26, Mean, 1074, 1078, "Mean", "", +27, Diurnal_IOP, 1079, 1090, "diurnal IOP", "", +28, BaseLineValue, 1103, 1109, "25 . 1", "", " \"25 . 1\"." +33799, SdDevBL, 1116, 1121, "3 . 1", "", " \"3 . 1\"." +32, mmHg, 1122, 1127, "mm Hg", "", " ." +29, BaseLineValue, 1132, 1138, "25 . 5", "", " \"25 . 5\"." +33800, SdDevBL, 1145, 1150, "2 . 5", "", " \"2 . 5\"." +33, mmHg, 1151, 1156, "mm Hg", "", +33801, TimePoint, 1160, 1168, "baseline", "", +78, Latanoprost, 1176, 1187, "latanoprost", "", +79, Carteolol, 1217, 1226, "carteolol", "", +80, Pilocarpine, 1236, 1247, "pilocarpine", "", +34, Diurnal_IOP, 1271, 1282, "Diurnal IOP", "", +144, TimePoint, 1328, 1336, "3 months", "", " \"3 months\"." +35, PValueChangeValue, 1354, 1363, "P < . 001", "", " \"P < . 001\". \"P < . 001\"." +82, Latanoprost, 1389, 1400, "latanoprost", "", +36, Mean, 1425, 1429, "mean", "", +37, Diurnal_IOP, 1430, 1441, "diurnal IOP", "", +38, Reduction, 1445, 1450, "7 . 2", "", " \"7 . 2\"." +33803, SdDevChangeValue, 1457, 1462, "2 . 5", "", " \"2 . 5\"." +40, mmHg, 1463, 1468, "mm Hg", "", +41, RelativeReduction, 1471, 1477, "28 . 7", "", " \"28 . 7\"." +83, Carteolol, 1486, 1495, "carteolol", "", +84, Pilocarpine, 1501, 1512, "pilocarpine", "", +42, Mean, 1525, 1529, "mean", "", +43, Diurnal_IOP, 1530, 1541, "diurnal IOP", "", +44, Reduction, 1545, 1550, "7 . 4", "", " \"7 . 4\"." +33804, SdDevChangeValue, 1557, 1562, "2 . 7", "", " \"2 . 7\"." +46, mmHg, 1563, 1568, "mm Hg", "", +47, RelativeReduction, 1571, 1573, "29", "", " \"29\"." +159, ObservedResult, 1580, 1676, "There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) .", "", " \"There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) .\". \"There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) .\"." +49, IOP, 1641, 1644, "IOP", "", +48, PvalueDiff, 1664, 1672, "P = . 51", "", " \"P = . 51\"." +33805, EndPointDescription, 1677, 1700, "Decreased visual acuity", "AdverseEffect", +33806, EndPointDescription, 1705, 1720, "twilight vision", "AdverseEffect", +92863, BlurredVison, 1723, 1737, "blurred vision", "", +163, Headache, 1744, 1752, "headache", "", +93008, ObservedResult, 1753, 1845, "were more frequent in the carteolol - plus - pilocarpine group than in the latanoprost group", "", +85, Carteolol, 1779, 1788, "carteolol", "", +86, Pilocarpine, 1798, 1809, "pilocarpine", "", +87, Latanoprost, 1828, 1839, "latanoprost", "", +167, PvalueDiff, 1848, 1856, "P < . 05", "", +55, ConclusionComment, 1875, 2075, "We concluded that latanoprost monotherapy was at least as effective as the carteolol - pilocarpine combination therapy in reducing mean diurnal IOP in newly diagnosed glaucoma or ocular hypertension .", "", " \"We concluded that latanoprost monotherapy was at least as effective as the carteolol - pilocarpine combination therapy in reducing mean diurnal IOP in newly diagnosed glaucoma or ocular hypertension .\"." +88, Latanoprost, 1893, 1904, "latanoprost", "", +89, Carteolol, 1950, 1959, "carteolol", "", +90, Pilocarpine, 1962, 1973, "pilocarpine", "", +56, Mean, 2006, 2010, "mean", "", +57, Diurnal_IOP, 2011, 2022, "diurnal IOP", "", +33809, Precondition, 2026, 2073, "newly diagnosed glaucoma or ocular hypertension", "", +91, Glaucoma, 2042, 2050, "glaucoma", "", +58, OcularHypertension, 2054, 2073, "ocular hypertension", "", +59, PMID, 2083, 2091, "12586182", "", " \"12586182\"." diff --git a/data/gl 12586182_admin.n-triples b/data/gl 12586182_admin.n-triples new file mode 100644 index 0000000..a4877d5 --- /dev/null +++ b/data/gl 12586182_admin.n-triples @@ -0,0 +1,121 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the intraocular pressure lowering effect of latanoprost and carteolol - pilocarpine combination in newly diagnosed glaucoma ." . + "Ozdemir M" . + "2003" . + "Jpn J Ophthalmol" . + "12586182" . + . + "Ozdemir G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma ." . + "51" . + "3 - month" . + . + . + . + "We concluded that latanoprost monotherapy was at least as effective as the carteolol - pilocarpine combination therapy in reducing mean diurnal IOP in newly diagnosed glaucoma or ocular hypertension ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "newly diagnosed glaucoma" . + . + . + . + "newly diagnosed glaucoma or ocular hypertension" . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + . + . + . + . + "Arm-pil-car" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-car" . + . + "twice daily" . + . + . + "Intervention-pil" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-car" . + . + "2" . + . + . + . + "Medication-pil" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-lat" . + . + "25 . 1" . + "3 . 1" . + "7 . 2" . + "28 . 7" . + "P < . 001" . + "2 . 5" . + "There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) ." . + "3 months" . + . + "Outcome-iop-pil-car" . + . + "25 . 5" . + "2 . 5" . + "7 . 4" . + "29" . + "P < . 001" . + "2 . 7" . + "There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop" . + "P = . 51" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12586182_export.csv b/data/gl 12586182_export.csv new file mode 100644 index 0000000..19b2ee9 --- /dev/null +++ b/data/gl 12586182_export.csv @@ -0,0 +1,415 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +473, 1, 1, 1, 0, 3, 0, 3, "Jpn" +473, 1, 2, 2, 4, 5, 4, 5, "J" +473, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +473, 1, 4, 4, 17, 18, 17, 18, "." +473, 2, 1, 5, 0, 4, 19, 23, "2003" +473, 2, 2, 6, 5, 8, 24, 27, "Jan" +473, 2, 3, 7, 9, 10, 28, 29, "-" +473, 2, 4, 8, 11, 14, 30, 33, "Feb" +473, 2, 5, 9, 15, 16, 34, 35, ";" +473, 2, 6, 10, 17, 19, 36, 38, "47" +473, 2, 7, 11, 20, 21, 39, 40, "(" +473, 2, 8, 12, 22, 23, 41, 42, "1" +473, 2, 9, 13, 24, 25, 43, 44, ")" +473, 2, 10, 14, 26, 27, 45, 46, ":" +473, 2, 11, 15, 28, 30, 47, 49, "72" +473, 2, 12, 16, 31, 32, 50, 51, "-" +473, 2, 13, 17, 33, 34, 52, 53, "6" +473, 2, 14, 18, 35, 36, 54, 55, "." +473, 3, 1, 19, 0, 10, 56, 66, "Comparison" +473, 3, 2, 20, 11, 13, 67, 69, "of" +473, 3, 3, 21, 14, 17, 70, 73, "the" +473, 3, 4, 22, 18, 29, 74, 85, "intraocular" +473, 3, 5, 23, 30, 38, 86, 94, "pressure" +473, 3, 6, 24, 39, 47, 95, 103, "lowering" +473, 3, 7, 25, 48, 54, 104, 110, "effect" +473, 3, 8, 26, 55, 57, 111, 113, "of" +473, 3, 9, 27, 58, 69, 114, 125, "latanoprost" +473, 3, 10, 28, 70, 73, 126, 129, "and" +473, 3, 11, 29, 74, 83, 130, 139, "carteolol" +473, 3, 12, 30, 84, 85, 140, 141, "-" +473, 3, 13, 31, 86, 97, 142, 153, "pilocarpine" +473, 3, 14, 32, 98, 109, 154, 165, "combination" +473, 3, 15, 33, 110, 112, 166, 168, "in" +473, 3, 16, 34, 113, 118, 169, 174, "newly" +473, 3, 17, 35, 119, 128, 175, 184, "diagnosed" +473, 3, 18, 36, 129, 137, 185, 193, "glaucoma" +473, 3, 19, 37, 138, 139, 194, 195, "." +473, 4, 1, 38, 0, 7, 196, 203, "Ozdemir" +473, 4, 2, 39, 8, 9, 204, 205, "M" +473, 4, 3, 40, 10, 11, 206, 207, "(" +473, 4, 4, 41, 12, 13, 208, 209, "1" +473, 4, 5, 42, 14, 15, 210, 211, ")" +473, 4, 6, 43, 16, 17, 212, 213, "," +473, 4, 7, 44, 18, 25, 214, 221, "Ozdemir" +473, 4, 8, 45, 26, 27, 222, 223, "G" +473, 4, 9, 46, 28, 29, 224, 225, "." +473, 4, 10, 47, 30, 36, 226, 232, "Author" +473, 4, 11, 48, 37, 48, 233, 244, "information" +473, 4, 12, 49, 49, 50, 245, 246, ":" +473, 4, 13, 50, 51, 52, 247, 248, "(" +473, 4, 14, 51, 53, 54, 249, 250, "1" +473, 4, 15, 52, 55, 56, 251, 252, ")" +473, 4, 16, 53, 57, 67, 253, 263, "Department" +473, 4, 17, 54, 68, 70, 264, 266, "of" +473, 4, 18, 55, 71, 84, 267, 280, "Ophthalmology" +473, 4, 19, 56, 85, 86, 281, 282, "," +473, 4, 20, 57, 87, 94, 283, 290, "Medical" +473, 4, 21, 58, 95, 101, 291, 297, "School" +473, 4, 22, 59, 102, 104, 298, 300, "of" +473, 4, 23, 60, 105, 108, 301, 304, "KSU" +473, 4, 24, 61, 109, 110, 305, 306, "," +473, 4, 25, 62, 111, 124, 307, 320, "Kahramanmaras" +473, 4, 26, 63, 125, 126, 321, 322, "," +473, 4, 27, 64, 127, 133, 323, 329, "Turkey" +473, 4, 28, 65, 134, 135, 330, 331, "." +473, 5, 1, 66, 0, 7, 332, 339, "PURPOSE" +473, 5, 2, 67, 8, 9, 340, 341, ":" +473, 5, 3, 68, 10, 12, 342, 344, "To" +473, 5, 4, 69, 13, 21, 345, 353, "evaluate" +473, 5, 5, 70, 22, 25, 354, 357, "the" +473, 5, 6, 71, 26, 37, 358, 369, "comparative" +473, 5, 7, 72, 38, 46, 370, 378, "efficacy" +473, 5, 8, 73, 47, 49, 379, 381, "of" +473, 5, 9, 74, 50, 61, 382, 393, "latanoprost" +473, 5, 10, 75, 62, 73, 394, 405, "monotherapy" +473, 5, 11, 76, 74, 80, 406, 412, "versus" +473, 5, 12, 77, 81, 89, 413, 421, "combined" +473, 5, 13, 78, 90, 99, 422, 431, "carteolol" +473, 5, 14, 79, 100, 103, 432, 435, "and" +473, 5, 15, 80, 104, 115, 436, 447, "pilocarpine" +473, 5, 16, 81, 116, 123, 448, 455, "therapy" +473, 5, 17, 82, 124, 126, 456, 458, "in" +473, 5, 18, 83, 127, 135, 459, 467, "patients" +473, 5, 19, 84, 136, 140, 468, 472, "with" +473, 5, 20, 85, 141, 146, 473, 478, "newly" +473, 5, 21, 86, 147, 156, 479, 488, "diagnosed" +473, 5, 22, 87, 157, 165, 489, 497, "glaucoma" +473, 5, 23, 88, 166, 167, 498, 499, "." +473, 6, 1, 89, 0, 7, 500, 507, "METHODS" +473, 6, 2, 90, 8, 9, 508, 509, ":" +473, 6, 3, 91, 10, 16, 510, 516, "Masked" +473, 6, 4, 92, 17, 27, 517, 527, "randomized" +473, 6, 5, 93, 28, 39, 528, 539, "prospective" +473, 6, 6, 94, 40, 45, 540, 545, "trial" +473, 6, 7, 95, 46, 47, 546, 547, "." +473, 7, 1, 96, 0, 4, 548, 552, "This" +473, 7, 2, 97, 5, 10, 553, 558, "study" +473, 7, 3, 98, 11, 19, 559, 567, "included" +473, 7, 4, 99, 20, 22, 568, 570, "51" +473, 7, 5, 100, 23, 31, 571, 579, "patients" +473, 7, 6, 101, 32, 33, 580, 581, "(" +473, 7, 7, 102, 34, 36, 582, 584, "64" +473, 7, 8, 103, 37, 41, 585, 589, "eyes" +473, 7, 9, 104, 42, 43, 590, 591, ")" +473, 7, 10, 105, 44, 48, 592, 596, "with" +473, 7, 11, 106, 49, 54, 597, 602, "newly" +473, 7, 12, 107, 55, 64, 603, 612, "diagnosed" +473, 7, 13, 108, 65, 73, 613, 621, "glaucoma" +473, 7, 14, 109, 74, 76, 622, 624, "or" +473, 7, 15, 110, 77, 83, 625, 631, "ocular" +473, 7, 16, 111, 84, 96, 632, 644, "hypertension" +473, 7, 17, 112, 97, 98, 645, 646, "." +473, 8, 1, 113, 0, 3, 647, 650, "The" +473, 8, 2, 114, 4, 9, 651, 656, "cases" +473, 8, 3, 115, 10, 14, 657, 661, "were" +473, 8, 4, 116, 15, 23, 662, 670, "randomly" +473, 8, 5, 117, 24, 31, 671, 678, "divided" +473, 8, 6, 118, 32, 36, 679, 683, "into" +473, 8, 7, 119, 37, 40, 684, 687, "two" +473, 8, 8, 120, 41, 50, 688, 697, "treatment" +473, 8, 9, 121, 51, 57, 698, 704, "groups" +473, 8, 10, 122, 58, 61, 705, 708, "for" +473, 8, 11, 123, 62, 76, 709, 723, "administration" +473, 8, 12, 124, 77, 79, 724, 726, "of" +473, 8, 13, 125, 80, 91, 727, 738, "latanoprost" +473, 8, 14, 126, 92, 93, 739, 740, "0" +473, 8, 15, 127, 94, 95, 741, 742, "." +473, 8, 16, 128, 96, 99, 743, 746, "005" +473, 8, 17, 129, 100, 101, 747, 748, "%" +473, 8, 18, 130, 102, 106, 749, 753, "once" +473, 8, 19, 131, 107, 112, 754, 759, "daily" +473, 8, 20, 132, 113, 114, 760, 761, "," +473, 8, 21, 133, 115, 117, 762, 764, "or" +473, 8, 22, 134, 118, 120, 765, 767, "of" +473, 8, 23, 135, 121, 130, 768, 777, "carteolol" +473, 8, 24, 136, 131, 132, 778, 779, "2" +473, 8, 25, 137, 133, 134, 780, 781, "%" +473, 8, 26, 138, 135, 140, 782, 787, "twice" +473, 8, 27, 139, 141, 146, 788, 793, "daily" +473, 8, 28, 140, 147, 150, 794, 797, "and" +473, 8, 29, 141, 151, 162, 798, 809, "pilocarpine" +473, 8, 30, 142, 163, 164, 810, 811, "2" +473, 8, 31, 143, 165, 166, 812, 813, "%" +473, 8, 32, 144, 167, 172, 814, 819, "twice" +473, 8, 33, 145, 173, 178, 820, 825, "daily" +473, 8, 34, 146, 179, 180, 826, 827, "." +473, 9, 1, 147, 0, 4, 828, 832, "Mean" +473, 9, 2, 148, 5, 12, 833, 840, "diurnal" +473, 9, 3, 149, 13, 24, 841, 852, "intraocular" +473, 9, 4, 150, 25, 33, 853, 861, "pressure" +473, 9, 5, 151, 34, 35, 862, 863, "(" +473, 9, 6, 152, 36, 39, 864, 867, "IOP" +473, 9, 7, 153, 40, 41, 868, 869, ")" +473, 9, 8, 154, 42, 45, 870, 873, "was" +473, 9, 9, 155, 46, 54, 874, 882, "measured" +473, 9, 10, 156, 55, 57, 883, 885, "at" +473, 9, 11, 157, 58, 66, 886, 894, "baseline" +473, 9, 12, 158, 67, 68, 895, 896, "," +473, 9, 13, 159, 69, 73, 897, 901, "week" +473, 9, 14, 160, 74, 75, 902, 903, "2" +473, 9, 15, 161, 76, 77, 904, 905, "," +473, 9, 16, 162, 78, 82, 906, 910, "week" +473, 9, 17, 163, 83, 84, 911, 912, "4" +473, 9, 18, 164, 85, 86, 913, 914, "," +473, 9, 19, 165, 87, 90, 915, 918, "and" +473, 9, 20, 166, 91, 96, 919, 924, "month" +473, 9, 21, 167, 97, 98, 925, 926, "3" +473, 9, 22, 168, 99, 104, 927, 932, "after" +473, 9, 23, 169, 105, 108, 933, 936, "the" +473, 9, 24, 170, 109, 118, 937, 946, "beginning" +473, 9, 25, 171, 119, 121, 947, 949, "of" +473, 9, 26, 172, 122, 131, 950, 959, "treatment" +473, 9, 27, 173, 132, 133, 960, 961, "." +473, 10, 1, 174, 0, 7, 962, 969, "Changes" +473, 10, 2, 175, 8, 10, 970, 972, "in" +473, 10, 3, 176, 11, 15, 973, 977, "mean" +473, 10, 4, 177, 16, 19, 978, 981, "IOP" +473, 10, 5, 178, 20, 24, 982, 986, "from" +473, 10, 6, 179, 25, 33, 987, 995, "baseline" +473, 10, 7, 180, 34, 36, 996, 998, "to" +473, 10, 8, 181, 37, 40, 999, 1002, "the" +473, 10, 9, 182, 41, 42, 1003, 1004, "3" +473, 10, 10, 183, 43, 44, 1005, 1006, "-" +473, 10, 11, 184, 45, 50, 1007, 1012, "month" +473, 10, 12, 185, 51, 56, 1013, 1018, "visit" +473, 10, 13, 186, 57, 61, 1019, 1023, "were" +473, 10, 14, 187, 62, 72, 1024, 1034, "determined" +473, 10, 15, 188, 73, 75, 1035, 1037, "by" +473, 10, 16, 189, 76, 78, 1038, 1040, "an" +473, 10, 17, 190, 79, 87, 1041, 1049, "analysis" +473, 10, 18, 191, 88, 90, 1050, 1052, "of" +473, 10, 19, 192, 91, 99, 1053, 1061, "variance" +473, 10, 20, 193, 100, 101, 1062, 1063, "." +473, 11, 1, 194, 0, 7, 1064, 1071, "RESULTS" +473, 11, 2, 195, 8, 9, 1072, 1073, ":" +473, 11, 3, 196, 10, 14, 1074, 1078, "Mean" +473, 11, 4, 197, 15, 22, 1079, 1086, "diurnal" +473, 11, 5, 198, 23, 26, 1087, 1090, "IOP" +473, 11, 6, 199, 27, 33, 1091, 1097, "values" +473, 11, 7, 200, 34, 38, 1098, 1102, "were" +473, 11, 8, 201, 39, 41, 1103, 1105, "25" +473, 11, 9, 202, 42, 43, 1106, 1107, "." +473, 11, 10, 203, 44, 45, 1108, 1109, "1" +473, 11, 11, 204, 46, 47, 1110, 1111, "+" +473, 11, 12, 205, 48, 49, 1112, 1113, "/" +473, 11, 13, 206, 50, 51, 1114, 1115, "-" +473, 11, 14, 207, 52, 53, 1116, 1117, "3" +473, 11, 15, 208, 54, 55, 1118, 1119, "." +473, 11, 16, 209, 56, 57, 1120, 1121, "1" +473, 11, 17, 210, 58, 60, 1122, 1124, "mm" +473, 11, 18, 211, 61, 63, 1125, 1127, "Hg" +473, 11, 19, 212, 64, 67, 1128, 1131, "and" +473, 11, 20, 213, 68, 70, 1132, 1134, "25" +473, 11, 21, 214, 71, 72, 1135, 1136, "." +473, 11, 22, 215, 73, 74, 1137, 1138, "5" +473, 11, 23, 216, 75, 76, 1139, 1140, "+" +473, 11, 24, 217, 77, 78, 1141, 1142, "/" +473, 11, 25, 218, 79, 80, 1143, 1144, "-" +473, 11, 26, 219, 81, 82, 1145, 1146, "2" +473, 11, 27, 220, 83, 84, 1147, 1148, "." +473, 11, 28, 221, 85, 86, 1149, 1150, "5" +473, 11, 29, 222, 87, 89, 1151, 1153, "mm" +473, 11, 30, 223, 90, 92, 1154, 1156, "Hg" +473, 11, 31, 224, 93, 95, 1157, 1159, "at" +473, 11, 32, 225, 96, 104, 1160, 1168, "baseline" +473, 11, 33, 226, 105, 107, 1169, 1171, "in" +473, 11, 34, 227, 108, 111, 1172, 1175, "the" +473, 11, 35, 228, 112, 123, 1176, 1187, "latanoprost" +473, 11, 36, 229, 124, 135, 1188, 1199, "monotherapy" +473, 11, 37, 230, 136, 141, 1200, 1205, "group" +473, 11, 38, 231, 142, 145, 1206, 1209, "and" +473, 11, 39, 232, 146, 148, 1210, 1212, "in" +473, 11, 40, 233, 149, 152, 1213, 1216, "the" +473, 11, 41, 234, 153, 162, 1217, 1226, "carteolol" +473, 11, 42, 235, 163, 164, 1227, 1228, "-" +473, 11, 43, 236, 165, 169, 1229, 1233, "plus" +473, 11, 44, 237, 170, 171, 1234, 1235, "-" +473, 11, 45, 238, 172, 183, 1236, 1247, "pilocarpine" +473, 11, 46, 239, 184, 189, 1248, 1253, "group" +473, 11, 47, 240, 190, 191, 1254, 1255, "," +473, 11, 48, 241, 192, 204, 1256, 1268, "respectively" +473, 11, 49, 242, 205, 206, 1269, 1270, "." +473, 12, 1, 243, 0, 7, 1271, 1278, "Diurnal" +473, 12, 2, 244, 8, 11, 1279, 1282, "IOP" +473, 12, 3, 245, 12, 15, 1283, 1286, "was" +473, 12, 4, 246, 16, 29, 1287, 1300, "significantly" +473, 12, 5, 247, 30, 39, 1301, 1310, "decreased" +473, 12, 6, 248, 40, 44, 1311, 1315, "from" +473, 12, 7, 249, 45, 53, 1316, 1324, "baseline" +473, 12, 8, 250, 54, 56, 1325, 1327, "to" +473, 12, 9, 251, 57, 58, 1328, 1329, "3" +473, 12, 10, 252, 59, 65, 1330, 1336, "months" +473, 12, 11, 253, 66, 68, 1337, 1339, "in" +473, 12, 12, 254, 69, 73, 1340, 1344, "both" +473, 12, 13, 255, 74, 80, 1345, 1351, "groups" +473, 12, 14, 256, 81, 82, 1352, 1353, "(" +473, 12, 15, 257, 83, 84, 1354, 1355, "P" +473, 12, 16, 258, 85, 86, 1356, 1357, "<" +473, 12, 17, 259, 87, 88, 1358, 1359, "." +473, 12, 18, 260, 89, 92, 1360, 1363, "001" +473, 12, 19, 261, 93, 94, 1364, 1365, ")" +473, 12, 20, 262, 95, 96, 1366, 1367, "." +473, 13, 1, 263, 0, 2, 1368, 1370, "At" +473, 13, 2, 264, 3, 7, 1371, 1375, "this" +473, 13, 3, 265, 8, 12, 1376, 1380, "time" +473, 13, 4, 266, 13, 18, 1381, 1386, "point" +473, 13, 5, 267, 19, 20, 1387, 1388, "," +473, 13, 6, 268, 21, 32, 1389, 1400, "latanoprost" +473, 13, 7, 269, 33, 44, 1401, 1412, "monotherapy" +473, 13, 8, 270, 45, 48, 1413, 1416, "had" +473, 13, 9, 271, 49, 56, 1417, 1424, "reduced" +473, 13, 10, 272, 57, 61, 1425, 1429, "mean" +473, 13, 11, 273, 62, 69, 1430, 1437, "diurnal" +473, 13, 12, 274, 70, 73, 1438, 1441, "IOP" +473, 13, 13, 275, 74, 76, 1442, 1444, "by" +473, 13, 14, 276, 77, 78, 1445, 1446, "7" +473, 13, 15, 277, 79, 80, 1447, 1448, "." +473, 13, 16, 278, 81, 82, 1449, 1450, "2" +473, 13, 17, 279, 83, 84, 1451, 1452, "+" +473, 13, 18, 280, 85, 86, 1453, 1454, "/" +473, 13, 19, 281, 87, 88, 1455, 1456, "-" +473, 13, 20, 282, 89, 90, 1457, 1458, "2" +473, 13, 21, 283, 91, 92, 1459, 1460, "." +473, 13, 22, 284, 93, 94, 1461, 1462, "5" +473, 13, 23, 285, 95, 97, 1463, 1465, "mm" +473, 13, 24, 286, 98, 100, 1466, 1468, "Hg" +473, 13, 25, 287, 101, 102, 1469, 1470, "(" +473, 13, 26, 288, 103, 105, 1471, 1473, "28" +473, 13, 27, 289, 106, 107, 1474, 1475, "." +473, 13, 28, 290, 108, 109, 1476, 1477, "7" +473, 13, 29, 291, 110, 111, 1478, 1479, "%" +473, 13, 30, 292, 112, 113, 1480, 1481, ")" +473, 13, 31, 293, 114, 117, 1482, 1485, "and" +473, 13, 32, 294, 118, 127, 1486, 1495, "carteolol" +473, 13, 33, 295, 128, 132, 1496, 1500, "plus" +473, 13, 34, 296, 133, 144, 1501, 1512, "pilocarpine" +473, 13, 35, 297, 145, 148, 1513, 1516, "had" +473, 13, 36, 298, 149, 156, 1517, 1524, "reduced" +473, 13, 37, 299, 157, 161, 1525, 1529, "mean" +473, 13, 38, 300, 162, 169, 1530, 1537, "diurnal" +473, 13, 39, 301, 170, 173, 1538, 1541, "IOP" +473, 13, 40, 302, 174, 176, 1542, 1544, "by" +473, 13, 41, 303, 177, 178, 1545, 1546, "7" +473, 13, 42, 304, 179, 180, 1547, 1548, "." +473, 13, 43, 305, 181, 182, 1549, 1550, "4" +473, 13, 44, 306, 183, 184, 1551, 1552, "+" +473, 13, 45, 307, 185, 186, 1553, 1554, "/" +473, 13, 46, 308, 187, 188, 1555, 1556, "-" +473, 13, 47, 309, 189, 190, 1557, 1558, "2" +473, 13, 48, 310, 191, 192, 1559, 1560, "." +473, 13, 49, 311, 193, 194, 1561, 1562, "7" +473, 13, 50, 312, 195, 197, 1563, 1565, "mm" +473, 13, 51, 313, 198, 200, 1566, 1568, "Hg" +473, 13, 52, 314, 201, 202, 1569, 1570, "(" +473, 13, 53, 315, 203, 205, 1571, 1573, "29" +473, 13, 54, 316, 206, 207, 1574, 1575, "%" +473, 13, 55, 317, 208, 209, 1576, 1577, ")" +473, 13, 56, 318, 210, 211, 1578, 1579, "." +473, 14, 1, 319, 0, 5, 1580, 1585, "There" +473, 14, 2, 320, 6, 9, 1586, 1589, "was" +473, 14, 3, 321, 10, 12, 1590, 1592, "no" +473, 14, 4, 322, 13, 23, 1593, 1603, "difference" +473, 14, 5, 323, 24, 31, 1604, 1611, "between" +473, 14, 6, 324, 32, 35, 1612, 1615, "the" +473, 14, 7, 325, 36, 42, 1616, 1622, "groups" +473, 14, 8, 326, 43, 45, 1623, 1625, "in" +473, 14, 9, 327, 46, 51, 1626, 1631, "terms" +473, 14, 10, 328, 52, 54, 1632, 1634, "of" +473, 14, 11, 329, 55, 60, 1635, 1640, "their" +473, 14, 12, 330, 61, 64, 1641, 1644, "IOP" +473, 14, 13, 331, 65, 74, 1645, 1654, "reduction" +473, 14, 14, 332, 75, 81, 1655, 1661, "effect" +473, 14, 15, 333, 82, 83, 1662, 1663, "(" +473, 14, 16, 334, 84, 85, 1664, 1665, "P" +473, 14, 17, 335, 86, 87, 1666, 1667, "=" +473, 14, 18, 336, 88, 89, 1668, 1669, "." +473, 14, 19, 337, 90, 92, 1670, 1672, "51" +473, 14, 20, 338, 93, 94, 1673, 1674, ")" +473, 14, 21, 339, 95, 96, 1675, 1676, "." +473, 15, 1, 340, 0, 9, 1677, 1686, "Decreased" +473, 15, 2, 341, 10, 16, 1687, 1693, "visual" +473, 15, 3, 342, 17, 23, 1694, 1700, "acuity" +473, 15, 4, 343, 24, 27, 1701, 1704, "and" +473, 15, 5, 344, 28, 36, 1705, 1713, "twilight" +473, 15, 6, 345, 37, 43, 1714, 1720, "vision" +473, 15, 7, 346, 44, 45, 1721, 1722, "," +473, 15, 8, 347, 46, 53, 1723, 1730, "blurred" +473, 15, 9, 348, 54, 60, 1731, 1737, "vision" +473, 15, 10, 349, 61, 62, 1738, 1739, "," +473, 15, 11, 350, 63, 66, 1740, 1743, "and" +473, 15, 12, 351, 67, 75, 1744, 1752, "headache" +473, 15, 13, 352, 76, 80, 1753, 1757, "were" +473, 15, 14, 353, 81, 85, 1758, 1762, "more" +473, 15, 15, 354, 86, 94, 1763, 1771, "frequent" +473, 15, 16, 355, 95, 97, 1772, 1774, "in" +473, 15, 17, 356, 98, 101, 1775, 1778, "the" +473, 15, 18, 357, 102, 111, 1779, 1788, "carteolol" +473, 15, 19, 358, 112, 113, 1789, 1790, "-" +473, 15, 20, 359, 114, 118, 1791, 1795, "plus" +473, 15, 21, 360, 119, 120, 1796, 1797, "-" +473, 15, 22, 361, 121, 132, 1798, 1809, "pilocarpine" +473, 15, 23, 362, 133, 138, 1810, 1815, "group" +473, 15, 24, 363, 139, 143, 1816, 1820, "than" +473, 15, 25, 364, 144, 146, 1821, 1823, "in" +473, 15, 26, 365, 147, 150, 1824, 1827, "the" +473, 15, 27, 366, 151, 162, 1828, 1839, "latanoprost" +473, 15, 28, 367, 163, 168, 1840, 1845, "group" +473, 15, 29, 368, 169, 170, 1846, 1847, "(" +473, 15, 30, 369, 171, 172, 1848, 1849, "P" +473, 15, 31, 370, 173, 174, 1850, 1851, "<" +473, 15, 32, 371, 175, 176, 1852, 1853, "." +473, 15, 33, 372, 177, 179, 1854, 1856, "05" +473, 15, 34, 373, 180, 181, 1857, 1858, ")" +473, 15, 35, 374, 182, 183, 1859, 1860, "." +473, 16, 1, 375, 0, 11, 1861, 1872, "CONCLUSIONS" +473, 16, 2, 376, 12, 13, 1873, 1874, ":" +473, 16, 3, 377, 14, 16, 1875, 1877, "We" +473, 16, 4, 378, 17, 26, 1878, 1887, "concluded" +473, 16, 5, 379, 27, 31, 1888, 1892, "that" +473, 16, 6, 380, 32, 43, 1893, 1904, "latanoprost" +473, 16, 7, 381, 44, 55, 1905, 1916, "monotherapy" +473, 16, 8, 382, 56, 59, 1917, 1920, "was" +473, 16, 9, 383, 60, 62, 1921, 1923, "at" +473, 16, 10, 384, 63, 68, 1924, 1929, "least" +473, 16, 11, 385, 69, 71, 1930, 1932, "as" +473, 16, 12, 386, 72, 81, 1933, 1942, "effective" +473, 16, 13, 387, 82, 84, 1943, 1945, "as" +473, 16, 14, 388, 85, 88, 1946, 1949, "the" +473, 16, 15, 389, 89, 98, 1950, 1959, "carteolol" +473, 16, 16, 390, 99, 100, 1960, 1961, "-" +473, 16, 17, 391, 101, 112, 1962, 1973, "pilocarpine" +473, 16, 18, 392, 113, 124, 1974, 1985, "combination" +473, 16, 19, 393, 125, 132, 1986, 1993, "therapy" +473, 16, 20, 394, 133, 135, 1994, 1996, "in" +473, 16, 21, 395, 136, 144, 1997, 2005, "reducing" +473, 16, 22, 396, 145, 149, 2006, 2010, "mean" +473, 16, 23, 397, 150, 157, 2011, 2018, "diurnal" +473, 16, 24, 398, 158, 161, 2019, 2022, "IOP" +473, 16, 25, 399, 162, 164, 2023, 2025, "in" +473, 16, 26, 400, 165, 170, 2026, 2031, "newly" +473, 16, 27, 401, 171, 180, 2032, 2041, "diagnosed" +473, 16, 28, 402, 181, 189, 2042, 2050, "glaucoma" +473, 16, 29, 403, 190, 192, 2051, 2053, "or" +473, 16, 30, 404, 193, 199, 2054, 2060, "ocular" +473, 16, 31, 405, 200, 212, 2061, 2073, "hypertension" +473, 16, 32, 406, 213, 214, 2074, 2075, "." +473, 17, 1, 407, 0, 4, 2076, 2080, "PMID" +473, 17, 2, 408, 5, 6, 2081, 2082, ":" +473, 17, 3, 409, 7, 15, 2083, 2091, "12586182" +473, 17, 4, 410, 16, 17, 2092, 2093, "[" +473, 17, 5, 411, 18, 25, 2094, 2101, "Indexed" +473, 17, 6, 412, 26, 29, 2102, 2105, "for" +473, 17, 7, 413, 30, 37, 2106, 2113, "MEDLINE" +473, 17, 8, 414, 38, 39, 2114, 2115, "]" diff --git a/data/gl 12586182_jshahinitiran.annodb b/data/gl 12586182_jshahinitiran.annodb new file mode 100644 index 0000000..4a4fdda --- /dev/null +++ b/data/gl 12586182_jshahinitiran.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7099, Journal, 0, 16, "Jpn J Ophthalmol", "", +7100, PublicationYear, 19, 23, "2003", "", +7101, Title, 56, 195, "Comparison of the intraocular pressure lowering effect of latanoprost and carteolol - pilocarpine combination in newly diagnosed glaucoma .", "", +7102, IOP, 74, 94, "intraocular pressure", "", +26324, Latanoprost, 114, 125, "latanoprost", "", +26325, Carteolol, 130, 139, "carteolol", "", +26326, Pilocarpine, 142, 153, "pilocarpine", "", +26328, Precondition, 169, 184, "newly diagnosed", "", +26327, Glaucoma, 185, 193, "glaucoma", "", +7108, Author, 196, 205, "Ozdemir M", "", +7109, Author, 214, 223, "Ozdemir G", "", +7110, Turkey, 323, 329, "Turkey", "", +7111, ObjectiveDescription, 342, 499, "To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma .", "", +26329, Latanoprost, 382, 393, "latanoprost", "", +26330, Carteolol, 422, 431, "carteolol", "", +26331, Pilocarpine, 436, 447, "pilocarpine", "", +26332, Precondition, 473, 488, "newly diagnosed", "", +26333, Glaucoma, 489, 497, "glaucoma", "", +7117, Blind, 510, 516, "Masked", "", +26334, Randomized, 517, 527, "randomized", "", +39049, Prospective, 528, 539, "prospective", "", +7120, NumberPatientsCT, 568, 570, "51", "prospective", +26335, Precondition, 597, 612, "newly diagnosed", "", +26336, Glaucoma, 613, 621, "glaucoma", "", +7123, OcularHypertension, 625, 644, "ocular hypertension", "", +26337, Randomized, 662, 670, "randomly", "", +26338, Latanoprost, 727, 738, "latanoprost", "", +7126, DoseValue, 739, 746, "0 . 005", "", +7127, Percentage, 747, 748, "%", "", +7128, Frequency, 749, 759, "once daily", "", +26339, Carteolol, 768, 777, "carteolol", "", +7130, DoseValue, 778, 779, "2", "", +7131, Percentage, 780, 781, "%", "", +7132, Frequency, 782, 793, "twice daily", "", +26340, Pilocarpine, 798, 809, "pilocarpine", "", +7134, DoseValue, 810, 811, "2", "", +7135, Percentage, 812, 813, "%", "", +7136, Frequency, 814, 825, "twice daily", "", +7137, Mean, 828, 832, "Mean", "", +7138, Diurnal_IOP, 833, 861, "diurnal intraocular pressure", "", +7139, IOP, 864, 867, "IOP", "", +39050, TimePoint, 886, 894, "baseline", "", +39051, TimePoint, 897, 903, "week 2", "", +39052, TimePoint, 906, 912, "week 4", "", +39053, TimePoint, 919, 926, "month 3", "", +7141, Mean, 973, 977, "mean", "", +7142, IOP, 978, 981, "IOP", "", +26341, Duration, 1003, 1012, "3 - month", "", +7144, Mean, 1074, 1078, "Mean", "", +7145, Diurnal_IOP, 1079, 1090, "diurnal IOP", "", +7146, BaseLineValue, 1103, 1109, "25 . 1", "", +7148, SdErrorBL, 1116, 1121, "3 . 1", "", +7150, mmHg, 1122, 1127, "mm Hg", "bl", +7147, BaseLineValue, 1132, 1138, "25 . 5", "", +7149, SdErrorBL, 1145, 1150, "2 . 5", "", +7151, mmHg, 1151, 1156, "mm Hg", "bl", +39054, TimePoint, 1160, 1168, "baseline", "", +26342, Latanoprost, 1176, 1187, "latanoprost", "", +26343, Carteolol, 1217, 1226, "carteolol", "", +26344, Pilocarpine, 1236, 1247, "pilocarpine", "", +7155, Diurnal_IOP, 1271, 1282, "Diurnal IOP", "", +39055, TimePoint, 1316, 1324, "baseline", "", +39056, TimePoint, 1328, 1336, "3 months", "", +7156, PValueChangeValue, 1354, 1363, "P < . 001", "", +26346, Latanoprost, 1389, 1400, "latanoprost", "", +7158, Mean, 1425, 1429, "mean", "", +7159, Diurnal_IOP, 1430, 1441, "diurnal IOP", "", +7160, Reduction, 1445, 1450, "7 . 2", "", +7161, SdErrorChangeValue, 1457, 1462, "2 . 5", "", +7162, mmHg, 1463, 1468, "mm Hg", "", +7163, RelativeReduction, 1471, 1477, "28 . 7", "", +26347, Carteolol, 1486, 1495, "carteolol", "", +26348, Pilocarpine, 1501, 1512, "pilocarpine", "", +7166, Mean, 1525, 1529, "mean", "", +7167, Diurnal_IOP, 1530, 1541, "diurnal IOP", "", +7168, Reduction, 1545, 1550, "7 . 4", "", +7169, SdErrorChangeValue, 1557, 1562, "2 . 7", "", +7170, mmHg, 1563, 1568, "mm Hg", "", +7171, RelativeReduction, 1571, 1573, "29", "", +7173, IOP, 1641, 1644, "IOP", "", +7172, PvalueDiff, 1664, 1672, "P = . 51", "", +26349, Carteolol, 1779, 1788, "carteolol", "", +26350, Pilocarpine, 1798, 1809, "pilocarpine", "", +26351, Latanoprost, 1828, 1839, "latanoprost", "", +7178, PValueNumAffected, 1848, 1856, "P < . 05", "", +7179, ConclusionComment, 1875, 2075, "We concluded that latanoprost monotherapy was at least as effective as the carteolol - pilocarpine combination therapy in reducing mean diurnal IOP in newly diagnosed glaucoma or ocular hypertension .", "", +26352, Latanoprost, 1893, 1904, "latanoprost", "", +26353, Carteolol, 1950, 1959, "carteolol", "", +26354, Pilocarpine, 1962, 1973, "pilocarpine", "", +7183, Mean, 2006, 2010, "mean", "", +7184, Diurnal_IOP, 2011, 2022, "diurnal IOP", "", +26356, Precondition, 2026, 2041, "newly diagnosed", "", +26355, Glaucoma, 2042, 2050, "glaucoma", "", +7187, OcularHypertension, 2054, 2073, "ocular hypertension", "", +7188, PMID, 2083, 2091, "12586182", "", diff --git a/data/gl 12586182_jshahinitiran.n-triples b/data/gl 12586182_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12586182_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12586182_tstrakeljahn.annodb b/data/gl 12586182_tstrakeljahn.annodb new file mode 100644 index 0000000..967b8e4 --- /dev/null +++ b/data/gl 12586182_tstrakeljahn.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30917, Journal, 0, 16, "Jpn J Ophthalmol", "", +30918, PublicationYear, 19, 23, "2003", "", +30924, Title, 56, 195, "Comparison of the intraocular pressure lowering effect of latanoprost and carteolol - pilocarpine combination in newly diagnosed glaucoma .", "", +30919, IOP, 74, 94, "intraocular pressure", "", +30920, Latanoprost, 114, 125, "latanoprost", "", +30921, Carteolol, 130, 139, "carteolol", "", +30922, Pilocarpine, 142, 153, "pilocarpine", "", +30923, Glaucoma, 185, 193, "glaucoma", "", +30925, Author, 196, 205, "Ozdemir M", "", +30926, Author, 214, 223, "Ozdemir G", "", +30927, Turkey, 323, 329, "Turkey", "", +30932, ObjectiveDescription, 342, 499, "To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma .", "", +30928, Latanoprost, 382, 393, "latanoprost", "", +30929, Carteolol, 422, 431, "carteolol", "", +30930, Pilocarpine, 436, 447, "pilocarpine", "", +30931, Glaucoma, 489, 497, "glaucoma", "", +30933, Blind, 510, 516, "Masked", "", +30934, Randomized, 517, 527, "randomized", "", +30935, NumberPatientsCT, 568, 570, "51", "", +30936, Glaucoma, 613, 621, "glaucoma", "", +30937, OcularHypertension, 625, 644, "ocular hypertension", "", +30938, Randomized, 662, 678, "randomly divided", "", +30939, Latanoprost, 727, 738, "latanoprost", "", +30942, DoseValue, 739, 746, "0 . 005", "", +30948, Percentage, 747, 748, "%", "", +30947, Frequency, 749, 759, "once daily", "", +30940, Carteolol, 768, 777, "carteolol", "", +30943, DoseValue, 778, 779, "2", "", +30949, Percentage, 780, 781, "%", "", +30946, Frequency, 782, 793, "twice daily", "", +30941, Pilocarpine, 798, 809, "pilocarpine", "", +30944, DoseValue, 810, 811, "2", "", +30950, Percentage, 812, 819, "% twice", "", +30945, Frequency, 814, 825, "twice daily", "", +30951, Mean, 828, 832, "Mean", "", +30952, Diurnal_IOP, 833, 861, "diurnal intraocular pressure", "", +30953, IOP, 864, 867, "IOP", "", +30954, Mean, 973, 977, "mean", "", +30955, IOP, 978, 981, "IOP", "", +30956, Mean, 1074, 1078, "Mean", "", +30958, Diurnal_IOP, 1079, 1090, "diurnal IOP", "", +30959, BaseLineValue, 1103, 1109, "25 . 1", "", +30961, SdDevBL, 1110, 1121, "+ / - 3 . 1", "", +30963, mmHg, 1122, 1127, "mm Hg", "", +30960, BaseLineValue, 1132, 1138, "25 . 5", "", +30962, SdDevBL, 1139, 1150, "+ / - 2 . 5", "", +30964, mmHg, 1151, 1156, "mm Hg", "", +30965, Latanoprost, 1176, 1187, "latanoprost", "", +30966, Carteolol, 1217, 1226, "carteolol", "", +30967, Pilocarpine, 1236, 1247, "pilocarpine", "", +30968, Diurnal_IOP, 1271, 1282, "Diurnal IOP", "", +30969, TimePoint, 1328, 1336, "3 months", "", +30970, PValueResValue, 1354, 1363, "P < . 001", "", +30971, Latanoprost, 1389, 1400, "latanoprost", "", +30972, Mean, 1425, 1429, "mean", "", +30973, Diurnal_IOP, 1430, 1441, "diurnal IOP", "", +30974, Reduction, 1445, 1450, "7 . 2", "", +30978, SdDevChangeValue, 1451, 1462, "+ / - 2 . 5", "", +30976, mmHg, 1463, 1468, "mm Hg", "", +30981, RelativeReduction, 1471, 1477, "28 . 7", "", +30975, Reduction, 1545, 1550, "7 . 4", "", +30980, SdDevChangeValue, 1551, 1562, "+ / - 2 . 7", "", +30977, mmHg, 1563, 1568, "mm Hg", "", +30982, RelativeReduction, 1571, 1573, "29", "", +30985, ObservedResult, 1580, 1676, "There was no difference between the groups in terms of their IOP reduction effect ( P = . 51 ) .", "", +30983, IOP, 1641, 1644, "IOP", "", +30984, PvalueDiff, 1664, 1672, "P = . 51", "", +30989, Headache, 1744, 1752, "headache", "", +30990, Carteolol, 1779, 1788, "carteolol", "", +30991, Pilocarpine, 1798, 1809, "pilocarpine", "", +30992, Latanoprost, 1828, 1839, "latanoprost", "", +30993, PvalueDiff, 1848, 1856, "P < . 05", "", +31003, ConclusionComment, 1875, 2075, "We concluded that latanoprost monotherapy was at least as effective as the carteolol - pilocarpine combination therapy in reducing mean diurnal IOP in newly diagnosed glaucoma or ocular hypertension .", "", +30994, Latanoprost, 1893, 1904, "latanoprost", "", +30995, Carteolol, 1950, 1959, "carteolol", "", +30996, Pilocarpine, 1962, 1973, "pilocarpine", "", +30997, Mean, 2006, 2010, "mean", "", +30999, Diurnal_IOP, 2011, 2022, "diurnal IOP", "", +31000, Glaucoma, 2042, 2050, "glaucoma", "", +31001, OcularHypertension, 2054, 2073, "ocular hypertension", "", +31002, PMID, 2083, 2091, "12586182", "", diff --git a/data/gl 12586182_tstrakeljahn.n-triples b/data/gl 12586182_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12586182_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12660585_admin.annodb b/data/gl 12660585_admin.annodb new file mode 100644 index 0000000..4f32ecb --- /dev/null +++ b/data/gl 12660585_admin.annodb @@ -0,0 +1,169 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "J Fr Ophtalmol .", "", " \"J Fr Ophtalmol .\"." +1, PublicationYear, 17, 21, "2003", "", " \"2003\"." +135, Title, 51, 114, "Efficacy and safety of long - acting carteolol 1 % once daily .", "", " \"Efficacy and safety of long - acting carteolol 1 % once daily .\"." +60704, Drug, 74, 97, "long - acting carteolol", "", +60561, Carteolol, 88, 97, "carteolol", "", +60559, DoseValue, 98, 99, "1", "", +3, Percentage, 100, 101, "%", "", +4, Frequency, 102, 112, "once daily", "", +5, DoubleBlind, 117, 132, "double - masked", "", " ." +99, Randomized, 135, 145, "randomized", "", " ." +6, Author, 178, 189, "Trinquand C", "", " \"Trinquand C\"." +7, Author, 198, 208, "Romanet JP", "", " \"Romanet JP\"." +8, Author, 211, 222, "Nordmann JP", "", " \"Nordmann JP\"." +9, Author, 225, 234, "Allaire C", "", " \"Allaire C\"." +10, France, 335, 341, "France", "", " ." +87, Carteolol, 354, 363, "Carteolol", "", +16, IOP, 467, 487, "intraocular pressure", "", +100, Frequency, 514, 525, "twice daily", "", +85, Frequency, 554, 566, "once - daily", "", +88, Carteolol, 584, 593, "carteolol", "", +101, DoseValue, 614, 615, "1", "", +102, Percentage, 616, 617, "%", "", +86, Carteolol, 760, 769, "carteolol", "", +15, ObjectiveDescription, 803, 965, "The objective of this study was to evaluate the efficacy and safety of long - acting 1 % carteolol alginate solution compared to standard 1 % carteolol solution .", "", " \"The objective of this study was to evaluate the efficacy and safety of long - acting 1 % carteolol alginate solution compared to standard 1 % carteolol solution .\"." +103, DoseValue, 888, 889, "1", "", +104, Percentage, 890, 891, "%", "", +106383, Drug, 892, 910, "carteolol alginate", "", +105, DoseValue, 941, 942, "1", "", " \"1\"." +106, Percentage, 943, 944, "%", "", +89, Carteolol, 945, 954, "carteolol", "", +17, DoubleBlind, 987, 1002, "double - masked", "", +149, Parallel, 1005, 1019, "parallel group", "", " ." +19, Multicenter, 1022, 1033, "multicentre", "", +60563, Precondition, 1042, 1098, "Patients with ocular hypertension or open angle glaucoma", "", " \"Patients with ocular hypertension or open angle glaucoma\"." +20, OcularHypertension, 1056, 1075, "ocular hypertension", "", " ." +21, OpenAngleGlaucoma, 1079, 1098, "open angle glaucoma", "", " ." +22, NumberPatientsCT, 1105, 1108, "151", "", " \"151\"." +111, Randomized, 1116, 1124, "randomly", "", +107, DoseValue, 1152, 1153, "1", "", " \"1\"." +109, Percentage, 1154, 1155, "%", "", " ." +95, Drug, 1156, 1174, "carteolol alginate", "", " . ." +23, Frequency, 1175, 1185, "once daily", "", " \"once daily\"." +158, Morning, 1188, 1190, "AM", "", " ." +108, DoseValue, 1205, 1206, "1", "", +110, Percentage, 1207, 1208, "%", "", " ." +90, Carteolol, 1209, 1218, "carteolol", "", " ." +24, Frequency, 1228, 1239, "twice daily", "", " \"twice daily\"." +25, Duration, 1244, 1252, "2 months", "", " \"2 months\"." +60564, Blind, 1259, 1266, "masking", "", " ." +26, Placebo, 1303, 1310, "placebo", "", " ." +165, Evening, 1318, 1325, "evening", "", " ." +28, IOP, 1393, 1413, "intraocular pressure", "", +29, IOP, 1416, 1419, "IOP", "", +60565, DoseValue, 1430, 1432, "23", "", +30, mmHg, 1433, 1437, "mmHg", "", +60566, DoseValue, 1442, 1444, "32", "", +31, mmHg, 1445, 1449, "mmHg", "", +170, TimePoint, 1453, 1457, "9 AM", "", +171, TimePoint, 1462, 1467, "11 AM", "", +172, Precondition, 1470, 1551, "Patients using ocular hypotensive medication were required to undergo a washout .", "", " \"Patients using ocular hypotensive medication were required to undergo a washout .\"." +112, AngleClosureGlaucoma, 1644, 1657, "angle closure", "", +113, Glaucoma, 1660, 1670, "congenital", "", +114, Secondary_AngleClosureGlaucoma, 1673, 1691, "secondary glaucoma", "", +116, Glaucoma, 1695, 1712, "advanced glaucoma", "", +60582, DisorderOrSyndrome, 1719, 1756, "intraocular infection or inflammation", "", +60584, DisorderOrSyndrome, 1759, 1772, "ocular trauma", "", +60598, Duration, 1835, 1843, "3 months", "", +60611, Drug, 1878, 1907, "beta adrenoceptor antagonists", "", +32, IOP, 1948, 1951, "IOP", "", +60599, Duration, 1995, 2003, "3 months", "", +60606, Drug, 2006, 2020, "ocular steroid", "", +120, TimePoint, 2109, 2117, "baseline", "", +121, TimePoint, 2120, 2134, "15 and 60 days", "", +122, TimePoint, 2127, 2134, "60 days", "", +33, IOP, 2142, 2145, "IOP", "", +189, TimePoint, 2162, 2166, "9 AM", "", +190, TimePoint, 2171, 2176, "11 AM", "", +123, TimePoint, 2182, 2188, "day 15", "", +124, TimePoint, 2193, 2199, "day 60", "", +182, IOP, 2202, 2205, "IOP", "", +183, RelativeTime, 2219, 2257, "just before instillation of medication", "", +184, TimePoint, 2260, 2264, "9 AM", "", +179, RelativeTime, 2271, 2284, "2 hours after", "", +185, TimePoint, 2287, 2292, "11 AM", "", +55, HeartRate, 2398, 2408, "heart rate", "", +56, BloodPressure, 2413, 2427, "blood pressure", "", +193, TimePoint, 2430, 2435, "10 AM", "", +60624, EndPointDescription, 2442, 2458, "ocular tolerance", "", +195, RelativeTime, 2459, 2475, "after medication", "", +194, TimePoint, 2478, 2483, "11 AM", "", +34, IOP, 2539, 2542, "IOP", "", +60628, TimePoint, 2548, 2556, "baseline", "", +197, TimePoint, 2560, 2566, "day 60", "", +198, TimePoint, 2591, 2595, "9 AM", "", +199, TimePoint, 2600, 2605, "11 AM", "", +117, IOP, 2650, 2653, "IOP", "", +125, TimePoint, 2657, 2662, "day 0", "", +22, NumberPatientsCT, 2723, 2726, "151", "", " \"151\"." +82, FinalNumPatientsCT, 2760, 2763, "149", "", " \"149\"." +83, NumPatientsLeftCT, 2781, 2784, "two", "", " \"two\"." +204, FinalNumPatientsArm, 2835, 2837, "74", "", " \"74\"." +205, FinalNumPatientsArm, 2864, 2866, "75", "", " \"75\"." +84, BloodPressure, 2965, 2979, "blood pressure", "", +46, IOP, 2986, 2989, "IOP", "", +212, TimePoint, 3013, 3020, "09 . 00", "", +52, Trough_IOP, 3038, 3044, "trough", "", " ." +37, TimePoint, 3050, 3056, "day 60", "", " \"day 60\". \"day 60\"." +38, Mean, 3059, 3063, "mean", "", " . ." +60645, TimePoint, 3080, 3088, "baseline", "", +45, Trough_IOP, 3092, 3112, "intraocular pressure", "", +39, Reduction, 3118, 3124, "6 . 32", "", " \"6 . 32\"." +60658, SdDevChangeValue, 3131, 3137, "2 . 87", "", " \"2 . 87\"." +41, Reduction, 3142, 3148, "5 . 67", "", " \"5 . 67\"." +60660, SdDevChangeValue, 3155, 3161, "3 . 30", "", " \"3 . 30\"." +43, mmHg, 3162, 3166, "mmHg", "", " ." +96, Drug, 3175, 3193, "alginate carteolol", "", +213, TimePoint, 3234, 3241, "11 . 00", "", " \"11 . 00\". \"11 . 00\"." +53, Peak_IOP, 3259, 3263, "peak", "", " ." +44, Mean, 3268, 3272, "mean", "", " . ." +47, Reduction, 3289, 3295, "6 . 70", "", " \"6 . 70\"." +260, SdDevChangeValue, 3302, 3308, "2 . 81", "", " \"2 . 81\"." +48, Reduction, 3313, 3319, "6 . 55", "", " \"6 . 55\"." +261, SdDevChangeValue, 3326, 3332, "3 . 35", "", " \"3 . 35\"." +51, mmHg, 3333, 3337, "mmHg", "", " ." +54, PValueChangeValue, 3434, 3445, "p < 0 . 005", "", " \"p < 0 . 005\". \"p < 0 . 005\". \"p < 0 . 005\". \"p < 0 . 005\"." +57, BloodPressure, 3566, 3580, "blood pressure", "", +60, ObservedResult, 3592, 3746, "Slight decreases in heart rate and blood pressure means were observed in both groups at follow - up visits with no significant difference between groups .", "", +59, HeartRate, 3612, 3622, "heart rate", "", +58, BloodPressure, 3627, 3641, "blood pressure", "", +222, Mean, 3642, 3647, "means", "", +223, TimePoint, 3818, 3824, "day 60", "", +224, PercentageAffected, 3828, 3831, "100", "", +225, PercentageAffected, 3862, 3868, "98 . 7", "", +60676, EndPointDescription, 3894, 3914, "Transient discomfort", "", " . ." +226, Stinging, 3924, 3932, "stinging", "", +60679, EndPointDescription, 3936, 3953, "burning sensation", "", +60682, PercentageAffected, 3986, 3995, "4 % - 6 %", "", +92864, BlurredVison, 4050, 4064, "blurred vision", "", +61, NumberAffected, 4091, 4092, "2", "", +118, NumberPatientsArm, 4100, 4102, "74", "", +233, NumberAffected, 4146, 4148, "17", "", +60687, EndPointDescription, 4158, 4172, "adverse events", "", +63, NumberAffected, 4215, 4218, "one", "", " \"one\"." +60688, EndPointDescription, 4219, 4226, "vertigo", "", " . ." +65, NumberAffected, 4229, 4232, "one", "", " \"one\"." +60689, EndPointDescription, 4233, 4263, "superficial punctate keratitis", "", " . ." +66, NumberAffected, 4290, 4293, "one", "", " \"one\"." +60691, EndPointDescription, 4294, 4320, "decrease in blood pressure", "", " . ." +236, ObservedResult, 4345, 4384, "No serious adverse events were reported", "", +68, ConclusionComment, 4401, 4589, "The new alginate formulation of long - acting carteolol 1 % given once daily is as effective as standard 1 % carteolol given twice daily , with no meaningful differences regarding safety .", "", " \"The new alginate formulation of long - acting carteolol 1 % given once daily is as effective as standard 1 % carteolol given twice daily , with no meaningful differences regarding safety .\"." +60701, Drug, 4409, 4456, "alginate formulation of long - acting carteolol", "", +72, DoseValue, 4457, 4458, "1", "", +74, Percentage, 4459, 4460, "%", "", +76, Frequency, 4467, 4477, "once daily", "", +73, DoseValue, 4506, 4507, "1", "", +75, Percentage, 4508, 4509, "%", "", +91, Carteolol, 4510, 4519, "carteolol", "", +77, Frequency, 4526, 4537, "twice daily", "", +69, ConclusionComment, 4590, 4784, "This efficacy wasy was verified at 9 AM ( 24 hours after the last drop of long - acting carteolol or 12 hours after that of standard carteolol ) and at 11 AM ( 2 hours after the morning drop ) .", "", " \"This efficacy wasy was verified at 9 AM ( 24 hours after the last drop of long - acting carteolol or 12 hours after that of standard carteolol ) and at 11 AM ( 2 hours after the morning drop ) .\"." +60760, Drug, 4664, 4687, "long - acting carteolol", "", +92, Carteolol, 4723, 4732, "carteolol", "", +70, ConclusionComment, 4785, 4946, "The new alginate formulation of long - acting carteolol 1 % given once a day is effective and well tolerated by glaucoma patients who require chronic treatment .", "", " \"The new alginate formulation of long - acting carteolol 1 % given once a day is effective and well tolerated by glaucoma patients who require chronic treatment .\"." +98, Drug, 4793, 4840, "alginate formulation of long - acting carteolol", "", +78, DoseValue, 4841, 4842, "1", "", +79, Percentage, 4843, 4844, "%", "", +80, Frequency, 4851, 4861, "once a day", "", +81, Glaucoma, 4897, 4905, "glaucoma", "", +71, PMID, 4954, 4962, "12660585", "", " \"12660585\"." diff --git a/data/gl 12660585_admin.n-triples b/data/gl 12660585_admin.n-triples new file mode 100644 index 0000000..74b0e40 --- /dev/null +++ b/data/gl 12660585_admin.n-triples @@ -0,0 +1,182 @@ +# RDF export of group: Publication + . + "Publication" . + "Trinquand C" . + "2003" . + "J Fr Ophtalmol ." . + "12660585" . + . + "Efficacy and safety of long - acting carteolol 1 % once daily ." . + "Romanet JP" . + "Nordmann JP" . + "Allaire C" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The objective of this study was to evaluate the efficacy and safety of long - acting 1 % carteolol alginate solution compared to standard 1 % carteolol solution ." . + "151" . + "2 months" . + . + . + . + "The new alginate formulation of long - acting carteolol 1 % given once daily is as effective as standard 1 % carteolol given twice daily , with no meaningful differences regarding safety ." . + . + . + . + . + . + "149" . + "two" . + . + . + . + . + "This efficacy wasy was verified at 9 AM ( 24 hours after the last drop of long - acting carteolol or 12 hours after that of standard carteolol ) and at 11 AM ( 2 hours after the morning drop ) ." . + "The new alginate formulation of long - acting carteolol 1 % given once a day is effective and well tolerated by glaucoma patients who require chronic treatment ." . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with ocular hypertension or open angle glaucoma" . + . + . + . + "Patients using ocular hypotensive medication were required to undergo a washout ." . +# RDF export of group: Endpoint + . + "Endpoint-piop" . + . + . + . + . + . + . + "Endpoint-tiop" . + . + . + . + . + . + . + "Endpoint-dis" . + . + . + . + . + . + . + "Endpoint-vertigo" . + . + . + . + . + . + . + "Endpoint-keratitis" . + . + . + . + . + . + . + "Endpoint-bloodp" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-alg" . + "74" . + . + . + . + . + . + . + . + "Arm-car" . + "75" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-alg" . + . + "once daily" . + . + . + "Intervention-car" . + . + "twice daily" . + . + . + "Intervention-pla" . + . + . +# RDF export of group: Medication + . + "Medication-alg" . + . + . + "1" . + . + . + . + "Medication-car" . + . + "1" . + . + . + . + "Placebo" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-tiop-alg" . + . + "5 . 67" . + "p < 0 . 005" . + "3 . 30" . + "day 60" . + . + "Outcome-tiop-car" . + . + "6 . 32" . + "p < 0 . 005" . + "2 . 87" . + "day 60" . + . + "Outcome-piop-alg" . + . + "6 . 70" . + "p < 0 . 005" . + "2 . 81" . + "11 . 00" . + . + "Outcome-piop-car" . + . + "6 . 55" . + "p < 0 . 005" . + "3 . 35" . + "11 . 00" . + . + "Outcome-vertigo" . + . + "one" . + . + "Outcome-keratitis" . + . + "one" . + . + "Outcome-bloodp" . + . + "one" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12660585_export.csv b/data/gl 12660585_export.csv new file mode 100644 index 0000000..8834eb4 --- /dev/null +++ b/data/gl 12660585_export.csv @@ -0,0 +1,958 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +471, 1, 1, 1, 0, 1, 0, 1, "J" +471, 1, 2, 2, 2, 4, 2, 4, "Fr" +471, 1, 3, 3, 5, 14, 5, 14, "Ophtalmol" +471, 1, 4, 4, 15, 16, 15, 16, "." +471, 2, 1, 5, 0, 4, 17, 21, "2003" +471, 2, 2, 6, 5, 8, 22, 25, "Feb" +471, 2, 3, 7, 9, 10, 26, 27, ";" +471, 2, 4, 8, 11, 13, 28, 30, "26" +471, 2, 5, 9, 14, 15, 31, 32, "(" +471, 2, 6, 10, 16, 17, 33, 34, "2" +471, 2, 7, 11, 18, 19, 35, 36, ")" +471, 2, 8, 12, 20, 21, 37, 38, ":" +471, 2, 9, 13, 22, 25, 39, 42, "131" +471, 2, 10, 14, 26, 27, 43, 44, "-" +471, 2, 11, 15, 28, 29, 45, 46, "6" +471, 2, 12, 16, 30, 31, 47, 48, "." +471, 3, 1, 17, 0, 1, 49, 50, "[" +471, 3, 2, 18, 2, 10, 51, 59, "Efficacy" +471, 3, 3, 19, 11, 14, 60, 63, "and" +471, 3, 4, 20, 15, 21, 64, 70, "safety" +471, 3, 5, 21, 22, 24, 71, 73, "of" +471, 3, 6, 22, 25, 29, 74, 78, "long" +471, 3, 7, 23, 30, 31, 79, 80, "-" +471, 3, 8, 24, 32, 38, 81, 87, "acting" +471, 3, 9, 25, 39, 48, 88, 97, "carteolol" +471, 3, 10, 26, 49, 50, 98, 99, "1" +471, 3, 11, 27, 51, 52, 100, 101, "%" +471, 3, 12, 28, 53, 57, 102, 106, "once" +471, 3, 13, 29, 58, 63, 107, 112, "daily" +471, 3, 14, 30, 64, 65, 113, 114, "." +471, 4, 1, 31, 0, 1, 115, 116, "A" +471, 4, 2, 32, 2, 8, 117, 123, "double" +471, 4, 3, 33, 9, 10, 124, 125, "-" +471, 4, 4, 34, 11, 17, 126, 132, "masked" +471, 4, 5, 35, 18, 19, 133, 134, "," +471, 4, 6, 36, 20, 30, 135, 145, "randomized" +471, 4, 7, 37, 31, 36, 146, 151, "study" +471, 4, 8, 38, 37, 38, 152, 153, "]" +471, 4, 9, 39, 39, 40, 154, 155, "." +471, 5, 1, 40, 0, 1, 156, 157, "[" +471, 5, 2, 41, 2, 9, 158, 165, "Article" +471, 5, 3, 42, 10, 12, 166, 168, "in" +471, 5, 4, 43, 13, 19, 169, 175, "French" +471, 5, 5, 44, 20, 21, 176, 177, "]" +471, 5, 6, 45, 22, 31, 178, 187, "Trinquand" +471, 5, 7, 46, 32, 33, 188, 189, "C" +471, 5, 8, 47, 34, 35, 190, 191, "(" +471, 5, 9, 48, 36, 37, 192, 193, "1" +471, 5, 10, 49, 38, 39, 194, 195, ")" +471, 5, 11, 50, 40, 41, 196, 197, "," +471, 5, 12, 51, 42, 49, 198, 205, "Romanet" +471, 5, 13, 52, 50, 52, 206, 208, "JP" +471, 5, 14, 53, 53, 54, 209, 210, "," +471, 5, 15, 54, 55, 63, 211, 219, "Nordmann" +471, 5, 16, 55, 64, 66, 220, 222, "JP" +471, 5, 17, 56, 67, 68, 223, 224, "," +471, 5, 18, 57, 69, 76, 225, 232, "Allaire" +471, 5, 19, 58, 77, 78, 233, 234, "C" +471, 5, 20, 59, 79, 80, 235, 236, ";" +471, 5, 21, 60, 81, 87, 237, 243, "Groupe" +471, 5, 22, 61, 88, 89, 244, 245, "d" +471, 5, 23, 62, 90, 92, 246, 248, "'é" +471, 5, 24, 63, 93, 97, 249, 253, "tude" +471, 5, 25, 64, 98, 99, 254, 255, "." +471, 6, 1, 65, 0, 6, 256, 262, "Author" +471, 6, 2, 66, 7, 18, 263, 274, "information" +471, 6, 3, 67, 19, 20, 275, 276, ":" +471, 6, 4, 68, 21, 22, 277, 278, "(" +471, 6, 5, 69, 23, 24, 279, 280, "1" +471, 6, 6, 70, 25, 26, 281, 282, ")" +471, 6, 7, 71, 27, 38, 283, 294, "Laboratoire" +471, 6, 8, 72, 39, 46, 295, 302, "Chauvin" +471, 6, 9, 73, 47, 48, 303, 304, "/" +471, 6, 10, 74, 49, 55, 305, 311, "Bausch" +471, 6, 11, 75, 56, 57, 312, 313, "&" +471, 6, 12, 76, 58, 62, 314, 318, "Lomb" +471, 6, 13, 77, 63, 64, 319, 320, "," +471, 6, 14, 78, 65, 76, 321, 332, "Montpellier" +471, 6, 15, 79, 77, 78, 333, 334, "," +471, 6, 16, 80, 79, 85, 335, 341, "France" +471, 6, 17, 81, 86, 87, 342, 343, "." +471, 7, 1, 82, 0, 7, 344, 351, "PURPOSE" +471, 7, 2, 83, 8, 9, 352, 353, ":" +471, 7, 3, 84, 10, 19, 354, 363, "Carteolol" +471, 7, 4, 85, 20, 22, 364, 366, "is" +471, 7, 5, 86, 23, 24, 367, 368, "a" +471, 7, 6, 87, 25, 29, 369, 373, "beta" +471, 7, 7, 88, 30, 31, 374, 375, "-" +471, 7, 8, 89, 32, 44, 376, 388, "adrenoceptor" +471, 7, 9, 90, 45, 55, 389, 399, "antagonist" +471, 7, 10, 91, 56, 60, 400, 404, "with" +471, 7, 11, 92, 61, 70, 405, 414, "intrinsic" +471, 7, 12, 93, 71, 86, 415, 430, "sympathomimetic" +471, 7, 13, 94, 87, 95, 431, 439, "activity" +471, 7, 14, 95, 96, 97, 440, 441, "." +471, 8, 1, 96, 0, 4, 442, 446, "Used" +471, 8, 2, 97, 5, 14, 447, 456, "topically" +471, 8, 3, 98, 15, 17, 457, 459, "to" +471, 8, 4, 99, 18, 24, 460, 466, "reduce" +471, 8, 5, 100, 25, 36, 467, 478, "intraocular" +471, 8, 6, 101, 37, 45, 479, 487, "pressure" +471, 8, 7, 102, 46, 47, 488, 489, "," +471, 8, 8, 103, 48, 50, 490, 492, "it" +471, 8, 9, 104, 51, 53, 493, 495, "is" +471, 8, 10, 105, 54, 63, 496, 505, "typically" +471, 8, 11, 106, 64, 71, 506, 513, "applied" +471, 8, 12, 107, 72, 77, 514, 519, "twice" +471, 8, 13, 108, 78, 83, 520, 525, "daily" +471, 8, 14, 109, 84, 85, 526, 527, "." +471, 9, 1, 110, 0, 2, 528, 530, "In" +471, 9, 2, 111, 3, 5, 531, 533, "an" +471, 9, 3, 112, 6, 12, 534, 540, "effort" +471, 9, 4, 113, 13, 15, 541, 543, "to" +471, 9, 5, 114, 16, 23, 544, 551, "provide" +471, 9, 6, 115, 24, 25, 552, 553, "a" +471, 9, 7, 116, 26, 30, 554, 558, "once" +471, 9, 8, 117, 31, 32, 559, 560, "-" +471, 9, 9, 118, 33, 38, 561, 566, "daily" +471, 9, 10, 119, 39, 45, 567, 573, "dosing" +471, 9, 11, 120, 46, 53, 574, 581, "regimen" +471, 9, 12, 121, 54, 55, 582, 583, "," +471, 9, 13, 122, 56, 65, 584, 593, "carteolol" +471, 9, 14, 123, 66, 69, 594, 597, "was" +471, 9, 15, 124, 70, 80, 598, 608, "formulated" +471, 9, 16, 125, 81, 85, 609, 613, "with" +471, 9, 17, 126, 86, 87, 614, 615, "1" +471, 9, 18, 127, 88, 89, 616, 617, "%" +471, 9, 19, 128, 90, 97, 618, 625, "alginic" +471, 9, 20, 129, 98, 102, 626, 630, "acid" +471, 9, 21, 130, 103, 104, 631, 632, "." +471, 10, 1, 131, 0, 6, 633, 639, "Sodium" +471, 10, 2, 132, 7, 15, 640, 648, "alginate" +471, 10, 3, 133, 16, 18, 649, 651, "is" +471, 10, 4, 134, 19, 20, 652, 653, "a" +471, 10, 5, 135, 21, 28, 654, 661, "natural" +471, 10, 6, 136, 29, 36, 662, 669, "polymer" +471, 10, 7, 137, 37, 44, 670, 677, "product" +471, 10, 8, 138, 45, 49, 678, 682, "with" +471, 10, 9, 139, 50, 61, 683, 694, "bioadhesive" +471, 10, 10, 140, 62, 72, 695, 705, "properties" +471, 10, 11, 141, 73, 82, 706, 715, "providing" +471, 10, 12, 142, 83, 92, 716, 725, "increased" +471, 10, 13, 143, 93, 100, 726, 733, "corneal" +471, 10, 14, 144, 101, 108, 734, 741, "contact" +471, 10, 15, 145, 109, 113, 742, 746, "time" +471, 10, 16, 146, 114, 117, 747, 750, "and" +471, 10, 17, 147, 118, 119, 751, 752, "a" +471, 10, 18, 148, 120, 126, 753, 759, "better" +471, 10, 19, 149, 127, 136, 760, 769, "carteolol" +471, 10, 20, 150, 137, 148, 770, 781, "penetration" +471, 10, 21, 151, 149, 156, 782, 789, "through" +471, 10, 22, 152, 157, 160, 790, 793, "the" +471, 10, 23, 153, 161, 167, 794, 800, "cornea" +471, 10, 24, 154, 168, 169, 801, 802, "." +471, 11, 1, 155, 0, 3, 803, 806, "The" +471, 11, 2, 156, 4, 13, 807, 816, "objective" +471, 11, 3, 157, 14, 16, 817, 819, "of" +471, 11, 4, 158, 17, 21, 820, 824, "this" +471, 11, 5, 159, 22, 27, 825, 830, "study" +471, 11, 6, 160, 28, 31, 831, 834, "was" +471, 11, 7, 161, 32, 34, 835, 837, "to" +471, 11, 8, 162, 35, 43, 838, 846, "evaluate" +471, 11, 9, 163, 44, 47, 847, 850, "the" +471, 11, 10, 164, 48, 56, 851, 859, "efficacy" +471, 11, 11, 165, 57, 60, 860, 863, "and" +471, 11, 12, 166, 61, 67, 864, 870, "safety" +471, 11, 13, 167, 68, 70, 871, 873, "of" +471, 11, 14, 168, 71, 75, 874, 878, "long" +471, 11, 15, 169, 76, 77, 879, 880, "-" +471, 11, 16, 170, 78, 84, 881, 887, "acting" +471, 11, 17, 171, 85, 86, 888, 889, "1" +471, 11, 18, 172, 87, 88, 890, 891, "%" +471, 11, 19, 173, 89, 98, 892, 901, "carteolol" +471, 11, 20, 174, 99, 107, 902, 910, "alginate" +471, 11, 21, 175, 108, 116, 911, 919, "solution" +471, 11, 22, 176, 117, 125, 920, 928, "compared" +471, 11, 23, 177, 126, 128, 929, 931, "to" +471, 11, 24, 178, 129, 137, 932, 940, "standard" +471, 11, 25, 179, 138, 139, 941, 942, "1" +471, 11, 26, 180, 140, 141, 943, 944, "%" +471, 11, 27, 181, 142, 151, 945, 954, "carteolol" +471, 11, 28, 182, 152, 160, 955, 963, "solution" +471, 11, 29, 183, 161, 162, 964, 965, "." +471, 12, 1, 184, 0, 7, 966, 973, "METHODS" +471, 12, 2, 185, 8, 9, 974, 975, ":" +471, 12, 3, 186, 10, 14, 976, 980, "This" +471, 12, 4, 187, 15, 18, 981, 984, "was" +471, 12, 5, 188, 19, 20, 985, 986, "a" +471, 12, 6, 189, 21, 27, 987, 993, "double" +471, 12, 7, 190, 28, 29, 994, 995, "-" +471, 12, 8, 191, 30, 36, 996, 1002, "masked" +471, 12, 9, 192, 37, 38, 1003, 1004, "," +471, 12, 10, 193, 39, 47, 1005, 1013, "parallel" +471, 12, 11, 194, 48, 53, 1014, 1019, "group" +471, 12, 12, 195, 54, 55, 1020, 1021, "," +471, 12, 13, 196, 56, 67, 1022, 1033, "multicentre" +471, 12, 14, 197, 68, 73, 1034, 1039, "study" +471, 12, 15, 198, 74, 75, 1040, 1041, "." +471, 13, 1, 199, 0, 8, 1042, 1050, "Patients" +471, 13, 2, 200, 9, 13, 1051, 1055, "with" +471, 13, 3, 201, 14, 20, 1056, 1062, "ocular" +471, 13, 4, 202, 21, 33, 1063, 1075, "hypertension" +471, 13, 5, 203, 34, 36, 1076, 1078, "or" +471, 13, 6, 204, 37, 41, 1079, 1083, "open" +471, 13, 7, 205, 42, 47, 1084, 1089, "angle" +471, 13, 8, 206, 48, 56, 1090, 1098, "glaucoma" +471, 13, 9, 207, 57, 58, 1099, 1100, "(" +471, 13, 10, 208, 59, 60, 1101, 1102, "n" +471, 13, 11, 209, 61, 62, 1103, 1104, "=" +471, 13, 12, 210, 63, 66, 1105, 1108, "151" +471, 13, 13, 211, 67, 68, 1109, 1110, ")" +471, 13, 14, 212, 69, 73, 1111, 1115, "were" +471, 13, 15, 213, 74, 82, 1116, 1124, "randomly" +471, 13, 16, 214, 83, 91, 1125, 1133, "assigned" +471, 13, 17, 215, 92, 94, 1134, 1136, "to" +471, 13, 18, 216, 95, 102, 1137, 1144, "receive" +471, 13, 19, 217, 103, 109, 1145, 1151, "either" +471, 13, 20, 218, 110, 111, 1152, 1153, "1" +471, 13, 21, 219, 112, 113, 1154, 1155, "%" +471, 13, 22, 220, 114, 123, 1156, 1165, "carteolol" +471, 13, 23, 221, 124, 132, 1166, 1174, "alginate" +471, 13, 24, 222, 133, 137, 1175, 1179, "once" +471, 13, 25, 223, 138, 143, 1180, 1185, "daily" +471, 13, 26, 224, 144, 145, 1186, 1187, "(" +471, 13, 27, 225, 146, 148, 1188, 1190, "AM" +471, 13, 28, 226, 149, 150, 1191, 1192, ")" +471, 13, 29, 227, 151, 153, 1193, 1195, "or" +471, 13, 30, 228, 154, 162, 1196, 1204, "standard" +471, 13, 31, 229, 163, 164, 1205, 1206, "1" +471, 13, 32, 230, 165, 166, 1207, 1208, "%" +471, 13, 33, 231, 167, 176, 1209, 1218, "carteolol" +471, 13, 34, 232, 177, 185, 1219, 1227, "solution" +471, 13, 35, 233, 186, 191, 1228, 1233, "twice" +471, 13, 36, 234, 192, 197, 1234, 1239, "daily" +471, 13, 37, 235, 198, 201, 1240, 1243, "for" +471, 13, 38, 236, 202, 203, 1244, 1245, "2" +471, 13, 39, 237, 204, 210, 1246, 1252, "months" +471, 13, 40, 238, 211, 212, 1253, 1254, "." +471, 14, 1, 239, 0, 3, 1255, 1258, "The" +471, 14, 2, 240, 4, 11, 1259, 1266, "masking" +471, 14, 3, 241, 12, 15, 1267, 1270, "was" +471, 14, 4, 242, 16, 26, 1271, 1281, "maintained" +471, 14, 5, 243, 27, 34, 1282, 1289, "through" +471, 14, 6, 244, 35, 38, 1290, 1293, "the" +471, 14, 7, 245, 39, 42, 1294, 1297, "use" +471, 14, 8, 246, 43, 45, 1298, 1300, "of" +471, 14, 9, 247, 46, 47, 1301, 1302, "a" +471, 14, 10, 248, 48, 55, 1303, 1310, "placebo" +471, 14, 11, 249, 56, 58, 1311, 1313, "in" +471, 14, 12, 250, 59, 62, 1314, 1317, "the" +471, 14, 13, 251, 63, 70, 1318, 1325, "evening" +471, 14, 14, 252, 71, 74, 1326, 1329, "for" +471, 14, 15, 253, 75, 78, 1330, 1333, "the" +471, 14, 16, 254, 79, 87, 1334, 1342, "alginate" +471, 14, 17, 255, 88, 93, 1343, 1348, "group" +471, 14, 18, 256, 94, 95, 1349, 1350, "." +471, 15, 1, 257, 0, 5, 1351, 1356, "Entry" +471, 15, 2, 258, 6, 10, 1357, 1361, "into" +471, 15, 3, 259, 11, 14, 1362, 1365, "the" +471, 15, 4, 260, 15, 20, 1366, 1371, "study" +471, 15, 5, 261, 21, 29, 1372, 1380, "required" +471, 15, 6, 262, 30, 41, 1381, 1392, "unmedicated" +471, 15, 7, 263, 42, 53, 1393, 1404, "intraocular" +471, 15, 8, 264, 54, 62, 1405, 1413, "pressure" +471, 15, 9, 265, 63, 64, 1414, 1415, "(" +471, 15, 10, 266, 65, 68, 1416, 1419, "IOP" +471, 15, 11, 267, 69, 70, 1420, 1421, ")" +471, 15, 12, 268, 71, 78, 1422, 1429, "between" +471, 15, 13, 269, 79, 81, 1430, 1432, "23" +471, 15, 14, 270, 82, 86, 1433, 1437, "mmHg" +471, 15, 15, 271, 87, 90, 1438, 1441, "and" +471, 15, 16, 272, 91, 93, 1442, 1444, "32" +471, 15, 17, 273, 94, 98, 1445, 1449, "mmHg" +471, 15, 18, 274, 99, 101, 1450, 1452, "at" +471, 15, 19, 275, 102, 103, 1453, 1454, "9" +471, 15, 20, 276, 104, 106, 1455, 1457, "AM" +471, 15, 21, 277, 107, 110, 1458, 1461, "and" +471, 15, 22, 278, 111, 113, 1462, 1464, "11" +471, 15, 23, 279, 114, 116, 1465, 1467, "AM" +471, 15, 24, 280, 117, 118, 1468, 1469, "." +471, 16, 1, 281, 0, 8, 1470, 1478, "Patients" +471, 16, 2, 282, 9, 14, 1479, 1484, "using" +471, 16, 3, 283, 15, 21, 1485, 1491, "ocular" +471, 16, 4, 284, 22, 33, 1492, 1503, "hypotensive" +471, 16, 5, 285, 34, 44, 1504, 1514, "medication" +471, 16, 6, 286, 45, 49, 1515, 1519, "were" +471, 16, 7, 287, 50, 58, 1520, 1528, "required" +471, 16, 8, 288, 59, 61, 1529, 1531, "to" +471, 16, 9, 289, 62, 69, 1532, 1539, "undergo" +471, 16, 10, 290, 70, 71, 1540, 1541, "a" +471, 16, 11, 291, 72, 79, 1542, 1549, "washout" +471, 16, 12, 292, 80, 81, 1550, 1551, "." +471, 17, 1, 293, 0, 3, 1552, 1555, "All" +471, 17, 2, 294, 4, 12, 1556, 1564, "patients" +471, 17, 3, 295, 13, 21, 1565, 1573, "provided" +471, 17, 4, 296, 22, 29, 1574, 1581, "written" +471, 17, 5, 297, 30, 38, 1582, 1590, "informed" +471, 17, 6, 298, 39, 46, 1591, 1598, "consent" +471, 17, 7, 299, 47, 48, 1599, 1600, "." +471, 18, 1, 300, 0, 8, 1601, 1609, "Excluded" +471, 18, 2, 301, 9, 13, 1610, 1614, "from" +471, 18, 3, 302, 14, 17, 1615, 1618, "the" +471, 18, 4, 303, 18, 23, 1619, 1624, "study" +471, 18, 5, 304, 24, 28, 1625, 1629, "were" +471, 18, 6, 305, 29, 37, 1630, 1638, "patients" +471, 18, 7, 306, 38, 42, 1639, 1643, "with" +471, 18, 8, 307, 43, 48, 1644, 1649, "angle" +471, 18, 9, 308, 49, 56, 1650, 1657, "closure" +471, 18, 10, 309, 57, 58, 1658, 1659, "," +471, 18, 11, 310, 59, 69, 1660, 1670, "congenital" +471, 18, 12, 311, 70, 71, 1671, 1672, "," +471, 18, 13, 312, 72, 81, 1673, 1682, "secondary" +471, 18, 14, 313, 82, 90, 1683, 1691, "glaucoma" +471, 18, 15, 314, 91, 93, 1692, 1694, "or" +471, 18, 16, 315, 94, 102, 1695, 1703, "advanced" +471, 18, 17, 316, 103, 111, 1704, 1712, "glaucoma" +471, 18, 18, 317, 112, 113, 1713, 1714, ";" +471, 18, 19, 318, 114, 117, 1715, 1718, "any" +471, 18, 20, 319, 118, 129, 1719, 1730, "intraocular" +471, 18, 21, 320, 130, 139, 1731, 1740, "infection" +471, 18, 22, 321, 140, 142, 1741, 1743, "or" +471, 18, 23, 322, 143, 155, 1744, 1756, "inflammation" +471, 18, 24, 323, 156, 157, 1757, 1758, "," +471, 18, 25, 324, 158, 164, 1759, 1765, "ocular" +471, 18, 26, 325, 165, 171, 1766, 1772, "trauma" +471, 18, 27, 326, 172, 173, 1773, 1774, "," +471, 18, 28, 327, 174, 180, 1775, 1781, "ocular" +471, 18, 29, 328, 181, 188, 1782, 1789, "surgery" +471, 18, 30, 329, 189, 191, 1790, 1792, "or" +471, 18, 31, 330, 192, 197, 1793, 1798, "laser" +471, 18, 32, 331, 198, 213, 1799, 1814, "trabeculoplasty" +471, 18, 33, 332, 214, 220, 1815, 1821, "within" +471, 18, 34, 333, 221, 224, 1822, 1825, "the" +471, 18, 35, 334, 225, 233, 1826, 1834, "previous" +471, 18, 36, 335, 234, 235, 1835, 1836, "3" +471, 18, 37, 336, 236, 242, 1837, 1843, "months" +471, 18, 38, 337, 243, 244, 1844, 1845, ";" +471, 18, 39, 338, 245, 262, 1846, 1863, "contraindications" +471, 18, 40, 339, 263, 265, 1864, 1866, "to" +471, 18, 41, 340, 266, 269, 1867, 1870, "the" +471, 18, 42, 341, 270, 273, 1871, 1874, "use" +471, 18, 43, 342, 274, 276, 1875, 1877, "of" +471, 18, 44, 343, 277, 281, 1878, 1882, "beta" +471, 18, 45, 344, 282, 294, 1883, 1895, "adrenoceptor" +471, 18, 46, 345, 295, 306, 1896, 1907, "antagonists" +471, 18, 47, 346, 307, 308, 1908, 1909, ";" +471, 18, 48, 347, 309, 317, 1910, 1918, "systemic" +471, 18, 49, 348, 318, 329, 1919, 1930, "medications" +471, 18, 50, 349, 330, 336, 1931, 1937, "likely" +471, 18, 51, 350, 337, 339, 1938, 1940, "to" +471, 18, 52, 351, 340, 346, 1941, 1947, "modify" +471, 18, 53, 352, 347, 350, 1948, 1951, "IOP" +471, 18, 54, 353, 351, 361, 1952, 1962, "prescribed" +471, 18, 55, 354, 362, 364, 1963, 1965, "or" +471, 18, 56, 355, 365, 373, 1966, 1974, "modified" +471, 18, 57, 356, 374, 380, 1975, 1981, "during" +471, 18, 58, 357, 381, 384, 1982, 1985, "the" +471, 18, 59, 358, 385, 393, 1986, 1994, "previous" +471, 18, 60, 359, 394, 395, 1995, 1996, "3" +471, 18, 61, 360, 396, 402, 1997, 2003, "months" +471, 18, 62, 361, 403, 404, 2004, 2005, ";" +471, 18, 63, 362, 405, 411, 2006, 2012, "ocular" +471, 18, 64, 363, 412, 419, 2013, 2020, "steroid" +471, 18, 65, 364, 420, 423, 2021, 2024, "use" +471, 18, 66, 365, 424, 425, 2025, 2026, ";" +471, 18, 67, 366, 426, 433, 2027, 2034, "contact" +471, 18, 68, 367, 434, 438, 2035, 2039, "lens" +471, 18, 69, 368, 439, 443, 2040, 2044, "wear" +471, 18, 70, 369, 444, 445, 2045, 2046, ";" +471, 18, 71, 370, 446, 449, 2047, 2050, "and" +471, 18, 72, 371, 450, 458, 2051, 2059, "pregnant" +471, 18, 73, 372, 459, 462, 2060, 2063, "and" +471, 18, 74, 373, 463, 472, 2064, 2073, "lactating" +471, 18, 75, 374, 473, 478, 2074, 2079, "women" +471, 18, 76, 375, 479, 480, 2080, 2081, "." +471, 19, 1, 376, 0, 8, 2082, 2090, "Patients" +471, 19, 2, 377, 9, 13, 2091, 2095, "were" +471, 19, 3, 378, 14, 23, 2096, 2105, "evaluated" +471, 19, 4, 379, 24, 26, 2106, 2108, "at" +471, 19, 5, 380, 27, 35, 2109, 2117, "baseline" +471, 19, 6, 381, 36, 37, 2118, 2119, "," +471, 19, 7, 382, 38, 40, 2120, 2122, "15" +471, 19, 8, 383, 41, 44, 2123, 2126, "and" +471, 19, 9, 384, 45, 47, 2127, 2129, "60" +471, 19, 10, 385, 48, 52, 2130, 2134, "days" +471, 19, 11, 386, 53, 54, 2135, 2136, "," +471, 19, 12, 387, 55, 59, 2137, 2141, "with" +471, 19, 13, 388, 60, 63, 2142, 2145, "IOP" +471, 19, 14, 389, 64, 76, 2146, 2158, "measurements" +471, 19, 15, 390, 77, 79, 2159, 2161, "at" +471, 19, 16, 391, 80, 81, 2162, 2163, "9" +471, 19, 17, 392, 82, 84, 2164, 2166, "AM" +471, 19, 18, 393, 85, 88, 2167, 2170, "and" +471, 19, 19, 394, 89, 91, 2171, 2173, "11" +471, 19, 20, 395, 92, 94, 2174, 2176, "AM" +471, 19, 21, 396, 95, 96, 2177, 2178, "." +471, 20, 1, 397, 0, 2, 2179, 2181, "At" +471, 20, 2, 398, 3, 6, 2182, 2185, "day" +471, 20, 3, 399, 7, 9, 2186, 2188, "15" +471, 20, 4, 400, 10, 13, 2189, 2192, "and" +471, 20, 5, 401, 14, 17, 2193, 2196, "day" +471, 20, 6, 402, 18, 20, 2197, 2199, "60" +471, 20, 7, 403, 21, 22, 2200, 2201, "," +471, 20, 8, 404, 23, 26, 2202, 2205, "IOP" +471, 20, 9, 405, 27, 30, 2206, 2209, "was" +471, 20, 10, 406, 31, 39, 2210, 2218, "measured" +471, 20, 11, 407, 40, 44, 2219, 2223, "just" +471, 20, 12, 408, 45, 51, 2224, 2230, "before" +471, 20, 13, 409, 52, 64, 2231, 2243, "instillation" +471, 20, 14, 410, 65, 67, 2244, 2246, "of" +471, 20, 15, 411, 68, 78, 2247, 2257, "medication" +471, 20, 16, 412, 79, 80, 2258, 2259, "(" +471, 20, 17, 413, 81, 82, 2260, 2261, "9" +471, 20, 18, 414, 83, 85, 2262, 2264, "AM" +471, 20, 19, 415, 86, 87, 2265, 2266, ")" +471, 20, 20, 416, 88, 91, 2267, 2270, "and" +471, 20, 21, 417, 92, 93, 2271, 2272, "2" +471, 20, 22, 418, 94, 99, 2273, 2278, "hours" +471, 20, 23, 419, 100, 105, 2279, 2284, "after" +471, 20, 24, 420, 106, 107, 2285, 2286, "(" +471, 20, 25, 421, 108, 110, 2287, 2289, "11" +471, 20, 26, 422, 111, 113, 2290, 2292, "AM" +471, 20, 27, 423, 114, 115, 2293, 2294, ")" +471, 20, 28, 424, 116, 117, 2295, 2296, "." +471, 21, 1, 425, 0, 4, 2297, 2301, "Slit" +471, 21, 2, 426, 5, 9, 2302, 2306, "lamp" +471, 21, 3, 427, 10, 22, 2307, 2319, "examinations" +471, 21, 4, 428, 23, 27, 2320, 2324, "were" +471, 21, 5, 429, 28, 37, 2325, 2334, "performed" +471, 21, 6, 430, 38, 40, 2335, 2337, "at" +471, 21, 7, 431, 41, 45, 2338, 2342, "each" +471, 21, 8, 432, 46, 52, 2343, 2349, "follow" +471, 21, 9, 433, 53, 54, 2350, 2351, "-" +471, 21, 10, 434, 55, 57, 2352, 2354, "up" +471, 21, 11, 435, 58, 69, 2355, 2366, "examination" +471, 21, 12, 436, 70, 71, 2367, 2368, "," +471, 21, 13, 437, 72, 80, 2369, 2377, "together" +471, 21, 14, 438, 81, 85, 2378, 2382, "with" +471, 21, 15, 439, 86, 97, 2383, 2394, "measurement" +471, 21, 16, 440, 98, 100, 2395, 2397, "of" +471, 21, 17, 441, 101, 106, 2398, 2403, "heart" +471, 21, 18, 442, 107, 111, 2404, 2408, "rate" +471, 21, 19, 443, 112, 115, 2409, 2412, "and" +471, 21, 20, 444, 116, 121, 2413, 2418, "blood" +471, 21, 21, 445, 122, 130, 2419, 2427, "pressure" +471, 21, 22, 446, 131, 132, 2428, 2429, "(" +471, 21, 23, 447, 133, 135, 2430, 2432, "10" +471, 21, 24, 448, 136, 138, 2433, 2435, "AM" +471, 21, 25, 449, 139, 140, 2436, 2437, ")" +471, 21, 26, 450, 141, 144, 2438, 2441, "and" +471, 21, 27, 451, 145, 151, 2442, 2448, "ocular" +471, 21, 28, 452, 152, 161, 2449, 2458, "tolerance" +471, 21, 29, 453, 162, 167, 2459, 2464, "after" +471, 21, 30, 454, 168, 178, 2465, 2475, "medication" +471, 21, 31, 455, 179, 180, 2476, 2477, "(" +471, 21, 32, 456, 181, 183, 2478, 2480, "11" +471, 21, 33, 457, 184, 186, 2481, 2483, "AM" +471, 21, 34, 458, 187, 188, 2484, 2485, ")" +471, 21, 35, 459, 189, 190, 2486, 2487, "." +471, 22, 1, 460, 0, 3, 2488, 2491, "The" +471, 22, 2, 461, 4, 11, 2492, 2499, "primary" +471, 22, 3, 462, 12, 20, 2500, 2508, "efficacy" +471, 22, 4, 463, 21, 30, 2509, 2518, "criterion" +471, 22, 5, 464, 31, 34, 2519, 2522, "was" +471, 22, 6, 465, 35, 38, 2523, 2526, "the" +471, 22, 7, 466, 39, 47, 2527, 2535, "decrease" +471, 22, 8, 467, 48, 50, 2536, 2538, "in" +471, 22, 9, 468, 51, 54, 2539, 2542, "IOP" +471, 22, 10, 469, 55, 59, 2543, 2547, "from" +471, 22, 11, 470, 60, 68, 2548, 2556, "baseline" +471, 22, 12, 471, 69, 71, 2557, 2559, "at" +471, 22, 13, 472, 72, 75, 2560, 2563, "day" +471, 22, 14, 473, 76, 78, 2564, 2566, "60" +471, 22, 15, 474, 79, 82, 2567, 2570, "for" +471, 22, 16, 475, 83, 87, 2571, 2575, "each" +471, 22, 17, 476, 88, 99, 2576, 2587, "measurement" +471, 22, 18, 477, 100, 102, 2588, 2590, "at" +471, 22, 19, 478, 103, 104, 2591, 2592, "9" +471, 22, 20, 479, 105, 107, 2593, 2595, "AM" +471, 22, 21, 480, 108, 111, 2596, 2599, "and" +471, 22, 22, 481, 112, 114, 2600, 2602, "11" +471, 22, 23, 482, 115, 117, 2603, 2605, "AM" +471, 22, 24, 483, 118, 119, 2606, 2607, "." +471, 23, 1, 484, 0, 3, 2608, 2611, "The" +471, 23, 2, 485, 4, 9, 2612, 2617, "study" +471, 23, 3, 486, 10, 13, 2618, 2621, "eye" +471, 23, 4, 487, 14, 17, 2622, 2625, "was" +471, 23, 5, 488, 18, 21, 2626, 2629, "the" +471, 23, 6, 489, 22, 25, 2630, 2633, "eye" +471, 23, 7, 490, 26, 30, 2634, 2638, "with" +471, 23, 8, 491, 31, 34, 2639, 2642, "the" +471, 23, 9, 492, 35, 41, 2643, 2649, "higher" +471, 23, 10, 493, 42, 45, 2650, 2653, "IOP" +471, 23, 11, 494, 46, 48, 2654, 2656, "at" +471, 23, 12, 495, 49, 52, 2657, 2660, "day" +471, 23, 13, 496, 53, 54, 2661, 2662, "0" +471, 23, 14, 497, 55, 57, 2663, 2665, "or" +471, 23, 15, 498, 58, 59, 2666, 2667, "," +471, 23, 16, 499, 60, 62, 2668, 2670, "if" +471, 23, 17, 500, 63, 68, 2671, 2676, "equal" +471, 23, 18, 501, 69, 70, 2677, 2678, "," +471, 23, 19, 502, 71, 74, 2679, 2682, "the" +471, 23, 20, 503, 75, 80, 2683, 2688, "right" +471, 23, 21, 504, 81, 84, 2689, 2692, "eye" +471, 23, 22, 505, 85, 86, 2693, 2694, "." +471, 24, 1, 506, 0, 7, 2695, 2702, "RESULTS" +471, 24, 2, 507, 8, 9, 2703, 2704, ":" +471, 24, 3, 508, 10, 18, 2705, 2713, "Efficacy" +471, 24, 4, 509, 19, 20, 2714, 2715, "-" +471, 24, 5, 510, 21, 23, 2716, 2718, "of" +471, 24, 6, 511, 24, 27, 2719, 2722, "the" +471, 24, 7, 512, 28, 31, 2723, 2726, "151" +471, 24, 8, 513, 32, 40, 2727, 2735, "patients" +471, 24, 9, 514, 41, 49, 2736, 2744, "included" +471, 24, 10, 515, 50, 52, 2745, 2747, "in" +471, 24, 11, 516, 53, 56, 2748, 2751, "the" +471, 24, 12, 517, 57, 62, 2752, 2757, "study" +471, 24, 13, 518, 63, 64, 2758, 2759, "," +471, 24, 14, 519, 65, 68, 2760, 2763, "149" +471, 24, 15, 520, 69, 73, 2764, 2768, "were" +471, 24, 16, 521, 74, 83, 2769, 2778, "evaluated" +471, 24, 17, 522, 84, 85, 2779, 2780, "(" +471, 24, 18, 523, 86, 89, 2781, 2784, "two" +471, 24, 19, 524, 90, 98, 2785, 2793, "patients" +471, 24, 20, 525, 99, 103, 2794, 2798, "were" +471, 24, 21, 526, 104, 108, 2799, 2803, "lost" +471, 24, 22, 527, 109, 111, 2804, 2806, "to" +471, 24, 23, 528, 112, 118, 2807, 2813, "follow" +471, 24, 24, 529, 119, 120, 2814, 2815, "-" +471, 24, 25, 530, 121, 123, 2816, 2818, "up" +471, 24, 26, 531, 124, 129, 2819, 2824, "after" +471, 24, 27, 532, 130, 133, 2825, 2828, "day" +471, 24, 28, 533, 134, 135, 2829, 2830, "0" +471, 24, 29, 534, 136, 137, 2831, 2832, ")" +471, 24, 30, 535, 138, 139, 2833, 2834, ":" +471, 24, 31, 536, 140, 142, 2835, 2837, "74" +471, 24, 32, 537, 143, 145, 2838, 2840, "in" +471, 24, 33, 538, 146, 149, 2841, 2844, "the" +471, 24, 34, 539, 150, 158, 2845, 2853, "alginate" +471, 24, 35, 540, 159, 164, 2854, 2859, "group" +471, 24, 36, 541, 165, 168, 2860, 2863, "and" +471, 24, 37, 542, 169, 171, 2864, 2866, "75" +471, 24, 38, 543, 172, 174, 2867, 2869, "in" +471, 24, 39, 544, 175, 178, 2870, 2873, "the" +471, 24, 40, 545, 179, 187, 2874, 2882, "standard" +471, 24, 41, 546, 188, 193, 2883, 2888, "group" +471, 24, 42, 547, 194, 195, 2889, 2890, "." +471, 25, 1, 548, 0, 4, 2891, 2895, "Both" +471, 25, 2, 549, 5, 14, 2896, 2905, "treatment" +471, 25, 3, 550, 15, 21, 2906, 2912, "groups" +471, 25, 4, 551, 22, 26, 2913, 2917, "were" +471, 25, 5, 552, 27, 37, 2918, 2928, "comparable" +471, 25, 6, 553, 38, 40, 2929, 2931, "at" +471, 25, 7, 554, 41, 44, 2932, 2935, "day" +471, 25, 8, 555, 45, 46, 2936, 2937, "0" +471, 25, 9, 556, 47, 53, 2938, 2944, "except" +471, 25, 10, 557, 54, 57, 2945, 2948, "for" +471, 25, 11, 558, 58, 61, 2949, 2952, "sex" +471, 25, 12, 559, 62, 63, 2953, 2954, "," +471, 25, 13, 560, 64, 73, 2955, 2964, "diastolic" +471, 25, 14, 561, 74, 79, 2965, 2970, "blood" +471, 25, 15, 562, 80, 88, 2971, 2979, "pressure" +471, 25, 16, 563, 89, 90, 2980, 2981, "," +471, 25, 17, 564, 91, 94, 2982, 2985, "and" +471, 25, 18, 565, 95, 98, 2986, 2989, "IOP" +471, 25, 19, 566, 99, 101, 2990, 2992, "in" +471, 25, 20, 567, 102, 105, 2993, 2996, "the" +471, 25, 21, 568, 106, 112, 2997, 3003, "fellow" +471, 25, 22, 569, 113, 116, 3004, 3007, "eye" +471, 25, 23, 570, 117, 118, 3008, 3009, "." +471, 26, 1, 571, 0, 2, 3010, 3012, "At" +471, 26, 2, 572, 3, 5, 3013, 3015, "09" +471, 26, 3, 573, 6, 7, 3016, 3017, "." +471, 26, 4, 574, 8, 10, 3018, 3020, "00" +471, 26, 5, 575, 11, 16, 3021, 3026, "hours" +471, 26, 6, 576, 17, 18, 3027, 3028, "(" +471, 26, 7, 577, 19, 27, 3029, 3037, "presumed" +471, 26, 8, 578, 28, 34, 3038, 3044, "trough" +471, 26, 9, 579, 35, 36, 3045, 3046, ")" +471, 26, 10, 580, 37, 39, 3047, 3049, "on" +471, 26, 11, 581, 40, 43, 3050, 3053, "day" +471, 26, 12, 582, 44, 46, 3054, 3056, "60" +471, 26, 13, 583, 47, 48, 3057, 3058, "," +471, 26, 14, 584, 49, 53, 3059, 3063, "mean" +471, 26, 15, 585, 54, 64, 3064, 3074, "reductions" +471, 26, 16, 586, 65, 69, 3075, 3079, "from" +471, 26, 17, 587, 70, 78, 3080, 3088, "baseline" +471, 26, 18, 588, 79, 81, 3089, 3091, "in" +471, 26, 19, 589, 82, 93, 3092, 3103, "intraocular" +471, 26, 20, 590, 94, 102, 3104, 3112, "pressure" +471, 26, 21, 591, 103, 107, 3113, 3117, "were" +471, 26, 22, 592, 108, 109, 3118, 3119, "6" +471, 26, 23, 593, 110, 111, 3120, 3121, "." +471, 26, 24, 594, 112, 114, 3122, 3124, "32" +471, 26, 25, 595, 115, 116, 3125, 3126, "+" +471, 26, 26, 596, 117, 118, 3127, 3128, "/" +471, 26, 27, 597, 119, 120, 3129, 3130, "-" +471, 26, 28, 598, 121, 122, 3131, 3132, "2" +471, 26, 29, 599, 123, 124, 3133, 3134, "." +471, 26, 30, 600, 125, 127, 3135, 3137, "87" +471, 26, 31, 601, 128, 131, 3138, 3141, "and" +471, 26, 32, 602, 132, 133, 3142, 3143, "5" +471, 26, 33, 603, 134, 135, 3144, 3145, "." +471, 26, 34, 604, 136, 138, 3146, 3148, "67" +471, 26, 35, 605, 139, 140, 3149, 3150, "+" +471, 26, 36, 606, 141, 142, 3151, 3152, "/" +471, 26, 37, 607, 143, 144, 3153, 3154, "-" +471, 26, 38, 608, 145, 146, 3155, 3156, "3" +471, 26, 39, 609, 147, 148, 3157, 3158, "." +471, 26, 40, 610, 149, 151, 3159, 3161, "30" +471, 26, 41, 611, 152, 156, 3162, 3166, "mmHg" +471, 26, 42, 612, 157, 160, 3167, 3170, "for" +471, 26, 43, 613, 161, 164, 3171, 3174, "the" +471, 26, 44, 614, 165, 173, 3175, 3183, "alginate" +471, 26, 45, 615, 174, 183, 3184, 3193, "carteolol" +471, 26, 46, 616, 184, 187, 3194, 3197, "and" +471, 26, 47, 617, 188, 196, 3198, 3206, "standard" +471, 26, 48, 618, 197, 203, 3207, 3213, "groups" +471, 26, 49, 619, 204, 205, 3214, 3215, "," +471, 26, 50, 620, 206, 218, 3216, 3228, "respectively" +471, 26, 51, 621, 219, 220, 3229, 3230, "." +471, 27, 1, 622, 0, 2, 3231, 3233, "At" +471, 27, 2, 623, 3, 5, 3234, 3236, "11" +471, 27, 3, 624, 6, 7, 3237, 3238, "." +471, 27, 4, 625, 8, 10, 3239, 3241, "00" +471, 27, 5, 626, 11, 16, 3242, 3247, "hours" +471, 27, 6, 627, 17, 18, 3248, 3249, "(" +471, 27, 7, 628, 19, 27, 3250, 3258, "presumed" +471, 27, 8, 629, 28, 32, 3259, 3263, "peak" +471, 27, 9, 630, 33, 34, 3264, 3265, ")" +471, 27, 10, 631, 35, 36, 3266, 3267, "," +471, 27, 11, 632, 37, 41, 3268, 3272, "mean" +471, 27, 12, 633, 42, 52, 3273, 3283, "reductions" +471, 27, 13, 634, 53, 57, 3284, 3288, "were" +471, 27, 14, 635, 58, 59, 3289, 3290, "6" +471, 27, 15, 636, 60, 61, 3291, 3292, "." +471, 27, 16, 637, 62, 64, 3293, 3295, "70" +471, 27, 17, 638, 65, 66, 3296, 3297, "+" +471, 27, 18, 639, 67, 68, 3298, 3299, "/" +471, 27, 19, 640, 69, 70, 3300, 3301, "-" +471, 27, 20, 641, 71, 72, 3302, 3303, "2" +471, 27, 21, 642, 73, 74, 3304, 3305, "." +471, 27, 22, 643, 75, 77, 3306, 3308, "81" +471, 27, 23, 644, 78, 81, 3309, 3312, "and" +471, 27, 24, 645, 82, 83, 3313, 3314, "6" +471, 27, 25, 646, 84, 85, 3315, 3316, "." +471, 27, 26, 647, 86, 88, 3317, 3319, "55" +471, 27, 27, 648, 89, 90, 3320, 3321, "+" +471, 27, 28, 649, 91, 92, 3322, 3323, "/" +471, 27, 29, 650, 93, 94, 3324, 3325, "-" +471, 27, 30, 651, 95, 96, 3326, 3327, "3" +471, 27, 31, 652, 97, 98, 3328, 3329, "." +471, 27, 32, 653, 99, 101, 3330, 3332, "35" +471, 27, 33, 654, 102, 106, 3333, 3337, "mmHg" +471, 27, 34, 655, 107, 108, 3338, 3339, "," +471, 27, 35, 656, 109, 121, 3340, 3352, "respectively" +471, 27, 36, 657, 122, 123, 3353, 3354, "." +471, 28, 1, 658, 0, 2, 3355, 3357, "At" +471, 28, 2, 659, 3, 7, 3358, 3362, "each" +471, 28, 3, 660, 8, 18, 3363, 3373, "evaluation" +471, 28, 4, 661, 19, 23, 3374, 3378, "time" +471, 28, 5, 662, 24, 25, 3379, 3380, "," +471, 28, 6, 663, 26, 29, 3381, 3384, "the" +471, 28, 7, 664, 30, 33, 3385, 3388, "two" +471, 28, 8, 665, 34, 44, 3389, 3399, "unilateral" +471, 28, 9, 666, 45, 46, 3400, 3401, "t" +471, 28, 10, 667, 47, 52, 3402, 3407, "tests" +471, 28, 11, 668, 53, 57, 3408, 3412, "were" +471, 28, 12, 669, 58, 64, 3413, 3419, "highly" +471, 28, 13, 670, 65, 76, 3420, 3431, "significant" +471, 28, 14, 671, 77, 78, 3432, 3433, "(" +471, 28, 15, 672, 79, 80, 3434, 3435, "p" +471, 28, 16, 673, 81, 82, 3436, 3437, "<" +471, 28, 17, 674, 83, 84, 3438, 3439, "0" +471, 28, 18, 675, 85, 86, 3440, 3441, "." +471, 28, 19, 676, 87, 90, 3442, 3445, "005" +471, 28, 20, 677, 91, 92, 3446, 3447, ")" +471, 28, 21, 678, 93, 94, 3448, 3449, "," +471, 28, 22, 679, 95, 105, 3450, 3460, "confirming" +471, 28, 23, 680, 106, 109, 3461, 3464, "the" +471, 28, 24, 681, 110, 121, 3465, 3476, "equivalence" +471, 28, 25, 682, 122, 124, 3477, 3479, "of" +471, 28, 26, 683, 125, 129, 3480, 3484, "both" +471, 28, 27, 684, 130, 140, 3485, 3495, "treatments" +471, 28, 28, 685, 141, 142, 3496, 3497, "." +471, 29, 1, 686, 0, 11, 3498, 3509, "Conclusions" +471, 29, 2, 687, 12, 16, 3510, 3514, "were" +471, 29, 3, 688, 17, 20, 3515, 3518, "not" +471, 29, 4, 689, 21, 29, 3519, 3527, "modified" +471, 29, 5, 690, 30, 36, 3528, 3534, "taking" +471, 29, 6, 691, 37, 41, 3535, 3539, "into" +471, 29, 7, 692, 42, 49, 3540, 3547, "account" +471, 29, 8, 693, 50, 53, 3548, 3551, "sex" +471, 29, 9, 694, 54, 57, 3552, 3555, "and" +471, 29, 10, 695, 58, 67, 3556, 3565, "diastolic" +471, 29, 11, 696, 68, 73, 3566, 3571, "blood" +471, 29, 12, 697, 74, 82, 3572, 3580, "pressure" +471, 29, 13, 698, 83, 84, 3581, 3582, "." +471, 30, 1, 699, 0, 6, 3583, 3589, "Safety" +471, 30, 2, 700, 7, 8, 3590, 3591, "-" +471, 30, 3, 701, 9, 15, 3592, 3598, "Slight" +471, 30, 4, 702, 16, 25, 3599, 3608, "decreases" +471, 30, 5, 703, 26, 28, 3609, 3611, "in" +471, 30, 6, 704, 29, 34, 3612, 3617, "heart" +471, 30, 7, 705, 35, 39, 3618, 3622, "rate" +471, 30, 8, 706, 40, 43, 3623, 3626, "and" +471, 30, 9, 707, 44, 49, 3627, 3632, "blood" +471, 30, 10, 708, 50, 58, 3633, 3641, "pressure" +471, 30, 11, 709, 59, 64, 3642, 3647, "means" +471, 30, 12, 710, 65, 69, 3648, 3652, "were" +471, 30, 13, 711, 70, 78, 3653, 3661, "observed" +471, 30, 14, 712, 79, 81, 3662, 3664, "in" +471, 30, 15, 713, 82, 86, 3665, 3669, "both" +471, 30, 16, 714, 87, 93, 3670, 3676, "groups" +471, 30, 17, 715, 94, 96, 3677, 3679, "at" +471, 30, 18, 716, 97, 103, 3680, 3686, "follow" +471, 30, 19, 717, 104, 105, 3687, 3688, "-" +471, 30, 20, 718, 106, 108, 3689, 3691, "up" +471, 30, 21, 719, 109, 115, 3692, 3698, "visits" +471, 30, 22, 720, 116, 120, 3699, 3703, "with" +471, 30, 23, 721, 121, 123, 3704, 3706, "no" +471, 30, 24, 722, 124, 135, 3707, 3718, "significant" +471, 30, 25, 723, 136, 146, 3719, 3729, "difference" +471, 30, 26, 724, 147, 154, 3730, 3737, "between" +471, 30, 27, 725, 155, 161, 3738, 3744, "groups" +471, 30, 28, 726, 162, 163, 3745, 3746, "." +471, 31, 1, 727, 0, 10, 3747, 3757, "Subjective" +471, 31, 2, 728, 11, 20, 3758, 3767, "tolerance" +471, 31, 3, 729, 21, 25, 3768, 3772, "upon" +471, 31, 4, 730, 26, 38, 3773, 3785, "instillation" +471, 31, 5, 731, 39, 42, 3786, 3789, "was" +471, 31, 6, 732, 43, 49, 3790, 3796, "judged" +471, 31, 7, 733, 50, 54, 3797, 3801, "good" +471, 31, 8, 734, 55, 57, 3802, 3804, "or" +471, 31, 9, 735, 58, 62, 3805, 3809, "very" +471, 31, 10, 736, 63, 67, 3810, 3814, "good" +471, 31, 11, 737, 68, 70, 3815, 3817, "at" +471, 31, 12, 738, 71, 74, 3818, 3821, "day" +471, 31, 13, 739, 75, 77, 3822, 3824, "60" +471, 31, 14, 740, 78, 80, 3825, 3827, "by" +471, 31, 15, 741, 81, 84, 3828, 3831, "100" +471, 31, 16, 742, 85, 86, 3832, 3833, "%" +471, 31, 17, 743, 87, 89, 3834, 3836, "of" +471, 31, 18, 744, 90, 98, 3837, 3845, "alginate" +471, 31, 19, 745, 99, 107, 3846, 3854, "patients" +471, 31, 20, 746, 108, 111, 3855, 3858, "and" +471, 31, 21, 747, 112, 114, 3859, 3861, "by" +471, 31, 22, 748, 115, 117, 3862, 3864, "98" +471, 31, 23, 749, 118, 119, 3865, 3866, "." +471, 31, 24, 750, 120, 121, 3867, 3868, "7" +471, 31, 25, 751, 122, 123, 3869, 3870, "%" +471, 31, 26, 752, 124, 126, 3871, 3873, "of" +471, 31, 27, 753, 127, 135, 3874, 3882, "standard" +471, 31, 28, 754, 136, 144, 3883, 3891, "patients" +471, 31, 29, 755, 145, 146, 3892, 3893, "." +471, 32, 1, 756, 0, 9, 3894, 3903, "Transient" +471, 32, 2, 757, 10, 20, 3904, 3914, "discomfort" +471, 32, 3, 758, 21, 22, 3915, 3916, "(" +471, 32, 4, 759, 23, 29, 3917, 3923, "mainly" +471, 32, 5, 760, 30, 38, 3924, 3932, "stinging" +471, 32, 6, 761, 39, 41, 3933, 3935, "or" +471, 32, 7, 762, 42, 49, 3936, 3943, "burning" +471, 32, 8, 763, 50, 59, 3944, 3953, "sensation" +471, 32, 9, 764, 60, 61, 3954, 3955, ")" +471, 32, 10, 765, 62, 65, 3956, 3959, "was" +471, 32, 11, 766, 66, 74, 3960, 3968, "reported" +471, 32, 12, 767, 75, 77, 3969, 3971, "by" +471, 32, 13, 768, 78, 91, 3972, 3985, "approximately" +471, 32, 14, 769, 92, 93, 3986, 3987, "4" +471, 32, 15, 770, 94, 95, 3988, 3989, "%" +471, 32, 16, 771, 96, 97, 3990, 3991, "-" +471, 32, 17, 772, 98, 99, 3992, 3993, "6" +471, 32, 18, 773, 100, 101, 3994, 3995, "%" +471, 32, 19, 774, 102, 104, 3996, 3998, "of" +471, 32, 20, 775, 105, 113, 3999, 4007, "patients" +471, 32, 21, 776, 114, 116, 4008, 4010, "in" +471, 32, 22, 777, 117, 121, 4011, 4015, "each" +471, 32, 23, 778, 122, 131, 4016, 4025, "treatment" +471, 32, 24, 779, 132, 137, 4026, 4031, "group" +471, 32, 25, 780, 138, 140, 4032, 4034, "at" +471, 32, 26, 781, 141, 145, 4035, 4039, "each" +471, 32, 27, 782, 146, 151, 4040, 4045, "visit" +471, 32, 28, 783, 152, 153, 4046, 4047, "." +471, 33, 1, 784, 0, 1, 4048, 4049, "A" +471, 33, 2, 785, 2, 9, 4050, 4057, "blurred" +471, 33, 3, 786, 10, 16, 4058, 4064, "vision" +471, 33, 4, 787, 17, 26, 4065, 4074, "sensation" +471, 33, 5, 788, 27, 30, 4075, 4078, "was" +471, 33, 6, 789, 31, 39, 4079, 4087, "reported" +471, 33, 7, 790, 40, 42, 4088, 4090, "by" +471, 33, 8, 791, 43, 44, 4091, 4092, "2" +471, 33, 9, 792, 45, 48, 4093, 4096, "out" +471, 33, 10, 793, 49, 51, 4097, 4099, "of" +471, 33, 11, 794, 52, 54, 4100, 4102, "74" +471, 33, 12, 795, 55, 63, 4103, 4111, "patients" +471, 33, 13, 796, 64, 66, 4112, 4114, "of" +471, 33, 14, 797, 67, 70, 4115, 4118, "the" +471, 33, 15, 798, 71, 79, 4119, 4127, "alginate" +471, 33, 16, 799, 80, 85, 4128, 4133, "group" +471, 33, 17, 800, 86, 87, 4134, 4135, "." +471, 34, 1, 801, 0, 5, 4136, 4141, "Among" +471, 34, 2, 802, 6, 9, 4142, 4145, "the" +471, 34, 3, 803, 10, 12, 4146, 4148, "17" +471, 34, 4, 804, 13, 21, 4149, 4157, "reported" +471, 34, 5, 805, 22, 29, 4158, 4165, "adverse" +471, 34, 6, 806, 30, 36, 4166, 4172, "events" +471, 34, 7, 807, 37, 38, 4173, 4174, "," +471, 34, 8, 808, 39, 44, 4175, 4180, "three" +471, 34, 9, 809, 45, 49, 4181, 4185, "were" +471, 34, 10, 810, 50, 58, 4186, 4194, "assessed" +471, 34, 11, 811, 59, 61, 4195, 4197, "as" +471, 34, 12, 812, 62, 66, 4198, 4202, "drug" +471, 34, 13, 813, 67, 68, 4203, 4204, "-" +471, 34, 14, 814, 69, 76, 4205, 4212, "related" +471, 34, 15, 815, 77, 78, 4213, 4214, ":" +471, 34, 16, 816, 79, 82, 4215, 4218, "one" +471, 34, 17, 817, 83, 90, 4219, 4226, "vertigo" +471, 34, 18, 818, 91, 92, 4227, 4228, "," +471, 34, 19, 819, 93, 96, 4229, 4232, "one" +471, 34, 20, 820, 97, 108, 4233, 4244, "superficial" +471, 34, 21, 821, 109, 117, 4245, 4253, "punctate" +471, 34, 22, 822, 118, 127, 4254, 4263, "keratitis" +471, 34, 23, 823, 128, 130, 4264, 4266, "in" +471, 34, 24, 824, 131, 134, 4267, 4270, "the" +471, 34, 25, 825, 135, 143, 4271, 4279, "alginate" +471, 34, 26, 826, 144, 149, 4280, 4285, "group" +471, 34, 27, 827, 150, 153, 4286, 4289, "and" +471, 34, 28, 828, 154, 157, 4290, 4293, "one" +471, 34, 29, 829, 158, 166, 4294, 4302, "decrease" +471, 34, 30, 830, 167, 169, 4303, 4305, "in" +471, 34, 31, 831, 170, 175, 4306, 4311, "blood" +471, 34, 32, 832, 176, 184, 4312, 4320, "pressure" +471, 34, 33, 833, 185, 187, 4321, 4323, "in" +471, 34, 34, 834, 188, 191, 4324, 4327, "the" +471, 34, 35, 835, 192, 200, 4328, 4336, "standard" +471, 34, 36, 836, 201, 206, 4337, 4342, "group" +471, 34, 37, 837, 207, 208, 4343, 4344, "." +471, 35, 1, 838, 0, 2, 4345, 4347, "No" +471, 35, 2, 839, 3, 10, 4348, 4355, "serious" +471, 35, 3, 840, 11, 18, 4356, 4363, "adverse" +471, 35, 4, 841, 19, 25, 4364, 4370, "events" +471, 35, 5, 842, 26, 30, 4371, 4375, "were" +471, 35, 6, 843, 31, 39, 4376, 4384, "reported" +471, 35, 7, 844, 40, 41, 4385, 4386, "." +471, 36, 1, 845, 0, 11, 4387, 4398, "CONCLUSIONS" +471, 36, 2, 846, 12, 13, 4399, 4400, ":" +471, 36, 3, 847, 14, 17, 4401, 4404, "The" +471, 36, 4, 848, 18, 21, 4405, 4408, "new" +471, 36, 5, 849, 22, 30, 4409, 4417, "alginate" +471, 36, 6, 850, 31, 42, 4418, 4429, "formulation" +471, 36, 7, 851, 43, 45, 4430, 4432, "of" +471, 36, 8, 852, 46, 50, 4433, 4437, "long" +471, 36, 9, 853, 51, 52, 4438, 4439, "-" +471, 36, 10, 854, 53, 59, 4440, 4446, "acting" +471, 36, 11, 855, 60, 69, 4447, 4456, "carteolol" +471, 36, 12, 856, 70, 71, 4457, 4458, "1" +471, 36, 13, 857, 72, 73, 4459, 4460, "%" +471, 36, 14, 858, 74, 79, 4461, 4466, "given" +471, 36, 15, 859, 80, 84, 4467, 4471, "once" +471, 36, 16, 860, 85, 90, 4472, 4477, "daily" +471, 36, 17, 861, 91, 93, 4478, 4480, "is" +471, 36, 18, 862, 94, 96, 4481, 4483, "as" +471, 36, 19, 863, 97, 106, 4484, 4493, "effective" +471, 36, 20, 864, 107, 109, 4494, 4496, "as" +471, 36, 21, 865, 110, 118, 4497, 4505, "standard" +471, 36, 22, 866, 119, 120, 4506, 4507, "1" +471, 36, 23, 867, 121, 122, 4508, 4509, "%" +471, 36, 24, 868, 123, 132, 4510, 4519, "carteolol" +471, 36, 25, 869, 133, 138, 4520, 4525, "given" +471, 36, 26, 870, 139, 144, 4526, 4531, "twice" +471, 36, 27, 871, 145, 150, 4532, 4537, "daily" +471, 36, 28, 872, 151, 152, 4538, 4539, "," +471, 36, 29, 873, 153, 157, 4540, 4544, "with" +471, 36, 30, 874, 158, 160, 4545, 4547, "no" +471, 36, 31, 875, 161, 171, 4548, 4558, "meaningful" +471, 36, 32, 876, 172, 183, 4559, 4570, "differences" +471, 36, 33, 877, 184, 193, 4571, 4580, "regarding" +471, 36, 34, 878, 194, 200, 4581, 4587, "safety" +471, 36, 35, 879, 201, 202, 4588, 4589, "." +471, 37, 1, 880, 0, 4, 4590, 4594, "This" +471, 37, 2, 881, 5, 13, 4595, 4603, "efficacy" +471, 37, 3, 882, 14, 18, 4604, 4608, "wasy" +471, 37, 4, 883, 19, 22, 4609, 4612, "was" +471, 37, 5, 884, 23, 31, 4613, 4621, "verified" +471, 37, 6, 885, 32, 34, 4622, 4624, "at" +471, 37, 7, 886, 35, 36, 4625, 4626, "9" +471, 37, 8, 887, 37, 39, 4627, 4629, "AM" +471, 37, 9, 888, 40, 41, 4630, 4631, "(" +471, 37, 10, 889, 42, 44, 4632, 4634, "24" +471, 37, 11, 890, 45, 50, 4635, 4640, "hours" +471, 37, 12, 891, 51, 56, 4641, 4646, "after" +471, 37, 13, 892, 57, 60, 4647, 4650, "the" +471, 37, 14, 893, 61, 65, 4651, 4655, "last" +471, 37, 15, 894, 66, 70, 4656, 4660, "drop" +471, 37, 16, 895, 71, 73, 4661, 4663, "of" +471, 37, 17, 896, 74, 78, 4664, 4668, "long" +471, 37, 18, 897, 79, 80, 4669, 4670, "-" +471, 37, 19, 898, 81, 87, 4671, 4677, "acting" +471, 37, 20, 899, 88, 97, 4678, 4687, "carteolol" +471, 37, 21, 900, 98, 100, 4688, 4690, "or" +471, 37, 22, 901, 101, 103, 4691, 4693, "12" +471, 37, 23, 902, 104, 109, 4694, 4699, "hours" +471, 37, 24, 903, 110, 115, 4700, 4705, "after" +471, 37, 25, 904, 116, 120, 4706, 4710, "that" +471, 37, 26, 905, 121, 123, 4711, 4713, "of" +471, 37, 27, 906, 124, 132, 4714, 4722, "standard" +471, 37, 28, 907, 133, 142, 4723, 4732, "carteolol" +471, 37, 29, 908, 143, 144, 4733, 4734, ")" +471, 37, 30, 909, 145, 148, 4735, 4738, "and" +471, 37, 31, 910, 149, 151, 4739, 4741, "at" +471, 37, 32, 911, 152, 154, 4742, 4744, "11" +471, 37, 33, 912, 155, 157, 4745, 4747, "AM" +471, 37, 34, 913, 158, 159, 4748, 4749, "(" +471, 37, 35, 914, 160, 161, 4750, 4751, "2" +471, 37, 36, 915, 162, 167, 4752, 4757, "hours" +471, 37, 37, 916, 168, 173, 4758, 4763, "after" +471, 37, 38, 917, 174, 177, 4764, 4767, "the" +471, 37, 39, 918, 178, 185, 4768, 4775, "morning" +471, 37, 40, 919, 186, 190, 4776, 4780, "drop" +471, 37, 41, 920, 191, 192, 4781, 4782, ")" +471, 37, 42, 921, 193, 194, 4783, 4784, "." +471, 38, 1, 922, 0, 3, 4785, 4788, "The" +471, 38, 2, 923, 4, 7, 4789, 4792, "new" +471, 38, 3, 924, 8, 16, 4793, 4801, "alginate" +471, 38, 4, 925, 17, 28, 4802, 4813, "formulation" +471, 38, 5, 926, 29, 31, 4814, 4816, "of" +471, 38, 6, 927, 32, 36, 4817, 4821, "long" +471, 38, 7, 928, 37, 38, 4822, 4823, "-" +471, 38, 8, 929, 39, 45, 4824, 4830, "acting" +471, 38, 9, 930, 46, 55, 4831, 4840, "carteolol" +471, 38, 10, 931, 56, 57, 4841, 4842, "1" +471, 38, 11, 932, 58, 59, 4843, 4844, "%" +471, 38, 12, 933, 60, 65, 4845, 4850, "given" +471, 38, 13, 934, 66, 70, 4851, 4855, "once" +471, 38, 14, 935, 71, 72, 4856, 4857, "a" +471, 38, 15, 936, 73, 76, 4858, 4861, "day" +471, 38, 16, 937, 77, 79, 4862, 4864, "is" +471, 38, 17, 938, 80, 89, 4865, 4874, "effective" +471, 38, 18, 939, 90, 93, 4875, 4878, "and" +471, 38, 19, 940, 94, 98, 4879, 4883, "well" +471, 38, 20, 941, 99, 108, 4884, 4893, "tolerated" +471, 38, 21, 942, 109, 111, 4894, 4896, "by" +471, 38, 22, 943, 112, 120, 4897, 4905, "glaucoma" +471, 38, 23, 944, 121, 129, 4906, 4914, "patients" +471, 38, 24, 945, 130, 133, 4915, 4918, "who" +471, 38, 25, 946, 134, 141, 4919, 4926, "require" +471, 38, 26, 947, 142, 149, 4927, 4934, "chronic" +471, 38, 27, 948, 150, 159, 4935, 4944, "treatment" +471, 38, 28, 949, 160, 161, 4945, 4946, "." +471, 39, 1, 950, 0, 4, 4947, 4951, "PMID" +471, 39, 2, 951, 5, 6, 4952, 4953, ":" +471, 39, 3, 952, 7, 15, 4954, 4962, "12660585" +471, 39, 4, 953, 16, 17, 4963, 4964, "[" +471, 39, 5, 954, 18, 25, 4965, 4972, "Indexed" +471, 39, 6, 955, 26, 29, 4973, 4976, "for" +471, 39, 7, 956, 30, 37, 4977, 4984, "MEDLINE" +471, 39, 8, 957, 38, 39, 4985, 4986, "]" diff --git a/data/gl 12660585_jshahinitiran.annodb b/data/gl 12660585_jshahinitiran.annodb new file mode 100644 index 0000000..f11dd12 --- /dev/null +++ b/data/gl 12660585_jshahinitiran.annodb @@ -0,0 +1,125 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7189, Journal, 0, 14, "J Fr Ophtalmol", "", +7191, PublicationYear, 17, 21, "2003", "", +7192, Title, 51, 112, "Efficacy and safety of long - acting carteolol 1 % once daily", "", +10395, Drug, 74, 97, "long - acting carteolol", "", +7195, Percentage, 100, 101, "%", "", +7196, Frequency, 102, 112, "once daily", "", +7197, DoubleBlind, 117, 132, "double - masked", "", +26357, Randomized, 135, 145, "randomized", "", +7199, Author, 178, 189, "Trinquand C", "", +7200, Author, 198, 208, "Romanet JP", "", +7201, Author, 211, 222, "Nordmann JP", "", +7202, Author, 225, 234, "Allaire C", "", +7203, France, 335, 341, "France", "", +7204, ObjectiveDescription, 354, 441, "Carteolol is a beta - adrenoceptor antagonist with intrinsic sympathomimetic activity .", "", +10389, Carteolol, 354, 363, "Carteolol", "", +7205, ObjectiveDescription, 442, 527, "Used topically to reduce intraocular pressure , it is typically applied twice daily .", "", +7210, IOP, 467, 487, "intraocular pressure", "", +26358, Frequency, 514, 525, "twice daily", "", +7206, ObjectiveDescription, 528, 632, "In an effort to provide a once - daily dosing regimen , carteolol was formulated with 1 % alginic acid .", "", +10387, Frequency, 554, 566, "once - daily", "", +10390, Carteolol, 584, 593, "carteolol", "", +26359, DoseValue, 614, 615, "1", "", +26360, Percentage, 616, 617, "%", "", +7207, ObjectiveDescription, 633, 802, "Sodium alginate is a natural polymer product with bioadhesive properties providing increased corneal contact time and a better carteolol penetration through the cornea .", "", +10388, Carteolol, 760, 769, "carteolol", "", +7208, ObjectiveDescription, 803, 965, "The objective of this study was to evaluate the efficacy and safety of long - acting 1 % carteolol alginate solution compared to standard 1 % carteolol solution .", "", +26361, DoseValue, 888, 889, "1", "", +26362, Percentage, 890, 891, "%", "", +10396, Drug, 892, 910, "carteolol alginate", "", +26363, DoseValue, 941, 942, "1", "", +26364, Percentage, 943, 944, "%", "", +10391, Carteolol, 945, 954, "carteolol", "", +7218, DoubleBlind, 987, 1002, "double - masked", "", +7219, Parallel, 1005, 1013, "parallel", "", +7220, Multicenter, 1022, 1033, "multicentre", "", +7221, OcularHypertension, 1056, 1075, "ocular hypertension", "", +7222, OpenAngleGlaucoma, 1079, 1098, "open angle glaucoma", "", +7223, NumberPatientsCT, 1105, 1108, "151", "", +26369, Randomized, 1116, 1124, "randomly", "", +26365, DoseValue, 1152, 1153, "1", "", +26367, Percentage, 1154, 1155, "%", "", +10397, Drug, 1156, 1174, "carteolol alginate", "", +7228, Frequency, 1175, 1185, "once daily", "", +26366, DoseValue, 1205, 1206, "1", "", +26368, Percentage, 1207, 1208, "%", "", +10392, Carteolol, 1209, 1218, "carteolol", "", +7234, Frequency, 1228, 1239, "twice daily", "", +7235, Duration, 1244, 1252, "2 months", "", +7236, Placebo, 1303, 1310, "placebo", "", +7237, Precondition, 1381, 1469, "unmedicated intraocular pressure ( IOP ) between 23 mmHg and 32 mmHg at 9 AM and 11 AM .", "", +7238, IOP, 1393, 1413, "intraocular pressure", "", +7239, IOP, 1416, 1419, "IOP", "", +7240, mmHg, 1433, 1437, "mmHg", "", +7241, mmHg, 1445, 1449, "mmHg", "", +26370, AngleClosureGlaucoma, 1644, 1657, "angle closure", "", +26371, Glaucoma, 1660, 1670, "congenital", "congenital", +26372, Secondary_AngleClosureGlaucoma, 1673, 1691, "secondary glaucoma", "", +26373, Secondary_OpenAngleGlaucoma, 1673, 1691, "secondary glaucoma", "", +26374, Glaucoma, 1695, 1712, "advanced glaucoma", "advanced", +7242, IOP, 1948, 1951, "IOP", "", +39057, TimePoint, 2109, 2117, "baseline", "", +39058, TimePoint, 2120, 2134, "15 and 60 days", "", +39059, TimePoint, 2127, 2134, "60 days", "", +7243, IOP, 2142, 2145, "IOP", "", +39060, TimePoint, 2182, 2188, "day 15", "", +39061, TimePoint, 2193, 2199, "day 60", "", +7268, HeartRate, 2398, 2408, "heart rate", "", +7269, BloodPressure, 2413, 2427, "blood pressure", "", +7244, IOP, 2539, 2542, "IOP", "", +26375, IOP, 2650, 2653, "IOP", "advanced", +39062, TimePoint, 2657, 2662, "day 0", "", +7223, NumberPatientsCT, 2723, 2726, "151", "", +10384, FinalNumPatientsCT, 2760, 2763, "149", "", +10385, NumPatientsLeftCT, 2781, 2784, "two", "", +7246, NumberPatientsArm, 2835, 2837, "74", "", +7247, NumberPatientsArm, 2864, 2866, "75", "", +10386, BloodPressure, 2965, 2979, "blood pressure", "", +7259, IOP, 2986, 2989, "IOP", "", +7265, Trough_IOP, 3038, 3044, "trough", "", +7248, TimePoint, 3050, 3056, "day 60", "", +7249, Mean, 3059, 3063, "mean", "", +7258, Trough_IOP, 3092, 3112, "intraocular pressure", "", +7251, Reduction, 3118, 3124, "6 . 32", "", +7252, SdErrorChangeValue, 3131, 3137, "2 . 87", "", +7254, Reduction, 3142, 3148, "5 . 67", "", +7255, SdErrorChangeValue, 3155, 3161, "3 . 30", "", +7256, mmHg, 3162, 3166, "mmHg", "", +10398, Drug, 3175, 3193, "alginate carteolol", "", +7266, Peak_IOP, 3259, 3263, "peak", "", +7257, Mean, 3268, 3272, "mean", "", +7260, Reduction, 3289, 3295, "6 . 70", "", +7262, SdErrorChangeValue, 3302, 3308, "2 . 81", "", +7261, Reduction, 3313, 3319, "6 . 55", "", +7263, SdErrorChangeValue, 3326, 3332, "3 . 35", "", +7264, mmHg, 3333, 3337, "mmHg", "", +7267, PValueChangeValue, 3434, 3445, "p < 0 . 005", "", +7270, BloodPressure, 3566, 3580, "blood pressure", "", +7273, ObservedResult, 3592, 3746, "Slight decreases in heart rate and blood pressure means were observed in both groups at follow - up visits with no significant difference between groups .", "", +7272, HeartRate, 3612, 3622, "heart rate", "", +7271, BloodPressure, 3627, 3641, "blood pressure", "", +7274, NumberAffected, 4091, 4092, "2", "", +26376, NumberPatientsArm, 4100, 4102, "74", "advanced", +7276, NumberAffected, 4215, 4218, "one", "", +7278, NumberAffected, 4229, 4232, "one", "", +7279, NumberAffected, 4290, 4293, "one", "", +26377, BloodPressure, 4306, 4320, "blood pressure", "advanced", +7282, ConclusionComment, 4401, 4589, "The new alginate formulation of long - acting carteolol 1 % given once daily is as effective as standard 1 % carteolol given twice daily , with no meaningful differences regarding safety .", "", +10399, Drug, 4409, 4456, "alginate formulation of long - acting carteolol", "", +7290, DoseValue, 4457, 4458, "1", "", +7292, Percentage, 4459, 4460, "%", "", +7294, Frequency, 4467, 4477, "once daily", "", +7291, DoseValue, 4506, 4507, "1", "", +7293, Percentage, 4508, 4509, "%", "", +10393, Carteolol, 4510, 4519, "carteolol", "", +7295, Frequency, 4526, 4537, "twice daily", "", +7283, ConclusionComment, 4590, 4784, "This efficacy wasy was verified at 9 AM ( 24 hours after the last drop of long - acting carteolol or 12 hours after that of standard carteolol ) and at 11 AM ( 2 hours after the morning drop ) .", "", +10394, Carteolol, 4723, 4732, "carteolol", "", +7284, ConclusionComment, 4785, 4946, "The new alginate formulation of long - acting carteolol 1 % given once a day is effective and well tolerated by glaucoma patients who require chronic treatment .", "", +10400, Drug, 4793, 4840, "alginate formulation of long - acting carteolol", "", +7297, DoseValue, 4841, 4842, "1", "", +7298, Percentage, 4843, 4844, "%", "", +7299, Frequency, 4851, 4861, "once a day", "", +7300, Glaucoma, 4897, 4905, "glaucoma", "", +7285, PMID, 4954, 4962, "12660585", "", diff --git a/data/gl 12660585_jshahinitiran.n-triples b/data/gl 12660585_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12660585_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12660585_tstrakeljahn.annodb b/data/gl 12660585_tstrakeljahn.annodb new file mode 100644 index 0000000..3ca1a2b --- /dev/null +++ b/data/gl 12660585_tstrakeljahn.annodb @@ -0,0 +1,134 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +55501, Journal, 0, 14, "J Fr Ophtalmol", "", +55502, PublicationYear, 17, 21, "2003", "", +55510, Title, 51, 114, "Efficacy and safety of long - acting carteolol 1 % once daily .", "", +55503, DoubleBlind, 117, 132, "double - masked", "", +55504, Randomized, 135, 145, "randomized", "", +55505, Author, 178, 189, "Trinquand C", "", +55506, Author, 198, 208, "Romanet JP", "", +55507, Author, 211, 222, "Nordmann JP", "", +55508, Author, 225, 234, "Allaire C", "", +55509, France, 335, 341, "France", "", +55512, IOP, 467, 487, "intraocular pressure", "", +55511, Frequency, 514, 525, "twice daily", "", +55513, Frequency, 554, 566, "once - daily", "", +55514, Carteolol, 584, 593, "carteolol", "", +55515, DoseValue, 614, 615, "1", "", +55516, Percentage, 616, 617, "%", "", +55523, ObjectiveDescription, 803, 965, "The objective of this study was to evaluate the efficacy and safety of long - acting 1 % carteolol alginate solution compared to standard 1 % carteolol solution .", "", +55517, DoseValue, 888, 889, "1", "", +55518, Percentage, 890, 891, "%", "", +55807, Drug, 892, 919, "carteolol alginate solution", "", +55520, DoseValue, 941, 942, "1", "", +55521, Percentage, 943, 944, "%", "", +55522, Carteolol, 945, 963, "carteolol solution", "", +55524, DoubleBlind, 987, 1002, "double - masked", "", +55525, Parallel, 1005, 1019, "parallel group", "", +55526, Multicenter, 1022, 1033, "multicentre", "", +55527, OcularHypertension, 1056, 1075, "ocular hypertension", "", +55528, OpenAngleGlaucoma, 1079, 1098, "open angle glaucoma", "", +55529, NumberPatientsCT, 1105, 1108, "151", "", +55530, Randomized, 1116, 1124, "randomly", "", +55531, DoseValue, 1152, 1153, "1", "", +55532, Percentage, 1154, 1155, "%", "", +55806, Drug, 1156, 1174, "carteolol alginate", "", +55534, Frequency, 1175, 1185, "once daily", "", +55535, Morning, 1188, 1190, "AM", "", +55536, DoseValue, 1205, 1206, "1", "", +55537, Percentage, 1207, 1208, "%", "", +55538, Carteolol, 1209, 1227, "carteolol solution", "", +55539, Frequency, 1228, 1239, "twice daily", "", +55540, Duration, 1244, 1252, "2 months", "", +55541, Placebo, 1303, 1310, "placebo", "", +55542, Evening, 1311, 1325, "in the evening", "", +55805, Drug, 1334, 1342, "alginate", "", +55544, IOP, 1393, 1413, "intraocular pressure", "", +55545, IOP, 1416, 1419, "IOP", "", +55546, mmHg, 1433, 1437, "mmHg", "", +55547, mmHg, 1445, 1449, "mmHg", "", +55548, TimePoint, 1453, 1457, "9 AM", "", +55549, TimePoint, 1462, 1467, "11 AM", "", +55550, Precondition, 1470, 1551, "Patients using ocular hypotensive medication were required to undergo a washout .", "", +55554, Precondition, 1601, 1845, "Excluded from the study were patients with angle closure , congenital , secondary glaucoma or advanced glaucoma ; any intraocular infection or inflammation , ocular trauma , ocular surgery or laser trabeculoplasty within the previous 3 months ;", "", +55551, AngleClosureGlaucoma, 1644, 1657, "angle closure", "", +55552, Glaucoma, 1683, 1691, "glaucoma", "", +55553, Glaucoma, 1704, 1712, "glaucoma", "", +55555, Precondition, 1846, 2081, "contraindications to the use of beta adrenoceptor antagonists ; systemic medications likely to modify IOP prescribed or modified during the previous 3 months ; ocular steroid use ; contact lens wear ; and pregnant and lactating women .", "", +55564, TimePoint, 2109, 2117, "baseline", "", +55565, TimePoint, 2120, 2134, "15 and 60 days", "", +55566, TimePoint, 2127, 2134, "60 days", "", +55556, IOP, 2142, 2145, "IOP", "", +55567, TimePoint, 2162, 2166, "9 AM", "", +55568, TimePoint, 2171, 2176, "11 AM", "", +55558, TimePoint, 2182, 2188, "day 15", "", +55559, TimePoint, 2193, 2199, "day 60", "", +55560, IOP, 2202, 2205, "IOP", "", +55561, RelativeTime, 2219, 2257, "just before instillation of medication", "", +55562, TimePoint, 2260, 2264, "9 AM", "", +55557, RelativeTime, 2271, 2284, "2 hours after", "", +55563, TimePoint, 2287, 2292, "11 AM", "", +55569, HeartRate, 2398, 2408, "heart rate", "", +55570, BloodPressure, 2413, 2427, "blood pressure", "", +55571, TimePoint, 2430, 2435, "10 AM", "", +55573, RelativeTime, 2459, 2475, "after medication", "", +55572, TimePoint, 2478, 2483, "11 AM", "", +55578, Endpoint, 2488, 2607, "The primary efficacy criterion was the decrease in IOP from baseline at day 60 for each measurement at 9 AM and 11 AM .", "", +55574, IOP, 2539, 2542, "IOP", "", +55575, TimePoint, 2560, 2566, "day 60", "", +55576, TimePoint, 2591, 2595, "9 AM", "", +55577, TimePoint, 2600, 2605, "11 AM", "", +55799, CTDesign, 2608, 2694, "The study eye was the eye with the higher IOP at day 0 or , if equal , the right eye .", "", +55800, NumberPatientsCT, 2723, 2726, "151", "", +55801, FinalNumPatientsCT, 2760, 2763, "149", "", +55802, FinalNumPatientsArm, 2835, 2837, "74", "", +55804, Drug, 2845, 2853, "alginate", "", +55803, FinalNumPatientsArm, 2864, 2866, "75", "", +55808, BloodPressure, 2965, 2979, "blood pressure", "", +55809, IOP, 2986, 2989, "IOP", "", +55810, TimePoint, 3013, 3020, "09 . 00", "", +55812, Trough_IOP, 3038, 3044, "trough", "", +55861, Reduction, 3118, 3124, "6 . 32", "", +55863, SdDevChangeValue, 3125, 3137, "+ / - 2 . 87", "", +55859, Reduction, 3142, 3148, "5 . 67", "", +55864, SdDevChangeValue, 3149, 3161, "+ / - 3 . 30", "", +55818, mmHg, 3162, 3166, "mmHg", "", +55820, Drug, 3175, 3193, "alginate carteolol", "", +55811, TimePoint, 3234, 3241, "11 . 00", "", +55813, Peak_IOP, 3259, 3263, "peak", "", +55860, Reduction, 3289, 3295, "6 . 70", "", +55865, SdDevChangeValue, 3302, 3308, "2 . 81", "", +55862, Reduction, 3313, 3319, "6 . 55", "", +55868, SdDevChangeValue, 3326, 3332, "3 . 35", "", +55819, mmHg, 3333, 3337, "mmHg", "", +55824, PvalueDiff, 3434, 3445, "p < 0 . 005", "", +55825, HeartRate, 3612, 3622, "heart rate", "", +55826, BloodPressure, 3627, 3641, "blood pressure", "", +55827, Mean, 3642, 3647, "means", "", +55828, TimePoint, 3818, 3824, "day 60", "", +55829, PercentageAffected, 3828, 3831, "100", "", +55830, PercentageAffected, 3862, 3868, "98 . 7", "", +55831, Stinging, 3924, 3932, "stinging", "", +55834, NumberAffected, 4091, 4092, "2", "", +55832, FinalNumPatientsArm, 4100, 4102, "74", "", +55833, Drug, 4119, 4127, "alginate", "", +55838, NumberAffected, 4146, 4148, "17", "", +55839, Drug, 4271, 4279, "alginate", "", +55840, BloodPressure, 4306, 4320, "blood pressure", "", +55841, ObservedResult, 4345, 4384, "No serious adverse events were reported", "", +55856, ConclusionComment, 4401, 4589, "The new alginate formulation of long - acting carteolol 1 % given once daily is as effective as standard 1 % carteolol given twice daily , with no meaningful differences regarding safety .", "", +55842, Drug, 4433, 4456, "long - acting carteolol", "", +55846, DoseValue, 4457, 4458, "1", "", +55848, Percentage, 4459, 4460, "%", "", +55844, Frequency, 4467, 4477, "once daily", "", +55847, DoseValue, 4506, 4507, "1", "", +55849, Percentage, 4508, 4509, "%", "", +55843, Carteolol, 4510, 4519, "carteolol", "", +55845, Frequency, 4526, 4537, "twice daily", "", +55857, ConclusionComment, 4590, 4784, "This efficacy wasy was verified at 9 AM ( 24 hours after the last drop of long - acting carteolol or 12 hours after that of standard carteolol ) and at 11 AM ( 2 hours after the morning drop ) .", "", +55858, ConclusionComment, 4785, 4946, "The new alginate formulation of long - acting carteolol 1 % given once a day is effective and well tolerated by glaucoma patients who require chronic treatment .", "", +55850, Drug, 4793, 4840, "alginate formulation of long - acting carteolol", "", +55851, DoseValue, 4841, 4842, "1", "", +55852, Percentage, 4843, 4844, "%", "", +55853, Frequency, 4851, 4861, "once a day", "", +55854, Glaucoma, 4897, 4905, "glaucoma", "", +55855, PMID, 4954, 4962, "12660585", "", diff --git a/data/gl 12660585_tstrakeljahn.n-triples b/data/gl 12660585_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12660585_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12780402_admin.annodb b/data/gl 12780402_admin.annodb new file mode 100644 index 0000000..9838830 --- /dev/null +++ b/data/gl 12780402_admin.annodb @@ -0,0 +1,71 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "Acta Ophthalmol Scand .", "", " \"Acta Ophthalmol Scand .\"." +1, PublicationYear, 24, 28, "2003", "", " \"2003\"." +12, Title, 56, 185, "Efficacy and safety of timolol maleate / latanoprost fixed combination versus timolol maleate and brimonidine given twice daily .", "", " \"Efficacy and safety of timolol maleate / latanoprost fixed combination versus timolol maleate and brimonidine given twice daily .\"." +2, Timolol, 79, 94, "timolol maleate", "", +71, Lat/TimFC, 79, 126, "timolol maleate / latanoprost fixed combination", "", +3, Latanoprost, 97, 108, "latanoprost", "", +5, Timolol, 134, 149, "timolol maleate", "", +6, Brimonidine, 154, 165, "brimonidine", "", +7, Frequency, 172, 183, "twice daily", "", +8, Author, 186, 196, "Stewart WC", "", " \"Stewart WC\"." +9, Author, 205, 215, "Stewart JA", "", " \"Stewart JA\"." +10, Author, 218, 223, "Day D", "", " \"Day D\"." +11, Author, 226, 235, "Sharpe ED", "", " \"Sharpe ED\"." +13, USA, 348, 351, "USA", "", +80, ObjectiveDescription, 387, 510, "To evaluate the efficacy and safety of the timolol maleate / latanoprost fixed combination ( TLFC ) given once each evening", "", " \"To evaluate the efficacy and safety of the timolol maleate / latanoprost fixed combination ( TLFC ) given once each evening\"." +14, Timolol, 430, 445, "timolol maleate", "", +84, Lat/TimFC, 430, 477, "timolol maleate / latanoprost fixed combination", "", " ." +15, Latanoprost, 448, 459, "latanoprost", "", +16, Lat/TimFC, 480, 484, "TLFC", "", +86, Frequency, 493, 510, "once each evening", "", " \"once each evening\"." +81, ObjectiveDescription, 511, 658, "versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open - angle glaucoma or ocular hypertension patients .", "", " \"versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open - angle glaucoma or ocular hypertension patients .\"." +20, Brimonidine, 518, 529, "brimonidine", "", " ." +21, Timolol, 534, 541, "timolol", "", " ." +22, Frequency, 557, 568, "twice daily", "", " \"twice daily\"." +23, Primary_OpenAngleGlaucoma, 595, 624, "primary open - angle glaucoma", "", " ." +24, OcularHypertension, 628, 647, "ocular hypertension", "", " ." +25, Timolol, 702, 709, "timolol", "", +26, Frequency, 716, 727, "twice daily", "", +95, Duration, 732, 739, "1 month", "", +27, Randomized, 749, 759, "randomized", "", " ." +28, Lat/TimFC, 770, 774, "TLFC", "", +29, Brimonidine, 778, 789, "brimonidine", "", +30, Timolol, 794, 801, "timolol", "", +100, Duration, 826, 833, "6 weeks", "", " \"6 weeks\"." +31, IOP, 897, 918, "Intraocular pressures", "", +32, IOP, 921, 925, "IOPs", "", +103, TimePoint, 993, 1001, "baseline", "", +34, TimePoint, 1013, 1029, "end of periods 1", "", +35, TimePoint, 1013, 1035, "end of periods 1 and 2", "", +106, NumberPatientsCT, 1073, 1075, "32", "", " \"32\"." +37, Diurnal_IOP, 1089, 1106, "IOP diurnal curve", "", " ." +38, Timolol, 1110, 1117, "timolol", "", +39, BaseLineValue, 1126, 1132, "20 . 9", "", " \"20 . 9\". \"20 . 9\"." +40, SdDevBL, 1139, 1144, "2 . 8", "", " \"2 . 8\". \"2 . 8\"." +43, mmHg, 1145, 1149, "mmHg", "", " ." +41, ResultMeasuredValue, 1165, 1171, "17 . 9", "", " \"17 . 9\"." +45, SdDevResValue, 1178, 1183, "3 . 2", "", " \"3 . 2\"." +44, mmHg, 1184, 1188, "mmHg", "", +50, Lat/TimFC, 1221, 1225, "TLFC", "", +42, ResultMeasuredValue, 1233, 1239, "19 . 0", "", " \"19 . 0\"." +46, SdDevResValue, 1246, 1251, "2 . 4", "", " \"2 . 4\"." +47, mmHg, 1252, 1256, "mmHg", "", +48, Brimonidine, 1289, 1300, "brimonidine", "", +49, Timolol, 1305, 1312, "timolol", "", +51, PvalueDiff, 1317, 1325, "= 0 . 02", "", " \"= 0 . 02\"." +52, IOP, 1330, 1351, "Intraocular pressures", "", +54, Lat/TimFC, 1521, 1525, "TLFC", "", +55, IOP, 1580, 1584, "IOPs", "", +126, PvalueDiff, 1686, 1706, "p & lt ; or = 0 . 05", "", +57, ObservedResult, 1711, 1802, "The incidence of both solicited and unsolicited side - effects was similar between groups .", "", +100308, EndPointDescription, 1759, 1773, "side - effects", "", +64, ConclusionComment, 1816, 1971, "This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily .", "", " \"This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily .\"." +58, Lat/TimFC, 1841, 1845, "TLFC", "", +130, Evening, 1859, 1866, "evening", "", " ." +59, Mean, 1879, 1883, "mean", "", +60, Diurnal_IOP, 1892, 1903, "diurnal IOP", "", +61, Brimonidine, 1914, 1925, "brimonidine", "", +62, Timolol, 1930, 1937, "timolol", "", +63, Frequency, 1958, 1969, "twice daily", "", +65, PMID, 2032, 2040, "12780402", "", " \"12780402\"." diff --git a/data/gl 12780402_admin.n-triples b/data/gl 12780402_admin.n-triples new file mode 100644 index 0000000..389fef3 --- /dev/null +++ b/data/gl 12780402_admin.n-triples @@ -0,0 +1,104 @@ +# RDF export of group: Publication + . + "Publication 88485" . + "Efficacy and safety of timolol maleate / latanoprost fixed combination versus timolol maleate and brimonidine given twice daily ." . + "Stewart WC" . + "2003" . + "Acta Ophthalmol Scand ." . + "12780402" . + . + "Stewart JA" . + "Day D" . + "Sharpe ED" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 88492" . + "To evaluate the efficacy and safety of the timolol maleate / latanoprost fixed combination ( TLFC ) given once each evening" . + "32" . + "6 weeks" . + . + . + . + "This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily ." . + . + . + . + . + . + . + . + "versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open - angle glaucoma or ocular hypertension patients ." . +# RDF export of group: Population + . + "Population 88508" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . +# RDF export of group: Arm + . + "tlfc" . + . + . + . + . + "brti" . + . + . + . +# RDF export of group: Intervention + . + "tlfc" . + . + "once each evening" . + . + . + "brto" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "bri" . + . + . + . + . + "tim2" . + . + . + . + . + "com" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "20 . 9" . + "2 . 8" . + "17 . 9" . + "3 . 2" . + . + "iop 2" . + . + "20 . 9" . + "2 . 8" . + "19 . 0" . + "2 . 4" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "= 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12780402_export.csv b/data/gl 12780402_export.csv new file mode 100644 index 0000000..bcb955f --- /dev/null +++ b/data/gl 12780402_export.csv @@ -0,0 +1,409 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +556, 1, 1, 1, 0, 4, 0, 4, "Acta" +556, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +556, 1, 3, 3, 16, 21, 16, 21, "Scand" +556, 1, 4, 4, 22, 23, 22, 23, "." +556, 2, 1, 5, 0, 4, 24, 28, "2003" +556, 2, 2, 6, 5, 8, 29, 32, "Jun" +556, 2, 3, 7, 9, 10, 33, 34, ";" +556, 2, 4, 8, 11, 13, 35, 37, "81" +556, 2, 5, 9, 14, 15, 38, 39, "(" +556, 2, 6, 10, 16, 17, 40, 41, "3" +556, 2, 7, 11, 18, 19, 42, 43, ")" +556, 2, 8, 12, 20, 21, 44, 45, ":" +556, 2, 9, 13, 22, 25, 46, 49, "242" +556, 2, 10, 14, 26, 27, 50, 51, "-" +556, 2, 11, 15, 28, 29, 52, 53, "6" +556, 2, 12, 16, 30, 31, 54, 55, "." +556, 3, 1, 17, 0, 8, 56, 64, "Efficacy" +556, 3, 2, 18, 9, 12, 65, 68, "and" +556, 3, 3, 19, 13, 19, 69, 75, "safety" +556, 3, 4, 20, 20, 22, 76, 78, "of" +556, 3, 5, 21, 23, 30, 79, 86, "timolol" +556, 3, 6, 22, 31, 38, 87, 94, "maleate" +556, 3, 7, 23, 39, 40, 95, 96, "/" +556, 3, 8, 24, 41, 52, 97, 108, "latanoprost" +556, 3, 9, 25, 53, 58, 109, 114, "fixed" +556, 3, 10, 26, 59, 70, 115, 126, "combination" +556, 3, 11, 27, 71, 77, 127, 133, "versus" +556, 3, 12, 28, 78, 85, 134, 141, "timolol" +556, 3, 13, 29, 86, 93, 142, 149, "maleate" +556, 3, 14, 30, 94, 97, 150, 153, "and" +556, 3, 15, 31, 98, 109, 154, 165, "brimonidine" +556, 3, 16, 32, 110, 115, 166, 171, "given" +556, 3, 17, 33, 116, 121, 172, 177, "twice" +556, 3, 18, 34, 122, 127, 178, 183, "daily" +556, 3, 19, 35, 128, 129, 184, 185, "." +556, 4, 1, 36, 0, 7, 186, 193, "Stewart" +556, 4, 2, 37, 8, 10, 194, 196, "WC" +556, 4, 3, 38, 11, 12, 197, 198, "(" +556, 4, 4, 39, 13, 14, 199, 200, "1" +556, 4, 5, 40, 15, 16, 201, 202, ")" +556, 4, 6, 41, 17, 18, 203, 204, "," +556, 4, 7, 42, 19, 26, 205, 212, "Stewart" +556, 4, 8, 43, 27, 29, 213, 215, "JA" +556, 4, 9, 44, 30, 31, 216, 217, "," +556, 4, 10, 45, 32, 35, 218, 221, "Day" +556, 4, 11, 46, 36, 37, 222, 223, "D" +556, 4, 12, 47, 38, 39, 224, 225, "," +556, 4, 13, 48, 40, 46, 226, 232, "Sharpe" +556, 4, 14, 49, 47, 49, 233, 235, "ED" +556, 4, 15, 50, 50, 51, 236, 237, "." +556, 5, 1, 51, 0, 6, 238, 244, "Author" +556, 5, 2, 52, 7, 18, 245, 256, "information" +556, 5, 3, 53, 19, 20, 257, 258, ":" +556, 5, 4, 54, 21, 22, 259, 260, "(" +556, 5, 5, 55, 23, 24, 261, 262, "1" +556, 5, 6, 56, 25, 26, 263, 264, ")" +556, 5, 7, 57, 27, 41, 265, 279, "Pharmaceutical" +556, 5, 8, 58, 42, 50, 280, 288, "Research" +556, 5, 9, 59, 51, 58, 289, 296, "Network" +556, 5, 10, 60, 59, 60, 297, 298, "," +556, 5, 11, 61, 61, 64, 299, 302, "LLC" +556, 5, 12, 62, 65, 66, 303, 304, "," +556, 5, 13, 63, 67, 77, 305, 315, "Charleston" +556, 5, 14, 64, 78, 79, 316, 317, "," +556, 5, 15, 65, 80, 85, 318, 323, "South" +556, 5, 16, 66, 86, 94, 324, 332, "Carolina" +556, 5, 17, 67, 95, 100, 333, 338, "29412" +556, 5, 18, 68, 101, 102, 339, 340, "-" +556, 5, 19, 69, 103, 107, 341, 345, "2464" +556, 5, 20, 70, 108, 109, 346, 347, "," +556, 5, 21, 71, 110, 113, 348, 351, "USA" +556, 5, 22, 72, 114, 115, 352, 353, "." +556, 6, 1, 73, 0, 4, 354, 358, "prnc" +556, 6, 2, 74, 5, 6, 359, 360, "@" +556, 6, 3, 75, 7, 16, 361, 370, "bellsouth" +556, 6, 4, 76, 17, 18, 371, 372, "." +556, 6, 5, 77, 19, 22, 373, 376, "net" +556, 6, 6, 78, 23, 30, 377, 384, "PURPOSE" +556, 6, 7, 79, 31, 32, 385, 386, ":" +556, 6, 8, 80, 33, 35, 387, 389, "To" +556, 6, 9, 81, 36, 44, 390, 398, "evaluate" +556, 6, 10, 82, 45, 48, 399, 402, "the" +556, 6, 11, 83, 49, 57, 403, 411, "efficacy" +556, 6, 12, 84, 58, 61, 412, 415, "and" +556, 6, 13, 85, 62, 68, 416, 422, "safety" +556, 6, 14, 86, 69, 71, 423, 425, "of" +556, 6, 15, 87, 72, 75, 426, 429, "the" +556, 6, 16, 88, 76, 83, 430, 437, "timolol" +556, 6, 17, 89, 84, 91, 438, 445, "maleate" +556, 6, 18, 90, 92, 93, 446, 447, "/" +556, 6, 19, 91, 94, 105, 448, 459, "latanoprost" +556, 6, 20, 92, 106, 111, 460, 465, "fixed" +556, 6, 21, 93, 112, 123, 466, 477, "combination" +556, 6, 22, 94, 124, 125, 478, 479, "(" +556, 6, 23, 95, 126, 130, 480, 484, "TLFC" +556, 6, 24, 96, 131, 132, 485, 486, ")" +556, 6, 25, 97, 133, 138, 487, 492, "given" +556, 6, 26, 98, 139, 143, 493, 497, "once" +556, 6, 27, 99, 144, 148, 498, 502, "each" +556, 6, 28, 100, 149, 156, 503, 510, "evening" +556, 6, 29, 101, 157, 163, 511, 517, "versus" +556, 6, 30, 102, 164, 175, 518, 529, "brimonidine" +556, 6, 31, 103, 176, 179, 530, 533, "and" +556, 6, 32, 104, 180, 187, 534, 541, "timolol" +556, 6, 33, 105, 188, 196, 542, 550, "solution" +556, 6, 34, 106, 197, 202, 551, 556, "given" +556, 6, 35, 107, 203, 208, 557, 562, "twice" +556, 6, 36, 108, 209, 214, 563, 568, "daily" +556, 6, 37, 109, 215, 217, 569, 571, "as" +556, 6, 38, 110, 218, 229, 572, 583, "concomitant" +556, 6, 39, 111, 230, 237, 584, 591, "therapy" +556, 6, 40, 112, 238, 240, 592, 594, "in" +556, 6, 41, 113, 241, 248, 595, 602, "primary" +556, 6, 42, 114, 249, 253, 603, 607, "open" +556, 6, 43, 115, 254, 255, 608, 609, "-" +556, 6, 44, 116, 256, 261, 610, 615, "angle" +556, 6, 45, 117, 262, 270, 616, 624, "glaucoma" +556, 6, 46, 118, 271, 273, 625, 627, "or" +556, 6, 47, 119, 274, 280, 628, 634, "ocular" +556, 6, 48, 120, 281, 293, 635, 647, "hypertension" +556, 6, 49, 121, 294, 302, 648, 656, "patients" +556, 6, 50, 122, 303, 304, 657, 658, "." +556, 7, 1, 123, 0, 7, 659, 666, "METHODS" +556, 7, 2, 124, 8, 9, 667, 668, ":" +556, 7, 3, 125, 10, 19, 669, 678, "Qualified" +556, 7, 4, 126, 20, 28, 679, 687, "subjects" +556, 7, 5, 127, 29, 33, 688, 692, "were" +556, 7, 6, 128, 34, 39, 693, 698, "begun" +556, 7, 7, 129, 40, 42, 699, 701, "on" +556, 7, 8, 130, 43, 50, 702, 709, "timolol" +556, 7, 9, 131, 51, 56, 710, 715, "alone" +556, 7, 10, 132, 57, 62, 716, 721, "twice" +556, 7, 11, 133, 63, 68, 722, 727, "daily" +556, 7, 12, 134, 69, 72, 728, 731, "for" +556, 7, 13, 135, 73, 74, 732, 733, "1" +556, 7, 14, 136, 75, 80, 734, 739, "month" +556, 7, 15, 137, 81, 84, 740, 743, "and" +556, 7, 16, 138, 85, 89, 744, 748, "then" +556, 7, 17, 139, 90, 100, 749, 759, "randomized" +556, 7, 18, 140, 101, 103, 760, 762, "to" +556, 7, 19, 141, 104, 110, 763, 769, "either" +556, 7, 20, 142, 111, 115, 770, 774, "TLFC" +556, 7, 21, 143, 116, 118, 775, 777, "or" +556, 7, 22, 144, 119, 130, 778, 789, "brimonidine" +556, 7, 23, 145, 131, 134, 790, 793, "and" +556, 7, 24, 146, 135, 142, 794, 801, "timolol" +556, 7, 25, 147, 143, 154, 802, 813, "concomitant" +556, 7, 26, 148, 155, 162, 814, 821, "therapy" +556, 7, 27, 149, 163, 166, 822, 825, "for" +556, 7, 28, 150, 167, 168, 826, 827, "6" +556, 7, 29, 151, 169, 174, 828, 833, "weeks" +556, 7, 30, 152, 175, 176, 834, 835, "." +556, 8, 1, 153, 0, 8, 836, 844, "Patients" +556, 8, 2, 154, 9, 13, 845, 849, "were" +556, 8, 3, 155, 14, 18, 850, 854, "then" +556, 8, 4, 156, 19, 27, 855, 863, "switched" +556, 8, 5, 157, 28, 30, 864, 866, "to" +556, 8, 6, 158, 31, 34, 867, 870, "the" +556, 8, 7, 159, 35, 40, 871, 876, "other" +556, 8, 8, 160, 41, 50, 877, 886, "treatment" +556, 8, 9, 161, 51, 58, 887, 894, "regimen" +556, 8, 10, 162, 59, 60, 895, 896, "." +556, 9, 1, 163, 0, 11, 897, 908, "Intraocular" +556, 9, 2, 164, 12, 21, 909, 918, "pressures" +556, 9, 3, 165, 22, 23, 919, 920, "(" +556, 9, 4, 166, 24, 28, 921, 925, "IOPs" +556, 9, 5, 167, 29, 30, 926, 927, ")" +556, 9, 6, 168, 31, 35, 928, 932, "were" +556, 9, 7, 169, 36, 44, 933, 941, "measured" +556, 9, 8, 170, 45, 50, 942, 947, "every" +556, 9, 9, 171, 51, 52, 948, 949, "2" +556, 9, 10, 172, 53, 58, 950, 955, "hours" +556, 9, 11, 173, 59, 66, 956, 963, "between" +556, 9, 12, 174, 67, 69, 964, 966, "08" +556, 9, 13, 175, 70, 71, 967, 968, ":" +556, 9, 14, 176, 72, 74, 969, 971, "00" +556, 9, 15, 177, 75, 78, 972, 975, "and" +556, 9, 16, 178, 79, 81, 976, 978, "20" +556, 9, 17, 179, 82, 83, 979, 980, ":" +556, 9, 18, 180, 84, 86, 981, 983, "00" +556, 9, 19, 181, 87, 92, 984, 989, "hours" +556, 9, 20, 182, 93, 95, 990, 992, "at" +556, 9, 21, 183, 96, 104, 993, 1001, "baseline" +556, 9, 22, 184, 105, 108, 1002, 1005, "and" +556, 9, 23, 185, 109, 111, 1006, 1008, "at" +556, 9, 24, 186, 112, 115, 1009, 1012, "the" +556, 9, 25, 187, 116, 119, 1013, 1016, "end" +556, 9, 26, 188, 120, 122, 1017, 1019, "of" +556, 9, 27, 189, 123, 130, 1020, 1027, "periods" +556, 9, 28, 190, 131, 132, 1028, 1029, "1" +556, 9, 29, 191, 133, 136, 1030, 1033, "and" +556, 9, 30, 192, 137, 138, 1034, 1035, "2" +556, 9, 31, 193, 139, 140, 1036, 1037, "." +556, 10, 1, 194, 0, 7, 1038, 1045, "RESULTS" +556, 10, 2, 195, 8, 9, 1046, 1047, ":" +556, 10, 3, 196, 10, 14, 1048, 1052, "This" +556, 10, 4, 197, 15, 20, 1053, 1058, "study" +556, 10, 5, 198, 21, 26, 1059, 1064, "found" +556, 10, 6, 199, 27, 31, 1065, 1069, "that" +556, 10, 7, 200, 32, 34, 1070, 1072, "in" +556, 10, 8, 201, 35, 37, 1073, 1075, "32" +556, 10, 9, 202, 38, 46, 1076, 1084, "subjects" +556, 10, 10, 203, 47, 50, 1085, 1088, "the" +556, 10, 11, 204, 51, 54, 1089, 1092, "IOP" +556, 10, 12, 205, 55, 62, 1093, 1100, "diurnal" +556, 10, 13, 206, 63, 68, 1101, 1106, "curve" +556, 10, 14, 207, 69, 71, 1107, 1109, "on" +556, 10, 15, 208, 72, 79, 1110, 1117, "timolol" +556, 10, 16, 209, 80, 85, 1118, 1123, "alone" +556, 10, 17, 210, 86, 87, 1124, 1125, "(" +556, 10, 18, 211, 88, 90, 1126, 1128, "20" +556, 10, 19, 212, 91, 92, 1129, 1130, "." +556, 10, 20, 213, 93, 94, 1131, 1132, "9" +556, 10, 21, 214, 95, 96, 1133, 1134, "+" +556, 10, 22, 215, 97, 98, 1135, 1136, "/" +556, 10, 23, 216, 99, 100, 1137, 1138, "-" +556, 10, 24, 217, 101, 102, 1139, 1140, "2" +556, 10, 25, 218, 103, 104, 1141, 1142, "." +556, 10, 26, 219, 105, 106, 1143, 1144, "8" +556, 10, 27, 220, 107, 111, 1145, 1149, "mmHg" +556, 10, 28, 221, 112, 113, 1150, 1151, ")" +556, 10, 29, 222, 114, 123, 1152, 1161, "decreased" +556, 10, 30, 223, 124, 126, 1162, 1164, "to" +556, 10, 31, 224, 127, 129, 1165, 1167, "17" +556, 10, 32, 225, 130, 131, 1168, 1169, "." +556, 10, 33, 226, 132, 133, 1170, 1171, "9" +556, 10, 34, 227, 134, 135, 1172, 1173, "+" +556, 10, 35, 228, 136, 137, 1174, 1175, "/" +556, 10, 36, 229, 138, 139, 1176, 1177, "-" +556, 10, 37, 230, 140, 141, 1178, 1179, "3" +556, 10, 38, 231, 142, 143, 1180, 1181, "." +556, 10, 39, 232, 144, 145, 1182, 1183, "2" +556, 10, 40, 233, 146, 150, 1184, 1188, "mmHg" +556, 10, 41, 234, 151, 155, 1189, 1193, "when" +556, 10, 42, 235, 156, 164, 1194, 1202, "patients" +556, 10, 43, 236, 165, 169, 1203, 1207, "were" +556, 10, 44, 237, 170, 177, 1208, 1215, "treated" +556, 10, 45, 238, 178, 182, 1216, 1220, "with" +556, 10, 46, 239, 183, 187, 1221, 1225, "TLFC" +556, 10, 47, 240, 188, 191, 1226, 1229, "and" +556, 10, 48, 241, 192, 194, 1230, 1232, "to" +556, 10, 49, 242, 195, 197, 1233, 1235, "19" +556, 10, 50, 243, 198, 199, 1236, 1237, "." +556, 10, 51, 244, 200, 201, 1238, 1239, "0" +556, 10, 52, 245, 202, 203, 1240, 1241, "+" +556, 10, 53, 246, 204, 205, 1242, 1243, "/" +556, 10, 54, 247, 206, 207, 1244, 1245, "-" +556, 10, 55, 248, 208, 209, 1246, 1247, "2" +556, 10, 56, 249, 210, 211, 1248, 1249, "." +556, 10, 57, 250, 212, 213, 1250, 1251, "4" +556, 10, 58, 251, 214, 218, 1252, 1256, "mmHg" +556, 10, 59, 252, 219, 223, 1257, 1261, "when" +556, 10, 60, 253, 224, 232, 1262, 1270, "patients" +556, 10, 61, 254, 233, 237, 1271, 1275, "were" +556, 10, 62, 255, 238, 245, 1276, 1283, "treated" +556, 10, 63, 256, 246, 250, 1284, 1288, "with" +556, 10, 64, 257, 251, 262, 1289, 1300, "brimonidine" +556, 10, 65, 258, 263, 266, 1301, 1304, "and" +556, 10, 66, 259, 267, 274, 1305, 1312, "timolol" +556, 10, 67, 260, 275, 276, 1313, 1314, "(" +556, 10, 68, 261, 277, 278, 1315, 1316, "p" +556, 10, 69, 262, 279, 280, 1317, 1318, "=" +556, 10, 70, 263, 281, 282, 1319, 1320, "0" +556, 10, 71, 264, 283, 284, 1321, 1322, "." +556, 10, 72, 265, 285, 287, 1323, 1325, "02" +556, 10, 73, 266, 288, 289, 1326, 1327, ")" +556, 10, 74, 267, 290, 291, 1328, 1329, "." +556, 11, 1, 268, 0, 11, 1330, 1341, "Intraocular" +556, 11, 2, 269, 12, 21, 1342, 1351, "pressures" +556, 11, 3, 270, 22, 24, 1352, 1354, "at" +556, 11, 4, 271, 25, 35, 1355, 1365, "individual" +556, 11, 5, 272, 36, 40, 1366, 1370, "time" +556, 11, 6, 273, 41, 42, 1371, 1372, "-" +556, 11, 7, 274, 43, 49, 1373, 1379, "points" +556, 11, 8, 275, 50, 54, 1380, 1384, "were" +556, 11, 9, 276, 55, 68, 1385, 1398, "statistically" +556, 11, 10, 277, 69, 76, 1399, 1406, "similar" +556, 11, 11, 278, 77, 84, 1407, 1414, "between" +556, 11, 12, 279, 85, 88, 1415, 1418, "the" +556, 11, 13, 280, 89, 95, 1419, 1425, "groups" +556, 11, 14, 281, 96, 98, 1426, 1428, "at" +556, 11, 15, 282, 99, 102, 1429, 1432, "the" +556, 11, 16, 283, 103, 105, 1433, 1435, "08" +556, 11, 17, 284, 106, 107, 1436, 1437, ":" +556, 11, 18, 285, 108, 110, 1438, 1440, "00" +556, 11, 19, 286, 111, 117, 1441, 1447, "trough" +556, 11, 20, 287, 118, 121, 1448, 1451, "and" +556, 11, 21, 288, 122, 123, 1452, 1453, "2" +556, 11, 22, 289, 124, 127, 1454, 1457, "and" +556, 11, 23, 290, 128, 129, 1458, 1459, "4" +556, 11, 24, 291, 130, 135, 1460, 1465, "hours" +556, 11, 25, 292, 136, 141, 1466, 1471, "after" +556, 11, 26, 293, 142, 148, 1472, 1478, "dosing" +556, 11, 27, 294, 149, 150, 1479, 1480, "." +556, 12, 1, 295, 0, 7, 1481, 1488, "However" +556, 12, 2, 296, 8, 9, 1489, 1490, "," +556, 12, 3, 297, 10, 16, 1491, 1497, "beyond" +556, 12, 4, 298, 17, 18, 1498, 1499, "4" +556, 12, 5, 299, 19, 24, 1500, 1505, "hours" +556, 12, 6, 300, 25, 30, 1506, 1511, "after" +556, 12, 7, 301, 31, 37, 1512, 1518, "dosing" +556, 12, 8, 302, 38, 39, 1519, 1520, "," +556, 12, 9, 303, 40, 44, 1521, 1525, "TLFC" +556, 12, 10, 304, 45, 46, 1526, 1527, "-" +556, 12, 11, 305, 47, 54, 1528, 1535, "treated" +556, 12, 12, 306, 55, 63, 1536, 1544, "subjects" +556, 12, 13, 307, 64, 76, 1545, 1557, "demonstrated" +556, 12, 14, 308, 77, 78, 1558, 1559, "a" +556, 12, 15, 309, 79, 84, 1560, 1565, "trend" +556, 12, 16, 310, 85, 92, 1566, 1573, "towards" +556, 12, 17, 311, 93, 98, 1574, 1579, "lower" +556, 12, 18, 312, 99, 103, 1580, 1584, "IOPs" +556, 12, 19, 313, 104, 106, 1585, 1587, "at" +556, 12, 20, 314, 107, 111, 1588, 1592, "each" +556, 12, 21, 315, 112, 113, 1593, 1594, "2" +556, 12, 22, 316, 114, 115, 1595, 1596, "-" +556, 12, 23, 317, 116, 120, 1597, 1601, "hour" +556, 12, 24, 318, 121, 125, 1602, 1606, "time" +556, 12, 25, 319, 126, 127, 1607, 1608, "-" +556, 12, 26, 320, 128, 133, 1609, 1614, "point" +556, 12, 27, 321, 134, 138, 1615, 1619, "that" +556, 12, 28, 322, 139, 142, 1620, 1623, "was" +556, 12, 29, 323, 143, 146, 1624, 1627, "not" +556, 12, 30, 324, 147, 160, 1628, 1641, "statistically" +556, 12, 31, 325, 161, 172, 1642, 1653, "significant" +556, 12, 32, 326, 173, 178, 1654, 1659, "after" +556, 12, 33, 327, 179, 180, 1660, 1661, "a" +556, 12, 34, 328, 181, 191, 1662, 1672, "Bonferroni" +556, 12, 35, 329, 192, 202, 1673, 1683, "correction" +556, 12, 36, 330, 203, 204, 1684, 1685, "(" +556, 12, 37, 331, 205, 206, 1686, 1687, "p" +556, 12, 38, 332, 207, 208, 1688, 1689, "&" +556, 12, 39, 333, 209, 211, 1690, 1692, "lt" +556, 12, 40, 334, 212, 213, 1693, 1694, ";" +556, 12, 41, 335, 214, 216, 1695, 1697, "or" +556, 12, 42, 336, 217, 218, 1698, 1699, "=" +556, 12, 43, 337, 219, 220, 1700, 1701, "0" +556, 12, 44, 338, 221, 222, 1702, 1703, "." +556, 12, 45, 339, 223, 225, 1704, 1706, "05" +556, 12, 46, 340, 226, 227, 1707, 1708, ")" +556, 12, 47, 341, 228, 229, 1709, 1710, "." +556, 13, 1, 342, 0, 3, 1711, 1714, "The" +556, 13, 2, 343, 4, 13, 1715, 1724, "incidence" +556, 13, 3, 344, 14, 16, 1725, 1727, "of" +556, 13, 4, 345, 17, 21, 1728, 1732, "both" +556, 13, 5, 346, 22, 31, 1733, 1742, "solicited" +556, 13, 6, 347, 32, 35, 1743, 1746, "and" +556, 13, 7, 348, 36, 47, 1747, 1758, "unsolicited" +556, 13, 8, 349, 48, 52, 1759, 1763, "side" +556, 13, 9, 350, 53, 54, 1764, 1765, "-" +556, 13, 10, 351, 55, 62, 1766, 1773, "effects" +556, 13, 11, 352, 63, 66, 1774, 1777, "was" +556, 13, 12, 353, 67, 74, 1778, 1785, "similar" +556, 13, 13, 354, 75, 82, 1786, 1793, "between" +556, 13, 14, 355, 83, 89, 1794, 1800, "groups" +556, 13, 15, 356, 90, 91, 1801, 1802, "." +556, 14, 1, 357, 0, 10, 1803, 1813, "CONCLUSION" +556, 14, 2, 358, 11, 12, 1814, 1815, ":" +556, 14, 3, 359, 13, 17, 1816, 1820, "This" +556, 14, 4, 360, 18, 23, 1821, 1826, "study" +556, 14, 5, 361, 24, 32, 1827, 1835, "suggests" +556, 14, 6, 362, 33, 37, 1836, 1840, "that" +556, 14, 7, 363, 38, 42, 1841, 1845, "TLFC" +556, 14, 8, 364, 43, 48, 1846, 1851, "given" +556, 14, 9, 365, 49, 51, 1852, 1854, "in" +556, 14, 10, 366, 52, 55, 1855, 1858, "the" +556, 14, 11, 367, 56, 63, 1859, 1866, "evening" +556, 14, 12, 368, 64, 71, 1867, 1874, "reduces" +556, 14, 13, 369, 72, 75, 1875, 1878, "the" +556, 14, 14, 370, 76, 80, 1879, 1883, "mean" +556, 14, 15, 371, 81, 88, 1884, 1891, "daytime" +556, 14, 16, 372, 89, 96, 1892, 1899, "diurnal" +556, 14, 17, 373, 97, 100, 1900, 1903, "IOP" +556, 14, 18, 374, 101, 105, 1904, 1908, "more" +556, 14, 19, 375, 106, 110, 1909, 1913, "than" +556, 14, 20, 376, 111, 122, 1914, 1925, "brimonidine" +556, 14, 21, 377, 123, 126, 1926, 1929, "and" +556, 14, 22, 378, 127, 134, 1930, 1937, "timolol" +556, 14, 23, 379, 135, 140, 1938, 1943, "given" +556, 14, 24, 380, 141, 154, 1944, 1957, "concomitantly" +556, 14, 25, 381, 155, 160, 1958, 1963, "twice" +556, 14, 26, 382, 161, 166, 1964, 1969, "daily" +556, 14, 27, 383, 167, 168, 1970, 1971, "." +556, 15, 1, 384, 0, 3, 1972, 1975, "DOI" +556, 15, 2, 385, 4, 5, 1976, 1977, ":" +556, 15, 3, 386, 6, 8, 1978, 1980, "10" +556, 15, 4, 387, 9, 10, 1981, 1982, "." +556, 15, 5, 388, 11, 15, 1983, 1987, "1034" +556, 15, 6, 389, 16, 17, 1988, 1989, "/" +556, 15, 7, 390, 18, 19, 1990, 1991, "j" +556, 15, 8, 391, 20, 21, 1992, 1993, "." +556, 15, 9, 392, 22, 26, 1994, 1998, "1600" +556, 15, 10, 393, 27, 28, 1999, 2000, "-" +556, 15, 11, 394, 29, 33, 2001, 2005, "0420" +556, 15, 12, 395, 34, 35, 2006, 2007, "." +556, 15, 13, 396, 36, 40, 2008, 2012, "2003" +556, 15, 14, 397, 41, 42, 2013, 2014, "." +556, 15, 15, 398, 43, 48, 2015, 2020, "00065" +556, 15, 16, 399, 49, 50, 2021, 2022, "." +556, 15, 17, 400, 51, 52, 2023, 2024, "x" +556, 15, 18, 401, 53, 57, 2025, 2029, "PMID" +556, 15, 19, 402, 58, 59, 2030, 2031, ":" +556, 15, 20, 403, 60, 68, 2032, 2040, "12780402" +556, 15, 21, 404, 69, 70, 2041, 2042, "[" +556, 15, 22, 405, 71, 78, 2043, 2050, "Indexed" +556, 15, 23, 406, 79, 82, 2051, 2054, "for" +556, 15, 24, 407, 83, 90, 2055, 2062, "MEDLINE" +556, 15, 25, 408, 91, 92, 2063, 2064, "]" diff --git a/data/gl 12780402_jshahinitiran.annodb b/data/gl 12780402_jshahinitiran.annodb new file mode 100644 index 0000000..642fcd7 --- /dev/null +++ b/data/gl 12780402_jshahinitiran.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82415, Journal, 0, 21, "Acta Ophthalmol Scand", "", +82416, PublicationYear, 24, 28, "2003", "", +82417, Title, 56, 185, "Efficacy and safety of timolol maleate / latanoprost fixed combination versus timolol maleate and brimonidine given twice daily .", "", +82418, Timolol, 79, 94, "timolol maleate", "", +82420, Lat/TimFC, 79, 126, "timolol maleate / latanoprost fixed combination", "", +82419, Latanoprost, 97, 108, "latanoprost", "", +82421, Timolol, 134, 149, "timolol maleate", "", +82422, Brimonidine, 154, 165, "brimonidine", "", +82423, Frequency, 172, 183, "twice daily", "", +82424, Author, 186, 196, "Stewart WC", "", +82425, Author, 205, 215, "Stewart JA", "", +82426, Author, 218, 223, "Day D", "", +82427, Author, 226, 235, "Sharpe ED", "", +82428, USA, 348, 351, "USA", "", +82429, ObjectiveDescription, 387, 510, "To evaluate the efficacy and safety of the timolol maleate / latanoprost fixed combination ( TLFC ) given once each evening", "", +82433, Lat/TimFC, 430, 477, "timolol maleate / latanoprost fixed combination", "", +82431, Timolol, 430, 445, "timolol maleate", "", +82432, Latanoprost, 448, 459, "latanoprost", "", +82434, Lat/TimFC, 480, 484, "TLFC", "", +82435, Frequency, 493, 497, "once", "", +82436, Evening, 503, 510, "evening", "", +82430, ObjectiveDescription, 511, 658, "versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open - angle glaucoma or ocular hypertension patients .", "", +82437, Brimonidine, 518, 529, "brimonidine", "", +82438, Timolol, 534, 541, "timolol", "", +82439, Frequency, 557, 568, "twice daily", "", +82440, Primary_OpenAngleGlaucoma, 595, 624, "primary open - angle glaucoma", "", +82441, OcularHypertension, 628, 647, "ocular hypertension", "", +82442, Timolol, 702, 709, "timolol", "", +82443, Frequency, 716, 727, "twice daily", "", +82444, Duration, 732, 739, "1 month", "", +82445, Randomized, 749, 759, "randomized", "", +82446, Lat/TimFC, 770, 774, "TLFC", "", +82447, Brimonidine, 778, 789, "brimonidine", "", +82448, Timolol, 794, 801, "timolol", "", +82449, Duration, 826, 833, "6 weeks", "", +82450, IOP, 897, 918, "Intraocular pressures", "", +82451, IOP, 921, 925, "IOPs", "", +82452, TimePoint, 993, 1001, "baseline", "", +82453, TimePoint, 1009, 1035, "the end of periods 1 and 2", "", +82454, TimePoint, 1009, 1029, "the end of periods 1", "", +82455, NumberPatientsCT, 1073, 1075, "32", "", +82456, Diurnal_IOP, 1089, 1106, "IOP diurnal curve", "", +82457, Timolol, 1110, 1117, "timolol", "", +82458, BaseLineValue, 1126, 1132, "20 . 9", "", +82459, SdErrorBL, 1139, 1144, "2 . 8", "", +82460, mmHg, 1145, 1149, "mmHg", "", +82463, ResultMeasuredValue, 1165, 1171, "17 . 9", "", +82465, SdErrorResValue, 1178, 1183, "3 . 2", "", +82461, mmHg, 1184, 1188, "mmHg", "", +82469, Lat/TimFC, 1221, 1225, "TLFC", "", +82464, ResultMeasuredValue, 1233, 1239, "19 . 0", "", +82466, SdErrorResValue, 1246, 1251, "2 . 4", "", +82462, mmHg, 1252, 1256, "mmHg", "", +82467, Brimonidine, 1289, 1300, "brimonidine", "", +82468, Brimonidine, 1305, 1312, "timolol", "", +82470, PValueResValue, 1315, 1325, "p = 0 . 02", "", +82471, IOP, 1330, 1351, "Intraocular pressures", "", +82472, ObservedResult, 1330, 1480, "Intraocular pressures at individual time - points were statistically similar between the groups at the 08 : 00 trough and 2 and 4 hours after dosing .", "", +82476, ObservedResult, 1481, 1710, "However , beyond 4 hours after dosing , TLFC - treated subjects demonstrated a trend towards lower IOPs at each 2 - hour time - point that was not statistically significant after a Bonferroni correction ( p & lt ; or = 0 . 05 ) .", "", +82473, Lat/TimFC, 1521, 1525, "TLFC", "", +82474, IOP, 1580, 1584, "IOPs", "", +82475, PvalueDiff, 1686, 1706, "p & lt ; or = 0 . 05", "", +82477, ConclusionComment, 1816, 1971, "This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily .", "", +82478, Lat/TimFC, 1841, 1845, "TLFC", "", +82479, Evening, 1859, 1866, "evening", "", +82480, Mean, 1879, 1883, "mean", "", +82481, Diurnal_IOP, 1892, 1903, "diurnal IOP", "", +82482, Brimonidine, 1914, 1925, "brimonidine", "", +82483, Timolol, 1930, 1937, "timolol", "", +82484, Frequency, 1958, 1969, "twice daily", "", +82485, PMID, 2032, 2040, "12780402", "", diff --git a/data/gl 12780402_jshahinitiran.n-triples b/data/gl 12780402_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12780402_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12780402_tstrakeljahn.annodb b/data/gl 12780402_tstrakeljahn.annodb new file mode 100644 index 0000000..757407f --- /dev/null +++ b/data/gl 12780402_tstrakeljahn.annodb @@ -0,0 +1,67 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82165, Journal, 0, 21, "Acta Ophthalmol Scand", "", +82166, PublicationYear, 24, 28, "2003", "", +82177, Title, 56, 185, "Efficacy and safety of timolol maleate / latanoprost fixed combination versus timolol maleate and brimonidine given twice daily .", "", +82167, Timolol, 79, 94, "timolol maleate", "", +82169, Lat/TimFC, 79, 108, "timolol maleate / latanoprost", "", +82168, Latanoprost, 97, 108, "latanoprost", "", +82170, Timolol, 134, 149, "timolol maleate", "", +82171, Brimonidine, 154, 165, "brimonidine", "", +82172, Frequency, 172, 183, "twice daily", "", +82173, Author, 186, 196, "Stewart WC", "", +82174, Author, 205, 215, "Stewart JA", "", +82175, Author, 218, 223, "Day D", "", +82176, Author, 226, 235, "Sharpe ED", "", +82178, USA, 348, 351, "USA", "", +82179, Timolol, 430, 445, "timolol maleate", "", +82182, Lat/TimFC, 430, 459, "timolol maleate / latanoprost", "", +82180, Latanoprost, 448, 459, "latanoprost", "", +82181, Lat/TimFC, 480, 484, "TLFC", "", +82183, Frequency, 493, 510, "once each evening", "", +82184, Evening, 503, 510, "evening", "", +82185, Brimonidine, 518, 529, "brimonidine", "", +82186, Timolol, 534, 541, "timolol", "", +82187, Frequency, 557, 568, "twice daily", "", +82188, Primary_OpenAngleGlaucoma, 595, 624, "primary open - angle glaucoma", "", +82189, OcularHypertension, 628, 647, "ocular hypertension", "", +82190, Timolol, 702, 709, "timolol", "", +82191, Frequency, 716, 727, "twice daily", "", +82192, Randomized, 749, 759, "randomized", "", +82193, Lat/TimFC, 770, 774, "TLFC", "", +82194, Brimonidine, 778, 789, "brimonidine", "", +82195, Timolol, 794, 801, "timolol", "", +82196, IOP, 897, 918, "Intraocular pressures", "", +82197, IOP, 921, 925, "IOPs", "", +82198, TimePoint, 990, 1001, "at baseline", "", +82199, TimePoint, 1013, 1029, "end of periods 1", "", +82200, TimePoint, 1013, 1035, "end of periods 1 and 2", "", +82201, FinalNumPatientsCT, 1073, 1075, "32", "", +82202, Diurnal_IOP, 1089, 1106, "IOP diurnal curve", "", +82204, Timolol, 1110, 1117, "timolol", "", +82205, BaseLineValue, 1126, 1132, "20 . 9", "", +82206, SdDevBL, 1139, 1144, "2 . 8", "", +82209, mmHg, 1145, 1149, "mmHg", "", +82207, ResultMeasuredValue, 1165, 1171, "17 . 9", "", +82211, SdDevResValue, 1178, 1183, "3 . 2", "", +82210, mmHg, 1184, 1188, "mmHg", "", +82216, Lat/TimFC, 1221, 1225, "TLFC", "", +82208, ResultMeasuredValue, 1233, 1239, "19 . 0", "", +82212, SdDevResValue, 1246, 1251, "2 . 4", "", +82213, mmHg, 1252, 1256, "mmHg", "", +82214, Brimonidine, 1289, 1300, "brimonidine", "", +82215, Timolol, 1305, 1312, "timolol", "", +82217, PvalueDiff, 1317, 1325, "= 0 . 02", "", +82218, IOP, 1330, 1351, "Intraocular pressures", "", +82220, ObservedResult, 1330, 1480, "Intraocular pressures at individual time - points were statistically similar between the groups at the 08 : 00 trough and 2 and 4 hours after dosing .", "", +82223, ObservedResult, 1481, 1710, "However , beyond 4 hours after dosing , TLFC - treated subjects demonstrated a trend towards lower IOPs at each 2 - hour time - point that was not statistically significant after a Bonferroni correction ( p & lt ; or = 0 . 05 ) .", "", +82221, Lat/TimFC, 1521, 1525, "TLFC", "", +82222, IOP, 1580, 1584, "IOPs", "", +82224, ObservedResult, 1711, 1802, "The incidence of both solicited and unsolicited side - effects was similar between groups .", "", +82231, ConclusionComment, 1816, 1971, "This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily .", "", +82225, Lat/TimFC, 1841, 1845, "TLFC", "", +82226, Mean, 1879, 1883, "mean", "", +82227, Diurnal_IOP, 1892, 1903, "diurnal IOP", "", +82228, Brimonidine, 1914, 1925, "brimonidine", "", +82229, Timolol, 1930, 1937, "timolol", "", +82230, Frequency, 1958, 1969, "twice daily", "", +82232, PMID, 2032, 2040, "12780402", "", diff --git a/data/gl 12780402_tstrakeljahn.n-triples b/data/gl 12780402_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12780402_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12859261_admin.annodb b/data/gl 12859261_admin.annodb new file mode 100644 index 0000000..d2fcfc9 --- /dev/null +++ b/data/gl 12859261_admin.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Acta Ophthalmol Scand", "", " \"Acta Ophthalmol Scand\"." +1, PublicationYear, 24, 28, "2003", "", " \"2003\"." +38478, Dorz/TimFC, 57, 90, "Timolol 0 . 5 % / dorzolamide 2 %", "", +79, Timolol, 57, 64, "Timolol", "", +113, Title, 57, 234, "Timolol 0 . 5 % / dorzolamide 2 % fixed combination versus timolol 0 . 5 % / pilocarpine 2 % fixed combination in primary open - angle glaucoma or ocular hypertensive patients .", "", " \"Timolol 0 . 5 % / dorzolamide 2 % fixed combination versus timolol 0 . 5 % / pilocarpine 2 % fixed combination in primary open - angle glaucoma or ocular hypertensive patients .\"." +2, DoseValue, 65, 70, "0 . 5", "", +3, Percentage, 71, 72, "%", "", +80, Dorzolamide, 75, 86, "dorzolamide", "", +4, DoseValue, 87, 88, "2", "", +5, Percentage, 89, 90, "%", "", +81, Timolol, 116, 123, "timolol", "", +38510, Pilo/TimFC, 116, 149, "timolol 0 . 5 % / pilocarpine 2 %", "", +6, DoseValue, 124, 129, "0 . 5", "", +7, Percentage, 130, 131, "%", "", +82, Pilocarpine, 134, 145, "pilocarpine", "", +8, DoseValue, 146, 147, "2", "", +9, Percentage, 148, 149, "%", "", +83, Primary_OpenAngleGlaucoma, 171, 200, "primary open - angle glaucoma", "", " ." +54378, Precondition, 171, 232, "primary open - angle glaucoma or ocular hypertensive patients", "", " \"primary open - angle glaucoma or ocular hypertensive patients\"." +10, OcularHypertension, 204, 223, "ocular hypertensive", "", " ." +11, Author, 235, 247, "Ka ł uzny JJ", "", " \"Ka ł uzny JJ\"." +12, Author, 256, 265, "Szaflik J", "", " \"Szaflik J\"." +13, Author, 268, 290, "Czechowicz - Janicka K", "", " \"Czechowicz - Janicka K\"." +14, Author, 293, 304, "Ka ł uzny J", "", " \"Ka ł uzny J\"." +15, Author, 307, 321, "Orzalkiewicz A", "", " \"Orzalkiewicz A\"." +16, Author, 324, 333, "Zaleska A", "", " \"Zaleska A\"." +17, Author, 336, 347, "Krajewska M", "", " \"Krajewska M\"." +18, Author, 350, 360, "Stewart JA", "", " \"Stewart JA\"." +19, Author, 363, 371, "Leech JN", "", " \"Leech JN\"." +20, Author, 374, 384, "Stewart WC", "", " \"Stewart WC\"." +21, Poland, 447, 453, "Poland", "", " ." +22, ObjectiveDescription, 466, 720, "To establish the efficacy and safety of timolol maleate / dorzolamide fixed combination ( TDFC ) versus timolol maleate / pilocarpine fixed combination ( TPFC ) , each given twice daily , in primary open - angle glaucoma or ocular hypertensive patients .", "", " \"To establish the efficacy and safety of timolol maleate / dorzolamide fixed combination ( TDFC ) versus timolol maleate / pilocarpine fixed combination ( TPFC ) , each given twice daily , in primary open - angle glaucoma or ocular hypertensive patients .\"." +38479, Dorz/TimFC, 506, 535, "timolol maleate / dorzolamide", "", " ." +84, Timolol, 506, 521, "timolol maleate", "", +85, Dorzolamide, 524, 535, "dorzolamide", "", +38480, Dorz/TimFC, 556, 560, "TDFC", "", +86, Timolol, 570, 585, "timolol maleate", "", +38511, Pilo/TimFC, 570, 599, "timolol maleate / pilocarpine", "", " ." +87, Pilocarpine, 588, 599, "pilocarpine", "", +38512, Pilo/TimFC, 620, 624, "TPFC", "", +23, Frequency, 640, 651, "twice daily", "", " \"twice daily\". \"twice daily\"." +88, Primary_OpenAngleGlaucoma, 657, 686, "primary open - angle glaucoma", "", +10, OcularHypertension, 690, 709, "ocular hypertensive", "", " ." +77573, Prospective, 739, 750, "prospective", "", " ." +25, Multicenter, 753, 765, "multicentred", "", " ." +26, DoubleBlind, 768, 783, "double - masked", "", " ." +27, NumberPatientsCT, 792, 794, "37", "", " \"37\"." +77572, Precondition, 795, 853, "patients were treated twice daily with timolol for 4 weeks", "", " \"patients were treated twice daily with timolol for 4 weeks\"." +29, Frequency, 817, 828, "twice daily", "", +89, Timolol, 834, 841, "timolol", "", +28, Duration, 846, 853, "4 weeks", "", +33959, Randomized, 871, 881, "randomized", "", " ." +30, Duration, 922, 929, "6 weeks", "", " \"6 weeks\". \"6 weeks\"." +90, Timolol, 967, 974, "timolol", "", +31, Duration, 985, 992, "2 weeks", "", +91, Duration, 1054, 1061, "6 weeks", "", +61, FinalNumPatientsCT, 1085, 1087, "36", "", " \"36\"." +33, Mean, 1125, 1129, "mean", "", " . ." +92, IOP, 1139, 1159, "intraocular pressure", "", " . ." +93, IOP, 1162, 1165, "IOP", "", +34, BaseLineValue, 1172, 1178, "22 . 3", "", " \"22 . 3\". \"22 . 3\"." +35, SdErrorBL, 1185, 1190, "3 . 7", "", " \"3 . 7\". \"3 . 7\"." +36, mmHg, 1191, 1195, "mmHg", "", " ." +94, Duration, 1208, 1215, "6 weeks", "", +37, Mean, 1235, 1239, "mean", "", " . ." +38, Trough_IOP, 1240, 1268, "trough ( 08 . 00 hours ) IOP", "", " ." +77578, TimePoint, 1249, 1262, "08 . 00 hours", "", +39, ResultMeasuredValue, 1273, 1279, "18 . 0", "", " \"18 . 0\"." +40, SdErrorResValue, 1286, 1291, "2 . 2", "", " \"2 . 2\"." +41, mmHg, 1292, 1296, "mmHg", "", " ." +38481, Dorz/TimFC, 1301, 1305, "TDFC", "", +42, ResultMeasuredValue, 1310, 1316, "17 . 4", "", " \"17 . 4\"." +43, SdErrorResValue, 1323, 1328, "2 . 0", "", " \"2 . 0\"." +44, mmHg, 1329, 1333, "mmHg", "", +38513, Pilo/TimFC, 1338, 1342, "TPFC", "", +77574, PvalueDiff, 1345, 1355, "p = 0 . 22", "", " \"p = 0 . 22\"." +46, Mean, 1364, 1368, "mean", "", " . ." +47, Diurnal_IOP, 1369, 1386, "diurnal curve IOP", "", " ." +48, ResultMeasuredValue, 1391, 1397, "18 . 1", "", " \"18 . 1\"." +50, SdErrorResValue, 1404, 1409, "2 . 2", "", " \"2 . 2\"." +52, mmHg, 1410, 1414, "mmHg", "", " ." +38482, Dorz/TimFC, 1419, 1423, "TDFC", "", +49, ResultMeasuredValue, 1428, 1434, "16 . 7", "", " \"16 . 7\"." +51, SdErrorResValue, 1441, 1446, "1 . 9", "", " \"1 . 9\"." +53, mmHg, 1447, 1451, "mmHg", "", " ." +38514, Pilo/TimFC, 1456, 1460, "TPFC", "", +77575, PvalueDiff, 1463, 1475, "p = 0 . 0007", "", " \"p = 0 . 0007\"." +77576, TimePoint, 1497, 1550, "time - points ( 10 . 00 , 18 . 00 and 20 . 00 hours )", "", +38515, Pilo/TimFC, 1553, 1557, "TPFC", "", +76, IOP, 1558, 1562, "IOPs", "", +38483, Dorz/TimFC, 1593, 1597, "TDFC", "", +77, IOP, 1598, 1602, "IOPs", "", +78, PvalueDiff, 1605, 1615, "p < 0 . 03", "", " \"p < 0 . 03\"." +75, ObservedResult, 1620, 1738, "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )", "", " \"There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )\". \"There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )\". \"There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )\". \"There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )\"." +33958, EndPointDescription, 1673, 1686, "vision change", "AdverseEffect", " . ." +33956, EndPointDescription, 1691, 1702, "ocular pain", "AdverseEffect", " . ." +38516, Pilo/TimFC, 1719, 1723, "TPFC", "", +33960, PvalueDiff, 1726, 1736, "p = 0 . 04", "", " \"p = 0 . 04\". \"p = 0 . 04\"." +55, NumPatientsLeftArm, 1741, 1744, "Six", "", " \"Six\"." +38517, Pilo/TimFC, 1783, 1787, "TPFC", "", +33962, RelNumPatientsLeftArm, 1798, 1800, "17", "", " \"17\"." +56, NumPatientsLeftArm, 1812, 1815, "two", "", " \"two\"." +38484, Dorz/TimFC, 1821, 1825, "TDFC", "", +33963, RelNumPatientsLeftArm, 1828, 1829, "6", "", " \"6\"." +57, ConclusionComment, 1865, 2034, "This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open - angle glaucoma or ocular hypertension .\"." +38518, Pilo/TimFC, 1890, 1894, "TPFC", "", +58, IOP, 1951, 1954, "IOP", "", +38485, Dorz/TimFC, 1958, 1962, "TDFC", "", +96, Primary_OpenAngleGlaucoma, 1980, 2009, "primary open - angle glaucoma", "", +59, OcularHypertension, 2013, 2032, "ocular hypertension", "", +60, PMID, 2042, 2050, "12859261", "", " \"12859261\"." diff --git a/data/gl 12859261_admin.n-triples b/data/gl 12859261_admin.n-triples new file mode 100644 index 0000000..6505631 --- /dev/null +++ b/data/gl 12859261_admin.n-triples @@ -0,0 +1,206 @@ +# RDF export of group: Publication + . + "Publication " . + "Timolol 0 . 5 % / dorzolamide 2 % fixed combination versus timolol 0 . 5 % / pilocarpine 2 % fixed combination in primary open - angle glaucoma or ocular hypertensive patients ." . + "Ka ł uzny JJ" . + "2003" . + "Acta Ophthalmol Scand" . + "12859261" . + . + "Szaflik J" . + "Czechowicz - Janicka K" . + "Ka ł uzny J" . + "Orzalkiewicz A" . + "Zaleska A" . + "Krajewska M" . + "Stewart JA" . + "Leech JN" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To establish the efficacy and safety of timolol maleate / dorzolamide fixed combination ( TDFC ) versus timolol maleate / pilocarpine fixed combination ( TPFC ) , each given twice daily , in primary open - angle glaucoma or ocular hypertensive patients ." . + "37" . + . + . + . + "This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open - angle glaucoma or ocular hypertension ." . + . + . + . + . + . + "36" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "primary open - angle glaucoma or ocular hypertensive patients" . + . + . + . + "patients were treated twice daily with timolol for 4 weeks" . +# RDF export of group: Endpoint + . + "Endpoint IOP " . + . + . + . + . + . + . + . + "Endpoint t IOP " . + . + . + . + . + . + . + "Endpoint d IOP " . + . + . + . + . + . + . + "Endpoint v change" . + . + . + . + . + . + . + "Endpoint o p" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Dorz/TimFC" . + . + . + . + "two" . + "6" . + . + . + . + . + "Arm Pilo/TimFC" . + . + . + . + "Six" . + "17" . + . + . + . +# RDF export of group: Intervention + . + "Intervention Dorz/TimFC" . + . + "twice daily" . + "6 weeks" . + . + . + "Intervention Pilo/TimFC" . + . + "twice daily" . + "6 weeks" . + . +# RDF export of group: Medication + . + "Medication Dorz/TimFC" . + . + . + . + . + "Medication Pilo/TimFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP dt" . + . + "22 . 3" . + "3 . 7" . + . + "Outcome IOP pt" . + . + "22 . 3" . + "3 . 7" . + . + "Outcome t IOP dt " . + . + "18 . 0" . + "2 . 2" . + . + "Outcome t IOP pt" . + . + "17 . 4" . + "2 . 0" . + . + "Outcome d IOP dt " . + . + "18 . 1" . + "2 . 2" . + . + "Outcome d IOP pt " . + . + "16 . 7" . + "1 . 9" . + . + "Outcome v change dt " . + . + "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )" . + . + "Outcome v change pt" . + . + "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )" . + . + "Outcome o p dt " . + . + "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )" . + . + "Outcome o p pt" . + . + "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups t IOP " . + "p = 0 . 22" . + . + . + . + "DiffBetweenGroups d IOP " . + "p = 0 . 0007" . + . + . + . + "DiffBetweenGroups IOP " . + "p < 0 . 03" . + . + . + . + "DiffBetweenGroups v change " . + "p = 0 . 04" . + . + . + . + "DiffBetweenGroups o p" . + "p = 0 . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12859261_export.csv b/data/gl 12859261_export.csv new file mode 100644 index 0000000..1b22687 --- /dev/null +++ b/data/gl 12859261_export.csv @@ -0,0 +1,457 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +470, 1, 1, 1, 0, 4, 0, 4, "Acta" +470, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +470, 1, 3, 3, 16, 21, 16, 21, "Scand" +470, 1, 4, 4, 22, 23, 22, 23, "." +470, 2, 1, 5, 0, 4, 24, 28, "2003" +470, 2, 2, 6, 5, 8, 29, 32, "Aug" +470, 2, 3, 7, 9, 10, 33, 34, ";" +470, 2, 4, 8, 11, 13, 35, 37, "81" +470, 2, 5, 9, 14, 15, 38, 39, "(" +470, 2, 6, 10, 16, 17, 40, 41, "4" +470, 2, 7, 11, 18, 19, 42, 43, ")" +470, 2, 8, 12, 20, 21, 44, 45, ":" +470, 2, 9, 13, 22, 25, 46, 49, "349" +470, 2, 10, 14, 26, 27, 50, 51, "-" +470, 2, 11, 15, 28, 30, 52, 54, "54" +470, 2, 12, 16, 31, 32, 55, 56, "." +470, 3, 1, 17, 0, 7, 57, 64, "Timolol" +470, 3, 2, 18, 8, 9, 65, 66, "0" +470, 3, 3, 19, 10, 11, 67, 68, "." +470, 3, 4, 20, 12, 13, 69, 70, "5" +470, 3, 5, 21, 14, 15, 71, 72, "%" +470, 3, 6, 22, 16, 17, 73, 74, "/" +470, 3, 7, 23, 18, 29, 75, 86, "dorzolamide" +470, 3, 8, 24, 30, 31, 87, 88, "2" +470, 3, 9, 25, 32, 33, 89, 90, "%" +470, 3, 10, 26, 34, 39, 91, 96, "fixed" +470, 3, 11, 27, 40, 51, 97, 108, "combination" +470, 3, 12, 28, 52, 58, 109, 115, "versus" +470, 3, 13, 29, 59, 66, 116, 123, "timolol" +470, 3, 14, 30, 67, 68, 124, 125, "0" +470, 3, 15, 31, 69, 70, 126, 127, "." +470, 3, 16, 32, 71, 72, 128, 129, "5" +470, 3, 17, 33, 73, 74, 130, 131, "%" +470, 3, 18, 34, 75, 76, 132, 133, "/" +470, 3, 19, 35, 77, 88, 134, 145, "pilocarpine" +470, 3, 20, 36, 89, 90, 146, 147, "2" +470, 3, 21, 37, 91, 92, 148, 149, "%" +470, 3, 22, 38, 93, 98, 150, 155, "fixed" +470, 3, 23, 39, 99, 110, 156, 167, "combination" +470, 3, 24, 40, 111, 113, 168, 170, "in" +470, 3, 25, 41, 114, 121, 171, 178, "primary" +470, 3, 26, 42, 122, 126, 179, 183, "open" +470, 3, 27, 43, 127, 128, 184, 185, "-" +470, 3, 28, 44, 129, 134, 186, 191, "angle" +470, 3, 29, 45, 135, 143, 192, 200, "glaucoma" +470, 3, 30, 46, 144, 146, 201, 203, "or" +470, 3, 31, 47, 147, 153, 204, 210, "ocular" +470, 3, 32, 48, 154, 166, 211, 223, "hypertensive" +470, 3, 33, 49, 167, 175, 224, 232, "patients" +470, 3, 34, 50, 176, 177, 233, 234, "." +470, 4, 1, 51, 0, 2, 235, 237, "Ka" +470, 4, 2, 52, 3, 4, 238, 239, "ł" +470, 4, 3, 53, 5, 9, 240, 244, "uzny" +470, 4, 4, 54, 10, 12, 245, 247, "JJ" +470, 4, 5, 55, 13, 14, 248, 249, "(" +470, 4, 6, 56, 15, 16, 250, 251, "1" +470, 4, 7, 57, 17, 18, 252, 253, ")" +470, 4, 8, 58, 19, 20, 254, 255, "," +470, 4, 9, 59, 21, 28, 256, 263, "Szaflik" +470, 4, 10, 60, 29, 30, 264, 265, "J" +470, 4, 11, 61, 31, 32, 266, 267, "," +470, 4, 12, 62, 33, 43, 268, 278, "Czechowicz" +470, 4, 13, 63, 44, 45, 279, 280, "-" +470, 4, 14, 64, 46, 53, 281, 288, "Janicka" +470, 4, 15, 65, 54, 55, 289, 290, "K" +470, 4, 16, 66, 56, 57, 291, 292, "," +470, 4, 17, 67, 58, 60, 293, 295, "Ka" +470, 4, 18, 68, 61, 62, 296, 297, "ł" +470, 4, 19, 69, 63, 67, 298, 302, "uzny" +470, 4, 20, 70, 68, 69, 303, 304, "J" +470, 4, 21, 71, 70, 71, 305, 306, "," +470, 4, 22, 72, 72, 84, 307, 319, "Orzalkiewicz" +470, 4, 23, 73, 85, 86, 320, 321, "A" +470, 4, 24, 74, 87, 88, 322, 323, "," +470, 4, 25, 75, 89, 96, 324, 331, "Zaleska" +470, 4, 26, 76, 97, 98, 332, 333, "A" +470, 4, 27, 77, 99, 100, 334, 335, "," +470, 4, 28, 78, 101, 110, 336, 345, "Krajewska" +470, 4, 29, 79, 111, 112, 346, 347, "M" +470, 4, 30, 80, 113, 114, 348, 349, "," +470, 4, 31, 81, 115, 122, 350, 357, "Stewart" +470, 4, 32, 82, 123, 125, 358, 360, "JA" +470, 4, 33, 83, 126, 127, 361, 362, "," +470, 4, 34, 84, 128, 133, 363, 368, "Leech" +470, 4, 35, 85, 134, 136, 369, 371, "JN" +470, 4, 36, 86, 137, 138, 372, 373, "," +470, 4, 37, 87, 139, 146, 374, 381, "Stewart" +470, 4, 38, 88, 147, 149, 382, 384, "WC" +470, 4, 39, 89, 150, 151, 385, 386, "." +470, 5, 1, 90, 0, 6, 387, 393, "Author" +470, 5, 2, 91, 7, 18, 394, 405, "information" +470, 5, 3, 92, 19, 20, 406, 407, ":" +470, 5, 4, 93, 21, 22, 408, 409, "(" +470, 5, 5, 94, 23, 24, 410, 411, "1" +470, 5, 6, 95, 25, 26, 412, 413, ")" +470, 5, 7, 96, 27, 34, 414, 421, "Klinika" +470, 5, 8, 97, 35, 45, 422, 432, "Okulistyki" +470, 5, 9, 98, 46, 47, 433, 434, "," +470, 5, 10, 99, 48, 57, 435, 444, "Bydgoszcz" +470, 5, 11, 100, 58, 59, 445, 446, "," +470, 5, 12, 101, 60, 66, 447, 453, "Poland" +470, 5, 13, 102, 67, 68, 454, 455, "." +470, 6, 1, 103, 0, 7, 456, 463, "PURPOSE" +470, 6, 2, 104, 8, 9, 464, 465, ":" +470, 6, 3, 105, 10, 12, 466, 468, "To" +470, 6, 4, 106, 13, 22, 469, 478, "establish" +470, 6, 5, 107, 23, 26, 479, 482, "the" +470, 6, 6, 108, 27, 35, 483, 491, "efficacy" +470, 6, 7, 109, 36, 39, 492, 495, "and" +470, 6, 8, 110, 40, 46, 496, 502, "safety" +470, 6, 9, 111, 47, 49, 503, 505, "of" +470, 6, 10, 112, 50, 57, 506, 513, "timolol" +470, 6, 11, 113, 58, 65, 514, 521, "maleate" +470, 6, 12, 114, 66, 67, 522, 523, "/" +470, 6, 13, 115, 68, 79, 524, 535, "dorzolamide" +470, 6, 14, 116, 80, 85, 536, 541, "fixed" +470, 6, 15, 117, 86, 97, 542, 553, "combination" +470, 6, 16, 118, 98, 99, 554, 555, "(" +470, 6, 17, 119, 100, 104, 556, 560, "TDFC" +470, 6, 18, 120, 105, 106, 561, 562, ")" +470, 6, 19, 121, 107, 113, 563, 569, "versus" +470, 6, 20, 122, 114, 121, 570, 577, "timolol" +470, 6, 21, 123, 122, 129, 578, 585, "maleate" +470, 6, 22, 124, 130, 131, 586, 587, "/" +470, 6, 23, 125, 132, 143, 588, 599, "pilocarpine" +470, 6, 24, 126, 144, 149, 600, 605, "fixed" +470, 6, 25, 127, 150, 161, 606, 617, "combination" +470, 6, 26, 128, 162, 163, 618, 619, "(" +470, 6, 27, 129, 164, 168, 620, 624, "TPFC" +470, 6, 28, 130, 169, 170, 625, 626, ")" +470, 6, 29, 131, 171, 172, 627, 628, "," +470, 6, 30, 132, 173, 177, 629, 633, "each" +470, 6, 31, 133, 178, 183, 634, 639, "given" +470, 6, 32, 134, 184, 189, 640, 645, "twice" +470, 6, 33, 135, 190, 195, 646, 651, "daily" +470, 6, 34, 136, 196, 197, 652, 653, "," +470, 6, 35, 137, 198, 200, 654, 656, "in" +470, 6, 36, 138, 201, 208, 657, 664, "primary" +470, 6, 37, 139, 209, 213, 665, 669, "open" +470, 6, 38, 140, 214, 215, 670, 671, "-" +470, 6, 39, 141, 216, 221, 672, 677, "angle" +470, 6, 40, 142, 222, 230, 678, 686, "glaucoma" +470, 6, 41, 143, 231, 233, 687, 689, "or" +470, 6, 42, 144, 234, 240, 690, 696, "ocular" +470, 6, 43, 145, 241, 253, 697, 709, "hypertensive" +470, 6, 44, 146, 254, 262, 710, 718, "patients" +470, 6, 45, 147, 263, 264, 719, 720, "." +470, 7, 1, 148, 0, 7, 721, 728, "METHODS" +470, 7, 2, 149, 8, 9, 729, 730, ":" +470, 7, 3, 150, 10, 12, 731, 733, "In" +470, 7, 4, 151, 13, 17, 734, 738, "this" +470, 7, 5, 152, 18, 29, 739, 750, "prospective" +470, 7, 6, 153, 30, 31, 751, 752, "," +470, 7, 7, 154, 32, 44, 753, 765, "multicentred" +470, 7, 8, 155, 45, 46, 766, 767, "," +470, 7, 9, 156, 47, 53, 768, 774, "double" +470, 7, 10, 157, 54, 55, 775, 776, "-" +470, 7, 11, 158, 56, 62, 777, 783, "masked" +470, 7, 12, 159, 63, 68, 784, 789, "trial" +470, 7, 13, 160, 69, 70, 790, 791, "," +470, 7, 14, 161, 71, 73, 792, 794, "37" +470, 7, 15, 162, 74, 82, 795, 803, "patients" +470, 7, 16, 163, 83, 87, 804, 808, "were" +470, 7, 17, 164, 88, 95, 809, 816, "treated" +470, 7, 18, 165, 96, 101, 817, 822, "twice" +470, 7, 19, 166, 102, 107, 823, 828, "daily" +470, 7, 20, 167, 108, 112, 829, 833, "with" +470, 7, 21, 168, 113, 120, 834, 841, "timolol" +470, 7, 22, 169, 121, 124, 842, 845, "for" +470, 7, 23, 170, 125, 126, 846, 847, "4" +470, 7, 24, 171, 127, 132, 848, 853, "weeks" +470, 7, 25, 172, 133, 134, 854, 855, "." +470, 8, 1, 173, 0, 4, 856, 860, "They" +470, 8, 2, 174, 5, 9, 861, 865, "were" +470, 8, 3, 175, 10, 14, 866, 870, "then" +470, 8, 4, 176, 15, 25, 871, 881, "randomized" +470, 8, 5, 177, 26, 28, 882, 884, "to" +470, 8, 6, 178, 29, 32, 885, 888, "one" +470, 8, 7, 179, 33, 35, 889, 891, "of" +470, 8, 8, 180, 36, 39, 892, 895, "the" +470, 8, 9, 181, 40, 49, 896, 905, "treatment" +470, 8, 10, 182, 50, 61, 906, 917, "medications" +470, 8, 11, 183, 62, 65, 918, 921, "for" +470, 8, 12, 184, 66, 67, 922, 923, "6" +470, 8, 13, 185, 68, 73, 924, 929, "weeks" +470, 8, 14, 186, 74, 75, 930, 931, "," +470, 8, 15, 187, 76, 81, 932, 937, "after" +470, 8, 16, 188, 82, 87, 938, 943, "which" +470, 8, 17, 189, 88, 92, 944, 948, "they" +470, 8, 18, 190, 93, 97, 949, 953, "were" +470, 8, 19, 191, 98, 105, 954, 961, "treated" +470, 8, 20, 192, 106, 110, 962, 966, "with" +470, 8, 21, 193, 111, 118, 967, 974, "timolol" +470, 8, 22, 194, 119, 124, 975, 980, "again" +470, 8, 23, 195, 125, 128, 981, 984, "for" +470, 8, 24, 196, 129, 130, 985, 986, "2" +470, 8, 25, 197, 131, 136, 987, 992, "weeks" +470, 8, 26, 198, 137, 143, 993, 999, "before" +470, 8, 27, 199, 144, 149, 1000, 1005, "being" +470, 8, 28, 200, 150, 156, 1006, 1012, "placed" +470, 8, 29, 201, 157, 159, 1013, 1015, "on" +470, 8, 30, 202, 160, 163, 1016, 1019, "the" +470, 8, 31, 203, 164, 172, 1020, 1028, "opposite" +470, 8, 32, 204, 173, 182, 1029, 1038, "treatment" +470, 8, 33, 205, 183, 193, 1039, 1049, "medication" +470, 8, 34, 206, 194, 197, 1050, 1053, "for" +470, 8, 35, 207, 198, 199, 1054, 1055, "6" +470, 8, 36, 208, 200, 205, 1056, 1061, "weeks" +470, 8, 37, 209, 206, 207, 1062, 1063, "." +470, 9, 1, 210, 0, 7, 1064, 1071, "RESULTS" +470, 9, 2, 211, 8, 9, 1072, 1073, ":" +470, 9, 3, 212, 10, 11, 1074, 1075, "A" +470, 9, 4, 213, 12, 17, 1076, 1081, "total" +470, 9, 5, 214, 18, 20, 1082, 1084, "of" +470, 9, 6, 215, 21, 23, 1085, 1087, "36" +470, 9, 7, 216, 24, 32, 1088, 1096, "patients" +470, 9, 8, 217, 33, 42, 1097, 1106, "completed" +470, 9, 9, 218, 43, 46, 1107, 1110, "the" +470, 9, 10, 219, 47, 52, 1111, 1116, "trial" +470, 9, 11, 220, 53, 54, 1117, 1118, "." +470, 10, 1, 221, 0, 5, 1119, 1124, "Their" +470, 10, 2, 222, 6, 10, 1125, 1129, "mean" +470, 10, 3, 223, 11, 19, 1130, 1138, "baseline" +470, 10, 4, 224, 20, 31, 1139, 1150, "intraocular" +470, 10, 5, 225, 32, 40, 1151, 1159, "pressure" +470, 10, 6, 226, 41, 42, 1160, 1161, "(" +470, 10, 7, 227, 43, 46, 1162, 1165, "IOP" +470, 10, 8, 228, 47, 48, 1166, 1167, ")" +470, 10, 9, 229, 49, 52, 1168, 1171, "was" +470, 10, 10, 230, 53, 55, 1172, 1174, "22" +470, 10, 11, 231, 56, 57, 1175, 1176, "." +470, 10, 12, 232, 58, 59, 1177, 1178, "3" +470, 10, 13, 233, 60, 61, 1179, 1180, "+" +470, 10, 14, 234, 62, 63, 1181, 1182, "/" +470, 10, 15, 235, 64, 65, 1183, 1184, "-" +470, 10, 16, 236, 66, 67, 1185, 1186, "3" +470, 10, 17, 237, 68, 69, 1187, 1188, "." +470, 10, 18, 238, 70, 71, 1189, 1190, "7" +470, 10, 19, 239, 72, 76, 1191, 1195, "mmHg" +470, 10, 20, 240, 77, 78, 1196, 1197, "." +470, 11, 1, 241, 0, 9, 1198, 1207, "Following" +470, 11, 2, 242, 10, 11, 1208, 1209, "6" +470, 11, 3, 243, 12, 17, 1210, 1215, "weeks" +470, 11, 4, 244, 18, 20, 1216, 1218, "of" +470, 11, 5, 245, 21, 30, 1219, 1228, "treatment" +470, 11, 6, 246, 31, 32, 1229, 1230, "," +470, 11, 7, 247, 33, 36, 1231, 1234, "the" +470, 11, 8, 248, 37, 41, 1235, 1239, "mean" +470, 11, 9, 249, 42, 48, 1240, 1246, "trough" +470, 11, 10, 250, 49, 50, 1247, 1248, "(" +470, 11, 11, 251, 51, 53, 1249, 1251, "08" +470, 11, 12, 252, 54, 55, 1252, 1253, "." +470, 11, 13, 253, 56, 58, 1254, 1256, "00" +470, 11, 14, 254, 59, 64, 1257, 1262, "hours" +470, 11, 15, 255, 65, 66, 1263, 1264, ")" +470, 11, 16, 256, 67, 70, 1265, 1268, "IOP" +470, 11, 17, 257, 71, 74, 1269, 1272, "was" +470, 11, 18, 258, 75, 77, 1273, 1275, "18" +470, 11, 19, 259, 78, 79, 1276, 1277, "." +470, 11, 20, 260, 80, 81, 1278, 1279, "0" +470, 11, 21, 261, 82, 83, 1280, 1281, "+" +470, 11, 22, 262, 84, 85, 1282, 1283, "/" +470, 11, 23, 263, 86, 87, 1284, 1285, "-" +470, 11, 24, 264, 88, 89, 1286, 1287, "2" +470, 11, 25, 265, 90, 91, 1288, 1289, "." +470, 11, 26, 266, 92, 93, 1290, 1291, "2" +470, 11, 27, 267, 94, 98, 1292, 1296, "mmHg" +470, 11, 28, 268, 99, 102, 1297, 1300, "for" +470, 11, 29, 269, 103, 107, 1301, 1305, "TDFC" +470, 11, 30, 270, 108, 111, 1306, 1309, "and" +470, 11, 31, 271, 112, 114, 1310, 1312, "17" +470, 11, 32, 272, 115, 116, 1313, 1314, "." +470, 11, 33, 273, 117, 118, 1315, 1316, "4" +470, 11, 34, 274, 119, 120, 1317, 1318, "+" +470, 11, 35, 275, 121, 122, 1319, 1320, "/" +470, 11, 36, 276, 123, 124, 1321, 1322, "-" +470, 11, 37, 277, 125, 126, 1323, 1324, "2" +470, 11, 38, 278, 127, 128, 1325, 1326, "." +470, 11, 39, 279, 129, 130, 1327, 1328, "0" +470, 11, 40, 280, 131, 135, 1329, 1333, "mmHg" +470, 11, 41, 281, 136, 139, 1334, 1337, "for" +470, 11, 42, 282, 140, 144, 1338, 1342, "TPFC" +470, 11, 43, 283, 145, 146, 1343, 1344, "(" +470, 11, 44, 284, 147, 148, 1345, 1346, "p" +470, 11, 45, 285, 149, 150, 1347, 1348, "=" +470, 11, 46, 286, 151, 152, 1349, 1350, "0" +470, 11, 47, 287, 153, 154, 1351, 1352, "." +470, 11, 48, 288, 155, 157, 1353, 1355, "22" +470, 11, 49, 289, 158, 159, 1356, 1357, ")" +470, 11, 50, 290, 160, 161, 1358, 1359, "." +470, 12, 1, 291, 0, 3, 1360, 1363, "The" +470, 12, 2, 292, 4, 8, 1364, 1368, "mean" +470, 12, 3, 293, 9, 16, 1369, 1376, "diurnal" +470, 12, 4, 294, 17, 22, 1377, 1382, "curve" +470, 12, 5, 295, 23, 26, 1383, 1386, "IOP" +470, 12, 6, 296, 27, 30, 1387, 1390, "was" +470, 12, 7, 297, 31, 33, 1391, 1393, "18" +470, 12, 8, 298, 34, 35, 1394, 1395, "." +470, 12, 9, 299, 36, 37, 1396, 1397, "1" +470, 12, 10, 300, 38, 39, 1398, 1399, "+" +470, 12, 11, 301, 40, 41, 1400, 1401, "/" +470, 12, 12, 302, 42, 43, 1402, 1403, "-" +470, 12, 13, 303, 44, 45, 1404, 1405, "2" +470, 12, 14, 304, 46, 47, 1406, 1407, "." +470, 12, 15, 305, 48, 49, 1408, 1409, "2" +470, 12, 16, 306, 50, 54, 1410, 1414, "mmHg" +470, 12, 17, 307, 55, 58, 1415, 1418, "for" +470, 12, 18, 308, 59, 63, 1419, 1423, "TDFC" +470, 12, 19, 309, 64, 67, 1424, 1427, "and" +470, 12, 20, 310, 68, 70, 1428, 1430, "16" +470, 12, 21, 311, 71, 72, 1431, 1432, "." +470, 12, 22, 312, 73, 74, 1433, 1434, "7" +470, 12, 23, 313, 75, 76, 1435, 1436, "+" +470, 12, 24, 314, 77, 78, 1437, 1438, "/" +470, 12, 25, 315, 79, 80, 1439, 1440, "-" +470, 12, 26, 316, 81, 82, 1441, 1442, "1" +470, 12, 27, 317, 83, 84, 1443, 1444, "." +470, 12, 28, 318, 85, 86, 1445, 1446, "9" +470, 12, 29, 319, 87, 91, 1447, 1451, "mmHg" +470, 12, 30, 320, 92, 95, 1452, 1455, "for" +470, 12, 31, 321, 96, 100, 1456, 1460, "TPFC" +470, 12, 32, 322, 101, 102, 1461, 1462, "(" +470, 12, 33, 323, 103, 104, 1463, 1464, "p" +470, 12, 34, 324, 105, 106, 1465, 1466, "=" +470, 12, 35, 325, 107, 108, 1467, 1468, "0" +470, 12, 36, 326, 109, 110, 1469, 1470, "." +470, 12, 37, 327, 111, 115, 1471, 1475, "0007" +470, 12, 38, 328, 116, 117, 1476, 1477, ")" +470, 12, 39, 329, 118, 119, 1478, 1479, "." +470, 13, 1, 330, 0, 2, 1480, 1482, "At" +470, 13, 2, 331, 3, 6, 1483, 1486, "the" +470, 13, 3, 332, 7, 16, 1487, 1496, "remaining" +470, 13, 4, 333, 17, 21, 1497, 1501, "time" +470, 13, 5, 334, 22, 23, 1502, 1503, "-" +470, 13, 6, 335, 24, 30, 1504, 1510, "points" +470, 13, 7, 336, 31, 32, 1511, 1512, "(" +470, 13, 8, 337, 33, 35, 1513, 1515, "10" +470, 13, 9, 338, 36, 37, 1516, 1517, "." +470, 13, 10, 339, 38, 40, 1518, 1520, "00" +470, 13, 11, 340, 41, 42, 1521, 1522, "," +470, 13, 12, 341, 43, 45, 1523, 1525, "18" +470, 13, 13, 342, 46, 47, 1526, 1527, "." +470, 13, 14, 343, 48, 50, 1528, 1530, "00" +470, 13, 15, 344, 51, 54, 1531, 1534, "and" +470, 13, 16, 345, 55, 57, 1535, 1537, "20" +470, 13, 17, 346, 58, 59, 1538, 1539, "." +470, 13, 18, 347, 60, 62, 1540, 1542, "00" +470, 13, 19, 348, 63, 68, 1543, 1548, "hours" +470, 13, 20, 349, 69, 70, 1549, 1550, ")" +470, 13, 21, 350, 71, 72, 1551, 1552, "," +470, 13, 22, 351, 73, 77, 1553, 1557, "TPFC" +470, 13, 23, 352, 78, 82, 1558, 1562, "IOPs" +470, 13, 24, 353, 83, 87, 1563, 1567, "were" +470, 13, 25, 354, 88, 101, 1568, 1581, "statistically" +470, 13, 26, 355, 102, 107, 1582, 1587, "lower" +470, 13, 27, 356, 108, 112, 1588, 1592, "than" +470, 13, 28, 357, 113, 117, 1593, 1597, "TDFC" +470, 13, 29, 358, 118, 122, 1598, 1602, "IOPs" +470, 13, 30, 359, 123, 124, 1603, 1604, "(" +470, 13, 31, 360, 125, 126, 1605, 1606, "p" +470, 13, 32, 361, 127, 128, 1607, 1608, "<" +470, 13, 33, 362, 129, 130, 1609, 1610, "0" +470, 13, 34, 363, 131, 132, 1611, 1612, "." +470, 13, 35, 364, 133, 135, 1613, 1615, "03" +470, 13, 36, 365, 136, 137, 1616, 1617, ")" +470, 13, 37, 366, 138, 139, 1618, 1619, "." +470, 14, 1, 367, 0, 5, 1620, 1625, "There" +470, 14, 2, 368, 6, 10, 1626, 1630, "were" +470, 14, 3, 369, 11, 24, 1631, 1644, "statistically" +470, 14, 4, 370, 25, 29, 1645, 1649, "more" +470, 14, 5, 371, 30, 41, 1650, 1661, "unsolicited" +470, 14, 6, 372, 42, 49, 1662, 1669, "reports" +470, 14, 7, 373, 50, 52, 1670, 1672, "of" +470, 14, 8, 374, 53, 59, 1673, 1679, "vision" +470, 14, 9, 375, 60, 66, 1680, 1686, "change" +470, 14, 10, 376, 67, 70, 1687, 1690, "and" +470, 14, 11, 377, 71, 77, 1691, 1697, "ocular" +470, 14, 12, 378, 78, 82, 1698, 1702, "pain" +470, 14, 13, 379, 83, 93, 1703, 1713, "associated" +470, 14, 14, 380, 94, 98, 1714, 1718, "with" +470, 14, 15, 381, 99, 103, 1719, 1723, "TPFC" +470, 14, 16, 382, 104, 105, 1724, 1725, "(" +470, 14, 17, 383, 106, 107, 1726, 1727, "p" +470, 14, 18, 384, 108, 109, 1728, 1729, "=" +470, 14, 19, 385, 110, 111, 1730, 1731, "0" +470, 14, 20, 386, 112, 113, 1732, 1733, "." +470, 14, 21, 387, 114, 116, 1734, 1736, "04" +470, 14, 22, 388, 117, 118, 1737, 1738, ")" +470, 14, 23, 389, 119, 120, 1739, 1740, "." +470, 15, 1, 390, 0, 3, 1741, 1744, "Six" +470, 15, 2, 391, 4, 12, 1745, 1753, "patients" +470, 15, 3, 392, 13, 17, 1754, 1758, "were" +470, 15, 4, 393, 18, 30, 1759, 1771, "discontinued" +470, 15, 5, 394, 31, 36, 1772, 1777, "early" +470, 15, 6, 395, 37, 41, 1778, 1782, "from" +470, 15, 7, 396, 42, 46, 1783, 1787, "TPFC" +470, 15, 8, 397, 47, 54, 1788, 1795, "therapy" +470, 15, 9, 398, 55, 56, 1796, 1797, "(" +470, 15, 10, 399, 57, 59, 1798, 1800, "17" +470, 15, 11, 400, 60, 61, 1801, 1802, "%" +470, 15, 12, 401, 62, 63, 1803, 1804, ")" +470, 15, 13, 402, 64, 70, 1805, 1811, "versus" +470, 15, 14, 403, 71, 74, 1812, 1815, "two" +470, 15, 15, 404, 75, 79, 1816, 1820, "from" +470, 15, 16, 405, 80, 84, 1821, 1825, "TDFC" +470, 15, 17, 406, 85, 86, 1826, 1827, "(" +470, 15, 18, 407, 87, 88, 1828, 1829, "6" +470, 15, 19, 408, 89, 90, 1830, 1831, "%" +470, 15, 20, 409, 91, 92, 1832, 1833, ")" +470, 15, 21, 410, 93, 94, 1834, 1835, "(" +470, 15, 22, 411, 95, 96, 1836, 1837, "p" +470, 15, 23, 412, 97, 98, 1838, 1839, "=" +470, 15, 24, 413, 99, 100, 1840, 1841, "0" +470, 15, 25, 414, 101, 102, 1842, 1843, "." +470, 15, 26, 415, 103, 105, 1844, 1846, "13" +470, 15, 27, 416, 106, 107, 1847, 1848, ")" +470, 15, 28, 417, 108, 109, 1849, 1850, "." +470, 16, 1, 418, 0, 11, 1851, 1862, "CONCLUSIONS" +470, 16, 2, 419, 12, 13, 1863, 1864, ":" +470, 16, 3, 420, 14, 18, 1865, 1869, "This" +470, 16, 4, 421, 19, 24, 1870, 1875, "study" +470, 16, 5, 422, 25, 33, 1876, 1884, "suggests" +470, 16, 6, 423, 34, 38, 1885, 1889, "that" +470, 16, 7, 424, 39, 43, 1890, 1894, "TPFC" +470, 16, 8, 425, 44, 47, 1895, 1898, "can" +470, 16, 9, 426, 48, 55, 1899, 1906, "provide" +470, 16, 10, 427, 56, 58, 1907, 1909, "at" +470, 16, 11, 428, 59, 64, 1910, 1915, "least" +470, 16, 12, 429, 65, 66, 1916, 1917, "a" +470, 16, 13, 430, 67, 74, 1918, 1925, "similar" +470, 16, 14, 431, 75, 86, 1926, 1937, "efficacious" +470, 16, 15, 432, 87, 96, 1938, 1947, "reduction" +470, 16, 16, 433, 97, 99, 1948, 1950, "in" +470, 16, 17, 434, 100, 103, 1951, 1954, "IOP" +470, 16, 18, 435, 104, 106, 1955, 1957, "as" +470, 16, 19, 436, 107, 111, 1958, 1962, "TDFC" +470, 16, 20, 437, 112, 114, 1963, 1965, "in" +470, 16, 21, 438, 115, 123, 1966, 1974, "patients" +470, 16, 22, 439, 124, 128, 1975, 1979, "with" +470, 16, 23, 440, 129, 136, 1980, 1987, "primary" +470, 16, 24, 441, 137, 141, 1988, 1992, "open" +470, 16, 25, 442, 142, 143, 1993, 1994, "-" +470, 16, 26, 443, 144, 149, 1995, 2000, "angle" +470, 16, 27, 444, 150, 158, 2001, 2009, "glaucoma" +470, 16, 28, 445, 159, 161, 2010, 2012, "or" +470, 16, 29, 446, 162, 168, 2013, 2019, "ocular" +470, 16, 30, 447, 169, 181, 2020, 2032, "hypertension" +470, 16, 31, 448, 182, 183, 2033, 2034, "." +470, 17, 1, 449, 0, 4, 2035, 2039, "PMID" +470, 17, 2, 450, 5, 6, 2040, 2041, ":" +470, 17, 3, 451, 7, 15, 2042, 2050, "12859261" +470, 17, 4, 452, 16, 17, 2051, 2052, "[" +470, 17, 5, 453, 18, 25, 2053, 2060, "Indexed" +470, 17, 6, 454, 26, 29, 2061, 2064, "for" +470, 17, 7, 455, 30, 37, 2065, 2072, "MEDLINE" +470, 17, 8, 456, 38, 39, 2073, 2074, "]" diff --git a/data/gl 12859261_jshahinitiran.annodb b/data/gl 12859261_jshahinitiran.annodb new file mode 100644 index 0000000..5e7533c --- /dev/null +++ b/data/gl 12859261_jshahinitiran.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +386, Journal, 0, 21, "Acta Ophthalmol Scand", "", +387, PublicationYear, 24, 28, "2003", "", +26378, Timolol, 57, 64, "Timolol", "", +39063, Title, 57, 234, "Timolol 0 . 5 % / dorzolamide 2 % fixed combination versus timolol 0 . 5 % / pilocarpine 2 % fixed combination in primary open - angle glaucoma or ocular hypertensive patients .", "", +39064, Dorz/TimFC, 57, 108, "Timolol 0 . 5 % / dorzolamide 2 % fixed combination", "", +404, DoseValue, 65, 70, "0 . 5", "tim", +405, Percentage, 71, 72, "%", "tim", +26379, Dorzolamide, 75, 86, "dorzolamide", "", +406, DoseValue, 87, 88, "2", "dor", +407, Percentage, 89, 90, "%", "dor", +26380, Timolol, 116, 123, "timolol", "", +39065, Pilo/TimFC, 116, 167, "timolol 0 . 5 % / pilocarpine 2 % fixed combination", "", +408, DoseValue, 124, 129, "0 . 5", "tim", +409, Percentage, 130, 131, "%", "tim", +26381, Pilocarpine, 134, 145, "pilocarpine", "", +410, DoseValue, 146, 147, "2", "pil", +411, Percentage, 148, 149, "%", "pil", +26382, Primary_OpenAngleGlaucoma, 171, 200, "primary open - angle glaucoma", "", +413, OcularHypertension, 204, 223, "ocular hypertensive", "", +414, Author, 235, 247, "Ka ł uzny JJ", "", +415, Author, 256, 265, "Szaflik J", "", +416, Author, 268, 290, "Czechowicz - Janicka K", "", +417, Author, 293, 304, "Ka ł uzny J", "", +418, Author, 307, 321, "Orzalkiewicz A", "", +419, Author, 324, 333, "Zaleska A", "", +420, Author, 336, 347, "Krajewska M", "", +421, Author, 350, 360, "Stewart JA", "", +422, Author, 363, 371, "Leech JN", "", +423, Author, 374, 384, "Stewart WC", "", +424, Poland, 447, 453, "Poland", "", +425, ObjectiveDescription, 466, 720, "To establish the efficacy and safety of timolol maleate / dorzolamide fixed combination ( TDFC ) versus timolol maleate / pilocarpine fixed combination ( TPFC ) , each given twice daily , in primary open - angle glaucoma or ocular hypertensive patients .", "", +26384, Timolol, 506, 521, "timolol maleate", "", +39066, Dorz/TimFC, 506, 553, "timolol maleate / dorzolamide fixed combination", "", +26385, Dorzolamide, 524, 535, "dorzolamide", "", +39067, Dorz/TimFC, 556, 560, "TDFC", "", +26386, Timolol, 570, 585, "timolol maleate", "", +39068, Pilo/TimFC, 570, 617, "timolol maleate / pilocarpine fixed combination", "", +26387, Pilocarpine, 588, 599, "pilocarpine", "", +39069, Pilo/TimFC, 620, 624, "TPFC", "", +426, Frequency, 640, 651, "twice daily", "", +26388, Primary_OpenAngleGlaucoma, 657, 686, "primary open - angle glaucoma", "", +413, OcularHypertension, 690, 709, "ocular hypertensive", "", +39070, Prospective, 739, 750, "prospective", "", +433, Multicenter, 753, 765, "multicentred", "", +434, DoubleBlind, 768, 783, "double - masked", "", +435, NumberPatientsCT, 792, 794, "37", "", +437, Frequency, 817, 828, "twice daily", "int1", +26389, Timolol, 834, 841, "timolol", "", +436, Duration, 846, 853, "4 weeks", "int1", +440, Randomized, 871, 881, "randomized", "", +438, Duration, 922, 929, "6 weeks", "intA/B", +26390, Timolol, 967, 974, "timolol", "", +439, Duration, 985, 992, "2 weeks", "int2", +26391, Duration, 1054, 1061, "6 weeks", "", +8770, FinalNumPatientsCT, 1085, 1087, "36", "", +441, Mean, 1125, 1129, "mean", "bl", +26392, IOP, 1139, 1159, "intraocular pressure", "", +26393, IOP, 1162, 1165, "IOP", "", +444, BaseLineValue, 1172, 1178, "22 . 3", "", +445, SdErrorBL, 1185, 1190, "3 . 7", "", +446, mmHg, 1191, 1195, "mmHg", "bl", +26394, Duration, 1208, 1215, "6 weeks", "", +7303, Mean, 1235, 1239, "mean", "", +7304, Trough_IOP, 1240, 1268, "trough ( 08 . 00 hours ) IOP", "", +7305, ResultMeasuredValue, 1273, 1279, "18 . 0", "", +7306, SdErrorResValue, 1286, 1291, "2 . 2", "", +7307, mmHg, 1292, 1296, "mmHg", "", +39071, Dorz/TimFC, 1301, 1305, "TDFC", "", +7308, ResultMeasuredValue, 1310, 1316, "17 . 4", "", +7309, SdErrorResValue, 1323, 1328, "2 . 0", "", +7310, mmHg, 1329, 1333, "mmHg", "", +39072, Pilo/TimFC, 1338, 1342, "TPFC", "", +7311, PValueResValue, 1345, 1355, "p = 0 . 22", "", +7312, Mean, 1364, 1368, "mean", "", +7313, Diurnal_IOP, 1369, 1386, "diurnal curve IOP", "", +7314, ResultMeasuredValue, 1391, 1397, "18 . 1", "", +7316, SdErrorResValue, 1404, 1409, "2 . 2", "", +7318, mmHg, 1410, 1414, "mmHg", "", +39075, Dorz/TimFC, 1419, 1423, "TDFC", "", +7315, ResultMeasuredValue, 1428, 1434, "16 . 7", "", +7317, SdErrorResValue, 1441, 1446, "1 . 9", "", +7319, mmHg, 1447, 1451, "mmHg", "", +39073, Pilo/TimFC, 1456, 1460, "TPFC", "", +7320, PValueResValue, 1463, 1475, "p = 0 . 0007", "", +39074, Pilo/TimFC, 1553, 1557, "TPFC", "", +10415, IOP, 1558, 1562, "IOPs", "", +39076, Dorz/TimFC, 1593, 1597, "TDFC", "", +10416, IOP, 1598, 1602, "IOPs", "", +10417, PvalueDiff, 1605, 1615, "p < 0 . 03", "", +10414, ObservedResult, 1620, 1738, "There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC ( p = 0 . 04 )", "", +39079, Pilo/TimFC, 1719, 1723, "TPFC", "", +26395, PValueNumAffected, 1726, 1736, "p = 0 . 04", "", +7321, NumPatientsLeftArm, 1741, 1744, "Six", "", +39080, Pilo/TimFC, 1783, 1787, "TPFC", "", +7322, NumPatientsLeftArm, 1812, 1815, "two", "", +39077, Dorz/TimFC, 1821, 1825, "TDFC", "", +7323, ConclusionComment, 1865, 2034, "This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open - angle glaucoma or ocular hypertension .", "", +39081, Pilo/TimFC, 1890, 1894, "TPFC", "", +7324, IOP, 1951, 1954, "IOP", "", +39078, Dorz/TimFC, 1958, 1962, "TDFC", "", +26396, Primary_OpenAngleGlaucoma, 1980, 2009, "primary open - angle glaucoma", "", +7326, OcularHypertension, 2013, 2032, "ocular hypertension", "", +7327, PMID, 2042, 2050, "12859261", "", diff --git a/data/gl 12859261_jshahinitiran.n-triples b/data/gl 12859261_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12859261_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12859261_tstrakeljahn.annodb b/data/gl 12859261_tstrakeljahn.annodb new file mode 100644 index 0000000..ab065ad --- /dev/null +++ b/data/gl 12859261_tstrakeljahn.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30872, Journal, 0, 21, "Acta Ophthalmol Scand", "", +30873, PublicationYear, 24, 28, "2003", "", +30874, Timolol, 57, 64, "Timolol", "", +30888, Title, 57, 234, "Timolol 0 . 5 % / dorzolamide 2 % fixed combination versus timolol 0 . 5 % / pilocarpine 2 % fixed combination in primary open - angle glaucoma or ocular hypertensive patients .", "", +79610, Dorz/TimFC, 57, 86, "Timolol 0 . 5 % / dorzolamide", "", +30875, DoseValue, 65, 70, "0 . 5", "", +30880, Percentage, 71, 72, "%", "", +30876, Dorzolamide, 75, 86, "dorzolamide", "", +30877, DoseValue, 87, 88, "2", "", +30881, Percentage, 89, 90, "%", "", +79613, Pilo/TimFC, 116, 145, "timolol 0 . 5 % / pilocarpine", "", +30878, DoseValue, 124, 129, "0 . 5", "", +30882, Percentage, 130, 131, "%", "", +30886, Pilocarpine, 134, 145, "pilocarpine", "", +30879, DoseValue, 146, 147, "2", "", +30883, Percentage, 148, 149, "%", "", +30884, Primary_OpenAngleGlaucoma, 171, 200, "primary open - angle glaucoma", "", +30885, OcularHypertension, 204, 223, "ocular hypertensive", "", +30887, Author, 235, 247, "Ka ł uzny JJ", "", +30889, Author, 256, 265, "Szaflik J", "", +30890, Author, 268, 290, "Czechowicz - Janicka K", "", +30891, Author, 293, 304, "Ka ł uzny J", "", +30892, Author, 307, 321, "Orzalkiewicz A", "", +30893, Author, 324, 333, "Zaleska A", "", +30894, Author, 336, 347, "Krajewska M", "", +30895, Author, 350, 360, "Stewart JA", "", +30896, Author, 363, 371, "Leech JN", "", +30897, Author, 374, 384, "Stewart WC", "", +30898, Poland, 447, 453, "Poland", "", +30899, Timolol, 506, 521, "timolol maleate", "", +79615, Dorz/TimFC, 506, 535, "timolol maleate / dorzolamide", "", +30900, Dorzolamide, 524, 535, "dorzolamide", "", +79617, Dorz/TimFC, 556, 560, "TDFC", "", +30901, Drug, 556, 560, "TDFC", "Timolol Dorzolamide Fixed Combination", +30902, Timolol, 570, 585, "timolol maleate", "", +30903, Pilocarpine, 588, 599, "pilocarpine", "", +30904, Drug, 620, 624, "TPFC", "Timolol Pilocarpine Fixed Combination", +30905, Frequency, 640, 651, "twice daily", "", +30906, Primary_OpenAngleGlaucoma, 657, 686, "primary open - angle glaucoma", "", +30907, OcularHypertension, 690, 709, "ocular hypertensive", "", +30908, Multicenter, 753, 765, "multicentred", "", +30909, DoubleBlind, 768, 783, "double - masked", "", +30910, NumberPatientsCT, 792, 794, "37", "", +30913, Precondition, 809, 853, "treated twice daily with timolol for 4 weeks", "", +30911, Frequency, 817, 828, "twice daily", "", +30912, Timolol, 834, 841, "timolol", "", +30915, Randomized, 871, 881, "randomized", "", +79624, Timolol, 967, 974, "timolol", "", +79626, FinalNumPatientsCT, 1085, 1087, "36", "", +79628, Mean, 1125, 1129, "mean", "", +79629, IOP, 1139, 1159, "intraocular pressure", "", +79631, IOP, 1162, 1165, "IOP", "", +79632, BaseLineValue, 1172, 1178, "22 . 3", "", +79634, SdDevBL, 1185, 1190, "3 . 7", "", +79636, mmHg, 1191, 1195, "mmHg", "", +79638, Mean, 1235, 1239, "mean", "", +79639, Trough_IOP, 1240, 1268, "trough ( 08 . 00 hours ) IOP", "", +79640, Trough_IOP, 1273, 1279, "18 . 0", "", +79644, SdDevResValue, 1286, 1291, "2 . 2", "", +79647, mmHg, 1292, 1296, "mmHg", "", +79650, Dorz/TimFC, 1301, 1305, "TDFC", "", +79641, Trough_IOP, 1310, 1316, "17 . 4", "", +79646, SdDevResValue, 1323, 1328, "2 . 0", "", +79648, mmHg, 1329, 1333, "mmHg", "", +79652, Pilo/TimFC, 1338, 1342, "TPFC", "", +79654, PvalueDiff, 1347, 1355, "= 0 . 22", "", +79656, Mean, 1364, 1368, "mean", "", +79657, Diurnal_IOP, 1369, 1386, "diurnal curve IOP", "", +79667, ResultMeasuredValue, 1391, 1397, "18 . 1", "", +79669, SdDevResValue, 1404, 1409, "2 . 2", "", +79671, mmHg, 1410, 1414, "mmHg", "", +79673, Dorz/TimFC, 1419, 1423, "TDFC", "", +79668, ResultMeasuredValue, 1428, 1434, "16 . 7", "", +79670, SdDevResValue, 1441, 1446, "1 . 9", "", +79672, mmHg, 1447, 1451, "mmHg", "", +79674, Pilo/TimFC, 1456, 1460, "TPFC", "", +79675, PvalueDiff, 1465, 1475, "= 0 . 0007", "", +79676, Morning, 1513, 1520, "10 . 00", "", +79677, Afternoon, 1523, 1530, "18 . 00", "", +79678, Evening, 1535, 1542, "20 . 00", "", +79679, Pilo/TimFC, 1553, 1557, "TPFC", "", +79680, IOP, 1558, 1562, "IOPs", "", +79682, Dorz/TimFC, 1593, 1597, "TDFC", "", +79681, IOP, 1598, 1602, "IOPs", "", +79684, PvalueDiff, 1607, 1615, "< 0 . 03", "", +79689, Pilo/TimFC, 1719, 1723, "TPFC", "", +79691, PvalueDiff, 1728, 1736, "= 0 . 04", "", +79695, NumberAffected, 1741, 1744, "Six", "", +79693, SubGroupDescription, 1759, 1771, "discontinued", "", +79700, Pilocarpine, 1783, 1787, "TPFC", "", +79698, PercentageAffected, 1798, 1800, "17", "", +79696, NumberAffected, 1812, 1815, "two", "", +79701, Dorz/TimFC, 1821, 1825, "TDFC", "", +79699, PercentageAffected, 1828, 1829, "6", "", +79702, PvalueDiff, 1838, 1846, "= 0 . 13", "", +79709, ConclusionComment, 1865, 2034, "This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open - angle glaucoma or ocular hypertension .", "", +79703, Pilo/TimFC, 1890, 1894, "TPFC", "", +79705, IOP, 1951, 1954, "IOP", "", +79704, Dorz/TimFC, 1958, 1962, "TDFC", "", +79706, Primary_OpenAngleGlaucoma, 1980, 2009, "primary open - angle glaucoma", "", +79707, OcularHypertension, 2013, 2032, "ocular hypertension", "", +79708, PMID, 2042, 2050, "12859261", "", diff --git a/data/gl 12859261_tstrakeljahn.n-triples b/data/gl 12859261_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12859261_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12867391_admin.annodb b/data/gl 12867391_admin.annodb new file mode 100644 index 0000000..386b31e --- /dev/null +++ b/data/gl 12867391_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2003", "", " \"2003\"." +13, Title, 51, 199, "Twenty - four - hour diurnal curve comparison of commercially available latanoprost 0 . 005 % versus the timolol and dorzolamide fixed combination .", "", " \"Twenty - four - hour diurnal curve comparison of commercially available latanoprost 0 . 005 % versus the timolol and dorzolamide fixed combination .\"." +2, Latanoprost, 123, 134, "latanoprost", "", +6, DoseValue, 135, 142, "0 . 005", "", +7, Percentage, 143, 144, "%", "", +105, Dorz/TimFC, 156, 197, "timolol and dorzolamide fixed combination", "", +3, Timolol, 156, 163, "timolol", "", +4, Dorzolamide, 168, 179, "dorzolamide", "", +8, Author, 200, 210, "Konstas AG", "", " \"Konstas AG\"." +9, Author, 219, 230, "Papapanos P", "", " \"Papapanos P\"." +10, Author, 233, 241, "Tersis I", "", " \"Tersis I\"." +11, Author, 244, 254, "Houliara D", "", " \"Houliara D\"." +12, Author, 257, 267, "Stewart WC", "", " \"Stewart WC\"." +14, Greece, 370, 376, "Greece", "", +112, ObjectiveDescription, 389, 562, "To evaluate the efficacy and safety of commercially available latanoprost 0 . 005 % given every evening versus timolol 0 . 5 % and dorzolamide 2 % fixed combination ( TDFC )", "", " \"To evaluate the efficacy and safety of commercially available latanoprost 0 . 005 % given every evening versus timolol 0 . 5 % and dorzolamide 2 % fixed combination ( TDFC )\"." +15, Latanoprost, 451, 462, "latanoprost", "", " . ." +16, DoseValue, 463, 470, "0 . 005", "", " \"0 . 005\"." +19, Percentage, 471, 472, "%", "", " ." +123, Evening, 485, 492, "evening", "", " ." +120, Dorz/TimFC, 500, 553, "timolol 0 . 5 % and dorzolamide 2 % fixed combination", "", " ." +24, Timolol, 500, 507, "timolol", "", +17, DoseValue, 508, 513, "0 . 5", "", +20, Percentage, 514, 515, "%", "", +22, Dorzolamide, 520, 531, "dorzolamide", "", +18, DoseValue, 532, 533, "2", "", +21, Percentage, 534, 535, "%", "", +23, Dorz/TimFC, 556, 560, "TDFC", "", +112, ObjectiveDescription, 563, 666, "given twice daily to white Greeks with primary open - angle glaucoma and ocular hypertensive patients .", "", " \"given twice daily to white Greeks with primary open - angle glaucoma and ocular hypertensive patients .\"." +25, Frequency, 569, 580, "twice daily", "", " \"twice daily\"." +100499, Precondition, 584, 664, "white Greeks with primary open - angle glaucoma and ocular hypertensive patients", "", " \"white Greeks with primary open - angle glaucoma and ocular hypertensive patients\"." +28, Ethnicity, 584, 596, "white Greeks", "", " . ." +26, Primary_OpenAngleGlaucoma, 602, 631, "primary open - angle glaucoma", "", " ." +27, OcularHypertension, 636, 655, "ocular hypertensive", "", " ." +127, Blind, 678, 693, "single - masked", "", " ." +32, Multicenter, 696, 708, "two - center", "", " ." +33, Crossover, 711, 720, "crossover", "", " ." +130, Duration, 741, 749, "6 - week", "", " \"6 - week\"." +35, Diurnal_IOP, 829, 864, "Diurnal curve intraocular pressures", "", +36, TimePoint, 879, 888, "2 : 00 AM", "", +37, TimePoint, 891, 900, "6 : 00 AM", "", +38, TimePoint, 903, 913, "10 : 00 AM", "", +39, TimePoint, 916, 925, "2 : 00 PM", "", +40, TimePoint, 928, 937, "6 : 00 PM", "", +41, TimePoint, 944, 954, "10 : 00 PM", "", +42, NumberPatientsCT, 972, 985, "Thirty - four", "", " \"Thirty - four\"." +100501, Precondition, 986, 1052, "subjects with primary open - angle glaucoma or ocular hypertension", "", " \"subjects with primary open - angle glaucoma or ocular hypertension\"." +43, Primary_OpenAngleGlaucoma, 1000, 1029, "primary open - angle glaucoma", "", +44, OcularHypertension, 1033, 1052, "ocular hypertension", "", +45, Latanoprost, 1085, 1096, "Latanoprost", "", +46, DoseValue, 1097, 1104, "0 . 005", "", +47, Percentage, 1105, 1106, "%", "", +50, Frequency, 1113, 1126, "every evening", "", " \"every evening\"." +49, Evening, 1119, 1126, "evening", "", +81, Dorz/TimFC, 1131, 1135, "TDFC", "", +48, Frequency, 1136, 1147, "twice daily", "", +51, Diurnal_IOP, 1208, 1236, "diurnal intraocular pressure", "", +52, FinalNumPatientsCT, 1249, 1263, "Thirty - three", "", " \"Thirty - three\"." +100502, TimePoint, 1298, 1310, "the last day", "", +53, Mean, 1330, 1334, "mean", "", " \"Thirty - three\"." +54, Diurnal_IOP, 1335, 1363, "diurnal intraocular pressure", "", " ." +55, Latanoprost, 1368, 1379, "latanoprost", "", +56, ResultMeasuredValue, 1384, 1390, "15 . 9", "", " \"15 . 9\"." +60, SdDevResValue, 1397, 1402, "2 . 3", "", " \"2 . 3\"." +58, mmHg, 1403, 1407, "mmHg", "", " ." +82, Dorz/TimFC, 1416, 1420, "TDFC", "", +57, ResultMeasuredValue, 1425, 1431, "15 . 3", "", " \"15 . 3\"." +61, SdDevResValue, 1438, 1443, "2 . 0", "", " \"2 . 0\"." +59, mmHg, 1444, 1448, "mmHg", "", +62, PvalueDiff, 1453, 1461, "= 0 . 05", "", " \"= 0 . 05\"." +63, IOP, 1493, 1513, "intraocular pressure", "", +64, TimePoint, 1576, 1586, "10 : 00 PM", "", " \"10 : 00 PM\". \"10 : 00 PM\"." +65, Mean, 1609, 1613, "mean", "", +83, Dorz/TimFC, 1618, 1622, "TDFC", "", +66, ResultMeasuredValue, 1627, 1633, "14 . 6", "", " \"14 . 6\"." +68, SdDevResValue, 1640, 1645, "2 . 7", "", " \"2 . 7\"." +71, mmHg, 1646, 1650, "mmHg", "", +72, Latanoprost, 1659, 1670, "latanoprost", "", +67, ResultMeasuredValue, 1675, 1681, "16 . 6", "", " \"16 . 6\"." +69, SdDevResValue, 1688, 1693, "3 . 1", "", " \"3 . 1\"." +70, mmHg, 1694, 1698, "mmHg", "", +100503, PvalueDiff, 1701, 1717, "P & lt ; 0 . 006", "", " \"P & lt ; 0 . 006\"." +73, Latanoprost, 1758, 1769, "latanoprost", "", +74, Frequency, 1864, 1874, "once daily", "", +100504, EndPointDescription, 1884, 1898, "Adverse events", "", +100505, ObservedResult, 1899, 1946, "were not significantly different between groups", "", +100506, EndPointDescription, 1961, 1973, "bitter taste", "", " . ." +79, Dorz/TimFC, 2005, 2009, "TDFC", "", +84, NumberAffected, 2016, 2017, "9", "", " \"9\"." +87, Latanoprost, 2030, 2041, "latanoprost", "", +85, NumberAffected, 2048, 2049, "0", "", +86, PvalueDiff, 2054, 2063, "= 0 . 009", "", " \"= 0 . 009\"." +171, NumPatientsLeftArm, 2132, 2138, "single", "", " \"single\"." +88, Dorz/TimFC, 2170, 2174, "TDFC", "", +100507, EndPointDescription, 2186, 2204, "new - onset asthma", "", +96, ConclusionComment, 2221, 2461, "This study indicates that the 24 - hour diurnal intraocular pressure is lowered more , by a small but statistically significant amount , with TDFC compared with latanoprost in primary open - angle glaucoma and ocular hypertensive patients .", "", " \"This study indicates that the 24 - hour diurnal intraocular pressure is lowered more , by a small but statistically significant amount , with TDFC compared with latanoprost in primary open - angle glaucoma and ocular hypertensive patients .\"." +91, Diurnal_IOP, 2261, 2289, "diurnal intraocular pressure", "", +92, Dorz/TimFC, 2363, 2367, "TDFC", "", +93, Latanoprost, 2382, 2393, "latanoprost", "", +94, Primary_OpenAngleGlaucoma, 2397, 2426, "primary open - angle glaucoma", "", +95, OcularHypertension, 2431, 2450, "ocular hypertensive", "", +97, PMID, 2517, 2525, "12867391", "", " \"12867391\"." diff --git a/data/gl 12867391_admin.n-triples b/data/gl 12867391_admin.n-triples new file mode 100644 index 0000000..577c1cc --- /dev/null +++ b/data/gl 12867391_admin.n-triples @@ -0,0 +1,145 @@ +# RDF export of group: Publication + . + "Publication 88650" . + "Twenty - four - hour diurnal curve comparison of commercially available latanoprost 0 . 005 % versus the timolol and dorzolamide fixed combination ." . + "Konstas AG" . + "2003" . + "Ophthalmology" . + "12867391" . + . + "Papapanos P" . + "Tersis I" . + "Houliara D" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 88657" . + "To evaluate the efficacy and safety of commercially available latanoprost 0 . 005 % given every evening versus timolol 0 . 5 % and dorzolamide 2 % fixed combination ( TDFC )" . + "given twice daily to white Greeks with primary open - angle glaucoma and ocular hypertensive patients ." . + "Thirty - four" . + "6 - week" . + . + . + . + "This study indicates that the 24 - hour diurnal intraocular pressure is lowered more , by a small but statistically significant amount , with TDFC compared with latanoprost in primary open - angle glaucoma and ocular hypertensive patients ." . + . + . + . + . + . + "Thirty - three" . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 88673" . + "white Greeks with primary open - angle glaucoma and ocular hypertensive patients" . + . + . + . + "subjects with primary open - angle glaucoma or ocular hypertension" . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "tast" . + . + . + . + . + . +# RDF export of group: Arm + . + "lat" . + . + . + . + . + . + "comb" . + . + . + . + "single" . + . +# RDF export of group: Intervention + . + "lat" . + . + "every evening" . + . + . + "comb" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "lat" . + . + . + "0 . 005" . + . + . + . + "fix" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "15 . 9" . + "2 . 3" . + . + "iop 2 " . + . + "15 . 3" . + "2 . 0" . + . + "iop10 1" . + . + "16 . 6" . + "3 . 1" . + "10 : 00 PM" . + . + "iop10 2" . + . + "14 . 6" . + "2 . 7" . + "10 : 00 PM" . + . + "tast 1" . + . + . + "tast 2" . + . + "9" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "= 0 . 05" . + . + . + . + "iop10" . + "P & lt ; 0 . 006" . + . + . + . + "tast" . + "= 0 . 009" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12867391_export.csv b/data/gl 12867391_export.csv new file mode 100644 index 0000000..a112d87 --- /dev/null +++ b/data/gl 12867391_export.csv @@ -0,0 +1,514 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +534, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +534, 1, 2, 2, 14, 15, 14, 15, "." +534, 2, 1, 3, 0, 4, 16, 20, "2003" +534, 2, 2, 4, 5, 8, 21, 24, "Jul" +534, 2, 3, 5, 9, 10, 25, 26, ";" +534, 2, 4, 6, 11, 14, 27, 30, "110" +534, 2, 5, 7, 15, 16, 31, 32, "(" +534, 2, 6, 8, 17, 18, 33, 34, "7" +534, 2, 7, 9, 19, 20, 35, 36, ")" +534, 2, 8, 10, 21, 22, 37, 38, ":" +534, 2, 9, 11, 23, 27, 39, 43, "1357" +534, 2, 10, 12, 28, 29, 44, 45, "-" +534, 2, 11, 13, 30, 32, 46, 48, "60" +534, 2, 12, 14, 33, 34, 49, 50, "." +534, 3, 1, 15, 0, 6, 51, 57, "Twenty" +534, 3, 2, 16, 7, 8, 58, 59, "-" +534, 3, 3, 17, 9, 13, 60, 64, "four" +534, 3, 4, 18, 14, 15, 65, 66, "-" +534, 3, 5, 19, 16, 20, 67, 71, "hour" +534, 3, 6, 20, 21, 28, 72, 79, "diurnal" +534, 3, 7, 21, 29, 34, 80, 85, "curve" +534, 3, 8, 22, 35, 45, 86, 96, "comparison" +534, 3, 9, 23, 46, 48, 97, 99, "of" +534, 3, 10, 24, 49, 61, 100, 112, "commercially" +534, 3, 11, 25, 62, 71, 113, 122, "available" +534, 3, 12, 26, 72, 83, 123, 134, "latanoprost" +534, 3, 13, 27, 84, 85, 135, 136, "0" +534, 3, 14, 28, 86, 87, 137, 138, "." +534, 3, 15, 29, 88, 91, 139, 142, "005" +534, 3, 16, 30, 92, 93, 143, 144, "%" +534, 3, 17, 31, 94, 100, 145, 151, "versus" +534, 3, 18, 32, 101, 104, 152, 155, "the" +534, 3, 19, 33, 105, 112, 156, 163, "timolol" +534, 3, 20, 34, 113, 116, 164, 167, "and" +534, 3, 21, 35, 117, 128, 168, 179, "dorzolamide" +534, 3, 22, 36, 129, 134, 180, 185, "fixed" +534, 3, 23, 37, 135, 146, 186, 197, "combination" +534, 3, 24, 38, 147, 148, 198, 199, "." +534, 4, 1, 39, 0, 7, 200, 207, "Konstas" +534, 4, 2, 40, 8, 10, 208, 210, "AG" +534, 4, 3, 41, 11, 12, 211, 212, "(" +534, 4, 4, 42, 13, 14, 213, 214, "1" +534, 4, 5, 43, 15, 16, 215, 216, ")" +534, 4, 6, 44, 17, 18, 217, 218, "," +534, 4, 7, 45, 19, 28, 219, 228, "Papapanos" +534, 4, 8, 46, 29, 30, 229, 230, "P" +534, 4, 9, 47, 31, 32, 231, 232, "," +534, 4, 10, 48, 33, 39, 233, 239, "Tersis" +534, 4, 11, 49, 40, 41, 240, 241, "I" +534, 4, 12, 50, 42, 43, 242, 243, "," +534, 4, 13, 51, 44, 52, 244, 252, "Houliara" +534, 4, 14, 52, 53, 54, 253, 254, "D" +534, 4, 15, 53, 55, 56, 255, 256, "," +534, 4, 16, 54, 57, 64, 257, 264, "Stewart" +534, 4, 17, 55, 65, 67, 265, 267, "WC" +534, 4, 18, 56, 68, 69, 268, 269, "." +534, 5, 1, 57, 0, 6, 270, 276, "Author" +534, 5, 2, 58, 7, 18, 277, 288, "information" +534, 5, 3, 59, 19, 20, 289, 290, ":" +534, 5, 4, 60, 21, 22, 291, 292, "(" +534, 5, 5, 61, 23, 24, 293, 294, "1" +534, 5, 6, 62, 25, 26, 295, 296, ")" +534, 5, 7, 63, 27, 37, 297, 307, "University" +534, 5, 8, 64, 38, 48, 308, 318, "Department" +534, 5, 9, 65, 49, 51, 319, 321, "of" +534, 5, 10, 66, 52, 65, 322, 335, "Ophthalmology" +534, 5, 11, 67, 66, 67, 336, 337, "," +534, 5, 12, 68, 68, 73, 338, 343, "AHEPA" +534, 5, 13, 69, 74, 82, 344, 352, "Hospital" +534, 5, 14, 70, 83, 84, 353, 354, "," +534, 5, 15, 71, 85, 97, 355, 367, "Thessaloniki" +534, 5, 16, 72, 98, 99, 368, 369, "," +534, 5, 17, 73, 100, 106, 370, 376, "Greece" +534, 5, 18, 74, 107, 108, 377, 378, "." +534, 6, 1, 75, 0, 7, 379, 386, "PURPOSE" +534, 6, 2, 76, 8, 9, 387, 388, ":" +534, 6, 3, 77, 10, 12, 389, 391, "To" +534, 6, 4, 78, 13, 21, 392, 400, "evaluate" +534, 6, 5, 79, 22, 25, 401, 404, "the" +534, 6, 6, 80, 26, 34, 405, 413, "efficacy" +534, 6, 7, 81, 35, 38, 414, 417, "and" +534, 6, 8, 82, 39, 45, 418, 424, "safety" +534, 6, 9, 83, 46, 48, 425, 427, "of" +534, 6, 10, 84, 49, 61, 428, 440, "commercially" +534, 6, 11, 85, 62, 71, 441, 450, "available" +534, 6, 12, 86, 72, 83, 451, 462, "latanoprost" +534, 6, 13, 87, 84, 85, 463, 464, "0" +534, 6, 14, 88, 86, 87, 465, 466, "." +534, 6, 15, 89, 88, 91, 467, 470, "005" +534, 6, 16, 90, 92, 93, 471, 472, "%" +534, 6, 17, 91, 94, 99, 473, 478, "given" +534, 6, 18, 92, 100, 105, 479, 484, "every" +534, 6, 19, 93, 106, 113, 485, 492, "evening" +534, 6, 20, 94, 114, 120, 493, 499, "versus" +534, 6, 21, 95, 121, 128, 500, 507, "timolol" +534, 6, 22, 96, 129, 130, 508, 509, "0" +534, 6, 23, 97, 131, 132, 510, 511, "." +534, 6, 24, 98, 133, 134, 512, 513, "5" +534, 6, 25, 99, 135, 136, 514, 515, "%" +534, 6, 26, 100, 137, 140, 516, 519, "and" +534, 6, 27, 101, 141, 152, 520, 531, "dorzolamide" +534, 6, 28, 102, 153, 154, 532, 533, "2" +534, 6, 29, 103, 155, 156, 534, 535, "%" +534, 6, 30, 104, 157, 162, 536, 541, "fixed" +534, 6, 31, 105, 163, 174, 542, 553, "combination" +534, 6, 32, 106, 175, 176, 554, 555, "(" +534, 6, 33, 107, 177, 181, 556, 560, "TDFC" +534, 6, 34, 108, 182, 183, 561, 562, ")" +534, 6, 35, 109, 184, 189, 563, 568, "given" +534, 6, 36, 110, 190, 195, 569, 574, "twice" +534, 6, 37, 111, 196, 201, 575, 580, "daily" +534, 6, 38, 112, 202, 204, 581, 583, "to" +534, 6, 39, 113, 205, 210, 584, 589, "white" +534, 6, 40, 114, 211, 217, 590, 596, "Greeks" +534, 6, 41, 115, 218, 222, 597, 601, "with" +534, 6, 42, 116, 223, 230, 602, 609, "primary" +534, 6, 43, 117, 231, 235, 610, 614, "open" +534, 6, 44, 118, 236, 237, 615, 616, "-" +534, 6, 45, 119, 238, 243, 617, 622, "angle" +534, 6, 46, 120, 244, 252, 623, 631, "glaucoma" +534, 6, 47, 121, 253, 256, 632, 635, "and" +534, 6, 48, 122, 257, 263, 636, 642, "ocular" +534, 6, 49, 123, 264, 276, 643, 655, "hypertensive" +534, 6, 50, 124, 277, 285, 656, 664, "patients" +534, 6, 51, 125, 286, 287, 665, 666, "." +534, 7, 1, 126, 0, 6, 667, 673, "DESIGN" +534, 7, 2, 127, 7, 8, 674, 675, ":" +534, 7, 3, 128, 9, 10, 676, 677, "A" +534, 7, 4, 129, 11, 17, 678, 684, "single" +534, 7, 5, 130, 18, 19, 685, 686, "-" +534, 7, 6, 131, 20, 26, 687, 693, "masked" +534, 7, 7, 132, 27, 28, 694, 695, "," +534, 7, 8, 133, 29, 32, 696, 699, "two" +534, 7, 9, 134, 33, 34, 700, 701, "-" +534, 7, 10, 135, 35, 41, 702, 708, "center" +534, 7, 11, 136, 42, 43, 709, 710, "," +534, 7, 12, 137, 44, 53, 711, 720, "crossover" +534, 7, 13, 138, 54, 64, 721, 731, "comparison" +534, 7, 14, 139, 65, 69, 732, 736, "with" +534, 7, 15, 140, 70, 73, 737, 740, "two" +534, 7, 16, 141, 74, 75, 741, 742, "6" +534, 7, 17, 142, 76, 77, 743, 744, "-" +534, 7, 18, 143, 78, 82, 745, 749, "week" +534, 7, 19, 144, 83, 92, 750, 759, "treatment" +534, 7, 20, 145, 93, 100, 760, 767, "periods" +534, 7, 21, 146, 101, 110, 768, 777, "occurring" +534, 7, 22, 147, 111, 116, 778, 783, "after" +534, 7, 23, 148, 117, 119, 784, 786, "at" +534, 7, 24, 149, 120, 125, 787, 792, "least" +534, 7, 25, 150, 126, 127, 793, 794, "a" +534, 7, 26, 151, 128, 129, 795, 796, "3" +534, 7, 27, 152, 130, 131, 797, 798, "-" +534, 7, 28, 153, 132, 136, 799, 803, "week" +534, 7, 29, 154, 137, 145, 804, 812, "medicine" +534, 7, 30, 155, 146, 147, 813, 814, "-" +534, 7, 31, 156, 148, 152, 815, 819, "free" +534, 7, 32, 157, 153, 159, 820, 826, "period" +534, 7, 33, 158, 160, 161, 827, 828, "." +534, 8, 1, 159, 0, 7, 829, 836, "Diurnal" +534, 8, 2, 160, 8, 13, 837, 842, "curve" +534, 8, 3, 161, 14, 25, 843, 854, "intraocular" +534, 8, 4, 162, 26, 35, 855, 864, "pressures" +534, 8, 5, 163, 36, 40, 865, 869, "were" +534, 8, 6, 164, 41, 46, 870, 875, "taken" +534, 8, 7, 165, 47, 49, 876, 878, "at" +534, 8, 8, 166, 50, 51, 879, 880, "2" +534, 8, 9, 167, 52, 53, 881, 882, ":" +534, 8, 10, 168, 54, 56, 883, 885, "00" +534, 8, 11, 169, 57, 59, 886, 888, "AM" +534, 8, 12, 170, 60, 61, 889, 890, "," +534, 8, 13, 171, 62, 63, 891, 892, "6" +534, 8, 14, 172, 64, 65, 893, 894, ":" +534, 8, 15, 173, 66, 68, 895, 897, "00" +534, 8, 16, 174, 69, 71, 898, 900, "AM" +534, 8, 17, 175, 72, 73, 901, 902, "," +534, 8, 18, 176, 74, 76, 903, 905, "10" +534, 8, 19, 177, 77, 78, 906, 907, ":" +534, 8, 20, 178, 79, 81, 908, 910, "00" +534, 8, 21, 179, 82, 84, 911, 913, "AM" +534, 8, 22, 180, 85, 86, 914, 915, "," +534, 8, 23, 181, 87, 88, 916, 917, "2" +534, 8, 24, 182, 89, 90, 918, 919, ":" +534, 8, 25, 183, 91, 93, 920, 922, "00" +534, 8, 26, 184, 94, 96, 923, 925, "PM" +534, 8, 27, 185, 97, 98, 926, 927, "," +534, 8, 28, 186, 99, 100, 928, 929, "6" +534, 8, 29, 187, 101, 102, 930, 931, ":" +534, 8, 30, 188, 103, 105, 932, 934, "00" +534, 8, 31, 189, 106, 108, 935, 937, "PM" +534, 8, 32, 190, 109, 110, 938, 939, "," +534, 8, 33, 191, 111, 114, 940, 943, "and" +534, 8, 34, 192, 115, 117, 944, 946, "10" +534, 8, 35, 193, 118, 119, 947, 948, ":" +534, 8, 36, 194, 120, 122, 949, 951, "00" +534, 8, 37, 195, 123, 125, 952, 954, "PM" +534, 8, 38, 196, 126, 127, 955, 956, "." +534, 9, 1, 197, 0, 12, 957, 969, "PARTICIPANTS" +534, 9, 2, 198, 13, 14, 970, 971, ":" +534, 9, 3, 199, 15, 21, 972, 978, "Thirty" +534, 9, 4, 200, 22, 23, 979, 980, "-" +534, 9, 5, 201, 24, 28, 981, 985, "four" +534, 9, 6, 202, 29, 37, 986, 994, "subjects" +534, 9, 7, 203, 38, 42, 995, 999, "with" +534, 9, 8, 204, 43, 50, 1000, 1007, "primary" +534, 9, 9, 205, 51, 55, 1008, 1012, "open" +534, 9, 10, 206, 56, 57, 1013, 1014, "-" +534, 9, 11, 207, 58, 63, 1015, 1020, "angle" +534, 9, 12, 208, 64, 72, 1021, 1029, "glaucoma" +534, 9, 13, 209, 73, 75, 1030, 1032, "or" +534, 9, 14, 210, 76, 82, 1033, 1039, "ocular" +534, 9, 15, 211, 83, 95, 1040, 1052, "hypertension" +534, 9, 16, 212, 96, 100, 1053, 1057, "were" +534, 9, 17, 213, 101, 109, 1058, 1066, "enrolled" +534, 9, 18, 214, 110, 111, 1067, 1068, "." +534, 10, 1, 215, 0, 13, 1069, 1082, "INTERVENTIONS" +534, 10, 2, 216, 14, 15, 1083, 1084, ":" +534, 10, 3, 217, 16, 27, 1085, 1096, "Latanoprost" +534, 10, 4, 218, 28, 29, 1097, 1098, "0" +534, 10, 5, 219, 30, 31, 1099, 1100, "." +534, 10, 6, 220, 32, 35, 1101, 1104, "005" +534, 10, 7, 221, 36, 37, 1105, 1106, "%" +534, 10, 8, 222, 38, 43, 1107, 1112, "given" +534, 10, 9, 223, 44, 49, 1113, 1118, "every" +534, 10, 10, 224, 50, 57, 1119, 1126, "evening" +534, 10, 11, 225, 58, 61, 1127, 1130, "and" +534, 10, 12, 226, 62, 66, 1131, 1135, "TDFC" +534, 10, 13, 227, 67, 72, 1136, 1141, "twice" +534, 10, 14, 228, 73, 78, 1142, 1147, "daily" +534, 10, 15, 229, 79, 80, 1148, 1149, "." +534, 11, 1, 230, 0, 4, 1150, 1154, "MAIN" +534, 11, 2, 231, 5, 12, 1155, 1162, "OUTCOME" +534, 11, 3, 232, 13, 21, 1163, 1171, "MEASURES" +534, 11, 4, 233, 22, 23, 1172, 1173, ":" +534, 11, 5, 234, 24, 27, 1174, 1177, "The" +534, 11, 6, 235, 28, 35, 1178, 1185, "primary" +534, 11, 7, 236, 36, 44, 1186, 1194, "efficacy" +534, 11, 8, 237, 45, 53, 1195, 1203, "variable" +534, 11, 9, 238, 54, 57, 1204, 1207, "was" +534, 11, 10, 239, 58, 65, 1208, 1215, "diurnal" +534, 11, 11, 240, 66, 77, 1216, 1227, "intraocular" +534, 11, 12, 241, 78, 86, 1228, 1236, "pressure" +534, 11, 13, 242, 87, 88, 1237, 1238, "." +534, 12, 1, 243, 0, 7, 1239, 1246, "RESULTS" +534, 12, 2, 244, 8, 9, 1247, 1248, ":" +534, 12, 3, 245, 10, 16, 1249, 1255, "Thirty" +534, 12, 4, 246, 17, 18, 1256, 1257, "-" +534, 12, 5, 247, 19, 24, 1258, 1263, "three" +534, 12, 6, 248, 25, 33, 1264, 1272, "patients" +534, 12, 7, 249, 34, 43, 1273, 1282, "completed" +534, 12, 8, 250, 44, 47, 1283, 1286, "the" +534, 12, 9, 251, 48, 53, 1287, 1292, "study" +534, 12, 10, 252, 54, 55, 1293, 1294, "." +534, 13, 1, 253, 0, 2, 1295, 1297, "On" +534, 13, 2, 254, 3, 6, 1298, 1301, "the" +534, 13, 3, 255, 7, 11, 1302, 1306, "last" +534, 13, 4, 256, 12, 15, 1307, 1310, "day" +534, 13, 5, 257, 16, 18, 1311, 1313, "of" +534, 13, 6, 258, 19, 28, 1314, 1323, "treatment" +534, 13, 7, 259, 29, 30, 1324, 1325, "," +534, 13, 8, 260, 31, 34, 1326, 1329, "the" +534, 13, 9, 261, 35, 39, 1330, 1334, "mean" +534, 13, 10, 262, 40, 47, 1335, 1342, "diurnal" +534, 13, 11, 263, 48, 59, 1343, 1354, "intraocular" +534, 13, 12, 264, 60, 68, 1355, 1363, "pressure" +534, 13, 13, 265, 69, 72, 1364, 1367, "for" +534, 13, 14, 266, 73, 84, 1368, 1379, "latanoprost" +534, 13, 15, 267, 85, 88, 1380, 1383, "was" +534, 13, 16, 268, 89, 91, 1384, 1386, "15" +534, 13, 17, 269, 92, 93, 1387, 1388, "." +534, 13, 18, 270, 94, 95, 1389, 1390, "9" +534, 13, 19, 271, 96, 97, 1391, 1392, "+" +534, 13, 20, 272, 98, 99, 1393, 1394, "/" +534, 13, 21, 273, 100, 101, 1395, 1396, "-" +534, 13, 22, 274, 102, 103, 1397, 1398, "2" +534, 13, 23, 275, 104, 105, 1399, 1400, "." +534, 13, 24, 276, 106, 107, 1401, 1402, "3" +534, 13, 25, 277, 108, 112, 1403, 1407, "mmHg" +534, 13, 26, 278, 113, 116, 1408, 1411, "and" +534, 13, 27, 279, 117, 120, 1412, 1415, "for" +534, 13, 28, 280, 121, 125, 1416, 1420, "TDFC" +534, 13, 29, 281, 126, 129, 1421, 1424, "was" +534, 13, 30, 282, 130, 132, 1425, 1427, "15" +534, 13, 31, 283, 133, 134, 1428, 1429, "." +534, 13, 32, 284, 135, 136, 1430, 1431, "3" +534, 13, 33, 285, 137, 138, 1432, 1433, "+" +534, 13, 34, 286, 139, 140, 1434, 1435, "/" +534, 13, 35, 287, 141, 142, 1436, 1437, "-" +534, 13, 36, 288, 143, 144, 1438, 1439, "2" +534, 13, 37, 289, 145, 146, 1440, 1441, "." +534, 13, 38, 290, 147, 148, 1442, 1443, "0" +534, 13, 39, 291, 149, 153, 1444, 1448, "mmHg" +534, 13, 40, 292, 154, 155, 1449, 1450, "(" +534, 13, 41, 293, 156, 157, 1451, 1452, "P" +534, 13, 42, 294, 158, 159, 1453, 1454, "=" +534, 13, 43, 295, 160, 161, 1455, 1456, "0" +534, 13, 44, 296, 162, 163, 1457, 1458, "." +534, 13, 45, 297, 164, 166, 1459, 1461, "05" +534, 13, 46, 298, 167, 168, 1462, 1463, ")" +534, 13, 47, 299, 169, 170, 1464, 1465, "." +534, 14, 1, 300, 0, 10, 1466, 1476, "Individual" +534, 14, 2, 301, 11, 15, 1477, 1481, "time" +534, 14, 3, 302, 16, 22, 1482, 1488, "points" +534, 14, 4, 303, 23, 26, 1489, 1492, "for" +534, 14, 5, 304, 27, 38, 1493, 1504, "intraocular" +534, 14, 6, 305, 39, 47, 1505, 1513, "pressure" +534, 14, 7, 306, 48, 52, 1514, 1518, "were" +534, 14, 8, 307, 53, 56, 1519, 1522, "not" +534, 14, 9, 308, 57, 70, 1523, 1536, "statistically" +534, 14, 10, 309, 71, 80, 1537, 1546, "different" +534, 14, 11, 310, 81, 88, 1547, 1554, "between" +534, 14, 12, 311, 89, 95, 1555, 1561, "groups" +534, 14, 13, 312, 96, 102, 1562, 1568, "except" +534, 14, 14, 313, 103, 105, 1569, 1571, "at" +534, 14, 15, 314, 106, 109, 1572, 1575, "the" +534, 14, 16, 315, 110, 112, 1576, 1578, "10" +534, 14, 17, 316, 113, 114, 1579, 1580, ":" +534, 14, 18, 317, 115, 117, 1581, 1583, "00" +534, 14, 19, 318, 118, 120, 1584, 1586, "PM" +534, 14, 20, 319, 121, 125, 1587, 1591, "time" +534, 14, 21, 320, 126, 131, 1592, 1597, "point" +534, 14, 22, 321, 132, 133, 1598, 1599, "," +534, 14, 23, 322, 134, 138, 1600, 1604, "when" +534, 14, 24, 323, 139, 142, 1605, 1608, "the" +534, 14, 25, 324, 143, 147, 1609, 1613, "mean" +534, 14, 26, 325, 148, 151, 1614, 1617, "for" +534, 14, 27, 326, 152, 156, 1618, 1622, "TDFC" +534, 14, 28, 327, 157, 160, 1623, 1626, "was" +534, 14, 29, 328, 161, 163, 1627, 1629, "14" +534, 14, 30, 329, 164, 165, 1630, 1631, "." +534, 14, 31, 330, 166, 167, 1632, 1633, "6" +534, 14, 32, 331, 168, 169, 1634, 1635, "+" +534, 14, 33, 332, 170, 171, 1636, 1637, "/" +534, 14, 34, 333, 172, 173, 1638, 1639, "-" +534, 14, 35, 334, 174, 175, 1640, 1641, "2" +534, 14, 36, 335, 176, 177, 1642, 1643, "." +534, 14, 37, 336, 178, 179, 1644, 1645, "7" +534, 14, 38, 337, 180, 184, 1646, 1650, "mmHg" +534, 14, 39, 338, 185, 188, 1651, 1654, "and" +534, 14, 40, 339, 189, 192, 1655, 1658, "for" +534, 14, 41, 340, 193, 204, 1659, 1670, "latanoprost" +534, 14, 42, 341, 205, 208, 1671, 1674, "was" +534, 14, 43, 342, 209, 211, 1675, 1677, "16" +534, 14, 44, 343, 212, 213, 1678, 1679, "." +534, 14, 45, 344, 214, 215, 1680, 1681, "6" +534, 14, 46, 345, 216, 217, 1682, 1683, "+" +534, 14, 47, 346, 218, 219, 1684, 1685, "/" +534, 14, 48, 347, 220, 221, 1686, 1687, "-" +534, 14, 49, 348, 222, 223, 1688, 1689, "3" +534, 14, 50, 349, 224, 225, 1690, 1691, "." +534, 14, 51, 350, 226, 227, 1692, 1693, "1" +534, 14, 52, 351, 228, 232, 1694, 1698, "mmHg" +534, 14, 53, 352, 233, 234, 1699, 1700, "(" +534, 14, 54, 353, 235, 236, 1701, 1702, "P" +534, 14, 55, 354, 237, 238, 1703, 1704, "&" +534, 14, 56, 355, 239, 241, 1705, 1707, "lt" +534, 14, 57, 356, 242, 243, 1708, 1709, ";" +534, 14, 58, 357, 244, 245, 1710, 1711, "0" +534, 14, 59, 358, 246, 247, 1712, 1713, "." +534, 14, 60, 359, 248, 251, 1714, 1717, "006" +534, 14, 61, 360, 252, 253, 1718, 1719, ")" +534, 14, 62, 361, 254, 255, 1720, 1721, "." +534, 15, 1, 362, 0, 8, 1722, 1730, "Eighteen" +534, 15, 2, 363, 9, 17, 1731, 1739, "patients" +534, 15, 3, 364, 18, 25, 1740, 1747, "overall" +534, 15, 4, 365, 26, 35, 1748, 1757, "preferred" +534, 15, 5, 366, 36, 47, 1758, 1769, "latanoprost" +534, 15, 6, 367, 48, 54, 1770, 1776, "versus" +534, 15, 7, 368, 55, 56, 1777, 1778, "2" +534, 15, 8, 369, 57, 65, 1779, 1787, "patients" +534, 15, 9, 370, 66, 69, 1788, 1791, "for" +534, 15, 10, 371, 70, 73, 1792, 1795, "the" +534, 15, 11, 372, 74, 79, 1796, 1801, "fixed" +534, 15, 12, 373, 80, 91, 1802, 1813, "combination" +534, 15, 13, 374, 92, 93, 1814, 1815, "," +534, 15, 14, 375, 94, 103, 1816, 1825, "generally" +534, 15, 15, 376, 104, 111, 1826, 1833, "because" +534, 15, 16, 377, 112, 114, 1834, 1836, "of" +534, 15, 17, 378, 115, 118, 1837, 1840, "the" +534, 15, 18, 379, 119, 126, 1841, 1848, "greater" +534, 15, 19, 380, 127, 138, 1849, 1860, "convenience" +534, 15, 20, 381, 139, 141, 1861, 1863, "of" +534, 15, 21, 382, 142, 146, 1864, 1868, "once" +534, 15, 22, 383, 147, 152, 1869, 1874, "daily" +534, 15, 23, 384, 153, 159, 1875, 1881, "dosing" +534, 15, 24, 385, 160, 161, 1882, 1883, "." +534, 16, 1, 386, 0, 7, 1884, 1891, "Adverse" +534, 16, 2, 387, 8, 14, 1892, 1898, "events" +534, 16, 3, 388, 15, 19, 1899, 1903, "were" +534, 16, 4, 389, 20, 23, 1904, 1907, "not" +534, 16, 5, 390, 24, 37, 1908, 1921, "significantly" +534, 16, 6, 391, 38, 47, 1922, 1931, "different" +534, 16, 7, 392, 48, 55, 1932, 1939, "between" +534, 16, 8, 393, 56, 62, 1940, 1946, "groups" +534, 16, 9, 394, 63, 69, 1947, 1953, "except" +534, 16, 10, 395, 70, 74, 1954, 1958, "that" +534, 16, 11, 396, 75, 76, 1959, 1960, "a" +534, 16, 12, 397, 77, 83, 1961, 1967, "bitter" +534, 16, 13, 398, 84, 89, 1968, 1973, "taste" +534, 16, 14, 399, 90, 93, 1974, 1977, "was" +534, 16, 15, 400, 94, 99, 1978, 1983, "found" +534, 16, 16, 401, 100, 104, 1984, 1988, "more" +534, 16, 17, 402, 105, 115, 1989, 1999, "frequently" +534, 16, 18, 403, 116, 120, 2000, 2004, "with" +534, 16, 19, 404, 121, 125, 2005, 2009, "TDFC" +534, 16, 20, 405, 126, 127, 2010, 2011, "(" +534, 16, 21, 406, 128, 129, 2012, 2013, "n" +534, 16, 22, 407, 130, 131, 2014, 2015, "=" +534, 16, 23, 408, 132, 133, 2016, 2017, "9" +534, 16, 24, 409, 134, 135, 2018, 2019, ")" +534, 16, 25, 410, 136, 140, 2020, 2024, "than" +534, 16, 26, 411, 141, 145, 2025, 2029, "with" +534, 16, 27, 412, 146, 157, 2030, 2041, "latanoprost" +534, 16, 28, 413, 158, 159, 2042, 2043, "(" +534, 16, 29, 414, 160, 161, 2044, 2045, "n" +534, 16, 30, 415, 162, 163, 2046, 2047, "=" +534, 16, 31, 416, 164, 165, 2048, 2049, "0" +534, 16, 32, 417, 166, 167, 2050, 2051, ";" +534, 16, 33, 418, 168, 169, 2052, 2053, "P" +534, 16, 34, 419, 170, 171, 2054, 2055, "=" +534, 16, 35, 420, 172, 173, 2056, 2057, "0" +534, 16, 36, 421, 174, 175, 2058, 2059, "." +534, 16, 37, 422, 176, 179, 2060, 2063, "009" +534, 16, 38, 423, 180, 181, 2064, 2065, ")" +534, 16, 39, 424, 182, 183, 2066, 2067, "." +534, 17, 1, 425, 0, 7, 2068, 2075, "Despite" +534, 17, 2, 426, 8, 17, 2076, 2085, "screening" +534, 17, 3, 427, 18, 20, 2086, 2088, "to" +534, 17, 4, 428, 21, 28, 2089, 2096, "exclude" +534, 17, 5, 429, 29, 40, 2097, 2108, "intolerance" +534, 17, 6, 430, 41, 43, 2109, 2111, "to" +534, 17, 7, 431, 44, 48, 2112, 2116, "beta" +534, 17, 8, 432, 49, 50, 2117, 2118, "-" +534, 17, 9, 433, 51, 59, 2119, 2127, "blockers" +534, 17, 10, 434, 60, 61, 2128, 2129, "," +534, 17, 11, 435, 62, 63, 2130, 2131, "a" +534, 17, 12, 436, 64, 70, 2132, 2138, "single" +534, 17, 13, 437, 71, 78, 2139, 2146, "patient" +534, 17, 14, 438, 79, 82, 2147, 2150, "had" +534, 17, 15, 439, 83, 85, 2151, 2153, "to" +534, 17, 16, 440, 86, 97, 2154, 2165, "discontinue" +534, 17, 17, 441, 98, 101, 2166, 2169, "the" +534, 17, 18, 442, 102, 106, 2170, 2174, "TDFC" +534, 17, 19, 443, 107, 114, 2175, 2182, "because" +534, 17, 20, 444, 115, 117, 2183, 2185, "of" +534, 17, 21, 445, 118, 121, 2186, 2189, "new" +534, 17, 22, 446, 122, 123, 2190, 2191, "-" +534, 17, 23, 447, 124, 129, 2192, 2197, "onset" +534, 17, 24, 448, 130, 136, 2198, 2204, "asthma" +534, 17, 25, 449, 137, 138, 2205, 2206, "." +534, 18, 1, 450, 0, 11, 2207, 2218, "CONCLUSIONS" +534, 18, 2, 451, 12, 13, 2219, 2220, ":" +534, 18, 3, 452, 14, 18, 2221, 2225, "This" +534, 18, 4, 453, 19, 24, 2226, 2231, "study" +534, 18, 5, 454, 25, 34, 2232, 2241, "indicates" +534, 18, 6, 455, 35, 39, 2242, 2246, "that" +534, 18, 7, 456, 40, 43, 2247, 2250, "the" +534, 18, 8, 457, 44, 46, 2251, 2253, "24" +534, 18, 9, 458, 47, 48, 2254, 2255, "-" +534, 18, 10, 459, 49, 53, 2256, 2260, "hour" +534, 18, 11, 460, 54, 61, 2261, 2268, "diurnal" +534, 18, 12, 461, 62, 73, 2269, 2280, "intraocular" +534, 18, 13, 462, 74, 82, 2281, 2289, "pressure" +534, 18, 14, 463, 83, 85, 2290, 2292, "is" +534, 18, 15, 464, 86, 93, 2293, 2300, "lowered" +534, 18, 16, 465, 94, 98, 2301, 2305, "more" +534, 18, 17, 466, 99, 100, 2306, 2307, "," +534, 18, 18, 467, 101, 103, 2308, 2310, "by" +534, 18, 19, 468, 104, 105, 2311, 2312, "a" +534, 18, 20, 469, 106, 111, 2313, 2318, "small" +534, 18, 21, 470, 112, 115, 2319, 2322, "but" +534, 18, 22, 471, 116, 129, 2323, 2336, "statistically" +534, 18, 23, 472, 130, 141, 2337, 2348, "significant" +534, 18, 24, 473, 142, 148, 2349, 2355, "amount" +534, 18, 25, 474, 149, 150, 2356, 2357, "," +534, 18, 26, 475, 151, 155, 2358, 2362, "with" +534, 18, 27, 476, 156, 160, 2363, 2367, "TDFC" +534, 18, 28, 477, 161, 169, 2368, 2376, "compared" +534, 18, 29, 478, 170, 174, 2377, 2381, "with" +534, 18, 30, 479, 175, 186, 2382, 2393, "latanoprost" +534, 18, 31, 480, 187, 189, 2394, 2396, "in" +534, 18, 32, 481, 190, 197, 2397, 2404, "primary" +534, 18, 33, 482, 198, 202, 2405, 2409, "open" +534, 18, 34, 483, 203, 204, 2410, 2411, "-" +534, 18, 35, 484, 205, 210, 2412, 2417, "angle" +534, 18, 36, 485, 211, 219, 2418, 2426, "glaucoma" +534, 18, 37, 486, 220, 223, 2427, 2430, "and" +534, 18, 38, 487, 224, 230, 2431, 2437, "ocular" +534, 18, 39, 488, 231, 243, 2438, 2450, "hypertensive" +534, 18, 40, 489, 244, 252, 2451, 2459, "patients" +534, 18, 41, 490, 253, 254, 2460, 2461, "." +534, 19, 1, 491, 0, 3, 2462, 2465, "DOI" +534, 19, 2, 492, 4, 5, 2466, 2467, ":" +534, 19, 3, 493, 6, 8, 2468, 2470, "10" +534, 19, 4, 494, 9, 10, 2471, 2472, "." +534, 19, 5, 495, 11, 15, 2473, 2477, "1016" +534, 19, 6, 496, 16, 17, 2478, 2479, "/" +534, 19, 7, 497, 18, 23, 2480, 2485, "S0161" +534, 19, 8, 498, 24, 25, 2486, 2487, "-" +534, 19, 9, 499, 26, 30, 2488, 2492, "6420" +534, 19, 10, 500, 31, 32, 2493, 2494, "(" +534, 19, 11, 501, 33, 35, 2495, 2497, "03" +534, 19, 12, 502, 36, 37, 2498, 2499, ")" +534, 19, 13, 503, 38, 43, 2500, 2505, "00404" +534, 19, 14, 504, 44, 45, 2506, 2507, "-" +534, 19, 15, 505, 46, 47, 2508, 2509, "4" +534, 19, 16, 506, 48, 52, 2510, 2514, "PMID" +534, 19, 17, 507, 53, 54, 2515, 2516, ":" +534, 19, 18, 508, 55, 63, 2517, 2525, "12867391" +534, 19, 19, 509, 64, 65, 2526, 2527, "[" +534, 19, 20, 510, 66, 73, 2528, 2535, "Indexed" +534, 19, 21, 511, 74, 77, 2536, 2539, "for" +534, 19, 22, 512, 78, 85, 2540, 2547, "MEDLINE" +534, 19, 23, 513, 86, 87, 2548, 2549, "]" diff --git a/data/gl 12867391_jshahinitiran.annodb b/data/gl 12867391_jshahinitiran.annodb new file mode 100644 index 0000000..53c23c3 --- /dev/null +++ b/data/gl 12867391_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82486, Journal, 0, 13, "Ophthalmology", "", +82487, PublicationYear, 16, 20, "2003", "", +82488, Title, 51, 199, "Twenty - four - hour diurnal curve comparison of commercially available latanoprost 0 . 005 % versus the timolol and dorzolamide fixed combination .", "", +82489, Latanoprost, 123, 134, "latanoprost", "", +82492, DoseValue, 135, 142, "0 . 005", "", +82490, Timolol, 156, 163, "timolol", "", +82493, Dorz/TimFC, 156, 197, "timolol and dorzolamide fixed combination", "", +82491, Dorzolamide, 168, 179, "dorzolamide", "", +82494, Author, 200, 210, "Konstas AG", "", +82495, Author, 219, 230, "Papapanos P", "", +82496, Author, 233, 241, "Tersis I", "", +82497, Author, 244, 254, "Houliara D", "", +82498, Author, 257, 267, "Stewart WC", "", +82499, Greece, 370, 376, "Greece", "", +82500, ObjectiveDescription, 389, 562, "To evaluate the efficacy and safety of commercially available latanoprost 0 . 005 % given every evening versus timolol 0 . 5 % and dorzolamide 2 % fixed combination ( TDFC )", "", +82502, Latanoprost, 451, 462, "latanoprost", "", +82505, DoseValue, 463, 470, "0 . 005", "", +82511, Evening, 485, 492, "evening", "", +82503, Timolol, 500, 507, "timolol", "", +82508, Dorz/TimFC, 500, 553, "timolol 0 . 5 % and dorzolamide 2 % fixed combination", "", +82506, DoseValue, 508, 513, "0 . 5", "", +82504, Dorzolamide, 520, 531, "dorzolamide", "", +82507, DoseValue, 532, 533, "2", "", +82509, Dorz/TimFC, 556, 560, "TDFC", "", +82501, ObjectiveDescription, 563, 666, "given twice daily to white Greeks with primary open - angle glaucoma and ocular hypertensive patients .", "", +82510, Frequency, 569, 580, "twice daily", "", +82512, Ethnicity, 584, 596, "white Greeks", "", +82513, Primary_OpenAngleGlaucoma, 602, 631, "primary open - angle glaucoma", "", +82514, OcularHypertension, 636, 655, "ocular hypertensive", "", +82515, Blind, 678, 693, "single - masked", "", +82517, Multicenter, 696, 708, "two - center", "", +82518, Crossover, 711, 720, "crossover", "", +82519, Duration, 741, 749, "6 - week", "", +82520, Diurnal_IOP, 829, 864, "Diurnal curve intraocular pressures", "", +82521, NumberPatientsCT, 972, 985, "Thirty - four", "", +82522, Primary_OpenAngleGlaucoma, 1000, 1029, "primary open - angle glaucoma", "", +82523, OcularHypertension, 1033, 1052, "ocular hypertension", "", +82524, Latanoprost, 1085, 1096, "Latanoprost", "", +82525, DoseValue, 1097, 1104, "0 . 005", "", +82526, Evening, 1119, 1126, "evening", "", +82527, Dorz/TimFC, 1131, 1135, "TDFC", "", +82528, Frequency, 1136, 1147, "twice daily", "", +82529, Diurnal_IOP, 1208, 1236, "diurnal intraocular pressure", "", +82530, FinalNumPatientsCT, 1249, 1263, "Thirty - three", "", +82531, Mean, 1330, 1334, "mean", "", +82532, Diurnal_IOP, 1335, 1363, "diurnal intraocular pressure", "", +82533, Latanoprost, 1368, 1379, "latanoprost", "", +82534, ResultMeasuredValue, 1384, 1390, "15 . 9", "", +82536, SdErrorResValue, 1397, 1402, "2 . 3", "", +82538, mmHg, 1403, 1407, "mmHg", "", +82540, Dorz/TimFC, 1416, 1420, "TDFC", "", +82535, ResultMeasuredValue, 1425, 1431, "15 . 3", "", +82537, SdErrorResValue, 1438, 1443, "2 . 0", "", +82539, mmHg, 1444, 1448, "mmHg", "", +82541, PValueResValue, 1451, 1461, "P = 0 . 05", "", +82553, ObservedResult, 1466, 1721, "Individual time points for intraocular pressure were not statistically different between groups except at the 10 : 00 PM time point , when the mean for TDFC was 14 . 6 + / - 2 . 7 mmHg and for latanoprost was 16 . 6 + / - 3 . 1 mmHg ( P & lt ; 0 . 006 ) .", "", +82542, IOP, 1493, 1513, "intraocular pressure", "", +82543, Mean, 1609, 1613, "mean", "", +82544, Dorz/TimFC, 1618, 1622, "TDFC", "", +82545, ResultMeasuredValue, 1627, 1633, "14 . 6", "", +82547, SdErrorResValue, 1640, 1645, "2 . 7", "", +82549, mmHg, 1646, 1650, "mmHg", "", +82551, Latanoprost, 1659, 1670, "latanoprost", "", +82546, ResultMeasuredValue, 1675, 1681, "16 . 6", "", +82548, SdErrorResValue, 1688, 1693, "3 . 1", "", +82550, mmHg, 1694, 1698, "mmHg", "", +82552, PValueResValue, 1701, 1717, "P & lt ; 0 . 006", "", +82555, Dorz/TimFC, 2005, 2009, "TDFC", "", +82557, NumberAffected, 2016, 2017, "9", "", +82556, Latanoprost, 2030, 2041, "latanoprost", "", +82558, NumberAffected, 2048, 2049, "0", "", +82559, PValueNumAffected, 2052, 2063, "P = 0 . 009", "", +82560, NumPatientsLeftArm, 2132, 2138, "single", "", +82561, Dorz/TimFC, 2170, 2174, "TDFC", "", +82563, ConclusionComment, 2221, 2461, "This study indicates that the 24 - hour diurnal intraocular pressure is lowered more , by a small but statistically significant amount , with TDFC compared with latanoprost in primary open - angle glaucoma and ocular hypertensive patients .", "", +82564, IOP, 2261, 2289, "diurnal intraocular pressure", "", +82565, Dorz/TimFC, 2363, 2367, "TDFC", "", +82566, Latanoprost, 2382, 2393, "latanoprost", "", +82567, Primary_OpenAngleGlaucoma, 2397, 2426, "primary open - angle glaucoma", "", +82568, OcularHypertension, 2431, 2450, "ocular hypertensive", "", +82569, PMID, 2517, 2525, "12867391", "", diff --git a/data/gl 12867391_jshahinitiran.n-triples b/data/gl 12867391_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12867391_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 12867391_tstrakeljahn.annodb b/data/gl 12867391_tstrakeljahn.annodb new file mode 100644 index 0000000..34d2b36 --- /dev/null +++ b/data/gl 12867391_tstrakeljahn.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82233, Journal, 0, 13, "Ophthalmology", "", +82234, PublicationYear, 16, 20, "2003", "", +82246, Title, 51, 199, "Twenty - four - hour diurnal curve comparison of commercially available latanoprost 0 . 005 % versus the timolol and dorzolamide fixed combination .", "", +82235, Latanoprost, 123, 134, "latanoprost", "", +82239, DoseValue, 135, 142, "0 . 005", "", +82240, Percentage, 143, 144, "%", "", +82236, Timolol, 156, 163, "timolol", "", +82238, Dorz/TimFC, 156, 179, "timolol and dorzolamide", "", +82237, Dorzolamide, 168, 179, "dorzolamide", "", +82241, Author, 200, 210, "Konstas AG", "", +82242, Author, 219, 230, "Papapanos P", "", +82243, Author, 233, 241, "Tersis I", "", +82244, Author, 244, 254, "Houliara D", "", +82245, Author, 257, 267, "Stewart WC", "", +82247, Greece, 370, 376, "Greece", "", +82262, ObjectiveDescription, 389, 642, "To evaluate the efficacy and safety of commercially available latanoprost 0 . 005 % given every evening versus timolol 0 . 5 % and dorzolamide 2 % fixed combination ( TDFC ) given twice daily to white Greeks with primary open - angle glaucoma and ocular", "", +82248, Latanoprost, 451, 462, "latanoprost", "", +82249, DoseValue, 463, 470, "0 . 005", "", +82252, Percentage, 471, 472, "%", "", +82257, Timolol, 500, 507, "timolol", "", +82316, Dorz/TimFC, 500, 535, "timolol 0 . 5 % and dorzolamide 2 %", "", +82250, DoseValue, 508, 513, "0 . 5", "", +82253, Percentage, 514, 515, "%", "", +82255, Dorzolamide, 520, 531, "dorzolamide", "", +82251, DoseValue, 532, 533, "2", "", +82254, Percentage, 534, 535, "%", "", +82256, Dorz/TimFC, 556, 560, "TDFC", "", +82258, Frequency, 569, 580, "twice daily", "", +82261, Ethnicity, 584, 596, "white Greeks", "", +82259, Primary_OpenAngleGlaucoma, 602, 631, "primary open - angle glaucoma", "", +82260, OcularHypertension, 636, 655, "ocular hypertensive", "", +82263, ObjectiveDescription, 656, 666, "patients .", "", +82264, Blind, 676, 693, "A single - masked", "", +82265, Multicenter, 696, 708, "two - center", "", +82266, Crossover, 711, 720, "crossover", "", +82267, Precondition, 784, 826, "at least a 3 - week medicine - free period", "", +82268, Diurnal_IOP, 829, 864, "Diurnal curve intraocular pressures", "", +82269, TimePoint, 879, 888, "2 : 00 AM", "", +82270, TimePoint, 891, 900, "6 : 00 AM", "", +82271, TimePoint, 903, 913, "10 : 00 AM", "", +82272, TimePoint, 916, 925, "2 : 00 PM", "", +82273, TimePoint, 928, 937, "6 : 00 PM", "", +82274, TimePoint, 944, 954, "10 : 00 PM", "", +82275, NumberPatientsCT, 972, 985, "Thirty - four", "", +82276, Primary_OpenAngleGlaucoma, 1000, 1029, "primary open - angle glaucoma", "", +82277, OcularHypertension, 1033, 1052, "ocular hypertension", "", +82278, Latanoprost, 1085, 1096, "Latanoprost", "", +82279, DoseValue, 1097, 1104, "0 . 005", "", +82280, Percentage, 1105, 1106, "%", "", +82284, Frequency, 1113, 1126, "every evening", "", +82283, Evening, 1119, 1126, "evening", "", +82317, Dorz/TimFC, 1131, 1135, "TDFC", "", +82282, Frequency, 1136, 1147, "twice daily", "", +82285, Diurnal_IOP, 1208, 1236, "diurnal intraocular pressure", "", +82286, FinalNumPatientsCT, 1249, 1263, "Thirty - three", "", +82287, Mean, 1330, 1334, "mean", "", +82288, Diurnal_IOP, 1335, 1363, "diurnal intraocular pressure", "", +82289, Latanoprost, 1368, 1379, "latanoprost", "", +82290, ResultMeasuredValue, 1384, 1390, "15 . 9", "", +82294, SdDevResValue, 1397, 1402, "2 . 3", "", +82292, mmHg, 1403, 1407, "mmHg", "", +82318, Dorz/TimFC, 1416, 1420, "TDFC", "", +82291, ResultMeasuredValue, 1425, 1431, "15 . 3", "", +82295, SdDevResValue, 1438, 1443, "2 . 0", "", +82293, mmHg, 1444, 1448, "mmHg", "", +82297, PvalueDiff, 1453, 1461, "= 0 . 05", "", +82298, IOP, 1493, 1513, "intraocular pressure", "", +82299, TimePoint, 1576, 1586, "10 : 00 PM", "", +82300, Mean, 1609, 1613, "mean", "", +82319, Dorz/TimFC, 1618, 1622, "TDFC", "", +82302, ResultMeasuredValue, 1627, 1633, "14 . 6", "", +82304, SdDevResValue, 1640, 1645, "2 . 7", "", +82307, mmHg, 1646, 1650, "mmHg", "", +82308, Latanoprost, 1659, 1670, "latanoprost", "", +82303, ResultMeasuredValue, 1675, 1681, "16 . 6", "", +82305, SdDevResValue, 1688, 1693, "3 . 1", "", +82306, mmHg, 1694, 1698, "mmHg", "", +82311, NumberAffected, 1722, 1730, "Eighteen", "", +82313, ObservedResult, 1722, 1883, "Eighteen patients overall preferred latanoprost versus 2 patients for the fixed combination , generally because of the greater convenience of once daily dosing .", "", +82309, Latanoprost, 1758, 1769, "latanoprost", "", +82312, NumberAffected, 1777, 1778, "2", "", +82310, Frequency, 1864, 1874, "once daily", "", +82315, Dorz/TimFC, 2005, 2009, "TDFC", "", +82320, NumberAffected, 2016, 2017, "9", "", +82323, Latanoprost, 2030, 2041, "latanoprost", "", +82321, NumberAffected, 2048, 2049, "0", "", +82322, PvalueDiff, 2054, 2063, "= 0 . 009", "", +82326, ObservedResult, 2068, 2206, "Despite screening to exclude intolerance to beta - blockers , a single patient had to discontinue the TDFC because of new - onset asthma .", "", +82324, Dorz/TimFC, 2170, 2174, "TDFC", "", +82332, ConclusionComment, 2221, 2461, "This study indicates that the 24 - hour diurnal intraocular pressure is lowered more , by a small but statistically significant amount , with TDFC compared with latanoprost in primary open - angle glaucoma and ocular hypertensive patients .", "", +82327, Diurnal_IOP, 2261, 2289, "diurnal intraocular pressure", "", +82328, Dorz/TimFC, 2363, 2367, "TDFC", "", +82329, Latanoprost, 2382, 2393, "latanoprost", "", +82330, Primary_OpenAngleGlaucoma, 2397, 2426, "primary open - angle glaucoma", "", +82331, OcularHypertension, 2431, 2450, "ocular hypertensive", "", +82333, PMID, 2517, 2525, "12867391", "", diff --git a/data/gl 12867391_tstrakeljahn.n-triples b/data/gl 12867391_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 12867391_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14736774_admin.annodb b/data/gl 14736774_admin.annodb new file mode 100644 index 0000000..fc27b1d --- /dev/null +++ b/data/gl 14736774_admin.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2004", "", " \"2004\"." +2, Title, 52, 243, "A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension .", "", " \"A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension .\"." +3, Duration, 54, 61, "12 week", "", +6, Lat/TimFC, 82, 126, "fixed combination of latanoprost and timolol", "", +4, Latanoprost, 103, 114, "latanoprost", "", +82, Lat/TimFC, 103, 126, "latanoprost and timolol", "", +5, Timolol, 119, 126, "timolol", "", +7, OpenAngleGlaucoma, 198, 217, "open angle glaucoma", "", " ." +8, OcularHypertension, 222, 241, "ocular hypertension", "", " ." +9, Author, 244, 258, "Diestelhorst M", "", " \"Diestelhorst M\"." +10, Author, 267, 277, "Larsson LI", "", " \"Larsson LI\"." +11, Germany, 498, 505, "Germany", "", +12, ObjectiveDescription, 573, 759, "To compare the intraocular pressure ( IOP ) lowering effect and safety of the fixed combination of latanoprost and timolol with that of the concomitant use of the individual components .", "", " \"To compare the intraocular pressure ( IOP ) lowering effect and safety of the fixed combination of latanoprost and timolol with that of the concomitant use of the individual components .\"." +13, IOP, 588, 608, "intraocular pressure", "", +14, IOP, 611, 614, "IOP", "", +17, Lat/TimFC, 651, 695, "fixed combination of latanoprost and timolol", "", +15, Latanoprost, 672, 683, "latanoprost", "", +16, Timolol, 688, 695, "timolol", "", +18, Duration, 772, 779, "12 week", "", " \"12 week\"." +19, DoubleBlind, 782, 795, "double masked", "", " ." +20, Randomized, 798, 808, "randomised", "", " ." +21, Crossover, 811, 820, "crossover", "", " ." +22, Multicenter, 823, 834, "multicentre", "", " ." +100673, Precondition, 844, 951, "patients with open angle glaucoma or ocular hypertension and IOP controlled on ocular hypotensive treatment", "", " \"patients with open angle glaucoma or ocular hypertension and IOP controlled on ocular hypotensive treatment\"." +23, OpenAngleGlaucoma, 858, 877, "open angle glaucoma", "", +24, OcularHypertension, 881, 900, "ocular hypertension", "", +25, IOP, 905, 908, "IOP", "", +27, mmHg, 974, 978, "mmHg", "", +28, Frequency, 1010, 1020, "once daily", "", " \"once daily\"." +29, Morning, 1021, 1028, "morning", "", " ." +32, Lat/TimFC, 1041, 1103, "fixed combination of latanoprost 0 . 005 % and timolol 0 . 5 %", "", " ." +30, Latanoprost, 1062, 1073, "latanoprost", "", +33, DoseValue, 1074, 1081, "0 . 005", "", +112, Percentage, 1082, 1083, "%", "", +31, Timolol, 1088, 1095, "timolol", "", +34, DoseValue, 1096, 1101, "0 . 5", "", +113, Percentage, 1102, 1103, "%", "", +35, Frequency, 1107, 1117, "once daily", "", " \"once daily\"." +36, Evening, 1118, 1125, "evening", "", " ." +37, Latanoprost, 1126, 1137, "latanoprost", "", " . ." +40, DoseValue, 1138, 1145, "0 . 005", "", " \"0 . 005\"." +114, Percentage, 1146, 1147, "%", "", " ." +38, Frequency, 1152, 1163, "twice daily", "", " \"twice daily\"." +39, Timolol, 1164, 1171, "timolol", "", " ." +41, DoseValue, 1172, 1177, "0 . 5", "", " \"0 . 5\"." +115, Percentage, 1178, 1179, "%", "", " ." +42, Duration, 1184, 1193, "six weeks", "", +43, Diurnal_IOP, 1308, 1319, "diurnal IOP", "", +44, Duration, 1375, 1384, "six weeks", "", " \"six weeks\". \"six weeks\". \"six weeks\"." +45, Mean, 1456, 1460, "mean", "", +46, IOP, 1475, 1478, "IOP", "", +47, mmHg, 1492, 1496, "mmHg", "", +48, NumberPatientsCT, 1639, 1642, "190", "", " \"190\"." +49, NumberPatientsArm, 1695, 1697, "93", "", " \"93\"." +50, NumberPatientsArm, 1729, 1731, "97", "", " \"97\"." +51, Mean, 1765, 1769, "Mean", "", +52, IOP, 1770, 1773, "IOP", "", +53, TimePoint, 1777, 1785, "baseline", "", +54, BaseLineValue, 1790, 1796, "16 . 9", "", " \"16 . 9\". \"16 . 9\"." +55, mmHg, 1797, 1801, "mmHg", "", +56, Mean, 1823, 1827, "mean", "", " . ." +57, Diurnal_IOP, 1828, 1839, "diurnal IOP", "", " ." +58, ResultMeasuredValue, 1844, 1850, "17 . 0", "", " \"17 . 0\"." +59, mmHg, 1851, 1855, "mmHg", "", " ." +61, ResultMeasuredValue, 1894, 1900, "15 . 9", "", " \"15 . 9\"." +60, mmHg, 1901, 1905, "mmHg", "", +62, PValueResValue, 1942, 1959, "p & lt ; 0 . 0001", "", " \"p & lt ; 0 . 0001\". \"p & lt ; 0 . 0001\"." +63, Mean, 1982, 1986, "mean", "", +64, Diurnal_IOP, 2004, 2015, "diurnal IOP", "", +65, DiffGroupAbsValue, 2020, 2025, "1 . 1", "", " \"1 . 1\"." +66, mmHg, 2026, 2030, "mmHg", "", +67, ConfIntervalDiff, 2067, 2094, "95 % CI 0 . 8 to 1 . 4 mmHg", "", " \"95 % CI 0 . 8 to 1 . 4 mmHg\"." +68, mmHg, 2090, 2094, "mmHg", "", +143, ObservedResult, 2099, 2136, "Both treatments were tolerated well .", "", +69, ConclusionComment, 2151, 2318, "Although the primary efficacy endpoint was not met , once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective .", "", " \"Although the primary efficacy endpoint was not met , once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective .\"." +71, Frequency, 2204, 2214, "once daily", "", +74, Lat/TimFC, 2237, 2281, "fixed combination of latanoprost and timolol", "", +72, Latanoprost, 2258, 2269, "latanoprost", "", +73, Timolol, 2274, 2281, "timolol", "", +70, ConclusionComment, 2319, 2443, "The fixed combination provides a convenient alternative to the three instillations required with the individual components .", "", " \"The fixed combination provides a convenient alternative to the three instillations required with the individual components .\"." +76, PMID, 2508, 2516, "14736774", "", " \"14736774\"." diff --git a/data/gl 14736774_admin.n-triples b/data/gl 14736774_admin.n-triples new file mode 100644 index 0000000..a68463a --- /dev/null +++ b/data/gl 14736774_admin.n-triples @@ -0,0 +1,119 @@ +# RDF export of group: Publication + . + "Publication 88946" . + "A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension ." . + "Diestelhorst M" . + "2004" . + "Br J Ophthalmol ." . + "14736774" . + . + "Larsson LI" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 88953" . + "To compare the intraocular pressure ( IOP ) lowering effect and safety of the fixed combination of latanoprost and timolol with that of the concomitant use of the individual components ." . + "190" . + "12 week" . + . + . + . + "Although the primary efficacy endpoint was not met , once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective ." . + . + . + . + . + . + . + . + "The fixed combination provides a convenient alternative to the three instillations required with the individual components ." . + . + . + . +# RDF export of group: Population + . + "Population 88969" . + "patients with open angle glaucoma or ocular hypertension and IOP controlled on ocular hypotensive treatment" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "fixed" . + "93" . + . + . + . + . + "notfixed" . + "97" . + . + . + . + . +# RDF export of group: Intervention + . + "fixed" . + "once daily" . + "six weeks" . + . + . + . + "latnot" . + . + "once daily" . + "six weeks" . + . + . + "timnot" . + . + "twice daily" . + "six weeks" . + . +# RDF export of group: Medication + . + "latnot" . + . + . + "0 . 005" . + . + . + . + "timnot" . + . + "0 . 5" . + . + . + . + "fix" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "16 . 9" . + "17 . 0" . + "p & lt ; 0 . 0001" . + . + "iop2" . + . + "16 . 9" . + "15 . 9" . + "p & lt ; 0 . 0001" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "1 . 1" . + "95 % CI 0 . 8 to 1 . 4 mmHg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14736774_export.csv b/data/gl 14736774_export.csv new file mode 100644 index 0000000..59a07a6 --- /dev/null +++ b/data/gl 14736774_export.csv @@ -0,0 +1,485 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +555, 1, 1, 1, 0, 2, 0, 2, "Br" +555, 1, 2, 2, 3, 4, 3, 4, "J" +555, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +555, 1, 4, 4, 16, 17, 16, 17, "." +555, 2, 1, 5, 0, 4, 18, 22, "2004" +555, 2, 2, 6, 5, 8, 23, 26, "Feb" +555, 2, 3, 7, 9, 10, 27, 28, ";" +555, 2, 4, 8, 11, 13, 29, 31, "88" +555, 2, 5, 9, 14, 15, 32, 33, "(" +555, 2, 6, 10, 16, 17, 34, 35, "2" +555, 2, 7, 11, 18, 19, 36, 37, ")" +555, 2, 8, 12, 20, 21, 38, 39, ":" +555, 2, 9, 13, 22, 25, 40, 43, "199" +555, 2, 10, 14, 26, 27, 44, 45, "-" +555, 2, 11, 15, 28, 31, 46, 49, "203" +555, 2, 12, 16, 32, 33, 50, 51, "." +555, 3, 1, 17, 0, 1, 52, 53, "A" +555, 3, 2, 18, 2, 4, 54, 56, "12" +555, 3, 3, 19, 5, 9, 57, 61, "week" +555, 3, 4, 20, 10, 15, 62, 67, "study" +555, 3, 5, 21, 16, 25, 68, 77, "comparing" +555, 3, 6, 22, 26, 29, 78, 81, "the" +555, 3, 7, 23, 30, 35, 82, 87, "fixed" +555, 3, 8, 24, 36, 47, 88, 99, "combination" +555, 3, 9, 25, 48, 50, 100, 102, "of" +555, 3, 10, 26, 51, 62, 103, 114, "latanoprost" +555, 3, 11, 27, 63, 66, 115, 118, "and" +555, 3, 12, 28, 67, 74, 119, 126, "timolol" +555, 3, 13, 29, 75, 79, 127, 131, "with" +555, 3, 14, 30, 80, 83, 132, 135, "the" +555, 3, 15, 31, 84, 95, 136, 147, "concomitant" +555, 3, 16, 32, 96, 99, 148, 151, "use" +555, 3, 17, 33, 100, 102, 152, 154, "of" +555, 3, 18, 34, 103, 106, 155, 158, "the" +555, 3, 19, 35, 107, 117, 159, 169, "individual" +555, 3, 20, 36, 118, 128, 170, 180, "components" +555, 3, 21, 37, 129, 131, 181, 183, "in" +555, 3, 22, 38, 132, 140, 184, 192, "patients" +555, 3, 23, 39, 141, 145, 193, 197, "with" +555, 3, 24, 40, 146, 150, 198, 202, "open" +555, 3, 25, 41, 151, 156, 203, 208, "angle" +555, 3, 26, 42, 157, 165, 209, 217, "glaucoma" +555, 3, 27, 43, 166, 169, 218, 221, "and" +555, 3, 28, 44, 170, 176, 222, 228, "ocular" +555, 3, 29, 45, 177, 189, 229, 241, "hypertension" +555, 3, 30, 46, 190, 191, 242, 243, "." +555, 4, 1, 47, 0, 12, 244, 256, "Diestelhorst" +555, 4, 2, 48, 13, 14, 257, 258, "M" +555, 4, 3, 49, 15, 16, 259, 260, "(" +555, 4, 4, 50, 17, 18, 261, 262, "1" +555, 4, 5, 51, 19, 20, 263, 264, ")" +555, 4, 6, 52, 21, 22, 265, 266, "," +555, 4, 7, 53, 23, 30, 267, 274, "Larsson" +555, 4, 8, 54, 31, 33, 275, 277, "LI" +555, 4, 9, 55, 34, 35, 278, 279, ";" +555, 4, 10, 56, 36, 44, 280, 288, "European" +555, 4, 11, 57, 45, 56, 289, 300, "Latanoprost" +555, 4, 12, 58, 57, 62, 301, 306, "Fixed" +555, 4, 13, 59, 63, 74, 307, 318, "Combination" +555, 4, 14, 60, 75, 80, 319, 324, "Study" +555, 4, 15, 61, 81, 86, 325, 330, "Group" +555, 4, 16, 62, 87, 88, 331, 332, "." +555, 5, 1, 63, 0, 6, 333, 339, "Author" +555, 5, 2, 64, 7, 18, 340, 351, "information" +555, 5, 3, 65, 19, 20, 352, 353, ":" +555, 5, 4, 66, 21, 22, 354, 355, "(" +555, 5, 5, 67, 23, 24, 356, 357, "1" +555, 5, 6, 68, 25, 26, 358, 359, ")" +555, 5, 7, 69, 27, 37, 360, 370, "Department" +555, 5, 8, 70, 38, 40, 371, 373, "of" +555, 5, 9, 71, 41, 54, 374, 387, "Ophthalmology" +555, 5, 10, 72, 55, 56, 388, 389, "," +555, 5, 11, 73, 57, 67, 390, 400, "University" +555, 5, 12, 74, 68, 71, 401, 404, "Eye" +555, 5, 13, 75, 72, 78, 405, 411, "Clinic" +555, 5, 14, 76, 79, 80, 412, 413, "," +555, 5, 15, 77, 81, 91, 414, 424, "University" +555, 5, 16, 78, 92, 94, 425, 427, "of" +555, 5, 17, 79, 95, 102, 428, 435, "Cologne" +555, 5, 18, 80, 103, 104, 436, 437, "," +555, 5, 19, 81, 105, 111, 438, 444, "Joseph" +555, 5, 20, 82, 112, 113, 445, 446, "-" +555, 5, 21, 83, 114, 123, 447, 456, "Stelzmann" +555, 5, 22, 84, 124, 125, 457, 458, "-" +555, 5, 23, 85, 126, 133, 459, 466, "Strasse" +555, 5, 24, 86, 134, 135, 467, 468, "9" +555, 5, 25, 87, 136, 137, 469, 470, "," +555, 5, 26, 88, 138, 145, 471, 478, "Cologne" +555, 5, 27, 89, 146, 147, 479, 480, "(" +555, 5, 28, 90, 148, 149, 481, 482, "K" +555, 5, 29, 91, 150, 151, 483, 484, "ö" +555, 5, 30, 92, 152, 154, 485, 487, "ln" +555, 5, 31, 93, 155, 156, 488, 489, ")" +555, 5, 32, 94, 157, 162, 490, 495, "50931" +555, 5, 33, 95, 163, 164, 496, 497, "," +555, 5, 34, 96, 165, 172, 498, 505, "Germany" +555, 5, 35, 97, 173, 174, 506, 507, "." +555, 6, 1, 98, 0, 7, 508, 515, "michael" +555, 6, 2, 99, 8, 9, 516, 517, "." +555, 6, 3, 100, 10, 22, 518, 530, "diestelhorst" +555, 6, 4, 101, 23, 24, 531, 532, "@" +555, 6, 5, 102, 25, 32, 533, 540, "medizin" +555, 6, 6, 103, 33, 34, 541, 542, "." +555, 6, 7, 104, 35, 38, 543, 546, "uni" +555, 6, 8, 105, 39, 40, 547, 548, "-" +555, 6, 9, 106, 41, 46, 549, 554, "koeln" +555, 6, 10, 107, 47, 48, 555, 556, "." +555, 6, 11, 108, 49, 51, 557, 559, "de" +555, 6, 12, 109, 52, 62, 560, 570, "BACKGROUND" +555, 6, 13, 110, 63, 64, 571, 572, ":" +555, 6, 14, 111, 65, 67, 573, 575, "To" +555, 6, 15, 112, 68, 75, 576, 583, "compare" +555, 6, 16, 113, 76, 79, 584, 587, "the" +555, 6, 17, 114, 80, 91, 588, 599, "intraocular" +555, 6, 18, 115, 92, 100, 600, 608, "pressure" +555, 6, 19, 116, 101, 102, 609, 610, "(" +555, 6, 20, 117, 103, 106, 611, 614, "IOP" +555, 6, 21, 118, 107, 108, 615, 616, ")" +555, 6, 22, 119, 109, 117, 617, 625, "lowering" +555, 6, 23, 120, 118, 124, 626, 632, "effect" +555, 6, 24, 121, 125, 128, 633, 636, "and" +555, 6, 25, 122, 129, 135, 637, 643, "safety" +555, 6, 26, 123, 136, 138, 644, 646, "of" +555, 6, 27, 124, 139, 142, 647, 650, "the" +555, 6, 28, 125, 143, 148, 651, 656, "fixed" +555, 6, 29, 126, 149, 160, 657, 668, "combination" +555, 6, 30, 127, 161, 163, 669, 671, "of" +555, 6, 31, 128, 164, 175, 672, 683, "latanoprost" +555, 6, 32, 129, 176, 179, 684, 687, "and" +555, 6, 33, 130, 180, 187, 688, 695, "timolol" +555, 6, 34, 131, 188, 192, 696, 700, "with" +555, 6, 35, 132, 193, 197, 701, 705, "that" +555, 6, 36, 133, 198, 200, 706, 708, "of" +555, 6, 37, 134, 201, 204, 709, 712, "the" +555, 6, 38, 135, 205, 216, 713, 724, "concomitant" +555, 6, 39, 136, 217, 220, 725, 728, "use" +555, 6, 40, 137, 221, 223, 729, 731, "of" +555, 6, 41, 138, 224, 227, 732, 735, "the" +555, 6, 42, 139, 228, 238, 736, 746, "individual" +555, 6, 43, 140, 239, 249, 747, 757, "components" +555, 6, 44, 141, 250, 251, 758, 759, "." +555, 7, 1, 142, 0, 7, 760, 767, "METHODS" +555, 7, 2, 143, 8, 9, 768, 769, ":" +555, 7, 3, 144, 10, 11, 770, 771, "A" +555, 7, 4, 145, 12, 14, 772, 774, "12" +555, 7, 5, 146, 15, 19, 775, 779, "week" +555, 7, 6, 147, 20, 21, 780, 781, "," +555, 7, 7, 148, 22, 28, 782, 788, "double" +555, 7, 8, 149, 29, 35, 789, 795, "masked" +555, 7, 9, 150, 36, 37, 796, 797, "," +555, 7, 10, 151, 38, 48, 798, 808, "randomised" +555, 7, 11, 152, 49, 50, 809, 810, "," +555, 7, 12, 153, 51, 60, 811, 820, "crossover" +555, 7, 13, 154, 61, 62, 821, 822, "," +555, 7, 14, 155, 63, 74, 823, 834, "multicentre" +555, 7, 15, 156, 75, 80, 835, 840, "study" +555, 7, 16, 157, 81, 83, 841, 843, "of" +555, 7, 17, 158, 84, 92, 844, 852, "patients" +555, 7, 18, 159, 93, 97, 853, 857, "with" +555, 7, 19, 160, 98, 102, 858, 862, "open" +555, 7, 20, 161, 103, 108, 863, 868, "angle" +555, 7, 21, 162, 109, 117, 869, 877, "glaucoma" +555, 7, 22, 163, 118, 120, 878, 880, "or" +555, 7, 23, 164, 121, 127, 881, 887, "ocular" +555, 7, 24, 165, 128, 140, 888, 900, "hypertension" +555, 7, 25, 166, 141, 144, 901, 904, "and" +555, 7, 26, 167, 145, 148, 905, 908, "IOP" +555, 7, 27, 168, 149, 159, 909, 919, "controlled" +555, 7, 28, 169, 160, 162, 920, 922, "on" +555, 7, 29, 170, 163, 169, 923, 929, "ocular" +555, 7, 30, 171, 170, 181, 930, 941, "hypotensive" +555, 7, 31, 172, 182, 191, 942, 951, "treatment" +555, 7, 32, 173, 192, 193, 952, 953, "(" +555, 7, 33, 174, 194, 198, 954, 958, "mean" +555, 7, 34, 175, 199, 200, 959, 960, "&" +555, 7, 35, 176, 201, 203, 961, 963, "lt" +555, 7, 36, 177, 204, 205, 964, 965, ";" +555, 7, 37, 178, 206, 208, 966, 968, "or" +555, 7, 38, 179, 209, 210, 969, 970, "=" +555, 7, 39, 180, 211, 213, 971, 973, "21" +555, 7, 40, 181, 214, 218, 974, 978, "mmHg" +555, 7, 41, 182, 219, 220, 979, 980, ")" +555, 7, 42, 183, 221, 222, 981, 982, "." +555, 8, 1, 184, 0, 8, 983, 991, "Patients" +555, 8, 2, 185, 9, 17, 992, 1000, "received" +555, 8, 3, 186, 18, 24, 1001, 1007, "either" +555, 8, 4, 187, 25, 26, 1008, 1009, "a" +555, 8, 5, 188, 27, 31, 1010, 1014, "once" +555, 8, 6, 189, 32, 37, 1015, 1020, "daily" +555, 8, 7, 190, 38, 45, 1021, 1028, "morning" +555, 8, 8, 191, 46, 50, 1029, 1033, "dose" +555, 8, 9, 192, 51, 53, 1034, 1036, "of" +555, 8, 10, 193, 54, 57, 1037, 1040, "the" +555, 8, 11, 194, 58, 63, 1041, 1046, "fixed" +555, 8, 12, 195, 64, 75, 1047, 1058, "combination" +555, 8, 13, 196, 76, 78, 1059, 1061, "of" +555, 8, 14, 197, 79, 90, 1062, 1073, "latanoprost" +555, 8, 15, 198, 91, 92, 1074, 1075, "0" +555, 8, 16, 199, 93, 94, 1076, 1077, "." +555, 8, 17, 200, 95, 98, 1078, 1081, "005" +555, 8, 18, 201, 99, 100, 1082, 1083, "%" +555, 8, 19, 202, 101, 104, 1084, 1087, "and" +555, 8, 20, 203, 105, 112, 1088, 1095, "timolol" +555, 8, 21, 204, 113, 114, 1096, 1097, "0" +555, 8, 22, 205, 115, 116, 1098, 1099, "." +555, 8, 23, 206, 117, 118, 1100, 1101, "5" +555, 8, 24, 207, 119, 120, 1102, 1103, "%" +555, 8, 25, 208, 121, 123, 1104, 1106, "or" +555, 8, 26, 209, 124, 128, 1107, 1111, "once" +555, 8, 27, 210, 129, 134, 1112, 1117, "daily" +555, 8, 28, 211, 135, 142, 1118, 1125, "evening" +555, 8, 29, 212, 143, 154, 1126, 1137, "latanoprost" +555, 8, 30, 213, 155, 156, 1138, 1139, "0" +555, 8, 31, 214, 157, 158, 1140, 1141, "." +555, 8, 32, 215, 159, 162, 1142, 1145, "005" +555, 8, 33, 216, 163, 164, 1146, 1147, "%" +555, 8, 34, 217, 165, 168, 1148, 1151, "and" +555, 8, 35, 218, 169, 174, 1152, 1157, "twice" +555, 8, 36, 219, 175, 180, 1158, 1163, "daily" +555, 8, 37, 220, 181, 188, 1164, 1171, "timolol" +555, 8, 38, 221, 189, 190, 1172, 1173, "0" +555, 8, 39, 222, 191, 192, 1174, 1175, "." +555, 8, 40, 223, 193, 194, 1176, 1177, "5" +555, 8, 41, 224, 195, 196, 1178, 1179, "%" +555, 8, 42, 225, 197, 200, 1180, 1183, "for" +555, 8, 43, 226, 201, 204, 1184, 1187, "six" +555, 8, 44, 227, 205, 210, 1188, 1193, "weeks" +555, 8, 45, 228, 211, 214, 1194, 1197, "and" +555, 8, 46, 229, 215, 219, 1198, 1202, "then" +555, 8, 47, 230, 220, 228, 1203, 1211, "switched" +555, 8, 48, 231, 229, 231, 1212, 1214, "to" +555, 8, 49, 232, 232, 235, 1215, 1218, "the" +555, 8, 50, 233, 236, 241, 1219, 1224, "other" +555, 8, 51, 234, 242, 253, 1225, 1236, "combination" +555, 8, 52, 235, 254, 255, 1237, 1238, "." +555, 9, 1, 236, 0, 3, 1239, 1242, "The" +555, 9, 2, 237, 4, 11, 1243, 1250, "primary" +555, 9, 3, 238, 12, 20, 1251, 1259, "efficacy" +555, 9, 4, 239, 21, 29, 1260, 1268, "endpoint" +555, 9, 5, 240, 30, 33, 1269, 1272, "was" +555, 9, 6, 241, 34, 37, 1273, 1276, "the" +555, 9, 7, 242, 38, 44, 1277, 1283, "within" +555, 9, 8, 243, 45, 46, 1284, 1285, "-" +555, 9, 9, 244, 47, 54, 1286, 1293, "patient" +555, 9, 10, 245, 55, 65, 1294, 1304, "difference" +555, 9, 11, 246, 66, 68, 1305, 1307, "in" +555, 9, 12, 247, 69, 76, 1308, 1315, "diurnal" +555, 9, 13, 248, 77, 80, 1316, 1319, "IOP" +555, 9, 14, 249, 81, 88, 1320, 1327, "between" +555, 9, 15, 250, 89, 94, 1328, 1333, "fixed" +555, 9, 16, 251, 95, 98, 1334, 1337, "and" +555, 9, 17, 252, 99, 106, 1338, 1345, "unfixed" +555, 9, 18, 253, 107, 116, 1346, 1355, "treatment" +555, 9, 19, 254, 117, 129, 1356, 1368, "combinations" +555, 9, 20, 255, 130, 135, 1369, 1374, "after" +555, 9, 21, 256, 136, 139, 1375, 1378, "six" +555, 9, 22, 257, 140, 145, 1379, 1384, "weeks" +555, 9, 23, 258, 146, 148, 1385, 1387, "of" +555, 9, 24, 259, 149, 158, 1388, 1397, "treatment" +555, 9, 25, 260, 159, 160, 1398, 1399, ";" +555, 9, 26, 261, 161, 162, 1400, 1401, "a" +555, 9, 27, 262, 163, 166, 1402, 1405, "one" +555, 9, 28, 263, 167, 172, 1406, 1411, "sided" +555, 9, 29, 264, 173, 175, 1412, 1414, "97" +555, 9, 30, 265, 176, 177, 1415, 1416, "." +555, 9, 31, 266, 178, 179, 1417, 1418, "5" +555, 9, 32, 267, 180, 181, 1419, 1420, "%" +555, 9, 33, 268, 182, 192, 1421, 1431, "confidence" +555, 9, 34, 269, 193, 201, 1432, 1440, "interval" +555, 9, 35, 270, 202, 203, 1441, 1442, "(" +555, 9, 36, 271, 204, 206, 1443, 1445, "CI" +555, 9, 37, 272, 207, 208, 1446, 1447, ")" +555, 9, 38, 273, 209, 212, 1448, 1451, "for" +555, 9, 39, 274, 213, 216, 1452, 1455, "the" +555, 9, 40, 275, 217, 221, 1456, 1460, "mean" +555, 9, 41, 276, 222, 232, 1461, 1471, "difference" +555, 9, 42, 277, 233, 235, 1472, 1474, "in" +555, 9, 43, 278, 236, 239, 1475, 1478, "IOP" +555, 9, 44, 279, 240, 241, 1479, 1480, "&" +555, 9, 45, 280, 242, 244, 1481, 1483, "lt" +555, 9, 46, 281, 245, 246, 1484, 1485, ";" +555, 9, 47, 282, 247, 248, 1486, 1487, "1" +555, 9, 48, 283, 249, 250, 1488, 1489, "." +555, 9, 49, 284, 251, 252, 1490, 1491, "0" +555, 9, 50, 285, 253, 257, 1492, 1496, "mmHg" +555, 9, 51, 286, 258, 267, 1497, 1506, "indicated" +555, 9, 52, 287, 268, 271, 1507, 1510, "the" +555, 9, 53, 288, 272, 277, 1511, 1516, "fixed" +555, 9, 54, 289, 278, 289, 1517, 1528, "combination" +555, 9, 55, 290, 290, 293, 1529, 1532, "was" +555, 9, 56, 291, 294, 297, 1533, 1536, "not" +555, 9, 57, 292, 298, 306, 1537, 1545, "inferior" +555, 9, 58, 293, 307, 309, 1546, 1548, "to" +555, 9, 59, 294, 310, 313, 1549, 1552, "the" +555, 9, 60, 295, 314, 321, 1553, 1560, "unfixed" +555, 9, 61, 296, 322, 333, 1561, 1572, "combination" +555, 9, 62, 297, 334, 335, 1573, 1574, "." +555, 10, 1, 298, 0, 7, 1575, 1582, "Adverse" +555, 10, 2, 299, 8, 14, 1583, 1589, "events" +555, 10, 3, 300, 15, 19, 1590, 1594, "were" +555, 10, 4, 301, 20, 28, 1595, 1603, "recorded" +555, 10, 5, 302, 29, 31, 1604, 1606, "at" +555, 10, 6, 303, 32, 36, 1607, 1611, "each" +555, 10, 7, 304, 37, 42, 1612, 1617, "visit" +555, 10, 8, 305, 43, 44, 1618, 1619, "." +555, 11, 1, 306, 0, 7, 1620, 1627, "RESULTS" +555, 11, 2, 307, 8, 9, 1628, 1629, ":" +555, 11, 3, 308, 10, 12, 1630, 1632, "In" +555, 11, 4, 309, 13, 16, 1633, 1636, "all" +555, 11, 5, 310, 17, 18, 1637, 1638, "," +555, 11, 6, 311, 19, 22, 1639, 1642, "190" +555, 11, 7, 312, 23, 31, 1643, 1651, "patients" +555, 11, 8, 313, 32, 36, 1652, 1656, "were" +555, 11, 9, 314, 37, 45, 1657, 1665, "included" +555, 11, 10, 315, 46, 48, 1666, 1668, "in" +555, 11, 11, 316, 49, 57, 1669, 1677, "observed" +555, 11, 12, 317, 58, 63, 1678, 1683, "cases" +555, 11, 13, 318, 64, 72, 1684, 1692, "analyses" +555, 11, 14, 319, 73, 74, 1693, 1694, "(" +555, 11, 15, 320, 75, 77, 1695, 1697, "93" +555, 11, 16, 321, 78, 83, 1698, 1703, "fixed" +555, 11, 17, 322, 84, 86, 1704, 1706, "to" +555, 11, 18, 323, 87, 94, 1707, 1714, "unfixed" +555, 11, 19, 324, 95, 106, 1715, 1726, "combination" +555, 11, 20, 325, 107, 108, 1727, 1728, ";" +555, 11, 21, 326, 109, 111, 1729, 1731, "97" +555, 11, 22, 327, 112, 119, 1732, 1739, "unfixed" +555, 11, 23, 328, 120, 122, 1740, 1742, "to" +555, 11, 24, 329, 123, 128, 1743, 1748, "fixed" +555, 11, 25, 330, 129, 140, 1749, 1760, "combination" +555, 11, 26, 331, 141, 142, 1761, 1762, ")" +555, 11, 27, 332, 143, 144, 1763, 1764, "." +555, 12, 1, 333, 0, 4, 1765, 1769, "Mean" +555, 12, 2, 334, 5, 8, 1770, 1773, "IOP" +555, 12, 3, 335, 9, 11, 1774, 1776, "at" +555, 12, 4, 336, 12, 20, 1777, 1785, "baseline" +555, 12, 5, 337, 21, 24, 1786, 1789, "was" +555, 12, 6, 338, 25, 27, 1790, 1792, "16" +555, 12, 7, 339, 28, 29, 1793, 1794, "." +555, 12, 8, 340, 30, 31, 1795, 1796, "9" +555, 12, 9, 341, 32, 36, 1797, 1801, "mmHg" +555, 12, 10, 342, 37, 39, 1802, 1804, "in" +555, 12, 11, 343, 40, 44, 1805, 1809, "both" +555, 12, 12, 344, 45, 51, 1810, 1816, "groups" +555, 12, 13, 345, 52, 53, 1817, 1818, "." +555, 13, 1, 346, 0, 3, 1819, 1822, "The" +555, 13, 2, 347, 4, 8, 1823, 1827, "mean" +555, 13, 3, 348, 9, 16, 1828, 1835, "diurnal" +555, 13, 4, 349, 17, 20, 1836, 1839, "IOP" +555, 13, 5, 350, 21, 24, 1840, 1843, "was" +555, 13, 6, 351, 25, 27, 1844, 1846, "17" +555, 13, 7, 352, 28, 29, 1847, 1848, "." +555, 13, 8, 353, 30, 31, 1849, 1850, "0" +555, 13, 9, 354, 32, 36, 1851, 1855, "mmHg" +555, 13, 10, 355, 37, 42, 1856, 1861, "after" +555, 13, 11, 356, 43, 48, 1862, 1867, "fixed" +555, 13, 12, 357, 49, 60, 1868, 1879, "combination" +555, 13, 13, 358, 61, 70, 1880, 1889, "treatment" +555, 13, 14, 359, 71, 74, 1890, 1893, "and" +555, 13, 15, 360, 75, 77, 1894, 1896, "15" +555, 13, 16, 361, 78, 79, 1897, 1898, "." +555, 13, 17, 362, 80, 81, 1899, 1900, "9" +555, 13, 18, 363, 82, 86, 1901, 1905, "mmHg" +555, 13, 19, 364, 87, 92, 1906, 1911, "after" +555, 13, 20, 365, 93, 100, 1912, 1919, "unfixed" +555, 13, 21, 366, 101, 112, 1920, 1931, "combination" +555, 13, 22, 367, 113, 120, 1932, 1939, "therapy" +555, 13, 23, 368, 121, 122, 1940, 1941, "(" +555, 13, 24, 369, 123, 124, 1942, 1943, "p" +555, 13, 25, 370, 125, 126, 1944, 1945, "&" +555, 13, 26, 371, 127, 129, 1946, 1948, "lt" +555, 13, 27, 372, 130, 131, 1949, 1950, ";" +555, 13, 28, 373, 132, 133, 1951, 1952, "0" +555, 13, 29, 374, 134, 135, 1953, 1954, "." +555, 13, 30, 375, 136, 140, 1955, 1959, "0001" +555, 13, 31, 376, 141, 142, 1960, 1961, ")" +555, 13, 32, 377, 143, 144, 1962, 1963, "." +555, 14, 1, 378, 0, 3, 1964, 1967, "The" +555, 14, 2, 379, 4, 14, 1968, 1978, "difference" +555, 14, 3, 380, 15, 17, 1979, 1981, "in" +555, 14, 4, 381, 18, 22, 1982, 1986, "mean" +555, 14, 5, 382, 23, 29, 1987, 1993, "within" +555, 14, 6, 383, 30, 31, 1994, 1995, "-" +555, 14, 7, 384, 32, 39, 1996, 2003, "patient" +555, 14, 8, 385, 40, 47, 2004, 2011, "diurnal" +555, 14, 9, 386, 48, 51, 2012, 2015, "IOP" +555, 14, 10, 387, 52, 55, 2016, 2019, "was" +555, 14, 11, 388, 56, 57, 2020, 2021, "1" +555, 14, 12, 389, 58, 59, 2022, 2023, "." +555, 14, 13, 390, 60, 61, 2024, 2025, "1" +555, 14, 14, 391, 62, 66, 2026, 2030, "mmHg" +555, 14, 15, 392, 67, 76, 2031, 2040, "favouring" +555, 14, 16, 393, 77, 80, 2041, 2044, "the" +555, 14, 17, 394, 81, 88, 2045, 2052, "unfixed" +555, 14, 18, 395, 89, 100, 2053, 2064, "combination" +555, 14, 19, 396, 101, 102, 2065, 2066, "(" +555, 14, 20, 397, 103, 105, 2067, 2069, "95" +555, 14, 21, 398, 106, 107, 2070, 2071, "%" +555, 14, 22, 399, 108, 110, 2072, 2074, "CI" +555, 14, 23, 400, 111, 112, 2075, 2076, "0" +555, 14, 24, 401, 113, 114, 2077, 2078, "." +555, 14, 25, 402, 115, 116, 2079, 2080, "8" +555, 14, 26, 403, 117, 119, 2081, 2083, "to" +555, 14, 27, 404, 120, 121, 2084, 2085, "1" +555, 14, 28, 405, 122, 123, 2086, 2087, "." +555, 14, 29, 406, 124, 125, 2088, 2089, "4" +555, 14, 30, 407, 126, 130, 2090, 2094, "mmHg" +555, 14, 31, 408, 131, 132, 2095, 2096, ")" +555, 14, 32, 409, 133, 134, 2097, 2098, "." +555, 15, 1, 410, 0, 4, 2099, 2103, "Both" +555, 15, 2, 411, 5, 15, 2104, 2114, "treatments" +555, 15, 3, 412, 16, 20, 2115, 2119, "were" +555, 15, 4, 413, 21, 30, 2120, 2129, "tolerated" +555, 15, 5, 414, 31, 35, 2130, 2134, "well" +555, 15, 6, 415, 36, 37, 2135, 2136, "." +555, 16, 1, 416, 0, 11, 2137, 2148, "CONCLUSIONS" +555, 16, 2, 417, 12, 13, 2149, 2150, ":" +555, 16, 3, 418, 14, 22, 2151, 2159, "Although" +555, 16, 4, 419, 23, 26, 2160, 2163, "the" +555, 16, 5, 420, 27, 34, 2164, 2171, "primary" +555, 16, 6, 421, 35, 43, 2172, 2180, "efficacy" +555, 16, 7, 422, 44, 52, 2181, 2189, "endpoint" +555, 16, 8, 423, 53, 56, 2190, 2193, "was" +555, 16, 9, 424, 57, 60, 2194, 2197, "not" +555, 16, 10, 425, 61, 64, 2198, 2201, "met" +555, 16, 11, 426, 65, 66, 2202, 2203, "," +555, 16, 12, 427, 67, 71, 2204, 2208, "once" +555, 16, 13, 428, 72, 77, 2209, 2214, "daily" +555, 16, 14, 429, 78, 92, 2215, 2229, "administration" +555, 16, 15, 430, 93, 95, 2230, 2232, "of" +555, 16, 16, 431, 96, 99, 2233, 2236, "the" +555, 16, 17, 432, 100, 105, 2237, 2242, "fixed" +555, 16, 18, 433, 106, 117, 2243, 2254, "combination" +555, 16, 19, 434, 118, 120, 2255, 2257, "of" +555, 16, 20, 435, 121, 132, 2258, 2269, "latanoprost" +555, 16, 21, 436, 133, 136, 2270, 2273, "and" +555, 16, 22, 437, 137, 144, 2274, 2281, "timolol" +555, 16, 23, 438, 145, 148, 2282, 2285, "was" +555, 16, 24, 439, 149, 154, 2286, 2291, "found" +555, 16, 25, 440, 155, 157, 2292, 2294, "to" +555, 16, 26, 441, 158, 160, 2295, 2297, "be" +555, 16, 27, 442, 161, 165, 2298, 2302, "safe" +555, 16, 28, 443, 166, 169, 2303, 2306, "and" +555, 16, 29, 444, 170, 179, 2307, 2316, "effective" +555, 16, 30, 445, 180, 181, 2317, 2318, "." +555, 17, 1, 446, 0, 3, 2319, 2322, "The" +555, 17, 2, 447, 4, 9, 2323, 2328, "fixed" +555, 17, 3, 448, 10, 21, 2329, 2340, "combination" +555, 17, 4, 449, 22, 30, 2341, 2349, "provides" +555, 17, 5, 450, 31, 32, 2350, 2351, "a" +555, 17, 6, 451, 33, 43, 2352, 2362, "convenient" +555, 17, 7, 452, 44, 55, 2363, 2374, "alternative" +555, 17, 8, 453, 56, 58, 2375, 2377, "to" +555, 17, 9, 454, 59, 62, 2378, 2381, "the" +555, 17, 10, 455, 63, 68, 2382, 2387, "three" +555, 17, 11, 456, 69, 82, 2388, 2401, "instillations" +555, 17, 12, 457, 83, 91, 2402, 2410, "required" +555, 17, 13, 458, 92, 96, 2411, 2415, "with" +555, 17, 14, 459, 97, 100, 2416, 2419, "the" +555, 17, 15, 460, 101, 111, 2420, 2430, "individual" +555, 17, 16, 461, 112, 122, 2431, 2441, "components" +555, 17, 17, 462, 123, 124, 2442, 2443, "." +555, 18, 1, 463, 0, 3, 2444, 2447, "DOI" +555, 18, 2, 464, 4, 5, 2448, 2449, ":" +555, 18, 3, 465, 6, 8, 2450, 2452, "10" +555, 18, 4, 466, 9, 10, 2453, 2454, "." +555, 18, 5, 467, 11, 15, 2455, 2459, "1136" +555, 18, 6, 468, 16, 17, 2460, 2461, "/" +555, 18, 7, 469, 18, 21, 2462, 2465, "bjo" +555, 18, 8, 470, 22, 23, 2466, 2467, "." +555, 18, 9, 471, 24, 28, 2468, 2472, "2003" +555, 18, 10, 472, 29, 30, 2473, 2474, "." +555, 18, 11, 473, 31, 37, 2475, 2481, "018234" +555, 18, 12, 474, 38, 43, 2482, 2487, "PMCID" +555, 18, 13, 475, 44, 45, 2488, 2489, ":" +555, 18, 14, 476, 46, 56, 2490, 2500, "PMC1771993" +555, 18, 15, 477, 57, 61, 2501, 2505, "PMID" +555, 18, 16, 478, 62, 63, 2506, 2507, ":" +555, 18, 17, 479, 64, 72, 2508, 2516, "14736774" +555, 18, 18, 480, 73, 74, 2517, 2518, "[" +555, 18, 19, 481, 75, 82, 2519, 2526, "Indexed" +555, 18, 20, 482, 83, 86, 2527, 2530, "for" +555, 18, 21, 483, 87, 94, 2531, 2538, "MEDLINE" +555, 18, 22, 484, 95, 96, 2539, 2540, "]" diff --git a/data/gl 14736774_jshahinitiran.annodb b/data/gl 14736774_jshahinitiran.annodb new file mode 100644 index 0000000..1b3a168 --- /dev/null +++ b/data/gl 14736774_jshahinitiran.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82570, Journal, 0, 15, "Br J Ophthalmol", "", +82571, PublicationYear, 18, 22, "2004", "", +82572, Title, 52, 243, "A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension .", "", +82573, Duration, 54, 61, "12 week", "", +82576, Lat/TimFC, 82, 126, "fixed combination of latanoprost and timolol", "", +82574, Latanoprost, 103, 114, "latanoprost", "", +82575, Timolol, 119, 126, "timolol", "", +82577, OpenAngleGlaucoma, 198, 217, "open angle glaucoma", "", +82578, OcularHypertension, 222, 241, "ocular hypertension", "", +82579, Author, 244, 258, "Diestelhorst M", "", +82580, Author, 267, 277, "Larsson LI", "", +82581, Germany, 498, 505, "Germany", "", +82582, ObjectiveDescription, 573, 759, "To compare the intraocular pressure ( IOP ) lowering effect and safety of the fixed combination of latanoprost and timolol with that of the concomitant use of the individual components .", "", +82583, IOP, 588, 608, "intraocular pressure", "", +82584, IOP, 611, 614, "IOP", "", +82587, Lat/TimFC, 651, 695, "fixed combination of latanoprost and timolol", "", +82585, Latanoprost, 672, 683, "latanoprost", "", +82586, Timolol, 688, 695, "timolol", "", +82588, Duration, 772, 779, "12 week", "", +82589, DoubleBlind, 782, 795, "double masked", "", +82590, Randomized, 798, 808, "randomised", "", +82591, Crossover, 811, 820, "crossover", "", +82592, Multicenter, 823, 834, "multicentre", "", +82593, OpenAngleGlaucoma, 858, 877, "open angle glaucoma", "", +82594, OcularHypertension, 881, 900, "ocular hypertension", "", +82595, IOP, 905, 908, "IOP", "", +82596, Precondition, 905, 980, "IOP controlled on ocular hypotensive treatment ( mean & lt ; or = 21 mmHg )", "", +82597, mmHg, 974, 978, "mmHg", "", +82598, Frequency, 1010, 1020, "once daily", "", +82599, Morning, 1021, 1028, "morning", "", +82602, Lat/TimFC, 1041, 1103, "fixed combination of latanoprost 0 . 005 % and timolol 0 . 5 %", "", +82600, Latanoprost, 1062, 1073, "latanoprost", "", +82603, DoseValue, 1074, 1081, "0 . 005", "", +82601, Timolol, 1088, 1095, "timolol", "", +82604, DoseValue, 1096, 1101, "0 . 5", "", +82605, Frequency, 1107, 1117, "once daily", "", +82606, Evening, 1118, 1125, "evening", "", +82607, Latanoprost, 1126, 1137, "latanoprost", "", +82610, DoseValue, 1138, 1145, "0 . 005", "", +82608, Frequency, 1152, 1163, "twice daily", "", +82609, Timolol, 1164, 1171, "timolol", "", +82611, DoseValue, 1172, 1177, "0 . 5", "", +82612, Duration, 1184, 1193, "six weeks", "", +82613, Diurnal_IOP, 1308, 1319, "diurnal IOP", "", +82614, Duration, 1375, 1384, "six weeks", "", +82615, Mean, 1456, 1460, "mean", "", +82616, IOP, 1475, 1478, "IOP", "", +82617, mmHg, 1492, 1496, "mmHg", "", +82618, NumberPatientsCT, 1639, 1642, "190", "", +82619, NumberPatientsArm, 1695, 1697, "93", "", +82620, NumberPatientsArm, 1729, 1731, "97", "", +82621, Mean, 1765, 1769, "Mean", "", +82622, IOP, 1770, 1773, "IOP", "", +82623, TimePoint, 1777, 1785, "baseline", "", +82624, BaseLineValue, 1790, 1796, "16 . 9", "", +82626, mmHg, 1797, 1801, "mmHg", "", +82627, Mean, 1823, 1827, "mean", "", +82628, Diurnal_IOP, 1828, 1839, "diurnal IOP", "", +82629, ResultMeasuredValue, 1844, 1850, "17 . 0", "", +82630, mmHg, 1851, 1855, "mmHg", "", +82632, ResultMeasuredValue, 1894, 1900, "15 . 9", "", +82631, mmHg, 1901, 1905, "mmHg", "", +82633, PValueResValue, 1942, 1959, "p & lt ; 0 . 0001", "", +82634, Mean, 1982, 1986, "mean", "", +82635, Diurnal_IOP, 2004, 2015, "diurnal IOP", "", +82636, DiffGroupAbsValue, 2020, 2025, "1 . 1", "", +82637, mmHg, 2026, 2030, "mmHg", "", +82638, ConfIntervalDiff, 2067, 2094, "95 % CI 0 . 8 to 1 . 4 mmHg", "", +82639, mmHg, 2090, 2094, "mmHg", "", +82640, ConclusionComment, 2151, 2318, "Although the primary efficacy endpoint was not met , once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective .", "", +82642, Frequency, 2204, 2214, "once daily", "", +82645, Lat/TimFC, 2237, 2281, "fixed combination of latanoprost and timolol", "", +82643, Latanoprost, 2258, 2269, "latanoprost", "", +82644, Timolol, 2274, 2281, "timolol", "", +82641, ConclusionComment, 2319, 2443, "The fixed combination provides a convenient alternative to the three instillations required with the individual components .", "", +82646, Lat/TimFC, 2323, 2340, "fixed combination", "", +82647, PMID, 2508, 2516, "14736774", "", diff --git a/data/gl 14736774_jshahinitiran.n-triples b/data/gl 14736774_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 14736774_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14736774_tstrakeljahn.annodb b/data/gl 14736774_tstrakeljahn.annodb new file mode 100644 index 0000000..d8de5c7 --- /dev/null +++ b/data/gl 14736774_tstrakeljahn.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82752, Journal, 0, 15, "Br J Ophthalmol", "", +82753, PublicationYear, 18, 22, "2004", "", +82760, Title, 52, 243, "A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension .", "", +82754, Duration, 54, 61, "12 week", "", +82755, Latanoprost, 103, 114, "latanoprost", "", +82757, Lat/TimFC, 103, 126, "latanoprost and timolol", "", +82756, Timolol, 119, 126, "timolol", "", +82758, OpenAngleGlaucoma, 198, 217, "open angle glaucoma", "", +82759, OcularHypertension, 222, 241, "ocular hypertension", "", +82761, Author, 244, 258, "Diestelhorst M", "", +82762, Author, 267, 277, "Larsson LI", "", +82763, IOP, 588, 608, "intraocular pressure", "", +82764, IOP, 611, 614, "IOP", "", +82765, Latanoprost, 672, 683, "latanoprost", "", +82767, Lat/TimFC, 672, 695, "latanoprost and timolol", "", +82766, Timolol, 688, 695, "timolol", "", +82768, Duration, 772, 779, "12 week", "", +82769, DoubleBlind, 782, 795, "double masked", "", +82770, Randomized, 798, 808, "randomised", "", +82771, Crossover, 811, 820, "crossover", "", +82772, Multicenter, 823, 834, "multicentre", "", +82773, OpenAngleGlaucoma, 858, 877, "open angle glaucoma", "", +82774, OcularHypertension, 881, 900, "ocular hypertension", "", +82775, IOP, 905, 908, "IOP", "", +82780, Frequency, 1010, 1020, "once daily", "", +82791, Morning, 1021, 1028, "morning", "", +82776, Latanoprost, 1062, 1073, "latanoprost", "", +82783, DoseValue, 1074, 1081, "0 . 005", "", +82787, Percentage, 1082, 1083, "%", "", +82777, Timolol, 1088, 1095, "timolol", "", +82784, DoseValue, 1096, 1101, "0 . 5", "", +82788, Percentage, 1102, 1103, "%", "", +82781, Frequency, 1107, 1117, "once daily", "", +82792, Evening, 1118, 1125, "evening", "", +82779, Latanoprost, 1126, 1137, "latanoprost", "", +82785, DoseValue, 1138, 1145, "0 . 005", "", +82789, Percentage, 1146, 1147, "%", "", +82782, Frequency, 1152, 1163, "twice daily", "", +82778, Timolol, 1164, 1171, "timolol", "", +82786, DoseValue, 1172, 1177, "0 . 5", "", +82790, Percentage, 1178, 1179, "%", "", +82794, Endpoint, 1277, 1397, "within - patient difference in diurnal IOP between fixed and unfixed treatment combinations after six weeks of treatment", "", +82793, Diurnal_IOP, 1308, 1319, "diurnal IOP", "", +82795, Mean, 1456, 1460, "mean", "", +82796, IOP, 1475, 1478, "IOP", "", +82797, mmHg, 1492, 1496, "mmHg", "", +82798, FinalNumPatientsCT, 1639, 1642, "190", "", +82799, FinalNumPatientsArm, 1695, 1697, "93", "", +82800, FinalNumPatientsArm, 1729, 1731, "97", "", +82801, Mean, 1765, 1769, "Mean", "", +82802, IOP, 1770, 1773, "IOP", "", +82803, TimePoint, 1774, 1785, "at baseline", "", +82804, BaseLineValue, 1790, 1796, "16 . 9", "", +82805, mmHg, 1797, 1801, "mmHg", "", +82806, Mean, 1823, 1827, "mean", "", +82807, Diurnal_IOP, 1828, 1839, "diurnal IOP", "", +82808, ResultMeasuredValue, 1844, 1850, "17 . 0", "", +82810, mmHg, 1851, 1855, "mmHg", "", +82809, ResultMeasuredValue, 1894, 1900, "15 . 9", "", +82811, mmHg, 1901, 1905, "mmHg", "", +82812, Mean, 1982, 1986, "mean", "", +82813, Diurnal_IOP, 2004, 2015, "diurnal IOP", "", +82814, DiffGroupAbsValue, 2020, 2025, "1 . 1", "", +82815, mmHg, 2026, 2030, "mmHg", "", +82816, ConfIntervalDiff, 2075, 2089, "0 . 8 to 1 . 4", "", +82817, mmHg, 2090, 2094, "mmHg", "", +82818, ObservedResult, 2099, 2136, "Both treatments were tolerated well .", "", +82823, ConclusionComment, 2151, 2318, "Although the primary efficacy endpoint was not met , once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective .", "", +82819, Frequency, 2204, 2214, "once daily", "", +82820, Latanoprost, 2258, 2269, "latanoprost", "", +82822, Lat/TimFC, 2258, 2281, "latanoprost and timolol", "", +82821, Timolol, 2274, 2281, "timolol", "", +82824, ConclusionComment, 2319, 2443, "The fixed combination provides a convenient alternative to the three instillations required with the individual components .", "", +82825, PMID, 2508, 2516, "14736774", "", diff --git a/data/gl 14736774_tstrakeljahn.n-triples b/data/gl 14736774_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 14736774_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14746165_admin.annodb b/data/gl 14746165_admin.annodb new file mode 100644 index 0000000..65cdbaa --- /dev/null +++ b/data/gl 14746165_admin.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Coll Antropol", "", " \"Coll Antropol\"." +83, PublicationYear, 16, 20, "2003", "", " \"2003\"." +88, Title, 49, 145, "A study of replacement of timolol - pilocarpine with latanoprost in pseudoexfoliation glaucoma .", "", " \"A study of replacement of timolol - pilocarpine with latanoprost in pseudoexfoliation glaucoma .\"." +41, Timolol, 75, 82, "timolol", "", " ." +42, Pilocarpine, 85, 96, "pilocarpine", "", " ." +43, Latanoprost, 102, 113, "latanoprost", "", " . ." +44, Glaucoma, 117, 143, "pseudoexfoliation glaucoma", "", " . ." +3, Author, 146, 154, "Boji ć L", "", " \"Boji ć L\"." +4, Author, 163, 172, "Mandi ć Z", "", " \"Mandi ć Z\"." +5, Author, 175, 189, "Novak - Laus K", "", " \"Novak - Laus K\"." +6, Author, 192, 201, "Sonicki Z", "", " \"Sonicki Z\"." +7, Author, 204, 216, "Karelovi ć D", "", " \"Karelovi ć D\"." +94, Croatia, 295, 302, "Croatia", "", " ." +9, ObjectiveDescription, 305, 538, "The aim of the study was to evaluate the efficacy of replacing current dual local therapy ( timolol and pilocarpine ) with latanoprost 0 . 005 % in 71 pseudoexfoliation glaucoma patients with controlled intraocular pressure ( IOP ) .", "", " \"The aim of the study was to evaluate the efficacy of replacing current dual local therapy ( timolol and pilocarpine ) with latanoprost 0 . 005 % in 71 pseudoexfoliation glaucoma patients with controlled intraocular pressure ( IOP ) .\"." +46, Timolol, 397, 404, "timolol", "", +47, Pilocarpine, 409, 420, "pilocarpine", "", +48, Latanoprost, 428, 439, "latanoprost", "", +49, DoseValue, 440, 447, "0 . 005", "", +50, Percentage, 448, 449, "%", "", +10, NumberPatientsCT, 453, 455, "71", "", " \"71\"." +45, Glaucoma, 456, 482, "pseudoexfoliation glaucoma", "", +104, Precondition, 483, 528, "patients with controlled intraocular pressure", "", " \"patients with controlled intraocular pressure\"." +11, IOP, 508, 528, "intraocular pressure", "", +12, IOP, 531, 534, "IOP", "", +14, NumberPatientsArm, 539, 541, "39", "", " \"39\"." +51, Latanoprost, 563, 574, "latanoprost", "", +52, DoseValue, 575, 582, "0 . 005", "", " \"0 . 005\"." +53, Percentage, 583, 584, "%", "", " \"0 . 005\"." +15, NumberPatientsArm, 591, 593, "32", "", " \"32\"." +54, Timolol, 613, 620, "timolol", "", +55, Pilocarpine, 623, 634, "pilocarpine", "", +56, Mean, 645, 649, "Mean", "", " . ." +57, Diurnal_IOP, 650, 663, "diurnal ( IOP", "", " ." +114, IOP, 660, 663, "IOP", "", +58, TimePoint, 682, 690, "baseline", "", +59, TimePoint, 699, 725, "0 . 5 , 1 , 3 and 6 months", "", +60, TimePoint, 747, 755, "6 months", "", " \"6 months\". \"6 months\"." +16, FinalNumPatientsArm, 756, 758, "38", "", " \"38\"." +61, Latanoprost, 773, 784, "latanoprost", "", +17, FinalNumPatientsArm, 789, 791, "30", "", " \"30\"." +62, Timolol, 806, 813, "timolol", "", +63, Pilocarpine, 816, 827, "pilocarpine", "", +34126, TimePoint, 857, 865, "baseline", "", +64, Mean, 870, 874, "mean", "", +65, Diurnal_IOP, 875, 886, "diurnal IOP", "", +18, BaseLineValue, 891, 897, "20 . 4", "", +34127, SdDevBL, 904, 909, "2 . 0", "", " \"2 . 0\"." +20, mmHg, 910, 914, "mmHg", "", " ." +66, Latanoprost, 931, 942, "latanoprost", "", +22, BaseLineValue, 963, 969, "21 . 4", "", " \"21 . 4\"." +34128, SdDevBL, 976, 981, "2 . 1", "", " \"2 . 1\"." +21, mmHg, 982, 986, "mmHg", "", +67, Timolol, 1003, 1010, "timolol", "", +68, Pilocarpine, 1013, 1024, "pilocarpine", "", +69, Duration, 1065, 1073, "6 months", "", " \"6 months\"." +70, Mean, 1093, 1097, "mean", "", +71, Diurnal_IOP, 1098, 1109, "diurnal IOP", "", +24, ResultMeasuredValue, 1122, 1128, "16 . 6", "", " \"16 . 6\"." +34130, SdDevResValue, 1135, 1140, "2 . 4", "", " \"2 . 4\"." +25, ResultMeasuredValue, 1145, 1151, "17 . 9", "", " \"17 . 9\"." +34131, SdDevResValue, 1158, 1163, "2 . 0", "", " \"2 . 0\"." +28, mmHg, 1164, 1168, "mmHg", "", +29, IOP, 1184, 1187, "IOP", "", +30, PValueChangeValue, 1244, 1255, "p < 0 . 001", "", " \"p < 0 . 001\". \"p < 0 . 001\"." +72, Mean, 1264, 1268, "mean", "", +73, Diurnal_IOP, 1269, 1280, "diurnal IOP", "", +31, Reduction, 1308, 1313, "3 . 3", "", " \"3 . 3\"." +33, SdErrorChangeValue, 1320, 1325, "0 . 5", "", " \"0 . 5\"." +35, mmHg, 1326, 1330, "mmHg", "", +74, Mean, 1333, 1337, "mean", "", +75, Latanoprost, 1389, 1400, "latanoprost", "", +32, Reduction, 1407, 1412, "3 . 2", "", " \"3 . 2\"." +34, SdErrorChangeValue, 1419, 1424, "0 . 4", "", " \"0 . 4\"." +36, mmHg, 1425, 1429, "mmHg", "", +80, Timolol, 1460, 1467, "timolol", "", +81, Pilocarpine, 1470, 1481, "pilocarpine", "", +37, IOP, 1503, 1506, "IOP", "", +38, PvalueDiff, 1581, 1591, "p = 0 . 49", "", " \"p = 0 . 49\"." +39, ConclusionComment, 1596, 1754, "This study showed that combination therapy ( timolol plus pilocarpine ) in pseudoexfoliation glaucoma can effectively be replaced by latanoprost monotherapy .", "", " \"This study showed that combination therapy ( timolol plus pilocarpine ) in pseudoexfoliation glaucoma can effectively be replaced by latanoprost monotherapy .\"." +76, Timolol, 1641, 1648, "timolol", "", +77, Pilocarpine, 1654, 1665, "pilocarpine", "", +78, Glaucoma, 1671, 1697, "pseudoexfoliation glaucoma", "", +79, Latanoprost, 1729, 1740, "latanoprost", "", +40, PMID, 1762, 1770, "14746165", "", " \"14746165\"." diff --git a/data/gl 14746165_admin.n-triples b/data/gl 14746165_admin.n-triples new file mode 100644 index 0000000..91eebea --- /dev/null +++ b/data/gl 14746165_admin.n-triples @@ -0,0 +1,121 @@ +# RDF export of group: Publication + . + "Publication" . + "A study of replacement of timolol - pilocarpine with latanoprost in pseudoexfoliation glaucoma ." . + "Boji ć L" . + "2003" . + "Coll Antropol" . + "14746165" . + . + "Mandi ć Z" . + "Novak - Laus K" . + "Sonicki Z" . + "Karelovi ć D" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The aim of the study was to evaluate the efficacy of replacing current dual local therapy ( timolol and pilocarpine ) with latanoprost 0 . 005 % in 71 pseudoexfoliation glaucoma patients with controlled intraocular pressure ( IOP ) ." . + "71" . + "6 months" . + . + . + . + "This study showed that combination therapy ( timolol plus pilocarpine ) in pseudoexfoliation glaucoma can effectively be replaced by latanoprost monotherapy ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with controlled intraocular pressure" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-lat" . + "39" . + "38" . + . + . + . + . + "Arm-tim-pil" . + "32" . + "30" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + . + . + "Intervention-tim" . + . + . + . + "Intervention-pil" . + . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-tim" . + . + . + . + . + "Medication-pil" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-lat" . + . + "2 . 0" . + "16 . 6" . + "2 . 4" . + "3 . 3" . + "p < 0 . 001" . + "0 . 5" . + "6 months" . + . + "Outcome-tim-pil" . + . + "21 . 4" . + "2 . 1" . + "17 . 9" . + "2 . 0" . + "3 . 2" . + "p < 0 . 001" . + "0 . 4" . + "6 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "p = 0 . 49" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14746165_export.csv b/data/gl 14746165_export.csv new file mode 100644 index 0000000..278fee8 --- /dev/null +++ b/data/gl 14746165_export.csv @@ -0,0 +1,380 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +466, 1, 1, 1, 0, 4, 0, 4, "Coll" +466, 1, 2, 2, 5, 13, 5, 13, "Antropol" +466, 1, 3, 3, 14, 15, 14, 15, "." +466, 2, 1, 4, 0, 4, 16, 20, "2003" +466, 2, 2, 5, 5, 8, 21, 24, "Dec" +466, 2, 3, 6, 9, 10, 25, 26, ";" +466, 2, 4, 7, 11, 13, 27, 29, "27" +466, 2, 5, 8, 14, 15, 30, 31, "(" +466, 2, 6, 9, 16, 17, 32, 33, "2" +466, 2, 7, 10, 18, 19, 34, 35, ")" +466, 2, 8, 11, 20, 21, 36, 37, ":" +466, 2, 9, 12, 22, 25, 38, 41, "729" +466, 2, 10, 13, 26, 27, 42, 43, "-" +466, 2, 11, 14, 28, 30, 44, 46, "34" +466, 2, 12, 15, 31, 32, 47, 48, "." +466, 3, 1, 16, 0, 1, 49, 50, "A" +466, 3, 2, 17, 2, 7, 51, 56, "study" +466, 3, 3, 18, 8, 10, 57, 59, "of" +466, 3, 4, 19, 11, 22, 60, 71, "replacement" +466, 3, 5, 20, 23, 25, 72, 74, "of" +466, 3, 6, 21, 26, 33, 75, 82, "timolol" +466, 3, 7, 22, 34, 35, 83, 84, "-" +466, 3, 8, 23, 36, 47, 85, 96, "pilocarpine" +466, 3, 9, 24, 48, 52, 97, 101, "with" +466, 3, 10, 25, 53, 64, 102, 113, "latanoprost" +466, 3, 11, 26, 65, 67, 114, 116, "in" +466, 3, 12, 27, 68, 85, 117, 134, "pseudoexfoliation" +466, 3, 13, 28, 86, 94, 135, 143, "glaucoma" +466, 3, 14, 29, 95, 96, 144, 145, "." +466, 4, 1, 30, 0, 4, 146, 150, "Boji" +466, 4, 2, 31, 5, 6, 151, 152, "ć" +466, 4, 3, 32, 7, 8, 153, 154, "L" +466, 4, 4, 33, 9, 10, 155, 156, "(" +466, 4, 5, 34, 11, 12, 157, 158, "1" +466, 4, 6, 35, 13, 14, 159, 160, ")" +466, 4, 7, 36, 15, 16, 161, 162, "," +466, 4, 8, 37, 17, 22, 163, 168, "Mandi" +466, 4, 9, 38, 23, 24, 169, 170, "ć" +466, 4, 10, 39, 25, 26, 171, 172, "Z" +466, 4, 11, 40, 27, 28, 173, 174, "," +466, 4, 12, 41, 29, 34, 175, 180, "Novak" +466, 4, 13, 42, 35, 36, 181, 182, "-" +466, 4, 14, 43, 37, 41, 183, 187, "Laus" +466, 4, 15, 44, 42, 43, 188, 189, "K" +466, 4, 16, 45, 44, 45, 190, 191, "," +466, 4, 17, 46, 46, 53, 192, 199, "Sonicki" +466, 4, 18, 47, 54, 55, 200, 201, "Z" +466, 4, 19, 48, 56, 57, 202, 203, "," +466, 4, 20, 49, 58, 66, 204, 212, "Karelovi" +466, 4, 21, 50, 67, 68, 213, 214, "ć" +466, 4, 22, 51, 69, 70, 215, 216, "D" +466, 4, 23, 52, 71, 72, 217, 218, "." +466, 4, 24, 53, 73, 79, 219, 225, "Author" +466, 4, 25, 54, 80, 91, 226, 237, "information" +466, 4, 26, 55, 92, 93, 238, 239, ":" +466, 4, 27, 56, 94, 95, 240, 241, "(" +466, 4, 28, 57, 96, 97, 242, 243, "1" +466, 4, 29, 58, 98, 99, 244, 245, ")" +466, 4, 30, 59, 100, 103, 246, 249, "Eye" +466, 4, 31, 60, 104, 110, 250, 256, "Clinic" +466, 4, 32, 61, 111, 112, 257, 258, "," +466, 4, 33, 62, 113, 123, 259, 269, "University" +466, 4, 34, 63, 124, 132, 270, 278, "Hospital" +466, 4, 35, 64, 133, 138, 279, 284, "Split" +466, 4, 36, 65, 139, 140, 285, 286, "," +466, 4, 37, 66, 141, 146, 287, 292, "Split" +466, 4, 38, 67, 147, 148, 293, 294, "," +466, 4, 39, 68, 149, 156, 295, 302, "Croatia" +466, 4, 40, 69, 157, 158, 303, 304, "." +466, 5, 1, 70, 0, 3, 305, 308, "The" +466, 5, 2, 71, 4, 7, 309, 312, "aim" +466, 5, 3, 72, 8, 10, 313, 315, "of" +466, 5, 4, 73, 11, 14, 316, 319, "the" +466, 5, 5, 74, 15, 20, 320, 325, "study" +466, 5, 6, 75, 21, 24, 326, 329, "was" +466, 5, 7, 76, 25, 27, 330, 332, "to" +466, 5, 8, 77, 28, 36, 333, 341, "evaluate" +466, 5, 9, 78, 37, 40, 342, 345, "the" +466, 5, 10, 79, 41, 49, 346, 354, "efficacy" +466, 5, 11, 80, 50, 52, 355, 357, "of" +466, 5, 12, 81, 53, 62, 358, 367, "replacing" +466, 5, 13, 82, 63, 70, 368, 375, "current" +466, 5, 14, 83, 71, 75, 376, 380, "dual" +466, 5, 15, 84, 76, 81, 381, 386, "local" +466, 5, 16, 85, 82, 89, 387, 394, "therapy" +466, 5, 17, 86, 90, 91, 395, 396, "(" +466, 5, 18, 87, 92, 99, 397, 404, "timolol" +466, 5, 19, 88, 100, 103, 405, 408, "and" +466, 5, 20, 89, 104, 115, 409, 420, "pilocarpine" +466, 5, 21, 90, 116, 117, 421, 422, ")" +466, 5, 22, 91, 118, 122, 423, 427, "with" +466, 5, 23, 92, 123, 134, 428, 439, "latanoprost" +466, 5, 24, 93, 135, 136, 440, 441, "0" +466, 5, 25, 94, 137, 138, 442, 443, "." +466, 5, 26, 95, 139, 142, 444, 447, "005" +466, 5, 27, 96, 143, 144, 448, 449, "%" +466, 5, 28, 97, 145, 147, 450, 452, "in" +466, 5, 29, 98, 148, 150, 453, 455, "71" +466, 5, 30, 99, 151, 168, 456, 473, "pseudoexfoliation" +466, 5, 31, 100, 169, 177, 474, 482, "glaucoma" +466, 5, 32, 101, 178, 186, 483, 491, "patients" +466, 5, 33, 102, 187, 191, 492, 496, "with" +466, 5, 34, 103, 192, 202, 497, 507, "controlled" +466, 5, 35, 104, 203, 214, 508, 519, "intraocular" +466, 5, 36, 105, 215, 223, 520, 528, "pressure" +466, 5, 37, 106, 224, 225, 529, 530, "(" +466, 5, 38, 107, 226, 229, 531, 534, "IOP" +466, 5, 39, 108, 230, 231, 535, 536, ")" +466, 5, 40, 109, 232, 233, 537, 538, "." +466, 6, 1, 110, 0, 2, 539, 541, "39" +466, 6, 2, 111, 3, 11, 542, 550, "patients" +466, 6, 3, 112, 12, 20, 551, 559, "switched" +466, 6, 4, 113, 21, 23, 560, 562, "to" +466, 6, 5, 114, 24, 35, 563, 574, "latanoprost" +466, 6, 6, 115, 36, 37, 575, 576, "0" +466, 6, 7, 116, 38, 39, 577, 578, "." +466, 6, 8, 117, 40, 43, 579, 582, "005" +466, 6, 9, 118, 44, 45, 583, 584, "%" +466, 6, 10, 119, 46, 47, 585, 586, ")" +466, 6, 11, 120, 48, 51, 587, 590, "and" +466, 6, 12, 121, 52, 54, 591, 593, "32" +466, 6, 13, 122, 55, 63, 594, 602, "patients" +466, 6, 14, 123, 64, 73, 603, 612, "continued" +466, 6, 15, 124, 74, 81, 613, 620, "timolol" +466, 6, 16, 125, 82, 83, 621, 622, "-" +466, 6, 17, 126, 84, 95, 623, 634, "pilocarpine" +466, 6, 18, 127, 96, 103, 635, 642, "therapy" +466, 6, 19, 128, 104, 105, 643, 644, "." +466, 7, 1, 129, 0, 4, 645, 649, "Mean" +466, 7, 2, 130, 5, 12, 650, 657, "diurnal" +466, 7, 3, 131, 13, 14, 658, 659, "(" +466, 7, 4, 132, 15, 18, 660, 663, "IOP" +466, 7, 5, 133, 19, 20, 664, 665, ")" +466, 7, 6, 134, 21, 24, 666, 669, "was" +466, 7, 7, 135, 25, 33, 670, 678, "measured" +466, 7, 8, 136, 34, 36, 679, 681, "at" +466, 7, 9, 137, 37, 45, 682, 690, "baseline" +466, 7, 10, 138, 46, 47, 691, 692, "," +466, 7, 11, 139, 48, 53, 693, 698, "after" +466, 7, 12, 140, 54, 55, 699, 700, "0" +466, 7, 13, 141, 56, 57, 701, 702, "." +466, 7, 14, 142, 58, 59, 703, 704, "5" +466, 7, 15, 143, 60, 61, 705, 706, "," +466, 7, 16, 144, 62, 63, 707, 708, "1" +466, 7, 17, 145, 64, 65, 709, 710, "," +466, 7, 18, 146, 66, 67, 711, 712, "3" +466, 7, 19, 147, 68, 71, 713, 716, "and" +466, 7, 20, 148, 72, 73, 717, 718, "6" +466, 7, 21, 149, 74, 80, 719, 725, "months" +466, 7, 22, 150, 81, 83, 726, 728, "of" +466, 7, 23, 151, 84, 93, 729, 738, "treatment" +466, 7, 24, 152, 94, 95, 739, 740, "." +466, 8, 1, 153, 0, 5, 741, 746, "After" +466, 8, 2, 154, 6, 7, 747, 748, "6" +466, 8, 3, 155, 8, 14, 749, 755, "months" +466, 8, 4, 156, 15, 17, 756, 758, "38" +466, 8, 5, 157, 18, 26, 759, 767, "patients" +466, 8, 6, 158, 27, 31, 768, 772, "with" +466, 8, 7, 159, 32, 43, 773, 784, "latanoprost" +466, 8, 8, 160, 44, 47, 785, 788, "and" +466, 8, 9, 161, 48, 50, 789, 791, "30" +466, 8, 10, 162, 51, 59, 792, 800, "patients" +466, 8, 11, 163, 60, 64, 801, 805, "with" +466, 8, 12, 164, 65, 72, 806, 813, "timolol" +466, 8, 13, 165, 73, 74, 814, 815, "-" +466, 8, 14, 166, 75, 86, 816, 827, "pilocarpine" +466, 8, 15, 167, 87, 90, 828, 831, "had" +466, 8, 16, 168, 91, 100, 832, 841, "completed" +466, 8, 17, 169, 101, 104, 842, 845, "the" +466, 8, 18, 170, 105, 110, 846, 851, "study" +466, 8, 19, 171, 111, 112, 852, 853, "." +466, 9, 1, 172, 0, 2, 854, 856, "At" +466, 9, 2, 173, 3, 11, 857, 865, "baseline" +466, 9, 3, 174, 12, 15, 866, 869, "the" +466, 9, 4, 175, 16, 20, 870, 874, "mean" +466, 9, 5, 176, 21, 28, 875, 882, "diurnal" +466, 9, 6, 177, 29, 32, 883, 886, "IOP" +466, 9, 7, 178, 33, 36, 887, 890, "was" +466, 9, 8, 179, 37, 39, 891, 893, "20" +466, 9, 9, 180, 40, 41, 894, 895, "." +466, 9, 10, 181, 42, 43, 896, 897, "4" +466, 9, 11, 182, 44, 45, 898, 899, "+" +466, 9, 12, 183, 46, 47, 900, 901, "/" +466, 9, 13, 184, 48, 49, 902, 903, "-" +466, 9, 14, 185, 50, 51, 904, 905, "2" +466, 9, 15, 186, 52, 53, 906, 907, "." +466, 9, 16, 187, 54, 55, 908, 909, "0" +466, 9, 17, 188, 56, 60, 910, 914, "mmHg" +466, 9, 18, 189, 61, 64, 915, 918, "for" +466, 9, 19, 190, 65, 73, 919, 927, "patients" +466, 9, 20, 191, 74, 76, 928, 930, "in" +466, 9, 21, 192, 77, 88, 931, 942, "latanoprost" +466, 9, 22, 193, 89, 98, 943, 952, "treatment" +466, 9, 23, 194, 99, 104, 953, 958, "group" +466, 9, 24, 195, 105, 108, 959, 962, "and" +466, 9, 25, 196, 109, 111, 963, 965, "21" +466, 9, 26, 197, 112, 113, 966, 967, "." +466, 9, 27, 198, 114, 115, 968, 969, "4" +466, 9, 28, 199, 116, 117, 970, 971, "+" +466, 9, 29, 200, 118, 119, 972, 973, "/" +466, 9, 30, 201, 120, 121, 974, 975, "-" +466, 9, 31, 202, 122, 123, 976, 977, "2" +466, 9, 32, 203, 124, 125, 978, 979, "." +466, 9, 33, 204, 126, 127, 980, 981, "1" +466, 9, 34, 205, 128, 132, 982, 986, "mmHg" +466, 9, 35, 206, 133, 136, 987, 990, "for" +466, 9, 36, 207, 137, 145, 991, 999, "patients" +466, 9, 37, 208, 146, 148, 1000, 1002, "in" +466, 9, 38, 209, 149, 156, 1003, 1010, "timolol" +466, 9, 39, 210, 157, 158, 1011, 1012, "-" +466, 9, 40, 211, 159, 170, 1013, 1024, "pilocarpine" +466, 9, 41, 212, 171, 176, 1025, 1030, "group" +466, 9, 42, 213, 177, 178, 1031, 1032, "." +466, 10, 1, 214, 0, 2, 1033, 1035, "At" +466, 10, 2, 215, 3, 6, 1036, 1039, "the" +466, 10, 3, 216, 7, 10, 1040, 1043, "end" +466, 10, 4, 217, 11, 13, 1044, 1046, "of" +466, 10, 5, 218, 14, 17, 1047, 1050, "the" +466, 10, 6, 219, 18, 23, 1051, 1056, "study" +466, 10, 7, 220, 24, 25, 1057, 1058, "," +466, 10, 8, 221, 26, 31, 1059, 1064, "after" +466, 10, 9, 222, 32, 33, 1065, 1066, "6" +466, 10, 10, 223, 34, 40, 1067, 1073, "months" +466, 10, 11, 224, 41, 43, 1074, 1076, "of" +466, 10, 12, 225, 44, 53, 1077, 1086, "treatment" +466, 10, 13, 226, 54, 55, 1087, 1088, "," +466, 10, 14, 227, 56, 59, 1089, 1092, "the" +466, 10, 15, 228, 60, 64, 1093, 1097, "mean" +466, 10, 16, 229, 65, 72, 1098, 1105, "diurnal" +466, 10, 17, 230, 73, 76, 1106, 1109, "IOP" +466, 10, 18, 231, 77, 83, 1110, 1116, "values" +466, 10, 19, 232, 84, 88, 1117, 1121, "were" +466, 10, 20, 233, 89, 91, 1122, 1124, "16" +466, 10, 21, 234, 92, 93, 1125, 1126, "." +466, 10, 22, 235, 94, 95, 1127, 1128, "6" +466, 10, 23, 236, 96, 97, 1129, 1130, "+" +466, 10, 24, 237, 98, 99, 1131, 1132, "/" +466, 10, 25, 238, 100, 101, 1133, 1134, "-" +466, 10, 26, 239, 102, 103, 1135, 1136, "2" +466, 10, 27, 240, 104, 105, 1137, 1138, "." +466, 10, 28, 241, 106, 107, 1139, 1140, "4" +466, 10, 29, 242, 108, 111, 1141, 1144, "and" +466, 10, 30, 243, 112, 114, 1145, 1147, "17" +466, 10, 31, 244, 115, 116, 1148, 1149, "." +466, 10, 32, 245, 117, 118, 1150, 1151, "9" +466, 10, 33, 246, 119, 120, 1152, 1153, "+" +466, 10, 34, 247, 121, 122, 1154, 1155, "/" +466, 10, 35, 248, 123, 124, 1156, 1157, "-" +466, 10, 36, 249, 125, 126, 1158, 1159, "2" +466, 10, 37, 250, 127, 128, 1160, 1161, "." +466, 10, 38, 251, 129, 130, 1162, 1163, "0" +466, 10, 39, 252, 131, 135, 1164, 1168, "mmHg" +466, 10, 40, 253, 136, 148, 1169, 1181, "respectively" +466, 10, 41, 254, 149, 150, 1182, 1183, "." +466, 11, 1, 255, 0, 3, 1184, 1187, "IOP" +466, 11, 2, 256, 4, 7, 1188, 1191, "was" +466, 11, 3, 257, 8, 21, 1192, 1205, "statistically" +466, 11, 4, 258, 22, 35, 1206, 1219, "significantly" +466, 11, 5, 259, 36, 43, 1220, 1227, "reduced" +466, 11, 6, 260, 44, 48, 1228, 1232, "from" +466, 11, 7, 261, 49, 57, 1233, 1241, "baseline" +466, 11, 8, 262, 58, 59, 1242, 1243, "(" +466, 11, 9, 263, 60, 61, 1244, 1245, "p" +466, 11, 10, 264, 62, 63, 1246, 1247, "<" +466, 11, 11, 265, 64, 65, 1248, 1249, "0" +466, 11, 12, 266, 66, 67, 1250, 1251, "." +466, 11, 13, 267, 68, 71, 1252, 1255, "001" +466, 11, 14, 268, 72, 73, 1256, 1257, ")" +466, 11, 15, 269, 74, 75, 1258, 1259, "." +466, 12, 1, 270, 0, 3, 1260, 1263, "The" +466, 12, 2, 271, 4, 8, 1264, 1268, "mean" +466, 12, 3, 272, 9, 16, 1269, 1276, "diurnal" +466, 12, 4, 273, 17, 20, 1277, 1280, "IOP" +466, 12, 5, 274, 21, 27, 1281, 1287, "change" +466, 12, 6, 275, 28, 32, 1288, 1292, "from" +466, 12, 7, 276, 33, 41, 1293, 1301, "baseline" +466, 12, 8, 277, 42, 45, 1302, 1305, "was" +466, 12, 9, 278, 46, 47, 1306, 1307, "-" +466, 12, 10, 279, 48, 49, 1308, 1309, "3" +466, 12, 11, 280, 50, 51, 1310, 1311, "." +466, 12, 12, 281, 52, 53, 1312, 1313, "3" +466, 12, 13, 282, 54, 55, 1314, 1315, "+" +466, 12, 14, 283, 56, 57, 1316, 1317, "/" +466, 12, 15, 284, 58, 59, 1318, 1319, "-" +466, 12, 16, 285, 60, 61, 1320, 1321, "0" +466, 12, 17, 286, 62, 63, 1322, 1323, "." +466, 12, 18, 287, 64, 65, 1324, 1325, "5" +466, 12, 19, 288, 66, 70, 1326, 1330, "mmHg" +466, 12, 20, 289, 71, 72, 1331, 1332, "(" +466, 12, 21, 290, 73, 77, 1333, 1337, "mean" +466, 12, 22, 291, 78, 79, 1338, 1339, "+" +466, 12, 23, 292, 80, 81, 1340, 1341, "/" +466, 12, 24, 293, 82, 83, 1342, 1343, "-" +466, 12, 25, 294, 84, 87, 1344, 1347, "SEM" +466, 12, 26, 295, 88, 89, 1348, 1349, "," +466, 12, 27, 296, 90, 96, 1350, 1356, "ANCOVA" +466, 12, 28, 297, 97, 98, 1357, 1358, ")" +466, 12, 29, 298, 99, 102, 1359, 1362, "for" +466, 12, 30, 299, 103, 106, 1363, 1366, "the" +466, 12, 31, 300, 107, 115, 1367, 1375, "patients" +466, 12, 32, 301, 116, 123, 1376, 1383, "treated" +466, 12, 33, 302, 124, 128, 1384, 1388, "with" +466, 12, 34, 303, 129, 140, 1389, 1400, "latanoprost" +466, 12, 35, 304, 141, 144, 1401, 1404, "and" +466, 12, 36, 305, 145, 146, 1405, 1406, "-" +466, 12, 37, 306, 147, 148, 1407, 1408, "3" +466, 12, 38, 307, 149, 150, 1409, 1410, "." +466, 12, 39, 308, 151, 152, 1411, 1412, "2" +466, 12, 40, 309, 153, 154, 1413, 1414, "+" +466, 12, 41, 310, 155, 156, 1415, 1416, "/" +466, 12, 42, 311, 157, 158, 1417, 1418, "-" +466, 12, 43, 312, 159, 160, 1419, 1420, "0" +466, 12, 44, 313, 161, 162, 1421, 1422, "." +466, 12, 45, 314, 163, 164, 1423, 1424, "4" +466, 12, 46, 315, 165, 169, 1425, 1429, "mmHg" +466, 12, 47, 316, 170, 173, 1430, 1433, "for" +466, 12, 48, 317, 174, 177, 1434, 1437, "the" +466, 12, 49, 318, 178, 186, 1438, 1446, "patients" +466, 12, 50, 319, 187, 194, 1447, 1454, "treated" +466, 12, 51, 320, 195, 199, 1455, 1459, "with" +466, 12, 52, 321, 200, 207, 1460, 1467, "timolol" +466, 12, 53, 322, 208, 209, 1468, 1469, "+" +466, 12, 54, 323, 210, 221, 1470, 1481, "pilocarpine" +466, 12, 55, 324, 222, 223, 1482, 1483, "." +466, 13, 1, 325, 0, 4, 1484, 1488, "This" +466, 13, 2, 326, 5, 15, 1489, 1499, "difference" +466, 13, 3, 327, 16, 18, 1500, 1502, "in" +466, 13, 4, 328, 19, 22, 1503, 1506, "IOP" +466, 13, 5, 329, 23, 32, 1507, 1516, "reduction" +466, 13, 6, 330, 33, 40, 1517, 1524, "between" +466, 13, 7, 331, 41, 47, 1525, 1531, "groups" +466, 13, 8, 332, 48, 51, 1532, 1535, "was" +466, 13, 9, 333, 52, 55, 1536, 1539, "not" +466, 13, 10, 334, 56, 69, 1540, 1553, "statistically" +466, 13, 11, 335, 70, 81, 1554, 1565, "significant" +466, 13, 12, 336, 82, 83, 1566, 1567, "(" +466, 13, 13, 337, 84, 85, 1568, 1569, "z" +466, 13, 14, 338, 86, 87, 1570, 1571, "=" +466, 13, 15, 339, 88, 89, 1572, 1573, "0" +466, 13, 16, 340, 90, 91, 1574, 1575, "." +466, 13, 17, 341, 92, 94, 1576, 1578, "69" +466, 13, 18, 342, 95, 96, 1579, 1580, ";" +466, 13, 19, 343, 97, 98, 1581, 1582, "p" +466, 13, 20, 344, 99, 100, 1583, 1584, "=" +466, 13, 21, 345, 101, 102, 1585, 1586, "0" +466, 13, 22, 346, 103, 104, 1587, 1588, "." +466, 13, 23, 347, 105, 107, 1589, 1591, "49" +466, 13, 24, 348, 108, 109, 1592, 1593, ")" +466, 13, 25, 349, 110, 111, 1594, 1595, "." +466, 14, 1, 350, 0, 4, 1596, 1600, "This" +466, 14, 2, 351, 5, 10, 1601, 1606, "study" +466, 14, 3, 352, 11, 17, 1607, 1613, "showed" +466, 14, 4, 353, 18, 22, 1614, 1618, "that" +466, 14, 5, 354, 23, 34, 1619, 1630, "combination" +466, 14, 6, 355, 35, 42, 1631, 1638, "therapy" +466, 14, 7, 356, 43, 44, 1639, 1640, "(" +466, 14, 8, 357, 45, 52, 1641, 1648, "timolol" +466, 14, 9, 358, 53, 57, 1649, 1653, "plus" +466, 14, 10, 359, 58, 69, 1654, 1665, "pilocarpine" +466, 14, 11, 360, 70, 71, 1666, 1667, ")" +466, 14, 12, 361, 72, 74, 1668, 1670, "in" +466, 14, 13, 362, 75, 92, 1671, 1688, "pseudoexfoliation" +466, 14, 14, 363, 93, 101, 1689, 1697, "glaucoma" +466, 14, 15, 364, 102, 105, 1698, 1701, "can" +466, 14, 16, 365, 106, 117, 1702, 1713, "effectively" +466, 14, 17, 366, 118, 120, 1714, 1716, "be" +466, 14, 18, 367, 121, 129, 1717, 1725, "replaced" +466, 14, 19, 368, 130, 132, 1726, 1728, "by" +466, 14, 20, 369, 133, 144, 1729, 1740, "latanoprost" +466, 14, 21, 370, 145, 156, 1741, 1752, "monotherapy" +466, 14, 22, 371, 157, 158, 1753, 1754, "." +466, 15, 1, 372, 0, 4, 1755, 1759, "PMID" +466, 15, 2, 373, 5, 6, 1760, 1761, ":" +466, 15, 3, 374, 7, 15, 1762, 1770, "14746165" +466, 15, 4, 375, 16, 17, 1771, 1772, "[" +466, 15, 5, 376, 18, 25, 1773, 1780, "Indexed" +466, 15, 6, 377, 26, 29, 1781, 1784, "for" +466, 15, 7, 378, 30, 37, 1785, 1792, "MEDLINE" +466, 15, 8, 379, 38, 39, 1793, 1794, "]" diff --git a/data/gl 14746165_jshahinitiran.annodb b/data/gl 14746165_jshahinitiran.annodb new file mode 100644 index 0000000..a270518 --- /dev/null +++ b/data/gl 14746165_jshahinitiran.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8687, Journal, 0, 13, "Coll Antropol", "", +8688, PublicationYear, 16, 24, "2003 Dec", "", +8689, Title, 49, 143, "A study of replacement of timolol - pilocarpine with latanoprost in pseudoexfoliation glaucoma", "", +27829, Timolol, 75, 82, "timolol", "", +27830, Pilocarpine, 85, 96, "pilocarpine", "", +27831, Latanoprost, 102, 113, "latanoprost", "", +27832, Glaucoma, 117, 143, "pseudoexfoliation glaucoma", "pseudoexfoliation", +8694, Author, 146, 154, "Boji ć L", "", +8695, Author, 163, 172, "Mandi ć Z", "", +8696, Author, 175, 189, "Novak - Laus K", "", +8697, Author, 192, 201, "Sonicki Z", "", +8698, Author, 204, 216, "Karelovi ć D", "", +8699, Croatia, 295, 304, "Croatia .", "", +8700, ObjectiveDescription, 305, 538, "The aim of the study was to evaluate the efficacy of replacing current dual local therapy ( timolol and pilocarpine ) with latanoprost 0 . 005 % in 71 pseudoexfoliation glaucoma patients with controlled intraocular pressure ( IOP ) .", "", +27834, Timolol, 397, 404, "timolol", "", +27835, Pilocarpine, 409, 420, "pilocarpine", "", +27836, Latanoprost, 428, 439, "latanoprost", "", +27837, DoseValue, 440, 447, "0 . 005", "", +27838, Percentage, 448, 449, "%", "", +8706, NumberPatientsCT, 453, 455, "71", "", +27833, Glaucoma, 456, 482, "pseudoexfoliation glaucoma", "pseudoexfoliation", +8710, Precondition, 497, 538, "controlled intraocular pressure ( IOP ) .", "", +8708, IOP, 508, 528, "intraocular pressure", "", +8709, IOP, 531, 534, "IOP", "", +8711, NumberPatientsArm, 539, 541, "39", "", +27839, Latanoprost, 563, 574, "latanoprost", "", +27840, DoseValue, 575, 582, "0 . 005", "", +27841, Percentage, 583, 584, "%", "", +8715, NumberPatientsArm, 591, 593, "32", "", +27842, Timolol, 613, 620, "timolol", "", +27843, Pilocarpine, 623, 634, "pilocarpine", "", +27844, Mean, 645, 649, "Mean", "", +27845, Diurnal_IOP, 650, 663, "diurnal ( IOP", "", +27846, TimePoint, 682, 690, "baseline", "", +27847, TimePoint, 699, 725, "0 . 5 , 1 , 3 and 6 months", "", +39082, TimePoint, 707, 725, "1 , 3 and 6 months", "", +39083, TimePoint, 711, 725, "3 and 6 months", "", +39084, TimePoint, 717, 725, "6 months", "", +27848, TimePoint, 747, 755, "6 months", "", +8722, FinalNumPatientsArm, 756, 758, "38", "", +27849, Latanoprost, 773, 784, "latanoprost", "", +8723, FinalNumPatientsArm, 789, 791, "30", "", +27850, Timolol, 806, 813, "timolol", "", +27851, Pilocarpine, 816, 827, "pilocarpine", "", +27852, Mean, 870, 874, "mean", "", +27853, Diurnal_IOP, 875, 886, "diurnal IOP", "", +8729, BaseLineValue, 891, 897, "20 . 4", "", +8730, SdErrorBL, 904, 909, "2 . 0", "", +8731, mmHg, 910, 914, "mmHg", "", +27854, Latanoprost, 931, 942, "latanoprost", "", +8734, BaseLineValue, 963, 969, "21 . 4", "", +8735, SdErrorBL, 976, 981, "2 . 1", "", +8733, mmHg, 982, 986, "mmHg", "", +27855, Timolol, 1003, 1010, "timolol", "", +27856, Pilocarpine, 1013, 1024, "pilocarpine", "", +27857, Duration, 1065, 1073, "6 months", "", +27858, Mean, 1093, 1097, "mean", "", +27859, Diurnal_IOP, 1098, 1109, "diurnal IOP", "", +8741, ResultMeasuredValue, 1122, 1128, "16 . 6", "", +8743, SdErrorResValue, 1135, 1140, "2 . 4", "", +8742, ResultMeasuredValue, 1145, 1151, "17 . 9", "", +8744, SdErrorResValue, 1158, 1163, "2 . 0", "", +8745, mmHg, 1164, 1168, "mmHg", "", +8746, IOP, 1184, 1187, "IOP", "", +8747, PValueChangeValue, 1244, 1255, "p < 0 . 001", "", +27860, Mean, 1264, 1268, "mean", "", +27861, Diurnal_IOP, 1269, 1280, "diurnal IOP", "", +8750, Reduction, 1308, 1313, "3 . 3", "", +8752, SdErrorChangeValue, 1320, 1325, "0 . 5", "", +8754, mmHg, 1326, 1330, "mmHg", "", +27863, Mean, 1333, 1337, "mean", "", +27864, Latanoprost, 1389, 1400, "latanoprost", "", +8751, Reduction, 1407, 1412, "3 . 2", "", +8753, SdErrorChangeValue, 1419, 1424, "0 . 4", "", +8755, mmHg, 1425, 1429, "mmHg", "", +27869, Timolol, 1460, 1467, "timolol", "", +27870, Pilocarpine, 1470, 1481, "pilocarpine", "", +8759, IOP, 1503, 1506, "IOP", "", +8760, PvalueDiff, 1581, 1591, "p = 0 . 49", "", +8761, ConclusionComment, 1596, 1754, "This study showed that combination therapy ( timolol plus pilocarpine ) in pseudoexfoliation glaucoma can effectively be replaced by latanoprost monotherapy .", "", +27865, Timolol, 1641, 1648, "timolol", "", +27866, Pilocarpine, 1654, 1665, "pilocarpine", "", +27867, Glaucoma, 1671, 1697, "pseudoexfoliation glaucoma", "pseudoexfoliation", +27868, Latanoprost, 1729, 1740, "latanoprost", "", +8766, PMID, 1762, 1770, "14746165", "", diff --git a/data/gl 14746165_jshahinitiran.n-triples b/data/gl 14746165_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 14746165_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 14746165_tstrakeljahn.annodb b/data/gl 14746165_tstrakeljahn.annodb new file mode 100644 index 0000000..fec5146 --- /dev/null +++ b/data/gl 14746165_tstrakeljahn.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30795, Journal, 0, 13, "Coll Antropol", "", +30796, PublicationYear, 16, 20, "2003", "", +30801, Title, 49, 145, "A study of replacement of timolol - pilocarpine with latanoprost in pseudoexfoliation glaucoma .", "", +30797, Timolol, 75, 82, "timolol", "", +30798, Pilocarpine, 85, 96, "pilocarpine", "", +30799, Latanoprost, 102, 113, "latanoprost", "", +30800, Glaucoma, 135, 143, "glaucoma", "", +30802, Author, 146, 154, "Boji ć L", "", +30803, Author, 163, 172, "Mandi ć Z", "", +30804, Author, 175, 189, "Novak - Laus K", "", +30805, Author, 192, 201, "Sonicki Z", "", +30806, Author, 204, 216, "Karelovi ć D", "", +30807, Croatia, 295, 302, "Croatia", "", +30808, Timolol, 397, 404, "timolol", "", +30809, Pilocarpine, 409, 420, "pilocarpine", "", +30810, Latanoprost, 428, 439, "latanoprost", "", +30811, DoseValue, 440, 447, "0 . 005", "", +30812, Percentage, 448, 449, "%", "", +30814, NumberPatientsCT, 453, 455, "71", "", +30813, Glaucoma, 474, 482, "glaucoma", "", +30817, Precondition, 483, 528, "patients with controlled intraocular pressure", "", +30815, IOP, 508, 528, "intraocular pressure", "", +30816, IOP, 531, 534, "IOP", "", +30818, NumberPatientsArm, 539, 541, "39", "", +30820, Latanoprost, 563, 574, "latanoprost", "", +30821, DoseValue, 575, 582, "0 . 005", "", +30822, Percentage, 583, 584, "%", "", +30819, NumberPatientsArm, 591, 593, "32", "", +30823, Timolol, 613, 620, "timolol", "", +30824, Pilocarpine, 623, 634, "pilocarpine", "", +30825, Mean, 645, 649, "Mean", "", +30826, Diurnal_IOP, 650, 657, "diurnal", "", +30827, IOP, 660, 663, "IOP", "", +30828, FinalNumPatientsArm, 756, 758, "38", "", +30830, Latanoprost, 773, 784, "latanoprost", "", +30829, FinalNumPatientsArm, 789, 791, "30", "", +30831, Timolol, 806, 813, "timolol", "", +30832, Pilocarpine, 816, 827, "pilocarpine", "", +30833, Mean, 870, 874, "mean", "", +30834, Diurnal_IOP, 875, 886, "diurnal IOP", "", +30835, BaseLineValue, 891, 897, "20 . 4", "", +30836, SdDevBL, 898, 909, "+ / - 2 . 0", "", +30837, mmHg, 910, 914, "mmHg", "", +30838, Latanoprost, 931, 942, "latanoprost", "", +30839, BaseLineValue, 963, 969, "21 . 4", "", +30840, SdDevBL, 970, 981, "+ / - 2 . 1", "", +30841, mmHg, 982, 986, "mmHg", "", +30842, Timolol, 1003, 1010, "timolol", "", +30843, Pilocarpine, 1013, 1024, "pilocarpine", "", +30844, TimePoint, 1059, 1073, "after 6 months", "", +30845, Mean, 1093, 1097, "mean", "", +30846, Diurnal_IOP, 1098, 1109, "diurnal IOP", "", +30847, ResultMeasuredValue, 1122, 1128, "16 . 6", "", +30849, SdDevResValue, 1129, 1140, "+ / - 2 . 4", "", +30848, ResultMeasuredValue, 1145, 1151, "17 . 9", "", +30850, SdDevResValue, 1152, 1163, "+ / - 2 . 0", "", +30851, mmHg, 1164, 1168, "mmHg", "", +30852, PValueResValue, 1244, 1255, "p < 0 . 001", "", +30853, Mean, 1264, 1268, "mean", "", +30854, Diurnal_IOP, 1269, 1280, "diurnal IOP", "", +30855, Reduction, 1308, 1313, "3 . 3", "", +30856, SdErrorChangeValue, 1314, 1325, "+ / - 0 . 5", "", +30858, mmHg, 1326, 1330, "mmHg", "", +30860, Latanoprost, 1389, 1400, "latanoprost", "", +30861, Reduction, 1407, 1412, "3 . 2", "", +30857, SdErrorChangeValue, 1413, 1424, "+ / - 0 . 4", "", +30859, mmHg, 1425, 1429, "mmHg", "", +30862, Timolol, 1460, 1467, "timolol", "", +30863, Pilocarpine, 1470, 1481, "pilocarpine", "", +30864, IOP, 1503, 1506, "IOP", "", +30865, PvalueDiff, 1581, 1591, "p = 0 . 49", "", +30870, ConclusionComment, 1596, 1754, "This study showed that combination therapy ( timolol plus pilocarpine ) in pseudoexfoliation glaucoma can effectively be replaced by latanoprost monotherapy .", "", +30866, Timolol, 1641, 1648, "timolol", "", +30867, Pilocarpine, 1654, 1665, "pilocarpine", "", +30868, Glaucoma, 1689, 1697, "glaucoma", "", +30869, Latanoprost, 1729, 1740, "latanoprost", "", +30871, PMID, 1762, 1770, "14746165", "", diff --git a/data/gl 14746165_tstrakeljahn.n-triples b/data/gl 14746165_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 14746165_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15019375_admin.annodb b/data/gl 15019375_admin.annodb new file mode 100644 index 0000000..f6e27c1 --- /dev/null +++ b/data/gl 15019375_admin.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2004", "", " \"2004\"." +9, Title, 50, 195, "Efficacy and safety of the fixed combinations latanoprost / timolol versus dorzolamide / timolol in patients with elevated intraocular pressure .", "", " \"Efficacy and safety of the fixed combinations latanoprost / timolol versus dorzolamide / timolol in patients with elevated intraocular pressure .\"." +112, Lat/TimFC, 77, 117, "fixed combinations latanoprost / timolol", "", +2, Latanoprost, 96, 107, "latanoprost", "", +3, Timolol, 110, 117, "timolol", "", +5, Dorzolamide, 125, 136, "dorzolamide", "", +7, Dorz/TimFC, 125, 146, "dorzolamide / timolol", "", +4, Timolol, 139, 146, "timolol", "", +8, IOP, 173, 193, "intraocular pressure", "", +10, Author, 196, 203, "Shin DH", "", " \"Shin DH\"." +11, Author, 212, 222, "Feldman RM", "", " \"Feldman RM\"." +12, Author, 225, 232, "Sheu WP", "", " \"Sheu WP\"." +119, Lat/TimFC, 235, 274, "Fixed Combination Latanoprost / Timolol", "", +13, Latanoprost, 253, 264, "Latanoprost", "", +14, Timolol, 267, 274, "Timolol", "", +16, USA, 385, 388, "USA", "", " ." +25, ObjectiveDescription, 401, 607, "To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure ( IOP ) .", "", " \"To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure ( IOP ) .\"." +122, Lat/TimFC, 443, 487, "fixed combination of latanoprost and timolol", "", +17, Latanoprost, 464, 475, "latanoprost", "", +18, Timolol, 480, 487, "timolol", "", +125, Dorz/TimFC, 506, 550, "fixed combination of dorzolamide and timolol", "", +20, Dorzolamide, 527, 538, "dorzolamide", "", +19, Timolol, 543, 550, "timolol", "", +130, Precondition, 554, 605, "patients with elevated intraocular pressure ( IOP )", "", +23, IOP, 577, 597, "intraocular pressure", "", +24, IOP, 600, 603, "IOP", "", +26, Duration, 617, 630, "Three - month", "", " \"Three - month\"." +27, Randomized, 633, 643, "randomized", "", " ." +133, Parallel, 646, 660, "parallel group", "", " ." +29, Blind, 663, 681, "evaluator - masked", "", " ." +30, Multicenter, 684, 695, "multicenter", "", " ." +34, Precondition, 719, 844, "Patients with primary open - angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy", "", " \"Patients with primary open - angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy\"." +31, Primary_OpenAngleGlaucoma, 733, 762, "primary open - angle glaucoma", "", " ." +32, OcularHypertension, 766, 785, "ocular hypertension", "", " ." +33, IOP, 800, 803, "IOP", "", +35, NumberPatientsCT, 847, 850, "253", "", " \"253\"." +38, Randomized, 851, 861, "randomized", "", +36, NumberPatientsArm, 864, 867, "125", "", " \"125\"." +145, Lat/TimFC, 881, 943, "fixed combination of latanoprost 0 . 005 % and timolol 0 . 5 %", "", " ." +39, Latanoprost, 902, 913, "latanoprost", "", +43, DoseValue, 914, 921, "0 . 005", "", +49, Percentage, 922, 923, "%", "", +41, Timolol, 928, 935, "timolol", "", +44, DoseValue, 936, 941, "0 . 5", "", +50, Percentage, 942, 943, "%", "", +47, Frequency, 944, 954, "once daily", "", " \"once daily\"." +37, NumberPatientsArm, 961, 964, "128", "", " \"128\"." +154, Dorz/TimFC, 978, 1034, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", " ." +42, Dorzolamide, 999, 1010, "dorzolamide", "", +45, DoseValue, 1011, 1012, "2", "", +51, Percentage, 1013, 1014, "%", "", +40, Timolol, 1019, 1026, "timolol", "", +46, DoseValue, 1027, 1032, "0 . 5", "", +52, Percentage, 1033, 1034, "%", "", +48, Frequency, 1035, 1046, "twice daily", "", " \"twice daily\"." +155, TimePoint, 1192, 1200, "baseline", "", +156, Randomized, 1203, 1216, "randomization", "", +157, TimePoint, 1231, 1245, "1 and 3 months", "", +158, TimePoint, 1237, 1245, "3 months", "", +55, IOP, 1259, 1279, "Intraocular pressure", "", +56, TimePoint, 1310, 1314, "8 am", "", +57, TimePoint, 1317, 1322, "12 pm", "", +58, TimePoint, 1329, 1333, "4 pm", "", +59, Diurnal_IOP, 1360, 1371, "diurnal IOP", "", +60, Mean, 1394, 1398, "mean", "", +61, Mean, 1552, 1556, "mean", "", +62, Diurnal_IOP, 1557, 1568, "diurnal IOP", "", +63, TimePoint, 1574, 1582, "baseline", "", +64, TimePoint, 1586, 1593, "month 3", "", +65, Mean, 1606, 1610, "Mean", "", +66, Diurnal_IOP, 1611, 1622, "diurnal IOP", "", +168, TimePoint, 1646, 1654, "baseline", "", +67, Mean, 1657, 1661, "Mean", "", " . ." +68, Diurnal_IOP, 1713, 1724, "diurnal IOP", "", " ." +69, TimePoint, 1730, 1738, "baseline", "", +70, TimePoint, 1742, 1749, "month 3", "", " \"month 3\". \"month 3\"." +71, Reduction, 1755, 1760, "9 . 4", "", " \"9 . 4\"." +73, SdErrorChangeValue, 1767, 1773, "0 . 27", "", " \"0 . 27\"." +76, mmHg, 1774, 1778, "mmHg", "", " ." +77, Latanoprost, 1786, 1797, "latanoprost", "", +181, Lat/TimFC, 1786, 1827, "latanoprost / timolol fixed - combination", "", +78, Timolol, 1800, 1807, "timolol", "", +72, Reduction, 1843, 1848, "8 . 4", "", " \"8 . 4\"." +74, SdErrorChangeValue, 1855, 1861, "0 . 26", "", " \"0 . 26\"." +75, mmHg, 1862, 1866, "mmHg", "", +80, Dorzolamide, 1893, 1904, "dorzolamide", "", +184, Dorz/TimFC, 1893, 1932, "dorzolamide / timolol fixed combination", "", +79, Timolol, 1907, 1914, "timolol", "", +84, Mean, 1939, 1943, "mean", "", +85, Diurnal_IOP, 1958, 1969, "diurnal IOP", "", +86, DiffGroupAbsValue, 2003, 2009, "1 . 00", "", " \"1 . 00\"." +88, mmHg, 2010, 2014, "mmHg", "", +189, ConfIntervalDiff, 2017, 2059, "95 % confidence interval , 0 . 31 - 1 . 69", "", " \"95 % confidence interval , 0 . 31 - 1 . 69\"." +190, PvalueDiff, 2062, 2073, "P = 0 . 005", "", " \"P = 0 . 005\"." +193, Lat/TimFC, 2092, 2131, "latanoprost / timolol fixed combination", "", +89, Latanoprost, 2092, 2103, "latanoprost", "", +90, Timolol, 2106, 2113, "timolol", "", +102, ConclusionComment, 2196, 2392, "The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP , and both treatments were generally well tolerated .", "", " \"The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP , and both treatments were generally well tolerated .\"." +197, Lat/TimFC, 2200, 2244, "fixed combination of latanoprost and timolol", "", +94, Latanoprost, 2221, 2232, "latanoprost", "", +96, Lat/TimFC, 2221, 2244, "latanoprost and timolol", "", +95, Timolol, 2237, 2244, "timolol", "", +97, Dorzolamide, 2286, 2297, "dorzolamide", "", +99, Dorz/TimFC, 2286, 2309, "dorzolamide and timolol", "", +98, Timolol, 2302, 2309, "timolol", "", +100, Mean, 2322, 2326, "mean", "", +101, Diurnal_IOP, 2327, 2338, "diurnal IOP", "", +103, PMID, 2447, 2455, "15019375", "", " \"15019375\"." diff --git a/data/gl 15019375_admin.n-triples b/data/gl 15019375_admin.n-triples new file mode 100644 index 0000000..efe0f25 --- /dev/null +++ b/data/gl 15019375_admin.n-triples @@ -0,0 +1,103 @@ +# RDF export of group: Publication + . + "Publication 89124" . + "Efficacy and safety of the fixed combinations latanoprost / timolol versus dorzolamide / timolol in patients with elevated intraocular pressure ." . + "Shin DH" . + "2004" . + "Ophthalmology" . + "15019375" . + . + "Feldman RM" . + "Sheu WP" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 89131" . + "To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure ( IOP ) ." . + "253" . + "Three - month" . + . + . + . + "The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP , and both treatments were generally well tolerated ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 89147" . + "Patients with primary open - angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "lati" . + "125" . + . + . + . + . + "doti" . + "128" . + . + . + . +# RDF export of group: Intervention + . + "lati" . + "once daily" . + . + . + . + "doti" . + "twice daily" . + . + . +# RDF export of group: Medication + . + "lati" . + . + . + . + . + "doto" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "9 . 4" . + "0 . 27" . + "month 3" . + . + "iop 2" . + . + "8 . 4" . + "0 . 26" . + "month 3" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "1 . 00" . + "P = 0 . 005" . + "95 % confidence interval , 0 . 31 - 1 . 69" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15019375_export.csv b/data/gl 15019375_export.csv new file mode 100644 index 0000000..9667e61 --- /dev/null +++ b/data/gl 15019375_export.csv @@ -0,0 +1,480 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +539, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +539, 1, 2, 2, 14, 15, 14, 15, "." +539, 2, 1, 3, 0, 4, 16, 20, "2004" +539, 2, 2, 4, 5, 8, 21, 24, "Feb" +539, 2, 3, 5, 9, 10, 25, 26, ";" +539, 2, 4, 6, 11, 14, 27, 30, "111" +539, 2, 5, 7, 15, 16, 31, 32, "(" +539, 2, 6, 8, 17, 18, 33, 34, "2" +539, 2, 7, 9, 19, 20, 35, 36, ")" +539, 2, 8, 10, 21, 22, 37, 38, ":" +539, 2, 9, 11, 23, 26, 39, 42, "276" +539, 2, 10, 12, 27, 28, 43, 44, "-" +539, 2, 11, 13, 29, 31, 45, 47, "82" +539, 2, 12, 14, 32, 33, 48, 49, "." +539, 3, 1, 15, 0, 8, 50, 58, "Efficacy" +539, 3, 2, 16, 9, 12, 59, 62, "and" +539, 3, 3, 17, 13, 19, 63, 69, "safety" +539, 3, 4, 18, 20, 22, 70, 72, "of" +539, 3, 5, 19, 23, 26, 73, 76, "the" +539, 3, 6, 20, 27, 32, 77, 82, "fixed" +539, 3, 7, 21, 33, 45, 83, 95, "combinations" +539, 3, 8, 22, 46, 57, 96, 107, "latanoprost" +539, 3, 9, 23, 58, 59, 108, 109, "/" +539, 3, 10, 24, 60, 67, 110, 117, "timolol" +539, 3, 11, 25, 68, 74, 118, 124, "versus" +539, 3, 12, 26, 75, 86, 125, 136, "dorzolamide" +539, 3, 13, 27, 87, 88, 137, 138, "/" +539, 3, 14, 28, 89, 96, 139, 146, "timolol" +539, 3, 15, 29, 97, 99, 147, 149, "in" +539, 3, 16, 30, 100, 108, 150, 158, "patients" +539, 3, 17, 31, 109, 113, 159, 163, "with" +539, 3, 18, 32, 114, 122, 164, 172, "elevated" +539, 3, 19, 33, 123, 134, 173, 184, "intraocular" +539, 3, 20, 34, 135, 143, 185, 193, "pressure" +539, 3, 21, 35, 144, 145, 194, 195, "." +539, 4, 1, 36, 0, 4, 196, 200, "Shin" +539, 4, 2, 37, 5, 7, 201, 203, "DH" +539, 4, 3, 38, 8, 9, 204, 205, "(" +539, 4, 4, 39, 10, 11, 206, 207, "1" +539, 4, 5, 40, 12, 13, 208, 209, ")" +539, 4, 6, 41, 14, 15, 210, 211, "," +539, 4, 7, 42, 16, 23, 212, 219, "Feldman" +539, 4, 8, 43, 24, 26, 220, 222, "RM" +539, 4, 9, 44, 27, 28, 223, 224, "," +539, 4, 10, 45, 29, 33, 225, 229, "Sheu" +539, 4, 11, 46, 34, 36, 230, 232, "WP" +539, 4, 12, 47, 37, 38, 233, 234, ";" +539, 4, 13, 48, 39, 44, 235, 240, "Fixed" +539, 4, 14, 49, 45, 56, 241, 252, "Combination" +539, 4, 15, 50, 57, 68, 253, 264, "Latanoprost" +539, 4, 16, 51, 69, 70, 265, 266, "/" +539, 4, 17, 52, 71, 78, 267, 274, "Timolol" +539, 4, 18, 53, 79, 84, 275, 280, "Study" +539, 4, 19, 54, 85, 90, 281, 286, "Group" +539, 4, 20, 55, 91, 92, 287, 288, "." +539, 5, 1, 56, 0, 6, 289, 295, "Author" +539, 5, 2, 57, 7, 18, 296, 307, "information" +539, 5, 3, 58, 19, 20, 308, 309, ":" +539, 5, 4, 59, 21, 22, 310, 311, "(" +539, 5, 5, 60, 23, 24, 312, 313, "1" +539, 5, 6, 61, 25, 26, 314, 315, ")" +539, 5, 7, 62, 27, 33, 316, 322, "Kresge" +539, 5, 8, 63, 34, 37, 323, 326, "Eye" +539, 5, 9, 64, 38, 47, 327, 336, "Institute" +539, 5, 10, 65, 48, 49, 337, 338, "," +539, 5, 11, 66, 50, 55, 339, 344, "Wayne" +539, 5, 12, 67, 56, 61, 345, 350, "State" +539, 5, 13, 68, 62, 72, 351, 361, "University" +539, 5, 14, 69, 73, 74, 362, 363, "," +539, 5, 15, 70, 75, 82, 364, 371, "Detroit" +539, 5, 16, 71, 83, 84, 372, 373, "," +539, 5, 17, 72, 85, 93, 374, 382, "Michigan" +539, 5, 18, 73, 94, 95, 383, 384, "," +539, 5, 19, 74, 96, 99, 385, 388, "USA" +539, 5, 20, 75, 100, 101, 389, 390, "." +539, 6, 1, 76, 0, 7, 391, 398, "PURPOSE" +539, 6, 2, 77, 8, 9, 399, 400, ":" +539, 6, 3, 78, 10, 12, 401, 403, "To" +539, 6, 4, 79, 13, 20, 404, 411, "compare" +539, 6, 5, 80, 21, 24, 412, 415, "the" +539, 6, 6, 81, 25, 33, 416, 424, "efficacy" +539, 6, 7, 82, 34, 37, 425, 428, "and" +539, 6, 8, 83, 38, 44, 429, 435, "safety" +539, 6, 9, 84, 45, 47, 436, 438, "of" +539, 6, 10, 85, 48, 51, 439, 442, "the" +539, 6, 11, 86, 52, 57, 443, 448, "fixed" +539, 6, 12, 87, 58, 69, 449, 460, "combination" +539, 6, 13, 88, 70, 72, 461, 463, "of" +539, 6, 14, 89, 73, 84, 464, 475, "latanoprost" +539, 6, 15, 90, 85, 88, 476, 479, "and" +539, 6, 16, 91, 89, 96, 480, 487, "timolol" +539, 6, 17, 92, 97, 101, 488, 492, "with" +539, 6, 18, 93, 102, 107, 493, 498, "those" +539, 6, 19, 94, 108, 110, 499, 501, "of" +539, 6, 20, 95, 111, 114, 502, 505, "the" +539, 6, 21, 96, 115, 120, 506, 511, "fixed" +539, 6, 22, 97, 121, 132, 512, 523, "combination" +539, 6, 23, 98, 133, 135, 524, 526, "of" +539, 6, 24, 99, 136, 147, 527, 538, "dorzolamide" +539, 6, 25, 100, 148, 151, 539, 542, "and" +539, 6, 26, 101, 152, 159, 543, 550, "timolol" +539, 6, 27, 102, 160, 162, 551, 553, "in" +539, 6, 28, 103, 163, 171, 554, 562, "patients" +539, 6, 29, 104, 172, 176, 563, 567, "with" +539, 6, 30, 105, 177, 185, 568, 576, "elevated" +539, 6, 31, 106, 186, 197, 577, 588, "intraocular" +539, 6, 32, 107, 198, 206, 589, 597, "pressure" +539, 6, 33, 108, 207, 208, 598, 599, "(" +539, 6, 34, 109, 209, 212, 600, 603, "IOP" +539, 6, 35, 110, 213, 214, 604, 605, ")" +539, 6, 36, 111, 215, 216, 606, 607, "." +539, 7, 1, 112, 0, 6, 608, 614, "DESIGN" +539, 7, 2, 113, 7, 8, 615, 616, ":" +539, 7, 3, 114, 9, 14, 617, 622, "Three" +539, 7, 4, 115, 15, 16, 623, 624, "-" +539, 7, 5, 116, 17, 22, 625, 630, "month" +539, 7, 6, 117, 23, 24, 631, 632, "," +539, 7, 7, 118, 25, 35, 633, 643, "randomized" +539, 7, 8, 119, 36, 37, 644, 645, "," +539, 7, 9, 120, 38, 46, 646, 654, "parallel" +539, 7, 10, 121, 47, 52, 655, 660, "group" +539, 7, 11, 122, 53, 54, 661, 662, "," +539, 7, 12, 123, 55, 64, 663, 672, "evaluator" +539, 7, 13, 124, 65, 66, 673, 674, "-" +539, 7, 14, 125, 67, 73, 675, 681, "masked" +539, 7, 15, 126, 74, 75, 682, 683, "," +539, 7, 16, 127, 76, 87, 684, 695, "multicenter" +539, 7, 17, 128, 88, 93, 696, 701, "study" +539, 7, 18, 129, 94, 95, 702, 703, "." +539, 8, 1, 130, 0, 12, 704, 716, "PARTICIPANTS" +539, 8, 2, 131, 13, 14, 717, 718, ":" +539, 8, 3, 132, 15, 23, 719, 727, "Patients" +539, 8, 4, 133, 24, 28, 728, 732, "with" +539, 8, 5, 134, 29, 36, 733, 740, "primary" +539, 8, 6, 135, 37, 41, 741, 745, "open" +539, 8, 7, 136, 42, 43, 746, 747, "-" +539, 8, 8, 137, 44, 49, 748, 753, "angle" +539, 8, 9, 138, 50, 58, 754, 762, "glaucoma" +539, 8, 10, 139, 59, 61, 763, 765, "or" +539, 8, 11, 140, 62, 68, 766, 772, "ocular" +539, 8, 12, 141, 69, 81, 773, 785, "hypertension" +539, 8, 13, 142, 82, 86, 786, 790, "with" +539, 8, 14, 143, 87, 95, 791, 799, "elevated" +539, 8, 15, 144, 96, 99, 800, 803, "IOP" +539, 8, 16, 145, 100, 114, 804, 818, "insufficiently" +539, 8, 17, 146, 115, 125, 819, 829, "responsive" +539, 8, 18, 147, 126, 128, 830, 832, "to" +539, 8, 19, 148, 129, 140, 833, 844, "monotherapy" +539, 8, 20, 149, 141, 142, 845, 846, ";" +539, 8, 21, 150, 143, 146, 847, 850, "253" +539, 8, 22, 151, 147, 157, 851, 861, "randomized" +539, 8, 23, 152, 158, 159, 862, 863, ":" +539, 8, 24, 153, 160, 163, 864, 867, "125" +539, 8, 25, 154, 164, 166, 868, 870, "to" +539, 8, 26, 155, 167, 174, 871, 878, "receive" +539, 8, 27, 156, 175, 176, 879, 880, "a" +539, 8, 28, 157, 177, 182, 881, 886, "fixed" +539, 8, 29, 158, 183, 194, 887, 898, "combination" +539, 8, 30, 159, 195, 197, 899, 901, "of" +539, 8, 31, 160, 198, 209, 902, 913, "latanoprost" +539, 8, 32, 161, 210, 211, 914, 915, "0" +539, 8, 33, 162, 212, 213, 916, 917, "." +539, 8, 34, 163, 214, 217, 918, 921, "005" +539, 8, 35, 164, 218, 219, 922, 923, "%" +539, 8, 36, 165, 220, 223, 924, 927, "and" +539, 8, 37, 166, 224, 231, 928, 935, "timolol" +539, 8, 38, 167, 232, 233, 936, 937, "0" +539, 8, 39, 168, 234, 235, 938, 939, "." +539, 8, 40, 169, 236, 237, 940, 941, "5" +539, 8, 41, 170, 238, 239, 942, 943, "%" +539, 8, 42, 171, 240, 244, 944, 948, "once" +539, 8, 43, 172, 245, 250, 949, 954, "daily" +539, 8, 44, 173, 251, 252, 955, 956, "," +539, 8, 45, 174, 253, 256, 957, 960, "and" +539, 8, 46, 175, 257, 260, 961, 964, "128" +539, 8, 47, 176, 261, 263, 965, 967, "to" +539, 8, 48, 177, 264, 271, 968, 975, "receive" +539, 8, 49, 178, 272, 273, 976, 977, "a" +539, 8, 50, 179, 274, 279, 978, 983, "fixed" +539, 8, 51, 180, 280, 291, 984, 995, "combination" +539, 8, 52, 181, 292, 294, 996, 998, "of" +539, 8, 53, 182, 295, 306, 999, 1010, "dorzolamide" +539, 8, 54, 183, 307, 308, 1011, 1012, "2" +539, 8, 55, 184, 309, 310, 1013, 1014, "%" +539, 8, 56, 185, 311, 314, 1015, 1018, "and" +539, 8, 57, 186, 315, 322, 1019, 1026, "timolol" +539, 8, 58, 187, 323, 324, 1027, 1028, "0" +539, 8, 59, 188, 325, 326, 1029, 1030, "." +539, 8, 60, 189, 327, 328, 1031, 1032, "5" +539, 8, 61, 190, 329, 330, 1033, 1034, "%" +539, 8, 62, 191, 331, 336, 1035, 1040, "twice" +539, 8, 63, 192, 337, 342, 1041, 1046, "daily" +539, 8, 64, 193, 343, 344, 1047, 1048, "." +539, 9, 1, 194, 0, 7, 1049, 1056, "METHODS" +539, 9, 2, 195, 8, 9, 1057, 1058, ":" +539, 9, 3, 196, 10, 16, 1059, 1065, "Visits" +539, 9, 4, 197, 17, 21, 1066, 1070, "were" +539, 9, 5, 198, 22, 24, 1071, 1073, "at" +539, 9, 6, 199, 25, 34, 1074, 1083, "screening" +539, 9, 7, 200, 35, 36, 1084, 1085, "(" +539, 9, 8, 201, 37, 44, 1086, 1093, "current" +539, 9, 9, 202, 45, 51, 1094, 1100, "ocular" +539, 9, 10, 203, 52, 63, 1101, 1112, "hypotensive" +539, 9, 11, 204, 64, 71, 1113, 1120, "therapy" +539, 9, 12, 205, 72, 75, 1121, 1124, "was" +539, 9, 13, 206, 76, 88, 1125, 1137, "discontinued" +539, 9, 14, 207, 89, 90, 1138, 1139, ")" +539, 9, 15, 208, 91, 92, 1140, 1141, "," +539, 9, 16, 209, 93, 94, 1142, 1143, "2" +539, 9, 17, 210, 95, 100, 1144, 1149, "weeks" +539, 9, 18, 211, 101, 102, 1150, 1151, "(" +539, 9, 19, 212, 103, 105, 1152, 1154, "if" +539, 9, 20, 213, 106, 112, 1155, 1161, "needed" +539, 9, 21, 214, 113, 116, 1162, 1165, "for" +539, 9, 22, 215, 117, 119, 1166, 1168, "an" +539, 9, 23, 216, 120, 123, 1169, 1172, "IOP" +539, 9, 24, 217, 124, 125, 1173, 1174, "-" +539, 9, 25, 218, 126, 132, 1175, 1181, "safety" +539, 9, 26, 219, 133, 138, 1182, 1187, "check" +539, 9, 27, 220, 139, 140, 1188, 1189, ")" +539, 9, 28, 221, 141, 142, 1190, 1191, "," +539, 9, 29, 222, 143, 151, 1192, 1200, "baseline" +539, 9, 30, 223, 152, 153, 1201, 1202, "(" +539, 9, 31, 224, 154, 167, 1203, 1216, "randomization" +539, 9, 32, 225, 168, 169, 1217, 1218, ")" +539, 9, 33, 226, 170, 171, 1219, 1220, "," +539, 9, 34, 227, 172, 175, 1221, 1224, "and" +539, 9, 35, 228, 176, 181, 1225, 1230, "after" +539, 9, 36, 229, 182, 183, 1231, 1232, "1" +539, 9, 37, 230, 184, 187, 1233, 1236, "and" +539, 9, 38, 231, 188, 189, 1237, 1238, "3" +539, 9, 39, 232, 190, 196, 1239, 1245, "months" +539, 9, 40, 233, 197, 199, 1246, 1248, "of" +539, 9, 41, 234, 200, 207, 1249, 1256, "therapy" +539, 9, 42, 235, 208, 209, 1257, 1258, "." +539, 10, 1, 236, 0, 11, 1259, 1270, "Intraocular" +539, 10, 2, 237, 12, 20, 1271, 1279, "pressure" +539, 10, 3, 238, 21, 24, 1280, 1283, "was" +539, 10, 4, 239, 25, 33, 1284, 1292, "measured" +539, 10, 5, 240, 34, 36, 1293, 1295, "in" +539, 10, 6, 241, 37, 47, 1296, 1306, "triplicate" +539, 10, 7, 242, 48, 50, 1307, 1309, "at" +539, 10, 8, 243, 51, 52, 1310, 1311, "8" +539, 10, 9, 244, 53, 55, 1312, 1314, "am" +539, 10, 10, 245, 56, 57, 1315, 1316, "," +539, 10, 11, 246, 58, 60, 1317, 1319, "12" +539, 10, 12, 247, 61, 63, 1320, 1322, "pm" +539, 10, 13, 248, 64, 65, 1323, 1324, "," +539, 10, 14, 249, 66, 69, 1325, 1328, "and" +539, 10, 15, 250, 70, 71, 1329, 1330, "4" +539, 10, 16, 251, 72, 74, 1331, 1333, "pm" +539, 10, 17, 252, 75, 77, 1334, 1336, "at" +539, 10, 18, 253, 78, 82, 1337, 1341, "each" +539, 10, 19, 254, 83, 88, 1342, 1347, "study" +539, 10, 20, 255, 89, 94, 1348, 1353, "visit" +539, 10, 21, 256, 95, 96, 1354, 1355, "," +539, 10, 22, 257, 97, 100, 1356, 1359, "and" +539, 10, 23, 258, 101, 108, 1360, 1367, "diurnal" +539, 10, 24, 259, 109, 112, 1368, 1371, "IOP" +539, 10, 25, 260, 113, 116, 1372, 1375, "was" +539, 10, 26, 261, 117, 127, 1376, 1386, "calculated" +539, 10, 27, 262, 128, 130, 1387, 1389, "as" +539, 10, 28, 263, 131, 134, 1390, 1393, "the" +539, 10, 29, 264, 135, 139, 1394, 1398, "mean" +539, 10, 30, 265, 140, 145, 1399, 1404, "value" +539, 10, 31, 266, 146, 148, 1405, 1407, "of" +539, 10, 32, 267, 149, 154, 1408, 1413, "these" +539, 10, 33, 268, 155, 165, 1414, 1424, "recordings" +539, 10, 34, 269, 166, 167, 1425, 1426, "." +539, 11, 1, 270, 0, 7, 1427, 1434, "Adverse" +539, 11, 2, 271, 8, 14, 1435, 1441, "events" +539, 11, 3, 272, 15, 19, 1442, 1446, "were" +539, 11, 4, 273, 20, 28, 1447, 1455, "recorded" +539, 11, 5, 274, 29, 31, 1456, 1458, "at" +539, 11, 6, 275, 32, 36, 1459, 1463, "each" +539, 11, 7, 276, 37, 42, 1464, 1469, "visit" +539, 11, 8, 277, 43, 44, 1470, 1471, "." +539, 12, 1, 278, 0, 4, 1472, 1476, "MAIN" +539, 12, 2, 279, 5, 12, 1477, 1484, "OUTCOME" +539, 12, 3, 280, 13, 20, 1485, 1492, "MEASURE" +539, 12, 4, 281, 21, 22, 1493, 1494, ":" +539, 12, 5, 282, 23, 26, 1495, 1498, "The" +539, 12, 6, 283, 27, 37, 1499, 1509, "difference" +539, 12, 7, 284, 38, 45, 1510, 1517, "between" +539, 12, 8, 285, 46, 55, 1518, 1527, "treatment" +539, 12, 9, 286, 56, 62, 1528, 1534, "groups" +539, 12, 10, 287, 63, 65, 1535, 1537, "in" +539, 12, 11, 288, 66, 69, 1538, 1541, "the" +539, 12, 12, 289, 70, 76, 1542, 1548, "change" +539, 12, 13, 290, 77, 79, 1549, 1551, "in" +539, 12, 14, 291, 80, 84, 1552, 1556, "mean" +539, 12, 15, 292, 85, 92, 1557, 1564, "diurnal" +539, 12, 16, 293, 93, 96, 1565, 1568, "IOP" +539, 12, 17, 294, 97, 101, 1569, 1573, "from" +539, 12, 18, 295, 102, 110, 1574, 1582, "baseline" +539, 12, 19, 296, 111, 113, 1583, 1585, "to" +539, 12, 20, 297, 114, 119, 1586, 1591, "month" +539, 12, 21, 298, 120, 121, 1592, 1593, "3" +539, 12, 22, 299, 122, 123, 1594, 1595, "." +539, 13, 1, 300, 0, 7, 1596, 1603, "RESULTS" +539, 13, 2, 301, 8, 9, 1604, 1605, ":" +539, 13, 3, 302, 10, 14, 1606, 1610, "Mean" +539, 13, 4, 303, 15, 22, 1611, 1618, "diurnal" +539, 13, 5, 304, 23, 26, 1619, 1622, "IOP" +539, 13, 6, 305, 27, 33, 1623, 1629, "levels" +539, 13, 7, 306, 34, 38, 1630, 1634, "were" +539, 13, 8, 307, 39, 46, 1635, 1642, "similar" +539, 13, 9, 308, 47, 49, 1643, 1645, "at" +539, 13, 10, 309, 50, 58, 1646, 1654, "baseline" +539, 13, 11, 310, 59, 60, 1655, 1656, "." +539, 14, 1, 311, 0, 4, 1657, 1661, "Mean" +539, 14, 2, 312, 5, 6, 1662, 1663, "(" +539, 14, 3, 313, 7, 8, 1664, 1665, "+" +539, 14, 4, 314, 9, 10, 1666, 1667, "/" +539, 14, 5, 315, 11, 12, 1668, 1669, "-" +539, 14, 6, 316, 13, 21, 1670, 1678, "standard" +539, 14, 7, 317, 22, 27, 1679, 1684, "error" +539, 14, 8, 318, 28, 30, 1685, 1687, "of" +539, 14, 9, 319, 31, 34, 1688, 1691, "the" +539, 14, 10, 320, 35, 39, 1692, 1696, "mean" +539, 14, 11, 321, 40, 41, 1697, 1698, ")" +539, 14, 12, 322, 42, 52, 1699, 1709, "reductions" +539, 14, 13, 323, 53, 55, 1710, 1712, "in" +539, 14, 14, 324, 56, 63, 1713, 1720, "diurnal" +539, 14, 15, 325, 64, 67, 1721, 1724, "IOP" +539, 14, 16, 326, 68, 72, 1725, 1729, "from" +539, 14, 17, 327, 73, 81, 1730, 1738, "baseline" +539, 14, 18, 328, 82, 84, 1739, 1741, "to" +539, 14, 19, 329, 85, 90, 1742, 1747, "month" +539, 14, 20, 330, 91, 92, 1748, 1749, "3" +539, 14, 21, 331, 93, 97, 1750, 1754, "were" +539, 14, 22, 332, 98, 99, 1755, 1756, "9" +539, 14, 23, 333, 100, 101, 1757, 1758, "." +539, 14, 24, 334, 102, 103, 1759, 1760, "4" +539, 14, 25, 335, 104, 105, 1761, 1762, "+" +539, 14, 26, 336, 106, 107, 1763, 1764, "/" +539, 14, 27, 337, 108, 109, 1765, 1766, "-" +539, 14, 28, 338, 110, 111, 1767, 1768, "0" +539, 14, 29, 339, 112, 113, 1769, 1770, "." +539, 14, 30, 340, 114, 116, 1771, 1773, "27" +539, 14, 31, 341, 117, 121, 1774, 1778, "mmHg" +539, 14, 32, 342, 122, 124, 1779, 1781, "in" +539, 14, 33, 343, 125, 128, 1782, 1785, "the" +539, 14, 34, 344, 129, 140, 1786, 1797, "latanoprost" +539, 14, 35, 345, 141, 142, 1798, 1799, "/" +539, 14, 36, 346, 143, 150, 1800, 1807, "timolol" +539, 14, 37, 347, 151, 156, 1808, 1813, "fixed" +539, 14, 38, 348, 157, 158, 1814, 1815, "-" +539, 14, 39, 349, 159, 170, 1816, 1827, "combination" +539, 14, 40, 350, 171, 176, 1828, 1833, "group" +539, 14, 41, 351, 177, 178, 1834, 1835, "," +539, 14, 42, 352, 179, 185, 1836, 1842, "versus" +539, 14, 43, 353, 186, 187, 1843, 1844, "8" +539, 14, 44, 354, 188, 189, 1845, 1846, "." +539, 14, 45, 355, 190, 191, 1847, 1848, "4" +539, 14, 46, 356, 192, 193, 1849, 1850, "+" +539, 14, 47, 357, 194, 195, 1851, 1852, "/" +539, 14, 48, 358, 196, 197, 1853, 1854, "-" +539, 14, 49, 359, 198, 199, 1855, 1856, "0" +539, 14, 50, 360, 200, 201, 1857, 1858, "." +539, 14, 51, 361, 202, 204, 1859, 1861, "26" +539, 14, 52, 362, 205, 209, 1862, 1866, "mmHg" +539, 14, 53, 363, 210, 212, 1867, 1869, "in" +539, 14, 54, 364, 213, 221, 1870, 1878, "patients" +539, 14, 55, 365, 222, 231, 1879, 1888, "receiving" +539, 14, 56, 366, 232, 235, 1889, 1892, "the" +539, 14, 57, 367, 236, 247, 1893, 1904, "dorzolamide" +539, 14, 58, 368, 248, 249, 1905, 1906, "/" +539, 14, 59, 369, 250, 257, 1907, 1914, "timolol" +539, 14, 60, 370, 258, 263, 1915, 1920, "fixed" +539, 14, 61, 371, 264, 275, 1921, 1932, "combination" +539, 14, 62, 372, 276, 277, 1933, 1934, "." +539, 15, 1, 373, 0, 3, 1935, 1938, "The" +539, 15, 2, 374, 4, 8, 1939, 1943, "mean" +539, 15, 3, 375, 9, 19, 1944, 1954, "difference" +539, 15, 4, 376, 20, 22, 1955, 1957, "in" +539, 15, 5, 377, 23, 30, 1958, 1965, "diurnal" +539, 15, 6, 378, 31, 34, 1966, 1969, "IOP" +539, 15, 7, 379, 35, 44, 1970, 1979, "reduction" +539, 15, 8, 380, 45, 52, 1980, 1987, "between" +539, 15, 9, 381, 53, 63, 1988, 1998, "treatments" +539, 15, 10, 382, 64, 67, 1999, 2002, "was" +539, 15, 11, 383, 68, 69, 2003, 2004, "1" +539, 15, 12, 384, 70, 71, 2005, 2006, "." +539, 15, 13, 385, 72, 74, 2007, 2009, "00" +539, 15, 14, 386, 75, 79, 2010, 2014, "mmHg" +539, 15, 15, 387, 80, 81, 2015, 2016, "(" +539, 15, 16, 388, 82, 84, 2017, 2019, "95" +539, 15, 17, 389, 85, 86, 2020, 2021, "%" +539, 15, 18, 390, 87, 97, 2022, 2032, "confidence" +539, 15, 19, 391, 98, 106, 2033, 2041, "interval" +539, 15, 20, 392, 107, 108, 2042, 2043, "," +539, 15, 21, 393, 109, 110, 2044, 2045, "0" +539, 15, 22, 394, 111, 112, 2046, 2047, "." +539, 15, 23, 395, 113, 115, 2048, 2050, "31" +539, 15, 24, 396, 116, 117, 2051, 2052, "-" +539, 15, 25, 397, 118, 119, 2053, 2054, "1" +539, 15, 26, 398, 120, 121, 2055, 2056, "." +539, 15, 27, 399, 122, 124, 2057, 2059, "69" +539, 15, 28, 400, 125, 126, 2060, 2061, ";" +539, 15, 29, 401, 127, 128, 2062, 2063, "P" +539, 15, 30, 402, 129, 130, 2064, 2065, "=" +539, 15, 31, 403, 131, 132, 2066, 2067, "0" +539, 15, 32, 404, 133, 134, 2068, 2069, "." +539, 15, 33, 405, 135, 138, 2070, 2073, "005" +539, 15, 34, 406, 139, 140, 2074, 2075, ")" +539, 15, 35, 407, 141, 143, 2076, 2078, "in" +539, 15, 36, 408, 144, 149, 2079, 2084, "favor" +539, 15, 37, 409, 150, 152, 2085, 2087, "of" +539, 15, 38, 410, 153, 156, 2088, 2091, "the" +539, 15, 39, 411, 157, 168, 2092, 2103, "latanoprost" +539, 15, 40, 412, 169, 170, 2104, 2105, "/" +539, 15, 41, 413, 171, 178, 2106, 2113, "timolol" +539, 15, 42, 414, 179, 184, 2114, 2119, "fixed" +539, 15, 43, 415, 185, 196, 2120, 2131, "combination" +539, 15, 44, 416, 197, 198, 2132, 2133, "." +539, 16, 1, 417, 0, 4, 2134, 2138, "Both" +539, 16, 2, 418, 5, 15, 2139, 2149, "treatments" +539, 16, 3, 419, 16, 25, 2150, 2159, "generally" +539, 16, 4, 420, 26, 30, 2160, 2164, "were" +539, 16, 5, 421, 31, 35, 2165, 2169, "well" +539, 16, 6, 422, 36, 45, 2170, 2179, "tolerated" +539, 16, 7, 423, 46, 47, 2180, 2181, "." +539, 17, 1, 424, 0, 11, 2182, 2193, "CONCLUSIONS" +539, 17, 2, 425, 12, 13, 2194, 2195, ":" +539, 17, 3, 426, 14, 17, 2196, 2199, "The" +539, 17, 4, 427, 18, 23, 2200, 2205, "fixed" +539, 17, 5, 428, 24, 35, 2206, 2217, "combination" +539, 17, 6, 429, 36, 38, 2218, 2220, "of" +539, 17, 7, 430, 39, 50, 2221, 2232, "latanoprost" +539, 17, 8, 431, 51, 54, 2233, 2236, "and" +539, 17, 9, 432, 55, 62, 2237, 2244, "timolol" +539, 17, 10, 433, 63, 66, 2245, 2248, "was" +539, 17, 11, 434, 67, 75, 2249, 2257, "slightly" +539, 17, 12, 435, 76, 80, 2258, 2262, "more" +539, 17, 13, 436, 81, 90, 2263, 2272, "effective" +539, 17, 14, 437, 91, 95, 2273, 2277, "than" +539, 17, 15, 438, 96, 100, 2278, 2282, "that" +539, 17, 16, 439, 101, 103, 2283, 2285, "of" +539, 17, 17, 440, 104, 115, 2286, 2297, "dorzolamide" +539, 17, 18, 441, 116, 119, 2298, 2301, "and" +539, 17, 19, 442, 120, 127, 2302, 2309, "timolol" +539, 17, 20, 443, 128, 130, 2310, 2312, "in" +539, 17, 21, 444, 131, 139, 2313, 2321, "reducing" +539, 17, 22, 445, 140, 144, 2322, 2326, "mean" +539, 17, 23, 446, 145, 152, 2327, 2334, "diurnal" +539, 17, 24, 447, 153, 156, 2335, 2338, "IOP" +539, 17, 25, 448, 157, 158, 2339, 2340, "," +539, 17, 26, 449, 159, 162, 2341, 2344, "and" +539, 17, 27, 450, 163, 167, 2345, 2349, "both" +539, 17, 28, 451, 168, 178, 2350, 2360, "treatments" +539, 17, 29, 452, 179, 183, 2361, 2365, "were" +539, 17, 30, 453, 184, 193, 2366, 2375, "generally" +539, 17, 31, 454, 194, 198, 2376, 2380, "well" +539, 17, 32, 455, 199, 208, 2381, 2390, "tolerated" +539, 17, 33, 456, 209, 210, 2391, 2392, "." +539, 18, 1, 457, 0, 3, 2393, 2396, "DOI" +539, 18, 2, 458, 4, 5, 2397, 2398, ":" +539, 18, 3, 459, 6, 8, 2399, 2401, "10" +539, 18, 4, 460, 9, 10, 2402, 2403, "." +539, 18, 5, 461, 11, 15, 2404, 2408, "1016" +539, 18, 6, 462, 16, 17, 2409, 2410, "/" +539, 18, 7, 463, 18, 19, 2411, 2412, "j" +539, 18, 8, 464, 20, 21, 2413, 2414, "." +539, 18, 9, 465, 22, 28, 2415, 2421, "ophtha" +539, 18, 10, 466, 29, 30, 2422, 2423, "." +539, 18, 11, 467, 31, 35, 2424, 2428, "2003" +539, 18, 12, 468, 36, 37, 2429, 2430, "." +539, 18, 13, 469, 38, 40, 2431, 2433, "05" +539, 18, 14, 470, 41, 42, 2434, 2435, "." +539, 18, 15, 471, 43, 46, 2436, 2439, "019" +539, 18, 16, 472, 47, 51, 2440, 2444, "PMID" +539, 18, 17, 473, 52, 53, 2445, 2446, ":" +539, 18, 18, 474, 54, 62, 2447, 2455, "15019375" +539, 18, 19, 475, 63, 64, 2456, 2457, "[" +539, 18, 20, 476, 65, 72, 2458, 2465, "Indexed" +539, 18, 21, 477, 73, 76, 2466, 2469, "for" +539, 18, 22, 478, 77, 84, 2470, 2477, "MEDLINE" +539, 18, 23, 479, 85, 86, 2478, 2479, "]" diff --git a/data/gl 15019375_jshahinitiran.annodb b/data/gl 15019375_jshahinitiran.annodb new file mode 100644 index 0000000..e402220 --- /dev/null +++ b/data/gl 15019375_jshahinitiran.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +83924, Journal, 0, 13, "Ophthalmology", "", +83926, PublicationYear, 16, 20, "2004", "", +83927, Title, 50, 195, "Efficacy and safety of the fixed combinations latanoprost / timolol versus dorzolamide / timolol in patients with elevated intraocular pressure .", "", +83933, Lat/TimFC, 77, 117, "fixed combinations latanoprost / timolol", "", +83928, Latanoprost, 96, 107, "latanoprost", "", +83929, Timolol, 110, 117, "timolol", "", +83930, Dorzolamide, 125, 136, "dorzolamide", "", +83934, Dorz/TimFC, 125, 146, "dorzolamide / timolol", "", +83931, Timolol, 139, 146, "timolol", "", +83932, IOP, 173, 193, "intraocular pressure", "", +83935, Author, 196, 203, "Shin DH", "", +83936, Author, 212, 222, "Feldman RM", "", +83937, Author, 225, 232, "Sheu WP", "", +83940, Lat/TimFC, 235, 274, "Fixed Combination Latanoprost / Timolol", "", +83938, Latanoprost, 253, 264, "Latanoprost", "", +83939, Timolol, 267, 274, "Timolol", "", +83941, USA, 385, 388, "USA", "", +83942, ObjectiveDescription, 401, 607, "To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure ( IOP ) .", "", +83943, Lat/TimFC, 443, 487, "fixed combination of latanoprost and timolol", "", +83944, Latanoprost, 464, 475, "latanoprost", "", +83945, Timolol, 480, 487, "timolol", "", +83946, Dorz/TimFC, 506, 550, "fixed combination of dorzolamide and timolol", "", +83947, Dorzolamide, 527, 538, "dorzolamide", "", +83948, Timolol, 543, 550, "timolol", "", +83951, Precondition, 568, 605, "elevated intraocular pressure ( IOP )", "", +83949, IOP, 577, 597, "intraocular pressure", "", +83950, IOP, 600, 603, "IOP", "", +83952, Duration, 617, 630, "Three - month", "", +83953, Randomized, 633, 643, "randomized", "", +83954, Parallel, 646, 660, "parallel group", "", +83955, Blind, 663, 681, "evaluator - masked", "", +83956, Multicenter, 684, 695, "multicenter", "", +83957, Primary_OpenAngleGlaucoma, 733, 762, "primary open - angle glaucoma", "", +83958, OcularHypertension, 766, 785, "ocular hypertension", "", +83960, Precondition, 791, 844, "elevated IOP insufficiently responsive to monotherapy", "", +83959, IOP, 800, 803, "IOP", "", +83961, NumberPatientsCT, 847, 850, "253", "", +83962, Randomized, 851, 861, "randomized", "", +83963, NumberPatientsArm, 864, 867, "125", "", +83966, Lat/TimFC, 881, 943, "fixed combination of latanoprost 0 . 005 % and timolol 0 . 5 %", "", +83964, Latanoprost, 902, 913, "latanoprost", "", +83967, DoseValue, 914, 921, "0 . 005", "", +83965, Timolol, 928, 935, "timolol", "", +83968, DoseValue, 936, 941, "0 . 5", "", +83971, Frequency, 944, 954, "once daily", "", +83975, Dorz/TimFC, 978, 1034, "fixed combination of dorzolamide 2 % and timolol 0 . 5 %", "", +83974, Dorzolamide, 999, 1010, "dorzolamide", "", +83969, DoseValue, 1011, 1012, "2", "", +83973, Timolol, 1019, 1026, "timolol", "", +83970, DoseValue, 1027, 1032, "0 . 5", "", +83972, Frequency, 1035, 1046, "twice daily", "", +83976, TimePoint, 1192, 1200, "baseline", "", +83977, Randomized, 1203, 1216, "randomization", "", +83978, TimePoint, 1231, 1245, "1 and 3 months", "", +83979, TimePoint, 1237, 1245, "3 months", "", +83980, IOP, 1259, 1279, "Intraocular pressure", "", +83981, Diurnal_IOP, 1360, 1371, "diurnal IOP", "", +83982, Mean, 1394, 1398, "mean", "", +83983, Mean, 1552, 1556, "mean", "", +83984, Diurnal_IOP, 1557, 1568, "diurnal IOP", "", +83985, TimePoint, 1574, 1582, "baseline", "", +83986, TimePoint, 1586, 1593, "month 3", "", +83987, Mean, 1606, 1610, "Mean", "", +83988, Diurnal_IOP, 1611, 1622, "diurnal IOP", "", +83989, TimePoint, 1646, 1654, "baseline", "", +83990, Mean, 1657, 1661, "Mean", "", +83991, Diurnal_IOP, 1713, 1724, "diurnal IOP", "", +83992, TimePoint, 1730, 1738, "baseline", "", +83993, TimePoint, 1742, 1749, "month 3", "", +83994, Reduction, 1755, 1760, "9 . 4", "", +83996, SdErrorChangeValue, 1767, 1773, "0 . 27", "", +83998, mmHg, 1774, 1778, "mmHg", "", +84000, Latanoprost, 1786, 1797, "latanoprost", "", +84002, Lat/TimFC, 1786, 1827, "latanoprost / timolol fixed - combination", "", +84001, Timolol, 1800, 1807, "timolol", "", +83995, Reduction, 1843, 1848, "8 . 4", "", +83997, SdErrorChangeValue, 1855, 1861, "0 . 26", "", +83999, mmHg, 1862, 1866, "mmHg", "", +84004, Dorzolamide, 1893, 1904, "dorzolamide", "", +84005, Dorz/TimFC, 1893, 1932, "dorzolamide / timolol fixed combination", "", +84003, Timolol, 1907, 1914, "timolol", "", +84006, Mean, 1939, 1943, "mean", "", +84007, Diurnal_IOP, 1958, 1969, "diurnal IOP", "", +84008, DiffGroupAbsValue, 2003, 2009, "1 . 00", "", +84009, mmHg, 2010, 2014, "mmHg", "", +84010, ConfIntervalDiff, 2017, 2059, "95 % confidence interval , 0 . 31 - 1 . 69", "", +84011, PvalueDiff, 2062, 2073, "P = 0 . 005", "", +84012, Latanoprost, 2092, 2103, "latanoprost", "", +84014, Lat/TimFC, 2092, 2131, "latanoprost / timolol fixed combination", "", +84013, Timolol, 2106, 2113, "timolol", "", +84015, ConclusionComment, 2196, 2392, "The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP , and both treatments were generally well tolerated .", "", +84018, Lat/TimFC, 2200, 2244, "fixed combination of latanoprost and timolol", "", +84016, Latanoprost, 2221, 2232, "latanoprost", "", +84017, Timolol, 2237, 2244, "timolol", "", +84019, Dorzolamide, 2286, 2297, "dorzolamide", "", +84020, Timolol, 2302, 2309, "timolol", "", +84021, Mean, 2322, 2326, "mean", "", +84022, Diurnal_IOP, 2327, 2338, "diurnal IOP", "", +84023, PMID, 2447, 2455, "15019375", "", diff --git a/data/gl 15019375_jshahinitiran.n-triples b/data/gl 15019375_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15019375_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15019375_tstrakeljahn.annodb b/data/gl 15019375_tstrakeljahn.annodb new file mode 100644 index 0000000..a6cce15 --- /dev/null +++ b/data/gl 15019375_tstrakeljahn.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82648, Journal, 0, 13, "Ophthalmology", "", +82649, PublicationYear, 16, 20, "2004", "", +82657, Title, 50, 195, "Efficacy and safety of the fixed combinations latanoprost / timolol versus dorzolamide / timolol in patients with elevated intraocular pressure .", "", +82650, Latanoprost, 96, 107, "latanoprost", "", +82654, Lat/TimFC, 96, 117, "latanoprost / timolol", "", +82651, Timolol, 110, 117, "timolol", "", +82653, Dorzolamide, 125, 136, "dorzolamide", "", +82655, Dorz/TimFC, 125, 146, "dorzolamide / timolol", "", +82652, Timolol, 139, 146, "timolol", "", +82656, IOP, 173, 193, "intraocular pressure", "", +82658, Author, 196, 203, "Shin DH", "", +82659, Author, 212, 222, "Feldman RM", "", +82660, Author, 225, 232, "Sheu WP", "", +82661, Latanoprost, 253, 264, "Latanoprost", "", +82663, Lat/TimFC, 253, 274, "Latanoprost / Timolol", "", +82662, Timolol, 267, 274, "Timolol", "", +82664, USA, 385, 388, "USA", "", +82673, ObjectiveDescription, 401, 607, "To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure ( IOP ) .", "", +82665, Latanoprost, 464, 475, "latanoprost", "", +82669, Lat/TimFC, 464, 487, "latanoprost and timolol", "", +82666, Timolol, 480, 487, "timolol", "", +82668, Dorzolamide, 527, 538, "dorzolamide", "", +82670, Dorz/TimFC, 527, 550, "dorzolamide and timolol", "", +82667, Timolol, 543, 550, "timolol", "", +82671, IOP, 577, 597, "intraocular pressure", "", +82672, IOP, 600, 603, "IOP", "", +82674, Duration, 617, 630, "Three - month", "", +82675, Randomized, 633, 643, "randomized", "", +82676, Parallel, 646, 654, "parallel", "", +82677, Blind, 663, 681, "evaluator - masked", "", +82678, Multicenter, 684, 695, "multicenter", "", +82682, Precondition, 719, 844, "Patients with primary open - angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy", "", +82679, Primary_OpenAngleGlaucoma, 733, 762, "primary open - angle glaucoma", "", +82680, OcularHypertension, 766, 785, "ocular hypertension", "", +82681, IOP, 800, 803, "IOP", "", +82683, NumberPatientsCT, 847, 850, "253", "", +82686, Randomized, 851, 861, "randomized", "", +82684, NumberPatientsArm, 864, 867, "125", "", +82701, Lat/TimFC, 902, 941, "latanoprost 0 . 005 % and timolol 0 . 5", "", +82687, Latanoprost, 902, 913, "latanoprost", "", +82691, DoseValue, 914, 921, "0 . 005", "", +82697, Percentage, 922, 923, "%", "", +82689, Timolol, 928, 935, "timolol", "", +82692, DoseValue, 936, 941, "0 . 5", "", +82698, Percentage, 942, 943, "%", "", +82695, Frequency, 944, 954, "once daily", "", +82685, NumberPatientsArm, 961, 964, "128", "", +82690, Dorzolamide, 999, 1010, "dorzolamide", "", +82702, Dorz/TimFC, 999, 1032, "dorzolamide 2 % and timolol 0 . 5", "", +82693, DoseValue, 1011, 1012, "2", "", +82699, Percentage, 1013, 1014, "%", "", +82688, Timolol, 1019, 1026, "timolol", "", +82694, DoseValue, 1027, 1032, "0 . 5", "", +82700, Percentage, 1033, 1034, "%", "", +82696, Frequency, 1035, 1046, "twice daily", "", +82703, IOP, 1259, 1279, "Intraocular pressure", "", +82704, TimePoint, 1310, 1314, "8 am", "", +82705, TimePoint, 1317, 1322, "12 pm", "", +82706, TimePoint, 1329, 1333, "4 pm", "", +82707, Diurnal_IOP, 1360, 1371, "diurnal IOP", "", +82708, Mean, 1394, 1398, "mean", "", +82709, Mean, 1552, 1556, "mean", "", +82710, Diurnal_IOP, 1557, 1568, "diurnal IOP", "", +82711, TimePoint, 1574, 1582, "baseline", "", +82712, TimePoint, 1586, 1593, "month 3", "", +82713, Mean, 1606, 1610, "Mean", "", +82731, ObservedResult, 1606, 1656, "Mean diurnal IOP levels were similar at baseline .", "", +82714, Diurnal_IOP, 1611, 1622, "diurnal IOP", "", +82715, Mean, 1657, 1661, "Mean", "", +82716, Diurnal_IOP, 1713, 1724, "diurnal IOP", "", +82717, TimePoint, 1730, 1738, "baseline", "", +82718, TimePoint, 1742, 1749, "month 3", "", +82719, Reduction, 1755, 1760, "9 . 4", "", +82721, SdErrorChangeValue, 1767, 1773, "0 . 27", "", +82724, mmHg, 1774, 1778, "mmHg", "", +82725, Latanoprost, 1786, 1797, "latanoprost", "", +82730, Lat/TimFC, 1786, 1807, "latanoprost / timolol", "", +82726, Timolol, 1800, 1807, "timolol", "", +82720, Reduction, 1843, 1848, "8 . 4", "", +82722, SdErrorChangeValue, 1855, 1861, "0 . 26", "", +82723, mmHg, 1862, 1866, "mmHg", "", +82728, Dorzolamide, 1893, 1904, "dorzolamide", "", +82729, Dorz/TimFC, 1893, 1914, "dorzolamide / timolol", "", +82727, Timolol, 1907, 1914, "timolol", "", +82732, Mean, 1939, 1943, "mean", "", +82733, Diurnal_IOP, 1958, 1969, "diurnal IOP", "", +82734, DiffGroupAbsValue, 2003, 2009, "1 . 00", "", +82736, mmHg, 2010, 2014, "mmHg", "", +82740, ConfIntervalDiff, 2044, 2059, "0 . 31 - 1 . 69", "", +82735, PvalueDiff, 2064, 2073, "= 0 . 005", "", +82737, Latanoprost, 2092, 2103, "latanoprost", "", +82739, Lat/TimFC, 2092, 2113, "latanoprost / timolol", "", +82738, Timolol, 2106, 2113, "timolol", "", +82741, ObservedResult, 2134, 2181, "Both treatments generally were well tolerated .", "", +82750, ConclusionComment, 2196, 2392, "The fixed combination of latanoprost and timolol was slightly more effective than that of dorzolamide and timolol in reducing mean diurnal IOP , and both treatments were generally well tolerated .", "", +82742, Latanoprost, 2221, 2232, "latanoprost", "", +82744, Lat/TimFC, 2221, 2244, "latanoprost and timolol", "", +82743, Timolol, 2237, 2244, "timolol", "", +82745, Dorzolamide, 2286, 2297, "dorzolamide", "", +82747, Dorz/TimFC, 2286, 2309, "dorzolamide and timolol", "", +82746, Timolol, 2302, 2309, "timolol", "", +82748, Mean, 2322, 2326, "mean", "", +82749, Diurnal_IOP, 2327, 2338, "diurnal IOP", "", +82751, PMID, 2447, 2455, "15019375", "", diff --git a/data/gl 15019375_tstrakeljahn.n-triples b/data/gl 15019375_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15019375_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15037890_admin.annodb b/data/gl 15037890_admin.annodb new file mode 100644 index 0000000..f0f7848 --- /dev/null +++ b/data/gl 15037890_admin.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 12, "Eye ( Lond )", "", " \"Eye ( Lond )\"." +1, PublicationYear, 15, 19, "2004", "", " \"2004\"." +2, Title, 48, 175, "Efficacy and safety of the latanoprost / timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy .", "", " \"Efficacy and safety of the latanoprost / timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy .\"." +3, Latanoprost, 75, 86, "latanoprost", "", +5, Lat/TimFC, 75, 122, "latanoprost / timolol maleate fixed combination", "", +4, Timolol, 89, 104, "timolol maleate", "", +6, Brimonidine, 138, 149, "brimonidine", "", +7, Latanoprost, 154, 165, "latanoprost", "", +8, Author, 176, 186, "Stewart WC", "", " \"Stewart WC\"." +9, Author, 195, 205, "Stewart JA", "", " \"Stewart JA\"." +10, Author, 208, 214, "Day DG", "", " \"Day DG\"." +11, Author, 217, 226, "Sharpe ED", "", " \"Sharpe ED\"." +85, Author, 229, 239, "Jenkins JN", "", " \"Jenkins JN\"." +13, USA, 331, 334, "USA", "", +14, ObjectiveDescription, 367, 479, "To evaluate the efficacy and safety of latanoprost / timolol maleate fixed combination ( LTFC ) given once daily", "", " \"To evaluate the efficacy and safety of latanoprost / timolol maleate fixed combination ( LTFC ) given once daily\"." +16, Latanoprost, 406, 417, "latanoprost", "", +18, Lat/TimFC, 406, 453, "latanoprost / timolol maleate fixed combination", "", " ." +17, Timolol, 420, 435, "timolol maleate", "", +19, Lat/TimFC, 456, 460, "LTFC", "", +20, Frequency, 469, 479, "once daily", "", " \"once daily\"." +14, ObjectiveDescription, 480, 627, "vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open - angle glaucoma or ocular hypertensive subjects .", "", " \"vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open - angle glaucoma or ocular hypertensive subjects .\"." +21, Brimonidine, 510, 521, "brimonidine", "", " ." +22, Frequency, 522, 533, "twice daily", "", " \"twice daily\"." +23, Latanoprost, 538, 549, "latanoprost", "", " . ." +24, Frequency, 550, 560, "once daily", "", " \"once daily\"." +25, Primary_OpenAngleGlaucoma, 564, 593, "primary open - angle glaucoma", "", " ." +26, OcularHypertension, 597, 616, "ocular hypertensive", "", " ." +27, Prospective, 640, 651, "prospective", "", " ." +28, DoubleBlind, 654, 669, "double - masked", "", " ." +29, CTDesign, 672, 691, "active - controlled", "", " . ." +30, Glaucoma, 739, 747, "glaucoma", "", +31, Precondition, 739, 782, "glaucoma medicines discontinued for 1 month", "", " \"glaucoma medicines discontinued for 1 month\"." +101036, Duration, 775, 782, "1 month", "", +32, Randomized, 797, 807, "randomized", "", " ." +33, Lat/TimFC, 818, 822, "LTFC", "", +34, Brimonidine, 826, 837, "brimonidine", "", +35, Latanoprost, 842, 853, "latanoprost", "", +36, Duration, 878, 885, "6 weeks", "", " \"6 weeks\"." +37, IOP, 949, 969, "intraocular pressure", "", +38, IOP, 972, 975, "IOP", "", +110, TimePoint, 994, 998, "0800", "", +111, TimePoint, 1001, 1005, "1200", "", +112, TimePoint, 1012, 1018, "1600 h", "", +113, TimePoint, 1019, 1030, "at baseline", "", +114, TimePoint, 1035, 1058, "at the end of Periods 1", "", +115, TimePoint, 1035, 1071, "at the end of Periods 1 and Period 2", "", +101038, NumberPatientsCT, 1087, 1089, "32", "", " \"32\"." +41, Diurnal_IOP, 1136, 1139, "IOP", "", " ." +42, BaseLineValue, 1143, 1149, "26 . 0", "", " \"26 . 0\". \"26 . 0\"." +120, SdDevBL, 1156, 1161, "3 . 4", "", " \"3 . 4\". \"3 . 4\"." +44, ResultMeasuredValue, 1175, 1181, "17 . 8", "", " \"17 . 8\"." +123, SdDevResValue, 1188, 1193, "2 . 5", "", " \"2 . 5\"." +48, Lat/TimFC, 1197, 1201, "LTFC", "", +45, ResultMeasuredValue, 1206, 1212, "17 . 2", "", " \"17 . 2\"." +124, SdDevResValue, 1219, 1224, "2 . 8", "", " \"2 . 8\"." +49, mmHg, 1225, 1229, "mmHg", "", " ." +50, Brimonidine, 1233, 1244, "brimonidine", "", +51, Latanoprost, 1249, 1260, "latanoprost", "", +106252, PvalueDiff, 1263, 1273, "P = 0 . 31", "", " \"P = 0 . 31\"." +130, TimePoint, 1281, 1285, "0800", "", " \"0800\". \"0800\"." +131, TimePoint, 1290, 1296, "1600 h", "", " \"1600 h\"." +53, IOP, 1303, 1307, "IOPs", "", +133, PvalueDiff, 1358, 1371, "& gt ; 0 . 05", "", " \"& gt ; 0 . 05\". \"& gt ; 0 . 05\"." +134, TimePoint, 1379, 1385, "1200 h", "", " \"1200 h\". \"1200 h\"." +55, Latanoprost, 1390, 1401, "latanoprost", "", +56, Brimonidine, 1406, 1417, "brimonidine", "", +57, IOP, 1428, 1431, "IOP", "", +58, ResultMeasuredValue, 1458, 1464, "16 . 2", "", " \"16 . 2\"." +140, SdDevResValue, 1471, 1476, "3 . 2", "", " \"3 . 2\"." +62, Lat/TimFC, 1484, 1488, "LTFC", "", +59, ResultMeasuredValue, 1491, 1497, "18 . 0", "", " \"18 . 0\"." +141, SdDevResValue, 1504, 1509, "2 . 8", "", " \"2 . 8\"." +63, mmHg, 1510, 1514, "mmHg", "", +146, ObservedResult, 1519, 1684, "However , the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve for each therapy ( P & lt ; 0 . 05 ) .", "", +64, IOP, 1541, 1544, "IOP", "", +145, PvalueDiff, 1667, 1680, "& lt ; 0 . 05", "", +147, PvalueDiff, 1771, 1784, "& gt ; 0 . 05", "", +67, ConclusionComment, 1802, 1967, "This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline .", "", " \"This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline .\"." +68, Lat/TimFC, 1827, 1831, "LTFC", "", +69, Brimonidine, 1859, 1870, "brimonidine", "", +70, Latanoprost, 1875, 1886, "latanoprost", "", +71, Diurnal_IOP, 1917, 1928, "diurnal IOP", "", +72, PMID, 2012, 2020, "15037890", "", " \"15037890\"." diff --git a/data/gl 15037890_admin.n-triples b/data/gl 15037890_admin.n-triples new file mode 100644 index 0000000..1b2ae6e --- /dev/null +++ b/data/gl 15037890_admin.n-triples @@ -0,0 +1,161 @@ +# RDF export of group: Publication + . + "Publication 89290" . + "Efficacy and safety of the latanoprost / timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy ." . + "Stewart WC" . + "2004" . + "Eye ( Lond )" . + "15037890" . + . + "Stewart JA" . + "Day DG" . + "Sharpe ED" . + "Jenkins JN" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 89297" . + "To evaluate the efficacy and safety of latanoprost / timolol maleate fixed combination ( LTFC ) given once daily" . + "vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open - angle glaucoma or ocular hypertensive subjects ." . + "32" . + "6 weeks" . + . + . + . + "This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 89313" . + "glaucoma medicines discontinued for 1 month" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . +# RDF export of group: Arm + . + "lati" . + . + . + . + . + . + . + . + "brila" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lati" . + "once daily" . + . + . + . + "bri" . + . + "twice daily" . + . + . + "la" . + . + "once daily" . + . +# RDF export of group: Medication + . + "bri" . + . + . + . + . + "la 2" . + . + . + . + . + . + "lati" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "26 . 0" . + "3 . 4" . + "17 . 8" . + "2 . 5" . + . + "iop 2" . + . + "26 . 0" . + "3 . 4" . + "17 . 2" . + "2 . 8" . + . + "iop8 1" . + . + "0800" . + . + "iop8 2" . + . + "0800" . + . + "iop16 1" . + . + "1600 h" . + . + "iop16 2" . + . + . + "iop12 1" . + . + "18 . 0" . + "2 . 8" . + "1200 h" . + . + "iop12 2" . + . + "16 . 2" . + "3 . 2" . + "1200 h" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "P = 0 . 31" . + . + . + . + "iop8" . + "& gt ; 0 . 05" . + . + . + . + "iop16" . + "& gt ; 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15037890_export.csv b/data/gl 15037890_export.csv new file mode 100644 index 0000000..ee087e4 --- /dev/null +++ b/data/gl 15037890_export.csv @@ -0,0 +1,423 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +554, 1, 1, 1, 0, 3, 0, 3, "Eye" +554, 1, 2, 2, 4, 5, 4, 5, "(" +554, 1, 3, 3, 6, 10, 6, 10, "Lond" +554, 1, 4, 4, 11, 12, 11, 12, ")" +554, 1, 5, 5, 13, 14, 13, 14, "." +554, 2, 1, 6, 0, 4, 15, 19, "2004" +554, 2, 2, 7, 5, 8, 20, 23, "Oct" +554, 2, 3, 8, 9, 10, 24, 25, ";" +554, 2, 4, 9, 11, 13, 26, 28, "18" +554, 2, 5, 10, 14, 15, 29, 30, "(" +554, 2, 6, 11, 16, 18, 31, 33, "10" +554, 2, 7, 12, 19, 20, 34, 35, ")" +554, 2, 8, 13, 21, 22, 36, 37, ":" +554, 2, 9, 14, 23, 26, 38, 41, "990" +554, 2, 10, 15, 27, 28, 42, 43, "-" +554, 2, 11, 16, 29, 30, 44, 45, "5" +554, 2, 12, 17, 31, 32, 46, 47, "." +554, 3, 1, 18, 0, 8, 48, 56, "Efficacy" +554, 3, 2, 19, 9, 12, 57, 60, "and" +554, 3, 3, 20, 13, 19, 61, 67, "safety" +554, 3, 4, 21, 20, 22, 68, 70, "of" +554, 3, 5, 22, 23, 26, 71, 74, "the" +554, 3, 6, 23, 27, 38, 75, 86, "latanoprost" +554, 3, 7, 24, 39, 40, 87, 88, "/" +554, 3, 8, 25, 41, 48, 89, 96, "timolol" +554, 3, 9, 26, 49, 56, 97, 104, "maleate" +554, 3, 10, 27, 57, 62, 105, 110, "fixed" +554, 3, 11, 28, 63, 74, 111, 122, "combination" +554, 3, 12, 29, 75, 77, 123, 125, "vs" +554, 3, 13, 30, 78, 89, 126, 137, "concomitant" +554, 3, 14, 31, 90, 101, 138, 149, "brimonidine" +554, 3, 15, 32, 102, 105, 150, 153, "and" +554, 3, 16, 33, 106, 117, 154, 165, "latanoprost" +554, 3, 17, 34, 118, 125, 166, 173, "therapy" +554, 3, 18, 35, 126, 127, 174, 175, "." +554, 4, 1, 36, 0, 7, 176, 183, "Stewart" +554, 4, 2, 37, 8, 10, 184, 186, "WC" +554, 4, 3, 38, 11, 12, 187, 188, "(" +554, 4, 4, 39, 13, 14, 189, 190, "1" +554, 4, 5, 40, 15, 16, 191, 192, ")" +554, 4, 6, 41, 17, 18, 193, 194, "," +554, 4, 7, 42, 19, 26, 195, 202, "Stewart" +554, 4, 8, 43, 27, 29, 203, 205, "JA" +554, 4, 9, 44, 30, 31, 206, 207, "," +554, 4, 10, 45, 32, 35, 208, 211, "Day" +554, 4, 11, 46, 36, 38, 212, 214, "DG" +554, 4, 12, 47, 39, 40, 215, 216, "," +554, 4, 13, 48, 41, 47, 217, 223, "Sharpe" +554, 4, 14, 49, 48, 50, 224, 226, "ED" +554, 4, 15, 50, 51, 52, 227, 228, "," +554, 4, 16, 51, 53, 60, 229, 236, "Jenkins" +554, 4, 17, 52, 61, 63, 237, 239, "JN" +554, 4, 18, 53, 64, 65, 240, 241, "." +554, 5, 1, 54, 0, 6, 242, 248, "Author" +554, 5, 2, 55, 7, 18, 249, 260, "information" +554, 5, 3, 56, 19, 20, 261, 262, ":" +554, 5, 4, 57, 21, 22, 263, 264, "(" +554, 5, 5, 58, 23, 24, 265, 266, "1" +554, 5, 6, 59, 25, 26, 267, 268, ")" +554, 5, 7, 60, 27, 41, 269, 283, "Pharmaceutical" +554, 5, 8, 61, 42, 50, 284, 292, "Research" +554, 5, 9, 62, 51, 58, 293, 300, "Network" +554, 5, 10, 63, 59, 62, 301, 304, "LLC" +554, 5, 11, 64, 63, 64, 305, 306, "," +554, 5, 12, 65, 65, 75, 307, 317, "Charleston" +554, 5, 13, 66, 76, 77, 318, 319, "," +554, 5, 14, 67, 78, 80, 320, 322, "SC" +554, 5, 15, 68, 81, 86, 323, 328, "29412" +554, 5, 16, 69, 87, 88, 329, 330, "," +554, 5, 17, 70, 89, 92, 331, 334, "USA" +554, 5, 18, 71, 93, 94, 335, 336, "." +554, 6, 1, 72, 0, 4, 337, 341, "prnc" +554, 6, 2, 73, 5, 6, 342, 343, "@" +554, 6, 3, 74, 7, 16, 344, 353, "bellsouth" +554, 6, 4, 75, 17, 18, 354, 355, "." +554, 6, 5, 76, 19, 22, 356, 359, "net" +554, 6, 6, 77, 23, 27, 360, 364, "AIMS" +554, 6, 7, 78, 28, 29, 365, 366, ":" +554, 6, 8, 79, 30, 32, 367, 369, "To" +554, 6, 9, 80, 33, 41, 370, 378, "evaluate" +554, 6, 10, 81, 42, 45, 379, 382, "the" +554, 6, 11, 82, 46, 54, 383, 391, "efficacy" +554, 6, 12, 83, 55, 58, 392, 395, "and" +554, 6, 13, 84, 59, 65, 396, 402, "safety" +554, 6, 14, 85, 66, 68, 403, 405, "of" +554, 6, 15, 86, 69, 80, 406, 417, "latanoprost" +554, 6, 16, 87, 81, 82, 418, 419, "/" +554, 6, 17, 88, 83, 90, 420, 427, "timolol" +554, 6, 18, 89, 91, 98, 428, 435, "maleate" +554, 6, 19, 90, 99, 104, 436, 441, "fixed" +554, 6, 20, 91, 105, 116, 442, 453, "combination" +554, 6, 21, 92, 117, 118, 454, 455, "(" +554, 6, 22, 93, 119, 123, 456, 460, "LTFC" +554, 6, 23, 94, 124, 125, 461, 462, ")" +554, 6, 24, 95, 126, 131, 463, 468, "given" +554, 6, 25, 96, 132, 136, 469, 473, "once" +554, 6, 26, 97, 137, 142, 474, 479, "daily" +554, 6, 27, 98, 143, 145, 480, 482, "vs" +554, 6, 28, 99, 146, 149, 483, 486, "the" +554, 6, 29, 100, 150, 161, 487, 498, "concomitant" +554, 6, 30, 101, 162, 169, 499, 506, "therapy" +554, 6, 31, 102, 170, 172, 507, 509, "of" +554, 6, 32, 103, 173, 184, 510, 521, "brimonidine" +554, 6, 33, 104, 185, 190, 522, 527, "twice" +554, 6, 34, 105, 191, 196, 528, 533, "daily" +554, 6, 35, 106, 197, 200, 534, 537, "and" +554, 6, 36, 107, 201, 212, 538, 549, "latanoprost" +554, 6, 37, 108, 213, 217, 550, 554, "once" +554, 6, 38, 109, 218, 223, 555, 560, "daily" +554, 6, 39, 110, 224, 226, 561, 563, "in" +554, 6, 40, 111, 227, 234, 564, 571, "primary" +554, 6, 41, 112, 235, 239, 572, 576, "open" +554, 6, 42, 113, 240, 241, 577, 578, "-" +554, 6, 43, 114, 242, 247, 579, 584, "angle" +554, 6, 44, 115, 248, 256, 585, 593, "glaucoma" +554, 6, 45, 116, 257, 259, 594, 596, "or" +554, 6, 46, 117, 260, 266, 597, 603, "ocular" +554, 6, 47, 118, 267, 279, 604, 616, "hypertensive" +554, 6, 48, 119, 280, 288, 617, 625, "subjects" +554, 6, 49, 120, 289, 290, 626, 627, "." +554, 7, 1, 121, 0, 7, 628, 635, "METHODS" +554, 7, 2, 122, 8, 9, 636, 637, ":" +554, 7, 3, 123, 10, 11, 638, 639, "A" +554, 7, 4, 124, 12, 23, 640, 651, "prospective" +554, 7, 5, 125, 24, 25, 652, 653, "," +554, 7, 6, 126, 26, 32, 654, 660, "double" +554, 7, 7, 127, 33, 34, 661, 662, "-" +554, 7, 8, 128, 35, 41, 663, 669, "masked" +554, 7, 9, 129, 42, 43, 670, 671, "," +554, 7, 10, 130, 44, 50, 672, 678, "active" +554, 7, 11, 131, 51, 52, 679, 680, "-" +554, 7, 12, 132, 53, 63, 681, 691, "controlled" +554, 7, 13, 133, 64, 74, 692, 702, "comparison" +554, 7, 14, 134, 75, 77, 703, 705, "in" +554, 7, 15, 135, 78, 83, 706, 711, "which" +554, 7, 16, 136, 84, 93, 712, 721, "qualified" +554, 7, 17, 137, 94, 102, 722, 730, "subjects" +554, 7, 18, 138, 103, 106, 731, 734, "had" +554, 7, 19, 139, 107, 110, 735, 738, "all" +554, 7, 20, 140, 111, 119, 739, 747, "glaucoma" +554, 7, 21, 141, 120, 129, 748, 757, "medicines" +554, 7, 22, 142, 130, 142, 758, 770, "discontinued" +554, 7, 23, 143, 143, 146, 771, 774, "for" +554, 7, 24, 144, 147, 148, 775, 776, "1" +554, 7, 25, 145, 149, 154, 777, 782, "month" +554, 7, 26, 146, 155, 158, 783, 786, "and" +554, 7, 27, 147, 159, 163, 787, 791, "then" +554, 7, 28, 148, 164, 168, 792, 796, "were" +554, 7, 29, 149, 169, 179, 797, 807, "randomized" +554, 7, 30, 150, 180, 182, 808, 810, "to" +554, 7, 31, 151, 183, 189, 811, 817, "either" +554, 7, 32, 152, 190, 194, 818, 822, "LTFC" +554, 7, 33, 153, 195, 197, 823, 825, "or" +554, 7, 34, 154, 198, 209, 826, 837, "brimonidine" +554, 7, 35, 155, 210, 213, 838, 841, "and" +554, 7, 36, 156, 214, 225, 842, 853, "latanoprost" +554, 7, 37, 157, 226, 237, 854, 865, "concomitant" +554, 7, 38, 158, 238, 245, 866, 873, "therapy" +554, 7, 39, 159, 246, 249, 874, 877, "for" +554, 7, 40, 160, 250, 251, 878, 879, "6" +554, 7, 41, 161, 252, 257, 880, 885, "weeks" +554, 7, 42, 162, 258, 259, 886, 887, "." +554, 8, 1, 163, 0, 4, 888, 892, "They" +554, 8, 2, 164, 5, 9, 893, 897, "were" +554, 8, 3, 165, 10, 14, 898, 902, "then" +554, 8, 4, 166, 15, 23, 903, 911, "switched" +554, 8, 5, 167, 24, 26, 912, 914, "to" +554, 8, 6, 168, 27, 30, 915, 918, "the" +554, 8, 7, 169, 31, 36, 919, 924, "other" +554, 8, 8, 170, 37, 46, 925, 934, "treatment" +554, 8, 9, 171, 47, 54, 935, 942, "regimen" +554, 8, 10, 172, 55, 56, 943, 944, "." +554, 9, 1, 173, 0, 3, 945, 948, "The" +554, 9, 2, 174, 4, 15, 949, 960, "intraocular" +554, 9, 3, 175, 16, 24, 961, 969, "pressure" +554, 9, 4, 176, 25, 26, 970, 971, "(" +554, 9, 5, 177, 27, 30, 972, 975, "IOP" +554, 9, 6, 178, 31, 32, 976, 977, ")" +554, 9, 7, 179, 33, 36, 978, 981, "was" +554, 9, 8, 180, 37, 45, 982, 990, "measured" +554, 9, 9, 181, 46, 48, 991, 993, "at" +554, 9, 10, 182, 49, 53, 994, 998, "0800" +554, 9, 11, 183, 54, 55, 999, 1000, "," +554, 9, 12, 184, 56, 60, 1001, 1005, "1200" +554, 9, 13, 185, 61, 62, 1006, 1007, "," +554, 9, 14, 186, 63, 66, 1008, 1011, "and" +554, 9, 15, 187, 67, 71, 1012, 1016, "1600" +554, 9, 16, 188, 72, 73, 1017, 1018, "h" +554, 9, 17, 189, 74, 76, 1019, 1021, "at" +554, 9, 18, 190, 77, 85, 1022, 1030, "baseline" +554, 9, 19, 191, 86, 89, 1031, 1034, "and" +554, 9, 20, 192, 90, 92, 1035, 1037, "at" +554, 9, 21, 193, 93, 96, 1038, 1041, "the" +554, 9, 22, 194, 97, 100, 1042, 1045, "end" +554, 9, 23, 195, 101, 103, 1046, 1048, "of" +554, 9, 24, 196, 104, 111, 1049, 1056, "Periods" +554, 9, 25, 197, 112, 113, 1057, 1058, "1" +554, 9, 26, 198, 114, 117, 1059, 1062, "and" +554, 9, 27, 199, 118, 124, 1063, 1069, "Period" +554, 9, 28, 200, 125, 126, 1070, 1071, "2" +554, 9, 29, 201, 127, 128, 1072, 1073, "." +554, 10, 1, 202, 0, 7, 1074, 1081, "RESULTS" +554, 10, 2, 203, 8, 9, 1082, 1083, ":" +554, 10, 3, 204, 10, 12, 1084, 1086, "In" +554, 10, 4, 205, 13, 15, 1087, 1089, "32" +554, 10, 5, 206, 16, 24, 1090, 1098, "subjects" +554, 10, 6, 207, 25, 26, 1099, 1100, "," +554, 10, 7, 208, 27, 30, 1101, 1104, "the" +554, 10, 8, 209, 31, 38, 1105, 1112, "diurnal" +554, 10, 9, 210, 39, 44, 1113, 1118, "curve" +554, 10, 10, 211, 45, 47, 1119, 1121, "of" +554, 10, 11, 212, 48, 51, 1122, 1125, "the" +554, 10, 12, 213, 52, 61, 1126, 1135, "untreated" +554, 10, 13, 214, 62, 65, 1136, 1139, "IOP" +554, 10, 14, 215, 66, 68, 1140, 1142, "of" +554, 10, 15, 216, 69, 71, 1143, 1145, "26" +554, 10, 16, 217, 72, 73, 1146, 1147, "." +554, 10, 17, 218, 74, 75, 1148, 1149, "0" +554, 10, 18, 219, 76, 77, 1150, 1151, "+" +554, 10, 19, 220, 78, 79, 1152, 1153, "/" +554, 10, 20, 221, 80, 81, 1154, 1155, "-" +554, 10, 21, 222, 82, 83, 1156, 1157, "3" +554, 10, 22, 223, 84, 85, 1158, 1159, "." +554, 10, 23, 224, 86, 87, 1160, 1161, "4" +554, 10, 24, 225, 88, 97, 1162, 1171, "decreased" +554, 10, 25, 226, 98, 100, 1172, 1174, "to" +554, 10, 26, 227, 101, 103, 1175, 1177, "17" +554, 10, 27, 228, 104, 105, 1178, 1179, "." +554, 10, 28, 229, 106, 107, 1180, 1181, "8" +554, 10, 29, 230, 108, 109, 1182, 1183, "+" +554, 10, 30, 231, 110, 111, 1184, 1185, "/" +554, 10, 31, 232, 112, 113, 1186, 1187, "-" +554, 10, 32, 233, 114, 115, 1188, 1189, "2" +554, 10, 33, 234, 116, 117, 1190, 1191, "." +554, 10, 34, 235, 118, 119, 1192, 1193, "5" +554, 10, 35, 236, 120, 122, 1194, 1196, "on" +554, 10, 36, 237, 123, 127, 1197, 1201, "LTFC" +554, 10, 37, 238, 128, 131, 1202, 1205, "and" +554, 10, 38, 239, 132, 134, 1206, 1208, "17" +554, 10, 39, 240, 135, 136, 1209, 1210, "." +554, 10, 40, 241, 137, 138, 1211, 1212, "2" +554, 10, 41, 242, 139, 140, 1213, 1214, "+" +554, 10, 42, 243, 141, 142, 1215, 1216, "/" +554, 10, 43, 244, 143, 144, 1217, 1218, "-" +554, 10, 44, 245, 145, 146, 1219, 1220, "2" +554, 10, 45, 246, 147, 148, 1221, 1222, "." +554, 10, 46, 247, 149, 150, 1223, 1224, "8" +554, 10, 47, 248, 151, 155, 1225, 1229, "mmHg" +554, 10, 48, 249, 156, 158, 1230, 1232, "on" +554, 10, 49, 250, 159, 170, 1233, 1244, "brimonidine" +554, 10, 50, 251, 171, 174, 1245, 1248, "and" +554, 10, 51, 252, 175, 186, 1249, 1260, "latanoprost" +554, 10, 52, 253, 187, 188, 1261, 1262, "(" +554, 10, 53, 254, 189, 190, 1263, 1264, "P" +554, 10, 54, 255, 191, 192, 1265, 1266, "=" +554, 10, 55, 256, 193, 194, 1267, 1268, "0" +554, 10, 56, 257, 195, 196, 1269, 1270, "." +554, 10, 57, 258, 197, 199, 1271, 1273, "31" +554, 10, 58, 259, 200, 201, 1274, 1275, ")" +554, 10, 59, 260, 202, 203, 1276, 1277, "." +554, 11, 1, 261, 0, 2, 1278, 1280, "At" +554, 11, 2, 262, 3, 7, 1281, 1285, "0800" +554, 11, 3, 263, 8, 11, 1286, 1289, "and" +554, 11, 4, 264, 12, 16, 1290, 1294, "1600" +554, 11, 5, 265, 17, 18, 1295, 1296, "h" +554, 11, 6, 266, 19, 20, 1297, 1298, "," +554, 11, 7, 267, 21, 24, 1299, 1302, "the" +554, 11, 8, 268, 25, 29, 1303, 1307, "IOPs" +554, 11, 9, 269, 30, 34, 1308, 1312, "were" +554, 11, 10, 270, 35, 48, 1313, 1326, "statistically" +554, 11, 11, 271, 49, 56, 1327, 1334, "similar" +554, 11, 12, 272, 57, 64, 1335, 1342, "between" +554, 11, 13, 273, 65, 68, 1343, 1346, "the" +554, 11, 14, 274, 69, 75, 1347, 1353, "groups" +554, 11, 15, 275, 76, 77, 1354, 1355, "(" +554, 11, 16, 276, 78, 79, 1356, 1357, "P" +554, 11, 17, 277, 80, 81, 1358, 1359, "&" +554, 11, 18, 278, 82, 84, 1360, 1362, "gt" +554, 11, 19, 279, 85, 86, 1363, 1364, ";" +554, 11, 20, 280, 87, 88, 1365, 1366, "0" +554, 11, 21, 281, 89, 90, 1367, 1368, "." +554, 11, 22, 282, 91, 93, 1369, 1371, "05" +554, 11, 23, 283, 94, 95, 1372, 1373, ")" +554, 11, 24, 284, 96, 97, 1374, 1375, "." +554, 12, 1, 285, 0, 2, 1376, 1378, "At" +554, 12, 2, 286, 3, 7, 1379, 1383, "1200" +554, 12, 3, 287, 8, 9, 1384, 1385, "h" +554, 12, 4, 288, 10, 13, 1386, 1389, "the" +554, 12, 5, 289, 14, 25, 1390, 1401, "latanoprost" +554, 12, 6, 290, 26, 29, 1402, 1405, "and" +554, 12, 7, 291, 30, 41, 1406, 1417, "brimonidine" +554, 12, 8, 292, 42, 51, 1418, 1427, "treatment" +554, 12, 9, 293, 52, 55, 1428, 1431, "IOP" +554, 12, 10, 294, 56, 59, 1432, 1435, "was" +554, 12, 11, 295, 60, 73, 1436, 1449, "statistically" +554, 12, 12, 296, 74, 79, 1450, 1455, "lower" +554, 12, 13, 297, 80, 81, 1456, 1457, "(" +554, 12, 14, 298, 82, 84, 1458, 1460, "16" +554, 12, 15, 299, 85, 86, 1461, 1462, "." +554, 12, 16, 300, 87, 88, 1463, 1464, "2" +554, 12, 17, 301, 89, 90, 1465, 1466, "+" +554, 12, 18, 302, 91, 92, 1467, 1468, "/" +554, 12, 19, 303, 93, 94, 1469, 1470, "-" +554, 12, 20, 304, 95, 96, 1471, 1472, "3" +554, 12, 21, 305, 97, 98, 1473, 1474, "." +554, 12, 22, 306, 99, 100, 1475, 1476, "2" +554, 12, 23, 307, 101, 102, 1477, 1478, ")" +554, 12, 24, 308, 103, 107, 1479, 1483, "than" +554, 12, 25, 309, 108, 112, 1484, 1488, "LTFC" +554, 12, 26, 310, 113, 114, 1489, 1490, "(" +554, 12, 27, 311, 115, 117, 1491, 1493, "18" +554, 12, 28, 312, 118, 119, 1494, 1495, "." +554, 12, 29, 313, 120, 121, 1496, 1497, "0" +554, 12, 30, 314, 122, 123, 1498, 1499, "+" +554, 12, 31, 315, 124, 125, 1500, 1501, "/" +554, 12, 32, 316, 126, 127, 1502, 1503, "-" +554, 12, 33, 317, 128, 129, 1504, 1505, "2" +554, 12, 34, 318, 130, 131, 1506, 1507, "." +554, 12, 35, 319, 132, 133, 1508, 1509, "8" +554, 12, 36, 320, 134, 138, 1510, 1514, "mmHg" +554, 12, 37, 321, 139, 140, 1515, 1516, ")" +554, 12, 38, 322, 141, 142, 1517, 1518, "." +554, 13, 1, 323, 0, 7, 1519, 1526, "However" +554, 13, 2, 324, 8, 9, 1527, 1528, "," +554, 13, 3, 325, 10, 13, 1529, 1532, "the" +554, 13, 4, 326, 14, 21, 1533, 1540, "reduced" +554, 13, 5, 327, 22, 25, 1541, 1544, "IOP" +554, 13, 6, 328, 26, 30, 1545, 1549, "from" +554, 13, 7, 329, 31, 40, 1550, 1559, "untreated" +554, 13, 8, 330, 41, 49, 1560, 1568, "baseline" +554, 13, 9, 331, 50, 53, 1569, 1572, "was" +554, 13, 10, 332, 54, 57, 1573, 1576, "not" +554, 13, 11, 333, 58, 71, 1577, 1590, "statistically" +554, 13, 12, 334, 72, 81, 1591, 1600, "different" +554, 13, 13, 335, 82, 84, 1601, 1603, "at" +554, 13, 14, 336, 85, 89, 1604, 1608, "each" +554, 13, 15, 337, 90, 94, 1609, 1613, "time" +554, 13, 16, 338, 95, 100, 1614, 1619, "point" +554, 13, 17, 339, 101, 104, 1620, 1623, "and" +554, 13, 18, 340, 105, 108, 1624, 1627, "for" +554, 13, 19, 341, 109, 112, 1628, 1631, "the" +554, 13, 20, 342, 113, 120, 1632, 1639, "diurnal" +554, 13, 21, 343, 121, 126, 1640, 1645, "curve" +554, 13, 22, 344, 127, 130, 1646, 1649, "for" +554, 13, 23, 345, 131, 135, 1650, 1654, "each" +554, 13, 24, 346, 136, 143, 1655, 1662, "therapy" +554, 13, 25, 347, 144, 145, 1663, 1664, "(" +554, 13, 26, 348, 146, 147, 1665, 1666, "P" +554, 13, 27, 349, 148, 149, 1667, 1668, "&" +554, 13, 28, 350, 150, 152, 1669, 1671, "lt" +554, 13, 29, 351, 153, 154, 1672, 1673, ";" +554, 13, 30, 352, 155, 156, 1674, 1675, "0" +554, 13, 31, 353, 157, 158, 1676, 1677, "." +554, 13, 32, 354, 159, 161, 1678, 1680, "05" +554, 13, 33, 355, 162, 163, 1681, 1682, ")" +554, 13, 34, 356, 164, 165, 1683, 1684, "." +554, 14, 1, 357, 0, 6, 1685, 1691, "Safety" +554, 14, 2, 358, 7, 10, 1692, 1695, "was" +554, 14, 3, 359, 11, 18, 1696, 1703, "similar" +554, 14, 4, 360, 19, 26, 1704, 1711, "between" +554, 14, 5, 361, 27, 33, 1712, 1718, "groups" +554, 14, 6, 362, 34, 37, 1719, 1722, "for" +554, 14, 7, 363, 38, 42, 1723, 1727, "both" +554, 14, 8, 364, 43, 52, 1728, 1737, "solicited" +554, 14, 9, 365, 53, 56, 1738, 1741, "and" +554, 14, 10, 366, 57, 68, 1742, 1753, "unsolicited" +554, 14, 11, 367, 69, 73, 1754, 1758, "side" +554, 14, 12, 368, 74, 81, 1759, 1766, "effects" +554, 14, 13, 369, 82, 83, 1767, 1768, "(" +554, 14, 14, 370, 84, 85, 1769, 1770, "P" +554, 14, 15, 371, 86, 87, 1771, 1772, "&" +554, 14, 16, 372, 88, 90, 1773, 1775, "gt" +554, 14, 17, 373, 91, 92, 1776, 1777, ";" +554, 14, 18, 374, 93, 94, 1778, 1779, "0" +554, 14, 19, 375, 95, 96, 1780, 1781, "." +554, 14, 20, 376, 97, 99, 1782, 1784, "05" +554, 14, 21, 377, 100, 101, 1785, 1786, ")" +554, 14, 22, 378, 102, 103, 1787, 1788, "." +554, 15, 1, 379, 0, 10, 1789, 1799, "CONCLUSION" +554, 15, 2, 380, 11, 12, 1800, 1801, ":" +554, 15, 3, 381, 13, 17, 1802, 1806, "This" +554, 15, 4, 382, 18, 23, 1807, 1812, "study" +554, 15, 5, 383, 24, 32, 1813, 1821, "suggests" +554, 15, 6, 384, 33, 37, 1822, 1826, "that" +554, 15, 7, 385, 38, 42, 1827, 1831, "LTFC" +554, 15, 8, 386, 43, 46, 1832, 1835, "and" +554, 15, 9, 387, 47, 58, 1836, 1847, "concomitant" +554, 15, 10, 388, 59, 66, 1848, 1855, "therapy" +554, 15, 11, 389, 67, 69, 1856, 1858, "of" +554, 15, 12, 390, 70, 81, 1859, 1870, "brimonidine" +554, 15, 13, 391, 82, 85, 1871, 1874, "and" +554, 15, 14, 392, 86, 97, 1875, 1886, "latanoprost" +554, 15, 15, 393, 98, 105, 1887, 1894, "provide" +554, 15, 16, 394, 106, 119, 1895, 1908, "statistically" +554, 15, 17, 395, 120, 127, 1909, 1916, "similar" +554, 15, 18, 396, 128, 135, 1917, 1924, "diurnal" +554, 15, 19, 397, 136, 139, 1925, 1928, "IOP" +554, 15, 20, 398, 140, 149, 1929, 1938, "reduction" +554, 15, 21, 399, 150, 154, 1939, 1943, "from" +554, 15, 22, 400, 155, 157, 1944, 1946, "an" +554, 15, 23, 401, 158, 167, 1947, 1956, "untreated" +554, 15, 24, 402, 168, 176, 1957, 1965, "baseline" +554, 15, 25, 403, 177, 178, 1966, 1967, "." +554, 16, 1, 404, 0, 3, 1968, 1971, "DOI" +554, 16, 2, 405, 4, 5, 1972, 1973, ":" +554, 16, 3, 406, 6, 8, 1974, 1976, "10" +554, 16, 4, 407, 9, 10, 1977, 1978, "." +554, 16, 5, 408, 11, 15, 1979, 1983, "1038" +554, 16, 6, 409, 16, 17, 1984, 1985, "/" +554, 16, 7, 410, 18, 20, 1986, 1988, "sj" +554, 16, 8, 411, 21, 22, 1989, 1990, "." +554, 16, 9, 412, 23, 26, 1991, 1994, "eye" +554, 16, 10, 413, 27, 28, 1995, 1996, "." +554, 16, 11, 414, 29, 36, 1997, 2004, "6701375" +554, 16, 12, 415, 37, 41, 2005, 2009, "PMID" +554, 16, 13, 416, 42, 43, 2010, 2011, ":" +554, 16, 14, 417, 44, 52, 2012, 2020, "15037890" +554, 16, 15, 418, 53, 54, 2021, 2022, "[" +554, 16, 16, 419, 55, 62, 2023, 2030, "Indexed" +554, 16, 17, 420, 63, 66, 2031, 2034, "for" +554, 16, 18, 421, 67, 74, 2035, 2042, "MEDLINE" +554, 16, 19, 422, 75, 76, 2043, 2044, "]" diff --git a/data/gl 15037890_jshahinitiran.annodb b/data/gl 15037890_jshahinitiran.annodb new file mode 100644 index 0000000..e66269f --- /dev/null +++ b/data/gl 15037890_jshahinitiran.annodb @@ -0,0 +1,74 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84024, Journal, 0, 12, "Eye ( Lond )", "", +84025, PublicationYear, 15, 19, "2004", "", +84026, Title, 48, 175, "Efficacy and safety of the latanoprost / timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy .", "", +84027, Latanoprost, 75, 86, "latanoprost", "", +84029, Lat/TimFC, 75, 122, "latanoprost / timolol maleate fixed combination", "", +84028, Timolol, 89, 104, "timolol maleate", "", +84030, Brimonidine, 138, 149, "brimonidine", "", +84031, Latanoprost, 154, 165, "latanoprost", "", +84032, Author, 176, 186, "Stewart WC", "", +84033, Author, 195, 205, "Stewart JA", "", +84034, Author, 208, 214, "Day DG", "", +84035, Author, 217, 226, "Sharpe ED", "", +84036, Author, 229, 241, "Jenkins JN .", "", +84037, USA, 331, 334, "USA", "", +84038, ObjectiveDescription, 367, 479, "To evaluate the efficacy and safety of latanoprost / timolol maleate fixed combination ( LTFC ) given once daily", "", +84040, Latanoprost, 406, 417, "latanoprost", "", +84042, Lat/TimFC, 406, 453, "latanoprost / timolol maleate fixed combination", "", +84041, Timolol, 420, 435, "timolol maleate", "", +84043, Lat/TimFC, 456, 460, "LTFC", "", +84044, Frequency, 469, 479, "once daily", "", +84039, ObjectiveDescription, 480, 627, "vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open - angle glaucoma or ocular hypertensive subjects .", "", +84045, Brimonidine, 510, 521, "brimonidine", "", +84046, Frequency, 522, 533, "twice daily", "", +84047, Latanoprost, 538, 549, "latanoprost", "", +84048, Frequency, 550, 560, "once daily", "", +84049, Primary_OpenAngleGlaucoma, 564, 593, "primary open - angle glaucoma", "", +84050, OcularHypertension, 597, 616, "ocular hypertensive", "", +84051, Prospective, 640, 651, "prospective", "", +84052, DoubleBlind, 654, 669, "double - masked", "", +84053, CTDesign, 672, 691, "active - controlled", "", +84055, Precondition, 735, 782, "all glaucoma medicines discontinued for 1 month", "", +84054, Glaucoma, 739, 747, "glaucoma", "", +84056, Randomized, 797, 807, "randomized", "", +84057, Lat/TimFC, 818, 822, "LTFC", "", +84058, Brimonidine, 826, 837, "brimonidine", "", +84059, Latanoprost, 842, 853, "latanoprost", "", +84060, Duration, 878, 885, "6 weeks", "", +84061, IOP, 949, 969, "intraocular pressure", "", +84062, IOP, 972, 975, "IOP", "", +84063, BaseLineValue, 1022, 1030, "baseline", "", +84064, NumberPatientsCT, 1087, 1089, "32", "", +84065, Diurnal_IOP, 1136, 1139, "IOP", "", +84066, BaseLineValue, 1143, 1149, "26 . 0", "", +84067, SdErrorBL, 1156, 1161, "3 . 4", "", +84068, ResultMeasuredValue, 1175, 1181, "17 . 8", "", +84070, SdErrorResValue, 1188, 1193, "2 . 5", "", +84072, Lat/TimFC, 1197, 1201, "LTFC", "", +84069, ResultMeasuredValue, 1206, 1212, "17 . 2", "", +84071, SdErrorResValue, 1219, 1224, "2 . 8", "", +84073, mmHg, 1225, 1229, "mmHg", "", +84074, Brimonidine, 1233, 1244, "brimonidine", "", +84075, Latanoprost, 1249, 1260, "latanoprost", "", +84076, PValueResValue, 1263, 1273, "P = 0 . 31", "", +84077, IOP, 1303, 1307, "IOPs", "", +84078, PValueResValue, 1356, 1371, "P & gt ; 0 . 05", "", +84079, Latanoprost, 1390, 1401, "latanoprost", "", +84080, Brimonidine, 1406, 1417, "brimonidine", "", +84081, IOP, 1428, 1431, "IOP", "", +84082, ResultMeasuredValue, 1458, 1464, "16 . 2", "", +84084, SdErrorResValue, 1471, 1476, "3 . 2", "", +84086, Lat/TimFC, 1484, 1488, "LTFC", "", +84083, ResultMeasuredValue, 1491, 1497, "18 . 0", "", +84085, SdErrorResValue, 1504, 1509, "2 . 8", "", +84087, mmHg, 1510, 1514, "mmHg", "", +84088, IOP, 1541, 1544, "IOP", "", +84089, PValueResValue, 1665, 1680, "P & lt ; 0 . 05", "", +84090, PValueNumAffected, 1769, 1784, "P & gt ; 0 . 05", "", +84091, ConclusionComment, 1802, 1967, "This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline .", "", +84092, Lat/TimFC, 1827, 1831, "LTFC", "", +84093, Brimonidine, 1859, 1870, "brimonidine", "", +84094, Latanoprost, 1875, 1886, "latanoprost", "", +84095, Diurnal_IOP, 1917, 1928, "diurnal IOP", "", +84096, PMID, 2012, 2020, "15037890", "", diff --git a/data/gl 15037890_jshahinitiran.n-triples b/data/gl 15037890_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15037890_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15037890_tstrakeljahn.annodb b/data/gl 15037890_tstrakeljahn.annodb new file mode 100644 index 0000000..dd16b27 --- /dev/null +++ b/data/gl 15037890_tstrakeljahn.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +85693, Journal, 0, 12, "Eye ( Lond )", "", +85694, PublicationYear, 15, 19, "2004", "", +85700, Title, 48, 175, "Efficacy and safety of the latanoprost / timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy .", "", +85695, Latanoprost, 75, 86, "latanoprost", "", +85699, Lat/TimFC, 75, 104, "latanoprost / timolol maleate", "", +85696, Timolol, 89, 104, "timolol maleate", "", +85697, Brimonidine, 138, 149, "brimonidine", "", +85698, Latanoprost, 154, 165, "latanoprost", "", +85701, Author, 176, 186, "Stewart WC", "", +85702, Author, 195, 205, "Stewart JA", "", +85703, Author, 208, 214, "Day DG", "", +85704, Author, 217, 226, "Sharpe ED", "", +85705, Author, 229, 239, "Jenkins JN", "", +85707, USA, 331, 334, "USA", "", +85740, ObjectiveDescription, 367, 616, "To evaluate the efficacy and safety of latanoprost / timolol maleate fixed combination ( LTFC ) given once daily vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open - angle glaucoma or ocular hypertensive", "", +85711, Latanoprost, 406, 417, "latanoprost", "", +85715, Lat/TimFC, 406, 435, "latanoprost / timolol maleate", "", +85712, Timolol, 420, 435, "timolol maleate", "", +85717, Lat/TimFC, 456, 460, "LTFC", "", +85724, Frequency, 469, 479, "once daily", "", +85722, Brimonidine, 510, 521, "brimonidine", "", +85725, Frequency, 522, 533, "twice daily", "", +85719, Latanoprost, 538, 549, "latanoprost", "", +85727, Frequency, 550, 560, "once daily", "", +85728, Primary_OpenAngleGlaucoma, 564, 593, "primary open - angle glaucoma", "", +85738, OcularHypertension, 597, 625, "ocular hypertensive subjects", "", +85744, ObjectiveDescription, 617, 627, "subjects .", "", +85754, Prospective, 640, 651, "prospective", "", +85755, DoubleBlind, 654, 669, "double - masked", "", +85757, Precondition, 735, 782, "all glaucoma medicines discontinued for 1 month", "", +85756, Glaucoma, 739, 747, "glaucoma", "", +85758, Randomized, 797, 807, "randomized", "", +85759, Lat/TimFC, 818, 822, "LTFC", "", +85760, Brimonidine, 826, 837, "brimonidine", "", +85761, Latanoprost, 842, 853, "latanoprost", "", +85762, IOP, 949, 969, "intraocular pressure", "", +85763, IOP, 972, 975, "IOP", "", +85764, TimePoint, 994, 998, "0800", "", +85765, TimePoint, 1001, 1005, "1200", "", +85766, TimePoint, 1012, 1018, "1600 h", "", +85767, TimePoint, 1019, 1030, "at baseline", "", +85768, TimePoint, 1035, 1058, "at the end of Periods 1", "", +85769, TimePoint, 1035, 1071, "at the end of Periods 1 and Period 2", "", +85771, FinalNumPatientsCT, 1087, 1089, "32", "", +85772, NumberAffected, 1087, 1089, "32", "", +85770, IOP, 1136, 1139, "IOP", "", +85773, BaseLineValue, 1143, 1149, "26 . 0", "", +85774, SdDevBL, 1156, 1161, "3 . 4", "", +85775, ResultMeasuredValue, 1175, 1181, "17 . 8", "", +85777, SdDevResValue, 1188, 1193, "2 . 5", "", +85779, Lat/TimFC, 1197, 1201, "LTFC", "", +85776, ResultMeasuredValue, 1206, 1212, "17 . 2", "", +85778, SdDevResValue, 1219, 1224, "2 . 8", "", +85780, mmHg, 1225, 1229, "mmHg", "", +85781, Brimonidine, 1233, 1244, "brimonidine", "", +85782, Latanoprost, 1249, 1260, "latanoprost", "", +85783, PValueResValue, 1265, 1273, "= 0 . 31", "", +85784, TimePoint, 1281, 1285, "0800", "", +85785, TimePoint, 1290, 1296, "1600 h", "", +85786, IOP, 1303, 1307, "IOPs", "", +85787, PvalueDiff, 1358, 1371, "& gt ; 0 . 05", "", +85788, TimePoint, 1379, 1385, "1200 h", "", +85789, Latanoprost, 1390, 1401, "latanoprost", "", +85790, Brimonidine, 1406, 1417, "brimonidine", "", +85791, IOP, 1428, 1431, "IOP", "", +85792, ResultMeasuredValue, 1458, 1464, "16 . 2", "", +85794, SdDevResValue, 1471, 1476, "3 . 2", "", +85797, Lat/TimFC, 1484, 1488, "LTFC", "", +85793, ResultMeasuredValue, 1491, 1497, "18 . 0", "", +85795, SdDevResValue, 1504, 1509, "2 . 8", "", +85796, mmHg, 1510, 1514, "mmHg", "", +85800, ObservedResult, 1519, 1684, "However , the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve for each therapy ( P & lt ; 0 . 05 ) .", "", +85798, IOP, 1541, 1544, "IOP", "", +85799, PvalueDiff, 1667, 1680, "& lt ; 0 . 05", "", +85802, ObservedResult, 1685, 1788, "Safety was similar between groups for both solicited and unsolicited side effects ( P & gt ; 0 . 05 ) .", "", +85801, PvalueDiff, 1771, 1784, "& gt ; 0 . 05", "", +85807, ConclusionComment, 1802, 1967, "This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline .", "", +85803, Lat/TimFC, 1827, 1831, "LTFC", "", +85804, Brimonidine, 1859, 1870, "brimonidine", "", +85805, Latanoprost, 1875, 1886, "latanoprost", "", +85806, Diurnal_IOP, 1917, 1928, "diurnal IOP", "", +85808, PMID, 2012, 2020, "15037890", "", diff --git a/data/gl 15037890_tstrakeljahn.n-triples b/data/gl 15037890_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15037890_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15094733_admin.annodb b/data/gl 15094733_admin.annodb new file mode 100644 index 0000000..9fc295c --- /dev/null +++ b/data/gl 15094733_admin.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2005", "", " \"2005\"." +45, Brimonidine, 47, 58, "Brimonidine", "", " ." +2, Title, 47, 218, "Brimonidine 0 . 2 % vs unoprostone 0 . 15 % both added to timolol maleate 0 . 5 % given twice daily to patients with primary open - angle glaucoma or ocular hypertension .", "", " \"Brimonidine 0 . 2 % vs unoprostone 0 . 15 % both added to timolol maleate 0 . 5 % given twice daily to patients with primary open - angle glaucoma or ocular hypertension .\"." +48, DoseValue, 59, 64, "0 . 2", "", " \"0 . 2\"." +51, Percentage, 65, 66, "%", "", " ." +46, Unoprostone, 70, 81, "unoprostone", "", " ." +49, DoseValue, 82, 88, "0 . 15", "", " \"0 . 15\"." +52, Percentage, 89, 90, "%", "", " ." +47, Timolol, 105, 120, "timolol maleate", "", " ." +50, DoseValue, 121, 126, "0 . 5", "", " \"0 . 5\"." +53, Percentage, 127, 128, "%", "", " ." +54, Frequency, 135, 146, "twice daily", "", " \"twice daily\". \"twice daily\"." +85404, Precondition, 150, 216, "patients with primary open - angle glaucoma or ocular hypertension", "", " \"patients with primary open - angle glaucoma or ocular hypertension\"." +55, Primary_OpenAngleGlaucoma, 164, 193, "primary open - angle glaucoma", "", " ." +3, OcularHypertension, 197, 216, "ocular hypertension", "", " ." +4, Author, 219, 228, "Sharpe ED", "", " \"Sharpe ED\"." +5, Author, 237, 245, "Henry CJ", "", " \"Henry CJ\"." +6, Author, 248, 258, "Mundorf TK", "", " \"Mundorf TK\"." +7, Author, 261, 267, "Day DG", "", " \"Day DG\"." +8, Author, 270, 280, "Stewart JA", "", " \"Stewart JA\"." +9, Author, 283, 293, "Jenkins JN", "", " \"Jenkins JN\"." +10, Author, 296, 306, "Stewart WC", "", " \"Stewart WC\"." +11, USA, 383, 386, "USA", "", " ." +12, ObjectiveDescription, 399, 545, "To compare the efficacy and safety of brimonidine 0 . 2 % vs unoprostone 0 . 15 % , both added to timolol maleate 0 . 5 % each given twice daily .", "", " \"To compare the efficacy and safety of brimonidine 0 . 2 % vs unoprostone 0 . 15 % , both added to timolol maleate 0 . 5 % each given twice daily .\"." +56, Brimonidine, 437, 448, "brimonidine", "", +59, DoseValue, 449, 454, "0 . 2", "", +62, Percentage, 455, 456, "%", "", +57, Unoprostone, 460, 471, "unoprostone", "", +60, DoseValue, 472, 478, "0 . 15", "", +63, Percentage, 479, 480, "%", "", +58, Timolol, 497, 512, "timolol maleate", "", +61, DoseValue, 513, 518, "0 . 5", "", +64, Percentage, 519, 520, "%", "", +65, Frequency, 532, 543, "twice daily", "", +124, Prospective, 564, 575, "prospective", "", " ." +14, Multicenter, 578, 593, "multi - centred", "", " ." +15, DoubleBlind, 596, 611, "double - masked", "", " ." +16, Crossover, 614, 623, "crossover", "", " ." +17, Randomized, 651, 661, "randomized", "", " ." +18, Duration, 691, 699, "6 - week", "", " \"6 - week\"." +66, Crossover, 728, 740, "crossed over", "", +85407, TimePoint, 800, 804, "0800", "", +85408, TimePoint, 807, 811, "1000", "", +85409, TimePoint, 814, 818, "1600", "", +85410, TimePoint, 821, 825, "1800", "", +85411, TimePoint, 832, 836, "2000", "", +85406, TimePoint, 842, 850, "baseline", "", +19, NumberPatientsCT, 912, 914, "33", "", " \"33\"." +20, FinalNumPatientsCT, 947, 949, "29", "", " \"29\"." +67, Trough_IOP, 975, 1002, "trough intraocular pressure", "", " ." +137, IOP, 1005, 1008, "IOP", "", +21, BaseLineValue, 1015, 1021, "23 . 3", "", " \"23 . 3\". \"23 . 3\"." +140, SdDevBL, 1028, 1033, "2 . 4", "", " \"2 . 4\". \"2 . 4\"." +23, Diurnal_IOP, 1042, 1059, "diurnal curve IOP", "", " ." +24, BaseLineValue, 1064, 1070, "22 . 0", "", " \"22 . 0\". \"22 . 0\"." +143, SdDevBL, 1077, 1082, "1 . 3", "", " \"1 . 3\". \"1 . 3\"." +26, mmHg, 1083, 1087, "mmHg", "", " . ." +69, Brimonidine, 1098, 1109, "brimonidine", "", +70, Timolol, 1114, 1129, "timolol maleate", "", +71, Trough_IOP, 1152, 1162, "trough IOP", "", +27, ResultMeasuredValue, 1167, 1173, "21 . 6", "", " \"21 . 6\"." +97106, SdDevResValue, 1180, 1185, "3 . 3", "", " \"3 . 3\"." +72, Diurnal_IOP, 1194, 1211, "diurnal curve IOP", "", +29, ResultMeasuredValue, 1216, 1222, "19 . 8", "", " \"19 . 8\"." +97107, SdDevResValue, 1229, 1234, "2 . 1", "", " \"2 . 1\"." +31, mmHg, 1235, 1239, "mmHg", "", +73, Timolol, 1252, 1259, "timolol", "", +74, Unoprostone, 1264, 1275, "unoprostone", "", +75, Trough_IOP, 1295, 1305, "trough IOP", "", +32, ResultMeasuredValue, 1309, 1315, "20 . 9", "", " \"20 . 9\"." +97108, SdDevResValue, 1322, 1327, "3 . 8", "", " \"3 . 8\"." +76, Diurnal_IOP, 1334, 1351, "diurnal curve IOP", "", +34, ResultMeasuredValue, 1355, 1361, "19 . 3", "", " \"19 . 3\"." +97109, SdDevResValue, 1368, 1373, "2 . 4", "", " \"2 . 4\"." +36, mmHg, 1374, 1378, "mmHg", "", +164, ObservedResult, 1381, 1534, "There was no significant difference between treatment groups at any time point for the diurnal curve , or in the reduction from baseline ( P > 0 . 05 ) .", "", +77, Diurnal_IOP, 1468, 1481, "diurnal curve", "", +42, PvalueDiff, 1520, 1530, "P > 0 . 05", "", " \"P > 0 . 05\"." +78, IOP, 1586, 1589, "IOP", "", +85412, TimePoint, 1607, 1613, "1800 h", "", +39, ObservedResult, 1749, 1852, "more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey .", "", " \"more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey .\". \"more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey .\"." +37, EndPointDescription, 1754, 1761, "dryness", "", " . ." +85413, PvalueDiff, 1764, 1774, "P = 0 . 02", "", +38, EndPointDescription, 1781, 1788, "burning", "", " . ." +169, PvalueDiff, 1811, 1821, "< 0 . 0001", "", +79, Unoprostone, 1829, 1840, "unoprostone", "", +40, ConclusionComment, 1866, 2017, "Brimonidine 0 . 2 % or unoprostone 0 . 15 % added to timolol maleate 0 . 5 % provide similar efficacy and safety throughout the daytime diurnal curve .", "", " \"Brimonidine 0 . 2 % or unoprostone 0 . 15 % added to timolol maleate 0 . 5 % provide similar efficacy and safety throughout the daytime diurnal curve .\"." +80, Brimonidine, 1866, 1877, "Brimonidine", "", +83, DoseValue, 1878, 1883, "0 . 2", "", +86, Percentage, 1884, 1885, "%", "", +81, Unoprostone, 1889, 1900, "unoprostone", "", +84, DoseValue, 1901, 1907, "0 . 15", "", +87, Percentage, 1908, 1909, "%", "", +82, Timolol, 1919, 1934, "timolol maleate", "", +85, DoseValue, 1935, 1940, "0 . 5", "", +88, Percentage, 1941, 1942, "%", "", +89, Diurnal_IOP, 2002, 2015, "diurnal curve", "", +41, PMID, 2062, 2070, "15094733", "", " \"15094733\"." diff --git a/data/gl 15094733_admin.n-triples b/data/gl 15094733_admin.n-triples new file mode 100644 index 0000000..8c1fce4 --- /dev/null +++ b/data/gl 15094733_admin.n-triples @@ -0,0 +1,164 @@ +# RDF export of group: Publication + . + "Publication" . + "Brimonidine 0 . 2 % vs unoprostone 0 . 15 % both added to timolol maleate 0 . 5 % given twice daily to patients with primary open - angle glaucoma or ocular hypertension ." . + "Sharpe ED" . + "2005" . + "Eye ( Lond ) ." . + "15094733" . + . + "Henry CJ" . + "Mundorf TK" . + "Day DG" . + "Stewart JA" . + "Jenkins JN" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and safety of brimonidine 0 . 2 % vs unoprostone 0 . 15 % , both added to timolol maleate 0 . 5 % each given twice daily ." . + "33" . + "6 - week" . + . + . + . + "Brimonidine 0 . 2 % or unoprostone 0 . 15 % added to timolol maleate 0 . 5 % provide similar efficacy and safety throughout the daytime diurnal curve ." . + . + . + . + . + . + "29" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-tiop" . + . + . + . + . + . + "Endpoint-diop" . + . + . + . + . + . + "Endpoint-dryness" . + . + . + . + . + . + . + "Endpoint-burning" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-tim-bri" . + . + . + . + . + . + . + "Arm-tim-uno" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-tim-bri" . + . + "twice daily" . + . + . + . + "Intervention-tim-uno" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication-tim" . + . + "0 . 5" . + . + . + . + "Medication-bri" . + . + "0 . 2" . + . + . + . + "Medication-uno" . + . + "0 . 15" . + . + . +# RDF export of group: Outcome + . + "Outcome-tiop-bri" . + . + "23 . 3" . + "2 . 4" . + "21 . 6" . + "3 . 3" . + . + "Outcome-tiop-uno" . + . + "23 . 3" . + "2 . 4" . + "20 . 9" . + "3 . 8" . + . + "Outcome-diop-bri" . + . + "22 . 0" . + "1 . 3" . + "19 . 8" . + "2 . 1" . + . + "Outcome-diop-uno" . + . + "22 . 0" . + "1 . 3" . + "19 . 3" . + "2 . 4" . + . + "Outcome_dryness" . + . + "more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey ." . + . + "Outcome_burning" . + . + "more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-diop" . + "P > 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15094733_export.csv b/data/gl 15094733_export.csv new file mode 100644 index 0000000..b20561c --- /dev/null +++ b/data/gl 15094733_export.csv @@ -0,0 +1,463 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +464, 1, 1, 1, 0, 3, 0, 3, "Eye" +464, 1, 2, 2, 4, 5, 4, 5, "(" +464, 1, 3, 3, 6, 10, 6, 10, "Lond" +464, 1, 4, 4, 11, 12, 11, 12, ")" +464, 1, 5, 5, 13, 14, 13, 14, "." +464, 2, 1, 6, 0, 4, 15, 19, "2005" +464, 2, 2, 7, 5, 8, 20, 23, "Jan" +464, 2, 3, 8, 9, 10, 24, 25, ";" +464, 2, 4, 9, 11, 13, 26, 28, "19" +464, 2, 5, 10, 14, 15, 29, 30, "(" +464, 2, 6, 11, 16, 17, 31, 32, "1" +464, 2, 7, 12, 18, 19, 33, 34, ")" +464, 2, 8, 13, 20, 21, 35, 36, ":" +464, 2, 9, 14, 22, 24, 37, 39, "35" +464, 2, 10, 15, 25, 26, 40, 41, "-" +464, 2, 11, 16, 27, 29, 42, 44, "40" +464, 2, 12, 17, 30, 31, 45, 46, "." +464, 3, 1, 18, 0, 11, 47, 58, "Brimonidine" +464, 3, 2, 19, 12, 13, 59, 60, "0" +464, 3, 3, 20, 14, 15, 61, 62, "." +464, 3, 4, 21, 16, 17, 63, 64, "2" +464, 3, 5, 22, 18, 19, 65, 66, "%" +464, 3, 6, 23, 20, 22, 67, 69, "vs" +464, 3, 7, 24, 23, 34, 70, 81, "unoprostone" +464, 3, 8, 25, 35, 36, 82, 83, "0" +464, 3, 9, 26, 37, 38, 84, 85, "." +464, 3, 10, 27, 39, 41, 86, 88, "15" +464, 3, 11, 28, 42, 43, 89, 90, "%" +464, 3, 12, 29, 44, 48, 91, 95, "both" +464, 3, 13, 30, 49, 54, 96, 101, "added" +464, 3, 14, 31, 55, 57, 102, 104, "to" +464, 3, 15, 32, 58, 65, 105, 112, "timolol" +464, 3, 16, 33, 66, 73, 113, 120, "maleate" +464, 3, 17, 34, 74, 75, 121, 122, "0" +464, 3, 18, 35, 76, 77, 123, 124, "." +464, 3, 19, 36, 78, 79, 125, 126, "5" +464, 3, 20, 37, 80, 81, 127, 128, "%" +464, 3, 21, 38, 82, 87, 129, 134, "given" +464, 3, 22, 39, 88, 93, 135, 140, "twice" +464, 3, 23, 40, 94, 99, 141, 146, "daily" +464, 3, 24, 41, 100, 102, 147, 149, "to" +464, 3, 25, 42, 103, 111, 150, 158, "patients" +464, 3, 26, 43, 112, 116, 159, 163, "with" +464, 3, 27, 44, 117, 124, 164, 171, "primary" +464, 3, 28, 45, 125, 129, 172, 176, "open" +464, 3, 29, 46, 130, 131, 177, 178, "-" +464, 3, 30, 47, 132, 137, 179, 184, "angle" +464, 3, 31, 48, 138, 146, 185, 193, "glaucoma" +464, 3, 32, 49, 147, 149, 194, 196, "or" +464, 3, 33, 50, 150, 156, 197, 203, "ocular" +464, 3, 34, 51, 157, 169, 204, 216, "hypertension" +464, 3, 35, 52, 170, 171, 217, 218, "." +464, 4, 1, 53, 0, 6, 219, 225, "Sharpe" +464, 4, 2, 54, 7, 9, 226, 228, "ED" +464, 4, 3, 55, 10, 11, 229, 230, "(" +464, 4, 4, 56, 12, 13, 231, 232, "1" +464, 4, 5, 57, 14, 15, 233, 234, ")" +464, 4, 6, 58, 16, 17, 235, 236, "," +464, 4, 7, 59, 18, 23, 237, 242, "Henry" +464, 4, 8, 60, 24, 26, 243, 245, "CJ" +464, 4, 9, 61, 27, 28, 246, 247, "," +464, 4, 10, 62, 29, 36, 248, 255, "Mundorf" +464, 4, 11, 63, 37, 39, 256, 258, "TK" +464, 4, 12, 64, 40, 41, 259, 260, "," +464, 4, 13, 65, 42, 45, 261, 264, "Day" +464, 4, 14, 66, 46, 48, 265, 267, "DG" +464, 4, 15, 67, 49, 50, 268, 269, "," +464, 4, 16, 68, 51, 58, 270, 277, "Stewart" +464, 4, 17, 69, 59, 61, 278, 280, "JA" +464, 4, 18, 70, 62, 63, 281, 282, "," +464, 4, 19, 71, 64, 71, 283, 290, "Jenkins" +464, 4, 20, 72, 72, 74, 291, 293, "JN" +464, 4, 21, 73, 75, 76, 294, 295, "," +464, 4, 22, 74, 77, 84, 296, 303, "Stewart" +464, 4, 23, 75, 85, 87, 304, 306, "WC" +464, 4, 24, 76, 88, 89, 307, 308, "." +464, 5, 1, 77, 0, 6, 309, 315, "Author" +464, 5, 2, 78, 7, 18, 316, 327, "information" +464, 5, 3, 79, 19, 20, 328, 329, ":" +464, 5, 4, 80, 21, 22, 330, 331, "(" +464, 5, 5, 81, 23, 24, 332, 333, "1" +464, 5, 6, 82, 25, 26, 334, 335, ")" +464, 5, 7, 83, 27, 33, 336, 342, "Center" +464, 5, 8, 84, 34, 37, 343, 346, "for" +464, 5, 9, 85, 38, 41, 347, 350, "Eye" +464, 5, 10, 86, 42, 50, 351, 359, "Research" +464, 5, 11, 87, 51, 52, 360, 361, "," +464, 5, 12, 88, 53, 55, 362, 364, "Mt" +464, 5, 13, 89, 56, 57, 365, 366, "." +464, 6, 1, 90, 0, 8, 367, 375, "Pleasant" +464, 6, 2, 91, 9, 10, 376, 377, "," +464, 6, 3, 92, 11, 13, 378, 380, "SC" +464, 6, 4, 93, 14, 15, 381, 382, "," +464, 6, 5, 94, 16, 19, 383, 386, "USA" +464, 6, 6, 95, 20, 21, 387, 388, "." +464, 7, 1, 96, 0, 7, 389, 396, "PURPOSE" +464, 7, 2, 97, 8, 9, 397, 398, ":" +464, 7, 3, 98, 10, 12, 399, 401, "To" +464, 7, 4, 99, 13, 20, 402, 409, "compare" +464, 7, 5, 100, 21, 24, 410, 413, "the" +464, 7, 6, 101, 25, 33, 414, 422, "efficacy" +464, 7, 7, 102, 34, 37, 423, 426, "and" +464, 7, 8, 103, 38, 44, 427, 433, "safety" +464, 7, 9, 104, 45, 47, 434, 436, "of" +464, 7, 10, 105, 48, 59, 437, 448, "brimonidine" +464, 7, 11, 106, 60, 61, 449, 450, "0" +464, 7, 12, 107, 62, 63, 451, 452, "." +464, 7, 13, 108, 64, 65, 453, 454, "2" +464, 7, 14, 109, 66, 67, 455, 456, "%" +464, 7, 15, 110, 68, 70, 457, 459, "vs" +464, 7, 16, 111, 71, 82, 460, 471, "unoprostone" +464, 7, 17, 112, 83, 84, 472, 473, "0" +464, 7, 18, 113, 85, 86, 474, 475, "." +464, 7, 19, 114, 87, 89, 476, 478, "15" +464, 7, 20, 115, 90, 91, 479, 480, "%" +464, 7, 21, 116, 92, 93, 481, 482, "," +464, 7, 22, 117, 94, 98, 483, 487, "both" +464, 7, 23, 118, 99, 104, 488, 493, "added" +464, 7, 24, 119, 105, 107, 494, 496, "to" +464, 7, 25, 120, 108, 115, 497, 504, "timolol" +464, 7, 26, 121, 116, 123, 505, 512, "maleate" +464, 7, 27, 122, 124, 125, 513, 514, "0" +464, 7, 28, 123, 126, 127, 515, 516, "." +464, 7, 29, 124, 128, 129, 517, 518, "5" +464, 7, 30, 125, 130, 131, 519, 520, "%" +464, 7, 31, 126, 132, 136, 521, 525, "each" +464, 7, 32, 127, 137, 142, 526, 531, "given" +464, 7, 33, 128, 143, 148, 532, 537, "twice" +464, 7, 34, 129, 149, 154, 538, 543, "daily" +464, 7, 35, 130, 155, 156, 544, 545, "." +464, 8, 1, 131, 0, 7, 546, 553, "METHODS" +464, 8, 2, 132, 8, 9, 554, 555, ":" +464, 8, 3, 133, 10, 12, 556, 558, "In" +464, 8, 4, 134, 13, 17, 559, 563, "this" +464, 8, 5, 135, 18, 29, 564, 575, "prospective" +464, 8, 6, 136, 30, 31, 576, 577, "," +464, 8, 7, 137, 32, 37, 578, 583, "multi" +464, 8, 8, 138, 38, 39, 584, 585, "-" +464, 8, 9, 139, 40, 47, 586, 593, "centred" +464, 8, 10, 140, 48, 49, 594, 595, "," +464, 8, 11, 141, 50, 56, 596, 602, "double" +464, 8, 12, 142, 57, 58, 603, 604, "-" +464, 8, 13, 143, 59, 65, 605, 611, "masked" +464, 8, 14, 144, 66, 67, 612, 613, "," +464, 8, 15, 145, 68, 77, 614, 623, "crossover" +464, 8, 16, 146, 78, 88, 624, 634, "comparison" +464, 8, 17, 147, 89, 90, 635, 636, "," +464, 8, 18, 148, 91, 99, 637, 645, "patients" +464, 8, 19, 149, 100, 104, 646, 650, "were" +464, 8, 20, 150, 105, 115, 651, 661, "randomized" +464, 8, 21, 151, 116, 118, 662, 664, "to" +464, 8, 22, 152, 119, 122, 665, 668, "one" +464, 8, 23, 153, 123, 132, 669, 678, "treatment" +464, 8, 24, 154, 133, 138, 679, 684, "group" +464, 8, 25, 155, 139, 142, 685, 688, "for" +464, 8, 26, 156, 143, 144, 689, 690, "a" +464, 8, 27, 157, 145, 146, 691, 692, "6" +464, 8, 28, 158, 147, 148, 693, 694, "-" +464, 8, 29, 159, 149, 153, 695, 699, "week" +464, 8, 30, 160, 154, 163, 700, 709, "treatment" +464, 8, 31, 161, 164, 170, 710, 716, "period" +464, 8, 32, 162, 171, 172, 717, 718, "," +464, 8, 33, 163, 173, 176, 719, 722, "and" +464, 8, 34, 164, 177, 181, 723, 727, "then" +464, 8, 35, 165, 182, 189, 728, 735, "crossed" +464, 8, 36, 166, 190, 194, 736, 740, "over" +464, 8, 37, 167, 195, 197, 741, 743, "to" +464, 8, 38, 168, 198, 201, 744, 747, "the" +464, 8, 39, 169, 202, 210, 748, 756, "opposite" +464, 8, 40, 170, 211, 220, 757, 766, "treatment" +464, 8, 41, 171, 221, 222, 767, 768, "." +464, 9, 1, 172, 0, 12, 769, 781, "Measurements" +464, 9, 2, 173, 13, 17, 782, 786, "were" +464, 9, 3, 174, 18, 27, 787, 796, "performed" +464, 9, 4, 175, 28, 30, 797, 799, "at" +464, 9, 5, 176, 31, 35, 800, 804, "0800" +464, 9, 6, 177, 36, 37, 805, 806, "," +464, 9, 7, 178, 38, 42, 807, 811, "1000" +464, 9, 8, 179, 43, 44, 812, 813, "," +464, 9, 9, 180, 45, 49, 814, 818, "1600" +464, 9, 10, 181, 50, 51, 819, 820, "," +464, 9, 11, 182, 52, 56, 821, 825, "1800" +464, 9, 12, 183, 57, 58, 826, 827, "," +464, 9, 13, 184, 59, 62, 828, 831, "and" +464, 9, 14, 185, 63, 67, 832, 836, "2000" +464, 9, 15, 186, 68, 69, 837, 838, "h" +464, 9, 16, 187, 70, 72, 839, 841, "at" +464, 9, 17, 188, 73, 81, 842, 850, "baseline" +464, 9, 18, 189, 82, 85, 851, 854, "and" +464, 9, 19, 190, 86, 88, 855, 857, "at" +464, 9, 20, 191, 89, 92, 858, 861, "the" +464, 9, 21, 192, 93, 96, 862, 865, "end" +464, 9, 22, 193, 97, 99, 866, 868, "of" +464, 9, 23, 194, 100, 104, 869, 873, "each" +464, 9, 24, 195, 105, 114, 874, 883, "treatment" +464, 9, 25, 196, 115, 121, 884, 890, "period" +464, 9, 26, 197, 122, 123, 891, 892, "." +464, 10, 1, 198, 0, 7, 893, 900, "RESULTS" +464, 10, 2, 199, 8, 9, 901, 902, ":" +464, 10, 3, 200, 10, 12, 903, 905, "In" +464, 10, 4, 201, 13, 16, 906, 909, "all" +464, 10, 5, 202, 17, 18, 910, 911, "," +464, 10, 6, 203, 19, 21, 912, 914, "33" +464, 10, 7, 204, 22, 30, 915, 923, "patients" +464, 10, 8, 205, 31, 38, 924, 931, "entered" +464, 10, 9, 206, 39, 43, 932, 936, "this" +464, 10, 10, 207, 44, 49, 937, 942, "trial" +464, 10, 11, 208, 50, 53, 943, 946, "and" +464, 10, 12, 209, 54, 56, 947, 949, "29" +464, 10, 13, 210, 57, 66, 950, 959, "completed" +464, 10, 14, 211, 67, 68, 960, 961, "." +464, 11, 1, 212, 0, 3, 962, 965, "The" +464, 11, 2, 213, 4, 12, 966, 974, "baseline" +464, 11, 3, 214, 13, 19, 975, 981, "trough" +464, 11, 4, 215, 20, 31, 982, 993, "intraocular" +464, 11, 5, 216, 32, 40, 994, 1002, "pressure" +464, 11, 6, 217, 41, 42, 1003, 1004, "(" +464, 11, 7, 218, 43, 46, 1005, 1008, "IOP" +464, 11, 8, 219, 47, 48, 1009, 1010, ")" +464, 11, 9, 220, 49, 52, 1011, 1014, "was" +464, 11, 10, 221, 53, 55, 1015, 1017, "23" +464, 11, 11, 222, 56, 57, 1018, 1019, "." +464, 11, 12, 223, 58, 59, 1020, 1021, "3" +464, 11, 13, 224, 60, 61, 1022, 1023, "+" +464, 11, 14, 225, 62, 63, 1024, 1025, "/" +464, 11, 15, 226, 64, 65, 1026, 1027, "-" +464, 11, 16, 227, 66, 67, 1028, 1029, "2" +464, 11, 17, 228, 68, 69, 1030, 1031, "." +464, 11, 18, 229, 70, 71, 1032, 1033, "4" +464, 11, 19, 230, 72, 75, 1034, 1037, "and" +464, 11, 20, 231, 76, 79, 1038, 1041, "the" +464, 11, 21, 232, 80, 87, 1042, 1049, "diurnal" +464, 11, 22, 233, 88, 93, 1050, 1055, "curve" +464, 11, 23, 234, 94, 97, 1056, 1059, "IOP" +464, 11, 24, 235, 98, 101, 1060, 1063, "was" +464, 11, 25, 236, 102, 104, 1064, 1066, "22" +464, 11, 26, 237, 105, 106, 1067, 1068, "." +464, 11, 27, 238, 107, 108, 1069, 1070, "0" +464, 11, 28, 239, 109, 110, 1071, 1072, "+" +464, 11, 29, 240, 111, 112, 1073, 1074, "/" +464, 11, 30, 241, 113, 114, 1075, 1076, "-" +464, 11, 31, 242, 115, 116, 1077, 1078, "1" +464, 11, 32, 243, 117, 118, 1079, 1080, "." +464, 11, 33, 244, 119, 120, 1081, 1082, "3" +464, 11, 34, 245, 121, 125, 1083, 1087, "mmHg" +464, 11, 35, 246, 126, 127, 1088, 1089, "." +464, 12, 1, 247, 0, 3, 1090, 1093, "For" +464, 12, 2, 248, 4, 7, 1094, 1097, "the" +464, 12, 3, 249, 8, 19, 1098, 1109, "brimonidine" +464, 12, 4, 250, 20, 23, 1110, 1113, "and" +464, 12, 5, 251, 24, 31, 1114, 1121, "timolol" +464, 12, 6, 252, 32, 39, 1122, 1129, "maleate" +464, 12, 7, 253, 40, 49, 1130, 1139, "treatment" +464, 12, 8, 254, 50, 55, 1140, 1145, "group" +464, 12, 9, 255, 56, 57, 1146, 1147, "," +464, 12, 10, 256, 58, 61, 1148, 1151, "the" +464, 12, 11, 257, 62, 68, 1152, 1158, "trough" +464, 12, 12, 258, 69, 72, 1159, 1162, "IOP" +464, 12, 13, 259, 73, 76, 1163, 1166, "was" +464, 12, 14, 260, 77, 79, 1167, 1169, "21" +464, 12, 15, 261, 80, 81, 1170, 1171, "." +464, 12, 16, 262, 82, 83, 1172, 1173, "6" +464, 12, 17, 263, 84, 85, 1174, 1175, "+" +464, 12, 18, 264, 86, 87, 1176, 1177, "/" +464, 12, 19, 265, 88, 89, 1178, 1179, "-" +464, 12, 20, 266, 90, 91, 1180, 1181, "3" +464, 12, 21, 267, 92, 93, 1182, 1183, "." +464, 12, 22, 268, 94, 95, 1184, 1185, "3" +464, 12, 23, 269, 96, 99, 1186, 1189, "and" +464, 12, 24, 270, 100, 103, 1190, 1193, "the" +464, 12, 25, 271, 104, 111, 1194, 1201, "diurnal" +464, 12, 26, 272, 112, 117, 1202, 1207, "curve" +464, 12, 27, 273, 118, 121, 1208, 1211, "IOP" +464, 12, 28, 274, 122, 125, 1212, 1215, "was" +464, 12, 29, 275, 126, 128, 1216, 1218, "19" +464, 12, 30, 276, 129, 130, 1219, 1220, "." +464, 12, 31, 277, 131, 132, 1221, 1222, "8" +464, 12, 32, 278, 133, 134, 1223, 1224, "+" +464, 12, 33, 279, 135, 136, 1225, 1226, "/" +464, 12, 34, 280, 137, 138, 1227, 1228, "-" +464, 12, 35, 281, 139, 140, 1229, 1230, "2" +464, 12, 36, 282, 141, 142, 1231, 1232, "." +464, 12, 37, 283, 143, 144, 1233, 1234, "1" +464, 12, 38, 284, 145, 149, 1235, 1239, "mmHg" +464, 12, 39, 285, 150, 151, 1240, 1241, "," +464, 12, 40, 286, 152, 157, 1242, 1247, "while" +464, 12, 41, 287, 158, 161, 1248, 1251, "the" +464, 12, 42, 288, 162, 169, 1252, 1259, "timolol" +464, 12, 43, 289, 170, 173, 1260, 1263, "and" +464, 12, 44, 290, 174, 185, 1264, 1275, "unoprostone" +464, 12, 45, 291, 186, 195, 1276, 1285, "treatment" +464, 12, 46, 292, 196, 202, 1286, 1292, "showed" +464, 12, 47, 293, 203, 204, 1293, 1294, "a" +464, 12, 48, 294, 205, 211, 1295, 1301, "trough" +464, 12, 49, 295, 212, 215, 1302, 1305, "IOP" +464, 12, 50, 296, 216, 218, 1306, 1308, "of" +464, 12, 51, 297, 219, 221, 1309, 1311, "20" +464, 12, 52, 298, 222, 223, 1312, 1313, "." +464, 12, 53, 299, 224, 225, 1314, 1315, "9" +464, 12, 54, 300, 226, 227, 1316, 1317, "+" +464, 12, 55, 301, 228, 229, 1318, 1319, "/" +464, 12, 56, 302, 230, 231, 1320, 1321, "-" +464, 12, 57, 303, 232, 233, 1322, 1323, "3" +464, 12, 58, 304, 234, 235, 1324, 1325, "." +464, 12, 59, 305, 236, 237, 1326, 1327, "8" +464, 12, 60, 306, 238, 241, 1328, 1331, "and" +464, 12, 61, 307, 242, 243, 1332, 1333, "a" +464, 12, 62, 308, 244, 251, 1334, 1341, "diurnal" +464, 12, 63, 309, 252, 257, 1342, 1347, "curve" +464, 12, 64, 310, 258, 261, 1348, 1351, "IOP" +464, 12, 65, 311, 262, 264, 1352, 1354, "of" +464, 12, 66, 312, 265, 267, 1355, 1357, "19" +464, 12, 67, 313, 268, 269, 1358, 1359, "." +464, 12, 68, 314, 270, 271, 1360, 1361, "3" +464, 12, 69, 315, 272, 273, 1362, 1363, "+" +464, 12, 70, 316, 274, 275, 1364, 1365, "/" +464, 12, 71, 317, 276, 277, 1366, 1367, "-" +464, 12, 72, 318, 278, 279, 1368, 1369, "2" +464, 12, 73, 319, 280, 281, 1370, 1371, "." +464, 12, 74, 320, 282, 283, 1372, 1373, "4" +464, 12, 75, 321, 284, 288, 1374, 1378, "mmHg" +464, 12, 76, 322, 289, 290, 1379, 1380, "." +464, 13, 1, 323, 0, 5, 1381, 1386, "There" +464, 13, 2, 324, 6, 9, 1387, 1390, "was" +464, 13, 3, 325, 10, 12, 1391, 1393, "no" +464, 13, 4, 326, 13, 24, 1394, 1405, "significant" +464, 13, 5, 327, 25, 35, 1406, 1416, "difference" +464, 13, 6, 328, 36, 43, 1417, 1424, "between" +464, 13, 7, 329, 44, 53, 1425, 1434, "treatment" +464, 13, 8, 330, 54, 60, 1435, 1441, "groups" +464, 13, 9, 331, 61, 63, 1442, 1444, "at" +464, 13, 10, 332, 64, 67, 1445, 1448, "any" +464, 13, 11, 333, 68, 72, 1449, 1453, "time" +464, 13, 12, 334, 73, 78, 1454, 1459, "point" +464, 13, 13, 335, 79, 82, 1460, 1463, "for" +464, 13, 14, 336, 83, 86, 1464, 1467, "the" +464, 13, 15, 337, 87, 94, 1468, 1475, "diurnal" +464, 13, 16, 338, 95, 100, 1476, 1481, "curve" +464, 13, 17, 339, 101, 102, 1482, 1483, "," +464, 13, 18, 340, 103, 105, 1484, 1486, "or" +464, 13, 19, 341, 106, 108, 1487, 1489, "in" +464, 13, 20, 342, 109, 112, 1490, 1493, "the" +464, 13, 21, 343, 113, 122, 1494, 1503, "reduction" +464, 13, 22, 344, 123, 127, 1504, 1508, "from" +464, 13, 23, 345, 128, 136, 1509, 1517, "baseline" +464, 13, 24, 346, 137, 138, 1518, 1519, "(" +464, 13, 25, 347, 139, 140, 1520, 1521, "P" +464, 13, 26, 348, 141, 142, 1522, 1523, ">" +464, 13, 27, 349, 143, 144, 1524, 1525, "0" +464, 13, 28, 350, 145, 146, 1526, 1527, "." +464, 13, 29, 351, 147, 149, 1528, 1530, "05" +464, 13, 30, 352, 150, 151, 1531, 1532, ")" +464, 13, 31, 353, 152, 153, 1533, 1534, "." +464, 14, 1, 354, 0, 4, 1535, 1539, "Both" +464, 14, 2, 355, 5, 15, 1540, 1550, "treatments" +464, 14, 3, 356, 16, 22, 1551, 1557, "failed" +464, 14, 4, 357, 23, 25, 1558, 1560, "to" +464, 14, 5, 358, 26, 39, 1561, 1574, "statistically" +464, 14, 6, 359, 40, 46, 1575, 1581, "reduce" +464, 14, 7, 360, 47, 50, 1582, 1585, "the" +464, 14, 8, 361, 51, 54, 1586, 1589, "IOP" +464, 14, 9, 362, 55, 59, 1590, 1594, "from" +464, 14, 10, 363, 60, 68, 1595, 1603, "baseline" +464, 14, 11, 364, 69, 71, 1604, 1606, "at" +464, 14, 12, 365, 72, 76, 1607, 1611, "1800" +464, 14, 13, 366, 77, 78, 1612, 1613, "h" +464, 14, 14, 367, 79, 80, 1614, 1615, "." +464, 14, 15, 368, 81, 86, 1616, 1621, "There" +464, 14, 16, 369, 87, 90, 1622, 1625, "was" +464, 14, 17, 370, 91, 93, 1626, 1628, "no" +464, 14, 18, 371, 94, 104, 1629, 1639, "difference" +464, 14, 19, 372, 105, 112, 1640, 1647, "between" +464, 14, 20, 373, 113, 122, 1648, 1657, "treatment" +464, 14, 21, 374, 123, 129, 1658, 1664, "groups" +464, 14, 22, 375, 130, 139, 1665, 1674, "regarding" +464, 14, 23, 376, 140, 146, 1675, 1681, "ocular" +464, 14, 24, 377, 147, 150, 1682, 1685, "and" +464, 14, 25, 378, 151, 159, 1686, 1694, "systemic" +464, 14, 26, 379, 160, 171, 1695, 1706, "unsolicited" +464, 14, 27, 380, 172, 179, 1707, 1714, "adverse" +464, 14, 28, 381, 180, 186, 1715, 1721, "events" +464, 14, 29, 382, 187, 188, 1722, 1723, "," +464, 14, 30, 383, 189, 192, 1724, 1727, "but" +464, 14, 31, 384, 193, 201, 1728, 1736, "patients" +464, 14, 32, 385, 202, 210, 1737, 1745, "admitted" +464, 14, 33, 386, 211, 213, 1746, 1748, "to" +464, 14, 34, 387, 214, 218, 1749, 1753, "more" +464, 14, 35, 388, 219, 226, 1754, 1761, "dryness" +464, 14, 36, 389, 227, 228, 1762, 1763, "(" +464, 14, 37, 390, 229, 230, 1764, 1765, "P" +464, 14, 38, 391, 231, 232, 1766, 1767, "=" +464, 14, 39, 392, 233, 234, 1768, 1769, "0" +464, 14, 40, 393, 235, 236, 1770, 1771, "." +464, 14, 41, 394, 237, 239, 1772, 1774, "02" +464, 14, 42, 395, 240, 241, 1775, 1776, ")" +464, 14, 43, 396, 242, 245, 1777, 1780, "and" +464, 14, 44, 397, 246, 253, 1781, 1788, "burning" +464, 14, 45, 398, 254, 258, 1789, 1793, "upon" +464, 14, 46, 399, 259, 271, 1794, 1806, "instillation" +464, 14, 47, 400, 272, 273, 1807, 1808, "(" +464, 14, 48, 401, 274, 275, 1809, 1810, "P" +464, 14, 49, 402, 276, 277, 1811, 1812, "<" +464, 14, 50, 403, 278, 279, 1813, 1814, "0" +464, 14, 51, 404, 280, 281, 1815, 1816, "." +464, 14, 52, 405, 282, 286, 1817, 1821, "0001" +464, 14, 53, 406, 287, 288, 1822, 1823, ")" +464, 14, 54, 407, 289, 293, 1824, 1828, "with" +464, 14, 55, 408, 294, 305, 1829, 1840, "unoprostone" +464, 14, 56, 409, 306, 308, 1841, 1843, "by" +464, 14, 57, 410, 309, 315, 1844, 1850, "survey" +464, 14, 58, 411, 316, 317, 1851, 1852, "." +464, 15, 1, 412, 0, 10, 1853, 1863, "CONCLUSION" +464, 15, 2, 413, 11, 12, 1864, 1865, ":" +464, 15, 3, 414, 13, 24, 1866, 1877, "Brimonidine" +464, 15, 4, 415, 25, 26, 1878, 1879, "0" +464, 15, 5, 416, 27, 28, 1880, 1881, "." +464, 15, 6, 417, 29, 30, 1882, 1883, "2" +464, 15, 7, 418, 31, 32, 1884, 1885, "%" +464, 15, 8, 419, 33, 35, 1886, 1888, "or" +464, 15, 9, 420, 36, 47, 1889, 1900, "unoprostone" +464, 15, 10, 421, 48, 49, 1901, 1902, "0" +464, 15, 11, 422, 50, 51, 1903, 1904, "." +464, 15, 12, 423, 52, 54, 1905, 1907, "15" +464, 15, 13, 424, 55, 56, 1908, 1909, "%" +464, 15, 14, 425, 57, 62, 1910, 1915, "added" +464, 15, 15, 426, 63, 65, 1916, 1918, "to" +464, 15, 16, 427, 66, 73, 1919, 1926, "timolol" +464, 15, 17, 428, 74, 81, 1927, 1934, "maleate" +464, 15, 18, 429, 82, 83, 1935, 1936, "0" +464, 15, 19, 430, 84, 85, 1937, 1938, "." +464, 15, 20, 431, 86, 87, 1939, 1940, "5" +464, 15, 21, 432, 88, 89, 1941, 1942, "%" +464, 15, 22, 433, 90, 97, 1943, 1950, "provide" +464, 15, 23, 434, 98, 105, 1951, 1958, "similar" +464, 15, 24, 435, 106, 114, 1959, 1967, "efficacy" +464, 15, 25, 436, 115, 118, 1968, 1971, "and" +464, 15, 26, 437, 119, 125, 1972, 1978, "safety" +464, 15, 27, 438, 126, 136, 1979, 1989, "throughout" +464, 15, 28, 439, 137, 140, 1990, 1993, "the" +464, 15, 29, 440, 141, 148, 1994, 2001, "daytime" +464, 15, 30, 441, 149, 156, 2002, 2009, "diurnal" +464, 15, 31, 442, 157, 162, 2010, 2015, "curve" +464, 15, 32, 443, 163, 164, 2016, 2017, "." +464, 16, 1, 444, 0, 3, 2018, 2021, "DOI" +464, 16, 2, 445, 4, 5, 2022, 2023, ":" +464, 16, 3, 446, 6, 8, 2024, 2026, "10" +464, 16, 4, 447, 9, 10, 2027, 2028, "." +464, 16, 5, 448, 11, 15, 2029, 2033, "1038" +464, 16, 6, 449, 16, 17, 2034, 2035, "/" +464, 16, 7, 450, 18, 20, 2036, 2038, "sj" +464, 16, 8, 451, 21, 22, 2039, 2040, "." +464, 16, 9, 452, 23, 26, 2041, 2044, "eye" +464, 16, 10, 453, 27, 28, 2045, 2046, "." +464, 16, 11, 454, 29, 36, 2047, 2054, "6701392" +464, 16, 12, 455, 37, 41, 2055, 2059, "PMID" +464, 16, 13, 456, 42, 43, 2060, 2061, ":" +464, 16, 14, 457, 44, 52, 2062, 2070, "15094733" +464, 16, 15, 458, 53, 54, 2071, 2072, "[" +464, 16, 16, 459, 55, 62, 2073, 2080, "Indexed" +464, 16, 17, 460, 63, 66, 2081, 2084, "for" +464, 16, 18, 461, 67, 74, 2085, 2092, "MEDLINE" +464, 16, 19, 462, 75, 76, 2093, 2094, "]" diff --git a/data/gl 15094733_jshahinitiran.annodb b/data/gl 15094733_jshahinitiran.annodb new file mode 100644 index 0000000..25a9312 --- /dev/null +++ b/data/gl 15094733_jshahinitiran.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8771, Journal, 0, 12, "Eye ( Lond )", "", +8772, PublicationYear, 15, 19, "2005", "", +8773, Title, 47, 218, "Brimonidine 0 . 2 % vs unoprostone 0 . 15 % both added to timolol maleate 0 . 5 % given twice daily to patients with primary open - angle glaucoma or ocular hypertension .", "", +27871, Brimonidine, 47, 58, "Brimonidine", "", +27874, DoseValue, 59, 64, "0 . 2", "", +27877, Percentage, 65, 66, "%", "", +27872, Unoprostone, 70, 81, "unoprostone", "", +27875, DoseValue, 82, 88, "0 . 15", "", +27878, Percentage, 89, 90, "%", "", +27873, Timolol, 105, 120, "timolol maleate", "", +27876, DoseValue, 121, 126, "0 . 5", "", +27879, Percentage, 127, 128, "%", "", +27880, Frequency, 135, 146, "twice daily", "", +27881, Primary_OpenAngleGlaucoma, 164, 193, "primary open - angle glaucoma", "", +8785, OcularHypertension, 197, 216, "ocular hypertension", "", +8786, Author, 219, 228, "Sharpe ED", "", +8787, Author, 237, 245, "Henry CJ", "", +8788, Author, 248, 258, "Mundorf TK", "", +8789, Author, 261, 267, "Day DG", "", +8790, Author, 270, 280, "Stewart JA", "", +8791, Author, 283, 293, "Jenkins JN", "", +8792, Author, 296, 306, "Stewart WC", "", +8793, USA, 383, 386, "USA", "", +8794, ObjectiveDescription, 399, 545, "To compare the efficacy and safety of brimonidine 0 . 2 % vs unoprostone 0 . 15 % , both added to timolol maleate 0 . 5 % each given twice daily .", "", +27882, Brimonidine, 437, 448, "brimonidine", "", +27885, DoseValue, 449, 454, "0 . 2", "", +27888, Percentage, 455, 456, "%", "", +27883, Unoprostone, 460, 471, "unoprostone", "", +27886, DoseValue, 472, 478, "0 . 15", "", +27889, Percentage, 479, 480, "%", "", +27884, Timolol, 497, 512, "timolol maleate", "", +27887, DoseValue, 513, 518, "0 . 5", "", +27890, Percentage, 519, 520, "%", "", +27891, Frequency, 532, 543, "twice daily", "", +8805, CTDesign, 564, 575, "prospective", "prospective", +8806, Multicenter, 578, 593, "multi - centred", "", +8807, DoubleBlind, 596, 611, "double - masked", "", +8808, Crossover, 614, 623, "crossover", "", +8809, Randomized, 651, 661, "randomized", "", +8810, Duration, 691, 699, "6 - week", "", +27892, Crossover, 728, 740, "crossed over", "", +8811, NumberPatientsCT, 912, 914, "33", "", +8812, FinalNumPatientsCT, 947, 949, "29", "", +27893, Trough_IOP, 975, 1002, "trough intraocular pressure", "", +27894, Trough_IOP, 1005, 1008, "IOP", "", +8815, BaseLineValue, 1015, 1021, "23 . 3", "", +8816, SdErrorBL, 1028, 1033, "2 . 4", "", +8817, Diurnal_IOP, 1042, 1059, "diurnal curve IOP", "", +8818, BaseLineValue, 1064, 1070, "22 . 0", "", +8819, SdErrorBL, 1077, 1082, "1 . 3", "", +8820, mmHg, 1083, 1087, "mmHg", "", +27895, Brimonidine, 1098, 1109, "brimonidine", "", +27896, Timolol, 1114, 1129, "timolol maleate", "", +27897, Trough_IOP, 1152, 1162, "trough IOP", "", +8824, ResultMeasuredValue, 1167, 1173, "21 . 6", "", +8825, SdErrorResValue, 1180, 1185, "3 . 3", "", +27898, Diurnal_IOP, 1194, 1211, "diurnal curve IOP", "", +8827, ResultMeasuredValue, 1216, 1222, "19 . 8", "", +8828, SdErrorResValue, 1229, 1234, "2 . 1", "", +8829, mmHg, 1235, 1239, "mmHg", "", +27899, Timolol, 1252, 1259, "timolol", "", +27900, Unoprostone, 1264, 1275, "unoprostone", "", +27901, Trough_IOP, 1295, 1305, "trough IOP", "", +8833, ResultMeasuredValue, 1309, 1315, "20 . 9", "", +8834, SdErrorResValue, 1322, 1327, "3 . 8", "", +27902, Diurnal_IOP, 1334, 1351, "diurnal curve IOP", "", +8836, ResultMeasuredValue, 1355, 1361, "19 . 3", "", +8837, SdErrorResValue, 1368, 1373, "2 . 4", "", +8838, mmHg, 1374, 1378, "mmHg", "", +27903, Diurnal_IOP, 1468, 1481, "diurnal curve", "", +8855, PvalueDiff, 1520, 1530, "P > 0 . 05", "", +27904, IOP, 1586, 1589, "IOP", "", +8842, ObservedResult, 1749, 1852, "more dryness ( P = 0 . 02 ) and burning upon instillation ( P < 0 . 0001 ) with unoprostone by survey .", "", +8839, EndPointDescription, 1754, 1761, "dryness", "", +8857, PValueNumAffected, 1764, 1774, "P = 0 . 02", "", +8840, EndPointDescription, 1781, 1788, "burning", "", +8856, PValueNumAffected, 1809, 1821, "P < 0 . 0001", "", +27905, Unoprostone, 1829, 1840, "unoprostone", "", +27906, Brimonidine, 1866, 1877, "Brimonidine", "", +8843, ConclusionComment, 1866, 2017, "Brimonidine 0 . 2 % or unoprostone 0 . 15 % added to timolol maleate 0 . 5 % provide similar efficacy and safety throughout the daytime diurnal curve .", "", +27909, DoseValue, 1878, 1883, "0 . 2", "", +27912, Percentage, 1884, 1885, "%", "", +27907, Unoprostone, 1889, 1900, "unoprostone", "", +27910, DoseValue, 1901, 1907, "0 . 15", "", +27913, Percentage, 1908, 1909, "%", "", +27908, Timolol, 1919, 1934, "timolol maleate", "", +27911, DoseValue, 1935, 1940, "0 . 5", "", +27914, Percentage, 1941, 1942, "%", "", +27915, Diurnal_IOP, 2002, 2015, "diurnal curve", "", +8854, PMID, 2062, 2070, "15094733", "", diff --git a/data/gl 15094733_jshahinitiran.n-triples b/data/gl 15094733_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15094733_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15094733_tstrakeljahn.annodb b/data/gl 15094733_tstrakeljahn.annodb new file mode 100644 index 0000000..e7d64fd --- /dev/null +++ b/data/gl 15094733_tstrakeljahn.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +78754, Journal, 0, 12, "Eye ( Lond )", "", +78755, PublicationYear, 15, 19, "2005", "", +78756, Brimonidine, 47, 58, "Brimonidine", "", +78768, Title, 47, 218, "Brimonidine 0 . 2 % vs unoprostone 0 . 15 % both added to timolol maleate 0 . 5 % given twice daily to patients with primary open - angle glaucoma or ocular hypertension .", "", +78759, DoseValue, 59, 64, "0 . 2", "", +78762, Percentage, 65, 66, "%", "", +78757, Unoprostone, 70, 81, "unoprostone", "", +78760, DoseValue, 82, 88, "0 . 15", "", +78763, Percentage, 89, 90, "%", "", +78758, Timolol, 105, 120, "timolol maleate", "", +78761, DoseValue, 121, 126, "0 . 5", "", +78764, Percentage, 127, 128, "%", "", +78765, Frequency, 135, 146, "twice daily", "", +78766, Primary_OpenAngleGlaucoma, 164, 193, "primary open - angle glaucoma", "", +78767, OcularHypertension, 197, 216, "ocular hypertension", "", +78769, Author, 219, 228, "Sharpe ED", "", +78770, Author, 237, 245, "Henry CJ", "", +78771, Author, 248, 258, "Mundorf TK", "", +78772, Author, 261, 267, "Day DG", "", +78773, Author, 270, 280, "Stewart JA", "", +78774, Author, 283, 293, "Jenkins JN", "", +78775, Author, 296, 306, "Stewart WC", "", +78776, USA, 383, 386, "USA", "", +78797, ObjectiveDescription, 399, 545, "To compare the efficacy and safety of brimonidine 0 . 2 % vs unoprostone 0 . 15 % , both added to timolol maleate 0 . 5 % each given twice daily .", "", +78777, Brimonidine, 437, 448, "brimonidine", "", +78781, DoseValue, 449, 454, "0 . 2", "", +78784, Percentage, 455, 456, "%", "", +78778, Unoprostone, 460, 471, "unoprostone", "", +78782, DoseValue, 472, 478, "0 . 15", "", +78785, Percentage, 479, 480, "%", "", +78779, Timolol, 497, 512, "timolol maleate", "", +78783, DoseValue, 513, 518, "0 . 5", "", +78786, Percentage, 519, 520, "%", "", +78780, Frequency, 532, 543, "twice daily", "", +78787, Prospective, 564, 575, "prospective", "", +78788, Multicenter, 578, 593, "multi - centred", "", +78789, DoubleBlind, 596, 611, "double - masked", "", +30794, Crossover, 614, 623, "crossover", "", +78790, Randomized, 651, 661, "randomized", "", +78791, Duration, 691, 699, "6 - week", "", +78792, RelativeTime, 800, 804, "0800", "", +78793, RelativeTime, 807, 811, "1000", "", +78794, RelativeTime, 814, 818, "1600", "", +78795, RelativeTime, 821, 825, "1800", "", +78796, RelativeTime, 832, 836, "2000", "", +78798, NumberPatientsCT, 912, 914, "33", "", +78799, FinalNumPatientsCT, 947, 949, "29", "", +78802, Trough_IOP, 975, 1002, "trough intraocular pressure", "", +78801, IOP, 1005, 1008, "IOP", "", +78803, BaseLineValue, 1015, 1021, "23 . 3", "", +78804, SdDevBL, 1028, 1033, "2 . 4", "", +78805, Diurnal_IOP, 1042, 1059, "diurnal curve IOP", "", +78806, BaseLineValue, 1064, 1070, "22 . 0", "", +78807, SdDevBL, 1077, 1082, "1 . 3", "", +78808, mmHg, 1083, 1087, "mmHg", "", +78809, Brimonidine, 1098, 1109, "brimonidine", "", +78810, Timolol, 1114, 1129, "timolol maleate", "", +78811, Trough_IOP, 1152, 1162, "trough IOP", "", +78812, ResultMeasuredValue, 1167, 1173, "21 . 6", "", +78816, SdDevBL, 1180, 1185, "3 . 3", "", +78819, Diurnal_IOP, 1194, 1211, "diurnal curve IOP", "", +78813, ResultMeasuredValue, 1216, 1222, "19 . 8", "", +78817, SdDevBL, 1229, 1234, "2 . 1", "", +78818, mmHg, 1235, 1239, "mmHg", "", +78820, Timolol, 1252, 1259, "timolol", "", +78821, Unoprostone, 1264, 1275, "unoprostone", "", +78822, Trough_IOP, 1295, 1305, "trough IOP", "", +78814, ResultMeasuredValue, 1309, 1315, "20 . 9", "", +78823, SdDevChangeValue, 1322, 1327, "3 . 8", "", +78825, Diurnal_IOP, 1334, 1351, "diurnal curve IOP", "", +78815, ResultMeasuredValue, 1355, 1361, "19 . 3", "", +78824, SdDevChangeValue, 1368, 1373, "2 . 4", "", +78826, mmHg, 1374, 1378, "mmHg", "", +78828, ObservedResult, 1381, 1534, "There was no significant difference between treatment groups at any time point for the diurnal curve , or in the reduction from baseline ( P > 0 . 05 ) .", "", +78827, PvalueDiff, 1522, 1530, "> 0 . 05", "", +78829, IOP, 1586, 1589, "IOP", "", +78830, RelativeTime, 1607, 1611, "1800", "", +78833, PvalueDiff, 1811, 1821, "< 0 . 0001", "", +78834, Unoprostone, 1829, 1840, "unoprostone", "", +78835, Brimonidine, 1866, 1877, "Brimonidine", "", +78838, DoseValue, 1866, 1883, "Brimonidine 0 . 2", "", +78845, ConclusionComment, 1866, 2017, "Brimonidine 0 . 2 % or unoprostone 0 . 15 % added to timolol maleate 0 . 5 % provide similar efficacy and safety throughout the daytime diurnal curve .", "", +78841, Percentage, 1884, 1885, "%", "", +78836, Unoprostone, 1889, 1900, "unoprostone", "", +78839, DoseValue, 1889, 1907, "unoprostone 0 . 15", "", +78842, Percentage, 1908, 1909, "%", "", +78837, Timolol, 1919, 1934, "timolol maleate", "", +78840, DoseValue, 1927, 1940, "maleate 0 . 5", "", +78843, Percentage, 1941, 1942, "%", "", +78844, Percentage, 2062, 2070, "15094733", "", diff --git a/data/gl 15094733_tstrakeljahn.n-triples b/data/gl 15094733_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15094733_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15097262_admin.annodb b/data/gl 15097262_admin.annodb new file mode 100644 index 0000000..900ff92 --- /dev/null +++ b/data/gl 15097262_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2004", "", " \"2004\"." +2, Dorzolamide, 46, 57, "Dorzolamide", "", +38487, Dorz/TimFC, 46, 67, "Dorzolamide / Timolol", "", " ." +9, Title, 46, 279, "Dorzolamide / Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure : a 3 - month comparison of efficacy , tolerability , and patient - reported measures", "", " \"Dorzolamide / Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure : a 3 - month comparison of efficacy , tolerability , and patient - reported measures\"." +3, Timolol, 60, 67, "Timolol", "", +4, Brimonidine, 123, 134, "brimonidine", "", +5, Timolol, 139, 146, "timolol", "", +7, Precondition, 164, 193, "elevated intraocular pressure", "", " \"elevated intraocular pressure\"." +6, IOP, 173, 193, "intraocular pressure", "", +8, Duration, 198, 207, "3 - month", "", " \"3 - month\"." +73, Author, 282, 291, "Solish AM", "", " \"Solish AM\"." +74, Author, 300, 310, "DeLucca PT", "", " \"DeLucca PT\"." +75, Author, 313, 322, "Cassel DA", "", " \"Cassel DA\"." +76, Author, 325, 335, "Kolodny AH", "", " \"Kolodny AH\"." +77, Author, 338, 347, "Hustad CM", "", " \"Hustad CM\"." +78, Author, 350, 363, "Skobieranda F", "", " \"Skobieranda F\"." +10, USA, 460, 463, "USA", "", " ." +102, ObjectiveDescription, 479, 713, "To compare the intraocular pressure ( IOP ) lowering effect , tolerability , and patient - reported measures of the dorzolamide / timolol fixed combination and the concomitant administration of brimonidine and timolol after 3 months .", "", " \"To compare the intraocular pressure ( IOP ) lowering effect , tolerability , and patient - reported measures of the dorzolamide / timolol fixed combination and the concomitant administration of brimonidine and timolol after 3 months .\"." +12, IOP, 494, 514, "intraocular pressure", "", +13, IOP, 517, 520, "IOP", "", +38486, Dorz/TimFC, 595, 616, "dorzolamide / timolol", "", +14, Dorzolamide, 595, 606, "dorzolamide", "", +15, Timolol, 609, 616, "timolol", "", +16, Brimonidine, 673, 684, "brimonidine", "", +17, Timolol, 689, 696, "timolol", "", +18, Duration, 703, 711, "3 months", "", +19, NumberPatientsCT, 724, 749, "Four hundred ninety - two", "", +20, OcularHypertension, 764, 783, "ocular hypertension", "", " ." +49, Primary_OpenAngleGlaucoma, 786, 815, "primary open - angle glaucoma", "", " ." +21, Glaucoma, 818, 838, "exfoliative glaucoma", "", +22, PigmentaryGlaucoma, 844, 863, "pigmentary glaucoma", "", " ." +23, Randomized, 885, 895, "randomized", "", " ." +24, Blind, 898, 915, "observer - masked", "", " ." +25, Multicenter, 918, 929, "multicenter", "", " ." +34294, Precondition, 938, 1023, "Following 3 weeks of timolol monotherapy , patients with a peak IOP of > or = 2 mm Hg", "", " \"Following 3 weeks of timolol monotherapy , patients with a peak IOP of > or = 2 mm Hg\"." +34288, Duration, 948, 955, "3 weeks", "", +26, Timolol, 959, 966, "timolol", "", +27, Peak_IOP, 997, 1005, "peak IOP", "", " ." +29, mmHg, 1018, 1023, "mm Hg", "", +30, Randomized, 1029, 1039, "randomized", "", +38488, Dorz/TimFC, 1076, 1097, "dorzolamide / timolol", "", +50, Dorzolamide, 1076, 1087, "dorzolamide", "", +51, Timolol, 1090, 1097, "timolol", "", +31, Frequency, 1098, 1109, "twice daily", "", " \"twice daily\"." +52, Brimonidine, 1125, 1136, "brimonidine", "", " ." +53, Timolol, 1142, 1149, "timolol", "", " ." +32, Frequency, 1150, 1161, "twice daily", "", " \"twice daily\"." +33, Duration, 1166, 1174, "3 months", "", +34, IOP, 1181, 1184, "IOP", "", +54, Peak_IOP, 1207, 1211, "peak", "", +55, Trough_IOP, 1216, 1222, "trough", "", +56, TimePoint, 1309, 1325, "months 1 and 3 .", "", +57, TimePoint, 1339, 1346, "month 3", "", " \"month 3\". \"month 3\"." +60, Peak_IOP, 1347, 1351, "peak", "", +38489, Dorz/TimFC, 1358, 1379, "dorzolamide / timolol", "", +58, Dorzolamide, 1358, 1369, "dorzolamide", "", +59, Timolol, 1372, 1379, "timolol", "", +35, Mean, 1402, 1406, "mean", "", " . ." +36, IOP, 1435, 1438, "IOP", "", +37, Reduction, 1444, 1450, "4 . 30", "", " \"4 . 30\"." +38, SdErrorChangeValue, 1453, 1459, "0 . 24", "", " \"0 . 24\"." +39, mmHg, 1462, 1467, "mm Hg", "", +40, Reduction, 1477, 1483, "5 . 27", "", " \"5 . 27\"." +41, SdErrorChangeValue, 1486, 1492, "0 . 23", "", " \"0 . 23\"." +42, mmHg, 1495, 1500, "mm Hg", "", " ." +61, Brimonidine, 1508, 1519, "brimonidine", "", +62, Timolol, 1529, 1536, "timolol", "", +43, DiffGroupAbsValue, 1576, 1582, "0 . 97", "", " \"0 . 97\"." +44, mmHg, 1583, 1588, "mm Hg", "", +45, ConfIntervalDiff, 1591, 1616, "95 % CI : 0 . 40 , 1 . 53", "", " \"95 % CI : 0 . 40 , 1 . 53\"." +63, TimePoint, 1628, 1635, "month 3", "", +64, Trough_IOP, 1636, 1642, "trough", "", +46, TimePoint, 1662, 1669, "month 1", "", +65, mmHg, 1792, 1797, "mm Hg", "", +144, ObservedResult, 1800, 1890, "The incidence of drug - related adverse experiences was similar between treatment groups .", "", +34297, EndPointDescription, 1832, 1851, "adverse experiences", "AdverseEffects", +145, ObservedResult, 1891, 2028, "Patient - reported assessments of convenience and satisfaction showed no statistically significant differences between treatment groups .", "", +71, ConclusionComment, 2043, 2208, "The IOP - lowering effect of the dorzolamide / timolol fixed combination and concomitant brimonidine plus timolol were comparable at 3 of the 4 timepoints measured .", "", " \"The IOP - lowering effect of the dorzolamide / timolol fixed combination and concomitant brimonidine plus timolol were comparable at 3 of the 4 timepoints measured .\"." +47, IOP, 2047, 2050, "IOP", "", +38490, Dorz/TimFC, 2076, 2097, "dorzolamide / timolol", "", +66, Dorzolamide, 2076, 2087, "dorzolamide", "", +67, Timolol, 2090, 2097, "timolol", "", +68, Brimonidine, 2132, 2143, "brimonidine", "", +69, Timolol, 2149, 2156, "timolol", "", +72, ConclusionComment, 2209, 2317, "Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar .", "", " \"Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar .\"." +48, PMID, 2325, 2333, "15097262", "", " \"15097262\"." diff --git a/data/gl 15097262_admin.n-triples b/data/gl 15097262_admin.n-triples new file mode 100644 index 0000000..00ce092 --- /dev/null +++ b/data/gl 15097262_admin.n-triples @@ -0,0 +1,110 @@ +# RDF export of group: Publication + . + "Publication" . + "Dorzolamide / Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure : a 3 - month comparison of efficacy , tolerability , and patient - reported measures" . + "Solish AM" . + "2004" . + "J Glaucoma" . + "15097262" . + . + "DeLucca PT" . + "Cassel DA" . + "Kolodny AH" . + "Hustad CM" . + "Skobieranda F" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ( IOP ) lowering effect , tolerability , and patient - reported measures of the dorzolamide / timolol fixed combination and the concomitant administration of brimonidine and timolol after 3 months ." . + "3 - month" . + . + . + . + "The IOP - lowering effect of the dorzolamide / timolol fixed combination and concomitant brimonidine plus timolol were comparable at 3 of the 4 timepoints measured ." . + . + . + . + . + . + . + . + "Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "elevated intraocular pressure" . + . + . + . + "Following 3 weeks of timolol monotherapy , patients with a peak IOP of > or = 2 mm Hg" . +# RDF export of group: Endpoint + . + "Endpoint-piop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-dor-tim" . + . + . + . + . + "Arm-bri-tim" . + . + . + . +# RDF export of group: Intervention + . + "Intervention-dor-tim" . + . + "twice daily" . + . + . + "Intervention-bri-tim" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication-tim" . + . + . + . + . + "Medication-bri" . + . + . + . + . + "Medication-dor-tim" . + . + . + . +# RDF export of group: Outcome + . + "Outcome-piop-dor" . + . + "4 . 30" . + "0 . 24" . + "month 3" . + . + "Outcome-piop-bri" . + . + "5 . 27" . + "0 . 23" . + "month 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "0 . 97" . + "95 % CI : 0 . 40 , 1 . 53" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15097262_export.csv b/data/gl 15097262_export.csv new file mode 100644 index 0000000..ae737bd --- /dev/null +++ b/data/gl 15097262_export.csv @@ -0,0 +1,434 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +463, 1, 1, 1, 0, 1, 0, 1, "J" +463, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +463, 1, 3, 3, 11, 12, 11, 12, "." +463, 2, 1, 4, 0, 4, 13, 17, "2004" +463, 2, 2, 5, 5, 8, 18, 21, "Apr" +463, 2, 3, 6, 9, 10, 22, 23, ";" +463, 2, 4, 7, 11, 13, 24, 26, "13" +463, 2, 5, 8, 14, 15, 27, 28, "(" +463, 2, 6, 9, 16, 17, 29, 30, "2" +463, 2, 7, 10, 18, 19, 31, 32, ")" +463, 2, 8, 11, 20, 21, 33, 34, ":" +463, 2, 9, 12, 22, 25, 35, 38, "149" +463, 2, 10, 13, 26, 27, 39, 40, "-" +463, 2, 11, 14, 28, 30, 41, 43, "57" +463, 2, 12, 15, 31, 32, 44, 45, "." +463, 3, 1, 16, 0, 11, 46, 57, "Dorzolamide" +463, 3, 2, 17, 12, 13, 58, 59, "/" +463, 3, 3, 18, 14, 21, 60, 67, "Timolol" +463, 3, 4, 19, 22, 27, 68, 73, "fixed" +463, 3, 5, 20, 28, 39, 74, 85, "combination" +463, 3, 6, 21, 40, 46, 86, 92, "versus" +463, 3, 7, 22, 47, 58, 93, 104, "concomitant" +463, 3, 8, 23, 59, 73, 105, 119, "administration" +463, 3, 9, 24, 74, 76, 120, 122, "of" +463, 3, 10, 25, 77, 88, 123, 134, "brimonidine" +463, 3, 11, 26, 89, 92, 135, 138, "and" +463, 3, 12, 27, 93, 100, 139, 146, "timolol" +463, 3, 13, 28, 101, 103, 147, 149, "in" +463, 3, 14, 29, 104, 112, 150, 158, "patients" +463, 3, 15, 30, 113, 117, 159, 163, "with" +463, 3, 16, 31, 118, 126, 164, 172, "elevated" +463, 3, 17, 32, 127, 138, 173, 184, "intraocular" +463, 3, 18, 33, 139, 147, 185, 193, "pressure" +463, 3, 19, 34, 148, 149, 194, 195, ":" +463, 3, 20, 35, 150, 151, 196, 197, "a" +463, 3, 21, 36, 152, 153, 198, 199, "3" +463, 3, 22, 37, 154, 155, 200, 201, "-" +463, 3, 23, 38, 156, 161, 202, 207, "month" +463, 3, 24, 39, 162, 172, 208, 218, "comparison" +463, 3, 25, 40, 173, 175, 219, 221, "of" +463, 3, 26, 41, 176, 184, 222, 230, "efficacy" +463, 3, 27, 42, 185, 186, 231, 232, "," +463, 3, 28, 43, 187, 199, 233, 245, "tolerability" +463, 3, 29, 44, 200, 201, 246, 247, "," +463, 3, 30, 45, 202, 205, 248, 251, "and" +463, 3, 31, 46, 206, 213, 252, 259, "patient" +463, 3, 32, 47, 214, 215, 260, 261, "-" +463, 3, 33, 48, 216, 224, 262, 270, "reported" +463, 3, 34, 49, 225, 233, 271, 279, "measures" +463, 3, 35, 50, 234, 235, 280, 281, "." +463, 4, 1, 51, 0, 6, 282, 288, "Solish" +463, 4, 2, 52, 7, 9, 289, 291, "AM" +463, 4, 3, 53, 10, 11, 292, 293, "(" +463, 4, 4, 54, 12, 13, 294, 295, "1" +463, 4, 5, 55, 14, 15, 296, 297, ")" +463, 4, 6, 56, 16, 17, 298, 299, "," +463, 4, 7, 57, 18, 25, 300, 307, "DeLucca" +463, 4, 8, 58, 26, 28, 308, 310, "PT" +463, 4, 9, 59, 29, 30, 311, 312, "," +463, 4, 10, 60, 31, 37, 313, 319, "Cassel" +463, 4, 11, 61, 38, 40, 320, 322, "DA" +463, 4, 12, 62, 41, 42, 323, 324, "," +463, 4, 13, 63, 43, 50, 325, 332, "Kolodny" +463, 4, 14, 64, 51, 53, 333, 335, "AH" +463, 4, 15, 65, 54, 55, 336, 337, "," +463, 4, 16, 66, 56, 62, 338, 344, "Hustad" +463, 4, 17, 67, 63, 65, 345, 347, "CM" +463, 4, 18, 68, 66, 67, 348, 349, "," +463, 4, 19, 69, 68, 79, 350, 361, "Skobieranda" +463, 4, 20, 70, 80, 81, 362, 363, "F" +463, 4, 21, 71, 82, 83, 364, 365, "." +463, 4, 22, 72, 84, 90, 366, 372, "Author" +463, 4, 23, 73, 91, 102, 373, 384, "information" +463, 4, 24, 74, 103, 104, 385, 386, ":" +463, 4, 25, 75, 105, 106, 387, 388, "(" +463, 4, 26, 76, 107, 108, 389, 390, "1" +463, 4, 27, 77, 109, 110, 391, 392, ")" +463, 4, 28, 78, 111, 119, 393, 401, "Southern" +463, 4, 29, 79, 120, 130, 402, 412, "California" +463, 4, 30, 80, 131, 139, 413, 421, "Glaucoma" +463, 4, 31, 81, 140, 151, 422, 433, "Consultants" +463, 4, 32, 82, 152, 153, 434, 435, "," +463, 4, 33, 83, 154, 162, 436, 444, "Pasadena" +463, 4, 34, 84, 163, 164, 445, 446, "," +463, 4, 35, 85, 165, 175, 447, 457, "California" +463, 4, 36, 86, 176, 177, 458, 459, "," +463, 4, 37, 87, 178, 181, 460, 463, "USA" +463, 4, 38, 88, 182, 183, 464, 465, "." +463, 5, 1, 89, 0, 10, 466, 476, "BACKGROUND" +463, 5, 2, 90, 11, 12, 477, 478, ":" +463, 5, 3, 91, 13, 15, 479, 481, "To" +463, 5, 4, 92, 16, 23, 482, 489, "compare" +463, 5, 5, 93, 24, 27, 490, 493, "the" +463, 5, 6, 94, 28, 39, 494, 505, "intraocular" +463, 5, 7, 95, 40, 48, 506, 514, "pressure" +463, 5, 8, 96, 49, 50, 515, 516, "(" +463, 5, 9, 97, 51, 54, 517, 520, "IOP" +463, 5, 10, 98, 55, 56, 521, 522, ")" +463, 5, 11, 99, 57, 65, 523, 531, "lowering" +463, 5, 12, 100, 66, 72, 532, 538, "effect" +463, 5, 13, 101, 73, 74, 539, 540, "," +463, 5, 14, 102, 75, 87, 541, 553, "tolerability" +463, 5, 15, 103, 88, 89, 554, 555, "," +463, 5, 16, 104, 90, 93, 556, 559, "and" +463, 5, 17, 105, 94, 101, 560, 567, "patient" +463, 5, 18, 106, 102, 103, 568, 569, "-" +463, 5, 19, 107, 104, 112, 570, 578, "reported" +463, 5, 20, 108, 113, 121, 579, 587, "measures" +463, 5, 21, 109, 122, 124, 588, 590, "of" +463, 5, 22, 110, 125, 128, 591, 594, "the" +463, 5, 23, 111, 129, 140, 595, 606, "dorzolamide" +463, 5, 24, 112, 141, 142, 607, 608, "/" +463, 5, 25, 113, 143, 150, 609, 616, "timolol" +463, 5, 26, 114, 151, 156, 617, 622, "fixed" +463, 5, 27, 115, 157, 168, 623, 634, "combination" +463, 5, 28, 116, 169, 172, 635, 638, "and" +463, 5, 29, 117, 173, 176, 639, 642, "the" +463, 5, 30, 118, 177, 188, 643, 654, "concomitant" +463, 5, 31, 119, 189, 203, 655, 669, "administration" +463, 5, 32, 120, 204, 206, 670, 672, "of" +463, 5, 33, 121, 207, 218, 673, 684, "brimonidine" +463, 5, 34, 122, 219, 222, 685, 688, "and" +463, 5, 35, 123, 223, 230, 689, 696, "timolol" +463, 5, 36, 124, 231, 236, 697, 702, "after" +463, 5, 37, 125, 237, 238, 703, 704, "3" +463, 5, 38, 126, 239, 245, 705, 711, "months" +463, 5, 39, 127, 246, 247, 712, 713, "." +463, 6, 1, 128, 0, 7, 714, 721, "METHODS" +463, 6, 2, 129, 8, 9, 722, 723, ":" +463, 6, 3, 130, 10, 14, 724, 728, "Four" +463, 6, 4, 131, 15, 22, 729, 736, "hundred" +463, 6, 5, 132, 23, 29, 737, 743, "ninety" +463, 6, 6, 133, 30, 31, 744, 745, "-" +463, 6, 7, 134, 32, 35, 746, 749, "two" +463, 6, 8, 135, 36, 44, 750, 758, "patients" +463, 6, 9, 136, 45, 49, 759, 763, "with" +463, 6, 10, 137, 50, 56, 764, 770, "ocular" +463, 6, 11, 138, 57, 69, 771, 783, "hypertension" +463, 6, 12, 139, 70, 71, 784, 785, "," +463, 6, 13, 140, 72, 79, 786, 793, "primary" +463, 6, 14, 141, 80, 84, 794, 798, "open" +463, 6, 15, 142, 85, 86, 799, 800, "-" +463, 6, 16, 143, 87, 92, 801, 806, "angle" +463, 6, 17, 144, 93, 101, 807, 815, "glaucoma" +463, 6, 18, 145, 102, 103, 816, 817, "," +463, 6, 19, 146, 104, 115, 818, 829, "exfoliative" +463, 6, 20, 147, 116, 124, 830, 838, "glaucoma" +463, 6, 21, 148, 125, 126, 839, 840, "," +463, 6, 22, 149, 127, 129, 841, 843, "or" +463, 6, 23, 150, 130, 140, 844, 854, "pigmentary" +463, 6, 24, 151, 141, 149, 855, 863, "glaucoma" +463, 6, 25, 152, 150, 162, 864, 876, "participated" +463, 6, 26, 153, 163, 165, 877, 879, "in" +463, 6, 27, 154, 166, 170, 880, 884, "this" +463, 6, 28, 155, 171, 181, 885, 895, "randomized" +463, 6, 29, 156, 182, 183, 896, 897, "," +463, 6, 30, 157, 184, 192, 898, 906, "observer" +463, 6, 31, 158, 193, 194, 907, 908, "-" +463, 6, 32, 159, 195, 201, 909, 915, "masked" +463, 6, 33, 160, 202, 203, 916, 917, "," +463, 6, 34, 161, 204, 215, 918, 929, "multicenter" +463, 6, 35, 162, 216, 221, 930, 935, "study" +463, 6, 36, 163, 222, 223, 936, 937, "." +463, 7, 1, 164, 0, 9, 938, 947, "Following" +463, 7, 2, 165, 10, 11, 948, 949, "3" +463, 7, 3, 166, 12, 17, 950, 955, "weeks" +463, 7, 4, 167, 18, 20, 956, 958, "of" +463, 7, 5, 168, 21, 28, 959, 966, "timolol" +463, 7, 6, 169, 29, 40, 967, 978, "monotherapy" +463, 7, 7, 170, 41, 42, 979, 980, "," +463, 7, 8, 171, 43, 51, 981, 989, "patients" +463, 7, 9, 172, 52, 56, 990, 994, "with" +463, 7, 10, 173, 57, 58, 995, 996, "a" +463, 7, 11, 174, 59, 63, 997, 1001, "peak" +463, 7, 12, 175, 64, 67, 1002, 1005, "IOP" +463, 7, 13, 176, 68, 70, 1006, 1008, "of" +463, 7, 14, 177, 71, 72, 1009, 1010, ">" +463, 7, 15, 178, 73, 75, 1011, 1013, "or" +463, 7, 16, 179, 76, 77, 1014, 1015, "=" +463, 7, 17, 180, 78, 79, 1016, 1017, "2" +463, 7, 18, 181, 80, 82, 1018, 1020, "mm" +463, 7, 19, 182, 83, 85, 1021, 1023, "Hg" +463, 7, 20, 183, 86, 90, 1024, 1028, "were" +463, 7, 21, 184, 91, 101, 1029, 1039, "randomized" +463, 7, 22, 185, 102, 104, 1040, 1042, "to" +463, 7, 23, 186, 105, 112, 1043, 1050, "receive" +463, 7, 24, 187, 113, 119, 1051, 1057, "either" +463, 7, 25, 188, 120, 125, 1058, 1063, "fixed" +463, 7, 26, 189, 126, 137, 1064, 1075, "combination" +463, 7, 27, 190, 138, 149, 1076, 1087, "dorzolamide" +463, 7, 28, 191, 150, 151, 1088, 1089, "/" +463, 7, 29, 192, 152, 159, 1090, 1097, "timolol" +463, 7, 30, 193, 160, 165, 1098, 1103, "twice" +463, 7, 31, 194, 166, 171, 1104, 1109, "daily" +463, 7, 32, 195, 172, 174, 1110, 1112, "or" +463, 7, 33, 196, 175, 186, 1113, 1124, "concomitant" +463, 7, 34, 197, 187, 198, 1125, 1136, "brimonidine" +463, 7, 35, 198, 199, 203, 1137, 1141, "plus" +463, 7, 36, 199, 204, 211, 1142, 1149, "timolol" +463, 7, 37, 200, 212, 217, 1150, 1155, "twice" +463, 7, 38, 201, 218, 223, 1156, 1161, "daily" +463, 7, 39, 202, 224, 227, 1162, 1165, "for" +463, 7, 40, 203, 228, 229, 1166, 1167, "3" +463, 7, 41, 204, 230, 236, 1168, 1174, "months" +463, 7, 42, 205, 237, 238, 1175, 1176, "." +463, 8, 1, 206, 0, 3, 1177, 1180, "The" +463, 8, 2, 207, 4, 7, 1181, 1184, "IOP" +463, 8, 3, 208, 8, 9, 1185, 1186, "-" +463, 8, 4, 209, 10, 18, 1187, 1195, "lowering" +463, 8, 5, 210, 19, 26, 1196, 1203, "effects" +463, 8, 6, 211, 27, 29, 1204, 1206, "at" +463, 8, 7, 212, 30, 34, 1207, 1211, "peak" +463, 8, 8, 213, 35, 38, 1212, 1215, "and" +463, 8, 9, 214, 39, 45, 1216, 1222, "trough" +463, 8, 10, 215, 46, 47, 1223, 1224, "," +463, 8, 11, 216, 48, 60, 1225, 1237, "tolerability" +463, 8, 12, 217, 61, 62, 1238, 1239, "," +463, 8, 13, 218, 63, 66, 1240, 1243, "and" +463, 8, 14, 219, 67, 74, 1244, 1251, "patient" +463, 8, 15, 220, 75, 76, 1252, 1253, "-" +463, 8, 16, 221, 77, 85, 1254, 1262, "reported" +463, 8, 17, 222, 86, 97, 1263, 1274, "convenience" +463, 8, 18, 223, 98, 101, 1275, 1278, "and" +463, 8, 19, 224, 102, 114, 1279, 1291, "satisfaction" +463, 8, 20, 225, 115, 119, 1292, 1296, "were" +463, 8, 21, 226, 120, 128, 1297, 1305, "measured" +463, 8, 22, 227, 129, 131, 1306, 1308, "at" +463, 8, 23, 228, 132, 138, 1309, 1315, "months" +463, 8, 24, 229, 139, 140, 1316, 1317, "1" +463, 8, 25, 230, 141, 144, 1318, 1321, "and" +463, 8, 26, 231, 145, 146, 1322, 1323, "3" +463, 8, 27, 232, 147, 148, 1324, 1325, "." +463, 9, 1, 233, 0, 7, 1326, 1333, "RESULTS" +463, 9, 2, 234, 8, 9, 1334, 1335, ":" +463, 9, 3, 235, 10, 12, 1336, 1338, "At" +463, 9, 4, 236, 13, 18, 1339, 1344, "month" +463, 9, 5, 237, 19, 20, 1345, 1346, "3" +463, 9, 6, 238, 21, 25, 1347, 1351, "peak" +463, 9, 7, 239, 26, 27, 1352, 1353, "," +463, 9, 8, 240, 28, 31, 1354, 1357, "the" +463, 9, 9, 241, 32, 43, 1358, 1369, "dorzolamide" +463, 9, 10, 242, 44, 45, 1370, 1371, "/" +463, 9, 11, 243, 46, 53, 1372, 1379, "timolol" +463, 9, 12, 244, 54, 59, 1380, 1385, "group" +463, 9, 13, 245, 60, 63, 1386, 1389, "had" +463, 9, 14, 246, 64, 66, 1390, 1392, "an" +463, 9, 15, 247, 67, 75, 1393, 1401, "adjusted" +463, 9, 16, 248, 76, 80, 1402, 1406, "mean" +463, 9, 17, 249, 81, 82, 1407, 1408, "(" +463, 9, 18, 250, 83, 85, 1409, 1411, "SE" +463, 9, 19, 251, 86, 87, 1412, 1413, ")" +463, 9, 20, 252, 88, 94, 1414, 1420, "change" +463, 9, 21, 253, 95, 99, 1421, 1425, "from" +463, 9, 22, 254, 100, 108, 1426, 1434, "baseline" +463, 9, 23, 255, 109, 112, 1435, 1438, "IOP" +463, 9, 24, 256, 113, 115, 1439, 1441, "of" +463, 9, 25, 257, 116, 117, 1442, 1443, "-" +463, 9, 26, 258, 118, 119, 1444, 1445, "4" +463, 9, 27, 259, 120, 121, 1446, 1447, "." +463, 9, 28, 260, 122, 124, 1448, 1450, "30" +463, 9, 29, 261, 125, 126, 1451, 1452, "(" +463, 9, 30, 262, 127, 128, 1453, 1454, "0" +463, 9, 31, 263, 129, 130, 1455, 1456, "." +463, 9, 32, 264, 131, 133, 1457, 1459, "24" +463, 9, 33, 265, 134, 135, 1460, 1461, ")" +463, 9, 34, 266, 136, 138, 1462, 1464, "mm" +463, 9, 35, 267, 139, 141, 1465, 1467, "Hg" +463, 9, 36, 268, 142, 148, 1468, 1474, "versus" +463, 9, 37, 269, 149, 150, 1475, 1476, "-" +463, 9, 38, 270, 151, 152, 1477, 1478, "5" +463, 9, 39, 271, 153, 154, 1479, 1480, "." +463, 9, 40, 272, 155, 157, 1481, 1483, "27" +463, 9, 41, 273, 158, 159, 1484, 1485, "(" +463, 9, 42, 274, 160, 161, 1486, 1487, "0" +463, 9, 43, 275, 162, 163, 1488, 1489, "." +463, 9, 44, 276, 164, 166, 1490, 1492, "23" +463, 9, 45, 277, 167, 168, 1493, 1494, ")" +463, 9, 46, 278, 169, 171, 1495, 1497, "mm" +463, 9, 47, 279, 172, 174, 1498, 1500, "Hg" +463, 9, 48, 280, 175, 177, 1501, 1503, "in" +463, 9, 49, 281, 178, 181, 1504, 1507, "the" +463, 9, 50, 282, 182, 193, 1508, 1519, "brimonidine" +463, 9, 51, 283, 194, 195, 1520, 1521, "-" +463, 9, 52, 284, 196, 200, 1522, 1526, "plus" +463, 9, 53, 285, 201, 202, 1527, 1528, "-" +463, 9, 54, 286, 203, 210, 1529, 1536, "timolol" +463, 9, 55, 287, 211, 216, 1537, 1542, "group" +463, 9, 56, 288, 217, 218, 1543, 1544, "," +463, 9, 57, 289, 219, 223, 1545, 1549, "with" +463, 9, 58, 290, 224, 225, 1550, 1551, "a" +463, 9, 59, 291, 226, 235, 1552, 1561, "treatment" +463, 9, 60, 292, 236, 246, 1562, 1572, "difference" +463, 9, 61, 293, 247, 249, 1573, 1575, "of" +463, 9, 62, 294, 250, 251, 1576, 1577, "0" +463, 9, 63, 295, 252, 253, 1578, 1579, "." +463, 9, 64, 296, 254, 256, 1580, 1582, "97" +463, 9, 65, 297, 257, 259, 1583, 1585, "mm" +463, 9, 66, 298, 260, 262, 1586, 1588, "Hg" +463, 9, 67, 299, 263, 264, 1589, 1590, "(" +463, 9, 68, 300, 265, 267, 1591, 1593, "95" +463, 9, 69, 301, 268, 269, 1594, 1595, "%" +463, 9, 70, 302, 270, 272, 1596, 1598, "CI" +463, 9, 71, 303, 273, 274, 1599, 1600, ":" +463, 9, 72, 304, 275, 276, 1601, 1602, "0" +463, 9, 73, 305, 277, 278, 1603, 1604, "." +463, 9, 74, 306, 279, 281, 1605, 1607, "40" +463, 9, 75, 307, 282, 283, 1608, 1609, "," +463, 9, 76, 308, 284, 285, 1610, 1611, "1" +463, 9, 77, 309, 286, 287, 1612, 1613, "." +463, 9, 78, 310, 288, 290, 1614, 1616, "53" +463, 9, 79, 311, 291, 292, 1617, 1618, ")" +463, 9, 80, 312, 293, 294, 1619, 1620, "." +463, 10, 1, 313, 0, 2, 1621, 1623, "At" +463, 10, 2, 314, 3, 6, 1624, 1627, "the" +463, 10, 3, 315, 7, 12, 1628, 1633, "month" +463, 10, 4, 316, 13, 14, 1634, 1635, "3" +463, 10, 5, 317, 15, 21, 1636, 1642, "trough" +463, 10, 6, 318, 22, 31, 1643, 1652, "timepoint" +463, 10, 7, 319, 32, 35, 1653, 1656, "and" +463, 10, 8, 320, 36, 40, 1657, 1661, "both" +463, 10, 9, 321, 41, 46, 1662, 1667, "month" +463, 10, 10, 322, 47, 48, 1668, 1669, "1" +463, 10, 11, 323, 49, 59, 1670, 1680, "timepoints" +463, 10, 12, 324, 60, 61, 1681, 1682, "," +463, 10, 13, 325, 62, 65, 1683, 1686, "the" +463, 10, 14, 326, 66, 68, 1687, 1689, "95" +463, 10, 15, 327, 69, 70, 1690, 1691, "%" +463, 10, 16, 328, 71, 74, 1692, 1695, "CIs" +463, 10, 17, 329, 75, 77, 1696, 1698, "of" +463, 10, 18, 330, 78, 81, 1699, 1702, "the" +463, 10, 19, 331, 82, 91, 1703, 1712, "treatment" +463, 10, 20, 332, 92, 103, 1713, 1724, "differences" +463, 10, 21, 333, 104, 108, 1725, 1729, "were" +463, 10, 22, 334, 109, 115, 1730, 1736, "within" +463, 10, 23, 335, 116, 119, 1737, 1740, "the" +463, 10, 24, 336, 120, 132, 1741, 1753, "prespecified" +463, 10, 25, 337, 133, 146, 1754, 1767, "comparability" +463, 10, 26, 338, 147, 155, 1768, 1776, "boundary" +463, 10, 27, 339, 156, 158, 1777, 1779, "of" +463, 10, 28, 340, 159, 160, 1780, 1781, "+" +463, 10, 29, 341, 161, 162, 1782, 1783, "/" +463, 10, 30, 342, 163, 164, 1784, 1785, "-" +463, 10, 31, 343, 165, 166, 1786, 1787, "1" +463, 10, 32, 344, 167, 168, 1788, 1789, "." +463, 10, 33, 345, 169, 170, 1790, 1791, "5" +463, 10, 34, 346, 171, 173, 1792, 1794, "mm" +463, 10, 35, 347, 174, 176, 1795, 1797, "Hg" +463, 10, 36, 348, 177, 178, 1798, 1799, "." +463, 11, 1, 349, 0, 3, 1800, 1803, "The" +463, 11, 2, 350, 4, 13, 1804, 1813, "incidence" +463, 11, 3, 351, 14, 16, 1814, 1816, "of" +463, 11, 4, 352, 17, 21, 1817, 1821, "drug" +463, 11, 5, 353, 22, 23, 1822, 1823, "-" +463, 11, 6, 354, 24, 31, 1824, 1831, "related" +463, 11, 7, 355, 32, 39, 1832, 1839, "adverse" +463, 11, 8, 356, 40, 51, 1840, 1851, "experiences" +463, 11, 9, 357, 52, 55, 1852, 1855, "was" +463, 11, 10, 358, 56, 63, 1856, 1863, "similar" +463, 11, 11, 359, 64, 71, 1864, 1871, "between" +463, 11, 12, 360, 72, 81, 1872, 1881, "treatment" +463, 11, 13, 361, 82, 88, 1882, 1888, "groups" +463, 11, 14, 362, 89, 90, 1889, 1890, "." +463, 12, 1, 363, 0, 7, 1891, 1898, "Patient" +463, 12, 2, 364, 8, 9, 1899, 1900, "-" +463, 12, 3, 365, 10, 18, 1901, 1909, "reported" +463, 12, 4, 366, 19, 30, 1910, 1921, "assessments" +463, 12, 5, 367, 31, 33, 1922, 1924, "of" +463, 12, 6, 368, 34, 45, 1925, 1936, "convenience" +463, 12, 7, 369, 46, 49, 1937, 1940, "and" +463, 12, 8, 370, 50, 62, 1941, 1953, "satisfaction" +463, 12, 9, 371, 63, 69, 1954, 1960, "showed" +463, 12, 10, 372, 70, 72, 1961, 1963, "no" +463, 12, 11, 373, 73, 86, 1964, 1977, "statistically" +463, 12, 12, 374, 87, 98, 1978, 1989, "significant" +463, 12, 13, 375, 99, 110, 1990, 2001, "differences" +463, 12, 14, 376, 111, 118, 2002, 2009, "between" +463, 12, 15, 377, 119, 128, 2010, 2019, "treatment" +463, 12, 16, 378, 129, 135, 2020, 2026, "groups" +463, 12, 17, 379, 136, 137, 2027, 2028, "." +463, 13, 1, 380, 0, 11, 2029, 2040, "CONCLUSIONS" +463, 13, 2, 381, 12, 13, 2041, 2042, ":" +463, 13, 3, 382, 14, 17, 2043, 2046, "The" +463, 13, 4, 383, 18, 21, 2047, 2050, "IOP" +463, 13, 5, 384, 22, 23, 2051, 2052, "-" +463, 13, 6, 385, 24, 32, 2053, 2061, "lowering" +463, 13, 7, 386, 33, 39, 2062, 2068, "effect" +463, 13, 8, 387, 40, 42, 2069, 2071, "of" +463, 13, 9, 388, 43, 46, 2072, 2075, "the" +463, 13, 10, 389, 47, 58, 2076, 2087, "dorzolamide" +463, 13, 11, 390, 59, 60, 2088, 2089, "/" +463, 13, 12, 391, 61, 68, 2090, 2097, "timolol" +463, 13, 13, 392, 69, 74, 2098, 2103, "fixed" +463, 13, 14, 393, 75, 86, 2104, 2115, "combination" +463, 13, 15, 394, 87, 90, 2116, 2119, "and" +463, 13, 16, 395, 91, 102, 2120, 2131, "concomitant" +463, 13, 17, 396, 103, 114, 2132, 2143, "brimonidine" +463, 13, 18, 397, 115, 119, 2144, 2148, "plus" +463, 13, 19, 398, 120, 127, 2149, 2156, "timolol" +463, 13, 20, 399, 128, 132, 2157, 2161, "were" +463, 13, 21, 400, 133, 143, 2162, 2172, "comparable" +463, 13, 22, 401, 144, 146, 2173, 2175, "at" +463, 13, 23, 402, 147, 148, 2176, 2177, "3" +463, 13, 24, 403, 149, 151, 2178, 2180, "of" +463, 13, 25, 404, 152, 155, 2181, 2184, "the" +463, 13, 26, 405, 156, 157, 2185, 2186, "4" +463, 13, 27, 406, 158, 168, 2187, 2197, "timepoints" +463, 13, 28, 407, 169, 177, 2198, 2206, "measured" +463, 13, 29, 408, 178, 179, 2207, 2208, "." +463, 14, 1, 409, 0, 7, 2209, 2216, "Patient" +463, 14, 2, 410, 8, 9, 2217, 2218, "-" +463, 14, 3, 411, 10, 18, 2219, 2227, "reported" +463, 14, 4, 412, 19, 27, 2228, 2236, "measures" +463, 14, 5, 413, 28, 31, 2237, 2240, "and" +463, 14, 6, 414, 32, 35, 2241, 2244, "the" +463, 14, 7, 415, 36, 45, 2245, 2254, "incidence" +463, 14, 8, 416, 46, 48, 2255, 2257, "of" +463, 14, 9, 417, 49, 56, 2258, 2265, "adverse" +463, 14, 10, 418, 57, 68, 2266, 2277, "experiences" +463, 14, 11, 419, 69, 71, 2278, 2280, "in" +463, 14, 12, 420, 72, 76, 2281, 2285, "both" +463, 14, 13, 421, 77, 86, 2286, 2295, "treatment" +463, 14, 14, 422, 87, 93, 2296, 2302, "groups" +463, 14, 15, 423, 94, 98, 2303, 2307, "were" +463, 14, 16, 424, 99, 106, 2308, 2315, "similar" +463, 14, 17, 425, 107, 108, 2316, 2317, "." +463, 15, 1, 426, 0, 4, 2318, 2322, "PMID" +463, 15, 2, 427, 5, 6, 2323, 2324, ":" +463, 15, 3, 428, 7, 15, 2325, 2333, "15097262" +463, 15, 4, 429, 16, 17, 2334, 2335, "[" +463, 15, 5, 430, 18, 25, 2336, 2343, "Indexed" +463, 15, 6, 431, 26, 29, 2344, 2347, "for" +463, 15, 7, 432, 30, 37, 2348, 2355, "MEDLINE" +463, 15, 8, 433, 38, 39, 2356, 2357, "]" diff --git a/data/gl 15097262_jshahinitiran.annodb b/data/gl 15097262_jshahinitiran.annodb new file mode 100644 index 0000000..119f6fb --- /dev/null +++ b/data/gl 15097262_jshahinitiran.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8858, Journal, 0, 10, "J Glaucoma", "", +8859, PublicationYear, 13, 17, "2004", "", +8860, Dorzolamide, 46, 57, "Dorzolamide", "", +8867, Title, 46, 279, "Dorzolamide / Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure : a 3 - month comparison of efficacy , tolerability , and patient - reported measures", "", +8861, Timolol, 60, 67, "Timolol", "", +8862, Brimonidine, 123, 134, "brimonidine", "", +8863, Timolol, 139, 146, "timolol", "", +8865, Precondition, 164, 193, "elevated intraocular pressure", "", +8864, IOP, 173, 193, "intraocular pressure", "", +8866, Duration, 198, 207, "3 - month", "", +27940, Author, 282, 291, "Solish AM", "", +27941, Author, 300, 310, "DeLucca PT", "", +27942, Author, 313, 322, "Cassel DA", "", +27943, Author, 325, 335, "Kolodny AH", "", +27944, Author, 338, 347, "Hustad CM", "", +27945, Author, 350, 363, "Skobieranda F", "", +8868, USA, 460, 463, "USA", "", +8869, ObjectiveDescription, 479, 711, "To compare the intraocular pressure ( IOP ) lowering effect , tolerability , and patient - reported measures of the dorzolamide / timolol fixed combination and the concomitant administration of brimonidine and timolol after 3 months", "", +8870, IOP, 494, 514, "intraocular pressure", "", +8871, IOP, 517, 520, "IOP", "", +8872, Dorzolamide, 595, 606, "dorzolamide", "", +8873, Timolol, 609, 616, "timolol", "", +8874, Brimonidine, 673, 684, "brimonidine", "", +8875, Timolol, 689, 696, "timolol", "", +8876, Duration, 703, 711, "3 months", "", +8877, NumberPatientsCT, 724, 749, "Four hundred ninety - two", "", +8878, OcularHypertension, 764, 783, "ocular hypertension", "", +27916, Primary_OpenAngleGlaucoma, 786, 815, "primary open - angle glaucoma", "", +8880, Glaucoma, 818, 838, "exfoliative glaucoma", "exfoliative", +8881, PigmentaryGlaucoma, 844, 863, "pigmentary glaucoma", "", +8883, Randomized, 885, 895, "randomized", "", +8884, Blind, 898, 915, "observer - masked", "", +8885, Multicenter, 918, 929, "multicenter", "", +8886, Timolol, 959, 966, "timolol", "", +8887, Peak_IOP, 997, 1005, "peak IOP", "", +8888, Precondition, 997, 1023, "peak IOP of > or = 2 mm Hg", "", +8889, mmHg, 1018, 1023, "mm Hg", "", +8890, Randomized, 1029, 1039, "randomized", "", +27917, Dorzolamide, 1076, 1087, "dorzolamide", "", +27918, Timolol, 1090, 1097, "timolol", "", +8893, Frequency, 1098, 1109, "twice daily", "", +27919, Brimonidine, 1125, 1136, "brimonidine", "", +27920, Timolol, 1142, 1149, "timolol", "", +8896, Frequency, 1150, 1161, "twice daily", "", +8897, Duration, 1166, 1174, "3 months", "", +8898, IOP, 1181, 1184, "IOP", "", +27921, Peak_IOP, 1207, 1211, "peak", "", +27922, Trough_IOP, 1216, 1222, "trough", "", +27923, TimePoint, 1309, 1325, "months 1 and 3 .", "", +27924, TimePoint, 1339, 1346, "month 3", "", +27927, Peak_IOP, 1347, 1351, "peak", "", +27925, Dorzolamide, 1358, 1369, "dorzolamide", "", +27926, Timolol, 1372, 1379, "timolol", "", +8905, Mean, 1402, 1406, "mean", "", +8906, IOP, 1435, 1438, "IOP", "", +8907, Reduction, 1444, 1450, "4 . 30", "", +8908, SdErrorChangeValue, 1453, 1459, "0 . 24", "", +8909, mmHg, 1462, 1467, "mm Hg", "", +8910, Reduction, 1477, 1483, "5 . 27", "", +8911, SdErrorChangeValue, 1486, 1492, "0 . 23", "", +8912, mmHg, 1495, 1500, "mm Hg", "", +27928, Brimonidine, 1508, 1519, "brimonidine", "", +27929, Timolol, 1529, 1536, "timolol", "", +8915, DiffGroupAbsValue, 1576, 1582, "0 . 97", "", +8916, mmHg, 1583, 1588, "mm Hg", "", +8917, ConfIntervalDiff, 1591, 1616, "95 % CI : 0 . 40 , 1 . 53", "", +27930, TimePoint, 1628, 1635, "month 3", "", +27931, Trough_IOP, 1636, 1642, "trough", "", +8920, TimePoint, 1662, 1669, "month 1", "", +27932, mmHg, 1792, 1797, "mm Hg", "", +27938, ConclusionComment, 2043, 2208, "The IOP - lowering effect of the dorzolamide / timolol fixed combination and concomitant brimonidine plus timolol were comparable at 3 of the 4 timepoints measured .", "", +8921, IOP, 2047, 2050, "IOP", "", +27933, Dorzolamide, 2076, 2087, "dorzolamide", "", +27934, Timolol, 2090, 2097, "timolol", "", +27935, Brimonidine, 2132, 2143, "brimonidine", "", +27936, Timolol, 2149, 2156, "timolol", "", +27937, ObservedResult, 2209, 2317, "Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar .", "", +27939, ConclusionComment, 2209, 2317, "Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar .", "", +8926, PMID, 2325, 2333, "15097262", "", diff --git a/data/gl 15097262_jshahinitiran.n-triples b/data/gl 15097262_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15097262_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15097262_tstrakeljahn.annodb b/data/gl 15097262_tstrakeljahn.annodb new file mode 100644 index 0000000..6ab7bf6 --- /dev/null +++ b/data/gl 15097262_tstrakeljahn.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30718, Journal, 0, 10, "J Glaucoma", "", +30719, PublicationYear, 13, 17, "2004", "", +30720, Dorzolamide, 46, 57, "Dorzolamide", "", +30726, Title, 46, 279, "Dorzolamide / Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure : a 3 - month comparison of efficacy , tolerability , and patient - reported measures", "", +30721, Timolol, 60, 67, "Timolol", "", +30722, Brimonidine, 123, 134, "brimonidine", "", +30723, Timolol, 139, 146, "timolol", "", +30724, IOP, 173, 193, "intraocular pressure", "", +30725, Duration, 198, 207, "3 - month", "", +30727, Author, 282, 291, "Solish AM", "", +30728, Author, 300, 310, "DeLucca PT", "", +30729, Author, 313, 322, "Cassel DA", "", +30730, Author, 325, 335, "Kolodny AH", "", +30731, Author, 338, 347, "Hustad CM", "", +30732, Author, 350, 363, "Skobieranda F", "", +30733, USA, 460, 463, "USA", "", +30741, ObjectiveDescription, 479, 713, "To compare the intraocular pressure ( IOP ) lowering effect , tolerability , and patient - reported measures of the dorzolamide / timolol fixed combination and the concomitant administration of brimonidine and timolol after 3 months .", "", +30734, IOP, 494, 514, "intraocular pressure", "", +30735, IOP, 517, 520, "IOP", "", +30736, Dorzolamide, 595, 606, "dorzolamide", "", +30737, Timolol, 609, 616, "timolol", "", +30738, Brimonidine, 673, 684, "brimonidine", "", +30739, Timolol, 689, 696, "timolol", "", +30740, Duration, 703, 711, "3 months", "", +30742, NumberPatientsCT, 724, 749, "Four hundred ninety - two", "", +30743, OcularHypertension, 764, 783, "ocular hypertension", "", +30744, Primary_OpenAngleGlaucoma, 786, 815, "primary open - angle glaucoma", "", +30745, Glaucoma, 830, 838, "glaucoma", "", +30746, PigmentaryGlaucoma, 844, 863, "pigmentary glaucoma", "", +30747, Randomized, 885, 895, "randomized", "", +30748, Blind, 898, 915, "observer - masked", "", +30749, Multicenter, 918, 929, "multicenter", "", +30750, Peak_IOP, 997, 1005, "peak IOP", "", +30751, mmHg, 1018, 1023, "mm Hg", "", +30752, Randomized, 1029, 1039, "randomized", "", +30753, Dorzolamide, 1076, 1087, "dorzolamide", "", +30754, Timolol, 1090, 1097, "timolol", "", +30755, Frequency, 1098, 1109, "twice daily", "", +30756, Brimonidine, 1125, 1136, "brimonidine", "", +30757, Timolol, 1142, 1149, "timolol", "", +30758, Frequency, 1150, 1161, "twice daily", "", +30759, Duration, 1166, 1174, "3 months", "", +30760, IOP, 1181, 1184, "IOP", "", +30761, Peak_IOP, 1207, 1211, "peak", "", +30762, Trough_IOP, 1216, 1222, "trough", "", +30763, TimePoint, 1339, 1346, "month 3", "", +30766, Dorzolamide, 1358, 1369, "dorzolamide", "", +30767, Timolol, 1372, 1379, "timolol", "", +30768, Mean, 1402, 1406, "mean", "", +30765, Peak_IOP, 1435, 1438, "IOP", "", +30769, Reduction, 1444, 1450, "4 . 30", "", +30773, SdErrorChangeValue, 1453, 1459, "0 . 24", "", +30771, mmHg, 1462, 1467, "mm Hg", "", +30770, Reduction, 1477, 1483, "5 . 27", "", +30774, SdErrorChangeValue, 1486, 1492, "0 . 23", "", +30772, mmHg, 1495, 1500, "mm Hg", "", +30775, Brimonidine, 1508, 1519, "brimonidine", "", +30776, Timolol, 1529, 1536, "timolol", "", +30777, DiffGroupAbsValue, 1576, 1582, "0 . 97", "", +30778, mmHg, 1583, 1588, "mm Hg", "", +30779, ConfIntervalDiff, 1601, 1616, "0 . 40 , 1 . 53", "", +30764, TimePoint, 1628, 1635, "month 3", "", +30780, TimePoint, 1662, 1669, "month 1", "", +30782, SdDevDiff, 1780, 1791, "+ / - 1 . 5", "", +30781, mmHg, 1792, 1797, "mm Hg", "", +30783, ObservedResult, 1800, 1890, "The incidence of drug - related adverse experiences was similar between treatment groups .", "", +30784, ObservedResult, 1891, 2028, "Patient - reported assessments of convenience and satisfaction showed no statistically significant differences between treatment groups .", "", +30790, ConclusionComment, 2043, 2208, "The IOP - lowering effect of the dorzolamide / timolol fixed combination and concomitant brimonidine plus timolol were comparable at 3 of the 4 timepoints measured .", "", +30785, IOP, 2047, 2050, "IOP", "", +30786, Dorzolamide, 2076, 2087, "dorzolamide", "", +30787, Timolol, 2090, 2097, "timolol", "", +30788, Brimonidine, 2132, 2143, "brimonidine", "", +30789, Timolol, 2149, 2156, "timolol", "", +30791, ConclusionComment, 2209, 2317, "Patient - reported measures and the incidence of adverse experiences in both treatment groups were similar .", "", +30792, PMID, 2325, 2333, "15097262", "", diff --git a/data/gl 15097262_tstrakeljahn.n-triples b/data/gl 15097262_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15097262_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15205229_admin.annodb b/data/gl 15205229_admin.annodb new file mode 100644 index 0000000..b058516 --- /dev/null +++ b/data/gl 15205229_admin.annodb @@ -0,0 +1,116 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2004", "", " \"2004\"." +129, Title, 51, 220, "A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure .", "", " \"A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure .\"." +5, Lat/TimFC, 71, 115, "fixed combination of latanoprost and timolol", "", +3, Latanoprost, 92, 103, "latanoprost", "", +4, Timolol, 108, 115, "timolol", "", +6, Brimonidine, 148, 159, "brimonidine", "", +7, Timolol, 164, 171, "timolol", "", +9, Precondition, 175, 218, "patients with elevated intraocular pressure", "", +8, IOP, 198, 218, "intraocular pressure", "", +129, Title, 221, 283, "A six month , evaluator masked , multicentre study in Europe .", "", " \"A six month , evaluator masked , multicentre study in Europe .\"." +11, Duration, 223, 232, "six month", "", " \"six month\"." +12, Blind, 235, 251, "evaluator masked", "", " ." +13, Multicenter, 254, 265, "multicentre", "", " ." +14, Author, 284, 306, "Garc í a - S á nchez J", "", " \"Garc í a - S á nchez J\"." +15, Author, 315, 325, "Rouland JF", "", " \"Rouland JF\"." +16, Author, 328, 337, "Spiegel D", "", " \"Spiegel D\"." +17, Author, 340, 347, "Pajic B", "", " \"Pajic B\"." +18, Author, 350, 360, "Cunliffe I", "", " \"Cunliffe I\"." +19, Author, 363, 373, "Traverso C", "", " \"Traverso C\"." +20, Author, 376, 384, "Landry J", "", " \"Landry J\"." +21, Spain, 515, 520, "Spain", "", +22, ObjectiveDescription, 559, 767, "To compare the intraocular pressure ( IOP ) reducing effect and safety of fixed combination ( FC ) latanoprost / timolol with unfixed combination ( UFC ) brimonidine / timolol in patients with increased IOP .", "", " \"To compare the intraocular pressure ( IOP ) reducing effect and safety of fixed combination ( FC ) latanoprost / timolol with unfixed combination ( UFC ) brimonidine / timolol in patients with increased IOP .\"." +23, IOP, 574, 594, "intraocular pressure", "", +24, IOP, 597, 600, "IOP", "", +27, Lat/TimFC, 633, 679, "fixed combination ( FC ) latanoprost / timolol", "", " ." +25, Latanoprost, 658, 669, "latanoprost", "", +26, Timolol, 672, 679, "timolol", "", +28, Brimonidine, 713, 724, "brimonidine", "", +29, Timolol, 727, 734, "timolol", "", +126, IOP, 762, 765, "IOP", "", +31, Duration, 786, 793, "6 month", "", +32, Randomized, 796, 806, "randomised", "", " ." +33, Blind, 809, 825, "evaluator masked", "", +34, Parallel, 828, 842, "parallel group", "", " ." +101259, Precondition, 860, 984, "patients with glaucoma or ocular hypertension and IOP & gt ; or = 21 mm Hg on monotherapy or & gt ; 16 mm Hg on dual therapy", "", " \"patients with glaucoma or ocular hypertension and IOP & gt ; or = 21 mm Hg on monotherapy or & gt ; 16 mm Hg on dual therapy\"." +35, Glaucoma, 874, 882, "glaucoma", "", " . ." +36, OcularHypertension, 886, 905, "ocular hypertension", "", " ." +143, IOP, 910, 913, "IOP", "", +38, mmHg, 929, 934, "mm Hg", "", +40, mmHg, 963, 968, "mm Hg", "", +44, Lat/TimFC, 1001, 1025, "FC latanoprost / timolol", "", +42, Latanoprost, 1004, 1015, "latanoprost", "", +43, Timolol, 1018, 1025, "timolol", "", +106253, RelativeTime, 1029, 1037, "8 : 00AM", "", " . ." +45, Brimonidine, 1045, 1056, "brimonidine", "", " ." +46, Timolol, 1059, 1066, "timolol", "", " ." +106254, RelativeTime, 1070, 1078, "8 : 00AM", "", " . ." +106255, RelativeTime, 1083, 1091, "8 : 00PM", "", " . ." +47, TimePoint, 1138, 1146, "baseline", "", +48, TimePoint, 1150, 1157, "month 6", "", +49, Mean, 1161, 1165, "mean", "", " . ." +50, Diurnal_IOP, 1166, 1177, "diurnal IOP", "", +159, FinalNumPatientsCT, 1200, 1203, "325", "", " \"325\"." +51, NumberPatientsCT, 1207, 1210, "334", "", " \"334\"." +52, Randomized, 1211, 1221, "randomised", "", +53, IntentionToTreat, 1248, 1263, "intent to treat", "", " ." +56, Lat/TimFC, 1275, 1299, "FC latanoprost / timolol", "", +54, Latanoprost, 1278, 1289, "latanoprost", "", +55, Timolol, 1292, 1299, "timolol", "", +59, NumberPatientsArm, 1302, 1305, "163", "", " \"163\"." +57, Brimonidine, 1312, 1323, "brimonidine", "", +58, Timolol, 1326, 1333, "timolol", "", +60, NumberPatientsArm, 1336, 1339, "162", "", " \"162\"." +61, Diurnal_IOP, 1353, 1364, "diurnal IOP", "", " ." +175, Lat/TimFC, 1387, 1411, "FC latanoprost / timolol", "", +62, Latanoprost, 1390, 1401, "latanoprost", "", +63, Timolol, 1404, 1411, "timolol", "", +64, BaseLineValue, 1414, 1420, "26 . 4", "", " \"26 . 4\"." +65, SdDevBL, 1426, 1431, "2 . 7", "", " \"2 . 7\"." +66, mmHg, 1434, 1439, "mm Hg", "", " ." +67, Brimonidine, 1446, 1457, "brimonidine", "", +68, Timolol, 1460, 1467, "timolol", "", +69, BaseLineValue, 1470, 1476, "26 . 5", "", " \"26 . 5\"." +70, SdDevBL, 1482, 1487, "2 . 8", "", " \"2 . 8\"." +71, mmHg, 1490, 1495, "mm Hg", "", +72, PValueBL, 1498, 1509, "p = 0 . 851", "", " \"p = 0 . 851\". \"p = 0 . 851\"." +73, TimePoint, 1517, 1524, "month 6", "", " \"month 6\". \"month 6\"." +74, ResultMeasuredValue, 1539, 1545, "16 . 9", "", " \"16 . 9\"." +76, SdDevResValue, 1551, 1556, "2 . 8", "", " \"2 . 8\"." +78, mmHg, 1559, 1564, "mm Hg", "", +82, Lat/TimFC, 1568, 1592, "FC latanoprost / timolol", "", +80, Latanoprost, 1571, 1582, "latanoprost", "", +81, Timolol, 1585, 1592, "timolol", "", +75, ResultMeasuredValue, 1606, 1612, "18 . 2", "", " \"18 . 2\"." +77, SdDevResValue, 1618, 1623, "3 . 1", "", " \"3 . 1\"." +79, mmHg, 1626, 1631, "mm Hg", "", +83, Brimonidine, 1639, 1650, "brimonidine", "", +84, Timolol, 1653, 1660, "timolol", "", +101261, PvalueDiff, 1672, 1688, "p & lt ; 0 . 001", "", " \"p & lt ; 0 . 001\"." +203, ObservedResult, 1693, 1844, "No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively", "", " \"No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively\". \"No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively\"." +101262, EndPointDescription, 1693, 1710, "No adverse events", "", " . ." +86, PercentageAffected, 1728, 1734, "76 . 4", "", " \"76 . 4\"." +87, PercentageAffected, 1741, 1747, "75 . 5", "", " \"75 . 5\"." +92, Lat/TimFC, 1772, 1796, "FC latanoprost / timolol", "", +88, Latanoprost, 1775, 1786, "latanoprost", "", +89, Timolol, 1789, 1796, "timolol", "", +91, Brimonidine, 1808, 1819, "brimonidine", "", +90, Timolol, 1822, 1829, "timolol", "", +93, Brimonidine, 1869, 1880, "brimonidine", "", +94, Timolol, 1883, 1890, "timolol", "", +101263, EndPointDescription, 1942, 1956, "adverse events", "", " . ." +95, PercentageAffected, 1959, 1965, "18 . 6", "", " \"18 . 6\"." +96, PercentageAffected, 1970, 1975, "7 . 3", "", " \"7 . 3\"." +208, RelNumPatientsLeftArm, 2035, 2041, "10 . 8", "", " \"10 . 8\"." +209, RelNumPatientsLeftArm, 2046, 2051, "1 . 8", "", " \"1 . 8\"." +99, ConclusionComment, 2071, 2235, "Fixed combination latanoprost / timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine / timolol .", "", " \"Fixed combination latanoprost / timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine / timolol .\"." +103, Lat/TimFC, 2071, 2110, "Fixed combination latanoprost / timolol", "", +100, Latanoprost, 2089, 2100, "latanoprost", "", +101, Timolol, 2103, 2110, "timolol", "", +104, Frequency, 2124, 2134, "once daily", "", " \"once daily\"." +105, Frequency, 2184, 2195, "twice daily", "", " \"twice daily\"." +106, Brimonidine, 2212, 2223, "brimonidine", "", +102, Timolol, 2226, 2233, "timolol", "", +107, PMID, 2300, 2308, "15205229", "", " \"15205229\"." diff --git a/data/gl 15205229_admin.n-triples b/data/gl 15205229_admin.n-triples new file mode 100644 index 0000000..527dc40 --- /dev/null +++ b/data/gl 15205229_admin.n-triples @@ -0,0 +1,160 @@ +# RDF export of group: Publication + . + "Publication 89653" . + "A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure ." . + "A six month , evaluator masked , multicentre study in Europe ." . + "Garc í a - S á nchez J" . + "2004" . + "Br J Ophthalmol ." . + "15205229" . + . + "Rouland JF" . + "Spiegel D" . + "Pajic B" . + "Cunliffe I" . + "Traverso C" . + "Landry J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 89660" . + "To compare the intraocular pressure ( IOP ) reducing effect and safety of fixed combination ( FC ) latanoprost / timolol with unfixed combination ( UFC ) brimonidine / timolol in patients with increased IOP ." . + "334" . + "six month" . + . + . + . + "Fixed combination latanoprost / timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine / timolol ." . + . + . + . + . + . + . + "325" . + . + . + . + . + . +# RDF export of group: Population + . + "Population 89676" . + "patients with glaucoma or ocular hypertension and IOP & gt ; or = 21 mm Hg on monotherapy or & gt ; 16 mm Hg on dual therapy" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "ae2" . + . + . + . + . + . +# RDF export of group: Arm + . + "lati" . + "163" . + . + . + . + "1 . 8" . + . + . + "briti" . + "162" . + . + . + . + "10 . 8" . + . +# RDF export of group: Intervention + . + "lati" . + "once daily" . + . + . + . + . + "briti" . + . + "twice daily" . + . + . + . + . + . +# RDF export of group: Medication + . + "bri" . + . + . + . + . + "ti2" . + . + . + . + . + "lati" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "26 . 4" . + "p = 0 . 851" . + "2 . 7" . + "16 . 9" . + "2 . 8" . + "month 6" . + . + "iop 2" . + . + "26 . 5" . + "p = 0 . 851" . + "2 . 8" . + "18 . 2" . + "3 . 1" . + "month 6" . + . + "ae 1" . + . + "76 . 4" . + "No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively" . + . + "ae 2" . + . + "75 . 5" . + "No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively" . + . + "ae2 1" . + . + "7 . 3" . + . + "ae2 2" . + . + "18 . 6" . +# RDF export of group: DiffBetweenGroups + . + "pio" . + "p & lt ; 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15205229_export.csv b/data/gl 15205229_export.csv new file mode 100644 index 0000000..63bb4bd --- /dev/null +++ b/data/gl 15205229_export.csv @@ -0,0 +1,493 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +553, 1, 1, 1, 0, 2, 0, 2, "Br" +553, 1, 2, 2, 3, 4, 3, 4, "J" +553, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +553, 1, 4, 4, 16, 17, 16, 17, "." +553, 2, 1, 5, 0, 4, 18, 22, "2004" +553, 2, 2, 6, 5, 8, 23, 26, "Jul" +553, 2, 3, 7, 9, 10, 27, 28, ";" +553, 2, 4, 8, 11, 13, 29, 31, "88" +553, 2, 5, 9, 14, 15, 32, 33, "(" +553, 2, 6, 10, 16, 17, 34, 35, "7" +553, 2, 7, 11, 18, 19, 36, 37, ")" +553, 2, 8, 12, 20, 21, 38, 39, ":" +553, 2, 9, 13, 22, 25, 40, 43, "877" +553, 2, 10, 14, 26, 27, 44, 45, "-" +553, 2, 11, 15, 28, 30, 46, 48, "83" +553, 2, 12, 16, 31, 32, 49, 50, "." +553, 3, 1, 17, 0, 1, 51, 52, "A" +553, 3, 2, 18, 2, 12, 53, 63, "comparison" +553, 3, 3, 19, 13, 15, 64, 66, "of" +553, 3, 4, 20, 16, 19, 67, 70, "the" +553, 3, 5, 21, 20, 25, 71, 76, "fixed" +553, 3, 6, 22, 26, 37, 77, 88, "combination" +553, 3, 7, 23, 38, 40, 89, 91, "of" +553, 3, 8, 24, 41, 52, 92, 103, "latanoprost" +553, 3, 9, 25, 53, 56, 104, 107, "and" +553, 3, 10, 26, 57, 64, 108, 115, "timolol" +553, 3, 11, 27, 65, 69, 116, 120, "with" +553, 3, 12, 28, 70, 73, 121, 124, "the" +553, 3, 13, 29, 74, 81, 125, 132, "unfixed" +553, 3, 14, 30, 82, 93, 133, 144, "combination" +553, 3, 15, 31, 94, 96, 145, 147, "of" +553, 3, 16, 32, 97, 108, 148, 159, "brimonidine" +553, 3, 17, 33, 109, 112, 160, 163, "and" +553, 3, 18, 34, 113, 120, 164, 171, "timolol" +553, 3, 19, 35, 121, 123, 172, 174, "in" +553, 3, 20, 36, 124, 132, 175, 183, "patients" +553, 3, 21, 37, 133, 137, 184, 188, "with" +553, 3, 22, 38, 138, 146, 189, 197, "elevated" +553, 3, 23, 39, 147, 158, 198, 209, "intraocular" +553, 3, 24, 40, 159, 167, 210, 218, "pressure" +553, 3, 25, 41, 168, 169, 219, 220, "." +553, 4, 1, 42, 0, 1, 221, 222, "A" +553, 4, 2, 43, 2, 5, 223, 226, "six" +553, 4, 3, 44, 6, 11, 227, 232, "month" +553, 4, 4, 45, 12, 13, 233, 234, "," +553, 4, 5, 46, 14, 23, 235, 244, "evaluator" +553, 4, 6, 47, 24, 30, 245, 251, "masked" +553, 4, 7, 48, 31, 32, 252, 253, "," +553, 4, 8, 49, 33, 44, 254, 265, "multicentre" +553, 4, 9, 50, 45, 50, 266, 271, "study" +553, 4, 10, 51, 51, 53, 272, 274, "in" +553, 4, 11, 52, 54, 60, 275, 281, "Europe" +553, 4, 12, 53, 61, 62, 282, 283, "." +553, 5, 1, 54, 0, 4, 284, 288, "Garc" +553, 5, 2, 55, 5, 6, 289, 290, "í" +553, 5, 3, 56, 7, 8, 291, 292, "a" +553, 5, 4, 57, 9, 10, 293, 294, "-" +553, 5, 5, 58, 11, 12, 295, 296, "S" +553, 5, 6, 59, 13, 14, 297, 298, "á" +553, 5, 7, 60, 15, 20, 299, 304, "nchez" +553, 5, 8, 61, 21, 22, 305, 306, "J" +553, 5, 9, 62, 23, 24, 307, 308, "(" +553, 5, 10, 63, 25, 26, 309, 310, "1" +553, 5, 11, 64, 27, 28, 311, 312, ")" +553, 5, 12, 65, 29, 30, 313, 314, "," +553, 5, 13, 66, 31, 38, 315, 322, "Rouland" +553, 5, 14, 67, 39, 41, 323, 325, "JF" +553, 5, 15, 68, 42, 43, 326, 327, "," +553, 5, 16, 69, 44, 51, 328, 335, "Spiegel" +553, 5, 17, 70, 52, 53, 336, 337, "D" +553, 5, 18, 71, 54, 55, 338, 339, "," +553, 5, 19, 72, 56, 61, 340, 345, "Pajic" +553, 5, 20, 73, 62, 63, 346, 347, "B" +553, 5, 21, 74, 64, 65, 348, 349, "," +553, 5, 22, 75, 66, 74, 350, 358, "Cunliffe" +553, 5, 23, 76, 75, 76, 359, 360, "I" +553, 5, 24, 77, 77, 78, 361, 362, "," +553, 5, 25, 78, 79, 87, 363, 371, "Traverso" +553, 5, 26, 79, 88, 89, 372, 373, "C" +553, 5, 27, 80, 90, 91, 374, 375, "," +553, 5, 28, 81, 92, 98, 376, 382, "Landry" +553, 5, 29, 82, 99, 100, 383, 384, "J" +553, 5, 30, 83, 101, 102, 385, 386, "." +553, 6, 1, 84, 0, 6, 387, 393, "Author" +553, 6, 2, 85, 7, 18, 394, 405, "information" +553, 6, 3, 86, 19, 20, 406, 407, ":" +553, 6, 4, 87, 21, 22, 408, 409, "(" +553, 6, 5, 88, 23, 24, 410, 411, "1" +553, 6, 6, 89, 25, 26, 412, 413, ")" +553, 6, 7, 90, 27, 35, 414, 422, "Servicio" +553, 6, 8, 91, 36, 38, 423, 425, "de" +553, 6, 9, 92, 39, 51, 426, 438, "Oftalmologia" +553, 6, 10, 93, 52, 53, 439, 440, "," +553, 6, 11, 94, 54, 62, 441, 449, "Hospital" +553, 6, 12, 95, 63, 70, 450, 457, "Clinico" +553, 6, 13, 96, 71, 74, 458, 461, "San" +553, 6, 14, 97, 75, 81, 462, 468, "Carlos" +553, 6, 15, 98, 82, 83, 469, 470, "," +553, 6, 16, 99, 84, 90, 471, 477, "Ciudad" +553, 6, 17, 100, 91, 104, 478, 491, "Universitaria" +553, 6, 18, 101, 105, 106, 492, 493, "s" +553, 6, 19, 102, 107, 108, 494, 495, "/" +553, 6, 20, 103, 109, 110, 496, 497, "n" +553, 6, 21, 104, 111, 112, 498, 499, "," +553, 6, 22, 105, 113, 118, 500, 505, "28040" +553, 6, 23, 106, 119, 125, 506, 512, "Madrid" +553, 6, 24, 107, 126, 127, 513, 514, "," +553, 6, 25, 108, 128, 133, 515, 520, "Spain" +553, 6, 26, 109, 134, 135, 521, 522, "." +553, 7, 1, 110, 0, 8, 523, 531, "iiorcdir" +553, 7, 2, 111, 9, 10, 532, 533, "@" +553, 7, 3, 112, 11, 14, 534, 537, "med" +553, 7, 4, 113, 15, 16, 538, 539, "." +553, 7, 5, 114, 17, 20, 540, 543, "ucm" +553, 7, 6, 115, 21, 22, 544, 545, "." +553, 7, 7, 116, 23, 25, 546, 548, "es" +553, 7, 8, 117, 26, 33, 549, 556, "PURPOSE" +553, 7, 9, 118, 34, 35, 557, 558, ":" +553, 7, 10, 119, 36, 38, 559, 561, "To" +553, 7, 11, 120, 39, 46, 562, 569, "compare" +553, 7, 12, 121, 47, 50, 570, 573, "the" +553, 7, 13, 122, 51, 62, 574, 585, "intraocular" +553, 7, 14, 123, 63, 71, 586, 594, "pressure" +553, 7, 15, 124, 72, 73, 595, 596, "(" +553, 7, 16, 125, 74, 77, 597, 600, "IOP" +553, 7, 17, 126, 78, 79, 601, 602, ")" +553, 7, 18, 127, 80, 88, 603, 611, "reducing" +553, 7, 19, 128, 89, 95, 612, 618, "effect" +553, 7, 20, 129, 96, 99, 619, 622, "and" +553, 7, 21, 130, 100, 106, 623, 629, "safety" +553, 7, 22, 131, 107, 109, 630, 632, "of" +553, 7, 23, 132, 110, 115, 633, 638, "fixed" +553, 7, 24, 133, 116, 127, 639, 650, "combination" +553, 7, 25, 134, 128, 129, 651, 652, "(" +553, 7, 26, 135, 130, 132, 653, 655, "FC" +553, 7, 27, 136, 133, 134, 656, 657, ")" +553, 7, 28, 137, 135, 146, 658, 669, "latanoprost" +553, 7, 29, 138, 147, 148, 670, 671, "/" +553, 7, 30, 139, 149, 156, 672, 679, "timolol" +553, 7, 31, 140, 157, 161, 680, 684, "with" +553, 7, 32, 141, 162, 169, 685, 692, "unfixed" +553, 7, 33, 142, 170, 181, 693, 704, "combination" +553, 7, 34, 143, 182, 183, 705, 706, "(" +553, 7, 35, 144, 184, 187, 707, 710, "UFC" +553, 7, 36, 145, 188, 189, 711, 712, ")" +553, 7, 37, 146, 190, 201, 713, 724, "brimonidine" +553, 7, 38, 147, 202, 203, 725, 726, "/" +553, 7, 39, 148, 204, 211, 727, 734, "timolol" +553, 7, 40, 149, 212, 214, 735, 737, "in" +553, 7, 41, 150, 215, 223, 738, 746, "patients" +553, 7, 42, 151, 224, 228, 747, 751, "with" +553, 7, 43, 152, 229, 238, 752, 761, "increased" +553, 7, 44, 153, 239, 242, 762, 765, "IOP" +553, 7, 45, 154, 243, 244, 766, 767, "." +553, 8, 1, 155, 0, 7, 768, 775, "METHODS" +553, 8, 2, 156, 8, 9, 776, 777, ":" +553, 8, 3, 157, 10, 12, 778, 780, "In" +553, 8, 4, 158, 13, 17, 781, 785, "this" +553, 8, 5, 159, 18, 19, 786, 787, "6" +553, 8, 6, 160, 20, 25, 788, 793, "month" +553, 8, 7, 161, 26, 27, 794, 795, "," +553, 8, 8, 162, 28, 38, 796, 806, "randomised" +553, 8, 9, 163, 39, 40, 807, 808, "," +553, 8, 10, 164, 41, 50, 809, 818, "evaluator" +553, 8, 11, 165, 51, 57, 819, 825, "masked" +553, 8, 12, 166, 58, 59, 826, 827, "," +553, 8, 13, 167, 60, 68, 828, 836, "parallel" +553, 8, 14, 168, 69, 74, 837, 842, "group" +553, 8, 15, 169, 75, 83, 843, 851, "European" +553, 8, 16, 170, 84, 89, 852, 857, "study" +553, 8, 17, 171, 90, 91, 858, 859, "," +553, 8, 18, 172, 92, 100, 860, 868, "patients" +553, 8, 19, 173, 101, 105, 869, 873, "with" +553, 8, 20, 174, 106, 114, 874, 882, "glaucoma" +553, 8, 21, 175, 115, 117, 883, 885, "or" +553, 8, 22, 176, 118, 124, 886, 892, "ocular" +553, 8, 23, 177, 125, 137, 893, 905, "hypertension" +553, 8, 24, 178, 138, 141, 906, 909, "and" +553, 8, 25, 179, 142, 145, 910, 913, "IOP" +553, 8, 26, 180, 146, 147, 914, 915, "&" +553, 8, 27, 181, 148, 150, 916, 918, "gt" +553, 8, 28, 182, 151, 152, 919, 920, ";" +553, 8, 29, 183, 153, 155, 921, 923, "or" +553, 8, 30, 184, 156, 157, 924, 925, "=" +553, 8, 31, 185, 158, 160, 926, 928, "21" +553, 8, 32, 186, 161, 163, 929, 931, "mm" +553, 8, 33, 187, 164, 166, 932, 934, "Hg" +553, 8, 34, 188, 167, 169, 935, 937, "on" +553, 8, 35, 189, 170, 181, 938, 949, "monotherapy" +553, 8, 36, 190, 182, 184, 950, 952, "or" +553, 8, 37, 191, 185, 186, 953, 954, "&" +553, 8, 38, 192, 187, 189, 955, 957, "gt" +553, 8, 39, 193, 190, 191, 958, 959, ";" +553, 8, 40, 194, 192, 194, 960, 962, "16" +553, 8, 41, 195, 195, 197, 963, 965, "mm" +553, 8, 42, 196, 198, 200, 966, 968, "Hg" +553, 8, 43, 197, 201, 203, 969, 971, "on" +553, 8, 44, 198, 204, 208, 972, 976, "dual" +553, 8, 45, 199, 209, 216, 977, 984, "therapy" +553, 8, 46, 200, 217, 225, 985, 993, "received" +553, 8, 47, 201, 226, 232, 994, 1000, "either" +553, 8, 48, 202, 233, 235, 1001, 1003, "FC" +553, 8, 49, 203, 236, 247, 1004, 1015, "latanoprost" +553, 8, 50, 204, 248, 249, 1016, 1017, "/" +553, 8, 51, 205, 250, 257, 1018, 1025, "timolol" +553, 8, 52, 206, 258, 260, 1026, 1028, "at" +553, 8, 53, 207, 261, 262, 1029, 1030, "8" +553, 8, 54, 208, 263, 264, 1031, 1032, ":" +553, 8, 55, 209, 265, 269, 1033, 1037, "00AM" +553, 8, 56, 210, 270, 272, 1038, 1040, "or" +553, 8, 57, 211, 273, 276, 1041, 1044, "UFC" +553, 8, 58, 212, 277, 288, 1045, 1056, "brimonidine" +553, 8, 59, 213, 289, 290, 1057, 1058, "/" +553, 8, 60, 214, 291, 298, 1059, 1066, "timolol" +553, 8, 61, 215, 299, 301, 1067, 1069, "at" +553, 8, 62, 216, 302, 303, 1070, 1071, "8" +553, 8, 63, 217, 304, 305, 1072, 1073, ":" +553, 8, 64, 218, 306, 310, 1074, 1078, "00AM" +553, 8, 65, 219, 311, 314, 1079, 1082, "and" +553, 8, 66, 220, 315, 316, 1083, 1084, "8" +553, 8, 67, 221, 317, 318, 1085, 1086, ":" +553, 8, 68, 222, 319, 323, 1087, 1091, "00PM" +553, 8, 69, 223, 324, 325, 1092, 1093, "." +553, 9, 1, 224, 0, 3, 1094, 1097, "The" +553, 9, 2, 225, 4, 11, 1098, 1105, "primary" +553, 9, 3, 226, 12, 19, 1106, 1113, "outcome" +553, 9, 4, 227, 20, 23, 1114, 1117, "was" +553, 9, 5, 228, 24, 27, 1118, 1121, "the" +553, 9, 6, 229, 28, 38, 1122, 1132, "difference" +553, 9, 7, 230, 39, 43, 1133, 1137, "from" +553, 9, 8, 231, 44, 52, 1138, 1146, "baseline" +553, 9, 9, 232, 53, 55, 1147, 1149, "to" +553, 9, 10, 233, 56, 61, 1150, 1155, "month" +553, 9, 11, 234, 62, 63, 1156, 1157, "6" +553, 9, 12, 235, 64, 66, 1158, 1160, "in" +553, 9, 13, 236, 67, 71, 1161, 1165, "mean" +553, 9, 14, 237, 72, 79, 1166, 1173, "diurnal" +553, 9, 15, 238, 80, 83, 1174, 1177, "IOP" +553, 9, 16, 239, 84, 93, 1178, 1187, "reduction" +553, 9, 17, 240, 94, 95, 1188, 1189, "." +553, 10, 1, 241, 0, 7, 1190, 1197, "RESULTS" +553, 10, 2, 242, 8, 9, 1198, 1199, ":" +553, 10, 3, 243, 10, 13, 1200, 1203, "325" +553, 10, 4, 244, 14, 16, 1204, 1206, "of" +553, 10, 5, 245, 17, 20, 1207, 1210, "334" +553, 10, 6, 246, 21, 31, 1211, 1221, "randomised" +553, 10, 7, 247, 32, 40, 1222, 1230, "patients" +553, 10, 8, 248, 41, 45, 1231, 1235, "were" +553, 10, 9, 249, 46, 54, 1236, 1244, "included" +553, 10, 10, 250, 55, 57, 1245, 1247, "in" +553, 10, 11, 251, 58, 64, 1248, 1254, "intent" +553, 10, 12, 252, 65, 67, 1255, 1257, "to" +553, 10, 13, 253, 68, 73, 1258, 1263, "treat" +553, 10, 14, 254, 74, 82, 1264, 1272, "analyses" +553, 10, 15, 255, 83, 84, 1273, 1274, "(" +553, 10, 16, 256, 85, 87, 1275, 1277, "FC" +553, 10, 17, 257, 88, 99, 1278, 1289, "latanoprost" +553, 10, 18, 258, 100, 101, 1290, 1291, "/" +553, 10, 19, 259, 102, 109, 1292, 1299, "timolol" +553, 10, 20, 260, 110, 111, 1300, 1301, "," +553, 10, 21, 261, 112, 115, 1302, 1305, "163" +553, 10, 22, 262, 116, 117, 1306, 1307, ";" +553, 10, 23, 263, 118, 121, 1308, 1311, "UFC" +553, 10, 24, 264, 122, 133, 1312, 1323, "brimonidine" +553, 10, 25, 265, 134, 135, 1324, 1325, "/" +553, 10, 26, 266, 136, 143, 1326, 1333, "timolol" +553, 10, 27, 267, 144, 145, 1334, 1335, "," +553, 10, 28, 268, 146, 149, 1336, 1339, "162" +553, 10, 29, 269, 150, 151, 1340, 1341, ")" +553, 10, 30, 270, 152, 153, 1342, 1343, "." +553, 11, 1, 271, 0, 8, 1344, 1352, "Baseline" +553, 11, 2, 272, 9, 16, 1353, 1360, "diurnal" +553, 11, 3, 273, 17, 20, 1361, 1364, "IOP" +553, 11, 4, 274, 21, 27, 1365, 1371, "levels" +553, 11, 5, 275, 28, 32, 1372, 1376, "were" +553, 11, 6, 276, 33, 40, 1377, 1384, "similar" +553, 11, 7, 277, 41, 42, 1385, 1386, ":" +553, 11, 8, 278, 43, 45, 1387, 1389, "FC" +553, 11, 9, 279, 46, 57, 1390, 1401, "latanoprost" +553, 11, 10, 280, 58, 59, 1402, 1403, "/" +553, 11, 11, 281, 60, 67, 1404, 1411, "timolol" +553, 11, 12, 282, 68, 69, 1412, 1413, "," +553, 11, 13, 283, 70, 72, 1414, 1416, "26" +553, 11, 14, 284, 73, 74, 1417, 1418, "." +553, 11, 15, 285, 75, 76, 1419, 1420, "4" +553, 11, 16, 286, 77, 78, 1421, 1422, "(" +553, 11, 17, 287, 79, 81, 1423, 1425, "SD" +553, 11, 18, 288, 82, 83, 1426, 1427, "2" +553, 11, 19, 289, 84, 85, 1428, 1429, "." +553, 11, 20, 290, 86, 87, 1430, 1431, "7" +553, 11, 21, 291, 88, 89, 1432, 1433, ")" +553, 11, 22, 292, 90, 92, 1434, 1436, "mm" +553, 11, 23, 293, 93, 95, 1437, 1439, "Hg" +553, 11, 24, 294, 96, 97, 1440, 1441, ";" +553, 11, 25, 295, 98, 101, 1442, 1445, "UFC" +553, 11, 26, 296, 102, 113, 1446, 1457, "brimonidine" +553, 11, 27, 297, 114, 115, 1458, 1459, "/" +553, 11, 28, 298, 116, 123, 1460, 1467, "timolol" +553, 11, 29, 299, 124, 125, 1468, 1469, "," +553, 11, 30, 300, 126, 128, 1470, 1472, "26" +553, 11, 31, 301, 129, 130, 1473, 1474, "." +553, 11, 32, 302, 131, 132, 1475, 1476, "5" +553, 11, 33, 303, 133, 134, 1477, 1478, "(" +553, 11, 34, 304, 135, 137, 1479, 1481, "SD" +553, 11, 35, 305, 138, 139, 1482, 1483, "2" +553, 11, 36, 306, 140, 141, 1484, 1485, "." +553, 11, 37, 307, 142, 143, 1486, 1487, "8" +553, 11, 38, 308, 144, 145, 1488, 1489, ")" +553, 11, 39, 309, 146, 148, 1490, 1492, "mm" +553, 11, 40, 310, 149, 151, 1493, 1495, "Hg" +553, 11, 41, 311, 152, 153, 1496, 1497, "(" +553, 11, 42, 312, 154, 155, 1498, 1499, "p" +553, 11, 43, 313, 156, 157, 1500, 1501, "=" +553, 11, 44, 314, 158, 159, 1502, 1503, "0" +553, 11, 45, 315, 160, 161, 1504, 1505, "." +553, 11, 46, 316, 162, 165, 1506, 1509, "851" +553, 11, 47, 317, 166, 167, 1510, 1511, ")" +553, 11, 48, 318, 168, 169, 1512, 1513, "." +553, 12, 1, 319, 0, 2, 1514, 1516, "At" +553, 12, 2, 320, 3, 8, 1517, 1522, "month" +553, 12, 3, 321, 9, 10, 1523, 1524, "6" +553, 12, 4, 322, 11, 12, 1525, 1526, "," +553, 12, 5, 323, 13, 19, 1527, 1533, "levels" +553, 12, 6, 324, 20, 24, 1534, 1538, "were" +553, 12, 7, 325, 25, 27, 1539, 1541, "16" +553, 12, 8, 326, 28, 29, 1542, 1543, "." +553, 12, 9, 327, 30, 31, 1544, 1545, "9" +553, 12, 10, 328, 32, 33, 1546, 1547, "(" +553, 12, 11, 329, 34, 36, 1548, 1550, "SD" +553, 12, 12, 330, 37, 38, 1551, 1552, "2" +553, 12, 13, 331, 39, 40, 1553, 1554, "." +553, 12, 14, 332, 41, 42, 1555, 1556, "8" +553, 12, 15, 333, 43, 44, 1557, 1558, ")" +553, 12, 16, 334, 45, 47, 1559, 1561, "mm" +553, 12, 17, 335, 48, 50, 1562, 1564, "Hg" +553, 12, 18, 336, 51, 53, 1565, 1567, "in" +553, 12, 19, 337, 54, 56, 1568, 1570, "FC" +553, 12, 20, 338, 57, 68, 1571, 1582, "latanoprost" +553, 12, 21, 339, 69, 70, 1583, 1584, "/" +553, 12, 22, 340, 71, 78, 1585, 1592, "timolol" +553, 12, 23, 341, 79, 87, 1593, 1601, "patients" +553, 12, 24, 342, 88, 91, 1602, 1605, "and" +553, 12, 25, 343, 92, 94, 1606, 1608, "18" +553, 12, 26, 344, 95, 96, 1609, 1610, "." +553, 12, 27, 345, 97, 98, 1611, 1612, "2" +553, 12, 28, 346, 99, 100, 1613, 1614, "(" +553, 12, 29, 347, 101, 103, 1615, 1617, "SD" +553, 12, 30, 348, 104, 105, 1618, 1619, "3" +553, 12, 31, 349, 106, 107, 1620, 1621, "." +553, 12, 32, 350, 108, 109, 1622, 1623, "1" +553, 12, 33, 351, 110, 111, 1624, 1625, ")" +553, 12, 34, 352, 112, 114, 1626, 1628, "mm" +553, 12, 35, 353, 115, 117, 1629, 1631, "Hg" +553, 12, 36, 354, 118, 120, 1632, 1634, "in" +553, 12, 37, 355, 121, 124, 1635, 1638, "UFC" +553, 12, 38, 356, 125, 136, 1639, 1650, "brimonidine" +553, 12, 39, 357, 137, 138, 1651, 1652, "/" +553, 12, 40, 358, 139, 146, 1653, 1660, "timolol" +553, 12, 41, 359, 147, 155, 1661, 1669, "patients" +553, 12, 42, 360, 156, 157, 1670, 1671, "(" +553, 12, 43, 361, 158, 159, 1672, 1673, "p" +553, 12, 44, 362, 160, 161, 1674, 1675, "&" +553, 12, 45, 363, 162, 164, 1676, 1678, "lt" +553, 12, 46, 364, 165, 166, 1679, 1680, ";" +553, 12, 47, 365, 167, 168, 1681, 1682, "0" +553, 12, 48, 366, 169, 170, 1683, 1684, "." +553, 12, 49, 367, 171, 174, 1685, 1688, "001" +553, 12, 50, 368, 175, 176, 1689, 1690, ")" +553, 12, 51, 369, 177, 178, 1691, 1692, "." +553, 13, 1, 370, 0, 2, 1693, 1695, "No" +553, 13, 2, 371, 3, 10, 1696, 1703, "adverse" +553, 13, 3, 372, 11, 17, 1704, 1710, "events" +553, 13, 4, 373, 18, 22, 1711, 1715, "were" +553, 13, 5, 374, 23, 31, 1716, 1724, "reported" +553, 13, 6, 375, 32, 34, 1725, 1727, "by" +553, 13, 7, 376, 35, 37, 1728, 1730, "76" +553, 13, 8, 377, 38, 39, 1731, 1732, "." +553, 13, 9, 378, 40, 41, 1733, 1734, "4" +553, 13, 10, 379, 42, 43, 1735, 1736, "%" +553, 13, 11, 380, 44, 47, 1737, 1740, "and" +553, 13, 12, 381, 48, 50, 1741, 1743, "75" +553, 13, 13, 382, 51, 52, 1744, 1745, "." +553, 13, 14, 383, 53, 54, 1746, 1747, "5" +553, 13, 15, 384, 55, 56, 1748, 1749, "%" +553, 13, 16, 385, 57, 59, 1750, 1752, "of" +553, 13, 17, 386, 60, 68, 1753, 1761, "patients" +553, 13, 18, 387, 69, 78, 1762, 1771, "receiving" +553, 13, 19, 388, 79, 81, 1772, 1774, "FC" +553, 13, 20, 389, 82, 93, 1775, 1786, "latanoprost" +553, 13, 21, 390, 94, 95, 1787, 1788, "/" +553, 13, 22, 391, 96, 103, 1789, 1796, "timolol" +553, 13, 23, 392, 104, 110, 1797, 1803, "versus" +553, 13, 24, 393, 111, 114, 1804, 1807, "UFC" +553, 13, 25, 394, 115, 126, 1808, 1819, "brimonidine" +553, 13, 26, 395, 127, 128, 1820, 1821, "/" +553, 13, 27, 396, 129, 136, 1822, 1829, "timolol" +553, 13, 28, 397, 137, 138, 1830, 1831, "," +553, 13, 29, 398, 139, 151, 1832, 1844, "respectively" +553, 13, 30, 399, 152, 153, 1845, 1846, "." +553, 14, 1, 400, 0, 6, 1847, 1853, "Larger" +553, 14, 2, 401, 7, 18, 1854, 1865, "proportions" +553, 14, 3, 402, 19, 21, 1866, 1868, "of" +553, 14, 4, 403, 22, 33, 1869, 1880, "brimonidine" +553, 14, 5, 404, 34, 35, 1881, 1882, "/" +553, 14, 6, 405, 36, 43, 1883, 1890, "timolol" +553, 14, 7, 406, 44, 51, 1891, 1898, "treated" +553, 14, 8, 407, 52, 60, 1899, 1907, "patients" +553, 14, 9, 408, 61, 69, 1908, 1916, "reported" +553, 14, 10, 409, 70, 75, 1917, 1922, "study" +553, 14, 11, 410, 76, 86, 1923, 1933, "medication" +553, 14, 12, 411, 87, 94, 1934, 1941, "related" +553, 14, 13, 412, 95, 102, 1942, 1949, "adverse" +553, 14, 14, 413, 103, 109, 1950, 1956, "events" +553, 14, 15, 414, 110, 111, 1957, 1958, "(" +553, 14, 16, 415, 112, 114, 1959, 1961, "18" +553, 14, 17, 416, 115, 116, 1962, 1963, "." +553, 14, 18, 417, 117, 118, 1964, 1965, "6" +553, 14, 19, 418, 119, 120, 1966, 1967, "%" +553, 14, 20, 419, 121, 122, 1968, 1969, "v" +553, 14, 21, 420, 123, 124, 1970, 1971, "7" +553, 14, 22, 421, 125, 126, 1972, 1973, "." +553, 14, 23, 422, 127, 128, 1974, 1975, "3" +553, 14, 24, 423, 129, 130, 1976, 1977, "%" +553, 14, 25, 424, 131, 132, 1978, 1979, ")" +553, 14, 26, 425, 133, 136, 1980, 1983, "and" +553, 14, 27, 426, 137, 149, 1984, 1996, "discontinued" +553, 14, 28, 427, 150, 155, 1997, 2002, "study" +553, 14, 29, 428, 156, 169, 2003, 2016, "participation" +553, 14, 30, 429, 170, 177, 2017, 2024, "because" +553, 14, 31, 430, 178, 180, 2025, 2027, "of" +553, 14, 32, 431, 181, 185, 2028, 2032, "this" +553, 14, 33, 432, 186, 187, 2033, 2034, "(" +553, 14, 34, 433, 188, 190, 2035, 2037, "10" +553, 14, 35, 434, 191, 192, 2038, 2039, "." +553, 14, 36, 435, 193, 194, 2040, 2041, "8" +553, 14, 37, 436, 195, 196, 2042, 2043, "%" +553, 14, 38, 437, 197, 198, 2044, 2045, "v" +553, 14, 39, 438, 199, 200, 2046, 2047, "1" +553, 14, 40, 439, 201, 202, 2048, 2049, "." +553, 14, 41, 440, 203, 204, 2050, 2051, "8" +553, 14, 42, 441, 205, 206, 2052, 2053, "%" +553, 14, 43, 442, 207, 208, 2054, 2055, ")" +553, 14, 44, 443, 209, 210, 2056, 2057, "." +553, 15, 1, 444, 0, 10, 2058, 2068, "CONCLUSION" +553, 15, 2, 445, 11, 12, 2069, 2070, ":" +553, 15, 3, 446, 13, 18, 2071, 2076, "Fixed" +553, 15, 4, 447, 19, 30, 2077, 2088, "combination" +553, 15, 5, 448, 31, 42, 2089, 2100, "latanoprost" +553, 15, 6, 449, 43, 44, 2101, 2102, "/" +553, 15, 7, 450, 45, 52, 2103, 2110, "timolol" +553, 15, 8, 451, 53, 65, 2111, 2123, "administered" +553, 15, 9, 452, 66, 70, 2124, 2128, "once" +553, 15, 10, 453, 71, 76, 2129, 2134, "daily" +553, 15, 11, 454, 77, 79, 2135, 2137, "is" +553, 15, 12, 455, 80, 84, 2138, 2142, "both" +553, 15, 13, 456, 85, 89, 2143, 2147, "more" +553, 15, 14, 457, 90, 99, 2148, 2157, "effective" +553, 15, 15, 458, 100, 103, 2158, 2161, "and" +553, 15, 16, 459, 104, 110, 2162, 2168, "better" +553, 15, 17, 460, 111, 120, 2169, 2178, "tolerated" +553, 15, 18, 461, 121, 125, 2179, 2183, "than" +553, 15, 19, 462, 126, 131, 2184, 2189, "twice" +553, 15, 20, 463, 132, 137, 2190, 2195, "daily" +553, 15, 21, 464, 138, 144, 2196, 2202, "dosing" +553, 15, 22, 465, 145, 149, 2203, 2207, "with" +553, 15, 23, 466, 150, 153, 2208, 2211, "UFC" +553, 15, 24, 467, 154, 165, 2212, 2223, "brimonidine" +553, 15, 25, 468, 166, 167, 2224, 2225, "/" +553, 15, 26, 469, 168, 175, 2226, 2233, "timolol" +553, 15, 27, 470, 176, 177, 2234, 2235, "." +553, 16, 1, 471, 0, 3, 2236, 2239, "DOI" +553, 16, 2, 472, 4, 5, 2240, 2241, ":" +553, 16, 3, 473, 6, 8, 2242, 2244, "10" +553, 16, 4, 474, 9, 10, 2245, 2246, "." +553, 16, 5, 475, 11, 15, 2247, 2251, "1136" +553, 16, 6, 476, 16, 17, 2252, 2253, "/" +553, 16, 7, 477, 18, 21, 2254, 2257, "bjo" +553, 16, 8, 478, 22, 23, 2258, 2259, "." +553, 16, 9, 479, 24, 28, 2260, 2264, "2003" +553, 16, 10, 480, 29, 30, 2265, 2266, "." +553, 16, 11, 481, 31, 37, 2267, 2273, "029330" +553, 16, 12, 482, 38, 43, 2274, 2279, "PMCID" +553, 16, 13, 483, 44, 45, 2280, 2281, ":" +553, 16, 14, 484, 46, 56, 2282, 2292, "PMC1772215" +553, 16, 15, 485, 57, 61, 2293, 2297, "PMID" +553, 16, 16, 486, 62, 63, 2298, 2299, ":" +553, 16, 17, 487, 64, 72, 2300, 2308, "15205229" +553, 16, 18, 488, 73, 74, 2309, 2310, "[" +553, 16, 19, 489, 75, 82, 2311, 2318, "Indexed" +553, 16, 20, 490, 83, 86, 2319, 2322, "for" +553, 16, 21, 491, 87, 94, 2323, 2330, "MEDLINE" +553, 16, 22, 492, 95, 96, 2331, 2332, "]" diff --git a/data/gl 15205229_jshahinitiran.annodb b/data/gl 15205229_jshahinitiran.annodb new file mode 100644 index 0000000..c3ef94d --- /dev/null +++ b/data/gl 15205229_jshahinitiran.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84437, Journal, 0, 15, "Br J Ophthalmol", "", +84438, PublicationYear, 18, 22, "2004", "", +84439, Title, 51, 218, "A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure", "", +84442, Lat/TimFC, 71, 115, "fixed combination of latanoprost and timolol", "", +84440, Latanoprost, 92, 103, "latanoprost", "", +84441, Timolol, 108, 115, "timolol", "", +84443, Brimonidine, 148, 159, "brimonidine", "", +84444, Timolol, 164, 171, "timolol", "", +84446, Precondition, 189, 218, "elevated intraocular pressure", "", +84445, IOP, 198, 218, "intraocular pressure", "", +84447, Title, 221, 283, "A six month , evaluator masked , multicentre study in Europe .", "", +84448, Duration, 223, 232, "six month", "", +84449, Blind, 235, 251, "evaluator masked", "", +84450, Multicenter, 254, 265, "multicentre", "", +84451, Author, 284, 306, "Garc í a - S á nchez J", "", +84452, Author, 315, 325, "Rouland JF", "", +84453, Author, 328, 337, "Spiegel D", "", +84454, Author, 340, 347, "Pajic B", "", +84455, Author, 350, 360, "Cunliffe I", "", +84456, Author, 363, 373, "Traverso C", "", +84457, Author, 376, 384, "Landry J", "", +84458, Spain, 515, 520, "Spain", "", +84459, ObjectiveDescription, 559, 767, "To compare the intraocular pressure ( IOP ) reducing effect and safety of fixed combination ( FC ) latanoprost / timolol with unfixed combination ( UFC ) brimonidine / timolol in patients with increased IOP .", "", +84460, IOP, 574, 594, "intraocular pressure", "", +84461, IOP, 597, 600, "IOP", "", +84464, Lat/TimFC, 633, 679, "fixed combination ( FC ) latanoprost / timolol", "", +84462, Latanoprost, 658, 669, "latanoprost", "", +84463, Timolol, 672, 679, "timolol", "", +84465, Brimonidine, 713, 724, "brimonidine", "", +84466, Timolol, 727, 734, "timolol", "", +84467, IOP, 752, 765, "increased IOP", "", +84468, Duration, 786, 793, "6 month", "", +84469, Randomized, 796, 806, "randomised", "", +84470, Blind, 809, 825, "evaluator masked", "", +84471, Parallel, 828, 842, "parallel group", "", +84472, Glaucoma, 874, 882, "glaucoma", "", +84473, OcularHypertension, 886, 905, "ocular hypertension", "", +84475, Precondition, 910, 934, "IOP & gt ; or = 21 mm Hg", "", +84477, Precondition, 910, 949, "IOP & gt ; or = 21 mm Hg on monotherapy", "", +84476, mmHg, 929, 934, "mm Hg", "", +84479, Precondition, 953, 984, "& gt ; 16 mm Hg on dual therapy", "", +84478, mmHg, 963, 968, "mm Hg", "", +84482, Lat/TimFC, 1001, 1025, "FC latanoprost / timolol", "", +84480, Latanoprost, 1004, 1015, "latanoprost", "", +84481, Timolol, 1018, 1025, "timolol", "", +84483, Brimonidine, 1045, 1056, "brimonidine", "", +84484, Timolol, 1059, 1066, "timolol", "", +84485, TimePoint, 1138, 1146, "baseline", "", +84486, TimePoint, 1150, 1157, "month 6", "", +84487, Mean, 1161, 1165, "mean", "", +84488, Diurnal_IOP, 1166, 1177, "diurnal IOP", "", +84489, NumberPatientsCT, 1207, 1210, "334", "", +84490, Randomized, 1211, 1221, "randomised", "", +84491, IntentionToTreat, 1248, 1263, "intent to treat", "", +84494, Lat/TimFC, 1275, 1299, "FC latanoprost / timolol", "", +84492, Latanoprost, 1278, 1289, "latanoprost", "", +84493, Timolol, 1292, 1299, "timolol", "", +84497, NumberPatientsArm, 1302, 1305, "163", "", +84495, Brimonidine, 1312, 1323, "brimonidine", "", +84496, Timolol, 1326, 1333, "timolol", "", +84498, NumberPatientsArm, 1336, 1339, "162", "", +84499, Diurnal_IOP, 1353, 1364, "diurnal IOP", "", +84500, Latanoprost, 1390, 1401, "latanoprost", "", +84501, Timolol, 1404, 1411, "timolol", "", +84502, BaseLineValue, 1414, 1420, "26 . 4", "", +84503, SdDevBL, 1426, 1431, "2 . 7", "", +84504, mmHg, 1434, 1439, "mm Hg", "", +84505, Brimonidine, 1446, 1457, "brimonidine", "", +84506, Timolol, 1460, 1467, "timolol", "", +84507, BaseLineValue, 1470, 1476, "26 . 5", "", +84508, SdDevBL, 1482, 1487, "2 . 8", "", +84509, mmHg, 1490, 1495, "mm Hg", "", +84510, PValueBL, 1498, 1509, "p = 0 . 851", "", +84511, TimePoint, 1517, 1524, "month 6", "", +84512, ResultMeasuredValue, 1539, 1545, "16 . 9", "", +84514, SdDevResValue, 1551, 1556, "2 . 8", "", +84516, mmHg, 1559, 1564, "mm Hg", "", +84520, Lat/TimFC, 1568, 1592, "FC latanoprost / timolol", "", +84518, Latanoprost, 1571, 1582, "latanoprost", "", +84519, Timolol, 1585, 1592, "timolol", "", +84513, ResultMeasuredValue, 1606, 1612, "18 . 2", "", +84515, SdDevResValue, 1618, 1623, "3 . 1", "", +84517, mmHg, 1626, 1631, "mm Hg", "", +84521, Brimonidine, 1639, 1650, "brimonidine", "", +84522, Timolol, 1653, 1660, "timolol", "", +84523, PValueResValue, 1672, 1688, "p & lt ; 0 . 001", "", +84524, PercentageAffected, 1728, 1734, "76 . 4", "", +84525, PercentageAffected, 1741, 1747, "75 . 5", "", +84530, Lat/TimFC, 1772, 1796, "FC latanoprost / timolol", "", +84526, Latanoprost, 1775, 1786, "latanoprost", "", +84527, Timolol, 1789, 1796, "timolol", "", +84529, Brimonidine, 1808, 1819, "brimonidine", "", +84528, Timolol, 1822, 1829, "timolol", "", +84531, Brimonidine, 1869, 1880, "brimonidine", "", +84532, Timolol, 1883, 1890, "timolol", "", +84533, PercentageAffected, 1959, 1965, "18 . 6", "", +84534, PercentageAffected, 1970, 1975, "7 . 3", "", +84535, RelNumPatientsLeftArm, 2035, 2043, "10 . 8 %", "", +84536, RelNumPatientsLeftArm, 2046, 2053, "1 . 8 %", "", +84537, ConclusionComment, 2071, 2235, "Fixed combination latanoprost / timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine / timolol .", "", +84541, Lat/TimFC, 2071, 2110, "Fixed combination latanoprost / timolol", "", +84538, Latanoprost, 2089, 2100, "latanoprost", "", +84539, Timolol, 2103, 2110, "timolol", "", +84542, Frequency, 2124, 2134, "once daily", "", +84543, Frequency, 2184, 2195, "twice daily", "", +84544, Brimonidine, 2212, 2223, "brimonidine", "", +84540, Timolol, 2226, 2233, "timolol", "", +84545, PMID, 2300, 2308, "15205229", "", diff --git a/data/gl 15205229_jshahinitiran.n-triples b/data/gl 15205229_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15205229_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15205229_tstrakeljahn.annodb b/data/gl 15205229_tstrakeljahn.annodb new file mode 100644 index 0000000..9a1b3c7 --- /dev/null +++ b/data/gl 15205229_tstrakeljahn.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +85809, Journal, 0, 15, "Br J Ophthalmol", "", +85810, PublicationYear, 18, 22, "2004", "", +85832, Title, 51, 220, "A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure .", "", +85811, Latanoprost, 92, 103, "latanoprost", "", +85814, Lat/TimFC, 92, 115, "latanoprost and timolol", "", +85812, Timolol, 108, 115, "timolol", "", +85815, Brimonidine, 148, 159, "brimonidine", "", +85813, Timolol, 164, 171, "timolol", "", +85830, IOP, 198, 218, "intraocular pressure", "", +85817, Duration, 223, 232, "six month", "", +85818, Blind, 235, 251, "evaluator masked", "", +85819, Multicenter, 254, 265, "multicentre", "", +85833, Author, 284, 306, "Garc í a - S á nchez J", "", +85834, Author, 315, 325, "Rouland JF", "", +85835, Author, 328, 337, "Spiegel D", "", +85836, Author, 340, 347, "Pajic B", "", +85837, Author, 350, 360, "Cunliffe I", "", +85838, Author, 363, 373, "Traverso C", "", +85839, Author, 376, 384, "Landry J", "", +85820, Spain, 515, 520, "Spain", "", +85840, ObjectiveDescription, 559, 767, "To compare the intraocular pressure ( IOP ) reducing effect and safety of fixed combination ( FC ) latanoprost / timolol with unfixed combination ( UFC ) brimonidine / timolol in patients with increased IOP .", "", +85821, IOP, 574, 594, "intraocular pressure", "", +85822, IOP, 597, 600, "IOP", "", +85823, Latanoprost, 658, 669, "latanoprost", "", +85827, Lat/TimFC, 658, 679, "latanoprost / timolol", "", +85824, Timolol, 672, 679, "timolol", "", +85825, Brimonidine, 713, 724, "brimonidine", "", +85826, Timolol, 727, 734, "timolol", "", +85828, IOP, 762, 765, "IOP", "", +85829, Duration, 786, 793, "6 month", "", +85841, Randomized, 796, 806, "randomised", "", +85842, Blind, 809, 825, "evaluator masked", "", +85843, Parallel, 828, 836, "parallel", "", +85849, Precondition, 860, 984, "patients with glaucoma or ocular hypertension and IOP & gt ; or = 21 mm Hg on monotherapy or & gt ; 16 mm Hg on dual therapy", "", +85844, Glaucoma, 874, 882, "glaucoma", "", +85845, OcularHypertension, 886, 905, "ocular hypertension", "", +85846, IOP, 910, 913, "IOP", "", +85847, mmHg, 929, 934, "mm Hg", "", +85848, mmHg, 963, 968, "mm Hg", "", +85850, Lat/TimFC, 1004, 1025, "latanoprost / timolol", "", +85851, TimePoint, 1029, 1037, "8 : 00AM", "", +85852, Brimonidine, 1045, 1056, "brimonidine", "", +85853, Timolol, 1059, 1066, "timolol", "", +85854, TimePoint, 1070, 1078, "8 : 00AM", "", +85855, TimePoint, 1083, 1091, "8 : 00PM", "", +85861, Endpoint, 1122, 1187, "difference from baseline to month 6 in mean diurnal IOP reduction", "", +85857, TimePoint, 1138, 1146, "baseline", "", +85856, TimePoint, 1150, 1157, "month 6", "", +85858, Mean, 1161, 1165, "mean", "", +85859, Diurnal_IOP, 1166, 1173, "diurnal", "", +85860, IOP, 1174, 1177, "IOP", "", +85862, FinalNumPatientsCT, 1200, 1203, "325", "", +85863, NumberPatientsCT, 1207, 1210, "334", "", +85865, Randomized, 1211, 1221, "randomised", "", +85864, IntentionToTreat, 1248, 1263, "intent to treat", "", +85866, Latanoprost, 1278, 1289, "latanoprost", "", +85870, Lat/TimFC, 1278, 1299, "latanoprost / timolol", "", +85867, Timolol, 1292, 1299, "timolol", "", +85871, FinalNumPatientsArm, 1302, 1305, "163", "", +85868, Brimonidine, 1312, 1323, "brimonidine", "", +85869, Timolol, 1326, 1333, "timolol", "", +85872, FinalNumPatientsArm, 1336, 1339, "162", "", +85873, Diurnal_IOP, 1353, 1364, "diurnal IOP", "", +85874, Latanoprost, 1390, 1401, "latanoprost", "", +85878, Lat/TimFC, 1390, 1411, "latanoprost / timolol", "", +85875, Timolol, 1404, 1411, "timolol", "", +85881, BaseLineValue, 1414, 1420, "26 . 4", "", +85885, SdDevBL, 1426, 1431, "2 . 7", "", +85883, mmHg, 1434, 1439, "mm Hg", "", +85877, Brimonidine, 1446, 1457, "brimonidine", "", +85876, Timolol, 1460, 1467, "timolol", "", +85882, BaseLineValue, 1470, 1476, "26 . 5", "", +85886, SdDevBL, 1482, 1487, "2 . 8", "", +85884, mmHg, 1490, 1495, "mm Hg", "", +85895, PValueBL, 1500, 1509, "= 0 . 851", "", +85900, TimePoint, 1517, 1524, "month 6", "", +85902, ResultMeasuredValue, 1539, 1545, "16 . 9", "", +85906, SdDevResValue, 1551, 1556, "2 . 8", "", +85908, mmHg, 1559, 1564, "mm Hg", "", +85911, Latanoprost, 1571, 1582, "latanoprost", "", +85915, Lat/TimFC, 1571, 1592, "latanoprost / timolol", "", +85912, Timolol, 1585, 1592, "timolol", "", +85904, ResultMeasuredValue, 1606, 1612, "18 . 2", "", +85907, SdDevResValue, 1618, 1623, "3 . 1", "", +85909, mmHg, 1626, 1631, "mm Hg", "", +85914, Brimonidine, 1639, 1650, "brimonidine", "", +85913, Timolol, 1653, 1660, "timolol", "", +85917, PValueResValue, 1674, 1688, "& lt ; 0 . 001", "", +85936, ObservedResult, 1693, 1844, "No adverse events were reported by 76 . 4 % and 75 . 5 % of patients receiving FC latanoprost / timolol versus UFC brimonidine / timolol , respectively", "", +85918, PercentageAffected, 1728, 1734, "76 . 4", "", +85919, PercentageAffected, 1741, 1747, "75 . 5", "", +85920, Latanoprost, 1775, 1786, "latanoprost", "", +85925, Lat/TimFC, 1775, 1796, "latanoprost / timolol", "", +85921, Timolol, 1789, 1796, "timolol", "", +85922, Brimonidine, 1808, 1819, "brimonidine", "", +85923, Timolol, 1822, 1829, "timolol", "", +85943, Brimonidine, 1869, 1880, "brimonidine", "", +85947, Timolol, 1883, 1890, "timolol", "", +85949, PercentageAffected, 1959, 1965, "18 . 6", "", +85950, PercentageAffected, 1970, 1975, "7 . 3", "", +85956, RelNumPatientsLeftArm, 2035, 2041, "10 . 8", "", +85958, RelNumPatientsLeftArm, 2046, 2051, "1 . 8", "", +85967, ConclusionComment, 2071, 2235, "Fixed combination latanoprost / timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine / timolol .", "", +85959, Latanoprost, 2089, 2100, "latanoprost", "", +85961, Lat/TimFC, 2089, 2110, "latanoprost / timolol", "", +85960, Timolol, 2103, 2110, "timolol", "", +85962, Frequency, 2124, 2134, "once daily", "", +85963, Frequency, 2184, 2195, "twice daily", "", +85964, Brimonidine, 2212, 2223, "brimonidine", "", +85965, Timolol, 2226, 2233, "timolol", "", +85969, PMID, 2300, 2308, "15205229", "", diff --git a/data/gl 15205229_tstrakeljahn.n-triples b/data/gl 15205229_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15205229_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15220019_admin.annodb b/data/gl 15220019_admin.annodb new file mode 100644 index 0000000..22b5151 --- /dev/null +++ b/data/gl 15220019_admin.annodb @@ -0,0 +1,139 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2004", "", " \"2004\"." +2, Title, 45, 276, "Comparison of latanoprost with fixed - combination dorzolamide and timolol in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label , parallel - group , multicenter study in Latin America .", "", " \"Comparison of latanoprost with fixed - combination dorzolamide and timolol in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label , parallel - group , multicenter study in Latin America .\"." +3, Latanoprost, 59, 70, "latanoprost", "", +6, Dorz/TimFC, 76, 119, "fixed - combination dorzolamide and timolol", "", +4, Dorzolamide, 96, 107, "dorzolamide", "", +5, Timolol, 112, 119, "timolol", "", +121, Precondition, 123, 172, "adult patients with elevated intraocular pressure", "", " \"adult patients with elevated intraocular pressure\"." +7, IOP, 152, 172, "intraocular pressure", "", +9, Duration, 178, 190, "eight - week", "", " \"eight - week\"." +10, Randomized, 193, 203, "randomized", "", " ." +11, OpenLabel, 206, 218, "open - label", "", " ." +12, Parallel, 221, 237, "parallel - group", "", " ." +13, Multicenter, 240, 251, "multicenter", "", +14, Author, 277, 289, "Susanna R Jr", "", " \"Susanna R Jr\"." +15, Author, 298, 305, "Sheu WP", "", " \"Sheu WP\"." +108, Glaucoma, 323, 331, "Glaucoma", "", " . ." +126, Glaucoma, 369, 377, "Glaucoma", "", +16, Brazil, 466, 472, "Brazil", "", +17, Glaucoma, 571, 579, "glaucoma", "", +18, OcularHypertension, 584, 603, "ocular hypertension", "", " ." +19, OcularHypertension, 606, 609, "OHT", "", +20, Latanoprost, 620, 631, "latanoprost", "", +102051, Dorz/TimFC, 682, 728, "fixed combination of dorzolamide hydrochloride", "", " ." +21, Dorzolamide, 703, 728, "dorzolamide hydrochloride", "", +102051, Dorz/TimFC, 764, 783, "and timolol maleate", "", +22, Timolol, 768, 783, "timolol maleate", "", +23, ObjectiveDescription, 817, 975, "The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks .", "", " \"The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks .\"." +24, Latanoprost, 887, 898, "latanoprost", "", +102055, Dorz/TimFC, 912, 960, "the fixed combination of dorzolamide and timolol", "", +25, Dorzolamide, 937, 948, "dorzolamide", "", +26, Timolol, 953, 960, "timolol", "", +27, Duration, 966, 973, "8 weeks", "", +28, CTDesign, 991, 1005, "interventional", "", " . ." +29, Duration, 1008, 1016, "8 - week", "", +30, Randomized, 1019, 1029, "randomized", "", +31, OpenLabel, 1032, 1044, "open - label", "", +32, Parallel, 1047, 1063, "parallel - group", "", +33, Multicenter, 1087, 1097, "18 centers", "", " ." +150, Precondition, 1130, 1234, "Patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT", "", " \"Patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT\"." +34, Primary_OpenAngleGlaucoma, 1168, 1188, "primary open - angle", "", " ." +35, PigmentaryGlaucoma, 1191, 1201, "pigmentary", "", " ." +146, Glaucoma, 1207, 1227, "exfoliative glaucoma", "", " . ." +34, Primary_OpenAngleGlaucoma, 1219, 1227, "glaucoma", "", " ." +35, PigmentaryGlaucoma, 1219, 1227, "glaucoma", "", " ." +36, OcularHypertension, 1231, 1234, "OHT", "", +37, Randomized, 1240, 1250, "randomized", "", +38, Latanoprost, 1262, 1273, "latanoprost", "", " . ." +153, Eyedrops, 1278, 1282, "drop", "", " ." +39, Frequency, 1303, 1305, "QD", "", " \"QD\"." +40, Evening, 1308, 1315, "evening", "", " ." +102060, Dorz/TimFC, 1323, 1364, "fixed - combination dorzolamide / timolol", "", +41, Dorzolamide, 1343, 1354, "dorzolamide", "", +42, Timolol, 1357, 1364, "timolol", "", +102062, DoseDescription, 1367, 1393, "1 drop in the affected eye", "", +159, Eyedrops, 1369, 1373, "drop", "", +43, Frequency, 1394, 1397, "BID", "", " \"BID\"." +44, Morning, 1400, 1407, "morning", "", " ." +45, Evening, 1412, 1419, "evening", "", " ." +163, Eyedrops, 1465, 1469, "drop", "", +46, TimePoint, 1492, 1500, "baseline", "", +47, TimePoint, 1505, 1511, "week 8", "", +48, IOP, 1514, 1534, "intraocular pressure", "", +167, IOP, 1537, 1540, "IOP", "", +168, TimePoint, 1572, 1581, "8 : 30 am", "", +169, TimePoint, 1584, 1594, "10 : 00 am", "", +170, TimePoint, 1597, 1606, "2 : 00 pm", "", +171, TimePoint, 1613, 1622, "5 : 00 pm", "", +102063, TimePoint, 1627, 1658, "after the water - drinking test", "", +50, Peak_IOP, 1681, 1689, "IOP peak", "", +173, Diurnal_IOP, 1693, 1714, "diurnal tension curve", "", +174, TimePoint, 1741, 1750, "5 : 00 pm", "", +51, IOP, 1751, 1754, "IOP", "", +52, Diurnal_IOP, 1811, 1822, "diurnal IOP", "", +53, Mean, 1829, 1833, "mean", "", +54, IOP, 1837, 1840, "IOP", "", +55, TimePoint, 1861, 1869, "baseline", "", +56, TimePoint, 1873, 1879, "week 8", "", +57, NumberPatientsCT, 1960, 1963, "229", "", " \"229\"." +58, Randomized, 1978, 1988, "randomized", "", +61, Latanoprost, 1991, 2002, "latanoprost", "", +59, NumberPatientsArm, 2009, 2012, "112", "", " \"112\"." +188, Dorz/TimFC, 2015, 2036, "dorzolamide / timolol", "", +62, Dorzolamide, 2015, 2026, "dorzolamide", "", +63, Timolol, 2029, 2036, "timolol", "", +60, NumberPatientsArm, 2043, 2046, "117", "", " \"117\"." +64, Mean, 2051, 2055, "Mean", "", +65, Diurnal_IOP, 2065, 2076, "diurnal IOP", "", +66, Mean, 2120, 2124, "Mean", "", " . ." +193, Diurnal_IOP, 2132, 2143, "diurnal IOP", "", " ." +68, TimePoint, 2158, 2164, "week 8", "", " \"week 8\". \"week 8\"." +102070, TimePoint, 2165, 2192, "before the water - drinking", "", +69, Reduction, 2203, 2208, "6 . 9", "", " \"6 . 9\"." +71, SdDevChangeValue, 2211, 2216, "3 . 0", "", " \"3 . 0\"." +73, mmHg, 2219, 2224, "mm Hg", "", " ." +75, Latanoprost, 2233, 2244, "latanoprost", "", +70, Reduction, 2255, 2260, "6 . 4", "", " \"6 . 4\"." +72, SdDevChangeValue, 2263, 2268, "3 . 2", "", " \"3 . 2\"." +74, mmHg, 2271, 2276, "mm Hg", "", +76, Dorzolamide, 2285, 2296, "dorzolamide", "", +203, Dorz/TimFC, 2285, 2306, "dorzolamide / timolol", "", +77, Timolol, 2299, 2306, "timolol", "", +78, Mean, 2315, 2319, "Mean", "", +82, ObservedResult, 2315, 2473, "Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) .", "", " \"Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) .\". \"Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) .\"." +79, IOP, 2320, 2323, "IOP", "", +207, TimePoint, 2373, 2382, "5 : 00 pm", "", " \"5 : 00 pm\". \"5 : 00 pm\"." +80, Latanoprost, 2425, 2436, "latanoprost", "", +81, PvalueDiff, 2456, 2469, "( P = 0 . 025", "", " \"( P = 0 . 025\"." +221, ObservedResult, 2474, 2682, "After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) .", "", " \"After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) .\". \"After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) .\"." +83, IOP, 2524, 2527, "IOP", "", +84, TimePoint, 2565, 2573, "baseline", "", +86, Latanoprost, 2587, 2598, "latanoprost", "", +213, TimePoint, 2621, 2627, "week 8", "", " \"week 8\". \"week 8\"." +87, DiffGroupAbsValue, 2652, 2658, "1 . 08", "", " \"1 . 08\"." +88, mmHg, 2659, 2664, "mm Hg", "", +89, PvalueDiff, 2667, 2678, "P = 0 . 012", "", " \"P = 0 . 012\"." +220, ObservedResult, 2683, 2754, "Fewer patients treated with latanoprost reported ocular or systemic AEs", "", " \"Fewer patients treated with latanoprost reported ocular or systemic AEs\". \"Fewer patients treated with latanoprost reported ocular or systemic AEs\"." +90, Latanoprost, 2711, 2722, "latanoprost", "", +102068, EndPointDescription, 2732, 2754, "ocular or systemic AEs", "", " . ." +91, PValueNumAffected, 2757, 2768, "P = 0 . 025", "", " \"P = 0 . 025\"." +92, PValueNumAffected, 2773, 2789, "P & lt ; 0 . 001", "", " \"P & lt ; 0 . 001\"." +93, ConclusionComment, 2823, 3009, "In this study of patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups ,", "", " \"In this study of patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups ,\"." +95, Primary_OpenAngleGlaucoma, 2878, 2937, "primary open - angle , pigmentary , or exfoliative glaucoma", "", +96, PigmentaryGlaucoma, 2901, 2937, "pigmentary , or exfoliative glaucoma", "", +222, Glaucoma, 2917, 2937, "exfoliative glaucoma", "", +97, OcularHypertension, 2941, 2944, "OHT", "", +98, IOP, 2945, 2948, "IOP", "", +93, ConclusionComment, 3010, 3115, "except at 5 : 00 pm , when the mean IOP level was significantly lower in latanoprost - treated patients .", "", " \"except at 5 : 00 pm , when the mean IOP level was significantly lower in latanoprost - treated patients .\"." +227, TimePoint, 3020, 3029, "5 : 00 pm", "", +99, Mean, 3041, 3045, "mean", "", +100, IOP, 3046, 3049, "IOP", "", +101, Latanoprost, 3083, 3094, "latanoprost", "", +103, Latanoprost, 3116, 3127, "Latanoprost", "", +93, ConclusionComment, 3116, 3199, "Latanoprost was better tolerated than fixed - combination dorzolamide and timolol .", "", " \"Latanoprost was better tolerated than fixed - combination dorzolamide and timolol .\"." +104, Dorz/TimFC, 3154, 3197, "fixed - combination dorzolamide and timolol", "", +105, Dorzolamide, 3174, 3185, "dorzolamide", "", +106, Timolol, 3190, 3197, "timolol", "", +107, PMID, 3255, 3263, "15220019", "", " \"15220019\"." diff --git a/data/gl 15220019_admin.n-triples b/data/gl 15220019_admin.n-triples new file mode 100644 index 0000000..926e479 --- /dev/null +++ b/data/gl 15220019_admin.n-triples @@ -0,0 +1,160 @@ +# RDF export of group: Publication + . + "Publication 89945" . + "Comparison of latanoprost with fixed - combination dorzolamide and timolol in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label , parallel - group , multicenter study in Latin America ." . + "Susanna R Jr" . + "2004" . + "Clin Ther ." . + "15220019" . + . + "Sheu WP" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 89952" . + "The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks ." . + "229" . + "eight - week" . + . + . + . + "In this study of patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups ," . + "except at 5 : 00 pm , when the mean IOP level was significantly lower in latanoprost - treated patients ." . + "Latanoprost was better tolerated than fixed - combination dorzolamide and timolol ." . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 89968" . + "adult patients with elevated intraocular pressure" . + . + . + . + "Patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT" . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . +# RDF export of group: Arm + . + "la" . + "112" . + . + . + . + . + . + . + "doti" . + "117" . + . + . + . + . + . +# RDF export of group: Intervention + . + "la" . + . + "QD" . + . + . + "doti" . + . + "BID" . + . + . +# RDF export of group: Medication + . + "lla" . + . + . + . + . + . + "doti" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "6 . 9" . + "3 . 0" . + "Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) ." . + "week 8" . + . + "iop 2" . + . + "6 . 4" . + "3 . 2" . + "Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) ." . + "week 8" . + . + "iop5 1" . + . + "5 : 00 pm" . + . + "iop5 2" . + . + "5 : 00 pm" . + . + "iopwat 1" . + . + "After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) ." . + "week 8" . + . + "iopwat 2" . + . + "After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) ." . + "week 8" . + . + "ae 1" . + . + "P = 0 . 025" . + "Fewer patients treated with latanoprost reported ocular or systemic AEs" . + . + "ae 2" . + . + "P & lt ; 0 . 001" . + "Fewer patients treated with latanoprost reported ocular or systemic AEs" . +# RDF export of group: DiffBetweenGroups + . + "iop5" . + "( P = 0 . 025" . + . + . + . + "iopwar" . + "1 . 08" . + "P = 0 . 012" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15220019_export.csv b/data/gl 15220019_export.csv new file mode 100644 index 0000000..7752578 --- /dev/null +++ b/data/gl 15220019_export.csv @@ -0,0 +1,668 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +552, 1, 1, 1, 0, 4, 0, 4, "Clin" +552, 1, 2, 2, 5, 9, 5, 9, "Ther" +552, 1, 3, 3, 10, 11, 10, 11, "." +552, 2, 1, 4, 0, 4, 12, 16, "2004" +552, 2, 2, 5, 5, 8, 17, 20, "May" +552, 2, 3, 6, 9, 10, 21, 22, ";" +552, 2, 4, 7, 11, 13, 23, 25, "26" +552, 2, 5, 8, 14, 15, 26, 27, "(" +552, 2, 6, 9, 16, 17, 28, 29, "5" +552, 2, 7, 10, 18, 19, 30, 31, ")" +552, 2, 8, 11, 20, 21, 32, 33, ":" +552, 2, 9, 12, 22, 25, 34, 37, "755" +552, 2, 10, 13, 26, 27, 38, 39, "-" +552, 2, 11, 14, 28, 30, 40, 42, "68" +552, 2, 12, 15, 31, 32, 43, 44, "." +552, 3, 1, 16, 0, 10, 45, 55, "Comparison" +552, 3, 2, 17, 11, 13, 56, 58, "of" +552, 3, 3, 18, 14, 25, 59, 70, "latanoprost" +552, 3, 4, 19, 26, 30, 71, 75, "with" +552, 3, 5, 20, 31, 36, 76, 81, "fixed" +552, 3, 6, 21, 37, 38, 82, 83, "-" +552, 3, 7, 22, 39, 50, 84, 95, "combination" +552, 3, 8, 23, 51, 62, 96, 107, "dorzolamide" +552, 3, 9, 24, 63, 66, 108, 111, "and" +552, 3, 10, 25, 67, 74, 112, 119, "timolol" +552, 3, 11, 26, 75, 77, 120, 122, "in" +552, 3, 12, 27, 78, 83, 123, 128, "adult" +552, 3, 13, 28, 84, 92, 129, 137, "patients" +552, 3, 14, 29, 93, 97, 138, 142, "with" +552, 3, 15, 30, 98, 106, 143, 151, "elevated" +552, 3, 16, 31, 107, 118, 152, 163, "intraocular" +552, 3, 17, 32, 119, 127, 164, 172, "pressure" +552, 3, 18, 33, 128, 129, 173, 174, ":" +552, 3, 19, 34, 130, 132, 175, 177, "an" +552, 3, 20, 35, 133, 138, 178, 183, "eight" +552, 3, 21, 36, 139, 140, 184, 185, "-" +552, 3, 22, 37, 141, 145, 186, 190, "week" +552, 3, 23, 38, 146, 147, 191, 192, "," +552, 3, 24, 39, 148, 158, 193, 203, "randomized" +552, 3, 25, 40, 159, 160, 204, 205, "," +552, 3, 26, 41, 161, 165, 206, 210, "open" +552, 3, 27, 42, 166, 167, 211, 212, "-" +552, 3, 28, 43, 168, 173, 213, 218, "label" +552, 3, 29, 44, 174, 175, 219, 220, "," +552, 3, 30, 45, 176, 184, 221, 229, "parallel" +552, 3, 31, 46, 185, 186, 230, 231, "-" +552, 3, 32, 47, 187, 192, 232, 237, "group" +552, 3, 33, 48, 193, 194, 238, 239, "," +552, 3, 34, 49, 195, 206, 240, 251, "multicenter" +552, 3, 35, 50, 207, 212, 252, 257, "study" +552, 3, 36, 51, 213, 215, 258, 260, "in" +552, 3, 37, 52, 216, 221, 261, 266, "Latin" +552, 3, 38, 53, 222, 229, 267, 274, "America" +552, 3, 39, 54, 230, 231, 275, 276, "." +552, 4, 1, 55, 0, 7, 277, 284, "Susanna" +552, 4, 2, 56, 8, 9, 285, 286, "R" +552, 4, 3, 57, 10, 12, 287, 289, "Jr" +552, 4, 4, 58, 13, 14, 290, 291, "(" +552, 4, 5, 59, 15, 16, 292, 293, "1" +552, 4, 6, 60, 17, 18, 294, 295, ")" +552, 4, 7, 61, 19, 20, 296, 297, "," +552, 4, 8, 62, 21, 25, 298, 302, "Sheu" +552, 4, 9, 63, 26, 28, 303, 305, "WP" +552, 4, 10, 64, 29, 30, 306, 307, ";" +552, 4, 11, 65, 31, 36, 308, 313, "Latin" +552, 4, 12, 66, 37, 45, 314, 322, "American" +552, 4, 13, 67, 46, 54, 323, 331, "Glaucoma" +552, 4, 14, 68, 55, 62, 332, 339, "Society" +552, 4, 15, 69, 63, 64, 340, 341, "." +552, 5, 1, 70, 0, 6, 342, 348, "Author" +552, 5, 2, 71, 7, 18, 349, 360, "information" +552, 5, 3, 72, 19, 20, 361, 362, ":" +552, 5, 4, 73, 21, 22, 363, 364, "(" +552, 5, 5, 74, 23, 24, 365, 366, "1" +552, 5, 6, 75, 25, 26, 367, 368, ")" +552, 5, 7, 76, 27, 35, 369, 377, "Glaucoma" +552, 5, 8, 77, 36, 43, 378, 385, "Service" +552, 5, 9, 78, 44, 45, 386, 387, "," +552, 5, 10, 79, 46, 56, 388, 398, "University" +552, 5, 11, 80, 57, 59, 399, 401, "of" +552, 5, 12, 81, 60, 61, 402, 403, "S" +552, 5, 13, 82, 62, 63, 404, 405, "ã" +552, 5, 14, 83, 64, 65, 406, 407, "o" +552, 5, 15, 84, 66, 71, 408, 413, "Paulo" +552, 5, 16, 85, 72, 73, 414, 415, "," +552, 5, 17, 86, 74, 76, 416, 418, "Av" +552, 5, 18, 87, 77, 78, 419, 420, "." +552, 6, 1, 88, 0, 1, 421, 422, "S" +552, 6, 2, 89, 2, 3, 423, 424, "ã" +552, 6, 3, 90, 4, 5, 425, 426, "o" +552, 6, 4, 91, 6, 13, 427, 434, "Gualter" +552, 6, 5, 92, 14, 16, 435, 437, "99" +552, 6, 6, 93, 17, 18, 438, 439, "," +552, 6, 7, 94, 19, 24, 440, 445, "05455" +552, 6, 8, 95, 25, 26, 446, 447, "-" +552, 6, 9, 96, 27, 30, 448, 451, "000" +552, 6, 10, 97, 31, 32, 452, 453, "S" +552, 6, 11, 98, 33, 34, 454, 455, "ã" +552, 6, 12, 99, 35, 36, 456, 457, "o" +552, 6, 13, 100, 37, 42, 458, 463, "Paulo" +552, 6, 14, 101, 43, 44, 464, 465, "," +552, 6, 15, 102, 45, 51, 466, 472, "Brazil" +552, 6, 16, 103, 52, 53, 473, 474, "." +552, 7, 1, 104, 0, 8, 475, 483, "rsusanna" +552, 7, 2, 105, 9, 10, 484, 485, "@" +552, 7, 3, 106, 11, 16, 486, 491, "terra" +552, 7, 4, 107, 17, 18, 492, 493, "." +552, 7, 5, 108, 19, 22, 494, 497, "com" +552, 7, 6, 109, 23, 24, 498, 499, "." +552, 7, 7, 110, 25, 27, 500, 502, "br" +552, 7, 8, 111, 28, 38, 503, 513, "BACKGROUND" +552, 7, 9, 112, 39, 40, 514, 515, ":" +552, 7, 10, 113, 41, 44, 516, 519, "The" +552, 7, 11, 114, 45, 50, 520, 525, "newer" +552, 7, 12, 115, 51, 57, 526, 532, "ocular" +552, 7, 13, 116, 58, 69, 533, 544, "hypotensive" +552, 7, 14, 117, 70, 76, 545, 551, "agents" +552, 7, 15, 118, 77, 86, 552, 561, "available" +552, 7, 16, 119, 87, 89, 562, 564, "to" +552, 7, 17, 120, 90, 95, 565, 570, "treat" +552, 7, 18, 121, 96, 104, 571, 579, "glaucoma" +552, 7, 19, 122, 105, 108, 580, 583, "and" +552, 7, 20, 123, 109, 115, 584, 590, "ocular" +552, 7, 21, 124, 116, 128, 591, 603, "hypertension" +552, 7, 22, 125, 129, 130, 604, 605, "(" +552, 7, 23, 126, 131, 134, 606, 609, "OHT" +552, 7, 24, 127, 135, 136, 610, 611, ")" +552, 7, 25, 128, 137, 144, 612, 619, "include" +552, 7, 26, 129, 145, 156, 620, 631, "latanoprost" +552, 7, 27, 130, 157, 158, 632, 633, "," +552, 7, 28, 131, 159, 160, 634, 635, "a" +552, 7, 29, 132, 161, 174, 636, 649, "prostaglandin" +552, 7, 30, 133, 175, 176, 650, 651, "F" +552, 7, 31, 134, 177, 178, 652, 653, "(" +552, 7, 32, 135, 179, 185, 654, 660, "2alpha" +552, 7, 33, 136, 186, 187, 661, 662, ")" +552, 7, 34, 137, 188, 196, 663, 671, "analogue" +552, 7, 35, 138, 197, 198, 672, 673, "," +552, 7, 36, 139, 199, 202, 674, 677, "and" +552, 7, 37, 140, 203, 206, 678, 681, "the" +552, 7, 38, 141, 207, 212, 682, 687, "fixed" +552, 7, 39, 142, 213, 224, 688, 699, "combination" +552, 7, 40, 143, 225, 227, 700, 702, "of" +552, 7, 41, 144, 228, 239, 703, 714, "dorzolamide" +552, 7, 42, 145, 240, 253, 715, 728, "hydrochloride" +552, 7, 43, 146, 254, 255, 729, 730, "," +552, 7, 44, 147, 256, 257, 731, 732, "a" +552, 7, 45, 148, 258, 266, 733, 741, "carbonic" +552, 7, 46, 149, 267, 276, 742, 751, "anhydrase" +552, 7, 47, 150, 277, 286, 752, 761, "inhibitor" +552, 7, 48, 151, 287, 288, 762, 763, "," +552, 7, 49, 152, 289, 292, 764, 767, "and" +552, 7, 50, 153, 293, 300, 768, 775, "timolol" +552, 7, 51, 154, 301, 308, 776, 783, "maleate" +552, 7, 52, 155, 309, 310, 784, 785, "," +552, 7, 53, 156, 311, 312, 786, 787, "a" +552, 7, 54, 157, 313, 317, 788, 792, "beta" +552, 7, 55, 158, 318, 319, 793, 794, "-" +552, 7, 56, 159, 320, 327, 795, 802, "blocker" +552, 7, 57, 160, 328, 329, 803, 804, "." +552, 8, 1, 161, 0, 9, 805, 814, "OBJECTIVE" +552, 8, 2, 162, 10, 11, 815, 816, ":" +552, 8, 3, 163, 12, 15, 817, 820, "The" +552, 8, 4, 164, 16, 19, 821, 824, "aim" +552, 8, 5, 165, 20, 22, 825, 827, "of" +552, 8, 6, 166, 23, 27, 828, 832, "this" +552, 8, 7, 167, 28, 33, 833, 838, "study" +552, 8, 8, 168, 34, 37, 839, 842, "was" +552, 8, 9, 169, 38, 40, 843, 845, "to" +552, 8, 10, 170, 41, 48, 846, 853, "compare" +552, 8, 11, 171, 49, 52, 854, 857, "the" +552, 8, 12, 172, 53, 61, 858, 866, "efficacy" +552, 8, 13, 173, 62, 65, 867, 870, "and" +552, 8, 14, 174, 66, 78, 871, 883, "tolerability" +552, 8, 15, 175, 79, 81, 884, 886, "of" +552, 8, 16, 176, 82, 93, 887, 898, "latanoprost" +552, 8, 17, 177, 94, 98, 899, 903, "with" +552, 8, 18, 178, 99, 103, 904, 908, "that" +552, 8, 19, 179, 104, 106, 909, 911, "of" +552, 8, 20, 180, 107, 110, 912, 915, "the" +552, 8, 21, 181, 111, 116, 916, 921, "fixed" +552, 8, 22, 182, 117, 128, 922, 933, "combination" +552, 8, 23, 183, 129, 131, 934, 936, "of" +552, 8, 24, 184, 132, 143, 937, 948, "dorzolamide" +552, 8, 25, 185, 144, 147, 949, 952, "and" +552, 8, 26, 186, 148, 155, 953, 960, "timolol" +552, 8, 27, 187, 156, 160, 961, 965, "over" +552, 8, 28, 188, 161, 162, 966, 967, "8" +552, 8, 29, 189, 163, 168, 968, 973, "weeks" +552, 8, 30, 190, 169, 170, 974, 975, "." +552, 9, 1, 191, 0, 7, 976, 983, "METHODS" +552, 9, 2, 192, 8, 9, 984, 985, ":" +552, 9, 3, 193, 10, 14, 986, 990, "This" +552, 9, 4, 194, 15, 29, 991, 1005, "interventional" +552, 9, 5, 195, 30, 31, 1006, 1007, "," +552, 9, 6, 196, 32, 33, 1008, 1009, "8" +552, 9, 7, 197, 34, 35, 1010, 1011, "-" +552, 9, 8, 198, 36, 40, 1012, 1016, "week" +552, 9, 9, 199, 41, 42, 1017, 1018, "," +552, 9, 10, 200, 43, 53, 1019, 1029, "randomized" +552, 9, 11, 201, 54, 55, 1030, 1031, "," +552, 9, 12, 202, 56, 60, 1032, 1036, "open" +552, 9, 13, 203, 61, 62, 1037, 1038, "-" +552, 9, 14, 204, 63, 68, 1039, 1044, "label" +552, 9, 15, 205, 69, 70, 1045, 1046, "," +552, 9, 16, 206, 71, 79, 1047, 1055, "parallel" +552, 9, 17, 207, 80, 81, 1056, 1057, "-" +552, 9, 18, 208, 82, 87, 1058, 1063, "group" +552, 9, 19, 209, 88, 93, 1064, 1069, "study" +552, 9, 20, 210, 94, 97, 1070, 1073, "was" +552, 9, 21, 211, 98, 107, 1074, 1083, "conducted" +552, 9, 22, 212, 108, 110, 1084, 1086, "at" +552, 9, 23, 213, 111, 113, 1087, 1089, "18" +552, 9, 24, 214, 114, 121, 1090, 1097, "centers" +552, 9, 25, 215, 122, 124, 1098, 1100, "in" +552, 9, 26, 216, 125, 126, 1101, 1102, "6" +552, 9, 27, 217, 127, 132, 1103, 1108, "Latin" +552, 9, 28, 218, 133, 141, 1109, 1117, "American" +552, 9, 29, 219, 142, 151, 1118, 1127, "countries" +552, 9, 30, 220, 152, 153, 1128, 1129, "." +552, 10, 1, 221, 0, 8, 1130, 1138, "Patients" +552, 10, 2, 222, 9, 13, 1139, 1143, "with" +552, 10, 3, 223, 14, 24, 1144, 1154, "unilateral" +552, 10, 4, 224, 25, 27, 1155, 1157, "or" +552, 10, 5, 225, 28, 37, 1158, 1167, "bilateral" +552, 10, 6, 226, 38, 45, 1168, 1175, "primary" +552, 10, 7, 227, 46, 50, 1176, 1180, "open" +552, 10, 8, 228, 51, 52, 1181, 1182, "-" +552, 10, 9, 229, 53, 58, 1183, 1188, "angle" +552, 10, 10, 230, 59, 60, 1189, 1190, "," +552, 10, 11, 231, 61, 71, 1191, 1201, "pigmentary" +552, 10, 12, 232, 72, 73, 1202, 1203, "," +552, 10, 13, 233, 74, 76, 1204, 1206, "or" +552, 10, 14, 234, 77, 88, 1207, 1218, "exfoliative" +552, 10, 15, 235, 89, 97, 1219, 1227, "glaucoma" +552, 10, 16, 236, 98, 100, 1228, 1230, "or" +552, 10, 17, 237, 101, 104, 1231, 1234, "OHT" +552, 10, 18, 238, 105, 109, 1235, 1239, "were" +552, 10, 19, 239, 110, 120, 1240, 1250, "randomized" +552, 10, 20, 240, 121, 123, 1251, 1253, "to" +552, 10, 21, 241, 124, 131, 1254, 1261, "receive" +552, 10, 22, 242, 132, 143, 1262, 1273, "latanoprost" +552, 10, 23, 243, 144, 145, 1274, 1275, "," +552, 10, 24, 244, 146, 147, 1276, 1277, "1" +552, 10, 25, 245, 148, 152, 1278, 1282, "drop" +552, 10, 26, 246, 153, 155, 1283, 1285, "in" +552, 10, 27, 247, 156, 159, 1286, 1289, "the" +552, 10, 28, 248, 160, 168, 1290, 1298, "affected" +552, 10, 29, 249, 169, 172, 1299, 1302, "eye" +552, 10, 30, 250, 173, 175, 1303, 1305, "QD" +552, 10, 31, 251, 176, 177, 1306, 1307, "(" +552, 10, 32, 252, 178, 185, 1308, 1315, "evening" +552, 10, 33, 253, 186, 187, 1316, 1317, ")" +552, 10, 34, 254, 188, 189, 1318, 1319, "," +552, 10, 35, 255, 190, 192, 1320, 1322, "or" +552, 10, 36, 256, 193, 198, 1323, 1328, "fixed" +552, 10, 37, 257, 199, 200, 1329, 1330, "-" +552, 10, 38, 258, 201, 212, 1331, 1342, "combination" +552, 10, 39, 259, 213, 224, 1343, 1354, "dorzolamide" +552, 10, 40, 260, 225, 226, 1355, 1356, "/" +552, 10, 41, 261, 227, 234, 1357, 1364, "timolol" +552, 10, 42, 262, 235, 236, 1365, 1366, "," +552, 10, 43, 263, 237, 238, 1367, 1368, "1" +552, 10, 44, 264, 239, 243, 1369, 1373, "drop" +552, 10, 45, 265, 244, 246, 1374, 1376, "in" +552, 10, 46, 266, 247, 250, 1377, 1380, "the" +552, 10, 47, 267, 251, 259, 1381, 1389, "affected" +552, 10, 48, 268, 260, 263, 1390, 1393, "eye" +552, 10, 49, 269, 264, 267, 1394, 1397, "BID" +552, 10, 50, 270, 268, 269, 1398, 1399, "(" +552, 10, 51, 271, 270, 277, 1400, 1407, "morning" +552, 10, 52, 272, 278, 281, 1408, 1411, "and" +552, 10, 53, 273, 282, 289, 1412, 1419, "evening" +552, 10, 54, 274, 290, 291, 1420, 1421, ")" +552, 10, 55, 275, 292, 293, 1422, 1423, "." +552, 11, 1, 276, 0, 11, 1424, 1435, "Medications" +552, 11, 2, 277, 12, 16, 1436, 1440, "were" +552, 11, 3, 278, 17, 21, 1441, 1445, "self" +552, 11, 4, 279, 22, 23, 1446, 1447, "-" +552, 11, 5, 280, 24, 36, 1448, 1460, "administered" +552, 11, 6, 281, 37, 38, 1461, 1462, "," +552, 11, 7, 282, 39, 40, 1463, 1464, "1" +552, 11, 8, 283, 41, 45, 1465, 1469, "drop" +552, 11, 9, 284, 46, 49, 1470, 1473, "per" +552, 11, 10, 285, 50, 58, 1474, 1482, "affected" +552, 11, 11, 286, 59, 62, 1483, 1486, "eye" +552, 11, 12, 287, 63, 64, 1487, 1488, "." +552, 12, 1, 288, 0, 2, 1489, 1491, "At" +552, 12, 2, 289, 3, 11, 1492, 1500, "baseline" +552, 12, 3, 290, 12, 15, 1501, 1504, "and" +552, 12, 4, 291, 16, 20, 1505, 1509, "week" +552, 12, 5, 292, 21, 22, 1510, 1511, "8" +552, 12, 6, 293, 23, 24, 1512, 1513, "," +552, 12, 7, 294, 25, 36, 1514, 1525, "intraocular" +552, 12, 8, 295, 37, 45, 1526, 1534, "pressure" +552, 12, 9, 296, 46, 47, 1535, 1536, "(" +552, 12, 10, 297, 48, 51, 1537, 1540, "IOP" +552, 12, 11, 298, 52, 53, 1541, 1542, ")" +552, 12, 12, 299, 54, 57, 1543, 1546, "was" +552, 12, 13, 300, 58, 66, 1547, 1555, "measured" +552, 12, 14, 301, 67, 68, 1556, 1557, "3" +552, 12, 15, 302, 69, 74, 1558, 1563, "times" +552, 12, 16, 303, 75, 79, 1564, 1568, "each" +552, 12, 17, 304, 80, 82, 1569, 1571, "at" +552, 12, 18, 305, 83, 84, 1572, 1573, "8" +552, 12, 19, 306, 85, 86, 1574, 1575, ":" +552, 12, 20, 307, 87, 89, 1576, 1578, "30" +552, 12, 21, 308, 90, 92, 1579, 1581, "am" +552, 12, 22, 309, 93, 94, 1582, 1583, "," +552, 12, 23, 310, 95, 97, 1584, 1586, "10" +552, 12, 24, 311, 98, 99, 1587, 1588, ":" +552, 12, 25, 312, 100, 102, 1589, 1591, "00" +552, 12, 26, 313, 103, 105, 1592, 1594, "am" +552, 12, 27, 314, 106, 107, 1595, 1596, "," +552, 12, 28, 315, 108, 109, 1597, 1598, "2" +552, 12, 29, 316, 110, 111, 1599, 1600, ":" +552, 12, 30, 317, 112, 114, 1601, 1603, "00" +552, 12, 31, 318, 115, 117, 1604, 1606, "pm" +552, 12, 32, 319, 118, 119, 1607, 1608, "," +552, 12, 33, 320, 120, 123, 1609, 1612, "and" +552, 12, 34, 321, 124, 125, 1613, 1614, "5" +552, 12, 35, 322, 126, 127, 1615, 1616, ":" +552, 12, 36, 323, 128, 130, 1617, 1619, "00" +552, 12, 37, 324, 131, 133, 1620, 1622, "pm" +552, 12, 38, 325, 134, 137, 1623, 1626, "and" +552, 12, 39, 326, 138, 143, 1627, 1632, "after" +552, 12, 40, 327, 144, 147, 1633, 1636, "the" +552, 12, 41, 328, 148, 153, 1637, 1642, "water" +552, 12, 42, 329, 154, 155, 1643, 1644, "-" +552, 12, 43, 330, 156, 164, 1645, 1653, "drinking" +552, 12, 44, 331, 165, 169, 1654, 1658, "test" +552, 12, 45, 332, 170, 171, 1659, 1660, "," +552, 12, 46, 333, 172, 177, 1661, 1666, "which" +552, 12, 47, 334, 178, 187, 1667, 1676, "estimates" +552, 12, 48, 335, 188, 191, 1677, 1680, "the" +552, 12, 49, 336, 192, 195, 1681, 1684, "IOP" +552, 12, 50, 337, 196, 200, 1685, 1689, "peak" +552, 12, 51, 338, 201, 203, 1690, 1692, "of" +552, 12, 52, 339, 204, 211, 1693, 1700, "diurnal" +552, 12, 53, 340, 212, 219, 1701, 1708, "tension" +552, 12, 54, 341, 220, 225, 1709, 1714, "curve" +552, 12, 55, 342, 226, 227, 1715, 1716, "," +552, 12, 56, 343, 228, 237, 1717, 1726, "performed" +552, 12, 57, 344, 238, 247, 1727, 1736, "following" +552, 12, 58, 345, 248, 251, 1737, 1740, "the" +552, 12, 59, 346, 252, 253, 1741, 1742, "5" +552, 12, 60, 347, 254, 255, 1743, 1744, ":" +552, 12, 61, 348, 256, 258, 1745, 1747, "00" +552, 12, 62, 349, 259, 261, 1748, 1750, "pm" +552, 12, 63, 350, 262, 265, 1751, 1754, "IOP" +552, 12, 64, 351, 266, 276, 1755, 1765, "assessment" +552, 12, 65, 352, 277, 278, 1766, 1767, "." +552, 13, 1, 353, 0, 3, 1768, 1771, "The" +552, 13, 2, 354, 4, 11, 1772, 1779, "primary" +552, 13, 3, 355, 12, 20, 1780, 1788, "efficacy" +552, 13, 4, 356, 21, 28, 1789, 1796, "outcome" +552, 13, 5, 357, 29, 32, 1797, 1800, "was" +552, 13, 6, 358, 33, 39, 1801, 1807, "change" +552, 13, 7, 359, 40, 42, 1808, 1810, "in" +552, 13, 8, 360, 43, 50, 1811, 1818, "diurnal" +552, 13, 9, 361, 51, 54, 1819, 1822, "IOP" +552, 13, 10, 362, 55, 56, 1823, 1824, "(" +552, 13, 11, 363, 57, 60, 1825, 1828, "the" +552, 13, 12, 364, 61, 65, 1829, 1833, "mean" +552, 13, 13, 365, 66, 68, 1834, 1836, "of" +552, 13, 14, 366, 69, 72, 1837, 1840, "IOP" +552, 13, 15, 367, 73, 85, 1841, 1853, "measurements" +552, 13, 16, 368, 86, 87, 1854, 1855, ")" +552, 13, 17, 369, 88, 92, 1856, 1860, "from" +552, 13, 18, 370, 93, 101, 1861, 1869, "baseline" +552, 13, 19, 371, 102, 104, 1870, 1872, "to" +552, 13, 20, 372, 105, 109, 1873, 1877, "week" +552, 13, 21, 373, 110, 111, 1878, 1879, "8" +552, 13, 22, 374, 112, 113, 1880, 1881, "." +552, 14, 1, 375, 0, 7, 1882, 1889, "Adverse" +552, 14, 2, 376, 8, 14, 1890, 1896, "effect" +552, 14, 3, 377, 15, 16, 1897, 1898, "(" +552, 14, 4, 378, 17, 19, 1899, 1901, "AE" +552, 14, 5, 379, 20, 21, 1902, 1903, ")" +552, 14, 6, 380, 22, 26, 1904, 1908, "data" +552, 14, 7, 381, 27, 31, 1909, 1913, "were" +552, 14, 8, 382, 32, 40, 1914, 1922, "recorded" +552, 14, 9, 383, 41, 43, 1923, 1925, "at" +552, 14, 10, 384, 44, 48, 1926, 1930, "each" +552, 14, 11, 385, 49, 54, 1931, 1936, "visit" +552, 14, 12, 386, 55, 56, 1937, 1938, "." +552, 15, 1, 387, 0, 7, 1939, 1946, "RESULTS" +552, 15, 2, 388, 8, 9, 1947, 1948, ":" +552, 15, 3, 389, 10, 11, 1949, 1950, "A" +552, 15, 4, 390, 12, 17, 1951, 1956, "total" +552, 15, 5, 391, 18, 20, 1957, 1959, "of" +552, 15, 6, 392, 21, 24, 1960, 1963, "229" +552, 15, 7, 393, 25, 33, 1964, 1972, "patients" +552, 15, 8, 394, 34, 38, 1973, 1977, "were" +552, 15, 9, 395, 39, 49, 1978, 1988, "randomized" +552, 15, 10, 396, 50, 51, 1989, 1990, "(" +552, 15, 11, 397, 52, 63, 1991, 2002, "latanoprost" +552, 15, 12, 398, 64, 65, 2003, 2004, "," +552, 15, 13, 399, 66, 67, 2005, 2006, "n" +552, 15, 14, 400, 68, 69, 2007, 2008, "=" +552, 15, 15, 401, 70, 73, 2009, 2012, "112" +552, 15, 16, 402, 74, 75, 2013, 2014, ";" +552, 15, 17, 403, 76, 87, 2015, 2026, "dorzolamide" +552, 15, 18, 404, 88, 89, 2027, 2028, "/" +552, 15, 19, 405, 90, 97, 2029, 2036, "timolol" +552, 15, 20, 406, 98, 99, 2037, 2038, "," +552, 15, 21, 407, 100, 101, 2039, 2040, "n" +552, 15, 22, 408, 102, 103, 2041, 2042, "=" +552, 15, 23, 409, 104, 107, 2043, 2046, "117" +552, 15, 24, 410, 108, 109, 2047, 2048, ")" +552, 15, 25, 411, 110, 111, 2049, 2050, "." +552, 16, 1, 412, 0, 4, 2051, 2055, "Mean" +552, 16, 2, 413, 5, 13, 2056, 2064, "baseline" +552, 16, 3, 414, 14, 21, 2065, 2072, "diurnal" +552, 16, 4, 415, 22, 25, 2073, 2076, "IOP" +552, 16, 5, 416, 26, 32, 2077, 2083, "values" +552, 16, 6, 417, 33, 37, 2084, 2088, "were" +552, 16, 7, 418, 38, 45, 2089, 2096, "similar" +552, 16, 8, 419, 46, 53, 2097, 2104, "between" +552, 16, 9, 420, 54, 57, 2105, 2108, "the" +552, 16, 10, 421, 58, 59, 2109, 2110, "2" +552, 16, 11, 422, 60, 66, 2111, 2117, "groups" +552, 16, 12, 423, 67, 68, 2118, 2119, "." +552, 17, 1, 424, 0, 4, 2120, 2124, "Mean" +552, 17, 2, 425, 5, 6, 2125, 2126, "(" +552, 17, 3, 426, 7, 9, 2127, 2129, "SD" +552, 17, 4, 427, 10, 11, 2130, 2131, ")" +552, 17, 5, 428, 12, 19, 2132, 2139, "diurnal" +552, 17, 6, 429, 20, 23, 2140, 2143, "IOP" +552, 17, 7, 430, 24, 34, 2144, 2154, "reductions" +552, 17, 8, 431, 35, 37, 2155, 2157, "at" +552, 17, 9, 432, 38, 42, 2158, 2162, "week" +552, 17, 10, 433, 43, 44, 2163, 2164, "8" +552, 17, 11, 434, 45, 51, 2165, 2171, "before" +552, 17, 12, 435, 52, 55, 2172, 2175, "the" +552, 17, 13, 436, 56, 61, 2176, 2181, "water" +552, 17, 14, 437, 62, 63, 2182, 2183, "-" +552, 17, 15, 438, 64, 72, 2184, 2192, "drinking" +552, 17, 16, 439, 73, 77, 2193, 2197, "test" +552, 17, 17, 440, 78, 82, 2198, 2202, "were" +552, 17, 18, 441, 83, 84, 2203, 2204, "6" +552, 17, 19, 442, 85, 86, 2205, 2206, "." +552, 17, 20, 443, 87, 88, 2207, 2208, "9" +552, 17, 21, 444, 89, 90, 2209, 2210, "(" +552, 17, 22, 445, 91, 92, 2211, 2212, "3" +552, 17, 23, 446, 93, 94, 2213, 2214, "." +552, 17, 24, 447, 95, 96, 2215, 2216, "0" +552, 17, 25, 448, 97, 98, 2217, 2218, ")" +552, 17, 26, 449, 99, 101, 2219, 2221, "mm" +552, 17, 27, 450, 102, 104, 2222, 2224, "Hg" +552, 17, 28, 451, 105, 108, 2225, 2228, "for" +552, 17, 29, 452, 109, 112, 2229, 2232, "the" +552, 17, 30, 453, 113, 124, 2233, 2244, "latanoprost" +552, 17, 31, 454, 125, 130, 2245, 2250, "group" +552, 17, 32, 455, 131, 134, 2251, 2254, "and" +552, 17, 33, 456, 135, 136, 2255, 2256, "6" +552, 17, 34, 457, 137, 138, 2257, 2258, "." +552, 17, 35, 458, 139, 140, 2259, 2260, "4" +552, 17, 36, 459, 141, 142, 2261, 2262, "(" +552, 17, 37, 460, 143, 144, 2263, 2264, "3" +552, 17, 38, 461, 145, 146, 2265, 2266, "." +552, 17, 39, 462, 147, 148, 2267, 2268, "2" +552, 17, 40, 463, 149, 150, 2269, 2270, ")" +552, 17, 41, 464, 151, 153, 2271, 2273, "mm" +552, 17, 42, 465, 154, 156, 2274, 2276, "Hg" +552, 17, 43, 466, 157, 160, 2277, 2280, "for" +552, 17, 44, 467, 161, 164, 2281, 2284, "the" +552, 17, 45, 468, 165, 176, 2285, 2296, "dorzolamide" +552, 17, 46, 469, 177, 178, 2297, 2298, "/" +552, 17, 47, 470, 179, 186, 2299, 2306, "timolol" +552, 17, 48, 471, 187, 192, 2307, 2312, "group" +552, 17, 49, 472, 193, 194, 2313, 2314, "." +552, 18, 1, 473, 0, 4, 2315, 2319, "Mean" +552, 18, 2, 474, 5, 8, 2320, 2323, "IOP" +552, 18, 3, 475, 9, 15, 2324, 2330, "values" +552, 18, 4, 476, 16, 20, 2331, 2335, "were" +552, 18, 5, 477, 21, 28, 2336, 2343, "similar" +552, 18, 6, 478, 29, 31, 2344, 2346, "at" +552, 18, 7, 479, 32, 35, 2347, 2350, "all" +552, 18, 8, 480, 36, 40, 2351, 2355, "time" +552, 18, 9, 481, 41, 47, 2356, 2362, "points" +552, 18, 10, 482, 48, 54, 2363, 2369, "except" +552, 18, 11, 483, 55, 57, 2370, 2372, "at" +552, 18, 12, 484, 58, 59, 2373, 2374, "5" +552, 18, 13, 485, 60, 61, 2375, 2376, ":" +552, 18, 14, 486, 62, 64, 2377, 2379, "00" +552, 18, 15, 487, 65, 67, 2380, 2382, "pm" +552, 18, 16, 488, 68, 69, 2383, 2384, "," +552, 18, 17, 489, 70, 74, 2385, 2389, "when" +552, 18, 18, 490, 75, 81, 2390, 2396, "levels" +552, 18, 19, 491, 82, 86, 2397, 2401, "were" +552, 18, 20, 492, 87, 100, 2402, 2415, "significantly" +552, 18, 21, 493, 101, 106, 2416, 2421, "lower" +552, 18, 22, 494, 107, 109, 2422, 2424, "in" +552, 18, 23, 495, 110, 121, 2425, 2436, "latanoprost" +552, 18, 24, 496, 122, 123, 2437, 2438, "-" +552, 18, 25, 497, 124, 131, 2439, 2446, "treated" +552, 18, 26, 498, 132, 140, 2447, 2455, "patients" +552, 18, 27, 499, 141, 142, 2456, 2457, "(" +552, 18, 28, 500, 143, 144, 2458, 2459, "P" +552, 18, 29, 501, 145, 146, 2460, 2461, "=" +552, 18, 30, 502, 147, 148, 2462, 2463, "0" +552, 18, 31, 503, 149, 150, 2464, 2465, "." +552, 18, 32, 504, 151, 154, 2466, 2469, "025" +552, 18, 33, 505, 155, 156, 2470, 2471, ")" +552, 18, 34, 506, 157, 158, 2472, 2473, "." +552, 19, 1, 507, 0, 5, 2474, 2479, "After" +552, 19, 2, 508, 6, 9, 2480, 2483, "the" +552, 19, 3, 509, 10, 15, 2484, 2489, "water" +552, 19, 4, 510, 16, 17, 2490, 2491, "-" +552, 19, 5, 511, 18, 26, 2492, 2500, "drinking" +552, 19, 6, 512, 27, 31, 2501, 2505, "test" +552, 19, 7, 513, 32, 33, 2506, 2507, "," +552, 19, 8, 514, 34, 37, 2508, 2511, "the" +552, 19, 9, 515, 38, 46, 2512, 2520, "increase" +552, 19, 10, 516, 47, 49, 2521, 2523, "in" +552, 19, 11, 517, 50, 53, 2524, 2527, "IOP" +552, 19, 12, 518, 54, 60, 2528, 2534, "values" +552, 19, 13, 519, 61, 64, 2535, 2538, "was" +552, 19, 14, 520, 65, 72, 2539, 2546, "similar" +552, 19, 15, 521, 73, 80, 2547, 2554, "between" +552, 19, 16, 522, 81, 87, 2555, 2561, "groups" +552, 19, 17, 523, 88, 90, 2562, 2564, "at" +552, 19, 18, 524, 91, 99, 2565, 2573, "baseline" +552, 19, 19, 525, 100, 103, 2574, 2577, "but" +552, 19, 20, 526, 104, 109, 2578, 2583, "lower" +552, 19, 21, 527, 110, 112, 2584, 2586, "in" +552, 19, 22, 528, 113, 124, 2587, 2598, "latanoprost" +552, 19, 23, 529, 125, 126, 2599, 2600, "-" +552, 19, 24, 530, 127, 134, 2601, 2608, "treated" +552, 19, 25, 531, 135, 143, 2609, 2617, "patients" +552, 19, 26, 532, 144, 146, 2618, 2620, "at" +552, 19, 27, 533, 147, 151, 2621, 2625, "week" +552, 19, 28, 534, 152, 153, 2626, 2627, "8" +552, 19, 29, 535, 154, 155, 2628, 2629, "(" +552, 19, 30, 536, 156, 164, 2630, 2638, "adjusted" +552, 19, 31, 537, 165, 175, 2639, 2649, "difference" +552, 19, 32, 538, 176, 177, 2650, 2651, "," +552, 19, 33, 539, 178, 179, 2652, 2653, "1" +552, 19, 34, 540, 180, 181, 2654, 2655, "." +552, 19, 35, 541, 182, 184, 2656, 2658, "08" +552, 19, 36, 542, 185, 187, 2659, 2661, "mm" +552, 19, 37, 543, 188, 190, 2662, 2664, "Hg" +552, 19, 38, 544, 191, 192, 2665, 2666, ";" +552, 19, 39, 545, 193, 194, 2667, 2668, "P" +552, 19, 40, 546, 195, 196, 2669, 2670, "=" +552, 19, 41, 547, 197, 198, 2671, 2672, "0" +552, 19, 42, 548, 199, 200, 2673, 2674, "." +552, 19, 43, 549, 201, 204, 2675, 2678, "012" +552, 19, 44, 550, 205, 206, 2679, 2680, ")" +552, 19, 45, 551, 207, 208, 2681, 2682, "." +552, 20, 1, 552, 0, 5, 2683, 2688, "Fewer" +552, 20, 2, 553, 6, 14, 2689, 2697, "patients" +552, 20, 3, 554, 15, 22, 2698, 2705, "treated" +552, 20, 4, 555, 23, 27, 2706, 2710, "with" +552, 20, 5, 556, 28, 39, 2711, 2722, "latanoprost" +552, 20, 6, 557, 40, 48, 2723, 2731, "reported" +552, 20, 7, 558, 49, 55, 2732, 2738, "ocular" +552, 20, 8, 559, 56, 58, 2739, 2741, "or" +552, 20, 9, 560, 59, 67, 2742, 2750, "systemic" +552, 20, 10, 561, 68, 71, 2751, 2754, "AEs" +552, 20, 11, 562, 72, 73, 2755, 2756, "(" +552, 20, 12, 563, 74, 75, 2757, 2758, "P" +552, 20, 13, 564, 76, 77, 2759, 2760, "=" +552, 20, 14, 565, 78, 79, 2761, 2762, "0" +552, 20, 15, 566, 80, 81, 2763, 2764, "." +552, 20, 16, 567, 82, 85, 2765, 2768, "025" +552, 20, 17, 568, 86, 89, 2769, 2772, "and" +552, 20, 18, 569, 90, 91, 2773, 2774, "P" +552, 20, 19, 570, 92, 93, 2775, 2776, "&" +552, 20, 20, 571, 94, 96, 2777, 2779, "lt" +552, 20, 21, 572, 97, 98, 2780, 2781, ";" +552, 20, 22, 573, 99, 100, 2782, 2783, "0" +552, 20, 23, 574, 101, 102, 2784, 2785, "." +552, 20, 24, 575, 103, 106, 2786, 2789, "001" +552, 20, 25, 576, 107, 108, 2790, 2791, "," +552, 20, 26, 577, 109, 121, 2792, 2804, "respectively" +552, 20, 27, 578, 122, 123, 2805, 2806, ")" +552, 20, 28, 579, 124, 125, 2807, 2808, "." +552, 21, 1, 580, 0, 11, 2809, 2820, "CONCLUSIONS" +552, 21, 2, 581, 12, 13, 2821, 2822, ":" +552, 21, 3, 582, 14, 16, 2823, 2825, "In" +552, 21, 4, 583, 17, 21, 2826, 2830, "this" +552, 21, 5, 584, 22, 27, 2831, 2836, "study" +552, 21, 6, 585, 28, 30, 2837, 2839, "of" +552, 21, 7, 586, 31, 39, 2840, 2848, "patients" +552, 21, 8, 587, 40, 44, 2849, 2853, "with" +552, 21, 9, 588, 45, 55, 2854, 2864, "unilateral" +552, 21, 10, 589, 56, 58, 2865, 2867, "or" +552, 21, 11, 590, 59, 68, 2868, 2877, "bilateral" +552, 21, 12, 591, 69, 76, 2878, 2885, "primary" +552, 21, 13, 592, 77, 81, 2886, 2890, "open" +552, 21, 14, 593, 82, 83, 2891, 2892, "-" +552, 21, 15, 594, 84, 89, 2893, 2898, "angle" +552, 21, 16, 595, 90, 91, 2899, 2900, "," +552, 21, 17, 596, 92, 102, 2901, 2911, "pigmentary" +552, 21, 18, 597, 103, 104, 2912, 2913, "," +552, 21, 19, 598, 105, 107, 2914, 2916, "or" +552, 21, 20, 599, 108, 119, 2917, 2928, "exfoliative" +552, 21, 21, 600, 120, 128, 2929, 2937, "glaucoma" +552, 21, 22, 601, 129, 131, 2938, 2940, "or" +552, 21, 23, 602, 132, 135, 2941, 2944, "OHT" +552, 21, 24, 603, 136, 139, 2945, 2948, "IOP" +552, 21, 25, 604, 140, 150, 2949, 2959, "reductions" +552, 21, 26, 605, 151, 160, 2960, 2969, "generally" +552, 21, 27, 606, 161, 165, 2970, 2974, "were" +552, 21, 28, 607, 166, 173, 2975, 2982, "similar" +552, 21, 29, 608, 174, 181, 2983, 2990, "between" +552, 21, 30, 609, 182, 191, 2991, 3000, "treatment" +552, 21, 31, 610, 192, 198, 3001, 3007, "groups" +552, 21, 32, 611, 199, 200, 3008, 3009, "," +552, 21, 33, 612, 201, 207, 3010, 3016, "except" +552, 21, 34, 613, 208, 210, 3017, 3019, "at" +552, 21, 35, 614, 211, 212, 3020, 3021, "5" +552, 21, 36, 615, 213, 214, 3022, 3023, ":" +552, 21, 37, 616, 215, 217, 3024, 3026, "00" +552, 21, 38, 617, 218, 220, 3027, 3029, "pm" +552, 21, 39, 618, 221, 222, 3030, 3031, "," +552, 21, 40, 619, 223, 227, 3032, 3036, "when" +552, 21, 41, 620, 228, 231, 3037, 3040, "the" +552, 21, 42, 621, 232, 236, 3041, 3045, "mean" +552, 21, 43, 622, 237, 240, 3046, 3049, "IOP" +552, 21, 44, 623, 241, 246, 3050, 3055, "level" +552, 21, 45, 624, 247, 250, 3056, 3059, "was" +552, 21, 46, 625, 251, 264, 3060, 3073, "significantly" +552, 21, 47, 626, 265, 270, 3074, 3079, "lower" +552, 21, 48, 627, 271, 273, 3080, 3082, "in" +552, 21, 49, 628, 274, 285, 3083, 3094, "latanoprost" +552, 21, 50, 629, 286, 287, 3095, 3096, "-" +552, 21, 51, 630, 288, 295, 3097, 3104, "treated" +552, 21, 52, 631, 296, 304, 3105, 3113, "patients" +552, 21, 53, 632, 305, 306, 3114, 3115, "." +552, 22, 1, 633, 0, 11, 3116, 3127, "Latanoprost" +552, 22, 2, 634, 12, 15, 3128, 3131, "was" +552, 22, 3, 635, 16, 22, 3132, 3138, "better" +552, 22, 4, 636, 23, 32, 3139, 3148, "tolerated" +552, 22, 5, 637, 33, 37, 3149, 3153, "than" +552, 22, 6, 638, 38, 43, 3154, 3159, "fixed" +552, 22, 7, 639, 44, 45, 3160, 3161, "-" +552, 22, 8, 640, 46, 57, 3162, 3173, "combination" +552, 22, 9, 641, 58, 69, 3174, 3185, "dorzolamide" +552, 22, 10, 642, 70, 73, 3186, 3189, "and" +552, 22, 11, 643, 74, 81, 3190, 3197, "timolol" +552, 22, 12, 644, 82, 83, 3198, 3199, "." +552, 23, 1, 645, 0, 3, 3200, 3203, "DOI" +552, 23, 2, 646, 4, 5, 3204, 3205, ":" +552, 23, 3, 647, 6, 8, 3206, 3208, "10" +552, 23, 4, 648, 9, 10, 3209, 3210, "." +552, 23, 5, 649, 11, 15, 3211, 3215, "1016" +552, 23, 6, 650, 16, 17, 3216, 3217, "/" +552, 23, 7, 651, 18, 23, 3218, 3223, "s0149" +552, 23, 8, 652, 24, 25, 3224, 3225, "-" +552, 23, 9, 653, 26, 30, 3226, 3230, "2918" +552, 23, 10, 654, 31, 32, 3231, 3232, "(" +552, 23, 11, 655, 33, 35, 3233, 3235, "04" +552, 23, 12, 656, 36, 37, 3236, 3237, ")" +552, 23, 13, 657, 38, 43, 3238, 3243, "90075" +552, 23, 14, 658, 44, 45, 3244, 3245, "-" +552, 23, 15, 659, 46, 47, 3246, 3247, "6" +552, 23, 16, 660, 48, 52, 3248, 3252, "PMID" +552, 23, 17, 661, 53, 54, 3253, 3254, ":" +552, 23, 18, 662, 55, 63, 3255, 3263, "15220019" +552, 23, 19, 663, 64, 65, 3264, 3265, "[" +552, 23, 20, 664, 66, 73, 3266, 3273, "Indexed" +552, 23, 21, 665, 74, 77, 3274, 3277, "for" +552, 23, 22, 666, 78, 85, 3278, 3285, "MEDLINE" +552, 23, 23, 667, 86, 87, 3286, 3287, "]" diff --git a/data/gl 15220019_jshahinitiran.annodb b/data/gl 15220019_jshahinitiran.annodb new file mode 100644 index 0000000..ca1f023 --- /dev/null +++ b/data/gl 15220019_jshahinitiran.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84546, Journal, 0, 9, "Clin Ther", "", +84547, PublicationYear, 12, 16, "2004", "", +84548, Title, 45, 276, "Comparison of latanoprost with fixed - combination dorzolamide and timolol in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label , parallel - group , multicenter study in Latin America .", "", +84549, Latanoprost, 59, 70, "latanoprost", "", +84552, Dorz/TimFC, 76, 119, "fixed - combination dorzolamide and timolol", "", +84550, Dorzolamide, 96, 107, "dorzolamide", "", +84551, Timolol, 112, 119, "timolol", "", +84554, Precondition, 123, 174, "adult patients with elevated intraocular pressure :", "", +84553, IOP, 152, 172, "intraocular pressure", "", +84555, Duration, 178, 190, "eight - week", "", +84556, Randomized, 193, 203, "randomized", "", +84557, OpenLabel, 206, 218, "open - label", "", +84558, Parallel, 221, 237, "parallel - group", "", +84559, Multicenter, 240, 251, "multicenter", "", +84560, Author, 277, 289, "Susanna R Jr", "", +84561, Author, 298, 305, "Sheu WP", "", +84654, Glaucoma, 323, 331, "Glaucoma", "", +84562, Brazil, 466, 472, "Brazil", "", +84563, Glaucoma, 571, 579, "glaucoma", "", +84564, OcularHypertension, 584, 603, "ocular hypertension", "", +84565, OcularHypertension, 606, 609, "OHT", "", +84566, Latanoprost, 620, 631, "latanoprost", "", +84567, Dorzolamide, 703, 728, "dorzolamide hydrochloride", "", +84568, Timolol, 768, 783, "timolol maleate", "", +84569, ObjectiveDescription, 817, 975, "The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks .", "", +84570, Latanoprost, 887, 898, "latanoprost", "", +84571, Dorzolamide, 937, 948, "dorzolamide", "", +84572, Timolol, 953, 960, "timolol", "", +84573, Duration, 966, 973, "8 weeks", "", +84574, CTDesign, 991, 1005, "interventional", "", +84575, Duration, 1008, 1016, "8 - week", "", +84576, Randomized, 1019, 1029, "randomized", "", +84577, OpenLabel, 1032, 1044, "open - label", "", +84578, Parallel, 1047, 1063, "parallel - group", "", +84579, Multicenter, 1087, 1097, "18 centers", "", +84580, Primary_OpenAngleGlaucoma, 1168, 1227, "primary open - angle , pigmentary , or exfoliative glaucoma", "", +84581, PigmentaryGlaucoma, 1191, 1227, "pigmentary , or exfoliative glaucoma", "", +84582, OcularHypertension, 1231, 1234, "OHT", "", +84583, Randomized, 1240, 1250, "randomized", "", +84584, Latanoprost, 1262, 1273, "latanoprost", "", +84585, Frequency, 1303, 1305, "QD", "", +84586, Evening, 1308, 1315, "evening", "", +84587, Dorzolamide, 1343, 1354, "dorzolamide", "", +84588, Timolol, 1357, 1364, "timolol", "", +84589, Frequency, 1394, 1397, "BID", "", +84590, Morning, 1400, 1407, "morning", "", +84591, Evening, 1412, 1419, "evening", "", +84592, TimePoint, 1492, 1500, "baseline", "", +84593, TimePoint, 1505, 1511, "week 8", "", +84594, IOP, 1514, 1534, "intraocular pressure", "", +84595, IOP, 1537, 1542, "IOP )", "", +84596, Peak_IOP, 1681, 1689, "IOP peak", "", +84597, IOP, 1751, 1754, "IOP", "", +84598, Diurnal_IOP, 1811, 1822, "diurnal IOP", "", +84599, Mean, 1829, 1833, "mean", "", +84600, IOP, 1837, 1840, "IOP", "", +84601, TimePoint, 1861, 1869, "baseline", "", +84602, TimePoint, 1873, 1879, "week 8", "", +84603, NumberPatientsCT, 1960, 1963, "229", "", +84604, Randomized, 1978, 1988, "randomized", "", +84607, Latanoprost, 1991, 2002, "latanoprost", "", +84605, NumberPatientsArm, 2009, 2012, "112", "", +84608, Dorzolamide, 2015, 2026, "dorzolamide", "", +84609, Timolol, 2029, 2036, "timolol", "", +84606, NumberPatientsArm, 2043, 2046, "117", "", +84610, Mean, 2051, 2055, "Mean", "", +84611, Diurnal_IOP, 2065, 2076, "diurnal IOP", "", +84612, Mean, 2120, 2124, "Mean", "", +84613, IOP, 2132, 2143, "diurnal IOP", "", +84614, TimePoint, 2158, 2164, "week 8", "", +84615, Reduction, 2203, 2208, "6 . 9", "", +84617, SdDevChangeValue, 2211, 2216, "3 . 0", "", +84619, mmHg, 2219, 2224, "mm Hg", "", +84621, Latanoprost, 2233, 2244, "latanoprost", "", +84616, Reduction, 2255, 2260, "6 . 4", "", +84618, SdDevChangeValue, 2263, 2268, "3 . 2", "", +84620, mmHg, 2271, 2276, "mm Hg", "", +84622, Dorzolamide, 2285, 2296, "dorzolamide", "", +84623, Timolol, 2299, 2306, "timolol", "", +84624, Mean, 2315, 2319, "Mean", "", +84628, ObservedResult, 2315, 2473, "Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) .", "", +84625, IOP, 2320, 2323, "IOP", "", +84626, Latanoprost, 2425, 2436, "latanoprost", "", +84627, PvalueDiff, 2456, 2469, "( P = 0 . 025", "", +84629, IOP, 2524, 2527, "IOP", "", +84630, TimePoint, 2565, 2573, "baseline", "", +84632, Latanoprost, 2587, 2598, "latanoprost", "", +84631, TimePoint, 2621, 2629, "week 8 (", "", +84633, DiffGroupAbsValue, 2652, 2658, "1 . 08", "", +84634, mmHg, 2659, 2664, "mm Hg", "", +84635, PvalueDiff, 2667, 2678, "P = 0 . 012", "", +84636, Latanoprost, 2711, 2722, "latanoprost", "", +84637, PValueNumAffected, 2757, 2768, "P = 0 . 025", "", +84638, PValueNumAffected, 2773, 2789, "P & lt ; 0 . 001", "", +84639, ConclusionComment, 2823, 3009, "In this study of patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups ,", "", +84641, Primary_OpenAngleGlaucoma, 2878, 2937, "primary open - angle , pigmentary , or exfoliative glaucoma", "", +84642, PigmentaryGlaucoma, 2901, 2937, "pigmentary , or exfoliative glaucoma", "", +84643, OcularHypertension, 2941, 2944, "OHT", "", +84644, IOP, 2945, 2948, "IOP", "", +84640, ConclusionComment, 3010, 3115, "except at 5 : 00 pm , when the mean IOP level was significantly lower in latanoprost - treated patients .", "", +84645, Mean, 3041, 3045, "mean", "", +84646, IOP, 3046, 3049, "IOP", "", +84647, Latanoprost, 3083, 3094, "latanoprost", "", +84648, ConclusionComment, 3116, 3199, "Latanoprost was better tolerated than fixed - combination dorzolamide and timolol .", "", +84649, Latanoprost, 3116, 3127, "Latanoprost", "", +84650, Dorz/TimFC, 3154, 3197, "fixed - combination dorzolamide and timolol", "", +84651, Dorzolamide, 3174, 3185, "dorzolamide", "", +84652, Timolol, 3190, 3197, "timolol", "", +84653, PMID, 3255, 3263, "15220019", "", diff --git a/data/gl 15220019_jshahinitiran.n-triples b/data/gl 15220019_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15220019_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15220019_tstrakeljahn.annodb b/data/gl 15220019_tstrakeljahn.annodb new file mode 100644 index 0000000..dccec74 --- /dev/null +++ b/data/gl 15220019_tstrakeljahn.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +91119, Journal, 0, 9, "Clin Ther", "", +91120, PublicationYear, 12, 16, "2004", "", +91132, Title, 45, 276, "Comparison of latanoprost with fixed - combination dorzolamide and timolol in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label , parallel - group , multicenter study in Latin America .", "", +91121, Latanoprost, 59, 70, "latanoprost", "", +91122, Dorzolamide, 96, 107, "dorzolamide", "", +91130, Dorz/TimFC, 96, 119, "dorzolamide and timolol", "", +91123, Timolol, 112, 119, "timolol", "", +91131, Precondition, 123, 172, "adult patients with elevated intraocular pressure", "", +91124, IOP, 152, 172, "intraocular pressure", "", +91125, Duration, 178, 190, "eight - week", "", +91126, Randomized, 193, 203, "randomized", "", +91127, OpenLabel, 206, 218, "open - label", "", +91128, Parallel, 221, 229, "parallel", "", +91129, Multicenter, 240, 251, "multicenter", "", +91133, Author, 277, 289, "Susanna R Jr", "", +91134, Author, 298, 305, "Sheu WP", "", +91135, Glaucoma, 323, 331, "Glaucoma", "", +91136, Glaucoma, 369, 377, "Glaucoma", "", +91137, Brazil, 466, 472, "Brazil", "", +91138, Glaucoma, 571, 579, "glaucoma", "", +91139, OcularHypertension, 584, 603, "ocular hypertension", "", +91140, OcularHypertension, 606, 609, "OHT", "", +91141, Latanoprost, 620, 631, "latanoprost", "", +91142, Dorzolamide, 703, 728, "dorzolamide hydrochloride", "", +91144, Dorz/TimFC, 703, 783, "dorzolamide hydrochloride , a carbonic anhydrase inhibitor , and timolol maleate", "", +91143, Timolol, 768, 783, "timolol maleate", "", +91149, ObjectiveDescription, 817, 975, "The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks .", "", +91145, Latanoprost, 887, 898, "latanoprost", "", +91146, Dorzolamide, 937, 948, "dorzolamide", "", +91147, Timolol, 953, 960, "timolol", "", +91148, Duration, 966, 973, "8 weeks", "", +91150, CTDesign, 991, 1005, "interventional", "", +91151, Duration, 1008, 1016, "8 - week", "", +91152, Randomized, 1019, 1029, "randomized", "", +91153, OpenLabel, 1032, 1044, "open - label", "", +91154, Parallel, 1047, 1055, "parallel", "", +91155, Multicenter, 1087, 1097, "18 centers", "", +91160, Precondition, 1130, 1234, "Patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT", "", +91158, Primary_OpenAngleGlaucoma, 1168, 1227, "primary open - angle , pigmentary , or exfoliative glaucoma", "", +91157, PigmentaryGlaucoma, 1191, 1227, "pigmentary , or exfoliative glaucoma", "", +91156, Glaucoma, 1207, 1227, "exfoliative glaucoma", "", +91159, OcularHypertension, 1231, 1234, "OHT", "", +91161, Randomized, 1240, 1250, "randomized", "", +91162, Latanoprost, 1262, 1273, "latanoprost", "", +91163, Eyedrops, 1278, 1282, "drop", "", +91164, Frequency, 1303, 1305, "QD", "", +91165, Evening, 1308, 1315, "evening", "", +91166, Dorzolamide, 1343, 1354, "dorzolamide", "", +91168, Dorz/TimFC, 1343, 1364, "dorzolamide / timolol", "", +91167, Timolol, 1357, 1364, "timolol", "", +91169, Eyedrops, 1369, 1373, "drop", "", +91170, Frequency, 1394, 1397, "BID", "", +91171, Morning, 1400, 1407, "morning", "", +91172, Evening, 1412, 1419, "evening", "", +91173, Eyedrops, 1465, 1469, "drop", "", +91174, TimePoint, 1492, 1500, "baseline", "", +91175, TimePoint, 1505, 1511, "week 8", "", +91176, IOP, 1514, 1534, "intraocular pressure", "", +91177, IOP, 1537, 1540, "IOP", "", +91178, TimePoint, 1572, 1581, "8 : 30 am", "", +91179, TimePoint, 1584, 1594, "10 : 00 am", "", +91180, TimePoint, 1597, 1606, "2 : 00 pm", "", +91181, TimePoint, 1613, 1622, "5 : 00 pm", "", +91182, Peak_IOP, 1681, 1689, "IOP peak", "", +91184, Diurnal_IOP, 1693, 1714, "diurnal tension curve", "", +91185, TimePoint, 1741, 1750, "5 : 00 pm", "", +91186, IOP, 1751, 1754, "IOP", "", +91187, Diurnal_IOP, 1811, 1822, "diurnal IOP", "", +91188, Mean, 1829, 1833, "mean", "", +91189, IOP, 1837, 1840, "IOP", "", +91190, TimePoint, 1861, 1869, "baseline", "", +91191, TimePoint, 1873, 1879, "week 8", "", +91192, NumberPatientsCT, 1960, 1963, "229", "", +91193, Randomized, 1978, 1988, "randomized", "", +91194, Latanoprost, 1991, 2002, "latanoprost", "", +91195, NumberPatientsArm, 2009, 2012, "112", "", +91197, Dorzolamide, 2015, 2026, "dorzolamide", "", +91199, Dorz/TimFC, 2015, 2036, "dorzolamide / timolol", "", +91198, Timolol, 2029, 2036, "timolol", "", +91196, NumberPatientsArm, 2043, 2046, "117", "", +91200, Mean, 2051, 2055, "Mean", "", +91202, ObservedResult, 2051, 2119, "Mean baseline diurnal IOP values were similar between the 2 groups .", "", +91201, Diurnal_IOP, 2065, 2076, "diurnal IOP", "", +91203, Mean, 2120, 2124, "Mean", "", +91204, Diurnal_IOP, 2132, 2143, "diurnal IOP", "", +91205, TimePoint, 2158, 2164, "week 8", "", +91206, Reduction, 2203, 2208, "6 . 9", "", +91208, SdDevChangeValue, 2211, 2216, "3 . 0", "", +91210, mmHg, 2219, 2224, "mm Hg", "", +91215, Latanoprost, 2233, 2244, "latanoprost", "", +91207, Reduction, 2255, 2260, "6 . 4", "", +91209, SdDevChangeValue, 2263, 2268, "3 . 2", "", +91211, mmHg, 2271, 2276, "mm Hg", "", +91212, Dorzolamide, 2285, 2296, "dorzolamide", "", +91214, Dorz/TimFC, 2285, 2306, "dorzolamide / timolol", "", +91213, Timolol, 2299, 2306, "timolol", "", +91216, Mean, 2315, 2319, "Mean", "", +91221, ObservedResult, 2315, 2473, "Mean IOP values were similar at all time points except at 5 : 00 pm , when levels were significantly lower in latanoprost - treated patients ( P = 0 . 025 ) .", "", +91217, IOP, 2320, 2323, "IOP", "", +91218, TimePoint, 2373, 2382, "5 : 00 pm", "", +91219, Latanoprost, 2425, 2436, "latanoprost", "", +91220, PvalueDiff, 2460, 2469, "= 0 . 025", "", +91232, ObservedResult, 2474, 2682, "After the water - drinking test , the increase in IOP values was similar between groups at baseline but lower in latanoprost - treated patients at week 8 ( adjusted difference , 1 . 08 mm Hg ; P = 0 . 012 ) .", "", +91222, IOP, 2524, 2527, "IOP", "", +91223, Latanoprost, 2587, 2598, "latanoprost", "", +91224, TimePoint, 2621, 2627, "week 8", "", +91225, DiffGroupAbsValue, 2652, 2658, "1 . 08", "", +91226, mmHg, 2659, 2664, "mm Hg", "", +91227, PvalueDiff, 2669, 2678, "= 0 . 012", "", +91231, ObservedResult, 2683, 2808, "Fewer patients treated with latanoprost reported ocular or systemic AEs ( P = 0 . 025 and P & lt ; 0 . 001 , respectively ) .", "", +91228, Latanoprost, 2711, 2722, "latanoprost", "", +91229, PValueNumAffected, 2759, 2768, "= 0 . 025", "", +91230, PValueNumAffected, 2775, 2789, "& lt ; 0 . 001", "", +91242, ConclusionComment, 2823, 3073, "In this study of patients with unilateral or bilateral primary open - angle , pigmentary , or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups , except at 5 : 00 pm , when the mean IOP level was significantly", "", +91235, Primary_OpenAngleGlaucoma, 2878, 2937, "primary open - angle , pigmentary , or exfoliative glaucoma", "", +91234, PigmentaryGlaucoma, 2901, 2937, "pigmentary , or exfoliative glaucoma", "", +91233, Glaucoma, 2917, 2937, "exfoliative glaucoma", "", +91236, OcularHypertension, 2941, 2944, "OHT", "", +91237, IOP, 2945, 2948, "IOP", "", +91238, TimePoint, 3020, 3029, "5 : 00 pm", "", +91239, Mean, 3041, 3045, "mean", "", +91240, IOP, 3046, 3049, "IOP", "", +91243, ConclusionComment, 3074, 3115, "lower in latanoprost - treated patients .", "", +91241, Latanoprost, 3083, 3094, "latanoprost", "", +91244, Latanoprost, 3116, 3127, "Latanoprost", "", +91248, ConclusionComment, 3116, 3199, "Latanoprost was better tolerated than fixed - combination dorzolamide and timolol .", "", +91245, Dorzolamide, 3174, 3185, "dorzolamide", "", +91247, Dorz/TimFC, 3174, 3197, "dorzolamide and timolol", "", +91246, Timolol, 3190, 3197, "timolol", "", +91249, PMID, 3255, 3263, "15220019", "", diff --git a/data/gl 15220019_tstrakeljahn.n-triples b/data/gl 15220019_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15220019_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1524115_admin.annodb b/data/gl 1524115_admin.annodb new file mode 100644 index 0000000..e675010 --- /dev/null +++ b/data/gl 1524115_admin.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Am J Ophthalmol .", "", " \"Am J Ophthalmol .\"." +1, PublicationYear, 18, 22, "1992", "", " \"1992\"." +2, Title, 54, 116, "Short - term effects of levobunolol on ocular pulsatile flow .", "", " \"Short - term effects of levobunolol on ocular pulsatile flow .\"." +6, Levobunolol, 78, 89, "levobunolol", "", +7, OcularBloodFlow, 93, 114, "ocular pulsatile flow", "", +3, Author, 117, 125, "Bosem ME", "", " \"Bosem ME\"." +4, Author, 134, 141, "Lusky M", "", " \"Lusky M\"." +5, Author, 144, 154, "Weinreb RN", "", " \"Weinreb RN\"." +102211, Country, 228, 250, "California , San Diego", "", +87, ObjectiveDescription, 253, 505, "In a randomized , double - masked , placebo - controlled study , we evaluated the effect of levobunolol 0 . 5 % , a nonselective beta - blocker , on intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients", "", " \"In a randomized , double - masked , placebo - controlled study , we evaluated the effect of levobunolol 0 . 5 % , a nonselective beta - blocker , on intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients\". \"with glaucoma .\"." +8, Randomized, 258, 268, "randomized", "", " ." +9, DoubleBlind, 271, 286, "double - masked", "", " ." +10, Placebo, 289, 296, "placebo", "", " ." +11, CTDesign, 289, 309, "placebo - controlled", "", " . ." +12, Levobunolol, 345, 356, "levobunolol", "", " ." +13, DoseValue, 357, 362, "0 . 5", "", " \"0 . 5\"." +86, Percentage, 363, 364, "%", "", " ." +83, Precondition, 402, 519, "intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients with glaucoma", "", " \"intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients with glaucoma\"." +14, IOP, 402, 422, "intraocular pressure", "", +15, EndPointDescription, 425, 441, "volume amplitude", "", +16, OcularBloodFlow, 448, 469, "ocular pulsatile flow", "", +87, ObjectiveDescription, 506, 521, "with glaucoma .", "", " \"with glaucoma .\"." +17, Glaucoma, 511, 519, "glaucoma", "", " . ." +18, EndPointDescription, 522, 538, "Volume amplitude", "", +19, OcularBloodFlow, 543, 564, "ocular pulsatile flow", "", +20, MeasurementDevice, 622, 637, "pneumatonometer", "", " . . . ." +102216, DoseDescription, 640, 668, "Two hours after instillation", "", " \"Two hours after instillation\"." +102214, DeliveryMethod, 656, 668, "instillation", "", " . ." +21, Levobunolol, 672, 683, "levobunolol", "", +22, IOP, 686, 706, "intraocular pressure", "", " . ." +23, BaseLineValue, 722, 728, "26 . 0", "", " \"26 . 0\"." +92, SdDevBL, 735, 740, "5 . 1", "", " \"5 . 1\"." +26, mmHg, 741, 746, "mm Hg", "", " ." +24, ResultMeasuredValue, 750, 756, "17 . 8", "", " \"17 . 8\"." +97, SdDevResValue, 763, 768, "3 . 9", "", " \"3 . 9\"." +27, mmHg, 769, 774, "mm Hg", "", +29, RelativeReduction, 777, 783, "28 . 3", "", " \"28 . 3\"." +30, PValueResValue, 790, 807, "P less than . 001", "", " \"P less than . 001\"." +106256, SubGroupDescription, 813, 830, "glaucomatous eyes", "", " \"glaucomatous eyes\"." +31, BaseLineValue, 835, 841, "20 . 2", "", " \"20 . 2\"." +100, SdDevBL, 848, 853, "3 . 6", "", " \"3 . 6\"." +35, mmHg, 854, 859, "mm Hg", "", +32, ResultMeasuredValue, 863, 869, "14 . 5", "", " \"14 . 5\"." +98, SdDevResValue, 876, 881, "4 . 2", "", " \"4 . 2\"." +36, mmHg, 882, 887, "mm Hg", "", +37, RelativeReduction, 890, 896, "29 . 6", "", " \"29 . 6\"." +38, PValueResValue, 903, 920, "P less than . 001", "", " \"P less than . 001\"." +106257, SubGroupDescription, 926, 938, "healthy eyes", "", " \"healthy eyes\"." +39, OcularBloodFlow, 941, 962, "Ocular pulsatile flow", "", " ." +40, Levobunolol, 998, 1009, "levobunolol", "", +41, BaseLineValue, 1015, 1022, "482 . 1", "", " \"482 . 1\"." +109, SdDevBL, 1029, 1036, "133 . 3", "", " \"133 . 3\"." +43, BioAndMedicalUnit, 1037, 1056, "microliter / minute", "", " . ." +44, ResultMeasuredValue, 1060, 1067, "548 . 5", "", " \"548 . 5\"." +111, SdDevResValue, 1074, 1081, "180 . 3", "", " \"180 . 3\"." +46, BioAndMedicalUnit, 1082, 1101, "microliter / minute", "", +47, RelativeIncrement, 1104, 1110, "13 . 3", "", " \"13 . 3\"." +48, PValueResValue, 1117, 1134, "P less than . 006", "", " \"P less than . 006\"." +106258, SubGroupDescription, 1140, 1157, "glaucomatous eyes", "", " \"glaucomatous eyes\"." +49, BaseLineValue, 1162, 1169, "457 . 6", "", " \"457 . 6\"." +115, SdDevBL, 1176, 1183, "178 . 2", "", " \"178 . 2\"." +51, BioAndMedicalUnit, 1184, 1203, "microliter / minute", "", +53, ResultMeasuredValue, 1207, 1210, "528", "", " \"528\"." +117, SdDevResValue, 1217, 1224, "223 . 8", "", " \"223 . 8\"." +52, BioAndMedicalUnit, 1225, 1244, "microliter / minute", "", +55, RelativeIncrement, 1247, 1253, "12 . 3", "", " \"12 . 3\"." +56, PValueResValue, 1260, 1279, "P greater than . 05", "", " \"P greater than . 05\"." +106259, SubGroupDescription, 1285, 1297, "healthy eyes", "", " \"healthy eyes\"." +102217, ObservedResult, 1300, 1334, "There was no significant change in", "", " \"There was no significant change in\". \"in placebo - treated eyes\". \"There was no significant change in\". \"in placebo - treated eyes\". \"There was no significant change in\". \"in placebo - treated eyes\"." +57, IOP, 1335, 1355, "intraocular pressure", "", +58, EndPointDescription, 1358, 1374, "volume amplitude", "", " . ." +59, OcularBloodFlow, 1380, 1401, "ocular pulsatile flow", "", +102217, ObservedResult, 1402, 1427, "in placebo - treated eyes", "", +60, Placebo, 1405, 1412, "placebo", "", +66, ConclusionComment, 1430, 1495, "The implication of these data for glaucoma therapy is not clear .", "", " \"The implication of these data for glaucoma therapy is not clear .\". \"Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow .\". \"Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells .\"." +62, Glaucoma, 1464, 1472, "glaucoma", "", +66, ConclusionComment, 1496, 1677, "Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow .", "", " \"Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow .\"." +63, OcularBloodFlow, 1558, 1572, "pulsatile flow", "", +135, OcularBloodFlow, 1590, 1612, "optic nerve blood flow", "", +66, ConclusionComment, 1678, 1907, "Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells .", "", " \"Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells .\"." +65, OcularBloodFlow, 1749, 1766, "ocular blood flow", "", +69, PMID, 1963, 1970, "1524115", "", " \"1524115\"." diff --git a/data/gl 1524115_admin.n-triples b/data/gl 1524115_admin.n-triples new file mode 100644 index 0000000..e01653c --- /dev/null +++ b/data/gl 1524115_admin.n-triples @@ -0,0 +1,160 @@ +# RDF export of group: Publication + . + "Publication 90290" . + "Short - term effects of levobunolol on ocular pulsatile flow ." . + "Bosem ME" . + "1992" . + "Am J Ophthalmol ." . + "1524115" . + . + "Lusky M" . + "Weinreb RN" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 90297" . + "In a randomized , double - masked , placebo - controlled study , we evaluated the effect of levobunolol 0 . 5 % , a nonselective beta - blocker , on intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients" . + "with glaucoma ." . + . + . + . + "The implication of these data for glaucoma therapy is not clear ." . + "Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow ." . + "Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 90313" . + "intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients with glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "obf" . + . + . + . + . + . + . + . + "va" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "lev" . + . + . + . + . + . + . + . + "pl" . + . + . + . + . + . +# RDF export of group: Intervention + . + "lev" . + . + . + . + "pl" . + . + . +# RDF export of group: Medication + . + "le" . + . + "0 . 5" . + . + . + . + "Two hours after instillation" . + . + "pl" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "26 . 0" . + "5 . 1" . + "17 . 8" . + "P less than . 001" . + "3 . 9" . + "28 . 3" . + "glaucomatous eyes" . + . + "ioph 1" . + . + "20 . 2" . + "3 . 6" . + "14 . 5" . + "P less than . 001" . + "4 . 2" . + "29 . 6" . + "healthy eyes" . + . + "obf 1" . + . + "482 . 1" . + "133 . 3" . + "548 . 5" . + "P less than . 006" . + "180 . 3" . + "13 . 3" . + "glaucomatous eyes" . + . + "obfh 1" . + . + "457 . 6" . + "178 . 2" . + "528" . + "P greater than . 05" . + "223 . 8" . + "12 . 3" . + "healthy eyes" . + . + "iop 2" . + . + "There was no significant change in" . + "in placebo - treated eyes" . + . + "obf 2" . + . + "There was no significant change in" . + "in placebo - treated eyes" . + . + "va 2" . + . + "There was no significant change in" . + "in placebo - treated eyes" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1524115_export.csv b/data/gl 1524115_export.csv new file mode 100644 index 0000000..cfadc77 --- /dev/null +++ b/data/gl 1524115_export.csv @@ -0,0 +1,437 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +525, 1, 1, 1, 0, 2, 0, 2, "Am" +525, 1, 2, 2, 3, 4, 3, 4, "J" +525, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +525, 1, 4, 4, 16, 17, 16, 17, "." +525, 2, 1, 5, 0, 4, 18, 22, "1992" +525, 2, 2, 6, 5, 8, 23, 26, "Sep" +525, 2, 3, 7, 9, 11, 27, 29, "15" +525, 2, 4, 8, 12, 13, 30, 31, ";" +525, 2, 5, 9, 14, 17, 32, 35, "114" +525, 2, 6, 10, 18, 19, 36, 37, "(" +525, 2, 7, 11, 20, 21, 38, 39, "3" +525, 2, 8, 12, 22, 23, 40, 41, ")" +525, 2, 9, 13, 24, 25, 42, 43, ":" +525, 2, 10, 14, 26, 29, 44, 47, "280" +525, 2, 11, 15, 30, 31, 48, 49, "-" +525, 2, 12, 16, 32, 33, 50, 51, "6" +525, 2, 13, 17, 34, 35, 52, 53, "." +525, 3, 1, 18, 0, 5, 54, 59, "Short" +525, 3, 2, 19, 6, 7, 60, 61, "-" +525, 3, 3, 20, 8, 12, 62, 66, "term" +525, 3, 4, 21, 13, 20, 67, 74, "effects" +525, 3, 5, 22, 21, 23, 75, 77, "of" +525, 3, 6, 23, 24, 35, 78, 89, "levobunolol" +525, 3, 7, 24, 36, 38, 90, 92, "on" +525, 3, 8, 25, 39, 45, 93, 99, "ocular" +525, 3, 9, 26, 46, 55, 100, 109, "pulsatile" +525, 3, 10, 27, 56, 60, 110, 114, "flow" +525, 3, 11, 28, 61, 62, 115, 116, "." +525, 4, 1, 29, 0, 5, 117, 122, "Bosem" +525, 4, 2, 30, 6, 8, 123, 125, "ME" +525, 4, 3, 31, 9, 10, 126, 127, "(" +525, 4, 4, 32, 11, 12, 128, 129, "1" +525, 4, 5, 33, 13, 14, 130, 131, ")" +525, 4, 6, 34, 15, 16, 132, 133, "," +525, 4, 7, 35, 17, 22, 134, 139, "Lusky" +525, 4, 8, 36, 23, 24, 140, 141, "M" +525, 4, 9, 37, 25, 26, 142, 143, "," +525, 4, 10, 38, 27, 34, 144, 151, "Weinreb" +525, 4, 11, 39, 35, 37, 152, 154, "RN" +525, 4, 12, 40, 38, 39, 155, 156, "." +525, 5, 1, 41, 0, 6, 157, 163, "Author" +525, 5, 2, 42, 7, 18, 164, 175, "information" +525, 5, 3, 43, 19, 20, 176, 177, ":" +525, 5, 4, 44, 21, 22, 178, 179, "(" +525, 5, 5, 45, 23, 24, 180, 181, "1" +525, 5, 6, 46, 25, 26, 182, 183, ")" +525, 5, 7, 47, 27, 37, 184, 194, "Department" +525, 5, 8, 48, 38, 40, 195, 197, "of" +525, 5, 9, 49, 41, 54, 198, 211, "Ophthalmology" +525, 5, 10, 50, 55, 56, 212, 213, "," +525, 5, 11, 51, 57, 67, 214, 224, "University" +525, 5, 12, 52, 68, 70, 225, 227, "of" +525, 5, 13, 53, 71, 81, 228, 238, "California" +525, 5, 14, 54, 82, 83, 239, 240, "," +525, 5, 15, 55, 84, 87, 241, 244, "San" +525, 5, 16, 56, 88, 93, 245, 250, "Diego" +525, 5, 17, 57, 94, 95, 251, 252, "." +525, 6, 1, 58, 0, 2, 253, 255, "In" +525, 6, 2, 59, 3, 4, 256, 257, "a" +525, 6, 3, 60, 5, 15, 258, 268, "randomized" +525, 6, 4, 61, 16, 17, 269, 270, "," +525, 6, 5, 62, 18, 24, 271, 277, "double" +525, 6, 6, 63, 25, 26, 278, 279, "-" +525, 6, 7, 64, 27, 33, 280, 286, "masked" +525, 6, 8, 65, 34, 35, 287, 288, "," +525, 6, 9, 66, 36, 43, 289, 296, "placebo" +525, 6, 10, 67, 44, 45, 297, 298, "-" +525, 6, 11, 68, 46, 56, 299, 309, "controlled" +525, 6, 12, 69, 57, 62, 310, 315, "study" +525, 6, 13, 70, 63, 64, 316, 317, "," +525, 6, 14, 71, 65, 67, 318, 320, "we" +525, 6, 15, 72, 68, 77, 321, 330, "evaluated" +525, 6, 16, 73, 78, 81, 331, 334, "the" +525, 6, 17, 74, 82, 88, 335, 341, "effect" +525, 6, 18, 75, 89, 91, 342, 344, "of" +525, 6, 19, 76, 92, 103, 345, 356, "levobunolol" +525, 6, 20, 77, 104, 105, 357, 358, "0" +525, 6, 21, 78, 106, 107, 359, 360, "." +525, 6, 22, 79, 108, 109, 361, 362, "5" +525, 6, 23, 80, 110, 111, 363, 364, "%" +525, 6, 24, 81, 112, 113, 365, 366, "," +525, 6, 25, 82, 114, 115, 367, 368, "a" +525, 6, 26, 83, 116, 128, 369, 381, "nonselective" +525, 6, 27, 84, 129, 133, 382, 386, "beta" +525, 6, 28, 85, 134, 135, 387, 388, "-" +525, 6, 29, 86, 136, 143, 389, 396, "blocker" +525, 6, 30, 87, 144, 145, 397, 398, "," +525, 6, 31, 88, 146, 148, 399, 401, "on" +525, 6, 32, 89, 149, 160, 402, 413, "intraocular" +525, 6, 33, 90, 161, 169, 414, 422, "pressure" +525, 6, 34, 91, 170, 171, 423, 424, "," +525, 6, 35, 92, 172, 178, 425, 431, "volume" +525, 6, 36, 93, 179, 188, 432, 441, "amplitude" +525, 6, 37, 94, 189, 190, 442, 443, "," +525, 6, 38, 95, 191, 194, 444, 447, "and" +525, 6, 39, 96, 195, 201, 448, 454, "ocular" +525, 6, 40, 97, 202, 211, 455, 464, "pulsatile" +525, 6, 41, 98, 212, 216, 465, 469, "flow" +525, 6, 42, 99, 217, 219, 470, 472, "in" +525, 6, 43, 100, 220, 227, 473, 480, "healthy" +525, 6, 44, 101, 228, 239, 481, 492, "individuals" +525, 6, 45, 102, 240, 243, 493, 496, "and" +525, 6, 46, 103, 244, 252, 497, 505, "patients" +525, 6, 47, 104, 253, 257, 506, 510, "with" +525, 6, 48, 105, 258, 266, 511, 519, "glaucoma" +525, 6, 49, 106, 267, 268, 520, 521, "." +525, 7, 1, 107, 0, 6, 522, 528, "Volume" +525, 7, 2, 108, 7, 16, 529, 538, "amplitude" +525, 7, 3, 109, 17, 20, 539, 542, "and" +525, 7, 4, 110, 21, 27, 543, 549, "ocular" +525, 7, 5, 111, 28, 37, 550, 559, "pulsatile" +525, 7, 6, 112, 38, 42, 560, 564, "flow" +525, 7, 7, 113, 43, 47, 565, 569, "were" +525, 7, 8, 114, 48, 55, 570, 577, "derived" +525, 7, 9, 115, 56, 60, 578, 582, "from" +525, 7, 10, 116, 61, 73, 583, 595, "measurements" +525, 7, 11, 117, 74, 76, 596, 598, "of" +525, 7, 12, 118, 77, 82, 599, 604, "pulse" +525, 7, 13, 119, 83, 92, 605, 614, "amplitude" +525, 7, 14, 120, 93, 97, 615, 619, "with" +525, 7, 15, 121, 98, 99, 620, 621, "a" +525, 7, 16, 122, 100, 115, 622, 637, "pneumatonometer" +525, 7, 17, 123, 116, 117, 638, 639, "." +525, 8, 1, 124, 0, 3, 640, 643, "Two" +525, 8, 2, 125, 4, 9, 644, 649, "hours" +525, 8, 3, 126, 10, 15, 650, 655, "after" +525, 8, 4, 127, 16, 28, 656, 668, "instillation" +525, 8, 5, 128, 29, 31, 669, 671, "of" +525, 8, 6, 129, 32, 43, 672, 683, "levobunolol" +525, 8, 7, 130, 44, 45, 684, 685, "," +525, 8, 8, 131, 46, 57, 686, 697, "intraocular" +525, 8, 9, 132, 58, 66, 698, 706, "pressure" +525, 8, 10, 133, 67, 76, 707, 716, "decreased" +525, 8, 11, 134, 77, 81, 717, 721, "from" +525, 8, 12, 135, 82, 84, 722, 724, "26" +525, 8, 13, 136, 85, 86, 725, 726, "." +525, 8, 14, 137, 87, 88, 727, 728, "0" +525, 8, 15, 138, 89, 90, 729, 730, "+" +525, 8, 16, 139, 91, 92, 731, 732, "/" +525, 8, 17, 140, 93, 94, 733, 734, "-" +525, 8, 18, 141, 95, 96, 735, 736, "5" +525, 8, 19, 142, 97, 98, 737, 738, "." +525, 8, 20, 143, 99, 100, 739, 740, "1" +525, 8, 21, 144, 101, 103, 741, 743, "mm" +525, 8, 22, 145, 104, 106, 744, 746, "Hg" +525, 8, 23, 146, 107, 109, 747, 749, "to" +525, 8, 24, 147, 110, 112, 750, 752, "17" +525, 8, 25, 148, 113, 114, 753, 754, "." +525, 8, 26, 149, 115, 116, 755, 756, "8" +525, 8, 27, 150, 117, 118, 757, 758, "+" +525, 8, 28, 151, 119, 120, 759, 760, "/" +525, 8, 29, 152, 121, 122, 761, 762, "-" +525, 8, 30, 153, 123, 124, 763, 764, "3" +525, 8, 31, 154, 125, 126, 765, 766, "." +525, 8, 32, 155, 127, 128, 767, 768, "9" +525, 8, 33, 156, 129, 131, 769, 771, "mm" +525, 8, 34, 157, 132, 134, 772, 774, "Hg" +525, 8, 35, 158, 135, 136, 775, 776, "(" +525, 8, 36, 159, 137, 139, 777, 779, "28" +525, 8, 37, 160, 140, 141, 780, 781, "." +525, 8, 38, 161, 142, 143, 782, 783, "3" +525, 8, 39, 162, 144, 145, 784, 785, "%" +525, 8, 40, 163, 146, 147, 786, 787, ")" +525, 8, 41, 164, 148, 149, 788, 789, "(" +525, 8, 42, 165, 150, 151, 790, 791, "P" +525, 8, 43, 166, 152, 156, 792, 796, "less" +525, 8, 44, 167, 157, 161, 797, 801, "than" +525, 8, 45, 168, 162, 163, 802, 803, "." +525, 8, 46, 169, 164, 167, 804, 807, "001" +525, 8, 47, 170, 168, 169, 808, 809, ")" +525, 8, 48, 171, 170, 172, 810, 812, "in" +525, 8, 49, 172, 173, 185, 813, 825, "glaucomatous" +525, 8, 50, 173, 186, 190, 826, 830, "eyes" +525, 8, 51, 174, 191, 194, 831, 834, "and" +525, 8, 52, 175, 195, 197, 835, 837, "20" +525, 8, 53, 176, 198, 199, 838, 839, "." +525, 8, 54, 177, 200, 201, 840, 841, "2" +525, 8, 55, 178, 202, 203, 842, 843, "+" +525, 8, 56, 179, 204, 205, 844, 845, "/" +525, 8, 57, 180, 206, 207, 846, 847, "-" +525, 8, 58, 181, 208, 209, 848, 849, "3" +525, 8, 59, 182, 210, 211, 850, 851, "." +525, 8, 60, 183, 212, 213, 852, 853, "6" +525, 8, 61, 184, 214, 216, 854, 856, "mm" +525, 8, 62, 185, 217, 219, 857, 859, "Hg" +525, 8, 63, 186, 220, 222, 860, 862, "to" +525, 8, 64, 187, 223, 225, 863, 865, "14" +525, 8, 65, 188, 226, 227, 866, 867, "." +525, 8, 66, 189, 228, 229, 868, 869, "5" +525, 8, 67, 190, 230, 231, 870, 871, "+" +525, 8, 68, 191, 232, 233, 872, 873, "/" +525, 8, 69, 192, 234, 235, 874, 875, "-" +525, 8, 70, 193, 236, 237, 876, 877, "4" +525, 8, 71, 194, 238, 239, 878, 879, "." +525, 8, 72, 195, 240, 241, 880, 881, "2" +525, 8, 73, 196, 242, 244, 882, 884, "mm" +525, 8, 74, 197, 245, 247, 885, 887, "Hg" +525, 8, 75, 198, 248, 249, 888, 889, "(" +525, 8, 76, 199, 250, 252, 890, 892, "29" +525, 8, 77, 200, 253, 254, 893, 894, "." +525, 8, 78, 201, 255, 256, 895, 896, "6" +525, 8, 79, 202, 257, 258, 897, 898, "%" +525, 8, 80, 203, 259, 260, 899, 900, ")" +525, 8, 81, 204, 261, 262, 901, 902, "(" +525, 8, 82, 205, 263, 264, 903, 904, "P" +525, 8, 83, 206, 265, 269, 905, 909, "less" +525, 8, 84, 207, 270, 274, 910, 914, "than" +525, 8, 85, 208, 275, 276, 915, 916, "." +525, 8, 86, 209, 277, 280, 917, 920, "001" +525, 8, 87, 210, 281, 282, 921, 922, ")" +525, 8, 88, 211, 283, 285, 923, 925, "in" +525, 8, 89, 212, 286, 293, 926, 933, "healthy" +525, 8, 90, 213, 294, 298, 934, 938, "eyes" +525, 8, 91, 214, 299, 300, 939, 940, "." +525, 9, 1, 215, 0, 6, 941, 947, "Ocular" +525, 9, 2, 216, 7, 16, 948, 957, "pulsatile" +525, 9, 3, 217, 17, 21, 958, 962, "flow" +525, 9, 4, 218, 22, 25, 963, 966, "was" +525, 9, 5, 219, 26, 35, 967, 976, "increased" +525, 9, 6, 220, 36, 41, 977, 982, "after" +525, 9, 7, 221, 42, 51, 983, 992, "treatment" +525, 9, 8, 222, 52, 56, 993, 997, "with" +525, 9, 9, 223, 57, 68, 998, 1009, "levobunolol" +525, 9, 10, 224, 69, 73, 1010, 1014, "from" +525, 9, 11, 225, 74, 77, 1015, 1018, "482" +525, 9, 12, 226, 78, 79, 1019, 1020, "." +525, 9, 13, 227, 80, 81, 1021, 1022, "1" +525, 9, 14, 228, 82, 83, 1023, 1024, "+" +525, 9, 15, 229, 84, 85, 1025, 1026, "/" +525, 9, 16, 230, 86, 87, 1027, 1028, "-" +525, 9, 17, 231, 88, 91, 1029, 1032, "133" +525, 9, 18, 232, 92, 93, 1033, 1034, "." +525, 9, 19, 233, 94, 95, 1035, 1036, "3" +525, 9, 20, 234, 96, 106, 1037, 1047, "microliter" +525, 9, 21, 235, 107, 108, 1048, 1049, "/" +525, 9, 22, 236, 109, 115, 1050, 1056, "minute" +525, 9, 23, 237, 116, 118, 1057, 1059, "to" +525, 9, 24, 238, 119, 122, 1060, 1063, "548" +525, 9, 25, 239, 123, 124, 1064, 1065, "." +525, 9, 26, 240, 125, 126, 1066, 1067, "5" +525, 9, 27, 241, 127, 128, 1068, 1069, "+" +525, 9, 28, 242, 129, 130, 1070, 1071, "/" +525, 9, 29, 243, 131, 132, 1072, 1073, "-" +525, 9, 30, 244, 133, 136, 1074, 1077, "180" +525, 9, 31, 245, 137, 138, 1078, 1079, "." +525, 9, 32, 246, 139, 140, 1080, 1081, "3" +525, 9, 33, 247, 141, 151, 1082, 1092, "microliter" +525, 9, 34, 248, 152, 153, 1093, 1094, "/" +525, 9, 35, 249, 154, 160, 1095, 1101, "minute" +525, 9, 36, 250, 161, 162, 1102, 1103, "(" +525, 9, 37, 251, 163, 165, 1104, 1106, "13" +525, 9, 38, 252, 166, 167, 1107, 1108, "." +525, 9, 39, 253, 168, 169, 1109, 1110, "3" +525, 9, 40, 254, 170, 171, 1111, 1112, "%" +525, 9, 41, 255, 172, 173, 1113, 1114, ")" +525, 9, 42, 256, 174, 175, 1115, 1116, "(" +525, 9, 43, 257, 176, 177, 1117, 1118, "P" +525, 9, 44, 258, 178, 182, 1119, 1123, "less" +525, 9, 45, 259, 183, 187, 1124, 1128, "than" +525, 9, 46, 260, 188, 189, 1129, 1130, "." +525, 9, 47, 261, 190, 193, 1131, 1134, "006" +525, 9, 48, 262, 194, 195, 1135, 1136, ")" +525, 9, 49, 263, 196, 198, 1137, 1139, "in" +525, 9, 50, 264, 199, 211, 1140, 1152, "glaucomatous" +525, 9, 51, 265, 212, 216, 1153, 1157, "eyes" +525, 9, 52, 266, 217, 220, 1158, 1161, "and" +525, 9, 53, 267, 221, 224, 1162, 1165, "457" +525, 9, 54, 268, 225, 226, 1166, 1167, "." +525, 9, 55, 269, 227, 228, 1168, 1169, "6" +525, 9, 56, 270, 229, 230, 1170, 1171, "+" +525, 9, 57, 271, 231, 232, 1172, 1173, "/" +525, 9, 58, 272, 233, 234, 1174, 1175, "-" +525, 9, 59, 273, 235, 238, 1176, 1179, "178" +525, 9, 60, 274, 239, 240, 1180, 1181, "." +525, 9, 61, 275, 241, 242, 1182, 1183, "2" +525, 9, 62, 276, 243, 253, 1184, 1194, "microliter" +525, 9, 63, 277, 254, 255, 1195, 1196, "/" +525, 9, 64, 278, 256, 262, 1197, 1203, "minute" +525, 9, 65, 279, 263, 265, 1204, 1206, "to" +525, 9, 66, 280, 266, 269, 1207, 1210, "528" +525, 9, 67, 281, 270, 271, 1211, 1212, "+" +525, 9, 68, 282, 272, 273, 1213, 1214, "/" +525, 9, 69, 283, 274, 275, 1215, 1216, "-" +525, 9, 70, 284, 276, 279, 1217, 1220, "223" +525, 9, 71, 285, 280, 281, 1221, 1222, "." +525, 9, 72, 286, 282, 283, 1223, 1224, "8" +525, 9, 73, 287, 284, 294, 1225, 1235, "microliter" +525, 9, 74, 288, 295, 296, 1236, 1237, "/" +525, 9, 75, 289, 297, 303, 1238, 1244, "minute" +525, 9, 76, 290, 304, 305, 1245, 1246, "(" +525, 9, 77, 291, 306, 308, 1247, 1249, "12" +525, 9, 78, 292, 309, 310, 1250, 1251, "." +525, 9, 79, 293, 311, 312, 1252, 1253, "3" +525, 9, 80, 294, 313, 314, 1254, 1255, "%" +525, 9, 81, 295, 315, 316, 1256, 1257, ")" +525, 9, 82, 296, 317, 318, 1258, 1259, "(" +525, 9, 83, 297, 319, 320, 1260, 1261, "P" +525, 9, 84, 298, 321, 328, 1262, 1269, "greater" +525, 9, 85, 299, 329, 333, 1270, 1274, "than" +525, 9, 86, 300, 334, 335, 1275, 1276, "." +525, 9, 87, 301, 336, 338, 1277, 1279, "05" +525, 9, 88, 302, 339, 340, 1280, 1281, ")" +525, 9, 89, 303, 341, 343, 1282, 1284, "in" +525, 9, 90, 304, 344, 351, 1285, 1292, "healthy" +525, 9, 91, 305, 352, 356, 1293, 1297, "eyes" +525, 9, 92, 306, 357, 358, 1298, 1299, "." +525, 10, 1, 307, 0, 5, 1300, 1305, "There" +525, 10, 2, 308, 6, 9, 1306, 1309, "was" +525, 10, 3, 309, 10, 12, 1310, 1312, "no" +525, 10, 4, 310, 13, 24, 1313, 1324, "significant" +525, 10, 5, 311, 25, 31, 1325, 1331, "change" +525, 10, 6, 312, 32, 34, 1332, 1334, "in" +525, 10, 7, 313, 35, 46, 1335, 1346, "intraocular" +525, 10, 8, 314, 47, 55, 1347, 1355, "pressure" +525, 10, 9, 315, 56, 57, 1356, 1357, "," +525, 10, 10, 316, 58, 64, 1358, 1364, "volume" +525, 10, 11, 317, 65, 74, 1365, 1374, "amplitude" +525, 10, 12, 318, 75, 76, 1375, 1376, "," +525, 10, 13, 319, 77, 79, 1377, 1379, "or" +525, 10, 14, 320, 80, 86, 1380, 1386, "ocular" +525, 10, 15, 321, 87, 96, 1387, 1396, "pulsatile" +525, 10, 16, 322, 97, 101, 1397, 1401, "flow" +525, 10, 17, 323, 102, 104, 1402, 1404, "in" +525, 10, 18, 324, 105, 112, 1405, 1412, "placebo" +525, 10, 19, 325, 113, 114, 1413, 1414, "-" +525, 10, 20, 326, 115, 122, 1415, 1422, "treated" +525, 10, 21, 327, 123, 127, 1423, 1427, "eyes" +525, 10, 22, 328, 128, 129, 1428, 1429, "." +525, 11, 1, 329, 0, 3, 1430, 1433, "The" +525, 11, 2, 330, 4, 15, 1434, 1445, "implication" +525, 11, 3, 331, 16, 18, 1446, 1448, "of" +525, 11, 4, 332, 19, 24, 1449, 1454, "these" +525, 11, 5, 333, 25, 29, 1455, 1459, "data" +525, 11, 6, 334, 30, 33, 1460, 1463, "for" +525, 11, 7, 335, 34, 42, 1464, 1472, "glaucoma" +525, 11, 8, 336, 43, 50, 1473, 1480, "therapy" +525, 11, 9, 337, 51, 53, 1481, 1483, "is" +525, 11, 10, 338, 54, 57, 1484, 1487, "not" +525, 11, 11, 339, 58, 63, 1488, 1493, "clear" +525, 11, 12, 340, 64, 65, 1494, 1495, "." +525, 12, 1, 341, 0, 8, 1496, 1504, "Although" +525, 12, 2, 342, 9, 11, 1505, 1507, "we" +525, 12, 3, 343, 12, 16, 1508, 1512, "used" +525, 12, 4, 344, 17, 19, 1513, 1515, "an" +525, 12, 5, 345, 20, 30, 1516, 1526, "instrument" +525, 12, 6, 346, 31, 35, 1527, 1531, "that" +525, 12, 7, 347, 36, 46, 1532, 1542, "supposedly" +525, 12, 8, 348, 47, 55, 1543, 1551, "measures" +525, 12, 9, 349, 56, 61, 1552, 1557, "total" +525, 12, 10, 350, 62, 71, 1558, 1567, "pulsatile" +525, 12, 11, 351, 72, 76, 1568, 1572, "flow" +525, 12, 12, 352, 77, 78, 1573, 1574, "," +525, 12, 13, 353, 79, 81, 1575, 1577, "it" +525, 12, 14, 354, 82, 85, 1578, 1581, "may" +525, 12, 15, 355, 86, 88, 1582, 1584, "be" +525, 12, 16, 356, 89, 93, 1585, 1589, "that" +525, 12, 17, 357, 94, 99, 1590, 1595, "optic" +525, 12, 18, 358, 100, 105, 1596, 1601, "nerve" +525, 12, 19, 359, 106, 111, 1602, 1607, "blood" +525, 12, 20, 360, 112, 116, 1608, 1612, "flow" +525, 12, 21, 361, 117, 119, 1613, 1615, "is" +525, 12, 22, 362, 120, 129, 1616, 1625, "dependent" +525, 12, 23, 363, 130, 132, 1626, 1628, "on" +525, 12, 24, 364, 133, 138, 1629, 1634, "total" +525, 12, 25, 365, 139, 140, 1635, 1636, "," +525, 12, 26, 366, 141, 145, 1637, 1641, "both" +525, 12, 27, 367, 146, 155, 1642, 1651, "pulsatile" +525, 12, 28, 368, 156, 159, 1652, 1655, "and" +525, 12, 29, 369, 160, 172, 1656, 1668, "nonpulsatile" +525, 12, 30, 370, 173, 174, 1669, 1670, "," +525, 12, 31, 371, 175, 179, 1671, 1675, "flow" +525, 12, 32, 372, 180, 181, 1676, 1677, "." +525, 13, 1, 373, 0, 7, 1678, 1685, "Further" +525, 13, 2, 374, 8, 9, 1686, 1687, "," +525, 13, 3, 375, 10, 14, 1688, 1692, "even" +525, 13, 4, 376, 15, 21, 1693, 1699, "though" +525, 13, 5, 377, 22, 29, 1700, 1707, "retinal" +525, 13, 6, 378, 30, 35, 1708, 1713, "blood" +525, 13, 7, 379, 36, 40, 1714, 1718, "flow" +525, 13, 8, 380, 41, 43, 1719, 1721, "is" +525, 13, 9, 381, 44, 45, 1722, 1723, "a" +525, 13, 10, 382, 46, 51, 1724, 1729, "small" +525, 13, 11, 383, 52, 61, 1730, 1739, "component" +525, 13, 12, 384, 62, 64, 1740, 1742, "of" +525, 13, 13, 385, 65, 70, 1743, 1748, "total" +525, 13, 14, 386, 71, 77, 1749, 1755, "ocular" +525, 13, 15, 387, 78, 83, 1756, 1761, "blood" +525, 13, 16, 388, 84, 88, 1762, 1766, "flow" +525, 13, 17, 389, 89, 90, 1767, 1768, "," +525, 13, 18, 390, 91, 93, 1769, 1771, "it" +525, 13, 19, 391, 94, 97, 1772, 1775, "may" +525, 13, 20, 392, 98, 100, 1776, 1778, "be" +525, 13, 21, 393, 101, 108, 1779, 1786, "equally" +525, 13, 22, 394, 109, 111, 1787, 1789, "or" +525, 13, 23, 395, 112, 116, 1790, 1794, "more" +525, 13, 24, 396, 117, 126, 1795, 1804, "important" +525, 13, 25, 397, 127, 131, 1805, 1809, "than" +525, 13, 26, 398, 132, 141, 1810, 1819, "choroidal" +525, 13, 27, 399, 142, 146, 1820, 1824, "flow" +525, 13, 28, 400, 147, 154, 1825, 1832, "because" +525, 13, 29, 401, 155, 157, 1833, 1835, "of" +525, 13, 30, 402, 158, 161, 1836, 1839, "the" +525, 13, 31, 403, 162, 171, 1840, 1849, "necessity" +525, 13, 32, 404, 172, 174, 1850, 1852, "to" +525, 13, 33, 405, 175, 183, 1853, 1861, "maintain" +525, 13, 34, 406, 184, 187, 1862, 1865, "the" +525, 13, 35, 407, 188, 197, 1866, 1875, "perfusion" +525, 13, 36, 408, 198, 200, 1876, 1878, "of" +525, 13, 37, 409, 201, 204, 1879, 1882, "the" +525, 13, 38, 410, 205, 212, 1883, 1890, "retinal" +525, 13, 39, 411, 213, 221, 1891, 1899, "ganglion" +525, 13, 40, 412, 222, 227, 1900, 1905, "cells" +525, 13, 41, 413, 228, 229, 1906, 1907, "." +525, 14, 1, 414, 0, 3, 1908, 1911, "DOI" +525, 14, 2, 415, 4, 5, 1912, 1913, ":" +525, 14, 3, 416, 6, 8, 1914, 1916, "10" +525, 14, 4, 417, 9, 10, 1917, 1918, "." +525, 14, 5, 418, 11, 15, 1919, 1923, "1016" +525, 14, 6, 419, 16, 17, 1924, 1925, "/" +525, 14, 7, 420, 18, 23, 1926, 1931, "s0002" +525, 14, 8, 421, 24, 25, 1932, 1933, "-" +525, 14, 9, 422, 26, 30, 1934, 1938, "9394" +525, 14, 10, 423, 31, 32, 1939, 1940, "(" +525, 14, 11, 424, 33, 35, 1941, 1943, "14" +525, 14, 12, 425, 36, 37, 1944, 1945, ")" +525, 14, 13, 426, 38, 43, 1946, 1951, "71791" +525, 14, 14, 427, 44, 45, 1952, 1953, "-" +525, 14, 15, 428, 46, 47, 1954, 1955, "x" +525, 14, 16, 429, 48, 52, 1956, 1960, "PMID" +525, 14, 17, 430, 53, 54, 1961, 1962, ":" +525, 14, 18, 431, 55, 62, 1963, 1970, "1524115" +525, 14, 19, 432, 63, 64, 1971, 1972, "[" +525, 14, 20, 433, 65, 72, 1973, 1980, "Indexed" +525, 14, 21, 434, 73, 76, 1981, 1984, "for" +525, 14, 22, 435, 77, 84, 1985, 1992, "MEDLINE" +525, 14, 23, 436, 85, 86, 1993, 1994, "]" diff --git a/data/gl 1524115_jshahinitiran.annodb b/data/gl 1524115_jshahinitiran.annodb new file mode 100644 index 0000000..d63cc9d --- /dev/null +++ b/data/gl 1524115_jshahinitiran.annodb @@ -0,0 +1,71 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84655, Journal, 0, 15, "Am J Ophthalmol", "", +84656, PublicationYear, 18, 22, "1992", "", +84657, Title, 54, 116, "Short - term effects of levobunolol on ocular pulsatile flow .", "", +84661, Levobunolol, 78, 89, "levobunolol", "", +84662, OcularBloodFlow, 93, 114, "ocular pulsatile flow", "", +84658, Author, 117, 125, "Bosem ME", "", +84659, Author, 134, 141, "Lusky M", "", +84660, Author, 144, 154, "Weinreb RN", "", +84663, Randomized, 258, 268, "randomized", "", +84664, DoubleBlind, 271, 286, "double - masked", "", +84665, Placebo, 289, 296, "placebo", "", +84666, CTDesign, 289, 309, "placebo - controlled", "", +84667, Levobunolol, 345, 356, "levobunolol", "", +84668, DoseValue, 357, 362, "0 . 5", "", +84669, IOP, 402, 422, "intraocular pressure", "", +84670, EndPointDescription, 425, 441, "volume amplitude", "", +84671, OcularBloodFlow, 448, 469, "ocular pulsatile flow", "", +84672, Glaucoma, 511, 519, "glaucoma", "", +84673, EndPointDescription, 522, 538, "Volume amplitude", "", +84674, OcularBloodFlow, 543, 564, "ocular pulsatile flow", "", +84675, MeasurementDevice, 622, 637, "pneumatonometer", "", +84676, Levobunolol, 672, 683, "levobunolol", "", +84677, IOP, 686, 706, "intraocular pressure", "", +84678, BaseLineValue, 722, 728, "26 . 0", "", +84680, SdErrorBL, 735, 740, "5 . 1", "", +84681, mmHg, 741, 746, "mm Hg", "", +84679, ResultMeasuredValue, 750, 756, "17 . 8", "", +84683, SdErrorResValue, 763, 768, "3 . 9", "", +84682, mmHg, 769, 774, "mm Hg", "", +84684, RelativeReduction, 777, 783, "28 . 3", "", +84685, PValueResValue, 790, 807, "P less than . 001", "", +84686, BaseLineValue, 835, 841, "20 . 2", "", +84688, SdErrorBL, 848, 853, "3 . 6", "", +84690, mmHg, 854, 859, "mm Hg", "", +84687, ResultMeasuredValue, 863, 869, "14 . 5", "", +84689, SdErrorResValue, 876, 881, "4 . 2", "", +84691, mmHg, 882, 887, "mm Hg", "", +84692, RelativeReduction, 890, 896, "29 . 6", "", +84693, PValueResValue, 903, 920, "P less than . 001", "", +84694, OcularBloodFlow, 941, 962, "Ocular pulsatile flow", "", +84695, Levobunolol, 998, 1009, "levobunolol", "", +84696, BaseLineValue, 1015, 1022, "482 . 1", "", +84697, SdErrorBL, 1029, 1036, "133 . 3", "", +84698, BioAndMedicalUnit, 1037, 1056, "microliter / minute", "", +84699, ResultMeasuredValue, 1060, 1067, "548 . 5", "", +84700, SdErrorResValue, 1074, 1081, "180 . 3", "", +84701, BioAndMedicalUnit, 1082, 1101, "microliter / minute", "", +84702, RelativeIncrement, 1104, 1110, "13 . 3", "", +84703, PValueResValue, 1117, 1134, "P less than . 006", "", +84704, BaseLineValue, 1162, 1169, "457 . 6", "", +84705, SdErrorBL, 1176, 1183, "178 . 2", "", +84706, BioAndMedicalUnit, 1184, 1203, "microliter / minute", "", +84708, ResultMeasuredValue, 1207, 1210, "528", "", +84709, SdErrorResValue, 1217, 1224, "223 . 8", "", +84707, BioAndMedicalUnit, 1225, 1244, "microliter / minute", "", +84710, RelativeIncrement, 1247, 1253, "12 . 3", "", +84711, PValueResValue, 1260, 1279, "P greater than . 05", "", +84717, ObservedResult, 1300, 1429, "There was no significant change in intraocular pressure , volume amplitude , or ocular pulsatile flow in placebo - treated eyes .", "", +84712, IOP, 1335, 1355, "intraocular pressure", "", +84713, EndPointDescription, 1358, 1374, "volume amplitude", "", +84715, OcularBloodFlow, 1380, 1401, "ocular pulsatile flow", "", +84716, Placebo, 1405, 1412, "placebo", "", +84722, ConclusionComment, 1430, 1495, "The implication of these data for glaucoma therapy is not clear .", "", +84718, Glaucoma, 1464, 1472, "glaucoma", "", +84723, ConclusionComment, 1496, 1677, "Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow .", "", +84719, OcularBloodFlow, 1558, 1572, "pulsatile flow", "", +84720, OcularBloodFlow, 1671, 1675, "flow", "", +84724, ConclusionComment, 1678, 1905, "Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells", "", +84721, OcularBloodFlow, 1749, 1766, "ocular blood flow", "", +84725, PMID, 1963, 1970, "1524115", "", diff --git a/data/gl 1524115_jshahinitiran.n-triples b/data/gl 1524115_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 1524115_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1524115_tstrakeljahn.annodb b/data/gl 1524115_tstrakeljahn.annodb new file mode 100644 index 0000000..4fc5e7b --- /dev/null +++ b/data/gl 1524115_tstrakeljahn.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +91250, Journal, 0, 15, "Am J Ophthalmol", "", +91251, PublicationYear, 18, 22, "1992", "", +91253, Title, 54, 116, "Short - term effects of levobunolol on ocular pulsatile flow .", "", +91252, Levobunolol, 78, 89, "levobunolol", "", +91254, Author, 117, 125, "Bosem ME", "", +91255, Author, 134, 141, "Lusky M", "", +91256, Author, 144, 154, "Weinreb RN", "", +91267, ObjectiveDescription, 253, 505, "In a randomized , double - masked , placebo - controlled study , we evaluated the effect of levobunolol 0 . 5 % , a nonselective beta - blocker , on intraocular pressure , volume amplitude , and ocular pulsatile flow in healthy individuals and patients", "", +91257, Randomized, 258, 268, "randomized", "", +91258, DoubleBlind, 271, 286, "double - masked", "", +91259, Placebo, 289, 296, "placebo", "", +91260, Levobunolol, 345, 356, "levobunolol", "", +91265, DoseValue, 357, 362, "0 . 5", "", +91266, Percentage, 363, 364, "%", "", +91261, IOP, 402, 422, "intraocular pressure", "", +91264, Endpoint, 425, 441, "volume amplitude", "", +91309, OcularBloodFlow, 448, 469, "ocular pulsatile flow", "", +91263, Precondition, 473, 510, "healthy individuals and patients with", "", +91268, ObjectiveDescription, 506, 521, "with glaucoma .", "", +91262, Glaucoma, 511, 519, "glaucoma", "", +91312, Endpoint, 522, 538, "Volume amplitude", "", +91311, OcularBloodFlow, 543, 564, "ocular pulsatile flow", "", +91269, Levobunolol, 672, 683, "levobunolol", "", +91270, IOP, 686, 706, "intraocular pressure", "", +91271, BaseLineValue, 722, 728, "26 . 0", "", +91272, SdDevBL, 735, 740, "5 . 1", "", +91275, mmHg, 741, 746, "mm Hg", "", +91273, ResultMeasuredValue, 750, 756, "17 . 8", "", +91277, SdDevResValue, 763, 768, "3 . 9", "", +91276, mmHg, 769, 774, "mm Hg", "", +91283, RelativeReduction, 777, 783, "28 . 3", "", +91286, PValueResValue, 792, 807, "less than . 001", "", +91279, BaseLineValue, 835, 841, "20 . 2", "", +91280, SdDevBL, 848, 853, "3 . 6", "", +91281, mmHg, 854, 859, "mm Hg", "", +91274, ResultMeasuredValue, 863, 869, "14 . 5", "", +91278, SdDevResValue, 876, 881, "4 . 2", "", +91282, mmHg, 882, 887, "mm Hg", "", +91284, RelativeReduction, 890, 896, "29 . 6", "", +91285, PValueResValue, 905, 920, "less than . 001", "", +91310, OcularBloodFlow, 941, 962, "Ocular pulsatile flow", "", +91287, Levobunolol, 998, 1009, "levobunolol", "", +91290, BaseLineValue, 1015, 1022, "482 . 1", "", +91291, SdDevBL, 1029, 1036, "133 . 3", "", +91304, BioAndMedicalUnit, 1037, 1056, "microliter / minute", "", +91292, ResultMeasuredValue, 1060, 1067, "548 . 5", "", +91293, SdDevResValue, 1074, 1081, "180 . 3", "", +91303, BioAndMedicalUnit, 1082, 1101, "microliter / minute", "", +91294, RelativeIncrement, 1104, 1110, "13 . 3", "", +91295, PValueResValue, 1119, 1134, "less than . 006", "", +91296, BaseLineValue, 1162, 1169, "457 . 6", "", +91297, SdDevBL, 1176, 1183, "178 . 2", "", +91305, BioAndMedicalUnit, 1184, 1203, "microliter / minute", "", +91298, ResultMeasuredValue, 1207, 1210, "528", "", +91299, SdDevResValue, 1217, 1224, "223 . 8", "", +91302, BioAndMedicalUnit, 1225, 1244, "microliter / minute", "", +91300, RelativeReduction, 1247, 1253, "12 . 3", "", +91301, PValueResValue, 1262, 1279, "greater than . 05", "", +91314, ObservedResult, 1300, 1429, "There was no significant change in intraocular pressure , volume amplitude , or ocular pulsatile flow in placebo - treated eyes .", "", +91306, IOP, 1335, 1355, "intraocular pressure", "", +91307, Endpoint, 1358, 1374, "volume amplitude", "", +91308, OcularBloodFlow, 1380, 1401, "ocular pulsatile flow", "", +91313, Placebo, 1405, 1412, "placebo", "", +91316, ConclusionComment, 1430, 1495, "The implication of these data for glaucoma therapy is not clear .", "", +91315, Glaucoma, 1464, 1472, "glaucoma", "", +91318, ConclusionComment, 1496, 1677, "Although we used an instrument that supposedly measures total pulsatile flow , it may be that optic nerve blood flow is dependent on total , both pulsatile and nonpulsatile , flow .", "", +91317, OcularBloodFlow, 1590, 1612, "optic nerve blood flow", "", +91321, ConclusionComment, 1678, 1907, "Further , even though retinal blood flow is a small component of total ocular blood flow , it may be equally or more important than choroidal flow because of the necessity to maintain the perfusion of the retinal ganglion cells .", "", +91319, OcularBloodFlow, 1700, 1718, "retinal blood flow", "", +91320, OcularBloodFlow, 1749, 1766, "ocular blood flow", "", +91322, PMID, 1963, 1970, "1524115", "", diff --git a/data/gl 1524115_tstrakeljahn.n-triples b/data/gl 1524115_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 1524115_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15598478_admin.annodb b/data/gl 15598478_admin.annodb new file mode 100644 index 0000000..d7e8f07 --- /dev/null +++ b/data/gl 15598478_admin.annodb @@ -0,0 +1,129 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 9, "Clin Ther", "", " \"Clin Ther\"." +1, PublicationYear, 12, 16, "2004", "", " \"2004\"." +2, Title, 47, 237, "Switching from latanoprost to fixed - combination latanoprost - timolol : a 21 - day , randomized , double - masked , active - control study in patients with glaucoma and ocular hypertension", "", " \"Switching from latanoprost to fixed - combination latanoprost - timolol : a 21 - day , randomized , double - masked , active - control study in patients with glaucoma and ocular hypertension\"." +3, Latanoprost, 62, 73, "latanoprost", "", +4, Latanoprost, 97, 108, "latanoprost", "", +38492, Lat/TimFC, 97, 118, "latanoprost - timolol", "", +5, Timolol, 111, 118, "timolol", "", +71, Duration, 123, 131, "21 - day", "", " \"21 - day\"." +72, Randomized, 134, 144, "randomized", "", " ." +73, DoubleBlind, 147, 162, "double - masked", "", " ." +34525, Precondition, 191, 237, "patients with glaucoma and ocular hypertension", "", " \"patients with glaucoma and ocular hypertension\"." +6, Glaucoma, 205, 213, "glaucoma", "", " . ." +7, OcularHypertension, 218, 237, "ocular hypertension", "", " ." +8, Author, 240, 249, "Olander K", "", " \"Olander K\"." +9, Author, 258, 270, "Zimmerman TJ", "", " \"Zimmerman TJ\"." +10, Author, 273, 281, "Downes N", "", " \"Downes N\"." +11, Author, 284, 298, "Schoenfelder J", "", " \"Schoenfelder J\"." +136, Latanoprost, 311, 322, "Latanoprost", "", +12, USA, 432, 435, "USA", "", " ." +75, Glaucoma, 509, 517, "glaucoma", "", +13, IOP, 566, 586, "intraocular pressure", "", +14, IOP, 589, 592, "IOP", "", +140, Frequency, 692, 704, "once - daily", "", +15, ObjectiveDescription, 763, 911, "The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 % QD", "", " \"The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 % QD\"." +17, Latanoprost, 861, 872, "latanoprost", "", +38491, Lat/TimFC, 861, 908, "latanoprost 0 . 005 % + timolol maleate 0 . 5 %", "", " ." +18, DoseValue, 873, 880, "0 . 005", "", +19, Percentage, 881, 882, "%", "", +20, Timolol, 885, 900, "timolol maleate", "", +21, DoseValue, 901, 906, "0 . 5", "", +22, Percentage, 907, 908, "%", "", +76, Frequency, 909, 911, "QD", "", " \"QD\"." +16, ObjectiveDescription, 912, 1058, "with those of latanoprost 0 . 005 % monotherapy QD in patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .", "", " \"with those of latanoprost 0 . 005 % monotherapy QD in patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .\"." +77, Latanoprost, 926, 937, "latanoprost", "", " . ." +78, DoseValue, 938, 945, "0 . 005", "", " \"0 . 005\"." +79, Percentage, 946, 947, "%", "", " ." +80, Frequency, 960, 962, "QD", "", " \"QD\"." +81, Precondition, 966, 1058, "patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .", "", " \"patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .\"." +82, IOP, 990, 993, "IOP", "", +83, mmHg, 1006, 1011, "mm Hg", "", +84, Latanoprost, 1045, 1056, "latanoprost", "", +85, Duration, 1074, 1082, "21 - day", "", +86, Randomized, 1085, 1095, "randomized", "", +87, DoubleBlind, 1098, 1113, "double - masked", "", +88, CTDesign, 1116, 1132, "active - control", "", " . ." +89, Multicenter, 1156, 1170, "49 study sites", "", " ." +23, Argentina, 1174, 1183, "Argentina", "", " ." +24, Brazil, 1186, 1192, "Brazil", "", " ." +25, Colombia, 1195, 1203, "Colombia", "", " ." +26, Mexico, 1206, 1212, "Mexico", "", " ." +27, Peru, 1215, 1219, "Peru", "", " ." +28, USA, 1226, 1239, "United States", "", +29, Venezuela, 1246, 1255, "Venezuela", "", +34526, Precondition, 1258, 1395, "Adults with glaucoma or ocular hypertension who had failed to reach an IOP of < 21 mm Hg while receiving latanoprost for at least 28 days", "", " \"Adults with glaucoma or ocular hypertension who had failed to reach an IOP of < 21 mm Hg while receiving latanoprost for at least 28 days\"." +31, Glaucoma, 1270, 1278, "glaucoma", "", +32, OcularHypertension, 1282, 1301, "ocular hypertension", "", +34, IOP, 1329, 1332, "IOP", "", +35, mmHg, 1341, 1346, "mm Hg", "", +90, Latanoprost, 1363, 1374, "latanoprost", "", +34527, Duration, 1388, 1395, "28 days", "", +34528, Duration, 1432, 1439, "28 days", "", +91, Latanoprost, 1443, 1454, "latanoprost", "", +92, Randomized, 1480, 1488, "randomly", "", +93, Latanoprost, 1510, 1521, "latanoprost", "", +36, Duration, 1576, 1583, "21 days", "", +37, IntentionToTreat, 1590, 1609, "intent - to - treat", "", " ." +38, IntentionToTreat, 1612, 1615, "ITT", "", +94, DoubleBlind, 1683, 1698, "double - masked", "", +39, PerProtocol, 1722, 1736, "per - protocol", "", " ." +40, PerProtocol, 1739, 1741, "PP", "", +41, IOP, 1842, 1845, "IOP", "", +96, TimePoint, 1867, 1875, "baseline", "", +95, TimePoint, 1883, 1889, "day 21", "", +42, EndPointDescription, 1922, 2017, "proportion of patients whose IOP was decreased > or = 2 mm Hg from the baseline level on day 21", "", " . ." +98, IOP, 1951, 1954, "IOP", "", +97, mmHg, 1978, 1983, "mm Hg", "", +99, TimePoint, 2011, 2017, "day 21", "", +100, IOP, 2058, 2061, "IOP", "", +34530, EndPointDescription, 2058, 2111, "IOP decreases > or = 3 , > or = 4 , or > or = 5 mm Hg", "", +101, mmHg, 2106, 2111, "mm Hg", "", +102, IOP, 2164, 2167, "10P", "", +34531, EndPointDescription, 2164, 2183, "10P < or = 18 mm Hg", "", +103, mmHg, 2178, 2183, "mm Hg", "", +43, NumberPatientsCT, 2266, 2269, "350", "", " \"350\"." +70, FinalNumPatientsCT, 2304, 2307, "348", "", " \"348\"." +69, IntentionToTreat, 2338, 2341, "ITT", "", +44, NumberPatientsArm, 2394, 2397, "175", "", " \"175\"." +104, Latanoprost, 2400, 2411, "latanoprost", "", +45, NumberPatientsArm, 2418, 2421, "173", "", " \"173\"." +185, Mean, 2424, 2428, "mean", "", +46, AvgAge, 2442, 2448, "64 . 4", "", +47, AvgAge, 2464, 2470, "63 . 2", "", +42, EndPointDescription, 2681, 2715, "IOP decreases of 2 mm Hg on day 21", "", " . ." +50, IOP, 2681, 2684, "IOP", "", +51, mmHg, 2700, 2705, "mm Hg", "", " ." +52, TimePoint, 2709, 2715, "day 21", "", " \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\"." +194, Latanoprost, 2751, 2762, "latanoprost", "", +53, PercentageAffected, 2784, 2790, "79 . 4", "", " \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\". \"day 21\"." +54, PercentageAffected, 2796, 2802, "51 . 4", "", " \"51 . 4\"." +55, PvalueDiff, 2822, 2833, "P < 0 . 001", "", " \"P < 0 . 001\"." +39, PerProtocol, 2838, 2840, "PP", "", " ." +57, ObservedResult, 2861, 2965, "more patients in the fixed - combination group had IOP decreases > or = 3 , > or = 4 , or > or = 5 mm Hg", "", +56, IOP, 2912, 2915, "IOP", "", +34529, EndPointDescription, 2912, 2965, "IOP decreases > or = 3 , > or = 4 , or > or = 5 mm Hg", "", " . ." +61, mmHg, 2960, 2965, "mm Hg", "", " ." +200, PvalueDiff, 2992, 3003, "P < 0 . 001", "", " \"P < 0 . 001\"." +105, Latanoprost, 3007, 3018, "latanoprost", "", +58, EndPointDescription, 3030, 3048, "final IOP 18 mm Hg", "", " . ." +59, IOP, 3036, 3039, "IOP", "", +60, mmHg, 3043, 3048, "mm Hg", "", " ." +62, PercentageAffected, 3073, 3079, "35 . 1", "", " \"35 . 1\"." +106, Latanoprost, 3084, 3095, "latanoprost", "", +63, PercentageAffected, 3098, 3104, "17 . 8", "", " \"17 . 8\"." +64, PvalueDiff, 3109, 3120, "P < 0 . 001", "", " \"P < 0 . 001\"." +208, ObservedResult, 3125, 3162, "Both treatments were well tolerated .", "", +65, ObservedResult, 3163, 3331, "Similar proportions of patients in the fixed - combination and latanoprost groups reported at least 1 treatment - emergent AE ( 10 . 9 % and 12 . 1 % , respectively ) .", "", +115, Latanoprost, 3226, 3237, "latanoprost", "", +34535, EndPointDescription, 3277, 3288, "emergent AE", "AdverseEffect", " . ." +66, PercentageAffected, 3291, 3297, "10 . 9", "", " \"10 . 9\"." +67, PercentageAffected, 3304, 3310, "12 . 1", "", " \"12 . 1\"." +116, ConclusionComment, 3345, 3593, "In this selected population of patients with an inadequate initial IOP response to latanoprost , switching to fixed - combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost", "", " \"In this selected population of patients with an inadequate initial IOP response to latanoprost , switching to fixed - combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost\"." +118, IOP, 3412, 3415, "IOP", "", +119, Latanoprost, 3428, 3439, "latanoprost", "", +38493, Lat/TimFC, 3475, 3493, "latanoprosttimolol", "", +120, IOP, 3528, 3531, "IOP", "", +121, Latanoprost, 3582, 3593, "latanoprost", "", +117, ConclusionComment, 3594, 3603, "therapy .", "", " \"therapy .\"." +68, PMID, 3661, 3669, "15598478", "", " \"15598478\"." diff --git a/data/gl 15598478_admin.n-triples b/data/gl 15598478_admin.n-triples new file mode 100644 index 0000000..641f789 --- /dev/null +++ b/data/gl 15598478_admin.n-triples @@ -0,0 +1,180 @@ +# RDF export of group: Publication + . + "Publication" . + "Switching from latanoprost to fixed - combination latanoprost - timolol : a 21 - day , randomized , double - masked , active - control study in patients with glaucoma and ocular hypertension" . + "Olander K" . + "2004" . + "Clin Ther" . + "15598478" . + . + "Zimmerman TJ" . + "Downes N" . + "Schoenfelder J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 % QD" . + "350" . + "21 - day" . + . + . + . + "In this selected population of patients with an inadequate initial IOP response to latanoprost , switching to fixed - combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost" . + . + . + . + . + . + . + "348" . + "with those of latanoprost 0 . 005 % monotherapy QD in patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost ." . + . + . + . + . + . + "therapy ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with glaucoma and ocular hypertension" . + . + . + . + "patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost ." . + "Adults with glaucoma or ocular hypertension who had failed to reach an IOP of < 21 mm Hg while receiving latanoprost for at least 28 days" . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_2mmhg" . + . + . + . + . + . + . + "Endpoint_3mmhg" . + . + . + . + . + . + . + "Endpoint_18mmhg" . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat-tim" . + "175" . + . + . + . + . + . + . + "Arm-lat" . + "173" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat-tim" . + . + "QD" . + . + . + "Intervention-lat" . + . + "QD" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_lat-tim" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_2mmhg_lat" . + . + "51 . 4" . + "day 21" . + . + "Outcome_2mmhg_lat-tim" . + . + "79 . 4" . + "day 21" . + . + "Outcome_3mmhg_lat" . + . + "day 21" . + . + "Outcome_3mmhg_lat-tim" . + . + "day 21" . + . + "Outcome_18mmhg_lat" . + . + "17 . 8" . + "day 21" . + . + "Outcome_18mmhg_lat-tim" . + . + "35 . 1" . + "day 21" . + . + "AE_lat" . + . + "12 . 1" . + "day 21" . + . + "AE_lat-tim" . + . + "10 . 9" . + "day 21" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_2mmhg" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_3mmhg" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_18mmhg" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15598478_export.csv b/data/gl 15598478_export.csv new file mode 100644 index 0000000..e0a79f0 --- /dev/null +++ b/data/gl 15598478_export.csv @@ -0,0 +1,748 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +461, 1, 1, 1, 0, 4, 0, 4, "Clin" +461, 1, 2, 2, 5, 9, 5, 9, "Ther" +461, 1, 3, 3, 10, 11, 10, 11, "." +461, 2, 1, 4, 0, 4, 12, 16, "2004" +461, 2, 2, 5, 5, 8, 17, 20, "Oct" +461, 2, 3, 6, 9, 10, 21, 22, ";" +461, 2, 4, 7, 11, 13, 23, 25, "26" +461, 2, 5, 8, 14, 15, 26, 27, "(" +461, 2, 6, 9, 16, 18, 28, 30, "10" +461, 2, 7, 10, 19, 20, 31, 32, ")" +461, 2, 8, 11, 21, 22, 33, 34, ":" +461, 2, 9, 12, 23, 27, 35, 39, "1619" +461, 2, 10, 13, 28, 29, 40, 41, "-" +461, 2, 11, 14, 30, 32, 42, 44, "29" +461, 2, 12, 15, 33, 34, 45, 46, "." +461, 3, 1, 16, 0, 9, 47, 56, "Switching" +461, 3, 2, 17, 10, 14, 57, 61, "from" +461, 3, 3, 18, 15, 26, 62, 73, "latanoprost" +461, 3, 4, 19, 27, 29, 74, 76, "to" +461, 3, 5, 20, 30, 35, 77, 82, "fixed" +461, 3, 6, 21, 36, 37, 83, 84, "-" +461, 3, 7, 22, 38, 49, 85, 96, "combination" +461, 3, 8, 23, 50, 61, 97, 108, "latanoprost" +461, 3, 9, 24, 62, 63, 109, 110, "-" +461, 3, 10, 25, 64, 71, 111, 118, "timolol" +461, 3, 11, 26, 72, 73, 119, 120, ":" +461, 3, 12, 27, 74, 75, 121, 122, "a" +461, 3, 13, 28, 76, 78, 123, 125, "21" +461, 3, 14, 29, 79, 80, 126, 127, "-" +461, 3, 15, 30, 81, 84, 128, 131, "day" +461, 3, 16, 31, 85, 86, 132, 133, "," +461, 3, 17, 32, 87, 97, 134, 144, "randomized" +461, 3, 18, 33, 98, 99, 145, 146, "," +461, 3, 19, 34, 100, 106, 147, 153, "double" +461, 3, 20, 35, 107, 108, 154, 155, "-" +461, 3, 21, 36, 109, 115, 156, 162, "masked" +461, 3, 22, 37, 116, 117, 163, 164, "," +461, 3, 23, 38, 118, 124, 165, 171, "active" +461, 3, 24, 39, 125, 126, 172, 173, "-" +461, 3, 25, 40, 127, 134, 174, 181, "control" +461, 3, 26, 41, 135, 140, 182, 187, "study" +461, 3, 27, 42, 141, 143, 188, 190, "in" +461, 3, 28, 43, 144, 152, 191, 199, "patients" +461, 3, 29, 44, 153, 157, 200, 204, "with" +461, 3, 30, 45, 158, 166, 205, 213, "glaucoma" +461, 3, 31, 46, 167, 170, 214, 217, "and" +461, 3, 32, 47, 171, 177, 218, 224, "ocular" +461, 3, 33, 48, 178, 190, 225, 237, "hypertension" +461, 3, 34, 49, 191, 192, 238, 239, "." +461, 4, 1, 50, 0, 7, 240, 247, "Olander" +461, 4, 2, 51, 8, 9, 248, 249, "K" +461, 4, 3, 52, 10, 11, 250, 251, "(" +461, 4, 4, 53, 12, 13, 252, 253, "1" +461, 4, 5, 54, 14, 15, 254, 255, ")" +461, 4, 6, 55, 16, 17, 256, 257, "," +461, 4, 7, 56, 18, 27, 258, 267, "Zimmerman" +461, 4, 8, 57, 28, 30, 268, 270, "TJ" +461, 4, 9, 58, 31, 32, 271, 272, "," +461, 4, 10, 59, 33, 39, 273, 279, "Downes" +461, 4, 11, 60, 40, 41, 280, 281, "N" +461, 4, 12, 61, 42, 43, 282, 283, "," +461, 4, 13, 62, 44, 56, 284, 296, "Schoenfelder" +461, 4, 14, 63, 57, 58, 297, 298, "J" +461, 4, 15, 64, 59, 60, 299, 300, ";" +461, 4, 16, 65, 61, 68, 301, 308, "Xalacom" +461, 4, 17, 66, 69, 70, 309, 310, "/" +461, 4, 18, 67, 71, 82, 311, 322, "Latanoprost" +461, 4, 19, 68, 83, 88, 323, 328, "Study" +461, 4, 20, 69, 89, 94, 329, 334, "Group" +461, 4, 21, 70, 95, 96, 335, 336, "." +461, 5, 1, 71, 0, 6, 337, 343, "Author" +461, 5, 2, 72, 7, 18, 344, 355, "information" +461, 5, 3, 73, 19, 20, 356, 357, ":" +461, 5, 4, 74, 21, 22, 358, 359, "(" +461, 5, 5, 75, 23, 24, 360, 361, "1" +461, 5, 6, 76, 25, 26, 362, 363, ")" +461, 5, 7, 77, 27, 36, 364, 373, "Maryville" +461, 5, 8, 78, 37, 40, 374, 377, "Eye" +461, 5, 9, 79, 41, 47, 378, 384, "Center" +461, 5, 10, 80, 48, 49, 385, 386, "," +461, 5, 11, 81, 50, 53, 387, 390, "622" +461, 5, 12, 82, 54, 63, 391, 400, "Smithview" +461, 5, 13, 83, 64, 69, 401, 406, "Drive" +461, 5, 14, 84, 70, 71, 407, 408, "," +461, 5, 15, 85, 72, 81, 409, 418, "Maryville" +461, 5, 16, 86, 82, 83, 419, 420, "," +461, 5, 17, 87, 84, 86, 421, 423, "TN" +461, 5, 18, 88, 87, 92, 424, 429, "37803" +461, 5, 19, 89, 93, 94, 430, 431, "," +461, 5, 20, 90, 95, 98, 432, 435, "USA" +461, 5, 21, 91, 99, 100, 436, 437, "." +461, 6, 1, 92, 0, 9, 438, 447, "kwolaser7" +461, 6, 2, 93, 10, 11, 448, 449, "@" +461, 6, 3, 94, 12, 15, 450, 453, "aol" +461, 6, 4, 95, 16, 17, 454, 455, "." +461, 6, 5, 96, 18, 21, 456, 459, "com" +461, 6, 6, 97, 22, 32, 460, 470, "BACKGROUND" +461, 6, 7, 98, 33, 34, 471, 472, ":" +461, 6, 8, 99, 35, 48, 473, 486, "Approximately" +461, 6, 9, 100, 49, 51, 487, 489, "40" +461, 6, 10, 101, 52, 53, 490, 491, "%" +461, 6, 11, 102, 54, 56, 492, 494, "of" +461, 6, 12, 103, 57, 65, 495, 503, "patients" +461, 6, 13, 104, 66, 70, 504, 508, "with" +461, 6, 14, 105, 71, 79, 509, 517, "glaucoma" +461, 6, 15, 106, 80, 83, 518, 521, "are" +461, 6, 16, 107, 84, 97, 522, 535, "concomitantly" +461, 6, 17, 108, 98, 108, 536, 546, "prescribed" +461, 6, 18, 109, 109, 110, 547, 548, ">" +461, 6, 19, 110, 111, 113, 549, 551, "or" +461, 6, 20, 111, 114, 115, 552, 553, "=" +461, 6, 21, 112, 116, 117, 554, 555, "2" +461, 6, 22, 113, 118, 127, 556, 565, "different" +461, 6, 23, 114, 128, 139, 566, 577, "intraocular" +461, 6, 24, 115, 140, 148, 578, 586, "pressure" +461, 6, 25, 116, 149, 150, 587, 588, "(" +461, 6, 26, 117, 151, 154, 589, 592, "IOP" +461, 6, 27, 118, 155, 156, 593, 594, ")" +461, 6, 28, 119, 157, 158, 595, 596, "-" +461, 6, 29, 120, 159, 167, 597, 605, "lowering" +461, 6, 30, 121, 168, 179, 606, 617, "medications" +461, 6, 31, 122, 180, 181, 618, 619, "." +461, 7, 1, 123, 0, 2, 620, 622, "An" +461, 7, 2, 124, 3, 12, 623, 632, "effective" +461, 7, 3, 125, 13, 16, 633, 636, "and" +461, 7, 4, 126, 17, 21, 637, 641, "well" +461, 7, 5, 127, 22, 23, 642, 643, "-" +461, 7, 6, 128, 24, 33, 644, 653, "tolerated" +461, 7, 7, 129, 34, 39, 654, 659, "fixed" +461, 7, 8, 130, 40, 51, 660, 671, "combination" +461, 7, 9, 131, 52, 54, 672, 674, "of" +461, 7, 10, 132, 55, 61, 675, 681, "agents" +461, 7, 11, 133, 62, 71, 682, 691, "requiring" +461, 7, 12, 134, 72, 76, 692, 696, "once" +461, 7, 13, 135, 77, 78, 697, 698, "-" +461, 7, 14, 136, 79, 84, 699, 704, "daily" +461, 7, 15, 137, 85, 97, 705, 717, "instillation" +461, 7, 16, 138, 98, 101, 718, 721, "may" +461, 7, 17, 139, 102, 109, 722, 729, "improve" +461, 7, 18, 140, 110, 117, 730, 737, "patient" +461, 7, 19, 141, 118, 128, 738, 748, "compliance" +461, 7, 20, 142, 129, 130, 749, 750, "." +461, 8, 1, 143, 0, 9, 751, 760, "OBJECTIVE" +461, 8, 2, 144, 10, 11, 761, 762, ":" +461, 8, 3, 145, 12, 15, 763, 766, "The" +461, 8, 4, 146, 16, 23, 767, 774, "purpose" +461, 8, 5, 147, 24, 26, 775, 777, "of" +461, 8, 6, 148, 27, 31, 778, 782, "this" +461, 8, 7, 149, 32, 37, 783, 788, "study" +461, 8, 8, 150, 38, 41, 789, 792, "was" +461, 8, 9, 151, 42, 44, 793, 795, "to" +461, 8, 10, 152, 45, 52, 796, 803, "compare" +461, 8, 11, 153, 53, 56, 804, 807, "the" +461, 8, 12, 154, 57, 65, 808, 816, "efficacy" +461, 8, 13, 155, 66, 69, 817, 820, "and" +461, 8, 14, 156, 70, 76, 821, 827, "safety" +461, 8, 15, 157, 77, 84, 828, 835, "profile" +461, 8, 16, 158, 85, 87, 836, 838, "of" +461, 8, 17, 159, 88, 91, 839, 842, "the" +461, 8, 18, 160, 92, 97, 843, 848, "fixed" +461, 8, 19, 161, 98, 109, 849, 860, "combination" +461, 8, 20, 162, 110, 121, 861, 872, "latanoprost" +461, 8, 21, 163, 122, 123, 873, 874, "0" +461, 8, 22, 164, 124, 125, 875, 876, "." +461, 8, 23, 165, 126, 129, 877, 880, "005" +461, 8, 24, 166, 130, 131, 881, 882, "%" +461, 8, 25, 167, 132, 133, 883, 884, "+" +461, 8, 26, 168, 134, 141, 885, 892, "timolol" +461, 8, 27, 169, 142, 149, 893, 900, "maleate" +461, 8, 28, 170, 150, 151, 901, 902, "0" +461, 8, 29, 171, 152, 153, 903, 904, "." +461, 8, 30, 172, 154, 155, 905, 906, "5" +461, 8, 31, 173, 156, 157, 907, 908, "%" +461, 8, 32, 174, 158, 160, 909, 911, "QD" +461, 8, 33, 175, 161, 165, 912, 916, "with" +461, 8, 34, 176, 166, 171, 917, 922, "those" +461, 8, 35, 177, 172, 174, 923, 925, "of" +461, 8, 36, 178, 175, 186, 926, 937, "latanoprost" +461, 8, 37, 179, 187, 188, 938, 939, "0" +461, 8, 38, 180, 189, 190, 940, 941, "." +461, 8, 39, 181, 191, 194, 942, 945, "005" +461, 8, 40, 182, 195, 196, 946, 947, "%" +461, 8, 41, 183, 197, 208, 948, 959, "monotherapy" +461, 8, 42, 184, 209, 211, 960, 962, "QD" +461, 8, 43, 185, 212, 214, 963, 965, "in" +461, 8, 44, 186, 215, 223, 966, 974, "patients" +461, 8, 45, 187, 224, 229, 975, 980, "whose" +461, 8, 46, 188, 230, 238, 981, 989, "elevated" +461, 8, 47, 189, 239, 242, 990, 993, "IOP" +461, 8, 48, 190, 243, 244, 994, 995, "(" +461, 8, 49, 191, 245, 246, 996, 997, ">" +461, 8, 50, 192, 247, 249, 998, 1000, "or" +461, 8, 51, 193, 250, 251, 1001, 1002, "=" +461, 8, 52, 194, 252, 254, 1003, 1005, "21" +461, 8, 53, 195, 255, 257, 1006, 1008, "mm" +461, 8, 54, 196, 258, 260, 1009, 1011, "Hg" +461, 8, 55, 197, 261, 262, 1012, 1013, ")" +461, 8, 56, 198, 263, 266, 1014, 1017, "was" +461, 8, 57, 199, 267, 279, 1018, 1030, "inadequately" +461, 8, 58, 200, 280, 290, 1031, 1041, "controlled" +461, 8, 59, 201, 291, 293, 1042, 1044, "by" +461, 8, 60, 202, 294, 305, 1045, 1056, "latanoprost" +461, 8, 61, 203, 306, 307, 1057, 1058, "." +461, 9, 1, 204, 0, 7, 1059, 1066, "METHODS" +461, 9, 2, 205, 8, 9, 1067, 1068, ":" +461, 9, 3, 206, 10, 14, 1069, 1073, "This" +461, 9, 4, 207, 15, 17, 1074, 1076, "21" +461, 9, 5, 208, 18, 19, 1077, 1078, "-" +461, 9, 6, 209, 20, 23, 1079, 1082, "day" +461, 9, 7, 210, 24, 25, 1083, 1084, "," +461, 9, 8, 211, 26, 36, 1085, 1095, "randomized" +461, 9, 9, 212, 37, 38, 1096, 1097, "," +461, 9, 10, 213, 39, 45, 1098, 1104, "double" +461, 9, 11, 214, 46, 47, 1105, 1106, "-" +461, 9, 12, 215, 48, 54, 1107, 1113, "masked" +461, 9, 13, 216, 55, 56, 1114, 1115, "," +461, 9, 14, 217, 57, 63, 1116, 1122, "active" +461, 9, 15, 218, 64, 65, 1123, 1124, "-" +461, 9, 16, 219, 66, 73, 1125, 1132, "control" +461, 9, 17, 220, 74, 79, 1133, 1138, "study" +461, 9, 18, 221, 80, 83, 1139, 1142, "was" +461, 9, 19, 222, 84, 93, 1143, 1152, "conducted" +461, 9, 20, 223, 94, 96, 1153, 1155, "at" +461, 9, 21, 224, 97, 99, 1156, 1158, "49" +461, 9, 22, 225, 100, 105, 1159, 1164, "study" +461, 9, 23, 226, 106, 111, 1165, 1170, "sites" +461, 9, 24, 227, 112, 114, 1171, 1173, "in" +461, 9, 25, 228, 115, 124, 1174, 1183, "Argentina" +461, 9, 26, 229, 125, 126, 1184, 1185, "," +461, 9, 27, 230, 127, 133, 1186, 1192, "Brazil" +461, 9, 28, 231, 134, 135, 1193, 1194, "," +461, 9, 29, 232, 136, 144, 1195, 1203, "Colombia" +461, 9, 30, 233, 145, 146, 1204, 1205, "," +461, 9, 31, 234, 147, 153, 1206, 1212, "Mexico" +461, 9, 32, 235, 154, 155, 1213, 1214, "," +461, 9, 33, 236, 156, 160, 1215, 1219, "Peru" +461, 9, 34, 237, 161, 162, 1220, 1221, "," +461, 9, 35, 238, 163, 166, 1222, 1225, "the" +461, 9, 36, 239, 167, 173, 1226, 1232, "United" +461, 9, 37, 240, 174, 180, 1233, 1239, "States" +461, 9, 38, 241, 181, 182, 1240, 1241, "," +461, 9, 39, 242, 183, 186, 1242, 1245, "and" +461, 9, 40, 243, 187, 196, 1246, 1255, "Venezuela" +461, 9, 41, 244, 197, 198, 1256, 1257, "." +461, 10, 1, 245, 0, 6, 1258, 1264, "Adults" +461, 10, 2, 246, 7, 11, 1265, 1269, "with" +461, 10, 3, 247, 12, 20, 1270, 1278, "glaucoma" +461, 10, 4, 248, 21, 23, 1279, 1281, "or" +461, 10, 5, 249, 24, 30, 1282, 1288, "ocular" +461, 10, 6, 250, 31, 43, 1289, 1301, "hypertension" +461, 10, 7, 251, 44, 47, 1302, 1305, "who" +461, 10, 8, 252, 48, 51, 1306, 1309, "had" +461, 10, 9, 253, 52, 58, 1310, 1316, "failed" +461, 10, 10, 254, 59, 61, 1317, 1319, "to" +461, 10, 11, 255, 62, 67, 1320, 1325, "reach" +461, 10, 12, 256, 68, 70, 1326, 1328, "an" +461, 10, 13, 257, 71, 74, 1329, 1332, "IOP" +461, 10, 14, 258, 75, 77, 1333, 1335, "of" +461, 10, 15, 259, 78, 79, 1336, 1337, "<" +461, 10, 16, 260, 80, 82, 1338, 1340, "21" +461, 10, 17, 261, 83, 85, 1341, 1343, "mm" +461, 10, 18, 262, 86, 88, 1344, 1346, "Hg" +461, 10, 19, 263, 89, 94, 1347, 1352, "while" +461, 10, 20, 264, 95, 104, 1353, 1362, "receiving" +461, 10, 21, 265, 105, 116, 1363, 1374, "latanoprost" +461, 10, 22, 266, 117, 120, 1375, 1378, "for" +461, 10, 23, 267, 121, 123, 1379, 1381, "at" +461, 10, 24, 268, 124, 129, 1382, 1387, "least" +461, 10, 25, 269, 130, 132, 1388, 1390, "28" +461, 10, 26, 270, 133, 137, 1391, 1395, "days" +461, 10, 27, 271, 138, 142, 1396, 1400, "were" +461, 10, 28, 272, 143, 151, 1401, 1409, "enrolled" +461, 10, 29, 273, 152, 153, 1410, 1411, "." +461, 11, 1, 274, 0, 5, 1412, 1417, "After" +461, 11, 2, 275, 6, 8, 1418, 1420, "an" +461, 11, 3, 276, 9, 19, 1421, 1431, "additional" +461, 11, 4, 277, 20, 22, 1432, 1434, "28" +461, 11, 5, 278, 23, 27, 1435, 1439, "days" +461, 11, 6, 279, 28, 30, 1440, 1442, "of" +461, 11, 7, 280, 31, 42, 1443, 1454, "latanoprost" +461, 11, 8, 281, 43, 46, 1455, 1458, "run" +461, 11, 9, 282, 47, 48, 1459, 1460, "-" +461, 11, 10, 283, 49, 51, 1461, 1463, "in" +461, 11, 11, 284, 52, 53, 1464, 1465, "," +461, 11, 12, 285, 54, 62, 1466, 1474, "patients" +461, 11, 13, 286, 63, 67, 1475, 1479, "were" +461, 11, 14, 287, 68, 76, 1480, 1488, "randomly" +461, 11, 15, 288, 77, 85, 1489, 1497, "assigned" +461, 11, 16, 289, 86, 88, 1498, 1500, "to" +461, 11, 17, 290, 89, 97, 1501, 1509, "continue" +461, 11, 18, 291, 98, 109, 1510, 1521, "latanoprost" +461, 11, 19, 292, 110, 121, 1522, 1533, "monotherapy" +461, 11, 20, 293, 122, 124, 1534, 1536, "or" +461, 11, 21, 294, 125, 127, 1537, 1539, "to" +461, 11, 22, 295, 128, 134, 1540, 1546, "switch" +461, 11, 23, 296, 135, 137, 1547, 1549, "to" +461, 11, 24, 297, 138, 141, 1550, 1553, "the" +461, 11, 25, 298, 142, 147, 1554, 1559, "fixed" +461, 11, 26, 299, 148, 159, 1560, 1571, "combination" +461, 11, 27, 300, 160, 163, 1572, 1575, "for" +461, 11, 28, 301, 164, 166, 1576, 1578, "21" +461, 11, 29, 302, 167, 171, 1579, 1583, "days" +461, 11, 30, 303, 172, 173, 1584, 1585, "." +461, 12, 1, 304, 0, 3, 1586, 1589, "The" +461, 12, 2, 305, 4, 10, 1590, 1596, "intent" +461, 12, 3, 306, 11, 12, 1597, 1598, "-" +461, 12, 4, 307, 13, 15, 1599, 1601, "to" +461, 12, 5, 308, 16, 17, 1602, 1603, "-" +461, 12, 6, 309, 18, 23, 1604, 1609, "treat" +461, 12, 7, 310, 24, 25, 1610, 1611, "(" +461, 12, 8, 311, 26, 29, 1612, 1615, "ITT" +461, 12, 9, 312, 30, 31, 1616, 1617, ")" +461, 12, 10, 313, 32, 42, 1618, 1628, "population" +461, 12, 11, 314, 43, 51, 1629, 1637, "included" +461, 12, 12, 315, 52, 55, 1638, 1641, "all" +461, 12, 13, 316, 56, 64, 1642, 1650, "patients" +461, 12, 14, 317, 65, 68, 1651, 1654, "who" +461, 12, 15, 318, 69, 77, 1655, 1663, "received" +461, 12, 16, 319, 78, 80, 1664, 1666, "at" +461, 12, 17, 320, 81, 86, 1667, 1672, "least" +461, 12, 18, 321, 87, 88, 1673, 1674, "1" +461, 12, 19, 322, 89, 93, 1675, 1679, "dose" +461, 12, 20, 323, 94, 96, 1680, 1682, "of" +461, 12, 21, 324, 97, 103, 1683, 1689, "double" +461, 12, 22, 325, 104, 105, 1690, 1691, "-" +461, 12, 23, 326, 106, 112, 1692, 1698, "masked" +461, 12, 24, 327, 113, 118, 1699, 1704, "study" +461, 12, 25, 328, 119, 129, 1705, 1715, "medication" +461, 12, 26, 329, 130, 131, 1716, 1717, ";" +461, 12, 27, 330, 132, 135, 1718, 1721, "the" +461, 12, 28, 331, 136, 139, 1722, 1725, "per" +461, 12, 29, 332, 140, 141, 1726, 1727, "-" +461, 12, 30, 333, 142, 150, 1728, 1736, "protocol" +461, 12, 31, 334, 151, 152, 1737, 1738, "(" +461, 12, 32, 335, 153, 155, 1739, 1741, "PP" +461, 12, 33, 336, 156, 157, 1742, 1743, ")" +461, 12, 34, 337, 158, 166, 1744, 1752, "analysis" +461, 12, 35, 338, 167, 175, 1753, 1761, "included" +461, 12, 36, 339, 176, 184, 1762, 1770, "patients" +461, 12, 37, 340, 185, 188, 1771, 1774, "who" +461, 12, 38, 341, 189, 198, 1775, 1784, "completed" +461, 12, 39, 342, 199, 202, 1785, 1788, "the" +461, 12, 40, 343, 203, 208, 1789, 1794, "study" +461, 12, 41, 344, 209, 216, 1795, 1802, "without" +461, 12, 42, 345, 217, 218, 1803, 1804, "a" +461, 12, 43, 346, 219, 224, 1805, 1810, "major" +461, 12, 44, 347, 225, 233, 1811, 1819, "protocol" +461, 12, 45, 348, 234, 243, 1820, 1829, "violation" +461, 12, 46, 349, 244, 247, 1830, 1833, "and" +461, 12, 47, 350, 248, 251, 1834, 1837, "who" +461, 12, 48, 351, 252, 255, 1838, 1841, "had" +461, 12, 49, 352, 256, 259, 1842, 1845, "IOP" +461, 12, 50, 353, 260, 272, 1846, 1858, "measurements" +461, 12, 51, 354, 273, 277, 1859, 1863, "both" +461, 12, 52, 355, 278, 280, 1864, 1866, "at" +461, 12, 53, 356, 281, 289, 1867, 1875, "baseline" +461, 12, 54, 357, 290, 293, 1876, 1879, "and" +461, 12, 55, 358, 294, 296, 1880, 1882, "at" +461, 12, 56, 359, 297, 300, 1883, 1886, "day" +461, 12, 57, 360, 301, 303, 1887, 1889, "21" +461, 12, 58, 361, 304, 305, 1890, 1891, "." +461, 13, 1, 362, 0, 3, 1892, 1895, "The" +461, 13, 2, 363, 4, 11, 1896, 1903, "primary" +461, 13, 3, 364, 12, 15, 1904, 1907, "end" +461, 13, 4, 365, 16, 21, 1908, 1913, "point" +461, 13, 5, 366, 22, 25, 1914, 1917, "was" +461, 13, 6, 367, 26, 29, 1918, 1921, "the" +461, 13, 7, 368, 30, 40, 1922, 1932, "proportion" +461, 13, 8, 369, 41, 43, 1933, 1935, "of" +461, 13, 9, 370, 44, 52, 1936, 1944, "patients" +461, 13, 10, 371, 53, 58, 1945, 1950, "whose" +461, 13, 11, 372, 59, 62, 1951, 1954, "IOP" +461, 13, 12, 373, 63, 66, 1955, 1958, "was" +461, 13, 13, 374, 67, 76, 1959, 1968, "decreased" +461, 13, 14, 375, 77, 78, 1969, 1970, ">" +461, 13, 15, 376, 79, 81, 1971, 1973, "or" +461, 13, 16, 377, 82, 83, 1974, 1975, "=" +461, 13, 17, 378, 84, 85, 1976, 1977, "2" +461, 13, 18, 379, 86, 88, 1978, 1980, "mm" +461, 13, 19, 380, 89, 91, 1981, 1983, "Hg" +461, 13, 20, 381, 92, 96, 1984, 1988, "from" +461, 13, 21, 382, 97, 100, 1989, 1992, "the" +461, 13, 22, 383, 101, 109, 1993, 2001, "baseline" +461, 13, 23, 384, 110, 115, 2002, 2007, "level" +461, 13, 24, 385, 116, 118, 2008, 2010, "on" +461, 13, 25, 386, 119, 122, 2011, 2014, "day" +461, 13, 26, 387, 123, 125, 2015, 2017, "21" +461, 13, 27, 388, 126, 127, 2018, 2019, "." +461, 14, 1, 389, 0, 11, 2020, 2031, "Proportions" +461, 14, 2, 390, 12, 14, 2032, 2034, "of" +461, 14, 3, 391, 15, 23, 2035, 2043, "patients" +461, 14, 4, 392, 24, 37, 2044, 2057, "demonstrating" +461, 14, 5, 393, 38, 41, 2058, 2061, "IOP" +461, 14, 6, 394, 42, 51, 2062, 2071, "decreases" +461, 14, 7, 395, 52, 53, 2072, 2073, ">" +461, 14, 8, 396, 54, 56, 2074, 2076, "or" +461, 14, 9, 397, 57, 58, 2077, 2078, "=" +461, 14, 10, 398, 59, 60, 2079, 2080, "3" +461, 14, 11, 399, 61, 62, 2081, 2082, "," +461, 14, 12, 400, 63, 64, 2083, 2084, ">" +461, 14, 13, 401, 65, 67, 2085, 2087, "or" +461, 14, 14, 402, 68, 69, 2088, 2089, "=" +461, 14, 15, 403, 70, 71, 2090, 2091, "4" +461, 14, 16, 404, 72, 73, 2092, 2093, "," +461, 14, 17, 405, 74, 76, 2094, 2096, "or" +461, 14, 18, 406, 77, 78, 2097, 2098, ">" +461, 14, 19, 407, 79, 81, 2099, 2101, "or" +461, 14, 20, 408, 82, 83, 2102, 2103, "=" +461, 14, 21, 409, 84, 85, 2104, 2105, "5" +461, 14, 22, 410, 86, 88, 2106, 2108, "mm" +461, 14, 23, 411, 89, 91, 2109, 2111, "Hg" +461, 14, 24, 412, 92, 96, 2112, 2116, "from" +461, 14, 25, 413, 97, 100, 2117, 2120, "the" +461, 14, 26, 414, 101, 109, 2121, 2129, "baseline" +461, 14, 27, 415, 110, 115, 2130, 2135, "level" +461, 14, 28, 416, 116, 119, 2136, 2139, "and" +461, 14, 29, 417, 120, 122, 2140, 2142, "of" +461, 14, 30, 418, 123, 131, 2143, 2151, "patients" +461, 14, 31, 419, 132, 140, 2152, 2160, "reaching" +461, 14, 32, 420, 141, 143, 2161, 2163, "an" +461, 14, 33, 421, 144, 147, 2164, 2167, "10P" +461, 14, 34, 422, 148, 149, 2168, 2169, "<" +461, 14, 35, 423, 150, 152, 2170, 2172, "or" +461, 14, 36, 424, 153, 154, 2173, 2174, "=" +461, 14, 37, 425, 155, 157, 2175, 2177, "18" +461, 14, 38, 426, 158, 160, 2178, 2180, "mm" +461, 14, 39, 427, 161, 163, 2181, 2183, "Hg" +461, 14, 40, 428, 164, 168, 2184, 2188, "were" +461, 14, 41, 429, 169, 178, 2189, 2198, "evaluated" +461, 14, 42, 430, 179, 180, 2199, 2200, "." +461, 15, 1, 431, 0, 7, 2201, 2208, "Adverse" +461, 15, 2, 432, 8, 14, 2209, 2215, "events" +461, 15, 3, 433, 15, 16, 2216, 2217, "(" +461, 15, 4, 434, 17, 20, 2218, 2221, "AEs" +461, 15, 5, 435, 21, 22, 2222, 2223, ")" +461, 15, 6, 436, 23, 27, 2224, 2228, "were" +461, 15, 7, 437, 28, 32, 2229, 2233, "also" +461, 15, 8, 438, 33, 41, 2234, 2242, "assessed" +461, 15, 9, 439, 42, 43, 2243, 2244, "." +461, 16, 1, 440, 0, 7, 2245, 2252, "RESULTS" +461, 16, 2, 441, 8, 9, 2253, 2254, ":" +461, 16, 3, 442, 10, 11, 2255, 2256, "A" +461, 16, 4, 443, 12, 17, 2257, 2262, "total" +461, 16, 5, 444, 18, 20, 2263, 2265, "of" +461, 16, 6, 445, 21, 24, 2266, 2269, "350" +461, 16, 7, 446, 25, 33, 2270, 2278, "patients" +461, 16, 8, 447, 34, 38, 2279, 2283, "were" +461, 16, 9, 448, 39, 47, 2284, 2292, "enrolled" +461, 16, 10, 449, 48, 49, 2293, 2294, "." +461, 17, 1, 450, 0, 2, 2295, 2297, "In" +461, 17, 2, 451, 3, 6, 2298, 2301, "all" +461, 17, 3, 452, 7, 8, 2302, 2303, "," +461, 17, 4, 453, 9, 12, 2304, 2307, "348" +461, 17, 5, 454, 13, 21, 2308, 2316, "patients" +461, 17, 6, 455, 22, 26, 2317, 2321, "were" +461, 17, 7, 456, 27, 35, 2322, 2330, "included" +461, 17, 8, 457, 36, 38, 2331, 2333, "in" +461, 17, 9, 458, 39, 42, 2334, 2337, "the" +461, 17, 10, 459, 43, 46, 2338, 2341, "ITT" +461, 17, 11, 460, 47, 50, 2342, 2345, "and" +461, 17, 12, 461, 51, 63, 2346, 2358, "tolerability" +461, 17, 13, 462, 64, 72, 2359, 2367, "analyses" +461, 17, 14, 463, 73, 74, 2368, 2369, "(" +461, 17, 15, 464, 75, 80, 2370, 2375, "fixed" +461, 17, 16, 465, 81, 92, 2376, 2387, "combination" +461, 17, 17, 466, 93, 94, 2388, 2389, "," +461, 17, 18, 467, 95, 96, 2390, 2391, "n" +461, 17, 19, 468, 97, 98, 2392, 2393, "=" +461, 17, 20, 469, 99, 102, 2394, 2397, "175" +461, 17, 21, 470, 103, 104, 2398, 2399, ";" +461, 17, 22, 471, 105, 116, 2400, 2411, "latanoprost" +461, 17, 23, 472, 117, 118, 2412, 2413, "," +461, 17, 24, 473, 119, 120, 2414, 2415, "n" +461, 17, 25, 474, 121, 122, 2416, 2417, "=" +461, 17, 26, 475, 123, 126, 2418, 2421, "173" +461, 17, 27, 476, 127, 128, 2422, 2423, ";" +461, 17, 28, 477, 129, 133, 2424, 2428, "mean" +461, 17, 29, 478, 134, 135, 2429, 2430, "[" +461, 17, 30, 479, 136, 138, 2431, 2433, "SD" +461, 17, 31, 480, 139, 140, 2434, 2435, "]" +461, 17, 32, 481, 141, 144, 2436, 2439, "age" +461, 17, 33, 482, 145, 146, 2440, 2441, "," +461, 17, 34, 483, 147, 149, 2442, 2444, "64" +461, 17, 35, 484, 150, 151, 2445, 2446, "." +461, 17, 36, 485, 152, 153, 2447, 2448, "4" +461, 17, 37, 486, 154, 155, 2449, 2450, "[" +461, 17, 38, 487, 156, 158, 2451, 2453, "13" +461, 17, 39, 488, 159, 160, 2454, 2455, "." +461, 17, 40, 489, 161, 162, 2456, 2457, "2" +461, 17, 41, 490, 163, 164, 2458, 2459, "]" +461, 17, 42, 491, 165, 168, 2460, 2463, "and" +461, 17, 43, 492, 169, 171, 2464, 2466, "63" +461, 17, 44, 493, 172, 173, 2467, 2468, "." +461, 17, 45, 494, 174, 175, 2469, 2470, "2" +461, 17, 46, 495, 176, 177, 2471, 2472, "[" +461, 17, 47, 496, 178, 180, 2473, 2475, "14" +461, 17, 48, 497, 181, 182, 2476, 2477, "." +461, 17, 49, 498, 183, 184, 2478, 2479, "0" +461, 17, 50, 499, 185, 186, 2480, 2481, "]" +461, 17, 51, 500, 187, 192, 2482, 2487, "years" +461, 17, 52, 501, 193, 194, 2488, 2489, "," +461, 17, 53, 502, 195, 207, 2490, 2502, "respectively" +461, 17, 54, 503, 208, 209, 2503, 2504, ";" +461, 17, 55, 504, 210, 213, 2505, 2508, "103" +461, 17, 56, 505, 214, 219, 2509, 2514, "women" +461, 17, 57, 506, 220, 222, 2515, 2517, "in" +461, 17, 58, 507, 223, 227, 2518, 2522, "each" +461, 17, 59, 508, 228, 233, 2523, 2528, "group" +461, 17, 60, 509, 234, 235, 2529, 2530, ")" +461, 17, 61, 510, 236, 237, 2531, 2532, "." +461, 18, 1, 511, 0, 8, 2533, 2541, "Baseline" +461, 18, 2, 512, 9, 20, 2542, 2553, "demographic" +461, 18, 3, 513, 21, 24, 2554, 2557, "and" +461, 18, 4, 514, 25, 33, 2558, 2566, "clinical" +461, 18, 5, 515, 34, 49, 2567, 2582, "characteristics" +461, 18, 6, 516, 50, 54, 2583, 2587, "were" +461, 18, 7, 517, 55, 62, 2588, 2595, "similar" +461, 18, 8, 518, 63, 70, 2596, 2603, "between" +461, 18, 9, 519, 71, 77, 2604, 2610, "groups" +461, 18, 10, 520, 78, 79, 2611, 2612, "." +461, 19, 1, 521, 0, 1, 2613, 2614, "A" +461, 19, 2, 522, 2, 8, 2615, 2621, "higher" +461, 19, 3, 523, 9, 19, 2622, 2632, "percentage" +461, 19, 4, 524, 20, 22, 2633, 2635, "of" +461, 19, 5, 525, 23, 31, 2636, 2644, "patients" +461, 19, 6, 526, 32, 41, 2645, 2654, "receiving" +461, 19, 7, 527, 42, 45, 2655, 2658, "the" +461, 19, 8, 528, 46, 51, 2659, 2664, "fixed" +461, 19, 9, 529, 52, 63, 2665, 2676, "combination" +461, 19, 10, 530, 64, 67, 2677, 2680, "had" +461, 19, 11, 531, 68, 71, 2681, 2684, "IOP" +461, 19, 12, 532, 72, 81, 2685, 2694, "decreases" +461, 19, 13, 533, 82, 84, 2695, 2697, "of" +461, 19, 14, 534, 85, 86, 2698, 2699, "2" +461, 19, 15, 535, 87, 89, 2700, 2702, "mm" +461, 19, 16, 536, 90, 92, 2703, 2705, "Hg" +461, 19, 17, 537, 93, 95, 2706, 2708, "on" +461, 19, 18, 538, 96, 99, 2709, 2712, "day" +461, 19, 19, 539, 100, 102, 2713, 2715, "21" +461, 19, 20, 540, 103, 111, 2716, 2724, "relative" +461, 19, 21, 541, 112, 114, 2725, 2727, "to" +461, 19, 22, 542, 115, 123, 2728, 2736, "baseline" +461, 19, 23, 543, 124, 132, 2737, 2745, "compared" +461, 19, 24, 544, 133, 137, 2746, 2750, "with" +461, 19, 25, 545, 138, 149, 2751, 2762, "latanoprost" +461, 19, 26, 546, 150, 151, 2763, 2764, "-" +461, 19, 27, 547, 152, 159, 2765, 2772, "treated" +461, 19, 28, 548, 160, 168, 2773, 2781, "patients" +461, 19, 29, 549, 169, 170, 2782, 2783, "(" +461, 19, 30, 550, 171, 173, 2784, 2786, "79" +461, 19, 31, 551, 174, 175, 2787, 2788, "." +461, 19, 32, 552, 176, 177, 2789, 2790, "4" +461, 19, 33, 553, 178, 179, 2791, 2792, "%" +461, 19, 34, 554, 180, 182, 2793, 2795, "vs" +461, 19, 35, 555, 183, 185, 2796, 2798, "51" +461, 19, 36, 556, 186, 187, 2799, 2800, "." +461, 19, 37, 557, 188, 189, 2801, 2802, "4" +461, 19, 38, 558, 190, 191, 2803, 2804, "%" +461, 19, 39, 559, 192, 193, 2805, 2806, "," +461, 19, 40, 560, 194, 206, 2807, 2819, "respectively" +461, 19, 41, 561, 207, 208, 2820, 2821, ";" +461, 19, 42, 562, 209, 210, 2822, 2823, "P" +461, 19, 43, 563, 211, 212, 2824, 2825, "<" +461, 19, 44, 564, 213, 214, 2826, 2827, "0" +461, 19, 45, 565, 215, 216, 2828, 2829, "." +461, 19, 46, 566, 217, 220, 2830, 2833, "001" +461, 19, 47, 567, 221, 222, 2834, 2835, ")" +461, 19, 48, 568, 223, 224, 2836, 2837, "." +461, 20, 1, 569, 0, 2, 2838, 2840, "PP" +461, 20, 2, 570, 3, 11, 2841, 2849, "analyses" +461, 20, 3, 571, 12, 17, 2850, 2855, "found" +461, 20, 4, 572, 18, 22, 2856, 2860, "that" +461, 20, 5, 573, 23, 27, 2861, 2865, "more" +461, 20, 6, 574, 28, 36, 2866, 2874, "patients" +461, 20, 7, 575, 37, 39, 2875, 2877, "in" +461, 20, 8, 576, 40, 43, 2878, 2881, "the" +461, 20, 9, 577, 44, 49, 2882, 2887, "fixed" +461, 20, 10, 578, 50, 51, 2888, 2889, "-" +461, 20, 11, 579, 52, 63, 2890, 2901, "combination" +461, 20, 12, 580, 64, 69, 2902, 2907, "group" +461, 20, 13, 581, 70, 73, 2908, 2911, "had" +461, 20, 14, 582, 74, 77, 2912, 2915, "IOP" +461, 20, 15, 583, 78, 87, 2916, 2925, "decreases" +461, 20, 16, 584, 88, 89, 2926, 2927, ">" +461, 20, 17, 585, 90, 92, 2928, 2930, "or" +461, 20, 18, 586, 93, 94, 2931, 2932, "=" +461, 20, 19, 587, 95, 96, 2933, 2934, "3" +461, 20, 20, 588, 97, 98, 2935, 2936, "," +461, 20, 21, 589, 99, 100, 2937, 2938, ">" +461, 20, 22, 590, 101, 103, 2939, 2941, "or" +461, 20, 23, 591, 104, 105, 2942, 2943, "=" +461, 20, 24, 592, 106, 107, 2944, 2945, "4" +461, 20, 25, 593, 108, 109, 2946, 2947, "," +461, 20, 26, 594, 110, 112, 2948, 2950, "or" +461, 20, 27, 595, 113, 114, 2951, 2952, ">" +461, 20, 28, 596, 115, 117, 2953, 2955, "or" +461, 20, 29, 597, 118, 119, 2956, 2957, "=" +461, 20, 30, 598, 120, 121, 2958, 2959, "5" +461, 20, 31, 599, 122, 124, 2960, 2962, "mm" +461, 20, 32, 600, 125, 127, 2963, 2965, "Hg" +461, 20, 33, 601, 128, 129, 2966, 2967, "(" +461, 20, 34, 602, 130, 133, 2968, 2971, "for" +461, 20, 35, 603, 134, 138, 2972, 2976, "each" +461, 20, 36, 604, 139, 145, 2977, 2983, "target" +461, 20, 37, 605, 146, 151, 2984, 2989, "level" +461, 20, 38, 606, 152, 153, 2990, 2991, "," +461, 20, 39, 607, 154, 155, 2992, 2993, "P" +461, 20, 40, 608, 156, 157, 2994, 2995, "<" +461, 20, 41, 609, 158, 159, 2996, 2997, "0" +461, 20, 42, 610, 160, 161, 2998, 2999, "." +461, 20, 43, 611, 162, 165, 3000, 3003, "001" +461, 20, 44, 612, 166, 168, 3004, 3006, "vs" +461, 20, 45, 613, 169, 180, 3007, 3018, "latanoprost" +461, 20, 46, 614, 181, 186, 3019, 3024, "group" +461, 20, 47, 615, 187, 188, 3025, 3026, ")" +461, 20, 48, 616, 189, 191, 3027, 3029, "or" +461, 20, 49, 617, 192, 197, 3030, 3035, "final" +461, 20, 50, 618, 198, 201, 3036, 3039, "IOP" +461, 20, 51, 619, 202, 204, 3040, 3042, "18" +461, 20, 52, 620, 205, 207, 3043, 3045, "mm" +461, 20, 53, 621, 208, 210, 3046, 3048, "Hg" +461, 20, 54, 622, 211, 212, 3049, 3050, "(" +461, 20, 55, 623, 213, 218, 3051, 3056, "fixed" +461, 20, 56, 624, 219, 220, 3057, 3058, "-" +461, 20, 57, 625, 221, 232, 3059, 3070, "combination" +461, 20, 58, 626, 233, 234, 3071, 3072, "," +461, 20, 59, 627, 235, 237, 3073, 3075, "35" +461, 20, 60, 628, 238, 239, 3076, 3077, "." +461, 20, 61, 629, 240, 241, 3078, 3079, "1" +461, 20, 62, 630, 242, 243, 3080, 3081, "%" +461, 20, 63, 631, 244, 245, 3082, 3083, ";" +461, 20, 64, 632, 246, 257, 3084, 3095, "latanoprost" +461, 20, 65, 633, 258, 259, 3096, 3097, "," +461, 20, 66, 634, 260, 262, 3098, 3100, "17" +461, 20, 67, 635, 263, 264, 3101, 3102, "." +461, 20, 68, 636, 265, 266, 3103, 3104, "8" +461, 20, 69, 637, 267, 268, 3105, 3106, "%" +461, 20, 70, 638, 269, 270, 3107, 3108, ";" +461, 20, 71, 639, 271, 272, 3109, 3110, "P" +461, 20, 72, 640, 273, 274, 3111, 3112, "<" +461, 20, 73, 641, 275, 276, 3113, 3114, "0" +461, 20, 74, 642, 277, 278, 3115, 3116, "." +461, 20, 75, 643, 279, 282, 3117, 3120, "001" +461, 20, 76, 644, 283, 284, 3121, 3122, ")" +461, 20, 77, 645, 285, 286, 3123, 3124, "." +461, 21, 1, 646, 0, 4, 3125, 3129, "Both" +461, 21, 2, 647, 5, 15, 3130, 3140, "treatments" +461, 21, 3, 648, 16, 20, 3141, 3145, "were" +461, 21, 4, 649, 21, 25, 3146, 3150, "well" +461, 21, 5, 650, 26, 35, 3151, 3160, "tolerated" +461, 21, 6, 651, 36, 37, 3161, 3162, "." +461, 22, 1, 652, 0, 7, 3163, 3170, "Similar" +461, 22, 2, 653, 8, 19, 3171, 3182, "proportions" +461, 22, 3, 654, 20, 22, 3183, 3185, "of" +461, 22, 4, 655, 23, 31, 3186, 3194, "patients" +461, 22, 5, 656, 32, 34, 3195, 3197, "in" +461, 22, 6, 657, 35, 38, 3198, 3201, "the" +461, 22, 7, 658, 39, 44, 3202, 3207, "fixed" +461, 22, 8, 659, 45, 46, 3208, 3209, "-" +461, 22, 9, 660, 47, 58, 3210, 3221, "combination" +461, 22, 10, 661, 59, 62, 3222, 3225, "and" +461, 22, 11, 662, 63, 74, 3226, 3237, "latanoprost" +461, 22, 12, 663, 75, 81, 3238, 3244, "groups" +461, 22, 13, 664, 82, 90, 3245, 3253, "reported" +461, 22, 14, 665, 91, 93, 3254, 3256, "at" +461, 22, 15, 666, 94, 99, 3257, 3262, "least" +461, 22, 16, 667, 100, 101, 3263, 3264, "1" +461, 22, 17, 668, 102, 111, 3265, 3274, "treatment" +461, 22, 18, 669, 112, 113, 3275, 3276, "-" +461, 22, 19, 670, 114, 122, 3277, 3285, "emergent" +461, 22, 20, 671, 123, 125, 3286, 3288, "AE" +461, 22, 21, 672, 126, 127, 3289, 3290, "(" +461, 22, 22, 673, 128, 130, 3291, 3293, "10" +461, 22, 23, 674, 131, 132, 3294, 3295, "." +461, 22, 24, 675, 133, 134, 3296, 3297, "9" +461, 22, 25, 676, 135, 136, 3298, 3299, "%" +461, 22, 26, 677, 137, 140, 3300, 3303, "and" +461, 22, 27, 678, 141, 143, 3304, 3306, "12" +461, 22, 28, 679, 144, 145, 3307, 3308, "." +461, 22, 29, 680, 146, 147, 3309, 3310, "1" +461, 22, 30, 681, 148, 149, 3311, 3312, "%" +461, 22, 31, 682, 150, 151, 3313, 3314, "," +461, 22, 32, 683, 152, 164, 3315, 3327, "respectively" +461, 22, 33, 684, 165, 166, 3328, 3329, ")" +461, 22, 34, 685, 167, 168, 3330, 3331, "." +461, 23, 1, 686, 0, 10, 3332, 3342, "CONCLUSION" +461, 23, 2, 687, 11, 12, 3343, 3344, ":" +461, 23, 3, 688, 13, 15, 3345, 3347, "In" +461, 23, 4, 689, 16, 20, 3348, 3352, "this" +461, 23, 5, 690, 21, 29, 3353, 3361, "selected" +461, 23, 6, 691, 30, 40, 3362, 3372, "population" +461, 23, 7, 692, 41, 43, 3373, 3375, "of" +461, 23, 8, 693, 44, 52, 3376, 3384, "patients" +461, 23, 9, 694, 53, 57, 3385, 3389, "with" +461, 23, 10, 695, 58, 60, 3390, 3392, "an" +461, 23, 11, 696, 61, 71, 3393, 3403, "inadequate" +461, 23, 12, 697, 72, 79, 3404, 3411, "initial" +461, 23, 13, 698, 80, 83, 3412, 3415, "IOP" +461, 23, 14, 699, 84, 92, 3416, 3424, "response" +461, 23, 15, 700, 93, 95, 3425, 3427, "to" +461, 23, 16, 701, 96, 107, 3428, 3439, "latanoprost" +461, 23, 17, 702, 108, 109, 3440, 3441, "," +461, 23, 18, 703, 110, 119, 3442, 3451, "switching" +461, 23, 19, 704, 120, 122, 3452, 3454, "to" +461, 23, 20, 705, 123, 128, 3455, 3460, "fixed" +461, 23, 21, 706, 129, 130, 3461, 3462, "-" +461, 23, 22, 707, 131, 142, 3463, 3474, "combination" +461, 23, 23, 708, 143, 161, 3475, 3493, "latanoprosttimolol" +461, 23, 24, 709, 162, 170, 3494, 3502, "resulted" +461, 23, 25, 710, 171, 173, 3503, 3505, "in" +461, 23, 26, 711, 174, 175, 3506, 3507, "a" +461, 23, 27, 712, 176, 183, 3508, 3515, "greater" +461, 23, 28, 713, 184, 192, 3516, 3524, "decrease" +461, 23, 29, 714, 193, 195, 3525, 3527, "in" +461, 23, 30, 715, 196, 199, 3528, 3531, "IOP" +461, 23, 31, 716, 200, 203, 3532, 3535, "and" +461, 23, 32, 717, 204, 211, 3536, 3543, "similar" +461, 23, 33, 718, 212, 224, 3544, 3556, "tolerability" +461, 23, 34, 719, 225, 233, 3557, 3565, "compared" +461, 23, 35, 720, 234, 238, 3566, 3570, "with" +461, 23, 36, 721, 239, 249, 3571, 3581, "continuing" +461, 23, 37, 722, 250, 261, 3582, 3593, "latanoprost" +461, 23, 38, 723, 262, 269, 3594, 3601, "therapy" +461, 23, 39, 724, 270, 271, 3602, 3603, "." +461, 24, 1, 725, 0, 3, 3604, 3607, "DOI" +461, 24, 2, 726, 4, 5, 3608, 3609, ":" +461, 24, 3, 727, 6, 8, 3610, 3612, "10" +461, 24, 4, 728, 9, 10, 3613, 3614, "." +461, 24, 5, 729, 11, 15, 3615, 3619, "1016" +461, 24, 6, 730, 16, 17, 3620, 3621, "/" +461, 24, 7, 731, 18, 19, 3622, 3623, "j" +461, 24, 8, 732, 20, 21, 3624, 3625, "." +461, 24, 9, 733, 22, 31, 3626, 3635, "clinthera" +461, 24, 10, 734, 32, 33, 3636, 3637, "." +461, 24, 11, 735, 34, 38, 3638, 3642, "2004" +461, 24, 12, 736, 39, 40, 3643, 3644, "." +461, 24, 13, 737, 41, 43, 3645, 3647, "10" +461, 24, 14, 738, 44, 45, 3648, 3649, "." +461, 24, 15, 739, 46, 49, 3650, 3653, "009" +461, 24, 16, 740, 50, 54, 3654, 3658, "PMID" +461, 24, 17, 741, 55, 56, 3659, 3660, ":" +461, 24, 18, 742, 57, 65, 3661, 3669, "15598478" +461, 24, 19, 743, 66, 67, 3670, 3671, "[" +461, 24, 20, 744, 68, 75, 3672, 3679, "Indexed" +461, 24, 21, 745, 76, 79, 3680, 3683, "for" +461, 24, 22, 746, 80, 87, 3684, 3691, "MEDLINE" +461, 24, 23, 747, 88, 89, 3692, 3693, "]" diff --git a/data/gl 15598478_jshahinitiran.annodb b/data/gl 15598478_jshahinitiran.annodb new file mode 100644 index 0000000..c77070e --- /dev/null +++ b/data/gl 15598478_jshahinitiran.annodb @@ -0,0 +1,125 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8929, Journal, 0, 9, "Clin Ther", "", +8930, PublicationYear, 12, 16, "2004", "", +8931, Title, 47, 237, "Switching from latanoprost to fixed - combination latanoprost - timolol : a 21 - day , randomized , double - masked , active - control study in patients with glaucoma and ocular hypertension", "", +8932, Latanoprost, 62, 73, "latanoprost", "", +27982, Drug, 77, 118, "fixed - combination latanoprost - timolol", "Fixed-Combination", +8933, Latanoprost, 97, 108, "latanoprost", "", +8934, Timolol, 111, 118, "timolol", "", +27946, Duration, 123, 131, "21 - day", "", +27947, Randomized, 134, 144, "randomized", "", +27948, DoubleBlind, 147, 162, "double - masked", "", +27949, CTDesign, 165, 181, "active - control", "", +8939, Glaucoma, 205, 213, "glaucoma", "", +8940, OcularHypertension, 218, 237, "ocular hypertension", "", +8941, Author, 240, 249, "Olander K", "", +8942, Author, 258, 270, "Zimmerman TJ", "", +8943, Author, 273, 281, "Downes N", "", +8944, Author, 284, 298, "Schoenfelder J", "", +8945, USA, 432, 435, "USA", "", +27950, Glaucoma, 509, 517, "glaucoma", "", +8946, IOP, 566, 586, "intraocular pressure", "", +8947, IOP, 589, 592, "IOP", "", +8948, ObjectiveDescription, 763, 911, "The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 % QD", "", +27983, Drug, 843, 908, "fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 %", "Fixed-Combination", +8950, Latanoprost, 861, 872, "latanoprost", "", +8951, DoseValue, 873, 880, "0 . 005", "", +8952, Percentage, 881, 882, "%", "", +8953, Timolol, 885, 900, "timolol maleate", "", +8954, DoseValue, 901, 906, "0 . 5", "", +8955, Percentage, 907, 908, "%", "", +27951, Frequency, 909, 911, "QD", "", +8949, ObjectiveDescription, 912, 1058, "with those of latanoprost 0 . 005 % monotherapy QD in patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .", "", +27952, Latanoprost, 926, 937, "latanoprost", "", +27953, DoseValue, 938, 945, "0 . 005", "", +27954, Percentage, 946, 947, "%", "", +27955, Frequency, 960, 962, "QD", "", +27956, Precondition, 966, 1058, "patients whose elevated IOP ( > or = 21 mm Hg ) was inadequately controlled by latanoprost .", "", +27957, IOP, 990, 993, "IOP", "", +27958, mmHg, 1006, 1011, "mm Hg", "", +27959, Latanoprost, 1045, 1056, "latanoprost", "", +27960, Duration, 1074, 1082, "21 - day", "", +27961, Randomized, 1085, 1095, "randomized", "", +27962, DoubleBlind, 1098, 1113, "double - masked", "", +27963, CTDesign, 1116, 1132, "active - control", "", +27964, Multicenter, 1156, 1170, "49 study sites", "", +8961, Argentina, 1174, 1183, "Argentina", "", +8962, Brazil, 1186, 1192, "Brazil", "", +8963, Colombia, 1195, 1203, "Colombia", "", +8964, Mexico, 1206, 1212, "Mexico", "", +8965, Peru, 1215, 1219, "Peru", "", +8966, USA, 1226, 1239, "United States", "", +8967, Venezuela, 1246, 1255, "Venezuela", "", +8968, Precondition, 1258, 1264, "Adults", "", +8969, Glaucoma, 1270, 1278, "glaucoma", "", +8970, OcularHypertension, 1282, 1301, "ocular hypertension", "", +8971, Precondition, 1302, 1395, "who had failed to reach an IOP of < 21 mm Hg while receiving latanoprost for at least 28 days", "", +8972, IOP, 1329, 1332, "IOP", "", +8973, mmHg, 1341, 1346, "mm Hg", "", +27965, Latanoprost, 1363, 1374, "latanoprost", "", +27966, Latanoprost, 1443, 1454, "latanoprost", "", +27967, Randomized, 1480, 1488, "randomly", "", +27968, Latanoprost, 1510, 1521, "latanoprost", "", +27984, Drug, 1554, 1571, "fixed combination", "Fixed-Combination", +8978, Duration, 1576, 1583, "21 days", "", +8979, IntentionToTreat, 1590, 1609, "intent - to - treat", "", +8980, IntentionToTreat, 1612, 1615, "ITT", "", +27969, DoubleBlind, 1683, 1698, "double - masked", "", +8981, PerProtocol, 1722, 1736, "per - protocol", "", +8982, PerProtocol, 1739, 1741, "PP", "", +8983, IOP, 1842, 1845, "IOP", "", +27971, TimePoint, 1867, 1875, "baseline", "", +27970, TimePoint, 1883, 1889, "day 21", "", +8984, EndPointDescription, 1922, 2017, "proportion of patients whose IOP was decreased > or = 2 mm Hg from the baseline level on day 21", "", +27973, IOP, 1951, 1954, "IOP", "", +27972, mmHg, 1978, 1983, "mm Hg", "", +27974, TimePoint, 2011, 2017, "day 21", "", +27975, IOP, 2058, 2061, "IOP", "", +27976, mmHg, 2106, 2111, "mm Hg", "", +27977, IOP, 2164, 2167, "10P", "", +27978, mmHg, 2178, 2183, "mm Hg", "", +8985, NumberPatientsCT, 2266, 2269, "350", "", +10472, FinalNumPatientsCT, 2304, 2307, "348", "", +10470, IntentionToTreat, 2338, 2341, "ITT", "", +27985, Drug, 2370, 2387, "fixed combination", "Fixed-Combination", +8986, NumberPatientsArm, 2394, 2397, "175", "", +27979, Latanoprost, 2400, 2411, "latanoprost", "", +8987, NumberPatientsArm, 2418, 2421, "173", "", +8988, AvgAge, 2442, 2448, "64 . 4", "", +8989, AvgAge, 2464, 2470, "63 . 2", "", +8990, Female, 2509, 2514, "women", "", +8991, ObservedResult, 2613, 2781, "A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost - treated patients", "", +27986, Drug, 2659, 2676, "fixed combination", "Fixed-Combination", +8992, IOP, 2681, 2684, "IOP", "", +8984, EndPointDescription, 2681, 2715, "IOP decreases of 2 mm Hg on day 21", "", +8993, mmHg, 2700, 2705, "mm Hg", "", +8994, TimePoint, 2709, 2715, "day 21", "", +8996, PercentageAffected, 2784, 2790, "79 . 4", "", +8997, PercentageAffected, 2796, 2802, "51 . 4", "", +8998, PvalueDiff, 2822, 2833, "P < 0 . 001", "", +8981, PerProtocol, 2838, 2840, "PP", "", +9001, ObservedResult, 2861, 2965, "more patients in the fixed - combination group had IOP decreases > or = 3 , > or = 4 , or > or = 5 mm Hg", "", +27987, Drug, 2882, 2901, "fixed - combination", "Fixed-Combination", +9000, IOP, 2912, 2915, "IOP", "", +9005, mmHg, 2960, 2965, "mm Hg", "", +27980, Latanoprost, 3007, 3018, "latanoprost", "", +9002, EndPointDescription, 3030, 3048, "final IOP 18 mm Hg", "", +9003, IOP, 3036, 3039, "IOP", "", +9004, mmHg, 3043, 3048, "mm Hg", "", +9006, PercentageAffected, 3073, 3079, "35 . 1", "", +27981, Latanoprost, 3084, 3095, "latanoprost", "", +9007, PercentageAffected, 3098, 3104, "17 . 8", "", +9008, PvalueDiff, 3109, 3120, "P < 0 . 001", "", +9009, ObservedResult, 3163, 3331, "Similar proportions of patients in the fixed - combination and latanoprost groups reported at least 1 treatment - emergent AE ( 10 . 9 % and 12 . 1 % , respectively ) .", "", +27988, Drug, 3202, 3221, "fixed - combination", "Fixed-Combination", +27990, Latanoprost, 3226, 3237, "latanoprost", "", +9010, PercentageAffected, 3291, 3297, "10 . 9", "", +9011, PercentageAffected, 3304, 3310, "12 . 1", "", +27991, ConclusionComment, 3345, 3593, "In this selected population of patients with an inadequate initial IOP response to latanoprost , switching to fixed - combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost", "", +27993, IOP, 3412, 3415, "IOP", "", +27994, Latanoprost, 3428, 3439, "latanoprost", "", +27989, Drug, 3455, 3493, "fixed - combination latanoprosttimolol", "Fixed-Combination", +27995, IOP, 3528, 3531, "IOP", "", +27996, Latanoprost, 3582, 3593, "latanoprost", "", +27992, ConclusionComment, 3594, 3603, "therapy .", "", +9014, PMID, 3661, 3669, "15598478", "", diff --git a/data/gl 15598478_jshahinitiran.n-triples b/data/gl 15598478_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15598478_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15598478_tstrakeljahn.annodb b/data/gl 15598478_tstrakeljahn.annodb new file mode 100644 index 0000000..75e9146 --- /dev/null +++ b/data/gl 15598478_tstrakeljahn.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30617, Journal, 0, 9, "Clin Ther", "", +30618, PublicationYear, 12, 16, "2004", "", +30660, Title, 47, 237, "Switching from latanoprost to fixed - combination latanoprost - timolol : a 21 - day , randomized , double - masked , active - control study in patients with glaucoma and ocular hypertension", "", +30619, Latanoprost, 62, 73, "latanoprost", "", +30620, Latanoprost, 97, 108, "latanoprost", "", +30621, Timolol, 111, 118, "timolol", "", +30622, Duration, 123, 131, "21 - day", "", +30623, Randomized, 134, 144, "randomized", "", +30624, DoubleBlind, 147, 162, "double - masked", "", +30625, Glaucoma, 205, 213, "glaucoma", "", +30626, OcularHypertension, 218, 237, "ocular hypertension", "", +30627, Author, 240, 249, "Olander K", "", +30628, Author, 258, 270, "Zimmerman TJ", "", +30629, Author, 273, 281, "Downes N", "", +30630, Author, 284, 298, "Schoenfelder J", "", +30631, Latanoprost, 311, 322, "Latanoprost", "", +30632, USA, 432, 435, "USA", "", +30633, IOP, 566, 586, "intraocular pressure", "", +30634, IOP, 589, 592, "IOP", "", +30635, Frequency, 692, 704, "once - daily", "", +30658, ObjectiveDescription, 763, 1017, "The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0 . 005 % + timolol maleate 0 . 5 % QD with those of latanoprost 0 . 005 % monotherapy QD in patients whose elevated IOP ( > or = 21 mm Hg ) was", "", +30636, Latanoprost, 861, 872, "latanoprost", "", +30639, DoseValue, 873, 880, "0 . 005", "", +30637, Timolol, 885, 900, "timolol maleate", "", +30640, DoseValue, 901, 906, "0 . 5", "", +30642, Percentage, 907, 908, "%", "", +30638, Latanoprost, 926, 937, "latanoprost", "", +30641, DoseValue, 938, 945, "0 . 005", "", +30643, Percentage, 946, 947, "%", "", +30644, Frequency, 960, 962, "QD", "", +30645, IOP, 990, 993, "IOP", "", +30646, mmHg, 1006, 1011, "mm Hg", "", +30659, ObjectiveDescription, 1018, 1058, "inadequately controlled by latanoprost .", "", +30647, Latanoprost, 1045, 1056, "latanoprost", "", +30648, Duration, 1074, 1082, "21 - day", "", +30649, Randomized, 1085, 1095, "randomized", "", +30650, DoubleBlind, 1098, 1113, "double - masked", "", +30651, Argentina, 1174, 1183, "Argentina", "", +30652, Brazil, 1186, 1192, "Brazil", "", +30653, Colombia, 1195, 1203, "Colombia", "", +30654, Mexico, 1206, 1212, "Mexico", "", +30655, Peru, 1215, 1219, "Peru", "", +30656, USA, 1226, 1239, "United States", "", +30657, Venezuela, 1246, 1255, "Venezuela", "", +30661, Glaucoma, 1270, 1278, "glaucoma", "", +30662, OcularHypertension, 1282, 1301, "ocular hypertension", "", +30663, IOP, 1329, 1332, "IOP", "", +30664, mmHg, 1341, 1346, "mm Hg", "", +30665, Latanoprost, 1363, 1374, "latanoprost", "", +30666, Latanoprost, 1443, 1454, "latanoprost", "", +30668, Randomized, 1480, 1497, "randomly assigned", "", +30669, Latanoprost, 1510, 1521, "latanoprost", "", +30670, IOP, 1842, 1845, "IOP", "", +30671, IOP, 1951, 1954, "IOP", "", +30672, mmHg, 1978, 1983, "mm Hg", "", +30673, IOP, 2058, 2061, "IOP", "", +30674, mmHg, 2106, 2111, "mm Hg", "", +30675, IOP, 2164, 2167, "10P", "", +30676, mmHg, 2178, 2183, "mm Hg", "", +30677, NumberPatientsCT, 2266, 2269, "350", "", +30678, NumberPatientsArm, 2394, 2397, "175", "", +30680, Latanoprost, 2400, 2411, "latanoprost", "", +30679, NumberPatientsArm, 2418, 2421, "173", "", +30681, Mean, 2424, 2428, "mean", "", +30682, AvgAge, 2442, 2448, "64 . 4", "", +30683, AvgAge, 2464, 2470, "63 . 2", "", +30684, Female, 2505, 2508, "103", "", +30685, ObservedResult, 2533, 2612, "Baseline demographic and clinical characteristics were similar between groups .", "", +30686, IOP, 2681, 2684, "IOP", "", +30687, Reduction, 2698, 2699, "2", "", +30688, mmHg, 2700, 2705, "mm Hg", "", +30689, TimePoint, 2709, 2715, "day 21", "", +30690, Latanoprost, 2751, 2762, "latanoprost", "", +30691, PercentageAffected, 2784, 2790, "79 . 4", "", +30692, PercentageAffected, 2796, 2802, "51 . 4", "", +30693, PvalueDiff, 2822, 2833, "P < 0 . 001", "", +30694, IOP, 2912, 2915, "IOP", "", +30695, mmHg, 2960, 2965, "mm Hg", "", +30696, PvalueDiff, 2992, 3003, "P < 0 . 001", "", +30697, IOP, 3036, 3039, "IOP", "", +30698, ResultMeasuredValue, 3040, 3042, "18", "", +30699, mmHg, 3043, 3048, "mm Hg", "", +30700, PercentageAffected, 3073, 3079, "35 . 1", "", +30701, Latanoprost, 3084, 3095, "latanoprost", "", +30702, PercentageAffected, 3098, 3104, "17 . 8", "", +30703, PvalueDiff, 3109, 3120, "P < 0 . 001", "", +30704, ObservedResult, 3125, 3162, "Both treatments were well tolerated .", "", +30709, ObservedResult, 3163, 3331, "Similar proportions of patients in the fixed - combination and latanoprost groups reported at least 1 treatment - emergent AE ( 10 . 9 % and 12 . 1 % , respectively ) .", "", +30705, Latanoprost, 3226, 3237, "latanoprost", "", +30707, PercentageAffected, 3291, 3297, "10 . 9", "", +30708, PercentageAffected, 3304, 3310, "12 . 1", "", +30716, ConclusionComment, 3345, 3593, "In this selected population of patients with an inadequate initial IOP response to latanoprost , switching to fixed - combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost", "", +30710, IOP, 3412, 3415, "IOP", "", +30711, Latanoprost, 3428, 3439, "latanoprost", "", +30712, Drug, 3455, 3493, "fixed - combination latanoprosttimolol", "Fixed Combination Latanoprost Timolol", +30713, IOP, 3528, 3531, "IOP", "", +30714, Latanoprost, 3582, 3593, "latanoprost", "", +30717, ConclusionComment, 3594, 3603, "therapy .", "", +30715, PMID, 3661, 3669, "15598478", "", diff --git a/data/gl 15598478_tstrakeljahn.n-triples b/data/gl 15598478_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15598478_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15741820_admin.annodb b/data/gl 15741820_admin.annodb new file mode 100644 index 0000000..d1b1cd6 --- /dev/null +++ b/data/gl 15741820_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2005", "", " \"2005\"." +38, Latanoprost, 45, 56, "Latanoprost", "", +2, Title, 45, 161, "Latanoprost or brimonidine as treatment for elevated intraocular pressure : multicenter trial in the United States .", "", " \"Latanoprost or brimonidine as treatment for elevated intraocular pressure : multicenter trial in the United States .\"." +39, Brimonidine, 60, 71, "brimonidine", "", +40, IOP, 98, 118, "intraocular pressure", "", +41, Multicenter, 121, 132, "multicenter", "", " ." +42, USA, 146, 159, "United States", "", " ." +3, Author, 162, 171, "Camras CB", "", " \"Camras CB\"." +4, Author, 180, 187, "Sheu WP", "", " \"Sheu WP\"." +43, USA, 190, 203, "United States", "", +44, Latanoprost, 204, 215, "Latanoprost", "", +45, Brimonidine, 218, 229, "Brimonidine", "", +46, USA, 373, 376, "USA", "", +5, ObjectiveDescription, 411, 536, "To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure ( IOP )", "", " \"To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure ( IOP )\"." +47, Latanoprost, 455, 466, "latanoprost", "", +48, Brimonidine, 470, 481, "brimonidine", "", +54379, Precondition, 485, 536, "patients with elevated intraocular pressure ( IOP )", "", " \"patients with elevated intraocular pressure ( IOP )\"." +49, IOP, 508, 528, "intraocular pressure", "", +50, IOP, 531, 534, "IOP", "", +37049, Prospective, 568, 579, "prospective", "", " ." +51, Randomized, 582, 592, "randomized", "", " ." +34683, Blind, 595, 601, "masked", "", " ." +8, Parallel, 616, 624, "parallel", "", " ." +52, Multicenter, 635, 646, "multicenter", "", +53, USA, 660, 673, "United States", "", +54, Primary_OpenAngleGlaucoma, 697, 724, "primary open angle glaucoma", "", " ." +9, OcularHypertension, 728, 747, "ocular hypertension", "", " ." +55, Latanoprost, 768, 779, "latanoprost", "", " . ." +10, DoseValue, 780, 787, "0 . 005", "", " \"0 . 005\"." +11, Percentage, 788, 789, "%", "", " ." +12, Frequency, 790, 800, "once daily", "", " \"once daily\"." +13, NumberPatientsArm, 819, 822, "152", "", " \"152\"." +56, Brimonidine, 828, 848, "brimonidine tartrate", "", " ." +14, DoseValue, 849, 854, "0 . 2", "", " \"0 . 2\"." +15, Percentage, 855, 856, "%", "", " ." +16, Frequency, 857, 868, "twice daily", "", " \"twice daily\"." +17, NumberPatientsArm, 901, 904, "151", "", " \"151\"." +59, TimePoint, 954, 962, "baseline", "", +57, Randomized, 965, 978, "randomization", "", +58, TimePoint, 993, 1017, "0 . 5 , 3 , and 6 months", "", +37050, TimePoint, 1001, 1017, "3 , and 6 months", "", +37051, TimePoint, 1009, 1017, "6 months", "", +18, IOP, 1033, 1036, "IOP", "", +60, TimePoint, 1102, 1110, "baseline", "", +61, TimePoint, 1119, 1133, "months 3 and 6", "", +37052, TimePoint, 1119, 1127, "months 3", "", +62, TimePoint, 1168, 1174, "week 2", "", +63, Diurnal_IOP, 1224, 1235, "diurnal IOP", "", +64, TimePoint, 1248, 1256, "baseline", "", +65, TimePoint, 1260, 1267, "month 6", "", +66, Mean, 1359, 1363, "mean", "", " . ." +67, Diurnal_IOP, 1364, 1375, "diurnal IOP", "", " ." +68, TimePoint, 1416, 1423, "month 6", "", " \"month 6\". \"month 6\"." +69, Mean, 1439, 1443, "mean", "", +70, Diurnal_IOP, 1458, 1469, "diurnal IOP", "", +19, Reduction, 1484, 1489, "5 . 7", "", +20, SdErrorChangeValue, 1496, 1501, "0 . 3", "", " \"0 . 3\"." +21, mmHg, 1502, 1507, "mm Hg", "", " ." +71, Latanoprost, 1515, 1526, "latanoprost", "", +22, Reduction, 1537, 1542, "3 . 1", "", " \"3 . 1\"." +23, SdErrorChangeValue, 1549, 1554, "0 . 3", "", " \"0 . 3\"." +24, mmHg, 1555, 1560, "mm Hg", "", +72, Brimonidine, 1583, 1594, "brimonidine", "", +127, PvalueDiff, 1597, 1608, "P < 0 . 001", "", +73, Mean, 1617, 1621, "mean", "", +74, Diurnal_IOP, 1636, 1647, "diurnal IOP", "", +130, DiffGroupAbsValue, 1662, 1667, "2 . 5", "", " \"2 . 5\"." +34691, SdDevDiff, 1674, 1679, "0 . 3", "", " \"0 . 3\"." +29, mmHg, 1680, 1685, "mm Hg", "", +28, ConfIntervalDiff, 1688, 1711, "95 % CI : 1 . 9 , 3 . 2", "", " \"95 % CI : 1 . 9 , 3 . 2\"." +30, PvalueDiff, 1714, 1725, "P < 0 . 001", "", " \"P < 0 . 001\"." +75, Brimonidine, 1765, 1776, "brimonidine", "", +76, Latanoprost, 1782, 1793, "latanoprost", "", +77, Latanoprost, 1861, 1872, "Latanoprost", "", +144, ConclusionComment, 1861, 2043, "Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension .", "", " \"Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension .\"." +12, Frequency, 1883, 1893, "once daily", "", " \"once daily\"." +78, Brimonidine, 1938, 1949, "brimonidine", "", +16, Frequency, 1963, 1974, "twice daily", "", " \"twice daily\"." +31, Glaucoma, 2010, 2018, "glaucoma", "", " . ." +32, OcularHypertension, 2022, 2041, "ocular hypertension", "", +37, ConclusionComment, 2044, 2150, "During therapy , the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine .", "", " \"During therapy , the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine .\"." +33, IOP, 2095, 2098, "IOP", "", +79, Latanoprost, 2111, 2122, "latanoprost", "", +80, Brimonidine, 2137, 2148, "brimonidine", "", +35, PMID, 2158, 2166, "15741820", "", " \"15741820\"." diff --git a/data/gl 15741820_admin.n-triples b/data/gl 15741820_admin.n-triples new file mode 100644 index 0000000..a280232 --- /dev/null +++ b/data/gl 15741820_admin.n-triples @@ -0,0 +1,107 @@ +# RDF export of group: Publication + . + "Publication" . + "Latanoprost or brimonidine as treatment for elevated intraocular pressure : multicenter trial in the United States ." . + "Camras CB" . + "2005" . + "J Glaucoma" . + "15741820" . + . + "Sheu WP" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure ( IOP )" . + . + . + . + "Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension ." . + . + . + . + . + . + . + . + . + . + "During therapy , the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with elevated intraocular pressure ( IOP )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm-bri" . + "151" . + . + . + . + . + "Arm-lat" . + "152" . + . + . + . +# RDF export of group: Intervention + . + "Intervention-lat" . + . + "once daily" . + . + . + "Intervention-bri" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication-lat" . + . + . + "0 . 005" . + . + . + . + "Medication-bri" . + . + "0 . 2" . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-lat" . + . + "0 . 3" . + "month 6" . + . + "Outcome-iop-bri" . + . + "3 . 1" . + "0 . 3" . + "month 6" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "2 . 5" . + "P < 0 . 001" . + "95 % CI : 1 . 9 , 3 . 2" . + "0 . 3" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15741820_export.csv b/data/gl 15741820_export.csv new file mode 100644 index 0000000..8b59c58 --- /dev/null +++ b/data/gl 15741820_export.csv @@ -0,0 +1,454 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +460, 1, 1, 1, 0, 1, 0, 1, "J" +460, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +460, 1, 3, 3, 11, 12, 11, 12, "." +460, 2, 1, 4, 0, 4, 13, 17, "2005" +460, 2, 2, 5, 5, 8, 18, 21, "Apr" +460, 2, 3, 6, 9, 10, 22, 23, ";" +460, 2, 4, 7, 11, 13, 24, 26, "14" +460, 2, 5, 8, 14, 15, 27, 28, "(" +460, 2, 6, 9, 16, 17, 29, 30, "2" +460, 2, 7, 10, 18, 19, 31, 32, ")" +460, 2, 8, 11, 20, 21, 33, 34, ":" +460, 2, 9, 12, 22, 25, 35, 38, "161" +460, 2, 10, 13, 26, 27, 39, 40, "-" +460, 2, 11, 14, 28, 29, 41, 42, "7" +460, 2, 12, 15, 30, 31, 43, 44, "." +460, 3, 1, 16, 0, 11, 45, 56, "Latanoprost" +460, 3, 2, 17, 12, 14, 57, 59, "or" +460, 3, 3, 18, 15, 26, 60, 71, "brimonidine" +460, 3, 4, 19, 27, 29, 72, 74, "as" +460, 3, 5, 20, 30, 39, 75, 84, "treatment" +460, 3, 6, 21, 40, 43, 85, 88, "for" +460, 3, 7, 22, 44, 52, 89, 97, "elevated" +460, 3, 8, 23, 53, 64, 98, 109, "intraocular" +460, 3, 9, 24, 65, 73, 110, 118, "pressure" +460, 3, 10, 25, 74, 75, 119, 120, ":" +460, 3, 11, 26, 76, 87, 121, 132, "multicenter" +460, 3, 12, 27, 88, 93, 133, 138, "trial" +460, 3, 13, 28, 94, 96, 139, 141, "in" +460, 3, 14, 29, 97, 100, 142, 145, "the" +460, 3, 15, 30, 101, 107, 146, 152, "United" +460, 3, 16, 31, 108, 114, 153, 159, "States" +460, 3, 17, 32, 115, 116, 160, 161, "." +460, 4, 1, 33, 0, 6, 162, 168, "Camras" +460, 4, 2, 34, 7, 9, 169, 171, "CB" +460, 4, 3, 35, 10, 11, 172, 173, "(" +460, 4, 4, 36, 12, 13, 174, 175, "1" +460, 4, 5, 37, 14, 15, 176, 177, ")" +460, 4, 6, 38, 16, 17, 178, 179, "," +460, 4, 7, 39, 18, 22, 180, 184, "Sheu" +460, 4, 8, 40, 23, 25, 185, 187, "WP" +460, 4, 9, 41, 26, 27, 188, 189, ";" +460, 4, 10, 42, 28, 34, 190, 196, "United" +460, 4, 11, 43, 35, 41, 197, 203, "States" +460, 4, 12, 44, 42, 53, 204, 215, "Latanoprost" +460, 4, 13, 45, 54, 55, 216, 217, "-" +460, 4, 14, 46, 56, 67, 218, 229, "Brimonidine" +460, 4, 15, 47, 68, 73, 230, 235, "Study" +460, 4, 16, 48, 74, 79, 236, 241, "Group" +460, 4, 17, 49, 80, 81, 242, 243, "." +460, 5, 1, 50, 0, 6, 244, 250, "Author" +460, 5, 2, 51, 7, 18, 251, 262, "information" +460, 5, 3, 52, 19, 20, 263, 264, ":" +460, 5, 4, 53, 21, 22, 265, 266, "(" +460, 5, 5, 54, 23, 24, 267, 268, "1" +460, 5, 6, 55, 25, 26, 269, 270, ")" +460, 5, 7, 56, 27, 37, 271, 281, "Department" +460, 5, 8, 57, 38, 40, 282, 284, "of" +460, 5, 9, 58, 41, 54, 285, 298, "Ophthalmology" +460, 5, 10, 59, 55, 56, 299, 300, "," +460, 5, 11, 60, 57, 67, 301, 311, "University" +460, 5, 12, 61, 68, 70, 312, 314, "of" +460, 5, 13, 62, 71, 79, 315, 323, "Nebraska" +460, 5, 14, 63, 80, 87, 324, 331, "Medical" +460, 5, 15, 64, 88, 94, 332, 338, "Center" +460, 5, 16, 65, 95, 96, 339, 340, "," +460, 5, 17, 66, 97, 102, 341, 346, "Omaha" +460, 5, 18, 67, 103, 104, 347, 348, "," +460, 5, 19, 68, 105, 113, 349, 357, "Nebraska" +460, 5, 20, 69, 114, 119, 358, 363, "68198" +460, 5, 21, 70, 120, 121, 364, 365, "-" +460, 5, 22, 71, 122, 126, 366, 370, "5540" +460, 5, 23, 72, 127, 128, 371, 372, "," +460, 5, 24, 73, 129, 132, 373, 376, "USA" +460, 5, 25, 74, 133, 134, 377, 378, "." +460, 6, 1, 75, 0, 8, 379, 387, "cbcamras" +460, 6, 2, 76, 9, 10, 388, 389, "@" +460, 6, 3, 77, 11, 15, 390, 394, "unmc" +460, 6, 4, 78, 16, 17, 395, 396, "." +460, 6, 5, 79, 18, 21, 397, 400, "edu" +460, 6, 6, 80, 22, 29, 401, 408, "PURPOSE" +460, 6, 7, 81, 30, 31, 409, 410, ":" +460, 6, 8, 82, 32, 34, 411, 413, "To" +460, 6, 9, 83, 35, 42, 414, 421, "compare" +460, 6, 10, 84, 43, 46, 422, 425, "the" +460, 6, 11, 85, 47, 55, 426, 434, "efficacy" +460, 6, 12, 86, 56, 59, 435, 438, "and" +460, 6, 13, 87, 60, 72, 439, 451, "tolerability" +460, 6, 14, 88, 73, 75, 452, 454, "of" +460, 6, 15, 89, 76, 87, 455, 466, "latanoprost" +460, 6, 16, 90, 88, 90, 467, 469, "or" +460, 6, 17, 91, 91, 102, 470, 481, "brimonidine" +460, 6, 18, 92, 103, 105, 482, 484, "in" +460, 6, 19, 93, 106, 114, 485, 493, "patients" +460, 6, 20, 94, 115, 119, 494, 498, "with" +460, 6, 21, 95, 120, 128, 499, 507, "elevated" +460, 6, 22, 96, 129, 140, 508, 519, "intraocular" +460, 6, 23, 97, 141, 149, 520, 528, "pressure" +460, 6, 24, 98, 150, 151, 529, 530, "(" +460, 6, 25, 99, 152, 155, 531, 534, "IOP" +460, 6, 26, 100, 156, 157, 535, 536, ")" +460, 6, 27, 101, 158, 159, 537, 538, "." +460, 7, 1, 102, 0, 9, 539, 548, "MATERIALS" +460, 7, 2, 103, 10, 13, 549, 552, "AND" +460, 7, 3, 104, 14, 21, 553, 560, "METHODS" +460, 7, 4, 105, 22, 23, 561, 562, ":" +460, 7, 5, 106, 24, 28, 563, 567, "This" +460, 7, 6, 107, 29, 40, 568, 579, "prospective" +460, 7, 7, 108, 41, 42, 580, 581, "," +460, 7, 8, 109, 43, 53, 582, 592, "randomized" +460, 7, 9, 110, 54, 55, 593, 594, "," +460, 7, 10, 111, 56, 62, 595, 601, "masked" +460, 7, 11, 112, 63, 64, 602, 603, "-" +460, 7, 12, 113, 65, 74, 604, 613, "evaluator" +460, 7, 13, 114, 75, 76, 614, 615, "," +460, 7, 14, 115, 77, 85, 616, 624, "parallel" +460, 7, 15, 116, 86, 87, 625, 626, "-" +460, 7, 16, 117, 88, 93, 627, 632, "group" +460, 7, 17, 118, 94, 95, 633, 634, "," +460, 7, 18, 119, 96, 107, 635, 646, "multicenter" +460, 7, 19, 120, 108, 113, 647, 652, "study" +460, 7, 20, 121, 114, 116, 653, 655, "in" +460, 7, 21, 122, 117, 120, 656, 659, "the" +460, 7, 22, 123, 121, 127, 660, 666, "United" +460, 7, 23, 124, 128, 134, 667, 673, "States" +460, 7, 24, 125, 135, 143, 674, 682, "included" +460, 7, 25, 126, 144, 152, 683, 691, "patients" +460, 7, 26, 127, 153, 157, 692, 696, "with" +460, 7, 27, 128, 158, 165, 697, 704, "primary" +460, 7, 28, 129, 166, 170, 705, 709, "open" +460, 7, 29, 130, 171, 176, 710, 715, "angle" +460, 7, 30, 131, 177, 185, 716, 724, "glaucoma" +460, 7, 31, 132, 186, 188, 725, 727, "or" +460, 7, 32, 133, 189, 195, 728, 734, "ocular" +460, 7, 33, 134, 196, 208, 735, 747, "hypertension" +460, 7, 34, 135, 209, 210, 748, 749, "." +460, 8, 1, 136, 0, 8, 750, 758, "Patients" +460, 8, 2, 137, 9, 17, 759, 767, "received" +460, 8, 3, 138, 18, 29, 768, 779, "latanoprost" +460, 8, 4, 139, 30, 31, 780, 781, "0" +460, 8, 5, 140, 32, 33, 782, 783, "." +460, 8, 6, 141, 34, 37, 784, 787, "005" +460, 8, 7, 142, 38, 39, 788, 789, "%" +460, 8, 8, 143, 40, 44, 790, 794, "once" +460, 8, 9, 144, 45, 50, 795, 800, "daily" +460, 8, 10, 145, 51, 52, 801, 802, "(" +460, 8, 11, 146, 53, 54, 803, 804, "8" +460, 8, 12, 147, 55, 56, 805, 806, ":" +460, 8, 13, 148, 57, 59, 807, 809, "00" +460, 8, 14, 149, 60, 62, 810, 812, "AM" +460, 8, 15, 150, 63, 64, 813, 814, ";" +460, 8, 16, 151, 65, 66, 815, 816, "n" +460, 8, 17, 152, 67, 68, 817, 818, "=" +460, 8, 18, 153, 69, 72, 819, 822, "152" +460, 8, 19, 154, 73, 74, 823, 824, ")" +460, 8, 20, 155, 75, 77, 825, 827, "or" +460, 8, 21, 156, 78, 89, 828, 839, "brimonidine" +460, 8, 22, 157, 90, 98, 840, 848, "tartrate" +460, 8, 23, 158, 99, 100, 849, 850, "0" +460, 8, 24, 159, 101, 102, 851, 852, "." +460, 8, 25, 160, 103, 104, 853, 854, "2" +460, 8, 26, 161, 105, 106, 855, 856, "%" +460, 8, 27, 162, 107, 112, 857, 862, "twice" +460, 8, 28, 163, 113, 118, 863, 868, "daily" +460, 8, 29, 164, 119, 120, 869, 870, "(" +460, 8, 30, 165, 121, 122, 871, 872, "8" +460, 8, 31, 166, 123, 124, 873, 874, ":" +460, 8, 32, 167, 125, 127, 875, 877, "00" +460, 8, 33, 168, 128, 130, 878, 880, "AM" +460, 8, 34, 169, 131, 134, 881, 884, "and" +460, 8, 35, 170, 135, 136, 885, 886, "8" +460, 8, 36, 171, 137, 138, 887, 888, ":" +460, 8, 37, 172, 139, 141, 889, 891, "00" +460, 8, 38, 173, 142, 144, 892, 894, "PM" +460, 8, 39, 174, 145, 146, 895, 896, ";" +460, 8, 40, 175, 147, 148, 897, 898, "n" +460, 8, 41, 176, 149, 150, 899, 900, "=" +460, 8, 42, 177, 151, 154, 901, 904, "151" +460, 8, 43, 178, 155, 156, 905, 906, ")" +460, 8, 44, 179, 157, 158, 907, 908, "." +460, 9, 1, 180, 0, 8, 909, 917, "Patients" +460, 9, 2, 181, 9, 18, 918, 927, "underwent" +460, 9, 3, 182, 19, 29, 928, 938, "evaluation" +460, 9, 4, 183, 30, 32, 939, 941, "at" +460, 9, 5, 184, 33, 42, 942, 951, "screening" +460, 9, 6, 185, 43, 44, 952, 953, "," +460, 9, 7, 186, 45, 53, 954, 962, "baseline" +460, 9, 8, 187, 54, 55, 963, 964, "(" +460, 9, 9, 188, 56, 69, 965, 978, "randomization" +460, 9, 10, 189, 70, 71, 979, 980, ")" +460, 9, 11, 190, 72, 73, 981, 982, "," +460, 9, 12, 191, 74, 77, 983, 986, "and" +460, 9, 13, 192, 78, 83, 987, 992, "after" +460, 9, 14, 193, 84, 85, 993, 994, "0" +460, 9, 15, 194, 86, 87, 995, 996, "." +460, 9, 16, 195, 88, 89, 997, 998, "5" +460, 9, 17, 196, 90, 91, 999, 1000, "," +460, 9, 18, 197, 92, 93, 1001, 1002, "3" +460, 9, 19, 198, 94, 95, 1003, 1004, "," +460, 9, 20, 199, 96, 99, 1005, 1008, "and" +460, 9, 21, 200, 100, 101, 1009, 1010, "6" +460, 9, 22, 201, 102, 108, 1011, 1017, "months" +460, 9, 23, 202, 109, 111, 1018, 1020, "of" +460, 9, 24, 203, 112, 121, 1021, 1030, "treatment" +460, 9, 25, 204, 122, 123, 1031, 1032, "." +460, 10, 1, 205, 0, 3, 1033, 1036, "IOP" +460, 10, 2, 206, 4, 7, 1037, 1040, "was" +460, 10, 3, 207, 8, 16, 1041, 1049, "measured" +460, 10, 4, 208, 17, 19, 1050, 1052, "at" +460, 10, 5, 209, 20, 21, 1053, 1054, "8" +460, 10, 6, 210, 22, 23, 1055, 1056, ":" +460, 10, 7, 211, 24, 26, 1057, 1059, "00" +460, 10, 8, 212, 27, 29, 1060, 1062, "AM" +460, 10, 9, 213, 30, 31, 1063, 1064, "," +460, 10, 10, 214, 32, 34, 1065, 1067, "10" +460, 10, 11, 215, 35, 36, 1068, 1069, ":" +460, 10, 12, 216, 37, 39, 1070, 1072, "00" +460, 10, 13, 217, 40, 42, 1073, 1075, "AM" +460, 10, 14, 218, 43, 44, 1076, 1077, "," +460, 10, 15, 219, 45, 49, 1078, 1082, "noon" +460, 10, 16, 220, 50, 51, 1083, 1084, "," +460, 10, 17, 221, 52, 55, 1085, 1088, "and" +460, 10, 18, 222, 56, 57, 1089, 1090, "4" +460, 10, 19, 223, 58, 59, 1091, 1092, ":" +460, 10, 20, 224, 60, 62, 1093, 1095, "00" +460, 10, 21, 225, 63, 65, 1096, 1098, "PM" +460, 10, 22, 226, 66, 68, 1099, 1101, "at" +460, 10, 23, 227, 69, 77, 1102, 1110, "baseline" +460, 10, 24, 228, 78, 81, 1111, 1114, "and" +460, 10, 25, 229, 82, 85, 1115, 1118, "the" +460, 10, 26, 230, 86, 92, 1119, 1125, "months" +460, 10, 27, 231, 93, 94, 1126, 1127, "3" +460, 10, 28, 232, 95, 98, 1128, 1131, "and" +460, 10, 29, 233, 99, 100, 1132, 1133, "6" +460, 10, 30, 234, 101, 107, 1134, 1140, "visits" +460, 10, 31, 235, 108, 109, 1141, 1142, "," +460, 10, 32, 236, 110, 113, 1143, 1146, "and" +460, 10, 33, 237, 114, 116, 1147, 1149, "at" +460, 10, 34, 238, 117, 118, 1150, 1151, "8" +460, 10, 35, 239, 119, 120, 1152, 1153, ":" +460, 10, 36, 240, 121, 123, 1154, 1156, "00" +460, 10, 37, 241, 124, 126, 1157, 1159, "AM" +460, 10, 38, 242, 127, 131, 1160, 1164, "only" +460, 10, 39, 243, 132, 134, 1165, 1167, "at" +460, 10, 40, 244, 135, 139, 1168, 1172, "week" +460, 10, 41, 245, 140, 141, 1173, 1174, "2" +460, 10, 42, 246, 142, 143, 1175, 1176, "." +460, 11, 1, 247, 0, 3, 1177, 1180, "The" +460, 11, 2, 248, 4, 8, 1181, 1185, "main" +460, 11, 3, 249, 9, 16, 1186, 1193, "outcome" +460, 11, 4, 250, 17, 24, 1194, 1201, "measure" +460, 11, 5, 251, 25, 28, 1202, 1205, "was" +460, 11, 6, 252, 29, 32, 1206, 1209, "the" +460, 11, 7, 253, 33, 43, 1210, 1220, "difference" +460, 11, 8, 254, 44, 46, 1221, 1223, "in" +460, 11, 9, 255, 47, 54, 1224, 1231, "diurnal" +460, 11, 10, 256, 55, 58, 1232, 1235, "IOP" +460, 11, 11, 257, 59, 65, 1236, 1242, "change" +460, 11, 12, 258, 66, 70, 1243, 1247, "from" +460, 11, 13, 259, 71, 79, 1248, 1256, "baseline" +460, 11, 14, 260, 80, 82, 1257, 1259, "to" +460, 11, 15, 261, 83, 88, 1260, 1265, "month" +460, 11, 16, 262, 89, 90, 1266, 1267, "6" +460, 11, 17, 263, 91, 98, 1268, 1275, "between" +460, 11, 18, 264, 99, 108, 1276, 1285, "treatment" +460, 11, 19, 265, 109, 115, 1286, 1292, "groups" +460, 11, 20, 266, 116, 117, 1293, 1294, "." +460, 12, 1, 267, 0, 7, 1295, 1302, "Adverse" +460, 12, 2, 268, 8, 14, 1303, 1309, "events" +460, 12, 3, 269, 15, 19, 1310, 1314, "were" +460, 12, 4, 270, 20, 28, 1315, 1323, "recorded" +460, 12, 5, 271, 29, 31, 1324, 1326, "at" +460, 12, 6, 272, 32, 36, 1327, 1331, "each" +460, 12, 7, 273, 37, 42, 1332, 1337, "visit" +460, 12, 8, 274, 43, 44, 1338, 1339, "." +460, 13, 1, 275, 0, 7, 1340, 1347, "RESULTS" +460, 13, 2, 276, 8, 9, 1348, 1349, ":" +460, 13, 3, 277, 10, 18, 1350, 1358, "Baseline" +460, 13, 4, 278, 19, 23, 1359, 1363, "mean" +460, 13, 5, 279, 24, 31, 1364, 1371, "diurnal" +460, 13, 6, 280, 32, 35, 1372, 1375, "IOP" +460, 13, 7, 281, 36, 42, 1376, 1382, "levels" +460, 13, 8, 282, 43, 47, 1383, 1387, "were" +460, 13, 9, 283, 48, 55, 1388, 1395, "similar" +460, 13, 10, 284, 56, 63, 1396, 1403, "between" +460, 13, 11, 285, 64, 70, 1404, 1410, "groups" +460, 13, 12, 286, 71, 72, 1411, 1412, "." +460, 14, 1, 287, 0, 2, 1413, 1415, "At" +460, 14, 2, 288, 3, 8, 1416, 1421, "month" +460, 14, 3, 289, 9, 10, 1422, 1423, "6" +460, 14, 4, 290, 11, 12, 1424, 1425, "," +460, 14, 5, 291, 13, 16, 1426, 1429, "the" +460, 14, 6, 292, 17, 25, 1430, 1438, "adjusted" +460, 14, 7, 293, 26, 30, 1439, 1443, "mean" +460, 14, 8, 294, 31, 32, 1444, 1445, "(" +460, 14, 9, 295, 33, 34, 1446, 1447, "+" +460, 14, 10, 296, 35, 36, 1448, 1449, "/" +460, 14, 11, 297, 37, 38, 1450, 1451, "-" +460, 14, 12, 298, 39, 42, 1452, 1455, "SEM" +460, 14, 13, 299, 43, 44, 1456, 1457, ")" +460, 14, 14, 300, 45, 52, 1458, 1465, "diurnal" +460, 14, 15, 301, 53, 56, 1466, 1469, "IOP" +460, 14, 16, 302, 57, 66, 1470, 1479, "reduction" +460, 14, 17, 303, 67, 70, 1480, 1483, "was" +460, 14, 18, 304, 71, 72, 1484, 1485, "5" +460, 14, 19, 305, 73, 74, 1486, 1487, "." +460, 14, 20, 306, 75, 76, 1488, 1489, "7" +460, 14, 21, 307, 77, 78, 1490, 1491, "+" +460, 14, 22, 308, 79, 80, 1492, 1493, "/" +460, 14, 23, 309, 81, 82, 1494, 1495, "-" +460, 14, 24, 310, 83, 84, 1496, 1497, "0" +460, 14, 25, 311, 85, 86, 1498, 1499, "." +460, 14, 26, 312, 87, 88, 1500, 1501, "3" +460, 14, 27, 313, 89, 91, 1502, 1504, "mm" +460, 14, 28, 314, 92, 94, 1505, 1507, "Hg" +460, 14, 29, 315, 95, 97, 1508, 1510, "in" +460, 14, 30, 316, 98, 101, 1511, 1514, "the" +460, 14, 31, 317, 102, 113, 1515, 1526, "latanoprost" +460, 14, 32, 318, 114, 119, 1527, 1532, "group" +460, 14, 33, 319, 120, 123, 1533, 1536, "and" +460, 14, 34, 320, 124, 125, 1537, 1538, "3" +460, 14, 35, 321, 126, 127, 1539, 1540, "." +460, 14, 36, 322, 128, 129, 1541, 1542, "1" +460, 14, 37, 323, 130, 131, 1543, 1544, "+" +460, 14, 38, 324, 132, 133, 1545, 1546, "/" +460, 14, 39, 325, 134, 135, 1547, 1548, "-" +460, 14, 40, 326, 136, 137, 1549, 1550, "0" +460, 14, 41, 327, 138, 139, 1551, 1552, "." +460, 14, 42, 328, 140, 141, 1553, 1554, "3" +460, 14, 43, 329, 142, 144, 1555, 1557, "mm" +460, 14, 44, 330, 145, 147, 1558, 1560, "Hg" +460, 14, 45, 331, 148, 150, 1561, 1563, "in" +460, 14, 46, 332, 151, 159, 1564, 1572, "patients" +460, 14, 47, 333, 160, 169, 1573, 1582, "receiving" +460, 14, 48, 334, 170, 181, 1583, 1594, "brimonidine" +460, 14, 49, 335, 182, 183, 1595, 1596, "(" +460, 14, 50, 336, 184, 185, 1597, 1598, "P" +460, 14, 51, 337, 186, 187, 1599, 1600, "<" +460, 14, 52, 338, 188, 189, 1601, 1602, "0" +460, 14, 53, 339, 190, 191, 1603, 1604, "." +460, 14, 54, 340, 192, 195, 1605, 1608, "001" +460, 14, 55, 341, 196, 197, 1609, 1610, ")" +460, 14, 56, 342, 198, 199, 1611, 1612, "." +460, 15, 1, 343, 0, 3, 1613, 1616, "The" +460, 15, 2, 344, 4, 8, 1617, 1621, "mean" +460, 15, 3, 345, 9, 19, 1622, 1632, "difference" +460, 15, 4, 346, 20, 22, 1633, 1635, "in" +460, 15, 5, 347, 23, 30, 1636, 1643, "diurnal" +460, 15, 6, 348, 31, 34, 1644, 1647, "IOP" +460, 15, 7, 349, 35, 44, 1648, 1657, "reduction" +460, 15, 8, 350, 45, 48, 1658, 1661, "was" +460, 15, 9, 351, 49, 50, 1662, 1663, "2" +460, 15, 10, 352, 51, 52, 1664, 1665, "." +460, 15, 11, 353, 53, 54, 1666, 1667, "5" +460, 15, 12, 354, 55, 56, 1668, 1669, "+" +460, 15, 13, 355, 57, 58, 1670, 1671, "/" +460, 15, 14, 356, 59, 60, 1672, 1673, "-" +460, 15, 15, 357, 61, 62, 1674, 1675, "0" +460, 15, 16, 358, 63, 64, 1676, 1677, "." +460, 15, 17, 359, 65, 66, 1678, 1679, "3" +460, 15, 18, 360, 67, 69, 1680, 1682, "mm" +460, 15, 19, 361, 70, 72, 1683, 1685, "Hg" +460, 15, 20, 362, 73, 74, 1686, 1687, "(" +460, 15, 21, 363, 75, 77, 1688, 1690, "95" +460, 15, 22, 364, 78, 79, 1691, 1692, "%" +460, 15, 23, 365, 80, 82, 1693, 1695, "CI" +460, 15, 24, 366, 83, 84, 1696, 1697, ":" +460, 15, 25, 367, 85, 86, 1698, 1699, "1" +460, 15, 26, 368, 87, 88, 1700, 1701, "." +460, 15, 27, 369, 89, 90, 1702, 1703, "9" +460, 15, 28, 370, 91, 92, 1704, 1705, "," +460, 15, 29, 371, 93, 94, 1706, 1707, "3" +460, 15, 30, 372, 95, 96, 1708, 1709, "." +460, 15, 31, 373, 97, 98, 1710, 1711, "2" +460, 15, 32, 374, 99, 100, 1712, 1713, ";" +460, 15, 33, 375, 101, 102, 1714, 1715, "P" +460, 15, 34, 376, 103, 104, 1716, 1717, "<" +460, 15, 35, 377, 105, 106, 1718, 1719, "0" +460, 15, 36, 378, 107, 108, 1720, 1721, "." +460, 15, 37, 379, 109, 112, 1722, 1725, "001" +460, 15, 38, 380, 113, 114, 1726, 1727, ")" +460, 15, 39, 381, 115, 116, 1728, 1729, "." +460, 16, 1, 382, 0, 4, 1730, 1734, "Five" +460, 16, 2, 383, 5, 10, 1735, 1740, "times" +460, 16, 3, 384, 11, 15, 1741, 1745, "more" +460, 16, 4, 385, 16, 24, 1746, 1754, "patients" +460, 16, 5, 386, 25, 34, 1755, 1764, "receiving" +460, 16, 6, 387, 35, 46, 1765, 1776, "brimonidine" +460, 16, 7, 388, 47, 51, 1777, 1781, "than" +460, 16, 8, 389, 52, 63, 1782, 1793, "latanoprost" +460, 16, 9, 390, 64, 68, 1794, 1798, "were" +460, 16, 10, 391, 69, 78, 1799, 1808, "withdrawn" +460, 16, 11, 392, 79, 83, 1809, 1813, "from" +460, 16, 12, 393, 84, 87, 1814, 1817, "the" +460, 16, 13, 394, 88, 93, 1818, 1823, "study" +460, 16, 14, 395, 94, 97, 1824, 1827, "due" +460, 16, 15, 396, 98, 100, 1828, 1830, "to" +460, 16, 16, 397, 101, 108, 1831, 1838, "adverse" +460, 16, 17, 398, 109, 115, 1839, 1845, "events" +460, 16, 18, 399, 116, 117, 1846, 1847, "." +460, 17, 1, 400, 0, 10, 1848, 1858, "CONCLUSION" +460, 17, 2, 401, 11, 12, 1859, 1860, ":" +460, 17, 3, 402, 13, 24, 1861, 1872, "Latanoprost" +460, 17, 4, 403, 25, 34, 1873, 1882, "instilled" +460, 17, 5, 404, 35, 39, 1883, 1887, "once" +460, 17, 6, 405, 40, 45, 1888, 1893, "daily" +460, 17, 7, 406, 46, 48, 1894, 1896, "is" +460, 17, 8, 407, 49, 53, 1897, 1901, "more" +460, 17, 9, 408, 54, 63, 1902, 1911, "effective" +460, 17, 10, 409, 64, 67, 1912, 1915, "and" +460, 17, 11, 410, 68, 74, 1916, 1922, "better" +460, 17, 12, 411, 75, 84, 1923, 1932, "tolerated" +460, 17, 13, 412, 85, 89, 1933, 1937, "than" +460, 17, 14, 413, 90, 101, 1938, 1949, "brimonidine" +460, 17, 15, 414, 102, 114, 1950, 1962, "administered" +460, 17, 16, 415, 115, 120, 1963, 1968, "twice" +460, 17, 17, 416, 121, 126, 1969, 1974, "daily" +460, 17, 18, 417, 127, 130, 1975, 1978, "for" +460, 17, 19, 418, 131, 134, 1979, 1982, "the" +460, 17, 20, 419, 135, 144, 1983, 1992, "treatment" +460, 17, 21, 420, 145, 147, 1993, 1995, "of" +460, 17, 22, 421, 148, 156, 1996, 2004, "patients" +460, 17, 23, 422, 157, 161, 2005, 2009, "with" +460, 17, 24, 423, 162, 170, 2010, 2018, "glaucoma" +460, 17, 25, 424, 171, 173, 2019, 2021, "or" +460, 17, 26, 425, 174, 180, 2022, 2028, "ocular" +460, 17, 27, 426, 181, 193, 2029, 2041, "hypertension" +460, 17, 28, 427, 194, 195, 2042, 2043, "." +460, 18, 1, 428, 0, 6, 2044, 2050, "During" +460, 18, 2, 429, 7, 14, 2051, 2058, "therapy" +460, 18, 3, 430, 15, 16, 2059, 2060, "," +460, 18, 4, 431, 17, 20, 2061, 2064, "the" +460, 18, 5, 432, 21, 26, 2065, 2070, "range" +460, 18, 6, 433, 27, 29, 2071, 2073, "of" +460, 18, 7, 434, 30, 35, 2074, 2079, "daily" +460, 18, 8, 435, 36, 47, 2080, 2091, "fluctuation" +460, 18, 9, 436, 48, 50, 2092, 2094, "of" +460, 18, 10, 437, 51, 54, 2095, 2098, "IOP" +460, 18, 11, 438, 55, 57, 2099, 2101, "is" +460, 18, 12, 439, 58, 62, 2102, 2106, "less" +460, 18, 13, 440, 63, 66, 2107, 2110, "for" +460, 18, 14, 441, 67, 78, 2111, 2122, "latanoprost" +460, 18, 15, 442, 79, 87, 2123, 2131, "compared" +460, 18, 16, 443, 88, 92, 2132, 2136, "with" +460, 18, 17, 444, 93, 104, 2137, 2148, "brimonidine" +460, 18, 18, 445, 105, 106, 2149, 2150, "." +460, 19, 1, 446, 0, 4, 2151, 2155, "PMID" +460, 19, 2, 447, 5, 6, 2156, 2157, ":" +460, 19, 3, 448, 7, 15, 2158, 2166, "15741820" +460, 19, 4, 449, 16, 17, 2167, 2168, "[" +460, 19, 5, 450, 18, 25, 2169, 2176, "Indexed" +460, 19, 6, 451, 26, 29, 2177, 2180, "for" +460, 19, 7, 452, 30, 37, 2181, 2188, "MEDLINE" +460, 19, 8, 453, 38, 39, 2189, 2190, "]" diff --git a/data/gl 15741820_jshahinitiran.annodb b/data/gl 15741820_jshahinitiran.annodb new file mode 100644 index 0000000..c9d923d --- /dev/null +++ b/data/gl 15741820_jshahinitiran.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9015, Journal, 0, 10, "J Glaucoma", "", +9016, PublicationYear, 13, 17, "2005", "", +9017, Title, 45, 161, "Latanoprost or brimonidine as treatment for elevated intraocular pressure : multicenter trial in the United States .", "", +27997, Latanoprost, 45, 56, "Latanoprost", "", +27998, Brimonidine, 60, 71, "brimonidine", "", +27999, IOP, 98, 118, "intraocular pressure", "", +28000, Multicenter, 121, 132, "multicenter", "", +28001, USA, 146, 159, "United States", "", +9023, Author, 162, 171, "Camras CB", "", +9024, Author, 180, 187, "Sheu WP", "", +28002, USA, 190, 203, "United States", "", +28003, Latanoprost, 204, 215, "Latanoprost", "", +28004, Brimonidine, 218, 229, "Brimonidine", "", +28005, USA, 373, 376, "USA", "", +9027, ObjectiveDescription, 411, 536, "To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure ( IOP )", "", +28006, Latanoprost, 455, 466, "latanoprost", "", +28007, Brimonidine, 470, 481, "brimonidine", "", +28008, IOP, 508, 528, "intraocular pressure", "", +28009, IOP, 531, 534, "IOP", "", +9032, CTDesign, 568, 579, "prospective", "", +28010, Randomized, 582, 592, "randomized", "", +9034, Blind, 595, 613, "masked - evaluator", "", +9035, Parallel, 616, 624, "parallel", "", +28011, Multicenter, 635, 646, "multicenter", "", +28012, USA, 660, 673, "United States", "", +28013, Primary_OpenAngleGlaucoma, 697, 724, "primary open angle glaucoma", "", +9039, OcularHypertension, 728, 747, "ocular hypertension", "", +28014, Latanoprost, 768, 779, "latanoprost", "", +9041, DoseValue, 780, 787, "0 . 005", "", +9042, Percentage, 788, 789, "%", "", +9043, Frequency, 790, 800, "once daily", "", +9044, NumberPatientsArm, 819, 822, "152", "", +28015, Brimonidine, 828, 848, "brimonidine tartrate", "", +9049, DoseValue, 849, 854, "0 . 2", "", +9050, Percentage, 855, 856, "%", "", +9051, Frequency, 857, 868, "twice daily", "", +9052, NumberPatientsArm, 901, 904, "151", "", +28018, TimePoint, 954, 962, "baseline", "", +28016, Randomized, 965, 978, "randomization", "", +28017, TimePoint, 993, 1017, "0 . 5 , 3 , and 6 months", "", +9053, IOP, 1033, 1036, "IOP", "", +28019, TimePoint, 1102, 1110, "baseline", "", +28020, TimePoint, 1119, 1133, "months 3 and 6", "", +28021, TimePoint, 1168, 1174, "week 2", "", +28022, Diurnal_IOP, 1224, 1235, "diurnal IOP", "", +28023, TimePoint, 1248, 1256, "baseline", "", +28024, TimePoint, 1260, 1267, "month 6", "", +28025, Mean, 1359, 1363, "mean", "", +28026, Diurnal_IOP, 1364, 1375, "diurnal IOP", "", +28027, TimePoint, 1416, 1423, "month 6", "", +28028, Mean, 1439, 1443, "mean", "", +28029, Diurnal_IOP, 1458, 1469, "diurnal IOP", "", +9061, Reduction, 1484, 1489, "5 . 7", "", +9062, SdErrorChangeValue, 1496, 1501, "0 . 3", "", +9063, mmHg, 1502, 1507, "mm Hg", "", +28030, Latanoprost, 1515, 1526, "latanoprost", "", +9065, Reduction, 1537, 1542, "3 . 1", "", +9066, SdErrorChangeValue, 1549, 1554, "0 . 3", "", +9067, mmHg, 1555, 1560, "mm Hg", "", +28031, Brimonidine, 1583, 1594, "brimonidine", "", +9069, PValueChangeValue, 1597, 1608, "P < 0 . 001", "", +28032, Mean, 1617, 1621, "mean", "", +28033, Diurnal_IOP, 1636, 1647, "diurnal IOP", "", +9071, DiffBetweenGroups, 1662, 1667, "2 . 5", "", +9072, SdErrorDiff, 1674, 1679, "0 . 3", "", +9074, mmHg, 1680, 1685, "mm Hg", "", +9073, ConfIntervalDiff, 1688, 1711, "95 % CI : 1 . 9 , 3 . 2", "", +9075, PvalueDiff, 1714, 1725, "P < 0 . 001", "", +28034, Brimonidine, 1765, 1776, "brimonidine", "", +28035, Latanoprost, 1782, 1793, "latanoprost", "", +28036, Latanoprost, 1861, 1872, "Latanoprost", "", +10484, ConclusionComment, 1861, 2041, "Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension", "", +9043, Frequency, 1883, 1893, "once daily", "", +28037, Brimonidine, 1938, 1949, "brimonidine", "", +9051, Frequency, 1963, 1974, "twice daily", "", +9082, Glaucoma, 2010, 2018, "glaucoma", "", +9083, OcularHypertension, 2022, 2041, "ocular hypertension", "", +10486, ConclusionComment, 2044, 2150, "During therapy , the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine .", "", +9087, ObservedResult, 2061, 2150, "the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine .", "", +9084, IOP, 2095, 2098, "IOP", "", +28038, Latanoprost, 2111, 2122, "latanoprost", "", +28039, Brimonidine, 2137, 2148, "brimonidine", "", +9089, PMID, 2158, 2166, "15741820", "", diff --git a/data/gl 15741820_jshahinitiran.n-triples b/data/gl 15741820_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15741820_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15741820_tstrakeljahn.annodb b/data/gl 15741820_tstrakeljahn.annodb new file mode 100644 index 0000000..fd2f3d7 --- /dev/null +++ b/data/gl 15741820_tstrakeljahn.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30546, Journal, 0, 10, "J Glaucoma", "", +30547, PublicationYear, 13, 17, "2005", "", +30548, Latanoprost, 45, 56, "Latanoprost", "", +30614, Title, 45, 159, "Latanoprost or brimonidine as treatment for elevated intraocular pressure : multicenter trial in the United States", "", +30549, Brimonidine, 60, 71, "brimonidine", "", +30550, IOP, 98, 118, "intraocular pressure", "", +30552, Multicenter, 121, 132, "multicenter", "", +30551, USA, 146, 159, "United States", "", +30615, Author, 162, 171, "Camras CB", "", +30616, Author, 180, 187, "Sheu WP", "", +30554, Latanoprost, 204, 215, "Latanoprost", "", +30553, Brimonidine, 218, 229, "Brimonidine", "", +30555, USA, 373, 376, "USA", "", +30560, ObjectiveDescription, 411, 536, "To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure ( IOP )", "", +30556, Latanoprost, 455, 466, "latanoprost", "", +30557, Brimonidine, 470, 481, "brimonidine", "", +30558, IOP, 508, 528, "intraocular pressure", "", +30559, IOP, 531, 534, "IOP", "", +30561, Randomized, 582, 592, "randomized", "", +30562, Blind, 595, 613, "masked - evaluator", "", +30563, Parallel, 616, 632, "parallel - group", "", +30564, Multicenter, 635, 646, "multicenter", "", +30565, USA, 660, 673, "United States", "", +30566, Primary_OpenAngleGlaucoma, 697, 724, "primary open angle glaucoma", "", +30567, OcularHypertension, 728, 747, "ocular hypertension", "", +30568, Latanoprost, 768, 779, "latanoprost", "", +30570, DoseValue, 780, 787, "0 . 005", "", +30572, Frequency, 790, 800, "once daily", "", +30574, NumberPatientsArm, 819, 822, "152", "", +30569, Brimonidine, 828, 848, "brimonidine tartrate", "", +30571, DoseValue, 849, 854, "0 . 2", "", +30573, Frequency, 857, 868, "twice daily", "", +30575, NumberPatientsArm, 901, 904, "151", "", +30576, Randomized, 965, 978, "randomization", "", +30577, IOP, 1033, 1036, "IOP", "", +30578, Diurnal_IOP, 1224, 1235, "diurnal IOP", "", +30581, ObservedResult, 1350, 1410, "Baseline mean diurnal IOP levels were similar between groups", "", +30579, Mean, 1359, 1363, "mean", "", +30580, Diurnal_IOP, 1364, 1375, "diurnal IOP", "", +30582, TimePoint, 1416, 1423, "month 6", "", +30583, Mean, 1439, 1443, "mean", "", +30584, Diurnal_IOP, 1458, 1469, "diurnal IOP", "", +30585, Reduction, 1484, 1489, "5 . 7", "", +30587, SdErrorChangeValue, 1490, 1501, "+ / - 0 . 3", "", +30589, mmHg, 1502, 1507, "mm Hg", "", +30586, Reduction, 1537, 1542, "3 . 1", "", +30588, SdErrorChangeValue, 1543, 1554, "+ / - 0 . 3", "", +30590, mmHg, 1555, 1560, "mm Hg", "", +30591, Brimonidine, 1583, 1594, "brimonidine", "", +30592, PvalueDiff, 1597, 1608, "P < 0 . 001", "", +30593, Mean, 1617, 1621, "mean", "", +30594, IOP, 1636, 1647, "diurnal IOP", "", +30595, DiffGroupAbsValue, 1662, 1667, "2 . 5", "", +30596, SdErrorDiff, 1668, 1679, "+ / - 0 . 3", "", +30597, mmHg, 1680, 1685, "mm Hg", "", +30599, ConfIntervalDiff, 1698, 1711, "1 . 9 , 3 . 2", "", +30598, PvalueDiff, 1714, 1725, "P < 0 . 001", "", +30602, ObservedResult, 1730, 1847, "Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events .", "", +30600, Brimonidine, 1765, 1776, "brimonidine", "", +30601, Latanoprost, 1782, 1793, "latanoprost", "", +30603, Latanoprost, 1861, 1872, "Latanoprost", "", +30609, ConclusionComment, 1861, 2043, "Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension .", "", +30604, Frequency, 1883, 1893, "once daily", "", +30605, Brimonidine, 1938, 1949, "brimonidine", "", +30606, Frequency, 1963, 1974, "twice daily", "", +30607, Glaucoma, 2010, 2018, "glaucoma", "", +30608, OcularHypertension, 2022, 2041, "ocular hypertension", "", +30610, IOP, 2095, 2098, "IOP", "", +30611, Latanoprost, 2111, 2122, "latanoprost", "", +30612, Brimonidine, 2137, 2148, "brimonidine", "", +30613, PMID, 2158, 2166, "15741820", "", diff --git a/data/gl 15741820_tstrakeljahn.n-triples b/data/gl 15741820_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15741820_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15857284_admin.annodb b/data/gl 15857284_admin.annodb new file mode 100644 index 0000000..e2ff27f --- /dev/null +++ b/data/gl 15857284_admin.annodb @@ -0,0 +1,92 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "J Ocul Pharmacol Ther", "", " \"J Ocul Pharmacol Ther\"." +1, PublicationYear, 24, 28, "2005", "", " \"2005\"." +2, Title, 56, 221, "The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .", "", " \"The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .\"." +34845, Topic, 83, 90, "topical", "", +3, Brinzolamide, 91, 103, "brinzolamide", "", +4, Dorzolamide, 108, 119, "dorzolamide", "", +5, Latanoprost, 161, 172, "latanoprost", "", +34870, Drug, 179, 193, "beta - blocker", "", +6, Glaucoma, 211, 219, "glaucoma", "", " . ." +76, Author, 222, 233, "Tsukamoto H", "", " \"Tsukamoto H\"." +77, Author, 242, 248, "Noma H", "", " \"Noma H\"." +78, Author, 251, 262, "Matsuyama S", "", " \"Matsuyama S\"." +79, Author, 265, 272, "Ikeda H", "", " \"Ikeda H\"." +80, Author, 275, 285, "Mishima HK", "", " \"Mishima HK\"." +7, Japan, 439, 444, "Japan", "", " ." +9, Brinzolamide, 490, 502, "Brinzolamide", "", +10, Dorzolamide, 507, 518, "dorzolamide", "", +8, ObjectiveDescription, 587, 796, "The purpose of this study was to compare the efficacy and safety of brinzolamide 1 % versus dorzolamide 1 % when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .", "", " \"The purpose of this study was to compare the efficacy and safety of brinzolamide 1 % versus dorzolamide 1 % when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .\"." +11, Brinzolamide, 655, 667, "brinzolamide", "", +13, DoseValue, 668, 669, "1", "", +14, Percentage, 670, 671, "%", "", +12, Dorzolamide, 679, 690, "dorzolamide", "", +16, DoseValue, 691, 692, "1", "", +15, Percentage, 693, 694, "%", "", +17, Latanoprost, 736, 747, "latanoprost", "", +37053, Drug, 754, 768, "beta - blocker", "", +18, Glaucoma, 786, 794, "glaucoma", "", +81, Duration, 810, 818, "8 - week", "", " \"8 - week\"." +19, Randomized, 821, 831, "randomized", "", " ." +20, OpenLabel, 834, 846, "open - label", "", " ." +21, NumberPatientsCT, 882, 884, "52", "", " \"52\"." +22, Glaucoma, 899, 907, "glaucoma", "", +23, Brinzolamide, 910, 922, "Brinzolamide", "", " ." +24, DoseValue, 923, 924, "1", "", " \"1\"." +25, Percentage, 925, 926, "%", "", " ." +26, Frequency, 929, 940, "twice a day", "", " \"twice a day\"." +27, Dorzolamide, 946, 957, "dorzolamide", "", " ." +28, DoseValue, 958, 959, "1", "", " \"1\"." +29, Percentage, 960, 961, "%", "", " ." +30, Frequency, 964, 977, "3 times a day", "", " \"3 times a day\"." +31, Randomized, 984, 992, "randomly", "", +34862, Precondition, 1013, 1082, "patients who had been treated with both latanoprost and a betablocker", "", " \"patients who had been treated with both latanoprost and a betablocker\"." +32, Latanoprost, 1053, 1064, "latanoprost", "", +34861, Drug, 1071, 1082, "betablocker", "", +33, IOP, 1095, 1115, "Intraocular pressure", "", " . ." +34, IOP, 1118, 1121, "IOP", "", +35, PValueChangeValue, 1160, 1172, "P < 0 . 0001", "", " \"P < 0 . 0001\". \"P < 0 . 0001\"." +36, BaseLineValue, 1180, 1186, "18 . 6", "", " \"18 . 6\"." +34863, SdDevBL, 1193, 1198, "2 . 3", "", " \"2 . 3\"." +37, mmHg, 1199, 1203, "mmHg", "", +39, ResultMeasuredValue, 1207, 1213, "16 . 7", "", " \"16 . 7\"." +34864, SdDevResValue, 1220, 1225, "2 . 3", "", " \"2 . 3\"." +38, mmHg, 1226, 1230, "mmHg", "", +40, BaseLineValue, 1240, 1246, "18 . 4", "", " \"18 . 4\"." +34865, SdDevBL, 1253, 1258, "2 . 6", "", " \"2 . 6\"." +41, mmHg, 1259, 1263, "mmHg", "", +42, ResultMeasuredValue, 1267, 1273, "16 . 6", "", " \"16 . 6\"." +34866, SdDevResValue, 1280, 1285, "2 . 5", "", " \"2 . 5\"." +43, mmHg, 1286, 1290, "mmHg", "", " ." +136, TimePoint, 1308, 1315, "8 weeks", "", " \"8 weeks\". \"8 weeks\"." +44, Brinzolamide, 1338, 1350, "brinzolamide", "", +45, Dorzolamide, 1354, 1365, "dorzolamide", "", +50, PvalueDiff, 1434, 1444, "P = 0 . 86", "", " \"P = 0 . 86\"." +34867, EndPointDescription, 1466, 1483, "ocular irritation", "AdverseEffect", " . ." +142, PvalueDiff, 1511, 1523, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +52, Dorzolamide, 1533, 1544, "dorzolamide", "", +53, PercentageAffected, 1553, 1555, "74", "", " \"74\"." +54, Brinzolamide, 1569, 1581, "brinzolamide", "", +55, PercentageAffected, 1590, 1592, "16", "", " \"16\"." +92865, BlurredVison, 1642, 1656, "blurred vision", "", " ." +56, Dorzolamide, 1678, 1689, "dorzolamide", "", +58, PercentageAffected, 1690, 1692, "37", "", " \"37\"." +57, Brinzolamide, 1702, 1714, "brinzolamide", "", +59, PercentageAffected, 1715, 1717, "52", "", " \"52\"." +152, PvalueDiff, 1722, 1732, "P = 0 . 40", "", " \"P = 0 . 40\"." +61, ConclusionComment, 1751, 1991, "We concluded that the efficacy of brinzolamide 1 % was equivalent to dorzolamide 1 % ; however , the safety of brinzolamide 1 % was superior to dorzolamide 1 % as adjunctive therapy to the combination with latanoprost and a beta - blocker .", "", " \"We concluded that the efficacy of brinzolamide 1 % was equivalent to dorzolamide 1 % ; however , the safety of brinzolamide 1 % was superior to dorzolamide 1 % as adjunctive therapy to the combination with latanoprost and a beta - blocker .\"." +62, Brinzolamide, 1785, 1797, "brinzolamide", "", +67, DoseValue, 1798, 1799, "1", "", +71, Percentage, 1800, 1801, "%", "", +63, Dorzolamide, 1820, 1831, "dorzolamide", "", +68, DoseValue, 1832, 1833, "1", "", +72, Percentage, 1834, 1835, "%", "", +64, Brinzolamide, 1862, 1874, "brinzolamide", "", +69, DoseValue, 1875, 1876, "1", "", +73, Percentage, 1877, 1878, "%", "", +65, Dorzolamide, 1895, 1906, "dorzolamide", "", +70, DoseValue, 1907, 1908, "1", "", +74, Percentage, 1909, 1910, "%", "", +66, Latanoprost, 1957, 1968, "latanoprost", "", +34869, Drug, 1975, 1989, "beta - blocker", "", +75, PMID, 2039, 2047, "15857284", "", " \"15857284\"." diff --git a/data/gl 15857284_admin.n-triples b/data/gl 15857284_admin.n-triples new file mode 100644 index 0000000..f1b67b9 --- /dev/null +++ b/data/gl 15857284_admin.n-triples @@ -0,0 +1,150 @@ +# RDF export of group: Publication + . + "Publication" . + "The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma ." . + "Tsukamoto H" . + "2005" . + "J Ocul Pharmacol Ther" . + "15857284" . + . + "Noma H" . + "Matsuyama S" . + "Ikeda H" . + "Mishima HK" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The purpose of this study was to compare the efficacy and safety of brinzolamide 1 % versus dorzolamide 1 % when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma ." . + "52" . + "8 - week" . + . + . + . + "We concluded that the efficacy of brinzolamide 1 % was equivalent to dorzolamide 1 % ; however , the safety of brinzolamide 1 % was superior to dorzolamide 1 % as adjunctive therapy to the combination with latanoprost and a beta - blocker ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients who had been treated with both latanoprost and a betablocker" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint-iop" . + . + . + . + . + . + . + "Endpoint-irritation" . + . + . + . + . + . + . + "Endpoint-blurred" . + . + . + . + . +# RDF export of group: Arm + . + "Arm-bri" . + . + . + . + . + . + "Arm-dor" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention-bri" . + . + "twice a day" . + . + . + "Intervention-dor" . + . + "3 times a day" . + . +# RDF export of group: Medication + . + "Medication-bri" . + . + "1" . + . + . + . + "Medication-dor" . + . + "1" . + . + . +# RDF export of group: Outcome + . + "Outcome-iop-bri" . + . + "18 . 6" . + "2 . 3" . + "16 . 7" . + "2 . 3" . + "P < 0 . 0001" . + "8 weeks" . + . + "Outcome-iop-dor" . + . + "18 . 4" . + "2 . 6" . + "16 . 6" . + "2 . 5" . + "P < 0 . 0001" . + "8 weeks" . + . + "Outcome-irritation-bri" . + . + "16" . + . + "Outcome-irriratation-dor" . + . + "74" . + . + "Outcome-blurred-bri" . + . + "52" . + . + "Outcome-blurred-dor" . + . + "37" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups-iop" . + "P = 0 . 86" . + . + . + . + "DiffBetweenGroups-irritation" . + "P < 0 . 0001" . + . + . + . + "DiffBetweenGroups-blurred" . + "P = 0 . 40" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15857284_export.csv b/data/gl 15857284_export.csv new file mode 100644 index 0000000..7bcb43f --- /dev/null +++ b/data/gl 15857284_export.csv @@ -0,0 +1,429 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +458, 1, 1, 1, 0, 1, 0, 1, "J" +458, 1, 2, 2, 2, 6, 2, 6, "Ocul" +458, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +458, 1, 4, 4, 17, 21, 17, 21, "Ther" +458, 1, 5, 5, 22, 23, 22, 23, "." +458, 2, 1, 6, 0, 4, 24, 28, "2005" +458, 2, 2, 7, 5, 8, 29, 32, "Apr" +458, 2, 3, 8, 9, 10, 33, 34, ";" +458, 2, 4, 9, 11, 13, 35, 37, "21" +458, 2, 5, 10, 14, 15, 38, 39, "(" +458, 2, 6, 11, 16, 17, 40, 41, "2" +458, 2, 7, 12, 18, 19, 42, 43, ")" +458, 2, 8, 13, 20, 21, 44, 45, ":" +458, 2, 9, 14, 22, 25, 46, 49, "170" +458, 2, 10, 15, 26, 27, 50, 51, "-" +458, 2, 11, 16, 28, 29, 52, 53, "3" +458, 2, 12, 17, 30, 31, 54, 55, "." +458, 3, 1, 18, 0, 3, 56, 59, "The" +458, 3, 2, 19, 4, 12, 60, 68, "efficacy" +458, 3, 3, 20, 13, 16, 69, 72, "and" +458, 3, 4, 21, 17, 23, 73, 79, "safety" +458, 3, 5, 22, 24, 26, 80, 82, "of" +458, 3, 6, 23, 27, 34, 83, 90, "topical" +458, 3, 7, 24, 35, 47, 91, 103, "brinzolamide" +458, 3, 8, 25, 48, 51, 104, 107, "and" +458, 3, 9, 26, 52, 63, 108, 119, "dorzolamide" +458, 3, 10, 27, 64, 68, 120, 124, "when" +458, 3, 11, 28, 69, 74, 125, 130, "added" +458, 3, 12, 29, 75, 77, 131, 133, "to" +458, 3, 13, 30, 78, 81, 134, 137, "the" +458, 3, 14, 31, 82, 93, 138, 149, "combination" +458, 3, 15, 32, 94, 101, 150, 157, "therapy" +458, 3, 16, 33, 102, 104, 158, 160, "of" +458, 3, 17, 34, 105, 116, 161, 172, "latanoprost" +458, 3, 18, 35, 117, 120, 173, 176, "and" +458, 3, 19, 36, 121, 122, 177, 178, "a" +458, 3, 20, 37, 123, 127, 179, 183, "beta" +458, 3, 21, 38, 128, 129, 184, 185, "-" +458, 3, 22, 39, 130, 137, 186, 193, "blocker" +458, 3, 23, 40, 138, 140, 194, 196, "in" +458, 3, 24, 41, 141, 149, 197, 205, "patients" +458, 3, 25, 42, 150, 154, 206, 210, "with" +458, 3, 26, 43, 155, 163, 211, 219, "glaucoma" +458, 3, 27, 44, 164, 165, 220, 221, "." +458, 4, 1, 45, 0, 9, 222, 231, "Tsukamoto" +458, 4, 2, 46, 10, 11, 232, 233, "H" +458, 4, 3, 47, 12, 13, 234, 235, "(" +458, 4, 4, 48, 14, 15, 236, 237, "1" +458, 4, 5, 49, 16, 17, 238, 239, ")" +458, 4, 6, 50, 18, 19, 240, 241, "," +458, 4, 7, 51, 20, 24, 242, 246, "Noma" +458, 4, 8, 52, 25, 26, 247, 248, "H" +458, 4, 9, 53, 27, 28, 249, 250, "," +458, 4, 10, 54, 29, 38, 251, 260, "Matsuyama" +458, 4, 11, 55, 39, 40, 261, 262, "S" +458, 4, 12, 56, 41, 42, 263, 264, "," +458, 4, 13, 57, 43, 48, 265, 270, "Ikeda" +458, 4, 14, 58, 49, 50, 271, 272, "H" +458, 4, 15, 59, 51, 52, 273, 274, "," +458, 4, 16, 60, 53, 60, 275, 282, "Mishima" +458, 4, 17, 61, 61, 63, 283, 285, "HK" +458, 4, 18, 62, 64, 65, 286, 287, "." +458, 5, 1, 63, 0, 6, 288, 294, "Author" +458, 5, 2, 64, 7, 18, 295, 306, "information" +458, 5, 3, 65, 19, 20, 307, 308, ":" +458, 5, 4, 66, 21, 22, 309, 310, "(" +458, 5, 5, 67, 23, 24, 311, 312, "1" +458, 5, 6, 68, 25, 26, 313, 314, ")" +458, 5, 7, 69, 27, 37, 315, 325, "Department" +458, 5, 8, 70, 38, 40, 326, 328, "of" +458, 5, 9, 71, 41, 54, 329, 342, "Ophthalmology" +458, 5, 10, 72, 55, 58, 343, 346, "and" +458, 5, 11, 73, 59, 65, 347, 353, "Visual" +458, 5, 12, 74, 66, 74, 354, 362, "Sciences" +458, 5, 13, 75, 75, 76, 363, 364, "," +458, 5, 14, 76, 77, 86, 365, 374, "Hiroshima" +458, 5, 15, 77, 87, 97, 375, 385, "University" +458, 5, 16, 78, 98, 106, 386, 394, "Graduate" +458, 5, 17, 79, 107, 113, 395, 401, "School" +458, 5, 18, 80, 114, 116, 402, 404, "of" +458, 5, 19, 81, 117, 127, 405, 415, "Biomedical" +458, 5, 20, 82, 128, 136, 416, 424, "Sciences" +458, 5, 21, 83, 137, 138, 425, 426, "," +458, 5, 22, 84, 139, 148, 427, 436, "Hiroshima" +458, 5, 23, 85, 149, 150, 437, 438, "," +458, 5, 24, 86, 151, 156, 439, 444, "Japan" +458, 5, 25, 87, 157, 158, 445, 446, "." +458, 6, 1, 88, 0, 6, 447, 453, "htsuka" +458, 6, 2, 89, 7, 8, 454, 455, "@" +458, 6, 3, 90, 9, 18, 456, 465, "hiroshima" +458, 6, 4, 91, 19, 20, 466, 467, "-" +458, 6, 5, 92, 21, 22, 468, 469, "u" +458, 6, 6, 93, 23, 24, 470, 471, "." +458, 6, 7, 94, 25, 27, 472, 474, "ac" +458, 6, 8, 95, 28, 29, 475, 476, "." +458, 6, 9, 96, 30, 32, 477, 479, "jp" +458, 6, 10, 97, 33, 40, 480, 487, "PURPOSE" +458, 6, 11, 98, 41, 42, 488, 489, ":" +458, 6, 12, 99, 43, 55, 490, 502, "Brinzolamide" +458, 6, 13, 100, 56, 59, 503, 506, "and" +458, 6, 14, 101, 60, 71, 507, 518, "dorzolamide" +458, 6, 15, 102, 72, 75, 519, 522, "are" +458, 6, 16, 103, 76, 81, 523, 528, "often" +458, 6, 17, 104, 82, 86, 529, 533, "used" +458, 6, 18, 105, 87, 89, 534, 536, "as" +458, 6, 19, 106, 90, 100, 537, 547, "adjunctive" +458, 6, 20, 107, 101, 108, 548, 555, "therapy" +458, 6, 21, 108, 109, 111, 556, 558, "to" +458, 6, 22, 109, 112, 117, 559, 564, "other" +458, 6, 23, 110, 118, 130, 565, 577, "antiglaucoma" +458, 6, 24, 111, 131, 137, 578, 584, "agents" +458, 6, 25, 112, 138, 139, 585, 586, "." +458, 7, 1, 113, 0, 3, 587, 590, "The" +458, 7, 2, 114, 4, 11, 591, 598, "purpose" +458, 7, 3, 115, 12, 14, 599, 601, "of" +458, 7, 4, 116, 15, 19, 602, 606, "this" +458, 7, 5, 117, 20, 25, 607, 612, "study" +458, 7, 6, 118, 26, 29, 613, 616, "was" +458, 7, 7, 119, 30, 32, 617, 619, "to" +458, 7, 8, 120, 33, 40, 620, 627, "compare" +458, 7, 9, 121, 41, 44, 628, 631, "the" +458, 7, 10, 122, 45, 53, 632, 640, "efficacy" +458, 7, 11, 123, 54, 57, 641, 644, "and" +458, 7, 12, 124, 58, 64, 645, 651, "safety" +458, 7, 13, 125, 65, 67, 652, 654, "of" +458, 7, 14, 126, 68, 80, 655, 667, "brinzolamide" +458, 7, 15, 127, 81, 82, 668, 669, "1" +458, 7, 16, 128, 83, 84, 670, 671, "%" +458, 7, 17, 129, 85, 91, 672, 678, "versus" +458, 7, 18, 130, 92, 103, 679, 690, "dorzolamide" +458, 7, 19, 131, 104, 105, 691, 692, "1" +458, 7, 20, 132, 106, 107, 693, 694, "%" +458, 7, 21, 133, 108, 112, 695, 699, "when" +458, 7, 22, 134, 113, 118, 700, 705, "added" +458, 7, 23, 135, 119, 121, 706, 708, "to" +458, 7, 24, 136, 122, 125, 709, 712, "the" +458, 7, 25, 137, 126, 137, 713, 724, "combination" +458, 7, 26, 138, 138, 145, 725, 732, "therapy" +458, 7, 27, 139, 146, 148, 733, 735, "of" +458, 7, 28, 140, 149, 160, 736, 747, "latanoprost" +458, 7, 29, 141, 161, 164, 748, 751, "and" +458, 7, 30, 142, 165, 166, 752, 753, "a" +458, 7, 31, 143, 167, 171, 754, 758, "beta" +458, 7, 32, 144, 172, 173, 759, 760, "-" +458, 7, 33, 145, 174, 181, 761, 768, "blocker" +458, 7, 34, 146, 182, 184, 769, 771, "in" +458, 7, 35, 147, 185, 193, 772, 780, "patients" +458, 7, 36, 148, 194, 198, 781, 785, "with" +458, 7, 37, 149, 199, 207, 786, 794, "glaucoma" +458, 7, 38, 150, 208, 209, 795, 796, "." +458, 8, 1, 151, 0, 7, 797, 804, "METHODS" +458, 8, 2, 152, 8, 9, 805, 806, ":" +458, 8, 3, 153, 10, 12, 807, 809, "An" +458, 8, 4, 154, 13, 14, 810, 811, "8" +458, 8, 5, 155, 15, 16, 812, 813, "-" +458, 8, 6, 156, 17, 21, 814, 818, "week" +458, 8, 7, 157, 22, 23, 819, 820, "," +458, 8, 8, 158, 24, 34, 821, 831, "randomized" +458, 8, 9, 159, 35, 36, 832, 833, "," +458, 8, 10, 160, 37, 41, 834, 838, "open" +458, 8, 11, 161, 42, 43, 839, 840, "-" +458, 8, 12, 162, 44, 49, 841, 846, "label" +458, 8, 13, 163, 50, 61, 847, 858, "comparative" +458, 8, 14, 164, 62, 67, 859, 864, "study" +458, 8, 15, 165, 68, 71, 865, 868, "was" +458, 8, 16, 166, 72, 81, 869, 878, "performed" +458, 8, 17, 167, 82, 84, 879, 881, "in" +458, 8, 18, 168, 85, 87, 882, 884, "52" +458, 8, 19, 169, 88, 96, 885, 893, "patients" +458, 8, 20, 170, 97, 101, 894, 898, "with" +458, 8, 21, 171, 102, 110, 899, 907, "glaucoma" +458, 8, 22, 172, 111, 112, 908, 909, "." +458, 9, 1, 173, 0, 12, 910, 922, "Brinzolamide" +458, 9, 2, 174, 13, 14, 923, 924, "1" +458, 9, 3, 175, 15, 16, 925, 926, "%" +458, 9, 4, 176, 17, 18, 927, 928, "(" +458, 9, 5, 177, 19, 24, 929, 934, "twice" +458, 9, 6, 178, 25, 26, 935, 936, "a" +458, 9, 7, 179, 27, 30, 937, 940, "day" +458, 9, 8, 180, 31, 32, 941, 942, ")" +458, 9, 9, 181, 33, 35, 943, 945, "or" +458, 9, 10, 182, 36, 47, 946, 957, "dorzolamide" +458, 9, 11, 183, 48, 49, 958, 959, "1" +458, 9, 12, 184, 50, 51, 960, 961, "%" +458, 9, 13, 185, 52, 53, 962, 963, "(" +458, 9, 14, 186, 54, 55, 964, 965, "3" +458, 9, 15, 187, 56, 61, 966, 971, "times" +458, 9, 16, 188, 62, 63, 972, 973, "a" +458, 9, 17, 189, 64, 67, 974, 977, "day" +458, 9, 18, 190, 68, 69, 978, 979, ")" +458, 9, 19, 191, 70, 73, 980, 983, "was" +458, 9, 20, 192, 74, 82, 984, 992, "randomly" +458, 9, 21, 193, 83, 95, 993, 1005, "administered" +458, 9, 22, 194, 96, 98, 1006, 1008, "to" +458, 9, 23, 195, 99, 102, 1009, 1012, "the" +458, 9, 24, 196, 103, 111, 1013, 1021, "patients" +458, 9, 25, 197, 112, 115, 1022, 1025, "who" +458, 9, 26, 198, 116, 119, 1026, 1029, "had" +458, 9, 27, 199, 120, 124, 1030, 1034, "been" +458, 9, 28, 200, 125, 132, 1035, 1042, "treated" +458, 9, 29, 201, 133, 137, 1043, 1047, "with" +458, 9, 30, 202, 138, 142, 1048, 1052, "both" +458, 9, 31, 203, 143, 154, 1053, 1064, "latanoprost" +458, 9, 32, 204, 155, 158, 1065, 1068, "and" +458, 9, 33, 205, 159, 160, 1069, 1070, "a" +458, 9, 34, 206, 161, 172, 1071, 1082, "betablocker" +458, 9, 35, 207, 173, 174, 1083, 1084, "." +458, 10, 1, 208, 0, 7, 1085, 1092, "RESULTS" +458, 10, 2, 209, 8, 9, 1093, 1094, ":" +458, 10, 3, 210, 10, 21, 1095, 1106, "Intraocular" +458, 10, 4, 211, 22, 30, 1107, 1115, "pressure" +458, 10, 5, 212, 31, 32, 1116, 1117, "(" +458, 10, 6, 213, 33, 36, 1118, 1121, "IOP" +458, 10, 7, 214, 37, 38, 1122, 1123, ")" +458, 10, 8, 215, 39, 43, 1124, 1128, "were" +458, 10, 9, 216, 44, 48, 1129, 1133, "both" +458, 10, 10, 217, 49, 58, 1134, 1143, "decreased" +458, 10, 11, 218, 59, 72, 1144, 1157, "significantly" +458, 10, 12, 219, 73, 74, 1158, 1159, "(" +458, 10, 13, 220, 75, 76, 1160, 1161, "P" +458, 10, 14, 221, 77, 78, 1162, 1163, "<" +458, 10, 15, 222, 79, 80, 1164, 1165, "0" +458, 10, 16, 223, 81, 82, 1166, 1167, "." +458, 10, 17, 224, 83, 87, 1168, 1172, "0001" +458, 10, 18, 225, 88, 89, 1173, 1174, ")" +458, 10, 19, 226, 90, 94, 1175, 1179, "from" +458, 10, 20, 227, 95, 97, 1180, 1182, "18" +458, 10, 21, 228, 98, 99, 1183, 1184, "." +458, 10, 22, 229, 100, 101, 1185, 1186, "6" +458, 10, 23, 230, 102, 103, 1187, 1188, "+" +458, 10, 24, 231, 104, 105, 1189, 1190, "/" +458, 10, 25, 232, 106, 107, 1191, 1192, "-" +458, 10, 26, 233, 108, 109, 1193, 1194, "2" +458, 10, 27, 234, 110, 111, 1195, 1196, "." +458, 10, 28, 235, 112, 113, 1197, 1198, "3" +458, 10, 29, 236, 114, 118, 1199, 1203, "mmHg" +458, 10, 30, 237, 119, 121, 1204, 1206, "to" +458, 10, 31, 238, 122, 124, 1207, 1209, "16" +458, 10, 32, 239, 125, 126, 1210, 1211, "." +458, 10, 33, 240, 127, 128, 1212, 1213, "7" +458, 10, 34, 241, 129, 130, 1214, 1215, "+" +458, 10, 35, 242, 131, 132, 1216, 1217, "/" +458, 10, 36, 243, 133, 134, 1218, 1219, "-" +458, 10, 37, 244, 135, 136, 1220, 1221, "2" +458, 10, 38, 245, 137, 138, 1222, 1223, "." +458, 10, 39, 246, 139, 140, 1224, 1225, "3" +458, 10, 40, 247, 141, 145, 1226, 1230, "mmHg" +458, 10, 41, 248, 146, 149, 1231, 1234, "and" +458, 10, 42, 249, 150, 154, 1235, 1239, "from" +458, 10, 43, 250, 155, 157, 1240, 1242, "18" +458, 10, 44, 251, 158, 159, 1243, 1244, "." +458, 10, 45, 252, 160, 161, 1245, 1246, "4" +458, 10, 46, 253, 162, 163, 1247, 1248, "+" +458, 10, 47, 254, 164, 165, 1249, 1250, "/" +458, 10, 48, 255, 166, 167, 1251, 1252, "-" +458, 10, 49, 256, 168, 169, 1253, 1254, "2" +458, 10, 50, 257, 170, 171, 1255, 1256, "." +458, 10, 51, 258, 172, 173, 1257, 1258, "6" +458, 10, 52, 259, 174, 178, 1259, 1263, "mmHg" +458, 10, 53, 260, 179, 181, 1264, 1266, "to" +458, 10, 54, 261, 182, 184, 1267, 1269, "16" +458, 10, 55, 262, 185, 186, 1270, 1271, "." +458, 10, 56, 263, 187, 188, 1272, 1273, "6" +458, 10, 57, 264, 189, 190, 1274, 1275, "+" +458, 10, 58, 265, 191, 192, 1276, 1277, "/" +458, 10, 59, 266, 193, 194, 1278, 1279, "-" +458, 10, 60, 267, 195, 196, 1280, 1281, "2" +458, 10, 61, 268, 197, 198, 1282, 1283, "." +458, 10, 62, 269, 199, 200, 1284, 1285, "5" +458, 10, 63, 270, 201, 205, 1286, 1290, "mmHg" +458, 10, 64, 271, 206, 207, 1291, 1292, "," +458, 10, 65, 272, 208, 220, 1293, 1305, "respectively" +458, 10, 66, 273, 221, 222, 1306, 1307, "," +458, 10, 67, 274, 223, 224, 1308, 1309, "8" +458, 10, 68, 275, 225, 230, 1310, 1315, "weeks" +458, 10, 69, 276, 231, 236, 1316, 1321, "after" +458, 10, 70, 277, 237, 240, 1322, 1325, "the" +458, 10, 71, 278, 241, 249, 1326, 1334, "addition" +458, 10, 72, 279, 250, 252, 1335, 1337, "of" +458, 10, 73, 280, 253, 265, 1338, 1350, "brinzolamide" +458, 10, 74, 281, 266, 268, 1351, 1353, "or" +458, 10, 75, 282, 269, 280, 1354, 1365, "dorzolamide" +458, 10, 76, 283, 281, 282, 1366, 1367, "." +458, 11, 1, 284, 0, 7, 1368, 1375, "However" +458, 11, 2, 285, 8, 9, 1376, 1377, "," +458, 11, 3, 286, 10, 13, 1378, 1381, "the" +458, 11, 4, 287, 14, 24, 1382, 1392, "difference" +458, 11, 5, 288, 25, 32, 1393, 1400, "between" +458, 11, 6, 289, 33, 36, 1401, 1404, "the" +458, 11, 7, 290, 37, 43, 1405, 1411, "groups" +458, 11, 8, 291, 44, 47, 1412, 1415, "was" +458, 11, 9, 292, 48, 51, 1416, 1419, "not" +458, 11, 10, 293, 52, 63, 1420, 1431, "significant" +458, 11, 11, 294, 64, 65, 1432, 1433, "(" +458, 11, 12, 295, 66, 67, 1434, 1435, "P" +458, 11, 13, 296, 68, 69, 1436, 1437, "=" +458, 11, 14, 297, 70, 71, 1438, 1439, "0" +458, 11, 15, 298, 72, 73, 1440, 1441, "." +458, 11, 16, 299, 74, 76, 1442, 1444, "86" +458, 11, 17, 300, 77, 78, 1445, 1446, ")" +458, 11, 18, 301, 79, 80, 1447, 1448, "." +458, 12, 1, 302, 0, 3, 1449, 1452, "The" +458, 12, 2, 303, 4, 13, 1453, 1462, "incidence" +458, 12, 3, 304, 14, 16, 1463, 1465, "of" +458, 12, 4, 305, 17, 23, 1466, 1472, "ocular" +458, 12, 5, 306, 24, 34, 1473, 1483, "irritation" +458, 12, 6, 307, 35, 38, 1484, 1487, "was" +458, 12, 7, 308, 39, 52, 1488, 1501, "significantly" +458, 12, 8, 309, 53, 59, 1502, 1508, "higher" +458, 12, 9, 310, 60, 61, 1509, 1510, "(" +458, 12, 10, 311, 62, 63, 1511, 1512, "P" +458, 12, 11, 312, 64, 65, 1513, 1514, "<" +458, 12, 12, 313, 66, 67, 1515, 1516, "0" +458, 12, 13, 314, 68, 69, 1517, 1518, "." +458, 12, 14, 315, 70, 74, 1519, 1523, "0001" +458, 12, 15, 316, 75, 76, 1524, 1525, ")" +458, 12, 16, 317, 77, 79, 1526, 1528, "in" +458, 12, 17, 318, 80, 83, 1529, 1532, "the" +458, 12, 18, 319, 84, 95, 1533, 1544, "dorzolamide" +458, 12, 19, 320, 96, 101, 1545, 1550, "group" +458, 12, 20, 321, 102, 103, 1551, 1552, "(" +458, 12, 21, 322, 104, 106, 1553, 1555, "74" +458, 12, 22, 323, 107, 108, 1556, 1557, "%" +458, 12, 23, 324, 109, 110, 1558, 1559, ")" +458, 12, 24, 325, 111, 115, 1560, 1564, "than" +458, 12, 25, 326, 116, 119, 1565, 1568, "the" +458, 12, 26, 327, 120, 132, 1569, 1581, "brinzolamide" +458, 12, 27, 328, 133, 138, 1582, 1587, "group" +458, 12, 28, 329, 139, 140, 1588, 1589, "(" +458, 12, 29, 330, 141, 143, 1590, 1592, "16" +458, 12, 30, 331, 144, 145, 1593, 1594, "%" +458, 12, 31, 332, 146, 147, 1595, 1596, ")" +458, 12, 32, 333, 148, 149, 1597, 1598, "," +458, 12, 33, 334, 150, 153, 1599, 1602, "but" +458, 12, 34, 335, 154, 159, 1603, 1608, "there" +458, 12, 35, 336, 160, 163, 1609, 1612, "was" +458, 12, 36, 337, 164, 166, 1613, 1615, "no" +458, 12, 37, 338, 167, 178, 1616, 1627, "significant" +458, 12, 38, 339, 179, 189, 1628, 1638, "difference" +458, 12, 39, 340, 190, 192, 1639, 1641, "in" +458, 12, 40, 341, 193, 200, 1642, 1649, "blurred" +458, 12, 41, 342, 201, 207, 1650, 1656, "vision" +458, 12, 42, 343, 208, 215, 1657, 1664, "between" +458, 12, 43, 344, 216, 219, 1665, 1668, "the" +458, 12, 44, 345, 220, 226, 1669, 1675, "groups" +458, 12, 45, 346, 227, 228, 1676, 1677, "(" +458, 12, 46, 347, 229, 240, 1678, 1689, "dorzolamide" +458, 12, 47, 348, 241, 243, 1690, 1692, "37" +458, 12, 48, 349, 244, 245, 1693, 1694, "%" +458, 12, 49, 350, 246, 252, 1695, 1701, "versus" +458, 12, 50, 351, 253, 265, 1702, 1714, "brinzolamide" +458, 12, 51, 352, 266, 268, 1715, 1717, "52" +458, 12, 52, 353, 269, 270, 1718, 1719, "%" +458, 12, 53, 354, 271, 272, 1720, 1721, "," +458, 12, 54, 355, 273, 274, 1722, 1723, "P" +458, 12, 55, 356, 275, 276, 1724, 1725, "=" +458, 12, 56, 357, 277, 278, 1726, 1727, "0" +458, 12, 57, 358, 279, 280, 1728, 1729, "." +458, 12, 58, 359, 281, 283, 1730, 1732, "40" +458, 12, 59, 360, 284, 285, 1733, 1734, ")" +458, 12, 60, 361, 286, 287, 1735, 1736, "." +458, 13, 1, 362, 0, 11, 1737, 1748, "CONCLUSIONS" +458, 13, 2, 363, 12, 13, 1749, 1750, ":" +458, 13, 3, 364, 14, 16, 1751, 1753, "We" +458, 13, 4, 365, 17, 26, 1754, 1763, "concluded" +458, 13, 5, 366, 27, 31, 1764, 1768, "that" +458, 13, 6, 367, 32, 35, 1769, 1772, "the" +458, 13, 7, 368, 36, 44, 1773, 1781, "efficacy" +458, 13, 8, 369, 45, 47, 1782, 1784, "of" +458, 13, 9, 370, 48, 60, 1785, 1797, "brinzolamide" +458, 13, 10, 371, 61, 62, 1798, 1799, "1" +458, 13, 11, 372, 63, 64, 1800, 1801, "%" +458, 13, 12, 373, 65, 68, 1802, 1805, "was" +458, 13, 13, 374, 69, 79, 1806, 1816, "equivalent" +458, 13, 14, 375, 80, 82, 1817, 1819, "to" +458, 13, 15, 376, 83, 94, 1820, 1831, "dorzolamide" +458, 13, 16, 377, 95, 96, 1832, 1833, "1" +458, 13, 17, 378, 97, 98, 1834, 1835, "%" +458, 13, 18, 379, 99, 100, 1836, 1837, ";" +458, 13, 19, 380, 101, 108, 1838, 1845, "however" +458, 13, 20, 381, 109, 110, 1846, 1847, "," +458, 13, 21, 382, 111, 114, 1848, 1851, "the" +458, 13, 22, 383, 115, 121, 1852, 1858, "safety" +458, 13, 23, 384, 122, 124, 1859, 1861, "of" +458, 13, 24, 385, 125, 137, 1862, 1874, "brinzolamide" +458, 13, 25, 386, 138, 139, 1875, 1876, "1" +458, 13, 26, 387, 140, 141, 1877, 1878, "%" +458, 13, 27, 388, 142, 145, 1879, 1882, "was" +458, 13, 28, 389, 146, 154, 1883, 1891, "superior" +458, 13, 29, 390, 155, 157, 1892, 1894, "to" +458, 13, 30, 391, 158, 169, 1895, 1906, "dorzolamide" +458, 13, 31, 392, 170, 171, 1907, 1908, "1" +458, 13, 32, 393, 172, 173, 1909, 1910, "%" +458, 13, 33, 394, 174, 176, 1911, 1913, "as" +458, 13, 34, 395, 177, 187, 1914, 1924, "adjunctive" +458, 13, 35, 396, 188, 195, 1925, 1932, "therapy" +458, 13, 36, 397, 196, 198, 1933, 1935, "to" +458, 13, 37, 398, 199, 202, 1936, 1939, "the" +458, 13, 38, 399, 203, 214, 1940, 1951, "combination" +458, 13, 39, 400, 215, 219, 1952, 1956, "with" +458, 13, 40, 401, 220, 231, 1957, 1968, "latanoprost" +458, 13, 41, 402, 232, 235, 1969, 1972, "and" +458, 13, 42, 403, 236, 237, 1973, 1974, "a" +458, 13, 43, 404, 238, 242, 1975, 1979, "beta" +458, 13, 44, 405, 243, 244, 1980, 1981, "-" +458, 13, 45, 406, 245, 252, 1982, 1989, "blocker" +458, 13, 46, 407, 253, 254, 1990, 1991, "." +458, 14, 1, 408, 0, 3, 1992, 1995, "DOI" +458, 14, 2, 409, 4, 5, 1996, 1997, ":" +458, 14, 3, 410, 6, 8, 1998, 2000, "10" +458, 14, 4, 411, 9, 10, 2001, 2002, "." +458, 14, 5, 412, 11, 15, 2003, 2007, "1089" +458, 14, 6, 413, 16, 17, 2008, 2009, "/" +458, 14, 7, 414, 18, 21, 2010, 2013, "jop" +458, 14, 8, 415, 22, 23, 2014, 2015, "." +458, 14, 9, 416, 24, 28, 2016, 2020, "2005" +458, 14, 10, 417, 29, 30, 2021, 2022, "." +458, 14, 11, 418, 31, 33, 2023, 2025, "21" +458, 14, 12, 419, 34, 35, 2026, 2027, "." +458, 14, 13, 420, 36, 39, 2028, 2031, "170" +458, 14, 14, 421, 40, 44, 2032, 2036, "PMID" +458, 14, 15, 422, 45, 46, 2037, 2038, ":" +458, 14, 16, 423, 47, 55, 2039, 2047, "15857284" +458, 14, 17, 424, 56, 57, 2048, 2049, "[" +458, 14, 18, 425, 58, 65, 2050, 2057, "Indexed" +458, 14, 19, 426, 66, 69, 2058, 2061, "for" +458, 14, 20, 427, 70, 77, 2062, 2069, "MEDLINE" +458, 14, 21, 428, 78, 79, 2070, 2071, "]" diff --git a/data/gl 15857284_jshahinitiran.annodb b/data/gl 15857284_jshahinitiran.annodb new file mode 100644 index 0000000..d32004c --- /dev/null +++ b/data/gl 15857284_jshahinitiran.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +9122, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +9123, PublicationYear, 24, 28, "2005", "", +10560, Title, 56, 221, "The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .", "", +10562, Brinzolamide, 91, 103, "brinzolamide", "", +10564, Dorzolamide, 108, 119, "dorzolamide", "", +10566, Latanoprost, 161, 172, "latanoprost", "", +10567, Glaucoma, 211, 219, "glaucoma", "", +10755, Author, 222, 233, "Tsukamoto H", "", +10756, Author, 242, 248, "Noma H", "", +10757, Author, 251, 262, "Matsuyama S", "", +10758, Author, 265, 272, "Ikeda H", "", +10759, Author, 275, 285, "Mishima HK", "", +10574, Japan, 439, 444, "Japan", "", +10578, Brinzolamide, 490, 502, "Brinzolamide", "", +10580, Dorzolamide, 507, 518, "dorzolamide", "", +10576, ObjectiveDescription, 587, 796, "The purpose of this study was to compare the efficacy and safety of brinzolamide 1 % versus dorzolamide 1 % when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .", "", +10581, Brinzolamide, 655, 667, "brinzolamide", "", +10585, DoseValue, 668, 669, "1", "", +10587, Percentage, 670, 671, "%", "", +10582, Dorzolamide, 679, 690, "dorzolamide", "", +10590, DoseValue, 691, 692, "1", "", +10589, Percentage, 693, 694, "%", "", +10591, Latanoprost, 736, 747, "latanoprost", "", +10592, Glaucoma, 786, 794, "glaucoma", "", +28040, Duration, 810, 818, "8 - week", "", +10594, Randomized, 821, 831, "randomized", "", +10596, OpenLabel, 834, 846, "open - label", "", +10599, NumberPatientsCT, 882, 884, "52", "", +10600, Glaucoma, 899, 907, "glaucoma", "", +10601, Brinzolamide, 910, 922, "Brinzolamide", "", +10603, DoseValue, 923, 924, "1", "", +10604, Percentage, 925, 926, "%", "", +10605, Frequency, 929, 940, "twice a day", "", +10607, Dorzolamide, 946, 957, "dorzolamide", "", +10609, DoseValue, 958, 959, "1", "", +10610, Percentage, 960, 961, "%", "", +10611, Frequency, 964, 977, "3 times a day", "", +10612, Randomized, 984, 992, "randomly", "", +10616, Latanoprost, 1053, 1064, "latanoprost", "", +10619, IOP, 1095, 1115, "Intraocular pressure", "", +10621, IOP, 1118, 1121, "IOP", "", +10625, PValueChangeValue, 1160, 1172, "P < 0 . 0001", "", +10628, BaseLineValue, 1180, 1186, "18 . 6", "", +10651, SdErrorBL, 1193, 1198, "2 . 3", "", +10630, mmHg, 1199, 1203, "mmHg", "", +10638, ResultMeasuredValue, 1207, 1213, "16 . 7", "", +10655, SdErrorResValue, 1220, 1225, "2 . 3", "", +10635, mmHg, 1226, 1230, "mmHg", "", +10641, BaseLineValue, 1240, 1246, "18 . 4", "", +10652, SdErrorBL, 1253, 1258, "2 . 6", "", +10644, mmHg, 1259, 1263, "mmHg", "", +10646, ResultMeasuredValue, 1267, 1273, "16 . 6", "", +10656, SdErrorResValue, 1280, 1285, "2 . 5", "", +10647, mmHg, 1286, 1290, "mmHg", "", +28041, Duration, 1308, 1315, "8 weeks", "", +10649, Brinzolamide, 1338, 1350, "brinzolamide", "", +10650, Dorzolamide, 1354, 1365, "dorzolamide", "", +10659, PvalueDiff, 1434, 1444, "P = 0 . 86", "", +10665, PValueNumAffected, 1511, 1523, "P < 0 . 0001", "", +10667, Dorzolamide, 1533, 1544, "dorzolamide", "", +10668, PercentageAffected, 1553, 1555, "74", "", +10670, Brinzolamide, 1569, 1581, "brinzolamide", "", +10672, PercentageAffected, 1590, 1592, "16", "", +10675, Dorzolamide, 1678, 1689, "dorzolamide", "", +10680, PercentageAffected, 1690, 1692, "37", "", +10676, Brinzolamide, 1702, 1714, "brinzolamide", "", +10681, PercentageAffected, 1715, 1717, "52", "", +10684, PValueNumAffected, 1722, 1732, "P = 0 . 40", "", +10688, ConclusionComment, 1751, 1991, "We concluded that the efficacy of brinzolamide 1 % was equivalent to dorzolamide 1 % ; however , the safety of brinzolamide 1 % was superior to dorzolamide 1 % as adjunctive therapy to the combination with latanoprost and a beta - blocker .", "", +10690, Brinzolamide, 1785, 1797, "brinzolamide", "", +10700, DoseValue, 1798, 1799, "1", "", +10706, Percentage, 1800, 1801, "%", "", +10693, Dorzolamide, 1820, 1831, "dorzolamide", "", +10701, DoseValue, 1832, 1833, "1", "", +10707, Percentage, 1834, 1835, "%", "", +10696, Brinzolamide, 1862, 1874, "brinzolamide", "", +10702, DoseValue, 1875, 1876, "1", "", +10708, Percentage, 1877, 1878, "%", "", +10697, Dorzolamide, 1895, 1906, "dorzolamide", "", +10704, DoseValue, 1907, 1908, "1", "", +10710, Percentage, 1909, 1910, "%", "", +10698, Latanoprost, 1957, 1968, "latanoprost", "", +10711, PMID, 2039, 2047, "15857284", "", diff --git a/data/gl 15857284_jshahinitiran.n-triples b/data/gl 15857284_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15857284_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15857284_tstrakeljahn.annodb b/data/gl 15857284_tstrakeljahn.annodb new file mode 100644 index 0000000..94a898d --- /dev/null +++ b/data/gl 15857284_tstrakeljahn.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30391, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +30401, PublicationYear, 24, 28, "2005", "", +30406, Title, 56, 219, "The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma", "", +30402, Brinzolamide, 91, 103, "brinzolamide", "", +30403, Dorzolamide, 108, 119, "dorzolamide", "", +30404, Latanoprost, 161, 172, "latanoprost", "", +30405, Glaucoma, 211, 219, "glaucoma", "", +30407, Author, 222, 233, "Tsukamoto H", "", +30408, Author, 242, 248, "Noma H", "", +30409, Author, 251, 262, "Matsuyama S", "", +30410, Author, 265, 272, "Ikeda H", "", +30411, Author, 275, 285, "Mishima HK", "", +30412, Japan, 439, 444, "Japan", "", +30413, Brinzolamide, 490, 502, "Brinzolamide", "", +30414, Dorzolamide, 507, 518, "dorzolamide", "", +30423, ObjectiveDescription, 587, 796, "The purpose of this study was to compare the efficacy and safety of brinzolamide 1 % versus dorzolamide 1 % when added to the combination therapy of latanoprost and a beta - blocker in patients with glaucoma .", "", +30415, Brinzolamide, 655, 667, "brinzolamide", "", +30419, DoseValue, 668, 669, "1", "", +30421, Percentage, 670, 671, "%", "", +30416, Dorzolamide, 679, 690, "dorzolamide", "", +30420, DoseValue, 691, 692, "1", "", +30422, Percentage, 693, 694, "%", "", +30417, Latanoprost, 736, 747, "latanoprost", "", +30418, Glaucoma, 786, 794, "glaucoma", "", +30424, Duration, 810, 818, "8 - week", "", +30425, Randomized, 821, 831, "randomized", "", +30426, OpenLabel, 834, 846, "open - label", "", +30427, NumberPatientsCT, 882, 884, "52", "", +30428, Glaucoma, 899, 907, "glaucoma", "", +30429, Brinzolamide, 910, 922, "Brinzolamide", "", +30432, DoseValue, 923, 924, "1", "", +30434, Percentage, 925, 926, "%", "", +30436, Frequency, 929, 940, "twice a day", "", +30430, Dorzolamide, 946, 957, "dorzolamide", "", +30433, DoseValue, 958, 959, "1", "", +30435, Percentage, 960, 961, "%", "", +30437, Frequency, 964, 977, "3 times a day", "", +30431, Latanoprost, 1053, 1064, "latanoprost", "", +30438, IOP, 1095, 1115, "Intraocular pressure", "", +30439, IOP, 1118, 1121, "IOP", "", +30440, PValueResValue, 1160, 1172, "P < 0 . 0001", "", +30441, BaseLineValue, 1180, 1186, "18 . 6", "", +30444, SdDevBL, 1187, 1198, "+ / - 2 . 3", "", +30446, mmHg, 1199, 1203, "mmHg", "", +30448, ResultMeasuredValue, 1207, 1213, "16 . 7", "", +30450, SdDevResValue, 1214, 1225, "+ / - 2 . 3", "", +30453, mmHg, 1226, 1230, "mmHg", "", +30443, BaseLineValue, 1240, 1246, "18 . 4", "", +30445, SdDevBL, 1247, 1258, "+ / - 2 . 6", "", +30447, mmHg, 1259, 1263, "mmHg", "", +30449, ResultMeasuredValue, 1267, 1273, "16 . 6", "", +30451, SdDevResValue, 1274, 1285, "+ / - 2 . 5", "", +30452, mmHg, 1286, 1290, "mmHg", "", +30454, TimePoint, 1308, 1315, "8 weeks", "", +30455, Brinzolamide, 1338, 1350, "brinzolamide", "", +30456, Dorzolamide, 1354, 1365, "dorzolamide", "", +30458, ObservedResult, 1368, 1448, "However , the difference between the groups was not significant ( P = 0 . 86 ) .", "", +30457, PvalueDiff, 1434, 1444, "P = 0 . 86", "", +30460, PvalueDiff, 1511, 1523, "P < 0 . 0001", "", +30464, Dorzolamide, 1533, 1544, "dorzolamide", "", +30461, PercentageAffected, 1553, 1555, "74", "", +30463, Brinzolamide, 1569, 1581, "brinzolamide", "", +30462, PercentageAffected, 1590, 1592, "16", "", +30466, Dorzolamide, 1678, 1689, "dorzolamide", "", +30468, PercentageAffected, 1690, 1692, "37", "", +30467, Brinzolamide, 1702, 1714, "brinzolamide", "", +30469, PercentageAffected, 1715, 1717, "52", "", +30470, PvalueDiff, 1722, 1732, "P = 0 . 40", "", +30484, ConclusionComment, 1751, 1991, "We concluded that the efficacy of brinzolamide 1 % was equivalent to dorzolamide 1 % ; however , the safety of brinzolamide 1 % was superior to dorzolamide 1 % as adjunctive therapy to the combination with latanoprost and a beta - blocker .", "", +30471, Brinzolamide, 1785, 1797, "brinzolamide", "", +30476, DoseValue, 1798, 1799, "1", "", +30478, Percentage, 1800, 1801, "%", "", +30472, Dorzolamide, 1820, 1831, "dorzolamide", "", +30477, DoseValue, 1832, 1833, "1", "", +30479, Percentage, 1834, 1835, "%", "", +30474, Brinzolamide, 1862, 1874, "brinzolamide", "", +30482, DoseValue, 1875, 1876, "1", "", +30480, Percentage, 1877, 1878, "%", "", +30473, Dorzolamide, 1895, 1906, "dorzolamide", "", +30483, DoseValue, 1907, 1908, "1", "", +30481, Percentage, 1909, 1910, "%", "", +30475, Latanoprost, 1957, 1968, "latanoprost", "", +30485, PMID, 2039, 2047, "15857284", "", diff --git a/data/gl 15857284_tstrakeljahn.n-triples b/data/gl 15857284_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15857284_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15945001_admin.annodb b/data/gl 15945001_admin.annodb new file mode 100644 index 0000000..a0dc8e7 --- /dev/null +++ b/data/gl 15945001_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 18, "Eur J Ophthalmol .", "", " \"Eur J Ophthalmol .\"." +1, PublicationYear, 19, 23, "2005", "", " \"2005\"." +2, Title, 58, 170, "Safety and efficacy of bimatoprost 0 . 03 % versus timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination .", "", " \"Safety and efficacy of bimatoprost 0 . 03 % versus timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination .\"." +3, Bimatoprost, 81, 92, "bimatoprost", "", " ." +6, DoseValue, 93, 99, "0 . 03", "", " \"0 . 03\"." +84, Percentage, 100, 101, "%", "", " ." +4, Timolol, 109, 124, "timolol maleate", "", +9, Dorz/TimFC, 109, 168, "timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination", "", " ." +7, DoseValue, 125, 130, "0 . 5", "", +85, Percentage, 131, 132, "%", "", +5, Dorzolamide, 135, 146, "dorzolamide", "", +8, DoseValue, 147, 148, "2", "", +86, Percentage, 149, 150, "%", "", +10, Author, 171, 177, "Day DG", "", " \"Day DG\"." +11, Author, 186, 195, "Sharpe ED", "", " \"Sharpe ED\"." +12, Author, 198, 209, "Beischel CJ", "", " \"Beischel CJ\"." +13, Author, 212, 222, "Jenkins JN", "", " \"Jenkins JN\"." +14, Author, 225, 235, "Stewart JA", "", " \"Stewart JA\"." +15, Author, 238, 248, "Stewart WC", "", " \"Stewart WC\"." +16, USA, 313, 316, "USA", "", +17, ObjectiveDescription, 329, 538, "To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide / timolol fixed combination ( DTFC ) given twice daily in open - angle glaucoma and ocular hypertensive patients .", "", " \"To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide / timolol fixed combination ( DTFC ) given twice daily in open - angle glaucoma and ocular hypertensive patients .\"." +18, Bimatoprost, 369, 380, "bimatoprost", "", +106, Frequency, 387, 400, "every evening", "", " \"every evening\"." +20, Dorzolamide, 412, 423, "dorzolamide", "", +22, Dorz/TimFC, 412, 451, "dorzolamide / timolol fixed combination", "", +21, Timolol, 426, 433, "timolol", "", +23, Dorz/TimFC, 454, 458, "DTFC", "", +24, Frequency, 467, 478, "twice daily", "", " \"twice daily\"." +25, OpenAngleGlaucoma, 482, 503, "open - angle glaucoma", "", " ." +103, Precondition, 482, 536, "open - angle glaucoma and ocular hypertensive patients", "", " \"open - angle glaucoma and ocular hypertensive patients\"." +26, OcularHypertension, 508, 527, "ocular hypertensive", "", " ." +27, DoubleBlind, 551, 566, "double - masked", "", " ." +28, Multicenter, 569, 583, "three - center", "", " ." +29, Prospective, 586, 597, "prospective", "", " ." +30, Randomized, 600, 610, "randomized", "", " ." +31, Crossover, 613, 622, "crossover", "", " ." +32, Duration, 643, 651, "8 - week", "", " \"8 - week\"." +113, Precondition, 670, 719, "following a 4 - week medicine free washout period", "", " \"following a 4 - week medicine free washout period\"." +33, Duration, 682, 690, "4 - week", "", +34, Diurnal_IOP, 722, 757, "Diurnal curve intraocular pressures", "", +35, Diurnal_IOP, 760, 764, "IOPs", "", +116, TimePoint, 781, 788, "08 : 00", "", +117, Trough_IOP, 791, 797, "trough", "", +118, TimePoint, 804, 811, "10 : 00", "", +119, TimePoint, 816, 829, "16 : 00 hours", "", +36, NumberPatientsCT, 853, 855, "35", "", " \"35\"." +37, FinalNumPatientsCT, 883, 885, "32", "", " \"32\"." +38, Diurnal_IOP, 945, 966, "intraocular pressures", "", " ." +39, BaseLineValue, 971, 977, "24 . 8", "", " \"24 . 8\". \"24 . 8\"." +124, SdDevBL, 984, 989, "2 . 4", "", " \"2 . 4\". \"2 . 4\"." +41, mmHg, 990, 994, "mmHg", "", " ." +42, Mean, 1030, 1034, "mean", "", " . ." +43, Diurnal_IOP, 1035, 1064, "diurnal intraocular pressures", "", +44, ResultMeasuredValue, 1069, 1075, "17 . 4", "", " \"17 . 4\"." +130, SdDevResValue, 1082, 1087, "2 . 9", "", " \"2 . 9\"." +48, Bimatoprost, 1092, 1103, "bimatoprost", "", +45, ResultMeasuredValue, 1108, 1114, "18 . 1", "", " \"18 . 1\"." +131, SdDevResValue, 1121, 1126, "2 . 8", "", " \"2 . 8\"." +49, mmHg, 1127, 1131, "mmHg", "", +50, Dorz/TimFC, 1136, 1140, "DTFC", "", +135, PvalueDiff, 1145, 1153, "= 0 . 35", "", " \"= 0 . 35\"." +52, IOP, 1189, 1210, "intraocular pressures", "", +53, IOP, 1299, 1320, "intraocular pressures", "", +102388, TimePoint, 1326, 1334, "baseline", "", +139, Diurnal_IOP, 1367, 1380, "diurnal curve", "", +54, PValueChangeValue, 1383, 1398, "p & lt ; 0 . 05", "", " \"p & lt ; 0 . 05\". \"p & lt ; 0 . 05\"." +55, ConjunctivalHyperemia, 1461, 1483, "conjunctival hyperemia", "", " ." +56, Bimatoprost, 1489, 1500, "bimatoprost", "", +58, NumberAffected, 1507, 1509, "15", "", " \"15\"." +57, Dorz/TimFC, 1522, 1526, "DTFC", "", +59, NumberAffected, 1533, 1534, "7", "", " \"7\"." +152, PvalueDiff, 1539, 1548, "= 0 . 013", "", " \"= 0 . 013\"." +102396, EndPointDescription, 1560, 1580, "burning and stinging", "", " . ." +63, Dorz/TimFC, 1586, 1590, "DTFC", "", +64, NumberAffected, 1597, 1599, "12", "", " \"12\"." +66, Bimatoprost, 1612, 1623, "bimatoprost", "", +65, NumberAffected, 1630, 1631, "0", "", +153, PvalueDiff, 1634, 1646, "p = 0 . 0005", "", " \"p = 0 . 0005\"." +68, PvalueDiff, 1775, 1790, "p & gt ; 0 . 05", "", +69, ConclusionComment, 1809, 2000, "This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open - angle glaucoma and ocular hypertensive patients .", "", " \"This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open - angle glaucoma and ocular hypertensive patients .\"." +70, IOP, 1839, 1860, "intraocular pressures", "", +71, Dorz/TimFC, 1912, 1916, "DTFC", "", +72, Bimatoprost, 1929, 1940, "bimatoprost", "", +73, OpenAngleGlaucoma, 1944, 1965, "open - angle glaucoma", "", +74, OcularHypertension, 1970, 1989, "ocular hypertensive", "", +75, PMID, 2045, 2053, "15945001", "", " \"15945001\"." diff --git a/data/gl 15945001_admin.n-triples b/data/gl 15945001_admin.n-triples new file mode 100644 index 0000000..b463ef0 --- /dev/null +++ b/data/gl 15945001_admin.n-triples @@ -0,0 +1,151 @@ +# RDF export of group: Publication + . + "Safety and efficacy of bimatoprost 0 . 03 % versus timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination ." . + "Day DG" . + "2005" . + "Eur J Ophthalmol ." . + "15945001" . + . + "Sharpe ED" . + "Beischel CJ" . + "Jenkins JN" . + "Stewart JA" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 90582" . + "To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide / timolol fixed combination ( DTFC ) given twice daily in open - angle glaucoma and ocular hypertensive patients ." . + "35" . + "8 - week" . + . + . + . + "This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open - angle glaucoma and ocular hypertensive patients ." . + . + . + . + . + . + "32" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 90598" . + "open - angle glaucoma and ocular hypertensive patients" . + . + . + . + "following a 4 - week medicine free washout period" . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "ch" . + . + . + . + . + . + "bs" . + . + . + . + . + . +# RDF export of group: Arm + . + "bim" . + . + . + . + . + . + "doti" . + . + . + . + . +# RDF export of group: Intervention + . + "bim" . + . + "every evening" . + . + . + "doti" . + "twice daily" . + . + . +# RDF export of group: Medication + . + "bim" . + . + "0 . 03" . + . + . + . + "doti" . + . + . + . +# RDF export of group: Outcome + . + "iop1 " . + . + "24 . 8" . + "2 . 4" . + "17 . 4" . + "2 . 9" . + "p & lt ; 0 . 05" . + . + "iop 2" . + . + "24 . 8" . + "2 . 4" . + "18 . 1" . + "2 . 8" . + "p & lt ; 0 . 05" . + . + "ch 1" . + . + "15" . + . + "ch 2" . + . + "7" . + . + "bs 1" . + . + . + "bs 2" . + . + "12" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "= 0 . 35" . + . + . + . + "ch" . + "= 0 . 013" . + . + . + . + "bs" . + "p = 0 . 0005" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15945001_export.csv b/data/gl 15945001_export.csv new file mode 100644 index 0000000..aaf1b15 --- /dev/null +++ b/data/gl 15945001_export.csv @@ -0,0 +1,427 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +551, 1, 1, 1, 0, 3, 0, 3, "Eur" +551, 1, 2, 2, 4, 5, 4, 5, "J" +551, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +551, 1, 4, 4, 17, 18, 17, 18, "." +551, 2, 1, 5, 0, 4, 19, 23, "2005" +551, 2, 2, 6, 5, 8, 24, 27, "May" +551, 2, 3, 7, 9, 10, 28, 29, "-" +551, 2, 4, 8, 11, 14, 30, 33, "Jun" +551, 2, 5, 9, 15, 16, 34, 35, ";" +551, 2, 6, 10, 17, 19, 36, 38, "15" +551, 2, 7, 11, 20, 21, 39, 40, "(" +551, 2, 8, 12, 22, 23, 41, 42, "3" +551, 2, 9, 13, 24, 25, 43, 44, ")" +551, 2, 10, 14, 26, 27, 45, 46, ":" +551, 2, 11, 15, 28, 31, 47, 50, "336" +551, 2, 12, 16, 32, 33, 51, 52, "-" +551, 2, 13, 17, 34, 36, 53, 55, "42" +551, 2, 14, 18, 37, 38, 56, 57, "." +551, 3, 1, 19, 0, 6, 58, 64, "Safety" +551, 3, 2, 20, 7, 10, 65, 68, "and" +551, 3, 3, 21, 11, 19, 69, 77, "efficacy" +551, 3, 4, 22, 20, 22, 78, 80, "of" +551, 3, 5, 23, 23, 34, 81, 92, "bimatoprost" +551, 3, 6, 24, 35, 36, 93, 94, "0" +551, 3, 7, 25, 37, 38, 95, 96, "." +551, 3, 8, 26, 39, 41, 97, 99, "03" +551, 3, 9, 27, 42, 43, 100, 101, "%" +551, 3, 10, 28, 44, 50, 102, 108, "versus" +551, 3, 11, 29, 51, 58, 109, 116, "timolol" +551, 3, 12, 30, 59, 66, 117, 124, "maleate" +551, 3, 13, 31, 67, 68, 125, 126, "0" +551, 3, 14, 32, 69, 70, 127, 128, "." +551, 3, 15, 33, 71, 72, 129, 130, "5" +551, 3, 16, 34, 73, 74, 131, 132, "%" +551, 3, 17, 35, 75, 76, 133, 134, "/" +551, 3, 18, 36, 77, 88, 135, 146, "dorzolamide" +551, 3, 19, 37, 89, 90, 147, 148, "2" +551, 3, 20, 38, 91, 92, 149, 150, "%" +551, 3, 21, 39, 93, 98, 151, 156, "fixed" +551, 3, 22, 40, 99, 110, 157, 168, "combination" +551, 3, 23, 41, 111, 112, 169, 170, "." +551, 4, 1, 42, 0, 3, 171, 174, "Day" +551, 4, 2, 43, 4, 6, 175, 177, "DG" +551, 4, 3, 44, 7, 8, 178, 179, "(" +551, 4, 4, 45, 9, 10, 180, 181, "1" +551, 4, 5, 46, 11, 12, 182, 183, ")" +551, 4, 6, 47, 13, 14, 184, 185, "," +551, 4, 7, 48, 15, 21, 186, 192, "Sharpe" +551, 4, 8, 49, 22, 24, 193, 195, "ED" +551, 4, 9, 50, 25, 26, 196, 197, "," +551, 4, 10, 51, 27, 35, 198, 206, "Beischel" +551, 4, 11, 52, 36, 38, 207, 209, "CJ" +551, 4, 12, 53, 39, 40, 210, 211, "," +551, 4, 13, 54, 41, 48, 212, 219, "Jenkins" +551, 4, 14, 55, 49, 51, 220, 222, "JN" +551, 4, 15, 56, 52, 53, 223, 224, "," +551, 4, 16, 57, 54, 61, 225, 232, "Stewart" +551, 4, 17, 58, 62, 64, 233, 235, "JA" +551, 4, 18, 59, 65, 66, 236, 237, "," +551, 4, 19, 60, 67, 74, 238, 245, "Stewart" +551, 4, 20, 61, 75, 77, 246, 248, "WC" +551, 4, 21, 62, 78, 79, 249, 250, "." +551, 5, 1, 63, 0, 6, 251, 257, "Author" +551, 5, 2, 64, 7, 18, 258, 269, "information" +551, 5, 3, 65, 19, 20, 270, 271, ":" +551, 5, 4, 66, 21, 22, 272, 273, "(" +551, 5, 5, 67, 23, 24, 274, 275, "1" +551, 5, 6, 68, 25, 26, 276, 277, ")" +551, 5, 7, 69, 27, 31, 278, 282, "Omni" +551, 5, 8, 70, 32, 35, 283, 286, "Eye" +551, 5, 9, 71, 36, 44, 287, 295, "Services" +551, 5, 10, 72, 45, 46, 296, 297, "," +551, 5, 11, 73, 47, 54, 298, 305, "Atlanta" +551, 5, 12, 74, 55, 56, 306, 307, "," +551, 5, 13, 75, 57, 59, 308, 310, "GA" +551, 5, 14, 76, 60, 61, 311, 312, "," +551, 5, 15, 77, 62, 65, 313, 316, "USA" +551, 5, 16, 78, 66, 67, 317, 318, "." +551, 6, 1, 79, 0, 7, 319, 326, "PURPOSE" +551, 6, 2, 80, 8, 9, 327, 328, ":" +551, 6, 3, 81, 10, 12, 329, 331, "To" +551, 6, 4, 82, 13, 22, 332, 341, "determine" +551, 6, 5, 83, 23, 26, 342, 345, "the" +551, 6, 6, 84, 27, 35, 346, 354, "efficacy" +551, 6, 7, 85, 36, 39, 355, 358, "and" +551, 6, 8, 86, 40, 46, 359, 365, "safety" +551, 6, 9, 87, 47, 49, 366, 368, "of" +551, 6, 10, 88, 50, 61, 369, 380, "bimatoprost" +551, 6, 11, 89, 62, 67, 381, 386, "given" +551, 6, 12, 90, 68, 73, 387, 392, "every" +551, 6, 13, 91, 74, 81, 393, 400, "evening" +551, 6, 14, 92, 82, 88, 401, 407, "versus" +551, 6, 15, 93, 89, 92, 408, 411, "the" +551, 6, 16, 94, 93, 104, 412, 423, "dorzolamide" +551, 6, 17, 95, 105, 106, 424, 425, "/" +551, 6, 18, 96, 107, 114, 426, 433, "timolol" +551, 6, 19, 97, 115, 120, 434, 439, "fixed" +551, 6, 20, 98, 121, 132, 440, 451, "combination" +551, 6, 21, 99, 133, 134, 452, 453, "(" +551, 6, 22, 100, 135, 139, 454, 458, "DTFC" +551, 6, 23, 101, 140, 141, 459, 460, ")" +551, 6, 24, 102, 142, 147, 461, 466, "given" +551, 6, 25, 103, 148, 153, 467, 472, "twice" +551, 6, 26, 104, 154, 159, 473, 478, "daily" +551, 6, 27, 105, 160, 162, 479, 481, "in" +551, 6, 28, 106, 163, 167, 482, 486, "open" +551, 6, 29, 107, 168, 169, 487, 488, "-" +551, 6, 30, 108, 170, 175, 489, 494, "angle" +551, 6, 31, 109, 176, 184, 495, 503, "glaucoma" +551, 6, 32, 110, 185, 188, 504, 507, "and" +551, 6, 33, 111, 189, 195, 508, 514, "ocular" +551, 6, 34, 112, 196, 208, 515, 527, "hypertensive" +551, 6, 35, 113, 209, 217, 528, 536, "patients" +551, 6, 36, 114, 218, 219, 537, 538, "." +551, 7, 1, 115, 0, 7, 539, 546, "METHODS" +551, 7, 2, 116, 8, 9, 547, 548, ":" +551, 7, 3, 117, 10, 11, 549, 550, "A" +551, 7, 4, 118, 12, 18, 551, 557, "double" +551, 7, 5, 119, 19, 20, 558, 559, "-" +551, 7, 6, 120, 21, 27, 560, 566, "masked" +551, 7, 7, 121, 28, 29, 567, 568, "," +551, 7, 8, 122, 30, 35, 569, 574, "three" +551, 7, 9, 123, 36, 37, 575, 576, "-" +551, 7, 10, 124, 38, 44, 577, 583, "center" +551, 7, 11, 125, 45, 46, 584, 585, "," +551, 7, 12, 126, 47, 58, 586, 597, "prospective" +551, 7, 13, 127, 59, 60, 598, 599, "," +551, 7, 14, 128, 61, 71, 600, 610, "randomized" +551, 7, 15, 129, 72, 73, 611, 612, "," +551, 7, 16, 130, 74, 83, 613, 622, "crossover" +551, 7, 17, 131, 84, 94, 623, 633, "comparison" +551, 7, 18, 132, 95, 99, 634, 638, "with" +551, 7, 19, 133, 100, 103, 639, 642, "two" +551, 7, 20, 134, 104, 105, 643, 644, "8" +551, 7, 21, 135, 106, 107, 645, 646, "-" +551, 7, 22, 136, 108, 112, 647, 651, "week" +551, 7, 23, 137, 113, 122, 652, 661, "treatment" +551, 7, 24, 138, 123, 130, 662, 669, "periods" +551, 7, 25, 139, 131, 140, 670, 679, "following" +551, 7, 26, 140, 141, 142, 680, 681, "a" +551, 7, 27, 141, 143, 144, 682, 683, "4" +551, 7, 28, 142, 145, 146, 684, 685, "-" +551, 7, 29, 143, 147, 151, 686, 690, "week" +551, 7, 30, 144, 152, 160, 691, 699, "medicine" +551, 7, 31, 145, 161, 165, 700, 704, "free" +551, 7, 32, 146, 166, 173, 705, 712, "washout" +551, 7, 33, 147, 174, 180, 713, 719, "period" +551, 7, 34, 148, 181, 182, 720, 721, "." +551, 8, 1, 149, 0, 7, 722, 729, "Diurnal" +551, 8, 2, 150, 8, 13, 730, 735, "curve" +551, 8, 3, 151, 14, 25, 736, 747, "intraocular" +551, 8, 4, 152, 26, 35, 748, 757, "pressures" +551, 8, 5, 153, 36, 37, 758, 759, "(" +551, 8, 6, 154, 38, 42, 760, 764, "IOPs" +551, 8, 7, 155, 43, 44, 765, 766, ")" +551, 8, 8, 156, 45, 49, 767, 771, "were" +551, 8, 9, 157, 50, 55, 772, 777, "taken" +551, 8, 10, 158, 56, 58, 778, 780, "at" +551, 8, 11, 159, 59, 61, 781, 783, "08" +551, 8, 12, 160, 62, 63, 784, 785, ":" +551, 8, 13, 161, 64, 66, 786, 788, "00" +551, 8, 14, 162, 67, 68, 789, 790, "(" +551, 8, 15, 163, 69, 75, 791, 797, "trough" +551, 8, 16, 164, 76, 77, 798, 799, ")" +551, 8, 17, 165, 78, 81, 800, 803, "and" +551, 8, 18, 166, 82, 84, 804, 806, "10" +551, 8, 19, 167, 85, 86, 807, 808, ":" +551, 8, 20, 168, 87, 89, 809, 811, "00" +551, 8, 21, 169, 90, 93, 812, 815, "and" +551, 8, 22, 170, 94, 96, 816, 818, "16" +551, 8, 23, 171, 97, 98, 819, 820, ":" +551, 8, 24, 172, 99, 101, 821, 823, "00" +551, 8, 25, 173, 102, 107, 824, 829, "hours" +551, 8, 26, 174, 108, 109, 830, 831, "." +551, 9, 1, 175, 0, 7, 832, 839, "RESULTS" +551, 9, 2, 176, 8, 9, 840, 841, ":" +551, 9, 3, 177, 10, 11, 842, 843, "A" +551, 9, 4, 178, 12, 17, 844, 849, "total" +551, 9, 5, 179, 18, 20, 850, 852, "of" +551, 9, 6, 180, 21, 23, 853, 855, "35" +551, 9, 7, 181, 24, 32, 856, 864, "patients" +551, 9, 8, 182, 33, 37, 865, 869, "were" +551, 9, 9, 183, 38, 46, 870, 878, "enrolled" +551, 9, 10, 184, 47, 50, 879, 882, "and" +551, 9, 11, 185, 51, 53, 883, 885, "32" +551, 9, 12, 186, 54, 63, 886, 895, "completed" +551, 9, 13, 187, 64, 67, 896, 899, "all" +551, 9, 14, 188, 68, 79, 900, 911, "evaluations" +551, 9, 15, 189, 80, 81, 912, 913, "." +551, 10, 1, 190, 0, 3, 914, 917, "The" +551, 10, 2, 191, 4, 11, 918, 925, "diurnal" +551, 10, 3, 192, 12, 21, 926, 935, "untreated" +551, 10, 4, 193, 22, 30, 936, 944, "baseline" +551, 10, 5, 194, 31, 42, 945, 956, "intraocular" +551, 10, 6, 195, 43, 52, 957, 966, "pressures" +551, 10, 7, 196, 53, 56, 967, 970, "was" +551, 10, 8, 197, 57, 59, 971, 973, "24" +551, 10, 9, 198, 60, 61, 974, 975, "." +551, 10, 10, 199, 62, 63, 976, 977, "8" +551, 10, 11, 200, 64, 65, 978, 979, "+" +551, 10, 12, 201, 66, 67, 980, 981, "/" +551, 10, 13, 202, 68, 69, 982, 983, "-" +551, 10, 14, 203, 70, 71, 984, 985, "2" +551, 10, 15, 204, 72, 73, 986, 987, "." +551, 10, 16, 205, 74, 75, 988, 989, "4" +551, 10, 17, 206, 76, 80, 990, 994, "mmHg" +551, 10, 18, 207, 81, 82, 995, 996, "." +551, 11, 1, 208, 0, 2, 997, 999, "On" +551, 11, 2, 209, 3, 6, 1000, 1003, "the" +551, 11, 3, 210, 7, 11, 1004, 1008, "last" +551, 11, 4, 211, 12, 15, 1009, 1012, "day" +551, 11, 5, 212, 16, 18, 1013, 1015, "of" +551, 11, 6, 213, 19, 28, 1016, 1025, "treatment" +551, 11, 7, 214, 29, 32, 1026, 1029, "the" +551, 11, 8, 215, 33, 37, 1030, 1034, "mean" +551, 11, 9, 216, 38, 45, 1035, 1042, "diurnal" +551, 11, 10, 217, 46, 57, 1043, 1054, "intraocular" +551, 11, 11, 218, 58, 67, 1055, 1064, "pressures" +551, 11, 12, 219, 68, 71, 1065, 1068, "was" +551, 11, 13, 220, 72, 74, 1069, 1071, "17" +551, 11, 14, 221, 75, 76, 1072, 1073, "." +551, 11, 15, 222, 77, 78, 1074, 1075, "4" +551, 11, 16, 223, 79, 80, 1076, 1077, "+" +551, 11, 17, 224, 81, 82, 1078, 1079, "/" +551, 11, 18, 225, 83, 84, 1080, 1081, "-" +551, 11, 19, 226, 85, 86, 1082, 1083, "2" +551, 11, 20, 227, 87, 88, 1084, 1085, "." +551, 11, 21, 228, 89, 90, 1086, 1087, "9" +551, 11, 22, 229, 91, 94, 1088, 1091, "for" +551, 11, 23, 230, 95, 106, 1092, 1103, "bimatoprost" +551, 11, 24, 231, 107, 110, 1104, 1107, "and" +551, 11, 25, 232, 111, 113, 1108, 1110, "18" +551, 11, 26, 233, 114, 115, 1111, 1112, "." +551, 11, 27, 234, 116, 117, 1113, 1114, "1" +551, 11, 28, 235, 118, 119, 1115, 1116, "+" +551, 11, 29, 236, 120, 121, 1117, 1118, "/" +551, 11, 30, 237, 122, 123, 1119, 1120, "-" +551, 11, 31, 238, 124, 125, 1121, 1122, "2" +551, 11, 32, 239, 126, 127, 1123, 1124, "." +551, 11, 33, 240, 128, 129, 1125, 1126, "8" +551, 11, 34, 241, 130, 134, 1127, 1131, "mmHg" +551, 11, 35, 242, 135, 138, 1132, 1135, "for" +551, 11, 36, 243, 139, 143, 1136, 1140, "DTFC" +551, 11, 37, 244, 144, 145, 1141, 1142, "(" +551, 11, 38, 245, 146, 147, 1143, 1144, "p" +551, 11, 39, 246, 148, 149, 1145, 1146, "=" +551, 11, 40, 247, 150, 151, 1147, 1148, "0" +551, 11, 41, 248, 152, 153, 1149, 1150, "." +551, 11, 42, 249, 154, 156, 1151, 1153, "35" +551, 11, 43, 250, 157, 158, 1154, 1155, ")" +551, 11, 44, 251, 159, 160, 1156, 1157, "." +551, 12, 1, 252, 0, 3, 1158, 1161, "The" +551, 12, 2, 253, 4, 14, 1162, 1172, "individual" +551, 12, 3, 254, 15, 19, 1173, 1177, "time" +551, 12, 4, 255, 20, 26, 1178, 1184, "points" +551, 12, 5, 256, 27, 30, 1185, 1188, "for" +551, 12, 6, 257, 31, 42, 1189, 1200, "intraocular" +551, 12, 7, 258, 43, 52, 1201, 1210, "pressures" +551, 12, 8, 259, 53, 57, 1211, 1215, "were" +551, 12, 9, 260, 58, 61, 1216, 1219, "not" +551, 12, 10, 261, 62, 75, 1220, 1233, "statistically" +551, 12, 11, 262, 76, 85, 1234, 1243, "different" +551, 12, 12, 263, 86, 93, 1244, 1251, "between" +551, 12, 13, 264, 94, 100, 1252, 1258, "groups" +551, 12, 14, 265, 101, 102, 1259, 1260, "." +551, 13, 1, 266, 0, 4, 1261, 1265, "Both" +551, 13, 2, 267, 5, 11, 1266, 1272, "groups" +551, 13, 3, 268, 12, 25, 1273, 1286, "statistically" +551, 13, 4, 269, 26, 33, 1287, 1294, "reduced" +551, 13, 5, 270, 34, 37, 1295, 1298, "the" +551, 13, 6, 271, 38, 49, 1299, 1310, "intraocular" +551, 13, 7, 272, 50, 59, 1311, 1320, "pressures" +551, 13, 8, 273, 60, 64, 1321, 1325, "from" +551, 13, 9, 274, 65, 73, 1326, 1334, "baseline" +551, 13, 10, 275, 74, 77, 1335, 1338, "for" +551, 13, 11, 276, 78, 82, 1339, 1343, "each" +551, 13, 12, 277, 83, 87, 1344, 1348, "time" +551, 13, 13, 278, 88, 93, 1349, 1354, "point" +551, 13, 14, 279, 94, 97, 1355, 1358, "and" +551, 13, 15, 280, 98, 101, 1359, 1362, "for" +551, 13, 16, 281, 102, 105, 1363, 1366, "the" +551, 13, 17, 282, 106, 113, 1367, 1374, "diurnal" +551, 13, 18, 283, 114, 119, 1375, 1380, "curve" +551, 13, 19, 284, 120, 121, 1381, 1382, "(" +551, 13, 20, 285, 122, 123, 1383, 1384, "p" +551, 13, 21, 286, 124, 125, 1385, 1386, "&" +551, 13, 22, 287, 126, 128, 1387, 1389, "lt" +551, 13, 23, 288, 129, 130, 1390, 1391, ";" +551, 13, 24, 289, 131, 132, 1392, 1393, "0" +551, 13, 25, 290, 133, 134, 1394, 1395, "." +551, 13, 26, 291, 135, 137, 1396, 1398, "05" +551, 13, 27, 292, 138, 139, 1399, 1400, ")" +551, 13, 28, 293, 140, 141, 1401, 1402, "." +551, 14, 1, 294, 0, 9, 1403, 1412, "Regarding" +551, 14, 2, 295, 10, 16, 1413, 1419, "ocular" +551, 14, 3, 296, 17, 23, 1420, 1426, "safety" +551, 14, 4, 297, 24, 27, 1427, 1430, "and" +551, 14, 5, 298, 28, 40, 1431, 1443, "tolerability" +551, 14, 6, 299, 41, 42, 1444, 1445, "," +551, 14, 7, 300, 43, 48, 1446, 1451, "there" +551, 14, 8, 301, 49, 52, 1452, 1455, "was" +551, 14, 9, 302, 53, 57, 1456, 1460, "more" +551, 14, 10, 303, 58, 70, 1461, 1473, "conjunctival" +551, 14, 11, 304, 71, 80, 1474, 1483, "hyperemia" +551, 14, 12, 305, 81, 85, 1484, 1488, "with" +551, 14, 13, 306, 86, 97, 1489, 1500, "bimatoprost" +551, 14, 14, 307, 98, 99, 1501, 1502, "(" +551, 14, 15, 308, 100, 101, 1503, 1504, "n" +551, 14, 16, 309, 102, 103, 1505, 1506, "=" +551, 14, 17, 310, 104, 106, 1507, 1509, "15" +551, 14, 18, 311, 107, 108, 1510, 1511, ")" +551, 14, 19, 312, 109, 113, 1512, 1516, "than" +551, 14, 20, 313, 114, 118, 1517, 1521, "with" +551, 14, 21, 314, 119, 123, 1522, 1526, "DTFC" +551, 14, 22, 315, 124, 125, 1527, 1528, "(" +551, 14, 23, 316, 126, 127, 1529, 1530, "n" +551, 14, 24, 317, 128, 129, 1531, 1532, "=" +551, 14, 25, 318, 130, 131, 1533, 1534, "7" +551, 14, 26, 319, 132, 133, 1535, 1536, "," +551, 14, 27, 320, 134, 135, 1537, 1538, "p" +551, 14, 28, 321, 136, 137, 1539, 1540, "=" +551, 14, 29, 322, 138, 139, 1541, 1542, "0" +551, 14, 30, 323, 140, 141, 1543, 1544, "." +551, 14, 31, 324, 142, 145, 1545, 1548, "013" +551, 14, 32, 325, 146, 147, 1549, 1550, ")" +551, 14, 33, 326, 148, 151, 1551, 1554, "and" +551, 14, 34, 327, 152, 156, 1555, 1559, "more" +551, 14, 35, 328, 157, 164, 1560, 1567, "burning" +551, 14, 36, 329, 165, 168, 1568, 1571, "and" +551, 14, 37, 330, 169, 177, 1572, 1580, "stinging" +551, 14, 38, 331, 178, 182, 1581, 1585, "with" +551, 14, 39, 332, 183, 187, 1586, 1590, "DTFC" +551, 14, 40, 333, 188, 189, 1591, 1592, "(" +551, 14, 41, 334, 190, 191, 1593, 1594, "n" +551, 14, 42, 335, 192, 193, 1595, 1596, "=" +551, 14, 43, 336, 194, 196, 1597, 1599, "12" +551, 14, 44, 337, 197, 198, 1600, 1601, ")" +551, 14, 45, 338, 199, 203, 1602, 1606, "than" +551, 14, 46, 339, 204, 208, 1607, 1611, "with" +551, 14, 47, 340, 209, 220, 1612, 1623, "bimatoprost" +551, 14, 48, 341, 221, 222, 1624, 1625, "(" +551, 14, 49, 342, 223, 224, 1626, 1627, "n" +551, 14, 50, 343, 225, 226, 1628, 1629, "=" +551, 14, 51, 344, 227, 228, 1630, 1631, "0" +551, 14, 52, 345, 229, 230, 1632, 1633, "," +551, 14, 53, 346, 231, 232, 1634, 1635, "p" +551, 14, 54, 347, 233, 234, 1636, 1637, "=" +551, 14, 55, 348, 235, 236, 1638, 1639, "0" +551, 14, 56, 349, 237, 238, 1640, 1641, "." +551, 14, 57, 350, 239, 243, 1642, 1646, "0005" +551, 14, 58, 351, 244, 245, 1647, 1648, ")" +551, 14, 59, 352, 246, 247, 1649, 1650, "." +551, 15, 1, 353, 0, 3, 1651, 1654, "Few" +551, 15, 2, 354, 4, 12, 1655, 1663, "systemic" +551, 15, 3, 355, 13, 20, 1664, 1671, "adverse" +551, 15, 4, 356, 21, 27, 1672, 1678, "events" +551, 15, 5, 357, 28, 32, 1679, 1683, "were" +551, 15, 6, 358, 33, 41, 1684, 1692, "recorded" +551, 15, 7, 359, 42, 45, 1693, 1696, "and" +551, 15, 8, 360, 46, 51, 1697, 1702, "there" +551, 15, 9, 361, 52, 55, 1703, 1706, "was" +551, 15, 10, 362, 56, 58, 1707, 1709, "no" +551, 15, 11, 363, 59, 70, 1710, 1721, "statistical" +551, 15, 12, 364, 71, 81, 1722, 1732, "difference" +551, 15, 13, 365, 82, 89, 1733, 1740, "between" +551, 15, 14, 366, 90, 96, 1741, 1747, "groups" +551, 15, 15, 367, 97, 100, 1748, 1751, "for" +551, 15, 16, 368, 101, 104, 1752, 1755, "any" +551, 15, 17, 369, 105, 115, 1756, 1766, "individual" +551, 15, 18, 370, 116, 121, 1767, 1772, "event" +551, 15, 19, 371, 122, 123, 1773, 1774, "(" +551, 15, 20, 372, 124, 125, 1775, 1776, "p" +551, 15, 21, 373, 126, 127, 1777, 1778, "&" +551, 15, 22, 374, 128, 130, 1779, 1781, "gt" +551, 15, 23, 375, 131, 132, 1782, 1783, ";" +551, 15, 24, 376, 133, 134, 1784, 1785, "0" +551, 15, 25, 377, 135, 136, 1786, 1787, "." +551, 15, 26, 378, 137, 139, 1788, 1790, "05" +551, 15, 27, 379, 140, 141, 1791, 1792, ")" +551, 15, 28, 380, 142, 143, 1793, 1794, "." +551, 16, 1, 381, 0, 11, 1795, 1806, "CONCLUSIONS" +551, 16, 2, 382, 12, 13, 1807, 1808, ":" +551, 16, 3, 383, 14, 18, 1809, 1813, "This" +551, 16, 4, 384, 19, 24, 1814, 1819, "study" +551, 16, 5, 385, 25, 34, 1820, 1829, "indicates" +551, 16, 6, 386, 35, 39, 1830, 1834, "that" +551, 16, 7, 387, 40, 43, 1835, 1838, "the" +551, 16, 8, 388, 44, 55, 1839, 1850, "intraocular" +551, 16, 9, 389, 56, 65, 1851, 1860, "pressures" +551, 16, 10, 390, 66, 69, 1861, 1864, "are" +551, 16, 11, 391, 70, 77, 1865, 1872, "lowered" +551, 16, 12, 392, 78, 80, 1873, 1875, "to" +551, 16, 13, 393, 81, 82, 1876, 1877, "a" +551, 16, 14, 394, 83, 96, 1878, 1891, "statistically" +551, 16, 15, 395, 97, 104, 1892, 1899, "similar" +551, 16, 16, 396, 105, 111, 1900, 1906, "amount" +551, 16, 17, 397, 112, 116, 1907, 1911, "with" +551, 16, 18, 398, 117, 121, 1912, 1916, "DTFC" +551, 16, 19, 399, 122, 130, 1917, 1925, "compared" +551, 16, 20, 400, 131, 133, 1926, 1928, "to" +551, 16, 21, 401, 134, 145, 1929, 1940, "bimatoprost" +551, 16, 22, 402, 146, 148, 1941, 1943, "in" +551, 16, 23, 403, 149, 153, 1944, 1948, "open" +551, 16, 24, 404, 154, 155, 1949, 1950, "-" +551, 16, 25, 405, 156, 161, 1951, 1956, "angle" +551, 16, 26, 406, 162, 170, 1957, 1965, "glaucoma" +551, 16, 27, 407, 171, 174, 1966, 1969, "and" +551, 16, 28, 408, 175, 181, 1970, 1976, "ocular" +551, 16, 29, 409, 182, 194, 1977, 1989, "hypertensive" +551, 16, 30, 410, 195, 203, 1990, 1998, "patients" +551, 16, 31, 411, 204, 205, 1999, 2000, "." +551, 17, 1, 412, 0, 3, 2001, 2004, "DOI" +551, 17, 2, 413, 4, 5, 2005, 2006, ":" +551, 17, 3, 414, 6, 8, 2007, 2009, "10" +551, 17, 4, 415, 9, 10, 2010, 2011, "." +551, 17, 5, 416, 11, 15, 2012, 2016, "1177" +551, 17, 6, 417, 16, 17, 2017, 2018, "/" +551, 17, 7, 418, 18, 36, 2019, 2037, "112067210501500304" +551, 17, 8, 419, 37, 41, 2038, 2042, "PMID" +551, 17, 9, 420, 42, 43, 2043, 2044, ":" +551, 17, 10, 421, 44, 52, 2045, 2053, "15945001" +551, 17, 11, 422, 53, 54, 2054, 2055, "[" +551, 17, 12, 423, 55, 62, 2056, 2063, "Indexed" +551, 17, 13, 424, 63, 66, 2064, 2067, "for" +551, 17, 14, 425, 67, 74, 2068, 2075, "MEDLINE" +551, 17, 15, 426, 75, 76, 2076, 2077, "]" diff --git a/data/gl 15945001_jshahinitiran.annodb b/data/gl 15945001_jshahinitiran.annodb new file mode 100644 index 0000000..dfc348a --- /dev/null +++ b/data/gl 15945001_jshahinitiran.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +85567, Journal, 0, 16, "Eur J Ophthalmol", "", +85568, PublicationYear, 19, 23, "2005", "", +85569, Title, 58, 170, "Safety and efficacy of bimatoprost 0 . 03 % versus timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination .", "", +85570, Bimatoprost, 81, 92, "bimatoprost", "", +85573, DoseValue, 93, 99, "0 . 03", "", +85571, Timolol, 109, 124, "timolol maleate", "", +85576, Dorz/TimFC, 109, 168, "timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination", "", +85574, DoseValue, 125, 130, "0 . 5", "", +85572, Dorzolamide, 135, 146, "dorzolamide", "", +85575, DoseValue, 147, 148, "2", "", +85577, Author, 171, 177, "Day DG", "", +85578, Author, 186, 195, "Sharpe ED", "", +85579, Author, 198, 209, "Beischel CJ", "", +85580, Author, 212, 222, "Jenkins JN", "", +85581, Author, 225, 235, "Stewart JA", "", +85582, Author, 238, 248, "Stewart WC", "", +85606, USA, 313, 316, "USA", "", +85609, ObjectiveDescription, 329, 538, "To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide / timolol fixed combination ( DTFC ) given twice daily in open - angle glaucoma and ocular hypertensive patients .", "", +85657, Bimatoprost, 369, 380, "bimatoprost", "", +85659, Evening, 393, 400, "evening", "", +85660, Dorzolamide, 412, 423, "dorzolamide", "", +85665, Dorz/TimFC, 412, 451, "dorzolamide / timolol fixed combination", "", +85662, Timolol, 426, 433, "timolol", "", +85666, Dorz/TimFC, 454, 458, "DTFC", "", +85668, Frequency, 467, 478, "twice daily", "", +85669, OpenAngleGlaucoma, 482, 503, "open - angle glaucoma", "", +85670, OcularHypertension, 508, 527, "ocular hypertensive", "", +85672, DoubleBlind, 551, 566, "double - masked", "", +85673, Multicenter, 569, 583, "three - center", "", +85675, Prospective, 586, 597, "prospective", "", +85676, Randomized, 600, 610, "randomized", "", +85678, Crossover, 613, 622, "crossover", "", +85679, Duration, 643, 651, "8 - week", "", +85680, Duration, 682, 690, "4 - week", "", +85682, Diurnal_IOP, 722, 757, "Diurnal curve intraocular pressures", "", +85684, Diurnal_IOP, 760, 764, "IOPs", "", +85687, NumberPatientsCT, 853, 855, "35", "", +85688, FinalNumPatientsCT, 883, 885, "32", "", +85689, Diurnal_IOP, 945, 966, "intraocular pressures", "", +85690, BaseLineValue, 971, 977, "24 . 8", "", +85691, SdErrorBL, 984, 989, "2 . 4", "", +85692, mmHg, 990, 994, "mmHg", "", +85706, Mean, 1030, 1034, "mean", "", +85708, Diurnal_IOP, 1035, 1064, "diurnal intraocular pressures", "", +85709, ResultMeasuredValue, 1069, 1075, "17 . 4", "", +85713, SdErrorResValue, 1082, 1087, "2 . 9", "", +85716, Bimatoprost, 1092, 1103, "bimatoprost", "", +85710, ResultMeasuredValue, 1108, 1114, "18 . 1", "", +85714, SdErrorResValue, 1121, 1126, "2 . 8", "", +85718, mmHg, 1127, 1131, "mmHg", "", +85720, Dorz/TimFC, 1136, 1140, "DTFC", "", +85721, PValueResValue, 1143, 1153, "p = 0 . 35", "", +85723, IOP, 1189, 1210, "intraocular pressures", "", +85726, IOP, 1299, 1320, "intraocular pressures", "", +85729, PValueChangeValue, 1383, 1398, "p & lt ; 0 . 05", "", +85730, ConjunctivalHyperemia, 1461, 1483, "conjunctival hyperemia", "", +85731, Bimatoprost, 1489, 1500, "bimatoprost", "", +85733, NumberAffected, 1507, 1509, "15", "", +85732, Dorz/TimFC, 1522, 1526, "DTFC", "", +85734, NumberAffected, 1533, 1534, "7", "", +85735, PValueNumAffected, 1537, 1548, "p = 0 . 013", "", +85737, Stinging, 1572, 1580, "stinging", "", +85739, Dorz/TimFC, 1586, 1590, "DTFC", "", +85741, NumberAffected, 1597, 1599, "12", "", +85743, Bimatoprost, 1612, 1623, "bimatoprost", "", +85742, NumberAffected, 1630, 1631, "0", "", +85745, PValueNumAffected, 1634, 1646, "p = 0 . 0005", "", +85746, PvalueDiff, 1775, 1790, "p & gt ; 0 . 05", "", +85747, ConclusionComment, 1809, 2000, "This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open - angle glaucoma and ocular hypertensive patients .", "", +85748, IOP, 1839, 1860, "intraocular pressures", "", +85749, Dorz/TimFC, 1912, 1916, "DTFC", "", +85750, Bimatoprost, 1929, 1940, "bimatoprost", "", +85751, OpenAngleGlaucoma, 1944, 1965, "open - angle glaucoma", "", +85752, OcularHypertension, 1970, 1989, "ocular hypertensive", "", +85753, PMID, 2045, 2053, "15945001", "", diff --git a/data/gl 15945001_jshahinitiran.n-triples b/data/gl 15945001_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15945001_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15945001_tstrakeljahn.annodb b/data/gl 15945001_tstrakeljahn.annodb new file mode 100644 index 0000000..9f1295b --- /dev/null +++ b/data/gl 15945001_tstrakeljahn.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90930, Journal, 0, 16, "Eur J Ophthalmol", "", +90931, PublicationYear, 19, 23, "2005", "", +90942, Title, 58, 170, "Safety and efficacy of bimatoprost 0 . 03 % versus timolol maleate 0 . 5 % / dorzolamide 2 % fixed combination .", "", +90932, Bimatoprost, 81, 92, "bimatoprost", "", +90935, DoseValue, 93, 99, "0 . 03", "", +90938, Percentage, 100, 101, "%", "", +90933, Timolol, 109, 124, "timolol maleate", "", +90941, Dorz/TimFC, 109, 150, "timolol maleate 0 . 5 % / dorzolamide 2 %", "", +90936, DoseValue, 125, 130, "0 . 5", "", +90939, Percentage, 131, 132, "%", "", +90934, Dorzolamide, 135, 146, "dorzolamide", "", +90937, DoseValue, 147, 148, "2", "", +90940, Percentage, 149, 150, "%", "", +90943, Author, 171, 177, "Day DG", "", +90944, Author, 186, 195, "Sharpe ED", "", +90945, Author, 198, 209, "Beischel CJ", "", +90946, Author, 212, 222, "Jenkins JN", "", +90947, Author, 225, 235, "Stewart JA", "", +90948, Author, 238, 248, "Stewart WC", "", +90949, USA, 313, 316, "USA", "", +90961, ObjectiveDescription, 329, 538, "To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide / timolol fixed combination ( DTFC ) given twice daily in open - angle glaucoma and ocular hypertensive patients .", "", +90950, Bimatoprost, 369, 380, "bimatoprost", "", +90960, Frequency, 387, 400, "every evening", "", +90959, Evening, 393, 400, "evening", "", +90951, Dorzolamide, 412, 423, "dorzolamide", "", +90954, Dorz/TimFC, 412, 433, "dorzolamide / timolol", "", +90952, Timolol, 426, 433, "timolol", "", +90953, Dorz/TimFC, 454, 458, "DTFC", "", +90958, Frequency, 467, 478, "twice daily", "", +90955, OpenAngleGlaucoma, 482, 503, "open - angle glaucoma", "", +90957, Precondition, 482, 536, "open - angle glaucoma and ocular hypertensive patients", "", +90956, OcularHypertension, 508, 527, "ocular hypertensive", "", +90962, DoubleBlind, 551, 566, "double - masked", "", +90963, Multicenter, 569, 583, "three - center", "", +90964, Prospective, 586, 597, "prospective", "", +90965, Randomized, 600, 610, "randomized", "", +90966, Crossover, 613, 622, "crossover", "", +90967, Precondition, 670, 719, "following a 4 - week medicine free washout period", "", +90968, Diurnal_IOP, 722, 757, "Diurnal curve intraocular pressures", "", +90969, IOP, 760, 764, "IOPs", "", +90970, TimePoint, 781, 788, "08 : 00", "", +90971, Trough_IOP, 791, 797, "trough", "", +90972, TimePoint, 804, 811, "10 : 00", "", +90973, TimePoint, 816, 829, "16 : 00 hours", "", +90975, NumberPatientsCT, 853, 855, "35", "", +90974, FinalNumPatientsCT, 883, 885, "32", "", +90976, IOP, 945, 966, "intraocular pressures", "", +90977, BaseLineValue, 971, 977, "24 . 8", "", +90978, SdDevBL, 984, 989, "2 . 4", "", +90979, mmHg, 990, 994, "mmHg", "", +90980, Mean, 1030, 1034, "mean", "", +90981, Diurnal_IOP, 1035, 1064, "diurnal intraocular pressures", "", +90982, ResultMeasuredValue, 1069, 1075, "17 . 4", "", +90984, SdDevResValue, 1082, 1087, "2 . 9", "", +90986, Bimatoprost, 1092, 1103, "bimatoprost", "", +90983, ResultMeasuredValue, 1108, 1114, "18 . 1", "", +90985, SdDevResValue, 1121, 1126, "2 . 8", "", +90987, mmHg, 1127, 1131, "mmHg", "", +90988, Dorz/TimFC, 1136, 1140, "DTFC", "", +90989, PvalueDiff, 1145, 1153, "= 0 . 35", "", +90991, ObservedResult, 1158, 1260, "The individual time points for intraocular pressures were not statistically different between groups .", "", +90990, IOP, 1189, 1210, "intraocular pressures", "", +91008, ObservedResult, 1261, 1402, "Both groups statistically reduced the intraocular pressures from baseline for each time point and for the diurnal curve ( p & lt ; 0 . 05 ) .", "", +90992, IOP, 1299, 1320, "intraocular pressures", "", +90993, Diurnal_IOP, 1367, 1380, "diurnal curve", "", +90994, PValueResValue, 1385, 1398, "& lt ; 0 . 05", "", +90995, ConjunctivalHyperemia, 1461, 1483, "conjunctival hyperemia", "", +90996, Bimatoprost, 1489, 1500, "bimatoprost", "", +90997, NumberAffected, 1507, 1509, "15", "", +90999, Dorz/TimFC, 1522, 1526, "DTFC", "", +90998, NumberAffected, 1533, 1534, "7", "", +91006, PvalueDiff, 1539, 1548, "= 0 . 013", "", +91005, Stinging, 1572, 1580, "stinging", "", +91000, Dorz/TimFC, 1586, 1590, "DTFC", "", +91002, NumberAffected, 1597, 1599, "12", "", +91001, Bimatoprost, 1612, 1623, "bimatoprost", "", +91003, NumberAffected, 1630, 1631, "0", "", +91007, PvalueDiff, 1636, 1646, "= 0 . 0005", "", +91010, ObservedResult, 1651, 1794, "Few systemic adverse events were recorded and there was no statistical difference between groups for any individual event ( p & gt ; 0 . 05 ) .", "", +91009, PvalueDiff, 1777, 1790, "& gt ; 0 . 05", "", +91016, ConclusionComment, 1809, 2000, "This study indicates that the intraocular pressures are lowered to a statistically similar amount with DTFC compared to bimatoprost in open - angle glaucoma and ocular hypertensive patients .", "", +91011, IOP, 1839, 1860, "intraocular pressures", "", +91012, Dorz/TimFC, 1912, 1916, "DTFC", "", +91013, Bimatoprost, 1929, 1940, "bimatoprost", "", +91014, OpenAngleGlaucoma, 1944, 1965, "open - angle glaucoma", "", +91015, OcularHypertension, 1970, 1989, "ocular hypertensive", "", +91017, PMID, 2045, 2053, "15945001", "", diff --git a/data/gl 15945001_tstrakeljahn.n-triples b/data/gl 15945001_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15945001_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15969642_admin.annodb b/data/gl 15969642_admin.annodb new file mode 100644 index 0000000..659b781 --- /dev/null +++ b/data/gl 15969642_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2005", "", " \"2005\"." +101, Title, 56, 283, "Efficacy of the dorzolamide / timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma : combined analysis of pooled data from two large randomized observer and patient - masked studies .", "", " \"Efficacy of the dorzolamide / timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma : combined analysis of pooled data from two large randomized observer and patient - masked studies .\"." +95, Dorz/TimFC, 72, 111, "dorzolamide / timolol fixed combination", "", +56223, Dorzolamide, 72, 83, "dorzolamide", "", +56221, Timolol, 86, 93, "timolol", "", +5, Latanoprost, 119, 130, "latanoprost", "", +6, OcularHypertension, 151, 170, "ocular hypertension", "", " ." +7, Glaucoma, 174, 182, "glaucoma", "", " . ." +8, Randomized, 233, 243, "randomized", "", " ." +9, DoubleBlind, 244, 273, "observer and patient - masked", "", " ." +10, Author, 284, 295, "Fechtner RD", "", " \"Fechtner RD\"." +11, Author, 304, 316, "McCarroll KA", "", " \"McCarroll KA\"." +12, Author, 319, 327, "Lines CR", "", " \"Lines CR\"." +13, Author, 330, 341, "Adamsons IA", "", " \"Adamsons IA\"." +14, USA, 441, 444, "USA", "", " ." +15, Randomized, 502, 512, "randomized", "", +109, Dorz/TimFC, 563, 602, "dorzolamide / timolol fixed combination", "", +56211, Dorzolamide, 563, 574, "dorzolamide", "", +56220, Timolol, 577, 584, "timolol", "", +110, Dorz/TimFC, 605, 611, "COSOPT", "", +22, Latanoprost, 618, 629, "latanoprost", "", +23, Latanoprost, 632, 639, "XALATAN", "", +24, Mean, 709, 713, "mean", "", " . ." +113, Diurnal_IOP, 722, 750, "diurnal intraocular pressure", "", " ." +26, IOP, 753, 756, "IOP", "", +27, Duration, 920, 929, "3 - month", "", " \"3 - month\"." +116, Parallel, 932, 946, "parallel group", "", " ." +29, Randomized, 949, 959, "randomized", "", +30, DoubleBlind, 962, 1000, "observer - masked and patient - masked", "", +31, Multicenter, 1003, 1014, "multicenter", "", " ." +33, Precondition, 1025, 1069, "Patients with a baseline IOP > or = 24 mm Hg", "", " \"Patients with a baseline IOP > or = 24 mm Hg\"." +32, IOP, 1050, 1053, "IOP", "", +121, mmHg, 1064, 1069, "mm Hg", "", +34, Randomized, 1075, 1085, "randomized", "", +35, DoseValue, 1100, 1101, "2", "", +56215, Dorz/TimFC, 1100, 1145, "2 % dorzolamide / 0 . 5 % timolol combination", "", " ." +38, Percentage, 1102, 1103, "%", "", +41, Dorzolamide, 1104, 1115, "dorzolamide", "", +36, DoseValue, 1118, 1123, "0 . 5", "", +39, Percentage, 1124, 1125, "%", "", +42, Timolol, 1126, 1133, "timolol", "", +43, Eyedrops, 1146, 1155, "eye drops", "", " ." +44, Frequency, 1156, 1167, "twice daily", "", " \"twice daily\"." +45, NumberPatientsArm, 1174, 1177, "273", "", " \"273\"." +37, DoseValue, 1183, 1190, "0 . 005", "", " \"0 . 005\"." +40, Percentage, 1191, 1192, "%", "", " ." +46, Latanoprost, 1193, 1204, "latanoprost", "", " . ." +47, Eyedrops, 1205, 1214, "eye drops", "", " ." +48, Frequency, 1215, 1225, "once daily", "", " \"once daily\"." +49, NumberPatientsArm, 1232, 1235, "271", "", " \"271\"." +50, IOP, 1244, 1247, "IOP", "", +138, TimePoint, 1274, 1278, "8 AM", "", +139, TimePoint, 1281, 1286, "10 AM", "", +140, TimePoint, 1289, 1293, "2 PM", "", +141, TimePoint, 1300, 1304, "4 PM", "", +56207, TimePoint, 1312, 1320, "baseline", "", +52, IOP, 1491, 1494, "IOP", "", +51, Mean, 1511, 1515, "mean", "", +53, IOP, 1516, 1519, "IOP", "", +144, SubGroupDescription, 1539, 1592, "patients with high IOP ( > or = 30 mmHg ) at baseline", "", +143, IOP, 1558, 1561, "IOP", "", +55, Mean, 1599, 1603, "mean", "", +56, IOP, 1604, 1607, "IOP", "", +57, FinalNumPatientsArm, 1672, 1675, "259", "", " \"259\"." +151, Dorz/TimFC, 1692, 1713, "dorzolamide / timolol", "", +56212, Dorzolamide, 1692, 1703, "dorzolamide", "", +56225, Timolol, 1706, 1713, "timolol", "", +58, FinalNumPatientsArm, 1724, 1727, "268", "", " \"268\"." +61, Latanoprost, 1744, 1755, "latanoprost", "", +153, TimePoint, 1803, 1814, "At 3 months", "", " \"At 3 months\". \"At 3 months\". \"At 3 months\". \"At 3 months\"." +63, IOP, 1930, 1933, "IOP", "", +100522, IOP_target, 1956, 1974, "40 % IOP reduction", "", " ." +66, PercentageAffected, 1978, 1980, "15", "", " \"15\"." +157, Dorz/TimFC, 1986, 2019, "dorzolamide / timolol combination", "", +56224, Dorzolamide, 1986, 1997, "dorzolamide", "", +56222, Timolol, 2000, 2007, "timolol", "", +69, PercentageAffected, 2033, 2035, "13", "", " \"13\"." +70, Latanoprost, 2041, 2052, "latanoprost", "", +71, Mean, 2066, 2070, "mean", "", +72, IOP, 2071, 2074, "IOP", "", +73, IOP, 2113, 2116, "IOP", "", +56210, TimePoint, 2120, 2128, "baseline", "", +56209, Dorz/TimFC, 2131, 2164, "dorzolamide / timolol combination", "", +56216, Dorzolamide, 2131, 2142, "dorzolamide", "", +56218, Timolol, 2145, 2152, "timolol", "", +77, Reduction, 2167, 2173, "12 . 5", "", " \"12 . 5\"." +78, mmHg, 2174, 2178, "mmHg", "", " ." +76, Latanoprost, 2181, 2192, "latanoprost", "", +79, Reduction, 2195, 2201, "12 . 6", "", " \"12 . 6\"." +80, mmHg, 2202, 2206, "mmHg", "", +81, Mean, 2215, 2219, "mean", "", +82, IOP, 2220, 2223, "IOP", "", +175, ConclusionComment, 2260, 2443, "By the measures used in this analysis , the dorzolamide / timolol combination and latanoprost were equally effective at lowering IOP in patients with ocular hypertension or glaucoma .", "", " \"By the measures used in this analysis , the dorzolamide / timolol combination and latanoprost were equally effective at lowering IOP in patients with ocular hypertension or glaucoma .\"." +170, Dorz/TimFC, 2304, 2337, "dorzolamide / timolol combination", "", +56217, Dorzolamide, 2304, 2315, "dorzolamide", "", +56219, Timolol, 2318, 2325, "timolol", "", +85, Latanoprost, 2342, 2353, "latanoprost", "", +86, IOP, 2389, 2392, "IOP", "", +87, OcularHypertension, 2410, 2429, "ocular hypertension", "", +88, Glaucoma, 2433, 2441, "glaucoma", "", +90, PMID, 2491, 2499, "15969642", "", " \"15969642\"." diff --git a/data/gl 15969642_admin.n-triples b/data/gl 15969642_admin.n-triples new file mode 100644 index 0000000..f7484ae --- /dev/null +++ b/data/gl 15969642_admin.n-triples @@ -0,0 +1,116 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy of the dorzolamide / timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma : combined analysis of pooled data from two large randomized observer and patient - masked studies ." . + "Fechtner RD" . + "2005" . + "J Ocul Pharmacol Ther ." . + "15969642" . + . + "McCarroll KA" . + "Lines CR" . + "Adamsons IA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "3 - month" . + . + . + . + "By the measures used in this analysis , the dorzolamide / timolol combination and latanoprost were equally effective at lowering IOP in patients with ocular hypertension or glaucoma ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with a baseline IOP > or = 24 mm Hg" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_40" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_dor-tim" . + "273" . + "259" . + . + . + . + . + . + "Arm_lat" . + "271" . + "268" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_dor-tim" . + . + "twice daily" . + . + . + "Intervention_lat" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_Dor-tim" . + . + . + . + . + "Medication_lat" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "Outcome_40_dor-tim" . + . + "15" . + "At 3 months" . + . + "Outcome_40_lat" . + . + "13" . + "At 3 months" . + . + "Outcome_iop_dor-tim" . + . + "12 . 5" . + "At 3 months" . + . + "Outcome_iop_lat" . + . + "12 . 6" . + "At 3 months" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15969642_export.csv b/data/gl 15969642_export.csv new file mode 100644 index 0000000..b0a91fe --- /dev/null +++ b/data/gl 15969642_export.csv @@ -0,0 +1,496 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +457, 1, 1, 1, 0, 1, 0, 1, "J" +457, 1, 2, 2, 2, 6, 2, 6, "Ocul" +457, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +457, 1, 4, 4, 17, 21, 17, 21, "Ther" +457, 1, 5, 5, 22, 23, 22, 23, "." +457, 2, 1, 6, 0, 4, 24, 28, "2005" +457, 2, 2, 7, 5, 8, 29, 32, "Jun" +457, 2, 3, 8, 9, 10, 33, 34, ";" +457, 2, 4, 9, 11, 13, 35, 37, "21" +457, 2, 5, 10, 14, 15, 38, 39, "(" +457, 2, 6, 11, 16, 17, 40, 41, "3" +457, 2, 7, 12, 18, 19, 42, 43, ")" +457, 2, 8, 13, 20, 21, 44, 45, ":" +457, 2, 9, 14, 22, 25, 46, 49, "242" +457, 2, 10, 15, 26, 27, 50, 51, "-" +457, 2, 11, 16, 28, 29, 52, 53, "9" +457, 2, 12, 17, 30, 31, 54, 55, "." +457, 3, 1, 18, 0, 8, 56, 64, "Efficacy" +457, 3, 2, 19, 9, 11, 65, 67, "of" +457, 3, 3, 20, 12, 15, 68, 71, "the" +457, 3, 4, 21, 16, 27, 72, 83, "dorzolamide" +457, 3, 5, 22, 28, 29, 84, 85, "/" +457, 3, 6, 23, 30, 37, 86, 93, "timolol" +457, 3, 7, 24, 38, 43, 94, 99, "fixed" +457, 3, 8, 25, 44, 55, 100, 111, "combination" +457, 3, 9, 26, 56, 62, 112, 118, "versus" +457, 3, 10, 27, 63, 74, 119, 130, "latanoprost" +457, 3, 11, 28, 75, 77, 131, 133, "in" +457, 3, 12, 29, 78, 81, 134, 137, "the" +457, 3, 13, 30, 82, 91, 138, 147, "treatment" +457, 3, 14, 31, 92, 94, 148, 150, "of" +457, 3, 15, 32, 95, 101, 151, 157, "ocular" +457, 3, 16, 33, 102, 114, 158, 170, "hypertension" +457, 3, 17, 34, 115, 117, 171, 173, "or" +457, 3, 18, 35, 118, 126, 174, 182, "glaucoma" +457, 3, 19, 36, 127, 128, 183, 184, ":" +457, 3, 20, 37, 129, 137, 185, 193, "combined" +457, 3, 21, 38, 138, 146, 194, 202, "analysis" +457, 3, 22, 39, 147, 149, 203, 205, "of" +457, 3, 23, 40, 150, 156, 206, 212, "pooled" +457, 3, 24, 41, 157, 161, 213, 217, "data" +457, 3, 25, 42, 162, 166, 218, 222, "from" +457, 3, 26, 43, 167, 170, 223, 226, "two" +457, 3, 27, 44, 171, 176, 227, 232, "large" +457, 3, 28, 45, 177, 187, 233, 243, "randomized" +457, 3, 29, 46, 188, 196, 244, 252, "observer" +457, 3, 30, 47, 197, 200, 253, 256, "and" +457, 3, 31, 48, 201, 208, 257, 264, "patient" +457, 3, 32, 49, 209, 210, 265, 266, "-" +457, 3, 33, 50, 211, 217, 267, 273, "masked" +457, 3, 34, 51, 218, 225, 274, 281, "studies" +457, 3, 35, 52, 226, 227, 282, 283, "." +457, 4, 1, 53, 0, 8, 284, 292, "Fechtner" +457, 4, 2, 54, 9, 11, 293, 295, "RD" +457, 4, 3, 55, 12, 13, 296, 297, "(" +457, 4, 4, 56, 14, 15, 298, 299, "1" +457, 4, 5, 57, 16, 17, 300, 301, ")" +457, 4, 6, 58, 18, 19, 302, 303, "," +457, 4, 7, 59, 20, 29, 304, 313, "McCarroll" +457, 4, 8, 60, 30, 32, 314, 316, "KA" +457, 4, 9, 61, 33, 34, 317, 318, "," +457, 4, 10, 62, 35, 40, 319, 324, "Lines" +457, 4, 11, 63, 41, 43, 325, 327, "CR" +457, 4, 12, 64, 44, 45, 328, 329, "," +457, 4, 13, 65, 46, 54, 330, 338, "Adamsons" +457, 4, 14, 66, 55, 57, 339, 341, "IA" +457, 4, 15, 67, 58, 59, 342, 343, "." +457, 5, 1, 68, 0, 6, 344, 350, "Author" +457, 5, 2, 69, 7, 18, 351, 362, "information" +457, 5, 3, 70, 19, 20, 363, 364, ":" +457, 5, 4, 71, 21, 22, 365, 366, "(" +457, 5, 5, 72, 23, 24, 367, 368, "1" +457, 5, 6, 73, 25, 26, 369, 370, ")" +457, 5, 7, 74, 27, 35, 371, 379, "Glaucoma" +457, 5, 8, 75, 36, 44, 380, 388, "Division" +457, 5, 9, 76, 45, 46, 389, 390, "," +457, 5, 10, 77, 47, 50, 391, 394, "New" +457, 5, 11, 78, 51, 57, 395, 401, "Jersey" +457, 5, 12, 79, 58, 65, 402, 409, "Medical" +457, 5, 13, 80, 66, 72, 410, 416, "School" +457, 5, 14, 81, 73, 74, 417, 418, "," +457, 5, 15, 82, 75, 80, 419, 424, "UMNDJ" +457, 5, 16, 83, 81, 82, 425, 426, "," +457, 5, 17, 84, 83, 89, 427, 433, "Newark" +457, 5, 18, 85, 90, 91, 434, 435, "," +457, 5, 19, 86, 92, 94, 436, 438, "NJ" +457, 5, 20, 87, 95, 96, 439, 440, "," +457, 5, 21, 88, 97, 100, 441, 444, "USA" +457, 5, 22, 89, 101, 102, 445, 446, "." +457, 6, 1, 90, 0, 2, 447, 449, "In" +457, 6, 2, 91, 3, 11, 450, 458, "previous" +457, 6, 3, 92, 12, 20, 459, 467, "analyses" +457, 6, 4, 93, 21, 23, 468, 470, "of" +457, 6, 5, 94, 24, 31, 471, 478, "primary" +457, 6, 6, 95, 32, 40, 479, 487, "efficacy" +457, 6, 7, 96, 41, 45, 488, 492, "data" +457, 6, 8, 97, 46, 50, 493, 497, "from" +457, 6, 9, 98, 51, 54, 498, 501, "two" +457, 6, 10, 99, 55, 65, 502, 512, "randomized" +457, 6, 11, 100, 66, 74, 513, 521, "clinical" +457, 6, 12, 101, 75, 81, 522, 528, "trials" +457, 6, 13, 102, 82, 83, 529, 530, "," +457, 6, 14, 103, 84, 92, 531, 539, "standard" +457, 6, 15, 104, 93, 99, 540, 546, "dosing" +457, 6, 16, 105, 100, 108, 547, 555, "regimens" +457, 6, 17, 106, 109, 111, 556, 558, "of" +457, 6, 18, 107, 112, 115, 559, 562, "the" +457, 6, 19, 108, 116, 127, 563, 574, "dorzolamide" +457, 6, 20, 109, 128, 129, 575, 576, "/" +457, 6, 21, 110, 130, 137, 577, 584, "timolol" +457, 6, 22, 111, 138, 143, 585, 590, "fixed" +457, 6, 23, 112, 144, 155, 591, 602, "combination" +457, 6, 24, 113, 156, 157, 603, 604, "(" +457, 6, 25, 114, 158, 164, 605, 611, "COSOPT" +457, 6, 26, 115, 165, 166, 612, 613, ")" +457, 6, 27, 116, 167, 170, 614, 617, "and" +457, 6, 28, 117, 171, 182, 618, 629, "latanoprost" +457, 6, 29, 118, 183, 184, 630, 631, "(" +457, 6, 30, 119, 185, 192, 632, 639, "XALATAN" +457, 6, 31, 120, 193, 194, 640, 641, ")" +457, 6, 32, 121, 195, 199, 642, 646, "were" +457, 6, 33, 122, 200, 205, 647, 652, "shown" +457, 6, 34, 123, 206, 208, 653, 655, "to" +457, 6, 35, 124, 209, 213, 656, 660, "have" +457, 6, 36, 125, 214, 224, 661, 671, "equivalent" +457, 6, 37, 126, 225, 233, 672, 680, "efficacy" +457, 6, 38, 127, 234, 238, 681, 685, "with" +457, 6, 39, 128, 239, 245, 686, 692, "regard" +457, 6, 40, 129, 246, 248, 693, 695, "to" +457, 6, 41, 130, 249, 258, 696, 705, "reduction" +457, 6, 42, 131, 259, 261, 706, 708, "in" +457, 6, 43, 132, 262, 266, 709, 713, "mean" +457, 6, 44, 133, 267, 274, 714, 721, "daytime" +457, 6, 45, 134, 275, 282, 722, 729, "diurnal" +457, 6, 46, 135, 283, 294, 730, 741, "intraocular" +457, 6, 47, 136, 295, 303, 742, 750, "pressure" +457, 6, 48, 137, 304, 305, 751, 752, "(" +457, 6, 49, 138, 306, 309, 753, 756, "IOP" +457, 6, 50, 139, 310, 311, 757, 758, ")" +457, 6, 51, 140, 312, 313, 759, 760, "." +457, 7, 1, 141, 0, 2, 761, 763, "We" +457, 7, 2, 142, 3, 12, 764, 773, "performed" +457, 7, 3, 143, 13, 23, 774, 784, "additional" +457, 7, 4, 144, 24, 28, 785, 789, "post" +457, 7, 5, 145, 29, 32, 790, 793, "hoc" +457, 7, 6, 146, 33, 41, 794, 802, "analyses" +457, 7, 7, 147, 42, 44, 803, 805, "of" +457, 7, 8, 148, 45, 51, 806, 812, "pooled" +457, 7, 9, 149, 52, 56, 813, 817, "data" +457, 7, 10, 150, 57, 61, 818, 822, "from" +457, 7, 11, 151, 62, 67, 823, 828, "these" +457, 7, 12, 152, 68, 75, 829, 836, "studies" +457, 7, 13, 153, 76, 78, 837, 839, "to" +457, 7, 14, 154, 79, 86, 840, 847, "compare" +457, 7, 15, 155, 87, 94, 848, 855, "further" +457, 7, 16, 156, 95, 98, 856, 859, "the" +457, 7, 17, 157, 99, 107, 860, 868, "efficacy" +457, 7, 18, 158, 108, 110, 869, 871, "of" +457, 7, 19, 159, 111, 114, 872, 875, "the" +457, 7, 20, 160, 115, 118, 876, 879, "two" +457, 7, 21, 161, 119, 129, 880, 890, "treatments" +457, 7, 22, 162, 130, 131, 891, 892, "." +457, 8, 1, 163, 0, 3, 893, 896, "The" +457, 8, 2, 164, 4, 11, 897, 904, "studies" +457, 8, 3, 165, 12, 16, 905, 909, "used" +457, 8, 4, 166, 17, 26, 910, 919, "identical" +457, 8, 5, 167, 27, 28, 920, 921, "3" +457, 8, 6, 168, 29, 30, 922, 923, "-" +457, 8, 7, 169, 31, 36, 924, 929, "month" +457, 8, 8, 170, 37, 38, 930, 931, "," +457, 8, 9, 171, 39, 47, 932, 940, "parallel" +457, 8, 10, 172, 48, 53, 941, 946, "group" +457, 8, 11, 173, 54, 55, 947, 948, "," +457, 8, 12, 174, 56, 66, 949, 959, "randomized" +457, 8, 13, 175, 67, 68, 960, 961, "," +457, 8, 14, 176, 69, 77, 962, 970, "observer" +457, 8, 15, 177, 78, 79, 971, 972, "-" +457, 8, 16, 178, 80, 86, 973, 979, "masked" +457, 8, 17, 179, 87, 90, 980, 983, "and" +457, 8, 18, 180, 91, 98, 984, 991, "patient" +457, 8, 19, 181, 99, 100, 992, 993, "-" +457, 8, 20, 182, 101, 107, 994, 1000, "masked" +457, 8, 21, 183, 108, 109, 1001, 1002, "," +457, 8, 22, 184, 110, 121, 1003, 1014, "multicenter" +457, 8, 23, 185, 122, 129, 1015, 1022, "designs" +457, 8, 24, 186, 130, 131, 1023, 1024, "." +457, 9, 1, 187, 0, 8, 1025, 1033, "Patients" +457, 9, 2, 188, 9, 13, 1034, 1038, "with" +457, 9, 3, 189, 14, 15, 1039, 1040, "a" +457, 9, 4, 190, 16, 24, 1041, 1049, "baseline" +457, 9, 5, 191, 25, 28, 1050, 1053, "IOP" +457, 9, 6, 192, 29, 30, 1054, 1055, ">" +457, 9, 7, 193, 31, 33, 1056, 1058, "or" +457, 9, 8, 194, 34, 35, 1059, 1060, "=" +457, 9, 9, 195, 36, 38, 1061, 1063, "24" +457, 9, 10, 196, 39, 41, 1064, 1066, "mm" +457, 9, 11, 197, 42, 44, 1067, 1069, "Hg" +457, 9, 12, 198, 45, 49, 1070, 1074, "were" +457, 9, 13, 199, 50, 60, 1075, 1085, "randomized" +457, 9, 14, 200, 61, 63, 1086, 1088, "to" +457, 9, 15, 201, 64, 70, 1089, 1095, "either" +457, 9, 16, 202, 71, 74, 1096, 1099, "the" +457, 9, 17, 203, 75, 76, 1100, 1101, "2" +457, 9, 18, 204, 77, 78, 1102, 1103, "%" +457, 9, 19, 205, 79, 90, 1104, 1115, "dorzolamide" +457, 9, 20, 206, 91, 92, 1116, 1117, "/" +457, 9, 21, 207, 93, 94, 1118, 1119, "0" +457, 9, 22, 208, 95, 96, 1120, 1121, "." +457, 9, 23, 209, 97, 98, 1122, 1123, "5" +457, 9, 24, 210, 99, 100, 1124, 1125, "%" +457, 9, 25, 211, 101, 108, 1126, 1133, "timolol" +457, 9, 26, 212, 109, 120, 1134, 1145, "combination" +457, 9, 27, 213, 121, 124, 1146, 1149, "eye" +457, 9, 28, 214, 125, 130, 1150, 1155, "drops" +457, 9, 29, 215, 131, 136, 1156, 1161, "twice" +457, 9, 30, 216, 137, 142, 1162, 1167, "daily" +457, 9, 31, 217, 143, 144, 1168, 1169, "(" +457, 9, 32, 218, 145, 146, 1170, 1171, "n" +457, 9, 33, 219, 147, 148, 1172, 1173, "=" +457, 9, 34, 220, 149, 152, 1174, 1177, "273" +457, 9, 35, 221, 153, 154, 1178, 1179, ")" +457, 9, 36, 222, 155, 157, 1180, 1182, "or" +457, 9, 37, 223, 158, 159, 1183, 1184, "0" +457, 9, 38, 224, 160, 161, 1185, 1186, "." +457, 9, 39, 225, 162, 165, 1187, 1190, "005" +457, 9, 40, 226, 166, 167, 1191, 1192, "%" +457, 9, 41, 227, 168, 179, 1193, 1204, "latanoprost" +457, 9, 42, 228, 180, 183, 1205, 1208, "eye" +457, 9, 43, 229, 184, 189, 1209, 1214, "drops" +457, 9, 44, 230, 190, 194, 1215, 1219, "once" +457, 9, 45, 231, 195, 200, 1220, 1225, "daily" +457, 9, 46, 232, 201, 202, 1226, 1227, "(" +457, 9, 47, 233, 203, 204, 1228, 1229, "n" +457, 9, 48, 234, 205, 206, 1230, 1231, "=" +457, 9, 49, 235, 207, 210, 1232, 1235, "271" +457, 9, 50, 236, 211, 212, 1236, 1237, ")" +457, 9, 51, 237, 213, 214, 1238, 1239, "." +457, 10, 1, 238, 0, 3, 1240, 1243, "The" +457, 10, 2, 239, 4, 7, 1244, 1247, "IOP" +457, 10, 3, 240, 8, 20, 1248, 1260, "measurements" +457, 10, 4, 241, 21, 25, 1261, 1265, "were" +457, 10, 5, 242, 26, 30, 1266, 1270, "made" +457, 10, 6, 243, 31, 33, 1271, 1273, "at" +457, 10, 7, 244, 34, 35, 1274, 1275, "8" +457, 10, 8, 245, 36, 38, 1276, 1278, "AM" +457, 10, 9, 246, 39, 40, 1279, 1280, "," +457, 10, 10, 247, 41, 43, 1281, 1283, "10" +457, 10, 11, 248, 44, 46, 1284, 1286, "AM" +457, 10, 12, 249, 47, 48, 1287, 1288, "," +457, 10, 13, 250, 49, 50, 1289, 1290, "2" +457, 10, 14, 251, 51, 53, 1291, 1293, "PM" +457, 10, 15, 252, 54, 55, 1294, 1295, "," +457, 10, 16, 253, 56, 59, 1296, 1299, "and" +457, 10, 17, 254, 60, 61, 1300, 1301, "4" +457, 10, 18, 255, 62, 64, 1302, 1304, "PM" +457, 10, 19, 256, 65, 67, 1305, 1307, "at" +457, 10, 20, 257, 68, 71, 1308, 1311, "the" +457, 10, 21, 258, 72, 80, 1312, 1320, "baseline" +457, 10, 22, 259, 81, 86, 1321, 1326, "visit" +457, 10, 23, 260, 87, 90, 1327, 1330, "and" +457, 10, 24, 261, 91, 95, 1331, 1335, "then" +457, 10, 25, 262, 96, 98, 1336, 1338, "on" +457, 10, 26, 263, 99, 103, 1339, 1343, "each" +457, 10, 27, 264, 104, 106, 1344, 1346, "of" +457, 10, 28, 265, 107, 110, 1347, 1350, "the" +457, 10, 29, 266, 111, 112, 1351, 1352, "3" +457, 10, 30, 267, 113, 120, 1353, 1360, "monthly" +457, 10, 31, 268, 121, 131, 1361, 1371, "assessment" +457, 10, 32, 269, 132, 136, 1372, 1376, "days" +457, 10, 33, 270, 137, 138, 1377, 1378, "." +457, 11, 1, 271, 0, 3, 1379, 1382, "The" +457, 11, 2, 272, 4, 13, 1383, 1392, "following" +457, 11, 3, 273, 14, 22, 1393, 1401, "measures" +457, 11, 4, 274, 23, 27, 1402, 1406, "were" +457, 11, 5, 275, 28, 36, 1407, 1415, "analyzed" +457, 11, 6, 276, 37, 39, 1416, 1418, "on" +457, 11, 7, 277, 40, 41, 1419, 1420, "a" +457, 11, 8, 278, 42, 46, 1421, 1425, "post" +457, 11, 9, 279, 47, 50, 1426, 1429, "hoc" +457, 11, 10, 280, 51, 56, 1430, 1435, "basis" +457, 11, 11, 281, 57, 58, 1436, 1437, ":" +457, 11, 12, 282, 59, 60, 1438, 1439, "1" +457, 11, 13, 283, 61, 62, 1440, 1441, ")" +457, 11, 14, 284, 63, 74, 1442, 1453, "percentages" +457, 11, 15, 285, 75, 77, 1454, 1456, "of" +457, 11, 16, 286, 78, 86, 1457, 1465, "patients" +457, 11, 17, 287, 87, 94, 1466, 1473, "meeting" +457, 11, 18, 288, 95, 101, 1474, 1480, "target" +457, 11, 19, 289, 102, 108, 1481, 1487, "levels" +457, 11, 20, 290, 109, 111, 1488, 1490, "of" +457, 11, 21, 291, 112, 115, 1491, 1494, "IOP" +457, 11, 22, 292, 116, 125, 1495, 1504, "reduction" +457, 11, 23, 293, 126, 127, 1505, 1506, ";" +457, 11, 24, 294, 128, 129, 1507, 1508, "2" +457, 11, 25, 295, 130, 131, 1509, 1510, ")" +457, 11, 26, 296, 132, 136, 1511, 1515, "mean" +457, 11, 27, 297, 137, 140, 1516, 1519, "IOP" +457, 11, 28, 298, 141, 150, 1520, 1529, "reduction" +457, 11, 29, 299, 151, 153, 1530, 1532, "in" +457, 11, 30, 300, 154, 159, 1533, 1538, "those" +457, 11, 31, 301, 160, 168, 1539, 1547, "patients" +457, 11, 32, 302, 169, 173, 1548, 1552, "with" +457, 11, 33, 303, 174, 178, 1553, 1557, "high" +457, 11, 34, 304, 179, 182, 1558, 1561, "IOP" +457, 11, 35, 305, 183, 184, 1562, 1563, "(" +457, 11, 36, 306, 185, 186, 1564, 1565, ">" +457, 11, 37, 307, 187, 189, 1566, 1568, "or" +457, 11, 38, 308, 190, 191, 1569, 1570, "=" +457, 11, 39, 309, 192, 194, 1571, 1573, "30" +457, 11, 40, 310, 195, 199, 1574, 1578, "mmHg" +457, 11, 41, 311, 200, 201, 1579, 1580, ")" +457, 11, 42, 312, 202, 204, 1581, 1583, "at" +457, 11, 43, 313, 205, 213, 1584, 1592, "baseline" +457, 11, 44, 314, 214, 215, 1593, 1594, ";" +457, 11, 45, 315, 216, 217, 1595, 1596, "3" +457, 11, 46, 316, 218, 219, 1597, 1598, ")" +457, 11, 47, 317, 220, 224, 1599, 1603, "mean" +457, 11, 48, 318, 225, 228, 1604, 1607, "IOP" +457, 11, 49, 319, 229, 231, 1608, 1610, "at" +457, 11, 50, 320, 232, 236, 1611, 1615, "each" +457, 11, 51, 321, 237, 239, 1616, 1618, "of" +457, 11, 52, 322, 240, 243, 1619, 1622, "the" +457, 11, 53, 323, 244, 254, 1623, 1633, "assessment" +457, 11, 54, 324, 255, 259, 1634, 1638, "time" +457, 11, 55, 325, 260, 266, 1639, 1645, "points" +457, 11, 56, 326, 267, 273, 1646, 1652, "during" +457, 11, 57, 327, 274, 275, 1653, 1654, "a" +457, 11, 58, 328, 276, 279, 1655, 1658, "day" +457, 11, 59, 329, 280, 281, 1659, 1660, "." +457, 12, 1, 330, 0, 1, 1661, 1662, "A" +457, 12, 2, 331, 2, 7, 1663, 1668, "total" +457, 12, 3, 332, 8, 10, 1669, 1671, "of" +457, 12, 4, 333, 11, 14, 1672, 1675, "259" +457, 12, 5, 334, 15, 23, 1676, 1684, "patients" +457, 12, 6, 335, 24, 26, 1685, 1687, "in" +457, 12, 7, 336, 27, 30, 1688, 1691, "the" +457, 12, 8, 337, 31, 42, 1692, 1703, "dorzolamide" +457, 12, 9, 338, 43, 44, 1704, 1705, "/" +457, 12, 10, 339, 45, 52, 1706, 1713, "timolol" +457, 12, 11, 340, 53, 58, 1714, 1719, "group" +457, 12, 12, 341, 59, 62, 1720, 1723, "and" +457, 12, 13, 342, 63, 66, 1724, 1727, "268" +457, 12, 14, 343, 67, 75, 1728, 1736, "patients" +457, 12, 15, 344, 76, 78, 1737, 1739, "in" +457, 12, 16, 345, 79, 82, 1740, 1743, "the" +457, 12, 17, 346, 83, 94, 1744, 1755, "latanoprost" +457, 12, 18, 347, 95, 100, 1756, 1761, "group" +457, 12, 19, 348, 101, 105, 1762, 1766, "were" +457, 12, 20, 349, 106, 114, 1767, 1775, "included" +457, 12, 21, 350, 115, 117, 1776, 1778, "in" +457, 12, 22, 351, 118, 121, 1779, 1782, "the" +457, 12, 23, 352, 122, 130, 1783, 1791, "efficacy" +457, 12, 24, 353, 131, 139, 1792, 1800, "analysis" +457, 12, 25, 354, 140, 141, 1801, 1802, "." +457, 13, 1, 355, 0, 2, 1803, 1805, "At" +457, 13, 2, 356, 3, 4, 1806, 1807, "3" +457, 13, 3, 357, 5, 11, 1808, 1814, "months" +457, 13, 4, 358, 12, 13, 1815, 1816, "," +457, 13, 5, 359, 14, 18, 1817, 1821, "both" +457, 13, 6, 360, 19, 29, 1822, 1832, "treatments" +457, 13, 7, 361, 30, 36, 1833, 1839, "showed" +457, 13, 8, 362, 37, 44, 1840, 1847, "similar" +457, 13, 9, 363, 45, 53, 1848, 1856, "efficacy" +457, 13, 10, 364, 54, 58, 1857, 1861, "with" +457, 13, 11, 365, 59, 65, 1862, 1868, "regard" +457, 13, 12, 366, 66, 68, 1869, 1871, "to" +457, 13, 13, 367, 69, 72, 1872, 1875, "the" +457, 13, 14, 368, 73, 84, 1876, 1887, "percentages" +457, 13, 15, 369, 85, 87, 1888, 1890, "of" +457, 13, 16, 370, 88, 96, 1891, 1899, "patients" +457, 13, 17, 371, 97, 100, 1900, 1903, "who" +457, 13, 18, 372, 101, 109, 1904, 1912, "achieved" +457, 13, 19, 373, 110, 116, 1913, 1919, "target" +457, 13, 20, 374, 117, 123, 1920, 1926, "levels" +457, 13, 21, 375, 124, 126, 1927, 1929, "of" +457, 13, 22, 376, 127, 130, 1930, 1933, "IOP" +457, 13, 23, 377, 131, 140, 1934, 1943, "reduction" +457, 13, 24, 378, 141, 142, 1944, 1945, "(" +457, 13, 25, 379, 143, 144, 1946, 1947, "e" +457, 13, 26, 380, 145, 146, 1948, 1949, "." +457, 13, 27, 381, 147, 148, 1950, 1951, "g" +457, 13, 28, 382, 149, 150, 1952, 1953, "." +457, 13, 29, 383, 151, 152, 1954, 1955, "," +457, 13, 30, 384, 153, 155, 1956, 1958, "40" +457, 13, 31, 385, 156, 157, 1959, 1960, "%" +457, 13, 32, 386, 158, 161, 1961, 1964, "IOP" +457, 13, 33, 387, 162, 171, 1965, 1974, "reduction" +457, 13, 34, 388, 172, 174, 1975, 1977, "in" +457, 13, 35, 389, 175, 177, 1978, 1980, "15" +457, 13, 36, 390, 178, 179, 1981, 1982, "%" +457, 13, 37, 391, 180, 182, 1983, 1985, "of" +457, 13, 38, 392, 183, 194, 1986, 1997, "dorzolamide" +457, 13, 39, 393, 195, 196, 1998, 1999, "/" +457, 13, 40, 394, 197, 204, 2000, 2007, "timolol" +457, 13, 41, 395, 205, 216, 2008, 2019, "combination" +457, 13, 42, 396, 217, 225, 2020, 2028, "patients" +457, 13, 43, 397, 226, 229, 2029, 2032, "and" +457, 13, 44, 398, 230, 232, 2033, 2035, "13" +457, 13, 45, 399, 233, 234, 2036, 2037, "%" +457, 13, 46, 400, 235, 237, 2038, 2040, "of" +457, 13, 47, 401, 238, 249, 2041, 2052, "latanoprost" +457, 13, 48, 402, 250, 258, 2053, 2061, "patients" +457, 13, 49, 403, 259, 260, 2062, 2063, ")" +457, 13, 50, 404, 261, 262, 2064, 2065, "," +457, 13, 51, 405, 263, 267, 2066, 2070, "mean" +457, 13, 52, 406, 268, 271, 2071, 2074, "IOP" +457, 13, 53, 407, 272, 281, 2075, 2084, "reduction" +457, 13, 54, 408, 282, 284, 2085, 2087, "in" +457, 13, 55, 409, 285, 290, 2088, 2093, "those" +457, 13, 56, 410, 291, 299, 2094, 2102, "patients" +457, 13, 57, 411, 300, 304, 2103, 2107, "with" +457, 13, 58, 412, 305, 309, 2108, 2112, "high" +457, 13, 59, 413, 310, 313, 2113, 2116, "IOP" +457, 13, 60, 414, 314, 316, 2117, 2119, "at" +457, 13, 61, 415, 317, 325, 2120, 2128, "baseline" +457, 13, 62, 416, 326, 327, 2129, 2130, "(" +457, 13, 63, 417, 328, 339, 2131, 2142, "dorzolamide" +457, 13, 64, 418, 340, 341, 2143, 2144, "/" +457, 13, 65, 419, 342, 349, 2145, 2152, "timolol" +457, 13, 66, 420, 350, 361, 2153, 2164, "combination" +457, 13, 67, 421, 362, 363, 2165, 2166, "," +457, 13, 68, 422, 364, 366, 2167, 2169, "12" +457, 13, 69, 423, 367, 368, 2170, 2171, "." +457, 13, 70, 424, 369, 370, 2172, 2173, "5" +457, 13, 71, 425, 371, 375, 2174, 2178, "mmHg" +457, 13, 72, 426, 376, 377, 2179, 2180, "," +457, 13, 73, 427, 378, 389, 2181, 2192, "latanoprost" +457, 13, 74, 428, 390, 391, 2193, 2194, "," +457, 13, 75, 429, 392, 394, 2195, 2197, "12" +457, 13, 76, 430, 395, 396, 2198, 2199, "." +457, 13, 77, 431, 397, 398, 2200, 2201, "6" +457, 13, 78, 432, 399, 403, 2202, 2206, "mmHg" +457, 13, 79, 433, 404, 405, 2207, 2208, ")" +457, 13, 80, 434, 406, 407, 2209, 2210, "," +457, 13, 81, 435, 408, 411, 2211, 2214, "and" +457, 13, 82, 436, 412, 416, 2215, 2219, "mean" +457, 13, 83, 437, 417, 420, 2220, 2223, "IOP" +457, 13, 84, 438, 421, 423, 2224, 2226, "at" +457, 13, 85, 439, 424, 428, 2227, 2231, "each" +457, 13, 86, 440, 429, 433, 2232, 2236, "time" +457, 13, 87, 441, 434, 439, 2237, 2242, "point" +457, 13, 88, 442, 440, 446, 2243, 2249, "during" +457, 13, 89, 443, 447, 450, 2250, 2253, "the" +457, 13, 90, 444, 451, 454, 2254, 2257, "day" +457, 13, 91, 445, 455, 456, 2258, 2259, "." +457, 14, 1, 446, 0, 2, 2260, 2262, "By" +457, 14, 2, 447, 3, 6, 2263, 2266, "the" +457, 14, 3, 448, 7, 15, 2267, 2275, "measures" +457, 14, 4, 449, 16, 20, 2276, 2280, "used" +457, 14, 5, 450, 21, 23, 2281, 2283, "in" +457, 14, 6, 451, 24, 28, 2284, 2288, "this" +457, 14, 7, 452, 29, 37, 2289, 2297, "analysis" +457, 14, 8, 453, 38, 39, 2298, 2299, "," +457, 14, 9, 454, 40, 43, 2300, 2303, "the" +457, 14, 10, 455, 44, 55, 2304, 2315, "dorzolamide" +457, 14, 11, 456, 56, 57, 2316, 2317, "/" +457, 14, 12, 457, 58, 65, 2318, 2325, "timolol" +457, 14, 13, 458, 66, 77, 2326, 2337, "combination" +457, 14, 14, 459, 78, 81, 2338, 2341, "and" +457, 14, 15, 460, 82, 93, 2342, 2353, "latanoprost" +457, 14, 16, 461, 94, 98, 2354, 2358, "were" +457, 14, 17, 462, 99, 106, 2359, 2366, "equally" +457, 14, 18, 463, 107, 116, 2367, 2376, "effective" +457, 14, 19, 464, 117, 119, 2377, 2379, "at" +457, 14, 20, 465, 120, 128, 2380, 2388, "lowering" +457, 14, 21, 466, 129, 132, 2389, 2392, "IOP" +457, 14, 22, 467, 133, 135, 2393, 2395, "in" +457, 14, 23, 468, 136, 144, 2396, 2404, "patients" +457, 14, 24, 469, 145, 149, 2405, 2409, "with" +457, 14, 25, 470, 150, 156, 2410, 2416, "ocular" +457, 14, 26, 471, 157, 169, 2417, 2429, "hypertension" +457, 14, 27, 472, 170, 172, 2430, 2432, "or" +457, 14, 28, 473, 173, 181, 2433, 2441, "glaucoma" +457, 14, 29, 474, 182, 183, 2442, 2443, "." +457, 15, 1, 475, 0, 3, 2444, 2447, "DOI" +457, 15, 2, 476, 4, 5, 2448, 2449, ":" +457, 15, 3, 477, 6, 8, 2450, 2452, "10" +457, 15, 4, 478, 9, 10, 2453, 2454, "." +457, 15, 5, 479, 11, 15, 2455, 2459, "1089" +457, 15, 6, 480, 16, 17, 2460, 2461, "/" +457, 15, 7, 481, 18, 21, 2462, 2465, "jop" +457, 15, 8, 482, 22, 23, 2466, 2467, "." +457, 15, 9, 483, 24, 28, 2468, 2472, "2005" +457, 15, 10, 484, 29, 30, 2473, 2474, "." +457, 15, 11, 485, 31, 33, 2475, 2477, "21" +457, 15, 12, 486, 34, 35, 2478, 2479, "." +457, 15, 13, 487, 36, 39, 2480, 2483, "242" +457, 15, 14, 488, 40, 44, 2484, 2488, "PMID" +457, 15, 15, 489, 45, 46, 2489, 2490, ":" +457, 15, 16, 490, 47, 55, 2491, 2499, "15969642" +457, 15, 17, 491, 56, 57, 2500, 2501, "[" +457, 15, 18, 492, 58, 65, 2502, 2509, "Indexed" +457, 15, 19, 493, 66, 69, 2510, 2513, "for" +457, 15, 20, 494, 70, 77, 2514, 2521, "MEDLINE" +457, 15, 21, 495, 78, 79, 2522, 2523, "]" diff --git a/data/gl 15969642_jshahinitiran.annodb b/data/gl 15969642_jshahinitiran.annodb new file mode 100644 index 0000000..73d895c --- /dev/null +++ b/data/gl 15969642_jshahinitiran.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +10729, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +10731, PublicationYear, 24, 28, "2005", "", +10733, Title, 56, 281, "Efficacy of the dorzolamide / timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma : combined analysis of pooled data from two large randomized observer and patient - masked studies", "", +10734, Dorzolamide, 72, 83, "dorzolamide", "", +10736, Timolol, 86, 93, "timolol", "", +10737, Latanoprost, 119, 130, "latanoprost", "", +10739, OcularHypertension, 151, 170, "ocular hypertension", "", +10741, Glaucoma, 174, 182, "glaucoma", "", +10743, Randomized, 233, 243, "randomized", "", +10745, DoubleBlind, 244, 273, "observer and patient - masked", "", +10749, Author, 284, 295, "Fechtner RD", "", +10750, Author, 304, 316, "McCarroll KA", "", +10751, Author, 319, 327, "Lines CR", "", +10752, Author, 330, 341, "Adamsons IA", "", +10754, USA, 441, 444, "USA", "", +10763, Randomized, 502, 512, "randomized", "", +10764, Dorzolamide, 563, 574, "dorzolamide", "", +10773, Drug, 563, 602, "dorzolamide / timolol fixed combination", "COSPOT", +10765, Timolol, 577, 584, "timolol", "", +10775, Drug, 605, 613, "COSOPT )", "COSPOT", +10788, Latanoprost, 618, 629, "latanoprost", "", +10790, Latanoprost, 632, 639, "XALATAN", "", +10793, Mean, 709, 713, "mean", "", +10794, IOP, 730, 750, "intraocular pressure", "", +10796, IOP, 753, 756, "IOP", "", +10798, Duration, 920, 929, "3 - month", "", +10800, Parallel, 932, 940, "parallel", "", +10801, Randomized, 949, 959, "randomized", "", +10802, DoubleBlind, 962, 1000, "observer - masked and patient - masked", "", +10804, Multicenter, 1003, 1014, "multicenter", "", +10810, Precondition, 1041, 1069, "baseline IOP > or = 24 mm Hg", "", +10806, IOP, 1050, 1053, "IOP", "", +10813, Randomized, 1075, 1085, "randomized", "", +10814, DoseValue, 1100, 1101, "2", "", +10817, Percentage, 1102, 1103, "%", "", +10824, Dorzolamide, 1104, 1115, "dorzolamide", "", +10815, DoseValue, 1118, 1123, "0 . 5", "", +10819, Percentage, 1124, 1125, "%", "", +10826, Timolol, 1126, 1133, "timolol", "", +10827, Eyedrops, 1146, 1155, "eye drops", "", +10829, Frequency, 1156, 1167, "twice daily", "", +10830, NumberPatientsArm, 1174, 1177, "273", "", +10816, DoseValue, 1183, 1190, "0 . 005", "", +10822, Percentage, 1191, 1192, "%", "", +10831, Latanoprost, 1193, 1204, "latanoprost", "", +10833, Eyedrops, 1205, 1214, "eye drops", "", +10834, Frequency, 1215, 1225, "once daily", "", +10835, NumberPatientsArm, 1232, 1235, "271", "", +10836, IOP, 1244, 1247, "IOP", "", +10841, IOP, 1491, 1494, "IOP", "", +10840, Mean, 1511, 1515, "mean", "", +10842, IOP, 1516, 1519, "IOP", "", +10846, SubGroupDescription, 1553, 1592, "high IOP ( > or = 30 mmHg ) at baseline", "", +10848, Mean, 1599, 1603, "mean", "", +10850, IOP, 1604, 1607, "IOP", "", +10855, FinalNumPatientsArm, 1672, 1675, "259", "", +10780, Drug, 1692, 1713, "dorzolamide / timolol", "COSPOT", +10859, Dorzolamide, 1692, 1703, "dorzolamide", "", +10860, Timolol, 1706, 1713, "timolol", "", +10857, FinalNumPatientsArm, 1724, 1727, "268", "", +10862, Latanoprost, 1744, 1755, "latanoprost", "", +10864, TimePoint, 1806, 1814, "3 months", "", +10866, IOP, 1930, 1933, "IOP", "", +10872, EndPointDescription, 1956, 1974, "40 % IOP reduction", "", +10873, IOP, 1961, 1964, "IOP", "", +10874, PercentageAffected, 1978, 1980, "15", "", +10875, Dorzolamide, 1986, 1997, "dorzolamide", "", +28042, Drug, 1986, 2019, "dorzolamide / timolol combination", "COSPOT", +10877, Timolol, 2000, 2007, "timolol", "", +10879, PercentageAffected, 2033, 2035, "13", "", +10881, Latanoprost, 2041, 2052, "latanoprost", "", +10882, Mean, 2066, 2070, "mean", "", +10883, IOP, 2071, 2074, "IOP", "", +10846, SubGroupDescription, 2108, 2128, "high IOP at baseline", "", +10884, IOP, 2113, 2116, "IOP", "", +10887, Dorzolamide, 2131, 2142, "dorzolamide", "", +28044, Drug, 2131, 2164, "dorzolamide / timolol combination", "COSPOT", +10888, Timolol, 2145, 2152, "timolol", "", +10890, Reduction, 2167, 2173, "12 . 5", "", +10891, mmHg, 2174, 2178, "mmHg", "", +10889, Latanoprost, 2181, 2192, "latanoprost", "", +10892, Reduction, 2195, 2201, "12 . 6", "", +10893, mmHg, 2202, 2206, "mmHg", "", +10894, Mean, 2215, 2219, "mean", "", +10895, IOP, 2220, 2223, "IOP", "", +10902, ConclusionComment, 2260, 2441, "By the measures used in this analysis , the dorzolamide / timolol combination and latanoprost were equally effective at lowering IOP in patients with ocular hypertension or glaucoma", "", +10778, Drug, 2304, 2337, "dorzolamide / timolol combination", "COSPOT", +10896, Dorzolamide, 2304, 2315, "dorzolamide", "", +10897, Timolol, 2318, 2325, "timolol", "", +10898, Latanoprost, 2342, 2353, "latanoprost", "", +10899, IOP, 2389, 2392, "IOP", "", +10900, OcularHypertension, 2410, 2429, "ocular hypertension", "", +10901, Glaucoma, 2433, 2441, "glaucoma", "", +10903, PMID, 2491, 2499, "15969642", "", diff --git a/data/gl 15969642_jshahinitiran.n-triples b/data/gl 15969642_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15969642_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 15969642_tstrakeljahn.annodb b/data/gl 15969642_tstrakeljahn.annodb new file mode 100644 index 0000000..d23c949 --- /dev/null +++ b/data/gl 15969642_tstrakeljahn.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +55869, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +55870, PublicationYear, 24, 28, "2005", "", +55877, Title, 56, 283, "Efficacy of the dorzolamide / timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma : combined analysis of pooled data from two large randomized observer and patient - masked studies .", "", +55871, Dorz/TimFC, 72, 111, "dorzolamide / timolol fixed combination", "", +55872, Latanoprost, 119, 130, "latanoprost", "", +55873, OcularHypertension, 151, 170, "ocular hypertension", "", +55874, Glaucoma, 174, 182, "glaucoma", "", +55876, Randomized, 233, 243, "randomized", "", +55875, DoubleBlind, 244, 273, "observer and patient - masked", "", +55878, Author, 284, 295, "Fechtner RD", "", +55879, Author, 304, 316, "McCarroll KA", "", +55880, Author, 319, 327, "Lines CR", "", +55881, Author, 330, 341, "Adamsons IA", "", +55882, USA, 441, 444, "USA", "", +55883, Randomized, 502, 512, "randomized", "", +55884, ClinicalTrial, 513, 528, "clinical trials", "", +55885, Dorz/TimFC, 563, 602, "dorzolamide / timolol fixed combination", "", +55886, Dorz/TimFC, 605, 611, "COSOPT", "", +55887, Latanoprost, 618, 629, "latanoprost", "", +55888, Latanoprost, 632, 639, "XALATAN", "", +55889, Diurnal_IOP, 722, 750, "diurnal intraocular pressure", "", +55890, IOP, 753, 756, "IOP", "", +55891, Duration, 920, 929, "3 - month", "", +55892, Parallel, 932, 946, "parallel group", "", +55893, Randomized, 949, 959, "randomized", "", +55894, DoubleBlind, 962, 1000, "observer - masked and patient - masked", "", +55895, Multicenter, 1003, 1014, "multicenter", "", +55899, Precondition, 1041, 1069, "baseline IOP > or = 24 mm Hg", "", +55896, IOP, 1050, 1053, "IOP", "", +55897, mmHg, 1064, 1069, "mm Hg", "", +55898, Randomized, 1075, 1085, "randomized", "", +55900, DoseValue, 1100, 1101, "2", "", +55902, Percentage, 1102, 1103, "%", "", +55904, Dorzolamide, 1104, 1115, "dorzolamide", "", +55901, DoseValue, 1118, 1123, "0 . 5", "", +55903, Percentage, 1124, 1125, "%", "", +55905, Timolol, 1126, 1133, "timolol", "", +55907, Eyedrops, 1146, 1155, "eye drops", "", +55908, Frequency, 1156, 1167, "twice daily", "", +55928, NumberPatientsArm, 1174, 1177, "273", "", +55910, DoseValue, 1183, 1190, "0 . 005", "", +55911, Percentage, 1191, 1192, "%", "", +55912, Latanoprost, 1193, 1204, "latanoprost", "", +55913, Eyedrops, 1205, 1214, "eye drops", "", +55914, Frequency, 1215, 1225, "once daily", "", +55926, NumberPatientsArm, 1232, 1235, "271", "", +55916, IOP, 1244, 1247, "IOP", "", +55917, TimePoint, 1274, 1278, "8 AM", "", +55918, TimePoint, 1281, 1286, "10 AM", "", +55919, TimePoint, 1289, 1293, "2 PM", "", +55920, TimePoint, 1300, 1304, "4 PM", "", +55925, IOP, 1491, 1494, "IOP", "", +55921, IOP, 1516, 1519, "IOP", "", +55923, SubGroupDescription, 1539, 1592, "patients with high IOP ( > or = 30 mmHg ) at baseline", "", +55922, IOP, 1558, 1561, "IOP", "", +55924, IOP, 1604, 1607, "IOP", "", +55929, FinalNumPatientsArm, 1672, 1675, "259", "", +55931, Dorz/TimFC, 1692, 1713, "dorzolamide / timolol", "", +55930, FinalNumPatientsArm, 1724, 1727, "268", "", +55932, Latanoprost, 1744, 1755, "latanoprost", "", +55933, TimePoint, 1803, 1814, "At 3 months", "", +55934, IOP, 1930, 1933, "IOP", "", +55936, Endpoint, 1956, 1974, "40 % IOP reduction", "", +55935, IOP, 1961, 1964, "IOP", "", +55938, PercentageAffected, 1978, 1980, "15", "", +55937, Dorz/TimFC, 1986, 2007, "dorzolamide / timolol", "", +55939, PercentageAffected, 2033, 2035, "13", "", +55940, Latanoprost, 2041, 2052, "latanoprost", "", +55941, IOP, 2071, 2074, "IOP", "", +55942, IOP, 2113, 2116, "IOP", "", +55943, Dorzolamide, 2131, 2152, "dorzolamide / timolol", "", +55944, Reduction, 2167, 2173, "12 . 5", "", +55946, mmHg, 2174, 2178, "mmHg", "", +55948, Latanoprost, 2181, 2192, "latanoprost", "", +55945, Reduction, 2195, 2201, "12 . 6", "", +55947, mmHg, 2202, 2206, "mmHg", "", +55949, IOP, 2220, 2223, "IOP", "", +55955, ConclusionComment, 2260, 2443, "By the measures used in this analysis , the dorzolamide / timolol combination and latanoprost were equally effective at lowering IOP in patients with ocular hypertension or glaucoma .", "", +55950, Dorz/TimFC, 2304, 2337, "dorzolamide / timolol combination", "", +55951, Latanoprost, 2342, 2353, "latanoprost", "", +55952, IOP, 2389, 2392, "IOP", "", +55953, OcularHypertension, 2410, 2429, "ocular hypertension", "", +55954, Glaucoma, 2433, 2441, "glaucoma", "", +55956, PMID, 2491, 2499, "15969642", "", diff --git a/data/gl 15969642_tstrakeljahn.n-triples b/data/gl 15969642_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 15969642_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16009829_admin.annodb b/data/gl 16009829_admin.annodb new file mode 100644 index 0000000..5a3815c --- /dev/null +++ b/data/gl 16009829_admin.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Arch Ophthalmol .", "", " \"Arch Ophthalmol .\"." +1, PublicationYear, 18, 22, "2005", "", " \"2005\"." +2, Title, 53, 161, "Twenty - four - hour control with latanoprost - timolol - fixed combination therapy vs latanoprost therapy .", "", " \"Twenty - four - hour control with latanoprost - timolol - fixed combination therapy vs latanoprost therapy .\"." +3, Latanoprost, 87, 98, "latanoprost", "", +5, Lat/TimFC, 87, 128, "latanoprost - timolol - fixed combination", "", +4, Timolol, 101, 108, "timolol", "", +6, Latanoprost, 140, 151, "latanoprost", "", +7, Author, 162, 172, "Konstas AG", "", " \"Konstas AG\"." +8, Author, 181, 192, "Boboridis K", "", " \"Boboridis K\"." +9, Author, 195, 203, "Tzetzi D", "", " \"Tzetzi D\"." +10, Author, 206, 219, "Kallinderis K", "", " \"Kallinderis K\"." +11, Author, 222, 232, "Jenkins JN", "", " \"Jenkins JN\"." +12, Author, 235, 245, "Stewart WC", "", " \"Stewart WC\"." +86, Glaucoma, 275, 283, "Glaucoma", "", +13, Greece, 416, 422, "Greece", "", +14, ObjectiveDescription, 437, 611, "To evaluate the 24 - hour efficacy and safety of the latanoprost - timolol maleate - fixed combination vs latanoprost therapy in patients with primary open - angle glaucoma .", "", " \"To evaluate the 24 - hour efficacy and safety of the latanoprost - timolol maleate - fixed combination vs latanoprost therapy in patients with primary open - angle glaucoma .\"." +15, Latanoprost, 490, 501, "latanoprost", "", +17, Lat/TimFC, 490, 539, "latanoprost - timolol maleate - fixed combination", "", " ." +16, Timolol, 504, 519, "timolol maleate", "", +18, Latanoprost, 543, 554, "latanoprost", "", +97, Precondition, 566, 609, "patients with primary open - angle glaucoma", "", " \"patients with primary open - angle glaucoma\"." +19, Primary_OpenAngleGlaucoma, 580, 609, "primary open - angle glaucoma", "", " ." +20, Prospective, 624, 635, "prospective", "", " ." +21, Blind, 638, 655, "observer - masked", "", " ." +22, Crossover, 658, 667, "crossover", "", " ." +23, CTDesign, 670, 689, "active - controlled", "", " . ." +24, Randomized, 692, 702, "randomized", "", " ." +25, Duration, 731, 739, "6 - week", "", +26, Randomized, 779, 789, "randomized", "", +27, Latanoprost, 800, 811, "latanoprost", "", +29, Lat/TimFC, 800, 841, "latanoprost - timolol - fixed combination", "", +28, Timolol, 814, 821, "timolol", "", +30, Latanoprost, 853, 864, "latanoprost", "", " . ." +104, Frequency, 886, 903, "once each evening", "", " \"once each evening\". \"once each evening\"." +33, Duration, 916, 923, "8 weeks", "", " \"8 weeks\". \"8 weeks\". \"8 weeks\"." +34, Duration, 984, 991, "8 weeks", "", +105, Diurnal_IOP, 1056, 1069, "diurnal curve", "", +35, Mean, 1119, 1123, "mean", "", " . ." +36, Diurnal_IOP, 1133, 1146, "diurnal curve", "", " ." +37, FinalNumPatientsCT, 1150, 1152, "37", "", " \"37\"." +38, BaseLineValue, 1190, 1196, "24 . 2", "", " \"24 . 2\". \"24 . 2\"." +39, SdDevBL, 1203, 1208, "2 . 0", "", " \"2 . 0\". \"2 . 0\"." +40, mmHg, 1209, 1214, "mm Hg", "", " ." +41, Mean, 1221, 1225, "mean", "", +113, Diurnal_IOP, 1226, 1239, "diurnal curve", "", +43, ResultMeasuredValue, 1244, 1250, "19 . 2", "", " \"19 . 2\"." +45, SdDevResValue, 1257, 1262, "2 . 6", "", " \"2 . 6\"." +47, mmHg, 1263, 1268, "mm Hg", "", +49, Latanoprost, 1292, 1303, "latanoprost", "", +44, ResultMeasuredValue, 1322, 1328, "16 . 7", "", " \"16 . 7\"." +46, SdDevResValue, 1335, 1340, "2 . 1", "", " \"2 . 1\"." +48, mmHg, 1341, 1346, "mm Hg", "", +50, Lat/TimFC, 1374, 1391, "fixed combination", "", +102542, PvalueDiff, 1402, 1416, "P & lt ; . 001", "", " \"P & lt ; . 001\"." +102555, ObservedResult, 1456, 1508, "provided a lower absolute intraocular pressure level", "", " \"provided a lower absolute intraocular pressure level\"." +53, IOP, 1473, 1502, "absolute intraocular pressure", "", " . ." +106260, ResultMeasuredValue, 1511, 1516, "1 . 5", "", " \"1 . 5\"." +106261, ResultMeasuredValue, 1519, 1524, "2 . 9", "", " \"2 . 9\"." +54, mmHg, 1525, 1530, "mm Hg", "", " ." +126, PvalueDiff, 1533, 1547, "P & lt ; . 001", "", " \"P & lt ; . 001\"." +102548, ObservedResult, 1556, 1622, "greater intraocular pressure reduction from the untreated baseline", "", " \"greater intraocular pressure reduction from the untreated baseline\"." +56, IOP, 1564, 1594, "intraocular pressure reduction", "", " . ." +128, PvalueDiff, 1627, 1639, "& lt ; . 001", "", " \"& lt ; . 001\"." +58, Stinging, 1644, 1652, "Stinging", "", " ." +102549, ObservedResult, 1653, 1707, "was statistically lower with latanoprost therapy alone", "", " \"was statistically lower with latanoprost therapy alone\". \"was statistically lower with latanoprost therapy alone\"." +59, Latanoprost, 1682, 1693, "latanoprost", "", +131, PvalueDiff, 1712, 1718, "= . 04", "", " \"= . 04\"." +105205, Ocular_Itching, 1727, 1734, "itching", "", " ." +102550, ObservedResult, 1735, 1806, "was statistically increased compared with the fixed combination therapy", "", " \"was statistically increased compared with the fixed combination therapy\". \"was statistically increased compared with the fixed combination therapy\"." +62, Lat/TimFC, 1781, 1798, "fixed combination", "", +133, PvalueDiff, 1811, 1817, "= . 04", "", " \"= . 04\"." +64, ConclusionComment, 1835, 2041, "The result of this study suggests that the latanoprost - timolol - fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24 - hour diurnal curve", "", " \"The result of this study suggests that the latanoprost - timolol - fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24 - hour diurnal curve\"." +66, Latanoprost, 1878, 1889, "latanoprost", "", +68, Lat/TimFC, 1878, 1919, "latanoprost - timolol - fixed combination", "", +67, Timolol, 1892, 1899, "timolol", "", +69, Latanoprost, 1934, 1945, "latanoprost", "", +70, IOP, 1978, 1998, "intraocular pressure", "", +141, Diurnal_IOP, 2028, 2041, "diurnal curve", "", +64, ConclusionComment, 2042, 2125, "and for each individual time point in patients with primary open - angle glaucoma .", "", " \"and for each individual time point in patients with primary open - angle glaucoma .\"." +71, Primary_OpenAngleGlaucoma, 2094, 2123, "primary open - angle glaucoma", "", +72, PMID, 2176, 2184, "16009829", "", " \"16009829\"." diff --git a/data/gl 16009829_admin.n-triples b/data/gl 16009829_admin.n-triples new file mode 100644 index 0000000..e9017f1 --- /dev/null +++ b/data/gl 16009829_admin.n-triples @@ -0,0 +1,197 @@ +# RDF export of group: Publication + . + "Publication 90879" . + "Twenty - four - hour control with latanoprost - timolol - fixed combination therapy vs latanoprost therapy ." . + "Konstas AG" . + "2005" . + "Arch Ophthalmol ." . + "16009829" . + . + "Boboridis K" . + "Tzetzi D" . + "Kallinderis K" . + "Jenkins JN" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 90886" . + "To evaluate the 24 - hour efficacy and safety of the latanoprost - timolol maleate - fixed combination vs latanoprost therapy in patients with primary open - angle glaucoma ." . + "8 weeks" . + . + . + . + "The result of this study suggests that the latanoprost - timolol - fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24 - hour diurnal curve" . + "and for each individual time point in patients with primary open - angle glaucoma ." . + . + . + . + . + . + "37" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 90902" . + "patients with primary open - angle glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "iop2" . + . + . + . + . + . + . + "iop3" . + . + . + . + . + . + . + "sti" . + . + . + . + . + . + "it" . + . + . + . + . +# RDF export of group: Arm + . + "lati" . + . + . + . + . + . + . + . + "la" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lati" . + "once each evening" . + "8 weeks" . + . + . + . + "la" . + . + "once each evening" . + "8 weeks" . + . +# RDF export of group: Medication + . + "la2" . + . + . + . + . + . + "lati" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "24 . 2" . + "2 . 0" . + "16 . 7" . + "2 . 1" . + . + "iop 2" . + . + "24 . 2" . + "2 . 0" . + "19 . 2" . + "2 . 6" . + . + "iop2 1" . + . + "1 . 5" . + "provided a lower absolute intraocular pressure level" . + . + "iop2 2" . + . + "2 . 9" . + . + "iop3 1" . + . + "greater intraocular pressure reduction from the untreated baseline" . + . + "iop3 2" . + . + . + "sti 1" . + . + "was statistically lower with latanoprost therapy alone" . + . + "sti 2" . + . + "was statistically lower with latanoprost therapy alone" . + . + "it 1" . + . + "was statistically increased compared with the fixed combination therapy" . + . + "it 2" . + . + "was statistically increased compared with the fixed combination therapy" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "P & lt ; . 001" . + . + . + . + "iop2" . + "P & lt ; . 001" . + . + . + . + "iop3" . + "& lt ; . 001" . + . + . + . + "sti" . + "= . 04" . + . + . + . + "it" . + "= . 04" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16009829_export.csv b/data/gl 16009829_export.csv new file mode 100644 index 0000000..bfa0d7f --- /dev/null +++ b/data/gl 16009829_export.csv @@ -0,0 +1,434 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +550, 1, 1, 1, 0, 4, 0, 4, "Arch" +550, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +550, 1, 3, 3, 16, 17, 16, 17, "." +550, 2, 1, 4, 0, 4, 18, 22, "2005" +550, 2, 2, 5, 5, 8, 23, 26, "Jul" +550, 2, 3, 6, 9, 10, 27, 28, ";" +550, 2, 4, 7, 11, 14, 29, 32, "123" +550, 2, 5, 8, 15, 16, 33, 34, "(" +550, 2, 6, 9, 17, 18, 35, 36, "7" +550, 2, 7, 10, 19, 20, 37, 38, ")" +550, 2, 8, 11, 21, 22, 39, 40, ":" +550, 2, 9, 12, 23, 26, 41, 44, "898" +550, 2, 10, 13, 27, 28, 45, 46, "-" +550, 2, 11, 14, 29, 32, 47, 50, "902" +550, 2, 12, 15, 33, 34, 51, 52, "." +550, 3, 1, 16, 0, 6, 53, 59, "Twenty" +550, 3, 2, 17, 7, 8, 60, 61, "-" +550, 3, 3, 18, 9, 13, 62, 66, "four" +550, 3, 4, 19, 14, 15, 67, 68, "-" +550, 3, 5, 20, 16, 20, 69, 73, "hour" +550, 3, 6, 21, 21, 28, 74, 81, "control" +550, 3, 7, 22, 29, 33, 82, 86, "with" +550, 3, 8, 23, 34, 45, 87, 98, "latanoprost" +550, 3, 9, 24, 46, 47, 99, 100, "-" +550, 3, 10, 25, 48, 55, 101, 108, "timolol" +550, 3, 11, 26, 56, 57, 109, 110, "-" +550, 3, 12, 27, 58, 63, 111, 116, "fixed" +550, 3, 13, 28, 64, 75, 117, 128, "combination" +550, 3, 14, 29, 76, 83, 129, 136, "therapy" +550, 3, 15, 30, 84, 86, 137, 139, "vs" +550, 3, 16, 31, 87, 98, 140, 151, "latanoprost" +550, 3, 17, 32, 99, 106, 152, 159, "therapy" +550, 3, 18, 33, 107, 108, 160, 161, "." +550, 4, 1, 34, 0, 7, 162, 169, "Konstas" +550, 4, 2, 35, 8, 10, 170, 172, "AG" +550, 4, 3, 36, 11, 12, 173, 174, "(" +550, 4, 4, 37, 13, 14, 175, 176, "1" +550, 4, 5, 38, 15, 16, 177, 178, ")" +550, 4, 6, 39, 17, 18, 179, 180, "," +550, 4, 7, 40, 19, 28, 181, 190, "Boboridis" +550, 4, 8, 41, 29, 30, 191, 192, "K" +550, 4, 9, 42, 31, 32, 193, 194, "," +550, 4, 10, 43, 33, 39, 195, 201, "Tzetzi" +550, 4, 11, 44, 40, 41, 202, 203, "D" +550, 4, 12, 45, 42, 43, 204, 205, "," +550, 4, 13, 46, 44, 55, 206, 217, "Kallinderis" +550, 4, 14, 47, 56, 57, 218, 219, "K" +550, 4, 15, 48, 58, 59, 220, 221, "," +550, 4, 16, 49, 60, 67, 222, 229, "Jenkins" +550, 4, 17, 50, 68, 70, 230, 232, "JN" +550, 4, 18, 51, 71, 72, 233, 234, "," +550, 4, 19, 52, 73, 80, 235, 242, "Stewart" +550, 4, 20, 53, 81, 83, 243, 245, "WC" +550, 4, 21, 54, 84, 85, 246, 247, "." +550, 5, 1, 55, 0, 6, 248, 254, "Author" +550, 5, 2, 56, 7, 18, 255, 266, "information" +550, 5, 3, 57, 19, 20, 267, 268, ":" +550, 5, 4, 58, 21, 22, 269, 270, "(" +550, 5, 5, 59, 23, 24, 271, 272, "1" +550, 5, 6, 60, 25, 26, 273, 274, ")" +550, 5, 7, 61, 27, 35, 275, 283, "Glaucoma" +550, 5, 8, 62, 36, 40, 284, 288, "Unit" +550, 5, 9, 63, 41, 42, 289, 290, "," +550, 5, 10, 64, 43, 53, 291, 301, "University" +550, 5, 11, 65, 54, 64, 302, 312, "Department" +550, 5, 12, 66, 65, 67, 313, 315, "of" +550, 5, 13, 67, 68, 81, 316, 329, "Ophthalmology" +550, 5, 14, 68, 82, 83, 330, 331, "," +550, 5, 15, 69, 84, 96, 332, 344, "Australasian" +550, 5, 16, 70, 97, 105, 345, 353, "Hellenic" +550, 5, 17, 71, 106, 117, 354, 365, "Educational" +550, 5, 18, 72, 118, 129, 366, 377, "Progressive" +550, 5, 19, 73, 130, 141, 378, 389, "Association" +550, 5, 20, 74, 142, 150, 390, 398, "Hospital" +550, 5, 21, 75, 151, 152, 399, 400, "," +550, 5, 22, 76, 153, 165, 401, 413, "Thessaloniki" +550, 5, 23, 77, 166, 167, 414, 415, "," +550, 5, 24, 78, 168, 174, 416, 422, "Greece" +550, 5, 25, 79, 175, 176, 423, 424, "." +550, 6, 1, 80, 0, 9, 425, 434, "OBJECTIVE" +550, 6, 2, 81, 10, 11, 435, 436, ":" +550, 6, 3, 82, 12, 14, 437, 439, "To" +550, 6, 4, 83, 15, 23, 440, 448, "evaluate" +550, 6, 5, 84, 24, 27, 449, 452, "the" +550, 6, 6, 85, 28, 30, 453, 455, "24" +550, 6, 7, 86, 31, 32, 456, 457, "-" +550, 6, 8, 87, 33, 37, 458, 462, "hour" +550, 6, 9, 88, 38, 46, 463, 471, "efficacy" +550, 6, 10, 89, 47, 50, 472, 475, "and" +550, 6, 11, 90, 51, 57, 476, 482, "safety" +550, 6, 12, 91, 58, 60, 483, 485, "of" +550, 6, 13, 92, 61, 64, 486, 489, "the" +550, 6, 14, 93, 65, 76, 490, 501, "latanoprost" +550, 6, 15, 94, 77, 78, 502, 503, "-" +550, 6, 16, 95, 79, 86, 504, 511, "timolol" +550, 6, 17, 96, 87, 94, 512, 519, "maleate" +550, 6, 18, 97, 95, 96, 520, 521, "-" +550, 6, 19, 98, 97, 102, 522, 527, "fixed" +550, 6, 20, 99, 103, 114, 528, 539, "combination" +550, 6, 21, 100, 115, 117, 540, 542, "vs" +550, 6, 22, 101, 118, 129, 543, 554, "latanoprost" +550, 6, 23, 102, 130, 137, 555, 562, "therapy" +550, 6, 24, 103, 138, 140, 563, 565, "in" +550, 6, 25, 104, 141, 149, 566, 574, "patients" +550, 6, 26, 105, 150, 154, 575, 579, "with" +550, 6, 27, 106, 155, 162, 580, 587, "primary" +550, 6, 28, 107, 163, 167, 588, 592, "open" +550, 6, 29, 108, 168, 169, 593, 594, "-" +550, 6, 30, 109, 170, 175, 595, 600, "angle" +550, 6, 31, 110, 176, 184, 601, 609, "glaucoma" +550, 6, 32, 111, 185, 186, 610, 611, "." +550, 7, 1, 112, 0, 7, 612, 619, "METHODS" +550, 7, 2, 113, 8, 9, 620, 621, ":" +550, 7, 3, 114, 10, 11, 622, 623, "A" +550, 7, 4, 115, 12, 23, 624, 635, "prospective" +550, 7, 5, 116, 24, 25, 636, 637, "," +550, 7, 6, 117, 26, 34, 638, 646, "observer" +550, 7, 7, 118, 35, 36, 647, 648, "-" +550, 7, 8, 119, 37, 43, 649, 655, "masked" +550, 7, 9, 120, 44, 45, 656, 657, "," +550, 7, 10, 121, 46, 55, 658, 667, "crossover" +550, 7, 11, 122, 56, 57, 668, 669, "," +550, 7, 12, 123, 58, 64, 670, 676, "active" +550, 7, 13, 124, 65, 66, 677, 678, "-" +550, 7, 14, 125, 67, 77, 679, 689, "controlled" +550, 7, 15, 126, 78, 79, 690, 691, "," +550, 7, 16, 127, 80, 90, 692, 702, "randomized" +550, 7, 17, 128, 91, 101, 703, 713, "comparison" +550, 7, 18, 129, 102, 104, 714, 716, "in" +550, 7, 19, 130, 105, 110, 717, 722, "which" +550, 7, 20, 131, 111, 116, 723, 728, "after" +550, 7, 21, 132, 117, 118, 729, 730, "a" +550, 7, 22, 133, 119, 120, 731, 732, "6" +550, 7, 23, 134, 121, 122, 733, 734, "-" +550, 7, 24, 135, 123, 127, 735, 739, "week" +550, 7, 25, 136, 128, 136, 740, 748, "medicine" +550, 7, 26, 137, 137, 138, 749, 750, "-" +550, 7, 27, 138, 139, 143, 751, 755, "free" +550, 7, 28, 139, 144, 150, 756, 762, "period" +550, 7, 29, 140, 151, 152, 763, 764, "," +550, 7, 30, 141, 153, 161, 765, 773, "patients" +550, 7, 31, 142, 162, 166, 774, 778, "were" +550, 7, 32, 143, 167, 177, 779, 789, "randomized" +550, 7, 33, 144, 178, 180, 790, 792, "to" +550, 7, 34, 145, 181, 187, 793, 799, "either" +550, 7, 35, 146, 188, 199, 800, 811, "latanoprost" +550, 7, 36, 147, 200, 201, 812, 813, "-" +550, 7, 37, 148, 202, 209, 814, 821, "timolol" +550, 7, 38, 149, 210, 211, 822, 823, "-" +550, 7, 39, 150, 212, 217, 824, 829, "fixed" +550, 7, 40, 151, 218, 229, 830, 841, "combination" +550, 7, 41, 152, 230, 237, 842, 849, "therapy" +550, 7, 42, 153, 238, 240, 850, 852, "or" +550, 7, 43, 154, 241, 252, 853, 864, "latanoprost" +550, 7, 44, 155, 253, 260, 865, 872, "therapy" +550, 7, 45, 156, 261, 262, 873, 874, "," +550, 7, 46, 157, 263, 267, 875, 879, "both" +550, 7, 47, 158, 268, 273, 880, 885, "dosed" +550, 7, 48, 159, 274, 278, 886, 890, "once" +550, 7, 49, 160, 279, 283, 891, 895, "each" +550, 7, 50, 161, 284, 291, 896, 903, "evening" +550, 7, 51, 162, 292, 293, 904, 905, "," +550, 7, 52, 163, 294, 299, 906, 911, "alone" +550, 7, 53, 164, 300, 303, 912, 915, "for" +550, 7, 54, 165, 304, 305, 916, 917, "8" +550, 7, 55, 166, 306, 311, 918, 923, "weeks" +550, 7, 56, 167, 312, 313, 924, 925, "." +550, 8, 1, 168, 0, 8, 926, 934, "Patients" +550, 8, 2, 169, 9, 13, 935, 939, "were" +550, 8, 3, 170, 14, 18, 940, 944, "then" +550, 8, 4, 171, 19, 27, 945, 953, "switched" +550, 8, 5, 172, 28, 30, 954, 956, "to" +550, 8, 6, 173, 31, 34, 957, 960, "the" +550, 8, 7, 174, 35, 43, 961, 969, "opposite" +550, 8, 8, 175, 44, 53, 970, 979, "treatment" +550, 8, 9, 176, 54, 57, 980, 983, "for" +550, 8, 10, 177, 58, 59, 984, 985, "8" +550, 8, 11, 178, 60, 65, 986, 991, "weeks" +550, 8, 12, 179, 66, 67, 992, 993, "." +550, 9, 1, 180, 0, 2, 994, 996, "At" +550, 9, 2, 181, 3, 6, 997, 1000, "the" +550, 9, 3, 182, 7, 10, 1001, 1004, "end" +550, 9, 4, 183, 11, 13, 1005, 1007, "of" +550, 9, 5, 184, 14, 17, 1008, 1011, "the" +550, 9, 6, 185, 18, 25, 1012, 1019, "washout" +550, 9, 7, 186, 26, 29, 1020, 1023, "and" +550, 9, 8, 187, 30, 39, 1024, 1033, "treatment" +550, 9, 9, 188, 40, 47, 1034, 1041, "periods" +550, 9, 10, 189, 48, 49, 1042, 1043, "," +550, 9, 11, 190, 50, 51, 1044, 1045, "a" +550, 9, 12, 191, 52, 54, 1046, 1048, "24" +550, 9, 13, 192, 55, 56, 1049, 1050, "-" +550, 9, 14, 193, 57, 61, 1051, 1055, "hour" +550, 9, 15, 194, 62, 69, 1056, 1063, "diurnal" +550, 9, 16, 195, 70, 75, 1064, 1069, "curve" +550, 9, 17, 196, 76, 79, 1070, 1073, "was" +550, 9, 18, 197, 80, 89, 1074, 1083, "performed" +550, 9, 19, 198, 90, 91, 1084, 1085, "." +550, 10, 1, 199, 0, 7, 1086, 1093, "RESULTS" +550, 10, 2, 200, 8, 9, 1094, 1095, ":" +550, 10, 3, 201, 10, 13, 1096, 1099, "The" +550, 10, 4, 202, 14, 22, 1100, 1108, "baseline" +550, 10, 5, 203, 23, 32, 1109, 1118, "untreated" +550, 10, 6, 204, 33, 37, 1119, 1123, "mean" +550, 10, 7, 205, 38, 39, 1124, 1125, "+" +550, 10, 8, 206, 40, 41, 1126, 1127, "/" +550, 10, 9, 207, 42, 43, 1128, 1129, "-" +550, 10, 10, 208, 44, 46, 1130, 1132, "SD" +550, 10, 11, 209, 47, 54, 1133, 1140, "diurnal" +550, 10, 12, 210, 55, 60, 1141, 1146, "curve" +550, 10, 13, 211, 61, 63, 1147, 1149, "in" +550, 10, 14, 212, 64, 66, 1150, 1152, "37" +550, 10, 15, 213, 67, 75, 1153, 1161, "patients" +550, 10, 16, 214, 76, 79, 1162, 1165, "who" +550, 10, 17, 215, 80, 89, 1166, 1175, "completed" +550, 10, 18, 216, 90, 93, 1176, 1179, "the" +550, 10, 19, 217, 94, 99, 1180, 1185, "study" +550, 10, 20, 218, 100, 103, 1186, 1189, "was" +550, 10, 21, 219, 104, 106, 1190, 1192, "24" +550, 10, 22, 220, 107, 108, 1193, 1194, "." +550, 10, 23, 221, 109, 110, 1195, 1196, "2" +550, 10, 24, 222, 111, 112, 1197, 1198, "+" +550, 10, 25, 223, 113, 114, 1199, 1200, "/" +550, 10, 26, 224, 115, 116, 1201, 1202, "-" +550, 10, 27, 225, 117, 118, 1203, 1204, "2" +550, 10, 28, 226, 119, 120, 1205, 1206, "." +550, 10, 29, 227, 121, 122, 1207, 1208, "0" +550, 10, 30, 228, 123, 125, 1209, 1211, "mm" +550, 10, 31, 229, 126, 128, 1212, 1214, "Hg" +550, 10, 32, 230, 129, 130, 1215, 1216, "." +550, 11, 1, 231, 0, 3, 1217, 1220, "The" +550, 11, 2, 232, 4, 8, 1221, 1225, "mean" +550, 11, 3, 233, 9, 16, 1226, 1233, "diurnal" +550, 11, 4, 234, 17, 22, 1234, 1239, "curve" +550, 11, 5, 235, 23, 26, 1240, 1243, "was" +550, 11, 6, 236, 27, 29, 1244, 1246, "19" +550, 11, 7, 237, 30, 31, 1247, 1248, "." +550, 11, 8, 238, 32, 33, 1249, 1250, "2" +550, 11, 9, 239, 34, 35, 1251, 1252, "+" +550, 11, 10, 240, 36, 37, 1253, 1254, "/" +550, 11, 11, 241, 38, 39, 1255, 1256, "-" +550, 11, 12, 242, 40, 41, 1257, 1258, "2" +550, 11, 13, 243, 42, 43, 1259, 1260, "." +550, 11, 14, 244, 44, 45, 1261, 1262, "6" +550, 11, 15, 245, 46, 48, 1263, 1265, "mm" +550, 11, 16, 246, 49, 51, 1266, 1268, "Hg" +550, 11, 17, 247, 52, 55, 1269, 1272, "for" +550, 11, 18, 248, 56, 61, 1273, 1278, "those" +550, 11, 19, 249, 62, 65, 1279, 1282, "who" +550, 11, 20, 250, 66, 74, 1283, 1291, "received" +550, 11, 21, 251, 75, 86, 1292, 1303, "latanoprost" +550, 11, 22, 252, 87, 94, 1304, 1311, "therapy" +550, 11, 23, 253, 95, 100, 1312, 1317, "alone" +550, 11, 24, 254, 101, 104, 1318, 1321, "and" +550, 11, 25, 255, 105, 107, 1322, 1324, "16" +550, 11, 26, 256, 108, 109, 1325, 1326, "." +550, 11, 27, 257, 110, 111, 1327, 1328, "7" +550, 11, 28, 258, 112, 113, 1329, 1330, "+" +550, 11, 29, 259, 114, 115, 1331, 1332, "/" +550, 11, 30, 260, 116, 117, 1333, 1334, "-" +550, 11, 31, 261, 118, 119, 1335, 1336, "2" +550, 11, 32, 262, 120, 121, 1337, 1338, "." +550, 11, 33, 263, 122, 123, 1339, 1340, "1" +550, 11, 34, 264, 124, 126, 1341, 1343, "mm" +550, 11, 35, 265, 127, 129, 1344, 1346, "Hg" +550, 11, 36, 266, 130, 133, 1347, 1350, "for" +550, 11, 37, 267, 134, 139, 1351, 1356, "those" +550, 11, 38, 268, 140, 143, 1357, 1360, "who" +550, 11, 39, 269, 144, 152, 1361, 1369, "received" +550, 11, 40, 270, 153, 156, 1370, 1373, "the" +550, 11, 41, 271, 157, 162, 1374, 1379, "fixed" +550, 11, 42, 272, 163, 174, 1380, 1391, "combination" +550, 11, 43, 273, 175, 182, 1392, 1399, "therapy" +550, 11, 44, 274, 183, 184, 1400, 1401, "(" +550, 11, 45, 275, 185, 186, 1402, 1403, "P" +550, 11, 46, 276, 187, 188, 1404, 1405, "&" +550, 11, 47, 277, 189, 191, 1406, 1408, "lt" +550, 11, 48, 278, 192, 193, 1409, 1410, ";" +550, 11, 49, 279, 194, 195, 1411, 1412, "." +550, 11, 50, 280, 196, 199, 1413, 1416, "001" +550, 11, 51, 281, 200, 201, 1417, 1418, ")" +550, 11, 52, 282, 202, 203, 1419, 1420, "." +550, 12, 1, 283, 0, 3, 1421, 1424, "The" +550, 12, 2, 284, 4, 9, 1425, 1430, "fixed" +550, 12, 3, 285, 10, 21, 1431, 1442, "combination" +550, 12, 4, 286, 22, 29, 1443, 1450, "therapy" +550, 12, 5, 287, 30, 34, 1451, 1455, "also" +550, 12, 6, 288, 35, 43, 1456, 1464, "provided" +550, 12, 7, 289, 44, 45, 1465, 1466, "a" +550, 12, 8, 290, 46, 51, 1467, 1472, "lower" +550, 12, 9, 291, 52, 60, 1473, 1481, "absolute" +550, 12, 10, 292, 61, 72, 1482, 1493, "intraocular" +550, 12, 11, 293, 73, 81, 1494, 1502, "pressure" +550, 12, 12, 294, 82, 87, 1503, 1508, "level" +550, 12, 13, 295, 88, 89, 1509, 1510, "(" +550, 12, 14, 296, 90, 91, 1511, 1512, "1" +550, 12, 15, 297, 92, 93, 1513, 1514, "." +550, 12, 16, 298, 94, 95, 1515, 1516, "5" +550, 12, 17, 299, 96, 97, 1517, 1518, "-" +550, 12, 18, 300, 98, 99, 1519, 1520, "2" +550, 12, 19, 301, 100, 101, 1521, 1522, "." +550, 12, 20, 302, 102, 103, 1523, 1524, "9" +550, 12, 21, 303, 104, 106, 1525, 1527, "mm" +550, 12, 22, 304, 107, 109, 1528, 1530, "Hg" +550, 12, 23, 305, 110, 111, 1531, 1532, "," +550, 12, 24, 306, 112, 113, 1533, 1534, "P" +550, 12, 25, 307, 114, 115, 1535, 1536, "&" +550, 12, 26, 308, 116, 118, 1537, 1539, "lt" +550, 12, 27, 309, 119, 120, 1540, 1541, ";" +550, 12, 28, 310, 121, 122, 1542, 1543, "." +550, 12, 29, 311, 123, 126, 1544, 1547, "001" +550, 12, 30, 312, 127, 128, 1548, 1549, ")" +550, 12, 31, 313, 129, 132, 1550, 1553, "and" +550, 12, 32, 314, 133, 134, 1554, 1555, "a" +550, 12, 33, 315, 135, 142, 1556, 1563, "greater" +550, 12, 34, 316, 143, 154, 1564, 1575, "intraocular" +550, 12, 35, 317, 155, 163, 1576, 1584, "pressure" +550, 12, 36, 318, 164, 173, 1585, 1594, "reduction" +550, 12, 37, 319, 174, 178, 1595, 1599, "from" +550, 12, 38, 320, 179, 182, 1600, 1603, "the" +550, 12, 39, 321, 183, 192, 1604, 1613, "untreated" +550, 12, 40, 322, 193, 201, 1614, 1622, "baseline" +550, 12, 41, 323, 202, 203, 1623, 1624, "(" +550, 12, 42, 324, 204, 205, 1625, 1626, "P" +550, 12, 43, 325, 206, 207, 1627, 1628, "&" +550, 12, 44, 326, 208, 210, 1629, 1631, "lt" +550, 12, 45, 327, 211, 212, 1632, 1633, ";" +550, 12, 46, 328, 213, 214, 1634, 1635, "." +550, 12, 47, 329, 215, 218, 1636, 1639, "001" +550, 12, 48, 330, 219, 220, 1640, 1641, ")" +550, 12, 49, 331, 221, 222, 1642, 1643, "." +550, 13, 1, 332, 0, 8, 1644, 1652, "Stinging" +550, 13, 2, 333, 9, 12, 1653, 1656, "was" +550, 13, 3, 334, 13, 26, 1657, 1670, "statistically" +550, 13, 4, 335, 27, 32, 1671, 1676, "lower" +550, 13, 5, 336, 33, 37, 1677, 1681, "with" +550, 13, 6, 337, 38, 49, 1682, 1693, "latanoprost" +550, 13, 7, 338, 50, 57, 1694, 1701, "therapy" +550, 13, 8, 339, 58, 63, 1702, 1707, "alone" +550, 13, 9, 340, 64, 65, 1708, 1709, "(" +550, 13, 10, 341, 66, 67, 1710, 1711, "P" +550, 13, 11, 342, 68, 69, 1712, 1713, "=" +550, 13, 12, 343, 70, 71, 1714, 1715, "." +550, 13, 13, 344, 72, 74, 1716, 1718, "04" +550, 13, 14, 345, 75, 76, 1719, 1720, ")" +550, 13, 15, 346, 77, 78, 1721, 1722, "," +550, 13, 16, 347, 79, 82, 1723, 1726, "but" +550, 13, 17, 348, 83, 90, 1727, 1734, "itching" +550, 13, 18, 349, 91, 94, 1735, 1738, "was" +550, 13, 19, 350, 95, 108, 1739, 1752, "statistically" +550, 13, 20, 351, 109, 118, 1753, 1762, "increased" +550, 13, 21, 352, 119, 127, 1763, 1771, "compared" +550, 13, 22, 353, 128, 132, 1772, 1776, "with" +550, 13, 23, 354, 133, 136, 1777, 1780, "the" +550, 13, 24, 355, 137, 142, 1781, 1786, "fixed" +550, 13, 25, 356, 143, 154, 1787, 1798, "combination" +550, 13, 26, 357, 155, 162, 1799, 1806, "therapy" +550, 13, 27, 358, 163, 164, 1807, 1808, "(" +550, 13, 28, 359, 165, 166, 1809, 1810, "P" +550, 13, 29, 360, 167, 168, 1811, 1812, "=" +550, 13, 30, 361, 169, 170, 1813, 1814, "." +550, 13, 31, 362, 171, 173, 1815, 1817, "04" +550, 13, 32, 363, 174, 175, 1818, 1819, ")" +550, 13, 33, 364, 176, 177, 1820, 1821, "." +550, 14, 1, 365, 0, 10, 1822, 1832, "CONCLUSION" +550, 14, 2, 366, 11, 12, 1833, 1834, ":" +550, 14, 3, 367, 13, 16, 1835, 1838, "The" +550, 14, 4, 368, 17, 23, 1839, 1845, "result" +550, 14, 5, 369, 24, 26, 1846, 1848, "of" +550, 14, 6, 370, 27, 31, 1849, 1853, "this" +550, 14, 7, 371, 32, 37, 1854, 1859, "study" +550, 14, 8, 372, 38, 46, 1860, 1868, "suggests" +550, 14, 9, 373, 47, 51, 1869, 1873, "that" +550, 14, 10, 374, 52, 55, 1874, 1877, "the" +550, 14, 11, 375, 56, 67, 1878, 1889, "latanoprost" +550, 14, 12, 376, 68, 69, 1890, 1891, "-" +550, 14, 13, 377, 70, 77, 1892, 1899, "timolol" +550, 14, 14, 378, 78, 79, 1900, 1901, "-" +550, 14, 15, 379, 80, 85, 1902, 1907, "fixed" +550, 14, 16, 380, 86, 97, 1908, 1919, "combination" +550, 14, 17, 381, 98, 106, 1920, 1928, "compared" +550, 14, 18, 382, 107, 111, 1929, 1933, "with" +550, 14, 19, 383, 112, 123, 1934, 1945, "latanoprost" +550, 14, 20, 384, 124, 131, 1946, 1953, "therapy" +550, 14, 21, 385, 132, 137, 1954, 1959, "alone" +550, 14, 22, 386, 138, 146, 1960, 1968, "provides" +550, 14, 23, 387, 147, 155, 1969, 1977, "improved" +550, 14, 24, 388, 156, 167, 1978, 1989, "intraocular" +550, 14, 25, 389, 168, 176, 1990, 1998, "pressure" +550, 14, 26, 390, 177, 186, 1999, 2008, "reduction" +550, 14, 27, 391, 187, 191, 2009, 2013, "over" +550, 14, 28, 392, 192, 195, 2014, 2017, "the" +550, 14, 29, 393, 196, 198, 2018, 2020, "24" +550, 14, 30, 394, 199, 200, 2021, 2022, "-" +550, 14, 31, 395, 201, 205, 2023, 2027, "hour" +550, 14, 32, 396, 206, 213, 2028, 2035, "diurnal" +550, 14, 33, 397, 214, 219, 2036, 2041, "curve" +550, 14, 34, 398, 220, 223, 2042, 2045, "and" +550, 14, 35, 399, 224, 227, 2046, 2049, "for" +550, 14, 36, 400, 228, 232, 2050, 2054, "each" +550, 14, 37, 401, 233, 243, 2055, 2065, "individual" +550, 14, 38, 402, 244, 248, 2066, 2070, "time" +550, 14, 39, 403, 249, 254, 2071, 2076, "point" +550, 14, 40, 404, 255, 257, 2077, 2079, "in" +550, 14, 41, 405, 258, 266, 2080, 2088, "patients" +550, 14, 42, 406, 267, 271, 2089, 2093, "with" +550, 14, 43, 407, 272, 279, 2094, 2101, "primary" +550, 14, 44, 408, 280, 284, 2102, 2106, "open" +550, 14, 45, 409, 285, 286, 2107, 2108, "-" +550, 14, 46, 410, 287, 292, 2109, 2114, "angle" +550, 14, 47, 411, 293, 301, 2115, 2123, "glaucoma" +550, 14, 48, 412, 302, 303, 2124, 2125, "." +550, 15, 1, 413, 0, 3, 2126, 2129, "DOI" +550, 15, 2, 414, 4, 5, 2130, 2131, ":" +550, 15, 3, 415, 6, 8, 2132, 2134, "10" +550, 15, 4, 416, 9, 10, 2135, 2136, "." +550, 15, 5, 417, 11, 15, 2137, 2141, "1001" +550, 15, 6, 418, 16, 17, 2142, 2143, "/" +550, 15, 7, 419, 18, 26, 2144, 2152, "archopht" +550, 15, 8, 420, 27, 28, 2153, 2154, "." +550, 15, 9, 421, 29, 32, 2155, 2158, "123" +550, 15, 10, 422, 33, 34, 2159, 2160, "." +550, 15, 11, 423, 35, 36, 2161, 2162, "7" +550, 15, 12, 424, 37, 38, 2163, 2164, "." +550, 15, 13, 425, 39, 42, 2165, 2168, "898" +550, 15, 14, 426, 43, 47, 2169, 2173, "PMID" +550, 15, 15, 427, 48, 49, 2174, 2175, ":" +550, 15, 16, 428, 50, 58, 2176, 2184, "16009829" +550, 15, 17, 429, 59, 60, 2185, 2186, "[" +550, 15, 18, 430, 61, 68, 2187, 2194, "Indexed" +550, 15, 19, 431, 69, 72, 2195, 2198, "for" +550, 15, 20, 432, 73, 80, 2199, 2206, "MEDLINE" +550, 15, 21, 433, 81, 82, 2207, 2208, "]" diff --git a/data/gl 16009829_jshahinitiran.annodb b/data/gl 16009829_jshahinitiran.annodb new file mode 100644 index 0000000..08d6ac2 --- /dev/null +++ b/data/gl 16009829_jshahinitiran.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +85879, Journal, 0, 15, "Arch Ophthalmol", "", +85880, PublicationYear, 18, 22, "2005", "", +85887, Title, 53, 161, "Twenty - four - hour control with latanoprost - timolol - fixed combination therapy vs latanoprost therapy .", "", +85888, Latanoprost, 87, 98, "latanoprost", "", +85890, Lat/TimFC, 87, 128, "latanoprost - timolol - fixed combination", "", +85889, Timolol, 101, 108, "timolol", "", +85891, Latanoprost, 140, 151, "latanoprost", "", +85892, Author, 162, 172, "Konstas AG", "", +85893, Author, 181, 192, "Boboridis K", "", +85894, Author, 195, 203, "Tzetzi D", "", +85896, Author, 206, 219, "Kallinderis K", "", +85897, Author, 222, 232, "Jenkins JN", "", +85898, Author, 235, 245, "Stewart WC", "", +85899, Greece, 416, 422, "Greece", "", +85901, ObjectiveDescription, 437, 611, "To evaluate the 24 - hour efficacy and safety of the latanoprost - timolol maleate - fixed combination vs latanoprost therapy in patients with primary open - angle glaucoma .", "", +85903, Latanoprost, 490, 501, "latanoprost", "", +85910, Lat/TimFC, 490, 539, "latanoprost - timolol maleate - fixed combination", "", +85905, Timolol, 504, 519, "timolol maleate", "", +85916, Latanoprost, 543, 554, "latanoprost", "", +85924, Primary_OpenAngleGlaucoma, 580, 609, "primary open - angle glaucoma", "", +85926, Prospective, 624, 635, "prospective", "", +85927, Blind, 638, 655, "observer - masked", "", +85928, Crossover, 658, 667, "crossover", "", +85929, CTDesign, 670, 689, "active - controlled", "", +85930, Randomized, 692, 702, "randomized", "", +85931, Duration, 731, 739, "6 - week", "", +85932, Randomized, 779, 789, "randomized", "", +85933, Latanoprost, 800, 811, "latanoprost", "", +85935, Lat/TimFC, 800, 841, "latanoprost - timolol - fixed combination", "", +85934, Timolol, 814, 821, "timolol", "", +85937, Latanoprost, 853, 864, "latanoprost", "", +85938, Frequency, 886, 890, "once", "", +85939, Evening, 896, 903, "evening", "", +85940, Duration, 916, 923, "8 weeks", "", +85941, Duration, 984, 991, "8 weeks", "", +85942, Mean, 1119, 1123, "mean", "", +85945, Diurnal_IOP, 1133, 1140, "diurnal", "", +85948, FinalNumPatientsCT, 1150, 1152, "37", "", +85951, BaseLineValue, 1190, 1196, "24 . 2", "", +85953, SdDevBL, 1203, 1208, "2 . 0", "", +85954, mmHg, 1209, 1214, "mm Hg", "", +85955, Mean, 1221, 1225, "mean", "", +85957, Diurnal_IOP, 1226, 1233, "diurnal", "", +85966, ResultMeasuredValue, 1244, 1250, "19 . 2", "", +85970, SdDevResValue, 1257, 1262, "2 . 6", "", +85972, mmHg, 1263, 1268, "mm Hg", "", +85974, Latanoprost, 1292, 1303, "latanoprost", "", +85968, ResultMeasuredValue, 1322, 1328, "16 . 7", "", +85971, SdDevResValue, 1335, 1340, "2 . 1", "", +85973, mmHg, 1341, 1346, "mm Hg", "", +85975, Lat/TimFC, 1374, 1391, "fixed combination", "", +85976, PValueResValue, 1402, 1416, "P & lt ; . 001", "", +85977, Lat/TimFC, 1425, 1442, "fixed combination", "", +85978, IOP, 1482, 1502, "intraocular pressure", "", +85979, mmHg, 1525, 1530, "mm Hg", "", +85980, PValueResValue, 1533, 1547, "P & lt ; . 001", "", +85981, IOP, 1564, 1584, "intraocular pressure", "", +85982, PValueChangeValue, 1625, 1639, "P & lt ; . 001", "", +85983, Stinging, 1644, 1652, "Stinging", "", +85984, Latanoprost, 1682, 1693, "latanoprost", "", +85985, PValueNumAffected, 1710, 1718, "P = . 04", "", +85987, Lat/TimFC, 1781, 1798, "fixed combination", "", +85988, PValueNumAffected, 1809, 1817, "P = . 04", "", +85989, ConclusionComment, 1835, 2041, "The result of this study suggests that the latanoprost - timolol - fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24 - hour diurnal curve", "", +85991, Latanoprost, 1878, 1889, "latanoprost", "", +85993, Lat/TimFC, 1878, 1919, "latanoprost - timolol - fixed combination", "", +85992, Timolol, 1892, 1899, "timolol", "", +85994, Latanoprost, 1934, 1945, "latanoprost", "", +85995, IOP, 1978, 1998, "intraocular pressure", "", +85990, ConclusionComment, 2042, 2125, "and for each individual time point in patients with primary open - angle glaucoma .", "", +85996, Primary_OpenAngleGlaucoma, 2094, 2123, "primary open - angle glaucoma", "", +85997, PMID, 2176, 2184, "16009829", "", diff --git a/data/gl 16009829_jshahinitiran.n-triples b/data/gl 16009829_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16009829_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16009829_tstrakeljahn.annodb b/data/gl 16009829_tstrakeljahn.annodb new file mode 100644 index 0000000..256f2b4 --- /dev/null +++ b/data/gl 16009829_tstrakeljahn.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90856, Journal, 0, 15, "Arch Ophthalmol", "", +90857, PublicationYear, 18, 22, "2005", "", +90862, Title, 53, 161, "Twenty - four - hour control with latanoprost - timolol - fixed combination therapy vs latanoprost therapy .", "", +90858, Latanoprost, 87, 98, "latanoprost", "", +90861, Lat/TimFC, 87, 108, "latanoprost - timolol", "", +90859, Timolol, 101, 108, "timolol", "", +90860, Latanoprost, 140, 151, "latanoprost", "", +90863, Author, 162, 172, "Konstas AG", "", +90864, Author, 181, 192, "Boboridis K", "", +90865, Author, 195, 203, "Tzetzi D", "", +90866, Author, 206, 219, "Kallinderis K", "", +90867, Author, 222, 232, "Jenkins JN", "", +90868, Author, 235, 245, "Stewart WC", "", +90869, Glaucoma, 275, 283, "Glaucoma", "", +90870, Greece, 416, 422, "Greece", "", +90871, Latanoprost, 490, 501, "latanoprost", "", +90875, Lat/TimFC, 490, 519, "latanoprost - timolol maleate", "", +90872, Timolol, 504, 519, "timolol maleate", "", +90873, Latanoprost, 543, 554, "latanoprost", "", +90880, Precondition, 566, 609, "patients with primary open - angle glaucoma", "", +90874, Primary_OpenAngleGlaucoma, 580, 609, "primary open - angle glaucoma", "", +90876, Prospective, 624, 635, "prospective", "", +90877, Blind, 638, 655, "observer - masked", "", +90878, Crossover, 658, 667, "crossover", "", +90879, Randomized, 692, 702, "randomized", "", +90881, Randomized, 779, 789, "randomized", "", +90882, Latanoprost, 800, 811, "latanoprost", "", +90884, Lat/TimFC, 800, 821, "latanoprost - timolol", "", +90883, Timolol, 814, 821, "timolol", "", +90885, Latanoprost, 853, 864, "latanoprost", "", +90887, Frequency, 886, 903, "once each evening", "", +90886, Evening, 896, 903, "evening", "", +90888, Diurnal_IOP, 1056, 1069, "diurnal curve", "", +90889, Mean, 1119, 1123, "mean", "", +90890, Diurnal_IOP, 1133, 1146, "diurnal curve", "", +90891, FinalNumPatientsCT, 1150, 1152, "37", "", +90892, BaseLineValue, 1190, 1196, "24 . 2", "", +90893, SdDevBL, 1203, 1208, "2 . 0", "", +90894, mmHg, 1209, 1214, "mm Hg", "", +90895, Mean, 1221, 1225, "mean", "", +90896, Diurnal_IOP, 1226, 1239, "diurnal curve", "", +90897, ResultMeasuredValue, 1244, 1250, "19 . 2", "", +90899, SdDevResValue, 1257, 1262, "2 . 6", "", +90901, mmHg, 1263, 1268, "mm Hg", "", +90903, Latanoprost, 1292, 1303, "latanoprost", "", +90898, ResultMeasuredValue, 1322, 1328, "16 . 7", "", +90900, SdDevResValue, 1335, 1340, "2 . 1", "", +90902, mmHg, 1341, 1346, "mm Hg", "", +90904, ResultMeasuredValue, 1404, 1416, "& lt ; . 001", "", +90919, ObservedResult, 1421, 1643, "The fixed combination therapy also provided a lower absolute intraocular pressure level ( 1 . 5 - 2 . 9 mm Hg , P & lt ; . 001 ) and a greater intraocular pressure reduction from the untreated baseline ( P & lt ; . 001 ) .", "", +90906, IOP, 1482, 1502, "intraocular pressure", "", +90907, DiffGroupAbsValue, 1511, 1516, "1 . 5", "", +90908, DiffGroupAbsValue, 1519, 1524, "2 . 9", "", +90909, mmHg, 1525, 1530, "mm Hg", "", +90910, PvalueDiff, 1535, 1547, "& lt ; . 001", "", +90911, IOP, 1564, 1584, "intraocular pressure", "", +90912, PvalueDiff, 1627, 1639, "& lt ; . 001", "", +90913, Stinging, 1644, 1652, "Stinging", "", +90918, ObservedResult, 1644, 1821, "Stinging was statistically lower with latanoprost therapy alone ( P = . 04 ) , but itching was statistically increased compared with the fixed combination therapy ( P = . 04 ) .", "", +90914, Latanoprost, 1682, 1693, "latanoprost", "", +90915, PvalueDiff, 1712, 1718, "= . 04", "", +90917, PvalueDiff, 1811, 1817, "= . 04", "", +90927, ConclusionComment, 1835, 2088, "The result of this study suggests that the latanoprost - timolol - fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24 - hour diurnal curve and for each individual time point in patients", "", +90920, Latanoprost, 1878, 1889, "latanoprost", "", +90922, Lat/TimFC, 1878, 1899, "latanoprost - timolol", "", +90921, Timolol, 1892, 1899, "timolol", "", +90923, Latanoprost, 1934, 1945, "latanoprost", "", +90924, IOP, 1978, 1998, "intraocular pressure", "", +90925, Diurnal_IOP, 2028, 2041, "diurnal curve", "", +90928, ConclusionComment, 2089, 2125, "with primary open - angle glaucoma .", "", +90926, Primary_OpenAngleGlaucoma, 2094, 2123, "primary open - angle glaucoma", "", +90929, PMID, 2176, 2184, "16009829", "", diff --git a/data/gl 16009829_tstrakeljahn.n-triples b/data/gl 16009829_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16009829_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16263174_admin.annodb b/data/gl 16263174_admin.annodb new file mode 100644 index 0000000..1bc2187 --- /dev/null +++ b/data/gl 16263174_admin.annodb @@ -0,0 +1,98 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2006", "", " \"2006\"." +2, Title, 66, 230, "A 12 - week , randomized , double - masked , multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components .", "", " \"A 12 - week , randomized , double - masked , multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components .\"." +3, Duration, 68, 77, "12 - week", "", " \"12 - week\"." +4, Randomized, 80, 90, "randomized", "", " ." +5, DoubleBlind, 93, 108, "double - masked", "", " ." +6, Multicenter, 111, 122, "multicenter", "", " ." +9, Lat/TimFC, 136, 180, "fixed combination of latanoprost and timolol", "", " ." +7, Latanoprost, 157, 168, "latanoprost", "", +8, Timolol, 173, 180, "timolol", "", +98, Evening, 188, 195, "evening", "", +10, Author, 231, 245, "Diestelhorst M", "", " \"Diestelhorst M\"." +11, Author, 254, 264, "Larsson LI", "", " \"Larsson LI\"." +102, Latanoprost, 287, 298, "Latanoprost", "", +12, Germany, 454, 461, "Germany", "", +13, PublicationYear, 543, 547, "2006", "", +14, ObjectiveDescription, 584, 750, "To compare the efficacy and tolerability of fixed - combination latanoprost and timolol applied in the evening with the concomitant use of the individual components .", "", " \"To compare the efficacy and tolerability of fixed - combination latanoprost and timolol applied in the evening with the concomitant use of the individual components .\"." +17, Lat/TimFC, 628, 671, "fixed - combination latanoprost and timolol", "", +15, Latanoprost, 648, 659, "latanoprost", "", +16, Timolol, 664, 671, "timolol", "", +107, Evening, 687, 694, "evening", "", +18, Duration, 760, 773, "Twelve - week", "", +19, Randomized, 776, 786, "randomized", "", +20, DoubleBlind, 789, 804, "double - masked", "", +21, Multicenter, 807, 818, "multicenter", "", +22, NumberPatientsCT, 842, 864, "Five hundred seventeen", "", " \"Five hundred seventeen\"." +23, Randomized, 865, 875, "randomized", "", +122, Precondition, 876, 1055, "patients with ocular hypertension ; open - angle , pigmentary , or exfoliation glaucoma ; and baseline ( after washout ) intraocular pressure ( IOP ) levels between 23 and 33 mmHg", "", " \"patients with ocular hypertension ; open - angle , pigmentary , or exfoliation glaucoma ; and baseline ( after washout ) intraocular pressure ( IOP ) levels between 23 and 33 mmHg\"." +24, OcularHypertension, 890, 909, "ocular hypertension", "", " ." +25, OpenAngleGlaucoma, 912, 963, "open - angle , pigmentary , or exfoliation glaucoma", "", " ." +26, PigmentaryGlaucoma, 927, 963, "pigmentary , or exfoliation glaucoma", "", " ." +27, Glaucoma, 943, 963, "exfoliation glaucoma", "", " . ." +28, IOP, 997, 1017, "intraocular pressure", "", +29, IOP, 1020, 1023, "IOP", "", +30, mmHg, 1051, 1055, "mmHg", "", +33, Lat/TimFC, 1097, 1141, "fixed combination of latanoprost and timolol", "", +31, Latanoprost, 1118, 1129, "latanoprost", "", +32, Timolol, 1134, 1141, "timolol", "", +34, Frequency, 1142, 1152, "once daily", "", " \"once daily\"." +35, Evening, 1160, 1167, "evening", "", " ." +36, Placebo, 1174, 1181, "placebo", "", " ." +37, Morning, 1189, 1196, "morning", "", " ." +38, Evening, 1201, 1208, "evening", "", " ." +39, Latanoprost, 1239, 1250, "latanoprost", "", " . ." +40, Frequency, 1251, 1261, "once daily", "", " \"once daily\"." +41, Evening, 1269, 1276, "evening", "", " ." +42, Timolol, 1281, 1288, "timolol", "", " ." +43, Morning, 1296, 1303, "morning", "", " ." +44, Evening, 1308, 1315, "evening", "", " ." +45, TimePoint, 1339, 1359, "weeks 2 , 6 , and 12", "", +46, TimePoint, 1339, 1350, "weeks 2 , 6", "", +47, TimePoint, 1339, 1346, "weeks 2", "", +48, Mean, 1421, 1425, "mean", "", +50, TimePoint, 1438, 1446, "baseline", "", +49, TimePoint, 1450, 1457, "week 12", "", +51, Diurnal_IOP, 1461, 1472, "diurnal IOP", "", +52, Mean, 1475, 1479, "mean", "", +53, IOP, 1480, 1484, "IOPs", "", +146, TimePoint, 1488, 1492, "8 am", "", +147, TimePoint, 1495, 1500, "12 pm", "", +148, TimePoint, 1507, 1511, "4 pm", "", +150, ConfIntervalDiff, 1672, 1684, "& lt ; 1 . 5", "", +55, mmHg, 1685, 1689, "mmHg", "", +152, FinalNumPatientsCT, 1783, 1786, "502", "", " \"502\"." +56, IntentionToTreat, 1813, 1832, "intent - to - treat", "", " ." +153, FinalNumPatientsArm, 1868, 1871, "255", "", " \"255\"." +154, FinalNumPatientsArm, 1900, 1903, "247", "", " \"247\"." +60, Mean, 1959, 1963, "mean", "", " . ." +61, Diurnal_IOP, 1973, 1984, "diurnal IOP", "", " ." +62, BaseLineValue, 1997, 2003, "25 . 4", "", " \"25 . 4\"." +64, mmHg, 2004, 2008, "mmHg", "", +63, BaseLineValue, 2013, 2019, "25 . 2", "", " \"25 . 2\"." +65, mmHg, 2020, 2024, "mmHg", "", " ." +66, Mean, 2046, 2050, "mean", "", +67, Diurnal_IOP, 2051, 2062, "diurnal IOP", "", +68, Reduction, 2079, 2084, "8 . 7", "", " \"8 . 7\"." +70, mmHg, 2085, 2089, "mmHg", "", +69, Reduction, 2094, 2099, "9 . 0", "", " \"9 . 0\"." +71, mmHg, 2100, 2104, "mmHg", "", +72, DiffGroupAbsValue, 2140, 2145, "0 . 3", "", " \"0 . 3\"." +73, mmHg, 2146, 2150, "mmHg", "", +102730, ConfIntervalDiff, 2153, 2184, "95 % CI , - 0 . 1 to 0 . 7 mmHg", "", " \"95 % CI , - 0 . 1 to 0 . 7 mmHg\"." +169, mmHg, 2180, 2184, "mmHg", "", +172, PvalueDiff, 2189, 2197, "= 0 . 15", "", " \"= 0 . 15\"." +76, ConclusionComment, 2254, 2451, "The fixed combination of latanoprost and timolol administered once daily in the evening is not inferior to the unfixed combination of latanoprost once daily in the evening and timolol twice daily .", "", " \"The fixed combination of latanoprost and timolol administered once daily in the evening is not inferior to the unfixed combination of latanoprost once daily in the evening and timolol twice daily .\". \"The fixed combination provides an effective and well - tolerated alternative to multiple instillations .\"." +79, Lat/TimFC, 2258, 2302, "fixed combination of latanoprost and timolol", "", +77, Latanoprost, 2279, 2290, "latanoprost", "", +78, Timolol, 2295, 2302, "timolol", "", +80, Frequency, 2316, 2326, "once daily", "", +81, Evening, 2334, 2341, "evening", "", +82, Latanoprost, 2388, 2399, "latanoprost", "", +83, Frequency, 2400, 2410, "once daily", "", +84, Evening, 2418, 2425, "evening", "", +85, Timolol, 2430, 2437, "timolol", "", +86, Frequency, 2438, 2449, "twice daily", "", +76, ConclusionComment, 2452, 2556, "The fixed combination provides an effective and well - tolerated alternative to multiple instillations .", "", " \"The fixed combination provides an effective and well - tolerated alternative to multiple instillations .\"." +89, PMID, 2611, 2619, "16263174", "", " \"16263174\"." diff --git a/data/gl 16263174_admin.n-triples b/data/gl 16263174_admin.n-triples new file mode 100644 index 0000000..279efc3 --- /dev/null +++ b/data/gl 16263174_admin.n-triples @@ -0,0 +1,127 @@ +# RDF export of group: Publication + . + "Publication 91323" . + "A 12 - week , randomized , double - masked , multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components ." . + "Diestelhorst M" . + "2006" . + "Ophthalmology" . + "16263174" . + . + "Larsson LI" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 91330" . + "To compare the efficacy and tolerability of fixed - combination latanoprost and timolol applied in the evening with the concomitant use of the individual components ." . + "Five hundred seventeen" . + "12 - week" . + . + . + . + "The fixed combination of latanoprost and timolol administered once daily in the evening is not inferior to the unfixed combination of latanoprost once daily in the evening and timolol twice daily ." . + "The fixed combination provides an effective and well - tolerated alternative to multiple instillations ." . + . + . + . + . + . + "502" . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 91346" . + "patients with ocular hypertension ; open - angle , pigmentary , or exfoliation glaucoma ; and baseline ( after washout ) intraocular pressure ( IOP ) levels between 23 and 33 mmHg" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "fix" . + "255" . + . + . + . + . + . + "ufix" . + "247" . + . + . + . + . +# RDF export of group: Intervention + . + "fix" . + "once daily" . + . + . + . + "la" . + . + "once daily" . + . + . + "ti" . + . + . + . + . + "pl" . + . + . + . +# RDF export of group: Medication + . + "la" . + . + . + . + . + . + "ti" . + . + . + . + . + "pl" . + . + . + . + . + "lati" . + . + . + . +# RDF export of group: Outcome + . + "iop 1" . + . + "25 . 4" . + "8 . 7" . + . + "iop 2" . + . + "25 . 2" . + "9 . 0" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "0 . 3" . + "= 0 . 15" . + "95 % CI , - 0 . 1 to 0 . 7 mmHg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16263174_export.csv b/data/gl 16263174_export.csv new file mode 100644 index 0000000..e7dd5ed --- /dev/null +++ b/data/gl 16263174_export.csv @@ -0,0 +1,524 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +549, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +549, 1, 2, 2, 14, 15, 14, 15, "." +549, 2, 1, 3, 0, 4, 16, 20, "2006" +549, 2, 2, 4, 5, 8, 21, 24, "Jan" +549, 2, 3, 5, 9, 10, 25, 26, ";" +549, 2, 4, 6, 11, 14, 27, 30, "113" +549, 2, 5, 7, 15, 16, 31, 32, "(" +549, 2, 6, 8, 17, 18, 33, 34, "1" +549, 2, 7, 9, 19, 20, 35, 36, ")" +549, 2, 8, 10, 21, 22, 37, 38, ":" +549, 2, 9, 11, 23, 25, 39, 41, "70" +549, 2, 10, 12, 26, 27, 42, 43, "-" +549, 2, 11, 13, 28, 29, 44, 45, "6" +549, 2, 12, 14, 30, 31, 46, 47, "." +549, 3, 1, 15, 0, 4, 48, 52, "Epub" +549, 3, 2, 16, 5, 9, 53, 57, "2005" +549, 3, 3, 17, 10, 13, 58, 61, "Nov" +549, 3, 4, 18, 14, 15, 62, 63, "2" +549, 3, 5, 19, 16, 17, 64, 65, "." +549, 4, 1, 20, 0, 1, 66, 67, "A" +549, 4, 2, 21, 2, 4, 68, 70, "12" +549, 4, 3, 22, 5, 6, 71, 72, "-" +549, 4, 4, 23, 7, 11, 73, 77, "week" +549, 4, 5, 24, 12, 13, 78, 79, "," +549, 4, 6, 25, 14, 24, 80, 90, "randomized" +549, 4, 7, 26, 25, 26, 91, 92, "," +549, 4, 8, 27, 27, 33, 93, 99, "double" +549, 4, 9, 28, 34, 35, 100, 101, "-" +549, 4, 10, 29, 36, 42, 102, 108, "masked" +549, 4, 11, 30, 43, 44, 109, 110, "," +549, 4, 12, 31, 45, 56, 111, 122, "multicenter" +549, 4, 13, 32, 57, 62, 123, 128, "study" +549, 4, 14, 33, 63, 65, 129, 131, "of" +549, 4, 15, 34, 66, 69, 132, 135, "the" +549, 4, 16, 35, 70, 75, 136, 141, "fixed" +549, 4, 17, 36, 76, 87, 142, 153, "combination" +549, 4, 18, 37, 88, 90, 154, 156, "of" +549, 4, 19, 38, 91, 102, 157, 168, "latanoprost" +549, 4, 20, 39, 103, 106, 169, 172, "and" +549, 4, 21, 40, 107, 114, 173, 180, "timolol" +549, 4, 22, 41, 115, 117, 181, 183, "in" +549, 4, 23, 42, 118, 121, 184, 187, "the" +549, 4, 24, 43, 122, 129, 188, 195, "evening" +549, 4, 25, 44, 130, 136, 196, 202, "versus" +549, 4, 26, 45, 137, 140, 203, 206, "the" +549, 4, 27, 46, 141, 151, 207, 217, "individual" +549, 4, 28, 47, 152, 162, 218, 228, "components" +549, 4, 29, 48, 163, 164, 229, 230, "." +549, 5, 1, 49, 0, 12, 231, 243, "Diestelhorst" +549, 5, 2, 50, 13, 14, 244, 245, "M" +549, 5, 3, 51, 15, 16, 246, 247, "(" +549, 5, 4, 52, 17, 18, 248, 249, "1" +549, 5, 5, 53, 19, 20, 250, 251, ")" +549, 5, 6, 54, 21, 22, 252, 253, "," +549, 5, 7, 55, 23, 30, 254, 261, "Larsson" +549, 5, 8, 56, 31, 33, 262, 264, "LI" +549, 5, 9, 57, 34, 35, 265, 266, ";" +549, 5, 10, 58, 36, 44, 267, 275, "European" +549, 5, 11, 59, 45, 46, 276, 277, "-" +549, 5, 12, 60, 47, 55, 278, 286, "Canadian" +549, 5, 13, 61, 56, 67, 287, 298, "Latanoprost" +549, 5, 14, 62, 68, 73, 299, 304, "Fixed" +549, 5, 15, 63, 74, 85, 305, 316, "Combination" +549, 5, 16, 64, 86, 91, 317, 322, "Study" +549, 5, 17, 65, 92, 97, 323, 328, "Group" +549, 5, 18, 66, 98, 99, 329, 330, "." +549, 6, 1, 67, 0, 6, 331, 337, "Author" +549, 6, 2, 68, 7, 18, 338, 349, "information" +549, 6, 3, 69, 19, 20, 350, 351, ":" +549, 6, 4, 70, 21, 22, 352, 353, "(" +549, 6, 5, 71, 23, 24, 354, 355, "1" +549, 6, 6, 72, 25, 26, 356, 357, ")" +549, 6, 7, 73, 27, 37, 358, 368, "Department" +549, 6, 8, 74, 38, 40, 369, 371, "of" +549, 6, 9, 75, 41, 54, 372, 385, "Ophthalmology" +549, 6, 10, 76, 55, 56, 386, 387, "," +549, 6, 11, 77, 57, 67, 388, 398, "Univerisit" +549, 6, 12, 78, 68, 69, 399, 400, "ä" +549, 6, 13, 79, 70, 72, 401, 403, "ts" +549, 6, 14, 80, 73, 74, 404, 405, "-" +549, 6, 15, 81, 75, 86, 406, 417, "Augenklinik" +549, 6, 16, 82, 87, 88, 418, 419, "," +549, 6, 17, 83, 89, 99, 420, 430, "University" +549, 6, 18, 84, 100, 102, 431, 433, "of" +549, 6, 19, 85, 103, 110, 434, 441, "Cologne" +549, 6, 20, 86, 111, 112, 442, 443, "," +549, 6, 21, 87, 113, 120, 444, 451, "Cologne" +549, 6, 22, 88, 121, 122, 452, 453, "," +549, 6, 23, 89, 123, 130, 454, 461, "Germany" +549, 6, 24, 90, 131, 132, 462, 463, "." +549, 7, 1, 91, 0, 7, 464, 471, "michael" +549, 7, 2, 92, 8, 9, 472, 473, "." +549, 7, 3, 93, 10, 22, 474, 486, "diestelhorst" +549, 7, 4, 94, 23, 24, 487, 488, "@" +549, 7, 5, 95, 25, 32, 489, 496, "medizin" +549, 7, 6, 96, 33, 34, 497, 498, "." +549, 7, 7, 97, 35, 38, 499, 502, "uni" +549, 7, 8, 98, 39, 40, 503, 504, "-" +549, 7, 9, 99, 41, 46, 505, 510, "koeln" +549, 7, 10, 100, 47, 48, 511, 512, "." +549, 7, 11, 101, 49, 51, 513, 515, "de" +549, 7, 12, 102, 52, 59, 516, 523, "Comment" +549, 7, 13, 103, 60, 62, 524, 526, "in" +549, 7, 14, 104, 63, 76, 527, 540, "Ophthalmology" +549, 7, 15, 105, 77, 78, 541, 542, "." +549, 8, 1, 106, 0, 4, 543, 547, "2006" +549, 8, 2, 107, 5, 8, 548, 551, "Jan" +549, 8, 3, 108, 9, 10, 552, 553, ";" +549, 8, 4, 109, 11, 14, 554, 557, "113" +549, 8, 5, 110, 15, 16, 558, 559, "(" +549, 8, 6, 111, 17, 18, 560, 561, "1" +549, 8, 7, 112, 19, 20, 562, 563, ")" +549, 8, 8, 113, 21, 22, 564, 565, ":" +549, 8, 9, 114, 23, 24, 566, 567, "1" +549, 8, 10, 115, 25, 26, 568, 569, "-" +549, 8, 11, 116, 27, 28, 570, 571, "2" +549, 8, 12, 117, 29, 30, 572, 573, "." +549, 9, 1, 118, 0, 7, 574, 581, "PURPOSE" +549, 9, 2, 119, 8, 9, 582, 583, ":" +549, 9, 3, 120, 10, 12, 584, 586, "To" +549, 9, 4, 121, 13, 20, 587, 594, "compare" +549, 9, 5, 122, 21, 24, 595, 598, "the" +549, 9, 6, 123, 25, 33, 599, 607, "efficacy" +549, 9, 7, 124, 34, 37, 608, 611, "and" +549, 9, 8, 125, 38, 50, 612, 624, "tolerability" +549, 9, 9, 126, 51, 53, 625, 627, "of" +549, 9, 10, 127, 54, 59, 628, 633, "fixed" +549, 9, 11, 128, 60, 61, 634, 635, "-" +549, 9, 12, 129, 62, 73, 636, 647, "combination" +549, 9, 13, 130, 74, 85, 648, 659, "latanoprost" +549, 9, 14, 131, 86, 89, 660, 663, "and" +549, 9, 15, 132, 90, 97, 664, 671, "timolol" +549, 9, 16, 133, 98, 105, 672, 679, "applied" +549, 9, 17, 134, 106, 108, 680, 682, "in" +549, 9, 18, 135, 109, 112, 683, 686, "the" +549, 9, 19, 136, 113, 120, 687, 694, "evening" +549, 9, 20, 137, 121, 125, 695, 699, "with" +549, 9, 21, 138, 126, 129, 700, 703, "the" +549, 9, 22, 139, 130, 141, 704, 715, "concomitant" +549, 9, 23, 140, 142, 145, 716, 719, "use" +549, 9, 24, 141, 146, 148, 720, 722, "of" +549, 9, 25, 142, 149, 152, 723, 726, "the" +549, 9, 26, 143, 153, 163, 727, 737, "individual" +549, 9, 27, 144, 164, 174, 738, 748, "components" +549, 9, 28, 145, 175, 176, 749, 750, "." +549, 10, 1, 146, 0, 6, 751, 757, "DESIGN" +549, 10, 2, 147, 7, 8, 758, 759, ":" +549, 10, 3, 148, 9, 15, 760, 766, "Twelve" +549, 10, 4, 149, 16, 17, 767, 768, "-" +549, 10, 5, 150, 18, 22, 769, 773, "week" +549, 10, 6, 151, 23, 24, 774, 775, "," +549, 10, 7, 152, 25, 35, 776, 786, "randomized" +549, 10, 8, 153, 36, 37, 787, 788, "," +549, 10, 9, 154, 38, 44, 789, 795, "double" +549, 10, 10, 155, 45, 46, 796, 797, "-" +549, 10, 11, 156, 47, 53, 798, 804, "masked" +549, 10, 12, 157, 54, 55, 805, 806, "," +549, 10, 13, 158, 56, 67, 807, 818, "multicenter" +549, 10, 14, 159, 68, 73, 819, 824, "study" +549, 10, 15, 160, 74, 75, 825, 826, "." +549, 11, 1, 161, 0, 12, 827, 839, "PARTICIPANTS" +549, 11, 2, 162, 13, 14, 840, 841, ":" +549, 11, 3, 163, 15, 19, 842, 846, "Five" +549, 11, 4, 164, 20, 27, 847, 854, "hundred" +549, 11, 5, 165, 28, 37, 855, 864, "seventeen" +549, 11, 6, 166, 38, 48, 865, 875, "randomized" +549, 11, 7, 167, 49, 57, 876, 884, "patients" +549, 11, 8, 168, 58, 62, 885, 889, "with" +549, 11, 9, 169, 63, 69, 890, 896, "ocular" +549, 11, 10, 170, 70, 82, 897, 909, "hypertension" +549, 11, 11, 171, 83, 84, 910, 911, ";" +549, 11, 12, 172, 85, 89, 912, 916, "open" +549, 11, 13, 173, 90, 91, 917, 918, "-" +549, 11, 14, 174, 92, 97, 919, 924, "angle" +549, 11, 15, 175, 98, 99, 925, 926, "," +549, 11, 16, 176, 100, 110, 927, 937, "pigmentary" +549, 11, 17, 177, 111, 112, 938, 939, "," +549, 11, 18, 178, 113, 115, 940, 942, "or" +549, 11, 19, 179, 116, 127, 943, 954, "exfoliation" +549, 11, 20, 180, 128, 136, 955, 963, "glaucoma" +549, 11, 21, 181, 137, 138, 964, 965, ";" +549, 11, 22, 182, 139, 142, 966, 969, "and" +549, 11, 23, 183, 143, 151, 970, 978, "baseline" +549, 11, 24, 184, 152, 153, 979, 980, "(" +549, 11, 25, 185, 154, 159, 981, 986, "after" +549, 11, 26, 186, 160, 167, 987, 994, "washout" +549, 11, 27, 187, 168, 169, 995, 996, ")" +549, 11, 28, 188, 170, 181, 997, 1008, "intraocular" +549, 11, 29, 189, 182, 190, 1009, 1017, "pressure" +549, 11, 30, 190, 191, 192, 1018, 1019, "(" +549, 11, 31, 191, 193, 196, 1020, 1023, "IOP" +549, 11, 32, 192, 197, 198, 1024, 1025, ")" +549, 11, 33, 193, 199, 205, 1026, 1032, "levels" +549, 11, 34, 194, 206, 213, 1033, 1040, "between" +549, 11, 35, 195, 214, 216, 1041, 1043, "23" +549, 11, 36, 196, 217, 220, 1044, 1047, "and" +549, 11, 37, 197, 221, 223, 1048, 1050, "33" +549, 11, 38, 198, 224, 228, 1051, 1055, "mmHg" +549, 11, 39, 199, 229, 230, 1056, 1057, "." +549, 12, 1, 200, 0, 7, 1058, 1065, "METHODS" +549, 12, 2, 201, 8, 9, 1066, 1067, ":" +549, 12, 3, 202, 10, 18, 1068, 1076, "Patients" +549, 12, 4, 203, 19, 27, 1077, 1085, "received" +549, 12, 5, 204, 28, 34, 1086, 1092, "either" +549, 12, 6, 205, 35, 38, 1093, 1096, "the" +549, 12, 7, 206, 39, 44, 1097, 1102, "fixed" +549, 12, 8, 207, 45, 56, 1103, 1114, "combination" +549, 12, 9, 208, 57, 59, 1115, 1117, "of" +549, 12, 10, 209, 60, 71, 1118, 1129, "latanoprost" +549, 12, 11, 210, 72, 75, 1130, 1133, "and" +549, 12, 12, 211, 76, 83, 1134, 1141, "timolol" +549, 12, 13, 212, 84, 88, 1142, 1146, "once" +549, 12, 14, 213, 89, 94, 1147, 1152, "daily" +549, 12, 15, 214, 95, 97, 1153, 1155, "in" +549, 12, 16, 215, 98, 101, 1156, 1159, "the" +549, 12, 17, 216, 102, 109, 1160, 1167, "evening" +549, 12, 18, 217, 110, 113, 1168, 1171, "and" +549, 12, 19, 218, 114, 115, 1172, 1173, "a" +549, 12, 20, 219, 116, 123, 1174, 1181, "placebo" +549, 12, 21, 220, 124, 126, 1182, 1184, "in" +549, 12, 22, 221, 127, 130, 1185, 1188, "the" +549, 12, 23, 222, 131, 138, 1189, 1196, "morning" +549, 12, 24, 223, 139, 142, 1197, 1200, "and" +549, 12, 25, 224, 143, 150, 1201, 1208, "evening" +549, 12, 26, 225, 151, 153, 1209, 1211, "or" +549, 12, 27, 226, 154, 157, 1212, 1215, "the" +549, 12, 28, 227, 158, 165, 1216, 1223, "unfixed" +549, 12, 29, 228, 166, 177, 1224, 1235, "combination" +549, 12, 30, 229, 178, 180, 1236, 1238, "of" +549, 12, 31, 230, 181, 192, 1239, 1250, "latanoprost" +549, 12, 32, 231, 193, 197, 1251, 1255, "once" +549, 12, 33, 232, 198, 203, 1256, 1261, "daily" +549, 12, 34, 233, 204, 206, 1262, 1264, "in" +549, 12, 35, 234, 207, 210, 1265, 1268, "the" +549, 12, 36, 235, 211, 218, 1269, 1276, "evening" +549, 12, 37, 236, 219, 222, 1277, 1280, "and" +549, 12, 38, 237, 223, 230, 1281, 1288, "timolol" +549, 12, 39, 238, 231, 233, 1289, 1291, "in" +549, 12, 40, 239, 234, 237, 1292, 1295, "the" +549, 12, 41, 240, 238, 245, 1296, 1303, "morning" +549, 12, 42, 241, 246, 249, 1304, 1307, "and" +549, 12, 43, 242, 250, 257, 1308, 1315, "evening" +549, 12, 44, 243, 258, 259, 1316, 1317, "." +549, 13, 1, 244, 0, 5, 1318, 1323, "Study" +549, 13, 2, 245, 6, 12, 1324, 1330, "visits" +549, 13, 3, 246, 13, 17, 1331, 1335, "were" +549, 13, 4, 247, 18, 20, 1336, 1338, "at" +549, 13, 5, 248, 21, 26, 1339, 1344, "weeks" +549, 13, 6, 249, 27, 28, 1345, 1346, "2" +549, 13, 7, 250, 29, 30, 1347, 1348, "," +549, 13, 8, 251, 31, 32, 1349, 1350, "6" +549, 13, 9, 252, 33, 34, 1351, 1352, "," +549, 13, 10, 253, 35, 38, 1353, 1356, "and" +549, 13, 11, 254, 39, 41, 1357, 1359, "12" +549, 13, 12, 255, 42, 43, 1360, 1361, "." +549, 14, 1, 256, 0, 4, 1362, 1366, "MAIN" +549, 14, 2, 257, 5, 12, 1367, 1374, "OUTCOME" +549, 14, 3, 258, 13, 21, 1375, 1383, "MEASURES" +549, 14, 4, 259, 22, 23, 1384, 1385, ":" +549, 14, 5, 260, 24, 27, 1386, 1389, "The" +549, 14, 6, 261, 28, 35, 1390, 1397, "primary" +549, 14, 7, 262, 36, 44, 1398, 1406, "efficacy" +549, 14, 8, 263, 45, 48, 1407, 1410, "end" +549, 14, 9, 264, 49, 54, 1411, 1416, "point" +549, 14, 10, 265, 55, 58, 1417, 1420, "was" +549, 14, 11, 266, 59, 63, 1421, 1425, "mean" +549, 14, 12, 267, 64, 70, 1426, 1432, "change" +549, 14, 13, 268, 71, 75, 1433, 1437, "from" +549, 14, 14, 269, 76, 84, 1438, 1446, "baseline" +549, 14, 15, 270, 85, 87, 1447, 1449, "to" +549, 14, 16, 271, 88, 92, 1450, 1454, "week" +549, 14, 17, 272, 93, 95, 1455, 1457, "12" +549, 14, 18, 273, 96, 98, 1458, 1460, "in" +549, 14, 19, 274, 99, 106, 1461, 1468, "diurnal" +549, 14, 20, 275, 107, 110, 1469, 1472, "IOP" +549, 14, 21, 276, 111, 112, 1473, 1474, "(" +549, 14, 22, 277, 113, 117, 1475, 1479, "mean" +549, 14, 23, 278, 118, 122, 1480, 1484, "IOPs" +549, 14, 24, 279, 123, 125, 1485, 1487, "of" +549, 14, 25, 280, 126, 127, 1488, 1489, "8" +549, 14, 26, 281, 128, 130, 1490, 1492, "am" +549, 14, 27, 282, 131, 132, 1493, 1494, "," +549, 14, 28, 283, 133, 135, 1495, 1497, "12" +549, 14, 29, 284, 136, 138, 1498, 1500, "pm" +549, 14, 30, 285, 139, 140, 1501, 1502, "," +549, 14, 31, 286, 141, 144, 1503, 1506, "and" +549, 14, 32, 287, 145, 146, 1507, 1508, "4" +549, 14, 33, 288, 147, 149, 1509, 1511, "pm" +549, 14, 34, 289, 150, 151, 1512, 1513, ")" +549, 14, 35, 290, 152, 153, 1514, 1515, "." +549, 15, 1, 291, 0, 3, 1516, 1519, "The" +549, 15, 2, 292, 4, 9, 1520, 1525, "fixed" +549, 15, 3, 293, 10, 21, 1526, 1537, "combination" +549, 15, 4, 294, 22, 25, 1538, 1541, "was" +549, 15, 5, 295, 26, 36, 1542, 1552, "considered" +549, 15, 6, 296, 37, 48, 1553, 1564, "noninferior" +549, 15, 7, 297, 49, 51, 1565, 1567, "to" +549, 15, 8, 298, 52, 55, 1568, 1571, "the" +549, 15, 9, 299, 56, 63, 1572, 1579, "unfixed" +549, 15, 10, 300, 64, 75, 1580, 1591, "combination" +549, 15, 11, 301, 76, 78, 1592, 1594, "if" +549, 15, 12, 302, 79, 82, 1595, 1598, "the" +549, 15, 13, 303, 83, 88, 1599, 1604, "upper" +549, 15, 14, 304, 89, 94, 1605, 1610, "limit" +549, 15, 15, 305, 95, 97, 1611, 1613, "of" +549, 15, 16, 306, 98, 101, 1614, 1617, "the" +549, 15, 17, 307, 102, 104, 1618, 1620, "95" +549, 15, 18, 308, 105, 106, 1621, 1622, "%" +549, 15, 19, 309, 107, 117, 1623, 1633, "confidence" +549, 15, 20, 310, 118, 126, 1634, 1642, "interval" +549, 15, 21, 311, 127, 128, 1643, 1644, "(" +549, 15, 22, 312, 129, 131, 1645, 1647, "CI" +549, 15, 23, 313, 132, 133, 1648, 1649, ")" +549, 15, 24, 314, 134, 136, 1650, 1652, "of" +549, 15, 25, 315, 137, 140, 1653, 1656, "the" +549, 15, 26, 316, 141, 151, 1657, 1667, "difference" +549, 15, 27, 317, 152, 155, 1668, 1671, "was" +549, 15, 28, 318, 156, 157, 1672, 1673, "&" +549, 15, 29, 319, 158, 160, 1674, 1676, "lt" +549, 15, 30, 320, 161, 162, 1677, 1678, ";" +549, 15, 31, 321, 163, 164, 1679, 1680, "1" +549, 15, 32, 322, 165, 166, 1681, 1682, "." +549, 15, 33, 323, 167, 168, 1683, 1684, "5" +549, 15, 34, 324, 169, 173, 1685, 1689, "mmHg" +549, 15, 35, 325, 174, 175, 1690, 1691, "(" +549, 15, 36, 326, 176, 184, 1692, 1700, "analysis" +549, 15, 37, 327, 185, 187, 1701, 1703, "of" +549, 15, 38, 328, 188, 198, 1704, 1714, "covariance" +549, 15, 39, 329, 199, 200, 1715, 1716, ")" +549, 15, 40, 330, 201, 202, 1717, 1718, "." +549, 16, 1, 331, 0, 7, 1719, 1726, "Adverse" +549, 16, 2, 332, 8, 14, 1727, 1733, "events" +549, 16, 3, 333, 15, 19, 1734, 1738, "were" +549, 16, 4, 334, 20, 28, 1739, 1747, "recorded" +549, 16, 5, 335, 29, 31, 1748, 1750, "at" +549, 16, 6, 336, 32, 36, 1751, 1755, "each" +549, 16, 7, 337, 37, 42, 1756, 1761, "visit" +549, 16, 8, 338, 43, 44, 1762, 1763, "." +549, 17, 1, 339, 0, 7, 1764, 1771, "RESULTS" +549, 17, 2, 340, 8, 9, 1772, 1773, ":" +549, 17, 3, 341, 10, 12, 1774, 1776, "In" +549, 17, 4, 342, 13, 16, 1777, 1780, "all" +549, 17, 5, 343, 17, 18, 1781, 1782, "," +549, 17, 6, 344, 19, 22, 1783, 1786, "502" +549, 17, 7, 345, 23, 31, 1787, 1795, "patients" +549, 17, 8, 346, 32, 36, 1796, 1800, "were" +549, 17, 9, 347, 37, 45, 1801, 1809, "included" +549, 17, 10, 348, 46, 48, 1810, 1812, "in" +549, 17, 11, 349, 49, 55, 1813, 1819, "intent" +549, 17, 12, 350, 56, 57, 1820, 1821, "-" +549, 17, 13, 351, 58, 60, 1822, 1824, "to" +549, 17, 14, 352, 61, 62, 1825, 1826, "-" +549, 17, 15, 353, 63, 68, 1827, 1832, "treat" +549, 17, 16, 354, 69, 77, 1833, 1841, "analyses" +549, 17, 17, 355, 78, 79, 1842, 1843, "(" +549, 17, 18, 356, 80, 85, 1844, 1849, "fixed" +549, 17, 19, 357, 86, 97, 1850, 1861, "combination" +549, 17, 20, 358, 98, 99, 1862, 1863, "," +549, 17, 21, 359, 100, 101, 1864, 1865, "n" +549, 17, 22, 360, 102, 103, 1866, 1867, "=" +549, 17, 23, 361, 104, 107, 1868, 1871, "255" +549, 17, 24, 362, 108, 109, 1872, 1873, ";" +549, 17, 25, 363, 110, 117, 1874, 1881, "unfixed" +549, 17, 26, 364, 118, 129, 1882, 1893, "combination" +549, 17, 27, 365, 130, 131, 1894, 1895, "," +549, 17, 28, 366, 132, 133, 1896, 1897, "n" +549, 17, 29, 367, 134, 135, 1898, 1899, "=" +549, 17, 30, 368, 136, 139, 1900, 1903, "247" +549, 17, 31, 369, 140, 141, 1904, 1905, ")" +549, 17, 32, 370, 142, 143, 1906, 1907, "." +549, 18, 1, 371, 0, 3, 1908, 1911, "For" +549, 18, 2, 372, 4, 7, 1912, 1915, "the" +549, 18, 3, 373, 8, 13, 1916, 1921, "fixed" +549, 18, 4, 374, 14, 15, 1922, 1923, "-" +549, 18, 5, 375, 16, 19, 1924, 1927, "and" +549, 18, 6, 376, 20, 27, 1928, 1935, "unfixed" +549, 18, 7, 377, 28, 29, 1936, 1937, "-" +549, 18, 8, 378, 30, 41, 1938, 1949, "combination" +549, 18, 9, 379, 42, 48, 1950, 1956, "groups" +549, 18, 10, 380, 49, 50, 1957, 1958, "," +549, 18, 11, 381, 51, 55, 1959, 1963, "mean" +549, 18, 12, 382, 56, 64, 1964, 1972, "baseline" +549, 18, 13, 383, 65, 72, 1973, 1980, "diurnal" +549, 18, 14, 384, 73, 76, 1981, 1984, "IOP" +549, 18, 15, 385, 77, 83, 1985, 1991, "levels" +549, 18, 16, 386, 84, 88, 1992, 1996, "were" +549, 18, 17, 387, 89, 91, 1997, 1999, "25" +549, 18, 18, 388, 92, 93, 2000, 2001, "." +549, 18, 19, 389, 94, 95, 2002, 2003, "4" +549, 18, 20, 390, 96, 100, 2004, 2008, "mmHg" +549, 18, 21, 391, 101, 104, 2009, 2012, "and" +549, 18, 22, 392, 105, 107, 2013, 2015, "25" +549, 18, 23, 393, 108, 109, 2016, 2017, "." +549, 18, 24, 394, 110, 111, 2018, 2019, "2" +549, 18, 25, 395, 112, 116, 2020, 2024, "mmHg" +549, 18, 26, 396, 117, 118, 2025, 2026, "," +549, 18, 27, 397, 119, 131, 2027, 2039, "respectively" +549, 18, 28, 398, 132, 133, 2040, 2041, "," +549, 18, 29, 399, 134, 137, 2042, 2045, "and" +549, 18, 30, 400, 138, 142, 2046, 2050, "mean" +549, 18, 31, 401, 143, 150, 2051, 2058, "diurnal" +549, 18, 32, 402, 151, 154, 2059, 2062, "IOP" +549, 18, 33, 403, 155, 165, 2063, 2073, "reductions" +549, 18, 34, 404, 166, 170, 2074, 2078, "were" +549, 18, 35, 405, 171, 172, 2079, 2080, "8" +549, 18, 36, 406, 173, 174, 2081, 2082, "." +549, 18, 37, 407, 175, 176, 2083, 2084, "7" +549, 18, 38, 408, 177, 181, 2085, 2089, "mmHg" +549, 18, 39, 409, 182, 185, 2090, 2093, "and" +549, 18, 40, 410, 186, 187, 2094, 2095, "9" +549, 18, 41, 411, 188, 189, 2096, 2097, "." +549, 18, 42, 412, 190, 191, 2098, 2099, "0" +549, 18, 43, 413, 192, 196, 2100, 2104, "mmHg" +549, 18, 44, 414, 197, 198, 2105, 2106, "(" +549, 18, 45, 415, 199, 206, 2107, 2114, "between" +549, 18, 46, 416, 207, 208, 2115, 2116, "-" +549, 18, 47, 417, 209, 218, 2117, 2126, "treatment" +549, 18, 48, 418, 219, 229, 2127, 2137, "difference" +549, 18, 49, 419, 230, 231, 2138, 2139, "," +549, 18, 50, 420, 232, 233, 2140, 2141, "0" +549, 18, 51, 421, 234, 235, 2142, 2143, "." +549, 18, 52, 422, 236, 237, 2144, 2145, "3" +549, 18, 53, 423, 238, 242, 2146, 2150, "mmHg" +549, 18, 54, 424, 243, 244, 2151, 2152, ";" +549, 18, 55, 425, 245, 247, 2153, 2155, "95" +549, 18, 56, 426, 248, 249, 2156, 2157, "%" +549, 18, 57, 427, 250, 252, 2158, 2160, "CI" +549, 18, 58, 428, 253, 254, 2161, 2162, "," +549, 18, 59, 429, 255, 256, 2163, 2164, "-" +549, 18, 60, 430, 257, 258, 2165, 2166, "0" +549, 18, 61, 431, 259, 260, 2167, 2168, "." +549, 18, 62, 432, 261, 262, 2169, 2170, "1" +549, 18, 63, 433, 263, 265, 2171, 2173, "to" +549, 18, 64, 434, 266, 267, 2174, 2175, "0" +549, 18, 65, 435, 268, 269, 2176, 2177, "." +549, 18, 66, 436, 270, 271, 2178, 2179, "7" +549, 18, 67, 437, 272, 276, 2180, 2184, "mmHg" +549, 18, 68, 438, 277, 278, 2185, 2186, ";" +549, 18, 69, 439, 279, 280, 2187, 2188, "P" +549, 18, 70, 440, 281, 282, 2189, 2190, "=" +549, 18, 71, 441, 283, 284, 2191, 2192, "0" +549, 18, 72, 442, 285, 286, 2193, 2194, "." +549, 18, 73, 443, 287, 289, 2195, 2197, "15" +549, 18, 74, 444, 290, 291, 2198, 2199, ")" +549, 18, 75, 445, 292, 293, 2200, 2201, "." +549, 19, 1, 446, 0, 4, 2202, 2206, "Both" +549, 19, 2, 447, 5, 15, 2207, 2217, "treatments" +549, 19, 3, 448, 16, 20, 2218, 2222, "were" +549, 19, 4, 449, 21, 25, 2223, 2227, "well" +549, 19, 5, 450, 26, 35, 2228, 2237, "tolerated" +549, 19, 6, 451, 36, 37, 2238, 2239, "." +549, 20, 1, 452, 0, 11, 2240, 2251, "CONCLUSIONS" +549, 20, 2, 453, 12, 13, 2252, 2253, ":" +549, 20, 3, 454, 14, 17, 2254, 2257, "The" +549, 20, 4, 455, 18, 23, 2258, 2263, "fixed" +549, 20, 5, 456, 24, 35, 2264, 2275, "combination" +549, 20, 6, 457, 36, 38, 2276, 2278, "of" +549, 20, 7, 458, 39, 50, 2279, 2290, "latanoprost" +549, 20, 8, 459, 51, 54, 2291, 2294, "and" +549, 20, 9, 460, 55, 62, 2295, 2302, "timolol" +549, 20, 10, 461, 63, 75, 2303, 2315, "administered" +549, 20, 11, 462, 76, 80, 2316, 2320, "once" +549, 20, 12, 463, 81, 86, 2321, 2326, "daily" +549, 20, 13, 464, 87, 89, 2327, 2329, "in" +549, 20, 14, 465, 90, 93, 2330, 2333, "the" +549, 20, 15, 466, 94, 101, 2334, 2341, "evening" +549, 20, 16, 467, 102, 104, 2342, 2344, "is" +549, 20, 17, 468, 105, 108, 2345, 2348, "not" +549, 20, 18, 469, 109, 117, 2349, 2357, "inferior" +549, 20, 19, 470, 118, 120, 2358, 2360, "to" +549, 20, 20, 471, 121, 124, 2361, 2364, "the" +549, 20, 21, 472, 125, 132, 2365, 2372, "unfixed" +549, 20, 22, 473, 133, 144, 2373, 2384, "combination" +549, 20, 23, 474, 145, 147, 2385, 2387, "of" +549, 20, 24, 475, 148, 159, 2388, 2399, "latanoprost" +549, 20, 25, 476, 160, 164, 2400, 2404, "once" +549, 20, 26, 477, 165, 170, 2405, 2410, "daily" +549, 20, 27, 478, 171, 173, 2411, 2413, "in" +549, 20, 28, 479, 174, 177, 2414, 2417, "the" +549, 20, 29, 480, 178, 185, 2418, 2425, "evening" +549, 20, 30, 481, 186, 189, 2426, 2429, "and" +549, 20, 31, 482, 190, 197, 2430, 2437, "timolol" +549, 20, 32, 483, 198, 203, 2438, 2443, "twice" +549, 20, 33, 484, 204, 209, 2444, 2449, "daily" +549, 20, 34, 485, 210, 211, 2450, 2451, "." +549, 21, 1, 486, 0, 3, 2452, 2455, "The" +549, 21, 2, 487, 4, 9, 2456, 2461, "fixed" +549, 21, 3, 488, 10, 21, 2462, 2473, "combination" +549, 21, 4, 489, 22, 30, 2474, 2482, "provides" +549, 21, 5, 490, 31, 33, 2483, 2485, "an" +549, 21, 6, 491, 34, 43, 2486, 2495, "effective" +549, 21, 7, 492, 44, 47, 2496, 2499, "and" +549, 21, 8, 493, 48, 52, 2500, 2504, "well" +549, 21, 9, 494, 53, 54, 2505, 2506, "-" +549, 21, 10, 495, 55, 64, 2507, 2516, "tolerated" +549, 21, 11, 496, 65, 76, 2517, 2528, "alternative" +549, 21, 12, 497, 77, 79, 2529, 2531, "to" +549, 21, 13, 498, 80, 88, 2532, 2540, "multiple" +549, 21, 14, 499, 89, 102, 2541, 2554, "instillations" +549, 21, 15, 500, 103, 104, 2555, 2556, "." +549, 22, 1, 501, 0, 3, 2557, 2560, "DOI" +549, 22, 2, 502, 4, 5, 2561, 2562, ":" +549, 22, 3, 503, 6, 8, 2563, 2565, "10" +549, 22, 4, 504, 9, 10, 2566, 2567, "." +549, 22, 5, 505, 11, 15, 2568, 2572, "1016" +549, 22, 6, 506, 16, 17, 2573, 2574, "/" +549, 22, 7, 507, 18, 19, 2575, 2576, "j" +549, 22, 8, 508, 20, 21, 2577, 2578, "." +549, 22, 9, 509, 22, 28, 2579, 2585, "ophtha" +549, 22, 10, 510, 29, 30, 2586, 2587, "." +549, 22, 11, 511, 31, 35, 2588, 2592, "2005" +549, 22, 12, 512, 36, 37, 2593, 2594, "." +549, 22, 13, 513, 38, 40, 2595, 2597, "06" +549, 22, 14, 514, 41, 42, 2598, 2599, "." +549, 22, 15, 515, 43, 46, 2600, 2603, "027" +549, 22, 16, 516, 47, 51, 2604, 2608, "PMID" +549, 22, 17, 517, 52, 53, 2609, 2610, ":" +549, 22, 18, 518, 54, 62, 2611, 2619, "16263174" +549, 22, 19, 519, 63, 64, 2620, 2621, "[" +549, 22, 20, 520, 65, 72, 2622, 2629, "Indexed" +549, 22, 21, 521, 73, 76, 2630, 2633, "for" +549, 22, 22, 522, 77, 84, 2634, 2641, "MEDLINE" +549, 22, 23, 523, 85, 86, 2642, 2643, "]" diff --git a/data/gl 16263174_jshahinitiran.annodb b/data/gl 16263174_jshahinitiran.annodb new file mode 100644 index 0000000..ed8671c --- /dev/null +++ b/data/gl 16263174_jshahinitiran.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +86263, Journal, 0, 13, "Ophthalmology", "", +86264, PublicationYear, 16, 20, "2006", "", +86265, Title, 66, 230, "A 12 - week , randomized , double - masked , multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components .", "", +86266, Duration, 68, 77, "12 - week", "", +86267, Randomized, 80, 90, "randomized", "", +86268, DoubleBlind, 93, 108, "double - masked", "", +86269, Multicenter, 111, 122, "multicenter", "", +86272, Lat/TimFC, 136, 180, "fixed combination of latanoprost and timolol", "", +86270, Latanoprost, 157, 168, "latanoprost", "", +86271, Timolol, 173, 180, "timolol", "", +86273, Author, 231, 245, "Diestelhorst M", "", +86274, Author, 254, 264, "Larsson LI", "", +86275, Germany, 454, 461, "Germany", "", +86276, PublicationYear, 543, 547, "2006", "", +86277, ObjectiveDescription, 584, 750, "To compare the efficacy and tolerability of fixed - combination latanoprost and timolol applied in the evening with the concomitant use of the individual components .", "", +86280, Lat/TimFC, 628, 671, "fixed - combination latanoprost and timolol", "", +86278, Latanoprost, 648, 659, "latanoprost", "", +86279, Timolol, 664, 671, "timolol", "", +86281, Duration, 760, 773, "Twelve - week", "", +86282, Randomized, 776, 786, "randomized", "", +86283, DoubleBlind, 789, 804, "double - masked", "", +86284, Multicenter, 807, 818, "multicenter", "", +86285, NumberPatientsCT, 842, 864, "Five hundred seventeen", "", +86286, Randomized, 865, 875, "randomized", "", +86287, OcularHypertension, 890, 909, "ocular hypertension", "", +86289, OpenAngleGlaucoma, 912, 963, "open - angle , pigmentary , or exfoliation glaucoma", "", +86290, PigmentaryGlaucoma, 927, 963, "pigmentary , or exfoliation glaucoma", "", +86291, Glaucoma, 943, 963, "exfoliation glaucoma", "", +86292, IOP, 997, 1017, "intraocular pressure", "", +86293, IOP, 1020, 1023, "IOP", "", +86294, mmHg, 1051, 1055, "mmHg", "", +86297, Lat/TimFC, 1097, 1141, "fixed combination of latanoprost and timolol", "", +86295, Latanoprost, 1118, 1129, "latanoprost", "", +86296, Timolol, 1134, 1141, "timolol", "", +86298, Frequency, 1142, 1152, "once daily", "", +86299, Evening, 1160, 1167, "evening", "", +86300, Placebo, 1174, 1181, "placebo", "", +86301, Morning, 1189, 1196, "morning", "", +86302, Evening, 1201, 1208, "evening", "", +86303, Latanoprost, 1239, 1250, "latanoprost", "", +86304, Frequency, 1251, 1261, "once daily", "", +86305, Evening, 1269, 1276, "evening", "", +86306, Timolol, 1281, 1288, "timolol", "", +86307, Morning, 1296, 1303, "morning", "", +86308, Evening, 1308, 1315, "evening", "", +86309, TimePoint, 1339, 1359, "weeks 2 , 6 , and 12", "", +86310, TimePoint, 1339, 1350, "weeks 2 , 6", "", +86311, TimePoint, 1339, 1346, "weeks 2", "", +86312, Mean, 1421, 1425, "mean", "", +86314, TimePoint, 1438, 1446, "baseline", "", +86313, TimePoint, 1450, 1457, "week 12", "", +86315, Diurnal_IOP, 1461, 1472, "diurnal IOP", "", +86494, Mean, 1475, 1479, "mean", "", +86501, IOP, 1480, 1484, "IOPs", "", +86502, Lat/TimFC, 1520, 1537, "fixed combination", "", +86503, mmHg, 1685, 1689, "mmHg", "", +86507, NumberPatientsCT, 1783, 1786, "502", "", +86504, IntentionToTreat, 1813, 1832, "intent - to - treat", "", +86505, NumberPatientsArm, 1868, 1871, "255", "", +86506, NumberPatientsArm, 1900, 1903, "247", "", +86508, Mean, 1959, 1963, "mean", "", +86509, Diurnal_IOP, 1973, 1984, "diurnal IOP", "", +86510, BaseLineValue, 1997, 2003, "25 . 4", "", +86514, mmHg, 2004, 2008, "mmHg", "", +86512, BaseLineValue, 2013, 2019, "25 . 2", "", +86515, mmHg, 2020, 2024, "mmHg", "", +86517, Mean, 2046, 2050, "mean", "", +86518, Diurnal_IOP, 2051, 2062, "diurnal IOP", "", +86522, Reduction, 2079, 2084, "8 . 7", "", +86524, mmHg, 2085, 2089, "mmHg", "", +86523, Reduction, 2094, 2099, "9 . 0", "", +86525, mmHg, 2100, 2104, "mmHg", "", +86526, DiffGroupAbsValue, 2140, 2145, "0 . 3", "", +86527, mmHg, 2146, 2150, "mmHg", "", +86528, ConfIntervalChangeValue, 2153, 2184, "95 % CI , - 0 . 1 to 0 . 7 mmHg", "", +86530, PValueChangeValue, 2187, 2197, "P = 0 . 15", "", +86531, ConclusionComment, 2254, 2451, "The fixed combination of latanoprost and timolol administered once daily in the evening is not inferior to the unfixed combination of latanoprost once daily in the evening and timolol twice daily .", "", +86535, Lat/TimFC, 2258, 2302, "fixed combination of latanoprost and timolol", "", +86532, Latanoprost, 2279, 2290, "latanoprost", "", +86534, Timolol, 2295, 2302, "timolol", "", +86536, Frequency, 2316, 2326, "once daily", "", +86537, Evening, 2334, 2341, "evening", "", +86538, Latanoprost, 2388, 2399, "latanoprost", "", +86539, Frequency, 2400, 2410, "once daily", "", +86540, Evening, 2418, 2425, "evening", "", +86541, Timolol, 2430, 2437, "timolol", "", +86543, Frequency, 2438, 2449, "twice daily", "", +86544, ConclusionComment, 2452, 2556, "The fixed combination provides an effective and well - tolerated alternative to multiple instillations .", "", +86545, Lat/TimFC, 2456, 2473, "fixed combination", "", +86546, PMID, 2611, 2619, "16263174", "", diff --git a/data/gl 16263174_jshahinitiran.n-triples b/data/gl 16263174_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16263174_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16263174_tstrakeljahn.annodb b/data/gl 16263174_tstrakeljahn.annodb new file mode 100644 index 0000000..203e114 --- /dev/null +++ b/data/gl 16263174_tstrakeljahn.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90759, Journal, 0, 13, "Ophthalmology", "", +90760, PublicationYear, 16, 20, "2006", "", +90773, Title, 66, 230, "A 12 - week , randomized , double - masked , multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components .", "", +90761, Duration, 68, 77, "12 - week", "", +90762, Randomized, 80, 90, "randomized", "", +90763, DoubleBlind, 93, 108, "double - masked", "", +90764, Multicenter, 111, 122, "multicenter", "", +90765, Latanoprost, 157, 168, "latanoprost", "", +90768, Lat/TimFC, 157, 180, "latanoprost and timolol", "", +90766, Timolol, 173, 180, "timolol", "", +90767, Evening, 188, 195, "evening", "", +90769, Author, 231, 245, "Diestelhorst M", "", +90770, Author, 254, 264, "Larsson LI", "", +90771, Latanoprost, 287, 298, "Latanoprost", "", +90772, Germany, 454, 461, "Germany", "", +90774, Latanoprost, 648, 659, "latanoprost", "", +90777, Lat/TimFC, 648, 671, "latanoprost and timolol", "", +90775, Timolol, 664, 671, "timolol", "", +90776, Evening, 687, 694, "evening", "", +90780, Duration, 760, 773, "Twelve - week", "", +90778, Randomized, 776, 786, "randomized", "", +90781, DoubleBlind, 789, 804, "double - masked", "", +90782, Multicenter, 807, 818, "multicenter", "", +90783, NumberPatientsCT, 842, 864, "Five hundred seventeen", "", +90784, Randomized, 865, 875, "randomized", "", +90792, Precondition, 876, 1055, "patients with ocular hypertension ; open - angle , pigmentary , or exfoliation glaucoma ; and baseline ( after washout ) intraocular pressure ( IOP ) levels between 23 and 33 mmHg", "", +90785, OcularHypertension, 890, 909, "ocular hypertension", "", +90786, OpenAngleGlaucoma, 912, 963, "open - angle , pigmentary , or exfoliation glaucoma", "", +90787, PigmentaryGlaucoma, 927, 963, "pigmentary , or exfoliation glaucoma", "", +90788, Glaucoma, 943, 963, "exfoliation glaucoma", "", +90789, IOP, 997, 1017, "intraocular pressure", "", +90790, IOP, 1020, 1023, "IOP", "", +90791, mmHg, 1051, 1055, "mmHg", "", +90793, Latanoprost, 1118, 1129, "latanoprost", "", +90795, Lat/TimFC, 1118, 1141, "latanoprost and timolol", "", +90794, Timolol, 1134, 1141, "timolol", "", +90796, Frequency, 1142, 1152, "once daily", "", +90800, Evening, 1160, 1167, "evening", "", +90797, Placebo, 1174, 1181, "placebo", "", +90798, Morning, 1189, 1196, "morning", "", +90799, Evening, 1201, 1208, "evening", "", +90801, Latanoprost, 1239, 1250, "latanoprost", "", +90802, Frequency, 1251, 1261, "once daily", "", +90803, Evening, 1269, 1276, "evening", "", +90804, Timolol, 1281, 1288, "timolol", "", +90805, Morning, 1296, 1303, "morning", "", +90806, Evening, 1308, 1315, "evening", "", +90807, TimePoint, 1339, 1346, "weeks 2", "", +90808, TimePoint, 1339, 1350, "weeks 2 , 6", "", +90809, TimePoint, 1339, 1359, "weeks 2 , 6 , and 12", "", +90810, Mean, 1421, 1425, "mean", "", +90819, Endpoint, 1421, 1513, "mean change from baseline to week 12 in diurnal IOP ( mean IOPs of 8 am , 12 pm , and 4 pm )", "", +90811, TimePoint, 1438, 1446, "baseline", "", +90812, TimePoint, 1450, 1457, "week 12", "", +90813, Diurnal_IOP, 1461, 1472, "diurnal IOP", "", +90814, Mean, 1475, 1479, "mean", "", +90815, IOP, 1480, 1484, "IOPs", "", +90816, TimePoint, 1488, 1492, "8 am", "", +90817, TimePoint, 1495, 1500, "12 pm", "", +90818, TimePoint, 1507, 1511, "4 pm", "", +90820, ConfIntervalDiff, 1672, 1684, "& lt ; 1 . 5", "upper limit lower than", +90821, mmHg, 1685, 1689, "mmHg", "", +90822, FinalNumPatientsCT, 1783, 1786, "502", "", +90825, IntentionToTreat, 1813, 1832, "intent - to - treat", "", +90823, FinalNumPatientsArm, 1868, 1871, "255", "", +90824, FinalNumPatientsArm, 1900, 1903, "247", "", +90826, Mean, 1959, 1963, "mean", "", +90827, Diurnal_IOP, 1973, 1984, "diurnal IOP", "", +90828, BaseLineValue, 1997, 2003, "25 . 4", "", +90834, mmHg, 2004, 2008, "mmHg", "", +90829, BaseLineValue, 2013, 2019, "25 . 2", "", +90835, mmHg, 2020, 2024, "mmHg", "", +90830, Mean, 2046, 2050, "mean", "", +90831, Diurnal_IOP, 2051, 2062, "diurnal IOP", "", +90832, Reduction, 2079, 2084, "8 . 7", "", +90836, mmHg, 2085, 2089, "mmHg", "", +90833, Reduction, 2094, 2099, "9 . 0", "", +90837, mmHg, 2100, 2104, "mmHg", "", +90840, DiffGroupAbsValue, 2140, 2145, "0 . 3", "", +90838, mmHg, 2146, 2150, "mmHg", "", +90841, ConfIntervalDiff, 2163, 2179, "- 0 . 1 to 0 . 7", "", +90839, mmHg, 2180, 2184, "mmHg", "", +90842, PvalueDiff, 2189, 2197, "= 0 . 15", "", +90843, ObservedResult, 2202, 2239, "Both treatments were well tolerated .", "", +90853, ConclusionComment, 2254, 2451, "The fixed combination of latanoprost and timolol administered once daily in the evening is not inferior to the unfixed combination of latanoprost once daily in the evening and timolol twice daily .", "", +90844, Latanoprost, 2279, 2290, "latanoprost", "", +90845, Timolol, 2295, 2302, "timolol", "", +90846, Frequency, 2316, 2326, "once daily", "", +90847, Evening, 2334, 2341, "evening", "", +90848, Latanoprost, 2388, 2399, "latanoprost", "", +90849, Frequency, 2400, 2410, "once daily", "", +90850, Evening, 2418, 2425, "evening", "", +90851, Timolol, 2430, 2437, "timolol", "", +90852, Frequency, 2438, 2449, "twice daily", "", +90854, ConclusionComment, 2452, 2556, "The fixed combination provides an effective and well - tolerated alternative to multiple instillations .", "", +90855, PMID, 2611, 2619, "16263174", "", diff --git a/data/gl 16263174_tstrakeljahn.n-triples b/data/gl 16263174_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16263174_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16458964_admin.annodb b/data/gl 16458964_admin.annodb new file mode 100644 index 0000000..dce773c --- /dev/null +++ b/data/gl 16458964_admin.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2006", "", " \"2006\"." +2, Title, 67, 222, "Efficacy of latanoprost or fixed - combination latanoprost - timolol in patients switched from a combination of timolol and a nonprostaglandin medication .", "", " \"Efficacy of latanoprost or fixed - combination latanoprost - timolol in patients switched from a combination of timolol and a nonprostaglandin medication .\"." +3, Latanoprost, 79, 90, "latanoprost", "", +6, Lat/TimFC, 94, 135, "fixed - combination latanoprost - timolol", "", +4, Latanoprost, 114, 125, "latanoprost", "", +5, Timolol, 128, 135, "timolol", "", +123, Precondition, 139, 220, "patients switched from a combination of timolol and a nonprostaglandin medication", "", +7, Timolol, 179, 186, "timolol", "", +9, Author, 223, 232, "Magacho L", "", " \"Magacho L\"." +10, Author, 241, 247, "Reis R", "", " \"Reis R\"." +11, Author, 250, 259, "Shetty RK", "", " \"Shetty RK\"." +12, Author, 262, 271, "Santos LC", "", " \"Santos LC\"." +107, Author, 274, 282, "Avila MP", "", " \"Avila MP\"." +13, Brazil, 383, 389, "Brazil", "", " ." +14, ObjectiveDescription, 427, 644, "To compare latanoprost with the fixed - combination latanoprost - timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication .", "", " \"To compare latanoprost with the fixed - combination latanoprost - timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication .\"." +15, Latanoprost, 438, 449, "latanoprost", "", +18, Lat/TimFC, 459, 500, "fixed - combination latanoprost - timolol", "", +16, Latanoprost, 479, 490, "latanoprost", "", +17, Timolol, 493, 500, "timolol", "", +19, Glaucoma, 504, 512, "glaucoma", "", +124, Precondition, 504, 642, "glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication", "", +20, OcularHypertension, 516, 535, "ocular hypertension", "", +21, Glaucoma, 573, 581, "glaucoma", "", +22, Timolol, 595, 602, "timolol", "", +24, Prospective, 654, 665, "Prospective", "", " ." +25, Randomized, 666, 676, "randomized", "", " ." +26, Glaucoma, 704, 712, "Glaucoma", "", " . ." +136, Precondition, 704, 954, "Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0 . 5 % and another nonprostaglandin medication ( pilocarpine 4 % , alpha - agonist , or a topical carbonic anhydrase inhibitor ) underwent a 30 - day washout of their", "", " \"Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0 . 5 % and another nonprostaglandin medication ( pilocarpine 4 % , alpha - agonist , or a topical carbonic anhydrase inhibitor ) underwent a 30 - day washout of their\"." +27, OcularHypertension, 716, 735, "ocular hypertension", "", " ." +28, Timolol, 779, 786, "timolol", "", +29, DoseValue, 787, 792, "0 . 5", "", +130, Percentage, 793, 794, "%", "", +30, Pilocarpine, 837, 848, "pilocarpine", "", +31, DoseValue, 849, 850, "4", "", +133, Percentage, 851, 852, "%", "", +32, Duration, 929, 937, "30 - day", "", " \"30 - day\"." +136, Precondition, 955, 968, "medications .", "", " \"medications .\"." +33, Blind, 971, 986, "masked observer", "", " ." +34, IOP, 1007, 1027, "intraocular pressure", "", +35, IOP, 1030, 1033, "IOP", "", +36, Randomized, 1056, 1066, "randomized", "", +37, Latanoprost, 1077, 1088, "latanoprost", "", +40, Lat/TimFC, 1092, 1133, "fixed - combination latanoprost - timolol", "", +38, Latanoprost, 1112, 1123, "latanoprost", "", +39, Timolol, 1126, 1133, "timolol", "", +41, Eyedrops, 1134, 1142, "eyedrops", "", +42, Frequency, 1150, 1160, "once daily", "", " \"once daily\". \"once daily\"." +106351, Morning, 1164, 1168, "7 am", "", " . ." +43, IOP, 1175, 1178, "IOP", "", +44, TimePoint, 1198, 1205, "30 days", "", +46, Latanoprost, 1425, 1436, "latanoprost", "", " . ." +47, Latanoprost, 1457, 1468, "latanoprost", "", +155, Lat/TimFC, 1457, 1478, "latanoprost - timolol", "", " ." +48, Timolol, 1471, 1478, "timolol", "", +45, NumberPatientsCT, 1492, 1494, "28", "", " \"28\"." +49, IOP, 1537, 1540, "IOP", "", " . ." +50, Timolol, 1636, 1643, "timolol", "", +51, mmHg, 1687, 1709, "millimeters of mercury", "", " ." +52, Reduction, 1712, 1717, "7 . 7", "", " \"7 . 7\"." +163, SdDevChangeValue, 1724, 1729, "2 . 3", "", " \"2 . 3\"." +53, Reduction, 1735, 1740, "5 . 5", "", " \"7 . 7\"." +164, SdDevChangeValue, 1747, 1752, "2 . 3", "", +167, PvalueDiff, 1757, 1771, "& lt ; 0 . 001", "", +72, Latanoprost, 1782, 1793, "latanoprost", "", +54, Reduction, 1802, 1807, "8 . 5", "", " \"8 . 5\"." +165, SdDevChangeValue, 1814, 1819, "3 . 5", "", " \"3 . 5\"." +55, Reduction, 1825, 1830, "6 . 3", "", +166, SdDevChangeValue, 1837, 1842, "2 . 7", "", +169, PvalueDiff, 1845, 1861, "P & lt ; 0 . 001", "", +172, Lat/TimFC, 1872, 1893, "latanoprost - timolol", "", +73, Latanoprost, 1872, 1883, "latanoprost", "", +74, Timolol, 1886, 1893, "timolol", "", +56, RelativeReduction, 1919, 1925, "35 . 8", "", " \"35 . 8\"." +183, SdDevChangeValue, 1932, 1937, "8 . 2", "", +57, RelativeReduction, 1945, 1951, "25 . 6", "", +184, SdDevChangeValue, 1958, 1963, "8 . 9", "", +180, PvalueDiff, 1968, 1984, "P & lt ; 0 . 001", "", +75, Latanoprost, 1995, 2006, "latanoprost", "", +58, RelativeReduction, 2015, 2021, "38 . 6", "", " \"38 . 6\"." +185, SdDevChangeValue, 2028, 2033, "8 . 7", "", +59, RelativeReduction, 2041, 2047, "28 . 6", "", +186, SdDevChangeValue, 2054, 2059, "9 . 0", "", +182, PvalueDiff, 2064, 2080, "P & lt ; 0 . 001", "", +179, Lat/TimFC, 2091, 2112, "latanoprost - timolol", "", +76, Latanoprost, 2091, 2102, "latanoprost", "", +77, Timolol, 2105, 2112, "timolol", "", +78, Latanoprost, 2167, 2178, "latanoprost", "", +81, Lat/TimFC, 2183, 2224, "fixed - combination latanoprost - timolol", "", +79, Latanoprost, 2203, 2214, "latanoprost", "", +80, Timolol, 2217, 2224, "timolol", "", +82, IOP, 2237, 2240, "IOP", "", +83, mmHg, 2253, 2275, "millimeters of mercury", "", +192, PvalueDiff, 2280, 2287, "= 0 . 3", "", " \"= 0 . 3\"." +193, PvalueDiff, 2308, 2315, "= 0 . 2", "", +86, ConclusionComment, 2334, 2520, "Both latanoprost and fixed - combination latanoprost - timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients .", "", " \"Both latanoprost and fixed - combination latanoprost - timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients .\"." +87, Latanoprost, 2339, 2350, "latanoprost", "", +90, Lat/TimFC, 2355, 2396, "fixed - combination latanoprost - timolol", "", +88, Latanoprost, 2375, 2386, "latanoprost", "", +89, Timolol, 2389, 2396, "timolol", "", +91, Timolol, 2427, 2434, "timolol", "", +92, Glaucoma, 2478, 2486, "glaucoma", "", +93, OcularHypertension, 2490, 2509, "ocular hypertension", "", +94, PMID, 2575, 2583, "16458964", "", " \"16458964\"." diff --git a/data/gl 16458964_admin.n-triples b/data/gl 16458964_admin.n-triples new file mode 100644 index 0000000..8d3f9ee --- /dev/null +++ b/data/gl 16458964_admin.n-triples @@ -0,0 +1,103 @@ +# RDF export of group: Publication + . + "Publication " . + "Efficacy of latanoprost or fixed - combination latanoprost - timolol in patients switched from a combination of timolol and a nonprostaglandin medication ." . + "Magacho L" . + "2006" . + "Ophthalmology" . + "16458964" . + . + "Reis R" . + "Shetty RK" . + "Santos LC" . + "Avila MP" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare latanoprost with the fixed - combination latanoprost - timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication ." . + "28" . + "30 - day" . + . + . + . + "Both latanoprost and fixed - combination latanoprost - timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . + "Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0 . 5 % and another nonprostaglandin medication ( pilocarpine 4 % , alpha - agonist , or a topical carbonic anhydrase inhibitor ) underwent a 30 - day washout of their" . + "medications ." . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + "Arm lt" . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "once daily" . + . + . + "Intervention lt" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + . + . + "Medication lt" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP l " . + . + "7 . 7" . + "2 . 3" . + "35 . 8" . + . + "Outcome IOP lt" . + . + "8 . 5" . + "38 . 6" . + "3 . 5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP" . + "= 0 . 3" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16458964_export.csv b/data/gl 16458964_export.csv new file mode 100644 index 0000000..214325f --- /dev/null +++ b/data/gl 16458964_export.csv @@ -0,0 +1,543 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +548, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +548, 1, 2, 2, 14, 15, 14, 15, "." +548, 2, 1, 3, 0, 4, 16, 20, "2006" +548, 2, 2, 4, 5, 8, 21, 24, "Mar" +548, 2, 3, 5, 9, 10, 25, 26, ";" +548, 2, 4, 6, 11, 14, 27, 30, "113" +548, 2, 5, 7, 15, 16, 31, 32, "(" +548, 2, 6, 8, 17, 18, 33, 34, "3" +548, 2, 7, 9, 19, 20, 35, 36, ")" +548, 2, 8, 10, 21, 22, 37, 38, ":" +548, 2, 9, 11, 23, 26, 39, 42, "442" +548, 2, 10, 12, 27, 28, 43, 44, "-" +548, 2, 11, 13, 29, 30, 45, 46, "5" +548, 2, 12, 14, 31, 32, 47, 48, "." +548, 3, 1, 15, 0, 4, 49, 53, "Epub" +548, 3, 2, 16, 5, 9, 54, 58, "2006" +548, 3, 3, 17, 10, 13, 59, 62, "Feb" +548, 3, 4, 18, 14, 15, 63, 64, "3" +548, 3, 5, 19, 16, 17, 65, 66, "." +548, 4, 1, 20, 0, 8, 67, 75, "Efficacy" +548, 4, 2, 21, 9, 11, 76, 78, "of" +548, 4, 3, 22, 12, 23, 79, 90, "latanoprost" +548, 4, 4, 23, 24, 26, 91, 93, "or" +548, 4, 5, 24, 27, 32, 94, 99, "fixed" +548, 4, 6, 25, 33, 34, 100, 101, "-" +548, 4, 7, 26, 35, 46, 102, 113, "combination" +548, 4, 8, 27, 47, 58, 114, 125, "latanoprost" +548, 4, 9, 28, 59, 60, 126, 127, "-" +548, 4, 10, 29, 61, 68, 128, 135, "timolol" +548, 4, 11, 30, 69, 71, 136, 138, "in" +548, 4, 12, 31, 72, 80, 139, 147, "patients" +548, 4, 13, 32, 81, 89, 148, 156, "switched" +548, 4, 14, 33, 90, 94, 157, 161, "from" +548, 4, 15, 34, 95, 96, 162, 163, "a" +548, 4, 16, 35, 97, 108, 164, 175, "combination" +548, 4, 17, 36, 109, 111, 176, 178, "of" +548, 4, 18, 37, 112, 119, 179, 186, "timolol" +548, 4, 19, 38, 120, 123, 187, 190, "and" +548, 4, 20, 39, 124, 125, 191, 192, "a" +548, 4, 21, 40, 126, 142, 193, 209, "nonprostaglandin" +548, 4, 22, 41, 143, 153, 210, 220, "medication" +548, 4, 23, 42, 154, 155, 221, 222, "." +548, 5, 1, 43, 0, 7, 223, 230, "Magacho" +548, 5, 2, 44, 8, 9, 231, 232, "L" +548, 5, 3, 45, 10, 11, 233, 234, "(" +548, 5, 4, 46, 12, 13, 235, 236, "1" +548, 5, 5, 47, 14, 15, 237, 238, ")" +548, 5, 6, 48, 16, 17, 239, 240, "," +548, 5, 7, 49, 18, 22, 241, 245, "Reis" +548, 5, 8, 50, 23, 24, 246, 247, "R" +548, 5, 9, 51, 25, 26, 248, 249, "," +548, 5, 10, 52, 27, 33, 250, 256, "Shetty" +548, 5, 11, 53, 34, 36, 257, 259, "RK" +548, 5, 12, 54, 37, 38, 260, 261, "," +548, 5, 13, 55, 39, 45, 262, 268, "Santos" +548, 5, 14, 56, 46, 48, 269, 271, "LC" +548, 5, 15, 57, 49, 50, 272, 273, "," +548, 5, 16, 58, 51, 56, 274, 279, "Avila" +548, 5, 17, 59, 57, 59, 280, 282, "MP" +548, 5, 18, 60, 60, 61, 283, 284, "." +548, 6, 1, 61, 0, 6, 285, 291, "Author" +548, 6, 2, 62, 7, 18, 292, 303, "information" +548, 6, 3, 63, 19, 20, 304, 305, ":" +548, 6, 4, 64, 21, 22, 306, 307, "(" +548, 6, 5, 65, 23, 24, 308, 309, "1" +548, 6, 6, 66, 25, 26, 310, 311, ")" +548, 6, 7, 67, 27, 40, 312, 325, "Ophthalmology" +548, 6, 8, 68, 41, 51, 326, 336, "Department" +548, 6, 9, 69, 52, 53, 337, 338, "," +548, 6, 10, 70, 54, 61, 339, 346, "Federal" +548, 6, 11, 71, 62, 72, 347, 357, "University" +548, 6, 12, 72, 73, 75, 358, 360, "of" +548, 6, 13, 73, 76, 79, 361, 364, "Goi" +548, 6, 14, 74, 80, 81, 365, 366, "á" +548, 6, 15, 75, 82, 83, 367, 368, "s" +548, 6, 16, 76, 84, 85, 369, 370, "," +548, 6, 17, 77, 86, 89, 371, 374, "Goi" +548, 6, 18, 78, 90, 91, 375, 376, "â" +548, 6, 19, 79, 92, 95, 377, 380, "nia" +548, 6, 20, 80, 96, 97, 381, 382, "," +548, 6, 21, 81, 98, 104, 383, 389, "Brazil" +548, 6, 22, 82, 105, 106, 390, 391, "." +548, 7, 1, 83, 0, 8, 392, 400, "lmagacho" +548, 7, 2, 84, 9, 10, 401, 402, "@" +548, 7, 3, 85, 11, 18, 403, 410, "brturbo" +548, 7, 4, 86, 19, 20, 411, 412, "." +548, 7, 5, 87, 21, 24, 413, 416, "com" +548, 7, 6, 88, 25, 32, 417, 424, "PURPOSE" +548, 7, 7, 89, 33, 34, 425, 426, ":" +548, 7, 8, 90, 35, 37, 427, 429, "To" +548, 7, 9, 91, 38, 45, 430, 437, "compare" +548, 7, 10, 92, 46, 57, 438, 449, "latanoprost" +548, 7, 11, 93, 58, 62, 450, 454, "with" +548, 7, 12, 94, 63, 66, 455, 458, "the" +548, 7, 13, 95, 67, 72, 459, 464, "fixed" +548, 7, 14, 96, 73, 74, 465, 466, "-" +548, 7, 15, 97, 75, 86, 467, 478, "combination" +548, 7, 16, 98, 87, 98, 479, 490, "latanoprost" +548, 7, 17, 99, 99, 100, 491, 492, "-" +548, 7, 18, 100, 101, 108, 493, 500, "timolol" +548, 7, 19, 101, 109, 111, 501, 503, "in" +548, 7, 20, 102, 112, 120, 504, 512, "glaucoma" +548, 7, 21, 103, 121, 123, 513, 515, "or" +548, 7, 22, 104, 124, 130, 516, 522, "ocular" +548, 7, 23, 105, 131, 143, 523, 535, "hypertension" +548, 7, 24, 106, 144, 152, 536, 544, "patients" +548, 7, 25, 107, 153, 161, 545, 553, "switched" +548, 7, 26, 108, 162, 166, 554, 558, "from" +548, 7, 27, 109, 167, 168, 559, 560, "a" +548, 7, 28, 110, 169, 180, 561, 572, "combination" +548, 7, 29, 111, 181, 189, 573, 581, "glaucoma" +548, 7, 30, 112, 190, 197, 582, 589, "therapy" +548, 7, 31, 113, 198, 202, 590, 594, "with" +548, 7, 32, 114, 203, 210, 595, 602, "timolol" +548, 7, 33, 115, 211, 214, 603, 606, "and" +548, 7, 34, 116, 215, 222, 607, 614, "another" +548, 7, 35, 117, 223, 239, 615, 631, "nonprostaglandin" +548, 7, 36, 118, 240, 250, 632, 642, "medication" +548, 7, 37, 119, 251, 252, 643, 644, "." +548, 8, 1, 120, 0, 6, 645, 651, "DESIGN" +548, 8, 2, 121, 7, 8, 652, 653, ":" +548, 8, 3, 122, 9, 20, 654, 665, "Prospective" +548, 8, 4, 123, 21, 31, 666, 676, "randomized" +548, 8, 5, 124, 32, 40, 677, 685, "clinical" +548, 8, 6, 125, 41, 46, 686, 691, "trial" +548, 8, 7, 126, 47, 48, 692, 693, "." +548, 9, 1, 127, 0, 7, 694, 701, "METHODS" +548, 9, 2, 128, 8, 9, 702, 703, ":" +548, 9, 3, 129, 10, 18, 704, 712, "Glaucoma" +548, 9, 4, 130, 19, 21, 713, 715, "or" +548, 9, 5, 131, 22, 28, 716, 722, "ocular" +548, 9, 6, 132, 29, 41, 723, 735, "hypertension" +548, 9, 7, 133, 42, 50, 736, 744, "patients" +548, 9, 8, 134, 51, 60, 745, 754, "receiving" +548, 9, 9, 135, 61, 62, 755, 756, "a" +548, 9, 10, 136, 63, 71, 757, 765, "combined" +548, 9, 11, 137, 72, 81, 766, 775, "treatment" +548, 9, 12, 138, 82, 84, 776, 778, "of" +548, 9, 13, 139, 85, 92, 779, 786, "timolol" +548, 9, 14, 140, 93, 94, 787, 788, "0" +548, 9, 15, 141, 95, 96, 789, 790, "." +548, 9, 16, 142, 97, 98, 791, 792, "5" +548, 9, 17, 143, 99, 100, 793, 794, "%" +548, 9, 18, 144, 101, 104, 795, 798, "and" +548, 9, 19, 145, 105, 112, 799, 806, "another" +548, 9, 20, 146, 113, 129, 807, 823, "nonprostaglandin" +548, 9, 21, 147, 130, 140, 824, 834, "medication" +548, 9, 22, 148, 141, 142, 835, 836, "(" +548, 9, 23, 149, 143, 154, 837, 848, "pilocarpine" +548, 9, 24, 150, 155, 156, 849, 850, "4" +548, 9, 25, 151, 157, 158, 851, 852, "%" +548, 9, 26, 152, 159, 160, 853, 854, "," +548, 9, 27, 153, 161, 166, 855, 860, "alpha" +548, 9, 28, 154, 167, 168, 861, 862, "-" +548, 9, 29, 155, 169, 176, 863, 870, "agonist" +548, 9, 30, 156, 177, 178, 871, 872, "," +548, 9, 31, 157, 179, 181, 873, 875, "or" +548, 9, 32, 158, 182, 183, 876, 877, "a" +548, 9, 33, 159, 184, 191, 878, 885, "topical" +548, 9, 34, 160, 192, 200, 886, 894, "carbonic" +548, 9, 35, 161, 201, 210, 895, 904, "anhydrase" +548, 9, 36, 162, 211, 220, 905, 914, "inhibitor" +548, 9, 37, 163, 221, 222, 915, 916, ")" +548, 9, 38, 164, 223, 232, 917, 926, "underwent" +548, 9, 39, 165, 233, 234, 927, 928, "a" +548, 9, 40, 166, 235, 237, 929, 931, "30" +548, 9, 41, 167, 238, 239, 932, 933, "-" +548, 9, 42, 168, 240, 243, 934, 937, "day" +548, 9, 43, 169, 244, 251, 938, 945, "washout" +548, 9, 44, 170, 252, 254, 946, 948, "of" +548, 9, 45, 171, 255, 260, 949, 954, "their" +548, 9, 46, 172, 261, 272, 955, 966, "medications" +548, 9, 47, 173, 273, 274, 967, 968, "." +548, 10, 1, 174, 0, 1, 969, 970, "A" +548, 10, 2, 175, 2, 8, 971, 977, "masked" +548, 10, 3, 176, 9, 17, 978, 986, "observer" +548, 10, 4, 177, 18, 22, 987, 991, "then" +548, 10, 5, 178, 23, 31, 992, 1000, "measured" +548, 10, 6, 179, 32, 37, 1001, 1006, "their" +548, 10, 7, 180, 38, 49, 1007, 1018, "intraocular" +548, 10, 8, 181, 50, 58, 1019, 1027, "pressure" +548, 10, 9, 182, 59, 60, 1028, 1029, "(" +548, 10, 10, 183, 61, 64, 1030, 1033, "IOP" +548, 10, 11, 184, 65, 66, 1034, 1035, ")" +548, 10, 12, 185, 67, 68, 1036, 1037, "." +548, 11, 1, 186, 0, 3, 1038, 1041, "The" +548, 11, 2, 187, 4, 12, 1042, 1050, "subjects" +548, 11, 3, 188, 13, 17, 1051, 1055, "were" +548, 11, 4, 189, 18, 28, 1056, 1066, "randomized" +548, 11, 5, 190, 29, 31, 1067, 1069, "to" +548, 11, 6, 191, 32, 38, 1070, 1076, "either" +548, 11, 7, 192, 39, 50, 1077, 1088, "latanoprost" +548, 11, 8, 193, 51, 53, 1089, 1091, "or" +548, 11, 9, 194, 54, 59, 1092, 1097, "fixed" +548, 11, 10, 195, 60, 61, 1098, 1099, "-" +548, 11, 11, 196, 62, 73, 1100, 1111, "combination" +548, 11, 12, 197, 74, 85, 1112, 1123, "latanoprost" +548, 11, 13, 198, 86, 87, 1124, 1125, "-" +548, 11, 14, 199, 88, 95, 1126, 1133, "timolol" +548, 11, 15, 200, 96, 104, 1134, 1142, "eyedrops" +548, 11, 16, 201, 105, 107, 1143, 1145, "to" +548, 11, 17, 202, 108, 111, 1146, 1149, "use" +548, 11, 18, 203, 112, 116, 1150, 1154, "once" +548, 11, 19, 204, 117, 122, 1155, 1160, "daily" +548, 11, 20, 205, 123, 125, 1161, 1163, "at" +548, 11, 21, 206, 126, 127, 1164, 1165, "7" +548, 11, 22, 207, 128, 130, 1166, 1168, "am" +548, 11, 23, 208, 131, 132, 1169, 1170, "." +548, 12, 1, 209, 0, 3, 1171, 1174, "The" +548, 12, 2, 210, 4, 7, 1175, 1178, "IOP" +548, 12, 3, 211, 8, 11, 1179, 1182, "was" +548, 12, 4, 212, 12, 20, 1183, 1191, "measured" +548, 12, 5, 213, 21, 26, 1192, 1197, "again" +548, 12, 6, 214, 27, 29, 1198, 1200, "30" +548, 12, 7, 215, 30, 34, 1201, 1205, "days" +548, 12, 8, 216, 35, 40, 1206, 1211, "after" +548, 12, 9, 217, 41, 44, 1212, 1215, "the" +548, 12, 10, 218, 45, 53, 1216, 1224, "patients" +548, 12, 11, 219, 54, 61, 1225, 1232, "started" +548, 12, 12, 220, 62, 67, 1233, 1238, "using" +548, 12, 13, 221, 68, 71, 1239, 1242, "one" +548, 12, 14, 222, 72, 74, 1243, 1245, "of" +548, 12, 15, 223, 75, 78, 1246, 1249, "the" +548, 12, 16, 224, 79, 84, 1250, 1255, "study" +548, 12, 17, 225, 85, 90, 1256, 1261, "drugs" +548, 12, 18, 226, 91, 93, 1262, 1264, "by" +548, 12, 19, 227, 94, 97, 1265, 1268, "the" +548, 12, 20, 228, 98, 102, 1269, 1273, "same" +548, 12, 21, 229, 103, 111, 1274, 1282, "examiner" +548, 12, 22, 230, 112, 114, 1283, 1285, "at" +548, 12, 23, 231, 115, 118, 1286, 1289, "the" +548, 12, 24, 232, 119, 123, 1290, 1294, "same" +548, 12, 25, 233, 124, 128, 1295, 1299, "time" +548, 12, 26, 234, 129, 130, 1300, 1301, "." +548, 13, 1, 235, 0, 4, 1302, 1306, "MAIN" +548, 13, 2, 236, 5, 12, 1307, 1314, "OUTCOME" +548, 13, 3, 237, 13, 20, 1315, 1322, "MEASURE" +548, 13, 4, 238, 21, 22, 1323, 1324, ":" +548, 13, 5, 239, 23, 33, 1325, 1335, "Comparison" +548, 13, 6, 240, 34, 36, 1336, 1338, "of" +548, 13, 7, 241, 37, 40, 1339, 1342, "the" +548, 13, 8, 242, 41, 46, 1343, 1348, "study" +548, 13, 9, 243, 47, 58, 1349, 1360, "medications" +548, 13, 10, 244, 59, 60, 1361, 1362, "'" +548, 13, 11, 245, 61, 72, 1363, 1374, "hypotensive" +548, 13, 12, 246, 73, 79, 1375, 1381, "effect" +548, 13, 13, 247, 80, 81, 1382, 1383, "." +548, 14, 1, 248, 0, 7, 1384, 1391, "RESULTS" +548, 14, 2, 249, 8, 9, 1392, 1393, ":" +548, 14, 3, 250, 10, 15, 1394, 1399, "Fifty" +548, 14, 4, 251, 16, 17, 1400, 1401, "-" +548, 14, 5, 252, 18, 23, 1402, 1407, "three" +548, 14, 6, 253, 24, 28, 1408, 1412, "eyes" +548, 14, 7, 254, 29, 30, 1413, 1414, "(" +548, 14, 8, 255, 31, 33, 1415, 1417, "28" +548, 14, 9, 256, 34, 36, 1418, 1420, "in" +548, 14, 10, 257, 37, 40, 1421, 1424, "the" +548, 14, 11, 258, 41, 52, 1425, 1436, "latanoprost" +548, 14, 12, 259, 53, 58, 1437, 1442, "group" +548, 14, 13, 260, 59, 62, 1443, 1446, "and" +548, 14, 14, 261, 63, 65, 1447, 1449, "25" +548, 14, 15, 262, 66, 68, 1450, 1452, "in" +548, 14, 16, 263, 69, 72, 1453, 1456, "the" +548, 14, 17, 264, 73, 84, 1457, 1468, "latanoprost" +548, 14, 18, 265, 85, 86, 1469, 1470, "-" +548, 14, 19, 266, 87, 94, 1471, 1478, "timolol" +548, 14, 20, 267, 95, 100, 1479, 1484, "group" +548, 14, 21, 268, 101, 102, 1485, 1486, ")" +548, 14, 22, 269, 103, 107, 1487, 1491, "from" +548, 14, 23, 270, 108, 110, 1492, 1494, "28" +548, 14, 24, 271, 111, 119, 1495, 1503, "patients" +548, 14, 25, 272, 120, 124, 1504, 1508, "were" +548, 14, 26, 273, 125, 133, 1509, 1517, "included" +548, 14, 27, 274, 134, 136, 1518, 1520, "in" +548, 14, 28, 275, 137, 140, 1521, 1524, "the" +548, 14, 29, 276, 141, 146, 1525, 1530, "study" +548, 14, 30, 277, 147, 148, 1531, 1532, "." +548, 15, 1, 278, 0, 3, 1533, 1536, "The" +548, 15, 2, 279, 4, 7, 1537, 1540, "IOP" +548, 15, 3, 280, 8, 17, 1541, 1550, "reduction" +548, 15, 4, 281, 18, 21, 1551, 1554, "was" +548, 15, 5, 282, 22, 29, 1555, 1562, "greater" +548, 15, 6, 283, 30, 32, 1563, 1565, "in" +548, 15, 7, 284, 33, 37, 1566, 1570, "both" +548, 15, 8, 285, 38, 43, 1571, 1576, "study" +548, 15, 9, 286, 44, 50, 1577, 1583, "groups" +548, 15, 10, 287, 51, 59, 1584, 1592, "compared" +548, 15, 11, 288, 60, 64, 1593, 1597, "with" +548, 15, 12, 289, 65, 68, 1598, 1601, "the" +548, 15, 13, 290, 69, 77, 1602, 1610, "previous" +548, 15, 14, 291, 78, 89, 1611, 1622, "combination" +548, 15, 15, 292, 90, 97, 1623, 1630, "therapy" +548, 15, 16, 293, 98, 102, 1631, 1635, "with" +548, 15, 17, 294, 103, 110, 1636, 1643, "timolol" +548, 15, 18, 295, 111, 114, 1644, 1647, "and" +548, 15, 19, 296, 115, 122, 1648, 1655, "another" +548, 15, 20, 297, 123, 139, 1656, 1672, "nonprostaglandin" +548, 15, 21, 298, 140, 150, 1673, 1683, "medication" +548, 15, 22, 299, 151, 153, 1684, 1686, "in" +548, 15, 23, 300, 154, 165, 1687, 1698, "millimeters" +548, 15, 24, 301, 166, 168, 1699, 1701, "of" +548, 15, 25, 302, 169, 176, 1702, 1709, "mercury" +548, 15, 26, 303, 177, 178, 1710, 1711, "(" +548, 15, 27, 304, 179, 180, 1712, 1713, "7" +548, 15, 28, 305, 181, 182, 1714, 1715, "." +548, 15, 29, 306, 183, 184, 1716, 1717, "7" +548, 15, 30, 307, 185, 186, 1718, 1719, "+" +548, 15, 31, 308, 187, 188, 1720, 1721, "/" +548, 15, 32, 309, 189, 190, 1722, 1723, "-" +548, 15, 33, 310, 191, 192, 1724, 1725, "2" +548, 15, 34, 311, 193, 194, 1726, 1727, "." +548, 15, 35, 312, 195, 196, 1728, 1729, "3" +548, 15, 36, 313, 197, 199, 1730, 1732, "vs" +548, 15, 37, 314, 200, 201, 1733, 1734, "." +548, 15, 38, 315, 202, 203, 1735, 1736, "5" +548, 15, 39, 316, 204, 205, 1737, 1738, "." +548, 15, 40, 317, 206, 207, 1739, 1740, "5" +548, 15, 41, 318, 208, 209, 1741, 1742, "+" +548, 15, 42, 319, 210, 211, 1743, 1744, "/" +548, 15, 43, 320, 212, 213, 1745, 1746, "-" +548, 15, 44, 321, 214, 215, 1747, 1748, "2" +548, 15, 45, 322, 216, 217, 1749, 1750, "." +548, 15, 46, 323, 218, 219, 1751, 1752, "3" +548, 15, 47, 324, 220, 221, 1753, 1754, "," +548, 15, 48, 325, 222, 223, 1755, 1756, "P" +548, 15, 49, 326, 224, 225, 1757, 1758, "&" +548, 15, 50, 327, 226, 228, 1759, 1761, "lt" +548, 15, 51, 328, 229, 230, 1762, 1763, ";" +548, 15, 52, 329, 231, 232, 1764, 1765, "0" +548, 15, 53, 330, 233, 234, 1766, 1767, "." +548, 15, 54, 331, 235, 238, 1768, 1771, "001" +548, 15, 55, 332, 239, 240, 1772, 1773, "," +548, 15, 56, 333, 241, 244, 1774, 1777, "for" +548, 15, 57, 334, 245, 248, 1778, 1781, "the" +548, 15, 58, 335, 249, 260, 1782, 1793, "latanoprost" +548, 15, 59, 336, 261, 266, 1794, 1799, "group" +548, 15, 60, 337, 267, 268, 1800, 1801, ";" +548, 15, 61, 338, 269, 270, 1802, 1803, "8" +548, 15, 62, 339, 271, 272, 1804, 1805, "." +548, 15, 63, 340, 273, 274, 1806, 1807, "5" +548, 15, 64, 341, 275, 276, 1808, 1809, "+" +548, 15, 65, 342, 277, 278, 1810, 1811, "/" +548, 15, 66, 343, 279, 280, 1812, 1813, "-" +548, 15, 67, 344, 281, 282, 1814, 1815, "3" +548, 15, 68, 345, 283, 284, 1816, 1817, "." +548, 15, 69, 346, 285, 286, 1818, 1819, "5" +548, 15, 70, 347, 287, 289, 1820, 1822, "vs" +548, 15, 71, 348, 290, 291, 1823, 1824, "." +548, 15, 72, 349, 292, 293, 1825, 1826, "6" +548, 15, 73, 350, 294, 295, 1827, 1828, "." +548, 15, 74, 351, 296, 297, 1829, 1830, "3" +548, 15, 75, 352, 298, 299, 1831, 1832, "+" +548, 15, 76, 353, 300, 301, 1833, 1834, "/" +548, 15, 77, 354, 302, 303, 1835, 1836, "-" +548, 15, 78, 355, 304, 305, 1837, 1838, "2" +548, 15, 79, 356, 306, 307, 1839, 1840, "." +548, 15, 80, 357, 308, 309, 1841, 1842, "7" +548, 15, 81, 358, 310, 311, 1843, 1844, "," +548, 15, 82, 359, 312, 313, 1845, 1846, "P" +548, 15, 83, 360, 314, 315, 1847, 1848, "&" +548, 15, 84, 361, 316, 318, 1849, 1851, "lt" +548, 15, 85, 362, 319, 320, 1852, 1853, ";" +548, 15, 86, 363, 321, 322, 1854, 1855, "0" +548, 15, 87, 364, 323, 324, 1856, 1857, "." +548, 15, 88, 365, 325, 328, 1858, 1861, "001" +548, 15, 89, 366, 329, 330, 1862, 1863, "," +548, 15, 90, 367, 331, 334, 1864, 1867, "for" +548, 15, 91, 368, 335, 338, 1868, 1871, "the" +548, 15, 92, 369, 339, 350, 1872, 1883, "latanoprost" +548, 15, 93, 370, 351, 352, 1884, 1885, "-" +548, 15, 94, 371, 353, 360, 1886, 1893, "timolol" +548, 15, 95, 372, 361, 366, 1894, 1899, "group" +548, 15, 96, 373, 367, 368, 1900, 1901, ")" +548, 15, 97, 374, 369, 372, 1902, 1905, "and" +548, 15, 98, 375, 373, 383, 1906, 1916, "percentage" +548, 15, 99, 376, 384, 385, 1917, 1918, "(" +548, 15, 100, 377, 386, 388, 1919, 1921, "35" +548, 15, 101, 378, 389, 390, 1922, 1923, "." +548, 15, 102, 379, 391, 392, 1924, 1925, "8" +548, 15, 103, 380, 393, 394, 1926, 1927, "+" +548, 15, 104, 381, 395, 396, 1928, 1929, "/" +548, 15, 105, 382, 397, 398, 1930, 1931, "-" +548, 15, 106, 383, 399, 400, 1932, 1933, "8" +548, 15, 107, 384, 401, 402, 1934, 1935, "." +548, 15, 108, 385, 403, 404, 1936, 1937, "2" +548, 15, 109, 386, 405, 406, 1938, 1939, "%" +548, 15, 110, 387, 407, 409, 1940, 1942, "vs" +548, 15, 111, 388, 410, 411, 1943, 1944, "." +548, 15, 112, 389, 412, 414, 1945, 1947, "25" +548, 15, 113, 390, 415, 416, 1948, 1949, "." +548, 15, 114, 391, 417, 418, 1950, 1951, "6" +548, 15, 115, 392, 419, 420, 1952, 1953, "+" +548, 15, 116, 393, 421, 422, 1954, 1955, "/" +548, 15, 117, 394, 423, 424, 1956, 1957, "-" +548, 15, 118, 395, 425, 426, 1958, 1959, "8" +548, 15, 119, 396, 427, 428, 1960, 1961, "." +548, 15, 120, 397, 429, 430, 1962, 1963, "9" +548, 15, 121, 398, 431, 432, 1964, 1965, "%" +548, 15, 122, 399, 433, 434, 1966, 1967, "," +548, 15, 123, 400, 435, 436, 1968, 1969, "P" +548, 15, 124, 401, 437, 438, 1970, 1971, "&" +548, 15, 125, 402, 439, 441, 1972, 1974, "lt" +548, 15, 126, 403, 442, 443, 1975, 1976, ";" +548, 15, 127, 404, 444, 445, 1977, 1978, "0" +548, 15, 128, 405, 446, 447, 1979, 1980, "." +548, 15, 129, 406, 448, 451, 1981, 1984, "001" +548, 15, 130, 407, 452, 453, 1985, 1986, "," +548, 15, 131, 408, 454, 457, 1987, 1990, "for" +548, 15, 132, 409, 458, 461, 1991, 1994, "the" +548, 15, 133, 410, 462, 473, 1995, 2006, "latanoprost" +548, 15, 134, 411, 474, 479, 2007, 2012, "group" +548, 15, 135, 412, 480, 481, 2013, 2014, ";" +548, 15, 136, 413, 482, 484, 2015, 2017, "38" +548, 15, 137, 414, 485, 486, 2018, 2019, "." +548, 15, 138, 415, 487, 488, 2020, 2021, "6" +548, 15, 139, 416, 489, 490, 2022, 2023, "+" +548, 15, 140, 417, 491, 492, 2024, 2025, "/" +548, 15, 141, 418, 493, 494, 2026, 2027, "-" +548, 15, 142, 419, 495, 496, 2028, 2029, "8" +548, 15, 143, 420, 497, 498, 2030, 2031, "." +548, 15, 144, 421, 499, 500, 2032, 2033, "7" +548, 15, 145, 422, 501, 502, 2034, 2035, "%" +548, 15, 146, 423, 503, 505, 2036, 2038, "vs" +548, 15, 147, 424, 506, 507, 2039, 2040, "." +548, 15, 148, 425, 508, 510, 2041, 2043, "28" +548, 15, 149, 426, 511, 512, 2044, 2045, "." +548, 15, 150, 427, 513, 514, 2046, 2047, "6" +548, 15, 151, 428, 515, 516, 2048, 2049, "+" +548, 15, 152, 429, 517, 518, 2050, 2051, "/" +548, 15, 153, 430, 519, 520, 2052, 2053, "-" +548, 15, 154, 431, 521, 522, 2054, 2055, "9" +548, 15, 155, 432, 523, 524, 2056, 2057, "." +548, 15, 156, 433, 525, 526, 2058, 2059, "0" +548, 15, 157, 434, 527, 528, 2060, 2061, "%" +548, 15, 158, 435, 529, 530, 2062, 2063, "," +548, 15, 159, 436, 531, 532, 2064, 2065, "P" +548, 15, 160, 437, 533, 534, 2066, 2067, "&" +548, 15, 161, 438, 535, 537, 2068, 2070, "lt" +548, 15, 162, 439, 538, 539, 2071, 2072, ";" +548, 15, 163, 440, 540, 541, 2073, 2074, "0" +548, 15, 164, 441, 542, 543, 2075, 2076, "." +548, 15, 165, 442, 544, 547, 2077, 2080, "001" +548, 15, 166, 443, 548, 549, 2081, 2082, "," +548, 15, 167, 444, 550, 553, 2083, 2086, "for" +548, 15, 168, 445, 554, 557, 2087, 2090, "the" +548, 15, 169, 446, 558, 569, 2091, 2102, "latanoprost" +548, 15, 170, 447, 570, 571, 2103, 2104, "-" +548, 15, 171, 448, 572, 579, 2105, 2112, "timolol" +548, 15, 172, 449, 580, 585, 2113, 2118, "group" +548, 15, 173, 450, 586, 587, 2119, 2120, ")" +548, 15, 174, 451, 588, 589, 2121, 2122, "." +548, 16, 1, 452, 0, 5, 2123, 2128, "There" +548, 16, 2, 453, 6, 9, 2129, 2132, "was" +548, 16, 3, 454, 10, 12, 2133, 2135, "no" +548, 16, 4, 455, 13, 24, 2136, 2147, "statistical" +548, 16, 5, 456, 25, 35, 2148, 2158, "difference" +548, 16, 6, 457, 36, 43, 2159, 2166, "between" +548, 16, 7, 458, 44, 55, 2167, 2178, "latanoprost" +548, 16, 8, 459, 56, 59, 2179, 2182, "and" +548, 16, 9, 460, 60, 65, 2183, 2188, "fixed" +548, 16, 10, 461, 66, 67, 2189, 2190, "-" +548, 16, 11, 462, 68, 79, 2191, 2202, "combination" +548, 16, 12, 463, 80, 91, 2203, 2214, "latanoprost" +548, 16, 13, 464, 92, 93, 2215, 2216, "-" +548, 16, 14, 465, 94, 101, 2217, 2224, "timolol" +548, 16, 15, 466, 102, 104, 2225, 2227, "in" +548, 16, 16, 467, 105, 113, 2228, 2236, "reducing" +548, 16, 17, 468, 114, 117, 2237, 2240, "IOP" +548, 16, 18, 469, 118, 119, 2241, 2242, "," +548, 16, 19, 470, 120, 122, 2243, 2245, "in" +548, 16, 20, 471, 123, 129, 2246, 2252, "either" +548, 16, 21, 472, 130, 141, 2253, 2264, "millimeters" +548, 16, 22, 473, 142, 144, 2265, 2267, "of" +548, 16, 23, 474, 145, 152, 2268, 2275, "mercury" +548, 16, 24, 475, 153, 154, 2276, 2277, "(" +548, 16, 25, 476, 155, 156, 2278, 2279, "P" +548, 16, 26, 477, 157, 158, 2280, 2281, "=" +548, 16, 27, 478, 159, 160, 2282, 2283, "0" +548, 16, 28, 479, 161, 162, 2284, 2285, "." +548, 16, 29, 480, 163, 164, 2286, 2287, "3" +548, 16, 30, 481, 165, 166, 2288, 2289, ")" +548, 16, 31, 482, 167, 169, 2290, 2292, "or" +548, 16, 32, 483, 170, 180, 2293, 2303, "percentage" +548, 16, 33, 484, 181, 182, 2304, 2305, "(" +548, 16, 34, 485, 183, 184, 2306, 2307, "P" +548, 16, 35, 486, 185, 186, 2308, 2309, "=" +548, 16, 36, 487, 187, 188, 2310, 2311, "0" +548, 16, 37, 488, 189, 190, 2312, 2313, "." +548, 16, 38, 489, 191, 192, 2314, 2315, "2" +548, 16, 39, 490, 193, 194, 2316, 2317, ")" +548, 16, 40, 491, 195, 196, 2318, 2319, "." +548, 17, 1, 492, 0, 11, 2320, 2331, "CONCLUSIONS" +548, 17, 2, 493, 12, 13, 2332, 2333, ":" +548, 17, 3, 494, 14, 18, 2334, 2338, "Both" +548, 17, 4, 495, 19, 30, 2339, 2350, "latanoprost" +548, 17, 5, 496, 31, 34, 2351, 2354, "and" +548, 17, 6, 497, 35, 40, 2355, 2360, "fixed" +548, 17, 7, 498, 41, 42, 2361, 2362, "-" +548, 17, 8, 499, 43, 54, 2363, 2374, "combination" +548, 17, 9, 500, 55, 66, 2375, 2386, "latanoprost" +548, 17, 10, 501, 67, 68, 2387, 2388, "-" +548, 17, 11, 502, 69, 76, 2389, 2396, "timolol" +548, 17, 12, 503, 77, 80, 2397, 2400, "may" +548, 17, 13, 504, 81, 83, 2401, 2403, "be" +548, 17, 14, 505, 84, 90, 2404, 2410, "viable" +548, 17, 15, 506, 91, 102, 2411, 2422, "substitutes" +548, 17, 16, 507, 103, 106, 2423, 2426, "for" +548, 17, 17, 508, 107, 114, 2427, 2434, "timolol" +548, 17, 18, 509, 115, 118, 2435, 2438, "and" +548, 17, 19, 510, 119, 126, 2439, 2446, "another" +548, 17, 20, 511, 127, 143, 2447, 2463, "nonprostaglandin" +548, 17, 21, 512, 144, 154, 2464, 2474, "medication" +548, 17, 22, 513, 155, 157, 2475, 2477, "in" +548, 17, 23, 514, 158, 166, 2478, 2486, "glaucoma" +548, 17, 24, 515, 167, 169, 2487, 2489, "or" +548, 17, 25, 516, 170, 176, 2490, 2496, "ocular" +548, 17, 26, 517, 177, 189, 2497, 2509, "hypertension" +548, 17, 27, 518, 190, 198, 2510, 2518, "patients" +548, 17, 28, 519, 199, 200, 2519, 2520, "." +548, 18, 1, 520, 0, 3, 2521, 2524, "DOI" +548, 18, 2, 521, 4, 5, 2525, 2526, ":" +548, 18, 3, 522, 6, 8, 2527, 2529, "10" +548, 18, 4, 523, 9, 10, 2530, 2531, "." +548, 18, 5, 524, 11, 15, 2532, 2536, "1016" +548, 18, 6, 525, 16, 17, 2537, 2538, "/" +548, 18, 7, 526, 18, 19, 2539, 2540, "j" +548, 18, 8, 527, 20, 21, 2541, 2542, "." +548, 18, 9, 528, 22, 28, 2543, 2549, "ophtha" +548, 18, 10, 529, 29, 30, 2550, 2551, "." +548, 18, 11, 530, 31, 35, 2552, 2556, "2005" +548, 18, 12, 531, 36, 37, 2557, 2558, "." +548, 18, 13, 532, 38, 40, 2559, 2561, "11" +548, 18, 14, 533, 41, 42, 2562, 2563, "." +548, 18, 15, 534, 43, 46, 2564, 2567, "011" +548, 18, 16, 535, 47, 51, 2568, 2572, "PMID" +548, 18, 17, 536, 52, 53, 2573, 2574, ":" +548, 18, 18, 537, 54, 62, 2575, 2583, "16458964" +548, 18, 19, 538, 63, 64, 2584, 2585, "[" +548, 18, 20, 539, 65, 72, 2586, 2593, "Indexed" +548, 18, 21, 540, 73, 76, 2594, 2597, "for" +548, 18, 22, 541, 77, 84, 2598, 2605, "MEDLINE" +548, 18, 23, 542, 85, 86, 2606, 2607, "]" diff --git a/data/gl 16458964_jshahinitiran.annodb b/data/gl 16458964_jshahinitiran.annodb new file mode 100644 index 0000000..3d864da --- /dev/null +++ b/data/gl 16458964_jshahinitiran.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +86547, Journal, 0, 13, "Ophthalmology", "", +86548, PublicationYear, 16, 20, "2006", "", +86549, Title, 67, 222, "Efficacy of latanoprost or fixed - combination latanoprost - timolol in patients switched from a combination of timolol and a nonprostaglandin medication .", "", +86550, Latanoprost, 79, 90, "latanoprost", "", +86553, Lat/TimFC, 94, 135, "fixed - combination latanoprost - timolol", "", +86551, Latanoprost, 114, 125, "latanoprost", "", +86552, Timolol, 128, 135, "timolol", "", +86555, Precondition, 148, 220, "switched from a combination of timolol and a nonprostaglandin medication", "", +86554, Timolol, 179, 186, "timolol", "", +86556, Author, 223, 232, "Magacho L", "", +86557, Author, 241, 247, "Reis R", "", +86558, Author, 250, 259, "Shetty RK", "", +86559, Author, 262, 271, "Santos LC", "", +86560, Brazil, 383, 389, "Brazil", "", +86561, ObjectiveDescription, 427, 644, "To compare latanoprost with the fixed - combination latanoprost - timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication .", "", +86562, Latanoprost, 438, 449, "latanoprost", "", +86565, Lat/TimFC, 459, 500, "fixed - combination latanoprost - timolol", "", +86563, Latanoprost, 479, 490, "latanoprost", "", +86564, Timolol, 493, 500, "timolol", "", +86566, Glaucoma, 504, 512, "glaucoma", "", +86567, OcularHypertension, 516, 535, "ocular hypertension", "", +86570, Precondition, 545, 642, "switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication", "", +86568, Glaucoma, 573, 581, "glaucoma", "", +86569, Timolol, 595, 602, "timolol", "", +86571, Prospective, 654, 665, "Prospective", "", +86572, Randomized, 666, 676, "randomized", "", +86573, Glaucoma, 704, 712, "Glaucoma", "", +86574, OcularHypertension, 716, 735, "ocular hypertension", "", +86575, Timolol, 779, 786, "timolol", "", +86718, DoseValue, 787, 792, "0 . 5", "", +86721, Pilocarpine, 837, 848, "pilocarpine", "", +86722, DoseValue, 849, 850, "4", "", +86723, Duration, 929, 937, "30 - day", "", +86724, Blind, 971, 986, "masked observer", "", +86726, IOP, 1007, 1027, "intraocular pressure", "", +86732, IOP, 1030, 1033, "IOP", "", +86733, Randomized, 1056, 1066, "randomized", "", +86734, Latanoprost, 1077, 1088, "latanoprost", "", +86738, Lat/TimFC, 1092, 1133, "fixed - combination latanoprost - timolol", "", +86735, Latanoprost, 1112, 1123, "latanoprost", "", +86737, Timolol, 1126, 1133, "timolol", "", +86739, Eyedrops, 1134, 1142, "eyedrops", "", +86740, Frequency, 1150, 1160, "once daily", "", +86741, IOP, 1175, 1178, "IOP", "", +86886, TimePoint, 1198, 1205, "30 days", "", +86889, Latanoprost, 1425, 1436, "latanoprost", "", +86892, Latanoprost, 1457, 1468, "latanoprost", "", +86893, Timolol, 1471, 1478, "timolol", "", +86888, NumberPatientsCT, 1492, 1494, "28", "", +86896, IOP, 1537, 1540, "IOP", "", +86898, Timolol, 1636, 1643, "timolol", "", +86899, mmHg, 1687, 1709, "millimeters of mercury", "", +86900, Reduction, 1712, 1717, "7 . 7", "", +86909, SdErrorChangeValue, 1724, 1729, "2 . 3", "", +86902, Reduction, 1735, 1740, "5 . 5", "", +86911, SdErrorChangeValue, 1747, 1752, "2 . 3", "", +86919, PValueChangeValue, 1755, 1771, "P & lt ; 0 . 001", "", +86925, Latanoprost, 1782, 1793, "latanoprost", "", +86903, Reduction, 1802, 1807, "8 . 5", "", +86912, SdErrorChangeValue, 1814, 1819, "3 . 5", "", +86904, Reduction, 1825, 1830, "6 . 3", "", +86913, SdErrorChangeValue, 1837, 1842, "2 . 7", "", +86920, PValueChangeValue, 1845, 1861, "P & lt ; 0 . 001", "", +86926, Latanoprost, 1872, 1883, "latanoprost", "", +86927, Timolol, 1886, 1893, "timolol", "", +86905, RelativeReduction, 1919, 1925, "35 . 8", "", +86914, SdErrorChangeValue, 1932, 1937, "8 . 2", "", +86906, RelativeReduction, 1945, 1951, "25 . 6", "", +86915, SdErrorChangeValue, 1958, 1963, "8 . 9", "", +86922, PValueChangeValue, 1968, 1984, "P & lt ; 0 . 001", "", +86928, Latanoprost, 1995, 2006, "latanoprost", "", +86907, RelativeReduction, 2015, 2021, "38 . 6", "", +86917, SdErrorChangeValue, 2028, 2033, "8 . 7", "", +86908, RelativeReduction, 2041, 2047, "28 . 6", "", +86918, SdErrorChangeValue, 2054, 2059, "9 . 0", "", +86924, PValueChangeValue, 2064, 2080, "P & lt ; 0 . 001", "", +86929, Latanoprost, 2091, 2102, "latanoprost", "", +86930, Timolol, 2105, 2112, "timolol", "", +86931, Latanoprost, 2167, 2178, "latanoprost", "", +86934, Lat/TimFC, 2183, 2224, "fixed - combination latanoprost - timolol", "", +86932, Latanoprost, 2203, 2214, "latanoprost", "", +86933, Timolol, 2217, 2224, "timolol", "", +86935, IOP, 2237, 2240, "IOP", "", +86936, mmHg, 2253, 2275, "millimeters of mercury", "", +86937, PValueChangeValue, 2278, 2287, "P = 0 . 3", "", +86938, PValueChangeValue, 2306, 2315, "P = 0 . 2", "", +86939, ConclusionComment, 2334, 2520, "Both latanoprost and fixed - combination latanoprost - timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients .", "", +86940, Latanoprost, 2339, 2350, "latanoprost", "", +86943, Lat/TimFC, 2355, 2396, "fixed - combination latanoprost - timolol", "", +86941, Latanoprost, 2375, 2386, "latanoprost", "", +86942, Timolol, 2389, 2396, "timolol", "", +86944, Timolol, 2427, 2434, "timolol", "", +86945, Glaucoma, 2478, 2486, "glaucoma", "", +86946, OcularHypertension, 2490, 2509, "ocular hypertension", "", +86947, PMID, 2575, 2583, "16458964", "", diff --git a/data/gl 16458964_jshahinitiran.n-triples b/data/gl 16458964_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16458964_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16458964_tstrakeljahn.annodb b/data/gl 16458964_tstrakeljahn.annodb new file mode 100644 index 0000000..5d6209e --- /dev/null +++ b/data/gl 16458964_tstrakeljahn.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90649, Journal, 0, 13, "Ophthalmology", "", +90650, PublicationYear, 16, 20, "2006", "", +90656, Title, 67, 222, "Efficacy of latanoprost or fixed - combination latanoprost - timolol in patients switched from a combination of timolol and a nonprostaglandin medication .", "", +90651, Latanoprost, 79, 90, "latanoprost", "", +90652, Latanoprost, 114, 125, "latanoprost", "", +90663, Lat/TimFC, 114, 135, "latanoprost - timolol", "", +90653, Timolol, 128, 135, "timolol", "", +90677, Precondition, 139, 220, "patients switched from a combination of timolol and a nonprostaglandin medication", "", +90654, Timolol, 179, 186, "timolol", "", +90655, Drug, 193, 220, "nonprostaglandin medication", "nonprostaglandin medication", +90657, Author, 223, 232, "Magacho L", "", +90658, Author, 241, 247, "Reis R", "", +90659, Author, 250, 259, "Shetty RK", "", +90660, Author, 262, 271, "Santos LC", "", +90661, Author, 274, 282, "Avila MP", "", +90662, Brazil, 383, 389, "Brazil", "", +90673, ObjectiveDescription, 427, 644, "To compare latanoprost with the fixed - combination latanoprost - timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication .", "", +90664, Latanoprost, 438, 449, "latanoprost", "", +90665, Latanoprost, 479, 490, "latanoprost", "", +90672, Lat/TimFC, 479, 500, "latanoprost - timolol", "", +90666, Timolol, 493, 500, "timolol", "", +90667, Glaucoma, 504, 512, "glaucoma", "", +90678, Precondition, 504, 642, "glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication", "", +90668, OcularHypertension, 516, 535, "ocular hypertension", "", +90669, Glaucoma, 573, 581, "glaucoma", "", +90670, Timolol, 595, 602, "timolol", "", +90671, Drug, 615, 642, "nonprostaglandin medication", "nonprostaglandin medication", +90674, Prospective, 654, 665, "Prospective", "", +90675, Randomized, 666, 676, "randomized", "", +90676, ClinicalTrial, 677, 691, "clinical trial", "", +90679, Glaucoma, 704, 712, "Glaucoma", "", +90690, Precondition, 704, 954, "Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0 . 5 % and another nonprostaglandin medication ( pilocarpine 4 % , alpha - agonist , or a topical carbonic anhydrase inhibitor ) underwent a 30 - day washout of their", "", +90680, OcularHypertension, 716, 735, "ocular hypertension", "", +90681, Timolol, 779, 786, "timolol", "", +90683, DoseValue, 787, 792, "0 . 5", "", +90684, Percentage, 793, 794, "%", "", +90682, Drug, 807, 834, "nonprostaglandin medication", "nonprostaglandin medication", +90685, Pilocarpine, 837, 848, "pilocarpine", "", +90686, DoseValue, 849, 850, "4", "", +90687, Percentage, 851, 852, "%", "", +90688, Drug, 855, 870, "alpha - agonist", "alpha agonist", +90689, Drug, 878, 914, "topical carbonic anhydrase inhibitor", "topical carbonic anhydrase inhibitor", +90691, Precondition, 955, 968, "medications .", "", +90692, Blind, 971, 986, "masked observer", "", +90693, IOP, 1007, 1027, "intraocular pressure", "", +90694, IOP, 1030, 1033, "IOP", "", +90695, Randomized, 1056, 1066, "randomized", "", +90696, Latanoprost, 1077, 1088, "latanoprost", "", +90697, Latanoprost, 1112, 1123, "latanoprost", "", +90699, Lat/TimFC, 1112, 1133, "latanoprost - timolol", "", +90698, Timolol, 1126, 1133, "timolol", "", +90700, Eyedrops, 1134, 1142, "eyedrops", "", +90701, Frequency, 1150, 1160, "once daily", "", +90702, TimePoint, 1164, 1168, "7 am", "", +90703, IOP, 1175, 1178, "IOP", "", +90704, TimePoint, 1198, 1205, "30 days", "", +90706, Latanoprost, 1425, 1436, "latanoprost", "", +90707, Latanoprost, 1457, 1468, "latanoprost", "", +90709, Lat/TimFC, 1457, 1478, "latanoprost - timolol", "", +90708, Timolol, 1471, 1478, "timolol", "", +90705, FinalNumPatientsCT, 1492, 1494, "28", "", +90712, ObservedResult, 1533, 1709, "The IOP reduction was greater in both study groups compared with the previous combination therapy with timolol and another nonprostaglandin medication in millimeters of mercury", "", +90710, IOP, 1537, 1540, "IOP", "", +90711, Timolol, 1636, 1643, "timolol", "", +90713, Reduction, 1712, 1717, "7 . 7", "", +90717, SdDevChangeValue, 1724, 1729, "2 . 3", "", +90714, Reduction, 1735, 1740, "5 . 5", "", +90718, SdDevChangeValue, 1747, 1752, "2 . 3", "", +90721, PvalueDiff, 1757, 1771, "& lt ; 0 . 001", "", +90722, Latanoprost, 1782, 1793, "latanoprost", "", +90715, Reduction, 1802, 1807, "8 . 5", "", +90719, SdDevChangeValue, 1814, 1819, "3 . 5", "", +90716, Reduction, 1825, 1830, "6 . 3", "", +90720, SdDevChangeValue, 1837, 1842, "2 . 7", "", +90723, PvalueDiff, 1847, 1861, "& lt ; 0 . 001", "", +90724, Latanoprost, 1872, 1883, "latanoprost", "", +90726, Lat/TimFC, 1872, 1893, "latanoprost - timolol", "", +90725, Timolol, 1886, 1893, "timolol", "", +90727, RelativeReduction, 1919, 1925, "35 . 8", "", +90737, SdDevChangeValue, 1932, 1937, "8 . 2", "", +90728, RelativeReduction, 1945, 1951, "25 . 6", "", +90738, SdDevChangeValue, 1958, 1963, "8 . 9", "", +90734, PvalueDiff, 1970, 1984, "& lt ; 0 . 001", "", +90735, Latanoprost, 1995, 2006, "latanoprost", "", +90729, RelativeReduction, 2015, 2021, "38 . 6", "", +90739, SdDevChangeValue, 2028, 2033, "8 . 7", "", +90730, RelativeReduction, 2041, 2047, "28 . 6", "", +90740, SdDevChangeValue, 2054, 2059, "9 . 0", "", +90736, PvalueDiff, 2066, 2080, "& lt ; 0 . 001", "", +90731, Latanoprost, 2091, 2102, "latanoprost", "", +90733, Lat/TimFC, 2091, 2112, "latanoprost - timolol", "", +90732, Timolol, 2105, 2112, "timolol", "", +90748, ObservedResult, 2123, 2319, "There was no statistical difference between latanoprost and fixed - combination latanoprost - timolol in reducing IOP , in either millimeters of mercury ( P = 0 . 3 ) or percentage ( P = 0 . 2 ) .", "", +90741, Latanoprost, 2167, 2178, "latanoprost", "", +90742, Latanoprost, 2203, 2214, "latanoprost", "", +90744, Lat/TimFC, 2203, 2224, "latanoprost - timolol", "", +90743, Timolol, 2217, 2224, "timolol", "", +90745, IOP, 2237, 2240, "IOP", "", +90746, PvalueDiff, 2280, 2287, "= 0 . 3", "", +90747, PvalueDiff, 2308, 2315, "= 0 . 2", "", +90757, ConclusionComment, 2334, 2520, "Both latanoprost and fixed - combination latanoprost - timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients .", "", +90749, Latanoprost, 2339, 2350, "latanoprost", "", +90750, Latanoprost, 2375, 2386, "latanoprost", "", +90752, Lat/TimFC, 2375, 2396, "latanoprost - timolol", "", +90751, Timolol, 2389, 2396, "timolol", "", +90753, Timolol, 2427, 2434, "timolol", "", +90754, Drug, 2447, 2474, "nonprostaglandin medication", "nonprostaglandin medication", +90755, Glaucoma, 2478, 2486, "glaucoma", "", +90756, OcularHypertension, 2490, 2509, "ocular hypertension", "", +90758, PMID, 2575, 2583, "16458964", "", diff --git a/data/gl 16458964_tstrakeljahn.n-triples b/data/gl 16458964_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16458964_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16750448_admin.annodb b/data/gl 16750448_admin.annodb new file mode 100644 index 0000000..4de3421 --- /dev/null +++ b/data/gl 16750448_admin.annodb @@ -0,0 +1,169 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "2006", "", " \"2006\"." +149, Title, 44, 274, "A 6 - week , double - masked , parallel - group study of the efficacy and safety of travoprost 0 . 004 % compared with latanoprost 0 : 005 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"A 6 - week , double - masked , parallel - group study of the efficacy and safety of travoprost 0 . 004 % compared with latanoprost 0 : 005 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .\"." +3, Duration, 46, 54, "6 - week", "", " \"6 - week\"." +4, DoubleBlind, 57, 72, "double - masked", "", +5, Parallel, 75, 91, "parallel - group", "", +6, Travoprost, 128, 138, "travoprost", "", +9, DoseValue, 139, 146, "0 . 004", "", +146, Percentage, 147, 148, "%", "", +7, Latanoprost, 163, 174, "latanoprost", "", +175, Lat/TimFC, 163, 202, "latanoprost 0 : 005 % / timolol 0 . 5 %", "", +10, DoseValue, 175, 182, "0 : 005", "", +147, Percentage, 183, 184, "%", "", +8, Timolol, 187, 194, "timolol", "", +11, DoseValue, 195, 200, "0 . 5", "", +148, Percentage, 201, 202, "%", "", +150, Precondition, 206, 272, "patients with primary open - angle glaucoma or ocular hypertension", "", +12, Primary_OpenAngleGlaucoma, 220, 249, "primary open - angle glaucoma", "", " ." +13, OcularHypertension, 253, 272, "ocular hypertension", "", " ." +14, Author, 275, 284, "Franks WA", "", " \"Franks WA\"." +15, Author, 293, 302, "Renard JP", "", " \"Renard JP\"." +16, Author, 305, 316, "Cunliffe IA", "", " \"Cunliffe IA\"." +154, Author, 319, 334, "Rojanapongpun P", "", " \"Rojanapongpun P\"." +156, Glaucoma, 364, 372, "Glaucoma", "", +18, UK, 424, 438, "United Kingdom", "", " ." +19, ObjectiveDescription, 492, 640, "The objective of this study was to directly compare the intraocular pressure ( IOP ) - lowering efficacy and safety of travoprost 0 . 004 % eyedrops", "", " \"The objective of this study was to directly compare the intraocular pressure ( IOP ) - lowering efficacy and safety of travoprost 0 . 004 % eyedrops\"." +21, IOP, 548, 568, "intraocular pressure", "", " . ." +22, IOP, 571, 574, "IOP", "", +23, Travoprost, 611, 621, "travoprost", "", " ." +25, DoseValue, 622, 629, "0 . 004", "", " \"0 . 004\"." +169, Percentage, 630, 631, "%", "", " ." +24, Eyedrops, 632, 640, "eyedrops", "", " ." +20, ObjectiveDescription, 641, 791, "with the fixed combination of latanoprost 0 . 005 % / timolol 0 . 5 % eyedrops in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"with the fixed combination of latanoprost 0 . 005 % / timolol 0 . 5 % eyedrops in patients with primary open - angle glaucoma or ocular hypertension .\"." +26, Latanoprost, 671, 682, "latanoprost", "", " . ." +174, Lat/TimFC, 671, 710, "latanoprost 0 . 005 % / timolol 0 . 5 %", "", +28, DoseValue, 683, 690, "0 . 005", "", " \"0 . 005\"." +170, Percentage, 691, 692, "%", "", " ." +27, Timolol, 695, 702, "timolol", "", " ." +29, DoseValue, 703, 708, "0 . 5", "", " \"0 . 5\"." +171, Percentage, 709, 710, "%", "", " ." +30, Eyedrops, 711, 719, "eyedrops", "", " . ." +181, Precondition, 723, 789, "patients with primary open - angle glaucoma or ocular hypertension", "", +31, Primary_OpenAngleGlaucoma, 737, 766, "primary open - angle glaucoma", "", +32, OcularHypertension, 770, 789, "ocular hypertension", "", +33, Randomized, 813, 823, "randomized", "", " ." +34, DoubleBlind, 826, 841, "double - masked", "", " ." +35, Multicenter, 844, 855, "multicenter", "", " ." +36, Parallel, 858, 874, "parallel - group", "", " ." +37, CTDesign, 877, 896, "active - controlled", "", " . ." +183, Precondition, 911, 1039, "subjects with open - angle glaucoma ( with or without pseudoexfoliation or pigment dispersion component ) or ocular hypertension", "", " \"subjects with open - angle glaucoma ( with or without pseudoexfoliation or pigment dispersion component ) or ocular hypertension\"." +103368, OpenAngleGlaucoma, 925, 946, "open - angle glaucoma", "", +39, OcularHypertension, 1020, 1039, "ocular hypertension", "", +183, Precondition, 1069, 1164, "if their IOP was inadequately controlled with & gt ; or = 4 weeks of beta - blocker monotherapy", "", " \"if their IOP was inadequately controlled with & gt ; or = 4 weeks of beta - blocker monotherapy\"." +40, OcularHypertension, 1078, 1081, "IOP", "", +189, IOP, 1078, 1081, "IOP", "", +103246, Duration, 1127, 1134, "4 weeks", "", +185, Drug, 1138, 1152, "beta - blocker", "", +42, IOP, 1183, 1186, "IOP", "", +43, mmHg, 1199, 1204, "mm Hg", "", +188, TimePoint, 1208, 1212, "9 AM", "", +44, Randomized, 1242, 1250, "randomly", "", +45, AllocationRatio, 1265, 1270, "1 : 1", "", " . ." +46, Placebo, 1288, 1295, "placebo", "", " ." +47, Travoprost, 1298, 1308, "travoprost", "", +48, Latanoprost, 1312, 1323, "latanoprost", "", +196, Lat/TimFC, 1312, 1333, "latanoprost / timolol", "", +49, Timolol, 1326, 1333, "timolol", "", +50, Placebo, 1336, 1343, "placebo", "", +51, Travoprost, 1362, 1372, "travoprost", "", +52, Travoprost, 1392, 1402, "travoprost", "", +106355, Evening, 1406, 1410, "9 PM", "", " ." +53, Placebo, 1415, 1422, "placebo", "", +106354, Morning, 1426, 1430, "9 AM", "", " ." +54, Latanoprost, 1449, 1460, "latanoprost", "", +103372, Lat/TimFC, 1449, 1470, "latanoprost / timolol", "", +55, Timolol, 1463, 1470, "timolol", "", +56, Latanoprost, 1490, 1501, "latanoprost", "", +103374, Lat/TimFC, 1490, 1511, "latanoprost / timolol", "", +57, Timolol, 1504, 1511, "timolol", "", +106352, Morning, 1515, 1519, "9 AM", "", +58, Placebo, 1524, 1531, "placebo", "", +106353, Evening, 1535, 1539, "9 PM", "", " ." +59, IOP, 1542, 1545, "IOP", "", +103375, MeasurementDevice, 1580, 1610, "Goldmann applanation tonometry", "", " . ." +211, TimePoint, 1614, 1618, "9 AM", "", +212, TimePoint, 1623, 1627, "5 PM", "", +60, TimePoint, 1635, 1643, "week - 2", "", +61, TimePoint, 1648, 1656, "week - 6", "", +62, Randomized, 1761, 1771, "randomized", "", +63, NumberPatientsCT, 1867, 1882, "One hundred ten", "", " \"One hundred ten\"." +64, Randomized, 1897, 1907, "randomized", "", +65, FinalNumPatientsCT, 1918, 1921, "106", "", " \"106\"." +66, Travoprost, 1948, 1958, "travoprost", "", +223, FinalNumPatientsArm, 1965, 1967, "50", "", " \"50\"." +222, Lat/TimFC, 1970, 1991, "latanoprost / timolol", "", +69, Latanoprost, 1970, 1981, "latanoprost", "", +70, Timolol, 1984, 1991, "timolol", "", +224, FinalNumPatientsArm, 1998, 2000, "56", "", " \"56\"." +71, Mean, 2162, 2166, "Mean", "", " . ." +72, IOP, 2167, 2170, "IOP", "", +229, TimePoint, 2286, 2290, "9 Am", "", +73, TimePoint, 2305, 2312, "weeks 2", "", " \"weeks 2\"." +74, TimePoint, 2305, 2318, "weeks 2 and 6", "", +75, Mean, 2321, 2325, "mean", "", +76, IOP, 2334, 2337, "IOP", "", +77, Travoprost, 2353, 2363, "travoprost", "", +237, Lat/TimFC, 2368, 2389, "latanoprost / timolol", "", +78, Latanoprost, 2368, 2379, "latanoprost", "", +79, Timolol, 2382, 2389, "timolol", "", +80, Reduction, 2395, 2400, "7 . 0", "", " \"7 . 0\". \"7 . 0\"." +82, SdErrorChangeValue, 2403, 2408, "0 . 5", "", " \"0 . 5\". \"0 . 5\"." +81, Reduction, 2415, 2420, "6 . 4", "", " \"6 . 4\". \"6 . 4\"." +83, SdErrorChangeValue, 2423, 2428, "0 . 5", "", " \"0 . 5\". \"0 . 5\"." +84, mmHg, 2431, 2436, "mm Hg", "", +240, PvalueDiff, 2454, 2460, "P = NS", "", " \"P = NS\". \"P = NS\"." +103376, EndPointDescription, 2465, 2479, "Adverse events", "", " . ." +103378, ObservedResult, 2465, 2609, "Adverse events related to therapy were mild in nature , and there were no statistically significant differences between the 2 treatment groups .", "", " \"Adverse events related to therapy were mild in nature , and there were no statistically significant differences between the 2 treatment groups .\"." +86, Travoprost, 2664, 2674, "travoprost", "", +87, ConjunctivalHyperemia, 2686, 2702, "ocular hyperemia", "", " ." +98, PercentageAffected, 2705, 2710, "9 . 3", "", " \"9 . 3\"." +103379, EndPointDescription, 2717, 2739, "foreign body sensation", "", " . ." +99, PercentageAffected, 2742, 2747, "5 . 6", "", " \"5 . 6\"." +103380, EndPointDescription, 2754, 2769, "abnormal vision", "", " . ." +100, PercentageAffected, 2772, 2777, "1 . 9", "", " \"1 . 9\"." +103381, EndPointDescription, 2784, 2801, "allergic reaction", "", " . ." +101, PercentageAffected, 2804, 2809, "1 . 9", "", " \"1 . 9\"." +103382, EndPointDescription, 2816, 2830, "conjunctivitis", "", " . ." +102, PercentageAffected, 2833, 2838, "1 . 9", "", " \"1 . 9\"." +103383, EndPointDescription, 2845, 2859, "dacryocystitis", "", " . ." +103, PercentageAffected, 2862, 2867, "1 . 9", "", " \"1 . 9\"." +103384, EndPointDescription, 2874, 2887, "eye discharge", "", " . ." +104, PercentageAffected, 2890, 2895, "1 . 9", "", " \"1 . 9\"." +103385, EndPointDescription, 2902, 2914, "eye pruritus", "", " . ." +105, PercentageAffected, 2917, 2922, "1 . 9", "", " \"1 . 9\"." +103386, EndPointDescription, 2929, 2938, "lid edema", "", " . ." +106, PercentageAffected, 2941, 2946, "1 . 9", "", " \"1 . 9\"." +103387, EndPointDescription, 2953, 2965, "lid erythema", "", " . ." +107, PercentageAffected, 2968, 2973, "1 . 9", "", " \"1 . 9\"." +103388, EndPointDescription, 2984, 2991, "tearing", "", " . ." +108, PercentageAffected, 2994, 2999, "1 . 9", "", " \"1 . 9\"." +270, Lat/TimFC, 3013, 3034, "latanoprost / timolol", "", +115, Latanoprost, 3013, 3024, "latanoprost", "", +116, Timolol, 3027, 3034, "timolol", "", +103389, EndPointDescription, 3095, 3103, "cataract", "", " . ." +109, PercentageAffected, 3106, 3111, "1 . 8", "", " \"1 . 8\"." +103390, EndPointDescription, 3118, 3126, "dry eyes", "", " . ." +110, PercentageAffected, 3129, 3134, "1 . 8", "", " \"1 . 8\"." +103391, EndPointDescription, 3141, 3153, "eye pruritus", "", +111, PercentageAffected, 3156, 3161, "1 . 8", "", " \"1 . 8\"." +103392, EndPointDescription, 3168, 3190, "foreign body sensation", "", +112, PercentageAffected, 3193, 3198, "1 . 8", "", " \"1 . 8\"." +121, ConjunctivalHyperemia, 3209, 3225, "ocular hyperemia", "", +113, PercentageAffected, 3228, 3233, "1 . 8", "", " \"1 . 8\"." +114, Mean, 3254, 3258, "Mean", "", +122, ConclusionComment, 3254, 3439, "Mean IOP changes from baseline for travoprost 0 . 004 % and latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination were not significantly different at follow - up in these patients .", "", " \"Mean IOP changes from baseline for travoprost 0 . 004 % and latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination were not significantly different at follow - up in these patients .\"." +123, IOP, 3259, 3262, "IOP", "", +124, Travoprost, 3289, 3299, "travoprost", "", +127, DoseValue, 3300, 3307, "0 . 004", "", +289, Percentage, 3308, 3309, "%", "", +125, Latanoprost, 3314, 3325, "latanoprost", "", +130, Lat/TimFC, 3314, 3371, "latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination", "", +128, DoseValue, 3326, 3333, "0 . 005", "", +290, Percentage, 3334, 3335, "%", "", +126, Timolol, 3338, 3345, "timolol", "", +129, DoseValue, 3346, 3351, "0 . 5", "", +291, Percentage, 3352, 3353, "%", "", +131, ConclusionComment, 3440, 3478, "Both medications were well tolerated .", "", " \"Both medications were well tolerated .\"." +132, PMID, 3536, 3544, "16750448", "", " \"16750448\"." diff --git a/data/gl 16750448_admin.n-triples b/data/gl 16750448_admin.n-triples new file mode 100644 index 0000000..f6383f7 --- /dev/null +++ b/data/gl 16750448_admin.n-triples @@ -0,0 +1,333 @@ +# RDF export of group: Publication + . + "Publication " . + "A 6 - week , double - masked , parallel - group study of the efficacy and safety of travoprost 0 . 004 % compared with latanoprost 0 : 005 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension ." . + "Franks WA" . + "2006" . + "Clin Ther ." . + "16750448" . + . + "Renard JP" . + "Cunliffe IA" . + "Rojanapongpun P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The objective of this study was to directly compare the intraocular pressure ( IOP ) - lowering efficacy and safety of travoprost 0 . 004 % eyedrops" . + "One hundred ten" . + "6 - week" . + . + . + . + . + "Mean IOP changes from baseline for travoprost 0 . 004 % and latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination were not significantly different at follow - up in these patients ." . + . + . + . + . + . + "106" . + "with the fixed combination of latanoprost 0 . 005 % / timolol 0 . 5 % eyedrops in patients with primary open - angle glaucoma or ocular hypertension ." . + . + . + . + . + . + "Both medications were well tolerated ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "subjects with open - angle glaucoma ( with or without pseudoexfoliation or pigment dispersion component ) or ocular hypertension" . + "if their IOP was inadequately controlled with & gt ; or = 4 weeks of beta - blocker monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint oh" . + . + . + . + . + . + "Endpoint fbs" . + . + . + . + . + . + . + "Endpoint av" . + . + . + . + . + . + . + "Endpoint ar" . + . + . + . + . + . + . + "Endpoint c" . + . + . + . + . + . + . + "Endpoint d" . + . + . + . + . + . + . + "Endpoint ed" . + . + . + . + . + . + . + "Endpoint ep" . + . + . + . + . + . + . + "Endpoint le" . + . + . + . + . + . + . + "Endpoint l ery" . + . + . + . + . + . + . + "Endpoint t" . + . + . + . + . + . + . + "Endpoint cat" . + . + . + . + . + . + . + "Endpoint de" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm t" . + "50" . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + . + "Arm lt" . + "56" . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention t" . + . + . + . + . + "Intervention lt" . + . + . + . + . + "Intervention tp" . + . + . + . + "Intervention ltp" . + . + . +# RDF export of group: Medication + . + "Medication t" . + . + "0 . 004" . + . + . + . + "Medication l" . + . + . + "0 . 005" . + . + . + . + "Medication timolol" . + . + "0 . 5" . + . + . + . + "Medication placebo" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP w2 t" . + . + "7 . 0" . + "0 . 5" . + "weeks 2" . + . + "Outcome IOP w6 t" . + . + "7 . 0" . + "0 . 5" . + . + "Outcome IOP w2 lt" . + . + "6 . 4" . + "0 . 5" . + . + "Outcome IOP w6 lt" . + . + "6 . 4" . + "0 . 5" . + . + "Outcome aes both drugs" . + . + "Adverse events related to therapy were mild in nature , and there were no statistically significant differences between the 2 treatment groups ." . + . + "Outcome oh t" . + . + "9 . 3" . + . + "Outcome fbs t" . + . + "5 . 6" . + . + "Outcome av t" . + . + "1 . 9" . + . + "Outcome ar t" . + . + "1 . 9" . + . + "Outcome c t " . + . + "1 . 9" . + . + "Outcome d t " . + . + "1 . 9" . + . + "Outcome ed t" . + . + "1 . 9" . + . + "Outcome ep t" . + . + "1 . 9" . + . + "Outcome le t" . + . + "1 . 9" . + . + "Outcome l ery t" . + . + "1 . 9" . + . + "Outcome t t" . + . + "1 . 9" . + . + "Outcome cat lt" . + . + "1 . 8" . + . + "Outcome de lt" . + . + "1 . 8" . + . + "Outcome ep lt" . + . + "1 . 8" . + . + "Outcome fbs lt" . + . + "1 . 8" . + . + "Outcome oh lt" . + . + "1 . 8" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP w2" . + "P = NS" . + . + . + . + "DiffBetweenGroups IOP w6" . + "P = NS" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16750448_export.csv b/data/gl 16750448_export.csv new file mode 100644 index 0000000..6a1ca37 --- /dev/null +++ b/data/gl 16750448_export.csv @@ -0,0 +1,754 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +547, 1, 1, 1, 0, 4, 0, 4, "Clin" +547, 1, 2, 2, 5, 9, 5, 9, "Ther" +547, 1, 3, 3, 10, 11, 10, 11, "." +547, 2, 1, 4, 0, 4, 12, 16, "2006" +547, 2, 2, 5, 5, 8, 17, 20, "Mar" +547, 2, 3, 6, 9, 10, 21, 22, ";" +547, 2, 4, 7, 11, 13, 23, 25, "28" +547, 2, 5, 8, 14, 15, 26, 27, "(" +547, 2, 6, 9, 16, 17, 28, 29, "3" +547, 2, 7, 10, 18, 19, 30, 31, ")" +547, 2, 8, 11, 20, 21, 32, 33, ":" +547, 2, 9, 12, 22, 25, 34, 37, "332" +547, 2, 10, 13, 26, 27, 38, 39, "-" +547, 2, 11, 14, 28, 29, 40, 41, "9" +547, 2, 12, 15, 30, 31, 42, 43, "." +547, 3, 1, 16, 0, 1, 44, 45, "A" +547, 3, 2, 17, 2, 3, 46, 47, "6" +547, 3, 3, 18, 4, 5, 48, 49, "-" +547, 3, 4, 19, 6, 10, 50, 54, "week" +547, 3, 5, 20, 11, 12, 55, 56, "," +547, 3, 6, 21, 13, 19, 57, 63, "double" +547, 3, 7, 22, 20, 21, 64, 65, "-" +547, 3, 8, 23, 22, 28, 66, 72, "masked" +547, 3, 9, 24, 29, 30, 73, 74, "," +547, 3, 10, 25, 31, 39, 75, 83, "parallel" +547, 3, 11, 26, 40, 41, 84, 85, "-" +547, 3, 12, 27, 42, 47, 86, 91, "group" +547, 3, 13, 28, 48, 53, 92, 97, "study" +547, 3, 14, 29, 54, 56, 98, 100, "of" +547, 3, 15, 30, 57, 60, 101, 104, "the" +547, 3, 16, 31, 61, 69, 105, 113, "efficacy" +547, 3, 17, 32, 70, 73, 114, 117, "and" +547, 3, 18, 33, 74, 80, 118, 124, "safety" +547, 3, 19, 34, 81, 83, 125, 127, "of" +547, 3, 20, 35, 84, 94, 128, 138, "travoprost" +547, 3, 21, 36, 95, 96, 139, 140, "0" +547, 3, 22, 37, 97, 98, 141, 142, "." +547, 3, 23, 38, 99, 102, 143, 146, "004" +547, 3, 24, 39, 103, 104, 147, 148, "%" +547, 3, 25, 40, 105, 113, 149, 157, "compared" +547, 3, 26, 41, 114, 118, 158, 162, "with" +547, 3, 27, 42, 119, 130, 163, 174, "latanoprost" +547, 3, 28, 43, 131, 132, 175, 176, "0" +547, 3, 29, 44, 133, 134, 177, 178, ":" +547, 3, 30, 45, 135, 138, 179, 182, "005" +547, 3, 31, 46, 139, 140, 183, 184, "%" +547, 3, 32, 47, 141, 142, 185, 186, "/" +547, 3, 33, 48, 143, 150, 187, 194, "timolol" +547, 3, 34, 49, 151, 152, 195, 196, "0" +547, 3, 35, 50, 153, 154, 197, 198, "." +547, 3, 36, 51, 155, 156, 199, 200, "5" +547, 3, 37, 52, 157, 158, 201, 202, "%" +547, 3, 38, 53, 159, 161, 203, 205, "in" +547, 3, 39, 54, 162, 170, 206, 214, "patients" +547, 3, 40, 55, 171, 175, 215, 219, "with" +547, 3, 41, 56, 176, 183, 220, 227, "primary" +547, 3, 42, 57, 184, 188, 228, 232, "open" +547, 3, 43, 58, 189, 190, 233, 234, "-" +547, 3, 44, 59, 191, 196, 235, 240, "angle" +547, 3, 45, 60, 197, 205, 241, 249, "glaucoma" +547, 3, 46, 61, 206, 208, 250, 252, "or" +547, 3, 47, 62, 209, 215, 253, 259, "ocular" +547, 3, 48, 63, 216, 228, 260, 272, "hypertension" +547, 3, 49, 64, 229, 230, 273, 274, "." +547, 4, 1, 65, 0, 6, 275, 281, "Franks" +547, 4, 2, 66, 7, 9, 282, 284, "WA" +547, 4, 3, 67, 10, 11, 285, 286, "(" +547, 4, 4, 68, 12, 13, 287, 288, "1" +547, 4, 5, 69, 14, 15, 289, 290, ")" +547, 4, 6, 70, 16, 17, 291, 292, "," +547, 4, 7, 71, 18, 24, 293, 299, "Renard" +547, 4, 8, 72, 25, 27, 300, 302, "JP" +547, 4, 9, 73, 28, 29, 303, 304, "," +547, 4, 10, 74, 30, 38, 305, 313, "Cunliffe" +547, 4, 11, 75, 39, 41, 314, 316, "IA" +547, 4, 12, 76, 42, 43, 317, 318, "," +547, 4, 13, 77, 44, 57, 319, 332, "Rojanapongpun" +547, 4, 14, 78, 58, 59, 333, 334, "P" +547, 4, 15, 79, 60, 61, 335, 336, "." +547, 4, 16, 80, 62, 68, 337, 343, "Author" +547, 4, 17, 81, 69, 80, 344, 355, "information" +547, 4, 18, 82, 81, 82, 356, 357, ":" +547, 4, 19, 83, 83, 84, 358, 359, "(" +547, 4, 20, 84, 85, 86, 360, 361, "1" +547, 4, 21, 85, 87, 88, 362, 363, ")" +547, 4, 22, 86, 89, 97, 364, 372, "Glaucoma" +547, 4, 23, 87, 98, 106, 373, 381, "Research" +547, 4, 24, 88, 107, 111, 382, 386, "Unit" +547, 4, 25, 89, 112, 113, 387, 388, "," +547, 4, 26, 90, 114, 124, 389, 399, "Moorfields" +547, 4, 27, 91, 125, 128, 400, 403, "Eye" +547, 4, 28, 92, 129, 137, 404, 412, "Hospital" +547, 4, 29, 93, 138, 139, 413, 414, "," +547, 4, 30, 94, 140, 146, 415, 421, "London" +547, 4, 31, 95, 147, 148, 422, 423, "," +547, 4, 32, 96, 149, 155, 424, 430, "United" +547, 4, 33, 97, 156, 163, 431, 438, "Kingdom" +547, 4, 34, 98, 164, 165, 439, 440, "." +547, 5, 1, 99, 0, 5, 441, 446, "wendy" +547, 5, 2, 100, 6, 7, 447, 448, "." +547, 5, 3, 101, 8, 14, 449, 455, "franks" +547, 5, 4, 102, 15, 16, 456, 457, "@" +547, 5, 5, 103, 17, 27, 458, 468, "moorfields" +547, 5, 6, 104, 28, 29, 469, 470, "." +547, 5, 7, 105, 30, 33, 471, 474, "nhs" +547, 5, 8, 106, 34, 35, 475, 476, "." +547, 5, 9, 107, 36, 38, 477, 479, "uk" +547, 5, 10, 108, 39, 48, 480, 489, "OBJECTIVE" +547, 5, 11, 109, 49, 50, 490, 491, ":" +547, 5, 12, 110, 51, 54, 492, 495, "The" +547, 5, 13, 111, 55, 64, 496, 505, "objective" +547, 5, 14, 112, 65, 67, 506, 508, "of" +547, 5, 15, 113, 68, 72, 509, 513, "this" +547, 5, 16, 114, 73, 78, 514, 519, "study" +547, 5, 17, 115, 79, 82, 520, 523, "was" +547, 5, 18, 116, 83, 85, 524, 526, "to" +547, 5, 19, 117, 86, 94, 527, 535, "directly" +547, 5, 20, 118, 95, 102, 536, 543, "compare" +547, 5, 21, 119, 103, 106, 544, 547, "the" +547, 5, 22, 120, 107, 118, 548, 559, "intraocular" +547, 5, 23, 121, 119, 127, 560, 568, "pressure" +547, 5, 24, 122, 128, 129, 569, 570, "(" +547, 5, 25, 123, 130, 133, 571, 574, "IOP" +547, 5, 26, 124, 134, 135, 575, 576, ")" +547, 5, 27, 125, 136, 137, 577, 578, "-" +547, 5, 28, 126, 138, 146, 579, 587, "lowering" +547, 5, 29, 127, 147, 155, 588, 596, "efficacy" +547, 5, 30, 128, 156, 159, 597, 600, "and" +547, 5, 31, 129, 160, 166, 601, 607, "safety" +547, 5, 32, 130, 167, 169, 608, 610, "of" +547, 5, 33, 131, 170, 180, 611, 621, "travoprost" +547, 5, 34, 132, 181, 182, 622, 623, "0" +547, 5, 35, 133, 183, 184, 624, 625, "." +547, 5, 36, 134, 185, 188, 626, 629, "004" +547, 5, 37, 135, 189, 190, 630, 631, "%" +547, 5, 38, 136, 191, 199, 632, 640, "eyedrops" +547, 5, 39, 137, 200, 204, 641, 645, "with" +547, 5, 40, 138, 205, 208, 646, 649, "the" +547, 5, 41, 139, 209, 214, 650, 655, "fixed" +547, 5, 42, 140, 215, 226, 656, 667, "combination" +547, 5, 43, 141, 227, 229, 668, 670, "of" +547, 5, 44, 142, 230, 241, 671, 682, "latanoprost" +547, 5, 45, 143, 242, 243, 683, 684, "0" +547, 5, 46, 144, 244, 245, 685, 686, "." +547, 5, 47, 145, 246, 249, 687, 690, "005" +547, 5, 48, 146, 250, 251, 691, 692, "%" +547, 5, 49, 147, 252, 253, 693, 694, "/" +547, 5, 50, 148, 254, 261, 695, 702, "timolol" +547, 5, 51, 149, 262, 263, 703, 704, "0" +547, 5, 52, 150, 264, 265, 705, 706, "." +547, 5, 53, 151, 266, 267, 707, 708, "5" +547, 5, 54, 152, 268, 269, 709, 710, "%" +547, 5, 55, 153, 270, 278, 711, 719, "eyedrops" +547, 5, 56, 154, 279, 281, 720, 722, "in" +547, 5, 57, 155, 282, 290, 723, 731, "patients" +547, 5, 58, 156, 291, 295, 732, 736, "with" +547, 5, 59, 157, 296, 303, 737, 744, "primary" +547, 5, 60, 158, 304, 308, 745, 749, "open" +547, 5, 61, 159, 309, 310, 750, 751, "-" +547, 5, 62, 160, 311, 316, 752, 757, "angle" +547, 5, 63, 161, 317, 325, 758, 766, "glaucoma" +547, 5, 64, 162, 326, 328, 767, 769, "or" +547, 5, 65, 163, 329, 335, 770, 776, "ocular" +547, 5, 66, 164, 336, 348, 777, 789, "hypertension" +547, 5, 67, 165, 349, 350, 790, 791, "." +547, 6, 1, 166, 0, 7, 792, 799, "METHODS" +547, 6, 2, 167, 8, 9, 800, 801, ":" +547, 6, 3, 168, 10, 14, 802, 806, "This" +547, 6, 4, 169, 15, 18, 807, 810, "was" +547, 6, 5, 170, 19, 20, 811, 812, "a" +547, 6, 6, 171, 21, 31, 813, 823, "randomized" +547, 6, 7, 172, 32, 33, 824, 825, "," +547, 6, 8, 173, 34, 40, 826, 832, "double" +547, 6, 9, 174, 41, 42, 833, 834, "-" +547, 6, 10, 175, 43, 49, 835, 841, "masked" +547, 6, 11, 176, 50, 51, 842, 843, "," +547, 6, 12, 177, 52, 63, 844, 855, "multicenter" +547, 6, 13, 178, 64, 65, 856, 857, "," +547, 6, 14, 179, 66, 74, 858, 866, "parallel" +547, 6, 15, 180, 75, 76, 867, 868, "-" +547, 6, 16, 181, 77, 82, 869, 874, "group" +547, 6, 17, 182, 83, 84, 875, 876, "," +547, 6, 18, 183, 85, 91, 877, 883, "active" +547, 6, 19, 184, 92, 93, 884, 885, "-" +547, 6, 20, 185, 94, 104, 886, 896, "controlled" +547, 6, 21, 186, 105, 110, 897, 902, "study" +547, 6, 22, 187, 111, 112, 903, 904, "." +547, 7, 1, 188, 0, 5, 905, 910, "Adult" +547, 7, 2, 189, 6, 14, 911, 919, "subjects" +547, 7, 3, 190, 15, 19, 920, 924, "with" +547, 7, 4, 191, 20, 24, 925, 929, "open" +547, 7, 5, 192, 25, 26, 930, 931, "-" +547, 7, 6, 193, 27, 32, 932, 937, "angle" +547, 7, 7, 194, 33, 41, 938, 946, "glaucoma" +547, 7, 8, 195, 42, 43, 947, 948, "(" +547, 7, 9, 196, 44, 48, 949, 953, "with" +547, 7, 10, 197, 49, 51, 954, 956, "or" +547, 7, 11, 198, 52, 59, 957, 964, "without" +547, 7, 12, 199, 60, 77, 965, 982, "pseudoexfoliation" +547, 7, 13, 200, 78, 80, 983, 985, "or" +547, 7, 14, 201, 81, 88, 986, 993, "pigment" +547, 7, 15, 202, 89, 99, 994, 1004, "dispersion" +547, 7, 16, 203, 100, 109, 1005, 1014, "component" +547, 7, 17, 204, 110, 111, 1015, 1016, ")" +547, 7, 18, 205, 112, 114, 1017, 1019, "or" +547, 7, 19, 206, 115, 121, 1020, 1026, "ocular" +547, 7, 20, 207, 122, 134, 1027, 1039, "hypertension" +547, 7, 21, 208, 135, 139, 1040, 1044, "were" +547, 7, 22, 209, 140, 148, 1045, 1053, "eligible" +547, 7, 23, 210, 149, 151, 1054, 1056, "to" +547, 7, 24, 211, 152, 163, 1057, 1068, "participate" +547, 7, 25, 212, 164, 166, 1069, 1071, "if" +547, 7, 26, 213, 167, 172, 1072, 1077, "their" +547, 7, 27, 214, 173, 176, 1078, 1081, "IOP" +547, 7, 28, 215, 177, 180, 1082, 1085, "was" +547, 7, 29, 216, 181, 193, 1086, 1098, "inadequately" +547, 7, 30, 217, 194, 204, 1099, 1109, "controlled" +547, 7, 31, 218, 205, 209, 1110, 1114, "with" +547, 7, 32, 219, 210, 211, 1115, 1116, "&" +547, 7, 33, 220, 212, 214, 1117, 1119, "gt" +547, 7, 34, 221, 215, 216, 1120, 1121, ";" +547, 7, 35, 222, 217, 219, 1122, 1124, "or" +547, 7, 36, 223, 220, 221, 1125, 1126, "=" +547, 7, 37, 224, 222, 223, 1127, 1128, "4" +547, 7, 38, 225, 224, 229, 1129, 1134, "weeks" +547, 7, 39, 226, 230, 232, 1135, 1137, "of" +547, 7, 40, 227, 233, 237, 1138, 1142, "beta" +547, 7, 41, 228, 238, 239, 1143, 1144, "-" +547, 7, 42, 229, 240, 247, 1145, 1152, "blocker" +547, 7, 43, 230, 248, 259, 1153, 1164, "monotherapy" +547, 7, 44, 231, 260, 261, 1165, 1166, "," +547, 7, 45, 232, 262, 264, 1167, 1169, "as" +547, 7, 46, 233, 265, 274, 1170, 1179, "indicated" +547, 7, 47, 234, 275, 277, 1180, 1182, "by" +547, 7, 48, 235, 278, 281, 1183, 1186, "IOP" +547, 7, 49, 236, 282, 284, 1187, 1189, "of" +547, 7, 50, 237, 285, 287, 1190, 1192, "22" +547, 7, 51, 238, 288, 290, 1193, 1195, "to" +547, 7, 52, 239, 291, 293, 1196, 1198, "36" +547, 7, 53, 240, 294, 296, 1199, 1201, "mm" +547, 7, 54, 241, 297, 299, 1202, 1204, "Hg" +547, 7, 55, 242, 300, 302, 1205, 1207, "at" +547, 7, 56, 243, 303, 304, 1208, 1209, "9" +547, 7, 57, 244, 305, 307, 1210, 1212, "AM" +547, 7, 58, 245, 308, 310, 1213, 1215, "at" +547, 7, 59, 246, 311, 320, 1216, 1225, "screening" +547, 7, 60, 247, 321, 322, 1226, 1227, "." +547, 8, 1, 248, 0, 8, 1228, 1236, "Patients" +547, 8, 2, 249, 9, 13, 1237, 1241, "were" +547, 8, 3, 250, 14, 22, 1242, 1250, "randomly" +547, 8, 4, 251, 23, 31, 1251, 1259, "assigned" +547, 8, 5, 252, 32, 34, 1260, 1262, "in" +547, 8, 6, 253, 35, 36, 1263, 1264, "a" +547, 8, 7, 254, 37, 38, 1265, 1266, "1" +547, 8, 8, 255, 39, 40, 1267, 1268, ":" +547, 8, 9, 256, 41, 42, 1269, 1270, "1" +547, 8, 10, 257, 43, 48, 1271, 1276, "ratio" +547, 8, 11, 258, 49, 51, 1277, 1279, "to" +547, 8, 12, 259, 52, 59, 1280, 1287, "receive" +547, 8, 13, 260, 60, 67, 1288, 1295, "placebo" +547, 8, 14, 261, 68, 69, 1296, 1297, "+" +547, 8, 15, 262, 70, 80, 1298, 1308, "travoprost" +547, 8, 16, 263, 81, 83, 1309, 1311, "or" +547, 8, 17, 264, 84, 95, 1312, 1323, "latanoprost" +547, 8, 18, 265, 96, 97, 1324, 1325, "/" +547, 8, 19, 266, 98, 105, 1326, 1333, "timolol" +547, 8, 20, 267, 106, 107, 1334, 1335, "+" +547, 8, 21, 268, 108, 115, 1336, 1343, "placebo" +547, 8, 22, 269, 116, 117, 1344, 1345, "." +547, 9, 1, 270, 0, 8, 1346, 1354, "Patients" +547, 9, 2, 271, 9, 11, 1355, 1357, "in" +547, 9, 3, 272, 12, 15, 1358, 1361, "the" +547, 9, 4, 273, 16, 26, 1362, 1372, "travoprost" +547, 9, 5, 274, 27, 32, 1373, 1378, "group" +547, 9, 6, 275, 33, 45, 1379, 1391, "administered" +547, 9, 7, 276, 46, 56, 1392, 1402, "travoprost" +547, 9, 8, 277, 57, 59, 1403, 1405, "at" +547, 9, 9, 278, 60, 61, 1406, 1407, "9" +547, 9, 10, 279, 62, 64, 1408, 1410, "PM" +547, 9, 11, 280, 65, 68, 1411, 1414, "and" +547, 9, 12, 281, 69, 76, 1415, 1422, "placebo" +547, 9, 13, 282, 77, 79, 1423, 1425, "at" +547, 9, 14, 283, 80, 81, 1426, 1427, "9" +547, 9, 15, 284, 82, 84, 1428, 1430, "AM" +547, 9, 16, 285, 85, 86, 1431, 1432, ";" +547, 9, 17, 286, 87, 95, 1433, 1441, "patients" +547, 9, 18, 287, 96, 98, 1442, 1444, "in" +547, 9, 19, 288, 99, 102, 1445, 1448, "the" +547, 9, 20, 289, 103, 114, 1449, 1460, "latanoprost" +547, 9, 21, 290, 115, 116, 1461, 1462, "/" +547, 9, 22, 291, 117, 124, 1463, 1470, "timolol" +547, 9, 23, 292, 125, 130, 1471, 1476, "group" +547, 9, 24, 293, 131, 143, 1477, 1489, "administered" +547, 9, 25, 294, 144, 155, 1490, 1501, "latanoprost" +547, 9, 26, 295, 156, 157, 1502, 1503, "/" +547, 9, 27, 296, 158, 165, 1504, 1511, "timolol" +547, 9, 28, 297, 166, 168, 1512, 1514, "at" +547, 9, 29, 298, 169, 170, 1515, 1516, "9" +547, 9, 30, 299, 171, 173, 1517, 1519, "AM" +547, 9, 31, 300, 174, 177, 1520, 1523, "and" +547, 9, 32, 301, 178, 185, 1524, 1531, "placebo" +547, 9, 33, 302, 186, 188, 1532, 1534, "at" +547, 9, 34, 303, 189, 190, 1535, 1536, "9" +547, 9, 35, 304, 191, 193, 1537, 1539, "PM" +547, 9, 36, 305, 194, 195, 1540, 1541, "." +547, 10, 1, 306, 0, 3, 1542, 1545, "IOP" +547, 10, 2, 307, 4, 16, 1546, 1558, "measurements" +547, 10, 3, 308, 17, 21, 1559, 1563, "were" +547, 10, 4, 309, 22, 31, 1564, 1573, "performed" +547, 10, 5, 310, 32, 37, 1574, 1579, "using" +547, 10, 6, 311, 38, 46, 1580, 1588, "Goldmann" +547, 10, 7, 312, 47, 58, 1589, 1600, "applanation" +547, 10, 8, 313, 59, 68, 1601, 1610, "tonometry" +547, 10, 9, 314, 69, 71, 1611, 1613, "at" +547, 10, 10, 315, 72, 73, 1614, 1615, "9" +547, 10, 11, 316, 74, 76, 1616, 1618, "AM" +547, 10, 12, 317, 77, 80, 1619, 1622, "and" +547, 10, 13, 318, 81, 82, 1623, 1624, "5" +547, 10, 14, 319, 83, 85, 1625, 1627, "PM" +547, 10, 15, 320, 86, 88, 1628, 1630, "at" +547, 10, 16, 321, 89, 92, 1631, 1634, "the" +547, 10, 17, 322, 93, 97, 1635, 1639, "week" +547, 10, 18, 323, 98, 99, 1640, 1641, "-" +547, 10, 19, 324, 100, 101, 1642, 1643, "2" +547, 10, 20, 325, 102, 105, 1644, 1647, "and" +547, 10, 21, 326, 106, 110, 1648, 1652, "week" +547, 10, 22, 327, 111, 112, 1653, 1654, "-" +547, 10, 23, 328, 113, 114, 1655, 1656, "6" +547, 10, 24, 329, 115, 121, 1657, 1663, "visits" +547, 10, 25, 330, 122, 123, 1664, 1665, "." +547, 11, 1, 331, 0, 4, 1666, 1670, "Both" +547, 11, 2, 332, 5, 16, 1671, 1682, "volunteered" +547, 11, 3, 333, 17, 20, 1683, 1686, "and" +547, 11, 4, 334, 21, 29, 1687, 1695, "elicited" +547, 11, 5, 335, 30, 37, 1696, 1703, "reports" +547, 11, 6, 336, 38, 40, 1704, 1706, "of" +547, 11, 7, 337, 41, 48, 1707, 1714, "adverse" +547, 11, 8, 338, 49, 55, 1715, 1721, "events" +547, 11, 9, 339, 56, 60, 1722, 1726, "were" +547, 11, 10, 340, 61, 70, 1727, 1736, "collected" +547, 11, 11, 341, 71, 72, 1737, 1738, ";" +547, 11, 12, 342, 73, 76, 1739, 1742, "all" +547, 11, 13, 343, 77, 85, 1743, 1751, "patients" +547, 11, 14, 344, 86, 89, 1752, 1755, "who" +547, 11, 15, 345, 90, 94, 1756, 1760, "were" +547, 11, 16, 346, 95, 105, 1761, 1771, "randomized" +547, 11, 17, 347, 106, 109, 1772, 1775, "and" +547, 11, 18, 348, 110, 118, 1776, 1784, "received" +547, 11, 19, 349, 119, 120, 1785, 1786, "&" +547, 11, 20, 350, 121, 123, 1787, 1789, "gt" +547, 11, 21, 351, 124, 125, 1790, 1791, ";" +547, 11, 22, 352, 126, 128, 1792, 1794, "or" +547, 11, 23, 353, 129, 130, 1795, 1796, "=" +547, 11, 24, 354, 131, 132, 1797, 1798, "1" +547, 11, 25, 355, 133, 137, 1799, 1803, "dose" +547, 11, 26, 356, 138, 140, 1804, 1806, "of" +547, 11, 27, 357, 141, 146, 1807, 1812, "study" +547, 11, 28, 358, 147, 151, 1813, 1817, "drug" +547, 11, 29, 359, 152, 156, 1818, 1822, "were" +547, 11, 30, 360, 157, 165, 1823, 1831, "included" +547, 11, 31, 361, 166, 168, 1832, 1834, "in" +547, 11, 32, 362, 169, 172, 1835, 1838, "the" +547, 11, 33, 363, 173, 179, 1839, 1845, "safety" +547, 11, 34, 364, 180, 188, 1846, 1854, "analysis" +547, 11, 35, 365, 189, 190, 1855, 1856, "." +547, 12, 1, 366, 0, 7, 1857, 1864, "RESULTS" +547, 12, 2, 367, 8, 9, 1865, 1866, ":" +547, 12, 3, 368, 10, 13, 1867, 1870, "One" +547, 12, 4, 369, 14, 21, 1871, 1878, "hundred" +547, 12, 5, 370, 22, 25, 1879, 1882, "ten" +547, 12, 6, 371, 26, 34, 1883, 1891, "patients" +547, 12, 7, 372, 35, 39, 1892, 1896, "were" +547, 12, 8, 373, 40, 50, 1897, 1907, "randomized" +547, 12, 9, 374, 51, 52, 1908, 1909, "," +547, 12, 10, 375, 53, 55, 1910, 1912, "of" +547, 12, 11, 376, 56, 60, 1913, 1917, "whom" +547, 12, 12, 377, 61, 64, 1918, 1921, "106" +547, 12, 13, 378, 65, 73, 1922, 1930, "patients" +547, 12, 14, 379, 74, 78, 1931, 1935, "were" +547, 12, 15, 380, 79, 88, 1936, 1945, "evaluable" +547, 12, 16, 381, 89, 90, 1946, 1947, "(" +547, 12, 17, 382, 91, 101, 1948, 1958, "travoprost" +547, 12, 18, 383, 102, 103, 1959, 1960, "," +547, 12, 19, 384, 104, 105, 1961, 1962, "n" +547, 12, 20, 385, 106, 107, 1963, 1964, "=" +547, 12, 21, 386, 108, 110, 1965, 1967, "50" +547, 12, 22, 387, 111, 112, 1968, 1969, ";" +547, 12, 23, 388, 113, 124, 1970, 1981, "latanoprost" +547, 12, 24, 389, 125, 126, 1982, 1983, "/" +547, 12, 25, 390, 127, 134, 1984, 1991, "timolol" +547, 12, 26, 391, 135, 136, 1992, 1993, "," +547, 12, 27, 392, 137, 138, 1994, 1995, "n" +547, 12, 28, 393, 139, 140, 1996, 1997, "=" +547, 12, 29, 394, 141, 143, 1998, 2000, "56" +547, 12, 30, 395, 144, 145, 2001, 2002, ")" +547, 12, 31, 396, 146, 147, 2003, 2004, "." +547, 13, 1, 397, 0, 5, 2005, 2010, "There" +547, 13, 2, 398, 6, 10, 2011, 2015, "were" +547, 13, 3, 399, 11, 13, 2016, 2018, "no" +547, 13, 4, 400, 14, 27, 2019, 2032, "statistically" +547, 13, 5, 401, 28, 39, 2033, 2044, "significant" +547, 13, 6, 402, 40, 51, 2045, 2056, "differences" +547, 13, 7, 403, 52, 54, 2057, 2059, "at" +547, 13, 8, 404, 55, 63, 2060, 2068, "baseline" +547, 13, 9, 405, 64, 71, 2069, 2076, "between" +547, 13, 10, 406, 72, 75, 2077, 2080, "the" +547, 13, 11, 407, 76, 85, 2081, 2090, "treatment" +547, 13, 12, 408, 86, 92, 2091, 2097, "groups" +547, 13, 13, 409, 93, 94, 2098, 2099, "," +547, 13, 14, 410, 95, 100, 2100, 2105, "based" +547, 13, 15, 411, 101, 103, 2106, 2108, "on" +547, 13, 16, 412, 104, 107, 2109, 2112, "age" +547, 13, 17, 413, 108, 113, 2113, 2118, "group" +547, 13, 18, 414, 114, 115, 2119, 2120, "," +547, 13, 19, 415, 116, 119, 2121, 2124, "sex" +547, 13, 20, 416, 120, 121, 2125, 2126, "," +547, 13, 21, 417, 122, 126, 2127, 2131, "race" +547, 13, 22, 418, 127, 128, 2132, 2133, "," +547, 13, 23, 419, 129, 133, 2134, 2138, "iris" +547, 13, 24, 420, 134, 139, 2139, 2144, "color" +547, 13, 25, 421, 140, 141, 2145, 2146, "," +547, 13, 26, 422, 142, 144, 2147, 2149, "or" +547, 13, 27, 423, 145, 154, 2150, 2159, "diagnosis" +547, 13, 28, 424, 155, 156, 2160, 2161, "." +547, 14, 1, 425, 0, 4, 2162, 2166, "Mean" +547, 14, 2, 426, 5, 8, 2167, 2170, "IOP" +547, 14, 3, 427, 9, 15, 2171, 2177, "values" +547, 14, 4, 428, 16, 20, 2178, 2182, "were" +547, 14, 5, 429, 21, 24, 2183, 2186, "not" +547, 14, 6, 430, 25, 38, 2187, 2200, "statistically" +547, 14, 7, 431, 39, 48, 2201, 2210, "different" +547, 14, 8, 432, 49, 56, 2211, 2218, "between" +547, 14, 9, 433, 57, 63, 2219, 2225, "groups" +547, 14, 10, 434, 64, 66, 2226, 2228, "at" +547, 14, 11, 435, 67, 75, 2229, 2237, "baseline" +547, 14, 12, 436, 76, 78, 2238, 2240, "or" +547, 14, 13, 437, 79, 85, 2241, 2247, "during" +547, 14, 14, 438, 86, 95, 2248, 2257, "treatment" +547, 14, 15, 439, 96, 97, 2258, 2259, "." +547, 15, 1, 440, 0, 2, 2260, 2262, "In" +547, 15, 2, 441, 3, 6, 2263, 2266, "the" +547, 15, 3, 442, 7, 13, 2267, 2273, "pooled" +547, 15, 4, 443, 14, 21, 2274, 2281, "results" +547, 15, 5, 444, 22, 25, 2282, 2285, "for" +547, 15, 6, 445, 26, 27, 2286, 2287, "9" +547, 15, 7, 446, 28, 30, 2288, 2290, "Am" +547, 15, 8, 447, 31, 41, 2291, 2301, "assessment" +547, 15, 9, 448, 42, 44, 2302, 2304, "at" +547, 15, 10, 449, 45, 50, 2305, 2310, "weeks" +547, 15, 11, 450, 51, 52, 2311, 2312, "2" +547, 15, 12, 451, 53, 56, 2313, 2316, "and" +547, 15, 13, 452, 57, 58, 2317, 2318, "6" +547, 15, 14, 453, 59, 60, 2319, 2320, "," +547, 15, 15, 454, 61, 65, 2321, 2325, "mean" +547, 15, 16, 455, 66, 67, 2326, 2327, "(" +547, 15, 17, 456, 68, 71, 2328, 2331, "SEM" +547, 15, 18, 457, 72, 73, 2332, 2333, ")" +547, 15, 19, 458, 74, 77, 2334, 2337, "IOP" +547, 15, 20, 459, 78, 88, 2338, 2348, "reductions" +547, 15, 21, 460, 89, 92, 2349, 2352, "for" +547, 15, 22, 461, 93, 103, 2353, 2363, "travoprost" +547, 15, 23, 462, 104, 107, 2364, 2367, "and" +547, 15, 24, 463, 108, 119, 2368, 2379, "latanoprost" +547, 15, 25, 464, 120, 121, 2380, 2381, "/" +547, 15, 26, 465, 122, 129, 2382, 2389, "timolol" +547, 15, 27, 466, 130, 134, 2390, 2394, "were" +547, 15, 28, 467, 135, 136, 2395, 2396, "7" +547, 15, 29, 468, 137, 138, 2397, 2398, "." +547, 15, 30, 469, 139, 140, 2399, 2400, "0" +547, 15, 31, 470, 141, 142, 2401, 2402, "(" +547, 15, 32, 471, 143, 144, 2403, 2404, "0" +547, 15, 33, 472, 145, 146, 2405, 2406, "." +547, 15, 34, 473, 147, 148, 2407, 2408, "5" +547, 15, 35, 474, 149, 150, 2409, 2410, ")" +547, 15, 36, 475, 151, 154, 2411, 2414, "and" +547, 15, 37, 476, 155, 156, 2415, 2416, "6" +547, 15, 38, 477, 157, 158, 2417, 2418, "." +547, 15, 39, 478, 159, 160, 2419, 2420, "4" +547, 15, 40, 479, 161, 162, 2421, 2422, "(" +547, 15, 41, 480, 163, 164, 2423, 2424, "0" +547, 15, 42, 481, 165, 166, 2425, 2426, "." +547, 15, 43, 482, 167, 168, 2427, 2428, "5" +547, 15, 44, 483, 169, 170, 2429, 2430, ")" +547, 15, 45, 484, 171, 173, 2431, 2433, "mm" +547, 15, 46, 485, 174, 176, 2434, 2436, "Hg" +547, 15, 47, 486, 177, 178, 2437, 2438, "," +547, 15, 48, 487, 179, 191, 2439, 2451, "respectively" +547, 15, 49, 488, 192, 193, 2452, 2453, "(" +547, 15, 50, 489, 194, 195, 2454, 2455, "P" +547, 15, 51, 490, 196, 197, 2456, 2457, "=" +547, 15, 52, 491, 198, 200, 2458, 2460, "NS" +547, 15, 53, 492, 201, 202, 2461, 2462, ")" +547, 15, 54, 493, 203, 204, 2463, 2464, "." +547, 16, 1, 494, 0, 7, 2465, 2472, "Adverse" +547, 16, 2, 495, 8, 14, 2473, 2479, "events" +547, 16, 3, 496, 15, 22, 2480, 2487, "related" +547, 16, 4, 497, 23, 25, 2488, 2490, "to" +547, 16, 5, 498, 26, 33, 2491, 2498, "therapy" +547, 16, 6, 499, 34, 38, 2499, 2503, "were" +547, 16, 7, 500, 39, 43, 2504, 2508, "mild" +547, 16, 8, 501, 44, 46, 2509, 2511, "in" +547, 16, 9, 502, 47, 53, 2512, 2518, "nature" +547, 16, 10, 503, 54, 55, 2519, 2520, "," +547, 16, 11, 504, 56, 59, 2521, 2524, "and" +547, 16, 12, 505, 60, 65, 2525, 2530, "there" +547, 16, 13, 506, 66, 70, 2531, 2535, "were" +547, 16, 14, 507, 71, 73, 2536, 2538, "no" +547, 16, 15, 508, 74, 87, 2539, 2552, "statistically" +547, 16, 16, 509, 88, 99, 2553, 2564, "significant" +547, 16, 17, 510, 100, 111, 2565, 2576, "differences" +547, 16, 18, 511, 112, 119, 2577, 2584, "between" +547, 16, 19, 512, 120, 123, 2585, 2588, "the" +547, 16, 20, 513, 124, 125, 2589, 2590, "2" +547, 16, 21, 514, 126, 135, 2591, 2600, "treatment" +547, 16, 22, 515, 136, 142, 2601, 2607, "groups" +547, 16, 23, 516, 143, 144, 2608, 2609, "." +547, 17, 1, 517, 0, 3, 2610, 2613, "The" +547, 17, 2, 518, 4, 8, 2614, 2618, "most" +547, 17, 3, 519, 9, 19, 2619, 2629, "frequently" +547, 17, 4, 520, 20, 31, 2630, 2641, "experienced" +547, 17, 5, 521, 32, 39, 2642, 2649, "adverse" +547, 17, 6, 522, 40, 46, 2650, 2656, "events" +547, 17, 7, 523, 47, 49, 2657, 2659, "in" +547, 17, 8, 524, 50, 53, 2660, 2663, "the" +547, 17, 9, 525, 54, 64, 2664, 2674, "travoprost" +547, 17, 10, 526, 65, 70, 2675, 2680, "group" +547, 17, 11, 527, 71, 75, 2681, 2685, "were" +547, 17, 12, 528, 76, 82, 2686, 2692, "ocular" +547, 17, 13, 529, 83, 92, 2693, 2702, "hyperemia" +547, 17, 14, 530, 93, 94, 2703, 2704, "(" +547, 17, 15, 531, 95, 96, 2705, 2706, "9" +547, 17, 16, 532, 97, 98, 2707, 2708, "." +547, 17, 17, 533, 99, 100, 2709, 2710, "3" +547, 17, 18, 534, 101, 102, 2711, 2712, "%" +547, 17, 19, 535, 103, 104, 2713, 2714, ")" +547, 17, 20, 536, 105, 106, 2715, 2716, "," +547, 17, 21, 537, 107, 114, 2717, 2724, "foreign" +547, 17, 22, 538, 115, 119, 2725, 2729, "body" +547, 17, 23, 539, 120, 129, 2730, 2739, "sensation" +547, 17, 24, 540, 130, 131, 2740, 2741, "(" +547, 17, 25, 541, 132, 133, 2742, 2743, "5" +547, 17, 26, 542, 134, 135, 2744, 2745, "." +547, 17, 27, 543, 136, 137, 2746, 2747, "6" +547, 17, 28, 544, 138, 139, 2748, 2749, "%" +547, 17, 29, 545, 140, 141, 2750, 2751, ")" +547, 17, 30, 546, 142, 143, 2752, 2753, "," +547, 17, 31, 547, 144, 152, 2754, 2762, "abnormal" +547, 17, 32, 548, 153, 159, 2763, 2769, "vision" +547, 17, 33, 549, 160, 161, 2770, 2771, "(" +547, 17, 34, 550, 162, 163, 2772, 2773, "1" +547, 17, 35, 551, 164, 165, 2774, 2775, "." +547, 17, 36, 552, 166, 167, 2776, 2777, "9" +547, 17, 37, 553, 168, 169, 2778, 2779, "%" +547, 17, 38, 554, 170, 171, 2780, 2781, ")" +547, 17, 39, 555, 172, 173, 2782, 2783, "," +547, 17, 40, 556, 174, 182, 2784, 2792, "allergic" +547, 17, 41, 557, 183, 191, 2793, 2801, "reaction" +547, 17, 42, 558, 192, 193, 2802, 2803, "(" +547, 17, 43, 559, 194, 195, 2804, 2805, "1" +547, 17, 44, 560, 196, 197, 2806, 2807, "." +547, 17, 45, 561, 198, 199, 2808, 2809, "9" +547, 17, 46, 562, 200, 201, 2810, 2811, "%" +547, 17, 47, 563, 202, 203, 2812, 2813, ")" +547, 17, 48, 564, 204, 205, 2814, 2815, "," +547, 17, 49, 565, 206, 220, 2816, 2830, "conjunctivitis" +547, 17, 50, 566, 221, 222, 2831, 2832, "(" +547, 17, 51, 567, 223, 224, 2833, 2834, "1" +547, 17, 52, 568, 225, 226, 2835, 2836, "." +547, 17, 53, 569, 227, 228, 2837, 2838, "9" +547, 17, 54, 570, 229, 230, 2839, 2840, "%" +547, 17, 55, 571, 231, 232, 2841, 2842, ")" +547, 17, 56, 572, 233, 234, 2843, 2844, "," +547, 17, 57, 573, 235, 249, 2845, 2859, "dacryocystitis" +547, 17, 58, 574, 250, 251, 2860, 2861, "(" +547, 17, 59, 575, 252, 253, 2862, 2863, "1" +547, 17, 60, 576, 254, 255, 2864, 2865, "." +547, 17, 61, 577, 256, 257, 2866, 2867, "9" +547, 17, 62, 578, 258, 259, 2868, 2869, "%" +547, 17, 63, 579, 260, 261, 2870, 2871, ")" +547, 17, 64, 580, 262, 263, 2872, 2873, "," +547, 17, 65, 581, 264, 267, 2874, 2877, "eye" +547, 17, 66, 582, 268, 277, 2878, 2887, "discharge" +547, 17, 67, 583, 278, 279, 2888, 2889, "(" +547, 17, 68, 584, 280, 281, 2890, 2891, "1" +547, 17, 69, 585, 282, 283, 2892, 2893, "." +547, 17, 70, 586, 284, 285, 2894, 2895, "9" +547, 17, 71, 587, 286, 287, 2896, 2897, "%" +547, 17, 72, 588, 288, 289, 2898, 2899, ")" +547, 17, 73, 589, 290, 291, 2900, 2901, "," +547, 17, 74, 590, 292, 295, 2902, 2905, "eye" +547, 17, 75, 591, 296, 304, 2906, 2914, "pruritus" +547, 17, 76, 592, 305, 306, 2915, 2916, "(" +547, 17, 77, 593, 307, 308, 2917, 2918, "1" +547, 17, 78, 594, 309, 310, 2919, 2920, "." +547, 17, 79, 595, 311, 312, 2921, 2922, "9" +547, 17, 80, 596, 313, 314, 2923, 2924, "%" +547, 17, 81, 597, 315, 316, 2925, 2926, ")" +547, 17, 82, 598, 317, 318, 2927, 2928, "," +547, 17, 83, 599, 319, 322, 2929, 2932, "lid" +547, 17, 84, 600, 323, 328, 2933, 2938, "edema" +547, 17, 85, 601, 329, 330, 2939, 2940, "(" +547, 17, 86, 602, 331, 332, 2941, 2942, "1" +547, 17, 87, 603, 333, 334, 2943, 2944, "." +547, 17, 88, 604, 335, 336, 2945, 2946, "9" +547, 17, 89, 605, 337, 338, 2947, 2948, "%" +547, 17, 90, 606, 339, 340, 2949, 2950, ")" +547, 17, 91, 607, 341, 342, 2951, 2952, "," +547, 17, 92, 608, 343, 346, 2953, 2956, "lid" +547, 17, 93, 609, 347, 355, 2957, 2965, "erythema" +547, 17, 94, 610, 356, 357, 2966, 2967, "(" +547, 17, 95, 611, 358, 359, 2968, 2969, "1" +547, 17, 96, 612, 360, 361, 2970, 2971, "." +547, 17, 97, 613, 362, 363, 2972, 2973, "9" +547, 17, 98, 614, 364, 365, 2974, 2975, "%" +547, 17, 99, 615, 366, 367, 2976, 2977, ")" +547, 17, 100, 616, 368, 369, 2978, 2979, "," +547, 17, 101, 617, 370, 373, 2980, 2983, "and" +547, 17, 102, 618, 374, 381, 2984, 2991, "tearing" +547, 17, 103, 619, 382, 383, 2992, 2993, "(" +547, 17, 104, 620, 384, 385, 2994, 2995, "1" +547, 17, 105, 621, 386, 387, 2996, 2997, "." +547, 17, 106, 622, 388, 389, 2998, 2999, "9" +547, 17, 107, 623, 390, 391, 3000, 3001, "%" +547, 17, 108, 624, 392, 393, 3002, 3003, ")" +547, 17, 109, 625, 394, 395, 3004, 3005, "." +547, 18, 1, 626, 0, 2, 3006, 3008, "In" +547, 18, 2, 627, 3, 6, 3009, 3012, "the" +547, 18, 3, 628, 7, 18, 3013, 3024, "latanoprost" +547, 18, 4, 629, 19, 20, 3025, 3026, "/" +547, 18, 5, 630, 21, 28, 3027, 3034, "timolol" +547, 18, 6, 631, 29, 34, 3035, 3040, "group" +547, 18, 7, 632, 35, 36, 3041, 3042, "," +547, 18, 8, 633, 37, 40, 3043, 3046, "the" +547, 18, 9, 634, 41, 45, 3047, 3051, "most" +547, 18, 10, 635, 46, 56, 3052, 3062, "frequently" +547, 18, 11, 636, 57, 68, 3063, 3074, "experienced" +547, 18, 12, 637, 69, 76, 3075, 3082, "adverse" +547, 18, 13, 638, 77, 83, 3083, 3089, "events" +547, 18, 14, 639, 84, 88, 3090, 3094, "were" +547, 18, 15, 640, 89, 97, 3095, 3103, "cataract" +547, 18, 16, 641, 98, 99, 3104, 3105, "(" +547, 18, 17, 642, 100, 101, 3106, 3107, "1" +547, 18, 18, 643, 102, 103, 3108, 3109, "." +547, 18, 19, 644, 104, 105, 3110, 3111, "8" +547, 18, 20, 645, 106, 107, 3112, 3113, "%" +547, 18, 21, 646, 108, 109, 3114, 3115, ")" +547, 18, 22, 647, 110, 111, 3116, 3117, "," +547, 18, 23, 648, 112, 115, 3118, 3121, "dry" +547, 18, 24, 649, 116, 120, 3122, 3126, "eyes" +547, 18, 25, 650, 121, 122, 3127, 3128, "(" +547, 18, 26, 651, 123, 124, 3129, 3130, "1" +547, 18, 27, 652, 125, 126, 3131, 3132, "." +547, 18, 28, 653, 127, 128, 3133, 3134, "8" +547, 18, 29, 654, 129, 130, 3135, 3136, "%" +547, 18, 30, 655, 131, 132, 3137, 3138, ")" +547, 18, 31, 656, 133, 134, 3139, 3140, "," +547, 18, 32, 657, 135, 138, 3141, 3144, "eye" +547, 18, 33, 658, 139, 147, 3145, 3153, "pruritus" +547, 18, 34, 659, 148, 149, 3154, 3155, "(" +547, 18, 35, 660, 150, 151, 3156, 3157, "1" +547, 18, 36, 661, 152, 153, 3158, 3159, "." +547, 18, 37, 662, 154, 155, 3160, 3161, "8" +547, 18, 38, 663, 156, 157, 3162, 3163, "%" +547, 18, 39, 664, 158, 159, 3164, 3165, ")" +547, 18, 40, 665, 160, 161, 3166, 3167, "," +547, 18, 41, 666, 162, 169, 3168, 3175, "foreign" +547, 18, 42, 667, 170, 174, 3176, 3180, "body" +547, 18, 43, 668, 175, 184, 3181, 3190, "sensation" +547, 18, 44, 669, 185, 186, 3191, 3192, "(" +547, 18, 45, 670, 187, 188, 3193, 3194, "1" +547, 18, 46, 671, 189, 190, 3195, 3196, "." +547, 18, 47, 672, 191, 192, 3197, 3198, "8" +547, 18, 48, 673, 193, 194, 3199, 3200, "%" +547, 18, 49, 674, 195, 196, 3201, 3202, ")" +547, 18, 50, 675, 197, 198, 3203, 3204, "," +547, 18, 51, 676, 199, 202, 3205, 3208, "and" +547, 18, 52, 677, 203, 209, 3209, 3215, "ocular" +547, 18, 53, 678, 210, 219, 3216, 3225, "hyperemia" +547, 18, 54, 679, 220, 221, 3226, 3227, "(" +547, 18, 55, 680, 222, 223, 3228, 3229, "1" +547, 18, 56, 681, 224, 225, 3230, 3231, "." +547, 18, 57, 682, 226, 227, 3232, 3233, "8" +547, 18, 58, 683, 228, 229, 3234, 3235, "%" +547, 18, 59, 684, 230, 231, 3236, 3237, ")" +547, 18, 60, 685, 232, 233, 3238, 3239, "." +547, 19, 1, 686, 0, 11, 3240, 3251, "CONCLUSIONS" +547, 19, 2, 687, 12, 13, 3252, 3253, ":" +547, 19, 3, 688, 14, 18, 3254, 3258, "Mean" +547, 19, 4, 689, 19, 22, 3259, 3262, "IOP" +547, 19, 5, 690, 23, 30, 3263, 3270, "changes" +547, 19, 6, 691, 31, 35, 3271, 3275, "from" +547, 19, 7, 692, 36, 44, 3276, 3284, "baseline" +547, 19, 8, 693, 45, 48, 3285, 3288, "for" +547, 19, 9, 694, 49, 59, 3289, 3299, "travoprost" +547, 19, 10, 695, 60, 61, 3300, 3301, "0" +547, 19, 11, 696, 62, 63, 3302, 3303, "." +547, 19, 12, 697, 64, 67, 3304, 3307, "004" +547, 19, 13, 698, 68, 69, 3308, 3309, "%" +547, 19, 14, 699, 70, 73, 3310, 3313, "and" +547, 19, 15, 700, 74, 85, 3314, 3325, "latanoprost" +547, 19, 16, 701, 86, 87, 3326, 3327, "0" +547, 19, 17, 702, 88, 89, 3328, 3329, "." +547, 19, 18, 703, 90, 93, 3330, 3333, "005" +547, 19, 19, 704, 94, 95, 3334, 3335, "%" +547, 19, 20, 705, 96, 97, 3336, 3337, "/" +547, 19, 21, 706, 98, 105, 3338, 3345, "timolol" +547, 19, 22, 707, 106, 107, 3346, 3347, "0" +547, 19, 23, 708, 108, 109, 3348, 3349, "." +547, 19, 24, 709, 110, 111, 3350, 3351, "5" +547, 19, 25, 710, 112, 113, 3352, 3353, "%" +547, 19, 26, 711, 114, 119, 3354, 3359, "fixed" +547, 19, 27, 712, 120, 131, 3360, 3371, "combination" +547, 19, 28, 713, 132, 136, 3372, 3376, "were" +547, 19, 29, 714, 137, 140, 3377, 3380, "not" +547, 19, 30, 715, 141, 154, 3381, 3394, "significantly" +547, 19, 31, 716, 155, 164, 3395, 3404, "different" +547, 19, 32, 717, 165, 167, 3405, 3407, "at" +547, 19, 33, 718, 168, 174, 3408, 3414, "follow" +547, 19, 34, 719, 175, 176, 3415, 3416, "-" +547, 19, 35, 720, 177, 179, 3417, 3419, "up" +547, 19, 36, 721, 180, 182, 3420, 3422, "in" +547, 19, 37, 722, 183, 188, 3423, 3428, "these" +547, 19, 38, 723, 189, 197, 3429, 3437, "patients" +547, 19, 39, 724, 198, 199, 3438, 3439, "." +547, 20, 1, 725, 0, 4, 3440, 3444, "Both" +547, 20, 2, 726, 5, 16, 3445, 3456, "medications" +547, 20, 3, 727, 17, 21, 3457, 3461, "were" +547, 20, 4, 728, 22, 26, 3462, 3466, "well" +547, 20, 5, 729, 27, 36, 3467, 3476, "tolerated" +547, 20, 6, 730, 37, 38, 3477, 3478, "." +547, 21, 1, 731, 0, 3, 3479, 3482, "DOI" +547, 21, 2, 732, 4, 5, 3483, 3484, ":" +547, 21, 3, 733, 6, 8, 3485, 3487, "10" +547, 21, 4, 734, 9, 10, 3488, 3489, "." +547, 21, 5, 735, 11, 15, 3490, 3494, "1016" +547, 21, 6, 736, 16, 17, 3495, 3496, "/" +547, 21, 7, 737, 18, 19, 3497, 3498, "j" +547, 21, 8, 738, 20, 21, 3499, 3500, "." +547, 21, 9, 739, 22, 31, 3501, 3510, "clinthera" +547, 21, 10, 740, 32, 33, 3511, 3512, "." +547, 21, 11, 741, 34, 38, 3513, 3517, "2006" +547, 21, 12, 742, 39, 40, 3518, 3519, "." +547, 21, 13, 743, 41, 43, 3520, 3522, "03" +547, 21, 14, 744, 44, 45, 3523, 3524, "." +547, 21, 15, 745, 46, 49, 3525, 3528, "001" +547, 21, 16, 746, 50, 54, 3529, 3533, "PMID" +547, 21, 17, 747, 55, 56, 3534, 3535, ":" +547, 21, 18, 748, 57, 65, 3536, 3544, "16750448" +547, 21, 19, 749, 66, 67, 3545, 3546, "[" +547, 21, 20, 750, 68, 75, 3547, 3554, "Indexed" +547, 21, 21, 751, 76, 79, 3555, 3558, "for" +547, 21, 22, 752, 80, 87, 3559, 3566, "MEDLINE" +547, 21, 23, 753, 88, 89, 3567, 3568, "]" diff --git a/data/gl 16750448_jshahinitiran.annodb b/data/gl 16750448_jshahinitiran.annodb new file mode 100644 index 0000000..2d478d7 --- /dev/null +++ b/data/gl 16750448_jshahinitiran.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +86948, Journal, 0, 9, "Clin Ther", "", +86949, PublicationYear, 12, 16, "2006", "", +86950, Title, 44, 274, "A 6 - week , double - masked , parallel - group study of the efficacy and safety of travoprost 0 . 004 % compared with latanoprost 0 : 005 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .", "", +86951, Duration, 46, 54, "6 - week", "", +86952, DoubleBlind, 57, 72, "double - masked", "", +86953, Parallel, 75, 91, "parallel - group", "", +86954, Travoprost, 128, 138, "travoprost", "", +86957, DoseValue, 139, 146, "0 . 004", "", +86955, Latanoprost, 163, 174, "latanoprost", "", +86958, DoseValue, 175, 182, "0 : 005", "", +86956, Timolol, 187, 194, "timolol", "", +86959, DoseValue, 195, 200, "0 . 5", "", +86960, Primary_OpenAngleGlaucoma, 220, 249, "primary open - angle glaucoma", "", +86961, OcularHypertension, 253, 272, "ocular hypertension", "", +86962, Author, 275, 284, "Franks WA", "", +86963, Author, 293, 302, "Renard JP", "", +86964, Author, 305, 316, "Cunliffe IA", "", +86965, Author, 319, 332, "Rojanapongpun", "", +86966, UK, 424, 438, "United Kingdom", "", +86967, ObjectiveDescription, 492, 640, "The objective of this study was to directly compare the intraocular pressure ( IOP ) - lowering efficacy and safety of travoprost 0 . 004 % eyedrops", "", +86969, IOP, 548, 568, "intraocular pressure", "", +86970, IOP, 571, 574, "IOP", "", +86971, Travoprost, 611, 621, "travoprost", "", +86973, DoseValue, 622, 629, "0 . 004", "", +86972, Eyedrops, 632, 640, "eyedrops", "", +86968, ObjectiveDescription, 641, 791, "with the fixed combination of latanoprost 0 . 005 % / timolol 0 . 5 % eyedrops in patients with primary open - angle glaucoma or ocular hypertension .", "", +86974, Latanoprost, 671, 682, "latanoprost", "", +86976, DoseValue, 683, 690, "0 . 005", "", +86975, Timolol, 695, 702, "timolol", "", +86977, DoseValue, 703, 708, "0 . 5", "", +86978, Eyedrops, 711, 719, "eyedrops", "", +86979, Primary_OpenAngleGlaucoma, 737, 766, "primary open - angle glaucoma", "", +86980, OcularHypertension, 770, 789, "ocular hypertension", "", +86981, Randomized, 813, 823, "randomized", "", +86982, DoubleBlind, 826, 841, "double - masked", "", +86983, Multicenter, 844, 855, "multicenter", "", +86984, Parallel, 858, 874, "parallel - group", "", +86985, CTDesign, 877, 896, "active - controlled", "", +86986, OpenAngleGlaucoma, 925, 946, "open - angle glaucoma", "", +86987, OcularHypertension, 1020, 1039, "ocular hypertension", "", +86988, OcularHypertension, 1078, 1081, "IOP", "", +86989, Precondition, 1078, 1225, "IOP was inadequately controlled with & gt ; or = 4 weeks of beta - blocker monotherapy , as indicated by IOP of 22 to 36 mm Hg at 9 AM at screening", "", +86990, IOP, 1183, 1186, "IOP", "", +86991, mmHg, 1199, 1204, "mm Hg", "", +86992, Randomized, 1242, 1250, "randomly", "", +86993, AllocationRatio, 1265, 1270, "1 : 1", "", +86994, Placebo, 1288, 1295, "placebo", "", +86995, Travoprost, 1298, 1308, "travoprost", "", +86996, Latanoprost, 1312, 1323, "latanoprost", "", +86997, Timolol, 1326, 1333, "timolol", "", +86998, Placebo, 1336, 1343, "placebo", "", +86999, Travoprost, 1362, 1372, "travoprost", "", +87000, Travoprost, 1392, 1402, "travoprost", "", +87001, Placebo, 1415, 1422, "placebo", "", +87002, Latanoprost, 1449, 1460, "latanoprost", "", +87003, Timolol, 1463, 1470, "timolol", "", +87004, Latanoprost, 1490, 1501, "latanoprost", "", +87005, Timolol, 1504, 1511, "timolol", "", +87006, Placebo, 1524, 1531, "placebo", "", +87007, IOP, 1542, 1545, "IOP", "", +87008, TimePoint, 1635, 1643, "week - 2", "", +87009, TimePoint, 1648, 1656, "week - 6", "", +87010, Randomized, 1761, 1771, "randomized", "", +87011, NumberPatientsCT, 1867, 1882, "One hundred ten", "", +87012, Randomized, 1897, 1907, "randomized", "", +87013, FinalNumPatientsCT, 1918, 1921, "106", "", +87014, Travoprost, 1948, 1958, "travoprost", "", +87015, NumberPatientsArm, 1965, 1967, "50", "", +87017, Latanoprost, 1970, 1981, "latanoprost", "", +87018, Timolol, 1984, 1991, "timolol", "", +87016, NumberPatientsArm, 1998, 2000, "56", "", +87019, Mean, 2162, 2166, "Mean", "", +87020, IOP, 2167, 2170, "IOP", "", +87021, TimePoint, 2305, 2312, "weeks 2", "", +87022, TimePoint, 2305, 2318, "weeks 2 and 6", "", +87023, Mean, 2321, 2325, "mean", "", +87024, IOP, 2334, 2337, "IOP", "", +87025, Travoprost, 2353, 2363, "travoprost", "", +87026, Latanoprost, 2368, 2379, "latanoprost", "", +87027, Timolol, 2382, 2389, "timolol", "", +87028, Reduction, 2395, 2400, "7 . 0", "", +87030, SdErrorChangeValue, 2403, 2408, "0 . 5", "", +87029, Reduction, 2415, 2420, "6 . 4", "", +87031, SdErrorChangeValue, 2423, 2428, "0 . 5", "", +87032, mmHg, 2431, 2436, "mm Hg", "", +87033, PValueChangeValue, 2454, 2460, "P = NS", "", +87034, Travoprost, 2664, 2674, "travoprost", "", +87035, ConjunctivalHyperemia, 2686, 2702, "ocular hyperemia", "", +87046, PercentageAffected, 2705, 2710, "9 . 3", "", +87047, PercentageAffected, 2742, 2747, "5 . 6", "", +87048, PercentageAffected, 2772, 2777, "1 . 9", "", +87049, PercentageAffected, 2804, 2809, "1 . 9", "", +87050, PercentageAffected, 2833, 2838, "1 . 9", "", +87051, PercentageAffected, 2862, 2867, "1 . 9", "", +87052, PercentageAffected, 2890, 2895, "1 . 9", "", +87053, PercentageAffected, 2917, 2922, "1 . 9", "", +87054, PercentageAffected, 2941, 2946, "1 . 9", "", +87055, PercentageAffected, 2968, 2973, "1 . 9", "", +87056, PercentageAffected, 2994, 2999, "1 . 9", "", +87063, Latanoprost, 3013, 3024, "latanoprost", "", +87064, Timolol, 3027, 3034, "timolol", "", +87057, PercentageAffected, 3106, 3111, "1 . 8", "", +87058, PercentageAffected, 3129, 3134, "1 . 8", "", +87059, PercentageAffected, 3156, 3161, "1 . 8", "", +87060, PercentageAffected, 3193, 3198, "1 . 8", "", +87069, ConjunctivalHyperemia, 3209, 3225, "ocular hyperemia", "", +87061, PercentageAffected, 3228, 3233, "1 . 8", "", +87062, Mean, 3254, 3258, "Mean", "", +87070, ConclusionComment, 3254, 3439, "Mean IOP changes from baseline for travoprost 0 . 004 % and latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination were not significantly different at follow - up in these patients .", "", +87071, IOP, 3259, 3262, "IOP", "", +87072, Travoprost, 3289, 3299, "travoprost", "", +87075, DoseValue, 3300, 3307, "0 . 004", "", +87073, Latanoprost, 3314, 3325, "latanoprost", "", +87078, Lat/TimFC, 3314, 3371, "latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination", "", +87076, DoseValue, 3326, 3333, "0 . 005", "", +87074, Timolol, 3338, 3345, "timolol", "", +87077, DoseValue, 3346, 3351, "0 . 5", "", +87079, ConclusionComment, 3440, 3478, "Both medications were well tolerated .", "", +87080, PMID, 3536, 3544, "16750448", "", diff --git a/data/gl 16750448_jshahinitiran.n-triples b/data/gl 16750448_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16750448_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16750448_tstrakeljahn.annodb b/data/gl 16750448_tstrakeljahn.annodb new file mode 100644 index 0000000..9663200 --- /dev/null +++ b/data/gl 16750448_tstrakeljahn.annodb @@ -0,0 +1,150 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90486, Journal, 0, 9, "Clin Ther", "", +90487, PublicationYear, 12, 16, "2006", "", +90502, Title, 44, 274, "A 6 - week , double - masked , parallel - group study of the efficacy and safety of travoprost 0 . 004 % compared with latanoprost 0 : 005 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .", "", +90488, Duration, 46, 54, "6 - week", "", +90489, DoubleBlind, 57, 72, "double - masked", "", +90490, Parallel, 75, 83, "parallel", "", +90491, Travoprost, 128, 138, "travoprost", "", +90496, DoseValue, 139, 146, "0 . 004", "", +90499, Percentage, 147, 148, "%", "", +90492, Latanoprost, 163, 174, "latanoprost", "", +90528, Lat/TimFC, 163, 202, "latanoprost 0 : 005 % / timolol 0 . 5 %", "", +90497, DoseValue, 175, 182, "0 : 005", "", +90500, Percentage, 183, 184, "%", "", +90493, Timolol, 187, 194, "timolol", "", +90498, DoseValue, 195, 200, "0 . 5", "", +90501, Percentage, 201, 202, "%", "", +90503, Precondition, 206, 272, "patients with primary open - angle glaucoma or ocular hypertension", "", +90494, Primary_OpenAngleGlaucoma, 220, 249, "primary open - angle glaucoma", "", +90495, OcularHypertension, 253, 272, "ocular hypertension", "", +90504, Author, 275, 284, "Franks WA", "", +90505, Author, 293, 302, "Renard JP", "", +90506, Author, 305, 316, "Cunliffe IA", "", +90507, Author, 319, 334, "Rojanapongpun P", "", +90509, Glaucoma, 364, 372, "Glaucoma", "", +90508, UK, 424, 438, "United Kingdom", "", +90525, ObjectiveDescription, 492, 744, "The objective of this study was to directly compare the intraocular pressure ( IOP ) - lowering efficacy and safety of travoprost 0 . 004 % eyedrops with the fixed combination of latanoprost 0 . 005 % / timolol 0 . 5 % eyedrops in patients with primary", "", +90510, IOP, 548, 568, "intraocular pressure", "", +90511, IOP, 571, 574, "IOP", "", +90512, Travoprost, 611, 621, "travoprost", "", +90519, DoseValue, 622, 629, "0 . 004", "", +90522, Percentage, 630, 631, "%", "", +90513, Eyedrops, 632, 640, "eyedrops", "", +90514, Latanoprost, 671, 682, "latanoprost", "", +90527, Lat/TimFC, 671, 710, "latanoprost 0 . 005 % / timolol 0 . 5 %", "", +90520, DoseValue, 683, 690, "0 . 005", "", +90523, Percentage, 691, 692, "%", "", +90515, Timolol, 695, 702, "timolol", "", +90521, DoseValue, 703, 708, "0 . 5", "", +90524, Percentage, 709, 710, "%", "", +90516, Eyedrops, 711, 719, "eyedrops", "", +90534, Precondition, 723, 789, "patients with primary open - angle glaucoma or ocular hypertension", "", +90517, Primary_OpenAngleGlaucoma, 737, 766, "primary open - angle glaucoma", "", +90526, ObjectiveDescription, 767, 791, "or ocular hypertension .", "", +90518, OcularHypertension, 770, 789, "ocular hypertension", "", +90529, Randomized, 813, 823, "randomized", "", +90530, DoubleBlind, 826, 841, "double - masked", "", +90531, Multicenter, 844, 855, "multicenter", "", +90532, Parallel, 858, 866, "parallel", "", +90533, CTDesign, 877, 896, "active - controlled", "", +90536, Precondition, 911, 1039, "subjects with open - angle glaucoma ( with or without pseudoexfoliation or pigment dispersion component ) or ocular hypertension", "", +90535, OpenAngleGlaucoma, 925, 946, "open - angle glaucoma", "", +90537, OcularHypertension, 1020, 1039, "ocular hypertension", "", +90543, Precondition, 1069, 1227, "if their IOP was inadequately controlled with & gt ; or = 4 weeks of beta - blocker monotherapy , as indicated by IOP of 22 to 36 mm Hg at 9 AM at screening .", "", +90542, IOP, 1078, 1081, "IOP", "", +90538, Drug, 1138, 1152, "beta - blocker", "beta blocker", +90539, IOP, 1183, 1186, "IOP", "", +90540, mmHg, 1199, 1204, "mm Hg", "", +90541, TimePoint, 1208, 1212, "9 AM", "", +90544, AllocationRatio, 1265, 1270, "1 : 1", "", +90545, Placebo, 1288, 1295, "placebo", "", +90546, Travoprost, 1298, 1308, "travoprost", "", +90547, Latanoprost, 1312, 1323, "latanoprost", "", +90549, Lat/TimFC, 1312, 1333, "latanoprost / timolol", "", +90548, Timolol, 1326, 1333, "timolol", "", +90550, Placebo, 1336, 1343, "placebo", "", +90551, Travoprost, 1362, 1372, "travoprost", "", +90552, Travoprost, 1392, 1402, "travoprost", "", +90553, TimePoint, 1406, 1410, "9 PM", "", +90561, Placebo, 1415, 1422, "placebo", "", +90554, TimePoint, 1426, 1430, "9 AM", "", +90557, Latanoprost, 1449, 1460, "latanoprost", "", +90558, Timolol, 1463, 1470, "timolol", "", +90560, Latanoprost, 1490, 1501, "latanoprost", "", +90559, Timolol, 1504, 1511, "timolol", "", +90555, TimePoint, 1515, 1519, "9 AM", "", +90562, Placebo, 1524, 1531, "placebo", "", +90556, TimePoint, 1535, 1539, "9 PM", "", +90563, IOP, 1542, 1545, "IOP", "", +90564, TimePoint, 1614, 1618, "9 AM", "", +90565, TimePoint, 1623, 1627, "5 PM", "", +90566, TimePoint, 1635, 1643, "week - 2", "", +90567, TimePoint, 1648, 1656, "week - 6", "", +90568, Randomized, 1761, 1771, "randomized", "", +90569, NumberPatientsCT, 1867, 1891, "One hundred ten patients", "", +90570, Randomized, 1897, 1907, "randomized", "", +90571, FinalNumPatientsCT, 1918, 1921, "106", "", +90572, Travoprost, 1948, 1958, "travoprost", "", +90576, FinalNumPatientsArm, 1965, 1967, "50", "", +90573, Latanoprost, 1970, 1981, "latanoprost", "", +90575, Lat/TimFC, 1970, 1991, "latanoprost / timolol", "", +90574, Timolol, 1984, 1991, "timolol", "", +90577, FinalNumPatientsArm, 1998, 2000, "56", "", +90578, ObservedResult, 2005, 2161, "There were no statistically significant differences at baseline between the treatment groups , based on age group , sex , race , iris color , or diagnosis .", "", +90579, Mean, 2162, 2166, "Mean", "", +90581, ObservedResult, 2162, 2259, "Mean IOP values were not statistically different between groups at baseline or during treatment .", "", +90580, IOP, 2167, 2170, "IOP", "", +90582, TimePoint, 2286, 2290, "9 Am", "", +90583, TimePoint, 2305, 2312, "weeks 2", "", +90584, TimePoint, 2305, 2318, "weeks 2 and 6", "", +90585, Mean, 2321, 2325, "mean", "", +90586, IOP, 2334, 2337, "IOP", "", +90587, Travoprost, 2353, 2363, "travoprost", "", +90588, Latanoprost, 2368, 2379, "latanoprost", "", +90590, Lat/TimFC, 2368, 2389, "latanoprost / timolol", "", +90589, Timolol, 2382, 2389, "timolol", "", +90591, Reduction, 2395, 2400, "7 . 0", "", +90594, SdErrorChangeValue, 2403, 2408, "0 . 5", "", +90592, Reduction, 2415, 2420, "6 . 4", "", +90595, SdErrorChangeValue, 2423, 2428, "0 . 5", "", +90596, mmHg, 2431, 2436, "mm Hg", "", +90593, PvalueDiff, 2456, 2460, "= NS", "", +90597, ObservedResult, 2465, 2609, "Adverse events related to therapy were mild in nature , and there were no statistically significant differences between the 2 treatment groups .", "", +90598, Travoprost, 2664, 2674, "travoprost", "", +90599, ConjunctivalHyperemia, 2686, 2702, "ocular hyperemia", "", +90608, PercentageAffected, 2705, 2710, "9 . 3", "", +90609, PercentageAffected, 2742, 2747, "5 . 6", "", +90610, PercentageAffected, 2772, 2777, "1 . 9", "", +90611, PercentageAffected, 2804, 2809, "1 . 9", "", +90612, PercentageAffected, 2833, 2838, "1 . 9", "", +90613, PercentageAffected, 2862, 2867, "1 . 9", "", +90614, PercentageAffected, 2890, 2895, "1 . 9", "", +90615, PercentageAffected, 2917, 2922, "1 . 9", "", +90616, PercentageAffected, 2941, 2946, "1 . 9", "", +90617, PercentageAffected, 2968, 2973, "1 . 9", "", +90618, PercentageAffected, 2994, 2999, "1 . 9", "", +90621, Latanoprost, 3013, 3024, "latanoprost", "", +90623, Lat/TimFC, 3013, 3034, "latanoprost / timolol", "", +90622, Timolol, 3027, 3034, "timolol", "", +90629, PercentageAffected, 3106, 3111, "1 . 8", "", +90630, PercentageAffected, 3129, 3134, "1 . 8", "", +90631, PercentageAffected, 3156, 3161, "1 . 8", "", +90632, PercentageAffected, 3193, 3198, "1 . 8", "", +90628, ConjunctivalHyperemia, 3209, 3225, "ocular hyperemia", "", +90633, PercentageAffected, 3228, 3233, "1 . 8", "", +90634, Mean, 3254, 3258, "Mean", "", +90647, ConclusionComment, 3254, 3439, "Mean IOP changes from baseline for travoprost 0 . 004 % and latanoprost 0 . 005 % / timolol 0 . 5 % fixed combination were not significantly different at follow - up in these patients .", "", +90635, IOP, 3259, 3262, "IOP", "", +90636, Travoprost, 3289, 3299, "travoprost", "", +90639, DoseValue, 3300, 3307, "0 . 004", "", +90642, Percentage, 3308, 3309, "%", "", +90637, Latanoprost, 3314, 3325, "latanoprost", "", +90646, Lat/TimFC, 3314, 3353, "latanoprost 0 . 005 % / timolol 0 . 5 %", "", +90640, DoseValue, 3326, 3333, "0 . 005", "", +90643, Percentage, 3334, 3335, "%", "", +90638, Timolol, 3338, 3345, "timolol", "", +90641, DoseValue, 3346, 3351, "0 . 5", "", +90644, Percentage, 3352, 3353, "%", "", +90645, ConclusionComment, 3440, 3478, "Both medications were well tolerated .", "", +90648, PMID, 3536, 3544, "16750448", "", diff --git a/data/gl 16750448_tstrakeljahn.n-triples b/data/gl 16750448_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16750448_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16825272_admin.annodb b/data/gl 16825272_admin.annodb new file mode 100644 index 0000000..a3e0236 --- /dev/null +++ b/data/gl 16825272_admin.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2006", "", " \"2006\"." +2, PublicationYear, 57, 61, "2006", "", +3, Title, 70, 210, "Intraocular pressure - lowering efficacy of bimatoprost 0 . 03 % and travoprost 0 . 004 % in patients with glaucoma or ocular hypertension .", "", " \"Intraocular pressure - lowering efficacy of bimatoprost 0 . 03 % and travoprost 0 . 004 % in patients with glaucoma or ocular hypertension .\"." +82, IOP, 70, 90, "Intraocular pressure", "", +83, Bimatoprost, 114, 125, "bimatoprost", "", " ." +87, DoseValue, 126, 132, "0 . 03", "", " \"0 . 03\"." +89, Percentage, 133, 134, "%", "", " ." +84, Travoprost, 139, 149, "travoprost", "", " ." +88, DoseValue, 150, 157, "0 . 004", "", " \"0 . 004\"." +90, Percentage, 158, 159, "%", "", " ." +85, Glaucoma, 177, 185, "glaucoma", "", " . ." +86, OcularHypertension, 189, 208, "ocular hypertension", "", " ." +4, Author, 211, 220, "Cantor LB", "", " \"Cantor LB\"." +5, Author, 229, 235, "Hoop J", "", " \"Hoop J\"." +6, Author, 238, 246, "Morgan L", "", " \"Morgan L\"." +7, Author, 249, 257, "Wudunn D", "", " \"Wudunn D\"." +8, Author, 260, 269, "Catoira Y", "", " \"Catoira Y\"." +9, Bimatoprost, 272, 283, "Bimatoprost", "", +97, Travoprost, 286, 296, "Travoprost", "", +10, USA, 450, 453, "USA", "", " ." +11, PublicationYear, 507, 511, "2006", "", +12, ObjectiveDescription, 547, 704, "To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure ( IOP ) for the treatment of glaucoma and ocular hypertension .", "", " \"To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure ( IOP ) for the treatment of glaucoma and ocular hypertension .\"." +100, Bimatoprost, 577, 588, "bimatoprost", "", +101, Travoprost, 593, 603, "travoprost", "", +106361, IOP, 620, 640, "intraocular pressure", "", " . ." +103, IOP, 643, 646, "IOP", "", +104, Glaucoma, 670, 678, "glaucoma", "", +105, OcularHypertension, 683, 702, "ocular hypertension", "", +13, Prospective, 715, 726, "Prospective", "", " ." +14, Randomized, 729, 739, "randomised", "", " ." +15, Blind, 742, 764, "investigator - blinded", "", " ." +16, Parallel, 767, 783, "parallel - group", "", " ." +111, Glaucoma, 835, 843, "glaucoma", "", +17, NumberPatientsCT, 867, 870, "157", "", " \"157\"." +18, Randomized, 878, 888, "randomised", "", +19, Bimatoprost, 892, 903, "bimatoprost", "", +20, Travoprost, 907, 917, "travoprost", "", +21, Duration, 922, 930, "6 months", "", " \"6 months\"." +22, TimePoint, 948, 956, "baseline", "", +23, TimePoint, 959, 965, "1 week", "", +24, TimePoint, 972, 990, "1 , 3 and 6 months", "", +25, TimePoint, 976, 990, "3 and 6 months", "", +26, TimePoint, 982, 990, "6 months", "", +27, IOP, 993, 996, "IOP", "", +86511, TimePoint, 1013, 1022, "09 : 00 h", "", +86513, TimePoint, 1049, 1056, "13 : 00", "", +86516, TimePoint, 1061, 1070, "16 : 00 h", "", +28, TimePoint, 1074, 1082, "baseline", "", +29, TimePoint, 1090, 1104, "3 and 6 months", "", +30, TimePoint, 1096, 1104, "6 months", "", +31, IOP, 1177, 1180, "IOP", "", +32, TimePoint, 1184, 1192, "baseline", "", +86519, TimePoint, 1198, 1205, "09 : 00", "", +86520, TimePoint, 1208, 1215, "13 : 00", "", +86521, TimePoint, 1219, 1228, "16 : 00 h", "", +33, PValueBL, 1231, 1247, "p > or = 0 . 741", "", " \"p > or = 0 . 741\". \"p > or = 0 . 741\". \"p > or = 0 . 741\". \"p > or = 0 . 741\". \"p > or = 0 . 741\". \"p > or = 0 . 741\"." +34, TimePoint, 1258, 1266, "6 months", "", +35, IOP, 1302, 1305, "IOP", "", +36, PValueChangeValue, 1328, 1344, "p < or = 0 . 001", "", +37, TimePoint, 1355, 1363, "6 months", "", +38, Mean, 1366, 1370, "mean", "", " . ." +39, IOP, 1371, 1374, "IOP", "", +86529, TimePoint, 1388, 1397, "09 : 00 h", "", " \"09 : 00 h\". \"09 : 00 h\"." +40, Reduction, 1402, 1407, "7 . 1", "", " \"7 . 1\"." +41, mmHg, 1408, 1413, "mm Hg", "", +42, RelativeReduction, 1416, 1422, "27 . 9", "", " \"27 . 9\"." +43, Bimatoprost, 1432, 1443, "bimatoprost", "", +44, NumberPatientsArm, 1450, 1452, "76", "", " \"76\"." +47, Reduction, 1459, 1464, "5 . 7", "", " \"5 . 7\"." +48, mmHg, 1465, 1470, "mm Hg", "", +49, RelativeReduction, 1473, 1479, "23 . 3", "", " \"23 . 3\"." +46, Travoprost, 1489, 1499, "travoprost", "", +45, NumberPatientsArm, 1506, 1508, "81", "", " \"81\"." +153, PvalueDiff, 1511, 1522, "p = 0 . 014", "", " \"p = 0 . 014\"." +86533, TimePoint, 1530, 1539, "13 : 00 h", "", " \"13 : 00 h\". \"13 : 00 h\". \"13 : 00 h\"." +51, Mean, 1542, 1546, "mean", "", +53, IOP, 1547, 1550, "IOP", "", +55, Reduction, 1565, 1570, "5 . 9", "", " \"5 . 9\"." +59, mmHg, 1571, 1576, "mm Hg", "", +67, Bimatoprost, 1582, 1593, "bimatoprost", "", +63, RelativeReduction, 1596, 1602, "25 . 3", "", " \"25 . 3\"." +56, Reduction, 1611, 1616, "5 . 2", "", " \"5 . 2\". \"5 . 2\"." +60, mmHg, 1617, 1622, "mm Hg", "", +64, RelativeReduction, 1625, 1631, "22 . 4", "", " \"22 . 4\". \"22 . 4\"." +69, Travoprost, 1641, 1651, "travoprost", "", +173, PvalueDiff, 1654, 1665, "p = 0 . 213", "", " \"p = 0 . 213\". \"p = 0 . 213\"." +86542, TimePoint, 1673, 1682, "16 : 00 h", "", " \"16 : 00 h\"." +52, Mean, 1689, 1693, "mean", "", +54, IOP, 1694, 1697, "IOP", "", +57, Reduction, 1712, 1717, "5 . 3", "", " \"5 . 3\"." +61, mmHg, 1718, 1723, "mm Hg", "", +65, RelativeReduction, 1726, 1732, "22 . 5", "", " \"22 . 5\"." +68, Bimatoprost, 1742, 1753, "bimatoprost", "", +58, Reduction, 1758, 1763, "4 . 5", "", +62, mmHg, 1764, 1769, "mm Hg", "", +66, RelativeReduction, 1772, 1778, "18 . 9", "", +174, PvalueDiff, 1783, 1794, "p = 0 . 207", "", +70, Travoprost, 1802, 1812, "travoprost", "", +100524, EndPointDescription, 1859, 1873, "ocular redness", "", " . ." +176, ObservedResult, 1874, 1939, "the most commonly reported adverse event in both treatment groups", "", " \"the most commonly reported adverse event in both treatment groups\"." +74, ConclusionComment, 1956, 2022, "Bimatoprost provided greater mean IOP reductions than travoprost .", "", " \"Bimatoprost provided greater mean IOP reductions than travoprost .\"." +75, Bimatoprost, 1956, 1967, "Bimatoprost", "", +76, Mean, 1985, 1989, "mean", "", +77, IOP, 1990, 1993, "IOP", "", +78, Travoprost, 2010, 2020, "travoprost", "", +79, PMID, 2087, 2095, "16825272", "", " \"16825272\"." diff --git a/data/gl 16825272_admin.n-triples b/data/gl 16825272_admin.n-triples new file mode 100644 index 0000000..af2501f --- /dev/null +++ b/data/gl 16825272_admin.n-triples @@ -0,0 +1,161 @@ +# RDF export of group: Publication + . + "Publication" . + "Intraocular pressure - lowering efficacy of bimatoprost 0 . 03 % and travoprost 0 . 004 % in patients with glaucoma or ocular hypertension ." . + "Cantor LB" . + "2006" . + "Br J Ophthalmol ." . + "16825272" . + . + "Hoop J" . + "Morgan L" . + "Wudunn D" . + "Catoira Y" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure ( IOP ) for the treatment of glaucoma and ocular hypertension ." . + "157" . + "6 months" . + . + . + . + "Bimatoprost provided greater mean IOP reductions than travoprost ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "IOP" . + . + . + . + . + . + . + . + "AE" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bim" . + "76" . + . + . + . + . + . + . + "Arm_tra" . + "81" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_bim" . + . + . + . + "Intervention_tra" . + . + . +# RDF export of group: Medication + . + "Medication_bim" . + . + "0 . 03" . + . + . + . + "Medication_tra" . + . + "0 . 004" . + . + . +# RDF export of group: Outcome + . + "Outcome_bim_0900" . + . + "p > or = 0 . 741" . + "7 . 1" . + "27 . 9" . + "09 : 00 h" . + . + "Outcome_tra_0900" . + . + "p > or = 0 . 741" . + "5 . 7" . + "23 . 3" . + "09 : 00 h" . + . + "Outcome_bim_1300" . + . + "p > or = 0 . 741" . + "5 . 9" . + "25 . 3" . + "13 : 00 h" . + . + "Outcome_tra_1300" . + . + "p > or = 0 . 741" . + "5 . 2" . + "22 . 4" . + "13 : 00 h" . + . + "Outcome_bim_1600" . + . + "p > or = 0 . 741" . + "5 . 3" . + "22 . 5" . + "16 : 00 h" . + . + "Outcome_tra_1600" . + . + "p > or = 0 . 741" . + "5 . 2" . + "22 . 4" . + "13 : 00 h" . + . + "AE" . + . + "the most commonly reported adverse event in both treatment groups" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_0900" . + "p = 0 . 014" . + . + . + . + "DiffBetweenGroups_1300" . + "p = 0 . 213" . + . + . + . + "DiffBetweenGroups_1600" . + "p = 0 . 213" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16825272_export.csv b/data/gl 16825272_export.csv new file mode 100644 index 0000000..f31c350 --- /dev/null +++ b/data/gl 16825272_export.csv @@ -0,0 +1,497 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +520, 1, 1, 1, 0, 2, 0, 2, "Br" +520, 1, 2, 2, 3, 4, 3, 4, "J" +520, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +520, 1, 4, 4, 16, 17, 16, 17, "." +520, 2, 1, 5, 0, 4, 18, 22, "2006" +520, 2, 2, 6, 5, 8, 23, 26, "Nov" +520, 2, 3, 7, 9, 10, 27, 28, ";" +520, 2, 4, 8, 11, 13, 29, 31, "90" +520, 2, 5, 9, 14, 15, 32, 33, "(" +520, 2, 6, 10, 16, 18, 34, 36, "11" +520, 2, 7, 11, 19, 20, 37, 38, ")" +520, 2, 8, 12, 21, 22, 39, 40, ":" +520, 2, 9, 13, 23, 27, 41, 45, "1370" +520, 2, 10, 14, 28, 29, 46, 47, "-" +520, 2, 11, 15, 30, 31, 48, 49, "3" +520, 2, 12, 16, 32, 33, 50, 51, "." +520, 3, 1, 17, 0, 4, 52, 56, "Epub" +520, 3, 2, 18, 5, 9, 57, 61, "2006" +520, 3, 3, 19, 10, 13, 62, 65, "Jul" +520, 3, 4, 20, 14, 15, 66, 67, "6" +520, 3, 5, 21, 16, 17, 68, 69, "." +520, 4, 1, 22, 0, 11, 70, 81, "Intraocular" +520, 4, 2, 23, 12, 20, 82, 90, "pressure" +520, 4, 3, 24, 21, 22, 91, 92, "-" +520, 4, 4, 25, 23, 31, 93, 101, "lowering" +520, 4, 5, 26, 32, 40, 102, 110, "efficacy" +520, 4, 6, 27, 41, 43, 111, 113, "of" +520, 4, 7, 28, 44, 55, 114, 125, "bimatoprost" +520, 4, 8, 29, 56, 57, 126, 127, "0" +520, 4, 9, 30, 58, 59, 128, 129, "." +520, 4, 10, 31, 60, 62, 130, 132, "03" +520, 4, 11, 32, 63, 64, 133, 134, "%" +520, 4, 12, 33, 65, 68, 135, 138, "and" +520, 4, 13, 34, 69, 79, 139, 149, "travoprost" +520, 4, 14, 35, 80, 81, 150, 151, "0" +520, 4, 15, 36, 82, 83, 152, 153, "." +520, 4, 16, 37, 84, 87, 154, 157, "004" +520, 4, 17, 38, 88, 89, 158, 159, "%" +520, 4, 18, 39, 90, 92, 160, 162, "in" +520, 4, 19, 40, 93, 101, 163, 171, "patients" +520, 4, 20, 41, 102, 106, 172, 176, "with" +520, 4, 21, 42, 107, 115, 177, 185, "glaucoma" +520, 4, 22, 43, 116, 118, 186, 188, "or" +520, 4, 23, 44, 119, 125, 189, 195, "ocular" +520, 4, 24, 45, 126, 138, 196, 208, "hypertension" +520, 4, 25, 46, 139, 140, 209, 210, "." +520, 5, 1, 47, 0, 6, 211, 217, "Cantor" +520, 5, 2, 48, 7, 9, 218, 220, "LB" +520, 5, 3, 49, 10, 11, 221, 222, "(" +520, 5, 4, 50, 12, 13, 223, 224, "1" +520, 5, 5, 51, 14, 15, 225, 226, ")" +520, 5, 6, 52, 16, 17, 227, 228, "," +520, 5, 7, 53, 18, 22, 229, 233, "Hoop" +520, 5, 8, 54, 23, 24, 234, 235, "J" +520, 5, 9, 55, 25, 26, 236, 237, "," +520, 5, 10, 56, 27, 33, 238, 244, "Morgan" +520, 5, 11, 57, 34, 35, 245, 246, "L" +520, 5, 12, 58, 36, 37, 247, 248, "," +520, 5, 13, 59, 38, 44, 249, 255, "Wudunn" +520, 5, 14, 60, 45, 46, 256, 257, "D" +520, 5, 15, 61, 47, 48, 258, 259, "," +520, 5, 16, 62, 49, 56, 260, 267, "Catoira" +520, 5, 17, 63, 57, 58, 268, 269, "Y" +520, 5, 18, 64, 59, 60, 270, 271, ";" +520, 5, 19, 65, 61, 72, 272, 283, "Bimatoprost" +520, 5, 20, 66, 73, 74, 284, 285, "-" +520, 5, 21, 67, 75, 85, 286, 296, "Travoprost" +520, 5, 22, 68, 86, 91, 297, 302, "Study" +520, 5, 23, 69, 92, 97, 303, 308, "Group" +520, 5, 24, 70, 98, 99, 309, 310, "." +520, 6, 1, 71, 0, 6, 311, 317, "Author" +520, 6, 2, 72, 7, 18, 318, 329, "information" +520, 6, 3, 73, 19, 20, 330, 331, ":" +520, 6, 4, 74, 21, 22, 332, 333, "(" +520, 6, 5, 75, 23, 24, 334, 335, "1" +520, 6, 6, 76, 25, 26, 336, 337, ")" +520, 6, 7, 77, 27, 37, 338, 348, "Department" +520, 6, 8, 78, 38, 40, 349, 351, "of" +520, 6, 9, 79, 41, 54, 352, 365, "Ophthalmology" +520, 6, 10, 80, 55, 56, 366, 367, "," +520, 6, 11, 81, 57, 64, 368, 375, "Indiana" +520, 6, 12, 82, 65, 75, 376, 386, "University" +520, 6, 13, 83, 76, 83, 387, 394, "Medical" +520, 6, 14, 84, 84, 90, 395, 401, "Center" +520, 6, 15, 85, 91, 92, 402, 403, "," +520, 6, 16, 86, 93, 96, 404, 407, "702" +520, 6, 17, 87, 97, 103, 408, 414, "Rotary" +520, 6, 18, 88, 104, 110, 415, 421, "Circle" +520, 6, 19, 89, 111, 112, 422, 423, "," +520, 6, 20, 90, 113, 125, 424, 436, "Indianapolis" +520, 6, 21, 91, 126, 127, 437, 438, "," +520, 6, 22, 92, 128, 130, 439, 441, "IN" +520, 6, 23, 93, 131, 136, 442, 447, "46202" +520, 6, 24, 94, 137, 138, 448, 449, "," +520, 6, 25, 95, 139, 142, 450, 453, "USA" +520, 6, 26, 96, 143, 144, 454, 455, "." +520, 7, 1, 97, 0, 7, 456, 463, "lcantor" +520, 7, 2, 98, 8, 9, 464, 465, "@" +520, 7, 3, 99, 10, 15, 466, 471, "iupui" +520, 7, 4, 100, 16, 17, 472, 473, "." +520, 7, 5, 101, 18, 21, 474, 477, "edu" +520, 7, 6, 102, 22, 29, 478, 485, "Comment" +520, 7, 7, 103, 30, 32, 486, 488, "in" +520, 7, 8, 104, 33, 35, 489, 491, "Br" +520, 7, 9, 105, 36, 37, 492, 493, "J" +520, 7, 10, 106, 38, 48, 494, 504, "Ophthalmol" +520, 7, 11, 107, 49, 50, 505, 506, "." +520, 8, 1, 108, 0, 4, 507, 511, "2006" +520, 8, 2, 109, 5, 8, 512, 515, "Nov" +520, 8, 3, 110, 9, 10, 516, 517, ";" +520, 8, 4, 111, 11, 13, 518, 520, "90" +520, 8, 5, 112, 14, 15, 521, 522, "(" +520, 8, 6, 113, 16, 18, 523, 525, "11" +520, 8, 7, 114, 19, 20, 526, 527, ")" +520, 8, 8, 115, 21, 22, 528, 529, ":" +520, 8, 9, 116, 23, 27, 530, 534, "1336" +520, 8, 10, 117, 28, 29, 535, 536, "-" +520, 8, 11, 118, 30, 31, 537, 538, "7" +520, 8, 12, 119, 32, 33, 539, 540, "." +520, 9, 1, 120, 0, 3, 541, 544, "AIM" +520, 9, 2, 121, 4, 5, 545, 546, ":" +520, 9, 3, 122, 6, 8, 547, 549, "To" +520, 9, 4, 123, 9, 17, 550, 558, "evaluate" +520, 9, 5, 124, 18, 21, 559, 562, "the" +520, 9, 6, 125, 22, 32, 563, 573, "efficacies" +520, 9, 7, 126, 33, 35, 574, 576, "of" +520, 9, 8, 127, 36, 47, 577, 588, "bimatoprost" +520, 9, 9, 128, 48, 51, 589, 592, "and" +520, 9, 10, 129, 52, 62, 593, 603, "travoprost" +520, 9, 11, 130, 63, 66, 604, 607, "for" +520, 9, 12, 131, 67, 75, 608, 616, "lowering" +520, 9, 13, 132, 76, 78, 617, 619, "of" +520, 9, 14, 133, 79, 90, 620, 631, "intraocular" +520, 9, 15, 134, 91, 99, 632, 640, "pressure" +520, 9, 16, 135, 100, 101, 641, 642, "(" +520, 9, 17, 136, 102, 105, 643, 646, "IOP" +520, 9, 18, 137, 106, 107, 647, 648, ")" +520, 9, 19, 138, 108, 111, 649, 652, "for" +520, 9, 20, 139, 112, 115, 653, 656, "the" +520, 9, 21, 140, 116, 125, 657, 666, "treatment" +520, 9, 22, 141, 126, 128, 667, 669, "of" +520, 9, 23, 142, 129, 137, 670, 678, "glaucoma" +520, 9, 24, 143, 138, 141, 679, 682, "and" +520, 9, 25, 144, 142, 148, 683, 689, "ocular" +520, 9, 26, 145, 149, 161, 690, 702, "hypertension" +520, 9, 27, 146, 162, 163, 703, 704, "." +520, 10, 1, 147, 0, 7, 705, 712, "METHODS" +520, 10, 2, 148, 8, 9, 713, 714, ":" +520, 10, 3, 149, 10, 21, 715, 726, "Prospective" +520, 10, 4, 150, 22, 23, 727, 728, "," +520, 10, 5, 151, 24, 34, 729, 739, "randomised" +520, 10, 6, 152, 35, 36, 740, 741, "," +520, 10, 7, 153, 37, 49, 742, 754, "investigator" +520, 10, 8, 154, 50, 51, 755, 756, "-" +520, 10, 9, 155, 52, 59, 757, 764, "blinded" +520, 10, 10, 156, 60, 61, 765, 766, "," +520, 10, 11, 157, 62, 70, 767, 775, "parallel" +520, 10, 12, 158, 71, 72, 776, 777, "-" +520, 10, 13, 159, 73, 78, 778, 783, "group" +520, 10, 14, 160, 79, 87, 784, 792, "clinical" +520, 10, 15, 161, 88, 93, 793, 798, "trial" +520, 10, 16, 162, 94, 95, 799, 800, "." +520, 11, 1, 163, 0, 5, 801, 806, "After" +520, 11, 2, 164, 6, 16, 807, 817, "completing" +520, 11, 3, 165, 17, 18, 818, 819, "a" +520, 11, 4, 166, 19, 26, 820, 827, "washout" +520, 11, 5, 167, 27, 29, 828, 830, "of" +520, 11, 6, 168, 30, 33, 831, 834, "all" +520, 11, 7, 169, 34, 42, 835, 843, "glaucoma" +520, 11, 8, 170, 43, 48, 844, 849, "drugs" +520, 11, 9, 171, 49, 50, 850, 851, "," +520, 11, 10, 172, 51, 59, 852, 860, "patients" +520, 11, 11, 173, 60, 61, 861, 862, "(" +520, 11, 12, 174, 62, 63, 863, 864, "n" +520, 11, 13, 175, 64, 65, 865, 866, "=" +520, 11, 14, 176, 66, 69, 867, 870, "157" +520, 11, 15, 177, 70, 71, 871, 872, ")" +520, 11, 16, 178, 72, 76, 873, 877, "were" +520, 11, 17, 179, 77, 87, 878, 888, "randomised" +520, 11, 18, 180, 88, 90, 889, 891, "to" +520, 11, 19, 181, 91, 102, 892, 903, "bimatoprost" +520, 11, 20, 182, 103, 105, 904, 906, "or" +520, 11, 21, 183, 106, 116, 907, 917, "travoprost" +520, 11, 22, 184, 117, 120, 918, 921, "for" +520, 11, 23, 185, 121, 122, 922, 923, "6" +520, 11, 24, 186, 123, 129, 924, 930, "months" +520, 11, 25, 187, 130, 131, 931, 932, "." +520, 12, 1, 188, 0, 6, 933, 939, "Visits" +520, 12, 2, 189, 7, 11, 940, 944, "were" +520, 12, 3, 190, 12, 14, 945, 947, "at" +520, 12, 4, 191, 15, 23, 948, 956, "baseline" +520, 12, 5, 192, 24, 25, 957, 958, "," +520, 12, 6, 193, 26, 27, 959, 960, "1" +520, 12, 7, 194, 28, 32, 961, 965, "week" +520, 12, 8, 195, 33, 34, 966, 967, "," +520, 12, 9, 196, 35, 38, 968, 971, "and" +520, 12, 10, 197, 39, 40, 972, 973, "1" +520, 12, 11, 198, 41, 42, 974, 975, "," +520, 12, 12, 199, 43, 44, 976, 977, "3" +520, 12, 13, 200, 45, 48, 978, 981, "and" +520, 12, 14, 201, 49, 50, 982, 983, "6" +520, 12, 15, 202, 51, 57, 984, 990, "months" +520, 12, 16, 203, 58, 59, 991, 992, "." +520, 13, 1, 204, 0, 3, 993, 996, "IOP" +520, 13, 2, 205, 4, 7, 997, 1000, "was" +520, 13, 3, 206, 8, 16, 1001, 1009, "measured" +520, 13, 4, 207, 17, 19, 1010, 1012, "at" +520, 13, 5, 208, 20, 22, 1013, 1015, "09" +520, 13, 6, 209, 23, 24, 1016, 1017, ":" +520, 13, 7, 210, 25, 27, 1018, 1020, "00" +520, 13, 8, 211, 28, 29, 1021, 1022, "h" +520, 13, 9, 212, 30, 32, 1023, 1025, "at" +520, 13, 10, 213, 33, 37, 1026, 1030, "each" +520, 13, 11, 214, 38, 43, 1031, 1036, "visit" +520, 13, 12, 215, 44, 47, 1037, 1040, "and" +520, 13, 13, 216, 48, 52, 1041, 1045, "also" +520, 13, 14, 217, 53, 55, 1046, 1048, "at" +520, 13, 15, 218, 56, 58, 1049, 1051, "13" +520, 13, 16, 219, 59, 60, 1052, 1053, ":" +520, 13, 17, 220, 61, 63, 1054, 1056, "00" +520, 13, 18, 221, 64, 67, 1057, 1060, "and" +520, 13, 19, 222, 68, 70, 1061, 1063, "16" +520, 13, 20, 223, 71, 72, 1064, 1065, ":" +520, 13, 21, 224, 73, 75, 1066, 1068, "00" +520, 13, 22, 225, 76, 77, 1069, 1070, "h" +520, 13, 23, 226, 78, 80, 1071, 1073, "at" +520, 13, 24, 227, 81, 89, 1074, 1082, "baseline" +520, 13, 25, 228, 90, 93, 1083, 1086, "and" +520, 13, 26, 229, 94, 96, 1087, 1089, "at" +520, 13, 27, 230, 97, 98, 1090, 1091, "3" +520, 13, 28, 231, 99, 102, 1092, 1095, "and" +520, 13, 29, 232, 103, 104, 1096, 1097, "6" +520, 13, 30, 233, 105, 111, 1098, 1104, "months" +520, 13, 31, 234, 112, 113, 1105, 1106, "." +520, 14, 1, 235, 0, 7, 1107, 1114, "RESULTS" +520, 14, 2, 236, 8, 9, 1115, 1116, ":" +520, 14, 3, 237, 10, 12, 1117, 1119, "No" +520, 14, 4, 238, 13, 24, 1120, 1131, "significant" +520, 14, 5, 239, 25, 32, 1132, 1139, "between" +520, 14, 6, 240, 33, 34, 1140, 1141, "-" +520, 14, 7, 241, 35, 40, 1142, 1147, "group" +520, 14, 8, 242, 41, 52, 1148, 1159, "differences" +520, 14, 9, 243, 53, 57, 1160, 1164, "were" +520, 14, 10, 244, 58, 66, 1165, 1173, "observed" +520, 14, 11, 245, 67, 69, 1174, 1176, "in" +520, 14, 12, 246, 70, 73, 1177, 1180, "IOP" +520, 14, 13, 247, 74, 76, 1181, 1183, "at" +520, 14, 14, 248, 77, 85, 1184, 1192, "baseline" +520, 14, 15, 249, 86, 87, 1193, 1194, "," +520, 14, 16, 250, 88, 90, 1195, 1197, "at" +520, 14, 17, 251, 91, 93, 1198, 1200, "09" +520, 14, 18, 252, 94, 95, 1201, 1202, ":" +520, 14, 19, 253, 96, 98, 1203, 1205, "00" +520, 14, 20, 254, 99, 100, 1206, 1207, "," +520, 14, 21, 255, 101, 103, 1208, 1210, "13" +520, 14, 22, 256, 104, 105, 1211, 1212, ":" +520, 14, 23, 257, 106, 108, 1213, 1215, "00" +520, 14, 24, 258, 109, 111, 1216, 1218, "or" +520, 14, 25, 259, 112, 114, 1219, 1221, "16" +520, 14, 26, 260, 115, 116, 1222, 1223, ":" +520, 14, 27, 261, 117, 119, 1224, 1226, "00" +520, 14, 28, 262, 120, 121, 1227, 1228, "h" +520, 14, 29, 263, 122, 123, 1229, 1230, "(" +520, 14, 30, 264, 124, 125, 1231, 1232, "p" +520, 14, 31, 265, 126, 127, 1233, 1234, ">" +520, 14, 32, 266, 128, 130, 1235, 1237, "or" +520, 14, 33, 267, 131, 132, 1238, 1239, "=" +520, 14, 34, 268, 133, 134, 1240, 1241, "0" +520, 14, 35, 269, 135, 136, 1242, 1243, "." +520, 14, 36, 270, 137, 140, 1244, 1247, "741" +520, 14, 37, 271, 141, 142, 1248, 1249, ")" +520, 14, 38, 272, 143, 144, 1250, 1251, "." +520, 15, 1, 273, 0, 5, 1252, 1257, "After" +520, 15, 2, 274, 6, 7, 1258, 1259, "6" +520, 15, 3, 275, 8, 14, 1260, 1266, "months" +520, 15, 4, 276, 15, 16, 1267, 1268, "," +520, 15, 5, 277, 17, 21, 1269, 1273, "both" +520, 15, 6, 278, 22, 27, 1274, 1279, "drugs" +520, 15, 7, 279, 28, 41, 1280, 1293, "significantly" +520, 15, 8, 280, 42, 49, 1294, 1301, "reduced" +520, 15, 9, 281, 50, 53, 1302, 1305, "IOP" +520, 15, 10, 282, 54, 56, 1306, 1308, "at" +520, 15, 11, 283, 57, 62, 1309, 1314, "every" +520, 15, 12, 284, 63, 67, 1315, 1319, "time" +520, 15, 13, 285, 68, 73, 1320, 1325, "point" +520, 15, 14, 286, 74, 75, 1326, 1327, "(" +520, 15, 15, 287, 76, 77, 1328, 1329, "p" +520, 15, 16, 288, 78, 79, 1330, 1331, "<" +520, 15, 17, 289, 80, 82, 1332, 1334, "or" +520, 15, 18, 290, 83, 84, 1335, 1336, "=" +520, 15, 19, 291, 85, 86, 1337, 1338, "0" +520, 15, 20, 292, 87, 88, 1339, 1340, "." +520, 15, 21, 293, 89, 92, 1341, 1344, "001" +520, 15, 22, 294, 93, 94, 1345, 1346, ")" +520, 15, 23, 295, 95, 96, 1347, 1348, "." +520, 16, 1, 296, 0, 5, 1349, 1354, "After" +520, 16, 2, 297, 6, 7, 1355, 1356, "6" +520, 16, 3, 298, 8, 14, 1357, 1363, "months" +520, 16, 4, 299, 15, 16, 1364, 1365, "," +520, 16, 5, 300, 17, 21, 1366, 1370, "mean" +520, 16, 6, 301, 22, 25, 1371, 1374, "IOP" +520, 16, 7, 302, 26, 35, 1375, 1384, "reduction" +520, 16, 8, 303, 36, 38, 1385, 1387, "at" +520, 16, 9, 304, 39, 41, 1388, 1390, "09" +520, 16, 10, 305, 42, 43, 1391, 1392, ":" +520, 16, 11, 306, 44, 46, 1393, 1395, "00" +520, 16, 12, 307, 47, 48, 1396, 1397, "h" +520, 16, 13, 308, 49, 52, 1398, 1401, "was" +520, 16, 14, 309, 53, 54, 1402, 1403, "7" +520, 16, 15, 310, 55, 56, 1404, 1405, "." +520, 16, 16, 311, 57, 58, 1406, 1407, "1" +520, 16, 17, 312, 59, 61, 1408, 1410, "mm" +520, 16, 18, 313, 62, 64, 1411, 1413, "Hg" +520, 16, 19, 314, 65, 66, 1414, 1415, "(" +520, 16, 20, 315, 67, 69, 1416, 1418, "27" +520, 16, 21, 316, 70, 71, 1419, 1420, "." +520, 16, 22, 317, 72, 73, 1421, 1422, "9" +520, 16, 23, 318, 74, 75, 1423, 1424, "%" +520, 16, 24, 319, 76, 77, 1425, 1426, ")" +520, 16, 25, 320, 78, 82, 1427, 1431, "with" +520, 16, 26, 321, 83, 94, 1432, 1443, "bimatoprost" +520, 16, 27, 322, 95, 96, 1444, 1445, "(" +520, 16, 28, 323, 97, 98, 1446, 1447, "n" +520, 16, 29, 324, 99, 100, 1448, 1449, "=" +520, 16, 30, 325, 101, 103, 1450, 1452, "76" +520, 16, 31, 326, 104, 105, 1453, 1454, ")" +520, 16, 32, 327, 106, 109, 1455, 1458, "and" +520, 16, 33, 328, 110, 111, 1459, 1460, "5" +520, 16, 34, 329, 112, 113, 1461, 1462, "." +520, 16, 35, 330, 114, 115, 1463, 1464, "7" +520, 16, 36, 331, 116, 118, 1465, 1467, "mm" +520, 16, 37, 332, 119, 121, 1468, 1470, "Hg" +520, 16, 38, 333, 122, 123, 1471, 1472, "(" +520, 16, 39, 334, 124, 126, 1473, 1475, "23" +520, 16, 40, 335, 127, 128, 1476, 1477, "." +520, 16, 41, 336, 129, 130, 1478, 1479, "3" +520, 16, 42, 337, 131, 132, 1480, 1481, "%" +520, 16, 43, 338, 133, 134, 1482, 1483, ")" +520, 16, 44, 339, 135, 139, 1484, 1488, "with" +520, 16, 45, 340, 140, 150, 1489, 1499, "travoprost" +520, 16, 46, 341, 151, 152, 1500, 1501, "(" +520, 16, 47, 342, 153, 154, 1502, 1503, "n" +520, 16, 48, 343, 155, 156, 1504, 1505, "=" +520, 16, 49, 344, 157, 159, 1506, 1508, "81" +520, 16, 50, 345, 160, 161, 1509, 1510, ";" +520, 16, 51, 346, 162, 163, 1511, 1512, "p" +520, 16, 52, 347, 164, 165, 1513, 1514, "=" +520, 16, 53, 348, 166, 167, 1515, 1516, "0" +520, 16, 54, 349, 168, 169, 1517, 1518, "." +520, 16, 55, 350, 170, 173, 1519, 1522, "014" +520, 16, 56, 351, 174, 175, 1523, 1524, ")" +520, 16, 57, 352, 176, 177, 1525, 1526, "." +520, 17, 1, 353, 0, 2, 1527, 1529, "At" +520, 17, 2, 354, 3, 5, 1530, 1532, "13" +520, 17, 3, 355, 6, 7, 1533, 1534, ":" +520, 17, 4, 356, 8, 10, 1535, 1537, "00" +520, 17, 5, 357, 11, 12, 1538, 1539, "h" +520, 17, 6, 358, 13, 14, 1540, 1541, "," +520, 17, 7, 359, 15, 19, 1542, 1546, "mean" +520, 17, 8, 360, 20, 23, 1547, 1550, "IOP" +520, 17, 9, 361, 24, 33, 1551, 1560, "reduction" +520, 17, 10, 362, 34, 37, 1561, 1564, "was" +520, 17, 11, 363, 38, 39, 1565, 1566, "5" +520, 17, 12, 364, 40, 41, 1567, 1568, "." +520, 17, 13, 365, 42, 43, 1569, 1570, "9" +520, 17, 14, 366, 44, 46, 1571, 1573, "mm" +520, 17, 15, 367, 47, 49, 1574, 1576, "Hg" +520, 17, 16, 368, 50, 54, 1577, 1581, "with" +520, 17, 17, 369, 55, 66, 1582, 1593, "bimatoprost" +520, 17, 18, 370, 67, 68, 1594, 1595, "(" +520, 17, 19, 371, 69, 71, 1596, 1598, "25" +520, 17, 20, 372, 72, 73, 1599, 1600, "." +520, 17, 21, 373, 74, 75, 1601, 1602, "3" +520, 17, 22, 374, 76, 77, 1603, 1604, "%" +520, 17, 23, 375, 78, 79, 1605, 1606, ")" +520, 17, 24, 376, 80, 83, 1607, 1610, "and" +520, 17, 25, 377, 84, 85, 1611, 1612, "5" +520, 17, 26, 378, 86, 87, 1613, 1614, "." +520, 17, 27, 379, 88, 89, 1615, 1616, "2" +520, 17, 28, 380, 90, 92, 1617, 1619, "mm" +520, 17, 29, 381, 93, 95, 1620, 1622, "Hg" +520, 17, 30, 382, 96, 97, 1623, 1624, "(" +520, 17, 31, 383, 98, 100, 1625, 1627, "22" +520, 17, 32, 384, 101, 102, 1628, 1629, "." +520, 17, 33, 385, 103, 104, 1630, 1631, "4" +520, 17, 34, 386, 105, 106, 1632, 1633, "%" +520, 17, 35, 387, 107, 108, 1634, 1635, ")" +520, 17, 36, 388, 109, 113, 1636, 1640, "with" +520, 17, 37, 389, 114, 124, 1641, 1651, "travoprost" +520, 17, 38, 390, 125, 126, 1652, 1653, "(" +520, 17, 39, 391, 127, 128, 1654, 1655, "p" +520, 17, 40, 392, 129, 130, 1656, 1657, "=" +520, 17, 41, 393, 131, 132, 1658, 1659, "0" +520, 17, 42, 394, 133, 134, 1660, 1661, "." +520, 17, 43, 395, 135, 138, 1662, 1665, "213" +520, 17, 44, 396, 139, 140, 1666, 1667, ")" +520, 17, 45, 397, 141, 142, 1668, 1669, "." +520, 18, 1, 398, 0, 2, 1670, 1672, "At" +520, 18, 2, 399, 3, 5, 1673, 1675, "16" +520, 18, 3, 400, 6, 7, 1676, 1677, ":" +520, 18, 4, 401, 8, 10, 1678, 1680, "00" +520, 18, 5, 402, 11, 12, 1681, 1682, "h" +520, 18, 6, 403, 13, 14, 1683, 1684, "," +520, 18, 7, 404, 15, 18, 1685, 1688, "the" +520, 18, 8, 405, 19, 23, 1689, 1693, "mean" +520, 18, 9, 406, 24, 27, 1694, 1697, "IOP" +520, 18, 10, 407, 28, 37, 1698, 1707, "reduction" +520, 18, 11, 408, 38, 41, 1708, 1711, "was" +520, 18, 12, 409, 42, 43, 1712, 1713, "5" +520, 18, 13, 410, 44, 45, 1714, 1715, "." +520, 18, 14, 411, 46, 47, 1716, 1717, "3" +520, 18, 15, 412, 48, 50, 1718, 1720, "mm" +520, 18, 16, 413, 51, 53, 1721, 1723, "Hg" +520, 18, 17, 414, 54, 55, 1724, 1725, "(" +520, 18, 18, 415, 56, 58, 1726, 1728, "22" +520, 18, 19, 416, 59, 60, 1729, 1730, "." +520, 18, 20, 417, 61, 62, 1731, 1732, "5" +520, 18, 21, 418, 63, 64, 1733, 1734, "%" +520, 18, 22, 419, 65, 66, 1735, 1736, ")" +520, 18, 23, 420, 67, 71, 1737, 1741, "with" +520, 18, 24, 421, 72, 83, 1742, 1753, "bimatoprost" +520, 18, 25, 422, 84, 87, 1754, 1757, "and" +520, 18, 26, 423, 88, 89, 1758, 1759, "4" +520, 18, 27, 424, 90, 91, 1760, 1761, "." +520, 18, 28, 425, 92, 93, 1762, 1763, "5" +520, 18, 29, 426, 94, 96, 1764, 1766, "mm" +520, 18, 30, 427, 97, 99, 1767, 1769, "Hg" +520, 18, 31, 428, 100, 101, 1770, 1771, "(" +520, 18, 32, 429, 102, 104, 1772, 1774, "18" +520, 18, 33, 430, 105, 106, 1775, 1776, "." +520, 18, 34, 431, 107, 108, 1777, 1778, "9" +520, 18, 35, 432, 109, 110, 1779, 1780, "%" +520, 18, 36, 433, 111, 112, 1781, 1782, ";" +520, 18, 37, 434, 113, 114, 1783, 1784, "p" +520, 18, 38, 435, 115, 116, 1785, 1786, "=" +520, 18, 39, 436, 117, 118, 1787, 1788, "0" +520, 18, 40, 437, 119, 120, 1789, 1790, "." +520, 18, 41, 438, 121, 124, 1791, 1794, "207" +520, 18, 42, 439, 125, 126, 1795, 1796, ")" +520, 18, 43, 440, 127, 131, 1797, 1801, "with" +520, 18, 44, 441, 132, 142, 1802, 1812, "travoprost" +520, 18, 45, 442, 143, 144, 1813, 1814, "." +520, 19, 1, 443, 0, 4, 1815, 1819, "Both" +520, 19, 2, 444, 5, 10, 1820, 1825, "study" +520, 19, 3, 445, 11, 16, 1826, 1831, "drugs" +520, 19, 4, 446, 17, 21, 1832, 1836, "were" +520, 19, 5, 447, 22, 26, 1837, 1841, "well" +520, 19, 6, 448, 27, 36, 1842, 1851, "tolerated" +520, 19, 7, 449, 37, 38, 1852, 1853, "," +520, 19, 8, 450, 39, 43, 1854, 1858, "with" +520, 19, 9, 451, 44, 50, 1859, 1865, "ocular" +520, 19, 10, 452, 51, 58, 1866, 1873, "redness" +520, 19, 11, 453, 59, 62, 1874, 1877, "the" +520, 19, 12, 454, 63, 67, 1878, 1882, "most" +520, 19, 13, 455, 68, 76, 1883, 1891, "commonly" +520, 19, 14, 456, 77, 85, 1892, 1900, "reported" +520, 19, 15, 457, 86, 93, 1901, 1908, "adverse" +520, 19, 16, 458, 94, 99, 1909, 1914, "event" +520, 19, 17, 459, 100, 102, 1915, 1917, "in" +520, 19, 18, 460, 103, 107, 1918, 1922, "both" +520, 19, 19, 461, 108, 117, 1923, 1932, "treatment" +520, 19, 20, 462, 118, 124, 1933, 1939, "groups" +520, 19, 21, 463, 125, 126, 1940, 1941, "." +520, 20, 1, 464, 0, 11, 1942, 1953, "CONCLUSIONS" +520, 20, 2, 465, 12, 13, 1954, 1955, ":" +520, 20, 3, 466, 14, 25, 1956, 1967, "Bimatoprost" +520, 20, 4, 467, 26, 34, 1968, 1976, "provided" +520, 20, 5, 468, 35, 42, 1977, 1984, "greater" +520, 20, 6, 469, 43, 47, 1985, 1989, "mean" +520, 20, 7, 470, 48, 51, 1990, 1993, "IOP" +520, 20, 8, 471, 52, 62, 1994, 2004, "reductions" +520, 20, 9, 472, 63, 67, 2005, 2009, "than" +520, 20, 10, 473, 68, 78, 2010, 2020, "travoprost" +520, 20, 11, 474, 79, 80, 2021, 2022, "." +520, 21, 1, 475, 0, 3, 2023, 2026, "DOI" +520, 21, 2, 476, 4, 5, 2027, 2028, ":" +520, 21, 3, 477, 6, 8, 2029, 2031, "10" +520, 21, 4, 478, 9, 10, 2032, 2033, "." +520, 21, 5, 479, 11, 15, 2034, 2038, "1136" +520, 21, 6, 480, 16, 17, 2039, 2040, "/" +520, 21, 7, 481, 18, 21, 2041, 2044, "bjo" +520, 21, 8, 482, 22, 23, 2045, 2046, "." +520, 21, 9, 483, 24, 28, 2047, 2051, "2006" +520, 21, 10, 484, 29, 30, 2052, 2053, "." +520, 21, 11, 485, 31, 37, 2054, 2060, "094326" +520, 21, 12, 486, 38, 43, 2061, 2066, "PMCID" +520, 21, 13, 487, 44, 45, 2067, 2068, ":" +520, 21, 14, 488, 46, 56, 2069, 2079, "PMC1857505" +520, 21, 15, 489, 57, 61, 2080, 2084, "PMID" +520, 21, 16, 490, 62, 63, 2085, 2086, ":" +520, 21, 17, 491, 64, 72, 2087, 2095, "16825272" +520, 21, 18, 492, 73, 74, 2096, 2097, "[" +520, 21, 19, 493, 75, 82, 2098, 2105, "Indexed" +520, 21, 20, 494, 83, 86, 2106, 2109, "for" +520, 21, 21, 495, 87, 94, 2110, 2117, "MEDLINE" +520, 21, 22, 496, 95, 96, 2118, 2119, "]" diff --git a/data/gl 16825272_jshahinitiran.annodb b/data/gl 16825272_jshahinitiran.annodb new file mode 100644 index 0000000..0d7524d --- /dev/null +++ b/data/gl 16825272_jshahinitiran.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +57600, Journal, 0, 15, "Br J Ophthalmol", "", +57601, PublicationYear, 18, 22, "2006", "", +57602, PublicationYear, 57, 61, "2006", "", +57603, Title, 70, 210, "Intraocular pressure - lowering efficacy of bimatoprost 0 . 03 % and travoprost 0 . 004 % in patients with glaucoma or ocular hypertension .", "", +57604, Author, 211, 220, "Cantor LB", "", +57605, Author, 229, 235, "Hoop J", "", +57606, Author, 238, 246, "Morgan L", "", +57607, Author, 249, 257, "Wudunn D", "", +57608, Author, 260, 269, "Catoira Y", "", +57609, Bimatoprost, 272, 283, "Bimatoprost", "", +57610, USA, 450, 453, "USA", "", +57611, PublicationYear, 507, 511, "2006", "", +57612, ObjectiveDescription, 547, 704, "To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure ( IOP ) for the treatment of glaucoma and ocular hypertension .", "", +57613, Prospective, 715, 726, "Prospective", "", +57614, Randomized, 729, 739, "randomised", "", +57615, Blind, 742, 764, "investigator - blinded", "", +57616, Parallel, 767, 783, "parallel - group", "", +57617, NumberPatientsCT, 867, 870, "157", "", +57618, Randomized, 878, 888, "randomised", "", +57619, Bimatoprost, 892, 903, "bimatoprost", "", +57620, Travoprost, 907, 917, "travoprost", "", +57621, Duration, 922, 930, "6 months", "", +57622, TimePoint, 948, 956, "baseline", "", +57623, TimePoint, 959, 965, "1 week", "", +57624, TimePoint, 972, 990, "1 , 3 and 6 months", "", +57625, TimePoint, 976, 990, "3 and 6 months", "", +57626, TimePoint, 982, 990, "6 months", "", +57627, IOP, 993, 996, "IOP", "", +57628, TimePoint, 1074, 1082, "baseline", "", +57629, TimePoint, 1090, 1104, "3 and 6 months", "", +57630, TimePoint, 1096, 1104, "6 months", "", +57631, IOP, 1177, 1180, "IOP", "", +57632, TimePoint, 1184, 1192, "baseline", "", +57633, PValueBL, 1231, 1247, "p > or = 0 . 741", "", +57634, TimePoint, 1258, 1266, "6 months", "", +57635, IOP, 1302, 1305, "IOP", "", +57636, PValueChangeValue, 1328, 1344, "p < or = 0 . 001", "", +57637, TimePoint, 1355, 1363, "6 months", "", +57638, Mean, 1366, 1370, "mean", "", +57639, IOP, 1371, 1374, "IOP", "", +57640, Reduction, 1402, 1407, "7 . 1", "", +57641, mmHg, 1408, 1413, "mm Hg", "", +57642, RelativeReduction, 1416, 1422, "27 . 9", "", +57643, Bimatoprost, 1432, 1443, "bimatoprost", "", +57644, NumberPatientsArm, 1450, 1452, "76", "", +57647, Reduction, 1459, 1464, "5 . 7", "", +57648, mmHg, 1465, 1470, "mm Hg", "", +57649, RelativeReduction, 1473, 1479, "23 . 3", "", +57646, Travoprost, 1489, 1499, "travoprost", "", +57645, NumberPatientsArm, 1506, 1508, "81", "", +57650, PValueChangeValue, 1511, 1522, "p = 0 . 014", "", +57651, Mean, 1542, 1546, "mean", "", +57653, IOP, 1547, 1550, "IOP", "", +57655, Reduction, 1565, 1570, "5 . 9", "", +57659, mmHg, 1571, 1576, "mm Hg", "", +57667, Bimatoprost, 1582, 1593, "bimatoprost", "", +57663, RelativeReduction, 1596, 1602, "25 . 3", "", +57656, Reduction, 1611, 1616, "5 . 2", "", +57660, mmHg, 1617, 1622, "mm Hg", "", +57664, RelativeReduction, 1625, 1631, "22 . 4", "", +57669, Travoprost, 1641, 1651, "travoprost", "", +57671, PValueChangeValue, 1654, 1665, "p = 0 . 213", "", +57652, Mean, 1689, 1693, "mean", "", +57654, IOP, 1694, 1697, "IOP", "", +57657, Reduction, 1712, 1717, "5 . 3", "", +57661, mmHg, 1718, 1723, "mm Hg", "", +57665, RelativeReduction, 1726, 1732, "22 . 5", "", +57668, Bimatoprost, 1742, 1753, "bimatoprost", "", +57658, Reduction, 1758, 1763, "4 . 5", "", +57662, mmHg, 1764, 1769, "mm Hg", "", +57666, RelativeReduction, 1772, 1778, "18 . 9", "", +57672, PValueChangeValue, 1783, 1794, "p = 0 . 207", "", +57670, Travoprost, 1802, 1812, "travoprost", "", +57674, ConclusionComment, 1956, 2022, "Bimatoprost provided greater mean IOP reductions than travoprost .", "", +57675, Bimatoprost, 1956, 1967, "Bimatoprost", "", +57676, Mean, 1985, 1989, "mean", "", +57677, IOP, 1990, 1993, "IOP", "", +57678, Travoprost, 2010, 2020, "travoprost", "", +57679, PMID, 2087, 2095, "16825272", "", diff --git a/data/gl 16825272_jshahinitiran.n-triples b/data/gl 16825272_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16825272_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16825272_tstrakeljahn.annodb b/data/gl 16825272_tstrakeljahn.annodb new file mode 100644 index 0000000..00c3b29 --- /dev/null +++ b/data/gl 16825272_tstrakeljahn.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +79710, Journal, 0, 15, "Br J Ophthalmol", "", +79711, PublicationYear, 18, 22, "2006", "", +79712, IOP, 70, 90, "Intraocular pressure", "", +79729, Title, 70, 210, "Intraocular pressure - lowering efficacy of bimatoprost 0 . 03 % and travoprost 0 . 004 % in patients with glaucoma or ocular hypertension .", "", +79713, Bimatoprost, 114, 125, "bimatoprost", "", +79717, DoseValue, 126, 132, "0 . 03", "", +79719, Percentage, 133, 134, "%", "", +79714, Travoprost, 139, 149, "travoprost", "", +79718, DoseValue, 150, 157, "0 . 004", "", +79720, Percentage, 158, 159, "%", "", +79715, Glaucoma, 177, 185, "glaucoma", "", +79716, OcularHypertension, 189, 208, "ocular hypertension", "", +79721, Author, 211, 220, "Cantor LB", "", +79722, Author, 229, 235, "Hoop J", "", +79723, Author, 238, 246, "Morgan L", "", +79724, Author, 249, 257, "Wudunn D", "", +79725, Author, 260, 269, "Catoira Y", "", +79726, Bimatoprost, 272, 283, "Bimatoprost", "", +79727, Travoprost, 286, 296, "Travoprost", "", +79728, USA, 450, 453, "USA", "", +79731, Bimatoprost, 577, 588, "bimatoprost", "", +79732, Travoprost, 593, 603, "travoprost", "", +79733, IOP, 620, 640, "intraocular pressure", "", +79734, IOP, 643, 646, "IOP", "", +79736, Glaucoma, 670, 678, "glaucoma", "", +79737, OcularHypertension, 683, 702, "ocular hypertension", "", +79738, Prospective, 715, 726, "Prospective", "", +79739, Randomized, 729, 739, "randomised", "", +79740, Blind, 742, 764, "investigator - blinded", "", +79742, Parallel, 767, 775, "parallel", "", +79743, ClinicalTrial, 784, 798, "clinical trial", "", +79744, Glaucoma, 835, 843, "glaucoma", "", +79746, NumberPatientsCT, 867, 870, "157", "", +79748, Randomized, 878, 888, "randomised", "", +79749, Bimatoprost, 892, 903, "bimatoprost", "", +79750, Travoprost, 907, 917, "travoprost", "", +79751, Duration, 922, 930, "6 months", "", +79752, TimePoint, 945, 956, "at baseline", "", +79753, TimePoint, 959, 965, "1 week", "", +79756, TimePoint, 972, 990, "1 , 3 and 6 months", "", +79755, TimePoint, 976, 990, "3 and 6 months", "", +79754, TimePoint, 982, 990, "6 months", "", +79757, IOP, 993, 996, "IOP", "", +79758, Morning, 1013, 1020, "09 : 00", "", +79760, Afternoon, 1049, 1056, "13 : 00", "", +79761, Afternoon, 1061, 1068, "16 : 00", "", +79763, TimePoint, 1071, 1082, "at baseline", "", +79773, TimePoint, 1090, 1104, "3 and 6 months", "", +79771, TimePoint, 1096, 1104, "6 months", "", +79794, IOP, 1177, 1180, "IOP", "", +79795, TimePoint, 1181, 1192, "at baseline", "", +79799, Morning, 1198, 1205, "09 : 00", "", +79797, Afternoon, 1208, 1215, "13 : 00", "", +79798, Afternoon, 1219, 1226, "16 : 00", "", +79800, PvalueDiff, 1233, 1247, "> or = 0 . 741", "", +79801, TimePoint, 1252, 1266, "After 6 months", "", +79804, ObservedResult, 1252, 1348, "After 6 months , both drugs significantly reduced IOP at every time point ( p < or = 0 . 001 ) .", "", +79802, IOP, 1302, 1305, "IOP", "", +79803, PvalueDiff, 1330, 1344, "< or = 0 . 001", "", +79806, TimePoint, 1349, 1363, "After 6 months", "", +79807, Mean, 1366, 1370, "mean", "", +79808, IOP, 1371, 1374, "IOP", "", +79809, Morning, 1388, 1395, "09 : 00", "", +79810, Reduction, 1402, 1407, "7 . 1", "", +79814, mmHg, 1408, 1413, "mm Hg", "", +79812, RelativeReduction, 1416, 1422, "27 . 9", "", +79817, Bimatoprost, 1432, 1443, "bimatoprost", "", +79819, NumberPatientsArm, 1450, 1452, "76", "", +79811, Reduction, 1459, 1464, "5 . 7", "", +79816, mmHg, 1465, 1470, "mm Hg", "", +79813, RelativeReduction, 1473, 1479, "23 . 3", "", +79818, Travoprost, 1489, 1499, "travoprost", "", +79820, NumberPatientsArm, 1506, 1508, "81", "", +79821, PvalueDiff, 1513, 1522, "= 0 . 014", "", +79822, Afternoon, 1530, 1537, "13 : 00", "", +79823, Mean, 1542, 1546, "mean", "", +79825, IOP, 1547, 1550, "IOP", "", +79827, Reduction, 1565, 1570, "5 . 9", "", +79829, mmHg, 1571, 1576, "mm Hg", "", +79833, Bimatoprost, 1582, 1593, "bimatoprost", "", +79837, RelativeReduction, 1596, 1602, "25 . 3", "", +79831, mmHg, 1617, 1622, "mm Hg", "", +79838, RelativeReduction, 1625, 1631, "22 . 4", "", +79835, Travoprost, 1641, 1651, "travoprost", "", +79841, PvalueDiff, 1656, 1665, "= 0 . 213", "", +79824, Mean, 1689, 1693, "mean", "", +79826, IOP, 1694, 1697, "IOP", "", +79828, Reduction, 1712, 1717, "5 . 3", "", +79830, mmHg, 1718, 1723, "mm Hg", "", +79839, RelativeReduction, 1726, 1732, "22 . 5", "", +79834, Bimatoprost, 1742, 1753, "bimatoprost", "", +79832, mmHg, 1764, 1769, "mm Hg", "", +79840, RelativeReduction, 1772, 1778, "18 . 9", "", +79842, PvalueDiff, 1785, 1794, "= 0 . 207", "", +79836, Travoprost, 1802, 1812, "travoprost", "", +79844, ObservedResult, 1815, 1941, "Both study drugs were well tolerated , with ocular redness the most commonly reported adverse event in both treatment groups .", "", +79845, Bimatoprost, 1956, 1967, "Bimatoprost", "", +79850, ConclusionComment, 1956, 2022, "Bimatoprost provided greater mean IOP reductions than travoprost .", "", +79846, Mean, 1985, 1989, "mean", "", +79847, IOP, 1990, 1993, "IOP", "", +79848, Travoprost, 2010, 2020, "travoprost", "", +79849, PMID, 2087, 2095, "16825272", "", diff --git a/data/gl 16825272_tstrakeljahn.n-triples b/data/gl 16825272_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16825272_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16968583_admin.annodb b/data/gl 16968583_admin.annodb new file mode 100644 index 0000000..b261521 --- /dev/null +++ b/data/gl 16968583_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2006", "", " \"2006\"." +2, Title, 55, 224, "Comparison of the efficacy and safety of travoprost with a fixed - combination of dorzolamide and timolol in patients with open - angle glaucoma or ocular hypertension .", "", " \"Comparison of the efficacy and safety of travoprost with a fixed - combination of dorzolamide and timolol in patients with open - angle glaucoma or ocular hypertension .\"." +3, Travoprost, 96, 106, "travoprost", "", +6, Dorz/TimFC, 114, 160, "fixed - combination of dorzolamide and timolol", "", +4, Dorzolamide, 137, 148, "dorzolamide", "", +5, Timolol, 153, 160, "timolol", "", +180, Precondition, 164, 222, "patients with open - angle glaucoma or ocular hypertension", "", " \"patients with open - angle glaucoma or ocular hypertension\"." +103574, OpenAngleGlaucoma, 178, 199, "open - angle glaucoma", "", +8, OcularHypertension, 203, 222, "ocular hypertension", "", +9, Author, 225, 237, "Suzuki ER Jr", "", " \"Suzuki ER Jr\"." +10, Author, 246, 257, "Franklin LM", "", " \"Franklin LM\"." +11, Author, 260, 271, "da Silva LJ", "", " \"da Silva LJ\"." +12, Author, 274, 287, "Figueiredo CR", "", " \"Figueiredo CR\"." +13, Author, 290, 298, "Netto JA", "", " \"Netto JA\"." +14, Author, 301, 311, "Batista WD", "", " \"Batista WD\"." +15, Glaucoma, 341, 349, "Glaucoma", "", +16, Brazil, 407, 413, "Brazil", "", " ." +17, ObjectiveDescription, 452, 666, "The purpose of this study was to compare travoprost ( TRAV ; travoprost 0 . 004 % ) and the fixed - combination of dorzolamide / timolol ( DTFC ; dorzolamide 2 . 0 % / timolol maleate 0 . 5 % ) ophthalmic solutions", "", " \"The purpose of this study was to compare travoprost ( TRAV ; travoprost 0 . 004 % ) and the fixed - combination of dorzolamide / timolol ( DTFC ; dorzolamide 2 . 0 % / timolol maleate 0 . 5 % ) ophthalmic solutions\"." +19, Travoprost, 493, 503, "travoprost", "", " ." +20, Travoprost, 506, 510, "TRAV", "", +21, Travoprost, 513, 523, "travoprost", "", +28, DoseValue, 524, 531, "0 . 004", "", " \"0 . 004\"." +104, Percentage, 532, 533, "%", "", " ." +26, Dorz/TimFC, 544, 588, "fixed - combination of dorzolamide / timolol", "", " ." +22, Dorzolamide, 567, 578, "dorzolamide", "", +24, Timolol, 581, 588, "timolol", "", +27, Dorz/TimFC, 591, 595, "DTFC", "", +23, Dorzolamide, 598, 609, "dorzolamide", "", +29, DoseValue, 610, 615, "2 . 0", "", +113, Percentage, 616, 617, "%", "", +25, Timolol, 620, 635, "timolol maleate", "", +30, DoseValue, 636, 641, "0 . 5", "", +114, Percentage, 642, 643, "%", "", +18, ObjectiveDescription, 667, 796, "for reducing intraocular pressure ( IOP ) in patients with primary open - angle glaucoma ( OAG ) or ocular hypertension ( OHT ) .", "", " \"for reducing intraocular pressure ( IOP ) in patients with primary open - angle glaucoma ( OAG ) or ocular hypertension ( OHT ) .\"." +31, IOP, 680, 700, "intraocular pressure", "", +32, IOP, 703, 706, "IOP", "", +33, Primary_OpenAngleGlaucoma, 726, 755, "primary open - angle glaucoma", "", " ." +118, OpenAngleGlaucoma, 758, 761, "OAG", "", +35, OcularHypertension, 767, 786, "ocular hypertension", "", " ." +36, OcularHypertension, 789, 792, "OHT", "", +37, Randomized, 818, 828, "randomized", "", " ." +38, Blind, 829, 842, "single masked", "", " ." +39, Parallel, 856, 864, "parallel", "", " ." +40, Travoprost, 880, 884, "TRAV", "", +41, NumberPatientsArm, 897, 899, "29", "", " \"29\"." +43, Frequency, 908, 918, "once daily", "", " \"once daily\"." +106356, Evening, 922, 931, "9 : 00 PM", "", " ." +45, Dorz/TimFC, 942, 946, "DTFC", "", +42, NumberPatientsArm, 959, 961, "27", "", " \"27\"." +44, Frequency, 970, 981, "twice daily", "", " \"twice daily\"." +106357, Morning, 985, 994, "9 : 00 AM", "", " ." +106358, Evening, 999, 1008, "9 : 00 PM", "", " ." +46, IOP, 1011, 1014, "IOP", "", +47, TimePoint, 1031, 1039, "baseline", "", +48, TimePoint, 1056, 1063, "3 weeks", "", +49, TimePoint, 1068, 1075, "6 weeks", "", +139, TimePoint, 1092, 1101, "8 : 00 AM", "", +140, TimePoint, 1104, 1114, "12 : 00 PM", "", +141, TimePoint, 1117, 1126, "4 : 00 PM", "", +142, TimePoint, 1133, 1142, "8 : 00 PM", "", +50, Mean, 1155, 1159, "Mean", "", " . ." +51, IOP, 1168, 1171, "IOP", "", " . ." +52, Reduction, 1231, 1236, "7 . 5", "", " \"7 . 5\"." +58, RelativeReduction, 1239, 1245, "32 . 7", "", " \"32 . 7\"." +53, Reduction, 1254, 1259, "7 . 1", "", " \"7 . 5\"." +59, RelativeReduction, 1262, 1268, "30 . 7", "", " \"30 . 7\"." +56, mmHg, 1273, 1277, "mmHg", "", " ." +62, Travoprost, 1282, 1286, "TRAV", "", +54, Reduction, 1291, 1296, "4 . 8", "", " \"4 . 8\"." +60, RelativeReduction, 1299, 1305, "23 . 1", "", " \"23 . 1\"." +55, Reduction, 1314, 1319, "4 . 5", "", " \"4 . 5\"." +61, RelativeReduction, 1322, 1328, "21 . 7", "", " \"21 . 7\"." +57, mmHg, 1333, 1337, "mmHg", "", +63, Dorz/TimFC, 1342, 1346, "DTFC", "", +64, TimePoint, 1350, 1357, "3 weeks", "", " \"3 weeks\". \"3 weeks\"." +65, TimePoint, 1362, 1369, "6 weeks", "", " \"6 weeks\". \"6 weeks\"." +66, IOP, 1399, 1402, "IOP", "", +67, Travoprost, 1436, 1440, "TRAV", "", +68, TimePoint, 1483, 1495, "3 and 6 week", "", +69, TimePoint, 1489, 1495, "6 week", "", +70, PvalueDiff, 1547, 1562, "p & lt ; 0 . 01", "", " \"p & lt ; 0 . 01\". \"p & lt ; 0 . 01\"." +71, Duration, 1629, 1635, "6 week", "", " \"6 week\"." +168, ObservedResult, 1644, 1726, "Some factors such as taste perversion were reported more often in the DTFC group .", "", " \"Some factors such as taste perversion were reported more often in the DTFC group .\"." +103575, EndPointDescription, 1665, 1681, "taste perversion", "", " . ." +72, Dorz/TimFC, 1714, 1718, "DTFC", "", +74, ConclusionComment, 1741, 1924, "Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination .", "", " \"Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination .\"." +75, Travoprost, 1741, 1751, "Travoprost", "", +76, IOP, 1801, 1804, "IOP", "", +77, IOP, 1833, 1836, "IOP", "", +78, Dorzolamide, 1859, 1870, "dorzolamide", "", +80, Dorz/TimFC, 1859, 1922, "dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination", "", +81, DoseValue, 1871, 1876, "2 . 0", "", +176, Percentage, 1877, 1878, "%", "", +79, Timolol, 1881, 1896, "timolol maleate", "", +82, DoseValue, 1897, 1902, "0 . 5", "", +177, Percentage, 1903, 1904, "%", "", +83, PMID, 1967, 1975, "16968583", "", " \"16968583\"." diff --git a/data/gl 16968583_admin.n-triples b/data/gl 16968583_admin.n-triples new file mode 100644 index 0000000..d4f8812 --- /dev/null +++ b/data/gl 16968583_admin.n-triples @@ -0,0 +1,137 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of the efficacy and safety of travoprost with a fixed - combination of dorzolamide and timolol in patients with open - angle glaucoma or ocular hypertension ." . + "Suzuki ER Jr" . + "2006" . + "Curr Med Res Opin ." . + "16968583" . + . + "Franklin LM" . + "da Silva LJ" . + "Figueiredo CR" . + "Netto JA" . + "Batista WD" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The purpose of this study was to compare travoprost ( TRAV ; travoprost 0 . 004 % ) and the fixed - combination of dorzolamide / timolol ( DTFC ; dorzolamide 2 . 0 % / timolol maleate 0 . 5 % ) ophthalmic solutions" . + "6 week" . + . + . + . + "Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination ." . + . + . + . + . + . + "for reducing intraocular pressure ( IOP ) in patients with primary open - angle glaucoma ( OAG ) or ocular hypertension ( OHT ) ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint tp" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm t" . + "29" . + . + . + . + . + . + "Arm dt" . + "27" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention t" . + . + "once daily" . + . + . + "Intervention dt" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication t" . + . + "0 . 004" . + . + . + . + "Medication dT" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP w3 t" . + . + "7 . 5" . + "32 . 7" . + "3 weeks" . + . + "Outcome IOP w6 t" . + . + "7 . 1" . + "30 . 7" . + "6 weeks" . + . + "Outcome IOP w3 dt" . + . + "4 . 8" . + "23 . 1" . + "3 weeks" . + . + "Outcome IOP w6 dt" . + . + "4 . 5" . + "21 . 7" . + "6 weeks" . + . + "Outcome tp dt" . + . + "Some factors such as taste perversion were reported more often in the DTFC group ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP w3" . + "p & lt ; 0 . 01" . + . + . + . + "DiffBetweenGroups IOP w6" . + "p & lt ; 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16968583_export.csv b/data/gl 16968583_export.csv new file mode 100644 index 0000000..2ee1b41 --- /dev/null +++ b/data/gl 16968583_export.csv @@ -0,0 +1,443 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +546, 1, 1, 1, 0, 4, 0, 4, "Curr" +546, 1, 2, 2, 5, 8, 5, 8, "Med" +546, 1, 3, 3, 9, 12, 9, 12, "Res" +546, 1, 4, 4, 13, 17, 13, 17, "Opin" +546, 1, 5, 5, 18, 19, 18, 19, "." +546, 2, 1, 6, 0, 4, 20, 24, "2006" +546, 2, 2, 7, 5, 8, 25, 28, "Sep" +546, 2, 3, 8, 9, 10, 29, 30, ";" +546, 2, 4, 9, 11, 13, 31, 33, "22" +546, 2, 5, 10, 14, 15, 34, 35, "(" +546, 2, 6, 11, 16, 17, 36, 37, "9" +546, 2, 7, 12, 18, 19, 38, 39, ")" +546, 2, 8, 13, 20, 21, 40, 41, ":" +546, 2, 9, 14, 22, 26, 42, 46, "1799" +546, 2, 10, 15, 27, 28, 47, 48, "-" +546, 2, 11, 16, 29, 32, 49, 52, "805" +546, 2, 12, 17, 33, 34, 53, 54, "." +546, 3, 1, 18, 0, 10, 55, 65, "Comparison" +546, 3, 2, 19, 11, 13, 66, 68, "of" +546, 3, 3, 20, 14, 17, 69, 72, "the" +546, 3, 4, 21, 18, 26, 73, 81, "efficacy" +546, 3, 5, 22, 27, 30, 82, 85, "and" +546, 3, 6, 23, 31, 37, 86, 92, "safety" +546, 3, 7, 24, 38, 40, 93, 95, "of" +546, 3, 8, 25, 41, 51, 96, 106, "travoprost" +546, 3, 9, 26, 52, 56, 107, 111, "with" +546, 3, 10, 27, 57, 58, 112, 113, "a" +546, 3, 11, 28, 59, 64, 114, 119, "fixed" +546, 3, 12, 29, 65, 66, 120, 121, "-" +546, 3, 13, 30, 67, 78, 122, 133, "combination" +546, 3, 14, 31, 79, 81, 134, 136, "of" +546, 3, 15, 32, 82, 93, 137, 148, "dorzolamide" +546, 3, 16, 33, 94, 97, 149, 152, "and" +546, 3, 17, 34, 98, 105, 153, 160, "timolol" +546, 3, 18, 35, 106, 108, 161, 163, "in" +546, 3, 19, 36, 109, 117, 164, 172, "patients" +546, 3, 20, 37, 118, 122, 173, 177, "with" +546, 3, 21, 38, 123, 127, 178, 182, "open" +546, 3, 22, 39, 128, 129, 183, 184, "-" +546, 3, 23, 40, 130, 135, 185, 190, "angle" +546, 3, 24, 41, 136, 144, 191, 199, "glaucoma" +546, 3, 25, 42, 145, 147, 200, 202, "or" +546, 3, 26, 43, 148, 154, 203, 209, "ocular" +546, 3, 27, 44, 155, 167, 210, 222, "hypertension" +546, 3, 28, 45, 168, 169, 223, 224, "." +546, 4, 1, 46, 0, 6, 225, 231, "Suzuki" +546, 4, 2, 47, 7, 9, 232, 234, "ER" +546, 4, 3, 48, 10, 12, 235, 237, "Jr" +546, 4, 4, 49, 13, 14, 238, 239, "(" +546, 4, 5, 50, 15, 16, 240, 241, "1" +546, 4, 6, 51, 17, 18, 242, 243, ")" +546, 4, 7, 52, 19, 20, 244, 245, "," +546, 4, 8, 53, 21, 29, 246, 254, "Franklin" +546, 4, 9, 54, 30, 32, 255, 257, "LM" +546, 4, 10, 55, 33, 34, 258, 259, "," +546, 4, 11, 56, 35, 37, 260, 262, "da" +546, 4, 12, 57, 38, 43, 263, 268, "Silva" +546, 4, 13, 58, 44, 46, 269, 271, "LJ" +546, 4, 14, 59, 47, 48, 272, 273, "," +546, 4, 15, 60, 49, 59, 274, 284, "Figueiredo" +546, 4, 16, 61, 60, 62, 285, 287, "CR" +546, 4, 17, 62, 63, 64, 288, 289, "," +546, 4, 18, 63, 65, 70, 290, 295, "Netto" +546, 4, 19, 64, 71, 73, 296, 298, "JA" +546, 4, 20, 65, 74, 75, 299, 300, "," +546, 4, 21, 66, 76, 83, 301, 308, "Batista" +546, 4, 22, 67, 84, 86, 309, 311, "WD" +546, 4, 23, 68, 87, 88, 312, 313, "." +546, 5, 1, 69, 0, 6, 314, 320, "Author" +546, 5, 2, 70, 7, 18, 321, 332, "information" +546, 5, 3, 71, 19, 20, 333, 334, ":" +546, 5, 4, 72, 21, 22, 335, 336, "(" +546, 5, 5, 73, 23, 24, 337, 338, "1" +546, 5, 6, 74, 25, 26, 339, 340, ")" +546, 5, 7, 75, 27, 35, 341, 349, "Glaucoma" +546, 5, 8, 76, 36, 43, 350, 357, "Service" +546, 5, 9, 77, 44, 46, 358, 360, "of" +546, 5, 10, 78, 47, 52, 361, 366, "Santa" +546, 5, 11, 79, 53, 57, 367, 371, "Casa" +546, 5, 12, 80, 58, 60, 372, 374, "of" +546, 5, 13, 81, 61, 65, 375, 379, "Belo" +546, 5, 14, 82, 66, 75, 380, 389, "Horizonte" +546, 5, 15, 83, 76, 77, 390, 391, "-" +546, 5, 16, 84, 78, 83, 392, 397, "Minas" +546, 5, 17, 85, 84, 90, 398, 404, "Gerais" +546, 5, 18, 86, 91, 92, 405, 406, "," +546, 5, 19, 87, 93, 99, 407, 413, "Brazil" +546, 5, 20, 88, 100, 101, 414, 415, "." +546, 6, 1, 89, 0, 8, 416, 424, "drsuzuki" +546, 6, 2, 90, 9, 10, 425, 426, "@" +546, 6, 3, 91, 11, 14, 427, 430, "uol" +546, 6, 4, 92, 15, 16, 431, 432, "." +546, 6, 5, 93, 17, 20, 433, 436, "com" +546, 6, 6, 94, 21, 22, 437, 438, "." +546, 6, 7, 95, 23, 25, 439, 441, "br" +546, 6, 8, 96, 26, 33, 442, 449, "PURPOSE" +546, 6, 9, 97, 34, 35, 450, 451, ":" +546, 6, 10, 98, 36, 39, 452, 455, "The" +546, 6, 11, 99, 40, 47, 456, 463, "purpose" +546, 6, 12, 100, 48, 50, 464, 466, "of" +546, 6, 13, 101, 51, 55, 467, 471, "this" +546, 6, 14, 102, 56, 61, 472, 477, "study" +546, 6, 15, 103, 62, 65, 478, 481, "was" +546, 6, 16, 104, 66, 68, 482, 484, "to" +546, 6, 17, 105, 69, 76, 485, 492, "compare" +546, 6, 18, 106, 77, 87, 493, 503, "travoprost" +546, 6, 19, 107, 88, 89, 504, 505, "(" +546, 6, 20, 108, 90, 94, 506, 510, "TRAV" +546, 6, 21, 109, 95, 96, 511, 512, ";" +546, 6, 22, 110, 97, 107, 513, 523, "travoprost" +546, 6, 23, 111, 108, 109, 524, 525, "0" +546, 6, 24, 112, 110, 111, 526, 527, "." +546, 6, 25, 113, 112, 115, 528, 531, "004" +546, 6, 26, 114, 116, 117, 532, 533, "%" +546, 6, 27, 115, 118, 119, 534, 535, ")" +546, 6, 28, 116, 120, 123, 536, 539, "and" +546, 6, 29, 117, 124, 127, 540, 543, "the" +546, 6, 30, 118, 128, 133, 544, 549, "fixed" +546, 6, 31, 119, 134, 135, 550, 551, "-" +546, 6, 32, 120, 136, 147, 552, 563, "combination" +546, 6, 33, 121, 148, 150, 564, 566, "of" +546, 6, 34, 122, 151, 162, 567, 578, "dorzolamide" +546, 6, 35, 123, 163, 164, 579, 580, "/" +546, 6, 36, 124, 165, 172, 581, 588, "timolol" +546, 6, 37, 125, 173, 174, 589, 590, "(" +546, 6, 38, 126, 175, 179, 591, 595, "DTFC" +546, 6, 39, 127, 180, 181, 596, 597, ";" +546, 6, 40, 128, 182, 193, 598, 609, "dorzolamide" +546, 6, 41, 129, 194, 195, 610, 611, "2" +546, 6, 42, 130, 196, 197, 612, 613, "." +546, 6, 43, 131, 198, 199, 614, 615, "0" +546, 6, 44, 132, 200, 201, 616, 617, "%" +546, 6, 45, 133, 202, 203, 618, 619, "/" +546, 6, 46, 134, 204, 211, 620, 627, "timolol" +546, 6, 47, 135, 212, 219, 628, 635, "maleate" +546, 6, 48, 136, 220, 221, 636, 637, "0" +546, 6, 49, 137, 222, 223, 638, 639, "." +546, 6, 50, 138, 224, 225, 640, 641, "5" +546, 6, 51, 139, 226, 227, 642, 643, "%" +546, 6, 52, 140, 228, 229, 644, 645, ")" +546, 6, 53, 141, 230, 240, 646, 656, "ophthalmic" +546, 6, 54, 142, 241, 250, 657, 666, "solutions" +546, 6, 55, 143, 251, 254, 667, 670, "for" +546, 6, 56, 144, 255, 263, 671, 679, "reducing" +546, 6, 57, 145, 264, 275, 680, 691, "intraocular" +546, 6, 58, 146, 276, 284, 692, 700, "pressure" +546, 6, 59, 147, 285, 286, 701, 702, "(" +546, 6, 60, 148, 287, 290, 703, 706, "IOP" +546, 6, 61, 149, 291, 292, 707, 708, ")" +546, 6, 62, 150, 293, 295, 709, 711, "in" +546, 6, 63, 151, 296, 304, 712, 720, "patients" +546, 6, 64, 152, 305, 309, 721, 725, "with" +546, 6, 65, 153, 310, 317, 726, 733, "primary" +546, 6, 66, 154, 318, 322, 734, 738, "open" +546, 6, 67, 155, 323, 324, 739, 740, "-" +546, 6, 68, 156, 325, 330, 741, 746, "angle" +546, 6, 69, 157, 331, 339, 747, 755, "glaucoma" +546, 6, 70, 158, 340, 341, 756, 757, "(" +546, 6, 71, 159, 342, 345, 758, 761, "OAG" +546, 6, 72, 160, 346, 347, 762, 763, ")" +546, 6, 73, 161, 348, 350, 764, 766, "or" +546, 6, 74, 162, 351, 357, 767, 773, "ocular" +546, 6, 75, 163, 358, 370, 774, 786, "hypertension" +546, 6, 76, 164, 371, 372, 787, 788, "(" +546, 6, 77, 165, 373, 376, 789, 792, "OHT" +546, 6, 78, 166, 377, 378, 793, 794, ")" +546, 6, 79, 167, 379, 380, 795, 796, "." +546, 7, 1, 168, 0, 7, 797, 804, "METHODS" +546, 7, 2, 169, 8, 9, 805, 806, ":" +546, 7, 3, 170, 10, 14, 807, 811, "This" +546, 7, 4, 171, 15, 18, 812, 815, "was" +546, 7, 5, 172, 19, 20, 816, 817, "a" +546, 7, 6, 173, 21, 31, 818, 828, "randomized" +546, 7, 7, 174, 32, 38, 829, 835, "single" +546, 7, 8, 175, 39, 45, 836, 842, "masked" +546, 7, 9, 176, 46, 47, 843, 844, "," +546, 7, 10, 177, 48, 53, 845, 850, "study" +546, 7, 11, 178, 54, 58, 851, 855, "with" +546, 7, 12, 179, 59, 67, 856, 864, "parallel" +546, 7, 13, 180, 68, 76, 865, 873, "controls" +546, 7, 14, 181, 77, 78, 874, 875, "." +546, 8, 1, 182, 0, 3, 876, 879, "The" +546, 8, 2, 183, 4, 8, 880, 884, "TRAV" +546, 8, 3, 184, 9, 14, 885, 890, "group" +546, 8, 4, 185, 15, 16, 891, 892, "(" +546, 8, 5, 186, 17, 18, 893, 894, "n" +546, 8, 6, 187, 19, 20, 895, 896, "=" +546, 8, 7, 188, 21, 23, 897, 899, "29" +546, 8, 8, 189, 24, 25, 900, 901, ")" +546, 8, 9, 190, 26, 31, 902, 907, "dosed" +546, 8, 10, 191, 32, 36, 908, 912, "once" +546, 8, 11, 192, 37, 42, 913, 918, "daily" +546, 8, 12, 193, 43, 45, 919, 921, "at" +546, 8, 13, 194, 46, 47, 922, 923, "9" +546, 8, 14, 195, 48, 49, 924, 925, ":" +546, 8, 15, 196, 50, 52, 926, 928, "00" +546, 8, 16, 197, 53, 55, 929, 931, "PM" +546, 8, 17, 198, 56, 61, 932, 937, "while" +546, 8, 18, 199, 62, 65, 938, 941, "the" +546, 8, 19, 200, 66, 70, 942, 946, "DTFC" +546, 8, 20, 201, 71, 76, 947, 952, "group" +546, 8, 21, 202, 77, 78, 953, 954, "(" +546, 8, 22, 203, 79, 80, 955, 956, "n" +546, 8, 23, 204, 81, 82, 957, 958, "=" +546, 8, 24, 205, 83, 85, 959, 961, "27" +546, 8, 25, 206, 86, 87, 962, 963, ")" +546, 8, 26, 207, 88, 93, 964, 969, "dosed" +546, 8, 27, 208, 94, 99, 970, 975, "twice" +546, 8, 28, 209, 100, 105, 976, 981, "daily" +546, 8, 29, 210, 106, 108, 982, 984, "at" +546, 8, 30, 211, 109, 110, 985, 986, "9" +546, 8, 31, 212, 111, 112, 987, 988, ":" +546, 8, 32, 213, 113, 115, 989, 991, "00" +546, 8, 33, 214, 116, 118, 992, 994, "AM" +546, 8, 34, 215, 119, 122, 995, 998, "and" +546, 8, 35, 216, 123, 124, 999, 1000, "9" +546, 8, 36, 217, 125, 126, 1001, 1002, ":" +546, 8, 37, 218, 127, 129, 1003, 1005, "00" +546, 8, 38, 219, 130, 132, 1006, 1008, "PM" +546, 8, 39, 220, 133, 134, 1009, 1010, "." +546, 9, 1, 221, 0, 3, 1011, 1014, "IOP" +546, 9, 2, 222, 4, 7, 1015, 1018, "was" +546, 9, 3, 223, 8, 16, 1019, 1027, "measured" +546, 9, 4, 224, 17, 19, 1028, 1030, "at" +546, 9, 5, 225, 20, 28, 1031, 1039, "baseline" +546, 9, 6, 226, 29, 30, 1040, 1041, "," +546, 9, 7, 227, 31, 34, 1042, 1045, "and" +546, 9, 8, 228, 35, 44, 1046, 1055, "following" +546, 9, 9, 229, 45, 46, 1056, 1057, "3" +546, 9, 10, 230, 47, 52, 1058, 1063, "weeks" +546, 9, 11, 231, 53, 56, 1064, 1067, "and" +546, 9, 12, 232, 57, 58, 1068, 1069, "6" +546, 9, 13, 233, 59, 64, 1070, 1075, "weeks" +546, 9, 14, 234, 65, 67, 1076, 1078, "of" +546, 9, 15, 235, 68, 77, 1079, 1088, "treatment" +546, 9, 16, 236, 78, 80, 1089, 1091, "at" +546, 9, 17, 237, 81, 82, 1092, 1093, "8" +546, 9, 18, 238, 83, 84, 1094, 1095, ":" +546, 9, 19, 239, 85, 87, 1096, 1098, "00" +546, 9, 20, 240, 88, 90, 1099, 1101, "AM" +546, 9, 21, 241, 91, 92, 1102, 1103, "," +546, 9, 22, 242, 93, 95, 1104, 1106, "12" +546, 9, 23, 243, 96, 97, 1107, 1108, ":" +546, 9, 24, 244, 98, 100, 1109, 1111, "00" +546, 9, 25, 245, 101, 103, 1112, 1114, "PM" +546, 9, 26, 246, 104, 105, 1115, 1116, "," +546, 9, 27, 247, 106, 107, 1117, 1118, "4" +546, 9, 28, 248, 108, 109, 1119, 1120, ":" +546, 9, 29, 249, 110, 112, 1121, 1123, "00" +546, 9, 30, 250, 113, 115, 1124, 1126, "PM" +546, 9, 31, 251, 116, 117, 1127, 1128, "," +546, 9, 32, 252, 118, 121, 1129, 1132, "and" +546, 9, 33, 253, 122, 123, 1133, 1134, "8" +546, 9, 34, 254, 124, 125, 1135, 1136, ":" +546, 9, 35, 255, 126, 128, 1137, 1139, "00" +546, 9, 36, 256, 129, 131, 1140, 1142, "PM" +546, 9, 37, 257, 132, 133, 1143, 1144, "." +546, 10, 1, 258, 0, 7, 1145, 1152, "RESULTS" +546, 10, 2, 259, 8, 9, 1153, 1154, ":" +546, 10, 3, 260, 10, 14, 1155, 1159, "Mean" +546, 10, 4, 261, 15, 22, 1160, 1167, "average" +546, 10, 5, 262, 23, 26, 1168, 1171, "IOP" +546, 10, 6, 263, 27, 37, 1172, 1182, "reductions" +546, 10, 7, 264, 38, 42, 1183, 1187, "from" +546, 10, 8, 265, 43, 51, 1188, 1196, "baseline" +546, 10, 9, 266, 52, 58, 1197, 1203, "during" +546, 10, 10, 267, 59, 62, 1204, 1207, "the" +546, 10, 11, 268, 63, 69, 1208, 1214, "course" +546, 10, 12, 269, 70, 72, 1215, 1217, "of" +546, 10, 13, 270, 73, 76, 1218, 1221, "the" +546, 10, 14, 271, 77, 80, 1222, 1225, "day" +546, 10, 15, 272, 81, 85, 1226, 1230, "were" +546, 10, 16, 273, 86, 87, 1231, 1232, "7" +546, 10, 17, 274, 88, 89, 1233, 1234, "." +546, 10, 18, 275, 90, 91, 1235, 1236, "5" +546, 10, 19, 276, 92, 93, 1237, 1238, "(" +546, 10, 20, 277, 94, 96, 1239, 1241, "32" +546, 10, 21, 278, 97, 98, 1242, 1243, "." +546, 10, 22, 279, 99, 100, 1244, 1245, "7" +546, 10, 23, 280, 101, 102, 1246, 1247, "%" +546, 10, 24, 281, 103, 104, 1248, 1249, ")" +546, 10, 25, 282, 105, 108, 1250, 1253, "and" +546, 10, 26, 283, 109, 110, 1254, 1255, "7" +546, 10, 27, 284, 111, 112, 1256, 1257, "." +546, 10, 28, 285, 113, 114, 1258, 1259, "1" +546, 10, 29, 286, 115, 116, 1260, 1261, "(" +546, 10, 30, 287, 117, 119, 1262, 1264, "30" +546, 10, 31, 288, 120, 121, 1265, 1266, "." +546, 10, 32, 289, 122, 123, 1267, 1268, "7" +546, 10, 33, 290, 124, 125, 1269, 1270, "%" +546, 10, 34, 291, 126, 127, 1271, 1272, ")" +546, 10, 35, 292, 128, 132, 1273, 1277, "mmHg" +546, 10, 36, 293, 133, 136, 1278, 1281, "for" +546, 10, 37, 294, 137, 141, 1282, 1286, "TRAV" +546, 10, 38, 295, 142, 145, 1287, 1290, "and" +546, 10, 39, 296, 146, 147, 1291, 1292, "4" +546, 10, 40, 297, 148, 149, 1293, 1294, "." +546, 10, 41, 298, 150, 151, 1295, 1296, "8" +546, 10, 42, 299, 152, 153, 1297, 1298, "(" +546, 10, 43, 300, 154, 156, 1299, 1301, "23" +546, 10, 44, 301, 157, 158, 1302, 1303, "." +546, 10, 45, 302, 159, 160, 1304, 1305, "1" +546, 10, 46, 303, 161, 162, 1306, 1307, "%" +546, 10, 47, 304, 163, 164, 1308, 1309, ")" +546, 10, 48, 305, 165, 168, 1310, 1313, "and" +546, 10, 49, 306, 169, 170, 1314, 1315, "4" +546, 10, 50, 307, 171, 172, 1316, 1317, "." +546, 10, 51, 308, 173, 174, 1318, 1319, "5" +546, 10, 52, 309, 175, 176, 1320, 1321, "(" +546, 10, 53, 310, 177, 179, 1322, 1324, "21" +546, 10, 54, 311, 180, 181, 1325, 1326, "." +546, 10, 55, 312, 182, 183, 1327, 1328, "7" +546, 10, 56, 313, 184, 185, 1329, 1330, "%" +546, 10, 57, 314, 186, 187, 1331, 1332, ")" +546, 10, 58, 315, 188, 192, 1333, 1337, "mmHg" +546, 10, 59, 316, 193, 196, 1338, 1341, "for" +546, 10, 60, 317, 197, 201, 1342, 1346, "DTFC" +546, 10, 61, 318, 202, 204, 1347, 1349, "at" +546, 10, 62, 319, 205, 206, 1350, 1351, "3" +546, 10, 63, 320, 207, 212, 1352, 1357, "weeks" +546, 10, 64, 321, 213, 216, 1358, 1361, "and" +546, 10, 65, 322, 217, 218, 1362, 1363, "6" +546, 10, 66, 323, 219, 224, 1364, 1369, "weeks" +546, 10, 67, 324, 225, 226, 1370, 1371, "," +546, 10, 68, 325, 227, 239, 1372, 1384, "respectively" +546, 10, 69, 326, 240, 241, 1385, 1386, "." +546, 11, 1, 327, 0, 3, 1387, 1390, "The" +546, 11, 2, 328, 4, 11, 1391, 1398, "greater" +546, 11, 3, 329, 12, 15, 1399, 1402, "IOP" +546, 11, 4, 330, 16, 25, 1403, 1412, "reduction" +546, 11, 5, 331, 26, 29, 1413, 1416, "for" +546, 11, 6, 332, 30, 38, 1417, 1425, "patients" +546, 11, 7, 333, 39, 48, 1426, 1435, "receiving" +546, 11, 8, 334, 49, 53, 1436, 1440, "TRAV" +546, 11, 9, 335, 54, 57, 1441, 1444, "was" +546, 11, 10, 336, 58, 71, 1445, 1458, "statistically" +546, 11, 11, 337, 72, 83, 1459, 1470, "significant" +546, 11, 12, 338, 84, 86, 1471, 1473, "at" +546, 11, 13, 339, 87, 91, 1474, 1478, "both" +546, 11, 14, 340, 92, 95, 1479, 1482, "the" +546, 11, 15, 341, 96, 97, 1483, 1484, "3" +546, 11, 16, 342, 98, 101, 1485, 1488, "and" +546, 11, 17, 343, 102, 103, 1489, 1490, "6" +546, 11, 18, 344, 104, 108, 1491, 1495, "week" +546, 11, 19, 345, 109, 115, 1496, 1502, "visits" +546, 11, 20, 346, 116, 120, 1503, 1507, "when" +546, 11, 21, 347, 121, 129, 1508, 1516, "averaged" +546, 11, 22, 348, 130, 136, 1517, 1523, "across" +546, 11, 23, 349, 137, 140, 1524, 1527, "all" +546, 11, 24, 350, 141, 145, 1528, 1532, "four" +546, 11, 25, 351, 146, 150, 1533, 1537, "time" +546, 11, 26, 352, 151, 157, 1538, 1544, "points" +546, 11, 27, 353, 158, 159, 1545, 1546, "(" +546, 11, 28, 354, 160, 161, 1547, 1548, "p" +546, 11, 29, 355, 162, 163, 1549, 1550, "&" +546, 11, 30, 356, 164, 166, 1551, 1553, "lt" +546, 11, 31, 357, 167, 168, 1554, 1555, ";" +546, 11, 32, 358, 169, 170, 1556, 1557, "0" +546, 11, 33, 359, 171, 172, 1558, 1559, "." +546, 11, 34, 360, 173, 175, 1560, 1562, "01" +546, 11, 35, 361, 176, 177, 1563, 1564, ")" +546, 11, 36, 362, 178, 179, 1565, 1566, "." +546, 12, 1, 363, 0, 3, 1567, 1570, "The" +546, 12, 2, 364, 4, 7, 1571, 1574, "two" +546, 12, 3, 365, 8, 16, 1575, 1583, "products" +546, 12, 4, 366, 17, 21, 1584, 1588, "were" +546, 12, 5, 367, 22, 26, 1589, 1593, "well" +546, 12, 6, 368, 27, 28, 1594, 1595, "-" +546, 12, 7, 369, 29, 38, 1596, 1605, "tolerated" +546, 12, 8, 370, 39, 43, 1606, 1610, "over" +546, 12, 9, 371, 44, 47, 1611, 1614, "the" +546, 12, 10, 372, 48, 54, 1615, 1621, "course" +546, 12, 11, 373, 55, 57, 1622, 1624, "of" +546, 12, 12, 374, 58, 61, 1625, 1628, "the" +546, 12, 13, 375, 62, 63, 1629, 1630, "6" +546, 12, 14, 376, 64, 68, 1631, 1635, "week" +546, 12, 15, 377, 69, 74, 1636, 1641, "study" +546, 12, 16, 378, 75, 76, 1642, 1643, "." +546, 13, 1, 379, 0, 4, 1644, 1648, "Some" +546, 13, 2, 380, 5, 12, 1649, 1656, "factors" +546, 13, 3, 381, 13, 17, 1657, 1661, "such" +546, 13, 4, 382, 18, 20, 1662, 1664, "as" +546, 13, 5, 383, 21, 26, 1665, 1670, "taste" +546, 13, 6, 384, 27, 37, 1671, 1681, "perversion" +546, 13, 7, 385, 38, 42, 1682, 1686, "were" +546, 13, 8, 386, 43, 51, 1687, 1695, "reported" +546, 13, 9, 387, 52, 56, 1696, 1700, "more" +546, 13, 10, 388, 57, 62, 1701, 1706, "often" +546, 13, 11, 389, 63, 65, 1707, 1709, "in" +546, 13, 12, 390, 66, 69, 1710, 1713, "the" +546, 13, 13, 391, 70, 74, 1714, 1718, "DTFC" +546, 13, 14, 392, 75, 80, 1719, 1724, "group" +546, 13, 15, 393, 81, 82, 1725, 1726, "." +546, 14, 1, 394, 0, 11, 1727, 1738, "CONCLUSIONS" +546, 14, 2, 395, 12, 13, 1739, 1740, ":" +546, 14, 3, 396, 14, 24, 1741, 1751, "Travoprost" +546, 14, 4, 397, 25, 36, 1752, 1763, "monotherapy" +546, 14, 5, 398, 37, 45, 1764, 1772, "provided" +546, 14, 6, 399, 46, 52, 1773, 1779, "better" +546, 14, 7, 400, 53, 61, 1780, 1788, "efficacy" +546, 14, 8, 401, 62, 64, 1789, 1791, "in" +546, 14, 9, 402, 65, 70, 1792, 1797, "terms" +546, 14, 10, 403, 71, 73, 1798, 1800, "of" +546, 14, 11, 404, 74, 77, 1801, 1804, "IOP" +546, 14, 12, 405, 78, 87, 1805, 1814, "reduction" +546, 14, 13, 406, 88, 91, 1815, 1818, "and" +546, 14, 14, 407, 92, 102, 1819, 1829, "percentage" +546, 14, 15, 408, 103, 105, 1830, 1832, "of" +546, 14, 16, 409, 106, 109, 1833, 1836, "IOP" +546, 14, 17, 410, 110, 119, 1837, 1846, "reduction" +546, 14, 18, 411, 120, 128, 1847, 1855, "compared" +546, 14, 19, 412, 129, 131, 1856, 1858, "to" +546, 14, 20, 413, 132, 143, 1859, 1870, "dorzolamide" +546, 14, 21, 414, 144, 145, 1871, 1872, "2" +546, 14, 22, 415, 146, 147, 1873, 1874, "." +546, 14, 23, 416, 148, 149, 1875, 1876, "0" +546, 14, 24, 417, 150, 151, 1877, 1878, "%" +546, 14, 25, 418, 152, 153, 1879, 1880, "/" +546, 14, 26, 419, 154, 161, 1881, 1888, "timolol" +546, 14, 27, 420, 162, 169, 1889, 1896, "maleate" +546, 14, 28, 421, 170, 171, 1897, 1898, "0" +546, 14, 29, 422, 172, 173, 1899, 1900, "." +546, 14, 30, 423, 174, 175, 1901, 1902, "5" +546, 14, 31, 424, 176, 177, 1903, 1904, "%" +546, 14, 32, 425, 178, 183, 1905, 1910, "fixed" +546, 14, 33, 426, 184, 195, 1911, 1922, "combination" +546, 14, 34, 427, 196, 197, 1923, 1924, "." +546, 15, 1, 428, 0, 3, 1925, 1928, "DOI" +546, 15, 2, 429, 4, 5, 1929, 1930, ":" +546, 15, 3, 430, 6, 8, 1931, 1933, "10" +546, 15, 4, 431, 9, 10, 1934, 1935, "." +546, 15, 5, 432, 11, 15, 1936, 1940, "1185" +546, 15, 6, 433, 16, 17, 1941, 1942, "/" +546, 15, 7, 434, 18, 34, 1943, 1959, "030079906X121020" +546, 15, 8, 435, 35, 39, 1960, 1964, "PMID" +546, 15, 9, 436, 40, 41, 1965, 1966, ":" +546, 15, 10, 437, 42, 50, 1967, 1975, "16968583" +546, 15, 11, 438, 51, 52, 1976, 1977, "[" +546, 15, 12, 439, 53, 60, 1978, 1985, "Indexed" +546, 15, 13, 440, 61, 64, 1986, 1989, "for" +546, 15, 14, 441, 65, 72, 1990, 1997, "MEDLINE" +546, 15, 15, 442, 73, 74, 1998, 1999, "]" diff --git a/data/gl 16968583_jshahinitiran.annodb b/data/gl 16968583_jshahinitiran.annodb new file mode 100644 index 0000000..0d3d1b7 --- /dev/null +++ b/data/gl 16968583_jshahinitiran.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +87087, Journal, 0, 17, "Curr Med Res Opin", "", +87088, PublicationYear, 20, 24, "2006", "", +87089, Title, 55, 224, "Comparison of the efficacy and safety of travoprost with a fixed - combination of dorzolamide and timolol in patients with open - angle glaucoma or ocular hypertension .", "", +87090, Travoprost, 96, 106, "travoprost", "", +87093, Dorz/TimFC, 114, 160, "fixed - combination of dorzolamide and timolol", "", +87091, Dorzolamide, 137, 148, "dorzolamide", "", +87092, Timolol, 153, 160, "timolol", "", +87094, Primary_OpenAngleGlaucoma, 178, 199, "open - angle glaucoma", "", +87095, OcularHypertension, 203, 222, "ocular hypertension", "", +87096, Author, 225, 237, "Suzuki ER Jr", "", +87097, Author, 246, 257, "Franklin LM", "", +87098, Author, 260, 271, "da Silva LJ", "", +87099, Author, 274, 287, "Figueiredo CR", "", +87100, Author, 290, 298, "Netto JA", "", +87101, Author, 301, 311, "Batista WD", "", +87102, Glaucoma, 341, 349, "Glaucoma", "", +87103, Brazil, 407, 413, "Brazil", "", +87104, ObjectiveDescription, 452, 666, "The purpose of this study was to compare travoprost ( TRAV ; travoprost 0 . 004 % ) and the fixed - combination of dorzolamide / timolol ( DTFC ; dorzolamide 2 . 0 % / timolol maleate 0 . 5 % ) ophthalmic solutions", "", +87110, Travoprost, 493, 503, "travoprost", "", +87111, Travoprost, 506, 510, "TRAV", "", +87112, Travoprost, 513, 523, "travoprost", "", +87119, DoseValue, 524, 531, "0 . 004", "", +87117, Dorz/TimFC, 544, 588, "fixed - combination of dorzolamide / timolol", "", +87113, Dorzolamide, 567, 578, "dorzolamide", "", +87115, Timolol, 581, 588, "timolol", "", +87118, Dorz/TimFC, 591, 595, "DTFC", "", +87114, Dorzolamide, 598, 609, "dorzolamide", "", +87120, DoseValue, 610, 615, "2 . 0", "", +87116, Timolol, 620, 635, "timolol maleate", "", +87121, DoseValue, 636, 641, "0 . 5", "", +87105, ObjectiveDescription, 667, 796, "for reducing intraocular pressure ( IOP ) in patients with primary open - angle glaucoma ( OAG ) or ocular hypertension ( OHT ) .", "", +87122, IOP, 680, 700, "intraocular pressure", "", +87123, IOP, 703, 706, "IOP", "", +87124, Primary_OpenAngleGlaucoma, 726, 755, "primary open - angle glaucoma", "", +87125, Primary_OpenAngleGlaucoma, 758, 761, "OAG", "", +87126, OcularHypertension, 767, 786, "ocular hypertension", "", +87127, OcularHypertension, 789, 792, "OHT", "", +87128, Randomized, 818, 828, "randomized", "", +87129, Blind, 829, 842, "single masked", "", +87130, Parallel, 856, 864, "parallel", "", +87131, Travoprost, 880, 884, "TRAV", "", +87132, NumberPatientsArm, 897, 899, "29", "", +87134, Frequency, 908, 918, "once daily", "", +87136, Dorz/TimFC, 942, 946, "DTFC", "", +87133, NumberPatientsArm, 959, 961, "27", "", +87135, Frequency, 970, 981, "twice daily", "", +87137, IOP, 1011, 1014, "IOP", "", +87138, TimePoint, 1031, 1039, "baseline", "", +87139, TimePoint, 1056, 1063, "3 weeks", "", +87140, TimePoint, 1068, 1075, "6 weeks", "", +87141, Mean, 1155, 1159, "Mean", "", +87143, IOP, 1168, 1171, "IOP", "", +87144, Reduction, 1231, 1236, "7 . 5", "", +87150, RelativeReduction, 1239, 1245, "32 . 7", "", +87145, Reduction, 1254, 1259, "7 . 1", "", +87151, RelativeReduction, 1262, 1268, "30 . 7", "", +87148, mmHg, 1273, 1277, "mmHg", "", +87154, Travoprost, 1282, 1286, "TRAV", "", +87146, Reduction, 1291, 1296, "4 . 8", "", +87152, RelativeReduction, 1299, 1305, "23 . 1", "", +87147, Reduction, 1314, 1319, "4 . 5", "", +87153, RelativeReduction, 1322, 1328, "21 . 7", "", +87149, mmHg, 1333, 1337, "mmHg", "", +87155, Dorz/TimFC, 1342, 1346, "DTFC", "", +87156, TimePoint, 1350, 1357, "3 weeks", "", +87157, TimePoint, 1362, 1369, "6 weeks", "", +87158, IOP, 1399, 1402, "IOP", "", +87159, Travoprost, 1436, 1440, "TRAV", "", +87160, TimePoint, 1483, 1495, "3 and 6 week", "", +87161, TimePoint, 1489, 1495, "6 week", "", +87162, PvalueDiff, 1547, 1562, "p & lt ; 0 . 01", "", +87163, Duration, 1629, 1635, "6 week", "", +87164, Dorz/TimFC, 1714, 1718, "DTFC", "", +87166, ConclusionComment, 1741, 1924, "Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination .", "", +87167, Travoprost, 1741, 1751, "Travoprost", "", +87168, IOP, 1801, 1804, "IOP", "", +87169, IOP, 1833, 1836, "IOP", "", +87170, Dorzolamide, 1859, 1870, "dorzolamide", "", +87172, Dorz/TimFC, 1859, 1922, "dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination", "", +87173, DoseValue, 1871, 1876, "2 . 0", "", +87171, Timolol, 1881, 1896, "timolol maleate", "", +87174, DoseValue, 1897, 1902, "0 . 5", "", +87175, PMID, 1967, 1975, "16968583", "", diff --git a/data/gl 16968583_jshahinitiran.n-triples b/data/gl 16968583_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16968583_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 16968583_tstrakeljahn.annodb b/data/gl 16968583_tstrakeljahn.annodb new file mode 100644 index 0000000..7842540 --- /dev/null +++ b/data/gl 16968583_tstrakeljahn.annodb @@ -0,0 +1,98 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90318, Journal, 0, 17, "Curr Med Res Opin", "", +90319, PublicationYear, 20, 24, "2006", "", +90326, Title, 55, 224, "Comparison of the efficacy and safety of travoprost with a fixed - combination of dorzolamide and timolol in patients with open - angle glaucoma or ocular hypertension .", "", +90320, Travoprost, 96, 106, "travoprost", "", +90321, Dorzolamide, 137, 148, "dorzolamide", "", +90325, Dorz/TimFC, 137, 160, "dorzolamide and timolol", "", +90322, Timolol, 153, 160, "timolol", "", +90414, Precondition, 164, 222, "patients with open - angle glaucoma or ocular hypertension", "", +90323, OpenAngleGlaucoma, 178, 199, "open - angle glaucoma", "", +90324, OcularHypertension, 203, 222, "ocular hypertension", "", +90327, Author, 225, 237, "Suzuki ER Jr", "", +90328, Author, 246, 257, "Franklin LM", "", +90329, Author, 260, 271, "da Silva LJ", "", +90330, Author, 274, 287, "Figueiredo CR", "", +90331, Author, 290, 298, "Netto JA", "", +90332, Author, 301, 311, "Batista WD", "", +90333, Brazil, 407, 413, "Brazil", "", +90355, ObjectiveDescription, 452, 706, "The purpose of this study was to compare travoprost ( TRAV ; travoprost 0 . 004 % ) and the fixed - combination of dorzolamide / timolol ( DTFC ; dorzolamide 2 . 0 % / timolol maleate 0 . 5 % ) ophthalmic solutions for reducing intraocular pressure ( IOP", "", +90334, Travoprost, 493, 503, "travoprost", "", +90335, Travoprost, 506, 510, "TRAV", "", +90336, Travoprost, 513, 523, "travoprost", "", +90337, DoseValue, 524, 531, "0 . 004", "", +90338, Percentage, 532, 533, "%", "", +90339, Dorzolamide, 567, 578, "dorzolamide", "", +90342, Dorz/TimFC, 567, 588, "dorzolamide / timolol", "", +90340, Timolol, 581, 588, "timolol", "", +90341, Dorz/TimFC, 591, 595, "DTFC", "", +90343, Dorzolamide, 598, 609, "dorzolamide", "", +90345, DoseValue, 610, 615, "2 . 0", "", +90347, Percentage, 616, 617, "%", "", +90344, Timolol, 620, 635, "timolol maleate", "", +90346, DoseValue, 636, 641, "0 . 5", "", +90348, Percentage, 642, 643, "%", "", +90349, IOP, 680, 700, "intraocular pressure", "", +90350, IOP, 703, 706, "IOP", "", +90356, ObjectiveDescription, 707, 796, ") in patients with primary open - angle glaucoma ( OAG ) or ocular hypertension ( OHT ) .", "", +90351, Primary_OpenAngleGlaucoma, 726, 755, "primary open - angle glaucoma", "", +90352, OpenAngleGlaucoma, 758, 761, "OAG", "", +90353, OcularHypertension, 767, 786, "ocular hypertension", "", +90354, OcularHypertension, 789, 792, "OHT", "", +90357, Randomized, 818, 828, "randomized", "", +90358, Blind, 829, 842, "single masked", "", +90359, Parallel, 856, 864, "parallel", "", +90360, Travoprost, 880, 884, "TRAV", "", +90361, NumberPatientsArm, 897, 899, "29", "", +90362, Frequency, 908, 918, "once daily", "", +90364, TimePoint, 922, 931, "9 : 00 PM", "", +90367, Dorz/TimFC, 942, 946, "DTFC", "", +90368, NumberPatientsArm, 959, 961, "27", "", +90363, Frequency, 970, 981, "twice daily", "", +90365, TimePoint, 985, 994, "9 : 00 AM", "", +90366, TimePoint, 999, 1008, "9 : 00 PM", "", +90369, IOP, 1011, 1014, "IOP", "", +90370, TimePoint, 1031, 1039, "baseline", "", +90371, TimePoint, 1056, 1063, "3 weeks", "", +90372, TimePoint, 1068, 1075, "6 weeks", "", +90373, TimePoint, 1092, 1101, "8 : 00 AM", "", +90374, TimePoint, 1104, 1114, "12 : 00 PM", "", +90375, TimePoint, 1117, 1126, "4 : 00 PM", "", +90376, TimePoint, 1133, 1142, "8 : 00 PM", "", +90377, Mean, 1155, 1159, "Mean", "", +90378, IOP, 1168, 1171, "IOP", "", +90379, Reduction, 1231, 1236, "7 . 5", "", +90383, RelativeReduction, 1239, 1245, "32 . 7", "", +90380, Reduction, 1254, 1259, "7 . 1", "", +90384, RelativeReduction, 1262, 1268, "30 . 7", "", +90387, mmHg, 1273, 1277, "mmHg", "", +90389, Travoprost, 1282, 1286, "TRAV", "", +90381, Reduction, 1291, 1296, "4 . 8", "", +90385, RelativeReduction, 1299, 1305, "23 . 1", "", +90382, Reduction, 1314, 1319, "4 . 5", "", +90386, RelativeReduction, 1322, 1328, "21 . 7", "", +90388, mmHg, 1333, 1337, "mmHg", "", +90390, Dorz/TimFC, 1342, 1346, "DTFC", "", +90391, TimePoint, 1350, 1357, "3 weeks", "", +90392, TimePoint, 1362, 1369, "6 weeks", "", +90400, ObservedResult, 1387, 1566, "The greater IOP reduction for patients receiving TRAV was statistically significant at both the 3 and 6 week visits when averaged across all four time points ( p & lt ; 0 . 01 ) .", "", +90393, IOP, 1399, 1402, "IOP", "", +90394, Travoprost, 1436, 1440, "TRAV", "", +90396, TimePoint, 1483, 1495, "3 and 6 week", "", +90395, TimePoint, 1489, 1495, "6 week", "", +90397, PvalueDiff, 1549, 1562, "& lt ; 0 . 01", "", +90399, ObservedResult, 1567, 1643, "The two products were well - tolerated over the course of the 6 week study .", "", +90398, Duration, 1625, 1635, "the 6 week", "", +90402, ObservedResult, 1644, 1726, "Some factors such as taste perversion were reported more often in the DTFC group .", "", +90401, Dorz/TimFC, 1714, 1718, "DTFC", "", +90403, Travoprost, 1741, 1751, "Travoprost", "", +90412, ConclusionComment, 1741, 1924, "Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2 . 0 % / timolol maleate 0 . 5 % fixed combination .", "", +90404, IOP, 1801, 1804, "IOP", "", +90405, IOP, 1833, 1836, "IOP", "", +90406, Dorzolamide, 1859, 1870, "dorzolamide", "", +90408, DoseValue, 1871, 1876, "2 . 0", "", +90410, Percentage, 1877, 1878, "%", "", +90407, Timolol, 1881, 1896, "timolol maleate", "", +90409, DoseValue, 1897, 1902, "0 . 5", "", +90411, Percentage, 1903, 1904, "%", "", +90413, PMID, 1967, 1975, "16968583", "", diff --git a/data/gl 16968583_tstrakeljahn.n-triples b/data/gl 16968583_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 16968583_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17197028_admin.annodb b/data/gl 17197028_admin.annodb new file mode 100644 index 0000000..28f29a7 --- /dev/null +++ b/data/gl 17197028_admin.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2007", "", " \"2007\"." +2, Title, 68, 155, "Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients .", "", " \"Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients .\"." +68, Latanoprost, 91, 102, "latanoprost", "", +69, Travoprost, 110, 120, "travoprost", "", " ." +70, Glaucoma, 136, 144, "glaucoma", "", " . ." +3, Author, 156, 166, "Konstas AG", "", " \"Konstas AG\"." +4, Author, 175, 187, "Kozobolis VP", "", " \"Kozobolis VP\"." +5, Author, 190, 203, "Katsimpris IE", "", " \"Katsimpris IE\"." +6, Author, 206, 217, "Boboridis K", "", " \"Boboridis K\"." +7, Author, 220, 230, "Koukoula S", "", " \"Koukoula S\"." +8, Author, 233, 243, "Jenkins JN", "", " \"Jenkins JN\"." +9, Author, 246, 256, "Stewart WC", "", " \"Stewart WC\"." +10, Greece, 362, 368, "Greece", "", " ." +11, ObjectiveDescription, 383, 539, "To evaluate 24 - hour intraocular pressure ( IOP ) efficacy of latanoprost versus travoprost , each given every evening , in exfoliative glaucoma patients .", "", " \"To evaluate 24 - hour intraocular pressure ( IOP ) efficacy of latanoprost versus travoprost , each given every evening , in exfoliative glaucoma patients .\"." +12, IOP, 405, 425, "intraocular pressure", "", +13, IOP, 428, 431, "IOP", "", +14, Latanoprost, 446, 457, "latanoprost", "", +15, Travoprost, 465, 475, "travoprost", "", +84, Frequency, 489, 502, "every evening", "", " \"every evening\". \"every evening\"." +16, Glaucoma, 520, 528, "glaucoma", "", +17, Prospective, 549, 560, "Prospective", "", " ." +18, Blind, 563, 580, "observer - masked", "", +19, Crossover, 583, 592, "crossover", "", +20, NumberPatientsCT, 621, 626, "Forty", "", " \"Forty\"." +21, Glaucoma, 653, 661, "glaucoma", "", +98, Precondition, 674, 711, "Patients with a pressure of > 24 mmHg", "", " \"Patients with a pressure of > 24 mmHg\"." +92, mmHg, 707, 711, "mmHg", "", +24, Randomized, 717, 727, "randomized", "", " ." +25, Latanoprost, 731, 742, "latanoprost", "", " . ." +26, Travoprost, 746, 756, "travoprost", "", +27, Duration, 764, 772, "8 - week", "", " \"8 - week\"." +28, Duration, 798, 806, "6 - week", "", +29, IOP, 976, 979, "IOP", "", +86725, TimePoint, 996, 1000, "6 am", "", +86727, TimePoint, 1003, 1008, "10 am", "", +86728, TimePoint, 1011, 1015, "2 pm", "", +86729, TimePoint, 1018, 1022, "6 pm", "", +86730, TimePoint, 1025, 1030, "10 pm", "", +86731, TimePoint, 1037, 1041, "2 am", "", +30, Diurnal_IOP, 1067, 1078, "Diurnal IOP", "", " ." +31, Mean, 1095, 1099, "mean", "", " . ." +108, Diurnal_IOP, 1100, 1113, "24 - hour IOP", "", +33, BaseLineValue, 1118, 1124, "25 . 1", "", " \"25 . 1\". \"25 . 1\"." +110, SdDevBL, 1131, 1136, "2 . 5", "", " \"2 . 5\". \"2 . 5\"." +35, mmHg, 1137, 1141, "mmHg", "", " ." +86736, TimePoint, 1145, 1153, "baseline", "", +37, ResultMeasuredValue, 1156, 1162, "17 . 8", "", " \"17 . 8\"." +118, SdDevResValue, 1169, 1174, "2 . 1", "", " \"2 . 1\"." +36, mmHg, 1175, 1179, "mmHg", "", +39, Latanoprost, 1183, 1194, "latanoprost", "", +40, ResultMeasuredValue, 1201, 1207, "17 . 3", "", " \"17 . 3\"." +119, SdDevResValue, 1214, 1219, "2 . 2", "", " \"2 . 2\"." +42, mmHg, 1220, 1224, "mmHg", "", +43, Travoprost, 1228, 1238, "travoprost", "", +120, PvalueDiff, 1243, 1252, "= 0 . 001", "", " \"= 0 . 001\"." +121, TimePoint, 1324, 1328, "6 pm", "", " \"6 pm\". \"6 pm\"." +45, Travoprost, 1334, 1344, "travoprost", "", +46, IOP, 1360, 1363, "IOP", "", +47, ResultMeasuredValue, 1366, 1372, "16 . 7", "", " \"16 . 7\"." +126, SdDevResValue, 1379, 1384, "2 . 6", "", " \"2 . 6\"." +48, ResultMeasuredValue, 1388, 1394, "17 . 9", "", " \"17 . 9\"." +127, SdDevResValue, 1401, 1406, "2 . 5", "", " \"2 . 5\"." +51, mmHg, 1407, 1411, "mmHg", "", +129, PvalueDiff, 1414, 1425, "P < 0 . 001", "", " \"P < 0 . 001\"." +53, ConjunctivalHyperemia, 1457, 1479, "conjunctival hyperemia", "", " ." +54, Travoprost, 1485, 1495, "travoprost", "", +55, NumberAffected, 1502, 1504, "15", "", " \"15\"." +56, Latanoprost, 1512, 1523, "latanoprost", "", +57, NumberAffected, 1530, 1531, "6", "", " \"6\"." +134, PvalueDiff, 1536, 1544, "= 0 . 03", "", " \"= 0 . 03\"." +59, ConclusionComment, 1563, 1759, "Latanoprost and travoprost both significantly reduce the 24 - hour IOP from baseline in exfoliative glaucoma , but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon .", "", " \"Latanoprost and travoprost both significantly reduce the 24 - hour IOP from baseline in exfoliative glaucoma , but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon .\"." +60, Latanoprost, 1563, 1574, "Latanoprost", "", +61, Travoprost, 1579, 1589, "travoprost", "", +138, Diurnal_IOP, 1620, 1633, "24 - hour IOP", "", +63, Glaucoma, 1663, 1671, "glaucoma", "", +64, Travoprost, 1678, 1688, "travoprost", "", +65, PMID, 1814, 1822, "17197028", "", " \"17197028\"." diff --git a/data/gl 17197028_admin.n-triples b/data/gl 17197028_admin.n-triples new file mode 100644 index 0000000..cca48eb --- /dev/null +++ b/data/gl 17197028_admin.n-triples @@ -0,0 +1,146 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients ." . + "Konstas AG" . + "2007" . + "Ophthalmology" . + "17197028" . + . + "Kozobolis VP" . + "Katsimpris IE" . + "Boboridis K" . + "Koukoula S" . + "Jenkins JN" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate 24 - hour intraocular pressure ( IOP ) efficacy of latanoprost versus travoprost , each given every evening , in exfoliative glaucoma patients ." . + "Forty" . + "8 - week" . + . + . + . + "Latanoprost and travoprost both significantly reduce the 24 - hour IOP from baseline in exfoliative glaucoma , but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with a pressure of > 24 mmHg" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "AE" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + "Arm_tra" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "every evening" . + . + . + "Intervention_tra" . + . + "every evening" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + . + . + . + "Medication_tra" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_lat" . + . + "25 . 1" . + "2 . 5" . + "17 . 8" . + "2 . 1" . + . + "Outcome_trav" . + . + "25 . 1" . + "2 . 5" . + "17 . 3" . + "2 . 2" . + . + "Outcome_lat_1800" . + . + "16 . 7" . + "2 . 6" . + "6 pm" . + . + "Outcome_trav_1800" . + . + "17 . 9" . + "2 . 5" . + "6 pm" . + . + "AE_lat" . + . + "6" . + . + "AE_tra" . + . + "15" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "= 0 . 001" . + . + . + . + "DiffBetweenGroups_1800" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_AE" . + "= 0 . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17197028_export.csv b/data/gl 17197028_export.csv new file mode 100644 index 0000000..d5d3d68 --- /dev/null +++ b/data/gl 17197028_export.csv @@ -0,0 +1,395 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +517, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +517, 1, 2, 2, 14, 15, 14, 15, "." +517, 2, 1, 3, 0, 4, 16, 20, "2007" +517, 2, 2, 4, 5, 8, 21, 24, "Apr" +517, 2, 3, 5, 9, 10, 25, 26, ";" +517, 2, 4, 6, 11, 14, 27, 30, "114" +517, 2, 5, 7, 15, 16, 31, 32, "(" +517, 2, 6, 8, 17, 18, 33, 34, "4" +517, 2, 7, 9, 19, 20, 35, 36, ")" +517, 2, 8, 10, 21, 22, 37, 38, ":" +517, 2, 9, 11, 23, 26, 39, 42, "653" +517, 2, 10, 12, 27, 28, 43, 44, "-" +517, 2, 11, 13, 29, 30, 45, 46, "7" +517, 2, 12, 14, 31, 32, 47, 48, "." +517, 3, 1, 15, 0, 4, 49, 53, "Epub" +517, 3, 2, 16, 5, 9, 54, 58, "2006" +517, 3, 3, 17, 10, 13, 59, 62, "Dec" +517, 3, 4, 18, 14, 16, 63, 65, "29" +517, 3, 5, 19, 17, 18, 66, 67, "." +517, 4, 1, 20, 0, 8, 68, 76, "Efficacy" +517, 4, 2, 21, 9, 12, 77, 80, "and" +517, 4, 3, 22, 13, 19, 81, 87, "safety" +517, 4, 4, 23, 20, 22, 88, 90, "of" +517, 4, 5, 24, 23, 34, 91, 102, "latanoprost" +517, 4, 6, 25, 35, 41, 103, 109, "versus" +517, 4, 7, 26, 42, 52, 110, 120, "travoprost" +517, 4, 8, 27, 53, 55, 121, 123, "in" +517, 4, 9, 28, 56, 67, 124, 135, "exfoliative" +517, 4, 10, 29, 68, 76, 136, 144, "glaucoma" +517, 4, 11, 30, 77, 85, 145, 153, "patients" +517, 4, 12, 31, 86, 87, 154, 155, "." +517, 5, 1, 32, 0, 7, 156, 163, "Konstas" +517, 5, 2, 33, 8, 10, 164, 166, "AG" +517, 5, 3, 34, 11, 12, 167, 168, "(" +517, 5, 4, 35, 13, 14, 169, 170, "1" +517, 5, 5, 36, 15, 16, 171, 172, ")" +517, 5, 6, 37, 17, 18, 173, 174, "," +517, 5, 7, 38, 19, 28, 175, 184, "Kozobolis" +517, 5, 8, 39, 29, 31, 185, 187, "VP" +517, 5, 9, 40, 32, 33, 188, 189, "," +517, 5, 10, 41, 34, 44, 190, 200, "Katsimpris" +517, 5, 11, 42, 45, 47, 201, 203, "IE" +517, 5, 12, 43, 48, 49, 204, 205, "," +517, 5, 13, 44, 50, 59, 206, 215, "Boboridis" +517, 5, 14, 45, 60, 61, 216, 217, "K" +517, 5, 15, 46, 62, 63, 218, 219, "," +517, 5, 16, 47, 64, 72, 220, 228, "Koukoula" +517, 5, 17, 48, 73, 74, 229, 230, "S" +517, 5, 18, 49, 75, 76, 231, 232, "," +517, 5, 19, 50, 77, 84, 233, 240, "Jenkins" +517, 5, 20, 51, 85, 87, 241, 243, "JN" +517, 5, 21, 52, 88, 89, 244, 245, "," +517, 5, 22, 53, 90, 97, 246, 253, "Stewart" +517, 5, 23, 54, 98, 100, 254, 256, "WC" +517, 5, 24, 55, 101, 102, 257, 258, "." +517, 6, 1, 56, 0, 6, 259, 265, "Author" +517, 6, 2, 57, 7, 18, 266, 277, "information" +517, 6, 3, 58, 19, 20, 278, 279, ":" +517, 6, 4, 59, 21, 22, 280, 281, "(" +517, 6, 5, 60, 23, 24, 282, 283, "1" +517, 6, 6, 61, 25, 26, 284, 285, ")" +517, 6, 7, 62, 27, 35, 286, 294, "Glaucoma" +517, 6, 8, 63, 36, 40, 295, 299, "Unit" +517, 6, 9, 64, 41, 42, 300, 301, "," +517, 6, 10, 65, 43, 53, 302, 312, "Department" +517, 6, 11, 66, 54, 56, 313, 315, "of" +517, 6, 12, 67, 57, 70, 316, 329, "Ophthalmology" +517, 6, 13, 68, 71, 72, 330, 331, "," +517, 6, 14, 69, 73, 74, 332, 333, "A" +517, 6, 15, 70, 75, 85, 334, 344, "University" +517, 6, 16, 71, 86, 87, 345, 346, "," +517, 6, 17, 72, 88, 100, 347, 359, "Thessaloniki" +517, 6, 18, 73, 101, 102, 360, 361, "," +517, 6, 19, 74, 103, 109, 362, 368, "Greece" +517, 6, 20, 75, 110, 111, 369, 370, "." +517, 7, 1, 76, 0, 9, 371, 380, "OBJECTIVE" +517, 7, 2, 77, 10, 11, 381, 382, ":" +517, 7, 3, 78, 12, 14, 383, 385, "To" +517, 7, 4, 79, 15, 23, 386, 394, "evaluate" +517, 7, 5, 80, 24, 26, 395, 397, "24" +517, 7, 6, 81, 27, 28, 398, 399, "-" +517, 7, 7, 82, 29, 33, 400, 404, "hour" +517, 7, 8, 83, 34, 45, 405, 416, "intraocular" +517, 7, 9, 84, 46, 54, 417, 425, "pressure" +517, 7, 10, 85, 55, 56, 426, 427, "(" +517, 7, 11, 86, 57, 60, 428, 431, "IOP" +517, 7, 12, 87, 61, 62, 432, 433, ")" +517, 7, 13, 88, 63, 71, 434, 442, "efficacy" +517, 7, 14, 89, 72, 74, 443, 445, "of" +517, 7, 15, 90, 75, 86, 446, 457, "latanoprost" +517, 7, 16, 91, 87, 93, 458, 464, "versus" +517, 7, 17, 92, 94, 104, 465, 475, "travoprost" +517, 7, 18, 93, 105, 106, 476, 477, "," +517, 7, 19, 94, 107, 111, 478, 482, "each" +517, 7, 20, 95, 112, 117, 483, 488, "given" +517, 7, 21, 96, 118, 123, 489, 494, "every" +517, 7, 22, 97, 124, 131, 495, 502, "evening" +517, 7, 23, 98, 132, 133, 503, 504, "," +517, 7, 24, 99, 134, 136, 505, 507, "in" +517, 7, 25, 100, 137, 148, 508, 519, "exfoliative" +517, 7, 26, 101, 149, 157, 520, 528, "glaucoma" +517, 7, 27, 102, 158, 166, 529, 537, "patients" +517, 7, 28, 103, 167, 168, 538, 539, "." +517, 8, 1, 104, 0, 6, 540, 546, "DESIGN" +517, 8, 2, 105, 7, 8, 547, 548, ":" +517, 8, 3, 106, 9, 20, 549, 560, "Prospective" +517, 8, 4, 107, 21, 22, 561, 562, "," +517, 8, 5, 108, 23, 31, 563, 571, "observer" +517, 8, 6, 109, 32, 33, 572, 573, "-" +517, 8, 7, 110, 34, 40, 574, 580, "masked" +517, 8, 8, 111, 41, 42, 581, 582, "," +517, 8, 9, 112, 43, 52, 583, 592, "crossover" +517, 8, 10, 113, 53, 63, 593, 603, "comparison" +517, 8, 11, 114, 64, 65, 604, 605, "." +517, 9, 1, 115, 0, 12, 606, 618, "PARTICIPANTS" +517, 9, 2, 116, 13, 14, 619, 620, ":" +517, 9, 3, 117, 15, 20, 621, 626, "Forty" +517, 9, 4, 118, 21, 29, 627, 635, "patients" +517, 9, 5, 119, 30, 34, 636, 640, "with" +517, 9, 6, 120, 35, 46, 641, 652, "exfoliation" +517, 9, 7, 121, 47, 55, 653, 661, "glaucoma" +517, 9, 8, 122, 56, 57, 662, 663, "." +517, 10, 1, 123, 0, 7, 664, 671, "METHODS" +517, 10, 2, 124, 8, 9, 672, 673, ":" +517, 10, 3, 125, 10, 18, 674, 682, "Patients" +517, 10, 4, 126, 19, 23, 683, 687, "with" +517, 10, 5, 127, 24, 25, 688, 689, "a" +517, 10, 6, 128, 26, 34, 690, 698, "pressure" +517, 10, 7, 129, 35, 37, 699, 701, "of" +517, 10, 8, 130, 38, 39, 702, 703, ">" +517, 10, 9, 131, 40, 42, 704, 706, "24" +517, 10, 10, 132, 43, 47, 707, 711, "mmHg" +517, 10, 11, 133, 48, 52, 712, 716, "were" +517, 10, 12, 134, 53, 63, 717, 727, "randomized" +517, 10, 13, 135, 64, 66, 728, 730, "to" +517, 10, 14, 136, 67, 78, 731, 742, "latanoprost" +517, 10, 15, 137, 79, 81, 743, 745, "or" +517, 10, 16, 138, 82, 92, 746, 756, "travoprost" +517, 10, 17, 139, 93, 96, 757, 760, "for" +517, 10, 18, 140, 97, 99, 761, 763, "an" +517, 10, 19, 141, 100, 101, 764, 765, "8" +517, 10, 20, 142, 102, 103, 766, 767, "-" +517, 10, 21, 143, 104, 108, 768, 772, "week" +517, 10, 22, 144, 109, 118, 773, 782, "treatment" +517, 10, 23, 145, 119, 125, 783, 789, "period" +517, 10, 24, 146, 126, 131, 790, 795, "after" +517, 10, 25, 147, 132, 133, 796, 797, "a" +517, 10, 26, 148, 134, 135, 798, 799, "6" +517, 10, 27, 149, 136, 137, 800, 801, "-" +517, 10, 28, 150, 138, 142, 802, 806, "week" +517, 10, 29, 151, 143, 151, 807, 815, "medicine" +517, 10, 30, 152, 152, 153, 816, 817, "-" +517, 10, 31, 153, 154, 158, 818, 822, "free" +517, 10, 32, 154, 159, 165, 823, 829, "period" +517, 10, 33, 155, 166, 167, 830, 831, "." +517, 11, 1, 156, 0, 8, 832, 840, "Patients" +517, 11, 2, 157, 9, 13, 841, 845, "were" +517, 11, 3, 158, 14, 18, 846, 850, "then" +517, 11, 4, 159, 19, 27, 851, 859, "switched" +517, 11, 5, 160, 28, 30, 860, 862, "to" +517, 11, 6, 161, 31, 34, 863, 866, "the" +517, 11, 7, 162, 35, 43, 867, 875, "opposite" +517, 11, 8, 163, 44, 53, 876, 885, "treatment" +517, 11, 9, 164, 54, 57, 886, 889, "for" +517, 11, 10, 165, 58, 61, 890, 893, "the" +517, 11, 11, 166, 62, 68, 894, 900, "second" +517, 11, 12, 167, 69, 75, 901, 907, "period" +517, 11, 13, 168, 76, 77, 908, 909, "." +517, 12, 1, 169, 0, 2, 910, 912, "At" +517, 12, 2, 170, 3, 12, 913, 922, "untreated" +517, 12, 3, 171, 13, 21, 923, 931, "baseline" +517, 12, 4, 172, 22, 25, 932, 935, "and" +517, 12, 5, 173, 26, 28, 936, 938, "at" +517, 12, 6, 174, 29, 32, 939, 942, "the" +517, 12, 7, 175, 33, 36, 943, 946, "end" +517, 12, 8, 176, 37, 39, 947, 949, "of" +517, 12, 9, 177, 40, 44, 950, 954, "each" +517, 12, 10, 178, 45, 54, 955, 964, "treatment" +517, 12, 11, 179, 55, 61, 965, 971, "period" +517, 12, 12, 180, 62, 65, 972, 975, "the" +517, 12, 13, 181, 66, 69, 976, 979, "IOP" +517, 12, 14, 182, 70, 73, 980, 983, "was" +517, 12, 15, 183, 74, 82, 984, 992, "measured" +517, 12, 16, 184, 83, 85, 993, 995, "at" +517, 12, 17, 185, 86, 87, 996, 997, "6" +517, 12, 18, 186, 88, 90, 998, 1000, "am" +517, 12, 19, 187, 91, 92, 1001, 1002, "," +517, 12, 20, 188, 93, 95, 1003, 1005, "10" +517, 12, 21, 189, 96, 98, 1006, 1008, "am" +517, 12, 22, 190, 99, 100, 1009, 1010, "," +517, 12, 23, 191, 101, 102, 1011, 1012, "2" +517, 12, 24, 192, 103, 105, 1013, 1015, "pm" +517, 12, 25, 193, 106, 107, 1016, 1017, "," +517, 12, 26, 194, 108, 109, 1018, 1019, "6" +517, 12, 27, 195, 110, 112, 1020, 1022, "pm" +517, 12, 28, 196, 113, 114, 1023, 1024, "," +517, 12, 29, 197, 115, 117, 1025, 1027, "10" +517, 12, 30, 198, 118, 120, 1028, 1030, "pm" +517, 12, 31, 199, 121, 122, 1031, 1032, "," +517, 12, 32, 200, 123, 126, 1033, 1036, "and" +517, 12, 33, 201, 127, 128, 1037, 1038, "2" +517, 12, 34, 202, 129, 131, 1039, 1041, "am" +517, 12, 35, 203, 132, 133, 1042, 1043, "." +517, 13, 1, 204, 0, 4, 1044, 1048, "MAIN" +517, 13, 2, 205, 5, 12, 1049, 1056, "OUTCOME" +517, 13, 3, 206, 13, 20, 1057, 1064, "MEASURE" +517, 13, 4, 207, 21, 22, 1065, 1066, ":" +517, 13, 5, 208, 23, 30, 1067, 1074, "Diurnal" +517, 13, 6, 209, 31, 34, 1075, 1078, "IOP" +517, 13, 7, 210, 35, 36, 1079, 1080, "." +517, 14, 1, 211, 0, 7, 1081, 1088, "RESULTS" +517, 14, 2, 212, 8, 9, 1089, 1090, ":" +517, 14, 3, 213, 10, 13, 1091, 1094, "The" +517, 14, 4, 214, 14, 18, 1095, 1099, "mean" +517, 14, 5, 215, 19, 21, 1100, 1102, "24" +517, 14, 6, 216, 22, 23, 1103, 1104, "-" +517, 14, 7, 217, 24, 28, 1105, 1109, "hour" +517, 14, 8, 218, 29, 32, 1110, 1113, "IOP" +517, 14, 9, 219, 33, 36, 1114, 1117, "was" +517, 14, 10, 220, 37, 39, 1118, 1120, "25" +517, 14, 11, 221, 40, 41, 1121, 1122, "." +517, 14, 12, 222, 42, 43, 1123, 1124, "1" +517, 14, 13, 223, 44, 45, 1125, 1126, "+" +517, 14, 14, 224, 46, 47, 1127, 1128, "/" +517, 14, 15, 225, 48, 49, 1129, 1130, "-" +517, 14, 16, 226, 50, 51, 1131, 1132, "2" +517, 14, 17, 227, 52, 53, 1133, 1134, "." +517, 14, 18, 228, 54, 55, 1135, 1136, "5" +517, 14, 19, 229, 56, 60, 1137, 1141, "mmHg" +517, 14, 20, 230, 61, 63, 1142, 1144, "at" +517, 14, 21, 231, 64, 72, 1145, 1153, "baseline" +517, 14, 22, 232, 73, 74, 1154, 1155, "," +517, 14, 23, 233, 75, 77, 1156, 1158, "17" +517, 14, 24, 234, 78, 79, 1159, 1160, "." +517, 14, 25, 235, 80, 81, 1161, 1162, "8" +517, 14, 26, 236, 82, 83, 1163, 1164, "+" +517, 14, 27, 237, 84, 85, 1165, 1166, "/" +517, 14, 28, 238, 86, 87, 1167, 1168, "-" +517, 14, 29, 239, 88, 89, 1169, 1170, "2" +517, 14, 30, 240, 90, 91, 1171, 1172, "." +517, 14, 31, 241, 92, 93, 1173, 1174, "1" +517, 14, 32, 242, 94, 98, 1175, 1179, "mmHg" +517, 14, 33, 243, 99, 101, 1180, 1182, "on" +517, 14, 34, 244, 102, 113, 1183, 1194, "latanoprost" +517, 14, 35, 245, 114, 115, 1195, 1196, "," +517, 14, 36, 246, 116, 119, 1197, 1200, "and" +517, 14, 37, 247, 120, 122, 1201, 1203, "17" +517, 14, 38, 248, 123, 124, 1204, 1205, "." +517, 14, 39, 249, 125, 126, 1206, 1207, "3" +517, 14, 40, 250, 127, 128, 1208, 1209, "+" +517, 14, 41, 251, 129, 130, 1210, 1211, "/" +517, 14, 42, 252, 131, 132, 1212, 1213, "-" +517, 14, 43, 253, 133, 134, 1214, 1215, "2" +517, 14, 44, 254, 135, 136, 1216, 1217, "." +517, 14, 45, 255, 137, 138, 1218, 1219, "2" +517, 14, 46, 256, 139, 143, 1220, 1224, "mmHg" +517, 14, 47, 257, 144, 146, 1225, 1227, "on" +517, 14, 48, 258, 147, 157, 1228, 1238, "travoprost" +517, 14, 49, 259, 158, 159, 1239, 1240, "(" +517, 14, 50, 260, 160, 161, 1241, 1242, "P" +517, 14, 51, 261, 162, 163, 1243, 1244, "=" +517, 14, 52, 262, 164, 165, 1245, 1246, "0" +517, 14, 53, 263, 166, 167, 1247, 1248, "." +517, 14, 54, 264, 168, 171, 1249, 1252, "001" +517, 14, 55, 265, 172, 173, 1253, 1254, ")" +517, 14, 56, 266, 174, 175, 1255, 1256, "." +517, 15, 1, 267, 0, 10, 1257, 1267, "Individual" +517, 15, 2, 268, 11, 15, 1268, 1272, "time" +517, 15, 3, 269, 16, 22, 1273, 1279, "points" +517, 15, 4, 270, 23, 27, 1280, 1284, "were" +517, 15, 5, 271, 28, 35, 1285, 1292, "similar" +517, 15, 6, 272, 36, 43, 1293, 1300, "between" +517, 15, 7, 273, 44, 54, 1301, 1311, "treatments" +517, 15, 8, 274, 55, 56, 1312, 1313, "," +517, 15, 9, 275, 57, 63, 1314, 1320, "except" +517, 15, 10, 276, 64, 66, 1321, 1323, "at" +517, 15, 11, 277, 67, 68, 1324, 1325, "6" +517, 15, 12, 278, 69, 71, 1326, 1328, "pm" +517, 15, 13, 279, 72, 76, 1329, 1333, "when" +517, 15, 14, 280, 77, 87, 1334, 1344, "travoprost" +517, 15, 15, 281, 88, 96, 1345, 1353, "provided" +517, 15, 16, 282, 97, 102, 1354, 1359, "lower" +517, 15, 17, 283, 103, 106, 1360, 1363, "IOP" +517, 15, 18, 284, 107, 108, 1364, 1365, "(" +517, 15, 19, 285, 109, 111, 1366, 1368, "16" +517, 15, 20, 286, 112, 113, 1369, 1370, "." +517, 15, 21, 287, 114, 115, 1371, 1372, "7" +517, 15, 22, 288, 116, 117, 1373, 1374, "+" +517, 15, 23, 289, 118, 119, 1375, 1376, "/" +517, 15, 24, 290, 120, 121, 1377, 1378, "-" +517, 15, 25, 291, 122, 123, 1379, 1380, "2" +517, 15, 26, 292, 124, 125, 1381, 1382, "." +517, 15, 27, 293, 126, 127, 1383, 1384, "6" +517, 15, 28, 294, 128, 130, 1385, 1387, "vs" +517, 15, 29, 295, 131, 133, 1388, 1390, "17" +517, 15, 30, 296, 134, 135, 1391, 1392, "." +517, 15, 31, 297, 136, 137, 1393, 1394, "9" +517, 15, 32, 298, 138, 139, 1395, 1396, "+" +517, 15, 33, 299, 140, 141, 1397, 1398, "/" +517, 15, 34, 300, 142, 143, 1399, 1400, "-" +517, 15, 35, 301, 144, 145, 1401, 1402, "2" +517, 15, 36, 302, 146, 147, 1403, 1404, "." +517, 15, 37, 303, 148, 149, 1405, 1406, "5" +517, 15, 38, 304, 150, 154, 1407, 1411, "mmHg" +517, 15, 39, 305, 155, 156, 1412, 1413, "," +517, 15, 40, 306, 157, 158, 1414, 1415, "P" +517, 15, 41, 307, 159, 160, 1416, 1417, "<" +517, 15, 42, 308, 161, 162, 1418, 1419, "0" +517, 15, 43, 309, 163, 164, 1420, 1421, "." +517, 15, 44, 310, 165, 168, 1422, 1425, "001" +517, 15, 45, 311, 169, 170, 1426, 1427, ")" +517, 15, 46, 312, 171, 172, 1428, 1429, "." +517, 16, 1, 313, 0, 7, 1430, 1437, "Adverse" +517, 16, 2, 314, 8, 14, 1438, 1444, "events" +517, 16, 3, 315, 15, 21, 1445, 1451, "showed" +517, 16, 4, 316, 22, 26, 1452, 1456, "more" +517, 16, 5, 317, 27, 39, 1457, 1469, "conjunctival" +517, 16, 6, 318, 40, 49, 1470, 1479, "hyperemia" +517, 16, 7, 319, 50, 54, 1480, 1484, "with" +517, 16, 8, 320, 55, 65, 1485, 1495, "travoprost" +517, 16, 9, 321, 66, 67, 1496, 1497, "(" +517, 16, 10, 322, 68, 69, 1498, 1499, "n" +517, 16, 11, 323, 70, 71, 1500, 1501, "=" +517, 16, 12, 324, 72, 74, 1502, 1504, "15" +517, 16, 13, 325, 75, 76, 1505, 1506, ")" +517, 16, 14, 326, 77, 81, 1507, 1511, "than" +517, 16, 15, 327, 82, 93, 1512, 1523, "latanoprost" +517, 16, 16, 328, 94, 95, 1524, 1525, "(" +517, 16, 17, 329, 96, 97, 1526, 1527, "n" +517, 16, 18, 330, 98, 99, 1528, 1529, "=" +517, 16, 19, 331, 100, 101, 1530, 1531, "6" +517, 16, 20, 332, 102, 103, 1532, 1533, ";" +517, 16, 21, 333, 104, 105, 1534, 1535, "P" +517, 16, 22, 334, 106, 107, 1536, 1537, "=" +517, 16, 23, 335, 108, 109, 1538, 1539, "0" +517, 16, 24, 336, 110, 111, 1540, 1541, "." +517, 16, 25, 337, 112, 114, 1542, 1544, "03" +517, 16, 26, 338, 115, 116, 1545, 1546, ")" +517, 16, 27, 339, 117, 118, 1547, 1548, "." +517, 17, 1, 340, 0, 11, 1549, 1560, "CONCLUSIONS" +517, 17, 2, 341, 12, 13, 1561, 1562, ":" +517, 17, 3, 342, 14, 25, 1563, 1574, "Latanoprost" +517, 17, 4, 343, 26, 29, 1575, 1578, "and" +517, 17, 5, 344, 30, 40, 1579, 1589, "travoprost" +517, 17, 6, 345, 41, 45, 1590, 1594, "both" +517, 17, 7, 346, 46, 59, 1595, 1608, "significantly" +517, 17, 8, 347, 60, 66, 1609, 1615, "reduce" +517, 17, 9, 348, 67, 70, 1616, 1619, "the" +517, 17, 10, 349, 71, 73, 1620, 1622, "24" +517, 17, 11, 350, 74, 75, 1623, 1624, "-" +517, 17, 12, 351, 76, 80, 1625, 1629, "hour" +517, 17, 13, 352, 81, 84, 1630, 1633, "IOP" +517, 17, 14, 353, 85, 89, 1634, 1638, "from" +517, 17, 15, 354, 90, 98, 1639, 1647, "baseline" +517, 17, 16, 355, 99, 101, 1648, 1650, "in" +517, 17, 17, 356, 102, 113, 1651, 1662, "exfoliative" +517, 17, 18, 357, 114, 122, 1663, 1671, "glaucoma" +517, 17, 19, 358, 123, 124, 1672, 1673, "," +517, 17, 20, 359, 125, 128, 1674, 1677, "but" +517, 17, 21, 360, 129, 139, 1678, 1688, "travoprost" +517, 17, 22, 361, 140, 143, 1689, 1692, "may" +517, 17, 23, 362, 144, 155, 1693, 1704, "demonstrate" +517, 17, 24, 363, 156, 157, 1705, 1706, "a" +517, 17, 25, 364, 158, 165, 1707, 1714, "greater" +517, 17, 26, 365, 166, 177, 1715, 1726, "hypotensive" +517, 17, 27, 366, 178, 186, 1727, 1735, "efficacy" +517, 17, 28, 367, 187, 189, 1736, 1738, "in" +517, 17, 29, 368, 190, 193, 1739, 1742, "the" +517, 17, 30, 369, 194, 198, 1743, 1747, "late" +517, 17, 31, 370, 199, 208, 1748, 1757, "afternoon" +517, 17, 32, 371, 209, 210, 1758, 1759, "." +517, 18, 1, 372, 0, 3, 1760, 1763, "DOI" +517, 18, 2, 373, 4, 5, 1764, 1765, ":" +517, 18, 3, 374, 6, 8, 1766, 1768, "10" +517, 18, 4, 375, 9, 10, 1769, 1770, "." +517, 18, 5, 376, 11, 15, 1771, 1775, "1016" +517, 18, 6, 377, 16, 17, 1776, 1777, "/" +517, 18, 7, 378, 18, 19, 1778, 1779, "j" +517, 18, 8, 379, 20, 21, 1780, 1781, "." +517, 18, 9, 380, 22, 28, 1782, 1788, "ophtha" +517, 18, 10, 381, 29, 30, 1789, 1790, "." +517, 18, 11, 382, 31, 35, 1791, 1795, "2006" +517, 18, 12, 383, 36, 37, 1796, 1797, "." +517, 18, 13, 384, 38, 40, 1798, 1800, "07" +517, 18, 14, 385, 41, 42, 1801, 1802, "." +517, 18, 15, 386, 43, 46, 1803, 1806, "064" +517, 18, 16, 387, 47, 51, 1807, 1811, "PMID" +517, 18, 17, 388, 52, 53, 1812, 1813, ":" +517, 18, 18, 389, 54, 62, 1814, 1822, "17197028" +517, 18, 19, 390, 63, 64, 1823, 1824, "[" +517, 18, 20, 391, 65, 72, 1825, 1832, "Indexed" +517, 18, 21, 392, 73, 76, 1833, 1836, "for" +517, 18, 22, 393, 77, 84, 1837, 1844, "MEDLINE" +517, 18, 23, 394, 85, 86, 1845, 1846, "]" diff --git a/data/gl 17197028_jshahinitiran.annodb b/data/gl 17197028_jshahinitiran.annodb new file mode 100644 index 0000000..ee155d4 --- /dev/null +++ b/data/gl 17197028_jshahinitiran.annodb @@ -0,0 +1,67 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +78511, Journal, 0, 15, "Ophthalmology .", "", +78512, PublicationYear, 16, 20, "2007", "", +78513, Title, 68, 155, "Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients .", "", +78514, Author, 156, 166, "Konstas AG", "", +78515, Author, 175, 187, "Kozobolis VP", "", +78516, Author, 190, 203, "Katsimpris IE", "", +78517, Author, 206, 217, "Boboridis K", "", +78518, Author, 220, 230, "Koukoula S", "", +78519, Author, 233, 243, "Jenkins JN", "", +78520, Author, 246, 256, "Stewart WC", "", +78521, Greece, 362, 368, "Greece", "", +78522, ObjectiveDescription, 383, 539, "To evaluate 24 - hour intraocular pressure ( IOP ) efficacy of latanoprost versus travoprost , each given every evening , in exfoliative glaucoma patients .", "", +78523, IOP, 405, 425, "intraocular pressure", "", +78524, IOP, 428, 431, "IOP", "", +78525, Latanoprost, 446, 457, "latanoprost", "", +78526, Travoprost, 465, 475, "travoprost", "", +78527, Glaucoma, 520, 528, "glaucoma", "", +78528, Prospective, 549, 560, "Prospective", "", +78529, Blind, 563, 580, "observer - masked", "", +78530, Crossover, 583, 592, "crossover", "", +78531, NumberPatientsCT, 621, 626, "Forty", "", +78532, Glaucoma, 653, 661, "glaucoma", "", +78533, EndPointDescription, 683, 711, "with a pressure of > 24 mmHg", "", +78534, EndPointDescription, 707, 711, "mmHg", "", +78535, Randomized, 717, 727, "randomized", "", +78536, Latanoprost, 731, 742, "latanoprost", "", +78537, Travoprost, 746, 756, "travoprost", "", +78538, Duration, 764, 772, "8 - week", "", +78539, Duration, 798, 806, "6 - week", "", +78540, IOP, 976, 979, "IOP", "", +78541, Diurnal_IOP, 1067, 1078, "Diurnal IOP", "", +78542, Mean, 1095, 1099, "mean", "", +78543, IOP, 1110, 1113, "IOP", "", +78544, BaseLineValue, 1118, 1124, "25 . 1", "", +78546, SdErrorBL, 1131, 1136, "2 . 5", "", +78548, mmHg, 1137, 1141, "mmHg", "", +78550, ResultMeasuredValue, 1156, 1162, "17 . 8", "", +78551, SdErrorResValue, 1169, 1174, "2 . 1", "", +78549, mmHg, 1175, 1179, "mmHg", "", +78552, Latanoprost, 1183, 1194, "latanoprost", "", +78553, ResultMeasuredValue, 1201, 1207, "17 . 3", "", +78554, SdErrorResValue, 1214, 1219, "2 . 2", "", +78555, mmHg, 1220, 1224, "mmHg", "", +78556, Travoprost, 1228, 1238, "travoprost", "", +78557, PValueResValue, 1241, 1252, "P = 0 . 001", "", +78565, EndPointDescription, 1321, 1328, "at 6 pm", "", +78558, Travoprost, 1334, 1344, "travoprost", "", +78559, IOP, 1360, 1363, "IOP", "", +78560, ResultMeasuredValue, 1366, 1372, "16 . 7", "", +78562, SdErrorResValue, 1379, 1384, "2 . 6", "", +78561, ResultMeasuredValue, 1388, 1394, "17 . 9", "", +78563, SdErrorResValue, 1401, 1406, "2 . 5", "", +78564, mmHg, 1407, 1411, "mmHg", "", +78566, ConjunctivalHyperemia, 1457, 1479, "conjunctival hyperemia", "", +78567, Travoprost, 1485, 1495, "travoprost", "", +78568, NumberAffected, 1502, 1504, "15", "", +78569, Latanoprost, 1512, 1523, "latanoprost", "", +78570, NumberAffected, 1530, 1531, "6", "", +78571, PValueNumAffected, 1534, 1544, "P = 0 . 03", "", +78572, ConclusionComment, 1563, 1759, "Latanoprost and travoprost both significantly reduce the 24 - hour IOP from baseline in exfoliative glaucoma , but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon .", "", +78573, Latanoprost, 1563, 1574, "Latanoprost", "", +78574, Travoprost, 1579, 1589, "travoprost", "", +78575, IOP, 1630, 1633, "IOP", "", +78576, Glaucoma, 1663, 1671, "glaucoma", "", +78577, Travoprost, 1678, 1688, "travoprost", "", +78578, PMID, 1814, 1822, "17197028", "", diff --git a/data/gl 17197028_jshahinitiran.n-triples b/data/gl 17197028_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17197028_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17197028_tstrakeljahn.annodb b/data/gl 17197028_tstrakeljahn.annodb new file mode 100644 index 0000000..ef61a8b --- /dev/null +++ b/data/gl 17197028_tstrakeljahn.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80094, Journal, 0, 13, "Ophthalmology", "", +80095, PublicationYear, 16, 20, "2007", "", +80099, Title, 68, 155, "Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients .", "", +80096, Latanoprost, 91, 102, "latanoprost", "", +80097, Travoprost, 110, 120, "travoprost", "", +80098, Glaucoma, 136, 144, "glaucoma", "", +80100, Author, 156, 166, "Konstas AG", "", +80101, Author, 175, 187, "Kozobolis VP", "", +80102, Author, 190, 203, "Katsimpris IE", "", +80103, Author, 206, 217, "Boboridis K", "", +80104, Author, 220, 230, "Koukoula S", "", +80105, Author, 233, 243, "Jenkins JN", "", +80106, Author, 246, 256, "Stewart WC", "", +80107, Greece, 362, 368, "Greece", "", +80114, ObjectiveDescription, 383, 539, "To evaluate 24 - hour intraocular pressure ( IOP ) efficacy of latanoprost versus travoprost , each given every evening , in exfoliative glaucoma patients .", "", +80108, IOP, 405, 425, "intraocular pressure", "", +80109, IOP, 428, 431, "IOP", "", +80110, Latanoprost, 446, 457, "latanoprost", "", +80111, Travoprost, 465, 475, "travoprost", "", +80112, Frequency, 489, 502, "every evening", "", +80113, Glaucoma, 520, 528, "glaucoma", "", +80115, Prospective, 549, 560, "Prospective", "", +80116, Blind, 563, 580, "observer - masked", "", +80117, Crossover, 583, 592, "crossover", "", +80118, NumberPatientsCT, 621, 626, "Forty", "", +80119, Glaucoma, 653, 661, "glaucoma", "", +80126, Precondition, 674, 711, "Patients with a pressure of > 24 mmHg", "", +80120, mmHg, 707, 711, "mmHg", "", +80121, Randomized, 717, 727, "randomized", "", +80122, Latanoprost, 731, 742, "latanoprost", "", +80123, Travoprost, 746, 756, "travoprost", "", +80124, Duration, 764, 772, "8 - week", "", +80125, Precondition, 790, 829, "after a 6 - week medicine - free period", "", +80127, IOP, 976, 979, "IOP", "", +80128, Morning, 996, 1000, "6 am", "", +80129, Morning, 1003, 1008, "10 am", "", +80130, Afternoon, 1011, 1015, "2 pm", "", +80131, Evening, 1018, 1022, "6 pm", "", +80132, Bedtime, 1025, 1030, "10 pm", "", +80133, RelativeTime, 1037, 1041, "2 am", "", +80134, Diurnal_IOP, 1067, 1078, "Diurnal IOP", "", +80135, Mean, 1095, 1099, "mean", "", +80136, Diurnal_IOP, 1100, 1113, "24 - hour IOP", "", +80137, BaseLineValue, 1118, 1124, "25 . 1", "", +80138, SdDevBL, 1131, 1136, "2 . 5", "", +80139, mmHg, 1137, 1141, "mmHg", "", +80142, ResultMeasuredValue, 1156, 1162, "17 . 8", "", +80146, SdDevResValue, 1169, 1174, "2 . 1", "", +80140, mmHg, 1175, 1179, "mmHg", "", +80144, Latanoprost, 1183, 1194, "latanoprost", "", +80143, ResultMeasuredValue, 1201, 1207, "17 . 3", "", +80147, SdDevResValue, 1214, 1219, "2 . 2", "", +80141, mmHg, 1220, 1224, "mmHg", "", +80145, Travoprost, 1228, 1238, "travoprost", "", +80148, PvalueDiff, 1243, 1252, "= 0 . 001", "", +80149, TimePoint, 1324, 1328, "6 pm", "", +80150, Travoprost, 1334, 1344, "travoprost", "", +80151, IOP, 1360, 1363, "IOP", "", +80152, ResultMeasuredValue, 1366, 1372, "16 . 7", "", +80155, SdDevResValue, 1379, 1384, "2 . 6", "", +80154, ResultMeasuredValue, 1388, 1394, "17 . 9", "", +80156, SdDevResValue, 1401, 1406, "2 . 5", "", +80157, mmHg, 1407, 1411, "mmHg", "", +80158, PvalueDiff, 1416, 1425, "< 0 . 001", "", +80159, ConjunctivalHyperemia, 1457, 1479, "conjunctival hyperemia", "", +80160, Travoprost, 1485, 1495, "travoprost", "", +80161, NumberAffected, 1502, 1504, "15", "", +80164, Latanoprost, 1512, 1523, "latanoprost", "", +80162, NumberAffected, 1530, 1531, "6", "", +80163, PvalueDiff, 1536, 1544, "= 0 . 03", "", +80165, Latanoprost, 1563, 1574, "Latanoprost", "", +80171, ConclusionComment, 1563, 1759, "Latanoprost and travoprost both significantly reduce the 24 - hour IOP from baseline in exfoliative glaucoma , but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon .", "", +80166, Travoprost, 1579, 1589, "travoprost", "", +80167, Diurnal_IOP, 1620, 1633, "24 - hour IOP", "", +80168, Glaucoma, 1663, 1671, "glaucoma", "", +80169, Travoprost, 1678, 1688, "travoprost", "", +80170, Afternoon, 1743, 1757, "late afternoon", "", +80172, PMID, 1814, 1822, "17197028", "", diff --git a/data/gl 17197028_tstrakeljahn.n-triples b/data/gl 17197028_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17197028_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17244215_admin.annodb b/data/gl 17244215_admin.annodb new file mode 100644 index 0000000..aff598d --- /dev/null +++ b/data/gl 17244215_admin.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Acta Ophthalmol Scand", "", " \"Acta Ophthalmol Scand\"." +1, PublicationYear, 24, 28, "2007", "", " \"2007\"." +2, Title, 55, 221, "Comparison of the ocular hypotensive effects of bimatoprost and timolol - dorzolamide combination in patients with elevated intraocular pressure : a 6 - month study .", "", " \"Comparison of the ocular hypotensive effects of bimatoprost and timolol - dorzolamide combination in patients with elevated intraocular pressure : a 6 - month study .\"." +3, Bimatoprost, 103, 114, "bimatoprost", "", " ." +4, Timolol, 119, 126, "timolol", "", +38495, Dorz/TimFC, 119, 140, "timolol - dorzolamide", "", " ." +5, Dorzolamide, 129, 140, "dorzolamide", "", +8, Precondition, 170, 199, "elevated intraocular pressure", "", " \"elevated intraocular pressure\"." +6, IOP, 179, 199, "intraocular pressure", "", " . ." +7, Duration, 204, 213, "6 - month", "", " \"6 - month\"." +9, Author, 222, 230, "Ozturk F", "", " \"Ozturk F\"." +10, Author, 239, 247, "Ermis SS", "", " \"Ermis SS\"." +11, Author, 250, 257, "Inan UU", "", " \"Inan UU\"." +12, Turkey, 377, 383, "Turkey", "", " ." +88, ObjectiveDescription, 396, 620, "To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol - dorzolamide combination in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension during 6 months of treatment .", "", " \"To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol - dorzolamide combination in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension during 6 months of treatment .\"." +14, Bimatoprost, 461, 472, "bimatoprost", "", +15, Timolol, 477, 484, "timolol", "", +38494, Dorz/TimFC, 477, 498, "timolol - dorzolamide", "", +16, Dorzolamide, 487, 498, "dorzolamide", "", +62, Primary_OpenAngleGlaucoma, 528, 557, "primary open - angle glaucoma", "", " ." +63, Primary_OpenAngleGlaucoma, 560, 564, "POAG", "", +86, OcularHypertension, 570, 589, "ocular hypertension", "", " ." +17, Duration, 597, 605, "6 months", "", +18, NumberPatientsCT, 643, 645, "65", "", " \"65\"." +64, Primary_OpenAngleGlaucoma, 675, 679, "POAG", "", +91, OcularHypertension, 683, 702, "ocular hypertension", "", +19, Randomized, 708, 718, "randomized", "", " ." +20, Bimatoprost, 737, 748, "bimatoprost", "", +21, DoseValue, 749, 755, "0 . 03", "", " \"0 . 03\"." +22, Percentage, 756, 757, "%", "", " ." +23, Frequency, 758, 768, "once daily", "", " \"once daily\"." +24, Timolol, 772, 779, "timolol", "", +38500, Dorz/TimFC, 772, 793, "timolol - dorzolamide", "", +25, Dorzolamide, 782, 793, "dorzolamide", "", +26, Frequency, 806, 817, "twice daily", "", " \"twice daily\"." +66, TimePoint, 845, 853, "baseline", "", +67, TimePoint, 864, 871, "2 weeks", "", +68, TimePoint, 876, 894, "1 , 3 and 6 months", "", +37054, TimePoint, 880, 894, "3 and 6 months", "", +37055, TimePoint, 886, 894, "6 months", "", +27, IOP, 908, 928, "Intraocular pressure", "", +28, IOP, 931, 934, "IOP", "", +29, TimePoint, 1062, 1071, "6 - month", "", +30, IOP, 1254, 1257, "IOP", "", +121, ObservedResult, 1277, 1422, "Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) .", "", " \"Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) .\". \"Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) .\"." +31, IOP, 1292, 1295, "IOP", "", +32, Bimatoprost, 1308, 1319, "bimatoprost", "", +33, Timolol, 1324, 1331, "timolol", "", +38496, Dorz/TimFC, 1324, 1345, "timolol - dorzolamide", "", +34, Dorzolamide, 1334, 1345, "dorzolamide", "", +35, PvalueDiff, 1408, 1418, "p > 0 . 05", "", +36, Bimatoprost, 1430, 1441, "bimatoprost", "", +37, IOP, 1464, 1467, "IOP", "", +38, Reduction, 1482, 1487, "6 . 2", "", " \"6 . 2\"." +35011, SdDevChangeValue, 1494, 1499, "1 . 8", "", " \"1 . 8\"." +40, mmHg, 1500, 1504, "mmHg", "", " ." +41, Reduction, 1522, 1527, "6 . 5", "", " \"6 . 5\"." +35012, SdDevChangeValue, 1534, 1539, "2 . 3", "", " \"2 . 3\"." +43, mmHg, 1540, 1544, "mmHg", "", +38497, Dorz/TimFC, 1552, 1573, "timolol - dorzolamide", "", +44, Timolol, 1552, 1559, "timolol", "", +45, Dorzolamide, 1562, 1573, "dorzolamide", "", +119, TimePoint, 1586, 1594, "6 months", "", " \"6 months\". \"6 months\"." +47, PvalueDiff, 1661, 1671, "p = 0 . 48", "", " \"p = 0 . 48\"." +127, ConclusionComment, 1690, 1816, "The IOP - lowering efficacies of bimatoprost and timolol - dorzolamide combination were similar over a 6 - month follow - up .", "", " \"The IOP - lowering efficacies of bimatoprost and timolol - dorzolamide combination were similar over a 6 - month follow - up .\"." +49, IOP, 1694, 1697, "IOP", "", +50, Bimatoprost, 1723, 1734, "bimatoprost", "", +38498, Dorz/TimFC, 1739, 1760, "timolol - dorzolamide", "", +51, Timolol, 1739, 1746, "timolol", "", +52, Dorzolamide, 1749, 1760, "dorzolamide", "", +53, Duration, 1793, 1802, "6 - month", "", +54, ConclusionComment, 1817, 1897, "Both bimatoprost and the timolol - dorzolamide combination were well tolerated .", "", " \"Both bimatoprost and the timolol - dorzolamide combination were well tolerated .\"." +56, Bimatoprost, 1822, 1833, "bimatoprost", "", +38499, Dorz/TimFC, 1842, 1863, "timolol - dorzolamide", "", +57, Timolol, 1842, 1849, "timolol", "", +58, Dorzolamide, 1852, 1863, "dorzolamide", "", +55, ConclusionComment, 1898, 2004, "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension .", "", " \"Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension .\"." +59, Bimatoprost, 1898, 1909, "Bimatoprost", "", +65, Primary_OpenAngleGlaucoma, 1974, 1978, "POAG", "", +60, OcularHypertension, 1983, 2002, "ocular hypertension", "", +61, PMID, 2065, 2073, "17244215", "", " \"17244215\"." diff --git a/data/gl 17244215_admin.n-triples b/data/gl 17244215_admin.n-triples new file mode 100644 index 0000000..ef65a3a --- /dev/null +++ b/data/gl 17244215_admin.n-triples @@ -0,0 +1,101 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the ocular hypotensive effects of bimatoprost and timolol - dorzolamide combination in patients with elevated intraocular pressure : a 6 - month study ." . + "Ozturk F" . + "2007" . + "Acta Ophthalmol Scand" . + "17244215" . + . + "Ermis SS" . + "Inan UU" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol - dorzolamide combination in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension during 6 months of treatment ." . + "65" . + "6 - month" . + . + . + . + "The IOP - lowering efficacies of bimatoprost and timolol - dorzolamide combination were similar over a 6 - month follow - up ." . + . + . + . + . + . + "Both bimatoprost and the timolol - dorzolamide combination were well tolerated ." . + "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension ." . + . + . +# RDF export of group: Population + . + "Population" . + "elevated intraocular pressure" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bim" . + . + . + . + . + "Arm_dor-tim" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_dor-tim" . + . + "twice daily" . + . + . + "Intervention_bim" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_dor-tim" . + . + . + . + . + "Medication_bim" . + . + "0 . 03" . + . + . +# RDF export of group: Outcome + . + "Outcome_bim" . + . + "6 . 2" . + "1 . 8" . + "Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) ." . + "6 months" . + . + "Outcome_dor-tim" . + . + "6 . 5" . + "2 . 3" . + "Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) ." . + "6 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "p = 0 . 48" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17244215_export.csv b/data/gl 17244215_export.csv new file mode 100644 index 0000000..8f164b6 --- /dev/null +++ b/data/gl 17244215_export.csv @@ -0,0 +1,411 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +454, 1, 1, 1, 0, 4, 0, 4, "Acta" +454, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +454, 1, 3, 3, 16, 21, 16, 21, "Scand" +454, 1, 4, 4, 22, 23, 22, 23, "." +454, 2, 1, 5, 0, 4, 24, 28, "2007" +454, 2, 2, 6, 5, 8, 29, 32, "Feb" +454, 2, 3, 7, 9, 10, 33, 34, ";" +454, 2, 4, 8, 11, 13, 35, 37, "85" +454, 2, 5, 9, 14, 15, 38, 39, "(" +454, 2, 6, 10, 16, 17, 40, 41, "1" +454, 2, 7, 11, 18, 19, 42, 43, ")" +454, 2, 8, 12, 20, 21, 44, 45, ":" +454, 2, 9, 13, 22, 24, 46, 48, "80" +454, 2, 10, 14, 25, 26, 49, 50, "-" +454, 2, 11, 15, 27, 28, 51, 52, "3" +454, 2, 12, 16, 29, 30, 53, 54, "." +454, 3, 1, 17, 0, 10, 55, 65, "Comparison" +454, 3, 2, 18, 11, 13, 66, 68, "of" +454, 3, 3, 19, 14, 17, 69, 72, "the" +454, 3, 4, 20, 18, 24, 73, 79, "ocular" +454, 3, 5, 21, 25, 36, 80, 91, "hypotensive" +454, 3, 6, 22, 37, 44, 92, 99, "effects" +454, 3, 7, 23, 45, 47, 100, 102, "of" +454, 3, 8, 24, 48, 59, 103, 114, "bimatoprost" +454, 3, 9, 25, 60, 63, 115, 118, "and" +454, 3, 10, 26, 64, 71, 119, 126, "timolol" +454, 3, 11, 27, 72, 73, 127, 128, "-" +454, 3, 12, 28, 74, 85, 129, 140, "dorzolamide" +454, 3, 13, 29, 86, 97, 141, 152, "combination" +454, 3, 14, 30, 98, 100, 153, 155, "in" +454, 3, 15, 31, 101, 109, 156, 164, "patients" +454, 3, 16, 32, 110, 114, 165, 169, "with" +454, 3, 17, 33, 115, 123, 170, 178, "elevated" +454, 3, 18, 34, 124, 135, 179, 190, "intraocular" +454, 3, 19, 35, 136, 144, 191, 199, "pressure" +454, 3, 20, 36, 145, 146, 200, 201, ":" +454, 3, 21, 37, 147, 148, 202, 203, "a" +454, 3, 22, 38, 149, 150, 204, 205, "6" +454, 3, 23, 39, 151, 152, 206, 207, "-" +454, 3, 24, 40, 153, 158, 208, 213, "month" +454, 3, 25, 41, 159, 164, 214, 219, "study" +454, 3, 26, 42, 165, 166, 220, 221, "." +454, 4, 1, 43, 0, 6, 222, 228, "Ozturk" +454, 4, 2, 44, 7, 8, 229, 230, "F" +454, 4, 3, 45, 9, 10, 231, 232, "(" +454, 4, 4, 46, 11, 12, 233, 234, "1" +454, 4, 5, 47, 13, 14, 235, 236, ")" +454, 4, 6, 48, 15, 16, 237, 238, "," +454, 4, 7, 49, 17, 22, 239, 244, "Ermis" +454, 4, 8, 50, 23, 25, 245, 247, "SS" +454, 4, 9, 51, 26, 27, 248, 249, "," +454, 4, 10, 52, 28, 32, 250, 254, "Inan" +454, 4, 11, 53, 33, 35, 255, 257, "UU" +454, 4, 12, 54, 36, 37, 258, 259, "." +454, 5, 1, 55, 0, 6, 260, 266, "Author" +454, 5, 2, 56, 7, 18, 267, 278, "information" +454, 5, 3, 57, 19, 20, 279, 280, ":" +454, 5, 4, 58, 21, 22, 281, 282, "(" +454, 5, 5, 59, 23, 24, 283, 284, "1" +454, 5, 6, 60, 25, 26, 285, 286, ")" +454, 5, 7, 61, 27, 37, 287, 297, "Department" +454, 5, 8, 62, 38, 40, 298, 300, "of" +454, 5, 9, 63, 41, 54, 301, 314, "Ophthalmology" +454, 5, 10, 64, 55, 56, 315, 316, "," +454, 5, 11, 65, 57, 63, 317, 323, "School" +454, 5, 12, 66, 64, 66, 324, 326, "of" +454, 5, 13, 67, 67, 75, 327, 335, "Medicine" +454, 5, 14, 68, 76, 77, 336, 337, "," +454, 5, 15, 69, 78, 88, 338, 348, "University" +454, 5, 16, 70, 89, 91, 349, 351, "of" +454, 5, 17, 71, 92, 97, 352, 357, "Afyon" +454, 5, 18, 72, 98, 106, 358, 366, "Kocatepe" +454, 5, 19, 73, 107, 108, 367, 368, "," +454, 5, 20, 74, 109, 114, 369, 374, "Afyon" +454, 5, 21, 75, 115, 116, 375, 376, "," +454, 5, 22, 76, 117, 123, 377, 383, "Turkey" +454, 5, 23, 77, 124, 125, 384, 385, "." +454, 6, 1, 78, 0, 7, 386, 393, "PURPOSE" +454, 6, 2, 79, 8, 9, 394, 395, ":" +454, 6, 3, 80, 10, 12, 396, 398, "To" +454, 6, 4, 81, 13, 20, 399, 406, "compare" +454, 6, 5, 82, 21, 24, 407, 410, "the" +454, 6, 6, 83, 25, 31, 411, 417, "ocular" +454, 6, 7, 84, 32, 43, 418, 429, "hypotensive" +454, 6, 8, 85, 44, 52, 430, 438, "efficacy" +454, 6, 9, 86, 53, 56, 439, 442, "and" +454, 6, 10, 87, 57, 63, 443, 449, "safety" +454, 6, 11, 88, 64, 66, 450, 452, "of" +454, 6, 12, 89, 67, 74, 453, 460, "topical" +454, 6, 13, 90, 75, 86, 461, 472, "bimatoprost" +454, 6, 14, 91, 87, 90, 473, 476, "and" +454, 6, 15, 92, 91, 98, 477, 484, "timolol" +454, 6, 16, 93, 99, 100, 485, 486, "-" +454, 6, 17, 94, 101, 112, 487, 498, "dorzolamide" +454, 6, 18, 95, 113, 124, 499, 510, "combination" +454, 6, 19, 96, 125, 127, 511, 513, "in" +454, 6, 20, 97, 128, 136, 514, 522, "patients" +454, 6, 21, 98, 137, 141, 523, 527, "with" +454, 6, 22, 99, 142, 149, 528, 535, "primary" +454, 6, 23, 100, 150, 154, 536, 540, "open" +454, 6, 24, 101, 155, 156, 541, 542, "-" +454, 6, 25, 102, 157, 162, 543, 548, "angle" +454, 6, 26, 103, 163, 171, 549, 557, "glaucoma" +454, 6, 27, 104, 172, 173, 558, 559, "(" +454, 6, 28, 105, 174, 178, 560, 564, "POAG" +454, 6, 29, 106, 179, 180, 565, 566, ")" +454, 6, 30, 107, 181, 183, 567, 569, "or" +454, 6, 31, 108, 184, 190, 570, 576, "ocular" +454, 6, 32, 109, 191, 203, 577, 589, "hypertension" +454, 6, 33, 110, 204, 210, 590, 596, "during" +454, 6, 34, 111, 211, 212, 597, 598, "6" +454, 6, 35, 112, 213, 219, 599, 605, "months" +454, 6, 36, 113, 220, 222, 606, 608, "of" +454, 6, 37, 114, 223, 232, 609, 618, "treatment" +454, 6, 38, 115, 233, 234, 619, 620, "." +454, 7, 1, 116, 0, 7, 621, 628, "METHODS" +454, 7, 2, 117, 8, 9, 629, 630, ":" +454, 7, 3, 118, 10, 11, 631, 632, "A" +454, 7, 4, 119, 12, 18, 633, 639, "sample" +454, 7, 5, 120, 19, 21, 640, 642, "of" +454, 7, 6, 121, 22, 24, 643, 645, "65" +454, 7, 7, 122, 25, 33, 646, 654, "patients" +454, 7, 8, 123, 34, 38, 655, 659, "with" +454, 7, 9, 124, 39, 40, 660, 661, "a" +454, 7, 10, 125, 41, 50, 662, 671, "diagnosis" +454, 7, 11, 126, 51, 53, 672, 674, "of" +454, 7, 12, 127, 54, 58, 675, 679, "POAG" +454, 7, 13, 128, 59, 61, 680, 682, "or" +454, 7, 14, 129, 62, 68, 683, 689, "ocular" +454, 7, 15, 130, 69, 81, 690, 702, "hypertension" +454, 7, 16, 131, 82, 86, 703, 707, "were" +454, 7, 17, 132, 87, 97, 708, 718, "randomized" +454, 7, 18, 133, 98, 100, 719, 721, "to" +454, 7, 19, 134, 101, 108, 722, 729, "receive" +454, 7, 20, 135, 109, 115, 730, 736, "either" +454, 7, 21, 136, 116, 127, 737, 748, "bimatoprost" +454, 7, 22, 137, 128, 129, 749, 750, "0" +454, 7, 23, 138, 130, 131, 751, 752, "." +454, 7, 24, 139, 132, 134, 753, 755, "03" +454, 7, 25, 140, 135, 136, 756, 757, "%" +454, 7, 26, 141, 137, 141, 758, 762, "once" +454, 7, 27, 142, 142, 147, 763, 768, "daily" +454, 7, 28, 143, 148, 150, 769, 771, "or" +454, 7, 29, 144, 151, 158, 772, 779, "timolol" +454, 7, 30, 145, 159, 160, 780, 781, "-" +454, 7, 31, 146, 161, 172, 782, 793, "dorzolamide" +454, 7, 32, 147, 173, 184, 794, 805, "combination" +454, 7, 33, 148, 185, 190, 806, 811, "twice" +454, 7, 34, 149, 191, 196, 812, 817, "daily" +454, 7, 35, 150, 197, 198, 818, 819, "." +454, 8, 1, 151, 0, 5, 820, 825, "Study" +454, 8, 2, 152, 6, 12, 826, 832, "visits" +454, 8, 3, 153, 13, 21, 833, 841, "occurred" +454, 8, 4, 154, 22, 24, 842, 844, "at" +454, 8, 5, 155, 25, 33, 845, 853, "baseline" +454, 8, 6, 156, 34, 37, 854, 857, "and" +454, 8, 7, 157, 38, 43, 858, 863, "after" +454, 8, 8, 158, 44, 45, 864, 865, "2" +454, 8, 9, 159, 46, 51, 866, 871, "weeks" +454, 8, 10, 160, 52, 55, 872, 875, "and" +454, 8, 11, 161, 56, 57, 876, 877, "1" +454, 8, 12, 162, 58, 59, 878, 879, "," +454, 8, 13, 163, 60, 61, 880, 881, "3" +454, 8, 14, 164, 62, 65, 882, 885, "and" +454, 8, 15, 165, 66, 67, 886, 887, "6" +454, 8, 16, 166, 68, 74, 888, 894, "months" +454, 8, 17, 167, 75, 77, 895, 897, "of" +454, 8, 18, 168, 78, 85, 898, 905, "therapy" +454, 8, 19, 169, 86, 87, 906, 907, "." +454, 9, 1, 170, 0, 11, 908, 919, "Intraocular" +454, 9, 2, 171, 12, 20, 920, 928, "pressure" +454, 9, 3, 172, 21, 22, 929, 930, "(" +454, 9, 4, 173, 23, 26, 931, 934, "IOP" +454, 9, 5, 174, 27, 28, 935, 936, ")" +454, 9, 6, 175, 29, 41, 937, 949, "measurements" +454, 9, 7, 176, 42, 46, 950, 954, "were" +454, 9, 8, 177, 47, 56, 955, 964, "performed" +454, 9, 9, 178, 57, 59, 965, 967, "at" +454, 9, 10, 179, 60, 62, 968, 970, "12" +454, 9, 11, 180, 63, 64, 971, 972, "." +454, 9, 12, 181, 65, 67, 973, 975, "00" +454, 9, 13, 182, 68, 73, 976, 981, "hours" +454, 9, 14, 183, 74, 76, 982, 984, "at" +454, 9, 15, 184, 77, 80, 985, 988, "all" +454, 9, 16, 185, 81, 86, 989, 994, "study" +454, 9, 17, 186, 87, 93, 995, 1001, "visits" +454, 9, 18, 187, 94, 97, 1002, 1005, "and" +454, 9, 19, 188, 98, 102, 1006, 1010, "also" +454, 9, 20, 189, 103, 105, 1011, 1013, "at" +454, 9, 21, 190, 106, 108, 1014, 1016, "08" +454, 9, 22, 191, 109, 110, 1017, 1018, "." +454, 9, 23, 192, 111, 113, 1019, 1021, "00" +454, 9, 24, 193, 114, 119, 1022, 1027, "hours" +454, 9, 25, 194, 120, 123, 1028, 1031, "and" +454, 9, 26, 195, 124, 126, 1032, 1034, "16" +454, 9, 27, 196, 127, 128, 1035, 1036, "." +454, 9, 28, 197, 129, 131, 1037, 1039, "00" +454, 9, 29, 198, 132, 137, 1040, 1045, "hours" +454, 9, 30, 199, 138, 140, 1046, 1048, "at" +454, 9, 31, 200, 141, 149, 1049, 1057, "baseline" +454, 9, 32, 201, 150, 153, 1058, 1061, "and" +454, 9, 33, 202, 154, 155, 1062, 1063, "6" +454, 9, 34, 203, 156, 157, 1064, 1065, "-" +454, 9, 35, 204, 158, 163, 1066, 1071, "month" +454, 9, 36, 205, 164, 170, 1072, 1078, "visits" +454, 9, 37, 206, 171, 172, 1079, 1080, "." +454, 10, 1, 207, 0, 2, 1081, 1083, "At" +454, 10, 2, 208, 3, 7, 1084, 1088, "each" +454, 10, 3, 209, 8, 13, 1089, 1094, "visit" +454, 10, 4, 210, 14, 15, 1095, 1096, "," +454, 10, 5, 211, 16, 21, 1097, 1102, "local" +454, 10, 6, 212, 22, 25, 1103, 1106, "and" +454, 10, 7, 213, 26, 34, 1107, 1115, "systemic" +454, 10, 8, 214, 35, 39, 1116, 1120, "side" +454, 10, 9, 215, 40, 41, 1121, 1122, "-" +454, 10, 10, 216, 42, 49, 1123, 1130, "effects" +454, 10, 11, 217, 50, 54, 1131, 1135, "that" +454, 10, 12, 218, 55, 63, 1136, 1144, "occurred" +454, 10, 13, 219, 64, 70, 1145, 1151, "during" +454, 10, 14, 220, 71, 74, 1152, 1155, "the" +454, 10, 15, 221, 75, 84, 1156, 1165, "treatment" +454, 10, 16, 222, 85, 91, 1166, 1172, "period" +454, 10, 17, 223, 92, 96, 1173, 1177, "were" +454, 10, 18, 224, 97, 105, 1178, 1186, "recorded" +454, 10, 19, 225, 106, 107, 1187, 1188, "." +454, 11, 1, 226, 0, 7, 1189, 1196, "Student" +454, 11, 2, 227, 8, 9, 1197, 1198, "'" +454, 11, 3, 228, 10, 11, 1199, 1200, "s" +454, 11, 4, 229, 12, 13, 1201, 1202, "t" +454, 11, 5, 230, 14, 15, 1203, 1204, "-" +454, 11, 6, 231, 16, 20, 1205, 1209, "test" +454, 11, 7, 232, 21, 24, 1210, 1213, "was" +454, 11, 8, 233, 25, 29, 1214, 1218, "used" +454, 11, 9, 234, 30, 32, 1219, 1221, "to" +454, 11, 10, 235, 33, 40, 1222, 1229, "compare" +454, 11, 11, 236, 41, 44, 1230, 1233, "the" +454, 11, 12, 237, 45, 56, 1234, 1245, "differences" +454, 11, 13, 238, 57, 64, 1246, 1253, "between" +454, 11, 14, 239, 65, 68, 1254, 1257, "IOP" +454, 11, 15, 240, 69, 75, 1258, 1264, "values" +454, 11, 16, 241, 76, 77, 1265, 1266, "." +454, 12, 1, 242, 0, 7, 1267, 1274, "RESULTS" +454, 12, 2, 243, 8, 9, 1275, 1276, ":" +454, 12, 3, 244, 10, 21, 1277, 1288, "Differences" +454, 12, 4, 245, 22, 24, 1289, 1291, "in" +454, 12, 5, 246, 25, 28, 1292, 1295, "IOP" +454, 12, 6, 247, 29, 36, 1296, 1303, "between" +454, 12, 7, 248, 37, 40, 1304, 1307, "the" +454, 12, 8, 249, 41, 52, 1308, 1319, "bimatoprost" +454, 12, 9, 250, 53, 56, 1320, 1323, "and" +454, 12, 10, 251, 57, 64, 1324, 1331, "timolol" +454, 12, 11, 252, 65, 66, 1332, 1333, "-" +454, 12, 12, 253, 67, 78, 1334, 1345, "dorzolamide" +454, 12, 13, 254, 79, 85, 1346, 1352, "groups" +454, 12, 14, 255, 86, 90, 1353, 1357, "were" +454, 12, 15, 256, 91, 104, 1358, 1371, "statistically" +454, 12, 16, 257, 105, 118, 1372, 1385, "insignificant" +454, 12, 17, 258, 119, 121, 1386, 1388, "at" +454, 12, 18, 259, 122, 125, 1389, 1392, "all" +454, 12, 19, 260, 126, 131, 1393, 1398, "study" +454, 12, 20, 261, 132, 138, 1399, 1405, "visits" +454, 12, 21, 262, 139, 140, 1406, 1407, "(" +454, 12, 22, 263, 141, 142, 1408, 1409, "p" +454, 12, 23, 264, 143, 144, 1410, 1411, ">" +454, 12, 24, 265, 145, 146, 1412, 1413, "0" +454, 12, 25, 266, 147, 148, 1414, 1415, "." +454, 12, 26, 267, 149, 151, 1416, 1418, "05" +454, 12, 27, 268, 152, 153, 1419, 1420, ")" +454, 12, 28, 269, 154, 155, 1421, 1422, "." +454, 13, 1, 270, 0, 2, 1423, 1425, "In" +454, 13, 2, 271, 3, 6, 1426, 1429, "the" +454, 13, 3, 272, 7, 18, 1430, 1441, "bimatoprost" +454, 13, 4, 273, 19, 20, 1442, 1443, "-" +454, 13, 5, 274, 21, 28, 1444, 1451, "treated" +454, 13, 6, 275, 29, 34, 1452, 1457, "group" +454, 13, 7, 276, 35, 36, 1458, 1459, "," +454, 13, 8, 277, 37, 40, 1460, 1463, "the" +454, 13, 9, 278, 41, 44, 1464, 1467, "IOP" +454, 13, 10, 279, 45, 54, 1468, 1477, "reduction" +454, 13, 11, 280, 55, 58, 1478, 1481, "was" +454, 13, 12, 281, 59, 60, 1482, 1483, "6" +454, 13, 13, 282, 61, 62, 1484, 1485, "." +454, 13, 14, 283, 63, 64, 1486, 1487, "2" +454, 13, 15, 284, 65, 66, 1488, 1489, "+" +454, 13, 16, 285, 67, 68, 1490, 1491, "/" +454, 13, 17, 286, 69, 70, 1492, 1493, "-" +454, 13, 18, 287, 71, 72, 1494, 1495, "1" +454, 13, 19, 288, 73, 74, 1496, 1497, "." +454, 13, 20, 289, 75, 76, 1498, 1499, "8" +454, 13, 21, 290, 77, 81, 1500, 1504, "mmHg" +454, 13, 22, 291, 82, 83, 1505, 1506, "," +454, 13, 23, 292, 84, 91, 1507, 1514, "whereas" +454, 13, 24, 293, 92, 94, 1515, 1517, "it" +454, 13, 25, 294, 95, 98, 1518, 1521, "was" +454, 13, 26, 295, 99, 100, 1522, 1523, "6" +454, 13, 27, 296, 101, 102, 1524, 1525, "." +454, 13, 28, 297, 103, 104, 1526, 1527, "5" +454, 13, 29, 298, 105, 106, 1528, 1529, "+" +454, 13, 30, 299, 107, 108, 1530, 1531, "/" +454, 13, 31, 300, 109, 110, 1532, 1533, "-" +454, 13, 32, 301, 111, 112, 1534, 1535, "2" +454, 13, 33, 302, 113, 114, 1536, 1537, "." +454, 13, 34, 303, 115, 116, 1538, 1539, "3" +454, 13, 35, 304, 117, 121, 1540, 1544, "mmHg" +454, 13, 36, 305, 122, 124, 1545, 1547, "in" +454, 13, 37, 306, 125, 128, 1548, 1551, "the" +454, 13, 38, 307, 129, 136, 1552, 1559, "timolol" +454, 13, 39, 308, 137, 138, 1560, 1561, "-" +454, 13, 40, 309, 139, 150, 1562, 1573, "dorzolamide" +454, 13, 41, 310, 151, 156, 1574, 1579, "group" +454, 13, 42, 311, 157, 162, 1580, 1585, "after" +454, 13, 43, 312, 163, 164, 1586, 1587, "6" +454, 13, 44, 313, 165, 171, 1588, 1594, "months" +454, 13, 45, 314, 172, 174, 1595, 1597, "of" +454, 13, 46, 315, 175, 184, 1598, 1607, "treatment" +454, 13, 47, 316, 185, 186, 1608, 1609, "." +454, 14, 1, 317, 0, 3, 1610, 1613, "The" +454, 14, 2, 318, 4, 14, 1614, 1624, "difference" +454, 14, 3, 319, 15, 18, 1625, 1628, "was" +454, 14, 4, 320, 19, 22, 1629, 1632, "not" +454, 14, 5, 321, 23, 36, 1633, 1646, "statistically" +454, 14, 6, 322, 37, 48, 1647, 1658, "significant" +454, 14, 7, 323, 49, 50, 1659, 1660, "(" +454, 14, 8, 324, 51, 52, 1661, 1662, "p" +454, 14, 9, 325, 53, 54, 1663, 1664, "=" +454, 14, 10, 326, 55, 56, 1665, 1666, "0" +454, 14, 11, 327, 57, 58, 1667, 1668, "." +454, 14, 12, 328, 59, 61, 1669, 1671, "48" +454, 14, 13, 329, 62, 63, 1672, 1673, ")" +454, 14, 14, 330, 64, 65, 1674, 1675, "." +454, 15, 1, 331, 0, 11, 1676, 1687, "CONCLUSIONS" +454, 15, 2, 332, 12, 13, 1688, 1689, ":" +454, 15, 3, 333, 14, 17, 1690, 1693, "The" +454, 15, 4, 334, 18, 21, 1694, 1697, "IOP" +454, 15, 5, 335, 22, 23, 1698, 1699, "-" +454, 15, 6, 336, 24, 32, 1700, 1708, "lowering" +454, 15, 7, 337, 33, 43, 1709, 1719, "efficacies" +454, 15, 8, 338, 44, 46, 1720, 1722, "of" +454, 15, 9, 339, 47, 58, 1723, 1734, "bimatoprost" +454, 15, 10, 340, 59, 62, 1735, 1738, "and" +454, 15, 11, 341, 63, 70, 1739, 1746, "timolol" +454, 15, 12, 342, 71, 72, 1747, 1748, "-" +454, 15, 13, 343, 73, 84, 1749, 1760, "dorzolamide" +454, 15, 14, 344, 85, 96, 1761, 1772, "combination" +454, 15, 15, 345, 97, 101, 1773, 1777, "were" +454, 15, 16, 346, 102, 109, 1778, 1785, "similar" +454, 15, 17, 347, 110, 114, 1786, 1790, "over" +454, 15, 18, 348, 115, 116, 1791, 1792, "a" +454, 15, 19, 349, 117, 118, 1793, 1794, "6" +454, 15, 20, 350, 119, 120, 1795, 1796, "-" +454, 15, 21, 351, 121, 126, 1797, 1802, "month" +454, 15, 22, 352, 127, 133, 1803, 1809, "follow" +454, 15, 23, 353, 134, 135, 1810, 1811, "-" +454, 15, 24, 354, 136, 138, 1812, 1814, "up" +454, 15, 25, 355, 139, 140, 1815, 1816, "." +454, 16, 1, 356, 0, 4, 1817, 1821, "Both" +454, 16, 2, 357, 5, 16, 1822, 1833, "bimatoprost" +454, 16, 3, 358, 17, 20, 1834, 1837, "and" +454, 16, 4, 359, 21, 24, 1838, 1841, "the" +454, 16, 5, 360, 25, 32, 1842, 1849, "timolol" +454, 16, 6, 361, 33, 34, 1850, 1851, "-" +454, 16, 7, 362, 35, 46, 1852, 1863, "dorzolamide" +454, 16, 8, 363, 47, 58, 1864, 1875, "combination" +454, 16, 9, 364, 59, 63, 1876, 1880, "were" +454, 16, 10, 365, 64, 68, 1881, 1885, "well" +454, 16, 11, 366, 69, 78, 1886, 1895, "tolerated" +454, 16, 12, 367, 79, 80, 1896, 1897, "." +454, 17, 1, 368, 0, 11, 1898, 1909, "Bimatoprost" +454, 17, 2, 369, 12, 15, 1910, 1913, "can" +454, 17, 3, 370, 16, 18, 1914, 1916, "be" +454, 17, 4, 371, 19, 23, 1917, 1921, "used" +454, 17, 5, 372, 24, 26, 1922, 1924, "as" +454, 17, 6, 373, 27, 28, 1925, 1926, "a" +454, 17, 7, 374, 29, 37, 1927, 1935, "longterm" +454, 17, 8, 375, 38, 49, 1936, 1947, "monotherapy" +454, 17, 9, 376, 50, 55, 1948, 1953, "agent" +454, 17, 10, 377, 56, 58, 1954, 1956, "in" +454, 17, 11, 378, 59, 62, 1957, 1960, "the" +454, 17, 12, 379, 63, 72, 1961, 1970, "treatment" +454, 17, 13, 380, 73, 75, 1971, 1973, "of" +454, 17, 14, 381, 76, 80, 1974, 1978, "POAG" +454, 17, 15, 382, 81, 84, 1979, 1982, "and" +454, 17, 16, 383, 85, 91, 1983, 1989, "ocular" +454, 17, 17, 384, 92, 104, 1990, 2002, "hypertension" +454, 17, 18, 385, 105, 106, 2003, 2004, "." +454, 18, 1, 386, 0, 3, 2005, 2008, "DOI" +454, 18, 2, 387, 4, 5, 2009, 2010, ":" +454, 18, 3, 388, 6, 8, 2011, 2013, "10" +454, 18, 4, 389, 9, 10, 2014, 2015, "." +454, 18, 5, 390, 11, 15, 2016, 2020, "1111" +454, 18, 6, 391, 16, 17, 2021, 2022, "/" +454, 18, 7, 392, 18, 19, 2023, 2024, "j" +454, 18, 8, 393, 20, 21, 2025, 2026, "." +454, 18, 9, 394, 22, 26, 2027, 2031, "1600" +454, 18, 10, 395, 27, 28, 2032, 2033, "-" +454, 18, 11, 396, 29, 33, 2034, 2038, "0420" +454, 18, 12, 397, 34, 35, 2039, 2040, "." +454, 18, 13, 398, 36, 40, 2041, 2045, "2006" +454, 18, 14, 399, 41, 42, 2046, 2047, "." +454, 18, 15, 400, 43, 48, 2048, 2053, "00754" +454, 18, 16, 401, 49, 50, 2054, 2055, "." +454, 18, 17, 402, 51, 52, 2056, 2057, "x" +454, 18, 18, 403, 53, 57, 2058, 2062, "PMID" +454, 18, 19, 404, 58, 59, 2063, 2064, ":" +454, 18, 20, 405, 60, 68, 2065, 2073, "17244215" +454, 18, 21, 406, 69, 70, 2074, 2075, "[" +454, 18, 22, 407, 71, 78, 2076, 2083, "Indexed" +454, 18, 23, 408, 79, 82, 2084, 2087, "for" +454, 18, 24, 409, 83, 90, 2088, 2095, "MEDLINE" +454, 18, 25, 410, 91, 92, 2096, 2097, "]" diff --git a/data/gl 17244215_jshahinitiran.annodb b/data/gl 17244215_jshahinitiran.annodb new file mode 100644 index 0000000..16d491a --- /dev/null +++ b/data/gl 17244215_jshahinitiran.annodb @@ -0,0 +1,70 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +10904, Journal, 0, 21, "Acta Ophthalmol Scand", "", +10905, PublicationYear, 24, 28, "2007", "", +10906, Title, 55, 221, "Comparison of the ocular hypotensive effects of bimatoprost and timolol - dorzolamide combination in patients with elevated intraocular pressure : a 6 - month study .", "", +10907, Bimatoprost, 103, 114, "bimatoprost", "", +10908, Timolol, 119, 126, "timolol", "", +10909, Dorzolamide, 129, 140, "dorzolamide", "", +10912, Precondition, 170, 199, "elevated intraocular pressure", "", +10910, IOP, 179, 199, "intraocular pressure", "", +10911, Duration, 204, 213, "6 - month", "", +10913, Author, 222, 230, "Ozturk F", "", +10914, Author, 239, 247, "Ermis SS", "", +10915, Author, 250, 257, "Inan UU", "", +10916, Turkey, 377, 383, "Turkey", "", +10917, ObjectiveDescription, 396, 618, "To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol - dorzolamide combination in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension during 6 months of treatment", "", +10918, Bimatoprost, 461, 472, "bimatoprost", "", +10919, Timolol, 477, 484, "timolol", "", +10920, Dorzolamide, 487, 498, "dorzolamide", "", +28045, Primary_OpenAngleGlaucoma, 528, 557, "primary open - angle glaucoma", "", +28046, Primary_OpenAngleGlaucoma, 560, 564, "POAG", "", +10924, Duration, 597, 605, "6 months", "", +10925, NumberPatientsCT, 643, 645, "65", "", +28047, Primary_OpenAngleGlaucoma, 675, 679, "POAG", "", +10928, Randomized, 708, 718, "randomized", "", +10929, Bimatoprost, 737, 748, "bimatoprost", "", +10930, DoseValue, 749, 755, "0 . 03", "", +10931, Percentage, 756, 757, "%", "", +10932, Frequency, 758, 768, "once daily", "", +10933, Timolol, 772, 779, "timolol", "", +10934, Dorzolamide, 782, 793, "dorzolamide", "", +10935, Frequency, 806, 817, "twice daily", "", +28049, TimePoint, 845, 853, "baseline", "", +28050, TimePoint, 864, 871, "2 weeks", "", +28051, TimePoint, 876, 894, "1 , 3 and 6 months", "", +10937, IOP, 908, 928, "Intraocular pressure", "", +10938, IOP, 931, 934, "IOP", "", +10941, TimePoint, 1062, 1071, "6 - month", "", +10942, IOP, 1254, 1257, "IOP", "", +10943, IOP, 1292, 1295, "IOP", "", +10944, Bimatoprost, 1308, 1319, "bimatoprost", "", +10945, Timolol, 1324, 1331, "timolol", "", +10946, Dorzolamide, 1334, 1345, "dorzolamide", "", +10947, PvalueDiff, 1408, 1418, "p > 0 . 05", "", +10948, Bimatoprost, 1430, 1441, "bimatoprost", "", +10949, IOP, 1464, 1467, "IOP", "", +10950, Reduction, 1482, 1487, "6 . 2", "", +10951, SdErrorChangeValue, 1494, 1499, "1 . 8", "", +10952, mmHg, 1500, 1504, "mmHg", "", +10953, Reduction, 1522, 1527, "6 . 5", "", +10954, SdErrorChangeValue, 1534, 1539, "2 . 3", "", +10955, mmHg, 1540, 1544, "mmHg", "", +10956, Timolol, 1552, 1559, "timolol", "", +10957, Dorzolamide, 1562, 1573, "dorzolamide", "", +10958, Duration, 1586, 1594, "6 months", "", +10959, PvalueDiff, 1661, 1671, "p = 0 . 48", "", +10960, ConclusionComment, 1690, 1814, "The IOP - lowering efficacies of bimatoprost and timolol - dorzolamide combination were similar over a 6 - month follow - up", "", +10961, IOP, 1694, 1697, "IOP", "", +10962, Bimatoprost, 1723, 1734, "bimatoprost", "", +10963, Timolol, 1739, 1746, "timolol", "", +10964, Dorzolamide, 1749, 1760, "dorzolamide", "", +10965, Duration, 1793, 1802, "6 - month", "", +10966, ConclusionComment, 1817, 1897, "Both bimatoprost and the timolol - dorzolamide combination were well tolerated .", "", +10968, Bimatoprost, 1822, 1833, "bimatoprost", "", +10969, Timolol, 1842, 1849, "timolol", "", +10970, Dorzolamide, 1852, 1863, "dorzolamide", "", +10967, ConclusionComment, 1898, 2004, "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension .", "", +10971, Bimatoprost, 1898, 1909, "Bimatoprost", "", +28048, Primary_OpenAngleGlaucoma, 1974, 1978, "POAG", "", +10973, OcularHypertension, 1983, 2002, "ocular hypertension", "", +10974, PMID, 2065, 2073, "17244215", "", diff --git a/data/gl 17244215_jshahinitiran.n-triples b/data/gl 17244215_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17244215_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17244215_tstrakeljahn.annodb b/data/gl 17244215_tstrakeljahn.annodb new file mode 100644 index 0000000..d52d0f8 --- /dev/null +++ b/data/gl 17244215_tstrakeljahn.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30322, Journal, 0, 21, "Acta Ophthalmol Scand", "", +30323, PublicationYear, 24, 28, "2007", "", +30329, Title, 55, 221, "Comparison of the ocular hypotensive effects of bimatoprost and timolol - dorzolamide combination in patients with elevated intraocular pressure : a 6 - month study .", "", +30324, Bimatoprost, 103, 114, "bimatoprost", "", +30325, Timolol, 119, 126, "timolol", "", +30326, Dorzolamide, 129, 140, "dorzolamide", "", +30327, IOP, 179, 199, "intraocular pressure", "", +30328, Duration, 204, 213, "6 - month", "", +30330, Author, 222, 230, "Ozturk F", "", +30331, Author, 239, 247, "Ermis SS", "", +30332, Author, 250, 257, "Inan UU", "", +30333, Turkey, 377, 383, "Turkey", "", +30341, ObjectiveDescription, 396, 620, "To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol - dorzolamide combination in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension during 6 months of treatment .", "", +30334, Bimatoprost, 461, 472, "bimatoprost", "", +30335, Timolol, 477, 484, "timolol", "", +30336, Dorzolamide, 487, 498, "dorzolamide", "", +30337, Primary_OpenAngleGlaucoma, 528, 557, "primary open - angle glaucoma", "", +30338, Primary_OpenAngleGlaucoma, 560, 564, "POAG", "", +30339, OcularHypertension, 570, 589, "ocular hypertension", "", +30340, Duration, 597, 605, "6 months", "", +30342, NumberPatientsCT, 643, 645, "65", "", +30343, Primary_OpenAngleGlaucoma, 675, 679, "POAG", "", +30344, OcularHypertension, 683, 702, "ocular hypertension", "", +30345, Randomized, 708, 718, "randomized", "", +30346, Bimatoprost, 737, 748, "bimatoprost", "", +30349, DoseValue, 749, 755, "0 . 03", "", +30350, Percentage, 756, 757, "%", "", +30351, Frequency, 758, 768, "once daily", "", +30347, Timolol, 772, 779, "timolol", "", +30348, Dorzolamide, 782, 793, "dorzolamide", "", +30352, Frequency, 806, 817, "twice daily", "", +30353, IOP, 908, 928, "Intraocular pressure", "", +30354, IOP, 931, 934, "IOP", "", +30355, IOP, 1254, 1257, "IOP", "", +30374, ObservedResult, 1277, 1422, "Differences in IOP between the bimatoprost and timolol - dorzolamide groups were statistically insignificant at all study visits ( p > 0 . 05 ) .", "", +30356, IOP, 1292, 1295, "IOP", "", +30358, Bimatoprost, 1308, 1319, "bimatoprost", "", +30359, Timolol, 1324, 1331, "timolol", "", +30360, Dorzolamide, 1334, 1345, "dorzolamide", "", +30361, PvalueDiff, 1408, 1418, "p > 0 . 05", "", +30362, Bimatoprost, 1430, 1441, "bimatoprost", "", +30363, IOP, 1464, 1467, "IOP", "", +30364, Reduction, 1482, 1487, "6 . 2", "", +30365, SdDevChangeValue, 1488, 1499, "+ / - 1 . 8", "", +30367, mmHg, 1500, 1504, "mmHg", "", +30369, Reduction, 1522, 1527, "6 . 5", "", +30366, SdDevChangeValue, 1528, 1539, "+ / - 2 . 3", "", +30368, mmHg, 1540, 1544, "mmHg", "", +30370, Timolol, 1552, 1559, "timolol", "", +30371, Dorzolamide, 1562, 1573, "dorzolamide", "", +30372, TimePoint, 1586, 1594, "6 months", "", +30375, ObservedResult, 1610, 1675, "The difference was not statistically significant ( p = 0 . 48 ) .", "", +30373, PValueResValue, 1661, 1671, "p = 0 . 48", "", +30380, ConclusionComment, 1690, 1816, "The IOP - lowering efficacies of bimatoprost and timolol - dorzolamide combination were similar over a 6 - month follow - up .", "", +30357, IOP, 1694, 1697, "IOP", "", +30376, Bimatoprost, 1723, 1734, "bimatoprost", "", +30377, Timolol, 1739, 1746, "timolol", "", +30378, Dorzolamide, 1749, 1760, "dorzolamide", "", +30379, Duration, 1793, 1802, "6 - month", "", +30384, ConclusionComment, 1817, 1897, "Both bimatoprost and the timolol - dorzolamide combination were well tolerated .", "", +30381, Bimatoprost, 1822, 1833, "bimatoprost", "", +30382, Timolol, 1842, 1849, "timolol", "", +30383, Dorzolamide, 1852, 1863, "dorzolamide", "", +30385, Bimatoprost, 1898, 1909, "Bimatoprost", "", +30389, ConclusionComment, 1898, 2004, "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension .", "", +30387, Primary_OpenAngleGlaucoma, 1974, 1978, "POAG", "", +30388, OcularHypertension, 1983, 2002, "ocular hypertension", "", +30390, PMID, 2065, 2073, "17244215", "", diff --git a/data/gl 17244215_tstrakeljahn.n-triples b/data/gl 17244215_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17244215_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17407624_admin.annodb b/data/gl 17407624_admin.annodb new file mode 100644 index 0000000..705d507 --- /dev/null +++ b/data/gl 17407624_admin.annodb @@ -0,0 +1,119 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2007", "", " \"2007\"." +2, Title, 52, 201, "Comparing the fixed combination brimonidine - timolol versus fixed combination dorzolamide - timolol in patients with elevated intraocular pressure .", "", " \"Comparing the fixed combination brimonidine - timolol versus fixed combination dorzolamide - timolol in patients with elevated intraocular pressure .\"." +5, Brimo/TimFC, 66, 105, "fixed combination brimonidine - timolol", "", +3, Brimonidine, 84, 95, "brimonidine", "", +4, Timolol, 98, 105, "timolol", "", +8, Dorz/TimFC, 113, 152, "fixed combination dorzolamide - timolol", "", +6, Dorzolamide, 131, 142, "dorzolamide", "", +7, Timolol, 145, 152, "timolol", "", +115, Precondition, 156, 199, "patients with elevated intraocular pressure", "", " \"patients with elevated intraocular pressure\"." +9, IOP, 179, 199, "intraocular pressure", "", +10, Author, 202, 212, "Arcieri ES", "", " \"Arcieri ES\"." +11, Author, 221, 231, "Arcieri RS", "", " \"Arcieri RS\"." +12, Author, 234, 244, "Pereira AC", "", " \"Pereira AC\"." +13, Author, 247, 256, "Andreo EG", "", " \"Andreo EG\"." +14, Author, 259, 269, "Finotti IG", "", " \"Finotti IG\"." +15, Author, 272, 284, "S á Filho WF", "", " \"S á Filho WF\"." +16, Glaucoma, 314, 322, "Glaucoma", "", +17, Brazil, 425, 431, "Brazil", "", " ." +18, ObjectiveDescription, 471, 707, "To evaluate the efficacy of fixed combination brimonidine - timolol ( FCBT ) versus fixed combination dorzolamide - timolol ( FCDT ) given twice daily in patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", " \"To evaluate the efficacy of fixed combination brimonidine - timolol ( FCBT ) versus fixed combination dorzolamide - timolol ( FCDT ) given twice daily in patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH ) .\"." +23, Brimo/TimFC, 499, 538, "fixed combination brimonidine - timolol", "", +19, Brimonidine, 517, 528, "brimonidine", "", +21, Timolol, 531, 538, "timolol", "", +24, Brimo/TimFC, 541, 545, "FCBT", "", " ." +25, Dorz/TimFC, 555, 594, "fixed combination dorzolamide - timolol", "", " ." +20, Dorzolamide, 573, 584, "dorzolamide", "", +22, Timolol, 587, 594, "timolol", "", +26, Dorz/TimFC, 597, 601, "FCDT", "", +27, Frequency, 610, 621, "twice daily", "", " \"twice daily\". \"twice daily\"." +139, Precondition, 625, 705, "patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +28, Primary_OpenAngleGlaucoma, 639, 666, "primary open angle glaucoma", "", " ." +29, Primary_OpenAngleGlaucoma, 669, 673, "POAG", "", +30, OcularHypertension, 679, 698, "ocular hypertension", "", " ." +31, OcularHypertension, 701, 703, "OH", "", +32, Prospective, 717, 728, "Prospective", "", " ." +33, Multicenter, 731, 742, "multicentre", "", " ." +34, Blind, 745, 762, "masked - observer", "", " ." +35, Crossover, 765, 774, "crossover", "", " ." +145, NumberAffected, 803, 810, "Sixteen", "", +36, Primary_OpenAngleGlaucoma, 825, 829, "POAG", "", +146, NumberAffected, 834, 836, "14", "", +39, OcularHypertension, 842, 844, "OH", "", +149, Precondition, 892, 933, "washed out from their previous medication", "", " \"washed out from their previous medication\"." +40, Randomized, 938, 948, "randomized", "", " ." +41, Brimo/TimFC, 958, 962, "FCBT", "", +42, Dorz/TimFC, 966, 970, "FCDT", "", +43, Duration, 985, 993, "4 - week", "", +44, Duration, 1043, 1050, "4 weeks", "", +45, Duration, 1105, 1113, "4 - week", "", " \"4 - week\"." +46, IOP, 1123, 1143, "Intraocular pressure", "", " . ." +47, IOP, 1146, 1149, "IOP", "", +48, MeasurementDevice, 1172, 1202, "Goldmann applanation tonometer", "", " . ." +155, TimePoint, 1206, 1220, "8 : 00 a . m .", "", +156, TimePoint, 1223, 1235, "12 : 00 noon", "", +157, TimePoint, 1240, 1254, "4 : 00 p . m .", "", +49, TimePoint, 1263, 1271, "baseline", "", +159, TimePoint, 1276, 1311, "at the end of each treatment period", "", +50, IOP, 1411, 1414, "IOP", "", +51, Brimo/TimFC, 1434, 1438, "FCBT", "", +52, Dorz/TimFC, 1443, 1447, "FCDT", "", +53, Mean, 1473, 1477, "mean", "", +54, Diurnal_IOP, 1478, 1489, "diurnal IOP", "", +55, NumberPatientsCT, 1498, 1500, "30", "", " \"30\"." +56, BaseLineValue, 1526, 1532, "22 . 9", "", " \"22 . 9\". \"22 . 9\"." +167, SdDevBL, 1539, 1544, "1 . 6", "", " \"1 . 6\". \"1 . 6\"." +58, mmHg, 1545, 1549, "mmHg", "", +63, IOP, 1598, 1601, "IOP", "", +64, PValueChangeValue, 1627, 1645, "p & lt ; 0 . 00001", "", " \"p & lt ; 0 . 00001\". \"p & lt ; 0 . 00001\"." +65, Mean, 1654, 1658, "mean", "", +66, Diurnal_IOP, 1659, 1670, "diurnal IOP", "", +67, Duration, 1681, 1688, "4 weeks", "", +68, ResultMeasuredValue, 1704, 1710, "15 . 0", "", " \"15 . 0\"." +103781, SdDevResValue, 1717, 1722, "2 . 1", "", " \"2 . 1\"." +60, mmHg, 1723, 1727, "mmHg", "", +72, Brimo/TimFC, 1732, 1736, "FCBT", "", +69, ResultMeasuredValue, 1741, 1747, "15 . 4", "", " \"15 . 4\"." +103789, SdDevResValue, 1754, 1759, "2 . 1", "", " \"2 . 1\"." +59, mmHg, 1760, 1764, "mmHg", "", +73, Dorz/TimFC, 1769, 1773, "FCDT", "", +103790, PvalueDiff, 1776, 1787, "p = 0 . 510", "", +75, Mean, 1796, 1800, "mean", "", +76, Diurnal_IOP, 1801, 1812, "diurnal IOP", "", +77, Reduction, 1827, 1832, "7 . 8", "", " \"7 . 8\"." +176, SdDevChangeValue, 1839, 1844, "1 . 9", "", " \"1 . 9\"." +61, mmHg, 1845, 1849, "mmHg", "", +81, Brimo/TimFC, 1854, 1858, "FCBT", "", +78, Reduction, 1863, 1868, "7 . 4", "", " \"7 . 4\"." +177, SdDevChangeValue, 1875, 1880, "1 . 8", "", " \"1 . 8\"." +62, mmHg, 1881, 1885, "mmHg", "", +82, Dorz/TimFC, 1890, 1894, "FCDT", "", +182, PvalueDiff, 1899, 1908, "= 0 . 430", "", " \"= 0 . 430\"." +84, NumberAffected, 1923, 1925, "14", "", +103791, EndPointDescription, 1959, 1973, "adverse events", "", " . ." +85, NumberAffected, 1976, 1979, "two", "", " \"two\"." +88, Brimo/TimFC, 1989, 1993, "FCBT", "", +86, NumberAffected, 1996, 2001, "seven", "", " \"seven\"." +89, Dorz/TimFC, 2011, 2015, "FCDT", "", +103792, ObservedResult, 2020, 2039, "five for both drugs", "", " \"five for both drugs\". \"five for both drugs\"." +87, NumberAffected, 2020, 2024, "five", "", +90, Brimo/TimFC, 2159, 2163, "FCBT", "", +94, NumberAffected, 2170, 2171, "7", "", " \"7\"." +92, Dorz/TimFC, 2178, 2182, "FCDT", "", +95, NumberAffected, 2189, 2191, "12", "", " \"12\"." +198, PvalueDiff, 2198, 2207, "= 0 . 359", "", " \"= 0 . 359\"." +93, Dorz/TimFC, 2212, 2216, "FCDT", "", +200, Stinging, 2229, 2244, "ocular stinging", "", " ." +103793, DeliveryMethod, 2250, 2262, "instillation", "", +96, NumberAffected, 2269, 2270, "9", "", " \"9\"." +91, Brimo/TimFC, 2278, 2282, "FCBT", "", +97, NumberAffected, 2289, 2290, "1", "", " \"1\"." +204, PvalueDiff, 2297, 2306, "= 0 . 027", "", " \"= 0 . 027\"." +101, ConclusionComment, 2324, 2441, "This study suggests that FCBT and FCDT , each given twice daily , have similar efficacy in patients with POAG or OH .", "", " \"This study suggests that FCBT and FCDT , each given twice daily , have similar efficacy in patients with POAG or OH .\"." +102, Brimo/TimFC, 2349, 2353, "FCBT", "", +103, Dorz/TimFC, 2358, 2362, "FCDT", "", +104, Frequency, 2376, 2387, "twice daily", "", +105, Primary_OpenAngleGlaucoma, 2429, 2433, "POAG", "", +106, OcularHypertension, 2437, 2439, "OH", "", +107, PMID, 2484, 2492, "17407624", "", " \"17407624\"." diff --git a/data/gl 17407624_admin.n-triples b/data/gl 17407624_admin.n-triples new file mode 100644 index 0000000..85c440c --- /dev/null +++ b/data/gl 17407624_admin.n-triples @@ -0,0 +1,169 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparing the fixed combination brimonidine - timolol versus fixed combination dorzolamide - timolol in patients with elevated intraocular pressure ." . + "Arcieri ES" . + "2007" . + "Curr Med Res Opin ." . + "17407624" . + . + "Arcieri RS" . + "Pereira AC" . + "Andreo EG" . + "Finotti IG" . + "S á Filho WF" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the efficacy of fixed combination brimonidine - timolol ( FCBT ) versus fixed combination dorzolamide - timolol ( FCDT ) given twice daily in patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH ) ." . + "30" . + . + . + . + "This study suggests that FCBT and FCDT , each given twice daily , have similar efficacy in patients with POAG or OH ." . + . + . + . + . + . + . + . + . + . + "4 - week" . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with elevated intraocular pressure" . + . + . + . + "patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + "washed out from their previous medication" . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint aes" . + . + . + . + . + . + . + "Endpoint o st" . + . + . + . + . +# RDF export of group: Arm + . + "Arm bt" . + . + . + . + . + . + . + "Arm dt" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention bt" . + . + "twice daily" . + . + . + "Intervention dt" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication bt" . + . + . + . + . + "Medication dt" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP bt" . + . + "22 . 9" . + "1 . 6" . + "15 . 0" . + "2 . 1" . + "7 . 8" . + "p & lt ; 0 . 00001" . + "1 . 9" . + . + "Outcome IOP dt" . + . + "22 . 9" . + "1 . 6" . + "15 . 4" . + "2 . 1" . + "7 . 4" . + "p & lt ; 0 . 00001" . + "1 . 8" . + . + "Outcome aes bt" . + . + "two" . + "five for both drugs" . + . + "Outcome aes dt" . + . + "seven" . + "five for both drugs" . + . + "Outcome o st bt" . + . + "1" . + . + "Outcome o st dt" . + . + "9" . + . + "Outcome aes2? bt " . + . + "7" . + . + "Outcome aes2? dt" . + . + "12" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP change value" . + "= 0 . 430" . + . + . + . + "DiffBetweenGroups o st " . + "= 0 . 027" . + . + . + . + "DiffBetweenGroups aes2" . + "= 0 . 359" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17407624_export.csv b/data/gl 17407624_export.csv new file mode 100644 index 0000000..f3dd927 --- /dev/null +++ b/data/gl 17407624_export.csv @@ -0,0 +1,542 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +545, 1, 1, 1, 0, 4, 0, 4, "Curr" +545, 1, 2, 2, 5, 8, 5, 8, "Med" +545, 1, 3, 3, 9, 12, 9, 12, "Res" +545, 1, 4, 4, 13, 17, 13, 17, "Opin" +545, 1, 5, 5, 18, 19, 18, 19, "." +545, 2, 1, 6, 0, 4, 20, 24, "2007" +545, 2, 2, 7, 5, 8, 25, 28, "Apr" +545, 2, 3, 8, 9, 10, 29, 30, ";" +545, 2, 4, 9, 11, 13, 31, 33, "23" +545, 2, 5, 10, 14, 15, 34, 35, "(" +545, 2, 6, 11, 16, 17, 36, 37, "4" +545, 2, 7, 12, 18, 19, 38, 39, ")" +545, 2, 8, 13, 20, 21, 40, 41, ":" +545, 2, 9, 14, 22, 25, 42, 45, "683" +545, 2, 10, 15, 26, 27, 46, 47, "-" +545, 2, 11, 16, 28, 29, 48, 49, "9" +545, 2, 12, 17, 30, 31, 50, 51, "." +545, 3, 1, 18, 0, 9, 52, 61, "Comparing" +545, 3, 2, 19, 10, 13, 62, 65, "the" +545, 3, 3, 20, 14, 19, 66, 71, "fixed" +545, 3, 4, 21, 20, 31, 72, 83, "combination" +545, 3, 5, 22, 32, 43, 84, 95, "brimonidine" +545, 3, 6, 23, 44, 45, 96, 97, "-" +545, 3, 7, 24, 46, 53, 98, 105, "timolol" +545, 3, 8, 25, 54, 60, 106, 112, "versus" +545, 3, 9, 26, 61, 66, 113, 118, "fixed" +545, 3, 10, 27, 67, 78, 119, 130, "combination" +545, 3, 11, 28, 79, 90, 131, 142, "dorzolamide" +545, 3, 12, 29, 91, 92, 143, 144, "-" +545, 3, 13, 30, 93, 100, 145, 152, "timolol" +545, 3, 14, 31, 101, 103, 153, 155, "in" +545, 3, 15, 32, 104, 112, 156, 164, "patients" +545, 3, 16, 33, 113, 117, 165, 169, "with" +545, 3, 17, 34, 118, 126, 170, 178, "elevated" +545, 3, 18, 35, 127, 138, 179, 190, "intraocular" +545, 3, 19, 36, 139, 147, 191, 199, "pressure" +545, 3, 20, 37, 148, 149, 200, 201, "." +545, 4, 1, 38, 0, 7, 202, 209, "Arcieri" +545, 4, 2, 39, 8, 10, 210, 212, "ES" +545, 4, 3, 40, 11, 12, 213, 214, "(" +545, 4, 4, 41, 13, 14, 215, 216, "1" +545, 4, 5, 42, 15, 16, 217, 218, ")" +545, 4, 6, 43, 17, 18, 219, 220, "," +545, 4, 7, 44, 19, 26, 221, 228, "Arcieri" +545, 4, 8, 45, 27, 29, 229, 231, "RS" +545, 4, 9, 46, 30, 31, 232, 233, "," +545, 4, 10, 47, 32, 39, 234, 241, "Pereira" +545, 4, 11, 48, 40, 42, 242, 244, "AC" +545, 4, 12, 49, 43, 44, 245, 246, "," +545, 4, 13, 50, 45, 51, 247, 253, "Andreo" +545, 4, 14, 51, 52, 54, 254, 256, "EG" +545, 4, 15, 52, 55, 56, 257, 258, "," +545, 4, 16, 53, 57, 64, 259, 266, "Finotti" +545, 4, 17, 54, 65, 67, 267, 269, "IG" +545, 4, 18, 55, 68, 69, 270, 271, "," +545, 4, 19, 56, 70, 71, 272, 273, "S" +545, 4, 20, 57, 72, 73, 274, 275, "á" +545, 4, 21, 58, 74, 79, 276, 281, "Filho" +545, 4, 22, 59, 80, 82, 282, 284, "WF" +545, 4, 23, 60, 83, 84, 285, 286, "." +545, 5, 1, 61, 0, 6, 287, 293, "Author" +545, 5, 2, 62, 7, 18, 294, 305, "information" +545, 5, 3, 63, 19, 20, 306, 307, ":" +545, 5, 4, 64, 21, 22, 308, 309, "(" +545, 5, 5, 65, 23, 24, 310, 311, "1" +545, 5, 6, 66, 25, 26, 312, 313, ")" +545, 5, 7, 67, 27, 35, 314, 322, "Glaucoma" +545, 5, 8, 68, 36, 43, 323, 330, "Service" +545, 5, 9, 69, 44, 45, 331, 332, "," +545, 5, 10, 70, 46, 56, 333, 343, "Department" +545, 5, 11, 71, 57, 59, 344, 346, "of" +545, 5, 12, 72, 60, 73, 347, 360, "Ophthalmology" +545, 5, 13, 73, 74, 75, 361, 362, "," +545, 5, 14, 74, 76, 86, 363, 373, "University" +545, 5, 15, 75, 87, 89, 374, 376, "of" +545, 5, 16, 76, 90, 98, 377, 385, "Campinas" +545, 5, 17, 77, 99, 100, 386, 387, "(" +545, 5, 18, 78, 101, 108, 388, 395, "UNICAMP" +545, 5, 19, 79, 109, 110, 396, 397, ")" +545, 5, 20, 80, 111, 112, 398, 399, "," +545, 5, 21, 81, 113, 121, 400, 408, "Campinas" +545, 5, 22, 82, 122, 123, 409, 410, "," +545, 5, 23, 83, 124, 125, 411, 412, "S" +545, 5, 24, 84, 126, 127, 413, 414, "ã" +545, 5, 25, 85, 128, 129, 415, 416, "o" +545, 5, 26, 86, 130, 135, 417, 422, "Paulo" +545, 5, 27, 87, 136, 137, 423, 424, "," +545, 5, 28, 88, 138, 144, 425, 431, "Brazil" +545, 5, 29, 89, 145, 146, 432, 433, "." +545, 6, 1, 90, 0, 6, 434, 440, "rsaran" +545, 6, 2, 91, 7, 8, 441, 442, "@" +545, 6, 3, 92, 9, 15, 443, 449, "triang" +545, 6, 4, 93, 16, 17, 450, 451, "." +545, 6, 5, 94, 18, 21, 452, 455, "com" +545, 6, 6, 95, 22, 23, 456, 457, "." +545, 6, 7, 96, 24, 26, 458, 460, "br" +545, 6, 8, 97, 27, 34, 461, 468, "PURPOSE" +545, 6, 9, 98, 35, 36, 469, 470, ":" +545, 6, 10, 99, 37, 39, 471, 473, "To" +545, 6, 11, 100, 40, 48, 474, 482, "evaluate" +545, 6, 12, 101, 49, 52, 483, 486, "the" +545, 6, 13, 102, 53, 61, 487, 495, "efficacy" +545, 6, 14, 103, 62, 64, 496, 498, "of" +545, 6, 15, 104, 65, 70, 499, 504, "fixed" +545, 6, 16, 105, 71, 82, 505, 516, "combination" +545, 6, 17, 106, 83, 94, 517, 528, "brimonidine" +545, 6, 18, 107, 95, 96, 529, 530, "-" +545, 6, 19, 108, 97, 104, 531, 538, "timolol" +545, 6, 20, 109, 105, 106, 539, 540, "(" +545, 6, 21, 110, 107, 111, 541, 545, "FCBT" +545, 6, 22, 111, 112, 113, 546, 547, ")" +545, 6, 23, 112, 114, 120, 548, 554, "versus" +545, 6, 24, 113, 121, 126, 555, 560, "fixed" +545, 6, 25, 114, 127, 138, 561, 572, "combination" +545, 6, 26, 115, 139, 150, 573, 584, "dorzolamide" +545, 6, 27, 116, 151, 152, 585, 586, "-" +545, 6, 28, 117, 153, 160, 587, 594, "timolol" +545, 6, 29, 118, 161, 162, 595, 596, "(" +545, 6, 30, 119, 163, 167, 597, 601, "FCDT" +545, 6, 31, 120, 168, 169, 602, 603, ")" +545, 6, 32, 121, 170, 175, 604, 609, "given" +545, 6, 33, 122, 176, 181, 610, 615, "twice" +545, 6, 34, 123, 182, 187, 616, 621, "daily" +545, 6, 35, 124, 188, 190, 622, 624, "in" +545, 6, 36, 125, 191, 199, 625, 633, "patients" +545, 6, 37, 126, 200, 204, 634, 638, "with" +545, 6, 38, 127, 205, 212, 639, 646, "primary" +545, 6, 39, 128, 213, 217, 647, 651, "open" +545, 6, 40, 129, 218, 223, 652, 657, "angle" +545, 6, 41, 130, 224, 232, 658, 666, "glaucoma" +545, 6, 42, 131, 233, 234, 667, 668, "(" +545, 6, 43, 132, 235, 239, 669, 673, "POAG" +545, 6, 44, 133, 240, 241, 674, 675, ")" +545, 6, 45, 134, 242, 244, 676, 678, "or" +545, 6, 46, 135, 245, 251, 679, 685, "ocular" +545, 6, 47, 136, 252, 264, 686, 698, "hypertension" +545, 6, 48, 137, 265, 266, 699, 700, "(" +545, 6, 49, 138, 267, 269, 701, 703, "OH" +545, 6, 50, 139, 270, 271, 704, 705, ")" +545, 6, 51, 140, 272, 273, 706, 707, "." +545, 7, 1, 141, 0, 6, 708, 714, "DESIGN" +545, 7, 2, 142, 7, 8, 715, 716, ":" +545, 7, 3, 143, 9, 20, 717, 728, "Prospective" +545, 7, 4, 144, 21, 22, 729, 730, "," +545, 7, 5, 145, 23, 34, 731, 742, "multicentre" +545, 7, 6, 146, 35, 36, 743, 744, "," +545, 7, 7, 147, 37, 43, 745, 751, "masked" +545, 7, 8, 148, 44, 45, 752, 753, "-" +545, 7, 9, 149, 46, 54, 754, 762, "observer" +545, 7, 10, 150, 55, 56, 763, 764, "," +545, 7, 11, 151, 57, 66, 765, 774, "crossover" +545, 7, 12, 152, 67, 77, 775, 785, "comparison" +545, 7, 13, 153, 78, 79, 786, 787, "." +545, 8, 1, 154, 0, 12, 788, 800, "PARTICIPANTS" +545, 8, 2, 155, 13, 14, 801, 802, ":" +545, 8, 3, 156, 15, 22, 803, 810, "Sixteen" +545, 8, 4, 157, 23, 31, 811, 819, "patients" +545, 8, 5, 158, 32, 36, 820, 824, "with" +545, 8, 6, 159, 37, 41, 825, 829, "POAG" +545, 8, 7, 160, 42, 45, 830, 833, "and" +545, 8, 8, 161, 46, 48, 834, 836, "14" +545, 8, 9, 162, 49, 53, 837, 841, "with" +545, 8, 10, 163, 54, 56, 842, 844, "OH" +545, 8, 11, 164, 57, 58, 845, 846, "." +545, 9, 1, 165, 0, 7, 847, 854, "METHODS" +545, 9, 2, 166, 8, 9, 855, 856, ":" +545, 9, 3, 167, 10, 13, 857, 860, "The" +545, 9, 4, 168, 14, 26, 861, 873, "participants" +545, 9, 5, 169, 27, 29, 874, 876, "of" +545, 9, 6, 170, 30, 33, 877, 880, "the" +545, 9, 7, 171, 34, 39, 881, 886, "study" +545, 9, 8, 172, 40, 44, 887, 891, "were" +545, 9, 9, 173, 45, 51, 892, 898, "washed" +545, 9, 10, 174, 52, 55, 899, 902, "out" +545, 9, 11, 175, 56, 60, 903, 907, "from" +545, 9, 12, 176, 61, 66, 908, 913, "their" +545, 9, 13, 177, 67, 75, 914, 922, "previous" +545, 9, 14, 178, 76, 86, 923, 933, "medication" +545, 9, 15, 179, 87, 90, 934, 937, "and" +545, 9, 16, 180, 91, 101, 938, 948, "randomized" +545, 9, 17, 181, 102, 104, 949, 951, "to" +545, 9, 18, 182, 105, 110, 952, 957, "fixed" +545, 9, 19, 183, 111, 115, 958, 962, "FCBT" +545, 9, 20, 184, 116, 118, 963, 965, "or" +545, 9, 21, 185, 119, 123, 966, 970, "FCDT" +545, 9, 22, 186, 124, 127, 971, 974, "for" +545, 9, 23, 187, 128, 131, 975, 978, "the" +545, 9, 24, 188, 132, 137, 979, 984, "first" +545, 9, 25, 189, 138, 139, 985, 986, "4" +545, 9, 26, 190, 140, 141, 987, 988, "-" +545, 9, 27, 191, 142, 146, 989, 993, "week" +545, 9, 28, 192, 147, 156, 994, 1003, "treatment" +545, 9, 29, 193, 157, 163, 1004, 1010, "period" +545, 9, 30, 194, 164, 165, 1011, 1012, "." +545, 10, 1, 195, 0, 8, 1013, 1021, "Subjects" +545, 10, 2, 196, 9, 13, 1022, 1026, "then" +545, 10, 3, 197, 14, 18, 1027, 1031, "were" +545, 10, 4, 198, 19, 25, 1032, 1038, "washed" +545, 10, 5, 199, 26, 29, 1039, 1042, "for" +545, 10, 6, 200, 30, 31, 1043, 1044, "4" +545, 10, 7, 201, 32, 37, 1045, 1050, "weeks" +545, 10, 8, 202, 38, 41, 1051, 1054, "and" +545, 10, 9, 203, 42, 49, 1055, 1062, "started" +545, 10, 10, 204, 50, 52, 1063, 1065, "on" +545, 10, 11, 205, 53, 56, 1066, 1069, "the" +545, 10, 12, 206, 57, 65, 1070, 1078, "opposite" +545, 10, 13, 207, 66, 76, 1079, 1089, "medication" +545, 10, 14, 208, 77, 80, 1090, 1093, "for" +545, 10, 15, 209, 81, 84, 1094, 1097, "the" +545, 10, 16, 210, 85, 91, 1098, 1104, "second" +545, 10, 17, 211, 92, 93, 1105, 1106, "4" +545, 10, 18, 212, 94, 95, 1107, 1108, "-" +545, 10, 19, 213, 96, 100, 1109, 1113, "week" +545, 10, 20, 214, 101, 107, 1114, 1120, "period" +545, 10, 21, 215, 108, 109, 1121, 1122, "." +545, 11, 1, 216, 0, 11, 1123, 1134, "Intraocular" +545, 11, 2, 217, 12, 20, 1135, 1143, "pressure" +545, 11, 3, 218, 21, 22, 1144, 1145, "(" +545, 11, 4, 219, 23, 26, 1146, 1149, "IOP" +545, 11, 5, 220, 27, 28, 1150, 1151, ")" +545, 11, 6, 221, 29, 32, 1152, 1155, "was" +545, 11, 7, 222, 33, 41, 1156, 1164, "measured" +545, 11, 8, 223, 42, 46, 1165, 1169, "with" +545, 11, 9, 224, 47, 48, 1170, 1171, "a" +545, 11, 10, 225, 49, 57, 1172, 1180, "Goldmann" +545, 11, 11, 226, 58, 69, 1181, 1192, "applanation" +545, 11, 12, 227, 70, 79, 1193, 1202, "tonometer" +545, 11, 13, 228, 80, 82, 1203, 1205, "at" +545, 11, 14, 229, 83, 84, 1206, 1207, "8" +545, 11, 15, 230, 85, 86, 1208, 1209, ":" +545, 11, 16, 231, 87, 89, 1210, 1212, "00" +545, 11, 17, 232, 90, 91, 1213, 1214, "a" +545, 11, 18, 233, 92, 93, 1215, 1216, "." +545, 11, 19, 234, 94, 95, 1217, 1218, "m" +545, 11, 20, 235, 96, 97, 1219, 1220, "." +545, 11, 21, 236, 98, 99, 1221, 1222, "," +545, 11, 22, 237, 100, 102, 1223, 1225, "12" +545, 11, 23, 238, 103, 104, 1226, 1227, ":" +545, 11, 24, 239, 105, 107, 1228, 1230, "00" +545, 11, 25, 240, 108, 112, 1231, 1235, "noon" +545, 11, 26, 241, 113, 116, 1236, 1239, "and" +545, 11, 27, 242, 117, 118, 1240, 1241, "4" +545, 11, 28, 243, 119, 120, 1242, 1243, ":" +545, 11, 29, 244, 121, 123, 1244, 1246, "00" +545, 11, 30, 245, 124, 125, 1247, 1248, "p" +545, 11, 31, 246, 126, 127, 1249, 1250, "." +545, 11, 32, 247, 128, 129, 1251, 1252, "m" +545, 11, 33, 248, 130, 131, 1253, 1254, "." +545, 11, 34, 249, 132, 134, 1255, 1257, "at" +545, 11, 35, 250, 135, 139, 1258, 1262, "each" +545, 11, 36, 251, 140, 148, 1263, 1271, "baseline" +545, 11, 37, 252, 149, 152, 1272, 1275, "and" +545, 11, 38, 253, 153, 155, 1276, 1278, "at" +545, 11, 39, 254, 156, 159, 1279, 1282, "the" +545, 11, 40, 255, 160, 163, 1283, 1286, "end" +545, 11, 41, 256, 164, 166, 1287, 1289, "of" +545, 11, 42, 257, 167, 171, 1290, 1294, "each" +545, 11, 43, 258, 172, 181, 1295, 1304, "treatment" +545, 11, 44, 259, 182, 188, 1305, 1311, "period" +545, 11, 45, 260, 189, 190, 1312, 1313, "." +545, 12, 1, 261, 0, 11, 1314, 1325, "Unsolicited" +545, 12, 2, 262, 12, 18, 1326, 1332, "ocular" +545, 12, 3, 263, 19, 26, 1333, 1340, "adverse" +545, 12, 4, 264, 27, 33, 1341, 1347, "events" +545, 12, 5, 265, 34, 38, 1348, 1352, "were" +545, 12, 6, 266, 39, 43, 1353, 1357, "also" +545, 12, 7, 267, 44, 52, 1358, 1366, "recorded" +545, 12, 8, 268, 53, 54, 1367, 1368, "." +545, 13, 1, 269, 0, 4, 1369, 1373, "MAIN" +545, 13, 2, 270, 5, 12, 1374, 1381, "OUTCOME" +545, 13, 3, 271, 13, 21, 1382, 1390, "MEASURES" +545, 13, 4, 272, 22, 23, 1391, 1392, ":" +545, 13, 5, 273, 24, 34, 1393, 1403, "Comparison" +545, 13, 6, 274, 35, 37, 1404, 1406, "of" +545, 13, 7, 275, 38, 41, 1407, 1410, "the" +545, 13, 8, 276, 42, 45, 1411, 1414, "IOP" +545, 13, 9, 277, 46, 54, 1415, 1423, "lowering" +545, 13, 10, 278, 55, 61, 1424, 1430, "effect" +545, 13, 11, 279, 62, 64, 1431, 1433, "of" +545, 13, 12, 280, 65, 69, 1434, 1438, "FCBT" +545, 13, 13, 281, 70, 73, 1439, 1442, "and" +545, 13, 14, 282, 74, 78, 1443, 1447, "FCDT" +545, 13, 15, 283, 79, 80, 1448, 1449, "." +545, 14, 1, 284, 0, 7, 1450, 1457, "RESULTS" +545, 14, 2, 285, 8, 9, 1458, 1459, ":" +545, 14, 3, 286, 10, 13, 1460, 1463, "The" +545, 14, 4, 287, 14, 22, 1464, 1472, "baseline" +545, 14, 5, 288, 23, 27, 1473, 1477, "mean" +545, 14, 6, 289, 28, 35, 1478, 1485, "diurnal" +545, 14, 7, 290, 36, 39, 1486, 1489, "IOP" +545, 14, 8, 291, 40, 43, 1490, 1493, "for" +545, 14, 9, 292, 44, 47, 1494, 1497, "all" +545, 14, 10, 293, 48, 50, 1498, 1500, "30" +545, 14, 11, 294, 51, 59, 1501, 1509, "subjects" +545, 14, 12, 295, 60, 61, 1510, 1511, "(" +545, 14, 13, 296, 62, 64, 1512, 1514, "30" +545, 14, 14, 297, 65, 69, 1515, 1519, "eyes" +545, 14, 15, 298, 70, 71, 1520, 1521, ")" +545, 14, 16, 299, 72, 75, 1522, 1525, "was" +545, 14, 17, 300, 76, 78, 1526, 1528, "22" +545, 14, 18, 301, 79, 80, 1529, 1530, "." +545, 14, 19, 302, 81, 82, 1531, 1532, "9" +545, 14, 20, 303, 83, 84, 1533, 1534, "+" +545, 14, 21, 304, 85, 86, 1535, 1536, "/" +545, 14, 22, 305, 87, 88, 1537, 1538, "-" +545, 14, 23, 306, 89, 90, 1539, 1540, "1" +545, 14, 24, 307, 91, 92, 1541, 1542, "." +545, 14, 25, 308, 93, 94, 1543, 1544, "6" +545, 14, 26, 309, 95, 99, 1545, 1549, "mmHg" +545, 14, 27, 310, 100, 101, 1550, 1551, "." +545, 15, 1, 311, 0, 4, 1552, 1556, "Both" +545, 15, 2, 312, 5, 10, 1557, 1562, "fixed" +545, 15, 3, 313, 11, 23, 1563, 1575, "combinations" +545, 15, 4, 314, 24, 37, 1576, 1589, "significantly" +545, 15, 5, 315, 38, 45, 1590, 1597, "reduced" +545, 15, 6, 316, 46, 49, 1598, 1601, "IOP" +545, 15, 7, 317, 50, 58, 1602, 1610, "compared" +545, 15, 8, 318, 59, 63, 1611, 1615, "with" +545, 15, 9, 319, 64, 72, 1616, 1624, "baseline" +545, 15, 10, 320, 73, 74, 1625, 1626, "(" +545, 15, 11, 321, 75, 76, 1627, 1628, "p" +545, 15, 12, 322, 77, 78, 1629, 1630, "&" +545, 15, 13, 323, 79, 81, 1631, 1633, "lt" +545, 15, 14, 324, 82, 83, 1634, 1635, ";" +545, 15, 15, 325, 84, 85, 1636, 1637, "0" +545, 15, 16, 326, 86, 87, 1638, 1639, "." +545, 15, 17, 327, 88, 93, 1640, 1645, "00001" +545, 15, 18, 328, 94, 95, 1646, 1647, ")" +545, 15, 19, 329, 96, 97, 1648, 1649, "." +545, 16, 1, 330, 0, 3, 1650, 1653, "The" +545, 16, 2, 331, 4, 8, 1654, 1658, "mean" +545, 16, 3, 332, 9, 16, 1659, 1666, "diurnal" +545, 16, 4, 333, 17, 20, 1667, 1670, "IOP" +545, 16, 5, 334, 21, 30, 1671, 1680, "following" +545, 16, 6, 335, 31, 32, 1681, 1682, "4" +545, 16, 7, 336, 33, 38, 1683, 1688, "weeks" +545, 16, 8, 337, 39, 41, 1689, 1691, "of" +545, 16, 9, 338, 42, 49, 1692, 1699, "therapy" +545, 16, 10, 339, 50, 53, 1700, 1703, "was" +545, 16, 11, 340, 54, 56, 1704, 1706, "15" +545, 16, 12, 341, 57, 58, 1707, 1708, "." +545, 16, 13, 342, 59, 60, 1709, 1710, "0" +545, 16, 14, 343, 61, 62, 1711, 1712, "+" +545, 16, 15, 344, 63, 64, 1713, 1714, "/" +545, 16, 16, 345, 65, 66, 1715, 1716, "-" +545, 16, 17, 346, 67, 68, 1717, 1718, "2" +545, 16, 18, 347, 69, 70, 1719, 1720, "." +545, 16, 19, 348, 71, 72, 1721, 1722, "1" +545, 16, 20, 349, 73, 77, 1723, 1727, "mmHg" +545, 16, 21, 350, 78, 81, 1728, 1731, "for" +545, 16, 22, 351, 82, 86, 1732, 1736, "FCBT" +545, 16, 23, 352, 87, 90, 1737, 1740, "and" +545, 16, 24, 353, 91, 93, 1741, 1743, "15" +545, 16, 25, 354, 94, 95, 1744, 1745, "." +545, 16, 26, 355, 96, 97, 1746, 1747, "4" +545, 16, 27, 356, 98, 99, 1748, 1749, "+" +545, 16, 28, 357, 100, 101, 1750, 1751, "/" +545, 16, 29, 358, 102, 103, 1752, 1753, "-" +545, 16, 30, 359, 104, 105, 1754, 1755, "2" +545, 16, 31, 360, 106, 107, 1756, 1757, "." +545, 16, 32, 361, 108, 109, 1758, 1759, "1" +545, 16, 33, 362, 110, 114, 1760, 1764, "mmHg" +545, 16, 34, 363, 115, 118, 1765, 1768, "for" +545, 16, 35, 364, 119, 123, 1769, 1773, "FCDT" +545, 16, 36, 365, 124, 125, 1774, 1775, "(" +545, 16, 37, 366, 126, 127, 1776, 1777, "p" +545, 16, 38, 367, 128, 129, 1778, 1779, "=" +545, 16, 39, 368, 130, 131, 1780, 1781, "0" +545, 16, 40, 369, 132, 133, 1782, 1783, "." +545, 16, 41, 370, 134, 137, 1784, 1787, "510" +545, 16, 42, 371, 138, 139, 1788, 1789, ")" +545, 16, 43, 372, 140, 141, 1790, 1791, "." +545, 17, 1, 373, 0, 3, 1792, 1795, "The" +545, 17, 2, 374, 4, 8, 1796, 1800, "mean" +545, 17, 3, 375, 9, 16, 1801, 1808, "diurnal" +545, 17, 4, 376, 17, 20, 1809, 1812, "IOP" +545, 17, 5, 377, 21, 30, 1813, 1822, "reduction" +545, 17, 6, 378, 31, 34, 1823, 1826, "was" +545, 17, 7, 379, 35, 36, 1827, 1828, "7" +545, 17, 8, 380, 37, 38, 1829, 1830, "." +545, 17, 9, 381, 39, 40, 1831, 1832, "8" +545, 17, 10, 382, 41, 42, 1833, 1834, "+" +545, 17, 11, 383, 43, 44, 1835, 1836, "/" +545, 17, 12, 384, 45, 46, 1837, 1838, "-" +545, 17, 13, 385, 47, 48, 1839, 1840, "1" +545, 17, 14, 386, 49, 50, 1841, 1842, "." +545, 17, 15, 387, 51, 52, 1843, 1844, "9" +545, 17, 16, 388, 53, 57, 1845, 1849, "mmHg" +545, 17, 17, 389, 58, 61, 1850, 1853, "for" +545, 17, 18, 390, 62, 66, 1854, 1858, "FCBT" +545, 17, 19, 391, 67, 70, 1859, 1862, "and" +545, 17, 20, 392, 71, 72, 1863, 1864, "7" +545, 17, 21, 393, 73, 74, 1865, 1866, "." +545, 17, 22, 394, 75, 76, 1867, 1868, "4" +545, 17, 23, 395, 77, 78, 1869, 1870, "+" +545, 17, 24, 396, 79, 80, 1871, 1872, "/" +545, 17, 25, 397, 81, 82, 1873, 1874, "-" +545, 17, 26, 398, 83, 84, 1875, 1876, "1" +545, 17, 27, 399, 85, 86, 1877, 1878, "." +545, 17, 28, 400, 87, 88, 1879, 1880, "8" +545, 17, 29, 401, 89, 93, 1881, 1885, "mmHg" +545, 17, 30, 402, 94, 97, 1886, 1889, "for" +545, 17, 31, 403, 98, 102, 1890, 1894, "FCDT" +545, 17, 32, 404, 103, 104, 1895, 1896, "(" +545, 17, 33, 405, 105, 106, 1897, 1898, "p" +545, 17, 34, 406, 107, 108, 1899, 1900, "=" +545, 17, 35, 407, 109, 110, 1901, 1902, "0" +545, 17, 36, 408, 111, 112, 1903, 1904, "." +545, 17, 37, 409, 113, 116, 1905, 1908, "430" +545, 17, 38, 410, 117, 118, 1909, 1910, ")" +545, 17, 39, 411, 119, 120, 1911, 1912, "." +545, 18, 1, 412, 0, 7, 1913, 1920, "Overall" +545, 18, 2, 413, 8, 9, 1921, 1922, "," +545, 18, 3, 414, 10, 12, 1923, 1925, "14" +545, 18, 4, 415, 13, 21, 1926, 1934, "subjects" +545, 18, 5, 416, 22, 32, 1935, 1945, "complained" +545, 18, 6, 417, 33, 38, 1946, 1951, "about" +545, 18, 7, 418, 39, 45, 1952, 1958, "ocular" +545, 18, 8, 419, 46, 53, 1959, 1966, "adverse" +545, 18, 9, 420, 54, 60, 1967, 1973, "events" +545, 18, 10, 421, 61, 62, 1974, 1975, ":" +545, 18, 11, 422, 63, 66, 1976, 1979, "two" +545, 18, 12, 423, 67, 71, 1980, 1984, "only" +545, 18, 13, 424, 72, 75, 1985, 1988, "for" +545, 18, 14, 425, 76, 80, 1989, 1993, "FCBT" +545, 18, 15, 426, 81, 82, 1994, 1995, "," +545, 18, 16, 427, 83, 88, 1996, 2001, "seven" +545, 18, 17, 428, 89, 93, 2002, 2006, "only" +545, 18, 18, 429, 94, 97, 2007, 2010, "for" +545, 18, 19, 430, 98, 102, 2011, 2015, "FCDT" +545, 18, 20, 431, 103, 106, 2016, 2019, "and" +545, 18, 21, 432, 107, 111, 2020, 2024, "five" +545, 18, 22, 433, 112, 115, 2025, 2028, "for" +545, 18, 23, 434, 116, 120, 2029, 2033, "both" +545, 18, 24, 435, 121, 126, 2034, 2039, "drugs" +545, 18, 25, 436, 127, 128, 2040, 2041, "." +545, 19, 1, 437, 0, 8, 2042, 2050, "Although" +545, 19, 2, 438, 9, 14, 2051, 2056, "there" +545, 19, 3, 439, 15, 18, 2057, 2060, "was" +545, 19, 4, 440, 19, 21, 2061, 2063, "no" +545, 19, 5, 441, 22, 33, 2064, 2075, "significant" +545, 19, 6, 442, 34, 44, 2076, 2086, "difference" +545, 19, 7, 443, 45, 52, 2087, 2094, "between" +545, 19, 8, 444, 53, 56, 2095, 2098, "the" +545, 19, 9, 445, 57, 63, 2099, 2105, "number" +545, 19, 10, 446, 64, 66, 2106, 2108, "of" +545, 19, 11, 447, 67, 75, 2109, 2117, "subjects" +545, 19, 12, 448, 76, 80, 2118, 2122, "that" +545, 19, 13, 449, 81, 89, 2123, 2131, "reported" +545, 19, 14, 450, 90, 96, 2132, 2138, "ocular" +545, 19, 15, 451, 97, 104, 2139, 2146, "adverse" +545, 19, 16, 452, 105, 111, 2147, 2153, "events" +545, 19, 17, 453, 112, 116, 2154, 2158, "with" +545, 19, 18, 454, 117, 121, 2159, 2163, "FCBT" +545, 19, 19, 455, 122, 123, 2164, 2165, "(" +545, 19, 20, 456, 124, 125, 2166, 2167, "n" +545, 19, 21, 457, 126, 127, 2168, 2169, "=" +545, 19, 22, 458, 128, 129, 2170, 2171, "7" +545, 19, 23, 459, 130, 131, 2172, 2173, ")" +545, 19, 24, 460, 132, 135, 2174, 2177, "and" +545, 19, 25, 461, 136, 140, 2178, 2182, "FCDT" +545, 19, 26, 462, 141, 142, 2183, 2184, "(" +545, 19, 27, 463, 143, 144, 2185, 2186, "n" +545, 19, 28, 464, 145, 146, 2187, 2188, "=" +545, 19, 29, 465, 147, 149, 2189, 2191, "12" +545, 19, 30, 466, 150, 151, 2192, 2193, ")" +545, 19, 31, 467, 152, 153, 2194, 2195, "(" +545, 19, 32, 468, 154, 155, 2196, 2197, "p" +545, 19, 33, 469, 156, 157, 2198, 2199, "=" +545, 19, 34, 470, 158, 159, 2200, 2201, "0" +545, 19, 35, 471, 160, 161, 2202, 2203, "." +545, 19, 36, 472, 162, 165, 2204, 2207, "359" +545, 19, 37, 473, 166, 167, 2208, 2209, ")" +545, 19, 38, 474, 168, 169, 2210, 2211, "," +545, 19, 39, 475, 170, 174, 2212, 2216, "FCDT" +545, 19, 40, 476, 175, 181, 2217, 2223, "caused" +545, 19, 41, 477, 182, 186, 2224, 2228, "more" +545, 19, 42, 478, 187, 193, 2229, 2235, "ocular" +545, 19, 43, 479, 194, 202, 2236, 2244, "stinging" +545, 19, 44, 480, 203, 207, 2245, 2249, "upon" +545, 19, 45, 481, 208, 220, 2250, 2262, "instillation" +545, 19, 46, 482, 221, 222, 2263, 2264, "(" +545, 19, 47, 483, 223, 224, 2265, 2266, "n" +545, 19, 48, 484, 225, 226, 2267, 2268, "=" +545, 19, 49, 485, 227, 228, 2269, 2270, "9" +545, 19, 50, 486, 229, 230, 2271, 2272, ")" +545, 19, 51, 487, 231, 235, 2273, 2277, "than" +545, 19, 52, 488, 236, 240, 2278, 2282, "FCBT" +545, 19, 53, 489, 241, 242, 2283, 2284, "(" +545, 19, 54, 490, 243, 244, 2285, 2286, "n" +545, 19, 55, 491, 245, 246, 2287, 2288, "=" +545, 19, 56, 492, 247, 248, 2289, 2290, "1" +545, 19, 57, 493, 249, 250, 2291, 2292, ")" +545, 19, 58, 494, 251, 252, 2293, 2294, "(" +545, 19, 59, 495, 253, 254, 2295, 2296, "p" +545, 19, 60, 496, 255, 256, 2297, 2298, "=" +545, 19, 61, 497, 257, 258, 2299, 2300, "0" +545, 19, 62, 498, 259, 260, 2301, 2302, "." +545, 19, 63, 499, 261, 264, 2303, 2306, "027" +545, 19, 64, 500, 265, 266, 2307, 2308, ")" +545, 19, 65, 501, 267, 268, 2309, 2310, "." +545, 20, 1, 502, 0, 10, 2311, 2321, "CONCLUSION" +545, 20, 2, 503, 11, 12, 2322, 2323, ":" +545, 20, 3, 504, 13, 17, 2324, 2328, "This" +545, 20, 4, 505, 18, 23, 2329, 2334, "study" +545, 20, 5, 506, 24, 32, 2335, 2343, "suggests" +545, 20, 6, 507, 33, 37, 2344, 2348, "that" +545, 20, 7, 508, 38, 42, 2349, 2353, "FCBT" +545, 20, 8, 509, 43, 46, 2354, 2357, "and" +545, 20, 9, 510, 47, 51, 2358, 2362, "FCDT" +545, 20, 10, 511, 52, 53, 2363, 2364, "," +545, 20, 11, 512, 54, 58, 2365, 2369, "each" +545, 20, 12, 513, 59, 64, 2370, 2375, "given" +545, 20, 13, 514, 65, 70, 2376, 2381, "twice" +545, 20, 14, 515, 71, 76, 2382, 2387, "daily" +545, 20, 15, 516, 77, 78, 2388, 2389, "," +545, 20, 16, 517, 79, 83, 2390, 2394, "have" +545, 20, 17, 518, 84, 91, 2395, 2402, "similar" +545, 20, 18, 519, 92, 100, 2403, 2411, "efficacy" +545, 20, 19, 520, 101, 103, 2412, 2414, "in" +545, 20, 20, 521, 104, 112, 2415, 2423, "patients" +545, 20, 21, 522, 113, 117, 2424, 2428, "with" +545, 20, 22, 523, 118, 122, 2429, 2433, "POAG" +545, 20, 23, 524, 123, 125, 2434, 2436, "or" +545, 20, 24, 525, 126, 128, 2437, 2439, "OH" +545, 20, 25, 526, 129, 130, 2440, 2441, "." +545, 21, 1, 527, 0, 3, 2442, 2445, "DOI" +545, 21, 2, 528, 4, 5, 2446, 2447, ":" +545, 21, 3, 529, 6, 8, 2448, 2450, "10" +545, 21, 4, 530, 9, 10, 2451, 2452, "." +545, 21, 5, 531, 11, 15, 2453, 2457, "1185" +545, 21, 6, 532, 16, 17, 2458, 2459, "/" +545, 21, 7, 533, 18, 34, 2460, 2476, "030079907x178694" +545, 21, 8, 534, 35, 39, 2477, 2481, "PMID" +545, 21, 9, 535, 40, 41, 2482, 2483, ":" +545, 21, 10, 536, 42, 50, 2484, 2492, "17407624" +545, 21, 11, 537, 51, 52, 2493, 2494, "[" +545, 21, 12, 538, 53, 60, 2495, 2502, "Indexed" +545, 21, 13, 539, 61, 64, 2503, 2506, "for" +545, 21, 14, 540, 65, 72, 2507, 2514, "MEDLINE" +545, 21, 15, 541, 73, 74, 2515, 2516, "]" diff --git a/data/gl 17407624_jshahinitiran.annodb b/data/gl 17407624_jshahinitiran.annodb new file mode 100644 index 0000000..3295876 --- /dev/null +++ b/data/gl 17407624_jshahinitiran.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +87176, Journal, 0, 17, "Curr Med Res Opin", "", +87177, PublicationYear, 20, 24, "2007", "", +87178, Title, 52, 201, "Comparing the fixed combination brimonidine - timolol versus fixed combination dorzolamide - timolol in patients with elevated intraocular pressure .", "", +87181, Brimo/TimFC, 66, 105, "fixed combination brimonidine - timolol", "", +87179, Brimonidine, 84, 95, "brimonidine", "", +87180, Timolol, 98, 105, "timolol", "", +87184, Dorz/TimFC, 113, 152, "fixed combination dorzolamide - timolol", "", +87182, Dorzolamide, 131, 142, "dorzolamide", "", +87183, Timolol, 145, 152, "timolol", "", +87185, IOP, 179, 199, "intraocular pressure", "", +87186, Author, 202, 212, "Arcieri ES", "", +87187, Author, 221, 231, "Arcieri RS", "", +87188, Author, 234, 244, "Pereira AC", "", +87189, Author, 247, 256, "Andreo EG", "", +87190, Author, 259, 269, "Finotti IG", "", +87191, Author, 272, 284, "S á Filho WF", "", +87192, Glaucoma, 314, 322, "Glaucoma", "", +87193, Brazil, 425, 431, "Brazil", "", +87194, ObjectiveDescription, 471, 707, "To evaluate the efficacy of fixed combination brimonidine - timolol ( FCBT ) versus fixed combination dorzolamide - timolol ( FCDT ) given twice daily in patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", +87199, Brimo/TimFC, 499, 538, "fixed combination brimonidine - timolol", "", +87195, Brimonidine, 517, 528, "brimonidine", "", +87197, Timolol, 531, 538, "timolol", "", +87200, Brimo/TimFC, 541, 545, "FCBT", "", +87201, Dorz/TimFC, 555, 594, "fixed combination dorzolamide - timolol", "", +87196, Dorzolamide, 573, 584, "dorzolamide", "", +87198, Timolol, 587, 594, "timolol", "", +87202, Dorz/TimFC, 597, 601, "FCDT", "", +87203, Frequency, 610, 621, "twice daily", "", +87204, Primary_OpenAngleGlaucoma, 639, 666, "primary open angle glaucoma", "", +87205, Primary_OpenAngleGlaucoma, 669, 673, "POAG", "", +87206, OcularHypertension, 679, 698, "ocular hypertension", "", +87207, OcularHypertension, 701, 703, "OH", "", +87208, Prospective, 717, 728, "Prospective", "", +87209, Multicenter, 731, 742, "multicentre", "", +87210, Blind, 745, 762, "masked - observer", "", +87211, Crossover, 765, 774, "crossover", "", +87214, Number, 803, 810, "Sixteen", "", +87213, Primary_OpenAngleGlaucoma, 825, 829, "POAG", "", +87215, Number, 834, 836, "14", "", +87216, OcularHypertension, 842, 844, "OH", "", +87217, Randomized, 938, 948, "randomized", "", +87218, Brimo/TimFC, 958, 962, "FCBT", "", +87219, Dorz/TimFC, 966, 970, "FCDT", "", +87220, Duration, 985, 993, "4 - week", "", +87221, Duration, 1043, 1050, "4 weeks", "", +87222, Duration, 1105, 1113, "4 - week", "", +87223, IOP, 1123, 1143, "Intraocular pressure", "", +87224, IOP, 1146, 1149, "IOP", "", +87225, MeasurementDevice, 1172, 1202, "Goldmann applanation tonometer", "", +87226, TimePoint, 1263, 1271, "baseline", "", +87227, IOP, 1411, 1414, "IOP", "", +87228, Brimo/TimFC, 1434, 1438, "FCBT", "", +87229, Dorz/TimFC, 1443, 1447, "FCDT", "", +87230, Mean, 1473, 1477, "mean", "", +87231, Diurnal_IOP, 1478, 1489, "diurnal IOP", "", +87232, NumberPatientsCT, 1498, 1500, "30", "", +87233, BaseLineValue, 1526, 1532, "22 . 9", "", +87234, SdErrorBL, 1539, 1544, "1 . 6", "", +87235, mmHg, 1545, 1549, "mmHg", "", +87240, IOP, 1598, 1601, "IOP", "", +87241, PValueChangeValue, 1627, 1645, "p & lt ; 0 . 00001", "", +87242, Mean, 1654, 1658, "mean", "", +87243, Diurnal_IOP, 1659, 1670, "diurnal IOP", "", +87245, Duration, 1681, 1688, "4 weeks", "", +87246, ResultMeasuredValue, 1704, 1710, "15 . 0", "", +87248, SdErrorResValue, 1717, 1722, "2 . 1", "", +87237, mmHg, 1723, 1727, "mmHg", "", +87250, Brimo/TimFC, 1732, 1736, "FCBT", "", +87247, ResultMeasuredValue, 1741, 1747, "15 . 4", "", +87249, SdErrorResValue, 1754, 1759, "2 . 1", "", +87236, mmHg, 1760, 1764, "mmHg", "", +87251, Dorz/TimFC, 1769, 1773, "FCDT", "", +87252, PValueResValue, 1776, 1787, "p = 0 . 510", "", +87253, Mean, 1796, 1800, "mean", "", +87254, Diurnal_IOP, 1801, 1812, "diurnal IOP", "", +87255, Reduction, 1827, 1832, "7 . 8", "", +87257, SdErrorChangeValue, 1839, 1844, "1 . 9", "", +87238, mmHg, 1845, 1849, "mmHg", "", +87259, Brimo/TimFC, 1854, 1858, "FCBT", "", +87256, Reduction, 1863, 1868, "7 . 4", "", +87258, SdErrorChangeValue, 1875, 1880, "1 . 8", "", +87239, mmHg, 1881, 1885, "mmHg", "", +87260, Dorz/TimFC, 1890, 1894, "FCDT", "", +87261, PValueChangeValue, 1897, 1908, "p = 0 . 430", "", +87262, NumberAffected, 1923, 1925, "14", "", +87263, NumberAffected, 1976, 1979, "two", "", +87266, Brimo/TimFC, 1989, 1993, "FCBT", "", +87264, NumberAffected, 1996, 2001, "seven", "", +87267, Dorz/TimFC, 2011, 2015, "FCDT", "", +87265, NumberAffected, 2020, 2024, "five", "", +87268, Brimo/TimFC, 2159, 2163, "FCBT", "", +87272, NumberAffected, 2170, 2171, "7", "", +87270, Dorz/TimFC, 2178, 2182, "FCDT", "", +87273, NumberAffected, 2189, 2191, "12", "", +87276, PValueNumAffected, 2196, 2207, "p = 0 . 359", "", +87271, Dorz/TimFC, 2212, 2216, "FCDT", "", +87274, NumberAffected, 2269, 2270, "9", "", +87269, Brimo/TimFC, 2278, 2282, "FCBT", "", +87275, NumberAffected, 2289, 2290, "1", "", +87277, PValueNumAffected, 2295, 2306, "p = 0 . 027", "", +87279, ConclusionComment, 2324, 2441, "This study suggests that FCBT and FCDT , each given twice daily , have similar efficacy in patients with POAG or OH .", "", +87280, Brimo/TimFC, 2349, 2353, "FCBT", "", +87281, Dorz/TimFC, 2358, 2362, "FCDT", "", +87282, Frequency, 2376, 2387, "twice daily", "", +87283, Primary_OpenAngleGlaucoma, 2429, 2433, "POAG", "", +87284, OcularHypertension, 2437, 2439, "OH", "", +87285, PMID, 2484, 2492, "17407624", "", diff --git a/data/gl 17407624_jshahinitiran.n-triples b/data/gl 17407624_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17407624_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17407624_tstrakeljahn.annodb b/data/gl 17407624_tstrakeljahn.annodb new file mode 100644 index 0000000..750e53e --- /dev/null +++ b/data/gl 17407624_tstrakeljahn.annodb @@ -0,0 +1,105 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90212, Journal, 0, 17, "Curr Med Res Opin", "", +90213, PublicationYear, 20, 24, "2007", "", +90222, Title, 52, 201, "Comparing the fixed combination brimonidine - timolol versus fixed combination dorzolamide - timolol in patients with elevated intraocular pressure .", "", +90214, Brimonidine, 84, 95, "brimonidine", "", +90220, Brimo/TimFC, 84, 105, "brimonidine - timolol", "", +90215, Timolol, 98, 105, "timolol", "", +90216, Dorzolamide, 131, 142, "dorzolamide", "", +90221, Dorz/TimFC, 131, 152, "dorzolamide - timolol", "", +90217, Timolol, 145, 152, "timolol", "", +90219, Precondition, 156, 199, "patients with elevated intraocular pressure", "", +90218, IOP, 179, 199, "intraocular pressure", "", +90223, Author, 202, 212, "Arcieri ES", "", +90224, Author, 221, 231, "Arcieri RS", "", +90225, Author, 234, 244, "Pereira AC", "", +90226, Author, 247, 256, "Andreo EG", "", +90227, Author, 259, 269, "Finotti IG", "", +90228, Author, 272, 284, "S á Filho WF", "", +90229, Brazil, 425, 431, "Brazil", "", +90244, ObjectiveDescription, 471, 707, "To evaluate the efficacy of fixed combination brimonidine - timolol ( FCBT ) versus fixed combination dorzolamide - timolol ( FCDT ) given twice daily in patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH ) .", "", +90230, Brimonidine, 517, 528, "brimonidine", "", +90232, Brimo/TimFC, 517, 538, "brimonidine - timolol", "", +90231, Timolol, 531, 538, "timolol", "", +90233, Brimo/TimFC, 541, 545, "FCBT", "", +90234, Dorzolamide, 573, 584, "dorzolamide", "", +90236, Dorz/TimFC, 573, 594, "dorzolamide - timolol", "", +90235, Timolol, 587, 594, "timolol", "", +90237, Dorz/TimFC, 597, 601, "FCDT", "", +90238, Frequency, 610, 621, "twice daily", "", +90243, Precondition, 625, 705, "patients with primary open angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", +90239, Primary_OpenAngleGlaucoma, 639, 666, "primary open angle glaucoma", "", +90240, Primary_OpenAngleGlaucoma, 669, 673, "POAG", "", +90241, OcularHypertension, 679, 698, "ocular hypertension", "", +90242, OcularHypertension, 701, 703, "OH", "", +90245, Prospective, 717, 728, "Prospective", "", +90246, Multicenter, 731, 742, "multicentre", "", +90247, Blind, 745, 762, "masked - observer", "", +90248, Crossover, 765, 774, "crossover", "", +90249, NumberAffected, 803, 810, "Sixteen", "", +90251, Primary_OpenAngleGlaucoma, 825, 829, "POAG", "", +90250, NumberAffected, 834, 836, "14", "", +90252, OcularHypertension, 842, 844, "OH", "", +90253, Precondition, 892, 933, "washed out from their previous medication", "", +90254, Randomized, 938, 948, "randomized", "", +90255, Brimo/TimFC, 958, 962, "FCBT", "", +90256, Dorz/TimFC, 966, 970, "FCDT", "", +90257, IOP, 1123, 1143, "Intraocular pressure", "", +90258, IOP, 1146, 1149, "IOP", "", +90259, TimePoint, 1206, 1220, "8 : 00 a . m .", "", +90260, TimePoint, 1223, 1235, "12 : 00 noon", "", +90261, TimePoint, 1240, 1254, "4 : 00 p . m .", "", +90262, TimePoint, 1263, 1271, "baseline", "", +90263, TimePoint, 1276, 1311, "at the end of each treatment period", "", +90264, IOP, 1411, 1414, "IOP", "", +90265, Brimo/TimFC, 1434, 1438, "FCBT", "", +90266, Dorz/TimFC, 1443, 1447, "FCDT", "", +90267, Mean, 1473, 1477, "mean", "", +90268, Diurnal_IOP, 1478, 1489, "diurnal IOP", "", +90269, FinalNumPatientsCT, 1498, 1500, "30", "", +90270, BaseLineValue, 1526, 1532, "22 . 9", "", +90271, SdDevBL, 1539, 1544, "1 . 6", "", +90272, mmHg, 1545, 1549, "mmHg", "", +90275, ObservedResult, 1552, 1649, "Both fixed combinations significantly reduced IOP compared with baseline ( p & lt ; 0 . 00001 ) .", "", +90274, IOP, 1598, 1601, "IOP", "", +90273, PValueResValue, 1629, 1645, "& lt ; 0 . 00001", "", +90276, Mean, 1796, 1800, "mean", "", +90277, Diurnal_IOP, 1801, 1812, "diurnal IOP", "", +90278, Reduction, 1827, 1832, "7 . 8", "", +90280, SdDevChangeValue, 1839, 1844, "1 . 9", "", +90282, mmHg, 1845, 1849, "mmHg", "", +90284, Brimo/TimFC, 1854, 1858, "FCBT", "", +90279, Reduction, 1863, 1868, "7 . 4", "", +90281, SdDevChangeValue, 1875, 1880, "1 . 8", "", +90283, mmHg, 1881, 1885, "mmHg", "", +90285, Dorz/TimFC, 1890, 1894, "FCDT", "", +90286, PvalueDiff, 1899, 1908, "= 0 . 430", "", +90297, ObservedResult, 1913, 2041, "Overall , 14 subjects complained about ocular adverse events : two only for FCBT , seven only for FCDT and five for both drugs .", "", +90287, NumberAffected, 1923, 1925, "14", "", +90296, SubGroupDescription, 1935, 1973, "complained about ocular adverse events", "", +90288, NumberAffected, 1976, 1979, "two", "", +90293, SubGroupDescription, 1980, 1993, "only for FCBT", "", +90291, Brimo/TimFC, 1989, 1993, "FCBT", "", +90289, NumberAffected, 1996, 2001, "seven", "", +90294, SubGroupDescription, 2002, 2015, "only for FCDT", "", +90292, Dorz/TimFC, 2011, 2015, "FCDT", "", +90290, NumberAffected, 2020, 2024, "five", "", +90295, SubGroupDescription, 2025, 2039, "for both drugs", "", +90298, Brimo/TimFC, 2159, 2163, "FCBT", "", +90300, NumberAffected, 2170, 2171, "7", "", +90299, Dorz/TimFC, 2178, 2182, "FCDT", "", +90301, NumberAffected, 2189, 2191, "12", "", +90302, PvalueDiff, 2198, 2207, "= 0 . 359", "", +90303, Dorz/TimFC, 2212, 2216, "FCDT", "", +90304, Stinging, 2229, 2244, "ocular stinging", "", +90305, NumberAffected, 2269, 2270, "9", "", +90306, Brimo/TimFC, 2278, 2282, "FCBT", "", +90307, NumberAffected, 2289, 2290, "1", "", +90308, PvalueDiff, 2297, 2306, "= 0 . 027", "", +90316, ConclusionComment, 2324, 2441, "This study suggests that FCBT and FCDT , each given twice daily , have similar efficacy in patients with POAG or OH .", "", +90310, Brimo/TimFC, 2349, 2353, "FCBT", "", +90312, Dorz/TimFC, 2358, 2362, "FCDT", "", +90313, Frequency, 2376, 2387, "twice daily", "", +90314, Primary_OpenAngleGlaucoma, 2429, 2433, "POAG", "", +90315, OcularHypertension, 2437, 2439, "OH", "", +90317, PMID, 2484, 2492, "17407624", "", diff --git a/data/gl 17407624_tstrakeljahn.n-triples b/data/gl 17407624_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17407624_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17519068_admin.annodb b/data/gl 17519068_admin.annodb new file mode 100644 index 0000000..393ba62 --- /dev/null +++ b/data/gl 17519068_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2007", "", " \"2007\"." +2, Title, 54, 245, "A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open - angle glaucoma .", "", " \"A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open - angle glaucoma .\"." +81, IOP, 85, 105, "intraocular pressure", "", +82, Bimatoprost, 118, 129, "bimatoprost", "", +84, Bima/TimFC, 118, 157, "bimatoprost / timolol fixed combination", "", +83, Timolol, 132, 139, "timolol", "", +85, Latanoprost, 165, 176, "latanoprost", "", +87, Lat/TimFC, 165, 204, "latanoprost / timolol fixed combination", "", +86, Timolol, 179, 186, "timolol", "", +90, Precondition, 208, 243, "patients with open - angle glaucoma", "", +88, OpenAngleGlaucoma, 222, 243, "open - angle glaucoma", "", " ." +3, Author, 246, 256, "Martinez A", "", " \"Martinez A\"." +4, Author, 265, 274, "Sanchez M", "", " \"Sanchez M\"." +5, Spain, 381, 386, "Spain", "", " ." +6, ObjectiveDescription, 425, 647, "To compare the efficacy and tolerability of a once daily evening dose of the latanoprost / timolol fixed combination ( LTFC ) with that of a once - daily evening dose of the bimatoprost / timolol fixed combination ( BTFC )", "", " \"To compare the efficacy and tolerability of a once daily evening dose of the latanoprost / timolol fixed combination ( LTFC ) with that of a once - daily evening dose of the bimatoprost / timolol fixed combination ( BTFC )\"." +8, Frequency, 471, 481, "once daily", "", " \"once daily\"." +9, Evening, 482, 489, "evening", "", " ." +10, Latanoprost, 502, 513, "latanoprost", "", +13, Lat/TimFC, 502, 541, "latanoprost / timolol fixed combination", "", " ." +96, Timolol, 516, 523, "timolol", "", +14, Lat/TimFC, 544, 548, "LTFC", "", +15, Frequency, 566, 578, "once - daily", "", " \"once - daily\"." +16, Evening, 579, 586, "evening", "", " ." +17, Bimatoprost, 599, 610, "bimatoprost", "", +18, Bima/TimFC, 599, 638, "bimatoprost / timolol fixed combination", "", " ." +12, Timolol, 613, 620, "timolol", "", +19, Bima/TimFC, 641, 645, "BTFC", "", +7, ObjectiveDescription, 648, 815, "in patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides .", "", " \"in patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides .\"." +108, Precondition, 651, 813, "patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides", "", " \"patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides\"." +20, OpenAngleGlaucoma, 665, 686, "open - angle glaucoma", "", +21, IOP, 701, 721, "intraocular pressure", "", +22, IOP, 724, 727, "IOP", "", +23, Prospective, 825, 836, "Prospective", "", " ." +24, Randomized, 839, 849, "randomized", "", " ." +25, Blind, 852, 868, "evaluator masked", "", " ." +26, SingleCenter, 871, 886, "single - center", "", " ." +27, NumberPatientsCT, 910, 912, "36", "", " \"36\"." +118, Precondition, 913, 1117, "patients with a diagnosis of open - angle glaucoma , with or without pseudoexfoliation , and inadequate control of IOP , insufficiently responsive to monotherapy with prostaglandin analogues / prostamides", "", " \"patients with a diagnosis of open - angle glaucoma , with or without pseudoexfoliation , and inadequate control of IOP , insufficiently responsive to monotherapy with prostaglandin analogues / prostamides\"." +28, OpenAngleGlaucoma, 942, 963, "open - angle glaucoma", "", +29, IOP, 1028, 1031, "IOP", "", +33, IOP, 1187, 1190, "IOP", "", +126, TimePoint, 1194, 1203, "9 : 00 am", "", +34, TimePoint, 1209, 1217, "baseline", "", +35, TimePoint, 1221, 1227, "week 4", "", +36, Mean, 1281, 1285, "mean", "", " . ." +37, Diurnal_IOP, 1286, 1297, "diurnal IOP", "", " ." +38, TimePoint, 1313, 1321, "baseline", "", +39, TimePoint, 1325, 1331, "week 4", "", +40, Bima/TimFC, 1344, 1348, "BTFC", "", +41, Mean, 1380, 1384, "mean", "", +42, Diurnal_IOP, 1385, 1396, "diurnal IOP", "", +52, Mean, 1409, 1413, "mean", "", +43, Reduction, 1439, 1444, "2 . 8", "", " \"2 . 8\"." +45, SdDevChangeValue, 1447, 1452, "0 . 9", "", " \"0 . 9\"." +47, mmHg, 1455, 1459, "mmHg", "", " ." +49, Lat/TimFC, 1476, 1480, "LTFC", "", +44, Reduction, 1481, 1486, "2 . 1", "", " \"2 . 1\"." +46, SdDevChangeValue, 1489, 1494, "0 . 6", "", " \"0 . 6\"." +48, mmHg, 1497, 1501, "mmHg", "", +139, PvalueDiff, 1504, 1516, "p = 0 . 0214", "", " \"p = 0 . 0214\"." +51, IOP, 1561, 1564, "IOP", "", +54, TimePoint, 1570, 1578, "baseline", "", +53, IOP, 1587, 1590, "IOP", "", +55, PValueChangeValue, 1615, 1627, "p < 0 . 0001", "", +56, Mean, 1642, 1646, "mean", "", +57, Diurnal_IOP, 1647, 1658, "diurnal IOP", "", +58, PValueChangeValue, 1661, 1673, "p = 0 . 0049", "", " \"p = 0 . 0049\"." +59, Lat/TimFC, 1682, 1686, "LTFC", "", +60, PValueChangeValue, 1693, 1705, "p < 0 . 0001", "", " \"p < 0 . 0001\"." +61, Bima/TimFC, 1714, 1718, "BTFC", "", +62, ConjunctivalHyperemia, 1770, 1779, "hyperemia", "", " ." +74, ResultMeasuredValue, 1802, 1808, "1 . 25", "", " \"1 . 25\"." +76, SdDevResValue, 1811, 1816, "0 . 5", "", " \"0 . 5\"." +75, ResultMeasuredValue, 1824, 1830, "1 . 62", "", " \"1 . 62\"." +77, SdDevResValue, 1833, 1839, "0 . 69", "", " \"0 . 69\"." +154, PvalueDiff, 1846, 1856, "= 0 . 3835", "", " \"= 0 . 3835\"." +63, Lat/TimFC, 1867, 1871, "LTFC", "", +64, Bima/TimFC, 1880, 1884, "BTFC", "", +65, ConclusionComment, 1916, 2108, "The results of this study showed a significantly higher IOP - lowering effect of a once - daily evening dose of the BTFC compared to that of a once - daily evening administration of the LTFC .", "", " \"The results of this study showed a significantly higher IOP - lowering effect of a once - daily evening dose of the BTFC compared to that of a once - daily evening administration of the LTFC .\"." +66, IOP, 1972, 1975, "IOP", "", +67, Frequency, 1999, 2011, "once - daily", "", +68, Evening, 2012, 2019, "evening", "", +69, Bima/TimFC, 2032, 2036, "BTFC", "", +70, Frequency, 2059, 2071, "once - daily", "", +71, Evening, 2072, 2079, "evening", "", +72, Lat/TimFC, 2102, 2106, "LTFC", "", +73, PMID, 2151, 2159, "17519068", "", " \"17519068\"." diff --git a/data/gl 17519068_admin.n-triples b/data/gl 17519068_admin.n-triples new file mode 100644 index 0000000..da3e786 --- /dev/null +++ b/data/gl 17519068_admin.n-triples @@ -0,0 +1,120 @@ +# RDF export of group: Publication + . + "Publication " . + "A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open - angle glaucoma ." . + "Martinez A" . + "2007" . + "Curr Med Res Opin ." . + "17519068" . + . + "Sanchez M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy and tolerability of a once daily evening dose of the latanoprost / timolol fixed combination ( LTFC ) with that of a once - daily evening dose of the bimatoprost / timolol fixed combination ( BTFC )" . + "36" . + . + . + . + "The results of this study showed a significantly higher IOP - lowering effect of a once - daily evening dose of the BTFC compared to that of a once - daily evening administration of the LTFC ." . + . + . + . + . + . + "in patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides" . + . + . + . + "patients with a diagnosis of open - angle glaucoma , with or without pseudoexfoliation , and inadequate control of IOP , insufficiently responsive to monotherapy with prostaglandin analogues / prostamides" . +# RDF export of group: Endpoint + . + "Endpoint d IOP" . + . + . + . + . + . + . + "Endpoint hyperemia" . + . + . + . + . +# RDF export of group: Arm + . + "Arm lt" . + . + . + . + . + "Arm bt" . + . + . + . +# RDF export of group: Intervention + . + "Intervention lt" . + . + "once daily" . + . + . + "Intervention bt" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication lt" . + . + . + . + . + "Medication bt" . + . + . + . +# RDF export of group: Outcome + . + "Outcome d IOP lt" . + . + "2 . 1" . + "p = 0 . 0049" . + "0 . 6" . + . + "Outcome d IOP bt" . + . + "2 . 8" . + "p < 0 . 0001" . + "0 . 9" . + . + "Outcome h lt" . + . + "1 . 25" . + "0 . 5" . + . + "Outcome h bt" . + . + "1 . 62" . + "0 . 69" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups d IOP" . + "p = 0 . 0214" . + . + . + . + "DiffBetweenGroups h" . + "= 0 . 3835" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17519068_export.csv b/data/gl 17519068_export.csv new file mode 100644 index 0000000..9374d7d --- /dev/null +++ b/data/gl 17519068_export.csv @@ -0,0 +1,437 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +538, 1, 1, 1, 0, 4, 0, 4, "Curr" +538, 1, 2, 2, 5, 8, 5, 8, "Med" +538, 1, 3, 3, 9, 12, 9, 12, "Res" +538, 1, 4, 4, 13, 17, 13, 17, "Opin" +538, 1, 5, 5, 18, 19, 18, 19, "." +538, 2, 1, 6, 0, 4, 20, 24, "2007" +538, 2, 2, 7, 5, 8, 25, 28, "May" +538, 2, 3, 8, 9, 10, 29, 30, ";" +538, 2, 4, 9, 11, 13, 31, 33, "23" +538, 2, 5, 10, 14, 15, 34, 35, "(" +538, 2, 6, 11, 16, 17, 36, 37, "5" +538, 2, 7, 12, 18, 19, 38, 39, ")" +538, 2, 8, 13, 20, 21, 40, 41, ":" +538, 2, 9, 14, 22, 26, 42, 46, "1025" +538, 2, 10, 15, 27, 28, 47, 48, "-" +538, 2, 11, 16, 29, 31, 49, 51, "32" +538, 2, 12, 17, 32, 33, 52, 53, "." +538, 3, 1, 18, 0, 1, 54, 55, "A" +538, 3, 2, 19, 2, 12, 56, 66, "comparison" +538, 3, 3, 20, 13, 15, 67, 69, "of" +538, 3, 4, 21, 16, 19, 70, 73, "the" +538, 3, 5, 22, 20, 26, 74, 80, "safety" +538, 3, 6, 23, 27, 30, 81, 84, "and" +538, 3, 7, 24, 31, 42, 85, 96, "intraocular" +538, 3, 8, 25, 43, 51, 97, 105, "pressure" +538, 3, 9, 26, 52, 60, 106, 114, "lowering" +538, 3, 10, 27, 61, 63, 115, 117, "of" +538, 3, 11, 28, 64, 75, 118, 129, "bimatoprost" +538, 3, 12, 29, 76, 77, 130, 131, "/" +538, 3, 13, 30, 78, 85, 132, 139, "timolol" +538, 3, 14, 31, 86, 91, 140, 145, "fixed" +538, 3, 15, 32, 92, 103, 146, 157, "combination" +538, 3, 16, 33, 104, 110, 158, 164, "versus" +538, 3, 17, 34, 111, 122, 165, 176, "latanoprost" +538, 3, 18, 35, 123, 124, 177, 178, "/" +538, 3, 19, 36, 125, 132, 179, 186, "timolol" +538, 3, 20, 37, 133, 138, 187, 192, "fixed" +538, 3, 21, 38, 139, 150, 193, 204, "combination" +538, 3, 22, 39, 151, 153, 205, 207, "in" +538, 3, 23, 40, 154, 162, 208, 216, "patients" +538, 3, 24, 41, 163, 167, 217, 221, "with" +538, 3, 25, 42, 168, 172, 222, 226, "open" +538, 3, 26, 43, 173, 174, 227, 228, "-" +538, 3, 27, 44, 175, 180, 229, 234, "angle" +538, 3, 28, 45, 181, 189, 235, 243, "glaucoma" +538, 3, 29, 46, 190, 191, 244, 245, "." +538, 4, 1, 47, 0, 8, 246, 254, "Martinez" +538, 4, 2, 48, 9, 10, 255, 256, "A" +538, 4, 3, 49, 11, 12, 257, 258, "(" +538, 4, 4, 50, 13, 14, 259, 260, "1" +538, 4, 5, 51, 15, 16, 261, 262, ")" +538, 4, 6, 52, 17, 18, 263, 264, "," +538, 4, 7, 53, 19, 26, 265, 272, "Sanchez" +538, 4, 8, 54, 27, 28, 273, 274, "M" +538, 4, 9, 55, 29, 30, 275, 276, "." +538, 4, 10, 56, 31, 37, 277, 283, "Author" +538, 4, 11, 57, 38, 49, 284, 295, "information" +538, 4, 12, 58, 50, 51, 296, 297, ":" +538, 4, 13, 59, 52, 53, 298, 299, "(" +538, 4, 14, 60, 54, 55, 300, 301, "1" +538, 4, 15, 61, 56, 57, 302, 303, ")" +538, 4, 16, 62, 58, 67, 304, 313, "Instituto" +538, 4, 17, 63, 68, 75, 314, 321, "Gallego" +538, 4, 18, 64, 76, 78, 322, 324, "de" +538, 4, 19, 65, 79, 89, 325, 335, "Oftalmolog" +538, 4, 20, 66, 90, 91, 336, 337, "í" +538, 4, 21, 67, 92, 93, 338, 339, "a" +538, 4, 22, 68, 94, 95, 340, 341, "," +538, 4, 23, 69, 96, 104, 342, 350, "Santiago" +538, 4, 24, 70, 105, 107, 351, 353, "de" +538, 4, 25, 71, 108, 118, 354, 364, "Compostela" +538, 4, 26, 72, 119, 120, 365, 366, "," +538, 4, 27, 73, 121, 123, 367, 369, "La" +538, 4, 28, 74, 124, 128, 370, 374, "Coru" +538, 4, 29, 75, 129, 130, 375, 376, "ñ" +538, 4, 30, 76, 131, 132, 377, 378, "a" +538, 4, 31, 77, 133, 134, 379, 380, "," +538, 4, 32, 78, 135, 140, 381, 386, "Spain" +538, 4, 33, 79, 141, 142, 387, 388, "." +538, 5, 1, 80, 0, 11, 389, 400, "tontxu_1999" +538, 5, 2, 81, 12, 13, 401, 402, "@" +538, 5, 3, 82, 14, 19, 403, 408, "yahoo" +538, 5, 4, 83, 20, 21, 409, 410, "." +538, 5, 5, 84, 22, 25, 411, 414, "com" +538, 5, 6, 85, 26, 33, 415, 422, "PURPOSE" +538, 5, 7, 86, 34, 35, 423, 424, ":" +538, 5, 8, 87, 36, 38, 425, 427, "To" +538, 5, 9, 88, 39, 46, 428, 435, "compare" +538, 5, 10, 89, 47, 50, 436, 439, "the" +538, 5, 11, 90, 51, 59, 440, 448, "efficacy" +538, 5, 12, 91, 60, 63, 449, 452, "and" +538, 5, 13, 92, 64, 76, 453, 465, "tolerability" +538, 5, 14, 93, 77, 79, 466, 468, "of" +538, 5, 15, 94, 80, 81, 469, 470, "a" +538, 5, 16, 95, 82, 86, 471, 475, "once" +538, 5, 17, 96, 87, 92, 476, 481, "daily" +538, 5, 18, 97, 93, 100, 482, 489, "evening" +538, 5, 19, 98, 101, 105, 490, 494, "dose" +538, 5, 20, 99, 106, 108, 495, 497, "of" +538, 5, 21, 100, 109, 112, 498, 501, "the" +538, 5, 22, 101, 113, 124, 502, 513, "latanoprost" +538, 5, 23, 102, 125, 126, 514, 515, "/" +538, 5, 24, 103, 127, 134, 516, 523, "timolol" +538, 5, 25, 104, 135, 140, 524, 529, "fixed" +538, 5, 26, 105, 141, 152, 530, 541, "combination" +538, 5, 27, 106, 153, 154, 542, 543, "(" +538, 5, 28, 107, 155, 159, 544, 548, "LTFC" +538, 5, 29, 108, 160, 161, 549, 550, ")" +538, 5, 30, 109, 162, 166, 551, 555, "with" +538, 5, 31, 110, 167, 171, 556, 560, "that" +538, 5, 32, 111, 172, 174, 561, 563, "of" +538, 5, 33, 112, 175, 176, 564, 565, "a" +538, 5, 34, 113, 177, 181, 566, 570, "once" +538, 5, 35, 114, 182, 183, 571, 572, "-" +538, 5, 36, 115, 184, 189, 573, 578, "daily" +538, 5, 37, 116, 190, 197, 579, 586, "evening" +538, 5, 38, 117, 198, 202, 587, 591, "dose" +538, 5, 39, 118, 203, 205, 592, 594, "of" +538, 5, 40, 119, 206, 209, 595, 598, "the" +538, 5, 41, 120, 210, 221, 599, 610, "bimatoprost" +538, 5, 42, 121, 222, 223, 611, 612, "/" +538, 5, 43, 122, 224, 231, 613, 620, "timolol" +538, 5, 44, 123, 232, 237, 621, 626, "fixed" +538, 5, 45, 124, 238, 249, 627, 638, "combination" +538, 5, 46, 125, 250, 251, 639, 640, "(" +538, 5, 47, 126, 252, 256, 641, 645, "BTFC" +538, 5, 48, 127, 257, 258, 646, 647, ")" +538, 5, 49, 128, 259, 261, 648, 650, "in" +538, 5, 50, 129, 262, 270, 651, 659, "patients" +538, 5, 51, 130, 271, 275, 660, 664, "with" +538, 5, 52, 131, 276, 280, 665, 669, "open" +538, 5, 53, 132, 281, 282, 670, 671, "-" +538, 5, 54, 133, 283, 288, 672, 677, "angle" +538, 5, 55, 134, 289, 297, 678, 686, "glaucoma" +538, 5, 56, 135, 298, 302, 687, 691, "with" +538, 5, 57, 136, 303, 311, 692, 700, "elevated" +538, 5, 58, 137, 312, 323, 701, 712, "intraocular" +538, 5, 59, 138, 324, 332, 713, 721, "pressure" +538, 5, 60, 139, 333, 334, 722, 723, "(" +538, 5, 61, 140, 335, 338, 724, 727, "IOP" +538, 5, 62, 141, 339, 340, 728, 729, ")" +538, 5, 63, 142, 341, 355, 730, 744, "insufficiently" +538, 5, 64, 143, 356, 366, 745, 755, "responsive" +538, 5, 65, 144, 367, 369, 756, 758, "to" +538, 5, 66, 145, 370, 381, 759, 770, "monotherapy" +538, 5, 67, 146, 382, 386, 771, 775, "with" +538, 5, 68, 147, 387, 400, 776, 789, "prostaglandin" +538, 5, 69, 148, 401, 410, 790, 799, "analogues" +538, 5, 70, 149, 411, 412, 800, 801, "/" +538, 5, 71, 150, 413, 424, 802, 813, "prostamides" +538, 5, 72, 151, 425, 426, 814, 815, "." +538, 6, 1, 152, 0, 6, 816, 822, "DESIGN" +538, 6, 2, 153, 7, 8, 823, 824, ":" +538, 6, 3, 154, 9, 20, 825, 836, "Prospective" +538, 6, 4, 155, 21, 22, 837, 838, "," +538, 6, 5, 156, 23, 33, 839, 849, "randomized" +538, 6, 6, 157, 34, 35, 850, 851, "," +538, 6, 7, 158, 36, 45, 852, 861, "evaluator" +538, 6, 8, 159, 46, 52, 862, 868, "masked" +538, 6, 9, 160, 53, 54, 869, 870, "," +538, 6, 10, 161, 55, 61, 871, 877, "single" +538, 6, 11, 162, 62, 63, 878, 879, "-" +538, 6, 12, 163, 64, 70, 880, 886, "center" +538, 6, 13, 164, 71, 76, 887, 892, "study" +538, 6, 14, 165, 77, 78, 893, 894, "." +538, 7, 1, 166, 0, 12, 895, 907, "PARTICIPANTS" +538, 7, 2, 167, 13, 14, 908, 909, ":" +538, 7, 3, 168, 15, 17, 910, 912, "36" +538, 7, 4, 169, 18, 26, 913, 921, "patients" +538, 7, 5, 170, 27, 31, 922, 926, "with" +538, 7, 6, 171, 32, 33, 927, 928, "a" +538, 7, 7, 172, 34, 43, 929, 938, "diagnosis" +538, 7, 8, 173, 44, 46, 939, 941, "of" +538, 7, 9, 174, 47, 51, 942, 946, "open" +538, 7, 10, 175, 52, 53, 947, 948, "-" +538, 7, 11, 176, 54, 59, 949, 954, "angle" +538, 7, 12, 177, 60, 68, 955, 963, "glaucoma" +538, 7, 13, 178, 69, 70, 964, 965, "," +538, 7, 14, 179, 71, 75, 966, 970, "with" +538, 7, 15, 180, 76, 78, 971, 973, "or" +538, 7, 16, 181, 79, 86, 974, 981, "without" +538, 7, 17, 182, 87, 104, 982, 999, "pseudoexfoliation" +538, 7, 18, 183, 105, 106, 1000, 1001, "," +538, 7, 19, 184, 107, 110, 1002, 1005, "and" +538, 7, 20, 185, 111, 121, 1006, 1016, "inadequate" +538, 7, 21, 186, 122, 129, 1017, 1024, "control" +538, 7, 22, 187, 130, 132, 1025, 1027, "of" +538, 7, 23, 188, 133, 136, 1028, 1031, "IOP" +538, 7, 24, 189, 137, 138, 1032, 1033, "," +538, 7, 25, 190, 139, 153, 1034, 1048, "insufficiently" +538, 7, 26, 191, 154, 164, 1049, 1059, "responsive" +538, 7, 27, 192, 165, 167, 1060, 1062, "to" +538, 7, 28, 193, 168, 179, 1063, 1074, "monotherapy" +538, 7, 29, 194, 180, 184, 1075, 1079, "with" +538, 7, 30, 195, 185, 198, 1080, 1093, "prostaglandin" +538, 7, 31, 196, 199, 208, 1094, 1103, "analogues" +538, 7, 32, 197, 209, 210, 1104, 1105, "/" +538, 7, 33, 198, 211, 222, 1106, 1117, "prostamides" +538, 7, 34, 199, 223, 224, 1118, 1119, "." +538, 8, 1, 200, 0, 4, 1120, 1124, "MAIN" +538, 8, 2, 201, 5, 12, 1125, 1132, "OUTCOME" +538, 8, 3, 202, 13, 20, 1133, 1140, "MEASURE" +538, 8, 4, 203, 21, 22, 1141, 1142, ":" +538, 8, 5, 204, 23, 26, 1143, 1146, "The" +538, 8, 6, 205, 27, 34, 1147, 1154, "primary" +538, 8, 7, 206, 35, 38, 1155, 1158, "end" +538, 8, 8, 207, 39, 40, 1159, 1160, "-" +538, 8, 9, 208, 41, 47, 1161, 1167, "points" +538, 8, 10, 209, 48, 52, 1168, 1172, "were" +538, 8, 11, 210, 53, 56, 1173, 1176, "the" +538, 8, 12, 211, 57, 63, 1177, 1183, "change" +538, 8, 13, 212, 64, 66, 1184, 1186, "in" +538, 8, 14, 213, 67, 70, 1187, 1190, "IOP" +538, 8, 15, 214, 71, 73, 1191, 1193, "at" +538, 8, 16, 215, 74, 75, 1194, 1195, "9" +538, 8, 17, 216, 76, 77, 1196, 1197, ":" +538, 8, 18, 217, 78, 80, 1198, 1200, "00" +538, 8, 19, 218, 81, 83, 1201, 1203, "am" +538, 8, 20, 219, 84, 88, 1204, 1208, "from" +538, 8, 21, 220, 89, 97, 1209, 1217, "baseline" +538, 8, 22, 221, 98, 100, 1218, 1220, "to" +538, 8, 23, 222, 101, 105, 1221, 1225, "week" +538, 8, 24, 223, 106, 107, 1226, 1227, "4" +538, 8, 25, 224, 108, 109, 1228, 1229, "," +538, 8, 26, 225, 110, 113, 1230, 1233, "and" +538, 8, 27, 226, 114, 117, 1234, 1237, "the" +538, 8, 28, 227, 118, 128, 1238, 1248, "difference" +538, 8, 29, 228, 129, 136, 1249, 1256, "between" +538, 8, 30, 229, 137, 146, 1257, 1266, "treatment" +538, 8, 31, 230, 147, 153, 1267, 1273, "groups" +538, 8, 32, 231, 154, 156, 1274, 1276, "in" +538, 8, 33, 232, 157, 160, 1277, 1280, "the" +538, 8, 34, 233, 161, 165, 1281, 1285, "mean" +538, 8, 35, 234, 166, 173, 1286, 1293, "diurnal" +538, 8, 36, 235, 174, 177, 1294, 1297, "IOP" +538, 8, 37, 236, 178, 187, 1298, 1307, "reduction" +538, 8, 38, 237, 188, 192, 1308, 1312, "from" +538, 8, 39, 238, 193, 201, 1313, 1321, "baseline" +538, 8, 40, 239, 202, 204, 1322, 1324, "to" +538, 8, 41, 240, 205, 209, 1325, 1329, "week" +538, 8, 42, 241, 210, 211, 1330, 1331, "4" +538, 8, 43, 242, 212, 213, 1332, 1333, "." +538, 9, 1, 243, 0, 7, 1334, 1341, "RESULTS" +538, 9, 2, 244, 8, 9, 1342, 1343, ":" +538, 9, 3, 245, 10, 14, 1344, 1348, "BTFC" +538, 9, 4, 246, 15, 23, 1349, 1357, "provided" +538, 9, 5, 247, 24, 37, 1358, 1371, "significantly" +538, 9, 6, 248, 38, 45, 1372, 1379, "greater" +538, 9, 7, 249, 46, 50, 1380, 1384, "mean" +538, 9, 8, 250, 51, 58, 1385, 1392, "diurnal" +538, 9, 9, 251, 59, 62, 1393, 1396, "IOP" +538, 9, 10, 252, 63, 72, 1397, 1406, "reduction" +538, 9, 11, 253, 73, 74, 1407, 1408, "[" +538, 9, 12, 254, 75, 79, 1409, 1413, "mean" +538, 9, 13, 255, 80, 81, 1414, 1415, "(" +538, 9, 14, 256, 82, 90, 1416, 1424, "standard" +538, 9, 15, 257, 91, 100, 1425, 1434, "deviation" +538, 9, 16, 258, 101, 102, 1435, 1436, ")" +538, 9, 17, 259, 103, 104, 1437, 1438, "]" +538, 9, 18, 260, 105, 106, 1439, 1440, "2" +538, 9, 19, 261, 107, 108, 1441, 1442, "." +538, 9, 20, 262, 109, 110, 1443, 1444, "8" +538, 9, 21, 263, 111, 112, 1445, 1446, "(" +538, 9, 22, 264, 113, 114, 1447, 1448, "0" +538, 9, 23, 265, 115, 116, 1449, 1450, "." +538, 9, 24, 266, 117, 118, 1451, 1452, "9" +538, 9, 25, 267, 119, 120, 1453, 1454, ")" +538, 9, 26, 268, 121, 125, 1455, 1459, "mmHg" +538, 9, 27, 269, 126, 127, 1460, 1461, "," +538, 9, 28, 270, 128, 136, 1462, 1470, "compared" +538, 9, 29, 271, 137, 141, 1471, 1475, "with" +538, 9, 30, 272, 142, 146, 1476, 1480, "LTFC" +538, 9, 31, 273, 147, 148, 1481, 1482, "2" +538, 9, 32, 274, 149, 150, 1483, 1484, "." +538, 9, 33, 275, 151, 152, 1485, 1486, "1" +538, 9, 34, 276, 153, 154, 1487, 1488, "(" +538, 9, 35, 277, 155, 156, 1489, 1490, "0" +538, 9, 36, 278, 157, 158, 1491, 1492, "." +538, 9, 37, 279, 159, 160, 1493, 1494, "6" +538, 9, 38, 280, 161, 162, 1495, 1496, ")" +538, 9, 39, 281, 163, 167, 1497, 1501, "mmHg" +538, 9, 40, 282, 168, 169, 1502, 1503, "," +538, 9, 41, 283, 170, 171, 1504, 1505, "p" +538, 9, 42, 284, 172, 173, 1506, 1507, "=" +538, 9, 43, 285, 174, 175, 1508, 1509, "0" +538, 9, 44, 286, 176, 177, 1510, 1511, "." +538, 9, 45, 287, 178, 182, 1512, 1516, "0214" +538, 9, 46, 288, 183, 184, 1517, 1518, "." +538, 10, 1, 289, 0, 4, 1519, 1523, "Both" +538, 10, 2, 290, 5, 15, 1524, 1534, "treatments" +538, 10, 3, 291, 16, 29, 1535, 1548, "significantly" +538, 10, 4, 292, 30, 37, 1549, 1556, "reduced" +538, 10, 5, 293, 38, 41, 1557, 1560, "the" +538, 10, 6, 294, 42, 45, 1561, 1564, "IOP" +538, 10, 7, 295, 46, 50, 1565, 1569, "from" +538, 10, 8, 296, 51, 59, 1570, 1578, "baseline" +538, 10, 9, 297, 60, 62, 1579, 1581, "at" +538, 10, 10, 298, 63, 67, 1582, 1586, "each" +538, 10, 11, 299, 68, 71, 1587, 1590, "IOP" +538, 10, 12, 300, 72, 76, 1591, 1595, "time" +538, 10, 13, 301, 77, 78, 1596, 1597, "-" +538, 10, 14, 302, 79, 84, 1598, 1603, "point" +538, 10, 15, 303, 85, 93, 1604, 1612, "measured" +538, 10, 16, 304, 94, 95, 1613, 1614, "," +538, 10, 17, 305, 96, 97, 1615, 1616, "p" +538, 10, 18, 306, 98, 99, 1617, 1618, "<" +538, 10, 19, 307, 100, 101, 1619, 1620, "0" +538, 10, 20, 308, 102, 103, 1621, 1622, "." +538, 10, 21, 309, 104, 108, 1623, 1627, "0001" +538, 10, 22, 310, 109, 110, 1628, 1629, "," +538, 10, 23, 311, 111, 114, 1630, 1633, "and" +538, 10, 24, 312, 115, 118, 1634, 1637, "for" +538, 10, 25, 313, 119, 122, 1638, 1641, "the" +538, 10, 26, 314, 123, 127, 1642, 1646, "mean" +538, 10, 27, 315, 128, 135, 1647, 1654, "diurnal" +538, 10, 28, 316, 136, 139, 1655, 1658, "IOP" +538, 10, 29, 317, 140, 141, 1659, 1660, ";" +538, 10, 30, 318, 142, 143, 1661, 1662, "p" +538, 10, 31, 319, 144, 145, 1663, 1664, "=" +538, 10, 32, 320, 146, 147, 1665, 1666, "0" +538, 10, 33, 321, 148, 149, 1667, 1668, "." +538, 10, 34, 322, 150, 154, 1669, 1673, "0049" +538, 10, 35, 323, 155, 158, 1674, 1677, "for" +538, 10, 36, 324, 159, 162, 1678, 1681, "the" +538, 10, 37, 325, 163, 167, 1682, 1686, "LTFC" +538, 10, 38, 326, 168, 169, 1687, 1688, "," +538, 10, 39, 327, 170, 173, 1689, 1692, "and" +538, 10, 40, 328, 174, 175, 1693, 1694, "p" +538, 10, 41, 329, 176, 177, 1695, 1696, "<" +538, 10, 42, 330, 178, 179, 1697, 1698, "0" +538, 10, 43, 331, 180, 181, 1699, 1700, "." +538, 10, 44, 332, 182, 186, 1701, 1705, "0001" +538, 10, 45, 333, 187, 190, 1706, 1709, "for" +538, 10, 46, 334, 191, 194, 1710, 1713, "the" +538, 10, 47, 335, 195, 199, 1714, 1718, "BTFC" +538, 10, 48, 336, 200, 201, 1719, 1720, "." +538, 11, 1, 337, 0, 5, 1721, 1726, "There" +538, 11, 2, 338, 6, 10, 1727, 1731, "were" +538, 11, 3, 339, 11, 13, 1732, 1734, "no" +538, 11, 4, 340, 14, 25, 1735, 1746, "significant" +538, 11, 5, 341, 26, 37, 1747, 1758, "differences" +538, 11, 6, 342, 38, 40, 1759, 1761, "in" +538, 11, 7, 343, 41, 48, 1762, 1769, "average" +538, 11, 8, 344, 49, 58, 1770, 1779, "hyperemia" +538, 11, 9, 345, 59, 65, 1780, 1786, "scores" +538, 11, 10, 346, 66, 71, 1787, 1792, "among" +538, 11, 11, 347, 72, 78, 1793, 1799, "groups" +538, 11, 12, 348, 79, 80, 1800, 1801, "," +538, 11, 13, 349, 81, 82, 1802, 1803, "1" +538, 11, 14, 350, 83, 84, 1804, 1805, "." +538, 11, 15, 351, 85, 87, 1806, 1808, "25" +538, 11, 16, 352, 88, 89, 1809, 1810, "(" +538, 11, 17, 353, 90, 91, 1811, 1812, "0" +538, 11, 18, 354, 92, 93, 1813, 1814, "." +538, 11, 19, 355, 94, 95, 1815, 1816, "5" +538, 11, 20, 356, 96, 97, 1817, 1818, ")" +538, 11, 21, 357, 98, 100, 1819, 1821, "vs" +538, 11, 22, 358, 101, 102, 1822, 1823, "." +538, 11, 23, 359, 103, 104, 1824, 1825, "1" +538, 11, 24, 360, 105, 106, 1826, 1827, "." +538, 11, 25, 361, 107, 109, 1828, 1830, "62" +538, 11, 26, 362, 110, 111, 1831, 1832, "(" +538, 11, 27, 363, 112, 113, 1833, 1834, "0" +538, 11, 28, 364, 114, 115, 1835, 1836, "." +538, 11, 29, 365, 116, 118, 1837, 1839, "69" +538, 11, 30, 366, 119, 120, 1840, 1841, ")" +538, 11, 31, 367, 121, 122, 1842, 1843, "," +538, 11, 32, 368, 123, 124, 1844, 1845, "p" +538, 11, 33, 369, 125, 126, 1846, 1847, "=" +538, 11, 34, 370, 127, 128, 1848, 1849, "0" +538, 11, 35, 371, 129, 130, 1850, 1851, "." +538, 11, 36, 372, 131, 135, 1852, 1856, "3835" +538, 11, 37, 373, 136, 137, 1857, 1858, "," +538, 11, 38, 374, 138, 141, 1859, 1862, "for" +538, 11, 39, 375, 142, 145, 1863, 1866, "the" +538, 11, 40, 376, 146, 150, 1867, 1871, "LTFC" +538, 11, 41, 377, 151, 154, 1872, 1875, "and" +538, 11, 42, 378, 155, 158, 1876, 1879, "the" +538, 11, 43, 379, 159, 163, 1880, 1884, "BTFC" +538, 11, 44, 380, 164, 165, 1885, 1886, "," +538, 11, 45, 381, 166, 178, 1887, 1899, "respectively" +538, 11, 46, 382, 179, 180, 1900, 1901, "." +538, 12, 1, 383, 0, 11, 1902, 1913, "CONCLUSIONS" +538, 12, 2, 384, 12, 13, 1914, 1915, ":" +538, 12, 3, 385, 14, 17, 1916, 1919, "The" +538, 12, 4, 386, 18, 25, 1920, 1927, "results" +538, 12, 5, 387, 26, 28, 1928, 1930, "of" +538, 12, 6, 388, 29, 33, 1931, 1935, "this" +538, 12, 7, 389, 34, 39, 1936, 1941, "study" +538, 12, 8, 390, 40, 46, 1942, 1948, "showed" +538, 12, 9, 391, 47, 48, 1949, 1950, "a" +538, 12, 10, 392, 49, 62, 1951, 1964, "significantly" +538, 12, 11, 393, 63, 69, 1965, 1971, "higher" +538, 12, 12, 394, 70, 73, 1972, 1975, "IOP" +538, 12, 13, 395, 74, 75, 1976, 1977, "-" +538, 12, 14, 396, 76, 84, 1978, 1986, "lowering" +538, 12, 15, 397, 85, 91, 1987, 1993, "effect" +538, 12, 16, 398, 92, 94, 1994, 1996, "of" +538, 12, 17, 399, 95, 96, 1997, 1998, "a" +538, 12, 18, 400, 97, 101, 1999, 2003, "once" +538, 12, 19, 401, 102, 103, 2004, 2005, "-" +538, 12, 20, 402, 104, 109, 2006, 2011, "daily" +538, 12, 21, 403, 110, 117, 2012, 2019, "evening" +538, 12, 22, 404, 118, 122, 2020, 2024, "dose" +538, 12, 23, 405, 123, 125, 2025, 2027, "of" +538, 12, 24, 406, 126, 129, 2028, 2031, "the" +538, 12, 25, 407, 130, 134, 2032, 2036, "BTFC" +538, 12, 26, 408, 135, 143, 2037, 2045, "compared" +538, 12, 27, 409, 144, 146, 2046, 2048, "to" +538, 12, 28, 410, 147, 151, 2049, 2053, "that" +538, 12, 29, 411, 152, 154, 2054, 2056, "of" +538, 12, 30, 412, 155, 156, 2057, 2058, "a" +538, 12, 31, 413, 157, 161, 2059, 2063, "once" +538, 12, 32, 414, 162, 163, 2064, 2065, "-" +538, 12, 33, 415, 164, 169, 2066, 2071, "daily" +538, 12, 34, 416, 170, 177, 2072, 2079, "evening" +538, 12, 35, 417, 178, 192, 2080, 2094, "administration" +538, 12, 36, 418, 193, 195, 2095, 2097, "of" +538, 12, 37, 419, 196, 199, 2098, 2101, "the" +538, 12, 38, 420, 200, 204, 2102, 2106, "LTFC" +538, 12, 39, 421, 205, 206, 2107, 2108, "." +538, 13, 1, 422, 0, 3, 2109, 2112, "DOI" +538, 13, 2, 423, 4, 5, 2113, 2114, ":" +538, 13, 3, 424, 6, 8, 2115, 2117, "10" +538, 13, 4, 425, 9, 10, 2118, 2119, "." +538, 13, 5, 426, 11, 15, 2120, 2124, "1185" +538, 13, 6, 427, 16, 17, 2125, 2126, "/" +538, 13, 7, 428, 18, 34, 2127, 2143, "030079907x182149" +538, 13, 8, 429, 35, 39, 2144, 2148, "PMID" +538, 13, 9, 430, 40, 41, 2149, 2150, ":" +538, 13, 10, 431, 42, 50, 2151, 2159, "17519068" +538, 13, 11, 432, 51, 52, 2160, 2161, "[" +538, 13, 12, 433, 53, 60, 2162, 2169, "Indexed" +538, 13, 13, 434, 61, 64, 2170, 2173, "for" +538, 13, 14, 435, 65, 72, 2174, 2181, "MEDLINE" +538, 13, 15, 436, 73, 74, 2182, 2183, "]" diff --git a/data/gl 17519068_jshahinitiran.annodb b/data/gl 17519068_jshahinitiran.annodb new file mode 100644 index 0000000..cb875cc --- /dev/null +++ b/data/gl 17519068_jshahinitiran.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +87286, Journal, 0, 17, "Curr Med Res Opin", "", +87287, PublicationYear, 20, 24, "2007", "", +87288, Title, 54, 245, "A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open - angle glaucoma .", "", +87289, Author, 246, 256, "Martinez A", "", +87290, Author, 265, 274, "Sanchez M", "", +87291, Spain, 381, 386, "Spain", "", +87292, ObjectiveDescription, 425, 647, "To compare the efficacy and tolerability of a once daily evening dose of the latanoprost / timolol fixed combination ( LTFC ) with that of a once - daily evening dose of the bimatoprost / timolol fixed combination ( BTFC )", "", +87294, Frequency, 471, 481, "once daily", "", +87295, Evening, 482, 489, "evening", "", +87296, Latanoprost, 502, 513, "latanoprost", "", +87299, Lat/TimFC, 502, 541, "latanoprost / timolol fixed combination", "", +87297, Timolol, 516, 529, "timolol fixed", "", +87300, Lat/TimFC, 544, 548, "LTFC", "", +87301, Frequency, 566, 578, "once - daily", "", +87303, Evening, 579, 586, "evening", "", +87304, Bimatoprost, 599, 610, "bimatoprost", "", +87305, Bima/TimFC, 599, 638, "bimatoprost / timolol fixed combination", "", +87298, Timolol, 613, 620, "timolol", "", +87306, Bima/TimFC, 641, 645, "BTFC", "", +87293, ObjectiveDescription, 648, 815, "in patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides .", "", +87307, OpenAngleGlaucoma, 665, 686, "open - angle glaucoma", "", +87308, IOP, 701, 721, "intraocular pressure", "", +87309, IOP, 724, 727, "IOP", "", +87310, Prospective, 825, 836, "Prospective", "", +87311, Randomized, 839, 849, "randomized", "", +87312, Blind, 852, 868, "evaluator masked", "", +87313, SingleCenter, 871, 886, "single - center", "", +87314, NumberPatientsCT, 910, 912, "36", "", +87315, OpenAngleGlaucoma, 942, 963, "open - angle glaucoma", "", +87317, Precondition, 966, 999, "with or without pseudoexfoliation", "", +87318, Precondition, 1006, 1031, "inadequate control of IOP", "", +87316, IOP, 1028, 1031, "IOP", "", +87319, Precondition, 1034, 1117, "insufficiently responsive to monotherapy with prostaglandin analogues / prostamides", "", +87320, IOP, 1187, 1190, "IOP", "", +87321, TimePoint, 1209, 1217, "baseline", "", +87322, TimePoint, 1221, 1227, "week 4", "", +87323, Mean, 1281, 1285, "mean", "", +87324, Diurnal_IOP, 1286, 1297, "diurnal IOP", "", +87325, TimePoint, 1313, 1321, "baseline", "", +87326, TimePoint, 1325, 1331, "week 4", "", +87327, Bima/TimFC, 1344, 1348, "BTFC", "", +87328, Mean, 1380, 1384, "mean", "", +87329, Diurnal_IOP, 1385, 1396, "diurnal IOP", "", +87339, Mean, 1409, 1413, "mean", "", +87330, Reduction, 1439, 1444, "2 . 8", "", +87332, SdDevChangeValue, 1447, 1452, "0 . 9", "", +87334, mmHg, 1455, 1459, "mmHg", "", +87336, Lat/TimFC, 1476, 1480, "LTFC", "", +87331, Reduction, 1481, 1486, "2 . 1", "", +87333, SdDevChangeValue, 1489, 1494, "0 . 6", "", +87335, mmHg, 1497, 1501, "mmHg", "", +87337, PValueChangeValue, 1504, 1516, "p = 0 . 0214", "", +87338, IOP, 1561, 1564, "IOP", "", +87341, TimePoint, 1570, 1578, "baseline", "", +87340, IOP, 1587, 1590, "IOP", "", +87342, PValueChangeValue, 1615, 1627, "p < 0 . 0001", "", +87343, Mean, 1642, 1646, "mean", "", +87344, Diurnal_IOP, 1647, 1658, "diurnal IOP", "", +87345, PValueChangeValue, 1661, 1673, "p = 0 . 0049", "", +87346, Lat/TimFC, 1682, 1686, "LTFC", "", +87347, PValueChangeValue, 1693, 1705, "p < 0 . 0001", "", +87348, Bima/TimFC, 1714, 1718, "BTFC", "", +87349, ConjunctivalHyperemia, 1770, 1779, "hyperemia", "", +87361, ResultMeasuredValue, 1802, 1808, "1 . 25", "", +87363, SdDevResValue, 1811, 1816, "0 . 5", "", +87362, ResultMeasuredValue, 1824, 1830, "1 . 62", "", +87364, SdDevResValue, 1833, 1839, "0 . 69", "", +87365, PValueResValue, 1844, 1856, "p = 0 . 3835", "", +87350, Lat/TimFC, 1867, 1871, "LTFC", "", +87351, Bima/TimFC, 1880, 1884, "BTFC", "", +87352, ConclusionComment, 1916, 2108, "The results of this study showed a significantly higher IOP - lowering effect of a once - daily evening dose of the BTFC compared to that of a once - daily evening administration of the LTFC .", "", +87353, IOP, 1972, 1975, "IOP", "", +87354, Frequency, 1999, 2011, "once - daily", "", +87355, Evening, 2012, 2019, "evening", "", +87356, Bima/TimFC, 2032, 2036, "BTFC", "", +87357, Frequency, 2059, 2071, "once - daily", "", +87358, Evening, 2072, 2079, "evening", "", +87359, Lat/TimFC, 2102, 2106, "LTFC", "", +87360, PMID, 2151, 2159, "17519068", "", diff --git a/data/gl 17519068_jshahinitiran.n-triples b/data/gl 17519068_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17519068_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17519068_tstrakeljahn.annodb b/data/gl 17519068_tstrakeljahn.annodb new file mode 100644 index 0000000..f73e7b3 --- /dev/null +++ b/data/gl 17519068_tstrakeljahn.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90123, Journal, 0, 17, "Curr Med Res Opin", "", +90124, PublicationYear, 20, 24, "2007", "", +90135, Title, 54, 245, "A comparison of the safety and intraocular pressure lowering of bimatoprost / timolol fixed combination versus latanoprost / timolol fixed combination in patients with open - angle glaucoma .", "", +90125, IOP, 85, 105, "intraocular pressure", "", +90126, Bimatoprost, 118, 129, "bimatoprost", "", +90128, Bima/TimFC, 118, 139, "bimatoprost / timolol", "", +90127, Timolol, 132, 139, "timolol", "", +90129, Latanoprost, 165, 176, "latanoprost", "", +90131, Lat/TimFC, 165, 186, "latanoprost / timolol", "", +90130, Timolol, 179, 186, "timolol", "", +90134, Precondition, 208, 243, "patients with open - angle glaucoma", "", +90132, OpenAngleGlaucoma, 222, 243, "open - angle glaucoma", "", +90136, Author, 246, 256, "Martinez A", "", +90137, Author, 265, 274, "Sanchez M", "", +90133, Spain, 381, 386, "Spain", "", +90153, ObjectiveDescription, 425, 677, "To compare the efficacy and tolerability of a once daily evening dose of the latanoprost / timolol fixed combination ( LTFC ) with that of a once - daily evening dose of the bimatoprost / timolol fixed combination ( BTFC ) in patients with open - angle", "", +90138, Frequency, 471, 481, "once daily", "", +90139, Latanoprost, 502, 513, "latanoprost", "", +90141, Lat/TimFC, 502, 523, "latanoprost / timolol", "", +90140, Timolol, 516, 523, "timolol", "", +90142, Lat/TimFC, 544, 548, "LTFC", "", +90143, Frequency, 566, 578, "once - daily", "", +90144, Evening, 579, 586, "evening", "", +90145, Bimatoprost, 599, 610, "bimatoprost", "", +90147, Bima/TimFC, 599, 620, "bimatoprost / timolol", "", +90146, Timolol, 613, 620, "timolol", "", +90148, Bima/TimFC, 641, 645, "BTFC", "", +90152, Precondition, 651, 813, "patients with open - angle glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides", "", +90149, OpenAngleGlaucoma, 665, 686, "open - angle glaucoma", "", +90154, ObjectiveDescription, 678, 815, "glaucoma with elevated intraocular pressure ( IOP ) insufficiently responsive to monotherapy with prostaglandin analogues / prostamides .", "", +90150, IOP, 701, 721, "intraocular pressure", "", +90151, IOP, 724, 727, "IOP", "", +90155, Prospective, 825, 836, "Prospective", "", +90156, Randomized, 839, 849, "randomized", "", +90157, Blind, 852, 868, "evaluator masked", "", +90158, SingleCenter, 871, 886, "single - center", "", +90159, NumberPatientsCT, 910, 912, "36", "", +90162, Precondition, 922, 1117, "with a diagnosis of open - angle glaucoma , with or without pseudoexfoliation , and inadequate control of IOP , insufficiently responsive to monotherapy with prostaglandin analogues / prostamides", "", +90160, OpenAngleGlaucoma, 942, 963, "open - angle glaucoma", "", +90161, IOP, 1028, 1031, "IOP", "", +90171, Endpoint, 1177, 1227, "change in IOP at 9 : 00 am from baseline to week 4", "", +90163, IOP, 1187, 1190, "IOP", "", +90170, TimePoint, 1194, 1203, "9 : 00 am", "", +90164, TimePoint, 1209, 1217, "baseline", "", +90165, TimePoint, 1221, 1227, "week 4", "", +90172, Endpoint, 1238, 1331, "difference between treatment groups in the mean diurnal IOP reduction from baseline to week 4", "", +90166, Mean, 1281, 1285, "mean", "", +90167, Diurnal_IOP, 1286, 1297, "diurnal IOP", "", +90168, TimePoint, 1313, 1321, "baseline", "", +90169, TimePoint, 1325, 1331, "week 4", "", +90173, Bima/TimFC, 1344, 1348, "BTFC", "", +90174, Mean, 1380, 1384, "mean", "", +90175, Diurnal_IOP, 1385, 1396, "diurnal IOP", "", +90176, Reduction, 1439, 1444, "2 . 8", "", +90178, SdDevChangeValue, 1447, 1452, "0 . 9", "", +90180, mmHg, 1455, 1459, "mmHg", "", +90182, Lat/TimFC, 1476, 1480, "LTFC", "", +90177, Reduction, 1481, 1486, "2 . 1", "", +90179, SdDevChangeValue, 1489, 1494, "0 . 6", "", +90181, mmHg, 1497, 1501, "mmHg", "", +90183, PvalueDiff, 1506, 1516, "= 0 . 0214", "", +90201, ObservedResult, 1519, 1720, "Both treatments significantly reduced the IOP from baseline at each IOP time - point measured , p < 0 . 0001 , and for the mean diurnal IOP ; p = 0 . 0049 for the LTFC , and p < 0 . 0001 for the BTFC .", "", +90184, IOP, 1561, 1564, "IOP", "", +90185, IOP, 1587, 1590, "IOP", "", +90186, PValueResValue, 1617, 1627, "< 0 . 0001", "", +90187, Mean, 1642, 1646, "mean", "", +90188, Diurnal_IOP, 1647, 1658, "diurnal IOP", "", +90189, PValueResValue, 1663, 1673, "= 0 . 0049", "", +90191, Lat/TimFC, 1682, 1686, "LTFC", "", +90190, PValueResValue, 1695, 1705, "< 0 . 0001", "", +90192, Bima/TimFC, 1714, 1718, "BTFC", "", +90202, ObservedResult, 1721, 1901, "There were no significant differences in average hyperemia scores among groups , 1 . 25 ( 0 . 5 ) vs . 1 . 62 ( 0 . 69 ) , p = 0 . 3835 , for the LTFC and the BTFC , respectively .", "", +90193, ConjunctivalHyperemia, 1770, 1779, "hyperemia", "", +90194, ResultMeasuredValue, 1802, 1808, "1 . 25", "", +90196, SdDevResValue, 1811, 1816, "0 . 5", "", +90195, ResultMeasuredValue, 1824, 1830, "1 . 62", "", +90197, SdDevResValue, 1833, 1839, "0 . 69", "", +90198, PvalueDiff, 1846, 1856, "= 0 . 3835", "", +90199, Lat/TimFC, 1867, 1871, "LTFC", "", +90200, Bima/TimFC, 1880, 1884, "BTFC", "", +90210, ConclusionComment, 1916, 2108, "The results of this study showed a significantly higher IOP - lowering effect of a once - daily evening dose of the BTFC compared to that of a once - daily evening administration of the LTFC .", "", +90203, IOP, 1972, 1975, "IOP", "", +90204, Frequency, 1999, 2011, "once - daily", "", +90205, Evening, 2012, 2019, "evening", "", +90206, Bima/TimFC, 2032, 2036, "BTFC", "", +90207, Frequency, 2059, 2071, "once - daily", "", +90208, Evening, 2072, 2079, "evening", "", +90209, Lat/TimFC, 2102, 2106, "LTFC", "", +90211, PMID, 2151, 2159, "17519068", "", diff --git a/data/gl 17519068_tstrakeljahn.n-triples b/data/gl 17519068_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17519068_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17571086_admin.annodb b/data/gl 17571086_admin.annodb new file mode 100644 index 0000000..10e5b50 --- /dev/null +++ b/data/gl 17571086_admin.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2008", "", " \"2008\"." +2, Title, 68, 189, "Twenty - four - hour efficacy of the brimonidine / timolol fixed combination versus therapy with the unfixed components .", "", " \"Twenty - four - hour efficacy of the brimonidine / timolol fixed combination versus therapy with the unfixed components .\"." +73, Brimo/TimFC, 105, 144, "brimonidine / timolol fixed combination", "", " ." +3, Brimonidine, 105, 116, "brimonidine", "", +4, Timolol, 119, 126, "timolol", "", +5, Author, 190, 200, "Konstas AG", "", " \"Konstas AG\"." +6, Author, 209, 222, "Katsimpris IE", "", " \"Katsimpris IE\"." +7, Author, 225, 234, "Kaltsos K", "", " \"Kaltsos K\"." +8, Author, 237, 249, "Georgiadou I", "", " \"Georgiadou I\"." +9, Author, 252, 262, "Kordelou A", "", " \"Kordelou A\"." +10, Author, 265, 274, "Nelson LA", "", " \"Nelson LA\"." +11, Author, 277, 287, "Stewart WC", "", " \"Stewart WC\"." +12, Greece, 410, 416, "Greece", "", " ." +86891, ObjectiveDescription, 429, 599, "To evaluate the 24 - h intraocular pressure ( IOP ) control of brimonidine / timolol fixed combination ( BTFC ) versusthe unfixed combination of its individual components", "", " \"To evaluate the 24 - h intraocular pressure ( IOP ) control of brimonidine / timolol fixed combination ( BTFC ) versusthe unfixed combination of its individual components\"." +86887, Diurnal_IOP, 445, 472, "24 - h intraocular pressure", "", " ." +17, IOP, 475, 478, "IOP", "", +87, Brimo/TimFC, 492, 531, "brimonidine / timolol fixed combination", "", +18, Brimonidine, 492, 503, "brimonidine", "", +19, Timolol, 506, 513, "timolol", "", +20, Brimo/TimFC, 534, 538, "BTFC", "", +21, Frequency, 613, 624, "twice daily", "", " \"twice daily\". \"twice daily\"." +86894, Precondition, 630, 696, "patients with primary open - angle glaucoma or ocular hypertension", "", " \"patients with primary open - angle glaucoma or ocular hypertension\"." +22, Primary_OpenAngleGlaucoma, 644, 673, "primary open - angle glaucoma", "", " ." +23, OcularHypertension, 677, 696, "ocular hypertension", "", " ." +24, Blind, 712, 729, "observer - masked", "", " ." +25, Randomized, 732, 742, "randomized", "", " ." +26, Crossover, 745, 754, "crossover", "", " ." +27, Multicenter, 779, 791, "two - centre", "", " ." +28, Duration, 817, 825, "6 - week", "", +29, Randomized, 865, 875, "randomized", "", +30, Brimo/TimFC, 879, 883, "BTFC", "", +31, Brimonidine, 917, 928, "brimonidine", "", " ." +32, Timolol, 933, 940, "timolol", "", " ." +33, Duration, 945, 953, "3 months", "", " \"3 months\"." +34, Crossover, 975, 987, "crossed over", "", +35, Duration, 1026, 1034, "3 months", "", +86895, Diurnal_IOP, 1127, 1137, "24 - h IOP", "", +109, TimePoint, 1154, 1158, "0600", "", +110, TimePoint, 1161, 1165, "1000", "", +111, TimePoint, 1168, 1172, "1400", "", +112, TimePoint, 1175, 1179, "1800", "", +113, TimePoint, 1182, 1186, "2200", "", +114, TimePoint, 1193, 1197, "0200", "", +37, FinalNumPatientsCT, 1216, 1230, "Twenty - eight", "", " \"Twenty - eight\"." +38, Brimo/TimFC, 1268, 1272, "BTFC", "", +39, IOP, 1321, 1324, "IOP", "", +40, PValueChangeValue, 1361, 1373, "P < 0 . 0001", "", +86897, Diurnal_IOP, 1475, 1485, "24 - h IOP", "", +119, PvalueDiff, 1496, 1504, "> 0 . 05", "", +43, Mean, 1513, 1517, "mean", "", " . ." +86901, Diurnal_IOP, 1518, 1528, "24 - h IOP", "", +45, BaseLineValue, 1533, 1539, "24 . 6", "", " \"24 . 6\". \"24 . 6\"." +123, SdDevBL, 1546, 1551, "1 . 9", "", " \"1 . 9\". \"1 . 9\"." +59, ResultMeasuredValue, 1567, 1573, "19 . 2", "", " \"19 . 2\"." +126, SdDevResValue, 1580, 1585, "1 . 9", "", " \"1 . 9\"." +62, Brimo/TimFC, 1590, 1594, "BTFC", "", +60, ResultMeasuredValue, 1601, 1607, "19 . 2", "", " \"19 . 2\"." +127, SdDevResValue, 1614, 1619, "1 . 6", "", " \"1 . 6\"." +64, mmHg, 1620, 1624, "mmHg", "", " ." +130, PvalueDiff, 1654, 1663, "P = 1 . 0", "", " \"P = 1 . 0\"." +47, NumPatientsLeftCT, 1668, 1672, "Four", "", " \"Four\"." +86910, EndPointDescription, 1707, 1719, "side effects", "", +48, ConjunctivalHyperemia, 1763, 1780, "ocular hyperaemia", "", " ." +49, NumberAffected, 1787, 1788, "3", "", " \"3\"." +51, Brimo/TimFC, 1794, 1798, "BTFC", "", +50, NumberAffected, 1807, 1808, "5", "", " \"5\"." +137, PvalueDiff, 1839, 1848, "P = 0 . 7", "", " \"P = 0 . 7\"." +52, ConclusionComment, 1904, 2061, "This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24 - h IOP reduction from untreated baseline ,", "", " \"This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24 - h IOP reduction from untreated baseline ,\"." +54, Brimo/TimFC, 1934, 1938, "BTFC", "", +55, Brimonidine, 1969, 1980, "brimonidine", "", +56, Timolol, 1985, 1992, "timolol", "", +86916, Diurnal_IOP, 2015, 2025, "24 - h IOP", "", +52, ConclusionComment, 2062, 2173, "and statistically equal control when compared directly , at each time point and for the 24 - h pressure curve .", "", " \"and statistically equal control when compared directly , at each time point and for the 24 - h pressure curve .\"." +58, PMID, 2218, 2226, "17571086", "", " \"17571086\"." diff --git a/data/gl 17571086_admin.n-triples b/data/gl 17571086_admin.n-triples new file mode 100644 index 0000000..ad59ef1 --- /dev/null +++ b/data/gl 17571086_admin.n-triples @@ -0,0 +1,133 @@ +# RDF export of group: Publication + . + "Publication" . + "Twenty - four - hour efficacy of the brimonidine / timolol fixed combination versus therapy with the unfixed components ." . + "Konstas AG" . + "2008" . + "Eye ( Lond ) ." . + "17571086" . + . + "Katsimpris IE" . + "Kaltsos K" . + "Georgiadou I" . + "Kordelou A" . + "Nelson LA" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the 24 - h intraocular pressure ( IOP ) control of brimonidine / timolol fixed combination ( BTFC ) versusthe unfixed combination of its individual components" . + "3 months" . + . + . + . + "This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24 - h IOP reduction from untreated baseline ," . + "and statistically equal control when compared directly , at each time point and for the 24 - h pressure curve ." . + . + . + . + . + . + "Twenty - eight" . + "Four" . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "AE" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + . + . + . + . + "Arm_bri-tim" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + "twice daily" . + . + . + "Intervention_bri-tim" . + . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_bri" . + . + . + . + . + "Medication_tim" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC" . + . + "24 . 6" . + "1 . 9" . + "19 . 2" . + "1 . 9" . + . + "Outcome_bri-tim" . + . + "24 . 6" . + "1 . 9" . + "19 . 2" . + "1 . 6" . + . + "AE_BTFC" . + . + "3" . + . + "AE_bri-tim" . + . + "5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "P = 1 . 0" . + . + . + . + "DiffBetweenGroups_AE" . + "P = 0 . 7" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17571086_export.csv b/data/gl 17571086_export.csv new file mode 100644 index 0000000..87a705c --- /dev/null +++ b/data/gl 17571086_export.csv @@ -0,0 +1,465 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +516, 1, 1, 1, 0, 3, 0, 3, "Eye" +516, 1, 2, 2, 4, 5, 4, 5, "(" +516, 1, 3, 3, 6, 10, 6, 10, "Lond" +516, 1, 4, 4, 11, 12, 11, 12, ")" +516, 1, 5, 5, 13, 14, 13, 14, "." +516, 2, 1, 6, 0, 4, 15, 19, "2008" +516, 2, 2, 7, 5, 8, 20, 23, "Nov" +516, 2, 3, 8, 9, 10, 24, 25, ";" +516, 2, 4, 9, 11, 13, 26, 28, "22" +516, 2, 5, 10, 14, 15, 29, 30, "(" +516, 2, 6, 11, 16, 18, 31, 33, "11" +516, 2, 7, 12, 19, 20, 34, 35, ")" +516, 2, 8, 13, 21, 22, 36, 37, ":" +516, 2, 9, 14, 23, 27, 38, 42, "1391" +516, 2, 10, 15, 28, 29, 43, 44, "-" +516, 2, 11, 16, 30, 31, 45, 46, "7" +516, 2, 12, 17, 32, 33, 47, 48, "." +516, 3, 1, 18, 0, 4, 49, 53, "Epub" +516, 3, 2, 19, 5, 9, 54, 58, "2007" +516, 3, 3, 20, 10, 13, 59, 62, "Jun" +516, 3, 4, 21, 14, 16, 63, 65, "15" +516, 3, 5, 22, 17, 18, 66, 67, "." +516, 4, 1, 23, 0, 6, 68, 74, "Twenty" +516, 4, 2, 24, 7, 8, 75, 76, "-" +516, 4, 3, 25, 9, 13, 77, 81, "four" +516, 4, 4, 26, 14, 15, 82, 83, "-" +516, 4, 5, 27, 16, 20, 84, 88, "hour" +516, 4, 6, 28, 21, 29, 89, 97, "efficacy" +516, 4, 7, 29, 30, 32, 98, 100, "of" +516, 4, 8, 30, 33, 36, 101, 104, "the" +516, 4, 9, 31, 37, 48, 105, 116, "brimonidine" +516, 4, 10, 32, 49, 50, 117, 118, "/" +516, 4, 11, 33, 51, 58, 119, 126, "timolol" +516, 4, 12, 34, 59, 64, 127, 132, "fixed" +516, 4, 13, 35, 65, 76, 133, 144, "combination" +516, 4, 14, 36, 77, 83, 145, 151, "versus" +516, 4, 15, 37, 84, 91, 152, 159, "therapy" +516, 4, 16, 38, 92, 96, 160, 164, "with" +516, 4, 17, 39, 97, 100, 165, 168, "the" +516, 4, 18, 40, 101, 108, 169, 176, "unfixed" +516, 4, 19, 41, 109, 119, 177, 187, "components" +516, 4, 20, 42, 120, 121, 188, 189, "." +516, 5, 1, 43, 0, 7, 190, 197, "Konstas" +516, 5, 2, 44, 8, 10, 198, 200, "AG" +516, 5, 3, 45, 11, 12, 201, 202, "(" +516, 5, 4, 46, 13, 14, 203, 204, "1" +516, 5, 5, 47, 15, 16, 205, 206, ")" +516, 5, 6, 48, 17, 18, 207, 208, "," +516, 5, 7, 49, 19, 29, 209, 219, "Katsimpris" +516, 5, 8, 50, 30, 32, 220, 222, "IE" +516, 5, 9, 51, 33, 34, 223, 224, "," +516, 5, 10, 52, 35, 42, 225, 232, "Kaltsos" +516, 5, 11, 53, 43, 44, 233, 234, "K" +516, 5, 12, 54, 45, 46, 235, 236, "," +516, 5, 13, 55, 47, 57, 237, 247, "Georgiadou" +516, 5, 14, 56, 58, 59, 248, 249, "I" +516, 5, 15, 57, 60, 61, 250, 251, "," +516, 5, 16, 58, 62, 70, 252, 260, "Kordelou" +516, 5, 17, 59, 71, 72, 261, 262, "A" +516, 5, 18, 60, 73, 74, 263, 264, "," +516, 5, 19, 61, 75, 81, 265, 271, "Nelson" +516, 5, 20, 62, 82, 84, 272, 274, "LA" +516, 5, 21, 63, 85, 86, 275, 276, "," +516, 5, 22, 64, 87, 94, 277, 284, "Stewart" +516, 5, 23, 65, 95, 97, 285, 287, "WC" +516, 5, 24, 66, 98, 99, 288, 289, "." +516, 6, 1, 67, 0, 6, 290, 296, "Author" +516, 6, 2, 68, 7, 18, 297, 308, "information" +516, 6, 3, 69, 19, 20, 309, 310, ":" +516, 6, 4, 70, 21, 22, 311, 312, "(" +516, 6, 5, 71, 23, 24, 313, 314, "1" +516, 6, 6, 72, 25, 26, 315, 316, ")" +516, 6, 7, 73, 27, 35, 317, 325, "Glaucoma" +516, 6, 8, 74, 36, 40, 326, 330, "Unit" +516, 6, 9, 75, 41, 42, 331, 332, "," +516, 6, 10, 76, 43, 46, 333, 336, "1st" +516, 6, 11, 77, 47, 57, 337, 347, "University" +516, 6, 12, 78, 58, 68, 348, 358, "Department" +516, 6, 13, 79, 69, 71, 359, 361, "of" +516, 6, 14, 80, 72, 85, 362, 375, "Ophthalmology" +516, 6, 15, 81, 86, 87, 376, 377, "," +516, 6, 16, 82, 88, 93, 378, 383, "AHEPA" +516, 6, 17, 83, 94, 102, 384, 392, "Hospital" +516, 6, 18, 84, 103, 104, 393, 394, "," +516, 6, 19, 85, 105, 117, 395, 407, "Thessaloniki" +516, 6, 20, 86, 118, 119, 408, 409, "," +516, 6, 21, 87, 120, 126, 410, 416, "Greece" +516, 6, 22, 88, 127, 128, 417, 418, "." +516, 7, 1, 89, 0, 7, 419, 426, "PURPOSE" +516, 7, 2, 90, 8, 9, 427, 428, ":" +516, 7, 3, 91, 10, 12, 429, 431, "To" +516, 7, 4, 92, 13, 21, 432, 440, "evaluate" +516, 7, 5, 93, 22, 25, 441, 444, "the" +516, 7, 6, 94, 26, 28, 445, 447, "24" +516, 7, 7, 95, 29, 30, 448, 449, "-" +516, 7, 8, 96, 31, 32, 450, 451, "h" +516, 7, 9, 97, 33, 44, 452, 463, "intraocular" +516, 7, 10, 98, 45, 53, 464, 472, "pressure" +516, 7, 11, 99, 54, 55, 473, 474, "(" +516, 7, 12, 100, 56, 59, 475, 478, "IOP" +516, 7, 13, 101, 60, 61, 479, 480, ")" +516, 7, 14, 102, 62, 69, 481, 488, "control" +516, 7, 15, 103, 70, 72, 489, 491, "of" +516, 7, 16, 104, 73, 84, 492, 503, "brimonidine" +516, 7, 17, 105, 85, 86, 504, 505, "/" +516, 7, 18, 106, 87, 94, 506, 513, "timolol" +516, 7, 19, 107, 95, 100, 514, 519, "fixed" +516, 7, 20, 108, 101, 112, 520, 531, "combination" +516, 7, 21, 109, 113, 114, 532, 533, "(" +516, 7, 22, 110, 115, 119, 534, 538, "BTFC" +516, 7, 23, 111, 120, 121, 539, 540, ")" +516, 7, 24, 112, 122, 131, 541, 550, "versusthe" +516, 7, 25, 113, 132, 139, 551, 558, "unfixed" +516, 7, 26, 114, 140, 151, 559, 570, "combination" +516, 7, 27, 115, 152, 154, 571, 573, "of" +516, 7, 28, 116, 155, 158, 574, 577, "its" +516, 7, 29, 117, 159, 169, 578, 588, "individual" +516, 7, 30, 118, 170, 180, 589, 599, "components" +516, 7, 31, 119, 181, 182, 600, 601, "," +516, 7, 32, 120, 183, 187, 602, 606, "each" +516, 7, 33, 121, 188, 193, 607, 612, "dosed" +516, 7, 34, 122, 194, 199, 613, 618, "twice" +516, 7, 35, 123, 200, 205, 619, 624, "daily" +516, 7, 36, 124, 206, 207, 625, 626, "," +516, 7, 37, 125, 208, 210, 627, 629, "in" +516, 7, 38, 126, 211, 219, 630, 638, "patients" +516, 7, 39, 127, 220, 224, 639, 643, "with" +516, 7, 40, 128, 225, 232, 644, 651, "primary" +516, 7, 41, 129, 233, 237, 652, 656, "open" +516, 7, 42, 130, 238, 239, 657, 658, "-" +516, 7, 43, 131, 240, 245, 659, 664, "angle" +516, 7, 44, 132, 246, 254, 665, 673, "glaucoma" +516, 7, 45, 133, 255, 257, 674, 676, "or" +516, 7, 46, 134, 258, 264, 677, 683, "ocular" +516, 7, 47, 135, 265, 277, 684, 696, "hypertension" +516, 7, 48, 136, 278, 279, 697, 698, "." +516, 8, 1, 137, 0, 7, 699, 706, "METHODS" +516, 8, 2, 138, 8, 9, 707, 708, ":" +516, 8, 3, 139, 10, 12, 709, 711, "An" +516, 8, 4, 140, 13, 21, 712, 720, "observer" +516, 8, 5, 141, 22, 23, 721, 722, "-" +516, 8, 6, 142, 24, 30, 723, 729, "masked" +516, 8, 7, 143, 31, 32, 730, 731, "," +516, 8, 8, 144, 33, 43, 732, 742, "randomized" +516, 8, 9, 145, 44, 45, 743, 744, "," +516, 8, 10, 146, 46, 55, 745, 754, "crossover" +516, 8, 11, 147, 56, 57, 755, 756, "," +516, 8, 12, 148, 58, 64, 757, 763, "active" +516, 8, 13, 149, 65, 66, 764, 765, "-" +516, 8, 14, 150, 67, 77, 766, 776, "controlled" +516, 8, 15, 151, 78, 79, 777, 778, "," +516, 8, 16, 152, 80, 83, 779, 782, "two" +516, 8, 17, 153, 84, 85, 783, 784, "-" +516, 8, 18, 154, 86, 92, 785, 791, "centre" +516, 8, 19, 155, 93, 103, 792, 802, "comparison" +516, 8, 20, 156, 104, 105, 803, 804, "." +516, 9, 1, 157, 0, 9, 805, 814, "Following" +516, 9, 2, 158, 10, 11, 815, 816, "a" +516, 9, 3, 159, 12, 13, 817, 818, "6" +516, 9, 4, 160, 14, 15, 819, 820, "-" +516, 9, 5, 161, 16, 20, 821, 825, "week" +516, 9, 6, 162, 21, 29, 826, 834, "medicine" +516, 9, 7, 163, 30, 31, 835, 836, "-" +516, 9, 8, 164, 32, 36, 837, 841, "free" +516, 9, 9, 165, 37, 43, 842, 848, "period" +516, 9, 10, 166, 44, 45, 849, 850, "," +516, 9, 11, 167, 46, 54, 851, 859, "patients" +516, 9, 12, 168, 55, 59, 860, 864, "were" +516, 9, 13, 169, 60, 70, 865, 875, "randomized" +516, 9, 14, 170, 71, 73, 876, 878, "to" +516, 9, 15, 171, 74, 78, 879, 883, "BTFC" +516, 9, 16, 172, 79, 81, 884, 886, "or" +516, 9, 17, 173, 82, 84, 887, 889, "to" +516, 9, 18, 174, 85, 88, 890, 893, "the" +516, 9, 19, 175, 89, 96, 894, 901, "unfixed" +516, 9, 20, 176, 97, 108, 902, 913, "combination" +516, 9, 21, 177, 109, 111, 914, 916, "of" +516, 9, 22, 178, 112, 123, 917, 928, "brimonidine" +516, 9, 23, 179, 124, 127, 929, 932, "and" +516, 9, 24, 180, 128, 135, 933, 940, "timolol" +516, 9, 25, 181, 136, 139, 941, 944, "for" +516, 9, 26, 182, 140, 141, 945, 946, "3" +516, 9, 27, 183, 142, 148, 947, 953, "months" +516, 9, 28, 184, 149, 150, 954, 955, "." +516, 10, 1, 185, 0, 8, 956, 964, "Patients" +516, 10, 2, 186, 9, 13, 965, 969, "then" +516, 10, 3, 187, 14, 18, 970, 974, "were" +516, 10, 4, 188, 19, 26, 975, 982, "crossed" +516, 10, 5, 189, 27, 31, 983, 987, "over" +516, 10, 6, 190, 32, 34, 988, 990, "to" +516, 10, 7, 191, 35, 38, 991, 994, "the" +516, 10, 8, 192, 39, 47, 995, 1003, "opposite" +516, 10, 9, 193, 48, 57, 1004, 1013, "treatment" +516, 10, 10, 194, 58, 61, 1014, 1017, "for" +516, 10, 11, 195, 62, 69, 1018, 1025, "another" +516, 10, 12, 196, 70, 71, 1026, 1027, "3" +516, 10, 13, 197, 72, 78, 1028, 1034, "months" +516, 10, 14, 198, 79, 80, 1035, 1036, "." +516, 11, 1, 199, 0, 2, 1037, 1039, "At" +516, 11, 2, 200, 3, 6, 1040, 1043, "the" +516, 11, 3, 201, 7, 10, 1044, 1047, "end" +516, 11, 4, 202, 11, 13, 1048, 1050, "of" +516, 11, 5, 203, 14, 17, 1051, 1054, "the" +516, 11, 6, 204, 18, 26, 1055, 1063, "medicine" +516, 11, 7, 205, 27, 28, 1064, 1065, "-" +516, 11, 8, 206, 29, 33, 1066, 1070, "free" +516, 11, 9, 207, 34, 40, 1071, 1077, "period" +516, 11, 10, 208, 41, 42, 1078, 1079, "," +516, 11, 11, 209, 43, 46, 1080, 1083, "and" +516, 11, 12, 210, 47, 51, 1084, 1088, "each" +516, 11, 13, 211, 52, 61, 1089, 1098, "treatment" +516, 11, 14, 212, 62, 68, 1099, 1105, "period" +516, 11, 15, 213, 69, 70, 1106, 1107, "," +516, 11, 16, 214, 71, 79, 1108, 1116, "patients" +516, 11, 17, 215, 80, 89, 1117, 1126, "underwent" +516, 11, 18, 216, 90, 92, 1127, 1129, "24" +516, 11, 19, 217, 93, 94, 1130, 1131, "-" +516, 11, 20, 218, 95, 96, 1132, 1133, "h" +516, 11, 21, 219, 97, 100, 1134, 1137, "IOP" +516, 11, 22, 220, 101, 113, 1138, 1150, "measurements" +516, 11, 23, 221, 114, 116, 1151, 1153, "at" +516, 11, 24, 222, 117, 121, 1154, 1158, "0600" +516, 11, 25, 223, 122, 123, 1159, 1160, "," +516, 11, 26, 224, 124, 128, 1161, 1165, "1000" +516, 11, 27, 225, 129, 130, 1166, 1167, "," +516, 11, 28, 226, 131, 135, 1168, 1172, "1400" +516, 11, 29, 227, 136, 137, 1173, 1174, "," +516, 11, 30, 228, 138, 142, 1175, 1179, "1800" +516, 11, 31, 229, 143, 144, 1180, 1181, "," +516, 11, 32, 230, 145, 149, 1182, 1186, "2200" +516, 11, 33, 231, 150, 151, 1187, 1188, "," +516, 11, 34, 232, 152, 155, 1189, 1192, "and" +516, 11, 35, 233, 156, 160, 1193, 1197, "0200" +516, 11, 36, 234, 161, 166, 1198, 1203, "hours" +516, 11, 37, 235, 167, 168, 1204, 1205, "." +516, 12, 1, 236, 0, 7, 1206, 1213, "RESULTS" +516, 12, 2, 237, 8, 9, 1214, 1215, ":" +516, 12, 3, 238, 10, 16, 1216, 1222, "Twenty" +516, 12, 4, 239, 17, 18, 1223, 1224, "-" +516, 12, 5, 240, 19, 24, 1225, 1230, "eight" +516, 12, 6, 241, 25, 33, 1231, 1239, "patients" +516, 12, 7, 242, 34, 43, 1240, 1249, "completed" +516, 12, 8, 243, 44, 48, 1250, 1254, "this" +516, 12, 9, 244, 49, 54, 1255, 1260, "study" +516, 12, 10, 245, 55, 56, 1261, 1262, "." +516, 13, 1, 246, 0, 4, 1263, 1267, "Both" +516, 13, 2, 247, 5, 9, 1268, 1272, "BTFC" +516, 13, 3, 248, 10, 13, 1273, 1276, "and" +516, 13, 4, 249, 14, 17, 1277, 1280, "the" +516, 13, 5, 250, 18, 25, 1281, 1288, "unfixed" +516, 13, 6, 251, 26, 36, 1289, 1299, "components" +516, 13, 7, 252, 37, 43, 1300, 1306, "showed" +516, 13, 8, 253, 44, 45, 1307, 1308, "a" +516, 13, 9, 254, 46, 57, 1309, 1320, "significant" +516, 13, 10, 255, 58, 61, 1321, 1324, "IOP" +516, 13, 11, 256, 62, 71, 1325, 1334, "reduction" +516, 13, 12, 257, 72, 76, 1335, 1339, "from" +516, 13, 13, 258, 77, 86, 1340, 1349, "untreated" +516, 13, 14, 259, 87, 95, 1350, 1358, "baseline" +516, 13, 15, 260, 96, 97, 1359, 1360, "(" +516, 13, 16, 261, 98, 99, 1361, 1362, "P" +516, 13, 17, 262, 100, 101, 1363, 1364, "<" +516, 13, 18, 263, 102, 103, 1365, 1366, "0" +516, 13, 19, 264, 104, 105, 1367, 1368, "." +516, 13, 20, 265, 106, 110, 1369, 1373, "0001" +516, 13, 21, 266, 111, 112, 1374, 1375, ")" +516, 13, 22, 267, 113, 114, 1376, 1377, "," +516, 13, 23, 268, 115, 118, 1378, 1381, "and" +516, 13, 24, 269, 119, 123, 1382, 1386, "were" +516, 13, 25, 270, 124, 137, 1387, 1400, "statistically" +516, 13, 26, 271, 138, 143, 1401, 1406, "equal" +516, 13, 27, 272, 144, 148, 1407, 1411, "when" +516, 13, 28, 273, 149, 157, 1412, 1420, "compared" +516, 13, 29, 274, 158, 166, 1421, 1429, "directly" +516, 13, 30, 275, 167, 168, 1430, 1431, "," +516, 13, 31, 276, 169, 172, 1432, 1435, "for" +516, 13, 32, 277, 173, 177, 1436, 1440, "each" +516, 13, 33, 278, 178, 188, 1441, 1451, "individual" +516, 13, 34, 279, 189, 193, 1452, 1456, "time" +516, 13, 35, 280, 194, 199, 1457, 1462, "point" +516, 13, 36, 281, 200, 203, 1463, 1466, "and" +516, 13, 37, 282, 204, 207, 1467, 1470, "for" +516, 13, 38, 283, 208, 211, 1471, 1474, "the" +516, 13, 39, 284, 212, 214, 1475, 1477, "24" +516, 13, 40, 285, 215, 216, 1478, 1479, "-" +516, 13, 41, 286, 217, 218, 1480, 1481, "h" +516, 13, 42, 287, 219, 222, 1482, 1485, "IOP" +516, 13, 43, 288, 223, 228, 1486, 1491, "curve" +516, 13, 44, 289, 229, 230, 1492, 1493, "(" +516, 13, 45, 290, 231, 232, 1494, 1495, "P" +516, 13, 46, 291, 233, 234, 1496, 1497, ">" +516, 13, 47, 292, 235, 236, 1498, 1499, "0" +516, 13, 48, 293, 237, 238, 1500, 1501, "." +516, 13, 49, 294, 239, 241, 1502, 1504, "05" +516, 13, 50, 295, 242, 243, 1505, 1506, ")" +516, 13, 51, 296, 244, 245, 1507, 1508, "." +516, 14, 1, 297, 0, 3, 1509, 1512, "The" +516, 14, 2, 298, 4, 8, 1513, 1517, "mean" +516, 14, 3, 299, 9, 11, 1518, 1520, "24" +516, 14, 4, 300, 12, 13, 1521, 1522, "-" +516, 14, 5, 301, 14, 15, 1523, 1524, "h" +516, 14, 6, 302, 16, 19, 1525, 1528, "IOP" +516, 14, 7, 303, 20, 23, 1529, 1532, "was" +516, 14, 8, 304, 24, 26, 1533, 1535, "24" +516, 14, 9, 305, 27, 28, 1536, 1537, "." +516, 14, 10, 306, 29, 30, 1538, 1539, "6" +516, 14, 11, 307, 31, 32, 1540, 1541, "+" +516, 14, 12, 308, 33, 34, 1542, 1543, "/" +516, 14, 13, 309, 35, 36, 1544, 1545, "-" +516, 14, 14, 310, 37, 38, 1546, 1547, "1" +516, 14, 15, 311, 39, 40, 1548, 1549, "." +516, 14, 16, 312, 41, 42, 1550, 1551, "9" +516, 14, 17, 313, 43, 46, 1552, 1555, "for" +516, 14, 18, 314, 47, 55, 1556, 1564, "baseline" +516, 14, 19, 315, 56, 57, 1565, 1566, "," +516, 14, 20, 316, 58, 60, 1567, 1569, "19" +516, 14, 21, 317, 61, 62, 1570, 1571, "." +516, 14, 22, 318, 63, 64, 1572, 1573, "2" +516, 14, 23, 319, 65, 66, 1574, 1575, "+" +516, 14, 24, 320, 67, 68, 1576, 1577, "/" +516, 14, 25, 321, 69, 70, 1578, 1579, "-" +516, 14, 26, 322, 71, 72, 1580, 1581, "1" +516, 14, 27, 323, 73, 74, 1582, 1583, "." +516, 14, 28, 324, 75, 76, 1584, 1585, "9" +516, 14, 29, 325, 77, 80, 1586, 1589, "for" +516, 14, 30, 326, 81, 85, 1590, 1594, "BTFC" +516, 14, 31, 327, 86, 87, 1595, 1596, "," +516, 14, 32, 328, 88, 91, 1597, 1600, "and" +516, 14, 33, 329, 92, 94, 1601, 1603, "19" +516, 14, 34, 330, 95, 96, 1604, 1605, "." +516, 14, 35, 331, 97, 98, 1606, 1607, "2" +516, 14, 36, 332, 99, 100, 1608, 1609, "+" +516, 14, 37, 333, 101, 102, 1610, 1611, "/" +516, 14, 38, 334, 103, 104, 1612, 1613, "-" +516, 14, 39, 335, 105, 106, 1614, 1615, "1" +516, 14, 40, 336, 107, 108, 1616, 1617, "." +516, 14, 41, 337, 109, 110, 1618, 1619, "6" +516, 14, 42, 338, 111, 115, 1620, 1624, "mmHg" +516, 14, 43, 339, 116, 119, 1625, 1628, "for" +516, 14, 44, 340, 120, 123, 1629, 1632, "the" +516, 14, 45, 341, 124, 131, 1633, 1640, "unfixed" +516, 14, 46, 342, 132, 142, 1641, 1651, "components" +516, 14, 47, 343, 143, 144, 1652, 1653, "(" +516, 14, 48, 344, 145, 146, 1654, 1655, "P" +516, 14, 49, 345, 147, 148, 1656, 1657, "=" +516, 14, 50, 346, 149, 150, 1658, 1659, "1" +516, 14, 51, 347, 151, 152, 1660, 1661, "." +516, 14, 52, 348, 153, 154, 1662, 1663, "0" +516, 14, 53, 349, 155, 156, 1664, 1665, ")" +516, 14, 54, 350, 157, 158, 1666, 1667, "." +516, 15, 1, 351, 0, 4, 1668, 1672, "Four" +516, 15, 2, 352, 5, 13, 1673, 1681, "patients" +516, 15, 3, 353, 14, 18, 1682, 1686, "were" +516, 15, 4, 354, 19, 31, 1687, 1699, "discontinued" +516, 15, 5, 355, 32, 35, 1700, 1703, "due" +516, 15, 6, 356, 36, 38, 1704, 1706, "to" +516, 15, 7, 357, 39, 43, 1707, 1711, "side" +516, 15, 8, 358, 44, 51, 1712, 1719, "effects" +516, 15, 9, 359, 52, 53, 1720, 1721, "." +516, 16, 1, 360, 0, 3, 1722, 1725, "The" +516, 16, 2, 361, 4, 8, 1726, 1730, "most" +516, 16, 3, 362, 9, 15, 1731, 1737, "common" +516, 16, 4, 363, 16, 22, 1738, 1744, "ocular" +516, 16, 5, 364, 23, 30, 1745, 1752, "adverse" +516, 16, 6, 365, 31, 36, 1753, 1758, "event" +516, 16, 7, 366, 37, 40, 1759, 1762, "was" +516, 16, 8, 367, 41, 47, 1763, 1769, "ocular" +516, 16, 9, 368, 48, 58, 1770, 1780, "hyperaemia" +516, 16, 10, 369, 59, 60, 1781, 1782, "(" +516, 16, 11, 370, 61, 62, 1783, 1784, "n" +516, 16, 12, 371, 63, 64, 1785, 1786, "=" +516, 16, 13, 372, 65, 66, 1787, 1788, "3" +516, 16, 14, 373, 67, 71, 1789, 1793, "with" +516, 16, 15, 374, 72, 76, 1794, 1798, "BTFC" +516, 16, 16, 375, 77, 80, 1799, 1802, "and" +516, 16, 17, 376, 81, 82, 1803, 1804, "n" +516, 16, 18, 377, 83, 84, 1805, 1806, "=" +516, 16, 19, 378, 85, 86, 1807, 1808, "5" +516, 16, 20, 379, 87, 91, 1809, 1813, "with" +516, 16, 21, 380, 92, 95, 1814, 1817, "the" +516, 16, 22, 381, 96, 103, 1818, 1825, "unfixed" +516, 16, 23, 382, 104, 114, 1826, 1836, "components" +516, 16, 24, 383, 115, 116, 1837, 1838, "," +516, 16, 25, 384, 117, 118, 1839, 1840, "P" +516, 16, 26, 385, 119, 120, 1841, 1842, "=" +516, 16, 27, 386, 121, 122, 1843, 1844, "0" +516, 16, 28, 387, 123, 124, 1845, 1846, "." +516, 16, 29, 388, 125, 126, 1847, 1848, "7" +516, 16, 30, 389, 127, 128, 1849, 1850, ")" +516, 16, 31, 390, 129, 132, 1851, 1854, "and" +516, 16, 32, 391, 133, 141, 1855, 1863, "systemic" +516, 16, 33, 392, 142, 149, 1864, 1871, "adverse" +516, 16, 34, 393, 150, 156, 1872, 1878, "events" +516, 16, 35, 394, 157, 161, 1879, 1883, "were" +516, 16, 36, 395, 162, 166, 1884, 1888, "rare" +516, 16, 37, 396, 167, 168, 1889, 1890, "." +516, 17, 1, 397, 0, 10, 1891, 1901, "CONCLUSION" +516, 17, 2, 398, 11, 12, 1902, 1903, ":" +516, 17, 3, 399, 13, 17, 1904, 1908, "This" +516, 17, 4, 400, 18, 23, 1909, 1914, "study" +516, 17, 5, 401, 24, 32, 1915, 1923, "suggests" +516, 17, 6, 402, 33, 37, 1924, 1928, "that" +516, 17, 7, 403, 38, 42, 1929, 1933, "both" +516, 17, 8, 404, 43, 47, 1934, 1938, "BTFC" +516, 17, 9, 405, 48, 51, 1939, 1942, "and" +516, 17, 10, 406, 52, 55, 1943, 1946, "the" +516, 17, 11, 407, 56, 63, 1947, 1954, "unfixed" +516, 17, 12, 408, 64, 74, 1955, 1965, "components" +516, 17, 13, 409, 75, 77, 1966, 1968, "of" +516, 17, 14, 410, 78, 89, 1969, 1980, "brimonidine" +516, 17, 15, 411, 90, 93, 1981, 1984, "and" +516, 17, 16, 412, 94, 101, 1985, 1992, "timolol" +516, 17, 17, 413, 102, 109, 1993, 2000, "provide" +516, 17, 18, 414, 110, 111, 2001, 2002, "a" +516, 17, 19, 415, 112, 123, 2003, 2014, "significant" +516, 17, 20, 416, 124, 126, 2015, 2017, "24" +516, 17, 21, 417, 127, 128, 2018, 2019, "-" +516, 17, 22, 418, 129, 130, 2020, 2021, "h" +516, 17, 23, 419, 131, 134, 2022, 2025, "IOP" +516, 17, 24, 420, 135, 144, 2026, 2035, "reduction" +516, 17, 25, 421, 145, 149, 2036, 2040, "from" +516, 17, 26, 422, 150, 159, 2041, 2050, "untreated" +516, 17, 27, 423, 160, 168, 2051, 2059, "baseline" +516, 17, 28, 424, 169, 170, 2060, 2061, "," +516, 17, 29, 425, 171, 174, 2062, 2065, "and" +516, 17, 30, 426, 175, 188, 2066, 2079, "statistically" +516, 17, 31, 427, 189, 194, 2080, 2085, "equal" +516, 17, 32, 428, 195, 202, 2086, 2093, "control" +516, 17, 33, 429, 203, 207, 2094, 2098, "when" +516, 17, 34, 430, 208, 216, 2099, 2107, "compared" +516, 17, 35, 431, 217, 225, 2108, 2116, "directly" +516, 17, 36, 432, 226, 227, 2117, 2118, "," +516, 17, 37, 433, 228, 230, 2119, 2121, "at" +516, 17, 38, 434, 231, 235, 2122, 2126, "each" +516, 17, 39, 435, 236, 240, 2127, 2131, "time" +516, 17, 40, 436, 241, 246, 2132, 2137, "point" +516, 17, 41, 437, 247, 250, 2138, 2141, "and" +516, 17, 42, 438, 251, 254, 2142, 2145, "for" +516, 17, 43, 439, 255, 258, 2146, 2149, "the" +516, 17, 44, 440, 259, 261, 2150, 2152, "24" +516, 17, 45, 441, 262, 263, 2153, 2154, "-" +516, 17, 46, 442, 264, 265, 2155, 2156, "h" +516, 17, 47, 443, 266, 274, 2157, 2165, "pressure" +516, 17, 48, 444, 275, 280, 2166, 2171, "curve" +516, 17, 49, 445, 281, 282, 2172, 2173, "." +516, 18, 1, 446, 0, 3, 2174, 2177, "DOI" +516, 18, 2, 447, 4, 5, 2178, 2179, ":" +516, 18, 3, 448, 6, 8, 2180, 2182, "10" +516, 18, 4, 449, 9, 10, 2183, 2184, "." +516, 18, 5, 450, 11, 15, 2185, 2189, "1038" +516, 18, 6, 451, 16, 17, 2190, 2191, "/" +516, 18, 7, 452, 18, 20, 2192, 2194, "sj" +516, 18, 8, 453, 21, 22, 2195, 2196, "." +516, 18, 9, 454, 23, 26, 2197, 2200, "eye" +516, 18, 10, 455, 27, 28, 2201, 2202, "." +516, 18, 11, 456, 29, 36, 2203, 2210, "6702906" +516, 18, 12, 457, 37, 41, 2211, 2215, "PMID" +516, 18, 13, 458, 42, 43, 2216, 2217, ":" +516, 18, 14, 459, 44, 52, 2218, 2226, "17571086" +516, 18, 15, 460, 53, 54, 2227, 2228, "[" +516, 18, 16, 461, 55, 62, 2229, 2236, "Indexed" +516, 18, 17, 462, 63, 66, 2237, 2240, "for" +516, 18, 18, 463, 67, 74, 2241, 2248, "MEDLINE" +516, 18, 19, 464, 75, 76, 2249, 2250, "]" diff --git a/data/gl 17571086_jshahinitiran.annodb b/data/gl 17571086_jshahinitiran.annodb new file mode 100644 index 0000000..9146ce3 --- /dev/null +++ b/data/gl 17571086_jshahinitiran.annodb @@ -0,0 +1,70 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +57680, Journal, 0, 14, "Eye ( Lond ) .", "", +57681, PublicationYear, 15, 19, "2008", "", +57682, Title, 68, 189, "Twenty - four - hour efficacy of the brimonidine / timolol fixed combination versus therapy with the unfixed components .", "", +57684, Brimonidine, 105, 116, "brimonidine", "", +57685, Timolol, 119, 126, "timolol", "", +57686, Author, 190, 200, "Konstas AG", "", +57687, Author, 209, 222, "Katsimpris IE", "", +57688, Author, 225, 234, "Kaltsos K", "", +57689, Author, 237, 249, "Georgiadou I", "", +57690, Author, 252, 262, "Kordelou A", "", +57691, Author, 265, 274, "Nelson LA", "", +57692, Author, 277, 287, "Stewart WC", "", +57693, Greece, 410, 416, "Greece", "", +57695, ObjectiveDescription, 429, 601, "To evaluate the 24 - h intraocular pressure ( IOP ) control of brimonidine / timolol fixed combination ( BTFC ) versusthe unfixed combination of its individual components ,", "", +57694, Duration, 445, 451, "24 - h", "", +57697, IOP, 452, 472, "intraocular pressure", "", +57698, IOP, 475, 478, "IOP", "", +57699, Brimonidine, 492, 503, "brimonidine", "", +57700, Timolol, 506, 513, "timolol", "", +57701, Brimo/TimFC, 534, 538, "BTFC", "", +57696, ObjectiveDescription, 602, 698, "each dosed twice daily , in patients with primary open - angle glaucoma or ocular hypertension .", "", +57702, Frequency, 613, 624, "twice daily", "", +57703, Primary_OpenAngleGlaucoma, 644, 673, "primary open - angle glaucoma", "", +57704, OcularHypertension, 677, 696, "ocular hypertension", "", +57705, Blind, 712, 729, "observer - masked", "", +57706, Randomized, 732, 742, "randomized", "", +57707, Crossover, 745, 754, "crossover", "", +57708, Multicenter, 779, 791, "two - centre", "", +57709, Duration, 817, 825, "6 - week", "", +57710, Randomized, 865, 875, "randomized", "", +57711, Brimo/TimFC, 879, 883, "BTFC", "", +57712, Brimonidine, 917, 928, "brimonidine", "", +57713, Timolol, 933, 940, "timolol", "", +57714, Duration, 945, 953, "3 months", "", +57715, Crossover, 975, 987, "crossed over", "", +57716, Duration, 1026, 1034, "3 months", "", +57717, IOP, 1134, 1137, "IOP", "", +57718, FinalNumPatientsCT, 1216, 1230, "Twenty - eight", "", +57719, Brimo/TimFC, 1268, 1272, "BTFC", "", +57720, IOP, 1321, 1324, "IOP", "", +57721, PValueChangeValue, 1361, 1373, "P < 0 . 0001", "", +57722, IOP, 1482, 1485, "IOP", "", +57723, PValueChangeValue, 1494, 1504, "P > 0 . 05", "", +57724, Mean, 1513, 1517, "mean", "", +57725, IOP, 1525, 1528, "IOP", "", +57726, BaseLineValue, 1533, 1539, "24 . 6", "", +57727, SdErrorBL, 1546, 1551, "1 . 9", "", +78579, ResultMeasuredValue, 1567, 1573, "19 . 2", "", +78581, SdErrorResValue, 1580, 1585, "1 . 9", "", +78582, Brimo/TimFC, 1590, 1594, "BTFC", "", +78580, ResultMeasuredValue, 1601, 1607, "19 . 2", "", +78583, SdErrorResValue, 1614, 1619, "1 . 6", "", +78584, mmHg, 1620, 1624, "mmHg", "", +78586, Drug, 1633, 1651, "unfixed components", "", +78585, PValueResValue, 1654, 1665, "P = 1 . 0 )", "", +57728, NumPatientsLeftCT, 1668, 1672, "Four", "", +57729, ConjunctivalHyperemia, 1763, 1780, "ocular hyperaemia", "", +57730, NumberAffected, 1787, 1788, "3", "", +57732, Brimo/TimFC, 1794, 1798, "BTFC", "", +57731, NumberAffected, 1807, 1808, "5", "", +78587, Drug, 1818, 1836, "unfixed components", "", +78588, PValueNumAffected, 1839, 1848, "P = 0 . 7", "", +57733, ConclusionComment, 1904, 2061, "This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24 - h IOP reduction from untreated baseline ,", "", +57735, Brimo/TimFC, 1934, 1938, "BTFC", "", +57736, Brimonidine, 1969, 1980, "brimonidine", "", +57737, Timolol, 1985, 1992, "timolol", "", +57738, IOP, 2022, 2025, "IOP", "", +57734, ConclusionComment, 2062, 2173, "and statistically equal control when compared directly , at each time point and for the 24 - h pressure curve .", "", +57739, PMID, 2218, 2226, "17571086", "", diff --git a/data/gl 17571086_jshahinitiran.n-triples b/data/gl 17571086_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17571086_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 17571086_tstrakeljahn.annodb b/data/gl 17571086_tstrakeljahn.annodb new file mode 100644 index 0000000..af5b987 --- /dev/null +++ b/data/gl 17571086_tstrakeljahn.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80242, Journal, 0, 12, "Eye ( Lond )", "", +80243, PublicationYear, 15, 19, "2008", "", +80254, Title, 68, 189, "Twenty - four - hour efficacy of the brimonidine / timolol fixed combination versus therapy with the unfixed components .", "", +80244, Brimonidine, 105, 116, "brimonidine", "", +80246, Brimo/TimFC, 105, 126, "brimonidine / timolol", "", +80245, Timolol, 119, 126, "timolol", "", +80247, Author, 190, 200, "Konstas AG", "", +80248, Author, 209, 222, "Katsimpris IE", "", +80249, Author, 225, 234, "Kaltsos K", "", +80250, Author, 237, 249, "Georgiadou I", "", +80251, Author, 252, 262, "Kordelou A", "", +80252, Author, 265, 274, "Nelson LA", "", +80253, Author, 277, 287, "Stewart WC", "", +80255, Greece, 410, 416, "Greece", "", +80265, ObjectiveDescription, 429, 683, "To evaluate the 24 - h intraocular pressure ( IOP ) control of brimonidine / timolol fixed combination ( BTFC ) versusthe unfixed combination of its individual components , each dosed twice daily , in patients with primary open - angle glaucoma or ocular", "", +80256, IOP, 452, 472, "intraocular pressure", "", +80257, IOP, 475, 478, "IOP", "", +80258, Brimonidine, 492, 503, "brimonidine", "", +80260, Brimo/TimFC, 492, 513, "brimonidine / timolol", "", +80259, Timolol, 506, 513, "timolol", "", +80261, Brimo/TimFC, 534, 538, "BTFC", "", +80262, Frequency, 613, 624, "twice daily", "", +80263, Primary_OpenAngleGlaucoma, 644, 673, "primary open - angle glaucoma", "", +80264, OcularHypertension, 677, 696, "ocular hypertension", "", +80266, ObjectiveDescription, 684, 698, "hypertension .", "", +80267, Blind, 712, 729, "observer - masked", "", +80268, Randomized, 732, 742, "randomized", "", +80269, Crossover, 745, 754, "crossover", "", +80270, Multicenter, 779, 791, "two - centre", "", +80271, Precondition, 805, 848, "Following a 6 - week medicine - free period", "", +80272, Randomized, 865, 875, "randomized", "", +80273, Brimo/TimFC, 879, 883, "BTFC", "", +80274, Brimonidine, 917, 928, "brimonidine", "", +80275, Timolol, 933, 940, "timolol", "", +80276, Duration, 945, 953, "3 months", "", +80277, Duration, 1026, 1034, "3 months", "", +80278, TimePoint, 1037, 1077, "At the end of the medicine - free period", "", +80279, TimePoint, 1037, 1105, "At the end of the medicine - free period , and each treatment period", "", +80280, IOP, 1134, 1137, "IOP", "", +80282, TimePoint, 1154, 1158, "0600", "", +80283, TimePoint, 1161, 1165, "1000", "", +80284, TimePoint, 1168, 1172, "1400", "", +80285, TimePoint, 1175, 1179, "1800", "", +80286, TimePoint, 1182, 1186, "2200", "", +80287, TimePoint, 1193, 1197, "0200", "", +80281, FinalNumPatientsCT, 1216, 1230, "Twenty - eight", "", +80288, Brimo/TimFC, 1268, 1272, "BTFC", "", +80289, IOP, 1321, 1324, "IOP", "", +80290, PValueBL, 1363, 1373, "< 0 . 0001", "", +80291, IOP, 1482, 1485, "IOP", "", +80292, PvalueDiff, 1496, 1504, "> 0 . 05", "", +80293, Mean, 1513, 1517, "mean", "", +80294, IOP, 1525, 1528, "IOP", "", +80295, BaseLineValue, 1533, 1539, "24 . 6", "", +80296, SdDevBL, 1546, 1551, "1 . 9", "", +80297, ResultMeasuredValue, 1567, 1573, "19 . 2", "", +80299, SdDevResValue, 1580, 1585, "1 . 9", "", +80302, Brimo/TimFC, 1590, 1594, "BTFC", "", +80298, ResultMeasuredValue, 1601, 1607, "19 . 2", "", +80300, SdDevResValue, 1614, 1619, "1 . 6", "", +80301, mmHg, 1620, 1624, "mmHg", "", +80303, PvalueDiff, 1656, 1663, "= 1 . 0", "", +80304, NumberAffected, 1668, 1672, "Four", "", +80306, ConjunctivalHyperemia, 1763, 1780, "ocular hyperaemia", "", +80307, NumberAffected, 1787, 1788, "3", "", +80309, Brimo/TimFC, 1794, 1798, "BTFC", "", +80308, NumberAffected, 1807, 1808, "5", "", +80310, PvalueDiff, 1841, 1848, "= 0 . 7", "", +80315, ConclusionComment, 1904, 2156, "This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24 - h IOP reduction from untreated baseline , and statistically equal control when compared directly , at each time point and for the 24 - h", "", +80311, Brimo/TimFC, 1934, 1938, "BTFC", "", +80312, Brimonidine, 1969, 1980, "brimonidine", "", +80313, Timolol, 1985, 1992, "timolol", "", +80314, IOP, 2022, 2025, "IOP", "", +80316, ConclusionComment, 2157, 2173, "pressure curve .", "", diff --git a/data/gl 17571086_tstrakeljahn.n-triples b/data/gl 17571086_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 17571086_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18327364 copy_admin.annodb b/data/gl 18327364 copy_admin.annodb new file mode 100644 index 0000000..d2aaa6c --- /dev/null +++ b/data/gl 18327364 copy_admin.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4, Journal, 0, 11, "Saudi Med J", "", " \"Saudi Med J\"." +5, PublicationYear, 14, 18, "2008", "", " \"2008\"." +6, Title, 46, 169, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma .", "", " \"Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma .\"." +47, Latanoprost, 62, 73, "latanoprost", "", +48, Timolol, 81, 88, "timolol", "", +49, Dorzolamide, 91, 102, "dorzolamide", "", +50, Primary_OpenAngleGlaucoma, 140, 167, "primary open angle glaucoma", "", " ." +7, Author, 170, 183, "Rismanchian A", "", " \"Rismanchian A\"." +88, Author, 192, 200, "Eslami F", "", " \"Eslami F\"." +89, Author, 203, 211, "Moeini H", "", " \"Moeini H\"." +9, Author, 214, 225, "Attarzade H", "", " \"Attarzade H\"." +10, Author, 228, 240, "Naderibeni A", "", " \"Naderibeni A\"." +11, Iran, 366, 370, "Iran", "", +12, ObjectiveDescription, 385, 506, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma", "", " \"Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma\"." +51, Latanoprost, 401, 412, "latanoprost", "", +52, Timolol, 420, 427, "timolol", "", +53, Dorzolamide, 430, 441, "dorzolamide", "", +54, Primary_OpenAngleGlaucoma, 479, 506, "primary open angle glaucoma", "", +14, Duration, 545, 553, "6 months", "", " \"6 months\"." +55, Randomized, 554, 564, "randomized", "", " ." +15, Blind, 567, 584, "observer - masked", "", " ." +56, NumberPatientsCT, 602, 605, "120", "", " \"120\"." +104, Precondition, 606, 649, "patients with primary open - angle glaucoma", "", " \"patients with primary open - angle glaucoma\"." +102, Primary_OpenAngleGlaucoma, 620, 649, "primary open - angle glaucoma", "", +58, Iran, 679, 683, "Iran", "", " ." +59, Year, 691, 695, "2006", "", +60, Year, 699, 703, "2007", "", +61, Randomized, 724, 734, "randomized", "", +62, Latanoprost, 737, 748, "latanoprost", "", +16, NumberPatientsArm, 755, 757, "60", "", " \"60\"." +63, Dorzolamide, 760, 771, "dorzolamide", "", +64, Timolol, 774, 781, "timolol", "", +17, NumberPatientsArm, 788, 790, "60", "", " \"60\"." +65, Latanoprost, 818, 829, "latanoprost", "", " . ." +18, DoseValue, 832, 839, "0 . 005", "", " \"0 . 005\"." +21, Percentage, 840, 841, "%", "", " ." +24, Frequency, 842, 852, "once daily", "", " \"once daily\"." +66, Timolol, 877, 884, "timolol", "", " ." +19, DoseValue, 885, 890, "0 . 5", "", " \"0 . 5\"." +22, Percentage, 891, 892, "%", "", " ." +25, Frequency, 893, 904, "twice daily", "", " \"twice daily\"." +67, Dorzolamide, 911, 922, "dorzolamide", "", " ." +20, DoseValue, 923, 924, "2", "", " \"2\"." +23, Percentage, 925, 926, "%", "", " ." +26, Frequency, 927, 940, "3 times daily", "", " \"3 times daily\"." +27, Mean, 947, 951, "mean", "", " . ." +28, IOP, 952, 972, "intraocular pressure", "", " . ." +29, IOP, 975, 978, "IOP", "", +73, TimePoint, 987, 1009, "one , 3 , and 6 months", "", +37057, TimePoint, 993, 1009, "3 , and 6 months", "", +37058, TimePoint, 1001, 1009, "6 months", "", +68, NumberPatientsCT, 1089, 1092, "120", "", +69, Randomized, 1107, 1117, "randomized", "", +30, Mean, 1152, 1156, "mean", "", +31, IOP, 1166, 1169, "IOP", "", +0, Mean, 1217, 1221, "mean", "", +70, IOP, 1256, 1259, "IOP", "", +71, TimePoint, 1274, 1284, "months one", "", " \"months one\". \"months one\"." +32, Reduction, 1289, 1294, "7 . 2", "", " \"7 . 2\"." +38, SdErrorChangeValue, 1297, 1302, "0 . 4", "", " \"0 . 4\"." +72, TimePoint, 1310, 1317, "month 3", "", " \"month 3\". \"month 3\"." +33, Reduction, 1322, 1327, "7 . 3", "", " \"7 . 3\"." +39, SdErrorChangeValue, 1330, 1335, "0 . 4", "", " \"0 . 4\"." +74, TimePoint, 1347, 1354, "month 6", "", " \"month 6\". \"month 6\"." +34, Reduction, 1359, 1364, "7 . 1", "", " \"7 . 1\"." +40, SdErrorChangeValue, 1367, 1372, "0 . 3", "", " \"0 . 3\"." +2, mmHg, 1375, 1380, "mm Hg", "", " ." +75, Latanoprost, 1389, 1400, "latanoprost", "", +35, Reduction, 1411, 1416, "7 . 5", "", " \"7 . 5\"." +41, SdErrorChangeValue, 1419, 1424, "0 . 3", "", " \"0 . 3\"." +36, Reduction, 1429, 1434, "7 . 8", "", " \"7 . 8\"." +42, SdErrorChangeValue, 1437, 1442, "0 . 3", "", " \"0 . 3\"." +37, Reduction, 1451, 1456, "7 . 4", "", " \"7 . 4\"." +43, SdErrorChangeValue, 1459, 1464, "0 . 3", "", " \"0 . 3\"." +3, mmHg, 1467, 1472, "mm Hg", "", +76, Dorzolamide, 1481, 1492, "dorzolamide", "", +77, Timolol, 1495, 1502, "timolol", "", +44, ConclusionComment, 1567, 1692, "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .", "", " \"The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .\"." +78, Latanoprost, 1571, 1582, "latanoprost", "", +79, Dorzolamide, 1587, 1598, "dorzolamide", "", +80, Timolol, 1601, 1608, "timolol", "", +45, IOP, 1656, 1659, "IOP", "", +46, PMID, 1700, 1708, "18327364", "", " \"18327364\"." diff --git a/data/gl 18327364 copy_admin.n-triples b/data/gl 18327364 copy_admin.n-triples new file mode 100644 index 0000000..ff56399 --- /dev/null +++ b/data/gl 18327364 copy_admin.n-triples @@ -0,0 +1,139 @@ +# RDF export of group: Publication + . + "Publication 104493" . + "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma ." . + "Rismanchian A" . + "2008" . + "Saudi Med J" . + "18327364" . + . + "Eslami F" . + "Moeini H" . + "Attarzade H" . + "Naderibeni A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 104504" . + "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma" . + "120" . + "6 months" . + . + . + . + "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 104520" . + "patients with primary open - angle glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "lat" . + "60" . + . + . + . + . + . + . + "doti" . + "60" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "lat" . + . + "once daily" . + . + . + "do" . + . + "3 times daily" . + . + . + "ti" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "lat" . + . + . + "0 . 005" . + . + . + . + "do" . + . + "2" . + . + . + . + "ti" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "7 . 2" . + "0 . 4" . + "months one" . + . + "iop2" . + . + "7 . 5" . + "0 . 3" . + "months one" . + . + "iop31" . + . + "7 . 3" . + "0 . 4" . + "month 3" . + . + "iop32" . + . + "7 . 8" . + "0 . 3" . + "month 3" . + . + "iop61" . + . + "7 . 1" . + "0 . 3" . + "month 6" . + . + "iop62" . + . + "7 . 4" . + "0 . 3" . + "month 6" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18327364 copy_export.csv b/data/gl 18327364 copy_export.csv new file mode 100644 index 0000000..6336be2 --- /dev/null +++ b/data/gl 18327364 copy_export.csv @@ -0,0 +1,368 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +826, 1, 1, 1, 0, 5, 0, 5, "Saudi" +826, 1, 2, 2, 6, 9, 6, 9, "Med" +826, 1, 3, 3, 10, 11, 10, 11, "J" +826, 1, 4, 4, 12, 13, 12, 13, "." +826, 2, 1, 5, 0, 4, 14, 18, "2008" +826, 2, 2, 6, 5, 8, 19, 22, "Mar" +826, 2, 3, 7, 9, 10, 23, 24, ";" +826, 2, 4, 8, 11, 13, 25, 27, "29" +826, 2, 5, 9, 14, 15, 28, 29, "(" +826, 2, 6, 10, 16, 17, 30, 31, "3" +826, 2, 7, 11, 18, 19, 32, 33, ")" +826, 2, 8, 12, 20, 21, 34, 35, ":" +826, 2, 9, 13, 22, 25, 36, 39, "384" +826, 2, 10, 14, 26, 27, 40, 41, "-" +826, 2, 11, 15, 28, 29, 42, 43, "7" +826, 2, 12, 16, 30, 31, 44, 45, "." +826, 3, 1, 17, 0, 8, 46, 54, "Efficacy" +826, 3, 2, 18, 9, 11, 55, 57, "of" +826, 3, 3, 19, 12, 15, 58, 61, "the" +826, 3, 4, 20, 16, 27, 62, 73, "latanoprost" +826, 3, 5, 21, 28, 34, 74, 80, "versus" +826, 3, 6, 22, 35, 42, 81, 88, "timolol" +826, 3, 7, 23, 43, 44, 89, 90, "/" +826, 3, 8, 24, 45, 56, 91, 102, "dorzolamide" +826, 3, 9, 25, 57, 68, 103, 114, "combination" +826, 3, 10, 26, 69, 76, 115, 122, "therapy" +826, 3, 11, 27, 77, 79, 123, 125, "in" +826, 3, 12, 28, 80, 88, 126, 134, "patients" +826, 3, 13, 29, 89, 93, 135, 139, "with" +826, 3, 14, 30, 94, 101, 140, 147, "primary" +826, 3, 15, 31, 102, 106, 148, 152, "open" +826, 3, 16, 32, 107, 112, 153, 158, "angle" +826, 3, 17, 33, 113, 121, 159, 167, "glaucoma" +826, 3, 18, 34, 122, 123, 168, 169, "." +826, 4, 1, 35, 0, 11, 170, 181, "Rismanchian" +826, 4, 2, 36, 12, 13, 182, 183, "A" +826, 4, 3, 37, 14, 15, 184, 185, "(" +826, 4, 4, 38, 16, 17, 186, 187, "1" +826, 4, 5, 39, 18, 19, 188, 189, ")" +826, 4, 6, 40, 20, 21, 190, 191, "," +826, 4, 7, 41, 22, 28, 192, 198, "Eslami" +826, 4, 8, 42, 29, 30, 199, 200, "F" +826, 4, 9, 43, 31, 32, 201, 202, "," +826, 4, 10, 44, 33, 39, 203, 209, "Moeini" +826, 4, 11, 45, 40, 41, 210, 211, "H" +826, 4, 12, 46, 42, 43, 212, 213, "," +826, 4, 13, 47, 44, 53, 214, 223, "Attarzade" +826, 4, 14, 48, 54, 55, 224, 225, "H" +826, 4, 15, 49, 56, 57, 226, 227, "," +826, 4, 16, 50, 58, 68, 228, 238, "Naderibeni" +826, 4, 17, 51, 69, 70, 239, 240, "A" +826, 4, 18, 52, 71, 72, 241, 242, "." +826, 5, 1, 53, 0, 6, 243, 249, "Author" +826, 5, 2, 54, 7, 18, 250, 261, "information" +826, 5, 3, 55, 19, 20, 262, 263, ":" +826, 5, 4, 56, 21, 22, 264, 265, "(" +826, 5, 5, 57, 23, 24, 266, 267, "1" +826, 5, 6, 58, 25, 26, 268, 269, ")" +826, 5, 7, 59, 27, 37, 270, 280, "Department" +826, 5, 8, 60, 38, 40, 281, 283, "of" +826, 5, 9, 61, 41, 54, 284, 297, "Ophthalmology" +826, 5, 10, 62, 55, 56, 298, 299, "," +826, 5, 11, 63, 57, 64, 300, 307, "Isfahan" +826, 5, 12, 64, 65, 75, 308, 318, "University" +826, 5, 13, 65, 76, 78, 319, 321, "of" +826, 5, 14, 66, 79, 86, 322, 329, "Medical" +826, 5, 15, 67, 87, 94, 330, 337, "Science" +826, 5, 16, 68, 95, 96, 338, 339, "," +826, 5, 17, 69, 97, 101, 340, 344, "Feiz" +826, 5, 18, 70, 102, 110, 345, 353, "Hospital" +826, 5, 19, 71, 111, 112, 354, 355, "," +826, 5, 20, 72, 113, 120, 356, 363, "Isfahan" +826, 5, 21, 73, 121, 122, 364, 365, "," +826, 5, 22, 74, 123, 127, 366, 370, "Iran" +826, 5, 23, 75, 128, 129, 371, 372, "." +826, 6, 1, 76, 0, 9, 373, 382, "OBJECTIVE" +826, 6, 2, 77, 10, 11, 383, 384, ":" +826, 6, 3, 78, 12, 20, 385, 393, "Efficacy" +826, 6, 4, 79, 21, 23, 394, 396, "of" +826, 6, 5, 80, 24, 27, 397, 400, "the" +826, 6, 6, 81, 28, 39, 401, 412, "latanoprost" +826, 6, 7, 82, 40, 46, 413, 419, "versus" +826, 6, 8, 83, 47, 54, 420, 427, "timolol" +826, 6, 9, 84, 55, 56, 428, 429, "/" +826, 6, 10, 85, 57, 68, 430, 441, "dorzolamide" +826, 6, 11, 86, 69, 80, 442, 453, "combination" +826, 6, 12, 87, 81, 88, 454, 461, "therapy" +826, 6, 13, 88, 89, 91, 462, 464, "in" +826, 6, 14, 89, 92, 100, 465, 473, "patients" +826, 6, 15, 90, 101, 105, 474, 478, "with" +826, 6, 16, 91, 106, 113, 479, 486, "primary" +826, 6, 17, 92, 114, 118, 487, 491, "open" +826, 6, 18, 93, 119, 124, 492, 497, "angle" +826, 6, 19, 94, 125, 133, 498, 506, "glaucoma" +826, 6, 20, 95, 134, 141, 507, 514, "METHODS" +826, 6, 21, 96, 142, 143, 515, 516, ":" +826, 6, 22, 97, 144, 147, 517, 520, "The" +826, 6, 23, 98, 148, 153, 521, 526, "study" +826, 6, 24, 99, 154, 157, 527, 530, "was" +826, 6, 25, 100, 158, 166, 531, 539, "designed" +826, 6, 26, 101, 167, 169, 540, 542, "as" +826, 6, 27, 102, 170, 171, 543, 544, "a" +826, 6, 28, 103, 172, 173, 545, 546, "6" +826, 6, 29, 104, 174, 180, 547, 553, "months" +826, 6, 30, 105, 181, 191, 554, 564, "randomized" +826, 6, 31, 106, 192, 193, 565, 566, "," +826, 6, 32, 107, 194, 202, 567, 575, "observer" +826, 6, 33, 108, 203, 204, 576, 577, "-" +826, 6, 34, 109, 205, 211, 578, 584, "masked" +826, 6, 35, 110, 212, 217, 585, 590, "study" +826, 6, 36, 111, 218, 228, 591, 601, "comprising" +826, 6, 37, 112, 229, 232, 602, 605, "120" +826, 6, 38, 113, 233, 241, 606, 614, "patients" +826, 6, 39, 114, 242, 246, 615, 619, "with" +826, 6, 40, 115, 247, 254, 620, 627, "primary" +826, 6, 41, 116, 255, 259, 628, 632, "open" +826, 6, 42, 117, 260, 261, 633, 634, "-" +826, 6, 43, 118, 262, 267, 635, 640, "angle" +826, 6, 44, 119, 268, 276, 641, 649, "glaucoma" +826, 6, 45, 120, 277, 279, 650, 652, "in" +826, 6, 46, 121, 280, 284, 653, 657, "Feiz" +826, 6, 47, 122, 285, 293, 658, 666, "Hospital" +826, 6, 48, 123, 294, 295, 667, 668, "," +826, 6, 49, 124, 296, 303, 669, 676, "Isfahan" +826, 6, 50, 125, 304, 305, 677, 678, "," +826, 6, 51, 126, 306, 310, 679, 683, "Iran" +826, 6, 52, 127, 311, 312, 684, 685, "," +826, 6, 53, 128, 313, 317, 686, 690, "from" +826, 6, 54, 129, 318, 322, 691, 695, "2006" +826, 6, 55, 130, 323, 325, 696, 698, "to" +826, 6, 56, 131, 326, 330, 699, 703, "2007" +826, 6, 57, 132, 331, 332, 704, 705, "." +826, 7, 1, 133, 0, 3, 706, 709, "The" +826, 7, 2, 134, 4, 12, 710, 718, "patients" +826, 7, 3, 135, 13, 17, 719, 723, "were" +826, 7, 4, 136, 18, 28, 724, 734, "randomized" +826, 7, 5, 137, 29, 30, 735, 736, "(" +826, 7, 6, 138, 31, 42, 737, 748, "latanoprost" +826, 7, 7, 139, 43, 44, 749, 750, "," +826, 7, 8, 140, 45, 46, 751, 752, "n" +826, 7, 9, 141, 47, 48, 753, 754, "=" +826, 7, 10, 142, 49, 51, 755, 757, "60" +826, 7, 11, 143, 52, 53, 758, 759, ";" +826, 7, 12, 144, 54, 65, 760, 771, "dorzolamide" +826, 7, 13, 145, 66, 67, 772, 773, "/" +826, 7, 14, 146, 68, 75, 774, 781, "timolol" +826, 7, 15, 147, 76, 77, 782, 783, "," +826, 7, 16, 148, 78, 79, 784, 785, "n" +826, 7, 17, 149, 80, 81, 786, 787, "=" +826, 7, 18, 150, 82, 84, 788, 790, "60" +826, 7, 19, 151, 85, 86, 791, 792, ")" +826, 7, 20, 152, 87, 89, 793, 795, "to" +826, 7, 21, 153, 90, 99, 796, 805, "treatment" +826, 7, 22, 154, 100, 104, 806, 810, "with" +826, 7, 23, 155, 105, 111, 811, 817, "either" +826, 7, 24, 156, 112, 123, 818, 829, "latanoprost" +826, 7, 25, 157, 124, 125, 830, 831, "," +826, 7, 26, 158, 126, 127, 832, 833, "0" +826, 7, 27, 159, 128, 129, 834, 835, "." +826, 7, 28, 160, 130, 133, 836, 839, "005" +826, 7, 29, 161, 134, 135, 840, 841, "%" +826, 7, 30, 162, 136, 140, 842, 846, "once" +826, 7, 31, 163, 141, 146, 847, 852, "daily" +826, 7, 32, 164, 147, 148, 853, 854, "," +826, 7, 33, 165, 149, 151, 855, 857, "or" +826, 7, 34, 166, 152, 155, 858, 861, "the" +826, 7, 35, 167, 156, 167, 862, 873, "combination" +826, 7, 36, 168, 168, 170, 874, 876, "of" +826, 7, 37, 169, 171, 178, 877, 884, "timolol" +826, 7, 38, 170, 179, 180, 885, 886, "0" +826, 7, 39, 171, 181, 182, 887, 888, "." +826, 7, 40, 172, 183, 184, 889, 890, "5" +826, 7, 41, 173, 185, 186, 891, 892, "%" +826, 7, 42, 174, 187, 192, 893, 898, "twice" +826, 7, 43, 175, 193, 198, 899, 904, "daily" +826, 7, 44, 176, 199, 200, 905, 906, "," +826, 7, 45, 177, 201, 204, 907, 910, "and" +826, 7, 46, 178, 205, 216, 911, 922, "dorzolamide" +826, 7, 47, 179, 217, 218, 923, 924, "2" +826, 7, 48, 180, 219, 220, 925, 926, "%" +826, 7, 49, 181, 221, 222, 927, 928, "3" +826, 7, 50, 182, 223, 228, 929, 934, "times" +826, 7, 51, 183, 229, 234, 935, 940, "daily" +826, 7, 52, 184, 235, 236, 941, 942, "." +826, 8, 1, 185, 0, 3, 943, 946, "The" +826, 8, 2, 186, 4, 8, 947, 951, "mean" +826, 8, 3, 187, 9, 20, 952, 963, "intraocular" +826, 8, 4, 188, 21, 29, 964, 972, "pressure" +826, 8, 5, 189, 30, 31, 973, 974, "(" +826, 8, 6, 190, 32, 35, 975, 978, "IOP" +826, 8, 7, 191, 36, 37, 979, 980, ")" +826, 8, 8, 192, 38, 43, 981, 986, "after" +826, 8, 9, 193, 44, 47, 987, 990, "one" +826, 8, 10, 194, 48, 49, 991, 992, "," +826, 8, 11, 195, 50, 51, 993, 994, "3" +826, 8, 12, 196, 52, 53, 995, 996, "," +826, 8, 13, 197, 54, 57, 997, 1000, "and" +826, 8, 14, 198, 58, 59, 1001, 1002, "6" +826, 8, 15, 199, 60, 66, 1003, 1009, "months" +826, 8, 16, 200, 67, 69, 1010, 1012, "of" +826, 8, 17, 201, 70, 79, 1013, 1022, "treatment" +826, 8, 18, 202, 80, 83, 1023, 1026, "was" +826, 8, 19, 203, 84, 92, 1027, 1035, "compared" +826, 8, 20, 204, 93, 97, 1036, 1040, "with" +826, 8, 21, 205, 98, 106, 1041, 1049, "baseline" +826, 8, 22, 206, 107, 109, 1050, 1052, "in" +826, 8, 23, 207, 110, 113, 1053, 1056, "the" +826, 8, 24, 208, 114, 115, 1057, 1058, "2" +826, 8, 25, 209, 116, 122, 1059, 1065, "groups" +826, 8, 26, 210, 123, 124, 1066, 1067, "." +826, 9, 1, 211, 0, 7, 1068, 1075, "RESULTS" +826, 9, 2, 212, 8, 9, 1076, 1077, ":" +826, 9, 3, 213, 10, 11, 1078, 1079, "A" +826, 9, 4, 214, 12, 17, 1080, 1085, "total" +826, 9, 5, 215, 18, 20, 1086, 1088, "of" +826, 9, 6, 216, 21, 24, 1089, 1092, "120" +826, 9, 7, 217, 25, 33, 1093, 1101, "patients" +826, 9, 8, 218, 34, 38, 1102, 1106, "were" +826, 9, 9, 219, 39, 49, 1107, 1117, "randomized" +826, 9, 10, 220, 50, 52, 1118, 1120, "to" +826, 9, 11, 221, 53, 54, 1121, 1122, "2" +826, 9, 12, 222, 55, 60, 1123, 1128, "equal" +826, 9, 13, 223, 61, 70, 1129, 1138, "treatment" +826, 9, 14, 224, 71, 77, 1139, 1145, "groups" +826, 9, 15, 225, 78, 79, 1146, 1147, "." +826, 10, 1, 226, 0, 3, 1148, 1151, "The" +826, 10, 2, 227, 4, 8, 1152, 1156, "mean" +826, 10, 3, 228, 9, 17, 1157, 1165, "baseline" +826, 10, 4, 229, 18, 21, 1166, 1169, "IOP" +826, 10, 5, 230, 22, 28, 1170, 1176, "values" +826, 10, 6, 231, 29, 33, 1177, 1181, "were" +826, 10, 7, 232, 34, 41, 1182, 1189, "similar" +826, 10, 8, 233, 42, 49, 1190, 1197, "between" +826, 10, 9, 234, 50, 53, 1198, 1201, "the" +826, 10, 10, 235, 54, 55, 1202, 1203, "2" +826, 10, 11, 236, 56, 62, 1204, 1210, "groups" +826, 10, 12, 237, 63, 64, 1211, 1212, "." +826, 11, 1, 238, 0, 3, 1213, 1216, "The" +826, 11, 2, 239, 4, 8, 1217, 1221, "mean" +826, 11, 3, 240, 9, 10, 1222, 1223, "(" +826, 11, 4, 241, 11, 19, 1224, 1232, "standard" +826, 11, 5, 242, 20, 25, 1233, 1238, "error" +826, 11, 6, 243, 26, 28, 1239, 1241, "of" +826, 11, 7, 244, 29, 33, 1242, 1246, "mean" +826, 11, 8, 245, 34, 35, 1247, 1248, "[" +826, 11, 9, 246, 36, 38, 1249, 1251, "SE" +826, 11, 10, 247, 39, 40, 1252, 1253, "]" +826, 11, 11, 248, 41, 42, 1254, 1255, ")" +826, 11, 12, 249, 43, 46, 1256, 1259, "IOP" +826, 11, 13, 250, 47, 57, 1260, 1270, "reductions" +826, 11, 14, 251, 58, 60, 1271, 1273, "at" +826, 11, 15, 252, 61, 67, 1274, 1280, "months" +826, 11, 16, 253, 68, 71, 1281, 1284, "one" +826, 11, 17, 254, 72, 75, 1285, 1288, "was" +826, 11, 18, 255, 76, 77, 1289, 1290, "7" +826, 11, 19, 256, 78, 79, 1291, 1292, "." +826, 11, 20, 257, 80, 81, 1293, 1294, "2" +826, 11, 21, 258, 82, 83, 1295, 1296, "(" +826, 11, 22, 259, 84, 85, 1297, 1298, "0" +826, 11, 23, 260, 86, 87, 1299, 1300, "." +826, 11, 24, 261, 88, 89, 1301, 1302, "4" +826, 11, 25, 262, 90, 91, 1303, 1304, ")" +826, 11, 26, 263, 92, 93, 1305, 1306, "," +826, 11, 27, 264, 94, 96, 1307, 1309, "at" +826, 11, 28, 265, 97, 102, 1310, 1315, "month" +826, 11, 29, 266, 103, 104, 1316, 1317, "3" +826, 11, 30, 267, 105, 108, 1318, 1321, "was" +826, 11, 31, 268, 109, 110, 1322, 1323, "7" +826, 11, 32, 269, 111, 112, 1324, 1325, "." +826, 11, 33, 270, 113, 114, 1326, 1327, "3" +826, 11, 34, 271, 115, 116, 1328, 1329, "(" +826, 11, 35, 272, 117, 118, 1330, 1331, "0" +826, 11, 36, 273, 119, 120, 1332, 1333, "." +826, 11, 37, 274, 121, 122, 1334, 1335, "4" +826, 11, 38, 275, 123, 124, 1336, 1337, ")" +826, 11, 39, 276, 125, 126, 1338, 1339, "," +826, 11, 40, 277, 127, 130, 1340, 1343, "and" +826, 11, 41, 278, 131, 133, 1344, 1346, "at" +826, 11, 42, 279, 134, 139, 1347, 1352, "month" +826, 11, 43, 280, 140, 141, 1353, 1354, "6" +826, 11, 44, 281, 142, 145, 1355, 1358, "was" +826, 11, 45, 282, 146, 147, 1359, 1360, "7" +826, 11, 46, 283, 148, 149, 1361, 1362, "." +826, 11, 47, 284, 150, 151, 1363, 1364, "1" +826, 11, 48, 285, 152, 153, 1365, 1366, "(" +826, 11, 49, 286, 154, 155, 1367, 1368, "0" +826, 11, 50, 287, 156, 157, 1369, 1370, "." +826, 11, 51, 288, 158, 159, 1371, 1372, "3" +826, 11, 52, 289, 160, 161, 1373, 1374, ")" +826, 11, 53, 290, 162, 164, 1375, 1377, "mm" +826, 11, 54, 291, 165, 167, 1378, 1380, "Hg" +826, 11, 55, 292, 168, 171, 1381, 1384, "for" +826, 11, 56, 293, 172, 175, 1385, 1388, "the" +826, 11, 57, 294, 176, 187, 1389, 1400, "latanoprost" +826, 11, 58, 295, 188, 193, 1401, 1406, "group" +826, 11, 59, 296, 194, 197, 1407, 1410, "and" +826, 11, 60, 297, 198, 199, 1411, 1412, "7" +826, 11, 61, 298, 200, 201, 1413, 1414, "." +826, 11, 62, 299, 202, 203, 1415, 1416, "5" +826, 11, 63, 300, 204, 205, 1417, 1418, "(" +826, 11, 64, 301, 206, 207, 1419, 1420, "0" +826, 11, 65, 302, 208, 209, 1421, 1422, "." +826, 11, 66, 303, 210, 211, 1423, 1424, "3" +826, 11, 67, 304, 212, 213, 1425, 1426, ")" +826, 11, 68, 305, 214, 215, 1427, 1428, "," +826, 11, 69, 306, 216, 217, 1429, 1430, "7" +826, 11, 70, 307, 218, 219, 1431, 1432, "." +826, 11, 71, 308, 220, 221, 1433, 1434, "8" +826, 11, 72, 309, 222, 223, 1435, 1436, "(" +826, 11, 73, 310, 224, 225, 1437, 1438, "0" +826, 11, 74, 311, 226, 227, 1439, 1440, "." +826, 11, 75, 312, 228, 229, 1441, 1442, "3" +826, 11, 76, 313, 230, 231, 1443, 1444, ")" +826, 11, 77, 314, 232, 233, 1445, 1446, "," +826, 11, 78, 315, 234, 237, 1447, 1450, "and" +826, 11, 79, 316, 238, 239, 1451, 1452, "7" +826, 11, 80, 317, 240, 241, 1453, 1454, "." +826, 11, 81, 318, 242, 243, 1455, 1456, "4" +826, 11, 82, 319, 244, 245, 1457, 1458, "(" +826, 11, 83, 320, 246, 247, 1459, 1460, "0" +826, 11, 84, 321, 248, 249, 1461, 1462, "." +826, 11, 85, 322, 250, 251, 1463, 1464, "3" +826, 11, 86, 323, 252, 253, 1465, 1466, ")" +826, 11, 87, 324, 254, 256, 1467, 1469, "mm" +826, 11, 88, 325, 257, 259, 1470, 1472, "Hg" +826, 11, 89, 326, 260, 263, 1473, 1476, "for" +826, 11, 90, 327, 264, 267, 1477, 1480, "the" +826, 11, 91, 328, 268, 279, 1481, 1492, "dorzolamide" +826, 11, 92, 329, 280, 281, 1493, 1494, "/" +826, 11, 93, 330, 282, 289, 1495, 1502, "timolol" +826, 11, 94, 331, 290, 295, 1503, 1508, "group" +826, 11, 95, 332, 296, 297, 1509, 1510, "." +826, 12, 1, 333, 0, 3, 1511, 1514, "The" +826, 12, 2, 334, 4, 5, 1515, 1516, "2" +826, 12, 3, 335, 6, 15, 1517, 1526, "therapies" +826, 12, 4, 336, 16, 20, 1527, 1531, "were" +826, 12, 5, 337, 21, 30, 1532, 1541, "similarly" +826, 12, 6, 338, 31, 40, 1542, 1551, "effective" +826, 12, 7, 339, 41, 42, 1552, 1553, "." +826, 13, 1, 340, 0, 10, 1554, 1564, "CONCLUSION" +826, 13, 2, 341, 11, 12, 1565, 1566, ":" +826, 13, 3, 342, 13, 16, 1567, 1570, "The" +826, 13, 4, 343, 17, 28, 1571, 1582, "latanoprost" +826, 13, 5, 344, 29, 32, 1583, 1586, "and" +826, 13, 6, 345, 33, 44, 1587, 1598, "dorzolamide" +826, 13, 7, 346, 45, 46, 1599, 1600, "/" +826, 13, 8, 347, 47, 54, 1601, 1608, "timolol" +826, 13, 9, 348, 55, 66, 1609, 1620, "combination" +826, 13, 10, 349, 67, 71, 1621, 1625, "were" +826, 13, 11, 350, 72, 79, 1626, 1633, "equally" +826, 13, 12, 351, 80, 89, 1634, 1643, "effective" +826, 13, 13, 352, 90, 92, 1644, 1646, "at" +826, 13, 14, 353, 93, 101, 1647, 1655, "lowering" +826, 13, 15, 354, 102, 105, 1656, 1659, "IOP" +826, 13, 16, 355, 106, 114, 1660, 1668, "compared" +826, 13, 17, 356, 115, 117, 1669, 1671, "to" +826, 13, 18, 357, 118, 127, 1672, 1681, "untreated" +826, 13, 19, 358, 128, 136, 1682, 1690, "baseline" +826, 13, 20, 359, 137, 138, 1691, 1692, "." +826, 14, 1, 360, 0, 4, 1693, 1697, "PMID" +826, 14, 2, 361, 5, 6, 1698, 1699, ":" +826, 14, 3, 362, 7, 15, 1700, 1708, "18327364" +826, 14, 4, 363, 16, 17, 1709, 1710, "[" +826, 14, 5, 364, 18, 25, 1711, 1718, "Indexed" +826, 14, 6, 365, 26, 29, 1719, 1722, "for" +826, 14, 7, 366, 30, 37, 1723, 1730, "MEDLINE" +826, 14, 8, 367, 38, 39, 1731, 1732, "]" diff --git a/data/gl 18327364_admin.annodb b/data/gl 18327364_admin.annodb new file mode 100644 index 0000000..850cfd5 --- /dev/null +++ b/data/gl 18327364_admin.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +4, Journal, 0, 11, "Saudi Med J", "", " \"Saudi Med J\"." +5, PublicationYear, 14, 18, "2008", "", " \"2008\"." +6, Title, 46, 169, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma .", "", " \"Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma .\"." +47, Latanoprost, 62, 73, "latanoprost", "", " . ." +48, Timolol, 81, 88, "timolol", "", " ." +49, Dorzolamide, 91, 102, "dorzolamide", "", +50, Primary_OpenAngleGlaucoma, 140, 167, "primary open angle glaucoma", "", " ." +7, Author, 170, 183, "Rismanchian A", "", " \"Rismanchian A\"." +88, Author, 192, 200, "Eslami F", "", " \"Eslami F\"." +89, Author, 203, 211, "Moeini H", "", " \"Moeini H\"." +9, Author, 214, 225, "Attarzade H", "", " \"Attarzade H\"." +10, Author, 228, 240, "Naderibeni A", "", " \"Naderibeni A\"." +11, Iran, 366, 370, "Iran", "", " ." +12, ObjectiveDescription, 385, 506, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma", "", " \"Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma\"." +51, Latanoprost, 401, 412, "latanoprost", "", +52, Timolol, 420, 427, "timolol", "", +53, Dorzolamide, 430, 441, "dorzolamide", "", " ." +54, Primary_OpenAngleGlaucoma, 479, 506, "primary open angle glaucoma", "", +14, Duration, 545, 553, "6 months", "", " \"6 months\"." +55, Randomized, 554, 564, "randomized", "", " ." +15, Blind, 567, 584, "observer - masked", "", " ." +56, NumberPatientsCT, 602, 605, "120", "", " \"120\"." +104, Precondition, 606, 649, "patients with primary open - angle glaucoma", "", " \"patients with primary open - angle glaucoma\"." +102, Primary_OpenAngleGlaucoma, 620, 649, "primary open - angle glaucoma", "", +58, Iran, 679, 683, "Iran", "", +59, Year, 691, 695, "2006", "", +60, Year, 699, 703, "2007", "", +61, Randomized, 724, 734, "randomized", "", +62, Latanoprost, 737, 748, "latanoprost", "", +16, NumberPatientsArm, 755, 757, "60", "", " \"60\"." +63, Dorzolamide, 760, 771, "dorzolamide", "", +64, Timolol, 774, 781, "timolol", "", +17, NumberPatientsArm, 788, 790, "60", "", " \"60\"." +65, Latanoprost, 818, 829, "latanoprost", "", +18, DoseValue, 832, 839, "0 . 005", "", +21, Percentage, 840, 841, "%", "", " ." +24, Frequency, 842, 852, "once daily", "", " \"once daily\"." +66, Timolol, 877, 884, "timolol", "", +19, DoseValue, 885, 890, "0 . 5", "", " \"0 . 5\". \"0 . 5\"." +22, Percentage, 891, 892, "%", "", " ." +25, Frequency, 893, 904, "twice daily", "", " \"twice daily\"." +67, Dorzolamide, 911, 922, "dorzolamide", "", +20, DoseValue, 923, 924, "2", "", " \"2\"." +23, Percentage, 925, 926, "%", "", " ." +26, Frequency, 927, 940, "3 times daily", "", " \"3 times daily\"." +27, Mean, 947, 951, "mean", "", +28, IOP, 952, 972, "intraocular pressure", "", +29, IOP, 975, 978, "IOP", "", +73, TimePoint, 987, 1009, "one , 3 , and 6 months", "", +37057, TimePoint, 993, 1009, "3 , and 6 months", "", +37058, TimePoint, 1001, 1009, "6 months", "", +68, NumberPatientsCT, 1089, 1092, "120", "", +69, Randomized, 1107, 1117, "randomized", "", +30, Mean, 1152, 1156, "mean", "", +31, IOP, 1166, 1169, "IOP", "", +0, Mean, 1217, 1221, "mean", "", +70, IOP, 1256, 1259, "IOP", "", " . ." +71, TimePoint, 1274, 1284, "months one", "", " \"months one\". \"months one\"." +32, Reduction, 1289, 1294, "7 . 2", "", " \"7 . 2\"." +38, SdErrorChangeValue, 1297, 1302, "0 . 4", "", " \"0 . 4\"." +72, TimePoint, 1310, 1317, "month 3", "", " \"month 3\". \"month 3\"." +33, Reduction, 1322, 1327, "7 . 3", "", " \"7 . 3\"." +39, SdErrorChangeValue, 1330, 1335, "0 . 4", "", " \"0 . 4\"." +74, TimePoint, 1347, 1354, "month 6", "", " \"month 6\". \"month 6\"." +34, Reduction, 1359, 1364, "7 . 1", "", " \"7 . 1\"." +40, SdErrorChangeValue, 1367, 1372, "0 . 3", "", " \"0 . 3\"." +2, mmHg, 1375, 1380, "mm Hg", "", " ." +75, Latanoprost, 1389, 1400, "latanoprost", "", +35, Reduction, 1411, 1416, "7 . 5", "", " \"7 . 5\"." +41, SdErrorChangeValue, 1419, 1424, "0 . 3", "", " \"0 . 3\"." +36, Reduction, 1429, 1434, "7 . 8", "", " \"7 . 8\"." +42, SdErrorChangeValue, 1437, 1442, "0 . 3", "", " \"0 . 3\"." +37, Reduction, 1451, 1456, "7 . 4", "", " \"7 . 4\"." +43, SdErrorChangeValue, 1459, 1464, "0 . 3", "", " \"0 . 3\"." +3, mmHg, 1467, 1472, "mm Hg", "", +76, Dorzolamide, 1481, 1492, "dorzolamide", "", +77, Timolol, 1495, 1502, "timolol", "", +44, ConclusionComment, 1567, 1692, "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .", "", " \"The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .\"." +78, Latanoprost, 1571, 1582, "latanoprost", "", +79, Dorzolamide, 1587, 1598, "dorzolamide", "", +80, Timolol, 1601, 1608, "timolol", "", +45, IOP, 1656, 1659, "IOP", "", +46, PMID, 1700, 1708, "18327364", "", " \"18327364\"." diff --git a/data/gl 18327364_admin.n-triples b/data/gl 18327364_admin.n-triples new file mode 100644 index 0000000..1e0f7b6 --- /dev/null +++ b/data/gl 18327364_admin.n-triples @@ -0,0 +1,139 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma ." . + "Rismanchian A" . + "2008" . + "Saudi Med J" . + "18327364" . + . + "Eslami F" . + "Moeini H" . + "Attarzade H" . + "Naderibeni A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma" . + "120" . + "6 months" . + . + . + . + "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + "60" . + . + . + . + . + . + . + "Arm_tim-dor" . + "60" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_tim" . + . + "twice daily" . + . + . + "Intervention dor" . + "3 times daily" . + . + . +# RDF export of group: Medication + . + "Medication_tim" . + . + "0 . 5" . + . + . + . + "Medication_dor" . + . + "2" . + . + . + . + "Medication_lat" . + . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_tim-dor_1" . + . + "7 . 5" . + "0 . 3" . + "months one" . + . + "Outcome_tim-dor_3" . + . + "7 . 8" . + "0 . 3" . + "month 3" . + . + "Outcome_tim-dor_6" . + . + "7 . 4" . + "0 . 3" . + "month 6" . + . + "Outcome_lat_1" . + . + "7 . 2" . + "0 . 4" . + "months one" . + . + "Outcome_lat_3" . + . + "7 . 3" . + "0 . 4" . + "month 3" . + . + "Outcome_lat_6" . + . + "7 . 1" . + "0 . 3" . + "month 6" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18327364_export.csv b/data/gl 18327364_export.csv new file mode 100644 index 0000000..c8d1df1 --- /dev/null +++ b/data/gl 18327364_export.csv @@ -0,0 +1,368 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +451, 1, 1, 1, 0, 5, 0, 5, "Saudi" +451, 1, 2, 2, 6, 9, 6, 9, "Med" +451, 1, 3, 3, 10, 11, 10, 11, "J" +451, 1, 4, 4, 12, 13, 12, 13, "." +451, 2, 1, 5, 0, 4, 14, 18, "2008" +451, 2, 2, 6, 5, 8, 19, 22, "Mar" +451, 2, 3, 7, 9, 10, 23, 24, ";" +451, 2, 4, 8, 11, 13, 25, 27, "29" +451, 2, 5, 9, 14, 15, 28, 29, "(" +451, 2, 6, 10, 16, 17, 30, 31, "3" +451, 2, 7, 11, 18, 19, 32, 33, ")" +451, 2, 8, 12, 20, 21, 34, 35, ":" +451, 2, 9, 13, 22, 25, 36, 39, "384" +451, 2, 10, 14, 26, 27, 40, 41, "-" +451, 2, 11, 15, 28, 29, 42, 43, "7" +451, 2, 12, 16, 30, 31, 44, 45, "." +451, 3, 1, 17, 0, 8, 46, 54, "Efficacy" +451, 3, 2, 18, 9, 11, 55, 57, "of" +451, 3, 3, 19, 12, 15, 58, 61, "the" +451, 3, 4, 20, 16, 27, 62, 73, "latanoprost" +451, 3, 5, 21, 28, 34, 74, 80, "versus" +451, 3, 6, 22, 35, 42, 81, 88, "timolol" +451, 3, 7, 23, 43, 44, 89, 90, "/" +451, 3, 8, 24, 45, 56, 91, 102, "dorzolamide" +451, 3, 9, 25, 57, 68, 103, 114, "combination" +451, 3, 10, 26, 69, 76, 115, 122, "therapy" +451, 3, 11, 27, 77, 79, 123, 125, "in" +451, 3, 12, 28, 80, 88, 126, 134, "patients" +451, 3, 13, 29, 89, 93, 135, 139, "with" +451, 3, 14, 30, 94, 101, 140, 147, "primary" +451, 3, 15, 31, 102, 106, 148, 152, "open" +451, 3, 16, 32, 107, 112, 153, 158, "angle" +451, 3, 17, 33, 113, 121, 159, 167, "glaucoma" +451, 3, 18, 34, 122, 123, 168, 169, "." +451, 4, 1, 35, 0, 11, 170, 181, "Rismanchian" +451, 4, 2, 36, 12, 13, 182, 183, "A" +451, 4, 3, 37, 14, 15, 184, 185, "(" +451, 4, 4, 38, 16, 17, 186, 187, "1" +451, 4, 5, 39, 18, 19, 188, 189, ")" +451, 4, 6, 40, 20, 21, 190, 191, "," +451, 4, 7, 41, 22, 28, 192, 198, "Eslami" +451, 4, 8, 42, 29, 30, 199, 200, "F" +451, 4, 9, 43, 31, 32, 201, 202, "," +451, 4, 10, 44, 33, 39, 203, 209, "Moeini" +451, 4, 11, 45, 40, 41, 210, 211, "H" +451, 4, 12, 46, 42, 43, 212, 213, "," +451, 4, 13, 47, 44, 53, 214, 223, "Attarzade" +451, 4, 14, 48, 54, 55, 224, 225, "H" +451, 4, 15, 49, 56, 57, 226, 227, "," +451, 4, 16, 50, 58, 68, 228, 238, "Naderibeni" +451, 4, 17, 51, 69, 70, 239, 240, "A" +451, 4, 18, 52, 71, 72, 241, 242, "." +451, 5, 1, 53, 0, 6, 243, 249, "Author" +451, 5, 2, 54, 7, 18, 250, 261, "information" +451, 5, 3, 55, 19, 20, 262, 263, ":" +451, 5, 4, 56, 21, 22, 264, 265, "(" +451, 5, 5, 57, 23, 24, 266, 267, "1" +451, 5, 6, 58, 25, 26, 268, 269, ")" +451, 5, 7, 59, 27, 37, 270, 280, "Department" +451, 5, 8, 60, 38, 40, 281, 283, "of" +451, 5, 9, 61, 41, 54, 284, 297, "Ophthalmology" +451, 5, 10, 62, 55, 56, 298, 299, "," +451, 5, 11, 63, 57, 64, 300, 307, "Isfahan" +451, 5, 12, 64, 65, 75, 308, 318, "University" +451, 5, 13, 65, 76, 78, 319, 321, "of" +451, 5, 14, 66, 79, 86, 322, 329, "Medical" +451, 5, 15, 67, 87, 94, 330, 337, "Science" +451, 5, 16, 68, 95, 96, 338, 339, "," +451, 5, 17, 69, 97, 101, 340, 344, "Feiz" +451, 5, 18, 70, 102, 110, 345, 353, "Hospital" +451, 5, 19, 71, 111, 112, 354, 355, "," +451, 5, 20, 72, 113, 120, 356, 363, "Isfahan" +451, 5, 21, 73, 121, 122, 364, 365, "," +451, 5, 22, 74, 123, 127, 366, 370, "Iran" +451, 5, 23, 75, 128, 129, 371, 372, "." +451, 6, 1, 76, 0, 9, 373, 382, "OBJECTIVE" +451, 6, 2, 77, 10, 11, 383, 384, ":" +451, 6, 3, 78, 12, 20, 385, 393, "Efficacy" +451, 6, 4, 79, 21, 23, 394, 396, "of" +451, 6, 5, 80, 24, 27, 397, 400, "the" +451, 6, 6, 81, 28, 39, 401, 412, "latanoprost" +451, 6, 7, 82, 40, 46, 413, 419, "versus" +451, 6, 8, 83, 47, 54, 420, 427, "timolol" +451, 6, 9, 84, 55, 56, 428, 429, "/" +451, 6, 10, 85, 57, 68, 430, 441, "dorzolamide" +451, 6, 11, 86, 69, 80, 442, 453, "combination" +451, 6, 12, 87, 81, 88, 454, 461, "therapy" +451, 6, 13, 88, 89, 91, 462, 464, "in" +451, 6, 14, 89, 92, 100, 465, 473, "patients" +451, 6, 15, 90, 101, 105, 474, 478, "with" +451, 6, 16, 91, 106, 113, 479, 486, "primary" +451, 6, 17, 92, 114, 118, 487, 491, "open" +451, 6, 18, 93, 119, 124, 492, 497, "angle" +451, 6, 19, 94, 125, 133, 498, 506, "glaucoma" +451, 6, 20, 95, 134, 141, 507, 514, "METHODS" +451, 6, 21, 96, 142, 143, 515, 516, ":" +451, 6, 22, 97, 144, 147, 517, 520, "The" +451, 6, 23, 98, 148, 153, 521, 526, "study" +451, 6, 24, 99, 154, 157, 527, 530, "was" +451, 6, 25, 100, 158, 166, 531, 539, "designed" +451, 6, 26, 101, 167, 169, 540, 542, "as" +451, 6, 27, 102, 170, 171, 543, 544, "a" +451, 6, 28, 103, 172, 173, 545, 546, "6" +451, 6, 29, 104, 174, 180, 547, 553, "months" +451, 6, 30, 105, 181, 191, 554, 564, "randomized" +451, 6, 31, 106, 192, 193, 565, 566, "," +451, 6, 32, 107, 194, 202, 567, 575, "observer" +451, 6, 33, 108, 203, 204, 576, 577, "-" +451, 6, 34, 109, 205, 211, 578, 584, "masked" +451, 6, 35, 110, 212, 217, 585, 590, "study" +451, 6, 36, 111, 218, 228, 591, 601, "comprising" +451, 6, 37, 112, 229, 232, 602, 605, "120" +451, 6, 38, 113, 233, 241, 606, 614, "patients" +451, 6, 39, 114, 242, 246, 615, 619, "with" +451, 6, 40, 115, 247, 254, 620, 627, "primary" +451, 6, 41, 116, 255, 259, 628, 632, "open" +451, 6, 42, 117, 260, 261, 633, 634, "-" +451, 6, 43, 118, 262, 267, 635, 640, "angle" +451, 6, 44, 119, 268, 276, 641, 649, "glaucoma" +451, 6, 45, 120, 277, 279, 650, 652, "in" +451, 6, 46, 121, 280, 284, 653, 657, "Feiz" +451, 6, 47, 122, 285, 293, 658, 666, "Hospital" +451, 6, 48, 123, 294, 295, 667, 668, "," +451, 6, 49, 124, 296, 303, 669, 676, "Isfahan" +451, 6, 50, 125, 304, 305, 677, 678, "," +451, 6, 51, 126, 306, 310, 679, 683, "Iran" +451, 6, 52, 127, 311, 312, 684, 685, "," +451, 6, 53, 128, 313, 317, 686, 690, "from" +451, 6, 54, 129, 318, 322, 691, 695, "2006" +451, 6, 55, 130, 323, 325, 696, 698, "to" +451, 6, 56, 131, 326, 330, 699, 703, "2007" +451, 6, 57, 132, 331, 332, 704, 705, "." +451, 7, 1, 133, 0, 3, 706, 709, "The" +451, 7, 2, 134, 4, 12, 710, 718, "patients" +451, 7, 3, 135, 13, 17, 719, 723, "were" +451, 7, 4, 136, 18, 28, 724, 734, "randomized" +451, 7, 5, 137, 29, 30, 735, 736, "(" +451, 7, 6, 138, 31, 42, 737, 748, "latanoprost" +451, 7, 7, 139, 43, 44, 749, 750, "," +451, 7, 8, 140, 45, 46, 751, 752, "n" +451, 7, 9, 141, 47, 48, 753, 754, "=" +451, 7, 10, 142, 49, 51, 755, 757, "60" +451, 7, 11, 143, 52, 53, 758, 759, ";" +451, 7, 12, 144, 54, 65, 760, 771, "dorzolamide" +451, 7, 13, 145, 66, 67, 772, 773, "/" +451, 7, 14, 146, 68, 75, 774, 781, "timolol" +451, 7, 15, 147, 76, 77, 782, 783, "," +451, 7, 16, 148, 78, 79, 784, 785, "n" +451, 7, 17, 149, 80, 81, 786, 787, "=" +451, 7, 18, 150, 82, 84, 788, 790, "60" +451, 7, 19, 151, 85, 86, 791, 792, ")" +451, 7, 20, 152, 87, 89, 793, 795, "to" +451, 7, 21, 153, 90, 99, 796, 805, "treatment" +451, 7, 22, 154, 100, 104, 806, 810, "with" +451, 7, 23, 155, 105, 111, 811, 817, "either" +451, 7, 24, 156, 112, 123, 818, 829, "latanoprost" +451, 7, 25, 157, 124, 125, 830, 831, "," +451, 7, 26, 158, 126, 127, 832, 833, "0" +451, 7, 27, 159, 128, 129, 834, 835, "." +451, 7, 28, 160, 130, 133, 836, 839, "005" +451, 7, 29, 161, 134, 135, 840, 841, "%" +451, 7, 30, 162, 136, 140, 842, 846, "once" +451, 7, 31, 163, 141, 146, 847, 852, "daily" +451, 7, 32, 164, 147, 148, 853, 854, "," +451, 7, 33, 165, 149, 151, 855, 857, "or" +451, 7, 34, 166, 152, 155, 858, 861, "the" +451, 7, 35, 167, 156, 167, 862, 873, "combination" +451, 7, 36, 168, 168, 170, 874, 876, "of" +451, 7, 37, 169, 171, 178, 877, 884, "timolol" +451, 7, 38, 170, 179, 180, 885, 886, "0" +451, 7, 39, 171, 181, 182, 887, 888, "." +451, 7, 40, 172, 183, 184, 889, 890, "5" +451, 7, 41, 173, 185, 186, 891, 892, "%" +451, 7, 42, 174, 187, 192, 893, 898, "twice" +451, 7, 43, 175, 193, 198, 899, 904, "daily" +451, 7, 44, 176, 199, 200, 905, 906, "," +451, 7, 45, 177, 201, 204, 907, 910, "and" +451, 7, 46, 178, 205, 216, 911, 922, "dorzolamide" +451, 7, 47, 179, 217, 218, 923, 924, "2" +451, 7, 48, 180, 219, 220, 925, 926, "%" +451, 7, 49, 181, 221, 222, 927, 928, "3" +451, 7, 50, 182, 223, 228, 929, 934, "times" +451, 7, 51, 183, 229, 234, 935, 940, "daily" +451, 7, 52, 184, 235, 236, 941, 942, "." +451, 8, 1, 185, 0, 3, 943, 946, "The" +451, 8, 2, 186, 4, 8, 947, 951, "mean" +451, 8, 3, 187, 9, 20, 952, 963, "intraocular" +451, 8, 4, 188, 21, 29, 964, 972, "pressure" +451, 8, 5, 189, 30, 31, 973, 974, "(" +451, 8, 6, 190, 32, 35, 975, 978, "IOP" +451, 8, 7, 191, 36, 37, 979, 980, ")" +451, 8, 8, 192, 38, 43, 981, 986, "after" +451, 8, 9, 193, 44, 47, 987, 990, "one" +451, 8, 10, 194, 48, 49, 991, 992, "," +451, 8, 11, 195, 50, 51, 993, 994, "3" +451, 8, 12, 196, 52, 53, 995, 996, "," +451, 8, 13, 197, 54, 57, 997, 1000, "and" +451, 8, 14, 198, 58, 59, 1001, 1002, "6" +451, 8, 15, 199, 60, 66, 1003, 1009, "months" +451, 8, 16, 200, 67, 69, 1010, 1012, "of" +451, 8, 17, 201, 70, 79, 1013, 1022, "treatment" +451, 8, 18, 202, 80, 83, 1023, 1026, "was" +451, 8, 19, 203, 84, 92, 1027, 1035, "compared" +451, 8, 20, 204, 93, 97, 1036, 1040, "with" +451, 8, 21, 205, 98, 106, 1041, 1049, "baseline" +451, 8, 22, 206, 107, 109, 1050, 1052, "in" +451, 8, 23, 207, 110, 113, 1053, 1056, "the" +451, 8, 24, 208, 114, 115, 1057, 1058, "2" +451, 8, 25, 209, 116, 122, 1059, 1065, "groups" +451, 8, 26, 210, 123, 124, 1066, 1067, "." +451, 9, 1, 211, 0, 7, 1068, 1075, "RESULTS" +451, 9, 2, 212, 8, 9, 1076, 1077, ":" +451, 9, 3, 213, 10, 11, 1078, 1079, "A" +451, 9, 4, 214, 12, 17, 1080, 1085, "total" +451, 9, 5, 215, 18, 20, 1086, 1088, "of" +451, 9, 6, 216, 21, 24, 1089, 1092, "120" +451, 9, 7, 217, 25, 33, 1093, 1101, "patients" +451, 9, 8, 218, 34, 38, 1102, 1106, "were" +451, 9, 9, 219, 39, 49, 1107, 1117, "randomized" +451, 9, 10, 220, 50, 52, 1118, 1120, "to" +451, 9, 11, 221, 53, 54, 1121, 1122, "2" +451, 9, 12, 222, 55, 60, 1123, 1128, "equal" +451, 9, 13, 223, 61, 70, 1129, 1138, "treatment" +451, 9, 14, 224, 71, 77, 1139, 1145, "groups" +451, 9, 15, 225, 78, 79, 1146, 1147, "." +451, 10, 1, 226, 0, 3, 1148, 1151, "The" +451, 10, 2, 227, 4, 8, 1152, 1156, "mean" +451, 10, 3, 228, 9, 17, 1157, 1165, "baseline" +451, 10, 4, 229, 18, 21, 1166, 1169, "IOP" +451, 10, 5, 230, 22, 28, 1170, 1176, "values" +451, 10, 6, 231, 29, 33, 1177, 1181, "were" +451, 10, 7, 232, 34, 41, 1182, 1189, "similar" +451, 10, 8, 233, 42, 49, 1190, 1197, "between" +451, 10, 9, 234, 50, 53, 1198, 1201, "the" +451, 10, 10, 235, 54, 55, 1202, 1203, "2" +451, 10, 11, 236, 56, 62, 1204, 1210, "groups" +451, 10, 12, 237, 63, 64, 1211, 1212, "." +451, 11, 1, 238, 0, 3, 1213, 1216, "The" +451, 11, 2, 239, 4, 8, 1217, 1221, "mean" +451, 11, 3, 240, 9, 10, 1222, 1223, "(" +451, 11, 4, 241, 11, 19, 1224, 1232, "standard" +451, 11, 5, 242, 20, 25, 1233, 1238, "error" +451, 11, 6, 243, 26, 28, 1239, 1241, "of" +451, 11, 7, 244, 29, 33, 1242, 1246, "mean" +451, 11, 8, 245, 34, 35, 1247, 1248, "[" +451, 11, 9, 246, 36, 38, 1249, 1251, "SE" +451, 11, 10, 247, 39, 40, 1252, 1253, "]" +451, 11, 11, 248, 41, 42, 1254, 1255, ")" +451, 11, 12, 249, 43, 46, 1256, 1259, "IOP" +451, 11, 13, 250, 47, 57, 1260, 1270, "reductions" +451, 11, 14, 251, 58, 60, 1271, 1273, "at" +451, 11, 15, 252, 61, 67, 1274, 1280, "months" +451, 11, 16, 253, 68, 71, 1281, 1284, "one" +451, 11, 17, 254, 72, 75, 1285, 1288, "was" +451, 11, 18, 255, 76, 77, 1289, 1290, "7" +451, 11, 19, 256, 78, 79, 1291, 1292, "." +451, 11, 20, 257, 80, 81, 1293, 1294, "2" +451, 11, 21, 258, 82, 83, 1295, 1296, "(" +451, 11, 22, 259, 84, 85, 1297, 1298, "0" +451, 11, 23, 260, 86, 87, 1299, 1300, "." +451, 11, 24, 261, 88, 89, 1301, 1302, "4" +451, 11, 25, 262, 90, 91, 1303, 1304, ")" +451, 11, 26, 263, 92, 93, 1305, 1306, "," +451, 11, 27, 264, 94, 96, 1307, 1309, "at" +451, 11, 28, 265, 97, 102, 1310, 1315, "month" +451, 11, 29, 266, 103, 104, 1316, 1317, "3" +451, 11, 30, 267, 105, 108, 1318, 1321, "was" +451, 11, 31, 268, 109, 110, 1322, 1323, "7" +451, 11, 32, 269, 111, 112, 1324, 1325, "." +451, 11, 33, 270, 113, 114, 1326, 1327, "3" +451, 11, 34, 271, 115, 116, 1328, 1329, "(" +451, 11, 35, 272, 117, 118, 1330, 1331, "0" +451, 11, 36, 273, 119, 120, 1332, 1333, "." +451, 11, 37, 274, 121, 122, 1334, 1335, "4" +451, 11, 38, 275, 123, 124, 1336, 1337, ")" +451, 11, 39, 276, 125, 126, 1338, 1339, "," +451, 11, 40, 277, 127, 130, 1340, 1343, "and" +451, 11, 41, 278, 131, 133, 1344, 1346, "at" +451, 11, 42, 279, 134, 139, 1347, 1352, "month" +451, 11, 43, 280, 140, 141, 1353, 1354, "6" +451, 11, 44, 281, 142, 145, 1355, 1358, "was" +451, 11, 45, 282, 146, 147, 1359, 1360, "7" +451, 11, 46, 283, 148, 149, 1361, 1362, "." +451, 11, 47, 284, 150, 151, 1363, 1364, "1" +451, 11, 48, 285, 152, 153, 1365, 1366, "(" +451, 11, 49, 286, 154, 155, 1367, 1368, "0" +451, 11, 50, 287, 156, 157, 1369, 1370, "." +451, 11, 51, 288, 158, 159, 1371, 1372, "3" +451, 11, 52, 289, 160, 161, 1373, 1374, ")" +451, 11, 53, 290, 162, 164, 1375, 1377, "mm" +451, 11, 54, 291, 165, 167, 1378, 1380, "Hg" +451, 11, 55, 292, 168, 171, 1381, 1384, "for" +451, 11, 56, 293, 172, 175, 1385, 1388, "the" +451, 11, 57, 294, 176, 187, 1389, 1400, "latanoprost" +451, 11, 58, 295, 188, 193, 1401, 1406, "group" +451, 11, 59, 296, 194, 197, 1407, 1410, "and" +451, 11, 60, 297, 198, 199, 1411, 1412, "7" +451, 11, 61, 298, 200, 201, 1413, 1414, "." +451, 11, 62, 299, 202, 203, 1415, 1416, "5" +451, 11, 63, 300, 204, 205, 1417, 1418, "(" +451, 11, 64, 301, 206, 207, 1419, 1420, "0" +451, 11, 65, 302, 208, 209, 1421, 1422, "." +451, 11, 66, 303, 210, 211, 1423, 1424, "3" +451, 11, 67, 304, 212, 213, 1425, 1426, ")" +451, 11, 68, 305, 214, 215, 1427, 1428, "," +451, 11, 69, 306, 216, 217, 1429, 1430, "7" +451, 11, 70, 307, 218, 219, 1431, 1432, "." +451, 11, 71, 308, 220, 221, 1433, 1434, "8" +451, 11, 72, 309, 222, 223, 1435, 1436, "(" +451, 11, 73, 310, 224, 225, 1437, 1438, "0" +451, 11, 74, 311, 226, 227, 1439, 1440, "." +451, 11, 75, 312, 228, 229, 1441, 1442, "3" +451, 11, 76, 313, 230, 231, 1443, 1444, ")" +451, 11, 77, 314, 232, 233, 1445, 1446, "," +451, 11, 78, 315, 234, 237, 1447, 1450, "and" +451, 11, 79, 316, 238, 239, 1451, 1452, "7" +451, 11, 80, 317, 240, 241, 1453, 1454, "." +451, 11, 81, 318, 242, 243, 1455, 1456, "4" +451, 11, 82, 319, 244, 245, 1457, 1458, "(" +451, 11, 83, 320, 246, 247, 1459, 1460, "0" +451, 11, 84, 321, 248, 249, 1461, 1462, "." +451, 11, 85, 322, 250, 251, 1463, 1464, "3" +451, 11, 86, 323, 252, 253, 1465, 1466, ")" +451, 11, 87, 324, 254, 256, 1467, 1469, "mm" +451, 11, 88, 325, 257, 259, 1470, 1472, "Hg" +451, 11, 89, 326, 260, 263, 1473, 1476, "for" +451, 11, 90, 327, 264, 267, 1477, 1480, "the" +451, 11, 91, 328, 268, 279, 1481, 1492, "dorzolamide" +451, 11, 92, 329, 280, 281, 1493, 1494, "/" +451, 11, 93, 330, 282, 289, 1495, 1502, "timolol" +451, 11, 94, 331, 290, 295, 1503, 1508, "group" +451, 11, 95, 332, 296, 297, 1509, 1510, "." +451, 12, 1, 333, 0, 3, 1511, 1514, "The" +451, 12, 2, 334, 4, 5, 1515, 1516, "2" +451, 12, 3, 335, 6, 15, 1517, 1526, "therapies" +451, 12, 4, 336, 16, 20, 1527, 1531, "were" +451, 12, 5, 337, 21, 30, 1532, 1541, "similarly" +451, 12, 6, 338, 31, 40, 1542, 1551, "effective" +451, 12, 7, 339, 41, 42, 1552, 1553, "." +451, 13, 1, 340, 0, 10, 1554, 1564, "CONCLUSION" +451, 13, 2, 341, 11, 12, 1565, 1566, ":" +451, 13, 3, 342, 13, 16, 1567, 1570, "The" +451, 13, 4, 343, 17, 28, 1571, 1582, "latanoprost" +451, 13, 5, 344, 29, 32, 1583, 1586, "and" +451, 13, 6, 345, 33, 44, 1587, 1598, "dorzolamide" +451, 13, 7, 346, 45, 46, 1599, 1600, "/" +451, 13, 8, 347, 47, 54, 1601, 1608, "timolol" +451, 13, 9, 348, 55, 66, 1609, 1620, "combination" +451, 13, 10, 349, 67, 71, 1621, 1625, "were" +451, 13, 11, 350, 72, 79, 1626, 1633, "equally" +451, 13, 12, 351, 80, 89, 1634, 1643, "effective" +451, 13, 13, 352, 90, 92, 1644, 1646, "at" +451, 13, 14, 353, 93, 101, 1647, 1655, "lowering" +451, 13, 15, 354, 102, 105, 1656, 1659, "IOP" +451, 13, 16, 355, 106, 114, 1660, 1668, "compared" +451, 13, 17, 356, 115, 117, 1669, 1671, "to" +451, 13, 18, 357, 118, 127, 1672, 1681, "untreated" +451, 13, 19, 358, 128, 136, 1682, 1690, "baseline" +451, 13, 20, 359, 137, 138, 1691, 1692, "." +451, 14, 1, 360, 0, 4, 1693, 1697, "PMID" +451, 14, 2, 361, 5, 6, 1698, 1699, ":" +451, 14, 3, 362, 7, 15, 1700, 1708, "18327364" +451, 14, 4, 363, 16, 17, 1709, 1710, "[" +451, 14, 5, 364, 18, 25, 1711, 1718, "Indexed" +451, 14, 6, 365, 26, 29, 1719, 1722, "for" +451, 14, 7, 366, 30, 37, 1723, 1730, "MEDLINE" +451, 14, 8, 367, 38, 39, 1731, 1732, "]" diff --git a/data/gl 18327364_jshahinitiran.annodb b/data/gl 18327364_jshahinitiran.annodb new file mode 100644 index 0000000..ba0acac --- /dev/null +++ b/data/gl 18327364_jshahinitiran.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11709, Journal, 0, 11, "Saudi Med J", "", +11710, PublicationYear, 14, 18, "2008", "", +11711, Title, 46, 169, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma .", "", +28094, Latanoprost, 62, 73, "latanoprost", "", +28095, Timolol, 81, 88, "timolol", "", +28096, Dorzolamide, 91, 102, "dorzolamide", "", +28097, Primary_OpenAngleGlaucoma, 140, 167, "primary open angle glaucoma", "", +11721, Author, , , "", "", +11722, Author, 170, 183, "Rismanchian A", "", +11723, Author, 192, 211, "Eslami F , Moeini H", "", +11724, Author, 214, 225, "Attarzade H", "", +11725, Author, 228, 240, "Naderibeni A", "", +11726, Iran, 366, 370, "Iran", "", +11727, ObjectiveDescription, 385, 506, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma", "", +28098, Latanoprost, 401, 412, "latanoprost", "", +28099, Timolol, 420, 427, "timolol", "", +28100, Dorzolamide, 430, 441, "dorzolamide", "", +28101, Primary_OpenAngleGlaucoma, 479, 506, "primary open angle glaucoma", "", +11728, ObjectiveDescription, 507, 705, "METHODS : The study was designed as a 6 months randomized , observer - masked study comprising 120 patients with primary open - angle glaucoma in Feiz Hospital , Isfahan , Iran , from 2006 to 2007 .", "", +11732, Duration, 545, 553, "6 months", "", +28102, Randomized, 554, 564, "randomized", "", +11734, Blind, 567, 584, "observer - masked", "", +28103, NumberPatientsCT, 602, 605, "120", "", +28104, Primary_OpenAngleGlaucoma, 606, 649, "patients with primary open - angle glaucoma", "", +28105, Iran, 679, 683, "Iran", "", +28106, Year, 691, 695, "2006", "", +28107, Year, 699, 703, "2007", "", +28108, Randomized, 724, 734, "randomized", "", +28109, Latanoprost, 737, 748, "latanoprost", "", +11737, NumberPatientsArm, 755, 757, "60", "", +28110, Dorzolamide, 760, 771, "dorzolamide", "", +28111, Timolol, 774, 781, "timolol", "", +11738, NumberPatientsArm, 788, 790, "60", "", +28112, Latanoprost, 818, 829, "latanoprost", "", +11741, DoseValue, 832, 839, "0 . 005", "", +11744, Percentage, 840, 841, "%", "", +11747, Frequency, 842, 852, "once daily", "", +28113, Timolol, 877, 884, "timolol", "", +11742, DoseValue, 885, 890, "0 . 5", "", +11745, Percentage, 891, 892, "%", "", +11749, Frequency, 893, 904, "twice daily", "", +28114, Dorzolamide, 911, 922, "dorzolamide", "", +11743, DoseValue, 923, 924, "2", "", +11746, Percentage, 925, 926, "%", "", +11751, Frequency, 927, 940, "3 times daily", "", +11752, Mean, 947, 951, "mean", "", +11753, IOP, 952, 972, "intraocular pressure", "", +11754, IOP, 975, 978, "IOP", "", +28120, TimePoint, 987, 1009, "one , 3 , and 6 months", "", +28115, NumberPatientsCT, 1089, 1092, "120", "", +28116, Randomized, 1107, 1117, "randomized", "", +11760, Mean, 1152, 1156, "mean", "", +11761, IOP, 1166, 1169, "IOP", "", +226, Mean, 1217, 1221, "mean", "", +28117, IOP, 1256, 1259, "IOP", "", +230, Reduction, 1260, 1270, "reductions", "", +28118, TimePoint, 1274, 1284, "months one", "", +11767, Reduction, 1289, 1294, "7 . 2", "", +11773, SdErrorChangeValue, 1297, 1302, "0 . 4", "", +28119, TimePoint, 1310, 1317, "month 3", "", +11768, Reduction, 1322, 1327, "7 . 3", "", +11776, SdErrorChangeValue, 1330, 1335, "0 . 4", "", +28121, TimePoint, 1347, 1354, "month 6", "", +11769, Reduction, 1359, 1364, "7 . 1", "", +11777, SdErrorChangeValue, 1367, 1372, "0 . 3", "", +249, mmHg, 1375, 1380, "mm Hg", "", +28122, Latanoprost, 1389, 1400, "latanoprost", "", +11770, Reduction, 1411, 1416, "7 . 5", "", +11778, SdErrorChangeValue, 1419, 1424, "0 . 3", "", +11771, Reduction, 1429, 1434, "7 . 8", "", +11779, SdErrorChangeValue, 1437, 1442, "0 . 3", "", +11772, Reduction, 1451, 1456, "7 . 4", "", +11780, SdErrorChangeValue, 1459, 1464, "0 . 3", "", +250, mmHg, 1467, 1472, "mm Hg", "", +28123, Dorzolamide, 1481, 1492, "dorzolamide", "", +28124, Timolol, 1495, 1502, "timolol", "", +11781, ConclusionComment, 1567, 1692, "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .", "", +28125, Latanoprost, 1571, 1582, "latanoprost", "", +28126, Dorzolamide, 1587, 1598, "dorzolamide", "", +28127, Timolol, 1601, 1608, "timolol", "", +11784, IOP, 1656, 1659, "IOP", "", +11785, PMID, 1700, 1708, "18327364", "", diff --git a/data/gl 18327364_jshahinitiran.n-triples b/data/gl 18327364_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18327364_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18327364_tstrakeljahn.annodb b/data/gl 18327364_tstrakeljahn.annodb new file mode 100644 index 0000000..8e0a18a --- /dev/null +++ b/data/gl 18327364_tstrakeljahn.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30162, Journal, 0, 11, "Saudi Med J", "", +30163, PublicationYear, 14, 18, "2008", "", +30174, Title, 46, 167, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma", "", +30164, Latanoprost, 62, 73, "latanoprost", "", +30165, Timolol, 81, 88, "timolol", "", +30166, Dorzolamide, 91, 102, "dorzolamide", "", +30167, Primary_OpenAngleGlaucoma, 140, 167, "primary open angle glaucoma", "", +30168, Author, 170, 183, "Rismanchian A", "", +30169, Author, 192, 200, "Eslami F", "", +30170, Author, 203, 211, "Moeini H", "", +30171, Author, 214, 225, "Attarzade H", "", +30172, Author, 228, 240, "Naderibeni A", "", +30173, Iran, 366, 370, "Iran", "", +30186, ObjectiveDescription, 385, 640, "Efficacy of the latanoprost versus timolol / dorzolamide combination therapy in patients with primary open angle glaucoma METHODS : The study was designed as a 6 months randomized , observer - masked study comprising 120 patients with primary open - angle", "", +30175, Latanoprost, 401, 412, "latanoprost", "", +30176, Timolol, 420, 427, "timolol", "", +30177, Dorzolamide, 430, 441, "dorzolamide", "", +30178, Primary_OpenAngleGlaucoma, 479, 506, "primary open angle glaucoma", "", +30179, Duration, 545, 553, "6 months", "", +30180, Randomized, 554, 564, "randomized", "", +30181, Blind, 567, 584, "observer - masked", "", +30182, NumberPatientsCT, 602, 605, "120", "", +30185, Precondition, 606, 649, "patients with primary open - angle glaucoma", "", +30183, Primary_OpenAngleGlaucoma, 620, 649, "primary open - angle glaucoma", "", +30187, ObjectiveDescription, 641, 705, "glaucoma in Feiz Hospital , Isfahan , Iran , from 2006 to 2007 .", "", +30184, Iran, 679, 683, "Iran", "", +30188, Randomized, 724, 734, "randomized", "", +30189, Latanoprost, 737, 748, "latanoprost", "", +30190, NumberPatientsArm, 755, 757, "60", "", +30192, Dorzolamide, 760, 771, "dorzolamide", "", +30193, Timolol, 774, 781, "timolol", "", +30191, NumberPatientsArm, 788, 790, "60", "", +30194, Latanoprost, 818, 829, "latanoprost", "", +30197, DoseValue, 832, 839, "0 . 005", "", +30200, Percentage, 840, 841, "%", "", +30203, Frequency, 842, 852, "once daily", "", +30195, Timolol, 877, 884, "timolol", "", +30198, DoseValue, 885, 890, "0 . 5", "", +30201, Percentage, 891, 892, "%", "", +30205, Frequency, 893, 904, "twice daily", "", +30196, Dorzolamide, 911, 922, "dorzolamide", "", +30199, DoseValue, 923, 924, "2", "", +30202, Percentage, 925, 926, "%", "", +30204, Frequency, 927, 940, "3 times daily", "", +30206, Mean, 947, 951, "mean", "", +30207, IOP, 952, 972, "intraocular pressure", "", +30208, IOP, 975, 978, "IOP", "", +30209, TimePoint, 987, 1009, "one , 3 , and 6 months", "", +30210, NumberPatientsCT, 1089, 1092, "120", "", +30211, Randomized, 1107, 1117, "randomized", "", +30212, Mean, 1152, 1156, "mean", "", +30213, IOP, 1166, 1169, "IOP", "", +30214, Mean, 1217, 1221, "mean", "", +30215, IOP, 1256, 1259, "IOP", "", +30216, TimePoint, 1274, 1284, "months one", "", +30224, Reduction, 1289, 1294, "7 . 2", "", +30230, SdErrorChangeValue, 1297, 1302, "0 . 4", "", +30217, TimePoint, 1310, 1317, "month 3", "", +30225, Reduction, 1322, 1327, "7 . 3", "", +30231, SdErrorChangeValue, 1330, 1335, "0 . 4", "", +30218, TimePoint, 1347, 1354, "month 6", "", +30226, Reduction, 1359, 1364, "7 . 1", "", +30232, SdErrorChangeValue, 1367, 1372, "0 . 3", "", +30219, mmHg, 1375, 1380, "mm Hg", "", +30220, Latanoprost, 1389, 1400, "latanoprost", "", +30227, Reduction, 1411, 1416, "7 . 5", "", +30233, SdErrorChangeValue, 1419, 1424, "0 . 3", "", +30228, Reduction, 1429, 1434, "7 . 8", "", +30234, SdErrorChangeValue, 1437, 1442, "0 . 3", "", +30229, Reduction, 1451, 1456, "7 . 4", "", +30235, SdErrorChangeValue, 1459, 1464, "0 . 3", "", +30221, mmHg, 1467, 1472, "mm Hg", "", +30222, Dorzolamide, 1481, 1492, "dorzolamide", "", +30223, Timolol, 1495, 1502, "timolol", "", +30236, ObservedResult, 1511, 1553, "The 2 therapies were similarly effective .", "", +30242, ConclusionComment, 1567, 1692, "The latanoprost and dorzolamide / timolol combination were equally effective at lowering IOP compared to untreated baseline .", "", +30237, ObservedResult, 1571, 1582, "latanoprost", "", +30238, Dorzolamide, 1587, 1598, "dorzolamide", "", +30239, Timolol, 1601, 1608, "timolol", "", +30240, IOP, 1656, 1659, "IOP", "", +30241, PMID, 1700, 1708, "18327364", "", diff --git a/data/gl 18327364_tstrakeljahn.n-triples b/data/gl 18327364_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18327364_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18402717 copy_admin.annodb b/data/gl 18402717 copy_admin.annodb new file mode 100644 index 0000000..b655c41 --- /dev/null +++ b/data/gl 18402717 copy_admin.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15, Journal, 0, 17, "Curr Med Res Opin", "", " \"Curr Med Res Opin\"." +16, PublicationYear, 20, 24, "2008", "", " \"2008\"." +56, Brimonidine, 109, 127, "Brimonidine purite", "", +17, Title, 109, 247, "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .", "", " \"Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .\"." +59, DoseValue, 128, 133, "0 . 1", "", +61, Percentage, 134, 135, "%", "", +57, Brinzolamide, 143, 155, "brinzolamide", "", +60, DoseValue, 156, 157, "1", "", +62, Percentage, 158, 159, "%", "", +58, Latanoprost, 185, 196, "latanoprost", "", +18, Glaucoma, 214, 222, "glaucoma", "", " . ." +19, OcularHypertension, 226, 245, "ocular hypertension", "", " ." +20, Author, 248, 254, "Day DG", "", " \"Day DG\"." +21, Author, 263, 275, "Hollander DA", "", " \"Hollander DA\"." +22, USA, 340, 343, "USA", "", +23, ObjectiveDescription, 384, 597, "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .", "", " \"To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .\"." +63, Brimonidine, 429, 447, "brimonidine purite", "", " ." +65, DoseValue, 448, 453, "0 . 1", "", " \"0 . 1\"." +67, Percentage, 454, 455, "%", "", " ." +64, Brinzolamide, 473, 485, "brinzolamide", "", " ." +66, DoseValue, 486, 487, "1", "", " \"1\"." +68, Percentage, 488, 489, "%", "", " ." +116, Latanoprost, 525, 536, "latanoprost", "", +24, DoseValue, 537, 544, "0 . 005", "", +25, Percentage, 545, 546, "%", "", +26, Glaucoma, 564, 572, "glaucoma", "", +27, OcularHypertension, 576, 595, "ocular hypertension", "", +69, Randomized, 608, 618, "Randomized", "", " ." +28, SingleCenter, 621, 636, "single - center", "", " ." +35544, Blind, 654, 660, "masked", "", " ." +30, Parallel, 663, 671, "parallel", "", " ." +32, Precondition, 711, 763, "IOP > or = 18 mmHg while on once - daily latanoprost", "", " \"IOP > or = 18 mmHg while on once - daily latanoprost\"." +31, IOP, 711, 714, "IOP", "", +33, mmHg, 725, 729, "mmHg", "", +34, Frequency, 739, 751, "once - daily", "", " \"once - daily\"." +70, Latanoprost, 752, 763, "latanoprost", "", " . ." +71, Randomized, 769, 779, "randomized", "", +72, Brimonidine, 809, 827, "brimonidine purite", "", +35, Frequency, 828, 831, "TID", "", " \"TID\"." +36, NumberPatientsArm, 838, 840, "20", "", " \"20\"." +73, Brinzolamide, 846, 858, "brinzolamide", "", +37, Frequency, 859, 862, "TID", "", " \"TID\"." +38, NumberPatientsArm, 869, 871, "20", "", " \"20\"." +39, Duration, 878, 886, "3 months", "", " \"3 months\"." +40, IOP, 889, 909, "Intraocular pressure", "", +41, IOP, 912, 915, "IOP", "", +74, Latanoprost, 976, 987, "latanoprost", "", +76, TimePoint, 998, 1006, "baseline", "", +75, TimePoint, 1017, 1031, "1 and 3 months", "", +37059, TimePoint, 1023, 1031, "3 months", "", +77, Latanoprost, 1035, 1046, "latanoprost", "", +42, Eyedrops, 1145, 1153, "eye drop", "", " . ." +43, Mean, 1188, 1192, "mean", "", " . ." +78, Diurnal_IOP, 1193, 1204, "diurnal IOP", "", " ." +1, mmHg, 1234, 1238, "mmHg", "", " ." +79, Latanoprost, 1244, 1255, "latanoprost", "", +80, Brimonidine, 1288, 1306, "brimonidine purite", "", +2, BaseLineValue, 1309, 1315, "19 . 6", "", " \"19 . 6\"." +3, SdDevBL, 1322, 1328, "2 . 94", "", " \"2 . 94\"." +81, Brinzolamide, 1331, 1343, "brinzolamide", "", +4, BaseLineValue, 1346, 1352, "19 . 8", "", " \"19 . 8\"." +5, SdDevBL, 1359, 1365, "3 . 25", "", " \"3 . 25\"." +157, PvalueDiff, 1372, 1379, "0 . 846", "", +0, Mean, 1384, 1388, "Mean", "", +82, Diurnal_IOP, 1389, 1400, "diurnal IOP", "", +7, TimePoint, 1404, 1411, "Month 3", "", " \"Month 3\". \"Month 3\"." +8, ResultMeasuredValue, 1416, 1422, "16 . 3", "", " \"16 . 3\"." +9, SdDevResValue, 1429, 1435, "2 . 63", "", " \"2 . 63\"." +10, mmHg, 1436, 1440, "mmHg", "", +83, Brimonidine, 1446, 1464, "brimonidine purite", "", +11, ResultMeasuredValue, 1469, 1475, "17 . 8", "", " \"17 . 8\"." +12, SdDevResValue, 1482, 1488, "2 . 19", "", " \"2 . 19\"." +13, mmHg, 1489, 1493, "mmHg", "", +84, Brinzolamide, 1499, 1511, "brinzolamide", "", +170, PvalueDiff, 1518, 1525, "0 . 028", "", " \"0 . 028\"." +47, ObservedResult, 1530, 1749, "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .", "", " \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\"." +85, Brimonidine, 1548, 1566, "brimonidine purite", "", +44, IOP, 1584, 1587, "IOP", "", +86, Brinzolamide, 1602, 1614, "brinzolamide", "", +174, TimePoint, 1618, 1628, "10 a . m .", "", " \"10 a . m .\". \"10 a . m .\"." +45, PvalueDiff, 1631, 1642, "p < 0 . 001", "", " \"p < 0 . 001\"." +175, TimePoint, 1649, 1658, "4 p . m .", "", " \"4 p . m .\". \"4 p . m .\"." +177, PvalueDiff, 1661, 1672, "p = 0 . 050", "", " \"p = 0 . 050\"." +87, IOP, 1690, 1693, "IOP", "", +88, Brinzolamide, 1706, 1718, "brinzolamide", "", +181, TimePoint, 1722, 1731, "8 a . m .", "", " \"8 a . m .\". \"8 a . m .\"." +46, PvalueDiff, 1734, 1745, "p = 0 . 716", "", " \"p = 0 . 716\"." +189, ObservedResult, 1750, 1873, "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .", "", " \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\". \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\". \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\"." +92866, BlurredVison, 1750, 1764, "Blurred vision", "", " ." +89, TimePoint, 1768, 1775, "Month 1", "", " \"Month 1\"." +35547, EndPointDescription, 1780, 1792, "bitter taste", "AdverseEffect", " . ." +37060, TimePoint, 1796, 1804, "Months 1", "", " \"Months 1\"." +90, TimePoint, 1796, 1810, "Months 1 and 3", "", " \"Months 1 and 3\"." +91, Brinzolamide, 1849, 1861, "brinzolamide", "", +48, Eyedrops, 1862, 1871, "eye drops", "", +92, Brimonidine, 1887, 1905, "Brimonidine purite", "", +49, ConclusionComment, 1887, 2026, "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .", "", " \"Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .\"." +94, DoseValue, 1906, 1911, "0 . 1", "", +96, Percentage, 1912, 1913, "%", "", +53, IOP, 1943, 1946, "IOP", "", " \"Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs\"." +93, Brinzolamide, 1961, 1973, "brinzolamide", "", +95, DoseValue, 1974, 1975, "1", "", +97, Percentage, 1976, 1977, "%", "", +98, Latanoprost, 2013, 2024, "latanoprost", "", +50, ConclusionComment, 2027, 2074, "Both adjunctive therapies were well tolerated .", "", " \"Both adjunctive therapies were well tolerated .\"." +51, ConclusionComment, 2075, 2155, "Limitations of this study include the use of a single site and the sample size .", "", " \"Limitations of this study include the use of a single site and the sample size .\"." +55, SingleCenter, 2122, 2133, "single site", "", +52, ConclusionComment, 2156, 2264, "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs", "", " \"Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs\"." +92851, ProstaglandinAnalogs, 2243, 2264, "prostaglandin analogs", "", +54, PMID, 2309, 2317, "18402717", "", " \"18402717\"." diff --git a/data/gl 18402717 copy_admin.n-triples b/data/gl 18402717 copy_admin.n-triples new file mode 100644 index 0000000..9025182 --- /dev/null +++ b/data/gl 18402717 copy_admin.n-triples @@ -0,0 +1,206 @@ +# RDF export of group: Publication + . + "Publication 104759" . + "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension ." . + "Day DG" . + "2008" . + "Curr Med Res Opin" . + "18402717" . + . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 104766" . + "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension ." . + "3 months" . + . + . + . + "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost ." . + . + . + . + . + . + . + . + . + "Both adjunctive therapies were well tolerated ." . + "Limitations of this study include the use of a single site and the sample size ." . + "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs" . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 104782" . + "IOP > or = 18 mmHg while on once - daily latanoprost" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "blurr" . + . + . + . + . + . + "bitter" . + . + . + . + . + . +# RDF export of group: Arm + . + "brim" . + "20" . + . + . + . + . + . + . + . + . + "brin" . + "20" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "brim" . + . + "TID" . + . + . + "brin" . + . + "TID" . + . + . + "lat" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "brim" . + . + "0 . 1" . + . + . + . + "brin" . + . + "1" . + . + . + . + "lat" . + . + . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "19 . 6" . + "2 . 94" . + "16 . 3" . + "2 . 63" . + "Month 3" . + . + "iop2" . + . + "19 . 8" . + "3 . 25" . + "17 . 8" . + "2 . 19" . + "Month 3" . + . + "ioplow101" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "10 a . m ." . + . + "ioplow102" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "10 a . m ." . + . + "ioplow41" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "4 p . m ." . + . + "ioplow42" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "4 p . m ." . + . + "ioplow81" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "8 a . m ." . + . + "ioplow82" . + . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "8 a . m ." . + . + "blur2" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Month 1" . + . + "bitter2" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Months 1" . + . + "bitter32" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Months 1 and 3" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "0 . 028" . + . + . + . + "ioplow10" . + "p < 0 . 001" . + . + . + . + "ioplow4" . + "p = 0 . 050" . + . + . + . + "ioplow8" . + "p = 0 . 716" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18402717 copy_export.csv b/data/gl 18402717 copy_export.csv new file mode 100644 index 0000000..cd31eeb --- /dev/null +++ b/data/gl 18402717 copy_export.csv @@ -0,0 +1,493 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +827, 1, 1, 1, 0, 4, 0, 4, "Curr" +827, 1, 2, 2, 5, 8, 5, 8, "Med" +827, 1, 3, 3, 9, 12, 9, 12, "Res" +827, 1, 4, 4, 13, 17, 13, 17, "Opin" +827, 1, 5, 5, 18, 19, 18, 19, "." +827, 2, 1, 6, 0, 4, 20, 24, "2008" +827, 2, 2, 7, 5, 8, 25, 28, "May" +827, 2, 3, 8, 9, 10, 29, 30, ";" +827, 2, 4, 9, 11, 13, 31, 33, "24" +827, 2, 5, 10, 14, 15, 34, 35, "(" +827, 2, 6, 11, 16, 17, 36, 37, "5" +827, 2, 7, 12, 18, 19, 38, 39, ")" +827, 2, 8, 13, 20, 21, 40, 41, ":" +827, 2, 9, 14, 22, 26, 42, 46, "1435" +827, 2, 10, 15, 27, 28, 47, 48, "-" +827, 2, 11, 16, 29, 31, 49, 51, "42" +827, 2, 12, 17, 32, 33, 52, 53, "." +827, 2, 13, 18, 34, 37, 54, 57, "doi" +827, 2, 14, 19, 38, 39, 58, 59, ":" +827, 2, 15, 20, 40, 42, 60, 62, "10" +827, 2, 16, 21, 43, 44, 63, 64, "." +827, 2, 17, 22, 45, 49, 65, 69, "1185" +827, 2, 18, 23, 50, 51, 70, 71, "/" +827, 2, 19, 24, 52, 68, 72, 88, "030079908X301848" +827, 2, 20, 25, 69, 70, 89, 90, "." +827, 3, 1, 26, 0, 4, 91, 95, "Epub" +827, 3, 2, 27, 5, 9, 96, 100, "2008" +827, 3, 3, 28, 10, 13, 101, 104, "Apr" +827, 3, 4, 29, 14, 15, 105, 106, "9" +827, 3, 5, 30, 16, 17, 107, 108, "." +827, 4, 1, 31, 0, 11, 109, 120, "Brimonidine" +827, 4, 2, 32, 12, 18, 121, 127, "purite" +827, 4, 3, 33, 19, 20, 128, 129, "0" +827, 4, 4, 34, 21, 22, 130, 131, "." +827, 4, 5, 35, 23, 24, 132, 133, "1" +827, 4, 6, 36, 25, 26, 134, 135, "%" +827, 4, 7, 37, 27, 33, 136, 142, "versus" +827, 4, 8, 38, 34, 46, 143, 155, "brinzolamide" +827, 4, 9, 39, 47, 48, 156, 157, "1" +827, 4, 10, 40, 49, 50, 158, 159, "%" +827, 4, 11, 41, 51, 53, 160, 162, "as" +827, 4, 12, 42, 54, 64, 163, 173, "adjunctive" +827, 4, 13, 43, 65, 72, 174, 181, "therapy" +827, 4, 14, 44, 73, 75, 182, 184, "to" +827, 4, 15, 45, 76, 87, 185, 196, "latanoprost" +827, 4, 16, 46, 88, 90, 197, 199, "in" +827, 4, 17, 47, 91, 99, 200, 208, "patients" +827, 4, 18, 48, 100, 104, 209, 213, "with" +827, 4, 19, 49, 105, 113, 214, 222, "glaucoma" +827, 4, 20, 50, 114, 116, 223, 225, "or" +827, 4, 21, 51, 117, 123, 226, 232, "ocular" +827, 4, 22, 52, 124, 136, 233, 245, "hypertension" +827, 4, 23, 53, 137, 138, 246, 247, "." +827, 5, 1, 54, 0, 3, 248, 251, "Day" +827, 5, 2, 55, 4, 6, 252, 254, "DG" +827, 5, 3, 56, 7, 8, 255, 256, "(" +827, 5, 4, 57, 9, 10, 257, 258, "1" +827, 5, 5, 58, 11, 12, 259, 260, ")" +827, 5, 6, 59, 13, 14, 261, 262, "," +827, 5, 7, 60, 15, 24, 263, 272, "Hollander" +827, 5, 8, 61, 25, 27, 273, 275, "DA" +827, 5, 9, 62, 28, 29, 276, 277, "." +827, 6, 1, 63, 0, 6, 278, 284, "Author" +827, 6, 2, 64, 7, 18, 285, 296, "information" +827, 6, 3, 65, 19, 20, 297, 298, ":" +827, 6, 4, 66, 21, 22, 299, 300, "(" +827, 6, 5, 67, 23, 24, 301, 302, "1" +827, 6, 6, 68, 25, 26, 303, 304, ")" +827, 6, 7, 69, 27, 31, 305, 309, "Omni" +827, 6, 8, 70, 32, 35, 310, 313, "Eye" +827, 6, 9, 71, 36, 44, 314, 322, "Services" +827, 6, 10, 72, 45, 46, 323, 324, "," +827, 6, 11, 73, 47, 54, 325, 332, "Atlanta" +827, 6, 12, 74, 55, 56, 333, 334, "," +827, 6, 13, 75, 57, 59, 335, 337, "GA" +827, 6, 14, 76, 60, 61, 338, 339, "," +827, 6, 15, 77, 62, 65, 340, 343, "USA" +827, 6, 16, 78, 66, 67, 344, 345, "." +827, 7, 1, 79, 0, 7, 346, 353, "dougday" +827, 7, 2, 80, 8, 9, 354, 355, "@" +827, 7, 3, 81, 10, 19, 356, 365, "bellsouth" +827, 7, 4, 82, 20, 21, 366, 367, "." +827, 7, 5, 83, 22, 25, 368, 371, "net" +827, 7, 6, 84, 26, 35, 372, 381, "OBJECTIVE" +827, 7, 7, 85, 36, 37, 382, 383, ":" +827, 7, 8, 86, 38, 40, 384, 386, "To" +827, 7, 9, 87, 41, 49, 387, 395, "evaluate" +827, 7, 10, 88, 50, 53, 396, 399, "the" +827, 7, 11, 89, 54, 62, 400, 408, "efficacy" +827, 7, 12, 90, 63, 66, 409, 412, "and" +827, 7, 13, 91, 67, 79, 413, 425, "tolerability" +827, 7, 14, 92, 80, 82, 426, 428, "of" +827, 7, 15, 93, 83, 94, 429, 440, "brimonidine" +827, 7, 16, 94, 95, 101, 441, 447, "purite" +827, 7, 17, 95, 102, 103, 448, 449, "0" +827, 7, 18, 96, 104, 105, 450, 451, "." +827, 7, 19, 97, 106, 107, 452, 453, "1" +827, 7, 20, 98, 108, 109, 454, 455, "%" +827, 7, 21, 99, 110, 112, 456, 458, "in" +827, 7, 22, 100, 113, 123, 459, 469, "comparison" +827, 7, 23, 101, 124, 126, 470, 472, "to" +827, 7, 24, 102, 127, 139, 473, 485, "brinzolamide" +827, 7, 25, 103, 140, 141, 486, 487, "1" +827, 7, 26, 104, 142, 143, 488, 489, "%" +827, 7, 27, 105, 144, 148, 490, 494, "when" +827, 7, 28, 106, 149, 153, 495, 499, "used" +827, 7, 29, 107, 154, 156, 500, 502, "as" +827, 7, 30, 108, 157, 167, 503, 513, "adjunctive" +827, 7, 31, 109, 168, 175, 514, 521, "therapy" +827, 7, 32, 110, 176, 178, 522, 524, "to" +827, 7, 33, 111, 179, 190, 525, 536, "latanoprost" +827, 7, 34, 112, 191, 192, 537, 538, "0" +827, 7, 35, 113, 193, 194, 539, 540, "." +827, 7, 36, 114, 195, 198, 541, 544, "005" +827, 7, 37, 115, 199, 200, 545, 546, "%" +827, 7, 38, 116, 201, 203, 547, 549, "in" +827, 7, 39, 117, 204, 212, 550, 558, "patients" +827, 7, 40, 118, 213, 217, 559, 563, "with" +827, 7, 41, 119, 218, 226, 564, 572, "glaucoma" +827, 7, 42, 120, 227, 229, 573, 575, "or" +827, 7, 43, 121, 230, 236, 576, 582, "ocular" +827, 7, 44, 122, 237, 249, 583, 595, "hypertension" +827, 7, 45, 123, 250, 251, 596, 597, "." +827, 8, 1, 124, 0, 7, 598, 605, "METHODS" +827, 8, 2, 125, 8, 9, 606, 607, ":" +827, 8, 3, 126, 10, 20, 608, 618, "Randomized" +827, 8, 4, 127, 21, 22, 619, 620, "," +827, 8, 5, 128, 23, 29, 621, 627, "single" +827, 8, 6, 129, 30, 31, 628, 629, "-" +827, 8, 7, 130, 32, 38, 630, 636, "center" +827, 8, 8, 131, 39, 40, 637, 638, "," +827, 8, 9, 132, 41, 53, 639, 651, "investigator" +827, 8, 10, 133, 54, 55, 652, 653, "-" +827, 8, 11, 134, 56, 62, 654, 660, "masked" +827, 8, 12, 135, 63, 64, 661, 662, "," +827, 8, 13, 136, 65, 73, 663, 671, "parallel" +827, 8, 14, 137, 74, 75, 672, 673, "-" +827, 8, 15, 138, 76, 81, 674, 679, "group" +827, 8, 16, 139, 82, 90, 680, 688, "clinical" +827, 8, 17, 140, 91, 96, 689, 694, "study" +827, 8, 18, 141, 97, 98, 695, 696, "." +827, 9, 1, 142, 0, 8, 697, 705, "Patients" +827, 9, 2, 143, 9, 13, 706, 710, "with" +827, 9, 3, 144, 14, 17, 711, 714, "IOP" +827, 9, 4, 145, 18, 19, 715, 716, ">" +827, 9, 5, 146, 20, 22, 717, 719, "or" +827, 9, 6, 147, 23, 24, 720, 721, "=" +827, 9, 7, 148, 25, 27, 722, 724, "18" +827, 9, 8, 149, 28, 32, 725, 729, "mmHg" +827, 9, 9, 150, 33, 38, 730, 735, "while" +827, 9, 10, 151, 39, 41, 736, 738, "on" +827, 9, 11, 152, 42, 46, 739, 743, "once" +827, 9, 12, 153, 47, 48, 744, 745, "-" +827, 9, 13, 154, 49, 54, 746, 751, "daily" +827, 9, 14, 155, 55, 66, 752, 763, "latanoprost" +827, 9, 15, 156, 67, 71, 764, 768, "were" +827, 9, 16, 157, 72, 82, 769, 779, "randomized" +827, 9, 17, 158, 83, 85, 780, 782, "to" +827, 9, 18, 159, 86, 96, 783, 793, "adjunctive" +827, 9, 19, 160, 97, 106, 794, 803, "treatment" +827, 9, 20, 161, 107, 111, 804, 808, "with" +827, 9, 21, 162, 112, 123, 809, 820, "brimonidine" +827, 9, 22, 163, 124, 130, 821, 827, "purite" +827, 9, 23, 164, 131, 134, 828, 831, "TID" +827, 9, 24, 165, 135, 136, 832, 833, "(" +827, 9, 25, 166, 137, 138, 834, 835, "n" +827, 9, 26, 167, 139, 140, 836, 837, "=" +827, 9, 27, 168, 141, 143, 838, 840, "20" +827, 9, 28, 169, 144, 145, 841, 842, ")" +827, 9, 29, 170, 146, 148, 843, 845, "or" +827, 9, 30, 171, 149, 161, 846, 858, "brinzolamide" +827, 9, 31, 172, 162, 165, 859, 862, "TID" +827, 9, 32, 173, 166, 167, 863, 864, "(" +827, 9, 33, 174, 168, 169, 865, 866, "n" +827, 9, 34, 175, 170, 171, 867, 868, "=" +827, 9, 35, 176, 172, 174, 869, 871, "20" +827, 9, 36, 177, 175, 176, 872, 873, ")" +827, 9, 37, 178, 177, 180, 874, 877, "for" +827, 9, 38, 179, 181, 182, 878, 879, "3" +827, 9, 39, 180, 183, 189, 880, 886, "months" +827, 9, 40, 181, 190, 191, 887, 888, "." +827, 10, 1, 182, 0, 11, 889, 900, "Intraocular" +827, 10, 2, 183, 12, 20, 901, 909, "pressure" +827, 10, 3, 184, 21, 22, 910, 911, "(" +827, 10, 4, 185, 23, 26, 912, 915, "IOP" +827, 10, 5, 186, 27, 28, 916, 917, ")" +827, 10, 6, 187, 29, 32, 918, 921, "was" +827, 10, 7, 188, 33, 41, 922, 930, "measured" +827, 10, 8, 189, 42, 44, 931, 933, "at" +827, 10, 9, 190, 45, 46, 934, 935, "8" +827, 10, 10, 191, 47, 48, 936, 937, "a" +827, 10, 11, 192, 49, 50, 938, 939, "." +827, 10, 12, 193, 51, 52, 940, 941, "m" +827, 10, 13, 194, 53, 54, 942, 943, "." +827, 10, 14, 195, 55, 56, 944, 945, "," +827, 10, 15, 196, 57, 59, 946, 948, "10" +827, 10, 16, 197, 60, 61, 949, 950, "a" +827, 10, 17, 198, 62, 63, 951, 952, "." +827, 10, 18, 199, 64, 65, 953, 954, "m" +827, 10, 19, 200, 66, 67, 955, 956, "." +827, 10, 20, 201, 68, 69, 957, 958, "," +827, 10, 21, 202, 70, 73, 959, 962, "and" +827, 10, 22, 203, 74, 75, 963, 964, "4" +827, 10, 23, 204, 76, 77, 965, 966, "p" +827, 10, 24, 205, 78, 79, 967, 968, "." +827, 10, 25, 206, 80, 81, 969, 970, "m" +827, 10, 26, 207, 82, 83, 971, 972, "." +827, 10, 27, 208, 84, 86, 973, 975, "at" +827, 10, 28, 209, 87, 98, 976, 987, "latanoprost" +827, 10, 29, 210, 99, 100, 988, 989, "-" +827, 10, 30, 211, 101, 108, 990, 997, "treated" +827, 10, 31, 212, 109, 117, 998, 1006, "baseline" +827, 10, 32, 213, 118, 121, 1007, 1010, "and" +827, 10, 33, 214, 122, 127, 1011, 1016, "after" +827, 10, 34, 215, 128, 129, 1017, 1018, "1" +827, 10, 35, 216, 130, 133, 1019, 1022, "and" +827, 10, 36, 217, 134, 135, 1023, 1024, "3" +827, 10, 37, 218, 136, 142, 1025, 1031, "months" +827, 10, 38, 219, 143, 145, 1032, 1034, "of" +827, 10, 39, 220, 146, 157, 1035, 1046, "latanoprost" +827, 10, 40, 221, 158, 161, 1047, 1050, "and" +827, 10, 41, 222, 162, 172, 1051, 1061, "adjunctive" +827, 10, 42, 223, 173, 180, 1062, 1069, "therapy" +827, 10, 43, 224, 181, 182, 1070, 1071, "." +827, 11, 1, 225, 0, 1, 1072, 1073, "A" +827, 11, 2, 226, 2, 9, 1074, 1081, "patient" +827, 11, 3, 227, 10, 23, 1082, 1095, "questionnaire" +827, 11, 4, 228, 24, 27, 1096, 1099, "was" +827, 11, 5, 229, 28, 40, 1100, 1112, "administered" +827, 11, 6, 230, 41, 43, 1113, 1115, "to" +827, 11, 7, 231, 44, 52, 1116, 1124, "evaluate" +827, 11, 8, 232, 53, 56, 1125, 1128, "the" +827, 11, 9, 233, 57, 69, 1129, 1141, "tolerability" +827, 11, 10, 234, 70, 72, 1142, 1144, "of" +827, 11, 11, 235, 73, 76, 1145, 1148, "eye" +827, 11, 12, 236, 77, 81, 1149, 1153, "drop" +827, 11, 13, 237, 82, 94, 1154, 1166, "instillation" +827, 11, 14, 238, 95, 96, 1167, 1168, "." +827, 12, 1, 239, 0, 7, 1169, 1176, "RESULTS" +827, 12, 2, 240, 8, 9, 1177, 1178, ":" +827, 12, 3, 241, 10, 18, 1179, 1187, "Baseline" +827, 12, 4, 242, 19, 23, 1188, 1192, "mean" +827, 12, 5, 243, 24, 31, 1193, 1200, "diurnal" +827, 12, 6, 244, 32, 35, 1201, 1204, "IOP" +827, 12, 7, 245, 36, 37, 1205, 1206, "(" +827, 12, 8, 246, 38, 39, 1207, 1208, "+" +827, 12, 9, 247, 40, 41, 1209, 1210, "/" +827, 12, 10, 248, 42, 43, 1211, 1212, "-" +827, 12, 11, 249, 44, 52, 1213, 1221, "standard" +827, 12, 12, 250, 53, 62, 1222, 1231, "deviation" +827, 12, 13, 251, 63, 64, 1232, 1233, "," +827, 12, 14, 252, 65, 69, 1234, 1238, "mmHg" +827, 12, 15, 253, 70, 71, 1239, 1240, ")" +827, 12, 16, 254, 72, 74, 1241, 1243, "on" +827, 12, 17, 255, 75, 86, 1244, 1255, "latanoprost" +827, 12, 18, 256, 87, 90, 1256, 1259, "was" +827, 12, 19, 257, 91, 101, 1260, 1270, "comparable" +827, 12, 20, 258, 102, 109, 1271, 1278, "between" +827, 12, 21, 259, 110, 116, 1279, 1285, "groups" +827, 12, 22, 260, 117, 118, 1286, 1287, "(" +827, 12, 23, 261, 119, 130, 1288, 1299, "brimonidine" +827, 12, 24, 262, 131, 137, 1300, 1306, "purite" +827, 12, 25, 263, 138, 139, 1307, 1308, ":" +827, 12, 26, 264, 140, 142, 1309, 1311, "19" +827, 12, 27, 265, 143, 144, 1312, 1313, "." +827, 12, 28, 266, 145, 146, 1314, 1315, "6" +827, 12, 29, 267, 147, 148, 1316, 1317, "+" +827, 12, 30, 268, 149, 150, 1318, 1319, "/" +827, 12, 31, 269, 151, 152, 1320, 1321, "-" +827, 12, 32, 270, 153, 154, 1322, 1323, "2" +827, 12, 33, 271, 155, 156, 1324, 1325, "." +827, 12, 34, 272, 157, 159, 1326, 1328, "94" +827, 12, 35, 273, 160, 161, 1329, 1330, ";" +827, 12, 36, 274, 162, 174, 1331, 1343, "brinzolamide" +827, 12, 37, 275, 175, 176, 1344, 1345, ":" +827, 12, 38, 276, 177, 179, 1346, 1348, "19" +827, 12, 39, 277, 180, 181, 1349, 1350, "." +827, 12, 40, 278, 182, 183, 1351, 1352, "8" +827, 12, 41, 279, 184, 185, 1353, 1354, "+" +827, 12, 42, 280, 186, 187, 1355, 1356, "/" +827, 12, 43, 281, 188, 189, 1357, 1358, "-" +827, 12, 44, 282, 190, 191, 1359, 1360, "3" +827, 12, 45, 283, 192, 193, 1361, 1362, "." +827, 12, 46, 284, 194, 196, 1363, 1365, "25" +827, 12, 47, 285, 197, 198, 1366, 1367, ";" +827, 12, 48, 286, 199, 200, 1368, 1369, "p" +827, 12, 49, 287, 201, 202, 1370, 1371, "=" +827, 12, 50, 288, 203, 204, 1372, 1373, "0" +827, 12, 51, 289, 205, 206, 1374, 1375, "." +827, 12, 52, 290, 207, 210, 1376, 1379, "846" +827, 12, 53, 291, 211, 212, 1380, 1381, ")" +827, 12, 54, 292, 213, 214, 1382, 1383, "." +827, 13, 1, 293, 0, 4, 1384, 1388, "Mean" +827, 13, 2, 294, 5, 12, 1389, 1396, "diurnal" +827, 13, 3, 295, 13, 16, 1397, 1400, "IOP" +827, 13, 4, 296, 17, 19, 1401, 1403, "at" +827, 13, 5, 297, 20, 25, 1404, 1409, "Month" +827, 13, 6, 298, 26, 27, 1410, 1411, "3" +827, 13, 7, 299, 28, 31, 1412, 1415, "was" +827, 13, 8, 300, 32, 34, 1416, 1418, "16" +827, 13, 9, 301, 35, 36, 1419, 1420, "." +827, 13, 10, 302, 37, 38, 1421, 1422, "3" +827, 13, 11, 303, 39, 40, 1423, 1424, "+" +827, 13, 12, 304, 41, 42, 1425, 1426, "/" +827, 13, 13, 305, 43, 44, 1427, 1428, "-" +827, 13, 14, 306, 45, 46, 1429, 1430, "2" +827, 13, 15, 307, 47, 48, 1431, 1432, "." +827, 13, 16, 308, 49, 51, 1433, 1435, "63" +827, 13, 17, 309, 52, 56, 1436, 1440, "mmHg" +827, 13, 18, 310, 57, 61, 1441, 1445, "with" +827, 13, 19, 311, 62, 73, 1446, 1457, "brimonidine" +827, 13, 20, 312, 74, 80, 1458, 1464, "purite" +827, 13, 21, 313, 81, 84, 1465, 1468, "and" +827, 13, 22, 314, 85, 87, 1469, 1471, "17" +827, 13, 23, 315, 88, 89, 1472, 1473, "." +827, 13, 24, 316, 90, 91, 1474, 1475, "8" +827, 13, 25, 317, 92, 93, 1476, 1477, "+" +827, 13, 26, 318, 94, 95, 1478, 1479, "/" +827, 13, 27, 319, 96, 97, 1480, 1481, "-" +827, 13, 28, 320, 98, 99, 1482, 1483, "2" +827, 13, 29, 321, 100, 101, 1484, 1485, "." +827, 13, 30, 322, 102, 104, 1486, 1488, "19" +827, 13, 31, 323, 105, 109, 1489, 1493, "mmHg" +827, 13, 32, 324, 110, 114, 1494, 1498, "with" +827, 13, 33, 325, 115, 127, 1499, 1511, "brinzolamide" +827, 13, 34, 326, 128, 129, 1512, 1513, "(" +827, 13, 35, 327, 130, 131, 1514, 1515, "p" +827, 13, 36, 328, 132, 133, 1516, 1517, "=" +827, 13, 37, 329, 134, 135, 1518, 1519, "0" +827, 13, 38, 330, 136, 137, 1520, 1521, "." +827, 13, 39, 331, 138, 141, 1522, 1525, "028" +827, 13, 40, 332, 142, 143, 1526, 1527, ")" +827, 13, 41, 333, 144, 145, 1528, 1529, "." +827, 14, 1, 334, 0, 10, 1530, 1540, "Adjunctive" +827, 14, 2, 335, 11, 14, 1541, 1544, "use" +827, 14, 3, 336, 15, 17, 1545, 1547, "of" +827, 14, 4, 337, 18, 29, 1548, 1559, "brimonidine" +827, 14, 5, 338, 30, 36, 1560, 1566, "purite" +827, 14, 6, 339, 37, 45, 1567, 1575, "provided" +827, 14, 7, 340, 46, 53, 1576, 1583, "greater" +827, 14, 8, 341, 54, 57, 1584, 1587, "IOP" +827, 14, 9, 342, 58, 66, 1588, 1596, "lowering" +827, 14, 10, 343, 67, 71, 1597, 1601, "than" +827, 14, 11, 344, 72, 84, 1602, 1614, "brinzolamide" +827, 14, 12, 345, 85, 87, 1615, 1617, "at" +827, 14, 13, 346, 88, 90, 1618, 1620, "10" +827, 14, 14, 347, 91, 92, 1621, 1622, "a" +827, 14, 15, 348, 93, 94, 1623, 1624, "." +827, 14, 16, 349, 95, 96, 1625, 1626, "m" +827, 14, 17, 350, 97, 98, 1627, 1628, "." +827, 14, 18, 351, 99, 100, 1629, 1630, "(" +827, 14, 19, 352, 101, 102, 1631, 1632, "p" +827, 14, 20, 353, 103, 104, 1633, 1634, "<" +827, 14, 21, 354, 105, 106, 1635, 1636, "0" +827, 14, 22, 355, 107, 108, 1637, 1638, "." +827, 14, 23, 356, 109, 112, 1639, 1642, "001" +827, 14, 24, 357, 113, 114, 1643, 1644, ")" +827, 14, 25, 358, 115, 118, 1645, 1648, "and" +827, 14, 26, 359, 119, 120, 1649, 1650, "4" +827, 14, 27, 360, 121, 122, 1651, 1652, "p" +827, 14, 28, 361, 123, 124, 1653, 1654, "." +827, 14, 29, 362, 125, 126, 1655, 1656, "m" +827, 14, 30, 363, 127, 128, 1657, 1658, "." +827, 14, 31, 364, 129, 130, 1659, 1660, "(" +827, 14, 32, 365, 131, 132, 1661, 1662, "p" +827, 14, 33, 366, 133, 134, 1663, 1664, "=" +827, 14, 34, 367, 135, 136, 1665, 1666, "0" +827, 14, 35, 368, 137, 138, 1667, 1668, "." +827, 14, 36, 369, 139, 142, 1669, 1672, "050" +827, 14, 37, 370, 143, 144, 1673, 1674, ")" +827, 14, 38, 371, 145, 148, 1675, 1678, "and" +827, 14, 39, 372, 149, 159, 1679, 1689, "equivalent" +827, 14, 40, 373, 160, 163, 1690, 1693, "IOP" +827, 14, 41, 374, 164, 172, 1694, 1702, "lowering" +827, 14, 42, 375, 173, 175, 1703, 1705, "to" +827, 14, 43, 376, 176, 188, 1706, 1718, "brinzolamide" +827, 14, 44, 377, 189, 191, 1719, 1721, "at" +827, 14, 45, 378, 192, 193, 1722, 1723, "8" +827, 14, 46, 379, 194, 195, 1724, 1725, "a" +827, 14, 47, 380, 196, 197, 1726, 1727, "." +827, 14, 48, 381, 198, 199, 1728, 1729, "m" +827, 14, 49, 382, 200, 201, 1730, 1731, "." +827, 14, 50, 383, 202, 203, 1732, 1733, "(" +827, 14, 51, 384, 204, 205, 1734, 1735, "p" +827, 14, 52, 385, 206, 207, 1736, 1737, "=" +827, 14, 53, 386, 208, 209, 1738, 1739, "0" +827, 14, 54, 387, 210, 211, 1740, 1741, "." +827, 14, 55, 388, 212, 215, 1742, 1745, "716" +827, 14, 56, 389, 216, 217, 1746, 1747, ")" +827, 14, 57, 390, 218, 219, 1748, 1749, "." +827, 15, 1, 391, 0, 7, 1750, 1757, "Blurred" +827, 15, 2, 392, 8, 14, 1758, 1764, "vision" +827, 15, 3, 393, 15, 17, 1765, 1767, "at" +827, 15, 4, 394, 18, 23, 1768, 1773, "Month" +827, 15, 5, 395, 24, 25, 1774, 1775, "1" +827, 15, 6, 396, 26, 29, 1776, 1779, "and" +827, 15, 7, 397, 30, 36, 1780, 1786, "bitter" +827, 15, 8, 398, 37, 42, 1787, 1792, "taste" +827, 15, 9, 399, 43, 45, 1793, 1795, "at" +827, 15, 10, 400, 46, 52, 1796, 1802, "Months" +827, 15, 11, 401, 53, 54, 1803, 1804, "1" +827, 15, 12, 402, 55, 58, 1805, 1808, "and" +827, 15, 13, 403, 59, 60, 1809, 1810, "3" +827, 15, 14, 404, 61, 65, 1811, 1815, "were" +827, 15, 15, 405, 66, 70, 1816, 1820, "more" +827, 15, 16, 406, 71, 77, 1821, 1827, "common" +827, 15, 17, 407, 78, 82, 1828, 1832, "upon" +827, 15, 18, 408, 83, 95, 1833, 1845, "instillation" +827, 15, 19, 409, 96, 98, 1846, 1848, "of" +827, 15, 20, 410, 99, 111, 1849, 1861, "brinzolamide" +827, 15, 21, 411, 112, 115, 1862, 1865, "eye" +827, 15, 22, 412, 116, 121, 1866, 1871, "drops" +827, 15, 23, 413, 122, 123, 1872, 1873, "." +827, 16, 1, 414, 0, 10, 1874, 1884, "CONCLUSION" +827, 16, 2, 415, 11, 12, 1885, 1886, ":" +827, 16, 3, 416, 13, 24, 1887, 1898, "Brimonidine" +827, 16, 4, 417, 25, 31, 1899, 1905, "purite" +827, 16, 5, 418, 32, 33, 1906, 1907, "0" +827, 16, 6, 419, 34, 35, 1908, 1909, "." +827, 16, 7, 420, 36, 37, 1910, 1911, "1" +827, 16, 8, 421, 38, 39, 1912, 1913, "%" +827, 16, 9, 422, 40, 48, 1914, 1922, "provided" +827, 16, 10, 423, 49, 62, 1923, 1936, "significantly" +827, 16, 11, 424, 63, 68, 1937, 1942, "lower" +827, 16, 12, 425, 69, 72, 1943, 1946, "IOP" +827, 16, 13, 426, 73, 81, 1947, 1955, "compared" +827, 16, 14, 427, 82, 86, 1956, 1960, "with" +827, 16, 15, 428, 87, 99, 1961, 1973, "brinzolamide" +827, 16, 16, 429, 100, 101, 1974, 1975, "1" +827, 16, 17, 430, 102, 103, 1976, 1977, "%" +827, 16, 18, 431, 104, 108, 1978, 1982, "when" +827, 16, 19, 432, 109, 113, 1983, 1987, "used" +827, 16, 20, 433, 114, 116, 1988, 1990, "as" +827, 16, 21, 434, 117, 127, 1991, 2001, "adjunctive" +827, 16, 22, 435, 128, 135, 2002, 2009, "therapy" +827, 16, 23, 436, 136, 138, 2010, 2012, "to" +827, 16, 24, 437, 139, 150, 2013, 2024, "latanoprost" +827, 16, 25, 438, 151, 152, 2025, 2026, "." +827, 17, 1, 439, 0, 4, 2027, 2031, "Both" +827, 17, 2, 440, 5, 15, 2032, 2042, "adjunctive" +827, 17, 3, 441, 16, 25, 2043, 2052, "therapies" +827, 17, 4, 442, 26, 30, 2053, 2057, "were" +827, 17, 5, 443, 31, 35, 2058, 2062, "well" +827, 17, 6, 444, 36, 45, 2063, 2072, "tolerated" +827, 17, 7, 445, 46, 47, 2073, 2074, "." +827, 18, 1, 446, 0, 11, 2075, 2086, "Limitations" +827, 18, 2, 447, 12, 14, 2087, 2089, "of" +827, 18, 3, 448, 15, 19, 2090, 2094, "this" +827, 18, 4, 449, 20, 25, 2095, 2100, "study" +827, 18, 5, 450, 26, 33, 2101, 2108, "include" +827, 18, 6, 451, 34, 37, 2109, 2112, "the" +827, 18, 7, 452, 38, 41, 2113, 2116, "use" +827, 18, 8, 453, 42, 44, 2117, 2119, "of" +827, 18, 9, 454, 45, 46, 2120, 2121, "a" +827, 18, 10, 455, 47, 53, 2122, 2128, "single" +827, 18, 11, 456, 54, 58, 2129, 2133, "site" +827, 18, 12, 457, 59, 62, 2134, 2137, "and" +827, 18, 13, 458, 63, 66, 2138, 2141, "the" +827, 18, 14, 459, 67, 73, 2142, 2148, "sample" +827, 18, 15, 460, 74, 78, 2149, 2153, "size" +827, 18, 16, 461, 79, 80, 2154, 2155, "." +827, 19, 1, 462, 0, 10, 2156, 2166, "Additional" +827, 19, 2, 463, 11, 18, 2167, 2174, "studies" +827, 19, 3, 464, 19, 22, 2175, 2178, "are" +827, 19, 4, 465, 23, 29, 2179, 2185, "needed" +827, 19, 5, 466, 30, 32, 2186, 2188, "to" +827, 19, 6, 467, 33, 40, 2189, 2196, "further" +827, 19, 7, 468, 41, 49, 2197, 2205, "evaluate" +827, 19, 8, 469, 50, 55, 2206, 2211, "these" +827, 19, 9, 470, 56, 61, 2212, 2217, "drugs" +827, 19, 10, 471, 62, 64, 2218, 2220, "as" +827, 19, 11, 472, 65, 75, 2221, 2231, "adjunctive" +827, 19, 12, 473, 76, 83, 2232, 2239, "therapy" +827, 19, 13, 474, 84, 86, 2240, 2242, "to" +827, 19, 14, 475, 87, 100, 2243, 2256, "prostaglandin" +827, 19, 15, 476, 101, 108, 2257, 2264, "analogs" +827, 19, 16, 477, 109, 110, 2265, 2266, "." +827, 20, 1, 478, 0, 3, 2267, 2270, "DOI" +827, 20, 2, 479, 4, 5, 2271, 2272, ":" +827, 20, 3, 480, 6, 8, 2273, 2275, "10" +827, 20, 4, 481, 9, 10, 2276, 2277, "." +827, 20, 5, 482, 11, 15, 2278, 2282, "1185" +827, 20, 6, 483, 16, 17, 2283, 2284, "/" +827, 20, 7, 484, 18, 34, 2285, 2301, "030079908X301848" +827, 20, 8, 485, 35, 39, 2302, 2306, "PMID" +827, 20, 9, 486, 40, 41, 2307, 2308, ":" +827, 20, 10, 487, 42, 50, 2309, 2317, "18402717" +827, 20, 11, 488, 51, 52, 2318, 2319, "[" +827, 20, 12, 489, 53, 60, 2320, 2327, "Indexed" +827, 20, 13, 490, 61, 64, 2328, 2331, "for" +827, 20, 14, 491, 65, 72, 2332, 2339, "MEDLINE" +827, 20, 15, 492, 73, 74, 2340, 2341, "]" diff --git a/data/gl 18402717_admin.annodb b/data/gl 18402717_admin.annodb new file mode 100644 index 0000000..92aa832 --- /dev/null +++ b/data/gl 18402717_admin.annodb @@ -0,0 +1,111 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15, Journal, 0, 17, "Curr Med Res Opin", "", " \"Curr Med Res Opin\"." +16, PublicationYear, 20, 24, "2008", "", " \"2008\"." +17, Title, 109, 247, "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .", "", " \"Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .\"." +56, Brimonidine, 109, 127, "Brimonidine purite", "", +59, DoseValue, 128, 133, "0 . 1", "", +61, Percentage, 134, 135, "%", "", +57, Brinzolamide, 143, 155, "brinzolamide", "", +60, DoseValue, 156, 157, "1", "", +62, Percentage, 158, 159, "%", "", +58, Latanoprost, 185, 196, "latanoprost", "", +18, Glaucoma, 214, 222, "glaucoma", "", " . ." +19, OcularHypertension, 226, 245, "ocular hypertension", "", " ." +20, Author, 248, 254, "Day DG", "", " \"Day DG\"." +21, Author, 263, 275, "Hollander DA", "", " \"Hollander DA\"." +22, USA, 340, 343, "USA", "", " ." +23, ObjectiveDescription, 384, 597, "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .", "", " \"To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .\"." +63, Brimonidine, 429, 447, "brimonidine purite", "", " ." +65, DoseValue, 448, 453, "0 . 1", "", " \"0 . 1\"." +67, Percentage, 454, 455, "%", "", " ." +64, Brinzolamide, 473, 485, "brinzolamide", "", " ." +66, DoseValue, 486, 487, "1", "", " \"1\"." +68, Percentage, 488, 489, "%", "", " ." +116, Latanoprost, 525, 536, "latanoprost", "", +24, DoseValue, 537, 544, "0 . 005", "", +25, Percentage, 545, 546, "%", "", +26, Glaucoma, 564, 572, "glaucoma", "", +27, OcularHypertension, 576, 595, "ocular hypertension", "", +69, Randomized, 608, 618, "Randomized", "", " ." +28, SingleCenter, 621, 636, "single - center", "", " ." +35544, Blind, 654, 660, "masked", "", " ." +30, Parallel, 663, 671, "parallel", "", " ." +31, IOP, 711, 714, "IOP", "", +32, Precondition, 711, 763, "IOP > or = 18 mmHg while on once - daily latanoprost", "", " \"IOP > or = 18 mmHg while on once - daily latanoprost\"." +33, mmHg, 725, 729, "mmHg", "", +34, Frequency, 739, 751, "once - daily", "", +70, Latanoprost, 752, 763, "latanoprost", "", +71, Randomized, 769, 779, "randomized", "", +72, Brimonidine, 809, 827, "brimonidine purite", "", +35, Frequency, 828, 831, "TID", "", " \"TID\"." +36, NumberPatientsArm, 838, 840, "20", "", " \"20\"." +73, Brinzolamide, 846, 858, "brinzolamide", "", +37, Frequency, 859, 862, "TID", "", " \"TID\"." +38, NumberPatientsArm, 869, 871, "20", "", " \"20\"." +39, Duration, 878, 886, "3 months", "", " \"3 months\"." +40, IOP, 889, 909, "Intraocular pressure", "", +41, IOP, 912, 915, "IOP", "", +74, Latanoprost, 976, 987, "latanoprost", "", +76, TimePoint, 998, 1006, "baseline", "", +75, TimePoint, 1017, 1031, "1 and 3 months", "", +37059, TimePoint, 1023, 1031, "3 months", "", +77, Latanoprost, 1035, 1046, "latanoprost", "", +42, Eyedrops, 1145, 1153, "eye drop", "", " . ." +43, Mean, 1188, 1192, "mean", "", " . ." +78, Diurnal_IOP, 1193, 1204, "diurnal IOP", "", " ." +1, mmHg, 1234, 1238, "mmHg", "", +79, Latanoprost, 1244, 1255, "latanoprost", "", +80, Brimonidine, 1288, 1306, "brimonidine purite", "", +2, BaseLineValue, 1309, 1315, "19 . 6", "", " \"19 . 6\"." +3, SdDevBL, 1322, 1328, "2 . 94", "", " \"2 . 94\"." +81, Brinzolamide, 1331, 1343, "brinzolamide", "", +4, BaseLineValue, 1346, 1352, "19 . 8", "", " \"19 . 8\"." +5, SdDevBL, 1359, 1365, "3 . 25", "", " \"3 . 25\"." +157, PvalueDiff, 1372, 1379, "0 . 846", "", +0, Mean, 1384, 1388, "Mean", "", +82, Diurnal_IOP, 1389, 1400, "diurnal IOP", "", +7, TimePoint, 1404, 1411, "Month 3", "", " \"Month 3\"." +8, ResultMeasuredValue, 1416, 1422, "16 . 3", "", " \"16 . 3\"." +9, SdDevResValue, 1429, 1435, "2 . 63", "", " \"2 . 63\"." +10, mmHg, 1436, 1440, "mmHg", "", +83, Brimonidine, 1446, 1464, "brimonidine purite", "", +11, ResultMeasuredValue, 1469, 1475, "17 . 8", "", " \"17 . 8\"." +12, SdDevResValue, 1482, 1488, "2 . 19", "", " \"2 . 19\"." +13, mmHg, 1489, 1493, "mmHg", "", +84, Brinzolamide, 1499, 1511, "brinzolamide", "", +170, PvalueDiff, 1518, 1525, "0 . 028", "", " \"0 . 028\"." +47, ObservedResult, 1530, 1749, "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .", "", " \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\". \"Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .\"." +85, Brimonidine, 1548, 1566, "brimonidine purite", "", +44, IOP, 1584, 1587, "IOP", "", +86, Brinzolamide, 1602, 1614, "brinzolamide", "", +174, TimePoint, 1618, 1628, "10 a . m .", "", +45, PvalueDiff, 1631, 1642, "p < 0 . 001", "", +175, TimePoint, 1649, 1658, "4 p . m .", "", +177, PvalueDiff, 1661, 1672, "p = 0 . 050", "", +87, IOP, 1690, 1693, "IOP", "", +88, Brinzolamide, 1706, 1718, "brinzolamide", "", +181, TimePoint, 1722, 1731, "8 a . m .", "", +46, PvalueDiff, 1734, 1745, "p = 0 . 716", "", +92866, BlurredVison, 1750, 1764, "Blurred vision", "", " ." +189, ObservedResult, 1750, 1873, "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .", "", " \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\". \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\". \"Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .\"." +89, TimePoint, 1768, 1775, "Month 1", "", " \"Month 1\"." +35547, EndPointDescription, 1780, 1792, "bitter taste", "AdverseEffect", " . ." +90, TimePoint, 1796, 1810, "Months 1 and 3", "", " \"Months 1 and 3\"." +37060, TimePoint, 1796, 1804, "Months 1", "", " \"Months 1\"." +91, Brinzolamide, 1849, 1861, "brinzolamide", "", +48, Eyedrops, 1862, 1871, "eye drops", "", +49, ConclusionComment, 1887, 2026, "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .", "", " \"Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .\"." +92, Brimonidine, 1887, 1905, "Brimonidine purite", "", +94, DoseValue, 1906, 1911, "0 . 1", "", +96, Percentage, 1912, 1913, "%", "", +53, IOP, 1943, 1946, "IOP", "", " \"Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs\"." +93, Brinzolamide, 1961, 1973, "brinzolamide", "", +95, DoseValue, 1974, 1975, "1", "", +97, Percentage, 1976, 1977, "%", "", +98, Latanoprost, 2013, 2024, "latanoprost", "", +50, ConclusionComment, 2027, 2074, "Both adjunctive therapies were well tolerated .", "", " \"Both adjunctive therapies were well tolerated .\"." +51, ConclusionComment, 2075, 2155, "Limitations of this study include the use of a single site and the sample size .", "", " \"Limitations of this study include the use of a single site and the sample size .\"." +55, SingleCenter, 2122, 2133, "single site", "", +52, ConclusionComment, 2156, 2264, "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs", "", " \"Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs\"." +92851, ProstaglandinAnalogs, 2243, 2264, "prostaglandin analogs", "", +54, PMID, 2309, 2317, "18402717", "", " \"18402717\"." diff --git a/data/gl 18402717_admin.n-triples b/data/gl 18402717_admin.n-triples new file mode 100644 index 0000000..84fb4b0 --- /dev/null +++ b/data/gl 18402717_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication" . + "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension ." . + "Day DG" . + "2008" . + "Curr Med Res Opin" . + "18402717" . + . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension ." . + "3 months" . + . + . + . + "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost ." . + . + . + . + . + . + . + . + . + . + "Both adjunctive therapies were well tolerated ." . + "Limitations of this study include the use of a single site and the sample size ." . + "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs" . + . + . +# RDF export of group: Population + . + "Population" . + "IOP > or = 18 mmHg while on once - daily latanoprost" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint" . + . + . + . + . + . + . + "Endpoint_BV" . + . + . + . + . + . + "Endpoint_T" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_brim" . + "20" . + . + . + . + . + "Arm_brinz" . + "20" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_brim" . + "TID" . + . + . + . + "Intervention_brinz" . + "TID" . + . + . +# RDF export of group: Medication + . + "Medication_brim" . + . + "0 . 1" . + . + . + . + "Medication_brinz" . + . + "1" . + . + . +# RDF export of group: Outcome + . + "Outcome_brim" . + . + "19 . 6" . + "2 . 94" . + "16 . 3" . + "2 . 63" . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + "Month 3" . + . + "Outcome_brinz" . + . + "19 . 8" . + "3 . 25" . + "17 . 8" . + "2 . 19" . + "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) ." . + . + "Outcome_brinz_BV" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Month 1" . + . + "Outcome_brinz_T" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Months 1" . + . + "Outcome_brinz_T_3" . + . + "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops ." . + "Months 1 and 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "0 . 028" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18402717_export.csv b/data/gl 18402717_export.csv new file mode 100644 index 0000000..4533530 --- /dev/null +++ b/data/gl 18402717_export.csv @@ -0,0 +1,493 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +450, 1, 1, 1, 0, 4, 0, 4, "Curr" +450, 1, 2, 2, 5, 8, 5, 8, "Med" +450, 1, 3, 3, 9, 12, 9, 12, "Res" +450, 1, 4, 4, 13, 17, 13, 17, "Opin" +450, 1, 5, 5, 18, 19, 18, 19, "." +450, 2, 1, 6, 0, 4, 20, 24, "2008" +450, 2, 2, 7, 5, 8, 25, 28, "May" +450, 2, 3, 8, 9, 10, 29, 30, ";" +450, 2, 4, 9, 11, 13, 31, 33, "24" +450, 2, 5, 10, 14, 15, 34, 35, "(" +450, 2, 6, 11, 16, 17, 36, 37, "5" +450, 2, 7, 12, 18, 19, 38, 39, ")" +450, 2, 8, 13, 20, 21, 40, 41, ":" +450, 2, 9, 14, 22, 26, 42, 46, "1435" +450, 2, 10, 15, 27, 28, 47, 48, "-" +450, 2, 11, 16, 29, 31, 49, 51, "42" +450, 2, 12, 17, 32, 33, 52, 53, "." +450, 2, 13, 18, 34, 37, 54, 57, "doi" +450, 2, 14, 19, 38, 39, 58, 59, ":" +450, 2, 15, 20, 40, 42, 60, 62, "10" +450, 2, 16, 21, 43, 44, 63, 64, "." +450, 2, 17, 22, 45, 49, 65, 69, "1185" +450, 2, 18, 23, 50, 51, 70, 71, "/" +450, 2, 19, 24, 52, 68, 72, 88, "030079908X301848" +450, 2, 20, 25, 69, 70, 89, 90, "." +450, 3, 1, 26, 0, 4, 91, 95, "Epub" +450, 3, 2, 27, 5, 9, 96, 100, "2008" +450, 3, 3, 28, 10, 13, 101, 104, "Apr" +450, 3, 4, 29, 14, 15, 105, 106, "9" +450, 3, 5, 30, 16, 17, 107, 108, "." +450, 4, 1, 31, 0, 11, 109, 120, "Brimonidine" +450, 4, 2, 32, 12, 18, 121, 127, "purite" +450, 4, 3, 33, 19, 20, 128, 129, "0" +450, 4, 4, 34, 21, 22, 130, 131, "." +450, 4, 5, 35, 23, 24, 132, 133, "1" +450, 4, 6, 36, 25, 26, 134, 135, "%" +450, 4, 7, 37, 27, 33, 136, 142, "versus" +450, 4, 8, 38, 34, 46, 143, 155, "brinzolamide" +450, 4, 9, 39, 47, 48, 156, 157, "1" +450, 4, 10, 40, 49, 50, 158, 159, "%" +450, 4, 11, 41, 51, 53, 160, 162, "as" +450, 4, 12, 42, 54, 64, 163, 173, "adjunctive" +450, 4, 13, 43, 65, 72, 174, 181, "therapy" +450, 4, 14, 44, 73, 75, 182, 184, "to" +450, 4, 15, 45, 76, 87, 185, 196, "latanoprost" +450, 4, 16, 46, 88, 90, 197, 199, "in" +450, 4, 17, 47, 91, 99, 200, 208, "patients" +450, 4, 18, 48, 100, 104, 209, 213, "with" +450, 4, 19, 49, 105, 113, 214, 222, "glaucoma" +450, 4, 20, 50, 114, 116, 223, 225, "or" +450, 4, 21, 51, 117, 123, 226, 232, "ocular" +450, 4, 22, 52, 124, 136, 233, 245, "hypertension" +450, 4, 23, 53, 137, 138, 246, 247, "." +450, 5, 1, 54, 0, 3, 248, 251, "Day" +450, 5, 2, 55, 4, 6, 252, 254, "DG" +450, 5, 3, 56, 7, 8, 255, 256, "(" +450, 5, 4, 57, 9, 10, 257, 258, "1" +450, 5, 5, 58, 11, 12, 259, 260, ")" +450, 5, 6, 59, 13, 14, 261, 262, "," +450, 5, 7, 60, 15, 24, 263, 272, "Hollander" +450, 5, 8, 61, 25, 27, 273, 275, "DA" +450, 5, 9, 62, 28, 29, 276, 277, "." +450, 6, 1, 63, 0, 6, 278, 284, "Author" +450, 6, 2, 64, 7, 18, 285, 296, "information" +450, 6, 3, 65, 19, 20, 297, 298, ":" +450, 6, 4, 66, 21, 22, 299, 300, "(" +450, 6, 5, 67, 23, 24, 301, 302, "1" +450, 6, 6, 68, 25, 26, 303, 304, ")" +450, 6, 7, 69, 27, 31, 305, 309, "Omni" +450, 6, 8, 70, 32, 35, 310, 313, "Eye" +450, 6, 9, 71, 36, 44, 314, 322, "Services" +450, 6, 10, 72, 45, 46, 323, 324, "," +450, 6, 11, 73, 47, 54, 325, 332, "Atlanta" +450, 6, 12, 74, 55, 56, 333, 334, "," +450, 6, 13, 75, 57, 59, 335, 337, "GA" +450, 6, 14, 76, 60, 61, 338, 339, "," +450, 6, 15, 77, 62, 65, 340, 343, "USA" +450, 6, 16, 78, 66, 67, 344, 345, "." +450, 7, 1, 79, 0, 7, 346, 353, "dougday" +450, 7, 2, 80, 8, 9, 354, 355, "@" +450, 7, 3, 81, 10, 19, 356, 365, "bellsouth" +450, 7, 4, 82, 20, 21, 366, 367, "." +450, 7, 5, 83, 22, 25, 368, 371, "net" +450, 7, 6, 84, 26, 35, 372, 381, "OBJECTIVE" +450, 7, 7, 85, 36, 37, 382, 383, ":" +450, 7, 8, 86, 38, 40, 384, 386, "To" +450, 7, 9, 87, 41, 49, 387, 395, "evaluate" +450, 7, 10, 88, 50, 53, 396, 399, "the" +450, 7, 11, 89, 54, 62, 400, 408, "efficacy" +450, 7, 12, 90, 63, 66, 409, 412, "and" +450, 7, 13, 91, 67, 79, 413, 425, "tolerability" +450, 7, 14, 92, 80, 82, 426, 428, "of" +450, 7, 15, 93, 83, 94, 429, 440, "brimonidine" +450, 7, 16, 94, 95, 101, 441, 447, "purite" +450, 7, 17, 95, 102, 103, 448, 449, "0" +450, 7, 18, 96, 104, 105, 450, 451, "." +450, 7, 19, 97, 106, 107, 452, 453, "1" +450, 7, 20, 98, 108, 109, 454, 455, "%" +450, 7, 21, 99, 110, 112, 456, 458, "in" +450, 7, 22, 100, 113, 123, 459, 469, "comparison" +450, 7, 23, 101, 124, 126, 470, 472, "to" +450, 7, 24, 102, 127, 139, 473, 485, "brinzolamide" +450, 7, 25, 103, 140, 141, 486, 487, "1" +450, 7, 26, 104, 142, 143, 488, 489, "%" +450, 7, 27, 105, 144, 148, 490, 494, "when" +450, 7, 28, 106, 149, 153, 495, 499, "used" +450, 7, 29, 107, 154, 156, 500, 502, "as" +450, 7, 30, 108, 157, 167, 503, 513, "adjunctive" +450, 7, 31, 109, 168, 175, 514, 521, "therapy" +450, 7, 32, 110, 176, 178, 522, 524, "to" +450, 7, 33, 111, 179, 190, 525, 536, "latanoprost" +450, 7, 34, 112, 191, 192, 537, 538, "0" +450, 7, 35, 113, 193, 194, 539, 540, "." +450, 7, 36, 114, 195, 198, 541, 544, "005" +450, 7, 37, 115, 199, 200, 545, 546, "%" +450, 7, 38, 116, 201, 203, 547, 549, "in" +450, 7, 39, 117, 204, 212, 550, 558, "patients" +450, 7, 40, 118, 213, 217, 559, 563, "with" +450, 7, 41, 119, 218, 226, 564, 572, "glaucoma" +450, 7, 42, 120, 227, 229, 573, 575, "or" +450, 7, 43, 121, 230, 236, 576, 582, "ocular" +450, 7, 44, 122, 237, 249, 583, 595, "hypertension" +450, 7, 45, 123, 250, 251, 596, 597, "." +450, 8, 1, 124, 0, 7, 598, 605, "METHODS" +450, 8, 2, 125, 8, 9, 606, 607, ":" +450, 8, 3, 126, 10, 20, 608, 618, "Randomized" +450, 8, 4, 127, 21, 22, 619, 620, "," +450, 8, 5, 128, 23, 29, 621, 627, "single" +450, 8, 6, 129, 30, 31, 628, 629, "-" +450, 8, 7, 130, 32, 38, 630, 636, "center" +450, 8, 8, 131, 39, 40, 637, 638, "," +450, 8, 9, 132, 41, 53, 639, 651, "investigator" +450, 8, 10, 133, 54, 55, 652, 653, "-" +450, 8, 11, 134, 56, 62, 654, 660, "masked" +450, 8, 12, 135, 63, 64, 661, 662, "," +450, 8, 13, 136, 65, 73, 663, 671, "parallel" +450, 8, 14, 137, 74, 75, 672, 673, "-" +450, 8, 15, 138, 76, 81, 674, 679, "group" +450, 8, 16, 139, 82, 90, 680, 688, "clinical" +450, 8, 17, 140, 91, 96, 689, 694, "study" +450, 8, 18, 141, 97, 98, 695, 696, "." +450, 9, 1, 142, 0, 8, 697, 705, "Patients" +450, 9, 2, 143, 9, 13, 706, 710, "with" +450, 9, 3, 144, 14, 17, 711, 714, "IOP" +450, 9, 4, 145, 18, 19, 715, 716, ">" +450, 9, 5, 146, 20, 22, 717, 719, "or" +450, 9, 6, 147, 23, 24, 720, 721, "=" +450, 9, 7, 148, 25, 27, 722, 724, "18" +450, 9, 8, 149, 28, 32, 725, 729, "mmHg" +450, 9, 9, 150, 33, 38, 730, 735, "while" +450, 9, 10, 151, 39, 41, 736, 738, "on" +450, 9, 11, 152, 42, 46, 739, 743, "once" +450, 9, 12, 153, 47, 48, 744, 745, "-" +450, 9, 13, 154, 49, 54, 746, 751, "daily" +450, 9, 14, 155, 55, 66, 752, 763, "latanoprost" +450, 9, 15, 156, 67, 71, 764, 768, "were" +450, 9, 16, 157, 72, 82, 769, 779, "randomized" +450, 9, 17, 158, 83, 85, 780, 782, "to" +450, 9, 18, 159, 86, 96, 783, 793, "adjunctive" +450, 9, 19, 160, 97, 106, 794, 803, "treatment" +450, 9, 20, 161, 107, 111, 804, 808, "with" +450, 9, 21, 162, 112, 123, 809, 820, "brimonidine" +450, 9, 22, 163, 124, 130, 821, 827, "purite" +450, 9, 23, 164, 131, 134, 828, 831, "TID" +450, 9, 24, 165, 135, 136, 832, 833, "(" +450, 9, 25, 166, 137, 138, 834, 835, "n" +450, 9, 26, 167, 139, 140, 836, 837, "=" +450, 9, 27, 168, 141, 143, 838, 840, "20" +450, 9, 28, 169, 144, 145, 841, 842, ")" +450, 9, 29, 170, 146, 148, 843, 845, "or" +450, 9, 30, 171, 149, 161, 846, 858, "brinzolamide" +450, 9, 31, 172, 162, 165, 859, 862, "TID" +450, 9, 32, 173, 166, 167, 863, 864, "(" +450, 9, 33, 174, 168, 169, 865, 866, "n" +450, 9, 34, 175, 170, 171, 867, 868, "=" +450, 9, 35, 176, 172, 174, 869, 871, "20" +450, 9, 36, 177, 175, 176, 872, 873, ")" +450, 9, 37, 178, 177, 180, 874, 877, "for" +450, 9, 38, 179, 181, 182, 878, 879, "3" +450, 9, 39, 180, 183, 189, 880, 886, "months" +450, 9, 40, 181, 190, 191, 887, 888, "." +450, 10, 1, 182, 0, 11, 889, 900, "Intraocular" +450, 10, 2, 183, 12, 20, 901, 909, "pressure" +450, 10, 3, 184, 21, 22, 910, 911, "(" +450, 10, 4, 185, 23, 26, 912, 915, "IOP" +450, 10, 5, 186, 27, 28, 916, 917, ")" +450, 10, 6, 187, 29, 32, 918, 921, "was" +450, 10, 7, 188, 33, 41, 922, 930, "measured" +450, 10, 8, 189, 42, 44, 931, 933, "at" +450, 10, 9, 190, 45, 46, 934, 935, "8" +450, 10, 10, 191, 47, 48, 936, 937, "a" +450, 10, 11, 192, 49, 50, 938, 939, "." +450, 10, 12, 193, 51, 52, 940, 941, "m" +450, 10, 13, 194, 53, 54, 942, 943, "." +450, 10, 14, 195, 55, 56, 944, 945, "," +450, 10, 15, 196, 57, 59, 946, 948, "10" +450, 10, 16, 197, 60, 61, 949, 950, "a" +450, 10, 17, 198, 62, 63, 951, 952, "." +450, 10, 18, 199, 64, 65, 953, 954, "m" +450, 10, 19, 200, 66, 67, 955, 956, "." +450, 10, 20, 201, 68, 69, 957, 958, "," +450, 10, 21, 202, 70, 73, 959, 962, "and" +450, 10, 22, 203, 74, 75, 963, 964, "4" +450, 10, 23, 204, 76, 77, 965, 966, "p" +450, 10, 24, 205, 78, 79, 967, 968, "." +450, 10, 25, 206, 80, 81, 969, 970, "m" +450, 10, 26, 207, 82, 83, 971, 972, "." +450, 10, 27, 208, 84, 86, 973, 975, "at" +450, 10, 28, 209, 87, 98, 976, 987, "latanoprost" +450, 10, 29, 210, 99, 100, 988, 989, "-" +450, 10, 30, 211, 101, 108, 990, 997, "treated" +450, 10, 31, 212, 109, 117, 998, 1006, "baseline" +450, 10, 32, 213, 118, 121, 1007, 1010, "and" +450, 10, 33, 214, 122, 127, 1011, 1016, "after" +450, 10, 34, 215, 128, 129, 1017, 1018, "1" +450, 10, 35, 216, 130, 133, 1019, 1022, "and" +450, 10, 36, 217, 134, 135, 1023, 1024, "3" +450, 10, 37, 218, 136, 142, 1025, 1031, "months" +450, 10, 38, 219, 143, 145, 1032, 1034, "of" +450, 10, 39, 220, 146, 157, 1035, 1046, "latanoprost" +450, 10, 40, 221, 158, 161, 1047, 1050, "and" +450, 10, 41, 222, 162, 172, 1051, 1061, "adjunctive" +450, 10, 42, 223, 173, 180, 1062, 1069, "therapy" +450, 10, 43, 224, 181, 182, 1070, 1071, "." +450, 11, 1, 225, 0, 1, 1072, 1073, "A" +450, 11, 2, 226, 2, 9, 1074, 1081, "patient" +450, 11, 3, 227, 10, 23, 1082, 1095, "questionnaire" +450, 11, 4, 228, 24, 27, 1096, 1099, "was" +450, 11, 5, 229, 28, 40, 1100, 1112, "administered" +450, 11, 6, 230, 41, 43, 1113, 1115, "to" +450, 11, 7, 231, 44, 52, 1116, 1124, "evaluate" +450, 11, 8, 232, 53, 56, 1125, 1128, "the" +450, 11, 9, 233, 57, 69, 1129, 1141, "tolerability" +450, 11, 10, 234, 70, 72, 1142, 1144, "of" +450, 11, 11, 235, 73, 76, 1145, 1148, "eye" +450, 11, 12, 236, 77, 81, 1149, 1153, "drop" +450, 11, 13, 237, 82, 94, 1154, 1166, "instillation" +450, 11, 14, 238, 95, 96, 1167, 1168, "." +450, 12, 1, 239, 0, 7, 1169, 1176, "RESULTS" +450, 12, 2, 240, 8, 9, 1177, 1178, ":" +450, 12, 3, 241, 10, 18, 1179, 1187, "Baseline" +450, 12, 4, 242, 19, 23, 1188, 1192, "mean" +450, 12, 5, 243, 24, 31, 1193, 1200, "diurnal" +450, 12, 6, 244, 32, 35, 1201, 1204, "IOP" +450, 12, 7, 245, 36, 37, 1205, 1206, "(" +450, 12, 8, 246, 38, 39, 1207, 1208, "+" +450, 12, 9, 247, 40, 41, 1209, 1210, "/" +450, 12, 10, 248, 42, 43, 1211, 1212, "-" +450, 12, 11, 249, 44, 52, 1213, 1221, "standard" +450, 12, 12, 250, 53, 62, 1222, 1231, "deviation" +450, 12, 13, 251, 63, 64, 1232, 1233, "," +450, 12, 14, 252, 65, 69, 1234, 1238, "mmHg" +450, 12, 15, 253, 70, 71, 1239, 1240, ")" +450, 12, 16, 254, 72, 74, 1241, 1243, "on" +450, 12, 17, 255, 75, 86, 1244, 1255, "latanoprost" +450, 12, 18, 256, 87, 90, 1256, 1259, "was" +450, 12, 19, 257, 91, 101, 1260, 1270, "comparable" +450, 12, 20, 258, 102, 109, 1271, 1278, "between" +450, 12, 21, 259, 110, 116, 1279, 1285, "groups" +450, 12, 22, 260, 117, 118, 1286, 1287, "(" +450, 12, 23, 261, 119, 130, 1288, 1299, "brimonidine" +450, 12, 24, 262, 131, 137, 1300, 1306, "purite" +450, 12, 25, 263, 138, 139, 1307, 1308, ":" +450, 12, 26, 264, 140, 142, 1309, 1311, "19" +450, 12, 27, 265, 143, 144, 1312, 1313, "." +450, 12, 28, 266, 145, 146, 1314, 1315, "6" +450, 12, 29, 267, 147, 148, 1316, 1317, "+" +450, 12, 30, 268, 149, 150, 1318, 1319, "/" +450, 12, 31, 269, 151, 152, 1320, 1321, "-" +450, 12, 32, 270, 153, 154, 1322, 1323, "2" +450, 12, 33, 271, 155, 156, 1324, 1325, "." +450, 12, 34, 272, 157, 159, 1326, 1328, "94" +450, 12, 35, 273, 160, 161, 1329, 1330, ";" +450, 12, 36, 274, 162, 174, 1331, 1343, "brinzolamide" +450, 12, 37, 275, 175, 176, 1344, 1345, ":" +450, 12, 38, 276, 177, 179, 1346, 1348, "19" +450, 12, 39, 277, 180, 181, 1349, 1350, "." +450, 12, 40, 278, 182, 183, 1351, 1352, "8" +450, 12, 41, 279, 184, 185, 1353, 1354, "+" +450, 12, 42, 280, 186, 187, 1355, 1356, "/" +450, 12, 43, 281, 188, 189, 1357, 1358, "-" +450, 12, 44, 282, 190, 191, 1359, 1360, "3" +450, 12, 45, 283, 192, 193, 1361, 1362, "." +450, 12, 46, 284, 194, 196, 1363, 1365, "25" +450, 12, 47, 285, 197, 198, 1366, 1367, ";" +450, 12, 48, 286, 199, 200, 1368, 1369, "p" +450, 12, 49, 287, 201, 202, 1370, 1371, "=" +450, 12, 50, 288, 203, 204, 1372, 1373, "0" +450, 12, 51, 289, 205, 206, 1374, 1375, "." +450, 12, 52, 290, 207, 210, 1376, 1379, "846" +450, 12, 53, 291, 211, 212, 1380, 1381, ")" +450, 12, 54, 292, 213, 214, 1382, 1383, "." +450, 13, 1, 293, 0, 4, 1384, 1388, "Mean" +450, 13, 2, 294, 5, 12, 1389, 1396, "diurnal" +450, 13, 3, 295, 13, 16, 1397, 1400, "IOP" +450, 13, 4, 296, 17, 19, 1401, 1403, "at" +450, 13, 5, 297, 20, 25, 1404, 1409, "Month" +450, 13, 6, 298, 26, 27, 1410, 1411, "3" +450, 13, 7, 299, 28, 31, 1412, 1415, "was" +450, 13, 8, 300, 32, 34, 1416, 1418, "16" +450, 13, 9, 301, 35, 36, 1419, 1420, "." +450, 13, 10, 302, 37, 38, 1421, 1422, "3" +450, 13, 11, 303, 39, 40, 1423, 1424, "+" +450, 13, 12, 304, 41, 42, 1425, 1426, "/" +450, 13, 13, 305, 43, 44, 1427, 1428, "-" +450, 13, 14, 306, 45, 46, 1429, 1430, "2" +450, 13, 15, 307, 47, 48, 1431, 1432, "." +450, 13, 16, 308, 49, 51, 1433, 1435, "63" +450, 13, 17, 309, 52, 56, 1436, 1440, "mmHg" +450, 13, 18, 310, 57, 61, 1441, 1445, "with" +450, 13, 19, 311, 62, 73, 1446, 1457, "brimonidine" +450, 13, 20, 312, 74, 80, 1458, 1464, "purite" +450, 13, 21, 313, 81, 84, 1465, 1468, "and" +450, 13, 22, 314, 85, 87, 1469, 1471, "17" +450, 13, 23, 315, 88, 89, 1472, 1473, "." +450, 13, 24, 316, 90, 91, 1474, 1475, "8" +450, 13, 25, 317, 92, 93, 1476, 1477, "+" +450, 13, 26, 318, 94, 95, 1478, 1479, "/" +450, 13, 27, 319, 96, 97, 1480, 1481, "-" +450, 13, 28, 320, 98, 99, 1482, 1483, "2" +450, 13, 29, 321, 100, 101, 1484, 1485, "." +450, 13, 30, 322, 102, 104, 1486, 1488, "19" +450, 13, 31, 323, 105, 109, 1489, 1493, "mmHg" +450, 13, 32, 324, 110, 114, 1494, 1498, "with" +450, 13, 33, 325, 115, 127, 1499, 1511, "brinzolamide" +450, 13, 34, 326, 128, 129, 1512, 1513, "(" +450, 13, 35, 327, 130, 131, 1514, 1515, "p" +450, 13, 36, 328, 132, 133, 1516, 1517, "=" +450, 13, 37, 329, 134, 135, 1518, 1519, "0" +450, 13, 38, 330, 136, 137, 1520, 1521, "." +450, 13, 39, 331, 138, 141, 1522, 1525, "028" +450, 13, 40, 332, 142, 143, 1526, 1527, ")" +450, 13, 41, 333, 144, 145, 1528, 1529, "." +450, 14, 1, 334, 0, 10, 1530, 1540, "Adjunctive" +450, 14, 2, 335, 11, 14, 1541, 1544, "use" +450, 14, 3, 336, 15, 17, 1545, 1547, "of" +450, 14, 4, 337, 18, 29, 1548, 1559, "brimonidine" +450, 14, 5, 338, 30, 36, 1560, 1566, "purite" +450, 14, 6, 339, 37, 45, 1567, 1575, "provided" +450, 14, 7, 340, 46, 53, 1576, 1583, "greater" +450, 14, 8, 341, 54, 57, 1584, 1587, "IOP" +450, 14, 9, 342, 58, 66, 1588, 1596, "lowering" +450, 14, 10, 343, 67, 71, 1597, 1601, "than" +450, 14, 11, 344, 72, 84, 1602, 1614, "brinzolamide" +450, 14, 12, 345, 85, 87, 1615, 1617, "at" +450, 14, 13, 346, 88, 90, 1618, 1620, "10" +450, 14, 14, 347, 91, 92, 1621, 1622, "a" +450, 14, 15, 348, 93, 94, 1623, 1624, "." +450, 14, 16, 349, 95, 96, 1625, 1626, "m" +450, 14, 17, 350, 97, 98, 1627, 1628, "." +450, 14, 18, 351, 99, 100, 1629, 1630, "(" +450, 14, 19, 352, 101, 102, 1631, 1632, "p" +450, 14, 20, 353, 103, 104, 1633, 1634, "<" +450, 14, 21, 354, 105, 106, 1635, 1636, "0" +450, 14, 22, 355, 107, 108, 1637, 1638, "." +450, 14, 23, 356, 109, 112, 1639, 1642, "001" +450, 14, 24, 357, 113, 114, 1643, 1644, ")" +450, 14, 25, 358, 115, 118, 1645, 1648, "and" +450, 14, 26, 359, 119, 120, 1649, 1650, "4" +450, 14, 27, 360, 121, 122, 1651, 1652, "p" +450, 14, 28, 361, 123, 124, 1653, 1654, "." +450, 14, 29, 362, 125, 126, 1655, 1656, "m" +450, 14, 30, 363, 127, 128, 1657, 1658, "." +450, 14, 31, 364, 129, 130, 1659, 1660, "(" +450, 14, 32, 365, 131, 132, 1661, 1662, "p" +450, 14, 33, 366, 133, 134, 1663, 1664, "=" +450, 14, 34, 367, 135, 136, 1665, 1666, "0" +450, 14, 35, 368, 137, 138, 1667, 1668, "." +450, 14, 36, 369, 139, 142, 1669, 1672, "050" +450, 14, 37, 370, 143, 144, 1673, 1674, ")" +450, 14, 38, 371, 145, 148, 1675, 1678, "and" +450, 14, 39, 372, 149, 159, 1679, 1689, "equivalent" +450, 14, 40, 373, 160, 163, 1690, 1693, "IOP" +450, 14, 41, 374, 164, 172, 1694, 1702, "lowering" +450, 14, 42, 375, 173, 175, 1703, 1705, "to" +450, 14, 43, 376, 176, 188, 1706, 1718, "brinzolamide" +450, 14, 44, 377, 189, 191, 1719, 1721, "at" +450, 14, 45, 378, 192, 193, 1722, 1723, "8" +450, 14, 46, 379, 194, 195, 1724, 1725, "a" +450, 14, 47, 380, 196, 197, 1726, 1727, "." +450, 14, 48, 381, 198, 199, 1728, 1729, "m" +450, 14, 49, 382, 200, 201, 1730, 1731, "." +450, 14, 50, 383, 202, 203, 1732, 1733, "(" +450, 14, 51, 384, 204, 205, 1734, 1735, "p" +450, 14, 52, 385, 206, 207, 1736, 1737, "=" +450, 14, 53, 386, 208, 209, 1738, 1739, "0" +450, 14, 54, 387, 210, 211, 1740, 1741, "." +450, 14, 55, 388, 212, 215, 1742, 1745, "716" +450, 14, 56, 389, 216, 217, 1746, 1747, ")" +450, 14, 57, 390, 218, 219, 1748, 1749, "." +450, 15, 1, 391, 0, 7, 1750, 1757, "Blurred" +450, 15, 2, 392, 8, 14, 1758, 1764, "vision" +450, 15, 3, 393, 15, 17, 1765, 1767, "at" +450, 15, 4, 394, 18, 23, 1768, 1773, "Month" +450, 15, 5, 395, 24, 25, 1774, 1775, "1" +450, 15, 6, 396, 26, 29, 1776, 1779, "and" +450, 15, 7, 397, 30, 36, 1780, 1786, "bitter" +450, 15, 8, 398, 37, 42, 1787, 1792, "taste" +450, 15, 9, 399, 43, 45, 1793, 1795, "at" +450, 15, 10, 400, 46, 52, 1796, 1802, "Months" +450, 15, 11, 401, 53, 54, 1803, 1804, "1" +450, 15, 12, 402, 55, 58, 1805, 1808, "and" +450, 15, 13, 403, 59, 60, 1809, 1810, "3" +450, 15, 14, 404, 61, 65, 1811, 1815, "were" +450, 15, 15, 405, 66, 70, 1816, 1820, "more" +450, 15, 16, 406, 71, 77, 1821, 1827, "common" +450, 15, 17, 407, 78, 82, 1828, 1832, "upon" +450, 15, 18, 408, 83, 95, 1833, 1845, "instillation" +450, 15, 19, 409, 96, 98, 1846, 1848, "of" +450, 15, 20, 410, 99, 111, 1849, 1861, "brinzolamide" +450, 15, 21, 411, 112, 115, 1862, 1865, "eye" +450, 15, 22, 412, 116, 121, 1866, 1871, "drops" +450, 15, 23, 413, 122, 123, 1872, 1873, "." +450, 16, 1, 414, 0, 10, 1874, 1884, "CONCLUSION" +450, 16, 2, 415, 11, 12, 1885, 1886, ":" +450, 16, 3, 416, 13, 24, 1887, 1898, "Brimonidine" +450, 16, 4, 417, 25, 31, 1899, 1905, "purite" +450, 16, 5, 418, 32, 33, 1906, 1907, "0" +450, 16, 6, 419, 34, 35, 1908, 1909, "." +450, 16, 7, 420, 36, 37, 1910, 1911, "1" +450, 16, 8, 421, 38, 39, 1912, 1913, "%" +450, 16, 9, 422, 40, 48, 1914, 1922, "provided" +450, 16, 10, 423, 49, 62, 1923, 1936, "significantly" +450, 16, 11, 424, 63, 68, 1937, 1942, "lower" +450, 16, 12, 425, 69, 72, 1943, 1946, "IOP" +450, 16, 13, 426, 73, 81, 1947, 1955, "compared" +450, 16, 14, 427, 82, 86, 1956, 1960, "with" +450, 16, 15, 428, 87, 99, 1961, 1973, "brinzolamide" +450, 16, 16, 429, 100, 101, 1974, 1975, "1" +450, 16, 17, 430, 102, 103, 1976, 1977, "%" +450, 16, 18, 431, 104, 108, 1978, 1982, "when" +450, 16, 19, 432, 109, 113, 1983, 1987, "used" +450, 16, 20, 433, 114, 116, 1988, 1990, "as" +450, 16, 21, 434, 117, 127, 1991, 2001, "adjunctive" +450, 16, 22, 435, 128, 135, 2002, 2009, "therapy" +450, 16, 23, 436, 136, 138, 2010, 2012, "to" +450, 16, 24, 437, 139, 150, 2013, 2024, "latanoprost" +450, 16, 25, 438, 151, 152, 2025, 2026, "." +450, 17, 1, 439, 0, 4, 2027, 2031, "Both" +450, 17, 2, 440, 5, 15, 2032, 2042, "adjunctive" +450, 17, 3, 441, 16, 25, 2043, 2052, "therapies" +450, 17, 4, 442, 26, 30, 2053, 2057, "were" +450, 17, 5, 443, 31, 35, 2058, 2062, "well" +450, 17, 6, 444, 36, 45, 2063, 2072, "tolerated" +450, 17, 7, 445, 46, 47, 2073, 2074, "." +450, 18, 1, 446, 0, 11, 2075, 2086, "Limitations" +450, 18, 2, 447, 12, 14, 2087, 2089, "of" +450, 18, 3, 448, 15, 19, 2090, 2094, "this" +450, 18, 4, 449, 20, 25, 2095, 2100, "study" +450, 18, 5, 450, 26, 33, 2101, 2108, "include" +450, 18, 6, 451, 34, 37, 2109, 2112, "the" +450, 18, 7, 452, 38, 41, 2113, 2116, "use" +450, 18, 8, 453, 42, 44, 2117, 2119, "of" +450, 18, 9, 454, 45, 46, 2120, 2121, "a" +450, 18, 10, 455, 47, 53, 2122, 2128, "single" +450, 18, 11, 456, 54, 58, 2129, 2133, "site" +450, 18, 12, 457, 59, 62, 2134, 2137, "and" +450, 18, 13, 458, 63, 66, 2138, 2141, "the" +450, 18, 14, 459, 67, 73, 2142, 2148, "sample" +450, 18, 15, 460, 74, 78, 2149, 2153, "size" +450, 18, 16, 461, 79, 80, 2154, 2155, "." +450, 19, 1, 462, 0, 10, 2156, 2166, "Additional" +450, 19, 2, 463, 11, 18, 2167, 2174, "studies" +450, 19, 3, 464, 19, 22, 2175, 2178, "are" +450, 19, 4, 465, 23, 29, 2179, 2185, "needed" +450, 19, 5, 466, 30, 32, 2186, 2188, "to" +450, 19, 6, 467, 33, 40, 2189, 2196, "further" +450, 19, 7, 468, 41, 49, 2197, 2205, "evaluate" +450, 19, 8, 469, 50, 55, 2206, 2211, "these" +450, 19, 9, 470, 56, 61, 2212, 2217, "drugs" +450, 19, 10, 471, 62, 64, 2218, 2220, "as" +450, 19, 11, 472, 65, 75, 2221, 2231, "adjunctive" +450, 19, 12, 473, 76, 83, 2232, 2239, "therapy" +450, 19, 13, 474, 84, 86, 2240, 2242, "to" +450, 19, 14, 475, 87, 100, 2243, 2256, "prostaglandin" +450, 19, 15, 476, 101, 108, 2257, 2264, "analogs" +450, 19, 16, 477, 109, 110, 2265, 2266, "." +450, 20, 1, 478, 0, 3, 2267, 2270, "DOI" +450, 20, 2, 479, 4, 5, 2271, 2272, ":" +450, 20, 3, 480, 6, 8, 2273, 2275, "10" +450, 20, 4, 481, 9, 10, 2276, 2277, "." +450, 20, 5, 482, 11, 15, 2278, 2282, "1185" +450, 20, 6, 483, 16, 17, 2283, 2284, "/" +450, 20, 7, 484, 18, 34, 2285, 2301, "030079908X301848" +450, 20, 8, 485, 35, 39, 2302, 2306, "PMID" +450, 20, 9, 486, 40, 41, 2307, 2308, ":" +450, 20, 10, 487, 42, 50, 2309, 2317, "18402717" +450, 20, 11, 488, 51, 52, 2318, 2319, "[" +450, 20, 12, 489, 53, 60, 2320, 2327, "Indexed" +450, 20, 13, 490, 61, 64, 2328, 2331, "for" +450, 20, 14, 491, 65, 72, 2332, 2339, "MEDLINE" +450, 20, 15, 492, 73, 74, 2340, 2341, "]" diff --git a/data/gl 18402717_jshahinitiran.annodb b/data/gl 18402717_jshahinitiran.annodb new file mode 100644 index 0000000..be28878 --- /dev/null +++ b/data/gl 18402717_jshahinitiran.annodb @@ -0,0 +1,100 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11786, Journal, 0, 17, "Curr Med Res Opin", "", +11787, PublicationYear, 20, 24, "2008", "", +11788, Title, 109, 247, "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .", "", +28128, Brimonidine, 109, 127, "Brimonidine purite", "", +28131, DoseValue, 128, 133, "0 . 1", "", +28133, Percentage, 134, 135, "%", "", +28129, Brinzolamide, 143, 155, "brinzolamide", "", +28132, DoseValue, 156, 157, "1", "", +28134, Percentage, 158, 159, "%", "", +28130, Latanoprost, 185, 196, "latanoprost", "", +11792, Glaucoma, 214, 222, "glaucoma", "", +11793, OcularHypertension, 226, 245, "ocular hypertension", "", +11798, Author, 248, 254, "Day DG", "", +11799, Author, 263, 275, "Hollander DA", "", +11800, USA, 340, 343, "USA", "", +11801, ObjectiveDescription, 384, 597, "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .", "", +28135, Brimonidine, 429, 447, "brimonidine purite", "", +28137, DoseValue, 448, 453, "0 . 1", "", +28139, Percentage, 454, 455, "%", "", +28136, Brinzolamide, 473, 485, "brinzolamide", "", +28138, DoseValue, 486, 487, "1", "", +28140, Percentage, 488, 489, "%", "", +11809, DoseValue, 537, 544, "0 . 005", "", +11810, Percentage, 545, 546, "%", "", +11811, Glaucoma, 564, 572, "glaucoma", "", +11812, OcularHypertension, 576, 595, "ocular hypertension", "", +28141, Randomized, 608, 618, "Randomized", "", +11814, SingleCenter, 621, 636, "single - center", "", +11815, Blind, 639, 660, "investigator - masked", "", +11816, Parallel, 663, 671, "parallel", "", +11817, IOP, 711, 714, "IOP", "", +11818, Precondition, 711, 763, "IOP > or = 18 mmHg while on once - daily latanoprost", "", +11819, mmHg, 725, 729, "mmHg", "", +11820, Frequency, 739, 751, "once - daily", "", +28142, Latanoprost, 752, 763, "latanoprost", "", +28143, Randomized, 769, 779, "randomized", "", +28144, Brimonidine, 809, 827, "brimonidine purite", "", +11824, Frequency, 828, 831, "TID", "", +11825, NumberPatientsArm, 838, 840, "20", "", +28145, Brinzolamide, 846, 858, "brinzolamide", "", +11827, Frequency, 859, 862, "TID", "", +11828, NumberPatientsArm, 869, 871, "20", "", +11829, Duration, 878, 886, "3 months", "", +11830, IOP, 889, 909, "Intraocular pressure", "", +11831, IOP, 912, 915, "IOP", "", +28146, Latanoprost, 976, 987, "latanoprost", "", +28148, TimePoint, 998, 1006, "baseline", "", +28147, TimePoint, 1017, 1031, "1 and 3 months", "", +28149, Latanoprost, 1035, 1046, "latanoprost", "", +11836, Eyedrops, 1145, 1153, "eye drop", "", +11837, Mean, 1188, 1192, "mean", "", +28150, Diurnal_IOP, 1193, 1204, "diurnal IOP", "", +254, mmHg, 1234, 1238, "mmHg", "", +28151, Latanoprost, 1244, 1255, "latanoprost", "", +28152, Brimonidine, 1288, 1306, "brimonidine purite", "", +255, BaseLineValue, 1309, 1315, "19 . 6", "Bri", +256, SdDevBL, 1322, 1328, "2 . 94", "Bri", +28153, Brinzolamide, 1331, 1343, "brinzolamide", "", +257, BaseLineValue, 1346, 1352, "19 . 8", "Brz", +258, SdDevBL, 1359, 1365, "3 . 25", "Brz", +259, PValueBL, 1368, 1379, "p = 0 . 846", "", +251, Mean, 1384, 1388, "Mean", "", +28154, Diurnal_IOP, 1389, 1400, "diurnal IOP", "", +260, TimePoint, 1404, 1411, "Month 3", "", +261, ResultMeasuredValue, 1416, 1422, "16 . 3", "Bri", +262, SdDevResValue, 1429, 1435, "2 . 63", "Bri", +263, mmHg, 1436, 1440, "mmHg", "Bri", +28155, Brimonidine, 1446, 1464, "brimonidine purite", "", +264, ResultMeasuredValue, 1469, 1475, "17 . 8", "Brz", +265, SdDevResValue, 1482, 1488, "2 . 19", "Brz", +266, mmHg, 1489, 1493, "mmHg", "Brz", +28156, Brinzolamide, 1499, 1511, "brinzolamide", "", +267, PValueResValue, 1514, 1525, "p = 0 . 028", "", +11848, ObservedResult, 1530, 1749, "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .", "", +28157, Brimonidine, 1548, 1566, "brimonidine purite", "", +11844, IOP, 1584, 1587, "IOP", "", +28158, Brinzolamide, 1602, 1614, "brinzolamide", "", +11846, PvalueDiff, 1631, 1642, "p < 0 . 001", "", +28159, IOP, 1690, 1693, "IOP", "", +28160, Brinzolamide, 1706, 1718, "brinzolamide", "", +11847, PvalueDiff, 1734, 1745, "p = 0 . 716", "", +28161, TimePoint, 1768, 1775, "Month 1", "", +28162, TimePoint, 1796, 1810, "Months 1 and 3", "", +28163, Brinzolamide, 1849, 1861, "brinzolamide", "", +11853, Eyedrops, 1862, 1871, "eye drops", "", +28164, Brimonidine, 1887, 1905, "Brimonidine purite", "", +11854, ConclusionComment, 1887, 2026, "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .", "", +28167, DoseValue, 1906, 1911, "0 . 1", "", +28169, Percentage, 1912, 1913, "%", "", +11861, IOP, 1943, 1946, "IOP", "", +28165, Brinzolamide, 1961, 1973, "brinzolamide", "", +28168, DoseValue, 1974, 1975, "1", "", +28170, Percentage, 1976, 1977, "%", "", +28171, Latanoprost, 2013, 2024, "latanoprost", "", +11855, ConclusionComment, 2027, 2074, "Both adjunctive therapies were well tolerated .", "", +11856, ConclusionComment, 2075, 2155, "Limitations of this study include the use of a single site and the sample size .", "", +11867, SingleCenter, 2122, 2133, "single site", "", +11857, ConclusionComment, 2156, 2264, "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs", "", +11866, PMID, 2309, 2317, "18402717", "", diff --git a/data/gl 18402717_jshahinitiran.n-triples b/data/gl 18402717_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18402717_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18402717_tstrakeljahn.annodb b/data/gl 18402717_tstrakeljahn.annodb new file mode 100644 index 0000000..4046324 --- /dev/null +++ b/data/gl 18402717_tstrakeljahn.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +30048, Journal, 0, 17, "Curr Med Res Opin", "", +30049, PublicationYear, 20, 24, "2008", "", +30050, Brimonidine, 109, 127, "Brimonidine purite", "", +30059, Title, 109, 247, "Brimonidine purite 0 . 1 % versus brinzolamide 1 % as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension .", "", +30055, DoseValue, 128, 133, "0 . 1", "", +30057, Percentage, 134, 135, "%", "", +30051, Brinzolamide, 143, 155, "brinzolamide", "", +30056, DoseValue, 156, 157, "1", "", +30058, Percentage, 158, 159, "%", "", +30052, Latanoprost, 185, 196, "latanoprost", "", +30053, Glaucoma, 214, 222, "glaucoma", "", +30054, OcularHypertension, 226, 245, "ocular hypertension", "", +30060, Author, 248, 254, "Day DG", "", +30061, Author, 263, 275, "Hollander DA", "", +30062, USA, 340, 343, "USA", "", +30074, ObjectiveDescription, 384, 597, "To evaluate the efficacy and tolerability of brimonidine purite 0 . 1 % in comparison to brinzolamide 1 % when used as adjunctive therapy to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .", "", +30063, Brimonidine, 429, 447, "brimonidine purite", "", +30068, DoseValue, 448, 453, "0 . 1", "", +30071, Percentage, 454, 455, "%", "", +30064, Brinzolamide, 473, 485, "brinzolamide", "", +30069, DoseValue, 486, 487, "1", "", +30072, Percentage, 488, 489, "%", "", +30065, Latanoprost, 525, 536, "latanoprost", "", +30070, DoseValue, 537, 544, "0 . 005", "", +30073, Percentage, 545, 546, "%", "", +30066, Glaucoma, 564, 572, "glaucoma", "", +30067, OcularHypertension, 576, 595, "ocular hypertension", "", +30075, Randomized, 608, 618, "Randomized", "", +30076, SingleCenter, 621, 636, "single - center", "", +30077, Blind, 639, 660, "investigator - masked", "", +30080, Parallel, 663, 679, "parallel - group", "", +30078, ClinicalTrial, 680, 694, "clinical study", "", +30081, IOP, 711, 714, "IOP", "", +30082, mmHg, 725, 729, "mmHg", "", +30083, Frequency, 739, 751, "once - daily", "", +30084, Latanoprost, 752, 763, "latanoprost", "", +30085, Randomized, 769, 779, "randomized", "", +30086, Brimonidine, 809, 827, "brimonidine purite", "", +30087, Frequency, 828, 831, "TID", "", +30088, NumberPatientsArm, 838, 840, "20", "", +30091, Brinzolamide, 846, 858, "brinzolamide", "", +30092, Frequency, 859, 862, "TID", "", +30089, NumberPatientsArm, 869, 871, "20", "", +30090, Duration, 878, 886, "3 months", "", +30093, IOP, 889, 909, "Intraocular pressure", "", +30094, IOP, 912, 915, "IOP", "", +30095, Latanoprost, 976, 987, "latanoprost", "", +30096, Latanoprost, 1035, 1046, "latanoprost", "", +30097, Eyedrops, 1145, 1153, "eye drop", "", +30098, Mean, 1188, 1192, "mean", "", +30099, Diurnal_IOP, 1193, 1204, "diurnal IOP", "", +30108, mmHg, 1234, 1238, "mmHg", "", +30100, Latanoprost, 1244, 1255, "latanoprost", "", +30101, Brimonidine, 1288, 1306, "brimonidine purite", "", +30103, BaseLineValue, 1309, 1315, "19 . 6", "", +30105, SdDevBL, 1316, 1328, "+ / - 2 . 94", "", +30102, Brinzolamide, 1331, 1343, "brinzolamide", "", +30104, BaseLineValue, 1346, 1352, "19 . 8", "", +30106, SdDevBL, 1353, 1365, "+ / - 3 . 25", "", +30107, PvalueDiff, 1372, 1379, "0 . 846", "", +30110, Mean, 1384, 1388, "Mean", "", +30111, Diurnal_IOP, 1389, 1400, "diurnal IOP", "", +30109, TimePoint, 1404, 1411, "Month 3", "", +30112, ResultMeasuredValue, 1416, 1422, "16 . 3", "", +30113, SdDevResValue, 1423, 1435, "+ / - 2 . 63", "", +30114, mmHg, 1436, 1440, "mmHg", "", +30115, Brimonidine, 1446, 1464, "brimonidine purite", "", +30116, ResultMeasuredValue, 1469, 1475, "17 . 8", "", +30117, SdDevResValue, 1476, 1488, "+ / - 2 . 19", "", +30118, mmHg, 1489, 1493, "mmHg", "", +30119, Brinzolamide, 1499, 1511, "brinzolamide", "", +30120, PvalueDiff, 1518, 1525, "0 . 028", "", +30132, ObservedResult, 1530, 1749, "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a . m . ( p < 0 . 001 ) and 4 p . m . ( p = 0 . 050 ) and equivalent IOP lowering to brinzolamide at 8 a . m . ( p = 0 . 716 ) .", "", +30121, Brimonidine, 1548, 1566, "brimonidine purite", "", +30122, IOP, 1584, 1587, "IOP", "", +30123, Brinzolamide, 1602, 1614, "brinzolamide", "", +30124, TimePoint, 1618, 1628, "10 a . m .", "", +30126, PvalueDiff, 1631, 1642, "p < 0 . 001", "", +30125, TimePoint, 1649, 1658, "4 p . m .", "", +30127, PvalueDiff, 1661, 1672, "p = 0 . 050", "", +30129, IOP, 1690, 1693, "IOP", "", +30130, Brinzolamide, 1706, 1718, "brinzolamide", "", +30131, TimePoint, 1722, 1731, "8 a . m .", "", +30128, PvalueDiff, 1734, 1745, "p = 0 . 716", "", +30139, ObservedResult, 1750, 1873, "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops .", "", +30133, TimePoint, 1768, 1775, "Month 1", "", +30134, TimePoint, 1796, 1810, "Months 1 and 3", "", +30137, Brinzolamide, 1849, 1861, "brinzolamide", "", +30138, Eyedrops, 1862, 1871, "eye drops", "", +30140, Brimonidine, 1887, 1905, "Brimonidine purite", "", +30147, ConclusionComment, 1887, 2026, "Brimonidine purite 0 . 1 % provided significantly lower IOP compared with brinzolamide 1 % when used as adjunctive therapy to latanoprost .", "", +30143, DoseValue, 1906, 1911, "0 . 1", "", +30145, Percentage, 1912, 1913, "%", "", +30141, Brinzolamide, 1961, 1973, "brinzolamide", "", +30144, DoseValue, 1974, 1975, "1", "", +30146, Percentage, 1976, 1977, "%", "", +30142, Latanoprost, 2013, 2024, "latanoprost", "", +30148, ConclusionComment, 2027, 2074, "Both adjunctive therapies were well tolerated .", "", +30149, ConclusionComment, 2075, 2155, "Limitations of this study include the use of a single site and the sample size .", "", +30150, ConclusionComment, 2156, 2264, "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs", "", +30151, Drug, 2243, 2256, "prostaglandin", "Prostaglandin", +30152, PMID, 2309, 2317, "18402717", "", diff --git a/data/gl 18402717_tstrakeljahn.n-triples b/data/gl 18402717_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18402717_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18535605_admin.annodb b/data/gl 18535605_admin.annodb new file mode 100644 index 0000000..417eae7 --- /dev/null +++ b/data/gl 18535605_admin.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2009", "", " \"2009\"." +2, Bimatoprost, 102, 113, "Bimatoprost", "", +6, Title, 102, 220, "Bimatoprost / timolol fixed combination vs latanoprost / timolol fixed combination in open - angle glaucoma patients .", "", " \"Bimatoprost / timolol fixed combination vs latanoprost / timolol fixed combination in open - angle glaucoma patients .\"." +7, Bima/TimFC, 102, 141, "Bimatoprost / timolol fixed combination", "", +3, Timolol, 116, 123, "timolol", "", +4, Latanoprost, 145, 156, "latanoprost", "", +8, Lat/TimFC, 145, 184, "latanoprost / timolol fixed combination", "", +5, Timolol, 159, 166, "timolol", "", +9, OpenAngleGlaucoma, 188, 209, "open - angle glaucoma", "", " ." +10, Author, 221, 231, "Martinez A", "", " \"Martinez A\"." +11, Author, 240, 249, "Sanchez M", "", " \"Sanchez M\"." +12, Spain, 380, 385, "Spain", "", " ." +13, ObjectiveDescription, 426, 618, "To evaluate bimatoprost / timolol fixed combination ( BTFC ) vs latanoprost / timolol fixed combination ( LTFC ) given each evening over the 12 - h intraocular pressure ( IOP ) diurnal curve .", "", " \"To evaluate bimatoprost / timolol fixed combination ( BTFC ) vs latanoprost / timolol fixed combination ( LTFC ) given each evening over the 12 - h intraocular pressure ( IOP ) diurnal curve .\"." +14, Bimatoprost, 438, 449, "bimatoprost", "", +17, Bima/TimFC, 438, 477, "bimatoprost / timolol fixed combination", "", " ." +15, Timolol, 452, 459, "timolol", "", +18, Bima/TimFC, 480, 484, "BTFC", "", +19, Latanoprost, 490, 501, "latanoprost", "", +97, Lat/TimFC, 490, 529, "latanoprost / timolol fixed combination", "", " ." +16, Timolol, 504, 511, "timolol", "", +98, Lat/TimFC, 532, 536, "LTFC", "", +100, Diurnal_IOP, 574, 610, "intraocular pressure ( IOP ) diurnal", "", " ." +23, IOP, 597, 600, "IOP", "", +24, NumberPatientsCT, 651, 653, "54", "", " \"54\"." +87724, Precondition, 654, 662, "patients", "", +106, NumberAffected, 665, 667, "24", "", +87724, Precondition, 668, 702, "with primary open - angle glaucoma", "", +25, Primary_OpenAngleGlaucoma, 673, 702, "primary open - angle glaucoma", "", " ." +26, Primary_OpenAngleGlaucoma, 705, 709, "POAG", "", +107, NumberAffected, 716, 718, "30", "", +87724, Precondition, 719, 750, "with pseudoexfoliative glaucoma", "", +27, Glaucoma, 724, 750, "pseudoexfoliative glaucoma", "", " . ." +28, Glaucoma, 753, 756, "PXG", "", +29, Prospective, 783, 794, "prospective", "", " ." +30, Randomized, 797, 807, "randomized", "", " ." +31, Blind, 810, 828, "evaluator - masked", "", " ." +32, SingleCenter, 829, 842, "single centre", "", " ." +33, Crossover, 843, 852, "crossover", "", " ." +87723, Precondition, 861, 946, "Patients with an IOP of > or = 19 mmHg , under treatment with prostaglandin analogues", "", " \"Patients with an IOP of > or = 19 mmHg , under treatment with prostaglandin analogues\"." +34, IOP, 878, 881, "IOP", "", +35, mmHg, 895, 899, "mmHg", "", +87714, Drug, 923, 946, "prostaglandin analogues", "", +38, Randomized, 954, 964, "randomized", "", +39, Bima/TimFC, 968, 972, "BTFC", "", +40, Lat/TimFC, 976, 980, "LTFC", "", +41, Duration, 987, 996, "12 - week", "", " \"12 - week\"." +42, Duration, 1022, 1030, "6 - week", "", +43, Timolol, 1050, 1065, "timolol maleate", "", +44, DoseValue, 1066, 1071, "0 . 5", "", +121, Percentage, 1072, 1073, "%", "", +87728, DoseDescription, 1076, 1096, "one drop in each eye", "", +45, Frequency, 1097, 1111, "twice each day", "", +46, IOP, 1205, 1208, "IOP", "", +87730, TimePoint, 1250, 1258, "baseline", "", +47, Timolol, 1282, 1297, "timolol maleate", "", +48, DoseValue, 1298, 1303, "0 . 5", "", +129, Percentage, 1304, 1305, "%", "", +49, Frequency, 1306, 1309, "BID", "", +50, TimePoint, 1314, 1327, "week 6 and 12", "", +51, TimePoint, 1314, 1320, "week 6", "", +52, IOP, 1377, 1380, "IOP", "", +53, Mean, 1383, 1387, "mean", "", " . ." +54, BaseLineValue, 1409, 1415, "22 . 0", "", " \"22 . 0\". \"22 . 0\"." +55, SdDevBL, 1418, 1423, "1 . 0", "", " \"1 . 0\". \"1 . 0\"." +56, mmHg, 1426, 1430, "mmHg", "", " ." +87731, TimePoint, 1434, 1442, "baseline", "", +57, ResultMeasuredValue, 1445, 1451, "17 . 7", "", " \"17 . 7\"." +59, SdDevResValue, 1454, 1459, "0 . 8", "", " \"0 . 8\"." +62, mmHg, 1462, 1466, "mmHg", "", +63, Bima/TimFC, 1470, 1474, "BTFC", "", +58, ResultMeasuredValue, 1481, 1487, "18 . 5", "", " \"18 . 5\"." +60, SdDevResValue, 1490, 1495, "0 . 8", "", " \"0 . 8\"." +61, mmHg, 1498, 1502, "mmHg", "", +64, Lat/TimFC, 1506, 1510, "LTFC", "", +146, PvalueDiff, 1513, 1524, "P < 0 . 001", "", " \"P < 0 . 001\"." +147, TimePoint, 1610, 1614, "0800", "", +148, TimePoint, 1617, 1621, "0100", "", +149, TimePoint, 1624, 1628, "1200", "", +150, TimePoint, 1631, 1635, "1800", "", +151, TimePoint, 1642, 1646, "2000", "", +66, Bima/TimFC, 1658, 1662, "BTFC", "", +153, PvalueDiff, 1706, 1717, "P < 0 . 001", "", +159, ObservedResult, 1720, 1779, "The most frequently reported adverse event in the study was", "", +68, ConjunctivalHyperemia, 1780, 1803, "conjunctival hyperaemia", "", " ." +158, ObservedResult, 1806, 1898, "Average hyperaemia scores were slightly but significantly lower in the LTFC treatment period", "", " \"Average hyperaemia scores were slightly but significantly lower in the LTFC treatment period\"." +69, ConjunctivalHyperemia, 1814, 1824, "hyperaemia", "", +70, Lat/TimFC, 1877, 1881, "LTFC", "", +157, PvalueDiff, 1901, 1911, "P = 0 . 04", "", +72, ConclusionComment, 1929, 2114, "This study suggests that the evening - dosed BTFC provides better IOP control than that of LTFC over 12 h . However , the IOP difference was small and may not be clinically meaningful .", "", " \"This study suggests that the evening - dosed BTFC provides better IOP control than that of LTFC over 12 h . However , the IOP difference was small and may not be clinically meaningful .\"." +73, Bima/TimFC, 1974, 1978, "BTFC", "", +74, IOP, 1995, 1998, "IOP", "", +75, Lat/TimFC, 2020, 2024, "LTFC", "", +76, IOP, 2051, 2054, "IOP", "", +77, PMID, 2157, 2165, "18535605", "", " \"18535605\"." diff --git a/data/gl 18535605_admin.n-triples b/data/gl 18535605_admin.n-triples new file mode 100644 index 0000000..dea25d0 --- /dev/null +++ b/data/gl 18535605_admin.n-triples @@ -0,0 +1,111 @@ +# RDF export of group: Publication + . + "Publication" . + "Bimatoprost / timolol fixed combination vs latanoprost / timolol fixed combination in open - angle glaucoma patients ." . + "Martinez A" . + "2009" . + "Eye ( Lond ) ." . + "18535605" . + . + "Sanchez M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate bimatoprost / timolol fixed combination ( BTFC ) vs latanoprost / timolol fixed combination ( LTFC ) given each evening over the 12 - h intraocular pressure ( IOP ) diurnal curve ." . + "54" . + "12 - week" . + . + . + . + "This study suggests that the evening - dosed BTFC provides better IOP control than that of LTFC over 12 h . However , the IOP difference was small and may not be clinically meaningful ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with an IOP of > or = 19 mmHg , under treatment with prostaglandin analogues" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_H" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + . + . + . + . + "Arm_LTFC" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + . + . + "Intervention_LTFC" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_LTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC" . + . + "22 . 0" . + "1 . 0" . + "17 . 7" . + "0 . 8" . + . + "Outcome_LTFC" . + . + "22 . 0" . + "1 . 0" . + "18 . 5" . + "0 . 8" . + . + "Outcome_H" . + . + "Average hyperaemia scores were slightly but significantly lower in the LTFC treatment period" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18535605_export.csv b/data/gl 18535605_export.csv new file mode 100644 index 0000000..4782c5d --- /dev/null +++ b/data/gl 18535605_export.csv @@ -0,0 +1,474 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +515, 1, 1, 1, 0, 3, 0, 3, "Eye" +515, 1, 2, 2, 4, 5, 4, 5, "(" +515, 1, 3, 3, 6, 10, 6, 10, "Lond" +515, 1, 4, 4, 11, 12, 11, 12, ")" +515, 1, 5, 5, 13, 14, 13, 14, "." +515, 2, 1, 6, 0, 4, 15, 19, "2009" +515, 2, 2, 7, 5, 8, 20, 23, "Apr" +515, 2, 3, 8, 9, 10, 24, 25, ";" +515, 2, 4, 9, 11, 13, 26, 28, "23" +515, 2, 5, 10, 14, 15, 29, 30, "(" +515, 2, 6, 11, 16, 17, 31, 32, "4" +515, 2, 7, 12, 18, 19, 33, 34, ")" +515, 2, 8, 13, 20, 21, 35, 36, ":" +515, 2, 9, 14, 22, 25, 37, 40, "810" +515, 2, 10, 15, 26, 27, 41, 42, "-" +515, 2, 11, 16, 28, 29, 43, 44, "8" +515, 2, 12, 17, 30, 31, 45, 46, "." +515, 2, 13, 18, 32, 35, 47, 50, "doi" +515, 2, 14, 19, 36, 37, 51, 52, ":" +515, 2, 15, 20, 38, 40, 53, 55, "10" +515, 2, 16, 21, 41, 42, 56, 57, "." +515, 2, 17, 22, 43, 47, 58, 62, "1038" +515, 2, 18, 23, 48, 49, 63, 64, "/" +515, 2, 19, 24, 50, 53, 65, 68, "eye" +515, 2, 20, 25, 54, 55, 69, 70, "." +515, 2, 21, 26, 56, 60, 71, 75, "2008" +515, 2, 22, 27, 61, 62, 76, 77, "." +515, 2, 23, 28, 63, 66, 78, 81, "148" +515, 2, 24, 29, 67, 68, 82, 83, "." +515, 3, 1, 30, 0, 4, 84, 88, "Epub" +515, 3, 2, 31, 5, 9, 89, 93, "2008" +515, 3, 3, 32, 10, 13, 94, 97, "Jun" +515, 3, 4, 33, 14, 15, 98, 99, "6" +515, 3, 5, 34, 16, 17, 100, 101, "." +515, 4, 1, 35, 0, 11, 102, 113, "Bimatoprost" +515, 4, 2, 36, 12, 13, 114, 115, "/" +515, 4, 3, 37, 14, 21, 116, 123, "timolol" +515, 4, 4, 38, 22, 27, 124, 129, "fixed" +515, 4, 5, 39, 28, 39, 130, 141, "combination" +515, 4, 6, 40, 40, 42, 142, 144, "vs" +515, 4, 7, 41, 43, 54, 145, 156, "latanoprost" +515, 4, 8, 42, 55, 56, 157, 158, "/" +515, 4, 9, 43, 57, 64, 159, 166, "timolol" +515, 4, 10, 44, 65, 70, 167, 172, "fixed" +515, 4, 11, 45, 71, 82, 173, 184, "combination" +515, 4, 12, 46, 83, 85, 185, 187, "in" +515, 4, 13, 47, 86, 90, 188, 192, "open" +515, 4, 14, 48, 91, 92, 193, 194, "-" +515, 4, 15, 49, 93, 98, 195, 200, "angle" +515, 4, 16, 50, 99, 107, 201, 209, "glaucoma" +515, 4, 17, 51, 108, 116, 210, 218, "patients" +515, 4, 18, 52, 117, 118, 219, 220, "." +515, 5, 1, 53, 0, 8, 221, 229, "Martinez" +515, 5, 2, 54, 9, 10, 230, 231, "A" +515, 5, 3, 55, 11, 12, 232, 233, "(" +515, 5, 4, 56, 13, 14, 234, 235, "1" +515, 5, 5, 57, 15, 16, 236, 237, ")" +515, 5, 6, 58, 17, 18, 238, 239, "," +515, 5, 7, 59, 19, 26, 240, 247, "Sanchez" +515, 5, 8, 60, 27, 28, 248, 249, "M" +515, 5, 9, 61, 29, 30, 250, 251, "." +515, 5, 10, 62, 31, 37, 252, 258, "Author" +515, 5, 11, 63, 38, 49, 259, 270, "information" +515, 5, 12, 64, 50, 51, 271, 272, ":" +515, 5, 13, 65, 52, 53, 273, 274, "(" +515, 5, 14, 66, 54, 55, 275, 276, "1" +515, 5, 15, 67, 56, 57, 277, 278, ")" +515, 5, 16, 68, 58, 67, 279, 288, "Instituto" +515, 5, 17, 69, 68, 75, 289, 296, "Gallego" +515, 5, 18, 70, 76, 78, 297, 299, "de" +515, 5, 19, 71, 79, 89, 300, 310, "Oftalmolog" +515, 5, 20, 72, 90, 91, 311, 312, "í" +515, 5, 21, 73, 92, 93, 313, 314, "a" +515, 5, 22, 74, 94, 95, 315, 316, "," +515, 5, 23, 75, 96, 97, 317, 318, "C" +515, 5, 24, 76, 98, 99, 319, 320, "/" +515, 5, 25, 77, 100, 103, 321, 324, "Ram" +515, 5, 26, 78, 104, 105, 325, 326, "ó" +515, 5, 27, 79, 106, 107, 327, 328, "n" +515, 5, 28, 80, 108, 114, 329, 335, "Baltar" +515, 5, 29, 81, 115, 117, 336, 338, "Sn" +515, 5, 30, 82, 118, 119, 339, 340, "," +515, 5, 31, 83, 120, 128, 341, 349, "Santiago" +515, 5, 32, 84, 129, 131, 350, 352, "de" +515, 5, 33, 85, 132, 142, 353, 363, "Compostela" +515, 5, 34, 86, 143, 144, 364, 365, "," +515, 5, 35, 87, 145, 147, 366, 368, "La" +515, 5, 36, 88, 148, 152, 369, 373, "Coru" +515, 5, 37, 89, 153, 154, 374, 375, "ñ" +515, 5, 38, 90, 155, 156, 376, 377, "a" +515, 5, 39, 91, 157, 158, 378, 379, "," +515, 5, 40, 92, 159, 164, 380, 385, "Spain" +515, 5, 41, 93, 165, 166, 386, 387, "." +515, 6, 1, 94, 0, 11, 388, 399, "tontxu_1999" +515, 6, 2, 95, 12, 13, 400, 401, "@" +515, 6, 3, 96, 14, 19, 402, 407, "yahoo" +515, 6, 4, 97, 20, 21, 408, 409, "." +515, 6, 5, 98, 22, 25, 410, 413, "com" +515, 6, 6, 99, 26, 35, 414, 423, "OBJECTIVE" +515, 6, 7, 100, 36, 37, 424, 425, ":" +515, 6, 8, 101, 38, 40, 426, 428, "To" +515, 6, 9, 102, 41, 49, 429, 437, "evaluate" +515, 6, 10, 103, 50, 61, 438, 449, "bimatoprost" +515, 6, 11, 104, 62, 63, 450, 451, "/" +515, 6, 12, 105, 64, 71, 452, 459, "timolol" +515, 6, 13, 106, 72, 77, 460, 465, "fixed" +515, 6, 14, 107, 78, 89, 466, 477, "combination" +515, 6, 15, 108, 90, 91, 478, 479, "(" +515, 6, 16, 109, 92, 96, 480, 484, "BTFC" +515, 6, 17, 110, 97, 98, 485, 486, ")" +515, 6, 18, 111, 99, 101, 487, 489, "vs" +515, 6, 19, 112, 102, 113, 490, 501, "latanoprost" +515, 6, 20, 113, 114, 115, 502, 503, "/" +515, 6, 21, 114, 116, 123, 504, 511, "timolol" +515, 6, 22, 115, 124, 129, 512, 517, "fixed" +515, 6, 23, 116, 130, 141, 518, 529, "combination" +515, 6, 24, 117, 142, 143, 530, 531, "(" +515, 6, 25, 118, 144, 148, 532, 536, "LTFC" +515, 6, 26, 119, 149, 150, 537, 538, ")" +515, 6, 27, 120, 151, 156, 539, 544, "given" +515, 6, 28, 121, 157, 161, 545, 549, "each" +515, 6, 29, 122, 162, 169, 550, 557, "evening" +515, 6, 30, 123, 170, 174, 558, 562, "over" +515, 6, 31, 124, 175, 178, 563, 566, "the" +515, 6, 32, 125, 179, 181, 567, 569, "12" +515, 6, 33, 126, 182, 183, 570, 571, "-" +515, 6, 34, 127, 184, 185, 572, 573, "h" +515, 6, 35, 128, 186, 197, 574, 585, "intraocular" +515, 6, 36, 129, 198, 206, 586, 594, "pressure" +515, 6, 37, 130, 207, 208, 595, 596, "(" +515, 6, 38, 131, 209, 212, 597, 600, "IOP" +515, 6, 39, 132, 213, 214, 601, 602, ")" +515, 6, 40, 133, 215, 222, 603, 610, "diurnal" +515, 6, 41, 134, 223, 228, 611, 616, "curve" +515, 6, 42, 135, 229, 230, 617, 618, "." +515, 7, 1, 136, 0, 7, 619, 626, "METHODS" +515, 7, 2, 137, 8, 9, 627, 628, ":" +515, 7, 3, 138, 10, 11, 629, 630, "A" +515, 7, 4, 139, 12, 17, 631, 636, "total" +515, 7, 5, 140, 18, 20, 637, 639, "of" +515, 7, 6, 141, 21, 23, 640, 642, "54" +515, 7, 7, 142, 24, 28, 643, 647, "eyes" +515, 7, 8, 143, 29, 31, 648, 650, "of" +515, 7, 9, 144, 32, 34, 651, 653, "54" +515, 7, 10, 145, 35, 43, 654, 662, "patients" +515, 7, 11, 146, 44, 45, 663, 664, "(" +515, 7, 12, 147, 46, 48, 665, 667, "24" +515, 7, 13, 148, 49, 53, 668, 672, "with" +515, 7, 14, 149, 54, 61, 673, 680, "primary" +515, 7, 15, 150, 62, 66, 681, 685, "open" +515, 7, 16, 151, 67, 68, 686, 687, "-" +515, 7, 17, 152, 69, 74, 688, 693, "angle" +515, 7, 18, 153, 75, 83, 694, 702, "glaucoma" +515, 7, 19, 154, 84, 85, 703, 704, "(" +515, 7, 20, 155, 86, 90, 705, 709, "POAG" +515, 7, 21, 156, 91, 92, 710, 711, ")" +515, 7, 22, 157, 93, 96, 712, 715, "and" +515, 7, 23, 158, 97, 99, 716, 718, "30" +515, 7, 24, 159, 100, 104, 719, 723, "with" +515, 7, 25, 160, 105, 122, 724, 741, "pseudoexfoliative" +515, 7, 26, 161, 123, 131, 742, 750, "glaucoma" +515, 7, 27, 162, 132, 133, 751, 752, "(" +515, 7, 28, 163, 134, 137, 753, 756, "PXG" +515, 7, 29, 164, 138, 139, 757, 758, ")" +515, 7, 30, 165, 140, 141, 759, 760, ")" +515, 7, 31, 166, 142, 146, 761, 765, "were" +515, 7, 32, 167, 147, 155, 766, 774, "included" +515, 7, 33, 168, 156, 158, 775, 777, "in" +515, 7, 34, 169, 159, 163, 778, 782, "this" +515, 7, 35, 170, 164, 175, 783, 794, "prospective" +515, 7, 36, 171, 176, 177, 795, 796, "," +515, 7, 37, 172, 178, 188, 797, 807, "randomized" +515, 7, 38, 173, 189, 190, 808, 809, "," +515, 7, 39, 174, 191, 200, 810, 819, "evaluator" +515, 7, 40, 175, 201, 202, 820, 821, "-" +515, 7, 41, 176, 203, 209, 822, 828, "masked" +515, 7, 42, 177, 210, 216, 829, 835, "single" +515, 7, 43, 178, 217, 223, 836, 842, "centre" +515, 7, 44, 179, 224, 233, 843, 852, "crossover" +515, 7, 45, 180, 234, 239, 853, 858, "study" +515, 7, 46, 181, 240, 241, 859, 860, "." +515, 8, 1, 182, 0, 8, 861, 869, "Patients" +515, 8, 2, 183, 9, 13, 870, 874, "with" +515, 8, 3, 184, 14, 16, 875, 877, "an" +515, 8, 4, 185, 17, 20, 878, 881, "IOP" +515, 8, 5, 186, 21, 23, 882, 884, "of" +515, 8, 6, 187, 24, 25, 885, 886, ">" +515, 8, 7, 188, 26, 28, 887, 889, "or" +515, 8, 8, 189, 29, 30, 890, 891, "=" +515, 8, 9, 190, 31, 33, 892, 894, "19" +515, 8, 10, 191, 34, 38, 895, 899, "mmHg" +515, 8, 11, 192, 39, 40, 900, 901, "," +515, 8, 12, 193, 41, 46, 902, 907, "under" +515, 8, 13, 194, 47, 56, 908, 917, "treatment" +515, 8, 14, 195, 57, 61, 918, 922, "with" +515, 8, 15, 196, 62, 75, 923, 936, "prostaglandin" +515, 8, 16, 197, 76, 85, 937, 946, "analogues" +515, 8, 17, 198, 86, 87, 947, 948, "," +515, 8, 18, 199, 88, 92, 949, 953, "were" +515, 8, 19, 200, 93, 103, 954, 964, "randomized" +515, 8, 20, 201, 104, 106, 965, 967, "to" +515, 8, 21, 202, 107, 111, 968, 972, "BTFC" +515, 8, 22, 203, 112, 114, 973, 975, "or" +515, 8, 23, 204, 115, 119, 976, 980, "LTFC" +515, 8, 24, 205, 120, 123, 981, 984, "for" +515, 8, 25, 206, 124, 125, 985, 986, "a" +515, 8, 26, 207, 126, 128, 987, 989, "12" +515, 8, 27, 208, 129, 130, 990, 991, "-" +515, 8, 28, 209, 131, 135, 992, 996, "week" +515, 8, 29, 210, 136, 145, 997, 1006, "treatment" +515, 8, 30, 211, 146, 152, 1007, 1013, "period" +515, 8, 31, 212, 153, 158, 1014, 1019, "after" +515, 8, 32, 213, 159, 160, 1020, 1021, "a" +515, 8, 33, 214, 161, 162, 1022, 1023, "6" +515, 8, 34, 215, 163, 164, 1024, 1025, "-" +515, 8, 35, 216, 165, 169, 1026, 1030, "week" +515, 8, 36, 217, 170, 173, 1031, 1034, "run" +515, 8, 37, 218, 174, 175, 1035, 1036, "-" +515, 8, 38, 219, 176, 178, 1037, 1039, "in" +515, 8, 39, 220, 179, 185, 1040, 1046, "period" +515, 8, 40, 221, 186, 188, 1047, 1049, "on" +515, 8, 41, 222, 189, 196, 1050, 1057, "timolol" +515, 8, 42, 223, 197, 204, 1058, 1065, "maleate" +515, 8, 43, 224, 205, 206, 1066, 1067, "0" +515, 8, 44, 225, 207, 208, 1068, 1069, "." +515, 8, 45, 226, 209, 210, 1070, 1071, "5" +515, 8, 46, 227, 211, 212, 1072, 1073, "%" +515, 8, 47, 228, 213, 214, 1074, 1075, "(" +515, 8, 48, 229, 215, 218, 1076, 1079, "one" +515, 8, 49, 230, 219, 223, 1080, 1084, "drop" +515, 8, 50, 231, 224, 226, 1085, 1087, "in" +515, 8, 51, 232, 227, 231, 1088, 1092, "each" +515, 8, 52, 233, 232, 235, 1093, 1096, "eye" +515, 8, 53, 234, 236, 241, 1097, 1102, "twice" +515, 8, 54, 235, 242, 246, 1103, 1107, "each" +515, 8, 55, 236, 247, 250, 1108, 1111, "day" +515, 8, 56, 237, 251, 252, 1112, 1113, ")" +515, 8, 57, 238, 253, 254, 1114, 1115, "." +515, 9, 1, 239, 0, 8, 1116, 1124, "Patients" +515, 9, 2, 240, 9, 13, 1125, 1129, "were" +515, 9, 3, 241, 14, 18, 1130, 1134, "then" +515, 9, 4, 242, 19, 27, 1135, 1143, "switched" +515, 9, 5, 243, 28, 30, 1144, 1146, "to" +515, 9, 6, 244, 31, 34, 1147, 1150, "the" +515, 9, 7, 245, 35, 43, 1151, 1159, "opposite" +515, 9, 8, 246, 44, 53, 1160, 1169, "treatment" +515, 9, 9, 247, 54, 57, 1170, 1173, "for" +515, 9, 10, 248, 58, 61, 1174, 1177, "the" +515, 9, 11, 249, 62, 68, 1178, 1184, "second" +515, 9, 12, 250, 69, 75, 1185, 1191, "period" +515, 9, 13, 251, 76, 77, 1192, 1193, "." +515, 10, 1, 252, 0, 3, 1194, 1197, "Six" +515, 10, 2, 253, 4, 6, 1198, 1200, "12" +515, 10, 3, 254, 7, 8, 1201, 1202, "-" +515, 10, 4, 255, 9, 10, 1203, 1204, "h" +515, 10, 5, 256, 11, 14, 1205, 1208, "IOP" +515, 10, 6, 257, 15, 21, 1209, 1215, "curves" +515, 10, 7, 258, 22, 26, 1216, 1220, "were" +515, 10, 8, 259, 27, 35, 1221, 1229, "recorded" +515, 10, 9, 260, 36, 39, 1230, 1233, "for" +515, 10, 10, 261, 40, 44, 1234, 1238, "each" +515, 10, 11, 262, 45, 52, 1239, 1246, "patient" +515, 10, 12, 263, 53, 55, 1247, 1249, "at" +515, 10, 13, 264, 56, 64, 1250, 1258, "baseline" +515, 10, 14, 265, 65, 66, 1259, 1260, "(" +515, 10, 15, 266, 67, 72, 1261, 1266, "under" +515, 10, 16, 267, 73, 82, 1267, 1276, "treatment" +515, 10, 17, 268, 83, 87, 1277, 1281, "with" +515, 10, 18, 269, 88, 95, 1282, 1289, "timolol" +515, 10, 19, 270, 96, 103, 1290, 1297, "maleate" +515, 10, 20, 271, 104, 105, 1298, 1299, "0" +515, 10, 21, 272, 106, 107, 1300, 1301, "." +515, 10, 22, 273, 108, 109, 1302, 1303, "5" +515, 10, 23, 274, 110, 111, 1304, 1305, "%" +515, 10, 24, 275, 112, 115, 1306, 1309, "BID" +515, 10, 25, 276, 116, 117, 1310, 1311, ")" +515, 10, 26, 277, 118, 119, 1312, 1313, "," +515, 10, 27, 278, 120, 124, 1314, 1318, "week" +515, 10, 28, 279, 125, 126, 1319, 1320, "6" +515, 10, 29, 280, 127, 130, 1321, 1324, "and" +515, 10, 30, 281, 131, 133, 1325, 1327, "12" +515, 10, 31, 282, 134, 137, 1328, 1331, "for" +515, 10, 32, 283, 138, 142, 1332, 1336, "each" +515, 10, 33, 284, 143, 152, 1337, 1346, "treatment" +515, 10, 34, 285, 153, 159, 1347, 1353, "period" +515, 10, 35, 286, 160, 161, 1354, 1355, "." +515, 11, 1, 287, 0, 7, 1356, 1363, "RESULTS" +515, 11, 2, 288, 8, 9, 1364, 1365, ":" +515, 11, 3, 289, 10, 13, 1366, 1369, "The" +515, 11, 4, 290, 14, 16, 1370, 1372, "12" +515, 11, 5, 291, 17, 18, 1373, 1374, "-" +515, 11, 6, 292, 19, 20, 1375, 1376, "h" +515, 11, 7, 293, 21, 24, 1377, 1380, "IOP" +515, 11, 8, 294, 25, 26, 1381, 1382, "(" +515, 11, 9, 295, 27, 31, 1383, 1387, "mean" +515, 11, 10, 296, 32, 33, 1388, 1389, "(" +515, 11, 11, 297, 34, 36, 1390, 1392, "SD" +515, 11, 12, 298, 37, 38, 1393, 1394, ")" +515, 11, 13, 299, 39, 40, 1395, 1396, ")" +515, 11, 14, 300, 41, 47, 1397, 1403, "values" +515, 11, 15, 301, 48, 52, 1404, 1408, "were" +515, 11, 16, 302, 53, 55, 1409, 1411, "22" +515, 11, 17, 303, 56, 57, 1412, 1413, "." +515, 11, 18, 304, 58, 59, 1414, 1415, "0" +515, 11, 19, 305, 60, 61, 1416, 1417, "(" +515, 11, 20, 306, 62, 63, 1418, 1419, "1" +515, 11, 21, 307, 64, 65, 1420, 1421, "." +515, 11, 22, 308, 66, 67, 1422, 1423, "0" +515, 11, 23, 309, 68, 69, 1424, 1425, ")" +515, 11, 24, 310, 70, 74, 1426, 1430, "mmHg" +515, 11, 25, 311, 75, 77, 1431, 1433, "at" +515, 11, 26, 312, 78, 86, 1434, 1442, "baseline" +515, 11, 27, 313, 87, 88, 1443, 1444, "," +515, 11, 28, 314, 89, 91, 1445, 1447, "17" +515, 11, 29, 315, 92, 93, 1448, 1449, "." +515, 11, 30, 316, 94, 95, 1450, 1451, "7" +515, 11, 31, 317, 96, 97, 1452, 1453, "(" +515, 11, 32, 318, 98, 99, 1454, 1455, "0" +515, 11, 33, 319, 100, 101, 1456, 1457, "." +515, 11, 34, 320, 102, 103, 1458, 1459, "8" +515, 11, 35, 321, 104, 105, 1460, 1461, ")" +515, 11, 36, 322, 106, 110, 1462, 1466, "mmHg" +515, 11, 37, 323, 111, 113, 1467, 1469, "on" +515, 11, 38, 324, 114, 118, 1470, 1474, "BTFC" +515, 11, 39, 325, 119, 120, 1475, 1476, "," +515, 11, 40, 326, 121, 124, 1477, 1480, "and" +515, 11, 41, 327, 125, 127, 1481, 1483, "18" +515, 11, 42, 328, 128, 129, 1484, 1485, "." +515, 11, 43, 329, 130, 131, 1486, 1487, "5" +515, 11, 44, 330, 132, 133, 1488, 1489, "(" +515, 11, 45, 331, 134, 135, 1490, 1491, "0" +515, 11, 46, 332, 136, 137, 1492, 1493, "." +515, 11, 47, 333, 138, 139, 1494, 1495, "8" +515, 11, 48, 334, 140, 141, 1496, 1497, ")" +515, 11, 49, 335, 142, 146, 1498, 1502, "mmHg" +515, 11, 50, 336, 147, 149, 1503, 1505, "on" +515, 11, 51, 337, 150, 154, 1506, 1510, "LTFC" +515, 11, 52, 338, 155, 156, 1511, 1512, "(" +515, 11, 53, 339, 157, 158, 1513, 1514, "P" +515, 11, 54, 340, 159, 160, 1515, 1516, "<" +515, 11, 55, 341, 161, 162, 1517, 1518, "0" +515, 11, 56, 342, 163, 164, 1519, 1520, "." +515, 11, 57, 343, 165, 168, 1521, 1524, "001" +515, 11, 58, 344, 169, 170, 1525, 1526, ")" +515, 11, 59, 345, 171, 172, 1527, 1528, "." +515, 12, 1, 346, 0, 2, 1529, 1531, "At" +515, 12, 2, 347, 3, 13, 1532, 1542, "individual" +515, 12, 3, 348, 14, 18, 1543, 1547, "time" +515, 12, 4, 349, 19, 25, 1548, 1554, "points" +515, 12, 5, 350, 26, 27, 1555, 1556, "," +515, 12, 6, 351, 28, 33, 1557, 1562, "there" +515, 12, 7, 352, 34, 37, 1563, 1566, "was" +515, 12, 8, 353, 38, 39, 1567, 1568, "a" +515, 12, 9, 354, 40, 51, 1569, 1580, "significant" +515, 12, 10, 355, 52, 62, 1581, 1591, "difference" +515, 12, 11, 356, 63, 70, 1592, 1599, "between" +515, 12, 12, 357, 71, 77, 1600, 1606, "groups" +515, 12, 13, 358, 78, 80, 1607, 1609, "at" +515, 12, 14, 359, 81, 85, 1610, 1614, "0800" +515, 12, 15, 360, 86, 87, 1615, 1616, "," +515, 12, 16, 361, 88, 92, 1617, 1621, "0100" +515, 12, 17, 362, 93, 94, 1622, 1623, "," +515, 12, 18, 363, 95, 99, 1624, 1628, "1200" +515, 12, 19, 364, 100, 101, 1629, 1630, "," +515, 12, 20, 365, 102, 106, 1631, 1635, "1800" +515, 12, 21, 366, 107, 108, 1636, 1637, "," +515, 12, 22, 367, 109, 112, 1638, 1641, "and" +515, 12, 23, 368, 113, 117, 1642, 1646, "2000" +515, 12, 24, 369, 118, 123, 1647, 1652, "hours" +515, 12, 25, 370, 124, 128, 1653, 1657, "with" +515, 12, 26, 371, 129, 133, 1658, 1662, "BTFC" +515, 12, 27, 372, 134, 140, 1663, 1669, "having" +515, 12, 28, 373, 141, 148, 1670, 1677, "greater" +515, 12, 29, 374, 149, 155, 1678, 1684, "ocular" +515, 12, 30, 375, 156, 167, 1685, 1696, "hypotensive" +515, 12, 31, 376, 168, 174, 1697, 1703, "effect" +515, 12, 32, 377, 175, 176, 1704, 1705, "," +515, 12, 33, 378, 177, 178, 1706, 1707, "P" +515, 12, 34, 379, 179, 180, 1708, 1709, "<" +515, 12, 35, 380, 181, 182, 1710, 1711, "0" +515, 12, 36, 381, 183, 184, 1712, 1713, "." +515, 12, 37, 382, 185, 188, 1714, 1717, "001" +515, 12, 38, 383, 189, 190, 1718, 1719, "." +515, 13, 1, 384, 0, 3, 1720, 1723, "The" +515, 13, 2, 385, 4, 8, 1724, 1728, "most" +515, 13, 3, 386, 9, 19, 1729, 1739, "frequently" +515, 13, 4, 387, 20, 28, 1740, 1748, "reported" +515, 13, 5, 388, 29, 36, 1749, 1756, "adverse" +515, 13, 6, 389, 37, 42, 1757, 1762, "event" +515, 13, 7, 390, 43, 45, 1763, 1765, "in" +515, 13, 8, 391, 46, 49, 1766, 1769, "the" +515, 13, 9, 392, 50, 55, 1770, 1775, "study" +515, 13, 10, 393, 56, 59, 1776, 1779, "was" +515, 13, 11, 394, 60, 72, 1780, 1792, "conjunctival" +515, 13, 12, 395, 73, 83, 1793, 1803, "hyperaemia" +515, 13, 13, 396, 84, 85, 1804, 1805, "." +515, 14, 1, 397, 0, 7, 1806, 1813, "Average" +515, 14, 2, 398, 8, 18, 1814, 1824, "hyperaemia" +515, 14, 3, 399, 19, 25, 1825, 1831, "scores" +515, 14, 4, 400, 26, 30, 1832, 1836, "were" +515, 14, 5, 401, 31, 39, 1837, 1845, "slightly" +515, 14, 6, 402, 40, 43, 1846, 1849, "but" +515, 14, 7, 403, 44, 57, 1850, 1863, "significantly" +515, 14, 8, 404, 58, 63, 1864, 1869, "lower" +515, 14, 9, 405, 64, 66, 1870, 1872, "in" +515, 14, 10, 406, 67, 70, 1873, 1876, "the" +515, 14, 11, 407, 71, 75, 1877, 1881, "LTFC" +515, 14, 12, 408, 76, 85, 1882, 1891, "treatment" +515, 14, 13, 409, 86, 92, 1892, 1898, "period" +515, 14, 14, 410, 93, 94, 1899, 1900, "(" +515, 14, 15, 411, 95, 96, 1901, 1902, "P" +515, 14, 16, 412, 97, 98, 1903, 1904, "=" +515, 14, 17, 413, 99, 100, 1905, 1906, "0" +515, 14, 18, 414, 101, 102, 1907, 1908, "." +515, 14, 19, 415, 103, 105, 1909, 1911, "04" +515, 14, 20, 416, 106, 107, 1912, 1913, ")" +515, 14, 21, 417, 108, 109, 1914, 1915, "." +515, 15, 1, 418, 0, 10, 1916, 1926, "CONCLUSION" +515, 15, 2, 419, 11, 12, 1927, 1928, ":" +515, 15, 3, 420, 13, 17, 1929, 1933, "This" +515, 15, 4, 421, 18, 23, 1934, 1939, "study" +515, 15, 5, 422, 24, 32, 1940, 1948, "suggests" +515, 15, 6, 423, 33, 37, 1949, 1953, "that" +515, 15, 7, 424, 38, 41, 1954, 1957, "the" +515, 15, 8, 425, 42, 49, 1958, 1965, "evening" +515, 15, 9, 426, 50, 51, 1966, 1967, "-" +515, 15, 10, 427, 52, 57, 1968, 1973, "dosed" +515, 15, 11, 428, 58, 62, 1974, 1978, "BTFC" +515, 15, 12, 429, 63, 71, 1979, 1987, "provides" +515, 15, 13, 430, 72, 78, 1988, 1994, "better" +515, 15, 14, 431, 79, 82, 1995, 1998, "IOP" +515, 15, 15, 432, 83, 90, 1999, 2006, "control" +515, 15, 16, 433, 91, 95, 2007, 2011, "than" +515, 15, 17, 434, 96, 100, 2012, 2016, "that" +515, 15, 18, 435, 101, 103, 2017, 2019, "of" +515, 15, 19, 436, 104, 108, 2020, 2024, "LTFC" +515, 15, 20, 437, 109, 113, 2025, 2029, "over" +515, 15, 21, 438, 114, 116, 2030, 2032, "12" +515, 15, 22, 439, 117, 118, 2033, 2034, "h" +515, 15, 23, 440, 119, 120, 2035, 2036, "." +515, 15, 24, 441, 121, 128, 2037, 2044, "However" +515, 15, 25, 442, 129, 130, 2045, 2046, "," +515, 15, 26, 443, 131, 134, 2047, 2050, "the" +515, 15, 27, 444, 135, 138, 2051, 2054, "IOP" +515, 15, 28, 445, 139, 149, 2055, 2065, "difference" +515, 15, 29, 446, 150, 153, 2066, 2069, "was" +515, 15, 30, 447, 154, 159, 2070, 2075, "small" +515, 15, 31, 448, 160, 163, 2076, 2079, "and" +515, 15, 32, 449, 164, 167, 2080, 2083, "may" +515, 15, 33, 450, 168, 171, 2084, 2087, "not" +515, 15, 34, 451, 172, 174, 2088, 2090, "be" +515, 15, 35, 452, 175, 185, 2091, 2101, "clinically" +515, 15, 36, 453, 186, 196, 2102, 2112, "meaningful" +515, 15, 37, 454, 197, 198, 2113, 2114, "." +515, 16, 1, 455, 0, 3, 2115, 2118, "DOI" +515, 16, 2, 456, 4, 5, 2119, 2120, ":" +515, 16, 3, 457, 6, 8, 2121, 2123, "10" +515, 16, 4, 458, 9, 10, 2124, 2125, "." +515, 16, 5, 459, 11, 15, 2126, 2130, "1038" +515, 16, 6, 460, 16, 17, 2131, 2132, "/" +515, 16, 7, 461, 18, 21, 2133, 2136, "eye" +515, 16, 8, 462, 22, 23, 2137, 2138, "." +515, 16, 9, 463, 24, 28, 2139, 2143, "2008" +515, 16, 10, 464, 29, 30, 2144, 2145, "." +515, 16, 11, 465, 31, 34, 2146, 2149, "148" +515, 16, 12, 466, 35, 39, 2150, 2154, "PMID" +515, 16, 13, 467, 40, 41, 2155, 2156, ":" +515, 16, 14, 468, 42, 50, 2157, 2165, "18535605" +515, 16, 15, 469, 51, 52, 2166, 2167, "[" +515, 16, 16, 470, 53, 60, 2168, 2175, "Indexed" +515, 16, 17, 471, 61, 64, 2176, 2179, "for" +515, 16, 18, 472, 65, 72, 2180, 2187, "MEDLINE" +515, 16, 19, 473, 73, 74, 2188, 2189, "]" diff --git a/data/gl 18535605_jshahinitiran.annodb b/data/gl 18535605_jshahinitiran.annodb new file mode 100644 index 0000000..d50f161 --- /dev/null +++ b/data/gl 18535605_jshahinitiran.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +57740, Journal, 0, 14, "Eye ( Lond ) .", "", +57741, PublicationYear, 15, 19, "2009", "", +57742, Bimatoprost, 102, 113, "Bimatoprost", "", +57746, Title, 102, 220, "Bimatoprost / timolol fixed combination vs latanoprost / timolol fixed combination in open - angle glaucoma patients .", "", +78589, Bima/TimFC, 102, 141, "Bimatoprost / timolol fixed combination", "", +57743, Timolol, 116, 123, "timolol", "", +57744, Latanoprost, 145, 156, "latanoprost", "", +78591, Lat/TimFC, 145, 184, "latanoprost / timolol fixed combination", "", +57745, Timolol, 159, 166, "timolol", "", +78592, OpenAngleGlaucoma, 188, 209, "open - angle glaucoma", "", +78593, Author, 221, 231, "Martinez A", "", +78594, Author, 240, 249, "Sanchez M", "", +78595, Spain, 380, 385, "Spain", "", +78596, ObjectiveDescription, 426, 618, "To evaluate bimatoprost / timolol fixed combination ( BTFC ) vs latanoprost / timolol fixed combination ( LTFC ) given each evening over the 12 - h intraocular pressure ( IOP ) diurnal curve .", "", +78597, Bimatoprost, 438, 449, "bimatoprost", "", +78600, Bima/TimFC, 438, 477, "bimatoprost / timolol fixed combination", "", +78598, Timolol, 452, 459, "timolol", "", +78601, Bima/TimFC, 480, 484, "BTFC", "", +78602, Latanoprost, 490, 501, "latanoprost", "", +78603, Latanoprost, 490, 529, "latanoprost / timolol fixed combination", "", +78599, Timolol, 504, 511, "timolol", "", +78604, Latanoprost, 532, 536, "LTFC", "", +78605, IOP, 574, 594, "intraocular pressure", "", +78606, IOP, 597, 600, "IOP", "", +78607, NumberPatientsCT, 651, 653, "54", "", +78608, Primary_OpenAngleGlaucoma, 673, 702, "primary open - angle glaucoma", "", +78609, Primary_OpenAngleGlaucoma, 705, 709, "POAG", "", +78610, Glaucoma, 724, 750, "pseudoexfoliative glaucoma", "", +78611, Glaucoma, 753, 756, "PXG", "", +78612, Prospective, 783, 794, "prospective", "", +78613, Randomized, 797, 807, "randomized", "", +78614, Blind, 810, 828, "evaluator - masked", "", +78615, SingleCenter, 829, 842, "single centre", "", +78616, Crossover, 843, 852, "crossover", "", +78619, Precondition, 861, 899, "Patients with an IOP of > or = 19 mmHg", "", +78617, IOP, 878, 881, "IOP", "", +78618, mmHg, 895, 899, "mmHg", "", +78620, Precondition, 902, 946, "under treatment with prostaglandin analogues", "", +78621, Randomized, 954, 964, "randomized", "", +78622, Bima/TimFC, 968, 972, "BTFC", "", +78623, Lat/TimFC, 976, 980, "LTFC", "", +78624, Duration, 987, 996, "12 - week", "", +78625, Duration, 1022, 1030, "6 - week", "", +78626, Timolol, 1050, 1065, "timolol maleate", "", +78627, DoseValue, 1066, 1071, "0 . 5", "", +78628, Frequency, 1097, 1111, "twice each day", "", +78629, IOP, 1205, 1208, "IOP", "", +78630, Timolol, 1282, 1297, "timolol maleate", "", +78631, DoseValue, 1298, 1303, "0 . 5", "", +78632, Frequency, 1306, 1309, "BID", "", +78633, TimePoint, 1314, 1327, "week 6 and 12", "", +78634, TimePoint, 1314, 1320, "week 6", "", +78635, IOP, 1377, 1380, "IOP", "", +78636, Mean, 1383, 1387, "mean", "", +78637, BaseLineValue, 1409, 1415, "22 . 0", "", +78638, SdDevBL, 1418, 1423, "1 . 0", "", +78639, mmHg, 1426, 1430, "mmHg", "", +78640, ResultMeasuredValue, 1445, 1451, "17 . 7", "", +78642, SdDevResValue, 1454, 1459, "0 . 8", "", +78645, mmHg, 1462, 1466, "mmHg", "", +78646, Bima/TimFC, 1470, 1474, "BTFC", "", +78641, ResultMeasuredValue, 1481, 1487, "18 . 5", "", +78643, SdDevResValue, 1490, 1495, "0 . 8", "", +78644, mmHg, 1498, 1502, "mmHg", "", +78647, Lat/TimFC, 1506, 1510, "LTFC", "", +78648, PValueResValue, 1513, 1524, "P < 0 . 001", "", +78650, ObservedResult, 1529, 1719, "At individual time points , there was a significant difference between groups at 0800 , 0100 , 1200 , 1800 , and 2000 hours with BTFC having greater ocular hypotensive effect , P < 0 . 001 .", "", +78649, Bima/TimFC, 1658, 1662, "BTFC", "", +78651, ConjunctivalHyperemia, 1780, 1803, "conjunctival hyperaemia", "", +78652, ConjunctivalHyperemia, 1814, 1824, "hyperaemia", "", +78653, Lat/TimFC, 1877, 1881, "LTFC", "", +78654, PValueNumAffected, 1901, 1911, "P = 0 . 04", "", +78655, ConclusionComment, 1929, 2114, "This study suggests that the evening - dosed BTFC provides better IOP control than that of LTFC over 12 h . However , the IOP difference was small and may not be clinically meaningful .", "", +78656, Bima/TimFC, 1974, 1978, "BTFC", "", +78657, IOP, 1995, 1998, "IOP", "", +78658, Lat/TimFC, 2020, 2024, "LTFC", "", +78659, IOP, 2051, 2054, "IOP", "", +78660, PMID, 2157, 2165, "18535605", "", diff --git a/data/gl 18535605_jshahinitiran.n-triples b/data/gl 18535605_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18535605_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18535605_tstrakeljahn.annodb b/data/gl 18535605_tstrakeljahn.annodb new file mode 100644 index 0000000..46bdf64 --- /dev/null +++ b/data/gl 18535605_tstrakeljahn.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80317, Journal, 0, 12, "Eye ( Lond )", "", +80318, PublicationYear, 15, 19, "2009", "", +80319, Bimatoprost, 102, 113, "Bimatoprost", "", +80323, Bima/TimFC, 102, 123, "Bimatoprost / timolol", "", +80325, Title, 102, 220, "Bimatoprost / timolol fixed combination vs latanoprost / timolol fixed combination in open - angle glaucoma patients .", "", +80320, Timolol, 116, 123, "timolol", "", +80321, Latanoprost, 145, 156, "latanoprost", "", +80324, Lat/TimFC, 145, 166, "latanoprost / timolol", "", +80322, Timolol, 159, 166, "timolol", "", +80326, OpenAngleGlaucoma, 188, 209, "open - angle glaucoma", "", +80327, Author, 221, 231, "Martinez A", "", +80328, Author, 240, 249, "Sanchez M", "", +80329, Spain, 380, 385, "Spain", "", +80340, ObjectiveDescription, 426, 618, "To evaluate bimatoprost / timolol fixed combination ( BTFC ) vs latanoprost / timolol fixed combination ( LTFC ) given each evening over the 12 - h intraocular pressure ( IOP ) diurnal curve .", "", +80330, Bimatoprost, 438, 449, "bimatoprost", "", +80335, Bima/TimFC, 438, 459, "bimatoprost / timolol", "", +80331, Timolol, 452, 459, "timolol", "", +80334, Bima/TimFC, 480, 484, "BTFC", "", +80333, Latanoprost, 490, 501, "latanoprost", "", +80336, Lat/TimFC, 490, 511, "latanoprost / timolol", "", +80332, Timolol, 504, 511, "timolol", "", +80337, Lat/TimFC, 532, 536, "LTFC", "", +80339, Diurnal_IOP, 574, 616, "intraocular pressure ( IOP ) diurnal curve", "", +80338, IOP, 597, 600, "IOP", "", +80341, NumberPatientsCT, 651, 653, "54", "", +80345, NumberAffected, 665, 667, "24", "", +80342, Primary_OpenAngleGlaucoma, 673, 702, "primary open - angle glaucoma", "", +80343, Primary_OpenAngleGlaucoma, 705, 709, "POAG", "", +80346, NumberAffected, 716, 718, "30", "", +80344, Glaucoma, 742, 750, "glaucoma", "", +80347, Prospective, 783, 794, "prospective", "", +80348, Randomized, 797, 807, "randomized", "", +80349, Blind, 810, 828, "evaluator - masked", "", +80350, Crossover, 843, 852, "crossover", "", +80351, IOP, 878, 881, "IOP", "", +80353, Precondition, 878, 946, "IOP of > or = 19 mmHg , under treatment with prostaglandin analogues", "", +80352, mmHg, 895, 899, "mmHg", "", +80354, Randomized, 954, 964, "randomized", "", +80355, Brimo/TimFC, 968, 972, "BTFC", "", +80356, Lat/TimFC, 976, 980, "LTFC", "", +80357, Duration, 987, 996, "12 - week", "", +80364, Precondition, 1014, 1113, "after a 6 - week run - in period on timolol maleate 0 . 5 % ( one drop in each eye twice each day )", "", +80358, Timolol, 1050, 1065, "timolol maleate", "", +80359, DoseValue, 1066, 1071, "0 . 5", "", +80360, Percentage, 1072, 1073, "%", "", +80362, DoseValue, 1076, 1079, "one", "", +80361, Eyedrops, 1080, 1084, "drop", "", +80363, Frequency, 1097, 1111, "twice each day", "", +80365, IOP, 1205, 1208, "IOP", "", +80366, Timolol, 1282, 1297, "timolol maleate", "", +80367, DoseValue, 1298, 1303, "0 . 5", "", +80368, Percentage, 1304, 1305, "%", "", +80369, Frequency, 1306, 1309, "BID", "", +80370, TimePoint, 1314, 1320, "week 6", "", +80371, TimePoint, 1314, 1327, "week 6 and 12", "", +80374, IOP, 1377, 1380, "IOP", "", +80373, Mean, 1383, 1387, "mean", "", +80375, BaseLineValue, 1409, 1415, "22 . 0", "", +80376, SdDevBL, 1418, 1423, "1 . 0", "", +80377, mmHg, 1426, 1430, "mmHg", "", +80380, ResultMeasuredValue, 1445, 1451, "17 . 7", "", +80382, SdDevChangeValue, 1454, 1459, "0 . 8", "", +80378, mmHg, 1462, 1466, "mmHg", "", +80384, Brimo/TimFC, 1470, 1474, "BTFC", "", +80381, ResultMeasuredValue, 1481, 1487, "18 . 5", "", +80383, SdDevChangeValue, 1490, 1495, "0 . 8", "", +80379, mmHg, 1498, 1502, "mmHg", "", +80385, Lat/TimFC, 1506, 1510, "LTFC", "", +80386, PvalueDiff, 1515, 1524, "< 0 . 001", "", +80394, ObservedResult, 1529, 1703, "At individual time points , there was a significant difference between groups at 0800 , 0100 , 1200 , 1800 , and 2000 hours with BTFC having greater ocular hypotensive effect", "", +80387, TimePoint, 1610, 1614, "0800", "", +80388, TimePoint, 1617, 1621, "0100", "", +80389, TimePoint, 1624, 1628, "1200", "", +80390, TimePoint, 1631, 1635, "1800", "", +80391, TimePoint, 1642, 1646, "2000", "", +80392, Brimo/TimFC, 1658, 1662, "BTFC", "", +80393, PvalueDiff, 1708, 1717, "< 0 . 001", "", +80399, ObservedResult, 1720, 1805, "The most frequently reported adverse event in the study was conjunctival hyperaemia .", "", +80395, ConjunctivalHyperemia, 1780, 1803, "conjunctival hyperaemia", "", +80398, ObservedResult, 1806, 1898, "Average hyperaemia scores were slightly but significantly lower in the LTFC treatment period", "", +80396, Lat/TimFC, 1877, 1881, "LTFC", "", +80397, PvalueDiff, 1903, 1911, "= 0 . 04", "", +80404, ConclusionComment, 1929, 2114, "This study suggests that the evening - dosed BTFC provides better IOP control than that of LTFC over 12 h . However , the IOP difference was small and may not be clinically meaningful .", "", +80400, Brimo/TimFC, 1974, 1978, "BTFC", "", +80401, IOP, 1995, 1998, "IOP", "", +80402, Lat/TimFC, 2020, 2024, "LTFC", "", +80403, IOP, 2051, 2054, "IOP", "", +80405, PMID, 2157, 2165, "18535605", "", diff --git a/data/gl 18535605_tstrakeljahn.n-triples b/data/gl 18535605_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18535605_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18721251 copy_admin.annodb b/data/gl 18721251 copy_admin.annodb new file mode 100644 index 0000000..78cc440 --- /dev/null +++ b/data/gl 18721251 copy_admin.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Acta Ophthalmol .", "", " \"Acta Ophthalmol .\"." +1, PublicationYear, 18, 22, "2008", "", " \"2008\"." +2, Title, 124, 285, "Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension .\"." +3, Latanoprost, 147, 158, "latanoprost", "", +4, Pilocarpine, 166, 177, "pilocarpine", "", +92, Pilo/TimFC, 166, 195, "pilocarpine / timolol maleate", "", +5, Timolol, 180, 195, "timolol maleate", "", +38, Primary_OpenAngleGlaucoma, 231, 260, "primary open - angle glaucoma", "", " ." +7, OcularHypertension, 264, 283, "ocular hypertension", "", " ." +8, Author, 286, 297, "Ka ł uzny J", "", " \"Ka ł uzny J\"." +9, Author, 306, 315, "Sobecki R", "", " \"Sobecki R\"." +10, Author, 318, 340, "Czechowicz - Janicka K", "", " \"Czechowicz - Janicka K\"." +11, Author, 343, 350, "Kecik D", "", " \"Kecik D\"." +12, Author, 353, 365, "Ka ł uzny BJ", "", " \"Ka ł uzny BJ\"." +13, Author, 368, 378, "Stewart JA", "", " \"Stewart JA\"." +14, Author, 381, 391, "Stewart WC", "", " \"Stewart WC\"." +15, Poland, 478, 484, "Poland", "", +16, ObjectiveDescription, 497, 613, "This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening", "", " \"This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening\"." +18, IOP, 550, 570, "intraocular pressure", "", +19, IOP, 573, 576, "IOP", "", +20, Latanoprost, 582, 593, "latanoprost", "", +78307, Interval, 600, 613, "every evening", "", +17, ObjectiveDescription, 614, 781, "versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +23, Pilocarpine, 621, 632, "pilocarpine", "", +108, Pilo/TimFC, 621, 650, "pilocarpine / timolol maleate", "", +24, Timolol, 635, 650, "timolol maleate", "", +109, Pilo/TimFC, 671, 675, "PTFC", "", +25, Frequency, 684, 695, "twice daily", "", +78313, Precondition, 699, 781, "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +39, Primary_OpenAngleGlaucoma, 713, 742, "primary open - angle glaucoma", "", +40, Primary_OpenAngleGlaucoma, 745, 749, "POAG", "", +26, OcularHypertension, 755, 774, "ocular hypertension", "", +27, OcularHypertension, 777, 779, "OH", "", +28, Randomized, 866, 876, "randomized", "", " ." +29, Placebo, 900, 907, "placebo", "", " ." +78316, Interval, 921, 934, "every morning", "", " \"every morning\"." +30, Morning, 927, 934, "morning", "", " ." +32, Latanoprost, 939, 950, "latanoprost", "", " . ." +34, Frequency, 951, 964, "every evening", "", " \"every evening\"." +120, Pilo/TimFC, 971, 975, "PTFC", "", " ." +35, Frequency, 989, 1000, "twice daily", "", " \"twice daily\"." +36, Duration, 1009, 1016, "8 weeks", "", " \"8 weeks\"." +37, IOP, 1032, 1035, "IOP", "", +78317, TimePoint, 1052, 1097, "08 . 00 , 10 . 00 , 16 . 00 and 18 . 00 hours", "", +78318, TimePoint, 1062, 1097, "10 . 00 , 16 . 00 and 18 . 00 hours", "", +78319, TimePoint, 1072, 1097, "16 . 00 and 18 . 00 hours", "", +78320, TimePoint, 1084, 1097, "18 . 00 hours", "", +124, FinalNumPatientsCT, 1231, 1243, "Thirty - two", "", " \"Thirty - two\"." +42, Diurnal_IOP, 1311, 1314, "IOP", "", +43, BaseLineValue, 1318, 1324, "24 . 1", "", " \"24 . 1\". \"24 . 1\"." +127, SdDevBL, 1331, 1336, "2 . 4", "", " \"2 . 4\". \"2 . 4\"." +45, mmHg, 1337, 1341, "mmHg", "", +46, Mean, 1344, 1348, "Mean", "", " . ." +130, Diurnal_IOP, 1349, 1365, "diurnal pressure", "", " ." +47, ResultMeasuredValue, 1370, 1376, "16 . 8", "", " \"16 . 8\"." +133, SdDevResValue, 1383, 1388, "2 . 1", "", " \"2 . 1\"." +51, mmHg, 1389, 1393, "mmHg", "", " ." +136, Pilo/TimFC, 1397, 1401, "PTFC", "", +48, ResultMeasuredValue, 1406, 1412, "16 . 9", "", " \"16 . 9\"." +134, SdDevResValue, 1419, 1424, "2 . 5", "", " \"2 . 5\"." +52, mmHg, 1425, 1429, "mmHg", "", +53, Latanoprost, 1433, 1444, "latanoprost", "", +139, PvalueDiff, 1449, 1457, "= 0 . 60", "", " \"= 0 . 60\"." +78341, ObservedResult, 1462, 1519, "No statistical difference between treatments was observed", "", " \"No statistical difference between treatments was observed\". \"No statistical difference between treatments was observed\"." +78342, TimePoint, 1523, 1550, "any individual time - point", "", " \"any individual time - point\". \"any individual time - point\"." +78327, TimePoint, 1561, 1574, "10 . 00 hours", "", " \"10 . 00 hours\". \"10 . 00 hours\"." +141, Pilo/TimFC, 1586, 1590, "PTFC", "", +60, IOP, 1613, 1616, "IOP", "", " . ." +61, ResultMeasuredValue, 1620, 1626, "15 . 9", "", " \"15 . 9\"." +145, SdDevResValue, 1633, 1638, "2 . 3", "", " \"2 . 3\"." +63, mmHg, 1639, 1643, "mmHg", "", " ." +64, Latanoprost, 1648, 1659, "latanoprost", "", +65, ResultMeasuredValue, 1660, 1666, "16 . 8", "", " \"16 . 8\"." +146, SdDevResValue, 1673, 1678, "2 . 7", "", " \"2 . 7\"." +67, mmHg, 1679, 1683, "mmHg", "", +149, PvalueDiff, 1688, 1696, "= 0 . 02", "", " \"= 0 . 02\"." +71, ObservedResult, 1701, 1753, "There were no statistical differences between groups", "", " \"There were no statistical differences between groups\". \"There were no statistical differences between groups\"." +78335, EndPointDescription, 1757, 1802, "unsolicited systemic or ocular adverse events", "", " . ." +150, PvalueDiff, 1807, 1815, "> 0 . 05", "", " \"> 0 . 05\"." +151, Pilo/TimFC, 1834, 1838, "PTFC", "", +73, Latanoprost, 1900, 1911, "latanoprost", "", +92867, BlurredVison, 1993, 2007, "blurred vision", "", " ." +163, Stinging, 2010, 2018, "stinging", "", " ." +78340, EndPointDescription, 2023, 2034, "ocular pain", "", " . ." +155, Pilo/TimFC, 2040, 2044, "PTFC", "", +165, PvalueDiff, 2049, 2058, "< 0 . 001", "", " \"< 0 . 001\". \"< 0 . 001\". \"< 0 . 001\"." +82, ConclusionComment, 2077, 2158, "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .", "", " \"Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .\"." +156, Pilo/TimFC, 2082, 2086, "PTFC", "", +78, Latanoprost, 2091, 2102, "latanoprost", "", +79, Diurnal_IOP, 2131, 2142, "diurnal IOP", "", +80, Primary_OpenAngleGlaucoma, 2146, 2150, "POAG", "", +81, OcularHypertension, 2154, 2156, "OH", "", +168, ConclusionComment, 2159, 2280, "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects .", "", " \"However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects .\"." +157, Pilo/TimFC, 2169, 2173, "PTFC", "", +84, Morning, 2208, 2215, "morning", "", +85, PMID, 2341, 2349, "18721251", "", " \"18721251\"." diff --git a/data/gl 18721251 copy_admin.n-triples b/data/gl 18721251 copy_admin.n-triples new file mode 100644 index 0000000..6be4949 --- /dev/null +++ b/data/gl 18721251 copy_admin.n-triples @@ -0,0 +1,237 @@ +# RDF export of group: Publication + . + "Publication 105584" . + "Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension ." . + "Ka ł uzny J" . + "2008" . + "Acta Ophthalmol ." . + "18721251" . + . + "Sobecki R" . + "Czechowicz - Janicka K" . + "Kecik D" . + "Ka ł uzny BJ" . + "Stewart JA" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 105591" . + "This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening" . + "8 weeks" . + . + . + . + "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH ." . + . + . + . + . + . + "Thirty - two" . + . + . + "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects ." . + "versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + . + . + . + . + . +# RDF export of group: Population + . + "Population 105607" . + "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "iop2" . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "blur" . + . + . + . + . + . + "st" . + . + . + . + . + . + "pain" . + . + . + . + . + . +# RDF export of group: Arm + . + "ptfc" . + . + . + . + . + . + . + . + . + . + "pl" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "ptfc" . + . + "twice daily" . + . + . + "pl" . + . + "every morning" . + . + . + "lat" . + . + "every evening" . + . +# RDF export of group: Medication + . + "ptfc" . + . + . + . + . + "pl" . + . + . + . + . + "lat" . + . + . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "24 . 1" . + "2 . 4" . + "16 . 8" . + "2 . 1" . + . + "iop2" . + . + "24 . 1" . + "2 . 4" . + "16 . 9" . + "2 . 5" . + . + "iopinsig1" . + . + "No statistical difference between treatments was observed" . + "any individual time - point" . + . + "iopinsig2" . + . + "No statistical difference between treatments was observed" . + "any individual time - point" . + . + "iopsig1" . + . + "15 . 9" . + "2 . 3" . + "10 . 00 hours" . + . + "iopsig2" . + . + "16 . 8" . + "2 . 7" . + "10 . 00 hours" . + . + "ae1" . + . + "There were no statistical differences between groups" . + . + "ae2" . + . + "There were no statistical differences between groups" . + . + "blur1" . + . + . + "blur2" . + . + . + "sting1" . + . + . + "sting2" . + . + . + "pain1" . + . + . + "pain2" . + . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "= 0 . 60" . + . + . + . + "iopsig" . + "= 0 . 02" . + . + . + . + "ae" . + "> 0 . 05" . + . + . + . + "blur" . + "< 0 . 001" . + . + . + . + "sting" . + "< 0 . 001" . + . + . + . + "pain" . + "< 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18721251 copy_export.csv b/data/gl 18721251 copy_export.csv new file mode 100644 index 0000000..6aecf3c --- /dev/null +++ b/data/gl 18721251 copy_export.csv @@ -0,0 +1,510 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +829, 1, 1, 1, 0, 4, 0, 4, "Acta" +829, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +829, 1, 3, 3, 16, 17, 16, 17, "." +829, 2, 1, 4, 0, 4, 18, 22, "2008" +829, 2, 2, 5, 5, 8, 23, 26, "Dec" +829, 2, 3, 6, 9, 10, 27, 28, ";" +829, 2, 4, 7, 11, 13, 29, 31, "86" +829, 2, 5, 8, 14, 15, 32, 33, "(" +829, 2, 6, 9, 16, 17, 34, 35, "8" +829, 2, 7, 10, 18, 19, 36, 37, ")" +829, 2, 8, 11, 20, 21, 38, 39, ":" +829, 2, 9, 12, 22, 25, 40, 43, "860" +829, 2, 10, 13, 26, 27, 44, 45, "-" +829, 2, 11, 14, 28, 29, 46, 47, "5" +829, 2, 12, 15, 30, 31, 48, 49, "." +829, 2, 13, 16, 32, 35, 50, 53, "doi" +829, 2, 14, 17, 36, 37, 54, 55, ":" +829, 2, 15, 18, 38, 40, 56, 58, "10" +829, 2, 16, 19, 41, 42, 59, 60, "." +829, 2, 17, 20, 43, 47, 61, 65, "1111" +829, 2, 18, 21, 48, 49, 66, 67, "/" +829, 2, 19, 22, 50, 51, 68, 69, "j" +829, 2, 20, 23, 52, 53, 70, 71, "." +829, 2, 21, 24, 54, 58, 72, 76, "1755" +829, 2, 22, 25, 59, 60, 77, 78, "-" +829, 2, 23, 26, 61, 65, 79, 83, "3768" +829, 2, 24, 27, 66, 67, 84, 85, "." +829, 2, 25, 28, 68, 72, 86, 90, "2008" +829, 2, 26, 29, 73, 74, 91, 92, "." +829, 2, 27, 30, 75, 80, 93, 98, "01324" +829, 2, 28, 31, 81, 82, 99, 100, "." +829, 2, 29, 32, 83, 84, 101, 102, "x" +829, 2, 30, 33, 85, 86, 103, 104, "." +829, 3, 1, 34, 0, 4, 105, 109, "Epub" +829, 3, 2, 35, 5, 9, 110, 114, "2008" +829, 3, 3, 36, 10, 13, 115, 118, "Aug" +829, 3, 4, 37, 14, 16, 119, 121, "20" +829, 3, 5, 38, 17, 18, 122, 123, "." +829, 4, 1, 39, 0, 8, 124, 132, "Efficacy" +829, 4, 2, 40, 9, 12, 133, 136, "and" +829, 4, 3, 41, 13, 19, 137, 143, "safety" +829, 4, 4, 42, 20, 22, 144, 146, "of" +829, 4, 5, 43, 23, 34, 147, 158, "latanoprost" +829, 4, 6, 44, 35, 41, 159, 165, "versus" +829, 4, 7, 45, 42, 53, 166, 177, "pilocarpine" +829, 4, 8, 46, 54, 55, 178, 179, "/" +829, 4, 9, 47, 56, 63, 180, 187, "timolol" +829, 4, 10, 48, 64, 71, 188, 195, "maleate" +829, 4, 11, 49, 72, 77, 196, 201, "fixed" +829, 4, 12, 50, 78, 89, 202, 213, "combination" +829, 4, 13, 51, 90, 92, 214, 216, "in" +829, 4, 14, 52, 93, 101, 217, 225, "patients" +829, 4, 15, 53, 102, 106, 226, 230, "with" +829, 4, 16, 54, 107, 114, 231, 238, "primary" +829, 4, 17, 55, 115, 119, 239, 243, "open" +829, 4, 18, 56, 120, 121, 244, 245, "-" +829, 4, 19, 57, 122, 127, 246, 251, "angle" +829, 4, 20, 58, 128, 136, 252, 260, "glaucoma" +829, 4, 21, 59, 137, 139, 261, 263, "or" +829, 4, 22, 60, 140, 146, 264, 270, "ocular" +829, 4, 23, 61, 147, 159, 271, 283, "hypertension" +829, 4, 24, 62, 160, 161, 284, 285, "." +829, 5, 1, 63, 0, 2, 286, 288, "Ka" +829, 5, 2, 64, 3, 4, 289, 290, "ł" +829, 5, 3, 65, 5, 9, 291, 295, "uzny" +829, 5, 4, 66, 10, 11, 296, 297, "J" +829, 5, 5, 67, 12, 13, 298, 299, "(" +829, 5, 6, 68, 14, 15, 300, 301, "1" +829, 5, 7, 69, 16, 17, 302, 303, ")" +829, 5, 8, 70, 18, 19, 304, 305, "," +829, 5, 9, 71, 20, 27, 306, 313, "Sobecki" +829, 5, 10, 72, 28, 29, 314, 315, "R" +829, 5, 11, 73, 30, 31, 316, 317, "," +829, 5, 12, 74, 32, 42, 318, 328, "Czechowicz" +829, 5, 13, 75, 43, 44, 329, 330, "-" +829, 5, 14, 76, 45, 52, 331, 338, "Janicka" +829, 5, 15, 77, 53, 54, 339, 340, "K" +829, 5, 16, 78, 55, 56, 341, 342, "," +829, 5, 17, 79, 57, 62, 343, 348, "Kecik" +829, 5, 18, 80, 63, 64, 349, 350, "D" +829, 5, 19, 81, 65, 66, 351, 352, "," +829, 5, 20, 82, 67, 69, 353, 355, "Ka" +829, 5, 21, 83, 70, 71, 356, 357, "ł" +829, 5, 22, 84, 72, 76, 358, 362, "uzny" +829, 5, 23, 85, 77, 79, 363, 365, "BJ" +829, 5, 24, 86, 80, 81, 366, 367, "," +829, 5, 25, 87, 82, 89, 368, 375, "Stewart" +829, 5, 26, 88, 90, 92, 376, 378, "JA" +829, 5, 27, 89, 93, 94, 379, 380, "," +829, 5, 28, 90, 95, 102, 381, 388, "Stewart" +829, 5, 29, 91, 103, 105, 389, 391, "WC" +829, 5, 30, 92, 106, 107, 392, 393, "." +829, 6, 1, 93, 0, 6, 394, 400, "Author" +829, 6, 2, 94, 7, 18, 401, 412, "information" +829, 6, 3, 95, 19, 20, 413, 414, ":" +829, 6, 4, 96, 21, 22, 415, 416, "(" +829, 6, 5, 97, 23, 24, 417, 418, "1" +829, 6, 6, 98, 25, 26, 419, 420, ")" +829, 6, 7, 99, 27, 40, 421, 434, "Ophthalmology" +829, 6, 8, 100, 41, 47, 435, 441, "Clinic" +829, 6, 9, 101, 48, 49, 442, 443, "," +829, 6, 10, 102, 50, 53, 444, 447, "UMK" +829, 6, 11, 103, 54, 61, 448, 455, "Medical" +829, 6, 12, 104, 62, 69, 456, 463, "College" +829, 6, 13, 105, 70, 71, 464, 465, "," +829, 6, 14, 106, 72, 81, 466, 475, "Bydgoszcz" +829, 6, 15, 107, 82, 83, 476, 477, "," +829, 6, 16, 108, 84, 90, 478, 484, "Poland" +829, 6, 17, 109, 91, 92, 485, 486, "." +829, 7, 1, 110, 0, 7, 487, 494, "PURPOSE" +829, 7, 2, 111, 8, 9, 495, 496, ":" +829, 7, 3, 112, 10, 14, 497, 501, "This" +829, 7, 4, 113, 15, 20, 502, 507, "study" +829, 7, 5, 114, 21, 26, 508, 513, "aimed" +829, 7, 6, 115, 27, 29, 514, 516, "to" +829, 7, 7, 116, 30, 37, 517, 524, "compare" +829, 7, 8, 117, 38, 41, 525, 528, "the" +829, 7, 9, 118, 42, 48, 529, 535, "safety" +829, 7, 10, 119, 49, 52, 536, 539, "and" +829, 7, 11, 120, 53, 59, 540, 546, "effect" +829, 7, 12, 121, 60, 62, 547, 549, "on" +829, 7, 13, 122, 63, 74, 550, 561, "intraocular" +829, 7, 14, 123, 75, 83, 562, 570, "pressure" +829, 7, 15, 124, 84, 85, 571, 572, "(" +829, 7, 16, 125, 86, 89, 573, 576, "IOP" +829, 7, 17, 126, 90, 91, 577, 578, ")" +829, 7, 18, 127, 92, 94, 579, 581, "of" +829, 7, 19, 128, 95, 106, 582, 593, "latanoprost" +829, 7, 20, 129, 107, 112, 594, 599, "given" +829, 7, 21, 130, 113, 118, 600, 605, "every" +829, 7, 22, 131, 119, 126, 606, 613, "evening" +829, 7, 23, 132, 127, 133, 614, 620, "versus" +829, 7, 24, 133, 134, 145, 621, 632, "pilocarpine" +829, 7, 25, 134, 146, 147, 633, 634, "/" +829, 7, 26, 135, 148, 155, 635, 642, "timolol" +829, 7, 27, 136, 156, 163, 643, 650, "maleate" +829, 7, 28, 137, 164, 169, 651, 656, "fixed" +829, 7, 29, 138, 170, 181, 657, 668, "combination" +829, 7, 30, 139, 182, 183, 669, 670, "(" +829, 7, 31, 140, 184, 188, 671, 675, "PTFC" +829, 7, 32, 141, 189, 190, 676, 677, ")" +829, 7, 33, 142, 191, 196, 678, 683, "given" +829, 7, 34, 143, 197, 202, 684, 689, "twice" +829, 7, 35, 144, 203, 208, 690, 695, "daily" +829, 7, 36, 145, 209, 211, 696, 698, "in" +829, 7, 37, 146, 212, 220, 699, 707, "patients" +829, 7, 38, 147, 221, 225, 708, 712, "with" +829, 7, 39, 148, 226, 233, 713, 720, "primary" +829, 7, 40, 149, 234, 238, 721, 725, "open" +829, 7, 41, 150, 239, 240, 726, 727, "-" +829, 7, 42, 151, 241, 246, 728, 733, "angle" +829, 7, 43, 152, 247, 255, 734, 742, "glaucoma" +829, 7, 44, 153, 256, 257, 743, 744, "(" +829, 7, 45, 154, 258, 262, 745, 749, "POAG" +829, 7, 46, 155, 263, 264, 750, 751, ")" +829, 7, 47, 156, 265, 267, 752, 754, "or" +829, 7, 48, 157, 268, 274, 755, 761, "ocular" +829, 7, 49, 158, 275, 287, 762, 774, "hypertension" +829, 7, 50, 159, 288, 289, 775, 776, "(" +829, 7, 51, 160, 290, 292, 777, 779, "OH" +829, 7, 52, 161, 293, 294, 780, 781, ")" +829, 7, 53, 162, 295, 296, 782, 783, "." +829, 8, 1, 163, 0, 7, 784, 791, "METHODS" +829, 8, 2, 164, 8, 9, 792, 793, ":" +829, 8, 3, 165, 10, 19, 794, 803, "Following" +829, 8, 4, 166, 20, 21, 804, 805, "a" +829, 8, 5, 167, 22, 23, 806, 807, "6" +829, 8, 6, 168, 24, 25, 808, 809, "-" +829, 8, 7, 169, 26, 30, 810, 814, "week" +829, 8, 8, 170, 31, 32, 815, 816, "," +829, 8, 9, 171, 33, 41, 817, 825, "medicine" +829, 8, 10, 172, 42, 43, 826, 827, "-" +829, 8, 11, 173, 44, 48, 828, 832, "free" +829, 8, 12, 174, 49, 55, 833, 839, "period" +829, 8, 13, 175, 56, 57, 840, 841, "," +829, 8, 14, 176, 58, 67, 842, 851, "qualified" +829, 8, 15, 177, 68, 76, 852, 860, "patients" +829, 8, 16, 178, 77, 81, 861, 865, "were" +829, 8, 17, 179, 82, 92, 866, 876, "randomized" +829, 8, 18, 180, 93, 96, 877, 880, "for" +829, 8, 19, 181, 97, 103, 881, 887, "Period" +829, 8, 20, 182, 104, 105, 888, 889, "1" +829, 8, 21, 183, 106, 108, 890, 892, "to" +829, 8, 22, 184, 109, 115, 893, 899, "either" +829, 8, 23, 185, 116, 123, 900, 907, "placebo" +829, 8, 24, 186, 124, 136, 908, 920, "administered" +829, 8, 25, 187, 137, 142, 921, 926, "every" +829, 8, 26, 188, 143, 150, 927, 934, "morning" +829, 8, 27, 189, 151, 154, 935, 938, "and" +829, 8, 28, 190, 155, 166, 939, 950, "latanoprost" +829, 8, 29, 191, 167, 172, 951, 956, "every" +829, 8, 30, 192, 173, 180, 957, 964, "evening" +829, 8, 31, 193, 181, 183, 965, 967, "or" +829, 8, 32, 194, 184, 186, 968, 970, "to" +829, 8, 33, 195, 187, 191, 971, 975, "PTFC" +829, 8, 34, 196, 192, 204, 976, 988, "administered" +829, 8, 35, 197, 205, 210, 989, 994, "twice" +829, 8, 36, 198, 211, 216, 995, 1000, "daily" +829, 8, 37, 199, 217, 218, 1001, 1002, "." +829, 9, 1, 200, 0, 5, 1003, 1008, "After" +829, 9, 2, 201, 6, 7, 1009, 1010, "8" +829, 9, 3, 202, 8, 13, 1011, 1016, "weeks" +829, 9, 4, 203, 14, 16, 1017, 1019, "of" +829, 9, 5, 204, 17, 26, 1020, 1029, "treatment" +829, 9, 6, 205, 27, 28, 1030, 1031, "," +829, 9, 7, 206, 29, 32, 1032, 1035, "IOP" +829, 9, 8, 207, 33, 36, 1036, 1039, "was" +829, 9, 9, 208, 37, 45, 1040, 1048, "measured" +829, 9, 10, 209, 46, 48, 1049, 1051, "at" +829, 9, 11, 210, 49, 51, 1052, 1054, "08" +829, 9, 12, 211, 52, 53, 1055, 1056, "." +829, 9, 13, 212, 54, 56, 1057, 1059, "00" +829, 9, 14, 213, 57, 58, 1060, 1061, "," +829, 9, 15, 214, 59, 61, 1062, 1064, "10" +829, 9, 16, 215, 62, 63, 1065, 1066, "." +829, 9, 17, 216, 64, 66, 1067, 1069, "00" +829, 9, 18, 217, 67, 68, 1070, 1071, "," +829, 9, 19, 218, 69, 71, 1072, 1074, "16" +829, 9, 20, 219, 72, 73, 1075, 1076, "." +829, 9, 21, 220, 74, 76, 1077, 1079, "00" +829, 9, 22, 221, 77, 80, 1080, 1083, "and" +829, 9, 23, 222, 81, 83, 1084, 1086, "18" +829, 9, 24, 223, 84, 85, 1087, 1088, "." +829, 9, 25, 224, 86, 88, 1089, 1091, "00" +829, 9, 26, 225, 89, 94, 1092, 1097, "hours" +829, 9, 27, 226, 95, 96, 1098, 1099, "." +829, 10, 1, 227, 0, 8, 1100, 1108, "Patients" +829, 10, 2, 228, 9, 13, 1109, 1113, "were" +829, 10, 3, 229, 14, 18, 1114, 1118, "then" +829, 10, 4, 230, 19, 27, 1119, 1127, "switched" +829, 10, 5, 231, 28, 30, 1128, 1130, "to" +829, 10, 6, 232, 31, 34, 1131, 1134, "the" +829, 10, 7, 233, 35, 43, 1135, 1143, "opposite" +829, 10, 8, 234, 44, 53, 1144, 1153, "treatment" +829, 10, 9, 235, 54, 57, 1154, 1157, "and" +829, 10, 10, 236, 58, 67, 1158, 1167, "underwent" +829, 10, 11, 237, 68, 69, 1168, 1169, "a" +829, 10, 12, 238, 70, 76, 1170, 1176, "second" +829, 10, 13, 239, 77, 84, 1177, 1184, "diurnal" +829, 10, 14, 240, 85, 95, 1185, 1195, "evaluation" +829, 10, 15, 241, 96, 98, 1196, 1198, "at" +829, 10, 16, 242, 99, 102, 1199, 1202, "the" +829, 10, 17, 243, 103, 106, 1203, 1206, "end" +829, 10, 18, 244, 107, 109, 1207, 1209, "of" +829, 10, 19, 245, 110, 116, 1210, 1216, "Period" +829, 10, 20, 246, 117, 118, 1217, 1218, "2" +829, 10, 21, 247, 119, 120, 1219, 1220, "." +829, 11, 1, 248, 0, 7, 1221, 1228, "RESULTS" +829, 11, 2, 249, 8, 9, 1229, 1230, ":" +829, 11, 3, 250, 10, 16, 1231, 1237, "Thirty" +829, 11, 4, 251, 17, 18, 1238, 1239, "-" +829, 11, 5, 252, 19, 22, 1240, 1243, "two" +829, 11, 6, 253, 23, 31, 1244, 1252, "patients" +829, 11, 7, 254, 32, 41, 1253, 1262, "completed" +829, 11, 8, 255, 42, 46, 1263, 1267, "this" +829, 11, 9, 256, 47, 52, 1268, 1273, "study" +829, 11, 10, 257, 53, 54, 1274, 1275, "." +829, 12, 1, 258, 0, 4, 1276, 1280, "They" +829, 12, 2, 259, 5, 17, 1281, 1293, "demonstrated" +829, 12, 3, 260, 18, 25, 1294, 1301, "diurnal" +829, 12, 4, 261, 26, 34, 1302, 1310, "baseline" +829, 12, 5, 262, 35, 38, 1311, 1314, "IOP" +829, 12, 6, 263, 39, 41, 1315, 1317, "of" +829, 12, 7, 264, 42, 44, 1318, 1320, "24" +829, 12, 8, 265, 45, 46, 1321, 1322, "." +829, 12, 9, 266, 47, 48, 1323, 1324, "1" +829, 12, 10, 267, 49, 50, 1325, 1326, "+" +829, 12, 11, 268, 51, 52, 1327, 1328, "/" +829, 12, 12, 269, 53, 54, 1329, 1330, "-" +829, 12, 13, 270, 55, 56, 1331, 1332, "2" +829, 12, 14, 271, 57, 58, 1333, 1334, "." +829, 12, 15, 272, 59, 60, 1335, 1336, "4" +829, 12, 16, 273, 61, 65, 1337, 1341, "mmHg" +829, 12, 17, 274, 66, 67, 1342, 1343, "." +829, 13, 1, 275, 0, 4, 1344, 1348, "Mean" +829, 13, 2, 276, 5, 12, 1349, 1356, "diurnal" +829, 13, 3, 277, 13, 21, 1357, 1365, "pressure" +829, 13, 4, 278, 22, 25, 1366, 1369, "was" +829, 13, 5, 279, 26, 28, 1370, 1372, "16" +829, 13, 6, 280, 29, 30, 1373, 1374, "." +829, 13, 7, 281, 31, 32, 1375, 1376, "8" +829, 13, 8, 282, 33, 34, 1377, 1378, "+" +829, 13, 9, 283, 35, 36, 1379, 1380, "/" +829, 13, 10, 284, 37, 38, 1381, 1382, "-" +829, 13, 11, 285, 39, 40, 1383, 1384, "2" +829, 13, 12, 286, 41, 42, 1385, 1386, "." +829, 13, 13, 287, 43, 44, 1387, 1388, "1" +829, 13, 14, 288, 45, 49, 1389, 1393, "mmHg" +829, 13, 15, 289, 50, 52, 1394, 1396, "on" +829, 13, 16, 290, 53, 57, 1397, 1401, "PTFC" +829, 13, 17, 291, 58, 61, 1402, 1405, "and" +829, 13, 18, 292, 62, 64, 1406, 1408, "16" +829, 13, 19, 293, 65, 66, 1409, 1410, "." +829, 13, 20, 294, 67, 68, 1411, 1412, "9" +829, 13, 21, 295, 69, 70, 1413, 1414, "+" +829, 13, 22, 296, 71, 72, 1415, 1416, "/" +829, 13, 23, 297, 73, 74, 1417, 1418, "-" +829, 13, 24, 298, 75, 76, 1419, 1420, "2" +829, 13, 25, 299, 77, 78, 1421, 1422, "." +829, 13, 26, 300, 79, 80, 1423, 1424, "5" +829, 13, 27, 301, 81, 85, 1425, 1429, "mmHg" +829, 13, 28, 302, 86, 88, 1430, 1432, "on" +829, 13, 29, 303, 89, 100, 1433, 1444, "latanoprost" +829, 13, 30, 304, 101, 102, 1445, 1446, "(" +829, 13, 31, 305, 103, 104, 1447, 1448, "p" +829, 13, 32, 306, 105, 106, 1449, 1450, "=" +829, 13, 33, 307, 107, 108, 1451, 1452, "0" +829, 13, 34, 308, 109, 110, 1453, 1454, "." +829, 13, 35, 309, 111, 113, 1455, 1457, "60" +829, 13, 36, 310, 114, 115, 1458, 1459, ")" +829, 13, 37, 311, 116, 117, 1460, 1461, "." +829, 14, 1, 312, 0, 2, 1462, 1464, "No" +829, 14, 2, 313, 3, 14, 1465, 1476, "statistical" +829, 14, 3, 314, 15, 25, 1477, 1487, "difference" +829, 14, 4, 315, 26, 33, 1488, 1495, "between" +829, 14, 5, 316, 34, 44, 1496, 1506, "treatments" +829, 14, 6, 317, 45, 48, 1507, 1510, "was" +829, 14, 7, 318, 49, 57, 1511, 1519, "observed" +829, 14, 8, 319, 58, 60, 1520, 1522, "at" +829, 14, 9, 320, 61, 64, 1523, 1526, "any" +829, 14, 10, 321, 65, 75, 1527, 1537, "individual" +829, 14, 11, 322, 76, 80, 1538, 1542, "time" +829, 14, 12, 323, 81, 82, 1543, 1544, "-" +829, 14, 13, 324, 83, 88, 1545, 1550, "point" +829, 14, 14, 325, 89, 95, 1551, 1557, "except" +829, 14, 15, 326, 96, 98, 1558, 1560, "at" +829, 14, 16, 327, 99, 101, 1561, 1563, "10" +829, 14, 17, 328, 102, 103, 1564, 1565, "." +829, 14, 18, 329, 104, 106, 1566, 1568, "00" +829, 14, 19, 330, 107, 112, 1569, 1574, "hours" +829, 14, 20, 331, 113, 114, 1575, 1576, "," +829, 14, 21, 332, 115, 119, 1577, 1581, "when" +829, 14, 22, 333, 120, 123, 1582, 1585, "the" +829, 14, 23, 334, 124, 128, 1586, 1590, "PTFC" +829, 14, 24, 335, 129, 134, 1591, 1596, "group" +829, 14, 25, 336, 135, 147, 1597, 1609, "demonstrated" +829, 14, 26, 337, 148, 150, 1610, 1612, "an" +829, 14, 27, 338, 151, 154, 1613, 1616, "IOP" +829, 14, 28, 339, 155, 157, 1617, 1619, "of" +829, 14, 29, 340, 158, 160, 1620, 1622, "15" +829, 14, 30, 341, 161, 162, 1623, 1624, "." +829, 14, 31, 342, 163, 164, 1625, 1626, "9" +829, 14, 32, 343, 165, 166, 1627, 1628, "+" +829, 14, 33, 344, 167, 168, 1629, 1630, "/" +829, 14, 34, 345, 169, 170, 1631, 1632, "-" +829, 14, 35, 346, 171, 172, 1633, 1634, "2" +829, 14, 36, 347, 173, 174, 1635, 1636, "." +829, 14, 37, 348, 175, 176, 1637, 1638, "3" +829, 14, 38, 349, 177, 181, 1639, 1643, "mmHg" +829, 14, 39, 350, 182, 185, 1644, 1647, "and" +829, 14, 40, 351, 186, 197, 1648, 1659, "latanoprost" +829, 14, 41, 352, 198, 200, 1660, 1662, "16" +829, 14, 42, 353, 201, 202, 1663, 1664, "." +829, 14, 43, 354, 203, 204, 1665, 1666, "8" +829, 14, 44, 355, 205, 206, 1667, 1668, "+" +829, 14, 45, 356, 207, 208, 1669, 1670, "/" +829, 14, 46, 357, 209, 210, 1671, 1672, "-" +829, 14, 47, 358, 211, 212, 1673, 1674, "2" +829, 14, 48, 359, 213, 214, 1675, 1676, "." +829, 14, 49, 360, 215, 216, 1677, 1678, "7" +829, 14, 50, 361, 217, 221, 1679, 1683, "mmHg" +829, 14, 51, 362, 222, 223, 1684, 1685, "(" +829, 14, 52, 363, 224, 225, 1686, 1687, "p" +829, 14, 53, 364, 226, 227, 1688, 1689, "=" +829, 14, 54, 365, 228, 229, 1690, 1691, "0" +829, 14, 55, 366, 230, 231, 1692, 1693, "." +829, 14, 56, 367, 232, 234, 1694, 1696, "02" +829, 14, 57, 368, 235, 236, 1697, 1698, ")" +829, 14, 58, 369, 237, 238, 1699, 1700, "." +829, 15, 1, 370, 0, 5, 1701, 1706, "There" +829, 15, 2, 371, 6, 10, 1707, 1711, "were" +829, 15, 3, 372, 11, 13, 1712, 1714, "no" +829, 15, 4, 373, 14, 25, 1715, 1726, "statistical" +829, 15, 5, 374, 26, 37, 1727, 1738, "differences" +829, 15, 6, 375, 38, 45, 1739, 1746, "between" +829, 15, 7, 376, 46, 52, 1747, 1753, "groups" +829, 15, 8, 377, 53, 55, 1754, 1756, "in" +829, 15, 9, 378, 56, 67, 1757, 1768, "unsolicited" +829, 15, 10, 379, 68, 76, 1769, 1777, "systemic" +829, 15, 11, 380, 77, 79, 1778, 1780, "or" +829, 15, 12, 381, 80, 86, 1781, 1787, "ocular" +829, 15, 13, 382, 87, 94, 1788, 1795, "adverse" +829, 15, 14, 383, 95, 101, 1796, 1802, "events" +829, 15, 15, 384, 102, 103, 1803, 1804, "(" +829, 15, 16, 385, 104, 105, 1805, 1806, "p" +829, 15, 17, 386, 106, 107, 1807, 1808, ">" +829, 15, 18, 387, 108, 109, 1809, 1810, "0" +829, 15, 19, 388, 110, 111, 1811, 1812, "." +829, 15, 20, 389, 112, 114, 1813, 1815, "05" +829, 15, 21, 390, 115, 116, 1816, 1817, ")" +829, 15, 22, 391, 117, 118, 1818, 1819, "." +829, 16, 1, 392, 0, 7, 1820, 1827, "However" +829, 16, 2, 393, 8, 9, 1828, 1829, "," +829, 16, 3, 394, 10, 13, 1830, 1833, "the" +829, 16, 4, 395, 14, 18, 1834, 1838, "PTFC" +829, 16, 5, 396, 19, 24, 1839, 1844, "group" +829, 16, 6, 397, 25, 31, 1845, 1851, "showed" +829, 16, 7, 398, 32, 33, 1852, 1853, "a" +829, 16, 8, 399, 34, 42, 1854, 1862, "narrower" +829, 16, 9, 400, 43, 48, 1863, 1868, "pupil" +829, 16, 10, 401, 49, 57, 1869, 1877, "diameter" +829, 16, 11, 402, 58, 59, 1878, 1879, "(" +829, 16, 12, 403, 60, 61, 1880, 1881, "2" +829, 16, 13, 404, 62, 63, 1882, 1883, "." +829, 16, 14, 405, 64, 65, 1884, 1885, "3" +829, 16, 15, 406, 66, 68, 1886, 1888, "mm" +829, 16, 16, 407, 69, 70, 1889, 1890, ")" +829, 16, 17, 408, 71, 75, 1891, 1895, "than" +829, 16, 18, 409, 76, 79, 1896, 1899, "the" +829, 16, 19, 410, 80, 91, 1900, 1911, "latanoprost" +829, 16, 20, 411, 92, 97, 1912, 1917, "group" +829, 16, 21, 412, 98, 99, 1918, 1919, "(" +829, 16, 22, 413, 100, 101, 1920, 1921, "3" +829, 16, 23, 414, 102, 103, 1922, 1923, "." +829, 16, 24, 415, 104, 105, 1924, 1925, "7" +829, 16, 25, 416, 106, 108, 1926, 1928, "mm" +829, 16, 26, 417, 109, 110, 1929, 1930, ")" +829, 16, 27, 418, 111, 112, 1931, 1932, "." +829, 17, 1, 419, 0, 12, 1933, 1945, "Additionally" +829, 17, 2, 420, 13, 14, 1946, 1947, "," +829, 17, 3, 421, 15, 16, 1948, 1949, "a" +829, 17, 4, 422, 17, 26, 1950, 1959, "solicited" +829, 17, 5, 423, 27, 34, 1960, 1967, "symptom" +829, 17, 6, 424, 35, 41, 1968, 1974, "survey" +829, 17, 7, 425, 42, 54, 1975, 1987, "demonstrated" +829, 17, 8, 426, 55, 59, 1988, 1992, "mild" +829, 17, 9, 427, 60, 67, 1993, 2000, "blurred" +829, 17, 10, 428, 68, 74, 2001, 2007, "vision" +829, 17, 11, 429, 75, 76, 2008, 2009, "," +829, 17, 12, 430, 77, 85, 2010, 2018, "stinging" +829, 17, 13, 431, 86, 89, 2019, 2022, "and" +829, 17, 14, 432, 90, 96, 2023, 2029, "ocular" +829, 17, 15, 433, 97, 101, 2030, 2034, "pain" +829, 17, 16, 434, 102, 106, 2035, 2039, "with" +829, 17, 17, 435, 107, 111, 2040, 2044, "PTFC" +829, 17, 18, 436, 112, 113, 2045, 2046, "(" +829, 17, 19, 437, 114, 115, 2047, 2048, "p" +829, 17, 20, 438, 116, 117, 2049, 2050, "<" +829, 17, 21, 439, 118, 119, 2051, 2052, "0" +829, 17, 22, 440, 120, 121, 2053, 2054, "." +829, 17, 23, 441, 122, 125, 2055, 2058, "001" +829, 17, 24, 442, 126, 127, 2059, 2060, ")" +829, 17, 25, 443, 128, 129, 2061, 2062, "." +829, 18, 1, 444, 0, 11, 2063, 2074, "CONCLUSIONS" +829, 18, 2, 445, 12, 13, 2075, 2076, ":" +829, 18, 3, 446, 14, 18, 2077, 2081, "Both" +829, 18, 4, 447, 19, 23, 2082, 2086, "PTFC" +829, 18, 5, 448, 24, 27, 2087, 2090, "and" +829, 18, 6, 449, 28, 39, 2091, 2102, "latanoprost" +829, 18, 7, 450, 40, 43, 2103, 2106, "are" +829, 18, 8, 451, 44, 55, 2107, 2118, "efficacious" +829, 18, 9, 452, 56, 58, 2119, 2121, "in" +829, 18, 10, 453, 59, 67, 2122, 2130, "reducing" +829, 18, 11, 454, 68, 75, 2131, 2138, "diurnal" +829, 18, 12, 455, 76, 79, 2139, 2142, "IOP" +829, 18, 13, 456, 80, 82, 2143, 2145, "in" +829, 18, 14, 457, 83, 87, 2146, 2150, "POAG" +829, 18, 15, 458, 88, 90, 2151, 2153, "or" +829, 18, 16, 459, 91, 93, 2154, 2156, "OH" +829, 18, 17, 460, 94, 95, 2157, 2158, "." +829, 19, 1, 461, 0, 7, 2159, 2166, "However" +829, 19, 2, 462, 8, 9, 2167, 2168, "," +829, 19, 3, 463, 10, 14, 2169, 2173, "PTFC" +829, 19, 4, 464, 15, 18, 2174, 2177, "may" +829, 19, 5, 465, 19, 21, 2178, 2180, "be" +829, 19, 6, 466, 22, 26, 2181, 2185, "more" +829, 19, 7, 467, 27, 36, 2186, 2195, "effective" +829, 19, 8, 468, 37, 39, 2196, 2198, "in" +829, 19, 9, 469, 40, 43, 2199, 2202, "the" +829, 19, 10, 470, 44, 48, 2203, 2207, "late" +829, 19, 11, 471, 49, 56, 2208, 2215, "morning" +829, 19, 12, 472, 57, 60, 2216, 2219, "and" +829, 19, 13, 473, 61, 64, 2220, 2223, "may" +829, 19, 14, 474, 65, 69, 2224, 2228, "have" +829, 19, 15, 475, 70, 71, 2229, 2230, "a" +829, 19, 16, 476, 72, 79, 2231, 2238, "greater" +829, 19, 17, 477, 80, 89, 2239, 2248, "incidence" +829, 19, 18, 478, 90, 92, 2249, 2251, "of" +829, 19, 19, 479, 93, 97, 2252, 2256, "mild" +829, 19, 20, 480, 98, 104, 2257, 2263, "ocular" +829, 19, 21, 481, 105, 109, 2264, 2268, "side" +829, 19, 22, 482, 110, 111, 2269, 2270, "-" +829, 19, 23, 483, 112, 119, 2271, 2278, "effects" +829, 19, 24, 484, 120, 121, 2279, 2280, "." +829, 20, 1, 485, 0, 3, 2281, 2284, "DOI" +829, 20, 2, 486, 4, 5, 2285, 2286, ":" +829, 20, 3, 487, 6, 8, 2287, 2289, "10" +829, 20, 4, 488, 9, 10, 2290, 2291, "." +829, 20, 5, 489, 11, 15, 2292, 2296, "1111" +829, 20, 6, 490, 16, 17, 2297, 2298, "/" +829, 20, 7, 491, 18, 19, 2299, 2300, "j" +829, 20, 8, 492, 20, 21, 2301, 2302, "." +829, 20, 9, 493, 22, 26, 2303, 2307, "1755" +829, 20, 10, 494, 27, 28, 2308, 2309, "-" +829, 20, 11, 495, 29, 33, 2310, 2314, "3768" +829, 20, 12, 496, 34, 35, 2315, 2316, "." +829, 20, 13, 497, 36, 40, 2317, 2321, "2008" +829, 20, 14, 498, 41, 42, 2322, 2323, "." +829, 20, 15, 499, 43, 48, 2324, 2329, "01324" +829, 20, 16, 500, 49, 50, 2330, 2331, "." +829, 20, 17, 501, 51, 52, 2332, 2333, "x" +829, 20, 18, 502, 53, 57, 2334, 2338, "PMID" +829, 20, 19, 503, 58, 59, 2339, 2340, ":" +829, 20, 20, 504, 60, 68, 2341, 2349, "18721251" +829, 20, 21, 505, 69, 70, 2350, 2351, "[" +829, 20, 22, 506, 71, 78, 2352, 2359, "Indexed" +829, 20, 23, 507, 79, 82, 2360, 2363, "for" +829, 20, 24, 508, 83, 90, 2364, 2371, "MEDLINE" +829, 20, 25, 509, 91, 92, 2372, 2373, "]" diff --git a/data/gl 18721251_admin.annodb b/data/gl 18721251_admin.annodb new file mode 100644 index 0000000..92c0df2 --- /dev/null +++ b/data/gl 18721251_admin.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Acta Ophthalmol .", "", " \"Acta Ophthalmol .\"." +1, PublicationYear, 18, 22, "2008", "", " \"2008\"." +2, Title, 124, 285, "Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension .\"." +3, Latanoprost, 147, 158, "latanoprost", "", " . ." +4, Pilocarpine, 166, 177, "pilocarpine", "", +92, Pilo/TimFC, 166, 195, "pilocarpine / timolol maleate", "", " ." +5, Timolol, 180, 195, "timolol maleate", "", +38, Primary_OpenAngleGlaucoma, 231, 260, "primary open - angle glaucoma", "", " ." +7, OcularHypertension, 264, 283, "ocular hypertension", "", " ." +8, Author, 286, 297, "Ka ł uzny J", "", " \"Ka ł uzny J\"." +9, Author, 306, 315, "Sobecki R", "", " \"Sobecki R\"." +10, Author, 318, 340, "Czechowicz - Janicka K", "", " \"Czechowicz - Janicka K\"." +11, Author, 343, 350, "Kecik D", "", " \"Kecik D\"." +12, Author, 353, 365, "Ka ł uzny BJ", "", " \"Ka ł uzny BJ\"." +13, Author, 368, 378, "Stewart JA", "", " \"Stewart JA\"." +14, Author, 381, 391, "Stewart WC", "", " \"Stewart WC\"." +15, Poland, 478, 484, "Poland", "", " ." +16, ObjectiveDescription, 497, 613, "This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening", "", " \"This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening\"." +18, IOP, 550, 570, "intraocular pressure", "", +19, IOP, 573, 576, "IOP", "", +20, Latanoprost, 582, 593, "latanoprost", "", +78307, Interval, 600, 613, "every evening", "", " \"every evening\"." +17, ObjectiveDescription, 614, 781, "versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +23, Pilocarpine, 621, 632, "pilocarpine", "", +108, Pilo/TimFC, 621, 650, "pilocarpine / timolol maleate", "", +24, Timolol, 635, 650, "timolol maleate", "", +109, Pilo/TimFC, 671, 675, "PTFC", "", +25, Frequency, 684, 695, "twice daily", "", " \"twice daily\"." +78313, Precondition, 699, 781, "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", " \"patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )\"." +39, Primary_OpenAngleGlaucoma, 713, 742, "primary open - angle glaucoma", "", +40, Primary_OpenAngleGlaucoma, 745, 749, "POAG", "", +26, OcularHypertension, 755, 774, "ocular hypertension", "", +27, OcularHypertension, 777, 779, "OH", "", +28, Randomized, 866, 876, "randomized", "", " ." +29, Placebo, 900, 907, "placebo", "", " ." +78316, Interval, 921, 934, "every morning", "", " \"every morning\"." +30, Morning, 927, 934, "morning", "", +32, Latanoprost, 939, 950, "latanoprost", "", +34, Frequency, 951, 964, "every evening", "", +120, Pilo/TimFC, 971, 975, "PTFC", "", +35, Frequency, 989, 1000, "twice daily", "", +36, Duration, 1009, 1016, "8 weeks", "", " \"8 weeks\"." +37, IOP, 1032, 1035, "IOP", "", +78317, TimePoint, 1052, 1097, "08 . 00 , 10 . 00 , 16 . 00 and 18 . 00 hours", "", +78318, TimePoint, 1062, 1097, "10 . 00 , 16 . 00 and 18 . 00 hours", "", +78319, TimePoint, 1072, 1097, "16 . 00 and 18 . 00 hours", "", +78320, TimePoint, 1084, 1097, "18 . 00 hours", "", +124, FinalNumPatientsCT, 1231, 1243, "Thirty - two", "", " \"Thirty - two\"." +42, Diurnal_IOP, 1311, 1314, "IOP", "", " ." +43, BaseLineValue, 1318, 1324, "24 . 1", "", " \"24 . 1\". \"24 . 1\"." +127, SdDevBL, 1331, 1336, "2 . 4", "", " \"2 . 4\". \"2 . 4\"." +45, mmHg, 1337, 1341, "mmHg", "", " ." +46, Mean, 1344, 1348, "Mean", "", " . ." +130, Diurnal_IOP, 1349, 1365, "diurnal pressure", "", +47, ResultMeasuredValue, 1370, 1376, "16 . 8", "", " \"16 . 8\"." +133, SdDevResValue, 1383, 1388, "2 . 1", "", " \"2 . 1\"." +51, mmHg, 1389, 1393, "mmHg", "", +136, Pilo/TimFC, 1397, 1401, "PTFC", "", +48, ResultMeasuredValue, 1406, 1412, "16 . 9", "", " \"16 . 9\"." +134, SdDevResValue, 1419, 1424, "2 . 5", "", " \"2 . 5\"." +52, mmHg, 1425, 1429, "mmHg", "", +53, Latanoprost, 1433, 1444, "latanoprost", "", +139, PvalueDiff, 1449, 1457, "= 0 . 60", "", " \"= 0 . 60\"." +78341, ObservedResult, 1462, 1519, "No statistical difference between treatments was observed", "", " \"No statistical difference between treatments was observed\"." +78342, TimePoint, 1523, 1550, "any individual time - point", "", " \"any individual time - point\"." +78327, TimePoint, 1561, 1574, "10 . 00 hours", "", " \"10 . 00 hours\". \"10 . 00 hours\"." +141, Pilo/TimFC, 1586, 1590, "PTFC", "", +60, IOP, 1613, 1616, "IOP", "", +61, ResultMeasuredValue, 1620, 1626, "15 . 9", "", " \"15 . 9\"." +145, SdDevResValue, 1633, 1638, "2 . 3", "", " \"2 . 3\"." +63, mmHg, 1639, 1643, "mmHg", "", +64, Latanoprost, 1648, 1659, "latanoprost", "", +65, ResultMeasuredValue, 1660, 1666, "16 . 8", "", " \"16 . 8\"." +146, SdDevResValue, 1673, 1678, "2 . 7", "", " \"2 . 7\"." +67, mmHg, 1679, 1683, "mmHg", "", +149, PvalueDiff, 1688, 1696, "= 0 . 02", "", " \"= 0 . 02\"." +71, ObservedResult, 1701, 1753, "There were no statistical differences between groups", "", " \"There were no statistical differences between groups\"." +78335, EndPointDescription, 1757, 1802, "unsolicited systemic or ocular adverse events", "", " . ." +150, PvalueDiff, 1807, 1815, "> 0 . 05", "", +151, Pilo/TimFC, 1834, 1838, "PTFC", "", +73, Latanoprost, 1900, 1911, "latanoprost", "", +92867, BlurredVison, 1993, 2007, "blurred vision", "", +163, Stinging, 2010, 2018, "stinging", "", +78340, EndPointDescription, 2023, 2034, "ocular pain", "", +155, Pilo/TimFC, 2040, 2044, "PTFC", "", +165, PvalueDiff, 2049, 2058, "< 0 . 001", "", +82, ConclusionComment, 2077, 2158, "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .", "", " \"Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .\"." +156, Pilo/TimFC, 2082, 2086, "PTFC", "", +78, Latanoprost, 2091, 2102, "latanoprost", "", +79, Diurnal_IOP, 2131, 2142, "diurnal IOP", "", +80, Primary_OpenAngleGlaucoma, 2146, 2150, "POAG", "", +81, OcularHypertension, 2154, 2156, "OH", "", +168, ConclusionComment, 2159, 2280, "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects .", "", " \"However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects .\"." +157, Pilo/TimFC, 2169, 2173, "PTFC", "", +84, Morning, 2208, 2215, "morning", "", +85, PMID, 2341, 2349, "18721251", "", " \"18721251\"." diff --git a/data/gl 18721251_admin.n-triples b/data/gl 18721251_admin.n-triples new file mode 100644 index 0000000..32d1000 --- /dev/null +++ b/data/gl 18721251_admin.n-triples @@ -0,0 +1,154 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension ." . + "Ka ł uzny J" . + "2008" . + "Acta Ophthalmol ." . + "18721251" . + . + "Sobecki R" . + "Czechowicz - Janicka K" . + "Kecik D" . + "Ka ł uzny BJ" . + "Stewart JA" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening" . + "8 weeks" . + . + . + . + "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH ." . + . + . + . + . + . + "Thirty - two" . + "versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint" . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + . + . + "Arm_PTFC" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "every evening" . + . + . + "Intervention_PTFC" . + . + "twice daily" . + . + . + "Intervention placebo" . + . + "every morning" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + . + . + . + "Medication_PTFC" . + . + . + . + . + "Medication placebo" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_lat" . + . + "24 . 1" . + "2 . 4" . + "16 . 9" . + "2 . 5" . + . + "Outcome_PTFC" . + . + "24 . 1" . + "2 . 4" . + "16 . 8" . + "2 . 1" . + . + "Outcome_lat_10" . + . + "16 . 8" . + "2 . 7" . + "10 . 00 hours" . + . + "Outcome_PTFC_10" . + . + "15 . 9" . + "2 . 3" . + "10 . 00 hours" . + . + "Outcome_AE" . + . + "There were no statistical differences between groups" . + . + "Outcome_AnyTimePoint" . + . + "No statistical difference between treatments was observed" . + "any individual time - point" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "= 0 . 60" . + . + . + . + "DiffBetweenGroups_10" . + "= 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18721251_export.csv b/data/gl 18721251_export.csv new file mode 100644 index 0000000..80a584e --- /dev/null +++ b/data/gl 18721251_export.csv @@ -0,0 +1,510 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +449, 1, 1, 1, 0, 4, 0, 4, "Acta" +449, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +449, 1, 3, 3, 16, 17, 16, 17, "." +449, 2, 1, 4, 0, 4, 18, 22, "2008" +449, 2, 2, 5, 5, 8, 23, 26, "Dec" +449, 2, 3, 6, 9, 10, 27, 28, ";" +449, 2, 4, 7, 11, 13, 29, 31, "86" +449, 2, 5, 8, 14, 15, 32, 33, "(" +449, 2, 6, 9, 16, 17, 34, 35, "8" +449, 2, 7, 10, 18, 19, 36, 37, ")" +449, 2, 8, 11, 20, 21, 38, 39, ":" +449, 2, 9, 12, 22, 25, 40, 43, "860" +449, 2, 10, 13, 26, 27, 44, 45, "-" +449, 2, 11, 14, 28, 29, 46, 47, "5" +449, 2, 12, 15, 30, 31, 48, 49, "." +449, 2, 13, 16, 32, 35, 50, 53, "doi" +449, 2, 14, 17, 36, 37, 54, 55, ":" +449, 2, 15, 18, 38, 40, 56, 58, "10" +449, 2, 16, 19, 41, 42, 59, 60, "." +449, 2, 17, 20, 43, 47, 61, 65, "1111" +449, 2, 18, 21, 48, 49, 66, 67, "/" +449, 2, 19, 22, 50, 51, 68, 69, "j" +449, 2, 20, 23, 52, 53, 70, 71, "." +449, 2, 21, 24, 54, 58, 72, 76, "1755" +449, 2, 22, 25, 59, 60, 77, 78, "-" +449, 2, 23, 26, 61, 65, 79, 83, "3768" +449, 2, 24, 27, 66, 67, 84, 85, "." +449, 2, 25, 28, 68, 72, 86, 90, "2008" +449, 2, 26, 29, 73, 74, 91, 92, "." +449, 2, 27, 30, 75, 80, 93, 98, "01324" +449, 2, 28, 31, 81, 82, 99, 100, "." +449, 2, 29, 32, 83, 84, 101, 102, "x" +449, 2, 30, 33, 85, 86, 103, 104, "." +449, 3, 1, 34, 0, 4, 105, 109, "Epub" +449, 3, 2, 35, 5, 9, 110, 114, "2008" +449, 3, 3, 36, 10, 13, 115, 118, "Aug" +449, 3, 4, 37, 14, 16, 119, 121, "20" +449, 3, 5, 38, 17, 18, 122, 123, "." +449, 4, 1, 39, 0, 8, 124, 132, "Efficacy" +449, 4, 2, 40, 9, 12, 133, 136, "and" +449, 4, 3, 41, 13, 19, 137, 143, "safety" +449, 4, 4, 42, 20, 22, 144, 146, "of" +449, 4, 5, 43, 23, 34, 147, 158, "latanoprost" +449, 4, 6, 44, 35, 41, 159, 165, "versus" +449, 4, 7, 45, 42, 53, 166, 177, "pilocarpine" +449, 4, 8, 46, 54, 55, 178, 179, "/" +449, 4, 9, 47, 56, 63, 180, 187, "timolol" +449, 4, 10, 48, 64, 71, 188, 195, "maleate" +449, 4, 11, 49, 72, 77, 196, 201, "fixed" +449, 4, 12, 50, 78, 89, 202, 213, "combination" +449, 4, 13, 51, 90, 92, 214, 216, "in" +449, 4, 14, 52, 93, 101, 217, 225, "patients" +449, 4, 15, 53, 102, 106, 226, 230, "with" +449, 4, 16, 54, 107, 114, 231, 238, "primary" +449, 4, 17, 55, 115, 119, 239, 243, "open" +449, 4, 18, 56, 120, 121, 244, 245, "-" +449, 4, 19, 57, 122, 127, 246, 251, "angle" +449, 4, 20, 58, 128, 136, 252, 260, "glaucoma" +449, 4, 21, 59, 137, 139, 261, 263, "or" +449, 4, 22, 60, 140, 146, 264, 270, "ocular" +449, 4, 23, 61, 147, 159, 271, 283, "hypertension" +449, 4, 24, 62, 160, 161, 284, 285, "." +449, 5, 1, 63, 0, 2, 286, 288, "Ka" +449, 5, 2, 64, 3, 4, 289, 290, "ł" +449, 5, 3, 65, 5, 9, 291, 295, "uzny" +449, 5, 4, 66, 10, 11, 296, 297, "J" +449, 5, 5, 67, 12, 13, 298, 299, "(" +449, 5, 6, 68, 14, 15, 300, 301, "1" +449, 5, 7, 69, 16, 17, 302, 303, ")" +449, 5, 8, 70, 18, 19, 304, 305, "," +449, 5, 9, 71, 20, 27, 306, 313, "Sobecki" +449, 5, 10, 72, 28, 29, 314, 315, "R" +449, 5, 11, 73, 30, 31, 316, 317, "," +449, 5, 12, 74, 32, 42, 318, 328, "Czechowicz" +449, 5, 13, 75, 43, 44, 329, 330, "-" +449, 5, 14, 76, 45, 52, 331, 338, "Janicka" +449, 5, 15, 77, 53, 54, 339, 340, "K" +449, 5, 16, 78, 55, 56, 341, 342, "," +449, 5, 17, 79, 57, 62, 343, 348, "Kecik" +449, 5, 18, 80, 63, 64, 349, 350, "D" +449, 5, 19, 81, 65, 66, 351, 352, "," +449, 5, 20, 82, 67, 69, 353, 355, "Ka" +449, 5, 21, 83, 70, 71, 356, 357, "ł" +449, 5, 22, 84, 72, 76, 358, 362, "uzny" +449, 5, 23, 85, 77, 79, 363, 365, "BJ" +449, 5, 24, 86, 80, 81, 366, 367, "," +449, 5, 25, 87, 82, 89, 368, 375, "Stewart" +449, 5, 26, 88, 90, 92, 376, 378, "JA" +449, 5, 27, 89, 93, 94, 379, 380, "," +449, 5, 28, 90, 95, 102, 381, 388, "Stewart" +449, 5, 29, 91, 103, 105, 389, 391, "WC" +449, 5, 30, 92, 106, 107, 392, 393, "." +449, 6, 1, 93, 0, 6, 394, 400, "Author" +449, 6, 2, 94, 7, 18, 401, 412, "information" +449, 6, 3, 95, 19, 20, 413, 414, ":" +449, 6, 4, 96, 21, 22, 415, 416, "(" +449, 6, 5, 97, 23, 24, 417, 418, "1" +449, 6, 6, 98, 25, 26, 419, 420, ")" +449, 6, 7, 99, 27, 40, 421, 434, "Ophthalmology" +449, 6, 8, 100, 41, 47, 435, 441, "Clinic" +449, 6, 9, 101, 48, 49, 442, 443, "," +449, 6, 10, 102, 50, 53, 444, 447, "UMK" +449, 6, 11, 103, 54, 61, 448, 455, "Medical" +449, 6, 12, 104, 62, 69, 456, 463, "College" +449, 6, 13, 105, 70, 71, 464, 465, "," +449, 6, 14, 106, 72, 81, 466, 475, "Bydgoszcz" +449, 6, 15, 107, 82, 83, 476, 477, "," +449, 6, 16, 108, 84, 90, 478, 484, "Poland" +449, 6, 17, 109, 91, 92, 485, 486, "." +449, 7, 1, 110, 0, 7, 487, 494, "PURPOSE" +449, 7, 2, 111, 8, 9, 495, 496, ":" +449, 7, 3, 112, 10, 14, 497, 501, "This" +449, 7, 4, 113, 15, 20, 502, 507, "study" +449, 7, 5, 114, 21, 26, 508, 513, "aimed" +449, 7, 6, 115, 27, 29, 514, 516, "to" +449, 7, 7, 116, 30, 37, 517, 524, "compare" +449, 7, 8, 117, 38, 41, 525, 528, "the" +449, 7, 9, 118, 42, 48, 529, 535, "safety" +449, 7, 10, 119, 49, 52, 536, 539, "and" +449, 7, 11, 120, 53, 59, 540, 546, "effect" +449, 7, 12, 121, 60, 62, 547, 549, "on" +449, 7, 13, 122, 63, 74, 550, 561, "intraocular" +449, 7, 14, 123, 75, 83, 562, 570, "pressure" +449, 7, 15, 124, 84, 85, 571, 572, "(" +449, 7, 16, 125, 86, 89, 573, 576, "IOP" +449, 7, 17, 126, 90, 91, 577, 578, ")" +449, 7, 18, 127, 92, 94, 579, 581, "of" +449, 7, 19, 128, 95, 106, 582, 593, "latanoprost" +449, 7, 20, 129, 107, 112, 594, 599, "given" +449, 7, 21, 130, 113, 118, 600, 605, "every" +449, 7, 22, 131, 119, 126, 606, 613, "evening" +449, 7, 23, 132, 127, 133, 614, 620, "versus" +449, 7, 24, 133, 134, 145, 621, 632, "pilocarpine" +449, 7, 25, 134, 146, 147, 633, 634, "/" +449, 7, 26, 135, 148, 155, 635, 642, "timolol" +449, 7, 27, 136, 156, 163, 643, 650, "maleate" +449, 7, 28, 137, 164, 169, 651, 656, "fixed" +449, 7, 29, 138, 170, 181, 657, 668, "combination" +449, 7, 30, 139, 182, 183, 669, 670, "(" +449, 7, 31, 140, 184, 188, 671, 675, "PTFC" +449, 7, 32, 141, 189, 190, 676, 677, ")" +449, 7, 33, 142, 191, 196, 678, 683, "given" +449, 7, 34, 143, 197, 202, 684, 689, "twice" +449, 7, 35, 144, 203, 208, 690, 695, "daily" +449, 7, 36, 145, 209, 211, 696, 698, "in" +449, 7, 37, 146, 212, 220, 699, 707, "patients" +449, 7, 38, 147, 221, 225, 708, 712, "with" +449, 7, 39, 148, 226, 233, 713, 720, "primary" +449, 7, 40, 149, 234, 238, 721, 725, "open" +449, 7, 41, 150, 239, 240, 726, 727, "-" +449, 7, 42, 151, 241, 246, 728, 733, "angle" +449, 7, 43, 152, 247, 255, 734, 742, "glaucoma" +449, 7, 44, 153, 256, 257, 743, 744, "(" +449, 7, 45, 154, 258, 262, 745, 749, "POAG" +449, 7, 46, 155, 263, 264, 750, 751, ")" +449, 7, 47, 156, 265, 267, 752, 754, "or" +449, 7, 48, 157, 268, 274, 755, 761, "ocular" +449, 7, 49, 158, 275, 287, 762, 774, "hypertension" +449, 7, 50, 159, 288, 289, 775, 776, "(" +449, 7, 51, 160, 290, 292, 777, 779, "OH" +449, 7, 52, 161, 293, 294, 780, 781, ")" +449, 7, 53, 162, 295, 296, 782, 783, "." +449, 8, 1, 163, 0, 7, 784, 791, "METHODS" +449, 8, 2, 164, 8, 9, 792, 793, ":" +449, 8, 3, 165, 10, 19, 794, 803, "Following" +449, 8, 4, 166, 20, 21, 804, 805, "a" +449, 8, 5, 167, 22, 23, 806, 807, "6" +449, 8, 6, 168, 24, 25, 808, 809, "-" +449, 8, 7, 169, 26, 30, 810, 814, "week" +449, 8, 8, 170, 31, 32, 815, 816, "," +449, 8, 9, 171, 33, 41, 817, 825, "medicine" +449, 8, 10, 172, 42, 43, 826, 827, "-" +449, 8, 11, 173, 44, 48, 828, 832, "free" +449, 8, 12, 174, 49, 55, 833, 839, "period" +449, 8, 13, 175, 56, 57, 840, 841, "," +449, 8, 14, 176, 58, 67, 842, 851, "qualified" +449, 8, 15, 177, 68, 76, 852, 860, "patients" +449, 8, 16, 178, 77, 81, 861, 865, "were" +449, 8, 17, 179, 82, 92, 866, 876, "randomized" +449, 8, 18, 180, 93, 96, 877, 880, "for" +449, 8, 19, 181, 97, 103, 881, 887, "Period" +449, 8, 20, 182, 104, 105, 888, 889, "1" +449, 8, 21, 183, 106, 108, 890, 892, "to" +449, 8, 22, 184, 109, 115, 893, 899, "either" +449, 8, 23, 185, 116, 123, 900, 907, "placebo" +449, 8, 24, 186, 124, 136, 908, 920, "administered" +449, 8, 25, 187, 137, 142, 921, 926, "every" +449, 8, 26, 188, 143, 150, 927, 934, "morning" +449, 8, 27, 189, 151, 154, 935, 938, "and" +449, 8, 28, 190, 155, 166, 939, 950, "latanoprost" +449, 8, 29, 191, 167, 172, 951, 956, "every" +449, 8, 30, 192, 173, 180, 957, 964, "evening" +449, 8, 31, 193, 181, 183, 965, 967, "or" +449, 8, 32, 194, 184, 186, 968, 970, "to" +449, 8, 33, 195, 187, 191, 971, 975, "PTFC" +449, 8, 34, 196, 192, 204, 976, 988, "administered" +449, 8, 35, 197, 205, 210, 989, 994, "twice" +449, 8, 36, 198, 211, 216, 995, 1000, "daily" +449, 8, 37, 199, 217, 218, 1001, 1002, "." +449, 9, 1, 200, 0, 5, 1003, 1008, "After" +449, 9, 2, 201, 6, 7, 1009, 1010, "8" +449, 9, 3, 202, 8, 13, 1011, 1016, "weeks" +449, 9, 4, 203, 14, 16, 1017, 1019, "of" +449, 9, 5, 204, 17, 26, 1020, 1029, "treatment" +449, 9, 6, 205, 27, 28, 1030, 1031, "," +449, 9, 7, 206, 29, 32, 1032, 1035, "IOP" +449, 9, 8, 207, 33, 36, 1036, 1039, "was" +449, 9, 9, 208, 37, 45, 1040, 1048, "measured" +449, 9, 10, 209, 46, 48, 1049, 1051, "at" +449, 9, 11, 210, 49, 51, 1052, 1054, "08" +449, 9, 12, 211, 52, 53, 1055, 1056, "." +449, 9, 13, 212, 54, 56, 1057, 1059, "00" +449, 9, 14, 213, 57, 58, 1060, 1061, "," +449, 9, 15, 214, 59, 61, 1062, 1064, "10" +449, 9, 16, 215, 62, 63, 1065, 1066, "." +449, 9, 17, 216, 64, 66, 1067, 1069, "00" +449, 9, 18, 217, 67, 68, 1070, 1071, "," +449, 9, 19, 218, 69, 71, 1072, 1074, "16" +449, 9, 20, 219, 72, 73, 1075, 1076, "." +449, 9, 21, 220, 74, 76, 1077, 1079, "00" +449, 9, 22, 221, 77, 80, 1080, 1083, "and" +449, 9, 23, 222, 81, 83, 1084, 1086, "18" +449, 9, 24, 223, 84, 85, 1087, 1088, "." +449, 9, 25, 224, 86, 88, 1089, 1091, "00" +449, 9, 26, 225, 89, 94, 1092, 1097, "hours" +449, 9, 27, 226, 95, 96, 1098, 1099, "." +449, 10, 1, 227, 0, 8, 1100, 1108, "Patients" +449, 10, 2, 228, 9, 13, 1109, 1113, "were" +449, 10, 3, 229, 14, 18, 1114, 1118, "then" +449, 10, 4, 230, 19, 27, 1119, 1127, "switched" +449, 10, 5, 231, 28, 30, 1128, 1130, "to" +449, 10, 6, 232, 31, 34, 1131, 1134, "the" +449, 10, 7, 233, 35, 43, 1135, 1143, "opposite" +449, 10, 8, 234, 44, 53, 1144, 1153, "treatment" +449, 10, 9, 235, 54, 57, 1154, 1157, "and" +449, 10, 10, 236, 58, 67, 1158, 1167, "underwent" +449, 10, 11, 237, 68, 69, 1168, 1169, "a" +449, 10, 12, 238, 70, 76, 1170, 1176, "second" +449, 10, 13, 239, 77, 84, 1177, 1184, "diurnal" +449, 10, 14, 240, 85, 95, 1185, 1195, "evaluation" +449, 10, 15, 241, 96, 98, 1196, 1198, "at" +449, 10, 16, 242, 99, 102, 1199, 1202, "the" +449, 10, 17, 243, 103, 106, 1203, 1206, "end" +449, 10, 18, 244, 107, 109, 1207, 1209, "of" +449, 10, 19, 245, 110, 116, 1210, 1216, "Period" +449, 10, 20, 246, 117, 118, 1217, 1218, "2" +449, 10, 21, 247, 119, 120, 1219, 1220, "." +449, 11, 1, 248, 0, 7, 1221, 1228, "RESULTS" +449, 11, 2, 249, 8, 9, 1229, 1230, ":" +449, 11, 3, 250, 10, 16, 1231, 1237, "Thirty" +449, 11, 4, 251, 17, 18, 1238, 1239, "-" +449, 11, 5, 252, 19, 22, 1240, 1243, "two" +449, 11, 6, 253, 23, 31, 1244, 1252, "patients" +449, 11, 7, 254, 32, 41, 1253, 1262, "completed" +449, 11, 8, 255, 42, 46, 1263, 1267, "this" +449, 11, 9, 256, 47, 52, 1268, 1273, "study" +449, 11, 10, 257, 53, 54, 1274, 1275, "." +449, 12, 1, 258, 0, 4, 1276, 1280, "They" +449, 12, 2, 259, 5, 17, 1281, 1293, "demonstrated" +449, 12, 3, 260, 18, 25, 1294, 1301, "diurnal" +449, 12, 4, 261, 26, 34, 1302, 1310, "baseline" +449, 12, 5, 262, 35, 38, 1311, 1314, "IOP" +449, 12, 6, 263, 39, 41, 1315, 1317, "of" +449, 12, 7, 264, 42, 44, 1318, 1320, "24" +449, 12, 8, 265, 45, 46, 1321, 1322, "." +449, 12, 9, 266, 47, 48, 1323, 1324, "1" +449, 12, 10, 267, 49, 50, 1325, 1326, "+" +449, 12, 11, 268, 51, 52, 1327, 1328, "/" +449, 12, 12, 269, 53, 54, 1329, 1330, "-" +449, 12, 13, 270, 55, 56, 1331, 1332, "2" +449, 12, 14, 271, 57, 58, 1333, 1334, "." +449, 12, 15, 272, 59, 60, 1335, 1336, "4" +449, 12, 16, 273, 61, 65, 1337, 1341, "mmHg" +449, 12, 17, 274, 66, 67, 1342, 1343, "." +449, 13, 1, 275, 0, 4, 1344, 1348, "Mean" +449, 13, 2, 276, 5, 12, 1349, 1356, "diurnal" +449, 13, 3, 277, 13, 21, 1357, 1365, "pressure" +449, 13, 4, 278, 22, 25, 1366, 1369, "was" +449, 13, 5, 279, 26, 28, 1370, 1372, "16" +449, 13, 6, 280, 29, 30, 1373, 1374, "." +449, 13, 7, 281, 31, 32, 1375, 1376, "8" +449, 13, 8, 282, 33, 34, 1377, 1378, "+" +449, 13, 9, 283, 35, 36, 1379, 1380, "/" +449, 13, 10, 284, 37, 38, 1381, 1382, "-" +449, 13, 11, 285, 39, 40, 1383, 1384, "2" +449, 13, 12, 286, 41, 42, 1385, 1386, "." +449, 13, 13, 287, 43, 44, 1387, 1388, "1" +449, 13, 14, 288, 45, 49, 1389, 1393, "mmHg" +449, 13, 15, 289, 50, 52, 1394, 1396, "on" +449, 13, 16, 290, 53, 57, 1397, 1401, "PTFC" +449, 13, 17, 291, 58, 61, 1402, 1405, "and" +449, 13, 18, 292, 62, 64, 1406, 1408, "16" +449, 13, 19, 293, 65, 66, 1409, 1410, "." +449, 13, 20, 294, 67, 68, 1411, 1412, "9" +449, 13, 21, 295, 69, 70, 1413, 1414, "+" +449, 13, 22, 296, 71, 72, 1415, 1416, "/" +449, 13, 23, 297, 73, 74, 1417, 1418, "-" +449, 13, 24, 298, 75, 76, 1419, 1420, "2" +449, 13, 25, 299, 77, 78, 1421, 1422, "." +449, 13, 26, 300, 79, 80, 1423, 1424, "5" +449, 13, 27, 301, 81, 85, 1425, 1429, "mmHg" +449, 13, 28, 302, 86, 88, 1430, 1432, "on" +449, 13, 29, 303, 89, 100, 1433, 1444, "latanoprost" +449, 13, 30, 304, 101, 102, 1445, 1446, "(" +449, 13, 31, 305, 103, 104, 1447, 1448, "p" +449, 13, 32, 306, 105, 106, 1449, 1450, "=" +449, 13, 33, 307, 107, 108, 1451, 1452, "0" +449, 13, 34, 308, 109, 110, 1453, 1454, "." +449, 13, 35, 309, 111, 113, 1455, 1457, "60" +449, 13, 36, 310, 114, 115, 1458, 1459, ")" +449, 13, 37, 311, 116, 117, 1460, 1461, "." +449, 14, 1, 312, 0, 2, 1462, 1464, "No" +449, 14, 2, 313, 3, 14, 1465, 1476, "statistical" +449, 14, 3, 314, 15, 25, 1477, 1487, "difference" +449, 14, 4, 315, 26, 33, 1488, 1495, "between" +449, 14, 5, 316, 34, 44, 1496, 1506, "treatments" +449, 14, 6, 317, 45, 48, 1507, 1510, "was" +449, 14, 7, 318, 49, 57, 1511, 1519, "observed" +449, 14, 8, 319, 58, 60, 1520, 1522, "at" +449, 14, 9, 320, 61, 64, 1523, 1526, "any" +449, 14, 10, 321, 65, 75, 1527, 1537, "individual" +449, 14, 11, 322, 76, 80, 1538, 1542, "time" +449, 14, 12, 323, 81, 82, 1543, 1544, "-" +449, 14, 13, 324, 83, 88, 1545, 1550, "point" +449, 14, 14, 325, 89, 95, 1551, 1557, "except" +449, 14, 15, 326, 96, 98, 1558, 1560, "at" +449, 14, 16, 327, 99, 101, 1561, 1563, "10" +449, 14, 17, 328, 102, 103, 1564, 1565, "." +449, 14, 18, 329, 104, 106, 1566, 1568, "00" +449, 14, 19, 330, 107, 112, 1569, 1574, "hours" +449, 14, 20, 331, 113, 114, 1575, 1576, "," +449, 14, 21, 332, 115, 119, 1577, 1581, "when" +449, 14, 22, 333, 120, 123, 1582, 1585, "the" +449, 14, 23, 334, 124, 128, 1586, 1590, "PTFC" +449, 14, 24, 335, 129, 134, 1591, 1596, "group" +449, 14, 25, 336, 135, 147, 1597, 1609, "demonstrated" +449, 14, 26, 337, 148, 150, 1610, 1612, "an" +449, 14, 27, 338, 151, 154, 1613, 1616, "IOP" +449, 14, 28, 339, 155, 157, 1617, 1619, "of" +449, 14, 29, 340, 158, 160, 1620, 1622, "15" +449, 14, 30, 341, 161, 162, 1623, 1624, "." +449, 14, 31, 342, 163, 164, 1625, 1626, "9" +449, 14, 32, 343, 165, 166, 1627, 1628, "+" +449, 14, 33, 344, 167, 168, 1629, 1630, "/" +449, 14, 34, 345, 169, 170, 1631, 1632, "-" +449, 14, 35, 346, 171, 172, 1633, 1634, "2" +449, 14, 36, 347, 173, 174, 1635, 1636, "." +449, 14, 37, 348, 175, 176, 1637, 1638, "3" +449, 14, 38, 349, 177, 181, 1639, 1643, "mmHg" +449, 14, 39, 350, 182, 185, 1644, 1647, "and" +449, 14, 40, 351, 186, 197, 1648, 1659, "latanoprost" +449, 14, 41, 352, 198, 200, 1660, 1662, "16" +449, 14, 42, 353, 201, 202, 1663, 1664, "." +449, 14, 43, 354, 203, 204, 1665, 1666, "8" +449, 14, 44, 355, 205, 206, 1667, 1668, "+" +449, 14, 45, 356, 207, 208, 1669, 1670, "/" +449, 14, 46, 357, 209, 210, 1671, 1672, "-" +449, 14, 47, 358, 211, 212, 1673, 1674, "2" +449, 14, 48, 359, 213, 214, 1675, 1676, "." +449, 14, 49, 360, 215, 216, 1677, 1678, "7" +449, 14, 50, 361, 217, 221, 1679, 1683, "mmHg" +449, 14, 51, 362, 222, 223, 1684, 1685, "(" +449, 14, 52, 363, 224, 225, 1686, 1687, "p" +449, 14, 53, 364, 226, 227, 1688, 1689, "=" +449, 14, 54, 365, 228, 229, 1690, 1691, "0" +449, 14, 55, 366, 230, 231, 1692, 1693, "." +449, 14, 56, 367, 232, 234, 1694, 1696, "02" +449, 14, 57, 368, 235, 236, 1697, 1698, ")" +449, 14, 58, 369, 237, 238, 1699, 1700, "." +449, 15, 1, 370, 0, 5, 1701, 1706, "There" +449, 15, 2, 371, 6, 10, 1707, 1711, "were" +449, 15, 3, 372, 11, 13, 1712, 1714, "no" +449, 15, 4, 373, 14, 25, 1715, 1726, "statistical" +449, 15, 5, 374, 26, 37, 1727, 1738, "differences" +449, 15, 6, 375, 38, 45, 1739, 1746, "between" +449, 15, 7, 376, 46, 52, 1747, 1753, "groups" +449, 15, 8, 377, 53, 55, 1754, 1756, "in" +449, 15, 9, 378, 56, 67, 1757, 1768, "unsolicited" +449, 15, 10, 379, 68, 76, 1769, 1777, "systemic" +449, 15, 11, 380, 77, 79, 1778, 1780, "or" +449, 15, 12, 381, 80, 86, 1781, 1787, "ocular" +449, 15, 13, 382, 87, 94, 1788, 1795, "adverse" +449, 15, 14, 383, 95, 101, 1796, 1802, "events" +449, 15, 15, 384, 102, 103, 1803, 1804, "(" +449, 15, 16, 385, 104, 105, 1805, 1806, "p" +449, 15, 17, 386, 106, 107, 1807, 1808, ">" +449, 15, 18, 387, 108, 109, 1809, 1810, "0" +449, 15, 19, 388, 110, 111, 1811, 1812, "." +449, 15, 20, 389, 112, 114, 1813, 1815, "05" +449, 15, 21, 390, 115, 116, 1816, 1817, ")" +449, 15, 22, 391, 117, 118, 1818, 1819, "." +449, 16, 1, 392, 0, 7, 1820, 1827, "However" +449, 16, 2, 393, 8, 9, 1828, 1829, "," +449, 16, 3, 394, 10, 13, 1830, 1833, "the" +449, 16, 4, 395, 14, 18, 1834, 1838, "PTFC" +449, 16, 5, 396, 19, 24, 1839, 1844, "group" +449, 16, 6, 397, 25, 31, 1845, 1851, "showed" +449, 16, 7, 398, 32, 33, 1852, 1853, "a" +449, 16, 8, 399, 34, 42, 1854, 1862, "narrower" +449, 16, 9, 400, 43, 48, 1863, 1868, "pupil" +449, 16, 10, 401, 49, 57, 1869, 1877, "diameter" +449, 16, 11, 402, 58, 59, 1878, 1879, "(" +449, 16, 12, 403, 60, 61, 1880, 1881, "2" +449, 16, 13, 404, 62, 63, 1882, 1883, "." +449, 16, 14, 405, 64, 65, 1884, 1885, "3" +449, 16, 15, 406, 66, 68, 1886, 1888, "mm" +449, 16, 16, 407, 69, 70, 1889, 1890, ")" +449, 16, 17, 408, 71, 75, 1891, 1895, "than" +449, 16, 18, 409, 76, 79, 1896, 1899, "the" +449, 16, 19, 410, 80, 91, 1900, 1911, "latanoprost" +449, 16, 20, 411, 92, 97, 1912, 1917, "group" +449, 16, 21, 412, 98, 99, 1918, 1919, "(" +449, 16, 22, 413, 100, 101, 1920, 1921, "3" +449, 16, 23, 414, 102, 103, 1922, 1923, "." +449, 16, 24, 415, 104, 105, 1924, 1925, "7" +449, 16, 25, 416, 106, 108, 1926, 1928, "mm" +449, 16, 26, 417, 109, 110, 1929, 1930, ")" +449, 16, 27, 418, 111, 112, 1931, 1932, "." +449, 17, 1, 419, 0, 12, 1933, 1945, "Additionally" +449, 17, 2, 420, 13, 14, 1946, 1947, "," +449, 17, 3, 421, 15, 16, 1948, 1949, "a" +449, 17, 4, 422, 17, 26, 1950, 1959, "solicited" +449, 17, 5, 423, 27, 34, 1960, 1967, "symptom" +449, 17, 6, 424, 35, 41, 1968, 1974, "survey" +449, 17, 7, 425, 42, 54, 1975, 1987, "demonstrated" +449, 17, 8, 426, 55, 59, 1988, 1992, "mild" +449, 17, 9, 427, 60, 67, 1993, 2000, "blurred" +449, 17, 10, 428, 68, 74, 2001, 2007, "vision" +449, 17, 11, 429, 75, 76, 2008, 2009, "," +449, 17, 12, 430, 77, 85, 2010, 2018, "stinging" +449, 17, 13, 431, 86, 89, 2019, 2022, "and" +449, 17, 14, 432, 90, 96, 2023, 2029, "ocular" +449, 17, 15, 433, 97, 101, 2030, 2034, "pain" +449, 17, 16, 434, 102, 106, 2035, 2039, "with" +449, 17, 17, 435, 107, 111, 2040, 2044, "PTFC" +449, 17, 18, 436, 112, 113, 2045, 2046, "(" +449, 17, 19, 437, 114, 115, 2047, 2048, "p" +449, 17, 20, 438, 116, 117, 2049, 2050, "<" +449, 17, 21, 439, 118, 119, 2051, 2052, "0" +449, 17, 22, 440, 120, 121, 2053, 2054, "." +449, 17, 23, 441, 122, 125, 2055, 2058, "001" +449, 17, 24, 442, 126, 127, 2059, 2060, ")" +449, 17, 25, 443, 128, 129, 2061, 2062, "." +449, 18, 1, 444, 0, 11, 2063, 2074, "CONCLUSIONS" +449, 18, 2, 445, 12, 13, 2075, 2076, ":" +449, 18, 3, 446, 14, 18, 2077, 2081, "Both" +449, 18, 4, 447, 19, 23, 2082, 2086, "PTFC" +449, 18, 5, 448, 24, 27, 2087, 2090, "and" +449, 18, 6, 449, 28, 39, 2091, 2102, "latanoprost" +449, 18, 7, 450, 40, 43, 2103, 2106, "are" +449, 18, 8, 451, 44, 55, 2107, 2118, "efficacious" +449, 18, 9, 452, 56, 58, 2119, 2121, "in" +449, 18, 10, 453, 59, 67, 2122, 2130, "reducing" +449, 18, 11, 454, 68, 75, 2131, 2138, "diurnal" +449, 18, 12, 455, 76, 79, 2139, 2142, "IOP" +449, 18, 13, 456, 80, 82, 2143, 2145, "in" +449, 18, 14, 457, 83, 87, 2146, 2150, "POAG" +449, 18, 15, 458, 88, 90, 2151, 2153, "or" +449, 18, 16, 459, 91, 93, 2154, 2156, "OH" +449, 18, 17, 460, 94, 95, 2157, 2158, "." +449, 19, 1, 461, 0, 7, 2159, 2166, "However" +449, 19, 2, 462, 8, 9, 2167, 2168, "," +449, 19, 3, 463, 10, 14, 2169, 2173, "PTFC" +449, 19, 4, 464, 15, 18, 2174, 2177, "may" +449, 19, 5, 465, 19, 21, 2178, 2180, "be" +449, 19, 6, 466, 22, 26, 2181, 2185, "more" +449, 19, 7, 467, 27, 36, 2186, 2195, "effective" +449, 19, 8, 468, 37, 39, 2196, 2198, "in" +449, 19, 9, 469, 40, 43, 2199, 2202, "the" +449, 19, 10, 470, 44, 48, 2203, 2207, "late" +449, 19, 11, 471, 49, 56, 2208, 2215, "morning" +449, 19, 12, 472, 57, 60, 2216, 2219, "and" +449, 19, 13, 473, 61, 64, 2220, 2223, "may" +449, 19, 14, 474, 65, 69, 2224, 2228, "have" +449, 19, 15, 475, 70, 71, 2229, 2230, "a" +449, 19, 16, 476, 72, 79, 2231, 2238, "greater" +449, 19, 17, 477, 80, 89, 2239, 2248, "incidence" +449, 19, 18, 478, 90, 92, 2249, 2251, "of" +449, 19, 19, 479, 93, 97, 2252, 2256, "mild" +449, 19, 20, 480, 98, 104, 2257, 2263, "ocular" +449, 19, 21, 481, 105, 109, 2264, 2268, "side" +449, 19, 22, 482, 110, 111, 2269, 2270, "-" +449, 19, 23, 483, 112, 119, 2271, 2278, "effects" +449, 19, 24, 484, 120, 121, 2279, 2280, "." +449, 20, 1, 485, 0, 3, 2281, 2284, "DOI" +449, 20, 2, 486, 4, 5, 2285, 2286, ":" +449, 20, 3, 487, 6, 8, 2287, 2289, "10" +449, 20, 4, 488, 9, 10, 2290, 2291, "." +449, 20, 5, 489, 11, 15, 2292, 2296, "1111" +449, 20, 6, 490, 16, 17, 2297, 2298, "/" +449, 20, 7, 491, 18, 19, 2299, 2300, "j" +449, 20, 8, 492, 20, 21, 2301, 2302, "." +449, 20, 9, 493, 22, 26, 2303, 2307, "1755" +449, 20, 10, 494, 27, 28, 2308, 2309, "-" +449, 20, 11, 495, 29, 33, 2310, 2314, "3768" +449, 20, 12, 496, 34, 35, 2315, 2316, "." +449, 20, 13, 497, 36, 40, 2317, 2321, "2008" +449, 20, 14, 498, 41, 42, 2322, 2323, "." +449, 20, 15, 499, 43, 48, 2324, 2329, "01324" +449, 20, 16, 500, 49, 50, 2330, 2331, "." +449, 20, 17, 501, 51, 52, 2332, 2333, "x" +449, 20, 18, 502, 53, 57, 2334, 2338, "PMID" +449, 20, 19, 503, 58, 59, 2339, 2340, ":" +449, 20, 20, 504, 60, 68, 2341, 2349, "18721251" +449, 20, 21, 505, 69, 70, 2350, 2351, "[" +449, 20, 22, 506, 71, 78, 2352, 2359, "Indexed" +449, 20, 23, 507, 79, 82, 2360, 2363, "for" +449, 20, 24, 508, 83, 90, 2364, 2371, "MEDLINE" +449, 20, 25, 509, 91, 92, 2372, 2373, "]" diff --git a/data/gl 18721251_jshahinitiran.annodb b/data/gl 18721251_jshahinitiran.annodb new file mode 100644 index 0000000..c89024f --- /dev/null +++ b/data/gl 18721251_jshahinitiran.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11868, Journal, 0, 15, "Acta Ophthalmol", "", +11869, PublicationYear, 18, 22, "2008", "", +11870, Title, 124, 285, "Efficacy and safety of latanoprost versus pilocarpine / timolol maleate fixed combination in patients with primary open - angle glaucoma or ocular hypertension .", "", +11871, Latanoprost, 147, 158, "latanoprost", "", +11872, Pilocarpine, 166, 177, "pilocarpine", "", +11874, Drug, 166, 213, "pilocarpine / timolol maleate fixed combination", "PTFC", +11873, Timolol, 180, 195, "timolol maleate", "", +35904, Primary_OpenAngleGlaucoma, 231, 260, "primary open - angle glaucoma", "", +11876, OcularHypertension, 264, 283, "ocular hypertension", "", +11877, Author, 286, 297, "Ka ł uzny J", "", +11878, Author, 306, 315, "Sobecki R", "", +11879, Author, 318, 340, "Czechowicz - Janicka K", "", +11880, Author, 343, 350, "Kecik D", "", +11881, Author, 353, 365, "Ka ł uzny BJ", "", +11882, Author, 368, 378, "Stewart JA", "", +11883, Author, 381, 391, "Stewart WC", "", +11884, Poland, 478, 484, "Poland", "", +11885, ObjectiveDescription, 497, 613, "This study aimed to compare the safety and effect on intraocular pressure ( IOP ) of latanoprost given every evening", "", +11887, IOP, 550, 570, "intraocular pressure", "", +11888, IOP, 573, 576, "IOP", "", +11889, Latanoprost, 582, 593, "latanoprost", "", +11891, Frequency, 600, 613, "every evening", "", +11890, Bedtime, 606, 613, "evening", "", +11886, ObjectiveDescription, 614, 781, "versus pilocarpine / timolol maleate fixed combination ( PTFC ) given twice daily in patients with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH )", "", +11892, Pilocarpine, 621, 632, "pilocarpine", "", +11874, Drug, 621, 668, "pilocarpine / timolol maleate fixed combination", "PTFC", +11893, Timolol, 635, 650, "timolol maleate", "", +11874, Drug, 671, 675, "PTFC", "PTFC", +11896, Frequency, 684, 695, "twice daily", "", +35905, Primary_OpenAngleGlaucoma, 713, 742, "primary open - angle glaucoma", "", +35906, Primary_OpenAngleGlaucoma, 745, 749, "POAG", "", +11899, OcularHypertension, 755, 774, "ocular hypertension", "", +11900, OcularHypertension, 777, 779, "OH", "", +11901, Randomized, 866, 876, "randomized", "", +11903, Placebo, 900, 907, "placebo", "", +11905, Frequency, 921, 934, "every morning", "", +11904, Morning, 927, 934, "morning", "", +11906, Latanoprost, 939, 950, "latanoprost", "", +11908, Frequency, 951, 964, "every evening", "", +11907, Bedtime, 957, 964, "evening", "", +11874, Drug, 971, 975, "PTFC", "PTFC", +11910, Frequency, 989, 1000, "twice daily", "", +11911, Duration, 1009, 1016, "8 weeks", "", +11912, IOP, 1032, 1035, "IOP", "", +35907, NumberPatientsCT, 1231, 1252, "Thirty - two patients", "", +35908, Diurnal_IOP, 1311, 1314, "IOP", "", +35909, BaseLineValue, 1318, 1324, "24 . 1", "", +35910, SdErrorBL, 1331, 1336, "2 . 4", "", +35911, mmHg, 1337, 1341, "mmHg", "", +35912, Mean, 1344, 1348, "Mean", "", +35913, ResultMeasuredValue, 1370, 1376, "16 . 8", "", +35915, SdErrorResValue, 1383, 1388, "2 . 1", "", +35917, mmHg, 1389, 1393, "mmHg", "", +35921, Drug, 1397, 1401, "PTFC", "PTFC", +35914, ResultMeasuredValue, 1406, 1412, "16 . 9", "", +35916, SdErrorResValue, 1419, 1424, "2 . 5", "", +35919, mmHg, 1425, 1429, "mmHg", "", +35920, Latanoprost, 1433, 1444, "latanoprost", "", +35936, PValueResValue, 1447, 1457, "p = 0 . 60", "", +35935, ObservedResult, 1462, 1700, "No statistical difference between treatments was observed at any individual time - point except at 10 . 00 hours , when the PTFC group demonstrated an IOP of 15 . 9 + / - 2 . 3 mmHg and latanoprost 16 . 8 + / - 2 . 7 mmHg ( p = 0 . 02 ) .", "", +35922, Drug, 1586, 1590, "PTFC", "PTFC", +35927, IOP, 1613, 1616, "IOP", "", +35928, ResultMeasuredValue, 1620, 1626, "15 . 9", "", +35929, SdErrorResValue, 1633, 1638, "2 . 3", "", +35930, mmHg, 1639, 1643, "mmHg", "", +35931, Latanoprost, 1648, 1659, "latanoprost", "", +35932, ResultMeasuredValue, 1660, 1666, "16 . 8", "", +35933, SdErrorResValue, 1673, 1678, "2 . 7", "", +35934, mmHg, 1679, 1683, "mmHg", "", +35937, PValueResValue, 1686, 1696, "p = 0 . 02", "", +35938, ObservedResult, 1701, 1819, "There were no statistical differences between groups in unsolicited systemic or ocular adverse events ( p > 0 . 05 ) .", "", +35953, PValueNumAffected, 1805, 1815, "p > 0 . 05", "", +35939, ObservedResult, 1820, 1932, "However , the PTFC group showed a narrower pupil diameter ( 2 . 3 mm ) than the latanoprost group ( 3 . 7 mm ) .", "", +35923, Drug, 1834, 1838, "PTFC", "PTFC", +35940, Latanoprost, 1900, 1911, "latanoprost", "", +35925, Drug, 2040, 2044, "PTFC", "PTFC", +35944, PValueNumAffected, 2047, 2058, "p < 0 . 001", "", +35949, ConclusionComment, 2077, 2158, "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .", "", +35924, Drug, 2082, 2086, "PTFC", "PTFC", +35945, Latanoprost, 2091, 2102, "latanoprost", "", +35946, Diurnal_IOP, 2131, 2142, "diurnal IOP", "", +35947, Primary_OpenAngleGlaucoma, 2146, 2150, "POAG", "", +35948, OcularHypertension, 2154, 2156, "OH", "", +35950, ConclusionComment, 2159, 2278, "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects", "", +35926, Drug, 2169, 2173, "PTFC", "PTFC", +35951, Morning, 2208, 2215, "morning", "", +35952, PMID, 2341, 2349, "18721251", "", diff --git a/data/gl 18721251_jshahinitiran.n-triples b/data/gl 18721251_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18721251_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 18721251_tstrakeljahn.annodb b/data/gl 18721251_tstrakeljahn.annodb new file mode 100644 index 0000000..b7ada15 --- /dev/null +++ b/data/gl 18721251_tstrakeljahn.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +77662, Journal, 0, 15, "Acta Ophthalmol", "", +77663, PublicationYear, 18, 22, "2008", "", +77664, Latanoprost, 147, 158, "latanoprost", "", +77665, Pilocarpine, 166, 177, "pilocarpine", "", +77667, Pilo/TimFC, 166, 195, "pilocarpine / timolol maleate", "", +77666, Timolol, 180, 195, "timolol maleate", "", +77668, Primary_OpenAngleGlaucoma, 231, 260, "primary open - angle glaucoma", "", +77669, OcularHypertension, 264, 283, "ocular hypertension", "", +77670, Author, 289, 297, "ł uzny J", "", +77671, Author, 306, 315, "Sobecki R", "", +77672, Author, 318, 340, "Czechowicz - Janicka K", "", +77673, Author, 343, 365, "Kecik D , Ka ł uzny BJ", "", +77674, Author, 368, 378, "Stewart JA", "", +77675, Author, 381, 391, "Stewart WC", "", +77676, Poland, 478, 484, "Poland", "", +77677, IOP, 550, 570, "intraocular pressure", "", +77678, IOP, 573, 576, "IOP", "", +77679, Latanoprost, 582, 593, "latanoprost", "", +77680, Frequency, 600, 613, "every evening", "", +77681, Pilocarpine, 621, 632, "pilocarpine", "", +77683, Pilo/TimFC, 621, 650, "pilocarpine / timolol maleate", "", +77682, Timolol, 635, 650, "timolol maleate", "", +77684, Pilo/TimFC, 671, 675, "PTFC", "", +77685, Frequency, 684, 695, "twice daily", "", +77686, Primary_OpenAngleGlaucoma, 713, 742, "primary open - angle glaucoma", "", +77687, Primary_OpenAngleGlaucoma, 745, 749, "POAG", "", +77688, OcularHypertension, 755, 774, "ocular hypertension", "", +77689, OcularHypertension, 777, 779, "OH", "", +77690, Precondition, 794, 839, "Following a 6 - week , medicine - free period", "", +77691, Randomized, 866, 876, "randomized", "", +77692, Placebo, 900, 907, "placebo", "", +77693, Frequency, 921, 934, "every morning", "", +77694, Latanoprost, 939, 950, "latanoprost", "", +77695, Pilo/TimFC, 971, 975, "PTFC", "", +77696, Frequency, 989, 1000, "twice daily", "", +77697, Duration, 1009, 1016, "8 weeks", "", +77698, IOP, 1032, 1035, "IOP", "", +77699, FinalNumPatientsCT, 1231, 1243, "Thirty - two", "", +77700, Diurnal_IOP, 1294, 1314, "diurnal baseline IOP", "", +77701, BaseLineValue, 1318, 1324, "24 . 1", "", +77702, SdDevBL, 1331, 1336, "2 . 4", "", +77703, mmHg, 1337, 1341, "mmHg", "", +77704, Mean, 1344, 1348, "Mean", "", +77705, Diurnal_IOP, 1349, 1365, "diurnal pressure", "", +77706, ResultMeasuredValue, 1370, 1376, "16 . 8", "", +77708, SdDevResValue, 1383, 1388, "2 . 1", "", +77710, mmHg, 1389, 1393, "mmHg", "", +77711, Pilo/TimFC, 1397, 1401, "PTFC", "", +77707, ResultMeasuredValue, 1406, 1412, "16 . 9", "", +77709, SdDevResValue, 1419, 1424, "2 . 5", "", +77712, mmHg, 1425, 1429, "mmHg", "", +77713, Latanoprost, 1433, 1444, "latanoprost", "", +77714, PvalueDiff, 1449, 1457, "= 0 . 60", "", +77715, RelativeTime, 1561, 1574, "10 . 00 hours", "", +77716, Pilo/TimFC, 1586, 1590, "PTFC", "", +77717, IOP, 1613, 1616, "IOP", "", +77718, ResultMeasuredValue, 1620, 1626, "15 . 9", "", +77720, SdDevResValue, 1633, 1638, "2 . 3", "", +77722, mmHg, 1639, 1643, "mmHg", "", +77719, ResultMeasuredValue, 1660, 1666, "16 . 8", "", +77721, SdDevResValue, 1673, 1678, "2 . 7", "", +77723, mmHg, 1679, 1683, "mmHg", "", +77724, PvalueDiff, 1688, 1696, "= 0 . 02", "", +77729, ObservedResult, 1701, 1819, "There were no statistical differences between groups in unsolicited systemic or ocular adverse events ( p > 0 . 05 ) .", "", +77725, PvalueDiff, 1807, 1815, "> 0 . 05", "", +77730, ObservedResult, 1820, 1932, "However , the PTFC group showed a narrower pupil diameter ( 2 . 3 mm ) than the latanoprost group ( 3 . 7 mm ) .", "", +77726, Pilo/TimFC, 1834, 1838, "PTFC", "", +77728, Latanoprost, 1900, 1911, "latanoprost", "", +77742, ObservedResult, 1933, 2062, "Additionally , a solicited symptom survey demonstrated mild blurred vision , stinging and ocular pain with PTFC ( p < 0 . 001 ) .", "", +77739, Stinging, 2010, 2018, "stinging", "", +77731, Pilo/TimFC, 2040, 2044, "PTFC", "", +77741, PvalueDiff, 2049, 2058, "< 0 . 001", "", +77743, ConclusionComment, 2077, 2158, "Both PTFC and latanoprost are efficacious in reducing diurnal IOP in POAG or OH .", "", +77732, Pilo/TimFC, 2082, 2086, "PTFC", "", +77734, Latanoprost, 2091, 2102, "latanoprost", "", +77735, Diurnal_IOP, 2131, 2142, "diurnal IOP", "", +77736, Primary_OpenAngleGlaucoma, 2146, 2150, "POAG", "", +77737, OcularHypertension, 2154, 2156, "OH", "", +77744, ConclusionComment, 2159, 2280, "However , PTFC may be more effective in the late morning and may have a greater incidence of mild ocular side - effects .", "", +77733, Pilo/TimFC, 2169, 2173, "PTFC", "", +77745, PMID, 2341, 2349, "18721251", "", diff --git a/data/gl 18721251_tstrakeljahn.n-triples b/data/gl 18721251_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 18721251_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1882923_admin.annodb b/data/gl 1882923_admin.annodb new file mode 100644 index 0000000..4d4c1a1 --- /dev/null +++ b/data/gl 1882923_admin.annodb @@ -0,0 +1,78 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Am J Ophthalmol .", "", " \"Am J Ophthalmol .\"." +1, PublicationYear, 18, 22, "1991", "", " \"1991\"." +2, Title, 54, 167, "Evaluation of once - daily levobunolol 0 . 25 % and timolol 0 . 25 % therapy for increased intraocular pressure .", "", " \"Evaluation of once - daily levobunolol 0 . 25 % and timolol 0 . 25 % therapy for increased intraocular pressure .\"." +3, Frequency, 68, 80, "once - daily", "", +4, Levobunolol, 81, 92, "levobunolol", "", +6, DoseValue, 93, 99, "0 . 25", "", +71, Percentage, 100, 101, "%", "", +5, Timolol, 106, 113, "timolol", "", +7, DoseValue, 114, 120, "0 . 25", "", +72, Percentage, 121, 122, "%", "", +8, IOP, 145, 165, "intraocular pressure", "", +9, Author, 168, 181, "Silverstone D", "", " \"Silverstone D\"." +10, Author, 190, 201, "Zimmerman T", "", " \"Zimmerman T\"." +11, Author, 204, 213, "Choplin N", "", " \"Choplin N\"." +12, Author, 216, 225, "Mundorf T", "", " \"Mundorf T\"." +13, Author, 228, 234, "Rose A", "", " \"Rose A\"." +14, Author, 237, 247, "Stoecker J", "", " \"Stoecker J\"." +15, Author, 250, 258, "Kelley E", "", " \"Kelley E\"." +16, Author, 261, 266, "Lue J", "", " \"Lue J\"." +104102, USA, 395, 406, "Connecticut", "", " ." +23, ObjectiveDescription, 409, 645, "In a three - month , double - masked , randomized clinical trial , we evaluated the once - daily ocular hypotensive efficacy of 0 . 25 % levobunolol and 0 . 25 % timolol in 80 patients with open - angle glaucoma or ocular hypertension .", "", " \"In a three - month , double - masked , randomized clinical trial , we evaluated the once - daily ocular hypotensive efficacy of 0 . 25 % levobunolol and 0 . 25 % timolol in 80 patients with open - angle glaucoma or ocular hypertension .\"." +17, Duration, 414, 427, "three - month", "", " \"three - month\"." +18, DoubleBlind, 430, 445, "double - masked", "", " ." +19, Randomized, 448, 458, "randomized", "", " ." +20, Frequency, 493, 505, "once - daily", "", " \"once - daily\". \"once - daily\"." +21, DoseValue, 537, 543, "0 . 25", "", +95, Percentage, 544, 545, "%", "", +24, Levobunolol, 546, 557, "levobunolol", "", +22, DoseValue, 562, 568, "0 . 25", "", +96, Percentage, 569, 570, "%", "", +25, Timolol, 571, 578, "timolol", "", +26, NumberPatientsCT, 582, 584, "80", "", " \"80\"." +92, Precondition, 585, 643, "patients with open - angle glaucoma or ocular hypertension", "", " \"patients with open - angle glaucoma or ocular hypertension\"." +27, OpenAngleGlaucoma, 599, 620, "open - angle glaucoma", "", " ." +28, OcularHypertension, 624, 643, "ocular hypertension", "", " ." +31, FinalNumPatientsArm, 646, 660, "Thirty - seven", "", " \"Thirty - seven\"." +29, NumberPatientsArm, 668, 670, "39", "", " \"39\"." +104, PercentageAffected, 682, 684, "95", "", +33, DoseValue, 696, 702, "0 . 25", "", " \"0 . 25\"." +111, Percentage, 703, 704, "%", "", " ." +35, Levobunolol, 705, 716, "levobunolol", "", " ." +32, FinalNumPatientsArm, 727, 729, "35", "", " \"35\"." +30, NumberPatientsArm, 737, 739, "41", "", " \"41\"." +105, PercentageAffected, 751, 753, "85", "", +34, DoseValue, 765, 771, "0 . 25", "", " \"0 . 25\"." +110, Percentage, 772, 773, "%", "", " ." +36, Timolol, 774, 781, "timolol", "", " ." +37, Duration, 815, 828, "three - month", "", +38, Mean, 856, 860, "mean", "", " . ." +39, IOP, 873, 893, "intraocular pressure", "", " . ." +40, Reduction, 898, 903, "5 . 3", "", " \"5 . 3\"." +42, mmHg, 904, 909, "mm Hg", "", " ." +44, RelativeReduction, 912, 914, "22", "", " \"22\"." +46, DoseValue, 926, 932, "0 . 25", "", +124, Percentage, 933, 934, "%", "", +48, Levobunolol, 935, 946, "levobunolol", "", +41, Reduction, 957, 962, "5 . 4", "", " \"5 . 4\"." +43, mmHg, 963, 968, "mm Hg", "", +45, RelativeReduction, 971, 973, "22", "", " \"22\"." +47, DoseValue, 985, 991, "0 . 25", "", +125, Percentage, 992, 993, "%", "", +49, Timolol, 994, 1001, "timolol", "", +104105, ObservedResult, 1062, 1147, "In both treatment groups , effects on mean heart rate and blood pressure were minimal", "", " \"In both treatment groups , effects on mean heart rate and blood pressure were minimal\". \"In both treatment groups , effects on mean heart rate and blood pressure were minimal\"." +50, Mean, 1100, 1104, "mean", "", " . . . ." +51, HeartRate, 1105, 1115, "heart rate", "", " . ." +52, BloodPressure, 1120, 1134, "blood pressure", "", " . ." +54, ConclusionComment, 1150, 1331, "The data suggest that levobunolol 0 . 25 % and timolol 0 . 25 % , administered once daily , are equally effective in the treatment of open - angle glaucoma and ocular hypertension .", "", " \"The data suggest that levobunolol 0 . 25 % and timolol 0 . 25 % , administered once daily , are equally effective in the treatment of open - angle glaucoma and ocular hypertension .\"." +55, Levobunolol, 1172, 1183, "levobunolol", "", +57, DoseValue, 1184, 1190, "0 . 25", "", +138, Percentage, 1191, 1192, "%", "", +56, Timolol, 1197, 1204, "timolol", "", +58, DoseValue, 1205, 1211, "0 . 25", "", +139, Percentage, 1212, 1213, "%", "", +59, Frequency, 1229, 1239, "once daily", "", +60, OpenAngleGlaucoma, 1284, 1305, "open - angle glaucoma", "", +61, OcularHypertension, 1310, 1329, "ocular hypertension", "", +62, PMID, 1387, 1394, "1882923", "", " \"1882923\"." diff --git a/data/gl 1882923_admin.n-triples b/data/gl 1882923_admin.n-triples new file mode 100644 index 0000000..167c8b8 --- /dev/null +++ b/data/gl 1882923_admin.n-triples @@ -0,0 +1,130 @@ +# RDF export of group: Publication + . + "Publication " . + "Evaluation of once - daily levobunolol 0 . 25 % and timolol 0 . 25 % therapy for increased intraocular pressure ." . + "Silverstone D" . + "1991" . + "Am J Ophthalmol ." . + "1882923" . + . + "Zimmerman T" . + "Choplin N" . + "Mundorf T" . + "Rose A" . + "Stoecker J" . + "Kelley E" . + "Lue J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "In a three - month , double - masked , randomized clinical trial , we evaluated the once - daily ocular hypotensive efficacy of 0 . 25 % levobunolol and 0 . 25 % timolol in 80 patients with open - angle glaucoma or ocular hypertension ." . + "80" . + "three - month" . + . + . + . + "The data suggest that levobunolol 0 . 25 % and timolol 0 . 25 % , administered once daily , are equally effective in the treatment of open - angle glaucoma and ocular hypertension ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients with open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint hr" . + . + . + . + . + . + . + . + "Endpoint bp" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + "39" . + "Thirty - seven" . + . + . + . + . + . + . + "Arm t" . + "41" . + "35" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "once - daily" . + . + . + "Intervention t" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication l" . + . + "0 . 25" . + . + . + . + "Medication t" . + . + "0 . 25" . + . + . +# RDF export of group: Outcome + . + "Outcome IOP l " . + . + "5 . 3" . + "22" . + . + "Outcome IOP t" . + . + "5 . 4" . + "22" . + . + "Outcome hr both drugs" . + . + "In both treatment groups , effects on mean heart rate and blood pressure were minimal" . + . + "Outcome bp both drugs" . + . + "In both treatment groups , effects on mean heart rate and blood pressure were minimal" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1882923_export.csv b/data/gl 1882923_export.csv new file mode 100644 index 0000000..4911ff9 --- /dev/null +++ b/data/gl 1882923_export.csv @@ -0,0 +1,309 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +527, 1, 1, 1, 0, 2, 0, 2, "Am" +527, 1, 2, 2, 3, 4, 3, 4, "J" +527, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +527, 1, 4, 4, 16, 17, 16, 17, "." +527, 2, 1, 5, 0, 4, 18, 22, "1991" +527, 2, 2, 6, 5, 8, 23, 26, "Jul" +527, 2, 3, 7, 9, 11, 27, 29, "15" +527, 2, 4, 8, 12, 13, 30, 31, ";" +527, 2, 5, 9, 14, 17, 32, 35, "112" +527, 2, 6, 10, 18, 19, 36, 37, "(" +527, 2, 7, 11, 20, 21, 38, 39, "1" +527, 2, 8, 12, 22, 23, 40, 41, ")" +527, 2, 9, 13, 24, 25, 42, 43, ":" +527, 2, 10, 14, 26, 28, 44, 46, "56" +527, 2, 11, 15, 29, 30, 47, 48, "-" +527, 2, 12, 16, 31, 33, 49, 51, "60" +527, 2, 13, 17, 34, 35, 52, 53, "." +527, 3, 1, 18, 0, 10, 54, 64, "Evaluation" +527, 3, 2, 19, 11, 13, 65, 67, "of" +527, 3, 3, 20, 14, 18, 68, 72, "once" +527, 3, 4, 21, 19, 20, 73, 74, "-" +527, 3, 5, 22, 21, 26, 75, 80, "daily" +527, 3, 6, 23, 27, 38, 81, 92, "levobunolol" +527, 3, 7, 24, 39, 40, 93, 94, "0" +527, 3, 8, 25, 41, 42, 95, 96, "." +527, 3, 9, 26, 43, 45, 97, 99, "25" +527, 3, 10, 27, 46, 47, 100, 101, "%" +527, 3, 11, 28, 48, 51, 102, 105, "and" +527, 3, 12, 29, 52, 59, 106, 113, "timolol" +527, 3, 13, 30, 60, 61, 114, 115, "0" +527, 3, 14, 31, 62, 63, 116, 117, "." +527, 3, 15, 32, 64, 66, 118, 120, "25" +527, 3, 16, 33, 67, 68, 121, 122, "%" +527, 3, 17, 34, 69, 76, 123, 130, "therapy" +527, 3, 18, 35, 77, 80, 131, 134, "for" +527, 3, 19, 36, 81, 90, 135, 144, "increased" +527, 3, 20, 37, 91, 102, 145, 156, "intraocular" +527, 3, 21, 38, 103, 111, 157, 165, "pressure" +527, 3, 22, 39, 112, 113, 166, 167, "." +527, 4, 1, 40, 0, 11, 168, 179, "Silverstone" +527, 4, 2, 41, 12, 13, 180, 181, "D" +527, 4, 3, 42, 14, 15, 182, 183, "(" +527, 4, 4, 43, 16, 17, 184, 185, "1" +527, 4, 5, 44, 18, 19, 186, 187, ")" +527, 4, 6, 45, 20, 21, 188, 189, "," +527, 4, 7, 46, 22, 31, 190, 199, "Zimmerman" +527, 4, 8, 47, 32, 33, 200, 201, "T" +527, 4, 9, 48, 34, 35, 202, 203, "," +527, 4, 10, 49, 36, 43, 204, 211, "Choplin" +527, 4, 11, 50, 44, 45, 212, 213, "N" +527, 4, 12, 51, 46, 47, 214, 215, "," +527, 4, 13, 52, 48, 55, 216, 223, "Mundorf" +527, 4, 14, 53, 56, 57, 224, 225, "T" +527, 4, 15, 54, 58, 59, 226, 227, "," +527, 4, 16, 55, 60, 64, 228, 232, "Rose" +527, 4, 17, 56, 65, 66, 233, 234, "A" +527, 4, 18, 57, 67, 68, 235, 236, "," +527, 4, 19, 58, 69, 77, 237, 245, "Stoecker" +527, 4, 20, 59, 78, 79, 246, 247, "J" +527, 4, 21, 60, 80, 81, 248, 249, "," +527, 4, 22, 61, 82, 88, 250, 256, "Kelley" +527, 4, 23, 62, 89, 90, 257, 258, "E" +527, 4, 24, 63, 91, 92, 259, 260, "," +527, 4, 25, 64, 93, 96, 261, 264, "Lue" +527, 4, 26, 65, 97, 98, 265, 266, "J" +527, 4, 27, 66, 99, 100, 267, 268, "." +527, 5, 1, 67, 0, 6, 269, 275, "Author" +527, 5, 2, 68, 7, 18, 276, 287, "information" +527, 5, 3, 69, 19, 20, 288, 289, ":" +527, 5, 4, 70, 21, 22, 290, 291, "(" +527, 5, 5, 71, 23, 24, 292, 293, "1" +527, 5, 6, 72, 25, 26, 294, 295, ")" +527, 5, 7, 73, 27, 37, 296, 306, "Department" +527, 5, 8, 74, 38, 40, 307, 309, "of" +527, 5, 9, 75, 41, 54, 310, 323, "Ophthalmology" +527, 5, 10, 76, 55, 58, 324, 327, "and" +527, 5, 11, 77, 59, 65, 328, 334, "Visual" +527, 5, 12, 78, 66, 74, 335, 343, "Sciences" +527, 5, 13, 79, 75, 76, 344, 345, "," +527, 5, 14, 80, 77, 81, 346, 350, "Yale" +527, 5, 15, 81, 82, 92, 351, 361, "University" +527, 5, 16, 82, 93, 99, 362, 368, "School" +527, 5, 17, 83, 100, 102, 369, 371, "of" +527, 5, 18, 84, 103, 111, 372, 380, "Medicine" +527, 5, 19, 85, 112, 113, 381, 382, "," +527, 5, 20, 86, 114, 117, 383, 386, "New" +527, 5, 21, 87, 118, 123, 387, 392, "Haven" +527, 5, 22, 88, 124, 125, 393, 394, "," +527, 5, 23, 89, 126, 137, 395, 406, "Connecticut" +527, 5, 24, 90, 138, 139, 407, 408, "." +527, 6, 1, 91, 0, 2, 409, 411, "In" +527, 6, 2, 92, 3, 4, 412, 413, "a" +527, 6, 3, 93, 5, 10, 414, 419, "three" +527, 6, 4, 94, 11, 12, 420, 421, "-" +527, 6, 5, 95, 13, 18, 422, 427, "month" +527, 6, 6, 96, 19, 20, 428, 429, "," +527, 6, 7, 97, 21, 27, 430, 436, "double" +527, 6, 8, 98, 28, 29, 437, 438, "-" +527, 6, 9, 99, 30, 36, 439, 445, "masked" +527, 6, 10, 100, 37, 38, 446, 447, "," +527, 6, 11, 101, 39, 49, 448, 458, "randomized" +527, 6, 12, 102, 50, 58, 459, 467, "clinical" +527, 6, 13, 103, 59, 64, 468, 473, "trial" +527, 6, 14, 104, 65, 66, 474, 475, "," +527, 6, 15, 105, 67, 69, 476, 478, "we" +527, 6, 16, 106, 70, 79, 479, 488, "evaluated" +527, 6, 17, 107, 80, 83, 489, 492, "the" +527, 6, 18, 108, 84, 88, 493, 497, "once" +527, 6, 19, 109, 89, 90, 498, 499, "-" +527, 6, 20, 110, 91, 96, 500, 505, "daily" +527, 6, 21, 111, 97, 103, 506, 512, "ocular" +527, 6, 22, 112, 104, 115, 513, 524, "hypotensive" +527, 6, 23, 113, 116, 124, 525, 533, "efficacy" +527, 6, 24, 114, 125, 127, 534, 536, "of" +527, 6, 25, 115, 128, 129, 537, 538, "0" +527, 6, 26, 116, 130, 131, 539, 540, "." +527, 6, 27, 117, 132, 134, 541, 543, "25" +527, 6, 28, 118, 135, 136, 544, 545, "%" +527, 6, 29, 119, 137, 148, 546, 557, "levobunolol" +527, 6, 30, 120, 149, 152, 558, 561, "and" +527, 6, 31, 121, 153, 154, 562, 563, "0" +527, 6, 32, 122, 155, 156, 564, 565, "." +527, 6, 33, 123, 157, 159, 566, 568, "25" +527, 6, 34, 124, 160, 161, 569, 570, "%" +527, 6, 35, 125, 162, 169, 571, 578, "timolol" +527, 6, 36, 126, 170, 172, 579, 581, "in" +527, 6, 37, 127, 173, 175, 582, 584, "80" +527, 6, 38, 128, 176, 184, 585, 593, "patients" +527, 6, 39, 129, 185, 189, 594, 598, "with" +527, 6, 40, 130, 190, 194, 599, 603, "open" +527, 6, 41, 131, 195, 196, 604, 605, "-" +527, 6, 42, 132, 197, 202, 606, 611, "angle" +527, 6, 43, 133, 203, 211, 612, 620, "glaucoma" +527, 6, 44, 134, 212, 214, 621, 623, "or" +527, 6, 45, 135, 215, 221, 624, 630, "ocular" +527, 6, 46, 136, 222, 234, 631, 643, "hypertension" +527, 6, 47, 137, 235, 236, 644, 645, "." +527, 7, 1, 138, 0, 6, 646, 652, "Thirty" +527, 7, 2, 139, 7, 8, 653, 654, "-" +527, 7, 3, 140, 9, 14, 655, 660, "seven" +527, 7, 4, 141, 15, 17, 661, 663, "of" +527, 7, 5, 142, 18, 21, 664, 667, "the" +527, 7, 6, 143, 22, 24, 668, 670, "39" +527, 7, 7, 144, 25, 33, 671, 679, "patients" +527, 7, 8, 145, 34, 35, 680, 681, "(" +527, 7, 9, 146, 36, 38, 682, 684, "95" +527, 7, 10, 147, 39, 40, 685, 686, "%" +527, 7, 11, 148, 41, 42, 687, 688, ")" +527, 7, 12, 149, 43, 45, 689, 691, "in" +527, 7, 13, 150, 46, 49, 692, 695, "the" +527, 7, 14, 151, 50, 51, 696, 697, "0" +527, 7, 15, 152, 52, 53, 698, 699, "." +527, 7, 16, 153, 54, 56, 700, 702, "25" +527, 7, 17, 154, 57, 58, 703, 704, "%" +527, 7, 18, 155, 59, 70, 705, 716, "levobunolol" +527, 7, 19, 156, 71, 76, 717, 722, "group" +527, 7, 20, 157, 77, 80, 723, 726, "and" +527, 7, 21, 158, 81, 83, 727, 729, "35" +527, 7, 22, 159, 84, 86, 730, 732, "of" +527, 7, 23, 160, 87, 90, 733, 736, "the" +527, 7, 24, 161, 91, 93, 737, 739, "41" +527, 7, 25, 162, 94, 102, 740, 748, "patients" +527, 7, 26, 163, 103, 104, 749, 750, "(" +527, 7, 27, 164, 105, 107, 751, 753, "85" +527, 7, 28, 165, 108, 109, 754, 755, "%" +527, 7, 29, 166, 110, 111, 756, 757, ")" +527, 7, 30, 167, 112, 114, 758, 760, "in" +527, 7, 31, 168, 115, 118, 761, 764, "the" +527, 7, 32, 169, 119, 120, 765, 766, "0" +527, 7, 33, 170, 121, 122, 767, 768, "." +527, 7, 34, 171, 123, 125, 769, 771, "25" +527, 7, 35, 172, 126, 127, 772, 773, "%" +527, 7, 36, 173, 128, 135, 774, 781, "timolol" +527, 7, 37, 174, 136, 141, 782, 787, "group" +527, 7, 38, 175, 142, 154, 788, 800, "successfully" +527, 7, 39, 176, 155, 164, 801, 810, "completed" +527, 7, 40, 177, 165, 168, 811, 814, "the" +527, 7, 41, 178, 169, 174, 815, 820, "three" +527, 7, 42, 179, 175, 176, 821, 822, "-" +527, 7, 43, 180, 177, 182, 823, 828, "month" +527, 7, 44, 181, 183, 188, 829, 834, "study" +527, 7, 45, 182, 189, 195, 835, 841, "period" +527, 7, 46, 183, 196, 197, 842, 843, "." +527, 8, 1, 184, 0, 3, 844, 847, "The" +527, 8, 2, 185, 4, 11, 848, 855, "overall" +527, 8, 3, 186, 12, 16, 856, 860, "mean" +527, 8, 4, 187, 17, 25, 861, 869, "decrease" +527, 8, 5, 188, 26, 28, 870, 872, "in" +527, 8, 6, 189, 29, 40, 873, 884, "intraocular" +527, 8, 7, 190, 41, 49, 885, 893, "pressure" +527, 8, 8, 191, 50, 53, 894, 897, "was" +527, 8, 9, 192, 54, 55, 898, 899, "5" +527, 8, 10, 193, 56, 57, 900, 901, "." +527, 8, 11, 194, 58, 59, 902, 903, "3" +527, 8, 12, 195, 60, 62, 904, 906, "mm" +527, 8, 13, 196, 63, 65, 907, 909, "Hg" +527, 8, 14, 197, 66, 67, 910, 911, "(" +527, 8, 15, 198, 68, 70, 912, 914, "22" +527, 8, 16, 199, 71, 72, 915, 916, "%" +527, 8, 17, 200, 73, 74, 917, 918, ")" +527, 8, 18, 201, 75, 77, 919, 921, "in" +527, 8, 19, 202, 78, 81, 922, 925, "the" +527, 8, 20, 203, 82, 83, 926, 927, "0" +527, 8, 21, 204, 84, 85, 928, 929, "." +527, 8, 22, 205, 86, 88, 930, 932, "25" +527, 8, 23, 206, 89, 90, 933, 934, "%" +527, 8, 24, 207, 91, 102, 935, 946, "levobunolol" +527, 8, 25, 208, 103, 108, 947, 952, "group" +527, 8, 26, 209, 109, 112, 953, 956, "and" +527, 8, 27, 210, 113, 114, 957, 958, "5" +527, 8, 28, 211, 115, 116, 959, 960, "." +527, 8, 29, 212, 117, 118, 961, 962, "4" +527, 8, 30, 213, 119, 121, 963, 965, "mm" +527, 8, 31, 214, 122, 124, 966, 968, "Hg" +527, 8, 32, 215, 125, 126, 969, 970, "(" +527, 8, 33, 216, 127, 129, 971, 973, "22" +527, 8, 34, 217, 130, 131, 974, 975, "%" +527, 8, 35, 218, 132, 133, 976, 977, ")" +527, 8, 36, 219, 134, 136, 978, 980, "in" +527, 8, 37, 220, 137, 140, 981, 984, "the" +527, 8, 38, 221, 141, 142, 985, 986, "0" +527, 8, 39, 222, 143, 144, 987, 988, "." +527, 8, 40, 223, 145, 147, 989, 991, "25" +527, 8, 41, 224, 148, 149, 992, 993, "%" +527, 8, 42, 225, 150, 157, 994, 1001, "timolol" +527, 8, 43, 226, 158, 163, 1002, 1007, "group" +527, 8, 44, 227, 164, 165, 1008, 1009, "." +527, 9, 1, 228, 0, 4, 1010, 1014, "This" +527, 9, 2, 229, 5, 15, 1015, 1025, "difference" +527, 9, 3, 230, 16, 19, 1026, 1029, "was" +527, 9, 4, 231, 20, 23, 1030, 1033, "not" +527, 9, 5, 232, 24, 37, 1034, 1047, "statistically" +527, 9, 6, 233, 38, 49, 1048, 1059, "significant" +527, 9, 7, 234, 50, 51, 1060, 1061, "." +527, 10, 1, 235, 0, 2, 1062, 1064, "In" +527, 10, 2, 236, 3, 7, 1065, 1069, "both" +527, 10, 3, 237, 8, 17, 1070, 1079, "treatment" +527, 10, 4, 238, 18, 24, 1080, 1086, "groups" +527, 10, 5, 239, 25, 26, 1087, 1088, "," +527, 10, 6, 240, 27, 34, 1089, 1096, "effects" +527, 10, 7, 241, 35, 37, 1097, 1099, "on" +527, 10, 8, 242, 38, 42, 1100, 1104, "mean" +527, 10, 9, 243, 43, 48, 1105, 1110, "heart" +527, 10, 10, 244, 49, 53, 1111, 1115, "rate" +527, 10, 11, 245, 54, 57, 1116, 1119, "and" +527, 10, 12, 246, 58, 63, 1120, 1125, "blood" +527, 10, 13, 247, 64, 72, 1126, 1134, "pressure" +527, 10, 14, 248, 73, 77, 1135, 1139, "were" +527, 10, 15, 249, 78, 85, 1140, 1147, "minimal" +527, 10, 16, 250, 86, 87, 1148, 1149, "." +527, 11, 1, 251, 0, 3, 1150, 1153, "The" +527, 11, 2, 252, 4, 8, 1154, 1158, "data" +527, 11, 3, 253, 9, 16, 1159, 1166, "suggest" +527, 11, 4, 254, 17, 21, 1167, 1171, "that" +527, 11, 5, 255, 22, 33, 1172, 1183, "levobunolol" +527, 11, 6, 256, 34, 35, 1184, 1185, "0" +527, 11, 7, 257, 36, 37, 1186, 1187, "." +527, 11, 8, 258, 38, 40, 1188, 1190, "25" +527, 11, 9, 259, 41, 42, 1191, 1192, "%" +527, 11, 10, 260, 43, 46, 1193, 1196, "and" +527, 11, 11, 261, 47, 54, 1197, 1204, "timolol" +527, 11, 12, 262, 55, 56, 1205, 1206, "0" +527, 11, 13, 263, 57, 58, 1207, 1208, "." +527, 11, 14, 264, 59, 61, 1209, 1211, "25" +527, 11, 15, 265, 62, 63, 1212, 1213, "%" +527, 11, 16, 266, 64, 65, 1214, 1215, "," +527, 11, 17, 267, 66, 78, 1216, 1228, "administered" +527, 11, 18, 268, 79, 83, 1229, 1233, "once" +527, 11, 19, 269, 84, 89, 1234, 1239, "daily" +527, 11, 20, 270, 90, 91, 1240, 1241, "," +527, 11, 21, 271, 92, 95, 1242, 1245, "are" +527, 11, 22, 272, 96, 103, 1246, 1253, "equally" +527, 11, 23, 273, 104, 113, 1254, 1263, "effective" +527, 11, 24, 274, 114, 116, 1264, 1266, "in" +527, 11, 25, 275, 117, 120, 1267, 1270, "the" +527, 11, 26, 276, 121, 130, 1271, 1280, "treatment" +527, 11, 27, 277, 131, 133, 1281, 1283, "of" +527, 11, 28, 278, 134, 138, 1284, 1288, "open" +527, 11, 29, 279, 139, 140, 1289, 1290, "-" +527, 11, 30, 280, 141, 146, 1291, 1296, "angle" +527, 11, 31, 281, 147, 155, 1297, 1305, "glaucoma" +527, 11, 32, 282, 156, 159, 1306, 1309, "and" +527, 11, 33, 283, 160, 166, 1310, 1316, "ocular" +527, 11, 34, 284, 167, 179, 1317, 1329, "hypertension" +527, 11, 35, 285, 180, 181, 1330, 1331, "." +527, 12, 1, 286, 0, 3, 1332, 1335, "DOI" +527, 12, 2, 287, 4, 5, 1336, 1337, ":" +527, 12, 3, 288, 6, 8, 1338, 1340, "10" +527, 12, 4, 289, 9, 10, 1341, 1342, "." +527, 12, 5, 290, 11, 15, 1343, 1347, "1016" +527, 12, 6, 291, 16, 17, 1348, 1349, "/" +527, 12, 7, 292, 18, 23, 1350, 1355, "s0002" +527, 12, 8, 293, 24, 25, 1356, 1357, "-" +527, 12, 9, 294, 26, 30, 1358, 1362, "9394" +527, 12, 10, 295, 31, 32, 1363, 1364, "(" +527, 12, 11, 296, 33, 35, 1365, 1367, "14" +527, 12, 12, 297, 36, 37, 1368, 1369, ")" +527, 12, 13, 298, 38, 43, 1370, 1375, "76213" +527, 12, 14, 299, 44, 45, 1376, 1377, "-" +527, 12, 15, 300, 46, 47, 1378, 1379, "0" +527, 12, 16, 301, 48, 52, 1380, 1384, "PMID" +527, 12, 17, 302, 53, 54, 1385, 1386, ":" +527, 12, 18, 303, 55, 62, 1387, 1394, "1882923" +527, 12, 19, 304, 63, 64, 1395, 1396, "[" +527, 12, 20, 305, 65, 72, 1397, 1404, "Indexed" +527, 12, 21, 306, 73, 76, 1405, 1408, "for" +527, 12, 22, 307, 77, 84, 1409, 1416, "MEDLINE" +527, 12, 23, 308, 85, 86, 1417, 1418, "]" diff --git a/data/gl 1882923_jshahinitiran.annodb b/data/gl 1882923_jshahinitiran.annodb new file mode 100644 index 0000000..827a579 --- /dev/null +++ b/data/gl 1882923_jshahinitiran.annodb @@ -0,0 +1,64 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +87366, Journal, 0, 15, "Am J Ophthalmol", "", +87367, PublicationYear, 18, 22, "1991", "", +87368, Title, 54, 167, "Evaluation of once - daily levobunolol 0 . 25 % and timolol 0 . 25 % therapy for increased intraocular pressure .", "", +87369, Frequency, 68, 80, "once - daily", "", +87370, Levobunolol, 81, 92, "levobunolol", "", +87372, DoseValue, 93, 99, "0 . 25", "", +87371, Timolol, 106, 113, "timolol", "", +87373, DoseValue, 114, 120, "0 . 25", "", +87374, IOP, 145, 165, "intraocular pressure", "", +87375, Author, 168, 181, "Silverstone D", "", +87376, Author, 190, 201, "Zimmerman T", "", +87377, Author, 204, 213, "Choplin N", "", +87378, Author, 216, 225, "Mundorf T", "", +87379, Author, 228, 234, "Rose A", "", +87380, Author, 237, 247, "Stoecker J", "", +87381, Author, 250, 258, "Kelley E", "", +87382, Author, 261, 266, "Lue J", "", +87389, ObjectiveDescription, 409, 645, "In a three - month , double - masked , randomized clinical trial , we evaluated the once - daily ocular hypotensive efficacy of 0 . 25 % levobunolol and 0 . 25 % timolol in 80 patients with open - angle glaucoma or ocular hypertension .", "", +87383, Duration, 414, 427, "three - month", "", +87384, DoubleBlind, 430, 445, "double - masked", "", +87385, Randomized, 448, 458, "randomized", "", +87386, Frequency, 493, 505, "once - daily", "", +87387, DoseValue, 537, 543, "0 . 25", "", +87390, Levobunolol, 546, 557, "levobunolol", "", +87388, DoseValue, 562, 568, "0 . 25", "", +87391, Timolol, 571, 578, "timolol", "", +87392, NumberPatientsCT, 582, 584, "80", "", +87393, OpenAngleGlaucoma, 599, 620, "open - angle glaucoma", "", +87394, OcularHypertension, 624, 643, "ocular hypertension", "", +87397, FinalNumPatientsArm, 646, 660, "Thirty - seven", "", +87395, NumberPatientsArm, 668, 670, "39", "", +87399, DoseValue, 696, 702, "0 . 25", "", +87401, Levobunolol, 705, 716, "levobunolol", "", +87398, FinalNumPatientsArm, 727, 729, "35", "", +87396, NumberPatientsArm, 737, 739, "41", "", +87400, DoseValue, 765, 771, "0 . 25", "", +87402, Timolol, 774, 781, "timolol", "", +87403, Duration, 815, 828, "three - month", "", +87404, Mean, 856, 860, "mean", "", +87405, IOP, 873, 893, "intraocular pressure", "", +87406, Reduction, 898, 903, "5 . 3", "", +87408, mmHg, 904, 909, "mm Hg", "", +87410, RelativeReduction, 912, 914, "22", "", +87412, DoseValue, 926, 932, "0 . 25", "", +87414, Levobunolol, 935, 946, "levobunolol", "", +87407, Reduction, 957, 962, "5 . 4", "", +87409, mmHg, 963, 968, "mm Hg", "", +87411, RelativeReduction, 971, 973, "22", "", +87413, DoseValue, 985, 991, "0 . 25", "", +87415, Timolol, 994, 1001, "timolol", "", +87419, ObservedResult, 1062, 1149, "In both treatment groups , effects on mean heart rate and blood pressure were minimal .", "", +87416, Mean, 1100, 1104, "mean", "", +87417, HeartRate, 1105, 1115, "heart rate", "", +87418, BloodPressure, 1120, 1134, "blood pressure", "", +87420, ConclusionComment, 1150, 1331, "The data suggest that levobunolol 0 . 25 % and timolol 0 . 25 % , administered once daily , are equally effective in the treatment of open - angle glaucoma and ocular hypertension .", "", +87421, Levobunolol, 1172, 1183, "levobunolol", "", +87423, DoseValue, 1184, 1190, "0 . 25", "", +87422, Timolol, 1197, 1204, "timolol", "", +87424, DoseValue, 1205, 1211, "0 . 25", "", +87425, Frequency, 1229, 1239, "once daily", "", +87426, OpenAngleGlaucoma, 1284, 1305, "open - angle glaucoma", "", +87427, OcularHypertension, 1310, 1329, "ocular hypertension", "", +87428, PMID, 1387, 1394, "1882923", "", diff --git a/data/gl 1882923_jshahinitiran.n-triples b/data/gl 1882923_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 1882923_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 1882923_tstrakeljahn.annodb b/data/gl 1882923_tstrakeljahn.annodb new file mode 100644 index 0000000..fbeb0e7 --- /dev/null +++ b/data/gl 1882923_tstrakeljahn.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +90042, Journal, 0, 15, "Am J Ophthalmol", "", +90043, PublicationYear, 18, 22, "1991", "", +90052, Title, 54, 167, "Evaluation of once - daily levobunolol 0 . 25 % and timolol 0 . 25 % therapy for increased intraocular pressure .", "", +90044, Frequency, 68, 80, "once - daily", "", +90045, Levobunolol, 81, 92, "levobunolol", "", +90048, DoseValue, 93, 99, "0 . 25", "", +90050, Percentage, 100, 101, "%", "", +90046, Timolol, 106, 113, "timolol", "", +90049, DoseValue, 114, 120, "0 . 25", "", +90051, Percentage, 121, 122, "%", "", +90047, IOP, 145, 165, "intraocular pressure", "", +90053, Author, 168, 181, "Silverstone D", "", +90054, Author, 190, 201, "Zimmerman T", "", +90055, Author, 204, 213, "Choplin N", "", +90056, Author, 216, 225, "Mundorf T", "", +90057, Author, 228, 234, "Rose A", "", +90058, Author, 237, 247, "Stoecker J", "", +90059, Author, 250, 258, "Kelley E", "", +90060, Author, 261, 266, "Lue J", "", +90076, ObjectiveDescription, 409, 645, "In a three - month , double - masked , randomized clinical trial , we evaluated the once - daily ocular hypotensive efficacy of 0 . 25 % levobunolol and 0 . 25 % timolol in 80 patients with open - angle glaucoma or ocular hypertension .", "", +90061, Duration, 414, 427, "three - month", "", +90062, DoubleBlind, 430, 445, "double - masked", "", +90063, Randomized, 448, 458, "randomized", "", +90064, ClinicalTrial, 459, 473, "clinical trial", "", +90065, Frequency, 493, 505, "once - daily", "", +90072, DoseValue, 537, 543, "0 . 25", "", +90074, Percentage, 544, 545, "%", "", +90066, Levobunolol, 546, 557, "levobunolol", "", +90073, DoseValue, 562, 568, "0 . 25", "", +90075, Percentage, 569, 570, "%", "", +90067, Timolol, 571, 578, "timolol", "", +90068, NumberPatientsCT, 582, 584, "80", "", +90071, Precondition, 585, 643, "patients with open - angle glaucoma or ocular hypertension", "", +90069, OpenAngleGlaucoma, 599, 620, "open - angle glaucoma", "", +90070, OcularHypertension, 624, 643, "ocular hypertension", "", +90079, FinalNumPatientsArm, 646, 660, "Thirty - seven", "", +90077, NumberPatientsArm, 668, 670, "39", "", +90083, PercentageAffected, 682, 684, "95", "", +90087, DoseValue, 696, 702, "0 . 25", "", +90090, Percentage, 703, 704, "%", "", +90085, Levobunolol, 705, 716, "levobunolol", "", +90080, FinalNumPatientsArm, 727, 729, "35", "", +90078, NumberPatientsArm, 737, 739, "41", "", +90084, PercentageAffected, 751, 753, "85", "", +90088, DoseValue, 765, 771, "0 . 25", "", +90089, Percentage, 772, 773, "%", "", +90086, Timolol, 774, 781, "timolol", "", +90082, SubGroupDescription, 788, 841, "successfully completed the three - month study period", "", +90081, Duration, 815, 828, "three - month", "", +90091, Mean, 856, 860, "mean", "", +90092, IOP, 873, 893, "intraocular pressure", "", +90093, Reduction, 898, 903, "5 . 3", "", +90097, mmHg, 904, 909, "mm Hg", "", +90101, RelativeReduction, 912, 914, "22", "", +90102, DoseValue, 926, 932, "0 . 25", "", +90104, Percentage, 933, 934, "%", "", +90099, Levobunolol, 935, 946, "levobunolol", "", +90094, Reduction, 957, 962, "5 . 4", "", +90098, mmHg, 963, 968, "mm Hg", "", +90095, RelativeReduction, 971, 973, "22", "", +90103, DoseValue, 985, 991, "0 . 25", "", +90105, Percentage, 992, 993, "%", "", +90100, Timolol, 994, 1001, "timolol", "", +90106, ObservedResult, 1010, 1061, "This difference was not statistically significant .", "", +90110, ObservedResult, 1062, 1149, "In both treatment groups , effects on mean heart rate and blood pressure were minimal .", "", +90107, Mean, 1100, 1104, "mean", "", +90108, HeartRate, 1105, 1115, "heart rate", "", +90109, BloodPressure, 1120, 1134, "blood pressure", "", +90122, ConclusionComment, 1150, 1331, "The data suggest that levobunolol 0 . 25 % and timolol 0 . 25 % , administered once daily , are equally effective in the treatment of open - angle glaucoma and ocular hypertension .", "", +90111, Levobunolol, 1172, 1183, "levobunolol", "", +90117, DoseValue, 1184, 1190, "0 . 25", "", +90119, Percentage, 1191, 1192, "%", "", +90112, Timolol, 1197, 1204, "timolol", "", +90118, DoseValue, 1205, 1211, "0 . 25", "", +90120, Percentage, 1212, 1213, "%", "", +90113, Frequency, 1229, 1239, "once daily", "", +90114, OpenAngleGlaucoma, 1284, 1305, "open - angle glaucoma", "", +90116, OcularHypertension, 1310, 1329, "ocular hypertension", "", +90121, PMID, 1387, 1394, "1882923", "", diff --git a/data/gl 1882923_tstrakeljahn.n-triples b/data/gl 1882923_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 1882923_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19092465 copy_admin.annodb b/data/gl 19092465 copy_admin.annodb new file mode 100644 index 0000000..3ec217c --- /dev/null +++ b/data/gl 19092465 copy_admin.annodb @@ -0,0 +1,147 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2008", "", " \"2008\"." +156, Title, 88, 339, "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of", "", " \"An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of\"." +4, Duration, 91, 103, "eight - week", "", +5, Multicenter, 106, 118, "multicentric", "", " ." +6, Randomized, 121, 131, "randomized", "", " ." +7, OpenLabel, 151, 163, "open - label", "", " ." +8, Parallel, 176, 184, "parallel", "", " ." +44428, Brimo/TimFC, 232, 311, "the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 %", "", +82, Timolol, 257, 272, "timolol maleate", "", +86, DoseValue, 273, 278, "0 . 5", "", +87, Percentage, 279, 280, "%", "", +83, Brimonidine, 283, 303, "brimonidine tartrate", "", +88, DoseValue, 304, 309, "0 . 2", "", +89, Percentage, 310, 311, "%", "", +44429, Dorz/TimFC, 319, 381, "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 %", "", +84, Timolol, 340, 355, "timolol maleate", "", +92, DoseValue, 356, 361, "0 . 5", "", +90, Percentage, 362, 363, "%", "", +85, Dorzolamide, 366, 377, "dorzolamide", "", +93, DoseValue, 378, 379, "2", "", +91, Percentage, 380, 381, "%", "", +9, IOP, 408, 428, "intraocular pressure", "", +10, Author, 431, 441, "Hatanaka M", "", " \"Hatanaka M\"." +11, Author, 450, 460, "Grigera DE", "", " \"Grigera DE\"." +12, Author, 463, 473, "Barbosa WL", "", " \"Barbosa WL\"." +13, Author, 476, 484, "Jordao M", "", " \"Jordao M\"." +14, Author, 487, 499, "Susanna R Jr", "", " \"Susanna R Jr\"." +94, Brazil, 588, 594, "Brazil", "", +15, ObjectiveDescription, 635, 765, "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus", "", " \"To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus\"." +95, Timolol, 704, 719, "timolol maleate", "", +97, DoseValue, 720, 725, "0 . 5", "", +99, Percentage, 726, 727, "%", "", +96, Brimonidine, 730, 750, "brimonidine tartrate", "", +98, DoseValue, 751, 756, "0 . 2", "", +100, Percentage, 757, 758, "%", "", +16, ObjectiveDescription, 766, 898, "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks .", "", " \"fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks .\"." +101, Timolol, 787, 802, "timolol maleate", "", +44430, Dorz/TimFC, 787, 828, "timolol maleate 0 . 5 % / dorzolamide 2 %", "", +103, DoseValue, 803, 808, "0 . 5", "", +104, Percentage, 809, 810, "%", "", +102, Dorzolamide, 813, 824, "dorzolamide", "", +106, DoseValue, 825, 826, "2", "", +105, Percentage, 827, 828, "%", "", +17, IOP, 855, 875, "intraocular pressure", "", +18, IOP, 878, 881, "IOP", "", +19, Duration, 889, 896, "8 weeks", "", " \"8 weeks\"." +20, Duration, 927, 935, "8 - week", "", +21, Multicenter, 938, 950, "multicentric", "", +129, Randomized, 970, 980, "randomized", "", +22, OpenLabel, 983, 995, "open - label", "", +23, Parallel, 998, 1012, "parallel group", "", +179, Brazil, 1049, 1055, "Brazil", "", " ." +24, Argentina, 1072, 1081, "Argentina", "", " ." +25, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", " ." +26, OcularHypertension, 1123, 1142, "ocular hypertension", "", " ." +107, Randomized, 1148, 1158, "randomized", "", +44431, Brimo/TimFC, 1182, 1240, "fixed combination of brimonidine / timolol maleate 0 . 5 %", "", " ." +108, Brimonidine, 1203, 1214, "brimonidine", "", +109, Timolol, 1217, 1232, "timolol maleate", "", +110, DoseValue, 1233, 1238, "0 . 5", "", " \"0 . 5\"." +111, Percentage, 1239, 1240, "%", "", " ." +44432, Dorz/TimFC, 1244, 1298, "fixed combination of dorzolamide 2 % / timolol 0 . 5 %", "", " ." +112, Dorzolamide, 1265, 1276, "dorzolamide", "", +114, DoseValue, 1277, 1278, "2", "", +117, Percentage, 1279, 1280, "%", "", +113, Timolol, 1283, 1290, "timolol", "", +115, DoseValue, 1291, 1296, "0 . 5", "", +116, Percentage, 1297, 1298, "%", "", +27, Frequency, 1299, 1310, "twice daily", "", " \"twice daily\". \"twice daily\"." +28, Peak_IOP, 1491, 1499, "IOP peak", "", +29, Diurnal_IOP, 1503, 1524, "diurnal tension curve", "", +118, TimePoint, 1549, 1557, "baseline", "", +119, TimePoint, 1562, 1570, "week - 8", "", +30, NumberPatientsCT, 1651, 1654, "210", "", " \"210\"." +120, Randomized, 1669, 1679, "randomized", "", +121, Brimonidine, 1682, 1693, "brimonidine", "", +44433, Brimo/TimFC, 1682, 1703, "brimonidine / timolol", "", +122, Timolol, 1696, 1703, "timolol", "", +31, NumberPatientsArm, 1710, 1713, "111", "", " \"111\"." +123, Dorzolamide, 1716, 1727, "dorzolamide", "", +44434, Dorz/TimFC, 1716, 1737, "dorzolamide / timolol", "", +124, Timolol, 1730, 1737, "timolol", "", +32, NumberPatientsArm, 1744, 1746, "99", "", " \"99\"." +33, Mean, 1751, 1755, "Mean", "", " . ." +34, IOP, 1765, 1768, "IOP", "", +35, BaseLineValue, 1773, 1780, "23 . 43", "", " \"23 . 43\"." +44437, SdDevBL, 1787, 1793, "3 . 22", "", " \"3 . 22\"." +37, mmHg, 1794, 1799, "mm Hg", "", " ." +38, BaseLineValue, 1804, 1811, "23 . 43", "", " \"23 . 43\"." +44438, SdDevBL, 1818, 1824, "4 . 06", "", " \"4 . 06\"." +40, mmHg, 1825, 1830, "mm Hg", "", +210, Brimonidine, 1860, 1871, "brimonidine", "", +44435, Brimo/TimFC, 1860, 1881, "brimonidine / timolol", "", +211, Timolol, 1874, 1881, "timolol", "", +213, Dorzolamide, 1886, 1897, "dorzolamide", "", +44436, Dorz/TimFC, 1886, 1907, "dorzolamide / timolol", "", +212, Timolol, 1900, 1907, "timolol", "", +214, PvalueDiff, 1929, 1936, "0 . 993", "", +42, Mean, 1941, 1945, "Mean", "", +43, Diurnal_IOP, 1946, 1957, "diurnal IOP", "", " ." +217, TimePoint, 1974, 1981, "8 weeks", "", " \"8 weeks\". \"8 weeks\"." +44, Reduction, 1987, 1993, "7 . 02", "", " \"7 . 02\"." +256, SdDevChangeValue, 2000, 2006, "3 . 06", "", " \"3 . 06\"." +46, mmHg, 2007, 2012, "mm Hg", "", +47, Reduction, 2017, 2023, "6 . 91", "", " \"6 . 91\"." +257, SdDevChangeValue, 2030, 2036, "3 . 67", "", " \"3 . 67\"." +49, mmHg, 2037, 2042, "mm Hg", "", +222, PvalueDiff, 2064, 2071, "0 . 811", "", " \"0 . 811\"." +224, TimePoint, 2145, 2151, "week 8", "", +51, PvalueDiff, 2188, 2199, "P = 0 . 847", "", +52, Mean, 2204, 2208, "Mean", "", " . ." +57, Peak_IOP, 2222, 2226, "peak", "", " ." +59, BaseLineValue, 2231, 2238, "27 . 79", "", " \"27 . 79\"." +44439, SdDevBL, 2245, 2251, "4 . 29", "", " \"4 . 29\"." +53, mmHg, 2252, 2257, "mm Hg", "", " . ." +125, Brimonidine, 2265, 2276, "brimonidine", "", +44441, Brimo/TimFC, 2265, 2286, "brimonidine / timolol", "", +126, Timolol, 2279, 2286, "timolol", "", +61, BaseLineValue, 2297, 2304, "27 . 68", "", " \"27 . 68\"." +259, SdDevBL, 2311, 2317, "5 . 46", "", " \"5 . 46\"." +54, mmHg, 2318, 2323, "mm Hg", "", +127, Dorzolamide, 2331, 2342, "dorzolamide", "", +44442, Dorz/TimFC, 2331, 2352, "dorzolamide / timolol", "", +128, Timolol, 2345, 2352, "timolol", "", +234, TimePoint, 2367, 2374, "8 weeks", "", " \"8 weeks\". \"8 weeks\"." +56, Mean, 2390, 2394, "mean", "", +58, Peak_IOP, 2399, 2404, "peaks", "", +63, ResultMeasuredValue, 2410, 2417, "20 . 94", "", " \"20 . 94\"." +239, SdDevResValue, 2424, 2430, "3 . 76", "", " \"3 . 76\"." +65, mmHg, 2431, 2436, "mm Hg", "", +66, PValueResValue, 2439, 2450, "P < 0 . 001", "", " \"P < 0 . 001\"." +67, ResultMeasuredValue, 2457, 2464, "20 . 98", "", " \"20 . 98\"." +240, SdDevResValue, 2471, 2477, "4 . 19", "", " \"4 . 19\"." +69, PValueResValue, 2480, 2491, "P < 0 . 001", "", " \"P < 0 . 001\"." +70, PvalueDiff, 2613, 2624, "P = 0 . 469", "", " \"P = 0 . 469\"." +71, ConclusionComment, 2723, 2875, "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .", "", " \"Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .\"." +74, Mean, 2790, 2794, "mean", "", +73, Diurnal_IOP, 2795, 2806, "diurnal IOP", "", +75, Mean, 2809, 2813, "mean", "", +76, Peak_IOP, 2814, 2826, "diurnal peak", "", +77, Mean, 2833, 2837, "mean", "", +44443, Peak_IOP, 2842, 2846, "peak", "", +249, TimePoint, 2853, 2860, "8 weeks", "", +72, ConclusionComment, 2876, 2949, "Also , both fixed combinations are well tolerated with few side effects .", "", " \"Also , both fixed combinations are well tolerated with few side effects .\"." +79, PMID, 2998, 3006, "19092465", "", " \"19092465\"." diff --git a/data/gl 19092465 copy_admin.n-triples b/data/gl 19092465 copy_admin.n-triples new file mode 100644 index 0000000..2f35656 --- /dev/null +++ b/data/gl 19092465 copy_admin.n-triples @@ -0,0 +1,143 @@ +# RDF export of group: Publication + . + "Publication 106157" . + "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of" . + "Hatanaka M" . + "2008" . + "J Glaucoma" . + "19092465" . + . + "Grigera DE" . + "Barbosa WL" . + "Jordao M" . + "Susanna R Jr" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 106164" . + "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus" . + "210" . + "8 weeks" . + . + . + . + "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment ." . + . + . + . + . + . + . + . + "Also , both fixed combinations are well tolerated with few side effects ." . + . + . + . + "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks ." . + . +# RDF export of group: Population + . + "Population 106180" . + . + . + . + . +# RDF export of group: Endpoint + . + "diiop" . + . + . + . + . + . + . + "piop" . + . + . + . + . + . +# RDF export of group: Arm + . + "briti" . + "111" . + . + . + . + . + . + "dorti" . + "99" . + . + . + . + . +# RDF export of group: Intervention + . + "briti" . + . + "twice daily" . + . + . + "dorti" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "briti" . + . + "0 . 5" . + . + . + . + "dorti" . + . + . + . +# RDF export of group: Outcome + . + "diiop1" . + . + "23 . 43" . + "3 . 22" . + "7 . 02" . + "3 . 06" . + "8 weeks" . + . + "diiop2" . + . + "23 . 43" . + "4 . 06" . + "6 . 91" . + "3 . 67" . + "8 weeks" . + . + "piop1" . + . + "27 . 79" . + "4 . 29" . + "20 . 94" . + "P < 0 . 001" . + "3 . 76" . + "8 weeks" . + . + "piop2" . + . + "27 . 68" . + "5 . 46" . + "20 . 98" . + "P < 0 . 001" . + "4 . 19" . + "8 weeks" . +# RDF export of group: DiffBetweenGroups + . + "diiop" . + "0 . 811" . + . + . + . + "piop" . + "P = 0 . 469" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19092465 copy_export.csv b/data/gl 19092465 copy_export.csv new file mode 100644 index 0000000..10c6dde --- /dev/null +++ b/data/gl 19092465 copy_export.csv @@ -0,0 +1,665 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +830, 1, 1, 1, 0, 1, 0, 1, "J" +830, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +830, 1, 3, 3, 11, 12, 11, 12, "." +830, 2, 1, 4, 0, 4, 13, 17, "2008" +830, 2, 2, 5, 5, 8, 18, 21, "Dec" +830, 2, 3, 6, 9, 10, 22, 23, ";" +830, 2, 4, 7, 11, 13, 24, 26, "17" +830, 2, 5, 8, 14, 15, 27, 28, "(" +830, 2, 6, 9, 16, 17, 29, 30, "8" +830, 2, 7, 10, 18, 19, 31, 32, ")" +830, 2, 8, 11, 20, 21, 33, 34, ":" +830, 2, 9, 12, 22, 25, 35, 38, "674" +830, 2, 10, 13, 26, 27, 39, 40, "-" +830, 2, 11, 14, 28, 29, 41, 42, "9" +830, 2, 12, 15, 30, 31, 43, 44, "." +830, 2, 13, 16, 32, 35, 45, 48, "doi" +830, 2, 14, 17, 36, 37, 49, 50, ":" +830, 2, 15, 18, 38, 40, 51, 53, "10" +830, 2, 16, 19, 41, 42, 54, 55, "." +830, 2, 17, 20, 43, 47, 56, 60, "1097" +830, 2, 18, 21, 48, 49, 61, 62, "/" +830, 2, 19, 22, 50, 53, 63, 66, "IJG" +830, 2, 20, 23, 54, 55, 67, 68, "." +830, 2, 21, 24, 56, 72, 69, 85, "0b013e318168f008" +830, 2, 22, 25, 73, 74, 86, 87, "." +830, 3, 1, 26, 0, 2, 88, 90, "An" +830, 3, 2, 27, 3, 8, 91, 96, "eight" +830, 3, 3, 28, 9, 10, 97, 98, "-" +830, 3, 4, 29, 11, 15, 99, 103, "week" +830, 3, 5, 30, 16, 17, 104, 105, "," +830, 3, 6, 31, 18, 30, 106, 118, "multicentric" +830, 3, 7, 32, 31, 32, 119, 120, "," +830, 3, 8, 33, 33, 43, 121, 131, "randomized" +830, 3, 9, 34, 44, 45, 132, 133, "," +830, 3, 10, 35, 46, 60, 134, 148, "interventional" +830, 3, 11, 36, 61, 62, 149, 150, "," +830, 3, 12, 37, 63, 67, 151, 155, "open" +830, 3, 13, 38, 68, 69, 156, 157, "-" +830, 3, 14, 39, 70, 75, 158, 163, "label" +830, 3, 15, 40, 76, 77, 164, 165, "," +830, 3, 16, 41, 78, 83, 166, 171, "phase" +830, 3, 17, 42, 84, 85, 172, 173, "4" +830, 3, 18, 43, 86, 87, 174, 175, "," +830, 3, 19, 44, 88, 96, 176, 184, "parallel" +830, 3, 20, 45, 97, 107, 185, 195, "comparison" +830, 3, 21, 46, 108, 110, 196, 198, "of" +830, 3, 22, 47, 111, 114, 199, 202, "the" +830, 3, 23, 48, 115, 123, 203, 211, "efficacy" +830, 3, 24, 49, 124, 127, 212, 215, "and" +830, 3, 25, 50, 128, 140, 216, 228, "tolerability" +830, 3, 26, 51, 141, 143, 229, 231, "of" +830, 3, 27, 52, 144, 147, 232, 235, "the" +830, 3, 28, 53, 148, 153, 236, 241, "fixed" +830, 3, 29, 54, 154, 165, 242, 253, "combination" +830, 3, 30, 55, 166, 168, 254, 256, "of" +830, 3, 31, 56, 169, 176, 257, 264, "timolol" +830, 3, 32, 57, 177, 184, 265, 272, "maleate" +830, 3, 33, 58, 185, 186, 273, 274, "0" +830, 3, 34, 59, 187, 188, 275, 276, "." +830, 3, 35, 60, 189, 190, 277, 278, "5" +830, 3, 36, 61, 191, 192, 279, 280, "%" +830, 3, 37, 62, 193, 194, 281, 282, "/" +830, 3, 38, 63, 195, 206, 283, 294, "brimonidine" +830, 3, 39, 64, 207, 215, 295, 303, "tartrate" +830, 3, 40, 65, 216, 217, 304, 305, "0" +830, 3, 41, 66, 218, 219, 306, 307, "." +830, 3, 42, 67, 220, 221, 308, 309, "2" +830, 3, 43, 68, 222, 223, 310, 311, "%" +830, 3, 44, 69, 224, 230, 312, 318, "versus" +830, 3, 45, 70, 231, 236, 319, 324, "fixed" +830, 3, 46, 71, 237, 248, 325, 336, "combination" +830, 3, 47, 72, 249, 251, 337, 339, "of" +830, 3, 48, 73, 252, 259, 340, 347, "timolol" +830, 3, 49, 74, 260, 267, 348, 355, "maleate" +830, 3, 50, 75, 268, 269, 356, 357, "0" +830, 3, 51, 76, 270, 271, 358, 359, "." +830, 3, 52, 77, 272, 273, 360, 361, "5" +830, 3, 53, 78, 274, 275, 362, 363, "%" +830, 3, 54, 79, 276, 277, 364, 365, "/" +830, 3, 55, 80, 278, 289, 366, 377, "dorzolamide" +830, 3, 56, 81, 290, 291, 378, 379, "2" +830, 3, 57, 82, 292, 293, 380, 381, "%" +830, 3, 58, 83, 294, 296, 382, 384, "in" +830, 3, 59, 84, 297, 305, 385, 393, "patients" +830, 3, 60, 85, 306, 310, 394, 398, "with" +830, 3, 61, 86, 311, 319, 399, 407, "elevated" +830, 3, 62, 87, 320, 331, 408, 419, "intraocular" +830, 3, 63, 88, 332, 340, 420, 428, "pressure" +830, 3, 64, 89, 341, 342, 429, 430, "." +830, 4, 1, 90, 0, 8, 431, 439, "Hatanaka" +830, 4, 2, 91, 9, 10, 440, 441, "M" +830, 4, 3, 92, 11, 12, 442, 443, "(" +830, 4, 4, 93, 13, 14, 444, 445, "1" +830, 4, 5, 94, 15, 16, 446, 447, ")" +830, 4, 6, 95, 17, 18, 448, 449, "," +830, 4, 7, 96, 19, 26, 450, 457, "Grigera" +830, 4, 8, 97, 27, 29, 458, 460, "DE" +830, 4, 9, 98, 30, 31, 461, 462, "," +830, 4, 10, 99, 32, 39, 463, 470, "Barbosa" +830, 4, 11, 100, 40, 42, 471, 473, "WL" +830, 4, 12, 101, 43, 44, 474, 475, "," +830, 4, 13, 102, 45, 51, 476, 482, "Jordao" +830, 4, 14, 103, 52, 53, 483, 484, "M" +830, 4, 15, 104, 54, 55, 485, 486, "," +830, 4, 16, 105, 56, 63, 487, 494, "Susanna" +830, 4, 17, 106, 64, 65, 495, 496, "R" +830, 4, 18, 107, 66, 68, 497, 499, "Jr" +830, 4, 19, 108, 69, 70, 500, 501, "." +830, 5, 1, 109, 0, 6, 502, 508, "Author" +830, 5, 2, 110, 7, 18, 509, 520, "information" +830, 5, 3, 111, 19, 20, 521, 522, ":" +830, 5, 4, 112, 21, 22, 523, 524, "(" +830, 5, 5, 113, 23, 24, 525, 526, "1" +830, 5, 6, 114, 25, 26, 527, 528, ")" +830, 5, 7, 115, 27, 37, 529, 539, "University" +830, 5, 8, 116, 38, 40, 540, 542, "of" +830, 5, 9, 117, 41, 42, 543, 544, "S" +830, 5, 10, 118, 43, 44, 545, 546, "ã" +830, 5, 11, 119, 45, 46, 547, 548, "o" +830, 5, 12, 120, 47, 52, 549, 554, "Paulo" +830, 5, 13, 121, 53, 59, 555, 561, "School" +830, 5, 14, 122, 60, 62, 562, 564, "of" +830, 5, 15, 123, 63, 71, 565, 573, "Medicine" +830, 5, 16, 124, 72, 73, 574, 575, "," +830, 5, 17, 125, 74, 77, 576, 579, "Sao" +830, 5, 18, 126, 78, 83, 580, 585, "Paulo" +830, 5, 19, 127, 84, 85, 586, 587, "," +830, 5, 20, 128, 86, 92, 588, 594, "Brazil" +830, 5, 21, 129, 93, 94, 595, 596, "." +830, 6, 1, 130, 0, 4, 597, 601, "info" +830, 6, 2, 131, 5, 6, 602, 603, "@" +830, 6, 3, 132, 7, 21, 604, 618, "centroavancado" +830, 6, 4, 133, 22, 23, 619, 620, "." +830, 6, 5, 134, 24, 27, 621, 624, "net" +830, 6, 6, 135, 28, 35, 625, 632, "PURPOSE" +830, 6, 7, 136, 36, 37, 633, 634, ":" +830, 6, 8, 137, 38, 40, 635, 637, "To" +830, 6, 9, 138, 41, 48, 638, 645, "compare" +830, 6, 10, 139, 49, 52, 646, 649, "the" +830, 6, 11, 140, 53, 61, 650, 658, "efficacy" +830, 6, 12, 141, 62, 65, 659, 662, "and" +830, 6, 13, 142, 66, 78, 663, 675, "tolerability" +830, 6, 14, 143, 79, 81, 676, 678, "of" +830, 6, 15, 144, 82, 85, 679, 682, "the" +830, 6, 16, 145, 86, 91, 683, 688, "fixed" +830, 6, 17, 146, 92, 103, 689, 700, "combination" +830, 6, 18, 147, 104, 106, 701, 703, "of" +830, 6, 19, 148, 107, 114, 704, 711, "timolol" +830, 6, 20, 149, 115, 122, 712, 719, "maleate" +830, 6, 21, 150, 123, 124, 720, 721, "0" +830, 6, 22, 151, 125, 126, 722, 723, "." +830, 6, 23, 152, 127, 128, 724, 725, "5" +830, 6, 24, 153, 129, 130, 726, 727, "%" +830, 6, 25, 154, 131, 132, 728, 729, "/" +830, 6, 26, 155, 133, 144, 730, 741, "brimonidine" +830, 6, 27, 156, 145, 153, 742, 750, "tartrate" +830, 6, 28, 157, 154, 155, 751, 752, "0" +830, 6, 29, 158, 156, 157, 753, 754, "." +830, 6, 30, 159, 158, 159, 755, 756, "2" +830, 6, 31, 160, 160, 161, 757, 758, "%" +830, 6, 32, 161, 162, 168, 759, 765, "versus" +830, 6, 33, 162, 169, 174, 766, 771, "fixed" +830, 6, 34, 163, 175, 186, 772, 783, "combination" +830, 6, 35, 164, 187, 189, 784, 786, "of" +830, 6, 36, 165, 190, 197, 787, 794, "timolol" +830, 6, 37, 166, 198, 205, 795, 802, "maleate" +830, 6, 38, 167, 206, 207, 803, 804, "0" +830, 6, 39, 168, 208, 209, 805, 806, "." +830, 6, 40, 169, 210, 211, 807, 808, "5" +830, 6, 41, 170, 212, 213, 809, 810, "%" +830, 6, 42, 171, 214, 215, 811, 812, "/" +830, 6, 43, 172, 216, 227, 813, 824, "dorzolamide" +830, 6, 44, 173, 228, 229, 825, 826, "2" +830, 6, 45, 174, 230, 231, 827, 828, "%" +830, 6, 46, 175, 232, 234, 829, 831, "in" +830, 6, 47, 176, 235, 243, 832, 840, "patients" +830, 6, 48, 177, 244, 248, 841, 845, "with" +830, 6, 49, 178, 249, 257, 846, 854, "elevated" +830, 6, 50, 179, 258, 269, 855, 866, "intraocular" +830, 6, 51, 180, 270, 278, 867, 875, "pressure" +830, 6, 52, 181, 279, 280, 876, 877, "(" +830, 6, 53, 182, 281, 284, 878, 881, "IOP" +830, 6, 54, 183, 285, 286, 882, 883, ")" +830, 6, 55, 184, 287, 291, 884, 888, "over" +830, 6, 56, 185, 292, 293, 889, 890, "8" +830, 6, 57, 186, 294, 299, 891, 896, "weeks" +830, 6, 58, 187, 300, 301, 897, 898, "." +830, 7, 1, 188, 0, 8, 899, 907, "PATIENTS" +830, 7, 2, 189, 9, 12, 908, 911, "AND" +830, 7, 3, 190, 13, 20, 912, 919, "METHODS" +830, 7, 4, 191, 21, 22, 920, 921, ":" +830, 7, 5, 192, 23, 27, 922, 926, "This" +830, 7, 6, 193, 28, 29, 927, 928, "8" +830, 7, 7, 194, 30, 31, 929, 930, "-" +830, 7, 8, 195, 32, 36, 931, 935, "week" +830, 7, 9, 196, 37, 38, 936, 937, "," +830, 7, 10, 197, 39, 51, 938, 950, "multicentric" +830, 7, 11, 198, 52, 53, 951, 952, "," +830, 7, 12, 199, 54, 68, 953, 967, "interventional" +830, 7, 13, 200, 69, 70, 968, 969, "," +830, 7, 14, 201, 71, 81, 970, 980, "randomized" +830, 7, 15, 202, 82, 83, 981, 982, "," +830, 7, 16, 203, 84, 88, 983, 987, "open" +830, 7, 17, 204, 89, 90, 988, 989, "-" +830, 7, 18, 205, 91, 96, 990, 995, "label" +830, 7, 19, 206, 97, 98, 996, 997, "," +830, 7, 20, 207, 99, 107, 998, 1006, "parallel" +830, 7, 21, 208, 108, 113, 1007, 1012, "group" +830, 7, 22, 209, 114, 119, 1013, 1018, "study" +830, 7, 23, 210, 120, 123, 1019, 1022, "was" +830, 7, 24, 211, 124, 133, 1023, 1032, "conducted" +830, 7, 25, 212, 134, 136, 1033, 1035, "at" +830, 7, 26, 213, 137, 138, 1036, 1037, "4" +830, 7, 27, 214, 139, 146, 1038, 1045, "centers" +830, 7, 28, 215, 147, 149, 1046, 1048, "in" +830, 7, 29, 216, 150, 156, 1049, 1055, "Brazil" +830, 7, 30, 217, 157, 160, 1056, 1059, "and" +830, 7, 31, 218, 161, 162, 1060, 1061, "1" +830, 7, 32, 219, 163, 169, 1062, 1068, "center" +830, 7, 33, 220, 170, 172, 1069, 1071, "in" +830, 7, 34, 221, 173, 182, 1072, 1081, "Argentina" +830, 7, 35, 222, 183, 184, 1082, 1083, "." +830, 8, 1, 223, 0, 8, 1084, 1092, "Patients" +830, 8, 2, 224, 9, 13, 1093, 1097, "with" +830, 8, 3, 225, 14, 18, 1098, 1102, "open" +830, 8, 4, 226, 19, 20, 1103, 1104, "-" +830, 8, 5, 227, 21, 26, 1105, 1110, "angle" +830, 8, 6, 228, 27, 35, 1111, 1119, "glaucoma" +830, 8, 7, 229, 36, 38, 1120, 1122, "or" +830, 8, 8, 230, 39, 45, 1123, 1129, "ocular" +830, 8, 9, 231, 46, 58, 1130, 1142, "hypertension" +830, 8, 10, 232, 59, 63, 1143, 1147, "were" +830, 8, 11, 233, 64, 74, 1148, 1158, "randomized" +830, 8, 12, 234, 75, 77, 1159, 1161, "to" +830, 8, 13, 235, 78, 85, 1162, 1169, "receive" +830, 8, 14, 236, 86, 97, 1170, 1181, "bilaterally" +830, 8, 15, 237, 98, 103, 1182, 1187, "fixed" +830, 8, 16, 238, 104, 115, 1188, 1199, "combination" +830, 8, 17, 239, 116, 118, 1200, 1202, "of" +830, 8, 18, 240, 119, 130, 1203, 1214, "brimonidine" +830, 8, 19, 241, 131, 132, 1215, 1216, "/" +830, 8, 20, 242, 133, 140, 1217, 1224, "timolol" +830, 8, 21, 243, 141, 148, 1225, 1232, "maleate" +830, 8, 22, 244, 149, 150, 1233, 1234, "0" +830, 8, 23, 245, 151, 152, 1235, 1236, "." +830, 8, 24, 246, 153, 154, 1237, 1238, "5" +830, 8, 25, 247, 155, 156, 1239, 1240, "%" +830, 8, 26, 248, 157, 159, 1241, 1243, "or" +830, 8, 27, 249, 160, 165, 1244, 1249, "fixed" +830, 8, 28, 250, 166, 177, 1250, 1261, "combination" +830, 8, 29, 251, 178, 180, 1262, 1264, "of" +830, 8, 30, 252, 181, 192, 1265, 1276, "dorzolamide" +830, 8, 31, 253, 193, 194, 1277, 1278, "2" +830, 8, 32, 254, 195, 196, 1279, 1280, "%" +830, 8, 33, 255, 197, 198, 1281, 1282, "/" +830, 8, 34, 256, 199, 206, 1283, 1290, "timolol" +830, 8, 35, 257, 207, 208, 1291, 1292, "0" +830, 8, 36, 258, 209, 210, 1293, 1294, "." +830, 8, 37, 259, 211, 212, 1295, 1296, "5" +830, 8, 38, 260, 213, 214, 1297, 1298, "%" +830, 8, 39, 261, 215, 220, 1299, 1304, "twice" +830, 8, 40, 262, 221, 226, 1305, 1310, "daily" +830, 8, 41, 263, 227, 229, 1311, 1313, "at" +830, 8, 42, 264, 230, 231, 1314, 1315, "8" +830, 8, 43, 265, 232, 233, 1316, 1317, ":" +830, 8, 44, 266, 234, 236, 1318, 1320, "00" +830, 8, 45, 267, 237, 239, 1321, 1323, "AM" +830, 8, 46, 268, 240, 243, 1324, 1327, "and" +830, 8, 47, 269, 244, 245, 1328, 1329, "8" +830, 8, 48, 270, 246, 247, 1330, 1331, ":" +830, 8, 49, 271, 248, 250, 1332, 1334, "00" +830, 8, 50, 272, 251, 253, 1335, 1337, "PM" +830, 8, 51, 273, 254, 255, 1338, 1339, "." +830, 9, 1, 274, 0, 1, 1340, 1341, "A" +830, 9, 2, 275, 2, 10, 1342, 1350, "modified" +830, 9, 3, 276, 11, 18, 1351, 1358, "diurnal" +830, 9, 4, 277, 19, 26, 1359, 1366, "tension" +830, 9, 5, 278, 27, 32, 1367, 1372, "curve" +830, 9, 6, 279, 33, 34, 1373, 1374, "(" +830, 9, 7, 280, 35, 36, 1375, 1376, "8" +830, 9, 8, 281, 37, 38, 1377, 1378, ":" +830, 9, 9, 282, 39, 41, 1379, 1381, "00" +830, 9, 10, 283, 42, 44, 1382, 1384, "AM" +830, 9, 11, 284, 45, 46, 1385, 1386, "," +830, 9, 12, 285, 47, 49, 1387, 1389, "10" +830, 9, 13, 286, 50, 51, 1390, 1391, ":" +830, 9, 14, 287, 52, 54, 1392, 1394, "30" +830, 9, 15, 288, 55, 57, 1395, 1397, "AM" +830, 9, 16, 289, 58, 59, 1398, 1399, "," +830, 9, 17, 290, 60, 62, 1400, 1402, "02" +830, 9, 18, 291, 63, 64, 1403, 1404, ":" +830, 9, 19, 292, 65, 67, 1405, 1407, "00" +830, 9, 20, 293, 68, 70, 1408, 1410, "PM" +830, 9, 21, 294, 71, 72, 1411, 1412, "," +830, 9, 22, 295, 73, 76, 1413, 1416, "and" +830, 9, 23, 296, 77, 78, 1417, 1418, "4" +830, 9, 24, 297, 79, 80, 1419, 1420, ":" +830, 9, 25, 298, 81, 83, 1421, 1423, "00" +830, 9, 26, 299, 84, 86, 1424, 1426, "PM" +830, 9, 27, 300, 87, 88, 1427, 1428, ")" +830, 9, 28, 301, 89, 97, 1429, 1437, "followed" +830, 9, 29, 302, 98, 100, 1438, 1440, "by" +830, 9, 30, 303, 101, 104, 1441, 1444, "the" +830, 9, 31, 304, 105, 110, 1445, 1450, "water" +830, 9, 32, 305, 111, 119, 1451, 1459, "drinking" +830, 9, 33, 306, 120, 124, 1460, 1464, "test" +830, 9, 34, 307, 125, 126, 1465, 1466, "(" +830, 9, 35, 308, 127, 130, 1467, 1470, "WDT" +830, 9, 36, 309, 131, 132, 1471, 1472, ")" +830, 9, 37, 310, 133, 134, 1473, 1474, "," +830, 9, 38, 311, 135, 140, 1475, 1480, "which" +830, 9, 39, 312, 141, 150, 1481, 1490, "estimates" +830, 9, 40, 313, 151, 154, 1491, 1494, "IOP" +830, 9, 41, 314, 155, 159, 1495, 1499, "peak" +830, 9, 42, 315, 160, 162, 1500, 1502, "of" +830, 9, 43, 316, 163, 170, 1503, 1510, "diurnal" +830, 9, 44, 317, 171, 178, 1511, 1518, "tension" +830, 9, 45, 318, 179, 184, 1519, 1524, "curve" +830, 9, 46, 319, 185, 186, 1525, 1526, "," +830, 9, 47, 320, 187, 191, 1527, 1531, "were" +830, 9, 48, 321, 192, 201, 1532, 1541, "performed" +830, 9, 49, 322, 202, 204, 1542, 1544, "in" +830, 9, 50, 323, 205, 208, 1545, 1548, "the" +830, 9, 51, 324, 209, 217, 1549, 1557, "baseline" +830, 9, 52, 325, 218, 221, 1558, 1561, "and" +830, 9, 53, 326, 222, 226, 1562, 1566, "week" +830, 9, 54, 327, 227, 228, 1567, 1568, "-" +830, 9, 55, 328, 229, 230, 1569, 1570, "8" +830, 9, 56, 329, 231, 237, 1571, 1577, "visits" +830, 9, 57, 330, 238, 239, 1578, 1579, "." +830, 10, 1, 331, 0, 7, 1580, 1587, "Adverse" +830, 10, 2, 332, 8, 14, 1588, 1594, "events" +830, 10, 3, 333, 15, 19, 1595, 1599, "data" +830, 10, 4, 334, 20, 24, 1600, 1604, "were" +830, 10, 5, 335, 25, 33, 1605, 1613, "recorded" +830, 10, 6, 336, 34, 36, 1614, 1616, "at" +830, 10, 7, 337, 37, 41, 1617, 1621, "each" +830, 10, 8, 338, 42, 47, 1622, 1627, "visit" +830, 10, 9, 339, 48, 49, 1628, 1629, "." +830, 11, 1, 340, 0, 7, 1630, 1637, "RESULTS" +830, 11, 2, 341, 8, 9, 1638, 1639, ":" +830, 11, 3, 342, 10, 11, 1640, 1641, "A" +830, 11, 4, 343, 12, 17, 1642, 1647, "total" +830, 11, 5, 344, 18, 20, 1648, 1650, "of" +830, 11, 6, 345, 21, 24, 1651, 1654, "210" +830, 11, 7, 346, 25, 33, 1655, 1663, "patients" +830, 11, 8, 347, 34, 38, 1664, 1668, "were" +830, 11, 9, 348, 39, 49, 1669, 1679, "randomized" +830, 11, 10, 349, 50, 51, 1680, 1681, "(" +830, 11, 11, 350, 52, 63, 1682, 1693, "brimonidine" +830, 11, 12, 351, 64, 65, 1694, 1695, "/" +830, 11, 13, 352, 66, 73, 1696, 1703, "timolol" +830, 11, 14, 353, 74, 75, 1704, 1705, "," +830, 11, 15, 354, 76, 77, 1706, 1707, "n" +830, 11, 16, 355, 78, 79, 1708, 1709, "=" +830, 11, 17, 356, 80, 83, 1710, 1713, "111" +830, 11, 18, 357, 84, 85, 1714, 1715, ";" +830, 11, 19, 358, 86, 97, 1716, 1727, "dorzolamide" +830, 11, 20, 359, 98, 99, 1728, 1729, "/" +830, 11, 21, 360, 100, 107, 1730, 1737, "timolol" +830, 11, 22, 361, 108, 109, 1738, 1739, "," +830, 11, 23, 362, 110, 111, 1740, 1741, "n" +830, 11, 24, 363, 112, 113, 1742, 1743, "=" +830, 11, 25, 364, 114, 116, 1744, 1746, "99" +830, 11, 26, 365, 117, 118, 1747, 1748, ")" +830, 11, 27, 366, 119, 120, 1749, 1750, "." +830, 12, 1, 367, 0, 4, 1751, 1755, "Mean" +830, 12, 2, 368, 5, 13, 1756, 1764, "baseline" +830, 12, 3, 369, 14, 17, 1765, 1768, "IOP" +830, 12, 4, 370, 18, 21, 1769, 1772, "was" +830, 12, 5, 371, 22, 24, 1773, 1775, "23" +830, 12, 6, 372, 25, 26, 1776, 1777, "." +830, 12, 7, 373, 27, 29, 1778, 1780, "43" +830, 12, 8, 374, 30, 31, 1781, 1782, "+" +830, 12, 9, 375, 32, 33, 1783, 1784, "/" +830, 12, 10, 376, 34, 35, 1785, 1786, "-" +830, 12, 11, 377, 36, 37, 1787, 1788, "3" +830, 12, 12, 378, 38, 39, 1789, 1790, "." +830, 12, 13, 379, 40, 42, 1791, 1793, "22" +830, 12, 14, 380, 43, 45, 1794, 1796, "mm" +830, 12, 15, 381, 46, 48, 1797, 1799, "Hg" +830, 12, 16, 382, 49, 52, 1800, 1803, "and" +830, 12, 17, 383, 53, 55, 1804, 1806, "23" +830, 12, 18, 384, 56, 57, 1807, 1808, "." +830, 12, 19, 385, 58, 60, 1809, 1811, "43" +830, 12, 20, 386, 61, 62, 1812, 1813, "+" +830, 12, 21, 387, 63, 64, 1814, 1815, "/" +830, 12, 22, 388, 65, 66, 1816, 1817, "-" +830, 12, 23, 389, 67, 68, 1818, 1819, "4" +830, 12, 24, 390, 69, 70, 1820, 1821, "." +830, 12, 25, 391, 71, 73, 1822, 1824, "06" +830, 12, 26, 392, 74, 76, 1825, 1827, "mm" +830, 12, 27, 393, 77, 79, 1828, 1830, "Hg" +830, 12, 28, 394, 80, 82, 1831, 1833, "in" +830, 12, 29, 395, 83, 86, 1834, 1837, "the" +830, 12, 30, 396, 87, 95, 1838, 1846, "patients" +830, 12, 31, 397, 96, 103, 1847, 1854, "treated" +830, 12, 32, 398, 104, 108, 1855, 1859, "with" +830, 12, 33, 399, 109, 120, 1860, 1871, "brimonidine" +830, 12, 34, 400, 121, 122, 1872, 1873, "/" +830, 12, 35, 401, 123, 130, 1874, 1881, "timolol" +830, 12, 36, 402, 131, 134, 1882, 1885, "and" +830, 12, 37, 403, 135, 146, 1886, 1897, "dorzolamide" +830, 12, 38, 404, 147, 148, 1898, 1899, "/" +830, 12, 39, 405, 149, 156, 1900, 1907, "timolol" +830, 12, 40, 406, 157, 158, 1908, 1909, "," +830, 12, 41, 407, 159, 171, 1910, 1922, "respectively" +830, 12, 42, 408, 172, 173, 1923, 1924, "(" +830, 12, 43, 409, 174, 175, 1925, 1926, "P" +830, 12, 44, 410, 176, 177, 1927, 1928, "=" +830, 12, 45, 411, 178, 179, 1929, 1930, "0" +830, 12, 46, 412, 180, 181, 1931, 1932, "." +830, 12, 47, 413, 182, 185, 1933, 1936, "993" +830, 12, 48, 414, 186, 187, 1937, 1938, ")" +830, 12, 49, 415, 188, 189, 1939, 1940, "." +830, 13, 1, 416, 0, 4, 1941, 1945, "Mean" +830, 13, 2, 417, 5, 12, 1946, 1953, "diurnal" +830, 13, 3, 418, 13, 16, 1954, 1957, "IOP" +830, 13, 4, 419, 17, 26, 1958, 1967, "reduction" +830, 13, 5, 420, 27, 32, 1968, 1973, "after" +830, 13, 6, 421, 33, 34, 1974, 1975, "8" +830, 13, 7, 422, 35, 40, 1976, 1981, "weeks" +830, 13, 8, 423, 41, 45, 1982, 1986, "were" +830, 13, 9, 424, 46, 47, 1987, 1988, "7" +830, 13, 10, 425, 48, 49, 1989, 1990, "." +830, 13, 11, 426, 50, 52, 1991, 1993, "02" +830, 13, 12, 427, 53, 54, 1994, 1995, "+" +830, 13, 13, 428, 55, 56, 1996, 1997, "/" +830, 13, 14, 429, 57, 58, 1998, 1999, "-" +830, 13, 15, 430, 59, 60, 2000, 2001, "3" +830, 13, 16, 431, 61, 62, 2002, 2003, "." +830, 13, 17, 432, 63, 65, 2004, 2006, "06" +830, 13, 18, 433, 66, 68, 2007, 2009, "mm" +830, 13, 19, 434, 69, 71, 2010, 2012, "Hg" +830, 13, 20, 435, 72, 75, 2013, 2016, "and" +830, 13, 21, 436, 76, 77, 2017, 2018, "6" +830, 13, 22, 437, 78, 79, 2019, 2020, "." +830, 13, 23, 438, 80, 82, 2021, 2023, "91" +830, 13, 24, 439, 83, 84, 2024, 2025, "+" +830, 13, 25, 440, 85, 86, 2026, 2027, "/" +830, 13, 26, 441, 87, 88, 2028, 2029, "-" +830, 13, 27, 442, 89, 90, 2030, 2031, "3" +830, 13, 28, 443, 91, 92, 2032, 2033, "." +830, 13, 29, 444, 93, 95, 2034, 2036, "67" +830, 13, 30, 445, 96, 98, 2037, 2039, "mm" +830, 13, 31, 446, 99, 101, 2040, 2042, "Hg" +830, 13, 32, 447, 102, 103, 2043, 2044, "," +830, 13, 33, 448, 104, 116, 2045, 2057, "respectively" +830, 13, 34, 449, 117, 118, 2058, 2059, "(" +830, 13, 35, 450, 119, 120, 2060, 2061, "P" +830, 13, 36, 451, 121, 122, 2062, 2063, "=" +830, 13, 37, 452, 123, 124, 2064, 2065, "0" +830, 13, 38, 453, 125, 126, 2066, 2067, "." +830, 13, 39, 454, 127, 130, 2068, 2071, "811" +830, 13, 40, 455, 131, 132, 2072, 2073, ")" +830, 13, 41, 456, 133, 134, 2074, 2075, "." +830, 14, 1, 457, 0, 3, 2076, 2079, "The" +830, 14, 2, 458, 4, 12, 2080, 2088, "adjusted" +830, 14, 3, 459, 13, 23, 2089, 2099, "difference" +830, 14, 4, 460, 24, 31, 2100, 2107, "between" +830, 14, 5, 461, 32, 38, 2108, 2114, "groups" +830, 14, 6, 462, 39, 40, 2115, 2116, "(" +830, 14, 7, 463, 41, 49, 2117, 2125, "analysis" +830, 14, 8, 464, 50, 52, 2126, 2128, "of" +830, 14, 9, 465, 53, 63, 2129, 2139, "covariance" +830, 14, 10, 466, 64, 65, 2140, 2141, ")" +830, 14, 11, 467, 66, 68, 2142, 2144, "at" +830, 14, 12, 468, 69, 73, 2145, 2149, "week" +830, 14, 13, 469, 74, 75, 2150, 2151, "8" +830, 14, 14, 470, 76, 79, 2152, 2155, "was" +830, 14, 15, 471, 80, 83, 2156, 2159, "not" +830, 14, 16, 472, 84, 97, 2160, 2173, "statistically" +830, 14, 17, 473, 98, 109, 2174, 2185, "significant" +830, 14, 18, 474, 110, 111, 2186, 2187, "(" +830, 14, 19, 475, 112, 113, 2188, 2189, "P" +830, 14, 20, 476, 114, 115, 2190, 2191, "=" +830, 14, 21, 477, 116, 117, 2192, 2193, "0" +830, 14, 22, 478, 118, 119, 2194, 2195, "." +830, 14, 23, 479, 120, 123, 2196, 2199, "847" +830, 14, 24, 480, 124, 125, 2200, 2201, ")" +830, 14, 25, 481, 126, 127, 2202, 2203, "." +830, 15, 1, 482, 0, 4, 2204, 2208, "Mean" +830, 15, 2, 483, 5, 13, 2209, 2217, "baseline" +830, 15, 3, 484, 14, 17, 2218, 2221, "WDT" +830, 15, 4, 485, 18, 22, 2222, 2226, "peak" +830, 15, 5, 486, 23, 26, 2227, 2230, "was" +830, 15, 6, 487, 27, 29, 2231, 2233, "27" +830, 15, 7, 488, 30, 31, 2234, 2235, "." +830, 15, 8, 489, 32, 34, 2236, 2238, "79" +830, 15, 9, 490, 35, 36, 2239, 2240, "+" +830, 15, 10, 491, 37, 38, 2241, 2242, "/" +830, 15, 11, 492, 39, 40, 2243, 2244, "-" +830, 15, 12, 493, 41, 42, 2245, 2246, "4" +830, 15, 13, 494, 43, 44, 2247, 2248, "." +830, 15, 14, 495, 45, 47, 2249, 2251, "29" +830, 15, 15, 496, 48, 50, 2252, 2254, "mm" +830, 15, 16, 497, 51, 53, 2255, 2257, "Hg" +830, 15, 17, 498, 54, 56, 2258, 2260, "in" +830, 15, 18, 499, 57, 60, 2261, 2264, "the" +830, 15, 19, 500, 61, 72, 2265, 2276, "brimonidine" +830, 15, 20, 501, 73, 74, 2277, 2278, "/" +830, 15, 21, 502, 75, 82, 2279, 2286, "timolol" +830, 15, 22, 503, 83, 88, 2287, 2292, "group" +830, 15, 23, 504, 89, 92, 2293, 2296, "and" +830, 15, 24, 505, 93, 95, 2297, 2299, "27" +830, 15, 25, 506, 96, 97, 2300, 2301, "." +830, 15, 26, 507, 98, 100, 2302, 2304, "68" +830, 15, 27, 508, 101, 102, 2305, 2306, "+" +830, 15, 28, 509, 103, 104, 2307, 2308, "/" +830, 15, 29, 510, 105, 106, 2309, 2310, "-" +830, 15, 30, 511, 107, 108, 2311, 2312, "5" +830, 15, 31, 512, 109, 110, 2313, 2314, "." +830, 15, 32, 513, 111, 113, 2315, 2317, "46" +830, 15, 33, 514, 114, 116, 2318, 2320, "mm" +830, 15, 34, 515, 117, 119, 2321, 2323, "Hg" +830, 15, 35, 516, 120, 122, 2324, 2326, "in" +830, 15, 36, 517, 123, 126, 2327, 2330, "the" +830, 15, 37, 518, 127, 138, 2331, 2342, "dorzolamide" +830, 15, 38, 519, 139, 140, 2343, 2344, "/" +830, 15, 39, 520, 141, 148, 2345, 2352, "timolol" +830, 15, 40, 521, 149, 154, 2353, 2358, "group" +830, 15, 41, 522, 155, 156, 2359, 2360, "." +830, 16, 1, 523, 0, 5, 2361, 2366, "After" +830, 16, 2, 524, 6, 7, 2367, 2368, "8" +830, 16, 3, 525, 8, 13, 2369, 2374, "weeks" +830, 16, 4, 526, 14, 16, 2375, 2377, "of" +830, 16, 5, 527, 17, 26, 2378, 2387, "treatment" +830, 16, 6, 528, 27, 28, 2388, 2389, "," +830, 16, 7, 529, 29, 33, 2390, 2394, "mean" +830, 16, 8, 530, 34, 37, 2395, 2398, "WDT" +830, 16, 9, 531, 38, 43, 2399, 2404, "peaks" +830, 16, 10, 532, 44, 48, 2405, 2409, "were" +830, 16, 11, 533, 49, 51, 2410, 2412, "20" +830, 16, 12, 534, 52, 53, 2413, 2414, "." +830, 16, 13, 535, 54, 56, 2415, 2417, "94" +830, 16, 14, 536, 57, 58, 2418, 2419, "+" +830, 16, 15, 537, 59, 60, 2420, 2421, "/" +830, 16, 16, 538, 61, 62, 2422, 2423, "-" +830, 16, 17, 539, 63, 64, 2424, 2425, "3" +830, 16, 18, 540, 65, 66, 2426, 2427, "." +830, 16, 19, 541, 67, 69, 2428, 2430, "76" +830, 16, 20, 542, 70, 72, 2431, 2433, "mm" +830, 16, 21, 543, 73, 75, 2434, 2436, "Hg" +830, 16, 22, 544, 76, 77, 2437, 2438, "(" +830, 16, 23, 545, 78, 79, 2439, 2440, "P" +830, 16, 24, 546, 80, 81, 2441, 2442, "<" +830, 16, 25, 547, 82, 83, 2443, 2444, "0" +830, 16, 26, 548, 84, 85, 2445, 2446, "." +830, 16, 27, 549, 86, 89, 2447, 2450, "001" +830, 16, 28, 550, 90, 91, 2451, 2452, ")" +830, 16, 29, 551, 92, 95, 2453, 2456, "and" +830, 16, 30, 552, 96, 98, 2457, 2459, "20" +830, 16, 31, 553, 99, 100, 2460, 2461, "." +830, 16, 32, 554, 101, 103, 2462, 2464, "98" +830, 16, 33, 555, 104, 105, 2465, 2466, "+" +830, 16, 34, 556, 106, 107, 2467, 2468, "/" +830, 16, 35, 557, 108, 109, 2469, 2470, "-" +830, 16, 36, 558, 110, 111, 2471, 2472, "4" +830, 16, 37, 559, 112, 113, 2473, 2474, "." +830, 16, 38, 560, 114, 116, 2475, 2477, "19" +830, 16, 39, 561, 117, 118, 2478, 2479, "(" +830, 16, 40, 562, 119, 120, 2480, 2481, "P" +830, 16, 41, 563, 121, 122, 2482, 2483, "<" +830, 16, 42, 564, 123, 124, 2484, 2485, "0" +830, 16, 43, 565, 125, 126, 2486, 2487, "." +830, 16, 44, 566, 127, 130, 2488, 2491, "001" +830, 16, 45, 567, 131, 132, 2492, 2493, ")" +830, 16, 46, 568, 133, 134, 2494, 2495, "," +830, 16, 47, 569, 135, 147, 2496, 2508, "respectively" +830, 16, 48, 570, 148, 149, 2509, 2510, "." +830, 17, 1, 571, 0, 3, 2511, 2514, "The" +830, 17, 2, 572, 4, 12, 2515, 2523, "adjusted" +830, 17, 3, 573, 13, 23, 2524, 2534, "difference" +830, 17, 4, 574, 24, 31, 2535, 2542, "between" +830, 17, 5, 575, 32, 38, 2543, 2549, "groups" +830, 17, 6, 576, 39, 40, 2550, 2551, "(" +830, 17, 7, 577, 41, 49, 2552, 2560, "analysis" +830, 17, 8, 578, 50, 52, 2561, 2563, "of" +830, 17, 9, 579, 53, 63, 2564, 2574, "covariance" +830, 17, 10, 580, 64, 65, 2575, 2576, ")" +830, 17, 11, 581, 66, 69, 2577, 2580, "was" +830, 17, 12, 582, 70, 73, 2581, 2584, "not" +830, 17, 13, 583, 74, 87, 2585, 2598, "statistically" +830, 17, 14, 584, 88, 99, 2599, 2610, "significant" +830, 17, 15, 585, 100, 101, 2611, 2612, "(" +830, 17, 16, 586, 102, 103, 2613, 2614, "P" +830, 17, 17, 587, 104, 105, 2615, 2616, "=" +830, 17, 18, 588, 106, 107, 2617, 2618, "0" +830, 17, 19, 589, 108, 109, 2619, 2620, "." +830, 17, 20, 590, 110, 113, 2621, 2624, "469" +830, 17, 21, 591, 114, 115, 2625, 2626, ")" +830, 17, 22, 592, 116, 117, 2627, 2628, "." +830, 18, 1, 593, 0, 2, 2629, 2631, "No" +830, 18, 2, 594, 3, 14, 2632, 2643, "statistical" +830, 18, 3, 595, 15, 25, 2644, 2654, "difference" +830, 18, 4, 596, 26, 28, 2655, 2657, "in" +830, 18, 5, 597, 29, 34, 2658, 2663, "terms" +830, 18, 6, 598, 35, 37, 2664, 2666, "of" +830, 18, 7, 599, 38, 45, 2667, 2674, "adverse" +830, 18, 8, 600, 46, 52, 2675, 2681, "events" +830, 18, 9, 601, 53, 56, 2682, 2685, "was" +830, 18, 10, 602, 57, 62, 2686, 2691, "found" +830, 18, 11, 603, 63, 70, 2692, 2699, "between" +830, 18, 12, 604, 71, 77, 2700, 2706, "groups" +830, 18, 13, 605, 78, 79, 2707, 2708, "." +830, 19, 1, 606, 0, 11, 2709, 2720, "CONCLUSIONS" +830, 19, 2, 607, 12, 13, 2721, 2722, ":" +830, 19, 3, 608, 14, 18, 2723, 2727, "Both" +830, 19, 4, 609, 19, 24, 2728, 2733, "fixed" +830, 19, 5, 610, 25, 37, 2734, 2746, "combinations" +830, 19, 6, 611, 38, 42, 2747, 2751, "were" +830, 19, 7, 612, 43, 50, 2752, 2759, "capable" +830, 19, 8, 613, 51, 53, 2760, 2762, "of" +830, 19, 9, 614, 54, 67, 2763, 2776, "significantly" +830, 19, 10, 615, 68, 76, 2777, 2785, "reducing" +830, 19, 11, 616, 77, 80, 2786, 2789, "the" +830, 19, 12, 617, 81, 85, 2790, 2794, "mean" +830, 19, 13, 618, 86, 93, 2795, 2802, "diurnal" +830, 19, 14, 619, 94, 97, 2803, 2806, "IOP" +830, 19, 15, 620, 98, 99, 2807, 2808, "," +830, 19, 16, 621, 100, 104, 2809, 2813, "mean" +830, 19, 17, 622, 105, 112, 2814, 2821, "diurnal" +830, 19, 18, 623, 113, 117, 2822, 2826, "peak" +830, 19, 19, 624, 118, 119, 2827, 2828, "," +830, 19, 20, 625, 120, 123, 2829, 2832, "and" +830, 19, 21, 626, 124, 128, 2833, 2837, "mean" +830, 19, 22, 627, 129, 132, 2838, 2841, "WDT" +830, 19, 23, 628, 133, 137, 2842, 2846, "peak" +830, 19, 24, 629, 138, 143, 2847, 2852, "after" +830, 19, 25, 630, 144, 145, 2853, 2854, "8" +830, 19, 26, 631, 146, 151, 2855, 2860, "weeks" +830, 19, 27, 632, 152, 154, 2861, 2863, "of" +830, 19, 28, 633, 155, 164, 2864, 2873, "treatment" +830, 19, 29, 634, 165, 166, 2874, 2875, "." +830, 20, 1, 635, 0, 4, 2876, 2880, "Also" +830, 20, 2, 636, 5, 6, 2881, 2882, "," +830, 20, 3, 637, 7, 11, 2883, 2887, "both" +830, 20, 4, 638, 12, 17, 2888, 2893, "fixed" +830, 20, 5, 639, 18, 30, 2894, 2906, "combinations" +830, 20, 6, 640, 31, 34, 2907, 2910, "are" +830, 20, 7, 641, 35, 39, 2911, 2915, "well" +830, 20, 8, 642, 40, 49, 2916, 2925, "tolerated" +830, 20, 9, 643, 50, 54, 2926, 2930, "with" +830, 20, 10, 644, 55, 58, 2931, 2934, "few" +830, 20, 11, 645, 59, 63, 2935, 2939, "side" +830, 20, 12, 646, 64, 71, 2940, 2947, "effects" +830, 20, 13, 647, 72, 73, 2948, 2949, "." +830, 21, 1, 648, 0, 3, 2950, 2953, "DOI" +830, 21, 2, 649, 4, 5, 2954, 2955, ":" +830, 21, 3, 650, 6, 8, 2956, 2958, "10" +830, 21, 4, 651, 9, 10, 2959, 2960, "." +830, 21, 5, 652, 11, 15, 2961, 2965, "1097" +830, 21, 6, 653, 16, 17, 2966, 2967, "/" +830, 21, 7, 654, 18, 21, 2968, 2971, "IJG" +830, 21, 8, 655, 22, 23, 2972, 2973, "." +830, 21, 9, 656, 24, 40, 2974, 2990, "0b013e318168f008" +830, 21, 10, 657, 41, 45, 2991, 2995, "PMID" +830, 21, 11, 658, 46, 47, 2996, 2997, ":" +830, 21, 12, 659, 48, 56, 2998, 3006, "19092465" +830, 21, 13, 660, 57, 58, 3007, 3008, "[" +830, 21, 14, 661, 59, 66, 3009, 3016, "Indexed" +830, 21, 15, 662, 67, 70, 3017, 3020, "for" +830, 21, 16, 663, 71, 78, 3021, 3028, "MEDLINE" +830, 21, 17, 664, 79, 80, 3029, 3030, "]" diff --git a/data/gl 19092465_admin.annodb b/data/gl 19092465_admin.annodb new file mode 100644 index 0000000..34567ce --- /dev/null +++ b/data/gl 19092465_admin.annodb @@ -0,0 +1,147 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2008", "", " \"2008\"." +156, Title, 88, 339, "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of", "", " \"An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of\"." +4, Duration, 91, 103, "eight - week", "", " \"eight - week\"." +5, Multicenter, 106, 118, "multicentric", "", " ." +6, Randomized, 121, 131, "randomized", "", " ." +7, OpenLabel, 151, 163, "open - label", "", " ." +8, Parallel, 176, 184, "parallel", "", " ." +44428, Brimo/TimFC, 232, 311, "the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 %", "", +82, Timolol, 257, 272, "timolol maleate", "", +86, DoseValue, 273, 278, "0 . 5", "", +87, Percentage, 279, 280, "%", "", +83, Brimonidine, 283, 303, "brimonidine tartrate", "", +88, DoseValue, 304, 309, "0 . 2", "", +89, Percentage, 310, 311, "%", "", +44429, Dorz/TimFC, 319, 381, "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 %", "", +84, Timolol, 340, 355, "timolol maleate", "", +92, DoseValue, 356, 361, "0 . 5", "", +90, Percentage, 362, 363, "%", "", +85, Dorzolamide, 366, 377, "dorzolamide", "", +93, DoseValue, 378, 379, "2", "", +91, Percentage, 380, 381, "%", "", +9, IOP, 408, 428, "intraocular pressure", "", +10, Author, 431, 441, "Hatanaka M", "", " \"Hatanaka M\"." +11, Author, 450, 460, "Grigera DE", "", " \"Grigera DE\"." +12, Author, 463, 473, "Barbosa WL", "", " \"Barbosa WL\"." +13, Author, 476, 484, "Jordao M", "", " \"Jordao M\"." +14, Author, 487, 499, "Susanna R Jr", "", " \"Susanna R Jr\"." +94, Brazil, 588, 594, "Brazil", "", " ." +15, ObjectiveDescription, 635, 765, "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus", "", " \"To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus\"." +95, Timolol, 704, 719, "timolol maleate", "", +97, DoseValue, 720, 725, "0 . 5", "", +99, Percentage, 726, 727, "%", "", +96, Brimonidine, 730, 750, "brimonidine tartrate", "", +98, DoseValue, 751, 756, "0 . 2", "", +100, Percentage, 757, 758, "%", "", +16, ObjectiveDescription, 766, 898, "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks .", "", " \"fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks .\"." +44430, Dorz/TimFC, 787, 828, "timolol maleate 0 . 5 % / dorzolamide 2 %", "", +101, Timolol, 787, 802, "timolol maleate", "", +103, DoseValue, 803, 808, "0 . 5", "", +104, Percentage, 809, 810, "%", "", +102, Dorzolamide, 813, 824, "dorzolamide", "", +106, DoseValue, 825, 826, "2", "", +105, Percentage, 827, 828, "%", "", +17, IOP, 855, 875, "intraocular pressure", "", +18, IOP, 878, 881, "IOP", "", +19, Duration, 889, 896, "8 weeks", "", +20, Duration, 927, 935, "8 - week", "", +21, Multicenter, 938, 950, "multicentric", "", +129, Randomized, 970, 980, "randomized", "", +22, OpenLabel, 983, 995, "open - label", "", +23, Parallel, 998, 1012, "parallel group", "", +179, Brazil, 1049, 1055, "Brazil", "", +24, Argentina, 1072, 1081, "Argentina", "", " ." +25, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", " ." +26, OcularHypertension, 1123, 1142, "ocular hypertension", "", " ." +107, Randomized, 1148, 1158, "randomized", "", +44431, Brimo/TimFC, 1182, 1240, "fixed combination of brimonidine / timolol maleate 0 . 5 %", "", " ." +108, Brimonidine, 1203, 1214, "brimonidine", "", +109, Timolol, 1217, 1232, "timolol maleate", "", +110, DoseValue, 1233, 1238, "0 . 5", "", +111, Percentage, 1239, 1240, "%", "", +44432, Dorz/TimFC, 1244, 1298, "fixed combination of dorzolamide 2 % / timolol 0 . 5 %", "", " ." +112, Dorzolamide, 1265, 1276, "dorzolamide", "", +114, DoseValue, 1277, 1278, "2", "", +117, Percentage, 1279, 1280, "%", "", +113, Timolol, 1283, 1290, "timolol", "", +115, DoseValue, 1291, 1296, "0 . 5", "", +116, Percentage, 1297, 1298, "%", "", +27, Frequency, 1299, 1310, "twice daily", "", " \"twice daily\". \"twice daily\"." +28, Peak_IOP, 1491, 1499, "IOP peak", "", +29, Diurnal_IOP, 1503, 1524, "diurnal tension curve", "", " ." +118, TimePoint, 1549, 1557, "baseline", "", +119, TimePoint, 1562, 1570, "week - 8", "", +30, NumberPatientsCT, 1651, 1654, "210", "", " \"210\"." +120, Randomized, 1669, 1679, "randomized", "", +121, Brimonidine, 1682, 1693, "brimonidine", "", +44433, Brimo/TimFC, 1682, 1703, "brimonidine / timolol", "", +122, Timolol, 1696, 1703, "timolol", "", +31, NumberPatientsArm, 1710, 1713, "111", "", " \"111\"." +123, Dorzolamide, 1716, 1727, "dorzolamide", "", +44434, Dorz/TimFC, 1716, 1737, "dorzolamide / timolol", "", +124, Timolol, 1730, 1737, "timolol", "", +32, NumberPatientsArm, 1744, 1746, "99", "", " \"99\"." +33, Mean, 1751, 1755, "Mean", "", " . ." +34, IOP, 1765, 1768, "IOP", "", +35, BaseLineValue, 1773, 1780, "23 . 43", "", " \"23 . 43\"." +44437, SdDevBL, 1787, 1793, "3 . 22", "", " \"3 . 22\"." +37, mmHg, 1794, 1799, "mm Hg", "", " ." +38, BaseLineValue, 1804, 1811, "23 . 43", "", " \"23 . 43\"." +44438, SdDevBL, 1818, 1824, "4 . 06", "", " \"4 . 06\"." +40, mmHg, 1825, 1830, "mm Hg", "", +210, Brimonidine, 1860, 1871, "brimonidine", "", +44435, Brimo/TimFC, 1860, 1881, "brimonidine / timolol", "", +211, Timolol, 1874, 1881, "timolol", "", +213, Dorzolamide, 1886, 1897, "dorzolamide", "", +44436, Dorz/TimFC, 1886, 1907, "dorzolamide / timolol", "", +212, Timolol, 1900, 1907, "timolol", "", +214, PvalueDiff, 1929, 1936, "0 . 993", "", +42, Mean, 1941, 1945, "Mean", "", +43, Diurnal_IOP, 1946, 1957, "diurnal IOP", "", +217, TimePoint, 1974, 1981, "8 weeks", "", " \"8 weeks\"." +44, Reduction, 1987, 1993, "7 . 02", "", " \"7 . 02\"." +256, SdDevChangeValue, 2000, 2006, "3 . 06", "", " \"3 . 06\"." +46, mmHg, 2007, 2012, "mm Hg", "", +47, Reduction, 2017, 2023, "6 . 91", "", " \"6 . 91\"." +257, SdDevChangeValue, 2030, 2036, "3 . 67", "", " \"3 . 67\"." +49, mmHg, 2037, 2042, "mm Hg", "", +222, PvalueDiff, 2064, 2071, "0 . 811", "", " \"0 . 811\"." +224, TimePoint, 2145, 2151, "week 8", "", +51, PvalueDiff, 2188, 2199, "P = 0 . 847", "", +52, Mean, 2204, 2208, "Mean", "", " . ." +57, Peak_IOP, 2222, 2226, "peak", "", " ." +59, BaseLineValue, 2231, 2238, "27 . 79", "", " \"27 . 79\"." +44439, SdDevBL, 2245, 2251, "4 . 29", "", " \"4 . 29\"." +53, mmHg, 2252, 2257, "mm Hg", "", " . ." +125, Brimonidine, 2265, 2276, "brimonidine", "", +44441, Brimo/TimFC, 2265, 2286, "brimonidine / timolol", "", +126, Timolol, 2279, 2286, "timolol", "", +61, BaseLineValue, 2297, 2304, "27 . 68", "", " \"27 . 68\"." +259, SdDevBL, 2311, 2317, "5 . 46", "", " \"5 . 46\"." +54, mmHg, 2318, 2323, "mm Hg", "", +127, Dorzolamide, 2331, 2342, "dorzolamide", "", +44442, Dorz/TimFC, 2331, 2352, "dorzolamide / timolol", "", +128, Timolol, 2345, 2352, "timolol", "", +234, TimePoint, 2367, 2374, "8 weeks", "", " \"8 weeks\". \"8 weeks\"." +56, Mean, 2390, 2394, "mean", "", +58, Peak_IOP, 2399, 2404, "peaks", "", +63, ResultMeasuredValue, 2410, 2417, "20 . 94", "", " \"20 . 94\"." +239, SdDevResValue, 2424, 2430, "3 . 76", "", " \"3 . 76\"." +65, mmHg, 2431, 2436, "mm Hg", "", +66, PValueResValue, 2439, 2450, "P < 0 . 001", "", " \"P < 0 . 001\"." +67, ResultMeasuredValue, 2457, 2464, "20 . 98", "", " \"20 . 98\"." +240, SdDevResValue, 2471, 2477, "4 . 19", "", " \"4 . 19\"." +69, PValueResValue, 2480, 2491, "P < 0 . 001", "", " \"P < 0 . 001\"." +70, PvalueDiff, 2613, 2624, "P = 0 . 469", "", " \"P = 0 . 469\"." +71, ConclusionComment, 2723, 2875, "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .", "", " \"Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .\"." +74, Mean, 2790, 2794, "mean", "", +73, Diurnal_IOP, 2795, 2806, "diurnal IOP", "", +75, Mean, 2809, 2813, "mean", "", +76, Peak_IOP, 2814, 2826, "diurnal peak", "", +77, Mean, 2833, 2837, "mean", "", +44443, Peak_IOP, 2842, 2846, "peak", "", +249, TimePoint, 2853, 2860, "8 weeks", "", +72, ConclusionComment, 2876, 2949, "Also , both fixed combinations are well tolerated with few side effects .", "", " \"Also , both fixed combinations are well tolerated with few side effects .\"." +79, PMID, 2998, 3006, "19092465", "", " \"19092465\"." diff --git a/data/gl 19092465_admin.n-triples b/data/gl 19092465_admin.n-triples new file mode 100644 index 0000000..ccea180 --- /dev/null +++ b/data/gl 19092465_admin.n-triples @@ -0,0 +1,141 @@ +# RDF export of group: Publication + . + "Publication" . + "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of" . + "Hatanaka M" . + "2008" . + "J Glaucoma" . + "19092465" . + . + "Grigera DE" . + "Barbosa WL" . + "Jordao M" . + "Susanna R Jr" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus" . + "210" . + "eight - week" . + . + . + . + "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment ." . + . + . + . + . + . + "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks ." . + . + . + . + "Also , both fixed combinations are well tolerated with few side effects ." . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_piop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + "111" . + . + . + . + . + . + "Arm_DTFC" . + "99" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + "twice daily" . + . + . + "Intervention_DTFC" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_DTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC" . + . + "23 . 43" . + "3 . 22" . + "7 . 02" . + "3 . 06" . + "8 weeks" . + . + "Outcome_DTFC" . + . + "23 . 43" . + "4 . 06" . + "6 . 91" . + "3 . 67" . + . + "Outcome_BTFC_piop" . + . + "27 . 79" . + "4 . 29" . + "20 . 94" . + "P < 0 . 001" . + "3 . 76" . + "8 weeks" . + . + "Outcome_DTFC_piop" . + . + "27 . 68" . + "5 . 46" . + "20 . 98" . + "P < 0 . 001" . + "4 . 19" . + "8 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "0 . 811" . + . + . + . + "DiffBetweenGroups_piop" . + "P = 0 . 469" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19092465_export.csv b/data/gl 19092465_export.csv new file mode 100644 index 0000000..efd35b6 --- /dev/null +++ b/data/gl 19092465_export.csv @@ -0,0 +1,665 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +448, 1, 1, 1, 0, 1, 0, 1, "J" +448, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +448, 1, 3, 3, 11, 12, 11, 12, "." +448, 2, 1, 4, 0, 4, 13, 17, "2008" +448, 2, 2, 5, 5, 8, 18, 21, "Dec" +448, 2, 3, 6, 9, 10, 22, 23, ";" +448, 2, 4, 7, 11, 13, 24, 26, "17" +448, 2, 5, 8, 14, 15, 27, 28, "(" +448, 2, 6, 9, 16, 17, 29, 30, "8" +448, 2, 7, 10, 18, 19, 31, 32, ")" +448, 2, 8, 11, 20, 21, 33, 34, ":" +448, 2, 9, 12, 22, 25, 35, 38, "674" +448, 2, 10, 13, 26, 27, 39, 40, "-" +448, 2, 11, 14, 28, 29, 41, 42, "9" +448, 2, 12, 15, 30, 31, 43, 44, "." +448, 2, 13, 16, 32, 35, 45, 48, "doi" +448, 2, 14, 17, 36, 37, 49, 50, ":" +448, 2, 15, 18, 38, 40, 51, 53, "10" +448, 2, 16, 19, 41, 42, 54, 55, "." +448, 2, 17, 20, 43, 47, 56, 60, "1097" +448, 2, 18, 21, 48, 49, 61, 62, "/" +448, 2, 19, 22, 50, 53, 63, 66, "IJG" +448, 2, 20, 23, 54, 55, 67, 68, "." +448, 2, 21, 24, 56, 72, 69, 85, "0b013e318168f008" +448, 2, 22, 25, 73, 74, 86, 87, "." +448, 3, 1, 26, 0, 2, 88, 90, "An" +448, 3, 2, 27, 3, 8, 91, 96, "eight" +448, 3, 3, 28, 9, 10, 97, 98, "-" +448, 3, 4, 29, 11, 15, 99, 103, "week" +448, 3, 5, 30, 16, 17, 104, 105, "," +448, 3, 6, 31, 18, 30, 106, 118, "multicentric" +448, 3, 7, 32, 31, 32, 119, 120, "," +448, 3, 8, 33, 33, 43, 121, 131, "randomized" +448, 3, 9, 34, 44, 45, 132, 133, "," +448, 3, 10, 35, 46, 60, 134, 148, "interventional" +448, 3, 11, 36, 61, 62, 149, 150, "," +448, 3, 12, 37, 63, 67, 151, 155, "open" +448, 3, 13, 38, 68, 69, 156, 157, "-" +448, 3, 14, 39, 70, 75, 158, 163, "label" +448, 3, 15, 40, 76, 77, 164, 165, "," +448, 3, 16, 41, 78, 83, 166, 171, "phase" +448, 3, 17, 42, 84, 85, 172, 173, "4" +448, 3, 18, 43, 86, 87, 174, 175, "," +448, 3, 19, 44, 88, 96, 176, 184, "parallel" +448, 3, 20, 45, 97, 107, 185, 195, "comparison" +448, 3, 21, 46, 108, 110, 196, 198, "of" +448, 3, 22, 47, 111, 114, 199, 202, "the" +448, 3, 23, 48, 115, 123, 203, 211, "efficacy" +448, 3, 24, 49, 124, 127, 212, 215, "and" +448, 3, 25, 50, 128, 140, 216, 228, "tolerability" +448, 3, 26, 51, 141, 143, 229, 231, "of" +448, 3, 27, 52, 144, 147, 232, 235, "the" +448, 3, 28, 53, 148, 153, 236, 241, "fixed" +448, 3, 29, 54, 154, 165, 242, 253, "combination" +448, 3, 30, 55, 166, 168, 254, 256, "of" +448, 3, 31, 56, 169, 176, 257, 264, "timolol" +448, 3, 32, 57, 177, 184, 265, 272, "maleate" +448, 3, 33, 58, 185, 186, 273, 274, "0" +448, 3, 34, 59, 187, 188, 275, 276, "." +448, 3, 35, 60, 189, 190, 277, 278, "5" +448, 3, 36, 61, 191, 192, 279, 280, "%" +448, 3, 37, 62, 193, 194, 281, 282, "/" +448, 3, 38, 63, 195, 206, 283, 294, "brimonidine" +448, 3, 39, 64, 207, 215, 295, 303, "tartrate" +448, 3, 40, 65, 216, 217, 304, 305, "0" +448, 3, 41, 66, 218, 219, 306, 307, "." +448, 3, 42, 67, 220, 221, 308, 309, "2" +448, 3, 43, 68, 222, 223, 310, 311, "%" +448, 3, 44, 69, 224, 230, 312, 318, "versus" +448, 3, 45, 70, 231, 236, 319, 324, "fixed" +448, 3, 46, 71, 237, 248, 325, 336, "combination" +448, 3, 47, 72, 249, 251, 337, 339, "of" +448, 3, 48, 73, 252, 259, 340, 347, "timolol" +448, 3, 49, 74, 260, 267, 348, 355, "maleate" +448, 3, 50, 75, 268, 269, 356, 357, "0" +448, 3, 51, 76, 270, 271, 358, 359, "." +448, 3, 52, 77, 272, 273, 360, 361, "5" +448, 3, 53, 78, 274, 275, 362, 363, "%" +448, 3, 54, 79, 276, 277, 364, 365, "/" +448, 3, 55, 80, 278, 289, 366, 377, "dorzolamide" +448, 3, 56, 81, 290, 291, 378, 379, "2" +448, 3, 57, 82, 292, 293, 380, 381, "%" +448, 3, 58, 83, 294, 296, 382, 384, "in" +448, 3, 59, 84, 297, 305, 385, 393, "patients" +448, 3, 60, 85, 306, 310, 394, 398, "with" +448, 3, 61, 86, 311, 319, 399, 407, "elevated" +448, 3, 62, 87, 320, 331, 408, 419, "intraocular" +448, 3, 63, 88, 332, 340, 420, 428, "pressure" +448, 3, 64, 89, 341, 342, 429, 430, "." +448, 4, 1, 90, 0, 8, 431, 439, "Hatanaka" +448, 4, 2, 91, 9, 10, 440, 441, "M" +448, 4, 3, 92, 11, 12, 442, 443, "(" +448, 4, 4, 93, 13, 14, 444, 445, "1" +448, 4, 5, 94, 15, 16, 446, 447, ")" +448, 4, 6, 95, 17, 18, 448, 449, "," +448, 4, 7, 96, 19, 26, 450, 457, "Grigera" +448, 4, 8, 97, 27, 29, 458, 460, "DE" +448, 4, 9, 98, 30, 31, 461, 462, "," +448, 4, 10, 99, 32, 39, 463, 470, "Barbosa" +448, 4, 11, 100, 40, 42, 471, 473, "WL" +448, 4, 12, 101, 43, 44, 474, 475, "," +448, 4, 13, 102, 45, 51, 476, 482, "Jordao" +448, 4, 14, 103, 52, 53, 483, 484, "M" +448, 4, 15, 104, 54, 55, 485, 486, "," +448, 4, 16, 105, 56, 63, 487, 494, "Susanna" +448, 4, 17, 106, 64, 65, 495, 496, "R" +448, 4, 18, 107, 66, 68, 497, 499, "Jr" +448, 4, 19, 108, 69, 70, 500, 501, "." +448, 5, 1, 109, 0, 6, 502, 508, "Author" +448, 5, 2, 110, 7, 18, 509, 520, "information" +448, 5, 3, 111, 19, 20, 521, 522, ":" +448, 5, 4, 112, 21, 22, 523, 524, "(" +448, 5, 5, 113, 23, 24, 525, 526, "1" +448, 5, 6, 114, 25, 26, 527, 528, ")" +448, 5, 7, 115, 27, 37, 529, 539, "University" +448, 5, 8, 116, 38, 40, 540, 542, "of" +448, 5, 9, 117, 41, 42, 543, 544, "S" +448, 5, 10, 118, 43, 44, 545, 546, "ã" +448, 5, 11, 119, 45, 46, 547, 548, "o" +448, 5, 12, 120, 47, 52, 549, 554, "Paulo" +448, 5, 13, 121, 53, 59, 555, 561, "School" +448, 5, 14, 122, 60, 62, 562, 564, "of" +448, 5, 15, 123, 63, 71, 565, 573, "Medicine" +448, 5, 16, 124, 72, 73, 574, 575, "," +448, 5, 17, 125, 74, 77, 576, 579, "Sao" +448, 5, 18, 126, 78, 83, 580, 585, "Paulo" +448, 5, 19, 127, 84, 85, 586, 587, "," +448, 5, 20, 128, 86, 92, 588, 594, "Brazil" +448, 5, 21, 129, 93, 94, 595, 596, "." +448, 6, 1, 130, 0, 4, 597, 601, "info" +448, 6, 2, 131, 5, 6, 602, 603, "@" +448, 6, 3, 132, 7, 21, 604, 618, "centroavancado" +448, 6, 4, 133, 22, 23, 619, 620, "." +448, 6, 5, 134, 24, 27, 621, 624, "net" +448, 6, 6, 135, 28, 35, 625, 632, "PURPOSE" +448, 6, 7, 136, 36, 37, 633, 634, ":" +448, 6, 8, 137, 38, 40, 635, 637, "To" +448, 6, 9, 138, 41, 48, 638, 645, "compare" +448, 6, 10, 139, 49, 52, 646, 649, "the" +448, 6, 11, 140, 53, 61, 650, 658, "efficacy" +448, 6, 12, 141, 62, 65, 659, 662, "and" +448, 6, 13, 142, 66, 78, 663, 675, "tolerability" +448, 6, 14, 143, 79, 81, 676, 678, "of" +448, 6, 15, 144, 82, 85, 679, 682, "the" +448, 6, 16, 145, 86, 91, 683, 688, "fixed" +448, 6, 17, 146, 92, 103, 689, 700, "combination" +448, 6, 18, 147, 104, 106, 701, 703, "of" +448, 6, 19, 148, 107, 114, 704, 711, "timolol" +448, 6, 20, 149, 115, 122, 712, 719, "maleate" +448, 6, 21, 150, 123, 124, 720, 721, "0" +448, 6, 22, 151, 125, 126, 722, 723, "." +448, 6, 23, 152, 127, 128, 724, 725, "5" +448, 6, 24, 153, 129, 130, 726, 727, "%" +448, 6, 25, 154, 131, 132, 728, 729, "/" +448, 6, 26, 155, 133, 144, 730, 741, "brimonidine" +448, 6, 27, 156, 145, 153, 742, 750, "tartrate" +448, 6, 28, 157, 154, 155, 751, 752, "0" +448, 6, 29, 158, 156, 157, 753, 754, "." +448, 6, 30, 159, 158, 159, 755, 756, "2" +448, 6, 31, 160, 160, 161, 757, 758, "%" +448, 6, 32, 161, 162, 168, 759, 765, "versus" +448, 6, 33, 162, 169, 174, 766, 771, "fixed" +448, 6, 34, 163, 175, 186, 772, 783, "combination" +448, 6, 35, 164, 187, 189, 784, 786, "of" +448, 6, 36, 165, 190, 197, 787, 794, "timolol" +448, 6, 37, 166, 198, 205, 795, 802, "maleate" +448, 6, 38, 167, 206, 207, 803, 804, "0" +448, 6, 39, 168, 208, 209, 805, 806, "." +448, 6, 40, 169, 210, 211, 807, 808, "5" +448, 6, 41, 170, 212, 213, 809, 810, "%" +448, 6, 42, 171, 214, 215, 811, 812, "/" +448, 6, 43, 172, 216, 227, 813, 824, "dorzolamide" +448, 6, 44, 173, 228, 229, 825, 826, "2" +448, 6, 45, 174, 230, 231, 827, 828, "%" +448, 6, 46, 175, 232, 234, 829, 831, "in" +448, 6, 47, 176, 235, 243, 832, 840, "patients" +448, 6, 48, 177, 244, 248, 841, 845, "with" +448, 6, 49, 178, 249, 257, 846, 854, "elevated" +448, 6, 50, 179, 258, 269, 855, 866, "intraocular" +448, 6, 51, 180, 270, 278, 867, 875, "pressure" +448, 6, 52, 181, 279, 280, 876, 877, "(" +448, 6, 53, 182, 281, 284, 878, 881, "IOP" +448, 6, 54, 183, 285, 286, 882, 883, ")" +448, 6, 55, 184, 287, 291, 884, 888, "over" +448, 6, 56, 185, 292, 293, 889, 890, "8" +448, 6, 57, 186, 294, 299, 891, 896, "weeks" +448, 6, 58, 187, 300, 301, 897, 898, "." +448, 7, 1, 188, 0, 8, 899, 907, "PATIENTS" +448, 7, 2, 189, 9, 12, 908, 911, "AND" +448, 7, 3, 190, 13, 20, 912, 919, "METHODS" +448, 7, 4, 191, 21, 22, 920, 921, ":" +448, 7, 5, 192, 23, 27, 922, 926, "This" +448, 7, 6, 193, 28, 29, 927, 928, "8" +448, 7, 7, 194, 30, 31, 929, 930, "-" +448, 7, 8, 195, 32, 36, 931, 935, "week" +448, 7, 9, 196, 37, 38, 936, 937, "," +448, 7, 10, 197, 39, 51, 938, 950, "multicentric" +448, 7, 11, 198, 52, 53, 951, 952, "," +448, 7, 12, 199, 54, 68, 953, 967, "interventional" +448, 7, 13, 200, 69, 70, 968, 969, "," +448, 7, 14, 201, 71, 81, 970, 980, "randomized" +448, 7, 15, 202, 82, 83, 981, 982, "," +448, 7, 16, 203, 84, 88, 983, 987, "open" +448, 7, 17, 204, 89, 90, 988, 989, "-" +448, 7, 18, 205, 91, 96, 990, 995, "label" +448, 7, 19, 206, 97, 98, 996, 997, "," +448, 7, 20, 207, 99, 107, 998, 1006, "parallel" +448, 7, 21, 208, 108, 113, 1007, 1012, "group" +448, 7, 22, 209, 114, 119, 1013, 1018, "study" +448, 7, 23, 210, 120, 123, 1019, 1022, "was" +448, 7, 24, 211, 124, 133, 1023, 1032, "conducted" +448, 7, 25, 212, 134, 136, 1033, 1035, "at" +448, 7, 26, 213, 137, 138, 1036, 1037, "4" +448, 7, 27, 214, 139, 146, 1038, 1045, "centers" +448, 7, 28, 215, 147, 149, 1046, 1048, "in" +448, 7, 29, 216, 150, 156, 1049, 1055, "Brazil" +448, 7, 30, 217, 157, 160, 1056, 1059, "and" +448, 7, 31, 218, 161, 162, 1060, 1061, "1" +448, 7, 32, 219, 163, 169, 1062, 1068, "center" +448, 7, 33, 220, 170, 172, 1069, 1071, "in" +448, 7, 34, 221, 173, 182, 1072, 1081, "Argentina" +448, 7, 35, 222, 183, 184, 1082, 1083, "." +448, 8, 1, 223, 0, 8, 1084, 1092, "Patients" +448, 8, 2, 224, 9, 13, 1093, 1097, "with" +448, 8, 3, 225, 14, 18, 1098, 1102, "open" +448, 8, 4, 226, 19, 20, 1103, 1104, "-" +448, 8, 5, 227, 21, 26, 1105, 1110, "angle" +448, 8, 6, 228, 27, 35, 1111, 1119, "glaucoma" +448, 8, 7, 229, 36, 38, 1120, 1122, "or" +448, 8, 8, 230, 39, 45, 1123, 1129, "ocular" +448, 8, 9, 231, 46, 58, 1130, 1142, "hypertension" +448, 8, 10, 232, 59, 63, 1143, 1147, "were" +448, 8, 11, 233, 64, 74, 1148, 1158, "randomized" +448, 8, 12, 234, 75, 77, 1159, 1161, "to" +448, 8, 13, 235, 78, 85, 1162, 1169, "receive" +448, 8, 14, 236, 86, 97, 1170, 1181, "bilaterally" +448, 8, 15, 237, 98, 103, 1182, 1187, "fixed" +448, 8, 16, 238, 104, 115, 1188, 1199, "combination" +448, 8, 17, 239, 116, 118, 1200, 1202, "of" +448, 8, 18, 240, 119, 130, 1203, 1214, "brimonidine" +448, 8, 19, 241, 131, 132, 1215, 1216, "/" +448, 8, 20, 242, 133, 140, 1217, 1224, "timolol" +448, 8, 21, 243, 141, 148, 1225, 1232, "maleate" +448, 8, 22, 244, 149, 150, 1233, 1234, "0" +448, 8, 23, 245, 151, 152, 1235, 1236, "." +448, 8, 24, 246, 153, 154, 1237, 1238, "5" +448, 8, 25, 247, 155, 156, 1239, 1240, "%" +448, 8, 26, 248, 157, 159, 1241, 1243, "or" +448, 8, 27, 249, 160, 165, 1244, 1249, "fixed" +448, 8, 28, 250, 166, 177, 1250, 1261, "combination" +448, 8, 29, 251, 178, 180, 1262, 1264, "of" +448, 8, 30, 252, 181, 192, 1265, 1276, "dorzolamide" +448, 8, 31, 253, 193, 194, 1277, 1278, "2" +448, 8, 32, 254, 195, 196, 1279, 1280, "%" +448, 8, 33, 255, 197, 198, 1281, 1282, "/" +448, 8, 34, 256, 199, 206, 1283, 1290, "timolol" +448, 8, 35, 257, 207, 208, 1291, 1292, "0" +448, 8, 36, 258, 209, 210, 1293, 1294, "." +448, 8, 37, 259, 211, 212, 1295, 1296, "5" +448, 8, 38, 260, 213, 214, 1297, 1298, "%" +448, 8, 39, 261, 215, 220, 1299, 1304, "twice" +448, 8, 40, 262, 221, 226, 1305, 1310, "daily" +448, 8, 41, 263, 227, 229, 1311, 1313, "at" +448, 8, 42, 264, 230, 231, 1314, 1315, "8" +448, 8, 43, 265, 232, 233, 1316, 1317, ":" +448, 8, 44, 266, 234, 236, 1318, 1320, "00" +448, 8, 45, 267, 237, 239, 1321, 1323, "AM" +448, 8, 46, 268, 240, 243, 1324, 1327, "and" +448, 8, 47, 269, 244, 245, 1328, 1329, "8" +448, 8, 48, 270, 246, 247, 1330, 1331, ":" +448, 8, 49, 271, 248, 250, 1332, 1334, "00" +448, 8, 50, 272, 251, 253, 1335, 1337, "PM" +448, 8, 51, 273, 254, 255, 1338, 1339, "." +448, 9, 1, 274, 0, 1, 1340, 1341, "A" +448, 9, 2, 275, 2, 10, 1342, 1350, "modified" +448, 9, 3, 276, 11, 18, 1351, 1358, "diurnal" +448, 9, 4, 277, 19, 26, 1359, 1366, "tension" +448, 9, 5, 278, 27, 32, 1367, 1372, "curve" +448, 9, 6, 279, 33, 34, 1373, 1374, "(" +448, 9, 7, 280, 35, 36, 1375, 1376, "8" +448, 9, 8, 281, 37, 38, 1377, 1378, ":" +448, 9, 9, 282, 39, 41, 1379, 1381, "00" +448, 9, 10, 283, 42, 44, 1382, 1384, "AM" +448, 9, 11, 284, 45, 46, 1385, 1386, "," +448, 9, 12, 285, 47, 49, 1387, 1389, "10" +448, 9, 13, 286, 50, 51, 1390, 1391, ":" +448, 9, 14, 287, 52, 54, 1392, 1394, "30" +448, 9, 15, 288, 55, 57, 1395, 1397, "AM" +448, 9, 16, 289, 58, 59, 1398, 1399, "," +448, 9, 17, 290, 60, 62, 1400, 1402, "02" +448, 9, 18, 291, 63, 64, 1403, 1404, ":" +448, 9, 19, 292, 65, 67, 1405, 1407, "00" +448, 9, 20, 293, 68, 70, 1408, 1410, "PM" +448, 9, 21, 294, 71, 72, 1411, 1412, "," +448, 9, 22, 295, 73, 76, 1413, 1416, "and" +448, 9, 23, 296, 77, 78, 1417, 1418, "4" +448, 9, 24, 297, 79, 80, 1419, 1420, ":" +448, 9, 25, 298, 81, 83, 1421, 1423, "00" +448, 9, 26, 299, 84, 86, 1424, 1426, "PM" +448, 9, 27, 300, 87, 88, 1427, 1428, ")" +448, 9, 28, 301, 89, 97, 1429, 1437, "followed" +448, 9, 29, 302, 98, 100, 1438, 1440, "by" +448, 9, 30, 303, 101, 104, 1441, 1444, "the" +448, 9, 31, 304, 105, 110, 1445, 1450, "water" +448, 9, 32, 305, 111, 119, 1451, 1459, "drinking" +448, 9, 33, 306, 120, 124, 1460, 1464, "test" +448, 9, 34, 307, 125, 126, 1465, 1466, "(" +448, 9, 35, 308, 127, 130, 1467, 1470, "WDT" +448, 9, 36, 309, 131, 132, 1471, 1472, ")" +448, 9, 37, 310, 133, 134, 1473, 1474, "," +448, 9, 38, 311, 135, 140, 1475, 1480, "which" +448, 9, 39, 312, 141, 150, 1481, 1490, "estimates" +448, 9, 40, 313, 151, 154, 1491, 1494, "IOP" +448, 9, 41, 314, 155, 159, 1495, 1499, "peak" +448, 9, 42, 315, 160, 162, 1500, 1502, "of" +448, 9, 43, 316, 163, 170, 1503, 1510, "diurnal" +448, 9, 44, 317, 171, 178, 1511, 1518, "tension" +448, 9, 45, 318, 179, 184, 1519, 1524, "curve" +448, 9, 46, 319, 185, 186, 1525, 1526, "," +448, 9, 47, 320, 187, 191, 1527, 1531, "were" +448, 9, 48, 321, 192, 201, 1532, 1541, "performed" +448, 9, 49, 322, 202, 204, 1542, 1544, "in" +448, 9, 50, 323, 205, 208, 1545, 1548, "the" +448, 9, 51, 324, 209, 217, 1549, 1557, "baseline" +448, 9, 52, 325, 218, 221, 1558, 1561, "and" +448, 9, 53, 326, 222, 226, 1562, 1566, "week" +448, 9, 54, 327, 227, 228, 1567, 1568, "-" +448, 9, 55, 328, 229, 230, 1569, 1570, "8" +448, 9, 56, 329, 231, 237, 1571, 1577, "visits" +448, 9, 57, 330, 238, 239, 1578, 1579, "." +448, 10, 1, 331, 0, 7, 1580, 1587, "Adverse" +448, 10, 2, 332, 8, 14, 1588, 1594, "events" +448, 10, 3, 333, 15, 19, 1595, 1599, "data" +448, 10, 4, 334, 20, 24, 1600, 1604, "were" +448, 10, 5, 335, 25, 33, 1605, 1613, "recorded" +448, 10, 6, 336, 34, 36, 1614, 1616, "at" +448, 10, 7, 337, 37, 41, 1617, 1621, "each" +448, 10, 8, 338, 42, 47, 1622, 1627, "visit" +448, 10, 9, 339, 48, 49, 1628, 1629, "." +448, 11, 1, 340, 0, 7, 1630, 1637, "RESULTS" +448, 11, 2, 341, 8, 9, 1638, 1639, ":" +448, 11, 3, 342, 10, 11, 1640, 1641, "A" +448, 11, 4, 343, 12, 17, 1642, 1647, "total" +448, 11, 5, 344, 18, 20, 1648, 1650, "of" +448, 11, 6, 345, 21, 24, 1651, 1654, "210" +448, 11, 7, 346, 25, 33, 1655, 1663, "patients" +448, 11, 8, 347, 34, 38, 1664, 1668, "were" +448, 11, 9, 348, 39, 49, 1669, 1679, "randomized" +448, 11, 10, 349, 50, 51, 1680, 1681, "(" +448, 11, 11, 350, 52, 63, 1682, 1693, "brimonidine" +448, 11, 12, 351, 64, 65, 1694, 1695, "/" +448, 11, 13, 352, 66, 73, 1696, 1703, "timolol" +448, 11, 14, 353, 74, 75, 1704, 1705, "," +448, 11, 15, 354, 76, 77, 1706, 1707, "n" +448, 11, 16, 355, 78, 79, 1708, 1709, "=" +448, 11, 17, 356, 80, 83, 1710, 1713, "111" +448, 11, 18, 357, 84, 85, 1714, 1715, ";" +448, 11, 19, 358, 86, 97, 1716, 1727, "dorzolamide" +448, 11, 20, 359, 98, 99, 1728, 1729, "/" +448, 11, 21, 360, 100, 107, 1730, 1737, "timolol" +448, 11, 22, 361, 108, 109, 1738, 1739, "," +448, 11, 23, 362, 110, 111, 1740, 1741, "n" +448, 11, 24, 363, 112, 113, 1742, 1743, "=" +448, 11, 25, 364, 114, 116, 1744, 1746, "99" +448, 11, 26, 365, 117, 118, 1747, 1748, ")" +448, 11, 27, 366, 119, 120, 1749, 1750, "." +448, 12, 1, 367, 0, 4, 1751, 1755, "Mean" +448, 12, 2, 368, 5, 13, 1756, 1764, "baseline" +448, 12, 3, 369, 14, 17, 1765, 1768, "IOP" +448, 12, 4, 370, 18, 21, 1769, 1772, "was" +448, 12, 5, 371, 22, 24, 1773, 1775, "23" +448, 12, 6, 372, 25, 26, 1776, 1777, "." +448, 12, 7, 373, 27, 29, 1778, 1780, "43" +448, 12, 8, 374, 30, 31, 1781, 1782, "+" +448, 12, 9, 375, 32, 33, 1783, 1784, "/" +448, 12, 10, 376, 34, 35, 1785, 1786, "-" +448, 12, 11, 377, 36, 37, 1787, 1788, "3" +448, 12, 12, 378, 38, 39, 1789, 1790, "." +448, 12, 13, 379, 40, 42, 1791, 1793, "22" +448, 12, 14, 380, 43, 45, 1794, 1796, "mm" +448, 12, 15, 381, 46, 48, 1797, 1799, "Hg" +448, 12, 16, 382, 49, 52, 1800, 1803, "and" +448, 12, 17, 383, 53, 55, 1804, 1806, "23" +448, 12, 18, 384, 56, 57, 1807, 1808, "." +448, 12, 19, 385, 58, 60, 1809, 1811, "43" +448, 12, 20, 386, 61, 62, 1812, 1813, "+" +448, 12, 21, 387, 63, 64, 1814, 1815, "/" +448, 12, 22, 388, 65, 66, 1816, 1817, "-" +448, 12, 23, 389, 67, 68, 1818, 1819, "4" +448, 12, 24, 390, 69, 70, 1820, 1821, "." +448, 12, 25, 391, 71, 73, 1822, 1824, "06" +448, 12, 26, 392, 74, 76, 1825, 1827, "mm" +448, 12, 27, 393, 77, 79, 1828, 1830, "Hg" +448, 12, 28, 394, 80, 82, 1831, 1833, "in" +448, 12, 29, 395, 83, 86, 1834, 1837, "the" +448, 12, 30, 396, 87, 95, 1838, 1846, "patients" +448, 12, 31, 397, 96, 103, 1847, 1854, "treated" +448, 12, 32, 398, 104, 108, 1855, 1859, "with" +448, 12, 33, 399, 109, 120, 1860, 1871, "brimonidine" +448, 12, 34, 400, 121, 122, 1872, 1873, "/" +448, 12, 35, 401, 123, 130, 1874, 1881, "timolol" +448, 12, 36, 402, 131, 134, 1882, 1885, "and" +448, 12, 37, 403, 135, 146, 1886, 1897, "dorzolamide" +448, 12, 38, 404, 147, 148, 1898, 1899, "/" +448, 12, 39, 405, 149, 156, 1900, 1907, "timolol" +448, 12, 40, 406, 157, 158, 1908, 1909, "," +448, 12, 41, 407, 159, 171, 1910, 1922, "respectively" +448, 12, 42, 408, 172, 173, 1923, 1924, "(" +448, 12, 43, 409, 174, 175, 1925, 1926, "P" +448, 12, 44, 410, 176, 177, 1927, 1928, "=" +448, 12, 45, 411, 178, 179, 1929, 1930, "0" +448, 12, 46, 412, 180, 181, 1931, 1932, "." +448, 12, 47, 413, 182, 185, 1933, 1936, "993" +448, 12, 48, 414, 186, 187, 1937, 1938, ")" +448, 12, 49, 415, 188, 189, 1939, 1940, "." +448, 13, 1, 416, 0, 4, 1941, 1945, "Mean" +448, 13, 2, 417, 5, 12, 1946, 1953, "diurnal" +448, 13, 3, 418, 13, 16, 1954, 1957, "IOP" +448, 13, 4, 419, 17, 26, 1958, 1967, "reduction" +448, 13, 5, 420, 27, 32, 1968, 1973, "after" +448, 13, 6, 421, 33, 34, 1974, 1975, "8" +448, 13, 7, 422, 35, 40, 1976, 1981, "weeks" +448, 13, 8, 423, 41, 45, 1982, 1986, "were" +448, 13, 9, 424, 46, 47, 1987, 1988, "7" +448, 13, 10, 425, 48, 49, 1989, 1990, "." +448, 13, 11, 426, 50, 52, 1991, 1993, "02" +448, 13, 12, 427, 53, 54, 1994, 1995, "+" +448, 13, 13, 428, 55, 56, 1996, 1997, "/" +448, 13, 14, 429, 57, 58, 1998, 1999, "-" +448, 13, 15, 430, 59, 60, 2000, 2001, "3" +448, 13, 16, 431, 61, 62, 2002, 2003, "." +448, 13, 17, 432, 63, 65, 2004, 2006, "06" +448, 13, 18, 433, 66, 68, 2007, 2009, "mm" +448, 13, 19, 434, 69, 71, 2010, 2012, "Hg" +448, 13, 20, 435, 72, 75, 2013, 2016, "and" +448, 13, 21, 436, 76, 77, 2017, 2018, "6" +448, 13, 22, 437, 78, 79, 2019, 2020, "." +448, 13, 23, 438, 80, 82, 2021, 2023, "91" +448, 13, 24, 439, 83, 84, 2024, 2025, "+" +448, 13, 25, 440, 85, 86, 2026, 2027, "/" +448, 13, 26, 441, 87, 88, 2028, 2029, "-" +448, 13, 27, 442, 89, 90, 2030, 2031, "3" +448, 13, 28, 443, 91, 92, 2032, 2033, "." +448, 13, 29, 444, 93, 95, 2034, 2036, "67" +448, 13, 30, 445, 96, 98, 2037, 2039, "mm" +448, 13, 31, 446, 99, 101, 2040, 2042, "Hg" +448, 13, 32, 447, 102, 103, 2043, 2044, "," +448, 13, 33, 448, 104, 116, 2045, 2057, "respectively" +448, 13, 34, 449, 117, 118, 2058, 2059, "(" +448, 13, 35, 450, 119, 120, 2060, 2061, "P" +448, 13, 36, 451, 121, 122, 2062, 2063, "=" +448, 13, 37, 452, 123, 124, 2064, 2065, "0" +448, 13, 38, 453, 125, 126, 2066, 2067, "." +448, 13, 39, 454, 127, 130, 2068, 2071, "811" +448, 13, 40, 455, 131, 132, 2072, 2073, ")" +448, 13, 41, 456, 133, 134, 2074, 2075, "." +448, 14, 1, 457, 0, 3, 2076, 2079, "The" +448, 14, 2, 458, 4, 12, 2080, 2088, "adjusted" +448, 14, 3, 459, 13, 23, 2089, 2099, "difference" +448, 14, 4, 460, 24, 31, 2100, 2107, "between" +448, 14, 5, 461, 32, 38, 2108, 2114, "groups" +448, 14, 6, 462, 39, 40, 2115, 2116, "(" +448, 14, 7, 463, 41, 49, 2117, 2125, "analysis" +448, 14, 8, 464, 50, 52, 2126, 2128, "of" +448, 14, 9, 465, 53, 63, 2129, 2139, "covariance" +448, 14, 10, 466, 64, 65, 2140, 2141, ")" +448, 14, 11, 467, 66, 68, 2142, 2144, "at" +448, 14, 12, 468, 69, 73, 2145, 2149, "week" +448, 14, 13, 469, 74, 75, 2150, 2151, "8" +448, 14, 14, 470, 76, 79, 2152, 2155, "was" +448, 14, 15, 471, 80, 83, 2156, 2159, "not" +448, 14, 16, 472, 84, 97, 2160, 2173, "statistically" +448, 14, 17, 473, 98, 109, 2174, 2185, "significant" +448, 14, 18, 474, 110, 111, 2186, 2187, "(" +448, 14, 19, 475, 112, 113, 2188, 2189, "P" +448, 14, 20, 476, 114, 115, 2190, 2191, "=" +448, 14, 21, 477, 116, 117, 2192, 2193, "0" +448, 14, 22, 478, 118, 119, 2194, 2195, "." +448, 14, 23, 479, 120, 123, 2196, 2199, "847" +448, 14, 24, 480, 124, 125, 2200, 2201, ")" +448, 14, 25, 481, 126, 127, 2202, 2203, "." +448, 15, 1, 482, 0, 4, 2204, 2208, "Mean" +448, 15, 2, 483, 5, 13, 2209, 2217, "baseline" +448, 15, 3, 484, 14, 17, 2218, 2221, "WDT" +448, 15, 4, 485, 18, 22, 2222, 2226, "peak" +448, 15, 5, 486, 23, 26, 2227, 2230, "was" +448, 15, 6, 487, 27, 29, 2231, 2233, "27" +448, 15, 7, 488, 30, 31, 2234, 2235, "." +448, 15, 8, 489, 32, 34, 2236, 2238, "79" +448, 15, 9, 490, 35, 36, 2239, 2240, "+" +448, 15, 10, 491, 37, 38, 2241, 2242, "/" +448, 15, 11, 492, 39, 40, 2243, 2244, "-" +448, 15, 12, 493, 41, 42, 2245, 2246, "4" +448, 15, 13, 494, 43, 44, 2247, 2248, "." +448, 15, 14, 495, 45, 47, 2249, 2251, "29" +448, 15, 15, 496, 48, 50, 2252, 2254, "mm" +448, 15, 16, 497, 51, 53, 2255, 2257, "Hg" +448, 15, 17, 498, 54, 56, 2258, 2260, "in" +448, 15, 18, 499, 57, 60, 2261, 2264, "the" +448, 15, 19, 500, 61, 72, 2265, 2276, "brimonidine" +448, 15, 20, 501, 73, 74, 2277, 2278, "/" +448, 15, 21, 502, 75, 82, 2279, 2286, "timolol" +448, 15, 22, 503, 83, 88, 2287, 2292, "group" +448, 15, 23, 504, 89, 92, 2293, 2296, "and" +448, 15, 24, 505, 93, 95, 2297, 2299, "27" +448, 15, 25, 506, 96, 97, 2300, 2301, "." +448, 15, 26, 507, 98, 100, 2302, 2304, "68" +448, 15, 27, 508, 101, 102, 2305, 2306, "+" +448, 15, 28, 509, 103, 104, 2307, 2308, "/" +448, 15, 29, 510, 105, 106, 2309, 2310, "-" +448, 15, 30, 511, 107, 108, 2311, 2312, "5" +448, 15, 31, 512, 109, 110, 2313, 2314, "." +448, 15, 32, 513, 111, 113, 2315, 2317, "46" +448, 15, 33, 514, 114, 116, 2318, 2320, "mm" +448, 15, 34, 515, 117, 119, 2321, 2323, "Hg" +448, 15, 35, 516, 120, 122, 2324, 2326, "in" +448, 15, 36, 517, 123, 126, 2327, 2330, "the" +448, 15, 37, 518, 127, 138, 2331, 2342, "dorzolamide" +448, 15, 38, 519, 139, 140, 2343, 2344, "/" +448, 15, 39, 520, 141, 148, 2345, 2352, "timolol" +448, 15, 40, 521, 149, 154, 2353, 2358, "group" +448, 15, 41, 522, 155, 156, 2359, 2360, "." +448, 16, 1, 523, 0, 5, 2361, 2366, "After" +448, 16, 2, 524, 6, 7, 2367, 2368, "8" +448, 16, 3, 525, 8, 13, 2369, 2374, "weeks" +448, 16, 4, 526, 14, 16, 2375, 2377, "of" +448, 16, 5, 527, 17, 26, 2378, 2387, "treatment" +448, 16, 6, 528, 27, 28, 2388, 2389, "," +448, 16, 7, 529, 29, 33, 2390, 2394, "mean" +448, 16, 8, 530, 34, 37, 2395, 2398, "WDT" +448, 16, 9, 531, 38, 43, 2399, 2404, "peaks" +448, 16, 10, 532, 44, 48, 2405, 2409, "were" +448, 16, 11, 533, 49, 51, 2410, 2412, "20" +448, 16, 12, 534, 52, 53, 2413, 2414, "." +448, 16, 13, 535, 54, 56, 2415, 2417, "94" +448, 16, 14, 536, 57, 58, 2418, 2419, "+" +448, 16, 15, 537, 59, 60, 2420, 2421, "/" +448, 16, 16, 538, 61, 62, 2422, 2423, "-" +448, 16, 17, 539, 63, 64, 2424, 2425, "3" +448, 16, 18, 540, 65, 66, 2426, 2427, "." +448, 16, 19, 541, 67, 69, 2428, 2430, "76" +448, 16, 20, 542, 70, 72, 2431, 2433, "mm" +448, 16, 21, 543, 73, 75, 2434, 2436, "Hg" +448, 16, 22, 544, 76, 77, 2437, 2438, "(" +448, 16, 23, 545, 78, 79, 2439, 2440, "P" +448, 16, 24, 546, 80, 81, 2441, 2442, "<" +448, 16, 25, 547, 82, 83, 2443, 2444, "0" +448, 16, 26, 548, 84, 85, 2445, 2446, "." +448, 16, 27, 549, 86, 89, 2447, 2450, "001" +448, 16, 28, 550, 90, 91, 2451, 2452, ")" +448, 16, 29, 551, 92, 95, 2453, 2456, "and" +448, 16, 30, 552, 96, 98, 2457, 2459, "20" +448, 16, 31, 553, 99, 100, 2460, 2461, "." +448, 16, 32, 554, 101, 103, 2462, 2464, "98" +448, 16, 33, 555, 104, 105, 2465, 2466, "+" +448, 16, 34, 556, 106, 107, 2467, 2468, "/" +448, 16, 35, 557, 108, 109, 2469, 2470, "-" +448, 16, 36, 558, 110, 111, 2471, 2472, "4" +448, 16, 37, 559, 112, 113, 2473, 2474, "." +448, 16, 38, 560, 114, 116, 2475, 2477, "19" +448, 16, 39, 561, 117, 118, 2478, 2479, "(" +448, 16, 40, 562, 119, 120, 2480, 2481, "P" +448, 16, 41, 563, 121, 122, 2482, 2483, "<" +448, 16, 42, 564, 123, 124, 2484, 2485, "0" +448, 16, 43, 565, 125, 126, 2486, 2487, "." +448, 16, 44, 566, 127, 130, 2488, 2491, "001" +448, 16, 45, 567, 131, 132, 2492, 2493, ")" +448, 16, 46, 568, 133, 134, 2494, 2495, "," +448, 16, 47, 569, 135, 147, 2496, 2508, "respectively" +448, 16, 48, 570, 148, 149, 2509, 2510, "." +448, 17, 1, 571, 0, 3, 2511, 2514, "The" +448, 17, 2, 572, 4, 12, 2515, 2523, "adjusted" +448, 17, 3, 573, 13, 23, 2524, 2534, "difference" +448, 17, 4, 574, 24, 31, 2535, 2542, "between" +448, 17, 5, 575, 32, 38, 2543, 2549, "groups" +448, 17, 6, 576, 39, 40, 2550, 2551, "(" +448, 17, 7, 577, 41, 49, 2552, 2560, "analysis" +448, 17, 8, 578, 50, 52, 2561, 2563, "of" +448, 17, 9, 579, 53, 63, 2564, 2574, "covariance" +448, 17, 10, 580, 64, 65, 2575, 2576, ")" +448, 17, 11, 581, 66, 69, 2577, 2580, "was" +448, 17, 12, 582, 70, 73, 2581, 2584, "not" +448, 17, 13, 583, 74, 87, 2585, 2598, "statistically" +448, 17, 14, 584, 88, 99, 2599, 2610, "significant" +448, 17, 15, 585, 100, 101, 2611, 2612, "(" +448, 17, 16, 586, 102, 103, 2613, 2614, "P" +448, 17, 17, 587, 104, 105, 2615, 2616, "=" +448, 17, 18, 588, 106, 107, 2617, 2618, "0" +448, 17, 19, 589, 108, 109, 2619, 2620, "." +448, 17, 20, 590, 110, 113, 2621, 2624, "469" +448, 17, 21, 591, 114, 115, 2625, 2626, ")" +448, 17, 22, 592, 116, 117, 2627, 2628, "." +448, 18, 1, 593, 0, 2, 2629, 2631, "No" +448, 18, 2, 594, 3, 14, 2632, 2643, "statistical" +448, 18, 3, 595, 15, 25, 2644, 2654, "difference" +448, 18, 4, 596, 26, 28, 2655, 2657, "in" +448, 18, 5, 597, 29, 34, 2658, 2663, "terms" +448, 18, 6, 598, 35, 37, 2664, 2666, "of" +448, 18, 7, 599, 38, 45, 2667, 2674, "adverse" +448, 18, 8, 600, 46, 52, 2675, 2681, "events" +448, 18, 9, 601, 53, 56, 2682, 2685, "was" +448, 18, 10, 602, 57, 62, 2686, 2691, "found" +448, 18, 11, 603, 63, 70, 2692, 2699, "between" +448, 18, 12, 604, 71, 77, 2700, 2706, "groups" +448, 18, 13, 605, 78, 79, 2707, 2708, "." +448, 19, 1, 606, 0, 11, 2709, 2720, "CONCLUSIONS" +448, 19, 2, 607, 12, 13, 2721, 2722, ":" +448, 19, 3, 608, 14, 18, 2723, 2727, "Both" +448, 19, 4, 609, 19, 24, 2728, 2733, "fixed" +448, 19, 5, 610, 25, 37, 2734, 2746, "combinations" +448, 19, 6, 611, 38, 42, 2747, 2751, "were" +448, 19, 7, 612, 43, 50, 2752, 2759, "capable" +448, 19, 8, 613, 51, 53, 2760, 2762, "of" +448, 19, 9, 614, 54, 67, 2763, 2776, "significantly" +448, 19, 10, 615, 68, 76, 2777, 2785, "reducing" +448, 19, 11, 616, 77, 80, 2786, 2789, "the" +448, 19, 12, 617, 81, 85, 2790, 2794, "mean" +448, 19, 13, 618, 86, 93, 2795, 2802, "diurnal" +448, 19, 14, 619, 94, 97, 2803, 2806, "IOP" +448, 19, 15, 620, 98, 99, 2807, 2808, "," +448, 19, 16, 621, 100, 104, 2809, 2813, "mean" +448, 19, 17, 622, 105, 112, 2814, 2821, "diurnal" +448, 19, 18, 623, 113, 117, 2822, 2826, "peak" +448, 19, 19, 624, 118, 119, 2827, 2828, "," +448, 19, 20, 625, 120, 123, 2829, 2832, "and" +448, 19, 21, 626, 124, 128, 2833, 2837, "mean" +448, 19, 22, 627, 129, 132, 2838, 2841, "WDT" +448, 19, 23, 628, 133, 137, 2842, 2846, "peak" +448, 19, 24, 629, 138, 143, 2847, 2852, "after" +448, 19, 25, 630, 144, 145, 2853, 2854, "8" +448, 19, 26, 631, 146, 151, 2855, 2860, "weeks" +448, 19, 27, 632, 152, 154, 2861, 2863, "of" +448, 19, 28, 633, 155, 164, 2864, 2873, "treatment" +448, 19, 29, 634, 165, 166, 2874, 2875, "." +448, 20, 1, 635, 0, 4, 2876, 2880, "Also" +448, 20, 2, 636, 5, 6, 2881, 2882, "," +448, 20, 3, 637, 7, 11, 2883, 2887, "both" +448, 20, 4, 638, 12, 17, 2888, 2893, "fixed" +448, 20, 5, 639, 18, 30, 2894, 2906, "combinations" +448, 20, 6, 640, 31, 34, 2907, 2910, "are" +448, 20, 7, 641, 35, 39, 2911, 2915, "well" +448, 20, 8, 642, 40, 49, 2916, 2925, "tolerated" +448, 20, 9, 643, 50, 54, 2926, 2930, "with" +448, 20, 10, 644, 55, 58, 2931, 2934, "few" +448, 20, 11, 645, 59, 63, 2935, 2939, "side" +448, 20, 12, 646, 64, 71, 2940, 2947, "effects" +448, 20, 13, 647, 72, 73, 2948, 2949, "." +448, 21, 1, 648, 0, 3, 2950, 2953, "DOI" +448, 21, 2, 649, 4, 5, 2954, 2955, ":" +448, 21, 3, 650, 6, 8, 2956, 2958, "10" +448, 21, 4, 651, 9, 10, 2959, 2960, "." +448, 21, 5, 652, 11, 15, 2961, 2965, "1097" +448, 21, 6, 653, 16, 17, 2966, 2967, "/" +448, 21, 7, 654, 18, 21, 2968, 2971, "IJG" +448, 21, 8, 655, 22, 23, 2972, 2973, "." +448, 21, 9, 656, 24, 40, 2974, 2990, "0b013e318168f008" +448, 21, 10, 657, 41, 45, 2991, 2995, "PMID" +448, 21, 11, 658, 46, 47, 2996, 2997, ":" +448, 21, 12, 659, 48, 56, 2998, 3006, "19092465" +448, 21, 13, 660, 57, 58, 3007, 3008, "[" +448, 21, 14, 661, 59, 66, 3009, 3016, "Indexed" +448, 21, 15, 662, 67, 70, 3017, 3020, "for" +448, 21, 16, 663, 71, 78, 3021, 3028, "MEDLINE" +448, 21, 17, 664, 79, 80, 3029, 3030, "]" diff --git a/data/gl 19092465_jshahinitiran.annodb b/data/gl 19092465_jshahinitiran.annodb new file mode 100644 index 0000000..0086c87 --- /dev/null +++ b/data/gl 19092465_jshahinitiran.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11913, Journal, 0, 10, "J Glaucoma", "", +11914, PublicationYear, 13, 17, "2008", "", +11915, Title, 88, 235, "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the", "", +11917, Duration, 91, 103, "eight - week", "", +11918, Multicenter, 106, 118, "multicentric", "", +11919, Randomized, 121, 131, "randomized", "", +28172, CTDesign, 134, 148, "interventional", "", +11920, OpenLabel, 151, 163, "open - label", "", +28173, CTDesign, 166, 173, "phase 4", "", +11921, Parallel, 176, 184, "parallel", "", +11916, Title, 236, 430, "fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure .", "", +28174, Timolol, 257, 272, "timolol maleate", "", +28178, DoseValue, 273, 278, "0 . 5", "", +28179, Percentage, 279, 280, "%", "", +28175, Brimonidine, 283, 303, "brimonidine tartrate", "", +28180, DoseValue, 304, 309, "0 . 2", "", +28181, Percentage, 310, 311, "%", "", +28176, Timolol, 340, 355, "timolol maleate", "", +28184, DoseValue, 356, 361, "0 . 5", "", +28182, Percentage, 362, 363, "%", "", +28177, Dorzolamide, 366, 377, "dorzolamide", "", +28185, DoseValue, 378, 379, "2", "", +28183, Percentage, 380, 381, "%", "", +11932, IOP, 408, 428, "intraocular pressure", "", +11935, Author, 431, 441, "Hatanaka M", "", +11936, Author, 450, 460, "Grigera DE", "", +11937, Author, 463, 473, "Barbosa WL", "", +11938, Author, 476, 484, "Jordao M", "", +11939, Author, 487, 499, "Susanna R Jr", "", +28186, Brazil, 588, 594, "Brazil", "", +11941, ObjectiveDescription, 635, 765, "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus", "", +28187, Timolol, 704, 719, "timolol maleate", "", +28189, DoseValue, 720, 725, "0 . 5", "", +28191, Percentage, 726, 727, "%", "", +28188, Brimonidine, 730, 750, "brimonidine tartrate", "", +28190, DoseValue, 751, 756, "0 . 2", "", +28192, Percentage, 757, 758, "%", "", +11942, ObjectiveDescription, 766, 898, "fixed combination of timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure ( IOP ) over 8 weeks .", "", +28193, Timolol, 787, 802, "timolol maleate", "", +28195, DoseValue, 803, 808, "0 . 5", "", +28196, Percentage, 809, 810, "%", "", +28194, Dorzolamide, 813, 824, "dorzolamide", "", +28198, DoseValue, 825, 826, "2", "", +28197, Percentage, 827, 828, "%", "", +11955, IOP, 855, 875, "intraocular pressure", "", +11956, IOP, 878, 881, "IOP", "", +11957, Duration, 889, 896, "8 weeks", "", +11958, Duration, 927, 935, "8 - week", "", +11959, Multicenter, 938, 950, "multicentric", "", +28223, CTDesign, 953, 967, "interventional", "", +28222, Randomized, 970, 980, "randomized", "", +11963, OpenLabel, 983, 995, "open - label", "", +11964, Parallel, 998, 1012, "parallel group", "", +11966, Argentina, 1072, 1081, "Argentina", "", +11967, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", +11968, OcularHypertension, 1123, 1142, "ocular hypertension", "", +28199, Randomized, 1148, 1158, "randomized", "", +28200, Brimonidine, 1203, 1214, "brimonidine", "", +28201, Timolol, 1217, 1232, "timolol maleate", "", +28202, DoseValue, 1233, 1238, "0 . 5", "", +28203, Percentage, 1239, 1240, "%", "", +28204, Dorzolamide, 1265, 1276, "dorzolamide", "", +28206, DoseValue, 1277, 1278, "2", "", +28209, Percentage, 1279, 1280, "%", "", +28205, Timolol, 1283, 1290, "timolol", "", +28207, DoseValue, 1291, 1296, "0 . 5", "", +28208, Percentage, 1297, 1298, "%", "", +11980, Frequency, 1299, 1310, "twice daily", "", +11981, Peak_IOP, 1491, 1499, "IOP peak", "", +11982, Diurnal_IOP, 1503, 1524, "diurnal tension curve", "", +28210, TimePoint, 1549, 1557, "baseline", "", +28212, TimePoint, 1562, 1570, "week - 8", "", +11983, NumberPatientsCT, 1651, 1654, "210", "", +28213, Randomized, 1669, 1679, "randomized", "", +28214, Brimonidine, 1682, 1693, "brimonidine", "", +28215, Timolol, 1696, 1703, "timolol", "", +11989, NumberPatientsArm, 1710, 1713, "111", "", +28216, Dorzolamide, 1716, 1727, "dorzolamide", "", +28217, Timolol, 1730, 1737, "timolol", "", +11990, NumberPatientsArm, 1744, 1746, "99", "", +11991, Mean, 1751, 1755, "Mean", "", +11992, IOP, 1765, 1768, "IOP", "", +11993, BaseLineValue, 1773, 1780, "23 . 43", "", +11994, SdErrorBL, 1787, 1793, "3 . 22", "", +11995, mmHg, 1794, 1799, "mm Hg", "", +11996, BaseLineValue, 1804, 1811, "23 . 43", "", +11997, SdErrorBL, 1818, 1824, "4 . 06", "", +11998, mmHg, 1825, 1830, "mm Hg", "", +12003, PValueBL, 1925, 1936, "P = 0 . 993", "", +12004, Mean, 1941, 1945, "Mean", "", +12005, Diurnal_IOP, 1946, 1957, "diurnal IOP", "", +12007, Reduction, 1987, 1993, "7 . 02", "", +12008, SdErrorChangeValue, 2000, 2006, "3 . 06", "", +12009, mmHg, 2007, 2012, "mm Hg", "", +12010, Reduction, 2017, 2023, "6 . 91", "", +12011, SdErrorChangeValue, 2030, 2036, "3 . 67", "", +12012, mmHg, 2037, 2042, "mm Hg", "", +12013, PValueChangeValue, 2060, 2071, "P = 0 . 811", "", +12015, PvalueDiff, 2188, 2199, "P = 0 . 847", "", +12016, Mean, 2204, 2208, "Mean", "", +12033, Peak_IOP, 2222, 2226, "peak", "", +12035, BaseLineValue, 2231, 2238, "27 . 79", "", +12036, SdErrorBL, 2245, 2251, "4 . 29", "", +12022, mmHg, 2252, 2257, "mm Hg", "", +28218, Brimonidine, 2265, 2276, "brimonidine", "", +28219, Timolol, 2279, 2286, "timolol", "", +12037, BaseLineValue, 2297, 2304, "27 . 68", "", +12038, SdErrorBL, 2311, 2317, "5 . 46", "", +12027, mmHg, 2318, 2323, "mm Hg", "", +28220, Dorzolamide, 2331, 2342, "dorzolamide", "", +28221, Timolol, 2345, 2352, "timolol", "", +12030, Duration, 2367, 2374, "8 weeks", "", +12031, Mean, 2390, 2394, "mean", "", +12034, Peak_IOP, 2399, 2404, "peaks", "", +12039, ResultMeasuredValue, 2410, 2417, "20 . 94", "", +12040, SdErrorResValue, 2424, 2430, "3 . 76", "", +12041, mmHg, 2431, 2436, "mm Hg", "", +12042, PValueResValue, 2439, 2450, "P < 0 . 001", "", +12043, ResultMeasuredValue, 2457, 2464, "20 . 98", "", +12044, SdErrorResValue, 2471, 2477, "4 . 19", "", +12045, PValueResValue, 2480, 2491, "P < 0 . 001", "", +12046, PvalueDiff, 2613, 2624, "P = 0 . 469", "", +12047, ConclusionComment, 2723, 2875, "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .", "", +12051, Mean, 2790, 2794, "mean", "", +12050, Diurnal_IOP, 2795, 2806, "diurnal IOP", "", +12052, Mean, 2809, 2813, "mean", "", +12053, Peak_IOP, 2814, 2826, "diurnal peak", "", +12054, Mean, 2833, 2837, "mean", "", +12056, Duration, 2853, 2860, "8 weeks", "", +12048, ConclusionComment, 2876, 2949, "Also , both fixed combinations are well tolerated with few side effects .", "", +12057, PMID, 2998, 3006, "19092465", "", diff --git a/data/gl 19092465_jshahinitiran.n-triples b/data/gl 19092465_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19092465_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19092465_tstrakeljahn.annodb b/data/gl 19092465_tstrakeljahn.annodb new file mode 100644 index 0000000..6de94c5 --- /dev/null +++ b/data/gl 19092465_tstrakeljahn.annodb @@ -0,0 +1,130 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +29914, Journal, 0, 10, "J Glaucoma", "", +29915, PublicationYear, 13, 17, "2008", "", +29939, Title, 88, 339, "An eight - week , multicentric , randomized , interventional , open - label , phase 4 , parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0 . 5 % / brimonidine tartrate 0 . 2 % versus fixed combination of", "", +29918, Duration, 91, 103, "eight - week", "", +29916, Multicenter, 106, 118, "multicentric", "", +29917, Randomized, 121, 131, "randomized", "", +29919, OpenLabel, 151, 163, "open - label", "", +29920, Parallel, 176, 184, "parallel", "", +29921, Timolol, 257, 272, "timolol maleate", "", +29926, DoseValue, 273, 278, "0 . 5", "", +29930, Percentage, 279, 280, "%", "", +29922, Brimonidine, 283, 303, "brimonidine tartrate", "", +29927, DoseValue, 304, 309, "0 . 2", "", +29931, Percentage, 310, 311, "%", "", +29923, Timolol, 340, 355, "timolol maleate", "", +29940, Title, 340, 430, "timolol maleate 0 . 5 % / dorzolamide 2 % in patients with elevated intraocular pressure .", "", +29928, DoseValue, 356, 361, "0 . 5", "", +29932, Percentage, 362, 363, "%", "", +29924, Dorzolamide, 366, 377, "dorzolamide", "", +29929, DoseValue, 378, 379, "2", "", +29933, Percentage, 380, 381, "%", "", +29925, IOP, 408, 428, "intraocular pressure", "", +29934, Author, 431, 441, "Hatanaka M", "", +29935, Author, 450, 460, "Grigera DE", "", +29936, Author, 463, 473, "Barbosa WL", "", +29937, Author, 476, 484, "Jordao M", "", +29938, Author, 487, 499, "Susanna R Jr", "", +29941, Brazil, 588, 594, "Brazil", "", +29942, Timolol, 704, 719, "timolol maleate", "", +29949, DoseValue, 720, 725, "0 . 5", "", +29953, Percentage, 726, 727, "%", "", +29943, Brimonidine, 730, 750, "brimonidine tartrate", "", +29950, DoseValue, 751, 756, "0 . 2", "", +29954, Percentage, 757, 758, "%", "", +29944, Timolol, 787, 802, "timolol maleate", "", +29951, DoseValue, 803, 808, "0 . 5", "", +29955, Percentage, 809, 810, "%", "", +29945, Dorzolamide, 813, 824, "dorzolamide", "", +29952, DoseValue, 825, 826, "2", "", +29956, Percentage, 827, 828, "%", "", +29946, IOP, 855, 875, "intraocular pressure", "", +29947, IOP, 878, 881, "IOP", "", +29948, Duration, 889, 896, "8 weeks", "", +29957, Duration, 927, 935, "8 - week", "", +29958, Multicenter, 938, 950, "multicentric", "", +29959, Randomized, 970, 980, "randomized", "", +29960, OpenLabel, 983, 995, "open - label", "", +29961, Parallel, 998, 1012, "parallel group", "", +29962, Brazil, 1049, 1055, "Brazil", "", +29963, Argentina, 1072, 1081, "Argentina", "", +29964, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", +29965, OcularHypertension, 1123, 1142, "ocular hypertension", "", +29966, Randomized, 1148, 1158, "randomized", "", +29967, Brimonidine, 1203, 1214, "brimonidine", "", +29968, Timolol, 1217, 1232, "timolol maleate", "", +29974, DoseValue, 1233, 1238, "0 . 5", "", +29977, Percentage, 1239, 1240, "%", "", +29969, Dorzolamide, 1265, 1276, "dorzolamide", "", +29975, DoseValue, 1277, 1278, "2", "", +29978, Percentage, 1279, 1280, "%", "", +29970, Timolol, 1283, 1290, "timolol", "", +29976, DoseValue, 1291, 1296, "0 . 5", "", +29979, Percentage, 1297, 1298, "%", "", +29971, Frequency, 1299, 1310, "twice daily", "", +29980, Diurnal_IOP, 1342, 1372, "modified diurnal tension curve", "", +29981, Peak_IOP, 1491, 1499, "IOP peak", "", +29982, NumberPatientsCT, 1651, 1654, "210", "", +29989, Randomized, 1669, 1679, "randomized", "", +29985, Brimonidine, 1682, 1693, "brimonidine", "", +29986, Timolol, 1696, 1703, "timolol", "", +29983, NumberPatientsArm, 1710, 1713, "111", "", +29988, Dorzolamide, 1716, 1727, "dorzolamide", "", +29987, Timolol, 1730, 1737, "timolol", "", +29984, NumberPatientsArm, 1744, 1746, "99", "", +29990, Mean, 1751, 1755, "Mean", "", +29991, IOP, 1765, 1768, "IOP", "", +29992, BaseLineValue, 1773, 1780, "23 . 43", "", +30155, SdDevBL, 1781, 1793, "+ / - 3 . 22", "", +30156, mmHg, 1794, 1799, "mm Hg", "", +29993, BaseLineValue, 1804, 1811, "23 . 43", "", +30157, SdDevBL, 1812, 1824, "+ / - 4 . 06", "", +29996, mmHg, 1825, 1830, "mm Hg", "", +29997, Brimonidine, 1860, 1871, "brimonidine", "", +29998, Timolol, 1874, 1881, "timolol", "", +30000, Dorzolamide, 1886, 1897, "dorzolamide", "", +29999, Timolol, 1900, 1907, "timolol", "", +30001, PvalueDiff, 1929, 1936, "0 . 993", "", +30002, Mean, 1941, 1945, "Mean", "", +30003, Diurnal_IOP, 1946, 1957, "diurnal IOP", "", +30004, TimePoint, 1974, 1981, "8 weeks", "", +30005, Reduction, 1987, 1993, "7 . 02", "", +30158, SdDevChangeValue, 1994, 2006, "+ / - 3 . 06", "", +30009, mmHg, 2007, 2012, "mm Hg", "", +30006, Reduction, 2017, 2023, "6 . 91", "", +30159, SdDevChangeValue, 2024, 2036, "+ / - 3 . 67", "", +30010, mmHg, 2037, 2042, "mm Hg", "", +30011, PvalueDiff, 2064, 2071, "0 . 811", "", +30013, TimePoint, 2145, 2151, "week 8", "", +30012, PvalueDiff, 2192, 2199, "0 . 847", "", +30014, Mean, 2204, 2208, "Mean", "", +30015, BaseLineValue, 2231, 2238, "27 . 79", "WDT", +30160, SdDevBL, 2239, 2251, "+ / - 4 . 29", "", +30021, mmHg, 2252, 2257, "mm Hg", "", +30022, Brimonidine, 2265, 2276, "brimonidine", "", +30023, Timolol, 2279, 2286, "timolol", "", +30017, BaseLineValue, 2297, 2304, "27 . 68", "WDT", +30161, SdDevBL, 2305, 2317, "+ / - 5 . 46", "", +30020, mmHg, 2318, 2323, "mm Hg", "", +30024, Dorzolamide, 2331, 2342, "dorzolamide", "", +30025, Timolol, 2345, 2352, "timolol", "", +30026, TimePoint, 2367, 2374, "8 weeks", "", +30027, Mean, 2390, 2394, "mean", "", +30028, Peak_IOP, 2399, 2404, "peaks", "", +30029, ResultMeasuredValue, 2410, 2417, "20 . 94", "", +30031, SdDevResValue, 2418, 2430, "+ / - 3 . 76", "", +30035, mmHg, 2431, 2436, "mm Hg", "", +30034, PValueResValue, 2439, 2450, "P < 0 . 001", "", +30030, ResultMeasuredValue, 2457, 2464, "20 . 98", "", +30032, SdDevResValue, 2465, 2477, "+ / - 4 . 19", "", +30033, PValueResValue, 2480, 2491, "P < 0 . 001", "", +30036, PvalueDiff, 2613, 2624, "P = 0 . 469", "", +30044, ConclusionComment, 2723, 2875, "Both fixed combinations were capable of significantly reducing the mean diurnal IOP , mean diurnal peak , and mean WDT peak after 8 weeks of treatment .", "", +30037, Mean, 2790, 2794, "mean", "", +30038, Diurnal_IOP, 2795, 2806, "diurnal IOP", "", +30042, Mean, 2809, 2813, "mean", "", +30039, Peak_IOP, 2814, 2826, "diurnal peak", "", +30043, TimePoint, 2853, 2860, "8 weeks", "", +30045, ConclusionComment, 2876, 2949, "Also , both fixed combinations are well tolerated with few side effects .", "", +30046, PMID, 2998, 3006, "19092465", "", diff --git a/data/gl 19092465_tstrakeljahn.n-triples b/data/gl 19092465_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19092465_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19123151 copy_admin.annodb b/data/gl 19123151 copy_admin.annodb new file mode 100644 index 0000000..26da2e0 --- /dev/null +++ b/data/gl 19123151 copy_admin.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Eur J Ophthalmol", "", " \"Eur J Ophthalmol\"." +1, PublicationYear, 19, 23, "2009", "", " \"2009\"." +2, Title, 57, 260, "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study", "", " \"Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study\"." +3, Bimatoprost, 95, 106, "bimatoprost", "", +4, Latanoprost, 110, 121, "latanoprost", "", +5, Timolol, 127, 134, "timolol", "", +6, Precondition, 147, 190, "uncontrolled with prostaglandin monotherapy", "", " \"uncontrolled with prostaglandin monotherapy\"." +92855, ProstaglandinAnalogs, 165, 178, "prostaglandin", "", +7, Multicenter, 195, 206, "multicenter", "", " ." +8, Randomized, 209, 219, "randomized", "", " ." +81, Blind, 237, 243, "masked", "", " ." +10, Author, 263, 275, "Centofanti M", "", " \"Centofanti M\"." +11, Author, 284, 292, "Oddone F", "", " \"Oddone F\"." +12, Author, 295, 305, "Vetrugno M", "", " \"Vetrugno M\"." +13, Author, 308, 315, "Manni G", "", " \"Manni G\"." +14, Author, 318, 329, "Fogagnolo P", "", " \"Fogagnolo P\"." +15, Author, 332, 339, "Tanga L", "", " \"Tanga L\"." +16, Author, 342, 351, "Ferreri P", "", " \"Ferreri P\"." +17, Author, 354, 364, "Rossetti L", "", " \"Rossetti L\"." +18, Italy, 437, 442, "Italy", "", +26778, PublicationYear, 512, 516, "2010", "", +19, ObjectiveDescription, 583, 706, "To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )", "", " \"To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )\"." +21, Frequency, 629, 641, "once - daily", "", " \"once - daily\"." +22, Bedtime, 642, 649, "evening", "", " ." +106184, Bima/TimFC, 658, 697, "bimatoprost / timolol fixed combination", "", +23, Bimatoprost, 658, 669, "bimatoprost", "", +24, Timolol, 672, 679, "timolol", "", +106186, Bima/TimFC, 700, 704, "BTFC", "", +20, ObjectiveDescription, 707, 870, "with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy .", "", " \"with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy .\"." +26, Frequency, 722, 734, "once - daily", "", " \"once - daily\"." +27, Bedtime, 735, 742, "evening", "", " ." +28, Latanoprost, 751, 762, "latanoprost", "", +106191, Lat/TimFC, 751, 790, "latanoprost / timolol fixed combination", "", +29, Timolol, 765, 772, "timolol", "", +106192, Lat/TimFC, 793, 797, "LTFC", "", +31, Precondition, 812, 868, "not controlled with prostaglandins analogues monotherapy", "", +92854, ProstaglandinAnalogs, 832, 856, "prostaglandins analogues", "", +32, NumberPatientsCT, 892, 894, "82", "", " \"82\"." +92852, ProstaglandinAnalogs, 907, 930, "prostaglandin analogues", "", " ." +36963, Prospective, 965, 976, "prospective", "", " ." +34, Multicenter, 979, 990, "multicenter", "", +105, Blind, 1006, 1012, "masked", "", +36, Randomized, 1039, 1049, "randomized", "", +106200, Bima/TimFC, 1060, 1064, "BTFC", "", " ." +37, NumberPatientsArm, 1071, 1073, "47", "", " \"47\"." +106193, Lat/TimFC, 1079, 1083, "LTFC", "", " ." +38, NumberPatientsArm, 1090, 1092, "35", "", " \"35\"." +36967, Topic, 1095, 1102, "topical", "", " . ." +113, Frequency, 1111, 1115, "once", "", +114, RelativeTime, 1116, 1124, "at night", "", +39, Duration, 1129, 1137, "12 weeks", "", " \"12 weeks\"." +40, Mean, 1193, 1197, "mean", "", +41, IOP, 1204, 1224, "intraocular pressure", "", +42, IOP, 1227, 1230, "IOP", "", +43, Mean, 1323, 1327, "mean", "", +44, IOP, 1334, 1337, "IOP", "", +26785, TimePoint, 1341, 1355, "1 and 3 months", "", +36964, TimePoint, 1347, 1355, "3 months", "", +45, Mean, 1418, 1422, "mean", "", +36971, EndPointDescription, 1418, 1480, "mean IOP reduction from baseline greater than or equal to 15 %", "", +36972, EndPointDescription, 1418, 1488, "mean IOP reduction from baseline greater than or equal to 15 % or 20 %", "", +46, IOP, 1423, 1426, "IOP", "", +49, Mean, 1501, 1505, "Mean", "", " . ." +50, IOP, 1506, 1509, "IOP", "", " . ." +36965, TimePoint, 1513, 1521, "baseline", "", +51, BaseLineValue, 1526, 1532, "22 . 7", "", " \"22 . 7\"." +130, SdDevBL, 1539, 1544, "2 . 0", "", " \"2 . 0\"." +53, BaseLineValue, 1549, 1555, "22 . 1", "", " \"22 . 1\"." +132, SdDevBL, 1562, 1567, "2 . 6", "", " \"2 . 6\"." +55, mmHg, 1568, 1572, "mmHg", "", " ." +106199, Bima/TimFC, 1580, 1584, "BTFC", "", +106194, Lat/TimFC, 1589, 1593, "LTFC", "", +136, PvalueDiff, 1618, 1628, "p = 0 . 23", "", +138, ObservedResult, 1633, 1697, "Both treatments were effective in reducing the IOP from baseline", "", " \"Both treatments were effective in reducing the IOP from baseline\". \"Both treatments were effective in reducing the IOP from baseline\"." +57, IOP, 1680, 1683, "IOP", "", +58, Mean, 1704, 1708, "mean", "", +59, IOP, 1709, 1712, "IOP", "", +106187, Bima/TimFC, 1756, 1760, "BTFC", "", +106195, Lat/TimFC, 1779, 1783, "LTFC", "", +60, RelativeReduction, 1794, 1800, "21 . 4", "", " \"21 . 4\"." +61, RelativeReduction, 1808, 1814, "13 . 7", "", " \"13 . 7\"." +145, PvalueDiff, 1819, 1830, "p < 0 . 001", "", " \"p < 0 . 001\"." +106188, Bima/TimFC, 1874, 1878, "BTFC", "", +63, Mean, 1894, 1898, "mean", "", +36968, EndPointDescription, 1894, 1938, "mean IOP reduction from baseline > or = 15 %", "", " . ." +64, IOP, 1899, 1902, "IOP", "", +65, PercentageAffected, 1941, 1947, "72 . 3", "", " \"72 . 3\"." +66, PercentageAffected, 1953, 1959, "40 . 0", "", " \"40 . 0\"." +36969, EndPointDescription, 1968, 1979, "> or = 20 %", "", " . ." +67, PercentageAffected, 1982, 1988, "61 . 7", "", " \"61 . 7\"." +68, PercentageAffected, 1994, 2000, "17 . 1", "", " \"17 . 1\"." +106196, Lat/TimFC, 2033, 2037, "LTFC", "", +69, ConclusionComment, 2060, 2152, "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues .", "", " \"Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues .\"." +106189, Bima/TimFC, 2065, 2069, "BTFC", "", +106197, Lat/TimFC, 2074, 2078, "LTFC", "", +92853, ProstaglandinAnalogs, 2127, 2150, "prostaglandin analogues", "", +106190, Bima/TimFC, 2153, 2157, "BTFC", "", +70, ConclusionComment, 2153, 2236, "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction .", "", " \"BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction .\"." +106198, Lat/TimFC, 2195, 2199, "LTFC", "", +71, IOP, 2221, 2224, "IOP", "", +72, PMID, 2244, 2252, "19123151", "", " \"19123151\"." diff --git a/data/gl 19123151 copy_admin.n-triples b/data/gl 19123151 copy_admin.n-triples new file mode 100644 index 0000000..d14acdb --- /dev/null +++ b/data/gl 19123151 copy_admin.n-triples @@ -0,0 +1,155 @@ +# RDF export of group: Publication + . + "Publication 106388" . + "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study" . + "Centofanti M" . + "2009" . + "Eur J Ophthalmol" . + "19123151" . + . + "Oddone F" . + "Vetrugno M" . + "Manni G" . + "Fogagnolo P" . + "Tanga L" . + "Ferreri P" . + "Rossetti L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 106395" . + "To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )" . + "82" . + "12 weeks" . + . + . + . + "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues ." . + . + . + . + . + . + . + "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction ." . + . + . + . + "with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy ." . +# RDF export of group: Population + . + "Population 106411" . + "uncontrolled with prostaglandin monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + . + "iopt" . + . + . + . + . + . + . + "iopt2" . + . + . + . + . + . +# RDF export of group: Arm + . + "btfc" . + "47" . + . + . + . + . + . + . + . + "ltfc" . + "35" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "btfc" . + . + "once - daily" . + . + . + "ltfc" . + . + "once - daily" . + . + . + "pro" . + . + . +# RDF export of group: Medication + . + "btfc" . + . + . + . + . + "ltfc" . + . + . + . + . + "pro" . + . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "22 . 7" . + "2 . 0" . + "21 . 4" . + "Both treatments were effective in reducing the IOP from baseline" . + . + "iop2" . + . + "22 . 1" . + "2 . 6" . + "13 . 7" . + "Both treatments were effective in reducing the IOP from baseline" . + . + "iopt1" . + . + "72 . 3" . + . + "iopt2" . + . + "40 . 0" . + . + "iopt21" . + . + "61 . 7" . + . + "iopt22" . + . + "17 . 1" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19123151 copy_export.csv b/data/gl 19123151 copy_export.csv new file mode 100644 index 0000000..f29e358 --- /dev/null +++ b/data/gl 19123151 copy_export.csv @@ -0,0 +1,478 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +831, 1, 1, 1, 0, 3, 0, 3, "Eur" +831, 1, 2, 2, 4, 5, 4, 5, "J" +831, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +831, 1, 4, 4, 17, 18, 17, 18, "." +831, 2, 1, 5, 0, 4, 19, 23, "2009" +831, 2, 2, 6, 5, 8, 24, 27, "Jan" +831, 2, 3, 7, 9, 10, 28, 29, "-" +831, 2, 4, 8, 11, 14, 30, 33, "Feb" +831, 2, 5, 9, 15, 16, 34, 35, ";" +831, 2, 6, 10, 17, 19, 36, 38, "19" +831, 2, 7, 11, 20, 21, 39, 40, "(" +831, 2, 8, 12, 22, 23, 41, 42, "1" +831, 2, 9, 13, 24, 25, 43, 44, ")" +831, 2, 10, 14, 26, 27, 45, 46, ":" +831, 2, 11, 15, 28, 30, 47, 49, "66" +831, 2, 12, 16, 31, 32, 50, 51, "-" +831, 2, 13, 17, 33, 35, 52, 54, "71" +831, 2, 14, 18, 36, 37, 55, 56, "." +831, 3, 1, 19, 0, 8, 57, 65, "Efficacy" +831, 3, 2, 20, 9, 11, 66, 68, "of" +831, 3, 3, 21, 12, 15, 69, 72, "the" +831, 3, 4, 22, 16, 21, 73, 78, "fixed" +831, 3, 5, 23, 22, 34, 79, 91, "combinations" +831, 3, 6, 24, 35, 37, 92, 94, "of" +831, 3, 7, 25, 38, 49, 95, 106, "bimatoprost" +831, 3, 8, 26, 50, 52, 107, 109, "or" +831, 3, 9, 27, 53, 64, 110, 121, "latanoprost" +831, 3, 10, 28, 65, 69, 122, 126, "plus" +831, 3, 11, 29, 70, 77, 127, 134, "timolol" +831, 3, 12, 30, 78, 80, 135, 137, "in" +831, 3, 13, 31, 81, 89, 138, 146, "patients" +831, 3, 14, 32, 90, 102, 147, 159, "uncontrolled" +831, 3, 15, 33, 103, 107, 160, 164, "with" +831, 3, 16, 34, 108, 121, 165, 178, "prostaglandin" +831, 3, 17, 35, 122, 133, 179, 190, "monotherapy" +831, 3, 18, 36, 134, 135, 191, 192, ":" +831, 3, 19, 37, 136, 137, 193, 194, "a" +831, 3, 20, 38, 138, 149, 195, 206, "multicenter" +831, 3, 21, 39, 150, 151, 207, 208, "," +831, 3, 22, 40, 152, 162, 209, 219, "randomized" +831, 3, 23, 41, 163, 164, 220, 221, "," +831, 3, 24, 42, 165, 177, 222, 234, "investigator" +831, 3, 25, 43, 178, 179, 235, 236, "-" +831, 3, 26, 44, 180, 186, 237, 243, "masked" +831, 3, 27, 45, 187, 188, 244, 245, "," +831, 3, 28, 46, 189, 197, 246, 254, "clinical" +831, 3, 29, 47, 198, 203, 255, 260, "study" +831, 3, 30, 48, 204, 205, 261, 262, "." +831, 4, 1, 49, 0, 10, 263, 273, "Centofanti" +831, 4, 2, 50, 11, 12, 274, 275, "M" +831, 4, 3, 51, 13, 14, 276, 277, "(" +831, 4, 4, 52, 15, 16, 278, 279, "1" +831, 4, 5, 53, 17, 18, 280, 281, ")" +831, 4, 6, 54, 19, 20, 282, 283, "," +831, 4, 7, 55, 21, 27, 284, 290, "Oddone" +831, 4, 8, 56, 28, 29, 291, 292, "F" +831, 4, 9, 57, 30, 31, 293, 294, "," +831, 4, 10, 58, 32, 40, 295, 303, "Vetrugno" +831, 4, 11, 59, 41, 42, 304, 305, "M" +831, 4, 12, 60, 43, 44, 306, 307, "," +831, 4, 13, 61, 45, 50, 308, 313, "Manni" +831, 4, 14, 62, 51, 52, 314, 315, "G" +831, 4, 15, 63, 53, 54, 316, 317, "," +831, 4, 16, 64, 55, 64, 318, 327, "Fogagnolo" +831, 4, 17, 65, 65, 66, 328, 329, "P" +831, 4, 18, 66, 67, 68, 330, 331, "," +831, 4, 19, 67, 69, 74, 332, 337, "Tanga" +831, 4, 20, 68, 75, 76, 338, 339, "L" +831, 4, 21, 69, 77, 78, 340, 341, "," +831, 4, 22, 70, 79, 86, 342, 349, "Ferreri" +831, 4, 23, 71, 87, 88, 350, 351, "P" +831, 4, 24, 72, 89, 90, 352, 353, "," +831, 4, 25, 73, 91, 99, 354, 362, "Rossetti" +831, 4, 26, 74, 100, 101, 363, 364, "L" +831, 4, 27, 75, 102, 103, 365, 366, "." +831, 4, 28, 76, 104, 110, 367, 373, "Author" +831, 4, 29, 77, 111, 122, 374, 385, "information" +831, 4, 30, 78, 123, 124, 386, 387, ":" +831, 4, 31, 79, 125, 126, 388, 389, "(" +831, 4, 32, 80, 127, 128, 390, 391, "1" +831, 4, 33, 81, 129, 130, 392, 393, ")" +831, 4, 34, 82, 131, 141, 394, 404, "Fondazione" +831, 4, 35, 83, 142, 143, 405, 406, "G" +831, 4, 36, 84, 144, 145, 407, 408, "." +831, 4, 37, 85, 146, 147, 409, 410, "B" +831, 4, 38, 86, 148, 149, 411, 412, "." +831, 5, 1, 87, 0, 6, 413, 419, "Bietti" +831, 5, 2, 88, 7, 8, 420, 421, "-" +831, 5, 3, 89, 9, 14, 422, 427, "IRCCS" +831, 5, 4, 90, 15, 16, 428, 429, "," +831, 5, 5, 91, 17, 21, 430, 434, "Roma" +831, 5, 6, 92, 22, 23, 435, 436, "," +831, 5, 7, 93, 24, 29, 437, 442, "Italy" +831, 5, 8, 94, 30, 31, 443, 444, "." +831, 6, 1, 95, 0, 5, 445, 450, "marco" +831, 6, 2, 96, 6, 7, 451, 452, "." +831, 6, 3, 97, 8, 18, 453, 463, "centofanti" +831, 6, 4, 98, 19, 20, 464, 465, "@" +831, 6, 5, 99, 21, 31, 466, 476, "fastwebnet" +831, 6, 6, 100, 32, 33, 477, 478, "." +831, 6, 7, 101, 34, 36, 479, 481, "it" +831, 6, 8, 102, 37, 44, 482, 489, "Comment" +831, 6, 9, 103, 45, 47, 490, 492, "in" +831, 6, 10, 104, 48, 51, 493, 496, "Eur" +831, 6, 11, 105, 52, 53, 497, 498, "J" +831, 6, 12, 106, 54, 64, 499, 509, "Ophthalmol" +831, 6, 13, 107, 65, 66, 510, 511, "." +831, 7, 1, 108, 0, 4, 512, 516, "2010" +831, 7, 2, 109, 5, 8, 517, 520, "Jan" +831, 7, 3, 110, 9, 10, 521, 522, "-" +831, 7, 4, 111, 11, 14, 523, 526, "Feb" +831, 7, 5, 112, 15, 16, 527, 528, ";" +831, 7, 6, 113, 17, 19, 529, 531, "20" +831, 7, 7, 114, 20, 21, 532, 533, "(" +831, 7, 8, 115, 22, 23, 534, 535, "1" +831, 7, 9, 116, 24, 25, 536, 537, ")" +831, 7, 10, 117, 26, 27, 538, 539, ":" +831, 7, 11, 118, 28, 31, 540, 543, "246" +831, 7, 12, 119, 32, 33, 544, 545, "-" +831, 7, 13, 120, 34, 35, 546, 547, "7" +831, 7, 14, 121, 36, 37, 548, 549, ";" +831, 7, 15, 122, 38, 44, 550, 556, "author" +831, 7, 16, 123, 45, 50, 557, 562, "reply" +831, 7, 17, 124, 51, 54, 563, 566, "247" +831, 7, 18, 125, 55, 56, 567, 568, "-" +831, 7, 19, 126, 57, 58, 569, 570, "8" +831, 7, 20, 127, 59, 60, 571, 572, "." +831, 8, 1, 128, 0, 7, 573, 580, "PURPOSE" +831, 8, 2, 129, 8, 9, 581, 582, ":" +831, 8, 3, 130, 10, 12, 583, 585, "To" +831, 8, 4, 131, 13, 20, 586, 593, "compare" +831, 8, 5, 132, 21, 24, 594, 597, "the" +831, 8, 6, 133, 25, 33, 598, 606, "efficacy" +831, 8, 7, 134, 34, 37, 607, 610, "and" +831, 8, 8, 135, 38, 50, 611, 623, "tolerability" +831, 8, 9, 136, 51, 53, 624, 626, "of" +831, 8, 10, 137, 54, 55, 627, 628, "a" +831, 8, 11, 138, 56, 60, 629, 633, "once" +831, 8, 12, 139, 61, 62, 634, 635, "-" +831, 8, 13, 140, 63, 68, 636, 641, "daily" +831, 8, 14, 141, 69, 76, 642, 649, "evening" +831, 8, 15, 142, 77, 81, 650, 654, "dose" +831, 8, 16, 143, 82, 84, 655, 657, "of" +831, 8, 17, 144, 85, 96, 658, 669, "bimatoprost" +831, 8, 18, 145, 97, 98, 670, 671, "/" +831, 8, 19, 146, 99, 106, 672, 679, "timolol" +831, 8, 20, 147, 107, 112, 680, 685, "fixed" +831, 8, 21, 148, 113, 124, 686, 697, "combination" +831, 8, 22, 149, 125, 126, 698, 699, "(" +831, 8, 23, 150, 127, 131, 700, 704, "BTFC" +831, 8, 24, 151, 132, 133, 705, 706, ")" +831, 8, 25, 152, 134, 138, 707, 711, "with" +831, 8, 26, 153, 139, 143, 712, 716, "that" +831, 8, 27, 154, 144, 146, 717, 719, "of" +831, 8, 28, 155, 147, 148, 720, 721, "a" +831, 8, 29, 156, 149, 153, 722, 726, "once" +831, 8, 30, 157, 154, 155, 727, 728, "-" +831, 8, 31, 158, 156, 161, 729, 734, "daily" +831, 8, 32, 159, 162, 169, 735, 742, "evening" +831, 8, 33, 160, 170, 174, 743, 747, "dose" +831, 8, 34, 161, 175, 177, 748, 750, "of" +831, 8, 35, 162, 178, 189, 751, 762, "latanoprost" +831, 8, 36, 163, 190, 191, 763, 764, "/" +831, 8, 37, 164, 192, 199, 765, 772, "timolol" +831, 8, 38, 165, 200, 205, 773, 778, "fixed" +831, 8, 39, 166, 206, 217, 779, 790, "combination" +831, 8, 40, 167, 218, 219, 791, 792, "(" +831, 8, 41, 168, 220, 224, 793, 797, "LTFC" +831, 8, 42, 169, 225, 226, 798, 799, ")" +831, 8, 43, 170, 227, 229, 800, 802, "in" +831, 8, 44, 171, 230, 238, 803, 811, "patients" +831, 8, 45, 172, 239, 242, 812, 815, "not" +831, 8, 46, 173, 243, 253, 816, 826, "controlled" +831, 8, 47, 174, 254, 258, 827, 831, "with" +831, 8, 48, 175, 259, 273, 832, 846, "prostaglandins" +831, 8, 49, 176, 274, 283, 847, 856, "analogues" +831, 8, 50, 177, 284, 295, 857, 868, "monotherapy" +831, 8, 51, 178, 296, 297, 869, 870, "." +831, 9, 1, 179, 0, 7, 871, 878, "METHODS" +831, 9, 2, 180, 8, 9, 879, 880, ":" +831, 9, 3, 181, 10, 11, 881, 882, "A" +831, 9, 4, 182, 12, 17, 883, 888, "total" +831, 9, 5, 183, 18, 20, 889, 891, "of" +831, 9, 6, 184, 21, 23, 892, 894, "82" +831, 9, 7, 185, 24, 32, 895, 903, "patients" +831, 9, 8, 186, 33, 35, 904, 906, "on" +831, 9, 9, 187, 36, 49, 907, 920, "prostaglandin" +831, 9, 10, 188, 50, 59, 921, 930, "analogues" +831, 9, 11, 189, 60, 71, 931, 942, "monotherapy" +831, 9, 12, 190, 72, 76, 943, 947, "were" +831, 9, 13, 191, 77, 85, 948, 956, "enrolled" +831, 9, 14, 192, 86, 88, 957, 959, "in" +831, 9, 15, 193, 89, 93, 960, 964, "this" +831, 9, 16, 194, 94, 105, 965, 976, "prospective" +831, 9, 17, 195, 106, 107, 977, 978, "," +831, 9, 18, 196, 108, 119, 979, 990, "multicenter" +831, 9, 19, 197, 120, 121, 991, 992, "," +831, 9, 20, 198, 122, 134, 993, 1005, "investigator" +831, 9, 21, 199, 135, 141, 1006, 1012, "masked" +831, 9, 22, 200, 142, 143, 1013, 1014, "," +831, 9, 23, 201, 144, 152, 1015, 1023, "clinical" +831, 9, 24, 202, 153, 158, 1024, 1029, "study" +831, 9, 25, 203, 159, 162, 1030, 1033, "and" +831, 9, 26, 204, 163, 167, 1034, 1038, "were" +831, 9, 27, 205, 168, 178, 1039, 1049, "randomized" +831, 9, 28, 206, 179, 181, 1050, 1052, "to" +831, 9, 29, 207, 182, 188, 1053, 1059, "either" +831, 9, 30, 208, 189, 193, 1060, 1064, "BTFC" +831, 9, 31, 209, 194, 195, 1065, 1066, "(" +831, 9, 32, 210, 196, 197, 1067, 1068, "n" +831, 9, 33, 211, 198, 199, 1069, 1070, "=" +831, 9, 34, 212, 200, 202, 1071, 1073, "47" +831, 9, 35, 213, 203, 204, 1074, 1075, ")" +831, 9, 36, 214, 205, 207, 1076, 1078, "or" +831, 9, 37, 215, 208, 212, 1079, 1083, "LTFC" +831, 9, 38, 216, 213, 214, 1084, 1085, "(" +831, 9, 39, 217, 215, 216, 1086, 1087, "n" +831, 9, 40, 218, 217, 218, 1088, 1089, "=" +831, 9, 41, 219, 219, 221, 1090, 1092, "35" +831, 9, 42, 220, 222, 223, 1093, 1094, ")" +831, 9, 43, 221, 224, 231, 1095, 1102, "topical" +831, 9, 44, 222, 232, 239, 1103, 1110, "therapy" +831, 9, 45, 223, 240, 244, 1111, 1115, "once" +831, 9, 46, 224, 245, 247, 1116, 1118, "at" +831, 9, 47, 225, 248, 253, 1119, 1124, "night" +831, 9, 48, 226, 254, 257, 1125, 1128, "for" +831, 9, 49, 227, 258, 260, 1129, 1131, "12" +831, 9, 50, 228, 261, 266, 1132, 1137, "weeks" +831, 9, 51, 229, 267, 268, 1138, 1139, "." +831, 10, 1, 230, 0, 3, 1140, 1143, "The" +831, 10, 2, 231, 4, 11, 1144, 1151, "primary" +831, 10, 3, 232, 12, 20, 1152, 1160, "endpoint" +831, 10, 4, 233, 21, 23, 1161, 1163, "of" +831, 10, 5, 234, 24, 27, 1164, 1167, "the" +831, 10, 6, 235, 28, 33, 1168, 1173, "study" +831, 10, 7, 236, 34, 37, 1174, 1177, "was" +831, 10, 8, 237, 38, 40, 1178, 1180, "to" +831, 10, 9, 238, 41, 48, 1181, 1188, "compare" +831, 10, 10, 239, 49, 52, 1189, 1192, "the" +831, 10, 11, 240, 53, 57, 1193, 1197, "mean" +831, 10, 12, 241, 58, 63, 1198, 1203, "daily" +831, 10, 13, 242, 64, 75, 1204, 1215, "intraocular" +831, 10, 14, 243, 76, 84, 1216, 1224, "pressure" +831, 10, 15, 244, 85, 86, 1225, 1226, "(" +831, 10, 16, 245, 87, 90, 1227, 1230, "IOP" +831, 10, 17, 246, 91, 92, 1231, 1232, ")" +831, 10, 18, 247, 93, 102, 1233, 1242, "reduction" +831, 10, 19, 248, 103, 107, 1243, 1247, "from" +831, 10, 20, 249, 108, 116, 1248, 1256, "baseline" +831, 10, 21, 250, 117, 124, 1257, 1264, "between" +831, 10, 22, 251, 125, 128, 1265, 1268, "the" +831, 10, 23, 252, 129, 132, 1269, 1272, "two" +831, 10, 24, 253, 133, 142, 1273, 1282, "treatment" +831, 10, 25, 254, 143, 147, 1283, 1287, "arms" +831, 10, 26, 255, 148, 149, 1288, 1289, "." +831, 11, 1, 256, 0, 9, 1290, 1299, "Secondary" +831, 11, 2, 257, 10, 19, 1300, 1309, "endpoints" +831, 11, 3, 258, 20, 28, 1310, 1318, "included" +831, 11, 4, 259, 29, 32, 1319, 1322, "the" +831, 11, 5, 260, 33, 37, 1323, 1327, "mean" +831, 11, 6, 261, 38, 43, 1328, 1333, "daily" +831, 11, 7, 262, 44, 47, 1334, 1337, "IOP" +831, 11, 8, 263, 48, 50, 1338, 1340, "at" +831, 11, 9, 264, 51, 52, 1341, 1342, "1" +831, 11, 10, 265, 53, 56, 1343, 1346, "and" +831, 11, 11, 266, 57, 58, 1347, 1348, "3" +831, 11, 12, 267, 59, 65, 1349, 1355, "months" +831, 11, 13, 268, 66, 74, 1356, 1364, "compared" +831, 11, 14, 269, 75, 77, 1365, 1367, "to" +831, 11, 15, 270, 78, 86, 1368, 1376, "baseline" +831, 11, 16, 271, 87, 90, 1377, 1380, "and" +831, 11, 17, 272, 91, 94, 1381, 1384, "the" +831, 11, 18, 273, 95, 105, 1385, 1395, "percentage" +831, 11, 19, 274, 106, 108, 1396, 1398, "of" +831, 11, 20, 275, 109, 117, 1399, 1407, "patients" +831, 11, 21, 276, 118, 125, 1408, 1415, "showing" +831, 11, 22, 277, 126, 127, 1416, 1417, "a" +831, 11, 23, 278, 128, 132, 1418, 1422, "mean" +831, 11, 24, 279, 133, 136, 1423, 1426, "IOP" +831, 11, 25, 280, 137, 146, 1427, 1436, "reduction" +831, 11, 26, 281, 147, 151, 1437, 1441, "from" +831, 11, 27, 282, 152, 160, 1442, 1450, "baseline" +831, 11, 28, 283, 161, 168, 1451, 1458, "greater" +831, 11, 29, 284, 169, 173, 1459, 1463, "than" +831, 11, 30, 285, 174, 176, 1464, 1466, "or" +831, 11, 31, 286, 177, 182, 1467, 1472, "equal" +831, 11, 32, 287, 183, 185, 1473, 1475, "to" +831, 11, 33, 288, 186, 188, 1476, 1478, "15" +831, 11, 34, 289, 189, 190, 1479, 1480, "%" +831, 11, 35, 290, 191, 193, 1481, 1483, "or" +831, 11, 36, 291, 194, 196, 1484, 1486, "20" +831, 11, 37, 292, 197, 198, 1487, 1488, "%" +831, 11, 38, 293, 199, 200, 1489, 1490, "." +831, 12, 1, 294, 0, 7, 1491, 1498, "RESULTS" +831, 12, 2, 295, 8, 9, 1499, 1500, ":" +831, 12, 3, 296, 10, 14, 1501, 1505, "Mean" +831, 12, 4, 297, 15, 18, 1506, 1509, "IOP" +831, 12, 5, 298, 19, 21, 1510, 1512, "at" +831, 12, 6, 299, 22, 30, 1513, 1521, "baseline" +831, 12, 7, 300, 31, 34, 1522, 1525, "was" +831, 12, 8, 301, 35, 37, 1526, 1528, "22" +831, 12, 9, 302, 38, 39, 1529, 1530, "." +831, 12, 10, 303, 40, 41, 1531, 1532, "7" +831, 12, 11, 304, 42, 43, 1533, 1534, "+" +831, 12, 12, 305, 44, 45, 1535, 1536, "/" +831, 12, 13, 306, 46, 47, 1537, 1538, "-" +831, 12, 14, 307, 48, 49, 1539, 1540, "2" +831, 12, 15, 308, 50, 51, 1541, 1542, "." +831, 12, 16, 309, 52, 53, 1543, 1544, "0" +831, 12, 17, 310, 54, 57, 1545, 1548, "and" +831, 12, 18, 311, 58, 60, 1549, 1551, "22" +831, 12, 19, 312, 61, 62, 1552, 1553, "." +831, 12, 20, 313, 63, 64, 1554, 1555, "1" +831, 12, 21, 314, 65, 66, 1556, 1557, "+" +831, 12, 22, 315, 67, 68, 1558, 1559, "/" +831, 12, 23, 316, 69, 70, 1560, 1561, "-" +831, 12, 24, 317, 71, 72, 1562, 1563, "2" +831, 12, 25, 318, 73, 74, 1564, 1565, "." +831, 12, 26, 319, 75, 76, 1566, 1567, "6" +831, 12, 27, 320, 77, 81, 1568, 1572, "mmHg" +831, 12, 28, 321, 82, 84, 1573, 1575, "in" +831, 12, 29, 322, 85, 88, 1576, 1579, "the" +831, 12, 30, 323, 89, 93, 1580, 1584, "BTFC" +831, 12, 31, 324, 94, 97, 1585, 1588, "and" +831, 12, 32, 325, 98, 102, 1589, 1593, "LTFC" +831, 12, 33, 326, 103, 109, 1594, 1600, "groups" +831, 12, 34, 327, 110, 111, 1601, 1602, "," +831, 12, 35, 328, 112, 124, 1603, 1615, "respectively" +831, 12, 36, 329, 125, 126, 1616, 1617, "(" +831, 12, 37, 330, 127, 128, 1618, 1619, "p" +831, 12, 38, 331, 129, 130, 1620, 1621, "=" +831, 12, 39, 332, 131, 132, 1622, 1623, "0" +831, 12, 40, 333, 133, 134, 1624, 1625, "." +831, 12, 41, 334, 135, 137, 1626, 1628, "23" +831, 12, 42, 335, 138, 139, 1629, 1630, ")" +831, 12, 43, 336, 140, 141, 1631, 1632, "." +831, 13, 1, 337, 0, 4, 1633, 1637, "Both" +831, 13, 2, 338, 5, 15, 1638, 1648, "treatments" +831, 13, 3, 339, 16, 20, 1649, 1653, "were" +831, 13, 4, 340, 21, 30, 1654, 1663, "effective" +831, 13, 5, 341, 31, 33, 1664, 1666, "in" +831, 13, 6, 342, 34, 42, 1667, 1675, "reducing" +831, 13, 7, 343, 43, 46, 1676, 1679, "the" +831, 13, 8, 344, 47, 50, 1680, 1683, "IOP" +831, 13, 9, 345, 51, 55, 1684, 1688, "from" +831, 13, 10, 346, 56, 64, 1689, 1697, "baseline" +831, 13, 11, 347, 65, 66, 1698, 1699, "." +831, 14, 1, 348, 0, 3, 1700, 1703, "The" +831, 14, 2, 349, 4, 8, 1704, 1708, "mean" +831, 14, 3, 350, 9, 12, 1709, 1712, "IOP" +831, 14, 4, 351, 13, 22, 1713, 1722, "reduction" +831, 14, 5, 352, 23, 26, 1723, 1726, "was" +831, 14, 6, 353, 27, 40, 1727, 1740, "significantly" +831, 14, 7, 354, 41, 48, 1741, 1748, "greater" +831, 14, 8, 355, 49, 51, 1749, 1751, "in" +831, 14, 9, 356, 52, 55, 1752, 1755, "the" +831, 14, 10, 357, 56, 60, 1756, 1760, "BTFC" +831, 14, 11, 358, 61, 66, 1761, 1766, "group" +831, 14, 12, 359, 67, 71, 1767, 1771, "than" +831, 14, 13, 360, 72, 74, 1772, 1774, "in" +831, 14, 14, 361, 75, 78, 1775, 1778, "the" +831, 14, 15, 362, 79, 83, 1779, 1783, "LTFC" +831, 14, 16, 363, 84, 89, 1784, 1789, "group" +831, 14, 17, 364, 90, 91, 1790, 1791, "(" +831, 14, 18, 365, 92, 93, 1792, 1793, "-" +831, 14, 19, 366, 94, 96, 1794, 1796, "21" +831, 14, 20, 367, 97, 98, 1797, 1798, "." +831, 14, 21, 368, 99, 100, 1799, 1800, "4" +831, 14, 22, 369, 101, 102, 1801, 1802, "%" +831, 14, 23, 370, 103, 105, 1803, 1805, "vs" +831, 14, 24, 371, 106, 107, 1806, 1807, "-" +831, 14, 25, 372, 108, 110, 1808, 1810, "13" +831, 14, 26, 373, 111, 112, 1811, 1812, "." +831, 14, 27, 374, 113, 114, 1813, 1814, "7" +831, 14, 28, 375, 115, 116, 1815, 1816, "%" +831, 14, 29, 376, 117, 118, 1817, 1818, "," +831, 14, 30, 377, 119, 120, 1819, 1820, "p" +831, 14, 31, 378, 121, 122, 1821, 1822, "<" +831, 14, 32, 379, 123, 124, 1823, 1824, "0" +831, 14, 33, 380, 125, 126, 1825, 1826, "." +831, 14, 34, 381, 127, 130, 1827, 1830, "001" +831, 14, 35, 382, 131, 132, 1831, 1832, ")" +831, 14, 36, 383, 133, 134, 1833, 1834, "." +831, 15, 1, 384, 0, 1, 1835, 1836, "A" +831, 15, 2, 385, 2, 8, 1837, 1843, "higher" +831, 15, 3, 386, 9, 19, 1844, 1854, "percentage" +831, 15, 4, 387, 20, 22, 1855, 1857, "of" +831, 15, 5, 388, 23, 31, 1858, 1866, "patients" +831, 15, 6, 389, 32, 34, 1867, 1869, "in" +831, 15, 7, 390, 35, 38, 1870, 1873, "the" +831, 15, 8, 391, 39, 43, 1874, 1878, "BTFC" +831, 15, 9, 392, 44, 49, 1879, 1884, "group" +831, 15, 10, 393, 50, 56, 1885, 1891, "showed" +831, 15, 11, 394, 57, 58, 1892, 1893, "a" +831, 15, 12, 395, 59, 63, 1894, 1898, "mean" +831, 15, 13, 396, 64, 67, 1899, 1902, "IOP" +831, 15, 14, 397, 68, 77, 1903, 1912, "reduction" +831, 15, 15, 398, 78, 82, 1913, 1917, "from" +831, 15, 16, 399, 83, 91, 1918, 1926, "baseline" +831, 15, 17, 400, 92, 93, 1927, 1928, ">" +831, 15, 18, 401, 94, 96, 1929, 1931, "or" +831, 15, 19, 402, 97, 98, 1932, 1933, "=" +831, 15, 20, 403, 99, 101, 1934, 1936, "15" +831, 15, 21, 404, 102, 103, 1937, 1938, "%" +831, 15, 22, 405, 104, 105, 1939, 1940, "(" +831, 15, 23, 406, 106, 108, 1941, 1943, "72" +831, 15, 24, 407, 109, 110, 1944, 1945, "." +831, 15, 25, 408, 111, 112, 1946, 1947, "3" +831, 15, 26, 409, 113, 114, 1948, 1949, "%" +831, 15, 27, 410, 115, 117, 1950, 1952, "vs" +831, 15, 28, 411, 118, 120, 1953, 1955, "40" +831, 15, 29, 412, 121, 122, 1956, 1957, "." +831, 15, 30, 413, 123, 124, 1958, 1959, "0" +831, 15, 31, 414, 125, 126, 1960, 1961, "%" +831, 15, 32, 415, 127, 128, 1962, 1963, ")" +831, 15, 33, 416, 129, 132, 1964, 1967, "and" +831, 15, 34, 417, 133, 134, 1968, 1969, ">" +831, 15, 35, 418, 135, 137, 1970, 1972, "or" +831, 15, 36, 419, 138, 139, 1973, 1974, "=" +831, 15, 37, 420, 140, 142, 1975, 1977, "20" +831, 15, 38, 421, 143, 144, 1978, 1979, "%" +831, 15, 39, 422, 145, 146, 1980, 1981, "(" +831, 15, 40, 423, 147, 149, 1982, 1984, "61" +831, 15, 41, 424, 150, 151, 1985, 1986, "." +831, 15, 42, 425, 152, 153, 1987, 1988, "7" +831, 15, 43, 426, 154, 155, 1989, 1990, "%" +831, 15, 44, 427, 156, 158, 1991, 1993, "vs" +831, 15, 45, 428, 159, 161, 1994, 1996, "17" +831, 15, 46, 429, 162, 163, 1997, 1998, "." +831, 15, 47, 430, 164, 165, 1999, 2000, "1" +831, 15, 48, 431, 166, 167, 2001, 2002, "%" +831, 15, 49, 432, 168, 169, 2003, 2004, ")" +831, 15, 50, 433, 170, 178, 2005, 2013, "compared" +831, 15, 51, 434, 179, 181, 2014, 2016, "to" +831, 15, 52, 435, 182, 190, 2017, 2025, "patients" +831, 15, 53, 436, 191, 193, 2026, 2028, "in" +831, 15, 54, 437, 194, 197, 2029, 2032, "the" +831, 15, 55, 438, 198, 202, 2033, 2037, "LTFC" +831, 15, 56, 439, 203, 208, 2038, 2043, "group" +831, 15, 57, 440, 209, 210, 2044, 2045, "." +831, 16, 1, 441, 0, 11, 2046, 2057, "CONCLUSIONS" +831, 16, 2, 442, 12, 13, 2058, 2059, ":" +831, 16, 3, 443, 14, 18, 2060, 2064, "Both" +831, 16, 4, 444, 19, 23, 2065, 2069, "BTFC" +831, 16, 5, 445, 24, 27, 2070, 2073, "and" +831, 16, 6, 446, 28, 32, 2074, 2078, "LTFC" +831, 16, 7, 447, 33, 37, 2079, 2083, "were" +831, 16, 8, 448, 38, 42, 2084, 2088, "more" +831, 16, 9, 449, 43, 52, 2089, 2098, "effective" +831, 16, 10, 450, 53, 59, 2099, 2105, "versus" +831, 16, 11, 451, 60, 63, 2106, 2109, "the" +831, 16, 12, 452, 64, 75, 2110, 2121, "monotherapy" +831, 16, 13, 453, 76, 80, 2122, 2126, "with" +831, 16, 14, 454, 81, 94, 2127, 2140, "prostaglandin" +831, 16, 15, 455, 95, 104, 2141, 2150, "analogues" +831, 16, 16, 456, 105, 106, 2151, 2152, "." +831, 17, 1, 457, 0, 4, 2153, 2157, "BTFC" +831, 17, 2, 458, 5, 17, 2158, 2170, "demonstrated" +831, 17, 3, 459, 18, 24, 2171, 2177, "higher" +831, 17, 4, 460, 25, 36, 2178, 2189, "performance" +831, 17, 5, 461, 37, 41, 2190, 2194, "than" +831, 17, 6, 462, 42, 46, 2195, 2199, "LTFC" +831, 17, 7, 463, 47, 49, 2200, 2202, "in" +831, 17, 8, 464, 50, 55, 2203, 2208, "terms" +831, 17, 9, 465, 56, 58, 2209, 2211, "of" +831, 17, 10, 466, 59, 67, 2212, 2220, "relative" +831, 17, 11, 467, 68, 71, 2221, 2224, "IOP" +831, 17, 12, 468, 72, 81, 2225, 2234, "reduction" +831, 17, 13, 469, 82, 83, 2235, 2236, "." +831, 18, 1, 470, 0, 4, 2237, 2241, "PMID" +831, 18, 2, 471, 5, 6, 2242, 2243, ":" +831, 18, 3, 472, 7, 15, 2244, 2252, "19123151" +831, 18, 4, 473, 16, 17, 2253, 2254, "[" +831, 18, 5, 474, 18, 25, 2255, 2262, "Indexed" +831, 18, 6, 475, 26, 29, 2263, 2266, "for" +831, 18, 7, 476, 30, 37, 2267, 2274, "MEDLINE" +831, 18, 8, 477, 38, 39, 2275, 2276, "]" diff --git a/data/gl 19123151_admin.annodb b/data/gl 19123151_admin.annodb new file mode 100644 index 0000000..55a45ff --- /dev/null +++ b/data/gl 19123151_admin.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Eur J Ophthalmol", "", " \"Eur J Ophthalmol\"." +1, PublicationYear, 19, 23, "2009", "", " \"2009\"." +2, Title, 57, 260, "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study", "", " \"Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study\"." +3, Bimatoprost, 95, 106, "bimatoprost", "", +4, Latanoprost, 110, 121, "latanoprost", "", +5, Timolol, 127, 134, "timolol", "", +6, Precondition, 147, 190, "uncontrolled with prostaglandin monotherapy", "", " \"uncontrolled with prostaglandin monotherapy\"." +92855, ProstaglandinAnalogs, 165, 178, "prostaglandin", "", +7, Multicenter, 195, 206, "multicenter", "", " ." +8, Randomized, 209, 219, "randomized", "", " ." +81, Blind, 237, 243, "masked", "", " ." +10, Author, 263, 275, "Centofanti M", "", " \"Centofanti M\"." +11, Author, 284, 292, "Oddone F", "", " \"Oddone F\"." +12, Author, 295, 305, "Vetrugno M", "", " \"Vetrugno M\"." +13, Author, 308, 315, "Manni G", "", " \"Manni G\"." +14, Author, 318, 329, "Fogagnolo P", "", " \"Fogagnolo P\"." +15, Author, 332, 339, "Tanga L", "", " \"Tanga L\"." +16, Author, 342, 351, "Ferreri P", "", " \"Ferreri P\"." +17, Author, 354, 364, "Rossetti L", "", " \"Rossetti L\"." +18, Italy, 437, 442, "Italy", "", " ." +26778, PublicationYear, 512, 516, "2010", "", +19, ObjectiveDescription, 583, 706, "To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )", "", " \"To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )\"." +21, Frequency, 629, 641, "once - daily", "", " \"once - daily\"." +22, Bedtime, 642, 649, "evening", "", " ." +106184, Bima/TimFC, 658, 697, "bimatoprost / timolol fixed combination", "", " ." +23, Bimatoprost, 658, 669, "bimatoprost", "", +24, Timolol, 672, 679, "timolol", "", +106186, Bima/TimFC, 700, 704, "BTFC", "", +20, ObjectiveDescription, 707, 870, "with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy .", "", " \"with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy .\"." +26, Frequency, 722, 734, "once - daily", "", " \"once - daily\"." +27, Bedtime, 735, 742, "evening", "", " ." +28, Latanoprost, 751, 762, "latanoprost", "", +106191, Lat/TimFC, 751, 790, "latanoprost / timolol fixed combination", "", " ." +29, Timolol, 765, 772, "timolol", "", +106192, Lat/TimFC, 793, 797, "LTFC", "", +31, Precondition, 812, 868, "not controlled with prostaglandins analogues monotherapy", "", " \"not controlled with prostaglandins analogues monotherapy\"." +92854, ProstaglandinAnalogs, 832, 856, "prostaglandins analogues", "", +32, NumberPatientsCT, 892, 894, "82", "", " \"82\"." +92852, ProstaglandinAnalogs, 907, 930, "prostaglandin analogues", "", +36963, Prospective, 965, 976, "prospective", "", " ." +34, Multicenter, 979, 990, "multicenter", "", +105, Blind, 1006, 1012, "masked", "", +36, Randomized, 1039, 1049, "randomized", "", +106200, Bima/TimFC, 1060, 1064, "BTFC", "", +37, NumberPatientsArm, 1071, 1073, "47", "", " \"47\"." +106193, Lat/TimFC, 1079, 1083, "LTFC", "", +38, NumberPatientsArm, 1090, 1092, "35", "", " \"35\"." +36967, Topic, 1095, 1102, "topical", "", +113, Frequency, 1111, 1115, "once", "", +114, RelativeTime, 1116, 1124, "at night", "", +39, Duration, 1129, 1137, "12 weeks", "", " \"12 weeks\"." +40, Mean, 1193, 1197, "mean", "", +41, IOP, 1204, 1224, "intraocular pressure", "", +42, IOP, 1227, 1230, "IOP", "", +43, Mean, 1323, 1327, "mean", "", +44, IOP, 1334, 1337, "IOP", "", +26785, TimePoint, 1341, 1355, "1 and 3 months", "", +36964, TimePoint, 1347, 1355, "3 months", "", +45, Mean, 1418, 1422, "mean", "", " . . . ." +36971, EndPointDescription, 1418, 1480, "mean IOP reduction from baseline greater than or equal to 15 %", "", " . ." +36972, EndPointDescription, 1418, 1488, "mean IOP reduction from baseline greater than or equal to 15 % or 20 %", "", " . ." +46, IOP, 1423, 1426, "IOP", "", +49, Mean, 1501, 1505, "Mean", "", " . ." +50, IOP, 1506, 1509, "IOP", "", " . ." +36965, TimePoint, 1513, 1521, "baseline", "", +51, BaseLineValue, 1526, 1532, "22 . 7", "", " \"22 . 7\"." +130, SdDevBL, 1539, 1544, "2 . 0", "", " \"2 . 0\"." +53, BaseLineValue, 1549, 1555, "22 . 1", "", " \"22 . 1\"." +132, SdDevBL, 1562, 1567, "2 . 6", "", " \"2 . 6\"." +55, mmHg, 1568, 1572, "mmHg", "", " . . ." +106199, Bima/TimFC, 1580, 1584, "BTFC", "", +106194, Lat/TimFC, 1589, 1593, "LTFC", "", +136, PvalueDiff, 1618, 1628, "p = 0 . 23", "", +138, ObservedResult, 1633, 1697, "Both treatments were effective in reducing the IOP from baseline", "", " \"Both treatments were effective in reducing the IOP from baseline\". \"Both treatments were effective in reducing the IOP from baseline\"." +57, IOP, 1680, 1683, "IOP", "", +58, Mean, 1704, 1708, "mean", "", +59, IOP, 1709, 1712, "IOP", "", +106187, Bima/TimFC, 1756, 1760, "BTFC", "", +106195, Lat/TimFC, 1779, 1783, "LTFC", "", +60, RelativeReduction, 1794, 1800, "21 . 4", "", " \"21 . 4\"." +61, RelativeReduction, 1808, 1814, "13 . 7", "", " \"13 . 7\"." +145, PvalueDiff, 1819, 1830, "p < 0 . 001", "", " \"p < 0 . 001\"." +106188, Bima/TimFC, 1874, 1878, "BTFC", "", +63, Mean, 1894, 1898, "mean", "", +36968, EndPointDescription, 1894, 1938, "mean IOP reduction from baseline > or = 15 %", "", +64, IOP, 1899, 1902, "IOP", "", +65, PercentageAffected, 1941, 1947, "72 . 3", "", " \"72 . 3\"." +66, PercentageAffected, 1953, 1959, "40 . 0", "", " \"40 . 0\"." +36969, EndPointDescription, 1968, 1979, "> or = 20 %", "", +67, PercentageAffected, 1982, 1988, "61 . 7", "", " \"61 . 7\"." +68, PercentageAffected, 1994, 2000, "17 . 1", "", " \"17 . 1\"." +106196, Lat/TimFC, 2033, 2037, "LTFC", "", +69, ConclusionComment, 2060, 2152, "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues .", "", " \"Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues .\"." +106189, Bima/TimFC, 2065, 2069, "BTFC", "", +106197, Lat/TimFC, 2074, 2078, "LTFC", "", +92853, ProstaglandinAnalogs, 2127, 2150, "prostaglandin analogues", "", +70, ConclusionComment, 2153, 2236, "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction .", "", " \"BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction .\"." +106190, Bima/TimFC, 2153, 2157, "BTFC", "", +106198, Lat/TimFC, 2195, 2199, "LTFC", "", +71, IOP, 2221, 2224, "IOP", "", +72, PMID, 2244, 2252, "19123151", "", " \"19123151\"." diff --git a/data/gl 19123151_admin.n-triples b/data/gl 19123151_admin.n-triples new file mode 100644 index 0000000..9ac4828 --- /dev/null +++ b/data/gl 19123151_admin.n-triples @@ -0,0 +1,147 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study" . + "Centofanti M" . + "2009" . + "Eur J Ophthalmol" . + "19123151" . + . + "Oddone F" . + "Vetrugno M" . + "Manni G" . + "Fogagnolo P" . + "Tanga L" . + "Ferreri P" . + "Rossetti L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )" . + "82" . + "12 weeks" . + . + . + . + "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues ." . + . + . + . + . + . + "with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy ." . + . + . + . + "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction ." . + . +# RDF export of group: Population + . + "Population" . + "uncontrolled with prostaglandin monotherapy" . + . + . + . + "not controlled with prostaglandins analogues monotherapy" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_15" . + . + . + . + . + . + . + . + "Endpoint_20" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + "47" . + . + . + . + . + . + . + "Arm_LTFC" . + "35" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + "once - daily" . + . + . + "Intervention_LTFC" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_LTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_BT" . + . + "22 . 7" . + "2 . 0" . + "21 . 4" . + "Both treatments were effective in reducing the IOP from baseline" . + . + "Outcome_iop_LT" . + . + "22 . 1" . + "2 . 6" . + "13 . 7" . + "Both treatments were effective in reducing the IOP from baseline" . + . + "Outcome_15_BT" . + . + "72 . 3" . + . + "Outcome_15_LT" . + . + "40 . 0" . + . + "Outcome_20_BT" . + . + "61 . 7" . + . + "Outcome_20_LT" . + . + "17 . 1" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19123151_export.csv b/data/gl 19123151_export.csv new file mode 100644 index 0000000..992ac86 --- /dev/null +++ b/data/gl 19123151_export.csv @@ -0,0 +1,478 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +447, 1, 1, 1, 0, 3, 0, 3, "Eur" +447, 1, 2, 2, 4, 5, 4, 5, "J" +447, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +447, 1, 4, 4, 17, 18, 17, 18, "." +447, 2, 1, 5, 0, 4, 19, 23, "2009" +447, 2, 2, 6, 5, 8, 24, 27, "Jan" +447, 2, 3, 7, 9, 10, 28, 29, "-" +447, 2, 4, 8, 11, 14, 30, 33, "Feb" +447, 2, 5, 9, 15, 16, 34, 35, ";" +447, 2, 6, 10, 17, 19, 36, 38, "19" +447, 2, 7, 11, 20, 21, 39, 40, "(" +447, 2, 8, 12, 22, 23, 41, 42, "1" +447, 2, 9, 13, 24, 25, 43, 44, ")" +447, 2, 10, 14, 26, 27, 45, 46, ":" +447, 2, 11, 15, 28, 30, 47, 49, "66" +447, 2, 12, 16, 31, 32, 50, 51, "-" +447, 2, 13, 17, 33, 35, 52, 54, "71" +447, 2, 14, 18, 36, 37, 55, 56, "." +447, 3, 1, 19, 0, 8, 57, 65, "Efficacy" +447, 3, 2, 20, 9, 11, 66, 68, "of" +447, 3, 3, 21, 12, 15, 69, 72, "the" +447, 3, 4, 22, 16, 21, 73, 78, "fixed" +447, 3, 5, 23, 22, 34, 79, 91, "combinations" +447, 3, 6, 24, 35, 37, 92, 94, "of" +447, 3, 7, 25, 38, 49, 95, 106, "bimatoprost" +447, 3, 8, 26, 50, 52, 107, 109, "or" +447, 3, 9, 27, 53, 64, 110, 121, "latanoprost" +447, 3, 10, 28, 65, 69, 122, 126, "plus" +447, 3, 11, 29, 70, 77, 127, 134, "timolol" +447, 3, 12, 30, 78, 80, 135, 137, "in" +447, 3, 13, 31, 81, 89, 138, 146, "patients" +447, 3, 14, 32, 90, 102, 147, 159, "uncontrolled" +447, 3, 15, 33, 103, 107, 160, 164, "with" +447, 3, 16, 34, 108, 121, 165, 178, "prostaglandin" +447, 3, 17, 35, 122, 133, 179, 190, "monotherapy" +447, 3, 18, 36, 134, 135, 191, 192, ":" +447, 3, 19, 37, 136, 137, 193, 194, "a" +447, 3, 20, 38, 138, 149, 195, 206, "multicenter" +447, 3, 21, 39, 150, 151, 207, 208, "," +447, 3, 22, 40, 152, 162, 209, 219, "randomized" +447, 3, 23, 41, 163, 164, 220, 221, "," +447, 3, 24, 42, 165, 177, 222, 234, "investigator" +447, 3, 25, 43, 178, 179, 235, 236, "-" +447, 3, 26, 44, 180, 186, 237, 243, "masked" +447, 3, 27, 45, 187, 188, 244, 245, "," +447, 3, 28, 46, 189, 197, 246, 254, "clinical" +447, 3, 29, 47, 198, 203, 255, 260, "study" +447, 3, 30, 48, 204, 205, 261, 262, "." +447, 4, 1, 49, 0, 10, 263, 273, "Centofanti" +447, 4, 2, 50, 11, 12, 274, 275, "M" +447, 4, 3, 51, 13, 14, 276, 277, "(" +447, 4, 4, 52, 15, 16, 278, 279, "1" +447, 4, 5, 53, 17, 18, 280, 281, ")" +447, 4, 6, 54, 19, 20, 282, 283, "," +447, 4, 7, 55, 21, 27, 284, 290, "Oddone" +447, 4, 8, 56, 28, 29, 291, 292, "F" +447, 4, 9, 57, 30, 31, 293, 294, "," +447, 4, 10, 58, 32, 40, 295, 303, "Vetrugno" +447, 4, 11, 59, 41, 42, 304, 305, "M" +447, 4, 12, 60, 43, 44, 306, 307, "," +447, 4, 13, 61, 45, 50, 308, 313, "Manni" +447, 4, 14, 62, 51, 52, 314, 315, "G" +447, 4, 15, 63, 53, 54, 316, 317, "," +447, 4, 16, 64, 55, 64, 318, 327, "Fogagnolo" +447, 4, 17, 65, 65, 66, 328, 329, "P" +447, 4, 18, 66, 67, 68, 330, 331, "," +447, 4, 19, 67, 69, 74, 332, 337, "Tanga" +447, 4, 20, 68, 75, 76, 338, 339, "L" +447, 4, 21, 69, 77, 78, 340, 341, "," +447, 4, 22, 70, 79, 86, 342, 349, "Ferreri" +447, 4, 23, 71, 87, 88, 350, 351, "P" +447, 4, 24, 72, 89, 90, 352, 353, "," +447, 4, 25, 73, 91, 99, 354, 362, "Rossetti" +447, 4, 26, 74, 100, 101, 363, 364, "L" +447, 4, 27, 75, 102, 103, 365, 366, "." +447, 4, 28, 76, 104, 110, 367, 373, "Author" +447, 4, 29, 77, 111, 122, 374, 385, "information" +447, 4, 30, 78, 123, 124, 386, 387, ":" +447, 4, 31, 79, 125, 126, 388, 389, "(" +447, 4, 32, 80, 127, 128, 390, 391, "1" +447, 4, 33, 81, 129, 130, 392, 393, ")" +447, 4, 34, 82, 131, 141, 394, 404, "Fondazione" +447, 4, 35, 83, 142, 143, 405, 406, "G" +447, 4, 36, 84, 144, 145, 407, 408, "." +447, 4, 37, 85, 146, 147, 409, 410, "B" +447, 4, 38, 86, 148, 149, 411, 412, "." +447, 5, 1, 87, 0, 6, 413, 419, "Bietti" +447, 5, 2, 88, 7, 8, 420, 421, "-" +447, 5, 3, 89, 9, 14, 422, 427, "IRCCS" +447, 5, 4, 90, 15, 16, 428, 429, "," +447, 5, 5, 91, 17, 21, 430, 434, "Roma" +447, 5, 6, 92, 22, 23, 435, 436, "," +447, 5, 7, 93, 24, 29, 437, 442, "Italy" +447, 5, 8, 94, 30, 31, 443, 444, "." +447, 6, 1, 95, 0, 5, 445, 450, "marco" +447, 6, 2, 96, 6, 7, 451, 452, "." +447, 6, 3, 97, 8, 18, 453, 463, "centofanti" +447, 6, 4, 98, 19, 20, 464, 465, "@" +447, 6, 5, 99, 21, 31, 466, 476, "fastwebnet" +447, 6, 6, 100, 32, 33, 477, 478, "." +447, 6, 7, 101, 34, 36, 479, 481, "it" +447, 6, 8, 102, 37, 44, 482, 489, "Comment" +447, 6, 9, 103, 45, 47, 490, 492, "in" +447, 6, 10, 104, 48, 51, 493, 496, "Eur" +447, 6, 11, 105, 52, 53, 497, 498, "J" +447, 6, 12, 106, 54, 64, 499, 509, "Ophthalmol" +447, 6, 13, 107, 65, 66, 510, 511, "." +447, 7, 1, 108, 0, 4, 512, 516, "2010" +447, 7, 2, 109, 5, 8, 517, 520, "Jan" +447, 7, 3, 110, 9, 10, 521, 522, "-" +447, 7, 4, 111, 11, 14, 523, 526, "Feb" +447, 7, 5, 112, 15, 16, 527, 528, ";" +447, 7, 6, 113, 17, 19, 529, 531, "20" +447, 7, 7, 114, 20, 21, 532, 533, "(" +447, 7, 8, 115, 22, 23, 534, 535, "1" +447, 7, 9, 116, 24, 25, 536, 537, ")" +447, 7, 10, 117, 26, 27, 538, 539, ":" +447, 7, 11, 118, 28, 31, 540, 543, "246" +447, 7, 12, 119, 32, 33, 544, 545, "-" +447, 7, 13, 120, 34, 35, 546, 547, "7" +447, 7, 14, 121, 36, 37, 548, 549, ";" +447, 7, 15, 122, 38, 44, 550, 556, "author" +447, 7, 16, 123, 45, 50, 557, 562, "reply" +447, 7, 17, 124, 51, 54, 563, 566, "247" +447, 7, 18, 125, 55, 56, 567, 568, "-" +447, 7, 19, 126, 57, 58, 569, 570, "8" +447, 7, 20, 127, 59, 60, 571, 572, "." +447, 8, 1, 128, 0, 7, 573, 580, "PURPOSE" +447, 8, 2, 129, 8, 9, 581, 582, ":" +447, 8, 3, 130, 10, 12, 583, 585, "To" +447, 8, 4, 131, 13, 20, 586, 593, "compare" +447, 8, 5, 132, 21, 24, 594, 597, "the" +447, 8, 6, 133, 25, 33, 598, 606, "efficacy" +447, 8, 7, 134, 34, 37, 607, 610, "and" +447, 8, 8, 135, 38, 50, 611, 623, "tolerability" +447, 8, 9, 136, 51, 53, 624, 626, "of" +447, 8, 10, 137, 54, 55, 627, 628, "a" +447, 8, 11, 138, 56, 60, 629, 633, "once" +447, 8, 12, 139, 61, 62, 634, 635, "-" +447, 8, 13, 140, 63, 68, 636, 641, "daily" +447, 8, 14, 141, 69, 76, 642, 649, "evening" +447, 8, 15, 142, 77, 81, 650, 654, "dose" +447, 8, 16, 143, 82, 84, 655, 657, "of" +447, 8, 17, 144, 85, 96, 658, 669, "bimatoprost" +447, 8, 18, 145, 97, 98, 670, 671, "/" +447, 8, 19, 146, 99, 106, 672, 679, "timolol" +447, 8, 20, 147, 107, 112, 680, 685, "fixed" +447, 8, 21, 148, 113, 124, 686, 697, "combination" +447, 8, 22, 149, 125, 126, 698, 699, "(" +447, 8, 23, 150, 127, 131, 700, 704, "BTFC" +447, 8, 24, 151, 132, 133, 705, 706, ")" +447, 8, 25, 152, 134, 138, 707, 711, "with" +447, 8, 26, 153, 139, 143, 712, 716, "that" +447, 8, 27, 154, 144, 146, 717, 719, "of" +447, 8, 28, 155, 147, 148, 720, 721, "a" +447, 8, 29, 156, 149, 153, 722, 726, "once" +447, 8, 30, 157, 154, 155, 727, 728, "-" +447, 8, 31, 158, 156, 161, 729, 734, "daily" +447, 8, 32, 159, 162, 169, 735, 742, "evening" +447, 8, 33, 160, 170, 174, 743, 747, "dose" +447, 8, 34, 161, 175, 177, 748, 750, "of" +447, 8, 35, 162, 178, 189, 751, 762, "latanoprost" +447, 8, 36, 163, 190, 191, 763, 764, "/" +447, 8, 37, 164, 192, 199, 765, 772, "timolol" +447, 8, 38, 165, 200, 205, 773, 778, "fixed" +447, 8, 39, 166, 206, 217, 779, 790, "combination" +447, 8, 40, 167, 218, 219, 791, 792, "(" +447, 8, 41, 168, 220, 224, 793, 797, "LTFC" +447, 8, 42, 169, 225, 226, 798, 799, ")" +447, 8, 43, 170, 227, 229, 800, 802, "in" +447, 8, 44, 171, 230, 238, 803, 811, "patients" +447, 8, 45, 172, 239, 242, 812, 815, "not" +447, 8, 46, 173, 243, 253, 816, 826, "controlled" +447, 8, 47, 174, 254, 258, 827, 831, "with" +447, 8, 48, 175, 259, 273, 832, 846, "prostaglandins" +447, 8, 49, 176, 274, 283, 847, 856, "analogues" +447, 8, 50, 177, 284, 295, 857, 868, "monotherapy" +447, 8, 51, 178, 296, 297, 869, 870, "." +447, 9, 1, 179, 0, 7, 871, 878, "METHODS" +447, 9, 2, 180, 8, 9, 879, 880, ":" +447, 9, 3, 181, 10, 11, 881, 882, "A" +447, 9, 4, 182, 12, 17, 883, 888, "total" +447, 9, 5, 183, 18, 20, 889, 891, "of" +447, 9, 6, 184, 21, 23, 892, 894, "82" +447, 9, 7, 185, 24, 32, 895, 903, "patients" +447, 9, 8, 186, 33, 35, 904, 906, "on" +447, 9, 9, 187, 36, 49, 907, 920, "prostaglandin" +447, 9, 10, 188, 50, 59, 921, 930, "analogues" +447, 9, 11, 189, 60, 71, 931, 942, "monotherapy" +447, 9, 12, 190, 72, 76, 943, 947, "were" +447, 9, 13, 191, 77, 85, 948, 956, "enrolled" +447, 9, 14, 192, 86, 88, 957, 959, "in" +447, 9, 15, 193, 89, 93, 960, 964, "this" +447, 9, 16, 194, 94, 105, 965, 976, "prospective" +447, 9, 17, 195, 106, 107, 977, 978, "," +447, 9, 18, 196, 108, 119, 979, 990, "multicenter" +447, 9, 19, 197, 120, 121, 991, 992, "," +447, 9, 20, 198, 122, 134, 993, 1005, "investigator" +447, 9, 21, 199, 135, 141, 1006, 1012, "masked" +447, 9, 22, 200, 142, 143, 1013, 1014, "," +447, 9, 23, 201, 144, 152, 1015, 1023, "clinical" +447, 9, 24, 202, 153, 158, 1024, 1029, "study" +447, 9, 25, 203, 159, 162, 1030, 1033, "and" +447, 9, 26, 204, 163, 167, 1034, 1038, "were" +447, 9, 27, 205, 168, 178, 1039, 1049, "randomized" +447, 9, 28, 206, 179, 181, 1050, 1052, "to" +447, 9, 29, 207, 182, 188, 1053, 1059, "either" +447, 9, 30, 208, 189, 193, 1060, 1064, "BTFC" +447, 9, 31, 209, 194, 195, 1065, 1066, "(" +447, 9, 32, 210, 196, 197, 1067, 1068, "n" +447, 9, 33, 211, 198, 199, 1069, 1070, "=" +447, 9, 34, 212, 200, 202, 1071, 1073, "47" +447, 9, 35, 213, 203, 204, 1074, 1075, ")" +447, 9, 36, 214, 205, 207, 1076, 1078, "or" +447, 9, 37, 215, 208, 212, 1079, 1083, "LTFC" +447, 9, 38, 216, 213, 214, 1084, 1085, "(" +447, 9, 39, 217, 215, 216, 1086, 1087, "n" +447, 9, 40, 218, 217, 218, 1088, 1089, "=" +447, 9, 41, 219, 219, 221, 1090, 1092, "35" +447, 9, 42, 220, 222, 223, 1093, 1094, ")" +447, 9, 43, 221, 224, 231, 1095, 1102, "topical" +447, 9, 44, 222, 232, 239, 1103, 1110, "therapy" +447, 9, 45, 223, 240, 244, 1111, 1115, "once" +447, 9, 46, 224, 245, 247, 1116, 1118, "at" +447, 9, 47, 225, 248, 253, 1119, 1124, "night" +447, 9, 48, 226, 254, 257, 1125, 1128, "for" +447, 9, 49, 227, 258, 260, 1129, 1131, "12" +447, 9, 50, 228, 261, 266, 1132, 1137, "weeks" +447, 9, 51, 229, 267, 268, 1138, 1139, "." +447, 10, 1, 230, 0, 3, 1140, 1143, "The" +447, 10, 2, 231, 4, 11, 1144, 1151, "primary" +447, 10, 3, 232, 12, 20, 1152, 1160, "endpoint" +447, 10, 4, 233, 21, 23, 1161, 1163, "of" +447, 10, 5, 234, 24, 27, 1164, 1167, "the" +447, 10, 6, 235, 28, 33, 1168, 1173, "study" +447, 10, 7, 236, 34, 37, 1174, 1177, "was" +447, 10, 8, 237, 38, 40, 1178, 1180, "to" +447, 10, 9, 238, 41, 48, 1181, 1188, "compare" +447, 10, 10, 239, 49, 52, 1189, 1192, "the" +447, 10, 11, 240, 53, 57, 1193, 1197, "mean" +447, 10, 12, 241, 58, 63, 1198, 1203, "daily" +447, 10, 13, 242, 64, 75, 1204, 1215, "intraocular" +447, 10, 14, 243, 76, 84, 1216, 1224, "pressure" +447, 10, 15, 244, 85, 86, 1225, 1226, "(" +447, 10, 16, 245, 87, 90, 1227, 1230, "IOP" +447, 10, 17, 246, 91, 92, 1231, 1232, ")" +447, 10, 18, 247, 93, 102, 1233, 1242, "reduction" +447, 10, 19, 248, 103, 107, 1243, 1247, "from" +447, 10, 20, 249, 108, 116, 1248, 1256, "baseline" +447, 10, 21, 250, 117, 124, 1257, 1264, "between" +447, 10, 22, 251, 125, 128, 1265, 1268, "the" +447, 10, 23, 252, 129, 132, 1269, 1272, "two" +447, 10, 24, 253, 133, 142, 1273, 1282, "treatment" +447, 10, 25, 254, 143, 147, 1283, 1287, "arms" +447, 10, 26, 255, 148, 149, 1288, 1289, "." +447, 11, 1, 256, 0, 9, 1290, 1299, "Secondary" +447, 11, 2, 257, 10, 19, 1300, 1309, "endpoints" +447, 11, 3, 258, 20, 28, 1310, 1318, "included" +447, 11, 4, 259, 29, 32, 1319, 1322, "the" +447, 11, 5, 260, 33, 37, 1323, 1327, "mean" +447, 11, 6, 261, 38, 43, 1328, 1333, "daily" +447, 11, 7, 262, 44, 47, 1334, 1337, "IOP" +447, 11, 8, 263, 48, 50, 1338, 1340, "at" +447, 11, 9, 264, 51, 52, 1341, 1342, "1" +447, 11, 10, 265, 53, 56, 1343, 1346, "and" +447, 11, 11, 266, 57, 58, 1347, 1348, "3" +447, 11, 12, 267, 59, 65, 1349, 1355, "months" +447, 11, 13, 268, 66, 74, 1356, 1364, "compared" +447, 11, 14, 269, 75, 77, 1365, 1367, "to" +447, 11, 15, 270, 78, 86, 1368, 1376, "baseline" +447, 11, 16, 271, 87, 90, 1377, 1380, "and" +447, 11, 17, 272, 91, 94, 1381, 1384, "the" +447, 11, 18, 273, 95, 105, 1385, 1395, "percentage" +447, 11, 19, 274, 106, 108, 1396, 1398, "of" +447, 11, 20, 275, 109, 117, 1399, 1407, "patients" +447, 11, 21, 276, 118, 125, 1408, 1415, "showing" +447, 11, 22, 277, 126, 127, 1416, 1417, "a" +447, 11, 23, 278, 128, 132, 1418, 1422, "mean" +447, 11, 24, 279, 133, 136, 1423, 1426, "IOP" +447, 11, 25, 280, 137, 146, 1427, 1436, "reduction" +447, 11, 26, 281, 147, 151, 1437, 1441, "from" +447, 11, 27, 282, 152, 160, 1442, 1450, "baseline" +447, 11, 28, 283, 161, 168, 1451, 1458, "greater" +447, 11, 29, 284, 169, 173, 1459, 1463, "than" +447, 11, 30, 285, 174, 176, 1464, 1466, "or" +447, 11, 31, 286, 177, 182, 1467, 1472, "equal" +447, 11, 32, 287, 183, 185, 1473, 1475, "to" +447, 11, 33, 288, 186, 188, 1476, 1478, "15" +447, 11, 34, 289, 189, 190, 1479, 1480, "%" +447, 11, 35, 290, 191, 193, 1481, 1483, "or" +447, 11, 36, 291, 194, 196, 1484, 1486, "20" +447, 11, 37, 292, 197, 198, 1487, 1488, "%" +447, 11, 38, 293, 199, 200, 1489, 1490, "." +447, 12, 1, 294, 0, 7, 1491, 1498, "RESULTS" +447, 12, 2, 295, 8, 9, 1499, 1500, ":" +447, 12, 3, 296, 10, 14, 1501, 1505, "Mean" +447, 12, 4, 297, 15, 18, 1506, 1509, "IOP" +447, 12, 5, 298, 19, 21, 1510, 1512, "at" +447, 12, 6, 299, 22, 30, 1513, 1521, "baseline" +447, 12, 7, 300, 31, 34, 1522, 1525, "was" +447, 12, 8, 301, 35, 37, 1526, 1528, "22" +447, 12, 9, 302, 38, 39, 1529, 1530, "." +447, 12, 10, 303, 40, 41, 1531, 1532, "7" +447, 12, 11, 304, 42, 43, 1533, 1534, "+" +447, 12, 12, 305, 44, 45, 1535, 1536, "/" +447, 12, 13, 306, 46, 47, 1537, 1538, "-" +447, 12, 14, 307, 48, 49, 1539, 1540, "2" +447, 12, 15, 308, 50, 51, 1541, 1542, "." +447, 12, 16, 309, 52, 53, 1543, 1544, "0" +447, 12, 17, 310, 54, 57, 1545, 1548, "and" +447, 12, 18, 311, 58, 60, 1549, 1551, "22" +447, 12, 19, 312, 61, 62, 1552, 1553, "." +447, 12, 20, 313, 63, 64, 1554, 1555, "1" +447, 12, 21, 314, 65, 66, 1556, 1557, "+" +447, 12, 22, 315, 67, 68, 1558, 1559, "/" +447, 12, 23, 316, 69, 70, 1560, 1561, "-" +447, 12, 24, 317, 71, 72, 1562, 1563, "2" +447, 12, 25, 318, 73, 74, 1564, 1565, "." +447, 12, 26, 319, 75, 76, 1566, 1567, "6" +447, 12, 27, 320, 77, 81, 1568, 1572, "mmHg" +447, 12, 28, 321, 82, 84, 1573, 1575, "in" +447, 12, 29, 322, 85, 88, 1576, 1579, "the" +447, 12, 30, 323, 89, 93, 1580, 1584, "BTFC" +447, 12, 31, 324, 94, 97, 1585, 1588, "and" +447, 12, 32, 325, 98, 102, 1589, 1593, "LTFC" +447, 12, 33, 326, 103, 109, 1594, 1600, "groups" +447, 12, 34, 327, 110, 111, 1601, 1602, "," +447, 12, 35, 328, 112, 124, 1603, 1615, "respectively" +447, 12, 36, 329, 125, 126, 1616, 1617, "(" +447, 12, 37, 330, 127, 128, 1618, 1619, "p" +447, 12, 38, 331, 129, 130, 1620, 1621, "=" +447, 12, 39, 332, 131, 132, 1622, 1623, "0" +447, 12, 40, 333, 133, 134, 1624, 1625, "." +447, 12, 41, 334, 135, 137, 1626, 1628, "23" +447, 12, 42, 335, 138, 139, 1629, 1630, ")" +447, 12, 43, 336, 140, 141, 1631, 1632, "." +447, 13, 1, 337, 0, 4, 1633, 1637, "Both" +447, 13, 2, 338, 5, 15, 1638, 1648, "treatments" +447, 13, 3, 339, 16, 20, 1649, 1653, "were" +447, 13, 4, 340, 21, 30, 1654, 1663, "effective" +447, 13, 5, 341, 31, 33, 1664, 1666, "in" +447, 13, 6, 342, 34, 42, 1667, 1675, "reducing" +447, 13, 7, 343, 43, 46, 1676, 1679, "the" +447, 13, 8, 344, 47, 50, 1680, 1683, "IOP" +447, 13, 9, 345, 51, 55, 1684, 1688, "from" +447, 13, 10, 346, 56, 64, 1689, 1697, "baseline" +447, 13, 11, 347, 65, 66, 1698, 1699, "." +447, 14, 1, 348, 0, 3, 1700, 1703, "The" +447, 14, 2, 349, 4, 8, 1704, 1708, "mean" +447, 14, 3, 350, 9, 12, 1709, 1712, "IOP" +447, 14, 4, 351, 13, 22, 1713, 1722, "reduction" +447, 14, 5, 352, 23, 26, 1723, 1726, "was" +447, 14, 6, 353, 27, 40, 1727, 1740, "significantly" +447, 14, 7, 354, 41, 48, 1741, 1748, "greater" +447, 14, 8, 355, 49, 51, 1749, 1751, "in" +447, 14, 9, 356, 52, 55, 1752, 1755, "the" +447, 14, 10, 357, 56, 60, 1756, 1760, "BTFC" +447, 14, 11, 358, 61, 66, 1761, 1766, "group" +447, 14, 12, 359, 67, 71, 1767, 1771, "than" +447, 14, 13, 360, 72, 74, 1772, 1774, "in" +447, 14, 14, 361, 75, 78, 1775, 1778, "the" +447, 14, 15, 362, 79, 83, 1779, 1783, "LTFC" +447, 14, 16, 363, 84, 89, 1784, 1789, "group" +447, 14, 17, 364, 90, 91, 1790, 1791, "(" +447, 14, 18, 365, 92, 93, 1792, 1793, "-" +447, 14, 19, 366, 94, 96, 1794, 1796, "21" +447, 14, 20, 367, 97, 98, 1797, 1798, "." +447, 14, 21, 368, 99, 100, 1799, 1800, "4" +447, 14, 22, 369, 101, 102, 1801, 1802, "%" +447, 14, 23, 370, 103, 105, 1803, 1805, "vs" +447, 14, 24, 371, 106, 107, 1806, 1807, "-" +447, 14, 25, 372, 108, 110, 1808, 1810, "13" +447, 14, 26, 373, 111, 112, 1811, 1812, "." +447, 14, 27, 374, 113, 114, 1813, 1814, "7" +447, 14, 28, 375, 115, 116, 1815, 1816, "%" +447, 14, 29, 376, 117, 118, 1817, 1818, "," +447, 14, 30, 377, 119, 120, 1819, 1820, "p" +447, 14, 31, 378, 121, 122, 1821, 1822, "<" +447, 14, 32, 379, 123, 124, 1823, 1824, "0" +447, 14, 33, 380, 125, 126, 1825, 1826, "." +447, 14, 34, 381, 127, 130, 1827, 1830, "001" +447, 14, 35, 382, 131, 132, 1831, 1832, ")" +447, 14, 36, 383, 133, 134, 1833, 1834, "." +447, 15, 1, 384, 0, 1, 1835, 1836, "A" +447, 15, 2, 385, 2, 8, 1837, 1843, "higher" +447, 15, 3, 386, 9, 19, 1844, 1854, "percentage" +447, 15, 4, 387, 20, 22, 1855, 1857, "of" +447, 15, 5, 388, 23, 31, 1858, 1866, "patients" +447, 15, 6, 389, 32, 34, 1867, 1869, "in" +447, 15, 7, 390, 35, 38, 1870, 1873, "the" +447, 15, 8, 391, 39, 43, 1874, 1878, "BTFC" +447, 15, 9, 392, 44, 49, 1879, 1884, "group" +447, 15, 10, 393, 50, 56, 1885, 1891, "showed" +447, 15, 11, 394, 57, 58, 1892, 1893, "a" +447, 15, 12, 395, 59, 63, 1894, 1898, "mean" +447, 15, 13, 396, 64, 67, 1899, 1902, "IOP" +447, 15, 14, 397, 68, 77, 1903, 1912, "reduction" +447, 15, 15, 398, 78, 82, 1913, 1917, "from" +447, 15, 16, 399, 83, 91, 1918, 1926, "baseline" +447, 15, 17, 400, 92, 93, 1927, 1928, ">" +447, 15, 18, 401, 94, 96, 1929, 1931, "or" +447, 15, 19, 402, 97, 98, 1932, 1933, "=" +447, 15, 20, 403, 99, 101, 1934, 1936, "15" +447, 15, 21, 404, 102, 103, 1937, 1938, "%" +447, 15, 22, 405, 104, 105, 1939, 1940, "(" +447, 15, 23, 406, 106, 108, 1941, 1943, "72" +447, 15, 24, 407, 109, 110, 1944, 1945, "." +447, 15, 25, 408, 111, 112, 1946, 1947, "3" +447, 15, 26, 409, 113, 114, 1948, 1949, "%" +447, 15, 27, 410, 115, 117, 1950, 1952, "vs" +447, 15, 28, 411, 118, 120, 1953, 1955, "40" +447, 15, 29, 412, 121, 122, 1956, 1957, "." +447, 15, 30, 413, 123, 124, 1958, 1959, "0" +447, 15, 31, 414, 125, 126, 1960, 1961, "%" +447, 15, 32, 415, 127, 128, 1962, 1963, ")" +447, 15, 33, 416, 129, 132, 1964, 1967, "and" +447, 15, 34, 417, 133, 134, 1968, 1969, ">" +447, 15, 35, 418, 135, 137, 1970, 1972, "or" +447, 15, 36, 419, 138, 139, 1973, 1974, "=" +447, 15, 37, 420, 140, 142, 1975, 1977, "20" +447, 15, 38, 421, 143, 144, 1978, 1979, "%" +447, 15, 39, 422, 145, 146, 1980, 1981, "(" +447, 15, 40, 423, 147, 149, 1982, 1984, "61" +447, 15, 41, 424, 150, 151, 1985, 1986, "." +447, 15, 42, 425, 152, 153, 1987, 1988, "7" +447, 15, 43, 426, 154, 155, 1989, 1990, "%" +447, 15, 44, 427, 156, 158, 1991, 1993, "vs" +447, 15, 45, 428, 159, 161, 1994, 1996, "17" +447, 15, 46, 429, 162, 163, 1997, 1998, "." +447, 15, 47, 430, 164, 165, 1999, 2000, "1" +447, 15, 48, 431, 166, 167, 2001, 2002, "%" +447, 15, 49, 432, 168, 169, 2003, 2004, ")" +447, 15, 50, 433, 170, 178, 2005, 2013, "compared" +447, 15, 51, 434, 179, 181, 2014, 2016, "to" +447, 15, 52, 435, 182, 190, 2017, 2025, "patients" +447, 15, 53, 436, 191, 193, 2026, 2028, "in" +447, 15, 54, 437, 194, 197, 2029, 2032, "the" +447, 15, 55, 438, 198, 202, 2033, 2037, "LTFC" +447, 15, 56, 439, 203, 208, 2038, 2043, "group" +447, 15, 57, 440, 209, 210, 2044, 2045, "." +447, 16, 1, 441, 0, 11, 2046, 2057, "CONCLUSIONS" +447, 16, 2, 442, 12, 13, 2058, 2059, ":" +447, 16, 3, 443, 14, 18, 2060, 2064, "Both" +447, 16, 4, 444, 19, 23, 2065, 2069, "BTFC" +447, 16, 5, 445, 24, 27, 2070, 2073, "and" +447, 16, 6, 446, 28, 32, 2074, 2078, "LTFC" +447, 16, 7, 447, 33, 37, 2079, 2083, "were" +447, 16, 8, 448, 38, 42, 2084, 2088, "more" +447, 16, 9, 449, 43, 52, 2089, 2098, "effective" +447, 16, 10, 450, 53, 59, 2099, 2105, "versus" +447, 16, 11, 451, 60, 63, 2106, 2109, "the" +447, 16, 12, 452, 64, 75, 2110, 2121, "monotherapy" +447, 16, 13, 453, 76, 80, 2122, 2126, "with" +447, 16, 14, 454, 81, 94, 2127, 2140, "prostaglandin" +447, 16, 15, 455, 95, 104, 2141, 2150, "analogues" +447, 16, 16, 456, 105, 106, 2151, 2152, "." +447, 17, 1, 457, 0, 4, 2153, 2157, "BTFC" +447, 17, 2, 458, 5, 17, 2158, 2170, "demonstrated" +447, 17, 3, 459, 18, 24, 2171, 2177, "higher" +447, 17, 4, 460, 25, 36, 2178, 2189, "performance" +447, 17, 5, 461, 37, 41, 2190, 2194, "than" +447, 17, 6, 462, 42, 46, 2195, 2199, "LTFC" +447, 17, 7, 463, 47, 49, 2200, 2202, "in" +447, 17, 8, 464, 50, 55, 2203, 2208, "terms" +447, 17, 9, 465, 56, 58, 2209, 2211, "of" +447, 17, 10, 466, 59, 67, 2212, 2220, "relative" +447, 17, 11, 467, 68, 71, 2221, 2224, "IOP" +447, 17, 12, 468, 72, 81, 2225, 2234, "reduction" +447, 17, 13, 469, 82, 83, 2235, 2236, "." +447, 18, 1, 470, 0, 4, 2237, 2241, "PMID" +447, 18, 2, 471, 5, 6, 2242, 2243, ":" +447, 18, 3, 472, 7, 15, 2244, 2252, "19123151" +447, 18, 4, 473, 16, 17, 2253, 2254, "[" +447, 18, 5, 474, 18, 25, 2255, 2262, "Indexed" +447, 18, 6, 475, 26, 29, 2263, 2266, "for" +447, 18, 7, 476, 30, 37, 2267, 2274, "MEDLINE" +447, 18, 8, 477, 38, 39, 2275, 2276, "]" diff --git a/data/gl 19123151_jshahinitiran.annodb b/data/gl 19123151_jshahinitiran.annodb new file mode 100644 index 0000000..1f46284 --- /dev/null +++ b/data/gl 19123151_jshahinitiran.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12058, Journal, 0, 16, "Eur J Ophthalmol", "", +12059, PublicationYear, 19, 23, "2009", "", +12060, Title, 57, 260, "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study", "", +12061, Bimatoprost, 95, 106, "bimatoprost", "", +12062, Latanoprost, 110, 121, "latanoprost", "", +12063, Timolol, 127, 134, "timolol", "", +12064, Precondition, 147, 190, "uncontrolled with prostaglandin monotherapy", "", +12065, Multicenter, 195, 206, "multicenter", "", +12066, Randomized, 209, 219, "randomized", "", +12067, Blind, 222, 243, "investigator - masked", "", +12068, Author, 263, 275, "Centofanti M", "", +12069, Author, 284, 292, "Oddone F", "", +12070, Author, 295, 305, "Vetrugno M", "", +12071, Author, 308, 315, "Manni G", "", +12072, Author, 318, 329, "Fogagnolo P", "", +12073, Author, 332, 339, "Tanga L", "", +12074, Author, 342, 351, "Ferreri P", "", +12075, Author, 354, 364, "Rossetti L", "", +12076, Italy, 437, 442, "Italy", "", +12077, ObjectiveDescription, 583, 706, "To compare the efficacy and tolerability of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC )", "", +12079, Frequency, 629, 641, "once - daily", "", +12080, Bedtime, 642, 649, "evening", "", +12081, Bimatoprost, 658, 669, "bimatoprost", "", +28224, Drug, 658, 697, "bimatoprost / timolol fixed combination", "BTFC", +12082, Timolol, 672, 679, "timolol", "", +28225, Drug, 700, 704, "BTFC", "BTFC", +12078, ObjectiveDescription, 707, 870, "with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy .", "", +12084, Frequency, 722, 734, "once - daily", "", +12085, Bedtime, 735, 742, "evening", "", +12086, Latanoprost, 751, 762, "latanoprost", "", +28232, Drug, 751, 790, "latanoprost / timolol fixed combination", "LTFC", +12087, Timolol, 765, 772, "timolol", "", +28233, Drug, 793, 797, "LTFC", "LTFC", +12092, Precondition, 812, 868, "not controlled with prostaglandins analogues monotherapy", "", +12093, NumberPatientsCT, 892, 894, "82", "", +12094, CTDesign, 965, 976, "prospective", "", +12095, Multicenter, 979, 990, "multicenter", "", +12096, Blind, 993, 1012, "investigator masked", "", +12097, Randomized, 1039, 1049, "randomized", "", +28226, Drug, 1060, 1064, "BTFC", "BTFC", +12099, NumberPatientsArm, 1071, 1073, "47", "", +28234, Drug, 1079, 1083, "LTFC", "LTFC", +12101, NumberPatientsArm, 1090, 1092, "35", "", +28241, Frequency, 1111, 1115, "once", "", +28240, Bedtime, 1119, 1124, "night", "", +12102, Duration, 1129, 1137, "12 weeks", "", +12103, Mean, 1193, 1197, "mean", "", +12104, IOP, 1204, 1224, "intraocular pressure", "", +12105, IOP, 1227, 1230, "IOP", "", +12106, Mean, 1323, 1327, "mean", "", +12107, IOP, 1334, 1337, "IOP", "", +12108, Mean, 1418, 1422, "mean", "", +12109, IOP, 1423, 1426, "IOP", "", +12112, Mean, 1501, 1505, "Mean", "", +12113, IOP, 1506, 1509, "IOP", "", +12114, BaseLineValue, 1526, 1532, "22 . 7", "", +12115, SdErrorBL, 1539, 1544, "2 . 0", "", +12116, BaseLineValue, 1549, 1555, "22 . 1", "", +12117, SdErrorBL, 1562, 1567, "2 . 6", "", +12118, mmHg, 1568, 1572, "mmHg", "", +28227, Drug, 1580, 1584, "BTFC", "BTFC", +28235, Drug, 1589, 1593, "LTFC", "LTFC", +12121, PValueBL, 1618, 1628, "p = 0 . 23", "", +12122, IOP, 1680, 1683, "IOP", "", +12123, Mean, 1704, 1708, "mean", "", +12124, IOP, 1709, 1712, "IOP", "", +28228, Drug, 1756, 1760, "BTFC", "BTFC", +28236, Drug, 1779, 1783, "LTFC", "LTFC", +12127, RelativeReduction, 1794, 1800, "21 . 4", "", +12128, RelativeReduction, 1808, 1814, "13 . 7", "", +12129, PValueChangeValue, 1819, 1830, "p < 0 . 001", "", +28229, Drug, 1874, 1878, "BTFC", "BTFC", +28242, EndPointDescription, 1894, 1938, "mean IOP reduction from baseline > or = 15 %", "", +12131, Mean, 1894, 1898, "mean", "", +12132, IOP, 1899, 1902, "IOP", "", +12134, PercentageAffected, 1941, 1947, "72 . 3", "", +12135, PercentageAffected, 1953, 1959, "40 . 0", "", +28243, EndPointDescription, 1968, 1979, "> or = 20 %", "", +12137, PercentageAffected, 1982, 1988, "61 . 7", "", +12138, PercentageAffected, 1994, 2000, "17 . 1", "", +28237, Drug, 2033, 2037, "LTFC", "LTFC", +12140, ConclusionComment, 2060, 2152, "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues .", "", +28230, Drug, 2065, 2069, "BTFC", "BTFC", +28238, Drug, 2074, 2078, "LTFC", "LTFC", +28231, Drug, 2153, 2157, "BTFC", "BTFC", +12141, ConclusionComment, 2153, 2236, "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction .", "", +28239, Drug, 2195, 2199, "LTFC", "LTFC", +12146, IOP, 2221, 2224, "IOP", "", +12147, PMID, 2244, 2252, "19123151", "", diff --git a/data/gl 19123151_jshahinitiran.n-triples b/data/gl 19123151_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19123151_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19123151_tstrakeljahn.annodb b/data/gl 19123151_tstrakeljahn.annodb new file mode 100644 index 0000000..5051edc --- /dev/null +++ b/data/gl 19123151_tstrakeljahn.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13942, Journal, 0, 16, "Eur J Ophthalmol", "", +13943, PublicationYear, 19, 23, "2009", "", +13952, Title, 57, 260, "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy : a multicenter , randomized , investigator - masked , clinical study", "", +13944, Bimatoprost, 95, 106, "bimatoprost", "", +13945, Latanoprost, 110, 121, "latanoprost", "", +13946, Timolol, 127, 134, "timolol", "", +13947, Medication, 165, 178, "prostaglandin", "prostaglandin", +13948, Multicenter, 195, 206, "multicenter", "", +13949, Randomized, 209, 219, "randomized", "", +13950, Blind, 237, 243, "masked", "", +13951, ClinicalTrial, 246, 260, "clinical study", "", +13953, Author, 263, 275, "Centofanti M", "", +13954, Author, 284, 292, "Oddone F", "", +13955, Author, 295, 305, "Vetrugno M", "", +13956, Author, 308, 315, "Manni G", "", +13957, Author, 318, 329, "Fogagnolo P", "", +13958, Author, 332, 339, "Tanga L", "", +13959, Author, 342, 351, "Ferreri P", "", +13960, Author, 354, 364, "Rossetti L", "", +13961, Italy, 437, 442, "Italy", "", +13986, ObjectiveDescription, 583, 623, "To compare the efficacy and tolerability", "", +13985, ObjectiveDescription, 624, 868, "of a once - daily evening dose of bimatoprost / timolol fixed combination ( BTFC ) with that of a once - daily evening dose of latanoprost / timolol fixed combination ( LTFC ) in patients not controlled with prostaglandins analogues monotherapy", "", +13969, Frequency, 629, 641, "once - daily", "", +13970, Bedtime, 642, 649, "evening", "", +13962, Bimatoprost, 658, 669, "bimatoprost", "", +13964, Timolol, 672, 679, "timolol", "", +13965, Medication, 700, 704, "BTFC", "bimatoprost / timolol fixed combination", +13971, Frequency, 722, 734, "once - daily", "", +13972, Bedtime, 735, 742, "evening", "", +13966, Latanoprost, 751, 762, "latanoprost", "", +13967, Timolol, 765, 772, "timolol", "", +13968, Medication, 793, 797, "LTFC", "latanoprost / timolol fixed combination", +13973, NumberPatientsCT, 892, 894, "82", "", +13974, Multicenter, 979, 990, "multicenter", "", +13975, Blind, 1006, 1012, "masked", "", +13976, ClinicalTrial, 1015, 1029, "clinical study", "", +13977, Randomized, 1039, 1049, "randomized", "", +13978, Medication, 1060, 1064, "BTFC", "bimatoprost / timolol fixed combination", +13980, NumberPatientsArm, 1071, 1073, "47", "", +13979, Medication, 1079, 1083, "LTFC", "latanoprost / timolol fixed combination", +13981, NumberPatientsArm, 1090, 1092, "35", "", +13983, Frequency, 1111, 1115, "once", "", +13984, RelativeTime, 1116, 1124, "at night", "", +13982, Duration, 1129, 1137, "12 weeks", "", +13987, Mean, 1193, 1197, "mean", "", +13988, Diurnal_IOP, 1198, 1224, "daily intraocular pressure", "", +13989, IOP, 1227, 1230, "IOP", "", +13991, Mean, 1323, 1327, "mean", "", +13992, Diurnal_IOP, 1328, 1337, "daily IOP", "", +13993, TimePoint, 1341, 1342, "1", "", +13994, TimePoint, 1347, 1355, "3 months", "", +13993, TimePoint, 1349, 1355, "months", "", +13998, Endpoint, 1381, 1488, "the percentage of patients showing a mean IOP reduction from baseline greater than or equal to 15 % or 20 %", "", +13996, Mean, 1418, 1422, "mean", "", +13997, IOP, 1423, 1426, "IOP", "", +13999, Mean, 1501, 1505, "Mean", "", +14000, IOP, 1506, 1509, "IOP", "", +14001, BaseLineValue, 1526, 1532, "22 . 7", "", +14002, SdDevBL, 1539, 1544, "2 . 0", "", +14003, BaseLineValue, 1549, 1555, "22 . 1", "", +14004, SdDevBL, 1562, 1567, "2 . 6", "", +14005, mmHg, 1568, 1572, "mmHg", "", +14006, Medication, 1580, 1584, "BTFC", "bimatoprost / timolol fixed combination", +14007, Medication, 1589, 1593, "LTFC", "latanoprost / timolol fixed combination", +14008, PvalueDiff, 1618, 1628, "p = 0 . 23", "", +14010, ObservedResult, 1633, 1697, "Both treatments were effective in reducing the IOP from baseline", "", +14009, IOP, 1680, 1683, "IOP", "", +14011, Mean, 1704, 1708, "mean", "", +14012, IOP, 1709, 1712, "IOP", "", +14013, Medication, 1756, 1760, "BTFC", "bimatoprost / timolol fixed combination", +14014, Medication, 1779, 1783, "LTFC", "latanoprost / timolol fixed combination", +14015, RelativeReduction, 1794, 1800, "21 . 4", "", +14016, RelativeReduction, 1808, 1814, "13 . 7", "", +14017, PvalueDiff, 1819, 1830, "p < 0 . 001", "", +14018, Medication, 1874, 1878, "BTFC", "bimatoprost / timolol fixed combination", +14023, Mean, 1894, 1898, "mean", "", +14024, IOP, 1899, 1902, "IOP", "", +14025, Endpoint, 1903, 1938, "reduction from baseline > or = 15 %", "", +14026, Endpoint, 1903, 1926, "reduction from baseline", "", +14028, PercentageAffected, 1941, 1947, "72 . 3", "", +14029, PercentageAffected, 1953, 1959, "40 . 0", "", +14026, Endpoint, 1968, 1979, "> or = 20 %", "", +14030, PercentageAffected, 1982, 1988, "61 . 7", "", +14031, PercentageAffected, 1994, 2000, "17 . 1", "", +14019, Medication, 2033, 2037, "LTFC", "latanoprost / timolol fixed combination", +14032, ConclusionComment, 2060, 2150, "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues", "", +14022, Medication, 2065, 2069, "BTFC", "bimatoprost / timolol fixed combination", +14021, Medication, 2074, 2078, "LTFC", "latanoprost / timolol fixed combination", +14033, Medication, 2153, 2157, "BTFC", "bimatoprost / timolol fixed combination", +14035, ConclusionComment, 2153, 2234, "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction", "", +14020, Medication, 2195, 2199, "LTFC", "latanoprost / timolol fixed combination", +14034, IOP, 2221, 2224, "IOP", "", +14036, PMID, 2244, 2252, "19123151", "", diff --git a/data/gl 19123151_tstrakeljahn.n-triples b/data/gl 19123151_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19123151_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19336424 copy_admin.annodb b/data/gl 19336424 copy_admin.annodb new file mode 100644 index 0000000..f546a5d --- /dev/null +++ b/data/gl 19336424 copy_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2009", "", " \"2009\"." +2, Title, 109, 225, "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .", "", " \"A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .\"." +3, Randomized, 111, 121, "randomised", "", " ." +4, Crossover, 122, 131, "crossover", "", " ." +5, Bimatoprost, 148, 159, "bimatoprost", "", +6, Latanoprost, 164, 175, "latanoprost", "", +73, Primary_AngleClosureGlaucoma, 193, 223, "primary angle closure glaucoma", "", " ." +7, Author, 226, 232, "How AC", "", " \"How AC\"." +8, Author, 241, 249, "Kumar RS", "", " \"Kumar RS\"." +9, Author, 252, 259, "Chen YM", "", " \"Chen YM\"." +10, Author, 262, 267, "Su DH", "", " \"Su DH\"." +11, Author, 270, 275, "Gao H", "", " \"Gao H\"." +12, Author, 278, 284, "Oen FT", "", " \"Oen FT\"." +13, Author, 287, 292, "Ho CL", "", " \"Ho CL\"." +14, Author, 295, 302, "Seah SK", "", " \"Seah SK\"." +15, Author, 305, 311, "Aung T", "", " \"Aung T\"." +16, Singapore, 373, 382, "Singapore", "", +107, ObjectiveDescription, 405, 600, "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .", "", " \"To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .\"." +18, IOP, 420, 440, "intraocular pressure", "", +19, IOP, 443, 446, "IOP", "", +20, Latanoprost, 487, 498, "latanoprost", "", " . ." +21, DoseValue, 499, 506, "0 . 005", "", " \"0 . 005\"." +22, Percentage, 507, 508, "%", "", " ." +23, Bimatoprost, 513, 524, "bimatoprost", "", " ." +77, DoseValue, 525, 531, "0 . 03", "", " \"0 . 03\"." +78, Percentage, 532, 533, "%", "", " ." +78500, Precondition, 537, 598, "subjects with chronic primary angle closure glaucoma ( PACG )", "", " \"subjects with chronic primary angle closure glaucoma ( PACG )\"." +75, Primary_AngleClosureGlaucoma, 559, 589, "primary angle closure glaucoma", "", +76, Primary_AngleClosureGlaucoma, 592, 596, "PACG", "", +24, Blind, 623, 640, "observer - masked", "", " ." +25, Randomized, 641, 651, "randomised", "", +26, Crossover, 652, 661, "crossover", "", +27, NumberPatientsCT, 671, 673, "60", "", " \"60\"." +74, Primary_AngleClosureGlaucoma, 674, 678, "PACG", "", +28, Latanoprost, 708, 719, "latanoprost", "", +29, Bimatoprost, 723, 734, "bimatoprost", "", +30, Duration, 739, 746, "6 weeks", "", " \"6 weeks\"." +32, Crossover, 771, 783, "crossed over", "", +31, Duration, 820, 827, "6 weeks", "", +33, IOP, 834, 837, "IOP", "", +34, IOP, 908, 911, "IOP", "", +78505, TimePoint, 918, 925, "6 weeks", "", +78504, TimePoint, 953, 961, "baseline", "", +36, FinalNumPatientsCT, 974, 986, "Fifty - four", "", " \"Fifty - four\"." +37, Latanoprost, 1030, 1041, "Latanoprost", "", +38, IOP, 1050, 1053, "IOP", "", " . ." +121, Mean, 1056, 1060, "mean", "", " . ." +39, Reduction, 1073, 1078, "8 . 4", "", " \"8 . 4\"." +40, SdDevChangeValue, 1081, 1086, "3 . 8", "", " \"3 . 8\"." +41, mmHg, 1089, 1094, "mm Hg", "", " ." +42, Bimatoprost, 1099, 1110, "bimatoprost", "", +43, Reduction, 1114, 1119, "8 . 9", "", " \"8 . 9\"." +44, SdDevChangeValue, 1122, 1127, "3 . 9", "", " \"3 . 9\"." +45, mmHg, 1130, 1135, "mm Hg", "", +78506, TimePoint, 1143, 1151, "baseline", "", +46, BaseLineValue, 1155, 1161, "25 . 2", "", " \"25 . 2\"." +47, SdDevBL, 1164, 1169, "3 . 6", "", " \"3 . 6\"." +48, mmHg, 1172, 1177, "mm Hg", "", +49, BaseLineValue, 1182, 1188, "25 . 2", "", " \"25 . 2\"." +50, SdDevBL, 1191, 1196, "3 . 6", "", " \"3 . 6\"." +51, mmHg, 1199, 1204, "mm Hg", "", +135, PvalueDiff, 1222, 1230, "= 0 . 23", "", " \"= 0 . 23\"." +78507, EndPointDescription, 1324, 1337, "adverse event", "", " . ." +53, Bimatoprost, 1345, 1356, "bimatoprost", "", +54, PercentageAffected, 1365, 1367, "81", "", " \"81\"." +55, Latanoprost, 1390, 1401, "latanoprost", "", +56, PercentageAffected, 1410, 1412, "40", "", " \"40\"." +141, PvalueDiff, 1419, 1427, "< 0 . 01", "", " \"< 0 . 01\"." +78510, EndPointDescription, 1432, 1449, "Ocular irritation", "", +58, NumberAffected, 1514, 1516, "22", "", " \"22\"." +59, PercentageAffected, 1528, 1534, "37 . 9", "", " \"37 . 9\"." +60, Bimatoprost, 1552, 1563, "bimatoprost", "", +146, OcularHypertension, 1576, 1593, "ocular hyperaemia", "", " ." +61, NumberAffected, 1611, 1613, "13", "", " \"13\"." +62, PercentageAffected, 1625, 1631, "22 . 4", "", " \"22 . 4\"." +63, Latanoprost, 1649, 1660, "latanoprost", "", +150, PvalueDiff, 1665, 1673, "= 0 . 11", "", " \"= 0 . 11\"." +67, Bimatoprost, 1692, 1703, "Bimatoprost", "", +65, ConclusionComment, 1692, 1823, "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .", "", " \"Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .\"." +68, Frequency, 1704, 1714, "once daily", "", " \"once daily\"." +69, IOP, 1751, 1754, "IOP", "", +70, Latanoprost, 1769, 1780, "latanoprost", "", +71, Frequency, 1781, 1791, "once daily", "", " \"once daily\"." +156, Primary_AngleClosureGlaucoma, 1817, 1821, "PACG", "", +66, ConclusionComment, 1824, 1888, "Both drugs were well tolerated with mild ocular adverse events .", "", " \"Both drugs were well tolerated with mild ocular adverse events .\"." +72, PMID, 1934, 1942, "19336424", "", " \"19336424\"." diff --git a/data/gl 19336424 copy_admin.n-triples b/data/gl 19336424 copy_admin.n-triples new file mode 100644 index 0000000..3455f0d --- /dev/null +++ b/data/gl 19336424 copy_admin.n-triples @@ -0,0 +1,157 @@ +# RDF export of group: Publication + . + "Publication 106691" . + "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma ." . + "How AC" . + "2009" . + "Br J Ophthalmol ." . + "19336424" . + . + "Kumar RS" . + "Chen YM" . + "Su DH" . + "Gao H" . + "Oen FT" . + "Ho CL" . + "Seah SK" . + "Aung T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 106698" . + "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) ." . + "60" . + "6 weeks" . + . + . + . + "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG ." . + . + . + . + . + . + "Fifty - four" . + . + . + "Both drugs were well tolerated with mild ocular adverse events ." . + . + . + . + . +# RDF export of group: Population + . + "Population 106714" . + "subjects with chronic primary angle closure glaucoma ( PACG )" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + . + "ae" . + . + . + . + . + . + . + "hy" . + . + . + . + . +# RDF export of group: Arm + . + "lat" . + . + . + . + . + . + "bim" . + . + . + . + . +# RDF export of group: Intervention + . + "lat" . + . + "once daily" . + . + . + "bim" . + . + "once daily" . + . +# RDF export of group: Medication + . + "lat" . + . + . + "0 . 005" . + . + . + . + "bim" . + . + "0 . 03" . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "25 . 2" . + "3 . 6" . + "8 . 4" . + "3 . 8" . + . + "iop2" . + . + "25 . 2" . + "3 . 6" . + "8 . 9" . + "3 . 9" . + . + "ae1" . + . + "40" . + . + "ae2" . + . + "81" . + . + "hy1" . + . + "13" . + "22 . 4" . + . + "hy2" . + . + "22" . + "37 . 9" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "= 0 . 23" . + . + . + . + "ae" . + "< 0 . 01" . + . + . + . + "hy" . + "= 0 . 11" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19336424 copy_export.csv b/data/gl 19336424 copy_export.csv new file mode 100644 index 0000000..18c5f3e --- /dev/null +++ b/data/gl 19336424 copy_export.csv @@ -0,0 +1,423 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +832, 1, 1, 1, 0, 2, 0, 2, "Br" +832, 1, 2, 2, 3, 4, 3, 4, "J" +832, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +832, 1, 4, 4, 16, 17, 16, 17, "." +832, 2, 1, 5, 0, 4, 18, 22, "2009" +832, 2, 2, 6, 5, 8, 23, 26, "Jun" +832, 2, 3, 7, 9, 10, 27, 28, ";" +832, 2, 4, 8, 11, 13, 29, 31, "93" +832, 2, 5, 9, 14, 15, 32, 33, "(" +832, 2, 6, 10, 16, 17, 34, 35, "6" +832, 2, 7, 11, 18, 19, 36, 37, ")" +832, 2, 8, 12, 20, 21, 38, 39, ":" +832, 2, 9, 13, 22, 25, 40, 43, "782" +832, 2, 10, 14, 26, 27, 44, 45, "-" +832, 2, 11, 15, 28, 29, 46, 47, "6" +832, 2, 12, 16, 30, 31, 48, 49, "." +832, 2, 13, 17, 32, 35, 50, 53, "doi" +832, 2, 14, 18, 36, 37, 54, 55, ":" +832, 2, 15, 19, 38, 40, 56, 58, "10" +832, 2, 16, 20, 41, 42, 59, 60, "." +832, 2, 17, 21, 43, 47, 61, 65, "1136" +832, 2, 18, 22, 48, 49, 66, 67, "/" +832, 2, 19, 23, 50, 53, 68, 71, "bjo" +832, 2, 20, 24, 54, 55, 72, 73, "." +832, 2, 21, 25, 56, 60, 74, 78, "2008" +832, 2, 22, 26, 61, 62, 79, 80, "." +832, 2, 23, 27, 63, 69, 81, 87, "144535" +832, 2, 24, 28, 70, 71, 88, 89, "." +832, 3, 1, 29, 0, 4, 90, 94, "Epub" +832, 3, 2, 30, 5, 9, 95, 99, "2009" +832, 3, 3, 31, 10, 13, 100, 103, "Mar" +832, 3, 4, 32, 14, 16, 104, 106, "30" +832, 3, 5, 33, 17, 18, 107, 108, "." +832, 4, 1, 34, 0, 1, 109, 110, "A" +832, 4, 2, 35, 2, 12, 111, 121, "randomised" +832, 4, 3, 36, 13, 22, 122, 131, "crossover" +832, 4, 4, 37, 23, 28, 132, 137, "study" +832, 4, 5, 38, 29, 38, 138, 147, "comparing" +832, 4, 6, 39, 39, 50, 148, 159, "bimatoprost" +832, 4, 7, 40, 51, 54, 160, 163, "and" +832, 4, 8, 41, 55, 66, 164, 175, "latanoprost" +832, 4, 9, 42, 67, 69, 176, 178, "in" +832, 4, 10, 43, 70, 78, 179, 187, "subjects" +832, 4, 11, 44, 79, 83, 188, 192, "with" +832, 4, 12, 45, 84, 91, 193, 200, "primary" +832, 4, 13, 46, 92, 97, 201, 206, "angle" +832, 4, 14, 47, 98, 105, 207, 214, "closure" +832, 4, 15, 48, 106, 114, 215, 223, "glaucoma" +832, 4, 16, 49, 115, 116, 224, 225, "." +832, 5, 1, 50, 0, 3, 226, 229, "How" +832, 5, 2, 51, 4, 6, 230, 232, "AC" +832, 5, 3, 52, 7, 8, 233, 234, "(" +832, 5, 4, 53, 9, 10, 235, 236, "1" +832, 5, 5, 54, 11, 12, 237, 238, ")" +832, 5, 6, 55, 13, 14, 239, 240, "," +832, 5, 7, 56, 15, 20, 241, 246, "Kumar" +832, 5, 8, 57, 21, 23, 247, 249, "RS" +832, 5, 9, 58, 24, 25, 250, 251, "," +832, 5, 10, 59, 26, 30, 252, 256, "Chen" +832, 5, 11, 60, 31, 33, 257, 259, "YM" +832, 5, 12, 61, 34, 35, 260, 261, "," +832, 5, 13, 62, 36, 38, 262, 264, "Su" +832, 5, 14, 63, 39, 41, 265, 267, "DH" +832, 5, 15, 64, 42, 43, 268, 269, "," +832, 5, 16, 65, 44, 47, 270, 273, "Gao" +832, 5, 17, 66, 48, 49, 274, 275, "H" +832, 5, 18, 67, 50, 51, 276, 277, "," +832, 5, 19, 68, 52, 55, 278, 281, "Oen" +832, 5, 20, 69, 56, 58, 282, 284, "FT" +832, 5, 21, 70, 59, 60, 285, 286, "," +832, 5, 22, 71, 61, 63, 287, 289, "Ho" +832, 5, 23, 72, 64, 66, 290, 292, "CL" +832, 5, 24, 73, 67, 68, 293, 294, "," +832, 5, 25, 74, 69, 73, 295, 299, "Seah" +832, 5, 26, 75, 74, 76, 300, 302, "SK" +832, 5, 27, 76, 77, 78, 303, 304, "," +832, 5, 28, 77, 79, 83, 305, 309, "Aung" +832, 5, 29, 78, 84, 85, 310, 311, "T" +832, 5, 30, 79, 86, 87, 312, 313, "." +832, 5, 31, 80, 88, 94, 314, 320, "Author" +832, 5, 32, 81, 95, 106, 321, 332, "information" +832, 5, 33, 82, 107, 108, 333, 334, ":" +832, 5, 34, 83, 109, 110, 335, 336, "(" +832, 5, 35, 84, 111, 112, 337, 338, "1" +832, 5, 36, 85, 113, 114, 339, 340, ")" +832, 5, 37, 86, 115, 124, 341, 350, "Singapore" +832, 5, 38, 87, 125, 133, 351, 359, "National" +832, 5, 39, 88, 134, 137, 360, 363, "Eye" +832, 5, 40, 89, 138, 144, 364, 370, "Centre" +832, 5, 41, 90, 145, 146, 371, 372, "," +832, 5, 42, 91, 147, 156, 373, 382, "Singapore" +832, 5, 43, 92, 157, 158, 383, 384, "." +832, 6, 1, 93, 0, 10, 385, 395, "BACKGROUND" +832, 6, 2, 94, 11, 12, 396, 397, "/" +832, 6, 3, 95, 13, 17, 398, 402, "AIMS" +832, 6, 4, 96, 18, 19, 403, 404, ":" +832, 6, 5, 97, 20, 22, 405, 407, "To" +832, 6, 6, 98, 23, 30, 408, 415, "compare" +832, 6, 7, 99, 31, 34, 416, 419, "the" +832, 6, 8, 100, 35, 46, 420, 431, "intraocular" +832, 6, 9, 101, 47, 55, 432, 440, "pressure" +832, 6, 10, 102, 56, 57, 441, 442, "(" +832, 6, 11, 103, 58, 61, 443, 446, "IOP" +832, 6, 12, 104, 62, 63, 447, 448, ")" +832, 6, 13, 105, 64, 72, 449, 457, "lowering" +832, 6, 14, 106, 73, 81, 458, 466, "efficacy" +832, 6, 15, 107, 82, 85, 467, 470, "and" +832, 6, 16, 108, 86, 90, 471, 475, "side" +832, 6, 17, 109, 91, 98, 476, 483, "effects" +832, 6, 18, 110, 99, 101, 484, 486, "of" +832, 6, 19, 111, 102, 113, 487, 498, "latanoprost" +832, 6, 20, 112, 114, 115, 499, 500, "0" +832, 6, 21, 113, 116, 117, 501, 502, "." +832, 6, 22, 114, 118, 121, 503, 506, "005" +832, 6, 23, 115, 122, 123, 507, 508, "%" +832, 6, 24, 116, 124, 127, 509, 512, "and" +832, 6, 25, 117, 128, 139, 513, 524, "bimatoprost" +832, 6, 26, 118, 140, 141, 525, 526, "0" +832, 6, 27, 119, 142, 143, 527, 528, "." +832, 6, 28, 120, 144, 146, 529, 531, "03" +832, 6, 29, 121, 147, 148, 532, 533, "%" +832, 6, 30, 122, 149, 151, 534, 536, "in" +832, 6, 31, 123, 152, 160, 537, 545, "subjects" +832, 6, 32, 124, 161, 165, 546, 550, "with" +832, 6, 33, 125, 166, 173, 551, 558, "chronic" +832, 6, 34, 126, 174, 181, 559, 566, "primary" +832, 6, 35, 127, 182, 187, 567, 572, "angle" +832, 6, 36, 128, 188, 195, 573, 580, "closure" +832, 6, 37, 129, 196, 204, 581, 589, "glaucoma" +832, 6, 38, 130, 205, 206, 590, 591, "(" +832, 6, 39, 131, 207, 211, 592, 596, "PACG" +832, 6, 40, 132, 212, 213, 597, 598, ")" +832, 6, 41, 133, 214, 215, 599, 600, "." +832, 7, 1, 134, 0, 7, 601, 608, "METHODS" +832, 7, 2, 135, 8, 9, 609, 610, ":" +832, 7, 3, 136, 10, 14, 611, 615, "This" +832, 7, 4, 137, 15, 18, 616, 619, "was" +832, 7, 5, 138, 19, 21, 620, 622, "an" +832, 7, 6, 139, 22, 30, 623, 631, "observer" +832, 7, 7, 140, 31, 32, 632, 633, "-" +832, 7, 8, 141, 33, 39, 634, 640, "masked" +832, 7, 9, 142, 40, 50, 641, 651, "randomised" +832, 7, 10, 143, 51, 60, 652, 661, "crossover" +832, 7, 11, 144, 61, 66, 662, 667, "study" +832, 7, 12, 145, 67, 69, 668, 670, "of" +832, 7, 13, 146, 70, 72, 671, 673, "60" +832, 7, 14, 147, 73, 77, 674, 678, "PACG" +832, 7, 15, 148, 78, 86, 679, 687, "subjects" +832, 7, 16, 149, 87, 90, 688, 691, "who" +832, 7, 17, 150, 91, 99, 692, 700, "received" +832, 7, 18, 151, 100, 106, 701, 707, "either" +832, 7, 19, 152, 107, 118, 708, 719, "latanoprost" +832, 7, 20, 153, 119, 121, 720, 722, "or" +832, 7, 21, 154, 122, 133, 723, 734, "bimatoprost" +832, 7, 22, 155, 134, 137, 735, 738, "for" +832, 7, 23, 156, 138, 139, 739, 740, "6" +832, 7, 24, 157, 140, 145, 741, 746, "weeks" +832, 7, 25, 158, 146, 147, 747, 748, "," +832, 7, 26, 159, 148, 153, 749, 754, "after" +832, 7, 27, 160, 154, 159, 755, 760, "which" +832, 7, 28, 161, 160, 164, 761, 765, "they" +832, 7, 29, 162, 165, 169, 766, 770, "were" +832, 7, 30, 163, 170, 177, 771, 778, "crossed" +832, 7, 31, 164, 178, 182, 779, 783, "over" +832, 7, 32, 165, 183, 185, 784, 786, "to" +832, 7, 33, 166, 186, 189, 787, 790, "the" +832, 7, 34, 167, 190, 195, 791, 796, "other" +832, 7, 35, 168, 196, 206, 797, 807, "medication" +832, 7, 36, 169, 207, 210, 808, 811, "for" +832, 7, 37, 170, 211, 218, 812, 819, "another" +832, 7, 38, 171, 219, 220, 820, 821, "6" +832, 7, 39, 172, 221, 226, 822, 827, "weeks" +832, 7, 40, 173, 227, 228, 828, 829, "." +832, 8, 1, 174, 0, 3, 830, 833, "The" +832, 8, 2, 175, 4, 7, 834, 837, "IOP" +832, 8, 3, 176, 8, 9, 838, 839, "-" +832, 8, 4, 177, 10, 18, 840, 848, "reducing" +832, 8, 5, 178, 19, 25, 849, 855, "effect" +832, 8, 6, 179, 26, 28, 856, 858, "of" +832, 8, 7, 180, 29, 32, 859, 862, "the" +832, 8, 8, 181, 33, 44, 863, 874, "medications" +832, 8, 9, 182, 45, 48, 875, 878, "was" +832, 8, 10, 183, 49, 57, 879, 887, "assessed" +832, 8, 11, 184, 58, 60, 888, 890, "by" +832, 8, 12, 185, 61, 64, 891, 894, "the" +832, 8, 13, 186, 65, 74, 895, 904, "reduction" +832, 8, 14, 187, 75, 77, 905, 907, "in" +832, 8, 15, 188, 78, 81, 908, 911, "IOP" +832, 8, 16, 189, 82, 87, 912, 917, "after" +832, 8, 17, 190, 88, 89, 918, 919, "6" +832, 8, 18, 191, 90, 95, 920, 925, "weeks" +832, 8, 19, 192, 96, 98, 926, 928, "of" +832, 8, 20, 193, 99, 108, 929, 938, "treatment" +832, 8, 21, 194, 109, 117, 939, 947, "compared" +832, 8, 22, 195, 118, 122, 948, 952, "with" +832, 8, 23, 196, 123, 131, 953, 961, "baseline" +832, 8, 24, 197, 132, 133, 962, 963, "." +832, 9, 1, 198, 0, 7, 964, 971, "RESULTS" +832, 9, 2, 199, 8, 9, 972, 973, ":" +832, 9, 3, 200, 10, 15, 974, 979, "Fifty" +832, 9, 4, 201, 16, 17, 980, 981, "-" +832, 9, 5, 202, 18, 22, 982, 986, "four" +832, 9, 6, 203, 23, 31, 987, 995, "subjects" +832, 9, 7, 204, 32, 33, 996, 997, "(" +832, 9, 8, 205, 34, 36, 998, 1000, "80" +832, 9, 9, 206, 37, 41, 1001, 1005, "eyes" +832, 9, 10, 207, 42, 43, 1006, 1007, ")" +832, 9, 11, 208, 44, 53, 1008, 1017, "completed" +832, 9, 12, 209, 54, 57, 1018, 1021, "the" +832, 9, 13, 210, 58, 63, 1022, 1027, "study" +832, 9, 14, 211, 64, 65, 1028, 1029, "." +832, 10, 1, 212, 0, 11, 1030, 1041, "Latanoprost" +832, 10, 2, 213, 12, 19, 1042, 1049, "reduced" +832, 10, 3, 214, 20, 23, 1050, 1053, "IOP" +832, 10, 4, 215, 24, 25, 1054, 1055, "(" +832, 10, 5, 216, 26, 30, 1056, 1060, "mean" +832, 10, 6, 217, 31, 32, 1061, 1062, "(" +832, 10, 7, 218, 33, 35, 1063, 1065, "SD" +832, 10, 8, 219, 36, 37, 1066, 1067, ")" +832, 10, 9, 220, 38, 39, 1068, 1069, ")" +832, 10, 10, 221, 40, 42, 1070, 1072, "by" +832, 10, 11, 222, 43, 44, 1073, 1074, "8" +832, 10, 12, 223, 45, 46, 1075, 1076, "." +832, 10, 13, 224, 47, 48, 1077, 1078, "4" +832, 10, 14, 225, 49, 50, 1079, 1080, "(" +832, 10, 15, 226, 51, 52, 1081, 1082, "3" +832, 10, 16, 227, 53, 54, 1083, 1084, "." +832, 10, 17, 228, 55, 56, 1085, 1086, "8" +832, 10, 18, 229, 57, 58, 1087, 1088, ")" +832, 10, 19, 230, 59, 61, 1089, 1091, "mm" +832, 10, 20, 231, 62, 64, 1092, 1094, "Hg" +832, 10, 21, 232, 65, 68, 1095, 1098, "and" +832, 10, 22, 233, 69, 80, 1099, 1110, "bimatoprost" +832, 10, 23, 234, 81, 83, 1111, 1113, "by" +832, 10, 24, 235, 84, 85, 1114, 1115, "8" +832, 10, 25, 236, 86, 87, 1116, 1117, "." +832, 10, 26, 237, 88, 89, 1118, 1119, "9" +832, 10, 27, 238, 90, 91, 1120, 1121, "(" +832, 10, 28, 239, 92, 93, 1122, 1123, "3" +832, 10, 29, 240, 94, 95, 1124, 1125, "." +832, 10, 30, 241, 96, 97, 1126, 1127, "9" +832, 10, 31, 242, 98, 99, 1128, 1129, ")" +832, 10, 32, 243, 100, 102, 1130, 1132, "mm" +832, 10, 33, 244, 103, 105, 1133, 1135, "Hg" +832, 10, 34, 245, 106, 110, 1136, 1140, "from" +832, 10, 35, 246, 111, 112, 1141, 1142, "a" +832, 10, 36, 247, 113, 121, 1143, 1151, "baseline" +832, 10, 37, 248, 122, 124, 1152, 1154, "of" +832, 10, 38, 249, 125, 127, 1155, 1157, "25" +832, 10, 39, 250, 128, 129, 1158, 1159, "." +832, 10, 40, 251, 130, 131, 1160, 1161, "2" +832, 10, 41, 252, 132, 133, 1162, 1163, "(" +832, 10, 42, 253, 134, 135, 1164, 1165, "3" +832, 10, 43, 254, 136, 137, 1166, 1167, "." +832, 10, 44, 255, 138, 139, 1168, 1169, "6" +832, 10, 45, 256, 140, 141, 1170, 1171, ")" +832, 10, 46, 257, 142, 144, 1172, 1174, "mm" +832, 10, 47, 258, 145, 147, 1175, 1177, "Hg" +832, 10, 48, 259, 148, 151, 1178, 1181, "and" +832, 10, 49, 260, 152, 154, 1182, 1184, "25" +832, 10, 50, 261, 155, 156, 1185, 1186, "." +832, 10, 51, 262, 157, 158, 1187, 1188, "2" +832, 10, 52, 263, 159, 160, 1189, 1190, "(" +832, 10, 53, 264, 161, 162, 1191, 1192, "3" +832, 10, 54, 265, 163, 164, 1193, 1194, "." +832, 10, 55, 266, 165, 166, 1195, 1196, "6" +832, 10, 56, 267, 167, 168, 1197, 1198, ")" +832, 10, 57, 268, 169, 171, 1199, 1201, "mm" +832, 10, 58, 269, 172, 174, 1202, 1204, "Hg" +832, 10, 59, 270, 175, 187, 1205, 1217, "respectively" +832, 10, 60, 271, 188, 189, 1218, 1219, "(" +832, 10, 61, 272, 190, 191, 1220, 1221, "p" +832, 10, 62, 273, 192, 193, 1222, 1223, "=" +832, 10, 63, 274, 194, 195, 1224, 1225, "0" +832, 10, 64, 275, 196, 197, 1226, 1227, "." +832, 10, 65, 276, 198, 200, 1228, 1230, "23" +832, 10, 66, 277, 201, 202, 1231, 1232, ")" +832, 10, 67, 278, 203, 204, 1233, 1234, "." +832, 11, 1, 279, 0, 7, 1235, 1242, "Adverse" +832, 11, 2, 280, 8, 14, 1243, 1249, "events" +832, 11, 3, 281, 15, 19, 1250, 1254, "were" +832, 11, 4, 282, 20, 24, 1255, 1259, "mild" +832, 11, 5, 283, 25, 27, 1260, 1262, "in" +832, 11, 6, 284, 28, 32, 1263, 1267, "both" +832, 11, 7, 285, 33, 39, 1268, 1274, "groups" +832, 11, 8, 286, 40, 41, 1275, 1276, ";" +832, 11, 9, 287, 42, 49, 1277, 1284, "however" +832, 11, 10, 288, 50, 55, 1285, 1290, "there" +832, 11, 11, 289, 56, 60, 1291, 1295, "were" +832, 11, 12, 290, 61, 66, 1296, 1301, "twice" +832, 11, 13, 291, 67, 69, 1302, 1304, "as" +832, 11, 14, 292, 70, 74, 1305, 1309, "many" +832, 11, 15, 293, 75, 82, 1310, 1317, "reports" +832, 11, 16, 294, 83, 85, 1318, 1320, "of" +832, 11, 17, 295, 86, 88, 1321, 1323, "an" +832, 11, 18, 296, 89, 96, 1324, 1331, "adverse" +832, 11, 19, 297, 97, 102, 1332, 1337, "event" +832, 11, 20, 298, 103, 105, 1338, 1340, "in" +832, 11, 21, 299, 106, 109, 1341, 1344, "the" +832, 11, 22, 300, 110, 121, 1345, 1356, "bimatoprost" +832, 11, 23, 301, 122, 127, 1357, 1362, "group" +832, 11, 24, 302, 128, 129, 1363, 1364, "(" +832, 11, 25, 303, 130, 132, 1365, 1367, "81" +832, 11, 26, 304, 133, 134, 1368, 1369, "%" +832, 11, 27, 305, 135, 136, 1370, 1371, ")" +832, 11, 28, 306, 137, 145, 1372, 1380, "compared" +832, 11, 29, 307, 146, 150, 1381, 1385, "with" +832, 11, 30, 308, 151, 154, 1386, 1389, "the" +832, 11, 31, 309, 155, 166, 1390, 1401, "latanoprost" +832, 11, 32, 310, 167, 172, 1402, 1407, "group" +832, 11, 33, 311, 173, 174, 1408, 1409, "(" +832, 11, 34, 312, 175, 177, 1410, 1412, "40" +832, 11, 35, 313, 178, 179, 1413, 1414, "%" +832, 11, 36, 314, 180, 181, 1415, 1416, "," +832, 11, 37, 315, 182, 183, 1417, 1418, "p" +832, 11, 38, 316, 184, 185, 1419, 1420, "<" +832, 11, 39, 317, 186, 187, 1421, 1422, "0" +832, 11, 40, 318, 188, 189, 1423, 1424, "." +832, 11, 41, 319, 190, 192, 1425, 1427, "01" +832, 11, 42, 320, 193, 194, 1428, 1429, ")" +832, 11, 43, 321, 195, 196, 1430, 1431, "." +832, 12, 1, 322, 0, 6, 1432, 1438, "Ocular" +832, 12, 2, 323, 7, 17, 1439, 1449, "irritation" +832, 12, 3, 324, 18, 21, 1450, 1453, "was" +832, 12, 4, 325, 22, 25, 1454, 1457, "the" +832, 12, 5, 326, 26, 30, 1458, 1462, "most" +832, 12, 6, 327, 31, 41, 1463, 1473, "frequently" +832, 12, 7, 328, 42, 50, 1474, 1482, "reported" +832, 12, 8, 329, 51, 58, 1483, 1490, "adverse" +832, 12, 9, 330, 59, 64, 1491, 1496, "event" +832, 12, 10, 331, 65, 67, 1497, 1499, "in" +832, 12, 11, 332, 68, 72, 1500, 1504, "both" +832, 12, 12, 333, 73, 79, 1505, 1511, "groups" +832, 12, 13, 334, 80, 81, 1512, 1513, ";" +832, 12, 14, 335, 82, 84, 1514, 1516, "22" +832, 12, 15, 336, 85, 93, 1517, 1525, "subjects" +832, 12, 16, 337, 94, 95, 1526, 1527, "(" +832, 12, 17, 338, 96, 98, 1528, 1530, "37" +832, 12, 18, 339, 99, 100, 1531, 1532, "." +832, 12, 19, 340, 101, 102, 1533, 1534, "9" +832, 12, 20, 341, 103, 104, 1535, 1536, "%" +832, 12, 21, 342, 105, 106, 1537, 1538, ")" +832, 12, 22, 343, 107, 114, 1539, 1546, "treated" +832, 12, 23, 344, 115, 119, 1547, 1551, "with" +832, 12, 24, 345, 120, 131, 1552, 1563, "bimatoprost" +832, 12, 25, 346, 132, 143, 1564, 1575, "experienced" +832, 12, 26, 347, 144, 150, 1576, 1582, "ocular" +832, 12, 27, 348, 151, 161, 1583, 1593, "hyperaemia" +832, 12, 28, 349, 162, 164, 1594, 1596, "as" +832, 12, 29, 350, 165, 173, 1597, 1605, "compared" +832, 12, 30, 351, 174, 178, 1606, 1610, "with" +832, 12, 31, 352, 179, 181, 1611, 1613, "13" +832, 12, 32, 353, 182, 190, 1614, 1622, "subjects" +832, 12, 33, 354, 191, 192, 1623, 1624, "(" +832, 12, 34, 355, 193, 195, 1625, 1627, "22" +832, 12, 35, 356, 196, 197, 1628, 1629, "." +832, 12, 36, 357, 198, 199, 1630, 1631, "4" +832, 12, 37, 358, 200, 201, 1632, 1633, "%" +832, 12, 38, 359, 202, 203, 1634, 1635, ")" +832, 12, 39, 360, 204, 211, 1636, 1643, "treated" +832, 12, 40, 361, 212, 216, 1644, 1648, "with" +832, 12, 41, 362, 217, 228, 1649, 1660, "latanoprost" +832, 12, 42, 363, 229, 230, 1661, 1662, "(" +832, 12, 43, 364, 231, 232, 1663, 1664, "p" +832, 12, 44, 365, 233, 234, 1665, 1666, "=" +832, 12, 45, 366, 235, 236, 1667, 1668, "0" +832, 12, 46, 367, 237, 238, 1669, 1670, "." +832, 12, 47, 368, 239, 241, 1671, 1673, "11" +832, 12, 48, 369, 242, 243, 1674, 1675, ")" +832, 12, 49, 370, 244, 245, 1676, 1677, "." +832, 13, 1, 371, 0, 11, 1678, 1689, "CONCLUSIONS" +832, 13, 2, 372, 12, 13, 1690, 1691, ":" +832, 13, 3, 373, 14, 25, 1692, 1703, "Bimatoprost" +832, 13, 4, 374, 26, 30, 1704, 1708, "once" +832, 13, 5, 375, 31, 36, 1709, 1714, "daily" +832, 13, 6, 376, 37, 40, 1715, 1718, "was" +832, 13, 7, 377, 41, 50, 1719, 1728, "similarly" +832, 13, 8, 378, 51, 60, 1729, 1738, "effective" +832, 13, 9, 379, 61, 63, 1739, 1741, "in" +832, 13, 10, 380, 64, 72, 1742, 1750, "reducing" +832, 13, 11, 381, 73, 76, 1751, 1754, "IOP" +832, 13, 12, 382, 77, 85, 1755, 1763, "compared" +832, 13, 13, 383, 86, 90, 1764, 1768, "with" +832, 13, 14, 384, 91, 102, 1769, 1780, "latanoprost" +832, 13, 15, 385, 103, 107, 1781, 1785, "once" +832, 13, 16, 386, 108, 113, 1786, 1791, "daily" +832, 13, 17, 387, 114, 116, 1792, 1794, "in" +832, 13, 18, 388, 117, 125, 1795, 1803, "subjects" +832, 13, 19, 389, 126, 130, 1804, 1808, "with" +832, 13, 20, 390, 131, 138, 1809, 1816, "chronic" +832, 13, 21, 391, 139, 143, 1817, 1821, "PACG" +832, 13, 22, 392, 144, 145, 1822, 1823, "." +832, 14, 1, 393, 0, 4, 1824, 1828, "Both" +832, 14, 2, 394, 5, 10, 1829, 1834, "drugs" +832, 14, 3, 395, 11, 15, 1835, 1839, "were" +832, 14, 4, 396, 16, 20, 1840, 1844, "well" +832, 14, 5, 397, 21, 30, 1845, 1854, "tolerated" +832, 14, 6, 398, 31, 35, 1855, 1859, "with" +832, 14, 7, 399, 36, 40, 1860, 1864, "mild" +832, 14, 8, 400, 41, 47, 1865, 1871, "ocular" +832, 14, 9, 401, 48, 55, 1872, 1879, "adverse" +832, 14, 10, 402, 56, 62, 1880, 1886, "events" +832, 14, 11, 403, 63, 64, 1887, 1888, "." +832, 15, 1, 404, 0, 3, 1889, 1892, "DOI" +832, 15, 2, 405, 4, 5, 1893, 1894, ":" +832, 15, 3, 406, 6, 8, 1895, 1897, "10" +832, 15, 4, 407, 9, 10, 1898, 1899, "." +832, 15, 5, 408, 11, 15, 1900, 1904, "1136" +832, 15, 6, 409, 16, 17, 1905, 1906, "/" +832, 15, 7, 410, 18, 21, 1907, 1910, "bjo" +832, 15, 8, 411, 22, 23, 1911, 1912, "." +832, 15, 9, 412, 24, 28, 1913, 1917, "2008" +832, 15, 10, 413, 29, 30, 1918, 1919, "." +832, 15, 11, 414, 31, 37, 1920, 1926, "144535" +832, 15, 12, 415, 38, 42, 1927, 1931, "PMID" +832, 15, 13, 416, 43, 44, 1932, 1933, ":" +832, 15, 14, 417, 45, 53, 1934, 1942, "19336424" +832, 15, 15, 418, 54, 55, 1943, 1944, "[" +832, 15, 16, 419, 56, 63, 1945, 1952, "Indexed" +832, 15, 17, 420, 64, 67, 1953, 1956, "for" +832, 15, 18, 421, 68, 75, 1957, 1964, "MEDLINE" +832, 15, 19, 422, 76, 77, 1965, 1966, "]" diff --git a/data/gl 19336424_admin.annodb b/data/gl 19336424_admin.annodb new file mode 100644 index 0000000..3a1890e --- /dev/null +++ b/data/gl 19336424_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2009", "", " \"2009\"." +2, Title, 109, 225, "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .", "", " \"A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .\"." +3, Randomized, 111, 121, "randomised", "", " ." +4, Crossover, 122, 131, "crossover", "", " ." +5, Bimatoprost, 148, 159, "bimatoprost", "", +6, Latanoprost, 164, 175, "latanoprost", "", " . ." +73, Primary_AngleClosureGlaucoma, 193, 223, "primary angle closure glaucoma", "", " ." +7, Author, 226, 232, "How AC", "", " \"How AC\"." +8, Author, 241, 249, "Kumar RS", "", " \"Kumar RS\"." +9, Author, 252, 259, "Chen YM", "", " \"Chen YM\"." +10, Author, 262, 267, "Su DH", "", " \"Su DH\"." +11, Author, 270, 275, "Gao H", "", " \"Gao H\"." +12, Author, 278, 284, "Oen FT", "", " \"Oen FT\"." +13, Author, 287, 292, "Ho CL", "", " \"Ho CL\"." +14, Author, 295, 302, "Seah SK", "", " \"Seah SK\"." +15, Author, 305, 311, "Aung T", "", " \"Aung T\"." +16, Singapore, 373, 382, "Singapore", "", " ." +107, ObjectiveDescription, 405, 600, "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .", "", " \"To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .\"." +18, IOP, 420, 440, "intraocular pressure", "", +19, IOP, 443, 446, "IOP", "", +20, Latanoprost, 487, 498, "latanoprost", "", +21, DoseValue, 499, 506, "0 . 005", "", " \"0 . 005\"." +22, Percentage, 507, 508, "%", "", " ." +23, Bimatoprost, 513, 524, "bimatoprost", "", " ." +77, DoseValue, 525, 531, "0 . 03", "", " \"0 . 03\"." +78, Percentage, 532, 533, "%", "", " ." +78500, Precondition, 537, 598, "subjects with chronic primary angle closure glaucoma ( PACG )", "", " \"subjects with chronic primary angle closure glaucoma ( PACG )\"." +75, Primary_AngleClosureGlaucoma, 559, 589, "primary angle closure glaucoma", "", +76, Primary_AngleClosureGlaucoma, 592, 596, "PACG", "", " ." +24, Blind, 623, 640, "observer - masked", "", " ." +25, Randomized, 641, 651, "randomised", "", +26, Crossover, 652, 661, "crossover", "", +27, NumberPatientsCT, 671, 673, "60", "", " \"60\"." +74, Primary_AngleClosureGlaucoma, 674, 678, "PACG", "", +28, Latanoprost, 708, 719, "latanoprost", "", +29, Bimatoprost, 723, 734, "bimatoprost", "", +30, Duration, 739, 746, "6 weeks", "", " \"6 weeks\"." +32, Crossover, 771, 783, "crossed over", "", +31, Duration, 820, 827, "6 weeks", "", +33, IOP, 834, 837, "IOP", "", +34, IOP, 908, 911, "IOP", "", +78505, TimePoint, 918, 925, "6 weeks", "", +78504, TimePoint, 953, 961, "baseline", "", +36, FinalNumPatientsCT, 974, 986, "Fifty - four", "", " \"Fifty - four\"." +37, Latanoprost, 1030, 1041, "Latanoprost", "", +38, IOP, 1050, 1053, "IOP", "", " . ." +121, Mean, 1056, 1060, "mean", "", " . ." +39, Reduction, 1073, 1078, "8 . 4", "", " \"8 . 4\"." +40, SdDevChangeValue, 1081, 1086, "3 . 8", "", " \"3 . 8\"." +41, mmHg, 1089, 1094, "mm Hg", "", +42, Bimatoprost, 1099, 1110, "bimatoprost", "", +43, Reduction, 1114, 1119, "8 . 9", "", " \"8 . 9\"." +44, SdDevChangeValue, 1122, 1127, "3 . 9", "", " \"3 . 9\"." +45, mmHg, 1130, 1135, "mm Hg", "", +78506, TimePoint, 1143, 1151, "baseline", "", +46, BaseLineValue, 1155, 1161, "25 . 2", "", " \"25 . 2\"." +47, SdDevBL, 1164, 1169, "3 . 6", "", " \"3 . 6\"." +48, mmHg, 1172, 1177, "mm Hg", "", +49, BaseLineValue, 1182, 1188, "25 . 2", "", " \"25 . 2\"." +50, SdDevBL, 1191, 1196, "3 . 6", "", " \"3 . 6\"." +51, mmHg, 1199, 1204, "mm Hg", "", " ." +135, PvalueDiff, 1222, 1230, "= 0 . 23", "", " \"= 0 . 23\"." +78507, EndPointDescription, 1324, 1337, "adverse event", "", " . ." +53, Bimatoprost, 1345, 1356, "bimatoprost", "", +54, PercentageAffected, 1365, 1367, "81", "", " \"81\"." +55, Latanoprost, 1390, 1401, "latanoprost", "", +56, PercentageAffected, 1410, 1412, "40", "", " \"40\"." +141, PvalueDiff, 1419, 1427, "< 0 . 01", "", " \"< 0 . 01\"." +78510, EndPointDescription, 1432, 1449, "Ocular irritation", "", " . ." +58, NumberAffected, 1514, 1516, "22", "", " \"22\"." +59, PercentageAffected, 1528, 1534, "37 . 9", "", " \"37 . 9\"." +60, Bimatoprost, 1552, 1563, "bimatoprost", "", +146, OcularHypertension, 1576, 1593, "ocular hyperaemia", "", " ." +61, NumberAffected, 1611, 1613, "13", "", " \"13\"." +62, PercentageAffected, 1625, 1631, "22 . 4", "", " \"22 . 4\"." +63, Latanoprost, 1649, 1660, "latanoprost", "", +150, PvalueDiff, 1665, 1673, "= 0 . 11", "", " \"= 0 . 11\"." +65, ConclusionComment, 1692, 1823, "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .", "", " \"Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .\"." +67, Bimatoprost, 1692, 1703, "Bimatoprost", "", +68, Frequency, 1704, 1714, "once daily", "", " \"once daily\"." +69, IOP, 1751, 1754, "IOP", "", +70, Latanoprost, 1769, 1780, "latanoprost", "", +71, Frequency, 1781, 1791, "once daily", "", " \"once daily\"." +156, Primary_AngleClosureGlaucoma, 1817, 1821, "PACG", "", +66, ConclusionComment, 1824, 1888, "Both drugs were well tolerated with mild ocular adverse events .", "", " \"Both drugs were well tolerated with mild ocular adverse events .\"." +72, PMID, 1934, 1942, "19336424", "", " \"19336424\"." diff --git a/data/gl 19336424_admin.n-triples b/data/gl 19336424_admin.n-triples new file mode 100644 index 0000000..0f6d942 --- /dev/null +++ b/data/gl 19336424_admin.n-triples @@ -0,0 +1,158 @@ +# RDF export of group: Publication + . + "Publication" . + "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma ." . + "How AC" . + "2009" . + "Br J Ophthalmol ." . + "19336424" . + . + "Kumar RS" . + "Chen YM" . + "Su DH" . + "Gao H" . + "Oen FT" . + "Ho CL" . + "Seah SK" . + "Aung T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) ." . + "60" . + "6 weeks" . + . + . + . + "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG ." . + . + . + . + . + . + "Fifty - four" . + . + . + . + "Both drugs were well tolerated with mild ocular adverse events ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "subjects with chronic primary angle closure glaucoma ( PACG )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . + . + "Endpoint_O" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + . + . + "Arm_bim" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_bim" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_bim" . + . + "0 . 03" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat" . + . + "25 . 2" . + "3 . 6" . + "8 . 4" . + "3 . 8" . + . + "Outcome_iop_bim" . + . + "25 . 2" . + "3 . 6" . + "8 . 9" . + "3 . 9" . + . + "Outcome_AE_lat" . + . + "40" . + . + "Outcome_AE_bim" . + . + "81" . + . + "Outcome_O_lat" . + . + "13" . + "22 . 4" . + . + "Outcome_O_bim" . + . + "22" . + "37 . 9" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "= 0 . 23" . + . + . + . + "DiffBetweenGroups_AE" . + "< 0 . 01" . + . + . + . + "DiffBetweenGroups_O" . + "= 0 . 11" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19336424_export.csv b/data/gl 19336424_export.csv new file mode 100644 index 0000000..6698a17 --- /dev/null +++ b/data/gl 19336424_export.csv @@ -0,0 +1,423 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +446, 1, 1, 1, 0, 2, 0, 2, "Br" +446, 1, 2, 2, 3, 4, 3, 4, "J" +446, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +446, 1, 4, 4, 16, 17, 16, 17, "." +446, 2, 1, 5, 0, 4, 18, 22, "2009" +446, 2, 2, 6, 5, 8, 23, 26, "Jun" +446, 2, 3, 7, 9, 10, 27, 28, ";" +446, 2, 4, 8, 11, 13, 29, 31, "93" +446, 2, 5, 9, 14, 15, 32, 33, "(" +446, 2, 6, 10, 16, 17, 34, 35, "6" +446, 2, 7, 11, 18, 19, 36, 37, ")" +446, 2, 8, 12, 20, 21, 38, 39, ":" +446, 2, 9, 13, 22, 25, 40, 43, "782" +446, 2, 10, 14, 26, 27, 44, 45, "-" +446, 2, 11, 15, 28, 29, 46, 47, "6" +446, 2, 12, 16, 30, 31, 48, 49, "." +446, 2, 13, 17, 32, 35, 50, 53, "doi" +446, 2, 14, 18, 36, 37, 54, 55, ":" +446, 2, 15, 19, 38, 40, 56, 58, "10" +446, 2, 16, 20, 41, 42, 59, 60, "." +446, 2, 17, 21, 43, 47, 61, 65, "1136" +446, 2, 18, 22, 48, 49, 66, 67, "/" +446, 2, 19, 23, 50, 53, 68, 71, "bjo" +446, 2, 20, 24, 54, 55, 72, 73, "." +446, 2, 21, 25, 56, 60, 74, 78, "2008" +446, 2, 22, 26, 61, 62, 79, 80, "." +446, 2, 23, 27, 63, 69, 81, 87, "144535" +446, 2, 24, 28, 70, 71, 88, 89, "." +446, 3, 1, 29, 0, 4, 90, 94, "Epub" +446, 3, 2, 30, 5, 9, 95, 99, "2009" +446, 3, 3, 31, 10, 13, 100, 103, "Mar" +446, 3, 4, 32, 14, 16, 104, 106, "30" +446, 3, 5, 33, 17, 18, 107, 108, "." +446, 4, 1, 34, 0, 1, 109, 110, "A" +446, 4, 2, 35, 2, 12, 111, 121, "randomised" +446, 4, 3, 36, 13, 22, 122, 131, "crossover" +446, 4, 4, 37, 23, 28, 132, 137, "study" +446, 4, 5, 38, 29, 38, 138, 147, "comparing" +446, 4, 6, 39, 39, 50, 148, 159, "bimatoprost" +446, 4, 7, 40, 51, 54, 160, 163, "and" +446, 4, 8, 41, 55, 66, 164, 175, "latanoprost" +446, 4, 9, 42, 67, 69, 176, 178, "in" +446, 4, 10, 43, 70, 78, 179, 187, "subjects" +446, 4, 11, 44, 79, 83, 188, 192, "with" +446, 4, 12, 45, 84, 91, 193, 200, "primary" +446, 4, 13, 46, 92, 97, 201, 206, "angle" +446, 4, 14, 47, 98, 105, 207, 214, "closure" +446, 4, 15, 48, 106, 114, 215, 223, "glaucoma" +446, 4, 16, 49, 115, 116, 224, 225, "." +446, 5, 1, 50, 0, 3, 226, 229, "How" +446, 5, 2, 51, 4, 6, 230, 232, "AC" +446, 5, 3, 52, 7, 8, 233, 234, "(" +446, 5, 4, 53, 9, 10, 235, 236, "1" +446, 5, 5, 54, 11, 12, 237, 238, ")" +446, 5, 6, 55, 13, 14, 239, 240, "," +446, 5, 7, 56, 15, 20, 241, 246, "Kumar" +446, 5, 8, 57, 21, 23, 247, 249, "RS" +446, 5, 9, 58, 24, 25, 250, 251, "," +446, 5, 10, 59, 26, 30, 252, 256, "Chen" +446, 5, 11, 60, 31, 33, 257, 259, "YM" +446, 5, 12, 61, 34, 35, 260, 261, "," +446, 5, 13, 62, 36, 38, 262, 264, "Su" +446, 5, 14, 63, 39, 41, 265, 267, "DH" +446, 5, 15, 64, 42, 43, 268, 269, "," +446, 5, 16, 65, 44, 47, 270, 273, "Gao" +446, 5, 17, 66, 48, 49, 274, 275, "H" +446, 5, 18, 67, 50, 51, 276, 277, "," +446, 5, 19, 68, 52, 55, 278, 281, "Oen" +446, 5, 20, 69, 56, 58, 282, 284, "FT" +446, 5, 21, 70, 59, 60, 285, 286, "," +446, 5, 22, 71, 61, 63, 287, 289, "Ho" +446, 5, 23, 72, 64, 66, 290, 292, "CL" +446, 5, 24, 73, 67, 68, 293, 294, "," +446, 5, 25, 74, 69, 73, 295, 299, "Seah" +446, 5, 26, 75, 74, 76, 300, 302, "SK" +446, 5, 27, 76, 77, 78, 303, 304, "," +446, 5, 28, 77, 79, 83, 305, 309, "Aung" +446, 5, 29, 78, 84, 85, 310, 311, "T" +446, 5, 30, 79, 86, 87, 312, 313, "." +446, 5, 31, 80, 88, 94, 314, 320, "Author" +446, 5, 32, 81, 95, 106, 321, 332, "information" +446, 5, 33, 82, 107, 108, 333, 334, ":" +446, 5, 34, 83, 109, 110, 335, 336, "(" +446, 5, 35, 84, 111, 112, 337, 338, "1" +446, 5, 36, 85, 113, 114, 339, 340, ")" +446, 5, 37, 86, 115, 124, 341, 350, "Singapore" +446, 5, 38, 87, 125, 133, 351, 359, "National" +446, 5, 39, 88, 134, 137, 360, 363, "Eye" +446, 5, 40, 89, 138, 144, 364, 370, "Centre" +446, 5, 41, 90, 145, 146, 371, 372, "," +446, 5, 42, 91, 147, 156, 373, 382, "Singapore" +446, 5, 43, 92, 157, 158, 383, 384, "." +446, 6, 1, 93, 0, 10, 385, 395, "BACKGROUND" +446, 6, 2, 94, 11, 12, 396, 397, "/" +446, 6, 3, 95, 13, 17, 398, 402, "AIMS" +446, 6, 4, 96, 18, 19, 403, 404, ":" +446, 6, 5, 97, 20, 22, 405, 407, "To" +446, 6, 6, 98, 23, 30, 408, 415, "compare" +446, 6, 7, 99, 31, 34, 416, 419, "the" +446, 6, 8, 100, 35, 46, 420, 431, "intraocular" +446, 6, 9, 101, 47, 55, 432, 440, "pressure" +446, 6, 10, 102, 56, 57, 441, 442, "(" +446, 6, 11, 103, 58, 61, 443, 446, "IOP" +446, 6, 12, 104, 62, 63, 447, 448, ")" +446, 6, 13, 105, 64, 72, 449, 457, "lowering" +446, 6, 14, 106, 73, 81, 458, 466, "efficacy" +446, 6, 15, 107, 82, 85, 467, 470, "and" +446, 6, 16, 108, 86, 90, 471, 475, "side" +446, 6, 17, 109, 91, 98, 476, 483, "effects" +446, 6, 18, 110, 99, 101, 484, 486, "of" +446, 6, 19, 111, 102, 113, 487, 498, "latanoprost" +446, 6, 20, 112, 114, 115, 499, 500, "0" +446, 6, 21, 113, 116, 117, 501, 502, "." +446, 6, 22, 114, 118, 121, 503, 506, "005" +446, 6, 23, 115, 122, 123, 507, 508, "%" +446, 6, 24, 116, 124, 127, 509, 512, "and" +446, 6, 25, 117, 128, 139, 513, 524, "bimatoprost" +446, 6, 26, 118, 140, 141, 525, 526, "0" +446, 6, 27, 119, 142, 143, 527, 528, "." +446, 6, 28, 120, 144, 146, 529, 531, "03" +446, 6, 29, 121, 147, 148, 532, 533, "%" +446, 6, 30, 122, 149, 151, 534, 536, "in" +446, 6, 31, 123, 152, 160, 537, 545, "subjects" +446, 6, 32, 124, 161, 165, 546, 550, "with" +446, 6, 33, 125, 166, 173, 551, 558, "chronic" +446, 6, 34, 126, 174, 181, 559, 566, "primary" +446, 6, 35, 127, 182, 187, 567, 572, "angle" +446, 6, 36, 128, 188, 195, 573, 580, "closure" +446, 6, 37, 129, 196, 204, 581, 589, "glaucoma" +446, 6, 38, 130, 205, 206, 590, 591, "(" +446, 6, 39, 131, 207, 211, 592, 596, "PACG" +446, 6, 40, 132, 212, 213, 597, 598, ")" +446, 6, 41, 133, 214, 215, 599, 600, "." +446, 7, 1, 134, 0, 7, 601, 608, "METHODS" +446, 7, 2, 135, 8, 9, 609, 610, ":" +446, 7, 3, 136, 10, 14, 611, 615, "This" +446, 7, 4, 137, 15, 18, 616, 619, "was" +446, 7, 5, 138, 19, 21, 620, 622, "an" +446, 7, 6, 139, 22, 30, 623, 631, "observer" +446, 7, 7, 140, 31, 32, 632, 633, "-" +446, 7, 8, 141, 33, 39, 634, 640, "masked" +446, 7, 9, 142, 40, 50, 641, 651, "randomised" +446, 7, 10, 143, 51, 60, 652, 661, "crossover" +446, 7, 11, 144, 61, 66, 662, 667, "study" +446, 7, 12, 145, 67, 69, 668, 670, "of" +446, 7, 13, 146, 70, 72, 671, 673, "60" +446, 7, 14, 147, 73, 77, 674, 678, "PACG" +446, 7, 15, 148, 78, 86, 679, 687, "subjects" +446, 7, 16, 149, 87, 90, 688, 691, "who" +446, 7, 17, 150, 91, 99, 692, 700, "received" +446, 7, 18, 151, 100, 106, 701, 707, "either" +446, 7, 19, 152, 107, 118, 708, 719, "latanoprost" +446, 7, 20, 153, 119, 121, 720, 722, "or" +446, 7, 21, 154, 122, 133, 723, 734, "bimatoprost" +446, 7, 22, 155, 134, 137, 735, 738, "for" +446, 7, 23, 156, 138, 139, 739, 740, "6" +446, 7, 24, 157, 140, 145, 741, 746, "weeks" +446, 7, 25, 158, 146, 147, 747, 748, "," +446, 7, 26, 159, 148, 153, 749, 754, "after" +446, 7, 27, 160, 154, 159, 755, 760, "which" +446, 7, 28, 161, 160, 164, 761, 765, "they" +446, 7, 29, 162, 165, 169, 766, 770, "were" +446, 7, 30, 163, 170, 177, 771, 778, "crossed" +446, 7, 31, 164, 178, 182, 779, 783, "over" +446, 7, 32, 165, 183, 185, 784, 786, "to" +446, 7, 33, 166, 186, 189, 787, 790, "the" +446, 7, 34, 167, 190, 195, 791, 796, "other" +446, 7, 35, 168, 196, 206, 797, 807, "medication" +446, 7, 36, 169, 207, 210, 808, 811, "for" +446, 7, 37, 170, 211, 218, 812, 819, "another" +446, 7, 38, 171, 219, 220, 820, 821, "6" +446, 7, 39, 172, 221, 226, 822, 827, "weeks" +446, 7, 40, 173, 227, 228, 828, 829, "." +446, 8, 1, 174, 0, 3, 830, 833, "The" +446, 8, 2, 175, 4, 7, 834, 837, "IOP" +446, 8, 3, 176, 8, 9, 838, 839, "-" +446, 8, 4, 177, 10, 18, 840, 848, "reducing" +446, 8, 5, 178, 19, 25, 849, 855, "effect" +446, 8, 6, 179, 26, 28, 856, 858, "of" +446, 8, 7, 180, 29, 32, 859, 862, "the" +446, 8, 8, 181, 33, 44, 863, 874, "medications" +446, 8, 9, 182, 45, 48, 875, 878, "was" +446, 8, 10, 183, 49, 57, 879, 887, "assessed" +446, 8, 11, 184, 58, 60, 888, 890, "by" +446, 8, 12, 185, 61, 64, 891, 894, "the" +446, 8, 13, 186, 65, 74, 895, 904, "reduction" +446, 8, 14, 187, 75, 77, 905, 907, "in" +446, 8, 15, 188, 78, 81, 908, 911, "IOP" +446, 8, 16, 189, 82, 87, 912, 917, "after" +446, 8, 17, 190, 88, 89, 918, 919, "6" +446, 8, 18, 191, 90, 95, 920, 925, "weeks" +446, 8, 19, 192, 96, 98, 926, 928, "of" +446, 8, 20, 193, 99, 108, 929, 938, "treatment" +446, 8, 21, 194, 109, 117, 939, 947, "compared" +446, 8, 22, 195, 118, 122, 948, 952, "with" +446, 8, 23, 196, 123, 131, 953, 961, "baseline" +446, 8, 24, 197, 132, 133, 962, 963, "." +446, 9, 1, 198, 0, 7, 964, 971, "RESULTS" +446, 9, 2, 199, 8, 9, 972, 973, ":" +446, 9, 3, 200, 10, 15, 974, 979, "Fifty" +446, 9, 4, 201, 16, 17, 980, 981, "-" +446, 9, 5, 202, 18, 22, 982, 986, "four" +446, 9, 6, 203, 23, 31, 987, 995, "subjects" +446, 9, 7, 204, 32, 33, 996, 997, "(" +446, 9, 8, 205, 34, 36, 998, 1000, "80" +446, 9, 9, 206, 37, 41, 1001, 1005, "eyes" +446, 9, 10, 207, 42, 43, 1006, 1007, ")" +446, 9, 11, 208, 44, 53, 1008, 1017, "completed" +446, 9, 12, 209, 54, 57, 1018, 1021, "the" +446, 9, 13, 210, 58, 63, 1022, 1027, "study" +446, 9, 14, 211, 64, 65, 1028, 1029, "." +446, 10, 1, 212, 0, 11, 1030, 1041, "Latanoprost" +446, 10, 2, 213, 12, 19, 1042, 1049, "reduced" +446, 10, 3, 214, 20, 23, 1050, 1053, "IOP" +446, 10, 4, 215, 24, 25, 1054, 1055, "(" +446, 10, 5, 216, 26, 30, 1056, 1060, "mean" +446, 10, 6, 217, 31, 32, 1061, 1062, "(" +446, 10, 7, 218, 33, 35, 1063, 1065, "SD" +446, 10, 8, 219, 36, 37, 1066, 1067, ")" +446, 10, 9, 220, 38, 39, 1068, 1069, ")" +446, 10, 10, 221, 40, 42, 1070, 1072, "by" +446, 10, 11, 222, 43, 44, 1073, 1074, "8" +446, 10, 12, 223, 45, 46, 1075, 1076, "." +446, 10, 13, 224, 47, 48, 1077, 1078, "4" +446, 10, 14, 225, 49, 50, 1079, 1080, "(" +446, 10, 15, 226, 51, 52, 1081, 1082, "3" +446, 10, 16, 227, 53, 54, 1083, 1084, "." +446, 10, 17, 228, 55, 56, 1085, 1086, "8" +446, 10, 18, 229, 57, 58, 1087, 1088, ")" +446, 10, 19, 230, 59, 61, 1089, 1091, "mm" +446, 10, 20, 231, 62, 64, 1092, 1094, "Hg" +446, 10, 21, 232, 65, 68, 1095, 1098, "and" +446, 10, 22, 233, 69, 80, 1099, 1110, "bimatoprost" +446, 10, 23, 234, 81, 83, 1111, 1113, "by" +446, 10, 24, 235, 84, 85, 1114, 1115, "8" +446, 10, 25, 236, 86, 87, 1116, 1117, "." +446, 10, 26, 237, 88, 89, 1118, 1119, "9" +446, 10, 27, 238, 90, 91, 1120, 1121, "(" +446, 10, 28, 239, 92, 93, 1122, 1123, "3" +446, 10, 29, 240, 94, 95, 1124, 1125, "." +446, 10, 30, 241, 96, 97, 1126, 1127, "9" +446, 10, 31, 242, 98, 99, 1128, 1129, ")" +446, 10, 32, 243, 100, 102, 1130, 1132, "mm" +446, 10, 33, 244, 103, 105, 1133, 1135, "Hg" +446, 10, 34, 245, 106, 110, 1136, 1140, "from" +446, 10, 35, 246, 111, 112, 1141, 1142, "a" +446, 10, 36, 247, 113, 121, 1143, 1151, "baseline" +446, 10, 37, 248, 122, 124, 1152, 1154, "of" +446, 10, 38, 249, 125, 127, 1155, 1157, "25" +446, 10, 39, 250, 128, 129, 1158, 1159, "." +446, 10, 40, 251, 130, 131, 1160, 1161, "2" +446, 10, 41, 252, 132, 133, 1162, 1163, "(" +446, 10, 42, 253, 134, 135, 1164, 1165, "3" +446, 10, 43, 254, 136, 137, 1166, 1167, "." +446, 10, 44, 255, 138, 139, 1168, 1169, "6" +446, 10, 45, 256, 140, 141, 1170, 1171, ")" +446, 10, 46, 257, 142, 144, 1172, 1174, "mm" +446, 10, 47, 258, 145, 147, 1175, 1177, "Hg" +446, 10, 48, 259, 148, 151, 1178, 1181, "and" +446, 10, 49, 260, 152, 154, 1182, 1184, "25" +446, 10, 50, 261, 155, 156, 1185, 1186, "." +446, 10, 51, 262, 157, 158, 1187, 1188, "2" +446, 10, 52, 263, 159, 160, 1189, 1190, "(" +446, 10, 53, 264, 161, 162, 1191, 1192, "3" +446, 10, 54, 265, 163, 164, 1193, 1194, "." +446, 10, 55, 266, 165, 166, 1195, 1196, "6" +446, 10, 56, 267, 167, 168, 1197, 1198, ")" +446, 10, 57, 268, 169, 171, 1199, 1201, "mm" +446, 10, 58, 269, 172, 174, 1202, 1204, "Hg" +446, 10, 59, 270, 175, 187, 1205, 1217, "respectively" +446, 10, 60, 271, 188, 189, 1218, 1219, "(" +446, 10, 61, 272, 190, 191, 1220, 1221, "p" +446, 10, 62, 273, 192, 193, 1222, 1223, "=" +446, 10, 63, 274, 194, 195, 1224, 1225, "0" +446, 10, 64, 275, 196, 197, 1226, 1227, "." +446, 10, 65, 276, 198, 200, 1228, 1230, "23" +446, 10, 66, 277, 201, 202, 1231, 1232, ")" +446, 10, 67, 278, 203, 204, 1233, 1234, "." +446, 11, 1, 279, 0, 7, 1235, 1242, "Adverse" +446, 11, 2, 280, 8, 14, 1243, 1249, "events" +446, 11, 3, 281, 15, 19, 1250, 1254, "were" +446, 11, 4, 282, 20, 24, 1255, 1259, "mild" +446, 11, 5, 283, 25, 27, 1260, 1262, "in" +446, 11, 6, 284, 28, 32, 1263, 1267, "both" +446, 11, 7, 285, 33, 39, 1268, 1274, "groups" +446, 11, 8, 286, 40, 41, 1275, 1276, ";" +446, 11, 9, 287, 42, 49, 1277, 1284, "however" +446, 11, 10, 288, 50, 55, 1285, 1290, "there" +446, 11, 11, 289, 56, 60, 1291, 1295, "were" +446, 11, 12, 290, 61, 66, 1296, 1301, "twice" +446, 11, 13, 291, 67, 69, 1302, 1304, "as" +446, 11, 14, 292, 70, 74, 1305, 1309, "many" +446, 11, 15, 293, 75, 82, 1310, 1317, "reports" +446, 11, 16, 294, 83, 85, 1318, 1320, "of" +446, 11, 17, 295, 86, 88, 1321, 1323, "an" +446, 11, 18, 296, 89, 96, 1324, 1331, "adverse" +446, 11, 19, 297, 97, 102, 1332, 1337, "event" +446, 11, 20, 298, 103, 105, 1338, 1340, "in" +446, 11, 21, 299, 106, 109, 1341, 1344, "the" +446, 11, 22, 300, 110, 121, 1345, 1356, "bimatoprost" +446, 11, 23, 301, 122, 127, 1357, 1362, "group" +446, 11, 24, 302, 128, 129, 1363, 1364, "(" +446, 11, 25, 303, 130, 132, 1365, 1367, "81" +446, 11, 26, 304, 133, 134, 1368, 1369, "%" +446, 11, 27, 305, 135, 136, 1370, 1371, ")" +446, 11, 28, 306, 137, 145, 1372, 1380, "compared" +446, 11, 29, 307, 146, 150, 1381, 1385, "with" +446, 11, 30, 308, 151, 154, 1386, 1389, "the" +446, 11, 31, 309, 155, 166, 1390, 1401, "latanoprost" +446, 11, 32, 310, 167, 172, 1402, 1407, "group" +446, 11, 33, 311, 173, 174, 1408, 1409, "(" +446, 11, 34, 312, 175, 177, 1410, 1412, "40" +446, 11, 35, 313, 178, 179, 1413, 1414, "%" +446, 11, 36, 314, 180, 181, 1415, 1416, "," +446, 11, 37, 315, 182, 183, 1417, 1418, "p" +446, 11, 38, 316, 184, 185, 1419, 1420, "<" +446, 11, 39, 317, 186, 187, 1421, 1422, "0" +446, 11, 40, 318, 188, 189, 1423, 1424, "." +446, 11, 41, 319, 190, 192, 1425, 1427, "01" +446, 11, 42, 320, 193, 194, 1428, 1429, ")" +446, 11, 43, 321, 195, 196, 1430, 1431, "." +446, 12, 1, 322, 0, 6, 1432, 1438, "Ocular" +446, 12, 2, 323, 7, 17, 1439, 1449, "irritation" +446, 12, 3, 324, 18, 21, 1450, 1453, "was" +446, 12, 4, 325, 22, 25, 1454, 1457, "the" +446, 12, 5, 326, 26, 30, 1458, 1462, "most" +446, 12, 6, 327, 31, 41, 1463, 1473, "frequently" +446, 12, 7, 328, 42, 50, 1474, 1482, "reported" +446, 12, 8, 329, 51, 58, 1483, 1490, "adverse" +446, 12, 9, 330, 59, 64, 1491, 1496, "event" +446, 12, 10, 331, 65, 67, 1497, 1499, "in" +446, 12, 11, 332, 68, 72, 1500, 1504, "both" +446, 12, 12, 333, 73, 79, 1505, 1511, "groups" +446, 12, 13, 334, 80, 81, 1512, 1513, ";" +446, 12, 14, 335, 82, 84, 1514, 1516, "22" +446, 12, 15, 336, 85, 93, 1517, 1525, "subjects" +446, 12, 16, 337, 94, 95, 1526, 1527, "(" +446, 12, 17, 338, 96, 98, 1528, 1530, "37" +446, 12, 18, 339, 99, 100, 1531, 1532, "." +446, 12, 19, 340, 101, 102, 1533, 1534, "9" +446, 12, 20, 341, 103, 104, 1535, 1536, "%" +446, 12, 21, 342, 105, 106, 1537, 1538, ")" +446, 12, 22, 343, 107, 114, 1539, 1546, "treated" +446, 12, 23, 344, 115, 119, 1547, 1551, "with" +446, 12, 24, 345, 120, 131, 1552, 1563, "bimatoprost" +446, 12, 25, 346, 132, 143, 1564, 1575, "experienced" +446, 12, 26, 347, 144, 150, 1576, 1582, "ocular" +446, 12, 27, 348, 151, 161, 1583, 1593, "hyperaemia" +446, 12, 28, 349, 162, 164, 1594, 1596, "as" +446, 12, 29, 350, 165, 173, 1597, 1605, "compared" +446, 12, 30, 351, 174, 178, 1606, 1610, "with" +446, 12, 31, 352, 179, 181, 1611, 1613, "13" +446, 12, 32, 353, 182, 190, 1614, 1622, "subjects" +446, 12, 33, 354, 191, 192, 1623, 1624, "(" +446, 12, 34, 355, 193, 195, 1625, 1627, "22" +446, 12, 35, 356, 196, 197, 1628, 1629, "." +446, 12, 36, 357, 198, 199, 1630, 1631, "4" +446, 12, 37, 358, 200, 201, 1632, 1633, "%" +446, 12, 38, 359, 202, 203, 1634, 1635, ")" +446, 12, 39, 360, 204, 211, 1636, 1643, "treated" +446, 12, 40, 361, 212, 216, 1644, 1648, "with" +446, 12, 41, 362, 217, 228, 1649, 1660, "latanoprost" +446, 12, 42, 363, 229, 230, 1661, 1662, "(" +446, 12, 43, 364, 231, 232, 1663, 1664, "p" +446, 12, 44, 365, 233, 234, 1665, 1666, "=" +446, 12, 45, 366, 235, 236, 1667, 1668, "0" +446, 12, 46, 367, 237, 238, 1669, 1670, "." +446, 12, 47, 368, 239, 241, 1671, 1673, "11" +446, 12, 48, 369, 242, 243, 1674, 1675, ")" +446, 12, 49, 370, 244, 245, 1676, 1677, "." +446, 13, 1, 371, 0, 11, 1678, 1689, "CONCLUSIONS" +446, 13, 2, 372, 12, 13, 1690, 1691, ":" +446, 13, 3, 373, 14, 25, 1692, 1703, "Bimatoprost" +446, 13, 4, 374, 26, 30, 1704, 1708, "once" +446, 13, 5, 375, 31, 36, 1709, 1714, "daily" +446, 13, 6, 376, 37, 40, 1715, 1718, "was" +446, 13, 7, 377, 41, 50, 1719, 1728, "similarly" +446, 13, 8, 378, 51, 60, 1729, 1738, "effective" +446, 13, 9, 379, 61, 63, 1739, 1741, "in" +446, 13, 10, 380, 64, 72, 1742, 1750, "reducing" +446, 13, 11, 381, 73, 76, 1751, 1754, "IOP" +446, 13, 12, 382, 77, 85, 1755, 1763, "compared" +446, 13, 13, 383, 86, 90, 1764, 1768, "with" +446, 13, 14, 384, 91, 102, 1769, 1780, "latanoprost" +446, 13, 15, 385, 103, 107, 1781, 1785, "once" +446, 13, 16, 386, 108, 113, 1786, 1791, "daily" +446, 13, 17, 387, 114, 116, 1792, 1794, "in" +446, 13, 18, 388, 117, 125, 1795, 1803, "subjects" +446, 13, 19, 389, 126, 130, 1804, 1808, "with" +446, 13, 20, 390, 131, 138, 1809, 1816, "chronic" +446, 13, 21, 391, 139, 143, 1817, 1821, "PACG" +446, 13, 22, 392, 144, 145, 1822, 1823, "." +446, 14, 1, 393, 0, 4, 1824, 1828, "Both" +446, 14, 2, 394, 5, 10, 1829, 1834, "drugs" +446, 14, 3, 395, 11, 15, 1835, 1839, "were" +446, 14, 4, 396, 16, 20, 1840, 1844, "well" +446, 14, 5, 397, 21, 30, 1845, 1854, "tolerated" +446, 14, 6, 398, 31, 35, 1855, 1859, "with" +446, 14, 7, 399, 36, 40, 1860, 1864, "mild" +446, 14, 8, 400, 41, 47, 1865, 1871, "ocular" +446, 14, 9, 401, 48, 55, 1872, 1879, "adverse" +446, 14, 10, 402, 56, 62, 1880, 1886, "events" +446, 14, 11, 403, 63, 64, 1887, 1888, "." +446, 15, 1, 404, 0, 3, 1889, 1892, "DOI" +446, 15, 2, 405, 4, 5, 1893, 1894, ":" +446, 15, 3, 406, 6, 8, 1895, 1897, "10" +446, 15, 4, 407, 9, 10, 1898, 1899, "." +446, 15, 5, 408, 11, 15, 1900, 1904, "1136" +446, 15, 6, 409, 16, 17, 1905, 1906, "/" +446, 15, 7, 410, 18, 21, 1907, 1910, "bjo" +446, 15, 8, 411, 22, 23, 1911, 1912, "." +446, 15, 9, 412, 24, 28, 1913, 1917, "2008" +446, 15, 10, 413, 29, 30, 1918, 1919, "." +446, 15, 11, 414, 31, 37, 1920, 1926, "144535" +446, 15, 12, 415, 38, 42, 1927, 1931, "PMID" +446, 15, 13, 416, 43, 44, 1932, 1933, ":" +446, 15, 14, 417, 45, 53, 1934, 1942, "19336424" +446, 15, 15, 418, 54, 55, 1943, 1944, "[" +446, 15, 16, 419, 56, 63, 1945, 1952, "Indexed" +446, 15, 17, 420, 64, 67, 1953, 1956, "for" +446, 15, 18, 421, 68, 75, 1957, 1964, "MEDLINE" +446, 15, 19, 422, 76, 77, 1965, 1966, "]" diff --git a/data/gl 19336424_jshahinitiran.annodb b/data/gl 19336424_jshahinitiran.annodb new file mode 100644 index 0000000..9400301 --- /dev/null +++ b/data/gl 19336424_jshahinitiran.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12148, Journal, 0, 15, "Br J Ophthalmol", "", +12149, PublicationYear, 18, 22, "2009", "", +12150, Title, 109, 225, "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .", "", +12151, Randomized, 111, 121, "randomised", "", +12152, Crossover, 122, 131, "crossover", "", +12153, Bimatoprost, 148, 159, "bimatoprost", "", +12154, Latanoprost, 164, 175, "latanoprost", "", +28244, Primary_AngleClosureGlaucoma, 193, 223, "primary angle closure glaucoma", "", +12156, Author, 226, 232, "How AC", "", +12157, Author, 241, 249, "Kumar RS", "", +12158, Author, 252, 259, "Chen YM", "", +12159, Author, 262, 267, "Su DH", "", +12160, Author, 270, 275, "Gao H", "", +12161, Author, 278, 284, "Oen FT", "", +12162, Author, 287, 292, "Ho CL", "", +12163, Author, 295, 302, "Seah SK", "", +12164, Author, 305, 311, "Aung T", "", +12165, Singapore, 373, 382, "Singapore", "", +12166, Title, 405, 600, "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .", "", +12167, IOP, 420, 440, "intraocular pressure", "", +12168, IOP, 443, 446, "IOP", "", +12169, Latanoprost, 487, 498, "latanoprost", "", +12170, DoseValue, 499, 506, "0 . 005", "", +12171, Percentage, 507, 508, "%", "", +12172, Bimatoprost, 513, 524, "bimatoprost", "", +28248, DoseValue, 525, 531, "0 . 03", "", +28249, Percentage, 532, 533, "%", "", +28246, Primary_AngleClosureGlaucoma, 559, 589, "primary angle closure glaucoma", "", +28247, Primary_AngleClosureGlaucoma, 592, 596, "PACG", "", +12173, Blind, 623, 640, "observer - masked", "", +12174, Randomized, 641, 651, "randomised", "", +12175, Crossover, 652, 661, "crossover", "", +12176, NumberPatientsCT, 671, 673, "60", "", +28245, Primary_AngleClosureGlaucoma, 674, 678, "PACG", "", +12177, Latanoprost, 708, 719, "latanoprost", "", +12178, Bimatoprost, 723, 734, "bimatoprost", "", +12179, Duration, 739, 746, "6 weeks", "", +12182, Crossover, 771, 783, "crossed over", "", +12181, Duration, 820, 827, "6 weeks", "", +12184, IOP, 834, 837, "IOP", "", +12186, IOP, 908, 911, "IOP", "", +12190, Duration, 918, 925, "6 weeks", "", +12202, FinalNumPatientsCT, 974, 986, "Fifty - four", "", +12208, Latanoprost, 1030, 1041, "Latanoprost", "", +12210, IOP, 1050, 1053, "IOP", "", +12213, Reduction, 1073, 1078, "8 . 4", "", +12216, SdDevChangeValue, 1081, 1086, "3 . 8", "", +12218, mmHg, 1089, 1094, "mm Hg", "", +12220, Bimatoprost, 1099, 1110, "bimatoprost", "", +12222, Reduction, 1114, 1119, "8 . 9", "", +12224, SdDevChangeValue, 1122, 1127, "3 . 9", "", +12226, mmHg, 1130, 1135, "mm Hg", "", +12228, BaseLineValue, 1155, 1161, "25 . 2", "", +12230, SdDevBL, 1164, 1169, "3 . 6", "", +12232, mmHg, 1172, 1177, "mm Hg", "", +12234, BaseLineValue, 1182, 1188, "25 . 2", "", +12236, SdDevBL, 1191, 1196, "3 . 6", "", +12237, mmHg, 1199, 1204, "mm Hg", "", +12239, PValueChangeValue, 1220, 1230, "p = 0 . 23", "", +12242, Bimatoprost, 1345, 1356, "bimatoprost", "", +12243, PercentageAffected, 1365, 1367, "81", "", +12245, Latanoprost, 1390, 1401, "latanoprost", "", +12246, PercentageAffected, 1410, 1412, "40", "", +12247, PValueNumAffected, 1417, 1427, "p < 0 . 01", "", +12249, NumberAffected, 1514, 1516, "22", "", +12250, PercentageAffected, 1528, 1534, "37 . 9", "", +12251, Bimatoprost, 1552, 1563, "bimatoprost", "", +12252, NumberAffected, 1611, 1613, "13", "", +12253, PercentageAffected, 1625, 1631, "22 . 4", "", +12254, Latanoprost, 1649, 1660, "latanoprost", "", +12256, PValueNumAffected, 1663, 1673, "p = 0 . 11", "", +12257, ConclusionComment, 1692, 1823, "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .", "", +12259, Bimatoprost, 1692, 1703, "Bimatoprost", "", +12261, Frequency, 1704, 1714, "once daily", "", +12262, IOP, 1751, 1754, "IOP", "", +12264, Latanoprost, 1769, 1780, "latanoprost", "", +12266, Frequency, 1781, 1791, "once daily", "", +12258, ConclusionComment, 1824, 1888, "Both drugs were well tolerated with mild ocular adverse events .", "", +12274, PMID, 1934, 1942, "19336424", "", diff --git a/data/gl 19336424_jshahinitiran.n-triples b/data/gl 19336424_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19336424_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19336424_tstrakeljahn.annodb b/data/gl 19336424_tstrakeljahn.annodb new file mode 100644 index 0000000..1af6624 --- /dev/null +++ b/data/gl 19336424_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +77579, Journal, 0, 15, "Br J Ophthalmol", "", +77580, PublicationYear, 18, 22, "2009", "", +77586, Title, 109, 225, "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma .", "", +77581, Randomized, 111, 121, "randomised", "", +77582, Crossover, 122, 131, "crossover", "", +77583, Bimatoprost, 148, 159, "bimatoprost", "", +77592, Latanoprost, 164, 175, "latanoprost", "", +77585, Primary_AngleClosureGlaucoma, 193, 223, "primary angle closure glaucoma", "", +77588, Author, 226, 232, "How AC", "", +77589, Author, 241, 249, "Kumar RS", "", +77590, Author, 252, 259, "Chen YM", "", +77591, Author, 262, 267, "Su DH", "", +77594, Author, 270, 275, "Gao H", "", +77595, Author, 278, 284, "Oen FT", "", +77596, Author, 287, 292, "Ho CL", "", +77597, Author, 295, 302, "Seah SK", "", +77598, Author, 305, 311, "Aung T", "", +77587, Singapore, 373, 382, "Singapore", "", +77609, ObjectiveDescription, 405, 600, "To compare the intraocular pressure ( IOP ) lowering efficacy and side effects of latanoprost 0 . 005 % and bimatoprost 0 . 03 % in subjects with chronic primary angle closure glaucoma ( PACG ) .", "", +77599, IOP, 420, 440, "intraocular pressure", "", +77600, IOP, 443, 446, "IOP", "", +77601, Latanoprost, 487, 498, "latanoprost", "", +77602, DoseValue, 499, 506, "0 . 005", "", +77603, Percentage, 507, 508, "%", "", +77604, Bimatoprost, 513, 524, "bimatoprost", "", +77605, DoseValue, 525, 531, "0 . 03", "", +77606, Percentage, 532, 533, "%", "", +77607, Primary_AngleClosureGlaucoma, 559, 589, "primary angle closure glaucoma", "", +77608, Primary_AngleClosureGlaucoma, 592, 596, "PACG", "", +77610, Blind, 623, 640, "observer - masked", "", +77611, Randomized, 641, 651, "randomised", "", +77612, Crossover, 652, 661, "crossover", "", +77614, NumberPatientsCT, 671, 673, "60", "", +77613, Primary_AngleClosureGlaucoma, 674, 678, "PACG", "", +77615, Latanoprost, 708, 719, "latanoprost", "", +77616, Bimatoprost, 723, 734, "bimatoprost", "", +77619, Endpoint, 830, 963, "The IOP - reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared with baseline .", "", +77617, IOP, 834, 837, "IOP", "", +77618, IOP, 908, 911, "IOP", "", +77620, FinalNumPatientsCT, 974, 986, "Fifty - four", "", +77621, Latanoprost, 1030, 1041, "Latanoprost", "", +77622, IOP, 1050, 1053, "IOP", "", +77623, Mean, 1056, 1060, "mean", "", +77624, Reduction, 1073, 1078, "8 . 4", "", +77625, SdDevChangeValue, 1081, 1086, "3 . 8", "", +77626, mmHg, 1089, 1094, "mm Hg", "", +77627, Bimatoprost, 1099, 1110, "bimatoprost", "", +77628, Reduction, 1114, 1119, "8 . 9", "", +77629, SdDevChangeValue, 1122, 1127, "3 . 9", "", +77630, mmHg, 1130, 1135, "mm Hg", "", +77631, BaseLineValue, 1155, 1161, "25 . 2", "", +77632, SdDevBL, 1164, 1169, "3 . 6", "", +77633, mmHg, 1172, 1177, "mm Hg", "", +77634, BaseLineValue, 1182, 1188, "25 . 2", "", +77635, SdDevBL, 1191, 1196, "3 . 6", "", +77636, mmHg, 1199, 1204, "mm Hg", "", +77637, PvalueDiff, 1222, 1230, "= 0 . 23", "", +77638, ObservedResult, 1235, 1274, "Adverse events were mild in both groups", "", +77639, Bimatoprost, 1345, 1356, "bimatoprost", "", +77641, PercentageAffected, 1365, 1367, "81", "", +77640, Latanoprost, 1390, 1401, "latanoprost", "", +77642, PercentageAffected, 1410, 1412, "40", "", +77643, PvalueDiff, 1419, 1427, "< 0 . 01", "", +77645, NumberAffected, 1514, 1516, "22", "", +77646, PercentageAffected, 1528, 1534, "37 . 9", "", +77647, Bimatoprost, 1552, 1563, "bimatoprost", "", +77648, OcularHypertension, 1576, 1593, "ocular hyperaemia", "", +77649, NumberAffected, 1611, 1613, "13", "", +77650, PercentageAffected, 1625, 1631, "22 . 4", "", +77651, Latanoprost, 1649, 1660, "latanoprost", "", +77652, PvalueDiff, 1665, 1673, "= 0 . 11", "", +77653, Bimatoprost, 1692, 1703, "Bimatoprost", "", +77659, ConclusionComment, 1692, 1823, "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG .", "", +77654, Frequency, 1704, 1714, "once daily", "", +77655, IOP, 1751, 1754, "IOP", "", +77656, Latanoprost, 1769, 1780, "latanoprost", "", +77657, Frequency, 1781, 1791, "once daily", "", +77658, Primary_AngleClosureGlaucoma, 1817, 1821, "PACG", "", +77660, ConclusionComment, 1824, 1888, "Both drugs were well tolerated with mild ocular adverse events .", "", +77661, PMID, 1934, 1942, "19336424", "", diff --git a/data/gl 19336424_tstrakeljahn.n-triples b/data/gl 19336424_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19336424_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19476406_admin.annodb b/data/gl 19476406_admin.annodb new file mode 100644 index 0000000..327582e --- /dev/null +++ b/data/gl 19476406_admin.annodb @@ -0,0 +1,159 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2009", "", " \"2009\"." +2, Title, 92, 232, "Three - month , randomized , parallel - group comparison of brimonidine - timolol versus dorzolamide - timolol fixed - combination therapy .", "", " \"Three - month , randomized , parallel - group comparison of brimonidine - timolol versus dorzolamide - timolol fixed - combination therapy .\"." +3, Duration, 92, 105, "Three - month", "", " \"Three - month\"." +4, Randomized, 108, 118, "randomized", "", " ." +117, Parallel, 121, 137, "parallel - group", "", " ." +120, Brimo/TimFC, 152, 173, "brimonidine - timolol", "", +6, Brimonidine, 152, 163, "brimonidine", "", +7, Timolol, 166, 173, "timolol", "", +123, Dorz/TimFC, 181, 222, "dorzolamide - timolol fixed - combination", "", +8, Dorzolamide, 181, 192, "dorzolamide", "", +9, Timolol, 195, 202, "timolol", "", +10, Author, 233, 241, "Nixon DR", "", " \"Nixon DR\"." +11, Author, 250, 256, "Yan DB", "", " \"Yan DB\"." +12, Author, 259, 271, "Chartrand JP", "", " \"Chartrand JP\"." +13, Author, 274, 287, "Piemontesi RL", "", " \"Piemontesi RL\"." +14, Author, 290, 299, "Simonyi S", "", " \"Simonyi S\"." +15, Author, 302, 314, "Hollander DA", "", " \"Hollander DA\"." +145, Brimo/TimFC, 406, 443, "0 . 2 % brimonidine - 0 . 5 % timolol", "", +17, DoseValue, 406, 411, "0 . 2", "", +18, Percentage, 412, 413, "%", "", +6, Brimonidine, 414, 425, "brimonidine", "", +22, DoseValue, 428, 433, "0 . 5", "", +19, Percentage, 434, 435, "%", "", +7, Timolol, 436, 443, "timolol", "", +146, Dorz/TimFC, 448, 481, "2 % dorzolamide - 0 . 5 % timolol", "", +23, DoseValue, 448, 449, "2", "", +20, Percentage, 450, 451, "%", "", +8, Dorzolamide, 452, 463, "dorzolamide", "", +24, DoseValue, 466, 471, "0 . 5", "", +21, Percentage, 472, 473, "%", "", +9, Timolol, 474, 481, "timolol", "", +25, IOP, 500, 520, "intraocular pressure", "", +26, IOP, 523, 526, "IOP", "", +156, ObjectiveDescription, 531, 783, "The objective of this study was to evaluate the IOP - lowering efficacy and ocular tolerability of brimonidine - timolol compared with dorzolamide - timolol when used as monotherapy or as adjunctive therapy to a prostaglandin analog ( PGA ) in patients", "", " \"The objective of this study was to evaluate the IOP - lowering efficacy and ocular tolerability of brimonidine - timolol compared with dorzolamide - timolol when used as monotherapy or as adjunctive therapy to a prostaglandin analog ( PGA ) in patients\"." +27, IOP, 579, 582, "IOP", "", +150, Brimo/TimFC, 630, 651, "brimonidine - timolol", "", " ." +6, Brimonidine, 630, 641, "brimonidine", "", +7, Timolol, 644, 651, "timolol", "", +153, Dorz/TimFC, 666, 687, "dorzolamide - timolol", "", " ." +8, Dorzolamide, 666, 677, "dorzolamide", "", +9, Timolol, 680, 687, "timolol", "", +92856, ProstaglandinAnalogs, 743, 763, "prostaglandin analog", "", +92857, ProstaglandinAnalogs, 766, 769, "PGA", "", +88009, Precondition, 775, 820, "patients with glaucoma or ocular hypertension", "", " \"patients with glaucoma or ocular hypertension\"." +157, ObjectiveDescription, 784, 822, "with glaucoma or ocular hypertension .", "", " \"with glaucoma or ocular hypertension .\"." +28, Glaucoma, 789, 797, "glaucoma", "", " . ." +29, OcularHypertension, 801, 820, "ocular hypertension", "", " ." +30, Randomized, 878, 888, "randomized", "", +31, Blind, 891, 912, "investigator - masked", "", " ." +32, Duration, 915, 924, "3 - month", "", +161, Parallel, 927, 943, "parallel - group", "", +34, Multicenter, 979, 988, "ten sites", "", " ." +35, NumberPatientsCT, 1002, 1005, "180", "", " \"180\"." +36, OpenAngleGlaucoma, 1020, 1041, "open - angle glaucoma", "", " ." +37, OcularHypertension, 1045, 1064, "ocular hypertension", "", +38, IOP, 1091, 1094, "IOP", "", +88010, DeliveryMethod, 1104, 1111, "topical", "", +173, Brimo/TimFC, 1112, 1133, "brimonidine - timolol", "", +6, Brimonidine, 1112, 1123, "brimonidine", "", +7, Timolol, 1126, 1133, "timolol", "", +39, Frequency, 1134, 1137, "BID", "", " \"BID\"." +174, Dorz/TimFC, 1141, 1162, "dorzolamide - timolol", "", +8, Dorzolamide, 1141, 1152, "dorzolamide", "", +9, Timolol, 1155, 1162, "timolol", "", +40, Frequency, 1163, 1166, "BID", "", " \"BID\"." +43, NumberPatientsArm, 1188, 1191, "101", "", " \"101\"." +92858, ProstaglandinAnalogs, 1224, 1227, "PGA", "", +44, Latanoprost, 1230, 1241, "latanoprost", "", +45, Bimatoprost, 1244, 1255, "bimatoprost", "", +46, Travoprost, 1261, 1271, "travoprost", "", +47, NumberPatientsArm, 1280, 1282, "79", "", " \"79\"." +48, IOP, 1460, 1463, "IOP", "", +181, RelativeTime, 1480, 1488, "10 a . m", "", +182, Peak_IOP, 1493, 1504, "peak effect", "", +49, TimePoint, 1510, 1518, "baseline", "", +185, TimePoint, 1526, 1540, "months 1 and 3", "", +50, TimePoint, 1526, 1534, "months 1", "", +52, Caucasian, 1735, 1744, "Caucasian", "", " ." +41, AvgAge, 1768, 1770, "68", "", " \"68\"." +53, IOP, 1873, 1876, "IOP", "", " ." +54, TimePoint, 1882, 1889, "month 3", "", " \"month 3\". \"month 3\"." +55, Mean, 1896, 1900, "mean", "", " . ." +56, IOP, 1932, 1935, "IOP", "", " . ." +57, Reduction, 1988, 1993, "7 . 7", "", " \"7 . 7\"." +58, SdDevChangeValue, 1996, 2001, "4 . 2", "", " \"4 . 2\"." +61, mmHg, 2004, 2008, "mmHg", "", " ." +63, RelativeReduction, 2011, 2017, "32 . 3", "", " \"32 . 3\"." +65, Brimonidine, 2027, 2038, "brimonidine", "", +205, Brimo/TimFC, 2027, 2048, "brimonidine - timolol", "", +66, Timolol, 2041, 2048, "timolol", "", +60, Reduction, 2056, 2061, "6 . 7", "", " \"6 . 7\"." +59, SdDevChangeValue, 2064, 2069, "5 . 0", "", " \"5 . 0\"." +62, mmHg, 2072, 2076, "mmHg", "", +64, RelativeReduction, 2079, 2085, "26 . 1", "", " \"26 . 1\"." +67, Dorzolamide, 2095, 2106, "dorzolamide", "", +206, Dorz/TimFC, 2095, 2116, "dorzolamide - timolol", "", +68, Timolol, 2109, 2116, "timolol", "", +207, PvalueDiff, 2121, 2130, "= 0 . 040", "", " \"= 0 . 040\"." +70, Mean, 2139, 2143, "mean", "", +106228, ProstaglandinAnalogs, 2159, 2162, "PGA", "", +106229, SubGroupDescription, 2159, 2240, "PGA - treated baseline IOP for patients on fixed - combination adjunctive therapy", "", " \"PGA - treated baseline IOP for patients on fixed - combination adjunctive therapy\". \"PGA - treated baseline IOP for patients on fixed - combination adjunctive therapy\"." +209, IOP, 2182, 2185, "IOP", "", +71, Reduction, 2245, 2250, "6 . 9", "", " \"6 . 9\"." +73, SdDevChangeValue, 2253, 2258, "4 . 8", "", " \"4 . 8\"." +75, mmHg, 2261, 2265, "mmHg", "", +77, RelativeReduction, 2268, 2274, "29 . 3", "", " \"29 . 3\"." +79, Brimonidine, 2284, 2295, "brimonidine", "", +220, Brimo/TimFC, 2284, 2305, "brimonidine - timolol", "", +80, Timolol, 2298, 2305, "timolol", "", +72, Reduction, 2313, 2318, "5 . 2", "", " \"5 . 2\"." +74, SdDevChangeValue, 2321, 2326, "3 . 7", "", " \"3 . 7\"." +76, mmHg, 2329, 2333, "mmHg", "", +78, RelativeReduction, 2336, 2344, "23 . 5 %", "", +213, RelativeReduction, 2336, 2342, "23 . 5", "", " \"23 . 5\"." +81, Dorzolamide, 2352, 2363, "dorzolamide", "", +223, Dorz/TimFC, 2352, 2373, "dorzolamide - timolol", "", +82, Timolol, 2366, 2373, "timolol", "", +83, PValueChangeValue, 2376, 2387, "p = 0 . 213", "", +224, PvalueDiff, 2378, 2387, "= 0 . 213", "", " \"= 0 . 213\"." +84, Brimonidine, 2404, 2415, "brimonidine", "", +227, Brimo/TimFC, 2404, 2425, "brimonidine - timolol", "", +85, Timolol, 2418, 2425, "timolol", "", +88012, ObservedResult, 2426, 2439, "reported less", "", +88011, EndPointDescription, 2440, 2447, "burning", "", " . ." +228, PvalueDiff, 2452, 2461, "< 0 . 001", "", " \"< 0 . 001\"." +232, Stinging, 2466, 2474, "stinging", "", " ." +229, PvalueDiff, 2479, 2488, "< 0 . 001", "", " \"< 0 . 001\"." +88013, EndPointDescription, 2497, 2510, "unusual taste", "", " . ." +230, PvalueDiff, 2515, 2524, "< 0 . 001", "", " \"< 0 . 001\"." +92, Dorzolamide, 2544, 2555, "dorzolamide", "", +236, Dorz/TimFC, 2544, 2565, "dorzolamide - timolol", "", +93, Timolol, 2558, 2565, "timolol", "", +94, ConclusionComment, 2582, 2723, "Fixed - combination brimonidine - timolol provided the same or greater IOP lowering compared with fixed - combination dorzolamide - timolol .", "", " \"Fixed - combination brimonidine - timolol provided the same or greater IOP lowering compared with fixed - combination dorzolamide - timolol .\"." +95, Brimonidine, 2602, 2613, "brimonidine", "", +243, Brimo/TimFC, 2602, 2623, "brimonidine - timolol", "", +96, Timolol, 2616, 2623, "timolol", "", +97, IOP, 2653, 2656, "IOP", "", +98, Dorzolamide, 2700, 2711, "dorzolamide", "", +244, Dorz/TimFC, 2700, 2721, "dorzolamide - timolol", "", +99, Timolol, 2714, 2721, "timolol", "", +259, ConclusionComment, 2724, 2793, "Both fixed - combination medications were safe and well - tolerated .", "", " \"Both fixed - combination medications were safe and well - tolerated .\"." +103, Brimonidine, 2794, 2805, "Brimonidine", "", +249, Brimo/TimFC, 2794, 2815, "Brimonidine - timolol", "", +260, ConclusionComment, 2794, 2886, "Brimonidine - timolol received higher ratings of ocular comfort than dorzolamide - timolol .", "", " \"Brimonidine - timolol received higher ratings of ocular comfort than dorzolamide - timolol .\"." +104, Timolol, 2808, 2815, "timolol", "", +106, Dorzolamide, 2863, 2874, "dorzolamide", "", +250, Dorz/TimFC, 2863, 2884, "dorzolamide - timolol", "", +105, Timolol, 2877, 2884, "timolol", "", +261, ConclusionComment, 2887, 3090, "The duration of the studies was 3 months , and additional studies will be needed to compare the efficacy and tolerability of brimonidine - timolol and dorzolamide - timolol during long - term treatment .", "", " \"The duration of the studies was 3 months , and additional studies will be needed to compare the efficacy and tolerability of brimonidine - timolol and dorzolamide - timolol during long - term treatment .\"." +107, Duration, 2919, 2927, "3 months", "", +108, Brimonidine, 3012, 3023, "brimonidine", "", +256, Brimo/TimFC, 3012, 3033, "brimonidine - timolol", "", +109, Timolol, 3026, 3033, "timolol", "", +111, Dorzolamide, 3038, 3049, "dorzolamide", "", +257, Dorz/TimFC, 3038, 3059, "dorzolamide - timolol", "", +110, Timolol, 3052, 3059, "timolol", "", +112, PMID, 3134, 3142, "19476406", "", " \"19476406\"." diff --git a/data/gl 19476406_admin.n-triples b/data/gl 19476406_admin.n-triples new file mode 100644 index 0000000..23493e4 --- /dev/null +++ b/data/gl 19476406_admin.n-triples @@ -0,0 +1,196 @@ +# RDF export of group: Publication + . + "Publication" . + "Three - month , randomized , parallel - group comparison of brimonidine - timolol versus dorzolamide - timolol fixed - combination therapy ." . + "Nixon DR" . + "2009" . + "Curr Med Res Opin ." . + "19476406" . + . + "Yan DB" . + "Chartrand JP" . + "Piemontesi RL" . + "Simonyi S" . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The objective of this study was to evaluate the IOP - lowering efficacy and ocular tolerability of brimonidine - timolol compared with dorzolamide - timolol when used as monotherapy or as adjunctive therapy to a prostaglandin analog ( PGA ) in patients" . + "180" . + "Three - month" . + . + . + . + "Fixed - combination brimonidine - timolol provided the same or greater IOP lowering compared with fixed - combination dorzolamide - timolol ." . + . + . + . + . + . + . + "with glaucoma or ocular hypertension ." . + . + . + . + "Both fixed - combination medications were safe and well - tolerated ." . + "Brimonidine - timolol received higher ratings of ocular comfort than dorzolamide - timolol ." . + "The duration of the studies was 3 months , and additional studies will be needed to compare the efficacy and tolerability of brimonidine - timolol and dorzolamide - timolol during long - term treatment ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with glaucoma or ocular hypertension" . + . + . + "68" . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_burning" . + . + . + . + . + . + . + "Endpoint_stinging" . + . + . + . + . + . + "Endpoint_taste" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BT" . + "101" . + . + . + . + . + . + . + . + "Arm_DT" . + "79" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + "BID" . + . + . + "Intervention_DTFC" . + . + "BID" . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_DTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_DTFC" . + . + "6 . 7" . + "26 . 1" . + "5 . 0" . + "month 3" . + . + "Outcome_iop_BTFC" . + . + "7 . 7" . + "32 . 3" . + "4 . 2" . + "month 3" . + . + "Outcome_iop_DTFC_pga" . + . + "5 . 2" . + "23 . 5" . + "3 . 7" . + "PGA - treated baseline IOP for patients on fixed - combination adjunctive therapy" . + . + "Outcome_iop_BTFC_pga" . + . + "6 . 9" . + "29 . 3" . + "4 . 8" . + "PGA - treated baseline IOP for patients on fixed - combination adjunctive therapy" . + . + "AE_burning_DTFC" . + . + . + "AE_burning_BTFC" . + . + . + "AE_stinging_DTFC" . + . + . + "AE_stinging_BTFC" . + . + . + "AE_taste_DTFC" . + . + . + "AE_taste_BTFC" . + . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "= 0 . 040" . + . + . + . + "DiffBetweenGroups_iop_pga" . + "= 0 . 213" . + . + . + . + "DiffBetweenGroups_AE_burning" . + "< 0 . 001" . + . + . + . + "DiffBetweenGroups_AE_stinging" . + "< 0 . 001" . + . + . + . + "DiffBetweenGroups_AE_taste" . + "< 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19476406_export.csv b/data/gl 19476406_export.csv new file mode 100644 index 0000000..0330aae --- /dev/null +++ b/data/gl 19476406_export.csv @@ -0,0 +1,634 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +443, 1, 1, 1, 0, 4, 0, 4, "Curr" +443, 1, 2, 2, 5, 8, 5, 8, "Med" +443, 1, 3, 3, 9, 12, 9, 12, "Res" +443, 1, 4, 4, 13, 17, 13, 17, "Opin" +443, 1, 5, 5, 18, 19, 18, 19, "." +443, 2, 1, 6, 0, 4, 20, 24, "2009" +443, 2, 2, 7, 5, 8, 25, 28, "Jul" +443, 2, 3, 8, 9, 10, 29, 30, ";" +443, 2, 4, 9, 11, 13, 31, 33, "25" +443, 2, 5, 10, 14, 15, 34, 35, "(" +443, 2, 6, 11, 16, 17, 36, 37, "7" +443, 2, 7, 12, 18, 19, 38, 39, ")" +443, 2, 8, 13, 20, 21, 40, 41, ":" +443, 2, 9, 14, 22, 26, 42, 46, "1645" +443, 2, 10, 15, 27, 28, 47, 48, "-" +443, 2, 11, 16, 29, 31, 49, 51, "53" +443, 2, 12, 17, 32, 33, 52, 53, "." +443, 2, 13, 18, 34, 37, 54, 57, "doi" +443, 2, 14, 19, 38, 39, 58, 59, ":" +443, 2, 15, 20, 40, 42, 60, 62, "10" +443, 2, 16, 21, 43, 44, 63, 64, "." +443, 2, 17, 22, 45, 49, 65, 69, "1185" +443, 2, 18, 23, 50, 51, 70, 71, "/" +443, 2, 19, 24, 52, 69, 72, 89, "03007990902994041" +443, 2, 20, 25, 70, 71, 90, 91, "." +443, 3, 1, 26, 0, 5, 92, 97, "Three" +443, 3, 2, 27, 6, 7, 98, 99, "-" +443, 3, 3, 28, 8, 13, 100, 105, "month" +443, 3, 4, 29, 14, 15, 106, 107, "," +443, 3, 5, 30, 16, 26, 108, 118, "randomized" +443, 3, 6, 31, 27, 28, 119, 120, "," +443, 3, 7, 32, 29, 37, 121, 129, "parallel" +443, 3, 8, 33, 38, 39, 130, 131, "-" +443, 3, 9, 34, 40, 45, 132, 137, "group" +443, 3, 10, 35, 46, 56, 138, 148, "comparison" +443, 3, 11, 36, 57, 59, 149, 151, "of" +443, 3, 12, 37, 60, 71, 152, 163, "brimonidine" +443, 3, 13, 38, 72, 73, 164, 165, "-" +443, 3, 14, 39, 74, 81, 166, 173, "timolol" +443, 3, 15, 40, 82, 88, 174, 180, "versus" +443, 3, 16, 41, 89, 100, 181, 192, "dorzolamide" +443, 3, 17, 42, 101, 102, 193, 194, "-" +443, 3, 18, 43, 103, 110, 195, 202, "timolol" +443, 3, 19, 44, 111, 116, 203, 208, "fixed" +443, 3, 20, 45, 117, 118, 209, 210, "-" +443, 3, 21, 46, 119, 130, 211, 222, "combination" +443, 3, 22, 47, 131, 138, 223, 230, "therapy" +443, 3, 23, 48, 139, 140, 231, 232, "." +443, 4, 1, 49, 0, 5, 233, 238, "Nixon" +443, 4, 2, 50, 6, 8, 239, 241, "DR" +443, 4, 3, 51, 9, 10, 242, 243, "(" +443, 4, 4, 52, 11, 12, 244, 245, "1" +443, 4, 5, 53, 13, 14, 246, 247, ")" +443, 4, 6, 54, 15, 16, 248, 249, "," +443, 4, 7, 55, 17, 20, 250, 253, "Yan" +443, 4, 8, 56, 21, 23, 254, 256, "DB" +443, 4, 9, 57, 24, 25, 257, 258, "," +443, 4, 10, 58, 26, 35, 259, 268, "Chartrand" +443, 4, 11, 59, 36, 38, 269, 271, "JP" +443, 4, 12, 60, 39, 40, 272, 273, "," +443, 4, 13, 61, 41, 51, 274, 284, "Piemontesi" +443, 4, 14, 62, 52, 54, 285, 287, "RL" +443, 4, 15, 63, 55, 56, 288, 289, "," +443, 4, 16, 64, 57, 64, 290, 297, "Simonyi" +443, 4, 17, 65, 65, 66, 298, 299, "S" +443, 4, 18, 66, 67, 68, 300, 301, "," +443, 4, 19, 67, 69, 78, 302, 311, "Hollander" +443, 4, 20, 68, 79, 81, 312, 314, "DA" +443, 4, 21, 69, 82, 83, 315, 316, "." +443, 5, 1, 70, 0, 6, 317, 323, "Author" +443, 5, 2, 71, 7, 18, 324, 335, "information" +443, 5, 3, 72, 19, 20, 336, 337, ":" +443, 5, 4, 73, 21, 22, 338, 339, "(" +443, 5, 5, 74, 23, 24, 340, 341, "1" +443, 5, 6, 75, 25, 26, 342, 343, ")" +443, 5, 7, 76, 27, 39, 344, 356, "trimedeyedoc" +443, 5, 8, 77, 40, 41, 357, 358, "@" +443, 5, 9, 78, 42, 48, 359, 365, "rogers" +443, 5, 10, 79, 49, 50, 366, 367, "." +443, 5, 11, 80, 51, 54, 368, 371, "com" +443, 5, 12, 81, 55, 64, 372, 381, "OBJECTIVE" +443, 5, 13, 82, 65, 66, 382, 383, ":" +443, 5, 14, 83, 67, 72, 384, 389, "Fixed" +443, 5, 15, 84, 73, 85, 390, 402, "combinations" +443, 5, 16, 85, 86, 88, 403, 405, "of" +443, 5, 17, 86, 89, 90, 406, 407, "0" +443, 5, 18, 87, 91, 92, 408, 409, "." +443, 5, 19, 88, 93, 94, 410, 411, "2" +443, 5, 20, 89, 95, 96, 412, 413, "%" +443, 5, 21, 90, 97, 108, 414, 425, "brimonidine" +443, 5, 22, 91, 109, 110, 426, 427, "-" +443, 5, 23, 92, 111, 112, 428, 429, "0" +443, 5, 24, 93, 113, 114, 430, 431, "." +443, 5, 25, 94, 115, 116, 432, 433, "5" +443, 5, 26, 95, 117, 118, 434, 435, "%" +443, 5, 27, 96, 119, 126, 436, 443, "timolol" +443, 5, 28, 97, 127, 130, 444, 447, "and" +443, 5, 29, 98, 131, 132, 448, 449, "2" +443, 5, 30, 99, 133, 134, 450, 451, "%" +443, 5, 31, 100, 135, 146, 452, 463, "dorzolamide" +443, 5, 32, 101, 147, 148, 464, 465, "-" +443, 5, 33, 102, 149, 150, 466, 467, "0" +443, 5, 34, 103, 151, 152, 468, 469, "." +443, 5, 35, 104, 153, 154, 470, 471, "5" +443, 5, 36, 105, 155, 156, 472, 473, "%" +443, 5, 37, 106, 157, 164, 474, 481, "timolol" +443, 5, 38, 107, 165, 168, 482, 485, "are" +443, 5, 39, 108, 169, 173, 486, 490, "used" +443, 5, 40, 109, 174, 176, 491, 493, "to" +443, 5, 41, 110, 177, 182, 494, 499, "lower" +443, 5, 42, 111, 183, 194, 500, 511, "intraocular" +443, 5, 43, 112, 195, 203, 512, 520, "pressure" +443, 5, 44, 113, 204, 205, 521, 522, "(" +443, 5, 45, 114, 206, 209, 523, 526, "IOP" +443, 5, 46, 115, 210, 211, 527, 528, ")" +443, 5, 47, 116, 212, 213, 529, 530, "." +443, 6, 1, 117, 0, 3, 531, 534, "The" +443, 6, 2, 118, 4, 13, 535, 544, "objective" +443, 6, 3, 119, 14, 16, 545, 547, "of" +443, 6, 4, 120, 17, 21, 548, 552, "this" +443, 6, 5, 121, 22, 27, 553, 558, "study" +443, 6, 6, 122, 28, 31, 559, 562, "was" +443, 6, 7, 123, 32, 34, 563, 565, "to" +443, 6, 8, 124, 35, 43, 566, 574, "evaluate" +443, 6, 9, 125, 44, 47, 575, 578, "the" +443, 6, 10, 126, 48, 51, 579, 582, "IOP" +443, 6, 11, 127, 52, 53, 583, 584, "-" +443, 6, 12, 128, 54, 62, 585, 593, "lowering" +443, 6, 13, 129, 63, 71, 594, 602, "efficacy" +443, 6, 14, 130, 72, 75, 603, 606, "and" +443, 6, 15, 131, 76, 82, 607, 613, "ocular" +443, 6, 16, 132, 83, 95, 614, 626, "tolerability" +443, 6, 17, 133, 96, 98, 627, 629, "of" +443, 6, 18, 134, 99, 110, 630, 641, "brimonidine" +443, 6, 19, 135, 111, 112, 642, 643, "-" +443, 6, 20, 136, 113, 120, 644, 651, "timolol" +443, 6, 21, 137, 121, 129, 652, 660, "compared" +443, 6, 22, 138, 130, 134, 661, 665, "with" +443, 6, 23, 139, 135, 146, 666, 677, "dorzolamide" +443, 6, 24, 140, 147, 148, 678, 679, "-" +443, 6, 25, 141, 149, 156, 680, 687, "timolol" +443, 6, 26, 142, 157, 161, 688, 692, "when" +443, 6, 27, 143, 162, 166, 693, 697, "used" +443, 6, 28, 144, 167, 169, 698, 700, "as" +443, 6, 29, 145, 170, 181, 701, 712, "monotherapy" +443, 6, 30, 146, 182, 184, 713, 715, "or" +443, 6, 31, 147, 185, 187, 716, 718, "as" +443, 6, 32, 148, 188, 198, 719, 729, "adjunctive" +443, 6, 33, 149, 199, 206, 730, 737, "therapy" +443, 6, 34, 150, 207, 209, 738, 740, "to" +443, 6, 35, 151, 210, 211, 741, 742, "a" +443, 6, 36, 152, 212, 225, 743, 756, "prostaglandin" +443, 6, 37, 153, 226, 232, 757, 763, "analog" +443, 6, 38, 154, 233, 234, 764, 765, "(" +443, 6, 39, 155, 235, 238, 766, 769, "PGA" +443, 6, 40, 156, 239, 240, 770, 771, ")" +443, 6, 41, 157, 241, 243, 772, 774, "in" +443, 6, 42, 158, 244, 252, 775, 783, "patients" +443, 6, 43, 159, 253, 257, 784, 788, "with" +443, 6, 44, 160, 258, 266, 789, 797, "glaucoma" +443, 6, 45, 161, 267, 269, 798, 800, "or" +443, 6, 46, 162, 270, 276, 801, 807, "ocular" +443, 6, 47, 163, 277, 289, 808, 820, "hypertension" +443, 6, 48, 164, 290, 291, 821, 822, "." +443, 7, 1, 165, 0, 5, 823, 828, "STUDY" +443, 7, 2, 166, 6, 12, 829, 835, "DESIGN" +443, 7, 3, 167, 13, 16, 836, 839, "AND" +443, 7, 4, 168, 17, 24, 840, 847, "METHODS" +443, 7, 5, 169, 25, 26, 848, 849, ":" +443, 7, 6, 170, 27, 33, 850, 856, "Pooled" +443, 7, 7, 171, 34, 38, 857, 861, "data" +443, 7, 8, 172, 39, 47, 862, 870, "analysis" +443, 7, 9, 173, 48, 50, 871, 873, "of" +443, 7, 10, 174, 51, 54, 874, 877, "two" +443, 7, 11, 175, 55, 65, 878, 888, "randomized" +443, 7, 12, 176, 66, 67, 889, 890, "," +443, 7, 13, 177, 68, 80, 891, 903, "investigator" +443, 7, 14, 178, 81, 82, 904, 905, "-" +443, 7, 15, 179, 83, 89, 906, 912, "masked" +443, 7, 16, 180, 90, 91, 913, 914, "," +443, 7, 17, 181, 92, 93, 915, 916, "3" +443, 7, 18, 182, 94, 95, 917, 918, "-" +443, 7, 19, 183, 96, 101, 919, 924, "month" +443, 7, 20, 184, 102, 103, 925, 926, "," +443, 7, 21, 185, 104, 112, 927, 935, "parallel" +443, 7, 22, 186, 113, 114, 936, 937, "-" +443, 7, 23, 187, 115, 120, 938, 943, "group" +443, 7, 24, 188, 121, 128, 944, 951, "studies" +443, 7, 25, 189, 129, 133, 952, 956, "with" +443, 7, 26, 190, 134, 143, 957, 966, "identical" +443, 7, 27, 191, 144, 153, 967, 976, "protocols" +443, 7, 28, 192, 154, 155, 977, 978, "(" +443, 7, 29, 193, 156, 159, 979, 982, "ten" +443, 7, 30, 194, 160, 165, 983, 988, "sites" +443, 7, 31, 195, 166, 167, 989, 990, ")" +443, 7, 32, 196, 168, 169, 991, 992, "." +443, 8, 1, 197, 0, 2, 993, 995, "In" +443, 8, 2, 198, 3, 6, 996, 999, "all" +443, 8, 3, 199, 7, 8, 1000, 1001, "," +443, 8, 4, 200, 9, 12, 1002, 1005, "180" +443, 8, 5, 201, 13, 21, 1006, 1014, "patients" +443, 8, 6, 202, 22, 26, 1015, 1019, "with" +443, 8, 7, 203, 27, 31, 1020, 1024, "open" +443, 8, 8, 204, 32, 33, 1025, 1026, "-" +443, 8, 9, 205, 34, 39, 1027, 1032, "angle" +443, 8, 10, 206, 40, 48, 1033, 1041, "glaucoma" +443, 8, 11, 207, 49, 51, 1042, 1044, "or" +443, 8, 12, 208, 52, 58, 1045, 1051, "ocular" +443, 8, 13, 209, 59, 71, 1052, 1064, "hypertension" +443, 8, 14, 210, 72, 75, 1065, 1068, "who" +443, 8, 15, 211, 76, 80, 1069, 1073, "were" +443, 8, 16, 212, 81, 83, 1074, 1076, "in" +443, 8, 17, 213, 84, 88, 1077, 1081, "need" +443, 8, 18, 214, 89, 91, 1082, 1084, "of" +443, 8, 19, 215, 92, 97, 1085, 1090, "lower" +443, 8, 20, 216, 98, 101, 1091, 1094, "IOP" +443, 8, 21, 217, 102, 110, 1095, 1103, "received" +443, 8, 22, 218, 111, 118, 1104, 1111, "topical" +443, 8, 23, 219, 119, 130, 1112, 1123, "brimonidine" +443, 8, 24, 220, 131, 132, 1124, 1125, "-" +443, 8, 25, 221, 133, 140, 1126, 1133, "timolol" +443, 8, 26, 222, 141, 144, 1134, 1137, "BID" +443, 8, 27, 223, 145, 147, 1138, 1140, "or" +443, 8, 28, 224, 148, 159, 1141, 1152, "dorzolamide" +443, 8, 29, 225, 160, 161, 1153, 1154, "-" +443, 8, 30, 226, 162, 169, 1155, 1162, "timolol" +443, 8, 31, 227, 170, 173, 1163, 1166, "BID" +443, 8, 32, 228, 174, 176, 1167, 1169, "as" +443, 8, 33, 229, 177, 188, 1170, 1181, "monotherapy" +443, 8, 34, 230, 189, 190, 1182, 1183, "(" +443, 8, 35, 231, 191, 192, 1184, 1185, "n" +443, 8, 36, 232, 193, 194, 1186, 1187, "=" +443, 8, 37, 233, 195, 198, 1188, 1191, "101" +443, 8, 38, 234, 199, 200, 1192, 1193, ")" +443, 8, 39, 235, 201, 203, 1194, 1196, "or" +443, 8, 40, 236, 204, 206, 1197, 1199, "as" +443, 8, 41, 237, 207, 217, 1200, 1210, "adjunctive" +443, 8, 42, 238, 218, 225, 1211, 1218, "therapy" +443, 8, 43, 239, 226, 228, 1219, 1221, "to" +443, 8, 44, 240, 229, 230, 1222, 1223, "a" +443, 8, 45, 241, 231, 234, 1224, 1227, "PGA" +443, 8, 46, 242, 235, 236, 1228, 1229, "(" +443, 8, 47, 243, 237, 248, 1230, 1241, "latanoprost" +443, 8, 48, 244, 249, 250, 1242, 1243, "," +443, 8, 49, 245, 251, 262, 1244, 1255, "bimatoprost" +443, 8, 50, 246, 263, 264, 1256, 1257, "," +443, 8, 51, 247, 265, 267, 1258, 1260, "or" +443, 8, 52, 248, 268, 278, 1261, 1271, "travoprost" +443, 8, 53, 249, 279, 280, 1272, 1273, ")" +443, 8, 54, 250, 281, 282, 1274, 1275, "(" +443, 8, 55, 251, 283, 284, 1276, 1277, "n" +443, 8, 56, 252, 285, 286, 1278, 1279, "=" +443, 8, 57, 253, 287, 289, 1280, 1282, "79" +443, 8, 58, 254, 290, 291, 1283, 1284, ")" +443, 8, 59, 255, 292, 293, 1285, 1286, "." +443, 9, 1, 256, 0, 8, 1287, 1295, "CLINICAL" +443, 9, 2, 257, 9, 14, 1296, 1301, "TRIAL" +443, 9, 3, 258, 15, 27, 1302, 1314, "REGISTRATION" +443, 9, 4, 259, 28, 29, 1315, 1316, ":" +443, 9, 5, 260, 30, 33, 1317, 1320, "The" +443, 9, 6, 261, 34, 41, 1321, 1328, "studies" +443, 9, 7, 262, 42, 45, 1329, 1332, "are" +443, 9, 8, 263, 46, 56, 1333, 1343, "registered" +443, 9, 9, 264, 57, 61, 1344, 1348, "with" +443, 9, 10, 265, 62, 65, 1349, 1352, "the" +443, 9, 11, 266, 66, 77, 1353, 1364, "identifiers" +443, 9, 12, 267, 78, 89, 1365, 1376, "NCT00822081" +443, 9, 13, 268, 90, 93, 1377, 1380, "and" +443, 9, 14, 269, 94, 105, 1381, 1392, "NCT00822055" +443, 9, 15, 270, 106, 108, 1393, 1395, "at" +443, 9, 16, 271, 109, 113, 1396, 1400, "http" +443, 9, 17, 272, 114, 115, 1401, 1402, ":" +443, 9, 18, 273, 116, 117, 1403, 1404, "/" +443, 9, 19, 274, 118, 119, 1405, 1406, "/" +443, 9, 20, 275, 120, 123, 1407, 1410, "www" +443, 9, 21, 276, 124, 125, 1411, 1412, "." +443, 9, 22, 277, 126, 140, 1413, 1427, "clinicaltrials" +443, 9, 23, 278, 141, 142, 1428, 1429, "." +443, 9, 24, 279, 143, 146, 1430, 1433, "gov" +443, 9, 25, 280, 147, 148, 1434, 1435, "." +443, 10, 1, 281, 0, 4, 1436, 1440, "MAIN" +443, 10, 2, 282, 5, 12, 1441, 1448, "OUTCOME" +443, 10, 3, 283, 13, 21, 1449, 1457, "MEASURES" +443, 10, 4, 284, 22, 23, 1458, 1459, ":" +443, 10, 5, 285, 24, 27, 1460, 1463, "IOP" +443, 10, 6, 286, 28, 31, 1464, 1467, "was" +443, 10, 7, 287, 32, 40, 1468, 1476, "measured" +443, 10, 8, 288, 41, 43, 1477, 1479, "at" +443, 10, 9, 289, 44, 46, 1480, 1482, "10" +443, 10, 10, 290, 47, 48, 1483, 1484, "a" +443, 10, 11, 291, 49, 50, 1485, 1486, "." +443, 10, 12, 292, 51, 52, 1487, 1488, "m" +443, 10, 13, 293, 53, 54, 1489, 1490, "." +443, 10, 14, 294, 55, 56, 1491, 1492, "(" +443, 10, 15, 295, 57, 61, 1493, 1497, "peak" +443, 10, 16, 296, 62, 68, 1498, 1504, "effect" +443, 10, 17, 297, 69, 70, 1505, 1506, ")" +443, 10, 18, 298, 71, 73, 1507, 1509, "at" +443, 10, 19, 299, 74, 82, 1510, 1518, "baseline" +443, 10, 20, 300, 83, 86, 1519, 1522, "and" +443, 10, 21, 301, 87, 89, 1523, 1525, "at" +443, 10, 22, 302, 90, 96, 1526, 1532, "months" +443, 10, 23, 303, 97, 98, 1533, 1534, "1" +443, 10, 24, 304, 99, 102, 1535, 1538, "and" +443, 10, 25, 305, 103, 104, 1539, 1540, "3" +443, 10, 26, 306, 105, 106, 1541, 1542, "." +443, 11, 1, 307, 0, 12, 1543, 1555, "Tolerability" +443, 11, 2, 308, 13, 14, 1556, 1557, "/" +443, 11, 3, 309, 15, 22, 1558, 1565, "comfort" +443, 11, 4, 310, 23, 26, 1566, 1569, "was" +443, 11, 5, 311, 27, 36, 1570, 1579, "evaluated" +443, 11, 6, 312, 37, 42, 1580, 1585, "using" +443, 11, 7, 313, 43, 44, 1586, 1587, "a" +443, 11, 8, 314, 45, 52, 1588, 1595, "patient" +443, 11, 9, 315, 53, 66, 1596, 1609, "questionnaire" +443, 11, 10, 316, 67, 68, 1610, 1611, "." +443, 12, 1, 317, 0, 7, 1612, 1619, "RESULTS" +443, 12, 2, 318, 8, 9, 1620, 1621, ":" +443, 12, 3, 319, 10, 15, 1622, 1627, "There" +443, 12, 4, 320, 16, 20, 1628, 1632, "were" +443, 12, 5, 321, 21, 23, 1633, 1635, "no" +443, 12, 6, 322, 24, 37, 1636, 1649, "statistically" +443, 12, 7, 323, 38, 49, 1650, 1661, "significant" +443, 12, 8, 324, 50, 57, 1662, 1669, "between" +443, 12, 9, 325, 58, 59, 1670, 1671, "-" +443, 12, 10, 326, 60, 65, 1672, 1677, "group" +443, 12, 11, 327, 66, 77, 1678, 1689, "differences" +443, 12, 12, 328, 78, 80, 1690, 1692, "in" +443, 12, 13, 329, 81, 88, 1693, 1700, "patient" +443, 12, 14, 330, 89, 101, 1701, 1713, "demographics" +443, 12, 15, 331, 102, 103, 1714, 1715, "." +443, 13, 1, 332, 0, 4, 1716, 1720, "Most" +443, 13, 2, 333, 5, 13, 1721, 1729, "patients" +443, 13, 3, 334, 14, 18, 1730, 1734, "were" +443, 13, 4, 335, 19, 28, 1735, 1744, "Caucasian" +443, 13, 5, 336, 29, 30, 1745, 1746, "," +443, 13, 6, 337, 31, 34, 1747, 1750, "and" +443, 13, 7, 338, 35, 38, 1751, 1754, "the" +443, 13, 8, 339, 39, 43, 1755, 1759, "mean" +443, 13, 9, 340, 44, 47, 1760, 1763, "age" +443, 13, 10, 341, 48, 51, 1764, 1767, "was" +443, 13, 11, 342, 52, 54, 1768, 1770, "68" +443, 13, 12, 343, 55, 60, 1771, 1776, "years" +443, 13, 13, 344, 61, 62, 1777, 1778, "." +443, 14, 1, 345, 0, 5, 1779, 1784, "There" +443, 14, 2, 346, 6, 10, 1785, 1789, "were" +443, 14, 3, 347, 11, 15, 1790, 1794, "also" +443, 14, 4, 348, 16, 18, 1795, 1797, "no" +443, 14, 5, 349, 19, 32, 1798, 1811, "statistically" +443, 14, 6, 350, 33, 44, 1812, 1823, "significant" +443, 14, 7, 351, 45, 56, 1824, 1835, "differences" +443, 14, 8, 352, 57, 64, 1836, 1843, "between" +443, 14, 9, 353, 65, 74, 1844, 1853, "treatment" +443, 14, 10, 354, 75, 81, 1854, 1860, "groups" +443, 14, 11, 355, 82, 84, 1861, 1863, "in" +443, 14, 12, 356, 85, 93, 1864, 1872, "baseline" +443, 14, 13, 357, 94, 97, 1873, 1876, "IOP" +443, 14, 14, 358, 98, 99, 1877, 1878, "." +443, 15, 1, 359, 0, 2, 1879, 1881, "At" +443, 15, 2, 360, 3, 8, 1882, 1887, "month" +443, 15, 3, 361, 9, 10, 1888, 1889, "3" +443, 15, 4, 362, 11, 12, 1890, 1891, "," +443, 15, 5, 363, 13, 16, 1892, 1895, "the" +443, 15, 6, 364, 17, 21, 1896, 1900, "mean" +443, 15, 7, 365, 22, 23, 1901, 1902, "(" +443, 15, 8, 366, 24, 26, 1903, 1905, "SD" +443, 15, 9, 367, 27, 28, 1906, 1907, ")" +443, 15, 10, 368, 29, 38, 1908, 1917, "reduction" +443, 15, 11, 369, 39, 43, 1918, 1922, "from" +443, 15, 12, 370, 44, 52, 1923, 1931, "baseline" +443, 15, 13, 371, 53, 56, 1932, 1935, "IOP" +443, 15, 14, 372, 57, 60, 1936, 1939, "for" +443, 15, 15, 373, 61, 69, 1940, 1948, "patients" +443, 15, 16, 374, 70, 72, 1949, 1951, "on" +443, 15, 17, 375, 73, 78, 1952, 1957, "fixed" +443, 15, 18, 376, 79, 80, 1958, 1959, "-" +443, 15, 19, 377, 81, 92, 1960, 1971, "combination" +443, 15, 20, 378, 93, 104, 1972, 1983, "monotherapy" +443, 15, 21, 379, 105, 108, 1984, 1987, "was" +443, 15, 22, 380, 109, 110, 1988, 1989, "7" +443, 15, 23, 381, 111, 112, 1990, 1991, "." +443, 15, 24, 382, 113, 114, 1992, 1993, "7" +443, 15, 25, 383, 115, 116, 1994, 1995, "(" +443, 15, 26, 384, 117, 118, 1996, 1997, "4" +443, 15, 27, 385, 119, 120, 1998, 1999, "." +443, 15, 28, 386, 121, 122, 2000, 2001, "2" +443, 15, 29, 387, 123, 124, 2002, 2003, ")" +443, 15, 30, 388, 125, 129, 2004, 2008, "mmHg" +443, 15, 31, 389, 130, 131, 2009, 2010, "(" +443, 15, 32, 390, 132, 134, 2011, 2013, "32" +443, 15, 33, 391, 135, 136, 2014, 2015, "." +443, 15, 34, 392, 137, 138, 2016, 2017, "3" +443, 15, 35, 393, 139, 140, 2018, 2019, "%" +443, 15, 36, 394, 141, 142, 2020, 2021, ")" +443, 15, 37, 395, 143, 147, 2022, 2026, "with" +443, 15, 38, 396, 148, 159, 2027, 2038, "brimonidine" +443, 15, 39, 397, 160, 161, 2039, 2040, "-" +443, 15, 40, 398, 162, 169, 2041, 2048, "timolol" +443, 15, 41, 399, 170, 176, 2049, 2055, "versus" +443, 15, 42, 400, 177, 178, 2056, 2057, "6" +443, 15, 43, 401, 179, 180, 2058, 2059, "." +443, 15, 44, 402, 181, 182, 2060, 2061, "7" +443, 15, 45, 403, 183, 184, 2062, 2063, "(" +443, 15, 46, 404, 185, 186, 2064, 2065, "5" +443, 15, 47, 405, 187, 188, 2066, 2067, "." +443, 15, 48, 406, 189, 190, 2068, 2069, "0" +443, 15, 49, 407, 191, 192, 2070, 2071, ")" +443, 15, 50, 408, 193, 197, 2072, 2076, "mmHg" +443, 15, 51, 409, 198, 199, 2077, 2078, "(" +443, 15, 52, 410, 200, 202, 2079, 2081, "26" +443, 15, 53, 411, 203, 204, 2082, 2083, "." +443, 15, 54, 412, 205, 206, 2084, 2085, "1" +443, 15, 55, 413, 207, 208, 2086, 2087, "%" +443, 15, 56, 414, 209, 210, 2088, 2089, ")" +443, 15, 57, 415, 211, 215, 2090, 2094, "with" +443, 15, 58, 416, 216, 227, 2095, 2106, "dorzolamide" +443, 15, 59, 417, 228, 229, 2107, 2108, "-" +443, 15, 60, 418, 230, 237, 2109, 2116, "timolol" +443, 15, 61, 419, 238, 239, 2117, 2118, "(" +443, 15, 62, 420, 240, 241, 2119, 2120, "p" +443, 15, 63, 421, 242, 243, 2121, 2122, "=" +443, 15, 64, 422, 244, 245, 2123, 2124, "0" +443, 15, 65, 423, 246, 247, 2125, 2126, "." +443, 15, 66, 424, 248, 251, 2127, 2130, "040" +443, 15, 67, 425, 252, 253, 2131, 2132, ")" +443, 15, 68, 426, 254, 255, 2133, 2134, "." +443, 16, 1, 427, 0, 3, 2135, 2138, "The" +443, 16, 2, 428, 4, 8, 2139, 2143, "mean" +443, 16, 3, 429, 9, 18, 2144, 2153, "reduction" +443, 16, 4, 430, 19, 23, 2154, 2158, "from" +443, 16, 5, 431, 24, 27, 2159, 2162, "PGA" +443, 16, 6, 432, 28, 29, 2163, 2164, "-" +443, 16, 7, 433, 30, 37, 2165, 2172, "treated" +443, 16, 8, 434, 38, 46, 2173, 2181, "baseline" +443, 16, 9, 435, 47, 50, 2182, 2185, "IOP" +443, 16, 10, 436, 51, 54, 2186, 2189, "for" +443, 16, 11, 437, 55, 63, 2190, 2198, "patients" +443, 16, 12, 438, 64, 66, 2199, 2201, "on" +443, 16, 13, 439, 67, 72, 2202, 2207, "fixed" +443, 16, 14, 440, 73, 74, 2208, 2209, "-" +443, 16, 15, 441, 75, 86, 2210, 2221, "combination" +443, 16, 16, 442, 87, 97, 2222, 2232, "adjunctive" +443, 16, 17, 443, 98, 105, 2233, 2240, "therapy" +443, 16, 18, 444, 106, 109, 2241, 2244, "was" +443, 16, 19, 445, 110, 111, 2245, 2246, "6" +443, 16, 20, 446, 112, 113, 2247, 2248, "." +443, 16, 21, 447, 114, 115, 2249, 2250, "9" +443, 16, 22, 448, 116, 117, 2251, 2252, "(" +443, 16, 23, 449, 118, 119, 2253, 2254, "4" +443, 16, 24, 450, 120, 121, 2255, 2256, "." +443, 16, 25, 451, 122, 123, 2257, 2258, "8" +443, 16, 26, 452, 124, 125, 2259, 2260, ")" +443, 16, 27, 453, 126, 130, 2261, 2265, "mmHg" +443, 16, 28, 454, 131, 132, 2266, 2267, "(" +443, 16, 29, 455, 133, 135, 2268, 2270, "29" +443, 16, 30, 456, 136, 137, 2271, 2272, "." +443, 16, 31, 457, 138, 139, 2273, 2274, "3" +443, 16, 32, 458, 140, 141, 2275, 2276, "%" +443, 16, 33, 459, 142, 143, 2277, 2278, ")" +443, 16, 34, 460, 144, 148, 2279, 2283, "with" +443, 16, 35, 461, 149, 160, 2284, 2295, "brimonidine" +443, 16, 36, 462, 161, 162, 2296, 2297, "-" +443, 16, 37, 463, 163, 170, 2298, 2305, "timolol" +443, 16, 38, 464, 171, 177, 2306, 2312, "versus" +443, 16, 39, 465, 178, 179, 2313, 2314, "5" +443, 16, 40, 466, 180, 181, 2315, 2316, "." +443, 16, 41, 467, 182, 183, 2317, 2318, "2" +443, 16, 42, 468, 184, 185, 2319, 2320, "(" +443, 16, 43, 469, 186, 187, 2321, 2322, "3" +443, 16, 44, 470, 188, 189, 2323, 2324, "." +443, 16, 45, 471, 190, 191, 2325, 2326, "7" +443, 16, 46, 472, 192, 193, 2327, 2328, ")" +443, 16, 47, 473, 194, 198, 2329, 2333, "mmHg" +443, 16, 48, 474, 199, 200, 2334, 2335, "(" +443, 16, 49, 475, 201, 203, 2336, 2338, "23" +443, 16, 50, 476, 204, 205, 2339, 2340, "." +443, 16, 51, 477, 206, 207, 2341, 2342, "5" +443, 16, 52, 478, 208, 209, 2343, 2344, "%" +443, 16, 53, 479, 210, 211, 2345, 2346, ")" +443, 16, 54, 480, 212, 216, 2347, 2351, "with" +443, 16, 55, 481, 217, 228, 2352, 2363, "dorzolamide" +443, 16, 56, 482, 229, 230, 2364, 2365, "-" +443, 16, 57, 483, 231, 238, 2366, 2373, "timolol" +443, 16, 58, 484, 239, 240, 2374, 2375, "(" +443, 16, 59, 485, 241, 242, 2376, 2377, "p" +443, 16, 60, 486, 243, 244, 2378, 2379, "=" +443, 16, 61, 487, 245, 246, 2380, 2381, "0" +443, 16, 62, 488, 247, 248, 2382, 2383, "." +443, 16, 63, 489, 249, 252, 2384, 2387, "213" +443, 16, 64, 490, 253, 254, 2388, 2389, ")" +443, 16, 65, 491, 255, 256, 2390, 2391, "." +443, 17, 1, 492, 0, 8, 2392, 2400, "Patients" +443, 17, 2, 493, 9, 11, 2401, 2403, "on" +443, 17, 3, 494, 12, 23, 2404, 2415, "brimonidine" +443, 17, 4, 495, 24, 25, 2416, 2417, "-" +443, 17, 5, 496, 26, 33, 2418, 2425, "timolol" +443, 17, 6, 497, 34, 42, 2426, 2434, "reported" +443, 17, 7, 498, 43, 47, 2435, 2439, "less" +443, 17, 8, 499, 48, 55, 2440, 2447, "burning" +443, 17, 9, 500, 56, 57, 2448, 2449, "(" +443, 17, 10, 501, 58, 59, 2450, 2451, "p" +443, 17, 11, 502, 60, 61, 2452, 2453, "<" +443, 17, 12, 503, 62, 63, 2454, 2455, "0" +443, 17, 13, 504, 64, 65, 2456, 2457, "." +443, 17, 14, 505, 66, 69, 2458, 2461, "001" +443, 17, 15, 506, 70, 71, 2462, 2463, ")" +443, 17, 16, 507, 72, 73, 2464, 2465, "," +443, 17, 17, 508, 74, 82, 2466, 2474, "stinging" +443, 17, 18, 509, 83, 84, 2475, 2476, "(" +443, 17, 19, 510, 85, 86, 2477, 2478, "p" +443, 17, 20, 511, 87, 88, 2479, 2480, "<" +443, 17, 21, 512, 89, 90, 2481, 2482, "0" +443, 17, 22, 513, 91, 92, 2483, 2484, "." +443, 17, 23, 514, 93, 96, 2485, 2488, "001" +443, 17, 24, 515, 97, 98, 2489, 2490, ")" +443, 17, 25, 516, 99, 100, 2491, 2492, "," +443, 17, 26, 517, 101, 104, 2493, 2496, "and" +443, 17, 27, 518, 105, 112, 2497, 2504, "unusual" +443, 17, 28, 519, 113, 118, 2505, 2510, "taste" +443, 17, 29, 520, 119, 120, 2511, 2512, "(" +443, 17, 30, 521, 121, 122, 2513, 2514, "p" +443, 17, 31, 522, 123, 124, 2515, 2516, "<" +443, 17, 32, 523, 125, 126, 2517, 2518, "0" +443, 17, 33, 524, 127, 128, 2519, 2520, "." +443, 17, 34, 525, 129, 132, 2521, 2524, "001" +443, 17, 35, 526, 133, 134, 2525, 2526, ")" +443, 17, 36, 527, 135, 139, 2527, 2531, "than" +443, 17, 37, 528, 140, 148, 2532, 2540, "patients" +443, 17, 38, 529, 149, 151, 2541, 2543, "on" +443, 17, 39, 530, 152, 163, 2544, 2555, "dorzolamide" +443, 17, 40, 531, 164, 165, 2556, 2557, "-" +443, 17, 41, 532, 166, 173, 2558, 2565, "timolol" +443, 17, 42, 533, 174, 175, 2566, 2567, "." +443, 18, 1, 534, 0, 11, 2568, 2579, "CONCLUSIONS" +443, 18, 2, 535, 12, 13, 2580, 2581, ":" +443, 18, 3, 536, 14, 19, 2582, 2587, "Fixed" +443, 18, 4, 537, 20, 21, 2588, 2589, "-" +443, 18, 5, 538, 22, 33, 2590, 2601, "combination" +443, 18, 6, 539, 34, 45, 2602, 2613, "brimonidine" +443, 18, 7, 540, 46, 47, 2614, 2615, "-" +443, 18, 8, 541, 48, 55, 2616, 2623, "timolol" +443, 18, 9, 542, 56, 64, 2624, 2632, "provided" +443, 18, 10, 543, 65, 68, 2633, 2636, "the" +443, 18, 11, 544, 69, 73, 2637, 2641, "same" +443, 18, 12, 545, 74, 76, 2642, 2644, "or" +443, 18, 13, 546, 77, 84, 2645, 2652, "greater" +443, 18, 14, 547, 85, 88, 2653, 2656, "IOP" +443, 18, 15, 548, 89, 97, 2657, 2665, "lowering" +443, 18, 16, 549, 98, 106, 2666, 2674, "compared" +443, 18, 17, 550, 107, 111, 2675, 2679, "with" +443, 18, 18, 551, 112, 117, 2680, 2685, "fixed" +443, 18, 19, 552, 118, 119, 2686, 2687, "-" +443, 18, 20, 553, 120, 131, 2688, 2699, "combination" +443, 18, 21, 554, 132, 143, 2700, 2711, "dorzolamide" +443, 18, 22, 555, 144, 145, 2712, 2713, "-" +443, 18, 23, 556, 146, 153, 2714, 2721, "timolol" +443, 18, 24, 557, 154, 155, 2722, 2723, "." +443, 19, 1, 558, 0, 4, 2724, 2728, "Both" +443, 19, 2, 559, 5, 10, 2729, 2734, "fixed" +443, 19, 3, 560, 11, 12, 2735, 2736, "-" +443, 19, 4, 561, 13, 24, 2737, 2748, "combination" +443, 19, 5, 562, 25, 36, 2749, 2760, "medications" +443, 19, 6, 563, 37, 41, 2761, 2765, "were" +443, 19, 7, 564, 42, 46, 2766, 2770, "safe" +443, 19, 8, 565, 47, 50, 2771, 2774, "and" +443, 19, 9, 566, 51, 55, 2775, 2779, "well" +443, 19, 10, 567, 56, 57, 2780, 2781, "-" +443, 19, 11, 568, 58, 67, 2782, 2791, "tolerated" +443, 19, 12, 569, 68, 69, 2792, 2793, "." +443, 20, 1, 570, 0, 11, 2794, 2805, "Brimonidine" +443, 20, 2, 571, 12, 13, 2806, 2807, "-" +443, 20, 3, 572, 14, 21, 2808, 2815, "timolol" +443, 20, 4, 573, 22, 30, 2816, 2824, "received" +443, 20, 5, 574, 31, 37, 2825, 2831, "higher" +443, 20, 6, 575, 38, 45, 2832, 2839, "ratings" +443, 20, 7, 576, 46, 48, 2840, 2842, "of" +443, 20, 8, 577, 49, 55, 2843, 2849, "ocular" +443, 20, 9, 578, 56, 63, 2850, 2857, "comfort" +443, 20, 10, 579, 64, 68, 2858, 2862, "than" +443, 20, 11, 580, 69, 80, 2863, 2874, "dorzolamide" +443, 20, 12, 581, 81, 82, 2875, 2876, "-" +443, 20, 13, 582, 83, 90, 2877, 2884, "timolol" +443, 20, 14, 583, 91, 92, 2885, 2886, "." +443, 21, 1, 584, 0, 3, 2887, 2890, "The" +443, 21, 2, 585, 4, 12, 2891, 2899, "duration" +443, 21, 3, 586, 13, 15, 2900, 2902, "of" +443, 21, 4, 587, 16, 19, 2903, 2906, "the" +443, 21, 5, 588, 20, 27, 2907, 2914, "studies" +443, 21, 6, 589, 28, 31, 2915, 2918, "was" +443, 21, 7, 590, 32, 33, 2919, 2920, "3" +443, 21, 8, 591, 34, 40, 2921, 2927, "months" +443, 21, 9, 592, 41, 42, 2928, 2929, "," +443, 21, 10, 593, 43, 46, 2930, 2933, "and" +443, 21, 11, 594, 47, 57, 2934, 2944, "additional" +443, 21, 12, 595, 58, 65, 2945, 2952, "studies" +443, 21, 13, 596, 66, 70, 2953, 2957, "will" +443, 21, 14, 597, 71, 73, 2958, 2960, "be" +443, 21, 15, 598, 74, 80, 2961, 2967, "needed" +443, 21, 16, 599, 81, 83, 2968, 2970, "to" +443, 21, 17, 600, 84, 91, 2971, 2978, "compare" +443, 21, 18, 601, 92, 95, 2979, 2982, "the" +443, 21, 19, 602, 96, 104, 2983, 2991, "efficacy" +443, 21, 20, 603, 105, 108, 2992, 2995, "and" +443, 21, 21, 604, 109, 121, 2996, 3008, "tolerability" +443, 21, 22, 605, 122, 124, 3009, 3011, "of" +443, 21, 23, 606, 125, 136, 3012, 3023, "brimonidine" +443, 21, 24, 607, 137, 138, 3024, 3025, "-" +443, 21, 25, 608, 139, 146, 3026, 3033, "timolol" +443, 21, 26, 609, 147, 150, 3034, 3037, "and" +443, 21, 27, 610, 151, 162, 3038, 3049, "dorzolamide" +443, 21, 28, 611, 163, 164, 3050, 3051, "-" +443, 21, 29, 612, 165, 172, 3052, 3059, "timolol" +443, 21, 30, 613, 173, 179, 3060, 3066, "during" +443, 21, 31, 614, 180, 184, 3067, 3071, "long" +443, 21, 32, 615, 185, 186, 3072, 3073, "-" +443, 21, 33, 616, 187, 191, 3074, 3078, "term" +443, 21, 34, 617, 192, 201, 3079, 3088, "treatment" +443, 21, 35, 618, 202, 203, 3089, 3090, "." +443, 22, 1, 619, 0, 3, 3091, 3094, "DOI" +443, 22, 2, 620, 4, 5, 3095, 3096, ":" +443, 22, 3, 621, 6, 8, 3097, 3099, "10" +443, 22, 4, 622, 9, 10, 3100, 3101, "." +443, 22, 5, 623, 11, 15, 3102, 3106, "1185" +443, 22, 6, 624, 16, 17, 3107, 3108, "/" +443, 22, 7, 625, 18, 35, 3109, 3126, "03007990902994041" +443, 22, 8, 626, 36, 40, 3127, 3131, "PMID" +443, 22, 9, 627, 41, 42, 3132, 3133, ":" +443, 22, 10, 628, 43, 51, 3134, 3142, "19476406" +443, 22, 11, 629, 52, 53, 3143, 3144, "[" +443, 22, 12, 630, 54, 61, 3145, 3152, "Indexed" +443, 22, 13, 631, 62, 65, 3153, 3156, "for" +443, 22, 14, 632, 66, 73, 3157, 3164, "MEDLINE" +443, 22, 15, 633, 74, 75, 3165, 3166, "]" diff --git a/data/gl 19476406_jshahinitiran.annodb b/data/gl 19476406_jshahinitiran.annodb new file mode 100644 index 0000000..7fd92bd --- /dev/null +++ b/data/gl 19476406_jshahinitiran.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13060, Journal, 0, 17, "Curr Med Res Opin", "", +13061, PublicationYear, 20, 24, "2009", "", +13062, Title, 92, 232, "Three - month , randomized , parallel - group comparison of brimonidine - timolol versus dorzolamide - timolol fixed - combination therapy .", "", +13064, Duration, 92, 105, "Three - month", "", +13065, Randomized, 108, 118, "randomized", "", +13066, Parallel, 121, 129, "parallel", "", +13067, Brimonidine, 152, 163, "brimonidine", "", +13068, Timolol, 166, 173, "timolol", "", +13069, Dorzolamide, 181, 192, "dorzolamide", "", +13070, Timolol, 195, 202, "timolol", "", +13071, Author, 233, 241, "Nixon DR", "", +13072, Author, 250, 256, "Yan DB", "", +13073, Author, 259, 271, "Chartrand JP", "", +13074, Author, 274, 287, "Piemontesi RL", "", +13075, Author, 290, 299, "Simonyi S", "", +13076, Author, 302, 314, "Hollander DA", "", +13077, ObjectiveDescription, 384, 530, "Fixed combinations of 0 . 2 % brimonidine - 0 . 5 % timolol and 2 % dorzolamide - 0 . 5 % timolol are used to lower intraocular pressure ( IOP ) .", "", +13078, DoseValue, 406, 411, "0 . 2", "", +13079, Percentage, 412, 413, "%", "", +13067, Brimonidine, 414, 425, "brimonidine", "", +13084, DoseValue, 428, 433, "0 . 5", "", +13081, Percentage, 434, 435, "%", "", +13068, Timolol, 436, 443, "timolol", "", +13085, DoseValue, 448, 449, "2", "", +13082, Percentage, 450, 451, "%", "", +13069, Dorzolamide, 452, 463, "dorzolamide", "", +13086, DoseValue, 466, 471, "0 . 5", "", +13083, Percentage, 472, 473, "%", "", +13070, Timolol, 474, 481, "timolol", "", +13090, IOP, 500, 520, "intraocular pressure", "", +13091, IOP, 523, 526, "IOP", "", +13092, IOP, 579, 582, "IOP", "", +13067, Brimonidine, 630, 641, "brimonidine", "", +13068, Timolol, 644, 651, "timolol", "", +13069, Dorzolamide, 666, 677, "dorzolamide", "", +13070, Timolol, 680, 687, "timolol", "", +13097, Glaucoma, 789, 797, "glaucoma", "", +13098, OcularHypertension, 801, 820, "ocular hypertension", "", +13099, Randomized, 878, 888, "randomized", "", +13100, Blind, 891, 912, "investigator - masked", "", +13101, Duration, 915, 924, "3 - month", "", +13102, Parallel, 927, 935, "parallel", "", +13103, Multicenter, 979, 988, "ten sites", "", +13104, NumberPatientsCT, 1002, 1005, "180", "", +13105, OpenAngleGlaucoma, 1020, 1041, "open - angle glaucoma", "", +13106, OcularHypertension, 1045, 1064, "ocular hypertension", "", +13107, IOP, 1091, 1094, "IOP", "", +13067, Brimonidine, 1112, 1123, "brimonidine", "", +13068, Timolol, 1126, 1133, "timolol", "", +13110, Frequency, 1134, 1137, "BID", "", +13069, Dorzolamide, 1141, 1152, "dorzolamide", "", +13070, Timolol, 1155, 1162, "timolol", "", +13113, Frequency, 1163, 1166, "BID", "", +35954, NumberPatientsArm, 1188, 1191, "101", "", +35955, Latanoprost, 1230, 1241, "latanoprost", "", +35956, Bimatoprost, 1244, 1255, "bimatoprost", "", +35957, Travoprost, 1261, 1271, "travoprost", "", +35958, NumberPatientsArm, 1280, 1282, "79", "", +35959, IOP, 1460, 1463, "IOP", "", +35960, TimePoint, 1510, 1518, "baseline", "", +35961, TimePoint, 1526, 1534, "months 1", "", +35962, TimePoint, 1539, 1540, "3", "", +35963, Caucasian, 1735, 1744, "Caucasian", "", +13115, Mean, 1755, 1759, "mean", "", +13114, AvgAge, 1768, 1770, "68", "", +35964, IOP, 1873, 1876, "IOP", "", +35965, TimePoint, 1882, 1889, "month 3", "", +35966, Mean, 1896, 1900, "mean", "", +35967, IOP, 1932, 1935, "IOP", "", +35968, Reduction, 1988, 1993, "7 . 7", "", +35969, SdDevChangeValue, 1996, 2001, "4 . 2", "", +35972, mmHg, 2004, 2008, "mmHg", "", +35974, RelativeReduction, 2011, 2017, "32 . 3", "", +35976, Brimonidine, 2027, 2038, "brimonidine", "", +35977, Timolol, 2041, 2048, "timolol", "", +35971, Reduction, 2056, 2061, "6 . 7", "", +35970, SdDevChangeValue, 2064, 2069, "5 . 0", "", +35973, mmHg, 2072, 2076, "mmHg", "", +35975, RelativeReduction, 2079, 2085, "26 . 1", "", +35978, Dorzolamide, 2095, 2106, "dorzolamide", "", +35979, Timolol, 2109, 2116, "timolol", "", +35980, PValueChangeValue, 2119, 2130, "p = 0 . 040", "", +35981, Mean, 2139, 2143, "mean", "", +35982, Reduction, 2245, 2250, "6 . 9", "", +35984, SdDevChangeValue, 2253, 2258, "4 . 8", "", +35986, mmHg, 2261, 2265, "mmHg", "", +35988, RelativeReduction, 2268, 2274, "29 . 3", "", +35990, Brimonidine, 2284, 2295, "brimonidine", "", +35991, Timolol, 2298, 2305, "timolol", "", +35983, Reduction, 2313, 2318, "5 . 2", "", +35985, SdDevChangeValue, 2321, 2326, "3 . 7", "", +35987, mmHg, 2329, 2333, "mmHg", "", +35989, RelativeReduction, 2336, 2344, "23 . 5 %", "", +35992, Dorzolamide, 2352, 2363, "dorzolamide", "", +35993, Timolol, 2366, 2373, "timolol", "", +35994, PValueChangeValue, 2376, 2387, "p = 0 . 213", "", +35995, Brimonidine, 2404, 2415, "brimonidine", "", +35996, Timolol, 2418, 2425, "timolol", "", +36000, PValueNumAffected, 2450, 2461, "p < 0 . 001", "", +36001, PValueNumAffected, 2477, 2488, "p < 0 . 001", "", +36002, PValueNumAffected, 2513, 2524, "p < 0 . 001", "", +36003, Dorzolamide, 2544, 2555, "dorzolamide", "", +36004, Timolol, 2558, 2565, "timolol", "", +36005, ConclusionComment, 2582, 2723, "Fixed - combination brimonidine - timolol provided the same or greater IOP lowering compared with fixed - combination dorzolamide - timolol .", "", +36006, Brimonidine, 2602, 2613, "brimonidine", "", +36007, Timolol, 2616, 2623, "timolol", "", +36008, IOP, 2653, 2656, "IOP", "", +36009, Dorzolamide, 2700, 2711, "dorzolamide", "", +36010, Timolol, 2714, 2721, "timolol", "", +36011, ConclusionComment, 2724, 2791, "Both fixed - combination medications were safe and well - tolerated", "", +36012, ConclusionComment, 2794, 2884, "Brimonidine - timolol received higher ratings of ocular comfort than dorzolamide - timolol", "", +36014, Brimonidine, 2794, 2805, "Brimonidine", "", +36015, Timolol, 2808, 2815, "timolol", "", +36017, Dorzolamide, 2863, 2874, "dorzolamide", "", +36016, Timolol, 2877, 2884, "timolol", "", +36013, ConclusionComment, 2887, 3088, "The duration of the studies was 3 months , and additional studies will be needed to compare the efficacy and tolerability of brimonidine - timolol and dorzolamide - timolol during long - term treatment", "", +36018, Duration, 2919, 2927, "3 months", "", +36019, Brimonidine, 3012, 3023, "brimonidine", "", +36020, Timolol, 3026, 3033, "timolol", "", +36022, Dorzolamide, 3038, 3049, "dorzolamide", "", +36021, Timolol, 3052, 3059, "timolol", "", +36023, PMID, 3134, 3142, "19476406", "", diff --git a/data/gl 19476406_jshahinitiran.n-triples b/data/gl 19476406_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19476406_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19476406_tstrakeljahn.annodb b/data/gl 19476406_tstrakeljahn.annodb new file mode 100644 index 0000000..fac3c76 --- /dev/null +++ b/data/gl 19476406_tstrakeljahn.annodb @@ -0,0 +1,149 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +76985, Journal, 0, 17, "Curr Med Res Opin", "", +76986, PublicationYear, 20, 24, "2009", "", +76987, Duration, 92, 105, "Three - month", "", +76996, Title, 92, 232, "Three - month , randomized , parallel - group comparison of brimonidine - timolol versus dorzolamide - timolol fixed - combination therapy .", "", +76988, Randomized, 108, 118, "randomized", "", +76989, Parallel, 121, 137, "parallel - group", "", +76990, Brimonidine, 152, 163, "brimonidine", "", +76992, Brimo/TimFC, 152, 173, "brimonidine - timolol", "", +76991, Timolol, 166, 173, "timolol", "", +76993, Dorzolamide, 181, 192, "dorzolamide", "", +76995, Dorz/TimFC, 181, 202, "dorzolamide - timolol", "", +76994, Timolol, 195, 202, "timolol", "", +76997, Author, 233, 241, "Nixon DR", "", +76998, Author, 250, 256, "Yan DB", "", +76999, Author, 259, 271, "Chartrand JP", "", +77000, Author, 274, 287, "Piemontesi RL", "", +77001, Author, 290, 299, "Simonyi S", "", +77002, Author, 302, 314, "Hollander DA", "", +77003, DoseValue, 406, 411, "0 . 2", "", +77017, Brimo/TimFC, 406, 443, "0 . 2 % brimonidine - 0 . 5 % timolol", "", +77004, Percentage, 412, 413, "%", "", +77005, Brimonidine, 414, 425, "brimonidine", "", +77006, DoseValue, 428, 433, "0 . 5", "", +77007, Percentage, 434, 435, "%", "", +77008, Timolol, 436, 443, "timolol", "", +77009, DoseValue, 448, 449, "2", "", +77018, Dorz/TimFC, 448, 481, "2 % dorzolamide - 0 . 5 % timolol", "", +77010, Percentage, 450, 451, "%", "", +77011, Dorzolamide, 452, 463, "dorzolamide", "", +77012, DoseValue, 466, 471, "0 . 5", "", +77013, Percentage, 472, 473, "%", "", +77014, Timolol, 474, 481, "timolol", "", +77015, IOP, 500, 520, "intraocular pressure", "", +77016, IOP, 523, 526, "IOP", "", +77028, ObjectiveDescription, 531, 783, "The objective of this study was to evaluate the IOP - lowering efficacy and ocular tolerability of brimonidine - timolol compared with dorzolamide - timolol when used as monotherapy or as adjunctive therapy to a prostaglandin analog ( PGA ) in patients", "", +77019, IOP, 579, 582, "IOP", "", +77020, Brimonidine, 630, 641, "brimonidine", "", +77022, Brimo/TimFC, 630, 651, "brimonidine - timolol", "", +77021, Timolol, 644, 651, "timolol", "", +77023, Dorzolamide, 666, 677, "dorzolamide", "", +77025, Dorz/TimFC, 666, 687, "dorzolamide - timolol", "", +77024, Timolol, 680, 687, "timolol", "", +77029, ObjectiveDescription, 784, 822, "with glaucoma or ocular hypertension .", "", +77026, Glaucoma, 789, 797, "glaucoma", "", +77027, OcularHypertension, 801, 820, "ocular hypertension", "", +77030, Randomized, 878, 888, "randomized", "", +77031, Blind, 891, 912, "investigator - masked", "", +77032, Duration, 915, 924, "3 - month", "", +77033, Parallel, 927, 943, "parallel - group", "", +77034, Multicenter, 979, 988, "ten sites", "", +77035, NumberPatientsCT, 1002, 1005, "180", "", +77036, OpenAngleGlaucoma, 1020, 1041, "open - angle glaucoma", "", +77037, OcularHypertension, 1045, 1064, "ocular hypertension", "", +77038, IOP, 1091, 1094, "IOP", "", +77039, Brimonidine, 1112, 1123, "brimonidine", "", +77045, Brimo/TimFC, 1112, 1133, "brimonidine - timolol", "", +77040, Timolol, 1126, 1133, "timolol", "", +77043, Frequency, 1134, 1137, "BID", "", +77042, Dorzolamide, 1141, 1152, "dorzolamide", "", +77046, Dorz/TimFC, 1141, 1162, "dorzolamide - timolol", "", +77041, Timolol, 1155, 1162, "timolol", "", +77044, Frequency, 1163, 1166, "BID", "", +77047, SubGroupDescription, 1167, 1193, "as monotherapy ( n = 101 )", "", +77048, SubGroupDescription, 1197, 1284, "as adjunctive therapy to a PGA ( latanoprost , bimatoprost , or travoprost ) ( n = 79 )", "", +77049, Latanoprost, 1230, 1241, "latanoprost", "", +77050, Bimatoprost, 1244, 1255, "bimatoprost", "", +77051, Travoprost, 1261, 1271, "travoprost", "", +77052, IOP, 1460, 1463, "IOP", "", +77053, RelativeTime, 1480, 1488, "10 a . m", "", +77054, Peak_IOP, 1493, 1504, "peak effect", "", +77055, TimePoint, 1510, 1518, "baseline", "", +77056, TimePoint, 1526, 1534, "months 1", "", +77057, TimePoint, 1526, 1540, "months 1 and 3", "", +77058, Caucasian, 1735, 1744, "Caucasian", "", +77059, Mean, 1755, 1759, "mean", "", +77060, AvgAge, 1768, 1770, "68", "", +77061, IOP, 1873, 1876, "IOP", "", +77062, TimePoint, 1882, 1889, "month 3", "", +77063, Mean, 1896, 1900, "mean", "", +77064, IOP, 1932, 1935, "IOP", "", +77065, Reduction, 1988, 1993, "7 . 7", "", +77069, SdDevChangeValue, 1996, 2001, "4 . 2", "", +77071, mmHg, 2004, 2008, "mmHg", "", +77067, RelativeReduction, 2011, 2017, "32 . 3", "", +77073, Brimonidine, 2027, 2038, "brimonidine", "", +77077, Brimo/TimFC, 2027, 2048, "brimonidine - timolol", "", +77074, Timolol, 2041, 2048, "timolol", "", +77066, Reduction, 2056, 2061, "6 . 7", "", +77070, SdDevChangeValue, 2064, 2069, "5 . 0", "", +77072, mmHg, 2072, 2076, "mmHg", "", +77068, RelativeReduction, 2079, 2085, "26 . 1", "", +77076, Dorzolamide, 2095, 2106, "dorzolamide", "", +77078, Dorz/TimFC, 2095, 2116, "dorzolamide - timolol", "", +77075, Timolol, 2109, 2116, "timolol", "", +77079, PvalueDiff, 2121, 2130, "= 0 . 040", "", +77080, Mean, 2139, 2143, "mean", "", +77081, IOP, 2182, 2185, "IOP", "", +77082, Reduction, 2245, 2250, "6 . 9", "", +77087, SdDevChangeValue, 2253, 2258, "4 . 8", "", +77088, mmHg, 2261, 2265, "mmHg", "", +77084, RelativeReduction, 2268, 2274, "29 . 3", "", +77090, Brimonidine, 2284, 2295, "brimonidine", "", +77092, Brimo/TimFC, 2284, 2305, "brimonidine - timolol", "", +77091, Timolol, 2298, 2305, "timolol", "", +77083, Reduction, 2313, 2318, "5 . 2", "", +77086, SdDevChangeValue, 2321, 2326, "3 . 7", "", +77089, mmHg, 2329, 2333, "mmHg", "", +77085, RelativeReduction, 2336, 2342, "23 . 5", "", +77093, Dorzolamide, 2352, 2363, "dorzolamide", "", +77095, Dorz/TimFC, 2352, 2373, "dorzolamide - timolol", "", +77094, Timolol, 2366, 2373, "timolol", "", +77096, PvalueDiff, 2378, 2387, "= 0 . 213", "", +77112, ObservedResult, 2392, 2567, "Patients on brimonidine - timolol reported less burning ( p < 0 . 001 ) , stinging ( p < 0 . 001 ) , and unusual taste ( p < 0 . 001 ) than patients on dorzolamide - timolol .", "", +77097, Brimonidine, 2404, 2415, "brimonidine", "", +77099, Brimo/TimFC, 2404, 2425, "brimonidine - timolol", "", +77098, Timolol, 2418, 2425, "timolol", "", +77100, PvalueDiff, 2452, 2461, "< 0 . 001", "", +77107, Stinging, 2466, 2474, "stinging", "", +77104, PvalueDiff, 2479, 2488, "< 0 . 001", "", +77105, PvalueDiff, 2515, 2524, "< 0 . 001", "", +77109, Dorzolamide, 2544, 2555, "dorzolamide", "", +77111, Dorz/TimFC, 2544, 2565, "dorzolamide - timolol", "", +77110, Timolol, 2558, 2565, "timolol", "", +77133, ConclusionComment, 2582, 2723, "Fixed - combination brimonidine - timolol provided the same or greater IOP lowering compared with fixed - combination dorzolamide - timolol .", "", +77113, Brimonidine, 2602, 2613, "brimonidine", "", +77118, Brimo/TimFC, 2602, 2623, "brimonidine - timolol", "", +77114, Timolol, 2616, 2623, "timolol", "", +77115, IOP, 2653, 2656, "IOP", "", +77116, Dorzolamide, 2700, 2711, "dorzolamide", "", +77119, Dorz/TimFC, 2700, 2721, "dorzolamide - timolol", "", +77117, Timolol, 2714, 2721, "timolol", "", +77134, ConclusionComment, 2724, 2793, "Both fixed - combination medications were safe and well - tolerated .", "", +77120, Brimonidine, 2794, 2805, "Brimonidine", "", +77124, Brimo/TimFC, 2794, 2815, "Brimonidine - timolol", "", +77135, ConclusionComment, 2794, 2886, "Brimonidine - timolol received higher ratings of ocular comfort than dorzolamide - timolol .", "", +77121, Timolol, 2808, 2815, "timolol", "", +77122, Dorzolamide, 2863, 2874, "dorzolamide", "", +77125, Dorz/TimFC, 2863, 2884, "dorzolamide - timolol", "", +77123, Timolol, 2877, 2884, "timolol", "", +77136, ConclusionComment, 2887, 3090, "The duration of the studies was 3 months , and additional studies will be needed to compare the efficacy and tolerability of brimonidine - timolol and dorzolamide - timolol during long - term treatment .", "", +77126, Duration, 2919, 2927, "3 months", "", +77127, Brimonidine, 3012, 3023, "brimonidine", "", +77131, Brimo/TimFC, 3012, 3033, "brimonidine - timolol", "", +77128, Timolol, 3026, 3033, "timolol", "", +77130, Dorzolamide, 3038, 3049, "dorzolamide", "", +77132, Dorz/TimFC, 3038, 3059, "dorzolamide - timolol", "", +77129, Timolol, 3052, 3059, "timolol", "", +77137, PMID, 3134, 3142, "19476406", "", diff --git a/data/gl 19476406_tstrakeljahn.n-triples b/data/gl 19476406_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19476406_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19726422 copy_admin.annodb b/data/gl 19726422 copy_admin.annodb new file mode 100644 index 0000000..02b4d46 --- /dev/null +++ b/data/gl 19726422 copy_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Br J Ophthalmol", "", " \"Br J Ophthalmol\"." +1, PublicationYear, 18, 22, "2010", "", " \"2010\"." +2, Title, 107, 273, "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .", "", " \"Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .\"." +27569, Bimatoprost, 136, 147, "bimatoprost", "", +36973, Travoprost, 155, 165, "travoprost", "", +31007, Precondition, 169, 203, "patients previously on latanoprost", "", +31005, Latanoprost, 192, 203, "latanoprost", "", +7, Duration, 208, 217, "3 - month", "", " \"3 - month\"." +8, Randomized, 220, 230, "randomised", "", " ." +31004, Blind, 233, 239, "masked", "", " ." +10, Multicenter, 254, 265, "multicentre", "", " ." +11, Author, 274, 283, "Kammer JA", "", " \"Kammer JA\"." +12, Author, 292, 301, "Katzman B", "", " \"Katzman B\"." +13, Author, 304, 315, "Ackerman SL", "", " \"Ackerman SL\"." +14, Author, 318, 330, "Hollander DA", "", " \"Hollander DA\"." +15, USA, 435, 438, "USA", "", +16, ObjectiveDescription, 483, 718, "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost .", "", " \"To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost .\"." +27576, Latanoprost, 532, 543, "latanoprost", "", +92859, ProstaglandinAnalogs, 557, 579, "prostaglandin analogue", "", +92860, ProstaglandinAnalogs, 582, 585, "PGA", "", +17, Glaucoma, 605, 613, "glaucoma", "", " . ." +18, OcularHypertension, 617, 636, "ocular hypertension", "", " ." +19, IOP, 658, 678, "intraocular pressure", "", +31022, IOP, 681, 684, "IOP", "", +27575, Latanoprost, 705, 716, "latanoprost", "", +36987, Prospective, 729, 740, "Prospective", "", " ." +22, Randomized, 743, 753, "randomised", "", +102, Blind, 771, 777, "masked", "", +31010, Multicenter, 780, 791, "multicentre", "", +106225, Precondition, 809, 888, "Patients on latanoprost 0 . 005 % monotherapy requiring additional IOP lowering", "", " \"Patients on latanoprost 0 . 005 % monotherapy requiring additional IOP lowering\"." +27577, Latanoprost, 821, 832, "latanoprost", "", +31014, DoseValue, 833, 840, "0 . 005", "", +26, Percentage, 841, 842, "%", "", +114, IOP, 876, 879, "IOP", "", +31015, Latanoprost, 902, 913, "latanoprost", "", +36974, Randomized, 923, 933, "randomised", "", +101, Bimatoprost, 937, 948, "bimatoprost", "", " ." +30, DoseValue, 949, 955, "0 . 03", "", " \"0 . 03\"." +31, Percentage, 956, 957, "%", "", " ." +32, NumberPatientsArm, 964, 967, "131", "", " \"131\"." +36975, Travoprost, 973, 983, "travoprost", "", " ." +33, DoseValue, 984, 991, "0 . 004", "", " \"0 . 004\"." +34, Percentage, 992, 993, "%", "", " ." +35, NumberPatientsArm, 1000, 1003, "135", "", " \"135\"." +36, IOP, 1008, 1011, "IOP", "", +120, Latanoprost, 1028, 1039, "latanoprost", "", +36976, TimePoint, 1050, 1058, "baseline", "", +31018, TimePoint, 1069, 1076, "1 month", "", +188, TimePoint, 1081, 1089, "3 months", "", +124, ObservedResult, 1125, 1192, "Baseline mean diurnal IOP on latanoprost was similar between groups", "", +39, Mean, 1134, 1138, "mean", "", +40, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +41, Latanoprost, 1154, 1165, "latanoprost", "", +133, ObservedResult, 1195, 1335, "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .", "", " \"The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .\". \"The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .\". \"The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .\". \"The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .\"." +42, Mean, 1199, 1203, "mean", "", " . ." +43, Diurnal_IOP, 1204, 1215, "diurnal IOP", "", " ." +27570, Bimatoprost, 1245, 1256, "bimatoprost", "", +36977, Travoprost, 1267, 1277, "travoprost", "", +31019, TimePoint, 1281, 1288, "1 month", "", " \"1 month\". \"1 month\"." +126, PvalueDiff, 1291, 1302, "p = 0 . 009", "", " \"p = 0 . 009\"." +125, TimePoint, 1309, 1317, "3 months", "", " \"3 months\". \"3 months\"." +127, PvalueDiff, 1320, 1331, "p = 0 . 024", "", " \"p = 0 . 024\"." +31011, PercentageAffected, 1346, 1352, "22 . 0", "", " \"22 . 0\". \"22 . 0\"." +27571, Bimatoprost, 1358, 1369, "bimatoprost", "", +47, PercentageAffected, 1386, 1392, "12 . 1", "", " \"12 . 1\". \"12 . 1\"." +36978, Travoprost, 1398, 1408, "travoprost", "", +48, EndPointDescription, 1429, 1465, "> or = 15 % reduction in diurnal IOP", "", " . ." +49, Diurnal_IOP, 1454, 1465, "diurnal IOP", "", +50, Latanoprost, 1471, 1482, "latanoprost", "", +36979, TimePoint, 1510, 1518, "months 1", "", " \"months 1\". \"months 1\"." +36980, TimePoint, 1510, 1524, "months 1 and 3", "", " \"months 1 and 3\". \"months 1 and 3\"." +143, PvalueDiff, 1527, 1538, "p = 0 . 033", "", " \"p = 0 . 033\". \"p = 0 . 033\"." +139, TimePoint, 1546, 1553, "month 3", "", " \"month 3\". \"month 3\"." +52, Mean, 1571, 1575, "mean", "", " . ." +53, Diurnal_IOP, 1576, 1587, "diurnal IOP", "", " . ." +147, Latanoprost, 1603, 1614, "latanoprost", "", +54, Reduction, 1638, 1643, "2 . 1", "", " \"2 . 1\"." +55, ConfIntervalChangeValue, 1646, 1668, "95 % CI 1 . 7 to 2 . 5", "", " \"95 % CI 1 . 7 to 2 . 5\"." +56, mmHg, 1671, 1676, "mm Hg", "", " ." +31012, RelativeReduction, 1679, 1685, "11 . 0", "", " \"11 . 0\"." +148, Bimatoprost, 1695, 1706, "bimatoprost", "", +58, Reduction, 1711, 1716, "1 . 4", "", " \"1 . 4\"." +150, ConfIntervalChangeValue, 1719, 1741, "95 % CI 0 . 9 to 1 . 8", "", " \"95 % CI 0 . 9 to 1 . 8\"." +60, mmHg, 1744, 1749, "mm Hg", "", +61, RelativeReduction, 1752, 1757, "7 . 4", "", " \"7 . 4\"." +36988, Travoprost, 1767, 1777, "travoprost", "", +158, PvalueDiff, 1780, 1791, "p = 0 . 024", "", " \"p = 0 . 024\"." +154, TimePoint, 1799, 1807, "3 months", "", +65, PercentageAffected, 1810, 1816, "11 . 5", "", " \"11 . 5\"." +27572, Bimatoprost, 1822, 1833, "bimatoprost", "", +66, PercentageAffected, 1838, 1844, "16 . 5", "", " \"16 . 5\"." +36981, Travoprost, 1850, 1860, "travoprost", "", +63, EndPointDescription, 1885, 1956, "> or = 1 - grade increase in physician - graded conjunctival hyperaemia", "", " . ." +36982, ConjunctivalHyperemia, 1933, 1956, "conjunctival hyperaemia", "", +166, PvalueDiff, 1959, 1970, "p = 0 . 288", "", " \"p = 0 . 288\"." +67, ConjunctivalHyperemia, 1975, 1985, "Hyperaemia", "", " ." +69, PercentageAffected, 2041, 2046, "3 . 1", "", " \"3 . 1\"." +27573, Bimatoprost, 2052, 2063, "bimatoprost", "", +70, PercentageAffected, 2068, 2073, "1 . 5", "", " \"1 . 5\"." +36983, Travoprost, 2079, 2089, "travoprost", "", +172, PvalueDiff, 2101, 2112, "p = 0 . 445", "", " \"p = 0 . 445\"." +72, ConclusionComment, 2130, 2310, "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .", "", " \"Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .\"." +74, Latanoprost, 2142, 2153, "latanoprost", "", +75, IOP, 2170, 2173, "IOP", "", +76, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +77, Latanoprost, 2244, 2255, "latanoprost", "", +36986, Bimatoprost, 2272, 2283, "bimatoprost", "", +36984, Travoprost, 2298, 2308, "travoprost", "", +27568, ConclusionComment, 2311, 2434, "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost .", "", " \"Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost .\"." +181, ConjunctivalHyperemia, 2324, 2334, "hyperaemia", "", +31021, Bimatoprost, 2374, 2385, "bimatoprost", "", +36985, Travoprost, 2389, 2399, "travoprost", "", +183, Latanoprost, 2421, 2432, "latanoprost", "", +79, PMID, 2499, 2507, "19726422", "", " \"19726422\"." diff --git a/data/gl 19726422 copy_admin.n-triples b/data/gl 19726422 copy_admin.n-triples new file mode 100644 index 0000000..877ca83 --- /dev/null +++ b/data/gl 19726422 copy_admin.n-triples @@ -0,0 +1,234 @@ +# RDF export of group: Publication + . + "Publication 107195" . + "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study ." . + "Kammer JA" . + "2010" . + "Br J Ophthalmol" . + "19726422" . + . + "Katzman B" . + "Ackerman SL" . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 107202" . + "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost ." . + "3 - month" . + . + . + . + "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost ." . + . + . + . + . + . + . + . + . + "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 107218" . + "Patients on latanoprost 0 . 005 % monotherapy requiring additional IOP lowering" . + . + . + . +# RDF export of group: Endpoint + . + "iop" . + . + . + . + . + . + . + "iopt" . + . + . + . + . + . + . + "iop3" . + . + . + . + . + . + . + "hyt" . + . + . + . + . + . + . + "hyp" . + . + . + . + . +# RDF export of group: Arm + . + "bi" . + "131" . + . + . + . + . + . + . + . + . + . + "tr" . + "135" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "bi" . + . + . + . + "tr" . + . + . +# RDF export of group: Medication + . + "bi" . + . + "0 . 03" . + . + . + . + "tr" . + . + "0 . 004" . + . + . +# RDF export of group: Outcome + . + "iop1" . + . + "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) ." . + "1 month" . + . + "iop2" . + . + "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) ." . + "1 month" . + . + "iop21" . + . + "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) ." . + "3 months" . + . + "iop22" . + . + "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) ." . + "3 months" . + . + "iopt1" . + . + "22 . 0" . + "months 1" . + . + "iopt2" . + . + "12 . 1" . + "months 1" . + . + "iopt21" . + . + "22 . 0" . + "months 1 and 3" . + . + "iopt22" . + . + "12 . 1" . + "months 1 and 3" . + . + "iop31" . + . + "2 . 1" . + "11 . 0" . + "95 % CI 1 . 7 to 2 . 5" . + "month 3" . + . + "iop32" . + . + "1 . 4" . + "7 . 4" . + "95 % CI 0 . 9 to 1 . 8" . + "month 3" . + . + "hyt1" . + . + "11 . 5" . + . + "hyt2" . + . + "16 . 5" . + . + "hyp1" . + . + "3 . 1" . + . + "hyp2" . + . + "1 . 5" . +# RDF export of group: DiffBetweenGroups + . + "iop" . + "p = 0 . 009" . + . + . + . + "iop2" . + "p = 0 . 024" . + . + . + . + "iopt1" . + "p = 0 . 033" . + . + . + . + "iopt2" . + "p = 0 . 033" . + . + . + . + "iop3" . + "p = 0 . 024" . + . + . + . + "hyt" . + "p = 0 . 288" . + . + . + . + "hyp" . + "p = 0 . 445" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19726422 copy_export.csv b/data/gl 19726422 copy_export.csv new file mode 100644 index 0000000..ad99099 --- /dev/null +++ b/data/gl 19726422 copy_export.csv @@ -0,0 +1,526 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +834, 1, 1, 1, 0, 2, 0, 2, "Br" +834, 1, 2, 2, 3, 4, 3, 4, "J" +834, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +834, 1, 4, 4, 16, 17, 16, 17, "." +834, 2, 1, 5, 0, 4, 18, 22, "2010" +834, 2, 2, 6, 5, 8, 23, 26, "Jan" +834, 2, 3, 7, 9, 10, 27, 28, ";" +834, 2, 4, 8, 11, 13, 29, 31, "94" +834, 2, 5, 9, 14, 15, 32, 33, "(" +834, 2, 6, 10, 16, 17, 34, 35, "1" +834, 2, 7, 11, 18, 19, 36, 37, ")" +834, 2, 8, 12, 20, 21, 38, 39, ":" +834, 2, 9, 13, 22, 24, 40, 42, "74" +834, 2, 10, 14, 25, 26, 43, 44, "-" +834, 2, 11, 15, 27, 28, 45, 46, "9" +834, 2, 12, 16, 29, 30, 47, 48, "." +834, 2, 13, 17, 31, 34, 49, 52, "doi" +834, 2, 14, 18, 35, 36, 53, 54, ":" +834, 2, 15, 19, 37, 39, 55, 57, "10" +834, 2, 16, 20, 40, 41, 58, 59, "." +834, 2, 17, 21, 42, 46, 60, 64, "1136" +834, 2, 18, 22, 47, 48, 65, 66, "/" +834, 2, 19, 23, 49, 52, 67, 70, "bjo" +834, 2, 20, 24, 53, 54, 71, 72, "." +834, 2, 21, 25, 55, 59, 73, 77, "2009" +834, 2, 22, 26, 60, 61, 78, 79, "." +834, 2, 23, 27, 62, 68, 80, 86, "158071" +834, 2, 24, 28, 69, 70, 87, 88, "." +834, 3, 1, 29, 0, 4, 89, 93, "Epub" +834, 3, 2, 30, 5, 9, 94, 98, "2009" +834, 3, 3, 31, 10, 13, 99, 102, "Sep" +834, 3, 4, 32, 14, 15, 103, 104, "1" +834, 3, 5, 33, 16, 17, 105, 106, "." +834, 4, 1, 34, 0, 8, 107, 115, "Efficacy" +834, 4, 2, 35, 9, 12, 116, 119, "and" +834, 4, 3, 36, 13, 25, 120, 132, "tolerability" +834, 4, 4, 37, 26, 28, 133, 135, "of" +834, 4, 5, 38, 29, 40, 136, 147, "bimatoprost" +834, 4, 6, 39, 41, 47, 148, 154, "versus" +834, 4, 7, 40, 48, 58, 155, 165, "travoprost" +834, 4, 8, 41, 59, 61, 166, 168, "in" +834, 4, 9, 42, 62, 70, 169, 177, "patients" +834, 4, 10, 43, 71, 81, 178, 188, "previously" +834, 4, 11, 44, 82, 84, 189, 191, "on" +834, 4, 12, 45, 85, 96, 192, 203, "latanoprost" +834, 4, 13, 46, 97, 98, 204, 205, ":" +834, 4, 14, 47, 99, 100, 206, 207, "a" +834, 4, 15, 48, 101, 102, 208, 209, "3" +834, 4, 16, 49, 103, 104, 210, 211, "-" +834, 4, 17, 50, 105, 110, 212, 217, "month" +834, 4, 18, 51, 111, 112, 218, 219, "," +834, 4, 19, 52, 113, 123, 220, 230, "randomised" +834, 4, 20, 53, 124, 125, 231, 232, "," +834, 4, 21, 54, 126, 132, 233, 239, "masked" +834, 4, 22, 55, 133, 134, 240, 241, "-" +834, 4, 23, 56, 135, 144, 242, 251, "evaluator" +834, 4, 24, 57, 145, 146, 252, 253, "," +834, 4, 25, 58, 147, 158, 254, 265, "multicentre" +834, 4, 26, 59, 159, 164, 266, 271, "study" +834, 4, 27, 60, 165, 166, 272, 273, "." +834, 5, 1, 61, 0, 6, 274, 280, "Kammer" +834, 5, 2, 62, 7, 9, 281, 283, "JA" +834, 5, 3, 63, 10, 11, 284, 285, "(" +834, 5, 4, 64, 12, 13, 286, 287, "1" +834, 5, 5, 65, 14, 15, 288, 289, ")" +834, 5, 6, 66, 16, 17, 290, 291, "," +834, 5, 7, 67, 18, 25, 292, 299, "Katzman" +834, 5, 8, 68, 26, 27, 300, 301, "B" +834, 5, 9, 69, 28, 29, 302, 303, "," +834, 5, 10, 70, 30, 38, 304, 312, "Ackerman" +834, 5, 11, 71, 39, 41, 313, 315, "SL" +834, 5, 12, 72, 42, 43, 316, 317, "," +834, 5, 13, 73, 44, 53, 318, 327, "Hollander" +834, 5, 14, 74, 54, 56, 328, 330, "DA" +834, 5, 15, 75, 57, 58, 331, 332, "." +834, 6, 1, 76, 0, 6, 333, 339, "Author" +834, 6, 2, 77, 7, 18, 340, 351, "information" +834, 6, 3, 78, 19, 20, 352, 353, ":" +834, 6, 4, 79, 21, 22, 354, 355, "(" +834, 6, 5, 80, 23, 24, 356, 357, "1" +834, 6, 6, 81, 25, 26, 358, 359, ")" +834, 6, 7, 82, 27, 37, 360, 370, "Vanderbilt" +834, 6, 8, 83, 38, 41, 371, 374, "Eye" +834, 6, 9, 84, 42, 51, 375, 384, "Institute" +834, 6, 10, 85, 52, 53, 385, 386, "," +834, 6, 11, 86, 54, 58, 387, 391, "2311" +834, 6, 12, 87, 59, 65, 392, 398, "Pierce" +834, 6, 13, 88, 66, 69, 399, 402, "Ave" +834, 6, 14, 89, 70, 71, 403, 404, "," +834, 6, 15, 90, 72, 81, 405, 414, "Nashville" +834, 6, 16, 91, 82, 83, 415, 416, "," +834, 6, 17, 92, 84, 86, 417, 419, "TN" +834, 6, 18, 93, 87, 92, 420, 425, "37232" +834, 6, 19, 94, 93, 94, 426, 427, "-" +834, 6, 20, 95, 95, 99, 428, 432, "8808" +834, 6, 21, 96, 100, 101, 433, 434, "," +834, 6, 22, 97, 102, 105, 435, 438, "USA" +834, 6, 23, 98, 106, 107, 439, 440, "." +834, 7, 1, 99, 0, 7, 441, 448, "jeffrey" +834, 7, 2, 100, 8, 9, 449, 450, "." +834, 7, 3, 101, 10, 16, 451, 457, "kammer" +834, 7, 4, 102, 17, 18, 458, 459, "@" +834, 7, 5, 103, 19, 29, 460, 470, "vanderbilt" +834, 7, 6, 104, 30, 31, 471, 472, "." +834, 7, 7, 105, 32, 35, 473, 476, "edu" +834, 7, 8, 106, 36, 39, 477, 480, "AIM" +834, 7, 9, 107, 40, 41, 481, 482, ":" +834, 7, 10, 108, 42, 44, 483, 485, "To" +834, 7, 11, 109, 45, 53, 486, 494, "evaluate" +834, 7, 12, 110, 54, 57, 495, 498, "the" +834, 7, 13, 111, 58, 66, 499, 507, "efficacy" +834, 7, 14, 112, 67, 70, 508, 511, "and" +834, 7, 15, 113, 71, 77, 512, 518, "safety" +834, 7, 16, 114, 78, 80, 519, 521, "of" +834, 7, 17, 115, 81, 90, 522, 531, "replacing" +834, 7, 18, 116, 91, 102, 532, 543, "latanoprost" +834, 7, 19, 117, 103, 107, 544, 548, "with" +834, 7, 20, 118, 108, 115, 549, 556, "another" +834, 7, 21, 119, 116, 129, 557, 570, "prostaglandin" +834, 7, 22, 120, 130, 138, 571, 579, "analogue" +834, 7, 23, 121, 139, 140, 580, 581, "(" +834, 7, 24, 122, 141, 144, 582, 585, "PGA" +834, 7, 25, 123, 145, 146, 586, 587, ")" +834, 7, 26, 124, 147, 149, 588, 590, "in" +834, 7, 27, 125, 150, 158, 591, 599, "patients" +834, 7, 28, 126, 159, 163, 600, 604, "with" +834, 7, 29, 127, 164, 172, 605, 613, "glaucoma" +834, 7, 30, 128, 173, 175, 614, 616, "or" +834, 7, 31, 129, 176, 182, 617, 623, "ocular" +834, 7, 32, 130, 183, 195, 624, 636, "hypertension" +834, 7, 33, 131, 196, 205, 637, 646, "requiring" +834, 7, 34, 132, 206, 216, 647, 657, "additional" +834, 7, 35, 133, 217, 228, 658, 669, "intraocular" +834, 7, 36, 134, 229, 237, 670, 678, "pressure" +834, 7, 37, 135, 238, 239, 679, 680, "(" +834, 7, 38, 136, 240, 243, 681, 684, "IOP" +834, 7, 39, 137, 244, 245, 685, 686, ")" +834, 7, 40, 138, 246, 254, 687, 695, "lowering" +834, 7, 41, 139, 255, 260, 696, 701, "while" +834, 7, 42, 140, 261, 263, 702, 704, "on" +834, 7, 43, 141, 264, 275, 705, 716, "latanoprost" +834, 7, 44, 142, 276, 277, 717, 718, "." +834, 8, 1, 143, 0, 7, 719, 726, "METHODS" +834, 8, 2, 144, 8, 9, 727, 728, ":" +834, 8, 3, 145, 10, 21, 729, 740, "Prospective" +834, 8, 4, 146, 22, 23, 741, 742, "," +834, 8, 5, 147, 24, 34, 743, 753, "randomised" +834, 8, 6, 148, 35, 36, 754, 755, "," +834, 8, 7, 149, 37, 49, 756, 768, "investigator" +834, 8, 8, 150, 50, 51, 769, 770, "-" +834, 8, 9, 151, 52, 58, 771, 777, "masked" +834, 8, 10, 152, 59, 60, 778, 779, "," +834, 8, 11, 153, 61, 72, 780, 791, "multicentre" +834, 8, 12, 154, 73, 81, 792, 800, "clinical" +834, 8, 13, 155, 82, 87, 801, 806, "trial" +834, 8, 14, 156, 88, 89, 807, 808, "." +834, 9, 1, 157, 0, 8, 809, 817, "Patients" +834, 9, 2, 158, 9, 11, 818, 820, "on" +834, 9, 3, 159, 12, 23, 821, 832, "latanoprost" +834, 9, 4, 160, 24, 25, 833, 834, "0" +834, 9, 5, 161, 26, 27, 835, 836, "." +834, 9, 6, 162, 28, 31, 837, 840, "005" +834, 9, 7, 163, 32, 33, 841, 842, "%" +834, 9, 8, 164, 34, 45, 843, 854, "monotherapy" +834, 9, 9, 165, 46, 55, 855, 864, "requiring" +834, 9, 10, 166, 56, 66, 865, 875, "additional" +834, 9, 11, 167, 67, 70, 876, 879, "IOP" +834, 9, 12, 168, 71, 79, 880, 888, "lowering" +834, 9, 13, 169, 80, 92, 889, 901, "discontinued" +834, 9, 14, 170, 93, 104, 902, 913, "latanoprost" +834, 9, 15, 171, 105, 108, 914, 917, "and" +834, 9, 16, 172, 109, 113, 918, 922, "were" +834, 9, 17, 173, 114, 124, 923, 933, "randomised" +834, 9, 18, 174, 125, 127, 934, 936, "to" +834, 9, 19, 175, 128, 139, 937, 948, "bimatoprost" +834, 9, 20, 176, 140, 141, 949, 950, "0" +834, 9, 21, 177, 142, 143, 951, 952, "." +834, 9, 22, 178, 144, 146, 953, 955, "03" +834, 9, 23, 179, 147, 148, 956, 957, "%" +834, 9, 24, 180, 149, 150, 958, 959, "(" +834, 9, 25, 181, 151, 152, 960, 961, "n" +834, 9, 26, 182, 153, 154, 962, 963, "=" +834, 9, 27, 183, 155, 158, 964, 967, "131" +834, 9, 28, 184, 159, 160, 968, 969, ")" +834, 9, 29, 185, 161, 163, 970, 972, "or" +834, 9, 30, 186, 164, 174, 973, 983, "travoprost" +834, 9, 31, 187, 175, 176, 984, 985, "0" +834, 9, 32, 188, 177, 178, 986, 987, "." +834, 9, 33, 189, 179, 182, 988, 991, "004" +834, 9, 34, 190, 183, 184, 992, 993, "%" +834, 9, 35, 191, 185, 186, 994, 995, "(" +834, 9, 36, 192, 187, 188, 996, 997, "n" +834, 9, 37, 193, 189, 190, 998, 999, "=" +834, 9, 38, 194, 191, 194, 1000, 1003, "135" +834, 9, 39, 195, 195, 196, 1004, 1005, ")" +834, 9, 40, 196, 197, 198, 1006, 1007, "." +834, 10, 1, 197, 0, 3, 1008, 1011, "IOP" +834, 10, 2, 198, 4, 7, 1012, 1015, "was" +834, 10, 3, 199, 8, 16, 1016, 1024, "measured" +834, 10, 4, 200, 17, 19, 1025, 1027, "at" +834, 10, 5, 201, 20, 31, 1028, 1039, "latanoprost" +834, 10, 6, 202, 32, 33, 1040, 1041, "-" +834, 10, 7, 203, 34, 41, 1042, 1049, "treated" +834, 10, 8, 204, 42, 50, 1050, 1058, "baseline" +834, 10, 9, 205, 51, 54, 1059, 1062, "and" +834, 10, 10, 206, 55, 60, 1063, 1068, "after" +834, 10, 11, 207, 61, 62, 1069, 1070, "1" +834, 10, 12, 208, 63, 68, 1071, 1076, "month" +834, 10, 13, 209, 69, 72, 1077, 1080, "and" +834, 10, 14, 210, 73, 74, 1081, 1082, "3" +834, 10, 15, 211, 75, 81, 1083, 1089, "months" +834, 10, 16, 212, 82, 84, 1090, 1092, "of" +834, 10, 17, 213, 85, 96, 1093, 1104, "replacement" +834, 10, 18, 214, 97, 104, 1105, 1112, "therapy" +834, 10, 19, 215, 105, 106, 1113, 1114, "." +834, 11, 1, 216, 0, 7, 1115, 1122, "RESULTS" +834, 11, 2, 217, 8, 9, 1123, 1124, ":" +834, 11, 3, 218, 10, 18, 1125, 1133, "Baseline" +834, 11, 4, 219, 19, 23, 1134, 1138, "mean" +834, 11, 5, 220, 24, 31, 1139, 1146, "diurnal" +834, 11, 6, 221, 32, 35, 1147, 1150, "IOP" +834, 11, 7, 222, 36, 38, 1151, 1153, "on" +834, 11, 8, 223, 39, 50, 1154, 1165, "latanoprost" +834, 11, 9, 224, 51, 54, 1166, 1169, "was" +834, 11, 10, 225, 55, 62, 1170, 1177, "similar" +834, 11, 11, 226, 63, 70, 1178, 1185, "between" +834, 11, 12, 227, 71, 77, 1186, 1192, "groups" +834, 11, 13, 228, 78, 79, 1193, 1194, "." +834, 12, 1, 229, 0, 3, 1195, 1198, "The" +834, 12, 2, 230, 4, 8, 1199, 1203, "mean" +834, 12, 3, 231, 9, 16, 1204, 1211, "diurnal" +834, 12, 4, 232, 17, 20, 1212, 1215, "IOP" +834, 12, 5, 233, 21, 24, 1216, 1219, "was" +834, 12, 6, 234, 25, 38, 1220, 1233, "significantly" +834, 12, 7, 235, 39, 44, 1234, 1239, "lower" +834, 12, 8, 236, 45, 49, 1240, 1244, "with" +834, 12, 9, 237, 50, 61, 1245, 1256, "bimatoprost" +834, 12, 10, 238, 62, 66, 1257, 1261, "than" +834, 12, 11, 239, 67, 71, 1262, 1266, "with" +834, 12, 12, 240, 72, 82, 1267, 1277, "travoprost" +834, 12, 13, 241, 83, 85, 1278, 1280, "at" +834, 12, 14, 242, 86, 87, 1281, 1282, "1" +834, 12, 15, 243, 88, 93, 1283, 1288, "month" +834, 12, 16, 244, 94, 95, 1289, 1290, "(" +834, 12, 17, 245, 96, 97, 1291, 1292, "p" +834, 12, 18, 246, 98, 99, 1293, 1294, "=" +834, 12, 19, 247, 100, 101, 1295, 1296, "0" +834, 12, 20, 248, 102, 103, 1297, 1298, "." +834, 12, 21, 249, 104, 107, 1299, 1302, "009" +834, 12, 22, 250, 108, 109, 1303, 1304, ")" +834, 12, 23, 251, 110, 113, 1305, 1308, "and" +834, 12, 24, 252, 114, 115, 1309, 1310, "3" +834, 12, 25, 253, 116, 122, 1311, 1317, "months" +834, 12, 26, 254, 123, 124, 1318, 1319, "(" +834, 12, 27, 255, 125, 126, 1320, 1321, "p" +834, 12, 28, 256, 127, 128, 1322, 1323, "=" +834, 12, 29, 257, 129, 130, 1324, 1325, "0" +834, 12, 30, 258, 131, 132, 1326, 1327, "." +834, 12, 31, 259, 133, 136, 1328, 1331, "024" +834, 12, 32, 260, 137, 138, 1332, 1333, ")" +834, 12, 33, 261, 139, 140, 1334, 1335, "." +834, 13, 1, 262, 0, 7, 1336, 1343, "Overall" +834, 13, 2, 263, 8, 9, 1344, 1345, "," +834, 13, 3, 264, 10, 12, 1346, 1348, "22" +834, 13, 4, 265, 13, 14, 1349, 1350, "." +834, 13, 5, 266, 15, 16, 1351, 1352, "0" +834, 13, 6, 267, 17, 18, 1353, 1354, "%" +834, 13, 7, 268, 19, 21, 1355, 1357, "of" +834, 13, 8, 269, 22, 33, 1358, 1369, "bimatoprost" +834, 13, 9, 270, 34, 42, 1370, 1378, "patients" +834, 13, 10, 271, 43, 49, 1379, 1385, "versus" +834, 13, 11, 272, 50, 52, 1386, 1388, "12" +834, 13, 12, 273, 53, 54, 1389, 1390, "." +834, 13, 13, 274, 55, 56, 1391, 1392, "1" +834, 13, 14, 275, 57, 58, 1393, 1394, "%" +834, 13, 15, 276, 59, 61, 1395, 1397, "of" +834, 13, 16, 277, 62, 72, 1398, 1408, "travoprost" +834, 13, 17, 278, 73, 81, 1409, 1417, "patients" +834, 13, 18, 279, 82, 90, 1418, 1426, "achieved" +834, 13, 19, 280, 91, 92, 1427, 1428, "a" +834, 13, 20, 281, 93, 94, 1429, 1430, ">" +834, 13, 21, 282, 95, 97, 1431, 1433, "or" +834, 13, 22, 283, 98, 99, 1434, 1435, "=" +834, 13, 23, 284, 100, 102, 1436, 1438, "15" +834, 13, 24, 285, 103, 104, 1439, 1440, "%" +834, 13, 25, 286, 105, 114, 1441, 1450, "reduction" +834, 13, 26, 287, 115, 117, 1451, 1453, "in" +834, 13, 27, 288, 118, 125, 1454, 1461, "diurnal" +834, 13, 28, 289, 126, 129, 1462, 1465, "IOP" +834, 13, 29, 290, 130, 134, 1466, 1470, "from" +834, 13, 30, 291, 135, 146, 1471, 1482, "latanoprost" +834, 13, 31, 292, 147, 148, 1483, 1484, "-" +834, 13, 32, 293, 149, 156, 1485, 1492, "treated" +834, 13, 33, 294, 157, 165, 1493, 1501, "baseline" +834, 13, 34, 295, 166, 168, 1502, 1504, "at" +834, 13, 35, 296, 169, 173, 1505, 1509, "both" +834, 13, 36, 297, 174, 180, 1510, 1516, "months" +834, 13, 37, 298, 181, 182, 1517, 1518, "1" +834, 13, 38, 299, 183, 186, 1519, 1522, "and" +834, 13, 39, 300, 187, 188, 1523, 1524, "3" +834, 13, 40, 301, 189, 190, 1525, 1526, "(" +834, 13, 41, 302, 191, 192, 1527, 1528, "p" +834, 13, 42, 303, 193, 194, 1529, 1530, "=" +834, 13, 43, 304, 195, 196, 1531, 1532, "0" +834, 13, 44, 305, 197, 198, 1533, 1534, "." +834, 13, 45, 306, 199, 202, 1535, 1538, "033" +834, 13, 46, 307, 203, 204, 1539, 1540, ")" +834, 13, 47, 308, 205, 206, 1541, 1542, "." +834, 14, 1, 309, 0, 2, 1543, 1545, "At" +834, 14, 2, 310, 3, 8, 1546, 1551, "month" +834, 14, 3, 311, 9, 10, 1552, 1553, "3" +834, 14, 4, 312, 11, 12, 1554, 1555, "," +834, 14, 5, 313, 13, 16, 1556, 1559, "the" +834, 14, 6, 314, 17, 27, 1560, 1570, "additional" +834, 14, 7, 315, 28, 32, 1571, 1575, "mean" +834, 14, 8, 316, 33, 40, 1576, 1583, "diurnal" +834, 14, 9, 317, 41, 44, 1584, 1587, "IOP" +834, 14, 10, 318, 45, 54, 1588, 1597, "reduction" +834, 14, 11, 319, 55, 59, 1598, 1602, "from" +834, 14, 12, 320, 60, 71, 1603, 1614, "latanoprost" +834, 14, 13, 321, 72, 73, 1615, 1616, "-" +834, 14, 14, 322, 74, 81, 1617, 1624, "treated" +834, 14, 15, 323, 82, 90, 1625, 1633, "baseline" +834, 14, 16, 324, 91, 94, 1634, 1637, "was" +834, 14, 17, 325, 95, 96, 1638, 1639, "2" +834, 14, 18, 326, 97, 98, 1640, 1641, "." +834, 14, 19, 327, 99, 100, 1642, 1643, "1" +834, 14, 20, 328, 101, 102, 1644, 1645, "(" +834, 14, 21, 329, 103, 105, 1646, 1648, "95" +834, 14, 22, 330, 106, 107, 1649, 1650, "%" +834, 14, 23, 331, 108, 110, 1651, 1653, "CI" +834, 14, 24, 332, 111, 112, 1654, 1655, "1" +834, 14, 25, 333, 113, 114, 1656, 1657, "." +834, 14, 26, 334, 115, 116, 1658, 1659, "7" +834, 14, 27, 335, 117, 119, 1660, 1662, "to" +834, 14, 28, 336, 120, 121, 1663, 1664, "2" +834, 14, 29, 337, 122, 123, 1665, 1666, "." +834, 14, 30, 338, 124, 125, 1667, 1668, "5" +834, 14, 31, 339, 126, 127, 1669, 1670, ")" +834, 14, 32, 340, 128, 130, 1671, 1673, "mm" +834, 14, 33, 341, 131, 133, 1674, 1676, "Hg" +834, 14, 34, 342, 134, 135, 1677, 1678, "(" +834, 14, 35, 343, 136, 138, 1679, 1681, "11" +834, 14, 36, 344, 139, 140, 1682, 1683, "." +834, 14, 37, 345, 141, 142, 1684, 1685, "0" +834, 14, 38, 346, 143, 144, 1686, 1687, "%" +834, 14, 39, 347, 145, 146, 1688, 1689, ")" +834, 14, 40, 348, 147, 151, 1690, 1694, "with" +834, 14, 41, 349, 152, 163, 1695, 1706, "bimatoprost" +834, 14, 42, 350, 164, 167, 1707, 1710, "and" +834, 14, 43, 351, 168, 169, 1711, 1712, "1" +834, 14, 44, 352, 170, 171, 1713, 1714, "." +834, 14, 45, 353, 172, 173, 1715, 1716, "4" +834, 14, 46, 354, 174, 175, 1717, 1718, "(" +834, 14, 47, 355, 176, 178, 1719, 1721, "95" +834, 14, 48, 356, 179, 180, 1722, 1723, "%" +834, 14, 49, 357, 181, 183, 1724, 1726, "CI" +834, 14, 50, 358, 184, 185, 1727, 1728, "0" +834, 14, 51, 359, 186, 187, 1729, 1730, "." +834, 14, 52, 360, 188, 189, 1731, 1732, "9" +834, 14, 53, 361, 190, 192, 1733, 1735, "to" +834, 14, 54, 362, 193, 194, 1736, 1737, "1" +834, 14, 55, 363, 195, 196, 1738, 1739, "." +834, 14, 56, 364, 197, 198, 1740, 1741, "8" +834, 14, 57, 365, 199, 200, 1742, 1743, ")" +834, 14, 58, 366, 201, 203, 1744, 1746, "mm" +834, 14, 59, 367, 204, 206, 1747, 1749, "Hg" +834, 14, 60, 368, 207, 208, 1750, 1751, "(" +834, 14, 61, 369, 209, 210, 1752, 1753, "7" +834, 14, 62, 370, 211, 212, 1754, 1755, "." +834, 14, 63, 371, 213, 214, 1756, 1757, "4" +834, 14, 64, 372, 215, 216, 1758, 1759, "%" +834, 14, 65, 373, 217, 218, 1760, 1761, ")" +834, 14, 66, 374, 219, 223, 1762, 1766, "with" +834, 14, 67, 375, 224, 234, 1767, 1777, "travoprost" +834, 14, 68, 376, 235, 236, 1778, 1779, "(" +834, 14, 69, 377, 237, 238, 1780, 1781, "p" +834, 14, 70, 378, 239, 240, 1782, 1783, "=" +834, 14, 71, 379, 241, 242, 1784, 1785, "0" +834, 14, 72, 380, 243, 244, 1786, 1787, "." +834, 14, 73, 381, 245, 248, 1788, 1791, "024" +834, 14, 74, 382, 249, 250, 1792, 1793, ")" +834, 14, 75, 383, 251, 252, 1794, 1795, "." +834, 15, 1, 384, 0, 2, 1796, 1798, "At" +834, 15, 2, 385, 3, 4, 1799, 1800, "3" +834, 15, 3, 386, 5, 11, 1801, 1807, "months" +834, 15, 4, 387, 12, 13, 1808, 1809, "," +834, 15, 5, 388, 14, 16, 1810, 1812, "11" +834, 15, 6, 389, 17, 18, 1813, 1814, "." +834, 15, 7, 390, 19, 20, 1815, 1816, "5" +834, 15, 8, 391, 21, 22, 1817, 1818, "%" +834, 15, 9, 392, 23, 25, 1819, 1821, "of" +834, 15, 10, 393, 26, 37, 1822, 1833, "bimatoprost" +834, 15, 11, 394, 38, 41, 1834, 1837, "and" +834, 15, 12, 395, 42, 44, 1838, 1840, "16" +834, 15, 13, 396, 45, 46, 1841, 1842, "." +834, 15, 14, 397, 47, 48, 1843, 1844, "5" +834, 15, 15, 398, 49, 50, 1845, 1846, "%" +834, 15, 16, 399, 51, 53, 1847, 1849, "of" +834, 15, 17, 400, 54, 64, 1850, 1860, "travoprost" +834, 15, 18, 401, 65, 73, 1861, 1869, "patients" +834, 15, 19, 402, 74, 86, 1870, 1882, "demonstrated" +834, 15, 20, 403, 87, 88, 1883, 1884, "a" +834, 15, 21, 404, 89, 90, 1885, 1886, ">" +834, 15, 22, 405, 91, 93, 1887, 1889, "or" +834, 15, 23, 406, 94, 95, 1890, 1891, "=" +834, 15, 24, 407, 96, 97, 1892, 1893, "1" +834, 15, 25, 408, 98, 99, 1894, 1895, "-" +834, 15, 26, 409, 100, 105, 1896, 1901, "grade" +834, 15, 27, 410, 106, 114, 1902, 1910, "increase" +834, 15, 28, 411, 115, 117, 1911, 1913, "in" +834, 15, 29, 412, 118, 127, 1914, 1923, "physician" +834, 15, 30, 413, 128, 129, 1924, 1925, "-" +834, 15, 31, 414, 130, 136, 1926, 1932, "graded" +834, 15, 32, 415, 137, 149, 1933, 1945, "conjunctival" +834, 15, 33, 416, 150, 160, 1946, 1956, "hyperaemia" +834, 15, 34, 417, 161, 162, 1957, 1958, "(" +834, 15, 35, 418, 163, 164, 1959, 1960, "p" +834, 15, 36, 419, 165, 166, 1961, 1962, "=" +834, 15, 37, 420, 167, 168, 1963, 1964, "0" +834, 15, 38, 421, 169, 170, 1965, 1966, "." +834, 15, 39, 422, 171, 174, 1967, 1970, "288" +834, 15, 40, 423, 175, 176, 1971, 1972, ")" +834, 15, 41, 424, 177, 178, 1973, 1974, "." +834, 16, 1, 425, 0, 10, 1975, 1985, "Hyperaemia" +834, 16, 2, 426, 11, 14, 1986, 1989, "was" +834, 16, 3, 427, 15, 23, 1990, 1998, "reported" +834, 16, 4, 428, 24, 26, 1999, 2001, "as" +834, 16, 5, 429, 27, 28, 2002, 2003, "a" +834, 16, 6, 430, 29, 38, 2004, 2013, "treatment" +834, 16, 7, 431, 39, 40, 2014, 2015, "-" +834, 16, 8, 432, 41, 48, 2016, 2023, "related" +834, 16, 9, 433, 49, 56, 2024, 2031, "adverse" +834, 16, 10, 434, 57, 62, 2032, 2037, "event" +834, 16, 11, 435, 63, 65, 2038, 2040, "in" +834, 16, 12, 436, 66, 67, 2041, 2042, "3" +834, 16, 13, 437, 68, 69, 2043, 2044, "." +834, 16, 14, 438, 70, 71, 2045, 2046, "1" +834, 16, 15, 439, 72, 73, 2047, 2048, "%" +834, 16, 16, 440, 74, 76, 2049, 2051, "of" +834, 16, 17, 441, 77, 88, 2052, 2063, "bimatoprost" +834, 16, 18, 442, 89, 92, 2064, 2067, "and" +834, 16, 19, 443, 93, 94, 2068, 2069, "1" +834, 16, 20, 444, 95, 96, 2070, 2071, "." +834, 16, 21, 445, 97, 98, 2072, 2073, "5" +834, 16, 22, 446, 99, 100, 2074, 2075, "%" +834, 16, 23, 447, 101, 103, 2076, 2078, "of" +834, 16, 24, 448, 104, 114, 2079, 2089, "travoprost" +834, 16, 25, 449, 115, 123, 2090, 2098, "patients" +834, 16, 26, 450, 124, 125, 2099, 2100, "(" +834, 16, 27, 451, 126, 127, 2101, 2102, "p" +834, 16, 28, 452, 128, 129, 2103, 2104, "=" +834, 16, 29, 453, 130, 131, 2105, 2106, "0" +834, 16, 30, 454, 132, 133, 2107, 2108, "." +834, 16, 31, 455, 134, 137, 2109, 2112, "445" +834, 16, 32, 456, 138, 139, 2113, 2114, ")" +834, 16, 33, 457, 140, 141, 2115, 2116, "." +834, 17, 1, 458, 0, 10, 2117, 2127, "CONCLUSION" +834, 17, 2, 459, 11, 12, 2128, 2129, ":" +834, 17, 3, 460, 13, 21, 2130, 2138, "Patients" +834, 17, 4, 461, 22, 24, 2139, 2141, "on" +834, 17, 5, 462, 25, 36, 2142, 2153, "latanoprost" +834, 17, 6, 463, 37, 46, 2154, 2163, "requiring" +834, 17, 7, 464, 47, 52, 2164, 2169, "lower" +834, 17, 8, 465, 53, 56, 2170, 2173, "IOP" +834, 17, 9, 466, 57, 65, 2174, 2182, "achieved" +834, 17, 10, 467, 66, 67, 2183, 2184, "a" +834, 17, 11, 468, 68, 75, 2185, 2192, "greater" +834, 17, 12, 469, 76, 86, 2193, 2203, "additional" +834, 17, 13, 470, 87, 92, 2204, 2209, "short" +834, 17, 14, 471, 93, 94, 2210, 2211, "-" +834, 17, 15, 472, 95, 99, 2212, 2216, "term" +834, 17, 16, 473, 100, 107, 2217, 2224, "diurnal" +834, 17, 17, 474, 108, 111, 2225, 2228, "IOP" +834, 17, 18, 475, 112, 121, 2229, 2238, "reduction" +834, 17, 19, 476, 122, 126, 2239, 2243, "when" +834, 17, 20, 477, 127, 138, 2244, 2255, "latanoprost" +834, 17, 21, 478, 139, 142, 2256, 2259, "was" +834, 17, 22, 479, 143, 151, 2260, 2268, "replaced" +834, 17, 23, 480, 152, 154, 2269, 2271, "by" +834, 17, 24, 481, 155, 166, 2272, 2283, "bimatoprost" +834, 17, 25, 482, 167, 175, 2284, 2292, "compared" +834, 17, 26, 483, 176, 180, 2293, 2297, "with" +834, 17, 27, 484, 181, 191, 2298, 2308, "travoprost" +834, 17, 28, 485, 192, 193, 2309, 2310, "." +834, 18, 1, 486, 0, 3, 2311, 2314, "Low" +834, 18, 2, 487, 4, 9, 2315, 2320, "rates" +834, 18, 3, 488, 10, 12, 2321, 2323, "of" +834, 18, 4, 489, 13, 23, 2324, 2334, "hyperaemia" +834, 18, 5, 490, 24, 28, 2335, 2339, "were" +834, 18, 6, 491, 29, 37, 2340, 2348, "observed" +834, 18, 7, 492, 38, 40, 2349, 2351, "in" +834, 18, 8, 493, 41, 49, 2352, 2360, "patients" +834, 18, 9, 494, 50, 57, 2361, 2368, "treated" +834, 18, 10, 495, 58, 62, 2369, 2373, "with" +834, 18, 11, 496, 63, 74, 2374, 2385, "bimatoprost" +834, 18, 12, 497, 75, 77, 2386, 2388, "or" +834, 18, 13, 498, 78, 88, 2389, 2399, "travoprost" +834, 18, 14, 499, 89, 94, 2400, 2405, "after" +834, 18, 15, 500, 95, 104, 2406, 2415, "switching" +834, 18, 16, 501, 105, 109, 2416, 2420, "from" +834, 18, 17, 502, 110, 121, 2421, 2432, "latanoprost" +834, 18, 18, 503, 122, 123, 2433, 2434, "." +834, 19, 1, 504, 0, 3, 2435, 2438, "DOI" +834, 19, 2, 505, 4, 5, 2439, 2440, ":" +834, 19, 3, 506, 6, 8, 2441, 2443, "10" +834, 19, 4, 507, 9, 10, 2444, 2445, "." +834, 19, 5, 508, 11, 15, 2446, 2450, "1136" +834, 19, 6, 509, 16, 17, 2451, 2452, "/" +834, 19, 7, 510, 18, 21, 2453, 2456, "bjo" +834, 19, 8, 511, 22, 23, 2457, 2458, "." +834, 19, 9, 512, 24, 28, 2459, 2463, "2009" +834, 19, 10, 513, 29, 30, 2464, 2465, "." +834, 19, 11, 514, 31, 37, 2466, 2472, "158071" +834, 19, 12, 515, 38, 43, 2473, 2478, "PMCID" +834, 19, 13, 516, 44, 45, 2479, 2480, ":" +834, 19, 14, 517, 46, 56, 2481, 2491, "PMC2793510" +834, 19, 15, 518, 57, 61, 2492, 2496, "PMID" +834, 19, 16, 519, 62, 63, 2497, 2498, ":" +834, 19, 17, 520, 64, 72, 2499, 2507, "19726422" +834, 19, 18, 521, 73, 74, 2508, 2509, "[" +834, 19, 19, 522, 75, 82, 2510, 2517, "Indexed" +834, 19, 20, 523, 83, 86, 2518, 2521, "for" +834, 19, 21, 524, 87, 94, 2522, 2529, "MEDLINE" +834, 19, 22, 525, 95, 96, 2530, 2531, "]" diff --git a/data/gl 19726422_admin.annodb b/data/gl 19726422_admin.annodb new file mode 100644 index 0000000..f85fd1b --- /dev/null +++ b/data/gl 19726422_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Br J Ophthalmol", "", " \"Br J Ophthalmol\"." +1, PublicationYear, 18, 22, "2010", "", " \"2010\"." +2, Title, 107, 273, "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .", "", " \"Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .\"." +27569, Bimatoprost, 136, 147, "bimatoprost", "", +36973, Travoprost, 155, 165, "travoprost", "", +31007, Precondition, 169, 203, "patients previously on latanoprost", "", " \"patients previously on latanoprost\"." +31005, Latanoprost, 192, 203, "latanoprost", "", +7, Duration, 208, 217, "3 - month", "", " \"3 - month\"." +8, Randomized, 220, 230, "randomised", "", " ." +31004, Blind, 233, 239, "masked", "", " ." +10, Multicenter, 254, 265, "multicentre", "", " ." +11, Author, 274, 283, "Kammer JA", "", " \"Kammer JA\"." +12, Author, 292, 301, "Katzman B", "", " \"Katzman B\"." +13, Author, 304, 315, "Ackerman SL", "", " \"Ackerman SL\"." +14, Author, 318, 330, "Hollander DA", "", " \"Hollander DA\"." +15, USA, 435, 438, "USA", "", " ." +16, ObjectiveDescription, 483, 718, "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost .", "", " \"To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost .\"." +27576, Latanoprost, 532, 543, "latanoprost", "", +92859, ProstaglandinAnalogs, 557, 579, "prostaglandin analogue", "", +92860, ProstaglandinAnalogs, 582, 585, "PGA", "", +17, Glaucoma, 605, 613, "glaucoma", "", " . ." +18, OcularHypertension, 617, 636, "ocular hypertension", "", " ." +19, IOP, 658, 678, "intraocular pressure", "", +31022, IOP, 681, 684, "IOP", "", +27575, Latanoprost, 705, 716, "latanoprost", "", +36987, Prospective, 729, 740, "Prospective", "", " ." +22, Randomized, 743, 753, "randomised", "", +102, Blind, 771, 777, "masked", "", +31010, Multicenter, 780, 791, "multicentre", "", +106225, Precondition, 809, 888, "Patients on latanoprost 0 . 005 % monotherapy requiring additional IOP lowering", "", +27577, Latanoprost, 821, 832, "latanoprost", "", +31014, DoseValue, 833, 840, "0 . 005", "", +26, Percentage, 841, 842, "%", "", +114, IOP, 876, 879, "IOP", "", +31015, Latanoprost, 902, 913, "latanoprost", "", +36974, Randomized, 923, 933, "randomised", "", +101, Bimatoprost, 937, 948, "bimatoprost", "", " ." +30, DoseValue, 949, 955, "0 . 03", "", " \"0 . 03\"." +31, Percentage, 956, 957, "%", "", " ." +32, NumberPatientsArm, 964, 967, "131", "", " \"131\"." +36975, Travoprost, 973, 983, "travoprost", "", " ." +33, DoseValue, 984, 991, "0 . 004", "", " \"0 . 004\"." +34, Percentage, 992, 993, "%", "", " ." +35, NumberPatientsArm, 1000, 1003, "135", "", " \"135\"." +36, IOP, 1008, 1011, "IOP", "", +120, Latanoprost, 1028, 1039, "latanoprost", "", +36976, TimePoint, 1050, 1058, "baseline", "", +31018, TimePoint, 1069, 1076, "1 month", "", +188, TimePoint, 1081, 1089, "3 months", "", +124, ObservedResult, 1125, 1192, "Baseline mean diurnal IOP on latanoprost was similar between groups", "", " \"Baseline mean diurnal IOP on latanoprost was similar between groups\". \"Baseline mean diurnal IOP on latanoprost was similar between groups\"." +39, Mean, 1134, 1138, "mean", "", +40, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +41, Latanoprost, 1154, 1165, "latanoprost", "", +133, ObservedResult, 1195, 1335, "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .", "", +42, Mean, 1199, 1203, "mean", "", " . ." +43, Diurnal_IOP, 1204, 1215, "diurnal IOP", "", " ." +27570, Bimatoprost, 1245, 1256, "bimatoprost", "", +36977, Travoprost, 1267, 1277, "travoprost", "", +31019, TimePoint, 1281, 1288, "1 month", "", +126, PvalueDiff, 1291, 1302, "p = 0 . 009", "", +125, TimePoint, 1309, 1317, "3 months", "", +127, PvalueDiff, 1320, 1331, "p = 0 . 024", "", +31011, PercentageAffected, 1346, 1352, "22 . 0", "", " \"22 . 0\"." +27571, Bimatoprost, 1358, 1369, "bimatoprost", "", +47, PercentageAffected, 1386, 1392, "12 . 1", "", " \"12 . 1\"." +36978, Travoprost, 1398, 1408, "travoprost", "", +48, EndPointDescription, 1429, 1465, "> or = 15 % reduction in diurnal IOP", "", " . ." +49, Diurnal_IOP, 1454, 1465, "diurnal IOP", "", +50, Latanoprost, 1471, 1482, "latanoprost", "", +36979, TimePoint, 1510, 1518, "months 1", "", +36980, TimePoint, 1510, 1524, "months 1 and 3", "", " \"months 1 and 3\". \"months 1 and 3\"." +143, PvalueDiff, 1527, 1538, "p = 0 . 033", "", " \"p = 0 . 033\"." +139, TimePoint, 1546, 1553, "month 3", "", " \"month 3\". \"month 3\"." +52, Mean, 1571, 1575, "mean", "", +53, Diurnal_IOP, 1576, 1587, "diurnal IOP", "", +147, Latanoprost, 1603, 1614, "latanoprost", "", +54, Reduction, 1638, 1643, "2 . 1", "", " \"2 . 1\"." +55, ConfIntervalChangeValue, 1646, 1668, "95 % CI 1 . 7 to 2 . 5", "", " \"95 % CI 1 . 7 to 2 . 5\"." +56, mmHg, 1671, 1676, "mm Hg", "", +31012, RelativeReduction, 1679, 1685, "11 . 0", "", " \"11 . 0\"." +148, Bimatoprost, 1695, 1706, "bimatoprost", "", +58, Reduction, 1711, 1716, "1 . 4", "", " \"1 . 4\"." +150, ConfIntervalChangeValue, 1719, 1741, "95 % CI 0 . 9 to 1 . 8", "", " \"95 % CI 0 . 9 to 1 . 8\"." +60, mmHg, 1744, 1749, "mm Hg", "", " ." +61, RelativeReduction, 1752, 1757, "7 . 4", "", " \"7 . 4\"." +36988, Travoprost, 1767, 1777, "travoprost", "", +158, PvalueDiff, 1780, 1791, "p = 0 . 024", "", " \"p = 0 . 024\"." +154, TimePoint, 1799, 1807, "3 months", "", " \"3 months\". \"3 months\"." +65, PercentageAffected, 1810, 1816, "11 . 5", "", " \"11 . 5\"." +27572, Bimatoprost, 1822, 1833, "bimatoprost", "", +66, PercentageAffected, 1838, 1844, "16 . 5", "", " \"16 . 5\"." +36981, Travoprost, 1850, 1860, "travoprost", "", +63, EndPointDescription, 1885, 1956, "> or = 1 - grade increase in physician - graded conjunctival hyperaemia", "", " . ." +36982, ConjunctivalHyperemia, 1933, 1956, "conjunctival hyperaemia", "", +166, PvalueDiff, 1959, 1970, "p = 0 . 288", "", " \"p = 0 . 288\"." +67, ConjunctivalHyperemia, 1975, 1985, "Hyperaemia", "", " ." +69, PercentageAffected, 2041, 2046, "3 . 1", "", " \"3 . 1\"." +27573, Bimatoprost, 2052, 2063, "bimatoprost", "", +70, PercentageAffected, 2068, 2073, "1 . 5", "", " \"1 . 5\"." +36983, Travoprost, 2079, 2089, "travoprost", "", +172, PvalueDiff, 2101, 2112, "p = 0 . 445", "", " \"p = 0 . 445\"." +72, ConclusionComment, 2130, 2310, "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .", "", " \"Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .\"." +74, Latanoprost, 2142, 2153, "latanoprost", "", +75, IOP, 2170, 2173, "IOP", "", +76, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +77, Latanoprost, 2244, 2255, "latanoprost", "", +36986, Bimatoprost, 2272, 2283, "bimatoprost", "", +36984, Travoprost, 2298, 2308, "travoprost", "", +27568, ConclusionComment, 2311, 2434, "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost .", "", " \"Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost .\"." +181, ConjunctivalHyperemia, 2324, 2334, "hyperaemia", "", +31021, Bimatoprost, 2374, 2385, "bimatoprost", "", +36985, Travoprost, 2389, 2399, "travoprost", "", +183, Latanoprost, 2421, 2432, "latanoprost", "", +79, PMID, 2499, 2507, "19726422", "", " \"19726422\"." diff --git a/data/gl 19726422_admin.n-triples b/data/gl 19726422_admin.n-triples new file mode 100644 index 0000000..b0134e2 --- /dev/null +++ b/data/gl 19726422_admin.n-triples @@ -0,0 +1,179 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study ." . + "Kammer JA" . + "2010" . + "Br J Ophthalmol" . + "19726422" . + "Katzman B" . + "Ackerman SL" . + "Hollander DA" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost ." . + "3 - month" . + . + . + . + "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost ." . + . + . + . + . + . + . + . + "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients previously on latanoprost" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_15" . + . + . + . + . + . + . + "Endpoint_1" . + . + . + . + . + . + . + "Endpoint_CH" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bim" . + "131" . + . + . + . + . + . + . + . + "Arm_tra" . + "135" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_bim" . + . + . + . + "Intervention_tra" . + . + . +# RDF export of group: Medication + . + "Medication_bim" . + . + "0 . 03" . + . + . + . + "Medication_trav" . + . + "0 . 004" . + . + . +# RDF export of group: Outcome + . + "Outcome_15_bim" . + . + "22 . 0" . + "months 1 and 3" . + . + "Outcome_15_tra" . + . + "12 . 1" . + "months 1 and 3" . + . + "Outcome_iop_bim" . + . + "2 . 1" . + "11 . 0" . + "95 % CI 1 . 7 to 2 . 5" . + "Baseline mean diurnal IOP on latanoprost was similar between groups" . + "month 3" . + . + "Outcome_iop_trav" . + . + "1 . 4" . + "7 . 4" . + "95 % CI 0 . 9 to 1 . 8" . + "Baseline mean diurnal IOP on latanoprost was similar between groups" . + "month 3" . + . + "Outcome_1_bim" . + . + "11 . 5" . + "3 months" . + . + "Outcome_1_tra" . + . + "16 . 5" . + "3 months" . + . + "Outcome_CH_bim" . + . + "3 . 1" . + . + "Outcome_CH_tra" . + . + "1 . 5" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_15" . + "p = 0 . 033" . + . + . + . + "DiffBetweenGroups_iop" . + "p = 0 . 024" . + . + . + . + "DiffBetweenGroups_1" . + "p = 0 . 288" . + . + . + . + "DiffBetweenGroups_CH" . + "p = 0 . 445" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19726422_export.csv b/data/gl 19726422_export.csv new file mode 100644 index 0000000..2ef9adb --- /dev/null +++ b/data/gl 19726422_export.csv @@ -0,0 +1,526 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +442, 1, 1, 1, 0, 2, 0, 2, "Br" +442, 1, 2, 2, 3, 4, 3, 4, "J" +442, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +442, 1, 4, 4, 16, 17, 16, 17, "." +442, 2, 1, 5, 0, 4, 18, 22, "2010" +442, 2, 2, 6, 5, 8, 23, 26, "Jan" +442, 2, 3, 7, 9, 10, 27, 28, ";" +442, 2, 4, 8, 11, 13, 29, 31, "94" +442, 2, 5, 9, 14, 15, 32, 33, "(" +442, 2, 6, 10, 16, 17, 34, 35, "1" +442, 2, 7, 11, 18, 19, 36, 37, ")" +442, 2, 8, 12, 20, 21, 38, 39, ":" +442, 2, 9, 13, 22, 24, 40, 42, "74" +442, 2, 10, 14, 25, 26, 43, 44, "-" +442, 2, 11, 15, 27, 28, 45, 46, "9" +442, 2, 12, 16, 29, 30, 47, 48, "." +442, 2, 13, 17, 31, 34, 49, 52, "doi" +442, 2, 14, 18, 35, 36, 53, 54, ":" +442, 2, 15, 19, 37, 39, 55, 57, "10" +442, 2, 16, 20, 40, 41, 58, 59, "." +442, 2, 17, 21, 42, 46, 60, 64, "1136" +442, 2, 18, 22, 47, 48, 65, 66, "/" +442, 2, 19, 23, 49, 52, 67, 70, "bjo" +442, 2, 20, 24, 53, 54, 71, 72, "." +442, 2, 21, 25, 55, 59, 73, 77, "2009" +442, 2, 22, 26, 60, 61, 78, 79, "." +442, 2, 23, 27, 62, 68, 80, 86, "158071" +442, 2, 24, 28, 69, 70, 87, 88, "." +442, 3, 1, 29, 0, 4, 89, 93, "Epub" +442, 3, 2, 30, 5, 9, 94, 98, "2009" +442, 3, 3, 31, 10, 13, 99, 102, "Sep" +442, 3, 4, 32, 14, 15, 103, 104, "1" +442, 3, 5, 33, 16, 17, 105, 106, "." +442, 4, 1, 34, 0, 8, 107, 115, "Efficacy" +442, 4, 2, 35, 9, 12, 116, 119, "and" +442, 4, 3, 36, 13, 25, 120, 132, "tolerability" +442, 4, 4, 37, 26, 28, 133, 135, "of" +442, 4, 5, 38, 29, 40, 136, 147, "bimatoprost" +442, 4, 6, 39, 41, 47, 148, 154, "versus" +442, 4, 7, 40, 48, 58, 155, 165, "travoprost" +442, 4, 8, 41, 59, 61, 166, 168, "in" +442, 4, 9, 42, 62, 70, 169, 177, "patients" +442, 4, 10, 43, 71, 81, 178, 188, "previously" +442, 4, 11, 44, 82, 84, 189, 191, "on" +442, 4, 12, 45, 85, 96, 192, 203, "latanoprost" +442, 4, 13, 46, 97, 98, 204, 205, ":" +442, 4, 14, 47, 99, 100, 206, 207, "a" +442, 4, 15, 48, 101, 102, 208, 209, "3" +442, 4, 16, 49, 103, 104, 210, 211, "-" +442, 4, 17, 50, 105, 110, 212, 217, "month" +442, 4, 18, 51, 111, 112, 218, 219, "," +442, 4, 19, 52, 113, 123, 220, 230, "randomised" +442, 4, 20, 53, 124, 125, 231, 232, "," +442, 4, 21, 54, 126, 132, 233, 239, "masked" +442, 4, 22, 55, 133, 134, 240, 241, "-" +442, 4, 23, 56, 135, 144, 242, 251, "evaluator" +442, 4, 24, 57, 145, 146, 252, 253, "," +442, 4, 25, 58, 147, 158, 254, 265, "multicentre" +442, 4, 26, 59, 159, 164, 266, 271, "study" +442, 4, 27, 60, 165, 166, 272, 273, "." +442, 5, 1, 61, 0, 6, 274, 280, "Kammer" +442, 5, 2, 62, 7, 9, 281, 283, "JA" +442, 5, 3, 63, 10, 11, 284, 285, "(" +442, 5, 4, 64, 12, 13, 286, 287, "1" +442, 5, 5, 65, 14, 15, 288, 289, ")" +442, 5, 6, 66, 16, 17, 290, 291, "," +442, 5, 7, 67, 18, 25, 292, 299, "Katzman" +442, 5, 8, 68, 26, 27, 300, 301, "B" +442, 5, 9, 69, 28, 29, 302, 303, "," +442, 5, 10, 70, 30, 38, 304, 312, "Ackerman" +442, 5, 11, 71, 39, 41, 313, 315, "SL" +442, 5, 12, 72, 42, 43, 316, 317, "," +442, 5, 13, 73, 44, 53, 318, 327, "Hollander" +442, 5, 14, 74, 54, 56, 328, 330, "DA" +442, 5, 15, 75, 57, 58, 331, 332, "." +442, 6, 1, 76, 0, 6, 333, 339, "Author" +442, 6, 2, 77, 7, 18, 340, 351, "information" +442, 6, 3, 78, 19, 20, 352, 353, ":" +442, 6, 4, 79, 21, 22, 354, 355, "(" +442, 6, 5, 80, 23, 24, 356, 357, "1" +442, 6, 6, 81, 25, 26, 358, 359, ")" +442, 6, 7, 82, 27, 37, 360, 370, "Vanderbilt" +442, 6, 8, 83, 38, 41, 371, 374, "Eye" +442, 6, 9, 84, 42, 51, 375, 384, "Institute" +442, 6, 10, 85, 52, 53, 385, 386, "," +442, 6, 11, 86, 54, 58, 387, 391, "2311" +442, 6, 12, 87, 59, 65, 392, 398, "Pierce" +442, 6, 13, 88, 66, 69, 399, 402, "Ave" +442, 6, 14, 89, 70, 71, 403, 404, "," +442, 6, 15, 90, 72, 81, 405, 414, "Nashville" +442, 6, 16, 91, 82, 83, 415, 416, "," +442, 6, 17, 92, 84, 86, 417, 419, "TN" +442, 6, 18, 93, 87, 92, 420, 425, "37232" +442, 6, 19, 94, 93, 94, 426, 427, "-" +442, 6, 20, 95, 95, 99, 428, 432, "8808" +442, 6, 21, 96, 100, 101, 433, 434, "," +442, 6, 22, 97, 102, 105, 435, 438, "USA" +442, 6, 23, 98, 106, 107, 439, 440, "." +442, 7, 1, 99, 0, 7, 441, 448, "jeffrey" +442, 7, 2, 100, 8, 9, 449, 450, "." +442, 7, 3, 101, 10, 16, 451, 457, "kammer" +442, 7, 4, 102, 17, 18, 458, 459, "@" +442, 7, 5, 103, 19, 29, 460, 470, "vanderbilt" +442, 7, 6, 104, 30, 31, 471, 472, "." +442, 7, 7, 105, 32, 35, 473, 476, "edu" +442, 7, 8, 106, 36, 39, 477, 480, "AIM" +442, 7, 9, 107, 40, 41, 481, 482, ":" +442, 7, 10, 108, 42, 44, 483, 485, "To" +442, 7, 11, 109, 45, 53, 486, 494, "evaluate" +442, 7, 12, 110, 54, 57, 495, 498, "the" +442, 7, 13, 111, 58, 66, 499, 507, "efficacy" +442, 7, 14, 112, 67, 70, 508, 511, "and" +442, 7, 15, 113, 71, 77, 512, 518, "safety" +442, 7, 16, 114, 78, 80, 519, 521, "of" +442, 7, 17, 115, 81, 90, 522, 531, "replacing" +442, 7, 18, 116, 91, 102, 532, 543, "latanoprost" +442, 7, 19, 117, 103, 107, 544, 548, "with" +442, 7, 20, 118, 108, 115, 549, 556, "another" +442, 7, 21, 119, 116, 129, 557, 570, "prostaglandin" +442, 7, 22, 120, 130, 138, 571, 579, "analogue" +442, 7, 23, 121, 139, 140, 580, 581, "(" +442, 7, 24, 122, 141, 144, 582, 585, "PGA" +442, 7, 25, 123, 145, 146, 586, 587, ")" +442, 7, 26, 124, 147, 149, 588, 590, "in" +442, 7, 27, 125, 150, 158, 591, 599, "patients" +442, 7, 28, 126, 159, 163, 600, 604, "with" +442, 7, 29, 127, 164, 172, 605, 613, "glaucoma" +442, 7, 30, 128, 173, 175, 614, 616, "or" +442, 7, 31, 129, 176, 182, 617, 623, "ocular" +442, 7, 32, 130, 183, 195, 624, 636, "hypertension" +442, 7, 33, 131, 196, 205, 637, 646, "requiring" +442, 7, 34, 132, 206, 216, 647, 657, "additional" +442, 7, 35, 133, 217, 228, 658, 669, "intraocular" +442, 7, 36, 134, 229, 237, 670, 678, "pressure" +442, 7, 37, 135, 238, 239, 679, 680, "(" +442, 7, 38, 136, 240, 243, 681, 684, "IOP" +442, 7, 39, 137, 244, 245, 685, 686, ")" +442, 7, 40, 138, 246, 254, 687, 695, "lowering" +442, 7, 41, 139, 255, 260, 696, 701, "while" +442, 7, 42, 140, 261, 263, 702, 704, "on" +442, 7, 43, 141, 264, 275, 705, 716, "latanoprost" +442, 7, 44, 142, 276, 277, 717, 718, "." +442, 8, 1, 143, 0, 7, 719, 726, "METHODS" +442, 8, 2, 144, 8, 9, 727, 728, ":" +442, 8, 3, 145, 10, 21, 729, 740, "Prospective" +442, 8, 4, 146, 22, 23, 741, 742, "," +442, 8, 5, 147, 24, 34, 743, 753, "randomised" +442, 8, 6, 148, 35, 36, 754, 755, "," +442, 8, 7, 149, 37, 49, 756, 768, "investigator" +442, 8, 8, 150, 50, 51, 769, 770, "-" +442, 8, 9, 151, 52, 58, 771, 777, "masked" +442, 8, 10, 152, 59, 60, 778, 779, "," +442, 8, 11, 153, 61, 72, 780, 791, "multicentre" +442, 8, 12, 154, 73, 81, 792, 800, "clinical" +442, 8, 13, 155, 82, 87, 801, 806, "trial" +442, 8, 14, 156, 88, 89, 807, 808, "." +442, 9, 1, 157, 0, 8, 809, 817, "Patients" +442, 9, 2, 158, 9, 11, 818, 820, "on" +442, 9, 3, 159, 12, 23, 821, 832, "latanoprost" +442, 9, 4, 160, 24, 25, 833, 834, "0" +442, 9, 5, 161, 26, 27, 835, 836, "." +442, 9, 6, 162, 28, 31, 837, 840, "005" +442, 9, 7, 163, 32, 33, 841, 842, "%" +442, 9, 8, 164, 34, 45, 843, 854, "monotherapy" +442, 9, 9, 165, 46, 55, 855, 864, "requiring" +442, 9, 10, 166, 56, 66, 865, 875, "additional" +442, 9, 11, 167, 67, 70, 876, 879, "IOP" +442, 9, 12, 168, 71, 79, 880, 888, "lowering" +442, 9, 13, 169, 80, 92, 889, 901, "discontinued" +442, 9, 14, 170, 93, 104, 902, 913, "latanoprost" +442, 9, 15, 171, 105, 108, 914, 917, "and" +442, 9, 16, 172, 109, 113, 918, 922, "were" +442, 9, 17, 173, 114, 124, 923, 933, "randomised" +442, 9, 18, 174, 125, 127, 934, 936, "to" +442, 9, 19, 175, 128, 139, 937, 948, "bimatoprost" +442, 9, 20, 176, 140, 141, 949, 950, "0" +442, 9, 21, 177, 142, 143, 951, 952, "." +442, 9, 22, 178, 144, 146, 953, 955, "03" +442, 9, 23, 179, 147, 148, 956, 957, "%" +442, 9, 24, 180, 149, 150, 958, 959, "(" +442, 9, 25, 181, 151, 152, 960, 961, "n" +442, 9, 26, 182, 153, 154, 962, 963, "=" +442, 9, 27, 183, 155, 158, 964, 967, "131" +442, 9, 28, 184, 159, 160, 968, 969, ")" +442, 9, 29, 185, 161, 163, 970, 972, "or" +442, 9, 30, 186, 164, 174, 973, 983, "travoprost" +442, 9, 31, 187, 175, 176, 984, 985, "0" +442, 9, 32, 188, 177, 178, 986, 987, "." +442, 9, 33, 189, 179, 182, 988, 991, "004" +442, 9, 34, 190, 183, 184, 992, 993, "%" +442, 9, 35, 191, 185, 186, 994, 995, "(" +442, 9, 36, 192, 187, 188, 996, 997, "n" +442, 9, 37, 193, 189, 190, 998, 999, "=" +442, 9, 38, 194, 191, 194, 1000, 1003, "135" +442, 9, 39, 195, 195, 196, 1004, 1005, ")" +442, 9, 40, 196, 197, 198, 1006, 1007, "." +442, 10, 1, 197, 0, 3, 1008, 1011, "IOP" +442, 10, 2, 198, 4, 7, 1012, 1015, "was" +442, 10, 3, 199, 8, 16, 1016, 1024, "measured" +442, 10, 4, 200, 17, 19, 1025, 1027, "at" +442, 10, 5, 201, 20, 31, 1028, 1039, "latanoprost" +442, 10, 6, 202, 32, 33, 1040, 1041, "-" +442, 10, 7, 203, 34, 41, 1042, 1049, "treated" +442, 10, 8, 204, 42, 50, 1050, 1058, "baseline" +442, 10, 9, 205, 51, 54, 1059, 1062, "and" +442, 10, 10, 206, 55, 60, 1063, 1068, "after" +442, 10, 11, 207, 61, 62, 1069, 1070, "1" +442, 10, 12, 208, 63, 68, 1071, 1076, "month" +442, 10, 13, 209, 69, 72, 1077, 1080, "and" +442, 10, 14, 210, 73, 74, 1081, 1082, "3" +442, 10, 15, 211, 75, 81, 1083, 1089, "months" +442, 10, 16, 212, 82, 84, 1090, 1092, "of" +442, 10, 17, 213, 85, 96, 1093, 1104, "replacement" +442, 10, 18, 214, 97, 104, 1105, 1112, "therapy" +442, 10, 19, 215, 105, 106, 1113, 1114, "." +442, 11, 1, 216, 0, 7, 1115, 1122, "RESULTS" +442, 11, 2, 217, 8, 9, 1123, 1124, ":" +442, 11, 3, 218, 10, 18, 1125, 1133, "Baseline" +442, 11, 4, 219, 19, 23, 1134, 1138, "mean" +442, 11, 5, 220, 24, 31, 1139, 1146, "diurnal" +442, 11, 6, 221, 32, 35, 1147, 1150, "IOP" +442, 11, 7, 222, 36, 38, 1151, 1153, "on" +442, 11, 8, 223, 39, 50, 1154, 1165, "latanoprost" +442, 11, 9, 224, 51, 54, 1166, 1169, "was" +442, 11, 10, 225, 55, 62, 1170, 1177, "similar" +442, 11, 11, 226, 63, 70, 1178, 1185, "between" +442, 11, 12, 227, 71, 77, 1186, 1192, "groups" +442, 11, 13, 228, 78, 79, 1193, 1194, "." +442, 12, 1, 229, 0, 3, 1195, 1198, "The" +442, 12, 2, 230, 4, 8, 1199, 1203, "mean" +442, 12, 3, 231, 9, 16, 1204, 1211, "diurnal" +442, 12, 4, 232, 17, 20, 1212, 1215, "IOP" +442, 12, 5, 233, 21, 24, 1216, 1219, "was" +442, 12, 6, 234, 25, 38, 1220, 1233, "significantly" +442, 12, 7, 235, 39, 44, 1234, 1239, "lower" +442, 12, 8, 236, 45, 49, 1240, 1244, "with" +442, 12, 9, 237, 50, 61, 1245, 1256, "bimatoprost" +442, 12, 10, 238, 62, 66, 1257, 1261, "than" +442, 12, 11, 239, 67, 71, 1262, 1266, "with" +442, 12, 12, 240, 72, 82, 1267, 1277, "travoprost" +442, 12, 13, 241, 83, 85, 1278, 1280, "at" +442, 12, 14, 242, 86, 87, 1281, 1282, "1" +442, 12, 15, 243, 88, 93, 1283, 1288, "month" +442, 12, 16, 244, 94, 95, 1289, 1290, "(" +442, 12, 17, 245, 96, 97, 1291, 1292, "p" +442, 12, 18, 246, 98, 99, 1293, 1294, "=" +442, 12, 19, 247, 100, 101, 1295, 1296, "0" +442, 12, 20, 248, 102, 103, 1297, 1298, "." +442, 12, 21, 249, 104, 107, 1299, 1302, "009" +442, 12, 22, 250, 108, 109, 1303, 1304, ")" +442, 12, 23, 251, 110, 113, 1305, 1308, "and" +442, 12, 24, 252, 114, 115, 1309, 1310, "3" +442, 12, 25, 253, 116, 122, 1311, 1317, "months" +442, 12, 26, 254, 123, 124, 1318, 1319, "(" +442, 12, 27, 255, 125, 126, 1320, 1321, "p" +442, 12, 28, 256, 127, 128, 1322, 1323, "=" +442, 12, 29, 257, 129, 130, 1324, 1325, "0" +442, 12, 30, 258, 131, 132, 1326, 1327, "." +442, 12, 31, 259, 133, 136, 1328, 1331, "024" +442, 12, 32, 260, 137, 138, 1332, 1333, ")" +442, 12, 33, 261, 139, 140, 1334, 1335, "." +442, 13, 1, 262, 0, 7, 1336, 1343, "Overall" +442, 13, 2, 263, 8, 9, 1344, 1345, "," +442, 13, 3, 264, 10, 12, 1346, 1348, "22" +442, 13, 4, 265, 13, 14, 1349, 1350, "." +442, 13, 5, 266, 15, 16, 1351, 1352, "0" +442, 13, 6, 267, 17, 18, 1353, 1354, "%" +442, 13, 7, 268, 19, 21, 1355, 1357, "of" +442, 13, 8, 269, 22, 33, 1358, 1369, "bimatoprost" +442, 13, 9, 270, 34, 42, 1370, 1378, "patients" +442, 13, 10, 271, 43, 49, 1379, 1385, "versus" +442, 13, 11, 272, 50, 52, 1386, 1388, "12" +442, 13, 12, 273, 53, 54, 1389, 1390, "." +442, 13, 13, 274, 55, 56, 1391, 1392, "1" +442, 13, 14, 275, 57, 58, 1393, 1394, "%" +442, 13, 15, 276, 59, 61, 1395, 1397, "of" +442, 13, 16, 277, 62, 72, 1398, 1408, "travoprost" +442, 13, 17, 278, 73, 81, 1409, 1417, "patients" +442, 13, 18, 279, 82, 90, 1418, 1426, "achieved" +442, 13, 19, 280, 91, 92, 1427, 1428, "a" +442, 13, 20, 281, 93, 94, 1429, 1430, ">" +442, 13, 21, 282, 95, 97, 1431, 1433, "or" +442, 13, 22, 283, 98, 99, 1434, 1435, "=" +442, 13, 23, 284, 100, 102, 1436, 1438, "15" +442, 13, 24, 285, 103, 104, 1439, 1440, "%" +442, 13, 25, 286, 105, 114, 1441, 1450, "reduction" +442, 13, 26, 287, 115, 117, 1451, 1453, "in" +442, 13, 27, 288, 118, 125, 1454, 1461, "diurnal" +442, 13, 28, 289, 126, 129, 1462, 1465, "IOP" +442, 13, 29, 290, 130, 134, 1466, 1470, "from" +442, 13, 30, 291, 135, 146, 1471, 1482, "latanoprost" +442, 13, 31, 292, 147, 148, 1483, 1484, "-" +442, 13, 32, 293, 149, 156, 1485, 1492, "treated" +442, 13, 33, 294, 157, 165, 1493, 1501, "baseline" +442, 13, 34, 295, 166, 168, 1502, 1504, "at" +442, 13, 35, 296, 169, 173, 1505, 1509, "both" +442, 13, 36, 297, 174, 180, 1510, 1516, "months" +442, 13, 37, 298, 181, 182, 1517, 1518, "1" +442, 13, 38, 299, 183, 186, 1519, 1522, "and" +442, 13, 39, 300, 187, 188, 1523, 1524, "3" +442, 13, 40, 301, 189, 190, 1525, 1526, "(" +442, 13, 41, 302, 191, 192, 1527, 1528, "p" +442, 13, 42, 303, 193, 194, 1529, 1530, "=" +442, 13, 43, 304, 195, 196, 1531, 1532, "0" +442, 13, 44, 305, 197, 198, 1533, 1534, "." +442, 13, 45, 306, 199, 202, 1535, 1538, "033" +442, 13, 46, 307, 203, 204, 1539, 1540, ")" +442, 13, 47, 308, 205, 206, 1541, 1542, "." +442, 14, 1, 309, 0, 2, 1543, 1545, "At" +442, 14, 2, 310, 3, 8, 1546, 1551, "month" +442, 14, 3, 311, 9, 10, 1552, 1553, "3" +442, 14, 4, 312, 11, 12, 1554, 1555, "," +442, 14, 5, 313, 13, 16, 1556, 1559, "the" +442, 14, 6, 314, 17, 27, 1560, 1570, "additional" +442, 14, 7, 315, 28, 32, 1571, 1575, "mean" +442, 14, 8, 316, 33, 40, 1576, 1583, "diurnal" +442, 14, 9, 317, 41, 44, 1584, 1587, "IOP" +442, 14, 10, 318, 45, 54, 1588, 1597, "reduction" +442, 14, 11, 319, 55, 59, 1598, 1602, "from" +442, 14, 12, 320, 60, 71, 1603, 1614, "latanoprost" +442, 14, 13, 321, 72, 73, 1615, 1616, "-" +442, 14, 14, 322, 74, 81, 1617, 1624, "treated" +442, 14, 15, 323, 82, 90, 1625, 1633, "baseline" +442, 14, 16, 324, 91, 94, 1634, 1637, "was" +442, 14, 17, 325, 95, 96, 1638, 1639, "2" +442, 14, 18, 326, 97, 98, 1640, 1641, "." +442, 14, 19, 327, 99, 100, 1642, 1643, "1" +442, 14, 20, 328, 101, 102, 1644, 1645, "(" +442, 14, 21, 329, 103, 105, 1646, 1648, "95" +442, 14, 22, 330, 106, 107, 1649, 1650, "%" +442, 14, 23, 331, 108, 110, 1651, 1653, "CI" +442, 14, 24, 332, 111, 112, 1654, 1655, "1" +442, 14, 25, 333, 113, 114, 1656, 1657, "." +442, 14, 26, 334, 115, 116, 1658, 1659, "7" +442, 14, 27, 335, 117, 119, 1660, 1662, "to" +442, 14, 28, 336, 120, 121, 1663, 1664, "2" +442, 14, 29, 337, 122, 123, 1665, 1666, "." +442, 14, 30, 338, 124, 125, 1667, 1668, "5" +442, 14, 31, 339, 126, 127, 1669, 1670, ")" +442, 14, 32, 340, 128, 130, 1671, 1673, "mm" +442, 14, 33, 341, 131, 133, 1674, 1676, "Hg" +442, 14, 34, 342, 134, 135, 1677, 1678, "(" +442, 14, 35, 343, 136, 138, 1679, 1681, "11" +442, 14, 36, 344, 139, 140, 1682, 1683, "." +442, 14, 37, 345, 141, 142, 1684, 1685, "0" +442, 14, 38, 346, 143, 144, 1686, 1687, "%" +442, 14, 39, 347, 145, 146, 1688, 1689, ")" +442, 14, 40, 348, 147, 151, 1690, 1694, "with" +442, 14, 41, 349, 152, 163, 1695, 1706, "bimatoprost" +442, 14, 42, 350, 164, 167, 1707, 1710, "and" +442, 14, 43, 351, 168, 169, 1711, 1712, "1" +442, 14, 44, 352, 170, 171, 1713, 1714, "." +442, 14, 45, 353, 172, 173, 1715, 1716, "4" +442, 14, 46, 354, 174, 175, 1717, 1718, "(" +442, 14, 47, 355, 176, 178, 1719, 1721, "95" +442, 14, 48, 356, 179, 180, 1722, 1723, "%" +442, 14, 49, 357, 181, 183, 1724, 1726, "CI" +442, 14, 50, 358, 184, 185, 1727, 1728, "0" +442, 14, 51, 359, 186, 187, 1729, 1730, "." +442, 14, 52, 360, 188, 189, 1731, 1732, "9" +442, 14, 53, 361, 190, 192, 1733, 1735, "to" +442, 14, 54, 362, 193, 194, 1736, 1737, "1" +442, 14, 55, 363, 195, 196, 1738, 1739, "." +442, 14, 56, 364, 197, 198, 1740, 1741, "8" +442, 14, 57, 365, 199, 200, 1742, 1743, ")" +442, 14, 58, 366, 201, 203, 1744, 1746, "mm" +442, 14, 59, 367, 204, 206, 1747, 1749, "Hg" +442, 14, 60, 368, 207, 208, 1750, 1751, "(" +442, 14, 61, 369, 209, 210, 1752, 1753, "7" +442, 14, 62, 370, 211, 212, 1754, 1755, "." +442, 14, 63, 371, 213, 214, 1756, 1757, "4" +442, 14, 64, 372, 215, 216, 1758, 1759, "%" +442, 14, 65, 373, 217, 218, 1760, 1761, ")" +442, 14, 66, 374, 219, 223, 1762, 1766, "with" +442, 14, 67, 375, 224, 234, 1767, 1777, "travoprost" +442, 14, 68, 376, 235, 236, 1778, 1779, "(" +442, 14, 69, 377, 237, 238, 1780, 1781, "p" +442, 14, 70, 378, 239, 240, 1782, 1783, "=" +442, 14, 71, 379, 241, 242, 1784, 1785, "0" +442, 14, 72, 380, 243, 244, 1786, 1787, "." +442, 14, 73, 381, 245, 248, 1788, 1791, "024" +442, 14, 74, 382, 249, 250, 1792, 1793, ")" +442, 14, 75, 383, 251, 252, 1794, 1795, "." +442, 15, 1, 384, 0, 2, 1796, 1798, "At" +442, 15, 2, 385, 3, 4, 1799, 1800, "3" +442, 15, 3, 386, 5, 11, 1801, 1807, "months" +442, 15, 4, 387, 12, 13, 1808, 1809, "," +442, 15, 5, 388, 14, 16, 1810, 1812, "11" +442, 15, 6, 389, 17, 18, 1813, 1814, "." +442, 15, 7, 390, 19, 20, 1815, 1816, "5" +442, 15, 8, 391, 21, 22, 1817, 1818, "%" +442, 15, 9, 392, 23, 25, 1819, 1821, "of" +442, 15, 10, 393, 26, 37, 1822, 1833, "bimatoprost" +442, 15, 11, 394, 38, 41, 1834, 1837, "and" +442, 15, 12, 395, 42, 44, 1838, 1840, "16" +442, 15, 13, 396, 45, 46, 1841, 1842, "." +442, 15, 14, 397, 47, 48, 1843, 1844, "5" +442, 15, 15, 398, 49, 50, 1845, 1846, "%" +442, 15, 16, 399, 51, 53, 1847, 1849, "of" +442, 15, 17, 400, 54, 64, 1850, 1860, "travoprost" +442, 15, 18, 401, 65, 73, 1861, 1869, "patients" +442, 15, 19, 402, 74, 86, 1870, 1882, "demonstrated" +442, 15, 20, 403, 87, 88, 1883, 1884, "a" +442, 15, 21, 404, 89, 90, 1885, 1886, ">" +442, 15, 22, 405, 91, 93, 1887, 1889, "or" +442, 15, 23, 406, 94, 95, 1890, 1891, "=" +442, 15, 24, 407, 96, 97, 1892, 1893, "1" +442, 15, 25, 408, 98, 99, 1894, 1895, "-" +442, 15, 26, 409, 100, 105, 1896, 1901, "grade" +442, 15, 27, 410, 106, 114, 1902, 1910, "increase" +442, 15, 28, 411, 115, 117, 1911, 1913, "in" +442, 15, 29, 412, 118, 127, 1914, 1923, "physician" +442, 15, 30, 413, 128, 129, 1924, 1925, "-" +442, 15, 31, 414, 130, 136, 1926, 1932, "graded" +442, 15, 32, 415, 137, 149, 1933, 1945, "conjunctival" +442, 15, 33, 416, 150, 160, 1946, 1956, "hyperaemia" +442, 15, 34, 417, 161, 162, 1957, 1958, "(" +442, 15, 35, 418, 163, 164, 1959, 1960, "p" +442, 15, 36, 419, 165, 166, 1961, 1962, "=" +442, 15, 37, 420, 167, 168, 1963, 1964, "0" +442, 15, 38, 421, 169, 170, 1965, 1966, "." +442, 15, 39, 422, 171, 174, 1967, 1970, "288" +442, 15, 40, 423, 175, 176, 1971, 1972, ")" +442, 15, 41, 424, 177, 178, 1973, 1974, "." +442, 16, 1, 425, 0, 10, 1975, 1985, "Hyperaemia" +442, 16, 2, 426, 11, 14, 1986, 1989, "was" +442, 16, 3, 427, 15, 23, 1990, 1998, "reported" +442, 16, 4, 428, 24, 26, 1999, 2001, "as" +442, 16, 5, 429, 27, 28, 2002, 2003, "a" +442, 16, 6, 430, 29, 38, 2004, 2013, "treatment" +442, 16, 7, 431, 39, 40, 2014, 2015, "-" +442, 16, 8, 432, 41, 48, 2016, 2023, "related" +442, 16, 9, 433, 49, 56, 2024, 2031, "adverse" +442, 16, 10, 434, 57, 62, 2032, 2037, "event" +442, 16, 11, 435, 63, 65, 2038, 2040, "in" +442, 16, 12, 436, 66, 67, 2041, 2042, "3" +442, 16, 13, 437, 68, 69, 2043, 2044, "." +442, 16, 14, 438, 70, 71, 2045, 2046, "1" +442, 16, 15, 439, 72, 73, 2047, 2048, "%" +442, 16, 16, 440, 74, 76, 2049, 2051, "of" +442, 16, 17, 441, 77, 88, 2052, 2063, "bimatoprost" +442, 16, 18, 442, 89, 92, 2064, 2067, "and" +442, 16, 19, 443, 93, 94, 2068, 2069, "1" +442, 16, 20, 444, 95, 96, 2070, 2071, "." +442, 16, 21, 445, 97, 98, 2072, 2073, "5" +442, 16, 22, 446, 99, 100, 2074, 2075, "%" +442, 16, 23, 447, 101, 103, 2076, 2078, "of" +442, 16, 24, 448, 104, 114, 2079, 2089, "travoprost" +442, 16, 25, 449, 115, 123, 2090, 2098, "patients" +442, 16, 26, 450, 124, 125, 2099, 2100, "(" +442, 16, 27, 451, 126, 127, 2101, 2102, "p" +442, 16, 28, 452, 128, 129, 2103, 2104, "=" +442, 16, 29, 453, 130, 131, 2105, 2106, "0" +442, 16, 30, 454, 132, 133, 2107, 2108, "." +442, 16, 31, 455, 134, 137, 2109, 2112, "445" +442, 16, 32, 456, 138, 139, 2113, 2114, ")" +442, 16, 33, 457, 140, 141, 2115, 2116, "." +442, 17, 1, 458, 0, 10, 2117, 2127, "CONCLUSION" +442, 17, 2, 459, 11, 12, 2128, 2129, ":" +442, 17, 3, 460, 13, 21, 2130, 2138, "Patients" +442, 17, 4, 461, 22, 24, 2139, 2141, "on" +442, 17, 5, 462, 25, 36, 2142, 2153, "latanoprost" +442, 17, 6, 463, 37, 46, 2154, 2163, "requiring" +442, 17, 7, 464, 47, 52, 2164, 2169, "lower" +442, 17, 8, 465, 53, 56, 2170, 2173, "IOP" +442, 17, 9, 466, 57, 65, 2174, 2182, "achieved" +442, 17, 10, 467, 66, 67, 2183, 2184, "a" +442, 17, 11, 468, 68, 75, 2185, 2192, "greater" +442, 17, 12, 469, 76, 86, 2193, 2203, "additional" +442, 17, 13, 470, 87, 92, 2204, 2209, "short" +442, 17, 14, 471, 93, 94, 2210, 2211, "-" +442, 17, 15, 472, 95, 99, 2212, 2216, "term" +442, 17, 16, 473, 100, 107, 2217, 2224, "diurnal" +442, 17, 17, 474, 108, 111, 2225, 2228, "IOP" +442, 17, 18, 475, 112, 121, 2229, 2238, "reduction" +442, 17, 19, 476, 122, 126, 2239, 2243, "when" +442, 17, 20, 477, 127, 138, 2244, 2255, "latanoprost" +442, 17, 21, 478, 139, 142, 2256, 2259, "was" +442, 17, 22, 479, 143, 151, 2260, 2268, "replaced" +442, 17, 23, 480, 152, 154, 2269, 2271, "by" +442, 17, 24, 481, 155, 166, 2272, 2283, "bimatoprost" +442, 17, 25, 482, 167, 175, 2284, 2292, "compared" +442, 17, 26, 483, 176, 180, 2293, 2297, "with" +442, 17, 27, 484, 181, 191, 2298, 2308, "travoprost" +442, 17, 28, 485, 192, 193, 2309, 2310, "." +442, 18, 1, 486, 0, 3, 2311, 2314, "Low" +442, 18, 2, 487, 4, 9, 2315, 2320, "rates" +442, 18, 3, 488, 10, 12, 2321, 2323, "of" +442, 18, 4, 489, 13, 23, 2324, 2334, "hyperaemia" +442, 18, 5, 490, 24, 28, 2335, 2339, "were" +442, 18, 6, 491, 29, 37, 2340, 2348, "observed" +442, 18, 7, 492, 38, 40, 2349, 2351, "in" +442, 18, 8, 493, 41, 49, 2352, 2360, "patients" +442, 18, 9, 494, 50, 57, 2361, 2368, "treated" +442, 18, 10, 495, 58, 62, 2369, 2373, "with" +442, 18, 11, 496, 63, 74, 2374, 2385, "bimatoprost" +442, 18, 12, 497, 75, 77, 2386, 2388, "or" +442, 18, 13, 498, 78, 88, 2389, 2399, "travoprost" +442, 18, 14, 499, 89, 94, 2400, 2405, "after" +442, 18, 15, 500, 95, 104, 2406, 2415, "switching" +442, 18, 16, 501, 105, 109, 2416, 2420, "from" +442, 18, 17, 502, 110, 121, 2421, 2432, "latanoprost" +442, 18, 18, 503, 122, 123, 2433, 2434, "." +442, 19, 1, 504, 0, 3, 2435, 2438, "DOI" +442, 19, 2, 505, 4, 5, 2439, 2440, ":" +442, 19, 3, 506, 6, 8, 2441, 2443, "10" +442, 19, 4, 507, 9, 10, 2444, 2445, "." +442, 19, 5, 508, 11, 15, 2446, 2450, "1136" +442, 19, 6, 509, 16, 17, 2451, 2452, "/" +442, 19, 7, 510, 18, 21, 2453, 2456, "bjo" +442, 19, 8, 511, 22, 23, 2457, 2458, "." +442, 19, 9, 512, 24, 28, 2459, 2463, "2009" +442, 19, 10, 513, 29, 30, 2464, 2465, "." +442, 19, 11, 514, 31, 37, 2466, 2472, "158071" +442, 19, 12, 515, 38, 43, 2473, 2478, "PMCID" +442, 19, 13, 516, 44, 45, 2479, 2480, ":" +442, 19, 14, 517, 46, 56, 2481, 2491, "PMC2793510" +442, 19, 15, 518, 57, 61, 2492, 2496, "PMID" +442, 19, 16, 519, 62, 63, 2497, 2498, ":" +442, 19, 17, 520, 64, 72, 2499, 2507, "19726422" +442, 19, 18, 521, 73, 74, 2508, 2509, "[" +442, 19, 19, 522, 75, 82, 2510, 2517, "Indexed" +442, 19, 20, 523, 83, 86, 2518, 2521, "for" +442, 19, 21, 524, 87, 94, 2522, 2529, "MEDLINE" +442, 19, 22, 525, 95, 96, 2530, 2531, "]" diff --git a/data/gl 19726422_jshahinitiran.annodb b/data/gl 19726422_jshahinitiran.annodb new file mode 100644 index 0000000..eb6e100 --- /dev/null +++ b/data/gl 19726422_jshahinitiran.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13116, Journal, 0, 15, "Br J Ophthalmol", "", +13117, PublicationYear, 18, 22, "2010", "", +13118, Title, 107, 273, "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .", "", +28250, Bimatoprost, 136, 147, "bimatoprost", "", +28251, Drug, 155, 165, "travoprost", "Tra", +13122, Precondition, 178, 203, "previously on latanoprost", "", +13123, Duration, 208, 217, "3 - month", "", +13124, Randomized, 220, 230, "randomised", "", +13125, Blind, 233, 251, "masked - evaluator", "", +13126, Multicenter, 254, 265, "multicentre", "", +13127, Author, 274, 283, "Kammer JA", "", +13128, Author, 292, 301, "Katzman B", "", +13129, Author, 304, 315, "Ackerman SL", "", +13130, Author, 318, 330, "Hollander DA", "", +13131, USA, 435, 438, "USA", "", +13132, ObjectiveDescription, 483, 718, "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost .", "", +28252, Latanoprost, 532, 543, "latanoprost", "", +13134, Glaucoma, 605, 613, "glaucoma", "", +13135, OcularHypertension, 617, 636, "ocular hypertension", "", +13136, IOP, 658, 678, "intraocular pressure", "", +13137, IOP, 681, 684, "IOP", "", +28253, Latanoprost, 705, 716, "latanoprost", "", +13139, CTDesign, 729, 740, "Prospective", "Prospective", +13140, Randomized, 743, 753, "randomised", "", +13141, Blind, 756, 777, "investigator - masked", "", +13142, Multicenter, 780, 791, "multicentre", "", +13146, Precondition, 818, 888, "on latanoprost 0 . 005 % monotherapy requiring additional IOP lowering", "", +13144, DoseValue, 833, 840, "0 . 005", "", +13145, Percentage, 841, 842, "%", "", +28254, IOP, 876, 879, "IOP", "", +28255, Latanoprost, 902, 913, "latanoprost", "", +13148, Randomized, 923, 933, "randomised", "", +28280, Bimatoprost, 937, 948, "bimatoprost", "", +13150, DoseValue, 949, 955, "0 . 03", "", +13151, Percentage, 956, 957, "%", "", +13152, NumberPatientsArm, 964, 967, "131", "", +13154, DoseValue, 984, 991, "0 . 004", "", +13155, Percentage, 992, 993, "%", "", +13156, NumberPatientsArm, 1000, 1003, "135", "", +13157, IOP, 1008, 1011, "IOP", "", +28256, Latanoprost, 1028, 1039, "latanoprost", "", +13158, TimePoint, 1069, 1076, "1 month", "", +28257, TimePoint, 1081, 1089, "3 months", "", +13160, Mean, 1134, 1138, "mean", "", +13161, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +13162, Latanoprost, 1154, 1165, "latanoprost", "", +13163, Mean, 1199, 1203, "mean", "", +13164, Diurnal_IOP, 1204, 1215, "diurnal IOP", "", +28258, Bimatoprost, 1245, 1256, "bimatoprost", "", +28259, Drug, 1267, 1277, "travoprost", "Tra", +13158, TimePoint, 1281, 1288, "1 month", "", +13168, PValueChangeValue, 1291, 1302, "p = 0 . 009", "", +28260, TimePoint, 1309, 1317, "3 months", "", +13169, PValueChangeValue, 1320, 1331, "p = 0 . 024", "", +13171, PercentageAffected, 1346, 1352, "22 . 0", "", +28261, Bimatoprost, 1358, 1369, "bimatoprost", "", +13173, PercentageAffected, 1386, 1392, "12 . 1", "", +28262, Drug, 1398, 1408, "travoprost", "Tra", +13175, EndPointDescription, 1429, 1465, "> or = 15 % reduction in diurnal IOP", "", +13176, Diurnal_IOP, 1454, 1465, "diurnal IOP", "", +13177, Latanoprost, 1471, 1482, "latanoprost", "", +28263, TimePoint, 1510, 1518, "months 1", "", +28264, TimePoint, 1523, 1524, "3", "", +13178, PValueNumAffected, 1527, 1538, "p = 0 . 033", "", +28265, TimePoint, 1546, 1553, "month 3", "", +13180, Mean, 1571, 1575, "mean", "", +13181, Diurnal_IOP, 1576, 1587, "diurnal IOP", "", +28266, Latanoprost, 1603, 1614, "latanoprost", "", +13182, Reduction, 1638, 1643, "2 . 1", "", +13183, ConfIntervalChangeValue, 1646, 1668, "95 % CI 1 . 7 to 2 . 5", "", +13184, mmHg, 1671, 1676, "mm Hg", "", +13185, RelativeReduction, 1679, 1685, "11 . 0", "", +28279, Bimatoprost, 1695, 1706, "bimatoprost", "", +13187, Reduction, 1711, 1716, "1 . 4", "", +13188, ConfIntervalChangeValue, 1719, 1741, "95 % CI 0 . 9 to 1 . 8", "", +13189, mmHg, 1744, 1749, "mm Hg", "", +13190, RelativeReduction, 1752, 1757, "7 . 4", "", +28267, Drug, 1767, 1777, "travoprost", "Tra", +13192, PValueChangeValue, 1780, 1791, "p = 0 . 024", "", +28269, TimePoint, 1799, 1807, "3 months", "Tra", +13196, PercentageAffected, 1810, 1816, "11 . 5", "", +28272, Bimatoprost, 1822, 1833, "bimatoprost", "", +13198, PercentageAffected, 1838, 1844, "16 . 5", "", +28271, Drug, 1850, 1860, "travoprost", "Tra", +13193, EndPointDescription, 1885, 1956, "> or = 1 - grade increase in physician - graded conjunctival hyperaemia", "", +13201, ConjunctivalHyperemia, 1933, 1956, "conjunctival hyperaemia", "", +13194, PValueNumAffected, 1959, 1970, "p = 0 . 288", "", +13200, ConjunctivalHyperemia, 1975, 1985, "Hyperaemia", "", +13202, PercentageAffected, 2041, 2046, "3 . 1", "", +28273, Bimatoprost, 2052, 2063, "bimatoprost", "", +13204, PercentageAffected, 2068, 2073, "1 . 5", "", +28274, Drug, 2079, 2089, "travoprost", "Tra", +13206, PValueNumAffected, 2101, 2112, "p = 0 . 445", "", +13207, ConclusionComment, 2130, 2310, "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .", "", +13146, Precondition, 2139, 2173, "on latanoprost requiring lower IOP", "", +13209, Latanoprost, 2142, 2153, "latanoprost", "", +13211, IOP, 2170, 2173, "IOP", "", +13212, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +13213, Latanoprost, 2244, 2255, "latanoprost", "", +13214, Bimatoprost, 2272, 2283, "bimatoprost", "", +28275, Drug, 2298, 2308, "travoprost", "Tra", +13208, ConclusionComment, 2311, 2432, "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost", "", +28277, Bimatoprost, 2374, 2385, "bimatoprost", "", +28276, Drug, 2389, 2399, "travoprost", "Tra", +28278, Latanoprost, 2421, 2432, "latanoprost", "", +13216, PMID, 2499, 2507, "19726422", "", diff --git a/data/gl 19726422_jshahinitiran.n-triples b/data/gl 19726422_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19726422_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19726422_tstrakeljahn.annodb b/data/gl 19726422_tstrakeljahn.annodb new file mode 100644 index 0000000..d4c70e3 --- /dev/null +++ b/data/gl 19726422_tstrakeljahn.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13715, Journal, 0, 15, "Br J Ophthalmol", "", +13716, PublicationYear, 18, 22, "2010", "", +13724, Title, 107, 273, "Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost : a 3 - month , randomised , masked - evaluator , multicentre study .", "", +13717, Bimatoprost, 136, 147, "bimatoprost", "", +29906, Drug, 155, 165, "travoprost", "Travoprost", +13719, Latanoprost, 192, 203, "latanoprost", "", +13720, Duration, 208, 217, "3 - month", "", +13721, Randomized, 220, 230, "randomised", "", +13722, Blind, 233, 239, "masked", "", +13723, Multicenter, 254, 265, "multicentre", "", +13725, Author, 274, 283, "Kammer JA", "", +13726, Author, 292, 301, "Katzman B", "", +13727, Author, 304, 315, "Ackerman SL", "", +13728, Author, 318, 330, "Hollander DA", "", +13729, USA, 435, 438, "USA", "", +13753, ObjectiveDescription, 483, 716, "To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue ( PGA ) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure ( IOP ) lowering while on latanoprost", "", +13730, Latanoprost, 532, 543, "latanoprost", "", +13731, Glaucoma, 605, 613, "glaucoma", "", +13732, OcularHypertension, 617, 636, "ocular hypertension", "", +13733, IOP, 658, 678, "intraocular pressure", "", +13734, IOP, 681, 684, "IOP", "", +13735, Latanoprost, 705, 716, "latanoprost", "", +13736, Randomized, 743, 753, "randomised", "", +13737, Blind, 771, 777, "masked", "", +13738, Multicenter, 780, 791, "multicentre", "", +13739, ClinicalTrial, 792, 806, "clinical trial", "", +13740, Latanoprost, 821, 832, "latanoprost", "", +13743, DoseValue, 833, 840, "0 . 005", "", +13746, Percentage, 841, 842, "%", "", +13749, IOP, 876, 879, "IOP", "", +13750, Latanoprost, 902, 913, "latanoprost", "", +13741, Bimatoprost, 937, 948, "bimatoprost", "", +13744, DoseValue, 949, 955, "0 . 03", "", +13747, Percentage, 956, 957, "%", "", +13751, NumberPatientsArm, 964, 967, "131", "", +29907, Drug, 973, 983, "travoprost", "Travoprost", +13745, DoseValue, 984, 991, "0 . 004", "", +13748, Percentage, 992, 993, "%", "", +13752, NumberPatientsArm, 1000, 1003, "135", "", +13754, IOP, 1008, 1011, "IOP", "", +13755, Latanoprost, 1028, 1039, "latanoprost", "", +13759, ObservedResult, 1125, 1194, "Baseline mean diurnal IOP on latanoprost was similar between groups .", "", +13756, Mean, 1134, 1138, "mean", "", +13757, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +13758, Latanoprost, 1154, 1165, "latanoprost", "", +13768, ObservedResult, 1195, 1335, "The mean diurnal IOP was significantly lower with bimatoprost than with travoprost at 1 month ( p = 0 . 009 ) and 3 months ( p = 0 . 024 ) .", "", +13760, Mean, 1199, 1203, "mean", "", +13761, Diurnal_IOP, 1204, 1215, "diurnal IOP", "", +13762, Bimatoprost, 1245, 1256, "bimatoprost", "", +30154, Drug, 1267, 1277, "travoprost", "Travoprost", +13764, TimePoint, 1281, 1288, "1 month", "", +13766, PvalueDiff, 1291, 1302, "p = 0 . 009", "", +13765, TimePoint, 1309, 1317, "3 months", "", +13767, PvalueDiff, 1320, 1331, "p = 0 . 024", "", +13772, PercentageAffected, 1346, 1352, "22 . 0", "", +13774, Bimatoprost, 1358, 1369, "bimatoprost", "", +13773, PercentageAffected, 1386, 1392, "12 . 1", "", +29908, Drug, 1398, 1408, "travoprost", "Travoprost", +13769, Endpoint, 1429, 1501, "> or = 15 % reduction in diurnal IOP from latanoprost - treated baseline", "", +13770, IOP, 1462, 1465, "IOP", "", +13771, Latanoprost, 1471, 1482, "latanoprost", "", +30153, TimePoint, 1510, 1524, "months 1 and 3", "", +13779, PvalueDiff, 1527, 1538, "p = 0 . 033", "", +13780, TimePoint, 1546, 1553, "month 3", "", +13781, Mean, 1571, 1575, "mean", "", +13782, Diurnal_IOP, 1576, 1587, "diurnal IOP", "", +13783, Latanoprost, 1603, 1614, "latanoprost", "", +13784, Reduction, 1638, 1643, "2 . 1", "", +13785, ConfIntervalChangeValue, 1654, 1668, "1 . 7 to 2 . 5", "", +13786, mmHg, 1671, 1676, "mm Hg", "", +13787, RelativeReduction, 1679, 1685, "11 . 0", "", +13789, Bimatoprost, 1695, 1706, "bimatoprost", "", +13790, Reduction, 1711, 1716, "1 . 4", "", +13791, ConfIntervalChangeValue, 1727, 1741, "0 . 9 to 1 . 8", "", +13792, mmHg, 1744, 1749, "mm Hg", "", +13788, RelativeReduction, 1752, 1757, "7 . 4", "", +29909, Drug, 1767, 1777, "travoprost", "Travoprost", +13794, PvalueDiff, 1780, 1791, "p = 0 . 024", "", +13795, TimePoint, 1799, 1807, "3 months", "", +13798, PercentageAffected, 1810, 1816, "11 . 5", "", +13800, Bimatoprost, 1822, 1833, "bimatoprost", "", +13799, PercentageAffected, 1838, 1844, "16 . 5", "", +29910, Drug, 1850, 1860, "travoprost", "Travoprost", +13797, Endpoint, 1885, 1956, "> or = 1 - grade increase in physician - graded conjunctival hyperaemia", "", +13796, ConjunctivalHyperemia, 1933, 1956, "conjunctival hyperaemia", "", +13802, PvalueDiff, 1959, 1970, "p = 0 . 288", "", +13803, ConjunctivalHyperemia, 1975, 1985, "Hyperaemia", "", +13804, PercentageAffected, 2041, 2046, "3 . 1", "", +13806, Bimatoprost, 2052, 2063, "bimatoprost", "", +13805, PercentageAffected, 2068, 2073, "1 . 5", "", +29911, Drug, 2079, 2089, "travoprost", "Travoprost", +13808, PvalueDiff, 2101, 2112, "p = 0 . 445", "", +13816, ConclusionComment, 2130, 2310, "Patients on latanoprost requiring lower IOP achieved a greater additional short - term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost .", "", +13809, Latanoprost, 2142, 2153, "latanoprost", "", +13810, IOP, 2170, 2173, "IOP", "", +13811, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +13812, Latanoprost, 2244, 2255, "latanoprost", "", +13813, Bimatoprost, 2272, 2283, "bimatoprost", "", +29913, Drug, 2298, 2308, "travoprost", "Travoprost", +13820, ConclusionComment, 2311, 2434, "Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost .", "", +13817, ConjunctivalHyperemia, 2324, 2334, "hyperaemia", "", +13818, Bimatoprost, 2374, 2385, "bimatoprost", "", +29912, Drug, 2389, 2399, "travoprost", "Travoprost", +13819, Latanoprost, 2421, 2432, "latanoprost", "", +13821, PMID, 2499, 2507, "19726422", "", diff --git a/data/gl 19726422_tstrakeljahn.n-triples b/data/gl 19726422_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19726422_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19787599_admin.annodb b/data/gl 19787599_admin.annodb new file mode 100644 index 0000000..19a8452 --- /dev/null +++ b/data/gl 19787599_admin.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 18, "Eur J Ophthalmol .", "", " \"Eur J Ophthalmol .\"." +1, PublicationYear, 19, 23, "2009", "", " \"2009\"." +2, Title, 57, 192, "Visual function , optic nerve structure , and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations .", "", " \"Visual function , optic nerve structure , and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations .\"." +76, EndPointDescription, 57, 72, "Visual function", "", +77, EndPointDescription, 75, 96, "optic nerve structure", "", +5, OcularBloodFlow, 103, 120, "ocular blood flow", "", +8, Precondition, 132, 190, "after 1 year of glaucoma treatment with fixed combinations", "", " \"after 1 year of glaucoma treatment with fixed combinations\"." +79, Duration, 138, 144, "1 year", "", +7, Glaucoma, 148, 156, "glaucoma", "", +10, Author, 193, 208, "Januleviciene I", "", " \"Januleviciene I\"." +11, Author, 217, 226, "Ehrlich R", "", " \"Ehrlich R\"." +12, Author, 229, 237, "Siesky B", "", " \"Siesky B\"." +13, Author, 240, 255, "Nedzelskien é I", "", " \"Nedzelskien é I\"." +14, Author, 258, 266, "Harris A", "", " \"Harris A\"." +6, Country, 350, 359, "Lithuania", "", " . ." +27, ObjectiveDescription, 408, 649, "To compare the effects of latanoprost / timolol ( LTFC ) versus dorzolamide / timolol ( DTFC ) fixed combinations on intraocular pressure ( IOP ) , visual function , and retrobulbar blood flow in patients with open - angle glaucoma ( OAG ) .", "", " \"To compare the effects of latanoprost / timolol ( LTFC ) versus dorzolamide / timolol ( DTFC ) fixed combinations on intraocular pressure ( IOP ) , visual function , and retrobulbar blood flow in patients with open - angle glaucoma ( OAG ) .\"." +15, Latanoprost, 434, 445, "latanoprost", "", " . ." +22, Lat/TimFC, 434, 455, "latanoprost / timolol", "", +16, Timolol, 448, 455, "timolol", "", " ." +21, Lat/TimFC, 458, 462, "LTFC", "", +18, Dorzolamide, 472, 483, "dorzolamide", "", " ." +19, Dorz/TimFC, 472, 493, "dorzolamide / timolol", "", +17, Timolol, 486, 493, "timolol", "", +20, Dorz/TimFC, 496, 500, "DTFC", "", +23, IOP, 525, 545, "intraocular pressure", "", +24, IOP, 548, 551, "IOP", "", +95, EndPointDescription, 556, 571, "visual function", "", +96, OcularBloodFlow, 578, 600, "retrobulbar blood flow", "", +34, Precondition, 604, 639, "patients with open - angle glaucoma", "", " \"patients with open - angle glaucoma\"." +25, OpenAngleGlaucoma, 618, 639, "open - angle glaucoma", "", " ." +26, OpenAngleGlaucoma, 642, 645, "OAG", "", +28, Prospective, 671, 682, "prospective", "", " ." +29, Randomized, 685, 695, "randomized", "", " ." +30, DoubleBlind, 698, 711, "double masked", "", " ." +31, Parallel, 714, 722, "parallel", "", " ." +32, NumberPatientsCT, 732, 734, "30", "", " \"30\"." +35, Precondition, 735, 752, "patients with OAG", "", +33, OpenAngleGlaucoma, 749, 752, "OAG", "", +105, Duration, 777, 784, "4 weeks", "", +36, Timolol, 788, 795, "timolol", "", +107, Randomized, 815, 828, "randomization", "", +37, Lat/TimFC, 832, 836, "LTFC", "", +38, Dorz/TimFC, 840, 844, "DTFC", "", +110, Randomized, 876, 889, "randomization", "", +42, TimePoint, 904, 925, "1 , 6 , and 12 months", "", +111, TimePoint, 904, 927, "1 , 6 , and 12 months ,", "", +41, TimePoint, 908, 925, "6 , and 12 months", "", +40, TimePoint, 916, 925, "12 months", "", +43, BloodPressure, 947, 961, "blood pressure", "", +44, IOP, 964, 967, "IOP", "", +116, EndPointDescription, 970, 1016, "color Doppler imaging of the ophthalmic artery", "", +117, EndPointDescription, 1019, 1021, "OA", "", +118, EndPointDescription, 1026, 1048, "central retinal artery", "", +119, EndPointDescription, 1055, 1085, "short posterior ciliary artery", "", +120, EndPointDescription, 1088, 1092, "SPCA", "", +121, EndPointDescription, 1097, 1123, "scanning laser polarimetry", "", +122, EndPointDescription, 1126, 1159, "Humphrey visual field examination", "", +45, IOP, 1193, 1196, "IOP", "", " . ." +46, Reduction, 1210, 1215, "5 . 0", "", " \"5 . 0\"." +48, mmHg, 1216, 1220, "mmHg", "", " ." +50, Dorz/TimFC, 1228, 1232, "DTFC", "", +130, PValueChangeValue, 1242, 1253, "p < 0 . 000", "", " \"p < 0 . 000\"." +47, Reduction, 1260, 1266, "5 . 44", "", " \"5 . 44\"." +49, mmHg, 1267, 1271, "mmHg", "", +51, Lat/TimFC, 1279, 1283, "LTFC", "", +131, PValueChangeValue, 1293, 1305, "p = 0 . 0001", "", " \"p = 0 . 0001\"." +101609, Duration, 1314, 1323, "12 months", "", +134, EndPointDescription, 1383, 1395, "visual field", "", " . ." +101611, EndPointDescription, 1399, 1426, "nerve fiber layer thickness", "", " . ." +133, Duration, 1477, 1486, "12 months", "", " \"12 months\"." +55, Mean, 1500, 1504, "Mean", "", +137, Duration, 1519, 1525, "1 year", "", +138, EndPointDescription, 1542, 1558, "ocular perfusion", "", " . ." +139, EndPointDescription, 1563, 1592, "diastolic perfusion pressures", "", " . ." +140, RelativeIncrement, 1598, 1605, "10 . 46", "", " \"10 . 46\"." +141, RelativeIncrement, 1612, 1619, "10 . 67", "", " \"10 . 67\"." +62, Dorz/TimFC, 1629, 1633, "DTFC", "", +142, RelativeIncrement, 1644, 1650, "7 . 47", "", " \"7 . 47\"." +143, RelativeIncrement, 1657, 1663, "5 . 61", "", " \"5 . 61\"." +61, Lat/TimFC, 1673, 1677, "LTFC", "", +147, EndPointDescription, 1701, 1719, "OA resistive index", "", " . ." +148, EndPointDescription, 1722, 1724, "RI", "", +149, EndPointDescription, 1731, 1738, "SPCA RI", "", " . ." +66, TimePoint, 1775, 1784, "12 months", "", +63, PvalueDiff, 1828, 1836, "= 0 . 05", "", " \"= 0 . 05\"." +64, PvalueDiff, 1843, 1852, "= 0 . 000", "", " \"= 0 . 000\"." +65, Dorz/TimFC, 1872, 1876, "DTFC", "", +153, EndPointDescription, 1910, 1912, "RI", "", +70, ConclusionComment, 1929, 2059, "One year of treatment with LTFC or DTFC resulted in similar IOP lowering effects as well as stable visual function and structure .", "", " \"One year of treatment with LTFC or DTFC resulted in similar IOP lowering effects as well as stable visual function and structure .\"." +156, Duration, 1929, 1937, "One year", "", +67, Lat/TimFC, 1956, 1960, "LTFC", "", +68, Dorz/TimFC, 1964, 1968, "DTFC", "", +69, IOP, 1989, 1992, "IOP", "", +74, ConclusionComment, 2060, 2159, "The DTFC group showed lower vascular resistance in retrobulbar vessels compared to the LTFC group .", "", " \"The DTFC group showed lower vascular resistance in retrobulbar vessels compared to the LTFC group .\"." +71, Dorz/TimFC, 2064, 2068, "DTFC", "", +162, EndPointDescription, 2088, 2130, "vascular resistance in retrobulbar vessels", "", +72, Lat/TimFC, 2147, 2151, "LTFC", "", +73, PMID, 2204, 2212, "19787599", "", " \"19787599\"." diff --git a/data/gl 19787599_admin.n-triples b/data/gl 19787599_admin.n-triples new file mode 100644 index 0000000..1c96c21 --- /dev/null +++ b/data/gl 19787599_admin.n-triples @@ -0,0 +1,189 @@ +# RDF export of group: Publication + . + "Publication " . + "Visual function , optic nerve structure , and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations ." . + "Januleviciene I" . + "2009" . + "Eur J Ophthalmol ." . + "19787599" . + . + "Ehrlich R" . + "Siesky B" . + "Nedzelskien é I" . + "Harris A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the effects of latanoprost / timolol ( LTFC ) versus dorzolamide / timolol ( DTFC ) fixed combinations on intraocular pressure ( IOP ) , visual function , and retrobulbar blood flow in patients with open - angle glaucoma ( OAG ) ." . + "30" . + "12 months" . + . + . + . + "One year of treatment with LTFC or DTFC resulted in similar IOP lowering effects as well as stable visual function and structure ." . + . + . + . + . + . + . + . + . + "The DTFC group showed lower vascular resistance in retrobulbar vessels compared to the LTFC group ." . + . + . +# RDF export of group: Population + . + "Population " . + "after 1 year of glaucoma treatment with fixed combinations" . + . + . + . + . + "patients with open - angle glaucoma" . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + "Endpoint visual field" . + . + . + . + . + . + . + "Endpoint nflt" . + . + . + . + . + . + . + "Endpoint op" . + . + . + . + . + . + . + "Endpoint dpp" . + . + . + . + . + . + . + "Endpoint RI" . + . + . + . + . + . + . + "Endpoint SPCA RI" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Lat/TimFC" . + . + . + . + . + . + . + . + "Arm Dorz/TimFC" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention Lat/TimFC" . + . + . + . + . + "Intervention Dorz/TimFC" . + . + . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + . + . + "Medication t" . + . + . + . + . + "Medication d" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP lt" . + . + "5 . 44" . + "p = 0 . 0001" . + . + "Outcome IOP dt" . + . + "5 . 0" . + "p < 0 . 000" . + . + "Outcome op dt" . + . + "10 . 46" . + . + "Outcome dpp dt" . + . + "10 . 67" . + . + "Outcome op lt" . + . + "7 . 47" . + . + "Outcome dpp lt" . + . + "5 . 61" . + . + "Outcome RI lt" . + . + . + "Outcome SPCA RI lt" . + . + . + "Outcome RI dt" . + . + . + "Outcome SPCA RI dt" . + . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups RI" . + "= 0 . 05" . + . + . + . + "DiffBetweenGroups SPCA RI" . + "= 0 . 000" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19787599_export.csv b/data/gl 19787599_export.csv new file mode 100644 index 0000000..01f1b74 --- /dev/null +++ b/data/gl 19787599_export.csv @@ -0,0 +1,440 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +537, 1, 1, 1, 0, 3, 0, 3, "Eur" +537, 1, 2, 2, 4, 5, 4, 5, "J" +537, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +537, 1, 4, 4, 17, 18, 17, 18, "." +537, 2, 1, 5, 0, 4, 19, 23, "2009" +537, 2, 2, 6, 5, 8, 24, 27, "Sep" +537, 2, 3, 7, 9, 10, 28, 29, "-" +537, 2, 4, 8, 11, 14, 30, 33, "Oct" +537, 2, 5, 9, 15, 16, 34, 35, ";" +537, 2, 6, 10, 17, 19, 36, 38, "19" +537, 2, 7, 11, 20, 21, 39, 40, "(" +537, 2, 8, 12, 22, 23, 41, 42, "5" +537, 2, 9, 13, 24, 25, 43, 44, ")" +537, 2, 10, 14, 26, 27, 45, 46, ":" +537, 2, 11, 15, 28, 31, 47, 50, "790" +537, 2, 12, 16, 32, 33, 51, 52, "-" +537, 2, 13, 17, 34, 35, 53, 54, "7" +537, 2, 14, 18, 36, 37, 55, 56, "." +537, 3, 1, 19, 0, 6, 57, 63, "Visual" +537, 3, 2, 20, 7, 15, 64, 72, "function" +537, 3, 3, 21, 16, 17, 73, 74, "," +537, 3, 4, 22, 18, 23, 75, 80, "optic" +537, 3, 5, 23, 24, 29, 81, 86, "nerve" +537, 3, 6, 24, 30, 39, 87, 96, "structure" +537, 3, 7, 25, 40, 41, 97, 98, "," +537, 3, 8, 26, 42, 45, 99, 102, "and" +537, 3, 9, 27, 46, 52, 103, 109, "ocular" +537, 3, 10, 28, 53, 58, 110, 115, "blood" +537, 3, 11, 29, 59, 63, 116, 120, "flow" +537, 3, 12, 30, 64, 74, 121, 131, "parameters" +537, 3, 13, 31, 75, 80, 132, 137, "after" +537, 3, 14, 32, 81, 82, 138, 139, "1" +537, 3, 15, 33, 83, 87, 140, 144, "year" +537, 3, 16, 34, 88, 90, 145, 147, "of" +537, 3, 17, 35, 91, 99, 148, 156, "glaucoma" +537, 3, 18, 36, 100, 109, 157, 166, "treatment" +537, 3, 19, 37, 110, 114, 167, 171, "with" +537, 3, 20, 38, 115, 120, 172, 177, "fixed" +537, 3, 21, 39, 121, 133, 178, 190, "combinations" +537, 3, 22, 40, 134, 135, 191, 192, "." +537, 4, 1, 41, 0, 13, 193, 206, "Januleviciene" +537, 4, 2, 42, 14, 15, 207, 208, "I" +537, 4, 3, 43, 16, 17, 209, 210, "(" +537, 4, 4, 44, 18, 19, 211, 212, "1" +537, 4, 5, 45, 20, 21, 213, 214, ")" +537, 4, 6, 46, 22, 23, 215, 216, "," +537, 4, 7, 47, 24, 31, 217, 224, "Ehrlich" +537, 4, 8, 48, 32, 33, 225, 226, "R" +537, 4, 9, 49, 34, 35, 227, 228, "," +537, 4, 10, 50, 36, 42, 229, 235, "Siesky" +537, 4, 11, 51, 43, 44, 236, 237, "B" +537, 4, 12, 52, 45, 46, 238, 239, "," +537, 4, 13, 53, 47, 58, 240, 251, "Nedzelskien" +537, 4, 14, 54, 59, 60, 252, 253, "é" +537, 4, 15, 55, 61, 62, 254, 255, "I" +537, 4, 16, 56, 63, 64, 256, 257, "," +537, 4, 17, 57, 65, 71, 258, 264, "Harris" +537, 4, 18, 58, 72, 73, 265, 266, "A" +537, 4, 19, 59, 74, 75, 267, 268, "." +537, 5, 1, 60, 0, 6, 269, 275, "Author" +537, 5, 2, 61, 7, 18, 276, 287, "information" +537, 5, 3, 62, 19, 20, 288, 289, ":" +537, 5, 4, 63, 21, 22, 290, 291, "(" +537, 5, 5, 64, 23, 24, 292, 293, "1" +537, 5, 6, 65, 25, 26, 294, 295, ")" +537, 5, 7, 66, 27, 30, 296, 299, "Eye" +537, 5, 8, 67, 31, 37, 300, 306, "Clinic" +537, 5, 9, 68, 38, 39, 307, 308, "," +537, 5, 10, 69, 40, 46, 309, 315, "Kaunas" +537, 5, 11, 70, 47, 57, 316, 326, "University" +537, 5, 12, 71, 58, 60, 327, 329, "of" +537, 5, 13, 72, 61, 69, 330, 338, "Medicine" +537, 5, 14, 73, 70, 71, 339, 340, "," +537, 5, 15, 74, 72, 78, 341, 347, "Kaunas" +537, 5, 16, 75, 79, 80, 348, 349, "-" +537, 5, 17, 76, 81, 90, 350, 359, "Lithuania" +537, 5, 18, 77, 91, 92, 360, 361, "." +537, 6, 1, 78, 0, 7, 362, 369, "ingrida" +537, 6, 2, 79, 8, 9, 370, 371, "." +537, 6, 3, 80, 10, 23, 372, 385, "januleviciene" +537, 6, 4, 81, 24, 25, 386, 387, "@" +537, 6, 5, 82, 26, 30, 388, 392, "kmuk" +537, 6, 6, 83, 31, 32, 393, 394, "." +537, 6, 7, 84, 33, 35, 395, 397, "lt" +537, 6, 8, 85, 36, 43, 398, 405, "PURPOSE" +537, 6, 9, 86, 44, 45, 406, 407, ":" +537, 6, 10, 87, 46, 48, 408, 410, "To" +537, 6, 11, 88, 49, 56, 411, 418, "compare" +537, 6, 12, 89, 57, 60, 419, 422, "the" +537, 6, 13, 90, 61, 68, 423, 430, "effects" +537, 6, 14, 91, 69, 71, 431, 433, "of" +537, 6, 15, 92, 72, 83, 434, 445, "latanoprost" +537, 6, 16, 93, 84, 85, 446, 447, "/" +537, 6, 17, 94, 86, 93, 448, 455, "timolol" +537, 6, 18, 95, 94, 95, 456, 457, "(" +537, 6, 19, 96, 96, 100, 458, 462, "LTFC" +537, 6, 20, 97, 101, 102, 463, 464, ")" +537, 6, 21, 98, 103, 109, 465, 471, "versus" +537, 6, 22, 99, 110, 121, 472, 483, "dorzolamide" +537, 6, 23, 100, 122, 123, 484, 485, "/" +537, 6, 24, 101, 124, 131, 486, 493, "timolol" +537, 6, 25, 102, 132, 133, 494, 495, "(" +537, 6, 26, 103, 134, 138, 496, 500, "DTFC" +537, 6, 27, 104, 139, 140, 501, 502, ")" +537, 6, 28, 105, 141, 146, 503, 508, "fixed" +537, 6, 29, 106, 147, 159, 509, 521, "combinations" +537, 6, 30, 107, 160, 162, 522, 524, "on" +537, 6, 31, 108, 163, 174, 525, 536, "intraocular" +537, 6, 32, 109, 175, 183, 537, 545, "pressure" +537, 6, 33, 110, 184, 185, 546, 547, "(" +537, 6, 34, 111, 186, 189, 548, 551, "IOP" +537, 6, 35, 112, 190, 191, 552, 553, ")" +537, 6, 36, 113, 192, 193, 554, 555, "," +537, 6, 37, 114, 194, 200, 556, 562, "visual" +537, 6, 38, 115, 201, 209, 563, 571, "function" +537, 6, 39, 116, 210, 211, 572, 573, "," +537, 6, 40, 117, 212, 215, 574, 577, "and" +537, 6, 41, 118, 216, 227, 578, 589, "retrobulbar" +537, 6, 42, 119, 228, 233, 590, 595, "blood" +537, 6, 43, 120, 234, 238, 596, 600, "flow" +537, 6, 44, 121, 239, 241, 601, 603, "in" +537, 6, 45, 122, 242, 250, 604, 612, "patients" +537, 6, 46, 123, 251, 255, 613, 617, "with" +537, 6, 47, 124, 256, 260, 618, 622, "open" +537, 6, 48, 125, 261, 262, 623, 624, "-" +537, 6, 49, 126, 263, 268, 625, 630, "angle" +537, 6, 50, 127, 269, 277, 631, 639, "glaucoma" +537, 6, 51, 128, 278, 279, 640, 641, "(" +537, 6, 52, 129, 280, 283, 642, 645, "OAG" +537, 6, 53, 130, 284, 285, 646, 647, ")" +537, 6, 54, 131, 286, 287, 648, 649, "." +537, 7, 1, 132, 0, 7, 650, 657, "METHODS" +537, 7, 2, 133, 8, 9, 658, 659, ":" +537, 7, 3, 134, 10, 14, 660, 664, "This" +537, 7, 4, 135, 15, 18, 665, 668, "was" +537, 7, 5, 136, 19, 20, 669, 670, "a" +537, 7, 6, 137, 21, 32, 671, 682, "prospective" +537, 7, 7, 138, 33, 34, 683, 684, "," +537, 7, 8, 139, 35, 45, 685, 695, "randomized" +537, 7, 9, 140, 46, 47, 696, 697, "," +537, 7, 10, 141, 48, 54, 698, 704, "double" +537, 7, 11, 142, 55, 61, 705, 711, "masked" +537, 7, 12, 143, 62, 63, 712, 713, "," +537, 7, 13, 144, 64, 72, 714, 722, "parallel" +537, 7, 14, 145, 73, 78, 723, 728, "study" +537, 7, 15, 146, 79, 81, 729, 731, "on" +537, 7, 16, 147, 82, 84, 732, 734, "30" +537, 7, 17, 148, 85, 93, 735, 743, "patients" +537, 7, 18, 149, 94, 98, 744, 748, "with" +537, 7, 19, 150, 99, 102, 749, 752, "OAG" +537, 7, 20, 151, 103, 104, 753, 754, "." +537, 8, 1, 152, 0, 3, 755, 758, "All" +537, 8, 2, 153, 4, 12, 759, 767, "patients" +537, 8, 3, 154, 13, 21, 768, 776, "received" +537, 8, 4, 155, 22, 23, 777, 778, "4" +537, 8, 5, 156, 24, 29, 779, 784, "weeks" +537, 8, 6, 157, 30, 32, 785, 787, "of" +537, 8, 7, 158, 33, 40, 788, 795, "timolol" +537, 8, 8, 159, 41, 50, 796, 805, "treatment" +537, 8, 9, 160, 51, 56, 806, 811, "prior" +537, 8, 10, 161, 57, 59, 812, 814, "to" +537, 8, 11, 162, 60, 73, 815, 828, "randomization" +537, 8, 12, 163, 74, 76, 829, 831, "to" +537, 8, 13, 164, 77, 81, 832, 836, "LTFC" +537, 8, 14, 165, 82, 84, 837, 839, "or" +537, 8, 15, 166, 85, 89, 840, 844, "DTFC" +537, 8, 16, 167, 90, 99, 845, 854, "treatment" +537, 8, 17, 168, 100, 101, 855, 856, "." +537, 9, 1, 169, 0, 12, 857, 869, "Measurements" +537, 9, 2, 170, 13, 18, 870, 875, "after" +537, 9, 3, 171, 19, 32, 876, 889, "randomization" +537, 9, 4, 172, 33, 37, 890, 894, "were" +537, 9, 5, 173, 38, 43, 895, 900, "taken" +537, 9, 6, 174, 44, 46, 901, 903, "at" +537, 9, 7, 175, 47, 48, 904, 905, "1" +537, 9, 8, 176, 49, 50, 906, 907, "," +537, 9, 9, 177, 51, 52, 908, 909, "6" +537, 9, 10, 178, 53, 54, 910, 911, "," +537, 9, 11, 179, 55, 58, 912, 915, "and" +537, 9, 12, 180, 59, 61, 916, 918, "12" +537, 9, 13, 181, 62, 68, 919, 925, "months" +537, 9, 14, 182, 69, 70, 926, 927, "," +537, 9, 15, 183, 71, 80, 928, 937, "including" +537, 9, 16, 184, 81, 89, 938, 946, "arterial" +537, 9, 17, 185, 90, 95, 947, 952, "blood" +537, 9, 18, 186, 96, 104, 953, 961, "pressure" +537, 9, 19, 187, 105, 106, 962, 963, ";" +537, 9, 20, 188, 107, 110, 964, 967, "IOP" +537, 9, 21, 189, 111, 112, 968, 969, ";" +537, 9, 22, 190, 113, 118, 970, 975, "color" +537, 9, 23, 191, 119, 126, 976, 983, "Doppler" +537, 9, 24, 192, 127, 134, 984, 991, "imaging" +537, 9, 25, 193, 135, 137, 992, 994, "of" +537, 9, 26, 194, 138, 141, 995, 998, "the" +537, 9, 27, 195, 142, 152, 999, 1009, "ophthalmic" +537, 9, 28, 196, 153, 159, 1010, 1016, "artery" +537, 9, 29, 197, 160, 161, 1017, 1018, "(" +537, 9, 30, 198, 162, 164, 1019, 1021, "OA" +537, 9, 31, 199, 165, 166, 1022, 1023, ")" +537, 9, 32, 200, 167, 168, 1024, 1025, "," +537, 9, 33, 201, 169, 176, 1026, 1033, "central" +537, 9, 34, 202, 177, 184, 1034, 1041, "retinal" +537, 9, 35, 203, 185, 191, 1042, 1048, "artery" +537, 9, 36, 204, 192, 193, 1049, 1050, "," +537, 9, 37, 205, 194, 197, 1051, 1054, "and" +537, 9, 38, 206, 198, 203, 1055, 1060, "short" +537, 9, 39, 207, 204, 213, 1061, 1070, "posterior" +537, 9, 40, 208, 214, 221, 1071, 1078, "ciliary" +537, 9, 41, 209, 222, 228, 1079, 1085, "artery" +537, 9, 42, 210, 229, 230, 1086, 1087, "(" +537, 9, 43, 211, 231, 235, 1088, 1092, "SPCA" +537, 9, 44, 212, 236, 237, 1093, 1094, ")" +537, 9, 45, 213, 238, 239, 1095, 1096, ";" +537, 9, 46, 214, 240, 248, 1097, 1105, "scanning" +537, 9, 47, 215, 249, 254, 1106, 1111, "laser" +537, 9, 48, 216, 255, 266, 1112, 1123, "polarimetry" +537, 9, 49, 217, 267, 268, 1124, 1125, ";" +537, 9, 50, 218, 269, 277, 1126, 1134, "Humphrey" +537, 9, 51, 219, 278, 284, 1135, 1141, "visual" +537, 9, 52, 220, 285, 290, 1142, 1147, "field" +537, 9, 53, 221, 291, 302, 1148, 1159, "examination" +537, 9, 54, 222, 303, 304, 1160, 1161, ";" +537, 9, 55, 223, 305, 308, 1162, 1165, "and" +537, 9, 56, 224, 309, 316, 1166, 1173, "adverse" +537, 9, 57, 225, 317, 323, 1174, 1180, "events" +537, 9, 58, 226, 324, 325, 1181, 1182, "." +537, 10, 1, 227, 0, 7, 1183, 1190, "RESULTS" +537, 10, 2, 228, 8, 9, 1191, 1192, ":" +537, 10, 3, 229, 10, 13, 1193, 1196, "IOP" +537, 10, 4, 230, 14, 23, 1197, 1206, "decreased" +537, 10, 5, 231, 24, 26, 1207, 1209, "by" +537, 10, 6, 232, 27, 28, 1210, 1211, "5" +537, 10, 7, 233, 29, 30, 1212, 1213, "." +537, 10, 8, 234, 31, 32, 1214, 1215, "0" +537, 10, 9, 235, 33, 37, 1216, 1220, "mmHg" +537, 10, 10, 236, 38, 40, 1221, 1223, "in" +537, 10, 11, 237, 41, 44, 1224, 1227, "the" +537, 10, 12, 238, 45, 49, 1228, 1232, "DTFC" +537, 10, 13, 239, 50, 56, 1233, 1239, "cohort" +537, 10, 14, 240, 57, 58, 1240, 1241, "(" +537, 10, 15, 241, 59, 60, 1242, 1243, "p" +537, 10, 16, 242, 61, 62, 1244, 1245, "<" +537, 10, 17, 243, 63, 64, 1246, 1247, "0" +537, 10, 18, 244, 65, 66, 1248, 1249, "." +537, 10, 19, 245, 67, 70, 1250, 1253, "000" +537, 10, 20, 246, 71, 72, 1254, 1255, ")" +537, 10, 21, 247, 73, 76, 1256, 1259, "and" +537, 10, 22, 248, 77, 78, 1260, 1261, "5" +537, 10, 23, 249, 79, 80, 1262, 1263, "." +537, 10, 24, 250, 81, 83, 1264, 1266, "44" +537, 10, 25, 251, 84, 88, 1267, 1271, "mmHg" +537, 10, 26, 252, 89, 91, 1272, 1274, "in" +537, 10, 27, 253, 92, 95, 1275, 1278, "the" +537, 10, 28, 254, 96, 100, 1279, 1283, "LTFC" +537, 10, 29, 255, 101, 107, 1284, 1290, "cohort" +537, 10, 30, 256, 108, 109, 1291, 1292, "(" +537, 10, 31, 257, 110, 111, 1293, 1294, "p" +537, 10, 32, 258, 112, 113, 1295, 1296, "=" +537, 10, 33, 259, 114, 115, 1297, 1298, "0" +537, 10, 34, 260, 116, 117, 1299, 1300, "." +537, 10, 35, 261, 118, 122, 1301, 1305, "0001" +537, 10, 36, 262, 123, 124, 1306, 1307, ")" +537, 10, 37, 263, 125, 130, 1308, 1313, "after" +537, 10, 38, 264, 131, 133, 1314, 1316, "12" +537, 10, 39, 265, 134, 140, 1317, 1323, "months" +537, 10, 40, 266, 141, 143, 1324, 1326, "of" +537, 10, 41, 267, 144, 153, 1327, 1336, "treatment" +537, 10, 42, 268, 154, 155, 1337, 1338, "." +537, 11, 1, 269, 0, 2, 1339, 1341, "No" +537, 11, 2, 270, 3, 16, 1342, 1355, "statistically" +537, 11, 3, 271, 17, 28, 1356, 1367, "significant" +537, 11, 4, 272, 29, 40, 1368, 1379, "differences" +537, 11, 5, 273, 41, 43, 1380, 1382, "in" +537, 11, 6, 274, 44, 50, 1383, 1389, "visual" +537, 11, 7, 275, 51, 56, 1390, 1395, "field" +537, 11, 8, 276, 57, 59, 1396, 1398, "or" +537, 11, 9, 277, 60, 65, 1399, 1404, "nerve" +537, 11, 10, 278, 66, 71, 1405, 1410, "fiber" +537, 11, 11, 279, 72, 77, 1411, 1416, "layer" +537, 11, 12, 280, 78, 87, 1417, 1426, "thickness" +537, 11, 13, 281, 88, 92, 1427, 1431, "were" +537, 11, 14, 282, 93, 101, 1432, 1440, "observed" +537, 11, 15, 283, 102, 109, 1441, 1448, "between" +537, 11, 16, 284, 110, 113, 1449, 1452, "the" +537, 11, 17, 285, 114, 123, 1453, 1462, "treatment" +537, 11, 18, 286, 124, 130, 1463, 1469, "groups" +537, 11, 19, 287, 131, 137, 1470, 1476, "during" +537, 11, 20, 288, 138, 140, 1477, 1479, "12" +537, 11, 21, 289, 141, 147, 1480, 1486, "months" +537, 11, 22, 290, 148, 150, 1487, 1489, "of" +537, 11, 23, 291, 151, 158, 1490, 1497, "therapy" +537, 11, 24, 292, 159, 160, 1498, 1499, "." +537, 12, 1, 293, 0, 4, 1500, 1504, "Mean" +537, 12, 2, 294, 5, 13, 1505, 1513, "increase" +537, 12, 3, 295, 14, 18, 1514, 1518, "over" +537, 12, 4, 296, 19, 20, 1519, 1520, "1" +537, 12, 5, 297, 21, 25, 1521, 1525, "year" +537, 12, 6, 298, 26, 28, 1526, 1528, "of" +537, 12, 7, 299, 29, 38, 1529, 1538, "treatment" +537, 12, 8, 300, 39, 41, 1539, 1541, "in" +537, 12, 9, 301, 42, 48, 1542, 1548, "ocular" +537, 12, 10, 302, 49, 58, 1549, 1558, "perfusion" +537, 12, 11, 303, 59, 62, 1559, 1562, "and" +537, 12, 12, 304, 63, 72, 1563, 1572, "diastolic" +537, 12, 13, 305, 73, 82, 1573, 1582, "perfusion" +537, 12, 14, 306, 83, 92, 1583, 1592, "pressures" +537, 12, 15, 307, 93, 97, 1593, 1597, "were" +537, 12, 16, 308, 98, 100, 1598, 1600, "10" +537, 12, 17, 309, 101, 102, 1601, 1602, "." +537, 12, 18, 310, 103, 105, 1603, 1605, "46" +537, 12, 19, 311, 106, 107, 1606, 1607, "%" +537, 12, 20, 312, 108, 111, 1608, 1611, "and" +537, 12, 21, 313, 112, 114, 1612, 1614, "10" +537, 12, 22, 314, 115, 116, 1615, 1616, "." +537, 12, 23, 315, 117, 119, 1617, 1619, "67" +537, 12, 24, 316, 120, 121, 1620, 1621, "%" +537, 12, 25, 317, 122, 124, 1622, 1624, "in" +537, 12, 26, 318, 125, 128, 1625, 1628, "the" +537, 12, 27, 319, 129, 133, 1629, 1633, "DTFC" +537, 12, 28, 320, 134, 139, 1634, 1639, "group" +537, 12, 29, 321, 140, 143, 1640, 1643, "and" +537, 12, 30, 322, 144, 145, 1644, 1645, "7" +537, 12, 31, 323, 146, 147, 1646, 1647, "." +537, 12, 32, 324, 148, 150, 1648, 1650, "47" +537, 12, 33, 325, 151, 152, 1651, 1652, "%" +537, 12, 34, 326, 153, 156, 1653, 1656, "and" +537, 12, 35, 327, 157, 158, 1657, 1658, "5" +537, 12, 36, 328, 159, 160, 1659, 1660, "." +537, 12, 37, 329, 161, 163, 1661, 1663, "61" +537, 12, 38, 330, 164, 165, 1664, 1665, "%" +537, 12, 39, 331, 166, 168, 1666, 1668, "in" +537, 12, 40, 332, 169, 172, 1669, 1672, "the" +537, 12, 41, 333, 173, 177, 1673, 1677, "LTFC" +537, 12, 42, 334, 178, 183, 1678, 1683, "group" +537, 12, 43, 335, 184, 185, 1684, 1685, "," +537, 12, 44, 336, 186, 198, 1686, 1698, "respectively" +537, 12, 45, 337, 199, 200, 1699, 1700, "." +537, 13, 1, 338, 0, 2, 1701, 1703, "OA" +537, 13, 2, 339, 3, 12, 1704, 1713, "resistive" +537, 13, 3, 340, 13, 18, 1714, 1719, "index" +537, 13, 4, 341, 19, 20, 1720, 1721, "(" +537, 13, 5, 342, 21, 23, 1722, 1724, "RI" +537, 13, 6, 343, 24, 25, 1725, 1726, ")" +537, 13, 7, 344, 26, 29, 1727, 1730, "and" +537, 13, 8, 345, 30, 34, 1731, 1735, "SPCA" +537, 13, 9, 346, 35, 37, 1736, 1738, "RI" +537, 13, 10, 347, 38, 42, 1739, 1743, "were" +537, 13, 11, 348, 43, 56, 1744, 1757, "significantly" +537, 13, 12, 349, 57, 66, 1758, 1767, "different" +537, 13, 13, 350, 67, 69, 1768, 1770, "at" +537, 13, 14, 351, 70, 73, 1771, 1774, "the" +537, 13, 15, 352, 74, 76, 1775, 1777, "12" +537, 13, 16, 353, 77, 83, 1778, 1784, "months" +537, 13, 17, 354, 84, 89, 1785, 1790, "visit" +537, 13, 18, 355, 90, 97, 1791, 1798, "between" +537, 13, 19, 356, 98, 101, 1799, 1802, "the" +537, 13, 20, 357, 102, 105, 1803, 1806, "two" +537, 13, 21, 358, 106, 115, 1807, 1816, "treatment" +537, 13, 22, 359, 116, 122, 1817, 1823, "groups" +537, 13, 23, 360, 123, 124, 1824, 1825, "(" +537, 13, 24, 361, 125, 126, 1826, 1827, "p" +537, 13, 25, 362, 127, 128, 1828, 1829, "=" +537, 13, 26, 363, 129, 130, 1830, 1831, "0" +537, 13, 27, 364, 131, 132, 1832, 1833, "." +537, 13, 28, 365, 133, 135, 1834, 1836, "05" +537, 13, 29, 366, 136, 139, 1837, 1840, "and" +537, 13, 30, 367, 140, 141, 1841, 1842, "p" +537, 13, 31, 368, 142, 143, 1843, 1844, "=" +537, 13, 32, 369, 144, 145, 1845, 1846, "0" +537, 13, 33, 370, 146, 147, 1847, 1848, "." +537, 13, 34, 371, 148, 151, 1849, 1852, "000" +537, 13, 35, 372, 152, 153, 1853, 1854, "," +537, 13, 36, 373, 154, 166, 1855, 1867, "respectively" +537, 13, 37, 374, 167, 168, 1868, 1869, ")" +537, 13, 38, 375, 169, 170, 1870, 1871, ":" +537, 13, 39, 376, 171, 175, 1872, 1876, "DTFC" +537, 13, 40, 377, 176, 185, 1877, 1886, "treatment" +537, 13, 41, 378, 186, 192, 1887, 1893, "showed" +537, 13, 42, 379, 193, 201, 1894, 1902, "decrease" +537, 13, 43, 380, 202, 204, 1903, 1905, "in" +537, 13, 44, 381, 205, 208, 1906, 1909, "the" +537, 13, 45, 382, 209, 211, 1910, 1912, "RI" +537, 13, 46, 383, 212, 213, 1913, 1914, "." +537, 14, 1, 384, 0, 11, 1915, 1926, "CONCLUSIONS" +537, 14, 2, 385, 12, 13, 1927, 1928, ":" +537, 14, 3, 386, 14, 17, 1929, 1932, "One" +537, 14, 4, 387, 18, 22, 1933, 1937, "year" +537, 14, 5, 388, 23, 25, 1938, 1940, "of" +537, 14, 6, 389, 26, 35, 1941, 1950, "treatment" +537, 14, 7, 390, 36, 40, 1951, 1955, "with" +537, 14, 8, 391, 41, 45, 1956, 1960, "LTFC" +537, 14, 9, 392, 46, 48, 1961, 1963, "or" +537, 14, 10, 393, 49, 53, 1964, 1968, "DTFC" +537, 14, 11, 394, 54, 62, 1969, 1977, "resulted" +537, 14, 12, 395, 63, 65, 1978, 1980, "in" +537, 14, 13, 396, 66, 73, 1981, 1988, "similar" +537, 14, 14, 397, 74, 77, 1989, 1992, "IOP" +537, 14, 15, 398, 78, 86, 1993, 2001, "lowering" +537, 14, 16, 399, 87, 94, 2002, 2009, "effects" +537, 14, 17, 400, 95, 97, 2010, 2012, "as" +537, 14, 18, 401, 98, 102, 2013, 2017, "well" +537, 14, 19, 402, 103, 105, 2018, 2020, "as" +537, 14, 20, 403, 106, 112, 2021, 2027, "stable" +537, 14, 21, 404, 113, 119, 2028, 2034, "visual" +537, 14, 22, 405, 120, 128, 2035, 2043, "function" +537, 14, 23, 406, 129, 132, 2044, 2047, "and" +537, 14, 24, 407, 133, 142, 2048, 2057, "structure" +537, 14, 25, 408, 143, 144, 2058, 2059, "." +537, 15, 1, 409, 0, 3, 2060, 2063, "The" +537, 15, 2, 410, 4, 8, 2064, 2068, "DTFC" +537, 15, 3, 411, 9, 14, 2069, 2074, "group" +537, 15, 4, 412, 15, 21, 2075, 2081, "showed" +537, 15, 5, 413, 22, 27, 2082, 2087, "lower" +537, 15, 6, 414, 28, 36, 2088, 2096, "vascular" +537, 15, 7, 415, 37, 47, 2097, 2107, "resistance" +537, 15, 8, 416, 48, 50, 2108, 2110, "in" +537, 15, 9, 417, 51, 62, 2111, 2122, "retrobulbar" +537, 15, 10, 418, 63, 70, 2123, 2130, "vessels" +537, 15, 11, 419, 71, 79, 2131, 2139, "compared" +537, 15, 12, 420, 80, 82, 2140, 2142, "to" +537, 15, 13, 421, 83, 86, 2143, 2146, "the" +537, 15, 14, 422, 87, 91, 2147, 2151, "LTFC" +537, 15, 15, 423, 92, 97, 2152, 2157, "group" +537, 15, 16, 424, 98, 99, 2158, 2159, "." +537, 16, 1, 425, 0, 3, 2160, 2163, "DOI" +537, 16, 2, 426, 4, 5, 2164, 2165, ":" +537, 16, 3, 427, 6, 8, 2166, 2168, "10" +537, 16, 4, 428, 9, 10, 2169, 2170, "." +537, 16, 5, 429, 11, 15, 2171, 2175, "1177" +537, 16, 6, 430, 16, 17, 2176, 2177, "/" +537, 16, 7, 431, 18, 36, 2178, 2196, "112067210901900517" +537, 16, 8, 432, 37, 41, 2197, 2201, "PMID" +537, 16, 9, 433, 42, 43, 2202, 2203, ":" +537, 16, 10, 434, 44, 52, 2204, 2212, "19787599" +537, 16, 11, 435, 53, 54, 2213, 2214, "[" +537, 16, 12, 436, 55, 62, 2215, 2222, "Indexed" +537, 16, 13, 437, 63, 66, 2223, 2226, "for" +537, 16, 14, 438, 67, 74, 2227, 2234, "MEDLINE" +537, 16, 15, 439, 75, 76, 2235, 2236, "]" diff --git a/data/gl 19787599_jshahinitiran.annodb b/data/gl 19787599_jshahinitiran.annodb new file mode 100644 index 0000000..5c8aa8a --- /dev/null +++ b/data/gl 19787599_jshahinitiran.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88360, Journal, 0, 16, "Eur J Ophthalmol", "", +88361, PublicationYear, 19, 23, "2009", "", +88362, Title, 57, 192, "Visual function , optic nerve structure , and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations .", "", +91563, EndPointDescription, 57, 72, "Visual function", "", +91564, EndPointDescription, 75, 96, "optic nerve structure", "", +91565, OcularBloodFlow, 103, 120, "ocular blood flow", "", +91566, Duration, 138, 144, "1 year", "", +91567, Glaucoma, 148, 156, "glaucoma", "", +91562, Author, 193, 208, "Januleviciene I", "", +91568, Author, 217, 226, "Ehrlich R", "", +91569, Author, 229, 237, "Siesky B", "", +91570, Author, 240, 255, "Nedzelskien é I", "", +91571, Author, 258, 266, "Harris A", "", +91572, Country, 350, 359, "Lithuania", "", +91573, ObjectiveDescription, 408, 649, "To compare the effects of latanoprost / timolol ( LTFC ) versus dorzolamide / timolol ( DTFC ) fixed combinations on intraocular pressure ( IOP ) , visual function , and retrobulbar blood flow in patients with open - angle glaucoma ( OAG ) .", "", +91574, Latanoprost, 434, 445, "latanoprost", "", +91575, Timolol, 448, 455, "timolol", "", +91578, Lat/TimFC, 458, 462, "LTFC", "", +91577, Dorzolamide, 472, 483, "dorzolamide", "", +91576, Timolol, 486, 493, "timolol", "", +91579, Dorz/TimFC, 496, 500, "DTFC", "", +91580, IOP, 525, 545, "intraocular pressure", "", +91581, IOP, 548, 551, "IOP", "", +91582, EndPointDescription, 556, 571, "visual function", "", +91583, OcularBloodFlow, 578, 600, "retrobulbar blood flow", "", +91584, OpenAngleGlaucoma, 618, 639, "open - angle glaucoma", "", +91585, OpenAngleGlaucoma, 642, 645, "OAG", "", +91586, Prospective, 671, 682, "prospective", "", +91587, Randomized, 685, 695, "randomized", "", +91588, DoubleBlind, 698, 711, "double masked", "", +91589, Parallel, 714, 722, "parallel", "", +91590, NumberPatientsCT, 732, 734, "30", "", +91591, OpenAngleGlaucoma, 749, 752, "OAG", "", +91592, Duration, 777, 784, "4 weeks", "", +91593, Timolol, 788, 795, "timolol", "", +91594, Randomized, 815, 828, "randomization", "", +91595, Lat/TimFC, 832, 836, "LTFC", "", +91596, Dorz/TimFC, 840, 844, "DTFC", "", +91597, Randomized, 876, 889, "randomization", "", +91598, TimePoint, 904, 927, "1 , 6 , and 12 months ,", "", +91599, TimePoint, 908, 925, "6 , and 12 months", "", +91600, TimePoint, 916, 925, "12 months", "", +91601, BloodPressure, 947, 961, "blood pressure", "", +91602, IOP, 964, 967, "IOP", "", +91603, EndPointDescription, 970, 1016, "color Doppler imaging of the ophthalmic artery", "", +91604, EndPointDescription, 1019, 1021, "OA", "", +91605, EndPointDescription, 1026, 1048, "central retinal artery", "", +91606, EndPointDescription, 1055, 1085, "short posterior ciliary artery", "", +91607, EndPointDescription, 1088, 1092, "SPCA", "", +91608, EndPointDescription, 1097, 1123, "scanning laser polarimetry", "", +91609, EndPointDescription, 1126, 1159, "Humphrey visual field examination", "", +91610, IOP, 1193, 1196, "IOP", "", +91611, Reduction, 1210, 1215, "5 . 0", "", +91614, mmHg, 1216, 1220, "mmHg", "", +91616, Dorz/TimFC, 1228, 1232, "DTFC", "", +91618, PValueChangeValue, 1242, 1253, "p < 0 . 000", "", +91613, Reduction, 1260, 1266, "5 . 44", "", +91615, mmHg, 1267, 1271, "mmHg", "", +91617, Lat/TimFC, 1279, 1283, "LTFC", "", +91619, PValueChangeValue, 1293, 1305, "p = 0 . 0001", "", +91620, TimePoint, 1314, 1323, "12 months", "", +91623, ObservedResult, 1339, 1499, "No statistically significant differences in visual field or nerve fiber layer thickness were observed between the treatment groups during 12 months of therapy .", "", +91622, EndPointDescription, 1383, 1395, "visual field", "", +91621, Duration, 1477, 1486, "12 months", "", +91624, Mean, 1500, 1504, "Mean", "", +91625, Duration, 1519, 1525, "1 year", "", +91626, EndPointDescription, 1542, 1558, "ocular perfusion", "", +91627, EndPointDescription, 1563, 1592, "diastolic perfusion pressures", "", +91628, RelativeIncrement, 1598, 1605, "10 . 46", "", +91629, RelativeIncrement, 1612, 1619, "10 . 67", "", +91632, Dorz/TimFC, 1629, 1633, "DTFC", "", +91630, RelativeIncrement, 1644, 1650, "7 . 47", "", +91631, RelativeIncrement, 1657, 1663, "5 . 61", "", +91633, Lat/TimFC, 1673, 1677, "LTFC", "", +91635, EndPointDescription, 1701, 1719, "OA resistive index", "", +91636, EndPointDescription, 1722, 1724, "RI", "", +91637, EndPointDescription, 1731, 1738, "SPCA RI", "", +91634, TimePoint, 1775, 1784, "12 months", "", +91638, PValueResValue, 1826, 1836, "p = 0 . 05", "", +91639, PValueResValue, 1841, 1852, "p = 0 . 000", "", +91640, Dorz/TimFC, 1872, 1876, "DTFC", "", +91641, EndPointDescription, 1910, 1912, "RI", "", +91642, ConclusionComment, 1929, 2059, "One year of treatment with LTFC or DTFC resulted in similar IOP lowering effects as well as stable visual function and structure .", "", +91644, Duration, 1929, 1937, "One year", "", +91645, Lat/TimFC, 1956, 1960, "LTFC", "", +91646, Dorz/TimFC, 1964, 1968, "DTFC", "", +91647, IOP, 1989, 1992, "IOP", "", +91643, ConclusionComment, 2060, 2159, "The DTFC group showed lower vascular resistance in retrobulbar vessels compared to the LTFC group .", "", +91648, Dorz/TimFC, 2064, 2068, "DTFC", "", +91650, EndPointDescription, 2088, 2130, "vascular resistance in retrobulbar vessels", "", +91649, Lat/TimFC, 2147, 2151, "LTFC", "", +91651, PMID, 2204, 2212, "19787599", "", diff --git a/data/gl 19787599_jshahinitiran.n-triples b/data/gl 19787599_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19787599_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19787599_tstrakeljahn.annodb b/data/gl 19787599_tstrakeljahn.annodb new file mode 100644 index 0000000..07ecd88 --- /dev/null +++ b/data/gl 19787599_tstrakeljahn.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89970, Journal, 0, 16, "Eur J Ophthalmol", "", +89971, PublicationYear, 19, 23, "2009", "", +89976, Title, 57, 192, "Visual function , optic nerve structure , and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations .", "", +89972, OcularBloodFlow, 103, 120, "ocular blood flow", "", +89975, Precondition, 132, 190, "after 1 year of glaucoma treatment with fixed combinations", "", +89974, Glaucoma, 148, 156, "glaucoma", "", +89977, Author, 193, 208, "Januleviciene I", "", +89978, Author, 217, 226, "Ehrlich R", "", +89979, Author, 229, 237, "Siesky B", "", +89980, Author, 240, 255, "Nedzelskien é I", "", +89981, Author, 258, 266, "Harris A", "", +89973, Country, 350, 359, "Lithuania", "Lithuania", +89994, ObjectiveDescription, 408, 649, "To compare the effects of latanoprost / timolol ( LTFC ) versus dorzolamide / timolol ( DTFC ) fixed combinations on intraocular pressure ( IOP ) , visual function , and retrobulbar blood flow in patients with open - angle glaucoma ( OAG ) .", "", +89982, Latanoprost, 434, 445, "latanoprost", "", +89989, Lat/TimFC, 434, 455, "latanoprost / timolol", "", +89983, Timolol, 448, 455, "timolol", "", +89988, Lat/TimFC, 458, 462, "LTFC", "", +89985, Dorzolamide, 472, 483, "dorzolamide", "", +89986, Dorz/TimFC, 472, 493, "dorzolamide / timolol", "", +89984, Timolol, 486, 493, "timolol", "", +89987, Dorz/TimFC, 496, 500, "DTFC", "", +89990, IOP, 525, 545, "intraocular pressure", "", +89991, IOP, 548, 551, "IOP", "", +90001, Precondition, 604, 639, "patients with open - angle glaucoma", "", +89992, OpenAngleGlaucoma, 618, 639, "open - angle glaucoma", "", +89993, OpenAngleGlaucoma, 642, 645, "OAG", "", +89995, Prospective, 671, 682, "prospective", "", +89996, Randomized, 685, 695, "randomized", "", +89997, DoubleBlind, 698, 711, "double masked", "", +89998, Parallel, 714, 722, "parallel", "", +89999, NumberPatientsCT, 732, 734, "30", "", +90002, Precondition, 735, 752, "patients with OAG", "", +90000, OpenAngleGlaucoma, 749, 752, "OAG", "", +90006, Precondition, 755, 856, "All patients received 4 weeks of timolol treatment prior to randomization to LTFC or DTFC treatment .", "", +90003, Timolol, 788, 795, "timolol", "", +90004, Lat/TimFC, 832, 836, "LTFC", "", +90005, Dorz/TimFC, 840, 844, "DTFC", "", +90009, TimePoint, 904, 925, "1 , 6 , and 12 months", "", +90008, TimePoint, 908, 925, "6 , and 12 months", "", +90007, TimePoint, 916, 925, "12 months", "", +90010, BloodPressure, 947, 961, "blood pressure", "", +90011, IOP, 964, 967, "IOP", "", +90012, IOP, 1193, 1196, "IOP", "", +90013, Reduction, 1210, 1215, "5 . 0", "", +90015, mmHg, 1216, 1220, "mmHg", "", +90017, Dorz/TimFC, 1228, 1232, "DTFC", "", +90019, PValueChangeValue, 1244, 1253, "< 0 . 000", "", +90014, Reduction, 1260, 1266, "5 . 44", "", +90016, mmHg, 1267, 1271, "mmHg", "", +90018, Lat/TimFC, 1279, 1283, "LTFC", "", +90020, PValueChangeValue, 1295, 1305, "= 0 . 0001", "", +90021, TimePoint, 1314, 1323, "12 months", "", +90023, ObservedResult, 1339, 1499, "No statistically significant differences in visual field or nerve fiber layer thickness were observed between the treatment groups during 12 months of therapy .", "", +90022, Mean, 1500, 1504, "Mean", "", +90024, RelativeChangeValue, 1598, 1605, "10 . 46", "", +90025, RelativeChangeValue, 1612, 1619, "10 . 67", "", +90029, Dorz/TimFC, 1629, 1633, "DTFC", "", +90026, RelativeChangeValue, 1644, 1650, "7 . 47", "", +90027, RelativeChangeValue, 1657, 1663, "5 . 61", "", +90028, Lat/TimFC, 1673, 1677, "LTFC", "", +90033, TimePoint, 1775, 1784, "12 months", "", +90030, PvalueDiff, 1828, 1836, "= 0 . 05", "", +90031, PvalueDiff, 1843, 1852, "= 0 . 000", "", +90032, Dorz/TimFC, 1872, 1876, "DTFC", "", +90037, ConclusionComment, 1929, 2059, "One year of treatment with LTFC or DTFC resulted in similar IOP lowering effects as well as stable visual function and structure .", "", +90034, Lat/TimFC, 1956, 1960, "LTFC", "", +90035, Dorz/TimFC, 1964, 1968, "DTFC", "", +90036, IOP, 1989, 1992, "IOP", "", +90041, ConclusionComment, 2060, 2159, "The DTFC group showed lower vascular resistance in retrobulbar vessels compared to the LTFC group .", "", +90038, Dorz/TimFC, 2064, 2068, "DTFC", "", +90039, Lat/TimFC, 2147, 2151, "LTFC", "", +90040, PMID, 2204, 2212, "19787599", "", diff --git a/data/gl 19787599_tstrakeljahn.n-triples b/data/gl 19787599_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19787599_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19860553_admin.annodb b/data/gl 19860553_admin.annodb new file mode 100644 index 0000000..184181b --- /dev/null +++ b/data/gl 19860553_admin.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "J Ocul Pharmacol Ther", "", " \"J Ocul Pharmacol Ther\"." +1, PublicationYear, 24, 28, "2009", "", " \"2009\"." +98, Title, 95, 314, "A comparison of bimatoprost 0 . 03 % versus the fixed - combination of latanoprost 0 . 005 % and timolol 0 . 5 % in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label trial .", "", " \"A comparison of bimatoprost 0 . 03 % versus the fixed - combination of latanoprost 0 . 005 % and timolol 0 . 5 % in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label trial .\"." +2, Bimatoprost, 111, 122, "bimatoprost", "", " ." +9, DoseValue, 123, 129, "0 . 03", "", " \"0 . 03\"." +12, Percentage, 130, 131, "%", "", " ." +3, Latanoprost, 166, 177, "latanoprost", "", " . ." +10, DoseValue, 178, 185, "0 . 005", "", " \"0 . 005\"." +13, Percentage, 186, 187, "%", "", " ." +4, Timolol, 192, 199, "timolol", "", " ." +11, DoseValue, 200, 205, "0 . 5", "", " \"0 . 5\"." +14, Percentage, 206, 207, "%", "", " ." +5, Precondition, 231, 260, "elevated intraocular pressure", "", " \"elevated intraocular pressure\"." +119, IOP, 240, 260, "intraocular pressure", "", +6, Duration, 266, 278, "eight - week", "", " \"eight - week\"." +7, Randomized, 281, 291, "randomized", "", " ." +8, OpenLabel, 294, 306, "open - label", "", " ." +16, Author, 315, 323, "Facio AC", "", " \"Facio AC\"." +17, Author, 332, 339, "Reis AS", "", " \"Reis AS\"." +18, Author, 342, 350, "Vidal KS", "", " \"Vidal KS\"." +19, Author, 353, 365, "de Moraes CG", "", " \"de Moraes CG\"." +20, Author, 368, 376, "Suzuki R", "", " \"Suzuki R\"." +21, Author, 379, 389, "Hatanaka M", "", " \"Hatanaka M\"." +22, Author, 392, 401, "Susanna R", "", " \"Susanna R\"." +23, Brazil, 541, 547, "Brazil", "", " ." +24, Bimatoprost, 577, 588, "Bimatoprost", "", +30, ObjectiveDescription, 577, 732, "Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension ( OHT ) .", "", " \"Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension ( OHT ) .\"." +25, Latanoprost, 618, 629, "latanoprost", "", +159, Timolol, 635, 650, "timolol maleate", "", +27, Glaucoma, 690, 698, "glaucoma", "", " . ." +28, OcularHypertension, 703, 722, "ocular hypertension", "", " ." +29, OcularHypertension, 725, 728, "OHT", "", +35, ObjectiveDescription, 733, 928, "The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure ( IOP ) after 8 weeks of treatment in patients with primary open angle glaucoma ( POAG ) or OHT .", "", " \"The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure ( IOP ) after 8 weeks of treatment in patients with primary open angle glaucoma ( POAG ) or OHT .\"." +31, IOP, 810, 830, "intraocular pressure", "", +32, IOP, 833, 836, "IOP", "", +113, Duration, 845, 852, "8 weeks", "", +161, Primary_OpenAngleGlaucoma, 883, 910, "primary open angle glaucoma", "", " ." +162, Primary_OpenAngleGlaucoma, 913, 917, "POAG", "", +34, OcularHypertension, 923, 926, "OHT", "", +36, Randomized, 947, 957, "randomized", "", +37, OpenLabel, 960, 972, "open - label", "", +38, NumberPatientsCT, 981, 983, "44", "", " \"44\"." +166, Primary_OpenAngleGlaucoma, 998, 1002, "POAG", "", +39, OcularHypertension, 1006, 1009, "OHT", "", +40, Bimatoprost, 1043, 1054, "bimatoprost", "", +41, DoseValue, 1057, 1058, "1", "", +44, Eyedrops, 1059, 1063, "drop", "", " ." +42, Frequency, 1064, 1066, "QD", "", " \"QD\"." +47, Latanoprost, 1072, 1083, "latanoprost", "", +48, Timolol, 1086, 1093, "timolol", "", +46, DoseValue, 1096, 1097, "1", "", +45, Eyedrops, 1098, 1102, "drop", "", " . ." +43, Frequency, 1103, 1105, "QD", "", " \"QD\"." +49, Mean, 1134, 1138, "mean", "", " . ." +50, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", " ." +171, TimePoint, 1170, 1178, "8th week", "", +51, Mean, 1199, 1203, "mean", "", +52, IOP, 1204, 1207, "IOP", "", +36989, TimePoint, 1230, 1239, "8 : 00 am", "", +36990, TimePoint, 1242, 1252, "10 : 00 am", "", +36991, TimePoint, 1259, 1269, "12 : 00 pm", "", +53, IOP, 1321, 1324, "IOP", "", +31213, IOP, 1409, 1412, "IOP", "", +55, Mean, 1496, 1500, "mean", "", +56, IOP, 1501, 1504, "IOP", "", +57, Latanoprost, 1515, 1526, "latanoprost", "", +58, Timolol, 1529, 1536, "timolol", "", +59, ResultMeasuredValue, 1539, 1546, "13 . 83", "", " \"13 . 83\"." +60, SdDevResValue, 1554, 1560, "2 . 54", "", " \"2 . 54\"." +61, Bimatoprost, 1595, 1606, "bimatoprost", "", +62, ResultMeasuredValue, 1609, 1616, "16 . 16", "", " \"16 . 16\"." +63, SdDevResValue, 1624, 1630, "3 . 28", "", " \"3 . 28\"." +64, PvalueDiff, 1633, 1645, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +65, TimePoint, 1651, 1657, "week 8", "", " \"week 8\". \"week 8\"." +66, Mean, 1681, 1685, "mean", "", +67, IOP, 1686, 1689, "IOP", "", +68, Latanoprost, 1729, 1740, "latanoprost", "", +69, Timolol, 1743, 1750, "timolol", "", +70, TimePoint, 1760, 1770, "10 : 00 am", "", +31216, PValueChangeValue, 1773, 1784, "P = 0 . 013", "", " \"P = 0 . 013\"." +71, TimePoint, 1791, 1801, "12 : 00 pm", "", +31218, PValueChangeValue, 1804, 1814, "P = 0 . 01", "", " \"P = 0 . 01\"." +72, TimePoint, 1830, 1839, "8 : 00 am", "", +31217, PValueChangeValue, 1842, 1848, "P = ns", "", " \"P = ns\"." +83, ObservedResult, 1853, 1982, "During the water - drinking test , there was no significant difference in IOP increase ( absolute and percentage ) between groups", "", +77, IOP, 1927, 1930, "IOP", "", +82, ObservedResult, 1983, 2081, "; however , there was a significant decrease in mean heart rate in the latanoprost / timolol group", "", " \"; however , there was a significant decrease in mean heart rate in the latanoprost / timolol group\"." +78, Mean, 2031, 2035, "mean", "", +79, HeartRate, 2036, 2046, "heart rate", "", " . ." +80, Latanoprost, 2054, 2065, "latanoprost", "", +81, Timolol, 2068, 2075, "timolol", "", +31220, ObservedResult, 2094, 2187, "no significant changes in blood pressure and lung spirometry were observed in either groups .", "", " \"no significant changes in blood pressure and lung spirometry were observed in either groups .\". \"no significant changes in blood pressure and lung spirometry were observed in either groups .\"." +84, BloodPressure, 2120, 2134, "blood pressure", "", " . ." +31221, EndPointDescription, 2139, 2154, "lung spirometry", "AdverseEffect", " . ." +94, ConclusionComment, 2202, 2343, "The fixed combination of latanoprost / timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT .", "", " \"The fixed combination of latanoprost / timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT .\"." +86, Latanoprost, 2227, 2238, "latanoprost", "", +31222, Drug, 2227, 2248, "latanoprost / timolol", "AdverseEffect", +87, Timolol, 2241, 2248, "timolol", "", +88, Bimatoprost, 2279, 2290, "bimatoprost", "", +89, IOP, 2309, 2312, "IOP", "", +184, Primary_OpenAngleGlaucoma, 2330, 2334, "POAG", "", +90, OcularHypertension, 2338, 2341, "OHT", "", +93, ConclusionComment, 2344, 2517, "Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost / timolol , as well as to better assess its profile of side effects .", "", " \"Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost / timolol , as well as to better assess its profile of side effects .\"." +91, Latanoprost, 2436, 2447, "latanoprost", "", +92, Timolol, 2450, 2457, "timolol", "", +95, PMID, 2561, 2569, "19860553", "", " \"19860553\"." diff --git a/data/gl 19860553_admin.n-triples b/data/gl 19860553_admin.n-triples new file mode 100644 index 0000000..d6b6190 --- /dev/null +++ b/data/gl 19860553_admin.n-triples @@ -0,0 +1,166 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparison of bimatoprost 0 . 03 % versus the fixed - combination of latanoprost 0 . 005 % and timolol 0 . 5 % in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label trial ." . + "Facio AC" . + "2009" . + "J Ocul Pharmacol Ther" . + "19860553" . + . + "Reis AS" . + "Vidal KS" . + "de Moraes CG" . + "Suzuki R" . + "Hatanaka M" . + "Susanna R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension ( OHT ) ." . + "44" . + "eight - week" . + . + . + . + "The fixed combination of latanoprost / timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT ." . + . + . + . + . + . + . + "The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure ( IOP ) after 8 weeks of treatment in patients with primary open angle glaucoma ( POAG ) or OHT ." . + . + "Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost / timolol , as well as to better assess its profile of side effects ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "elevated intraocular pressure" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_HR" . + . + . + . + . + . + . + "Endpoint_BP" . + . + . + . + . + . + . + "Endpoint_LS" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat-tim" . + . + . + . + . + . + . + . + . + . + "Arm_bim" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat-tim" . + . + "QD" . + . + . + . + "Intervention_bim" . + . + "QD" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_tim" . + . + "0 . 5" . + . + . + . + "Medication_bim" . + . + "0 . 03" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat/tim" . + . + "13 . 83" . + "2 . 54" . + "week 8" . + . + "Outcome_iop_bim" . + . + "16 . 16" . + "3 . 28" . + "week 8" . + . + "Outcome_iop_8am_lat/tim" . + . + "P = ns" . + . + "Outcome_iop_10am_lat/tim" . + . + "P = 0 . 013" . + . + "Outcome_iop_12pm_lat/tim" . + . + "P = 0 . 01" . + . + "Outcome_HR_lat/tim" . + . + "; however , there was a significant decrease in mean heart rate in the latanoprost / timolol group" . + . + "Outcome_BP" . + . + "no significant changes in blood pressure and lung spirometry were observed in either groups ." . + . + "Outcome_LS" . + . + "no significant changes in blood pressure and lung spirometry were observed in either groups ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "P < 0 . 0001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19860553_export.csv b/data/gl 19860553_export.csv new file mode 100644 index 0000000..20d93c0 --- /dev/null +++ b/data/gl 19860553_export.csv @@ -0,0 +1,547 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +439, 1, 1, 1, 0, 1, 0, 1, "J" +439, 1, 2, 2, 2, 6, 2, 6, "Ocul" +439, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +439, 1, 4, 4, 17, 21, 17, 21, "Ther" +439, 1, 5, 5, 22, 23, 22, 23, "." +439, 2, 1, 6, 0, 4, 24, 28, "2009" +439, 2, 2, 7, 5, 8, 29, 32, "Oct" +439, 2, 3, 8, 9, 10, 33, 34, ";" +439, 2, 4, 9, 11, 13, 35, 37, "25" +439, 2, 5, 10, 14, 15, 38, 39, "(" +439, 2, 6, 11, 16, 17, 40, 41, "5" +439, 2, 7, 12, 18, 19, 42, 43, ")" +439, 2, 8, 13, 20, 21, 44, 45, ":" +439, 2, 9, 14, 22, 25, 46, 49, "447" +439, 2, 10, 15, 26, 27, 50, 51, "-" +439, 2, 11, 16, 28, 30, 52, 54, "51" +439, 2, 12, 17, 31, 32, 55, 56, "." +439, 2, 13, 18, 33, 36, 57, 60, "doi" +439, 2, 14, 19, 37, 38, 61, 62, ":" +439, 2, 15, 20, 39, 41, 63, 65, "10" +439, 2, 16, 21, 42, 43, 66, 67, "." +439, 2, 17, 22, 44, 48, 68, 72, "1089" +439, 2, 18, 23, 49, 50, 73, 74, "/" +439, 2, 19, 24, 51, 54, 75, 78, "jop" +439, 2, 20, 25, 55, 56, 79, 80, "." +439, 2, 21, 26, 57, 61, 81, 85, "2009" +439, 2, 22, 27, 62, 63, 86, 87, "." +439, 2, 23, 28, 64, 68, 88, 92, "0018" +439, 2, 24, 29, 69, 70, 93, 94, "." +439, 3, 1, 30, 0, 1, 95, 96, "A" +439, 3, 2, 31, 2, 12, 97, 107, "comparison" +439, 3, 3, 32, 13, 15, 108, 110, "of" +439, 3, 4, 33, 16, 27, 111, 122, "bimatoprost" +439, 3, 5, 34, 28, 29, 123, 124, "0" +439, 3, 6, 35, 30, 31, 125, 126, "." +439, 3, 7, 36, 32, 34, 127, 129, "03" +439, 3, 8, 37, 35, 36, 130, 131, "%" +439, 3, 9, 38, 37, 43, 132, 138, "versus" +439, 3, 10, 39, 44, 47, 139, 142, "the" +439, 3, 11, 40, 48, 53, 143, 148, "fixed" +439, 3, 12, 41, 54, 55, 149, 150, "-" +439, 3, 13, 42, 56, 67, 151, 162, "combination" +439, 3, 14, 43, 68, 70, 163, 165, "of" +439, 3, 15, 44, 71, 82, 166, 177, "latanoprost" +439, 3, 16, 45, 83, 84, 178, 179, "0" +439, 3, 17, 46, 85, 86, 180, 181, "." +439, 3, 18, 47, 87, 90, 182, 185, "005" +439, 3, 19, 48, 91, 92, 186, 187, "%" +439, 3, 20, 49, 93, 96, 188, 191, "and" +439, 3, 21, 50, 97, 104, 192, 199, "timolol" +439, 3, 22, 51, 105, 106, 200, 201, "0" +439, 3, 23, 52, 107, 108, 202, 203, "." +439, 3, 24, 53, 109, 110, 204, 205, "5" +439, 3, 25, 54, 111, 112, 206, 207, "%" +439, 3, 26, 55, 113, 115, 208, 210, "in" +439, 3, 27, 56, 116, 121, 211, 216, "adult" +439, 3, 28, 57, 122, 130, 217, 225, "patients" +439, 3, 29, 58, 131, 135, 226, 230, "with" +439, 3, 30, 59, 136, 144, 231, 239, "elevated" +439, 3, 31, 60, 145, 156, 240, 251, "intraocular" +439, 3, 32, 61, 157, 165, 252, 260, "pressure" +439, 3, 33, 62, 166, 167, 261, 262, ":" +439, 3, 34, 63, 168, 170, 263, 265, "an" +439, 3, 35, 64, 171, 176, 266, 271, "eight" +439, 3, 36, 65, 177, 178, 272, 273, "-" +439, 3, 37, 66, 179, 183, 274, 278, "week" +439, 3, 38, 67, 184, 185, 279, 280, "," +439, 3, 39, 68, 186, 196, 281, 291, "randomized" +439, 3, 40, 69, 197, 198, 292, 293, "," +439, 3, 41, 70, 199, 203, 294, 298, "open" +439, 3, 42, 71, 204, 205, 299, 300, "-" +439, 3, 43, 72, 206, 211, 301, 306, "label" +439, 3, 44, 73, 212, 217, 307, 312, "trial" +439, 3, 45, 74, 218, 219, 313, 314, "." +439, 4, 1, 75, 0, 5, 315, 320, "Facio" +439, 4, 2, 76, 6, 8, 321, 323, "AC" +439, 4, 3, 77, 9, 10, 324, 325, "(" +439, 4, 4, 78, 11, 12, 326, 327, "1" +439, 4, 5, 79, 13, 14, 328, 329, ")" +439, 4, 6, 80, 15, 16, 330, 331, "," +439, 4, 7, 81, 17, 21, 332, 336, "Reis" +439, 4, 8, 82, 22, 24, 337, 339, "AS" +439, 4, 9, 83, 25, 26, 340, 341, "," +439, 4, 10, 84, 27, 32, 342, 347, "Vidal" +439, 4, 11, 85, 33, 35, 348, 350, "KS" +439, 4, 12, 86, 36, 37, 351, 352, "," +439, 4, 13, 87, 38, 40, 353, 355, "de" +439, 4, 14, 88, 41, 47, 356, 362, "Moraes" +439, 4, 15, 89, 48, 50, 363, 365, "CG" +439, 4, 16, 90, 51, 52, 366, 367, "," +439, 4, 17, 91, 53, 59, 368, 374, "Suzuki" +439, 4, 18, 92, 60, 61, 375, 376, "R" +439, 4, 19, 93, 62, 63, 377, 378, "," +439, 4, 20, 94, 64, 72, 379, 387, "Hatanaka" +439, 4, 21, 95, 73, 74, 388, 389, "M" +439, 4, 22, 96, 75, 76, 390, 391, "," +439, 4, 23, 97, 77, 84, 392, 399, "Susanna" +439, 4, 24, 98, 85, 86, 400, 401, "R" +439, 4, 25, 99, 87, 88, 402, 403, "." +439, 4, 26, 100, 89, 95, 404, 410, "Author" +439, 4, 27, 101, 96, 107, 411, 422, "information" +439, 4, 28, 102, 108, 109, 423, 424, ":" +439, 4, 29, 103, 110, 111, 425, 426, "(" +439, 4, 30, 104, 112, 113, 427, 428, "1" +439, 4, 31, 105, 114, 115, 429, 430, ")" +439, 4, 32, 106, 116, 124, 431, 439, "Glaucoma" +439, 4, 33, 107, 125, 132, 440, 447, "Service" +439, 4, 34, 108, 133, 134, 448, 449, "," +439, 4, 35, 109, 135, 145, 450, 460, "Department" +439, 4, 36, 110, 146, 148, 461, 463, "of" +439, 4, 37, 111, 149, 162, 464, 477, "Ophthalmology" +439, 4, 38, 112, 163, 164, 478, 479, "," +439, 4, 39, 113, 165, 175, 480, 490, "University" +439, 4, 40, 114, 176, 178, 491, 493, "of" +439, 4, 41, 115, 179, 180, 494, 495, "S" +439, 4, 42, 116, 181, 182, 496, 497, "ã" +439, 4, 43, 117, 183, 184, 498, 499, "o" +439, 4, 44, 118, 185, 190, 500, 505, "Paulo" +439, 4, 45, 119, 191, 197, 506, 512, "School" +439, 4, 46, 120, 198, 200, 513, 515, "of" +439, 4, 47, 121, 201, 209, 516, 524, "Medicine" +439, 4, 48, 122, 210, 211, 525, 526, "," +439, 4, 49, 123, 212, 213, 527, 528, "S" +439, 4, 50, 124, 214, 215, 529, 530, "ã" +439, 4, 51, 125, 216, 217, 531, 532, "o" +439, 4, 52, 126, 218, 223, 533, 538, "Paulo" +439, 4, 53, 127, 224, 225, 539, 540, "," +439, 4, 54, 128, 226, 232, 541, 547, "Brazil" +439, 4, 55, 129, 233, 234, 548, 549, "." +439, 5, 1, 130, 0, 12, 550, 562, "INTRODUCTION" +439, 5, 2, 131, 13, 16, 563, 566, "AND" +439, 5, 3, 132, 17, 24, 567, 574, "PURPOSE" +439, 5, 4, 133, 25, 26, 575, 576, ":" +439, 5, 5, 134, 27, 38, 577, 588, "Bimatoprost" +439, 5, 6, 135, 39, 42, 589, 592, "and" +439, 5, 7, 136, 43, 46, 593, 596, "the" +439, 5, 8, 137, 47, 52, 597, 602, "fixed" +439, 5, 9, 138, 53, 64, 603, 614, "combination" +439, 5, 10, 139, 65, 67, 615, 617, "of" +439, 5, 11, 140, 68, 79, 618, 629, "latanoprost" +439, 5, 12, 141, 80, 84, 630, 634, "with" +439, 5, 13, 142, 85, 92, 635, 642, "timolol" +439, 5, 14, 143, 93, 100, 643, 650, "maleate" +439, 5, 15, 144, 101, 104, 651, 654, "are" +439, 5, 16, 145, 105, 106, 655, 656, "2" +439, 5, 17, 146, 107, 118, 657, 668, "medications" +439, 5, 18, 147, 119, 125, 669, 675, "widely" +439, 5, 19, 148, 126, 130, 676, 680, "used" +439, 5, 20, 149, 131, 133, 681, 683, "to" +439, 5, 21, 150, 134, 139, 684, 689, "treat" +439, 5, 22, 151, 140, 148, 690, 698, "glaucoma" +439, 5, 23, 152, 149, 152, 699, 702, "and" +439, 5, 24, 153, 153, 159, 703, 709, "ocular" +439, 5, 25, 154, 160, 172, 710, 722, "hypertension" +439, 5, 26, 155, 173, 174, 723, 724, "(" +439, 5, 27, 156, 175, 178, 725, 728, "OHT" +439, 5, 28, 157, 179, 180, 729, 730, ")" +439, 5, 29, 158, 181, 182, 731, 732, "." +439, 6, 1, 159, 0, 3, 733, 736, "The" +439, 6, 2, 160, 4, 7, 737, 740, "aim" +439, 6, 3, 161, 8, 10, 741, 743, "of" +439, 6, 4, 162, 11, 14, 744, 747, "the" +439, 6, 5, 163, 15, 20, 748, 753, "study" +439, 6, 6, 164, 21, 23, 754, 756, "is" +439, 6, 7, 165, 24, 26, 757, 759, "to" +439, 6, 8, 166, 27, 34, 760, 767, "compare" +439, 6, 9, 167, 35, 38, 768, 771, "the" +439, 6, 10, 168, 39, 47, 772, 780, "efficacy" +439, 6, 11, 169, 48, 50, 781, 783, "of" +439, 6, 12, 170, 51, 56, 784, 789, "these" +439, 6, 13, 171, 57, 58, 790, 791, "2" +439, 6, 14, 172, 59, 64, 792, 797, "drugs" +439, 6, 15, 173, 65, 67, 798, 800, "in" +439, 6, 16, 174, 68, 76, 801, 809, "reducing" +439, 6, 17, 175, 77, 88, 810, 821, "intraocular" +439, 6, 18, 176, 89, 97, 822, 830, "pressure" +439, 6, 19, 177, 98, 99, 831, 832, "(" +439, 6, 20, 178, 100, 103, 833, 836, "IOP" +439, 6, 21, 179, 104, 105, 837, 838, ")" +439, 6, 22, 180, 106, 111, 839, 844, "after" +439, 6, 23, 181, 112, 113, 845, 846, "8" +439, 6, 24, 182, 114, 119, 847, 852, "weeks" +439, 6, 25, 183, 120, 122, 853, 855, "of" +439, 6, 26, 184, 123, 132, 856, 865, "treatment" +439, 6, 27, 185, 133, 135, 866, 868, "in" +439, 6, 28, 186, 136, 144, 869, 877, "patients" +439, 6, 29, 187, 145, 149, 878, 882, "with" +439, 6, 30, 188, 150, 157, 883, 890, "primary" +439, 6, 31, 189, 158, 162, 891, 895, "open" +439, 6, 32, 190, 163, 168, 896, 901, "angle" +439, 6, 33, 191, 169, 177, 902, 910, "glaucoma" +439, 6, 34, 192, 178, 179, 911, 912, "(" +439, 6, 35, 193, 180, 184, 913, 917, "POAG" +439, 6, 36, 194, 185, 186, 918, 919, ")" +439, 6, 37, 195, 187, 189, 920, 922, "or" +439, 6, 38, 196, 190, 193, 923, 926, "OHT" +439, 6, 39, 197, 194, 195, 927, 928, "." +439, 7, 1, 198, 0, 7, 929, 936, "METHODS" +439, 7, 2, 199, 8, 9, 937, 938, ":" +439, 7, 3, 200, 10, 12, 939, 941, "In" +439, 7, 4, 201, 13, 17, 942, 946, "this" +439, 7, 5, 202, 18, 28, 947, 957, "randomized" +439, 7, 6, 203, 29, 30, 958, 959, "," +439, 7, 7, 204, 31, 35, 960, 964, "open" +439, 7, 8, 205, 36, 37, 965, 966, "-" +439, 7, 9, 206, 38, 43, 967, 972, "label" +439, 7, 10, 207, 44, 49, 973, 978, "trial" +439, 7, 11, 208, 50, 51, 979, 980, "," +439, 7, 12, 209, 52, 54, 981, 983, "44" +439, 7, 13, 210, 55, 63, 984, 992, "patients" +439, 7, 14, 211, 64, 68, 993, 997, "with" +439, 7, 15, 212, 69, 73, 998, 1002, "POAG" +439, 7, 16, 213, 74, 76, 1003, 1005, "or" +439, 7, 17, 214, 77, 80, 1006, 1009, "OHT" +439, 7, 18, 215, 81, 85, 1010, 1014, "were" +439, 7, 19, 216, 86, 95, 1015, 1024, "allocated" +439, 7, 20, 217, 96, 98, 1025, 1027, "to" +439, 7, 21, 218, 99, 106, 1028, 1035, "receive" +439, 7, 22, 219, 107, 113, 1036, 1042, "either" +439, 7, 23, 220, 114, 125, 1043, 1054, "bimatoprost" +439, 7, 24, 221, 126, 127, 1055, 1056, "(" +439, 7, 25, 222, 128, 129, 1057, 1058, "1" +439, 7, 26, 223, 130, 134, 1059, 1063, "drop" +439, 7, 27, 224, 135, 137, 1064, 1066, "QD" +439, 7, 28, 225, 138, 139, 1067, 1068, ")" +439, 7, 29, 226, 140, 142, 1069, 1071, "or" +439, 7, 30, 227, 143, 154, 1072, 1083, "latanoprost" +439, 7, 31, 228, 155, 156, 1084, 1085, "/" +439, 7, 32, 229, 157, 164, 1086, 1093, "timolol" +439, 7, 33, 230, 165, 166, 1094, 1095, "(" +439, 7, 34, 231, 167, 168, 1096, 1097, "1" +439, 7, 35, 232, 169, 173, 1098, 1102, "drop" +439, 7, 36, 233, 174, 176, 1103, 1105, "QD" +439, 7, 37, 234, 177, 178, 1106, 1107, ")" +439, 7, 38, 235, 179, 180, 1108, 1109, "." +439, 8, 1, 236, 0, 7, 1110, 1117, "Primary" +439, 8, 2, 237, 8, 15, 1118, 1125, "outcome" +439, 8, 3, 238, 16, 19, 1126, 1129, "was" +439, 8, 4, 239, 20, 23, 1130, 1133, "the" +439, 8, 5, 240, 24, 28, 1134, 1138, "mean" +439, 8, 6, 241, 29, 36, 1139, 1146, "diurnal" +439, 8, 7, 242, 37, 40, 1147, 1150, "IOP" +439, 8, 8, 243, 41, 52, 1151, 1162, "measurement" +439, 8, 9, 244, 53, 55, 1163, 1165, "at" +439, 8, 10, 245, 56, 59, 1166, 1169, "the" +439, 8, 11, 246, 60, 63, 1170, 1173, "8th" +439, 8, 12, 247, 64, 68, 1174, 1178, "week" +439, 8, 13, 248, 69, 70, 1179, 1180, "," +439, 8, 14, 249, 71, 81, 1181, 1191, "calculated" +439, 8, 15, 250, 82, 84, 1192, 1194, "as" +439, 8, 16, 251, 85, 88, 1195, 1198, "the" +439, 8, 17, 252, 89, 93, 1199, 1203, "mean" +439, 8, 18, 253, 94, 97, 1204, 1207, "IOP" +439, 8, 19, 254, 98, 110, 1208, 1220, "measurements" +439, 8, 20, 255, 111, 116, 1221, 1226, "taken" +439, 8, 21, 256, 117, 119, 1227, 1229, "at" +439, 8, 22, 257, 120, 121, 1230, 1231, "8" +439, 8, 23, 258, 122, 123, 1232, 1233, ":" +439, 8, 24, 259, 124, 126, 1234, 1236, "00" +439, 8, 25, 260, 127, 129, 1237, 1239, "am" +439, 8, 26, 261, 130, 131, 1240, 1241, "," +439, 8, 27, 262, 132, 134, 1242, 1244, "10" +439, 8, 28, 263, 135, 136, 1245, 1246, ":" +439, 8, 29, 264, 137, 139, 1247, 1249, "00" +439, 8, 30, 265, 140, 142, 1250, 1252, "am" +439, 8, 31, 266, 143, 144, 1253, 1254, "," +439, 8, 32, 267, 145, 148, 1255, 1258, "and" +439, 8, 33, 268, 149, 151, 1259, 1261, "12" +439, 8, 34, 269, 152, 153, 1262, 1263, ":" +439, 8, 35, 270, 154, 156, 1264, 1266, "00" +439, 8, 36, 271, 157, 159, 1267, 1269, "pm" +439, 8, 37, 272, 160, 169, 1270, 1279, "Secondary" +439, 8, 38, 273, 170, 178, 1280, 1288, "outcomes" +439, 8, 39, 274, 179, 187, 1289, 1297, "included" +439, 8, 40, 275, 188, 191, 1298, 1301, "the" +439, 8, 41, 276, 192, 200, 1302, 1310, "baseline" +439, 8, 42, 277, 201, 207, 1311, 1317, "change" +439, 8, 43, 278, 208, 210, 1318, 1320, "in" +439, 8, 44, 279, 211, 214, 1321, 1324, "IOP" +439, 8, 45, 280, 215, 223, 1325, 1333, "measured" +439, 8, 46, 281, 224, 225, 1334, 1335, "3" +439, 8, 47, 282, 226, 231, 1336, 1341, "times" +439, 8, 48, 283, 232, 233, 1342, 1343, "a" +439, 8, 49, 284, 234, 237, 1344, 1347, "day" +439, 8, 50, 285, 238, 239, 1348, 1349, "," +439, 8, 51, 286, 240, 245, 1350, 1355, "after" +439, 8, 52, 287, 246, 249, 1356, 1359, "the" +439, 8, 53, 288, 250, 255, 1360, 1365, "water" +439, 8, 54, 289, 256, 257, 1366, 1367, "-" +439, 8, 55, 290, 258, 266, 1368, 1376, "drinking" +439, 8, 56, 291, 267, 271, 1377, 1381, "test" +439, 8, 57, 292, 272, 273, 1382, 1383, "(" +439, 8, 58, 293, 274, 283, 1384, 1393, "performed" +439, 8, 59, 294, 284, 289, 1394, 1399, "after" +439, 8, 60, 295, 290, 293, 1400, 1403, "the" +439, 8, 61, 296, 294, 298, 1404, 1408, "last" +439, 8, 62, 297, 299, 302, 1409, 1412, "IOP" +439, 8, 63, 298, 303, 314, 1413, 1424, "measurement" +439, 8, 64, 299, 315, 316, 1425, 1426, ")" +439, 8, 65, 300, 317, 318, 1427, 1428, "," +439, 8, 66, 301, 319, 322, 1429, 1432, "and" +439, 8, 67, 302, 323, 326, 1433, 1436, "the" +439, 8, 68, 303, 327, 337, 1437, 1447, "assessment" +439, 8, 69, 304, 338, 340, 1448, 1450, "of" +439, 8, 70, 305, 341, 345, 1451, 1455, "side" +439, 8, 71, 306, 346, 353, 1456, 1463, "effects" +439, 8, 72, 307, 354, 356, 1464, 1466, "of" +439, 8, 73, 308, 357, 361, 1467, 1471, "each" +439, 8, 74, 309, 362, 369, 1472, 1479, "therapy" +439, 8, 75, 310, 370, 371, 1480, 1481, "." +439, 9, 1, 311, 0, 7, 1482, 1489, "RESULTS" +439, 9, 2, 312, 8, 9, 1490, 1491, ":" +439, 9, 3, 313, 10, 13, 1492, 1495, "The" +439, 9, 4, 314, 14, 18, 1496, 1500, "mean" +439, 9, 5, 315, 19, 22, 1501, 1504, "IOP" +439, 9, 6, 316, 23, 29, 1505, 1511, "levels" +439, 9, 7, 317, 30, 32, 1512, 1514, "of" +439, 9, 8, 318, 33, 44, 1515, 1526, "latanoprost" +439, 9, 9, 319, 45, 46, 1527, 1528, "/" +439, 9, 10, 320, 47, 54, 1529, 1536, "timolol" +439, 9, 11, 321, 55, 56, 1537, 1538, "(" +439, 9, 12, 322, 57, 59, 1539, 1541, "13" +439, 9, 13, 323, 60, 61, 1542, 1543, "." +439, 9, 14, 324, 62, 64, 1544, 1546, "83" +439, 9, 15, 325, 65, 66, 1547, 1548, "," +439, 9, 16, 326, 67, 69, 1549, 1551, "SD" +439, 9, 17, 327, 70, 71, 1552, 1553, "=" +439, 9, 18, 328, 72, 73, 1554, 1555, "2" +439, 9, 19, 329, 74, 75, 1556, 1557, "." +439, 9, 20, 330, 76, 78, 1558, 1560, "54" +439, 9, 21, 331, 79, 80, 1561, 1562, ")" +439, 9, 22, 332, 81, 84, 1563, 1566, "was" +439, 9, 23, 333, 85, 98, 1567, 1580, "significantly" +439, 9, 24, 334, 99, 104, 1581, 1586, "lower" +439, 9, 25, 335, 105, 109, 1587, 1591, "than" +439, 9, 26, 336, 110, 112, 1592, 1594, "of" +439, 9, 27, 337, 113, 124, 1595, 1606, "bimatoprost" +439, 9, 28, 338, 125, 126, 1607, 1608, "(" +439, 9, 29, 339, 127, 129, 1609, 1611, "16" +439, 9, 30, 340, 130, 131, 1612, 1613, "." +439, 9, 31, 341, 132, 134, 1614, 1616, "16" +439, 9, 32, 342, 135, 136, 1617, 1618, "," +439, 9, 33, 343, 137, 139, 1619, 1621, "SD" +439, 9, 34, 344, 140, 141, 1622, 1623, "=" +439, 9, 35, 345, 142, 143, 1624, 1625, "3" +439, 9, 36, 346, 144, 145, 1626, 1627, "." +439, 9, 37, 347, 146, 148, 1628, 1630, "28" +439, 9, 38, 348, 149, 150, 1631, 1632, ";" +439, 9, 39, 349, 151, 152, 1633, 1634, "P" +439, 9, 40, 350, 153, 154, 1635, 1636, "<" +439, 9, 41, 351, 155, 156, 1637, 1638, "0" +439, 9, 42, 352, 157, 158, 1639, 1640, "." +439, 9, 43, 353, 159, 163, 1641, 1645, "0001" +439, 9, 44, 354, 164, 165, 1646, 1647, ")" +439, 9, 45, 355, 166, 168, 1648, 1650, "at" +439, 9, 46, 356, 169, 173, 1651, 1655, "week" +439, 9, 47, 357, 174, 175, 1656, 1657, "8" +439, 9, 48, 358, 176, 177, 1658, 1659, "." +439, 10, 1, 359, 0, 4, 1660, 1664, "Also" +439, 10, 2, 360, 5, 6, 1665, 1666, "," +439, 10, 3, 361, 7, 10, 1667, 1670, "the" +439, 10, 4, 362, 11, 17, 1671, 1677, "change" +439, 10, 5, 363, 18, 20, 1678, 1680, "in" +439, 10, 6, 364, 21, 25, 1681, 1685, "mean" +439, 10, 7, 365, 26, 29, 1686, 1689, "IOP" +439, 10, 8, 366, 30, 36, 1690, 1696, "values" +439, 10, 9, 367, 37, 40, 1697, 1700, "was" +439, 10, 10, 368, 41, 54, 1701, 1714, "significantly" +439, 10, 11, 369, 55, 61, 1715, 1721, "higher" +439, 10, 12, 370, 62, 64, 1722, 1724, "in" +439, 10, 13, 371, 65, 68, 1725, 1728, "the" +439, 10, 14, 372, 69, 80, 1729, 1740, "latanoprost" +439, 10, 15, 373, 81, 82, 1741, 1742, "/" +439, 10, 16, 374, 83, 90, 1743, 1750, "timolol" +439, 10, 17, 375, 91, 96, 1751, 1756, "group" +439, 10, 18, 376, 97, 99, 1757, 1759, "at" +439, 10, 19, 377, 100, 102, 1760, 1762, "10" +439, 10, 20, 378, 103, 104, 1763, 1764, ":" +439, 10, 21, 379, 105, 107, 1765, 1767, "00" +439, 10, 22, 380, 108, 110, 1768, 1770, "am" +439, 10, 23, 381, 111, 112, 1771, 1772, "(" +439, 10, 24, 382, 113, 114, 1773, 1774, "P" +439, 10, 25, 383, 115, 116, 1775, 1776, "=" +439, 10, 26, 384, 117, 118, 1777, 1778, "0" +439, 10, 27, 385, 119, 120, 1779, 1780, "." +439, 10, 28, 386, 121, 124, 1781, 1784, "013" +439, 10, 29, 387, 125, 126, 1785, 1786, ")" +439, 10, 30, 388, 127, 130, 1787, 1790, "and" +439, 10, 31, 389, 131, 133, 1791, 1793, "12" +439, 10, 32, 390, 134, 135, 1794, 1795, ":" +439, 10, 33, 391, 136, 138, 1796, 1798, "00" +439, 10, 34, 392, 139, 141, 1799, 1801, "pm" +439, 10, 35, 393, 142, 143, 1802, 1803, "(" +439, 10, 36, 394, 144, 145, 1804, 1805, "P" +439, 10, 37, 395, 146, 147, 1806, 1807, "=" +439, 10, 38, 396, 148, 149, 1808, 1809, "0" +439, 10, 39, 397, 150, 151, 1810, 1811, "." +439, 10, 40, 398, 152, 154, 1812, 1814, "01" +439, 10, 41, 399, 155, 156, 1815, 1816, ")" +439, 10, 42, 400, 157, 158, 1817, 1818, "," +439, 10, 43, 401, 159, 162, 1819, 1822, "but" +439, 10, 44, 402, 163, 166, 1823, 1826, "not" +439, 10, 45, 403, 167, 169, 1827, 1829, "at" +439, 10, 46, 404, 170, 171, 1830, 1831, "8" +439, 10, 47, 405, 172, 173, 1832, 1833, ":" +439, 10, 48, 406, 174, 176, 1834, 1836, "00" +439, 10, 49, 407, 177, 179, 1837, 1839, "am" +439, 10, 50, 408, 180, 181, 1840, 1841, "(" +439, 10, 51, 409, 182, 183, 1842, 1843, "P" +439, 10, 52, 410, 184, 185, 1844, 1845, "=" +439, 10, 53, 411, 186, 188, 1846, 1848, "ns" +439, 10, 54, 412, 189, 190, 1849, 1850, ")" +439, 10, 55, 413, 191, 192, 1851, 1852, "." +439, 11, 1, 414, 0, 6, 1853, 1859, "During" +439, 11, 2, 415, 7, 10, 1860, 1863, "the" +439, 11, 3, 416, 11, 16, 1864, 1869, "water" +439, 11, 4, 417, 17, 18, 1870, 1871, "-" +439, 11, 5, 418, 19, 27, 1872, 1880, "drinking" +439, 11, 6, 419, 28, 32, 1881, 1885, "test" +439, 11, 7, 420, 33, 34, 1886, 1887, "," +439, 11, 8, 421, 35, 40, 1888, 1893, "there" +439, 11, 9, 422, 41, 44, 1894, 1897, "was" +439, 11, 10, 423, 45, 47, 1898, 1900, "no" +439, 11, 11, 424, 48, 59, 1901, 1912, "significant" +439, 11, 12, 425, 60, 70, 1913, 1923, "difference" +439, 11, 13, 426, 71, 73, 1924, 1926, "in" +439, 11, 14, 427, 74, 77, 1927, 1930, "IOP" +439, 11, 15, 428, 78, 86, 1931, 1939, "increase" +439, 11, 16, 429, 87, 88, 1940, 1941, "(" +439, 11, 17, 430, 89, 97, 1942, 1950, "absolute" +439, 11, 18, 431, 98, 101, 1951, 1954, "and" +439, 11, 19, 432, 102, 112, 1955, 1965, "percentage" +439, 11, 20, 433, 113, 114, 1966, 1967, ")" +439, 11, 21, 434, 115, 122, 1968, 1975, "between" +439, 11, 22, 435, 123, 129, 1976, 1982, "groups" +439, 11, 23, 436, 130, 131, 1983, 1984, ";" +439, 11, 24, 437, 132, 139, 1985, 1992, "however" +439, 11, 25, 438, 140, 141, 1993, 1994, "," +439, 11, 26, 439, 142, 147, 1995, 2000, "there" +439, 11, 27, 440, 148, 151, 2001, 2004, "was" +439, 11, 28, 441, 152, 153, 2005, 2006, "a" +439, 11, 29, 442, 154, 165, 2007, 2018, "significant" +439, 11, 30, 443, 166, 174, 2019, 2027, "decrease" +439, 11, 31, 444, 175, 177, 2028, 2030, "in" +439, 11, 32, 445, 178, 182, 2031, 2035, "mean" +439, 11, 33, 446, 183, 188, 2036, 2041, "heart" +439, 11, 34, 447, 189, 193, 2042, 2046, "rate" +439, 11, 35, 448, 194, 196, 2047, 2049, "in" +439, 11, 36, 449, 197, 200, 2050, 2053, "the" +439, 11, 37, 450, 201, 212, 2054, 2065, "latanoprost" +439, 11, 38, 451, 213, 214, 2066, 2067, "/" +439, 11, 39, 452, 215, 222, 2068, 2075, "timolol" +439, 11, 40, 453, 223, 228, 2076, 2081, "group" +439, 11, 41, 454, 229, 230, 2082, 2083, "." +439, 12, 1, 455, 0, 7, 2084, 2091, "Finally" +439, 12, 2, 456, 8, 9, 2092, 2093, "," +439, 12, 3, 457, 10, 12, 2094, 2096, "no" +439, 12, 4, 458, 13, 24, 2097, 2108, "significant" +439, 12, 5, 459, 25, 32, 2109, 2116, "changes" +439, 12, 6, 460, 33, 35, 2117, 2119, "in" +439, 12, 7, 461, 36, 41, 2120, 2125, "blood" +439, 12, 8, 462, 42, 50, 2126, 2134, "pressure" +439, 12, 9, 463, 51, 54, 2135, 2138, "and" +439, 12, 10, 464, 55, 59, 2139, 2143, "lung" +439, 12, 11, 465, 60, 70, 2144, 2154, "spirometry" +439, 12, 12, 466, 71, 75, 2155, 2159, "were" +439, 12, 13, 467, 76, 84, 2160, 2168, "observed" +439, 12, 14, 468, 85, 87, 2169, 2171, "in" +439, 12, 15, 469, 88, 94, 2172, 2178, "either" +439, 12, 16, 470, 95, 101, 2179, 2185, "groups" +439, 12, 17, 471, 102, 103, 2186, 2187, "." +439, 13, 1, 472, 0, 11, 2188, 2199, "CONCLUSIONS" +439, 13, 2, 473, 12, 13, 2200, 2201, ":" +439, 13, 3, 474, 14, 17, 2202, 2205, "The" +439, 13, 4, 475, 18, 23, 2206, 2211, "fixed" +439, 13, 5, 476, 24, 35, 2212, 2223, "combination" +439, 13, 6, 477, 36, 38, 2224, 2226, "of" +439, 13, 7, 478, 39, 50, 2227, 2238, "latanoprost" +439, 13, 8, 479, 51, 52, 2239, 2240, "/" +439, 13, 9, 480, 53, 60, 2241, 2248, "timolol" +439, 13, 10, 481, 61, 64, 2249, 2252, "was" +439, 13, 11, 482, 65, 78, 2253, 2266, "significantly" +439, 13, 12, 483, 79, 87, 2267, 2275, "superior" +439, 13, 13, 484, 88, 90, 2276, 2278, "to" +439, 13, 14, 485, 91, 102, 2279, 2290, "bimatoprost" +439, 13, 15, 486, 103, 108, 2291, 2296, "alone" +439, 13, 16, 487, 109, 111, 2297, 2299, "in" +439, 13, 17, 488, 112, 120, 2300, 2308, "reducing" +439, 13, 18, 489, 121, 124, 2309, 2312, "IOP" +439, 13, 19, 490, 125, 127, 2313, 2315, "in" +439, 13, 20, 491, 128, 136, 2316, 2324, "patients" +439, 13, 21, 492, 137, 141, 2325, 2329, "with" +439, 13, 22, 493, 142, 146, 2330, 2334, "POAG" +439, 13, 23, 494, 147, 149, 2335, 2337, "or" +439, 13, 24, 495, 150, 153, 2338, 2341, "OHT" +439, 13, 25, 496, 154, 155, 2342, 2343, "." +439, 14, 1, 497, 0, 7, 2344, 2351, "Further" +439, 14, 2, 498, 8, 15, 2352, 2359, "studies" +439, 14, 3, 499, 16, 20, 2360, 2364, "with" +439, 14, 4, 500, 21, 26, 2365, 2370, "large" +439, 14, 5, 501, 27, 33, 2371, 2377, "sample" +439, 14, 6, 502, 34, 39, 2378, 2383, "sizes" +439, 14, 7, 503, 40, 46, 2384, 2390, "should" +439, 14, 8, 504, 47, 49, 2391, 2393, "be" +439, 14, 9, 505, 50, 55, 2394, 2399, "taken" +439, 14, 10, 506, 56, 58, 2400, 2402, "to" +439, 14, 11, 507, 59, 66, 2403, 2410, "support" +439, 14, 12, 508, 67, 70, 2411, 2414, "the" +439, 14, 13, 509, 71, 79, 2415, 2423, "superior" +439, 14, 14, 510, 80, 88, 2424, 2432, "efficacy" +439, 14, 15, 511, 89, 91, 2433, 2435, "of" +439, 14, 16, 512, 92, 103, 2436, 2447, "latanoprost" +439, 14, 17, 513, 104, 105, 2448, 2449, "/" +439, 14, 18, 514, 106, 113, 2450, 2457, "timolol" +439, 14, 19, 515, 114, 115, 2458, 2459, "," +439, 14, 20, 516, 116, 118, 2460, 2462, "as" +439, 14, 21, 517, 119, 123, 2463, 2467, "well" +439, 14, 22, 518, 124, 126, 2468, 2470, "as" +439, 14, 23, 519, 127, 129, 2471, 2473, "to" +439, 14, 24, 520, 130, 136, 2474, 2480, "better" +439, 14, 25, 521, 137, 143, 2481, 2487, "assess" +439, 14, 26, 522, 144, 147, 2488, 2491, "its" +439, 14, 27, 523, 148, 155, 2492, 2499, "profile" +439, 14, 28, 524, 156, 158, 2500, 2502, "of" +439, 14, 29, 525, 159, 163, 2503, 2507, "side" +439, 14, 30, 526, 164, 171, 2508, 2515, "effects" +439, 14, 31, 527, 172, 173, 2516, 2517, "." +439, 15, 1, 528, 0, 3, 2518, 2521, "DOI" +439, 15, 2, 529, 4, 5, 2522, 2523, ":" +439, 15, 3, 530, 6, 8, 2524, 2526, "10" +439, 15, 4, 531, 9, 10, 2527, 2528, "." +439, 15, 5, 532, 11, 15, 2529, 2533, "1089" +439, 15, 6, 533, 16, 17, 2534, 2535, "/" +439, 15, 7, 534, 18, 21, 2536, 2539, "jop" +439, 15, 8, 535, 22, 23, 2540, 2541, "." +439, 15, 9, 536, 24, 28, 2542, 2546, "2009" +439, 15, 10, 537, 29, 30, 2547, 2548, "." +439, 15, 11, 538, 31, 35, 2549, 2553, "0018" +439, 15, 12, 539, 36, 40, 2554, 2558, "PMID" +439, 15, 13, 540, 41, 42, 2559, 2560, ":" +439, 15, 14, 541, 43, 51, 2561, 2569, "19860553" +439, 15, 15, 542, 52, 53, 2570, 2571, "[" +439, 15, 16, 543, 54, 61, 2572, 2579, "Indexed" +439, 15, 17, 544, 62, 65, 2580, 2583, "for" +439, 15, 18, 545, 66, 73, 2584, 2591, "MEDLINE" +439, 15, 19, 546, 74, 75, 2592, 2593, "]" diff --git a/data/gl 19860553_jshahinitiran.annodb b/data/gl 19860553_jshahinitiran.annodb new file mode 100644 index 0000000..b799b64 --- /dev/null +++ b/data/gl 19860553_jshahinitiran.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15178, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +15179, PublicationYear, 24, 28, "2009", "", +15180, Title, 95, 314, "A comparison of bimatoprost 0 . 03 % versus the fixed - combination of latanoprost 0 . 005 % and timolol 0 . 5 % in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label trial .", "", +28281, Bimatoprost, 111, 122, "bimatoprost", "", +15468, DoseValue, 123, 129, "0 . 03", "", +15469, Percentage, 130, 131, "%", "", +28282, Latanoprost, 166, 177, "latanoprost", "", +15471, DoseValue, 178, 185, "0 . 005", "", +15474, Percentage, 186, 187, "%", "", +28283, Timolol, 192, 199, "timolol", "", +15472, DoseValue, 200, 205, "0 . 5", "", +15473, Percentage, 206, 207, "%", "", +15478, Precondition, 211, 216, "adult", "", +15477, Precondition, 231, 260, "elevated intraocular pressure", "", +15488, IOP, 240, 260, "intraocular pressure", "", +15476, Duration, 266, 278, "eight - week", "", +28284, Randomized, 281, 291, "randomized", "", +28285, OpenLabel, 294, 306, "open - label", "", +15181, Author, 315, 323, "Facio AC", "", +15182, Author, 332, 339, "Reis AS", "", +15183, Author, 342, 350, "Vidal KS", "", +15184, Author, 353, 365, "de Moraes CG", "", +15185, Author, 368, 376, "Suzuki R", "", +15186, Author, 379, 389, "Hatanaka M", "", +15187, Author, 392, 401, "Susanna R", "", +15188, Brazil, 541, 547, "Brazil", "", +28286, Bimatoprost, 577, 588, "Bimatoprost", "", +28287, Latanoprost, 618, 629, "latanoprost", "", +28288, Timolol, 635, 650, "timolol maleate", "", +15484, Glaucoma, 690, 698, "glaucoma", "", +15485, OcularHypertension, 703, 722, "ocular hypertension", "", +28289, OcularHypertension, 725, 728, "OHT", "", +15487, ObjectiveDescription, 733, 928, "The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure ( IOP ) after 8 weeks of treatment in patients with primary open angle glaucoma ( POAG ) or OHT .", "", +15489, IOP, 810, 830, "intraocular pressure", "", +15490, IOP, 833, 836, "IOP", "", +15476, Duration, 845, 852, "8 weeks", "", +28290, Primary_OpenAngleGlaucoma, 883, 910, "primary open angle glaucoma", "", +28291, Primary_OpenAngleGlaucoma, 913, 917, "POAG", "", +28292, OcularHypertension, 923, 926, "OHT", "", +28293, Randomized, 947, 957, "randomized", "", +28294, OpenLabel, 960, 972, "open - label", "", +15497, NumberPatientsCT, 981, 983, "44", "", +28295, Primary_OpenAngleGlaucoma, 998, 1002, "POAG", "", +28296, OcularHypertension, 1006, 1009, "OHT", "", +28297, Bimatoprost, 1043, 1054, "bimatoprost", "", +15542, Eyedrops, 1059, 1063, "drop", "", +15501, Frequency, 1064, 1066, "QD", "", +28298, Latanoprost, 1072, 1083, "latanoprost", "", +28299, Timolol, 1086, 1093, "timolol", "", +15541, Eyedrops, 1098, 1102, "drop", "", +15504, Frequency, 1103, 1105, "QD", "", +15505, Mean, 1134, 1138, "mean", "", +15506, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +28300, TimePoint, 1170, 1178, "8th week", "", +15508, Mean, 1199, 1203, "mean", "", +15509, IOP, 1204, 1207, "IOP", "", +15543, IOP, 1321, 1324, "IOP", "", +28301, IOP, 1409, 1412, "IOP", "", +15510, Mean, 1496, 1500, "mean", "", +15511, IOP, 1501, 1504, "IOP", "", +28302, Latanoprost, 1515, 1526, "latanoprost", "", +28303, Timolol, 1529, 1536, "timolol", "", +15514, ResultMeasuredValue, 1539, 1546, "13 . 83", "", +15515, SdDevResValue, 1554, 1560, "2 . 54", "", +28304, Bimatoprost, 1595, 1606, "bimatoprost", "", +15517, ResultMeasuredValue, 1609, 1616, "16 . 16", "", +15518, SdDevResValue, 1624, 1630, "3 . 28", "", +15519, PValueResValue, 1633, 1645, "P < 0 . 0001", "", +28305, TimePoint, 1651, 1657, "week 8", "", +15521, Mean, 1681, 1685, "mean", "", +15522, IOP, 1686, 1689, "IOP", "", +28306, Latanoprost, 1729, 1740, "latanoprost", "", +28307, Timolol, 1743, 1750, "timolol", "", +15546, PvalueDiff, 1773, 1784, "P = 0 . 013", "", +15545, PvalueDiff, 1804, 1814, "P = 0 . 01", "", +15544, PvalueDiff, 1842, 1848, "P = ns", "", +15528, IOP, 1927, 1930, "IOP", "", +15548, Mean, 2031, 2035, "mean", "", +15547, HeartRate, 2036, 2046, "heart rate", "", +28308, Latanoprost, 2054, 2065, "latanoprost", "", +28309, Timolol, 2068, 2075, "timolol", "", +15529, BloodPressure, 2120, 2134, "blood pressure", "", +15539, ConclusionComment, 2202, 2343, "The fixed combination of latanoprost / timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT .", "", +28310, Latanoprost, 2227, 2238, "latanoprost", "", +28311, Timolol, 2241, 2248, "timolol", "", +28312, Bimatoprost, 2279, 2290, "bimatoprost", "", +15533, IOP, 2309, 2312, "IOP", "", +28313, Primary_OpenAngleGlaucoma, 2330, 2334, "POAG", "", +28314, OcularHypertension, 2338, 2341, "OHT", "", +15540, ConclusionComment, 2344, 2517, "Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost / timolol , as well as to better assess its profile of side effects .", "", +28315, Latanoprost, 2436, 2447, "latanoprost", "", +28316, Timolol, 2450, 2457, "timolol", "", +15538, PMID, 2561, 2569, "19860553", "", diff --git a/data/gl 19860553_jshahinitiran.n-triples b/data/gl 19860553_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19860553_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 19860553_tstrakeljahn.annodb b/data/gl 19860553_tstrakeljahn.annodb new file mode 100644 index 0000000..78d5b83 --- /dev/null +++ b/data/gl 19860553_tstrakeljahn.annodb @@ -0,0 +1,97 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13548, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +13549, PublicationYear, 24, 28, "2009", "", +13563, Title, 95, 312, "A comparison of bimatoprost 0 . 03 % versus the fixed - combination of latanoprost 0 . 005 % and timolol 0 . 5 % in adult patients with elevated intraocular pressure : an eight - week , randomized , open - label trial", "", +13550, Bimatoprost, 111, 122, "bimatoprost", "", +13557, DoseValue, 123, 129, "0 . 03", "", +13560, Percentage, 130, 131, "%", "", +13551, Latanoprost, 166, 177, "latanoprost", "", +13558, DoseValue, 178, 185, "0 . 005", "", +13561, Percentage, 186, 187, "%", "", +13552, Timolol, 192, 199, "timolol", "", +13559, DoseValue, 200, 205, "0 . 5", "", +13562, Percentage, 206, 207, "%", "", +13553, Precondition, 231, 260, "elevated intraocular pressure", "", +13554, Duration, 266, 278, "eight - week", "", +13555, Randomized, 281, 291, "randomized", "", +13556, OpenLabel, 294, 306, "open - label", "", +13564, Author, 315, 323, "Facio AC", "", +13565, Author, 332, 339, "Reis AS", "", +13566, Author, 342, 350, "Vidal KS", "", +13567, Author, 353, 365, "de Moraes CG", "", +13568, Author, 368, 376, "Suzuki R", "", +13569, Author, 379, 389, "Hatanaka M", "", +13570, Author, 392, 401, "Susanna R", "", +13571, Brazil, 541, 547, "Brazil", "", +13572, Bimatoprost, 577, 588, "Bimatoprost", "", +13578, ObjectiveDescription, 577, 732, "Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension ( OHT ) .", "", +13573, Latanoprost, 618, 629, "latanoprost", "", +13574, Timolol, 635, 642, "timolol", "", +13575, Glaucoma, 690, 698, "glaucoma", "", +13576, OcularHypertension, 703, 722, "ocular hypertension", "", +13577, OcularHypertension, 725, 728, "OHT", "", +13583, ObjectiveDescription, 733, 928, "The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure ( IOP ) after 8 weeks of treatment in patients with primary open angle glaucoma ( POAG ) or OHT .", "", +13579, IOP, 810, 830, "intraocular pressure", "", +13580, IOP, 833, 836, "IOP", "", +13581, OpenAngleGlaucoma, 891, 910, "open angle glaucoma", "", +13582, OcularHypertension, 923, 926, "OHT", "", +13584, Randomized, 947, 957, "randomized", "", +13585, OpenLabel, 960, 972, "open - label", "", +13586, NumberPatientsCT, 981, 983, "44", "", +13587, OcularHypertension, 1006, 1009, "OHT", "", +13588, Bimatoprost, 1043, 1054, "bimatoprost", "", +13589, DoseValue, 1057, 1058, "1", "", +13592, Eyedrops, 1059, 1063, "drop", "", +13590, Frequency, 1064, 1066, "QD", "", +13595, Latanoprost, 1072, 1083, "latanoprost", "", +13596, Timolol, 1086, 1093, "timolol", "", +13594, DoseValue, 1096, 1097, "1", "", +13593, Eyedrops, 1098, 1102, "drop", "", +13591, Frequency, 1103, 1105, "QD", "", +13597, Mean, 1134, 1138, "mean", "", +13598, Diurnal_IOP, 1139, 1150, "diurnal IOP", "", +13599, Mean, 1199, 1203, "mean", "", +13600, IOP, 1204, 1207, "IOP", "", +13601, IOP, 1321, 1324, "IOP", "", +13602, IOP, 1409, 1412, "IOP", "", +13603, Mean, 1496, 1500, "mean", "", +13604, IOP, 1501, 1504, "IOP", "", +13605, Latanoprost, 1515, 1526, "latanoprost", "", +13606, Timolol, 1529, 1536, "timolol", "", +13607, ResultMeasuredValue, 1539, 1546, "13 . 83", "", +13608, SdDevResValue, 1554, 1560, "2 . 54", "", +13609, Bimatoprost, 1595, 1606, "bimatoprost", "", +13610, ResultMeasuredValue, 1609, 1616, "16 . 16", "", +13611, SdDevResValue, 1624, 1630, "3 . 28", "", +13612, PvalueDiff, 1633, 1645, "P < 0 . 0001", "", +13613, TimePoint, 1651, 1657, "week 8", "", +13624, ObservedResult, 1660, 1848, "Also , the change in mean IOP values was significantly higher in the latanoprost / timolol group at 10 : 00 am ( P = 0 . 013 ) and 12 : 00 pm ( P = 0 . 01 ) , but not at 8 : 00 am ( P = ns", "", +13614, Mean, 1681, 1685, "mean", "", +13615, IOP, 1686, 1689, "IOP", "", +13616, Latanoprost, 1729, 1740, "latanoprost", "", +13617, Timolol, 1743, 1750, "timolol", "", +13618, TimePoint, 1760, 1770, "10 : 00 am", "", +13621, PvalueDiff, 1773, 1784, "P = 0 . 013", "", +13619, TimePoint, 1791, 1801, "12 : 00 pm", "", +13622, PvalueDiff, 1804, 1814, "P = 0 . 01", "", +13620, TimePoint, 1830, 1839, "8 : 00 am", "", +13623, PvalueDiff, 1842, 1848, "P = ns", "not significant", +13631, ObservedResult, 1853, 1982, "During the water - drinking test , there was no significant difference in IOP increase ( absolute and percentage ) between groups", "", +13625, IOP, 1927, 1930, "IOP", "", +13630, ObservedResult, 1995, 2081, "there was a significant decrease in mean heart rate in the latanoprost / timolol group", "", +13626, Mean, 2031, 2035, "mean", "", +13627, HeartRate, 2036, 2046, "heart rate", "", +13628, Latanoprost, 2054, 2065, "latanoprost", "", +13629, Timolol, 2068, 2075, "timolol", "", +13633, ObservedResult, 2084, 2187, "Finally , no significant changes in blood pressure and lung spirometry were observed in either groups .", "", +13632, BloodPressure, 2120, 2134, "blood pressure", "", +13642, ConclusionComment, 2202, 2343, "The fixed combination of latanoprost / timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT .", "", +13634, Latanoprost, 2227, 2238, "latanoprost", "", +13635, Timolol, 2241, 2248, "timolol", "", +13636, Bimatoprost, 2279, 2290, "bimatoprost", "", +13637, IOP, 2309, 2312, "IOP", "", +13638, OcularHypertension, 2338, 2341, "OHT", "", +13641, ConclusionComment, 2344, 2517, "Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost / timolol , as well as to better assess its profile of side effects .", "", +13639, Latanoprost, 2436, 2447, "latanoprost", "", +13640, Timolol, 2450, 2457, "timolol", "", +13643, PMID, 2561, 2569, "19860553", "", diff --git a/data/gl 19860553_tstrakeljahn.n-triples b/data/gl 19860553_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 19860553_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20019759 copy_admin.annodb b/data/gl 20019759 copy_admin.annodb new file mode 100644 index 0000000..58d5dad --- /dev/null +++ b/data/gl 20019759 copy_admin.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2010", "", " \"2010\"." +2, Title, 105, 247, "Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension .", "", " \"Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension .\"." +96, Lat/TimFC, 150, 171, "latanoprost / timolol", "", +3, Latanoprost, 150, 161, "latanoprost", "", +4, Timolol, 164, 171, "timolol", "", +97, Dorz/TimFC, 176, 197, "dorzolamide / timolol", "", +5, Dorzolamide, 176, 187, "dorzolamide", "", +6, Timolol, 190, 197, "timolol", "", +7, OpenAngleGlaucoma, 201, 222, "open - angle glaucoma", "", +8, OcularHypertension, 226, 245, "ocular hypertension", "", +9, Author, 248, 257, "Miglior S", "", " \"Miglior S\"." +10, Author, 266, 276, "Grunden JW", "", " \"Grunden JW\"." +11, Author, 279, 285, "Kwok K", "", " \"Kwok K\"." +104, Lat/TimFC, 288, 295, "Xalacom", "", +103, Dorz/TimFC, 298, 304, "Cosopt", "", +106, Author, 344, 351, "Denis P", "", +107, Author, 354, 364, "Mouriaux F", "", +108, Author, 367, 375, "Peigne G", "", +109, Author, 378, 387, "Ridings B", "", +110, Author, 390, 397, "Rigal D", "", +111, Author, 400, 408, "Christ T", "", +112, Author, 411, 419, "Deuker H", "", +113, Author, 422, 432, "Hamacher T", "", +114, Author, 435, 445, "Hoffmann M", "", +115, Author, 448, 457, "Jelinek C", "", +116, Author, 460, 471, "Scherzer ML", "", +117, Author, 474, 486, "Karabatsas K", "", +118, Author, 489, 498, "Konstas A", "", +119, Author, 501, 513, "Kozombolis V", "", +120, Author, 516, 529, "Tsilimbaris M", "", +121, Author, 532, 541, "Carassa R", "", +122, Author, 544, 556, "Delle Noci N", "", +123, Author, 559, 567, "Iester M", "", +124, Author, 570, 584, "Mastropasqua L", "", +125, Author, 587, 596, "Miglior S", "", +126, Author, 599, 606, "Nardi M", "", +127, Author, 609, 618, "Chatila A", "", +128, Author, 621, 628, "Heijl A", "", +129, Author, 631, 641, "Lindblom B", "", +130, Author, 644, 652, "Vancea L", "", +12, Italy, 772, 777, "Italy", "", +13, ObjectiveDescription, 819, 990, "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .", "", " \"To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .\"." +14, IOP, 830, 850, "intraocular pressure", "", +15, IOP, 853, 856, "IOP", "", +16, Lat/TimFC, 875, 923, "fixed - combination ( FC ) latanoprost / timolol", "", +20, Latanoprost, 902, 913, "latanoprost", "", +21, Timolol, 916, 923, "timolol", "", +17, Frequency, 924, 934, "once daily", "", " \"once daily\"." +137, Evening, 935, 949, "in the evening", "", " ." +18, Dorz/TimFC, 950, 976, "vsFC dorzolamide / timolol", "", +22, Dorzolamide, 955, 966, "dorzolamide", "", +23, Timolol, 969, 976, "timolol", "", +19, Frequency, 977, 988, "twice daily", "", " \"twice daily\"." +24, Blind, 1006, 1024, "evaluator - masked", "", " ." +25, Multicenter, 1027, 1038, "multicentre", "", " ." +26, Randomized, 1067, 1077, "randomized", "", " ." +152, Precondition, 1078, 1243, "subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )", "", " \"subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )\"." +27, Primary_OpenAngleGlaucoma, 1092, 1121, "primary open - angle glaucoma", "", " ." +28, OcularHypertension, 1125, 1144, "ocular hypertension", "", " ." +30, IOP, 1150, 1153, "IOP", "", +31, IOP, 1218, 1221, "IOP", "", +32, mmHg, 1236, 1241, "mm Hg", "", +33, Lat/TimFC, 1247, 1271, "FC latanoprost - timolol", "", " ." +34, Latanoprost, 1250, 1261, "latanoprost", "", +35, Timolol, 1264, 1271, "timolol", "", +36, NumberPatientsArm, 1278, 1281, "135", "", " \"135\"." +37, Dorz/TimFC, 1287, 1311, "FC dorzolamide / timolol", "", " ." +38, Dorzolamide, 1290, 1301, "dorzolamide", "", +39, Timolol, 1304, 1311, "timolol", "", +40, NumberPatientsArm, 1318, 1321, "135", "", " \"135\"." +41, TimePoint, 1329, 1338, "screening", "", +42, TimePoint, 1341, 1349, "baseline", "", +43, TimePoint, 1362, 1376, "4 and 12 weeks", "", +44, TimePoint, 1368, 1376, "12 weeks", "", +45, IOP, 1390, 1393, "IOP", "", +162, TimePoint, 1422, 1426, "0800", "", +163, TimePoint, 1429, 1433, "1200", "", +164, TimePoint, 1440, 1444, "1600", "", +46, Mean, 1620, 1624, "mean", "", +88228, Diurnal_IOP, 1625, 1636, "daytime IOP", "", +48, TimePoint, 1642, 1650, "baseline", "", +49, TimePoint, 1654, 1661, "week 12", "", +50, Mean, 1674, 1678, "Mean", "", +88233, Diurnal_IOP, 1679, 1690, "daytime IOP", "", +52, TimePoint, 1714, 1722, "baseline", "", +53, Mean, 1725, 1729, "Mean", "", " . ." +88234, Diurnal_IOP, 1744, 1755, "daytime IOP", "", " ." +55, TimePoint, 1761, 1769, "baseline", "", +56, TimePoint, 1773, 1780, "week 12", "", " \"week 12\". \"week 12\"." +57, Reduction, 1788, 1793, "9 . 7", "", " \"9 . 7\"." +59, mmHg, 1794, 1799, "mm Hg", "", " ." +61, Lat/TimFC, 1804, 1828, "FC latanoprost - timolol", "", +62, Latanoprost, 1807, 1818, "latanoprost", "", +63, Timolol, 1821, 1828, "timolol", "", +58, Reduction, 1835, 1840, "9 . 5", "", " \"9 . 5\"." +60, mmHg, 1841, 1846, "mm Hg", "", +64, Dorz/TimFC, 1851, 1875, "FC dorzolamide / timolol", "", +65, Dorzolamide, 1854, 1865, "dorzolamide", "", +66, Timolol, 1868, 1875, "timolol", "", +67, Lat/TimFC, 1901, 1925, "FC latanoprost / timolol", "", +69, Latanoprost, 1904, 1915, "latanoprost", "", +70, Timolol, 1918, 1925, "timolol", "", +68, Dorz/TimFC, 1928, 1952, "FC dorzolamide - timolol", "", +189, Dorzolamide, 1931, 1942, "dorzolamide", "", +71, Timolol, 1945, 1952, "timolol", "", +72, DiffGroupAbsValue, 1959, 1964, "0 . 2", "", " \"0 . 2\"." +73, mmHg, 1965, 1970, "mm Hg", "", +106226, ConfIntervalDiff, 1973, 2031, "95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg", "", " \"95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg\"." +194, mmHg, 2026, 2031, "mm Hg", "", +75, mmHg, 2079, 2084, "mm Hg", "", +88236, ObservedResult, 2151, 2210, "a significantly greater percentage of subjects treated with", "", " \"a significantly greater percentage of subjects treated with\". \"achieved\". \"a significantly greater percentage of subjects treated with\". \"achieved\"." +76, Lat/TimFC, 2211, 2235, "FC latanoprost / timolol", "", +77, Latanoprost, 2214, 2225, "latanoprost", "", +78, Timolol, 2228, 2235, "timolol", "", +88236, ObservedResult, 2236, 2244, "achieved", "", " \"achieved\". \"achieved\"." +119901, IOP_target, 2245, 2279, "IOP levels < or = 16 and < or = 15", "", " ." +80, mmHg, 2280, 2285, "mm Hg", "", +203, PvalueDiff, 2288, 2303, "P < or = 0 . 01", "", " \"P < or = 0 . 01\"." +82, ConclusionComment, 2360, 2530, "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .", "", " \"When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .\"." +83, IOP, 2438, 2441, "IOP", "", +84, Lat/TimFC, 2454, 2478, "FC latanoprost / timolol", "", +85, Latanoprost, 2457, 2468, "latanoprost", "", +86, Timolol, 2471, 2478, "timolol", "", +87, mmHg, 2523, 2528, "mm Hg", "", +88, ConclusionComment, 2531, 2561, "Both FCs were well tolerated .", "", " \"Both FCs were well tolerated .\"." +89, PMID, 2604, 2612, "20019759", "", " \"20019759\"." diff --git a/data/gl 20019759 copy_admin.n-triples b/data/gl 20019759 copy_admin.n-triples new file mode 100644 index 0000000..c20f8f7 --- /dev/null +++ b/data/gl 20019759 copy_admin.n-triples @@ -0,0 +1,122 @@ +# RDF export of group: Publication + . + "Publication 107761" . + "Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension ." . + "Miglior S" . + "2010" . + "Eye ( Lond ) ." . + "20019759" . + . + "Grunden JW" . + "Kwok K" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 107768" . + "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily ." . + . + . + . + "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg ." . + . + . + . + . + . + . + . + "Both FCs were well tolerated ." . + . + . + . +# RDF export of group: Population + . + "Population 107784" . + "subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )" . + . + . + . +# RDF export of group: Endpoint + . + "diop" . + . + . + . + . + . + . + "iopt" . + . + . + . + . +# RDF export of group: Arm + . + "lati" . + "135" . + . + . + . + . + . + "doti" . + "135" . + . + . + . + . +# RDF export of group: Intervention + . + "lati" . + . + "once daily" . + . + . + "doti" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "lati" . + . + . + . + . + "doti" . + . + . + . +# RDF export of group: Outcome + . + "diop1" . + . + "9 . 7" . + "week 12" . + . + "diop2" . + . + "9 . 5" . + "week 12" . + . + "iopt1" . + . + "a significantly greater percentage of subjects treated with" . + "achieved" . + . + "iopt2" . + . + "a significantly greater percentage of subjects treated with" . + "achieved" . +# RDF export of group: DiffBetweenGroups + . + "diop" . + "0 . 2" . + "95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg" . + . + . + . + "iopt" . + "P < or = 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20019759 copy_export.csv b/data/gl 20019759 copy_export.csv new file mode 100644 index 0000000..1eae512 --- /dev/null +++ b/data/gl 20019759 copy_export.csv @@ -0,0 +1,570 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +835, 1, 1, 1, 0, 3, 0, 3, "Eye" +835, 1, 2, 2, 4, 5, 4, 5, "(" +835, 1, 3, 3, 6, 10, 6, 10, "Lond" +835, 1, 4, 4, 11, 12, 11, 12, ")" +835, 1, 5, 5, 13, 14, 13, 14, "." +835, 2, 1, 6, 0, 4, 15, 19, "2010" +835, 2, 2, 7, 5, 8, 20, 23, "Jul" +835, 2, 3, 8, 9, 10, 24, 25, ";" +835, 2, 4, 9, 11, 13, 26, 28, "24" +835, 2, 5, 10, 14, 15, 29, 30, "(" +835, 2, 6, 11, 16, 17, 31, 32, "7" +835, 2, 7, 12, 18, 19, 33, 34, ")" +835, 2, 8, 13, 20, 21, 35, 36, ":" +835, 2, 9, 14, 22, 26, 37, 41, "1234" +835, 2, 10, 15, 27, 28, 42, 43, "-" +835, 2, 11, 16, 29, 31, 44, 46, "42" +835, 2, 12, 17, 32, 33, 47, 48, "." +835, 2, 13, 18, 34, 37, 49, 52, "doi" +835, 2, 14, 19, 38, 39, 53, 54, ":" +835, 2, 15, 20, 40, 42, 55, 57, "10" +835, 2, 16, 21, 43, 44, 58, 59, "." +835, 2, 17, 22, 45, 49, 60, 64, "1038" +835, 2, 18, 23, 50, 51, 65, 66, "/" +835, 2, 19, 24, 52, 55, 67, 70, "eye" +835, 2, 20, 25, 56, 57, 71, 72, "." +835, 2, 21, 26, 58, 62, 73, 77, "2009" +835, 2, 22, 27, 63, 64, 78, 79, "." +835, 2, 23, 28, 65, 68, 80, 83, "307" +835, 2, 24, 29, 69, 70, 84, 85, "." +835, 3, 1, 30, 0, 4, 86, 90, "Epub" +835, 3, 2, 31, 5, 9, 91, 95, "2009" +835, 3, 3, 32, 10, 13, 96, 99, "Dec" +835, 3, 4, 33, 14, 16, 100, 102, "18" +835, 3, 5, 34, 17, 18, 103, 104, "." +835, 4, 1, 35, 0, 8, 105, 113, "Efficacy" +835, 4, 2, 36, 9, 12, 114, 117, "and" +835, 4, 3, 37, 13, 19, 118, 124, "safety" +835, 4, 4, 38, 20, 22, 125, 127, "of" +835, 4, 5, 39, 23, 28, 128, 133, "fixed" +835, 4, 6, 40, 29, 41, 134, 146, "combinations" +835, 4, 7, 41, 42, 44, 147, 149, "of" +835, 4, 8, 42, 45, 56, 150, 161, "latanoprost" +835, 4, 9, 43, 57, 58, 162, 163, "/" +835, 4, 10, 44, 59, 66, 164, 171, "timolol" +835, 4, 11, 45, 67, 70, 172, 175, "and" +835, 4, 12, 46, 71, 82, 176, 187, "dorzolamide" +835, 4, 13, 47, 83, 84, 188, 189, "/" +835, 4, 14, 48, 85, 92, 190, 197, "timolol" +835, 4, 15, 49, 93, 95, 198, 200, "in" +835, 4, 16, 50, 96, 100, 201, 205, "open" +835, 4, 17, 51, 101, 102, 206, 207, "-" +835, 4, 18, 52, 103, 108, 208, 213, "angle" +835, 4, 19, 53, 109, 117, 214, 222, "glaucoma" +835, 4, 20, 54, 118, 120, 223, 225, "or" +835, 4, 21, 55, 121, 127, 226, 232, "ocular" +835, 4, 22, 56, 128, 140, 233, 245, "hypertension" +835, 4, 23, 57, 141, 142, 246, 247, "." +835, 5, 1, 58, 0, 7, 248, 255, "Miglior" +835, 5, 2, 59, 8, 9, 256, 257, "S" +835, 5, 3, 60, 10, 11, 258, 259, "(" +835, 5, 4, 61, 12, 13, 260, 261, "1" +835, 5, 5, 62, 14, 15, 262, 263, ")" +835, 5, 6, 63, 16, 17, 264, 265, "," +835, 5, 7, 64, 18, 25, 266, 273, "Grunden" +835, 5, 8, 65, 26, 28, 274, 276, "JW" +835, 5, 9, 66, 29, 30, 277, 278, "," +835, 5, 10, 67, 31, 35, 279, 283, "Kwok" +835, 5, 11, 68, 36, 37, 284, 285, "K" +835, 5, 12, 69, 38, 39, 286, 287, ";" +835, 5, 13, 70, 40, 47, 288, 295, "Xalacom" +835, 5, 14, 71, 48, 49, 296, 297, "/" +835, 5, 15, 72, 50, 56, 298, 304, "Cosopt" +835, 5, 16, 73, 57, 65, 305, 313, "European" +835, 5, 17, 74, 66, 71, 314, 319, "Study" +835, 5, 18, 75, 72, 77, 320, 325, "Group" +835, 5, 19, 76, 78, 79, 326, 327, "." +835, 6, 1, 77, 0, 13, 328, 341, "Collaborators" +835, 6, 2, 78, 14, 15, 342, 343, ":" +835, 6, 3, 79, 16, 21, 344, 349, "Denis" +835, 6, 4, 80, 22, 23, 350, 351, "P" +835, 6, 5, 81, 24, 25, 352, 353, "," +835, 6, 6, 82, 26, 34, 354, 362, "Mouriaux" +835, 6, 7, 83, 35, 36, 363, 364, "F" +835, 6, 8, 84, 37, 38, 365, 366, "," +835, 6, 9, 85, 39, 45, 367, 373, "Peigne" +835, 6, 10, 86, 46, 47, 374, 375, "G" +835, 6, 11, 87, 48, 49, 376, 377, "," +835, 6, 12, 88, 50, 57, 378, 385, "Ridings" +835, 6, 13, 89, 58, 59, 386, 387, "B" +835, 6, 14, 90, 60, 61, 388, 389, "," +835, 6, 15, 91, 62, 67, 390, 395, "Rigal" +835, 6, 16, 92, 68, 69, 396, 397, "D" +835, 6, 17, 93, 70, 71, 398, 399, "," +835, 6, 18, 94, 72, 78, 400, 406, "Christ" +835, 6, 19, 95, 79, 80, 407, 408, "T" +835, 6, 20, 96, 81, 82, 409, 410, "," +835, 6, 21, 97, 83, 89, 411, 417, "Deuker" +835, 6, 22, 98, 90, 91, 418, 419, "H" +835, 6, 23, 99, 92, 93, 420, 421, "," +835, 6, 24, 100, 94, 102, 422, 430, "Hamacher" +835, 6, 25, 101, 103, 104, 431, 432, "T" +835, 6, 26, 102, 105, 106, 433, 434, "," +835, 6, 27, 103, 107, 115, 435, 443, "Hoffmann" +835, 6, 28, 104, 116, 117, 444, 445, "M" +835, 6, 29, 105, 118, 119, 446, 447, "," +835, 6, 30, 106, 120, 127, 448, 455, "Jelinek" +835, 6, 31, 107, 128, 129, 456, 457, "C" +835, 6, 32, 108, 130, 131, 458, 459, "," +835, 6, 33, 109, 132, 140, 460, 468, "Scherzer" +835, 6, 34, 110, 141, 143, 469, 471, "ML" +835, 6, 35, 111, 144, 145, 472, 473, "," +835, 6, 36, 112, 146, 156, 474, 484, "Karabatsas" +835, 6, 37, 113, 157, 158, 485, 486, "K" +835, 6, 38, 114, 159, 160, 487, 488, "," +835, 6, 39, 115, 161, 168, 489, 496, "Konstas" +835, 6, 40, 116, 169, 170, 497, 498, "A" +835, 6, 41, 117, 171, 172, 499, 500, "," +835, 6, 42, 118, 173, 183, 501, 511, "Kozombolis" +835, 6, 43, 119, 184, 185, 512, 513, "V" +835, 6, 44, 120, 186, 187, 514, 515, "," +835, 6, 45, 121, 188, 199, 516, 527, "Tsilimbaris" +835, 6, 46, 122, 200, 201, 528, 529, "M" +835, 6, 47, 123, 202, 203, 530, 531, "," +835, 6, 48, 124, 204, 211, 532, 539, "Carassa" +835, 6, 49, 125, 212, 213, 540, 541, "R" +835, 6, 50, 126, 214, 215, 542, 543, "," +835, 6, 51, 127, 216, 221, 544, 549, "Delle" +835, 6, 52, 128, 222, 226, 550, 554, "Noci" +835, 6, 53, 129, 227, 228, 555, 556, "N" +835, 6, 54, 130, 229, 230, 557, 558, "," +835, 6, 55, 131, 231, 237, 559, 565, "Iester" +835, 6, 56, 132, 238, 239, 566, 567, "M" +835, 6, 57, 133, 240, 241, 568, 569, "," +835, 6, 58, 134, 242, 254, 570, 582, "Mastropasqua" +835, 6, 59, 135, 255, 256, 583, 584, "L" +835, 6, 60, 136, 257, 258, 585, 586, "," +835, 6, 61, 137, 259, 266, 587, 594, "Miglior" +835, 6, 62, 138, 267, 268, 595, 596, "S" +835, 6, 63, 139, 269, 270, 597, 598, "," +835, 6, 64, 140, 271, 276, 599, 604, "Nardi" +835, 6, 65, 141, 277, 278, 605, 606, "M" +835, 6, 66, 142, 279, 280, 607, 608, "," +835, 6, 67, 143, 281, 288, 609, 616, "Chatila" +835, 6, 68, 144, 289, 290, 617, 618, "A" +835, 6, 69, 145, 291, 292, 619, 620, "," +835, 6, 70, 146, 293, 298, 621, 626, "Heijl" +835, 6, 71, 147, 299, 300, 627, 628, "A" +835, 6, 72, 148, 301, 302, 629, 630, "," +835, 6, 73, 149, 303, 311, 631, 639, "Lindblom" +835, 6, 74, 150, 312, 313, 640, 641, "B" +835, 6, 75, 151, 314, 315, 642, 643, "," +835, 6, 76, 152, 316, 322, 644, 650, "Vancea" +835, 6, 77, 153, 323, 324, 651, 652, "L" +835, 6, 78, 154, 325, 326, 653, 654, "." +835, 6, 79, 155, 327, 333, 655, 661, "Author" +835, 6, 80, 156, 334, 345, 662, 673, "information" +835, 6, 81, 157, 346, 347, 674, 675, ":" +835, 6, 82, 158, 348, 349, 676, 677, "(" +835, 6, 83, 159, 350, 351, 678, 679, "1" +835, 6, 84, 160, 352, 353, 680, 681, ")" +835, 6, 85, 161, 354, 361, 682, 689, "Clinica" +835, 6, 86, 162, 362, 372, 690, 700, "Oculistica" +835, 6, 87, 163, 373, 384, 701, 712, "Policlinico" +835, 6, 88, 164, 385, 387, 713, 715, "di" +835, 6, 89, 165, 388, 393, 716, 721, "Monza" +835, 6, 90, 166, 394, 395, 722, 723, "," +835, 6, 91, 167, 396, 406, 724, 734, "Universita" +835, 6, 92, 168, 407, 408, 735, 736, "'" +835, 6, 93, 169, 409, 411, 737, 739, "di" +835, 6, 94, 170, 412, 418, 740, 746, "Milano" +835, 6, 95, 171, 419, 426, 747, 754, "Bicocca" +835, 6, 96, 172, 427, 428, 755, 756, "," +835, 6, 97, 173, 429, 434, 757, 762, "Monza" +835, 6, 98, 174, 435, 436, 763, 764, "(" +835, 6, 99, 175, 437, 439, 765, 767, "MI" +835, 6, 100, 176, 440, 441, 768, 769, ")" +835, 6, 101, 177, 442, 443, 770, 771, "," +835, 6, 102, 178, 444, 449, 772, 777, "Italy" +835, 6, 103, 179, 450, 451, 778, 779, "." +835, 7, 1, 180, 0, 7, 780, 787, "stefano" +835, 7, 2, 181, 8, 9, 788, 789, "." +835, 7, 3, 182, 10, 17, 790, 797, "miglior" +835, 7, 4, 183, 18, 19, 798, 799, "@" +835, 7, 5, 184, 20, 26, 800, 806, "unimib" +835, 7, 6, 185, 27, 28, 807, 808, "." +835, 7, 7, 186, 29, 31, 809, 811, "it" +835, 7, 8, 187, 32, 36, 812, 816, "AIMS" +835, 7, 9, 188, 37, 38, 817, 818, ":" +835, 7, 10, 189, 39, 41, 819, 821, "To" +835, 7, 11, 190, 42, 49, 822, 829, "compare" +835, 7, 12, 191, 50, 61, 830, 841, "intraocular" +835, 7, 13, 192, 62, 70, 842, 850, "pressure" +835, 7, 14, 193, 71, 72, 851, 852, "(" +835, 7, 15, 194, 73, 76, 853, 856, "IOP" +835, 7, 16, 195, 77, 78, 857, 858, ")" +835, 7, 17, 196, 79, 89, 859, 869, "reductions" +835, 7, 18, 197, 90, 94, 870, 874, "with" +835, 7, 19, 198, 95, 100, 875, 880, "fixed" +835, 7, 20, 199, 101, 102, 881, 882, "-" +835, 7, 21, 200, 103, 114, 883, 894, "combination" +835, 7, 22, 201, 115, 116, 895, 896, "(" +835, 7, 23, 202, 117, 119, 897, 899, "FC" +835, 7, 24, 203, 120, 121, 900, 901, ")" +835, 7, 25, 204, 122, 133, 902, 913, "latanoprost" +835, 7, 26, 205, 134, 135, 914, 915, "/" +835, 7, 27, 206, 136, 143, 916, 923, "timolol" +835, 7, 28, 207, 144, 148, 924, 928, "once" +835, 7, 29, 208, 149, 154, 929, 934, "daily" +835, 7, 30, 209, 155, 157, 935, 937, "in" +835, 7, 31, 210, 158, 161, 938, 941, "the" +835, 7, 32, 211, 162, 169, 942, 949, "evening" +835, 7, 33, 212, 170, 174, 950, 954, "vsFC" +835, 7, 34, 213, 175, 186, 955, 966, "dorzolamide" +835, 7, 35, 214, 187, 188, 967, 968, "/" +835, 7, 36, 215, 189, 196, 969, 976, "timolol" +835, 7, 37, 216, 197, 202, 977, 982, "twice" +835, 7, 38, 217, 203, 208, 983, 988, "daily" +835, 7, 39, 218, 209, 210, 989, 990, "." +835, 8, 1, 219, 0, 7, 991, 998, "METHODS" +835, 8, 2, 220, 8, 9, 999, 1000, ":" +835, 8, 3, 221, 10, 14, 1001, 1005, "This" +835, 8, 4, 222, 15, 24, 1006, 1015, "evaluator" +835, 8, 5, 223, 25, 26, 1016, 1017, "-" +835, 8, 6, 224, 27, 33, 1018, 1024, "masked" +835, 8, 7, 225, 34, 35, 1025, 1026, "," +835, 8, 8, 226, 36, 47, 1027, 1038, "multicentre" +835, 8, 9, 227, 48, 49, 1039, 1040, "," +835, 8, 10, 228, 50, 60, 1041, 1051, "controlled" +835, 8, 11, 229, 61, 69, 1052, 1060, "clinical" +835, 8, 12, 230, 70, 75, 1061, 1066, "trial" +835, 8, 13, 231, 76, 86, 1067, 1077, "randomized" +835, 8, 14, 232, 87, 95, 1078, 1086, "subjects" +835, 8, 15, 233, 96, 100, 1087, 1091, "with" +835, 8, 16, 234, 101, 108, 1092, 1099, "primary" +835, 8, 17, 235, 109, 113, 1100, 1104, "open" +835, 8, 18, 236, 114, 115, 1105, 1106, "-" +835, 8, 19, 237, 116, 121, 1107, 1112, "angle" +835, 8, 20, 238, 122, 130, 1113, 1121, "glaucoma" +835, 8, 21, 239, 131, 133, 1122, 1124, "or" +835, 8, 22, 240, 134, 140, 1125, 1131, "ocular" +835, 8, 23, 241, 141, 153, 1132, 1144, "hypertension" +835, 8, 24, 242, 154, 158, 1145, 1149, "with" +835, 8, 25, 243, 159, 162, 1150, 1153, "IOP" +835, 8, 26, 244, 163, 177, 1154, 1168, "insufficiently" +835, 8, 27, 245, 178, 188, 1169, 1179, "responsive" +835, 8, 28, 246, 189, 191, 1180, 1182, "to" +835, 8, 29, 247, 192, 196, 1183, 1187, "beta" +835, 8, 30, 248, 197, 198, 1188, 1189, "-" +835, 8, 31, 249, 199, 206, 1190, 1197, "blocker" +835, 8, 32, 250, 207, 214, 1198, 1205, "therapy" +835, 8, 33, 251, 215, 216, 1206, 1207, "(" +835, 8, 34, 252, 217, 226, 1208, 1217, "screening" +835, 8, 35, 253, 227, 230, 1218, 1221, "IOP" +835, 8, 36, 254, 231, 232, 1222, 1223, ">" +835, 8, 37, 255, 233, 235, 1224, 1226, "21" +835, 8, 38, 256, 236, 239, 1227, 1230, "and" +835, 8, 39, 257, 240, 241, 1231, 1232, "<" +835, 8, 40, 258, 242, 244, 1233, 1235, "37" +835, 8, 41, 259, 245, 247, 1236, 1238, "mm" +835, 8, 42, 260, 248, 250, 1239, 1241, "Hg" +835, 8, 43, 261, 251, 252, 1242, 1243, ")" +835, 8, 44, 262, 253, 255, 1244, 1246, "to" +835, 8, 45, 263, 256, 258, 1247, 1249, "FC" +835, 8, 46, 264, 259, 270, 1250, 1261, "latanoprost" +835, 8, 47, 265, 271, 272, 1262, 1263, "-" +835, 8, 48, 266, 273, 280, 1264, 1271, "timolol" +835, 8, 49, 267, 281, 282, 1272, 1273, "(" +835, 8, 50, 268, 283, 284, 1274, 1275, "N" +835, 8, 51, 269, 285, 286, 1276, 1277, "=" +835, 8, 52, 270, 287, 290, 1278, 1281, "135" +835, 8, 53, 271, 291, 292, 1282, 1283, ")" +835, 8, 54, 272, 293, 295, 1284, 1286, "or" +835, 8, 55, 273, 296, 298, 1287, 1289, "FC" +835, 8, 56, 274, 299, 310, 1290, 1301, "dorzolamide" +835, 8, 57, 275, 311, 312, 1302, 1303, "/" +835, 8, 58, 276, 313, 320, 1304, 1311, "timolol" +835, 8, 59, 277, 321, 322, 1312, 1313, "(" +835, 8, 60, 278, 323, 324, 1314, 1315, "N" +835, 8, 61, 279, 325, 326, 1316, 1317, "=" +835, 8, 62, 280, 327, 330, 1318, 1321, "135" +835, 8, 63, 281, 331, 332, 1322, 1323, ")" +835, 8, 64, 282, 333, 334, 1324, 1325, "." +835, 9, 1, 283, 0, 2, 1326, 1328, "At" +835, 9, 2, 284, 3, 12, 1329, 1338, "screening" +835, 9, 3, 285, 13, 14, 1339, 1340, "," +835, 9, 4, 286, 15, 23, 1341, 1349, "baseline" +835, 9, 5, 287, 24, 25, 1350, 1351, "," +835, 9, 6, 288, 26, 29, 1352, 1355, "and" +835, 9, 7, 289, 30, 35, 1356, 1361, "after" +835, 9, 8, 290, 36, 37, 1362, 1363, "4" +835, 9, 9, 291, 38, 41, 1364, 1367, "and" +835, 9, 10, 292, 42, 44, 1368, 1370, "12" +835, 9, 11, 293, 45, 50, 1371, 1376, "weeks" +835, 9, 12, 294, 51, 53, 1377, 1379, "of" +835, 9, 13, 295, 54, 61, 1380, 1387, "therapy" +835, 9, 14, 296, 62, 63, 1388, 1389, "," +835, 9, 15, 297, 64, 67, 1390, 1393, "IOP" +835, 9, 16, 298, 68, 71, 1394, 1397, "was" +835, 9, 17, 299, 72, 80, 1398, 1406, "measured" +835, 9, 18, 300, 81, 86, 1407, 1412, "three" +835, 9, 19, 301, 87, 92, 1413, 1418, "times" +835, 9, 20, 302, 93, 95, 1419, 1421, "at" +835, 9, 21, 303, 96, 100, 1422, 1426, "0800" +835, 9, 22, 304, 101, 102, 1427, 1428, "," +835, 9, 23, 305, 103, 107, 1429, 1433, "1200" +835, 9, 24, 306, 108, 109, 1434, 1435, "," +835, 9, 25, 307, 110, 113, 1436, 1439, "and" +835, 9, 26, 308, 114, 118, 1440, 1444, "1600" +835, 9, 27, 309, 119, 124, 1445, 1450, "hours" +835, 9, 28, 310, 125, 126, 1451, 1452, "." +835, 10, 1, 311, 0, 7, 1453, 1460, "Adverse" +835, 10, 2, 312, 8, 14, 1461, 1467, "events" +835, 10, 3, 313, 15, 19, 1468, 1472, "were" +835, 10, 4, 314, 20, 28, 1473, 1481, "recorded" +835, 10, 5, 315, 29, 31, 1482, 1484, "at" +835, 10, 6, 316, 32, 36, 1485, 1489, "each" +835, 10, 7, 317, 37, 42, 1490, 1495, "visit" +835, 10, 8, 318, 43, 44, 1496, 1497, "." +835, 11, 1, 319, 0, 3, 1498, 1501, "The" +835, 11, 2, 320, 4, 11, 1502, 1509, "primary" +835, 11, 3, 321, 12, 20, 1510, 1518, "efficacy" +835, 11, 4, 322, 21, 24, 1519, 1522, "end" +835, 11, 5, 323, 25, 30, 1523, 1528, "point" +835, 11, 6, 324, 31, 34, 1529, 1532, "was" +835, 11, 7, 325, 35, 42, 1533, 1540, "whether" +835, 11, 8, 326, 43, 49, 1541, 1547, "either" +835, 11, 9, 327, 50, 52, 1548, 1550, "FC" +835, 11, 10, 328, 53, 58, 1551, 1556, "could" +835, 11, 11, 329, 59, 61, 1557, 1559, "be" +835, 11, 12, 330, 62, 67, 1560, 1565, "shown" +835, 11, 13, 331, 68, 70, 1566, 1568, "to" +835, 11, 14, 332, 71, 73, 1569, 1571, "be" +835, 11, 15, 333, 74, 82, 1572, 1580, "inferior" +835, 11, 16, 334, 83, 85, 1581, 1583, "to" +835, 11, 17, 335, 86, 89, 1584, 1587, "the" +835, 11, 18, 336, 90, 95, 1588, 1593, "other" +835, 11, 19, 337, 96, 100, 1594, 1598, "with" +835, 11, 20, 338, 101, 108, 1599, 1606, "respect" +835, 11, 21, 339, 109, 111, 1607, 1609, "to" +835, 11, 22, 340, 112, 118, 1610, 1616, "change" +835, 11, 23, 341, 119, 121, 1617, 1619, "in" +835, 11, 24, 342, 122, 126, 1620, 1624, "mean" +835, 11, 25, 343, 127, 134, 1625, 1632, "daytime" +835, 11, 26, 344, 135, 138, 1633, 1636, "IOP" +835, 11, 27, 345, 139, 143, 1637, 1641, "from" +835, 11, 28, 346, 144, 152, 1642, 1650, "baseline" +835, 11, 29, 347, 153, 155, 1651, 1653, "to" +835, 11, 30, 348, 156, 160, 1654, 1658, "week" +835, 11, 31, 349, 161, 163, 1659, 1661, "12" +835, 11, 32, 350, 164, 165, 1662, 1663, "." +835, 12, 1, 351, 0, 7, 1664, 1671, "RESULTS" +835, 12, 2, 352, 8, 9, 1672, 1673, ":" +835, 12, 3, 353, 10, 14, 1674, 1678, "Mean" +835, 12, 4, 354, 15, 22, 1679, 1686, "daytime" +835, 12, 5, 355, 23, 26, 1687, 1690, "IOP" +835, 12, 6, 356, 27, 33, 1691, 1697, "levels" +835, 12, 7, 357, 34, 38, 1698, 1702, "were" +835, 12, 8, 358, 39, 46, 1703, 1710, "similar" +835, 12, 9, 359, 47, 49, 1711, 1713, "at" +835, 12, 10, 360, 50, 58, 1714, 1722, "baseline" +835, 12, 11, 361, 59, 60, 1723, 1724, "." +835, 13, 1, 362, 0, 4, 1725, 1729, "Mean" +835, 13, 2, 363, 5, 15, 1730, 1740, "reductions" +835, 13, 3, 364, 16, 18, 1741, 1743, "in" +835, 13, 4, 365, 19, 26, 1744, 1751, "daytime" +835, 13, 5, 366, 27, 30, 1752, 1755, "IOP" +835, 13, 6, 367, 31, 35, 1756, 1760, "from" +835, 13, 7, 368, 36, 44, 1761, 1769, "baseline" +835, 13, 8, 369, 45, 47, 1770, 1772, "to" +835, 13, 9, 370, 48, 52, 1773, 1777, "week" +835, 13, 10, 371, 53, 55, 1778, 1780, "12" +835, 13, 11, 372, 56, 60, 1781, 1785, "were" +835, 13, 12, 373, 61, 62, 1786, 1787, "-" +835, 13, 13, 374, 63, 64, 1788, 1789, "9" +835, 13, 14, 375, 65, 66, 1790, 1791, "." +835, 13, 15, 376, 67, 68, 1792, 1793, "7" +835, 13, 16, 377, 69, 71, 1794, 1796, "mm" +835, 13, 17, 378, 72, 74, 1797, 1799, "Hg" +835, 13, 18, 379, 75, 78, 1800, 1803, "for" +835, 13, 19, 380, 79, 81, 1804, 1806, "FC" +835, 13, 20, 381, 82, 93, 1807, 1818, "latanoprost" +835, 13, 21, 382, 94, 95, 1819, 1820, "-" +835, 13, 22, 383, 96, 103, 1821, 1828, "timolol" +835, 13, 23, 384, 104, 107, 1829, 1832, "and" +835, 13, 24, 385, 108, 109, 1833, 1834, "-" +835, 13, 25, 386, 110, 111, 1835, 1836, "9" +835, 13, 26, 387, 112, 113, 1837, 1838, "." +835, 13, 27, 388, 114, 115, 1839, 1840, "5" +835, 13, 28, 389, 116, 118, 1841, 1843, "mm" +835, 13, 29, 390, 119, 121, 1844, 1846, "Hg" +835, 13, 30, 391, 122, 125, 1847, 1850, "for" +835, 13, 31, 392, 126, 128, 1851, 1853, "FC" +835, 13, 32, 393, 129, 140, 1854, 1865, "dorzolamide" +835, 13, 33, 394, 141, 142, 1866, 1867, "/" +835, 13, 34, 395, 143, 150, 1868, 1875, "timolol" +835, 13, 35, 396, 151, 152, 1876, 1877, "." +835, 14, 1, 397, 0, 3, 1878, 1881, "The" +835, 14, 2, 398, 4, 14, 1882, 1892, "difference" +835, 14, 3, 399, 15, 22, 1893, 1900, "between" +835, 14, 4, 400, 23, 25, 1901, 1903, "FC" +835, 14, 5, 401, 26, 37, 1904, 1915, "latanoprost" +835, 14, 6, 402, 38, 39, 1916, 1917, "/" +835, 14, 7, 403, 40, 47, 1918, 1925, "timolol" +835, 14, 8, 404, 48, 49, 1926, 1927, "-" +835, 14, 9, 405, 50, 52, 1928, 1930, "FC" +835, 14, 10, 406, 53, 64, 1931, 1942, "dorzolamide" +835, 14, 11, 407, 65, 66, 1943, 1944, "-" +835, 14, 12, 408, 67, 74, 1945, 1952, "timolol" +835, 14, 13, 409, 75, 78, 1953, 1956, "was" +835, 14, 14, 410, 79, 80, 1957, 1958, "-" +835, 14, 15, 411, 81, 82, 1959, 1960, "0" +835, 14, 16, 412, 83, 84, 1961, 1962, "." +835, 14, 17, 413, 85, 86, 1963, 1964, "2" +835, 14, 18, 414, 87, 89, 1965, 1967, "mm" +835, 14, 19, 415, 90, 92, 1968, 1970, "Hg" +835, 14, 20, 416, 93, 94, 1971, 1972, "(" +835, 14, 21, 417, 95, 97, 1973, 1975, "95" +835, 14, 22, 418, 98, 99, 1976, 1977, "%" +835, 14, 23, 419, 100, 110, 1978, 1988, "confidence" +835, 14, 24, 420, 111, 119, 1989, 1997, "interval" +835, 14, 25, 421, 120, 121, 1998, 1999, "(" +835, 14, 26, 422, 122, 124, 2000, 2002, "CI" +835, 14, 27, 423, 125, 126, 2003, 2004, ")" +835, 14, 28, 424, 127, 128, 2005, 2006, "," +835, 14, 29, 425, 129, 130, 2007, 2008, "-" +835, 14, 30, 426, 131, 132, 2009, 2010, "0" +835, 14, 31, 427, 133, 134, 2011, 2012, "." +835, 14, 32, 428, 135, 136, 2013, 2014, "8" +835, 14, 33, 429, 137, 139, 2015, 2017, "to" +835, 14, 34, 430, 140, 141, 2018, 2019, "-" +835, 14, 35, 431, 142, 143, 2020, 2021, "0" +835, 14, 36, 432, 144, 145, 2022, 2023, "." +835, 14, 37, 433, 146, 147, 2024, 2025, "4" +835, 14, 38, 434, 148, 150, 2026, 2028, "mm" +835, 14, 39, 435, 151, 153, 2029, 2031, "Hg" +835, 14, 40, 436, 154, 155, 2032, 2033, ")" +835, 14, 41, 437, 156, 157, 2034, 2035, "." +835, 15, 1, 438, 0, 3, 2036, 2039, "The" +835, 15, 2, 439, 4, 9, 2040, 2045, "upper" +835, 15, 3, 440, 10, 15, 2046, 2051, "bound" +835, 15, 4, 441, 16, 18, 2052, 2054, "of" +835, 15, 5, 442, 19, 22, 2055, 2058, "the" +835, 15, 6, 443, 23, 25, 2059, 2061, "95" +835, 15, 7, 444, 26, 27, 2062, 2063, "%" +835, 15, 8, 445, 28, 30, 2064, 2066, "CI" +835, 15, 9, 446, 31, 34, 2067, 2070, "was" +835, 15, 10, 447, 35, 36, 2071, 2072, "<" +835, 15, 11, 448, 37, 38, 2073, 2074, "1" +835, 15, 12, 449, 39, 40, 2075, 2076, "." +835, 15, 13, 450, 41, 42, 2077, 2078, "5" +835, 15, 14, 451, 43, 45, 2079, 2081, "mm" +835, 15, 15, 452, 46, 48, 2082, 2084, "Hg" +835, 15, 16, 453, 49, 50, 2085, 2086, "," +835, 15, 17, 454, 51, 61, 2087, 2097, "indicating" +835, 15, 18, 455, 62, 66, 2098, 2102, "that" +835, 15, 19, 456, 67, 74, 2103, 2110, "neither" +835, 15, 20, 457, 75, 77, 2111, 2113, "FC" +835, 15, 21, 458, 78, 80, 2114, 2116, "is" +835, 15, 22, 459, 81, 89, 2117, 2125, "inferior" +835, 15, 23, 460, 90, 92, 2126, 2128, "to" +835, 15, 24, 461, 93, 96, 2129, 2132, "the" +835, 15, 25, 462, 97, 102, 2133, 2138, "other" +835, 15, 26, 463, 103, 104, 2139, 2140, "." +835, 16, 1, 464, 0, 7, 2141, 2148, "However" +835, 16, 2, 465, 8, 9, 2149, 2150, "," +835, 16, 3, 466, 10, 11, 2151, 2152, "a" +835, 16, 4, 467, 12, 25, 2153, 2166, "significantly" +835, 16, 5, 468, 26, 33, 2167, 2174, "greater" +835, 16, 6, 469, 34, 44, 2175, 2185, "percentage" +835, 16, 7, 470, 45, 47, 2186, 2188, "of" +835, 16, 8, 471, 48, 56, 2189, 2197, "subjects" +835, 16, 9, 472, 57, 64, 2198, 2205, "treated" +835, 16, 10, 473, 65, 69, 2206, 2210, "with" +835, 16, 11, 474, 70, 72, 2211, 2213, "FC" +835, 16, 12, 475, 73, 84, 2214, 2225, "latanoprost" +835, 16, 13, 476, 85, 86, 2226, 2227, "/" +835, 16, 14, 477, 87, 94, 2228, 2235, "timolol" +835, 16, 15, 478, 95, 103, 2236, 2244, "achieved" +835, 16, 16, 479, 104, 107, 2245, 2248, "IOP" +835, 16, 17, 480, 108, 114, 2249, 2255, "levels" +835, 16, 18, 481, 115, 116, 2256, 2257, "<" +835, 16, 19, 482, 117, 119, 2258, 2260, "or" +835, 16, 20, 483, 120, 121, 2261, 2262, "=" +835, 16, 21, 484, 122, 124, 2263, 2265, "16" +835, 16, 22, 485, 125, 128, 2266, 2269, "and" +835, 16, 23, 486, 129, 130, 2270, 2271, "<" +835, 16, 24, 487, 131, 133, 2272, 2274, "or" +835, 16, 25, 488, 134, 135, 2275, 2276, "=" +835, 16, 26, 489, 136, 138, 2277, 2279, "15" +835, 16, 27, 490, 139, 141, 2280, 2282, "mm" +835, 16, 28, 491, 142, 144, 2283, 2285, "Hg" +835, 16, 29, 492, 145, 146, 2286, 2287, "(" +835, 16, 30, 493, 147, 148, 2288, 2289, "P" +835, 16, 31, 494, 149, 150, 2290, 2291, "<" +835, 16, 32, 495, 151, 153, 2292, 2294, "or" +835, 16, 33, 496, 154, 155, 2295, 2296, "=" +835, 16, 34, 497, 156, 157, 2297, 2298, "0" +835, 16, 35, 498, 158, 159, 2299, 2300, "." +835, 16, 36, 499, 160, 162, 2301, 2303, "01" +835, 16, 37, 500, 163, 164, 2304, 2305, ")" +835, 16, 38, 501, 165, 166, 2306, 2307, "." +835, 17, 1, 502, 0, 4, 2308, 2312, "Both" +835, 17, 2, 503, 5, 15, 2313, 2323, "treatments" +835, 17, 3, 504, 16, 20, 2324, 2328, "were" +835, 17, 4, 505, 21, 25, 2329, 2333, "well" +835, 17, 5, 506, 26, 35, 2334, 2343, "tolerated" +835, 17, 6, 507, 36, 37, 2344, 2345, "." +835, 18, 1, 508, 0, 11, 2346, 2357, "CONCLUSIONS" +835, 18, 2, 509, 12, 13, 2358, 2359, ":" +835, 18, 3, 510, 14, 18, 2360, 2364, "When" +835, 18, 4, 511, 19, 23, 2365, 2369, "beta" +835, 18, 5, 512, 24, 25, 2370, 2371, "-" +835, 18, 6, 513, 26, 33, 2372, 2379, "blocker" +835, 18, 7, 514, 34, 41, 2380, 2387, "therapy" +835, 18, 8, 515, 42, 44, 2388, 2390, "is" +835, 18, 9, 516, 45, 55, 2391, 2401, "inadequate" +835, 18, 10, 517, 56, 57, 2402, 2403, "," +835, 18, 11, 518, 58, 64, 2404, 2410, "either" +835, 18, 12, 519, 65, 67, 2411, 2413, "FC" +835, 18, 13, 520, 68, 71, 2414, 2417, "may" +835, 18, 14, 521, 72, 79, 2418, 2425, "achieve" +835, 18, 15, 522, 80, 83, 2426, 2429, "the" +835, 18, 16, 523, 84, 91, 2430, 2437, "desired" +835, 18, 17, 524, 92, 95, 2438, 2441, "IOP" +835, 18, 18, 525, 96, 101, 2442, 2447, "level" +835, 18, 19, 526, 102, 103, 2448, 2449, "," +835, 18, 20, 527, 104, 107, 2450, 2453, "but" +835, 18, 21, 528, 108, 110, 2454, 2456, "FC" +835, 18, 22, 529, 111, 122, 2457, 2468, "latanoprost" +835, 18, 23, 530, 123, 124, 2469, 2470, "/" +835, 18, 24, 531, 125, 132, 2471, 2478, "timolol" +835, 18, 25, 532, 133, 137, 2479, 2483, "more" +835, 18, 26, 533, 138, 143, 2484, 2489, "often" +835, 18, 27, 534, 144, 152, 2490, 2498, "achieves" +835, 18, 28, 535, 153, 154, 2499, 2500, "a" +835, 18, 29, 536, 155, 163, 2501, 2509, "pressure" +835, 18, 30, 537, 164, 166, 2510, 2512, "of" +835, 18, 31, 538, 167, 168, 2513, 2514, "<" +835, 18, 32, 539, 169, 171, 2515, 2517, "or" +835, 18, 33, 540, 172, 173, 2518, 2519, "=" +835, 18, 34, 541, 174, 176, 2520, 2522, "16" +835, 18, 35, 542, 177, 179, 2523, 2525, "mm" +835, 18, 36, 543, 180, 182, 2526, 2528, "Hg" +835, 18, 37, 544, 183, 184, 2529, 2530, "." +835, 19, 1, 545, 0, 4, 2531, 2535, "Both" +835, 19, 2, 546, 5, 8, 2536, 2539, "FCs" +835, 19, 3, 547, 9, 13, 2540, 2544, "were" +835, 19, 4, 548, 14, 18, 2545, 2549, "well" +835, 19, 5, 549, 19, 28, 2550, 2559, "tolerated" +835, 19, 6, 550, 29, 30, 2560, 2561, "." +835, 20, 1, 551, 0, 3, 2562, 2565, "DOI" +835, 20, 2, 552, 4, 5, 2566, 2567, ":" +835, 20, 3, 553, 6, 8, 2568, 2570, "10" +835, 20, 4, 554, 9, 10, 2571, 2572, "." +835, 20, 5, 555, 11, 15, 2573, 2577, "1038" +835, 20, 6, 556, 16, 17, 2578, 2579, "/" +835, 20, 7, 557, 18, 21, 2580, 2583, "eye" +835, 20, 8, 558, 22, 23, 2584, 2585, "." +835, 20, 9, 559, 24, 28, 2586, 2590, "2009" +835, 20, 10, 560, 29, 30, 2591, 2592, "." +835, 20, 11, 561, 31, 34, 2593, 2596, "307" +835, 20, 12, 562, 35, 39, 2597, 2601, "PMID" +835, 20, 13, 563, 40, 41, 2602, 2603, ":" +835, 20, 14, 564, 42, 50, 2604, 2612, "20019759" +835, 20, 15, 565, 51, 52, 2613, 2614, "[" +835, 20, 16, 566, 53, 60, 2615, 2622, "Indexed" +835, 20, 17, 567, 61, 64, 2623, 2626, "for" +835, 20, 18, 568, 65, 72, 2627, 2634, "MEDLINE" +835, 20, 19, 569, 73, 74, 2635, 2636, "]" diff --git a/data/gl 20019759_admin.annodb b/data/gl 20019759_admin.annodb new file mode 100644 index 0000000..d1958a7 --- /dev/null +++ b/data/gl 20019759_admin.annodb @@ -0,0 +1,128 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2010", "", " \"2010\"." +2, Title, 105, 247, "Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension .", "", " \"Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension .\"." +96, Lat/TimFC, 150, 171, "latanoprost / timolol", "", +3, Latanoprost, 150, 161, "latanoprost", "", +4, Timolol, 164, 171, "timolol", "", +97, Dorz/TimFC, 176, 197, "dorzolamide / timolol", "", +5, Dorzolamide, 176, 187, "dorzolamide", "", +6, Timolol, 190, 197, "timolol", "", +7, OpenAngleGlaucoma, 201, 222, "open - angle glaucoma", "", " ." +8, OcularHypertension, 226, 245, "ocular hypertension", "", " ." +9, Author, 248, 257, "Miglior S", "", " \"Miglior S\"." +10, Author, 266, 276, "Grunden JW", "", " \"Grunden JW\"." +11, Author, 279, 285, "Kwok K", "", " \"Kwok K\"." +104, Lat/TimFC, 288, 295, "Xalacom", "", +103, Dorz/TimFC, 298, 304, "Cosopt", "", +106, Author, 344, 351, "Denis P", "", " \"Denis P\"." +107, Author, 354, 364, "Mouriaux F", "", " \"Mouriaux F\"." +108, Author, 367, 375, "Peigne G", "", " \"Peigne G\"." +109, Author, 378, 387, "Ridings B", "", " \"Ridings B\"." +110, Author, 390, 397, "Rigal D", "", " \"Rigal D\"." +111, Author, 400, 408, "Christ T", "", " \"Christ T\"." +112, Author, 411, 419, "Deuker H", "", " \"Deuker H\"." +113, Author, 422, 432, "Hamacher T", "", " \"Hamacher T\"." +114, Author, 435, 445, "Hoffmann M", "", " \"Hoffmann M\"." +115, Author, 448, 457, "Jelinek C", "", " \"Jelinek C\"." +116, Author, 460, 471, "Scherzer ML", "", " \"Scherzer ML\"." +117, Author, 474, 486, "Karabatsas K", "", " \"Karabatsas K\"." +118, Author, 489, 498, "Konstas A", "", " \"Konstas A\"." +119, Author, 501, 513, "Kozombolis V", "", " \"Kozombolis V\"." +120, Author, 516, 529, "Tsilimbaris M", "", " \"Tsilimbaris M\"." +121, Author, 532, 541, "Carassa R", "", " \"Carassa R\"." +122, Author, 544, 556, "Delle Noci N", "", " \"Carassa R\"." +123, Author, 559, 567, "Iester M", "", " \"Iester M\"." +124, Author, 570, 584, "Mastropasqua L", "", " \"Mastropasqua L\"." +125, Author, 587, 596, "Miglior S", "", " \"Miglior S\"." +126, Author, 599, 606, "Nardi M", "", " \"Nardi M\"." +127, Author, 609, 618, "Chatila A", "", " \"Chatila A\"." +128, Author, 621, 628, "Heijl A", "", " \"Heijl A\"." +129, Author, 631, 641, "Lindblom B", "", " \"Lindblom B\"." +130, Author, 644, 652, "Vancea L", "", " \"Vancea L\"." +12, Italy, 772, 777, "Italy", "", " ." +13, ObjectiveDescription, 819, 990, "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .", "", " \"To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .\"." +14, IOP, 830, 850, "intraocular pressure", "", +15, IOP, 853, 856, "IOP", "", +16, Lat/TimFC, 875, 923, "fixed - combination ( FC ) latanoprost / timolol", "", " ." +20, Latanoprost, 902, 913, "latanoprost", "", +21, Timolol, 916, 923, "timolol", "", +17, Frequency, 924, 934, "once daily", "", " \"once daily\"." +137, Evening, 935, 949, "in the evening", "", " ." +18, Dorz/TimFC, 950, 976, "vsFC dorzolamide / timolol", "", +22, Dorzolamide, 955, 966, "dorzolamide", "", +23, Timolol, 969, 976, "timolol", "", +19, Frequency, 977, 988, "twice daily", "", " \"twice daily\"." +24, Blind, 1006, 1024, "evaluator - masked", "", " ." +25, Multicenter, 1027, 1038, "multicentre", "", " ." +26, Randomized, 1067, 1077, "randomized", "", " ." +152, Precondition, 1078, 1243, "subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )", "", " \"subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )\"." +27, Primary_OpenAngleGlaucoma, 1092, 1121, "primary open - angle glaucoma", "", " ." +28, OcularHypertension, 1125, 1144, "ocular hypertension", "", +30, IOP, 1150, 1153, "IOP", "", +31, IOP, 1218, 1221, "IOP", "", +32, mmHg, 1236, 1241, "mm Hg", "", +33, Lat/TimFC, 1247, 1271, "FC latanoprost - timolol", "", +34, Latanoprost, 1250, 1261, "latanoprost", "", +35, Timolol, 1264, 1271, "timolol", "", +36, NumberPatientsArm, 1278, 1281, "135", "", " \"135\"." +37, Dorz/TimFC, 1287, 1311, "FC dorzolamide / timolol", "", " ." +38, Dorzolamide, 1290, 1301, "dorzolamide", "", +39, Timolol, 1304, 1311, "timolol", "", +40, NumberPatientsArm, 1318, 1321, "135", "", " \"135\"." +41, TimePoint, 1329, 1338, "screening", "", +42, TimePoint, 1341, 1349, "baseline", "", +43, TimePoint, 1362, 1376, "4 and 12 weeks", "", +44, TimePoint, 1368, 1376, "12 weeks", "", +45, IOP, 1390, 1393, "IOP", "", +162, TimePoint, 1422, 1426, "0800", "", +163, TimePoint, 1429, 1433, "1200", "", +164, TimePoint, 1440, 1444, "1600", "", +46, Mean, 1620, 1624, "mean", "", +88228, Diurnal_IOP, 1625, 1636, "daytime IOP", "", +48, TimePoint, 1642, 1650, "baseline", "", +49, TimePoint, 1654, 1661, "week 12", "", +50, Mean, 1674, 1678, "Mean", "", +88233, Diurnal_IOP, 1679, 1690, "daytime IOP", "", +52, TimePoint, 1714, 1722, "baseline", "", +53, Mean, 1725, 1729, "Mean", "", " . ." +88234, Diurnal_IOP, 1744, 1755, "daytime IOP", "", " ." +55, TimePoint, 1761, 1769, "baseline", "", +56, TimePoint, 1773, 1780, "week 12", "", " \"week 12\". \"week 12\"." +57, Reduction, 1788, 1793, "9 . 7", "", " \"9 . 7\"." +59, mmHg, 1794, 1799, "mm Hg", "", " ." +61, Lat/TimFC, 1804, 1828, "FC latanoprost - timolol", "", +62, Latanoprost, 1807, 1818, "latanoprost", "", +63, Timolol, 1821, 1828, "timolol", "", +58, Reduction, 1835, 1840, "9 . 5", "", " \"9 . 5\"." +60, mmHg, 1841, 1846, "mm Hg", "", +64, Dorz/TimFC, 1851, 1875, "FC dorzolamide / timolol", "", +65, Dorzolamide, 1854, 1865, "dorzolamide", "", +66, Timolol, 1868, 1875, "timolol", "", +67, Lat/TimFC, 1901, 1925, "FC latanoprost / timolol", "", +69, Latanoprost, 1904, 1915, "latanoprost", "", +70, Timolol, 1918, 1925, "timolol", "", +68, Dorz/TimFC, 1928, 1952, "FC dorzolamide - timolol", "", +189, Dorzolamide, 1931, 1942, "dorzolamide", "", +71, Timolol, 1945, 1952, "timolol", "", +72, DiffGroupAbsValue, 1959, 1964, "0 . 2", "", " \"0 . 2\"." +73, mmHg, 1965, 1970, "mm Hg", "", +106226, ConfIntervalDiff, 1973, 2031, "95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg", "", " \"95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg\"." +194, mmHg, 2026, 2031, "mm Hg", "", +75, mmHg, 2079, 2084, "mm Hg", "", +88236, ObservedResult, 2151, 2210, "a significantly greater percentage of subjects treated with", "", " \"a significantly greater percentage of subjects treated with\". \"achieved\". \"a significantly greater percentage of subjects treated with\". \"achieved\"." +76, Lat/TimFC, 2211, 2235, "FC latanoprost / timolol", "", +77, Latanoprost, 2214, 2225, "latanoprost", "", +78, Timolol, 2228, 2235, "timolol", "", +88236, ObservedResult, 2236, 2244, "achieved", "", +119899, IOP_target, 2245, 2279, "IOP levels < or = 16 and < or = 15", "", " ." +80, mmHg, 2280, 2285, "mm Hg", "", " ." +203, PvalueDiff, 2288, 2303, "P < or = 0 . 01", "", +82, ConclusionComment, 2360, 2530, "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .", "", " \"When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .\"." +83, IOP, 2438, 2441, "IOP", "", +84, Lat/TimFC, 2454, 2478, "FC latanoprost / timolol", "", +85, Latanoprost, 2457, 2468, "latanoprost", "", +86, Timolol, 2471, 2478, "timolol", "", +87, mmHg, 2523, 2528, "mm Hg", "", +88, ConclusionComment, 2531, 2561, "Both FCs were well tolerated .", "", " \"Both FCs were well tolerated .\"." +89, PMID, 2604, 2612, "20019759", "", " \"20019759\"." diff --git a/data/gl 20019759_admin.n-triples b/data/gl 20019759_admin.n-triples new file mode 100644 index 0000000..c98e7ee --- /dev/null +++ b/data/gl 20019759_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension ." . + "Miglior S" . + "2010" . + "Eye ( Lond ) ." . + "20019759" . + . + "Grunden JW" . + "Kwok K" . + "Denis P" . + "Mouriaux F" . + "Peigne G" . + "Ridings B" . + "Rigal D" . + "Christ T" . + "Deuker H" . + "Hamacher T" . + "Hoffmann M" . + "Jelinek C" . + "Scherzer ML" . + "Karabatsas K" . + "Konstas A" . + "Kozombolis V" . + "Tsilimbaris M" . + "Carassa R" . + "Delle Noci N" . + "Iester M" . + "Mastropasqua L" . + "Nardi M" . + "Chatila A" . + "Heijl A" . + "Lindblom B" . + "Vancea L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily ." . + . + . + . + "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg ." . + . + . + . + . + . + . + "Both FCs were well tolerated ." . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint" . + . + . + . + . + . + . + "Endpoint_target" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_DTFC" . + "135" . + . + . + . + . + "Arm_LTFC" . + "135" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_DTFC" . + . + "twice daily" . + . + . + "Intervention_LTFC" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_DTFC" . + . + . + . + . + "Medication_LTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_DTFC" . + . + "9 . 5" . + "week 12" . + . + "Outcome_iop_LTFC" . + . + "9 . 7" . + "week 12" . + . + "Outcome_targetDTFC" . + . + "a significantly greater percentage of subjects treated with" . + "achieved" . + . + "Outcome_targetLTFC" . + . + "a significantly greater percentage of subjects treated with" . + "achieved" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "0 . 2" . + "95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20019759_export.csv b/data/gl 20019759_export.csv new file mode 100644 index 0000000..44d17eb --- /dev/null +++ b/data/gl 20019759_export.csv @@ -0,0 +1,570 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +513, 1, 1, 1, 0, 3, 0, 3, "Eye" +513, 1, 2, 2, 4, 5, 4, 5, "(" +513, 1, 3, 3, 6, 10, 6, 10, "Lond" +513, 1, 4, 4, 11, 12, 11, 12, ")" +513, 1, 5, 5, 13, 14, 13, 14, "." +513, 2, 1, 6, 0, 4, 15, 19, "2010" +513, 2, 2, 7, 5, 8, 20, 23, "Jul" +513, 2, 3, 8, 9, 10, 24, 25, ";" +513, 2, 4, 9, 11, 13, 26, 28, "24" +513, 2, 5, 10, 14, 15, 29, 30, "(" +513, 2, 6, 11, 16, 17, 31, 32, "7" +513, 2, 7, 12, 18, 19, 33, 34, ")" +513, 2, 8, 13, 20, 21, 35, 36, ":" +513, 2, 9, 14, 22, 26, 37, 41, "1234" +513, 2, 10, 15, 27, 28, 42, 43, "-" +513, 2, 11, 16, 29, 31, 44, 46, "42" +513, 2, 12, 17, 32, 33, 47, 48, "." +513, 2, 13, 18, 34, 37, 49, 52, "doi" +513, 2, 14, 19, 38, 39, 53, 54, ":" +513, 2, 15, 20, 40, 42, 55, 57, "10" +513, 2, 16, 21, 43, 44, 58, 59, "." +513, 2, 17, 22, 45, 49, 60, 64, "1038" +513, 2, 18, 23, 50, 51, 65, 66, "/" +513, 2, 19, 24, 52, 55, 67, 70, "eye" +513, 2, 20, 25, 56, 57, 71, 72, "." +513, 2, 21, 26, 58, 62, 73, 77, "2009" +513, 2, 22, 27, 63, 64, 78, 79, "." +513, 2, 23, 28, 65, 68, 80, 83, "307" +513, 2, 24, 29, 69, 70, 84, 85, "." +513, 3, 1, 30, 0, 4, 86, 90, "Epub" +513, 3, 2, 31, 5, 9, 91, 95, "2009" +513, 3, 3, 32, 10, 13, 96, 99, "Dec" +513, 3, 4, 33, 14, 16, 100, 102, "18" +513, 3, 5, 34, 17, 18, 103, 104, "." +513, 4, 1, 35, 0, 8, 105, 113, "Efficacy" +513, 4, 2, 36, 9, 12, 114, 117, "and" +513, 4, 3, 37, 13, 19, 118, 124, "safety" +513, 4, 4, 38, 20, 22, 125, 127, "of" +513, 4, 5, 39, 23, 28, 128, 133, "fixed" +513, 4, 6, 40, 29, 41, 134, 146, "combinations" +513, 4, 7, 41, 42, 44, 147, 149, "of" +513, 4, 8, 42, 45, 56, 150, 161, "latanoprost" +513, 4, 9, 43, 57, 58, 162, 163, "/" +513, 4, 10, 44, 59, 66, 164, 171, "timolol" +513, 4, 11, 45, 67, 70, 172, 175, "and" +513, 4, 12, 46, 71, 82, 176, 187, "dorzolamide" +513, 4, 13, 47, 83, 84, 188, 189, "/" +513, 4, 14, 48, 85, 92, 190, 197, "timolol" +513, 4, 15, 49, 93, 95, 198, 200, "in" +513, 4, 16, 50, 96, 100, 201, 205, "open" +513, 4, 17, 51, 101, 102, 206, 207, "-" +513, 4, 18, 52, 103, 108, 208, 213, "angle" +513, 4, 19, 53, 109, 117, 214, 222, "glaucoma" +513, 4, 20, 54, 118, 120, 223, 225, "or" +513, 4, 21, 55, 121, 127, 226, 232, "ocular" +513, 4, 22, 56, 128, 140, 233, 245, "hypertension" +513, 4, 23, 57, 141, 142, 246, 247, "." +513, 5, 1, 58, 0, 7, 248, 255, "Miglior" +513, 5, 2, 59, 8, 9, 256, 257, "S" +513, 5, 3, 60, 10, 11, 258, 259, "(" +513, 5, 4, 61, 12, 13, 260, 261, "1" +513, 5, 5, 62, 14, 15, 262, 263, ")" +513, 5, 6, 63, 16, 17, 264, 265, "," +513, 5, 7, 64, 18, 25, 266, 273, "Grunden" +513, 5, 8, 65, 26, 28, 274, 276, "JW" +513, 5, 9, 66, 29, 30, 277, 278, "," +513, 5, 10, 67, 31, 35, 279, 283, "Kwok" +513, 5, 11, 68, 36, 37, 284, 285, "K" +513, 5, 12, 69, 38, 39, 286, 287, ";" +513, 5, 13, 70, 40, 47, 288, 295, "Xalacom" +513, 5, 14, 71, 48, 49, 296, 297, "/" +513, 5, 15, 72, 50, 56, 298, 304, "Cosopt" +513, 5, 16, 73, 57, 65, 305, 313, "European" +513, 5, 17, 74, 66, 71, 314, 319, "Study" +513, 5, 18, 75, 72, 77, 320, 325, "Group" +513, 5, 19, 76, 78, 79, 326, 327, "." +513, 6, 1, 77, 0, 13, 328, 341, "Collaborators" +513, 6, 2, 78, 14, 15, 342, 343, ":" +513, 6, 3, 79, 16, 21, 344, 349, "Denis" +513, 6, 4, 80, 22, 23, 350, 351, "P" +513, 6, 5, 81, 24, 25, 352, 353, "," +513, 6, 6, 82, 26, 34, 354, 362, "Mouriaux" +513, 6, 7, 83, 35, 36, 363, 364, "F" +513, 6, 8, 84, 37, 38, 365, 366, "," +513, 6, 9, 85, 39, 45, 367, 373, "Peigne" +513, 6, 10, 86, 46, 47, 374, 375, "G" +513, 6, 11, 87, 48, 49, 376, 377, "," +513, 6, 12, 88, 50, 57, 378, 385, "Ridings" +513, 6, 13, 89, 58, 59, 386, 387, "B" +513, 6, 14, 90, 60, 61, 388, 389, "," +513, 6, 15, 91, 62, 67, 390, 395, "Rigal" +513, 6, 16, 92, 68, 69, 396, 397, "D" +513, 6, 17, 93, 70, 71, 398, 399, "," +513, 6, 18, 94, 72, 78, 400, 406, "Christ" +513, 6, 19, 95, 79, 80, 407, 408, "T" +513, 6, 20, 96, 81, 82, 409, 410, "," +513, 6, 21, 97, 83, 89, 411, 417, "Deuker" +513, 6, 22, 98, 90, 91, 418, 419, "H" +513, 6, 23, 99, 92, 93, 420, 421, "," +513, 6, 24, 100, 94, 102, 422, 430, "Hamacher" +513, 6, 25, 101, 103, 104, 431, 432, "T" +513, 6, 26, 102, 105, 106, 433, 434, "," +513, 6, 27, 103, 107, 115, 435, 443, "Hoffmann" +513, 6, 28, 104, 116, 117, 444, 445, "M" +513, 6, 29, 105, 118, 119, 446, 447, "," +513, 6, 30, 106, 120, 127, 448, 455, "Jelinek" +513, 6, 31, 107, 128, 129, 456, 457, "C" +513, 6, 32, 108, 130, 131, 458, 459, "," +513, 6, 33, 109, 132, 140, 460, 468, "Scherzer" +513, 6, 34, 110, 141, 143, 469, 471, "ML" +513, 6, 35, 111, 144, 145, 472, 473, "," +513, 6, 36, 112, 146, 156, 474, 484, "Karabatsas" +513, 6, 37, 113, 157, 158, 485, 486, "K" +513, 6, 38, 114, 159, 160, 487, 488, "," +513, 6, 39, 115, 161, 168, 489, 496, "Konstas" +513, 6, 40, 116, 169, 170, 497, 498, "A" +513, 6, 41, 117, 171, 172, 499, 500, "," +513, 6, 42, 118, 173, 183, 501, 511, "Kozombolis" +513, 6, 43, 119, 184, 185, 512, 513, "V" +513, 6, 44, 120, 186, 187, 514, 515, "," +513, 6, 45, 121, 188, 199, 516, 527, "Tsilimbaris" +513, 6, 46, 122, 200, 201, 528, 529, "M" +513, 6, 47, 123, 202, 203, 530, 531, "," +513, 6, 48, 124, 204, 211, 532, 539, "Carassa" +513, 6, 49, 125, 212, 213, 540, 541, "R" +513, 6, 50, 126, 214, 215, 542, 543, "," +513, 6, 51, 127, 216, 221, 544, 549, "Delle" +513, 6, 52, 128, 222, 226, 550, 554, "Noci" +513, 6, 53, 129, 227, 228, 555, 556, "N" +513, 6, 54, 130, 229, 230, 557, 558, "," +513, 6, 55, 131, 231, 237, 559, 565, "Iester" +513, 6, 56, 132, 238, 239, 566, 567, "M" +513, 6, 57, 133, 240, 241, 568, 569, "," +513, 6, 58, 134, 242, 254, 570, 582, "Mastropasqua" +513, 6, 59, 135, 255, 256, 583, 584, "L" +513, 6, 60, 136, 257, 258, 585, 586, "," +513, 6, 61, 137, 259, 266, 587, 594, "Miglior" +513, 6, 62, 138, 267, 268, 595, 596, "S" +513, 6, 63, 139, 269, 270, 597, 598, "," +513, 6, 64, 140, 271, 276, 599, 604, "Nardi" +513, 6, 65, 141, 277, 278, 605, 606, "M" +513, 6, 66, 142, 279, 280, 607, 608, "," +513, 6, 67, 143, 281, 288, 609, 616, "Chatila" +513, 6, 68, 144, 289, 290, 617, 618, "A" +513, 6, 69, 145, 291, 292, 619, 620, "," +513, 6, 70, 146, 293, 298, 621, 626, "Heijl" +513, 6, 71, 147, 299, 300, 627, 628, "A" +513, 6, 72, 148, 301, 302, 629, 630, "," +513, 6, 73, 149, 303, 311, 631, 639, "Lindblom" +513, 6, 74, 150, 312, 313, 640, 641, "B" +513, 6, 75, 151, 314, 315, 642, 643, "," +513, 6, 76, 152, 316, 322, 644, 650, "Vancea" +513, 6, 77, 153, 323, 324, 651, 652, "L" +513, 6, 78, 154, 325, 326, 653, 654, "." +513, 6, 79, 155, 327, 333, 655, 661, "Author" +513, 6, 80, 156, 334, 345, 662, 673, "information" +513, 6, 81, 157, 346, 347, 674, 675, ":" +513, 6, 82, 158, 348, 349, 676, 677, "(" +513, 6, 83, 159, 350, 351, 678, 679, "1" +513, 6, 84, 160, 352, 353, 680, 681, ")" +513, 6, 85, 161, 354, 361, 682, 689, "Clinica" +513, 6, 86, 162, 362, 372, 690, 700, "Oculistica" +513, 6, 87, 163, 373, 384, 701, 712, "Policlinico" +513, 6, 88, 164, 385, 387, 713, 715, "di" +513, 6, 89, 165, 388, 393, 716, 721, "Monza" +513, 6, 90, 166, 394, 395, 722, 723, "," +513, 6, 91, 167, 396, 406, 724, 734, "Universita" +513, 6, 92, 168, 407, 408, 735, 736, "'" +513, 6, 93, 169, 409, 411, 737, 739, "di" +513, 6, 94, 170, 412, 418, 740, 746, "Milano" +513, 6, 95, 171, 419, 426, 747, 754, "Bicocca" +513, 6, 96, 172, 427, 428, 755, 756, "," +513, 6, 97, 173, 429, 434, 757, 762, "Monza" +513, 6, 98, 174, 435, 436, 763, 764, "(" +513, 6, 99, 175, 437, 439, 765, 767, "MI" +513, 6, 100, 176, 440, 441, 768, 769, ")" +513, 6, 101, 177, 442, 443, 770, 771, "," +513, 6, 102, 178, 444, 449, 772, 777, "Italy" +513, 6, 103, 179, 450, 451, 778, 779, "." +513, 7, 1, 180, 0, 7, 780, 787, "stefano" +513, 7, 2, 181, 8, 9, 788, 789, "." +513, 7, 3, 182, 10, 17, 790, 797, "miglior" +513, 7, 4, 183, 18, 19, 798, 799, "@" +513, 7, 5, 184, 20, 26, 800, 806, "unimib" +513, 7, 6, 185, 27, 28, 807, 808, "." +513, 7, 7, 186, 29, 31, 809, 811, "it" +513, 7, 8, 187, 32, 36, 812, 816, "AIMS" +513, 7, 9, 188, 37, 38, 817, 818, ":" +513, 7, 10, 189, 39, 41, 819, 821, "To" +513, 7, 11, 190, 42, 49, 822, 829, "compare" +513, 7, 12, 191, 50, 61, 830, 841, "intraocular" +513, 7, 13, 192, 62, 70, 842, 850, "pressure" +513, 7, 14, 193, 71, 72, 851, 852, "(" +513, 7, 15, 194, 73, 76, 853, 856, "IOP" +513, 7, 16, 195, 77, 78, 857, 858, ")" +513, 7, 17, 196, 79, 89, 859, 869, "reductions" +513, 7, 18, 197, 90, 94, 870, 874, "with" +513, 7, 19, 198, 95, 100, 875, 880, "fixed" +513, 7, 20, 199, 101, 102, 881, 882, "-" +513, 7, 21, 200, 103, 114, 883, 894, "combination" +513, 7, 22, 201, 115, 116, 895, 896, "(" +513, 7, 23, 202, 117, 119, 897, 899, "FC" +513, 7, 24, 203, 120, 121, 900, 901, ")" +513, 7, 25, 204, 122, 133, 902, 913, "latanoprost" +513, 7, 26, 205, 134, 135, 914, 915, "/" +513, 7, 27, 206, 136, 143, 916, 923, "timolol" +513, 7, 28, 207, 144, 148, 924, 928, "once" +513, 7, 29, 208, 149, 154, 929, 934, "daily" +513, 7, 30, 209, 155, 157, 935, 937, "in" +513, 7, 31, 210, 158, 161, 938, 941, "the" +513, 7, 32, 211, 162, 169, 942, 949, "evening" +513, 7, 33, 212, 170, 174, 950, 954, "vsFC" +513, 7, 34, 213, 175, 186, 955, 966, "dorzolamide" +513, 7, 35, 214, 187, 188, 967, 968, "/" +513, 7, 36, 215, 189, 196, 969, 976, "timolol" +513, 7, 37, 216, 197, 202, 977, 982, "twice" +513, 7, 38, 217, 203, 208, 983, 988, "daily" +513, 7, 39, 218, 209, 210, 989, 990, "." +513, 8, 1, 219, 0, 7, 991, 998, "METHODS" +513, 8, 2, 220, 8, 9, 999, 1000, ":" +513, 8, 3, 221, 10, 14, 1001, 1005, "This" +513, 8, 4, 222, 15, 24, 1006, 1015, "evaluator" +513, 8, 5, 223, 25, 26, 1016, 1017, "-" +513, 8, 6, 224, 27, 33, 1018, 1024, "masked" +513, 8, 7, 225, 34, 35, 1025, 1026, "," +513, 8, 8, 226, 36, 47, 1027, 1038, "multicentre" +513, 8, 9, 227, 48, 49, 1039, 1040, "," +513, 8, 10, 228, 50, 60, 1041, 1051, "controlled" +513, 8, 11, 229, 61, 69, 1052, 1060, "clinical" +513, 8, 12, 230, 70, 75, 1061, 1066, "trial" +513, 8, 13, 231, 76, 86, 1067, 1077, "randomized" +513, 8, 14, 232, 87, 95, 1078, 1086, "subjects" +513, 8, 15, 233, 96, 100, 1087, 1091, "with" +513, 8, 16, 234, 101, 108, 1092, 1099, "primary" +513, 8, 17, 235, 109, 113, 1100, 1104, "open" +513, 8, 18, 236, 114, 115, 1105, 1106, "-" +513, 8, 19, 237, 116, 121, 1107, 1112, "angle" +513, 8, 20, 238, 122, 130, 1113, 1121, "glaucoma" +513, 8, 21, 239, 131, 133, 1122, 1124, "or" +513, 8, 22, 240, 134, 140, 1125, 1131, "ocular" +513, 8, 23, 241, 141, 153, 1132, 1144, "hypertension" +513, 8, 24, 242, 154, 158, 1145, 1149, "with" +513, 8, 25, 243, 159, 162, 1150, 1153, "IOP" +513, 8, 26, 244, 163, 177, 1154, 1168, "insufficiently" +513, 8, 27, 245, 178, 188, 1169, 1179, "responsive" +513, 8, 28, 246, 189, 191, 1180, 1182, "to" +513, 8, 29, 247, 192, 196, 1183, 1187, "beta" +513, 8, 30, 248, 197, 198, 1188, 1189, "-" +513, 8, 31, 249, 199, 206, 1190, 1197, "blocker" +513, 8, 32, 250, 207, 214, 1198, 1205, "therapy" +513, 8, 33, 251, 215, 216, 1206, 1207, "(" +513, 8, 34, 252, 217, 226, 1208, 1217, "screening" +513, 8, 35, 253, 227, 230, 1218, 1221, "IOP" +513, 8, 36, 254, 231, 232, 1222, 1223, ">" +513, 8, 37, 255, 233, 235, 1224, 1226, "21" +513, 8, 38, 256, 236, 239, 1227, 1230, "and" +513, 8, 39, 257, 240, 241, 1231, 1232, "<" +513, 8, 40, 258, 242, 244, 1233, 1235, "37" +513, 8, 41, 259, 245, 247, 1236, 1238, "mm" +513, 8, 42, 260, 248, 250, 1239, 1241, "Hg" +513, 8, 43, 261, 251, 252, 1242, 1243, ")" +513, 8, 44, 262, 253, 255, 1244, 1246, "to" +513, 8, 45, 263, 256, 258, 1247, 1249, "FC" +513, 8, 46, 264, 259, 270, 1250, 1261, "latanoprost" +513, 8, 47, 265, 271, 272, 1262, 1263, "-" +513, 8, 48, 266, 273, 280, 1264, 1271, "timolol" +513, 8, 49, 267, 281, 282, 1272, 1273, "(" +513, 8, 50, 268, 283, 284, 1274, 1275, "N" +513, 8, 51, 269, 285, 286, 1276, 1277, "=" +513, 8, 52, 270, 287, 290, 1278, 1281, "135" +513, 8, 53, 271, 291, 292, 1282, 1283, ")" +513, 8, 54, 272, 293, 295, 1284, 1286, "or" +513, 8, 55, 273, 296, 298, 1287, 1289, "FC" +513, 8, 56, 274, 299, 310, 1290, 1301, "dorzolamide" +513, 8, 57, 275, 311, 312, 1302, 1303, "/" +513, 8, 58, 276, 313, 320, 1304, 1311, "timolol" +513, 8, 59, 277, 321, 322, 1312, 1313, "(" +513, 8, 60, 278, 323, 324, 1314, 1315, "N" +513, 8, 61, 279, 325, 326, 1316, 1317, "=" +513, 8, 62, 280, 327, 330, 1318, 1321, "135" +513, 8, 63, 281, 331, 332, 1322, 1323, ")" +513, 8, 64, 282, 333, 334, 1324, 1325, "." +513, 9, 1, 283, 0, 2, 1326, 1328, "At" +513, 9, 2, 284, 3, 12, 1329, 1338, "screening" +513, 9, 3, 285, 13, 14, 1339, 1340, "," +513, 9, 4, 286, 15, 23, 1341, 1349, "baseline" +513, 9, 5, 287, 24, 25, 1350, 1351, "," +513, 9, 6, 288, 26, 29, 1352, 1355, "and" +513, 9, 7, 289, 30, 35, 1356, 1361, "after" +513, 9, 8, 290, 36, 37, 1362, 1363, "4" +513, 9, 9, 291, 38, 41, 1364, 1367, "and" +513, 9, 10, 292, 42, 44, 1368, 1370, "12" +513, 9, 11, 293, 45, 50, 1371, 1376, "weeks" +513, 9, 12, 294, 51, 53, 1377, 1379, "of" +513, 9, 13, 295, 54, 61, 1380, 1387, "therapy" +513, 9, 14, 296, 62, 63, 1388, 1389, "," +513, 9, 15, 297, 64, 67, 1390, 1393, "IOP" +513, 9, 16, 298, 68, 71, 1394, 1397, "was" +513, 9, 17, 299, 72, 80, 1398, 1406, "measured" +513, 9, 18, 300, 81, 86, 1407, 1412, "three" +513, 9, 19, 301, 87, 92, 1413, 1418, "times" +513, 9, 20, 302, 93, 95, 1419, 1421, "at" +513, 9, 21, 303, 96, 100, 1422, 1426, "0800" +513, 9, 22, 304, 101, 102, 1427, 1428, "," +513, 9, 23, 305, 103, 107, 1429, 1433, "1200" +513, 9, 24, 306, 108, 109, 1434, 1435, "," +513, 9, 25, 307, 110, 113, 1436, 1439, "and" +513, 9, 26, 308, 114, 118, 1440, 1444, "1600" +513, 9, 27, 309, 119, 124, 1445, 1450, "hours" +513, 9, 28, 310, 125, 126, 1451, 1452, "." +513, 10, 1, 311, 0, 7, 1453, 1460, "Adverse" +513, 10, 2, 312, 8, 14, 1461, 1467, "events" +513, 10, 3, 313, 15, 19, 1468, 1472, "were" +513, 10, 4, 314, 20, 28, 1473, 1481, "recorded" +513, 10, 5, 315, 29, 31, 1482, 1484, "at" +513, 10, 6, 316, 32, 36, 1485, 1489, "each" +513, 10, 7, 317, 37, 42, 1490, 1495, "visit" +513, 10, 8, 318, 43, 44, 1496, 1497, "." +513, 11, 1, 319, 0, 3, 1498, 1501, "The" +513, 11, 2, 320, 4, 11, 1502, 1509, "primary" +513, 11, 3, 321, 12, 20, 1510, 1518, "efficacy" +513, 11, 4, 322, 21, 24, 1519, 1522, "end" +513, 11, 5, 323, 25, 30, 1523, 1528, "point" +513, 11, 6, 324, 31, 34, 1529, 1532, "was" +513, 11, 7, 325, 35, 42, 1533, 1540, "whether" +513, 11, 8, 326, 43, 49, 1541, 1547, "either" +513, 11, 9, 327, 50, 52, 1548, 1550, "FC" +513, 11, 10, 328, 53, 58, 1551, 1556, "could" +513, 11, 11, 329, 59, 61, 1557, 1559, "be" +513, 11, 12, 330, 62, 67, 1560, 1565, "shown" +513, 11, 13, 331, 68, 70, 1566, 1568, "to" +513, 11, 14, 332, 71, 73, 1569, 1571, "be" +513, 11, 15, 333, 74, 82, 1572, 1580, "inferior" +513, 11, 16, 334, 83, 85, 1581, 1583, "to" +513, 11, 17, 335, 86, 89, 1584, 1587, "the" +513, 11, 18, 336, 90, 95, 1588, 1593, "other" +513, 11, 19, 337, 96, 100, 1594, 1598, "with" +513, 11, 20, 338, 101, 108, 1599, 1606, "respect" +513, 11, 21, 339, 109, 111, 1607, 1609, "to" +513, 11, 22, 340, 112, 118, 1610, 1616, "change" +513, 11, 23, 341, 119, 121, 1617, 1619, "in" +513, 11, 24, 342, 122, 126, 1620, 1624, "mean" +513, 11, 25, 343, 127, 134, 1625, 1632, "daytime" +513, 11, 26, 344, 135, 138, 1633, 1636, "IOP" +513, 11, 27, 345, 139, 143, 1637, 1641, "from" +513, 11, 28, 346, 144, 152, 1642, 1650, "baseline" +513, 11, 29, 347, 153, 155, 1651, 1653, "to" +513, 11, 30, 348, 156, 160, 1654, 1658, "week" +513, 11, 31, 349, 161, 163, 1659, 1661, "12" +513, 11, 32, 350, 164, 165, 1662, 1663, "." +513, 12, 1, 351, 0, 7, 1664, 1671, "RESULTS" +513, 12, 2, 352, 8, 9, 1672, 1673, ":" +513, 12, 3, 353, 10, 14, 1674, 1678, "Mean" +513, 12, 4, 354, 15, 22, 1679, 1686, "daytime" +513, 12, 5, 355, 23, 26, 1687, 1690, "IOP" +513, 12, 6, 356, 27, 33, 1691, 1697, "levels" +513, 12, 7, 357, 34, 38, 1698, 1702, "were" +513, 12, 8, 358, 39, 46, 1703, 1710, "similar" +513, 12, 9, 359, 47, 49, 1711, 1713, "at" +513, 12, 10, 360, 50, 58, 1714, 1722, "baseline" +513, 12, 11, 361, 59, 60, 1723, 1724, "." +513, 13, 1, 362, 0, 4, 1725, 1729, "Mean" +513, 13, 2, 363, 5, 15, 1730, 1740, "reductions" +513, 13, 3, 364, 16, 18, 1741, 1743, "in" +513, 13, 4, 365, 19, 26, 1744, 1751, "daytime" +513, 13, 5, 366, 27, 30, 1752, 1755, "IOP" +513, 13, 6, 367, 31, 35, 1756, 1760, "from" +513, 13, 7, 368, 36, 44, 1761, 1769, "baseline" +513, 13, 8, 369, 45, 47, 1770, 1772, "to" +513, 13, 9, 370, 48, 52, 1773, 1777, "week" +513, 13, 10, 371, 53, 55, 1778, 1780, "12" +513, 13, 11, 372, 56, 60, 1781, 1785, "were" +513, 13, 12, 373, 61, 62, 1786, 1787, "-" +513, 13, 13, 374, 63, 64, 1788, 1789, "9" +513, 13, 14, 375, 65, 66, 1790, 1791, "." +513, 13, 15, 376, 67, 68, 1792, 1793, "7" +513, 13, 16, 377, 69, 71, 1794, 1796, "mm" +513, 13, 17, 378, 72, 74, 1797, 1799, "Hg" +513, 13, 18, 379, 75, 78, 1800, 1803, "for" +513, 13, 19, 380, 79, 81, 1804, 1806, "FC" +513, 13, 20, 381, 82, 93, 1807, 1818, "latanoprost" +513, 13, 21, 382, 94, 95, 1819, 1820, "-" +513, 13, 22, 383, 96, 103, 1821, 1828, "timolol" +513, 13, 23, 384, 104, 107, 1829, 1832, "and" +513, 13, 24, 385, 108, 109, 1833, 1834, "-" +513, 13, 25, 386, 110, 111, 1835, 1836, "9" +513, 13, 26, 387, 112, 113, 1837, 1838, "." +513, 13, 27, 388, 114, 115, 1839, 1840, "5" +513, 13, 28, 389, 116, 118, 1841, 1843, "mm" +513, 13, 29, 390, 119, 121, 1844, 1846, "Hg" +513, 13, 30, 391, 122, 125, 1847, 1850, "for" +513, 13, 31, 392, 126, 128, 1851, 1853, "FC" +513, 13, 32, 393, 129, 140, 1854, 1865, "dorzolamide" +513, 13, 33, 394, 141, 142, 1866, 1867, "/" +513, 13, 34, 395, 143, 150, 1868, 1875, "timolol" +513, 13, 35, 396, 151, 152, 1876, 1877, "." +513, 14, 1, 397, 0, 3, 1878, 1881, "The" +513, 14, 2, 398, 4, 14, 1882, 1892, "difference" +513, 14, 3, 399, 15, 22, 1893, 1900, "between" +513, 14, 4, 400, 23, 25, 1901, 1903, "FC" +513, 14, 5, 401, 26, 37, 1904, 1915, "latanoprost" +513, 14, 6, 402, 38, 39, 1916, 1917, "/" +513, 14, 7, 403, 40, 47, 1918, 1925, "timolol" +513, 14, 8, 404, 48, 49, 1926, 1927, "-" +513, 14, 9, 405, 50, 52, 1928, 1930, "FC" +513, 14, 10, 406, 53, 64, 1931, 1942, "dorzolamide" +513, 14, 11, 407, 65, 66, 1943, 1944, "-" +513, 14, 12, 408, 67, 74, 1945, 1952, "timolol" +513, 14, 13, 409, 75, 78, 1953, 1956, "was" +513, 14, 14, 410, 79, 80, 1957, 1958, "-" +513, 14, 15, 411, 81, 82, 1959, 1960, "0" +513, 14, 16, 412, 83, 84, 1961, 1962, "." +513, 14, 17, 413, 85, 86, 1963, 1964, "2" +513, 14, 18, 414, 87, 89, 1965, 1967, "mm" +513, 14, 19, 415, 90, 92, 1968, 1970, "Hg" +513, 14, 20, 416, 93, 94, 1971, 1972, "(" +513, 14, 21, 417, 95, 97, 1973, 1975, "95" +513, 14, 22, 418, 98, 99, 1976, 1977, "%" +513, 14, 23, 419, 100, 110, 1978, 1988, "confidence" +513, 14, 24, 420, 111, 119, 1989, 1997, "interval" +513, 14, 25, 421, 120, 121, 1998, 1999, "(" +513, 14, 26, 422, 122, 124, 2000, 2002, "CI" +513, 14, 27, 423, 125, 126, 2003, 2004, ")" +513, 14, 28, 424, 127, 128, 2005, 2006, "," +513, 14, 29, 425, 129, 130, 2007, 2008, "-" +513, 14, 30, 426, 131, 132, 2009, 2010, "0" +513, 14, 31, 427, 133, 134, 2011, 2012, "." +513, 14, 32, 428, 135, 136, 2013, 2014, "8" +513, 14, 33, 429, 137, 139, 2015, 2017, "to" +513, 14, 34, 430, 140, 141, 2018, 2019, "-" +513, 14, 35, 431, 142, 143, 2020, 2021, "0" +513, 14, 36, 432, 144, 145, 2022, 2023, "." +513, 14, 37, 433, 146, 147, 2024, 2025, "4" +513, 14, 38, 434, 148, 150, 2026, 2028, "mm" +513, 14, 39, 435, 151, 153, 2029, 2031, "Hg" +513, 14, 40, 436, 154, 155, 2032, 2033, ")" +513, 14, 41, 437, 156, 157, 2034, 2035, "." +513, 15, 1, 438, 0, 3, 2036, 2039, "The" +513, 15, 2, 439, 4, 9, 2040, 2045, "upper" +513, 15, 3, 440, 10, 15, 2046, 2051, "bound" +513, 15, 4, 441, 16, 18, 2052, 2054, "of" +513, 15, 5, 442, 19, 22, 2055, 2058, "the" +513, 15, 6, 443, 23, 25, 2059, 2061, "95" +513, 15, 7, 444, 26, 27, 2062, 2063, "%" +513, 15, 8, 445, 28, 30, 2064, 2066, "CI" +513, 15, 9, 446, 31, 34, 2067, 2070, "was" +513, 15, 10, 447, 35, 36, 2071, 2072, "<" +513, 15, 11, 448, 37, 38, 2073, 2074, "1" +513, 15, 12, 449, 39, 40, 2075, 2076, "." +513, 15, 13, 450, 41, 42, 2077, 2078, "5" +513, 15, 14, 451, 43, 45, 2079, 2081, "mm" +513, 15, 15, 452, 46, 48, 2082, 2084, "Hg" +513, 15, 16, 453, 49, 50, 2085, 2086, "," +513, 15, 17, 454, 51, 61, 2087, 2097, "indicating" +513, 15, 18, 455, 62, 66, 2098, 2102, "that" +513, 15, 19, 456, 67, 74, 2103, 2110, "neither" +513, 15, 20, 457, 75, 77, 2111, 2113, "FC" +513, 15, 21, 458, 78, 80, 2114, 2116, "is" +513, 15, 22, 459, 81, 89, 2117, 2125, "inferior" +513, 15, 23, 460, 90, 92, 2126, 2128, "to" +513, 15, 24, 461, 93, 96, 2129, 2132, "the" +513, 15, 25, 462, 97, 102, 2133, 2138, "other" +513, 15, 26, 463, 103, 104, 2139, 2140, "." +513, 16, 1, 464, 0, 7, 2141, 2148, "However" +513, 16, 2, 465, 8, 9, 2149, 2150, "," +513, 16, 3, 466, 10, 11, 2151, 2152, "a" +513, 16, 4, 467, 12, 25, 2153, 2166, "significantly" +513, 16, 5, 468, 26, 33, 2167, 2174, "greater" +513, 16, 6, 469, 34, 44, 2175, 2185, "percentage" +513, 16, 7, 470, 45, 47, 2186, 2188, "of" +513, 16, 8, 471, 48, 56, 2189, 2197, "subjects" +513, 16, 9, 472, 57, 64, 2198, 2205, "treated" +513, 16, 10, 473, 65, 69, 2206, 2210, "with" +513, 16, 11, 474, 70, 72, 2211, 2213, "FC" +513, 16, 12, 475, 73, 84, 2214, 2225, "latanoprost" +513, 16, 13, 476, 85, 86, 2226, 2227, "/" +513, 16, 14, 477, 87, 94, 2228, 2235, "timolol" +513, 16, 15, 478, 95, 103, 2236, 2244, "achieved" +513, 16, 16, 479, 104, 107, 2245, 2248, "IOP" +513, 16, 17, 480, 108, 114, 2249, 2255, "levels" +513, 16, 18, 481, 115, 116, 2256, 2257, "<" +513, 16, 19, 482, 117, 119, 2258, 2260, "or" +513, 16, 20, 483, 120, 121, 2261, 2262, "=" +513, 16, 21, 484, 122, 124, 2263, 2265, "16" +513, 16, 22, 485, 125, 128, 2266, 2269, "and" +513, 16, 23, 486, 129, 130, 2270, 2271, "<" +513, 16, 24, 487, 131, 133, 2272, 2274, "or" +513, 16, 25, 488, 134, 135, 2275, 2276, "=" +513, 16, 26, 489, 136, 138, 2277, 2279, "15" +513, 16, 27, 490, 139, 141, 2280, 2282, "mm" +513, 16, 28, 491, 142, 144, 2283, 2285, "Hg" +513, 16, 29, 492, 145, 146, 2286, 2287, "(" +513, 16, 30, 493, 147, 148, 2288, 2289, "P" +513, 16, 31, 494, 149, 150, 2290, 2291, "<" +513, 16, 32, 495, 151, 153, 2292, 2294, "or" +513, 16, 33, 496, 154, 155, 2295, 2296, "=" +513, 16, 34, 497, 156, 157, 2297, 2298, "0" +513, 16, 35, 498, 158, 159, 2299, 2300, "." +513, 16, 36, 499, 160, 162, 2301, 2303, "01" +513, 16, 37, 500, 163, 164, 2304, 2305, ")" +513, 16, 38, 501, 165, 166, 2306, 2307, "." +513, 17, 1, 502, 0, 4, 2308, 2312, "Both" +513, 17, 2, 503, 5, 15, 2313, 2323, "treatments" +513, 17, 3, 504, 16, 20, 2324, 2328, "were" +513, 17, 4, 505, 21, 25, 2329, 2333, "well" +513, 17, 5, 506, 26, 35, 2334, 2343, "tolerated" +513, 17, 6, 507, 36, 37, 2344, 2345, "." +513, 18, 1, 508, 0, 11, 2346, 2357, "CONCLUSIONS" +513, 18, 2, 509, 12, 13, 2358, 2359, ":" +513, 18, 3, 510, 14, 18, 2360, 2364, "When" +513, 18, 4, 511, 19, 23, 2365, 2369, "beta" +513, 18, 5, 512, 24, 25, 2370, 2371, "-" +513, 18, 6, 513, 26, 33, 2372, 2379, "blocker" +513, 18, 7, 514, 34, 41, 2380, 2387, "therapy" +513, 18, 8, 515, 42, 44, 2388, 2390, "is" +513, 18, 9, 516, 45, 55, 2391, 2401, "inadequate" +513, 18, 10, 517, 56, 57, 2402, 2403, "," +513, 18, 11, 518, 58, 64, 2404, 2410, "either" +513, 18, 12, 519, 65, 67, 2411, 2413, "FC" +513, 18, 13, 520, 68, 71, 2414, 2417, "may" +513, 18, 14, 521, 72, 79, 2418, 2425, "achieve" +513, 18, 15, 522, 80, 83, 2426, 2429, "the" +513, 18, 16, 523, 84, 91, 2430, 2437, "desired" +513, 18, 17, 524, 92, 95, 2438, 2441, "IOP" +513, 18, 18, 525, 96, 101, 2442, 2447, "level" +513, 18, 19, 526, 102, 103, 2448, 2449, "," +513, 18, 20, 527, 104, 107, 2450, 2453, "but" +513, 18, 21, 528, 108, 110, 2454, 2456, "FC" +513, 18, 22, 529, 111, 122, 2457, 2468, "latanoprost" +513, 18, 23, 530, 123, 124, 2469, 2470, "/" +513, 18, 24, 531, 125, 132, 2471, 2478, "timolol" +513, 18, 25, 532, 133, 137, 2479, 2483, "more" +513, 18, 26, 533, 138, 143, 2484, 2489, "often" +513, 18, 27, 534, 144, 152, 2490, 2498, "achieves" +513, 18, 28, 535, 153, 154, 2499, 2500, "a" +513, 18, 29, 536, 155, 163, 2501, 2509, "pressure" +513, 18, 30, 537, 164, 166, 2510, 2512, "of" +513, 18, 31, 538, 167, 168, 2513, 2514, "<" +513, 18, 32, 539, 169, 171, 2515, 2517, "or" +513, 18, 33, 540, 172, 173, 2518, 2519, "=" +513, 18, 34, 541, 174, 176, 2520, 2522, "16" +513, 18, 35, 542, 177, 179, 2523, 2525, "mm" +513, 18, 36, 543, 180, 182, 2526, 2528, "Hg" +513, 18, 37, 544, 183, 184, 2529, 2530, "." +513, 19, 1, 545, 0, 4, 2531, 2535, "Both" +513, 19, 2, 546, 5, 8, 2536, 2539, "FCs" +513, 19, 3, 547, 9, 13, 2540, 2544, "were" +513, 19, 4, 548, 14, 18, 2545, 2549, "well" +513, 19, 5, 549, 19, 28, 2550, 2559, "tolerated" +513, 19, 6, 550, 29, 30, 2560, 2561, "." +513, 20, 1, 551, 0, 3, 2562, 2565, "DOI" +513, 20, 2, 552, 4, 5, 2566, 2567, ":" +513, 20, 3, 553, 6, 8, 2568, 2570, "10" +513, 20, 4, 554, 9, 10, 2571, 2572, "." +513, 20, 5, 555, 11, 15, 2573, 2577, "1038" +513, 20, 6, 556, 16, 17, 2578, 2579, "/" +513, 20, 7, 557, 18, 21, 2580, 2583, "eye" +513, 20, 8, 558, 22, 23, 2584, 2585, "." +513, 20, 9, 559, 24, 28, 2586, 2590, "2009" +513, 20, 10, 560, 29, 30, 2591, 2592, "." +513, 20, 11, 561, 31, 34, 2593, 2596, "307" +513, 20, 12, 562, 35, 39, 2597, 2601, "PMID" +513, 20, 13, 563, 40, 41, 2602, 2603, ":" +513, 20, 14, 564, 42, 50, 2604, 2612, "20019759" +513, 20, 15, 565, 51, 52, 2613, 2614, "[" +513, 20, 16, 566, 53, 60, 2615, 2622, "Indexed" +513, 20, 17, 567, 61, 64, 2623, 2626, "for" +513, 20, 18, 568, 65, 72, 2627, 2634, "MEDLINE" +513, 20, 19, 569, 73, 74, 2635, 2636, "]" diff --git a/data/gl 20019759_jshahinitiran.annodb b/data/gl 20019759_jshahinitiran.annodb new file mode 100644 index 0000000..fef1396 --- /dev/null +++ b/data/gl 20019759_jshahinitiran.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +57749, Journal, 0, 14, "Eye ( Lond ) .", "", +57750, PublicationYear, 15, 19, "2010", "", +57751, Title, 105, 247, "Efficacy and safety of fixed combinations of latanoprost / timolol and dorzolamide / timolol in open - angle glaucoma or ocular hypertension .", "", +57752, Latanoprost, 150, 161, "latanoprost", "", +57753, Timolol, 164, 171, "timolol", "", +57754, Dorzolamide, 176, 187, "dorzolamide", "", +57755, Timolol, 190, 197, "timolol", "", +57756, OpenAngleGlaucoma, 201, 222, "open - angle glaucoma", "", +57757, OcularHypertension, 226, 245, "ocular hypertension", "", +57758, Author, 248, 257, "Miglior S", "", +57759, Author, 266, 276, "Grunden JW", "", +57760, Author, 279, 285, "Kwok K", "", +57761, Italy, 772, 777, "Italy", "", +57762, ObjectiveDescription, 819, 990, "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .", "", +57763, IOP, 830, 850, "intraocular pressure", "", +57764, IOP, 853, 856, "IOP", "", +57765, Lat/TimFC, 875, 923, "fixed - combination ( FC ) latanoprost / timolol", "", +57770, Latanoprost, 902, 913, "latanoprost", "", +57771, Timolol, 916, 923, "timolol", "", +57766, Frequency, 924, 934, "once daily", "", +57768, Dorz/TimFC, 950, 976, "vsFC dorzolamide / timolol", "", +57772, Dorzolamide, 955, 966, "dorzolamide", "", +57773, Timolol, 969, 976, "timolol", "", +57769, Frequency, 977, 988, "twice daily", "", +57774, Blind, 1006, 1024, "evaluator - masked", "", +57775, Multicenter, 1027, 1038, "multicentre", "", +57776, Randomized, 1067, 1077, "randomized", "", +57777, Primary_OpenAngleGlaucoma, 1092, 1121, "primary open - angle glaucoma", "", +57778, OcularHypertension, 1125, 1144, "ocular hypertension", "", +57779, Precondition, 1145, 1243, "with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )", "", +57780, IOP, 1150, 1153, "IOP", "", +57781, IOP, 1218, 1221, "IOP", "", +57782, mmHg, 1236, 1241, "mm Hg", "", +57783, Lat/TimFC, 1247, 1271, "FC latanoprost - timolol", "", +57784, Latanoprost, 1250, 1261, "latanoprost", "", +57785, Timolol, 1264, 1271, "timolol", "", +57786, NumberPatientsArm, 1278, 1281, "135", "", +57787, Dorz/TimFC, 1287, 1311, "FC dorzolamide / timolol", "", +57788, Dorzolamide, 1290, 1301, "dorzolamide", "", +57789, Timolol, 1304, 1311, "timolol", "", +57790, NumberPatientsArm, 1318, 1321, "135", "", +57791, TimePoint, 1329, 1338, "screening", "", +57792, TimePoint, 1341, 1349, "baseline", "", +57793, TimePoint, 1362, 1376, "4 and 12 weeks", "", +57794, TimePoint, 1368, 1376, "12 weeks", "", +57795, IOP, 1390, 1393, "IOP", "", +57796, Mean, 1620, 1624, "mean", "", +57797, IOP, 1633, 1636, "IOP", "", +57798, TimePoint, 1642, 1650, "baseline", "", +57799, TimePoint, 1654, 1661, "week 12", "", +57800, Mean, 1674, 1678, "Mean", "", +57801, IOP, 1687, 1690, "IOP", "", +57802, TimePoint, 1714, 1722, "baseline", "", +57803, Mean, 1725, 1729, "Mean", "", +57804, IOP, 1752, 1755, "IOP", "", +57805, TimePoint, 1761, 1769, "baseline", "", +57806, TimePoint, 1773, 1780, "week 12", "", +57807, Reduction, 1788, 1793, "9 . 7", "", +57809, mmHg, 1794, 1799, "mm Hg", "", +57811, Lat/TimFC, 1804, 1828, "FC latanoprost - timolol", "", +57812, Latanoprost, 1807, 1818, "latanoprost", "", +57813, Timolol, 1821, 1828, "timolol", "", +57808, Reduction, 1835, 1840, "9 . 5", "", +57810, mmHg, 1841, 1846, "mm Hg", "", +57814, Dorz/TimFC, 1851, 1875, "FC dorzolamide / timolol", "", +57815, Dorzolamide, 1854, 1865, "dorzolamide", "", +57816, Timolol, 1868, 1875, "timolol", "", +57817, Lat/TimFC, 1901, 1925, "FC latanoprost / timolol", "", +57819, Latanoprost, 1904, 1915, "latanoprost", "", +57820, Timolol, 1918, 1925, "timolol", "", +57818, Dorz/TimFC, 1928, 1952, "FC dorzolamide - timolol", "", +57821, Timolol, 1945, 1952, "timolol", "", +57822, DiffGroupAbsValue, 1959, 1964, "0 . 2", "", +57823, mmHg, 1965, 1970, "mm Hg", "", +57824, ConfIntervalChangeValue, 1973, 2031, "95 % confidence interval ( CI ) , - 0 . 8 to - 0 . 4 mm Hg", "", +57825, mmHg, 2079, 2084, "mm Hg", "", +57831, ObservedResult, 2141, 2307, "However , a significantly greater percentage of subjects treated with FC latanoprost / timolol achieved IOP levels < or = 16 and < or = 15 mm Hg ( P < or = 0 . 01 ) .", "", +57826, Lat/TimFC, 2211, 2235, "FC latanoprost / timolol", "", +57827, Latanoprost, 2214, 2225, "latanoprost", "", +57828, Timolol, 2228, 2235, "timolol", "", +57829, IOP, 2245, 2248, "IOP", "", +57830, mmHg, 2280, 2285, "mm Hg", "", +57832, ConclusionComment, 2360, 2530, "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .", "", +57833, IOP, 2438, 2441, "IOP", "", +57834, Lat/TimFC, 2454, 2478, "FC latanoprost / timolol", "", +57835, Latanoprost, 2457, 2468, "latanoprost", "", +57836, Timolol, 2471, 2478, "timolol", "", +57837, mmHg, 2523, 2528, "mm Hg", "", +57838, ConclusionComment, 2531, 2561, "Both FCs were well tolerated .", "", +57839, PMID, 2604, 2612, "20019759", "", diff --git a/data/gl 20019759_jshahinitiran.n-triples b/data/gl 20019759_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20019759_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20019759_tstrakeljahn.annodb b/data/gl 20019759_tstrakeljahn.annodb new file mode 100644 index 0000000..ee008d1 --- /dev/null +++ b/data/gl 20019759_tstrakeljahn.annodb @@ -0,0 +1,126 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80494, Journal, 0, 12, "Eye ( Lond )", "", +80495, PublicationYear, 15, 19, "2010", "", +80496, Latanoprost, 150, 161, "latanoprost", "", +80500, Lat/TimFC, 150, 171, "latanoprost / timolol", "", +80497, Timolol, 164, 171, "timolol", "", +80499, Dorzolamide, 176, 187, "dorzolamide", "", +80501, Dorz/TimFC, 176, 197, "dorzolamide / timolol", "", +80498, Timolol, 190, 197, "timolol", "", +80502, OpenAngleGlaucoma, 201, 222, "open - angle glaucoma", "", +80503, OcularHypertension, 226, 245, "ocular hypertension", "", +80504, Author, 248, 257, "Miglior S", "", +80505, Author, 266, 276, "Grunden JW", "", +80506, Author, 279, 285, "Kwok K", "", +80508, Lat/TimFC, 288, 295, "Xalacom", "", +80507, Dorz/TimFC, 298, 304, "Cosopt", "", +80510, Author, 344, 351, "Denis P", "", +80511, Author, 354, 364, "Mouriaux F", "", +80512, Author, 367, 375, "Peigne G", "", +80513, Author, 378, 387, "Ridings B", "", +80514, Author, 390, 397, "Rigal D", "", +80515, Author, 400, 408, "Christ T", "", +80516, Author, 411, 419, "Deuker H", "", +80517, Author, 422, 432, "Hamacher T", "", +80518, Author, 435, 445, "Hoffmann M", "", +80519, Author, 448, 457, "Jelinek C", "", +80520, Author, 460, 471, "Scherzer ML", "", +80521, Author, 474, 486, "Karabatsas K", "", +80522, Author, 489, 498, "Konstas A", "", +80523, Author, 501, 513, "Kozombolis V", "", +80524, Author, 516, 529, "Tsilimbaris M", "", +80525, Author, 532, 541, "Carassa R", "", +80526, Author, 544, 556, "Delle Noci N", "", +80527, Author, 559, 567, "Iester M", "", +80528, Author, 570, 584, "Mastropasqua L", "", +80529, Author, 587, 596, "Miglior S", "", +80530, Author, 599, 606, "Nardi M", "", +80531, Author, 609, 618, "Chatila A", "", +80532, Author, 621, 628, "Heijl A", "", +80533, Author, 631, 641, "Lindblom B", "", +80534, Author, 644, 652, "Vancea L", "", +80509, Italy, 772, 777, "Italy", "", +80546, ObjectiveDescription, 819, 990, "To compare intraocular pressure ( IOP ) reductions with fixed - combination ( FC ) latanoprost / timolol once daily in the evening vsFC dorzolamide / timolol twice daily .", "", +80535, IOP, 830, 850, "intraocular pressure", "", +80536, IOP, 853, 856, "IOP", "", +80537, Latanoprost, 902, 913, "latanoprost", "", +80539, Lat/TimFC, 902, 923, "latanoprost / timolol", "", +80538, Timolol, 916, 923, "timolol", "", +80540, Frequency, 924, 934, "once daily", "", +80541, Evening, 935, 949, "in the evening", "", +80542, Dorzolamide, 955, 966, "dorzolamide", "", +80544, Dorz/TimFC, 955, 976, "dorzolamide / timolol", "", +80543, Timolol, 969, 976, "timolol", "", +80545, Frequency, 977, 988, "twice daily", "", +80547, Blind, 1006, 1024, "evaluator - masked", "", +80548, Multicenter, 1027, 1038, "multicentre", "", +80549, ClinicalTrial, 1052, 1066, "clinical trial", "", +80550, Randomized, 1067, 1077, "randomized", "", +80556, Precondition, 1078, 1243, "subjects with primary open - angle glaucoma or ocular hypertension with IOP insufficiently responsive to beta - blocker therapy ( screening IOP > 21 and < 37 mm Hg )", "", +80551, Primary_OpenAngleGlaucoma, 1092, 1121, "primary open - angle glaucoma", "", +80552, OcularHypertension, 1125, 1144, "ocular hypertension", "", +80553, IOP, 1150, 1153, "IOP", "", +80554, IOP, 1218, 1221, "IOP", "", +80555, mmHg, 1236, 1241, "mm Hg", "", +80557, Latanoprost, 1250, 1261, "latanoprost", "", +80561, Lat/TimFC, 1250, 1271, "latanoprost - timolol", "", +80558, Timolol, 1264, 1271, "timolol", "", +80563, NumberPatientsArm, 1278, 1281, "135", "", +80559, Dorzolamide, 1290, 1301, "dorzolamide", "", +80562, Dorz/TimFC, 1290, 1311, "dorzolamide / timolol", "", +80560, Timolol, 1304, 1311, "timolol", "", +80564, NumberPatientsArm, 1318, 1321, "135", "", +80571, TimePoint, 1326, 1338, "At screening", "", +80572, TimePoint, 1341, 1349, "baseline", "", +80570, TimePoint, 1362, 1376, "4 and 12 weeks", "", +80569, TimePoint, 1368, 1376, "12 weeks", "", +80565, IOP, 1390, 1393, "IOP", "", +80566, TimePoint, 1422, 1426, "0800", "", +80567, TimePoint, 1429, 1433, "1200", "", +80568, TimePoint, 1440, 1444, "1600", "", +80576, Endpoint, 1533, 1661, "whether either FC could be shown to be inferior to the other with respect to change in mean daytime IOP from baseline to week 12", "", +80573, Mean, 1620, 1624, "mean", "", +80574, IOP, 1633, 1636, "IOP", "", +80575, Duration, 1654, 1661, "week 12", "", +80577, Mean, 1674, 1678, "Mean", "", +80578, IOP, 1687, 1690, "IOP", "", +80579, Mean, 1725, 1729, "Mean", "", +80580, IOP, 1752, 1755, "IOP", "", +80581, Duration, 1773, 1780, "week 12", "", +80582, Reduction, 1788, 1793, "9 . 7", "", +80584, mmHg, 1794, 1799, "mm Hg", "", +80586, Latanoprost, 1807, 1818, "latanoprost", "", +80587, Timolol, 1821, 1828, "timolol", "", +80583, Reduction, 1835, 1840, "9 . 5", "", +80585, mmHg, 1841, 1846, "mm Hg", "", +80589, Dorzolamide, 1854, 1865, "dorzolamide", "", +80588, Timolol, 1868, 1875, "timolol", "", +80590, Latanoprost, 1904, 1915, "latanoprost", "", +80594, Lat/TimFC, 1904, 1925, "latanoprost / timolol", "", +80591, Timolol, 1918, 1925, "timolol", "", +80593, Dorzolamide, 1931, 1942, "dorzolamide", "", +80595, Dorz/TimFC, 1931, 1952, "dorzolamide - timolol", "", +80592, Timolol, 1945, 1952, "timolol", "", +80596, DiffGroupAbsValue, 1959, 1964, "0 . 2", "", +80597, mmHg, 1965, 1970, "mm Hg", "", +80599, ConfIntervalDiff, 2007, 2025, "- 0 . 8 to - 0 . 4", "", +80598, mmHg, 2026, 2031, "mm Hg", "", +80601, ObservedResult, 2036, 2140, "The upper bound of the 95 % CI was < 1 . 5 mm Hg , indicating that neither FC is inferior to the other .", "", +80600, mmHg, 2079, 2084, "mm Hg", "", +80609, ObservedResult, 2141, 2307, "However , a significantly greater percentage of subjects treated with FC latanoprost / timolol achieved IOP levels < or = 16 and < or = 15 mm Hg ( P < or = 0 . 01 ) .", "", +80603, Latanoprost, 2214, 2225, "latanoprost", "", +80605, Lat/TimFC, 2214, 2235, "latanoprost / timolol", "", +80604, Timolol, 2228, 2235, "timolol", "", +80608, SubGroupDescription, 2236, 2285, "achieved IOP levels < or = 16 and < or = 15 mm Hg", "", +80606, IOP, 2245, 2248, "IOP", "", +80602, mmHg, 2280, 2285, "mm Hg", "", +80607, PvalueDiff, 2290, 2303, "< or = 0 . 01", "", +80610, ObservedResult, 2308, 2345, "Both treatments were well tolerated .", "", +80616, ConclusionComment, 2360, 2530, "When beta - blocker therapy is inadequate , either FC may achieve the desired IOP level , but FC latanoprost / timolol more often achieves a pressure of < or = 16 mm Hg .", "", +80611, IOP, 2438, 2441, "IOP", "", +80612, Latanoprost, 2457, 2468, "latanoprost", "", +80614, Lat/TimFC, 2457, 2478, "latanoprost / timolol", "", +80613, Timolol, 2471, 2478, "timolol", "", +80615, mmHg, 2523, 2528, "mm Hg", "", +80617, ConclusionComment, 2531, 2561, "Both FCs were well tolerated .", "", +80618, PMID, 2604, 2612, "20019759", "", diff --git a/data/gl 20019759_tstrakeljahn.n-triples b/data/gl 20019759_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20019759_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20420586_admin.annodb b/data/gl 20420586_admin.annodb new file mode 100644 index 0000000..021f096 --- /dev/null +++ b/data/gl 20420586_admin.annodb @@ -0,0 +1,65 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +2, Journal, 0, 15, "Acta Ophthalmol", "", " \"Acta Ophthalmol\"." +3, PublicationYear, 18, 22, "2010", "", " \"2010\"." +16, Title, 104, 309, "Efficacy and safety of tafluprost 0 . 0015 % versus latanoprost 0 . 005 % eye drops in open - angle glaucoma and ocular hypertension : 24 - month results of a randomized , double - masked phase III study .", "", " \"Efficacy and safety of tafluprost 0 . 0015 % versus latanoprost 0 . 005 % eye drops in open - angle glaucoma and ocular hypertension : 24 - month results of a randomized , double - masked phase III study .\"." +4, Tafluprost, 127, 137, "tafluprost", "", " ." +12, DoseValue, 138, 146, "0 . 0015", "", +15, Percentage, 147, 148, "%", "", +5, Latanoprost, 156, 167, "latanoprost", "", +13, DoseValue, 168, 175, "0 . 005", "", +97, Percentage, 176, 177, "%", "", +6, Eyedrops, 178, 187, "eye drops", "", +7, OpenAngleGlaucoma, 191, 212, "open - angle glaucoma", "", " ." +8, OcularHypertension, 217, 236, "ocular hypertension", "", " ." +9, Duration, 239, 249, "24 - month", "", " \"24 - month\"." +10, Randomized, 263, 273, "randomized", "", " ." +11, DoubleBlind, 276, 291, "double - masked", "", " ." +17, Author, 310, 320, "Uusitalo H", "", " \"Uusitalo H\"." +18, Author, 329, 340, "Pillunat LE", "", " \"Pillunat LE\"." +19, Author, 343, 349, "Ropo A", "", " \"Ropo A\"." +20, Finland, 505, 512, "Finland", "", " ." +30, ObjectiveDescription, 553, 756, "The objective of the study was to compare the long - term efficacy and safety of tafluprost 0 . 0015 % with latanoprost 0 . 005 % eye drops in patients with open - angle glaucoma or ocular hypertension .", "", " \"The objective of the study was to compare the long - term efficacy and safety of tafluprost 0 . 0015 % with latanoprost 0 . 005 % eye drops in patients with open - angle glaucoma or ocular hypertension .\"." +21, Tafluprost, 634, 644, "tafluprost", "", +26, DoseValue, 645, 653, "0 . 0015", "", " \"0 . 0015\"." +28, Percentage, 654, 655, "%", "", " ." +22, Latanoprost, 661, 672, "latanoprost", "", " . ." +27, DoseValue, 673, 680, "0 . 005", "", " \"0 . 005\"." +29, Percentage, 681, 682, "%", "", " ." +23, Eyedrops, 683, 692, "eye drops", "", " . ." +24, OpenAngleGlaucoma, 710, 731, "open - angle glaucoma", "", +25, OcularHypertension, 735, 754, "ocular hypertension", "", +31, DoubleBlind, 772, 787, "double - masked", "", +71, CTDesign, 790, 809, "active - controlled", "", " . ." +32, Parallel, 812, 820, "parallel", "", " ." +73, CTDesign, 831, 844, "multinational", "", " . ." +33, Multicenter, 847, 858, "multicentre", "", " ." +36992, Frequency, 980, 990, "once daily", "", " \"once daily\". \"once daily\"." +36994, ApplicationCondition, 994, 1001, "20 : 00", "", " \"20 : 00\". \"20 : 00\"." +35, Duration, 1016, 1025, "24 months", "", +36, IOP, 1049, 1069, "intraocular pressure", "", " . ." +37, IOP, 1072, 1075, "IOP", "", +38, Tafluprost, 1182, 1192, "tafluprost", "", +39, Latanoprost, 1197, 1208, "latanoprost", "", +0, NumberPatientsCT, 1268, 1271, "533", "", " \"533\"." +40, Randomized, 1281, 1291, "randomized", "", +1, FinalNumPatientsCT, 1294, 1297, "402", "", +41, Duration, 1317, 1326, "24 months", "", +42, IOP, 1374, 1377, "IOP", "", +82, Reduction, 1437, 1442, "7 . 1", "", " \"7 . 1\"." +45, mmHg, 1443, 1447, "mmHg", "", " ." +49, Tafluprost, 1452, 1462, "tafluprost", "", +83, Reduction, 1469, 1474, "7 . 7", "", " \"7 . 7\"." +46, mmHg, 1475, 1479, "mmHg", "", +47, Latanoprost, 1484, 1495, "latanoprost", "", +48, TimePoint, 1499, 1508, "24 months", "", " \"24 months\". \"24 months\"." +50, IOP, 1526, 1529, "IOP", "", +51, Latanoprost, 1590, 1601, "latanoprost", "", +53, Tafluprost, 1667, 1677, "tafluprost", "", +52, Latanoprost, 1681, 1692, "latanoprost", "", +54, Diurnal_IOP, 1702, 1713, "diurnal IOP", "", +56, mmHg, 1922, 1926, "mmHg", "", +57, Tafluprost, 1943, 1953, "Tafluprost", "", +60, ConclusionComment, 1943, 2042, "Tafluprost is a new effective and well - tolerated treatment for glaucoma and ocular hypertension .", "", " \"Tafluprost is a new effective and well - tolerated treatment for glaucoma and ocular hypertension .\"." +58, Glaucoma, 2008, 2016, "glaucoma", "", +59, OcularHypertension, 2021, 2040, "ocular hypertension", "", +61, PMID, 2103, 2111, "20420586", "", " \"20420586\"." diff --git a/data/gl 20420586_admin.n-triples b/data/gl 20420586_admin.n-triples new file mode 100644 index 0000000..3114342 --- /dev/null +++ b/data/gl 20420586_admin.n-triples @@ -0,0 +1,100 @@ +# RDF export of group: Publication + . + "Publication" . + "Efficacy and safety of tafluprost 0 . 0015 % versus latanoprost 0 . 005 % eye drops in open - angle glaucoma and ocular hypertension : 24 - month results of a randomized , double - masked phase III study ." . + "Uusitalo H" . + "2010" . + "Acta Ophthalmol" . + "20420586" . + . + "Pillunat LE" . + "Ropo A" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The objective of the study was to compare the long - term efficacy and safety of tafluprost 0 . 0015 % with latanoprost 0 . 005 % eye drops in patients with open - angle glaucoma or ocular hypertension ." . + "533" . + "24 - month" . + . + . + . + "Tafluprost is a new effective and well - tolerated treatment for glaucoma and ocular hypertension ." . + . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_taf" . + . + . + . + . + "Arm_lat" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_taf" . + . + "once daily" . + . + . + "Intervention_lat" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_taf" . + . + "0 . 0015" . + . + . + "20 : 00" . + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + "20 : 00" . +# RDF export of group: Outcome + . + "Outcome_taf" . + . + "7 . 1" . + "24 months" . + . + "Outcome_lat" . + . + "7 . 7" . + "24 months" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20420586_export.csv b/data/gl 20420586_export.csv new file mode 100644 index 0000000..784edd2 --- /dev/null +++ b/data/gl 20420586_export.csv @@ -0,0 +1,415 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +437, 1, 1, 1, 0, 4, 0, 4, "Acta" +437, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +437, 1, 3, 3, 16, 17, 16, 17, "." +437, 2, 1, 4, 0, 4, 18, 22, "2010" +437, 2, 2, 5, 5, 8, 23, 26, "Feb" +437, 2, 3, 6, 9, 10, 27, 28, ";" +437, 2, 4, 7, 11, 13, 29, 31, "88" +437, 2, 5, 8, 14, 15, 32, 33, "(" +437, 2, 6, 9, 16, 17, 34, 35, "1" +437, 2, 7, 10, 18, 19, 36, 37, ")" +437, 2, 8, 11, 20, 21, 38, 39, ":" +437, 2, 9, 12, 22, 24, 40, 42, "12" +437, 2, 10, 13, 25, 26, 43, 44, "-" +437, 2, 11, 14, 27, 28, 45, 46, "9" +437, 2, 12, 15, 29, 30, 47, 48, "." +437, 2, 13, 16, 31, 34, 49, 52, "doi" +437, 2, 14, 17, 35, 36, 53, 54, ":" +437, 2, 15, 18, 37, 39, 55, 57, "10" +437, 2, 16, 19, 40, 41, 58, 59, "." +437, 2, 17, 20, 42, 46, 60, 64, "1111" +437, 2, 18, 21, 47, 48, 65, 66, "/" +437, 2, 19, 22, 49, 50, 67, 68, "j" +437, 2, 20, 23, 51, 52, 69, 70, "." +437, 2, 21, 24, 53, 57, 71, 75, "1755" +437, 2, 22, 25, 58, 59, 76, 77, "-" +437, 2, 23, 26, 60, 64, 78, 82, "3768" +437, 2, 24, 27, 65, 66, 83, 84, "." +437, 2, 25, 28, 67, 71, 85, 89, "2010" +437, 2, 26, 29, 72, 73, 90, 91, "." +437, 2, 27, 30, 74, 79, 92, 97, "01862" +437, 2, 28, 31, 80, 81, 98, 99, "." +437, 2, 29, 32, 82, 83, 100, 101, "x" +437, 2, 30, 33, 84, 85, 102, 103, "." +437, 3, 1, 34, 0, 8, 104, 112, "Efficacy" +437, 3, 2, 35, 9, 12, 113, 116, "and" +437, 3, 3, 36, 13, 19, 117, 123, "safety" +437, 3, 4, 37, 20, 22, 124, 126, "of" +437, 3, 5, 38, 23, 33, 127, 137, "tafluprost" +437, 3, 6, 39, 34, 35, 138, 139, "0" +437, 3, 7, 40, 36, 37, 140, 141, "." +437, 3, 8, 41, 38, 42, 142, 146, "0015" +437, 3, 9, 42, 43, 44, 147, 148, "%" +437, 3, 10, 43, 45, 51, 149, 155, "versus" +437, 3, 11, 44, 52, 63, 156, 167, "latanoprost" +437, 3, 12, 45, 64, 65, 168, 169, "0" +437, 3, 13, 46, 66, 67, 170, 171, "." +437, 3, 14, 47, 68, 71, 172, 175, "005" +437, 3, 15, 48, 72, 73, 176, 177, "%" +437, 3, 16, 49, 74, 77, 178, 181, "eye" +437, 3, 17, 50, 78, 83, 182, 187, "drops" +437, 3, 18, 51, 84, 86, 188, 190, "in" +437, 3, 19, 52, 87, 91, 191, 195, "open" +437, 3, 20, 53, 92, 93, 196, 197, "-" +437, 3, 21, 54, 94, 99, 198, 203, "angle" +437, 3, 22, 55, 100, 108, 204, 212, "glaucoma" +437, 3, 23, 56, 109, 112, 213, 216, "and" +437, 3, 24, 57, 113, 119, 217, 223, "ocular" +437, 3, 25, 58, 120, 132, 224, 236, "hypertension" +437, 3, 26, 59, 133, 134, 237, 238, ":" +437, 3, 27, 60, 135, 137, 239, 241, "24" +437, 3, 28, 61, 138, 139, 242, 243, "-" +437, 3, 29, 62, 140, 145, 244, 249, "month" +437, 3, 30, 63, 146, 153, 250, 257, "results" +437, 3, 31, 64, 154, 156, 258, 260, "of" +437, 3, 32, 65, 157, 158, 261, 262, "a" +437, 3, 33, 66, 159, 169, 263, 273, "randomized" +437, 3, 34, 67, 170, 171, 274, 275, "," +437, 3, 35, 68, 172, 178, 276, 282, "double" +437, 3, 36, 69, 179, 180, 283, 284, "-" +437, 3, 37, 70, 181, 187, 285, 291, "masked" +437, 3, 38, 71, 188, 193, 292, 297, "phase" +437, 3, 39, 72, 194, 197, 298, 301, "III" +437, 3, 40, 73, 198, 203, 302, 307, "study" +437, 3, 41, 74, 204, 205, 308, 309, "." +437, 4, 1, 75, 0, 8, 310, 318, "Uusitalo" +437, 4, 2, 76, 9, 10, 319, 320, "H" +437, 4, 3, 77, 11, 12, 321, 322, "(" +437, 4, 4, 78, 13, 14, 323, 324, "1" +437, 4, 5, 79, 15, 16, 325, 326, ")" +437, 4, 6, 80, 17, 18, 327, 328, "," +437, 4, 7, 81, 19, 27, 329, 337, "Pillunat" +437, 4, 8, 82, 28, 30, 338, 340, "LE" +437, 4, 9, 83, 31, 32, 341, 342, "," +437, 4, 10, 84, 33, 37, 343, 347, "Ropo" +437, 4, 11, 85, 38, 39, 348, 349, "A" +437, 4, 12, 86, 40, 41, 350, 351, ";" +437, 4, 13, 87, 42, 47, 352, 357, "Phase" +437, 4, 14, 88, 48, 51, 358, 361, "III" +437, 4, 15, 89, 52, 57, 362, 367, "Study" +437, 4, 16, 90, 58, 71, 368, 381, "Investigators" +437, 4, 17, 91, 72, 73, 382, 383, "." +437, 5, 1, 92, 0, 6, 384, 390, "Author" +437, 5, 2, 93, 7, 18, 391, 402, "information" +437, 5, 3, 94, 19, 20, 403, 404, ":" +437, 5, 4, 95, 21, 22, 405, 406, "(" +437, 5, 5, 96, 23, 24, 407, 408, "1" +437, 5, 6, 97, 25, 26, 409, 410, ")" +437, 5, 7, 98, 27, 37, 411, 421, "Department" +437, 5, 8, 99, 38, 40, 422, 424, "of" +437, 5, 9, 100, 41, 54, 425, 438, "Ophthalmology" +437, 5, 10, 101, 55, 56, 439, 440, "," +437, 5, 11, 102, 57, 64, 441, 448, "Tampere" +437, 5, 12, 103, 65, 75, 449, 459, "University" +437, 5, 13, 104, 76, 84, 460, 468, "Hospital" +437, 5, 14, 105, 85, 86, 469, 470, "," +437, 5, 15, 106, 87, 97, 471, 481, "University" +437, 5, 16, 107, 98, 100, 482, 484, "of" +437, 5, 17, 108, 101, 108, 485, 492, "Tampere" +437, 5, 18, 109, 109, 110, 493, 494, "," +437, 5, 19, 110, 111, 118, 495, 502, "Tampere" +437, 5, 20, 111, 119, 120, 503, 504, "," +437, 5, 21, 112, 121, 128, 505, 512, "Finland" +437, 5, 22, 113, 129, 130, 513, 514, "." +437, 6, 1, 114, 0, 5, 515, 520, "Hannu" +437, 6, 2, 115, 6, 7, 521, 522, "." +437, 6, 3, 116, 8, 16, 523, 531, "Uusitalo" +437, 6, 4, 117, 17, 18, 532, 533, "@" +437, 6, 5, 118, 19, 22, 534, 537, "uta" +437, 6, 6, 119, 23, 24, 538, 539, "." +437, 6, 7, 120, 25, 27, 540, 542, "fi" +437, 6, 8, 121, 28, 35, 543, 550, "PURPOSE" +437, 6, 9, 122, 36, 37, 551, 552, ":" +437, 6, 10, 123, 38, 41, 553, 556, "The" +437, 6, 11, 124, 42, 51, 557, 566, "objective" +437, 6, 12, 125, 52, 54, 567, 569, "of" +437, 6, 13, 126, 55, 58, 570, 573, "the" +437, 6, 14, 127, 59, 64, 574, 579, "study" +437, 6, 15, 128, 65, 68, 580, 583, "was" +437, 6, 16, 129, 69, 71, 584, 586, "to" +437, 6, 17, 130, 72, 79, 587, 594, "compare" +437, 6, 18, 131, 80, 83, 595, 598, "the" +437, 6, 19, 132, 84, 88, 599, 603, "long" +437, 6, 20, 133, 89, 90, 604, 605, "-" +437, 6, 21, 134, 91, 95, 606, 610, "term" +437, 6, 22, 135, 96, 104, 611, 619, "efficacy" +437, 6, 23, 136, 105, 108, 620, 623, "and" +437, 6, 24, 137, 109, 115, 624, 630, "safety" +437, 6, 25, 138, 116, 118, 631, 633, "of" +437, 6, 26, 139, 119, 129, 634, 644, "tafluprost" +437, 6, 27, 140, 130, 131, 645, 646, "0" +437, 6, 28, 141, 132, 133, 647, 648, "." +437, 6, 29, 142, 134, 138, 649, 653, "0015" +437, 6, 30, 143, 139, 140, 654, 655, "%" +437, 6, 31, 144, 141, 145, 656, 660, "with" +437, 6, 32, 145, 146, 157, 661, 672, "latanoprost" +437, 6, 33, 146, 158, 159, 673, 674, "0" +437, 6, 34, 147, 160, 161, 675, 676, "." +437, 6, 35, 148, 162, 165, 677, 680, "005" +437, 6, 36, 149, 166, 167, 681, 682, "%" +437, 6, 37, 150, 168, 171, 683, 686, "eye" +437, 6, 38, 151, 172, 177, 687, 692, "drops" +437, 6, 39, 152, 178, 180, 693, 695, "in" +437, 6, 40, 153, 181, 189, 696, 704, "patients" +437, 6, 41, 154, 190, 194, 705, 709, "with" +437, 6, 42, 155, 195, 199, 710, 714, "open" +437, 6, 43, 156, 200, 201, 715, 716, "-" +437, 6, 44, 157, 202, 207, 717, 722, "angle" +437, 6, 45, 158, 208, 216, 723, 731, "glaucoma" +437, 6, 46, 159, 217, 219, 732, 734, "or" +437, 6, 47, 160, 220, 226, 735, 741, "ocular" +437, 6, 48, 161, 227, 239, 742, 754, "hypertension" +437, 6, 49, 162, 240, 241, 755, 756, "." +437, 7, 1, 163, 0, 7, 757, 764, "METHODS" +437, 7, 2, 164, 8, 9, 765, 766, ":" +437, 7, 3, 165, 10, 14, 767, 771, "This" +437, 7, 4, 166, 15, 21, 772, 778, "double" +437, 7, 5, 167, 22, 23, 779, 780, "-" +437, 7, 6, 168, 24, 30, 781, 787, "masked" +437, 7, 7, 169, 31, 32, 788, 789, "," +437, 7, 8, 170, 33, 39, 790, 796, "active" +437, 7, 9, 171, 40, 41, 797, 798, "-" +437, 7, 10, 172, 42, 52, 799, 809, "controlled" +437, 7, 11, 173, 53, 54, 810, 811, "," +437, 7, 12, 174, 55, 63, 812, 820, "parallel" +437, 7, 13, 175, 64, 65, 821, 822, "-" +437, 7, 14, 176, 66, 71, 823, 828, "group" +437, 7, 15, 177, 72, 73, 829, 830, "," +437, 7, 16, 178, 74, 87, 831, 844, "multinational" +437, 7, 17, 179, 88, 89, 845, 846, "," +437, 7, 18, 180, 90, 101, 847, 858, "multicentre" +437, 7, 19, 181, 102, 103, 859, 860, "," +437, 7, 20, 182, 104, 109, 861, 866, "phase" +437, 7, 21, 183, 110, 113, 867, 870, "III" +437, 7, 22, 184, 114, 119, 871, 876, "study" +437, 7, 23, 185, 120, 123, 877, 880, "was" +437, 7, 24, 186, 124, 133, 881, 890, "conducted" +437, 7, 25, 187, 134, 136, 891, 893, "at" +437, 7, 26, 188, 137, 139, 894, 896, "49" +437, 7, 27, 189, 140, 147, 897, 904, "centres" +437, 7, 28, 190, 148, 150, 905, 907, "in" +437, 7, 29, 191, 151, 152, 908, 909, "8" +437, 7, 30, 192, 153, 162, 910, 919, "countries" +437, 7, 31, 193, 163, 164, 920, 921, "." +437, 8, 1, 194, 0, 8, 922, 930, "Eligible" +437, 8, 2, 195, 9, 17, 931, 939, "patients" +437, 8, 3, 196, 18, 22, 940, 944, "were" +437, 8, 4, 197, 23, 31, 945, 953, "assigned" +437, 8, 5, 198, 32, 34, 954, 956, "to" +437, 8, 6, 199, 35, 44, 957, 966, "treatment" +437, 8, 7, 200, 45, 57, 967, 979, "administered" +437, 8, 8, 201, 58, 62, 980, 984, "once" +437, 8, 9, 202, 63, 68, 985, 990, "daily" +437, 8, 10, 203, 69, 71, 991, 993, "at" +437, 8, 11, 204, 72, 74, 994, 996, "20" +437, 8, 12, 205, 75, 76, 997, 998, ":" +437, 8, 13, 206, 77, 79, 999, 1001, "00" +437, 8, 14, 207, 80, 83, 1002, 1005, "hrs" +437, 8, 15, 208, 84, 87, 1006, 1009, "for" +437, 8, 16, 209, 88, 90, 1010, 1012, "up" +437, 8, 17, 210, 91, 93, 1013, 1015, "to" +437, 8, 18, 211, 94, 96, 1016, 1018, "24" +437, 8, 19, 212, 97, 103, 1019, 1025, "months" +437, 8, 20, 213, 104, 105, 1026, 1027, "." +437, 9, 1, 214, 0, 6, 1028, 1034, "Change" +437, 9, 2, 215, 7, 11, 1035, 1039, "from" +437, 9, 3, 216, 12, 20, 1040, 1048, "baseline" +437, 9, 4, 217, 21, 32, 1049, 1060, "intraocular" +437, 9, 5, 218, 33, 41, 1061, 1069, "pressure" +437, 9, 6, 219, 42, 43, 1070, 1071, "(" +437, 9, 7, 220, 44, 47, 1072, 1075, "IOP" +437, 9, 8, 221, 48, 49, 1076, 1077, ")" +437, 9, 9, 222, 50, 53, 1078, 1081, "was" +437, 9, 10, 223, 54, 57, 1082, 1085, "the" +437, 9, 11, 224, 58, 65, 1086, 1093, "primary" +437, 9, 12, 225, 66, 74, 1094, 1102, "efficacy" +437, 9, 13, 226, 75, 83, 1103, 1111, "variable" +437, 9, 14, 227, 84, 85, 1112, 1113, "." +437, 10, 1, 228, 0, 7, 1114, 1121, "Adverse" +437, 10, 2, 229, 8, 14, 1122, 1128, "events" +437, 10, 3, 230, 15, 19, 1129, 1133, "were" +437, 10, 4, 231, 20, 28, 1134, 1142, "recorded" +437, 10, 5, 232, 29, 32, 1143, 1146, "and" +437, 10, 6, 233, 33, 39, 1147, 1153, "ocular" +437, 10, 7, 234, 40, 46, 1154, 1160, "safety" +437, 10, 8, 235, 47, 50, 1161, 1164, "was" +437, 10, 9, 236, 51, 60, 1165, 1174, "evaluated" +437, 10, 10, 237, 61, 62, 1175, 1176, "." +437, 11, 1, 238, 0, 4, 1177, 1181, "Both" +437, 11, 2, 239, 5, 15, 1182, 1192, "tafluprost" +437, 11, 3, 240, 16, 19, 1193, 1196, "and" +437, 11, 4, 241, 20, 31, 1197, 1208, "latanoprost" +437, 11, 5, 242, 32, 36, 1209, 1213, "were" +437, 11, 6, 243, 37, 46, 1214, 1223, "preserved" +437, 11, 7, 244, 47, 51, 1224, 1228, "with" +437, 11, 8, 245, 52, 64, 1229, 1241, "benzalkonium" +437, 11, 9, 246, 65, 73, 1242, 1250, "chloride" +437, 11, 10, 247, 74, 75, 1251, 1252, "." +437, 12, 1, 248, 0, 7, 1253, 1260, "RESULTS" +437, 12, 2, 249, 8, 9, 1261, 1262, ":" +437, 12, 3, 250, 10, 14, 1263, 1267, "From" +437, 12, 4, 251, 15, 18, 1268, 1271, "533" +437, 12, 5, 252, 19, 27, 1272, 1280, "patients" +437, 12, 6, 253, 28, 38, 1281, 1291, "randomized" +437, 12, 7, 254, 39, 40, 1292, 1293, "," +437, 12, 8, 255, 41, 44, 1294, 1297, "402" +437, 12, 9, 256, 45, 53, 1298, 1306, "patients" +437, 12, 10, 257, 54, 63, 1307, 1316, "completed" +437, 12, 11, 258, 64, 66, 1317, 1319, "24" +437, 12, 12, 259, 67, 73, 1320, 1326, "months" +437, 12, 13, 260, 74, 76, 1327, 1329, "of" +437, 12, 14, 261, 77, 84, 1330, 1337, "therapy" +437, 12, 15, 262, 85, 86, 1338, 1339, "." +437, 13, 1, 263, 0, 4, 1340, 1344, "Both" +437, 13, 2, 264, 5, 15, 1345, 1355, "treatments" +437, 13, 3, 265, 16, 19, 1356, 1359, "had" +437, 13, 4, 266, 20, 21, 1360, 1361, "a" +437, 13, 5, 267, 22, 33, 1362, 1373, "substantial" +437, 13, 6, 268, 34, 37, 1374, 1377, "IOP" +437, 13, 7, 269, 38, 39, 1378, 1379, "-" +437, 13, 8, 270, 40, 48, 1380, 1388, "lowering" +437, 13, 9, 271, 49, 55, 1389, 1395, "effect" +437, 13, 10, 272, 56, 61, 1396, 1401, "which" +437, 13, 11, 273, 62, 71, 1402, 1411, "persisted" +437, 13, 12, 274, 72, 82, 1412, 1422, "throughout" +437, 13, 13, 275, 83, 86, 1423, 1426, "the" +437, 13, 14, 276, 87, 92, 1427, 1432, "study" +437, 13, 15, 277, 93, 94, 1433, 1434, "(" +437, 13, 16, 278, 95, 96, 1435, 1436, "-" +437, 13, 17, 279, 97, 98, 1437, 1438, "7" +437, 13, 18, 280, 99, 100, 1439, 1440, "." +437, 13, 19, 281, 101, 102, 1441, 1442, "1" +437, 13, 20, 282, 103, 107, 1443, 1447, "mmHg" +437, 13, 21, 283, 108, 111, 1448, 1451, "for" +437, 13, 22, 284, 112, 122, 1452, 1462, "tafluprost" +437, 13, 23, 285, 123, 126, 1463, 1466, "and" +437, 13, 24, 286, 127, 128, 1467, 1468, "-" +437, 13, 25, 287, 129, 130, 1469, 1470, "7" +437, 13, 26, 288, 131, 132, 1471, 1472, "." +437, 13, 27, 289, 133, 134, 1473, 1474, "7" +437, 13, 28, 290, 135, 139, 1475, 1479, "mmHg" +437, 13, 29, 291, 140, 143, 1480, 1483, "for" +437, 13, 30, 292, 144, 155, 1484, 1495, "latanoprost" +437, 13, 31, 293, 156, 158, 1496, 1498, "at" +437, 13, 32, 294, 159, 161, 1499, 1501, "24" +437, 13, 33, 295, 162, 168, 1502, 1508, "months" +437, 13, 34, 296, 169, 170, 1509, 1510, ")" +437, 13, 35, 297, 171, 172, 1511, 1512, "." +437, 14, 1, 298, 0, 8, 1513, 1521, "Although" +437, 14, 2, 299, 9, 12, 1522, 1525, "the" +437, 14, 3, 300, 13, 16, 1526, 1529, "IOP" +437, 14, 4, 301, 17, 18, 1530, 1531, "-" +437, 14, 5, 302, 19, 27, 1532, 1540, "lowering" +437, 14, 6, 303, 28, 34, 1541, 1547, "effect" +437, 14, 7, 304, 35, 41, 1548, 1554, "during" +437, 14, 8, 305, 42, 45, 1555, 1558, "the" +437, 14, 9, 306, 46, 51, 1559, 1564, "study" +437, 14, 10, 307, 52, 55, 1565, 1568, "was" +437, 14, 11, 308, 56, 64, 1569, 1577, "slightly" +437, 14, 12, 309, 65, 71, 1578, 1584, "larger" +437, 14, 13, 310, 72, 76, 1585, 1589, "with" +437, 14, 14, 311, 77, 88, 1590, 1601, "latanoprost" +437, 14, 15, 312, 89, 90, 1602, 1603, "," +437, 14, 16, 313, 91, 95, 1604, 1608, "this" +437, 14, 17, 314, 96, 106, 1609, 1619, "difference" +437, 14, 18, 315, 107, 110, 1620, 1623, "was" +437, 14, 19, 316, 111, 121, 1624, 1634, "clinically" +437, 14, 20, 317, 122, 127, 1635, 1640, "small" +437, 14, 21, 318, 128, 131, 1641, 1644, "and" +437, 14, 22, 319, 132, 135, 1645, 1648, "the" +437, 14, 23, 320, 136, 150, 1649, 1663, "noninferiority" +437, 14, 24, 321, 151, 153, 1664, 1666, "of" +437, 14, 25, 322, 154, 164, 1667, 1677, "tafluprost" +437, 14, 26, 323, 165, 167, 1678, 1680, "to" +437, 14, 27, 324, 168, 179, 1681, 1692, "latanoprost" +437, 14, 28, 325, 180, 184, 1693, 1697, "over" +437, 14, 29, 326, 185, 188, 1698, 1701, "all" +437, 14, 30, 327, 189, 196, 1702, 1709, "diurnal" +437, 14, 31, 328, 197, 200, 1710, 1713, "IOP" +437, 14, 32, 329, 201, 213, 1714, 1726, "measurements" +437, 14, 33, 330, 214, 217, 1727, 1730, "was" +437, 14, 34, 331, 218, 223, 1731, 1736, "shown" +437, 14, 35, 332, 224, 228, 1737, 1741, "with" +437, 14, 36, 333, 229, 234, 1742, 1747, "anova" +437, 14, 37, 334, 235, 238, 1748, 1751, "and" +437, 14, 38, 335, 239, 245, 1752, 1758, "almost" +437, 14, 39, 336, 246, 253, 1759, 1766, "reached" +437, 14, 40, 337, 254, 258, 1767, 1771, "with" +437, 14, 41, 338, 259, 265, 1772, 1778, "ancova" +437, 14, 42, 339, 266, 267, 1779, 1780, "(" +437, 14, 43, 340, 268, 273, 1781, 1786, "upper" +437, 14, 44, 341, 274, 280, 1787, 1793, "limits" +437, 14, 45, 342, 281, 283, 1794, 1796, "of" +437, 14, 46, 343, 284, 287, 1797, 1800, "the" +437, 14, 47, 344, 288, 290, 1801, 1803, "95" +437, 14, 48, 345, 291, 292, 1804, 1805, "%" +437, 14, 49, 346, 293, 303, 1806, 1816, "confidence" +437, 14, 50, 347, 304, 313, 1817, 1826, "intervals" +437, 14, 51, 348, 314, 315, 1827, 1828, "1" +437, 14, 52, 349, 316, 317, 1829, 1830, "." +437, 14, 53, 350, 318, 320, 1831, 1833, "38" +437, 14, 54, 351, 321, 324, 1834, 1837, "and" +437, 14, 55, 352, 325, 326, 1838, 1839, "1" +437, 14, 56, 353, 327, 328, 1840, 1841, "." +437, 14, 57, 354, 329, 331, 1842, 1844, "52" +437, 14, 58, 355, 332, 335, 1845, 1848, "for" +437, 14, 59, 356, 336, 339, 1849, 1852, "the" +437, 14, 60, 357, 340, 347, 1853, 1860, "overall" +437, 14, 61, 358, 348, 354, 1861, 1867, "period" +437, 14, 62, 359, 355, 356, 1868, 1869, "," +437, 14, 63, 360, 357, 369, 1870, 1882, "respectively" +437, 14, 64, 361, 370, 371, 1883, 1884, ")" +437, 14, 65, 362, 372, 373, 1885, 1886, "." +437, 15, 1, 363, 0, 3, 1887, 1890, "The" +437, 15, 2, 364, 4, 18, 1891, 1905, "noninferiority" +437, 15, 3, 365, 19, 24, 1906, 1911, "limit" +437, 15, 4, 366, 25, 28, 1912, 1915, "was" +437, 15, 5, 367, 29, 30, 1916, 1917, "1" +437, 15, 6, 368, 31, 32, 1918, 1919, "." +437, 15, 7, 369, 33, 34, 1920, 1921, "5" +437, 15, 8, 370, 35, 39, 1922, 1926, "mmHg" +437, 15, 9, 371, 40, 41, 1927, 1928, "." +437, 16, 1, 372, 0, 11, 1929, 1940, "CONCLUSIONS" +437, 16, 2, 373, 12, 13, 1941, 1942, ":" +437, 16, 3, 374, 14, 24, 1943, 1953, "Tafluprost" +437, 16, 4, 375, 25, 27, 1954, 1956, "is" +437, 16, 5, 376, 28, 29, 1957, 1958, "a" +437, 16, 6, 377, 30, 33, 1959, 1962, "new" +437, 16, 7, 378, 34, 43, 1963, 1972, "effective" +437, 16, 8, 379, 44, 47, 1973, 1976, "and" +437, 16, 9, 380, 48, 52, 1977, 1981, "well" +437, 16, 10, 381, 53, 54, 1982, 1983, "-" +437, 16, 11, 382, 55, 64, 1984, 1993, "tolerated" +437, 16, 12, 383, 65, 74, 1994, 2003, "treatment" +437, 16, 13, 384, 75, 78, 2004, 2007, "for" +437, 16, 14, 385, 79, 87, 2008, 2016, "glaucoma" +437, 16, 15, 386, 88, 91, 2017, 2020, "and" +437, 16, 16, 387, 92, 98, 2021, 2027, "ocular" +437, 16, 17, 388, 99, 111, 2028, 2040, "hypertension" +437, 16, 18, 389, 112, 113, 2041, 2042, "." +437, 17, 1, 390, 0, 3, 2043, 2046, "DOI" +437, 17, 2, 391, 4, 5, 2047, 2048, ":" +437, 17, 3, 392, 6, 8, 2049, 2051, "10" +437, 17, 4, 393, 9, 10, 2052, 2053, "." +437, 17, 5, 394, 11, 15, 2054, 2058, "1111" +437, 17, 6, 395, 16, 17, 2059, 2060, "/" +437, 17, 7, 396, 18, 19, 2061, 2062, "j" +437, 17, 8, 397, 20, 21, 2063, 2064, "." +437, 17, 9, 398, 22, 26, 2065, 2069, "1755" +437, 17, 10, 399, 27, 28, 2070, 2071, "-" +437, 17, 11, 400, 29, 33, 2072, 2076, "3768" +437, 17, 12, 401, 34, 35, 2077, 2078, "." +437, 17, 13, 402, 36, 40, 2079, 2083, "2010" +437, 17, 14, 403, 41, 42, 2084, 2085, "." +437, 17, 15, 404, 43, 48, 2086, 2091, "01862" +437, 17, 16, 405, 49, 50, 2092, 2093, "." +437, 17, 17, 406, 51, 52, 2094, 2095, "x" +437, 17, 18, 407, 53, 57, 2096, 2100, "PMID" +437, 17, 19, 408, 58, 59, 2101, 2102, ":" +437, 17, 20, 409, 60, 68, 2103, 2111, "20420586" +437, 17, 21, 410, 69, 70, 2112, 2113, "[" +437, 17, 22, 411, 71, 78, 2114, 2121, "Indexed" +437, 17, 23, 412, 79, 82, 2122, 2125, "for" +437, 17, 24, 413, 83, 90, 2126, 2133, "MEDLINE" +437, 17, 25, 414, 91, 92, 2134, 2135, "]" diff --git a/data/gl 20420586_jshahinitiran.annodb b/data/gl 20420586_jshahinitiran.annodb new file mode 100644 index 0000000..284b4b0 --- /dev/null +++ b/data/gl 20420586_jshahinitiran.annodb @@ -0,0 +1,68 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15549, Journal, 0, 15, "Acta Ophthalmol", "", +15550, PublicationYear, 18, 22, "2010", "", +15551, Title, 104, 309, "Efficacy and safety of tafluprost 0 . 0015 % versus latanoprost 0 . 005 % eye drops in open - angle glaucoma and ocular hypertension : 24 - month results of a randomized , double - masked phase III study .", "", +28317, Tafluprost, 127, 137, "tafluprost", "", +28319, DoseValue, 138, 146, "0 . 0015", "", +28321, Percentage, 147, 148, "%", "", +28318, Latanoprost, 156, 167, "latanoprost", "", +28320, DoseValue, 168, 175, "0 . 005", "", +28322, Percentage, 176, 177, "%", "", +28323, Eyedrops, 178, 187, "eye drops", "", +28324, OpenAngleGlaucoma, 191, 212, "open - angle glaucoma", "", +28325, OcularHypertension, 217, 236, "ocular hypertension", "", +15561, Duration, 239, 249, "24 - month", "", +28326, Randomized, 263, 273, "randomized", "", +28327, DoubleBlind, 276, 291, "double - masked", "", +28328, CTDesign, 292, 301, "phase III", "", +15564, Author, 310, 320, "Uusitalo H", "", +15565, Author, 329, 340, "Pillunat LE", "", +15566, Author, 343, 349, "Ropo A", "", +28353, CTDesign, 352, 361, "Phase III", "", +15567, Finland, 505, 512, "Finland", "", +15568, ObjectiveDescription, 553, 756, "The objective of the study was to compare the long - term efficacy and safety of tafluprost 0 . 0015 % with latanoprost 0 . 005 % eye drops in patients with open - angle glaucoma or ocular hypertension .", "", +28329, Tafluprost, 634, 644, "tafluprost", "", +28331, DoseValue, 645, 653, "0 . 0015", "", +28333, Percentage, 654, 655, "%", "", +28330, Latanoprost, 661, 672, "latanoprost", "", +28332, DoseValue, 673, 680, "0 . 005", "", +28334, Percentage, 681, 682, "%", "", +28335, Eyedrops, 683, 692, "eye drops", "", +28336, OpenAngleGlaucoma, 710, 731, "open - angle glaucoma", "", +28337, OcularHypertension, 735, 754, "ocular hypertension", "", +28338, DoubleBlind, 772, 787, "double - masked", "", +15579, CTDesign, 790, 809, "active - controlled", "", +15580, Parallel, 812, 828, "parallel - group", "", +15581, CTDesign, 831, 844, "multinational", "", +15582, Multicenter, 847, 858, "multicentre", "", +28339, CTDesign, 861, 870, "phase III", "", +15583, Multicenter, 894, 904, "49 centres", "", +15584, Frequency, 980, 990, "once daily", "", +28352, Duration, 1016, 1025, "24 months", "", +15586, IOP, 1049, 1069, "intraocular pressure", "", +15587, IOP, 1072, 1075, "IOP", "", +28340, Tafluprost, 1182, 1192, "tafluprost", "", +28341, Latanoprost, 1197, 1208, "latanoprost", "", +15590, NumberPatientsCT, 1268, 1271, "533", "", +28342, Randomized, 1281, 1291, "randomized", "", +15592, FinalNumPatientsCT, 1294, 1297, "402", "", +28343, Duration, 1317, 1326, "24 months", "", +15594, IOP, 1374, 1377, "IOP", "", +15595, Reduction, 1437, 1442, "7 . 1", "", +15597, mmHg, 1443, 1447, "mmHg", "", +28344, Tafluprost, 1452, 1462, "tafluprost", "", +15596, Reduction, 1469, 1474, "7 . 7", "", +15598, mmHg, 1475, 1479, "mmHg", "", +28345, Latanoprost, 1484, 1495, "latanoprost", "", +28346, Duration, 1499, 1508, "24 months", "", +15602, IOP, 1526, 1529, "IOP", "", +28347, Latanoprost, 1590, 1601, "latanoprost", "", +28348, Tafluprost, 1667, 1677, "tafluprost", "", +28349, Latanoprost, 1681, 1692, "latanoprost", "", +15607, Diurnal_IOP, 1702, 1713, "diurnal IOP", "", +15608, mmHg, 1922, 1926, "mmHg", "", +28350, Tafluprost, 1943, 1953, "Tafluprost", "", +15613, ConclusionComment, 1943, 2042, "Tafluprost is a new effective and well - tolerated treatment for glaucoma and ocular hypertension .", "", +15610, Glaucoma, 2008, 2016, "glaucoma", "", +28351, OcularHypertension, 2021, 2040, "ocular hypertension", "", +15612, PMID, 2103, 2111, "20420586", "", diff --git a/data/gl 20420586_jshahinitiran.n-triples b/data/gl 20420586_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20420586_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20420586_tstrakeljahn.annodb b/data/gl 20420586_tstrakeljahn.annodb new file mode 100644 index 0000000..a9808c6 --- /dev/null +++ b/data/gl 20420586_tstrakeljahn.annodb @@ -0,0 +1,63 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13474, Journal, 0, 15, "Acta Ophthalmol", "", +13475, PublicationYear, 18, 22, "2010", "", +13488, Title, 104, 309, "Efficacy and safety of tafluprost 0 . 0015 % versus latanoprost 0 . 005 % eye drops in open - angle glaucoma and ocular hypertension : 24 - month results of a randomized , double - masked phase III study .", "", +13476, Tafluprost, 127, 137, "tafluprost", "", +13484, DoseValue, 138, 146, "0 . 0015", "", +13487, Percentage, 147, 148, "%", "", +13477, Latanoprost, 156, 167, "latanoprost", "", +13485, DoseValue, 168, 175, "0 . 005", "", +13486, Percentage, 176, 181, "% eye", "", +13478, Eyedrops, 178, 187, "eye drops", "", +13479, OpenAngleGlaucoma, 191, 212, "open - angle glaucoma", "", +13480, OcularHypertension, 217, 236, "ocular hypertension", "", +13481, Duration, 239, 249, "24 - month", "", +13482, Randomized, 263, 273, "randomized", "", +13483, DoubleBlind, 276, 291, "double - masked", "", +13489, Author, 310, 320, "Uusitalo H", "", +13490, Author, 329, 340, "Pillunat LE", "", +13491, Author, 343, 349, "Ropo A", "", +13492, Finland, 505, 512, "Finland", "", +13502, ObjectiveDescription, 553, 756, "The objective of the study was to compare the long - term efficacy and safety of tafluprost 0 . 0015 % with latanoprost 0 . 005 % eye drops in patients with open - angle glaucoma or ocular hypertension .", "", +13493, Tafluprost, 634, 644, "tafluprost", "", +13498, DoseValue, 645, 653, "0 . 0015", "", +13500, Percentage, 654, 655, "%", "", +13494, Latanoprost, 661, 672, "latanoprost", "", +13499, DoseValue, 673, 680, "0 . 005", "", +13501, Percentage, 681, 682, "%", "", +13495, Eyedrops, 683, 692, "eye drops", "", +13496, OpenAngleGlaucoma, 710, 731, "open - angle glaucoma", "", +13497, OcularHypertension, 735, 754, "ocular hypertension", "", +13503, DoubleBlind, 772, 787, "double - masked", "", +13504, Parallel, 812, 820, "parallel", "", +13505, Multicenter, 847, 858, "multicentre", "", +13506, Frequency, 980, 990, "once daily", "", +13507, Duration, 1016, 1025, "24 months", "", +13508, IOP, 1049, 1069, "intraocular pressure", "", +13509, IOP, 1072, 1075, "IOP", "", +13510, Tafluprost, 1182, 1192, "tafluprost", "", +13511, Latanoprost, 1197, 1208, "latanoprost", "", +13472, NumberPatientsCT, 1268, 1271, "533", "", +13512, Randomized, 1281, 1291, "randomized", "", +13473, FinalNumPatientsCT, 1294, 1297, "402", "", +13513, Duration, 1317, 1326, "24 months", "", +13514, IOP, 1374, 1377, "IOP", "", +13515, Reduction, 1435, 1442, "- 7 . 1", "", +13517, mmHg, 1443, 1447, "mmHg", "", +13521, Tafluprost, 1452, 1462, "tafluprost", "", +13516, Reduction, 1467, 1474, "- 7 . 7", "", +13518, mmHg, 1475, 1479, "mmHg", "", +13519, Latanoprost, 1484, 1495, "latanoprost", "", +13520, TimePoint, 1499, 1508, "24 months", "", +13522, IOP, 1526, 1529, "IOP", "", +13523, Latanoprost, 1590, 1601, "latanoprost", "", +13525, Tafluprost, 1667, 1677, "tafluprost", "", +13524, Latanoprost, 1681, 1692, "latanoprost", "", +13526, Diurnal_IOP, 1702, 1713, "diurnal IOP", "", +13527, ConfIntervalDiff, 1827, 1844, "1 . 38 and 1 . 52", "", +13528, mmHg, 1922, 1926, "mmHg", "", +13529, Tafluprost, 1943, 1953, "Tafluprost", "", +13532, ConclusionComment, 1943, 2042, "Tafluprost is a new effective and well - tolerated treatment for glaucoma and ocular hypertension .", "", +13530, Glaucoma, 2008, 2016, "glaucoma", "", +13531, OcularHypertension, 2021, 2040, "ocular hypertension", "", +13533, PMID, 2103, 2111, "20420586", "", diff --git a/data/gl 20420586_tstrakeljahn.n-triples b/data/gl 20420586_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20420586_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20429818_admin.annodb b/data/gl 20429818_admin.annodb new file mode 100644 index 0000000..2c7b3d4 --- /dev/null +++ b/data/gl 20429818_admin.annodb @@ -0,0 +1,116 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2010", "", " \"2010\"." +2, Title, 100, 215, "Comparison of ocular hypotensive actions of fixed combinations of brimonidine / timolol and dorzolamide / timolol .", "", " \"Comparison of ocular hypotensive actions of fixed combinations of brimonidine / timolol and dorzolamide / timolol .\"." +111, Brimo/TimFC, 166, 187, "brimonidine / timolol", "", +3, Brimonidine, 166, 177, "brimonidine", "", +4, Timolol, 180, 187, "timolol", "", +110, Dorz/TimFC, 192, 213, "dorzolamide / timolol", "", +5, Dorzolamide, 192, 203, "dorzolamide", "", +6, Timolol, 206, 213, "timolol", "", +8, Author, 216, 236, "Garc í a - Feijo ó J", "", " \"Garc í a - Feijo ó J\"." +9, Author, 245, 266, "S á enz - Franc é s F", "", " \"S á enz - Franc é s F\"." +10, Author, 269, 299, "Mart í nez - de - la - Casa JM", "", " \"Mart í nez - de - la - Casa JM\"." +11, Author, 302, 326, "M é ndez - Hern á ndez C", "", " \"M é ndez - Hern á ndez C\"." +12, Author, 329, 350, "Fern á ndez - Vidal A", "", " \"Fern á ndez - Vidal A\"." +13, Author, 353, 373, "Calvo - Gonz á lez C", "", " \"Calvo - Gonz á lez C\"." +14, Author, 376, 398, "Garc í a - S á nchez J", "", " \"Garc í a - S á nchez J\"." +7, Spain, 509, 514, "Spain", "", " ." +15, ObjectiveDescription, 529, 774, "To compare brimonidine / timolol fixed combination ( BrTFC ; Combigan * ) with dorzolamide / timolol fixed combination ( DTFC ; Cosopt dagger ) in terms of ability to lower intraocular pressure ( IOP ) in primary open - angle glaucoma ( POAG ) .", "", " \"To compare brimonidine / timolol fixed combination ( BrTFC ; Combigan * ) with dorzolamide / timolol fixed combination ( DTFC ; Cosopt dagger ) in terms of ability to lower intraocular pressure ( IOP ) in primary open - angle glaucoma ( POAG ) .\"." +122, Brimo/TimFC, 540, 561, "brimonidine / timolol", "", +16, Brimonidine, 540, 551, "brimonidine", "", +17, Timolol, 554, 561, "timolol", "", +123, Brimo/TimFC, 582, 587, "BrTFC", "", +126, Dorz/TimFC, 608, 629, "dorzolamide / timolol", "", +25, Dorzolamide, 608, 619, "dorzolamide", "", +26, Timolol, 622, 629, "timolol", "", +127, Dorz/TimFC, 650, 654, "DTFC", "", +34, IOP, 702, 722, "intraocular pressure", "", +35, IOP, 725, 728, "IOP", "", +36, Primary_OpenAngleGlaucoma, 734, 763, "primary open - angle glaucoma", "", " ." +37, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +132, Prospective, 796, 807, "prospective", "", " ." +133, Randomized, 810, 820, "randomized", "", " ." +134, DoubleBlind, 823, 838, "double - masked", "", " ." +135, Crossover, 841, 850, "crossover", "", " ." +38, Timolol, 889, 904, "timolol maleate", "", +39, DoseValue, 905, 910, "0 . 5", "", +40, Percentage, 911, 912, "%", "", +41, Frequency, 913, 924, "twice daily", "", +42, Randomized, 941, 951, "randomized", "", +140, Brimo/TimFC, 955, 960, "BrTFC", "", " ." +43, Frequency, 961, 972, "twice daily", "", " \"twice daily\"." +141, Dorz/TimFC, 976, 980, "DTFC", "", " ." +44, Frequency, 981, 992, "twice daily", "", " \"twice daily\"." +119913, Duration, 997, 1004, "6 weeks", "", +46, Crossover, 1020, 1032, "crossed over", "", +47, IOP, 1112, 1115, "IOP", "", +146, Mean, 1227, 1231, "mean", "", +48, Diurnal_IOP, 1232, 1243, "diurnal IOP", "", +50, TimePoint, 1249, 1257, "baseline", "", +49, TimePoint, 1261, 1268, "6 weeks", "", +51, EndPointDescription, 1297, 1338, "percentage of patients with IOP < 18 mmHg", "", +52, IOP, 1325, 1328, "IOP", "", +53, mmHg, 1334, 1338, "mmHg", "", +54, TimePoint, 1342, 1349, "6 weeks", "", +55, NumberPatientsCT, 1425, 1438, "Twenty - five", "", " \"Twenty - five\"." +56, Randomized, 1453, 1463, "randomized", "", +57, FinalNumPatientsCT, 1468, 1470, "20", "", " \"20\"." +58, Mean, 1493, 1497, "Mean", "", " . ." +59, Diurnal_IOP, 1498, 1509, "diurnal IOP", "", " ." +60, BaseLineValue, 1555, 1562, "20 . 28", "", " \"20 . 28\". \"20 . 28\"." +61, SdDevBL, 1569, 1575, "2 . 03", "", " \"2 . 03\". \"2 . 03\"." +62, mmHg, 1576, 1580, "mmHg", "", +63, Timolol, 1584, 1591, "timolol", "", +64, TimePoint, 1619, 1626, "6 weeks", "", " \"6 weeks\". \"6 weeks\"." +65, Mean, 1629, 1633, "mean", "", +67, Diurnal_IOP, 1634, 1645, "diurnal IOP", "", +68, ResultMeasuredValue, 1650, 1657, "16 . 28", "", " \"16 . 28\"." +69, SdDevResValue, 1664, 1670, "2 . 07", "", " \"2 . 07\"." +70, mmHg, 1671, 1675, "mmHg", "", +171, Brimo/TimFC, 1686, 1691, "BrTFC", "", +71, ResultMeasuredValue, 1696, 1703, "17 . 23", "", " \"17 . 23\"." +72, SdDevResValue, 1710, 1716, "2 . 29", "", " \"2 . 29\"." +73, mmHg, 1717, 1721, "mmHg", "", +172, Dorz/TimFC, 1732, 1736, "DTFC", "", +74, DiffGroupAbsValue, 1752, 1758, "0 . 95", "", " \"0 . 95\"." +75, mmHg, 1759, 1763, "mmHg", "", +106388, ConfIntervalDiff, 1766, 1789, "95 % CI 0 . 10 - 1 . 80", "", " \"95 % CI 0 . 10 - 1 . 80\"." +176, PvalueDiff, 1794, 1802, "= 0 . 03", "", " \"= 0 . 03\"." +66, Mean, 1807, 1811, "Mean", "", " . ." +78, IOP, 1812, 1815, "IOP", "", " . ." +78095, TimePoint, 1819, 1826, "09 . 00", "", +80, BaseLineValue, 1831, 1838, "20 . 95", "", " \"20 . 95\". \"20 . 95\"." +81, SdDevBL, 1845, 1851, "2 . 31", "", " \"2 . 31\". \"2 . 31\"." +82, mmHg, 1852, 1856, "mmHg", "", " ." +78096, TimePoint, 1860, 1868, "baseline", "", +83, ResultMeasuredValue, 1891, 1898, "15 . 85", "", " \"15 . 85\"." +85, SdDevResValue, 1905, 1911, "2 . 56", "", " \"2 . 56\"." +87, mmHg, 1912, 1916, "mmHg", "", +187, Brimo/TimFC, 1927, 1932, "BrTFC", "", +84, ResultMeasuredValue, 1937, 1944, "17 . 55", "", " \"17 . 55\"." +86, SdDevResValue, 1951, 1957, "2 . 67", "", " \"2 . 67\"." +88, mmHg, 1958, 1962, "mmHg", "", +190, Dorz/TimFC, 1973, 1977, "DTFC", "", +89, DiffGroupAbsValue, 1993, 1999, "1 . 70", "", " \"1 . 70\"." +106389, ConfIntervalDiff, 2002, 2025, "95 % CI 0 . 80 - 2 . 60", "", " \"95 % CI 0 . 80 - 2 . 60\"." +195, PvalueDiff, 2030, 2039, "= 0 . 001", "", " \"= 0 . 001\"." +196, RelativeTime, 2052, 2059, "12 . 00", "", +197, RelativeTime, 2064, 2071, "16 . 00", "", +92, Mean, 2089, 2093, "mean", "", +78097, EndPointDescription, 2186, 2209, "target IOP of < 18 mmHg", "", " . ." +94, mmHg, 2205, 2209, "mmHg", "", +96, PercentageAffected, 2215, 2217, "85", "", " \"85\"." +203, Brimo/TimFC, 2230, 2235, "BrTFC", "", +97, PercentageAffected, 2240, 2242, "60", "", " \"60\"." +204, Dorz/TimFC, 2255, 2259, "DTFC", "", +205, PvalueDiff, 2264, 2288, "= NS [ not significant ]", "", " \"= NS [ not significant ]\"." +119914, Duration, 2438, 2446, "6 - week", "", " \"6 - week\"." +213, ConclusionComment, 2559, 2660, "Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC .", "", " \"Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC .\"." +101, Mean, 2587, 2591, "mean", "", +102, Diurnal_IOP, 2592, 2603, "diurnal IOP", "", +209, Morning, 2608, 2615, "morning", "", +103, IOP, 2616, 2619, "IOP", "", +210, Brimo/TimFC, 2638, 2643, "BrTFC", "", +211, Dorz/TimFC, 2654, 2658, "DTFC", "", +104, PMID, 2711, 2719, "20429818", "", " \"20429818\"." diff --git a/data/gl 20429818_admin.n-triples b/data/gl 20429818_admin.n-triples new file mode 100644 index 0000000..b4acb60 --- /dev/null +++ b/data/gl 20429818_admin.n-triples @@ -0,0 +1,163 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of ocular hypotensive actions of fixed combinations of brimonidine / timolol and dorzolamide / timolol ." . + "Garc í a - Feijo ó J" . + "2010" . + "Curr Med Res Opin ." . + "20429818" . + . + "S á enz - Franc é s F" . + "Mart í nez - de - la - Casa JM" . + "M é ndez - Hern á ndez C" . + "Fern á ndez - Vidal A" . + "Calvo - Gonz á lez C" . + "Garc í a - S á nchez J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare brimonidine / timolol fixed combination ( BrTFC ; Combigan * ) with dorzolamide / timolol fixed combination ( DTFC ; Cosopt dagger ) in terms of ability to lower intraocular pressure ( IOP ) in primary open - angle glaucoma ( POAG ) ." . + "Twenty - five" . + . + . + . + "Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC ." . + . + . + . + . + . + "20" . + . + . + . + "6 - week" . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint d IOP " . + . + . + . + . + . + . + "Endpoint IOP " . + . + . + . + . + . + . + . + "Endpoint target IOP " . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Brim/TimFC" . + . + . + . + . + . + . + "Arm Dorz/TimFC" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention Brim/TimFC" . + . + "twice daily" . + . + . + "Intervention Dorz/TimFC" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication Brim/TimFC" . + . + . + . + . + "Medication Dorz/TimFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome d IOP bt" . + . + "20 . 28" . + "2 . 03" . + "16 . 28" . + "2 . 07" . + "6 weeks" . + . + "Outcome d IOP dt" . + . + "20 . 28" . + "2 . 03" . + "17 . 23" . + "2 . 29" . + "6 weeks" . + . + "Outcome IOP bt" . + . + "20 . 95" . + "2 . 31" . + "15 . 85" . + "2 . 56" . + . + "Outcome IOP dt " . + . + "20 . 95" . + "2 . 31" . + "17 . 55" . + "2 . 67" . + . + "Outcome target IOP bt" . + . + "85" . + . + "Outcome target IOP dt " . + . + "60" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups d IOP " . + "0 . 95" . + "= 0 . 03" . + "95 % CI 0 . 10 - 1 . 80" . + . + . + . + "DiffBetweenGroups IOP " . + "1 . 70" . + "= 0 . 001" . + "95 % CI 0 . 80 - 2 . 60" . + . + . + . + "DiffBetweenGroups target IOP " . + "= NS [ not significant ]" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20429818_export.csv b/data/gl 20429818_export.csv new file mode 100644 index 0000000..e3f55a3 --- /dev/null +++ b/data/gl 20429818_export.csv @@ -0,0 +1,623 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +436, 1, 1, 1, 0, 4, 0, 4, "Curr" +436, 1, 2, 2, 5, 8, 5, 8, "Med" +436, 1, 3, 3, 9, 12, 9, 12, "Res" +436, 1, 4, 4, 13, 17, 13, 17, "Opin" +436, 1, 5, 5, 18, 19, 18, 19, "." +436, 2, 1, 6, 0, 4, 20, 24, "2010" +436, 2, 2, 7, 5, 8, 25, 28, "Jul" +436, 2, 3, 8, 9, 10, 29, 30, ";" +436, 2, 4, 9, 11, 13, 31, 33, "26" +436, 2, 5, 10, 14, 15, 34, 35, "(" +436, 2, 6, 11, 16, 17, 36, 37, "7" +436, 2, 7, 12, 18, 19, 38, 39, ")" +436, 2, 8, 13, 20, 21, 40, 41, ":" +436, 2, 9, 14, 22, 26, 42, 46, "1599" +436, 2, 10, 15, 27, 28, 47, 48, "-" +436, 2, 11, 16, 29, 32, 49, 52, "606" +436, 2, 12, 17, 33, 34, 53, 54, "." +436, 2, 13, 18, 35, 38, 55, 58, "doi" +436, 2, 14, 19, 39, 40, 59, 60, ":" +436, 2, 15, 20, 41, 43, 61, 63, "10" +436, 2, 16, 21, 44, 45, 64, 65, "." +436, 2, 17, 22, 46, 50, 66, 70, "1185" +436, 2, 18, 23, 51, 52, 71, 72, "/" +436, 2, 19, 24, 53, 61, 73, 81, "03007995" +436, 2, 20, 25, 62, 63, 82, 83, "." +436, 2, 21, 26, 64, 68, 84, 88, "2010" +436, 2, 22, 27, 69, 70, 89, 90, "." +436, 2, 23, 28, 71, 77, 91, 97, "482017" +436, 2, 24, 29, 78, 79, 98, 99, "." +436, 3, 1, 30, 0, 10, 100, 110, "Comparison" +436, 3, 2, 31, 11, 13, 111, 113, "of" +436, 3, 3, 32, 14, 20, 114, 120, "ocular" +436, 3, 4, 33, 21, 32, 121, 132, "hypotensive" +436, 3, 5, 34, 33, 40, 133, 140, "actions" +436, 3, 6, 35, 41, 43, 141, 143, "of" +436, 3, 7, 36, 44, 49, 144, 149, "fixed" +436, 3, 8, 37, 50, 62, 150, 162, "combinations" +436, 3, 9, 38, 63, 65, 163, 165, "of" +436, 3, 10, 39, 66, 77, 166, 177, "brimonidine" +436, 3, 11, 40, 78, 79, 178, 179, "/" +436, 3, 12, 41, 80, 87, 180, 187, "timolol" +436, 3, 13, 42, 88, 91, 188, 191, "and" +436, 3, 14, 43, 92, 103, 192, 203, "dorzolamide" +436, 3, 15, 44, 104, 105, 204, 205, "/" +436, 3, 16, 45, 106, 113, 206, 213, "timolol" +436, 3, 17, 46, 114, 115, 214, 215, "." +436, 4, 1, 47, 0, 4, 216, 220, "Garc" +436, 4, 2, 48, 5, 6, 221, 222, "í" +436, 4, 3, 49, 7, 8, 223, 224, "a" +436, 4, 4, 50, 9, 10, 225, 226, "-" +436, 4, 5, 51, 11, 16, 227, 232, "Feijo" +436, 4, 6, 52, 17, 18, 233, 234, "ó" +436, 4, 7, 53, 19, 20, 235, 236, "J" +436, 4, 8, 54, 21, 22, 237, 238, "(" +436, 4, 9, 55, 23, 24, 239, 240, "1" +436, 4, 10, 56, 25, 26, 241, 242, ")" +436, 4, 11, 57, 27, 28, 243, 244, "," +436, 4, 12, 58, 29, 30, 245, 246, "S" +436, 4, 13, 59, 31, 32, 247, 248, "á" +436, 4, 14, 60, 33, 36, 249, 252, "enz" +436, 4, 15, 61, 37, 38, 253, 254, "-" +436, 4, 16, 62, 39, 44, 255, 260, "Franc" +436, 4, 17, 63, 45, 46, 261, 262, "é" +436, 4, 18, 64, 47, 48, 263, 264, "s" +436, 4, 19, 65, 49, 50, 265, 266, "F" +436, 4, 20, 66, 51, 52, 267, 268, "," +436, 4, 21, 67, 53, 57, 269, 273, "Mart" +436, 4, 22, 68, 58, 59, 274, 275, "í" +436, 4, 23, 69, 60, 63, 276, 279, "nez" +436, 4, 24, 70, 64, 65, 280, 281, "-" +436, 4, 25, 71, 66, 68, 282, 284, "de" +436, 4, 26, 72, 69, 70, 285, 286, "-" +436, 4, 27, 73, 71, 73, 287, 289, "la" +436, 4, 28, 74, 74, 75, 290, 291, "-" +436, 4, 29, 75, 76, 80, 292, 296, "Casa" +436, 4, 30, 76, 81, 83, 297, 299, "JM" +436, 4, 31, 77, 84, 85, 300, 301, "," +436, 4, 32, 78, 86, 87, 302, 303, "M" +436, 4, 33, 79, 88, 89, 304, 305, "é" +436, 4, 34, 80, 90, 94, 306, 310, "ndez" +436, 4, 35, 81, 95, 96, 311, 312, "-" +436, 4, 36, 82, 97, 101, 313, 317, "Hern" +436, 4, 37, 83, 102, 103, 318, 319, "á" +436, 4, 38, 84, 104, 108, 320, 324, "ndez" +436, 4, 39, 85, 109, 110, 325, 326, "C" +436, 4, 40, 86, 111, 112, 327, 328, "," +436, 4, 41, 87, 113, 117, 329, 333, "Fern" +436, 4, 42, 88, 118, 119, 334, 335, "á" +436, 4, 43, 89, 120, 124, 336, 340, "ndez" +436, 4, 44, 90, 125, 126, 341, 342, "-" +436, 4, 45, 91, 127, 132, 343, 348, "Vidal" +436, 4, 46, 92, 133, 134, 349, 350, "A" +436, 4, 47, 93, 135, 136, 351, 352, "," +436, 4, 48, 94, 137, 142, 353, 358, "Calvo" +436, 4, 49, 95, 143, 144, 359, 360, "-" +436, 4, 50, 96, 145, 149, 361, 365, "Gonz" +436, 4, 51, 97, 150, 151, 366, 367, "á" +436, 4, 52, 98, 152, 155, 368, 371, "lez" +436, 4, 53, 99, 156, 157, 372, 373, "C" +436, 4, 54, 100, 158, 159, 374, 375, "," +436, 4, 55, 101, 160, 164, 376, 380, "Garc" +436, 4, 56, 102, 165, 166, 381, 382, "í" +436, 4, 57, 103, 167, 168, 383, 384, "a" +436, 4, 58, 104, 169, 170, 385, 386, "-" +436, 4, 59, 105, 171, 172, 387, 388, "S" +436, 4, 60, 106, 173, 174, 389, 390, "á" +436, 4, 61, 107, 175, 180, 391, 396, "nchez" +436, 4, 62, 108, 181, 182, 397, 398, "J" +436, 4, 63, 109, 183, 184, 399, 400, "." +436, 5, 1, 110, 0, 6, 401, 407, "Author" +436, 5, 2, 111, 7, 18, 408, 419, "information" +436, 5, 3, 112, 19, 20, 420, 421, ":" +436, 5, 4, 113, 21, 22, 422, 423, "(" +436, 5, 5, 114, 23, 24, 424, 425, "1" +436, 5, 6, 115, 25, 26, 426, 427, ")" +436, 5, 7, 116, 27, 35, 428, 436, "Hospital" +436, 5, 8, 117, 36, 38, 437, 439, "Cl" +436, 5, 9, 118, 39, 40, 440, 441, "í" +436, 5, 10, 119, 41, 45, 442, 446, "nico" +436, 5, 11, 120, 46, 59, 447, 460, "Universitario" +436, 5, 12, 121, 60, 63, 461, 464, "San" +436, 5, 13, 122, 64, 70, 465, 471, "Carlos" +436, 5, 14, 123, 71, 72, 472, 473, "," +436, 5, 15, 124, 73, 84, 474, 485, "Universidad" +436, 5, 16, 125, 85, 96, 486, 497, "Complutense" +436, 5, 17, 126, 97, 98, 498, 499, "," +436, 5, 18, 127, 99, 105, 500, 506, "Madrid" +436, 5, 19, 128, 106, 107, 507, 508, "," +436, 5, 20, 129, 108, 113, 509, 514, "Spain" +436, 5, 21, 130, 114, 115, 515, 516, "." +436, 6, 1, 131, 0, 9, 517, 526, "OBJECTIVE" +436, 6, 2, 132, 10, 11, 527, 528, ":" +436, 6, 3, 133, 12, 14, 529, 531, "To" +436, 6, 4, 134, 15, 22, 532, 539, "compare" +436, 6, 5, 135, 23, 34, 540, 551, "brimonidine" +436, 6, 6, 136, 35, 36, 552, 553, "/" +436, 6, 7, 137, 37, 44, 554, 561, "timolol" +436, 6, 8, 138, 45, 50, 562, 567, "fixed" +436, 6, 9, 139, 51, 62, 568, 579, "combination" +436, 6, 10, 140, 63, 64, 580, 581, "(" +436, 6, 11, 141, 65, 70, 582, 587, "BrTFC" +436, 6, 12, 142, 71, 72, 588, 589, ";" +436, 6, 13, 143, 73, 81, 590, 598, "Combigan" +436, 6, 14, 144, 82, 83, 599, 600, "*" +436, 6, 15, 145, 84, 85, 601, 602, ")" +436, 6, 16, 146, 86, 90, 603, 607, "with" +436, 6, 17, 147, 91, 102, 608, 619, "dorzolamide" +436, 6, 18, 148, 103, 104, 620, 621, "/" +436, 6, 19, 149, 105, 112, 622, 629, "timolol" +436, 6, 20, 150, 113, 118, 630, 635, "fixed" +436, 6, 21, 151, 119, 130, 636, 647, "combination" +436, 6, 22, 152, 131, 132, 648, 649, "(" +436, 6, 23, 153, 133, 137, 650, 654, "DTFC" +436, 6, 24, 154, 138, 139, 655, 656, ";" +436, 6, 25, 155, 140, 146, 657, 663, "Cosopt" +436, 6, 26, 156, 147, 153, 664, 670, "dagger" +436, 6, 27, 157, 154, 155, 671, 672, ")" +436, 6, 28, 158, 156, 158, 673, 675, "in" +436, 6, 29, 159, 159, 164, 676, 681, "terms" +436, 6, 30, 160, 165, 167, 682, 684, "of" +436, 6, 31, 161, 168, 175, 685, 692, "ability" +436, 6, 32, 162, 176, 178, 693, 695, "to" +436, 6, 33, 163, 179, 184, 696, 701, "lower" +436, 6, 34, 164, 185, 196, 702, 713, "intraocular" +436, 6, 35, 165, 197, 205, 714, 722, "pressure" +436, 6, 36, 166, 206, 207, 723, 724, "(" +436, 6, 37, 167, 208, 211, 725, 728, "IOP" +436, 6, 38, 168, 212, 213, 729, 730, ")" +436, 6, 39, 169, 214, 216, 731, 733, "in" +436, 6, 40, 170, 217, 224, 734, 741, "primary" +436, 6, 41, 171, 225, 229, 742, 746, "open" +436, 6, 42, 172, 230, 231, 747, 748, "-" +436, 6, 43, 173, 232, 237, 749, 754, "angle" +436, 6, 44, 174, 238, 246, 755, 763, "glaucoma" +436, 6, 45, 175, 247, 248, 764, 765, "(" +436, 6, 46, 176, 249, 253, 766, 770, "POAG" +436, 6, 47, 177, 254, 255, 771, 772, ")" +436, 6, 48, 178, 256, 257, 773, 774, "." +436, 7, 1, 179, 0, 7, 775, 782, "METHODS" +436, 7, 2, 180, 8, 9, 783, 784, ":" +436, 7, 3, 181, 10, 14, 785, 789, "This" +436, 7, 4, 182, 15, 18, 790, 793, "was" +436, 7, 5, 183, 19, 20, 794, 795, "a" +436, 7, 6, 184, 21, 32, 796, 807, "prospective" +436, 7, 7, 185, 33, 34, 808, 809, "," +436, 7, 8, 186, 35, 45, 810, 820, "randomized" +436, 7, 9, 187, 46, 47, 821, 822, "," +436, 7, 10, 188, 48, 54, 823, 829, "double" +436, 7, 11, 189, 55, 56, 830, 831, "-" +436, 7, 12, 190, 57, 63, 832, 838, "masked" +436, 7, 13, 191, 64, 65, 839, 840, "," +436, 7, 14, 192, 66, 75, 841, 850, "crossover" +436, 7, 15, 193, 76, 81, 851, 856, "study" +436, 7, 16, 194, 82, 83, 857, 858, "." +436, 8, 1, 195, 0, 5, 859, 864, "After" +436, 8, 2, 196, 6, 7, 865, 866, "6" +436, 8, 3, 197, 8, 13, 867, 872, "weeks" +436, 8, 4, 198, 14, 16, 873, 875, "of" +436, 8, 5, 199, 17, 24, 876, 883, "therapy" +436, 8, 6, 200, 25, 29, 884, 888, "with" +436, 8, 7, 201, 30, 37, 889, 896, "timolol" +436, 8, 8, 202, 38, 45, 897, 904, "maleate" +436, 8, 9, 203, 46, 47, 905, 906, "0" +436, 8, 10, 204, 48, 49, 907, 908, "." +436, 8, 11, 205, 50, 51, 909, 910, "5" +436, 8, 12, 206, 52, 53, 911, 912, "%" +436, 8, 13, 207, 54, 59, 913, 918, "twice" +436, 8, 14, 208, 60, 65, 919, 924, "daily" +436, 8, 15, 209, 66, 67, 925, 926, "," +436, 8, 16, 210, 68, 76, 927, 935, "patients" +436, 8, 17, 211, 77, 81, 936, 940, "were" +436, 8, 18, 212, 82, 92, 941, 951, "randomized" +436, 8, 19, 213, 93, 95, 952, 954, "to" +436, 8, 20, 214, 96, 101, 955, 960, "BrTFC" +436, 8, 21, 215, 102, 107, 961, 966, "twice" +436, 8, 22, 216, 108, 113, 967, 972, "daily" +436, 8, 23, 217, 114, 116, 973, 975, "or" +436, 8, 24, 218, 117, 121, 976, 980, "DTFC" +436, 8, 25, 219, 122, 127, 981, 986, "twice" +436, 8, 26, 220, 128, 133, 987, 992, "daily" +436, 8, 27, 221, 134, 137, 993, 996, "for" +436, 8, 28, 222, 138, 139, 997, 998, "6" +436, 8, 29, 223, 140, 145, 999, 1004, "weeks" +436, 8, 30, 224, 146, 147, 1005, 1006, "," +436, 8, 31, 225, 148, 154, 1007, 1013, "before" +436, 8, 32, 226, 155, 160, 1014, 1019, "being" +436, 8, 33, 227, 161, 168, 1020, 1027, "crossed" +436, 8, 34, 228, 169, 173, 1028, 1032, "over" +436, 8, 35, 229, 174, 176, 1033, 1035, "to" +436, 8, 36, 230, 177, 180, 1036, 1039, "the" +436, 8, 37, 231, 181, 186, 1040, 1045, "other" +436, 8, 38, 232, 187, 196, 1046, 1055, "treatment" +436, 8, 39, 233, 197, 200, 1056, 1059, "arm" +436, 8, 40, 234, 201, 204, 1060, 1063, "for" +436, 8, 41, 235, 205, 206, 1064, 1065, "a" +436, 8, 42, 236, 207, 214, 1066, 1073, "further" +436, 8, 43, 237, 215, 216, 1074, 1075, "6" +436, 8, 44, 238, 217, 222, 1076, 1081, "weeks" +436, 8, 45, 239, 223, 224, 1082, 1083, "." +436, 9, 1, 240, 0, 2, 1084, 1086, "At" +436, 9, 2, 241, 3, 6, 1087, 1090, "all" +436, 9, 3, 242, 7, 13, 1091, 1097, "follow" +436, 9, 4, 243, 14, 15, 1098, 1099, "-" +436, 9, 5, 244, 16, 18, 1100, 1102, "up" +436, 9, 6, 245, 19, 25, 1103, 1109, "visits" +436, 9, 7, 246, 26, 27, 1110, 1111, "," +436, 9, 8, 247, 28, 31, 1112, 1115, "IOP" +436, 9, 9, 248, 32, 35, 1116, 1119, "was" +436, 9, 10, 249, 36, 44, 1120, 1128, "measured" +436, 9, 11, 250, 45, 47, 1129, 1131, "at" +436, 9, 12, 251, 48, 50, 1132, 1134, "09" +436, 9, 13, 252, 51, 52, 1135, 1136, "." +436, 9, 14, 253, 53, 55, 1137, 1139, "00" +436, 9, 15, 254, 56, 57, 1140, 1141, "(" +436, 9, 16, 255, 58, 61, 1142, 1145, "pre" +436, 9, 17, 256, 62, 63, 1146, 1147, "-" +436, 9, 18, 257, 64, 76, 1148, 1160, "instillation" +436, 9, 19, 258, 77, 78, 1161, 1162, ")" +436, 9, 20, 259, 79, 81, 1163, 1165, "12" +436, 9, 21, 260, 82, 83, 1166, 1167, "." +436, 9, 22, 261, 84, 86, 1168, 1170, "00" +436, 9, 23, 262, 87, 90, 1171, 1174, "and" +436, 9, 24, 263, 91, 93, 1175, 1177, "16" +436, 9, 25, 264, 94, 95, 1178, 1179, "." +436, 9, 26, 265, 96, 98, 1180, 1182, "00" +436, 9, 27, 266, 99, 100, 1183, 1184, "." +436, 10, 1, 267, 0, 3, 1185, 1188, "The" +436, 10, 2, 268, 4, 11, 1189, 1196, "primary" +436, 10, 3, 269, 12, 19, 1197, 1204, "outcome" +436, 10, 4, 270, 20, 27, 1205, 1212, "measure" +436, 10, 5, 271, 28, 31, 1213, 1216, "was" +436, 10, 6, 272, 32, 38, 1217, 1223, "change" +436, 10, 7, 273, 39, 41, 1224, 1226, "in" +436, 10, 8, 274, 42, 46, 1227, 1231, "mean" +436, 10, 9, 275, 47, 54, 1232, 1239, "diurnal" +436, 10, 10, 276, 55, 58, 1240, 1243, "IOP" +436, 10, 11, 277, 59, 63, 1244, 1248, "from" +436, 10, 12, 278, 64, 72, 1249, 1257, "baseline" +436, 10, 13, 279, 73, 75, 1258, 1260, "at" +436, 10, 14, 280, 76, 77, 1261, 1262, "6" +436, 10, 15, 281, 78, 83, 1263, 1268, "weeks" +436, 10, 16, 282, 84, 85, 1269, 1270, "." +436, 11, 1, 283, 0, 3, 1271, 1274, "The" +436, 11, 2, 284, 4, 13, 1275, 1284, "secondary" +436, 11, 3, 285, 14, 21, 1285, 1292, "outcome" +436, 11, 4, 286, 22, 25, 1293, 1296, "was" +436, 11, 5, 287, 26, 36, 1297, 1307, "percentage" +436, 11, 6, 288, 37, 39, 1308, 1310, "of" +436, 11, 7, 289, 40, 48, 1311, 1319, "patients" +436, 11, 8, 290, 49, 53, 1320, 1324, "with" +436, 11, 9, 291, 54, 57, 1325, 1328, "IOP" +436, 11, 10, 292, 58, 59, 1329, 1330, "<" +436, 11, 11, 293, 60, 62, 1331, 1333, "18" +436, 11, 12, 294, 63, 67, 1334, 1338, "mmHg" +436, 11, 13, 295, 68, 70, 1339, 1341, "at" +436, 11, 14, 296, 71, 72, 1342, 1343, "6" +436, 11, 15, 297, 73, 78, 1344, 1349, "weeks" +436, 11, 16, 298, 79, 80, 1350, 1351, "." +436, 12, 1, 299, 0, 4, 1352, 1356, "Data" +436, 12, 2, 300, 5, 9, 1357, 1361, "were" +436, 12, 3, 301, 10, 18, 1362, 1370, "analyzed" +436, 12, 4, 302, 19, 23, 1371, 1375, "from" +436, 12, 5, 303, 24, 27, 1376, 1379, "all" +436, 12, 6, 304, 28, 36, 1380, 1388, "patients" +436, 12, 7, 305, 37, 40, 1389, 1392, "who" +436, 12, 8, 306, 41, 50, 1393, 1402, "completed" +436, 12, 9, 307, 51, 54, 1403, 1406, "the" +436, 12, 10, 308, 55, 60, 1407, 1412, "study" +436, 12, 11, 309, 61, 62, 1413, 1414, "." +436, 13, 1, 310, 0, 7, 1415, 1422, "RESULTS" +436, 13, 2, 311, 8, 9, 1423, 1424, ":" +436, 13, 3, 312, 10, 16, 1425, 1431, "Twenty" +436, 13, 4, 313, 17, 18, 1432, 1433, "-" +436, 13, 5, 314, 19, 23, 1434, 1438, "five" +436, 13, 6, 315, 24, 32, 1439, 1447, "patients" +436, 13, 7, 316, 33, 37, 1448, 1452, "were" +436, 13, 8, 317, 38, 48, 1453, 1463, "randomized" +436, 13, 9, 318, 49, 52, 1464, 1467, "and" +436, 13, 10, 319, 53, 55, 1468, 1470, "20" +436, 13, 11, 320, 56, 65, 1471, 1480, "completed" +436, 13, 12, 321, 66, 69, 1481, 1484, "the" +436, 13, 13, 322, 70, 75, 1485, 1490, "study" +436, 13, 14, 323, 76, 77, 1491, 1492, "." +436, 14, 1, 324, 0, 4, 1493, 1497, "Mean" +436, 14, 2, 325, 5, 12, 1498, 1505, "diurnal" +436, 14, 3, 326, 13, 16, 1506, 1509, "IOP" +436, 14, 4, 327, 17, 18, 1510, 1511, "(" +436, 14, 5, 328, 19, 23, 1512, 1516, "mean" +436, 14, 6, 329, 24, 25, 1517, 1518, "+" +436, 14, 7, 330, 26, 27, 1519, 1520, "/" +436, 14, 8, 331, 28, 29, 1521, 1522, "-" +436, 14, 9, 332, 30, 38, 1523, 1531, "standard" +436, 14, 10, 333, 39, 48, 1532, 1541, "deviation" +436, 14, 11, 334, 49, 50, 1542, 1543, "[" +436, 14, 12, 335, 51, 53, 1544, 1546, "SD" +436, 14, 13, 336, 54, 55, 1547, 1548, "]" +436, 14, 14, 337, 56, 57, 1549, 1550, ")" +436, 14, 15, 338, 58, 61, 1551, 1554, "was" +436, 14, 16, 339, 62, 64, 1555, 1557, "20" +436, 14, 17, 340, 65, 66, 1558, 1559, "." +436, 14, 18, 341, 67, 69, 1560, 1562, "28" +436, 14, 19, 342, 70, 71, 1563, 1564, "+" +436, 14, 20, 343, 72, 73, 1565, 1566, "/" +436, 14, 21, 344, 74, 75, 1567, 1568, "-" +436, 14, 22, 345, 76, 77, 1569, 1570, "2" +436, 14, 23, 346, 78, 79, 1571, 1572, "." +436, 14, 24, 347, 80, 82, 1573, 1575, "03" +436, 14, 25, 348, 83, 87, 1576, 1580, "mmHg" +436, 14, 26, 349, 88, 90, 1581, 1583, "at" +436, 14, 27, 350, 91, 98, 1584, 1591, "timolol" +436, 14, 28, 351, 99, 100, 1592, 1593, "-" +436, 14, 29, 352, 101, 108, 1594, 1601, "treated" +436, 14, 30, 353, 109, 117, 1602, 1610, "baseline" +436, 14, 31, 354, 118, 119, 1611, 1612, "." +436, 15, 1, 355, 0, 5, 1613, 1618, "After" +436, 15, 2, 356, 6, 7, 1619, 1620, "6" +436, 15, 3, 357, 8, 13, 1621, 1626, "weeks" +436, 15, 4, 358, 14, 15, 1627, 1628, "," +436, 15, 5, 359, 16, 20, 1629, 1633, "mean" +436, 15, 6, 360, 21, 28, 1634, 1641, "diurnal" +436, 15, 7, 361, 29, 32, 1642, 1645, "IOP" +436, 15, 8, 362, 33, 36, 1646, 1649, "was" +436, 15, 9, 363, 37, 39, 1650, 1652, "16" +436, 15, 10, 364, 40, 41, 1653, 1654, "." +436, 15, 11, 365, 42, 44, 1655, 1657, "28" +436, 15, 12, 366, 45, 46, 1658, 1659, "+" +436, 15, 13, 367, 47, 48, 1660, 1661, "/" +436, 15, 14, 368, 49, 50, 1662, 1663, "-" +436, 15, 15, 369, 51, 52, 1664, 1665, "2" +436, 15, 16, 370, 53, 54, 1666, 1667, "." +436, 15, 17, 371, 55, 57, 1668, 1670, "07" +436, 15, 18, 372, 58, 62, 1671, 1675, "mmHg" +436, 15, 19, 373, 63, 72, 1676, 1685, "following" +436, 15, 20, 374, 73, 78, 1686, 1691, "BrTFC" +436, 15, 21, 375, 79, 82, 1692, 1695, "and" +436, 15, 22, 376, 83, 85, 1696, 1698, "17" +436, 15, 23, 377, 86, 87, 1699, 1700, "." +436, 15, 24, 378, 88, 90, 1701, 1703, "23" +436, 15, 25, 379, 91, 92, 1704, 1705, "+" +436, 15, 26, 380, 93, 94, 1706, 1707, "/" +436, 15, 27, 381, 95, 96, 1708, 1709, "-" +436, 15, 28, 382, 97, 98, 1710, 1711, "2" +436, 15, 29, 383, 99, 100, 1712, 1713, "." +436, 15, 30, 384, 101, 103, 1714, 1716, "29" +436, 15, 31, 385, 104, 108, 1717, 1721, "mmHg" +436, 15, 32, 386, 109, 118, 1722, 1731, "following" +436, 15, 33, 387, 119, 123, 1732, 1736, "DTFC" +436, 15, 34, 388, 124, 125, 1737, 1738, "(" +436, 15, 35, 389, 126, 136, 1739, 1749, "difference" +436, 15, 36, 390, 137, 138, 1750, 1751, ":" +436, 15, 37, 391, 139, 140, 1752, 1753, "0" +436, 15, 38, 392, 141, 142, 1754, 1755, "." +436, 15, 39, 393, 143, 145, 1756, 1758, "95" +436, 15, 40, 394, 146, 150, 1759, 1763, "mmHg" +436, 15, 41, 395, 151, 152, 1764, 1765, "," +436, 15, 42, 396, 153, 155, 1766, 1768, "95" +436, 15, 43, 397, 156, 157, 1769, 1770, "%" +436, 15, 44, 398, 158, 160, 1771, 1773, "CI" +436, 15, 45, 399, 161, 162, 1774, 1775, "0" +436, 15, 46, 400, 163, 164, 1776, 1777, "." +436, 15, 47, 401, 165, 167, 1778, 1780, "10" +436, 15, 48, 402, 168, 169, 1781, 1782, "-" +436, 15, 49, 403, 170, 171, 1783, 1784, "1" +436, 15, 50, 404, 172, 173, 1785, 1786, "." +436, 15, 51, 405, 174, 176, 1787, 1789, "80" +436, 15, 52, 406, 177, 178, 1790, 1791, "," +436, 15, 53, 407, 179, 180, 1792, 1793, "p" +436, 15, 54, 408, 181, 182, 1794, 1795, "=" +436, 15, 55, 409, 183, 184, 1796, 1797, "0" +436, 15, 56, 410, 185, 186, 1798, 1799, "." +436, 15, 57, 411, 187, 189, 1800, 1802, "03" +436, 15, 58, 412, 190, 191, 1803, 1804, ")" +436, 15, 59, 413, 192, 193, 1805, 1806, "." +436, 16, 1, 414, 0, 4, 1807, 1811, "Mean" +436, 16, 2, 415, 5, 8, 1812, 1815, "IOP" +436, 16, 3, 416, 9, 11, 1816, 1818, "at" +436, 16, 4, 417, 12, 14, 1819, 1821, "09" +436, 16, 5, 418, 15, 16, 1822, 1823, "." +436, 16, 6, 419, 17, 19, 1824, 1826, "00" +436, 16, 7, 420, 20, 23, 1827, 1830, "was" +436, 16, 8, 421, 24, 26, 1831, 1833, "20" +436, 16, 9, 422, 27, 28, 1834, 1835, "." +436, 16, 10, 423, 29, 31, 1836, 1838, "95" +436, 16, 11, 424, 32, 33, 1839, 1840, "+" +436, 16, 12, 425, 34, 35, 1841, 1842, "/" +436, 16, 13, 426, 36, 37, 1843, 1844, "-" +436, 16, 14, 427, 38, 39, 1845, 1846, "2" +436, 16, 15, 428, 40, 41, 1847, 1848, "." +436, 16, 16, 429, 42, 44, 1849, 1851, "31" +436, 16, 17, 430, 45, 49, 1852, 1856, "mmHg" +436, 16, 18, 431, 50, 52, 1857, 1859, "at" +436, 16, 19, 432, 53, 61, 1860, 1868, "baseline" +436, 16, 20, 433, 62, 63, 1869, 1870, "." +436, 17, 1, 434, 0, 4, 1871, 1875, "This" +436, 17, 2, 435, 5, 8, 1876, 1879, "was" +436, 17, 3, 436, 9, 16, 1880, 1887, "reduced" +436, 17, 4, 437, 17, 19, 1888, 1890, "to" +436, 17, 5, 438, 20, 22, 1891, 1893, "15" +436, 17, 6, 439, 23, 24, 1894, 1895, "." +436, 17, 7, 440, 25, 27, 1896, 1898, "85" +436, 17, 8, 441, 28, 29, 1899, 1900, "+" +436, 17, 9, 442, 30, 31, 1901, 1902, "/" +436, 17, 10, 443, 32, 33, 1903, 1904, "-" +436, 17, 11, 444, 34, 35, 1905, 1906, "2" +436, 17, 12, 445, 36, 37, 1907, 1908, "." +436, 17, 13, 446, 38, 40, 1909, 1911, "56" +436, 17, 14, 447, 41, 45, 1912, 1916, "mmHg" +436, 17, 15, 448, 46, 55, 1917, 1926, "following" +436, 17, 16, 449, 56, 61, 1927, 1932, "BrTFC" +436, 17, 17, 450, 62, 65, 1933, 1936, "and" +436, 17, 18, 451, 66, 68, 1937, 1939, "17" +436, 17, 19, 452, 69, 70, 1940, 1941, "." +436, 17, 20, 453, 71, 73, 1942, 1944, "55" +436, 17, 21, 454, 74, 75, 1945, 1946, "+" +436, 17, 22, 455, 76, 77, 1947, 1948, "/" +436, 17, 23, 456, 78, 79, 1949, 1950, "-" +436, 17, 24, 457, 80, 81, 1951, 1952, "2" +436, 17, 25, 458, 82, 83, 1953, 1954, "." +436, 17, 26, 459, 84, 86, 1955, 1957, "67" +436, 17, 27, 460, 87, 91, 1958, 1962, "mmHg" +436, 17, 28, 461, 92, 101, 1963, 1972, "following" +436, 17, 29, 462, 102, 106, 1973, 1977, "DTFC" +436, 17, 30, 463, 107, 108, 1978, 1979, "(" +436, 17, 31, 464, 109, 119, 1980, 1990, "difference" +436, 17, 32, 465, 120, 121, 1991, 1992, ":" +436, 17, 33, 466, 122, 123, 1993, 1994, "1" +436, 17, 34, 467, 124, 125, 1995, 1996, "." +436, 17, 35, 468, 126, 128, 1997, 1999, "70" +436, 17, 36, 469, 129, 130, 2000, 2001, "," +436, 17, 37, 470, 131, 133, 2002, 2004, "95" +436, 17, 38, 471, 134, 135, 2005, 2006, "%" +436, 17, 39, 472, 136, 138, 2007, 2009, "CI" +436, 17, 40, 473, 139, 140, 2010, 2011, "0" +436, 17, 41, 474, 141, 142, 2012, 2013, "." +436, 17, 42, 475, 143, 145, 2014, 2016, "80" +436, 17, 43, 476, 146, 147, 2017, 2018, "-" +436, 17, 44, 477, 148, 149, 2019, 2020, "2" +436, 17, 45, 478, 150, 151, 2021, 2022, "." +436, 17, 46, 479, 152, 154, 2023, 2025, "60" +436, 17, 47, 480, 155, 156, 2026, 2027, "," +436, 17, 48, 481, 157, 158, 2028, 2029, "p" +436, 17, 49, 482, 159, 160, 2030, 2031, "=" +436, 17, 50, 483, 161, 162, 2032, 2033, "0" +436, 17, 51, 484, 163, 164, 2034, 2035, "." +436, 17, 52, 485, 165, 168, 2036, 2039, "001" +436, 17, 53, 486, 169, 170, 2040, 2041, ")" +436, 17, 54, 487, 171, 172, 2042, 2043, "." +436, 18, 1, 488, 0, 3, 2044, 2047, "For" +436, 18, 2, 489, 4, 7, 2048, 2051, "the" +436, 18, 3, 490, 8, 10, 2052, 2054, "12" +436, 18, 4, 491, 11, 12, 2055, 2056, "." +436, 18, 5, 492, 13, 15, 2057, 2059, "00" +436, 18, 6, 493, 16, 19, 2060, 2063, "and" +436, 18, 7, 494, 20, 22, 2064, 2066, "16" +436, 18, 8, 495, 23, 24, 2067, 2068, "." +436, 18, 9, 496, 25, 27, 2069, 2071, "00" +436, 18, 10, 497, 28, 38, 2072, 2082, "timepoints" +436, 18, 11, 498, 39, 40, 2083, 2084, "," +436, 18, 12, 499, 41, 44, 2085, 2088, "the" +436, 18, 13, 500, 45, 49, 2089, 2093, "mean" +436, 18, 14, 501, 50, 57, 2094, 2101, "changes" +436, 18, 15, 502, 58, 62, 2102, 2106, "from" +436, 18, 16, 503, 63, 71, 2107, 2115, "baseline" +436, 18, 17, 504, 72, 74, 2116, 2118, "in" +436, 18, 18, 505, 75, 78, 2119, 2122, "the" +436, 18, 19, 506, 79, 82, 2123, 2126, "two" +436, 18, 20, 507, 83, 87, 2127, 2131, "arms" +436, 18, 21, 508, 88, 92, 2132, 2136, "were" +436, 18, 22, 509, 93, 103, 2137, 2147, "comparable" +436, 18, 23, 510, 104, 105, 2148, 2149, "." +436, 19, 1, 511, 0, 11, 2150, 2161, "Percentages" +436, 19, 2, 512, 12, 14, 2162, 2164, "of" +436, 19, 3, 513, 15, 23, 2165, 2173, "patients" +436, 19, 4, 514, 24, 33, 2174, 2183, "achieving" +436, 19, 5, 515, 34, 35, 2184, 2185, "a" +436, 19, 6, 516, 36, 42, 2186, 2192, "target" +436, 19, 7, 517, 43, 46, 2193, 2196, "IOP" +436, 19, 8, 518, 47, 49, 2197, 2199, "of" +436, 19, 9, 519, 50, 51, 2200, 2201, "<" +436, 19, 10, 520, 52, 54, 2202, 2204, "18" +436, 19, 11, 521, 55, 59, 2205, 2209, "mmHg" +436, 19, 12, 522, 60, 64, 2210, 2214, "were" +436, 19, 13, 523, 65, 67, 2215, 2217, "85" +436, 19, 14, 524, 68, 69, 2218, 2219, "%" +436, 19, 15, 525, 70, 79, 2220, 2229, "following" +436, 19, 16, 526, 80, 85, 2230, 2235, "BrTFC" +436, 19, 17, 527, 86, 89, 2236, 2239, "and" +436, 19, 18, 528, 90, 92, 2240, 2242, "60" +436, 19, 19, 529, 93, 94, 2243, 2244, "%" +436, 19, 20, 530, 95, 104, 2245, 2254, "following" +436, 19, 21, 531, 105, 109, 2255, 2259, "DTFC" +436, 19, 22, 532, 110, 111, 2260, 2261, "(" +436, 19, 23, 533, 112, 113, 2262, 2263, "p" +436, 19, 24, 534, 114, 115, 2264, 2265, "=" +436, 19, 25, 535, 116, 118, 2266, 2268, "NS" +436, 19, 26, 536, 119, 120, 2269, 2270, "[" +436, 19, 27, 537, 121, 124, 2271, 2274, "not" +436, 19, 28, 538, 125, 136, 2275, 2286, "significant" +436, 19, 29, 539, 137, 138, 2287, 2288, "]" +436, 19, 30, 540, 139, 140, 2289, 2290, ")" +436, 19, 31, 541, 141, 142, 2291, 2292, "." +436, 20, 1, 542, 0, 2, 2293, 2295, "No" +436, 20, 2, 543, 3, 12, 2296, 2305, "treatment" +436, 20, 3, 544, 13, 14, 2306, 2307, "-" +436, 20, 4, 545, 15, 22, 2308, 2315, "related" +436, 20, 5, 546, 23, 30, 2316, 2323, "adverse" +436, 20, 6, 547, 31, 37, 2324, 2330, "events" +436, 20, 7, 548, 38, 42, 2331, 2335, "were" +436, 20, 8, 549, 43, 51, 2336, 2344, "reported" +436, 20, 9, 550, 52, 56, 2345, 2349, "with" +436, 20, 10, 551, 57, 63, 2350, 2356, "either" +436, 20, 11, 552, 64, 71, 2357, 2364, "therapy" +436, 20, 12, 553, 72, 73, 2365, 2366, "." +436, 21, 1, 554, 0, 3, 2367, 2370, "Key" +436, 21, 2, 555, 4, 15, 2371, 2382, "limitations" +436, 21, 3, 556, 16, 23, 2383, 2390, "include" +436, 21, 4, 557, 24, 27, 2391, 2394, "the" +436, 21, 5, 558, 28, 33, 2395, 2400, "small" +436, 21, 6, 559, 34, 38, 2401, 2405, "size" +436, 21, 7, 560, 39, 41, 2406, 2408, "of" +436, 21, 8, 561, 42, 45, 2409, 2412, "the" +436, 21, 9, 562, 46, 51, 2413, 2418, "study" +436, 21, 10, 563, 52, 62, 2419, 2429, "population" +436, 21, 11, 564, 63, 66, 2430, 2433, "and" +436, 21, 12, 565, 67, 70, 2434, 2437, "the" +436, 21, 13, 566, 71, 72, 2438, 2439, "6" +436, 21, 14, 567, 73, 74, 2440, 2441, "-" +436, 21, 15, 568, 75, 79, 2442, 2446, "week" +436, 21, 16, 569, 80, 88, 2447, 2455, "duration" +436, 21, 17, 570, 89, 91, 2456, 2458, "of" +436, 21, 18, 571, 92, 101, 2459, 2468, "treatment" +436, 21, 19, 572, 102, 109, 2469, 2476, "periods" +436, 21, 20, 573, 110, 111, 2477, 2478, "," +436, 21, 21, 574, 112, 117, 2479, 2484, "which" +436, 21, 22, 575, 118, 126, 2485, 2493, "prevents" +436, 21, 23, 576, 127, 134, 2494, 2501, "drawing" +436, 21, 24, 577, 135, 146, 2502, 2513, "conclusions" +436, 21, 25, 578, 147, 156, 2514, 2523, "regarding" +436, 21, 26, 579, 157, 161, 2524, 2528, "long" +436, 21, 27, 580, 162, 163, 2529, 2530, "-" +436, 21, 28, 581, 164, 168, 2531, 2535, "term" +436, 21, 29, 582, 169, 176, 2536, 2543, "therapy" +436, 21, 30, 583, 177, 178, 2544, 2545, "." +436, 22, 1, 584, 0, 10, 2546, 2556, "CONCLUSION" +436, 22, 2, 585, 11, 12, 2557, 2558, ":" +436, 22, 3, 586, 13, 23, 2559, 2569, "Reductions" +436, 22, 4, 587, 24, 28, 2570, 2574, "from" +436, 22, 5, 588, 29, 37, 2575, 2583, "baseline" +436, 22, 6, 589, 38, 40, 2584, 2586, "in" +436, 22, 7, 590, 41, 45, 2587, 2591, "mean" +436, 22, 8, 591, 46, 53, 2592, 2599, "diurnal" +436, 22, 9, 592, 54, 57, 2600, 2603, "IOP" +436, 22, 10, 593, 58, 61, 2604, 2607, "and" +436, 22, 11, 594, 62, 69, 2608, 2615, "morning" +436, 22, 12, 595, 70, 73, 2616, 2619, "IOP" +436, 22, 13, 596, 74, 78, 2620, 2624, "were" +436, 22, 14, 597, 79, 86, 2625, 2632, "greater" +436, 22, 15, 598, 87, 91, 2633, 2637, "with" +436, 22, 16, 599, 92, 97, 2638, 2643, "BrTFC" +436, 22, 17, 600, 98, 102, 2644, 2648, "than" +436, 22, 18, 601, 103, 107, 2649, 2653, "with" +436, 22, 19, 602, 108, 112, 2654, 2658, "DTFC" +436, 22, 20, 603, 113, 114, 2659, 2660, "." +436, 23, 1, 604, 0, 3, 2661, 2664, "DOI" +436, 23, 2, 605, 4, 5, 2665, 2666, ":" +436, 23, 3, 606, 6, 8, 2667, 2669, "10" +436, 23, 4, 607, 9, 10, 2670, 2671, "." +436, 23, 5, 608, 11, 15, 2672, 2676, "1185" +436, 23, 6, 609, 16, 17, 2677, 2678, "/" +436, 23, 7, 610, 18, 26, 2679, 2687, "03007995" +436, 23, 8, 611, 27, 28, 2688, 2689, "." +436, 23, 9, 612, 29, 33, 2690, 2694, "2010" +436, 23, 10, 613, 34, 35, 2695, 2696, "." +436, 23, 11, 614, 36, 42, 2697, 2703, "482017" +436, 23, 12, 615, 43, 47, 2704, 2708, "PMID" +436, 23, 13, 616, 48, 49, 2709, 2710, ":" +436, 23, 14, 617, 50, 58, 2711, 2719, "20429818" +436, 23, 15, 618, 59, 60, 2720, 2721, "[" +436, 23, 16, 619, 61, 68, 2722, 2729, "Indexed" +436, 23, 17, 620, 69, 72, 2730, 2733, "for" +436, 23, 18, 621, 73, 80, 2734, 2741, "MEDLINE" +436, 23, 19, 622, 81, 82, 2742, 2743, "]" diff --git a/data/gl 20429818_jshahinitiran.annodb b/data/gl 20429818_jshahinitiran.annodb new file mode 100644 index 0000000..0e0c5ba --- /dev/null +++ b/data/gl 20429818_jshahinitiran.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +36024, Journal, 0, 17, "Curr Med Res Opin", "", +36025, PublicationYear, 20, 24, "2010", "", +36026, Title, 100, 213, "Comparison of ocular hypotensive actions of fixed combinations of brimonidine / timolol and dorzolamide / timolol", "", +36027, Brimonidine, 166, 177, "brimonidine", "", +36028, Timolol, 180, 187, "timolol", "", +36029, Dorzolamide, 192, 203, "dorzolamide", "", +36030, Timolol, 206, 213, "timolol", "", +36032, Author, 216, 236, "Garc í a - Feijo ó J", "", +36033, Author, 245, 266, "S á enz - Franc é s F", "", +36034, Author, 269, 299, "Mart í nez - de - la - Casa JM", "", +36035, Author, 302, 326, "M é ndez - Hern á ndez C", "", +36036, Author, 329, 350, "Fern á ndez - Vidal A", "", +36037, Author, 353, 373, "Calvo - Gonz á lez C", "", +36038, Author, 376, 398, "Garc í a - S á nchez J", "", +36031, Spain, 509, 514, "Spain", "", +36039, ObjectiveDescription, 529, 774, "To compare brimonidine / timolol fixed combination ( BrTFC ; Combigan * ) with dorzolamide / timolol fixed combination ( DTFC ; Cosopt dagger ) in terms of ability to lower intraocular pressure ( IOP ) in primary open - angle glaucoma ( POAG ) .", "", +36040, Brimonidine, 540, 551, "brimonidine", "", +36042, Drug, 540, 579, "brimonidine / timolol fixed combination", "BrTFC", +36041, Timolol, 554, 561, "timolol", "", +36043, Drug, 582, 587, "BrTFC", "BrTFC", +36049, Dorzolamide, 608, 619, "dorzolamide", "", +36053, Drug, 608, 647, "dorzolamide / timolol fixed combination", "DTFC", +36052, Timolol, 622, 629, "timolol", "", +36054, Drug, 650, 654, "DTFC", "DTFC", +36060, IOP, 702, 722, "intraocular pressure", "", +36061, IOP, 725, 728, "IOP", "", +36062, Primary_OpenAngleGlaucoma, 734, 763, "primary open - angle glaucoma", "", +36063, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +36064, Timolol, 889, 904, "timolol maleate", "", +36065, DoseValue, 905, 910, "0 . 5", "", +36066, Percentage, 911, 912, "%", "", +36067, Frequency, 913, 924, "twice daily", "", +36068, Randomized, 941, 951, "randomized", "", +36044, Drug, 955, 960, "BrTFC", "BrTFC", +36069, Frequency, 961, 972, "twice daily", "", +36055, Drug, 976, 980, "DTFC", "DTFC", +36070, Frequency, 981, 992, "twice daily", "", +36071, Duration, 997, 1004, "6 weeks", "", +36072, Crossover, 1020, 1032, "crossed over", "", +36073, IOP, 1112, 1115, "IOP", "", +36074, Diurnal_IOP, 1232, 1243, "diurnal IOP", "", +36076, TimePoint, 1249, 1257, "baseline", "", +36075, TimePoint, 1261, 1268, "6 weeks", "", +36077, EndPointDescription, 1297, 1338, "percentage of patients with IOP < 18 mmHg", "", +36078, IOP, 1325, 1328, "IOP", "", +36079, mmHg, 1334, 1338, "mmHg", "", +36080, TimePoint, 1342, 1349, "6 weeks", "", +36081, NumberPatientsCT, 1425, 1438, "Twenty - five", "", +36082, Randomized, 1453, 1463, "randomized", "", +36083, FinalNumPatientsCT, 1468, 1470, "20", "", +36084, Mean, 1493, 1497, "Mean", "", +36085, Diurnal_IOP, 1498, 1509, "diurnal IOP", "", +36086, BaseLineValue, 1555, 1562, "20 . 28", "", +36087, SdDevBL, 1569, 1575, "2 . 03", "", +36088, mmHg, 1576, 1580, "mmHg", "", +36089, Timolol, 1584, 1591, "timolol", "", +36090, TimePoint, 1619, 1626, "6 weeks", "", +36091, Mean, 1629, 1633, "mean", "", +36093, Diurnal_IOP, 1634, 1645, "diurnal IOP", "", +36094, ResultMeasuredValue, 1650, 1657, "16 . 28", "", +36095, SdDevResValue, 1664, 1670, "2 . 07", "", +36096, mmHg, 1671, 1675, "mmHg", "", +36045, Drug, 1686, 1691, "BrTFC", "BrTFC", +36097, ResultMeasuredValue, 1696, 1703, "17 . 23", "", +36098, SdDevResValue, 1710, 1716, "2 . 29", "", +36099, mmHg, 1717, 1721, "mmHg", "", +36056, Drug, 1732, 1736, "DTFC", "DTFC", +36100, DiffGroupAbsValue, 1752, 1758, "0 . 95", "", +36101, mmHg, 1759, 1763, "mmHg", "", +36102, ConfIntervalResValue, 1766, 1789, "95 % CI 0 . 10 - 1 . 80", "", +36103, PValueResValue, 1792, 1802, "p = 0 . 03", "", +36092, Mean, 1807, 1811, "Mean", "", +36104, IOP, 1812, 1815, "IOP", "", +36105, EndPointDescription, 1812, 1826, "IOP at 09 . 00", "", +36106, BaseLineValue, 1831, 1838, "20 . 95", "", +36107, SdDevBL, 1845, 1851, "2 . 31", "", +36108, mmHg, 1852, 1856, "mmHg", "", +36110, ResultMeasuredValue, 1891, 1898, "15 . 85", "", +36112, SdDevResValue, 1905, 1911, "2 . 56", "", +36114, mmHg, 1912, 1916, "mmHg", "", +36046, Drug, 1927, 1932, "BrTFC", "BrTFC", +36111, ResultMeasuredValue, 1937, 1944, "17 . 55", "", +36113, SdDevResValue, 1951, 1957, "2 . 67", "", +36115, mmHg, 1958, 1962, "mmHg", "", +36057, Drug, 1973, 1977, "DTFC", "DTFC", +36116, DiffGroupAbsValue, 1993, 1999, "1 . 70", "", +36117, ConfIntervalResValue, 2002, 2025, "95 % CI 0 . 80 - 2 . 60", "", +36118, PValueResValue, 2028, 2039, "p = 0 . 001", "", +36119, Mean, 2089, 2093, "mean", "", +36122, EndPointDescription, 2150, 2209, "Percentages of patients achieving a target IOP of < 18 mmHg", "", +36120, IOP, 2193, 2196, "IOP", "", +36121, mmHg, 2205, 2209, "mmHg", "", +36123, PercentageAffected, 2215, 2217, "85", "", +36047, Drug, 2230, 2235, "BrTFC", "BrTFC", +36124, PercentageAffected, 2240, 2242, "60", "", +36058, Drug, 2255, 2259, "DTFC", "DTFC", +36125, PValueNumAffected, 2262, 2268, "p = NS", "", +36126, Duration, 2438, 2446, "6 - week", "", +36127, ConclusionComment, 2559, 2658, "Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC", "", +36128, Mean, 2587, 2591, "mean", "", +36129, Diurnal_IOP, 2592, 2603, "diurnal IOP", "", +36130, IOP, 2616, 2619, "IOP", "", +36048, Drug, 2638, 2643, "BrTFC", "BrTFC", +36059, Drug, 2654, 2658, "DTFC", "DTFC", +36131, PMID, 2711, 2719, "20429818", "", diff --git a/data/gl 20429818_jshahinitiran.n-triples b/data/gl 20429818_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20429818_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20429818_tstrakeljahn.annodb b/data/gl 20429818_tstrakeljahn.annodb new file mode 100644 index 0000000..ece787d --- /dev/null +++ b/data/gl 20429818_tstrakeljahn.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +76776, Journal, 0, 17, "Curr Med Res Opin", "", +76777, Brimonidine, 166, 177, "brimonidine", "", +76784, Brimo/TimFC, 166, 187, "brimonidine / timolol", "", +76778, Timolol, 180, 187, "timolol", "", +76780, Dorzolamide, 192, 203, "dorzolamide", "", +76781, Dorz/TimFC, 192, 213, "dorzolamide / timolol", "", +76779, Timolol, 206, 213, "timolol", "", +76791, Author, 216, 236, "Garc í a - Feijo ó J", "", +76792, Author, 245, 266, "S á enz - Franc é s F", "", +76796, Author, 269, 299, "Mart í nez - de - la - Casa JM", "", +76797, Author, 302, 326, "M é ndez - Hern á ndez C", "", +76798, Author, 329, 350, "Fern á ndez - Vidal A", "", +76800, Author, 353, 373, "Calvo - Gonz á lez C", "", +76801, Author, 376, 398, "Garc í a - S á nchez J", "", +76786, Spain, 509, 514, "Spain", "", +76803, Brimonidine, 540, 551, "brimonidine", "", +76805, Brimo/TimFC, 540, 561, "brimonidine / timolol", "", +76804, Timolol, 554, 561, "timolol", "", +76806, Brimo/TimFC, 582, 587, "BrTFC", "", +76807, Dorzolamide, 608, 619, "dorzolamide", "", +76809, Dorz/TimFC, 608, 629, "dorzolamide / timolol", "", +76808, Timolol, 622, 629, "timolol", "", +76811, Dorz/TimFC, 650, 654, "DTFC", "", +76812, IOP, 702, 722, "intraocular pressure", "", +76813, IOP, 725, 728, "IOP", "", +76814, Primary_OpenAngleGlaucoma, 734, 763, "primary open - angle glaucoma", "", +76815, Primary_OpenAngleGlaucoma, 766, 770, "POAG", "", +76818, Prospective, 796, 807, "prospective", "", +76819, Randomized, 810, 820, "randomized", "", +76821, DoubleBlind, 823, 838, "double - masked", "", +76823, Crossover, 841, 850, "crossover", "", +76827, Timolol, 889, 904, "timolol maleate", "", +76831, DoseValue, 905, 910, "0 . 5", "", +76834, Percentage, 911, 912, "%", "", +76837, Frequency, 913, 924, "twice daily", "", +76845, Randomized, 941, 951, "randomized", "", +76841, Brimo/TimFC, 955, 960, "BrTFC", "", +76844, Frequency, 961, 972, "twice daily", "", +76842, Dorz/TimFC, 976, 980, "DTFC", "", +76847, Frequency, 981, 992, "twice daily", "", +76849, IOP, 1112, 1115, "IOP", "", +76880, EndPointDescription, 1217, 1257, "change in mean diurnal IOP from baseline", "", +76864, Mean, 1227, 1231, "mean", "", +76865, Diurnal_IOP, 1232, 1243, "diurnal IOP", "", +76868, TimePoint, 1261, 1268, "6 weeks", "", +76889, EndPointDescription, 1297, 1338, "percentage of patients with IOP < 18 mmHg", "", +76882, IOP, 1325, 1328, "IOP", "", +76884, mmHg, 1334, 1338, "mmHg", "", +76887, TimePoint, 1342, 1349, "6 weeks", "", +76892, NumberPatientsCT, 1425, 1438, "Twenty - five", "", +76899, Randomized, 1453, 1463, "randomized", "", +76895, FinalNumPatientsCT, 1468, 1470, "20", "", +76903, Mean, 1493, 1497, "Mean", "", +76904, Diurnal_IOP, 1498, 1509, "diurnal IOP", "", +76907, BaseLineValue, 1555, 1562, "20 . 28", "", +76909, SdDevBL, 1569, 1575, "2 . 03", "", +76911, mmHg, 1576, 1580, "mmHg", "", +76912, Timolol, 1584, 1591, "timolol", "", +76914, Mean, 1629, 1633, "mean", "", +76916, Diurnal_IOP, 1634, 1645, "diurnal IOP", "", +76921, ResultMeasuredValue, 1650, 1657, "16 . 28", "", +76923, SdDevResValue, 1664, 1670, "2 . 07", "", +76931, mmHg, 1671, 1675, "mmHg", "", +76932, Brimo/TimFC, 1686, 1691, "BrTFC", "", +76925, ResultMeasuredValue, 1696, 1703, "17 . 23", "", +76928, SdDevResValue, 1710, 1716, "2 . 29", "", +76930, mmHg, 1717, 1721, "mmHg", "", +76935, Dorz/TimFC, 1732, 1736, "DTFC", "", +76937, DiffBetweenGroups, 1752, 1758, "0 . 95", "", +76964, DiffGroupAbsValue, 1752, 1758, "0 . 95", "", +76939, mmHg, 1759, 1763, "mmHg", "", +76941, ConfIntervalDiff, 1774, 1789, "0 . 10 - 1 . 80", "", +76942, PvalueDiff, 1794, 1802, "= 0 . 03", "", +76947, Mean, 1807, 1811, "Mean", "", +76948, IOP, 1812, 1815, "IOP", "", +76950, RelativeTime, 1819, 1826, "09 . 00", "", +76951, BaseLineValue, 1831, 1838, "20 . 95", "", +76952, SdDevBL, 1845, 1851, "2 . 31", "", +76953, mmHg, 1852, 1856, "mmHg", "", +76954, ResultMeasuredValue, 1891, 1898, "15 . 85", "", +76955, SdDevResValue, 1905, 1911, "2 . 56", "", +76957, mmHg, 1912, 1916, "mmHg", "", +76958, Brimo/TimFC, 1927, 1932, "BrTFC", "", +76960, ResultMeasuredValue, 1937, 1944, "17 . 55", "", +76956, SdDevResValue, 1951, 1957, "2 . 67", "", +76959, mmHg, 1958, 1962, "mmHg", "", +76961, Dorz/TimFC, 1973, 1977, "DTFC", "", +76962, DiffBetweenGroups, 1993, 1999, "1 . 70", "", +76965, DiffGroupAbsValue, 1993, 1999, "1 . 70", "", +76963, ConfIntervalDiff, 2010, 2025, "0 . 80 - 2 . 60", "", +76966, PvalueDiff, 2030, 2039, "= 0 . 001", "", +76967, RelativeTime, 2052, 2059, "12 . 00", "", +76968, RelativeTime, 2064, 2071, "16 . 00", "", +76969, Mean, 2089, 2093, "mean", "", +76971, Endpoint, 2186, 2209, "target IOP of < 18 mmHg", "", +76970, Mean, 2205, 2209, "mmHg", "", +76972, PercentageAffected, 2215, 2217, "85", "", +76974, Brimo/TimFC, 2230, 2235, "BrTFC", "", +76973, PercentageAffected, 2240, 2242, "60", "", +76975, Dorz/TimFC, 2255, 2259, "DTFC", "", +76976, PvalueDiff, 2264, 2288, "= NS [ not significant ]", "", +76984, ConclusionComment, 2559, 2660, "Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC .", "", +76977, Mean, 2587, 2591, "mean", "", +76978, Diurnal_IOP, 2592, 2603, "diurnal IOP", "", +76980, Morning, 2608, 2615, "morning", "", +76979, IOP, 2616, 2619, "IOP", "", +76981, Brimo/TimFC, 2638, 2643, "BrTFC", "", +76982, Dorz/TimFC, 2654, 2658, "DTFC", "", +76983, PMID, 2711, 2719, "20429818", "", diff --git a/data/gl 20429818_tstrakeljahn.n-triples b/data/gl 20429818_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20429818_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20545217_admin.annodb b/data/gl 20545217_admin.annodb new file mode 100644 index 0000000..4ee6134 --- /dev/null +++ b/data/gl 20545217_admin.annodb @@ -0,0 +1,67 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +60, Journal, 0, 28, "Nippon Ganka Gakkai Zasshi .", "", " \"Nippon Ganka Gakkai Zasshi .\"." +1, PublicationYear, 29, 33, "2010", "", " \"2010\"." +11, Title, 65, 252, "Intraocular pressure lowering effect of 0 . 0015 % tafluprost as compared to placebo in patients with normal tension glaucoma : randomized , double - blind , multicenter , phase III study", "", " \"Intraocular pressure lowering effect of 0 . 0015 % tafluprost as compared to placebo in patients with normal tension glaucoma : randomized , double - blind , multicenter , phase III study\"." +2, IOP, 65, 85, "Intraocular pressure", "", " . ." +4, DoseValue, 105, 113, "0 . 0015", "", +5, Percentage, 114, 115, "%", "", +3, Tafluprost, 116, 126, "tafluprost", "", +6, Placebo, 142, 149, "placebo", "", +36998, NormalTensionGlaucoma, 167, 190, "normal tension glaucoma", "", " ." +8, Randomized, 193, 203, "randomized", "", " ." +9, DoubleBlind, 206, 220, "double - blind", "", " ." +10, Multicenter, 223, 234, "multicenter", "", " ." +69, Author, 281, 291, "Kuwayama Y", "", " \"Kuwayama Y\"." +70, Author, 300, 311, "Komemushi S", "", " \"Komemushi S\"." +106, Tafluprost, 314, 324, "Tafluprost", "", +12, Japan, 440, 445, "Japan", "", " ." +20, ObjectiveDescription, 458, 634, "To compare the efficacy and safety of 0 . 0015 % tafluprost ophthalmic solution ( Tafluprost ) with Placebo ophthalmic solution ( Placebo ) in normal tension glaucoma ( NTG ) .", "", " \"To compare the efficacy and safety of 0 . 0015 % tafluprost ophthalmic solution ( Tafluprost ) with Placebo ophthalmic solution ( Placebo ) in normal tension glaucoma ( NTG ) .\"." +13, DoseValue, 496, 504, "0 . 0015", "", " \"0 . 0015\"." +14, Percentage, 505, 506, "%", "", " ." +15, Tafluprost, 507, 537, "tafluprost ophthalmic solution", "", " ." +16, Tafluprost, 540, 550, "Tafluprost", "", +31864, Placebo, 558, 565, "Placebo", "", " ." +18, Placebo, 588, 595, "Placebo", "", +36999, NormalTensionGlaucoma, 601, 624, "normal tension glaucoma", "", +37000, NormalTensionGlaucoma, 627, 630, "NTG", "", +21, NumberPatientsCT, 654, 656, "94", "", " \"94\"." +22, Randomized, 680, 690, "randomized", "", +23, DoubleBlind, 693, 707, "double - blind", "", +24, Parallel, 710, 718, "parallel", "", " ." +25, Multicenter, 731, 742, "multicenter", "", +37001, NormalTensionGlaucoma, 774, 777, "NTG", "", +27, Randomized, 783, 791, "randomly", "", +28, Tafluprost, 811, 821, "Tafluprost", "", +29, Placebo, 825, 832, "Placebo", "", +30, Frequency, 876, 886, "once a day", "", " \"once a day\". \"once a day\"." +82, Morning, 894, 901, "morning", "", " . ." +32, Duration, 906, 913, "4 weeks", "", " \"4 weeks\"." +33, Mean, 926, 930, "Mean", "", " . ." +34, IOP, 931, 951, "intraocular pressure", "", +35, IOP, 954, 957, "IOP", "", +87, Reduction, 989, 994, "4 . 0", "", " \"4 . 0\"." +37, SdDevChangeValue, 1001, 1006, "1 . 7", "", " \"1 . 7\"." +38, mmHg, 1007, 1011, "mmHg", "", " ." +73, Tafluprost, 1015, 1025, "Tafluprost", "", +90, Reduction, 1054, 1059, "1 . 4", "", " \"1 . 4\"." +40, SdDevChangeValue, 1066, 1071, "1 . 8", "", " \"1 . 8\"." +41, mmHg, 1072, 1076, "mmHg", "", +42, Placebo, 1080, 1087, "Placebo", "", +43, TimePoint, 1113, 1120, "4 weeks", "", " \"4 weeks\". \"4 weeks\"." +44, PvalueDiff, 1169, 1180, "p < 0 . 001", "", " \"p < 0 . 001\"." +45, IOP, 1185, 1188, "IOP", "", +46, TimePoint, 1199, 1206, "4 weeks", "", +47, IOP, 1211, 1214, "IOP", "", +105, TimePoint, 1228, 1241, "2 and 4 weeks", "", +36995, TimePoint, 1234, 1241, "4 weeks", "", +48, Tafluprost, 1277, 1287, "Tafluprost", "", +49, Placebo, 1296, 1303, "Placebo", "", +31865, PercentageAffected, 1317, 1323, "51 . 0", "", " \"51 . 0\"." +52, Tafluprost, 1329, 1339, "Tafluprost", "", +53, PercentageAffected, 1358, 1363, "8 . 9", "", " \"8 . 9\"." +54, Placebo, 1369, 1376, "Placebo", "", +31867, EndPointDescription, 1400, 1422, "adverse drug reactions", "", " . ." +58, ConclusionComment, 1438, 1523, "These results indicate that Tafluprost is clinically useful in the treatment of NTG .", "", " \"These results indicate that Tafluprost is clinically useful in the treatment of NTG .\"." +56, Tafluprost, 1466, 1476, "Tafluprost", "", +36996, NormalTensionGlaucoma, 1518, 1521, "NTG", "", +59, PMID, 1531, 1539, "20545217", "", " \"20545217\"." diff --git a/data/gl 20545217_admin.n-triples b/data/gl 20545217_admin.n-triples new file mode 100644 index 0000000..2c535d9 --- /dev/null +++ b/data/gl 20545217_admin.n-triples @@ -0,0 +1,113 @@ +# RDF export of group: Publication + . + "Publication" . + "Intraocular pressure lowering effect of 0 . 0015 % tafluprost as compared to placebo in patients with normal tension glaucoma : randomized , double - blind , multicenter , phase III study" . + "Kuwayama Y" . + "2010" . + "Nippon Ganka Gakkai Zasshi ." . + "20545217" . + . + "Komemushi S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and safety of 0 . 0015 % tafluprost ophthalmic solution ( Tafluprost ) with Placebo ophthalmic solution ( Placebo ) in normal tension glaucoma ( NTG ) ." . + "94" . + "4 weeks" . + . + . + . + "These results indicate that Tafluprost is clinically useful in the treatment of NTG ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_AE" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_taf" . + . + . + . + . + "Arm_pla" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_taf" . + . + "once a day" . + . + . + "Intervention_pla" . + . + "once a day" . + . +# RDF export of group: Medication + . + "Medication_taf" . + . + "0 . 0015" . + . + . + . + "Medication_pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_taf" . + . + "4 . 0" . + "1 . 7" . + "4 weeks" . + . + "Outcome_pla" . + . + "1 . 4" . + "1 . 8" . + "4 weeks" . + . + "Outcome_AE_taf" . + . + "51 . 0" . + . + "Outcome_AE_pla" . + . + "8 . 9" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20545217_export.csv b/data/gl 20545217_export.csv new file mode 100644 index 0000000..b95f251 --- /dev/null +++ b/data/gl 20545217_export.csv @@ -0,0 +1,308 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +435, 1, 1, 1, 0, 6, 0, 6, "Nippon" +435, 1, 2, 2, 7, 12, 7, 12, "Ganka" +435, 1, 3, 3, 13, 19, 13, 19, "Gakkai" +435, 1, 4, 4, 20, 26, 20, 26, "Zasshi" +435, 1, 5, 5, 27, 28, 27, 28, "." +435, 2, 1, 6, 0, 4, 29, 33, "2010" +435, 2, 2, 7, 5, 8, 34, 37, "May" +435, 2, 3, 8, 9, 10, 38, 39, ";" +435, 2, 4, 9, 11, 14, 40, 43, "114" +435, 2, 5, 10, 15, 16, 44, 45, "(" +435, 2, 6, 11, 17, 18, 46, 47, "5" +435, 2, 7, 12, 19, 20, 48, 49, ")" +435, 2, 8, 13, 21, 22, 50, 51, ":" +435, 2, 9, 14, 23, 26, 52, 55, "436" +435, 2, 10, 15, 27, 28, 56, 57, "-" +435, 2, 11, 16, 29, 31, 58, 60, "43" +435, 2, 12, 17, 32, 33, 61, 62, "." +435, 3, 1, 18, 0, 1, 63, 64, "[" +435, 3, 2, 19, 2, 13, 65, 76, "Intraocular" +435, 3, 3, 20, 14, 22, 77, 85, "pressure" +435, 3, 4, 21, 23, 31, 86, 94, "lowering" +435, 3, 5, 22, 32, 38, 95, 101, "effect" +435, 3, 6, 23, 39, 41, 102, 104, "of" +435, 3, 7, 24, 42, 43, 105, 106, "0" +435, 3, 8, 25, 44, 45, 107, 108, "." +435, 3, 9, 26, 46, 50, 109, 113, "0015" +435, 3, 10, 27, 51, 52, 114, 115, "%" +435, 3, 11, 28, 53, 63, 116, 126, "tafluprost" +435, 3, 12, 29, 64, 66, 127, 129, "as" +435, 3, 13, 30, 67, 75, 130, 138, "compared" +435, 3, 14, 31, 76, 78, 139, 141, "to" +435, 3, 15, 32, 79, 86, 142, 149, "placebo" +435, 3, 16, 33, 87, 89, 150, 152, "in" +435, 3, 17, 34, 90, 98, 153, 161, "patients" +435, 3, 18, 35, 99, 103, 162, 166, "with" +435, 3, 19, 36, 104, 110, 167, 173, "normal" +435, 3, 20, 37, 111, 118, 174, 181, "tension" +435, 3, 21, 38, 119, 127, 182, 190, "glaucoma" +435, 3, 22, 39, 128, 129, 191, 192, ":" +435, 3, 23, 40, 130, 140, 193, 203, "randomized" +435, 3, 24, 41, 141, 142, 204, 205, "," +435, 3, 25, 42, 143, 149, 206, 212, "double" +435, 3, 26, 43, 150, 151, 213, 214, "-" +435, 3, 27, 44, 152, 157, 215, 220, "blind" +435, 3, 28, 45, 158, 159, 221, 222, "," +435, 3, 29, 46, 160, 171, 223, 234, "multicenter" +435, 3, 30, 47, 172, 173, 235, 236, "," +435, 3, 31, 48, 174, 179, 237, 242, "phase" +435, 3, 32, 49, 180, 183, 243, 246, "III" +435, 3, 33, 50, 184, 189, 247, 252, "study" +435, 3, 34, 51, 190, 191, 253, 254, "]" +435, 3, 35, 52, 192, 193, 255, 256, "." +435, 4, 1, 53, 0, 1, 257, 258, "[" +435, 4, 2, 54, 2, 9, 259, 266, "Article" +435, 4, 3, 55, 10, 12, 267, 269, "in" +435, 4, 4, 56, 13, 21, 270, 278, "Japanese" +435, 4, 5, 57, 22, 23, 279, 280, "]" +435, 4, 6, 58, 24, 32, 281, 289, "Kuwayama" +435, 4, 7, 59, 33, 34, 290, 291, "Y" +435, 4, 8, 60, 35, 36, 292, 293, "(" +435, 4, 9, 61, 37, 38, 294, 295, "1" +435, 4, 10, 62, 39, 40, 296, 297, ")" +435, 4, 11, 63, 41, 42, 298, 299, "," +435, 4, 12, 64, 43, 52, 300, 309, "Komemushi" +435, 4, 13, 65, 53, 54, 310, 311, "S" +435, 4, 14, 66, 55, 56, 312, 313, ";" +435, 4, 15, 67, 57, 67, 314, 324, "Tafluprost" +435, 4, 16, 68, 68, 73, 325, 330, "Multi" +435, 4, 17, 69, 74, 75, 331, 332, "-" +435, 4, 18, 70, 76, 82, 333, 339, "center" +435, 4, 19, 71, 83, 88, 340, 345, "Study" +435, 4, 20, 72, 89, 94, 346, 351, "Group" +435, 4, 21, 73, 95, 96, 352, 353, "." +435, 5, 1, 74, 0, 6, 354, 360, "Author" +435, 5, 2, 75, 7, 18, 361, 372, "information" +435, 5, 3, 76, 19, 20, 373, 374, ":" +435, 5, 4, 77, 21, 22, 375, 376, "(" +435, 5, 5, 78, 23, 24, 377, 378, "1" +435, 5, 6, 79, 25, 26, 379, 380, ")" +435, 5, 7, 80, 27, 37, 381, 391, "Department" +435, 5, 8, 81, 38, 40, 392, 394, "of" +435, 5, 9, 82, 41, 54, 395, 408, "Ophthalmology" +435, 5, 10, 83, 55, 56, 409, 410, "," +435, 5, 11, 84, 57, 62, 411, 416, "Osaka" +435, 5, 12, 85, 63, 74, 417, 428, "Koseinenkin" +435, 5, 13, 86, 75, 83, 429, 437, "Hospital" +435, 5, 14, 87, 84, 85, 438, 439, "," +435, 5, 15, 88, 86, 91, 440, 445, "Japan" +435, 5, 16, 89, 92, 93, 446, 447, "." +435, 6, 1, 90, 0, 7, 448, 455, "PURPOSE" +435, 6, 2, 91, 8, 9, 456, 457, ":" +435, 6, 3, 92, 10, 12, 458, 460, "To" +435, 6, 4, 93, 13, 20, 461, 468, "compare" +435, 6, 5, 94, 21, 24, 469, 472, "the" +435, 6, 6, 95, 25, 33, 473, 481, "efficacy" +435, 6, 7, 96, 34, 37, 482, 485, "and" +435, 6, 8, 97, 38, 44, 486, 492, "safety" +435, 6, 9, 98, 45, 47, 493, 495, "of" +435, 6, 10, 99, 48, 49, 496, 497, "0" +435, 6, 11, 100, 50, 51, 498, 499, "." +435, 6, 12, 101, 52, 56, 500, 504, "0015" +435, 6, 13, 102, 57, 58, 505, 506, "%" +435, 6, 14, 103, 59, 69, 507, 517, "tafluprost" +435, 6, 15, 104, 70, 80, 518, 528, "ophthalmic" +435, 6, 16, 105, 81, 89, 529, 537, "solution" +435, 6, 17, 106, 90, 91, 538, 539, "(" +435, 6, 18, 107, 92, 102, 540, 550, "Tafluprost" +435, 6, 19, 108, 103, 104, 551, 552, ")" +435, 6, 20, 109, 105, 109, 553, 557, "with" +435, 6, 21, 110, 110, 117, 558, 565, "Placebo" +435, 6, 22, 111, 118, 128, 566, 576, "ophthalmic" +435, 6, 23, 112, 129, 137, 577, 585, "solution" +435, 6, 24, 113, 138, 139, 586, 587, "(" +435, 6, 25, 114, 140, 147, 588, 595, "Placebo" +435, 6, 26, 115, 148, 149, 596, 597, ")" +435, 6, 27, 116, 150, 152, 598, 600, "in" +435, 6, 28, 117, 153, 159, 601, 607, "normal" +435, 6, 29, 118, 160, 167, 608, 615, "tension" +435, 6, 30, 119, 168, 176, 616, 624, "glaucoma" +435, 6, 31, 120, 177, 178, 625, 626, "(" +435, 6, 32, 121, 179, 182, 627, 630, "NTG" +435, 6, 33, 122, 183, 184, 631, 632, ")" +435, 6, 34, 123, 185, 186, 633, 634, "." +435, 7, 1, 124, 0, 7, 635, 642, "SETTING" +435, 7, 2, 125, 8, 9, 643, 644, ":" +435, 7, 3, 126, 10, 15, 645, 650, "Total" +435, 7, 4, 127, 16, 18, 651, 653, "of" +435, 7, 5, 128, 19, 21, 654, 656, "94" +435, 7, 6, 129, 22, 30, 657, 665, "patients" +435, 7, 7, 130, 31, 39, 666, 674, "enrolled" +435, 7, 8, 131, 40, 42, 675, 677, "in" +435, 7, 9, 132, 43, 44, 678, 679, "a" +435, 7, 10, 133, 45, 55, 680, 690, "randomized" +435, 7, 11, 134, 56, 57, 691, 692, "," +435, 7, 12, 135, 58, 64, 693, 699, "double" +435, 7, 13, 136, 65, 66, 700, 701, "-" +435, 7, 14, 137, 67, 72, 702, 707, "blind" +435, 7, 15, 138, 73, 74, 708, 709, "," +435, 7, 16, 139, 75, 83, 710, 718, "parallel" +435, 7, 17, 140, 84, 85, 719, 720, "-" +435, 7, 18, 141, 86, 91, 721, 726, "group" +435, 7, 19, 142, 92, 95, 727, 730, "and" +435, 7, 20, 143, 96, 107, 731, 742, "multicenter" +435, 7, 21, 144, 108, 113, 743, 748, "study" +435, 7, 22, 145, 114, 115, 749, 750, "." +435, 8, 1, 146, 0, 6, 751, 757, "METHOD" +435, 8, 2, 147, 7, 8, 758, 759, ":" +435, 8, 3, 148, 9, 17, 760, 768, "Patients" +435, 8, 4, 149, 18, 22, 769, 773, "with" +435, 8, 5, 150, 23, 26, 774, 777, "NTG" +435, 8, 6, 151, 27, 31, 778, 782, "were" +435, 8, 7, 152, 32, 40, 783, 791, "randomly" +435, 8, 8, 153, 41, 49, 792, 800, "assigned" +435, 8, 9, 154, 50, 52, 801, 803, "to" +435, 8, 10, 155, 53, 59, 804, 810, "either" +435, 8, 11, 156, 60, 70, 811, 821, "Tafluprost" +435, 8, 12, 157, 71, 73, 822, 824, "or" +435, 8, 13, 158, 74, 81, 825, 832, "Placebo" +435, 8, 14, 159, 82, 83, 833, 834, "." +435, 9, 1, 160, 0, 4, 835, 839, "Both" +435, 9, 2, 161, 5, 15, 840, 850, "ophthalmic" +435, 9, 3, 162, 16, 25, 851, 860, "solutions" +435, 9, 4, 163, 26, 30, 861, 865, "were" +435, 9, 5, 164, 31, 40, 866, 875, "instilled" +435, 9, 6, 165, 41, 45, 876, 880, "once" +435, 9, 7, 166, 46, 47, 881, 882, "a" +435, 9, 8, 167, 48, 51, 883, 886, "day" +435, 9, 9, 168, 52, 54, 887, 889, "in" +435, 9, 10, 169, 55, 58, 890, 893, "the" +435, 9, 11, 170, 59, 66, 894, 901, "morning" +435, 9, 12, 171, 67, 70, 902, 905, "for" +435, 9, 13, 172, 71, 72, 906, 907, "4" +435, 9, 14, 173, 73, 78, 908, 913, "weeks" +435, 9, 15, 174, 79, 80, 914, 915, "." +435, 10, 1, 175, 0, 7, 916, 923, "RESULTS" +435, 10, 2, 176, 8, 9, 924, 925, ":" +435, 10, 3, 177, 10, 14, 926, 930, "Mean" +435, 10, 4, 178, 15, 26, 931, 942, "intraocular" +435, 10, 5, 179, 27, 35, 943, 951, "pressure" +435, 10, 6, 180, 36, 37, 952, 953, "(" +435, 10, 7, 181, 38, 41, 954, 957, "IOP" +435, 10, 8, 182, 42, 43, 958, 959, ")" +435, 10, 9, 183, 44, 51, 960, 967, "changes" +435, 10, 10, 184, 52, 56, 968, 972, "from" +435, 10, 11, 185, 57, 65, 973, 981, "baseline" +435, 10, 12, 186, 66, 70, 982, 986, "were" +435, 10, 13, 187, 71, 72, 987, 988, "-" +435, 10, 14, 188, 73, 74, 989, 990, "4" +435, 10, 15, 189, 75, 76, 991, 992, "." +435, 10, 16, 190, 77, 78, 993, 994, "0" +435, 10, 17, 191, 79, 80, 995, 996, "+" +435, 10, 18, 192, 81, 82, 997, 998, "/" +435, 10, 19, 193, 83, 84, 999, 1000, "-" +435, 10, 20, 194, 85, 86, 1001, 1002, "1" +435, 10, 21, 195, 87, 88, 1003, 1004, "." +435, 10, 22, 196, 89, 90, 1005, 1006, "7" +435, 10, 23, 197, 91, 95, 1007, 1011, "mmHg" +435, 10, 24, 198, 96, 98, 1012, 1014, "in" +435, 10, 25, 199, 99, 109, 1015, 1025, "Tafluprost" +435, 10, 26, 200, 110, 122, 1026, 1038, "administered" +435, 10, 27, 201, 123, 131, 1039, 1047, "patients" +435, 10, 28, 202, 132, 135, 1048, 1051, "and" +435, 10, 29, 203, 136, 137, 1052, 1053, "-" +435, 10, 30, 204, 138, 139, 1054, 1055, "1" +435, 10, 31, 205, 140, 141, 1056, 1057, "." +435, 10, 32, 206, 142, 143, 1058, 1059, "4" +435, 10, 33, 207, 144, 145, 1060, 1061, "+" +435, 10, 34, 208, 146, 147, 1062, 1063, "/" +435, 10, 35, 209, 148, 149, 1064, 1065, "-" +435, 10, 36, 210, 150, 151, 1066, 1067, "1" +435, 10, 37, 211, 152, 153, 1068, 1069, "." +435, 10, 38, 212, 154, 155, 1070, 1071, "8" +435, 10, 39, 213, 156, 160, 1072, 1076, "mmHg" +435, 10, 40, 214, 161, 163, 1077, 1079, "in" +435, 10, 41, 215, 164, 171, 1080, 1087, "Placebo" +435, 10, 42, 216, 172, 184, 1088, 1100, "administered" +435, 10, 43, 217, 185, 193, 1101, 1109, "patients" +435, 10, 44, 218, 194, 196, 1110, 1112, "at" +435, 10, 45, 219, 197, 198, 1113, 1114, "4" +435, 10, 46, 220, 199, 204, 1115, 1120, "weeks" +435, 10, 47, 221, 205, 206, 1121, 1122, "," +435, 10, 48, 222, 207, 211, 1123, 1127, "with" +435, 10, 49, 223, 212, 213, 1128, 1129, "a" +435, 10, 50, 224, 214, 227, 1130, 1143, "statistically" +435, 10, 51, 225, 228, 239, 1144, 1155, "significant" +435, 10, 52, 226, 240, 250, 1156, 1166, "difference" +435, 10, 53, 227, 251, 252, 1167, 1168, "(" +435, 10, 54, 228, 253, 254, 1169, 1170, "p" +435, 10, 55, 229, 255, 256, 1171, 1172, "<" +435, 10, 56, 230, 257, 258, 1173, 1174, "0" +435, 10, 57, 231, 259, 260, 1175, 1176, "." +435, 10, 58, 232, 261, 264, 1177, 1180, "001" +435, 10, 59, 233, 265, 266, 1181, 1182, ")" +435, 10, 60, 234, 267, 268, 1183, 1184, "." +435, 11, 1, 235, 0, 3, 1185, 1188, "IOP" +435, 11, 2, 236, 4, 10, 1189, 1195, "change" +435, 11, 3, 237, 11, 13, 1196, 1198, "at" +435, 11, 4, 238, 14, 15, 1199, 1200, "4" +435, 11, 5, 239, 16, 21, 1201, 1206, "weeks" +435, 11, 6, 240, 22, 23, 1207, 1208, "," +435, 11, 7, 241, 24, 25, 1209, 1210, "%" +435, 11, 8, 242, 26, 29, 1211, 1214, "IOP" +435, 11, 9, 243, 30, 39, 1215, 1224, "reduction" +435, 11, 10, 244, 40, 42, 1225, 1227, "at" +435, 11, 11, 245, 43, 44, 1228, 1229, "2" +435, 11, 12, 246, 45, 48, 1230, 1233, "and" +435, 11, 13, 247, 49, 50, 1234, 1235, "4" +435, 11, 14, 248, 51, 56, 1236, 1241, "weeks" +435, 11, 15, 249, 57, 61, 1242, 1246, "were" +435, 11, 16, 250, 62, 66, 1247, 1251, "also" +435, 11, 17, 251, 67, 80, 1252, 1265, "significantly" +435, 11, 18, 252, 81, 88, 1266, 1273, "greater" +435, 11, 19, 253, 89, 91, 1274, 1276, "in" +435, 11, 20, 254, 92, 102, 1277, 1287, "Tafluprost" +435, 11, 21, 255, 103, 107, 1288, 1292, "than" +435, 11, 22, 256, 108, 110, 1293, 1295, "in" +435, 11, 23, 257, 111, 118, 1296, 1303, "Placebo" +435, 11, 24, 258, 119, 120, 1304, 1305, "." +435, 12, 1, 259, 0, 1, 1306, 1307, "A" +435, 12, 2, 260, 2, 7, 1308, 1313, "total" +435, 12, 3, 261, 8, 10, 1314, 1316, "of" +435, 12, 4, 262, 11, 13, 1317, 1319, "51" +435, 12, 5, 263, 14, 15, 1320, 1321, "." +435, 12, 6, 264, 16, 17, 1322, 1323, "0" +435, 12, 7, 265, 18, 19, 1324, 1325, "%" +435, 12, 8, 266, 20, 22, 1326, 1328, "in" +435, 12, 9, 267, 23, 33, 1329, 1339, "Tafluprost" +435, 12, 10, 268, 34, 41, 1340, 1347, "treated" +435, 12, 11, 269, 42, 47, 1348, 1353, "group" +435, 12, 12, 270, 48, 51, 1354, 1357, "and" +435, 12, 13, 271, 52, 53, 1358, 1359, "8" +435, 12, 14, 272, 54, 55, 1360, 1361, "." +435, 12, 15, 273, 56, 57, 1362, 1363, "9" +435, 12, 16, 274, 58, 59, 1364, 1365, "%" +435, 12, 17, 275, 60, 62, 1366, 1368, "in" +435, 12, 18, 276, 63, 70, 1369, 1376, "Placebo" +435, 12, 19, 277, 71, 78, 1377, 1384, "treated" +435, 12, 20, 278, 79, 84, 1385, 1390, "group" +435, 12, 21, 279, 85, 93, 1391, 1399, "reported" +435, 12, 22, 280, 94, 101, 1400, 1407, "adverse" +435, 12, 23, 281, 102, 106, 1408, 1412, "drug" +435, 12, 24, 282, 107, 116, 1413, 1422, "reactions" +435, 12, 25, 283, 117, 118, 1423, 1424, "." +435, 13, 1, 284, 0, 10, 1425, 1435, "CONCLUSION" +435, 13, 2, 285, 11, 12, 1436, 1437, ":" +435, 13, 3, 286, 13, 18, 1438, 1443, "These" +435, 13, 4, 287, 19, 26, 1444, 1451, "results" +435, 13, 5, 288, 27, 35, 1452, 1460, "indicate" +435, 13, 6, 289, 36, 40, 1461, 1465, "that" +435, 13, 7, 290, 41, 51, 1466, 1476, "Tafluprost" +435, 13, 8, 291, 52, 54, 1477, 1479, "is" +435, 13, 9, 292, 55, 65, 1480, 1490, "clinically" +435, 13, 10, 293, 66, 72, 1491, 1497, "useful" +435, 13, 11, 294, 73, 75, 1498, 1500, "in" +435, 13, 12, 295, 76, 79, 1501, 1504, "the" +435, 13, 13, 296, 80, 89, 1505, 1514, "treatment" +435, 13, 14, 297, 90, 92, 1515, 1517, "of" +435, 13, 15, 298, 93, 96, 1518, 1521, "NTG" +435, 13, 16, 299, 97, 98, 1522, 1523, "." +435, 14, 1, 300, 0, 4, 1524, 1528, "PMID" +435, 14, 2, 301, 5, 6, 1529, 1530, ":" +435, 14, 3, 302, 7, 15, 1531, 1539, "20545217" +435, 14, 4, 303, 16, 17, 1540, 1541, "[" +435, 14, 5, 304, 18, 25, 1542, 1549, "Indexed" +435, 14, 6, 305, 26, 29, 1550, 1553, "for" +435, 14, 7, 306, 30, 37, 1554, 1561, "MEDLINE" +435, 14, 8, 307, 38, 39, 1562, 1563, "]" diff --git a/data/gl 20545217_jshahinitiran.annodb b/data/gl 20545217_jshahinitiran.annodb new file mode 100644 index 0000000..a2f17a9 --- /dev/null +++ b/data/gl 20545217_jshahinitiran.annodb @@ -0,0 +1,64 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15614, Journal, 0, 28, "Nippon Ganka Gakkai Zasshi .", "", +15615, PublicationYear, 29, 33, "2010", "", +15616, Title, 65, 252, "Intraocular pressure lowering effect of 0 . 0015 % tafluprost as compared to placebo in patients with normal tension glaucoma : randomized , double - blind , multicenter , phase III study", "", +15617, IOP, 65, 85, "Intraocular pressure", "", +15618, DoseValue, 105, 113, "0 . 0015", "", +15619, Percentage, 114, 115, "%", "", +15632, Tafluprost, 116, 126, "tafluprost", "", +15636, Placebo, 142, 149, "placebo", "", +15640, Glaucoma, 167, 190, "normal tension glaucoma", "Normal Tension Glaucoma", +15623, Randomized, 193, 203, "randomized", "", +15624, DoubleBlind, 206, 220, "double - blind", "", +15625, Multicenter, 223, 234, "multicenter", "", +15626, Author, 281, 291, "Kuwayama Y", "", +15627, Author, 300, 311, "Komemushi S", "", +15628, Japan, 440, 445, "Japan", "", +15629, ObjectiveDescription, 458, 634, "To compare the efficacy and safety of 0 . 0015 % tafluprost ophthalmic solution ( Tafluprost ) with Placebo ophthalmic solution ( Placebo ) in normal tension glaucoma ( NTG ) .", "", +15618, DoseValue, 496, 504, "0 . 0015", "", +15619, Percentage, 505, 506, "%", "", +15632, Tafluprost, 507, 537, "tafluprost ophthalmic solution", "", +15632, Tafluprost, 540, 550, "Tafluprost", "", +15636, Placebo, 558, 585, "Placebo ophthalmic solution", "", +15636, Placebo, 588, 595, "Placebo", "", +15640, Glaucoma, 601, 624, "normal tension glaucoma", "Normal Tension Glaucoma", +15640, Glaucoma, 627, 630, "NTG", "Normal Tension Glaucoma", +15644, NumberPatientsCT, 654, 656, "94", "", +15646, Randomized, 680, 690, "randomized", "", +15647, DoubleBlind, 693, 707, "double - blind", "", +15648, Parallel, 710, 726, "parallel - group", "", +15649, Multicenter, 731, 742, "multicenter", "", +15640, Glaucoma, 774, 777, "NTG", "Normal Tension Glaucoma", +15632, Tafluprost, 811, 821, "Tafluprost", "", +15636, Placebo, 825, 832, "Placebo", "", +15653, Frequency, 876, 886, "once a day", "", +15654, Morning, 894, 901, "morning", "", +15655, Duration, 906, 913, "4 weeks", "", +15656, Mean, 926, 930, "Mean", "", +15657, IOP, 931, 951, "intraocular pressure", "", +15658, IOP, 954, 957, "IOP", "", +15659, Reduction, 989, 994, "4 . 0", "", +15660, SdErrorChangeValue, 1001, 1006, "1 . 7", "", +15661, mmHg, 1007, 1011, "mmHg", "", +15632, Tafluprost, 1015, 1025, "Tafluprost", "", +15663, Reduction, 1054, 1059, "1 . 4", "", +15664, SdErrorChangeValue, 1066, 1071, "1 . 8", "", +15665, mmHg, 1072, 1076, "mmHg", "", +15666, Placebo, 1080, 1087, "Placebo", "", +15685, TimePoint, 1113, 1120, "4 weeks", "", +15668, PvalueDiff, 1169, 1180, "p < 0 . 001", "", +15670, IOP, 1185, 1188, "IOP", "", +15686, TimePoint, 1199, 1206, "4 weeks", "", +15672, IOP, 1211, 1214, "IOP", "", +15673, TimePoint, 1228, 1229, "2", "", +15674, TimePoint, 1234, 1241, "4 weeks", "", +15632, Tafluprost, 1277, 1287, "Tafluprost", "", +15666, Placebo, 1296, 1303, "Placebo", "", +15677, PercentageAffected, 1317, 1323, "51 . 0", "", +15632, Tafluprost, 1329, 1339, "Tafluprost", "", +15679, PercentageAffected, 1358, 1363, "8 . 9", "", +15666, Placebo, 1369, 1376, "Placebo", "", +15684, ConclusionComment, 1438, 1523, "These results indicate that Tafluprost is clinically useful in the treatment of NTG .", "", +15632, Tafluprost, 1466, 1476, "Tafluprost", "", +15640, Glaucoma, 1518, 1521, "NTG", "Normal Tension Glaucoma", +15683, PMID, 1531, 1539, "20545217", "", diff --git a/data/gl 20545217_jshahinitiran.n-triples b/data/gl 20545217_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20545217_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 20545217_tstrakeljahn.annodb b/data/gl 20545217_tstrakeljahn.annodb new file mode 100644 index 0000000..1f27bfd --- /dev/null +++ b/data/gl 20545217_tstrakeljahn.annodb @@ -0,0 +1,63 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13408, Journal, 0, 26, "Nippon Ganka Gakkai Zasshi", "", +13409, PublicationYear, 29, 33, "2010", "", +13410, IOP, 65, 85, "Intraocular pressure", "", +13419, Title, 65, 252, "Intraocular pressure lowering effect of 0 . 0015 % tafluprost as compared to placebo in patients with normal tension glaucoma : randomized , double - blind , multicenter , phase III study", "", +13412, DoseValue, 105, 113, "0 . 0015", "", +13413, Percentage, 114, 115, "%", "", +13411, Tafluprost, 116, 126, "tafluprost", "", +13414, Placebo, 142, 149, "placebo", "", +13415, Glaucoma, 182, 190, "glaucoma", "", +13416, Randomized, 193, 203, "randomized", "", +13417, DoubleBlind, 206, 220, "double - blind", "", +13418, Multicenter, 223, 234, "multicenter", "", +29905, Tafluprost, 314, 324, "Tafluprost", "", +13420, Japan, 440, 445, "Japan", "", +13428, ObjectiveDescription, 458, 634, "To compare the efficacy and safety of 0 . 0015 % tafluprost ophthalmic solution ( Tafluprost ) with Placebo ophthalmic solution ( Placebo ) in normal tension glaucoma ( NTG ) .", "", +13421, DoseValue, 496, 504, "0 . 0015", "", +13422, Percentage, 505, 506, "%", "", +13423, Tafluprost, 507, 537, "tafluprost ophthalmic solution", "", +13424, Tafluprost, 540, 550, "Tafluprost", "", +13425, Placebo, 558, 585, "Placebo ophthalmic solution", "", +13426, Placebo, 588, 595, "Placebo", "", +13427, Glaucoma, 616, 624, "glaucoma", "", +13429, NumberPatientsCT, 654, 656, "94", "", +13430, Randomized, 680, 690, "randomized", "", +13431, DoubleBlind, 693, 707, "double - blind", "", +13432, Parallel, 710, 718, "parallel", "", +13433, Multicenter, 731, 742, "multicenter", "", +13434, Glaucoma, 774, 777, "NTG", "", +13435, Randomized, 783, 791, "randomly", "", +13436, Tafluprost, 811, 821, "Tafluprost", "", +13437, Placebo, 825, 832, "Placebo", "", +13438, Frequency, 876, 886, "once a day", "", +13439, Morning, 887, 901, "in the morning", "", +13440, Duration, 906, 913, "4 weeks", "", +13441, Mean, 926, 930, "Mean", "", +13442, IOP, 931, 951, "intraocular pressure", "", +13443, IOP, 954, 957, "IOP", "", +13444, Reduction, 987, 994, "- 4 . 0", "", +13445, SdDevChangeValue, 1001, 1006, "1 . 7", "", +13446, mmHg, 1007, 1011, "mmHg", "", +13447, Reduction, 1052, 1059, "- 1 . 4", "", +13448, SdDevChangeValue, 1066, 1071, "1 . 8", "", +13449, mmHg, 1072, 1076, "mmHg", "", +13450, Placebo, 1080, 1087, "Placebo", "", +13451, TimePoint, 1113, 1120, "4 weeks", "", +13452, PvalueDiff, 1169, 1180, "p < 0 . 001", "", +13453, IOP, 1185, 1188, "IOP", "", +13461, ObservedResult, 1185, 1303, "IOP change at 4 weeks , % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo", "", +13454, TimePoint, 1199, 1206, "4 weeks", "", +13455, IOP, 1211, 1214, "IOP", "", +29904, TimePoint, 1228, 1241, "2 and 4 weeks", "", +13459, Tafluprost, 1277, 1287, "Tafluprost", "", +13460, Placebo, 1296, 1303, "Placebo", "", +13466, ObservedResult, 1306, 1422, "A total of 51 . 0 % in Tafluprost treated group and 8 . 9 % in Placebo treated group reported adverse drug reactions", "", +13462, PercentageAffected, 1317, 1323, "51 . 0", "", +13463, Tafluprost, 1329, 1339, "Tafluprost", "", +13464, PercentageAffected, 1358, 1363, "8 . 9", "", +13465, Placebo, 1369, 1376, "Placebo", "", +13469, ConclusionComment, 1438, 1523, "These results indicate that Tafluprost is clinically useful in the treatment of NTG .", "", +13467, Tafluprost, 1466, 1476, "Tafluprost", "", +13468, Glaucoma, 1518, 1521, "NTG", "", +13470, PMID, 1531, 1539, "20545217", "", diff --git a/data/gl 20545217_tstrakeljahn.n-triples b/data/gl 20545217_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 20545217_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21034177_admin.annodb b/data/gl 21034177_admin.annodb new file mode 100644 index 0000000..d9f9860 --- /dev/null +++ b/data/gl 21034177_admin.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32101, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2010", "", " \"2010\"." +2, Bimatoprost, 114, 125, "Bimatoprost", "", +103, Title, 114, 223, "Bimatoprost versus travoprost in an Egyptian population : a hospital - based prospective , randomized study .", "", " \"Bimatoprost versus travoprost in an Egyptian population : a hospital - based prospective , randomized study .\"." +37003, Travoprost, 133, 143, "travoprost", "", +37002, Prospective, 191, 202, "prospective", "", " ." +3, Randomized, 205, 215, "randomized", "", " ." +4, Author, 224, 232, "Macky TA", "", " \"Macky TA\"." +5, Egypt, 349, 354, "Egypt", "", " ." +109, ObjectiveDescription, 392, 515, "To compare the efficacy of bimatoprost and travoprost on intraocular pressure ( IOP ) reduction in an Egyptian population .", "", " \"To compare the efficacy of bimatoprost and travoprost on intraocular pressure ( IOP ) reduction in an Egyptian population .\"." +6, Bimatoprost, 419, 430, "bimatoprost", "", +32083, Travoprost, 435, 445, "travoprost", "", +7, IOP, 449, 469, "intraocular pressure", "", " . ." +8, IOP, 472, 475, "IOP", "", +106360, Precondition, 526, 592, "Patients with primary open - angle glaucoma or ocular hypertension", "", " \"Patients with primary open - angle glaucoma or ocular hypertension\"." +32091, Primary_OpenAngleGlaucoma, 540, 569, "primary open - angle glaucoma", "", " ." +12, OcularHypertension, 573, 592, "ocular hypertension", "", " ." +13, Randomized, 598, 608, "randomized", "", +14, Bimatoprost, 627, 638, "bimatoprost", "", " ." +16, DoseValue, 639, 645, "0 . 03", "", " \"0 . 03\"." +18, Percentage, 646, 647, "%", "", " ." +32095, Travoprost, 651, 661, "travoprost", "", " ." +17, DoseValue, 662, 669, "0 . 004", "", " \"0 . 004\"." +19, Percentage, 670, 671, "%", "", " ." +15, Frequency, 672, 682, "once daily", "", " \"once daily\". \"once daily\"." +32092, IOP, 685, 689, "IOPs", "", +121, TimePoint, 707, 715, "baseline", "", +122, TimePoint, 718, 725, "2 weeks", "", +32105, TimePoint, 732, 756, "1 , 2 , 4 , and 6 months", "", +106242, TimePoint, 736, 756, "2 , 4 , and 6 months", "", +106243, TimePoint, 740, 756, "4 , and 6 months", "", +106244, TimePoint, 748, 756, "6 months", "", +32096, MeasurementDevice, 763, 793, "Goldman applanation tonometery", "", " . . . . . ." +127, NumberPatientsCT, 806, 819, "Seventy - two", "", " \"Seventy - two\"." +128, NumberPatientsArm, 845, 847, "34", "", " \"34\"." +129, NumberPatientsArm, 852, 854, "38", "", " \"38\"." +32102, PvalueDiff, 857, 870, "P  =  0 . 142", "", +32097, TimePoint, 880, 888, "baseline", "", +25, Mean, 889, 893, "mean", "", " . ." +26, IOP, 894, 897, "IOP", "", +27, BaseLineValue, 902, 909, "26 . 52", "", " \"26 . 52\". \"26 . 52\"." +29, SdDevBL, 914, 921, "5 . 185", "", " \"5 . 185\". \"5 . 185\"." +28, BaseLineValue, 926, 933, "26 . 36", "", " \"26 . 36\". \"26 . 36\"." +30, SdDevBL, 938, 945, "1 . 605", "", " \"1 . 605\". \"1 . 605\"." +31, mmHg, 948, 953, "mm Hg", "", " ." +32098, PvalueDiff, 956, 969, "P  =  0 . 629", "", +33, Bimatoprost, 976, 987, "bimatoprost", "", +32094, Travoprost, 992, 1002, "travoprost", "", +34, Eyedrops, 1025, 1030, "drops", "", " . ." +35, IOP, 1066, 1069, "IOP", "", +140, PValueChangeValue, 1111, 1124, "P  <  0 . 001", "", " \"P  <  0 . 001\". \"P  <  0 . 001\". \"P  <  0 . 001\". \"P  <  0 . 001\"." +37, Bimatoprost, 1129, 1140, "Bimatoprost", "", +38, Mean, 1177, 1181, "mean", "", +39, IOP, 1182, 1185, "IOP", "", +32093, Travoprost, 1216, 1226, "travoprost", "", +42, Mean, 1243, 1247, "Mean", "", +43, IOP, 1248, 1251, "IOP", "", +44, Reduction, 1267, 1273, "8 . 77", "", " \"8 . 77\"." +46, mmHg, 1276, 1281, "mm Hg", "", +48, RelativeReduction, 1284, 1291, "33 . 39", "", " \"33 . 39\"." +45, Reduction, 1300, 1306, "8 . 42", "", " \"8 . 42\"." +47, mmHg, 1309, 1314, "mm Hg", "", +49, RelativeReduction, 1317, 1324, "31 . 54", "", " \"31 . 54\"." +50, TimePoint, 1332, 1339, "2 weeks", "", " \"2 weeks\". \"2 weeks\"." +51, PvalueDiff, 1342, 1355, "P  =  0 . 703", "", " \"P  =  0 . 703\"." +52, Reduction, 1364, 1370, "8 . 47", "", " \"8 . 47\"." +56, mmHg, 1373, 1378, "mm Hg", "", +54, RelativeReduction, 1381, 1388, "31 . 61", "", " \"31 . 61\"." +53, Reduction, 1397, 1403, "7 . 84", "", " \"8 . 47\"." +57, mmHg, 1406, 1411, "mm Hg", "", +55, RelativeReduction, 1414, 1421, "29 . 50", "", " \"29 . 50\"." +58, TimePoint, 1429, 1437, "6 months", "", " \"6 months\". \"6 months\"." +59, PvalueDiff, 1440, 1453, "P  =  0 . 536", "", " \"P  =  0 . 536\"." +60, Bimatoprost, 1460, 1471, "bimatoprost", "", +32103, Travoprost, 1476, 1486, "travoprost", "", +32104, IOP, 1504, 1508, "IOPs", "", +62, TimePoint, 1512, 1519, "2 weeks", "", " \"2 weeks\". \"2 weeks\". \"2 weeks\"." +32107, EndPointDescription, 1525, 1537, "≤ 18   mm Hg", "IOP", " . ." +63, mmHg, 1532, 1537, "mm Hg", "", " ." +71, NumberAffected, 1541, 1543, "20", "", " \"20\"." +79, PercentageAffected, 1546, 1552, "58 . 8", "", " \"58 . 8\"." +73, NumberAffected, 1564, 1566, "19", "", " \"19\"." +80, PercentageAffected, 1569, 1571, "50", "", " \"50\"." +87, PvalueDiff, 1583, 1596, "P  =  0 . 603", "", " \"P  =  0 . 603\"." +32109, EndPointDescription, 1605, 1617, "≤ 16   mm Hg", "IOP", " . ." +66, mmHg, 1612, 1617, "mm Hg", "", " ." +72, NumberAffected, 1621, 1623, "12", "", " \"12\"." +81, PercentageAffected, 1626, 1628, "35", "", " \"35\"." +74, NumberAffected, 1640, 1642, "12", "", " \"12\"." +82, PercentageAffected, 1645, 1647, "32", "", " \"32\"." +88, PvalueDiff, 1659, 1672, "P  =  0 . 456", "", " \"P  =  0 . 456\"." +91, TimePoint, 1684, 1692, "6 months", "", " \"6 months\". \"6 months\". \"6 months\". \"6 months\"." +32108, EndPointDescription, 1693, 1705, "≤ 18   mm Hg", "IOP", +67, mmHg, 1700, 1705, "mm Hg", "", +75, NumberAffected, 1709, 1711, "22", "", " \"22\"." +83, PercentageAffected, 1714, 1716, "65", "", " \"65\"." +76, NumberAffected, 1728, 1730, "14", "", " \"14\"." +84, PercentageAffected, 1733, 1735, "37", "", " \"37\"." +89, PvalueDiff, 1747, 1760, "P  =  0 . 045", "", " \"P  =  0 . 045\"." +32110, EndPointDescription, 1769, 1781, "≤ 16   mm Hg", "IOP", +68, mmHg, 1776, 1781, "mm Hg", "", +77, NumberAffected, 1785, 1787, "12", "", " \"12\"." +85, PercentageAffected, 1790, 1792, "35", "", " \"35\"." +78, NumberAffected, 1804, 1805, "7", "", " \"7\"." +86, PercentageAffected, 1808, 1810, "18", "", " \"18\"." +90, PvalueDiff, 1822, 1835, "P  =  0 . 037", "", " \"P  =  0 . 037\"." +92, Bimatoprost, 1842, 1853, "bimatoprost", "", +32106, Travoprost, 1858, 1868, "travoprost", "", +94, ObservedResult, 1886, 1956, "Ocular adverse and clinical success occurred equally with both drops .", "", +93, Eyedrops, 1949, 1954, "drops", "", +99, ConclusionComment, 1970, 2094, "Both drops lowered IOP effectively but bimatoprost showed a greater non - significant reductions in mean IOP from baseline .", "", " \"Both drops lowered IOP effectively but bimatoprost showed a greater non - significant reductions in mean IOP from baseline .\"." +192, Eyedrops, 1975, 1980, "drops", "", +95, IOP, 1989, 1992, "IOP", "", +96, Bimatoprost, 2009, 2020, "bimatoprost", "", +97, Mean, 2070, 2074, "mean", "", +98, IOP, 2075, 2078, "IOP", "", +100, PMID, 2138, 2146, "21034177", "", " \"21034177\"." diff --git a/data/gl 21034177_admin.n-triples b/data/gl 21034177_admin.n-triples new file mode 100644 index 0000000..4d14945 --- /dev/null +++ b/data/gl 21034177_admin.n-triples @@ -0,0 +1,227 @@ +# RDF export of group: Publication + . + "Publication" . + "Bimatoprost versus travoprost in an Egyptian population : a hospital - based prospective , randomized study ." . + "Macky TA" . + "2010" . + "J Ocul Pharmacol Ther ." . + "21034177" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy of bimatoprost and travoprost on intraocular pressure ( IOP ) reduction in an Egyptian population ." . + "Seventy - two" . + . + . + . + "Both drops lowered IOP effectively but bimatoprost showed a greater non - significant reductions in mean IOP from baseline ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with primary open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + . + "Endpoint_18" . + . + . + . + . + . + . + . + "Endpoint_16" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bim" . + "34" . + . + . + . + . + . + . + . + . + . + "Arm_tra" . + "38" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_bim" . + . + "once daily" . + . + . + "Intervention_tra" . + . + "once daily" . + . +# RDF export of group: Medication + . + "Medication_bim" . + . + "0 . 03" . + . + . + . + "Medication_tra" . + . + "0 . 004" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_bim_2weeks" . + . + "26 . 52" . + "5 . 185" . + "8 . 77" . + "33 . 39" . + "P  <  0 . 001" . + "2 weeks" . + . + "Outcome_iop_tra_2weeks" . + . + "26 . 36" . + "1 . 605" . + "8 . 42" . + "31 . 54" . + "P  <  0 . 001" . + "2 weeks" . + . + "Outcome_iop_bim_6months" . + . + "26 . 52" . + "5 . 185" . + "8 . 47" . + "31 . 61" . + "P  <  0 . 001" . + "6 months" . + . + "Outcome_iop_tra_6month" . + . + "26 . 36" . + "1 . 605" . + "7 . 84" . + "29 . 50" . + "P  <  0 . 001" . + "6 months" . + . + "Outcome_18_bim_2weeks" . + . + "20" . + "58 . 8" . + "2 weeks" . + . + "Outcome_18_tra_2weeks" . + . + "19" . + "50" . + . + "Outcome_16_bim_2weeks" . + . + "12" . + "35" . + "2 weeks" . + . + "Outcome_16_tra_2weeks" . + . + "12" . + "32" . + "2 weeks" . + . + "Outcome_18_bim_6months" . + . + "22" . + "65" . + "6 months" . + . + "Outcome_18_tra_6months" . + . + "14" . + "37" . + "6 months" . + . + "Outcome_16_bim_6months" . + . + "12" . + "35" . + "6 months" . + . + "Outcome_16_tra_6months" . + . + "7" . + "18" . + "6 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop_2weeks" . + "P  =  0 . 703" . + . + . + . + "DiffBetweenGroups_iop_6months" . + "P  =  0 . 536" . + . + . + . + "DiffBetweenGroups_18_2weeks" . + "P  =  0 . 603" . + . + . + . + "DiffBetweenGroups_16_2weeks" . + "P  =  0 . 456" . + . + . + . + "DiffBetweenGroups_18_6months" . + "P  =  0 . 045" . + . + . + . + "DiffBetweenGroups_16_6months" . + "P  =  0 . 037" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21034177_export.csv b/data/gl 21034177_export.csv new file mode 100644 index 0000000..572336f --- /dev/null +++ b/data/gl 21034177_export.csv @@ -0,0 +1,514 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +434, 1, 1, 1, 0, 1, 0, 1, "J" +434, 1, 2, 2, 2, 6, 2, 6, "Ocul" +434, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +434, 1, 4, 4, 17, 21, 17, 21, "Ther" +434, 1, 5, 5, 22, 23, 22, 23, "." +434, 2, 1, 6, 0, 4, 24, 28, "2010" +434, 2, 2, 7, 5, 8, 29, 32, "Dec" +434, 2, 3, 8, 9, 10, 33, 34, ";" +434, 2, 4, 9, 11, 13, 35, 37, "26" +434, 2, 5, 10, 14, 15, 38, 39, "(" +434, 2, 6, 11, 16, 17, 40, 41, "6" +434, 2, 7, 12, 18, 19, 42, 43, ")" +434, 2, 8, 13, 20, 21, 44, 45, ":" +434, 2, 9, 14, 22, 25, 46, 49, "605" +434, 2, 10, 15, 26, 27, 50, 51, "-" +434, 2, 11, 16, 28, 30, 52, 54, "10" +434, 2, 12, 17, 31, 32, 55, 56, "." +434, 2, 13, 18, 33, 36, 57, 60, "doi" +434, 2, 14, 19, 37, 38, 61, 62, ":" +434, 2, 15, 20, 39, 41, 63, 65, "10" +434, 2, 16, 21, 42, 43, 66, 67, "." +434, 2, 17, 22, 44, 48, 68, 72, "1089" +434, 2, 18, 23, 49, 50, 73, 74, "/" +434, 2, 19, 24, 51, 54, 75, 78, "jop" +434, 2, 20, 25, 55, 56, 79, 80, "." +434, 2, 21, 26, 57, 61, 81, 85, "2010" +434, 2, 22, 27, 62, 63, 86, 87, "." +434, 2, 23, 28, 64, 68, 88, 92, "0068" +434, 2, 24, 29, 69, 70, 93, 94, "." +434, 3, 1, 30, 0, 4, 95, 99, "Epub" +434, 3, 2, 31, 5, 9, 100, 104, "2010" +434, 3, 3, 32, 10, 13, 105, 108, "Oct" +434, 3, 4, 33, 14, 16, 109, 111, "29" +434, 3, 5, 34, 17, 18, 112, 113, "." +434, 4, 1, 35, 0, 11, 114, 125, "Bimatoprost" +434, 4, 2, 36, 12, 18, 126, 132, "versus" +434, 4, 3, 37, 19, 29, 133, 143, "travoprost" +434, 4, 4, 38, 30, 32, 144, 146, "in" +434, 4, 5, 39, 33, 35, 147, 149, "an" +434, 4, 6, 40, 36, 44, 150, 158, "Egyptian" +434, 4, 7, 41, 45, 55, 159, 169, "population" +434, 4, 8, 42, 56, 57, 170, 171, ":" +434, 4, 9, 43, 58, 59, 172, 173, "a" +434, 4, 10, 44, 60, 68, 174, 182, "hospital" +434, 4, 11, 45, 69, 70, 183, 184, "-" +434, 4, 12, 46, 71, 76, 185, 190, "based" +434, 4, 13, 47, 77, 88, 191, 202, "prospective" +434, 4, 14, 48, 89, 90, 203, 204, "," +434, 4, 15, 49, 91, 101, 205, 215, "randomized" +434, 4, 16, 50, 102, 107, 216, 221, "study" +434, 4, 17, 51, 108, 109, 222, 223, "." +434, 5, 1, 52, 0, 5, 224, 229, "Macky" +434, 5, 2, 53, 6, 8, 230, 232, "TA" +434, 5, 3, 54, 9, 10, 233, 234, "(" +434, 5, 4, 55, 11, 12, 235, 236, "1" +434, 5, 5, 56, 13, 14, 237, 238, ")" +434, 5, 6, 57, 15, 16, 239, 240, "." +434, 6, 1, 58, 0, 6, 241, 247, "Author" +434, 6, 2, 59, 7, 18, 248, 259, "information" +434, 6, 3, 60, 19, 20, 260, 261, ":" +434, 6, 4, 61, 21, 22, 262, 263, "(" +434, 6, 5, 62, 23, 24, 264, 265, "1" +434, 6, 6, 63, 25, 26, 266, 267, ")" +434, 6, 7, 64, 27, 37, 268, 278, "Department" +434, 6, 8, 65, 38, 40, 279, 281, "of" +434, 6, 9, 66, 41, 54, 282, 295, "Ophthalmology" +434, 6, 10, 67, 55, 56, 296, 297, "," +434, 6, 11, 68, 57, 61, 298, 302, "Kasr" +434, 6, 12, 69, 62, 64, 303, 305, "El" +434, 6, 13, 70, 65, 69, 306, 310, "Aini" +434, 6, 14, 71, 70, 78, 311, 319, "Hospital" +434, 6, 15, 72, 79, 80, 320, 321, "," +434, 6, 16, 73, 81, 86, 322, 327, "Cairo" +434, 6, 17, 74, 87, 97, 328, 338, "University" +434, 6, 18, 75, 98, 99, 339, 340, "," +434, 6, 19, 76, 100, 105, 341, 346, "Cairo" +434, 6, 20, 77, 106, 107, 347, 348, "," +434, 6, 21, 78, 108, 113, 349, 354, "Egypt" +434, 6, 22, 79, 114, 115, 355, 356, "." +434, 7, 1, 80, 0, 10, 357, 367, "tamermacky" +434, 7, 2, 81, 11, 12, 368, 369, "@" +434, 7, 3, 82, 13, 18, 370, 375, "gmail" +434, 7, 4, 83, 19, 20, 376, 377, "." +434, 7, 5, 84, 21, 24, 378, 381, "com" +434, 7, 6, 85, 25, 32, 382, 389, "PURPOSE" +434, 7, 7, 86, 33, 34, 390, 391, ":" +434, 7, 8, 87, 35, 37, 392, 394, "To" +434, 7, 9, 88, 38, 45, 395, 402, "compare" +434, 7, 10, 89, 46, 49, 403, 406, "the" +434, 7, 11, 90, 50, 58, 407, 415, "efficacy" +434, 7, 12, 91, 59, 61, 416, 418, "of" +434, 7, 13, 92, 62, 73, 419, 430, "bimatoprost" +434, 7, 14, 93, 74, 77, 431, 434, "and" +434, 7, 15, 94, 78, 88, 435, 445, "travoprost" +434, 7, 16, 95, 89, 91, 446, 448, "on" +434, 7, 17, 96, 92, 103, 449, 460, "intraocular" +434, 7, 18, 97, 104, 112, 461, 469, "pressure" +434, 7, 19, 98, 113, 114, 470, 471, "(" +434, 7, 20, 99, 115, 118, 472, 475, "IOP" +434, 7, 21, 100, 119, 120, 476, 477, ")" +434, 7, 22, 101, 121, 130, 478, 487, "reduction" +434, 7, 23, 102, 131, 133, 488, 490, "in" +434, 7, 24, 103, 134, 136, 491, 493, "an" +434, 7, 25, 104, 137, 145, 494, 502, "Egyptian" +434, 7, 26, 105, 146, 156, 503, 513, "population" +434, 7, 27, 106, 157, 158, 514, 515, "." +434, 8, 1, 107, 0, 7, 516, 523, "METHODS" +434, 8, 2, 108, 8, 9, 524, 525, ":" +434, 8, 3, 109, 10, 18, 526, 534, "Patients" +434, 8, 4, 110, 19, 23, 535, 539, "with" +434, 8, 5, 111, 24, 31, 540, 547, "primary" +434, 8, 6, 112, 32, 36, 548, 552, "open" +434, 8, 7, 113, 37, 38, 553, 554, "-" +434, 8, 8, 114, 39, 44, 555, 560, "angle" +434, 8, 9, 115, 45, 53, 561, 569, "glaucoma" +434, 8, 10, 116, 54, 56, 570, 572, "or" +434, 8, 11, 117, 57, 63, 573, 579, "ocular" +434, 8, 12, 118, 64, 76, 580, 592, "hypertension" +434, 8, 13, 119, 77, 81, 593, 597, "were" +434, 8, 14, 120, 82, 92, 598, 608, "randomized" +434, 8, 15, 121, 93, 95, 609, 611, "to" +434, 8, 16, 122, 96, 103, 612, 619, "receive" +434, 8, 17, 123, 104, 110, 620, 626, "either" +434, 8, 18, 124, 111, 122, 627, 638, "bimatoprost" +434, 8, 19, 125, 123, 124, 639, 640, "0" +434, 8, 20, 126, 125, 126, 641, 642, "." +434, 8, 21, 127, 127, 129, 643, 645, "03" +434, 8, 22, 128, 130, 131, 646, 647, "%" +434, 8, 23, 129, 132, 134, 648, 650, "or" +434, 8, 24, 130, 135, 145, 651, 661, "travoprost" +434, 8, 25, 131, 146, 147, 662, 663, "0" +434, 8, 26, 132, 148, 149, 664, 665, "." +434, 8, 27, 133, 150, 153, 666, 669, "004" +434, 8, 28, 134, 154, 155, 670, 671, "%" +434, 8, 29, 135, 156, 160, 672, 676, "once" +434, 8, 30, 136, 161, 166, 677, 682, "daily" +434, 8, 31, 137, 167, 168, 683, 684, "." +434, 9, 1, 138, 0, 4, 685, 689, "IOPs" +434, 9, 2, 139, 5, 9, 690, 694, "were" +434, 9, 3, 140, 10, 18, 695, 703, "measured" +434, 9, 4, 141, 19, 21, 704, 706, "at" +434, 9, 5, 142, 22, 30, 707, 715, "baseline" +434, 9, 6, 143, 31, 32, 716, 717, ";" +434, 9, 7, 144, 33, 34, 718, 719, "2" +434, 9, 8, 145, 35, 40, 720, 725, "weeks" +434, 9, 9, 146, 41, 42, 726, 727, ";" +434, 9, 10, 147, 43, 46, 728, 731, "and" +434, 9, 11, 148, 47, 48, 732, 733, "1" +434, 9, 12, 149, 49, 50, 734, 735, "," +434, 9, 13, 150, 51, 52, 736, 737, "2" +434, 9, 14, 151, 53, 54, 738, 739, "," +434, 9, 15, 152, 55, 56, 740, 741, "4" +434, 9, 16, 153, 57, 58, 742, 743, "," +434, 9, 17, 154, 59, 62, 744, 747, "and" +434, 9, 18, 155, 63, 64, 748, 749, "6" +434, 9, 19, 156, 65, 71, 750, 756, "months" +434, 9, 20, 157, 72, 77, 757, 762, "using" +434, 9, 21, 158, 78, 85, 763, 770, "Goldman" +434, 9, 22, 159, 86, 97, 771, 782, "applanation" +434, 9, 23, 160, 98, 108, 783, 793, "tonometery" +434, 9, 24, 161, 109, 110, 794, 795, "." +434, 10, 1, 162, 0, 7, 796, 803, "RESULTS" +434, 10, 2, 163, 8, 9, 804, 805, ":" +434, 10, 3, 164, 10, 17, 806, 813, "Seventy" +434, 10, 4, 165, 18, 19, 814, 815, "-" +434, 10, 5, 166, 20, 23, 816, 819, "two" +434, 10, 6, 167, 24, 32, 820, 828, "patients" +434, 10, 7, 168, 33, 37, 829, 833, "were" +434, 10, 8, 169, 38, 46, 834, 842, "included" +434, 10, 9, 170, 47, 48, 843, 844, ":" +434, 10, 10, 171, 49, 51, 845, 847, "34" +434, 10, 11, 172, 52, 55, 848, 851, "and" +434, 10, 12, 173, 56, 58, 852, 854, "38" +434, 10, 13, 174, 59, 60, 855, 856, "(" +434, 10, 14, 175, 61, 62, 857, 858, "P" +434, 10, 15, 176, 63, 66, 859, 862, " = " +434, 10, 16, 177, 67, 68, 863, 864, "0" +434, 10, 17, 178, 69, 70, 865, 866, "." +434, 10, 18, 179, 71, 74, 867, 870, "142" +434, 10, 19, 180, 75, 76, 871, 872, ")" +434, 10, 20, 181, 77, 81, 873, 877, "with" +434, 10, 21, 182, 82, 83, 878, 879, "a" +434, 10, 22, 183, 84, 92, 880, 888, "baseline" +434, 10, 23, 184, 93, 97, 889, 893, "mean" +434, 10, 24, 185, 98, 101, 894, 897, "IOP" +434, 10, 25, 186, 102, 105, 898, 901, " = " +434, 10, 26, 187, 106, 108, 902, 904, "26" +434, 10, 27, 188, 109, 110, 905, 906, "." +434, 10, 28, 189, 111, 113, 907, 909, "52" +434, 10, 29, 190, 114, 117, 910, 913, " ± " +434, 10, 30, 191, 118, 119, 914, 915, "5" +434, 10, 31, 192, 120, 121, 916, 917, "." +434, 10, 32, 193, 122, 125, 918, 921, "185" +434, 10, 33, 194, 126, 129, 922, 925, "and" +434, 10, 34, 195, 130, 132, 926, 928, "26" +434, 10, 35, 196, 133, 134, 929, 930, "." +434, 10, 36, 197, 135, 137, 931, 933, "36" +434, 10, 37, 198, 138, 141, 934, 937, " ± " +434, 10, 38, 199, 142, 143, 938, 939, "1" +434, 10, 39, 200, 144, 145, 940, 941, "." +434, 10, 40, 201, 146, 149, 942, 945, "605" +434, 10, 41, 202, 150, 151, 946, 947, " " +434, 10, 42, 203, 152, 154, 948, 950, "mm" +434, 10, 43, 204, 155, 157, 951, 953, "Hg" +434, 10, 44, 205, 158, 159, 954, 955, "(" +434, 10, 45, 206, 160, 161, 956, 957, "P" +434, 10, 46, 207, 162, 165, 958, 961, " = " +434, 10, 47, 208, 166, 167, 962, 963, "0" +434, 10, 48, 209, 168, 169, 964, 965, "." +434, 10, 49, 210, 170, 173, 966, 969, "629" +434, 10, 50, 211, 174, 175, 970, 971, ")" +434, 10, 51, 212, 176, 179, 972, 975, "for" +434, 10, 52, 213, 180, 191, 976, 987, "bimatoprost" +434, 10, 53, 214, 192, 195, 988, 991, "and" +434, 10, 54, 215, 196, 206, 992, 1002, "travoprost" +434, 10, 55, 216, 207, 208, 1003, 1004, "," +434, 10, 56, 217, 209, 221, 1005, 1017, "respectively" +434, 10, 57, 218, 222, 223, 1018, 1019, "." +434, 11, 1, 219, 0, 4, 1020, 1024, "Both" +434, 11, 2, 220, 5, 10, 1025, 1030, "drops" +434, 11, 3, 221, 11, 19, 1031, 1039, "provided" +434, 11, 4, 222, 20, 33, 1040, 1053, "statistically" +434, 11, 5, 223, 34, 45, 1054, 1065, "significant" +434, 11, 6, 224, 46, 49, 1066, 1069, "IOP" +434, 11, 7, 225, 50, 60, 1070, 1080, "reductions" +434, 11, 8, 226, 61, 65, 1081, 1085, "from" +434, 11, 9, 227, 66, 74, 1086, 1094, "baseline" +434, 11, 10, 228, 75, 77, 1095, 1097, "at" +434, 11, 11, 229, 78, 81, 1098, 1101, "all" +434, 11, 12, 230, 82, 88, 1102, 1108, "visits" +434, 11, 13, 231, 89, 90, 1109, 1110, "(" +434, 11, 14, 232, 91, 92, 1111, 1112, "P" +434, 11, 15, 233, 93, 96, 1113, 1116, " < " +434, 11, 16, 234, 97, 98, 1117, 1118, "0" +434, 11, 17, 235, 99, 100, 1119, 1120, "." +434, 11, 18, 236, 101, 104, 1121, 1124, "001" +434, 11, 19, 237, 105, 106, 1125, 1126, ")" +434, 11, 20, 238, 107, 108, 1127, 1128, "." +434, 12, 1, 239, 0, 11, 1129, 1140, "Bimatoprost" +434, 12, 2, 240, 12, 20, 1141, 1149, "provided" +434, 12, 3, 241, 21, 28, 1150, 1157, "greater" +434, 12, 4, 242, 29, 30, 1158, 1159, "(" +434, 12, 5, 243, 31, 45, 1160, 1174, "nonsignificant" +434, 12, 6, 244, 46, 47, 1175, 1176, ")" +434, 12, 7, 245, 48, 52, 1177, 1181, "mean" +434, 12, 8, 246, 53, 56, 1182, 1185, "IOP" +434, 12, 9, 247, 57, 67, 1186, 1196, "reductions" +434, 12, 10, 248, 68, 72, 1197, 1201, "from" +434, 12, 11, 249, 73, 81, 1202, 1210, "baseline" +434, 12, 12, 250, 82, 86, 1211, 1215, "than" +434, 12, 13, 251, 87, 97, 1216, 1226, "travoprost" +434, 12, 14, 252, 98, 100, 1227, 1229, "at" +434, 12, 15, 253, 101, 105, 1230, 1234, "each" +434, 12, 16, 254, 106, 111, 1235, 1240, "visit" +434, 12, 17, 255, 112, 113, 1241, 1242, "." +434, 13, 1, 256, 0, 4, 1243, 1247, "Mean" +434, 13, 2, 257, 5, 8, 1248, 1251, "IOP" +434, 13, 3, 258, 9, 19, 1252, 1262, "reductions" +434, 13, 4, 259, 20, 23, 1263, 1266, "was" +434, 13, 5, 260, 24, 25, 1267, 1268, "8" +434, 13, 6, 261, 26, 27, 1269, 1270, "." +434, 13, 7, 262, 28, 30, 1271, 1273, "77" +434, 13, 8, 263, 31, 32, 1274, 1275, " " +434, 13, 9, 264, 33, 35, 1276, 1278, "mm" +434, 13, 10, 265, 36, 38, 1279, 1281, "Hg" +434, 13, 11, 266, 39, 40, 1282, 1283, "(" +434, 13, 12, 267, 41, 43, 1284, 1286, "33" +434, 13, 13, 268, 44, 45, 1287, 1288, "." +434, 13, 14, 269, 46, 48, 1289, 1291, "39" +434, 13, 15, 270, 49, 50, 1292, 1293, "%" +434, 13, 16, 271, 51, 52, 1294, 1295, ")" +434, 13, 17, 272, 53, 56, 1296, 1299, "and" +434, 13, 18, 273, 57, 58, 1300, 1301, "8" +434, 13, 19, 274, 59, 60, 1302, 1303, "." +434, 13, 20, 275, 61, 63, 1304, 1306, "42" +434, 13, 21, 276, 64, 65, 1307, 1308, " " +434, 13, 22, 277, 66, 68, 1309, 1311, "mm" +434, 13, 23, 278, 69, 71, 1312, 1314, "Hg" +434, 13, 24, 279, 72, 73, 1315, 1316, "(" +434, 13, 25, 280, 74, 76, 1317, 1319, "31" +434, 13, 26, 281, 77, 78, 1320, 1321, "." +434, 13, 27, 282, 79, 81, 1322, 1324, "54" +434, 13, 28, 283, 82, 83, 1325, 1326, "%" +434, 13, 29, 284, 84, 85, 1327, 1328, ")" +434, 13, 30, 285, 86, 88, 1329, 1331, "at" +434, 13, 31, 286, 89, 90, 1332, 1333, "2" +434, 13, 32, 287, 91, 96, 1334, 1339, "weeks" +434, 13, 33, 288, 97, 98, 1340, 1341, "(" +434, 13, 34, 289, 99, 100, 1342, 1343, "P" +434, 13, 35, 290, 101, 104, 1344, 1347, " = " +434, 13, 36, 291, 105, 106, 1348, 1349, "0" +434, 13, 37, 292, 107, 108, 1350, 1351, "." +434, 13, 38, 293, 109, 112, 1352, 1355, "703" +434, 13, 39, 294, 113, 114, 1356, 1357, ")" +434, 13, 40, 295, 115, 116, 1358, 1359, "," +434, 13, 41, 296, 117, 120, 1360, 1363, "and" +434, 13, 42, 297, 121, 122, 1364, 1365, "8" +434, 13, 43, 298, 123, 124, 1366, 1367, "." +434, 13, 44, 299, 125, 127, 1368, 1370, "47" +434, 13, 45, 300, 128, 129, 1371, 1372, " " +434, 13, 46, 301, 130, 132, 1373, 1375, "mm" +434, 13, 47, 302, 133, 135, 1376, 1378, "Hg" +434, 13, 48, 303, 136, 137, 1379, 1380, "(" +434, 13, 49, 304, 138, 140, 1381, 1383, "31" +434, 13, 50, 305, 141, 142, 1384, 1385, "." +434, 13, 51, 306, 143, 145, 1386, 1388, "61" +434, 13, 52, 307, 146, 147, 1389, 1390, "%" +434, 13, 53, 308, 148, 149, 1391, 1392, ")" +434, 13, 54, 309, 150, 153, 1393, 1396, "and" +434, 13, 55, 310, 154, 155, 1397, 1398, "7" +434, 13, 56, 311, 156, 157, 1399, 1400, "." +434, 13, 57, 312, 158, 160, 1401, 1403, "84" +434, 13, 58, 313, 161, 162, 1404, 1405, " " +434, 13, 59, 314, 163, 165, 1406, 1408, "mm" +434, 13, 60, 315, 166, 168, 1409, 1411, "Hg" +434, 13, 61, 316, 169, 170, 1412, 1413, "(" +434, 13, 62, 317, 171, 173, 1414, 1416, "29" +434, 13, 63, 318, 174, 175, 1417, 1418, "." +434, 13, 64, 319, 176, 178, 1419, 1421, "50" +434, 13, 65, 320, 179, 180, 1422, 1423, "%" +434, 13, 66, 321, 181, 182, 1424, 1425, ")" +434, 13, 67, 322, 183, 185, 1426, 1428, "at" +434, 13, 68, 323, 186, 187, 1429, 1430, "6" +434, 13, 69, 324, 188, 194, 1431, 1437, "months" +434, 13, 70, 325, 195, 196, 1438, 1439, "(" +434, 13, 71, 326, 197, 198, 1440, 1441, "P" +434, 13, 72, 327, 199, 202, 1442, 1445, " = " +434, 13, 73, 328, 203, 204, 1446, 1447, "0" +434, 13, 74, 329, 205, 206, 1448, 1449, "." +434, 13, 75, 330, 207, 210, 1450, 1453, "536" +434, 13, 76, 331, 211, 212, 1454, 1455, ")" +434, 13, 77, 332, 213, 216, 1456, 1459, "for" +434, 13, 78, 333, 217, 228, 1460, 1471, "bimatoprost" +434, 13, 79, 334, 229, 232, 1472, 1475, "and" +434, 13, 80, 335, 233, 243, 1476, 1486, "travoprost" +434, 13, 81, 336, 244, 245, 1487, 1488, "," +434, 13, 82, 337, 246, 258, 1489, 1501, "respectively" +434, 13, 83, 338, 259, 260, 1502, 1503, "." +434, 14, 1, 339, 0, 4, 1504, 1508, "IOPs" +434, 14, 2, 340, 5, 7, 1509, 1511, "at" +434, 14, 3, 341, 8, 9, 1512, 1513, "2" +434, 14, 4, 342, 10, 15, 1514, 1519, "weeks" +434, 14, 5, 343, 16, 20, 1520, 1524, "were" +434, 14, 6, 344, 21, 22, 1525, 1526, "≤" +434, 14, 7, 345, 23, 25, 1527, 1529, "18" +434, 14, 8, 346, 26, 27, 1530, 1531, " " +434, 14, 9, 347, 28, 30, 1532, 1534, "mm" +434, 14, 10, 348, 31, 33, 1535, 1537, "Hg" +434, 14, 11, 349, 34, 36, 1538, 1540, "in" +434, 14, 12, 350, 37, 39, 1541, 1543, "20" +434, 14, 13, 351, 40, 41, 1544, 1545, "(" +434, 14, 14, 352, 42, 44, 1546, 1548, "58" +434, 14, 15, 353, 45, 46, 1549, 1550, "." +434, 14, 16, 354, 47, 48, 1551, 1552, "8" +434, 14, 17, 355, 49, 50, 1553, 1554, "%" +434, 14, 18, 356, 51, 52, 1555, 1556, ")" +434, 14, 19, 357, 53, 59, 1557, 1563, "versus" +434, 14, 20, 358, 60, 62, 1564, 1566, "19" +434, 14, 21, 359, 63, 64, 1567, 1568, "(" +434, 14, 22, 360, 65, 67, 1569, 1571, "50" +434, 14, 23, 361, 68, 69, 1572, 1573, "%" +434, 14, 24, 362, 70, 71, 1574, 1575, ")" +434, 14, 25, 363, 72, 76, 1576, 1580, "eyes" +434, 14, 26, 364, 77, 78, 1581, 1582, "(" +434, 14, 27, 365, 79, 80, 1583, 1584, "P" +434, 14, 28, 366, 81, 84, 1585, 1588, " = " +434, 14, 29, 367, 85, 86, 1589, 1590, "0" +434, 14, 30, 368, 87, 88, 1591, 1592, "." +434, 14, 31, 369, 89, 92, 1593, 1596, "603" +434, 14, 32, 370, 93, 94, 1597, 1598, ")" +434, 14, 33, 371, 95, 96, 1599, 1600, "," +434, 14, 34, 372, 97, 100, 1601, 1604, "and" +434, 14, 35, 373, 101, 102, 1605, 1606, "≤" +434, 14, 36, 374, 103, 105, 1607, 1609, "16" +434, 14, 37, 375, 106, 107, 1610, 1611, " " +434, 14, 38, 376, 108, 110, 1612, 1614, "mm" +434, 14, 39, 377, 111, 113, 1615, 1617, "Hg" +434, 14, 40, 378, 114, 116, 1618, 1620, "in" +434, 14, 41, 379, 117, 119, 1621, 1623, "12" +434, 14, 42, 380, 120, 121, 1624, 1625, "(" +434, 14, 43, 381, 122, 124, 1626, 1628, "35" +434, 14, 44, 382, 125, 126, 1629, 1630, "%" +434, 14, 45, 383, 127, 128, 1631, 1632, ")" +434, 14, 46, 384, 129, 135, 1633, 1639, "versus" +434, 14, 47, 385, 136, 138, 1640, 1642, "12" +434, 14, 48, 386, 139, 140, 1643, 1644, "(" +434, 14, 49, 387, 141, 143, 1645, 1647, "32" +434, 14, 50, 388, 144, 145, 1648, 1649, "%" +434, 14, 51, 389, 146, 147, 1650, 1651, ")" +434, 14, 52, 390, 148, 152, 1652, 1656, "eyes" +434, 14, 53, 391, 153, 154, 1657, 1658, "(" +434, 14, 54, 392, 155, 156, 1659, 1660, "P" +434, 14, 55, 393, 157, 160, 1661, 1664, " = " +434, 14, 56, 394, 161, 162, 1665, 1666, "0" +434, 14, 57, 395, 163, 164, 1667, 1668, "." +434, 14, 58, 396, 165, 168, 1669, 1672, "456" +434, 14, 59, 397, 169, 170, 1673, 1674, ")" +434, 14, 60, 398, 171, 172, 1675, 1676, ";" +434, 14, 61, 399, 173, 176, 1677, 1680, "and" +434, 14, 62, 400, 177, 179, 1681, 1683, "at" +434, 14, 63, 401, 180, 181, 1684, 1685, "6" +434, 14, 64, 402, 182, 188, 1686, 1692, "months" +434, 14, 65, 403, 189, 190, 1693, 1694, "≤" +434, 14, 66, 404, 191, 193, 1695, 1697, "18" +434, 14, 67, 405, 194, 195, 1698, 1699, " " +434, 14, 68, 406, 196, 198, 1700, 1702, "mm" +434, 14, 69, 407, 199, 201, 1703, 1705, "Hg" +434, 14, 70, 408, 202, 204, 1706, 1708, "in" +434, 14, 71, 409, 205, 207, 1709, 1711, "22" +434, 14, 72, 410, 208, 209, 1712, 1713, "(" +434, 14, 73, 411, 210, 212, 1714, 1716, "65" +434, 14, 74, 412, 213, 214, 1717, 1718, "%" +434, 14, 75, 413, 215, 216, 1719, 1720, ")" +434, 14, 76, 414, 217, 223, 1721, 1727, "versus" +434, 14, 77, 415, 224, 226, 1728, 1730, "14" +434, 14, 78, 416, 227, 228, 1731, 1732, "(" +434, 14, 79, 417, 229, 231, 1733, 1735, "37" +434, 14, 80, 418, 232, 233, 1736, 1737, "%" +434, 14, 81, 419, 234, 235, 1738, 1739, ")" +434, 14, 82, 420, 236, 240, 1740, 1744, "eyes" +434, 14, 83, 421, 241, 242, 1745, 1746, "(" +434, 14, 84, 422, 243, 244, 1747, 1748, "P" +434, 14, 85, 423, 245, 248, 1749, 1752, " = " +434, 14, 86, 424, 249, 250, 1753, 1754, "0" +434, 14, 87, 425, 251, 252, 1755, 1756, "." +434, 14, 88, 426, 253, 256, 1757, 1760, "045" +434, 14, 89, 427, 257, 258, 1761, 1762, ")" +434, 14, 90, 428, 259, 260, 1763, 1764, "," +434, 14, 91, 429, 261, 264, 1765, 1768, "and" +434, 14, 92, 430, 265, 266, 1769, 1770, "≤" +434, 14, 93, 431, 267, 269, 1771, 1773, "16" +434, 14, 94, 432, 270, 271, 1774, 1775, " " +434, 14, 95, 433, 272, 274, 1776, 1778, "mm" +434, 14, 96, 434, 275, 277, 1779, 1781, "Hg" +434, 14, 97, 435, 278, 280, 1782, 1784, "in" +434, 14, 98, 436, 281, 283, 1785, 1787, "12" +434, 14, 99, 437, 284, 285, 1788, 1789, "(" +434, 14, 100, 438, 286, 288, 1790, 1792, "35" +434, 14, 101, 439, 289, 290, 1793, 1794, "%" +434, 14, 102, 440, 291, 292, 1795, 1796, ")" +434, 14, 103, 441, 293, 299, 1797, 1803, "versus" +434, 14, 104, 442, 300, 301, 1804, 1805, "7" +434, 14, 105, 443, 302, 303, 1806, 1807, "(" +434, 14, 106, 444, 304, 306, 1808, 1810, "18" +434, 14, 107, 445, 307, 308, 1811, 1812, "%" +434, 14, 108, 446, 309, 310, 1813, 1814, ")" +434, 14, 109, 447, 311, 315, 1815, 1819, "eyes" +434, 14, 110, 448, 316, 317, 1820, 1821, "(" +434, 14, 111, 449, 318, 319, 1822, 1823, "P" +434, 14, 112, 450, 320, 323, 1824, 1827, " = " +434, 14, 113, 451, 324, 325, 1828, 1829, "0" +434, 14, 114, 452, 326, 327, 1830, 1831, "." +434, 14, 115, 453, 328, 331, 1832, 1835, "037" +434, 14, 116, 454, 332, 333, 1836, 1837, ")" +434, 14, 117, 455, 334, 337, 1838, 1841, "for" +434, 14, 118, 456, 338, 349, 1842, 1853, "bimatoprost" +434, 14, 119, 457, 350, 353, 1854, 1857, "and" +434, 14, 120, 458, 354, 364, 1858, 1868, "travoprost" +434, 14, 121, 459, 365, 366, 1869, 1870, "," +434, 14, 122, 460, 367, 379, 1871, 1883, "respectively" +434, 14, 123, 461, 380, 381, 1884, 1885, "." +434, 15, 1, 462, 0, 6, 1886, 1892, "Ocular" +434, 15, 2, 463, 7, 14, 1893, 1900, "adverse" +434, 15, 3, 464, 15, 18, 1901, 1904, "and" +434, 15, 4, 465, 19, 27, 1905, 1913, "clinical" +434, 15, 5, 466, 28, 35, 1914, 1921, "success" +434, 15, 6, 467, 36, 44, 1922, 1930, "occurred" +434, 15, 7, 468, 45, 52, 1931, 1938, "equally" +434, 15, 8, 469, 53, 57, 1939, 1943, "with" +434, 15, 9, 470, 58, 62, 1944, 1948, "both" +434, 15, 10, 471, 63, 68, 1949, 1954, "drops" +434, 15, 11, 472, 69, 70, 1955, 1956, "." +434, 16, 1, 473, 0, 10, 1957, 1967, "CONCLUSION" +434, 16, 2, 474, 11, 12, 1968, 1969, ":" +434, 16, 3, 475, 13, 17, 1970, 1974, "Both" +434, 16, 4, 476, 18, 23, 1975, 1980, "drops" +434, 16, 5, 477, 24, 31, 1981, 1988, "lowered" +434, 16, 6, 478, 32, 35, 1989, 1992, "IOP" +434, 16, 7, 479, 36, 47, 1993, 2004, "effectively" +434, 16, 8, 480, 48, 51, 2005, 2008, "but" +434, 16, 9, 481, 52, 63, 2009, 2020, "bimatoprost" +434, 16, 10, 482, 64, 70, 2021, 2027, "showed" +434, 16, 11, 483, 71, 72, 2028, 2029, "a" +434, 16, 12, 484, 73, 80, 2030, 2037, "greater" +434, 16, 13, 485, 81, 84, 2038, 2041, "non" +434, 16, 14, 486, 85, 86, 2042, 2043, "-" +434, 16, 15, 487, 87, 98, 2044, 2055, "significant" +434, 16, 16, 488, 99, 109, 2056, 2066, "reductions" +434, 16, 17, 489, 110, 112, 2067, 2069, "in" +434, 16, 18, 490, 113, 117, 2070, 2074, "mean" +434, 16, 19, 491, 118, 121, 2075, 2078, "IOP" +434, 16, 20, 492, 122, 126, 2079, 2083, "from" +434, 16, 21, 493, 127, 135, 2084, 2092, "baseline" +434, 16, 22, 494, 136, 137, 2093, 2094, "." +434, 17, 1, 495, 0, 3, 2095, 2098, "DOI" +434, 17, 2, 496, 4, 5, 2099, 2100, ":" +434, 17, 3, 497, 6, 8, 2101, 2103, "10" +434, 17, 4, 498, 9, 10, 2104, 2105, "." +434, 17, 5, 499, 11, 15, 2106, 2110, "1089" +434, 17, 6, 500, 16, 17, 2111, 2112, "/" +434, 17, 7, 501, 18, 21, 2113, 2116, "jop" +434, 17, 8, 502, 22, 23, 2117, 2118, "." +434, 17, 9, 503, 24, 28, 2119, 2123, "2010" +434, 17, 10, 504, 29, 30, 2124, 2125, "." +434, 17, 11, 505, 31, 35, 2126, 2130, "0068" +434, 17, 12, 506, 36, 40, 2131, 2135, "PMID" +434, 17, 13, 507, 41, 42, 2136, 2137, ":" +434, 17, 14, 508, 43, 51, 2138, 2146, "21034177" +434, 17, 15, 509, 52, 53, 2147, 2148, "[" +434, 17, 16, 510, 54, 61, 2149, 2156, "Indexed" +434, 17, 17, 511, 62, 65, 2157, 2160, "for" +434, 17, 18, 512, 66, 73, 2161, 2168, "MEDLINE" +434, 17, 19, 513, 74, 75, 2169, 2170, "]" diff --git a/data/gl 21034177_jshahinitiran.annodb b/data/gl 21034177_jshahinitiran.annodb new file mode 100644 index 0000000..3dcb339 --- /dev/null +++ b/data/gl 21034177_jshahinitiran.annodb @@ -0,0 +1,112 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15687, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +15688, PublicationYear, 24, 28, "2010", "", +15689, Title, 114, 223, "Bimatoprost versus travoprost in an Egyptian population : a hospital - based prospective , randomized study .", "", +15690, Bimatoprost, 114, 125, "Bimatoprost", "", +15691, Drug, 133, 143, "travoprost", "Travoprost", +15692, Ethnicity, 150, 158, "Egyptian", "", +15693, CTDesign, 191, 202, "prospective", "prospective", +15704, Randomized, 205, 215, "randomized", "", +15695, Egypt, 349, 354, "Egypt", "", +15696, ObjectiveDescription, 392, 515, "To compare the efficacy of bimatoprost and travoprost on intraocular pressure ( IOP ) reduction in an Egyptian population .", "", +15690, Bimatoprost, 419, 430, "bimatoprost", "", +15691, Drug, 435, 445, "travoprost", "Travoprost", +15699, IOP, 449, 469, "intraocular pressure", "", +15700, IOP, 472, 475, "IOP", "", +15692, Ethnicity, 494, 502, "Egyptian", "", +15702, OpenAngleGlaucoma, 540, 569, "primary open - angle glaucoma", "", +15703, OcularHypertension, 573, 592, "ocular hypertension", "", +15704, Randomized, 598, 608, "randomized", "", +15690, Bimatoprost, 627, 638, "bimatoprost", "", +15708, DoseValue, 639, 645, "0 . 03", "", +15710, Percentage, 646, 647, "%", "", +15691, Drug, 651, 661, "travoprost", "Travoprost", +15709, DoseValue, 662, 669, "0 . 004", "", +15711, Percentage, 670, 671, "%", "", +15712, Frequency, 672, 682, "once daily", "", +15713, IOP, 685, 689, "IOPs", "", +15714, TimePoint, 707, 715, "baseline", "", +15715, TimePoint, 718, 725, "2 weeks", "", +15716, TimePoint, 732, 733, "1", "", +15717, TimePoint, 736, 737, "2", "", +15718, TimePoint, 740, 741, "4", "", +15719, TimePoint, 748, 756, "6 months", "", +15720, NumberPatientsCT, 806, 819, "Seventy - two", "", +15721, NumberPatientsArm, 845, 847, "34", "", +15722, NumberPatientsArm, 852, 854, "38", "", +15723, Mean, 889, 893, "mean", "", +15724, IOP, 894, 897, "IOP", "", +15725, BaseLineValue, 902, 909, "26 . 52", "", +15727, SdErrorBL, 914, 921, "5 . 185", "", +15726, BaseLineValue, 926, 933, "26 . 36", "", +15729, SdErrorBL, 938, 945, "1 . 605", "", +15730, mmHg, 948, 953, "mm Hg", "", +15731, PValueBL, 956, 969, "P  =  0 . 629", "", +15690, Bimatoprost, 976, 987, "bimatoprost", "", +15691, Drug, 992, 1002, "travoprost", "Travoprost", +15734, Eyedrops, 1025, 1030, "drops", "", +15735, IOP, 1066, 1069, "IOP", "", +15736, PValueChangeValue, 1111, 1124, "P  <  0 . 001", "", +15690, Bimatoprost, 1129, 1140, "Bimatoprost", "", +15738, Mean, 1177, 1181, "mean", "", +15739, IOP, 1182, 1185, "IOP", "", +15691, Drug, 1216, 1226, "travoprost", "Travoprost", +15741, Mean, 1243, 1247, "Mean", "", +15742, IOP, 1248, 1251, "IOP", "", +15743, Reduction, 1267, 1273, "8 . 77", "", +15747, mmHg, 1276, 1281, "mm Hg", "", +15754, RelativeReduction, 1284, 1291, "33 . 39", "", +15744, Reduction, 1300, 1306, "8 . 42", "", +15748, mmHg, 1309, 1314, "mm Hg", "", +15751, RelativeReduction, 1317, 1324, "31 . 54", "", +15755, TimePoint, 1332, 1339, "2 weeks", "", +15756, PValueChangeValue, 1342, 1355, "P  =  0 . 703", "", +15745, Reduction, 1364, 1370, "8 . 47", "", +15749, mmHg, 1373, 1378, "mm Hg", "", +15752, RelativeReduction, 1381, 1388, "31 . 61", "", +15746, Reduction, 1397, 1403, "7 . 84", "", +15750, mmHg, 1406, 1411, "mm Hg", "", +15753, RelativeReduction, 1414, 1421, "29 . 50", "", +15757, TimePoint, 1429, 1437, "6 months", "", +15758, PValueChangeValue, 1440, 1453, "P  =  0 . 536", "", +15690, Bimatoprost, 1460, 1471, "bimatoprost", "", +15691, Drug, 1476, 1486, "travoprost", "Travoprost", +15764, IOP, 1504, 1508, "IOPs", "", +15761, TimePoint, 1512, 1519, "2 weeks", "", +15762, EndPointDescription, 1525, 1537, "≤ 18   mm Hg", "", +15763, mmHg, 1532, 1537, "mm Hg", "", +15765, NumberAffected, 1541, 1543, "20", "", +15767, PercentageAffected, 1546, 1552, "58 . 8", "", +15766, NumberAffected, 1564, 1566, "19", "", +15768, PercentageAffected, 1569, 1571, "50", "", +15769, PValueNumAffected, 1583, 1596, "P  =  0 . 603", "", +15770, EndPointDescription, 1605, 1617, "≤ 16   mm Hg", "", +15771, mmHg, 1612, 1617, "mm Hg", "", +15772, NumberAffected, 1621, 1623, "12", "", +15774, PercentageAffected, 1626, 1628, "35", "", +15773, NumberAffected, 1640, 1642, "12", "", +15775, PercentageAffected, 1645, 1647, "32", "", +15776, PercentageAffected, 1659, 1672, "P  =  0 . 456", "", +15777, TimePoint, 1684, 1692, "6 months", "", +15762, EndPointDescription, 1693, 1705, "≤ 18   mm Hg", "", +15763, mmHg, 1700, 1705, "mm Hg", "", +15780, NumberAffected, 1709, 1711, "22", "", +15784, PercentageAffected, 1714, 1716, "65", "", +15781, NumberAffected, 1728, 1730, "14", "", +15785, PercentageAffected, 1733, 1735, "37", "", +15770, EndPointDescription, 1769, 1781, "≤ 16   mm Hg", "", +15771, mmHg, 1776, 1781, "mm Hg", "", +15782, NumberAffected, 1785, 1787, "12", "", +15786, PercentageAffected, 1790, 1792, "35", "", +15783, NumberAffected, 1804, 1805, "7", "", +15787, PercentageAffected, 1808, 1810, "18", "", +15788, PValueNumAffected, 1822, 1835, "P  =  0 . 037", "", +15690, Bimatoprost, 1842, 1853, "bimatoprost", "", +15691, Drug, 1858, 1868, "travoprost", "Travoprost", +15798, ConclusionComment, 1970, 2094, "Both drops lowered IOP effectively but bimatoprost showed a greater non - significant reductions in mean IOP from baseline .", "", +15799, Eyedrops, 1975, 1980, "drops", "", +15793, IOP, 1989, 1992, "IOP", "", +15690, Bimatoprost, 2009, 2020, "bimatoprost", "", +15795, Mean, 2070, 2074, "mean", "", +15796, IOP, 2075, 2078, "IOP", "", +15797, PMID, 2138, 2146, "21034177", "", diff --git a/data/gl 21034177_jshahinitiran.n-triples b/data/gl 21034177_jshahinitiran.n-triples new file mode 100644 index 0000000..e9adaad --- /dev/null +++ b/data/gl 21034177_jshahinitiran.n-triples @@ -0,0 +1,15 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication + . + "Medication 19168" . + . + . + . +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21034177_tstrakeljahn.annodb b/data/gl 21034177_tstrakeljahn.annodb new file mode 100644 index 0000000..5aa1f53 --- /dev/null +++ b/data/gl 21034177_tstrakeljahn.annodb @@ -0,0 +1,109 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13300, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +13301, PublicationYear, 24, 28, "2010", "", +13312, Title, 114, 221, "Bimatoprost versus travoprost in an Egyptian population : a hospital - based prospective , randomized study", "", +13302, Bimatoprost, 114, 125, "Bimatoprost", "", +29897, Drug, 133, 143, "travoprost", "Travoprost", +13304, Randomized, 205, 215, "randomized", "", +13305, Author, 224, 232, "Macky TA", "", +13306, Egypt, 349, 354, "Egypt", "", +13311, ObjectiveDescription, 392, 513, "To compare the efficacy of bimatoprost and travoprost on intraocular pressure ( IOP ) reduction in an Egyptian population", "", +13307, Bimatoprost, 419, 430, "bimatoprost", "", +29898, Drug, 435, 445, "travoprost", "Travoprost", +13309, IOP, 449, 469, "intraocular pressure", "", +13310, IOP, 472, 475, "IOP", "", +13313, OpenAngleGlaucoma, 548, 569, "open - angle glaucoma", "", +13314, OcularHypertension, 573, 592, "ocular hypertension", "", +13315, Randomized, 598, 608, "randomized", "", +13316, Bimatoprost, 627, 638, "bimatoprost", "", +13319, DoseValue, 639, 645, "0 . 03", "", +13321, Percentage, 646, 647, "%", "", +29899, Drug, 651, 661, "travoprost", "Travoprost", +13320, DoseValue, 662, 669, "0 . 004", "", +13322, Percentage, 670, 671, "%", "", +13318, Frequency, 672, 682, "once daily", "", +13323, IOP, 685, 689, "IOPs", "", +13324, FinalNumPatientsCT, 806, 819, "Seventy - two", "", +13325, FinalNumPatientsArm, 845, 847, "34", "", +13326, FinalNumPatientsArm, 852, 854, "38", "", +13327, PvalueDiff, 857, 870, "P  =  0 . 142", "", +13328, Mean, 889, 893, "mean", "", +13329, IOP, 894, 897, "IOP", "", +13330, BaseLineValue, 902, 909, "26 . 52", "", +13332, SdDevBL, 914, 921, "5 . 185", "", +13331, BaseLineValue, 926, 933, "26 . 36", "", +13333, SdDevBL, 938, 945, "1 . 605", "", +13334, mmHg, 948, 953, "mm Hg", "", +13335, PvalueDiff, 956, 969, "P  =  0 . 629", "", +13336, Bimatoprost, 976, 987, "bimatoprost", "", +29900, Drug, 992, 1002, "travoprost", "Travoprost", +13346, ObservedResult, 1020, 1128, "Both drops provided statistically significant IOP reductions from baseline at all visits ( P  <  0 . 001 ) .", "", +13338, Eyedrops, 1025, 1030, "drops", "", +13339, IOP, 1066, 1069, "IOP", "", +13340, PvalueDiff, 1111, 1124, "P  <  0 . 001", "", +13341, Bimatoprost, 1129, 1140, "Bimatoprost", "", +13345, ObservedResult, 1129, 1240, "Bimatoprost provided greater ( nonsignificant ) mean IOP reductions from baseline than travoprost at each visit", "", +13342, Mean, 1177, 1181, "mean", "", +13343, IOP, 1182, 1185, "IOP", "", +29901, Drug, 1216, 1226, "travoprost", "Travoprost", +13347, Mean, 1243, 1247, "Mean", "", +13348, IOP, 1248, 1251, "IOP", "", +13349, Reduction, 1267, 1273, "8 . 77", "", +13351, mmHg, 1276, 1281, "mm Hg", "", +13353, RelativeReduction, 1284, 1291, "33 . 39", "", +13350, Reduction, 1300, 1306, "8 . 42", "", +13352, mmHg, 1309, 1314, "mm Hg", "", +13354, RelativeReduction, 1317, 1324, "31 . 54", "", +13355, TimePoint, 1332, 1339, "2 weeks", "", +13356, PvalueDiff, 1342, 1355, "P  =  0 . 703", "", +13357, Reduction, 1364, 1370, "8 . 47", "", +13361, mmHg, 1373, 1378, "mm Hg", "", +13359, RelativeReduction, 1381, 1388, "31 . 61", "", +13358, Reduction, 1397, 1403, "7 . 84", "", +13362, mmHg, 1406, 1411, "mm Hg", "", +13360, RelativeReduction, 1414, 1421, "29 . 50", "", +13363, TimePoint, 1429, 1437, "6 months", "", +13364, PvalueDiff, 1440, 1453, "P  =  0 . 536", "", +13365, Bimatoprost, 1460, 1471, "bimatoprost", "", +29902, Drug, 1476, 1486, "travoprost", "Travoprost", +13367, IOP, 1504, 1508, "IOPs", "", +13370, Endpoint, 1504, 1537, "IOPs at 2 weeks were ≤ 18   mm Hg", "", +13368, TimePoint, 1512, 1519, "2 weeks", "", +13369, mmHg, 1532, 1537, "mm Hg", "", +13377, NumberAffected, 1541, 1543, "20", "", +13385, PercentageAffected, 1546, 1552, "58 . 8", "", +13379, NumberAffected, 1564, 1566, "19", "", +13386, PercentageAffected, 1569, 1571, "50", "", +13393, PvalueDiff, 1583, 1596, "P  =  0 . 603", "", +13371, Endpoint, 1605, 1617, "≤ 16   mm Hg", "", +13372, mmHg, 1612, 1617, "mm Hg", "", +13378, NumberAffected, 1621, 1623, "12", "", +13387, PercentageAffected, 1626, 1628, "35", "", +13380, NumberAffected, 1640, 1642, "12", "", +13388, PercentageAffected, 1645, 1647, "32", "", +13394, PvalueDiff, 1659, 1672, "P  =  0 . 456", "", +13397, TimePoint, 1684, 1692, "6 months", "", +13375, Endpoint, 1693, 1705, "≤ 18   mm Hg", "", +13373, mmHg, 1700, 1705, "mm Hg", "", +13381, NumberAffected, 1709, 1711, "22", "", +13389, PercentageAffected, 1714, 1716, "65", "", +13382, NumberAffected, 1728, 1730, "14", "", +13390, PercentageAffected, 1733, 1735, "37", "", +13395, PvalueDiff, 1747, 1760, "P  =  0 . 045", "", +13376, Endpoint, 1769, 1781, "≤ 16   mm Hg", "", +13374, mmHg, 1776, 1781, "mm Hg", "", +13383, NumberAffected, 1785, 1787, "12", "", +13391, PercentageAffected, 1790, 1792, "35", "", +13384, NumberAffected, 1804, 1805, "7", "", +13392, PercentageAffected, 1808, 1810, "18", "", +13396, PvalueDiff, 1822, 1835, "P  =  0 . 037", "", +13398, Bimatoprost, 1842, 1853, "bimatoprost", "", +29903, Drug, 1858, 1868, "travoprost", "Travoprost", +13401, ObservedResult, 1886, 1956, "Ocular adverse and clinical success occurred equally with both drops .", "", +13400, Eyedrops, 1949, 1954, "drops", "", +13406, ConclusionComment, 1970, 2094, "Both drops lowered IOP effectively but bimatoprost showed a greater non - significant reductions in mean IOP from baseline .", "", +13402, IOP, 1989, 1992, "IOP", "", +13403, Bimatoprost, 2009, 2020, "bimatoprost", "", +13404, Mean, 2070, 2074, "mean", "", +13405, IOP, 2075, 2078, "IOP", "", +13407, PMID, 2138, 2146, "21034177", "", diff --git a/data/gl 21034177_tstrakeljahn.n-triples b/data/gl 21034177_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21034177_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21048504_admin.annodb b/data/gl 21048504_admin.annodb new file mode 100644 index 0000000..c7a3799 --- /dev/null +++ b/data/gl 21048504_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2012", "", " \"2012\"." +2, IOP, 87, 107, "Intraocular pressure", "", +5, Title, 87, 220, "Intraocular pressure - lowering efficacy of brinzolamide when added to travoprost / timolol fixed combination as adjunctive therapy .", "", " \"Intraocular pressure - lowering efficacy of brinzolamide when added to travoprost / timolol fixed combination as adjunctive therapy .\"." +3, Brinzolamide, 131, 143, "brinzolamide", "", +32275, Travoprost, 158, 168, "travoprost", "", +44444, Trav/TimFC, 158, 196, "travoprost / timolol fixed combination", "", +4, Timolol, 171, 178, "timolol", "", +6, Author, 221, 231, "Goldberg I", "", " \"Goldberg I\"." +7, Author, 240, 251, "Crowston JG", "", " \"Crowston JG\"." +8, Author, 254, 262, "Jasek MC", "", " \"Jasek MC\"." +9, Author, 265, 275, "Stewart JA", "", " \"Stewart JA\"." +10, Author, 278, 288, "Stewart WC", "", " \"Stewart WC\"." +11, Australia, 624, 633, "Australia", "", " ." +90, ObjectiveDescription, 646, 789, "To compare the efficacy of brinzolamide versus placebo when added to travoprost / timolol fixed combination ( TTFC ) in uncontrolled patients .", "", " \"To compare the efficacy of brinzolamide versus placebo when added to travoprost / timolol fixed combination ( TTFC ) in uncontrolled patients .\"." +12, Brinzolamide, 673, 685, "brinzolamide", "", +13, Placebo, 693, 700, "placebo", "", +32276, Travoprost, 715, 725, "travoprost", "", +44445, Trav/TimFC, 715, 753, "travoprost / timolol fixed combination", "", +14, Timolol, 728, 735, "timolol", "", +38404, Trav/TimFC, 756, 760, "TTFC", "", +37004, Prospective, 824, 835, "prospective", "", " ." +15, DoubleBlind, 838, 853, "double - masked", "", " ." +16, Randomized, 856, 866, "randomized", "", " ." +17, Placebo, 869, 876, "placebo", "", +18, Parallel, 892, 900, "parallel", "", +19, OcularHypertension, 915, 934, "ocular hypertensive", "", +32281, Primary_OpenAngleGlaucoma, 938, 967, "primary open - angle glaucoma", "", " ." +106385, Precondition, 979, 1111, "Patients treated with a prostaglandin - based mono or adjunctive therapy were changed to TTFC qam ( every day dosing ) for 4 weeks .", "", " \"Patients treated with a prostaglandin - based mono or adjunctive therapy were changed to TTFC qam ( every day dosing ) for 4 weeks .\"." +92861, ProstaglandinAnalogs, 1003, 1016, "prostaglandin", "", +38405, Trav/TimFC, 1068, 1072, "TTFC", "", +100, Frequency, 1073, 1076, "qam", "", +32285, Frequency, 1079, 1088, "every day", "", +22, Duration, 1102, 1109, "4 weeks", "", +23, IOP, 1129, 1149, "intraocular pressure", "", +24, IOP, 1152, 1155, "IOP", "", +25, mmHg, 1170, 1175, "mm Hg", "", +26, Randomized, 1277, 1287, "randomized", "", +27, Placebo, 1298, 1305, "placebo", "", " ." +28, Brinzolamide, 1309, 1321, "brinzolamide", "", " ." +29, Frequency, 1328, 1339, "twice daily", "", " \"twice daily\". \"twice daily\"." +38407, Trav/TimFC, 1355, 1359, "TTFC", "", +32287, TimePoint, 1365, 1372, "week 12", "", " \"week 12\". \"week 12\"." +30, IOP, 1394, 1397, "IOP", "", +110, PerProtocol, 1436, 1448, "per protocol", "", " ." +111, NumberPatientsArm, 1471, 1473, "78", "", " \"78\"." +33, Placebo, 1474, 1481, "placebo", "", +112, NumberPatientsArm, 1486, 1488, "75", "", " \"75\"." +34, Brinzolamide, 1489, 1501, "brinzolamide", "", +35, Mean, 1531, 1535, "mean", "", +36, Diurnal_IOP, 1536, 1547, "diurnal IOP", "", +37, mmHg, 1550, 1555, "mm Hg", "", " ." +38, IOP, 1569, 1572, "IOP", "", +39, PvalueDiff, 1607, 1618, "P ≤ 0 . 005", "", +40, Brinzolamide, 1623, 1635, "Brinzolamide", "", +41, Mean, 1648, 1652, "mean", "", " . ." +42, Diurnal_IOP, 1653, 1664, "diurnal IOP", "", " ." +43, BaseLineValue, 1670, 1676, "20 . 3", "", " \"20 . 3\"." +44, SdDevBL, 1679, 1684, "2 . 0", "", " \"2 . 0\"." +45, ResultMeasuredValue, 1688, 1694, "17 . 5", "", " \"17 . 5\"." +46, SdDevResValue, 1697, 1702, "2 . 6", "", " \"2 . 6\"." +47, Placebo, 1713, 1720, "placebo", "", +48, IOP, 1729, 1732, "IOP", "", +49, BaseLineValue, 1738, 1744, "20 . 9", "", " \"20 . 9\"." +50, SdDevBL, 1747, 1752, "2 . 7", "", " \"2 . 7\"." +51, ResultMeasuredValue, 1756, 1762, "19 . 4", "", " \"19 . 4\"." +52, SdDevResValue, 1765, 1770, "3 . 8", "", " \"3 . 8\"." +53, Mean, 1777, 1781, "mean", "", " \"3 . 8\"." +54, Diurnal_IOP, 1782, 1793, "diurnal IOP", "", +56, TimePoint, 1832, 1839, "08 : 00", "", +57, TimePoint, 1844, 1851, "16 : 00", "", +55, Brinzolamide, 1877, 1889, "brinzolamide", "", +58, Placebo, 1910, 1917, "placebo", "", +59, PvalueDiff, 1920, 1931, "P ≤ 0 . 014", "", " \"P ≤ 0 . 014\"." +60, NumberAffected, 1947, 1949, "30", "", " \"30\"." +32288, EndPointDescription, 1950, 1964, "adverse events", "", " . ." +61, Placebo, 1970, 1977, "placebo", "", +62, NumberAffected, 1982, 1984, "24", "", " \"24\"." +63, Brinzolamide, 1990, 2002, "brinzolamide", "", +64, IntentionToTreat, 2005, 2024, "intent - to - treat", "", " ." +139, PvalueDiff, 2135, 2145, "P = 0 . 47", "", " \"P = 0 . 47\"." +74, ConclusionComment, 2164, 2354, "This study suggests that brinzolamide may be safely added to TTFC therapy to provide further significant reduction in IOP patients with ocular hypertensive or primary open - angle glaucoma .", "", " \"This study suggests that brinzolamide may be safely added to TTFC therapy to provide further significant reduction in IOP patients with ocular hypertensive or primary open - angle glaucoma .\"." +69, Brinzolamide, 2189, 2201, "brinzolamide", "", +38406, Trav/TimFC, 2225, 2229, "TTFC", "", +70, IOP, 2282, 2285, "IOP", "", +71, OcularHypertension, 2300, 2319, "ocular hypertensive", "", +32278, Primary_OpenAngleGlaucoma, 2323, 2352, "primary open - angle glaucoma", "", +73, PMID, 2403, 2411, "21048504", "", " \"21048504\"." diff --git a/data/gl 21048504_admin.n-triples b/data/gl 21048504_admin.n-triples new file mode 100644 index 0000000..7fa4685 --- /dev/null +++ b/data/gl 21048504_admin.n-triples @@ -0,0 +1,126 @@ +# RDF export of group: Publication + . + "Publication" . + "Intraocular pressure - lowering efficacy of brinzolamide when added to travoprost / timolol fixed combination as adjunctive therapy ." . + "Goldberg I" . + "2012" . + "J Glaucoma" . + "21048504" . + . + "Crowston JG" . + "Jasek MC" . + "Stewart JA" . + "Stewart WC" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 36635" . + "To compare the efficacy of brinzolamide versus placebo when added to travoprost / timolol fixed combination ( TTFC ) in uncontrolled patients ." . + . + . + . + "This study suggests that brinzolamide may be safely added to TTFC therapy to provide further significant reduction in IOP patients with ocular hypertensive or primary open - angle glaucoma ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Patients treated with a prostaglandin - based mono or adjunctive therapy were changed to TTFC qam ( every day dosing ) for 4 weeks ." . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 36946 adverse event" . + . + . + . + . + . + . + "Endpoint 37096 Diurnal IOP" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 37103 Trav/Tim + Placebo" . + "78" . + . + . + . + . + "Arm 37116 Trav/Tim + Brinzolamide" . + "75" . + . + . + . +# RDF export of group: Intervention + . + "Intervention 37129 Brinzolamide" . + "twice daily" . + . + . + . + "Intervention 39250 Placebo" . + "twice daily" . + . + . +# RDF export of group: Medication + . + "Medication 39235 Brinzolamide" . + . + . + . + . + "Medication 39242 Placebo" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 36518 Brinzolamide" . + "20 . 3" . + "2 . 0" . + "17 . 5" . + "2 . 6" . + "week 12" . + . + . + "Outcome 39265 Placebo" . + . + "20 . 9" . + "2 . 7" . + "19 . 4" . + "3 . 8" . + "week 12" . + . + "Outcome 39294 adverse event placebo" . + . + "30" . + . + "Outcome 41680 adverse event Brinzolamide" . + . + "24" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 36497 mean diurnal IOP" . + "P ≤ 0 . 014" . + . + . + . + "DiffBetweenGroups 36506 adverse events" . + "P = 0 . 47" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21048504_export.csv b/data/gl 21048504_export.csv new file mode 100644 index 0000000..00fba4a --- /dev/null +++ b/data/gl 21048504_export.csv @@ -0,0 +1,492 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +433, 1, 1, 1, 0, 1, 0, 1, "J" +433, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +433, 1, 3, 3, 11, 12, 11, 12, "." +433, 2, 1, 4, 0, 4, 13, 17, "2012" +433, 2, 2, 5, 5, 8, 18, 21, "Jan" +433, 2, 3, 6, 9, 10, 22, 23, ";" +433, 2, 4, 7, 11, 13, 24, 26, "21" +433, 2, 5, 8, 14, 15, 27, 28, "(" +433, 2, 6, 9, 16, 17, 29, 30, "1" +433, 2, 7, 10, 18, 19, 31, 32, ")" +433, 2, 8, 11, 20, 21, 33, 34, ":" +433, 2, 9, 12, 22, 24, 35, 37, "55" +433, 2, 10, 13, 25, 26, 38, 39, "-" +433, 2, 11, 14, 27, 28, 40, 41, "9" +433, 2, 12, 15, 29, 30, 42, 43, "." +433, 2, 13, 16, 31, 34, 44, 47, "doi" +433, 2, 14, 17, 35, 36, 48, 49, ":" +433, 2, 15, 18, 37, 39, 50, 52, "10" +433, 2, 16, 19, 40, 41, 53, 54, "." +433, 2, 17, 20, 42, 46, 55, 59, "1097" +433, 2, 18, 21, 47, 48, 60, 61, "/" +433, 2, 19, 22, 49, 52, 62, 65, "IJG" +433, 2, 20, 23, 53, 54, 66, 67, "." +433, 2, 21, 24, 55, 71, 68, 84, "0b013e3181fc8142" +433, 2, 22, 25, 72, 73, 85, 86, "." +433, 3, 1, 26, 0, 11, 87, 98, "Intraocular" +433, 3, 2, 27, 12, 20, 99, 107, "pressure" +433, 3, 3, 28, 21, 22, 108, 109, "-" +433, 3, 4, 29, 23, 31, 110, 118, "lowering" +433, 3, 5, 30, 32, 40, 119, 127, "efficacy" +433, 3, 6, 31, 41, 43, 128, 130, "of" +433, 3, 7, 32, 44, 56, 131, 143, "brinzolamide" +433, 3, 8, 33, 57, 61, 144, 148, "when" +433, 3, 9, 34, 62, 67, 149, 154, "added" +433, 3, 10, 35, 68, 70, 155, 157, "to" +433, 3, 11, 36, 71, 81, 158, 168, "travoprost" +433, 3, 12, 37, 82, 83, 169, 170, "/" +433, 3, 13, 38, 84, 91, 171, 178, "timolol" +433, 3, 14, 39, 92, 97, 179, 184, "fixed" +433, 3, 15, 40, 98, 109, 185, 196, "combination" +433, 3, 16, 41, 110, 112, 197, 199, "as" +433, 3, 17, 42, 113, 123, 200, 210, "adjunctive" +433, 3, 18, 43, 124, 131, 211, 218, "therapy" +433, 3, 19, 44, 132, 133, 219, 220, "." +433, 4, 1, 45, 0, 8, 221, 229, "Goldberg" +433, 4, 2, 46, 9, 10, 230, 231, "I" +433, 4, 3, 47, 11, 12, 232, 233, "(" +433, 4, 4, 48, 13, 14, 234, 235, "1" +433, 4, 5, 49, 15, 16, 236, 237, ")" +433, 4, 6, 50, 17, 18, 238, 239, "," +433, 4, 7, 51, 19, 27, 240, 248, "Crowston" +433, 4, 8, 52, 28, 30, 249, 251, "JG" +433, 4, 9, 53, 31, 32, 252, 253, "," +433, 4, 10, 54, 33, 38, 254, 259, "Jasek" +433, 4, 11, 55, 39, 41, 260, 262, "MC" +433, 4, 12, 56, 42, 43, 263, 264, "," +433, 4, 13, 57, 44, 51, 265, 272, "Stewart" +433, 4, 14, 58, 52, 54, 273, 275, "JA" +433, 4, 15, 59, 55, 56, 276, 277, "," +433, 4, 16, 60, 57, 64, 278, 285, "Stewart" +433, 4, 17, 61, 65, 67, 286, 288, "WC" +433, 4, 18, 62, 68, 69, 289, 290, ";" +433, 4, 19, 63, 70, 75, 291, 296, "ADAPT" +433, 4, 20, 64, 76, 81, 297, 302, "Study" +433, 4, 21, 65, 82, 94, 303, 315, "Investigator" +433, 4, 22, 66, 95, 100, 316, 321, "Group" +433, 4, 23, 67, 101, 102, 322, 323, "." +433, 5, 1, 68, 0, 13, 324, 337, "Collaborators" +433, 5, 2, 69, 14, 15, 338, 339, ":" +433, 5, 3, 70, 16, 24, 340, 348, "Crichton" +433, 5, 4, 71, 25, 27, 349, 351, "AC" +433, 5, 5, 72, 28, 29, 352, 353, "," +433, 5, 6, 73, 30, 34, 354, 358, "Ford" +433, 5, 7, 74, 35, 37, 359, 361, "BA" +433, 5, 8, 75, 38, 39, 362, 363, "," +433, 5, 9, 76, 40, 48, 364, 372, "Fredette" +433, 5, 10, 77, 49, 51, 373, 375, "MJ" +433, 5, 11, 78, 52, 53, 376, 377, "," +433, 5, 12, 79, 54, 58, 378, 382, "Lesk" +433, 5, 13, 80, 59, 61, 383, 385, "MR" +433, 5, 14, 81, 62, 63, 386, 387, "," +433, 5, 15, 82, 64, 71, 388, 395, "Rifkind" +433, 5, 16, 83, 72, 73, 396, 397, "A" +433, 5, 17, 84, 74, 75, 398, 399, "," +433, 5, 18, 85, 76, 85, 400, 409, "Schertzer" +433, 5, 19, 86, 86, 88, 410, 412, "RM" +433, 5, 20, 87, 89, 90, 413, 414, "," +433, 5, 21, 88, 91, 103, 415, 427, "Harasymowycz" +433, 5, 22, 89, 104, 105, 428, 429, "P" +433, 5, 23, 90, 106, 107, 430, 431, "," +433, 5, 24, 91, 108, 117, 432, 441, "Chiselita" +433, 5, 25, 92, 118, 119, 442, 443, "D" +433, 5, 26, 93, 120, 121, 444, 445, "," +433, 5, 27, 94, 122, 129, 446, 453, "Cvenkel" +433, 5, 28, 95, 130, 131, 454, 455, "B" +433, 5, 29, 96, 132, 133, 456, 457, "," +433, 5, 30, 97, 134, 140, 458, 464, "Graham" +433, 5, 31, 98, 141, 143, 465, 467, "SL" +433, 5, 32, 99, 144, 145, 468, 469, "," +433, 5, 33, 100, 146, 152, 470, 476, "Healey" +433, 5, 34, 101, 153, 155, 477, 479, "PR" +433, 5, 35, 102, 156, 157, 480, 481, "," +433, 5, 36, 103, 158, 161, 482, 485, "Liu" +433, 5, 37, 104, 162, 163, 486, 487, "L" +433, 5, 38, 105, 164, 165, 488, 489, "," +433, 5, 39, 106, 166, 175, 490, 499, "Liehneova" +433, 5, 40, 107, 176, 177, 500, 501, "I" +433, 5, 41, 108, 178, 179, 502, 503, "," +433, 5, 42, 109, 180, 187, 504, 511, "Petkova" +433, 5, 43, 110, 188, 189, 512, 513, "N" +433, 5, 44, 111, 190, 191, 514, 515, "," +433, 5, 45, 112, 192, 198, 516, 522, "Nelson" +433, 5, 46, 113, 199, 201, 523, 525, "LA" +433, 5, 47, 114, 202, 203, 526, 527, "." +433, 6, 1, 115, 0, 6, 528, 534, "Author" +433, 6, 2, 116, 7, 18, 535, 546, "information" +433, 6, 3, 117, 19, 20, 547, 548, ":" +433, 6, 4, 118, 21, 22, 549, 550, "(" +433, 6, 5, 119, 23, 24, 551, 552, "1" +433, 6, 6, 120, 25, 26, 553, 554, ")" +433, 6, 7, 121, 27, 33, 555, 561, "Sydney" +433, 6, 8, 122, 34, 37, 562, 565, "Eye" +433, 6, 9, 123, 38, 46, 566, 574, "Hospital" +433, 6, 10, 124, 47, 48, 575, 576, "," +433, 6, 11, 125, 49, 57, 577, 585, "Glaucoma" +433, 6, 12, 126, 58, 66, 586, 594, "Services" +433, 6, 13, 127, 67, 68, 595, 596, "," +433, 6, 14, 128, 69, 75, 597, 603, "Sydney" +433, 6, 15, 129, 76, 77, 604, 605, "," +433, 6, 16, 130, 78, 81, 606, 609, "New" +433, 6, 17, 131, 82, 87, 610, 615, "South" +433, 6, 18, 132, 88, 93, 616, 621, "Wales" +433, 6, 19, 133, 94, 95, 622, 623, "," +433, 6, 20, 134, 96, 105, 624, 633, "Australia" +433, 6, 21, 135, 106, 107, 634, 635, "." +433, 7, 1, 136, 0, 7, 636, 643, "PURPOSE" +433, 7, 2, 137, 8, 9, 644, 645, ":" +433, 7, 3, 138, 10, 12, 646, 648, "To" +433, 7, 4, 139, 13, 20, 649, 656, "compare" +433, 7, 5, 140, 21, 24, 657, 660, "the" +433, 7, 6, 141, 25, 33, 661, 669, "efficacy" +433, 7, 7, 142, 34, 36, 670, 672, "of" +433, 7, 8, 143, 37, 49, 673, 685, "brinzolamide" +433, 7, 9, 144, 50, 56, 686, 692, "versus" +433, 7, 10, 145, 57, 64, 693, 700, "placebo" +433, 7, 11, 146, 65, 69, 701, 705, "when" +433, 7, 12, 147, 70, 75, 706, 711, "added" +433, 7, 13, 148, 76, 78, 712, 714, "to" +433, 7, 14, 149, 79, 89, 715, 725, "travoprost" +433, 7, 15, 150, 90, 91, 726, 727, "/" +433, 7, 16, 151, 92, 99, 728, 735, "timolol" +433, 7, 17, 152, 100, 105, 736, 741, "fixed" +433, 7, 18, 153, 106, 117, 742, 753, "combination" +433, 7, 19, 154, 118, 119, 754, 755, "(" +433, 7, 20, 155, 120, 124, 756, 760, "TTFC" +433, 7, 21, 156, 125, 126, 761, 762, ")" +433, 7, 22, 157, 127, 129, 763, 765, "in" +433, 7, 23, 158, 130, 142, 766, 778, "uncontrolled" +433, 7, 24, 159, 143, 151, 779, 787, "patients" +433, 7, 25, 160, 152, 153, 788, 789, "." +433, 8, 1, 161, 0, 8, 790, 798, "PATIENTS" +433, 8, 2, 162, 9, 12, 799, 802, "AND" +433, 8, 3, 163, 13, 20, 803, 810, "METHODS" +433, 8, 4, 164, 21, 22, 811, 812, ":" +433, 8, 5, 165, 23, 27, 813, 817, "This" +433, 8, 6, 166, 28, 31, 818, 821, "was" +433, 8, 7, 167, 32, 33, 822, 823, "a" +433, 8, 8, 168, 34, 45, 824, 835, "prospective" +433, 8, 9, 169, 46, 47, 836, 837, "," +433, 8, 10, 170, 48, 54, 838, 844, "double" +433, 8, 11, 171, 55, 56, 845, 846, "-" +433, 8, 12, 172, 57, 63, 847, 853, "masked" +433, 8, 13, 173, 64, 65, 854, 855, "," +433, 8, 14, 174, 66, 76, 856, 866, "randomized" +433, 8, 15, 175, 77, 78, 867, 868, "," +433, 8, 16, 176, 79, 86, 869, 876, "placebo" +433, 8, 17, 177, 87, 88, 877, 878, "-" +433, 8, 18, 178, 89, 99, 879, 889, "controlled" +433, 8, 19, 179, 100, 101, 890, 891, "," +433, 8, 20, 180, 102, 110, 892, 900, "parallel" +433, 8, 21, 181, 111, 121, 901, 911, "comparison" +433, 8, 22, 182, 122, 124, 912, 914, "of" +433, 8, 23, 183, 125, 131, 915, 921, "ocular" +433, 8, 24, 184, 132, 144, 922, 934, "hypertensive" +433, 8, 25, 185, 145, 147, 935, 937, "or" +433, 8, 26, 186, 148, 155, 938, 945, "primary" +433, 8, 27, 187, 156, 160, 946, 950, "open" +433, 8, 28, 188, 161, 162, 951, 952, "-" +433, 8, 29, 189, 163, 168, 953, 958, "angle" +433, 8, 30, 190, 169, 177, 959, 967, "glaucoma" +433, 8, 31, 191, 178, 186, 968, 976, "patients" +433, 8, 32, 192, 187, 188, 977, 978, "." +433, 9, 1, 193, 0, 8, 979, 987, "Patients" +433, 9, 2, 194, 9, 16, 988, 995, "treated" +433, 9, 3, 195, 17, 21, 996, 1000, "with" +433, 9, 4, 196, 22, 23, 1001, 1002, "a" +433, 9, 5, 197, 24, 37, 1003, 1016, "prostaglandin" +433, 9, 6, 198, 38, 39, 1017, 1018, "-" +433, 9, 7, 199, 40, 45, 1019, 1024, "based" +433, 9, 8, 200, 46, 50, 1025, 1029, "mono" +433, 9, 9, 201, 51, 53, 1030, 1032, "or" +433, 9, 10, 202, 54, 64, 1033, 1043, "adjunctive" +433, 9, 11, 203, 65, 72, 1044, 1051, "therapy" +433, 9, 12, 204, 73, 77, 1052, 1056, "were" +433, 9, 13, 205, 78, 85, 1057, 1064, "changed" +433, 9, 14, 206, 86, 88, 1065, 1067, "to" +433, 9, 15, 207, 89, 93, 1068, 1072, "TTFC" +433, 9, 16, 208, 94, 97, 1073, 1076, "qam" +433, 9, 17, 209, 98, 99, 1077, 1078, "(" +433, 9, 18, 210, 100, 105, 1079, 1084, "every" +433, 9, 19, 211, 106, 109, 1085, 1088, "day" +433, 9, 20, 212, 110, 116, 1089, 1095, "dosing" +433, 9, 21, 213, 117, 118, 1096, 1097, ")" +433, 9, 22, 214, 119, 122, 1098, 1101, "for" +433, 9, 23, 215, 123, 124, 1102, 1103, "4" +433, 9, 24, 216, 125, 130, 1104, 1109, "weeks" +433, 9, 25, 217, 131, 132, 1110, 1111, "." +433, 10, 1, 218, 0, 8, 1112, 1120, "Patients" +433, 10, 2, 219, 9, 13, 1121, 1125, "with" +433, 10, 3, 220, 14, 16, 1126, 1128, "an" +433, 10, 4, 221, 17, 28, 1129, 1140, "intraocular" +433, 10, 5, 222, 29, 37, 1141, 1149, "pressure" +433, 10, 6, 223, 38, 39, 1150, 1151, "(" +433, 10, 7, 224, 40, 43, 1152, 1155, "IOP" +433, 10, 8, 225, 44, 45, 1156, 1157, ")" +433, 10, 9, 226, 46, 48, 1158, 1160, "of" +433, 10, 10, 227, 49, 51, 1161, 1163, "19" +433, 10, 11, 228, 52, 54, 1164, 1166, "to" +433, 10, 12, 229, 55, 57, 1167, 1169, "32" +433, 10, 13, 230, 58, 60, 1170, 1172, "mm" +433, 10, 14, 231, 61, 63, 1173, 1175, "Hg" +433, 10, 15, 232, 64, 66, 1176, 1178, "at" +433, 10, 16, 233, 67, 69, 1179, 1181, "08" +433, 10, 17, 234, 70, 71, 1182, 1183, ":" +433, 10, 18, 235, 72, 74, 1184, 1186, "00" +433, 10, 19, 236, 75, 80, 1187, 1192, "hours" +433, 10, 20, 237, 81, 90, 1193, 1202, "underwent" +433, 10, 21, 238, 91, 101, 1203, 1213, "additional" +433, 10, 22, 239, 102, 114, 1214, 1226, "measurements" +433, 10, 23, 240, 115, 117, 1227, 1229, "at" +433, 10, 24, 241, 118, 120, 1230, 1232, "12" +433, 10, 25, 242, 121, 122, 1233, 1234, ":" +433, 10, 26, 243, 123, 125, 1235, 1237, "00" +433, 10, 27, 244, 126, 129, 1238, 1241, "and" +433, 10, 28, 245, 130, 132, 1242, 1244, "16" +433, 10, 29, 246, 133, 134, 1245, 1246, ":" +433, 10, 30, 247, 135, 137, 1247, 1249, "00" +433, 10, 31, 248, 138, 143, 1250, 1255, "hours" +433, 10, 32, 249, 144, 145, 1256, 1257, "." +433, 11, 1, 250, 0, 8, 1258, 1266, "Patients" +433, 11, 2, 251, 9, 13, 1267, 1271, "were" +433, 11, 3, 252, 14, 18, 1272, 1276, "then" +433, 11, 4, 253, 19, 29, 1277, 1287, "randomized" +433, 11, 5, 254, 30, 32, 1288, 1290, "to" +433, 11, 6, 255, 33, 39, 1291, 1297, "either" +433, 11, 7, 256, 40, 47, 1298, 1305, "placebo" +433, 11, 8, 257, 48, 50, 1306, 1308, "or" +433, 11, 9, 258, 51, 63, 1309, 1321, "brinzolamide" +433, 11, 10, 259, 64, 69, 1322, 1327, "given" +433, 11, 11, 260, 70, 75, 1328, 1333, "twice" +433, 11, 12, 261, 76, 81, 1334, 1339, "daily" +433, 11, 13, 262, 82, 84, 1340, 1342, "in" +433, 11, 14, 263, 85, 93, 1343, 1351, "addition" +433, 11, 15, 264, 94, 96, 1352, 1354, "to" +433, 11, 16, 265, 97, 101, 1355, 1359, "TTFC" +433, 11, 17, 266, 102, 103, 1360, 1361, "." +433, 12, 1, 267, 0, 2, 1362, 1364, "At" +433, 12, 2, 268, 3, 7, 1365, 1369, "week" +433, 12, 3, 269, 8, 10, 1370, 1372, "12" +433, 12, 4, 270, 11, 12, 1373, 1374, "," +433, 12, 5, 271, 13, 21, 1375, 1383, "patients" +433, 12, 6, 272, 22, 25, 1384, 1387, "had" +433, 12, 7, 273, 26, 31, 1388, 1393, "their" +433, 12, 8, 274, 32, 35, 1394, 1397, "IOP" +433, 12, 9, 275, 36, 48, 1398, 1410, "measurements" +433, 12, 10, 276, 49, 57, 1411, 1419, "repeated" +433, 12, 11, 277, 58, 59, 1420, 1421, "." +433, 13, 1, 278, 0, 7, 1422, 1429, "RESULTS" +433, 13, 2, 279, 8, 9, 1430, 1431, ":" +433, 13, 3, 280, 10, 13, 1432, 1435, "The" +433, 13, 4, 281, 14, 17, 1436, 1439, "per" +433, 13, 5, 282, 18, 26, 1440, 1448, "protocol" +433, 13, 6, 283, 27, 34, 1449, 1456, "dataset" +433, 13, 7, 284, 35, 45, 1457, 1467, "consisting" +433, 13, 8, 285, 46, 48, 1468, 1470, "of" +433, 13, 9, 286, 49, 51, 1471, 1473, "78" +433, 13, 10, 287, 52, 59, 1474, 1481, "placebo" +433, 13, 11, 288, 60, 63, 1482, 1485, "and" +433, 13, 12, 289, 64, 66, 1486, 1488, "75" +433, 13, 13, 290, 67, 79, 1489, 1501, "brinzolamide" +433, 13, 14, 291, 80, 81, 1502, 1503, "-" +433, 13, 15, 292, 82, 89, 1504, 1511, "treated" +433, 13, 16, 293, 90, 98, 1512, 1520, "patients" +433, 13, 17, 294, 99, 108, 1521, 1530, "decreased" +433, 13, 18, 295, 109, 113, 1531, 1535, "mean" +433, 13, 19, 296, 114, 121, 1536, 1543, "diurnal" +433, 13, 20, 297, 122, 125, 1544, 1547, "IOP" +433, 13, 21, 298, 126, 127, 1548, 1549, "(" +433, 13, 22, 299, 128, 130, 1550, 1552, "mm" +433, 13, 23, 300, 131, 133, 1553, 1555, "Hg" +433, 13, 24, 301, 134, 135, 1556, 1557, ")" +433, 13, 25, 302, 136, 138, 1558, 1560, "as" +433, 13, 26, 303, 139, 143, 1561, 1565, "well" +433, 13, 27, 304, 144, 146, 1566, 1568, "as" +433, 13, 28, 305, 147, 150, 1569, 1572, "IOP" +433, 13, 29, 306, 151, 153, 1573, 1575, "at" +433, 13, 30, 307, 154, 157, 1576, 1579, "all" +433, 13, 31, 308, 158, 159, 1580, 1581, "3" +433, 13, 32, 309, 160, 170, 1582, 1592, "individual" +433, 13, 33, 310, 171, 175, 1593, 1597, "time" +433, 13, 34, 311, 176, 182, 1598, 1604, "points" +433, 13, 35, 312, 183, 184, 1605, 1606, "(" +433, 13, 36, 313, 185, 186, 1607, 1608, "P" +433, 13, 37, 314, 187, 188, 1609, 1610, "≤" +433, 13, 38, 315, 189, 190, 1611, 1612, "0" +433, 13, 39, 316, 191, 192, 1613, 1614, "." +433, 13, 40, 317, 193, 196, 1615, 1618, "005" +433, 13, 41, 318, 197, 198, 1619, 1620, ")" +433, 13, 42, 319, 199, 200, 1621, 1622, "." +433, 14, 1, 320, 0, 12, 1623, 1635, "Brinzolamide" +433, 14, 2, 321, 13, 20, 1636, 1643, "reduced" +433, 14, 3, 322, 21, 24, 1644, 1647, "the" +433, 14, 4, 323, 25, 29, 1648, 1652, "mean" +433, 14, 5, 324, 30, 37, 1653, 1660, "diurnal" +433, 14, 6, 325, 38, 41, 1661, 1664, "IOP" +433, 14, 7, 326, 42, 46, 1665, 1669, "from" +433, 14, 8, 327, 47, 49, 1670, 1672, "20" +433, 14, 9, 328, 50, 51, 1673, 1674, "." +433, 14, 10, 329, 52, 53, 1675, 1676, "3" +433, 14, 11, 330, 54, 55, 1677, 1678, "±" +433, 14, 12, 331, 56, 57, 1679, 1680, "2" +433, 14, 13, 332, 58, 59, 1681, 1682, "." +433, 14, 14, 333, 60, 61, 1683, 1684, "0" +433, 14, 15, 334, 62, 64, 1685, 1687, "to" +433, 14, 16, 335, 65, 67, 1688, 1690, "17" +433, 14, 17, 336, 68, 69, 1691, 1692, "." +433, 14, 18, 337, 70, 71, 1693, 1694, "5" +433, 14, 19, 338, 72, 73, 1695, 1696, "±" +433, 14, 20, 339, 74, 75, 1697, 1698, "2" +433, 14, 21, 340, 76, 77, 1699, 1700, "." +433, 14, 22, 341, 78, 79, 1701, 1702, "6" +433, 14, 23, 342, 80, 81, 1703, 1704, "," +433, 14, 24, 343, 82, 89, 1705, 1712, "whereas" +433, 14, 25, 344, 90, 97, 1713, 1720, "placebo" +433, 14, 26, 345, 98, 105, 1721, 1728, "reduced" +433, 14, 27, 346, 106, 109, 1729, 1732, "IOP" +433, 14, 28, 347, 110, 114, 1733, 1737, "from" +433, 14, 29, 348, 115, 117, 1738, 1740, "20" +433, 14, 30, 349, 118, 119, 1741, 1742, "." +433, 14, 31, 350, 120, 121, 1743, 1744, "9" +433, 14, 32, 351, 122, 123, 1745, 1746, "±" +433, 14, 33, 352, 124, 125, 1747, 1748, "2" +433, 14, 34, 353, 126, 127, 1749, 1750, "." +433, 14, 35, 354, 128, 129, 1751, 1752, "7" +433, 14, 36, 355, 130, 132, 1753, 1755, "to" +433, 14, 37, 356, 133, 135, 1756, 1758, "19" +433, 14, 38, 357, 136, 137, 1759, 1760, "." +433, 14, 39, 358, 138, 139, 1761, 1762, "4" +433, 14, 40, 359, 140, 141, 1763, 1764, "±" +433, 14, 41, 360, 142, 143, 1765, 1766, "3" +433, 14, 42, 361, 144, 145, 1767, 1768, "." +433, 14, 43, 362, 146, 147, 1769, 1770, "8" +433, 14, 44, 363, 148, 149, 1771, 1772, "." +433, 15, 1, 364, 0, 3, 1773, 1776, "The" +433, 15, 2, 365, 4, 8, 1777, 1781, "mean" +433, 15, 3, 366, 9, 16, 1782, 1789, "diurnal" +433, 15, 4, 367, 17, 20, 1790, 1793, "IOP" +433, 15, 5, 368, 21, 24, 1794, 1797, "was" +433, 15, 6, 369, 25, 32, 1798, 1805, "reduced" +433, 15, 7, 370, 33, 37, 1806, 1810, "from" +433, 15, 8, 371, 38, 46, 1811, 1819, "baseline" +433, 15, 9, 372, 47, 50, 1820, 1823, "and" +433, 15, 10, 373, 51, 54, 1824, 1827, "for" +433, 15, 11, 374, 55, 58, 1828, 1831, "the" +433, 15, 12, 375, 59, 61, 1832, 1834, "08" +433, 15, 13, 376, 62, 63, 1835, 1836, ":" +433, 15, 14, 377, 64, 66, 1837, 1839, "00" +433, 15, 15, 378, 67, 70, 1840, 1843, "and" +433, 15, 16, 379, 71, 73, 1844, 1846, "16" +433, 15, 17, 380, 74, 75, 1847, 1848, ":" +433, 15, 18, 381, 76, 78, 1849, 1851, "00" +433, 15, 19, 382, 79, 84, 1852, 1857, "hours" +433, 15, 20, 383, 85, 89, 1858, 1862, "time" +433, 15, 21, 384, 90, 96, 1863, 1869, "points" +433, 15, 22, 385, 97, 99, 1870, 1872, "in" +433, 15, 23, 386, 100, 103, 1873, 1876, "the" +433, 15, 24, 387, 104, 116, 1877, 1889, "brinzolamide" +433, 15, 25, 388, 117, 122, 1890, 1895, "group" +433, 15, 26, 389, 123, 131, 1896, 1904, "compared" +433, 15, 27, 390, 132, 136, 1905, 1909, "with" +433, 15, 28, 391, 137, 144, 1910, 1917, "placebo" +433, 15, 29, 392, 145, 146, 1918, 1919, "(" +433, 15, 30, 393, 147, 148, 1920, 1921, "P" +433, 15, 31, 394, 149, 150, 1922, 1923, "≤" +433, 15, 32, 395, 151, 152, 1924, 1925, "0" +433, 15, 33, 396, 153, 154, 1926, 1927, "." +433, 15, 34, 397, 155, 158, 1928, 1931, "014" +433, 15, 35, 398, 159, 160, 1932, 1933, ")" +433, 15, 36, 399, 161, 162, 1934, 1935, "." +433, 16, 1, 400, 0, 5, 1936, 1941, "There" +433, 16, 2, 401, 6, 10, 1942, 1946, "were" +433, 16, 3, 402, 11, 13, 1947, 1949, "30" +433, 16, 4, 403, 14, 21, 1950, 1957, "adverse" +433, 16, 5, 404, 22, 28, 1958, 1964, "events" +433, 16, 6, 405, 29, 33, 1965, 1969, "with" +433, 16, 7, 406, 34, 41, 1970, 1977, "placebo" +433, 16, 8, 407, 42, 45, 1978, 1981, "and" +433, 16, 9, 408, 46, 48, 1982, 1984, "24" +433, 16, 10, 409, 49, 53, 1985, 1989, "with" +433, 16, 11, 410, 54, 66, 1990, 2002, "brinzolamide" +433, 16, 12, 411, 67, 68, 2003, 2004, "(" +433, 16, 13, 412, 69, 75, 2005, 2011, "intent" +433, 16, 14, 413, 76, 77, 2012, 2013, "-" +433, 16, 15, 414, 78, 80, 2014, 2016, "to" +433, 16, 16, 415, 81, 82, 2017, 2018, "-" +433, 16, 17, 416, 83, 88, 2019, 2024, "treat" +433, 16, 18, 417, 89, 90, 2025, 2026, ")" +433, 16, 19, 418, 91, 92, 2027, 2028, "." +433, 17, 1, 419, 0, 5, 2029, 2034, "There" +433, 17, 2, 420, 6, 9, 2035, 2038, "was" +433, 17, 3, 421, 10, 12, 2039, 2041, "no" +433, 17, 4, 422, 13, 24, 2042, 2053, "statistical" +433, 17, 5, 423, 25, 35, 2054, 2064, "difference" +433, 17, 6, 424, 36, 39, 2065, 2068, "for" +433, 17, 7, 425, 40, 43, 2069, 2072, "the" +433, 17, 8, 426, 44, 48, 2073, 2077, "side" +433, 17, 9, 427, 49, 50, 2078, 2079, "-" +433, 17, 10, 428, 51, 57, 2080, 2086, "effect" +433, 17, 11, 429, 58, 65, 2087, 2094, "profile" +433, 17, 12, 430, 66, 74, 2095, 2103, "observed" +433, 17, 13, 431, 75, 82, 2104, 2111, "between" +433, 17, 14, 432, 83, 86, 2112, 2115, "the" +433, 17, 15, 433, 87, 96, 2116, 2125, "treatment" +433, 17, 16, 434, 97, 103, 2126, 2132, "groups" +433, 17, 17, 435, 104, 105, 2133, 2134, "(" +433, 17, 18, 436, 106, 107, 2135, 2136, "P" +433, 17, 19, 437, 108, 109, 2137, 2138, "=" +433, 17, 20, 438, 110, 111, 2139, 2140, "0" +433, 17, 21, 439, 112, 113, 2141, 2142, "." +433, 17, 22, 440, 114, 116, 2143, 2145, "47" +433, 17, 23, 441, 117, 118, 2146, 2147, ")" +433, 17, 24, 442, 119, 120, 2148, 2149, "." +433, 18, 1, 443, 0, 11, 2150, 2161, "CONCLUSIONS" +433, 18, 2, 444, 12, 13, 2162, 2163, ":" +433, 18, 3, 445, 14, 18, 2164, 2168, "This" +433, 18, 4, 446, 19, 24, 2169, 2174, "study" +433, 18, 5, 447, 25, 33, 2175, 2183, "suggests" +433, 18, 6, 448, 34, 38, 2184, 2188, "that" +433, 18, 7, 449, 39, 51, 2189, 2201, "brinzolamide" +433, 18, 8, 450, 52, 55, 2202, 2205, "may" +433, 18, 9, 451, 56, 58, 2206, 2208, "be" +433, 18, 10, 452, 59, 65, 2209, 2215, "safely" +433, 18, 11, 453, 66, 71, 2216, 2221, "added" +433, 18, 12, 454, 72, 74, 2222, 2224, "to" +433, 18, 13, 455, 75, 79, 2225, 2229, "TTFC" +433, 18, 14, 456, 80, 87, 2230, 2237, "therapy" +433, 18, 15, 457, 88, 90, 2238, 2240, "to" +433, 18, 16, 458, 91, 98, 2241, 2248, "provide" +433, 18, 17, 459, 99, 106, 2249, 2256, "further" +433, 18, 18, 460, 107, 118, 2257, 2268, "significant" +433, 18, 19, 461, 119, 128, 2269, 2278, "reduction" +433, 18, 20, 462, 129, 131, 2279, 2281, "in" +433, 18, 21, 463, 132, 135, 2282, 2285, "IOP" +433, 18, 22, 464, 136, 144, 2286, 2294, "patients" +433, 18, 23, 465, 145, 149, 2295, 2299, "with" +433, 18, 24, 466, 150, 156, 2300, 2306, "ocular" +433, 18, 25, 467, 157, 169, 2307, 2319, "hypertensive" +433, 18, 26, 468, 170, 172, 2320, 2322, "or" +433, 18, 27, 469, 173, 180, 2323, 2330, "primary" +433, 18, 28, 470, 181, 185, 2331, 2335, "open" +433, 18, 29, 471, 186, 187, 2336, 2337, "-" +433, 18, 30, 472, 188, 193, 2338, 2343, "angle" +433, 18, 31, 473, 194, 202, 2344, 2352, "glaucoma" +433, 18, 32, 474, 203, 204, 2353, 2354, "." +433, 19, 1, 475, 0, 3, 2355, 2358, "DOI" +433, 19, 2, 476, 4, 5, 2359, 2360, ":" +433, 19, 3, 477, 6, 8, 2361, 2363, "10" +433, 19, 4, 478, 9, 10, 2364, 2365, "." +433, 19, 5, 479, 11, 15, 2366, 2370, "1097" +433, 19, 6, 480, 16, 17, 2371, 2372, "/" +433, 19, 7, 481, 18, 21, 2373, 2376, "IJG" +433, 19, 8, 482, 22, 23, 2377, 2378, "." +433, 19, 9, 483, 24, 40, 2379, 2395, "0b013e3181fc8142" +433, 19, 10, 484, 41, 45, 2396, 2400, "PMID" +433, 19, 11, 485, 46, 47, 2401, 2402, ":" +433, 19, 12, 486, 48, 56, 2403, 2411, "21048504" +433, 19, 13, 487, 57, 58, 2412, 2413, "[" +433, 19, 14, 488, 59, 66, 2414, 2421, "Indexed" +433, 19, 15, 489, 67, 70, 2422, 2425, "for" +433, 19, 16, 490, 71, 78, 2426, 2433, "MEDLINE" +433, 19, 17, 491, 79, 80, 2434, 2435, "]" diff --git a/data/gl 21048504_jshahinitiran.annodb b/data/gl 21048504_jshahinitiran.annodb new file mode 100644 index 0000000..52ce5ab --- /dev/null +++ b/data/gl 21048504_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15800, Journal, 0, 10, "J Glaucoma", "", +15801, PublicationYear, 13, 17, "2012", "", +15802, Title, 87, 218, "Intraocular pressure - lowering efficacy of brinzolamide when added to travoprost / timolol fixed combination as adjunctive therapy", "", +15805, IOP, 87, 107, "Intraocular pressure", "", +15806, Brinzolamide, 131, 143, "brinzolamide", "", +15807, Drug, 158, 168, "travoprost", "Travoprost", +15810, Drug, 158, 196, "travoprost / timolol fixed combination", "TTFC", +15809, Timolol, 171, 178, "timolol", "", +15811, Author, 221, 231, "Goldberg I", "", +15813, Author, 240, 251, "Crowston JG", "", +15814, Author, 254, 262, "Jasek MC", "", +15815, Author, 265, 275, "Stewart JA", "", +15816, Author, 278, 288, "Stewart WC", "", +15881, Australia, 624, 633, "Australia", "", +15818, ObjectiveDescription, 646, 789, "To compare the efficacy of brinzolamide versus placebo when added to travoprost / timolol fixed combination ( TTFC ) in uncontrolled patients .", "", +15806, Brinzolamide, 673, 685, "brinzolamide", "", +15820, Placebo, 693, 700, "placebo", "", +15807, Drug, 715, 725, "travoprost", "Travoprost", +15810, Drug, 715, 753, "travoprost / timolol fixed combination", "TTFC", +15809, Timolol, 728, 735, "timolol", "", +15810, Drug, 756, 760, "TTFC", "TTFC", +15825, CTDesign, 824, 835, "prospective", "", +15826, DoubleBlind, 838, 853, "double - masked", "", +15827, Randomized, 856, 866, "randomized", "", +15882, Placebo, 869, 876, "placebo", "", +15828, CTDesign, 869, 889, "placebo - controlled", "", +15829, Parallel, 892, 900, "parallel", "", +15830, OcularHypertension, 915, 934, "ocular hypertensive", "", +15831, OpenAngleGlaucoma, 938, 967, "primary open - angle glaucoma", "", +15810, Drug, 1068, 1072, "TTFC", "TTFC", +15832, Morning, 1073, 1076, "qam", "", +15833, Frequency, 1073, 1076, "qam", "", +15835, Duration, 1102, 1109, "4 weeks", "", +15836, IOP, 1129, 1149, "intraocular pressure", "", +15837, IOP, 1152, 1155, "IOP", "", +15838, mmHg, 1170, 1175, "mm Hg", "", +15839, Randomized, 1277, 1287, "randomized", "", +15841, Placebo, 1298, 1305, "placebo", "", +15842, Brinzolamide, 1309, 1321, "brinzolamide", "", +15843, Frequency, 1328, 1339, "twice daily", "", +15810, Drug, 1355, 1359, "TTFC", "TTFC", +15845, IOP, 1394, 1397, "IOP", "", +15846, PerProtocol, 1436, 1448, "per protocol", "", +15847, NumberPatientsArm, 1471, 1473, "78", "", +15849, Placebo, 1474, 1481, "placebo", "", +15848, NumberPatientsArm, 1486, 1488, "75", "", +15850, Brinzolamide, 1489, 1501, "brinzolamide", "", +15851, Mean, 1531, 1535, "mean", "", +15852, Diurnal_IOP, 1536, 1547, "diurnal IOP", "", +15853, mmHg, 1550, 1555, "mm Hg", "", +15854, IOP, 1569, 1572, "IOP", "", +15855, PValueChangeValue, 1607, 1618, "P ≤ 0 . 005", "", +15856, Brinzolamide, 1623, 1635, "Brinzolamide", "", +15857, Mean, 1648, 1652, "mean", "", +15858, Diurnal_IOP, 1653, 1664, "diurnal IOP", "", +15859, BaseLineValue, 1670, 1676, "20 . 3", "", +15860, SdErrorBL, 1679, 1684, "2 . 0", "", +15861, ResultMeasuredValue, 1688, 1694, "17 . 5", "", +15862, SdErrorResValue, 1697, 1702, "2 . 6", "", +15864, Placebo, 1713, 1720, "placebo", "", +15863, IOP, 1729, 1732, "IOP", "", +15865, BaseLineValue, 1738, 1744, "20 . 9", "", +15866, SdErrorBL, 1747, 1752, "2 . 7", "", +15867, ResultMeasuredValue, 1756, 1762, "19 . 4", "", +15868, SdErrorResValue, 1765, 1770, "3 . 8", "", +15869, Mean, 1777, 1781, "mean", "", +15870, Diurnal_IOP, 1782, 1793, "diurnal IOP", "", +15871, Brinzolamide, 1877, 1889, "brinzolamide", "", +15872, Placebo, 1910, 1917, "placebo", "", +15873, PValueChangeValue, 1920, 1931, "P ≤ 0 . 014", "", +15883, Placebo, 1970, 1977, "placebo", "", +15884, Brinzolamide, 1990, 2002, "brinzolamide", "", +15874, IntentionToTreat, 2005, 2024, "intent - to - treat", "", +15875, PvalueDiff, 2135, 2145, "P = 0 . 47", "", +15803, ConclusionComment, 2164, 2354, "This study suggests that brinzolamide may be safely added to TTFC therapy to provide further significant reduction in IOP patients with ocular hypertensive or primary open - angle glaucoma .", "", +15876, Brinzolamide, 2189, 2201, "brinzolamide", "", +15810, Drug, 2225, 2229, "TTFC", "TTFC", +15878, IOP, 2282, 2285, "IOP", "", +15879, OcularHypertension, 2300, 2319, "ocular hypertensive", "", +15880, OpenAngleGlaucoma, 2323, 2354, "primary open - angle glaucoma .", "", +15804, PMID, 2403, 2411, "21048504", "", diff --git a/data/gl 21048504_jshahinitiran.n-triples b/data/gl 21048504_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21048504_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21048504_tstrakeljahn.annodb b/data/gl 21048504_tstrakeljahn.annodb new file mode 100644 index 0000000..638f5e1 --- /dev/null +++ b/data/gl 21048504_tstrakeljahn.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +13217, Journal, 0, 10, "J Glaucoma", "", +13218, PublicationYear, 13, 17, "2012", "", +13219, IOP, 87, 107, "Intraocular pressure", "", +13224, Title, 87, 220, "Intraocular pressure - lowering efficacy of brinzolamide when added to travoprost / timolol fixed combination as adjunctive therapy .", "", +13220, Brinzolamide, 131, 143, "brinzolamide", "", +29890, Drug, 158, 168, "travoprost", "Travoprost", +13223, Timolol, 171, 178, "timolol", "", +13225, Author, 221, 231, "Goldberg I", "", +13226, Author, 240, 251, "Crowston JG", "", +13227, Author, 254, 262, "Jasek MC", "", +13228, Author, 265, 275, "Stewart JA", "", +13229, Author, 278, 288, "Stewart WC", "", +13230, Australia, 624, 633, "Australia", "", +13290, ObjectiveDescription, 646, 787, "To compare the efficacy of brinzolamide versus placebo when added to travoprost / timolol fixed combination ( TTFC ) in uncontrolled patients", "", +13231, Brinzolamide, 673, 685, "brinzolamide", "", +13232, Placebo, 693, 700, "placebo", "", +29891, Drug, 715, 725, "travoprost", "Travoprost", +13233, Timolol, 728, 735, "timolol", "", +29893, Drug, 756, 760, "TTFC", "Travoprost Timolol Fixed Combination", +13235, DoubleBlind, 838, 853, "double - masked", "", +13236, Randomized, 856, 866, "randomized", "", +13237, Placebo, 869, 876, "placebo", "", +13238, Parallel, 892, 900, "parallel", "", +13239, OcularHypertension, 915, 934, "ocular hypertensive", "", +13240, OpenAngleGlaucoma, 946, 967, "open - angle glaucoma", "", +29894, Drug, 1068, 1072, "TTFC", "Travoprost Timolol Fixed Combination", +13242, Frequency, 1079, 1095, "every day dosing", "", +13243, Duration, 1102, 1109, "4 weeks", "", +13244, IOP, 1129, 1149, "intraocular pressure", "", +13245, IOP, 1152, 1155, "IOP", "", +13246, mmHg, 1170, 1175, "mm Hg", "", +13247, Randomized, 1277, 1287, "randomized", "", +13248, Placebo, 1298, 1305, "placebo", "", +13249, Brinzolamide, 1309, 1321, "brinzolamide", "", +13250, Frequency, 1328, 1339, "twice daily", "", +29895, Drug, 1355, 1359, "TTFC", "Travoprost Timolol Fixed Combination", +13252, IOP, 1394, 1397, "IOP", "", +29892, PerProtocol, 1436, 1448, "per protocol", "", +13254, FinalNumPatientsArm, 1471, 1473, "78", "", +13256, Placebo, 1474, 1481, "placebo", "", +13255, FinalNumPatientsArm, 1486, 1488, "75", "", +13257, Brinzolamide, 1489, 1501, "brinzolamide", "", +13258, Mean, 1531, 1535, "mean", "", +13259, Diurnal_IOP, 1536, 1547, "diurnal IOP", "", +13260, mmHg, 1550, 1555, "mm Hg", "", +13261, IOP, 1569, 1572, "IOP", "", +13262, PvalueDiff, 1607, 1618, "P ≤ 0 . 005", "", +13263, Brinzolamide, 1623, 1635, "Brinzolamide", "", +13264, Mean, 1648, 1652, "mean", "", +13265, Diurnal_IOP, 1653, 1664, "diurnal IOP", "", +13266, BaseLineValue, 1670, 1676, "20 . 3", "", +13267, SdDevBL, 1679, 1684, "2 . 0", "", +13268, ResultMeasuredValue, 1688, 1694, "17 . 5", "", +13269, SdDevResValue, 1697, 1702, "2 . 6", "", +13271, Placebo, 1713, 1720, "placebo", "", +13272, IOP, 1729, 1732, "IOP", "", +13273, BaseLineValue, 1738, 1744, "20 . 9", "", +13274, SdDevBL, 1747, 1752, "2 . 7", "", +13275, ResultMeasuredValue, 1756, 1762, "19 . 4", "", +13276, SdDevResValue, 1765, 1770, "3 . 8", "", +13277, Mean, 1777, 1781, "mean", "", +13278, Diurnal_IOP, 1782, 1793, "diurnal IOP", "", +13280, TimePoint, 1832, 1839, "08 : 00", "", +13281, TimePoint, 1844, 1851, "16 : 00", "", +13279, Brinzolamide, 1877, 1889, "brinzolamide", "", +13282, Placebo, 1910, 1917, "placebo", "", +13283, PvalueDiff, 1920, 1931, "P ≤ 0 . 014", "", +13289, ObservedResult, 1936, 2024, "There were 30 adverse events with placebo and 24 with brinzolamide ( intent - to - treat", "", +13284, NumberAffected, 1947, 1949, "30", "", +13285, Placebo, 1970, 1977, "placebo", "", +13286, NumberAffected, 1982, 1984, "24", "", +13287, Brinzolamide, 1990, 2002, "brinzolamide", "", +13288, IntentionToTreat, 2005, 2024, "intent - to - treat", "", +13292, ObservedResult, 2029, 2149, "There was no statistical difference for the side - effect profile observed between the treatment groups ( P = 0 . 47 ) .", "", +13291, PvalueDiff, 2133, 2145, "( P = 0 . 47", "", +13299, ConclusionComment, 2164, 2354, "This study suggests that brinzolamide may be safely added to TTFC therapy to provide further significant reduction in IOP patients with ocular hypertensive or primary open - angle glaucoma .", "", +13293, Brinzolamide, 2189, 2201, "brinzolamide", "", +29896, Drug, 2225, 2229, "TTFC", "Travoprost Timolol Fixed Combination", +13295, IOP, 2282, 2285, "IOP", "", +13296, OcularHypertension, 2300, 2319, "ocular hypertensive", "", +13297, OpenAngleGlaucoma, 2331, 2352, "open - angle glaucoma", "", +13298, PMID, 2403, 2411, "21048504", "", diff --git a/data/gl 21048504_tstrakeljahn.n-triples b/data/gl 21048504_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21048504_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21257146_admin.annodb b/data/gl 21257146_admin.annodb new file mode 100644 index 0000000..95735c7 --- /dev/null +++ b/data/gl 21257146_admin.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Am J Ophthalmol", "", " \"Am J Ophthalmol\"." +1, PublicationYear, 18, 22, "2011", "", " \"2011\"." +6, Title, 117, 254, "A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low - Pressure Glaucoma Treatment Study", "", " \"A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low - Pressure Glaucoma Treatment Study\"." +2, Randomized, 119, 129, "randomized", "", +3, Brimonidine, 139, 150, "brimonidine", "", " ." +4, Timolol, 158, 165, "timolol", "", " ." +37006, NormalTensionGlaucoma, 215, 238, "Low - Pressure Glaucoma", "", " ." +7, Author, 257, 265, "Krupin T", "", " \"Krupin T\"." +8, Author, 274, 285, "Liebmann JM", "", " \"Liebmann JM\"." +9, Author, 288, 301, "Greenfield DS", "", " \"Greenfield DS\"." +10, Author, 304, 311, "Ritch R", "", " \"Ritch R\"." +11, Author, 314, 324, "Gardiner S", "", " \"Gardiner S\"." +37007, NormalTensionGlaucoma, 327, 350, "Low - Pressure Glaucoma", "", +12, USA, 846, 849, "USA", "", " ." +84, ObjectiveDescription, 1151, 1341, "To compare the alpha2 - adrenergic agonist brimonidine tartrate 0 . 2 % to the beta - adrenergic antagonist timolol maleate 0 . 5 % in preserving visual function in low - pressure glaucoma .", "", " \"To compare the alpha2 - adrenergic agonist brimonidine tartrate 0 . 2 % to the beta - adrenergic antagonist timolol maleate 0 . 5 % in preserving visual function in low - pressure glaucoma .\"." +13, Brimonidine, 1194, 1214, "brimonidine tartrate", "", +16, DoseValue, 1215, 1220, "0 . 2", "", " \"0 . 2\"." +18, Percentage, 1221, 1222, "%", "", +14, Timolol, 1259, 1274, "timolol maleate", "", +17, DoseValue, 1275, 1280, "0 . 5", "", " \"0 . 5\"." +19, Percentage, 1281, 1282, "%", "", +37005, NormalTensionGlaucoma, 1316, 1339, "low - pressure glaucoma", "", +20, Randomized, 1351, 1361, "Randomized", "", " ." +21, DoubleBlind, 1364, 1379, "double - masked", "", " ." +22, Multicenter, 1382, 1393, "multicenter", "", " ." +24, IOP, 1459, 1479, "intraocular pressure", "", +25, IOP, 1482, 1485, "IOP", "", +26, mmHg, 1493, 1498, "mm Hg", "", " ." +27, Frequency, 1619, 1632, "twice - daily", "", " \"twice - daily\". \"twice - daily\"." +28, Randomized, 1645, 1655, "randomized", "", +29, Brimonidine, 1675, 1686, "brimonidine", "", +30, Timolol, 1692, 1699, "timolol", "", +111, EndPointDescription, 1812, 1829, "field progression", "", " . ." +31, Glaucoma, 2053, 2061, "glaucoma", "", " . ." +32, NumberPatientsArm, 2188, 2201, "Ninety - nine", "", " \"Ninety - nine\"." +34, Randomized, 2216, 2226, "randomized", "", +35, Brimonidine, 2230, 2241, "brimonidine", "", +33, NumberPatientsArm, 2246, 2248, "79", "", " \"79\"." +36, Timolol, 2252, 2259, "timolol", "", +37, Mean, 2262, 2266, "Mean", "", +38, Brimonidine, 2352, 2363, "brimonidine", "", +105, NumberAffected, 2385, 2386, "9", "", " \"9\"." +40, PercentageAffected, 2389, 2394, "9 . 1", "", " \"9 . 1\"." +111, EndPointDescription, 2403, 2427, "visual field progression", "", " . ." +43, Timolol, 2464, 2471, "timolol", "", +108, NumberAffected, 2493, 2495, "31", "", " \"31\"." +42, PercentageAffected, 2498, 2504, "39 . 2", "", " \"39 . 2\"." +44, PvalueDiff, 2529, 2538, "P = . 001", "", " \"P = . 001\"." +106251, ObservedResult, 2543, 2639, "Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points", "", " \"Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points\". \"Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points\"." +45, Mean, 2543, 2547, "Mean", "", " . ." +46, IOP, 2556, 2559, "IOP", "", " . ." +47, Brimonidine, 2576, 2587, "brimonidine", "", +48, Timolol, 2594, 2601, "timolol", "", +50, Brimonidine, 2647, 2658, "brimonidine", "", +118, NumPatientsLeftArm, 2671, 2673, "28", "", " \"28\"." +58, RelNumPatientsLeftArm, 2676, 2682, "28 . 3", "", " \"28 . 3\"." +55, Timolol, 2692, 2699, "timolol", "", +119, NumPatientsLeftArm, 2712, 2713, "9", "", " \"9\"." +60, RelNumPatientsLeftArm, 2716, 2722, "11 . 4", "", " \"11 . 4\"." +56, PvalueDiff, 2812, 2821, "P = . 008", "", +37009, NormalTensionGlaucoma, 2940, 2963, "Low - pressure glaucoma", "", +120, ConclusionComment, 2940, 3126, "Low - pressure glaucoma patients treated with brimonidine 0 . 2 % who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0 . 5 % .", "", " \"Low - pressure glaucoma patients treated with brimonidine 0 . 2 % who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0 . 5 % .\"." +63, Brimonidine, 2986, 2997, "brimonidine", "", +65, DoseValue, 2998, 3003, "0 . 2", "", +67, Percentage, 3004, 3005, "%", "", +105207, Ocular_Allergy, 3025, 3039, "ocular allergy", "", " ." +111, EndPointDescription, 3064, 3081, "field progression", "", " . ." +64, Timolol, 3109, 3116, "timolol", "", +66, DoseValue, 3117, 3122, "0 . 5", "", +68, Percentage, 3123, 3124, "%", "", +69, PMID, 3232, 3240, "21257146", "", " \"21257146\"." diff --git a/data/gl 21257146_admin.n-triples b/data/gl 21257146_admin.n-triples new file mode 100644 index 0000000..03d9476 --- /dev/null +++ b/data/gl 21257146_admin.n-triples @@ -0,0 +1,129 @@ +# RDF export of group: Publication + . + "Publication 43073" . + "A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low - Pressure Glaucoma Treatment Study" . + "Krupin T" . + "2011" . + "Am J Ophthalmol" . + "21257146" . + . + "Liebmann JM" . + "Greenfield DS" . + "Ritch R" . + "Gardiner S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 43084" . + "To compare the alpha2 - adrenergic agonist brimonidine tartrate 0 . 2 % to the beta - adrenergic antagonist timolol maleate 0 . 5 % in preserving visual function in low - pressure glaucoma ." . + . + . + . + "Low - pressure glaucoma patients treated with brimonidine 0 . 2 % who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0 . 5 % ." . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 43102" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 43110 IOP" . + . + . + . + . + . + . + . + "Endpoint 43116 visual field progression" . + . + . + . + . + . + . + "Endpoint 43126 ocular allergy" . + . + . + . + . +# RDF export of group: Arm + . + "Arm 43131 Brimonidine" . + "Ninety - nine" . + . + . + . + "28" . + "28 . 3" . + . + . + "Arm 43140 Timolol" . + . + . + . + "9" . + "11 . 4" . + "79" . + . +# RDF export of group: Intervention + . + "Intervention 43150 Brimonidine" . + . + "twice - daily" . + . + . + "Intervention 43156 Timolol" . + . + "twice - daily" . + . +# RDF export of group: Medication + . + "Medication 43162 Brimonidine" . + . + "0 . 2" . + . + . + . + "Medication 43169 Timolol" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome 43176 visual field progression brimonidine" . + . + "9" . + "9 . 1" . + . + "Outcome 43203 visual field progression timolol" . + . + "31" . + "39 . 2" . + . + "Outcome 43242 IOP brimonidine" . + . + "Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points" . + . + "Outcome 43269 IOP timolol" . + . + "Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 43230 visual field progression" . + "P = . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21257146_export.csv b/data/gl 21257146_export.csv new file mode 100644 index 0000000..dd5d73a --- /dev/null +++ b/data/gl 21257146_export.csv @@ -0,0 +1,685 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +431, 1, 1, 1, 0, 2, 0, 2, "Am" +431, 1, 2, 2, 3, 4, 3, 4, "J" +431, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +431, 1, 4, 4, 16, 17, 16, 17, "." +431, 2, 1, 5, 0, 4, 18, 22, "2011" +431, 2, 2, 6, 5, 8, 23, 26, "Apr" +431, 2, 3, 7, 9, 10, 27, 28, ";" +431, 2, 4, 8, 11, 14, 29, 32, "151" +431, 2, 5, 9, 15, 16, 33, 34, "(" +431, 2, 6, 10, 17, 18, 35, 36, "4" +431, 2, 7, 11, 19, 20, 37, 38, ")" +431, 2, 8, 12, 21, 22, 39, 40, ":" +431, 2, 9, 13, 23, 26, 41, 44, "671" +431, 2, 10, 14, 27, 28, 45, 46, "-" +431, 2, 11, 15, 29, 31, 47, 49, "81" +431, 2, 12, 16, 32, 33, 50, 51, "." +431, 2, 13, 17, 34, 37, 52, 55, "doi" +431, 2, 14, 18, 38, 39, 56, 57, ":" +431, 2, 15, 19, 40, 42, 58, 60, "10" +431, 2, 16, 20, 43, 44, 61, 62, "." +431, 2, 17, 21, 45, 49, 63, 67, "1016" +431, 2, 18, 22, 50, 51, 68, 69, "/" +431, 2, 19, 23, 52, 53, 70, 71, "j" +431, 2, 20, 24, 54, 55, 72, 73, "." +431, 2, 21, 25, 56, 59, 74, 77, "ajo" +431, 2, 22, 26, 60, 61, 78, 79, "." +431, 2, 23, 27, 62, 66, 80, 84, "2010" +431, 2, 24, 28, 67, 68, 85, 86, "." +431, 2, 25, 29, 69, 71, 87, 89, "09" +431, 2, 26, 30, 72, 73, 90, 91, "." +431, 2, 27, 31, 74, 77, 92, 95, "026" +431, 2, 28, 32, 78, 79, 96, 97, "." +431, 3, 1, 33, 0, 4, 98, 102, "Epub" +431, 3, 2, 34, 5, 9, 103, 107, "2011" +431, 3, 3, 35, 10, 13, 108, 111, "Jan" +431, 3, 4, 36, 14, 16, 112, 114, "22" +431, 3, 5, 37, 17, 18, 115, 116, "." +431, 4, 1, 38, 0, 1, 117, 118, "A" +431, 4, 2, 39, 2, 12, 119, 129, "randomized" +431, 4, 3, 40, 13, 18, 130, 135, "trial" +431, 4, 4, 41, 19, 21, 136, 138, "of" +431, 4, 5, 42, 22, 33, 139, 150, "brimonidine" +431, 4, 6, 43, 34, 40, 151, 157, "versus" +431, 4, 7, 44, 41, 48, 158, 165, "timolol" +431, 4, 8, 45, 49, 51, 166, 168, "in" +431, 4, 9, 46, 52, 62, 169, 179, "preserving" +431, 4, 10, 47, 63, 69, 180, 186, "visual" +431, 4, 11, 48, 70, 78, 187, 195, "function" +431, 4, 12, 49, 79, 80, 196, 197, ":" +431, 4, 13, 50, 81, 88, 198, 205, "results" +431, 4, 14, 51, 89, 93, 206, 210, "from" +431, 4, 15, 52, 94, 97, 211, 214, "the" +431, 4, 16, 53, 98, 101, 215, 218, "Low" +431, 4, 17, 54, 102, 103, 219, 220, "-" +431, 4, 18, 55, 104, 112, 221, 229, "Pressure" +431, 4, 19, 56, 113, 121, 230, 238, "Glaucoma" +431, 4, 20, 57, 122, 131, 239, 248, "Treatment" +431, 4, 21, 58, 132, 137, 249, 254, "Study" +431, 4, 22, 59, 138, 139, 255, 256, "." +431, 5, 1, 60, 0, 6, 257, 263, "Krupin" +431, 5, 2, 61, 7, 8, 264, 265, "T" +431, 5, 3, 62, 9, 10, 266, 267, "(" +431, 5, 4, 63, 11, 12, 268, 269, "1" +431, 5, 5, 64, 13, 14, 270, 271, ")" +431, 5, 6, 65, 15, 16, 272, 273, "," +431, 5, 7, 66, 17, 25, 274, 282, "Liebmann" +431, 5, 8, 67, 26, 28, 283, 285, "JM" +431, 5, 9, 68, 29, 30, 286, 287, "," +431, 5, 10, 69, 31, 41, 288, 298, "Greenfield" +431, 5, 11, 70, 42, 44, 299, 301, "DS" +431, 5, 12, 71, 45, 46, 302, 303, "," +431, 5, 13, 72, 47, 52, 304, 309, "Ritch" +431, 5, 14, 73, 53, 54, 310, 311, "R" +431, 5, 15, 74, 55, 56, 312, 313, "," +431, 5, 16, 75, 57, 65, 314, 322, "Gardiner" +431, 5, 17, 76, 66, 67, 323, 324, "S" +431, 5, 18, 77, 68, 69, 325, 326, ";" +431, 5, 19, 78, 70, 73, 327, 330, "Low" +431, 5, 20, 79, 74, 75, 331, 332, "-" +431, 5, 21, 80, 76, 84, 333, 341, "Pressure" +431, 5, 22, 81, 85, 93, 342, 350, "Glaucoma" +431, 5, 23, 82, 94, 99, 351, 356, "Study" +431, 5, 24, 83, 100, 105, 357, 362, "Group" +431, 5, 25, 84, 106, 107, 363, 364, "." +431, 6, 1, 85, 0, 13, 365, 378, "Collaborators" +431, 6, 2, 86, 14, 15, 379, 380, ":" +431, 6, 3, 87, 16, 22, 381, 387, "Krupin" +431, 6, 4, 88, 23, 24, 388, 389, "T" +431, 6, 5, 89, 25, 26, 390, 391, "," +431, 6, 6, 90, 27, 36, 392, 401, "Rosenberg" +431, 6, 7, 91, 37, 39, 402, 404, "LF" +431, 6, 8, 92, 40, 41, 405, 406, "," +431, 6, 9, 93, 42, 50, 407, 415, "Ruderman" +431, 6, 10, 94, 51, 53, 416, 418, "JM" +431, 6, 11, 95, 54, 55, 419, 420, "," +431, 6, 12, 96, 56, 60, 421, 425, "Yang" +431, 6, 13, 97, 61, 63, 426, 428, "JW" +431, 6, 14, 98, 64, 65, 429, 430, "," +431, 6, 15, 99, 66, 71, 431, 436, "Tello" +431, 6, 16, 100, 72, 73, 437, 438, "C" +431, 6, 17, 101, 74, 75, 439, 440, "," +431, 6, 18, 102, 76, 84, 441, 449, "Liebmann" +431, 6, 19, 103, 85, 87, 450, 452, "JM" +431, 6, 20, 104, 88, 89, 453, 454, "," +431, 6, 21, 105, 90, 95, 455, 460, "Ritch" +431, 6, 22, 106, 96, 97, 461, 462, "R" +431, 6, 23, 107, 98, 99, 463, 464, "," +431, 6, 24, 108, 100, 105, 465, 470, "Myers" +431, 6, 25, 109, 106, 108, 471, 473, "JS" +431, 6, 26, 110, 109, 110, 474, 475, "," +431, 6, 27, 111, 111, 115, 476, 480, "Katz" +431, 6, 28, 112, 116, 118, 481, 483, "LJ" +431, 6, 29, 113, 119, 120, 484, 485, "," +431, 6, 30, 114, 121, 127, 486, 492, "Spaeth" +431, 6, 31, 115, 128, 130, 493, 495, "GL" +431, 6, 32, 116, 131, 132, 496, 497, "," +431, 6, 33, 117, 133, 139, 498, 504, "Wilson" +431, 6, 34, 118, 140, 142, 505, 507, "RP" +431, 6, 35, 119, 143, 144, 508, 509, "," +431, 6, 36, 120, 145, 151, 510, 516, "Moster" +431, 6, 37, 121, 152, 154, 517, 519, "MR" +431, 6, 38, 122, 155, 156, 520, 521, "," +431, 6, 39, 123, 157, 163, 522, 528, "Cantor" +431, 6, 40, 124, 164, 166, 529, 531, "LB" +431, 6, 41, 125, 167, 168, 532, 533, "," +431, 6, 42, 126, 169, 174, 534, 539, "Gross" +431, 6, 43, 127, 175, 177, 540, 542, "RL" +431, 6, 44, 128, 178, 179, 543, 544, "," +431, 6, 45, 129, 180, 185, 545, 550, "Dirks" +431, 6, 46, 130, 186, 188, 551, 553, "MS" +431, 6, 47, 131, 189, 190, 554, 555, "," +431, 6, 48, 132, 191, 197, 556, 562, "Grimes" +431, 6, 49, 133, 198, 200, 563, 565, "SR" +431, 6, 50, 134, 201, 202, 566, 567, "," +431, 6, 51, 135, 203, 213, 568, 578, "Greenfield" +431, 6, 52, 136, 214, 216, 579, 581, "DS" +431, 6, 53, 137, 217, 218, 582, 583, "," +431, 6, 54, 138, 219, 224, 584, 589, "Bagga" +431, 6, 55, 139, 225, 226, 590, 591, "H" +431, 6, 56, 140, 227, 228, 592, 593, "," +431, 6, 57, 141, 229, 237, 594, 602, "Sherwood" +431, 6, 58, 142, 238, 240, 603, 605, "MB" +431, 6, 59, 143, 241, 242, 606, 607, "," +431, 6, 60, 144, 243, 248, 608, 613, "Feitl" +431, 6, 61, 145, 249, 251, 614, 616, "ME" +431, 6, 62, 146, 252, 253, 617, 618, "," +431, 6, 63, 147, 254, 259, 619, 624, "Henry" +431, 6, 64, 148, 260, 262, 625, 627, "JC" +431, 6, 65, 149, 263, 264, 628, 629, "," +431, 6, 66, 150, 265, 271, 630, 636, "Gieser" +431, 6, 67, 151, 272, 274, 637, 639, "DK" +431, 6, 68, 152, 275, 276, 640, 641, "," +431, 6, 69, 153, 277, 282, 642, 647, "Piltz" +431, 6, 70, 154, 283, 284, 648, 649, "-" +431, 6, 71, 155, 285, 292, 650, 657, "Seymour" +431, 6, 72, 156, 293, 295, 658, 660, "JR" +431, 6, 73, 157, 296, 297, 661, 662, "." +431, 7, 1, 158, 0, 6, 663, 669, "Author" +431, 7, 2, 159, 7, 18, 670, 681, "information" +431, 7, 3, 160, 19, 20, 682, 683, ":" +431, 7, 4, 161, 21, 22, 684, 685, "(" +431, 7, 5, 162, 23, 24, 686, 687, "1" +431, 7, 6, 163, 25, 26, 688, 689, ")" +431, 7, 7, 164, 27, 37, 690, 700, "Department" +431, 7, 8, 165, 38, 40, 701, 703, "of" +431, 7, 9, 166, 41, 54, 704, 717, "Ophthalmology" +431, 7, 10, 167, 55, 56, 718, 719, "," +431, 7, 11, 168, 57, 65, 720, 728, "Feinberg" +431, 7, 12, 169, 66, 72, 729, 735, "School" +431, 7, 13, 170, 73, 75, 736, 738, "of" +431, 7, 14, 171, 76, 84, 739, 747, "Medicine" +431, 7, 15, 172, 85, 86, 748, 749, "," +431, 7, 16, 173, 87, 99, 750, 762, "Northwestern" +431, 7, 17, 174, 100, 110, 763, 773, "University" +431, 7, 18, 175, 111, 114, 774, 777, "and" +431, 7, 19, 176, 115, 118, 778, 781, "the" +431, 7, 20, 177, 119, 126, 782, 789, "Chicago" +431, 7, 21, 178, 127, 133, 790, 796, "Center" +431, 7, 22, 179, 134, 137, 797, 800, "for" +431, 7, 23, 180, 138, 144, 801, 807, "Vision" +431, 7, 24, 181, 145, 153, 808, 816, "Research" +431, 7, 25, 182, 154, 155, 817, 818, "," +431, 7, 26, 183, 156, 163, 819, 826, "Chicago" +431, 7, 27, 184, 164, 165, 827, 828, "," +431, 7, 28, 185, 166, 174, 829, 837, "Illinois" +431, 7, 29, 186, 175, 180, 838, 843, "60611" +431, 7, 30, 187, 181, 182, 844, 845, "," +431, 7, 31, 188, 183, 186, 846, 849, "USA" +431, 7, 32, 189, 187, 188, 850, 851, "." +431, 8, 1, 190, 0, 6, 852, 858, "krupin" +431, 8, 2, 191, 7, 8, 859, 860, "@" +431, 8, 3, 192, 9, 21, 861, 873, "northwestern" +431, 8, 4, 193, 22, 23, 874, 875, "." +431, 8, 5, 194, 24, 27, 876, 879, "edu" +431, 8, 6, 195, 28, 35, 880, 887, "Erratum" +431, 8, 7, 196, 36, 38, 888, 890, "in" +431, 8, 8, 197, 39, 41, 891, 893, "Am" +431, 8, 9, 198, 42, 43, 894, 895, "J" +431, 8, 10, 199, 44, 54, 896, 906, "Ophthalmol" +431, 8, 11, 200, 55, 56, 907, 908, "." +431, 9, 1, 201, 0, 4, 909, 913, "2011" +431, 9, 2, 202, 5, 8, 914, 917, "Jun" +431, 9, 3, 203, 9, 10, 918, 919, ";" +431, 9, 4, 204, 11, 14, 920, 923, "151" +431, 9, 5, 205, 15, 16, 924, 925, "(" +431, 9, 6, 206, 17, 18, 926, 927, "6" +431, 9, 7, 207, 19, 20, 928, 929, ")" +431, 9, 8, 208, 21, 22, 930, 931, ":" +431, 9, 9, 209, 23, 27, 932, 936, "1108" +431, 9, 10, 210, 28, 29, 937, 938, "." +431, 10, 1, 211, 0, 7, 939, 946, "Comment" +431, 10, 2, 212, 8, 10, 947, 949, "in" +431, 10, 3, 213, 11, 13, 950, 952, "Am" +431, 10, 4, 214, 14, 15, 953, 954, "J" +431, 10, 5, 215, 16, 26, 955, 965, "Ophthalmol" +431, 10, 6, 216, 27, 28, 966, 967, "." +431, 11, 1, 217, 0, 4, 968, 972, "2011" +431, 11, 2, 218, 5, 8, 973, 976, "Nov" +431, 11, 3, 219, 9, 10, 977, 978, ";" +431, 11, 4, 220, 11, 14, 979, 982, "152" +431, 11, 5, 221, 15, 16, 983, 984, "(" +431, 11, 6, 222, 17, 18, 985, 986, "5" +431, 11, 7, 223, 19, 20, 987, 988, ")" +431, 11, 8, 224, 21, 22, 989, 990, ":" +431, 11, 9, 225, 23, 26, 991, 994, "715" +431, 11, 10, 226, 27, 28, 995, 996, "-" +431, 11, 11, 227, 29, 30, 997, 998, "6" +431, 11, 12, 228, 31, 32, 999, 1000, "." +431, 12, 1, 229, 0, 2, 1001, 1003, "Am" +431, 12, 2, 230, 3, 4, 1004, 1005, "J" +431, 12, 3, 231, 5, 15, 1006, 1016, "Ophthalmol" +431, 12, 4, 232, 16, 17, 1017, 1018, "." +431, 13, 1, 233, 0, 4, 1019, 1023, "2011" +431, 13, 2, 234, 5, 8, 1024, 1027, "Nov" +431, 13, 3, 235, 9, 10, 1028, 1029, ";" +431, 13, 4, 236, 11, 14, 1030, 1033, "152" +431, 13, 5, 237, 15, 16, 1034, 1035, "(" +431, 13, 6, 238, 17, 18, 1036, 1037, "5" +431, 13, 7, 239, 19, 20, 1038, 1039, ")" +431, 13, 8, 240, 21, 22, 1040, 1041, ":" +431, 13, 9, 241, 23, 26, 1042, 1045, "877" +431, 13, 10, 242, 27, 28, 1046, 1047, ";" +431, 13, 11, 243, 29, 35, 1048, 1054, "author" +431, 13, 12, 244, 36, 41, 1055, 1060, "reply" +431, 13, 13, 245, 42, 45, 1061, 1064, "877" +431, 13, 14, 246, 46, 47, 1065, 1066, "-" +431, 13, 15, 247, 48, 49, 1067, 1068, "8" +431, 13, 16, 248, 50, 51, 1069, 1070, "." +431, 14, 1, 249, 0, 2, 1071, 1073, "Am" +431, 14, 2, 250, 3, 4, 1074, 1075, "J" +431, 14, 3, 251, 5, 15, 1076, 1086, "Ophthalmol" +431, 14, 4, 252, 16, 17, 1087, 1088, "." +431, 15, 1, 253, 0, 4, 1089, 1093, "2011" +431, 15, 2, 254, 5, 8, 1094, 1097, "Nov" +431, 15, 3, 255, 9, 10, 1098, 1099, ";" +431, 15, 4, 256, 11, 14, 1100, 1103, "152" +431, 15, 5, 257, 15, 16, 1104, 1105, "(" +431, 15, 6, 258, 17, 18, 1106, 1107, "5" +431, 15, 7, 259, 19, 20, 1108, 1109, ")" +431, 15, 8, 260, 21, 22, 1110, 1111, ":" +431, 15, 9, 261, 23, 26, 1112, 1115, "880" +431, 15, 10, 262, 27, 28, 1116, 1117, ";" +431, 15, 11, 263, 29, 35, 1118, 1124, "author" +431, 15, 12, 264, 36, 41, 1125, 1130, "reply" +431, 15, 13, 265, 42, 45, 1131, 1134, "880" +431, 15, 14, 266, 46, 47, 1135, 1136, "-" +431, 15, 15, 267, 48, 49, 1137, 1138, "1" +431, 15, 16, 268, 50, 51, 1139, 1140, "." +431, 16, 1, 269, 0, 7, 1141, 1148, "PURPOSE" +431, 16, 2, 270, 8, 9, 1149, 1150, ":" +431, 16, 3, 271, 10, 12, 1151, 1153, "To" +431, 16, 4, 272, 13, 20, 1154, 1161, "compare" +431, 16, 5, 273, 21, 24, 1162, 1165, "the" +431, 16, 6, 274, 25, 31, 1166, 1172, "alpha2" +431, 16, 7, 275, 32, 33, 1173, 1174, "-" +431, 16, 8, 276, 34, 44, 1175, 1185, "adrenergic" +431, 16, 9, 277, 45, 52, 1186, 1193, "agonist" +431, 16, 10, 278, 53, 64, 1194, 1205, "brimonidine" +431, 16, 11, 279, 65, 73, 1206, 1214, "tartrate" +431, 16, 12, 280, 74, 75, 1215, 1216, "0" +431, 16, 13, 281, 76, 77, 1217, 1218, "." +431, 16, 14, 282, 78, 79, 1219, 1220, "2" +431, 16, 15, 283, 80, 81, 1221, 1222, "%" +431, 16, 16, 284, 82, 84, 1223, 1225, "to" +431, 16, 17, 285, 85, 88, 1226, 1229, "the" +431, 16, 18, 286, 89, 93, 1230, 1234, "beta" +431, 16, 19, 287, 94, 95, 1235, 1236, "-" +431, 16, 20, 288, 96, 106, 1237, 1247, "adrenergic" +431, 16, 21, 289, 107, 117, 1248, 1258, "antagonist" +431, 16, 22, 290, 118, 125, 1259, 1266, "timolol" +431, 16, 23, 291, 126, 133, 1267, 1274, "maleate" +431, 16, 24, 292, 134, 135, 1275, 1276, "0" +431, 16, 25, 293, 136, 137, 1277, 1278, "." +431, 16, 26, 294, 138, 139, 1279, 1280, "5" +431, 16, 27, 295, 140, 141, 1281, 1282, "%" +431, 16, 28, 296, 142, 144, 1283, 1285, "in" +431, 16, 29, 297, 145, 155, 1286, 1296, "preserving" +431, 16, 30, 298, 156, 162, 1297, 1303, "visual" +431, 16, 31, 299, 163, 171, 1304, 1312, "function" +431, 16, 32, 300, 172, 174, 1313, 1315, "in" +431, 16, 33, 301, 175, 178, 1316, 1319, "low" +431, 16, 34, 302, 179, 180, 1320, 1321, "-" +431, 16, 35, 303, 181, 189, 1322, 1330, "pressure" +431, 16, 36, 304, 190, 198, 1331, 1339, "glaucoma" +431, 16, 37, 305, 199, 200, 1340, 1341, "." +431, 17, 1, 306, 0, 6, 1342, 1348, "DESIGN" +431, 17, 2, 307, 7, 8, 1349, 1350, ":" +431, 17, 3, 308, 9, 19, 1351, 1361, "Randomized" +431, 17, 4, 309, 20, 21, 1362, 1363, "," +431, 17, 5, 310, 22, 28, 1364, 1370, "double" +431, 17, 6, 311, 29, 30, 1371, 1372, "-" +431, 17, 7, 312, 31, 37, 1373, 1379, "masked" +431, 17, 8, 313, 38, 39, 1380, 1381, "," +431, 17, 9, 314, 40, 51, 1382, 1393, "multicenter" +431, 17, 10, 315, 52, 60, 1394, 1402, "clinical" +431, 17, 11, 316, 61, 66, 1403, 1408, "trial" +431, 17, 12, 317, 67, 68, 1409, 1410, "." +431, 18, 1, 318, 0, 7, 1411, 1418, "METHODS" +431, 18, 2, 319, 8, 9, 1419, 1420, ":" +431, 18, 3, 320, 10, 19, 1421, 1430, "Exclusion" +431, 18, 4, 321, 20, 28, 1431, 1439, "criteria" +431, 18, 5, 322, 29, 37, 1440, 1448, "included" +431, 18, 6, 323, 38, 47, 1449, 1458, "untreated" +431, 18, 7, 324, 48, 59, 1459, 1470, "intraocular" +431, 18, 8, 325, 60, 68, 1471, 1479, "pressure" +431, 18, 9, 326, 69, 70, 1480, 1481, "(" +431, 18, 10, 327, 71, 74, 1482, 1485, "IOP" +431, 18, 11, 328, 75, 76, 1486, 1487, ")" +431, 18, 12, 329, 77, 78, 1488, 1489, ">" +431, 18, 13, 330, 79, 81, 1490, 1492, "21" +431, 18, 14, 331, 82, 84, 1493, 1495, "mm" +431, 18, 15, 332, 85, 87, 1496, 1498, "Hg" +431, 18, 16, 333, 88, 89, 1499, 1500, "," +431, 18, 17, 334, 90, 96, 1501, 1507, "visual" +431, 18, 18, 335, 97, 102, 1508, 1513, "field" +431, 18, 19, 336, 103, 107, 1514, 1518, "mean" +431, 18, 20, 337, 108, 117, 1519, 1528, "deviation" +431, 18, 21, 338, 118, 123, 1529, 1534, "worse" +431, 18, 22, 339, 124, 128, 1535, 1539, "than" +431, 18, 23, 340, 129, 130, 1540, 1541, "-" +431, 18, 24, 341, 131, 133, 1542, 1544, "16" +431, 18, 25, 342, 134, 142, 1545, 1553, "decibels" +431, 18, 26, 343, 143, 144, 1554, 1555, "," +431, 18, 27, 344, 145, 147, 1556, 1558, "or" +431, 18, 28, 345, 148, 165, 1559, 1576, "contraindications" +431, 18, 29, 346, 166, 168, 1577, 1579, "to" +431, 18, 30, 347, 169, 174, 1580, 1585, "study" +431, 18, 31, 348, 175, 186, 1586, 1597, "medications" +431, 18, 32, 349, 187, 188, 1598, 1599, "." +431, 19, 1, 350, 0, 4, 1600, 1604, "Both" +431, 19, 2, 351, 5, 9, 1605, 1609, "eyes" +431, 19, 3, 352, 10, 18, 1610, 1618, "received" +431, 19, 4, 353, 19, 24, 1619, 1624, "twice" +431, 19, 5, 354, 25, 26, 1625, 1626, "-" +431, 19, 6, 355, 27, 32, 1627, 1632, "daily" +431, 19, 7, 356, 33, 44, 1633, 1644, "monotherapy" +431, 19, 8, 357, 45, 55, 1645, 1655, "randomized" +431, 19, 9, 358, 56, 58, 1656, 1658, "in" +431, 19, 10, 359, 59, 65, 1659, 1665, "blocks" +431, 19, 11, 360, 66, 68, 1666, 1668, "of" +431, 19, 12, 361, 69, 70, 1669, 1670, "7" +431, 19, 13, 362, 71, 72, 1671, 1672, "(" +431, 19, 14, 363, 73, 74, 1673, 1674, "4" +431, 19, 15, 364, 75, 86, 1675, 1686, "brimonidine" +431, 19, 16, 365, 87, 89, 1687, 1689, "to" +431, 19, 17, 366, 90, 91, 1690, 1691, "3" +431, 19, 18, 367, 92, 99, 1692, 1699, "timolol" +431, 19, 19, 368, 100, 101, 1700, 1701, ")" +431, 19, 20, 369, 102, 103, 1702, 1703, "." +431, 20, 1, 370, 0, 8, 1704, 1712, "Standard" +431, 20, 2, 371, 9, 18, 1713, 1722, "automated" +431, 20, 3, 372, 19, 28, 1723, 1732, "perimetry" +431, 20, 4, 373, 29, 32, 1733, 1736, "and" +431, 20, 5, 374, 33, 42, 1737, 1746, "tonometry" +431, 20, 6, 375, 43, 47, 1747, 1751, "were" +431, 20, 7, 376, 48, 57, 1752, 1761, "performed" +431, 20, 8, 377, 58, 60, 1762, 1764, "at" +431, 20, 9, 378, 61, 62, 1765, 1766, "4" +431, 20, 10, 379, 63, 64, 1767, 1768, "-" +431, 20, 11, 380, 65, 70, 1769, 1774, "month" +431, 20, 12, 381, 71, 80, 1775, 1784, "intervals" +431, 20, 13, 382, 81, 82, 1785, 1786, "." +431, 21, 1, 383, 0, 4, 1787, 1791, "Main" +431, 21, 2, 384, 5, 12, 1792, 1799, "outcome" +431, 21, 3, 385, 13, 20, 1800, 1807, "measure" +431, 21, 4, 386, 21, 24, 1808, 1811, "was" +431, 21, 5, 387, 25, 30, 1812, 1817, "field" +431, 21, 6, 388, 31, 42, 1818, 1829, "progression" +431, 21, 7, 389, 43, 45, 1830, 1832, "in" +431, 21, 8, 390, 46, 52, 1833, 1839, "either" +431, 21, 9, 391, 53, 56, 1840, 1843, "eye" +431, 21, 10, 392, 57, 58, 1844, 1845, "," +431, 21, 11, 393, 59, 66, 1846, 1853, "defined" +431, 21, 12, 394, 67, 69, 1854, 1856, "as" +431, 21, 13, 395, 70, 73, 1857, 1860, "the" +431, 21, 14, 396, 74, 78, 1861, 1865, "same" +431, 21, 15, 397, 79, 80, 1866, 1867, "3" +431, 21, 16, 398, 81, 83, 1868, 1870, "or" +431, 21, 17, 399, 84, 88, 1871, 1875, "more" +431, 21, 18, 400, 89, 95, 1876, 1882, "points" +431, 21, 19, 401, 96, 100, 1883, 1887, "with" +431, 21, 20, 402, 101, 102, 1888, 1889, "a" +431, 21, 21, 403, 103, 111, 1890, 1898, "negative" +431, 21, 22, 404, 112, 117, 1899, 1904, "slope" +431, 21, 23, 405, 118, 120, 1905, 1907, "≥-" +431, 21, 24, 406, 121, 122, 1908, 1909, "1" +431, 21, 25, 407, 123, 125, 1910, 1912, "dB" +431, 21, 26, 408, 126, 127, 1913, 1914, "/" +431, 21, 27, 409, 128, 132, 1915, 1919, "year" +431, 21, 28, 410, 133, 135, 1920, 1922, "at" +431, 21, 29, 411, 136, 137, 1923, 1924, "P" +431, 21, 30, 412, 138, 139, 1925, 1926, "<" +431, 21, 31, 413, 140, 141, 1927, 1928, "5" +431, 21, 32, 414, 142, 143, 1929, 1930, "%" +431, 21, 33, 415, 144, 145, 1931, 1932, "," +431, 21, 34, 416, 146, 148, 1933, 1935, "on" +431, 21, 35, 417, 149, 150, 1936, 1937, "3" +431, 21, 36, 418, 151, 162, 1938, 1949, "consecutive" +431, 21, 37, 419, 163, 168, 1950, 1955, "tests" +431, 21, 38, 420, 169, 170, 1956, 1957, "," +431, 21, 39, 421, 171, 179, 1958, 1966, "assessed" +431, 21, 40, 422, 180, 182, 1967, 1969, "by" +431, 21, 41, 423, 183, 192, 1970, 1979, "pointwise" +431, 21, 42, 424, 193, 199, 1980, 1986, "linear" +431, 21, 43, 425, 200, 210, 1987, 1997, "regression" +431, 21, 44, 426, 211, 212, 1998, 1999, "." +431, 22, 1, 427, 0, 9, 2000, 2009, "Secondary" +431, 22, 2, 428, 10, 17, 2010, 2017, "outcome" +431, 22, 3, 429, 18, 26, 2018, 2026, "measures" +431, 22, 4, 430, 27, 31, 2027, 2031, "were" +431, 22, 5, 431, 32, 43, 2032, 2043, "progression" +431, 22, 6, 432, 44, 49, 2044, 2049, "based" +431, 22, 7, 433, 50, 52, 2050, 2052, "on" +431, 22, 8, 434, 53, 61, 2053, 2061, "glaucoma" +431, 22, 9, 435, 62, 68, 2062, 2068, "change" +431, 22, 10, 436, 69, 80, 2069, 2080, "probability" +431, 22, 11, 437, 81, 85, 2081, 2085, "maps" +431, 22, 12, 438, 86, 87, 2086, 2087, "(" +431, 22, 13, 439, 88, 92, 2088, 2092, "GCPM" +431, 22, 14, 440, 93, 94, 2093, 2094, ")" +431, 22, 15, 441, 95, 97, 2095, 2097, "of" +431, 22, 16, 442, 98, 105, 2098, 2105, "pattern" +431, 22, 17, 443, 106, 115, 2106, 2115, "deviation" +431, 22, 18, 444, 116, 119, 2116, 2119, "and" +431, 22, 19, 445, 120, 123, 2120, 2123, "the" +431, 22, 20, 446, 124, 125, 2124, 2125, "3" +431, 22, 21, 447, 126, 127, 2126, 2127, "-" +431, 22, 22, 448, 128, 136, 2128, 2136, "omitting" +431, 22, 23, 449, 137, 143, 2137, 2143, "method" +431, 22, 24, 450, 144, 147, 2144, 2147, "for" +431, 22, 25, 451, 148, 157, 2148, 2157, "pointwise" +431, 22, 26, 452, 158, 164, 2158, 2164, "linear" +431, 22, 27, 453, 165, 175, 2165, 2175, "regression" +431, 22, 28, 454, 176, 177, 2176, 2177, "." +431, 23, 1, 455, 0, 7, 2178, 2185, "RESULTS" +431, 23, 2, 456, 8, 9, 2186, 2187, ":" +431, 23, 3, 457, 10, 16, 2188, 2194, "Ninety" +431, 23, 4, 458, 17, 18, 2195, 2196, "-" +431, 23, 5, 459, 19, 23, 2197, 2201, "nine" +431, 23, 6, 460, 24, 32, 2202, 2210, "patients" +431, 23, 7, 461, 33, 37, 2211, 2215, "were" +431, 23, 8, 462, 38, 48, 2216, 2226, "randomized" +431, 23, 9, 463, 49, 51, 2227, 2229, "to" +431, 23, 10, 464, 52, 63, 2230, 2241, "brimonidine" +431, 23, 11, 465, 64, 67, 2242, 2245, "and" +431, 23, 12, 466, 68, 70, 2246, 2248, "79" +431, 23, 13, 467, 71, 73, 2249, 2251, "to" +431, 23, 14, 468, 74, 81, 2252, 2259, "timolol" +431, 23, 15, 469, 82, 83, 2260, 2261, "." +431, 24, 1, 470, 0, 4, 2262, 2266, "Mean" +431, 24, 2, 471, 5, 6, 2267, 2268, "(" +431, 24, 3, 472, 7, 8, 2269, 2270, "±" +431, 24, 4, 473, 9, 11, 2271, 2273, "SE" +431, 24, 5, 474, 12, 13, 2274, 2275, ")" +431, 24, 6, 475, 14, 20, 2276, 2282, "months" +431, 24, 7, 476, 21, 23, 2283, 2285, "of" +431, 24, 8, 477, 24, 30, 2286, 2292, "follow" +431, 24, 9, 478, 31, 32, 2293, 2294, "-" +431, 24, 10, 479, 33, 35, 2295, 2297, "up" +431, 24, 11, 480, 36, 39, 2298, 2301, "for" +431, 24, 12, 481, 40, 43, 2302, 2305, "all" +431, 24, 13, 482, 44, 52, 2306, 2314, "patients" +431, 24, 14, 483, 53, 56, 2315, 2318, "was" +431, 24, 15, 484, 57, 59, 2319, 2321, "30" +431, 24, 16, 485, 60, 61, 2322, 2323, "." +431, 24, 17, 486, 62, 63, 2324, 2325, "0" +431, 24, 18, 487, 64, 65, 2326, 2327, "±" +431, 24, 19, 488, 66, 67, 2328, 2329, "2" +431, 24, 20, 489, 68, 69, 2330, 2331, "." +431, 25, 1, 490, 0, 13, 2332, 2345, "Statistically" +431, 25, 2, 491, 14, 19, 2346, 2351, "fewer" +431, 25, 3, 492, 20, 31, 2352, 2363, "brimonidine" +431, 25, 4, 493, 32, 33, 2364, 2365, "-" +431, 25, 5, 494, 34, 41, 2366, 2373, "treated" +431, 25, 6, 495, 42, 50, 2374, 2382, "patients" +431, 25, 7, 496, 51, 52, 2383, 2384, "(" +431, 25, 8, 497, 53, 54, 2385, 2386, "9" +431, 25, 9, 498, 55, 56, 2387, 2388, "," +431, 25, 10, 499, 57, 58, 2389, 2390, "9" +431, 25, 11, 500, 59, 60, 2391, 2392, "." +431, 25, 12, 501, 61, 62, 2393, 2394, "1" +431, 25, 13, 502, 63, 64, 2395, 2396, "%" +431, 25, 14, 503, 65, 66, 2397, 2398, ")" +431, 25, 15, 504, 67, 70, 2399, 2402, "had" +431, 25, 16, 505, 71, 77, 2403, 2409, "visual" +431, 25, 17, 506, 78, 83, 2410, 2415, "field" +431, 25, 18, 507, 84, 95, 2416, 2427, "progression" +431, 25, 19, 508, 96, 98, 2428, 2430, "by" +431, 25, 20, 509, 99, 108, 2431, 2440, "pointwise" +431, 25, 21, 510, 109, 115, 2441, 2447, "linear" +431, 25, 22, 511, 116, 126, 2448, 2458, "regression" +431, 25, 23, 512, 127, 131, 2459, 2463, "than" +431, 25, 24, 513, 132, 139, 2464, 2471, "timolol" +431, 25, 25, 514, 140, 141, 2472, 2473, "-" +431, 25, 26, 515, 142, 149, 2474, 2481, "treated" +431, 25, 27, 516, 150, 158, 2482, 2490, "patients" +431, 25, 28, 517, 159, 160, 2491, 2492, "(" +431, 25, 29, 518, 161, 163, 2493, 2495, "31" +431, 25, 30, 519, 164, 165, 2496, 2497, "," +431, 25, 31, 520, 166, 168, 2498, 2500, "39" +431, 25, 32, 521, 169, 170, 2501, 2502, "." +431, 25, 33, 522, 171, 172, 2503, 2504, "2" +431, 25, 34, 523, 173, 174, 2505, 2506, "%" +431, 25, 35, 524, 175, 176, 2507, 2508, "," +431, 25, 36, 525, 177, 180, 2509, 2512, "log" +431, 25, 37, 526, 181, 182, 2513, 2514, "-" +431, 25, 38, 527, 183, 187, 2515, 2519, "rank" +431, 25, 39, 528, 188, 190, 2520, 2522, "12" +431, 25, 40, 529, 191, 192, 2523, 2524, "." +431, 25, 41, 530, 193, 194, 2525, 2526, "4" +431, 25, 42, 531, 195, 196, 2527, 2528, "," +431, 25, 43, 532, 197, 198, 2529, 2530, "P" +431, 25, 44, 533, 199, 200, 2531, 2532, "=" +431, 25, 45, 534, 201, 202, 2533, 2534, "." +431, 25, 46, 535, 203, 206, 2535, 2538, "001" +431, 25, 47, 536, 207, 208, 2539, 2540, ")" +431, 25, 48, 537, 209, 210, 2541, 2542, "." +431, 26, 1, 538, 0, 4, 2543, 2547, "Mean" +431, 26, 2, 539, 5, 12, 2548, 2555, "treated" +431, 26, 3, 540, 13, 16, 2556, 2559, "IOP" +431, 26, 4, 541, 17, 20, 2560, 2563, "was" +431, 26, 5, 542, 21, 28, 2564, 2571, "similar" +431, 26, 6, 543, 29, 32, 2572, 2575, "for" +431, 26, 7, 544, 33, 44, 2576, 2587, "brimonidine" +431, 26, 8, 545, 45, 46, 2588, 2589, "-" +431, 26, 9, 546, 47, 50, 2590, 2593, "and" +431, 26, 10, 547, 51, 58, 2594, 2601, "timolol" +431, 26, 11, 548, 59, 60, 2602, 2603, "-" +431, 26, 12, 549, 61, 68, 2604, 2611, "treated" +431, 26, 13, 550, 69, 77, 2612, 2620, "patients" +431, 26, 14, 551, 78, 80, 2621, 2623, "at" +431, 26, 15, 552, 81, 84, 2624, 2627, "all" +431, 26, 16, 553, 85, 89, 2628, 2632, "time" +431, 26, 17, 554, 90, 96, 2633, 2639, "points" +431, 26, 18, 555, 97, 98, 2640, 2641, "." +431, 27, 1, 556, 0, 4, 2642, 2646, "More" +431, 27, 2, 557, 5, 16, 2647, 2658, "brimonidine" +431, 27, 3, 558, 17, 18, 2659, 2660, "-" +431, 27, 4, 559, 19, 26, 2661, 2668, "treated" +431, 27, 5, 560, 27, 28, 2669, 2670, "(" +431, 27, 6, 561, 29, 31, 2671, 2673, "28" +431, 27, 7, 562, 32, 33, 2674, 2675, "," +431, 27, 8, 563, 34, 36, 2676, 2678, "28" +431, 27, 9, 564, 37, 38, 2679, 2680, "." +431, 27, 10, 565, 39, 40, 2681, 2682, "3" +431, 27, 11, 566, 41, 42, 2683, 2684, "%" +431, 27, 12, 567, 43, 44, 2685, 2686, ")" +431, 27, 13, 568, 45, 49, 2687, 2691, "than" +431, 27, 14, 569, 50, 57, 2692, 2699, "timolol" +431, 27, 15, 570, 58, 59, 2700, 2701, "-" +431, 27, 16, 571, 60, 67, 2702, 2709, "treated" +431, 27, 17, 572, 68, 69, 2710, 2711, "(" +431, 27, 18, 573, 70, 71, 2712, 2713, "9" +431, 27, 19, 574, 72, 73, 2714, 2715, "," +431, 27, 20, 575, 74, 76, 2716, 2718, "11" +431, 27, 21, 576, 77, 78, 2719, 2720, "." +431, 27, 22, 577, 79, 80, 2721, 2722, "4" +431, 27, 23, 578, 81, 82, 2723, 2724, "%" +431, 27, 24, 579, 83, 84, 2725, 2726, ")" +431, 27, 25, 580, 85, 93, 2727, 2735, "patients" +431, 27, 26, 581, 94, 106, 2736, 2748, "discontinued" +431, 27, 27, 582, 107, 112, 2749, 2754, "study" +431, 27, 28, 583, 113, 126, 2755, 2768, "participation" +431, 27, 29, 584, 127, 134, 2769, 2776, "because" +431, 27, 30, 585, 135, 137, 2777, 2779, "of" +431, 27, 31, 586, 138, 142, 2780, 2784, "drug" +431, 27, 32, 587, 143, 144, 2785, 2786, "-" +431, 27, 33, 588, 145, 152, 2787, 2794, "related" +431, 27, 34, 589, 153, 160, 2795, 2802, "adverse" +431, 27, 35, 590, 161, 167, 2803, 2809, "events" +431, 27, 36, 591, 168, 169, 2810, 2811, "(" +431, 27, 37, 592, 170, 171, 2812, 2813, "P" +431, 27, 38, 593, 172, 173, 2814, 2815, "=" +431, 27, 39, 594, 174, 175, 2816, 2817, "." +431, 27, 40, 595, 176, 179, 2818, 2821, "008" +431, 27, 41, 596, 180, 181, 2822, 2823, ")" +431, 27, 42, 597, 182, 183, 2824, 2825, "." +431, 28, 1, 598, 0, 7, 2826, 2833, "Similar" +431, 28, 2, 599, 8, 19, 2834, 2845, "differences" +431, 28, 3, 600, 20, 22, 2846, 2848, "in" +431, 28, 4, 601, 23, 34, 2849, 2860, "progression" +431, 28, 5, 602, 35, 39, 2861, 2865, "were" +431, 28, 6, 603, 40, 48, 2866, 2874, "observed" +431, 28, 7, 604, 49, 53, 2875, 2879, "when" +431, 28, 8, 605, 54, 62, 2880, 2888, "analyzed" +431, 28, 9, 606, 63, 65, 2889, 2891, "by" +431, 28, 10, 607, 66, 70, 2892, 2896, "GCPM" +431, 28, 11, 608, 71, 74, 2897, 2900, "and" +431, 28, 12, 609, 75, 78, 2901, 2904, "the" +431, 28, 13, 610, 79, 80, 2905, 2906, "3" +431, 28, 14, 611, 81, 82, 2907, 2908, "-" +431, 28, 15, 612, 83, 91, 2909, 2917, "omitting" +431, 28, 16, 613, 92, 98, 2918, 2924, "method" +431, 28, 17, 614, 99, 100, 2925, 2926, "." +431, 29, 1, 615, 0, 10, 2927, 2937, "CONCLUSION" +431, 29, 2, 616, 11, 12, 2938, 2939, ":" +431, 29, 3, 617, 13, 16, 2940, 2943, "Low" +431, 29, 4, 618, 17, 18, 2944, 2945, "-" +431, 29, 5, 619, 19, 27, 2946, 2954, "pressure" +431, 29, 6, 620, 28, 36, 2955, 2963, "glaucoma" +431, 29, 7, 621, 37, 45, 2964, 2972, "patients" +431, 29, 8, 622, 46, 53, 2973, 2980, "treated" +431, 29, 9, 623, 54, 58, 2981, 2985, "with" +431, 29, 10, 624, 59, 70, 2986, 2997, "brimonidine" +431, 29, 11, 625, 71, 72, 2998, 2999, "0" +431, 29, 12, 626, 73, 74, 3000, 3001, "." +431, 29, 13, 627, 75, 76, 3002, 3003, "2" +431, 29, 14, 628, 77, 78, 3004, 3005, "%" +431, 29, 15, 629, 79, 82, 3006, 3009, "who" +431, 29, 16, 630, 83, 85, 3010, 3012, "do" +431, 29, 17, 631, 86, 89, 3013, 3016, "not" +431, 29, 18, 632, 90, 97, 3017, 3024, "develop" +431, 29, 19, 633, 98, 104, 3025, 3031, "ocular" +431, 29, 20, 634, 105, 112, 3032, 3039, "allergy" +431, 29, 21, 635, 113, 116, 3040, 3043, "are" +431, 29, 22, 636, 117, 121, 3044, 3048, "less" +431, 29, 23, 637, 122, 128, 3049, 3055, "likely" +431, 29, 24, 638, 129, 131, 3056, 3058, "to" +431, 29, 25, 639, 132, 136, 3059, 3063, "have" +431, 29, 26, 640, 137, 142, 3064, 3069, "field" +431, 29, 27, 641, 143, 154, 3070, 3081, "progression" +431, 29, 28, 642, 155, 159, 3082, 3086, "than" +431, 29, 29, 643, 160, 168, 3087, 3095, "patients" +431, 29, 30, 644, 169, 176, 3096, 3103, "treated" +431, 29, 31, 645, 177, 181, 3104, 3108, "with" +431, 29, 32, 646, 182, 189, 3109, 3116, "timolol" +431, 29, 33, 647, 190, 191, 3117, 3118, "0" +431, 29, 34, 648, 192, 193, 3119, 3120, "." +431, 29, 35, 649, 194, 195, 3121, 3122, "5" +431, 29, 36, 650, 196, 197, 3123, 3124, "%" +431, 29, 37, 651, 198, 199, 3125, 3126, "." +431, 30, 1, 652, 0, 9, 3127, 3136, "Copyright" +431, 30, 2, 653, 10, 11, 3137, 3138, "©" +431, 30, 3, 654, 12, 16, 3139, 3143, "2011" +431, 30, 4, 655, 17, 25, 3144, 3152, "Elsevier" +431, 30, 5, 656, 26, 29, 3153, 3156, "Inc" +431, 30, 6, 657, 30, 31, 3157, 3158, "." +431, 30, 7, 658, 32, 35, 3159, 3162, "All" +431, 30, 8, 659, 36, 42, 3163, 3169, "rights" +431, 30, 9, 660, 43, 51, 3170, 3178, "reserved" +431, 30, 10, 661, 52, 53, 3179, 3180, "." +431, 31, 1, 662, 0, 3, 3181, 3184, "DOI" +431, 31, 2, 663, 4, 5, 3185, 3186, ":" +431, 31, 3, 664, 6, 8, 3187, 3189, "10" +431, 31, 4, 665, 9, 10, 3190, 3191, "." +431, 31, 5, 666, 11, 15, 3192, 3196, "1016" +431, 31, 6, 667, 16, 17, 3197, 3198, "/" +431, 31, 7, 668, 18, 19, 3199, 3200, "j" +431, 31, 8, 669, 20, 21, 3201, 3202, "." +431, 31, 9, 670, 22, 25, 3203, 3206, "ajo" +431, 31, 10, 671, 26, 27, 3207, 3208, "." +431, 31, 11, 672, 28, 32, 3209, 3213, "2010" +431, 31, 12, 673, 33, 34, 3214, 3215, "." +431, 31, 13, 674, 35, 37, 3216, 3218, "09" +431, 31, 14, 675, 38, 39, 3219, 3220, "." +431, 31, 15, 676, 40, 43, 3221, 3224, "026" +431, 31, 16, 677, 44, 48, 3225, 3229, "PMID" +431, 31, 17, 678, 49, 50, 3230, 3231, ":" +431, 31, 18, 679, 51, 59, 3232, 3240, "21257146" +431, 31, 19, 680, 60, 61, 3241, 3242, "[" +431, 31, 20, 681, 62, 69, 3243, 3250, "Indexed" +431, 31, 21, 682, 70, 73, 3251, 3254, "for" +431, 31, 22, 683, 74, 81, 3255, 3262, "MEDLINE" +431, 31, 23, 684, 82, 83, 3263, 3264, "]" diff --git a/data/gl 21257146_jshahinitiran.annodb b/data/gl 21257146_jshahinitiran.annodb new file mode 100644 index 0000000..b3620c0 --- /dev/null +++ b/data/gl 21257146_jshahinitiran.annodb @@ -0,0 +1,66 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +15960, Journal, 0, 15, "Am J Ophthalmol", "", +15962, PublicationYear, 18, 22, "2011", "", +15963, Title, 117, 254, "A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low - Pressure Glaucoma Treatment Study", "", +15964, Randomized, 119, 129, "randomized", "", +15965, Brimonidine, 139, 150, "brimonidine", "", +15966, Timolol, 158, 165, "timolol", "", +15967, Glaucoma, 230, 238, "Glaucoma", "", +15968, Author, 257, 265, "Krupin T", "", +15969, Author, 274, 285, "Liebmann JM", "", +15970, Author, 288, 301, "Greenfield DS", "", +15971, Author, 304, 311, "Ritch R", "", +15972, Author, 314, 324, "Gardiner S", "", +15973, USA, 846, 849, "USA", "", +15974, ObjectiveDescription, 1151, 1341, "To compare the alpha2 - adrenergic agonist brimonidine tartrate 0 . 2 % to the beta - adrenergic antagonist timolol maleate 0 . 5 % in preserving visual function in low - pressure glaucoma .", "", +15975, Brimonidine, 1166, 1214, "alpha2 - adrenergic agonist brimonidine tartrate", "", +15976, DoseValue, 1215, 1220, "0 . 2", "", +15978, Percentage, 1221, 1222, "%", "", +15980, Timolol, 1230, 1274, "beta - adrenergic antagonist timolol maleate", "", +15977, DoseValue, 1275, 1280, "0 . 5", "", +15979, Percentage, 1281, 1282, "%", "", +15981, Glaucoma, 1331, 1339, "glaucoma", "", +15982, Randomized, 1351, 1361, "Randomized", "", +15983, DoubleBlind, 1364, 1379, "double - masked", "", +15984, Multicenter, 1382, 1393, "multicenter", "", +15985, IOP, 1459, 1479, "intraocular pressure", "", +15986, IOP, 1482, 1485, "IOP", "", +15987, mmHg, 1493, 1498, "mm Hg", "", +15988, Frequency, 1619, 1632, "twice - daily", "", +15989, Randomized, 1645, 1655, "randomized", "", +16389, Brimonidine, 1675, 1686, "brimonidine", "", +16390, Timolol, 1692, 1699, "timolol", "", +16365, EndPointDescription, 1812, 1829, "field progression", "", +15990, Glaucoma, 2053, 2061, "glaucoma", "", +15996, NumberPatientsArm, 2188, 2201, "Ninety - nine", "", +15982, Randomized, 2216, 2226, "randomized", "", +15975, Brimonidine, 2230, 2241, "brimonidine", "", +15995, NumberPatientsArm, 2246, 2248, "79", "", +15980, Timolol, 2252, 2259, "timolol", "", +15997, Mean, 2262, 2266, "Mean", "", +15998, Brimonidine, 2352, 2363, "brimonidine", "", +16359, NumberAffected, 2385, 2386, "9", "", +16360, PercentageAffected, 2389, 2394, "9 . 1", "", +16365, EndPointDescription, 2403, 2427, "visual field progression", "", +16361, Timolol, 2464, 2471, "timolol", "", +16362, NumberAffected, 2493, 2495, "31", "", +16363, PercentageAffected, 2498, 2504, "39 . 2", "", +16364, PValueNumAffected, 2529, 2538, "P = . 001", "", +16366, Mean, 2543, 2547, "Mean", "", +16367, IOP, 2556, 2559, "IOP", "", +16368, Brimonidine, 2576, 2587, "brimonidine", "", +16369, Timolol, 2594, 2601, "timolol", "", +16370, Brimonidine, 2647, 2658, "brimonidine", "", +16376, NumPatientsLeftArm, 2671, 2673, "28", "", +16375, Timolol, 2692, 2699, "timolol", "", +16377, NumPatientsLeftArm, 2712, 2713, "9", "", +16378, ConclusionComment, 2940, 3126, "Low - pressure glaucoma patients treated with brimonidine 0 . 2 % who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0 . 5 % .", "", +16379, Glaucoma, 2955, 2963, "glaucoma", "", +16380, Brimonidine, 2986, 2997, "brimonidine", "", +16381, DoseValue, 2998, 3003, "0 . 2", "", +16382, Percentage, 3004, 3005, "%", "", +16365, EndPointDescription, 3064, 3081, "field progression", "", +16383, Timolol, 3109, 3116, "timolol", "", +16384, DoseValue, 3117, 3122, "0 . 5", "", +16385, Percentage, 3123, 3124, "%", "", +16387, PMID, 3232, 3240, "21257146", "", diff --git a/data/gl 21257146_jshahinitiran.n-triples b/data/gl 21257146_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21257146_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21257146_tstrakeljahn.annodb b/data/gl 21257146_tstrakeljahn.annodb new file mode 100644 index 0000000..1521b35 --- /dev/null +++ b/data/gl 21257146_tstrakeljahn.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12884, Journal, 0, 15, "Am J Ophthalmol", "", +12885, PublicationYear, 18, 22, "2011", "", +12890, Title, 117, 254, "A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low - Pressure Glaucoma Treatment Study", "", +12886, Randomized, 119, 129, "randomized", "", +12887, Brimonidine, 139, 150, "brimonidine", "", +12888, Timolol, 158, 165, "timolol", "", +12889, Glaucoma, 230, 238, "Glaucoma", "", +12891, Author, 257, 265, "Krupin T", "", +12892, Author, 274, 285, "Liebmann JM", "", +12893, Author, 288, 301, "Greenfield DS", "", +12894, Author, 304, 311, "Ritch R", "", +12895, Author, 314, 324, "Gardiner S", "", +12896, USA, 846, 849, "USA", "", +12898, Brimonidine, 1194, 1214, "brimonidine tartrate", "", +12901, DoseValue, 1215, 1220, "0 . 2", "", +12903, Percentage, 1221, 1222, "%", "", +12899, Timolol, 1259, 1274, "timolol maleate", "", +12902, DoseValue, 1275, 1280, "0 . 5", "", +12904, Percentage, 1281, 1282, "%", "", +12900, Glaucoma, 1331, 1339, "glaucoma", "", +12905, Randomized, 1351, 1361, "Randomized", "", +12906, DoubleBlind, 1364, 1379, "double - masked", "", +12907, Multicenter, 1382, 1393, "multicenter", "", +12908, ClinicalTrial, 1394, 1408, "clinical trial", "", +12909, IOP, 1459, 1479, "intraocular pressure", "", +12910, IOP, 1482, 1485, "IOP", "", +12911, mmHg, 1493, 1498, "mm Hg", "", +12912, Frequency, 1619, 1632, "twice - daily", "", +12913, Randomized, 1645, 1655, "randomized", "", +12914, Brimonidine, 1675, 1686, "brimonidine", "", +12915, Timolol, 1692, 1699, "timolol", "", +12916, Glaucoma, 2053, 2061, "glaucoma", "", +12917, NumberPatientsArm, 2188, 2201, "Ninety - nine", "", +12920, Randomized, 2216, 2226, "randomized", "", +12921, Brimonidine, 2230, 2241, "brimonidine", "", +12919, NumberPatientsArm, 2246, 2248, "79", "", +12922, Timolol, 2252, 2259, "timolol", "", +12923, Mean, 2262, 2266, "Mean", "", +12924, Brimonidine, 2352, 2363, "brimonidine", "", +12925, PercentageAffected, 2385, 2386, "9", "", +12926, PercentageAffected, 2389, 2394, "9 . 1", "", +12929, Timolol, 2464, 2471, "timolol", "", +12927, PercentageAffected, 2493, 2495, "31", "", +12928, PercentageAffected, 2498, 2504, "39 . 2", "", +12930, PvalueDiff, 2529, 2538, "P = . 001", "", +12931, Mean, 2543, 2547, "Mean", "", +12935, ObservedResult, 2543, 2639, "Mean treated IOP was similar for brimonidine - and timolol - treated patients at all time points", "", +12932, IOP, 2556, 2559, "IOP", "", +12933, Brimonidine, 2576, 2587, "brimonidine", "", +12934, Timolol, 2594, 2601, "timolol", "", +12936, Brimonidine, 2647, 2658, "brimonidine", "", +12937, PercentageAffected, 2671, 2673, "28", "", +12943, RelNumPatientsLeftArm, 2671, 2673, "28", "", +12938, PercentageAffected, 2676, 2682, "28 . 3", "", +12944, RelNumPatientsLeftArm, 2676, 2682, "28 . 3", "", +12941, Timolol, 2692, 2699, "timolol", "", +12939, PercentageAffected, 2712, 2713, "9", "", +12945, RelNumPatientsLeftArm, 2712, 2713, "9", "", +12940, PercentageAffected, 2716, 2722, "11 . 4", "", +12946, RelNumPatientsLeftArm, 2716, 2722, "11 . 4", "", +12942, PvalueDiff, 2812, 2821, "P = . 008", "", +12947, ObservedResult, 2826, 2924, "Similar differences in progression were observed when analyzed by GCPM and the 3 - omitting method", "", +12956, ConclusionComment, 2940, 3124, "Low - pressure glaucoma patients treated with brimonidine 0 . 2 % who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0 . 5 %", "", +12948, Glaucoma, 2955, 2963, "glaucoma", "", +12949, Brimonidine, 2986, 2997, "brimonidine", "", +12951, DoseValue, 2998, 3003, "0 . 2", "", +12953, Percentage, 3004, 3005, "%", "", +12950, Timolol, 3109, 3116, "timolol", "", +12952, DoseValue, 3117, 3122, "0 . 5", "", +12954, Percentage, 3123, 3124, "%", "", +12955, PMID, 3232, 3240, "21257146", "", diff --git a/data/gl 21257146_tstrakeljahn.n-triples b/data/gl 21257146_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21257146_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21499770_admin.annodb b/data/gl 21499770_admin.annodb new file mode 100644 index 0000000..ca19478 --- /dev/null +++ b/data/gl 21499770_admin.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 34, "Graefes Arch Clin Exp Ophthalmol .", "", " \"Graefes Arch Clin Exp Ophthalmol .\"." +1, PublicationYear, 35, 39, "2011", "", " \"2011\"." +2, Title, 133, 217, "Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension .", "", " \"Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension .\"." +6, Timolol, 133, 140, "Timolol", "", " ." +13, Brinzolamide, 148, 160, "brinzolamide", "", " ." +44604, Travoprost, 170, 180, "travoprost", "", " ." +20, Glaucoma, 184, 192, "glaucoma", "", " . ." +21, OcularHypertension, 196, 215, "ocular hypertension", "", " ." +3, Author, 218, 228, "Pfeiffer N", "", " \"Pfeiffer N\"." +4, Germany, 864, 871, "Germany", "", " ." +22, ObjectiveDescription, 932, 1122, "To compare the efficacy and safety of timolol 0 . 5 % versus brinzolamide 1 . 0 % when added to travoprost monotherapy in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"To compare the efficacy and safety of timolol 0 . 5 % versus brinzolamide 1 . 0 % when added to travoprost monotherapy in patients with primary open - angle glaucoma or ocular hypertension .\"." +7, Timolol, 970, 977, "timolol", "", +44, DoseValue, 978, 983, "0 . 5", "", " \"0 . 5\"." +25, Percentage, 984, 985, "%", "", " ." +14, Brinzolamide, 993, 1005, "brinzolamide", "", +23, DoseValue, 1006, 1011, "1 . 0", "", " \"1 . 0\"." +26, Percentage, 1012, 1013, "%", "", " ." +110, Travoprost, 1028, 1038, "travoprost", "", +109, Primary_OpenAngleGlaucoma, 1068, 1097, "primary open - angle glaucoma", "", " ." +27, OcularHypertension, 1101, 1120, "ocular hypertension", "", +5, Precondition, 1171, 1252, "IOP one eye 19   mmHg and ≤ 32   mmHg and IOP both eyes ≤ 32   mmHg at 8 : 00   h", "", " \"IOP one eye 19   mmHg and ≤ 32   mmHg and IOP both eyes ≤ 32   mmHg at 8 : 00   h\"." +49, IOP, 1171, 1174, "IOP", "", " . ." +112, mmHg, 1188, 1196, "mmHg and", "", +113, mmHg, 1204, 1208, "mmHg", "", " . ." +114, IOP, 1213, 1216, "IOP", "", +115, mmHg, 1234, 1238, "mmHg", "", +116, Travoprost, 1272, 1282, "travoprost", "", +50, Duration, 1299, 1308, "4   weeks", "", +106381, Precondition, 1311, 1410, "Patients then insufficiently controlled on travoprost ( IOP at 8 : 00   h ≥ 19   mmHg ) at baseline", "", " \"Patients then insufficiently controlled on travoprost ( IOP at 8 : 00   h ≥ 19   mmHg ) at baseline\"." +117, Travoprost, 1354, 1364, "travoprost", "", +53, IOP, 1367, 1370, "IOP", "", +52, mmHg, 1392, 1396, "mmHg", "", +28, Randomized, 1416, 1426, "randomized", "", " ." +120, Travoprost, 1445, 1455, "travoprost", "", +15, Brinzolamide, 1460, 1472, "brinzolamide", "", +121, Travoprost, 1476, 1486, "travoprost", "", +8, Timolol, 1491, 1498, "timolol", "", +57, DoubleBlind, 1504, 1519, "double - masked", "", " ." +58, Duration, 1532, 1542, "12   weeks", "", " \"12   weeks\"." +29, NumberPatientsCT, 1555, 1584, "Two hundred and fifty - three", "", " \"Two hundred and fifty - three\"." +30, Duration, 1608, 1616, "4 - week", "", +124, Travoprost, 1648, 1658, "travoprost", "", +60, IOP, 1680, 1683, "IOP", "", +127, mmHg, 1701, 1705, "mmHg", "", +61, PercentageAffected, 1712, 1718, "21 . 7", "", +62, TimePoint, 1741, 1751, "3   months", "", " \"3   months\". \"3   months\"." +63, Mean, 1830, 1834, "mean", "", " . . . ." +64, IOP, 1835, 1838, "IOP", "", +65, Mean, 1903, 1907, "mean", "", +66, Diurnal_IOP, 1908, 1919, "diurnal IOP", "", " ." +67, ResultMeasuredValue, 1932, 1938, "17 . 9", "", " \"17 . 9\"." +69, SdDevResValue, 1943, 1948, "2 . 6", "", " \"2 . 6\"." +72, mmHg, 1951, 1955, "mmHg", "", +16, Brinzolamide, 1964, 1976, "brinzolamide", "", +68, ResultMeasuredValue, 1987, 1993, "17 . 0", "", " \"17 . 0\"." +70, SdDevResValue, 1998, 2003, "3 . 2", "", " \"3 . 2\"." +71, mmHg, 2006, 2010, "mmHg", "", +9, Timolol, 2019, 2026, "timolol", "", +76, TimePoint, 2138, 2145, "16 : 00", "", " \"16 : 00\". \"16 : 00\"." +77, ResultMeasuredValue, 2168, 2174, "16 . 4", "", " \"16 . 4\"." +79, SdDevResValue, 2179, 2184, "3 . 2", "", " \"3 . 2\"." +82, mmHg, 2187, 2191, "mmHg", "", +78, ResultMeasuredValue, 2196, 2202, "17 . 3", "", " \"17 . 3\"." +80, SdDevResValue, 2207, 2212, "2 . 8", "", " \"2 . 8\"." +81, mmHg, 2215, 2219, "mmHg", "", +10, Timolol, 2228, 2235, "timolol", "", +17, Brinzolamide, 2240, 2252, "brinzolamide", "", +85, PvalueDiff, 2277, 2290, "p  =  0 . 038", "", " \"p  =  0 . 038\"." +86, PercentageAffected, 2295, 2300, "Fifty", "", +87, PercentageAffected, 2361, 2367, "13 . 2", "", +89, ConjunctivalHyperemia, 2413, 2422, "Hyperemia", "", " ." +90, PercentageAffected, 2446, 2451, "6 . 3", "", +98, ConclusionComment, 2487, 2670, "Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy , with timolol being slightly stronger 8 hours after instillation .", "", " \"Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy , with timolol being slightly stronger 8 hours after instillation .\"." +91, IOP, 2535, 2538, "IOP", "", +154, Travoprost, 2580, 2590, "travoprost", "", +11, Timolol, 2610, 2617, "timolol", "", +97, ConclusionComment, 2671, 2833, "Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost .", "", " \"Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost .\"." +18, Brinzolamide, 2697, 2709, "brinzolamide", "", +156, Travoprost, 2714, 2724, "travoprost", "", +12, Timolol, 2809, 2816, "timolol", "", +157, Travoprost, 2821, 2831, "travoprost", "", +99, PMID, 2883, 2891, "21499770", "", " \"21499770\"." diff --git a/data/gl 21499770_admin.n-triples b/data/gl 21499770_admin.n-triples new file mode 100644 index 0000000..50abfe7 --- /dev/null +++ b/data/gl 21499770_admin.n-triples @@ -0,0 +1,134 @@ +# RDF export of group: Publication + . + "Publication 44121" . + "Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension ." . + "Pfeiffer N" . + "2011" . + "Graefes Arch Clin Exp Ophthalmol ." . + "21499770" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 44128" . + "To compare the efficacy and safety of timolol 0 . 5 % versus brinzolamide 1 . 0 % when added to travoprost monotherapy in patients with primary open - angle glaucoma or ocular hypertension ." . + "Two hundred and fifty - three" . + "12   weeks" . + . + . + . + "Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy , with timolol being slightly stronger 8 hours after instillation ." . + . + . + . + . + . + . + "Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost ." . + . + . + . + . +# RDF export of group: Population + . + "Population 44164" . + "IOP one eye 19   mmHg and ≤ 32   mmHg and IOP both eyes ≤ 32   mmHg at 8 : 00   h" . + . + . + . + "Patients then insufficiently controlled on travoprost ( IOP at 8 : 00   h ≥ 19   mmHg ) at baseline" . +# RDF export of group: Endpoint + . + "Endpoint 44172 IOP" . + . + . + . + . + . + . + . + "Endpoint 46914 diurnal IOP" . + . + . + . + . + . + . + "Endpoint 46919 ConjunctivalHyperemia" . + . + . + . + . +# RDF export of group: Arm + . + "Arm 46868 Timolol and Travoprost" . + . + . + . + . + . + "Arm 46877 Brinzolamide and Travoprost" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 46854 Timolol and Travoprost" . + . + . + . + . + "Intervention 46860 Brinzolamide and Travoprost" . + . + . + . +# RDF export of group: Medication + . + "Medication 46833 Travoprost" . + . + . + . + . + "Medication 46840 Timolol" . + . + "0 . 5" . + . + . + . + "Medication 46847 Brinzolamide" . + . + "1 . 0" . + . + . +# RDF export of group: Outcome + . + "Outcome 46886 Timolol at 16:00" . + . + "16 . 4" . + "3 . 2" . + "16 : 00" . + . + "Outcome 46939 Brinzolamide at 16:00" . + . + "17 . 3" . + "2 . 8" . + "16 : 00" . + . + "Outcome 46966 Brinzolamide mean diurnal IOP" . + . + "17 . 9" . + "2 . 6" . + "3   months" . + . + "Outcome 46993 Timolol mean diurnal IOP" . + . + "17 . 0" . + "3 . 2" . + "3   months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 46925" . + "p  =  0 . 038" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21499770_export.csv b/data/gl 21499770_export.csv new file mode 100644 index 0000000..25b9d89 --- /dev/null +++ b/data/gl 21499770_export.csv @@ -0,0 +1,627 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +430, 1, 1, 1, 0, 7, 0, 7, "Graefes" +430, 1, 2, 2, 8, 12, 8, 12, "Arch" +430, 1, 3, 3, 13, 17, 13, 17, "Clin" +430, 1, 4, 4, 18, 21, 18, 21, "Exp" +430, 1, 5, 5, 22, 32, 22, 32, "Ophthalmol" +430, 1, 6, 6, 33, 34, 33, 34, "." +430, 2, 1, 7, 0, 4, 35, 39, "2011" +430, 2, 2, 8, 5, 8, 40, 43, "Jul" +430, 2, 3, 9, 9, 10, 44, 45, ";" +430, 2, 4, 10, 11, 14, 46, 49, "249" +430, 2, 5, 11, 15, 16, 50, 51, "(" +430, 2, 6, 12, 17, 18, 52, 53, "7" +430, 2, 7, 13, 19, 20, 54, 55, ")" +430, 2, 8, 14, 21, 22, 56, 57, ":" +430, 2, 9, 15, 23, 27, 58, 62, "1065" +430, 2, 10, 16, 28, 29, 63, 64, "-" +430, 2, 11, 17, 30, 32, 65, 67, "71" +430, 2, 12, 18, 33, 34, 68, 69, "." +430, 2, 13, 19, 35, 38, 70, 73, "doi" +430, 2, 14, 20, 39, 40, 74, 75, ":" +430, 2, 15, 21, 41, 43, 76, 78, "10" +430, 2, 16, 22, 44, 45, 79, 80, "." +430, 2, 17, 23, 46, 50, 81, 85, "1007" +430, 2, 18, 24, 51, 52, 86, 87, "/" +430, 2, 19, 25, 53, 59, 88, 94, "s00417" +430, 2, 20, 26, 60, 61, 95, 96, "-" +430, 2, 21, 27, 62, 65, 97, 100, "011" +430, 2, 22, 28, 66, 67, 101, 102, "-" +430, 2, 23, 29, 68, 72, 103, 107, "1650" +430, 2, 24, 30, 73, 74, 108, 109, "-" +430, 2, 25, 31, 75, 76, 110, 111, "8" +430, 2, 26, 32, 77, 78, 112, 113, "." +430, 3, 1, 33, 0, 4, 114, 118, "Epub" +430, 3, 2, 34, 5, 9, 119, 123, "2011" +430, 3, 3, 35, 10, 13, 124, 127, "Apr" +430, 3, 4, 36, 14, 16, 128, 130, "16" +430, 3, 5, 37, 17, 18, 131, 132, "." +430, 4, 1, 38, 0, 7, 133, 140, "Timolol" +430, 4, 2, 39, 8, 14, 141, 147, "versus" +430, 4, 3, 40, 15, 27, 148, 160, "brinzolamide" +430, 4, 4, 41, 28, 33, 161, 166, "added" +430, 4, 5, 42, 34, 36, 167, 169, "to" +430, 4, 6, 43, 37, 47, 170, 180, "travoprost" +430, 4, 7, 44, 48, 50, 181, 183, "in" +430, 4, 8, 45, 51, 59, 184, 192, "glaucoma" +430, 4, 9, 46, 60, 62, 193, 195, "or" +430, 4, 10, 47, 63, 69, 196, 202, "ocular" +430, 4, 11, 48, 70, 82, 203, 215, "hypertension" +430, 4, 12, 49, 83, 84, 216, 217, "." +430, 5, 1, 50, 0, 8, 218, 226, "Pfeiffer" +430, 5, 2, 51, 9, 10, 227, 228, "N" +430, 5, 3, 52, 11, 12, 229, 230, "(" +430, 5, 4, 53, 13, 14, 231, 232, "1" +430, 5, 5, 54, 15, 16, 233, 234, ")" +430, 5, 6, 55, 17, 18, 235, 236, ";" +430, 5, 7, 56, 19, 23, 237, 241, "TATS" +430, 5, 8, 57, 24, 25, 242, 243, "(" +430, 5, 9, 58, 26, 34, 244, 252, "Travatan" +430, 5, 10, 59, 35, 45, 253, 263, "Adjunctive" +430, 5, 11, 60, 46, 55, 264, 273, "Treatment" +430, 5, 12, 61, 56, 61, 274, 279, "Study" +430, 5, 13, 62, 62, 63, 280, 281, ")" +430, 5, 14, 63, 64, 69, 282, 287, "group" +430, 5, 15, 64, 70, 71, 288, 289, "." +430, 6, 1, 65, 0, 13, 290, 303, "Collaborators" +430, 6, 2, 66, 14, 15, 304, 305, ":" +430, 6, 3, 67, 16, 21, 306, 311, "Denis" +430, 6, 4, 68, 22, 23, 312, 313, "P" +430, 6, 5, 69, 24, 25, 314, 315, "," +430, 6, 6, 70, 26, 32, 316, 322, "Pierre" +430, 6, 7, 71, 33, 34, 323, 324, "-" +430, 6, 8, 72, 35, 37, 325, 327, "Lo" +430, 6, 9, 73, 38, 39, 328, 329, "ï" +430, 6, 10, 74, 40, 41, 330, 331, "c" +430, 6, 11, 75, 42, 43, 332, 333, "C" +430, 6, 12, 76, 44, 45, 334, 335, "," +430, 6, 13, 77, 46, 53, 336, 343, "Lachkar" +430, 6, 14, 78, 54, 55, 344, 345, "Y" +430, 6, 15, 79, 56, 57, 346, 347, "," +430, 6, 16, 80, 58, 63, 348, 353, "Doyle" +430, 6, 17, 81, 64, 65, 354, 355, "A" +430, 6, 18, 82, 66, 67, 356, 357, "," +430, 6, 19, 83, 68, 78, 358, 368, "Kinnebrock" +430, 6, 20, 84, 79, 80, 369, 370, "S" +430, 6, 21, 85, 81, 82, 371, 372, "," +430, 6, 22, 86, 83, 88, 373, 378, "Maser" +430, 6, 23, 87, 89, 90, 379, 380, "-" +430, 6, 24, 88, 91, 96, 381, 386, "Wahle" +430, 6, 25, 89, 97, 98, 387, 388, "M" +430, 6, 26, 90, 99, 100, 389, 390, "," +430, 6, 27, 91, 101, 106, 391, 396, "Lanzl" +430, 6, 28, 92, 107, 108, 397, 398, "I" +430, 6, 29, 93, 109, 110, 399, 400, "," +430, 6, 30, 94, 111, 118, 401, 408, "Pichler" +430, 6, 31, 95, 119, 120, 409, 410, "A" +430, 6, 32, 96, 121, 122, 411, 412, "," +430, 6, 33, 97, 123, 130, 413, 420, "Quentin" +430, 6, 34, 98, 131, 133, 421, 423, "KD" +430, 6, 35, 99, 134, 135, 424, 425, "," +430, 6, 36, 100, 136, 141, 426, 431, "Hache" +430, 6, 37, 101, 142, 143, 432, 433, "S" +430, 6, 38, 102, 144, 145, 434, 435, "," +430, 6, 39, 103, 146, 153, 436, 443, "Vorwerk" +430, 6, 40, 104, 154, 155, 444, 445, "C" +430, 6, 41, 105, 156, 157, 446, 447, "," +430, 6, 42, 106, 158, 162, 448, 452, "Pump" +430, 6, 43, 107, 163, 164, 453, 454, "-" +430, 6, 44, 108, 165, 172, 455, 462, "Schmidt" +430, 6, 45, 109, 173, 174, 463, 464, "C" +430, 6, 46, 110, 175, 176, 465, 466, "," +430, 6, 47, 111, 177, 185, 467, 475, "Strempel" +430, 6, 48, 112, 186, 187, 476, 477, "I" +430, 6, 49, 113, 188, 189, 478, 479, "," +430, 6, 50, 114, 190, 194, 480, 484, "Knop" +430, 6, 51, 115, 195, 196, 485, 486, "C" +430, 6, 52, 116, 197, 198, 487, 488, "," +430, 6, 53, 117, 199, 202, 489, 492, "Erb" +430, 6, 54, 118, 203, 204, 493, 494, "C" +430, 6, 55, 119, 205, 206, 495, 496, "," +430, 6, 56, 120, 207, 212, 497, 502, "Meyer" +430, 6, 57, 121, 213, 214, 503, 504, "M" +430, 6, 58, 122, 215, 216, 505, 506, "," +430, 6, 59, 123, 217, 224, 507, 514, "Bertoni" +430, 6, 60, 124, 225, 226, 515, 516, "G" +430, 6, 61, 125, 227, 228, 517, 518, "," +430, 6, 62, 126, 229, 236, 519, 526, "Mirella" +430, 6, 63, 127, 237, 238, 527, 528, "B" +430, 6, 64, 128, 239, 240, 529, 530, "," +430, 6, 65, 129, 241, 246, 531, 536, "David" +430, 6, 66, 130, 247, 248, 537, 538, "A" +430, 6, 67, 131, 249, 250, 539, 540, "," +430, 6, 68, 132, 251, 258, 541, 548, "Salerno" +430, 6, 69, 133, 259, 260, 549, 550, "D" +430, 6, 70, 134, 261, 262, 551, 552, "," +430, 6, 71, 135, 263, 269, 553, 559, "Meduri" +430, 6, 72, 136, 270, 272, 560, 562, "RA" +430, 6, 73, 137, 273, 274, 563, 564, "," +430, 6, 74, 138, 275, 283, 565, 573, "Scorolli" +430, 6, 75, 139, 284, 285, 574, 575, "L" +430, 6, 76, 140, 286, 287, 576, 577, "," +430, 6, 77, 141, 288, 297, 578, 587, "Scanlinci" +430, 6, 78, 142, 298, 300, 588, 590, "SZ" +430, 6, 79, 143, 301, 302, 591, 592, "," +430, 6, 80, 144, 303, 311, 593, 601, "Giardina" +430, 6, 81, 145, 312, 313, 602, 603, "D" +430, 6, 82, 146, 314, 315, 604, 605, "," +430, 6, 83, 147, 316, 321, 606, 611, "Galan" +430, 6, 84, 148, 322, 323, 612, 613, "A" +430, 6, 85, 149, 324, 325, 614, 615, "," +430, 6, 86, 150, 326, 330, 616, 620, "Garc" +430, 6, 87, 151, 331, 332, 621, 622, "í" +430, 6, 88, 152, 333, 334, 623, 624, "a" +430, 6, 89, 153, 335, 337, 625, 627, "AM" +430, 6, 90, 154, 338, 339, 628, 629, "," +430, 6, 91, 155, 340, 346, 630, 636, "Llopis" +430, 6, 92, 156, 347, 349, 637, 639, "MD" +430, 6, 93, 157, 350, 351, 640, 641, "," +430, 6, 94, 158, 352, 356, 642, 646, "Garc" +430, 6, 95, 159, 357, 358, 647, 648, "í" +430, 6, 96, 160, 359, 360, 649, 650, "a" +430, 6, 97, 161, 361, 362, 651, 652, "-" +430, 6, 98, 162, 363, 370, 653, 660, "Delpech" +430, 6, 99, 163, 371, 372, 661, 662, "S" +430, 6, 100, 164, 373, 374, 663, 664, "," +430, 6, 101, 165, 375, 379, 665, 669, "Garc" +430, 6, 102, 166, 380, 381, 670, 671, "í" +430, 6, 103, 167, 382, 383, 672, 673, "a" +430, 6, 104, 168, 384, 385, 674, 675, "-" +430, 6, 105, 169, 386, 390, 676, 680, "Pous" +430, 6, 106, 170, 391, 392, 681, 682, "M" +430, 6, 107, 171, 393, 394, 683, 684, "," +430, 6, 108, 172, 395, 403, 685, 693, "Honrubia" +430, 6, 109, 173, 404, 405, 694, 695, "F" +430, 6, 110, 174, 406, 407, 696, 697, "," +430, 6, 111, 175, 408, 413, 698, 703, "Pablo" +430, 6, 112, 176, 414, 415, 704, 705, "L" +430, 6, 113, 177, 416, 417, 706, 707, "," +430, 6, 114, 178, 418, 425, 708, 715, "Larrosa" +430, 6, 115, 179, 426, 428, 716, 718, "LM" +430, 6, 116, 180, 429, 430, 719, 720, "," +430, 6, 117, 181, 431, 435, 721, 725, "Polo" +430, 6, 118, 182, 436, 437, 726, 727, "V" +430, 6, 119, 183, 438, 439, 728, 729, "," +430, 6, 120, 184, 440, 446, 730, 736, "Tuesta" +430, 6, 121, 185, 447, 449, 737, 739, "SD" +430, 6, 122, 186, 450, 451, 740, 741, "," +430, 6, 123, 187, 452, 457, 742, 747, "Milla" +430, 6, 124, 188, 458, 459, 748, 749, "E" +430, 6, 125, 189, 460, 461, 750, 751, "." +430, 6, 126, 190, 462, 468, 752, 758, "Author" +430, 6, 127, 191, 469, 480, 759, 770, "information" +430, 6, 128, 192, 481, 482, 771, 772, ":" +430, 6, 129, 193, 483, 484, 773, 774, "(" +430, 6, 130, 194, 485, 486, 775, 776, "1" +430, 6, 131, 195, 487, 488, 777, 778, ")" +430, 6, 132, 196, 489, 499, 779, 789, "Department" +430, 6, 133, 197, 500, 502, 790, 792, "of" +430, 6, 134, 198, 503, 516, 793, 806, "Ophthalmology" +430, 6, 135, 199, 517, 518, 807, 808, "," +430, 6, 136, 200, 519, 524, 809, 814, "Mainz" +430, 6, 137, 201, 525, 535, 815, 825, "University" +430, 6, 138, 202, 536, 537, 826, 827, "," +430, 6, 139, 203, 538, 551, 828, 841, "Langenbeckstr" +430, 6, 140, 204, 552, 553, 842, 843, "." +430, 7, 1, 205, 0, 1, 844, 845, "1" +430, 7, 2, 206, 2, 3, 846, 847, "," +430, 7, 3, 207, 4, 9, 848, 853, "55131" +430, 7, 4, 208, 10, 11, 854, 855, "," +430, 7, 5, 209, 12, 17, 856, 861, "Mainz" +430, 7, 6, 210, 18, 19, 862, 863, "," +430, 7, 7, 211, 20, 27, 864, 871, "Germany" +430, 7, 8, 212, 28, 29, 872, 873, "." +430, 8, 1, 213, 0, 8, 874, 882, "pfeiffer" +430, 8, 2, 214, 9, 10, 883, 884, "@" +430, 8, 3, 215, 11, 16, 885, 890, "augen" +430, 8, 4, 216, 17, 18, 891, 892, "." +430, 8, 5, 217, 19, 25, 893, 899, "klinik" +430, 8, 6, 218, 26, 27, 900, 901, "." +430, 8, 7, 219, 28, 31, 902, 905, "uni" +430, 8, 8, 220, 32, 33, 906, 907, "-" +430, 8, 9, 221, 34, 39, 908, 913, "mainz" +430, 8, 10, 222, 40, 41, 914, 915, "." +430, 8, 11, 223, 42, 44, 916, 918, "de" +430, 8, 12, 224, 45, 55, 919, 929, "BACKGROUND" +430, 8, 13, 225, 56, 57, 930, 931, ":" +430, 8, 14, 226, 58, 60, 932, 934, "To" +430, 8, 15, 227, 61, 68, 935, 942, "compare" +430, 8, 16, 228, 69, 72, 943, 946, "the" +430, 8, 17, 229, 73, 81, 947, 955, "efficacy" +430, 8, 18, 230, 82, 85, 956, 959, "and" +430, 8, 19, 231, 86, 92, 960, 966, "safety" +430, 8, 20, 232, 93, 95, 967, 969, "of" +430, 8, 21, 233, 96, 103, 970, 977, "timolol" +430, 8, 22, 234, 104, 105, 978, 979, "0" +430, 8, 23, 235, 106, 107, 980, 981, "." +430, 8, 24, 236, 108, 109, 982, 983, "5" +430, 8, 25, 237, 110, 111, 984, 985, "%" +430, 8, 26, 238, 112, 118, 986, 992, "versus" +430, 8, 27, 239, 119, 131, 993, 1005, "brinzolamide" +430, 8, 28, 240, 132, 133, 1006, 1007, "1" +430, 8, 29, 241, 134, 135, 1008, 1009, "." +430, 8, 30, 242, 136, 137, 1010, 1011, "0" +430, 8, 31, 243, 138, 139, 1012, 1013, "%" +430, 8, 32, 244, 140, 144, 1014, 1018, "when" +430, 8, 33, 245, 145, 150, 1019, 1024, "added" +430, 8, 34, 246, 151, 153, 1025, 1027, "to" +430, 8, 35, 247, 154, 164, 1028, 1038, "travoprost" +430, 8, 36, 248, 165, 176, 1039, 1050, "monotherapy" +430, 8, 37, 249, 177, 179, 1051, 1053, "in" +430, 8, 38, 250, 180, 188, 1054, 1062, "patients" +430, 8, 39, 251, 189, 193, 1063, 1067, "with" +430, 8, 40, 252, 194, 201, 1068, 1075, "primary" +430, 8, 41, 253, 202, 206, 1076, 1080, "open" +430, 8, 42, 254, 207, 208, 1081, 1082, "-" +430, 8, 43, 255, 209, 214, 1083, 1088, "angle" +430, 8, 44, 256, 215, 223, 1089, 1097, "glaucoma" +430, 8, 45, 257, 224, 226, 1098, 1100, "or" +430, 8, 46, 258, 227, 233, 1101, 1107, "ocular" +430, 8, 47, 259, 234, 246, 1108, 1120, "hypertension" +430, 8, 48, 260, 247, 248, 1121, 1122, "." +430, 9, 1, 261, 0, 7, 1123, 1130, "METHODS" +430, 9, 2, 262, 8, 9, 1131, 1132, ":" +430, 9, 3, 263, 10, 18, 1133, 1141, "Patients" +430, 9, 4, 264, 19, 26, 1142, 1149, "meeting" +430, 9, 5, 265, 27, 36, 1150, 1159, "selection" +430, 9, 6, 266, 37, 45, 1160, 1168, "criteria" +430, 9, 7, 267, 46, 47, 1169, 1170, "(" +430, 9, 8, 268, 48, 51, 1171, 1174, "IOP" +430, 9, 9, 269, 52, 55, 1175, 1178, "one" +430, 9, 10, 270, 56, 59, 1179, 1182, "eye" +430, 9, 11, 271, 60, 62, 1183, 1185, "19" +430, 9, 12, 272, 63, 64, 1186, 1187, " " +430, 9, 13, 273, 65, 69, 1188, 1192, "mmHg" +430, 9, 14, 274, 70, 73, 1193, 1196, "and" +430, 9, 15, 275, 74, 75, 1197, 1198, "≤" +430, 9, 16, 276, 76, 78, 1199, 1201, "32" +430, 9, 17, 277, 79, 80, 1202, 1203, " " +430, 9, 18, 278, 81, 85, 1204, 1208, "mmHg" +430, 9, 19, 279, 86, 89, 1209, 1212, "and" +430, 9, 20, 280, 90, 93, 1213, 1216, "IOP" +430, 9, 21, 281, 94, 98, 1217, 1221, "both" +430, 9, 22, 282, 99, 103, 1222, 1226, "eyes" +430, 9, 23, 283, 104, 105, 1227, 1228, "≤" +430, 9, 24, 284, 106, 108, 1229, 1231, "32" +430, 9, 25, 285, 109, 110, 1232, 1233, " " +430, 9, 26, 286, 111, 115, 1234, 1238, "mmHg" +430, 9, 27, 287, 116, 118, 1239, 1241, "at" +430, 9, 28, 288, 119, 120, 1242, 1243, "8" +430, 9, 29, 289, 121, 122, 1244, 1245, ":" +430, 9, 30, 290, 123, 125, 1246, 1248, "00" +430, 9, 31, 291, 126, 127, 1249, 1250, " " +430, 9, 32, 292, 128, 129, 1251, 1252, "h" +430, 9, 33, 293, 130, 131, 1253, 1254, ")" +430, 9, 34, 294, 132, 136, 1255, 1259, "were" +430, 9, 35, 295, 137, 145, 1260, 1268, "switched" +430, 9, 36, 296, 146, 148, 1269, 1271, "to" +430, 9, 37, 297, 149, 159, 1272, 1282, "travoprost" +430, 9, 38, 298, 160, 171, 1283, 1294, "monotherapy" +430, 9, 39, 299, 172, 175, 1295, 1298, "for" +430, 9, 40, 300, 176, 177, 1299, 1300, "4" +430, 9, 41, 301, 178, 179, 1301, 1302, " " +430, 9, 42, 302, 180, 185, 1303, 1308, "weeks" +430, 9, 43, 303, 186, 187, 1309, 1310, "." +430, 10, 1, 304, 0, 8, 1311, 1319, "Patients" +430, 10, 2, 305, 9, 13, 1320, 1324, "then" +430, 10, 3, 306, 14, 28, 1325, 1339, "insufficiently" +430, 10, 4, 307, 29, 39, 1340, 1350, "controlled" +430, 10, 5, 308, 40, 42, 1351, 1353, "on" +430, 10, 6, 309, 43, 53, 1354, 1364, "travoprost" +430, 10, 7, 310, 54, 55, 1365, 1366, "(" +430, 10, 8, 311, 56, 59, 1367, 1370, "IOP" +430, 10, 9, 312, 60, 62, 1371, 1373, "at" +430, 10, 10, 313, 63, 64, 1374, 1375, "8" +430, 10, 11, 314, 65, 66, 1376, 1377, ":" +430, 10, 12, 315, 67, 69, 1378, 1380, "00" +430, 10, 13, 316, 70, 71, 1381, 1382, " " +430, 10, 14, 317, 72, 73, 1383, 1384, "h" +430, 10, 15, 318, 74, 75, 1385, 1386, "≥" +430, 10, 16, 319, 76, 78, 1387, 1389, "19" +430, 10, 17, 320, 79, 80, 1390, 1391, " " +430, 10, 18, 321, 81, 85, 1392, 1396, "mmHg" +430, 10, 19, 322, 86, 87, 1397, 1398, ")" +430, 10, 20, 323, 88, 90, 1399, 1401, "at" +430, 10, 21, 324, 91, 99, 1402, 1410, "baseline" +430, 10, 22, 325, 100, 104, 1411, 1415, "were" +430, 10, 23, 326, 105, 115, 1416, 1426, "randomized" +430, 10, 24, 327, 116, 118, 1427, 1429, "to" +430, 10, 25, 328, 119, 126, 1430, 1437, "receive" +430, 10, 26, 329, 127, 133, 1438, 1444, "either" +430, 10, 27, 330, 134, 144, 1445, 1455, "travoprost" +430, 10, 28, 331, 145, 148, 1456, 1459, "and" +430, 10, 29, 332, 149, 161, 1460, 1472, "brinzolamide" +430, 10, 30, 333, 162, 164, 1473, 1475, "or" +430, 10, 31, 334, 165, 175, 1476, 1486, "travoprost" +430, 10, 32, 335, 176, 179, 1487, 1490, "and" +430, 10, 33, 336, 180, 187, 1491, 1498, "timolol" +430, 10, 34, 337, 188, 190, 1499, 1501, "in" +430, 10, 35, 338, 191, 192, 1502, 1503, "a" +430, 10, 36, 339, 193, 199, 1504, 1510, "double" +430, 10, 37, 340, 200, 201, 1511, 1512, "-" +430, 10, 38, 341, 202, 208, 1513, 1519, "masked" +430, 10, 39, 342, 209, 216, 1520, 1527, "fashion" +430, 10, 40, 343, 217, 220, 1528, 1531, "for" +430, 10, 41, 344, 221, 223, 1532, 1534, "12" +430, 10, 42, 345, 224, 225, 1535, 1536, " " +430, 10, 43, 346, 226, 231, 1537, 1542, "weeks" +430, 10, 44, 347, 232, 233, 1543, 1544, "." +430, 11, 1, 348, 0, 7, 1545, 1552, "RESULTS" +430, 11, 2, 349, 8, 9, 1553, 1554, ":" +430, 11, 3, 350, 10, 13, 1555, 1558, "Two" +430, 11, 4, 351, 14, 21, 1559, 1566, "hundred" +430, 11, 5, 352, 22, 25, 1567, 1570, "and" +430, 11, 6, 353, 26, 31, 1571, 1576, "fifty" +430, 11, 7, 354, 32, 33, 1577, 1578, "-" +430, 11, 8, 355, 34, 39, 1579, 1584, "three" +430, 11, 9, 356, 40, 48, 1585, 1593, "patients" +430, 11, 10, 357, 49, 58, 1594, 1603, "underwent" +430, 11, 11, 358, 59, 62, 1604, 1607, "the" +430, 11, 12, 359, 63, 64, 1608, 1609, "4" +430, 11, 13, 360, 65, 66, 1610, 1611, "-" +430, 11, 14, 361, 67, 71, 1612, 1616, "week" +430, 11, 15, 362, 72, 75, 1617, 1620, "run" +430, 11, 16, 363, 76, 77, 1621, 1622, "-" +430, 11, 17, 364, 78, 80, 1623, 1625, "in" +430, 11, 18, 365, 81, 87, 1626, 1632, "period" +430, 11, 19, 366, 88, 89, 1633, 1634, "." +430, 12, 1, 367, 0, 9, 1635, 1644, "Switching" +430, 12, 2, 368, 10, 12, 1645, 1647, "to" +430, 12, 3, 369, 13, 23, 1648, 1658, "travoprost" +430, 12, 4, 370, 24, 32, 1659, 1667, "resulted" +430, 12, 5, 371, 33, 35, 1668, 1670, "in" +430, 12, 6, 372, 36, 44, 1671, 1679, "adequate" +430, 12, 7, 373, 45, 48, 1680, 1683, "IOP" +430, 12, 8, 374, 49, 56, 1684, 1691, "control" +430, 12, 9, 375, 57, 58, 1692, 1693, "(" +430, 12, 10, 376, 59, 60, 1694, 1695, "<" +430, 12, 11, 377, 61, 63, 1696, 1698, "19" +430, 12, 12, 378, 64, 65, 1699, 1700, " " +430, 12, 13, 379, 66, 70, 1701, 1705, "mmHg" +430, 12, 14, 380, 71, 72, 1706, 1707, ")" +430, 12, 15, 381, 73, 76, 1708, 1711, "for" +430, 12, 16, 382, 77, 79, 1712, 1714, "21" +430, 12, 17, 383, 80, 81, 1715, 1716, "." +430, 12, 18, 384, 82, 83, 1717, 1718, "7" +430, 12, 19, 385, 84, 85, 1719, 1720, "%" +430, 12, 20, 386, 86, 88, 1721, 1723, "of" +430, 12, 21, 387, 89, 97, 1724, 1732, "patients" +430, 12, 22, 388, 98, 99, 1733, 1734, "." +430, 13, 1, 389, 0, 5, 1735, 1740, "After" +430, 13, 2, 390, 6, 7, 1741, 1742, "3" +430, 13, 3, 391, 8, 9, 1743, 1744, " " +430, 13, 4, 392, 10, 16, 1745, 1751, "months" +430, 13, 5, 393, 17, 19, 1752, 1754, "of" +430, 13, 6, 394, 20, 29, 1755, 1764, "treatment" +430, 13, 7, 395, 30, 31, 1765, 1766, "," +430, 13, 8, 396, 32, 36, 1767, 1771, "both" +430, 13, 9, 397, 37, 41, 1772, 1776, "drug" +430, 13, 10, 398, 42, 54, 1777, 1789, "combinations" +430, 13, 11, 399, 55, 68, 1790, 1803, "statistically" +430, 13, 12, 400, 69, 82, 1804, 1817, "significantly" +430, 13, 13, 401, 83, 90, 1818, 1825, "reduced" +430, 13, 14, 402, 91, 94, 1826, 1829, "the" +430, 13, 15, 403, 95, 99, 1830, 1834, "mean" +430, 13, 16, 404, 100, 103, 1835, 1838, "IOP" +430, 13, 17, 405, 104, 106, 1839, 1841, "at" +430, 13, 18, 406, 107, 111, 1842, 1846, "each" +430, 13, 19, 407, 112, 116, 1847, 1851, "time" +430, 13, 20, 408, 117, 122, 1852, 1857, "point" +430, 13, 21, 409, 123, 124, 1858, 1859, "(" +430, 13, 22, 410, 125, 126, 1860, 1861, "8" +430, 13, 23, 411, 127, 128, 1862, 1863, ":" +430, 13, 24, 412, 129, 131, 1864, 1866, "00" +430, 13, 25, 413, 132, 133, 1867, 1868, "," +430, 13, 26, 414, 134, 136, 1869, 1871, "12" +430, 13, 27, 415, 137, 138, 1872, 1873, ":" +430, 13, 28, 416, 139, 141, 1874, 1876, "00" +430, 13, 29, 417, 142, 145, 1877, 1880, "and" +430, 13, 30, 418, 146, 148, 1881, 1883, "16" +430, 13, 31, 419, 149, 150, 1884, 1885, ":" +430, 13, 32, 420, 151, 153, 1886, 1888, "00" +430, 13, 33, 421, 154, 155, 1889, 1890, " " +430, 13, 34, 422, 156, 157, 1891, 1892, "h" +430, 13, 35, 423, 158, 159, 1893, 1894, ")" +430, 13, 36, 424, 160, 163, 1895, 1898, "and" +430, 13, 37, 425, 164, 167, 1899, 1902, "the" +430, 13, 38, 426, 168, 172, 1903, 1907, "mean" +430, 13, 39, 427, 173, 180, 1908, 1915, "diurnal" +430, 13, 40, 428, 181, 184, 1916, 1919, "IOP" +430, 13, 41, 429, 185, 186, 1920, 1921, "," +430, 13, 42, 430, 187, 192, 1922, 1927, "which" +430, 13, 43, 431, 193, 196, 1928, 1931, "was" +430, 13, 44, 432, 197, 199, 1932, 1934, "17" +430, 13, 45, 433, 200, 201, 1935, 1936, "." +430, 13, 46, 434, 202, 203, 1937, 1938, "9" +430, 13, 47, 435, 204, 207, 1939, 1942, " ± " +430, 13, 48, 436, 208, 209, 1943, 1944, "2" +430, 13, 49, 437, 210, 211, 1945, 1946, "." +430, 13, 50, 438, 212, 213, 1947, 1948, "6" +430, 13, 51, 439, 214, 215, 1949, 1950, " " +430, 13, 52, 440, 216, 220, 1951, 1955, "mmHg" +430, 13, 53, 441, 221, 224, 1956, 1959, "for" +430, 13, 54, 442, 225, 228, 1960, 1963, "the" +430, 13, 55, 443, 229, 241, 1964, 1976, "brinzolamide" +430, 13, 56, 444, 242, 247, 1977, 1982, "group" +430, 13, 57, 445, 248, 251, 1983, 1986, "and" +430, 13, 58, 446, 252, 254, 1987, 1989, "17" +430, 13, 59, 447, 255, 256, 1990, 1991, "." +430, 13, 60, 448, 257, 258, 1992, 1993, "0" +430, 13, 61, 449, 259, 262, 1994, 1997, " ± " +430, 13, 62, 450, 263, 264, 1998, 1999, "3" +430, 13, 63, 451, 265, 266, 2000, 2001, "." +430, 13, 64, 452, 267, 268, 2002, 2003, "2" +430, 13, 65, 453, 269, 270, 2004, 2005, " " +430, 13, 66, 454, 271, 275, 2006, 2010, "mmHg" +430, 13, 67, 455, 276, 279, 2011, 2014, "for" +430, 13, 68, 456, 280, 283, 2015, 2018, "the" +430, 13, 69, 457, 284, 291, 2019, 2026, "timolol" +430, 13, 70, 458, 292, 297, 2027, 2032, "group" +430, 13, 71, 459, 298, 299, 2033, 2034, "." +430, 14, 1, 460, 0, 4, 2035, 2039, "Both" +430, 14, 2, 461, 5, 17, 2040, 2052, "combinations" +430, 14, 3, 462, 18, 22, 2053, 2057, "were" +430, 14, 4, 463, 23, 27, 2058, 2062, "well" +430, 14, 5, 464, 28, 29, 2063, 2064, "-" +430, 14, 6, 465, 30, 39, 2065, 2074, "tolerated" +430, 14, 7, 466, 40, 41, 2075, 2076, "." +430, 15, 1, 467, 0, 7, 2077, 2084, "However" +430, 15, 2, 468, 8, 9, 2085, 2086, "," +430, 15, 3, 469, 10, 11, 2087, 2088, "a" +430, 15, 4, 470, 12, 25, 2089, 2102, "statistically" +430, 15, 5, 471, 26, 37, 2103, 2114, "significant" +430, 15, 6, 472, 38, 48, 2115, 2125, "difference" +430, 15, 7, 473, 49, 57, 2126, 2134, "occurred" +430, 15, 8, 474, 58, 60, 2135, 2137, "at" +430, 15, 9, 475, 61, 63, 2138, 2140, "16" +430, 15, 10, 476, 64, 65, 2141, 2142, ":" +430, 15, 11, 477, 66, 68, 2143, 2145, "00" +430, 15, 12, 478, 69, 70, 2146, 2147, "h" +430, 15, 13, 479, 71, 72, 2148, 2149, "," +430, 15, 14, 480, 73, 77, 2150, 2154, "with" +430, 15, 15, 481, 78, 87, 2155, 2164, "pressures" +430, 15, 16, 482, 88, 90, 2165, 2167, "of" +430, 15, 17, 483, 91, 93, 2168, 2170, "16" +430, 15, 18, 484, 94, 95, 2171, 2172, "." +430, 15, 19, 485, 96, 97, 2173, 2174, "4" +430, 15, 20, 486, 98, 101, 2175, 2178, " ± " +430, 15, 21, 487, 102, 103, 2179, 2180, "3" +430, 15, 22, 488, 104, 105, 2181, 2182, "." +430, 15, 23, 489, 106, 107, 2183, 2184, "2" +430, 15, 24, 490, 108, 109, 2185, 2186, " " +430, 15, 25, 491, 110, 114, 2187, 2191, "mmHg" +430, 15, 26, 492, 115, 118, 2192, 2195, "and" +430, 15, 27, 493, 119, 121, 2196, 2198, "17" +430, 15, 28, 494, 122, 123, 2199, 2200, "." +430, 15, 29, 495, 124, 125, 2201, 2202, "3" +430, 15, 30, 496, 126, 129, 2203, 2206, " ± " +430, 15, 31, 497, 130, 131, 2207, 2208, "2" +430, 15, 32, 498, 132, 133, 2209, 2210, "." +430, 15, 33, 499, 134, 135, 2211, 2212, "8" +430, 15, 34, 500, 136, 137, 2213, 2214, " " +430, 15, 35, 501, 138, 142, 2215, 2219, "mmHg" +430, 15, 36, 502, 143, 146, 2220, 2223, "for" +430, 15, 37, 503, 147, 150, 2224, 2227, "the" +430, 15, 38, 504, 151, 158, 2228, 2235, "timolol" +430, 15, 39, 505, 159, 162, 2236, 2239, "and" +430, 15, 40, 506, 163, 175, 2240, 2252, "brinzolamide" +430, 15, 41, 507, 176, 182, 2253, 2259, "groups" +430, 15, 42, 508, 183, 184, 2260, 2261, "," +430, 15, 43, 509, 185, 197, 2262, 2274, "respectively" +430, 15, 44, 510, 198, 199, 2275, 2276, "(" +430, 15, 45, 511, 200, 201, 2277, 2278, "p" +430, 15, 46, 512, 202, 205, 2279, 2282, " = " +430, 15, 47, 513, 206, 207, 2283, 2284, "0" +430, 15, 48, 514, 208, 209, 2285, 2286, "." +430, 15, 49, 515, 210, 213, 2287, 2290, "038" +430, 15, 50, 516, 214, 215, 2291, 2292, ")" +430, 15, 51, 517, 216, 217, 2293, 2294, "." +430, 16, 1, 518, 0, 5, 2295, 2300, "Fifty" +430, 16, 2, 519, 6, 13, 2301, 2308, "percent" +430, 16, 3, 520, 14, 16, 2309, 2311, "of" +430, 16, 4, 521, 17, 25, 2312, 2320, "patients" +430, 16, 5, 522, 26, 34, 2321, 2329, "reported" +430, 16, 6, 523, 35, 38, 2330, 2333, "one" +430, 16, 7, 524, 39, 46, 2334, 2341, "adverse" +430, 16, 8, 525, 47, 52, 2342, 2347, "event" +430, 16, 9, 526, 53, 54, 2348, 2349, "," +430, 16, 10, 527, 55, 62, 2350, 2357, "whereas" +430, 16, 11, 528, 63, 65, 2358, 2360, "in" +430, 16, 12, 529, 66, 68, 2361, 2363, "13" +430, 16, 13, 530, 69, 70, 2364, 2365, "." +430, 16, 14, 531, 71, 72, 2366, 2367, "2" +430, 16, 15, 532, 73, 74, 2368, 2369, "%" +430, 16, 16, 533, 75, 80, 2370, 2375, "three" +430, 16, 17, 534, 81, 83, 2376, 2378, "or" +430, 16, 18, 535, 84, 88, 2379, 2383, "more" +430, 16, 19, 536, 89, 96, 2384, 2391, "adverse" +430, 16, 20, 537, 97, 104, 2392, 2399, "effects" +430, 16, 21, 538, 105, 109, 2400, 2404, "were" +430, 16, 22, 539, 110, 115, 2405, 2410, "named" +430, 16, 23, 540, 116, 117, 2411, 2412, "." +430, 17, 1, 541, 0, 9, 2413, 2422, "Hyperemia" +430, 17, 2, 542, 10, 13, 2423, 2426, "was" +430, 17, 3, 543, 14, 19, 2427, 2432, "found" +430, 17, 4, 544, 20, 24, 2433, 2437, "most" +430, 17, 5, 545, 25, 30, 2438, 2443, "often" +430, 17, 6, 546, 31, 32, 2444, 2445, "(" +430, 17, 7, 547, 33, 34, 2446, 2447, "6" +430, 17, 8, 548, 35, 36, 2448, 2449, "." +430, 17, 9, 549, 37, 38, 2450, 2451, "3" +430, 17, 10, 550, 39, 40, 2452, 2453, "%" +430, 17, 11, 551, 41, 43, 2454, 2456, "of" +430, 17, 12, 552, 44, 47, 2457, 2460, "the" +430, 17, 13, 553, 48, 56, 2461, 2469, "patients" +430, 17, 14, 554, 57, 58, 2470, 2471, ")" +430, 17, 15, 555, 59, 60, 2472, 2473, "." +430, 18, 1, 556, 0, 10, 2474, 2484, "CONCLUSION" +430, 18, 2, 557, 11, 12, 2485, 2486, ":" +430, 18, 3, 558, 13, 17, 2487, 2491, "Both" +430, 18, 4, 559, 18, 28, 2492, 2502, "adjunctive" +430, 18, 5, 560, 29, 41, 2503, 2515, "combinations" +430, 18, 6, 561, 42, 52, 2516, 2526, "moderately" +430, 18, 7, 562, 53, 60, 2527, 2534, "reduced" +430, 18, 8, 563, 61, 64, 2535, 2538, "IOP" +430, 18, 9, 564, 65, 67, 2539, 2541, "in" +430, 18, 10, 565, 68, 76, 2542, 2550, "patients" +430, 18, 11, 566, 77, 89, 2551, 2563, "inadequately" +430, 18, 12, 567, 90, 100, 2564, 2574, "controlled" +430, 18, 13, 568, 101, 105, 2575, 2579, "with" +430, 18, 14, 569, 106, 116, 2580, 2590, "travoprost" +430, 18, 15, 570, 117, 128, 2591, 2602, "monotherapy" +430, 18, 16, 571, 129, 130, 2603, 2604, "," +430, 18, 17, 572, 131, 135, 2605, 2609, "with" +430, 18, 18, 573, 136, 143, 2610, 2617, "timolol" +430, 18, 19, 574, 144, 149, 2618, 2623, "being" +430, 18, 20, 575, 150, 158, 2624, 2632, "slightly" +430, 18, 21, 576, 159, 167, 2633, 2641, "stronger" +430, 18, 22, 577, 168, 169, 2642, 2643, "8" +430, 18, 23, 578, 170, 175, 2644, 2649, "hours" +430, 18, 24, 579, 176, 181, 2650, 2655, "after" +430, 18, 25, 580, 182, 194, 2656, 2668, "instillation" +430, 18, 26, 581, 195, 196, 2669, 2670, "." +430, 19, 1, 582, 0, 10, 2671, 2681, "Adjunctive" +430, 19, 2, 583, 11, 20, 2682, 2691, "treatment" +430, 19, 3, 584, 21, 25, 2692, 2696, "with" +430, 19, 4, 585, 26, 38, 2697, 2709, "brinzolamide" +430, 19, 5, 586, 39, 42, 2710, 2713, "and" +430, 19, 6, 587, 43, 53, 2714, 2724, "travoprost" +430, 19, 7, 588, 54, 57, 2725, 2728, "may" +430, 19, 8, 589, 58, 60, 2729, 2731, "be" +430, 19, 9, 590, 61, 63, 2732, 2734, "an" +430, 19, 10, 591, 64, 75, 2735, 2746, "alternative" +430, 19, 11, 592, 76, 79, 2747, 2750, "for" +430, 19, 12, 593, 80, 88, 2751, 2759, "patients" +430, 19, 13, 594, 89, 92, 2760, 2763, "not" +430, 19, 14, 595, 93, 101, 2764, 2772, "tolerant" +430, 19, 15, 596, 102, 104, 2773, 2775, "or" +430, 19, 16, 597, 105, 108, 2776, 2779, "not" +430, 19, 17, 598, 109, 119, 2780, 2790, "responsive" +430, 19, 18, 599, 120, 122, 2791, 2793, "to" +430, 19, 19, 600, 123, 132, 2794, 2803, "treatment" +430, 19, 20, 601, 133, 137, 2804, 2808, "with" +430, 19, 21, 602, 138, 145, 2809, 2816, "timolol" +430, 19, 22, 603, 146, 149, 2817, 2820, "and" +430, 19, 23, 604, 150, 160, 2821, 2831, "travoprost" +430, 19, 24, 605, 161, 162, 2832, 2833, "." +430, 20, 1, 606, 0, 3, 2834, 2837, "DOI" +430, 20, 2, 607, 4, 5, 2838, 2839, ":" +430, 20, 3, 608, 6, 8, 2840, 2842, "10" +430, 20, 4, 609, 9, 10, 2843, 2844, "." +430, 20, 5, 610, 11, 15, 2845, 2849, "1007" +430, 20, 6, 611, 16, 17, 2850, 2851, "/" +430, 20, 7, 612, 18, 24, 2852, 2858, "s00417" +430, 20, 8, 613, 25, 26, 2859, 2860, "-" +430, 20, 9, 614, 27, 30, 2861, 2864, "011" +430, 20, 10, 615, 31, 32, 2865, 2866, "-" +430, 20, 11, 616, 33, 37, 2867, 2871, "1650" +430, 20, 12, 617, 38, 39, 2872, 2873, "-" +430, 20, 13, 618, 40, 41, 2874, 2875, "8" +430, 20, 14, 619, 42, 46, 2876, 2880, "PMID" +430, 20, 15, 620, 47, 48, 2881, 2882, ":" +430, 20, 16, 621, 49, 57, 2883, 2891, "21499770" +430, 20, 17, 622, 58, 59, 2892, 2893, "[" +430, 20, 18, 623, 60, 67, 2894, 2901, "Indexed" +430, 20, 19, 624, 68, 71, 2902, 2905, "for" +430, 20, 20, 625, 72, 79, 2906, 2913, "MEDLINE" +430, 20, 21, 626, 80, 81, 2914, 2915, "]" diff --git a/data/gl 21499770_jshahinitiran.annodb b/data/gl 21499770_jshahinitiran.annodb new file mode 100644 index 0000000..26d2c66 --- /dev/null +++ b/data/gl 21499770_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +447, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +448, PublicationYear, 35, 39, "2011", "", +449, Title, 133, 217, "Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension .", "", +453, Timolol, 133, 140, "Timolol", "", +460, Brinzolamide, 148, 160, "brinzolamide", "", +466, Drug, 170, 180, "travoprost", "travoprost", +467, Glaucoma, 184, 192, "glaucoma", "", +469, OcularHypertension, 196, 215, "ocular hypertension", "", +450, Author, 218, 228, "Pfeiffer N", "", +451, Germany, 864, 871, "Germany", "", +472, ObjectiveDescription, 932, 1122, "To compare the efficacy and safety of timolol 0 . 5 % versus brinzolamide 1 . 0 % when added to travoprost monotherapy in patients with primary open - angle glaucoma or ocular hypertension .", "", +454, Timolol, 970, 977, "timolol", "", +477, DoseValue, 978, 979, "0", "tim", +478, Percentage, 984, 985, "%", "tim", +461, Brinzolamide, 993, 1005, "brinzolamide", "", +473, DoseValue, 1006, 1011, "1 . 0", "bri", +479, Percentage, 1012, 1013, "%", "bri", +36133, Travoprost, 1028, 1038, "travoprost", "", +36132, Primary_OpenAngleGlaucoma, 1068, 1097, "primary open - angle glaucoma", "", +483, OcularHypertension, 1101, 1120, "ocular hypertension", "", +36134, IOP, 1171, 1174, "IOP", "", +452, Precondition, 1171, 1252, "IOP one eye 19   mmHg and ≤ 32   mmHg and IOP both eyes ≤ 32   mmHg at 8 : 00   h", "", +36135, mmHg, 1188, 1196, "mmHg and", "", +36136, mmHg, 1204, 1208, "mmHg", "", +36137, IOP, 1213, 1216, "IOP", "", +36138, mmHg, 1234, 1238, "mmHg", "", +36139, Travoprost, 1272, 1282, "travoprost", "", +36148, Duration, 1299, 1308, "4   weeks", "", +36140, Travoprost, 1354, 1364, "travoprost", "", +36141, IOP, 1367, 1370, "IOP", "", +36142, mmHg, 1392, 1396, "mmHg", "", +484, Randomized, 1416, 1426, "randomized", "", +36143, Travoprost, 1445, 1455, "travoprost", "", +462, Brinzolamide, 1460, 1472, "brinzolamide", "", +36144, Travoprost, 1476, 1486, "travoprost", "", +455, Timolol, 1491, 1498, "timolol", "", +36145, DoubleBlind, 1504, 1519, "double - masked", "", +36146, Duration, 1532, 1544, "12   weeks .", "", +487, NumberPatientsCT, 1555, 1584, "Two hundred and fifty - three", "", +491, Duration, 1608, 1616, "4 - week", "run-in", +36147, Travoprost, 1648, 1658, "travoprost", "", +36149, IOP, 1680, 1683, "IOP", "", +36150, mmHg, 1699, 1705, "  mmHg", "", +36151, PercentageAffected, 1712, 1718, "21 . 7", "", +36152, TimePoint, 1741, 1751, "3   months", "", +36153, Mean, 1830, 1834, "mean", "", +36154, IOP, 1835, 1838, "IOP", "", +36155, Mean, 1903, 1907, "mean", "", +36156, Diurnal_IOP, 1908, 1919, "diurnal IOP", "", +36157, ResultMeasuredValue, 1932, 1938, "17 . 9", "", +36159, SdErrorResValue, 1943, 1948, "2 . 6", "", +36160, mmHg, 1951, 1955, "mmHg", "", +463, Brinzolamide, 1964, 1976, "brinzolamide", "", +36158, ResultMeasuredValue, 1987, 1993, "17 . 0", "", +36162, SdErrorResValue, 1998, 2003, "3 . 2", "", +36161, mmHg, 2006, 2010, "mmHg", "", +456, Timolol, 2019, 2026, "timolol", "", +36166, EndPointDescription, 2135, 2145, "at 16 : 00", "", +36163, ResultMeasuredValue, 2168, 2174, "16 . 4", "", +36164, SdErrorResValue, 2179, 2184, "3 . 2", "", +36165, mmHg, 2187, 2191, "mmHg", "", +36167, ResultMeasuredValue, 2196, 2202, "17 . 3", "", +36168, SdErrorResValue, 2207, 2212, "2 . 8", "", +36169, mmHg, 2215, 2219, "mmHg", "", +457, Timolol, 2228, 2235, "timolol", "", +464, Brinzolamide, 2240, 2252, "brinzolamide", "", +36170, PvalueDiff, 2277, 2290, "p  =  0 . 038", "", +36171, PercentageAffected, 2295, 2300, "Fifty", "", +36172, PercentageAffected, 2361, 2367, "13 . 2", "", +36173, ConjunctivalHyperemia, 2413, 2422, "Hyperemia", "", +36174, PercentageAffected, 2446, 2451, "6 . 3", "", +36175, PercentageAffected, 2487, 2668, "Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy , with timolol being slightly stronger 8 hours after instillation", "", +36176, IOP, 2535, 2538, "IOP", "", +36177, Travoprost, 2580, 2590, "travoprost", "", +458, Timolol, 2610, 2617, "timolol", "", +36178, ConclusionComment, 2671, 2831, "Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost", "", +465, Brinzolamide, 2697, 2709, "brinzolamide", "", +36179, Travoprost, 2714, 2724, "travoprost", "", +459, Timolol, 2809, 2816, "timolol", "", +36180, Travoprost, 2821, 2831, "travoprost", "", +36181, PMID, 2883, 2891, "21499770", "", diff --git a/data/gl 21499770_jshahinitiran.n-triples b/data/gl 21499770_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21499770_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21499770_tstrakeljahn.annodb b/data/gl 21499770_tstrakeljahn.annodb new file mode 100644 index 0000000..39933b8 --- /dev/null +++ b/data/gl 21499770_tstrakeljahn.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12805, Journal, 0, 32, "Graefes Arch Clin Exp Ophthalmol", "", +12806, PublicationYear, 35, 39, "2011", "", +12807, Timolol, 133, 140, "Timolol", "", +12815, Title, 133, 215, "Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension", "", +12808, Brinzolamide, 148, 160, "brinzolamide", "", +29881, Drug, 170, 180, "travoprost", "Travoprost", +12810, Glaucoma, 184, 192, "glaucoma", "", +12812, OcularHypertension, 196, 215, "ocular hypertension", "", +12813, Author, 218, 228, "Pfeiffer N", "", +12814, Germany, 864, 871, "Germany", "", +12825, Title, 932, 1120, "To compare the efficacy and safety of timolol 0 . 5 % versus brinzolamide 1 . 0 % when added to travoprost monotherapy in patients with primary open - angle glaucoma or ocular hypertension", "", +12816, Timolol, 970, 977, "timolol", "", +12821, DoseValue, 978, 983, "0 . 5", "", +12823, Percentage, 984, 985, "%", "", +12817, Brinzolamide, 993, 1005, "brinzolamide", "", +12822, DoseValue, 1006, 1011, "1 . 0", "", +12824, Percentage, 1012, 1013, "%", "", +29882, Drug, 1028, 1038, "travoprost", "Travoprost", +12819, OpenAngleGlaucoma, 1076, 1097, "open - angle glaucoma", "", +12820, OcularHypertension, 1101, 1120, "ocular hypertension", "", +12826, IOP, 1171, 1174, "IOP", "", +12829, Precondition, 1171, 1252, "IOP one eye 19   mmHg and ≤ 32   mmHg and IOP both eyes ≤ 32   mmHg at 8 : 00   h", "", +29883, Drug, 1272, 1282, "travoprost", "Travoprost", +12828, Duration, 1299, 1308, "4   weeks", "", +29886, Drug, 1354, 1364, "travoprost", "Travoprost", +12836, IOP, 1367, 1370, "IOP", "", +12835, mmHg, 1392, 1396, "mmHg", "", +12837, Randomized, 1416, 1426, "randomized", "", +29884, Drug, 1445, 1455, "travoprost", "Travoprost", +12838, Brinzolamide, 1460, 1472, "brinzolamide", "", +29885, Drug, 1476, 1486, "travoprost", "Travoprost", +12839, Timolol, 1491, 1498, "timolol", "", +12840, DoubleBlind, 1504, 1519, "double - masked", "", +12841, Duration, 1532, 1542, "12   weeks", "", +12842, NumberPatientsCT, 1555, 1584, "Two hundred and fifty - three", "", +29887, Drug, 1648, 1658, "travoprost", "Travoprost", +12843, IOP, 1680, 1683, "IOP", "", +12844, PercentageAffected, 1712, 1718, "21 . 7", "", +12845, TimePoint, 1741, 1751, "3   months", "", +12846, Mean, 1830, 1834, "mean", "", +12847, IOP, 1835, 1838, "IOP", "", +12848, Mean, 1903, 1907, "mean", "", +12849, Diurnal_IOP, 1908, 1919, "diurnal IOP", "", +12850, ResultMeasuredValue, 1932, 1938, "17 . 9", "", +12852, SdDevResValue, 1943, 1948, "2 . 6", "", +12855, mmHg, 1951, 1955, "mmHg", "", +12856, Brinzolamide, 1964, 1976, "brinzolamide", "", +12851, ResultMeasuredValue, 1987, 1993, "17 . 0", "", +12853, SdDevResValue, 1998, 2003, "3 . 2", "", +12854, mmHg, 2006, 2010, "mmHg", "", +12857, Timolol, 2019, 2026, "timolol", "", +12858, ObservedResult, 2035, 2074, "Both combinations were well - tolerated", "", +12859, TimePoint, 2138, 2145, "16 : 00", "", +12860, ResultMeasuredValue, 2168, 2174, "16 . 4", "", +12862, SdDevResValue, 2179, 2184, "3 . 2", "", +12865, mmHg, 2187, 2191, "mmHg", "", +12861, ResultMeasuredValue, 2196, 2202, "17 . 3", "", +12863, SdDevResValue, 2207, 2212, "2 . 8", "", +12864, mmHg, 2215, 2219, "mmHg", "", +12866, Timolol, 2228, 2235, "timolol", "", +12867, Brinzolamide, 2240, 2252, "brinzolamide", "", +12868, PvalueDiff, 2277, 2290, "p  =  0 . 038", "", +12869, PercentageAffected, 2295, 2300, "Fifty", "", +12871, ObservedResult, 2295, 2410, "Fifty percent of patients reported one adverse event , whereas in 13 . 2 % three or more adverse effects were named", "", +12870, PercentageAffected, 2361, 2367, "13 . 2", "", +12872, ConjunctivalHyperemia, 2413, 2422, "Hyperemia", "", +12873, PercentageAffected, 2446, 2451, "6 . 3", "", +12882, ConclusionComment, 2487, 2670, "Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy , with timolol being slightly stronger 8 hours after instillation .", "", +12874, IOP, 2535, 2538, "IOP", "", +12875, Medication, 2580, 2590, "travoprost", "travoprost", +12876, Timolol, 2610, 2617, "timolol", "", +12877, RelativeTime, 2642, 2668, "8 hours after instillation", "", +12881, ConclusionComment, 2671, 2831, "Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost", "", +12878, Brinzolamide, 2697, 2709, "brinzolamide", "", +29888, Drug, 2714, 2724, "travoprost", "Travoprost", +12879, Timolol, 2809, 2816, "timolol", "", +29889, Drug, 2821, 2831, "travoprost", "Travoprost", +12883, PMID, 2883, 2891, "21499770", "", diff --git a/data/gl 21499770_tstrakeljahn.n-triples b/data/gl 21499770_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21499770_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21680022_admin.annodb b/data/gl 21680022_admin.annodb new file mode 100644 index 0000000..78f4c20 --- /dev/null +++ b/data/gl 21680022_admin.annodb @@ -0,0 +1,131 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "2011", "", " \"2011\"." +2, Title, 120, 254, "Comparison of latanoprost and timolol in pediatric glaucoma : a phase 3 , 12 - week , randomized , double - masked multicenter study .", "", " \"Comparison of latanoprost and timolol in pediatric glaucoma : a phase 3 , 12 - week , randomized , double - masked multicenter study .\"." +5, Latanoprost, 134, 145, "latanoprost", "", +16, Timolol, 150, 157, "timolol", "", +119920, Glaucoma, 171, 179, "glaucoma", "", +74, Duration, 194, 203, "12 - week", "", " \"12 - week\"." +75, Randomized, 206, 216, "randomized", "", " ." +76, DoubleBlind, 219, 234, "double - masked", "", " ." +77, Multicenter, 235, 246, "multicenter", "", " ." +3, Author, 255, 273, "Maeda - Chubachi T", "", " \"Maeda - Chubachi T\"." +79, Author, 282, 296, "Chi - Burris K", "", " \"Chi - Burris K\"." +80, Author, 299, 308, "Simons BD", "", " \"Simons BD\"." +81, Author, 311, 322, "Freedman SF", "", " \"Freedman SF\"." +82, Author, 325, 332, "Khaw PT", "", " \"Khaw PT\"." +83, Author, 335, 345, "Wirostko B", "", " \"Wirostko B\"." +84, Author, 348, 353, "Yan E", "", " \"Yan E\"." +85, USA, 446, 449, "USA", "", " ." +4, ObjectiveDescription, 464, 566, "To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma .", "", " \"To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma .\"." +6, Latanoprost, 502, 513, "latanoprost", "", +17, Timolol, 521, 528, "timolol", "", +89, Precondition, 532, 564, "pediatric patients with glaucoma", "", " \"pediatric patients with glaucoma\"." +26, Glaucoma, 556, 564, "glaucoma", "", " . ." +44820, Prospective, 576, 587, "Prospective", "", " ." +30, Randomized, 590, 600, "randomized", "", +91, DoubleBlind, 603, 618, "double - masked", "", +31, Duration, 621, 630, "12 - week", "", " \"12 - week\"." +32, Multicenter, 633, 644, "multicenter", "", +95, Precondition, 668, 709, "Individuals aged ≤ 18 years with glaucoma", "", " \"Individuals aged ≤ 18 years with glaucoma\"." +27, MaxAge, 687, 695, "18 years", "", " \"18 years\"." +33, Glaucoma, 701, 709, "glaucoma", "", +34, Diurnal_IOP, 758, 778, "intraocular pressure", "", +35, Diurnal_IOP, 781, 784, "IOP", "", +29, Randomized, 809, 819, "randomized", "", +28, AllocationRatio, 822, 827, "1 : 1", "", " . ." +7, Latanoprost, 833, 844, "latanoprost", "", " . ." +40, TimePoint, 856, 860, "8 am", "", +10, Latanoprost, 865, 876, "latanoprost", "", " . ." +44, DoseValue, 877, 884, "0 . 005", "", " \"0 . 005\"." +45, Percentage, 885, 886, "%", "", " ." +41, TimePoint, 890, 894, "8 pm", "", +18, Timolol, 898, 905, "timolol", "", +46, DoseValue, 906, 911, "0 . 5", "", " \"0 . 5\"." +47, Percentage, 912, 913, "%", "", " ." +193, DoseValue, 916, 922, "0 . 25", "", +194, DoseValue, 923, 924, "%", "", +48, Frequency, 952, 963, "twice daily", "", " \"twice daily\"." +42, TimePoint, 966, 970, "8 am", "", +43, TimePoint, 973, 977, "8 pm", "", +195, TimePoint, 985, 993, "baseline", "", +196, TimePoint, 998, 1005, "weeks 1", "", +197, TimePoint, 1008, 1009, "4", "", +198, TimePoint, 1016, 1018, "12", "", +36, Diurnal_IOP, 1021, 1024, "IOP", "", +49, OpenLabel, 1116, 1128, "open - label", "", +9, Latanoprost, 1129, 1140, "latanoprost", "", +19, Timolol, 1148, 1155, "timolol", "", +38, Diurnal_IOP, 1183, 1186, "IOP", "", +50, Mean, 1213, 1217, "Mean", "", +37, Diurnal_IOP, 1218, 1221, "IOP", "", +199, TimePoint, 1249, 1256, "week 12", "", +8, Latanoprost, 1259, 1270, "Latanoprost", "", +20, Timolol, 1301, 1308, "timolol", "", +112, mmHg, 1395, 1399, "mmHg", "", +44835, Percentage, 1450, 1451, "%", "", +39, Diurnal_IOP, 1452, 1455, "IOP", "", +200, TimePoint, 1469, 1476, "weeks 4", "", +201, TimePoint, 1481, 1483, "12", "", +119916, Glaucoma, 1552, 1579, "primary congenital glaucoma", "", " . ." +119917, Glaucoma, 1582, 1585, "PCG", "", +204, Glaucoma, 1592, 1601, "non - PCG", "", " . ." +52, NumberPatientsCT, 1625, 1628, "137", "", " \"137\"." +117, Mean, 1751, 1755, "Mean", "", +53, AvgAge, 1764, 1769, "8 . 8", "", " \"137\"." +205, Mean, 1790, 1794, "mean", "", +54, Diurnal_IOP, 1804, 1807, "IOP", "", +55, BaseLineValue, 1812, 1818, "27 . 7", "", " \"27 . 7\". \"27 . 7\"." +120, SdDevBL, 1821, 1827, "6 . 17", "", " \"6 . 17\". \"6 . 17\"." +57, mmHg, 1828, 1832, "mmHg", "", +122, FinalNumPatientsCT, 1835, 1838, "125", "", " \"125\"." +58, PerProtocol, 1899, 1911, "per protocol", "", " ." +124, Mean, 1925, 1929, "Mean", "", " . ." +59, Diurnal_IOP, 1930, 1933, "IOP", "", " ." +11, Latanoprost, 1949, 1960, "latanoprost", "", +21, Timolol, 1965, 1972, "timolol", "", +128, TimePoint, 1976, 1983, "week 12", "", " \"week 12\". \"week 12\"." +129, Reduction, 1989, 1994, "7 . 2", "", " \"7 . 2\"." +130, Reduction, 1999, 2004, "5 . 7", "", " \"5 . 7\"." +62, mmHg, 2005, 2009, "mmHg", "", " ." +63, DiffGroupAbsValue, 2048, 2053, "1 . 5", "", " \"1 . 5\"." +64, mmHg, 2054, 2058, "mmHg", "", +44829, ConfIntervalDiff, 2061, 2087, "95 % CI , - 0 . 8 to 3 . 7", "", " \"95 % CI , - 0 . 8 to 3 . 7\"." +135, PvalueDiff, 2090, 2100, "P = 0 . 21", "", " \"P = 0 . 21\"." +106390, EndPointDescription, 2105, 2120, "Responder rates", "", " . ." +136, PercentageAffected, 2126, 2128, "60", "", " \"60\"." +12, Latanoprost, 2135, 2146, "latanoprost", "", +137, PercentageAffected, 2151, 2153, "52", "", " \"52\"." +22, Timolol, 2160, 2167, "timolol", "", +140, PvalueDiff, 2170, 2180, "P = 0 . 33", "", " \"P = 0 . 33\"." +174, Mean, 2220, 2224, "mean", "", +44837, Diurnal_IOP, 2225, 2228, "IOP", "", +119918, Glaucoma, 2243, 2246, "PCG", "", +44830, Glaucoma, 2251, 2260, "non - PCG", "", +144, DiffGroupAbsValue, 2276, 2281, "0 . 6", "", +146, mmHg, 2282, 2286, "mmHg", "", +148, ConfIntervalDiff, 2289, 2315, "95 % CI , - 2 . 3 to 3 . 4", "", +145, DiffGroupAbsValue, 2322, 2327, "2 . 6", "", +147, mmHg, 2328, 2332, "mmHg", "", +44832, ConfIntervalDiff, 2335, 2361, "95 % CI , - 0 . 8 to 6 . 1", "", +119915, EndPointDescription, 2381, 2396, "Responder rates", "", +13, Latanoprost, 2401, 2412, "latanoprost", "", +25, Timolol, 2420, 2427, "timolol", "", +152, PercentageAffected, 2433, 2435, "50", "", " \"50\"." +153, PercentageAffected, 2445, 2447, "46", "", " \"46\"." +106406, SubGroupDescription, 2458, 2467, "PCG group", "", " \"PCG group\". \"PCG group\"." +155, PercentageAffected, 2472, 2474, "72", "", " \"72\"." +156, PercentageAffected, 2484, 2486, "57", "", " \"57\"." +106407, SubGroupDescription, 2497, 2512, "non - PCG group", "", " \"non - PCG group\". \"non - PCG group\"." +15, Latanoprost, 2566, 2577, "Latanoprost", "", +67, ConclusionComment, 2566, 2763, "Latanoprost 0 . 005 % is not inferior ( i . e . , is either more or similarly effective ) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG .", "", " \"Latanoprost 0 . 005 % is not inferior ( i . e . , is either more or similarly effective ) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG .\"." +44, DoseValue, 2578, 2585, "0 . 005", "", " \"0 . 005\"." +45, Percentage, 2586, 2587, "%", "", " ." +23, Timolol, 2659, 2666, "timolol", "", +44836, Diurnal_IOP, 2700, 2703, "IOP", "", +119919, Glaucoma, 2758, 2761, "PCG", "", +68, ConclusionComment, 2764, 2866, "Both latanoprost and timolol had favorable safety profiles over the duration of this 3 - month trial .", "", " \"Both latanoprost and timolol had favorable safety profiles over the duration of this 3 - month trial .\"." +14, Latanoprost, 2769, 2780, "latanoprost", "", +24, Timolol, 2785, 2792, "timolol", "", +167, Duration, 2849, 2858, "3 - month", "", +170, PMID, 3126, 3134, "21680022", "", " \"21680022\"." diff --git a/data/gl 21680022_admin.n-triples b/data/gl 21680022_admin.n-triples new file mode 100644 index 0000000..d531455 --- /dev/null +++ b/data/gl 21680022_admin.n-triples @@ -0,0 +1,180 @@ +# RDF export of group: Publication + . + "Publication 47673" . + "Comparison of latanoprost and timolol in pediatric glaucoma : a phase 3 , 12 - week , randomized , double - masked multicenter study ." . + "Maeda - Chubachi T" . + "2011" . + "Ophthalmology" . + "21680022" . + . + "Chi - Burris K" . + "Simons BD" . + "Freedman SF" . + "Khaw PT" . + "Wirostko B" . + "Yan E" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 47686" . + "To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma ." . + "137" . + "12 - week" . + . + . + . + . + "Latanoprost 0 . 005 % is not inferior ( i . e . , is either more or similarly effective ) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG ." . + . + . + . + . + . + . + "125" . + . + . + . + "Both latanoprost and timolol had favorable safety profiles over the duration of this 3 - month trial ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 47709" . + "pediatric patients with glaucoma" . + . + . + "18 years" . + "8 . 8" . + . + "Individuals aged ≤ 18 years with glaucoma" . +# RDF export of group: Endpoint + . + "Endpoint_diurnalIOP" . + . + . + . + . + . + . + "Endpoint-ResponseRate" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 47723 Latanoprost and vehicle" . + . + . + . + . + . + . + . + . + "Arm 47778 Timolol" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 47732 Latanoprost vehicle" . + . + . + . + "Intervention 47738 Timolol" . + . + "twice daily" . + "12 - week" . + . + . + "Intervention 47772 Latanoprost" . + . + . +# RDF export of group: Medication + . + "Medication 47750 latanoprost vehicle" . + . + . + . + . + . + "Medication 47757 latanoprost" . + . + . + "0 . 005" . + . + . + . + "Medication 47764 timolol" . + "0 . 5" . + . + . + . +# RDF export of group: Outcome + . + "DiurnalIOP_Latanoprost" . + . + "27 . 7" . + "6 . 17" . + "7 . 2" . + "week 12" . + . + "DiurnalIOP_Timolol" . + . + "27 . 7" . + "6 . 17" . + "5 . 7" . + "week 12" . + . + "Outcome 47843 responder rate Latanoprost" . + . + "60" . + . + "Outcome 47870 responder rate Timolol" . + . + "52" . + . + "Outcome_Responder_lat_pcg" . + . + "50" . + "PCG group" . + . + "Outcome_Respond_lat_npcg" . + . + "72" . + "non - PCG group" . + . + "Outcome_Responder_tim_pcg" . + . + "46" . + "PCG group" . + . + "Outcome_Responder_tim_npcg" . + . + "57" . + "non - PCG group" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 53487 Diurnal IOP" . + "1 . 5" . + "P = 0 . 21" . + "95 % CI , - 0 . 8 to 3 . 7" . + . + . + . + "DiffBetweenGroups_Responder" . + "P = 0 . 33" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21680022_export.csv b/data/gl 21680022_export.csv new file mode 100644 index 0000000..8816b45 --- /dev/null +++ b/data/gl 21680022_export.csv @@ -0,0 +1,703 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +429, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +429, 1, 2, 2, 14, 15, 14, 15, "." +429, 2, 1, 3, 0, 4, 16, 20, "2011" +429, 2, 2, 4, 5, 8, 21, 24, "Oct" +429, 2, 3, 5, 9, 10, 25, 26, ";" +429, 2, 4, 6, 11, 14, 27, 30, "118" +429, 2, 5, 7, 15, 16, 31, 32, "(" +429, 2, 6, 8, 17, 19, 33, 35, "10" +429, 2, 7, 9, 20, 21, 36, 37, ")" +429, 2, 8, 10, 22, 23, 38, 39, ":" +429, 2, 9, 11, 24, 28, 40, 44, "2014" +429, 2, 10, 12, 29, 30, 45, 46, "-" +429, 2, 11, 13, 31, 33, 47, 49, "21" +429, 2, 12, 14, 34, 35, 50, 51, "." +429, 2, 13, 15, 36, 39, 52, 55, "doi" +429, 2, 14, 16, 40, 41, 56, 57, ":" +429, 2, 15, 17, 42, 44, 58, 60, "10" +429, 2, 16, 18, 45, 46, 61, 62, "." +429, 2, 17, 19, 47, 51, 63, 67, "1016" +429, 2, 18, 20, 52, 53, 68, 69, "/" +429, 2, 19, 21, 54, 55, 70, 71, "j" +429, 2, 20, 22, 56, 57, 72, 73, "." +429, 2, 21, 23, 58, 64, 74, 80, "ophtha" +429, 2, 22, 24, 65, 66, 81, 82, "." +429, 2, 23, 25, 67, 71, 83, 87, "2011" +429, 2, 24, 26, 72, 73, 88, 89, "." +429, 2, 25, 27, 74, 76, 90, 92, "03" +429, 2, 26, 28, 77, 78, 93, 94, "." +429, 2, 27, 29, 79, 82, 95, 98, "010" +429, 2, 28, 30, 83, 84, 99, 100, "." +429, 3, 1, 31, 0, 4, 101, 105, "Epub" +429, 3, 2, 32, 5, 9, 106, 110, "2011" +429, 3, 3, 33, 10, 13, 111, 114, "Jun" +429, 3, 4, 34, 14, 16, 115, 117, "16" +429, 3, 5, 35, 17, 18, 118, 119, "." +429, 4, 1, 36, 0, 10, 120, 130, "Comparison" +429, 4, 2, 37, 11, 13, 131, 133, "of" +429, 4, 3, 38, 14, 25, 134, 145, "latanoprost" +429, 4, 4, 39, 26, 29, 146, 149, "and" +429, 4, 5, 40, 30, 37, 150, 157, "timolol" +429, 4, 6, 41, 38, 40, 158, 160, "in" +429, 4, 7, 42, 41, 50, 161, 170, "pediatric" +429, 4, 8, 43, 51, 59, 171, 179, "glaucoma" +429, 4, 9, 44, 60, 61, 180, 181, ":" +429, 4, 10, 45, 62, 63, 182, 183, "a" +429, 4, 11, 46, 64, 69, 184, 189, "phase" +429, 4, 12, 47, 70, 71, 190, 191, "3" +429, 4, 13, 48, 72, 73, 192, 193, "," +429, 4, 14, 49, 74, 76, 194, 196, "12" +429, 4, 15, 50, 77, 78, 197, 198, "-" +429, 4, 16, 51, 79, 83, 199, 203, "week" +429, 4, 17, 52, 84, 85, 204, 205, "," +429, 4, 18, 53, 86, 96, 206, 216, "randomized" +429, 4, 19, 54, 97, 98, 217, 218, "," +429, 4, 20, 55, 99, 105, 219, 225, "double" +429, 4, 21, 56, 106, 107, 226, 227, "-" +429, 4, 22, 57, 108, 114, 228, 234, "masked" +429, 4, 23, 58, 115, 126, 235, 246, "multicenter" +429, 4, 24, 59, 127, 132, 247, 252, "study" +429, 4, 25, 60, 133, 134, 253, 254, "." +429, 5, 1, 61, 0, 5, 255, 260, "Maeda" +429, 5, 2, 62, 6, 7, 261, 262, "-" +429, 5, 3, 63, 8, 16, 263, 271, "Chubachi" +429, 5, 4, 64, 17, 18, 272, 273, "T" +429, 5, 5, 65, 19, 20, 274, 275, "(" +429, 5, 6, 66, 21, 22, 276, 277, "1" +429, 5, 7, 67, 23, 24, 278, 279, ")" +429, 5, 8, 68, 25, 26, 280, 281, "," +429, 5, 9, 69, 27, 30, 282, 285, "Chi" +429, 5, 10, 70, 31, 32, 286, 287, "-" +429, 5, 11, 71, 33, 39, 288, 294, "Burris" +429, 5, 12, 72, 40, 41, 295, 296, "K" +429, 5, 13, 73, 42, 43, 297, 298, "," +429, 5, 14, 74, 44, 50, 299, 305, "Simons" +429, 5, 15, 75, 51, 53, 306, 308, "BD" +429, 5, 16, 76, 54, 55, 309, 310, "," +429, 5, 17, 77, 56, 64, 311, 319, "Freedman" +429, 5, 18, 78, 65, 67, 320, 322, "SF" +429, 5, 19, 79, 68, 69, 323, 324, "," +429, 5, 20, 80, 70, 74, 325, 329, "Khaw" +429, 5, 21, 81, 75, 77, 330, 332, "PT" +429, 5, 22, 82, 78, 79, 333, 334, "," +429, 5, 23, 83, 80, 88, 335, 343, "Wirostko" +429, 5, 24, 84, 89, 90, 344, 345, "B" +429, 5, 25, 85, 91, 92, 346, 347, "," +429, 5, 26, 86, 93, 96, 348, 351, "Yan" +429, 5, 27, 87, 97, 98, 352, 353, "E" +429, 5, 28, 88, 99, 100, 354, 355, ";" +429, 5, 29, 89, 101, 109, 356, 364, "A6111137" +429, 5, 30, 90, 110, 115, 365, 370, "Study" +429, 5, 31, 91, 116, 121, 371, 376, "Group" +429, 5, 32, 92, 122, 123, 377, 378, "." +429, 6, 1, 93, 0, 6, 379, 385, "Author" +429, 6, 2, 94, 7, 18, 386, 397, "information" +429, 6, 3, 95, 19, 20, 398, 399, ":" +429, 6, 4, 96, 21, 22, 400, 401, "(" +429, 6, 5, 97, 23, 24, 402, 403, "1" +429, 6, 6, 98, 25, 26, 404, 405, ")" +429, 6, 7, 99, 27, 33, 406, 412, "Pfizer" +429, 6, 8, 100, 34, 37, 413, 416, "Inc" +429, 6, 9, 101, 38, 39, 417, 418, "," +429, 6, 10, 102, 40, 43, 419, 422, "New" +429, 6, 11, 103, 44, 50, 423, 429, "London" +429, 6, 12, 104, 51, 52, 430, 431, "," +429, 6, 13, 105, 53, 64, 432, 443, "Connecticut" +429, 6, 14, 106, 65, 66, 444, 445, "," +429, 6, 15, 107, 67, 70, 446, 449, "USA" +429, 6, 16, 108, 71, 72, 450, 451, "." +429, 7, 1, 109, 0, 9, 452, 461, "OBJECTIVE" +429, 7, 2, 110, 10, 11, 462, 463, ":" +429, 7, 3, 111, 12, 14, 464, 466, "To" +429, 7, 4, 112, 15, 22, 467, 474, "compare" +429, 7, 5, 113, 23, 26, 475, 478, "the" +429, 7, 6, 114, 27, 35, 479, 487, "efficacy" +429, 7, 7, 115, 36, 39, 488, 491, "and" +429, 7, 8, 116, 40, 46, 492, 498, "safety" +429, 7, 9, 117, 47, 49, 499, 501, "of" +429, 7, 10, 118, 50, 61, 502, 513, "latanoprost" +429, 7, 11, 119, 62, 68, 514, 520, "versus" +429, 7, 12, 120, 69, 76, 521, 528, "timolol" +429, 7, 13, 121, 77, 79, 529, 531, "in" +429, 7, 14, 122, 80, 89, 532, 541, "pediatric" +429, 7, 15, 123, 90, 98, 542, 550, "patients" +429, 7, 16, 124, 99, 103, 551, 555, "with" +429, 7, 17, 125, 104, 112, 556, 564, "glaucoma" +429, 7, 18, 126, 113, 114, 565, 566, "." +429, 8, 1, 127, 0, 6, 567, 573, "DESIGN" +429, 8, 2, 128, 7, 8, 574, 575, ":" +429, 8, 3, 129, 9, 20, 576, 587, "Prospective" +429, 8, 4, 130, 21, 22, 588, 589, "," +429, 8, 5, 131, 23, 33, 590, 600, "randomized" +429, 8, 6, 132, 34, 35, 601, 602, "," +429, 8, 7, 133, 36, 42, 603, 609, "double" +429, 8, 8, 134, 43, 44, 610, 611, "-" +429, 8, 9, 135, 45, 51, 612, 618, "masked" +429, 8, 10, 136, 52, 53, 619, 620, "," +429, 8, 11, 137, 54, 56, 621, 623, "12" +429, 8, 12, 138, 57, 58, 624, 625, "-" +429, 8, 13, 139, 59, 63, 626, 630, "week" +429, 8, 14, 140, 64, 65, 631, 632, "," +429, 8, 15, 141, 66, 77, 633, 644, "multicenter" +429, 8, 16, 142, 78, 83, 645, 650, "study" +429, 8, 17, 143, 84, 85, 651, 652, "." +429, 9, 1, 144, 0, 12, 653, 665, "PARTICIPANTS" +429, 9, 2, 145, 13, 14, 666, 667, ":" +429, 9, 3, 146, 15, 26, 668, 679, "Individuals" +429, 9, 4, 147, 27, 31, 680, 684, "aged" +429, 9, 5, 148, 32, 33, 685, 686, "≤" +429, 9, 6, 149, 34, 36, 687, 689, "18" +429, 9, 7, 150, 37, 42, 690, 695, "years" +429, 9, 8, 151, 43, 47, 696, 700, "with" +429, 9, 9, 152, 48, 56, 701, 709, "glaucoma" +429, 9, 10, 153, 57, 58, 710, 711, "." +429, 10, 1, 154, 0, 7, 712, 719, "METHODS" +429, 10, 2, 155, 8, 9, 720, 721, ":" +429, 10, 3, 156, 10, 20, 722, 732, "Stratified" +429, 10, 4, 157, 21, 23, 733, 735, "by" +429, 10, 5, 158, 24, 27, 736, 739, "age" +429, 10, 6, 159, 28, 29, 740, 741, "," +429, 10, 7, 160, 30, 39, 742, 751, "diagnosis" +429, 10, 8, 161, 40, 41, 752, 753, "," +429, 10, 9, 162, 42, 45, 754, 757, "and" +429, 10, 10, 163, 46, 57, 758, 769, "intraocular" +429, 10, 11, 164, 58, 66, 770, 778, "pressure" +429, 10, 12, 165, 67, 68, 779, 780, "(" +429, 10, 13, 166, 69, 72, 781, 784, "IOP" +429, 10, 14, 167, 73, 74, 785, 786, ")" +429, 10, 15, 168, 75, 80, 787, 792, "level" +429, 10, 16, 169, 81, 82, 793, 794, "," +429, 10, 17, 170, 83, 91, 795, 803, "subjects" +429, 10, 18, 171, 92, 96, 804, 808, "were" +429, 10, 19, 172, 97, 107, 809, 819, "randomized" +429, 10, 20, 173, 108, 109, 820, 821, "(" +429, 10, 21, 174, 110, 111, 822, 823, "1" +429, 10, 22, 175, 112, 113, 824, 825, ":" +429, 10, 23, 176, 114, 115, 826, 827, "1" +429, 10, 24, 177, 116, 117, 828, 829, ")" +429, 10, 25, 178, 118, 120, 830, 832, "to" +429, 10, 26, 179, 121, 132, 833, 844, "latanoprost" +429, 10, 27, 180, 133, 140, 845, 852, "vehicle" +429, 10, 28, 181, 141, 143, 853, 855, "at" +429, 10, 29, 182, 144, 145, 856, 857, "8" +429, 10, 30, 183, 146, 148, 858, 860, "am" +429, 10, 31, 184, 149, 152, 861, 864, "and" +429, 10, 32, 185, 153, 164, 865, 876, "latanoprost" +429, 10, 33, 186, 165, 166, 877, 878, "0" +429, 10, 34, 187, 167, 168, 879, 880, "." +429, 10, 35, 188, 169, 172, 881, 884, "005" +429, 10, 36, 189, 173, 174, 885, 886, "%" +429, 10, 37, 190, 175, 177, 887, 889, "at" +429, 10, 38, 191, 178, 179, 890, 891, "8" +429, 10, 39, 192, 180, 182, 892, 894, "pm" +429, 10, 40, 193, 183, 185, 895, 897, "or" +429, 10, 41, 194, 186, 193, 898, 905, "timolol" +429, 10, 42, 195, 194, 195, 906, 907, "0" +429, 10, 43, 196, 196, 197, 908, 909, "." +429, 10, 44, 197, 198, 199, 910, 911, "5" +429, 10, 45, 198, 200, 201, 912, 913, "%" +429, 10, 46, 199, 202, 203, 914, 915, "(" +429, 10, 47, 200, 204, 205, 916, 917, "0" +429, 10, 48, 201, 206, 207, 918, 919, "." +429, 10, 49, 202, 208, 210, 920, 922, "25" +429, 10, 50, 203, 211, 212, 923, 924, "%" +429, 10, 51, 204, 213, 216, 925, 928, "for" +429, 10, 52, 205, 217, 222, 929, 934, "those" +429, 10, 53, 206, 223, 227, 935, 939, "aged" +429, 10, 54, 207, 228, 229, 940, 941, "<" +429, 10, 55, 208, 230, 231, 942, 943, "3" +429, 10, 56, 209, 232, 237, 944, 949, "years" +429, 10, 57, 210, 238, 239, 950, 951, ")" +429, 10, 58, 211, 240, 245, 952, 957, "twice" +429, 10, 59, 212, 246, 251, 958, 963, "daily" +429, 10, 60, 213, 252, 253, 964, 965, "(" +429, 10, 61, 214, 254, 255, 966, 967, "8" +429, 10, 62, 215, 256, 258, 968, 970, "am" +429, 10, 63, 216, 259, 260, 971, 972, "," +429, 10, 64, 217, 261, 262, 973, 974, "8" +429, 10, 65, 218, 263, 265, 975, 977, "pm" +429, 10, 66, 219, 266, 267, 978, 979, ")" +429, 10, 67, 220, 268, 269, 980, 981, "." +429, 11, 1, 221, 0, 2, 982, 984, "At" +429, 11, 2, 222, 3, 11, 985, 993, "baseline" +429, 11, 3, 223, 12, 15, 994, 997, "and" +429, 11, 4, 224, 16, 21, 998, 1003, "weeks" +429, 11, 5, 225, 22, 23, 1004, 1005, "1" +429, 11, 6, 226, 24, 25, 1006, 1007, "," +429, 11, 7, 227, 26, 27, 1008, 1009, "4" +429, 11, 8, 228, 28, 29, 1010, 1011, "," +429, 11, 9, 229, 30, 33, 1012, 1015, "and" +429, 11, 10, 230, 34, 36, 1016, 1018, "12" +429, 11, 11, 231, 37, 38, 1019, 1020, "," +429, 11, 12, 232, 39, 42, 1021, 1024, "IOP" +429, 11, 13, 233, 43, 46, 1025, 1028, "and" +429, 11, 14, 234, 47, 53, 1029, 1035, "ocular" +429, 11, 15, 235, 54, 60, 1036, 1042, "safety" +429, 11, 16, 236, 61, 65, 1043, 1047, "were" +429, 11, 17, 237, 66, 74, 1048, 1056, "assessed" +429, 11, 18, 238, 75, 78, 1057, 1060, "and" +429, 11, 19, 239, 79, 86, 1061, 1068, "adverse" +429, 11, 20, 240, 87, 93, 1069, 1075, "events" +429, 11, 21, 241, 94, 98, 1076, 1080, "were" +429, 11, 22, 242, 99, 107, 1081, 1089, "recorded" +429, 11, 23, 243, 108, 109, 1090, 1091, "." +429, 12, 1, 244, 0, 7, 1092, 1099, "Therapy" +429, 12, 2, 245, 8, 11, 1100, 1103, "was" +429, 12, 3, 246, 12, 20, 1104, 1112, "switched" +429, 12, 4, 247, 21, 23, 1113, 1115, "to" +429, 12, 5, 248, 24, 28, 1116, 1120, "open" +429, 12, 6, 249, 29, 30, 1121, 1122, "-" +429, 12, 7, 250, 31, 36, 1123, 1128, "label" +429, 12, 8, 251, 37, 48, 1129, 1140, "latanoprost" +429, 12, 9, 252, 49, 51, 1141, 1143, "pm" +429, 12, 10, 253, 52, 55, 1144, 1147, "and" +429, 12, 11, 254, 56, 63, 1148, 1155, "timolol" +429, 12, 12, 255, 64, 66, 1156, 1158, "am" +429, 12, 13, 256, 67, 70, 1159, 1162, "and" +429, 12, 14, 257, 71, 73, 1163, 1165, "pm" +429, 12, 15, 258, 74, 77, 1166, 1169, "for" +429, 12, 16, 259, 78, 90, 1170, 1182, "uncontrolled" +429, 12, 17, 260, 91, 94, 1183, 1186, "IOP" +429, 12, 18, 261, 95, 96, 1187, 1188, "." +429, 13, 1, 262, 0, 4, 1189, 1193, "MAIN" +429, 13, 2, 263, 5, 12, 1194, 1201, "OUTCOME" +429, 13, 3, 264, 13, 21, 1202, 1210, "MEASURES" +429, 13, 4, 265, 22, 23, 1211, 1212, ":" +429, 13, 5, 266, 24, 28, 1213, 1217, "Mean" +429, 13, 6, 267, 29, 32, 1218, 1221, "IOP" +429, 13, 7, 268, 33, 42, 1222, 1231, "reduction" +429, 13, 8, 269, 43, 47, 1232, 1236, "from" +429, 13, 9, 270, 48, 56, 1237, 1245, "baseline" +429, 13, 10, 271, 57, 59, 1246, 1248, "to" +429, 13, 11, 272, 60, 64, 1249, 1253, "week" +429, 13, 12, 273, 65, 67, 1254, 1256, "12" +429, 13, 13, 274, 68, 69, 1257, 1258, "." +429, 14, 1, 275, 0, 11, 1259, 1270, "Latanoprost" +429, 14, 2, 276, 12, 15, 1271, 1274, "was" +429, 14, 3, 277, 16, 26, 1275, 1285, "considered" +429, 14, 4, 278, 27, 38, 1286, 1297, "noninferior" +429, 14, 5, 279, 39, 41, 1298, 1300, "to" +429, 14, 6, 280, 42, 49, 1301, 1308, "timolol" +429, 14, 7, 281, 50, 52, 1309, 1311, "if" +429, 14, 8, 282, 53, 56, 1312, 1315, "the" +429, 14, 9, 283, 57, 62, 1316, 1321, "lower" +429, 14, 10, 284, 63, 68, 1322, 1327, "limit" +429, 14, 11, 285, 69, 71, 1328, 1330, "of" +429, 14, 12, 286, 72, 75, 1331, 1334, "the" +429, 14, 13, 287, 76, 78, 1335, 1337, "95" +429, 14, 14, 288, 79, 80, 1338, 1339, "%" +429, 14, 15, 289, 81, 91, 1340, 1350, "confidence" +429, 14, 16, 290, 92, 100, 1351, 1359, "interval" +429, 14, 17, 291, 101, 102, 1360, 1361, "(" +429, 14, 18, 292, 103, 105, 1362, 1364, "CI" +429, 14, 19, 293, 106, 107, 1365, 1366, ")" +429, 14, 20, 294, 108, 110, 1367, 1369, "of" +429, 14, 21, 295, 111, 114, 1370, 1373, "the" +429, 14, 22, 296, 115, 125, 1374, 1384, "difference" +429, 14, 23, 297, 126, 129, 1385, 1388, "was" +429, 14, 24, 298, 130, 131, 1389, 1390, ">" +429, 14, 25, 299, 132, 133, 1391, 1392, "-" +429, 14, 26, 300, 134, 135, 1393, 1394, "3" +429, 14, 27, 301, 136, 140, 1395, 1399, "mmHg" +429, 14, 28, 302, 141, 142, 1400, 1401, "." +429, 15, 1, 303, 0, 1, 1402, 1403, "A" +429, 15, 2, 304, 2, 12, 1404, 1414, "proportion" +429, 15, 3, 305, 13, 15, 1415, 1417, "of" +429, 15, 4, 306, 16, 26, 1418, 1428, "responders" +429, 15, 5, 307, 27, 28, 1429, 1430, "(" +429, 15, 6, 308, 29, 37, 1431, 1439, "subjects" +429, 15, 7, 309, 38, 42, 1440, 1444, "with" +429, 15, 8, 310, 43, 44, 1445, 1446, "≥" +429, 15, 9, 311, 45, 47, 1447, 1449, "15" +429, 15, 10, 312, 48, 49, 1450, 1451, "%" +429, 15, 11, 313, 50, 53, 1452, 1455, "IOP" +429, 15, 12, 314, 54, 63, 1456, 1465, "reduction" +429, 15, 13, 315, 64, 66, 1466, 1468, "at" +429, 15, 14, 316, 67, 72, 1469, 1474, "weeks" +429, 15, 15, 317, 73, 74, 1475, 1476, "4" +429, 15, 16, 318, 75, 78, 1477, 1480, "and" +429, 15, 17, 319, 79, 81, 1481, 1483, "12" +429, 15, 18, 320, 82, 83, 1484, 1485, ")" +429, 15, 19, 321, 84, 88, 1486, 1490, "were" +429, 15, 20, 322, 89, 98, 1491, 1500, "evaluated" +429, 15, 21, 323, 99, 100, 1501, 1502, "." +429, 16, 1, 324, 0, 8, 1503, 1511, "Analyses" +429, 16, 2, 325, 9, 13, 1512, 1516, "were" +429, 16, 3, 326, 14, 23, 1517, 1526, "performed" +429, 16, 4, 327, 24, 26, 1527, 1529, "in" +429, 16, 5, 328, 27, 36, 1530, 1539, "diagnosis" +429, 16, 6, 329, 37, 46, 1540, 1549, "subgroups" +429, 16, 7, 330, 47, 48, 1550, 1551, ":" +429, 16, 8, 331, 49, 56, 1552, 1559, "primary" +429, 16, 9, 332, 57, 67, 1560, 1570, "congenital" +429, 16, 10, 333, 68, 76, 1571, 1579, "glaucoma" +429, 16, 11, 334, 77, 78, 1580, 1581, "(" +429, 16, 12, 335, 79, 82, 1582, 1585, "PCG" +429, 16, 13, 336, 83, 84, 1586, 1587, ")" +429, 16, 14, 337, 85, 88, 1588, 1591, "and" +429, 16, 15, 338, 89, 92, 1592, 1595, "non" +429, 16, 16, 339, 93, 94, 1596, 1597, "-" +429, 16, 17, 340, 95, 98, 1598, 1601, "PCG" +429, 16, 18, 341, 99, 100, 1602, 1603, "." +429, 17, 1, 342, 0, 7, 1604, 1611, "RESULTS" +429, 17, 2, 343, 8, 9, 1612, 1613, ":" +429, 17, 3, 344, 10, 12, 1614, 1616, "In" +429, 17, 4, 345, 13, 18, 1617, 1622, "total" +429, 17, 5, 346, 19, 20, 1623, 1624, "," +429, 17, 6, 347, 21, 24, 1625, 1628, "137" +429, 17, 7, 348, 25, 33, 1629, 1637, "subjects" +429, 17, 8, 349, 34, 38, 1638, 1642, "were" +429, 17, 9, 350, 39, 46, 1643, 1650, "treated" +429, 17, 10, 351, 47, 48, 1651, 1652, "(" +429, 17, 11, 352, 49, 55, 1653, 1659, "safety" +429, 17, 12, 353, 56, 66, 1660, 1670, "population" +429, 17, 13, 354, 67, 68, 1671, 1672, ";" +429, 17, 14, 355, 69, 71, 1673, 1675, "12" +429, 17, 15, 356, 72, 73, 1676, 1677, "-" +429, 17, 16, 357, 74, 76, 1678, 1680, "18" +429, 17, 17, 358, 77, 82, 1681, 1686, "years" +429, 17, 18, 359, 83, 84, 1687, 1688, "," +429, 17, 19, 360, 85, 86, 1689, 1690, "n" +429, 17, 20, 361, 87, 88, 1691, 1692, "=" +429, 17, 21, 362, 89, 91, 1693, 1695, "48" +429, 17, 22, 363, 92, 93, 1696, 1697, ";" +429, 17, 23, 364, 94, 95, 1698, 1699, "3" +429, 17, 24, 365, 96, 97, 1700, 1701, "-" +429, 17, 25, 366, 98, 99, 1702, 1703, "<" +429, 17, 26, 367, 100, 102, 1704, 1706, "12" +429, 17, 27, 368, 103, 108, 1707, 1712, "years" +429, 17, 28, 369, 109, 110, 1713, 1714, "," +429, 17, 29, 370, 111, 112, 1715, 1716, "n" +429, 17, 30, 371, 113, 114, 1717, 1718, "=" +429, 17, 31, 372, 115, 117, 1719, 1721, "55" +429, 17, 32, 373, 118, 119, 1722, 1723, ";" +429, 17, 33, 374, 120, 121, 1724, 1725, "0" +429, 17, 34, 375, 122, 123, 1726, 1727, "-" +429, 17, 35, 376, 124, 125, 1728, 1729, "<" +429, 17, 36, 377, 126, 127, 1730, 1731, "3" +429, 17, 37, 378, 128, 133, 1732, 1737, "years" +429, 17, 38, 379, 134, 135, 1738, 1739, "," +429, 17, 39, 380, 136, 137, 1740, 1741, "n" +429, 17, 40, 381, 138, 139, 1742, 1743, "=" +429, 17, 41, 382, 140, 142, 1744, 1746, "34" +429, 17, 42, 383, 143, 144, 1747, 1748, ")" +429, 17, 43, 384, 145, 146, 1749, 1750, "." +429, 18, 1, 385, 0, 4, 1751, 1755, "Mean" +429, 18, 2, 386, 5, 8, 1756, 1759, "age" +429, 18, 3, 387, 9, 12, 1760, 1763, "was" +429, 18, 4, 388, 13, 14, 1764, 1765, "8" +429, 18, 5, 389, 15, 16, 1766, 1767, "." +429, 18, 6, 390, 17, 18, 1768, 1769, "8" +429, 18, 7, 391, 19, 20, 1770, 1771, "±" +429, 18, 8, 392, 21, 22, 1772, 1773, "5" +429, 18, 9, 393, 23, 24, 1774, 1775, "." +429, 18, 10, 394, 25, 26, 1776, 1777, "5" +429, 18, 11, 395, 27, 32, 1778, 1783, "years" +429, 18, 12, 396, 33, 34, 1784, 1785, "," +429, 18, 13, 397, 35, 38, 1786, 1789, "and" +429, 18, 14, 398, 39, 43, 1790, 1794, "mean" +429, 18, 15, 399, 44, 52, 1795, 1803, "baseline" +429, 18, 16, 400, 53, 56, 1804, 1807, "IOP" +429, 18, 17, 401, 57, 60, 1808, 1811, "was" +429, 18, 18, 402, 61, 63, 1812, 1814, "27" +429, 18, 19, 403, 64, 65, 1815, 1816, "." +429, 18, 20, 404, 66, 67, 1817, 1818, "7" +429, 18, 21, 405, 68, 69, 1819, 1820, "±" +429, 18, 22, 406, 70, 71, 1821, 1822, "6" +429, 18, 23, 407, 72, 73, 1823, 1824, "." +429, 18, 24, 408, 74, 76, 1825, 1827, "17" +429, 18, 25, 409, 77, 81, 1828, 1832, "mmHg" +429, 18, 26, 410, 82, 83, 1833, 1834, ";" +429, 18, 27, 411, 84, 87, 1835, 1838, "125" +429, 18, 28, 412, 88, 96, 1839, 1847, "subjects" +429, 18, 29, 413, 97, 106, 1848, 1857, "completed" +429, 18, 30, 414, 107, 110, 1858, 1861, "the" +429, 18, 31, 415, 111, 116, 1862, 1867, "study" +429, 18, 32, 416, 117, 118, 1868, 1869, "," +429, 18, 33, 417, 119, 122, 1870, 1873, "and" +429, 18, 34, 418, 123, 126, 1874, 1877, "107" +429, 18, 35, 419, 127, 135, 1878, 1886, "subjects" +429, 18, 36, 420, 136, 140, 1887, 1891, "were" +429, 18, 37, 421, 141, 143, 1892, 1894, "in" +429, 18, 38, 422, 144, 147, 1895, 1898, "the" +429, 18, 39, 423, 148, 151, 1899, 1902, "per" +429, 18, 40, 424, 152, 160, 1903, 1911, "protocol" +429, 18, 41, 425, 161, 171, 1912, 1922, "population" +429, 18, 42, 426, 172, 173, 1923, 1924, "." +429, 19, 1, 427, 0, 4, 1925, 1929, "Mean" +429, 19, 2, 428, 5, 8, 1930, 1933, "IOP" +429, 19, 3, 429, 9, 19, 1934, 1944, "reductions" +429, 19, 4, 430, 20, 23, 1945, 1948, "for" +429, 19, 5, 431, 24, 35, 1949, 1960, "latanoprost" +429, 19, 6, 432, 36, 39, 1961, 1964, "and" +429, 19, 7, 433, 40, 47, 1965, 1972, "timolol" +429, 19, 8, 434, 48, 50, 1973, 1975, "at" +429, 19, 9, 435, 51, 55, 1976, 1980, "week" +429, 19, 10, 436, 56, 58, 1981, 1983, "12" +429, 19, 11, 437, 59, 63, 1984, 1988, "were" +429, 19, 12, 438, 64, 65, 1989, 1990, "7" +429, 19, 13, 439, 66, 67, 1991, 1992, "." +429, 19, 14, 440, 68, 69, 1993, 1994, "2" +429, 19, 15, 441, 70, 73, 1995, 1998, "and" +429, 19, 16, 442, 74, 75, 1999, 2000, "5" +429, 19, 17, 443, 76, 77, 2001, 2002, "." +429, 19, 18, 444, 78, 79, 2003, 2004, "7" +429, 19, 19, 445, 80, 84, 2005, 2009, "mmHg" +429, 19, 20, 446, 85, 86, 2010, 2011, "," +429, 19, 21, 447, 87, 99, 2012, 2024, "respectively" +429, 19, 22, 448, 100, 101, 2025, 2026, "," +429, 19, 23, 449, 102, 106, 2027, 2031, "with" +429, 19, 24, 450, 107, 108, 2032, 2033, "a" +429, 19, 25, 451, 109, 119, 2034, 2044, "difference" +429, 19, 26, 452, 120, 122, 2045, 2047, "of" +429, 19, 27, 453, 123, 124, 2048, 2049, "1" +429, 19, 28, 454, 125, 126, 2050, 2051, "." +429, 19, 29, 455, 127, 128, 2052, 2053, "5" +429, 19, 30, 456, 129, 133, 2054, 2058, "mmHg" +429, 19, 31, 457, 134, 135, 2059, 2060, "(" +429, 19, 32, 458, 136, 138, 2061, 2063, "95" +429, 19, 33, 459, 139, 140, 2064, 2065, "%" +429, 19, 34, 460, 141, 143, 2066, 2068, "CI" +429, 19, 35, 461, 144, 145, 2069, 2070, "," +429, 19, 36, 462, 146, 147, 2071, 2072, "-" +429, 19, 37, 463, 148, 149, 2073, 2074, "0" +429, 19, 38, 464, 150, 151, 2075, 2076, "." +429, 19, 39, 465, 152, 153, 2077, 2078, "8" +429, 19, 40, 466, 154, 156, 2079, 2081, "to" +429, 19, 41, 467, 157, 158, 2082, 2083, "3" +429, 19, 42, 468, 159, 160, 2084, 2085, "." +429, 19, 43, 469, 161, 162, 2086, 2087, "7" +429, 19, 44, 470, 163, 164, 2088, 2089, ";" +429, 19, 45, 471, 165, 166, 2090, 2091, "P" +429, 19, 46, 472, 167, 168, 2092, 2093, "=" +429, 19, 47, 473, 169, 170, 2094, 2095, "0" +429, 19, 48, 474, 171, 172, 2096, 2097, "." +429, 19, 49, 475, 173, 175, 2098, 2100, "21" +429, 19, 50, 476, 176, 177, 2101, 2102, ")" +429, 19, 51, 477, 178, 179, 2103, 2104, "." +429, 20, 1, 478, 0, 9, 2105, 2114, "Responder" +429, 20, 2, 479, 10, 15, 2115, 2120, "rates" +429, 20, 3, 480, 16, 20, 2121, 2125, "were" +429, 20, 4, 481, 21, 23, 2126, 2128, "60" +429, 20, 5, 482, 24, 25, 2129, 2130, "%" +429, 20, 6, 483, 26, 29, 2131, 2134, "for" +429, 20, 7, 484, 30, 41, 2135, 2146, "latanoprost" +429, 20, 8, 485, 42, 45, 2147, 2150, "and" +429, 20, 9, 486, 46, 48, 2151, 2153, "52" +429, 20, 10, 487, 49, 50, 2154, 2155, "%" +429, 20, 11, 488, 51, 54, 2156, 2159, "for" +429, 20, 12, 489, 55, 62, 2160, 2167, "timolol" +429, 20, 13, 490, 63, 64, 2168, 2169, "(" +429, 20, 14, 491, 65, 66, 2170, 2171, "P" +429, 20, 15, 492, 67, 68, 2172, 2173, "=" +429, 20, 16, 493, 69, 70, 2174, 2175, "0" +429, 20, 17, 494, 71, 72, 2176, 2177, "." +429, 20, 18, 495, 73, 75, 2178, 2180, "33" +429, 20, 19, 496, 76, 77, 2181, 2182, ")" +429, 20, 20, 497, 78, 79, 2183, 2184, "." +429, 21, 1, 498, 0, 7, 2185, 2192, "Between" +429, 21, 2, 499, 8, 9, 2193, 2194, "-" +429, 21, 3, 500, 10, 19, 2195, 2204, "treatment" +429, 21, 4, 501, 20, 31, 2205, 2216, "differences" +429, 21, 5, 502, 32, 34, 2217, 2219, "in" +429, 21, 6, 503, 35, 39, 2220, 2224, "mean" +429, 21, 7, 504, 40, 43, 2225, 2228, "IOP" +429, 21, 8, 505, 44, 53, 2229, 2238, "reduction" +429, 21, 9, 506, 54, 57, 2239, 2242, "for" +429, 21, 10, 507, 58, 61, 2243, 2246, "PCG" +429, 21, 11, 508, 62, 65, 2247, 2250, "and" +429, 21, 12, 509, 66, 69, 2251, 2254, "non" +429, 21, 13, 510, 70, 71, 2255, 2256, "-" +429, 21, 14, 511, 72, 75, 2257, 2260, "PCG" +429, 21, 15, 512, 76, 85, 2261, 2270, "subgroups" +429, 21, 16, 513, 86, 90, 2271, 2275, "were" +429, 21, 17, 514, 91, 92, 2276, 2277, "0" +429, 21, 18, 515, 93, 94, 2278, 2279, "." +429, 21, 19, 516, 95, 96, 2280, 2281, "6" +429, 21, 20, 517, 97, 101, 2282, 2286, "mmHg" +429, 21, 21, 518, 102, 103, 2287, 2288, "(" +429, 21, 22, 519, 104, 106, 2289, 2291, "95" +429, 21, 23, 520, 107, 108, 2292, 2293, "%" +429, 21, 24, 521, 109, 111, 2294, 2296, "CI" +429, 21, 25, 522, 112, 113, 2297, 2298, "," +429, 21, 26, 523, 114, 115, 2299, 2300, "-" +429, 21, 27, 524, 116, 117, 2301, 2302, "2" +429, 21, 28, 525, 118, 119, 2303, 2304, "." +429, 21, 29, 526, 120, 121, 2305, 2306, "3" +429, 21, 30, 527, 122, 124, 2307, 2309, "to" +429, 21, 31, 528, 125, 126, 2310, 2311, "3" +429, 21, 32, 529, 127, 128, 2312, 2313, "." +429, 21, 33, 530, 129, 130, 2314, 2315, "4" +429, 21, 34, 531, 131, 132, 2316, 2317, ")" +429, 21, 35, 532, 133, 136, 2318, 2321, "and" +429, 21, 36, 533, 137, 138, 2322, 2323, "2" +429, 21, 37, 534, 139, 140, 2324, 2325, "." +429, 21, 38, 535, 141, 142, 2326, 2327, "6" +429, 21, 39, 536, 143, 147, 2328, 2332, "mmHg" +429, 21, 40, 537, 148, 149, 2333, 2334, "(" +429, 21, 41, 538, 150, 152, 2335, 2337, "95" +429, 21, 42, 539, 153, 154, 2338, 2339, "%" +429, 21, 43, 540, 155, 157, 2340, 2342, "CI" +429, 21, 44, 541, 158, 159, 2343, 2344, "," +429, 21, 45, 542, 160, 161, 2345, 2346, "-" +429, 21, 46, 543, 162, 163, 2347, 2348, "0" +429, 21, 47, 544, 164, 165, 2349, 2350, "." +429, 21, 48, 545, 166, 167, 2351, 2352, "8" +429, 21, 49, 546, 168, 170, 2353, 2355, "to" +429, 21, 50, 547, 171, 172, 2356, 2357, "6" +429, 21, 51, 548, 173, 174, 2358, 2359, "." +429, 21, 52, 549, 175, 176, 2360, 2361, "1" +429, 21, 53, 550, 177, 178, 2362, 2363, ")" +429, 21, 54, 551, 179, 180, 2364, 2365, "," +429, 21, 55, 552, 181, 193, 2366, 2378, "respectively" +429, 21, 56, 553, 194, 195, 2379, 2380, "." +429, 22, 1, 554, 0, 9, 2381, 2390, "Responder" +429, 22, 2, 555, 10, 15, 2391, 2396, "rates" +429, 22, 3, 556, 16, 19, 2397, 2400, "for" +429, 22, 4, 557, 20, 31, 2401, 2412, "latanoprost" +429, 22, 5, 558, 32, 38, 2413, 2419, "versus" +429, 22, 6, 559, 39, 46, 2420, 2427, "timolol" +429, 22, 7, 560, 47, 51, 2428, 2432, "were" +429, 22, 8, 561, 52, 54, 2433, 2435, "50" +429, 22, 9, 562, 55, 56, 2436, 2437, "%" +429, 22, 10, 563, 57, 63, 2438, 2444, "versus" +429, 22, 11, 564, 64, 66, 2445, 2447, "46" +429, 22, 12, 565, 67, 68, 2448, 2449, "%" +429, 22, 13, 566, 69, 72, 2450, 2453, "for" +429, 22, 14, 567, 73, 76, 2454, 2457, "the" +429, 22, 15, 568, 77, 80, 2458, 2461, "PCG" +429, 22, 16, 569, 81, 86, 2462, 2467, "group" +429, 22, 17, 570, 87, 90, 2468, 2471, "and" +429, 22, 18, 571, 91, 93, 2472, 2474, "72" +429, 22, 19, 572, 94, 95, 2475, 2476, "%" +429, 22, 20, 573, 96, 102, 2477, 2483, "versus" +429, 22, 21, 574, 103, 105, 2484, 2486, "57" +429, 22, 22, 575, 106, 107, 2487, 2488, "%" +429, 22, 23, 576, 108, 111, 2489, 2492, "for" +429, 22, 24, 577, 112, 115, 2493, 2496, "the" +429, 22, 25, 578, 116, 119, 2497, 2500, "non" +429, 22, 26, 579, 120, 121, 2501, 2502, "-" +429, 22, 27, 580, 122, 125, 2503, 2506, "PCG" +429, 22, 28, 581, 126, 131, 2507, 2512, "group" +429, 22, 29, 582, 132, 133, 2513, 2514, "." +429, 23, 1, 583, 0, 4, 2515, 2519, "Both" +429, 23, 2, 584, 5, 14, 2520, 2529, "therapies" +429, 23, 3, 585, 15, 19, 2530, 2534, "were" +429, 23, 4, 586, 20, 24, 2535, 2539, "well" +429, 23, 5, 587, 25, 34, 2540, 2549, "tolerated" +429, 23, 6, 588, 35, 36, 2550, 2551, "." +429, 24, 1, 589, 0, 11, 2552, 2563, "CONCLUSIONS" +429, 24, 2, 590, 12, 13, 2564, 2565, ":" +429, 24, 3, 591, 14, 25, 2566, 2577, "Latanoprost" +429, 24, 4, 592, 26, 27, 2578, 2579, "0" +429, 24, 5, 593, 28, 29, 2580, 2581, "." +429, 24, 6, 594, 30, 33, 2582, 2585, "005" +429, 24, 7, 595, 34, 35, 2586, 2587, "%" +429, 24, 8, 596, 36, 38, 2588, 2590, "is" +429, 24, 9, 597, 39, 42, 2591, 2594, "not" +429, 24, 10, 598, 43, 51, 2595, 2603, "inferior" +429, 24, 11, 599, 52, 53, 2604, 2605, "(" +429, 24, 12, 600, 54, 55, 2606, 2607, "i" +429, 24, 13, 601, 56, 57, 2608, 2609, "." +429, 24, 14, 602, 58, 59, 2610, 2611, "e" +429, 24, 15, 603, 60, 61, 2612, 2613, "." +429, 24, 16, 604, 62, 63, 2614, 2615, "," +429, 24, 17, 605, 64, 66, 2616, 2618, "is" +429, 24, 18, 606, 67, 73, 2619, 2625, "either" +429, 24, 19, 607, 74, 78, 2626, 2630, "more" +429, 24, 20, 608, 79, 81, 2631, 2633, "or" +429, 24, 21, 609, 82, 91, 2634, 2643, "similarly" +429, 24, 22, 610, 92, 101, 2644, 2653, "effective" +429, 24, 23, 611, 102, 103, 2654, 2655, ")" +429, 24, 24, 612, 104, 106, 2656, 2658, "to" +429, 24, 25, 613, 107, 114, 2659, 2666, "timolol" +429, 24, 26, 614, 115, 118, 2667, 2670, "and" +429, 24, 27, 615, 119, 127, 2671, 2679, "produces" +429, 24, 28, 616, 128, 138, 2680, 2690, "clinically" +429, 24, 29, 617, 139, 147, 2691, 2699, "relevant" +429, 24, 30, 618, 148, 151, 2700, 2703, "IOP" +429, 24, 31, 619, 152, 162, 2704, 2714, "reductions" +429, 24, 32, 620, 163, 169, 2715, 2721, "across" +429, 24, 33, 621, 170, 179, 2722, 2731, "pediatric" +429, 24, 34, 622, 180, 188, 2732, 2740, "patients" +429, 24, 35, 623, 189, 193, 2741, 2745, "with" +429, 24, 36, 624, 194, 197, 2746, 2749, "and" +429, 24, 37, 625, 198, 205, 2750, 2757, "without" +429, 24, 38, 626, 206, 209, 2758, 2761, "PCG" +429, 24, 39, 627, 210, 211, 2762, 2763, "." +429, 25, 1, 628, 0, 4, 2764, 2768, "Both" +429, 25, 2, 629, 5, 16, 2769, 2780, "latanoprost" +429, 25, 3, 630, 17, 20, 2781, 2784, "and" +429, 25, 4, 631, 21, 28, 2785, 2792, "timolol" +429, 25, 5, 632, 29, 32, 2793, 2796, "had" +429, 25, 6, 633, 33, 42, 2797, 2806, "favorable" +429, 25, 7, 634, 43, 49, 2807, 2813, "safety" +429, 25, 8, 635, 50, 58, 2814, 2822, "profiles" +429, 25, 9, 636, 59, 63, 2823, 2827, "over" +429, 25, 10, 637, 64, 67, 2828, 2831, "the" +429, 25, 11, 638, 68, 76, 2832, 2840, "duration" +429, 25, 12, 639, 77, 79, 2841, 2843, "of" +429, 25, 13, 640, 80, 84, 2844, 2848, "this" +429, 25, 14, 641, 85, 86, 2849, 2850, "3" +429, 25, 15, 642, 87, 88, 2851, 2852, "-" +429, 25, 16, 643, 89, 94, 2853, 2858, "month" +429, 25, 17, 644, 95, 100, 2859, 2864, "trial" +429, 25, 18, 645, 101, 102, 2865, 2866, "." +429, 26, 1, 646, 0, 9, 2867, 2876, "FINANCIAL" +429, 26, 2, 647, 10, 20, 2877, 2887, "DISCLOSURE" +429, 26, 3, 648, 21, 22, 2888, 2889, "(" +429, 26, 4, 649, 23, 24, 2890, 2891, "S" +429, 26, 5, 650, 25, 26, 2892, 2893, ")" +429, 26, 6, 651, 27, 28, 2894, 2895, ":" +429, 26, 7, 652, 29, 40, 2896, 2907, "Proprietary" +429, 26, 8, 653, 41, 43, 2908, 2910, "or" +429, 26, 9, 654, 44, 54, 2911, 2921, "commercial" +429, 26, 10, 655, 55, 65, 2922, 2932, "disclosure" +429, 26, 11, 656, 66, 69, 2933, 2936, "may" +429, 26, 12, 657, 70, 72, 2937, 2939, "be" +429, 26, 13, 658, 73, 78, 2940, 2945, "found" +429, 26, 14, 659, 79, 84, 2946, 2951, "after" +429, 26, 15, 660, 85, 88, 2952, 2955, "the" +429, 26, 16, 661, 89, 99, 2956, 2966, "references" +429, 26, 17, 662, 100, 101, 2967, 2968, "." +429, 27, 1, 663, 0, 9, 2969, 2978, "Copyright" +429, 27, 2, 664, 10, 11, 2979, 2980, "©" +429, 27, 3, 665, 12, 16, 2981, 2985, "2011" +429, 27, 4, 666, 17, 25, 2986, 2994, "American" +429, 27, 5, 667, 26, 33, 2995, 3002, "Academy" +429, 27, 6, 668, 34, 36, 3003, 3005, "of" +429, 27, 7, 669, 37, 50, 3006, 3019, "Ophthalmology" +429, 27, 8, 670, 51, 52, 3020, 3021, "." +429, 28, 1, 671, 0, 9, 3022, 3031, "Published" +429, 28, 2, 672, 10, 12, 3032, 3034, "by" +429, 28, 3, 673, 13, 21, 3035, 3043, "Elsevier" +429, 28, 4, 674, 22, 25, 3044, 3047, "Inc" +429, 28, 5, 675, 26, 27, 3048, 3049, "." +429, 28, 6, 676, 28, 31, 3050, 3053, "All" +429, 28, 7, 677, 32, 38, 3054, 3060, "rights" +429, 28, 8, 678, 39, 47, 3061, 3069, "reserved" +429, 28, 9, 679, 48, 49, 3070, 3071, "." +429, 29, 1, 680, 0, 3, 3072, 3075, "DOI" +429, 29, 2, 681, 4, 5, 3076, 3077, ":" +429, 29, 3, 682, 6, 8, 3078, 3080, "10" +429, 29, 4, 683, 9, 10, 3081, 3082, "." +429, 29, 5, 684, 11, 15, 3083, 3087, "1016" +429, 29, 6, 685, 16, 17, 3088, 3089, "/" +429, 29, 7, 686, 18, 19, 3090, 3091, "j" +429, 29, 8, 687, 20, 21, 3092, 3093, "." +429, 29, 9, 688, 22, 28, 3094, 3100, "ophtha" +429, 29, 10, 689, 29, 30, 3101, 3102, "." +429, 29, 11, 690, 31, 35, 3103, 3107, "2011" +429, 29, 12, 691, 36, 37, 3108, 3109, "." +429, 29, 13, 692, 38, 40, 3110, 3112, "03" +429, 29, 14, 693, 41, 42, 3113, 3114, "." +429, 29, 15, 694, 43, 46, 3115, 3118, "010" +429, 29, 16, 695, 47, 51, 3119, 3123, "PMID" +429, 29, 17, 696, 52, 53, 3124, 3125, ":" +429, 29, 18, 697, 54, 62, 3126, 3134, "21680022" +429, 29, 19, 698, 63, 64, 3135, 3136, "[" +429, 29, 20, 699, 65, 72, 3137, 3144, "Indexed" +429, 29, 21, 700, 73, 76, 3145, 3148, "for" +429, 29, 22, 701, 77, 84, 3149, 3156, "MEDLINE" +429, 29, 23, 702, 85, 86, 3157, 3158, "]" diff --git a/data/gl 21680022_jshahinitiran.annodb b/data/gl 21680022_jshahinitiran.annodb new file mode 100644 index 0000000..d7c17b8 --- /dev/null +++ b/data/gl 21680022_jshahinitiran.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +493, Journal, 0, 13, "Ophthalmology", "", +494, PublicationYear, 16, 20, "2011", "", +495, Title, 120, 254, "Comparison of latanoprost and timolol in pediatric glaucoma : a phase 3 , 12 - week , randomized , double - masked multicenter study .", "", +498, Latanoprost, 134, 145, "latanoprost", "", +509, Timolol, 150, 157, "timolol", "", +36183, Glaucoma, 171, 179, "glaucoma", "", +36184, CTDesign, 184, 191, "phase 3", "", +16003, Duration, 194, 203, "12 - week", "", +16004, Randomized, 206, 216, "randomized", "", +16005, DoubleBlind, 219, 234, "double - masked", "", +16006, Multicenter, 235, 246, "multicenter", "", +496, Author, 255, 273, "Maeda - Chubachi T", "", +36185, Author, 282, 296, "Chi - Burris K", "", +36186, Author, 299, 308, "Simons BD", "", +36187, Author, 311, 322, "Freedman SF", "", +36188, Author, 325, 332, "Khaw PT", "", +36189, Author, 335, 345, "Wirostko B", "", +36190, Author, 348, 353, "Yan E", "", +16007, USA, 446, 449, "USA", "", +497, ObjectiveDescription, 464, 566, "To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma .", "", +499, Latanoprost, 502, 513, "latanoprost", "", +511, Timolol, 521, 528, "timolol", "", +520, Glaucoma, 556, 564, "glaucoma", "", +16008, CTDesign, 576, 587, "Prospective", "", +526, Randomized, 590, 600, "randomized", "", +16009, DoubleBlind, 603, 618, "double - masked", "", +527, Duration, 621, 630, "12 - week", "CT", +528, Multicenter, 633, 644, "multicenter", "", +521, MaxAge, 687, 695, "18 years", "", +529, Glaucoma, 701, 709, "glaucoma", "", +530, Diurnal_IOP, 758, 778, "intraocular pressure", "", +531, Diurnal_IOP, 781, 784, "IOP", "", +525, Randomized, 809, 819, "randomized", "", +524, AllocationRatio, 822, 827, "1 : 1", "", +500, Latanoprost, 833, 844, "latanoprost", "", +536, TimePoint, 856, 860, "8 am", "", +503, Latanoprost, 865, 876, "latanoprost", "", +540, DoseValue, 877, 884, "0 . 005", "lat", +541, Percentage, 885, 886, "%", "lat", +537, TimePoint, 890, 894, "8 pm", "", +512, Timolol, 898, 905, "timolol", "", +542, DoseValue, 906, 911, "0 . 5", "tim", +543, Percentage, 912, 913, "%", "tim", +36191, DoseValue, 916, 922, "0 . 25", "", +36192, DoseValue, 923, 924, "%", "", +544, Frequency, 952, 963, "twice daily", "tim", +538, TimePoint, 966, 970, "8 am", "", +539, TimePoint, 973, 977, "8 pm", "", +36193, TimePoint, 985, 993, "baseline", "", +36194, TimePoint, 998, 1005, "weeks 1", "", +36195, TimePoint, 1008, 1009, "4", "", +36196, TimePoint, 1016, 1018, "12", "", +532, Diurnal_IOP, 1021, 1024, "IOP", "", +545, OpenLabel, 1116, 1128, "open - label", "", +502, Latanoprost, 1129, 1140, "latanoprost", "", +513, Timolol, 1148, 1155, "timolol", "", +534, Diurnal_IOP, 1183, 1186, "IOP", "", +546, Mean, 1213, 1217, "Mean", "", +533, Diurnal_IOP, 1218, 1221, "IOP", "", +36197, TimePoint, 1249, 1256, "week 12", "", +501, Latanoprost, 1259, 1270, "Latanoprost", "", +514, Timolol, 1301, 1308, "timolol", "", +547, ConfIntervalResValue, 1335, 1359, "95 % confidence interval", "", +16010, mmHg, 1395, 1399, "mmHg", "", +535, Diurnal_IOP, 1452, 1455, "IOP", "", +36198, TimePoint, 1469, 1476, "weeks 4", "", +36199, TimePoint, 1481, 1483, "12", "", +36200, Glaucoma, 1552, 1579, "primary congenital glaucoma", "", +36201, Glaucoma, 1582, 1585, "PCG", "", +36202, Glaucoma, 1592, 1601, "non - PCG", "", +550, NumberPatientsCT, 1625, 1628, "137", "", +551, AvgAge, 1764, 1769, "8 . 8", "", +36203, Mean, 1790, 1794, "mean", "", +552, Diurnal_IOP, 1804, 1807, "IOP", "", +553, BaseLineValue, 1812, 1818, "27 . 7", "", +554, SdErrorBL, 1821, 1827, "6 . 17", "", +555, mmHg, 1828, 1832, "mmHg", "bl", +36204, FinalNumPatientsCT, 1835, 1838, "125", "", +556, PerProtocol, 1899, 1911, "per protocol", "", +557, Diurnal_IOP, 1930, 1933, "IOP", "", +504, Latanoprost, 1949, 1960, "latanoprost", "", +515, Timolol, 1965, 1972, "timolol", "", +16000, TimePoint, 1976, 1983, "week 12", "", +558, ResultMeasuredValue, 1989, 1994, "7 . 2", "lat", +560, ResultMeasuredValue, 1999, 2004, "5 . 7", "tim", +561, mmHg, 2005, 2009, "mmHg", "tim", +562, DiffGroupAbsValue, 2048, 2053, "1 . 5", "", +563, mmHg, 2054, 2058, "mmHg", "", +564, ConfIntervalResValue, 2061, 2087, "95 % CI , - 0 . 8 to 3 . 7", "", +565, PValueResValue, 2090, 2100, "P = 0 . 21", "", +36205, PercentageAffected, 2126, 2128, "60", "", +505, Latanoprost, 2135, 2146, "latanoprost", "", +36206, PercentageAffected, 2151, 2153, "52", "", +516, Timolol, 2160, 2167, "timolol", "", +36207, PValueNumAffected, 2170, 2180, "P = 0 . 33", "", +16001, Mean, 2220, 2224, "mean", "", +16002, IOP, 2225, 2228, "IOP", "", +36213, mmHg, 2282, 2286, "mmHg", "", +36208, ConfIntervalResValue, 2289, 2315, "95 % CI , - 2 . 3 to 3 . 4", "", +36212, mmHg, 2328, 2332, "mmHg", "", +36211, ConfIntervalResValue, 2335, 2363, "95 % CI , - 0 . 8 to 6 . 1 )", "", +506, Latanoprost, 2401, 2412, "latanoprost", "", +519, Timolol, 2420, 2427, "timolol", "", +36214, PercentageAffected, 2433, 2435, "50", "", +36215, PercentageAffected, 2445, 2447, "46", "", +36216, PercentageAffected, 2472, 2474, "72", "", +36217, PercentageAffected, 2484, 2486, "57", "", +566, ConclusionComment, 2566, 2763, "Latanoprost 0 . 005 % is not inferior ( i . e . , is either more or similarly effective ) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG .", "", +508, Latanoprost, 2566, 2577, "Latanoprost", "", +540, DoseValue, 2578, 2585, "0 . 005", "lat", +541, Percentage, 2586, 2587, "%", "lat", +517, Timolol, 2659, 2666, "timolol", "", +36218, IOP, 2700, 2703, "IOP", "", +567, ConclusionComment, 2764, 2866, "Both latanoprost and timolol had favorable safety profiles over the duration of this 3 - month trial .", "", +507, Latanoprost, 2769, 2780, "latanoprost", "", +518, Timolol, 2785, 2792, "timolol", "", +36219, Duration, 2849, 2858, "3 - month", "", +36182, ConflictInterest, 2896, 2966, "Proprietary or commercial disclosure may be found after the references", "", +15999, PMID, 3126, 3134, "21680022", "", diff --git a/data/gl 21680022_jshahinitiran.n-triples b/data/gl 21680022_jshahinitiran.n-triples new file mode 100644 index 0000000..eacc13f --- /dev/null +++ b/data/gl 21680022_jshahinitiran.n-triples @@ -0,0 +1,14 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population + . + . + . + . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21680022_tstrakeljahn.annodb b/data/gl 21680022_tstrakeljahn.annodb new file mode 100644 index 0000000..98457b1 --- /dev/null +++ b/data/gl 21680022_tstrakeljahn.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12700, Journal, 0, 13, "Ophthalmology", "", +12701, PublicationYear, 16, 20, "2011", "", +12804, Title, 120, 252, "Comparison of latanoprost and timolol in pediatric glaucoma : a phase 3 , 12 - week , randomized , double - masked multicenter study", "", +12702, Latanoprost, 134, 145, "latanoprost", "", +12703, Timolol, 150, 157, "timolol", "", +12704, Glaucoma, 171, 179, "glaucoma", "", +12705, Duration, 194, 203, "12 - week", "", +12706, Randomized, 206, 216, "randomized", "", +12707, DoubleBlind, 219, 234, "double - masked", "", +12708, Multicenter, 235, 246, "multicenter", "", +12709, Author, 255, 273, "Maeda - Chubachi T", "", +12710, Author, 282, 296, "Chi - Burris K", "", +12711, Author, 299, 308, "Simons BD", "", +12712, Author, 311, 322, "Freedman SF", "", +12713, Author, 325, 332, "Khaw PT", "", +12714, Author, 335, 345, "Wirostko B", "", +12715, Author, 348, 353, "Yan E", "", +12716, USA, 446, 449, "USA", "", +12717, Latanoprost, 502, 513, "latanoprost", "", +12718, Timolol, 521, 528, "timolol", "", +12720, Precondition, 532, 564, "pediatric patients with glaucoma", "", +12719, Glaucoma, 556, 564, "glaucoma", "", +12721, Randomized, 590, 600, "randomized", "", +12722, DoubleBlind, 603, 618, "double - masked", "", +12723, Duration, 621, 630, "12 - week", "", +12724, Multicenter, 633, 644, "multicenter", "", +12726, Precondition, 668, 709, "Individuals aged ≤ 18 years with glaucoma", "", +12725, Glaucoma, 701, 709, "glaucoma", "", +12727, IOP, 758, 778, "intraocular pressure", "", +12728, IOP, 781, 784, "IOP", "", +12729, Randomized, 809, 819, "randomized", "", +12730, AllocationRatio, 822, 827, "1 : 1", "", +12731, Placebo, 833, 852, "latanoprost vehicle", "", +12732, Latanoprost, 865, 876, "latanoprost", "", +12733, Timolol, 898, 905, "timolol", "", +12734, Frequency, 952, 963, "twice daily", "", +12735, IOP, 1021, 1024, "IOP", "", +12736, Latanoprost, 1129, 1140, "latanoprost", "", +12737, Timolol, 1148, 1155, "timolol", "", +12738, IOP, 1183, 1186, "IOP", "", +12739, Mean, 1213, 1217, "Mean", "", +12740, IOP, 1218, 1221, "IOP", "", +12741, Latanoprost, 1259, 1270, "Latanoprost", "", +12745, Endpoint, 1259, 1399, "Latanoprost was considered noninferior to timolol if the lower limit of the 95 % confidence interval ( CI ) of the difference was > - 3 mmHg", "", +12742, Timolol, 1301, 1308, "timolol", "", +12744, mmHg, 1395, 1399, "mmHg", "", +12746, PigmentaryGlaucoma, 1552, 1579, "primary congenital glaucoma", "", +12747, PigmentaryGlaucoma, 1582, 1585, "PCG", "", +12748, PigmentaryGlaucoma, 1598, 1601, "PCG", "", +12754, NumberPatientsCT, 1625, 1628, "137", "", +12750, Mean, 1751, 1755, "Mean", "", +12751, IOP, 1804, 1807, "IOP", "", +12752, BaseLineValue, 1812, 1818, "27 . 7", "", +12753, SdDevBL, 1821, 1827, "6 . 17", "", +12756, mmHg, 1828, 1832, "mmHg", "", +12755, FinalNumPatientsCT, 1835, 1838, "125", "", +12757, Mean, 1925, 1929, "Mean", "", +12758, IOP, 1930, 1933, "IOP", "", +12759, Latanoprost, 1949, 1960, "latanoprost", "", +12760, Timolol, 1965, 1972, "timolol", "", +12761, TimePoint, 1976, 1983, "week 12", "", +12762, Reduction, 1989, 1994, "7 . 2", "", +12763, Reduction, 1999, 2004, "5 . 7", "", +12764, mmHg, 2005, 2009, "mmHg", "", +12766, DiffGroupAbsValue, 2048, 2053, "1 . 5", "", +12765, mmHg, 2054, 2058, "mmHg", "", +12767, ConfIntervalDiff, 2071, 2087, "- 0 . 8 to 3 . 7", "", +12768, PvalueDiff, 2090, 2100, "P = 0 . 21", "", +12769, PercentageAffected, 2126, 2128, "60", "", +12771, Latanoprost, 2135, 2146, "latanoprost", "", +12770, PercentageAffected, 2151, 2153, "52", "", +12772, Timolol, 2160, 2167, "timolol", "", +12773, PvalueDiff, 2170, 2180, "P = 0 . 33", "", +12774, IOP, 2225, 2228, "IOP", "", +12775, PigmentaryGlaucoma, 2243, 2246, "PCG", "", +12776, PigmentaryGlaucoma, 2257, 2260, "PCG", "", +12777, DiffGroupAbsValue, 2276, 2281, "0 . 6", "", +12779, mmHg, 2282, 2286, "mmHg", "", +12781, ConfIntervalDiff, 2299, 2315, "- 2 . 3 to 3 . 4", "", +12778, DiffGroupAbsValue, 2322, 2327, "2 . 6", "", +12780, mmHg, 2328, 2332, "mmHg", "", +12782, ConfIntervalDiff, 2345, 2361, "- 0 . 8 to 6 . 1", "", +12783, Latanoprost, 2401, 2412, "latanoprost", "", +12784, Timolol, 2420, 2427, "timolol", "", +12785, PercentageAffected, 2433, 2435, "50", "", +12786, PercentageAffected, 2445, 2447, "46", "", +12787, PigmentaryGlaucoma, 2458, 2461, "PCG", "", +12788, PercentageAffected, 2472, 2474, "72", "", +12789, PercentageAffected, 2484, 2486, "57", "", +12790, PigmentaryGlaucoma, 2503, 2506, "PCG", "", +12791, ObservedResult, 2515, 2549, "Both therapies were well tolerated", "", +12802, ConclusionComment, 2566, 2763, "Latanoprost 0 . 005 % is not inferior ( i . e . , is either more or similarly effective ) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG .", "", +12792, Latanoprost, 2566, 2577, "Latanoprost", "", +12793, DoseValue, 2578, 2585, "0 . 005", "", +12794, Percentage, 2586, 2587, "%", "", +12795, Timolol, 2659, 2666, "timolol", "", +12796, IOP, 2700, 2703, "IOP", "", +12797, PigmentaryGlaucoma, 2758, 2761, "PCG", "", +12801, ConclusionComment, 2764, 2866, "Both latanoprost and timolol had favorable safety profiles over the duration of this 3 - month trial .", "", +12798, Latanoprost, 2769, 2780, "latanoprost", "", +12799, Timolol, 2785, 2792, "timolol", "", +12800, Duration, 2849, 2858, "3 - month", "", +12803, PMID, 3126, 3134, "21680022", "", diff --git a/data/gl 21680022_tstrakeljahn.n-triples b/data/gl 21680022_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21680022_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21792284_admin.annodb b/data/gl 21792284_admin.annodb new file mode 100644 index 0000000..6e74207 --- /dev/null +++ b/data/gl 21792284_admin.annodb @@ -0,0 +1,123 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Clin Ophthalmol", "", " \"Clin Ophthalmol\"." +1, PublicationYear, 18, 22, "2011", "", " \"2011\"." +116, Title, 92, 245, "Twelve - week , randomized , multicenter study comparing a fixed combination of brimonidine - timolol with timolol as therapy adjunctive to latanoprost .", "", " \"Twelve - week , randomized , multicenter study comparing a fixed combination of brimonidine - timolol with timolol as therapy adjunctive to latanoprost .\"." +2, Duration, 92, 105, "Twelve - week", "", " \"Twelve - week\"." +3, Randomized, 108, 118, "randomized", "", " ." +4, Multicenter, 121, 132, "multicenter", "", " ." +5, Brimonidine, 172, 183, "brimonidine", "", " ." +6, Timolol, 186, 193, "timolol", "", " ." +7, Timolol, 199, 206, "timolol", "", +8, Latanoprost, 232, 243, "latanoprost", "", " . ." +10, Author, 246, 257, "Fechtner RD", "", " \"Fechtner RD\"." +11, Author, 266, 280, "Harasymowycz P", "", " \"Harasymowycz P\"." +12, Author, 283, 291, "Nixon DR", "", " \"Nixon DR\"." +13, Author, 294, 301, "Vold SD", "", " \"Vold SD\"." +14, Author, 304, 311, "Zaman F", "", " \"Zaman F\"." +15, Author, 314, 325, "Williams JM", "", " \"Williams JM\"." +16, Author, 328, 340, "Hollander DA", "", " \"Hollander DA\"." +131, USA, 454, 457, "USA", "", " ." +132, ObjectiveDescription, 495, 696, "To evaluate the additive intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % / timolol 0 . 5 % compared with timolol 0 . 5 % at peak and trough effect", "", " \"To evaluate the additive intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % / timolol 0 . 5 % compared with timolol 0 . 5 % at peak and trough effect\"." +18, IOP, 520, 540, "intraocular pressure", "", +19, IOP, 543, 546, "IOP", "", +20, Brimonidine, 603, 614, "brimonidine", "", +30, DoseValue, 615, 620, "0 . 2", "", " \"0 . 2\"." +35, Percentage, 621, 622, "%", "", " ." +21, Timolol, 625, 632, "timolol", "", +31, DoseValue, 633, 638, "0 . 5", "", " \"0 . 5\"." +36, Percentage, 639, 640, "%", "", " ." +22, Timolol, 655, 662, "timolol", "", +32, DoseValue, 663, 668, "0 . 5", "", +37, Percentage, 669, 670, "%", "", +23, Peak_IOP, 674, 678, "peak", "", +146, Trough_IOP, 683, 689, "trough", "", +133, ObjectiveDescription, 697, 840, "when used as therapy adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering .", "", " \"when used as therapy adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering .\"." +25, Latanoprost, 732, 743, "latanoprost", "", +33, DoseValue, 744, 751, "0 . 005", "", " \"0 . 005\"." +34, Percentage, 752, 753, "%", "", " ." +26, Glaucoma, 771, 779, "glaucoma", "", " . ." +27, OcularHypertension, 783, 802, "ocular hypertension", "", " ." +28, IOP, 826, 829, "IOP", "", +153, CTDesign, 859, 870, "prospective", "", " . ." +40, Randomized, 873, 883, "randomized", "", +41, Multicenter, 886, 897, "multicenter", "", +42, Blind, 915, 921, "masked", "", " ." +43, Parallel, 924, 932, "parallel", "", " ." +44, Latanoprost, 976, 987, "latanoprost", "", +37010, Duration, 1013, 1023, "four weeks", "", +47, Latanoprost, 1059, 1070, "latanoprost", "", +50, Precondition, 1073, 1120, "patients with IOP ≥ 21 mmHg in at least one eye", "", " \"patients with IOP ≥ 21 mmHg in at least one eye\"." +48, IOP, 1087, 1090, "IOP", "", +49, mmHg, 1096, 1100, "mmHg", "", +51, Randomized, 1126, 1136, "randomized", "", +52, Frequency, 1140, 1153, "twice - daily", "", " \"twice - daily\". \"twice - daily\"." +53, Brimonidine, 1160, 1171, "brimonidine", "", " \"twice - daily\". \"twice - daily\"." +54, Timolol, 1174, 1181, "timolol", "", +55, NumberPatientsArm, 1188, 1191, "102", "", " \"102\"." +56, Timolol, 1197, 1204, "timolol", "", +57, NumberPatientsArm, 1211, 1214, "102", "", " \"102\"." +58, Latanoprost, 1238, 1249, "latanoprost", "", +46, Duration, 1254, 1262, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +59, IOP, 1265, 1268, "IOP", "", +37014, TimePoint, 1303, 1311, "baseline", "", +37013, TimePoint, 1314, 1320, "week 6", "", +37015, TimePoint, 1327, 1334, "week 12", "", " \"week 12\"." +171, PerProtocol, 1356, 1368, "per protocol", "", " ." +37016, Peak_IOP, 1416, 1424, "peak IOP", "", +37018, TimePoint, 1445, 1452, "week 12", "", +62, Mean, 1516, 1520, "mean", "", " . ." +63, IOP, 1521, 1524, "IOP", "", +64, Brimonidine, 1572, 1583, "brimonidine", "", +65, Timolol, 1586, 1593, "timolol", "", +66, BaseLineValue, 1594, 1600, "23 . 4", "", " \"23 . 4\"." +68, mmHg, 1601, 1605, "mmHg", "", " ." +70, Timolol, 1608, 1615, "timolol", "", +67, BaseLineValue, 1616, 1622, "23 . 0", "", " \"23 . 0\"." +69, mmHg, 1623, 1627, "mmHg", "", +71, Mean, 1636, 1640, "mean", "", +72, Latanoprost, 1667, 1678, "latanoprost", "", +74, IOP, 1698, 1701, "IOP", "", +73, Reduction, 1706, 1711, "8 . 3", "", " \"8 . 3\"." +76, mmHg, 1712, 1716, "mmHg", "", +81, RelativeReduction, 1719, 1725, "35 . 5", "", " \"35 . 5\"." +78, Brimonidine, 1741, 1752, "brimonidine", "", +79, Timolol, 1755, 1762, "timolol", "", +75, Reduction, 1767, 1772, "6 . 2", "", " \"6 . 2\"." +77, mmHg, 1773, 1777, "mmHg", "", +82, RelativeReduction, 1780, 1786, "27 . 0", "", " \"27 . 0\"." +80, Timolol, 1796, 1803, "timolol", "", +195, TimePoint, 1815, 1822, "week 12", "", " \"week 12\". \"week 12\". \"week 12\"." +83, PvalueDiff, 1825, 1836, "P < 0 . 001", "", " \"P < 0 . 001\"." +84, Brimonidine, 1869, 1880, "brimonidine", "", +85, Timolol, 1883, 1890, "timolol", "", +86, Latanoprost, 1905, 1916, "latanoprost", "", +87, Timolol, 1986, 1993, "timolol", "", +88, IOP, 2008, 2011, "IOP", "", +203, EndPointDescription, 2008, 2021, "IOP < 18 mmHg", "", " . ." +89, mmHg, 2017, 2021, "mmHg", "", +90, PvalueDiff, 2024, 2035, "P = 0 . 028", "", " \"P = 0 . 028\"." +205, EndPointDescription, 2044, 2081, "≥ 20 % reduction in IOP from baseline", "", " . ." +92, IOP, 2064, 2067, "IOP", "", +91, PvalueDiff, 2084, 2095, "P = 0 . 047", "", " \"P = 0 . 047\"." +93, TimePoint, 2124, 2131, "week 12", "", " \"week 12\". \"week 12\"." +119921, EndPointDescription, 2134, 2148, "Adverse events", "", " . ." +94, PercentageAffected, 2161, 2167, "14 . 7", "", " \"14 . 7\"." +96, Brimonidine, 2179, 2190, "brimonidine", "", +97, Timolol, 2193, 2200, "timolol", "", +95, PercentageAffected, 2214, 2220, "12 . 7", "", " \"12 . 7\"." +98, Timolol, 2226, 2233, "timolol", "", +214, Duration, 2316, 2324, "12 weeks", "", +215, ConclusionComment, 2353, 2549, "Fixed - combination brimonidine - timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension .", "", " \"Fixed - combination brimonidine - timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension .\"." +100, Brimonidine, 2373, 2384, "brimonidine", "", +101, Timolol, 2387, 2394, "timolol", "", +103, IOP, 2403, 2406, "IOP", "", +102, Timolol, 2443, 2450, "timolol", "", +104, Latanoprost, 2486, 2497, "latanoprost", "", +105, Glaucoma, 2515, 2523, "glaucoma", "", +106, OcularHypertension, 2528, 2547, "ocular hypertension", "", +216, ConclusionComment, 2550, 2652, "Both fixed brimonidine - timolol and timolol were well tolerated as agents adjunctive to latanoprost .", "", " \"Both fixed brimonidine - timolol and timolol were well tolerated as agents adjunctive to latanoprost .\"." +107, Brimonidine, 2561, 2572, "brimonidine", "", +108, Timolol, 2575, 2582, "timolol", "", +109, Timolol, 2587, 2594, "timolol", "", +110, Latanoprost, 2639, 2650, "latanoprost", "", +113, PMID, 2711, 2719, "21792284", "", " \"21792284\"." diff --git a/data/gl 21792284_admin.n-triples b/data/gl 21792284_admin.n-triples new file mode 100644 index 0000000..db7d8e3 --- /dev/null +++ b/data/gl 21792284_admin.n-triples @@ -0,0 +1,189 @@ +# RDF export of group: Publication + . + "Publication 53553" . + "Twelve - week , randomized , multicenter study comparing a fixed combination of brimonidine - timolol with timolol as therapy adjunctive to latanoprost ." . + "Fechtner RD" . + "2011" . + "Clin Ophthalmol" . + "21792284" . + . + "Harasymowycz P" . + "Nixon DR" . + "Vold SD" . + "Zaman F" . + "Williams JM" . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 53566" . + "To evaluate the additive intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % / timolol 0 . 5 % compared with timolol 0 . 5 % at peak and trough effect" . + "Twelve - week" . + . + . + . + "Fixed - combination brimonidine - timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension ." . + . + . + . + . + . + . + "when used as therapy adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering ." . + . + . + . + . + . + "Both fixed brimonidine - timolol and timolol were well tolerated as agents adjunctive to latanoprost ." . + . + . + . + . +# RDF export of group: Population + . + "Population 53589" . + "patients with IOP ≥ 21 mmHg in at least one eye" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 53597 IOP" . + . + . + . + . + . + . + . + "Endpoint 65216 IOP < 18 mmHg" . + . + . + . + . + . + . + "Endpoint 65221 ≥ 20% reduction in IOP" . + . + . + . + . + . + . + "AdverseEffects" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 65090 Brimonidine Timolol Latanoprost" . + "102" . + . + . + . + . + . + . + "Arm 65099 Timolol Latanoprost" . + "102" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 65060 Brimonidine Timolol" . + . + "twice - daily" . + "12 weeks" . + . + . + . + "Intervention 65068 Timolol" . + . + "twice - daily" . + "12 weeks" . + . + . + "Intervention 65084 Latanoprost" . + . + . +# RDF export of group: Medication + . + "Medication 65039 Brimonidine" . + . + "0 . 2" . + . + . + . + "Medication 65046 Timolol" . + . + "0 . 5" . + . + . + . + "Medication 65053 Latanoprost" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "Outcome 65012 Brimonidine Timolol" . + . + "23 . 4" . + "8 . 3" . + "35 . 5" . + "week 12" . + . + "Outcome 65108 Timolol" . + . + "23 . 0" . + "6 . 2" . + "27 . 0" . + "week 12" . + . + "Outcome 65135 Adverse Effects Brimonidine Timolol" . + . + "14 . 7" . + . + "Outcome 65162 Adverse Effects Timolol" . + . + "12 . 7" . + . + "Outcome 65235 reduction_bri" . + . + "week 12" . + . + "Outcome 65262 IOP < 18 mmHg_bri" . + . + "week 12" . + . + "Outcome 102229 reduction_tim" . + . + "week 12" . + . + "Outcome 102256 IOP <18mmHg_tim" . + . + "week 12" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 65226 ≥ 20 % reduction" . + "P = 0 . 047" . + . + . + . + "DiffBetweenGroups 65289 < 18 mmHg" . + "P = 0 . 028" . + . + . + . + "DiffBetweenGroups 65298" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21792284_export.csv b/data/gl 21792284_export.csv new file mode 100644 index 0000000..ddd8519 --- /dev/null +++ b/data/gl 21792284_export.csv @@ -0,0 +1,541 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +428, 1, 1, 1, 0, 4, 0, 4, "Clin" +428, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +428, 1, 3, 3, 16, 17, 16, 17, "." +428, 2, 1, 4, 0, 4, 18, 22, "2011" +428, 2, 2, 5, 5, 6, 23, 24, ";" +428, 2, 3, 6, 7, 8, 25, 26, "5" +428, 2, 4, 7, 9, 10, 27, 28, ":" +428, 2, 5, 8, 11, 14, 29, 32, "945" +428, 2, 6, 9, 15, 16, 33, 34, "-" +428, 2, 7, 10, 17, 19, 35, 37, "53" +428, 2, 8, 11, 20, 21, 38, 39, "." +428, 2, 9, 12, 22, 25, 40, 43, "doi" +428, 2, 10, 13, 26, 27, 44, 45, ":" +428, 2, 11, 14, 28, 30, 46, 48, "10" +428, 2, 12, 15, 31, 32, 49, 50, "." +428, 2, 13, 16, 33, 37, 51, 55, "2147" +428, 2, 14, 17, 38, 39, 56, 57, "/" +428, 2, 15, 18, 40, 44, 58, 62, "OPTH" +428, 2, 16, 19, 45, 46, 63, 64, "." +428, 2, 17, 20, 47, 53, 65, 71, "S19999" +428, 2, 18, 21, 54, 55, 72, 73, "." +428, 3, 1, 22, 0, 4, 74, 78, "Epub" +428, 3, 2, 23, 5, 9, 79, 83, "2011" +428, 3, 3, 24, 10, 13, 84, 87, "Jul" +428, 3, 4, 25, 14, 15, 88, 89, "8" +428, 3, 5, 26, 16, 17, 90, 91, "." +428, 4, 1, 27, 0, 6, 92, 98, "Twelve" +428, 4, 2, 28, 7, 8, 99, 100, "-" +428, 4, 3, 29, 9, 13, 101, 105, "week" +428, 4, 4, 30, 14, 15, 106, 107, "," +428, 4, 5, 31, 16, 26, 108, 118, "randomized" +428, 4, 6, 32, 27, 28, 119, 120, "," +428, 4, 7, 33, 29, 40, 121, 132, "multicenter" +428, 4, 8, 34, 41, 46, 133, 138, "study" +428, 4, 9, 35, 47, 56, 139, 148, "comparing" +428, 4, 10, 36, 57, 58, 149, 150, "a" +428, 4, 11, 37, 59, 64, 151, 156, "fixed" +428, 4, 12, 38, 65, 76, 157, 168, "combination" +428, 4, 13, 39, 77, 79, 169, 171, "of" +428, 4, 14, 40, 80, 91, 172, 183, "brimonidine" +428, 4, 15, 41, 92, 93, 184, 185, "-" +428, 4, 16, 42, 94, 101, 186, 193, "timolol" +428, 4, 17, 43, 102, 106, 194, 198, "with" +428, 4, 18, 44, 107, 114, 199, 206, "timolol" +428, 4, 19, 45, 115, 117, 207, 209, "as" +428, 4, 20, 46, 118, 125, 210, 217, "therapy" +428, 4, 21, 47, 126, 136, 218, 228, "adjunctive" +428, 4, 22, 48, 137, 139, 229, 231, "to" +428, 4, 23, 49, 140, 151, 232, 243, "latanoprost" +428, 4, 24, 50, 152, 153, 244, 245, "." +428, 5, 1, 51, 0, 8, 246, 254, "Fechtner" +428, 5, 2, 52, 9, 11, 255, 257, "RD" +428, 5, 3, 53, 12, 13, 258, 259, "(" +428, 5, 4, 54, 14, 15, 260, 261, "1" +428, 5, 5, 55, 16, 17, 262, 263, ")" +428, 5, 6, 56, 18, 19, 264, 265, "," +428, 5, 7, 57, 20, 32, 266, 278, "Harasymowycz" +428, 5, 8, 58, 33, 34, 279, 280, "P" +428, 5, 9, 59, 35, 36, 281, 282, "," +428, 5, 10, 60, 37, 42, 283, 288, "Nixon" +428, 5, 11, 61, 43, 45, 289, 291, "DR" +428, 5, 12, 62, 46, 47, 292, 293, "," +428, 5, 13, 63, 48, 52, 294, 298, "Vold" +428, 5, 14, 64, 53, 55, 299, 301, "SD" +428, 5, 15, 65, 56, 57, 302, 303, "," +428, 5, 16, 66, 58, 63, 304, 309, "Zaman" +428, 5, 17, 67, 64, 65, 310, 311, "F" +428, 5, 18, 68, 66, 67, 312, 313, "," +428, 5, 19, 69, 68, 76, 314, 322, "Williams" +428, 5, 20, 70, 77, 79, 323, 325, "JM" +428, 5, 21, 71, 80, 81, 326, 327, "," +428, 5, 22, 72, 82, 91, 328, 337, "Hollander" +428, 5, 23, 73, 92, 94, 338, 340, "DA" +428, 5, 24, 74, 95, 96, 341, 342, "." +428, 6, 1, 75, 0, 6, 343, 349, "Author" +428, 6, 2, 76, 7, 18, 350, 361, "information" +428, 6, 3, 77, 19, 20, 362, 363, ":" +428, 6, 4, 78, 21, 22, 364, 365, "(" +428, 6, 5, 79, 23, 24, 366, 367, "1" +428, 6, 6, 80, 25, 26, 368, 369, ")" +428, 6, 7, 81, 27, 35, 370, 378, "Glaucoma" +428, 6, 8, 82, 36, 44, 379, 387, "Division" +428, 6, 9, 83, 45, 46, 388, 389, "," +428, 6, 10, 84, 47, 57, 390, 400, "University" +428, 6, 11, 85, 58, 60, 401, 403, "of" +428, 6, 12, 86, 61, 69, 404, 412, "Medicine" +428, 6, 13, 87, 70, 73, 413, 416, "and" +428, 6, 14, 88, 74, 83, 417, 426, "Dentistry" +428, 6, 15, 89, 84, 87, 427, 430, "New" +428, 6, 16, 90, 88, 94, 431, 437, "Jersey" +428, 6, 17, 91, 95, 96, 438, 439, "," +428, 6, 18, 92, 97, 103, 440, 446, "Newark" +428, 6, 19, 93, 104, 105, 447, 448, "," +428, 6, 20, 94, 106, 108, 449, 451, "NJ" +428, 6, 21, 95, 109, 110, 452, 453, "," +428, 6, 22, 96, 111, 114, 454, 457, "USA" +428, 6, 23, 97, 115, 116, 458, 459, "." +428, 7, 1, 98, 0, 8, 460, 468, "fechtner" +428, 7, 2, 99, 9, 10, 469, 470, "@" +428, 7, 3, 100, 11, 16, 471, 476, "umdnj" +428, 7, 4, 101, 17, 18, 477, 478, "." +428, 7, 5, 102, 19, 22, 479, 482, "edu" +428, 7, 6, 103, 23, 32, 483, 492, "OBJECTIVE" +428, 7, 7, 104, 33, 34, 493, 494, ":" +428, 7, 8, 105, 35, 37, 495, 497, "To" +428, 7, 9, 106, 38, 46, 498, 506, "evaluate" +428, 7, 10, 107, 47, 50, 507, 510, "the" +428, 7, 11, 108, 51, 59, 511, 519, "additive" +428, 7, 12, 109, 60, 71, 520, 531, "intraocular" +428, 7, 13, 110, 72, 80, 532, 540, "pressure" +428, 7, 14, 111, 81, 82, 541, 542, "(" +428, 7, 15, 112, 83, 86, 543, 546, "IOP" +428, 7, 16, 113, 87, 88, 547, 548, ")" +428, 7, 17, 114, 89, 90, 549, 550, "-" +428, 7, 18, 115, 91, 99, 551, 559, "lowering" +428, 7, 19, 116, 100, 108, 560, 568, "efficacy" +428, 7, 20, 117, 109, 112, 569, 572, "and" +428, 7, 21, 118, 113, 119, 573, 579, "safety" +428, 7, 22, 119, 120, 122, 580, 582, "of" +428, 7, 23, 120, 123, 128, 583, 588, "fixed" +428, 7, 24, 121, 129, 130, 589, 590, "-" +428, 7, 25, 122, 131, 142, 591, 602, "combination" +428, 7, 26, 123, 143, 154, 603, 614, "brimonidine" +428, 7, 27, 124, 155, 156, 615, 616, "0" +428, 7, 28, 125, 157, 158, 617, 618, "." +428, 7, 29, 126, 159, 160, 619, 620, "2" +428, 7, 30, 127, 161, 162, 621, 622, "%" +428, 7, 31, 128, 163, 164, 623, 624, "/" +428, 7, 32, 129, 165, 172, 625, 632, "timolol" +428, 7, 33, 130, 173, 174, 633, 634, "0" +428, 7, 34, 131, 175, 176, 635, 636, "." +428, 7, 35, 132, 177, 178, 637, 638, "5" +428, 7, 36, 133, 179, 180, 639, 640, "%" +428, 7, 37, 134, 181, 189, 641, 649, "compared" +428, 7, 38, 135, 190, 194, 650, 654, "with" +428, 7, 39, 136, 195, 202, 655, 662, "timolol" +428, 7, 40, 137, 203, 204, 663, 664, "0" +428, 7, 41, 138, 205, 206, 665, 666, "." +428, 7, 42, 139, 207, 208, 667, 668, "5" +428, 7, 43, 140, 209, 210, 669, 670, "%" +428, 7, 44, 141, 211, 213, 671, 673, "at" +428, 7, 45, 142, 214, 218, 674, 678, "peak" +428, 7, 46, 143, 219, 222, 679, 682, "and" +428, 7, 47, 144, 223, 229, 683, 689, "trough" +428, 7, 48, 145, 230, 236, 690, 696, "effect" +428, 7, 49, 146, 237, 241, 697, 701, "when" +428, 7, 50, 147, 242, 246, 702, 706, "used" +428, 7, 51, 148, 247, 249, 707, 709, "as" +428, 7, 52, 149, 250, 257, 710, 717, "therapy" +428, 7, 53, 150, 258, 268, 718, 728, "adjunctive" +428, 7, 54, 151, 269, 271, 729, 731, "to" +428, 7, 55, 152, 272, 283, 732, 743, "latanoprost" +428, 7, 56, 153, 284, 285, 744, 745, "0" +428, 7, 57, 154, 286, 287, 746, 747, "." +428, 7, 58, 155, 288, 291, 748, 751, "005" +428, 7, 59, 156, 292, 293, 752, 753, "%" +428, 7, 60, 157, 294, 296, 754, 756, "in" +428, 7, 61, 158, 297, 305, 757, 765, "patients" +428, 7, 62, 159, 306, 310, 766, 770, "with" +428, 7, 63, 160, 311, 319, 771, 779, "glaucoma" +428, 7, 64, 161, 320, 322, 780, 782, "or" +428, 7, 65, 162, 323, 329, 783, 789, "ocular" +428, 7, 66, 163, 330, 342, 790, 802, "hypertension" +428, 7, 67, 164, 343, 346, 803, 806, "who" +428, 7, 68, 165, 347, 354, 807, 814, "require" +428, 7, 69, 166, 355, 365, 815, 825, "additional" +428, 7, 70, 167, 366, 369, 826, 829, "IOP" +428, 7, 71, 168, 370, 378, 830, 838, "lowering" +428, 7, 72, 169, 379, 380, 839, 840, "." +428, 8, 1, 170, 0, 7, 841, 848, "METHODS" +428, 8, 2, 171, 8, 9, 849, 850, ":" +428, 8, 3, 172, 10, 12, 851, 853, "In" +428, 8, 4, 173, 13, 17, 854, 858, "this" +428, 8, 5, 174, 18, 29, 859, 870, "prospective" +428, 8, 6, 175, 30, 31, 871, 872, "," +428, 8, 7, 176, 32, 42, 873, 883, "randomized" +428, 8, 8, 177, 43, 44, 884, 885, "," +428, 8, 9, 178, 45, 56, 886, 897, "multicenter" +428, 8, 10, 179, 57, 58, 898, 899, "," +428, 8, 11, 180, 59, 71, 900, 912, "investigator" +428, 8, 12, 181, 72, 73, 913, 914, "-" +428, 8, 13, 182, 74, 80, 915, 921, "masked" +428, 8, 14, 183, 81, 82, 922, 923, "," +428, 8, 15, 184, 83, 91, 924, 932, "parallel" +428, 8, 16, 185, 92, 93, 933, 934, "-" +428, 8, 17, 186, 94, 99, 935, 940, "group" +428, 8, 18, 187, 100, 105, 941, 946, "study" +428, 8, 19, 188, 106, 107, 947, 948, "," +428, 8, 20, 189, 108, 116, 949, 957, "patients" +428, 8, 21, 190, 117, 121, 958, 962, "were" +428, 8, 22, 191, 122, 129, 963, 970, "treated" +428, 8, 23, 192, 130, 134, 971, 975, "with" +428, 8, 24, 193, 135, 146, 976, 987, "latanoprost" +428, 8, 25, 194, 147, 158, 988, 999, "monotherapy" +428, 8, 26, 195, 159, 162, 1000, 1003, "for" +428, 8, 27, 196, 163, 165, 1004, 1006, "at" +428, 8, 28, 197, 166, 171, 1007, 1012, "least" +428, 8, 29, 198, 172, 176, 1013, 1017, "four" +428, 8, 30, 199, 177, 182, 1018, 1023, "weeks" +428, 8, 31, 200, 183, 188, 1024, 1029, "prior" +428, 8, 32, 201, 189, 191, 1030, 1032, "to" +428, 8, 33, 202, 192, 200, 1033, 1041, "baseline" +428, 8, 34, 203, 201, 202, 1042, 1043, "." +428, 9, 1, 204, 0, 2, 1044, 1046, "At" +428, 9, 2, 205, 3, 11, 1047, 1055, "baseline" +428, 9, 3, 206, 12, 14, 1056, 1058, "on" +428, 9, 4, 207, 15, 26, 1059, 1070, "latanoprost" +428, 9, 5, 208, 27, 28, 1071, 1072, "," +428, 9, 6, 209, 29, 37, 1073, 1081, "patients" +428, 9, 7, 210, 38, 42, 1082, 1086, "with" +428, 9, 8, 211, 43, 46, 1087, 1090, "IOP" +428, 9, 9, 212, 47, 48, 1091, 1092, "≥" +428, 9, 10, 213, 49, 51, 1093, 1095, "21" +428, 9, 11, 214, 52, 56, 1096, 1100, "mmHg" +428, 9, 12, 215, 57, 59, 1101, 1103, "in" +428, 9, 13, 216, 60, 62, 1104, 1106, "at" +428, 9, 14, 217, 63, 68, 1107, 1112, "least" +428, 9, 15, 218, 69, 72, 1113, 1116, "one" +428, 9, 16, 219, 73, 76, 1117, 1120, "eye" +428, 9, 17, 220, 77, 81, 1121, 1125, "were" +428, 9, 18, 221, 82, 92, 1126, 1136, "randomized" +428, 9, 19, 222, 93, 95, 1137, 1139, "to" +428, 9, 20, 223, 96, 101, 1140, 1145, "twice" +428, 9, 21, 224, 102, 103, 1146, 1147, "-" +428, 9, 22, 225, 104, 109, 1148, 1153, "daily" +428, 9, 23, 226, 110, 115, 1154, 1159, "fixed" +428, 9, 24, 227, 116, 127, 1160, 1171, "brimonidine" +428, 9, 25, 228, 128, 129, 1172, 1173, "-" +428, 9, 26, 229, 130, 137, 1174, 1181, "timolol" +428, 9, 27, 230, 138, 139, 1182, 1183, "(" +428, 9, 28, 231, 140, 141, 1184, 1185, "n" +428, 9, 29, 232, 142, 143, 1186, 1187, "=" +428, 9, 30, 233, 144, 147, 1188, 1191, "102" +428, 9, 31, 234, 148, 149, 1192, 1193, ")" +428, 9, 32, 235, 150, 152, 1194, 1196, "or" +428, 9, 33, 236, 153, 160, 1197, 1204, "timolol" +428, 9, 34, 237, 161, 162, 1205, 1206, "(" +428, 9, 35, 238, 163, 164, 1207, 1208, "n" +428, 9, 36, 239, 165, 166, 1209, 1210, "=" +428, 9, 37, 240, 167, 170, 1211, 1214, "102" +428, 9, 38, 241, 171, 172, 1215, 1216, ")" +428, 9, 39, 242, 173, 174, 1217, 1218, "," +428, 9, 40, 243, 175, 179, 1219, 1223, "each" +428, 9, 41, 244, 180, 190, 1224, 1234, "adjunctive" +428, 9, 42, 245, 191, 193, 1235, 1237, "to" +428, 9, 43, 246, 194, 205, 1238, 1249, "latanoprost" +428, 9, 44, 247, 206, 209, 1250, 1253, "for" +428, 9, 45, 248, 210, 212, 1254, 1256, "12" +428, 9, 46, 249, 213, 218, 1257, 1262, "weeks" +428, 9, 47, 250, 219, 220, 1263, 1264, "." +428, 10, 1, 251, 0, 3, 1265, 1268, "IOP" +428, 10, 2, 252, 4, 7, 1269, 1272, "was" +428, 10, 3, 253, 8, 16, 1273, 1281, "measured" +428, 10, 4, 254, 17, 19, 1282, 1284, "at" +428, 10, 5, 255, 20, 21, 1285, 1286, "8" +428, 10, 6, 256, 22, 24, 1287, 1289, "am" +428, 10, 7, 257, 25, 28, 1290, 1293, "and" +428, 10, 8, 258, 29, 31, 1294, 1296, "10" +428, 10, 9, 259, 32, 34, 1297, 1299, "am" +428, 10, 10, 260, 35, 37, 1300, 1302, "at" +428, 10, 11, 261, 38, 46, 1303, 1311, "baseline" +428, 10, 12, 262, 47, 48, 1312, 1313, "," +428, 10, 13, 263, 49, 53, 1314, 1318, "week" +428, 10, 14, 264, 54, 55, 1319, 1320, "6" +428, 10, 15, 265, 56, 57, 1321, 1322, "," +428, 10, 16, 266, 58, 61, 1323, 1326, "and" +428, 10, 17, 267, 62, 66, 1327, 1331, "week" +428, 10, 18, 268, 67, 69, 1332, 1334, "12" +428, 10, 19, 269, 70, 73, 1335, 1338, "and" +428, 10, 20, 270, 74, 83, 1339, 1348, "evaluated" +428, 10, 21, 271, 84, 86, 1349, 1351, "in" +428, 10, 22, 272, 87, 90, 1352, 1355, "the" +428, 10, 23, 273, 91, 94, 1356, 1359, "per" +428, 10, 24, 274, 95, 103, 1360, 1368, "protocol" +428, 10, 25, 275, 104, 114, 1369, 1379, "population" +428, 10, 26, 276, 115, 116, 1380, 1381, "." +428, 11, 1, 277, 0, 3, 1382, 1385, "The" +428, 11, 2, 278, 4, 11, 1386, 1393, "primary" +428, 11, 3, 279, 12, 20, 1394, 1402, "efficacy" +428, 11, 4, 280, 21, 29, 1403, 1411, "endpoint" +428, 11, 5, 281, 30, 33, 1412, 1415, "was" +428, 11, 6, 282, 34, 38, 1416, 1420, "peak" +428, 11, 7, 283, 39, 42, 1421, 1424, "IOP" +428, 11, 8, 284, 43, 51, 1425, 1433, "lowering" +428, 11, 9, 285, 52, 54, 1434, 1436, "at" +428, 11, 10, 286, 55, 57, 1437, 1439, "10" +428, 11, 11, 287, 58, 60, 1440, 1442, "am" +428, 11, 12, 288, 61, 62, 1443, 1444, "," +428, 11, 13, 289, 63, 67, 1445, 1449, "week" +428, 11, 14, 290, 68, 70, 1450, 1452, "12" +428, 11, 15, 291, 71, 72, 1453, 1454, "." +428, 12, 1, 292, 0, 6, 1455, 1461, "Safety" +428, 12, 2, 293, 7, 15, 1462, 1470, "measures" +428, 12, 3, 294, 16, 24, 1471, 1479, "included" +428, 12, 4, 295, 25, 32, 1480, 1487, "adverse" +428, 12, 5, 296, 33, 39, 1488, 1494, "events" +428, 12, 6, 297, 40, 41, 1495, 1496, "." +428, 13, 1, 298, 0, 7, 1497, 1504, "RESULTS" +428, 13, 2, 299, 8, 9, 1505, 1506, ":" +428, 13, 3, 300, 10, 18, 1507, 1515, "Baseline" +428, 13, 4, 301, 19, 23, 1516, 1520, "mean" +428, 13, 5, 302, 24, 27, 1521, 1524, "IOP" +428, 13, 6, 303, 28, 31, 1525, 1528, "was" +428, 13, 7, 304, 32, 39, 1529, 1536, "similar" +428, 13, 8, 305, 40, 42, 1537, 1539, "at" +428, 13, 9, 306, 43, 45, 1540, 1542, "10" +428, 13, 10, 307, 46, 48, 1543, 1545, "am" +428, 13, 11, 308, 49, 51, 1546, 1548, "in" +428, 13, 12, 309, 52, 55, 1549, 1552, "the" +428, 13, 13, 310, 56, 65, 1553, 1562, "treatment" +428, 13, 14, 311, 66, 72, 1563, 1569, "groups" +428, 13, 15, 312, 73, 74, 1570, 1571, "(" +428, 13, 16, 313, 75, 86, 1572, 1583, "brimonidine" +428, 13, 17, 314, 87, 88, 1584, 1585, "-" +428, 13, 18, 315, 89, 96, 1586, 1593, "timolol" +428, 13, 19, 316, 97, 99, 1594, 1596, "23" +428, 13, 20, 317, 100, 101, 1597, 1598, "." +428, 13, 21, 318, 102, 103, 1599, 1600, "4" +428, 13, 22, 319, 104, 108, 1601, 1605, "mmHg" +428, 13, 23, 320, 109, 110, 1606, 1607, ";" +428, 13, 24, 321, 111, 118, 1608, 1615, "timolol" +428, 13, 25, 322, 119, 121, 1616, 1618, "23" +428, 13, 26, 323, 122, 123, 1619, 1620, "." +428, 13, 27, 324, 124, 125, 1621, 1622, "0" +428, 13, 28, 325, 126, 130, 1623, 1627, "mmHg" +428, 13, 29, 326, 131, 132, 1628, 1629, ")" +428, 13, 30, 327, 133, 134, 1630, 1631, "." +428, 14, 1, 328, 0, 3, 1632, 1635, "The" +428, 14, 2, 329, 4, 8, 1636, 1640, "mean" +428, 14, 3, 330, 9, 19, 1641, 1651, "additional" +428, 14, 4, 331, 20, 29, 1652, 1661, "reduction" +428, 14, 5, 332, 30, 34, 1662, 1666, "from" +428, 14, 6, 333, 35, 46, 1667, 1678, "latanoprost" +428, 14, 7, 334, 47, 48, 1679, 1680, "-" +428, 14, 8, 335, 49, 56, 1681, 1688, "treated" +428, 14, 9, 336, 57, 65, 1689, 1697, "baseline" +428, 14, 10, 337, 66, 69, 1698, 1701, "IOP" +428, 14, 11, 338, 70, 73, 1702, 1705, "was" +428, 14, 12, 339, 74, 75, 1706, 1707, "8" +428, 14, 13, 340, 76, 77, 1708, 1709, "." +428, 14, 14, 341, 78, 79, 1710, 1711, "3" +428, 14, 15, 342, 80, 84, 1712, 1716, "mmHg" +428, 14, 16, 343, 85, 86, 1717, 1718, "(" +428, 14, 17, 344, 87, 89, 1719, 1721, "35" +428, 14, 18, 345, 90, 91, 1722, 1723, "." +428, 14, 19, 346, 92, 93, 1724, 1725, "5" +428, 14, 20, 347, 94, 95, 1726, 1727, "%" +428, 14, 21, 348, 96, 97, 1728, 1729, ")" +428, 14, 22, 349, 98, 102, 1730, 1734, "with" +428, 14, 23, 350, 103, 108, 1735, 1740, "fixed" +428, 14, 24, 351, 109, 120, 1741, 1752, "brimonidine" +428, 14, 25, 352, 121, 122, 1753, 1754, "-" +428, 14, 26, 353, 123, 130, 1755, 1762, "timolol" +428, 14, 27, 354, 131, 134, 1763, 1766, "and" +428, 14, 28, 355, 135, 136, 1767, 1768, "6" +428, 14, 29, 356, 137, 138, 1769, 1770, "." +428, 14, 30, 357, 139, 140, 1771, 1772, "2" +428, 14, 31, 358, 141, 145, 1773, 1777, "mmHg" +428, 14, 32, 359, 146, 147, 1778, 1779, "(" +428, 14, 33, 360, 148, 150, 1780, 1782, "27" +428, 14, 34, 361, 151, 152, 1783, 1784, "." +428, 14, 35, 362, 153, 154, 1785, 1786, "0" +428, 14, 36, 363, 155, 156, 1787, 1788, "%" +428, 14, 37, 364, 157, 158, 1789, 1790, ")" +428, 14, 38, 365, 159, 163, 1791, 1795, "with" +428, 14, 39, 366, 164, 171, 1796, 1803, "timolol" +428, 14, 40, 367, 172, 174, 1804, 1806, "at" +428, 14, 41, 368, 175, 177, 1807, 1809, "10" +428, 14, 42, 369, 178, 180, 1810, 1812, "am" +428, 14, 43, 370, 181, 182, 1813, 1814, "," +428, 14, 44, 371, 183, 187, 1815, 1819, "week" +428, 14, 45, 372, 188, 190, 1820, 1822, "12" +428, 14, 46, 373, 191, 192, 1823, 1824, "(" +428, 14, 47, 374, 193, 194, 1825, 1826, "P" +428, 14, 48, 375, 195, 196, 1827, 1828, "<" +428, 14, 49, 376, 197, 198, 1829, 1830, "0" +428, 14, 50, 377, 199, 200, 1831, 1832, "." +428, 14, 51, 378, 201, 204, 1833, 1836, "001" +428, 14, 52, 379, 205, 206, 1837, 1838, ")" +428, 14, 53, 380, 207, 208, 1839, 1840, "." +428, 15, 1, 381, 0, 8, 1841, 1849, "Patients" +428, 15, 2, 382, 9, 16, 1850, 1857, "treated" +428, 15, 3, 383, 17, 21, 1858, 1862, "with" +428, 15, 4, 384, 22, 27, 1863, 1868, "fixed" +428, 15, 5, 385, 28, 39, 1869, 1880, "brimonidine" +428, 15, 6, 386, 40, 41, 1881, 1882, "-" +428, 15, 7, 387, 42, 49, 1883, 1890, "timolol" +428, 15, 8, 388, 50, 60, 1891, 1901, "adjunctive" +428, 15, 9, 389, 61, 63, 1902, 1904, "to" +428, 15, 10, 390, 64, 75, 1905, 1916, "latanoprost" +428, 15, 11, 391, 76, 80, 1917, 1921, "were" +428, 15, 12, 392, 81, 94, 1922, 1935, "significantly" +428, 15, 13, 393, 95, 99, 1936, 1940, "more" +428, 15, 14, 394, 100, 106, 1941, 1947, "likely" +428, 15, 15, 395, 107, 111, 1948, 1952, "than" +428, 15, 16, 396, 112, 120, 1953, 1961, "patients" +428, 15, 17, 397, 121, 128, 1962, 1969, "treated" +428, 15, 18, 398, 129, 133, 1970, 1974, "with" +428, 15, 19, 399, 134, 144, 1975, 1985, "adjunctive" +428, 15, 20, 400, 145, 152, 1986, 1993, "timolol" +428, 15, 21, 401, 153, 155, 1994, 1996, "to" +428, 15, 22, 402, 156, 163, 1997, 2004, "achieve" +428, 15, 23, 403, 164, 166, 2005, 2007, "an" +428, 15, 24, 404, 167, 170, 2008, 2011, "IOP" +428, 15, 25, 405, 171, 172, 2012, 2013, "<" +428, 15, 26, 406, 173, 175, 2014, 2016, "18" +428, 15, 27, 407, 176, 180, 2017, 2021, "mmHg" +428, 15, 28, 408, 181, 182, 2022, 2023, "(" +428, 15, 29, 409, 183, 184, 2024, 2025, "P" +428, 15, 30, 410, 185, 186, 2026, 2027, "=" +428, 15, 31, 411, 187, 188, 2028, 2029, "0" +428, 15, 32, 412, 189, 190, 2030, 2031, "." +428, 15, 33, 413, 191, 194, 2032, 2035, "028" +428, 15, 34, 414, 195, 196, 2036, 2037, ")" +428, 15, 35, 415, 197, 200, 2038, 2041, "and" +428, 15, 36, 416, 201, 202, 2042, 2043, "a" +428, 15, 37, 417, 203, 204, 2044, 2045, "≥" +428, 15, 38, 418, 205, 207, 2046, 2048, "20" +428, 15, 39, 419, 208, 209, 2049, 2050, "%" +428, 15, 40, 420, 210, 219, 2051, 2060, "reduction" +428, 15, 41, 421, 220, 222, 2061, 2063, "in" +428, 15, 42, 422, 223, 226, 2064, 2067, "IOP" +428, 15, 43, 423, 227, 231, 2068, 2072, "from" +428, 15, 44, 424, 232, 240, 2073, 2081, "baseline" +428, 15, 45, 425, 241, 242, 2082, 2083, "(" +428, 15, 46, 426, 243, 244, 2084, 2085, "P" +428, 15, 47, 427, 245, 246, 2086, 2087, "=" +428, 15, 48, 428, 247, 248, 2088, 2089, "0" +428, 15, 49, 429, 249, 250, 2090, 2091, "." +428, 15, 50, 430, 251, 254, 2092, 2095, "047" +428, 15, 51, 431, 255, 256, 2096, 2097, ")" +428, 15, 52, 432, 257, 259, 2098, 2100, "at" +428, 15, 53, 433, 260, 264, 2101, 2105, "both" +428, 15, 54, 434, 265, 266, 2106, 2107, "8" +428, 15, 55, 435, 267, 269, 2108, 2110, "am" +428, 15, 56, 436, 270, 273, 2111, 2114, "and" +428, 15, 57, 437, 274, 276, 2115, 2117, "10" +428, 15, 58, 438, 277, 279, 2118, 2120, "am" +428, 15, 59, 439, 280, 282, 2121, 2123, "in" +428, 15, 60, 440, 283, 287, 2124, 2128, "week" +428, 15, 61, 441, 288, 290, 2129, 2131, "12" +428, 15, 62, 442, 291, 292, 2132, 2133, "." +428, 16, 1, 443, 0, 7, 2134, 2141, "Adverse" +428, 16, 2, 444, 8, 14, 2142, 2148, "events" +428, 16, 3, 445, 15, 23, 2149, 2157, "occurred" +428, 16, 4, 446, 24, 26, 2158, 2160, "in" +428, 16, 5, 447, 27, 29, 2161, 2163, "14" +428, 16, 6, 448, 30, 31, 2164, 2165, "." +428, 16, 7, 449, 32, 33, 2166, 2167, "7" +428, 16, 8, 450, 34, 35, 2168, 2169, "%" +428, 16, 9, 451, 36, 38, 2170, 2172, "of" +428, 16, 10, 452, 39, 44, 2173, 2178, "fixed" +428, 16, 11, 453, 45, 56, 2179, 2190, "brimonidine" +428, 16, 12, 454, 57, 58, 2191, 2192, "-" +428, 16, 13, 455, 59, 66, 2193, 2200, "timolol" +428, 16, 14, 456, 67, 75, 2201, 2209, "patients" +428, 16, 15, 457, 76, 79, 2210, 2213, "and" +428, 16, 16, 458, 80, 82, 2214, 2216, "12" +428, 16, 17, 459, 83, 84, 2217, 2218, "." +428, 16, 18, 460, 85, 86, 2219, 2220, "7" +428, 16, 19, 461, 87, 88, 2221, 2222, "%" +428, 16, 20, 462, 89, 91, 2223, 2225, "of" +428, 16, 21, 463, 92, 99, 2226, 2233, "timolol" +428, 16, 22, 464, 100, 108, 2234, 2242, "patients" +428, 16, 23, 465, 109, 110, 2243, 2244, "." +428, 17, 1, 466, 0, 13, 2245, 2258, "Biomicroscopy" +428, 17, 2, 467, 14, 22, 2259, 2267, "findings" +428, 17, 3, 468, 23, 27, 2268, 2272, "were" +428, 17, 4, 469, 28, 35, 2273, 2280, "similar" +428, 17, 5, 470, 36, 43, 2281, 2288, "between" +428, 17, 6, 471, 44, 47, 2289, 2292, "the" +428, 17, 7, 472, 48, 57, 2293, 2302, "treatment" +428, 17, 8, 473, 58, 64, 2303, 2309, "groups" +428, 17, 9, 474, 65, 70, 2310, 2315, "after" +428, 17, 10, 475, 71, 73, 2316, 2318, "12" +428, 17, 11, 476, 74, 79, 2319, 2324, "weeks" +428, 17, 12, 477, 80, 82, 2325, 2327, "of" +428, 17, 13, 478, 83, 92, 2328, 2337, "treatment" +428, 17, 14, 479, 93, 94, 2338, 2339, "." +428, 18, 1, 480, 0, 10, 2340, 2350, "CONCLUSION" +428, 18, 2, 481, 11, 12, 2351, 2352, ":" +428, 18, 3, 482, 13, 18, 2353, 2358, "Fixed" +428, 18, 4, 483, 19, 20, 2359, 2360, "-" +428, 18, 5, 484, 21, 32, 2361, 2372, "combination" +428, 18, 6, 485, 33, 44, 2373, 2384, "brimonidine" +428, 18, 7, 486, 45, 46, 2385, 2386, "-" +428, 18, 8, 487, 47, 54, 2387, 2394, "timolol" +428, 18, 9, 488, 55, 62, 2395, 2402, "reduced" +428, 18, 10, 489, 63, 66, 2403, 2406, "IOP" +428, 18, 11, 490, 67, 80, 2407, 2420, "significantly" +428, 18, 12, 491, 81, 85, 2421, 2425, "more" +428, 18, 13, 492, 86, 97, 2426, 2437, "effectively" +428, 18, 14, 493, 98, 102, 2438, 2442, "than" +428, 18, 15, 494, 103, 110, 2443, 2450, "timolol" +428, 18, 16, 495, 111, 115, 2451, 2455, "when" +428, 18, 17, 496, 116, 120, 2456, 2460, "used" +428, 18, 18, 497, 121, 123, 2461, 2463, "as" +428, 18, 19, 498, 124, 134, 2464, 2474, "adjunctive" +428, 18, 20, 499, 135, 142, 2475, 2482, "therapy" +428, 18, 21, 500, 143, 145, 2483, 2485, "to" +428, 18, 22, 501, 146, 157, 2486, 2497, "latanoprost" +428, 18, 23, 502, 158, 160, 2498, 2500, "in" +428, 18, 24, 503, 161, 169, 2501, 2509, "patients" +428, 18, 25, 504, 170, 174, 2510, 2514, "with" +428, 18, 26, 505, 175, 183, 2515, 2523, "glaucoma" +428, 18, 27, 506, 184, 187, 2524, 2527, "and" +428, 18, 28, 507, 188, 194, 2528, 2534, "ocular" +428, 18, 29, 508, 195, 207, 2535, 2547, "hypertension" +428, 18, 30, 509, 208, 209, 2548, 2549, "." +428, 19, 1, 510, 0, 4, 2550, 2554, "Both" +428, 19, 2, 511, 5, 10, 2555, 2560, "fixed" +428, 19, 3, 512, 11, 22, 2561, 2572, "brimonidine" +428, 19, 4, 513, 23, 24, 2573, 2574, "-" +428, 19, 5, 514, 25, 32, 2575, 2582, "timolol" +428, 19, 6, 515, 33, 36, 2583, 2586, "and" +428, 19, 7, 516, 37, 44, 2587, 2594, "timolol" +428, 19, 8, 517, 45, 49, 2595, 2599, "were" +428, 19, 9, 518, 50, 54, 2600, 2604, "well" +428, 19, 10, 519, 55, 64, 2605, 2614, "tolerated" +428, 19, 11, 520, 65, 67, 2615, 2617, "as" +428, 19, 12, 521, 68, 74, 2618, 2624, "agents" +428, 19, 13, 522, 75, 85, 2625, 2635, "adjunctive" +428, 19, 14, 523, 86, 88, 2636, 2638, "to" +428, 19, 15, 524, 89, 100, 2639, 2650, "latanoprost" +428, 19, 16, 525, 101, 102, 2651, 2652, "." +428, 20, 1, 526, 0, 3, 2653, 2656, "DOI" +428, 20, 2, 527, 4, 5, 2657, 2658, ":" +428, 20, 3, 528, 6, 8, 2659, 2661, "10" +428, 20, 4, 529, 9, 10, 2662, 2663, "." +428, 20, 5, 530, 11, 15, 2664, 2668, "2147" +428, 20, 6, 531, 16, 17, 2669, 2670, "/" +428, 20, 7, 532, 18, 22, 2671, 2675, "OPTH" +428, 20, 8, 533, 23, 24, 2676, 2677, "." +428, 20, 9, 534, 25, 31, 2678, 2684, "S19999" +428, 20, 10, 535, 32, 37, 2685, 2690, "PMCID" +428, 20, 11, 536, 38, 39, 2691, 2692, ":" +428, 20, 12, 537, 40, 50, 2693, 2703, "PMC3141858" +428, 20, 13, 538, 51, 55, 2704, 2708, "PMID" +428, 20, 14, 539, 56, 57, 2709, 2710, ":" +428, 20, 15, 540, 58, 66, 2711, 2719, "21792284" diff --git a/data/gl 21792284_jshahinitiran.annodb b/data/gl 21792284_jshahinitiran.annodb new file mode 100644 index 0000000..4602ce3 --- /dev/null +++ b/data/gl 21792284_jshahinitiran.annodb @@ -0,0 +1,117 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16011, Journal, 0, 15, "Clin Ophthalmol", "", +16012, PublicationYear, 18, 22, "2011", "", +16013, Title, 92, 245, "Twelve - week , randomized , multicenter study comparing a fixed combination of brimonidine - timolol with timolol as therapy adjunctive to latanoprost .", "", +16014, Duration, 92, 105, "Twelve - week", "", +16015, Randomized, 108, 118, "randomized", "", +16016, Multicenter, 121, 132, "multicenter", "", +16017, Brimonidine, 172, 183, "brimonidine", "", +16018, Timolol, 186, 193, "timolol", "", +16019, Timolol, 199, 206, "timolol", "", +16020, Latanoprost, 232, 243, "latanoprost", "", +16021, Author, 246, 257, "Fechtner RD", "", +16022, Author, 266, 280, "Harasymowycz P", "", +16023, Author, 283, 291, "Nixon DR", "", +16024, Author, 294, 301, "Vold SD", "", +16025, Author, 304, 311, "Zaman F", "", +16026, Author, 314, 325, "Williams JM", "", +16027, Author, 328, 340, "Hollander DA", "", +16028, USA, 454, 457, "USA", "", +16029, ObjectiveDescription, 495, 696, "To evaluate the additive intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % / timolol 0 . 5 % compared with timolol 0 . 5 % at peak and trough effect", "", +16031, IOP, 520, 540, "intraocular pressure", "", +16032, IOP, 543, 546, "IOP", "", +16033, Brimonidine, 603, 614, "brimonidine", "", +16035, DoseValue, 615, 620, "0 . 2", "", +16037, Percentage, 621, 622, "%", "", +16034, Timolol, 625, 632, "timolol", "", +16036, DoseValue, 633, 638, "0 . 5", "", +16038, Percentage, 639, 640, "%", "", +16039, Timolol, 655, 662, "timolol", "", +16040, DoseValue, 663, 668, "0 . 5", "", +16041, Percentage, 669, 670, "%", "", +16042, Peak_IOP, 674, 678, "peak", "", +16043, Trough_IOP, 683, 689, "trough", "", +16030, ObjectiveDescription, 697, 840, "when used as therapy adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering .", "", +16044, Latanoprost, 732, 743, "latanoprost", "", +16045, DoseValue, 744, 751, "0 . 005", "", +16046, Percentage, 752, 753, "%", "", +16047, Glaucoma, 771, 779, "glaucoma", "", +16048, OcularHypertension, 783, 802, "ocular hypertension", "", +16049, IOP, 826, 829, "IOP", "", +16050, CTDesign, 859, 870, "prospective", "", +16051, Randomized, 873, 883, "randomized", "", +16052, Multicenter, 886, 897, "multicenter", "", +16053, Blind, 900, 921, "investigator - masked", "", +16055, Parallel, 924, 932, "parallel", "", +16056, Latanoprost, 976, 987, "latanoprost", "", +16057, Latanoprost, 1059, 1070, "latanoprost", "", +16058, Precondition, 1087, 1120, "IOP ≥ 21 mmHg in at least one eye", "", +16059, IOP, 1087, 1090, "IOP", "", +16060, mmHg, 1096, 1100, "mmHg", "", +16061, Randomized, 1126, 1136, "randomized", "", +16062, Frequency, 1140, 1153, "twice - daily", "", +16063, Brimonidine, 1160, 1171, "brimonidine", "", +16064, Timolol, 1174, 1181, "timolol", "", +16065, NumberPatientsArm, 1188, 1191, "102", "", +16066, Timolol, 1197, 1204, "timolol", "", +16067, NumberPatientsArm, 1211, 1214, "102", "", +16068, IOP, 1265, 1268, "IOP", "", +16071, TimePoint, 1327, 1334, "week 12", "", +16069, PerProtocol, 1356, 1368, "per protocol", "", +16070, Peak_IOP, 1416, 1424, "peak IOP", "", +16071, TimePoint, 1445, 1452, "week 12", "", +16073, Mean, 1516, 1520, "mean", "", +16074, IOP, 1521, 1524, "IOP", "", +16075, Brimonidine, 1572, 1583, "brimonidine", "", +16076, Timolol, 1586, 1593, "timolol", "", +16077, BaseLineValue, 1594, 1600, "23 . 4", "", +16078, mmHg, 1601, 1605, "mmHg", "", +16079, Timolol, 1608, 1615, "timolol", "", +16080, BaseLineValue, 1616, 1622, "23 . 0", "", +16081, mmHg, 1623, 1627, "mmHg", "", +16082, Mean, 1636, 1640, "mean", "", +16083, Latanoprost, 1667, 1678, "latanoprost", "", +16084, IOP, 1698, 1701, "IOP", "", +16085, Reduction, 1706, 1711, "8 . 3", "", +16087, mmHg, 1712, 1716, "mmHg", "", +16089, RelativeReduction, 1719, 1725, "35 . 5", "", +16091, Brimonidine, 1741, 1752, "brimonidine", "", +16092, Timolol, 1755, 1762, "timolol", "", +16086, Reduction, 1767, 1772, "6 . 2", "", +16088, mmHg, 1773, 1777, "mmHg", "", +16090, RelativeReduction, 1780, 1786, "27 . 0", "", +16093, Timolol, 1796, 1803, "timolol", "", +16094, TimePoint, 1815, 1822, "week 12", "", +16095, PValueChangeValue, 1825, 1836, "P < 0 . 001", "", +16096, Brimonidine, 1869, 1880, "brimonidine", "", +16097, Timolol, 1883, 1890, "timolol", "", +16098, Latanoprost, 1905, 1916, "latanoprost", "", +16099, Timolol, 1986, 1993, "timolol", "", +16100, IOP, 2008, 2011, "IOP", "", +16102, EndPointDescription, 2008, 2021, "IOP < 18 mmHg", "", +16101, mmHg, 2017, 2021, "mmHg", "", +16107, PValueNumAffected, 2024, 2035, "P = 0 . 028", "", +16104, EndPointDescription, 2044, 2081, "≥ 20 % reduction in IOP from baseline", "", +16105, IOP, 2064, 2067, "IOP", "", +16106, PValueNumAffected, 2084, 2095, "P = 0 . 047", "", +16103, TimePoint, 2124, 2131, "week 12", "", +16108, PercentageAffected, 2161, 2167, "14 . 7", "", +16110, Brimonidine, 2179, 2190, "brimonidine", "", +16112, Timolol, 2193, 2200, "timolol", "", +16109, PercentageAffected, 2214, 2220, "12 . 7", "", +16113, Timolol, 2226, 2233, "timolol", "", +16114, Duration, 2316, 2324, "12 weeks", "", +16115, ConclusionComment, 2353, 2549, "Fixed - combination brimonidine - timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension .", "", +16117, Brimonidine, 2373, 2384, "brimonidine", "", +16118, Timolol, 2387, 2394, "timolol", "", +16120, IOP, 2403, 2406, "IOP", "", +16121, Timolol, 2443, 2450, "timolol", "", +16122, Latanoprost, 2486, 2497, "latanoprost", "", +16124, Glaucoma, 2515, 2523, "glaucoma", "", +16126, OcularHypertension, 2528, 2547, "ocular hypertension", "", +16116, ConclusionComment, 2550, 2652, "Both fixed brimonidine - timolol and timolol were well tolerated as agents adjunctive to latanoprost .", "", +16129, Brimonidine, 2561, 2572, "brimonidine", "", +16130, Timolol, 2575, 2582, "timolol", "", +16132, Timolol, 2587, 2594, "timolol", "", +16134, Latanoprost, 2639, 2650, "latanoprost", "", +16135, PMID, 2711, 2719, "21792284", "", diff --git a/data/gl 21792284_jshahinitiran.n-triples b/data/gl 21792284_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21792284_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21792284_tstrakeljahn.annodb b/data/gl 21792284_tstrakeljahn.annodb new file mode 100644 index 0000000..a682c5c --- /dev/null +++ b/data/gl 21792284_tstrakeljahn.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12586, Journal, 0, 15, "Clin Ophthalmol", "", +12587, PublicationYear, 18, 22, "2011", "", +12588, Duration, 92, 105, "Twelve - week", "", +12595, Title, 92, 243, "Twelve - week , randomized , multicenter study comparing a fixed combination of brimonidine - timolol with timolol as therapy adjunctive to latanoprost", "", +12589, Randomized, 108, 118, "randomized", "", +12590, Multicenter, 121, 132, "multicenter", "", +12591, Brimonidine, 172, 183, "brimonidine", "", +12592, Timolol, 186, 193, "timolol", "", +12593, Timolol, 199, 206, "timolol", "", +12594, Latanoprost, 232, 243, "latanoprost", "", +12596, Author, 246, 257, "Fechtner RD", "", +12597, Author, 266, 280, "Harasymowycz P", "", +12598, Author, 283, 291, "Nixon DR", "", +12599, Author, 294, 301, "Vold SD", "", +12600, Author, 304, 311, "Zaman F", "", +12601, Author, 314, 325, "Williams JM", "", +12602, Author, 328, 340, "Hollander DA", "", +12603, Country, 454, 457, "USA", "", +12625, ObjectiveDescription, 495, 582, "To evaluate the additive intraocular pressure ( IOP ) - lowering efficacy and safety of", "", +12604, IOP, 520, 540, "intraocular pressure", "", +12605, IOP, 543, 546, "IOP", "", +12624, ObjectiveDescription, 583, 838, "fixed - combination brimonidine 0 . 2 % / timolol 0 . 5 % compared with timolol 0 . 5 % at peak and trough effect when used as therapy adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering", "", +12606, Brimonidine, 603, 614, "brimonidine", "", +12616, DoseValue, 615, 620, "0 . 2", "", +12621, Percentage, 621, 622, "%", "", +12607, Timolol, 625, 632, "timolol", "", +12617, DoseValue, 633, 638, "0 . 5", "", +12622, Percentage, 639, 640, "%", "", +12608, Timolol, 655, 662, "timolol", "", +12618, DoseValue, 663, 668, "0 . 5", "", +12623, Percentage, 669, 670, "%", "", +12609, Peak_IOP, 674, 678, "peak", "", +12610, Peak_Trough_IOP, 683, 689, "trough", "", +12615, Precondition, 718, 838, "adjunctive to latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension who require additional IOP lowering", "", +12611, Latanoprost, 732, 743, "latanoprost", "", +12619, DoseValue, 744, 751, "0 . 005", "", +12620, Percentage, 752, 753, "%", "", +12612, Glaucoma, 771, 779, "glaucoma", "", +12613, OcularHypertension, 783, 802, "ocular hypertension", "", +12614, IOP, 826, 829, "IOP", "", +12626, Randomized, 873, 883, "randomized", "", +12627, Multicenter, 886, 897, "multicenter", "", +12628, Blind, 915, 921, "masked", "", +12629, Parallel, 924, 932, "parallel", "", +12631, Precondition, 949, 1041, "patients were treated with latanoprost monotherapy for at least four weeks prior to baseline", "", +12630, Latanoprost, 976, 987, "latanoprost", "", +12633, Latanoprost, 1059, 1070, "latanoprost", "", +12636, Precondition, 1073, 1120, "patients with IOP ≥ 21 mmHg in at least one eye", "", +12634, IOP, 1087, 1090, "IOP", "", +12635, mmHg, 1096, 1100, "mmHg", "", +12637, Randomized, 1126, 1136, "randomized", "", +12638, Frequency, 1140, 1153, "twice - daily", "", +12639, Brimonidine, 1160, 1171, "brimonidine", "", +12640, Timolol, 1174, 1181, "timolol", "", +12641, NumberPatientsArm, 1188, 1191, "102", "", +12642, Timolol, 1197, 1204, "timolol", "", +12643, NumberPatientsArm, 1211, 1214, "102", "", +12644, Latanoprost, 1238, 1249, "latanoprost", "", +12632, Duration, 1254, 1262, "12 weeks", "", +12645, IOP, 1265, 1268, "IOP", "", +12646, PerProtocol, 1339, 1379, "evaluated in the per protocol population", "", +12647, Peak_IOP, 1416, 1424, "peak IOP", "", +12648, Mean, 1516, 1520, "mean", "", +12649, IOP, 1521, 1524, "IOP", "", +12650, Brimonidine, 1572, 1583, "brimonidine", "", +12651, Timolol, 1586, 1593, "timolol", "", +12652, BaseLineValue, 1594, 1600, "23 . 4", "", +12654, mmHg, 1601, 1605, "mmHg", "", +12656, Timolol, 1608, 1615, "timolol", "", +12653, BaseLineValue, 1616, 1622, "23 . 0", "", +12655, mmHg, 1623, 1627, "mmHg", "", +12657, Mean, 1636, 1640, "mean", "", +12658, Latanoprost, 1667, 1678, "latanoprost", "", +12660, IOP, 1698, 1701, "IOP", "", +12659, Reduction, 1706, 1711, "8 . 3", "", +12662, mmHg, 1712, 1716, "mmHg", "", +12667, RelativeReduction, 1719, 1725, "35 . 5", "", +12664, Brimonidine, 1741, 1752, "brimonidine", "", +12665, Timolol, 1755, 1762, "timolol", "", +12661, Reduction, 1767, 1772, "6 . 2", "", +12663, mmHg, 1773, 1777, "mmHg", "", +12668, RelativeReduction, 1780, 1786, "27 . 0", "", +12666, Timolol, 1796, 1803, "timolol", "", +12669, PvalueDiff, 1825, 1836, "P < 0 . 001", "", +12670, Brimonidine, 1869, 1880, "brimonidine", "", +12671, Timolol, 1883, 1890, "timolol", "", +12672, Latanoprost, 1905, 1916, "latanoprost", "", +12673, Timolol, 1986, 1993, "timolol", "", +12674, IOP, 2008, 2011, "IOP", "", +12675, mmHg, 2017, 2021, "mmHg", "", +12676, PvalueDiff, 2024, 2035, "P = 0 . 028", "", +12678, IOP, 2064, 2067, "IOP", "", +12677, PvalueDiff, 2084, 2095, "P = 0 . 047", "", +12679, TimePoint, 2124, 2131, "week 12", "", +12685, ObservedResult, 2134, 2242, "Adverse events occurred in 14 . 7 % of fixed brimonidine - timolol patients and 12 . 7 % of timolol patients", "", +12680, PercentageAffected, 2161, 2167, "14 . 7", "", +12682, Brimonidine, 2179, 2190, "brimonidine", "", +12683, Timolol, 2193, 2200, "timolol", "", +12681, PercentageAffected, 2214, 2220, "12 . 7", "", +12684, Timolol, 2226, 2233, "timolol", "", +12697, ConclusionComment, 2353, 2547, "Fixed - combination brimonidine - timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension", "", +12686, Brimonidine, 2373, 2384, "brimonidine", "", +12687, Timolol, 2387, 2394, "timolol", "", +12689, IOP, 2403, 2406, "IOP", "", +12688, Timolol, 2443, 2450, "timolol", "", +12690, Latanoprost, 2486, 2497, "latanoprost", "", +12691, Glaucoma, 2515, 2523, "glaucoma", "", +12692, OcularHypertension, 2528, 2547, "ocular hypertension", "", +12698, ConclusionComment, 2550, 2650, "Both fixed brimonidine - timolol and timolol were well tolerated as agents adjunctive to latanoprost", "", +12693, Brimonidine, 2561, 2572, "brimonidine", "", +12694, Timolol, 2575, 2582, "timolol", "", +12695, Timolol, 2587, 2594, "timolol", "", +12696, Latanoprost, 2639, 2650, "latanoprost", "", +12699, PMID, 2711, 2719, "21792284", "", diff --git a/data/gl 21792284_tstrakeljahn.n-triples b/data/gl 21792284_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21792284_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21851642_admin.annodb b/data/gl 21851642_admin.annodb new file mode 100644 index 0000000..97b19f3 --- /dev/null +++ b/data/gl 21851642_admin.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "BMC Ophthalmol .", "", " \"BMC Ophthalmol .\"." +1, PublicationYear, 17, 21, "2011", "", " \"2011\"." +2, Title, 83, 253, "Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open - angle glaucoma or ocular hypertension .", "", " \"Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open - angle glaucoma or ocular hypertension .\"." +3, Latanoprost, 158, 169, "latanoprost", "", +98, Lat/TimFC, 158, 181, "latanoprost and timolol", "", +4, Timolol, 174, 181, "timolol", "", +5, Ethnicity, 185, 192, "Chinese", "", " . ." +6, OpenAngleGlaucoma, 207, 228, "open - angle glaucoma", "", " ." +7, OcularHypertension, 232, 251, "ocular hypertension", "", " ." +8, Author, 254, 261, "Zhao JL", "", " \"Zhao JL\"." +9, Author, 270, 274, "Ge J", "", " \"Ge J\"." +10, Author, 277, 282, "Li XX", "", " \"Li XX\"." +11, Author, 285, 290, "Li YM", "", " \"Li YM\"." +12, Author, 293, 301, "Sheng YH", "", " \"Sheng YH\"." +13, Author, 304, 310, "Sun NX", "", " \"Sun NX\"." +14, Author, 313, 319, "Sun XH", "", " \"Sun XH\"." +15, Author, 322, 327, "Yao K", "", " \"Yao K\"." +16, Author, 330, 337, "Zhong Z", "", " \"Zhong Z\"." +113, Lat/TimFC, 340, 347, "Xalacom", "", " ." +17, China, 363, 368, "China", "", " ." +18, China, 785, 790, "China", "", +19, ObjectiveDescription, 840, 1041, "A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed - combination latanoprost 50 μ g / mL and timolol 0 . 5 mg / mL ( Xalacom ®; LTFC ) , in Chinese patients", "", +21, Lat/TimFC, 930, 999, "fixed - combination latanoprost 50 μ g / mL and timolol 0 . 5 mg / mL", "", +22, Latanoprost, 950, 961, "latanoprost", "", +23, DoseValue, 962, 964, "50", "", +119, ConcentrationUnit, 965, 973, "μ g / mL", "", +24, Timolol, 978, 985, "timolol", "", +25, DoseValue, 986, 991, "0 . 5", "", +118, ConcentrationUnit, 992, 999, "mg / mL", "", +117, Lat/TimFC, 1002, 1009, "Xalacom", "", +26, Lat/TimFC, 1013, 1017, "LTFC", "", +27, Ethnicity, 1025, 1032, "Chinese", "", +20, ObjectiveDescription, 1042, 1213, "with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy .", "", " \"with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy .\"." +89463, Precondition, 1047, 1211, "primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy", "", " \"primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy\"." +28, Primary_OpenAngleGlaucoma, 1047, 1076, "primary open - angle glaucoma", "", " ." +29, Primary_OpenAngleGlaucoma, 1079, 1083, "POAG", "", +30, OcularHypertension, 1089, 1108, "ocular hypertension", "", +31, OcularHypertension, 1111, 1113, "OH", "", +33, Duration, 1229, 1237, "8 - week", "", " \"8 - week\". \"8 - week\"." +34, Randomized, 1240, 1250, "randomized", "", " ." +35, OpenLabel, 1253, 1265, "open - label", "", " ." +36, Parallel, 1268, 1284, "parallel - group", "", " ." +37, Frequency, 1317, 1329, "once - daily", "", " \"once - daily\"." +38, Evening, 1330, 1337, "evening", "", " ." +39, Lat/TimFC, 1348, 1352, "LTFC", "", +40, Latanoprost, 1385, 1396, "latanoprost", "", " . ." +89468, DoseDescription, 1399, 1407, "one drop", "", " \"one drop\"." +139, Eyedrops, 1403, 1407, "drop", "", " ." +41, Evening, 1415, 1422, "evening", "", " ." +42, Timolol, 1429, 1436, "timolol", "", " ." +89471, DoseDescription, 1439, 1447, "one drop", "", " \"one drop\"." +140, Eyedrops, 1443, 1447, "drop", "", " ." +43, Morning, 1455, 1462, "morning", "", " ." +44, Mean, 1513, 1517, "mean", "", " . ." +45, TimePoint, 1530, 1538, "baseline", "", +46, TimePoint, 1542, 1548, "week 8", "", +47, Diurnal_IOP, 1552, 1580, "diurnal intraocular pressure", "", " ." +48, IOP, 1583, 1586, "IOP", "", +145, Mean, 1589, 1593, "mean", "", +146, TimePoint, 1597, 1601, "8 AM", "", +147, TimePoint, 1604, 1609, "10 AM", "", +148, TimePoint, 1612, 1616, "2 PM", "", +149, TimePoint, 1619, 1623, "4 PM", "", +150, IOP, 1624, 1628, "IOPs", "", +49, Lat/TimFC, 1633, 1637, "LTFC", "", +50, mmHg, 1762, 1766, "mmHg", "", " ." +52, Lat/TimFC, 1848, 1852, "LTFC", "", +58, NumberPatientsArm, 1859, 1862, "125", "", " \"125\"." +53, Primary_OpenAngleGlaucoma, 1865, 1869, "POAG", "", +162, PercentageAffected, 1872, 1874, "70", "", +54, Mean, 1879, 1883, "mean", "", +55, IOP, 1884, 1887, "IOP", "", +56, BaseLineValue, 1890, 1896, "25 . 8", "", " \"25 . 8\"." +57, mmHg, 1897, 1901, "mmHg", "", +59, NumberPatientsArm, 1920, 1923, "125", "", +60, Primary_OpenAngleGlaucoma, 1926, 1930, "POAG", "", +163, PercentageAffected, 1933, 1935, "69", "", +61, Mean, 1940, 1944, "mean", "", +62, IOP, 1945, 1948, "IOP", "", +63, BaseLineValue, 1951, 1957, "26 . 0", "", " \"26 . 0\"." +64, mmHg, 1958, 1962, "mmHg", "", +65, Mean, 1967, 1971, "Mean", "", +66, Diurnal_IOP, 1972, 1983, "diurnal IOP", "", +67, TimePoint, 1997, 2005, "baseline", "", +68, TimePoint, 2009, 2015, "week 8", "", " \"week 8\". \"week 8\"." +69, Reduction, 2023, 2028, "8 . 6", "", " \"8 . 6\"." +71, mmHg, 2029, 2033, "mmHg", "", +73, Lat/TimFC, 2039, 2043, "LTFC", "", +70, Reduction, 2050, 2055, "8 . 9", "", " \"8 . 9\"." +72, mmHg, 2056, 2060, "mmHg", "", +74, DiffGroupAbsValue, 2107, 2112, "0 . 3", "", " \"0 . 3\"." +75, mmHg, 2113, 2117, "mmHg", "", +183, ConfIntervalDiff, 2120, 2148, "95 % - CI , - 0 . 3 to 1 . 0", "", " \"95 % - CI , - 0 . 3 to 1 . 0\"." +77, ConclusionComment, 2205, 2370, "A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects", "", " \"A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects\"." +79, Evening, 2214, 2221, "evening", "", +80, Lat/TimFC, 2230, 2234, "LTFC", "", +81, Latanoprost, 2291, 2302, "latanoprost", "", +89488, Evening, 2303, 2312, "in the PM", "", +82, Timolol, 2317, 2324, "timolol", "", +89489, Morning, 2325, 2334, "in the AM", "", +83, IOP, 2347, 2350, "IOP", "", +84, Ethnicity, 2354, 2361, "Chinese", "", +85, Primary_OpenAngleGlaucoma, 2376, 2380, "POAG", "", +86, OcularHypertension, 2384, 2386, "OH", "", +77, ConclusionComment, 2387, 2488, "whose IOP was insufficiently reduced with β- blocker monotherapy or β- blocker - based dual therapy .", "", " \"whose IOP was insufficiently reduced with β- blocker monotherapy or β- blocker - based dual therapy .\"." +87, IOP, 2393, 2396, "IOP", "", +88, ConclusionComment, 2489, 2569, "LTFC is an effective and well tolerated once - daily treatment for POAG and OH .", "", " \"LTFC is an effective and well tolerated once - daily treatment for POAG and OH .\"." +89, Lat/TimFC, 2489, 2493, "LTFC", "", +90, Frequency, 2529, 2541, "once - daily", "", +91, Primary_OpenAngleGlaucoma, 2556, 2560, "POAG", "", +92, OcularHypertension, 2565, 2567, "OH", "", +93, PMID, 2636, 2644, "21851642", "", " \"21851642\"." diff --git a/data/gl 21851642_admin.n-triples b/data/gl 21851642_admin.n-triples new file mode 100644 index 0000000..602c97b --- /dev/null +++ b/data/gl 21851642_admin.n-triples @@ -0,0 +1,122 @@ +# RDF export of group: Publication + . + "Publication 65312" . + "Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open - angle glaucoma or ocular hypertension ." . + "Zhao JL" . + "2011" . + "BMC Ophthalmol ." . + "21851642" . + . + "Ge J" . + "Li XX" . + "Li YM" . + "Sheng YH" . + "Sun NX" . + "Sun XH" . + "Yao K" . + "Zhong Z" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 65327" . + "8 - week" . + . + . + . + "A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects" . + "whose IOP was insufficiently reduced with β- blocker monotherapy or β- blocker - based dual therapy ." . + . + . + . + . + . + "with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy ." . + . + . + "LTFC is an effective and well tolerated once - daily treatment for POAG and OH ." . + . + . + . +# RDF export of group: Population + . + "Population 65353" . + "primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 65361 Diurnal IOP" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 65371 LTFC" . + "125" . + . + . + . + . + "Arm 65380 LTuFC" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 65389 LTFC" . + . + "once - daily" . + "8 - week" . + . + . + "Intervention 65395 Lat" . + . + . + . + "Intervention 98600 Timolol" . + . + . +# RDF export of group: Medication + . + "Medication 65403 LTFC" . + . + . + . + . + "Medication 65439 Latanoprost" . + . + . + . + . + "one drop" . + . + "Medication 65446 Timolol" . + . + . + . + "one drop" . +# RDF export of group: Outcome + . + "Outcome 65411 LTFC" . + . + "25 . 8" . + "8 . 6" . + "week 8" . + . + "Outcome 65454 LTuFC" . + . + "26 . 0" . + "8 . 9" . + "week 8" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 65481" . + "0 . 3" . + "95 % - CI , - 0 . 3 to 1 . 0" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21851642_export.csv b/data/gl 21851642_export.csv new file mode 100644 index 0000000..0988b94 --- /dev/null +++ b/data/gl 21851642_export.csv @@ -0,0 +1,606 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +511, 1, 1, 1, 0, 3, 0, 3, "BMC" +511, 1, 2, 2, 4, 14, 4, 14, "Ophthalmol" +511, 1, 3, 3, 15, 16, 15, 16, "." +511, 2, 1, 4, 0, 4, 17, 21, "2011" +511, 2, 2, 5, 5, 8, 22, 25, "Aug" +511, 2, 3, 6, 9, 11, 26, 28, "19" +511, 2, 4, 7, 12, 13, 29, 30, ";" +511, 2, 5, 8, 14, 16, 31, 33, "11" +511, 2, 6, 9, 17, 18, 34, 35, ":" +511, 2, 7, 10, 19, 21, 36, 38, "23" +511, 2, 8, 11, 22, 23, 39, 40, "." +511, 2, 9, 12, 24, 27, 41, 44, "doi" +511, 2, 10, 13, 28, 29, 45, 46, ":" +511, 2, 11, 14, 30, 32, 47, 49, "10" +511, 2, 12, 15, 33, 34, 50, 51, "." +511, 2, 13, 16, 35, 39, 52, 56, "1186" +511, 2, 14, 17, 40, 41, 57, 58, "/" +511, 2, 15, 18, 42, 46, 59, 63, "1471" +511, 2, 16, 19, 47, 48, 64, 65, "-" +511, 2, 17, 20, 49, 53, 66, 70, "2415" +511, 2, 18, 21, 54, 55, 71, 72, "-" +511, 2, 19, 22, 56, 58, 73, 75, "11" +511, 2, 20, 23, 59, 60, 76, 77, "-" +511, 2, 21, 24, 61, 63, 78, 80, "23" +511, 2, 22, 25, 64, 65, 81, 82, "." +511, 3, 1, 26, 0, 11, 83, 94, "Comparative" +511, 3, 2, 27, 12, 20, 95, 103, "efficacy" +511, 3, 3, 28, 21, 24, 104, 107, "and" +511, 3, 4, 29, 25, 31, 108, 114, "safety" +511, 3, 5, 30, 32, 34, 115, 117, "of" +511, 3, 6, 31, 35, 38, 118, 121, "the" +511, 3, 7, 32, 39, 44, 122, 127, "fixed" +511, 3, 8, 33, 45, 51, 128, 134, "versus" +511, 3, 9, 34, 52, 59, 135, 142, "unfixed" +511, 3, 10, 35, 60, 71, 143, 154, "combination" +511, 3, 11, 36, 72, 74, 155, 157, "of" +511, 3, 12, 37, 75, 86, 158, 169, "latanoprost" +511, 3, 13, 38, 87, 90, 170, 173, "and" +511, 3, 14, 39, 91, 98, 174, 181, "timolol" +511, 3, 15, 40, 99, 101, 182, 184, "in" +511, 3, 16, 41, 102, 109, 185, 192, "Chinese" +511, 3, 17, 42, 110, 118, 193, 201, "patients" +511, 3, 18, 43, 119, 123, 202, 206, "with" +511, 3, 19, 44, 124, 128, 207, 211, "open" +511, 3, 20, 45, 129, 130, 212, 213, "-" +511, 3, 21, 46, 131, 136, 214, 219, "angle" +511, 3, 22, 47, 137, 145, 220, 228, "glaucoma" +511, 3, 23, 48, 146, 148, 229, 231, "or" +511, 3, 24, 49, 149, 155, 232, 238, "ocular" +511, 3, 25, 50, 156, 168, 239, 251, "hypertension" +511, 3, 26, 51, 169, 170, 252, 253, "." +511, 4, 1, 52, 0, 4, 254, 258, "Zhao" +511, 4, 2, 53, 5, 7, 259, 261, "JL" +511, 4, 3, 54, 8, 9, 262, 263, "(" +511, 4, 4, 55, 10, 11, 264, 265, "1" +511, 4, 5, 56, 12, 13, 266, 267, ")" +511, 4, 6, 57, 14, 15, 268, 269, "," +511, 4, 7, 58, 16, 18, 270, 272, "Ge" +511, 4, 8, 59, 19, 20, 273, 274, "J" +511, 4, 9, 60, 21, 22, 275, 276, "," +511, 4, 10, 61, 23, 25, 277, 279, "Li" +511, 4, 11, 62, 26, 28, 280, 282, "XX" +511, 4, 12, 63, 29, 30, 283, 284, "," +511, 4, 13, 64, 31, 33, 285, 287, "Li" +511, 4, 14, 65, 34, 36, 288, 290, "YM" +511, 4, 15, 66, 37, 38, 291, 292, "," +511, 4, 16, 67, 39, 44, 293, 298, "Sheng" +511, 4, 17, 68, 45, 47, 299, 301, "YH" +511, 4, 18, 69, 48, 49, 302, 303, "," +511, 4, 19, 70, 50, 53, 304, 307, "Sun" +511, 4, 20, 71, 54, 56, 308, 310, "NX" +511, 4, 21, 72, 57, 58, 311, 312, "," +511, 4, 22, 73, 59, 62, 313, 316, "Sun" +511, 4, 23, 74, 63, 65, 317, 319, "XH" +511, 4, 24, 75, 66, 67, 320, 321, "," +511, 4, 25, 76, 68, 71, 322, 325, "Yao" +511, 4, 26, 77, 72, 73, 326, 327, "K" +511, 4, 27, 78, 74, 75, 328, 329, "," +511, 4, 28, 79, 76, 81, 330, 335, "Zhong" +511, 4, 29, 80, 82, 83, 336, 337, "Z" +511, 4, 30, 81, 84, 85, 338, 339, ";" +511, 4, 31, 82, 86, 93, 340, 347, "Xalacom" +511, 4, 32, 83, 94, 99, 348, 353, "Study" +511, 4, 33, 84, 100, 105, 354, 359, "Group" +511, 4, 34, 85, 106, 108, 360, 362, "in" +511, 4, 35, 86, 109, 114, 363, 368, "China" +511, 4, 36, 87, 115, 116, 369, 370, "." +511, 5, 1, 88, 0, 13, 371, 384, "Collaborators" +511, 5, 2, 89, 14, 15, 385, 386, ":" +511, 5, 3, 90, 16, 18, 387, 389, "Li" +511, 5, 4, 91, 19, 21, 390, 392, "XX" +511, 5, 5, 92, 22, 23, 393, 394, "," +511, 5, 6, 93, 24, 26, 395, 397, "Li" +511, 5, 7, 94, 27, 29, 398, 400, "LX" +511, 5, 8, 95, 30, 31, 401, 402, "," +511, 5, 9, 96, 32, 35, 403, 406, "Ren" +511, 5, 10, 97, 36, 38, 407, 409, "ZQ" +511, 5, 11, 98, 39, 40, 410, 411, "," +511, 5, 12, 99, 41, 44, 412, 415, "Hou" +511, 5, 13, 100, 45, 47, 416, 418, "XR" +511, 5, 14, 101, 48, 49, 419, 420, "," +511, 5, 15, 102, 50, 54, 421, 425, "Zhao" +511, 5, 16, 103, 55, 57, 426, 428, "JL" +511, 5, 17, 104, 58, 59, 429, 430, "," +511, 5, 18, 105, 60, 63, 431, 434, "Liu" +511, 5, 19, 106, 64, 66, 435, 437, "XL" +511, 5, 20, 107, 67, 68, 438, 439, "," +511, 5, 21, 108, 69, 72, 440, 443, "Sun" +511, 5, 22, 109, 73, 75, 444, 446, "XH" +511, 5, 23, 110, 76, 77, 447, 448, "," +511, 5, 24, 111, 78, 82, 449, 453, "Qian" +511, 5, 25, 112, 83, 85, 454, 456, "SH" +511, 5, 26, 113, 86, 87, 457, 458, "," +511, 5, 27, 114, 88, 92, 459, 463, "Kong" +511, 5, 28, 115, 93, 95, 464, 466, "XM" +511, 5, 29, 116, 96, 97, 467, 468, "," +511, 5, 30, 117, 98, 101, 469, 472, "Yao" +511, 5, 31, 118, 102, 103, 473, 474, "J" +511, 5, 32, 119, 104, 105, 475, 476, "," +511, 5, 33, 120, 106, 111, 477, 482, "Zhong" +511, 5, 34, 121, 112, 113, 483, 484, "Z" +511, 5, 35, 122, 114, 115, 485, 486, "," +511, 5, 36, 123, 116, 121, 487, 492, "Sheng" +511, 5, 37, 124, 122, 124, 493, 495, "YH" +511, 5, 38, 125, 125, 126, 496, 497, "," +511, 5, 39, 126, 127, 129, 498, 500, "Xu" +511, 5, 40, 127, 130, 132, 501, 503, "WH" +511, 5, 41, 128, 133, 134, 504, 505, "," +511, 5, 42, 129, 135, 140, 506, 511, "Zhang" +511, 5, 43, 130, 141, 143, 512, 514, "YQ" +511, 5, 44, 131, 144, 145, 515, 516, "," +511, 5, 45, 132, 146, 149, 517, 520, "Cen" +511, 5, 46, 133, 150, 151, 521, 522, "J" +511, 5, 47, 134, 152, 153, 523, 524, "," +511, 5, 48, 135, 154, 157, 525, 528, "Sun" +511, 5, 49, 136, 158, 160, 529, 531, "NX" +511, 5, 50, 137, 161, 162, 532, 533, "," +511, 5, 51, 138, 163, 167, 534, 538, "Wang" +511, 5, 52, 139, 168, 170, 539, 541, "JM" +511, 5, 53, 140, 171, 172, 542, 543, "," +511, 5, 54, 141, 173, 177, 544, 548, "Wang" +511, 5, 55, 142, 178, 179, 549, 550, "J" +511, 5, 56, 143, 180, 181, 551, 552, "," +511, 5, 57, 144, 182, 186, 553, 557, "Wang" +511, 5, 58, 145, 187, 188, 558, 559, "F" +511, 5, 59, 146, 189, 190, 560, 561, "," +511, 5, 60, 147, 191, 193, 562, 564, "Li" +511, 5, 61, 148, 194, 196, 565, 567, "YM" +511, 5, 62, 149, 197, 198, 568, 569, "," +511, 5, 63, 150, 199, 203, 570, 574, "Wang" +511, 5, 64, 151, 204, 206, 575, 577, "XY" +511, 5, 65, 152, 207, 208, 578, 579, "," +511, 5, 66, 153, 209, 212, 580, 583, "Yan" +511, 5, 67, 154, 213, 215, 584, 586, "JX" +511, 5, 68, 155, 216, 217, 587, 588, "," +511, 5, 69, 156, 218, 222, 589, 593, "Shen" +511, 5, 70, 157, 223, 225, 594, 596, "LP" +511, 5, 71, 158, 226, 227, 597, 598, "," +511, 5, 72, 159, 228, 231, 599, 602, "Yao" +511, 5, 73, 160, 232, 233, 603, 604, "K" +511, 5, 74, 161, 234, 235, 605, 606, "," +511, 5, 75, 162, 236, 238, 607, 609, "Wu" +511, 5, 76, 163, 239, 241, 610, 612, "RY" +511, 5, 77, 164, 242, 243, 613, 614, "," +511, 5, 78, 165, 244, 247, 615, 618, "Yin" +511, 5, 79, 166, 248, 250, 619, 621, "JF" +511, 5, 80, 167, 251, 252, 622, 623, "," +511, 5, 81, 168, 253, 257, 624, 628, "Xuan" +511, 5, 82, 169, 258, 260, 629, 631, "MZ" +511, 5, 83, 170, 261, 262, 632, 633, "," +511, 5, 84, 171, 263, 265, 634, 636, "Ge" +511, 5, 85, 172, 266, 267, 637, 638, "J" +511, 5, 86, 173, 268, 269, 639, 640, "," +511, 5, 87, 174, 270, 274, 641, 645, "Wang" +511, 5, 88, 175, 275, 276, 646, 647, "M" +511, 5, 89, 176, 277, 278, 648, 649, "," +511, 5, 90, 177, 279, 282, 650, 653, "Lin" +511, 5, 91, 178, 283, 285, 654, 656, "MK" +511, 5, 92, 179, 286, 287, 657, 658, "," +511, 5, 93, 180, 288, 293, 659, 664, "Huang" +511, 5, 94, 181, 294, 296, 665, 667, "SS" +511, 5, 95, 182, 297, 298, 668, 669, "." +511, 6, 1, 183, 0, 6, 670, 676, "Author" +511, 6, 2, 184, 7, 18, 677, 688, "information" +511, 6, 3, 185, 19, 20, 689, 690, ":" +511, 6, 4, 186, 21, 22, 691, 692, "(" +511, 6, 5, 187, 23, 24, 693, 694, "1" +511, 6, 6, 188, 25, 26, 695, 696, ")" +511, 6, 7, 189, 27, 34, 697, 704, "Chinese" +511, 6, 8, 190, 35, 42, 705, 712, "Academy" +511, 6, 9, 191, 43, 45, 713, 715, "of" +511, 6, 10, 192, 46, 53, 716, 723, "Medical" +511, 6, 11, 193, 54, 62, 724, 732, "Sciences" +511, 6, 12, 194, 63, 64, 733, 734, "," +511, 6, 13, 195, 65, 71, 735, 741, "Peking" +511, 6, 14, 196, 72, 77, 742, 747, "Union" +511, 6, 15, 197, 78, 85, 748, 755, "Medical" +511, 6, 16, 198, 86, 93, 756, 763, "College" +511, 6, 17, 199, 94, 102, 764, 772, "Hospital" +511, 6, 18, 200, 103, 104, 773, 774, "," +511, 6, 19, 201, 105, 112, 775, 782, "Beijing" +511, 6, 20, 202, 113, 114, 783, 784, "," +511, 6, 21, 203, 115, 120, 785, 790, "China" +511, 6, 22, 204, 121, 122, 791, 792, "." +511, 7, 1, 205, 0, 12, 793, 805, "zhaojialiang" +511, 7, 2, 206, 13, 14, 806, 807, "@" +511, 7, 3, 207, 15, 22, 808, 815, "medmail" +511, 7, 4, 208, 23, 24, 816, 817, "." +511, 7, 5, 209, 25, 28, 818, 821, "com" +511, 7, 6, 210, 29, 30, 822, 823, "." +511, 7, 7, 211, 31, 33, 824, 826, "cn" +511, 7, 8, 212, 34, 44, 827, 837, "BACKGROUND" +511, 7, 9, 213, 45, 46, 838, 839, ":" +511, 7, 10, 214, 47, 48, 840, 841, "A" +511, 7, 11, 215, 49, 63, 842, 856, "noninferiority" +511, 7, 12, 216, 64, 69, 857, 862, "trial" +511, 7, 13, 217, 70, 73, 863, 866, "was" +511, 7, 14, 218, 74, 83, 867, 876, "conducted" +511, 7, 15, 219, 84, 86, 877, 879, "to" +511, 7, 16, 220, 87, 95, 880, 888, "evaluate" +511, 7, 17, 221, 96, 99, 889, 892, "the" +511, 7, 18, 222, 100, 108, 893, 901, "efficacy" +511, 7, 19, 223, 109, 111, 902, 904, "of" +511, 7, 20, 224, 112, 113, 905, 906, "a" +511, 7, 21, 225, 114, 120, 907, 913, "single" +511, 7, 22, 226, 121, 128, 914, 921, "evening" +511, 7, 23, 227, 129, 133, 922, 926, "dose" +511, 7, 24, 228, 134, 136, 927, 929, "of" +511, 7, 25, 229, 137, 142, 930, 935, "fixed" +511, 7, 26, 230, 143, 144, 936, 937, "-" +511, 7, 27, 231, 145, 156, 938, 949, "combination" +511, 7, 28, 232, 157, 168, 950, 961, "latanoprost" +511, 7, 29, 233, 169, 171, 962, 964, "50" +511, 7, 30, 234, 172, 173, 965, 966, "μ" +511, 7, 31, 235, 174, 175, 967, 968, "g" +511, 7, 32, 236, 176, 177, 969, 970, "/" +511, 7, 33, 237, 178, 180, 971, 973, "mL" +511, 7, 34, 238, 181, 184, 974, 977, "and" +511, 7, 35, 239, 185, 192, 978, 985, "timolol" +511, 7, 36, 240, 193, 194, 986, 987, "0" +511, 7, 37, 241, 195, 196, 988, 989, "." +511, 7, 38, 242, 197, 198, 990, 991, "5" +511, 7, 39, 243, 199, 201, 992, 994, "mg" +511, 7, 40, 244, 202, 203, 995, 996, "/" +511, 7, 41, 245, 204, 206, 997, 999, "mL" +511, 7, 42, 246, 207, 208, 1000, 1001, "(" +511, 7, 43, 247, 209, 216, 1002, 1009, "Xalacom" +511, 7, 44, 248, 217, 219, 1010, 1012, "®;" +511, 7, 45, 249, 220, 224, 1013, 1017, "LTFC" +511, 7, 46, 250, 225, 226, 1018, 1019, ")" +511, 7, 47, 251, 227, 228, 1020, 1021, "," +511, 7, 48, 252, 229, 231, 1022, 1024, "in" +511, 7, 49, 253, 232, 239, 1025, 1032, "Chinese" +511, 7, 50, 254, 240, 248, 1033, 1041, "patients" +511, 7, 51, 255, 249, 253, 1042, 1046, "with" +511, 7, 52, 256, 254, 261, 1047, 1054, "primary" +511, 7, 53, 257, 262, 266, 1055, 1059, "open" +511, 7, 54, 258, 267, 268, 1060, 1061, "-" +511, 7, 55, 259, 269, 274, 1062, 1067, "angle" +511, 7, 56, 260, 275, 283, 1068, 1076, "glaucoma" +511, 7, 57, 261, 284, 285, 1077, 1078, "(" +511, 7, 58, 262, 286, 290, 1079, 1083, "POAG" +511, 7, 59, 263, 291, 292, 1084, 1085, ")" +511, 7, 60, 264, 293, 295, 1086, 1088, "or" +511, 7, 61, 265, 296, 302, 1089, 1095, "ocular" +511, 7, 62, 266, 303, 315, 1096, 1108, "hypertension" +511, 7, 63, 267, 316, 317, 1109, 1110, "(" +511, 7, 64, 268, 318, 320, 1111, 1113, "OH" +511, 7, 65, 269, 321, 322, 1114, 1115, ")" +511, 7, 66, 270, 323, 326, 1116, 1119, "who" +511, 7, 67, 271, 327, 331, 1120, 1124, "were" +511, 7, 68, 272, 332, 346, 1125, 1139, "insufficiently" +511, 7, 69, 273, 347, 357, 1140, 1150, "controlled" +511, 7, 70, 274, 358, 360, 1151, 1153, "on" +511, 7, 71, 275, 361, 363, 1154, 1156, "β-" +511, 7, 72, 276, 364, 371, 1157, 1164, "blocker" +511, 7, 73, 277, 372, 383, 1165, 1176, "monotherapy" +511, 7, 74, 278, 384, 386, 1177, 1179, "or" +511, 7, 75, 279, 387, 389, 1180, 1182, "β-" +511, 7, 76, 280, 390, 397, 1183, 1190, "blocker" +511, 7, 77, 281, 398, 399, 1191, 1192, "-" +511, 7, 78, 282, 400, 405, 1193, 1198, "based" +511, 7, 79, 283, 406, 410, 1199, 1203, "dual" +511, 7, 80, 284, 411, 418, 1204, 1211, "therapy" +511, 7, 81, 285, 419, 420, 1212, 1213, "." +511, 8, 1, 286, 0, 7, 1214, 1221, "METHODS" +511, 8, 2, 287, 8, 9, 1222, 1223, ":" +511, 8, 3, 288, 10, 14, 1224, 1228, "This" +511, 8, 4, 289, 15, 16, 1229, 1230, "8" +511, 8, 5, 290, 17, 18, 1231, 1232, "-" +511, 8, 6, 291, 19, 23, 1233, 1237, "week" +511, 8, 7, 292, 24, 25, 1238, 1239, "," +511, 8, 8, 293, 26, 36, 1240, 1250, "randomized" +511, 8, 9, 294, 37, 38, 1251, 1252, "," +511, 8, 10, 295, 39, 43, 1253, 1257, "open" +511, 8, 11, 296, 44, 45, 1258, 1259, "-" +511, 8, 12, 297, 46, 51, 1260, 1265, "label" +511, 8, 13, 298, 52, 53, 1266, 1267, "," +511, 8, 14, 299, 54, 62, 1268, 1276, "parallel" +511, 8, 15, 300, 63, 64, 1277, 1278, "-" +511, 8, 16, 301, 65, 70, 1279, 1284, "group" +511, 8, 17, 302, 71, 72, 1285, 1286, "," +511, 8, 18, 303, 73, 87, 1287, 1301, "noninferiority" +511, 8, 19, 304, 88, 93, 1302, 1307, "study" +511, 8, 20, 305, 94, 102, 1308, 1316, "compared" +511, 8, 21, 306, 103, 107, 1317, 1321, "once" +511, 8, 22, 307, 108, 109, 1322, 1323, "-" +511, 8, 23, 308, 110, 115, 1324, 1329, "daily" +511, 8, 24, 309, 116, 123, 1330, 1337, "evening" +511, 8, 25, 310, 124, 130, 1338, 1344, "dosing" +511, 8, 26, 311, 131, 133, 1345, 1347, "of" +511, 8, 27, 312, 134, 138, 1348, 1352, "LTFC" +511, 8, 28, 313, 139, 143, 1353, 1357, "with" +511, 8, 29, 314, 144, 147, 1358, 1361, "the" +511, 8, 30, 315, 148, 155, 1362, 1369, "unfixed" +511, 8, 31, 316, 156, 167, 1370, 1381, "combination" +511, 8, 32, 317, 168, 170, 1382, 1384, "of" +511, 8, 33, 318, 171, 182, 1385, 1396, "latanoprost" +511, 8, 34, 319, 183, 184, 1397, 1398, "," +511, 8, 35, 320, 185, 188, 1399, 1402, "one" +511, 8, 36, 321, 189, 193, 1403, 1407, "drop" +511, 8, 37, 322, 194, 196, 1408, 1410, "in" +511, 8, 38, 323, 197, 200, 1411, 1414, "the" +511, 8, 39, 324, 201, 208, 1415, 1422, "evening" +511, 8, 40, 325, 209, 210, 1423, 1424, "," +511, 8, 41, 326, 211, 214, 1425, 1428, "and" +511, 8, 42, 327, 215, 222, 1429, 1436, "timolol" +511, 8, 43, 328, 223, 224, 1437, 1438, "," +511, 8, 44, 329, 225, 228, 1439, 1442, "one" +511, 8, 45, 330, 229, 233, 1443, 1447, "drop" +511, 8, 46, 331, 234, 236, 1448, 1450, "in" +511, 8, 47, 332, 237, 240, 1451, 1454, "the" +511, 8, 48, 333, 241, 248, 1455, 1462, "morning" +511, 8, 49, 334, 249, 250, 1463, 1464, "(" +511, 8, 50, 335, 251, 256, 1465, 1470, "LTuFC" +511, 8, 51, 336, 257, 258, 1471, 1472, ")" +511, 8, 52, 337, 259, 260, 1473, 1474, "." +511, 9, 1, 338, 0, 3, 1475, 1478, "The" +511, 9, 2, 339, 4, 11, 1479, 1486, "primary" +511, 9, 3, 340, 12, 20, 1487, 1495, "efficacy" +511, 9, 4, 341, 21, 29, 1496, 1504, "endpoint" +511, 9, 5, 342, 30, 33, 1505, 1508, "was" +511, 9, 6, 343, 34, 37, 1509, 1512, "the" +511, 9, 7, 344, 38, 42, 1513, 1517, "mean" +511, 9, 8, 345, 43, 49, 1518, 1524, "change" +511, 9, 9, 346, 50, 54, 1525, 1529, "from" +511, 9, 10, 347, 55, 63, 1530, 1538, "baseline" +511, 9, 11, 348, 64, 66, 1539, 1541, "to" +511, 9, 12, 349, 67, 71, 1542, 1546, "week" +511, 9, 13, 350, 72, 73, 1547, 1548, "8" +511, 9, 14, 351, 74, 76, 1549, 1551, "in" +511, 9, 15, 352, 77, 84, 1552, 1559, "diurnal" +511, 9, 16, 353, 85, 96, 1560, 1571, "intraocular" +511, 9, 17, 354, 97, 105, 1572, 1580, "pressure" +511, 9, 18, 355, 106, 107, 1581, 1582, "(" +511, 9, 19, 356, 108, 111, 1583, 1586, "IOP" +511, 9, 20, 357, 112, 113, 1587, 1588, ";" +511, 9, 21, 358, 114, 118, 1589, 1593, "mean" +511, 9, 22, 359, 119, 121, 1594, 1596, "of" +511, 9, 23, 360, 122, 123, 1597, 1598, "8" +511, 9, 24, 361, 124, 126, 1599, 1601, "AM" +511, 9, 25, 362, 127, 128, 1602, 1603, "," +511, 9, 26, 363, 129, 131, 1604, 1606, "10" +511, 9, 27, 364, 132, 134, 1607, 1609, "AM" +511, 9, 28, 365, 135, 136, 1610, 1611, "," +511, 9, 29, 366, 137, 138, 1612, 1613, "2" +511, 9, 30, 367, 139, 141, 1614, 1616, "PM" +511, 9, 31, 368, 142, 143, 1617, 1618, "," +511, 9, 32, 369, 144, 145, 1619, 1620, "4" +511, 9, 33, 370, 146, 148, 1621, 1623, "PM" +511, 9, 34, 371, 149, 153, 1624, 1628, "IOPs" +511, 9, 35, 372, 154, 155, 1629, 1630, ")" +511, 9, 36, 373, 156, 157, 1631, 1632, "." +511, 10, 1, 374, 0, 4, 1633, 1637, "LTFC" +511, 10, 2, 375, 5, 8, 1638, 1641, "was" +511, 10, 3, 376, 9, 19, 1642, 1652, "considered" +511, 10, 4, 377, 20, 31, 1653, 1664, "noninferior" +511, 10, 5, 378, 32, 34, 1665, 1667, "to" +511, 10, 6, 379, 35, 40, 1668, 1673, "LTuFC" +511, 10, 7, 380, 41, 43, 1674, 1676, "if" +511, 10, 8, 381, 44, 47, 1677, 1680, "the" +511, 10, 9, 382, 48, 53, 1681, 1686, "upper" +511, 10, 10, 383, 54, 59, 1687, 1692, "limit" +511, 10, 11, 384, 60, 62, 1693, 1695, "of" +511, 10, 12, 385, 63, 66, 1696, 1699, "the" +511, 10, 13, 386, 67, 69, 1700, 1702, "95" +511, 10, 14, 387, 70, 71, 1703, 1704, "%" +511, 10, 15, 388, 72, 82, 1705, 1715, "confidence" +511, 10, 16, 389, 83, 91, 1716, 1724, "interval" +511, 10, 17, 390, 92, 93, 1725, 1726, "(" +511, 10, 18, 391, 94, 96, 1727, 1729, "CI" +511, 10, 19, 392, 97, 98, 1730, 1731, ")" +511, 10, 20, 393, 99, 101, 1732, 1734, "of" +511, 10, 21, 394, 102, 105, 1735, 1738, "the" +511, 10, 22, 395, 106, 116, 1739, 1749, "difference" +511, 10, 23, 396, 117, 120, 1750, 1753, "was" +511, 10, 24, 397, 121, 122, 1754, 1755, "<" +511, 10, 25, 398, 123, 124, 1756, 1757, "1" +511, 10, 26, 399, 125, 126, 1758, 1759, "." +511, 10, 27, 400, 127, 128, 1760, 1761, "5" +511, 10, 28, 401, 129, 133, 1762, 1766, "mmHg" +511, 10, 29, 402, 134, 135, 1767, 1768, "(" +511, 10, 30, 403, 136, 144, 1769, 1777, "analysis" +511, 10, 31, 404, 145, 147, 1778, 1780, "of" +511, 10, 32, 405, 148, 158, 1781, 1791, "covariance" +511, 10, 33, 406, 159, 160, 1792, 1793, ")" +511, 10, 34, 407, 161, 162, 1794, 1795, "." +511, 11, 1, 408, 0, 7, 1796, 1803, "RESULTS" +511, 11, 2, 409, 8, 9, 1804, 1805, ":" +511, 11, 3, 410, 10, 18, 1806, 1814, "Baseline" +511, 11, 4, 411, 19, 34, 1815, 1830, "characteristics" +511, 11, 5, 412, 35, 39, 1831, 1835, "were" +511, 11, 6, 413, 40, 47, 1836, 1843, "similar" +511, 11, 7, 414, 48, 51, 1844, 1847, "for" +511, 11, 8, 415, 52, 56, 1848, 1852, "LTFC" +511, 11, 9, 416, 57, 58, 1853, 1854, "(" +511, 11, 10, 417, 59, 60, 1855, 1856, "N" +511, 11, 11, 418, 61, 62, 1857, 1858, "=" +511, 11, 12, 419, 63, 66, 1859, 1862, "125" +511, 11, 13, 420, 67, 68, 1863, 1864, ";" +511, 11, 14, 421, 69, 73, 1865, 1869, "POAG" +511, 11, 15, 422, 74, 75, 1870, 1871, "," +511, 11, 16, 423, 76, 78, 1872, 1874, "70" +511, 11, 17, 424, 79, 80, 1875, 1876, "%" +511, 11, 18, 425, 81, 82, 1877, 1878, ";" +511, 11, 19, 426, 83, 87, 1879, 1883, "mean" +511, 11, 20, 427, 88, 91, 1884, 1887, "IOP" +511, 11, 21, 428, 92, 93, 1888, 1889, "," +511, 11, 22, 429, 94, 96, 1890, 1892, "25" +511, 11, 23, 430, 97, 98, 1893, 1894, "." +511, 11, 24, 431, 99, 100, 1895, 1896, "8" +511, 11, 25, 432, 101, 105, 1897, 1901, "mmHg" +511, 11, 26, 433, 106, 107, 1902, 1903, ")" +511, 11, 27, 434, 108, 111, 1904, 1907, "and" +511, 11, 28, 435, 112, 117, 1908, 1913, "LTuFC" +511, 11, 29, 436, 118, 119, 1914, 1915, "(" +511, 11, 30, 437, 120, 121, 1916, 1917, "N" +511, 11, 31, 438, 122, 123, 1918, 1919, "=" +511, 11, 32, 439, 124, 127, 1920, 1923, "125" +511, 11, 33, 440, 128, 129, 1924, 1925, ";" +511, 11, 34, 441, 130, 134, 1926, 1930, "POAG" +511, 11, 35, 442, 135, 136, 1931, 1932, "," +511, 11, 36, 443, 137, 139, 1933, 1935, "69" +511, 11, 37, 444, 140, 141, 1936, 1937, "%" +511, 11, 38, 445, 142, 143, 1938, 1939, ";" +511, 11, 39, 446, 144, 148, 1940, 1944, "mean" +511, 11, 40, 447, 149, 152, 1945, 1948, "IOP" +511, 11, 41, 448, 153, 154, 1949, 1950, "," +511, 11, 42, 449, 155, 157, 1951, 1953, "26" +511, 11, 43, 450, 158, 159, 1954, 1955, "." +511, 11, 44, 451, 160, 161, 1956, 1957, "0" +511, 11, 45, 452, 162, 166, 1958, 1962, "mmHg" +511, 11, 46, 453, 167, 168, 1963, 1964, ")" +511, 11, 47, 454, 169, 170, 1965, 1966, "." +511, 12, 1, 455, 0, 4, 1967, 1971, "Mean" +511, 12, 2, 456, 5, 12, 1972, 1979, "diurnal" +511, 12, 3, 457, 13, 16, 1980, 1983, "IOP" +511, 12, 4, 458, 17, 24, 1984, 1991, "changes" +511, 12, 5, 459, 25, 29, 1992, 1996, "from" +511, 12, 6, 460, 30, 38, 1997, 2005, "baseline" +511, 12, 7, 461, 39, 41, 2006, 2008, "to" +511, 12, 8, 462, 42, 46, 2009, 2013, "week" +511, 12, 9, 463, 47, 48, 2014, 2015, "8" +511, 12, 10, 464, 49, 53, 2016, 2020, "were" +511, 12, 11, 465, 54, 55, 2021, 2022, "-" +511, 12, 12, 466, 56, 57, 2023, 2024, "8" +511, 12, 13, 467, 58, 59, 2025, 2026, "." +511, 12, 14, 468, 60, 61, 2027, 2028, "6" +511, 12, 15, 469, 62, 66, 2029, 2033, "mmHg" +511, 12, 16, 470, 67, 71, 2034, 2038, "with" +511, 12, 17, 471, 72, 76, 2039, 2043, "LTFC" +511, 12, 18, 472, 77, 80, 2044, 2047, "and" +511, 12, 19, 473, 81, 82, 2048, 2049, "-" +511, 12, 20, 474, 83, 84, 2050, 2051, "8" +511, 12, 21, 475, 85, 86, 2052, 2053, "." +511, 12, 22, 476, 87, 88, 2054, 2055, "9" +511, 12, 23, 477, 89, 93, 2056, 2060, "mmHg" +511, 12, 24, 478, 94, 98, 2061, 2065, "with" +511, 12, 25, 479, 99, 104, 2066, 2071, "LTuFC" +511, 12, 26, 480, 105, 106, 2072, 2073, "(" +511, 12, 27, 481, 107, 114, 2074, 2081, "between" +511, 12, 28, 482, 115, 116, 2082, 2083, "-" +511, 12, 29, 483, 117, 126, 2084, 2093, "treatment" +511, 12, 30, 484, 127, 137, 2094, 2104, "difference" +511, 12, 31, 485, 138, 139, 2105, 2106, ":" +511, 12, 32, 486, 140, 141, 2107, 2108, "0" +511, 12, 33, 487, 142, 143, 2109, 2110, "." +511, 12, 34, 488, 144, 145, 2111, 2112, "3" +511, 12, 35, 489, 146, 150, 2113, 2117, "mmHg" +511, 12, 36, 490, 151, 152, 2118, 2119, ";" +511, 12, 37, 491, 153, 155, 2120, 2122, "95" +511, 12, 38, 492, 156, 157, 2123, 2124, "%" +511, 12, 39, 493, 158, 159, 2125, 2126, "-" +511, 12, 40, 494, 160, 162, 2127, 2129, "CI" +511, 12, 41, 495, 163, 164, 2130, 2131, "," +511, 12, 42, 496, 165, 166, 2132, 2133, "-" +511, 12, 43, 497, 167, 168, 2134, 2135, "0" +511, 12, 44, 498, 169, 170, 2136, 2137, "." +511, 12, 45, 499, 171, 172, 2138, 2139, "3" +511, 12, 46, 500, 173, 175, 2140, 2142, "to" +511, 12, 47, 501, 176, 177, 2143, 2144, "1" +511, 12, 48, 502, 178, 179, 2145, 2146, "." +511, 12, 49, 503, 180, 181, 2147, 2148, "0" +511, 12, 50, 504, 182, 183, 2149, 2150, ")" +511, 12, 51, 505, 184, 185, 2151, 2152, "." +511, 13, 1, 506, 0, 4, 2153, 2157, "Both" +511, 13, 2, 507, 5, 15, 2158, 2168, "treatments" +511, 13, 3, 508, 16, 20, 2169, 2173, "were" +511, 13, 4, 509, 21, 25, 2174, 2178, "well" +511, 13, 5, 510, 26, 35, 2179, 2188, "tolerated" +511, 13, 6, 511, 36, 37, 2189, 2190, "." +511, 14, 1, 512, 0, 11, 2191, 2202, "CONCLUSIONS" +511, 14, 2, 513, 12, 13, 2203, 2204, ":" +511, 14, 3, 514, 14, 15, 2205, 2206, "A" +511, 14, 4, 515, 16, 22, 2207, 2213, "single" +511, 14, 5, 516, 23, 30, 2214, 2221, "evening" +511, 14, 6, 517, 31, 35, 2222, 2226, "dose" +511, 14, 7, 518, 36, 38, 2227, 2229, "of" +511, 14, 8, 519, 39, 43, 2230, 2234, "LTFC" +511, 14, 9, 520, 44, 47, 2235, 2238, "was" +511, 14, 10, 521, 48, 50, 2239, 2241, "at" +511, 14, 11, 522, 51, 56, 2242, 2247, "least" +511, 14, 12, 523, 57, 59, 2248, 2250, "as" +511, 14, 13, 524, 60, 69, 2251, 2260, "effective" +511, 14, 14, 525, 70, 72, 2261, 2263, "as" +511, 14, 15, 526, 73, 76, 2264, 2267, "the" +511, 14, 16, 527, 77, 84, 2268, 2275, "unfixed" +511, 14, 17, 528, 85, 96, 2276, 2287, "combination" +511, 14, 18, 529, 97, 99, 2288, 2290, "of" +511, 14, 19, 530, 100, 111, 2291, 2302, "latanoprost" +511, 14, 20, 531, 112, 114, 2303, 2305, "in" +511, 14, 21, 532, 115, 118, 2306, 2309, "the" +511, 14, 22, 533, 119, 121, 2310, 2312, "PM" +511, 14, 23, 534, 122, 125, 2313, 2316, "and" +511, 14, 24, 535, 126, 133, 2317, 2324, "timolol" +511, 14, 25, 536, 134, 136, 2325, 2327, "in" +511, 14, 26, 537, 137, 140, 2328, 2331, "the" +511, 14, 27, 538, 141, 143, 2332, 2334, "AM" +511, 14, 28, 539, 144, 146, 2335, 2337, "in" +511, 14, 29, 540, 147, 155, 2338, 2346, "reducing" +511, 14, 30, 541, 156, 159, 2347, 2350, "IOP" +511, 14, 31, 542, 160, 162, 2351, 2353, "in" +511, 14, 32, 543, 163, 170, 2354, 2361, "Chinese" +511, 14, 33, 544, 171, 179, 2362, 2370, "subjects" +511, 14, 34, 545, 180, 184, 2371, 2375, "with" +511, 14, 35, 546, 185, 189, 2376, 2380, "POAG" +511, 14, 36, 547, 190, 192, 2381, 2383, "or" +511, 14, 37, 548, 193, 195, 2384, 2386, "OH" +511, 14, 38, 549, 196, 201, 2387, 2392, "whose" +511, 14, 39, 550, 202, 205, 2393, 2396, "IOP" +511, 14, 40, 551, 206, 209, 2397, 2400, "was" +511, 14, 41, 552, 210, 224, 2401, 2415, "insufficiently" +511, 14, 42, 553, 225, 232, 2416, 2423, "reduced" +511, 14, 43, 554, 233, 237, 2424, 2428, "with" +511, 14, 44, 555, 238, 240, 2429, 2431, "β-" +511, 14, 45, 556, 241, 248, 2432, 2439, "blocker" +511, 14, 46, 557, 249, 260, 2440, 2451, "monotherapy" +511, 14, 47, 558, 261, 263, 2452, 2454, "or" +511, 14, 48, 559, 264, 266, 2455, 2457, "β-" +511, 14, 49, 560, 267, 274, 2458, 2465, "blocker" +511, 14, 50, 561, 275, 276, 2466, 2467, "-" +511, 14, 51, 562, 277, 282, 2468, 2473, "based" +511, 14, 52, 563, 283, 287, 2474, 2478, "dual" +511, 14, 53, 564, 288, 295, 2479, 2486, "therapy" +511, 14, 54, 565, 296, 297, 2487, 2488, "." +511, 15, 1, 566, 0, 4, 2489, 2493, "LTFC" +511, 15, 2, 567, 5, 7, 2494, 2496, "is" +511, 15, 3, 568, 8, 10, 2497, 2499, "an" +511, 15, 4, 569, 11, 20, 2500, 2509, "effective" +511, 15, 5, 570, 21, 24, 2510, 2513, "and" +511, 15, 6, 571, 25, 29, 2514, 2518, "well" +511, 15, 7, 572, 30, 39, 2519, 2528, "tolerated" +511, 15, 8, 573, 40, 44, 2529, 2533, "once" +511, 15, 9, 574, 45, 46, 2534, 2535, "-" +511, 15, 10, 575, 47, 52, 2536, 2541, "daily" +511, 15, 11, 576, 53, 62, 2542, 2551, "treatment" +511, 15, 12, 577, 63, 66, 2552, 2555, "for" +511, 15, 13, 578, 67, 71, 2556, 2560, "POAG" +511, 15, 14, 579, 72, 75, 2561, 2564, "and" +511, 15, 15, 580, 76, 78, 2565, 2567, "OH" +511, 15, 16, 581, 79, 80, 2568, 2569, "." +511, 16, 1, 582, 0, 3, 2570, 2573, "DOI" +511, 16, 2, 583, 4, 5, 2574, 2575, ":" +511, 16, 3, 584, 6, 8, 2576, 2578, "10" +511, 16, 4, 585, 9, 10, 2579, 2580, "." +511, 16, 5, 586, 11, 15, 2581, 2585, "1186" +511, 16, 6, 587, 16, 17, 2586, 2587, "/" +511, 16, 7, 588, 18, 22, 2588, 2592, "1471" +511, 16, 8, 589, 23, 24, 2593, 2594, "-" +511, 16, 9, 590, 25, 29, 2595, 2599, "2415" +511, 16, 10, 591, 30, 31, 2600, 2601, "-" +511, 16, 11, 592, 32, 34, 2602, 2604, "11" +511, 16, 12, 593, 35, 36, 2605, 2606, "-" +511, 16, 13, 594, 37, 39, 2607, 2609, "23" +511, 16, 14, 595, 40, 45, 2610, 2615, "PMCID" +511, 16, 15, 596, 46, 47, 2616, 2617, ":" +511, 16, 16, 597, 48, 58, 2618, 2628, "PMC3175210" +511, 16, 17, 598, 59, 63, 2629, 2633, "PMID" +511, 16, 18, 599, 64, 65, 2634, 2635, ":" +511, 16, 19, 600, 66, 74, 2636, 2644, "21851642" +511, 16, 20, 601, 75, 76, 2645, 2646, "[" +511, 16, 21, 602, 77, 84, 2647, 2654, "Indexed" +511, 16, 22, 603, 85, 88, 2655, 2658, "for" +511, 16, 23, 604, 89, 96, 2659, 2666, "MEDLINE" +511, 16, 24, 605, 97, 98, 2667, 2668, "]" diff --git a/data/gl 21851642_jshahinitiran.annodb b/data/gl 21851642_jshahinitiran.annodb new file mode 100644 index 0000000..6df6ac0 --- /dev/null +++ b/data/gl 21851642_jshahinitiran.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +65505, Journal, 0, 16, "BMC Ophthalmol .", "", +65506, PublicationYear, 17, 21, "2011", "", +65507, Title, 83, 253, "Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open - angle glaucoma or ocular hypertension .", "", +65508, Latanoprost, 158, 169, "latanoprost", "", +65509, Timolol, 174, 181, "timolol", "", +65510, Ethnicity, 185, 192, "Chinese", "", +65511, OpenAngleGlaucoma, 207, 228, "open - angle glaucoma", "", +65512, OcularHypertension, 232, 251, "ocular hypertension", "", +65513, Author, 254, 261, "Zhao JL", "", +65514, Author, 270, 274, "Ge J", "", +65515, Author, 277, 282, "Li XX", "", +65516, Author, 285, 290, "Li YM", "", +65517, Author, 293, 301, "Sheng YH", "", +65518, Author, 304, 310, "Sun NX", "", +65519, Author, 313, 319, "Sun XH", "", +65520, Author, 322, 327, "Yao K", "", +65521, Author, 330, 337, "Zhong Z", "", +65522, China, 363, 368, "China", "", +65523, China, 785, 790, "China", "", +65524, ObjectiveDescription, 877, 1041, "to evaluate the efficacy of a single evening dose of fixed - combination latanoprost 50 μ g / mL and timolol 0 . 5 mg / mL ( Xalacom ®; LTFC ) , in Chinese patients", "", +65526, Lat/TimFC, 930, 999, "fixed - combination latanoprost 50 μ g / mL and timolol 0 . 5 mg / mL", "", +65527, Latanoprost, 950, 961, "latanoprost", "", +65528, DoseValue, 962, 964, "50", "", +65529, Timolol, 978, 985, "timolol", "", +65532, DoseValue, 986, 991, "0 . 5", "", +65533, Lat/TimFC, 1013, 1017, "LTFC", "", +65534, Ethnicity, 1025, 1032, "Chinese", "", +65525, ObjectiveDescription, 1042, 1213, "with primary open - angle glaucoma ( POAG ) or ocular hypertension ( OH ) who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy .", "", +65535, Primary_OpenAngleGlaucoma, 1047, 1076, "primary open - angle glaucoma", "", +65536, Primary_OpenAngleGlaucoma, 1079, 1083, "POAG", "", +65537, OcularHypertension, 1089, 1108, "ocular hypertension", "", +65538, OcularHypertension, 1111, 1113, "OH", "", +65539, Precondition, 1116, 1213, "who were insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy .", "", +65540, Duration, 1229, 1237, "8 - week", "", +65541, Randomized, 1240, 1250, "randomized", "", +65542, OpenLabel, 1253, 1265, "open - label", "", +65543, Parallel, 1268, 1284, "parallel - group", "", +65544, Frequency, 1317, 1329, "once - daily", "", +65545, Evening, 1330, 1337, "evening", "", +65546, Lat/TimFC, 1348, 1352, "LTFC", "", +65547, Latanoprost, 1385, 1396, "latanoprost", "", +65548, Evening, 1415, 1422, "evening", "", +65549, Timolol, 1429, 1436, "timolol", "", +65550, Morning, 1455, 1462, "morning", "", +65551, Mean, 1513, 1517, "mean", "", +65552, TimePoint, 1530, 1538, "baseline", "", +65553, TimePoint, 1542, 1548, "week 8", "", +65554, Diurnal_IOP, 1552, 1580, "diurnal intraocular pressure", "", +65555, IOP, 1583, 1586, "IOP", "", +65556, Lat/TimFC, 1633, 1637, "LTFC", "", +65558, ObservedResult, 1633, 1795, "LTFC was considered noninferior to LTuFC if the upper limit of the 95 % confidence interval ( CI ) of the difference was < 1 . 5 mmHg ( analysis of covariance ) .", "", +65557, mmHg, 1762, 1766, "mmHg", "", +65559, Lat/TimFC, 1848, 1852, "LTFC", "", +65566, NumberPatientsArm, 1859, 1862, "125", "", +65561, Primary_OpenAngleGlaucoma, 1865, 1869, "POAG", "", +65562, Mean, 1879, 1883, "mean", "", +65563, IOP, 1884, 1887, "IOP", "", +65564, BaseLineValue, 1890, 1896, "25 . 8", "", +65565, mmHg, 1897, 1901, "mmHg", "", +65567, NumberPatientsArm, 1920, 1923, "125", "", +65568, Primary_OpenAngleGlaucoma, 1926, 1930, "POAG", "", +65569, Mean, 1940, 1944, "mean", "", +65570, IOP, 1945, 1948, "IOP", "", +65571, BaseLineValue, 1951, 1957, "26 . 0", "", +65572, mmHg, 1958, 1962, "mmHg", "", +65573, Mean, 1967, 1971, "Mean", "", +65574, Diurnal_IOP, 1972, 1983, "diurnal IOP", "", +65575, TimePoint, 1997, 2005, "baseline", "", +65576, TimePoint, 2009, 2015, "week 8", "", +65577, Reduction, 2023, 2028, "8 . 6", "", +65579, mmHg, 2029, 2033, "mmHg", "", +65581, Lat/TimFC, 2039, 2043, "LTFC", "", +65578, Reduction, 2050, 2055, "8 . 9", "", +65580, mmHg, 2056, 2060, "mmHg", "", +65582, DiffGroupAbsValue, 2107, 2112, "0 . 3", "", +65583, mmHg, 2113, 2117, "mmHg", "", +65584, ConfIntervalChangeValue, 2120, 2148, "95 % - CI , - 0 . 3 to 1 . 0", "", +66198, ConclusionComment, 2205, 2370, "A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects", "", +66200, Evening, 2214, 2221, "evening", "", +66201, Lat/TimFC, 2230, 2234, "LTFC", "", +66202, Latanoprost, 2291, 2302, "latanoprost", "", +66203, Timolol, 2317, 2324, "timolol", "", +66204, IOP, 2347, 2350, "IOP", "", +66205, Ethnicity, 2354, 2361, "Chinese", "", +66199, ConclusionComment, 2371, 2488, "with POAG or OH whose IOP was insufficiently reduced with β- blocker monotherapy or β- blocker - based dual therapy .", "", +66206, Primary_OpenAngleGlaucoma, 2376, 2380, "POAG", "", +66207, OcularHypertension, 2384, 2386, "OH", "", +66209, IOP, 2393, 2396, "IOP", "", +66210, ConclusionComment, 2489, 2569, "LTFC is an effective and well tolerated once - daily treatment for POAG and OH .", "", +66211, Lat/TimFC, 2489, 2493, "LTFC", "", +66212, Frequency, 2529, 2541, "once - daily", "", +66213, Primary_OpenAngleGlaucoma, 2556, 2560, "POAG", "", +66214, OcularHypertension, 2565, 2567, "OH", "", +66215, PMID, 2636, 2644, "21851642", "", diff --git a/data/gl 21851642_jshahinitiran.n-triples b/data/gl 21851642_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21851642_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21851642_tstrakeljahn.annodb b/data/gl 21851642_tstrakeljahn.annodb new file mode 100644 index 0000000..54544be --- /dev/null +++ b/data/gl 21851642_tstrakeljahn.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80713, Journal, 0, 14, "BMC Ophthalmol", "", +80714, PublicationYear, 17, 21, "2011", "", +80723, Title, 83, 253, "Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open - angle glaucoma or ocular hypertension .", "", +80717, Latanoprost, 158, 169, "latanoprost", "", +80718, Lat/TimFC, 158, 181, "latanoprost and timolol", "", +80716, Timolol, 174, 181, "timolol", "", +80721, Ethnicity, 185, 192, "Chinese", "", +80719, OpenAngleGlaucoma, 207, 228, "open - angle glaucoma", "", +80720, OcularHypertension, 232, 251, "ocular hypertension", "", +80724, Author, 254, 261, "Zhao JL", "", +80725, Author, 270, 274, "Ge J", "", +80726, Author, 277, 282, "Li XX", "", +80727, Author, 285, 290, "Li YM", "", +80728, Author, 293, 301, "Sheng YH", "", +80729, Author, 304, 310, "Sun NX", "", +80730, Author, 313, 319, "Sun XH", "", +80731, Author, 322, 327, "Yao K", "", +80732, Author, 330, 337, "Zhong Z", "", +80733, Lat/TimFC, 340, 347, "Xalacom", "", +80722, China, 363, 368, "China", "", +80734, China, 785, 790, "China", "", +80735, Latanoprost, 950, 961, "latanoprost", "", +80742, ConcentrationUnit, 962, 973, "50 μ g / mL", "", +80736, Timolol, 978, 985, "timolol", "", +80741, ConcentrationUnit, 986, 999, "0 . 5 mg / mL", "", +80737, Lat/TimFC, 1002, 1009, "Xalacom", "", +80743, Lat/TimFC, 1013, 1017, "LTFC", "", +80744, Ethnicity, 1025, 1032, "Chinese", "", +80745, Primary_OpenAngleGlaucoma, 1047, 1076, "primary open - angle glaucoma", "", +80746, Primary_OpenAngleGlaucoma, 1079, 1083, "POAG", "", +80747, OcularHypertension, 1089, 1108, "ocular hypertension", "", +80748, OcularHypertension, 1111, 1113, "OH", "", +80749, Precondition, 1125, 1211, "insufficiently controlled on β- blocker monotherapy or β- blocker - based dual therapy", "", +80750, Duration, 1229, 1237, "8 - week", "", +80751, Randomized, 1240, 1250, "randomized", "", +80752, OpenLabel, 1253, 1265, "open - label", "", +80753, Parallel, 1268, 1276, "parallel", "", +80754, Frequency, 1317, 1329, "once - daily", "", +80755, Evening, 1330, 1337, "evening", "", +80756, Lat/TimFC, 1348, 1352, "LTFC", "", +80757, Latanoprost, 1385, 1396, "latanoprost", "", +80758, DoseValue, 1399, 1407, "one drop", "", +80762, Eyedrops, 1403, 1407, "drop", "", +80759, Evening, 1415, 1422, "evening", "", +80760, Timolol, 1429, 1436, "timolol", "", +80761, DoseValue, 1439, 1447, "one drop", "", +80763, Eyedrops, 1443, 1447, "drop", "", +80764, Morning, 1455, 1462, "morning", "", +80765, Mean, 1513, 1517, "mean", "", +80777, Endpoint, 1513, 1548, "mean change from baseline to week 8", "", +80776, TimePoint, 1530, 1538, "baseline", "", +80775, TimePoint, 1542, 1548, "week 8", "", +80767, Diurnal_IOP, 1552, 1580, "diurnal intraocular pressure", "", +80768, IOP, 1583, 1586, "IOP", "", +80769, Mean, 1589, 1593, "mean", "", +80770, TimePoint, 1597, 1601, "8 AM", "", +80771, TimePoint, 1604, 1609, "10 AM", "", +80772, TimePoint, 1612, 1616, "2 PM", "", +80773, TimePoint, 1619, 1623, "4 PM", "", +80774, IOP, 1624, 1628, "IOPs", "", +80778, Lat/TimFC, 1633, 1637, "LTFC", "", +80779, DiffBetweenGroups, 1754, 1761, "< 1 . 5", "", +80780, mmHg, 1762, 1766, "mmHg", "", +80781, Lat/TimFC, 1848, 1852, "LTFC", "", +80782, NumberPatientsArm, 1859, 1862, "125", "", +80784, Primary_OpenAngleGlaucoma, 1865, 1869, "POAG", "", +80786, PercentageAffected, 1872, 1874, "70", "percentage affected by POAG", +80790, Mean, 1879, 1883, "mean", "", +80792, IOP, 1884, 1887, "IOP", "", +80796, BaseLineValue, 1890, 1896, "25 . 8", "", +80794, mmHg, 1897, 1901, "mmHg", "", +80783, NumberPatientsArm, 1920, 1923, "125", "", +80785, Primary_OpenAngleGlaucoma, 1926, 1930, "POAG", "", +80789, PercentageAffected, 1933, 1935, "69", "percentage affected by POAG", +80791, Mean, 1940, 1944, "mean", "", +80793, IOP, 1945, 1948, "IOP", "", +80797, BaseLineValue, 1951, 1957, "26 . 0", "", +80795, mmHg, 1958, 1962, "mmHg", "", +80798, Mean, 1967, 1971, "Mean", "", +80799, Diurnal_IOP, 1972, 1983, "diurnal IOP", "", +80800, TimePoint, 1997, 2005, "baseline", "", +80801, TimePoint, 2009, 2015, "week 8", "", +80802, Reduction, 2023, 2028, "8 . 6", "", +80804, mmHg, 2029, 2033, "mmHg", "", +80806, Lat/TimFC, 2039, 2043, "LTFC", "", +80803, Reduction, 2050, 2055, "8 . 9", "", +80805, mmHg, 2056, 2060, "mmHg", "", +80807, DiffBetweenGroups, 2107, 2112, "0 . 3", "", +80808, mmHg, 2113, 2117, "mmHg", "", +80809, ConfIntervalDiff, 2132, 2148, "- 0 . 3 to 1 . 0", "", +80810, ObservedResult, 2153, 2190, "Both treatments were well tolerated .", "", +80822, ConclusionComment, 2205, 2234, "A single evening dose of LTFC", "", +80811, Evening, 2214, 2221, "evening", "", +80812, Lat/TimFC, 2230, 2234, "LTFC", "", +80821, ConclusionComment, 2235, 2488, "was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects with POAG or OH whose IOP was insufficiently reduced with β- blocker monotherapy or β- blocker - based dual therapy .", "", +80813, Latanoprost, 2291, 2302, "latanoprost", "", +80814, RelativeTime, 2303, 2312, "in the PM", "", +80815, RelativeTime, 2325, 2334, "in the AM", "", +80816, IOP, 2347, 2350, "IOP", "", +80817, Ethnicity, 2354, 2361, "Chinese", "", +80818, Primary_OpenAngleGlaucoma, 2376, 2380, "POAG", "", +80819, OcularHypertension, 2384, 2386, "OH", "", +80820, IOP, 2393, 2396, "IOP", "", +80823, Lat/TimFC, 2489, 2493, "LTFC", "", +80827, ConclusionComment, 2489, 2569, "LTFC is an effective and well tolerated once - daily treatment for POAG and OH .", "", +80824, Frequency, 2529, 2541, "once - daily", "", +80825, Primary_OpenAngleGlaucoma, 2556, 2560, "POAG", "", +80826, OcularHypertension, 2565, 2567, "OH", "", +80828, PMID, 2636, 2644, "21851642", "", diff --git a/data/gl 21851642_tstrakeljahn.n-triples b/data/gl 21851642_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21851642_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21960068_admin.annodb b/data/gl 21960068_admin.annodb new file mode 100644 index 0000000..7fd9e7d --- /dev/null +++ b/data/gl 21960068_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2012", "", " \"2012\"." +2, Title, 102, 275, "Twenty - four hour efficacy with the dorzolamide / timolol - fixed combination compared with the brimonidine / timolol - fixed combination in primary open - angle glaucoma .", "", " \"Twenty - four hour efficacy with the dorzolamide / timolol - fixed combination compared with the brimonidine / timolol - fixed combination in primary open - angle glaucoma .\"." +3, Dorzolamide, 139, 150, "dorzolamide", "", +5, Dorz/TimFC, 139, 180, "dorzolamide / timolol - fixed combination", "", " ." +4, Timolol, 153, 160, "timolol", "", +6, Brimonidine, 199, 210, "brimonidine", "", +8, Brimo/TimFC, 199, 240, "brimonidine / timolol - fixed combination", "", " ." +7, Timolol, 213, 220, "timolol", "", +9, Primary_OpenAngleGlaucoma, 244, 273, "primary open - angle glaucoma", "", " ." +10, Author, 276, 286, "Konstas AG", "", " \"Konstas AG\"." +11, Author, 295, 305, "Quaranta L", "", " \"Quaranta L\"." +12, Author, 308, 314, "Yan DB", "", " \"Yan DB\"." +13, Author, 317, 331, "Mikropoulos DG", "", " \"Mikropoulos DG\"." +14, Author, 334, 340, "Riva I", "", " \"Riva I\"." +15, Author, 343, 350, "Gill NK", "", " \"Gill NK\"." +16, Author, 353, 361, "Barton K", "", " \"Barton K\"." +17, Author, 364, 374, "Haidich AB", "", " \"Haidich AB\"." +18, Greece, 497, 503, "Greece", "", " ." +19, ObjectiveDescription, 538, 749, "The aim of this study is to compare the 24 - hour efficacy of dorzolamide / timolol - fixed combination ( DTFC ) and brimonidine / timolol - fixed combination ( BTFC ) in primary open - angle glaucoma ( POAG ) .", "", " \"The aim of this study is to compare the 24 - hour efficacy of dorzolamide / timolol - fixed combination ( DTFC ) and brimonidine / timolol - fixed combination ( BTFC ) in primary open - angle glaucoma ( POAG ) .\"." +20, Dorzolamide, 600, 611, "dorzolamide", "", +23, Dorz/TimFC, 600, 641, "dorzolamide / timolol - fixed combination", "", +21, Timolol, 614, 621, "timolol", "", +24, Dorz/TimFC, 644, 648, "DTFC", "", +25, Brimonidine, 655, 666, "brimonidine", "", +26, Brimo/TimFC, 655, 696, "brimonidine / timolol - fixed combination", "", +22, Timolol, 669, 676, "timolol", "", +27, Brimo/TimFC, 699, 703, "BTFC", "", +28, Primary_OpenAngleGlaucoma, 709, 738, "primary open - angle glaucoma", "", +29, Primary_OpenAngleGlaucoma, 741, 745, "POAG", "", +30, NumberPatientsCT, 776, 778, "77", "", " \"77\"." +31, Primary_OpenAngleGlaucoma, 779, 783, "POAG", "", +32, Prospective, 814, 825, "prospective", "", " ." +33, Blind, 828, 845, "observer - masked", "", " ." +34, Crossover, 848, 857, "crossover", "", " ." +35, Duration, 883, 892, "2 - month", "", +36, Timolol, 893, 900, "timolol", "", +37, IOP, 938, 958, "intraocular pressure", "", +38, IOP, 961, 964, "IOP", "", +100, TimePoint, 983, 987, "1000", "", +101, TimePoint, 990, 994, "1200", "", +102, TimePoint, 999, 1005, "1400 h", "", +39, Timolol, 1015, 1022, "timolol", "", +43, Precondition, 1035, 1092, "Patients showing at least a 20 % IOP reduction on timolol", "", " \"Patients showing at least a 20 % IOP reduction on timolol\"." +40, RelativeReduction, 1063, 1065, "20", "", +41, IOP, 1068, 1071, "IOP", "", +42, Timolol, 1085, 1092, "timolol", "", +44, Randomized, 1098, 1108, "randomised", "", " ." +45, Duration, 1112, 1120, "3 months", "", " \"3 months\"." +46, Dorz/TimFC, 1137, 1141, "DTFC", "", +47, Brimo/TimFC, 1145, 1149, "BTFC", "", +48, Crossover, 1166, 1178, "crossed over", "", +49, FinalNumPatientsCT, 1215, 1220, "Sixty", "", " \"Sixty\"." +50, Primary_OpenAngleGlaucoma, 1221, 1225, "POAG", "", +51, Mean, 1261, 1265, "mean", "", " . ." +89643, EndPointDescription, 1266, 1279, "24 - hour IOP", "", " . ." +53, Timolol, 1357, 1364, "timolol", "", +111, Diurnal_IOP, 1375, 1386, "diurnal IOP", "", +112, PvalueDiff, 1391, 1400, "< 0 . 001", "", +121, ObservedResult, 1405, 1534, "When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC", "", " \"When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC\". \"When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC\"." +56, Dorz/TimFC, 1462, 1466, "DTFC", "", +57, Mean, 1488, 1492, "mean", "", +89644, EndPointDescription, 1493, 1506, "24 - hour IOP", "", +59, Brimo/TimFC, 1530, 1534, "BTFC", "", +60, Mean, 1537, 1541, "mean", "", +134, DiffGroupAbsValue, 1555, 1562, "- 0 . 7", "", " \"- 0 . 7\"." +118, mmHg, 1563, 1568, "mm Hg", "", " ." +119, ConfIntervalDiff, 1571, 1624, "95 % confidence interval ( CI ) : ( - 1 . 0 , - 0 . 3", "", " \"95 % confidence interval ( CI ) : ( - 1 . 0 , - 0 . 3\"." +120, PvalueDiff, 1629, 1640, "P < 0 . 001", "", " \"P < 0 . 001\"." +122, Dorz/TimFC, 1677, 1681, "DTFC", "", " \"When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC\". \"When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC\"." +123, IOP, 1704, 1707, "IOP", "", " . ." +124, Brimo/TimFC, 1718, 1722, "BTFC", "", +125, TimePoint, 1728, 1734, "1800 h", "", " \"1800 h\". \"1800 h\"." +133, DiffGroupAbsValue, 1737, 1744, "- 1 . 0", "", " \"- 1 . 0\"." +127, mmHg, 1745, 1750, "mm Hg", "", " ." +129, ConfIntervalDiff, 1753, 1780, "95 % CI ( - 1 . 6 , - 0 . 5", "", " \"95 % CI ( - 1 . 6 , - 0 . 5\"." +130, PvalueDiff, 1785, 1796, "P = 0 . 001", "", " \"P = 0 . 001\"." +126, TimePoint, 1806, 1810, "0200", "", " \"0200\". \"0200\"." +135, DiffGroupAbsValue, 1813, 1820, "- 0 . 9", "", " \"- 0 . 9\"." +128, mmHg, 1821, 1826, "mm Hg", "", +132, ConfIntervalDiff, 1829, 1858, "95 % CI : ( - 1 . 4 , - 0 . 5", "", " \"95 % CI : ( - 1 . 4 , - 0 . 5\"." +131, PvalueDiff, 1863, 1874, "P = 0 . 001", "", " \"P = 0 . 001\"." +141, ConclusionComment, 1954, 2026, "Both the fixed combinations significantly reduce 24 - hour IOP in POAG .", "", " \"Both the fixed combinations significantly reduce 24 - hour IOP in POAG .\"." +137, IOP, 2013, 2016, "IOP", "", +138, Primary_OpenAngleGlaucoma, 2020, 2024, "POAG", "", +139, Dorz/TimFC, 2027, 2031, "DTFC", "", +141, ConclusionComment, 2027, 2082, "DTFC provided significantly better 24 - hour efficacy .", "", " \"DTFC provided significantly better 24 - hour efficacy .\"." +140, PMID, 2144, 2152, "21960068", "", " \"21960068\"." diff --git a/data/gl 21960068_admin.n-triples b/data/gl 21960068_admin.n-triples new file mode 100644 index 0000000..8a2a0f1 --- /dev/null +++ b/data/gl 21960068_admin.n-triples @@ -0,0 +1,145 @@ +# RDF export of group: Publication + . + "Publication 65490" . + "Twenty - four hour efficacy with the dorzolamide / timolol - fixed combination compared with the brimonidine / timolol - fixed combination in primary open - angle glaucoma ." . + "Konstas AG" . + "2012" . + "Eye ( Lond ) ." . + "21960068" . + . + "Quaranta L" . + "Yan DB" . + "Mikropoulos DG" . + "Riva I" . + "Gill NK" . + "Barton K" . + "Haidich AB" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 65504" . + "The aim of this study is to compare the 24 - hour efficacy of dorzolamide / timolol - fixed combination ( DTFC ) and brimonidine / timolol - fixed combination ( BTFC ) in primary open - angle glaucoma ( POAG ) ." . + "77" . + "3 months" . + . + . + . + "Both the fixed combinations significantly reduce 24 - hour IOP in POAG ." . + "DTFC provided significantly better 24 - hour efficacy ." . + . + . + . + . + . + "Sixty" . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 65525" . + "Patients showing at least a 20 % IOP reduction on timolol" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 24 hr IOP" . + . + . + . + . + . + . + . + "Endpoint 65700 IOP" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 65539 DTFC" . + . + . + . + . + . + . + "Arm 65548 BTFC" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 65571 DTFC" . + . + . + . + "Intervention 65577 BTFC" . + . + . +# RDF export of group: Medication + . + "Medication 65557 DTFC" . + . + . + . + . + "Medication 65564 BTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 65583 DTFC 24hr" . + . + "When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC" . + . + "Outcome 65619 BTFC 24hr" . + . + "When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC" . + . + "Outcome 65646 At 1800 BTFC" . + . + "1800 h" . + . + "Outcome 65673 at 0200 BTFC" . + . + "0200" . + . + "Outcome 102291 At 1800 DTFC" . + . + "1800 h" . + . + "Outcome 102318 At 0200 DTFC" . + . + "0200" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 65610 24 hr" . + . + . + "- 0 . 7" . + "P < 0 . 001" . + "95 % confidence interval ( CI ) : ( - 1 . 0 , - 0 . 3" . + . + "DiffBetweenGroups 65705 at 1800" . + "- 1 . 0" . + "P = 0 . 001" . + "95 % CI ( - 1 . 6 , - 0 . 5" . + . + . + . + "DiffBetweenGroups 65714 at 0200" . + "- 0 . 9" . + "P = 0 . 001" . + "95 % CI : ( - 1 . 4 , - 0 . 5" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21960068_export.csv b/data/gl 21960068_export.csv new file mode 100644 index 0000000..441e95d --- /dev/null +++ b/data/gl 21960068_export.csv @@ -0,0 +1,488 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +510, 1, 1, 1, 0, 3, 0, 3, "Eye" +510, 1, 2, 2, 4, 5, 4, 5, "(" +510, 1, 3, 3, 6, 10, 6, 10, "Lond" +510, 1, 4, 4, 11, 12, 11, 12, ")" +510, 1, 5, 5, 13, 14, 13, 14, "." +510, 2, 1, 6, 0, 4, 15, 19, "2012" +510, 2, 2, 7, 5, 8, 20, 23, "Jan" +510, 2, 3, 8, 9, 10, 24, 25, ";" +510, 2, 4, 9, 11, 13, 26, 28, "26" +510, 2, 5, 10, 14, 15, 29, 30, "(" +510, 2, 6, 11, 16, 17, 31, 32, "1" +510, 2, 7, 12, 18, 19, 33, 34, ")" +510, 2, 8, 13, 20, 21, 35, 36, ":" +510, 2, 9, 14, 22, 24, 37, 39, "80" +510, 2, 10, 15, 25, 26, 40, 41, "-" +510, 2, 11, 16, 27, 28, 42, 43, "7" +510, 2, 12, 17, 29, 30, 44, 45, "." +510, 2, 13, 18, 31, 34, 46, 49, "doi" +510, 2, 14, 19, 35, 36, 50, 51, ":" +510, 2, 15, 20, 37, 39, 52, 54, "10" +510, 2, 16, 21, 40, 41, 55, 56, "." +510, 2, 17, 22, 42, 46, 57, 61, "1038" +510, 2, 18, 23, 47, 48, 62, 63, "/" +510, 2, 19, 24, 49, 52, 64, 67, "eye" +510, 2, 20, 25, 53, 54, 68, 69, "." +510, 2, 21, 26, 55, 59, 70, 74, "2011" +510, 2, 22, 27, 60, 61, 75, 76, "." +510, 2, 23, 28, 62, 65, 77, 80, "239" +510, 2, 24, 29, 66, 67, 81, 82, "." +510, 3, 1, 30, 0, 4, 83, 87, "Epub" +510, 3, 2, 31, 5, 9, 88, 92, "2011" +510, 3, 3, 32, 10, 13, 93, 96, "Sep" +510, 3, 4, 33, 14, 16, 97, 99, "30" +510, 3, 5, 34, 17, 18, 100, 101, "." +510, 4, 1, 35, 0, 6, 102, 108, "Twenty" +510, 4, 2, 36, 7, 8, 109, 110, "-" +510, 4, 3, 37, 9, 13, 111, 115, "four" +510, 4, 4, 38, 14, 18, 116, 120, "hour" +510, 4, 5, 39, 19, 27, 121, 129, "efficacy" +510, 4, 6, 40, 28, 32, 130, 134, "with" +510, 4, 7, 41, 33, 36, 135, 138, "the" +510, 4, 8, 42, 37, 48, 139, 150, "dorzolamide" +510, 4, 9, 43, 49, 50, 151, 152, "/" +510, 4, 10, 44, 51, 58, 153, 160, "timolol" +510, 4, 11, 45, 59, 60, 161, 162, "-" +510, 4, 12, 46, 61, 66, 163, 168, "fixed" +510, 4, 13, 47, 67, 78, 169, 180, "combination" +510, 4, 14, 48, 79, 87, 181, 189, "compared" +510, 4, 15, 49, 88, 92, 190, 194, "with" +510, 4, 16, 50, 93, 96, 195, 198, "the" +510, 4, 17, 51, 97, 108, 199, 210, "brimonidine" +510, 4, 18, 52, 109, 110, 211, 212, "/" +510, 4, 19, 53, 111, 118, 213, 220, "timolol" +510, 4, 20, 54, 119, 120, 221, 222, "-" +510, 4, 21, 55, 121, 126, 223, 228, "fixed" +510, 4, 22, 56, 127, 138, 229, 240, "combination" +510, 4, 23, 57, 139, 141, 241, 243, "in" +510, 4, 24, 58, 142, 149, 244, 251, "primary" +510, 4, 25, 59, 150, 154, 252, 256, "open" +510, 4, 26, 60, 155, 156, 257, 258, "-" +510, 4, 27, 61, 157, 162, 259, 264, "angle" +510, 4, 28, 62, 163, 171, 265, 273, "glaucoma" +510, 4, 29, 63, 172, 173, 274, 275, "." +510, 5, 1, 64, 0, 7, 276, 283, "Konstas" +510, 5, 2, 65, 8, 10, 284, 286, "AG" +510, 5, 3, 66, 11, 12, 287, 288, "(" +510, 5, 4, 67, 13, 14, 289, 290, "1" +510, 5, 5, 68, 15, 16, 291, 292, ")" +510, 5, 6, 69, 17, 18, 293, 294, "," +510, 5, 7, 70, 19, 27, 295, 303, "Quaranta" +510, 5, 8, 71, 28, 29, 304, 305, "L" +510, 5, 9, 72, 30, 31, 306, 307, "," +510, 5, 10, 73, 32, 35, 308, 311, "Yan" +510, 5, 11, 74, 36, 38, 312, 314, "DB" +510, 5, 12, 75, 39, 40, 315, 316, "," +510, 5, 13, 76, 41, 52, 317, 328, "Mikropoulos" +510, 5, 14, 77, 53, 55, 329, 331, "DG" +510, 5, 15, 78, 56, 57, 332, 333, "," +510, 5, 16, 79, 58, 62, 334, 338, "Riva" +510, 5, 17, 80, 63, 64, 339, 340, "I" +510, 5, 18, 81, 65, 66, 341, 342, "," +510, 5, 19, 82, 67, 71, 343, 347, "Gill" +510, 5, 20, 83, 72, 74, 348, 350, "NK" +510, 5, 21, 84, 75, 76, 351, 352, "," +510, 5, 22, 85, 77, 83, 353, 359, "Barton" +510, 5, 23, 86, 84, 85, 360, 361, "K" +510, 5, 24, 87, 86, 87, 362, 363, "," +510, 5, 25, 88, 88, 95, 364, 371, "Haidich" +510, 5, 26, 89, 96, 98, 372, 374, "AB" +510, 5, 27, 90, 99, 100, 375, 376, "." +510, 6, 1, 91, 0, 6, 377, 383, "Author" +510, 6, 2, 92, 7, 18, 384, 395, "information" +510, 6, 3, 93, 19, 20, 396, 397, ":" +510, 6, 4, 94, 21, 22, 398, 399, "(" +510, 6, 5, 95, 23, 24, 400, 401, "1" +510, 6, 6, 96, 25, 26, 402, 403, ")" +510, 6, 7, 97, 27, 35, 404, 412, "Glaucoma" +510, 6, 8, 98, 36, 40, 413, 417, "Unit" +510, 6, 9, 99, 41, 42, 418, 419, "," +510, 6, 10, 100, 43, 46, 420, 423, "1st" +510, 6, 11, 101, 47, 57, 424, 434, "University" +510, 6, 12, 102, 58, 68, 435, 445, "Department" +510, 6, 13, 103, 69, 71, 446, 448, "of" +510, 6, 14, 104, 72, 85, 449, 462, "Ophthalmology" +510, 6, 15, 105, 86, 87, 463, 464, "," +510, 6, 16, 106, 88, 93, 465, 470, "AHEPA" +510, 6, 17, 107, 94, 102, 471, 479, "Hospital" +510, 6, 18, 108, 103, 104, 480, 481, "," +510, 6, 19, 109, 105, 117, 482, 494, "Thessaloniki" +510, 6, 20, 110, 118, 119, 495, 496, "," +510, 6, 21, 111, 120, 126, 497, 503, "Greece" +510, 6, 22, 112, 127, 128, 504, 505, "." +510, 7, 1, 113, 0, 7, 506, 513, "konstas" +510, 7, 2, 114, 8, 9, 514, 515, "@" +510, 7, 3, 115, 10, 13, 516, 519, "med" +510, 7, 4, 116, 14, 15, 520, 521, "." +510, 7, 5, 117, 16, 20, 522, 526, "auth" +510, 7, 6, 118, 21, 22, 527, 528, "." +510, 7, 7, 119, 23, 25, 529, 531, "gr" +510, 7, 8, 120, 26, 29, 532, 535, "AIM" +510, 7, 9, 121, 30, 31, 536, 537, ":" +510, 7, 10, 122, 32, 35, 538, 541, "The" +510, 7, 11, 123, 36, 39, 542, 545, "aim" +510, 7, 12, 124, 40, 42, 546, 548, "of" +510, 7, 13, 125, 43, 47, 549, 553, "this" +510, 7, 14, 126, 48, 53, 554, 559, "study" +510, 7, 15, 127, 54, 56, 560, 562, "is" +510, 7, 16, 128, 57, 59, 563, 565, "to" +510, 7, 17, 129, 60, 67, 566, 573, "compare" +510, 7, 18, 130, 68, 71, 574, 577, "the" +510, 7, 19, 131, 72, 74, 578, 580, "24" +510, 7, 20, 132, 75, 76, 581, 582, "-" +510, 7, 21, 133, 77, 81, 583, 587, "hour" +510, 7, 22, 134, 82, 90, 588, 596, "efficacy" +510, 7, 23, 135, 91, 93, 597, 599, "of" +510, 7, 24, 136, 94, 105, 600, 611, "dorzolamide" +510, 7, 25, 137, 106, 107, 612, 613, "/" +510, 7, 26, 138, 108, 115, 614, 621, "timolol" +510, 7, 27, 139, 116, 117, 622, 623, "-" +510, 7, 28, 140, 118, 123, 624, 629, "fixed" +510, 7, 29, 141, 124, 135, 630, 641, "combination" +510, 7, 30, 142, 136, 137, 642, 643, "(" +510, 7, 31, 143, 138, 142, 644, 648, "DTFC" +510, 7, 32, 144, 143, 144, 649, 650, ")" +510, 7, 33, 145, 145, 148, 651, 654, "and" +510, 7, 34, 146, 149, 160, 655, 666, "brimonidine" +510, 7, 35, 147, 161, 162, 667, 668, "/" +510, 7, 36, 148, 163, 170, 669, 676, "timolol" +510, 7, 37, 149, 171, 172, 677, 678, "-" +510, 7, 38, 150, 173, 178, 679, 684, "fixed" +510, 7, 39, 151, 179, 190, 685, 696, "combination" +510, 7, 40, 152, 191, 192, 697, 698, "(" +510, 7, 41, 153, 193, 197, 699, 703, "BTFC" +510, 7, 42, 154, 198, 199, 704, 705, ")" +510, 7, 43, 155, 200, 202, 706, 708, "in" +510, 7, 44, 156, 203, 210, 709, 716, "primary" +510, 7, 45, 157, 211, 215, 717, 721, "open" +510, 7, 46, 158, 216, 217, 722, 723, "-" +510, 7, 47, 159, 218, 223, 724, 729, "angle" +510, 7, 48, 160, 224, 232, 730, 738, "glaucoma" +510, 7, 49, 161, 233, 234, 739, 740, "(" +510, 7, 50, 162, 235, 239, 741, 745, "POAG" +510, 7, 51, 163, 240, 241, 746, 747, ")" +510, 7, 52, 164, 242, 243, 748, 749, "." +510, 8, 1, 165, 0, 7, 750, 757, "METHODS" +510, 8, 2, 166, 8, 9, 758, 759, ":" +510, 8, 3, 167, 10, 13, 760, 763, "One" +510, 8, 4, 168, 14, 17, 764, 767, "eye" +510, 8, 5, 169, 18, 22, 768, 772, "each" +510, 8, 6, 170, 23, 25, 773, 775, "of" +510, 8, 7, 171, 26, 28, 776, 778, "77" +510, 8, 8, 172, 29, 33, 779, 783, "POAG" +510, 8, 9, 173, 34, 42, 784, 792, "patients" +510, 8, 10, 174, 43, 46, 793, 796, "was" +510, 8, 11, 175, 47, 55, 797, 805, "included" +510, 8, 12, 176, 56, 58, 806, 808, "in" +510, 8, 13, 177, 59, 63, 809, 813, "this" +510, 8, 14, 178, 64, 75, 814, 825, "prospective" +510, 8, 15, 179, 76, 77, 826, 827, "," +510, 8, 16, 180, 78, 86, 828, 836, "observer" +510, 8, 17, 181, 87, 88, 837, 838, "-" +510, 8, 18, 182, 89, 95, 839, 845, "masked" +510, 8, 19, 183, 96, 97, 846, 847, "," +510, 8, 20, 184, 98, 107, 848, 857, "crossover" +510, 8, 21, 185, 108, 118, 858, 868, "comparison" +510, 8, 22, 186, 119, 120, 869, 870, "." +510, 9, 1, 187, 0, 9, 871, 880, "Following" +510, 9, 2, 188, 10, 11, 881, 882, "a" +510, 9, 3, 189, 12, 13, 883, 884, "2" +510, 9, 4, 190, 14, 15, 885, 886, "-" +510, 9, 5, 191, 16, 21, 887, 892, "month" +510, 9, 6, 192, 22, 29, 893, 900, "timolol" +510, 9, 7, 193, 30, 33, 901, 904, "run" +510, 9, 8, 194, 34, 35, 905, 906, "-" +510, 9, 9, 195, 36, 38, 907, 909, "in" +510, 9, 10, 196, 39, 45, 910, 916, "period" +510, 9, 11, 197, 46, 47, 917, 918, "," +510, 9, 12, 198, 48, 56, 919, 927, "patients" +510, 9, 13, 199, 57, 60, 928, 931, "had" +510, 9, 14, 200, 61, 66, 932, 937, "three" +510, 9, 15, 201, 67, 78, 938, 949, "intraocular" +510, 9, 16, 202, 79, 87, 950, 958, "pressure" +510, 9, 17, 203, 88, 89, 959, 960, "(" +510, 9, 18, 204, 90, 93, 961, 964, "IOP" +510, 9, 19, 205, 94, 95, 965, 966, ")" +510, 9, 20, 206, 96, 108, 967, 979, "measurements" +510, 9, 21, 207, 109, 111, 980, 982, "at" +510, 9, 22, 208, 112, 116, 983, 987, "1000" +510, 9, 23, 209, 117, 118, 988, 989, "," +510, 9, 24, 210, 119, 123, 990, 994, "1200" +510, 9, 25, 211, 124, 127, 995, 998, "and" +510, 9, 26, 212, 128, 132, 999, 1003, "1400" +510, 9, 27, 213, 133, 134, 1004, 1005, "h" +510, 9, 28, 214, 135, 140, 1006, 1011, "while" +510, 9, 29, 215, 141, 143, 1012, 1014, "on" +510, 9, 30, 216, 144, 151, 1015, 1022, "timolol" +510, 9, 31, 217, 152, 161, 1023, 1032, "treatment" +510, 9, 32, 218, 162, 163, 1033, 1034, "." +510, 10, 1, 219, 0, 8, 1035, 1043, "Patients" +510, 10, 2, 220, 9, 16, 1044, 1051, "showing" +510, 10, 3, 221, 17, 19, 1052, 1054, "at" +510, 10, 4, 222, 20, 25, 1055, 1060, "least" +510, 10, 5, 223, 26, 27, 1061, 1062, "a" +510, 10, 6, 224, 28, 30, 1063, 1065, "20" +510, 10, 7, 225, 31, 32, 1066, 1067, "%" +510, 10, 8, 226, 33, 36, 1068, 1071, "IOP" +510, 10, 9, 227, 37, 46, 1072, 1081, "reduction" +510, 10, 10, 228, 47, 49, 1082, 1084, "on" +510, 10, 11, 229, 50, 57, 1085, 1092, "timolol" +510, 10, 12, 230, 58, 62, 1093, 1097, "were" +510, 10, 13, 231, 63, 73, 1098, 1108, "randomised" +510, 10, 14, 232, 74, 76, 1109, 1111, "to" +510, 10, 15, 233, 77, 78, 1112, 1113, "3" +510, 10, 16, 234, 79, 85, 1114, 1120, "months" +510, 10, 17, 235, 86, 88, 1121, 1123, "of" +510, 10, 18, 236, 89, 96, 1124, 1131, "therapy" +510, 10, 19, 237, 97, 101, 1132, 1136, "with" +510, 10, 20, 238, 102, 106, 1137, 1141, "DTFC" +510, 10, 21, 239, 107, 109, 1142, 1144, "or" +510, 10, 22, 240, 110, 114, 1145, 1149, "BTFC" +510, 10, 23, 241, 115, 116, 1150, 1151, "," +510, 10, 24, 242, 117, 120, 1152, 1155, "and" +510, 10, 25, 243, 121, 125, 1156, 1160, "then" +510, 10, 26, 244, 126, 130, 1161, 1165, "were" +510, 10, 27, 245, 131, 138, 1166, 1173, "crossed" +510, 10, 28, 246, 139, 143, 1174, 1178, "over" +510, 10, 29, 247, 144, 146, 1179, 1181, "to" +510, 10, 30, 248, 147, 150, 1182, 1185, "the" +510, 10, 31, 249, 151, 159, 1186, 1194, "opposite" +510, 10, 32, 250, 160, 167, 1195, 1202, "therapy" +510, 10, 33, 251, 168, 169, 1203, 1204, "." +510, 11, 1, 252, 0, 7, 1205, 1212, "RESULTS" +510, 11, 2, 253, 8, 9, 1213, 1214, ":" +510, 11, 3, 254, 10, 15, 1215, 1220, "Sixty" +510, 11, 4, 255, 16, 20, 1221, 1225, "POAG" +510, 11, 5, 256, 21, 29, 1226, 1234, "patients" +510, 11, 6, 257, 30, 39, 1235, 1244, "completed" +510, 11, 7, 258, 40, 43, 1245, 1248, "the" +510, 11, 8, 259, 44, 49, 1249, 1254, "study" +510, 11, 9, 260, 50, 51, 1255, 1256, "." +510, 12, 1, 261, 0, 3, 1257, 1260, "The" +510, 12, 2, 262, 4, 8, 1261, 1265, "mean" +510, 12, 3, 263, 9, 11, 1266, 1268, "24" +510, 12, 4, 264, 12, 13, 1269, 1270, "-" +510, 12, 5, 265, 14, 18, 1271, 1275, "hour" +510, 12, 6, 266, 19, 22, 1276, 1279, "IOP" +510, 12, 7, 267, 23, 26, 1280, 1283, "was" +510, 12, 8, 268, 27, 40, 1284, 1297, "significantly" +510, 12, 9, 269, 41, 48, 1298, 1305, "reduced" +510, 12, 10, 270, 49, 53, 1306, 1310, "with" +510, 12, 11, 271, 54, 58, 1311, 1315, "both" +510, 12, 12, 272, 59, 62, 1316, 1319, "the" +510, 12, 13, 273, 63, 68, 1320, 1325, "fixed" +510, 12, 14, 274, 69, 81, 1326, 1338, "combinations" +510, 12, 15, 275, 82, 90, 1339, 1347, "compared" +510, 12, 16, 276, 91, 95, 1348, 1352, "with" +510, 12, 17, 277, 96, 99, 1353, 1356, "the" +510, 12, 18, 278, 100, 107, 1357, 1364, "timolol" +510, 12, 19, 279, 108, 109, 1365, 1366, "-" +510, 12, 20, 280, 110, 117, 1367, 1374, "treated" +510, 12, 21, 281, 118, 125, 1375, 1382, "diurnal" +510, 12, 22, 282, 126, 129, 1383, 1386, "IOP" +510, 12, 23, 283, 130, 131, 1387, 1388, "(" +510, 12, 24, 284, 132, 133, 1389, 1390, "P" +510, 12, 25, 285, 134, 135, 1391, 1392, "<" +510, 12, 26, 286, 136, 137, 1393, 1394, "0" +510, 12, 27, 287, 138, 139, 1395, 1396, "." +510, 12, 28, 288, 140, 143, 1397, 1400, "001" +510, 12, 29, 289, 144, 145, 1401, 1402, ")" +510, 12, 30, 290, 146, 147, 1403, 1404, "." +510, 13, 1, 291, 0, 4, 1405, 1409, "When" +510, 13, 2, 292, 5, 8, 1410, 1413, "the" +510, 13, 3, 293, 9, 12, 1414, 1417, "two" +510, 13, 4, 294, 13, 18, 1418, 1423, "fixed" +510, 13, 5, 295, 19, 31, 1424, 1436, "combinations" +510, 13, 6, 296, 32, 36, 1437, 1441, "were" +510, 13, 7, 297, 37, 45, 1442, 1450, "compared" +510, 13, 8, 298, 46, 54, 1451, 1459, "directly" +510, 13, 9, 299, 55, 56, 1460, 1461, "," +510, 13, 10, 300, 57, 61, 1462, 1466, "DTFC" +510, 13, 11, 301, 62, 74, 1467, 1479, "demonstrated" +510, 13, 12, 302, 75, 76, 1480, 1481, "a" +510, 13, 13, 303, 77, 82, 1482, 1487, "lower" +510, 13, 14, 304, 83, 87, 1488, 1492, "mean" +510, 13, 15, 305, 88, 90, 1493, 1495, "24" +510, 13, 16, 306, 91, 92, 1496, 1497, "-" +510, 13, 17, 307, 93, 97, 1498, 1502, "hour" +510, 13, 18, 308, 98, 101, 1503, 1506, "IOP" +510, 13, 19, 309, 102, 107, 1507, 1512, "level" +510, 13, 20, 310, 108, 110, 1513, 1515, "as" +510, 13, 21, 311, 111, 119, 1516, 1524, "compared" +510, 13, 22, 312, 120, 124, 1525, 1529, "with" +510, 13, 23, 313, 125, 129, 1530, 1534, "BTFC" +510, 13, 24, 314, 130, 131, 1535, 1536, "(" +510, 13, 25, 315, 132, 136, 1537, 1541, "mean" +510, 13, 26, 316, 137, 147, 1542, 1552, "difference" +510, 13, 27, 317, 148, 149, 1553, 1554, ":" +510, 13, 28, 318, 150, 151, 1555, 1556, "-" +510, 13, 29, 319, 152, 153, 1557, 1558, "0" +510, 13, 30, 320, 154, 155, 1559, 1560, "." +510, 13, 31, 321, 156, 157, 1561, 1562, "7" +510, 13, 32, 322, 158, 160, 1563, 1565, "mm" +510, 13, 33, 323, 161, 163, 1566, 1568, "Hg" +510, 13, 34, 324, 164, 165, 1569, 1570, "," +510, 13, 35, 325, 166, 168, 1571, 1573, "95" +510, 13, 36, 326, 169, 170, 1574, 1575, "%" +510, 13, 37, 327, 171, 181, 1576, 1586, "confidence" +510, 13, 38, 328, 182, 190, 1587, 1595, "interval" +510, 13, 39, 329, 191, 192, 1596, 1597, "(" +510, 13, 40, 330, 193, 195, 1598, 1600, "CI" +510, 13, 41, 331, 196, 197, 1601, 1602, ")" +510, 13, 42, 332, 198, 199, 1603, 1604, ":" +510, 13, 43, 333, 200, 201, 1605, 1606, "(" +510, 13, 44, 334, 202, 203, 1607, 1608, "-" +510, 13, 45, 335, 204, 205, 1609, 1610, "1" +510, 13, 46, 336, 206, 207, 1611, 1612, "." +510, 13, 47, 337, 208, 209, 1613, 1614, "0" +510, 13, 48, 338, 210, 211, 1615, 1616, "," +510, 13, 49, 339, 212, 213, 1617, 1618, "-" +510, 13, 50, 340, 214, 215, 1619, 1620, "0" +510, 13, 51, 341, 216, 217, 1621, 1622, "." +510, 13, 52, 342, 218, 219, 1623, 1624, "3" +510, 13, 53, 343, 220, 221, 1625, 1626, ")" +510, 13, 54, 344, 222, 223, 1627, 1628, "," +510, 13, 55, 345, 224, 225, 1629, 1630, "P" +510, 13, 56, 346, 226, 227, 1631, 1632, "<" +510, 13, 57, 347, 228, 229, 1633, 1634, "0" +510, 13, 58, 348, 230, 231, 1635, 1636, "." +510, 13, 59, 349, 232, 235, 1637, 1640, "001" +510, 13, 60, 350, 236, 237, 1641, 1642, ")" +510, 13, 61, 351, 238, 239, 1643, 1644, "." +510, 14, 1, 352, 0, 2, 1645, 1647, "At" +510, 14, 2, 353, 3, 6, 1648, 1651, "two" +510, 14, 3, 354, 7, 17, 1652, 1662, "individual" +510, 14, 4, 355, 18, 22, 1663, 1667, "time" +510, 14, 5, 356, 23, 29, 1668, 1674, "points" +510, 14, 6, 357, 30, 31, 1675, 1676, "," +510, 14, 7, 358, 32, 36, 1677, 1681, "DTFC" +510, 14, 8, 359, 37, 50, 1682, 1695, "significantly" +510, 14, 9, 360, 51, 58, 1696, 1703, "reduced" +510, 14, 10, 361, 59, 62, 1704, 1707, "IOP" +510, 14, 11, 362, 63, 67, 1708, 1712, "more" +510, 14, 12, 363, 68, 72, 1713, 1717, "than" +510, 14, 13, 364, 73, 77, 1718, 1722, "BTFC" +510, 14, 14, 365, 78, 79, 1723, 1724, ":" +510, 14, 15, 366, 80, 82, 1725, 1727, "at" +510, 14, 16, 367, 83, 87, 1728, 1732, "1800" +510, 14, 17, 368, 88, 89, 1733, 1734, "h" +510, 14, 18, 369, 90, 91, 1735, 1736, "(" +510, 14, 19, 370, 92, 93, 1737, 1738, "-" +510, 14, 20, 371, 94, 95, 1739, 1740, "1" +510, 14, 21, 372, 96, 97, 1741, 1742, "." +510, 14, 22, 373, 98, 99, 1743, 1744, "0" +510, 14, 23, 374, 100, 102, 1745, 1747, "mm" +510, 14, 24, 375, 103, 105, 1748, 1750, "Hg" +510, 14, 25, 376, 106, 107, 1751, 1752, "," +510, 14, 26, 377, 108, 110, 1753, 1755, "95" +510, 14, 27, 378, 111, 112, 1756, 1757, "%" +510, 14, 28, 379, 113, 115, 1758, 1760, "CI" +510, 14, 29, 380, 116, 117, 1761, 1762, "(" +510, 14, 30, 381, 118, 119, 1763, 1764, "-" +510, 14, 31, 382, 120, 121, 1765, 1766, "1" +510, 14, 32, 383, 122, 123, 1767, 1768, "." +510, 14, 33, 384, 124, 125, 1769, 1770, "6" +510, 14, 34, 385, 126, 127, 1771, 1772, "," +510, 14, 35, 386, 128, 129, 1773, 1774, "-" +510, 14, 36, 387, 130, 131, 1775, 1776, "0" +510, 14, 37, 388, 132, 133, 1777, 1778, "." +510, 14, 38, 389, 134, 135, 1779, 1780, "5" +510, 14, 39, 390, 136, 137, 1781, 1782, ")" +510, 14, 40, 391, 138, 139, 1783, 1784, "," +510, 14, 41, 392, 140, 141, 1785, 1786, "P" +510, 14, 42, 393, 142, 143, 1787, 1788, "=" +510, 14, 43, 394, 144, 145, 1789, 1790, "0" +510, 14, 44, 395, 146, 147, 1791, 1792, "." +510, 14, 45, 396, 148, 151, 1793, 1796, "001" +510, 14, 46, 397, 152, 153, 1797, 1798, ")" +510, 14, 47, 398, 154, 157, 1799, 1802, "and" +510, 14, 48, 399, 158, 160, 1803, 1805, "at" +510, 14, 49, 400, 161, 165, 1806, 1810, "0200" +510, 14, 50, 401, 166, 167, 1811, 1812, "(" +510, 14, 51, 402, 168, 169, 1813, 1814, "-" +510, 14, 52, 403, 170, 171, 1815, 1816, "0" +510, 14, 53, 404, 172, 173, 1817, 1818, "." +510, 14, 54, 405, 174, 175, 1819, 1820, "9" +510, 14, 55, 406, 176, 178, 1821, 1823, "mm" +510, 14, 56, 407, 179, 181, 1824, 1826, "Hg" +510, 14, 57, 408, 182, 183, 1827, 1828, "," +510, 14, 58, 409, 184, 186, 1829, 1831, "95" +510, 14, 59, 410, 187, 188, 1832, 1833, "%" +510, 14, 60, 411, 189, 191, 1834, 1836, "CI" +510, 14, 61, 412, 192, 193, 1837, 1838, ":" +510, 14, 62, 413, 194, 195, 1839, 1840, "(" +510, 14, 63, 414, 196, 197, 1841, 1842, "-" +510, 14, 64, 415, 198, 199, 1843, 1844, "1" +510, 14, 65, 416, 200, 201, 1845, 1846, "." +510, 14, 66, 417, 202, 203, 1847, 1848, "4" +510, 14, 67, 418, 204, 205, 1849, 1850, "," +510, 14, 68, 419, 206, 207, 1851, 1852, "-" +510, 14, 69, 420, 208, 209, 1853, 1854, "0" +510, 14, 70, 421, 210, 211, 1855, 1856, "." +510, 14, 71, 422, 212, 213, 1857, 1858, "5" +510, 14, 72, 423, 214, 215, 1859, 1860, ")" +510, 14, 73, 424, 216, 217, 1861, 1862, "," +510, 14, 74, 425, 218, 219, 1863, 1864, "P" +510, 14, 75, 426, 220, 221, 1865, 1866, "=" +510, 14, 76, 427, 222, 223, 1867, 1868, "0" +510, 14, 77, 428, 224, 225, 1869, 1870, "." +510, 14, 78, 429, 226, 229, 1871, 1874, "001" +510, 14, 79, 430, 230, 231, 1875, 1876, ")" +510, 14, 80, 431, 232, 233, 1877, 1878, "." +510, 15, 1, 432, 0, 2, 1879, 1881, "No" +510, 15, 2, 433, 3, 14, 1882, 1893, "significant" +510, 15, 3, 434, 15, 25, 1894, 1904, "difference" +510, 15, 4, 435, 26, 33, 1905, 1912, "existed" +510, 15, 5, 436, 34, 37, 1913, 1916, "for" +510, 15, 6, 437, 38, 41, 1917, 1920, "the" +510, 15, 7, 438, 42, 47, 1921, 1926, "other" +510, 15, 8, 439, 48, 52, 1927, 1931, "time" +510, 15, 9, 440, 53, 59, 1932, 1938, "points" +510, 15, 10, 441, 60, 61, 1939, 1940, "." +510, 16, 1, 442, 0, 10, 1941, 1951, "CONCLUSION" +510, 16, 2, 443, 11, 12, 1952, 1953, ":" +510, 16, 3, 444, 13, 17, 1954, 1958, "Both" +510, 16, 4, 445, 18, 21, 1959, 1962, "the" +510, 16, 5, 446, 22, 27, 1963, 1968, "fixed" +510, 16, 6, 447, 28, 40, 1969, 1981, "combinations" +510, 16, 7, 448, 41, 54, 1982, 1995, "significantly" +510, 16, 8, 449, 55, 61, 1996, 2002, "reduce" +510, 16, 9, 450, 62, 64, 2003, 2005, "24" +510, 16, 10, 451, 65, 66, 2006, 2007, "-" +510, 16, 11, 452, 67, 71, 2008, 2012, "hour" +510, 16, 12, 453, 72, 75, 2013, 2016, "IOP" +510, 16, 13, 454, 76, 78, 2017, 2019, "in" +510, 16, 14, 455, 79, 83, 2020, 2024, "POAG" +510, 16, 15, 456, 84, 85, 2025, 2026, "." +510, 17, 1, 457, 0, 4, 2027, 2031, "DTFC" +510, 17, 2, 458, 5, 13, 2032, 2040, "provided" +510, 17, 3, 459, 14, 27, 2041, 2054, "significantly" +510, 17, 4, 460, 28, 34, 2055, 2061, "better" +510, 17, 5, 461, 35, 37, 2062, 2064, "24" +510, 17, 6, 462, 38, 39, 2065, 2066, "-" +510, 17, 7, 463, 40, 44, 2067, 2071, "hour" +510, 17, 8, 464, 45, 53, 2072, 2080, "efficacy" +510, 17, 9, 465, 54, 55, 2081, 2082, "." +510, 18, 1, 466, 0, 3, 2083, 2086, "DOI" +510, 18, 2, 467, 4, 5, 2087, 2088, ":" +510, 18, 3, 468, 6, 8, 2089, 2091, "10" +510, 18, 4, 469, 9, 10, 2092, 2093, "." +510, 18, 5, 470, 11, 15, 2094, 2098, "1038" +510, 18, 6, 471, 16, 17, 2099, 2100, "/" +510, 18, 7, 472, 18, 21, 2101, 2104, "eye" +510, 18, 8, 473, 22, 23, 2105, 2106, "." +510, 18, 9, 474, 24, 28, 2107, 2111, "2011" +510, 18, 10, 475, 29, 30, 2112, 2113, "." +510, 18, 11, 476, 31, 34, 2114, 2117, "239" +510, 18, 12, 477, 35, 40, 2118, 2123, "PMCID" +510, 18, 13, 478, 41, 42, 2124, 2125, ":" +510, 18, 14, 479, 43, 53, 2126, 2136, "PMC3259580" +510, 18, 15, 480, 54, 58, 2137, 2141, "PMID" +510, 18, 16, 481, 59, 60, 2142, 2143, ":" +510, 18, 17, 482, 61, 69, 2144, 2152, "21960068" +510, 18, 18, 483, 70, 71, 2153, 2154, "[" +510, 18, 19, 484, 72, 79, 2155, 2162, "Indexed" +510, 18, 20, 485, 80, 83, 2163, 2166, "for" +510, 18, 21, 486, 84, 91, 2167, 2174, "MEDLINE" +510, 18, 22, 487, 92, 93, 2175, 2176, "]" diff --git a/data/gl 21960068_jshahinitiran.annodb b/data/gl 21960068_jshahinitiran.annodb new file mode 100644 index 0000000..f1d8298 --- /dev/null +++ b/data/gl 21960068_jshahinitiran.annodb @@ -0,0 +1,62 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +66216, Journal, 0, 14, "Eye ( Lond ) .", "", +66217, PublicationYear, 15, 19, "2012", "", +66218, Title, 102, 275, "Twenty - four hour efficacy with the dorzolamide / timolol - fixed combination compared with the brimonidine / timolol - fixed combination in primary open - angle glaucoma .", "", +66219, Dorzolamide, 139, 150, "dorzolamide", "", +66221, Dorz/TimFC, 139, 180, "dorzolamide / timolol - fixed combination", "", +66220, Timolol, 153, 160, "timolol", "", +66222, Brimonidine, 199, 210, "brimonidine", "", +66224, Brimo/TimFC, 199, 240, "brimonidine / timolol - fixed combination", "", +66223, Timolol, 213, 220, "timolol", "", +66225, Primary_OpenAngleGlaucoma, 244, 273, "primary open - angle glaucoma", "", +66226, Author, 276, 286, "Konstas AG", "", +66227, Author, 295, 305, "Quaranta L", "", +66228, Author, 308, 314, "Yan DB", "", +66229, Author, 317, 331, "Mikropoulos DG", "", +66230, Author, 334, 340, "Riva I", "", +66231, Author, 343, 350, "Gill NK", "", +66232, Author, 353, 361, "Barton K", "", +66233, Author, 364, 374, "Haidich AB", "", +66234, Greece, 497, 503, "Greece", "", +66235, ObjectiveDescription, 538, 749, "The aim of this study is to compare the 24 - hour efficacy of dorzolamide / timolol - fixed combination ( DTFC ) and brimonidine / timolol - fixed combination ( BTFC ) in primary open - angle glaucoma ( POAG ) .", "", +66236, Dorzolamide, 600, 611, "dorzolamide", "", +66239, Dorz/TimFC, 600, 641, "dorzolamide / timolol - fixed combination", "", +66237, Timolol, 614, 621, "timolol", "", +66240, Dorz/TimFC, 644, 648, "DTFC", "", +66241, Brimonidine, 655, 666, "brimonidine", "", +66242, Brimo/TimFC, 655, 696, "brimonidine / timolol - fixed combination", "", +66238, Timolol, 669, 676, "timolol", "", +66243, Brimo/TimFC, 699, 703, "BTFC", "", +66244, Primary_OpenAngleGlaucoma, 709, 738, "primary open - angle glaucoma", "", +66245, Primary_OpenAngleGlaucoma, 741, 745, "POAG", "", +66246, NumberPatientsCT, 776, 778, "77", "", +66247, Primary_OpenAngleGlaucoma, 779, 783, "POAG", "", +66248, Prospective, 814, 825, "prospective", "", +66249, Blind, 828, 845, "observer - masked", "", +66250, Crossover, 848, 857, "crossover", "", +66251, Duration, 883, 892, "2 - month", "", +66252, Timolol, 893, 900, "timolol", "", +66253, IOP, 938, 958, "intraocular pressure", "", +66254, IOP, 961, 964, "IOP", "", +66255, Timolol, 1015, 1022, "timolol", "", +66259, Precondition, 1035, 1092, "Patients showing at least a 20 % IOP reduction on timolol", "", +66256, RelativeReduction, 1063, 1065, "20", "", +66257, IOP, 1068, 1071, "IOP", "", +66258, Timolol, 1085, 1092, "timolol", "", +66260, Randomized, 1098, 1108, "randomised", "", +66261, Duration, 1112, 1120, "3 months", "", +66262, Dorz/TimFC, 1137, 1141, "DTFC", "", +66263, Brimo/TimFC, 1145, 1149, "BTFC", "", +66264, Crossover, 1166, 1178, "crossed over", "", +66265, FinalNumPatientsCT, 1215, 1220, "Sixty", "", +66266, Primary_OpenAngleGlaucoma, 1221, 1225, "POAG", "", +66267, Mean, 1261, 1265, "mean", "", +66268, IOP, 1276, 1279, "IOP", "", +66269, Timolol, 1357, 1364, "timolol", "", +66270, IOP, 1383, 1386, "IOP", "", +66271, PValueChangeValue, 1389, 1400, "P < 0 . 001", "", +66272, Dorz/TimFC, 1462, 1466, "DTFC", "", +66273, Mean, 1488, 1492, "mean", "", +66274, IOP, 1503, 1506, "IOP", "", +66275, Brimo/TimFC, 1530, 1534, "BTFC", "", +66276, Mean, 1537, 1541, "mean", "", diff --git a/data/gl 21960068_jshahinitiran.n-triples b/data/gl 21960068_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21960068_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 21960068_tstrakeljahn.annodb b/data/gl 21960068_tstrakeljahn.annodb new file mode 100644 index 0000000..e78c8e4 --- /dev/null +++ b/data/gl 21960068_tstrakeljahn.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +85583, Journal, 0, 12, "Eye ( Lond )", "", +85584, PublicationYear, 15, 19, "2012", "", +85592, Title, 102, 275, "Twenty - four hour efficacy with the dorzolamide / timolol - fixed combination compared with the brimonidine / timolol - fixed combination in primary open - angle glaucoma .", "", +85585, Dorzolamide, 139, 150, "dorzolamide", "", +85590, Dorz/TimFC, 139, 160, "dorzolamide / timolol", "", +85586, Timolol, 153, 160, "timolol", "", +85588, Brimonidine, 199, 210, "brimonidine", "", +85591, Brimo/TimFC, 199, 220, "brimonidine / timolol", "", +85587, Timolol, 213, 220, "timolol", "", +85589, Primary_OpenAngleGlaucoma, 244, 273, "primary open - angle glaucoma", "", +85593, Author, 276, 286, "Konstas AG", "", +85594, Author, 295, 305, "Quaranta L", "", +85595, Author, 308, 314, "Yan DB", "", +85596, Author, 317, 331, "Mikropoulos DG", "", +85597, Author, 334, 340, "Riva I", "", +85598, Author, 343, 350, "Gill NK", "", +85599, Author, 353, 361, "Barton K", "", +85600, Author, 364, 374, "Haidich AB", "", +85601, Greece, 497, 503, "Greece", "", +85614, ObjectiveDescription, 538, 749, "The aim of this study is to compare the 24 - hour efficacy of dorzolamide / timolol - fixed combination ( DTFC ) and brimonidine / timolol - fixed combination ( BTFC ) in primary open - angle glaucoma ( POAG ) .", "", +85602, Dorzolamide, 600, 611, "dorzolamide", "", +85607, Dorz/TimFC, 600, 621, "dorzolamide / timolol", "", +85603, Timolol, 614, 621, "timolol", "", +85608, Dorz/TimFC, 644, 648, "DTFC", "", +85605, Brimonidine, 655, 666, "brimonidine", "", +85610, Brimo/TimFC, 655, 676, "brimonidine / timolol", "", +85604, Timolol, 669, 676, "timolol", "", +85611, Brimo/TimFC, 699, 703, "BTFC", "", +85612, Primary_OpenAngleGlaucoma, 709, 738, "primary open - angle glaucoma", "", +85613, Primary_OpenAngleGlaucoma, 741, 745, "POAG", "", +85615, NumberPatientsCT, 776, 778, "77", "", +85616, Primary_OpenAngleGlaucoma, 779, 783, "POAG", "", +85617, Prospective, 814, 825, "prospective", "", +85618, Blind, 828, 845, "observer - masked", "", +85619, Crossover, 848, 857, "crossover", "", +85621, Timolol, 893, 900, "timolol", "", +85623, IOP, 938, 958, "intraocular pressure", "", +85624, IOP, 961, 964, "IOP", "", +85625, TimePoint, 983, 987, "1000", "", +85626, TimePoint, 990, 994, "1200", "", +85627, TimePoint, 999, 1005, "1400 h", "", +85628, Timolol, 1015, 1022, "timolol", "", +85630, SubGroupDescription, 1044, 1081, "showing at least a 20 % IOP reduction", "", +85629, IOP, 1068, 1071, "IOP", "", +85631, Dorz/TimFC, 1137, 1141, "DTFC", "", +85632, Brimo/TimFC, 1145, 1149, "BTFC", "", +85620, FinalNumPatientsCT, 1215, 1220, "Sixty", "", +85633, Mean, 1261, 1265, "mean", "", +85634, IOP, 1276, 1279, "IOP", "", +85635, Timolol, 1357, 1364, "timolol", "", +85636, Diurnal_IOP, 1375, 1386, "diurnal IOP", "", +85637, PvalueDiff, 1391, 1400, "< 0 . 001", "", +85647, ObservedResult, 1405, 1534, "When the two fixed combinations were compared directly , DTFC demonstrated a lower mean 24 - hour IOP level as compared with BTFC", "", +85638, Dorz/TimFC, 1462, 1466, "DTFC", "", +85639, Mean, 1488, 1492, "mean", "", +85640, IOP, 1503, 1506, "IOP", "", +85641, Brimo/TimFC, 1530, 1534, "BTFC", "", +85642, Mean, 1537, 1541, "mean", "", +85664, DiffGroupAbsValue, 1557, 1562, "0 . 7", "", +85644, mmHg, 1563, 1568, "mm Hg", "", +85645, ConfIntervalDiff, 1607, 1624, "- 1 . 0 , - 0 . 3", "", +85646, PvalueDiff, 1631, 1640, "< 0 . 001", "", +85648, Dorz/TimFC, 1677, 1681, "DTFC", "", +85649, IOP, 1704, 1707, "IOP", "", +85650, Brimo/TimFC, 1718, 1722, "BTFC", "", +85651, TimePoint, 1728, 1734, "1800 h", "", +85663, DiffGroupAbsValue, 1739, 1744, "1 . 0", "", +85653, mmHg, 1745, 1750, "mm Hg", "", +85655, ConfIntervalDiff, 1763, 1780, "- 1 . 6 , - 0 . 5", "", +85656, PvalueDiff, 1787, 1796, "= 0 . 001", "", +85652, TimePoint, 1806, 1810, "0200", "", +85667, DiffGroupAbsValue, 1815, 1820, "0 . 9", "", +85654, mmHg, 1821, 1826, "mm Hg", "", +85661, ConfIntervalDiff, 1841, 1858, "- 1 . 4 , - 0 . 5", "", +85658, PvalueDiff, 1865, 1874, "= 0 . 001", "", +85671, ObservedResult, 1879, 1940, "No significant difference existed for the other time points .", "", +85685, ConclusionComment, 1954, 2026, "Both the fixed combinations significantly reduce 24 - hour IOP in POAG .", "", +85674, IOP, 2013, 2016, "IOP", "", +85677, Primary_OpenAngleGlaucoma, 2020, 2024, "POAG", "", +85681, Dorz/TimFC, 2027, 2031, "DTFC", "", +85686, ConclusionComment, 2027, 2082, "DTFC provided significantly better 24 - hour efficacy .", "", +85683, PMID, 2144, 2152, "21960068", "", diff --git a/data/gl 21960068_tstrakeljahn.n-triples b/data/gl 21960068_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 21960068_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22207522_admin.annodb b/data/gl 22207522_admin.annodb new file mode 100644 index 0000000..08fa819 --- /dev/null +++ b/data/gl 22207522_admin.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Int Ophthalmol .", "", " \"Int Ophthalmol .\"." +1, PublicationYear, 17, 21, "2011", "", " \"2011\"." +2, Title, 113, 245, "Comparison of fixed combinations of dorzolamide / timolol and brimonidine / timolol in patients with primary open - angle glaucoma .", "", " \"Comparison of fixed combinations of dorzolamide / timolol and brimonidine / timolol in patients with primary open - angle glaucoma .\"." +67, Dorzolamide, 149, 160, "dorzolamide", "", +78, Dorz/TimFC, 149, 170, "dorzolamide / timolol", "", " ." +68, Timolol, 163, 170, "timolol", "", +69, Brimonidine, 175, 186, "brimonidine", "", +79, Brimo/TimFC, 175, 196, "brimonidine / timolol", "", " ." +70, Timolol, 189, 196, "timolol", "", +91869, Precondition, 200, 243, "patients with primary open - angle glaucoma", "", " \"patients with primary open - angle glaucoma\"." +71, Primary_OpenAngleGlaucoma, 214, 243, "primary open - angle glaucoma", "", " ." +3, Author, 246, 256, "Gulkilik G", "", " \"Gulkilik G\"." +4, Author, 265, 270, "Oba E", "", " \"Oba E\"." +5, Author, 273, 283, "Odabas ı M", "", " \"Odabas ı M\"." +6, Turkey, 369, 375, "Turkey", "", " ." +7, ObjectiveDescription, 405, 621, "To compare the short - term effectiveness and ocular side - effects of fixed combinations of dorzolamide / timolol ( DTFC ) and brimonidine / timolol ( BTFC ) in patients with primary open - angle glaucoma ( POAG ) .", "", " \"To compare the short - term effectiveness and ocular side - effects of fixed combinations of dorzolamide / timolol ( DTFC ) and brimonidine / timolol ( BTFC ) in patients with primary open - angle glaucoma ( POAG ) .\"." +10, Dorz/TimFC, 476, 519, "fixed combinations of dorzolamide / timolol", "", +8, Dorzolamide, 498, 509, "dorzolamide", "", +9, Timolol, 512, 519, "timolol", "", +11, Dorz/TimFC, 522, 526, "DTFC", "", +12, Brimonidine, 533, 544, "brimonidine", "", +91863, Brimo/TimFC, 533, 554, "brimonidine / timolol", "", +13, Timolol, 547, 554, "timolol", "", +14, Brimo/TimFC, 557, 561, "BTFC", "", +15, Primary_OpenAngleGlaucoma, 581, 610, "primary open - angle glaucoma", "", +16, Primary_OpenAngleGlaucoma, 613, 617, "POAG", "", +96, NumberPatientsCT, 642, 644, "42", "", " \"42\"." +98, Precondition, 654, 704, "newly diagnosed with primary open - angle glaucoma", "", " \"newly diagnosed with primary open - angle glaucoma\"." +19, Primary_OpenAngleGlaucoma, 675, 704, "primary open - angle glaucoma", "", +20, Dorz/TimFC, 792, 796, "DTFC", "", +106382, Frequency, 799, 806, "2  ×  1", "", " \"2  ×  1\"." +21, Duration, 813, 822, "4   weeks", "", " \"4   weeks\"." +22, Duration, 867, 875, "4 - week", "", +23, Brimo/TimFC, 960, 964, "BTFC", "", +102, Frequency, 967, 974, "2  ×  1", "", " \"2  ×  1\"." +24, Duration, 981, 990, "4   weeks", "", +25, IOP, 993, 1013, "Intraocular pressure", "", " . ." +26, IOP, 1016, 1019, "IOP", "", +108, TimePoint, 1078, 1082, "0800", "", +109, TimePoint, 1085, 1092, "1 , 200", "", +110, TimePoint, 1097, 1104, "1 , 600", "", +27, Mean, 1189, 1193, "mean", "", +28, IOP, 1203, 1206, "IOP", "", +29, Dorz/TimFC, 1218, 1222, "DTFC", "", +30, Brimo/TimFC, 1227, 1231, "BTFC", "", +31, BaseLineValue, 1237, 1243, "24 . 1", "", " \"24 . 1\"." +117, SdDevBL, 1248, 1253, "1 . 8", "", " \"1 . 8\"." +32, BaseLineValue, 1258, 1264, "24 . 6", "", " \"24 . 6\"." +118, SdDevBL, 1269, 1274, "2 . 4", "", " \"2 . 4\"." +35, mmHg, 1277, 1281, "mmHg", "", " ." +36, Mean, 1303, 1307, "mean", "", " . ." +37, IOP, 1308, 1311, "IOP", "", +91870, TimePoint, 1325, 1334, "4   weeks", "", " \"4   weeks\"." +39, Dorz/TimFC, 1353, 1357, "DTFC", "", +40, Brimo/TimFC, 1361, 1365, "BTFC", "", +41, ResultMeasuredValue, 1371, 1377, "17 . 1", "", " \"17 . 1\"." +127, SdDevResValue, 1382, 1387, "2 . 9", "", " \"2 . 9\"." +42, ResultMeasuredValue, 1392, 1398, "16 . 9", "", " \"16 . 9\"." +128, SdDevResValue, 1403, 1408, "2 . 5", "", " \"2 . 5\"." +45, mmHg, 1411, 1415, "mmHg", "", +133, ObservedResult, 1433, 1482, "Both medications reduced IOP values significantly", "", " \"Both medications reduced IOP values significantly\". \"Both medications reduced IOP values significantly\"." +46, IOP, 1458, 1461, "IOP", "", +47, PValueChangeValue, 1485, 1499, "P  =  0 . 0000", "", " \"P  =  0 . 0000\". \"P  =  0 . 0000\"." +91871, PValueChangeValue, 1556, 1570, "P  =  0 . 7363", "", +135, ObservedResult, 1575, 1628, "Both combinations significantly reduced the amount of", "", " \"Both combinations significantly reduced the amount of\". \"Both combinations significantly reduced the amount of\"." +91873, EndPointDescription, 1629, 1643, "tear secretion", "", " . ." +91874, EndPointDescription, 1648, 1668, "tear break - up time", "", " . ." +66, PValueChangeValue, 1671, 1685, "P  =  0 . 0000", "", " \"P  =  0 . 0000\". \"P  =  0 . 0000\"." +148, ObservedResult, 1690, 1742, "Eye burning was more common with DTFC than with BTFC", "", " \"Eye burning was more common with DTFC than with BTFC\". \"Eye burning was more common with DTFC than with BTFC\"." +91875, EndPointDescription, 1690, 1701, "Eye burning", "", " . ." +50, Dorz/TimFC, 1723, 1727, "DTFC", "", +51, Brimo/TimFC, 1738, 1742, "BTFC", "", +136, PvalueDiff, 1747, 1759, " =  0 . 0182", "", " \" =  0 . 0182\"." +62, ConclusionComment, 1841, 1949, "This study demonstrated that the IOP - reducing effects of DTFC and BTFC in patients with POAG are similar .", "", " \"This study demonstrated that the IOP - reducing effects of DTFC and BTFC in patients with POAG are similar .\"." +54, IOP, 1874, 1877, "IOP", "", +55, Dorz/TimFC, 1900, 1904, "DTFC", "", +56, Brimo/TimFC, 1909, 1913, "BTFC", "", +57, Primary_OpenAngleGlaucoma, 1931, 1935, "POAG", "", +63, ConclusionComment, 1950, 2012, "The side - effect profile of BTFC is similar to that of DTFC .", "", " \"The side - effect profile of BTFC is similar to that of DTFC .\"." +58, Brimo/TimFC, 1979, 1983, "BTFC", "", +59, Dorz/TimFC, 2006, 2010, "DTFC", "", +64, ConclusionComment, 2013, 2103, "Lower occurrence of a burning sensation may improve patient compliance in the BTFC group .", "", " \"Lower occurrence of a burning sensation may improve patient compliance in the BTFC group .\"." +91876, EndPointDescription, 2035, 2052, "burning sensation", "", " . ." +61, Brimo/TimFC, 2091, 2095, "BTFC", "", +65, PMID, 2153, 2161, "22207522", "", " \"22207522\"." diff --git a/data/gl 22207522_admin.n-triples b/data/gl 22207522_admin.n-triples new file mode 100644 index 0000000..d0f8d1c --- /dev/null +++ b/data/gl 22207522_admin.n-triples @@ -0,0 +1,157 @@ +# RDF export of group: Publication + . + "Publication 65732" . + "Comparison of fixed combinations of dorzolamide / timolol and brimonidine / timolol in patients with primary open - angle glaucoma ." . + "Gulkilik G" . + "2011" . + "Int Ophthalmol ." . + "22207522" . + . + "Oba E" . + "Odabas ı M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 65741" . + "To compare the short - term effectiveness and ocular side - effects of fixed combinations of dorzolamide / timolol ( DTFC ) and brimonidine / timolol ( BTFC ) in patients with primary open - angle glaucoma ( POAG ) ." . + "42" . + "4   weeks" . + . + . + . + "This study demonstrated that the IOP - reducing effects of DTFC and BTFC in patients with POAG are similar ." . + . + . + . + . + . + . + "The side - effect profile of BTFC is similar to that of DTFC ." . + "Lower occurrence of a burning sensation may improve patient compliance in the BTFC group ." . + . +# RDF export of group: Population + . + "Population 65760" . + "patients with primary open - angle glaucoma" . + . + . + . + "newly diagnosed with primary open - angle glaucoma" . +# RDF export of group: Endpoint + . + "Endpoint 65769 IOP" . + . + . + . + . + . + . + . + "Endpoint 65774 tear secretion" . + . + . + . + . + . + . + "Endpoint 65779 tear break up time" . + . + . + . + . + . + . + "Endpoint 65784 Eye burning" . + . + . + . + . + . + . + "Endpoint 65789 burning sensation" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 65992 DTFC" . + . + . + . + . + . + . + "Arm 66001 BTFC" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 65808 DTFC" . + . + . + "2  ×  1" . + . + "Intervention 65814 BTFC" . + . + "2  ×  1" . + . +# RDF export of group: Medication + . + "Medication 65794 DTFC" . + . + . + . + . + "Medication 65801 BTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 65821 DTFC" . + . + "24 . 1" . + "1 . 8" . + "17 . 1" . + "2 . 9" . + "P  =  0 . 0000" . + "Both medications reduced IOP values significantly" . + . + "Outcome 65848 BTFC" . + . + "24 . 6" . + "2 . 4" . + "16 . 9" . + "2 . 5" . + "P  =  0 . 0000" . + "Both medications reduced IOP values significantly" . + "4   weeks" . + . + "Outcome 65875 tear break up time" . + . + "P  =  0 . 0000" . + "Both combinations significantly reduced the amount of" . + . + "Outcome 65902 tear secretion" . + . + "P  =  0 . 0000" . + "Both combinations significantly reduced the amount of" . + . + "Outcome 65929 eye burning DTFC" . + . + "Eye burning was more common with DTFC than with BTFC" . + . + "Outcome 102348 eye burning BTFC" . + . + "Eye burning was more common with DTFC than with BTFC" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 65983" . + " =  0 . 0182" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22207522_export.csv b/data/gl 22207522_export.csv new file mode 100644 index 0000000..08feeed --- /dev/null +++ b/data/gl 22207522_export.csv @@ -0,0 +1,471 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +509, 1, 1, 1, 0, 3, 0, 3, "Int" +509, 1, 2, 2, 4, 14, 4, 14, "Ophthalmol" +509, 1, 3, 3, 15, 16, 15, 16, "." +509, 2, 1, 4, 0, 4, 17, 21, "2011" +509, 2, 2, 5, 5, 8, 22, 25, "Dec" +509, 2, 3, 6, 9, 10, 26, 27, ";" +509, 2, 4, 7, 11, 13, 28, 30, "31" +509, 2, 5, 8, 14, 15, 31, 32, "(" +509, 2, 6, 9, 16, 17, 33, 34, "6" +509, 2, 7, 10, 18, 19, 35, 36, ")" +509, 2, 8, 11, 20, 21, 37, 38, ":" +509, 2, 9, 12, 22, 25, 39, 42, "447" +509, 2, 10, 13, 26, 27, 43, 44, "-" +509, 2, 11, 14, 28, 30, 45, 47, "51" +509, 2, 12, 15, 31, 32, 48, 49, "." +509, 2, 13, 16, 33, 36, 50, 53, "doi" +509, 2, 14, 17, 37, 38, 54, 55, ":" +509, 2, 15, 18, 39, 41, 56, 58, "10" +509, 2, 16, 19, 42, 43, 59, 60, "." +509, 2, 17, 20, 44, 48, 61, 65, "1007" +509, 2, 18, 21, 49, 50, 66, 67, "/" +509, 2, 19, 22, 51, 57, 68, 74, "s10792" +509, 2, 20, 23, 58, 59, 75, 76, "-" +509, 2, 21, 24, 60, 63, 77, 80, "011" +509, 2, 22, 25, 64, 65, 81, 82, "-" +509, 2, 23, 26, 66, 70, 83, 87, "9495" +509, 2, 24, 27, 71, 72, 88, 89, "-" +509, 2, 25, 28, 73, 74, 90, 91, "z" +509, 2, 26, 29, 75, 76, 92, 93, "." +509, 3, 1, 30, 0, 4, 94, 98, "Epub" +509, 3, 2, 31, 5, 9, 99, 103, "2011" +509, 3, 3, 32, 10, 13, 104, 107, "Dec" +509, 3, 4, 33, 14, 16, 108, 110, "30" +509, 3, 5, 34, 17, 18, 111, 112, "." +509, 4, 1, 35, 0, 10, 113, 123, "Comparison" +509, 4, 2, 36, 11, 13, 124, 126, "of" +509, 4, 3, 37, 14, 19, 127, 132, "fixed" +509, 4, 4, 38, 20, 32, 133, 145, "combinations" +509, 4, 5, 39, 33, 35, 146, 148, "of" +509, 4, 6, 40, 36, 47, 149, 160, "dorzolamide" +509, 4, 7, 41, 48, 49, 161, 162, "/" +509, 4, 8, 42, 50, 57, 163, 170, "timolol" +509, 4, 9, 43, 58, 61, 171, 174, "and" +509, 4, 10, 44, 62, 73, 175, 186, "brimonidine" +509, 4, 11, 45, 74, 75, 187, 188, "/" +509, 4, 12, 46, 76, 83, 189, 196, "timolol" +509, 4, 13, 47, 84, 86, 197, 199, "in" +509, 4, 14, 48, 87, 95, 200, 208, "patients" +509, 4, 15, 49, 96, 100, 209, 213, "with" +509, 4, 16, 50, 101, 108, 214, 221, "primary" +509, 4, 17, 51, 109, 113, 222, 226, "open" +509, 4, 18, 52, 114, 115, 227, 228, "-" +509, 4, 19, 53, 116, 121, 229, 234, "angle" +509, 4, 20, 54, 122, 130, 235, 243, "glaucoma" +509, 4, 21, 55, 131, 132, 244, 245, "." +509, 5, 1, 56, 0, 8, 246, 254, "Gulkilik" +509, 5, 2, 57, 9, 10, 255, 256, "G" +509, 5, 3, 58, 11, 12, 257, 258, "(" +509, 5, 4, 59, 13, 14, 259, 260, "1" +509, 5, 5, 60, 15, 16, 261, 262, ")" +509, 5, 6, 61, 17, 18, 263, 264, "," +509, 5, 7, 62, 19, 22, 265, 268, "Oba" +509, 5, 8, 63, 23, 24, 269, 270, "E" +509, 5, 9, 64, 25, 26, 271, 272, "," +509, 5, 10, 65, 27, 33, 273, 279, "Odabas" +509, 5, 11, 66, 34, 35, 280, 281, "ı" +509, 5, 12, 67, 36, 37, 282, 283, "M" +509, 5, 13, 68, 38, 39, 284, 285, "." +509, 5, 14, 69, 40, 46, 286, 292, "Author" +509, 5, 15, 70, 47, 58, 293, 304, "information" +509, 5, 16, 71, 59, 60, 305, 306, ":" +509, 5, 17, 72, 61, 62, 307, 308, "(" +509, 5, 18, 73, 63, 64, 309, 310, "1" +509, 5, 19, 74, 65, 66, 311, 312, ")" +509, 5, 20, 75, 67, 72, 313, 318, "Sisli" +509, 5, 21, 76, 73, 78, 319, 324, "Etfal" +509, 5, 22, 77, 79, 87, 325, 333, "Training" +509, 5, 23, 78, 88, 91, 334, 337, "and" +509, 5, 24, 79, 92, 100, 338, 346, "Research" +509, 5, 25, 80, 101, 109, 347, 355, "Hospital" +509, 5, 26, 81, 110, 111, 356, 357, "," +509, 5, 27, 82, 112, 120, 358, 366, "Istanbul" +509, 5, 28, 83, 121, 122, 367, 368, "," +509, 5, 29, 84, 123, 129, 369, 375, "Turkey" +509, 5, 30, 85, 130, 131, 376, 377, "." +509, 6, 1, 86, 0, 1, 378, 379, "g" +509, 6, 2, 87, 2, 3, 380, 381, "." +509, 6, 3, 88, 4, 12, 382, 390, "gulkilik" +509, 6, 4, 89, 13, 14, 391, 392, "@" +509, 6, 5, 90, 15, 20, 393, 398, "gmail" +509, 6, 6, 91, 21, 22, 399, 400, "." +509, 6, 7, 92, 23, 26, 401, 404, "com" +509, 6, 8, 93, 27, 29, 405, 407, "To" +509, 6, 9, 94, 30, 37, 408, 415, "compare" +509, 6, 10, 95, 38, 41, 416, 419, "the" +509, 6, 11, 96, 42, 47, 420, 425, "short" +509, 6, 12, 97, 48, 49, 426, 427, "-" +509, 6, 13, 98, 50, 54, 428, 432, "term" +509, 6, 14, 99, 55, 68, 433, 446, "effectiveness" +509, 6, 15, 100, 69, 72, 447, 450, "and" +509, 6, 16, 101, 73, 79, 451, 457, "ocular" +509, 6, 17, 102, 80, 84, 458, 462, "side" +509, 6, 18, 103, 85, 86, 463, 464, "-" +509, 6, 19, 104, 87, 94, 465, 472, "effects" +509, 6, 20, 105, 95, 97, 473, 475, "of" +509, 6, 21, 106, 98, 103, 476, 481, "fixed" +509, 6, 22, 107, 104, 116, 482, 494, "combinations" +509, 6, 23, 108, 117, 119, 495, 497, "of" +509, 6, 24, 109, 120, 131, 498, 509, "dorzolamide" +509, 6, 25, 110, 132, 133, 510, 511, "/" +509, 6, 26, 111, 134, 141, 512, 519, "timolol" +509, 6, 27, 112, 142, 143, 520, 521, "(" +509, 6, 28, 113, 144, 148, 522, 526, "DTFC" +509, 6, 29, 114, 149, 150, 527, 528, ")" +509, 6, 30, 115, 151, 154, 529, 532, "and" +509, 6, 31, 116, 155, 166, 533, 544, "brimonidine" +509, 6, 32, 117, 167, 168, 545, 546, "/" +509, 6, 33, 118, 169, 176, 547, 554, "timolol" +509, 6, 34, 119, 177, 178, 555, 556, "(" +509, 6, 35, 120, 179, 183, 557, 561, "BTFC" +509, 6, 36, 121, 184, 185, 562, 563, ")" +509, 6, 37, 122, 186, 188, 564, 566, "in" +509, 6, 38, 123, 189, 197, 567, 575, "patients" +509, 6, 39, 124, 198, 202, 576, 580, "with" +509, 6, 40, 125, 203, 210, 581, 588, "primary" +509, 6, 41, 126, 211, 215, 589, 593, "open" +509, 6, 42, 127, 216, 217, 594, 595, "-" +509, 6, 43, 128, 218, 223, 596, 601, "angle" +509, 6, 44, 129, 224, 232, 602, 610, "glaucoma" +509, 6, 45, 130, 233, 234, 611, 612, "(" +509, 6, 46, 131, 235, 239, 613, 617, "POAG" +509, 6, 47, 132, 240, 241, 618, 619, ")" +509, 6, 48, 133, 242, 243, 620, 621, "." +509, 7, 1, 134, 0, 5, 622, 627, "Forty" +509, 7, 2, 135, 6, 7, 628, 629, "-" +509, 7, 3, 136, 8, 11, 630, 633, "two" +509, 7, 4, 137, 12, 16, 634, 638, "eyes" +509, 7, 5, 138, 17, 19, 639, 641, "of" +509, 7, 6, 139, 20, 22, 642, 644, "42" +509, 7, 7, 140, 23, 31, 645, 653, "patients" +509, 7, 8, 141, 32, 37, 654, 659, "newly" +509, 7, 9, 142, 38, 47, 660, 669, "diagnosed" +509, 7, 10, 143, 48, 52, 670, 674, "with" +509, 7, 11, 144, 53, 60, 675, 682, "primary" +509, 7, 12, 145, 61, 65, 683, 687, "open" +509, 7, 13, 146, 66, 67, 688, 689, "-" +509, 7, 14, 147, 68, 73, 690, 695, "angle" +509, 7, 15, 148, 74, 82, 696, 704, "glaucoma" +509, 7, 16, 149, 83, 87, 705, 709, "were" +509, 7, 17, 150, 88, 96, 710, 718, "assessed" +509, 7, 18, 151, 97, 110, 719, 732, "prospectively" +509, 7, 19, 152, 111, 112, 733, 734, "." +509, 8, 1, 153, 0, 3, 735, 738, "One" +509, 8, 2, 154, 4, 6, 739, 741, "of" +509, 8, 3, 155, 7, 10, 742, 745, "the" +509, 8, 4, 156, 11, 14, 746, 749, "two" +509, 8, 5, 157, 15, 19, 750, 754, "eyes" +509, 8, 6, 158, 20, 23, 755, 758, "was" +509, 8, 7, 159, 24, 30, 759, 765, "chosen" +509, 8, 8, 160, 31, 39, 766, 774, "randomly" +509, 8, 9, 161, 40, 43, 775, 778, "and" +509, 8, 10, 162, 44, 51, 779, 786, "treated" +509, 8, 11, 163, 52, 56, 787, 791, "with" +509, 8, 12, 164, 57, 61, 792, 796, "DTFC" +509, 8, 13, 165, 62, 63, 797, 798, "(" +509, 8, 14, 166, 64, 65, 799, 800, "2" +509, 8, 15, 167, 66, 69, 801, 804, " × " +509, 8, 16, 168, 70, 71, 805, 806, "1" +509, 8, 17, 169, 72, 73, 807, 808, ")" +509, 8, 18, 170, 74, 77, 809, 812, "for" +509, 8, 19, 171, 78, 79, 813, 814, "4" +509, 8, 20, 172, 80, 81, 815, 816, " " +509, 8, 21, 173, 82, 87, 817, 822, "weeks" +509, 8, 22, 174, 88, 89, 823, 824, "." +509, 9, 1, 175, 0, 3, 825, 828, "The" +509, 9, 2, 176, 4, 13, 829, 838, "treatment" +509, 9, 3, 177, 14, 17, 839, 842, "was" +509, 9, 4, 178, 18, 22, 843, 847, "then" +509, 9, 5, 179, 23, 30, 848, 855, "stopped" +509, 9, 6, 180, 31, 33, 856, 858, "to" +509, 9, 7, 181, 34, 39, 859, 864, "allow" +509, 9, 8, 182, 40, 41, 865, 866, "a" +509, 9, 9, 183, 42, 43, 867, 868, "4" +509, 9, 10, 184, 44, 45, 869, 870, "-" +509, 9, 11, 185, 46, 50, 871, 875, "week" +509, 9, 12, 186, 51, 55, 876, 880, "wash" +509, 9, 13, 187, 56, 57, 881, 882, "-" +509, 9, 14, 188, 58, 61, 883, 886, "out" +509, 9, 15, 189, 62, 68, 887, 893, "period" +509, 9, 16, 190, 69, 70, 894, 895, "." +509, 10, 1, 191, 0, 9, 896, 905, "Following" +509, 10, 2, 192, 10, 13, 906, 909, "the" +509, 10, 3, 193, 14, 18, 910, 914, "wash" +509, 10, 4, 194, 19, 20, 915, 916, "-" +509, 10, 5, 195, 21, 24, 917, 920, "out" +509, 10, 6, 196, 25, 31, 921, 927, "period" +509, 10, 7, 197, 32, 33, 928, 929, "," +509, 10, 8, 198, 34, 37, 930, 933, "the" +509, 10, 9, 199, 38, 42, 934, 938, "same" +509, 10, 10, 200, 43, 46, 939, 942, "eye" +509, 10, 11, 201, 47, 50, 943, 946, "was" +509, 10, 12, 202, 51, 58, 947, 954, "treated" +509, 10, 13, 203, 59, 63, 955, 959, "with" +509, 10, 14, 204, 64, 68, 960, 964, "BTFC" +509, 10, 15, 205, 69, 70, 965, 966, "(" +509, 10, 16, 206, 71, 72, 967, 968, "2" +509, 10, 17, 207, 73, 76, 969, 972, " × " +509, 10, 18, 208, 77, 78, 973, 974, "1" +509, 10, 19, 209, 79, 80, 975, 976, ")" +509, 10, 20, 210, 81, 84, 977, 980, "for" +509, 10, 21, 211, 85, 86, 981, 982, "4" +509, 10, 22, 212, 87, 88, 983, 984, " " +509, 10, 23, 213, 89, 94, 985, 990, "weeks" +509, 10, 24, 214, 95, 96, 991, 992, "." +509, 11, 1, 215, 0, 11, 993, 1004, "Intraocular" +509, 11, 2, 216, 12, 20, 1005, 1013, "pressure" +509, 11, 3, 217, 21, 22, 1014, 1015, "(" +509, 11, 4, 218, 23, 26, 1016, 1019, "IOP" +509, 11, 5, 219, 27, 28, 1020, 1021, ")" +509, 11, 6, 220, 29, 35, 1022, 1028, "values" +509, 11, 7, 221, 36, 40, 1029, 1033, "were" +509, 11, 8, 222, 41, 49, 1034, 1042, "measured" +509, 11, 9, 223, 50, 56, 1043, 1049, "before" +509, 11, 10, 224, 57, 60, 1050, 1053, "and" +509, 11, 11, 225, 61, 66, 1054, 1059, "after" +509, 11, 12, 226, 67, 71, 1060, 1064, "each" +509, 11, 13, 227, 72, 81, 1065, 1074, "treatment" +509, 11, 14, 228, 82, 84, 1075, 1077, "at" +509, 11, 15, 229, 85, 89, 1078, 1082, "0800" +509, 11, 16, 230, 90, 91, 1083, 1084, "," +509, 11, 17, 231, 92, 93, 1085, 1086, "1" +509, 11, 18, 232, 94, 95, 1087, 1088, "," +509, 11, 19, 233, 96, 99, 1089, 1092, "200" +509, 11, 20, 234, 100, 103, 1093, 1096, "and" +509, 11, 21, 235, 104, 105, 1097, 1098, "1" +509, 11, 22, 236, 106, 107, 1099, 1100, "," +509, 11, 23, 237, 108, 111, 1101, 1104, "600" +509, 11, 24, 238, 112, 113, 1105, 1106, " " +509, 11, 25, 239, 114, 115, 1107, 1108, "h" +509, 11, 26, 240, 116, 117, 1109, 1110, "." +509, 11, 27, 241, 118, 122, 1111, 1115, "Tear" +509, 11, 28, 242, 123, 131, 1116, 1124, "function" +509, 11, 29, 243, 132, 136, 1125, 1129, "test" +509, 11, 30, 244, 137, 144, 1130, 1137, "results" +509, 11, 31, 245, 145, 148, 1138, 1141, "and" +509, 11, 32, 246, 149, 155, 1142, 1148, "ocular" +509, 11, 33, 247, 156, 160, 1149, 1153, "side" +509, 11, 34, 248, 161, 162, 1154, 1155, "-" +509, 11, 35, 249, 163, 170, 1156, 1163, "effects" +509, 11, 36, 250, 171, 175, 1164, 1168, "were" +509, 11, 37, 251, 176, 180, 1169, 1173, "also" +509, 11, 38, 252, 181, 189, 1174, 1182, "recorded" +509, 11, 39, 253, 190, 191, 1183, 1184, "." +509, 12, 1, 254, 0, 3, 1185, 1188, "The" +509, 12, 2, 255, 4, 8, 1189, 1193, "mean" +509, 12, 3, 256, 9, 17, 1194, 1202, "baseline" +509, 12, 4, 257, 18, 21, 1203, 1206, "IOP" +509, 12, 5, 258, 22, 28, 1207, 1213, "values" +509, 12, 6, 259, 29, 32, 1214, 1217, "for" +509, 12, 7, 260, 33, 37, 1218, 1222, "DTFC" +509, 12, 8, 261, 38, 41, 1223, 1226, "and" +509, 12, 9, 262, 42, 46, 1227, 1231, "BTFC" +509, 12, 10, 263, 47, 51, 1232, 1236, "were" +509, 12, 11, 264, 52, 54, 1237, 1239, "24" +509, 12, 12, 265, 55, 56, 1240, 1241, "." +509, 12, 13, 266, 57, 58, 1242, 1243, "1" +509, 12, 14, 267, 59, 62, 1244, 1247, " ± " +509, 12, 15, 268, 63, 64, 1248, 1249, "1" +509, 12, 16, 269, 65, 66, 1250, 1251, "." +509, 12, 17, 270, 67, 68, 1252, 1253, "8" +509, 12, 18, 271, 69, 72, 1254, 1257, "and" +509, 12, 19, 272, 73, 75, 1258, 1260, "24" +509, 12, 20, 273, 76, 77, 1261, 1262, "." +509, 12, 21, 274, 78, 79, 1263, 1264, "6" +509, 12, 22, 275, 80, 83, 1265, 1268, " ± " +509, 12, 23, 276, 84, 85, 1269, 1270, "2" +509, 12, 24, 277, 86, 87, 1271, 1272, "." +509, 12, 25, 278, 88, 89, 1273, 1274, "4" +509, 12, 26, 279, 90, 91, 1275, 1276, " " +509, 12, 27, 280, 92, 96, 1277, 1281, "mmHg" +509, 12, 28, 281, 97, 98, 1282, 1283, "," +509, 12, 29, 282, 99, 111, 1284, 1296, "respectively" +509, 12, 30, 283, 112, 113, 1297, 1298, "." +509, 13, 1, 284, 0, 3, 1299, 1302, "The" +509, 13, 2, 285, 4, 8, 1303, 1307, "mean" +509, 13, 3, 286, 9, 12, 1308, 1311, "IOP" +509, 13, 4, 287, 13, 19, 1312, 1318, "values" +509, 13, 5, 288, 20, 25, 1319, 1324, "after" +509, 13, 6, 289, 26, 27, 1325, 1326, "4" +509, 13, 7, 290, 28, 29, 1327, 1328, " " +509, 13, 8, 291, 30, 35, 1329, 1334, "weeks" +509, 13, 9, 292, 36, 38, 1335, 1337, "of" +509, 13, 10, 293, 39, 48, 1338, 1347, "treatment" +509, 13, 11, 294, 49, 53, 1348, 1352, "with" +509, 13, 12, 295, 54, 58, 1353, 1357, "DTFC" +509, 13, 13, 296, 59, 61, 1358, 1360, "or" +509, 13, 14, 297, 62, 66, 1361, 1365, "BTFC" +509, 13, 15, 298, 67, 71, 1366, 1370, "were" +509, 13, 16, 299, 72, 74, 1371, 1373, "17" +509, 13, 17, 300, 75, 76, 1374, 1375, "." +509, 13, 18, 301, 77, 78, 1376, 1377, "1" +509, 13, 19, 302, 79, 82, 1378, 1381, " ± " +509, 13, 20, 303, 83, 84, 1382, 1383, "2" +509, 13, 21, 304, 85, 86, 1384, 1385, "." +509, 13, 22, 305, 87, 88, 1386, 1387, "9" +509, 13, 23, 306, 89, 92, 1388, 1391, "and" +509, 13, 24, 307, 93, 95, 1392, 1394, "16" +509, 13, 25, 308, 96, 97, 1395, 1396, "." +509, 13, 26, 309, 98, 99, 1397, 1398, "9" +509, 13, 27, 310, 100, 103, 1399, 1402, " ± " +509, 13, 28, 311, 104, 105, 1403, 1404, "2" +509, 13, 29, 312, 106, 107, 1405, 1406, "." +509, 13, 30, 313, 108, 109, 1407, 1408, "5" +509, 13, 31, 314, 110, 111, 1409, 1410, " " +509, 13, 32, 315, 112, 116, 1411, 1415, "mmHg" +509, 13, 33, 316, 117, 118, 1416, 1417, "," +509, 13, 34, 317, 119, 131, 1418, 1430, "respectively" +509, 13, 35, 318, 132, 133, 1431, 1432, "." +509, 14, 1, 319, 0, 4, 1433, 1437, "Both" +509, 14, 2, 320, 5, 16, 1438, 1449, "medications" +509, 14, 3, 321, 17, 24, 1450, 1457, "reduced" +509, 14, 4, 322, 25, 28, 1458, 1461, "IOP" +509, 14, 5, 323, 29, 35, 1462, 1468, "values" +509, 14, 6, 324, 36, 49, 1469, 1482, "significantly" +509, 14, 7, 325, 50, 51, 1483, 1484, "(" +509, 14, 8, 326, 52, 53, 1485, 1486, "P" +509, 14, 9, 327, 54, 57, 1487, 1490, " = " +509, 14, 10, 328, 58, 59, 1491, 1492, "0" +509, 14, 11, 329, 60, 61, 1493, 1494, "." +509, 14, 12, 330, 62, 66, 1495, 1499, "0000" +509, 14, 13, 331, 67, 68, 1500, 1501, ")" +509, 14, 14, 332, 69, 70, 1502, 1503, "." +509, 15, 1, 333, 0, 3, 1504, 1507, "The" +509, 15, 2, 334, 4, 17, 1508, 1521, "effectiveness" +509, 15, 3, 335, 18, 20, 1522, 1524, "of" +509, 15, 4, 336, 21, 25, 1525, 1529, "both" +509, 15, 5, 337, 26, 37, 1530, 1541, "medications" +509, 15, 6, 338, 38, 41, 1542, 1545, "was" +509, 15, 7, 339, 42, 49, 1546, 1553, "similar" +509, 15, 8, 340, 50, 51, 1554, 1555, "(" +509, 15, 9, 341, 52, 53, 1556, 1557, "P" +509, 15, 10, 342, 54, 57, 1558, 1561, " = " +509, 15, 11, 343, 58, 59, 1562, 1563, "0" +509, 15, 12, 344, 60, 61, 1564, 1565, "." +509, 15, 13, 345, 62, 66, 1566, 1570, "7363" +509, 15, 14, 346, 67, 68, 1571, 1572, ")" +509, 15, 15, 347, 69, 70, 1573, 1574, "." +509, 16, 1, 348, 0, 4, 1575, 1579, "Both" +509, 16, 2, 349, 5, 17, 1580, 1592, "combinations" +509, 16, 3, 350, 18, 31, 1593, 1606, "significantly" +509, 16, 4, 351, 32, 39, 1607, 1614, "reduced" +509, 16, 5, 352, 40, 43, 1615, 1618, "the" +509, 16, 6, 353, 44, 50, 1619, 1625, "amount" +509, 16, 7, 354, 51, 53, 1626, 1628, "of" +509, 16, 8, 355, 54, 58, 1629, 1633, "tear" +509, 16, 9, 356, 59, 68, 1634, 1643, "secretion" +509, 16, 10, 357, 69, 72, 1644, 1647, "and" +509, 16, 11, 358, 73, 77, 1648, 1652, "tear" +509, 16, 12, 359, 78, 83, 1653, 1658, "break" +509, 16, 13, 360, 84, 85, 1659, 1660, "-" +509, 16, 14, 361, 86, 88, 1661, 1663, "up" +509, 16, 15, 362, 89, 93, 1664, 1668, "time" +509, 16, 16, 363, 94, 95, 1669, 1670, "(" +509, 16, 17, 364, 96, 97, 1671, 1672, "P" +509, 16, 18, 365, 98, 101, 1673, 1676, " = " +509, 16, 19, 366, 102, 103, 1677, 1678, "0" +509, 16, 20, 367, 104, 105, 1679, 1680, "." +509, 16, 21, 368, 106, 110, 1681, 1685, "0000" +509, 16, 22, 369, 111, 112, 1686, 1687, ")" +509, 16, 23, 370, 113, 114, 1688, 1689, "." +509, 17, 1, 371, 0, 3, 1690, 1693, "Eye" +509, 17, 2, 372, 4, 11, 1694, 1701, "burning" +509, 17, 3, 373, 12, 15, 1702, 1705, "was" +509, 17, 4, 374, 16, 20, 1706, 1710, "more" +509, 17, 5, 375, 21, 27, 1711, 1717, "common" +509, 17, 6, 376, 28, 32, 1718, 1722, "with" +509, 17, 7, 377, 33, 37, 1723, 1727, "DTFC" +509, 17, 8, 378, 38, 42, 1728, 1732, "than" +509, 17, 9, 379, 43, 47, 1733, 1737, "with" +509, 17, 10, 380, 48, 52, 1738, 1742, "BTFC" +509, 17, 11, 381, 53, 54, 1743, 1744, "(" +509, 17, 12, 382, 55, 56, 1745, 1746, "P" +509, 17, 13, 383, 57, 60, 1747, 1750, " = " +509, 17, 14, 384, 61, 62, 1751, 1752, "0" +509, 17, 15, 385, 63, 64, 1753, 1754, "." +509, 17, 16, 386, 65, 69, 1755, 1759, "0182" +509, 17, 17, 387, 70, 71, 1760, 1761, ")" +509, 17, 18, 388, 72, 73, 1762, 1763, "." +509, 18, 1, 389, 0, 5, 1764, 1769, "Other" +509, 18, 2, 390, 6, 13, 1770, 1777, "adverse" +509, 18, 3, 391, 14, 21, 1778, 1785, "effects" +509, 18, 4, 392, 22, 26, 1786, 1790, "were" +509, 18, 5, 393, 27, 35, 1791, 1799, "observed" +509, 18, 6, 394, 36, 38, 1800, 1802, "at" +509, 18, 7, 395, 39, 46, 1803, 1810, "similar" +509, 18, 8, 396, 47, 52, 1811, 1816, "rates" +509, 18, 9, 397, 53, 56, 1817, 1820, "for" +509, 18, 10, 398, 57, 61, 1821, 1825, "both" +509, 18, 11, 399, 62, 74, 1826, 1838, "combinations" +509, 18, 12, 400, 75, 76, 1839, 1840, "." +509, 19, 1, 401, 0, 4, 1841, 1845, "This" +509, 19, 2, 402, 5, 10, 1846, 1851, "study" +509, 19, 3, 403, 11, 23, 1852, 1864, "demonstrated" +509, 19, 4, 404, 24, 28, 1865, 1869, "that" +509, 19, 5, 405, 29, 32, 1870, 1873, "the" +509, 19, 6, 406, 33, 36, 1874, 1877, "IOP" +509, 19, 7, 407, 37, 38, 1878, 1879, "-" +509, 19, 8, 408, 39, 47, 1880, 1888, "reducing" +509, 19, 9, 409, 48, 55, 1889, 1896, "effects" +509, 19, 10, 410, 56, 58, 1897, 1899, "of" +509, 19, 11, 411, 59, 63, 1900, 1904, "DTFC" +509, 19, 12, 412, 64, 67, 1905, 1908, "and" +509, 19, 13, 413, 68, 72, 1909, 1913, "BTFC" +509, 19, 14, 414, 73, 75, 1914, 1916, "in" +509, 19, 15, 415, 76, 84, 1917, 1925, "patients" +509, 19, 16, 416, 85, 89, 1926, 1930, "with" +509, 19, 17, 417, 90, 94, 1931, 1935, "POAG" +509, 19, 18, 418, 95, 98, 1936, 1939, "are" +509, 19, 19, 419, 99, 106, 1940, 1947, "similar" +509, 19, 20, 420, 107, 108, 1948, 1949, "." +509, 20, 1, 421, 0, 3, 1950, 1953, "The" +509, 20, 2, 422, 4, 8, 1954, 1958, "side" +509, 20, 3, 423, 9, 10, 1959, 1960, "-" +509, 20, 4, 424, 11, 17, 1961, 1967, "effect" +509, 20, 5, 425, 18, 25, 1968, 1975, "profile" +509, 20, 6, 426, 26, 28, 1976, 1978, "of" +509, 20, 7, 427, 29, 33, 1979, 1983, "BTFC" +509, 20, 8, 428, 34, 36, 1984, 1986, "is" +509, 20, 9, 429, 37, 44, 1987, 1994, "similar" +509, 20, 10, 430, 45, 47, 1995, 1997, "to" +509, 20, 11, 431, 48, 52, 1998, 2002, "that" +509, 20, 12, 432, 53, 55, 2003, 2005, "of" +509, 20, 13, 433, 56, 60, 2006, 2010, "DTFC" +509, 20, 14, 434, 61, 62, 2011, 2012, "." +509, 21, 1, 435, 0, 5, 2013, 2018, "Lower" +509, 21, 2, 436, 6, 16, 2019, 2029, "occurrence" +509, 21, 3, 437, 17, 19, 2030, 2032, "of" +509, 21, 4, 438, 20, 21, 2033, 2034, "a" +509, 21, 5, 439, 22, 29, 2035, 2042, "burning" +509, 21, 6, 440, 30, 39, 2043, 2052, "sensation" +509, 21, 7, 441, 40, 43, 2053, 2056, "may" +509, 21, 8, 442, 44, 51, 2057, 2064, "improve" +509, 21, 9, 443, 52, 59, 2065, 2072, "patient" +509, 21, 10, 444, 60, 70, 2073, 2083, "compliance" +509, 21, 11, 445, 71, 73, 2084, 2086, "in" +509, 21, 12, 446, 74, 77, 2087, 2090, "the" +509, 21, 13, 447, 78, 82, 2091, 2095, "BTFC" +509, 21, 14, 448, 83, 88, 2096, 2101, "group" +509, 21, 15, 449, 89, 90, 2102, 2103, "." +509, 22, 1, 450, 0, 3, 2104, 2107, "DOI" +509, 22, 2, 451, 4, 5, 2108, 2109, ":" +509, 22, 3, 452, 6, 8, 2110, 2112, "10" +509, 22, 4, 453, 9, 10, 2113, 2114, "." +509, 22, 5, 454, 11, 15, 2115, 2119, "1007" +509, 22, 6, 455, 16, 17, 2120, 2121, "/" +509, 22, 7, 456, 18, 24, 2122, 2128, "s10792" +509, 22, 8, 457, 25, 26, 2129, 2130, "-" +509, 22, 9, 458, 27, 30, 2131, 2134, "011" +509, 22, 10, 459, 31, 32, 2135, 2136, "-" +509, 22, 11, 460, 33, 37, 2137, 2141, "9495" +509, 22, 12, 461, 38, 39, 2142, 2143, "-" +509, 22, 13, 462, 40, 41, 2144, 2145, "z" +509, 22, 14, 463, 42, 46, 2146, 2150, "PMID" +509, 22, 15, 464, 47, 48, 2151, 2152, ":" +509, 22, 16, 465, 49, 57, 2153, 2161, "22207522" +509, 22, 17, 466, 58, 59, 2162, 2163, "[" +509, 22, 18, 467, 60, 67, 2164, 2171, "Indexed" +509, 22, 19, 468, 68, 71, 2172, 2175, "for" +509, 22, 20, 469, 72, 79, 2176, 2183, "MEDLINE" +509, 22, 21, 470, 80, 81, 2184, 2185, "]" diff --git a/data/gl 22207522_jshahinitiran.annodb b/data/gl 22207522_jshahinitiran.annodb new file mode 100644 index 0000000..70aa1d8 --- /dev/null +++ b/data/gl 22207522_jshahinitiran.annodb @@ -0,0 +1,71 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72512, Journal, 0, 14, "Int Ophthalmol", "", +72513, PublicationYear, 17, 21, "2011", "", +72514, Title, 113, 245, "Comparison of fixed combinations of dorzolamide / timolol and brimonidine / timolol in patients with primary open - angle glaucoma .", "", +72579, Dorzolamide, 149, 160, "dorzolamide", "", +72580, Timolol, 163, 170, "timolol", "", +72581, Brimonidine, 175, 186, "brimonidine", "", +72582, Timolol, 189, 196, "timolol", "", +72583, Primary_OpenAngleGlaucoma, 214, 243, "primary open - angle glaucoma", "", +72515, Author, 246, 256, "Gulkilik G", "", +72516, Author, 265, 270, "Oba E", "", +72517, Author, 273, 283, "Odabas ı M", "", +72518, Turkey, 369, 375, "Turkey", "", +72519, ObjectiveDescription, 405, 621, "To compare the short - term effectiveness and ocular side - effects of fixed combinations of dorzolamide / timolol ( DTFC ) and brimonidine / timolol ( BTFC ) in patients with primary open - angle glaucoma ( POAG ) .", "", +72522, Dorz/TimFC, 476, 519, "fixed combinations of dorzolamide / timolol", "", +72520, Dorzolamide, 498, 509, "dorzolamide", "", +72521, Timolol, 512, 519, "timolol", "", +72523, Dorz/TimFC, 522, 526, "DTFC", "", +72524, Brimonidine, 533, 544, "brimonidine", "", +72525, Timolol, 547, 554, "timolol", "", +72526, Brimo/TimFC, 557, 561, "BTFC", "", +72527, Primary_OpenAngleGlaucoma, 581, 610, "primary open - angle glaucoma", "", +72528, Primary_OpenAngleGlaucoma, 613, 617, "POAG", "", +72529, NumberPatientsCT, 622, 633, "Forty - two", "", +72530, Precondition, 654, 669, "newly diagnosed", "", +72531, Primary_OpenAngleGlaucoma, 675, 704, "primary open - angle glaucoma", "", +72532, Dorz/TimFC, 792, 796, "DTFC", "", +72533, Duration, 813, 822, "4   weeks", "", +72534, Duration, 867, 875, "4 - week", "", +72535, Brimo/TimFC, 960, 964, "BTFC", "", +72536, Duration, 981, 990, "4   weeks", "", +72537, IOP, 993, 1013, "Intraocular pressure", "", +72538, IOP, 1016, 1019, "IOP", "", +72539, Mean, 1189, 1193, "mean", "", +72540, IOP, 1203, 1206, "IOP", "", +72541, Dorz/TimFC, 1218, 1222, "DTFC", "", +72542, Brimo/TimFC, 1227, 1231, "BTFC", "", +72543, BaseLineValue, 1237, 1243, "24 . 1", "", +72545, SdErrorBL, 1248, 1253, "1 . 8", "", +72544, BaseLineValue, 1258, 1264, "24 . 6", "", +72546, SdErrorBL, 1269, 1274, "2 . 4", "", +72547, mmHg, 1277, 1281, "mmHg", "", +72548, Mean, 1303, 1307, "mean", "", +72549, IOP, 1308, 1311, "IOP", "", +72550, Duration, 1325, 1334, "4   weeks", "", +72551, Dorz/TimFC, 1353, 1357, "DTFC", "", +72552, Brimo/TimFC, 1361, 1365, "BTFC", "", +72553, ResultMeasuredValue, 1371, 1377, "17 . 1", "", +72555, SdErrorResValue, 1382, 1387, "2 . 9", "", +72554, ResultMeasuredValue, 1392, 1398, "16 . 9", "", +72556, SdErrorResValue, 1403, 1408, "2 . 5", "", +72557, mmHg, 1411, 1415, "mmHg", "", +72558, IOP, 1458, 1461, "IOP", "", +72559, PValueChangeValue, 1485, 1499, "P  =  0 . 0000", "", +72560, PValueResValue, 1556, 1570, "P  =  0 . 7363", "", +72578, PValueChangeValue, 1671, 1685, "P  =  0 . 0000", "", +72562, Dorz/TimFC, 1723, 1727, "DTFC", "", +72563, Brimo/TimFC, 1738, 1742, "BTFC", "", +72564, PValueNumAffected, 1745, 1759, "P  =  0 . 0182", "", +72565, ObservedResult, 1764, 1840, "Other adverse effects were observed at similar rates for both combinations .", "", +72574, ConclusionComment, 1841, 1949, "This study demonstrated that the IOP - reducing effects of DTFC and BTFC in patients with POAG are similar .", "", +72566, IOP, 1874, 1877, "IOP", "", +72567, Dorz/TimFC, 1900, 1904, "DTFC", "", +72568, Brimo/TimFC, 1909, 1913, "BTFC", "", +72569, Primary_OpenAngleGlaucoma, 1931, 1935, "POAG", "", +72575, ConclusionComment, 1950, 2012, "The side - effect profile of BTFC is similar to that of DTFC .", "", +72570, Brimo/TimFC, 1979, 1983, "BTFC", "", +72571, Dorz/TimFC, 2006, 2010, "DTFC", "", +72576, ConclusionComment, 2013, 2103, "Lower occurrence of a burning sensation may improve patient compliance in the BTFC group .", "", +72573, Brimo/TimFC, 2091, 2095, "BTFC", "", +72577, PMID, 2153, 2161, "22207522", "", diff --git a/data/gl 22207522_jshahinitiran.n-triples b/data/gl 22207522_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22207522_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22207522_tstrakeljahn.annodb b/data/gl 22207522_tstrakeljahn.annodb new file mode 100644 index 0000000..3d17796 --- /dev/null +++ b/data/gl 22207522_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +80829, Journal, 0, 14, "Int Ophthalmol", "", +80830, PublicationYear, 17, 21, "2011", "", +80838, Title, 113, 245, "Comparison of fixed combinations of dorzolamide / timolol and brimonidine / timolol in patients with primary open - angle glaucoma .", "", +80831, Dorzolamide, 149, 160, "dorzolamide", "", +80835, Dorz/TimFC, 149, 170, "dorzolamide / timolol", "", +80832, Timolol, 163, 170, "timolol", "", +80834, Brimonidine, 175, 186, "brimonidine", "", +80836, Brimo/TimFC, 175, 196, "brimonidine / timolol", "", +80833, Timolol, 189, 196, "timolol", "", +80837, Primary_OpenAngleGlaucoma, 214, 243, "primary open - angle glaucoma", "", +80839, Author, 246, 256, "Gulkilik G", "", +80840, Author, 265, 270, "Oba E", "", +80841, Author, 273, 283, "Odabas ı M", "", +80842, Turkey, 369, 375, "Turkey", "", +80856, ObjectiveDescription, 405, 621, "To compare the short - term effectiveness and ocular side - effects of fixed combinations of dorzolamide / timolol ( DTFC ) and brimonidine / timolol ( BTFC ) in patients with primary open - angle glaucoma ( POAG ) .", "", +80843, Dorzolamide, 498, 509, "dorzolamide", "", +80847, Dorz/TimFC, 498, 519, "dorzolamide / timolol", "", +80844, Timolol, 512, 519, "timolol", "", +80848, Dorz/TimFC, 522, 526, "DTFC", "", +80846, Brimonidine, 533, 544, "brimonidine", "", +80849, Dorz/TimFC, 533, 554, "brimonidine / timolol", "", +80845, Timolol, 547, 554, "timolol", "", +80850, Dorz/TimFC, 557, 561, "BTFC", "", +80851, Primary_OpenAngleGlaucoma, 581, 610, "primary open - angle glaucoma", "", +80852, Primary_OpenAngleGlaucoma, 613, 617, "POAG", "", +80853, NumberPatientsCT, 642, 644, "42", "", +80855, Precondition, 654, 704, "newly diagnosed with primary open - angle glaucoma", "", +80854, Primary_OpenAngleGlaucoma, 675, 704, "primary open - angle glaucoma", "", +80857, Dorz/TimFC, 792, 796, "DTFC", "", +80858, Frequency, 799, 806, "2  ×  1", "", +80860, Brimo/TimFC, 960, 964, "BTFC", "", +80859, Frequency, 967, 974, "2  ×  1", "", +80861, IOP, 993, 1013, "Intraocular pressure", "", +80862, IOP, 1016, 1019, "IOP", "", +80864, RelativeTime, 1043, 1074, "before and after each treatment", "", +80863, RelativeTime, 1054, 1074, "after each treatment", "", +80865, TimePoint, 1078, 1082, "0800", "", +80866, TimePoint, 1085, 1092, "1 , 200", "", +80867, TimePoint, 1097, 1104, "1 , 600", "", +80869, Mean, 1189, 1193, "mean", "", +80870, IOP, 1203, 1206, "IOP", "", +80871, Dorz/TimFC, 1218, 1222, "DTFC", "", +80872, Brimonidine, 1227, 1231, "BTFC", "", +80873, BaseLineValue, 1237, 1243, "24 . 1", "", +80875, SdDevBL, 1248, 1253, "1 . 8", "", +80874, BaseLineValue, 1258, 1264, "24 . 6", "", +80876, SdDevBL, 1269, 1274, "2 . 4", "", +80877, mmHg, 1277, 1281, "mmHg", "", +80878, Mean, 1303, 1307, "mean", "", +80879, IOP, 1308, 1311, "IOP", "", +80880, TimePoint, 1319, 1334, "after 4   weeks", "", +80881, Dorz/TimFC, 1353, 1357, "DTFC", "", +80882, Brimo/TimFC, 1361, 1365, "BTFC", "", +80883, ResultMeasuredValue, 1371, 1377, "17 . 1", "", +80885, SdDevResValue, 1382, 1387, "2 . 9", "", +80884, ResultMeasuredValue, 1392, 1398, "16 . 9", "", +80887, SdDevResValue, 1403, 1408, "2 . 5", "", +80888, mmHg, 1411, 1415, "mmHg", "", +80892, ObservedResult, 1433, 1482, "Both medications reduced IOP values significantly", "", +80889, IOP, 1458, 1461, "IOP", "", +80890, PValueResValue, 1487, 1499, " =  0 . 0000", "", +80893, ObservedResult, 1504, 1553, "The effectiveness of both medications was similar", "", +80891, PvalueDiff, 1558, 1570, " =  0 . 7363", "", +80894, ObservedResult, 1575, 1668, "Both combinations significantly reduced the amount of tear secretion and tear break - up time", "", +80907, ObservedResult, 1690, 1742, "Eye burning was more common with DTFC than with BTFC", "", +80897, Dorz/TimFC, 1723, 1727, "DTFC", "", +80900, Brimo/TimFC, 1738, 1742, "BTFC", "", +80895, PvalueDiff, 1747, 1759, " =  0 . 0182", "", +80908, ObservedResult, 1764, 1840, "Other adverse effects were observed at similar rates for both combinations .", "", +80909, ConclusionComment, 1841, 1949, "This study demonstrated that the IOP - reducing effects of DTFC and BTFC in patients with POAG are similar .", "", +80904, IOP, 1874, 1877, "IOP", "", +80898, Dorz/TimFC, 1900, 1904, "DTFC", "", +80901, Brimo/TimFC, 1909, 1913, "BTFC", "", +80903, Primary_OpenAngleGlaucoma, 1931, 1935, "POAG", "", +80910, ConclusionComment, 1950, 2012, "The side - effect profile of BTFC is similar to that of DTFC .", "", +80905, Brimo/TimFC, 1979, 1983, "BTFC", "", +80899, Dorz/TimFC, 2006, 2010, "DTFC", "", +80911, ConclusionComment, 2013, 2103, "Lower occurrence of a burning sensation may improve patient compliance in the BTFC group .", "", +80902, Brimo/TimFC, 2091, 2095, "BTFC", "", +80912, PMID, 2153, 2161, "22207522", "", diff --git a/data/gl 22207522_tstrakeljahn.n-triples b/data/gl 22207522_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22207522_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22320418_admin.annodb b/data/gl 22320418_admin.annodb new file mode 100644 index 0000000..de97033 --- /dev/null +++ b/data/gl 22320418_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2012", "", " \"2012\"." +2, Title, 112, 267, "Comparison of dorzolamide / timolol and latanoprost / timolol fixed combinations on diurnal intraocular pressure control in primary open - angle glaucoma .", "", " \"Comparison of dorzolamide / timolol and latanoprost / timolol fixed combinations on diurnal intraocular pressure control in primary open - angle glaucoma .\"." +96, Dorz/TimFC, 126, 147, "dorzolamide / timolol", "", +3, Dorzolamide, 126, 137, "dorzolamide", "", +4, Timolol, 140, 147, "timolol", "", +95, Lat/TimFC, 152, 173, "latanoprost / timolol", "", +5, Latanoprost, 152, 163, "latanoprost", "", +6, Timolol, 166, 173, "timolol", "", +7, Diurnal_IOP, 196, 224, "diurnal intraocular pressure", "", " ." +8, Primary_OpenAngleGlaucoma, 236, 265, "primary open - angle glaucoma", "", " ." +9, Author, 268, 275, "Eren MH", "", " \"Eren MH\"." +10, Author, 284, 292, "Gungel H", "", " \"Gungel H\"." +11, Author, 295, 302, "Altan C", "", " \"Altan C\"." +12, Author, 305, 316, "Pasaoglu IB", "", " \"Pasaoglu IB\"." +13, Author, 319, 330, "Sabanci S .", "", " \"Sabanci S .\"." +14, Turkey, 436, 442, "Turkey", "", " ." +15, ObjectiveDescription, 484, 684, "To compare the efficacy and safety of dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination ( DTFC ) with latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination ( LTFC )", "", " \"To compare the efficacy and safety of dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination ( DTFC ) with latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination ( LTFC )\"." +92036, Dorz/TimFC, 522, 595, "dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination", "", " ." +17, Dorzolamide, 522, 547, "dorzolamide hydrochloride", "", +19, DoseValue, 548, 549, "2", "", +105, Percentage, 550, 551, "%", "", +18, Timolol, 554, 569, "timolol maleate", "", +20, DoseValue, 570, 575, "0 . 5", "", +106, Percentage, 576, 577, "%", "", +21, Dorz/TimFC, 598, 602, "DTFC", "", +92044, Lat/TimFC, 610, 675, "latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination", "", " ." +22, Latanoprost, 610, 621, "latanoprost", "", +24, DoseValue, 622, 629, "0 . 005", "", +107, Percentage, 630, 631, "%", "", +23, Timolol, 634, 649, "timolol maleate", "", +25, DoseValue, 650, 655, "0 . 5", "", +108, Percentage, 656, 657, "%", "", +26, Lat/TimFC, 678, 682, "LTFC", "", +16, ObjectiveDescription, 685, 773, "on diurnal intraocular pressure ( IOP ) in patients with primary open - angle glaucoma .", "", " \"on diurnal intraocular pressure ( IOP ) in patients with primary open - angle glaucoma .\"." +111, Diurnal_IOP, 688, 716, "diurnal intraocular pressure", "", +112, IOP, 719, 722, "IOP", "", +113, Primary_OpenAngleGlaucoma, 742, 771, "primary open - angle glaucoma", "", +27, NumberPatientsCT, 784, 798, "Thirty - three", "", " \"Thirty - three\"." +28, Primary_OpenAngleGlaucoma, 799, 828, "primary open - angle glaucoma", "", +31, Precondition, 829, 885, "patients with IOP of 22 - 32   mmHg measured at any time", "", " \"patients with IOP of 22 - 32   mmHg measured at any time\"." +29, IOP, 843, 846, "IOP", "", +30, mmHg, 860, 864, "mmHg", "", +32, Randomized, 916, 926, "randomized", "", " ." +33, Dorz/TimFC, 937, 941, "DTFC", "", +34, Frequency, 942, 953, "twice daily", "", " \"twice daily\"." +35, Latanoprost, 957, 968, "latanoprost", "", +39, Lat/TimFC, 957, 1022, "latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination", "", +37, DoseValue, 969, 976, "0 . 005", "", +126, Percentage, 977, 978, "%", "", +36, Timolol, 981, 996, "timolol maleate", "", +38, DoseValue, 997, 1002, "0 . 5", "", +127, Percentage, 1003, 1004, "%", "", +40, Lat/TimFC, 1025, 1029, "LTFC", "", +41, Frequency, 1032, 1042, "once a day", "", " \"once a day\"." +42, Evening, 1050, 1057, "evening", "", " ." +43, Duration, 1068, 1076, "6 - week", "", " \"6 - week\". \"6 - week\". \"6 - week\"." +44, IOP, 1118, 1121, "IOP", "", +45, Duration, 1196, 1203, "6 weeks", "", +46, Duration, 1278, 1285, "6 weeks", "", +47, Mean, 1330, 1334, "mean", "", +48, IOP, 1344, 1347, "IOP", "", +49, BaseLineValue, 1352, 1359, "25 . 09", "", " \"25 . 09\". \"25 . 09\"." +137, SdDevBL, 1362, 1367, "2 . 8", "", " \"2 . 8\". \"2 . 8\"." +51, mmHg, 1370, 1374, "mmHg", "", +52, Mean, 1406, 1410, "mean", "", " . ." +53, Diurnal_IOP, 1411, 1422, "diurnal IOP", "", " . ." +54, Lat/TimFC, 1452, 1456, "LTFC", "", +55, ResultMeasuredValue, 1459, 1465, "16 . 3", "", " \"16 . 3\"." +57, mmHg, 1468, 1472, "mmHg", "", " ." +59, Dorz/TimFC, 1485, 1489, "DTFC", "", +56, ResultMeasuredValue, 1492, 1498, "17 . 3", "", " \"17 . 3\"." +58, mmHg, 1501, 1505, "mmHg", "", +60, Peak_IOP, 1518, 1526, "peak IOP", "", " ." +61, ResultMeasuredValue, 1537, 1543, "18 . 5", "", " \"18 . 5\"." +63, mmHg, 1546, 1550, "mmHg", "", " ." +65, Lat/TimFC, 1556, 1560, "LTFC", "", +62, ResultMeasuredValue, 1565, 1571, "19 . 9", "", " \"19 . 9\"." +151, SdDevResValue, 1574, 1579, "2 . 6", "", " \"2 . 6\"." +64, mmHg, 1582, 1586, "mmHg", "", +66, Dorz/TimFC, 1592, 1596, "DTFC", "", +152, PvalueDiff, 1601, 1609, "< 0 . 05", "", " \"< 0 . 05\"." +106408, ObservedResult, 1614, 1708, "No significant side effects were reported except stinging and bitter taste with the DTFC group", "", " \"No significant side effects were reported except stinging and bitter taste with the DTFC group\". \"No significant side effects were reported except stinging and bitter taste with the DTFC group\"." +92045, Stinging, 1663, 1671, "stinging", "", " ." +92046, EndPointDescription, 1676, 1688, "bitter taste", "", " . ." +71, Dorz/TimFC, 1698, 1702, "DTFC", "", +72, Mean, 1724, 1728, "Mean", "", +78, ConclusionComment, 1724, 1838, "Mean diurnal IOP and peak IOP were lower with LTFC than with DTFC in patients with primary open - angle glaucoma .", "", " \"Mean diurnal IOP and peak IOP were lower with LTFC than with DTFC in patients with primary open - angle glaucoma .\"." +73, Diurnal_IOP, 1729, 1740, "diurnal IOP", "", +74, Peak_IOP, 1745, 1753, "peak IOP", "", +75, Lat/TimFC, 1770, 1774, "LTFC", "", +76, Dorz/TimFC, 1785, 1789, "DTFC", "", +77, Primary_OpenAngleGlaucoma, 1807, 1836, "primary open - angle glaucoma", "", +79, PMID, 1882, 1890, "22320418", "", " \"22320418\"." diff --git a/data/gl 22320418_admin.n-triples b/data/gl 22320418_admin.n-triples new file mode 100644 index 0000000..0c64a48 --- /dev/null +++ b/data/gl 22320418_admin.n-triples @@ -0,0 +1,139 @@ +# RDF export of group: Publication + . + "Publication 66015" . + "Comparison of dorzolamide / timolol and latanoprost / timolol fixed combinations on diurnal intraocular pressure control in primary open - angle glaucoma ." . + "Eren MH" . + "2012" . + "J Ocul Pharmacol Ther ." . + "22320418" . + . + "Gungel H" . + "Altan C" . + "Pasaoglu IB" . + "Sabanci S ." . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 66027" . + "To compare the efficacy and safety of dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination ( DTFC ) with latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination ( LTFC )" . + "Thirty - three" . + "6 - week" . + . + . + . + "Mean diurnal IOP and peak IOP were lower with LTFC than with DTFC in patients with primary open - angle glaucoma ." . + . + . + . + . + . + "on diurnal intraocular pressure ( IOP ) in patients with primary open - angle glaucoma ." . + . +# RDF export of group: Population + . + "Population 66044" . + "patients with IOP of 22 - 32   mmHg measured at any time" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 66052 Diurnal IOP" . + . + . + . + . + . + . + "Endpoint 66057 peak IOP" . + . + . + . + . + . + "Endpoint 66062 stinging" . + . + . + . + . + . + "Endpoint 66067 bitter taste" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 66269 DTFC" . + . + . + . + . + . + . + "Arm 66278 LTFC" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 66257 DTFC" . + . + "twice daily" . + "6 - week" . + . + . + "Intervention 66263 LTFC" . + . + "once a day" . + "6 - week" . + . +# RDF export of group: Medication + . + "Medication 66243 DTFC" . + . + . + . + . + "Medication 66250 LTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 66072 LTFC" . + . + "25 . 09" . + "2 . 8" . + "16 . 3" . + . + "Outcome 66099 DTFC" . + . + "25 . 09" . + "2 . 8" . + "17 . 3" . + . + "Outcome 66126 LTFC peak IOP" . + . + "18 . 5" . + . + "Outcome 66153 DTFC peak IOP" . + . + "19 . 9" . + "2 . 6" . + . + "Outcome 66180 stinging" . + . + "No significant side effects were reported except stinging and bitter taste with the DTFC group" . + . + "Outcome 66207 bitter taste" . + . + "No significant side effects were reported except stinging and bitter taste with the DTFC group" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 66234" . + "< 0 . 05" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22320418_export.csv b/data/gl 22320418_export.csv new file mode 100644 index 0000000..b8bd2d2 --- /dev/null +++ b/data/gl 22320418_export.csv @@ -0,0 +1,414 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +508, 1, 1, 1, 0, 1, 0, 1, "J" +508, 1, 2, 2, 2, 6, 2, 6, "Ocul" +508, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +508, 1, 4, 4, 17, 21, 17, 21, "Ther" +508, 1, 5, 5, 22, 23, 22, 23, "." +508, 2, 1, 6, 0, 4, 24, 28, "2012" +508, 2, 2, 7, 5, 8, 29, 32, "Aug" +508, 2, 3, 8, 9, 10, 33, 34, ";" +508, 2, 4, 9, 11, 13, 35, 37, "28" +508, 2, 5, 10, 14, 15, 38, 39, "(" +508, 2, 6, 11, 16, 17, 40, 41, "4" +508, 2, 7, 12, 18, 19, 42, 43, ")" +508, 2, 8, 13, 20, 21, 44, 45, ":" +508, 2, 9, 14, 22, 25, 46, 49, "381" +508, 2, 10, 15, 26, 27, 50, 51, "-" +508, 2, 11, 16, 28, 29, 52, 53, "6" +508, 2, 12, 17, 30, 31, 54, 55, "." +508, 2, 13, 18, 32, 35, 56, 59, "doi" +508, 2, 14, 19, 36, 37, 60, 61, ":" +508, 2, 15, 20, 38, 40, 62, 64, "10" +508, 2, 16, 21, 41, 42, 65, 66, "." +508, 2, 17, 22, 43, 47, 67, 71, "1089" +508, 2, 18, 23, 48, 49, 72, 73, "/" +508, 2, 19, 24, 50, 53, 74, 77, "jop" +508, 2, 20, 25, 54, 55, 78, 79, "." +508, 2, 21, 26, 56, 60, 80, 84, "2011" +508, 2, 22, 27, 61, 62, 85, 86, "." +508, 2, 23, 28, 63, 67, 87, 91, "0105" +508, 2, 24, 29, 68, 69, 92, 93, "." +508, 3, 1, 30, 0, 4, 94, 98, "Epub" +508, 3, 2, 31, 5, 9, 99, 103, "2012" +508, 3, 3, 32, 10, 13, 104, 107, "Feb" +508, 3, 4, 33, 14, 15, 108, 109, "9" +508, 3, 5, 34, 16, 17, 110, 111, "." +508, 4, 1, 35, 0, 10, 112, 122, "Comparison" +508, 4, 2, 36, 11, 13, 123, 125, "of" +508, 4, 3, 37, 14, 25, 126, 137, "dorzolamide" +508, 4, 4, 38, 26, 27, 138, 139, "/" +508, 4, 5, 39, 28, 35, 140, 147, "timolol" +508, 4, 6, 40, 36, 39, 148, 151, "and" +508, 4, 7, 41, 40, 51, 152, 163, "latanoprost" +508, 4, 8, 42, 52, 53, 164, 165, "/" +508, 4, 9, 43, 54, 61, 166, 173, "timolol" +508, 4, 10, 44, 62, 67, 174, 179, "fixed" +508, 4, 11, 45, 68, 80, 180, 192, "combinations" +508, 4, 12, 46, 81, 83, 193, 195, "on" +508, 4, 13, 47, 84, 91, 196, 203, "diurnal" +508, 4, 14, 48, 92, 103, 204, 215, "intraocular" +508, 4, 15, 49, 104, 112, 216, 224, "pressure" +508, 4, 16, 50, 113, 120, 225, 232, "control" +508, 4, 17, 51, 121, 123, 233, 235, "in" +508, 4, 18, 52, 124, 131, 236, 243, "primary" +508, 4, 19, 53, 132, 136, 244, 248, "open" +508, 4, 20, 54, 137, 138, 249, 250, "-" +508, 4, 21, 55, 139, 144, 251, 256, "angle" +508, 4, 22, 56, 145, 153, 257, 265, "glaucoma" +508, 4, 23, 57, 154, 155, 266, 267, "." +508, 5, 1, 58, 0, 4, 268, 272, "Eren" +508, 5, 2, 59, 5, 7, 273, 275, "MH" +508, 5, 3, 60, 8, 9, 276, 277, "(" +508, 5, 4, 61, 10, 11, 278, 279, "1" +508, 5, 5, 62, 12, 13, 280, 281, ")" +508, 5, 6, 63, 14, 15, 282, 283, "," +508, 5, 7, 64, 16, 22, 284, 290, "Gungel" +508, 5, 8, 65, 23, 24, 291, 292, "H" +508, 5, 9, 66, 25, 26, 293, 294, "," +508, 5, 10, 67, 27, 32, 295, 300, "Altan" +508, 5, 11, 68, 33, 34, 301, 302, "C" +508, 5, 12, 69, 35, 36, 303, 304, "," +508, 5, 13, 70, 37, 45, 305, 313, "Pasaoglu" +508, 5, 14, 71, 46, 48, 314, 316, "IB" +508, 5, 15, 72, 49, 50, 317, 318, "," +508, 5, 16, 73, 51, 58, 319, 326, "Sabanci" +508, 5, 17, 74, 59, 60, 327, 328, "S" +508, 5, 18, 75, 61, 62, 329, 330, "." +508, 5, 19, 76, 63, 69, 331, 337, "Author" +508, 5, 20, 77, 70, 81, 338, 349, "information" +508, 5, 21, 78, 82, 83, 350, 351, ":" +508, 5, 22, 79, 84, 85, 352, 353, "(" +508, 5, 23, 80, 86, 87, 354, 355, "1" +508, 5, 24, 81, 88, 89, 356, 357, ")" +508, 5, 25, 82, 90, 97, 358, 365, "Beyoglu" +508, 5, 26, 83, 98, 101, 366, 369, "Eye" +508, 5, 27, 84, 102, 111, 370, 379, "Education" +508, 5, 28, 85, 112, 115, 380, 383, "and" +508, 5, 29, 86, 116, 124, 384, 392, "Research" +508, 5, 30, 87, 125, 133, 393, 401, "Hospital" +508, 5, 31, 88, 134, 135, 402, 403, "," +508, 5, 32, 89, 136, 144, 404, 412, "Kuledibi" +508, 5, 33, 90, 145, 146, 413, 414, "," +508, 5, 34, 91, 147, 154, 415, 422, "Beyoglu" +508, 5, 35, 92, 155, 156, 423, 424, "," +508, 5, 36, 93, 157, 165, 425, 433, "Istanbul" +508, 5, 37, 94, 166, 167, 434, 435, "," +508, 5, 38, 95, 168, 174, 436, 442, "Turkey" +508, 5, 39, 96, 175, 176, 443, 444, "." +508, 6, 1, 97, 0, 2, 445, 447, "dr" +508, 6, 2, 98, 3, 4, 448, 449, "." +508, 6, 3, 99, 5, 14, 450, 459, "hakaneren" +508, 6, 4, 100, 15, 16, 460, 461, "@" +508, 6, 5, 101, 17, 22, 462, 467, "gmail" +508, 6, 6, 102, 23, 24, 468, 469, "." +508, 6, 7, 103, 25, 28, 470, 473, "com" +508, 6, 8, 104, 29, 36, 474, 481, "PURPOSE" +508, 6, 9, 105, 37, 38, 482, 483, ":" +508, 6, 10, 106, 39, 41, 484, 486, "To" +508, 6, 11, 107, 42, 49, 487, 494, "compare" +508, 6, 12, 108, 50, 53, 495, 498, "the" +508, 6, 13, 109, 54, 62, 499, 507, "efficacy" +508, 6, 14, 110, 63, 66, 508, 511, "and" +508, 6, 15, 111, 67, 73, 512, 518, "safety" +508, 6, 16, 112, 74, 76, 519, 521, "of" +508, 6, 17, 113, 77, 88, 522, 533, "dorzolamide" +508, 6, 18, 114, 89, 102, 534, 547, "hydrochloride" +508, 6, 19, 115, 103, 104, 548, 549, "2" +508, 6, 20, 116, 105, 106, 550, 551, "%" +508, 6, 21, 117, 107, 108, 552, 553, "/" +508, 6, 22, 118, 109, 116, 554, 561, "timolol" +508, 6, 23, 119, 117, 124, 562, 569, "maleate" +508, 6, 24, 120, 125, 126, 570, 571, "0" +508, 6, 25, 121, 127, 128, 572, 573, "." +508, 6, 26, 122, 129, 130, 574, 575, "5" +508, 6, 27, 123, 131, 132, 576, 577, "%" +508, 6, 28, 124, 133, 138, 578, 583, "fixed" +508, 6, 29, 125, 139, 150, 584, 595, "combination" +508, 6, 30, 126, 151, 152, 596, 597, "(" +508, 6, 31, 127, 153, 157, 598, 602, "DTFC" +508, 6, 32, 128, 158, 159, 603, 604, ")" +508, 6, 33, 129, 160, 164, 605, 609, "with" +508, 6, 34, 130, 165, 176, 610, 621, "latanoprost" +508, 6, 35, 131, 177, 178, 622, 623, "0" +508, 6, 36, 132, 179, 180, 624, 625, "." +508, 6, 37, 133, 181, 184, 626, 629, "005" +508, 6, 38, 134, 185, 186, 630, 631, "%" +508, 6, 39, 135, 187, 188, 632, 633, "/" +508, 6, 40, 136, 189, 196, 634, 641, "timolol" +508, 6, 41, 137, 197, 204, 642, 649, "maleate" +508, 6, 42, 138, 205, 206, 650, 651, "0" +508, 6, 43, 139, 207, 208, 652, 653, "." +508, 6, 44, 140, 209, 210, 654, 655, "5" +508, 6, 45, 141, 211, 212, 656, 657, "%" +508, 6, 46, 142, 213, 218, 658, 663, "fixed" +508, 6, 47, 143, 219, 230, 664, 675, "combination" +508, 6, 48, 144, 231, 232, 676, 677, "(" +508, 6, 49, 145, 233, 237, 678, 682, "LTFC" +508, 6, 50, 146, 238, 239, 683, 684, ")" +508, 6, 51, 147, 240, 242, 685, 687, "on" +508, 6, 52, 148, 243, 250, 688, 695, "diurnal" +508, 6, 53, 149, 251, 262, 696, 707, "intraocular" +508, 6, 54, 150, 263, 271, 708, 716, "pressure" +508, 6, 55, 151, 272, 273, 717, 718, "(" +508, 6, 56, 152, 274, 277, 719, 722, "IOP" +508, 6, 57, 153, 278, 279, 723, 724, ")" +508, 6, 58, 154, 280, 282, 725, 727, "in" +508, 6, 59, 155, 283, 291, 728, 736, "patients" +508, 6, 60, 156, 292, 296, 737, 741, "with" +508, 6, 61, 157, 297, 304, 742, 749, "primary" +508, 6, 62, 158, 305, 309, 750, 754, "open" +508, 6, 63, 159, 310, 311, 755, 756, "-" +508, 6, 64, 160, 312, 317, 757, 762, "angle" +508, 6, 65, 161, 318, 326, 763, 771, "glaucoma" +508, 6, 66, 162, 327, 328, 772, 773, "." +508, 7, 1, 163, 0, 7, 774, 781, "METHODS" +508, 7, 2, 164, 8, 9, 782, 783, ":" +508, 7, 3, 165, 10, 16, 784, 790, "Thirty" +508, 7, 4, 166, 17, 18, 791, 792, "-" +508, 7, 5, 167, 19, 24, 793, 798, "three" +508, 7, 6, 168, 25, 32, 799, 806, "primary" +508, 7, 7, 169, 33, 37, 807, 811, "open" +508, 7, 8, 170, 38, 39, 812, 813, "-" +508, 7, 9, 171, 40, 45, 814, 819, "angle" +508, 7, 10, 172, 46, 54, 820, 828, "glaucoma" +508, 7, 11, 173, 55, 63, 829, 837, "patients" +508, 7, 12, 174, 64, 68, 838, 842, "with" +508, 7, 13, 175, 69, 72, 843, 846, "IOP" +508, 7, 14, 176, 73, 75, 847, 849, "of" +508, 7, 15, 177, 76, 78, 850, 852, "22" +508, 7, 16, 178, 79, 80, 853, 854, "-" +508, 7, 17, 179, 81, 83, 855, 857, "32" +508, 7, 18, 180, 84, 85, 858, 859, " " +508, 7, 19, 181, 86, 90, 860, 864, "mmHg" +508, 7, 20, 182, 91, 99, 865, 873, "measured" +508, 7, 21, 183, 100, 102, 874, 876, "at" +508, 7, 22, 184, 103, 106, 877, 880, "any" +508, 7, 23, 185, 107, 111, 881, 885, "time" +508, 7, 24, 186, 112, 116, 886, 890, "were" +508, 7, 25, 187, 117, 125, 891, 899, "included" +508, 7, 26, 188, 126, 127, 900, 901, "." +508, 8, 1, 189, 0, 8, 902, 910, "Patients" +508, 8, 2, 190, 9, 13, 911, 915, "were" +508, 8, 3, 191, 14, 24, 916, 926, "randomized" +508, 8, 4, 192, 25, 27, 927, 929, "to" +508, 8, 5, 193, 28, 34, 930, 936, "either" +508, 8, 6, 194, 35, 39, 937, 941, "DTFC" +508, 8, 7, 195, 40, 45, 942, 947, "twice" +508, 8, 8, 196, 46, 51, 948, 953, "daily" +508, 8, 9, 197, 52, 54, 954, 956, "or" +508, 8, 10, 198, 55, 66, 957, 968, "latanoprost" +508, 8, 11, 199, 67, 68, 969, 970, "0" +508, 8, 12, 200, 69, 70, 971, 972, "." +508, 8, 13, 201, 71, 74, 973, 976, "005" +508, 8, 14, 202, 75, 76, 977, 978, "%" +508, 8, 15, 203, 77, 78, 979, 980, "/" +508, 8, 16, 204, 79, 86, 981, 988, "timolol" +508, 8, 17, 205, 87, 94, 989, 996, "maleate" +508, 8, 18, 206, 95, 96, 997, 998, "0" +508, 8, 19, 207, 97, 98, 999, 1000, "." +508, 8, 20, 208, 99, 100, 1001, 1002, "5" +508, 8, 21, 209, 101, 102, 1003, 1004, "%" +508, 8, 22, 210, 103, 108, 1005, 1010, "fixed" +508, 8, 23, 211, 109, 120, 1011, 1022, "combination" +508, 8, 24, 212, 121, 122, 1023, 1024, "(" +508, 8, 25, 213, 123, 127, 1025, 1029, "LTFC" +508, 8, 26, 214, 128, 129, 1030, 1031, ")" +508, 8, 27, 215, 130, 134, 1032, 1036, "once" +508, 8, 28, 216, 135, 136, 1037, 1038, "a" +508, 8, 29, 217, 137, 140, 1039, 1042, "day" +508, 8, 30, 218, 141, 143, 1043, 1045, "in" +508, 8, 31, 219, 144, 147, 1046, 1049, "the" +508, 8, 32, 220, 148, 155, 1050, 1057, "evening" +508, 8, 33, 221, 156, 157, 1058, 1059, "." +508, 9, 1, 222, 0, 5, 1060, 1065, "After" +508, 9, 2, 223, 6, 7, 1066, 1067, "a" +508, 9, 3, 224, 8, 9, 1068, 1069, "6" +508, 9, 4, 225, 10, 11, 1070, 1071, "-" +508, 9, 5, 226, 12, 16, 1072, 1076, "week" +508, 9, 6, 227, 17, 26, 1077, 1086, "treatment" +508, 9, 7, 228, 27, 33, 1087, 1093, "period" +508, 9, 8, 229, 34, 38, 1094, 1098, "with" +508, 9, 9, 230, 39, 43, 1099, 1103, "each" +508, 9, 10, 231, 44, 55, 1104, 1115, "combination" +508, 9, 11, 232, 56, 57, 1116, 1117, "," +508, 9, 12, 233, 58, 61, 1118, 1121, "IOP" +508, 9, 13, 234, 62, 66, 1122, 1126, "were" +508, 9, 14, 235, 67, 75, 1127, 1135, "measured" +508, 9, 15, 236, 76, 81, 1136, 1141, "every" +508, 9, 16, 237, 82, 83, 1142, 1143, "4" +508, 9, 17, 238, 84, 85, 1144, 1145, " " +508, 9, 18, 239, 86, 87, 1146, 1147, "h" +508, 9, 19, 240, 88, 94, 1148, 1154, "during" +508, 9, 20, 241, 95, 97, 1155, 1157, "24" +508, 9, 21, 242, 98, 99, 1158, 1159, " " +508, 9, 22, 243, 100, 101, 1160, 1161, "h" +508, 9, 23, 244, 102, 103, 1162, 1163, "(" +508, 9, 24, 245, 104, 109, 1164, 1169, "first" +508, 9, 25, 246, 110, 117, 1170, 1177, "diurnal" +508, 9, 26, 247, 118, 123, 1178, 1183, "curve" +508, 9, 27, 248, 124, 125, 1184, 1185, ")" +508, 9, 28, 249, 126, 129, 1186, 1189, "and" +508, 9, 29, 250, 130, 135, 1190, 1195, "after" +508, 9, 30, 251, 136, 137, 1196, 1197, "6" +508, 9, 31, 252, 138, 143, 1198, 1203, "weeks" +508, 9, 32, 253, 144, 146, 1204, 1206, "of" +508, 9, 33, 254, 147, 154, 1207, 1214, "washout" +508, 9, 34, 255, 155, 161, 1215, 1221, "period" +508, 9, 35, 256, 162, 163, 1222, 1223, "," +508, 9, 36, 257, 164, 167, 1224, 1227, "the" +508, 9, 37, 258, 168, 176, 1228, 1236, "patients" +508, 9, 38, 259, 177, 181, 1237, 1241, "were" +508, 9, 39, 260, 182, 190, 1242, 1250, "switched" +508, 9, 40, 261, 191, 193, 1251, 1253, "to" +508, 9, 41, 262, 194, 197, 1254, 1257, "the" +508, 9, 42, 263, 198, 203, 1258, 1263, "other" +508, 9, 43, 264, 204, 213, 1264, 1273, "treatment" +508, 9, 44, 265, 214, 217, 1274, 1277, "for" +508, 9, 45, 266, 218, 219, 1278, 1279, "6" +508, 9, 46, 267, 220, 225, 1280, 1285, "weeks" +508, 9, 47, 268, 226, 228, 1286, 1288, "of" +508, 9, 48, 269, 229, 232, 1289, 1292, "the" +508, 9, 49, 270, 233, 239, 1293, 1299, "second" +508, 9, 50, 271, 240, 247, 1300, 1307, "diurnal" +508, 9, 51, 272, 248, 253, 1308, 1313, "curve" +508, 9, 52, 273, 254, 255, 1314, 1315, "." +508, 10, 1, 274, 0, 7, 1316, 1323, "RESULTS" +508, 10, 2, 275, 8, 9, 1324, 1325, ":" +508, 10, 3, 276, 10, 13, 1326, 1329, "The" +508, 10, 4, 277, 14, 18, 1330, 1334, "mean" +508, 10, 5, 278, 19, 27, 1335, 1343, "baseline" +508, 10, 6, 279, 28, 31, 1344, 1347, "IOP" +508, 10, 7, 280, 32, 35, 1348, 1351, "was" +508, 10, 8, 281, 36, 38, 1352, 1354, "25" +508, 10, 9, 282, 39, 40, 1355, 1356, "." +508, 10, 10, 283, 41, 43, 1357, 1359, "09" +508, 10, 11, 284, 44, 45, 1360, 1361, "±" +508, 10, 12, 285, 46, 47, 1362, 1363, "2" +508, 10, 13, 286, 48, 49, 1364, 1365, "." +508, 10, 14, 287, 50, 51, 1366, 1367, "8" +508, 10, 15, 288, 52, 53, 1368, 1369, " " +508, 10, 16, 289, 54, 58, 1370, 1374, "mmHg" +508, 10, 17, 290, 59, 60, 1375, 1376, "." +508, 11, 1, 291, 0, 5, 1377, 1382, "After" +508, 11, 2, 292, 6, 9, 1383, 1386, "the" +508, 11, 3, 293, 10, 19, 1387, 1396, "treatment" +508, 11, 4, 294, 20, 26, 1397, 1403, "period" +508, 11, 5, 295, 27, 28, 1404, 1405, "," +508, 11, 6, 296, 29, 33, 1406, 1410, "mean" +508, 11, 7, 297, 34, 41, 1411, 1418, "diurnal" +508, 11, 8, 298, 42, 45, 1419, 1422, "IOP" +508, 11, 9, 299, 46, 49, 1423, 1426, "was" +508, 11, 10, 300, 50, 63, 1427, 1440, "statistically" +508, 11, 11, 301, 64, 69, 1441, 1446, "lower" +508, 11, 12, 302, 70, 74, 1447, 1451, "with" +508, 11, 13, 303, 75, 79, 1452, 1456, "LTFC" +508, 11, 14, 304, 80, 81, 1457, 1458, "(" +508, 11, 15, 305, 82, 84, 1459, 1461, "16" +508, 11, 16, 306, 85, 86, 1462, 1463, "." +508, 11, 17, 307, 87, 88, 1464, 1465, "3" +508, 11, 18, 308, 89, 90, 1466, 1467, " " +508, 11, 19, 309, 91, 95, 1468, 1472, "mmHg" +508, 11, 20, 310, 96, 97, 1473, 1474, ")" +508, 11, 21, 311, 98, 102, 1475, 1479, "than" +508, 11, 22, 312, 103, 107, 1480, 1484, "with" +508, 11, 23, 313, 108, 112, 1485, 1489, "DTFC" +508, 11, 24, 314, 113, 114, 1490, 1491, "(" +508, 11, 25, 315, 115, 117, 1492, 1494, "17" +508, 11, 26, 316, 118, 119, 1495, 1496, "." +508, 11, 27, 317, 120, 121, 1497, 1498, "3" +508, 11, 28, 318, 122, 123, 1499, 1500, " " +508, 11, 29, 319, 124, 128, 1501, 1505, "mmHg" +508, 11, 30, 320, 129, 130, 1506, 1507, ")" +508, 11, 31, 321, 131, 132, 1508, 1509, "," +508, 11, 32, 322, 133, 136, 1510, 1513, "and" +508, 11, 33, 323, 137, 140, 1514, 1517, "the" +508, 11, 34, 324, 141, 145, 1518, 1522, "peak" +508, 11, 35, 325, 146, 149, 1523, 1526, "IOP" +508, 11, 36, 326, 150, 155, 1527, 1532, "value" +508, 11, 37, 327, 156, 159, 1533, 1536, "was" +508, 11, 38, 328, 160, 162, 1537, 1539, "18" +508, 11, 39, 329, 163, 164, 1540, 1541, "." +508, 11, 40, 330, 165, 166, 1542, 1543, "5" +508, 11, 41, 331, 167, 168, 1544, 1545, " " +508, 11, 42, 332, 169, 173, 1546, 1550, "mmHg" +508, 11, 43, 333, 174, 178, 1551, 1555, "with" +508, 11, 44, 334, 179, 183, 1556, 1560, "LTFC" +508, 11, 45, 335, 184, 187, 1561, 1564, "and" +508, 11, 46, 336, 188, 190, 1565, 1567, "19" +508, 11, 47, 337, 191, 192, 1568, 1569, "." +508, 11, 48, 338, 193, 194, 1570, 1571, "9" +508, 11, 49, 339, 195, 196, 1572, 1573, "±" +508, 11, 50, 340, 197, 198, 1574, 1575, "2" +508, 11, 51, 341, 199, 200, 1576, 1577, "." +508, 11, 52, 342, 201, 202, 1578, 1579, "6" +508, 11, 53, 343, 203, 204, 1580, 1581, " " +508, 11, 54, 344, 205, 209, 1582, 1586, "mmHg" +508, 11, 55, 345, 210, 214, 1587, 1591, "with" +508, 11, 56, 346, 215, 219, 1592, 1596, "DTFC" +508, 11, 57, 347, 220, 221, 1597, 1598, "(" +508, 11, 58, 348, 222, 223, 1599, 1600, "P" +508, 11, 59, 349, 224, 225, 1601, 1602, "<" +508, 11, 60, 350, 226, 227, 1603, 1604, "0" +508, 11, 61, 351, 228, 229, 1605, 1606, "." +508, 11, 62, 352, 230, 232, 1607, 1609, "05" +508, 11, 63, 353, 233, 234, 1610, 1611, ")" +508, 11, 64, 354, 235, 236, 1612, 1613, "." +508, 12, 1, 355, 0, 2, 1614, 1616, "No" +508, 12, 2, 356, 3, 14, 1617, 1628, "significant" +508, 12, 3, 357, 15, 19, 1629, 1633, "side" +508, 12, 4, 358, 20, 27, 1634, 1641, "effects" +508, 12, 5, 359, 28, 32, 1642, 1646, "were" +508, 12, 6, 360, 33, 41, 1647, 1655, "reported" +508, 12, 7, 361, 42, 48, 1656, 1662, "except" +508, 12, 8, 362, 49, 57, 1663, 1671, "stinging" +508, 12, 9, 363, 58, 61, 1672, 1675, "and" +508, 12, 10, 364, 62, 68, 1676, 1682, "bitter" +508, 12, 11, 365, 69, 74, 1683, 1688, "taste" +508, 12, 12, 366, 75, 79, 1689, 1693, "with" +508, 12, 13, 367, 80, 83, 1694, 1697, "the" +508, 12, 14, 368, 84, 88, 1698, 1702, "DTFC" +508, 12, 15, 369, 89, 94, 1703, 1708, "group" +508, 12, 16, 370, 95, 96, 1709, 1710, "." +508, 13, 1, 371, 0, 10, 1711, 1721, "CONCLUSION" +508, 13, 2, 372, 11, 12, 1722, 1723, ":" +508, 13, 3, 373, 13, 17, 1724, 1728, "Mean" +508, 13, 4, 374, 18, 25, 1729, 1736, "diurnal" +508, 13, 5, 375, 26, 29, 1737, 1740, "IOP" +508, 13, 6, 376, 30, 33, 1741, 1744, "and" +508, 13, 7, 377, 34, 38, 1745, 1749, "peak" +508, 13, 8, 378, 39, 42, 1750, 1753, "IOP" +508, 13, 9, 379, 43, 47, 1754, 1758, "were" +508, 13, 10, 380, 48, 53, 1759, 1764, "lower" +508, 13, 11, 381, 54, 58, 1765, 1769, "with" +508, 13, 12, 382, 59, 63, 1770, 1774, "LTFC" +508, 13, 13, 383, 64, 68, 1775, 1779, "than" +508, 13, 14, 384, 69, 73, 1780, 1784, "with" +508, 13, 15, 385, 74, 78, 1785, 1789, "DTFC" +508, 13, 16, 386, 79, 81, 1790, 1792, "in" +508, 13, 17, 387, 82, 90, 1793, 1801, "patients" +508, 13, 18, 388, 91, 95, 1802, 1806, "with" +508, 13, 19, 389, 96, 103, 1807, 1814, "primary" +508, 13, 20, 390, 104, 108, 1815, 1819, "open" +508, 13, 21, 391, 109, 110, 1820, 1821, "-" +508, 13, 22, 392, 111, 116, 1822, 1827, "angle" +508, 13, 23, 393, 117, 125, 1828, 1836, "glaucoma" +508, 13, 24, 394, 126, 127, 1837, 1838, "." +508, 14, 1, 395, 0, 3, 1839, 1842, "DOI" +508, 14, 2, 396, 4, 5, 1843, 1844, ":" +508, 14, 3, 397, 6, 8, 1845, 1847, "10" +508, 14, 4, 398, 9, 10, 1848, 1849, "." +508, 14, 5, 399, 11, 15, 1850, 1854, "1089" +508, 14, 6, 400, 16, 17, 1855, 1856, "/" +508, 14, 7, 401, 18, 21, 1857, 1860, "jop" +508, 14, 8, 402, 22, 23, 1861, 1862, "." +508, 14, 9, 403, 24, 28, 1863, 1867, "2011" +508, 14, 10, 404, 29, 30, 1868, 1869, "." +508, 14, 11, 405, 31, 35, 1870, 1874, "0105" +508, 14, 12, 406, 36, 40, 1875, 1879, "PMID" +508, 14, 13, 407, 41, 42, 1880, 1881, ":" +508, 14, 14, 408, 43, 51, 1882, 1890, "22320418" +508, 14, 15, 409, 52, 53, 1891, 1892, "[" +508, 14, 16, 410, 54, 61, 1893, 1900, "Indexed" +508, 14, 17, 411, 62, 65, 1901, 1904, "for" +508, 14, 18, 412, 66, 73, 1905, 1912, "MEDLINE" +508, 14, 19, 413, 74, 75, 1913, 1914, "]" diff --git a/data/gl 22320418_jshahinitiran.annodb b/data/gl 22320418_jshahinitiran.annodb new file mode 100644 index 0000000..7c58d52 --- /dev/null +++ b/data/gl 22320418_jshahinitiran.annodb @@ -0,0 +1,79 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72584, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", +72585, PublicationYear, 24, 28, "2012", "", +72586, Title, 112, 267, "Comparison of dorzolamide / timolol and latanoprost / timolol fixed combinations on diurnal intraocular pressure control in primary open - angle glaucoma .", "", +72587, Dorzolamide, 126, 137, "dorzolamide", "", +72588, Timolol, 140, 147, "timolol", "", +72589, Latanoprost, 152, 163, "latanoprost", "", +72590, Timolol, 166, 173, "timolol", "", +72591, Diurnal_IOP, 196, 224, "diurnal intraocular pressure", "", +72592, Primary_OpenAngleGlaucoma, 236, 265, "primary open - angle glaucoma", "", +72593, Author, 268, 275, "Eren MH", "", +72594, Author, 284, 292, "Gungel H", "", +72595, Author, 295, 302, "Altan C", "", +72596, Author, 305, 316, "Pasaoglu IB", "", +72597, Author, 319, 330, "Sabanci S .", "", +72598, Turkey, 436, 442, "Turkey", "", +72599, ObjectiveDescription, 484, 684, "To compare the efficacy and safety of dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination ( DTFC ) with latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination ( LTFC )", "", +72601, Dorzolamide, 522, 547, "dorzolamide hydrochloride", "", +72603, DoseValue, 548, 549, "2", "", +72602, Timolol, 554, 569, "timolol maleate", "", +72604, DoseValue, 570, 575, "0 . 5", "", +72605, Dorz/TimFC, 598, 602, "DTFC", "", +72606, Latanoprost, 610, 621, "latanoprost", "", +72609, DoseValue, 622, 629, "0 . 005", "", +72607, Timolol, 634, 649, "timolol maleate", "", +72610, DoseValue, 650, 655, "0 . 5", "", +72611, Lat/TimFC, 678, 682, "LTFC", "", +72600, ObjectiveDescription, 685, 773, "on diurnal intraocular pressure ( IOP ) in patients with primary open - angle glaucoma .", "", +72612, NumberPatientsCT, 784, 798, "Thirty - three", "", +72613, Primary_OpenAngleGlaucoma, 799, 828, "primary open - angle glaucoma", "", +72616, Precondition, 838, 885, "with IOP of 22 - 32   mmHg measured at any time", "", +72614, IOP, 843, 846, "IOP", "", +72615, mmHg, 860, 864, "mmHg", "", +72617, Randomized, 916, 926, "randomized", "", +72618, Dorz/TimFC, 937, 941, "DTFC", "", +72619, Frequency, 942, 953, "twice daily", "", +72620, Latanoprost, 957, 968, "latanoprost", "", +72624, Lat/TimFC, 957, 1022, "latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination", "", +72622, DoseValue, 969, 976, "0 . 005", "", +72621, Timolol, 981, 996, "timolol maleate", "", +72623, DoseValue, 997, 1002, "0 . 5", "", +72625, Lat/TimFC, 1025, 1029, "LTFC", "", +72626, Frequency, 1032, 1042, "once a day", "", +72627, Evening, 1050, 1057, "evening", "", +72628, Duration, 1068, 1076, "6 - week", "", +72629, IOP, 1118, 1121, "IOP", "", +72630, Duration, 1196, 1203, "6 weeks", "", +72631, Duration, 1278, 1285, "6 weeks", "", +72632, Mean, 1330, 1334, "mean", "", +72633, IOP, 1344, 1347, "IOP", "", +72634, BaseLineValue, 1352, 1359, "25 . 09", "", +72635, SdErrorBL, 1362, 1367, "2 . 8", "", +72636, mmHg, 1370, 1374, "mmHg", "", +72637, Mean, 1406, 1410, "mean", "", +72638, Diurnal_IOP, 1411, 1422, "diurnal IOP", "", +72639, Lat/TimFC, 1452, 1456, "LTFC", "", +72640, ResultMeasuredValue, 1459, 1465, "16 . 3", "", +72643, mmHg, 1468, 1472, "mmHg", "", +72645, Dorz/TimFC, 1485, 1489, "DTFC", "", +72642, ResultMeasuredValue, 1492, 1498, "17 . 3", "", +72644, mmHg, 1501, 1505, "mmHg", "", +72646, Peak_IOP, 1518, 1526, "peak IOP", "", +72647, ResultMeasuredValue, 1537, 1543, "18 . 5", "", +72649, mmHg, 1546, 1550, "mmHg", "", +72651, Lat/TimFC, 1556, 1560, "LTFC", "", +72648, ResultMeasuredValue, 1565, 1571, "19 . 9", "", +72653, SdErrorResValue, 1574, 1579, "2 . 6", "", +72650, mmHg, 1582, 1586, "mmHg", "", +72652, Dorz/TimFC, 1592, 1596, "DTFC", "", +72654, PValueResValue, 1599, 1609, "P < 0 . 05", "", +72657, Dorz/TimFC, 1698, 1702, "DTFC", "", +72658, Mean, 1724, 1728, "Mean", "", +72664, ConclusionComment, 1724, 1838, "Mean diurnal IOP and peak IOP were lower with LTFC than with DTFC in patients with primary open - angle glaucoma .", "", +72659, Diurnal_IOP, 1729, 1740, "diurnal IOP", "", +72660, Peak_IOP, 1745, 1753, "peak IOP", "", +72661, Lat/TimFC, 1770, 1774, "LTFC", "", +72662, Dorz/TimFC, 1785, 1789, "DTFC", "", +72663, Primary_OpenAngleGlaucoma, 1807, 1836, "primary open - angle glaucoma", "", +72665, PMID, 1882, 1890, "22320418", "", diff --git a/data/gl 22320418_jshahinitiran.n-triples b/data/gl 22320418_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22320418_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22320418_tstrakeljahn.annodb b/data/gl 22320418_tstrakeljahn.annodb new file mode 100644 index 0000000..f85b5be --- /dev/null +++ b/data/gl 22320418_tstrakeljahn.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +81213, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +81214, PublicationYear, 24, 28, "2012", "", +81221, Title, 112, 267, "Comparison of dorzolamide / timolol and latanoprost / timolol fixed combinations on diurnal intraocular pressure control in primary open - angle glaucoma .", "", +81215, Dorzolamide, 126, 137, "dorzolamide", "", +81229, Dorz/TimFC, 126, 147, "dorzolamide / timolol", "", +81216, Timolol, 140, 147, "timolol", "", +81218, Latanoprost, 152, 163, "latanoprost", "", +81228, Lat/TimFC, 152, 173, "latanoprost / timolol", "", +81217, Timolol, 166, 173, "timolol", "", +81219, Diurnal_IOP, 196, 224, "diurnal intraocular pressure", "", +81220, Primary_OpenAngleGlaucoma, 236, 265, "primary open - angle glaucoma", "", +81222, Author, 268, 275, "Eren MH", "", +81223, Author, 284, 292, "Gungel H", "", +81224, Author, 295, 302, "Altan C", "", +81225, Author, 305, 316, "Pasaoglu IB", "", +81226, Author, 319, 328, "Sabanci S", "", +81227, Turkey, 436, 442, "Turkey", "", +81247, ObjectiveDescription, 484, 736, "To compare the efficacy and safety of dorzolamide hydrochloride 2 % / timolol maleate 0 . 5 % fixed combination ( DTFC ) with latanoprost 0 . 005 % / timolol maleate 0 . 5 % fixed combination ( LTFC ) on diurnal intraocular pressure ( IOP ) in patients", "", +81230, Dorzolamide, 522, 547, "dorzolamide hydrochloride", "", +81234, DoseValue, 548, 549, "2", "", +81238, Percentage, 550, 551, "%", "", +81231, Timolol, 554, 569, "timolol maleate", "", +81235, DoseValue, 570, 575, "0 . 5", "", +81239, Percentage, 576, 577, "%", "", +81243, Dorz/TimFC, 598, 602, "DTFC", "", +81233, Latanoprost, 610, 621, "latanoprost", "", +81236, DoseValue, 622, 629, "0 . 005", "", +81240, Percentage, 630, 631, "%", "", +81232, Timolol, 634, 649, "timolol maleate", "", +81237, DoseValue, 650, 655, "0 . 5", "", +81241, Percentage, 656, 657, "%", "", +81242, Lat/TimFC, 678, 682, "LTFC", "", +81244, Diurnal_IOP, 688, 716, "diurnal intraocular pressure", "", +81245, IOP, 719, 722, "IOP", "", +81248, ObjectiveDescription, 737, 773, "with primary open - angle glaucoma .", "", +81246, Primary_OpenAngleGlaucoma, 742, 771, "primary open - angle glaucoma", "", +81249, FinalNumPatientsCT, 784, 798, "Thirty - three", "", +81250, Primary_OpenAngleGlaucoma, 799, 828, "primary open - angle glaucoma", "", +81251, IOP, 843, 846, "IOP", "", +81252, mmHg, 860, 864, "mmHg", "", +81253, Randomized, 916, 926, "randomized", "", +81254, Dorz/TimFC, 937, 941, "DTFC", "", +81264, Frequency, 942, 953, "twice daily", "", +81255, Latanoprost, 957, 968, "latanoprost", "", +81261, Lat/TimFC, 957, 1004, "latanoprost 0 . 005 % / timolol maleate 0 . 5 %", "", +81257, DoseValue, 969, 976, "0 . 005", "", +81259, Percentage, 977, 978, "%", "", +81256, Timolol, 981, 996, "timolol maleate", "", +81258, DoseValue, 997, 1002, "0 . 5", "", +81260, Percentage, 1003, 1004, "%", "", +81262, Lat/TimFC, 1025, 1029, "LTFC", "", +81263, Frequency, 1032, 1042, "once a day", "", +81265, Evening, 1050, 1057, "evening", "", +81267, IOP, 1118, 1121, "IOP", "", +81268, Mean, 1330, 1334, "mean", "", +81269, IOP, 1344, 1347, "IOP", "", +81270, BaseLineValue, 1352, 1359, "25 . 09", "", +81271, SdDevBL, 1362, 1367, "2 . 8", "", +81272, mmHg, 1370, 1374, "mmHg", "", +81273, Mean, 1406, 1410, "mean", "", +81274, Diurnal_IOP, 1411, 1422, "diurnal IOP", "", +81275, Lat/TimFC, 1452, 1456, "LTFC", "", +81281, ResultMeasuredValue, 1459, 1465, "16 . 3", "", +81287, mmHg, 1468, 1472, "mmHg", "", +81278, Dorz/TimFC, 1485, 1489, "DTFC", "", +81282, ResultMeasuredValue, 1492, 1498, "17 . 3", "", +81288, mmHg, 1501, 1505, "mmHg", "", +81289, Peak_IOP, 1518, 1526, "peak IOP", "", +81283, ResultMeasuredValue, 1537, 1543, "18 . 5", "", +81290, mmHg, 1546, 1550, "mmHg", "", +81276, Lat/TimFC, 1556, 1560, "LTFC", "", +81284, ResultMeasuredValue, 1565, 1571, "19 . 9", "", +81285, SdDevResValue, 1574, 1579, "2 . 6", "", +81291, mmHg, 1582, 1586, "mmHg", "", +81279, Dorz/TimFC, 1592, 1596, "DTFC", "", +81286, PvalueDiff, 1601, 1609, "< 0 . 05", "", +81292, ObservedResult, 1614, 1710, "No significant side effects were reported except stinging and bitter taste with the DTFC group .", "", +81280, Dorz/TimFC, 1698, 1702, "DTFC", "", +81293, Mean, 1724, 1728, "Mean", "", +81298, ConclusionComment, 1724, 1838, "Mean diurnal IOP and peak IOP were lower with LTFC than with DTFC in patients with primary open - angle glaucoma .", "", +81294, Diurnal_IOP, 1729, 1740, "diurnal IOP", "", +81295, Peak_IOP, 1745, 1753, "peak IOP", "", +81277, Lat/TimFC, 1770, 1774, "LTFC", "", +81296, Dorz/TimFC, 1785, 1789, "DTFC", "", +81297, Primary_OpenAngleGlaucoma, 1807, 1836, "primary open - angle glaucoma", "", +81299, PMID, 1882, 1890, "22320418", "", diff --git a/data/gl 22320418_tstrakeljahn.n-triples b/data/gl 22320418_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22320418_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22458918_admin.annodb b/data/gl 22458918_admin.annodb new file mode 100644 index 0000000..fa668b0 --- /dev/null +++ b/data/gl 22458918_admin.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +19265, Journal, 0, 19, "Curr Med Res Opin .", "", " \"Curr Med Res Opin .\"." +1, PublicationYear, 20, 24, "2012", "", " \"2012\"." +19268, Title, 116, 260, "Fixed - combination brimonidine - timolol versus latanoprost in glaucoma and ocular hypertension : a 12 - week , randomized , comparison study .", "", " \"Fixed - combination brimonidine - timolol versus latanoprost in glaucoma and ocular hypertension : a 12 - week , randomized , comparison study .\"." +38419, Brimo/TimFC, 136, 157, "brimonidine - timolol", "", " ." +2, Brimonidine, 136, 147, "brimonidine", "", +3, Timolol, 150, 157, "timolol", "", +4, Latanoprost, 165, 176, "latanoprost", "", " . ." +5, Glaucoma, 180, 188, "glaucoma", "", " . ." +6, OcularHypertension, 193, 212, "ocular hypertension", "", " ." +8, Duration, 217, 226, "12 - week", "", " \"12 - week\"." +7, Randomized, 229, 239, "randomized", "", " ." +9, Author, 261, 268, "Katz LJ", "", " \"Katz LJ\"." +10, Author, 277, 288, "Rauchman SH", "", " \"Rauchman SH\"." +11, Author, 291, 307, "Cottingham AJ Jr", "", " \"Cottingham AJ Jr\"." +12, Author, 310, 320, "Simmons ST", "", " \"Simmons ST\"." +13, Author, 323, 334, "Williams JM", "", " \"Williams JM\"." +14, Author, 337, 349, "Schiffman RM", "", " \"Schiffman RM\"." +15, Author, 352, 364, "Hollander DA", "", " \"Hollander DA\"." +16, USA, 435, 438, "USA", "", " ." +17, IOP, 490, 510, "intraocular pressure", "", " . ." +18, IOP, 513, 516, "IOP", "", +38418, Brimo/TimFC, 573, 610, "brimonidine 0 . 2 % - timolol 0 . 5 %", "", +19, Brimonidine, 573, 584, "brimonidine", "", +24, DoseValue, 585, 590, "0 . 2", "", +19267, Percentage, 591, 592, "%", "", +20, Timolol, 595, 602, "timolol", "", +117, DoseValue, 603, 608, "0 . 5", "", +0, Percentage, 609, 610, "%", "", +21, Latanoprost, 625, 636, "latanoprost", "", +25, DoseValue, 637, 644, "0 . 005", "", " \"0 . 005\"." +28, Percentage, 645, 646, "%", "", " ." +54375, Precondition, 650, 695, "patients with glaucoma or ocular hypertension", "", " \"patients with glaucoma or ocular hypertension\"." +22, Glaucoma, 664, 672, "glaucoma", "", +23, OcularHypertension, 676, 695, "ocular hypertension", "", +54374, Prospective, 739, 750, "prospective", "", " ." +30, Randomized, 753, 763, "randomized", "", +31, Multicenter, 766, 777, "multicenter", "", " ." +32, Blind, 795, 801, "masked", "", " ." +19274, Precondition, 825, 918, "washout of any previous IOP - lowering medications , patients with IOP of 24   mmHg or higher", "", " \"washout of any previous IOP - lowering medications , patients with IOP of 24   mmHg or higher\"." +34, IOP, 849, 852, "IOP", "", +35, IOP, 892, 895, "IOP", "", +131, mmHg, 904, 908, "mmHg", "", " ." +36, Randomized, 924, 934, "randomized", "", +37, Frequency, 938, 951, "twice - daily", "", " \"twice - daily\"." +38420, Brimo/TimFC, 972, 1009, "brimonidine 0 . 2 % - timolol 0 . 5 %", "", +38, Brimonidine, 972, 983, "brimonidine", "", +41, DoseValue, 984, 989, "0 . 2", "", +44, Percentage, 990, 991, "%", "", +39, Timolol, 994, 1001, "timolol", "", +42, DoseValue, 1002, 1007, "0 . 5", "", +45, Percentage, 1008, 1009, "%", "", +47, NumberPatientsArm, 1018, 1020, "73", "", " \"73\"." +142, Frequency, 1026, 1038, "once - daily", "", " \"once - daily\"." +40, Latanoprost, 1039, 1050, "latanoprost", "", +43, DoseValue, 1051, 1058, "0 . 005", "", +46, Percentage, 1059, 1060, "%", "", +48, NumberPatientsArm, 1069, 1071, "75", "", " \"75\"." +147, Bedtime, 1087, 1094, "evening", "", " ." +92843, Vehicle, 1102, 1109, "vehicle", "", +149, Morning, 1125, 1132, "morning", "", +52, Duration, 1159, 1167, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +54, IOP, 1170, 1173, "IOP", "", +37019, TimePoint, 1250, 1258, "baseline", "", +37020, TimePoint, 1261, 1267, "week 6", "", +152, TimePoint, 1274, 1281, "week 12", "", +55, Diurnal_IOP, 1468, 1479, "diurnal IOP", "", +154, TimePoint, 1540, 1547, "week 12", "", +19273, ObservedResult, 1601, 1731, "There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline ( p  =  0 . 118 ) .", "", +57, Mean, 1683, 1687, "mean", "", " . . . ." +58, Diurnal_IOP, 1688, 1699, "diurnal IOP", "", +59, PvalueDiff, 1714, 1727, "p  =  0 . 118", "", +158, TimePoint, 1735, 1742, "week 12", "", " \"week 12\". \"week 12\"." +60, Mean, 1749, 1753, "mean", "", +61, Diurnal_IOP, 1761, 1772, "diurnal IOP", "", +62, ResultMeasuredValue, 1777, 1783, "17 . 8", "", " \"17 . 8\"." +64, SdDevResValue, 1786, 1791, "2 . 9", "", " \"2 . 9\"." +66, mmHg, 1796, 1800, "mmHg", "", " ." +38411, Brimo/TimFC, 1806, 1827, "brimonidine - timolol", "", +68, Brimonidine, 1806, 1817, "brimonidine", "", +69, Timolol, 1820, 1827, "timolol", "", +63, ResultMeasuredValue, 1832, 1838, "17 . 9", "", " \"17 . 9\"." +65, SdDevResValue, 1841, 1846, "3 . 9", "", " \"3 . 9\"." +67, mmHg, 1851, 1855, "mmHg", "", +70, Latanoprost, 1861, 1872, "latanoprost", "", +170, PValueResValue, 1875, 1888, "p  =  0 . 794", "", " \"p  =  0 . 794\". \"p  =  0 . 794\"." +171, EndPointDescription, 1930, 1980, "at least a 20 % decrease from baseline diurnal IOP", "", " . ." +172, Diurnal_IOP, 1969, 1980, "diurnal IOP", "", +173, TimePoint, 1984, 1991, "week 12", "", " \"week 12\". \"week 12\"." +73, PercentageAffected, 1996, 2002, "87 . 7", "", " \"87 . 7\"." +38412, Brimo/TimFC, 2012, 2033, "brimonidine - timolol", "", +74, Brimonidine, 2012, 2023, "brimonidine", "", +75, Timolol, 2026, 2033, "timolol", "", +76, PercentageAffected, 2044, 2050, "77 . 3", "", " \"77 . 3\"." +77, Latanoprost, 2060, 2071, "latanoprost", "", +179, PValueNumAffected, 2080, 2093, "p  =  0 . 131", "", " \"p  =  0 . 131\". \"p  =  0 . 131\"." +154, TimePoint, 2147, 2154, "week 12", "", +191, ConclusionComment, 2202, 2342, "Fixed - combination brimonidine - timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension .", "", " \"Fixed - combination brimonidine - timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension .\"." +38413, Brimo/TimFC, 2222, 2243, "brimonidine - timolol", "", +80, Brimonidine, 2222, 2233, "brimonidine", "", +81, Timolol, 2236, 2243, "timolol", "", +82, Latanoprost, 2264, 2275, "latanoprost", "", +83, IOP, 2288, 2291, "IOP", "", +84, Glaucoma, 2309, 2317, "glaucoma", "", +85, OcularHypertension, 2321, 2340, "ocular hypertension", "", +192, ConclusionComment, 2343, 2403, "Both treatments demonstrated favorable ocular tolerability .", "", " \"Both treatments demonstrated favorable ocular tolerability .\". \"The duration of the study was 12 weeks , and additional studies will be needed to compare the efficacy and safety of fixed - combination brimonidine - timolol and latanoprost during long - term treatment .\"." +192, ConclusionComment, 2404, 2609, "The duration of the study was 12 weeks , and additional studies will be needed to compare the efficacy and safety of fixed - combination brimonidine - timolol and latanoprost during long - term treatment .", "", +187, Duration, 2434, 2442, "12 weeks", "", +38421, Brimo/TimFC, 2541, 2562, "brimonidine - timolol", "", +88, Brimonidine, 2541, 2552, "brimonidine", "", +89, Timolol, 2555, 2562, "timolol", "", +90, Latanoprost, 2567, 2578, "latanoprost", "", +91, PMID, 2660, 2668, "22458918", "", " \"22458918\"." diff --git a/data/gl 22458918_admin.n-triples b/data/gl 22458918_admin.n-triples new file mode 100644 index 0000000..ca2fdba --- /dev/null +++ b/data/gl 22458918_admin.n-triples @@ -0,0 +1,131 @@ +# RDF export of group: Publication + . + "Publication 66291" . + "Fixed - combination brimonidine - timolol versus latanoprost in glaucoma and ocular hypertension : a 12 - week , randomized , comparison study ." . + "Katz LJ" . + "2012" . + "Curr Med Res Opin ." . + "22458918" . + . + "Rauchman SH" . + "Cottingham AJ Jr" . + "Simmons ST" . + "Williams JM" . + "Schiffman RM" . + "Hollander DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 66304" . + "12 - week" . + . + . + . + "Fixed - combination brimonidine - timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension ." . + . + . + . + . + . + . + . + . + . + "Both treatments demonstrated favorable ocular tolerability ." . + "The duration of the study was 12 weeks , and additional studies will be needed to compare the efficacy and safety of fixed - combination brimonidine - timolol and latanoprost during long - term treatment ." . + . + . +# RDF export of group: Population + . + "Population 66326" . + "patients with glaucoma or ocular hypertension" . + . + . + . + "washout of any previous IOP - lowering medications , patients with IOP of 24   mmHg or higher" . +# RDF export of group: Endpoint + . + "Endpoint 66335 IOP" . + . + . + . + . + . + . + . + "Endpoint 66340 diurnal IOP20%" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 66390 BTFC" . + "73" . + . + . + . + . + . + "Arm 66399 Latanoprost" . + "75" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 66364 BTFC" . + . + "twice - daily" . + "12 weeks" . + . + . + "Intervention 66370 Latanoprost" . + . + "once - daily" . + "12 weeks" . + . +# RDF export of group: Medication + . + "Medication 66350 BTFC" . + . + . + . + . + "Medication 66357 Latanoprost" . + . + . + "0 . 005" . + . + . +# RDF export of group: Outcome + . + "Outcome 66440 BTFC" . + . + "17 . 8" . + "p  =  0 . 794" . + "2 . 9" . + "week 12" . + . + "Outcome 66467 Latanoprost" . + . + "17 . 9" . + "p  =  0 . 794" . + "3 . 9" . + "week 12" . + . + "Outcome 66494 at least 20% decrease from BL lat" . + . + "77 . 3" . + "p  =  0 . 131" . + "week 12" . + . + "Outcome 66521 at least 20% decrease from BL btfc" . + . + "87 . 7" . + "p  =  0 . 131" . + "week 12" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22458918_export.csv b/data/gl 22458918_export.csv new file mode 100644 index 0000000..a3cb73b --- /dev/null +++ b/data/gl 22458918_export.csv @@ -0,0 +1,567 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +425, 1, 1, 1, 0, 4, 0, 4, "Curr" +425, 1, 2, 2, 5, 8, 5, 8, "Med" +425, 1, 3, 3, 9, 12, 9, 12, "Res" +425, 1, 4, 4, 13, 17, 13, 17, "Opin" +425, 1, 5, 5, 18, 19, 18, 19, "." +425, 2, 1, 6, 0, 4, 20, 24, "2012" +425, 2, 2, 7, 5, 8, 25, 28, "May" +425, 2, 3, 8, 9, 10, 29, 30, ";" +425, 2, 4, 9, 11, 13, 31, 33, "28" +425, 2, 5, 10, 14, 15, 34, 35, "(" +425, 2, 6, 11, 16, 17, 36, 37, "5" +425, 2, 7, 12, 18, 19, 38, 39, ")" +425, 2, 8, 13, 20, 21, 40, 41, ":" +425, 2, 9, 14, 22, 25, 42, 45, "781" +425, 2, 10, 15, 26, 27, 46, 47, "-" +425, 2, 11, 16, 28, 29, 48, 49, "8" +425, 2, 12, 17, 30, 31, 50, 51, "." +425, 2, 13, 18, 32, 35, 52, 55, "doi" +425, 2, 14, 19, 36, 37, 56, 57, ":" +425, 2, 15, 20, 38, 40, 58, 60, "10" +425, 2, 16, 21, 41, 42, 61, 62, "." +425, 2, 17, 22, 43, 47, 63, 67, "1185" +425, 2, 18, 23, 48, 49, 68, 69, "/" +425, 2, 19, 24, 50, 58, 70, 78, "03007995" +425, 2, 20, 25, 59, 60, 79, 80, "." +425, 2, 21, 26, 61, 65, 81, 85, "2012" +425, 2, 22, 27, 66, 67, 86, 87, "." +425, 2, 23, 28, 68, 74, 88, 94, "681036" +425, 2, 24, 29, 75, 76, 95, 96, "." +425, 3, 1, 30, 0, 4, 97, 101, "Epub" +425, 3, 2, 31, 5, 9, 102, 106, "2012" +425, 3, 3, 32, 10, 13, 107, 110, "Apr" +425, 3, 4, 33, 14, 16, 111, 113, "25" +425, 3, 5, 34, 17, 18, 114, 115, "." +425, 4, 1, 35, 0, 5, 116, 121, "Fixed" +425, 4, 2, 36, 6, 7, 122, 123, "-" +425, 4, 3, 37, 8, 19, 124, 135, "combination" +425, 4, 4, 38, 20, 31, 136, 147, "brimonidine" +425, 4, 5, 39, 32, 33, 148, 149, "-" +425, 4, 6, 40, 34, 41, 150, 157, "timolol" +425, 4, 7, 41, 42, 48, 158, 164, "versus" +425, 4, 8, 42, 49, 60, 165, 176, "latanoprost" +425, 4, 9, 43, 61, 63, 177, 179, "in" +425, 4, 10, 44, 64, 72, 180, 188, "glaucoma" +425, 4, 11, 45, 73, 76, 189, 192, "and" +425, 4, 12, 46, 77, 83, 193, 199, "ocular" +425, 4, 13, 47, 84, 96, 200, 212, "hypertension" +425, 4, 14, 48, 97, 98, 213, 214, ":" +425, 4, 15, 49, 99, 100, 215, 216, "a" +425, 4, 16, 50, 101, 103, 217, 219, "12" +425, 4, 17, 51, 104, 105, 220, 221, "-" +425, 4, 18, 52, 106, 110, 222, 226, "week" +425, 4, 19, 53, 111, 112, 227, 228, "," +425, 4, 20, 54, 113, 123, 229, 239, "randomized" +425, 4, 21, 55, 124, 125, 240, 241, "," +425, 4, 22, 56, 126, 136, 242, 252, "comparison" +425, 4, 23, 57, 137, 142, 253, 258, "study" +425, 4, 24, 58, 143, 144, 259, 260, "." +425, 5, 1, 59, 0, 4, 261, 265, "Katz" +425, 5, 2, 60, 5, 7, 266, 268, "LJ" +425, 5, 3, 61, 8, 9, 269, 270, "(" +425, 5, 4, 62, 10, 11, 271, 272, "1" +425, 5, 5, 63, 12, 13, 273, 274, ")" +425, 5, 6, 64, 14, 15, 275, 276, "," +425, 5, 7, 65, 16, 24, 277, 285, "Rauchman" +425, 5, 8, 66, 25, 27, 286, 288, "SH" +425, 5, 9, 67, 28, 29, 289, 290, "," +425, 5, 10, 68, 30, 40, 291, 301, "Cottingham" +425, 5, 11, 69, 41, 43, 302, 304, "AJ" +425, 5, 12, 70, 44, 46, 305, 307, "Jr" +425, 5, 13, 71, 47, 48, 308, 309, "," +425, 5, 14, 72, 49, 56, 310, 317, "Simmons" +425, 5, 15, 73, 57, 59, 318, 320, "ST" +425, 5, 16, 74, 60, 61, 321, 322, "," +425, 5, 17, 75, 62, 70, 323, 331, "Williams" +425, 5, 18, 76, 71, 73, 332, 334, "JM" +425, 5, 19, 77, 74, 75, 335, 336, "," +425, 5, 20, 78, 76, 85, 337, 346, "Schiffman" +425, 5, 21, 79, 86, 88, 347, 349, "RM" +425, 5, 22, 80, 89, 90, 350, 351, "," +425, 5, 23, 81, 91, 100, 352, 361, "Hollander" +425, 5, 24, 82, 101, 103, 362, 364, "DA" +425, 5, 25, 83, 104, 105, 365, 366, "." +425, 6, 1, 84, 0, 6, 367, 373, "Author" +425, 6, 2, 85, 7, 18, 374, 385, "information" +425, 6, 3, 86, 19, 20, 386, 387, ":" +425, 6, 4, 87, 21, 22, 388, 389, "(" +425, 6, 5, 88, 23, 24, 390, 391, "1" +425, 6, 6, 89, 25, 26, 392, 393, ")" +425, 6, 7, 90, 27, 32, 394, 399, "Wills" +425, 6, 8, 91, 33, 36, 400, 403, "Eye" +425, 6, 9, 92, 37, 45, 404, 412, "Hospital" +425, 6, 10, 93, 46, 47, 413, 414, "," +425, 6, 11, 94, 48, 60, 415, 427, "Philadelphia" +425, 6, 12, 95, 61, 62, 428, 429, "," +425, 6, 13, 96, 63, 65, 430, 432, "PA" +425, 6, 14, 97, 66, 67, 433, 434, "," +425, 6, 15, 98, 68, 71, 435, 438, "USA" +425, 6, 16, 99, 72, 73, 439, 440, "." +425, 7, 1, 100, 0, 8, 441, 449, "ljk22222" +425, 7, 2, 101, 9, 10, 450, 451, "@" +425, 7, 3, 102, 11, 14, 452, 455, "aol" +425, 7, 4, 103, 15, 16, 456, 457, "." +425, 7, 5, 104, 17, 20, 458, 461, "com" +425, 7, 6, 105, 21, 30, 462, 471, "OBJECTIVE" +425, 7, 7, 106, 31, 32, 472, 473, ":" +425, 7, 8, 107, 33, 35, 474, 476, "To" +425, 7, 9, 108, 36, 44, 477, 485, "evaluate" +425, 7, 10, 109, 45, 48, 486, 489, "the" +425, 7, 11, 110, 49, 60, 490, 501, "intraocular" +425, 7, 12, 111, 61, 69, 502, 510, "pressure" +425, 7, 13, 112, 70, 71, 511, 512, "(" +425, 7, 14, 113, 72, 75, 513, 516, "IOP" +425, 7, 15, 114, 76, 77, 517, 518, ")" +425, 7, 16, 115, 78, 79, 519, 520, "-" +425, 7, 17, 116, 80, 88, 521, 529, "lowering" +425, 7, 18, 117, 89, 97, 530, 538, "efficacy" +425, 7, 19, 118, 98, 101, 539, 542, "and" +425, 7, 20, 119, 102, 108, 543, 549, "safety" +425, 7, 21, 120, 109, 111, 550, 552, "of" +425, 7, 22, 121, 112, 117, 553, 558, "fixed" +425, 7, 23, 122, 118, 119, 559, 560, "-" +425, 7, 24, 123, 120, 131, 561, 572, "combination" +425, 7, 25, 124, 132, 143, 573, 584, "brimonidine" +425, 7, 26, 125, 144, 145, 585, 586, "0" +425, 7, 27, 126, 146, 147, 587, 588, "." +425, 7, 28, 127, 148, 149, 589, 590, "2" +425, 7, 29, 128, 150, 151, 591, 592, "%" +425, 7, 30, 129, 152, 153, 593, 594, "-" +425, 7, 31, 130, 154, 161, 595, 602, "timolol" +425, 7, 32, 131, 162, 163, 603, 604, "0" +425, 7, 33, 132, 164, 165, 605, 606, "." +425, 7, 34, 133, 166, 167, 607, 608, "5" +425, 7, 35, 134, 168, 169, 609, 610, "%" +425, 7, 36, 135, 170, 178, 611, 619, "compared" +425, 7, 37, 136, 179, 183, 620, 624, "with" +425, 7, 38, 137, 184, 195, 625, 636, "latanoprost" +425, 7, 39, 138, 196, 197, 637, 638, "0" +425, 7, 40, 139, 198, 199, 639, 640, "." +425, 7, 41, 140, 200, 203, 641, 644, "005" +425, 7, 42, 141, 204, 205, 645, 646, "%" +425, 7, 43, 142, 206, 208, 647, 649, "in" +425, 7, 44, 143, 209, 217, 650, 658, "patients" +425, 7, 45, 144, 218, 222, 659, 663, "with" +425, 7, 46, 145, 223, 231, 664, 672, "glaucoma" +425, 7, 47, 146, 232, 234, 673, 675, "or" +425, 7, 48, 147, 235, 241, 676, 682, "ocular" +425, 7, 49, 148, 242, 254, 683, 695, "hypertension" +425, 7, 50, 149, 255, 256, 696, 697, "." +425, 8, 1, 150, 0, 8, 698, 706, "RESEARCH" +425, 8, 2, 151, 9, 15, 707, 713, "DESIGN" +425, 8, 3, 152, 16, 19, 714, 717, "AND" +425, 8, 4, 153, 20, 27, 718, 725, "METHODS" +425, 8, 5, 154, 28, 29, 726, 727, ":" +425, 8, 6, 155, 30, 34, 728, 732, "This" +425, 8, 7, 156, 35, 38, 733, 736, "was" +425, 8, 8, 157, 39, 40, 737, 738, "a" +425, 8, 9, 158, 41, 52, 739, 750, "prospective" +425, 8, 10, 159, 53, 54, 751, 752, "," +425, 8, 11, 160, 55, 65, 753, 763, "randomized" +425, 8, 12, 161, 66, 67, 764, 765, "," +425, 8, 13, 162, 68, 79, 766, 777, "multicenter" +425, 8, 14, 163, 80, 81, 778, 779, "," +425, 8, 15, 164, 82, 94, 780, 792, "investigator" +425, 8, 16, 165, 95, 96, 793, 794, "-" +425, 8, 17, 166, 97, 103, 795, 801, "masked" +425, 8, 18, 167, 104, 112, 802, 810, "clinical" +425, 8, 19, 168, 113, 118, 811, 816, "trial" +425, 8, 20, 169, 119, 120, 817, 818, "." +425, 9, 1, 170, 0, 5, 819, 824, "After" +425, 9, 2, 171, 6, 13, 825, 832, "washout" +425, 9, 3, 172, 14, 16, 833, 835, "of" +425, 9, 4, 173, 17, 20, 836, 839, "any" +425, 9, 5, 174, 21, 29, 840, 848, "previous" +425, 9, 6, 175, 30, 33, 849, 852, "IOP" +425, 9, 7, 176, 34, 35, 853, 854, "-" +425, 9, 8, 177, 36, 44, 855, 863, "lowering" +425, 9, 9, 178, 45, 56, 864, 875, "medications" +425, 9, 10, 179, 57, 58, 876, 877, "," +425, 9, 11, 180, 59, 67, 878, 886, "patients" +425, 9, 12, 181, 68, 72, 887, 891, "with" +425, 9, 13, 182, 73, 76, 892, 895, "IOP" +425, 9, 14, 183, 77, 79, 896, 898, "of" +425, 9, 15, 184, 80, 82, 899, 901, "24" +425, 9, 16, 185, 83, 84, 902, 903, " " +425, 9, 17, 186, 85, 89, 904, 908, "mmHg" +425, 9, 18, 187, 90, 92, 909, 911, "or" +425, 9, 19, 188, 93, 99, 912, 918, "higher" +425, 9, 20, 189, 100, 104, 919, 923, "were" +425, 9, 21, 190, 105, 115, 924, 934, "randomized" +425, 9, 22, 191, 116, 118, 935, 937, "to" +425, 9, 23, 192, 119, 124, 938, 943, "twice" +425, 9, 24, 193, 125, 126, 944, 945, "-" +425, 9, 25, 194, 127, 132, 946, 951, "daily" +425, 9, 26, 195, 133, 138, 952, 957, "fixed" +425, 9, 27, 196, 139, 140, 958, 959, "-" +425, 9, 28, 197, 141, 152, 960, 971, "combination" +425, 9, 29, 198, 153, 164, 972, 983, "brimonidine" +425, 9, 30, 199, 165, 166, 984, 985, "0" +425, 9, 31, 200, 167, 168, 986, 987, "." +425, 9, 32, 201, 169, 170, 988, 989, "2" +425, 9, 33, 202, 171, 172, 990, 991, "%" +425, 9, 34, 203, 173, 174, 992, 993, "-" +425, 9, 35, 204, 175, 182, 994, 1001, "timolol" +425, 9, 36, 205, 183, 184, 1002, 1003, "0" +425, 9, 37, 206, 185, 186, 1004, 1005, "." +425, 9, 38, 207, 187, 188, 1006, 1007, "5" +425, 9, 39, 208, 189, 190, 1008, 1009, "%" +425, 9, 40, 209, 191, 192, 1010, 1011, "(" +425, 9, 41, 210, 193, 194, 1012, 1013, "n" +425, 9, 42, 211, 195, 198, 1014, 1017, " = " +425, 9, 43, 212, 199, 201, 1018, 1020, "73" +425, 9, 44, 213, 202, 203, 1021, 1022, ")" +425, 9, 45, 214, 204, 206, 1023, 1025, "or" +425, 9, 46, 215, 207, 211, 1026, 1030, "once" +425, 9, 47, 216, 212, 213, 1031, 1032, "-" +425, 9, 48, 217, 214, 219, 1033, 1038, "daily" +425, 9, 49, 218, 220, 231, 1039, 1050, "latanoprost" +425, 9, 50, 219, 232, 233, 1051, 1052, "0" +425, 9, 51, 220, 234, 235, 1053, 1054, "." +425, 9, 52, 221, 236, 239, 1055, 1058, "005" +425, 9, 53, 222, 240, 241, 1059, 1060, "%" +425, 9, 54, 223, 242, 243, 1061, 1062, "(" +425, 9, 55, 224, 244, 245, 1063, 1064, "n" +425, 9, 56, 225, 246, 249, 1065, 1068, " = " +425, 9, 57, 226, 250, 252, 1069, 1071, "75" +425, 9, 58, 227, 253, 254, 1072, 1073, "," +425, 9, 59, 228, 255, 260, 1074, 1079, "dosed" +425, 9, 60, 229, 261, 263, 1080, 1082, "in" +425, 9, 61, 230, 264, 267, 1083, 1086, "the" +425, 9, 62, 231, 268, 275, 1087, 1094, "evening" +425, 9, 63, 232, 276, 277, 1095, 1096, "," +425, 9, 64, 233, 278, 282, 1097, 1101, "with" +425, 9, 65, 234, 283, 290, 1102, 1109, "vehicle" +425, 9, 66, 235, 291, 298, 1110, 1117, "control" +425, 9, 67, 236, 299, 301, 1118, 1120, "in" +425, 9, 68, 237, 302, 305, 1121, 1124, "the" +425, 9, 69, 238, 306, 313, 1125, 1132, "morning" +425, 9, 70, 239, 314, 316, 1133, 1135, "to" +425, 9, 71, 240, 317, 325, 1136, 1144, "maintain" +425, 9, 72, 241, 326, 333, 1145, 1152, "masking" +425, 9, 73, 242, 334, 335, 1153, 1154, ")" +425, 9, 74, 243, 336, 339, 1155, 1158, "for" +425, 9, 75, 244, 340, 342, 1159, 1161, "12" +425, 9, 76, 245, 343, 348, 1162, 1167, "weeks" +425, 9, 77, 246, 349, 350, 1168, 1169, "." +425, 10, 1, 247, 0, 3, 1170, 1173, "IOP" +425, 10, 2, 248, 4, 7, 1174, 1177, "was" +425, 10, 3, 249, 8, 16, 1178, 1186, "measured" +425, 10, 4, 250, 17, 19, 1187, 1189, "at" +425, 10, 5, 251, 20, 21, 1190, 1191, "8" +425, 10, 6, 252, 22, 23, 1192, 1193, "a" +425, 10, 7, 253, 24, 25, 1194, 1195, "." +425, 10, 8, 254, 26, 27, 1196, 1197, "m" +425, 10, 9, 255, 28, 29, 1198, 1199, "." +425, 10, 10, 256, 30, 31, 1200, 1201, "(" +425, 10, 11, 257, 32, 38, 1202, 1208, "before" +425, 10, 12, 258, 39, 45, 1209, 1215, "dosing" +425, 10, 13, 259, 46, 47, 1216, 1217, ")" +425, 10, 14, 260, 48, 49, 1218, 1219, "," +425, 10, 15, 261, 50, 52, 1220, 1222, "10" +425, 10, 16, 262, 53, 54, 1223, 1224, "a" +425, 10, 17, 263, 55, 56, 1225, 1226, "." +425, 10, 18, 264, 57, 58, 1227, 1228, "m" +425, 10, 19, 265, 59, 60, 1229, 1230, "." +425, 10, 20, 266, 61, 62, 1231, 1232, "," +425, 10, 21, 267, 63, 66, 1233, 1236, "and" +425, 10, 22, 268, 67, 68, 1237, 1238, "3" +425, 10, 23, 269, 69, 70, 1239, 1240, "p" +425, 10, 24, 270, 71, 72, 1241, 1242, "." +425, 10, 25, 271, 73, 74, 1243, 1244, "m" +425, 10, 26, 272, 75, 76, 1245, 1246, "." +425, 10, 27, 273, 77, 79, 1247, 1249, "at" +425, 10, 28, 274, 80, 88, 1250, 1258, "baseline" +425, 10, 29, 275, 89, 90, 1259, 1260, "," +425, 10, 30, 276, 91, 95, 1261, 1265, "week" +425, 10, 31, 277, 96, 97, 1266, 1267, "6" +425, 10, 32, 278, 98, 99, 1268, 1269, "," +425, 10, 33, 279, 100, 103, 1270, 1273, "and" +425, 10, 34, 280, 104, 108, 1274, 1278, "week" +425, 10, 35, 281, 109, 111, 1279, 1281, "12" +425, 10, 36, 282, 112, 113, 1282, 1283, "." +425, 11, 1, 283, 0, 8, 1284, 1292, "CLINICAL" +425, 11, 2, 284, 9, 14, 1293, 1298, "TRIAL" +425, 11, 3, 285, 15, 27, 1299, 1311, "REGISTRATION" +425, 11, 4, 286, 28, 29, 1312, 1313, ":" +425, 11, 5, 287, 30, 33, 1314, 1317, "The" +425, 11, 6, 288, 34, 39, 1318, 1323, "trial" +425, 11, 7, 289, 40, 42, 1324, 1326, "is" +425, 11, 8, 290, 43, 53, 1327, 1337, "registered" +425, 11, 9, 291, 54, 58, 1338, 1342, "with" +425, 11, 10, 292, 59, 62, 1343, 1346, "the" +425, 11, 11, 293, 63, 73, 1347, 1357, "identifier" +425, 11, 12, 294, 74, 82, 1358, 1366, "00811564" +425, 11, 13, 295, 83, 85, 1367, 1369, "at" +425, 11, 14, 296, 86, 90, 1370, 1374, "http" +425, 11, 15, 297, 91, 92, 1375, 1376, ":" +425, 11, 16, 298, 93, 94, 1377, 1378, "/" +425, 11, 17, 299, 95, 96, 1379, 1380, "/" +425, 11, 18, 300, 97, 100, 1381, 1384, "www" +425, 11, 19, 301, 101, 102, 1385, 1386, "." +425, 11, 20, 302, 103, 117, 1387, 1401, "clinicaltrials" +425, 11, 21, 303, 118, 119, 1402, 1403, "." +425, 11, 22, 304, 120, 123, 1404, 1407, "gov" +425, 11, 23, 305, 124, 125, 1408, 1409, "." +425, 12, 1, 306, 0, 4, 1410, 1414, "MAIN" +425, 12, 2, 307, 5, 12, 1415, 1422, "OUTCOME" +425, 12, 3, 308, 13, 21, 1423, 1431, "MEASURES" +425, 12, 4, 309, 22, 23, 1432, 1433, ":" +425, 12, 5, 310, 24, 27, 1434, 1437, "The" +425, 12, 6, 311, 28, 35, 1438, 1445, "primary" +425, 12, 7, 312, 36, 44, 1446, 1454, "efficacy" +425, 12, 8, 313, 45, 53, 1455, 1463, "endpoint" +425, 12, 9, 314, 54, 57, 1464, 1467, "was" +425, 12, 10, 315, 58, 65, 1468, 1475, "diurnal" +425, 12, 11, 316, 66, 69, 1476, 1479, "IOP" +425, 12, 12, 317, 70, 71, 1480, 1481, "(" +425, 12, 13, 318, 72, 80, 1482, 1490, "averaged" +425, 12, 14, 319, 81, 85, 1491, 1495, "over" +425, 12, 15, 320, 86, 87, 1496, 1497, "8" +425, 12, 16, 321, 88, 89, 1498, 1499, "a" +425, 12, 17, 322, 90, 91, 1500, 1501, "." +425, 12, 18, 323, 92, 93, 1502, 1503, "m" +425, 12, 19, 324, 94, 95, 1504, 1505, "." +425, 12, 20, 325, 96, 97, 1506, 1507, "," +425, 12, 21, 326, 98, 100, 1508, 1510, "10" +425, 12, 22, 327, 101, 102, 1511, 1512, "a" +425, 12, 23, 328, 103, 104, 1513, 1514, "." +425, 12, 24, 329, 105, 106, 1515, 1516, "m" +425, 12, 25, 330, 107, 108, 1517, 1518, "." +425, 12, 26, 331, 109, 110, 1519, 1520, "," +425, 12, 27, 332, 111, 114, 1521, 1524, "and" +425, 12, 28, 333, 115, 116, 1525, 1526, "3" +425, 12, 29, 334, 117, 118, 1527, 1528, "p" +425, 12, 30, 335, 119, 120, 1529, 1530, "." +425, 12, 31, 336, 121, 122, 1531, 1532, "m" +425, 12, 32, 337, 123, 124, 1533, 1534, "." +425, 12, 33, 338, 125, 126, 1535, 1536, ")" +425, 12, 34, 339, 127, 129, 1537, 1539, "at" +425, 12, 35, 340, 130, 134, 1540, 1544, "week" +425, 12, 36, 341, 135, 137, 1545, 1547, "12" +425, 12, 37, 342, 138, 139, 1548, 1549, "." +425, 13, 1, 343, 0, 6, 1550, 1556, "Safety" +425, 13, 2, 344, 7, 15, 1557, 1565, "measures" +425, 13, 3, 345, 16, 24, 1566, 1574, "included" +425, 13, 4, 346, 25, 38, 1575, 1588, "biomicroscopy" +425, 13, 5, 347, 39, 40, 1589, 1590, "." +425, 14, 1, 348, 0, 7, 1591, 1598, "RESULTS" +425, 14, 2, 349, 8, 9, 1599, 1600, ":" +425, 14, 3, 350, 10, 15, 1601, 1606, "There" +425, 14, 4, 351, 16, 19, 1607, 1610, "was" +425, 14, 5, 352, 20, 22, 1611, 1613, "no" +425, 14, 6, 353, 23, 36, 1614, 1627, "statistically" +425, 14, 7, 354, 37, 48, 1628, 1639, "significant" +425, 14, 8, 355, 49, 59, 1640, 1650, "difference" +425, 14, 9, 356, 60, 67, 1651, 1658, "between" +425, 14, 10, 357, 68, 71, 1659, 1662, "the" +425, 14, 11, 358, 72, 81, 1663, 1672, "treatment" +425, 14, 12, 359, 82, 88, 1673, 1679, "groups" +425, 14, 13, 360, 89, 91, 1680, 1682, "in" +425, 14, 14, 361, 92, 96, 1683, 1687, "mean" +425, 14, 15, 362, 97, 104, 1688, 1695, "diurnal" +425, 14, 16, 363, 105, 108, 1696, 1699, "IOP" +425, 14, 17, 364, 109, 111, 1700, 1702, "at" +425, 14, 18, 365, 112, 120, 1703, 1711, "baseline" +425, 14, 19, 366, 121, 122, 1712, 1713, "(" +425, 14, 20, 367, 123, 124, 1714, 1715, "p" +425, 14, 21, 368, 125, 128, 1716, 1719, " = " +425, 14, 22, 369, 129, 130, 1720, 1721, "0" +425, 14, 23, 370, 131, 132, 1722, 1723, "." +425, 14, 24, 371, 133, 136, 1724, 1727, "118" +425, 14, 25, 372, 137, 138, 1728, 1729, ")" +425, 14, 26, 373, 139, 140, 1730, 1731, "." +425, 15, 1, 374, 0, 2, 1732, 1734, "At" +425, 15, 2, 375, 3, 7, 1735, 1739, "week" +425, 15, 3, 376, 8, 10, 1740, 1742, "12" +425, 15, 4, 377, 11, 12, 1743, 1744, "," +425, 15, 5, 378, 13, 16, 1745, 1748, "the" +425, 15, 6, 379, 17, 21, 1749, 1753, "mean" +425, 15, 7, 380, 22, 23, 1754, 1755, "(" +425, 15, 8, 381, 24, 26, 1756, 1758, "SD" +425, 15, 9, 382, 27, 28, 1759, 1760, ")" +425, 15, 10, 383, 29, 36, 1761, 1768, "diurnal" +425, 15, 11, 384, 37, 40, 1769, 1772, "IOP" +425, 15, 12, 385, 41, 44, 1773, 1776, "was" +425, 15, 13, 386, 45, 47, 1777, 1779, "17" +425, 15, 14, 387, 48, 49, 1780, 1781, "." +425, 15, 15, 388, 50, 51, 1782, 1783, "8" +425, 15, 16, 389, 52, 53, 1784, 1785, "(" +425, 15, 17, 390, 54, 55, 1786, 1787, "2" +425, 15, 18, 391, 56, 57, 1788, 1789, "." +425, 15, 19, 392, 58, 59, 1790, 1791, "9" +425, 15, 20, 393, 60, 61, 1792, 1793, ")" +425, 15, 21, 394, 62, 63, 1794, 1795, " " +425, 15, 22, 395, 64, 68, 1796, 1800, "mmHg" +425, 15, 23, 396, 69, 73, 1801, 1805, "with" +425, 15, 24, 397, 74, 85, 1806, 1817, "brimonidine" +425, 15, 25, 398, 86, 87, 1818, 1819, "-" +425, 15, 26, 399, 88, 95, 1820, 1827, "timolol" +425, 15, 27, 400, 96, 99, 1828, 1831, "and" +425, 15, 28, 401, 100, 102, 1832, 1834, "17" +425, 15, 29, 402, 103, 104, 1835, 1836, "." +425, 15, 30, 403, 105, 106, 1837, 1838, "9" +425, 15, 31, 404, 107, 108, 1839, 1840, "(" +425, 15, 32, 405, 109, 110, 1841, 1842, "3" +425, 15, 33, 406, 111, 112, 1843, 1844, "." +425, 15, 34, 407, 113, 114, 1845, 1846, "9" +425, 15, 35, 408, 115, 116, 1847, 1848, ")" +425, 15, 36, 409, 117, 118, 1849, 1850, " " +425, 15, 37, 410, 119, 123, 1851, 1855, "mmHg" +425, 15, 38, 411, 124, 128, 1856, 1860, "with" +425, 15, 39, 412, 129, 140, 1861, 1872, "latanoprost" +425, 15, 40, 413, 141, 142, 1873, 1874, "(" +425, 15, 41, 414, 143, 144, 1875, 1876, "p" +425, 15, 42, 415, 145, 148, 1877, 1880, " = " +425, 15, 43, 416, 149, 150, 1881, 1882, "0" +425, 15, 44, 417, 151, 152, 1883, 1884, "." +425, 15, 45, 418, 153, 156, 1885, 1888, "794" +425, 15, 46, 419, 157, 158, 1889, 1890, ")" +425, 15, 47, 420, 159, 160, 1891, 1892, "." +425, 16, 1, 421, 0, 3, 1893, 1896, "The" +425, 16, 2, 422, 4, 14, 1897, 1907, "percentage" +425, 16, 3, 423, 15, 17, 1908, 1910, "of" +425, 16, 4, 424, 18, 26, 1911, 1919, "patients" +425, 16, 5, 425, 27, 36, 1920, 1929, "achieving" +425, 16, 6, 426, 37, 39, 1930, 1932, "at" +425, 16, 7, 427, 40, 45, 1933, 1938, "least" +425, 16, 8, 428, 46, 47, 1939, 1940, "a" +425, 16, 9, 429, 48, 50, 1941, 1943, "20" +425, 16, 10, 430, 51, 52, 1944, 1945, "%" +425, 16, 11, 431, 53, 61, 1946, 1954, "decrease" +425, 16, 12, 432, 62, 66, 1955, 1959, "from" +425, 16, 13, 433, 67, 75, 1960, 1968, "baseline" +425, 16, 14, 434, 76, 83, 1969, 1976, "diurnal" +425, 16, 15, 435, 84, 87, 1977, 1980, "IOP" +425, 16, 16, 436, 88, 90, 1981, 1983, "at" +425, 16, 17, 437, 91, 95, 1984, 1988, "week" +425, 16, 18, 438, 96, 98, 1989, 1991, "12" +425, 16, 19, 439, 99, 102, 1992, 1995, "was" +425, 16, 20, 440, 103, 105, 1996, 1998, "87" +425, 16, 21, 441, 106, 107, 1999, 2000, "." +425, 16, 22, 442, 108, 109, 2001, 2002, "7" +425, 16, 23, 443, 110, 111, 2003, 2004, "%" +425, 16, 24, 444, 112, 114, 2005, 2007, "in" +425, 16, 25, 445, 115, 118, 2008, 2011, "the" +425, 16, 26, 446, 119, 130, 2012, 2023, "brimonidine" +425, 16, 27, 447, 131, 132, 2024, 2025, "-" +425, 16, 28, 448, 133, 140, 2026, 2033, "timolol" +425, 16, 29, 449, 141, 146, 2034, 2039, "group" +425, 16, 30, 450, 147, 150, 2040, 2043, "and" +425, 16, 31, 451, 151, 153, 2044, 2046, "77" +425, 16, 32, 452, 154, 155, 2047, 2048, "." +425, 16, 33, 453, 156, 157, 2049, 2050, "3" +425, 16, 34, 454, 158, 159, 2051, 2052, "%" +425, 16, 35, 455, 160, 162, 2053, 2055, "in" +425, 16, 36, 456, 163, 166, 2056, 2059, "the" +425, 16, 37, 457, 167, 178, 2060, 2071, "latanoprost" +425, 16, 38, 458, 179, 184, 2072, 2077, "group" +425, 16, 39, 459, 185, 186, 2078, 2079, "(" +425, 16, 40, 460, 187, 188, 2080, 2081, "p" +425, 16, 41, 461, 189, 192, 2082, 2085, " = " +425, 16, 42, 462, 193, 194, 2086, 2087, "0" +425, 16, 43, 463, 195, 196, 2088, 2089, "." +425, 16, 44, 464, 197, 200, 2090, 2093, "131" +425, 16, 45, 465, 201, 202, 2094, 2095, ")" +425, 16, 46, 466, 203, 204, 2096, 2097, "." +425, 17, 1, 467, 0, 8, 2098, 2106, "Measured" +425, 17, 2, 468, 9, 23, 2107, 2121, "biomicroscopic" +425, 17, 3, 469, 24, 31, 2122, 2129, "changes" +425, 17, 4, 470, 32, 36, 2130, 2134, "from" +425, 17, 5, 471, 37, 45, 2135, 2143, "baseline" +425, 17, 6, 472, 46, 48, 2144, 2146, "to" +425, 17, 7, 473, 49, 53, 2147, 2151, "week" +425, 17, 8, 474, 54, 56, 2152, 2154, "12" +425, 17, 9, 475, 57, 61, 2155, 2159, "were" +425, 17, 10, 476, 62, 72, 2160, 2170, "infrequent" +425, 17, 11, 477, 73, 75, 2171, 2173, "in" +425, 17, 12, 478, 76, 80, 2174, 2178, "both" +425, 17, 13, 479, 81, 87, 2179, 2185, "groups" +425, 17, 14, 480, 88, 89, 2186, 2187, "." +425, 18, 1, 481, 0, 11, 2188, 2199, "CONCLUSIONS" +425, 18, 2, 482, 12, 13, 2200, 2201, ":" +425, 18, 3, 483, 14, 19, 2202, 2207, "Fixed" +425, 18, 4, 484, 20, 21, 2208, 2209, "-" +425, 18, 5, 485, 22, 33, 2210, 2221, "combination" +425, 18, 6, 486, 34, 45, 2222, 2233, "brimonidine" +425, 18, 7, 487, 46, 47, 2234, 2235, "-" +425, 18, 8, 488, 48, 55, 2236, 2243, "timolol" +425, 18, 9, 489, 56, 59, 2244, 2247, "was" +425, 18, 10, 490, 60, 62, 2248, 2250, "as" +425, 18, 11, 491, 63, 72, 2251, 2260, "effective" +425, 18, 12, 492, 73, 75, 2261, 2263, "as" +425, 18, 13, 493, 76, 87, 2264, 2275, "latanoprost" +425, 18, 14, 494, 88, 90, 2276, 2278, "in" +425, 18, 15, 495, 91, 99, 2279, 2287, "reducing" +425, 18, 16, 496, 100, 103, 2288, 2291, "IOP" +425, 18, 17, 497, 104, 106, 2292, 2294, "in" +425, 18, 18, 498, 107, 115, 2295, 2303, "patients" +425, 18, 19, 499, 116, 120, 2304, 2308, "with" +425, 18, 20, 500, 121, 129, 2309, 2317, "glaucoma" +425, 18, 21, 501, 130, 132, 2318, 2320, "or" +425, 18, 22, 502, 133, 139, 2321, 2327, "ocular" +425, 18, 23, 503, 140, 152, 2328, 2340, "hypertension" +425, 18, 24, 504, 153, 154, 2341, 2342, "." +425, 19, 1, 505, 0, 4, 2343, 2347, "Both" +425, 19, 2, 506, 5, 15, 2348, 2358, "treatments" +425, 19, 3, 507, 16, 28, 2359, 2371, "demonstrated" +425, 19, 4, 508, 29, 38, 2372, 2381, "favorable" +425, 19, 5, 509, 39, 45, 2382, 2388, "ocular" +425, 19, 6, 510, 46, 58, 2389, 2401, "tolerability" +425, 19, 7, 511, 59, 60, 2402, 2403, "." +425, 20, 1, 512, 0, 3, 2404, 2407, "The" +425, 20, 2, 513, 4, 12, 2408, 2416, "duration" +425, 20, 3, 514, 13, 15, 2417, 2419, "of" +425, 20, 4, 515, 16, 19, 2420, 2423, "the" +425, 20, 5, 516, 20, 25, 2424, 2429, "study" +425, 20, 6, 517, 26, 29, 2430, 2433, "was" +425, 20, 7, 518, 30, 32, 2434, 2436, "12" +425, 20, 8, 519, 33, 38, 2437, 2442, "weeks" +425, 20, 9, 520, 39, 40, 2443, 2444, "," +425, 20, 10, 521, 41, 44, 2445, 2448, "and" +425, 20, 11, 522, 45, 55, 2449, 2459, "additional" +425, 20, 12, 523, 56, 63, 2460, 2467, "studies" +425, 20, 13, 524, 64, 68, 2468, 2472, "will" +425, 20, 14, 525, 69, 71, 2473, 2475, "be" +425, 20, 15, 526, 72, 78, 2476, 2482, "needed" +425, 20, 16, 527, 79, 81, 2483, 2485, "to" +425, 20, 17, 528, 82, 89, 2486, 2493, "compare" +425, 20, 18, 529, 90, 93, 2494, 2497, "the" +425, 20, 19, 530, 94, 102, 2498, 2506, "efficacy" +425, 20, 20, 531, 103, 106, 2507, 2510, "and" +425, 20, 21, 532, 107, 113, 2511, 2517, "safety" +425, 20, 22, 533, 114, 116, 2518, 2520, "of" +425, 20, 23, 534, 117, 122, 2521, 2526, "fixed" +425, 20, 24, 535, 123, 124, 2527, 2528, "-" +425, 20, 25, 536, 125, 136, 2529, 2540, "combination" +425, 20, 26, 537, 137, 148, 2541, 2552, "brimonidine" +425, 20, 27, 538, 149, 150, 2553, 2554, "-" +425, 20, 28, 539, 151, 158, 2555, 2562, "timolol" +425, 20, 29, 540, 159, 162, 2563, 2566, "and" +425, 20, 30, 541, 163, 174, 2567, 2578, "latanoprost" +425, 20, 31, 542, 175, 181, 2579, 2585, "during" +425, 20, 32, 543, 182, 186, 2586, 2590, "long" +425, 20, 33, 544, 187, 188, 2591, 2592, "-" +425, 20, 34, 545, 189, 193, 2593, 2597, "term" +425, 20, 35, 546, 194, 203, 2598, 2607, "treatment" +425, 20, 36, 547, 204, 205, 2608, 2609, "." +425, 21, 1, 548, 0, 3, 2610, 2613, "DOI" +425, 21, 2, 549, 4, 5, 2614, 2615, ":" +425, 21, 3, 550, 6, 8, 2616, 2618, "10" +425, 21, 4, 551, 9, 10, 2619, 2620, "." +425, 21, 5, 552, 11, 15, 2621, 2625, "1185" +425, 21, 6, 553, 16, 17, 2626, 2627, "/" +425, 21, 7, 554, 18, 26, 2628, 2636, "03007995" +425, 21, 8, 555, 27, 28, 2637, 2638, "." +425, 21, 9, 556, 29, 33, 2639, 2643, "2012" +425, 21, 10, 557, 34, 35, 2644, 2645, "." +425, 21, 11, 558, 36, 42, 2646, 2652, "681036" +425, 21, 12, 559, 43, 47, 2653, 2657, "PMID" +425, 21, 13, 560, 48, 49, 2658, 2659, ":" +425, 21, 14, 561, 50, 58, 2660, 2668, "22458918" +425, 21, 15, 562, 59, 60, 2669, 2670, "[" +425, 21, 16, 563, 61, 68, 2671, 2678, "Indexed" +425, 21, 17, 564, 69, 72, 2679, 2682, "for" +425, 21, 18, 565, 73, 80, 2683, 2690, "MEDLINE" +425, 21, 19, 566, 81, 82, 2691, 2692, "]" diff --git a/data/gl 22458918_jshahinitiran.annodb b/data/gl 22458918_jshahinitiran.annodb new file mode 100644 index 0000000..afe9a78 --- /dev/null +++ b/data/gl 22458918_jshahinitiran.annodb @@ -0,0 +1,104 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16391, Journal, 0, 17, "Curr Med Res Opin", "", +16392, PublicationYear, 20, 24, "2012", "", +16393, Title, 116, 258, "Fixed - combination brimonidine - timolol versus latanoprost in glaucoma and ocular hypertension : a 12 - week , randomized , comparison study", "", +16394, Brimonidine, 136, 147, "brimonidine", "", +16395, Timolol, 150, 157, "timolol", "", +16396, Latanoprost, 165, 176, "latanoprost", "", +16397, Glaucoma, 180, 188, "glaucoma", "", +16398, OcularHypertension, 193, 212, "ocular hypertension", "", +16399, Duration, 217, 226, "12 - week", "", +16400, Randomized, 229, 239, "randomized", "", +16401, Author, 261, 268, "Katz LJ", "", +16402, Author, 277, 288, "Rauchman SH", "", +16403, Author, 291, 307, "Cottingham AJ Jr", "", +16404, Author, 310, 320, "Simmons ST", "", +16405, Author, 323, 334, "Williams JM", "", +16406, Author, 337, 349, "Schiffman RM", "", +16407, Author, 352, 364, "Hollander DA", "", +16408, USA, 435, 438, "USA", "", +16409, ObjectiveDescription, 474, 697, "To evaluate the intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % - timolol 0 . 5 % compared with latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension .", "", +16410, IOP, 490, 510, "intraocular pressure", "", +16411, IOP, 513, 516, "IOP", "", +16412, Brimonidine, 573, 584, "brimonidine", "", +16414, DoseValue, 585, 590, "0 . 2", "", +16416, Percentage, 591, 592, "%", "", +16413, Timolol, 595, 602, "timolol", "", +16415, DoseValue, 603, 608, "0 . 5", "", +16417, Percentage, 609, 610, "%", "", +16418, Latanoprost, 625, 636, "latanoprost", "", +16419, DoseValue, 637, 644, "0 . 005", "", +16420, Percentage, 645, 646, "%", "", +16421, Glaucoma, 664, 672, "glaucoma", "", +16422, OcularHypertension, 676, 695, "ocular hypertension", "", +16423, CTDesign, 739, 750, "prospective", "", +16424, Randomized, 753, 763, "randomized", "", +16425, Multicenter, 766, 777, "multicenter", "", +16426, Blind, 780, 801, "investigator - masked", "", +16427, IOP, 849, 852, "IOP", "", +16428, IOP, 892, 895, "IOP", "", +16430, Precondition, 892, 918, "IOP of 24   mmHg or higher", "", +16429, mmHg, 904, 908, "mmHg", "", +16431, Randomized, 924, 934, "randomized", "", +16432, Frequency, 938, 951, "twice - daily", "", +16433, Brimonidine, 972, 983, "brimonidine", "", +16435, DoseValue, 984, 989, "0 . 2", "", +16437, Percentage, 990, 991, "%", "", +16434, Timolol, 994, 1001, "timolol", "", +16436, DoseValue, 1002, 1007, "0 . 5", "", +16438, Percentage, 1008, 1009, "%", "", +16439, NumberPatientsArm, 1018, 1020, "73", "", +16440, Frequency, 1026, 1038, "once - daily", "", +16441, Latanoprost, 1039, 1050, "latanoprost", "", +16442, DoseValue, 1051, 1058, "0 . 005", "", +16443, Percentage, 1059, 1060, "%", "", +16444, NumberPatientsArm, 1069, 1071, "75", "", +16445, Bedtime, 1087, 1094, "evening", "", +16446, Placebo, 1102, 1109, "vehicle", "", +16447, Morning, 1125, 1132, "morning", "", +16448, Duration, 1159, 1167, "12 weeks", "", +16449, IOP, 1170, 1173, "IOP", "", +16450, TimePoint, 1274, 1281, "week 12", "", +16451, Diurnal_IOP, 1468, 1479, "diurnal IOP", "", +16493, Mean, 1482, 1490, "averaged", "", +16452, TimePoint, 1540, 1547, "week 12", "", +16453, Mean, 1683, 1687, "mean", "", +16454, Diurnal_IOP, 1688, 1699, "diurnal IOP", "", +16455, PvalueDiff, 1714, 1727, "p  =  0 . 118", "", +16456, TimePoint, 1735, 1742, "week 12", "", +16457, Mean, 1749, 1753, "mean", "", +16458, Diurnal_IOP, 1761, 1772, "diurnal IOP", "", +16459, ResultMeasuredValue, 1777, 1783, "17 . 8", "", +16460, SdDevResValue, 1786, 1791, "2 . 9", "", +16461, mmHg, 1796, 1800, "mmHg", "", +16462, Brimonidine, 1806, 1817, "brimonidine", "", +16463, Timolol, 1820, 1827, "timolol", "", +16464, ResultMeasuredValue, 1832, 1838, "17 . 9", "", +16465, SdDevResValue, 1841, 1846, "3 . 9", "", +16466, mmHg, 1851, 1855, "mmHg", "", +16467, Latanoprost, 1861, 1872, "latanoprost", "", +16468, PValueResValue, 1875, 1888, "p  =  0 . 794", "", +16469, EndPointDescription, 1930, 1980, "at least a 20 % decrease from baseline diurnal IOP", "", +16470, Diurnal_IOP, 1969, 1980, "diurnal IOP", "", +16471, TimePoint, 1984, 1991, "week 12", "", +16472, PercentageAffected, 1996, 2002, "87 . 7", "", +16474, Brimonidine, 2012, 2023, "brimonidine", "", +16475, Timolol, 2026, 2033, "timolol", "", +16473, PercentageAffected, 2044, 2050, "77 . 3", "", +16476, Latanoprost, 2060, 2071, "latanoprost", "", +16477, PValueNumAffected, 2080, 2093, "p  =  0 . 131", "", +16478, TimePoint, 2147, 2154, "week 12", "", +16489, ConclusionComment, 2202, 2342, "Fixed - combination brimonidine - timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension .", "", +16479, Brimonidine, 2222, 2233, "brimonidine", "", +16480, Timolol, 2236, 2243, "timolol", "", +16481, Latanoprost, 2264, 2275, "latanoprost", "", +16482, IOP, 2288, 2291, "IOP", "", +16483, Glaucoma, 2309, 2317, "glaucoma", "", +16484, OcularHypertension, 2321, 2340, "ocular hypertension", "", +16490, ConclusionComment, 2343, 2403, "Both treatments demonstrated favorable ocular tolerability .", "", +16491, ConclusionComment, 2404, 2607, "The duration of the study was 12 weeks , and additional studies will be needed to compare the efficacy and safety of fixed - combination brimonidine - timolol and latanoprost during long - term treatment", "", +16485, Duration, 2434, 2442, "12 weeks", "", +16486, Brimonidine, 2541, 2552, "brimonidine", "", +16487, Timolol, 2555, 2562, "timolol", "", +16488, Latanoprost, 2567, 2578, "latanoprost", "", +16492, PMID, 2660, 2668, "22458918", "", diff --git a/data/gl 22458918_jshahinitiran.n-triples b/data/gl 22458918_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22458918_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22458918_tstrakeljahn.annodb b/data/gl 22458918_tstrakeljahn.annodb new file mode 100644 index 0000000..8d79b42 --- /dev/null +++ b/data/gl 22458918_tstrakeljahn.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12394, Journal, 0, 17, "Curr Med Res Opin", "", +12395, PublicationYear, 20, 24, "2012", "", +12448, Title, 116, 258, "Fixed - combination brimonidine - timolol versus latanoprost in glaucoma and ocular hypertension : a 12 - week , randomized , comparison study", "", +12396, Brimonidine, 136, 147, "brimonidine", "", +12397, Timolol, 150, 157, "timolol", "", +12398, Latanoprost, 165, 176, "latanoprost", "", +12399, Glaucoma, 180, 188, "glaucoma", "", +12400, OcularHypertension, 193, 212, "ocular hypertension", "", +12402, Duration, 217, 226, "12 - week", "", +12401, Randomized, 229, 239, "randomized", "", +12403, Author, 261, 268, "Katz LJ", "", +12404, Author, 277, 288, "Rauchman SH", "", +12405, Author, 291, 307, "Cottingham AJ Jr", "", +12406, Author, 310, 320, "Simmons ST", "", +12407, Author, 323, 334, "Williams JM", "", +12408, Author, 337, 349, "Schiffman RM", "", +12409, Author, 352, 364, "Hollander DA", "", +12410, USA, 435, 438, "USA", "", +12424, ObjectiveDescription, 474, 695, "To evaluate the intraocular pressure ( IOP ) - lowering efficacy and safety of fixed - combination brimonidine 0 . 2 % - timolol 0 . 5 % compared with latanoprost 0 . 005 % in patients with glaucoma or ocular hypertension", "", +12411, IOP, 490, 510, "intraocular pressure", "", +12412, IOP, 513, 516, "IOP", "", +12413, Brimonidine, 573, 584, "brimonidine", "", +12418, DoseValue, 585, 590, "0 . 2", "", +12421, Percentage, 591, 592, "%", "", +12414, Timolol, 595, 602, "timolol", "", +12419, DoseValue, 603, 608, "0 . 5", "", +12422, Percentage, 609, 610, "%", "", +12415, Latanoprost, 625, 636, "latanoprost", "", +12420, DoseValue, 637, 644, "0 . 005", "", +12423, Percentage, 645, 646, "%", "", +12416, Glaucoma, 664, 672, "glaucoma", "", +12417, OcularHypertension, 676, 695, "ocular hypertension", "", +12425, Randomized, 753, 763, "randomized", "", +12426, Multicenter, 766, 777, "multicenter", "", +12427, Blind, 795, 801, "masked", "", +12428, ClinicalTrial, 802, 816, "clinical trial", "", +12429, IOP, 849, 852, "IOP", "", +12430, IOP, 892, 895, "IOP", "", +12431, Randomized, 924, 934, "randomized", "", +12432, Frequency, 938, 951, "twice - daily", "", +12433, Brimonidine, 972, 983, "brimonidine", "", +12436, DoseValue, 984, 989, "0 . 2", "", +12439, Percentage, 990, 991, "%", "", +12434, Timolol, 994, 1001, "timolol", "", +12437, DoseValue, 1002, 1007, "0 . 5", "", +12440, Percentage, 1008, 1009, "%", "", +12442, NumberPatientsArm, 1018, 1020, "73", "", +12435, Latanoprost, 1039, 1050, "latanoprost", "", +12438, DoseValue, 1051, 1058, "0 . 005", "", +12441, Percentage, 1059, 1060, "%", "", +12443, NumberPatientsArm, 1069, 1071, "75", "", +12445, Bedtime, 1080, 1094, "in the evening", "", +12444, Placebo, 1102, 1109, "vehicle", "", +12446, Morning, 1118, 1132, "in the morning", "", +12447, Duration, 1159, 1167, "12 weeks", "", +12449, IOP, 1170, 1173, "IOP", "", +12450, Diurnal_IOP, 1468, 1479, "diurnal IOP", "", +12451, Mean, 1482, 1490, "averaged", "", +12474, ObservedResult, 1601, 1729, "There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline ( p  =  0 . 118 )", "", +12452, Mean, 1683, 1687, "mean", "", +12453, Diurnal_IOP, 1688, 1699, "diurnal IOP", "", +12454, PvalueDiff, 1714, 1727, "p  =  0 . 118", "", +12455, Mean, 1749, 1753, "mean", "", +12456, Diurnal_IOP, 1761, 1772, "diurnal IOP", "", +12457, ResultMeasuredValue, 1777, 1783, "17 . 8", "", +12459, SdDevResValue, 1786, 1791, "2 . 9", "", +12461, mmHg, 1796, 1800, "mmHg", "", +12463, Brimonidine, 1806, 1817, "brimonidine", "", +12464, Timolol, 1820, 1827, "timolol", "", +12458, ResultMeasuredValue, 1832, 1838, "17 . 9", "", +12460, SdDevResValue, 1841, 1846, "3 . 9", "", +12462, mmHg, 1851, 1855, "mmHg", "", +12465, Latanoprost, 1861, 1872, "latanoprost", "", +12466, PvalueDiff, 1875, 1888, "p  =  0 . 794", "", +12467, Endpoint, 1930, 1991, "at least a 20 % decrease from baseline diurnal IOP at week 12", "", +12468, PercentageAffected, 1996, 2002, "87 . 7", "", +12469, Brimonidine, 2012, 2023, "brimonidine", "", +12470, Timolol, 2026, 2033, "timolol", "", +12471, PercentageAffected, 2044, 2050, "77 . 3", "", +12472, Latanoprost, 2060, 2071, "latanoprost", "", +12473, PvalueDiff, 2080, 2093, "p  =  0 . 131", "", +12482, ConclusionComment, 2202, 2340, "Fixed - combination brimonidine - timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension", "", +12475, Brimonidine, 2222, 2233, "brimonidine", "", +12476, Timolol, 2236, 2243, "timolol", "", +12477, Latanoprost, 2264, 2275, "latanoprost", "", +12478, IOP, 2288, 2291, "IOP", "", +12479, Glaucoma, 2309, 2317, "glaucoma", "", +12480, OcularHypertension, 2321, 2340, "ocular hypertension", "", +12481, ConclusionComment, 2343, 2401, "Both treatments demonstrated favorable ocular tolerability", "", +12487, ConclusionComment, 2404, 2607, "The duration of the study was 12 weeks , and additional studies will be needed to compare the efficacy and safety of fixed - combination brimonidine - timolol and latanoprost during long - term treatment", "", +12483, Brimonidine, 2541, 2552, "brimonidine", "", +12484, Timolol, 2555, 2562, "timolol", "", +12485, Latanoprost, 2567, 2578, "latanoprost", "", +12486, PMID, 2660, 2668, "22458918", "", diff --git a/data/gl 22458918_tstrakeljahn.n-triples b/data/gl 22458918_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22458918_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22775229_admin.annodb b/data/gl 22775229_admin.annodb new file mode 100644 index 0000000..7f34f0d --- /dev/null +++ b/data/gl 22775229_admin.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2012", "", " \"2012\"." +76, Title, 113, 365, "A double - masked randomized crossover study comparing the effect of latanoprost / timolol and brimonidine / timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"A double - masked randomized crossover study comparing the effect of latanoprost / timolol and brimonidine / timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open - angle glaucoma or ocular hypertension .\"." +10, DoubleBlind, 115, 130, "double - masked", "", " ." +11, Randomized, 131, 141, "randomized", "", " ." +12, Crossover, 142, 151, "crossover", "", " ." +13, Latanoprost, 182, 193, "latanoprost", "", +71, Lat/TimFC, 182, 203, "latanoprost / timolol", "", +14, Timolol, 196, 203, "timolol", "", +15, Brimonidine, 208, 219, "brimonidine", "", +72, Brimo/TimFC, 208, 229, "brimonidine / timolol", "", +16, Timolol, 222, 229, "timolol", "", +17, IOP, 251, 271, "intraocular pressure", "", " . ." +79130, OcularBloodFlow, 276, 293, "ocular blood flow", "", " ." +74, Primary_OpenAngleGlaucoma, 311, 340, "primary open - angle glaucoma", "", " ." +79122, OcularHypertension, 344, 363, "ocular hypertension", "", " ." +3, Author, 366, 374, "Hommer A", "", " \"Hommer A\"." +4, Author, 383, 390, "Sperl P", "", " \"Sperl P\"." +5, Author, 393, 400, "Resch H", "", " \"Resch H\"." +6, Author, 403, 423, "Popa - Cherecheanu A", "", " \"Popa - Cherecheanu A\"." +81, Author, 426, 432, "Qiao C", "", " \"Qiao C\"." +82, Author, 435, 448, "Schmetterer L", "", " \"Schmetterer L\"." +8, Author, 451, 463, "Garh ö fer G", "", " \"Garh ö fer G\"." +9, Austria, 571, 578, "Austria", "", " ." +79131, OcularBloodFlow, 591, 608, "Ocular blood flow", "", +61, Glaucoma, 666, 674, "glaucoma", "", +79132, OcularBloodFlow, 733, 750, "ocular blood flow", "", +23, ObjectiveDescription, 839, 1086, "In the present study , we set out to compare the effects of latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination and brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination on intraocular pressure ( IOP ) and ocular blood flow .", "", " \"In the present study , we set out to compare the effects of latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination and brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination on intraocular pressure ( IOP ) and ocular blood flow .\"." +13, Latanoprost, 899, 910, "latanoprost", "", +92, Lat/TimFC, 899, 963, "latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination", "", " ." +24, DoseValue, 911, 918, "0 . 005", "", +28, Percentage, 919, 920, "%", "", +14, Timolol, 923, 930, "timolol", "", +25, DoseValue, 931, 936, "0 . 5", "", +29, Percentage, 937, 938, "%", "", +93, Brimonidine, 968, 979, "brimonidine", "", +99, Brimo/TimFC, 968, 1030, "brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination", "", " ." +26, DoseValue, 980, 985, "0 . 2", "", +30, Percentage, 986, 987, "%", "", +16, Timolol, 990, 997, "timolol", "", +27, DoseValue, 998, 1003, "0 . 5", "", +31, Percentage, 1004, 1005, "%", "", +32, IOP, 1034, 1054, "intraocular pressure", "", +33, IOP, 1057, 1060, "IOP", "", +102, OcularBloodFlow, 1067, 1084, "ocular blood flow", "", +11, Randomized, 1137, 1147, "randomized", "", " ." +10, DoubleBlind, 1150, 1165, "double - masked", "", " ." +12, Crossover, 1174, 1183, "crossover", "", " ." +34, NumberPatientsCT, 1193, 1195, "16", "", +107, Primary_OpenAngleGlaucoma, 1210, 1239, "primary open - angle glaucoma", "", +35, NumberPatientsCT, 1244, 1245, "2", "", +79125, OcularHypertension, 1260, 1279, "ocular hypertension", "", +36, Duration, 1321, 1329, "6 - week", "", +111, Lat/TimFC, 1345, 1347, "LT", "", +57, Duration, 1354, 1362, "6 - week", "", +112, Brimo/TimFC, 1378, 1380, "BT", "", +79140, EndPointDescription, 1436, 1463, "Optic nerve head blood flow", "", " . ." +79141, EndPointDescription, 1466, 1471, "ONHBF", "", +37, MeasurementDevice, 1493, 1516, "laser Doppler flowmetry", "", " . ." +38, MeasurementDevice, 1567, 1588, "color Doppler imaging", "", +39, IOP, 1682, 1685, "IOP", "", +79136, TimePoint, 1702, 1706, "8 AM", "", +79138, TimePoint, 1709, 1714, "12 PM", "", +79139, TimePoint, 1721, 1725, "4 PM", "", +40, Mean, 1742, 1746, "mean", "", " . ." +41, IOP, 1756, 1759, "IOP", "", +42, BaseLineValue, 1764, 1770, "25 . 3", "", " \"25 . 3\". \"25 . 3\"." +117, SdDevBL, 1773, 1778, "2 . 8", "", " \"2 . 8\". \"2 . 8\"." +44, mmHg, 1781, 1785, "mmHg", "", " ." +45, IOP, 1834, 1837, "IOP", "", +120, Lat/TimFC, 1840, 1842, "LT", "", +46, RelativeReduction, 1847, 1853, "35 . 0", "", " \"35 . 0\"." +123, SdDevChangeValue, 1857, 1863, "10 . 0", "", " \"10 . 0\"." +121, Brimo/TimFC, 1868, 1870, "BT", "", +48, RelativeReduction, 1875, 1881, "33 . 6", "", " \"33 . 6\"." +125, SdDevChangeValue, 1885, 1890, "8 . 8", "", " \"8 . 8\"." +50, PvalueDiff, 1895, 1906, "P = 0 . 463", "", " \"P = 0 . 463\"." +79134, ObservedResult, 1940, 1953, "no difference", "", " \"no difference\". \"was observed between the 2 treatment groups\"." +79133, EndPointDescription, 1957, 1982, "ocular perfusion pressure", "", " . ." +79134, ObservedResult, 1983, 2026, "was observed between the 2 treatment groups", "", +51, PvalueDiff, 2029, 2038, "P = 0 . 1", "", +106409, ObservedResult, 2060, 2091, "Neither LT nor BT altered ONHBF", "", " \"Neither LT nor BT altered ONHBF\"." +128, Lat/TimFC, 2068, 2070, "LT", "", +129, Brimo/TimFC, 2075, 2077, "BT", "", +79142, EndPointDescription, 2086, 2091, "ONHBF", "", +52, PValueChangeValue, 2094, 2103, "P = 0 . 4", "", " \"P = 0 . 4\"." +55, ConclusionComment, 2249, 2346, "In the present study , a 6 - week treatment with LT or BT was equally effective in reducing IOP .", "", " \"In the present study , a 6 - week treatment with LT or BT was equally effective in reducing IOP .\"." +58, Duration, 2274, 2282, "6 - week", "", " \"6 - week\"." +79143, Lat/TimFC, 2298, 2300, "LT", "", +79144, Brimo/TimFC, 2304, 2306, "BT", "", +59, IOP, 2341, 2344, "IOP", "", +56, ConclusionComment, 2347, 2454, "In addition , none of the administered drugs induced a significant effect on ocular blood flow parameters .", "", " \"In addition , none of the administered drugs induced a significant effect on ocular blood flow parameters .\"." +130, OcularBloodFlow, 2424, 2441, "ocular blood flow", "", +60, PMID, 2498, 2506, "22775229", "", " \"22775229\"." diff --git a/data/gl 22775229_admin.n-triples b/data/gl 22775229_admin.n-triples new file mode 100644 index 0000000..4a50592 --- /dev/null +++ b/data/gl 22775229_admin.n-triples @@ -0,0 +1,137 @@ +# RDF export of group: Publication + . + "Publication 66561" . + "A double - masked randomized crossover study comparing the effect of latanoprost / timolol and brimonidine / timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open - angle glaucoma or ocular hypertension ." . + "Hommer A" . + "2012" . + "J Ocul Pharmacol Ther ." . + "22775229" . + . + "Sperl P" . + "Resch H" . + "Popa - Cherecheanu A" . + "Qiao C" . + "Schmetterer L" . + "Garh ö fer G" . +# RDF export of group: ClinicalTrial + . + "In the present study , we set out to compare the effects of latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination and brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination on intraocular pressure ( IOP ) and ocular blood flow ." . + "6 - week" . + . + . + . + "In the present study , a 6 - week treatment with LT or BT was equally effective in reducing IOP ." . + . + . + . + . + . + . + . + "In addition , none of the administered drugs induced a significant effect on ocular blood flow parameters ." . + . + . + . +# RDF export of group: Population + . + "Population 66580" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 66588 IOP" . + . + . + . + . + . + . + . + "Endpoint 66593 ocular blood flow" . + . + . + . + . + . + "Endpoint 66598 optic nerve head blood flow" . + . + . + . + . + . + . + . + "Endpoint 66603 ocular perfusion pressure" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm 66765 LTFC" . + . + . + . + . + . + . + "Arm 66774 BTFC" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 66627 LTFC" . + . + . + . + "Intervention 66633 BTFC" . + . + . +# RDF export of group: Medication + . + "Medication 66613 LTFC" . + . + . + . + . + "Medication 66620 BTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 66639 LTFC" . + . + "25 . 3" . + "2 . 8" . + "35 . 0" . + "10 . 0" . + . + "Outcome 66666 BTFC" . + . + "25 . 3" . + "2 . 8" . + "33 . 6" . + "8 . 8" . + . + "Outcome 66693 ocular perfusion pressure" . + . + "no difference" . + "was observed between the 2 treatment groups" . + . + "Outcome 66729 optic nerve head blood flow" . + . + "P = 0 . 4" . + "Neither LT nor BT altered ONHBF" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 66756" . + "P = 0 . 463" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22775229_export.csv b/data/gl 22775229_export.csv new file mode 100644 index 0000000..dd4c648 --- /dev/null +++ b/data/gl 22775229_export.csv @@ -0,0 +1,520 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +424, 1, 1, 1, 0, 1, 0, 1, "J" +424, 1, 2, 2, 2, 6, 2, 6, "Ocul" +424, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +424, 1, 4, 4, 17, 21, 17, 21, "Ther" +424, 1, 5, 5, 22, 23, 22, 23, "." +424, 2, 1, 6, 0, 4, 24, 28, "2012" +424, 2, 2, 7, 5, 8, 29, 32, "Dec" +424, 2, 3, 8, 9, 10, 33, 34, ";" +424, 2, 4, 9, 11, 13, 35, 37, "28" +424, 2, 5, 10, 14, 15, 38, 39, "(" +424, 2, 6, 11, 16, 17, 40, 41, "6" +424, 2, 7, 12, 18, 19, 42, 43, ")" +424, 2, 8, 13, 20, 21, 44, 45, ":" +424, 2, 9, 14, 22, 25, 46, 49, "569" +424, 2, 10, 15, 26, 27, 50, 51, "-" +424, 2, 11, 16, 28, 30, 52, 54, "75" +424, 2, 12, 17, 31, 32, 55, 56, "." +424, 2, 13, 18, 33, 36, 57, 60, "doi" +424, 2, 14, 19, 37, 38, 61, 62, ":" +424, 2, 15, 20, 39, 41, 63, 65, "10" +424, 2, 16, 21, 42, 43, 66, 67, "." +424, 2, 17, 22, 44, 48, 68, 72, "1089" +424, 2, 18, 23, 49, 50, 73, 74, "/" +424, 2, 19, 24, 51, 54, 75, 78, "jop" +424, 2, 20, 25, 55, 56, 79, 80, "." +424, 2, 21, 26, 57, 61, 81, 85, "2011" +424, 2, 22, 27, 62, 63, 86, 87, "." +424, 2, 23, 28, 64, 68, 88, 92, "0165" +424, 2, 24, 29, 69, 70, 93, 94, "." +424, 3, 1, 30, 0, 4, 95, 99, "Epub" +424, 3, 2, 31, 5, 9, 100, 104, "2012" +424, 3, 3, 32, 10, 13, 105, 108, "Jul" +424, 3, 4, 33, 14, 15, 109, 110, "9" +424, 3, 5, 34, 16, 17, 111, 112, "." +424, 4, 1, 35, 0, 1, 113, 114, "A" +424, 4, 2, 36, 2, 8, 115, 121, "double" +424, 4, 3, 37, 9, 10, 122, 123, "-" +424, 4, 4, 38, 11, 17, 124, 130, "masked" +424, 4, 5, 39, 18, 28, 131, 141, "randomized" +424, 4, 6, 40, 29, 38, 142, 151, "crossover" +424, 4, 7, 41, 39, 44, 152, 157, "study" +424, 4, 8, 42, 45, 54, 158, 167, "comparing" +424, 4, 9, 43, 55, 58, 168, 171, "the" +424, 4, 10, 44, 59, 65, 172, 178, "effect" +424, 4, 11, 45, 66, 68, 179, 181, "of" +424, 4, 12, 46, 69, 80, 182, 193, "latanoprost" +424, 4, 13, 47, 81, 82, 194, 195, "/" +424, 4, 14, 48, 83, 90, 196, 203, "timolol" +424, 4, 15, 49, 91, 94, 204, 207, "and" +424, 4, 16, 50, 95, 106, 208, 219, "brimonidine" +424, 4, 17, 51, 107, 108, 220, 221, "/" +424, 4, 18, 52, 109, 116, 222, 229, "timolol" +424, 4, 19, 53, 117, 122, 230, 235, "fixed" +424, 4, 20, 54, 123, 134, 236, 247, "combination" +424, 4, 21, 55, 135, 137, 248, 250, "on" +424, 4, 22, 56, 138, 149, 251, 262, "intraocular" +424, 4, 23, 57, 150, 158, 263, 271, "pressure" +424, 4, 24, 58, 159, 162, 272, 275, "and" +424, 4, 25, 59, 163, 169, 276, 282, "ocular" +424, 4, 26, 60, 170, 175, 283, 288, "blood" +424, 4, 27, 61, 176, 180, 289, 293, "flow" +424, 4, 28, 62, 181, 183, 294, 296, "in" +424, 4, 29, 63, 184, 192, 297, 305, "patients" +424, 4, 30, 64, 193, 197, 306, 310, "with" +424, 4, 31, 65, 198, 205, 311, 318, "primary" +424, 4, 32, 66, 206, 210, 319, 323, "open" +424, 4, 33, 67, 211, 212, 324, 325, "-" +424, 4, 34, 68, 213, 218, 326, 331, "angle" +424, 4, 35, 69, 219, 227, 332, 340, "glaucoma" +424, 4, 36, 70, 228, 230, 341, 343, "or" +424, 4, 37, 71, 231, 237, 344, 350, "ocular" +424, 4, 38, 72, 238, 250, 351, 363, "hypertension" +424, 4, 39, 73, 251, 252, 364, 365, "." +424, 5, 1, 74, 0, 6, 366, 372, "Hommer" +424, 5, 2, 75, 7, 8, 373, 374, "A" +424, 5, 3, 76, 9, 10, 375, 376, "(" +424, 5, 4, 77, 11, 12, 377, 378, "1" +424, 5, 5, 78, 13, 14, 379, 380, ")" +424, 5, 6, 79, 15, 16, 381, 382, "," +424, 5, 7, 80, 17, 22, 383, 388, "Sperl" +424, 5, 8, 81, 23, 24, 389, 390, "P" +424, 5, 9, 82, 25, 26, 391, 392, "," +424, 5, 10, 83, 27, 32, 393, 398, "Resch" +424, 5, 11, 84, 33, 34, 399, 400, "H" +424, 5, 12, 85, 35, 36, 401, 402, "," +424, 5, 13, 86, 37, 41, 403, 407, "Popa" +424, 5, 14, 87, 42, 43, 408, 409, "-" +424, 5, 15, 88, 44, 55, 410, 421, "Cherecheanu" +424, 5, 16, 89, 56, 57, 422, 423, "A" +424, 5, 17, 90, 58, 59, 424, 425, "," +424, 5, 18, 91, 60, 64, 426, 430, "Qiao" +424, 5, 19, 92, 65, 66, 431, 432, "C" +424, 5, 20, 93, 67, 68, 433, 434, "," +424, 5, 21, 94, 69, 80, 435, 446, "Schmetterer" +424, 5, 22, 95, 81, 82, 447, 448, "L" +424, 5, 23, 96, 83, 84, 449, 450, "," +424, 5, 24, 97, 85, 89, 451, 455, "Garh" +424, 5, 25, 98, 90, 91, 456, 457, "ö" +424, 5, 26, 99, 92, 95, 458, 461, "fer" +424, 5, 27, 100, 96, 97, 462, 463, "G" +424, 5, 28, 101, 98, 99, 464, 465, "." +424, 5, 29, 102, 100, 106, 466, 472, "Author" +424, 5, 30, 103, 107, 118, 473, 484, "information" +424, 5, 31, 104, 119, 120, 485, 486, ":" +424, 5, 32, 105, 121, 122, 487, 488, "(" +424, 5, 33, 106, 123, 124, 489, 490, "1" +424, 5, 34, 107, 125, 126, 491, 492, ")" +424, 5, 35, 108, 127, 137, 493, 503, "Department" +424, 5, 36, 109, 138, 140, 504, 506, "of" +424, 5, 37, 110, 141, 149, 507, 515, "Clinical" +424, 5, 38, 111, 150, 162, 516, 528, "Pharmacology" +424, 5, 39, 112, 163, 164, 529, 530, "," +424, 5, 40, 113, 165, 172, 531, 538, "Medical" +424, 5, 41, 114, 173, 183, 539, 549, "University" +424, 5, 42, 115, 184, 186, 550, 552, "of" +424, 5, 43, 116, 187, 193, 553, 559, "Vienna" +424, 5, 44, 117, 194, 195, 560, 561, "," +424, 5, 45, 118, 196, 202, 562, 568, "Vienna" +424, 5, 46, 119, 203, 204, 569, 570, "," +424, 5, 47, 120, 205, 212, 571, 578, "Austria" +424, 5, 48, 121, 213, 214, 579, 580, "." +424, 6, 1, 122, 0, 7, 581, 588, "PURPOSE" +424, 6, 2, 123, 8, 9, 589, 590, ":" +424, 6, 3, 124, 10, 16, 591, 597, "Ocular" +424, 6, 4, 125, 17, 22, 598, 603, "blood" +424, 6, 5, 126, 23, 27, 604, 608, "flow" +424, 6, 6, 127, 28, 41, 609, 622, "dysregulation" +424, 6, 7, 128, 42, 45, 623, 626, "has" +424, 6, 8, 129, 46, 50, 627, 631, "been" +424, 6, 9, 130, 51, 61, 632, 642, "implicated" +424, 6, 10, 131, 62, 64, 643, 645, "in" +424, 6, 11, 132, 65, 68, 646, 649, "the" +424, 6, 12, 133, 69, 81, 650, 662, "pathogenesis" +424, 6, 13, 134, 82, 84, 663, 665, "of" +424, 6, 14, 135, 85, 93, 666, 674, "glaucoma" +424, 6, 15, 136, 94, 95, 675, 676, "." +424, 7, 1, 137, 0, 7, 677, 684, "Whereas" +424, 7, 2, 138, 8, 11, 685, 688, "the" +424, 7, 3, 139, 12, 18, 689, 695, "effect" +424, 7, 4, 140, 19, 21, 696, 698, "of" +424, 7, 5, 141, 22, 28, 699, 705, "single" +424, 7, 6, 142, 29, 41, 706, 718, "antiglaucoma" +424, 7, 7, 143, 42, 52, 719, 729, "substances" +424, 7, 8, 144, 53, 55, 730, 732, "on" +424, 7, 9, 145, 56, 62, 733, 739, "ocular" +424, 7, 10, 146, 63, 68, 740, 745, "blood" +424, 7, 11, 147, 69, 73, 746, 750, "flow" +424, 7, 12, 148, 74, 77, 751, 754, "has" +424, 7, 13, 149, 78, 82, 755, 759, "been" +424, 7, 14, 150, 83, 92, 760, 769, "addressed" +424, 7, 15, 151, 93, 95, 770, 772, "in" +424, 7, 16, 152, 96, 103, 773, 780, "various" +424, 7, 17, 153, 104, 115, 781, 792, "experiments" +424, 7, 18, 154, 116, 117, 793, 794, "," +424, 7, 19, 155, 118, 126, 795, 803, "evidence" +424, 7, 20, 156, 127, 130, 804, 807, "for" +424, 7, 21, 157, 131, 136, 808, 813, "fixed" +424, 7, 22, 158, 137, 149, 814, 826, "combinations" +424, 7, 23, 159, 150, 152, 827, 829, "is" +424, 7, 24, 160, 153, 159, 830, 836, "sparse" +424, 7, 25, 161, 160, 161, 837, 838, "." +424, 8, 1, 162, 0, 2, 839, 841, "In" +424, 8, 2, 163, 3, 6, 842, 845, "the" +424, 8, 3, 164, 7, 14, 846, 853, "present" +424, 8, 4, 165, 15, 20, 854, 859, "study" +424, 8, 5, 166, 21, 22, 860, 861, "," +424, 8, 6, 167, 23, 25, 862, 864, "we" +424, 8, 7, 168, 26, 29, 865, 868, "set" +424, 8, 8, 169, 30, 33, 869, 872, "out" +424, 8, 9, 170, 34, 36, 873, 875, "to" +424, 8, 10, 171, 37, 44, 876, 883, "compare" +424, 8, 11, 172, 45, 48, 884, 887, "the" +424, 8, 12, 173, 49, 56, 888, 895, "effects" +424, 8, 13, 174, 57, 59, 896, 898, "of" +424, 8, 14, 175, 60, 71, 899, 910, "latanoprost" +424, 8, 15, 176, 72, 73, 911, 912, "0" +424, 8, 16, 177, 74, 75, 913, 914, "." +424, 8, 17, 178, 76, 79, 915, 918, "005" +424, 8, 18, 179, 80, 81, 919, 920, "%" +424, 8, 19, 180, 82, 83, 921, 922, "/" +424, 8, 20, 181, 84, 91, 923, 930, "timolol" +424, 8, 21, 182, 92, 93, 931, 932, "0" +424, 8, 22, 183, 94, 95, 933, 934, "." +424, 8, 23, 184, 96, 97, 935, 936, "5" +424, 8, 24, 185, 98, 99, 937, 938, "%" +424, 8, 25, 186, 100, 101, 939, 940, "(" +424, 8, 26, 187, 102, 104, 941, 943, "LT" +424, 8, 27, 188, 105, 106, 944, 945, ")" +424, 8, 28, 189, 107, 112, 946, 951, "fixed" +424, 8, 29, 190, 113, 124, 952, 963, "combination" +424, 8, 30, 191, 125, 128, 964, 967, "and" +424, 8, 31, 192, 129, 140, 968, 979, "brimonidine" +424, 8, 32, 193, 141, 142, 980, 981, "0" +424, 8, 33, 194, 143, 144, 982, 983, "." +424, 8, 34, 195, 145, 146, 984, 985, "2" +424, 8, 35, 196, 147, 148, 986, 987, "%" +424, 8, 36, 197, 149, 150, 988, 989, "/" +424, 8, 37, 198, 151, 158, 990, 997, "timolol" +424, 8, 38, 199, 159, 160, 998, 999, "0" +424, 8, 39, 200, 161, 162, 1000, 1001, "." +424, 8, 40, 201, 163, 164, 1002, 1003, "5" +424, 8, 41, 202, 165, 166, 1004, 1005, "%" +424, 8, 42, 203, 167, 168, 1006, 1007, "(" +424, 8, 43, 204, 169, 171, 1008, 1010, "BT" +424, 8, 44, 205, 172, 173, 1011, 1012, ")" +424, 8, 45, 206, 174, 179, 1013, 1018, "fixed" +424, 8, 46, 207, 180, 191, 1019, 1030, "combination" +424, 8, 47, 208, 192, 194, 1031, 1033, "on" +424, 8, 48, 209, 195, 206, 1034, 1045, "intraocular" +424, 8, 49, 210, 207, 215, 1046, 1054, "pressure" +424, 8, 50, 211, 216, 217, 1055, 1056, "(" +424, 8, 51, 212, 218, 221, 1057, 1060, "IOP" +424, 8, 52, 213, 222, 223, 1061, 1062, ")" +424, 8, 53, 214, 224, 227, 1063, 1066, "and" +424, 8, 54, 215, 228, 234, 1067, 1073, "ocular" +424, 8, 55, 216, 235, 240, 1074, 1079, "blood" +424, 8, 56, 217, 241, 245, 1080, 1084, "flow" +424, 8, 57, 218, 246, 247, 1085, 1086, "." +424, 9, 1, 219, 0, 7, 1087, 1094, "METHODS" +424, 9, 2, 220, 8, 9, 1095, 1096, ":" +424, 9, 3, 221, 10, 12, 1097, 1099, "In" +424, 9, 4, 222, 13, 16, 1100, 1103, "the" +424, 9, 5, 223, 17, 24, 1104, 1111, "present" +424, 9, 6, 224, 25, 30, 1112, 1117, "study" +424, 9, 7, 225, 31, 32, 1118, 1119, "," +424, 9, 8, 226, 33, 38, 1120, 1125, "which" +424, 9, 9, 227, 39, 47, 1126, 1134, "followed" +424, 9, 10, 228, 48, 49, 1135, 1136, "a" +424, 9, 11, 229, 50, 60, 1137, 1147, "randomized" +424, 9, 12, 230, 61, 62, 1148, 1149, "," +424, 9, 13, 231, 63, 69, 1150, 1156, "double" +424, 9, 14, 232, 70, 71, 1157, 1158, "-" +424, 9, 15, 233, 72, 78, 1159, 1165, "masked" +424, 9, 16, 234, 79, 80, 1166, 1167, "2" +424, 9, 17, 235, 81, 82, 1168, 1169, "-" +424, 9, 18, 236, 83, 86, 1170, 1173, "way" +424, 9, 19, 237, 87, 96, 1174, 1183, "crossover" +424, 9, 20, 238, 97, 103, 1184, 1190, "design" +424, 9, 21, 239, 104, 105, 1191, 1192, "," +424, 9, 22, 240, 106, 108, 1193, 1195, "16" +424, 9, 23, 241, 109, 117, 1196, 1204, "patients" +424, 9, 24, 242, 118, 122, 1205, 1209, "with" +424, 9, 25, 243, 123, 130, 1210, 1217, "primary" +424, 9, 26, 244, 131, 135, 1218, 1222, "open" +424, 9, 27, 245, 136, 137, 1223, 1224, "-" +424, 9, 28, 246, 138, 143, 1225, 1230, "angle" +424, 9, 29, 247, 144, 152, 1231, 1239, "glaucoma" +424, 9, 30, 248, 153, 156, 1240, 1243, "and" +424, 9, 31, 249, 157, 158, 1244, 1245, "2" +424, 9, 32, 250, 159, 167, 1246, 1254, "patients" +424, 9, 33, 251, 168, 172, 1255, 1259, "with" +424, 9, 34, 252, 173, 179, 1260, 1266, "ocular" +424, 9, 35, 253, 180, 192, 1267, 1279, "hypertension" +424, 9, 36, 254, 193, 197, 1280, 1284, "were" +424, 9, 37, 255, 198, 206, 1285, 1293, "included" +424, 9, 38, 256, 207, 208, 1294, 1295, "." +424, 10, 1, 257, 0, 3, 1296, 1299, "The" +424, 10, 2, 258, 4, 12, 1300, 1308, "patients" +424, 10, 3, 259, 13, 22, 1309, 1318, "underwent" +424, 10, 4, 260, 23, 24, 1319, 1320, "a" +424, 10, 5, 261, 25, 26, 1321, 1322, "6" +424, 10, 6, 262, 27, 28, 1323, 1324, "-" +424, 10, 7, 263, 29, 33, 1325, 1329, "week" +424, 10, 8, 264, 34, 43, 1330, 1339, "treatment" +424, 10, 9, 265, 44, 48, 1340, 1344, "with" +424, 10, 10, 266, 49, 51, 1345, 1347, "LT" +424, 10, 11, 267, 52, 55, 1348, 1351, "and" +424, 10, 12, 268, 56, 57, 1352, 1353, "a" +424, 10, 13, 269, 58, 59, 1354, 1355, "6" +424, 10, 14, 270, 60, 61, 1356, 1357, "-" +424, 10, 15, 271, 62, 66, 1358, 1362, "week" +424, 10, 16, 272, 67, 76, 1363, 1372, "treatment" +424, 10, 17, 273, 77, 81, 1373, 1377, "with" +424, 10, 18, 274, 82, 84, 1378, 1380, "BT" +424, 10, 19, 275, 85, 90, 1381, 1386, "after" +424, 10, 20, 276, 91, 92, 1387, 1388, "a" +424, 10, 21, 277, 93, 100, 1389, 1396, "washout" +424, 10, 22, 278, 101, 104, 1397, 1400, "for" +424, 10, 23, 279, 105, 113, 1401, 1409, "previous" +424, 10, 24, 280, 114, 126, 1410, 1422, "antiglaucoma" +424, 10, 25, 281, 127, 137, 1423, 1433, "medication" +424, 10, 26, 282, 138, 139, 1434, 1435, "." +424, 11, 1, 283, 0, 5, 1436, 1441, "Optic" +424, 11, 2, 284, 6, 11, 1442, 1447, "nerve" +424, 11, 3, 285, 12, 16, 1448, 1452, "head" +424, 11, 4, 286, 17, 22, 1453, 1458, "blood" +424, 11, 5, 287, 23, 27, 1459, 1463, "flow" +424, 11, 6, 288, 28, 29, 1464, 1465, "(" +424, 11, 7, 289, 30, 35, 1466, 1471, "ONHBF" +424, 11, 8, 290, 36, 37, 1472, 1473, ")" +424, 11, 9, 291, 38, 41, 1474, 1477, "was" +424, 11, 10, 292, 42, 50, 1478, 1486, "measured" +424, 11, 11, 293, 51, 56, 1487, 1492, "using" +424, 11, 12, 294, 57, 62, 1493, 1498, "laser" +424, 11, 13, 295, 63, 70, 1499, 1506, "Doppler" +424, 11, 14, 296, 71, 80, 1507, 1516, "flowmetry" +424, 11, 15, 297, 81, 82, 1517, 1518, ";" +424, 11, 16, 298, 83, 94, 1519, 1530, "retrobulbar" +424, 11, 17, 299, 95, 99, 1531, 1535, "flow" +424, 11, 18, 300, 100, 110, 1536, 1546, "velocities" +424, 11, 19, 301, 111, 115, 1547, 1551, "were" +424, 11, 20, 302, 116, 124, 1552, 1560, "measured" +424, 11, 21, 303, 125, 130, 1561, 1566, "using" +424, 11, 22, 304, 131, 136, 1567, 1572, "color" +424, 11, 23, 305, 137, 144, 1573, 1580, "Doppler" +424, 11, 24, 306, 145, 152, 1581, 1588, "imaging" +424, 11, 25, 307, 153, 155, 1589, 1591, "in" +424, 11, 26, 308, 156, 159, 1592, 1595, "the" +424, 11, 27, 309, 160, 170, 1596, 1606, "ophthalmic" +424, 11, 28, 310, 171, 177, 1607, 1613, "artery" +424, 11, 29, 311, 178, 179, 1614, 1615, "," +424, 11, 30, 312, 180, 183, 1616, 1619, "the" +424, 11, 31, 313, 184, 191, 1620, 1627, "central" +424, 11, 32, 314, 192, 199, 1628, 1635, "retinal" +424, 11, 33, 315, 200, 206, 1636, 1642, "artery" +424, 11, 34, 316, 207, 208, 1643, 1644, "," +424, 11, 35, 317, 209, 212, 1645, 1648, "and" +424, 11, 36, 318, 213, 216, 1649, 1652, "the" +424, 11, 37, 319, 217, 226, 1653, 1662, "posterior" +424, 11, 38, 320, 227, 234, 1663, 1670, "ciliary" +424, 11, 39, 321, 235, 243, 1671, 1679, "arteries" +424, 11, 40, 322, 244, 245, 1680, 1681, "." +424, 12, 1, 323, 0, 3, 1682, 1685, "IOP" +424, 12, 2, 324, 4, 7, 1686, 1689, "was" +424, 12, 3, 325, 8, 16, 1690, 1698, "measured" +424, 12, 4, 326, 17, 19, 1699, 1701, "at" +424, 12, 5, 327, 20, 21, 1702, 1703, "8" +424, 12, 6, 328, 22, 24, 1704, 1706, "AM" +424, 12, 7, 329, 25, 26, 1707, 1708, "," +424, 12, 8, 330, 27, 29, 1709, 1711, "12" +424, 12, 9, 331, 30, 32, 1712, 1714, "PM" +424, 12, 10, 332, 33, 34, 1715, 1716, "," +424, 12, 11, 333, 35, 38, 1717, 1720, "and" +424, 12, 12, 334, 39, 40, 1721, 1722, "4" +424, 12, 13, 335, 41, 43, 1723, 1725, "PM" +424, 12, 14, 336, 44, 45, 1726, 1727, "." +424, 13, 1, 337, 0, 7, 1728, 1735, "RESULTS" +424, 13, 2, 338, 8, 9, 1736, 1737, ":" +424, 13, 3, 339, 10, 13, 1738, 1741, "The" +424, 13, 4, 340, 14, 18, 1742, 1746, "mean" +424, 13, 5, 341, 19, 27, 1747, 1755, "baseline" +424, 13, 6, 342, 28, 31, 1756, 1759, "IOP" +424, 13, 7, 343, 32, 35, 1760, 1763, "was" +424, 13, 8, 344, 36, 38, 1764, 1766, "25" +424, 13, 9, 345, 39, 40, 1767, 1768, "." +424, 13, 10, 346, 41, 42, 1769, 1770, "3" +424, 13, 11, 347, 43, 44, 1771, 1772, "±" +424, 13, 12, 348, 45, 46, 1773, 1774, "2" +424, 13, 13, 349, 47, 48, 1775, 1776, "." +424, 13, 14, 350, 49, 50, 1777, 1778, "8" +424, 13, 15, 351, 51, 52, 1779, 1780, " " +424, 13, 16, 352, 53, 57, 1781, 1785, "mmHg" +424, 13, 17, 353, 58, 59, 1786, 1787, "." +424, 14, 1, 354, 0, 4, 1788, 1792, "Both" +424, 14, 2, 355, 5, 10, 1793, 1798, "drugs" +424, 14, 3, 356, 11, 15, 1799, 1803, "were" +424, 14, 4, 357, 16, 23, 1804, 1811, "equally" +424, 14, 5, 358, 24, 33, 1812, 1821, "effective" +424, 14, 6, 359, 34, 36, 1822, 1824, "in" +424, 14, 7, 360, 37, 45, 1825, 1833, "reducing" +424, 14, 8, 361, 46, 49, 1834, 1837, "IOP" +424, 14, 9, 362, 50, 51, 1838, 1839, "(" +424, 14, 10, 363, 52, 54, 1840, 1842, "LT" +424, 14, 11, 364, 55, 56, 1843, 1844, ":" +424, 14, 12, 365, 57, 58, 1845, 1846, "-" +424, 14, 13, 366, 59, 61, 1847, 1849, "35" +424, 14, 14, 367, 62, 63, 1850, 1851, "." +424, 14, 15, 368, 64, 65, 1852, 1853, "0" +424, 14, 16, 369, 66, 68, 1854, 1856, "%±" +424, 14, 17, 370, 69, 71, 1857, 1859, "10" +424, 14, 18, 371, 72, 73, 1860, 1861, "." +424, 14, 19, 372, 74, 75, 1862, 1863, "0" +424, 14, 20, 373, 76, 77, 1864, 1865, "%" +424, 14, 21, 374, 78, 79, 1866, 1867, ";" +424, 14, 22, 375, 80, 82, 1868, 1870, "BT" +424, 14, 23, 376, 83, 84, 1871, 1872, ":" +424, 14, 24, 377, 85, 86, 1873, 1874, "-" +424, 14, 25, 378, 87, 89, 1875, 1877, "33" +424, 14, 26, 379, 90, 91, 1878, 1879, "." +424, 14, 27, 380, 92, 93, 1880, 1881, "6" +424, 14, 28, 381, 94, 96, 1882, 1884, "%±" +424, 14, 29, 382, 97, 98, 1885, 1886, "8" +424, 14, 30, 383, 99, 100, 1887, 1888, "." +424, 14, 31, 384, 101, 102, 1889, 1890, "8" +424, 14, 32, 385, 103, 104, 1891, 1892, "%" +424, 14, 33, 386, 105, 106, 1893, 1894, "," +424, 14, 34, 387, 107, 108, 1895, 1896, "P" +424, 14, 35, 388, 109, 110, 1897, 1898, "=" +424, 14, 36, 389, 111, 112, 1899, 1900, "0" +424, 14, 37, 390, 113, 114, 1901, 1902, "." +424, 14, 38, 391, 115, 118, 1903, 1906, "463" +424, 14, 39, 392, 119, 126, 1907, 1914, "between" +424, 14, 40, 393, 127, 133, 1915, 1921, "groups" +424, 14, 41, 394, 134, 135, 1922, 1923, ")" +424, 14, 42, 395, 136, 137, 1924, 1925, "." +424, 15, 1, 396, 0, 2, 1926, 1928, "In" +424, 15, 2, 397, 3, 11, 1929, 1937, "addition" +424, 15, 3, 398, 12, 13, 1938, 1939, "," +424, 15, 4, 399, 14, 16, 1940, 1942, "no" +424, 15, 5, 400, 17, 27, 1943, 1953, "difference" +424, 15, 6, 401, 28, 30, 1954, 1956, "in" +424, 15, 7, 402, 31, 37, 1957, 1963, "ocular" +424, 15, 8, 403, 38, 47, 1964, 1973, "perfusion" +424, 15, 9, 404, 48, 56, 1974, 1982, "pressure" +424, 15, 10, 405, 57, 60, 1983, 1986, "was" +424, 15, 11, 406, 61, 69, 1987, 1995, "observed" +424, 15, 12, 407, 70, 77, 1996, 2003, "between" +424, 15, 13, 408, 78, 81, 2004, 2007, "the" +424, 15, 14, 409, 82, 83, 2008, 2009, "2" +424, 15, 15, 410, 84, 93, 2010, 2019, "treatment" +424, 15, 16, 411, 94, 100, 2020, 2026, "groups" +424, 15, 17, 412, 101, 102, 2027, 2028, "(" +424, 15, 18, 413, 103, 104, 2029, 2030, "P" +424, 15, 19, 414, 105, 106, 2031, 2032, "=" +424, 15, 20, 415, 107, 108, 2033, 2034, "0" +424, 15, 21, 416, 109, 110, 2035, 2036, "." +424, 15, 22, 417, 111, 112, 2037, 2038, "1" +424, 15, 23, 418, 113, 114, 2039, 2040, "," +424, 15, 24, 419, 115, 122, 2041, 2048, "between" +424, 15, 25, 420, 123, 129, 2049, 2055, "groups" +424, 15, 26, 421, 130, 131, 2056, 2057, ")" +424, 15, 27, 422, 132, 133, 2058, 2059, "." +424, 16, 1, 423, 0, 7, 2060, 2067, "Neither" +424, 16, 2, 424, 8, 10, 2068, 2070, "LT" +424, 16, 3, 425, 11, 14, 2071, 2074, "nor" +424, 16, 4, 426, 15, 17, 2075, 2077, "BT" +424, 16, 5, 427, 18, 25, 2078, 2085, "altered" +424, 16, 6, 428, 26, 31, 2086, 2091, "ONHBF" +424, 16, 7, 429, 32, 33, 2092, 2093, "(" +424, 16, 8, 430, 34, 35, 2094, 2095, "P" +424, 16, 9, 431, 36, 37, 2096, 2097, "=" +424, 16, 10, 432, 38, 39, 2098, 2099, "0" +424, 16, 11, 433, 40, 41, 2100, 2101, "." +424, 16, 12, 434, 42, 43, 2102, 2103, "4" +424, 16, 13, 435, 44, 45, 2104, 2105, "," +424, 16, 14, 436, 46, 54, 2106, 2114, "baseline" +424, 16, 15, 437, 55, 57, 2115, 2117, "vs" +424, 16, 16, 438, 58, 59, 2118, 2119, "." +424, 16, 17, 439, 60, 69, 2120, 2129, "treatment" +424, 16, 18, 440, 70, 71, 2130, 2131, ")" +424, 16, 19, 441, 72, 75, 2132, 2135, "and" +424, 16, 20, 442, 76, 78, 2136, 2138, "no" +424, 16, 21, 443, 79, 85, 2139, 2145, "effect" +424, 16, 22, 444, 86, 88, 2146, 2148, "on" +424, 16, 23, 445, 89, 93, 2149, 2153, "flow" +424, 16, 24, 446, 94, 104, 2154, 2164, "velocities" +424, 16, 25, 447, 105, 107, 2165, 2167, "in" +424, 16, 26, 448, 108, 111, 2168, 2171, "the" +424, 16, 27, 449, 112, 123, 2172, 2183, "retrobulbar" +424, 16, 28, 450, 124, 131, 2184, 2191, "vessels" +424, 16, 29, 451, 132, 135, 2192, 2195, "was" +424, 16, 30, 452, 136, 140, 2196, 2200, "seen" +424, 16, 31, 453, 141, 145, 2201, 2205, "with" +424, 16, 32, 454, 146, 152, 2206, 2212, "either" +424, 16, 33, 455, 153, 155, 2213, 2215, "of" +424, 16, 34, 456, 156, 159, 2216, 2219, "the" +424, 16, 35, 457, 160, 161, 2220, 2221, "2" +424, 16, 36, 458, 162, 172, 2222, 2232, "treatments" +424, 16, 37, 459, 173, 174, 2233, 2234, "." +424, 17, 1, 460, 0, 11, 2235, 2246, "CONCLUSIONS" +424, 17, 2, 461, 12, 13, 2247, 2248, ":" +424, 17, 3, 462, 14, 16, 2249, 2251, "In" +424, 17, 4, 463, 17, 20, 2252, 2255, "the" +424, 17, 5, 464, 21, 28, 2256, 2263, "present" +424, 17, 6, 465, 29, 34, 2264, 2269, "study" +424, 17, 7, 466, 35, 36, 2270, 2271, "," +424, 17, 8, 467, 37, 38, 2272, 2273, "a" +424, 17, 9, 468, 39, 40, 2274, 2275, "6" +424, 17, 10, 469, 41, 42, 2276, 2277, "-" +424, 17, 11, 470, 43, 47, 2278, 2282, "week" +424, 17, 12, 471, 48, 57, 2283, 2292, "treatment" +424, 17, 13, 472, 58, 62, 2293, 2297, "with" +424, 17, 14, 473, 63, 65, 2298, 2300, "LT" +424, 17, 15, 474, 66, 68, 2301, 2303, "or" +424, 17, 16, 475, 69, 71, 2304, 2306, "BT" +424, 17, 17, 476, 72, 75, 2307, 2310, "was" +424, 17, 18, 477, 76, 83, 2311, 2318, "equally" +424, 17, 19, 478, 84, 93, 2319, 2328, "effective" +424, 17, 20, 479, 94, 96, 2329, 2331, "in" +424, 17, 21, 480, 97, 105, 2332, 2340, "reducing" +424, 17, 22, 481, 106, 109, 2341, 2344, "IOP" +424, 17, 23, 482, 110, 111, 2345, 2346, "." +424, 18, 1, 483, 0, 2, 2347, 2349, "In" +424, 18, 2, 484, 3, 11, 2350, 2358, "addition" +424, 18, 3, 485, 12, 13, 2359, 2360, "," +424, 18, 4, 486, 14, 18, 2361, 2365, "none" +424, 18, 5, 487, 19, 21, 2366, 2368, "of" +424, 18, 6, 488, 22, 25, 2369, 2372, "the" +424, 18, 7, 489, 26, 38, 2373, 2385, "administered" +424, 18, 8, 490, 39, 44, 2386, 2391, "drugs" +424, 18, 9, 491, 45, 52, 2392, 2399, "induced" +424, 18, 10, 492, 53, 54, 2400, 2401, "a" +424, 18, 11, 493, 55, 66, 2402, 2413, "significant" +424, 18, 12, 494, 67, 73, 2414, 2420, "effect" +424, 18, 13, 495, 74, 76, 2421, 2423, "on" +424, 18, 14, 496, 77, 83, 2424, 2430, "ocular" +424, 18, 15, 497, 84, 89, 2431, 2436, "blood" +424, 18, 16, 498, 90, 94, 2437, 2441, "flow" +424, 18, 17, 499, 95, 105, 2442, 2452, "parameters" +424, 18, 18, 500, 106, 107, 2453, 2454, "." +424, 19, 1, 501, 0, 3, 2455, 2458, "DOI" +424, 19, 2, 502, 4, 5, 2459, 2460, ":" +424, 19, 3, 503, 6, 8, 2461, 2463, "10" +424, 19, 4, 504, 9, 10, 2464, 2465, "." +424, 19, 5, 505, 11, 15, 2466, 2470, "1089" +424, 19, 6, 506, 16, 17, 2471, 2472, "/" +424, 19, 7, 507, 18, 21, 2473, 2476, "jop" +424, 19, 8, 508, 22, 23, 2477, 2478, "." +424, 19, 9, 509, 24, 28, 2479, 2483, "2011" +424, 19, 10, 510, 29, 30, 2484, 2485, "." +424, 19, 11, 511, 31, 35, 2486, 2490, "0165" +424, 19, 12, 512, 36, 40, 2491, 2495, "PMID" +424, 19, 13, 513, 41, 42, 2496, 2497, ":" +424, 19, 14, 514, 43, 51, 2498, 2506, "22775229" +424, 19, 15, 515, 52, 53, 2507, 2508, "[" +424, 19, 16, 516, 54, 61, 2509, 2516, "Indexed" +424, 19, 17, 517, 62, 65, 2517, 2520, "for" +424, 19, 18, 518, 66, 73, 2521, 2528, "MEDLINE" +424, 19, 19, 519, 74, 75, 2529, 2530, "]" diff --git a/data/gl 22775229_jshahinitiran.annodb b/data/gl 22775229_jshahinitiran.annodb new file mode 100644 index 0000000..8ae4150 --- /dev/null +++ b/data/gl 22775229_jshahinitiran.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16494, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +16495, PublicationYear, 24, 28, "2012", "", +16496, Title, 113, 363, "A double - masked randomized crossover study comparing the effect of latanoprost / timolol and brimonidine / timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open - angle glaucoma or ocular hypertension", "", +16504, DoubleBlind, 115, 130, "double - masked", "", +16505, Randomized, 131, 141, "randomized", "", +16506, Crossover, 142, 151, "crossover", "", +16507, Latanoprost, 182, 193, "latanoprost", "", +16516, Drug, 182, 203, "latanoprost / timolol", "LT", +16508, Timolol, 196, 203, "timolol", "", +16509, Brimonidine, 208, 219, "brimonidine", "", +16518, Drug, 208, 229, "brimonidine / timolol", "BT", +16510, Timolol, 222, 229, "timolol", "", +16511, IOP, 251, 271, "intraocular pressure", "", +16513, EndPointDescription, 276, 293, "ocular blood flow", "", +16514, OpenAngleGlaucoma, 311, 340, "primary open - angle glaucoma", "", +16515, OcularHypertension, 344, 363, "ocular hypertension", "", +16497, Author, 366, 374, "Hommer A", "", +16498, Author, 383, 390, "Sperl P", "", +16499, Author, 393, 400, "Resch H", "", +16500, Author, 403, 423, "Popa - Cherecheanu A", "", +16501, Author, 426, 448, "Qiao C , Schmetterer L", "", +16502, Author, 451, 463, "Garh ö fer G", "", +16503, Austria, 571, 578, "Austria", "", +16583, Glaucoma, 666, 674, "glaucoma", "", +16513, EndPointDescription, 733, 750, "ocular blood flow", "", +16519, ObjectiveDescription, 839, 1086, "In the present study , we set out to compare the effects of latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination and brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination on intraocular pressure ( IOP ) and ocular blood flow .", "", +16507, Latanoprost, 899, 910, "latanoprost", "", +16516, Drug, 899, 938, "latanoprost 0 . 005 % / timolol 0 . 5 %", "LT", +16521, DoseValue, 911, 918, "0 . 005", "", +16525, Percentage, 919, 920, "%", "", +16508, Timolol, 923, 930, "timolol", "", +16522, DoseValue, 931, 936, "0 . 5", "", +16526, Percentage, 937, 938, "%", "", +16516, Drug, 941, 943, "LT", "LT", +16523, DoseValue, 980, 985, "0 . 2", "", +16518, Drug, 980, 1005, "0 . 2 % / timolol 0 . 5 %", "BT", +16527, Percentage, 986, 987, "%", "", +16510, Timolol, 990, 997, "timolol", "", +16524, DoseValue, 998, 1003, "0 . 5", "", +16528, Percentage, 1004, 1005, "%", "", +16518, Drug, 1008, 1010, "BT", "BT", +16535, IOP, 1034, 1054, "intraocular pressure", "", +16536, IOP, 1057, 1060, "IOP", "", +16513, EndPointDescription, 1067, 1084, "ocular blood flow", "", +16505, Randomized, 1137, 1147, "randomized", "", +16504, DoubleBlind, 1150, 1165, "double - masked", "", +16506, Crossover, 1174, 1183, "crossover", "", +16541, NumberPatientsCT, 1193, 1195, "16", "", +16514, OpenAngleGlaucoma, 1210, 1239, "primary open - angle glaucoma", "", +16543, NumberPatientsCT, 1244, 1245, "2", "", +16515, OcularHypertension, 1260, 1279, "ocular hypertension", "", +16545, Duration, 1321, 1329, "6 - week", "", +16516, Drug, 1345, 1347, "LT", "LT", +16576, Duration, 1354, 1362, "6 - week", "", +16518, Drug, 1378, 1380, "BT", "BT", +16513, EndPointDescription, 1436, 1463, "Optic nerve head blood flow", "", +16513, EndPointDescription, 1466, 1471, "ONHBF", "", +16551, MeasurementDevice, 1493, 1516, "laser Doppler flowmetry", "", +16552, MeasurementDevice, 1567, 1588, "color Doppler imaging", "", +16553, IOP, 1682, 1685, "IOP", "", +16554, Mean, 1742, 1746, "mean", "", +16555, IOP, 1756, 1759, "IOP", "", +16556, BaseLineValue, 1764, 1770, "25 . 3", "", +16557, SdErrorBL, 1773, 1778, "2 . 8", "", +16558, mmHg, 1781, 1785, "mmHg", "", +16559, IOP, 1834, 1837, "IOP", "", +16516, Drug, 1840, 1842, "LT", "LT", +16561, RelativeReduction, 1847, 1853, "35 . 0", "", +16562, SdErrorChangeValue, 1857, 1863, "10 . 0", "", +16518, Drug, 1868, 1870, "BT", "BT", +16564, RelativeReduction, 1875, 1881, "33 . 6", "", +16565, SdErrorChangeValue, 1885, 1890, "8 . 8", "", +16566, PvalueDiff, 1895, 1906, "P = 0 . 463", "", +16573, ObservedResult, 1940, 2059, "no difference in ocular perfusion pressure was observed between the 2 treatment groups ( P = 0 . 1 , between groups ) .", "", +16567, PvalueDiff, 2029, 2038, "P = 0 . 1", "", +16572, ObservedResult, 2060, 2234, "Neither LT nor BT altered ONHBF ( P = 0 . 4 , baseline vs . treatment ) and no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments .", "", +16516, Drug, 2068, 2070, "LT", "LT", +16518, Drug, 2075, 2077, "BT", "BT", +16513, EndPointDescription, 2086, 2091, "ONHBF", "", +16571, PValueChangeValue, 2094, 2103, "P = 0 . 4", "", +16574, ConclusionComment, 2249, 2346, "In the present study , a 6 - week treatment with LT or BT was equally effective in reducing IOP .", "", +16578, Duration, 2274, 2282, "6 - week", "", +16516, Drug, 2298, 2300, "LT", "LT", +16518, Drug, 2304, 2306, "BT", "BT", +16581, IOP, 2341, 2344, "IOP", "", +16575, ConclusionComment, 2347, 2454, "In addition , none of the administered drugs induced a significant effect on ocular blood flow parameters .", "", +16582, PMID, 2498, 2506, "22775229", "", diff --git a/data/gl 22775229_jshahinitiran.n-triples b/data/gl 22775229_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22775229_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 22775229_tstrakeljahn.annodb b/data/gl 22775229_tstrakeljahn.annodb new file mode 100644 index 0000000..d5bc190 --- /dev/null +++ b/data/gl 22775229_tstrakeljahn.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +74808, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +74809, PublicationYear, 24, 28, "2012", "", +74823, Title, 113, 365, "A double - masked randomized crossover study comparing the effect of latanoprost / timolol and brimonidine / timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open - angle glaucoma or ocular hypertension .", "", +74810, DoubleBlind, 115, 130, "double - masked", "", +74811, Randomized, 131, 141, "randomized", "", +74812, Crossover, 142, 151, "crossover", "", +74813, Latanoprost, 182, 193, "latanoprost", "", +74817, Lat/TimFC, 182, 203, "latanoprost / timolol", "", +74814, Timolol, 196, 203, "timolol", "", +74815, Brimonidine, 208, 219, "brimonidine", "", +74818, Brimo/TimFC, 208, 229, "brimonidine / timolol", "", +74816, Timolol, 222, 229, "timolol", "", +74819, IOP, 251, 271, "intraocular pressure", "", +74820, Primary_OpenAngleGlaucoma, 311, 340, "primary open - angle glaucoma", "", +74821, OcularHypertension, 344, 363, "ocular hypertension", "", +74825, Author, 366, 374, "Hommer A", "", +74826, Author, 383, 390, "Sperl P", "", +74827, Author, 393, 400, "Resch H", "", +74828, Author, 403, 423, "Popa - Cherecheanu A", "", +74829, Author, 426, 432, "Qiao C", "", +74830, Author, 435, 448, "Schmetterer L", "", +74831, Author, 451, 463, "Garh ö fer G", "", +74832, Austria, 571, 578, "Austria", "", +74833, Glaucoma, 666, 674, "glaucoma", "", +74851, ObjectiveDescription, 839, 1086, "In the present study , we set out to compare the effects of latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination and brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination on intraocular pressure ( IOP ) and ocular blood flow .", "", +74834, Latanoprost, 899, 910, "latanoprost", "", +74840, Lat/TimFC, 899, 963, "latanoprost 0 . 005 % / timolol 0 . 5 % ( LT ) fixed combination", "", +74835, DoseValue, 911, 918, "0 . 005", "", +74838, Percentage, 919, 920, "%", "", +74836, Timolol, 923, 930, "timolol", "", +74837, DoseValue, 931, 936, "0 . 5", "", +74839, Percentage, 937, 938, "%", "", +74841, Brimonidine, 968, 979, "brimonidine", "", +74847, Brimo/TimFC, 968, 1030, "brimonidine 0 . 2 % / timolol 0 . 5 % ( BT ) fixed combination", "", +74843, DoseValue, 980, 985, "0 . 2", "", +74845, Percentage, 986, 987, "%", "", +74842, Timolol, 990, 997, "timolol", "", +74844, DoseValue, 998, 1003, "0 . 5", "", +74846, Percentage, 1004, 1005, "%", "", +74848, IOP, 1034, 1054, "intraocular pressure", "", +74849, IOP, 1057, 1060, "IOP", "", +74850, OcularBloodFlow, 1067, 1084, "ocular blood flow", "", +74852, Randomized, 1137, 1147, "randomized", "", +74853, DoubleBlind, 1150, 1165, "double - masked", "", +74854, Crossover, 1174, 1183, "crossover", "", +74857, NumberAffected, 1193, 1195, "16", "", +74856, Primary_OpenAngleGlaucoma, 1210, 1239, "primary open - angle glaucoma", "", +74858, NumberAffected, 1244, 1245, "2", "", +74859, OcularHypertension, 1260, 1279, "ocular hypertension", "", +74860, Lat/TimFC, 1345, 1347, "LT", "", +74861, Brimo/TimFC, 1378, 1380, "BT", "", +74862, IOP, 1682, 1685, "IOP", "", +74863, Mean, 1742, 1746, "mean", "", +74864, IOP, 1756, 1759, "IOP", "", +74865, BaseLineValue, 1764, 1770, "25 . 3", "", +74866, SdDevBL, 1773, 1778, "2 . 8", "", +74867, mmHg, 1781, 1785, "mmHg", "", +74868, IOP, 1834, 1837, "IOP", "", +74869, Lat/TimFC, 1840, 1842, "LT", "", +74871, RelativeReduction, 1847, 1853, "35 . 0", "", +74872, SdDevChangeValue, 1857, 1863, "10 . 0", "", +74870, Brimo/TimFC, 1868, 1870, "BT", "", +74873, RelativeReduction, 1875, 1881, "33 . 6", "", +74874, SdDevChangeValue, 1885, 1890, "8 . 8", "", +74875, PvalueDiff, 1897, 1906, "= 0 . 463", "", +74876, PvalueDiff, 2031, 2038, "= 0 . 1", "", +74877, Lat/TimFC, 2068, 2070, "LT", "", +74878, Brimo/TimFC, 2075, 2077, "BT", "", +74881, ConclusionComment, 2249, 2346, "In the present study , a 6 - week treatment with LT or BT was equally effective in reducing IOP .", "", +74882, ConclusionComment, 2347, 2452, "In addition , none of the administered drugs induced a significant effect on ocular blood flow parameters", "", +74879, OcularBloodFlow, 2424, 2441, "ocular blood flow", "", +74880, PMID, 2498, 2506, "22775229", "", diff --git a/data/gl 22775229_tstrakeljahn.n-triples b/data/gl 22775229_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 22775229_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23203707_admin.annodb b/data/gl 23203707_admin.annodb new file mode 100644 index 0000000..03b2315 --- /dev/null +++ b/data/gl 23203707_admin.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2013", "", " \"2013\"." +4, Title, 120, 278, "Efficacy and safety of preservative - free latanoprost eyedrops , compared with BAK - preserved latanoprost in patients with ocular hypertension or glaucoma .", "", " \"Efficacy and safety of preservative - free latanoprost eyedrops , compared with BAK - preserved latanoprost in patients with ocular hypertension or glaucoma .\"." +79455, Preservative-Free_Latanoprost, 143, 174, "preservative - free latanoprost", "", " ." +73, Eyedrops, 175, 183, "eyedrops", "", " ." +70, OcularHypertension, 245, 264, "ocular hypertension", "", " ." +71, Glaucoma, 268, 276, "glaucoma", "", " . ." +5, Author, 279, 289, "Rouland JF", "", " \"Rouland JF\"." +6, Author, 298, 309, "Traverso CE", "", " \"Traverso CE\"." +7, Author, 312, 322, "Stalmans I", "", " \"Stalmans I\"." +8, Author, 325, 333, "Fekih LE", "", " \"Fekih LE\"." +9, Author, 336, 344, "Delval L", "", " \"Delval L\"." +10, Author, 347, 356, "Renault D", "", " \"Renault D\"." +11, Author, 359, 369, "Baudouin C", "", " \"Baudouin C\"." +79515, Preservative-Free_Latanoprost, 372, 377, "T2345", "", +65, France, 491, 497, "France", "", " ." +101, ObjectiveDescription, 526, 772, "To compare efficacy ( intraocular pressure ( IOP ) reduction ) and safety of preservative - free latanoprost ( T2345 ) to benzalkonium chloride ( BAK ) - preserved latanoprost ( BPL ; Xalatan ) in ocular hypertension ( OHT ) or primary open angle", "", " \"To compare efficacy ( intraocular pressure ( IOP ) reduction ) and safety of preservative - free latanoprost ( T2345 ) to benzalkonium chloride ( BAK ) - preserved latanoprost ( BPL ; Xalatan ) in ocular hypertension ( OHT ) or primary open angle\"." +13, IOP, 548, 568, "intraocular pressure", "", " . ." +14, IOP, 571, 574, "IOP", "", +79460, Preservative-Free_Latanoprost, 603, 634, "preservative - free latanoprost", "", +79461, Preservative-Free_Latanoprost, 637, 642, "T2345", "", +79484, BAK-preserved_Latanoprost, 648, 701, "benzalkonium chloride ( BAK ) - preserved latanoprost", "", " ." +79494, BAK-preserved_Latanoprost, 704, 707, "BPL", "", +18, OcularHypertension, 723, 742, "ocular hypertension", "", +18, OcularHypertension, 745, 748, "OHT", "", +94, Primary_OpenAngleGlaucoma, 754, 781, "primary open angle glaucoma", "", " ." +102, ObjectiveDescription, 773, 801, "glaucoma ( POAG ) patients .", "", " \"glaucoma ( POAG ) patients .\"." +95, Primary_OpenAngleGlaucoma, 784, 788, "POAG", "", +96, Prospective, 812, 823, "Prospective", "", " ." +22, Multicenter, 842, 853, "multicentre", "", " ." +23, Randomized, 856, 866, "randomised", "", " ." +24, Blind, 869, 890, "investigator - masked", "", " ." +25, Parallel, 893, 901, "parallel", "", " ." +103, Primary_OpenAngleGlaucoma, 946, 950, "POAG", "", +18, OcularHypertension, 954, 957, "OHT", "", +79496, BAK-preserved_Latanoprost, 991, 994, "BPL", "", +23, Randomized, 1009, 1017, "randomly", "", " ." +79517, Preservative-Free_Latanoprost, 1027, 1032, "T2345", "", +79519, BAK-preserved_Latanoprost, 1036, 1039, "BPL", "", +26, Eyedrops, 1046, 1050, "drop", "", " ." +27, Frequency, 1081, 1091, "once daily", "", " \"once daily\". \"once daily\"." +28, Duration, 1097, 1106, "D0 to D84", "", " \"D0 to D84\". \"D0 to D84\". \"D0 to D84\"." +29, IOP, 1119, 1122, "IOP", "", +108, TimePoint, 1139, 1156, "09 : 00 ( ± 1 h )", "", +30, Duration, 1162, 1171, "D0 to D84", "", +31, Mean, 1201, 1205, "Mean", "", " . ." +32, IOP, 1206, 1209, "IOP", "", +33, Duration, 1222, 1230, "D0 - D84", "", +34, Reduction, 1239, 1244, "8 . 6", "", " \"8 . 6\"." +115, SdDevChangeValue, 1245, 1252, "± 2 . 6", "", " \"± 2 . 6\"." +37, mmHg, 1253, 1258, "mm Hg", "", " ." +39, RelativeReduction, 1263, 1265, "36", "", " \"36\"." +79475, Preservative-Free_Latanoprost, 1273, 1278, "T2345", "", +40, Reduction, 1285, 1290, "9 . 0", "", " \"9 . 0\"." +116, SdDevChangeValue, 1293, 1298, "2 . 4", "", " \"2 . 4\"." +38, mmHg, 1299, 1304, "mm Hg", "", +41, RelativeReduction, 1309, 1311, "38", "", " \"38\"." +79498, BAK-preserved_Latanoprost, 1319, 1322, "BPL", "", +79477, Preservative-Free_Latanoprost, 1354, 1362, "of T2345", "", +79500, BAK-preserved_Latanoprost, 1366, 1369, "BPL", "", +79513, Preservative-Free_Latanoprost, 1393, 1398, "T2345", "", +42, TimePoint, 1417, 1420, "D15", "", +79396, EndPointDescription, 1464, 1480, "drug intolerance", "", " . ." +44, NumberAffected, 1499, 1500, "1", "", " \"1\"." +46, PercentageAffected, 1503, 1508, "0 . 5", "", " \"0 . 5\"." +79472, Preservative-Free_Latanoprost, 1524, 1529, "T2345", "", +45, NumberAffected, 1537, 1538, "4", "", " \"4\"." +47, PercentageAffected, 1541, 1546, "2 . 1", "", " \"2 . 1\"." +79502, BAK-preserved_Latanoprost, 1563, 1566, "BPL", "", +49, ConjunctivalHyperemia, 1588, 1611, "conjunctival hyperaemia", "", " ." +79468, Preservative-Free_Latanoprost, 1633, 1638, "T2345", "", +79505, BAK-preserved_Latanoprost, 1647, 1650, "BPL", "", +50, TimePoint, 1654, 1657, "D42", "", " \"D42\". \"D42\"." +51, PercentageAffected, 1660, 1666, "20 . 2", "", " \"20 . 2\"." +52, PercentageAffected, 1672, 1678, "30 . 6", "", " \"30 . 6\"." +55, PvalueDiff, 1683, 1694, "p = 0 . 003", "", " \"p = 0 . 003\"." +57, TimePoint, 1701, 1704, "D84", "", +53, PercentageAffected, 1707, 1713, "21 . 4", "", " \"30 . 6\"." +54, PercentageAffected, 1719, 1725, "29 . 1", "", " \"29 . 1\"." +56, PvalueDiff, 1730, 1740, "p = 0 . 02", "", " \"p = 0 . 02\"." +79470, Preservative-Free_Latanoprost, 1835, 1840, "T2345", "", +79503, BAK-preserved_Latanoprost, 1846, 1849, "BPL", "", +58, TimePoint, 1853, 1856, "D42", "", +59, PvalueDiff, 1878, 1889, "p = 0 . 001", "", +61, TimePoint, 1896, 1899, "D84", "", " \"D84\". \"D84\"." +60, PvalueDiff, 1921, 1932, "p = 0 . 001", "", +79466, Preservative-Free_Latanoprost, 1951, 1982, "Preservative - free latanoprost", "", +62, ConclusionComment, 1951, 2045, "Preservative - free latanoprost has the same efficacy as BPL , with improved local tolerance .", "", " \"Preservative - free latanoprost has the same efficacy as BPL , with improved local tolerance .\"." +79507, BAK-preserved_Latanoprost, 2008, 2011, "BPL", "", +64, PMID, 2100, 2108, "23203707", "", " \"23203707\"." diff --git a/data/gl 23203707_admin.n-triples b/data/gl 23203707_admin.n-triples new file mode 100644 index 0000000..7a81dd8 --- /dev/null +++ b/data/gl 23203707_admin.n-triples @@ -0,0 +1,161 @@ +# RDF export of group: Publication + . + "Publication 66789" . + "Efficacy and safety of preservative - free latanoprost eyedrops , compared with BAK - preserved latanoprost in patients with ocular hypertension or glaucoma ." . + "Rouland JF" . + "2013" . + "Br J Ophthalmol ." . + "23203707" . + . + "Traverso CE" . + "Stalmans I" . + "Fekih LE" . + "Delval L" . + "Renault D" . + "Baudouin C" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 66802" . + "To compare efficacy ( intraocular pressure ( IOP ) reduction ) and safety of preservative - free latanoprost ( T2345 ) to benzalkonium chloride ( BAK ) - preserved latanoprost ( BPL ; Xalatan ) in ocular hypertension ( OHT ) or primary open angle" . + "D0 to D84" . + . + . + . + "Preservative - free latanoprost has the same efficacy as BPL , with improved local tolerance ." . + . + . + . + . + . + "glaucoma ( POAG ) patients ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 66825" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint 66833 IOP" . + . + . + . + . + . + . + . + "Endpoint 66838 Drug intolerance" . + . + . + . + . + . + . + "Endpoint 66843 Conjunctival Hyperaemia" . + . + . + . + . +# RDF export of group: Arm + . + "Arm 67108 PFL" . + . + . + . + . + . + . + "Arm 67120 BPL" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention 66862 preservative free Latanoprost" . + . + "once daily" . + "D0 to D84" . + . + . + "Intervention 66868 BAK preserved Latanoprost" . + . + "once daily" . + "D0 to D84" . + . +# RDF export of group: Medication + . + "Medication 66848 preservative free Latanoprost" . + . + . + . + . + "Medication 66855 BAK preserved Latanoprost" . + . + . + . +# RDF export of group: Outcome + . + "Outcome 66874 PFL" . + . + "8 . 6" . + "36" . + "± 2 . 6" . + . + "Outcome 66901 BPL" . + . + "9 . 0" . + "38" . + "2 . 4" . + . + "Outcome 66928 drug intolerance PFL" . + . + "1" . + "0 . 5" . + . + "Outcome 66955 drug intolerance BPL" . + . + "4" . + "2 . 1" . + . + "Outcome 66982 conjunctival hyperaemia PFL D42" . + . + "20 . 2" . + "D42" . + . + "Outcome 67009 conjunctival hyperaemia BPL D42" . + . + "30 . 6" . + "D42" . + . + "Outcome 67036 conjunctival hyperaemia PFL D84" . + . + "21 . 4" . + "D84" . + . + "Outcome 67063 conjunctival hyperaemia BPL D84" . + . + "29 . 1" . + "D84" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups 67090 D42" . + "p = 0 . 003" . + . + . + . + "DiffBetweenGroups 67099 D84" . + "p = 0 . 02" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23203707_export.csv b/data/gl 23203707_export.csv new file mode 100644 index 0000000..7903fa9 --- /dev/null +++ b/data/gl 23203707_export.csv @@ -0,0 +1,490 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +422, 1, 1, 1, 0, 2, 0, 2, "Br" +422, 1, 2, 2, 3, 4, 3, 4, "J" +422, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +422, 1, 4, 4, 16, 17, 16, 17, "." +422, 2, 1, 5, 0, 4, 18, 22, "2013" +422, 2, 2, 6, 5, 8, 23, 26, "Feb" +422, 2, 3, 7, 9, 10, 27, 28, ";" +422, 2, 4, 8, 11, 13, 29, 31, "97" +422, 2, 5, 9, 14, 15, 32, 33, "(" +422, 2, 6, 10, 16, 17, 34, 35, "2" +422, 2, 7, 11, 18, 19, 36, 37, ")" +422, 2, 8, 12, 20, 21, 38, 39, ":" +422, 2, 9, 13, 22, 25, 40, 43, "196" +422, 2, 10, 14, 26, 27, 44, 45, "-" +422, 2, 11, 15, 28, 31, 46, 49, "200" +422, 2, 12, 16, 32, 33, 50, 51, "." +422, 2, 13, 17, 34, 37, 52, 55, "doi" +422, 2, 14, 18, 38, 39, 56, 57, ":" +422, 2, 15, 19, 40, 42, 58, 60, "10" +422, 2, 16, 20, 43, 44, 61, 62, "." +422, 2, 17, 21, 45, 49, 63, 67, "1136" +422, 2, 18, 22, 50, 51, 68, 69, "/" +422, 2, 19, 23, 52, 64, 70, 82, "bjophthalmol" +422, 2, 20, 24, 65, 66, 83, 84, "-" +422, 2, 21, 25, 67, 71, 85, 89, "2012" +422, 2, 22, 26, 72, 73, 90, 91, "-" +422, 2, 23, 27, 74, 80, 92, 98, "302121" +422, 2, 24, 28, 81, 82, 99, 100, "." +422, 3, 1, 29, 0, 4, 101, 105, "Epub" +422, 3, 2, 30, 5, 9, 106, 110, "2012" +422, 3, 3, 31, 10, 13, 111, 114, "Nov" +422, 3, 4, 32, 14, 16, 115, 117, "30" +422, 3, 5, 33, 17, 18, 118, 119, "." +422, 4, 1, 34, 0, 8, 120, 128, "Efficacy" +422, 4, 2, 35, 9, 12, 129, 132, "and" +422, 4, 3, 36, 13, 19, 133, 139, "safety" +422, 4, 4, 37, 20, 22, 140, 142, "of" +422, 4, 5, 38, 23, 35, 143, 155, "preservative" +422, 4, 6, 39, 36, 37, 156, 157, "-" +422, 4, 7, 40, 38, 42, 158, 162, "free" +422, 4, 8, 41, 43, 54, 163, 174, "latanoprost" +422, 4, 9, 42, 55, 63, 175, 183, "eyedrops" +422, 4, 10, 43, 64, 65, 184, 185, "," +422, 4, 11, 44, 66, 74, 186, 194, "compared" +422, 4, 12, 45, 75, 79, 195, 199, "with" +422, 4, 13, 46, 80, 83, 200, 203, "BAK" +422, 4, 14, 47, 84, 85, 204, 205, "-" +422, 4, 15, 48, 86, 95, 206, 215, "preserved" +422, 4, 16, 49, 96, 107, 216, 227, "latanoprost" +422, 4, 17, 50, 108, 110, 228, 230, "in" +422, 4, 18, 51, 111, 119, 231, 239, "patients" +422, 4, 19, 52, 120, 124, 240, 244, "with" +422, 4, 20, 53, 125, 131, 245, 251, "ocular" +422, 4, 21, 54, 132, 144, 252, 264, "hypertension" +422, 4, 22, 55, 145, 147, 265, 267, "or" +422, 4, 23, 56, 148, 156, 268, 276, "glaucoma" +422, 4, 24, 57, 157, 158, 277, 278, "." +422, 5, 1, 58, 0, 7, 279, 286, "Rouland" +422, 5, 2, 59, 8, 10, 287, 289, "JF" +422, 5, 3, 60, 11, 12, 290, 291, "(" +422, 5, 4, 61, 13, 14, 292, 293, "1" +422, 5, 5, 62, 15, 16, 294, 295, ")" +422, 5, 6, 63, 17, 18, 296, 297, "," +422, 5, 7, 64, 19, 27, 298, 306, "Traverso" +422, 5, 8, 65, 28, 30, 307, 309, "CE" +422, 5, 9, 66, 31, 32, 310, 311, "," +422, 5, 10, 67, 33, 41, 312, 320, "Stalmans" +422, 5, 11, 68, 42, 43, 321, 322, "I" +422, 5, 12, 69, 44, 45, 323, 324, "," +422, 5, 13, 70, 46, 51, 325, 330, "Fekih" +422, 5, 14, 71, 52, 54, 331, 333, "LE" +422, 5, 15, 72, 55, 56, 334, 335, "," +422, 5, 16, 73, 57, 63, 336, 342, "Delval" +422, 5, 17, 74, 64, 65, 343, 344, "L" +422, 5, 18, 75, 66, 67, 345, 346, "," +422, 5, 19, 76, 68, 75, 347, 354, "Renault" +422, 5, 20, 77, 76, 77, 355, 356, "D" +422, 5, 21, 78, 78, 79, 357, 358, "," +422, 5, 22, 79, 80, 88, 359, 367, "Baudouin" +422, 5, 23, 80, 89, 90, 368, 369, "C" +422, 5, 24, 81, 91, 92, 370, 371, ";" +422, 5, 25, 82, 93, 98, 372, 377, "T2345" +422, 5, 26, 83, 99, 104, 378, 383, "Study" +422, 5, 27, 84, 105, 110, 384, 389, "Group" +422, 5, 28, 85, 111, 112, 390, 391, "." +422, 6, 1, 86, 0, 6, 392, 398, "Author" +422, 6, 2, 87, 7, 18, 399, 410, "information" +422, 6, 3, 88, 19, 20, 411, 412, ":" +422, 6, 4, 89, 21, 22, 413, 414, "(" +422, 6, 5, 90, 23, 24, 415, 416, "1" +422, 6, 6, 91, 25, 26, 417, 418, ")" +422, 6, 7, 92, 27, 34, 419, 426, "Service" +422, 6, 8, 93, 35, 48, 427, 440, "ophtalmologie" +422, 6, 9, 94, 49, 50, 441, 442, "," +422, 6, 10, 95, 51, 55, 443, 447, "CHRU" +422, 6, 11, 96, 56, 58, 448, 450, "de" +422, 6, 12, 97, 59, 64, 451, 456, "Lille" +422, 6, 13, 98, 65, 66, 457, 458, "," +422, 6, 14, 99, 67, 72, 459, 464, "Place" +422, 6, 15, 100, 73, 75, 465, 467, "de" +422, 6, 16, 101, 76, 82, 468, 474, "Verdun" +422, 6, 17, 102, 83, 84, 475, 476, "," +422, 6, 18, 103, 85, 90, 477, 482, "Lille" +422, 6, 19, 104, 91, 96, 483, 488, "59000" +422, 6, 20, 105, 97, 98, 489, 490, "," +422, 6, 21, 106, 99, 105, 491, 497, "France" +422, 6, 22, 107, 106, 107, 498, 499, "." +422, 7, 1, 108, 0, 4, 500, 504, "jfr3" +422, 7, 2, 109, 5, 6, 505, 506, "@" +422, 7, 3, 110, 7, 14, 507, 514, "wanadoo" +422, 7, 4, 111, 15, 16, 515, 516, "." +422, 7, 5, 112, 17, 19, 517, 519, "fr" +422, 7, 6, 113, 20, 23, 520, 523, "AIM" +422, 7, 7, 114, 24, 25, 524, 525, ":" +422, 7, 8, 115, 26, 28, 526, 528, "To" +422, 7, 9, 116, 29, 36, 529, 536, "compare" +422, 7, 10, 117, 37, 45, 537, 545, "efficacy" +422, 7, 11, 118, 46, 47, 546, 547, "(" +422, 7, 12, 119, 48, 59, 548, 559, "intraocular" +422, 7, 13, 120, 60, 68, 560, 568, "pressure" +422, 7, 14, 121, 69, 70, 569, 570, "(" +422, 7, 15, 122, 71, 74, 571, 574, "IOP" +422, 7, 16, 123, 75, 76, 575, 576, ")" +422, 7, 17, 124, 77, 86, 577, 586, "reduction" +422, 7, 18, 125, 87, 88, 587, 588, ")" +422, 7, 19, 126, 89, 92, 589, 592, "and" +422, 7, 20, 127, 93, 99, 593, 599, "safety" +422, 7, 21, 128, 100, 102, 600, 602, "of" +422, 7, 22, 129, 103, 115, 603, 615, "preservative" +422, 7, 23, 130, 116, 117, 616, 617, "-" +422, 7, 24, 131, 118, 122, 618, 622, "free" +422, 7, 25, 132, 123, 134, 623, 634, "latanoprost" +422, 7, 26, 133, 135, 136, 635, 636, "(" +422, 7, 27, 134, 137, 142, 637, 642, "T2345" +422, 7, 28, 135, 143, 144, 643, 644, ")" +422, 7, 29, 136, 145, 147, 645, 647, "to" +422, 7, 30, 137, 148, 160, 648, 660, "benzalkonium" +422, 7, 31, 138, 161, 169, 661, 669, "chloride" +422, 7, 32, 139, 170, 171, 670, 671, "(" +422, 7, 33, 140, 172, 175, 672, 675, "BAK" +422, 7, 34, 141, 176, 177, 676, 677, ")" +422, 7, 35, 142, 178, 179, 678, 679, "-" +422, 7, 36, 143, 180, 189, 680, 689, "preserved" +422, 7, 37, 144, 190, 201, 690, 701, "latanoprost" +422, 7, 38, 145, 202, 203, 702, 703, "(" +422, 7, 39, 146, 204, 207, 704, 707, "BPL" +422, 7, 40, 147, 208, 209, 708, 709, ";" +422, 7, 41, 148, 210, 217, 710, 717, "Xalatan" +422, 7, 42, 149, 218, 219, 718, 719, ")" +422, 7, 43, 150, 220, 222, 720, 722, "in" +422, 7, 44, 151, 223, 229, 723, 729, "ocular" +422, 7, 45, 152, 230, 242, 730, 742, "hypertension" +422, 7, 46, 153, 243, 244, 743, 744, "(" +422, 7, 47, 154, 245, 248, 745, 748, "OHT" +422, 7, 48, 155, 249, 250, 749, 750, ")" +422, 7, 49, 156, 251, 253, 751, 753, "or" +422, 7, 50, 157, 254, 261, 754, 761, "primary" +422, 7, 51, 158, 262, 266, 762, 766, "open" +422, 7, 52, 159, 267, 272, 767, 772, "angle" +422, 7, 53, 160, 273, 281, 773, 781, "glaucoma" +422, 7, 54, 161, 282, 283, 782, 783, "(" +422, 7, 55, 162, 284, 288, 784, 788, "POAG" +422, 7, 56, 163, 289, 290, 789, 790, ")" +422, 7, 57, 164, 291, 299, 791, 799, "patients" +422, 7, 58, 165, 300, 301, 800, 801, "." +422, 8, 1, 166, 0, 7, 802, 809, "METHODS" +422, 8, 2, 167, 8, 9, 810, 811, ":" +422, 8, 3, 168, 10, 21, 812, 823, "Prospective" +422, 8, 4, 169, 22, 23, 824, 825, "," +422, 8, 5, 170, 24, 37, 826, 839, "international" +422, 8, 6, 171, 38, 39, 840, 841, "," +422, 8, 7, 172, 40, 51, 842, 853, "multicentre" +422, 8, 8, 173, 52, 53, 854, 855, "," +422, 8, 9, 174, 54, 64, 856, 866, "randomised" +422, 8, 10, 175, 65, 66, 867, 868, "," +422, 8, 11, 176, 67, 79, 869, 881, "investigator" +422, 8, 12, 177, 80, 81, 882, 883, "-" +422, 8, 13, 178, 82, 88, 884, 890, "masked" +422, 8, 14, 179, 89, 90, 891, 892, "," +422, 8, 15, 180, 91, 99, 893, 901, "parallel" +422, 8, 16, 181, 100, 101, 902, 903, "-" +422, 8, 17, 182, 102, 107, 904, 909, "group" +422, 8, 18, 183, 108, 113, 910, 915, "trial" +422, 8, 19, 184, 114, 115, 916, 917, "." +422, 9, 1, 185, 0, 5, 918, 923, "After" +422, 9, 2, 186, 6, 7, 924, 925, "a" +422, 9, 3, 187, 8, 12, 926, 930, "wash" +422, 9, 4, 188, 13, 14, 931, 932, "-" +422, 9, 5, 189, 15, 18, 933, 936, "out" +422, 9, 6, 190, 19, 25, 937, 943, "period" +422, 9, 7, 191, 26, 27, 944, 945, "," +422, 9, 8, 192, 28, 32, 946, 950, "POAG" +422, 9, 9, 193, 33, 35, 951, 953, "or" +422, 9, 10, 194, 36, 39, 954, 957, "OHT" +422, 9, 11, 195, 40, 48, 958, 966, "patients" +422, 9, 12, 196, 49, 50, 967, 968, "," +422, 9, 13, 197, 51, 61, 969, 979, "previously" +422, 9, 14, 198, 62, 69, 980, 987, "managed" +422, 9, 15, 199, 70, 72, 988, 990, "by" +422, 9, 16, 200, 73, 76, 991, 994, "BPL" +422, 9, 17, 201, 77, 88, 995, 1006, "monotherapy" +422, 9, 18, 202, 89, 90, 1007, 1008, "," +422, 9, 19, 203, 91, 99, 1009, 1017, "randomly" +422, 9, 20, 204, 100, 108, 1018, 1026, "received" +422, 9, 21, 205, 109, 114, 1027, 1032, "T2345" +422, 9, 22, 206, 115, 117, 1033, 1035, "or" +422, 9, 23, 207, 118, 121, 1036, 1039, "BPL" +422, 9, 24, 208, 122, 123, 1040, 1041, "(" +422, 9, 25, 209, 124, 127, 1042, 1045, "one" +422, 9, 26, 210, 128, 132, 1046, 1050, "drop" +422, 9, 27, 211, 133, 137, 1051, 1055, "into" +422, 9, 28, 212, 138, 141, 1056, 1059, "the" +422, 9, 29, 213, 142, 150, 1060, 1068, "affected" +422, 9, 30, 214, 151, 154, 1069, 1072, "eye" +422, 9, 31, 215, 155, 156, 1073, 1074, "(" +422, 9, 32, 216, 157, 158, 1075, 1076, "s" +422, 9, 33, 217, 159, 160, 1077, 1078, ")" +422, 9, 34, 218, 161, 162, 1079, 1080, ")" +422, 9, 35, 219, 163, 167, 1081, 1085, "once" +422, 9, 36, 220, 168, 173, 1086, 1091, "daily" +422, 9, 37, 221, 174, 178, 1092, 1096, "from" +422, 9, 38, 222, 179, 181, 1097, 1099, "D0" +422, 9, 39, 223, 182, 184, 1100, 1102, "to" +422, 9, 40, 224, 185, 188, 1103, 1106, "D84" +422, 9, 41, 225, 189, 190, 1107, 1108, "." +422, 10, 1, 226, 0, 6, 1109, 1115, "Change" +422, 10, 2, 227, 7, 9, 1116, 1118, "in" +422, 10, 3, 228, 10, 13, 1119, 1122, "IOP" +422, 10, 4, 229, 14, 17, 1123, 1126, "was" +422, 10, 5, 230, 18, 26, 1127, 1135, "measured" +422, 10, 6, 231, 27, 29, 1136, 1138, "at" +422, 10, 7, 232, 30, 32, 1139, 1141, "09" +422, 10, 8, 233, 33, 34, 1142, 1143, ":" +422, 10, 9, 234, 35, 37, 1144, 1146, "00" +422, 10, 10, 235, 38, 39, 1147, 1148, "(" +422, 10, 11, 236, 40, 41, 1149, 1150, "±" +422, 10, 12, 237, 42, 43, 1151, 1152, "1" +422, 10, 13, 238, 44, 45, 1153, 1154, "h" +422, 10, 14, 239, 46, 47, 1155, 1156, ")" +422, 10, 15, 240, 48, 52, 1157, 1161, "from" +422, 10, 16, 241, 53, 55, 1162, 1164, "D0" +422, 10, 17, 242, 56, 58, 1165, 1167, "to" +422, 10, 18, 243, 59, 62, 1168, 1171, "D84" +422, 10, 19, 244, 63, 65, 1172, 1174, "in" +422, 10, 20, 245, 66, 69, 1175, 1178, "the" +422, 10, 21, 246, 70, 75, 1179, 1184, "worse" +422, 10, 22, 247, 76, 79, 1185, 1188, "eye" +422, 10, 23, 248, 80, 81, 1189, 1190, "." +422, 11, 1, 249, 0, 7, 1191, 1198, "RESULTS" +422, 11, 2, 250, 8, 9, 1199, 1200, ":" +422, 11, 3, 251, 10, 14, 1201, 1205, "Mean" +422, 11, 4, 252, 15, 18, 1206, 1209, "IOP" +422, 11, 5, 253, 19, 28, 1210, 1219, "reduction" +422, 11, 6, 254, 29, 30, 1220, 1221, "(" +422, 11, 7, 255, 31, 33, 1222, 1224, "D0" +422, 11, 8, 256, 34, 35, 1225, 1226, "-" +422, 11, 9, 257, 36, 39, 1227, 1230, "D84" +422, 11, 10, 258, 40, 41, 1231, 1232, ")" +422, 11, 11, 259, 42, 45, 1233, 1236, "was" +422, 11, 12, 260, 46, 47, 1237, 1238, "-" +422, 11, 13, 261, 48, 49, 1239, 1240, "8" +422, 11, 14, 262, 50, 51, 1241, 1242, "." +422, 11, 15, 263, 52, 53, 1243, 1244, "6" +422, 11, 16, 264, 54, 55, 1245, 1246, "±" +422, 11, 17, 265, 56, 57, 1247, 1248, "2" +422, 11, 18, 266, 58, 59, 1249, 1250, "." +422, 11, 19, 267, 60, 61, 1251, 1252, "6" +422, 11, 20, 268, 62, 64, 1253, 1255, "mm" +422, 11, 21, 269, 65, 67, 1256, 1258, "Hg" +422, 11, 22, 270, 68, 69, 1259, 1260, "(" +422, 11, 23, 271, 70, 71, 1261, 1262, "-" +422, 11, 24, 272, 72, 74, 1263, 1265, "36" +422, 11, 25, 273, 75, 76, 1266, 1267, "%" +422, 11, 26, 274, 77, 78, 1268, 1269, ")" +422, 11, 27, 275, 79, 81, 1270, 1272, "on" +422, 11, 28, 276, 82, 87, 1273, 1278, "T2345" +422, 11, 29, 277, 88, 91, 1279, 1282, "and" +422, 11, 30, 278, 92, 93, 1283, 1284, "-" +422, 11, 31, 279, 94, 95, 1285, 1286, "9" +422, 11, 32, 280, 96, 97, 1287, 1288, "." +422, 11, 33, 281, 98, 99, 1289, 1290, "0" +422, 11, 34, 282, 100, 101, 1291, 1292, "±" +422, 11, 35, 283, 102, 103, 1293, 1294, "2" +422, 11, 36, 284, 104, 105, 1295, 1296, "." +422, 11, 37, 285, 106, 107, 1297, 1298, "4" +422, 11, 38, 286, 108, 110, 1299, 1301, "mm" +422, 11, 39, 287, 111, 113, 1302, 1304, "Hg" +422, 11, 40, 288, 114, 115, 1305, 1306, "(" +422, 11, 41, 289, 116, 117, 1307, 1308, "-" +422, 11, 42, 290, 118, 120, 1309, 1311, "38" +422, 11, 43, 291, 121, 122, 1312, 1313, "%" +422, 11, 44, 292, 123, 124, 1314, 1315, ")" +422, 11, 45, 293, 125, 127, 1316, 1318, "on" +422, 11, 46, 294, 128, 131, 1319, 1322, "BPL" +422, 11, 47, 295, 132, 133, 1323, 1324, "," +422, 11, 48, 296, 134, 144, 1325, 1335, "confirming" +422, 11, 49, 297, 145, 148, 1336, 1339, "non" +422, 11, 50, 298, 149, 150, 1340, 1341, "-" +422, 11, 51, 299, 151, 162, 1342, 1353, "inferiority" +422, 11, 52, 300, 163, 165, 1354, 1356, "of" +422, 11, 53, 301, 166, 171, 1357, 1362, "T2345" +422, 11, 54, 302, 172, 174, 1363, 1365, "to" +422, 11, 55, 303, 175, 178, 1366, 1369, "BPL" +422, 11, 56, 304, 179, 180, 1370, 1371, "." +422, 12, 1, 305, 0, 3, 1372, 1375, "Non" +422, 12, 2, 306, 4, 5, 1376, 1377, "-" +422, 12, 3, 307, 6, 17, 1378, 1389, "inferiority" +422, 12, 4, 308, 18, 20, 1390, 1392, "of" +422, 12, 5, 309, 21, 26, 1393, 1398, "T2345" +422, 12, 6, 310, 27, 30, 1399, 1402, "was" +422, 12, 7, 311, 31, 39, 1403, 1411, "observed" +422, 12, 8, 312, 40, 44, 1412, 1416, "from" +422, 12, 9, 313, 45, 48, 1417, 1420, "D15" +422, 12, 10, 314, 49, 50, 1421, 1422, "." +422, 13, 1, 315, 0, 3, 1423, 1426, "The" +422, 13, 2, 316, 4, 8, 1427, 1431, "most" +422, 13, 3, 317, 9, 17, 1432, 1440, "frequent" +422, 13, 4, 318, 18, 24, 1441, 1447, "ocular" +422, 13, 5, 319, 25, 32, 1448, 1455, "adverse" +422, 13, 6, 320, 33, 38, 1456, 1461, "event" +422, 13, 7, 321, 39, 40, 1462, 1463, "," +422, 13, 8, 322, 41, 45, 1464, 1468, "drug" +422, 13, 9, 323, 46, 57, 1469, 1480, "intolerance" +422, 13, 10, 324, 58, 59, 1481, 1482, "," +422, 13, 11, 325, 60, 63, 1483, 1486, "was" +422, 13, 12, 326, 64, 72, 1487, 1495, "reported" +422, 13, 13, 327, 73, 75, 1496, 1498, "in" +422, 13, 14, 328, 76, 77, 1499, 1500, "1" +422, 13, 15, 329, 78, 79, 1501, 1502, "(" +422, 13, 16, 330, 80, 81, 1503, 1504, "0" +422, 13, 17, 331, 82, 83, 1505, 1506, "." +422, 13, 18, 332, 84, 85, 1507, 1508, "5" +422, 13, 19, 333, 86, 87, 1509, 1510, "%" +422, 13, 20, 334, 88, 89, 1511, 1512, ")" +422, 13, 21, 335, 90, 97, 1513, 1520, "patient" +422, 13, 22, 336, 98, 100, 1521, 1523, "on" +422, 13, 23, 337, 101, 106, 1524, 1529, "T2345" +422, 13, 24, 338, 107, 113, 1530, 1536, "versus" +422, 13, 25, 339, 114, 115, 1537, 1538, "4" +422, 13, 26, 340, 116, 117, 1539, 1540, "(" +422, 13, 27, 341, 118, 119, 1541, 1542, "2" +422, 13, 28, 342, 120, 121, 1543, 1544, "." +422, 13, 29, 343, 122, 123, 1545, 1546, "1" +422, 13, 30, 344, 124, 125, 1547, 1548, "%" +422, 13, 31, 345, 126, 127, 1549, 1550, ")" +422, 13, 32, 346, 128, 136, 1551, 1559, "patients" +422, 13, 33, 347, 137, 139, 1560, 1562, "on" +422, 13, 34, 348, 140, 143, 1563, 1566, "BPL" +422, 13, 35, 349, 144, 145, 1567, 1568, "." +422, 14, 1, 350, 0, 8, 1569, 1577, "Moderate" +422, 14, 2, 351, 9, 11, 1578, 1580, "to" +422, 14, 3, 352, 12, 18, 1581, 1587, "severe" +422, 14, 4, 353, 19, 31, 1588, 1600, "conjunctival" +422, 14, 5, 354, 32, 42, 1601, 1611, "hyperaemia" +422, 14, 6, 355, 43, 46, 1612, 1615, "was" +422, 14, 7, 356, 47, 51, 1616, 1620, "less" +422, 14, 8, 357, 52, 60, 1621, 1629, "frequent" +422, 14, 9, 358, 61, 63, 1630, 1632, "on" +422, 14, 10, 359, 64, 69, 1633, 1638, "T2345" +422, 14, 11, 360, 70, 74, 1639, 1643, "than" +422, 14, 12, 361, 75, 77, 1644, 1646, "on" +422, 14, 13, 362, 78, 81, 1647, 1650, "BPL" +422, 14, 14, 363, 82, 84, 1651, 1653, "at" +422, 14, 15, 364, 85, 88, 1654, 1657, "D42" +422, 14, 16, 365, 89, 90, 1658, 1659, "(" +422, 14, 17, 366, 91, 93, 1660, 1662, "20" +422, 14, 18, 367, 94, 95, 1663, 1664, "." +422, 14, 19, 368, 96, 97, 1665, 1666, "2" +422, 14, 20, 369, 98, 99, 1667, 1668, "%" +422, 14, 21, 370, 100, 102, 1669, 1671, "vs" +422, 14, 22, 371, 103, 105, 1672, 1674, "30" +422, 14, 23, 372, 106, 107, 1675, 1676, "." +422, 14, 24, 373, 108, 109, 1677, 1678, "6" +422, 14, 25, 374, 110, 111, 1679, 1680, "%" +422, 14, 26, 375, 112, 113, 1681, 1682, ";" +422, 14, 27, 376, 114, 115, 1683, 1684, "p" +422, 14, 28, 377, 116, 117, 1685, 1686, "=" +422, 14, 29, 378, 118, 119, 1687, 1688, "0" +422, 14, 30, 379, 120, 121, 1689, 1690, "." +422, 14, 31, 380, 122, 125, 1691, 1694, "003" +422, 14, 32, 381, 126, 127, 1695, 1696, ")" +422, 14, 33, 382, 128, 131, 1697, 1700, "and" +422, 14, 34, 383, 132, 135, 1701, 1704, "D84" +422, 14, 35, 384, 136, 137, 1705, 1706, "(" +422, 14, 36, 385, 138, 140, 1707, 1709, "21" +422, 14, 37, 386, 141, 142, 1710, 1711, "." +422, 14, 38, 387, 143, 144, 1712, 1713, "4" +422, 14, 39, 388, 145, 146, 1714, 1715, "%" +422, 14, 40, 389, 147, 149, 1716, 1718, "vs" +422, 14, 41, 390, 150, 152, 1719, 1721, "29" +422, 14, 42, 391, 153, 154, 1722, 1723, "." +422, 14, 43, 392, 155, 156, 1724, 1725, "1" +422, 14, 44, 393, 157, 158, 1726, 1727, "%" +422, 14, 45, 394, 159, 160, 1728, 1729, ";" +422, 14, 46, 395, 161, 162, 1730, 1731, "p" +422, 14, 47, 396, 163, 164, 1732, 1733, "=" +422, 14, 48, 397, 165, 166, 1734, 1735, "0" +422, 14, 49, 398, 167, 168, 1736, 1737, "." +422, 14, 50, 399, 169, 171, 1738, 1740, "02" +422, 14, 51, 400, 172, 173, 1741, 1742, ")" +422, 14, 52, 401, 174, 175, 1743, 1744, "." +422, 15, 1, 402, 0, 4, 1745, 1749, "Upon" +422, 15, 2, 403, 5, 17, 1750, 1762, "instillation" +422, 15, 3, 404, 18, 19, 1763, 1764, "," +422, 15, 4, 405, 20, 23, 1765, 1768, "the" +422, 15, 5, 406, 24, 30, 1769, 1775, "global" +422, 15, 6, 407, 31, 41, 1776, 1786, "subjective" +422, 15, 7, 408, 42, 48, 1787, 1793, "ocular" +422, 15, 8, 409, 49, 56, 1794, 1801, "symptom" +422, 15, 9, 410, 57, 62, 1802, 1807, "score" +422, 15, 10, 411, 63, 66, 1808, 1811, "was" +422, 15, 11, 412, 67, 80, 1812, 1825, "significantly" +422, 15, 12, 413, 81, 86, 1826, 1831, "lower" +422, 15, 13, 414, 87, 89, 1832, 1834, "on" +422, 15, 14, 415, 90, 95, 1835, 1840, "T2345" +422, 15, 15, 416, 96, 100, 1841, 1845, "than" +422, 15, 16, 417, 101, 104, 1846, 1849, "BPL" +422, 15, 17, 418, 105, 107, 1850, 1852, "on" +422, 15, 18, 419, 108, 111, 1853, 1856, "D42" +422, 15, 19, 420, 112, 113, 1857, 1858, "(" +422, 15, 20, 421, 114, 115, 1859, 1860, "0" +422, 15, 21, 422, 116, 117, 1861, 1862, "." +422, 15, 22, 423, 118, 120, 1863, 1865, "15" +422, 15, 23, 424, 121, 123, 1866, 1868, "vs" +422, 15, 24, 425, 124, 125, 1869, 1870, "0" +422, 15, 25, 426, 126, 127, 1871, 1872, "." +422, 15, 26, 427, 128, 130, 1873, 1875, "41" +422, 15, 27, 428, 131, 132, 1876, 1877, ";" +422, 15, 28, 429, 133, 134, 1878, 1879, "p" +422, 15, 29, 430, 135, 136, 1880, 1881, "=" +422, 15, 30, 431, 137, 138, 1882, 1883, "0" +422, 15, 31, 432, 139, 140, 1884, 1885, "." +422, 15, 32, 433, 141, 144, 1886, 1889, "001" +422, 15, 33, 434, 145, 146, 1890, 1891, ")" +422, 15, 34, 435, 147, 150, 1892, 1895, "and" +422, 15, 35, 436, 151, 154, 1896, 1899, "D84" +422, 15, 36, 437, 155, 156, 1900, 1901, "(" +422, 15, 37, 438, 157, 158, 1902, 1903, "0" +422, 15, 38, 439, 159, 160, 1904, 1905, "." +422, 15, 39, 440, 161, 163, 1906, 1908, "18" +422, 15, 40, 441, 164, 166, 1909, 1911, "vs" +422, 15, 41, 442, 167, 168, 1912, 1913, "0" +422, 15, 42, 443, 169, 170, 1914, 1915, "." +422, 15, 43, 444, 171, 173, 1916, 1918, "46" +422, 15, 44, 445, 174, 175, 1919, 1920, ";" +422, 15, 45, 446, 176, 177, 1921, 1922, "p" +422, 15, 46, 447, 178, 179, 1923, 1924, "=" +422, 15, 47, 448, 180, 181, 1925, 1926, "0" +422, 15, 48, 449, 182, 183, 1927, 1928, "." +422, 15, 49, 450, 184, 187, 1929, 1932, "001" +422, 15, 50, 451, 188, 189, 1933, 1934, ")" +422, 15, 51, 452, 190, 191, 1935, 1936, "." +422, 16, 1, 453, 0, 11, 1937, 1948, "CONCLUSIONS" +422, 16, 2, 454, 12, 13, 1949, 1950, ":" +422, 16, 3, 455, 14, 26, 1951, 1963, "Preservative" +422, 16, 4, 456, 27, 28, 1964, 1965, "-" +422, 16, 5, 457, 29, 33, 1966, 1970, "free" +422, 16, 6, 458, 34, 45, 1971, 1982, "latanoprost" +422, 16, 7, 459, 46, 49, 1983, 1986, "has" +422, 16, 8, 460, 50, 53, 1987, 1990, "the" +422, 16, 9, 461, 54, 58, 1991, 1995, "same" +422, 16, 10, 462, 59, 67, 1996, 2004, "efficacy" +422, 16, 11, 463, 68, 70, 2005, 2007, "as" +422, 16, 12, 464, 71, 74, 2008, 2011, "BPL" +422, 16, 13, 465, 75, 76, 2012, 2013, "," +422, 16, 14, 466, 77, 81, 2014, 2018, "with" +422, 16, 15, 467, 82, 90, 2019, 2027, "improved" +422, 16, 16, 468, 91, 96, 2028, 2033, "local" +422, 16, 17, 469, 97, 106, 2034, 2043, "tolerance" +422, 16, 18, 470, 107, 108, 2044, 2045, "." +422, 17, 1, 471, 0, 3, 2046, 2049, "DOI" +422, 17, 2, 472, 4, 5, 2050, 2051, ":" +422, 17, 3, 473, 6, 8, 2052, 2054, "10" +422, 17, 4, 474, 9, 10, 2055, 2056, "." +422, 17, 5, 475, 11, 15, 2057, 2061, "1136" +422, 17, 6, 476, 16, 17, 2062, 2063, "/" +422, 17, 7, 477, 18, 30, 2064, 2076, "bjophthalmol" +422, 17, 8, 478, 31, 32, 2077, 2078, "-" +422, 17, 9, 479, 33, 37, 2079, 2083, "2012" +422, 17, 10, 480, 38, 39, 2084, 2085, "-" +422, 17, 11, 481, 40, 46, 2086, 2092, "302121" +422, 17, 12, 482, 47, 51, 2093, 2097, "PMID" +422, 17, 13, 483, 52, 53, 2098, 2099, ":" +422, 17, 14, 484, 54, 62, 2100, 2108, "23203707" +422, 17, 15, 485, 63, 64, 2109, 2110, "[" +422, 17, 16, 486, 65, 72, 2111, 2118, "Indexed" +422, 17, 17, 487, 73, 76, 2119, 2122, "for" +422, 17, 18, 488, 77, 84, 2123, 2130, "MEDLINE" +422, 17, 19, 489, 85, 86, 2131, 2132, "]" diff --git a/data/gl 23203707_jshahinitiran.annodb b/data/gl 23203707_jshahinitiran.annodb new file mode 100644 index 0000000..0ef3a72 --- /dev/null +++ b/data/gl 23203707_jshahinitiran.annodb @@ -0,0 +1,96 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16585, Journal, 0, 15, "Br J Ophthalmol", "", +16586, PublicationYear, 18, 22, "2013", "", +16587, Title, 120, 278, "Efficacy and safety of preservative - free latanoprost eyedrops , compared with BAK - preserved latanoprost in patients with ocular hypertension or glaucoma .", "", +35851, Drug, 143, 174, "preservative - free latanoprost", "", +35850, Latanoprost, 163, 174, "latanoprost", "", +35852, Drug, 200, 227, "BAK - preserved latanoprost", "", +35853, Latanoprost, 216, 227, "latanoprost", "", +35854, OcularHypertension, 245, 264, "ocular hypertension", "", +35855, Glaucoma, 268, 276, "glaucoma", "", +16588, Author, 279, 289, "Rouland JF", "", +16589, Author, 298, 309, "Traverso CE", "", +16590, Author, 312, 322, "Stalmans I", "", +16591, Author, 325, 333, "Fekih LE", "", +16592, Author, 336, 344, "Delval L", "", +16593, Author, 347, 356, "Renault D", "", +16594, Author, 359, 369, "Baudouin C", "", +35849, France, 491, 497, "France", "", +16595, ObjectiveDescription, 529, 781, "compare efficacy ( intraocular pressure ( IOP ) reduction ) and safety of preservative - free latanoprost ( T2345 ) to benzalkonium chloride ( BAK ) - preserved latanoprost ( BPL ; Xalatan ) in ocular hypertension ( OHT ) or primary open angle glaucoma", "", +16597, IOP, 548, 568, "intraocular pressure", "", +16598, IOP, 571, 574, "IOP", "", +16599, Drug, 603, 634, "preservative - free latanoprost", "FL", +16600, Latanoprost, 623, 634, "latanoprost", "", +16599, Drug, 637, 642, "T2345", "FL", +16602, Drug, 648, 669, "benzalkonium chloride", "PL", +16602, Drug, 672, 675, "BAK", "PL", +16602, Drug, 680, 701, "preserved latanoprost", "PL", +16654, Latanoprost, 690, 701, "latanoprost", "", +16602, Drug, 704, 707, "BPL", "PL", +16611, OcularHypertension, 723, 742, "ocular hypertension", "", +16611, OcularHypertension, 745, 748, "OHT", "", +16613, OpenAngleGlaucoma, 754, 781, "primary open angle glaucoma", "", +16595, ObjectiveDescription, 782, 801, "( POAG ) patients .", "", +16614, OpenAngleGlaucoma, 784, 788, "POAG", "", +16615, CTDesign, 812, 823, "Prospective", "", +16616, Multicenter, 842, 853, "multicentre", "", +16617, Randomized, 856, 866, "randomised", "", +16618, Blind, 869, 890, "investigator - masked", "", +16619, Parallel, 893, 901, "parallel", "", +16614, OpenAngleGlaucoma, 946, 950, "POAG", "", +16611, OcularHypertension, 954, 957, "OHT", "", +16602, Drug, 991, 994, "BPL", "PL", +16617, Randomized, 1009, 1017, "randomly", "", +16599, Drug, 1027, 1032, "T2345", "FL", +16602, Drug, 1036, 1039, "BPL", "PL", +16626, Eyedrops, 1046, 1050, "drop", "", +16627, Frequency, 1081, 1091, "once daily", "", +16628, Duration, 1097, 1106, "D0 to D84", "", +16629, IOP, 1119, 1122, "IOP", "", +16630, Duration, 1162, 1171, "D0 to D84", "", +16631, Mean, 1201, 1205, "Mean", "", +16632, IOP, 1206, 1209, "IOP", "", +16633, Duration, 1222, 1230, "D0 - D84", "", +16634, Reduction, 1239, 1244, "8 . 6", "", +16635, SdErrorChangeValue, 1247, 1252, "2 . 6", "", +16637, mmHg, 1253, 1258, "mm Hg", "", +16639, RelativeReduction, 1263, 1265, "36", "", +16599, Drug, 1273, 1278, "T2345", "FL", +16641, Reduction, 1285, 1290, "9 . 0", "", +16636, SdErrorChangeValue, 1293, 1298, "2 . 4", "", +16638, mmHg, 1299, 1304, "mm Hg", "", +16642, RelativeReduction, 1309, 1311, "38", "", +16602, Drug, 1319, 1322, "BPL", "PL", +16599, Drug, 1357, 1362, "T2345", "FL", +16602, Drug, 1366, 1369, "BPL", "PL", +16648, ObservedResult, 1372, 1422, "Non - inferiority of T2345 was observed from D15 .", "", +16599, Drug, 1393, 1398, "T2345", "FL", +16647, TimePoint, 1417, 1420, "D15", "", +16649, NumberAffected, 1499, 1500, "1", "", +16651, PercentageAffected, 1503, 1508, "0 . 5", "", +16599, Drug, 1524, 1529, "T2345", "FL", +16650, NumberAffected, 1537, 1538, "4", "", +16652, PercentageAffected, 1541, 1546, "2 . 1", "", +16602, Drug, 1563, 1566, "BPL", "PL", +16656, ConjunctivalHyperemia, 1588, 1611, "conjunctival hyperaemia", "", +16599, Drug, 1633, 1638, "T2345", "FL", +16602, Drug, 1647, 1650, "BPL", "PL", +16659, TimePoint, 1654, 1657, "D42", "", +16660, PercentageAffected, 1660, 1666, "20 . 2", "", +16661, PercentageAffected, 1672, 1678, "30 . 6", "", +16664, PvalueDiff, 1683, 1694, "p = 0 . 003", "", +16666, TimePoint, 1701, 1704, "D84", "", +16662, PercentageAffected, 1707, 1713, "21 . 4", "", +16663, PercentageAffected, 1719, 1725, "29 . 1", "", +16665, PvalueDiff, 1730, 1740, "p = 0 . 02", "", +16599, Drug, 1835, 1840, "T2345", "FL", +16602, Drug, 1846, 1849, "BPL", "PL", +16669, TimePoint, 1853, 1856, "D42", "", +16670, PvalueDiff, 1878, 1889, "p = 0 . 001", "", +16672, TimePoint, 1896, 1899, "D84", "", +16671, PvalueDiff, 1921, 1932, "p = 0 . 001", "", +16673, ConclusionComment, 1951, 2045, "Preservative - free latanoprost has the same efficacy as BPL , with improved local tolerance .", "", +16599, Drug, 1951, 1982, "Preservative - free latanoprost", "FL", +16676, Latanoprost, 1971, 1982, "latanoprost", "", +16602, Drug, 2008, 2011, "BPL", "PL", +16677, PMID, 2100, 2108, "23203707", "", diff --git a/data/gl 23203707_jshahinitiran.n-triples b/data/gl 23203707_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23203707_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23203707_tstrakeljahn.annodb b/data/gl 23203707_tstrakeljahn.annodb new file mode 100644 index 0000000..6b81cb5 --- /dev/null +++ b/data/gl 23203707_tstrakeljahn.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12368, Journal, 0, 15, "Br J Ophthalmol", "", +12369, PublicationYear, 18, 22, "2013", "", +76606, Title, 120, 278, "Efficacy and safety of preservative - free latanoprost eyedrops , compared with BAK - preserved latanoprost in patients with ocular hypertension or glaucoma .", "", +76600, Latanoprost, 163, 174, "latanoprost", "", +76601, Eyedrops, 175, 183, "eyedrops", "", +76605, Drug, 200, 227, "BAK - preserved latanoprost", "", +76602, Latanoprost, 216, 227, "latanoprost", "", +76603, OcularHypertension, 245, 264, "ocular hypertension", "", +76604, Glaucoma, 268, 276, "glaucoma", "", +76607, Author, 279, 289, "Rouland JF", "", +76608, Author, 298, 309, "Traverso CE", "", +76609, Author, 312, 322, "Stalmans I", "", +76610, Author, 325, 333, "Fekih LE", "", +76611, Author, 336, 344, "Delval L", "", +76612, Author, 347, 356, "Renault D", "", +76613, Author, 359, 369, "Baudouin C", "", +76614, France, 491, 497, "France", "", +76629, ObjectiveDescription, 526, 781, "To compare efficacy ( intraocular pressure ( IOP ) reduction ) and safety of preservative - free latanoprost ( T2345 ) to benzalkonium chloride ( BAK ) - preserved latanoprost ( BPL ; Xalatan ) in ocular hypertension ( OHT ) or primary open angle glaucoma", "", +76615, IOP, 548, 568, "intraocular pressure", "", +76616, IOP, 571, 574, "IOP", "", +76617, Latanoprost, 623, 634, "latanoprost", "", +76654, Latanoprost, 637, 642, "T2345", "", +76619, Drug, 648, 701, "benzalkonium chloride ( BAK ) - preserved latanoprost", "", +76618, Latanoprost, 690, 701, "latanoprost", "", +76620, OcularHypertension, 723, 742, "ocular hypertension", "", +76621, OcularHypertension, 745, 748, "OHT", "", +76622, Primary_OpenAngleGlaucoma, 754, 781, "primary open angle glaucoma", "", +76630, ObjectiveDescription, 773, 801, "glaucoma ( POAG ) patients .", "", +76623, Primary_OpenAngleGlaucoma, 784, 788, "POAG", "", +76624, Prospective, 812, 823, "Prospective", "", +76625, Multicenter, 842, 853, "multicentre", "", +76626, Randomized, 856, 866, "randomised", "", +76627, Blind, 869, 890, "investigator - masked", "", +76628, Parallel, 893, 901, "parallel", "", +76631, Primary_OpenAngleGlaucoma, 946, 950, "POAG", "", +76632, OcularHypertension, 954, 957, "OHT", "", +76655, Latanoprost, 1027, 1032, "T2345", "", +76656, Drug, 1036, 1039, "BPL", "", +76633, Frequency, 1081, 1091, "once daily", "", +76634, Duration, 1097, 1106, "D0 to D84", "", +76635, IOP, 1119, 1122, "IOP", "", +76636, TimePoint, 1139, 1156, "09 : 00 ( ± 1 h )", "", +76637, Duration, 1162, 1171, "D0 to D84", "", +76638, Mean, 1201, 1205, "Mean", "", +76639, IOP, 1206, 1209, "IOP", "", +76640, Duration, 1222, 1230, "D0 - D84", "", +76641, Reduction, 1239, 1244, "8 . 6", "", +76643, SdDevChangeValue, 1245, 1252, "± 2 . 6", "", +76645, mmHg, 1253, 1258, "mm Hg", "", +76647, RelativeReduction, 1263, 1265, "36", "", +76657, Latanoprost, 1273, 1278, "T2345", "", +76642, Reduction, 1285, 1290, "9 . 0", "", +76644, SdDevChangeValue, 1291, 1298, "± 2 . 4", "", +76646, mmHg, 1299, 1304, "mm Hg", "", +76648, RelativeReduction, 1309, 1311, "38", "", +76659, Drug, 1319, 1322, "BPL", "", +76658, Latanoprost, 1357, 1362, "T2345", "", +76649, ObservedResult, 1372, 1420, "Non - inferiority of T2345 was observed from D15", "", +76650, PercentageAffected, 1503, 1508, "0 . 5", "", +76651, PercentageAffected, 1541, 1546, "2 . 1", "", +76653, ConjunctivalHyperemia, 1588, 1611, "conjunctival hyperaemia", "", +76661, Latanoprost, 1633, 1638, "T2345", "", +76660, Drug, 1647, 1650, "BPL", "", +76662, TimePoint, 1654, 1657, "D42", "", +76663, PercentageAffected, 1660, 1666, "20 . 2", "", +76664, PercentageAffected, 1672, 1678, "30 . 6", "", +76665, PvalueDiff, 1683, 1694, "p = 0 . 003", "", +76666, TimePoint, 1701, 1704, "D84", "", +76667, PercentageAffected, 1707, 1713, "21 . 4", "", +76668, PercentageAffected, 1719, 1725, "29 . 1", "", +76669, PvalueDiff, 1732, 1740, "= 0 . 02", "", +76670, Latanoprost, 1835, 1840, "T2345", "", +76671, Drug, 1846, 1849, "BPL", "", +76672, TimePoint, 1853, 1856, "D42", "", +76673, PvalueDiff, 1880, 1889, "= 0 . 001", "", +76674, TimePoint, 1896, 1899, "D84", "", +76675, PvalueDiff, 1923, 1932, "= 0 . 001", "", +76679, ConclusionComment, 1951, 2045, "Preservative - free latanoprost has the same efficacy as BPL , with improved local tolerance .", "", +76676, Latanoprost, 1971, 1982, "latanoprost", "", +76677, Drug, 2008, 2011, "BPL", "", +76678, PMID, 2100, 2108, "23203707", "", diff --git a/data/gl 23203707_tstrakeljahn.n-triples b/data/gl 23203707_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23203707_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23429621_admin.annodb b/data/gl 23429621_admin.annodb new file mode 100644 index 0000000..218f73d --- /dev/null +++ b/data/gl 23429621_admin.annodb @@ -0,0 +1,110 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2014", "", " \"2014\"." +38423, Bima/TimFC, 94, 115, "Bimatoprost / timolol", "", " ." +2, Bimatoprost, 94, 105, "Bimatoprost", "", +100, Title, 94, 240, "Bimatoprost / timolol versus travoprost / timolol fixed combinations in an Egyptian population : a hospital - based prospective randomized study .", "", " \"Bimatoprost / timolol versus travoprost / timolol fixed combinations in an Egyptian population : a hospital - based prospective randomized study .\"." +3, Timolol, 108, 115, "timolol", "", +38422, Travoprost, 123, 133, "travoprost", "", +38431, Trav/TimFC, 123, 143, "travoprost / timolol", "", " ." +5, Timolol, 136, 143, "timolol", "", +54376, Prospective, 210, 221, "prospective", "", " ." +7, Randomized, 222, 232, "randomized", "", " ." +8, Author, 241, 249, "Macky TA", "", " \"Macky TA\"." +6, Egypt, 433, 438, "Egypt", "", " ." +110, ObjectiveDescription, 451, 630, "To compare the efficacy of bimatoprost / timolol ( BTFC ) or travoprost / timolol ( TTFC ) fixed combinations on intraocular pressure ( IOP ) reduction in an Egyptian population .", "", " \"To compare the efficacy of bimatoprost / timolol ( BTFC ) or travoprost / timolol ( TTFC ) fixed combinations on intraocular pressure ( IOP ) reduction in an Egyptian population .\"." +38424, Bima/TimFC, 478, 499, "bimatoprost / timolol", "", +9, Bimatoprost, 478, 489, "bimatoprost", "", +10, Timolol, 492, 499, "timolol", "", +38425, Bima/TimFC, 502, 506, "BTFC", "", +38432, Trav/TimFC, 512, 532, "travoprost / timolol", "", +37021, Travoprost, 512, 522, "travoprost", "", +13, Timolol, 525, 532, "timolol", "", +38433, Trav/TimFC, 535, 539, "TTFC", "", +15, IOP, 564, 584, "intraocular pressure", "", +16, IOP, 587, 590, "IOP", "", +106380, Ethnicity, 609, 617, "Egyptian", "", " . ." +54377, Precondition, 641, 682, "Patients with primary open angle glaucoma", "", " \"Patients with primary open angle glaucoma\"." +25187, Primary_OpenAngleGlaucoma, 655, 682, "primary open angle glaucoma", "", " ." +18, Randomized, 688, 698, "randomized", "", +38426, Bima/TimFC, 717, 721, "BTFC", "", +38434, Trav/TimFC, 725, 729, "TTFC", "", +21, IOP, 732, 736, "IOPs", "", +37022, TimePoint, 754, 762, "baseline", "", +147, TimePoint, 765, 772, "2 weeks", "", +25210, TimePoint, 779, 803, "1 , 2 , 4 , and 6 months", "", +37023, TimePoint, 783, 803, "2 , 4 , and 6 months", "", +37024, TimePoint, 787, 803, "4 , and 6 months", "", +37025, TimePoint, 795, 803, "6 months", "", +22, Mean, 842, 846, "mean", "", +23, IOP, 857, 860, "IOP", "", +121, NumberPatientsCT, 971, 977, "Eighty", "", " \"Eighty\"." +25, NumberPatientsArm, 1023, 1025, "40", "", " \"40\". \"40\"." +26, Mean, 1056, 1060, "mean", "", " . ." +124, IOP, 1061, 1065, "IOPs", "", " . ." +28, BaseLineValue, 1071, 1078, "24 . 78", "", " \"24 . 78\". \"24 . 78\"." +30, SdDevBL, 1081, 1087, "3 . 53", "", " \"3 . 53\". \"3 . 53\"." +29, BaseLineValue, 1092, 1099, "25 . 26", "", " \"25 . 26\". \"25 . 26\"." +31, SdDevBL, 1102, 1108, "3 . 51", "", " \"3 . 51\". \"3 . 51\"." +32, mmHg, 1109, 1114, "mm Hg", "", " ." +38427, Bima/TimFC, 1119, 1123, "BTFC", "", +38435, Trav/TimFC, 1128, 1132, "TTFC", "", +130, PValueBL, 1150, 1161, "P = 0 . 344", "", +38, Eyedrops, 1171, 1176, "drops", "", +36, IOP, 1212, 1215, "IOP", "", +132, PValueChangeValue, 1257, 1268, "P < 0 . 001", "", +40, Mean, 1307, 1311, "mean", "", +41, IOP, 1312, 1315, "IOP", "", +38436, Trav/TimFC, 1346, 1350, "TTFC", "", +43, PvalueDiff, 1367, 1378, "P < 0 . 001", "", +44, Mean, 1383, 1387, "Mean", "", +45, IOP, 1388, 1391, "IOP", "", +47, Reduction, 1408, 1415, "11 . 34", "", " \"11 . 34\"." +46, Reduction, 1420, 1426, "6 . 42", "", " \"6 . 42\"." +50, mmHg, 1427, 1432, "mm Hg", "", +52, TimePoint, 1436, 1443, "2 weeks", "", " \"2 weeks\". \"2 weeks\"." +53, PValueChangeValue, 1446, 1457, "P = 0 . 000", "", " \"2 weeks\". \"2 weeks\"." +48, Reduction, 1466, 1473, "11 . 17", "", " \"11 . 17\"." +49, Reduction, 1478, 1484, "7 . 89", "", " \"7 . 89\"." +51, mmHg, 1485, 1492, "mm   Hg", "", +55, TimePoint, 1496, 1504, "6 months", "", " \"6 months\". \"6 months\"." +54, PValueChangeValue, 1507, 1518, "P = 0 . 001", "", " \"P = 0 . 001\". \"P = 0 . 001\"." +38428, Bima/TimFC, 1525, 1529, "BTFC", "", +38442, Trav/TimFC, 1534, 1538, "TTFC", "", +60, IOP, 1556, 1560, "IOPs", "", +61, TimePoint, 1564, 1571, "2 weeks", "", " \"2 weeks\". \"2 weeks\". \"2 weeks\". \"2 weeks\"." +152, EndPointDescription, 1577, 1587, "≤ 18 mm Hg", "", " . ." +65, mmHg, 1582, 1587, "mm Hg", "", +69, NumberAffected, 1591, 1593, "36", "", " \"36\"." +77, PercentageAffected, 1596, 1602, "90 . 8", "", " \"90 . 8\"." +70, NumberAffected, 1614, 1616, "22", "", " \"22\"." +78, PercentageAffected, 1619, 1621, "55", "", " \"55\"." +163, EndPointDescription, 1635, 1645, "≤ 16 mm Hg", "", " . ." +66, mmHg, 1640, 1645, "mm Hg", "", +71, NumberAffected, 1649, 1651, "28", "", " \"28\"." +79, PercentageAffected, 1654, 1656, "70", "", " \"70\"." +72, NumberAffected, 1668, 1670, "16", "", " \"16\"." +80, PercentageAffected, 1673, 1675, "40", "", " \"40\"." +87, PvalueDiff, 1687, 1698, "P < 0 . 001", "", " \"P < 0 . 001\"." +62, TimePoint, 1710, 1718, "6 months", "", " \"6 months\". \"6 months\". \"6 months\". \"6 months\"." +152, EndPointDescription, 1721, 1731, "≤ 18 mm Hg", "", " . ." +67, mmHg, 1726, 1731, "mm Hg", "", +73, NumberAffected, 1735, 1737, "38", "", " \"38\"." +81, PercentageAffected, 1740, 1742, "95", "", " \"95\"." +74, NumberAffected, 1754, 1756, "28", "", " \"28\"." +82, PercentageAffected, 1759, 1761, "70", "", " \"70\"." +163, EndPointDescription, 1775, 1785, "≤ 16 mm Hg", "", +68, mmHg, 1780, 1785, "mm Hg", "", +75, NumberAffected, 1789, 1791, "30", "", " \"30\"." +83, PercentageAffected, 1794, 1796, "75", "", " \"75\"." +76, NumberAffected, 1808, 1810, "18", "", " \"18\"." +84, PercentageAffected, 1813, 1815, "45", "", " \"45\"." +38429, Bima/TimFC, 1829, 1833, "BTFC", "", +38440, Trav/TimFC, 1838, 1842, "TTFC", "", +88, PvalueDiff, 1860, 1871, "P < 0 . 001", "", " \"P < 0 . 001\"." +176, ConclusionComment, 1889, 2040, "Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC .", "", " \"Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC .\"." +91, Eyedrops, 1894, 1899, "drops", "", " . ." +92, IOP, 1919, 1922, "IOP", "", +38430, Bima/TimFC, 2019, 2023, "BTFC", "", +38437, Trav/TimFC, 2034, 2038, "TTFC", "", +95, PMID, 2089, 2097, "23429621", "", " \"23429621\"." diff --git a/data/gl 23429621_admin.n-triples b/data/gl 23429621_admin.n-triples new file mode 100644 index 0000000..08d56e6 --- /dev/null +++ b/data/gl 23429621_admin.n-triples @@ -0,0 +1,193 @@ +# RDF export of group: Publication + . + "Publication" . + "Bimatoprost / timolol versus travoprost / timolol fixed combinations in an Egyptian population : a hospital - based prospective randomized study ." . + "Macky TA" . + "2014" . + "J Glaucoma" . + "23429621" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy of bimatoprost / timolol ( BTFC ) or travoprost / timolol ( TTFC ) fixed combinations on intraocular pressure ( IOP ) reduction in an Egyptian population ." . + "Eighty" . + . + . + . + "Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC ." . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with primary open angle glaucoma" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_18" . + . + . + . + . + . + . + "Endpoint_16" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + "40" . + . + . + . + . + . + . + . + . + . + "Arm_TTFC" . + "40" . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + . + . + "Intervention_TTFC" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_TTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_BTFC_2weeks" . + . + "24 . 78" . + "3 . 53" . + "11 . 34" . + "P = 0 . 000" . + "2 weeks" . + . + "Outcome_iop_TTFC_2weeks" . + . + "25 . 26" . + "3 . 51" . + "6 . 42" . + "P = 0 . 000" . + "2 weeks" . + . + "Outcome_iop_BTFC_6months" . + . + "24 . 78" . + "3 . 53" . + "11 . 17" . + "P = 0 . 001" . + "6 months" . + . + "Outcome_iop_TTFC_6months" . + . + "25 . 26" . + "3 . 51" . + "7 . 89" . + "P = 0 . 001" . + "6 months" . + . + "Outcome_18_BTFC_2weeks" . + . + "36" . + "90 . 8" . + "2 weeks" . + . + "Outcome_18_TTFC_2weeks" . + . + "22" . + "55" . + "2 weeks" . + . + "Outcome_16_BTFC_2weeks" . + . + "28" . + "70" . + "2 weeks" . + . + "Outcome_16_TTFC_2weeks" . + . + "16" . + "40" . + "2 weeks" . + . + "Outcome_18_BTFC_6months" . + . + "38" . + "95" . + "6 months" . + . + "Outcome_18_TTFC_6months" . + . + "28" . + "70" . + "6 months" . + . + "Outcome_16_BTFC_6months" . + . + "30" . + "75" . + "6 months" . + . + "Outcome_16_TTFC_6months" . + . + "18" . + "45" . + "6 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_2weeks" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups_6months" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23429621_export.csv b/data/gl 23429621_export.csv new file mode 100644 index 0000000..0dfaa9e --- /dev/null +++ b/data/gl 23429621_export.csv @@ -0,0 +1,485 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +421, 1, 1, 1, 0, 1, 0, 1, "J" +421, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +421, 1, 3, 3, 11, 12, 11, 12, "." +421, 2, 1, 4, 0, 4, 13, 17, "2014" +421, 2, 2, 5, 5, 8, 18, 21, "Oct" +421, 2, 3, 6, 9, 10, 22, 23, "-" +421, 2, 4, 7, 11, 14, 24, 27, "Nov" +421, 2, 5, 8, 15, 16, 28, 29, ";" +421, 2, 6, 9, 17, 19, 30, 32, "23" +421, 2, 7, 10, 20, 21, 33, 34, "(" +421, 2, 8, 11, 22, 23, 35, 36, "8" +421, 2, 9, 12, 24, 25, 37, 38, ")" +421, 2, 10, 13, 26, 27, 39, 40, ":" +421, 2, 11, 14, 28, 31, 41, 44, "561" +421, 2, 12, 15, 32, 33, 45, 46, "-" +421, 2, 13, 16, 34, 35, 47, 48, "6" +421, 2, 14, 17, 36, 37, 49, 50, "." +421, 2, 15, 18, 38, 41, 51, 54, "doi" +421, 2, 16, 19, 42, 43, 55, 56, ":" +421, 2, 17, 20, 44, 46, 57, 59, "10" +421, 2, 18, 21, 47, 48, 60, 61, "." +421, 2, 19, 22, 49, 53, 62, 66, "1097" +421, 2, 20, 23, 54, 55, 67, 68, "/" +421, 2, 21, 24, 56, 59, 69, 72, "IJG" +421, 2, 22, 25, 60, 61, 73, 74, "." +421, 2, 23, 26, 62, 78, 75, 91, "0b013e3182867be3" +421, 2, 24, 27, 79, 80, 92, 93, "." +421, 3, 1, 28, 0, 11, 94, 105, "Bimatoprost" +421, 3, 2, 29, 12, 13, 106, 107, "/" +421, 3, 3, 30, 14, 21, 108, 115, "timolol" +421, 3, 4, 31, 22, 28, 116, 122, "versus" +421, 3, 5, 32, 29, 39, 123, 133, "travoprost" +421, 3, 6, 33, 40, 41, 134, 135, "/" +421, 3, 7, 34, 42, 49, 136, 143, "timolol" +421, 3, 8, 35, 50, 55, 144, 149, "fixed" +421, 3, 9, 36, 56, 68, 150, 162, "combinations" +421, 3, 10, 37, 69, 71, 163, 165, "in" +421, 3, 11, 38, 72, 74, 166, 168, "an" +421, 3, 12, 39, 75, 83, 169, 177, "Egyptian" +421, 3, 13, 40, 84, 94, 178, 188, "population" +421, 3, 14, 41, 95, 96, 189, 190, ":" +421, 3, 15, 42, 97, 98, 191, 192, "a" +421, 3, 16, 43, 99, 107, 193, 201, "hospital" +421, 3, 17, 44, 108, 109, 202, 203, "-" +421, 3, 18, 45, 110, 115, 204, 209, "based" +421, 3, 19, 46, 116, 127, 210, 221, "prospective" +421, 3, 20, 47, 128, 138, 222, 232, "randomized" +421, 3, 21, 48, 139, 144, 233, 238, "study" +421, 3, 22, 49, 145, 146, 239, 240, "." +421, 4, 1, 50, 0, 5, 241, 246, "Macky" +421, 4, 2, 51, 6, 8, 247, 249, "TA" +421, 4, 3, 52, 9, 10, 250, 251, "(" +421, 4, 4, 53, 11, 12, 252, 253, "1" +421, 4, 5, 54, 13, 14, 254, 255, ")" +421, 4, 6, 55, 15, 16, 256, 257, "." +421, 5, 1, 56, 0, 6, 258, 264, "Author" +421, 5, 2, 57, 7, 18, 265, 276, "information" +421, 5, 3, 58, 19, 20, 277, 278, ":" +421, 5, 4, 59, 21, 22, 279, 280, "(" +421, 5, 5, 60, 23, 24, 281, 282, "1" +421, 5, 6, 61, 25, 26, 283, 284, ")" +421, 5, 7, 62, 27, 28, 285, 286, "*" +421, 5, 8, 63, 29, 32, 287, 290, "The" +421, 5, 9, 64, 33, 43, 291, 301, "Department" +421, 5, 10, 65, 44, 46, 302, 304, "of" +421, 5, 11, 66, 47, 60, 305, 318, "Ophthalmology" +421, 5, 12, 67, 61, 62, 319, 320, "," +421, 5, 13, 68, 63, 73, 321, 331, "Diagnostic" +421, 5, 14, 69, 74, 79, 332, 337, "Laser" +421, 5, 15, 70, 80, 84, 338, 342, "Unit" +421, 5, 16, 71, 85, 86, 343, 344, "," +421, 5, 17, 72, 87, 91, 345, 349, "Kasr" +421, 5, 18, 73, 92, 94, 350, 352, "El" +421, 5, 19, 74, 95, 99, 353, 357, "Aini" +421, 5, 20, 75, 100, 108, 358, 366, "Hospital" +421, 5, 21, 76, 109, 110, 367, 368, "," +421, 5, 22, 77, 111, 116, 369, 374, "Cairo" +421, 5, 23, 78, 117, 127, 375, 385, "University" +421, 5, 24, 79, 128, 129, 386, 387, "," +421, 5, 25, 80, 130, 132, 388, 390, "El" +421, 5, 26, 81, 133, 134, 391, 392, "-" +421, 5, 27, 82, 135, 141, 393, 399, "Manial" +421, 5, 28, 83, 142, 143, 400, 401, "†" +421, 5, 29, 84, 144, 146, 402, 404, "Al" +421, 5, 30, 85, 147, 151, 405, 409, "Nour" +421, 5, 31, 86, 152, 155, 410, 413, "Eye" +421, 5, 32, 87, 156, 164, 414, 422, "Hospital" +421, 5, 33, 88, 165, 166, 423, 424, "," +421, 5, 34, 89, 167, 172, 425, 430, "Cairo" +421, 5, 35, 90, 173, 174, 431, 432, "," +421, 5, 36, 91, 175, 180, 433, 438, "Egypt" +421, 5, 37, 92, 181, 182, 439, 440, "." +421, 6, 1, 93, 0, 7, 441, 448, "PURPOSE" +421, 6, 2, 94, 8, 9, 449, 450, ":" +421, 6, 3, 95, 10, 12, 451, 453, "To" +421, 6, 4, 96, 13, 20, 454, 461, "compare" +421, 6, 5, 97, 21, 24, 462, 465, "the" +421, 6, 6, 98, 25, 33, 466, 474, "efficacy" +421, 6, 7, 99, 34, 36, 475, 477, "of" +421, 6, 8, 100, 37, 48, 478, 489, "bimatoprost" +421, 6, 9, 101, 49, 50, 490, 491, "/" +421, 6, 10, 102, 51, 58, 492, 499, "timolol" +421, 6, 11, 103, 59, 60, 500, 501, "(" +421, 6, 12, 104, 61, 65, 502, 506, "BTFC" +421, 6, 13, 105, 66, 67, 507, 508, ")" +421, 6, 14, 106, 68, 70, 509, 511, "or" +421, 6, 15, 107, 71, 81, 512, 522, "travoprost" +421, 6, 16, 108, 82, 83, 523, 524, "/" +421, 6, 17, 109, 84, 91, 525, 532, "timolol" +421, 6, 18, 110, 92, 93, 533, 534, "(" +421, 6, 19, 111, 94, 98, 535, 539, "TTFC" +421, 6, 20, 112, 99, 100, 540, 541, ")" +421, 6, 21, 113, 101, 106, 542, 547, "fixed" +421, 6, 22, 114, 107, 119, 548, 560, "combinations" +421, 6, 23, 115, 120, 122, 561, 563, "on" +421, 6, 24, 116, 123, 134, 564, 575, "intraocular" +421, 6, 25, 117, 135, 143, 576, 584, "pressure" +421, 6, 26, 118, 144, 145, 585, 586, "(" +421, 6, 27, 119, 146, 149, 587, 590, "IOP" +421, 6, 28, 120, 150, 151, 591, 592, ")" +421, 6, 29, 121, 152, 161, 593, 602, "reduction" +421, 6, 30, 122, 162, 164, 603, 605, "in" +421, 6, 31, 123, 165, 167, 606, 608, "an" +421, 6, 32, 124, 168, 176, 609, 617, "Egyptian" +421, 6, 33, 125, 177, 187, 618, 628, "population" +421, 6, 34, 126, 188, 189, 629, 630, "." +421, 7, 1, 127, 0, 7, 631, 638, "METHODS" +421, 7, 2, 128, 8, 9, 639, 640, ":" +421, 7, 3, 129, 10, 18, 641, 649, "Patients" +421, 7, 4, 130, 19, 23, 650, 654, "with" +421, 7, 5, 131, 24, 31, 655, 662, "primary" +421, 7, 6, 132, 32, 36, 663, 667, "open" +421, 7, 7, 133, 37, 42, 668, 673, "angle" +421, 7, 8, 134, 43, 51, 674, 682, "glaucoma" +421, 7, 9, 135, 52, 56, 683, 687, "were" +421, 7, 10, 136, 57, 67, 688, 698, "randomized" +421, 7, 11, 137, 68, 70, 699, 701, "to" +421, 7, 12, 138, 71, 78, 702, 709, "receive" +421, 7, 13, 139, 79, 85, 710, 716, "either" +421, 7, 14, 140, 86, 90, 717, 721, "BTFC" +421, 7, 15, 141, 91, 93, 722, 724, "or" +421, 7, 16, 142, 94, 98, 725, 729, "TTFC" +421, 7, 17, 143, 99, 100, 730, 731, "." +421, 8, 1, 144, 0, 4, 732, 736, "IOPs" +421, 8, 2, 145, 5, 9, 737, 741, "were" +421, 8, 3, 146, 10, 18, 742, 750, "measured" +421, 8, 4, 147, 19, 21, 751, 753, "at" +421, 8, 5, 148, 22, 30, 754, 762, "baseline" +421, 8, 6, 149, 31, 32, 763, 764, "," +421, 8, 7, 150, 33, 34, 765, 766, "2" +421, 8, 8, 151, 35, 40, 767, 772, "weeks" +421, 8, 9, 152, 41, 42, 773, 774, "," +421, 8, 10, 153, 43, 46, 775, 778, "and" +421, 8, 11, 154, 47, 48, 779, 780, "1" +421, 8, 12, 155, 49, 50, 781, 782, "," +421, 8, 13, 156, 51, 52, 783, 784, "2" +421, 8, 14, 157, 53, 54, 785, 786, "," +421, 8, 15, 158, 55, 56, 787, 788, "4" +421, 8, 16, 159, 57, 58, 789, 790, "," +421, 8, 17, 160, 59, 62, 791, 794, "and" +421, 8, 18, 161, 63, 64, 795, 796, "6" +421, 8, 19, 162, 65, 71, 797, 803, "months" +421, 8, 20, 163, 72, 73, 804, 805, "." +421, 9, 1, 164, 0, 3, 806, 809, "The" +421, 9, 2, 165, 4, 11, 810, 817, "primary" +421, 9, 3, 166, 12, 19, 818, 825, "outcome" +421, 9, 4, 167, 20, 27, 826, 833, "measure" +421, 9, 5, 168, 28, 31, 834, 837, "was" +421, 9, 6, 169, 32, 35, 838, 841, "the" +421, 9, 7, 170, 36, 40, 842, 846, "mean" +421, 9, 8, 171, 41, 47, 847, 853, "change" +421, 9, 9, 172, 48, 50, 854, 856, "in" +421, 9, 10, 173, 51, 54, 857, 860, "IOP" +421, 9, 11, 174, 55, 59, 861, 865, "from" +421, 9, 12, 175, 60, 68, 866, 874, "baseline" +421, 9, 13, 176, 69, 71, 875, 877, "at" +421, 9, 14, 177, 72, 76, 878, 882, "each" +421, 9, 15, 178, 77, 82, 883, 888, "visit" +421, 9, 16, 179, 83, 84, 889, 890, "." +421, 10, 1, 180, 0, 9, 891, 900, "Secondary" +421, 10, 2, 181, 10, 17, 901, 908, "outcome" +421, 10, 3, 182, 18, 26, 909, 917, "measures" +421, 10, 4, 183, 27, 35, 918, 926, "included" +421, 10, 5, 184, 36, 39, 927, 930, "the" +421, 10, 6, 185, 40, 49, 931, 940, "incidence" +421, 10, 7, 186, 50, 52, 941, 943, "of" +421, 10, 8, 187, 53, 60, 944, 951, "adverse" +421, 10, 9, 188, 61, 67, 952, 958, "events" +421, 10, 10, 189, 68, 69, 959, 960, "." +421, 11, 1, 190, 0, 7, 961, 968, "RESULTS" +421, 11, 2, 191, 8, 9, 969, 970, ":" +421, 11, 3, 192, 10, 16, 971, 977, "Eighty" +421, 11, 4, 193, 17, 25, 978, 986, "patients" +421, 11, 5, 194, 26, 27, 987, 988, "(" +421, 11, 6, 195, 28, 30, 989, 991, "80" +421, 11, 7, 196, 31, 35, 992, 996, "eyes" +421, 11, 8, 197, 36, 37, 997, 998, ")" +421, 11, 9, 198, 38, 42, 999, 1003, "were" +421, 11, 10, 199, 43, 51, 1004, 1012, "included" +421, 11, 11, 200, 52, 59, 1013, 1020, "finally" +421, 11, 12, 201, 60, 61, 1021, 1022, ":" +421, 11, 13, 202, 62, 64, 1023, 1025, "40" +421, 11, 14, 203, 65, 69, 1026, 1030, "eyes" +421, 11, 15, 204, 70, 72, 1031, 1033, "in" +421, 11, 16, 205, 73, 77, 1034, 1038, "each" +421, 11, 17, 206, 78, 83, 1039, 1044, "group" +421, 11, 18, 207, 84, 85, 1045, 1046, "." +421, 12, 1, 208, 0, 8, 1047, 1055, "Baseline" +421, 12, 2, 209, 9, 13, 1056, 1060, "mean" +421, 12, 3, 210, 14, 18, 1061, 1065, "IOPs" +421, 12, 4, 211, 19, 23, 1066, 1070, "were" +421, 12, 5, 212, 24, 26, 1071, 1073, "24" +421, 12, 6, 213, 27, 28, 1074, 1075, "." +421, 12, 7, 214, 29, 31, 1076, 1078, "78" +421, 12, 8, 215, 32, 33, 1079, 1080, "±" +421, 12, 9, 216, 34, 35, 1081, 1082, "3" +421, 12, 10, 217, 36, 37, 1083, 1084, "." +421, 12, 11, 218, 38, 40, 1085, 1087, "53" +421, 12, 12, 219, 41, 44, 1088, 1091, "and" +421, 12, 13, 220, 45, 47, 1092, 1094, "25" +421, 12, 14, 221, 48, 49, 1095, 1096, "." +421, 12, 15, 222, 50, 52, 1097, 1099, "26" +421, 12, 16, 223, 53, 54, 1100, 1101, "±" +421, 12, 17, 224, 55, 56, 1102, 1103, "3" +421, 12, 18, 225, 57, 58, 1104, 1105, "." +421, 12, 19, 226, 59, 61, 1106, 1108, "51" +421, 12, 20, 227, 62, 64, 1109, 1111, "mm" +421, 12, 21, 228, 65, 67, 1112, 1114, "Hg" +421, 12, 22, 229, 68, 71, 1115, 1118, "for" +421, 12, 23, 230, 72, 76, 1119, 1123, "BTFC" +421, 12, 24, 231, 77, 80, 1124, 1127, "and" +421, 12, 25, 232, 81, 85, 1128, 1132, "TTFC" +421, 12, 26, 233, 86, 87, 1133, 1134, "," +421, 12, 27, 234, 88, 100, 1135, 1147, "respectively" +421, 12, 28, 235, 101, 102, 1148, 1149, "(" +421, 12, 29, 236, 103, 104, 1150, 1151, "P" +421, 12, 30, 237, 105, 106, 1152, 1153, "=" +421, 12, 31, 238, 107, 108, 1154, 1155, "0" +421, 12, 32, 239, 109, 110, 1156, 1157, "." +421, 12, 33, 240, 111, 114, 1158, 1161, "344" +421, 12, 34, 241, 115, 116, 1162, 1163, ")" +421, 12, 35, 242, 117, 118, 1164, 1165, "." +421, 13, 1, 243, 0, 4, 1166, 1170, "Both" +421, 13, 2, 244, 5, 10, 1171, 1176, "drops" +421, 13, 3, 245, 11, 19, 1177, 1185, "provided" +421, 13, 4, 246, 20, 33, 1186, 1199, "statistically" +421, 13, 5, 247, 34, 45, 1200, 1211, "significant" +421, 13, 6, 248, 46, 49, 1212, 1215, "IOP" +421, 13, 7, 249, 50, 60, 1216, 1226, "reductions" +421, 13, 8, 250, 61, 65, 1227, 1231, "from" +421, 13, 9, 251, 66, 74, 1232, 1240, "baseline" +421, 13, 10, 252, 75, 77, 1241, 1243, "at" +421, 13, 11, 253, 78, 81, 1244, 1247, "all" +421, 13, 12, 254, 82, 88, 1248, 1254, "visits" +421, 13, 13, 255, 89, 90, 1255, 1256, "(" +421, 13, 14, 256, 91, 92, 1257, 1258, "P" +421, 13, 15, 257, 93, 94, 1259, 1260, "<" +421, 13, 16, 258, 95, 96, 1261, 1262, "0" +421, 13, 17, 259, 97, 98, 1263, 1264, "." +421, 13, 18, 260, 99, 102, 1265, 1268, "001" +421, 13, 19, 261, 103, 104, 1269, 1270, ")" +421, 13, 20, 262, 105, 106, 1271, 1272, "." +421, 14, 1, 263, 0, 4, 1273, 1277, "BTFC" +421, 14, 2, 264, 5, 13, 1278, 1286, "provided" +421, 14, 3, 265, 14, 21, 1287, 1294, "greater" +421, 14, 4, 266, 22, 33, 1295, 1306, "significant" +421, 14, 5, 267, 34, 38, 1307, 1311, "mean" +421, 14, 6, 268, 39, 42, 1312, 1315, "IOP" +421, 14, 7, 269, 43, 53, 1316, 1326, "reductions" +421, 14, 8, 270, 54, 58, 1327, 1331, "from" +421, 14, 9, 271, 59, 67, 1332, 1340, "baseline" +421, 14, 10, 272, 68, 72, 1341, 1345, "than" +421, 14, 11, 273, 73, 77, 1346, 1350, "TTFC" +421, 14, 12, 274, 78, 80, 1351, 1353, "at" +421, 14, 13, 275, 81, 85, 1354, 1358, "each" +421, 14, 14, 276, 86, 91, 1359, 1364, "visit" +421, 14, 15, 277, 92, 93, 1365, 1366, "(" +421, 14, 16, 278, 94, 95, 1367, 1368, "P" +421, 14, 17, 279, 96, 97, 1369, 1370, "<" +421, 14, 18, 280, 98, 99, 1371, 1372, "0" +421, 14, 19, 281, 100, 101, 1373, 1374, "." +421, 14, 20, 282, 102, 105, 1375, 1378, "001" +421, 14, 21, 283, 106, 107, 1379, 1380, ")" +421, 14, 22, 284, 108, 109, 1381, 1382, "." +421, 15, 1, 285, 0, 4, 1383, 1387, "Mean" +421, 15, 2, 286, 5, 8, 1388, 1391, "IOP" +421, 15, 3, 287, 9, 19, 1392, 1402, "reductions" +421, 15, 4, 288, 20, 24, 1403, 1407, "were" +421, 15, 5, 289, 25, 27, 1408, 1410, "11" +421, 15, 6, 290, 28, 29, 1411, 1412, "." +421, 15, 7, 291, 30, 32, 1413, 1415, "34" +421, 15, 8, 292, 33, 36, 1416, 1419, "and" +421, 15, 9, 293, 37, 38, 1420, 1421, "6" +421, 15, 10, 294, 39, 40, 1422, 1423, "." +421, 15, 11, 295, 41, 43, 1424, 1426, "42" +421, 15, 12, 296, 44, 46, 1427, 1429, "mm" +421, 15, 13, 297, 47, 49, 1430, 1432, "Hg" +421, 15, 14, 298, 50, 52, 1433, 1435, "at" +421, 15, 15, 299, 53, 54, 1436, 1437, "2" +421, 15, 16, 300, 55, 60, 1438, 1443, "weeks" +421, 15, 17, 301, 61, 62, 1444, 1445, "(" +421, 15, 18, 302, 63, 64, 1446, 1447, "P" +421, 15, 19, 303, 65, 66, 1448, 1449, "=" +421, 15, 20, 304, 67, 68, 1450, 1451, "0" +421, 15, 21, 305, 69, 70, 1452, 1453, "." +421, 15, 22, 306, 71, 74, 1454, 1457, "000" +421, 15, 23, 307, 75, 76, 1458, 1459, ")" +421, 15, 24, 308, 77, 78, 1460, 1461, "," +421, 15, 25, 309, 79, 82, 1462, 1465, "and" +421, 15, 26, 310, 83, 85, 1466, 1468, "11" +421, 15, 27, 311, 86, 87, 1469, 1470, "." +421, 15, 28, 312, 88, 90, 1471, 1473, "17" +421, 15, 29, 313, 91, 94, 1474, 1477, "and" +421, 15, 30, 314, 95, 96, 1478, 1479, "7" +421, 15, 31, 315, 97, 98, 1480, 1481, "." +421, 15, 32, 316, 99, 101, 1482, 1484, "89" +421, 15, 33, 317, 102, 104, 1485, 1487, "mm" +421, 15, 34, 318, 105, 106, 1488, 1489, " " +421, 15, 35, 319, 107, 109, 1490, 1492, "Hg" +421, 15, 36, 320, 110, 112, 1493, 1495, "at" +421, 15, 37, 321, 113, 114, 1496, 1497, "6" +421, 15, 38, 322, 115, 121, 1498, 1504, "months" +421, 15, 39, 323, 122, 123, 1505, 1506, "(" +421, 15, 40, 324, 124, 125, 1507, 1508, "P" +421, 15, 41, 325, 126, 127, 1509, 1510, "=" +421, 15, 42, 326, 128, 129, 1511, 1512, "0" +421, 15, 43, 327, 130, 131, 1513, 1514, "." +421, 15, 44, 328, 132, 135, 1515, 1518, "001" +421, 15, 45, 329, 136, 137, 1519, 1520, ")" +421, 15, 46, 330, 138, 141, 1521, 1524, "for" +421, 15, 47, 331, 142, 146, 1525, 1529, "BTFC" +421, 15, 48, 332, 147, 150, 1530, 1533, "and" +421, 15, 49, 333, 151, 155, 1534, 1538, "TTFC" +421, 15, 50, 334, 156, 157, 1539, 1540, "," +421, 15, 51, 335, 158, 170, 1541, 1553, "respectively" +421, 15, 52, 336, 171, 172, 1554, 1555, "." +421, 16, 1, 337, 0, 4, 1556, 1560, "IOPs" +421, 16, 2, 338, 5, 7, 1561, 1563, "at" +421, 16, 3, 339, 8, 9, 1564, 1565, "2" +421, 16, 4, 340, 10, 15, 1566, 1571, "weeks" +421, 16, 5, 341, 16, 20, 1572, 1576, "were" +421, 16, 6, 342, 21, 22, 1577, 1578, "≤" +421, 16, 7, 343, 23, 25, 1579, 1581, "18" +421, 16, 8, 344, 26, 28, 1582, 1584, "mm" +421, 16, 9, 345, 29, 31, 1585, 1587, "Hg" +421, 16, 10, 346, 32, 34, 1588, 1590, "in" +421, 16, 11, 347, 35, 37, 1591, 1593, "36" +421, 16, 12, 348, 38, 39, 1594, 1595, "(" +421, 16, 13, 349, 40, 42, 1596, 1598, "90" +421, 16, 14, 350, 43, 44, 1599, 1600, "." +421, 16, 15, 351, 45, 46, 1601, 1602, "8" +421, 16, 16, 352, 47, 48, 1603, 1604, "%" +421, 16, 17, 353, 49, 50, 1605, 1606, ")" +421, 16, 18, 354, 51, 57, 1607, 1613, "versus" +421, 16, 19, 355, 58, 60, 1614, 1616, "22" +421, 16, 20, 356, 61, 62, 1617, 1618, "(" +421, 16, 21, 357, 63, 65, 1619, 1621, "55" +421, 16, 22, 358, 66, 67, 1622, 1623, "%" +421, 16, 23, 359, 68, 69, 1624, 1625, ")" +421, 16, 24, 360, 70, 74, 1626, 1630, "eyes" +421, 16, 25, 361, 75, 78, 1631, 1634, "and" +421, 16, 26, 362, 79, 80, 1635, 1636, "≤" +421, 16, 27, 363, 81, 83, 1637, 1639, "16" +421, 16, 28, 364, 84, 86, 1640, 1642, "mm" +421, 16, 29, 365, 87, 89, 1643, 1645, "Hg" +421, 16, 30, 366, 90, 92, 1646, 1648, "in" +421, 16, 31, 367, 93, 95, 1649, 1651, "28" +421, 16, 32, 368, 96, 97, 1652, 1653, "(" +421, 16, 33, 369, 98, 100, 1654, 1656, "70" +421, 16, 34, 370, 101, 102, 1657, 1658, "%" +421, 16, 35, 371, 103, 104, 1659, 1660, ")" +421, 16, 36, 372, 105, 111, 1661, 1667, "versus" +421, 16, 37, 373, 112, 114, 1668, 1670, "16" +421, 16, 38, 374, 115, 116, 1671, 1672, "(" +421, 16, 39, 375, 117, 119, 1673, 1675, "40" +421, 16, 40, 376, 120, 121, 1676, 1677, "%" +421, 16, 41, 377, 122, 123, 1678, 1679, ")" +421, 16, 42, 378, 124, 128, 1680, 1684, "eyes" +421, 16, 43, 379, 129, 130, 1685, 1686, "(" +421, 16, 44, 380, 131, 132, 1687, 1688, "P" +421, 16, 45, 381, 133, 134, 1689, 1690, "<" +421, 16, 46, 382, 135, 136, 1691, 1692, "0" +421, 16, 47, 383, 137, 138, 1693, 1694, "." +421, 16, 48, 384, 139, 142, 1695, 1698, "001" +421, 16, 49, 385, 143, 144, 1699, 1700, ")" +421, 16, 50, 386, 145, 146, 1701, 1702, "," +421, 16, 51, 387, 147, 150, 1703, 1706, "and" +421, 16, 52, 388, 151, 153, 1707, 1709, "at" +421, 16, 53, 389, 154, 155, 1710, 1711, "6" +421, 16, 54, 390, 156, 162, 1712, 1718, "months" +421, 16, 55, 391, 163, 164, 1719, 1720, "," +421, 16, 56, 392, 165, 166, 1721, 1722, "≤" +421, 16, 57, 393, 167, 169, 1723, 1725, "18" +421, 16, 58, 394, 170, 172, 1726, 1728, "mm" +421, 16, 59, 395, 173, 175, 1729, 1731, "Hg" +421, 16, 60, 396, 176, 178, 1732, 1734, "in" +421, 16, 61, 397, 179, 181, 1735, 1737, "38" +421, 16, 62, 398, 182, 183, 1738, 1739, "(" +421, 16, 63, 399, 184, 186, 1740, 1742, "95" +421, 16, 64, 400, 187, 188, 1743, 1744, "%" +421, 16, 65, 401, 189, 190, 1745, 1746, ")" +421, 16, 66, 402, 191, 197, 1747, 1753, "versus" +421, 16, 67, 403, 198, 200, 1754, 1756, "28" +421, 16, 68, 404, 201, 202, 1757, 1758, "(" +421, 16, 69, 405, 203, 205, 1759, 1761, "70" +421, 16, 70, 406, 206, 207, 1762, 1763, "%" +421, 16, 71, 407, 208, 209, 1764, 1765, ")" +421, 16, 72, 408, 210, 214, 1766, 1770, "eyes" +421, 16, 73, 409, 215, 218, 1771, 1774, "and" +421, 16, 74, 410, 219, 220, 1775, 1776, "≤" +421, 16, 75, 411, 221, 223, 1777, 1779, "16" +421, 16, 76, 412, 224, 226, 1780, 1782, "mm" +421, 16, 77, 413, 227, 229, 1783, 1785, "Hg" +421, 16, 78, 414, 230, 232, 1786, 1788, "in" +421, 16, 79, 415, 233, 235, 1789, 1791, "30" +421, 16, 80, 416, 236, 237, 1792, 1793, "(" +421, 16, 81, 417, 238, 240, 1794, 1796, "75" +421, 16, 82, 418, 241, 242, 1797, 1798, "%" +421, 16, 83, 419, 243, 244, 1799, 1800, ")" +421, 16, 84, 420, 245, 251, 1801, 1807, "versus" +421, 16, 85, 421, 252, 254, 1808, 1810, "18" +421, 16, 86, 422, 255, 256, 1811, 1812, "(" +421, 16, 87, 423, 257, 259, 1813, 1815, "45" +421, 16, 88, 424, 260, 261, 1816, 1817, "%" +421, 16, 89, 425, 262, 263, 1818, 1819, ")" +421, 16, 90, 426, 264, 268, 1820, 1824, "eyes" +421, 16, 91, 427, 269, 272, 1825, 1828, "for" +421, 16, 92, 428, 273, 277, 1829, 1833, "BTFC" +421, 16, 93, 429, 278, 281, 1834, 1837, "and" +421, 16, 94, 430, 282, 286, 1838, 1842, "TTFC" +421, 16, 95, 431, 287, 288, 1843, 1844, "," +421, 16, 96, 432, 289, 301, 1845, 1857, "respectively" +421, 16, 97, 433, 302, 303, 1858, 1859, "(" +421, 16, 98, 434, 304, 305, 1860, 1861, "P" +421, 16, 99, 435, 306, 307, 1862, 1863, "<" +421, 16, 100, 436, 308, 309, 1864, 1865, "0" +421, 16, 101, 437, 310, 311, 1866, 1867, "." +421, 16, 102, 438, 312, 315, 1868, 1871, "001" +421, 16, 103, 439, 316, 317, 1872, 1873, ")" +421, 16, 104, 440, 318, 319, 1874, 1875, "." +421, 17, 1, 441, 0, 10, 1876, 1886, "CONCLUSION" +421, 17, 2, 442, 11, 12, 1887, 1888, ":" +421, 17, 3, 443, 13, 17, 1889, 1893, "Both" +421, 17, 4, 444, 18, 23, 1894, 1899, "drops" +421, 17, 5, 445, 24, 32, 1900, 1908, "provided" +421, 17, 6, 446, 33, 42, 1909, 1918, "effective" +421, 17, 7, 447, 43, 46, 1919, 1922, "IOP" +421, 17, 8, 448, 47, 56, 1923, 1932, "reduction" +421, 17, 9, 449, 57, 61, 1933, 1937, "that" +421, 17, 10, 450, 62, 65, 1938, 1941, "was" +421, 17, 11, 451, 66, 73, 1942, 1949, "greater" +421, 17, 12, 452, 74, 77, 1950, 1953, "and" +421, 17, 13, 453, 78, 86, 1954, 1962, "patients" +421, 17, 14, 454, 87, 91, 1963, 1967, "were" +421, 17, 15, 455, 92, 96, 1968, 1972, "more" +421, 17, 16, 456, 97, 103, 1973, 1979, "likely" +421, 17, 17, 457, 104, 106, 1980, 1982, "to" +421, 17, 18, 458, 107, 114, 1983, 1990, "achieve" +421, 17, 19, 459, 115, 120, 1991, 1996, "lower" +421, 17, 20, 460, 121, 127, 1997, 2003, "target" +421, 17, 21, 461, 128, 137, 2004, 2013, "pressures" +421, 17, 22, 462, 138, 142, 2014, 2018, "with" +421, 17, 23, 463, 143, 147, 2019, 2023, "BTFC" +421, 17, 24, 464, 148, 152, 2024, 2028, "than" +421, 17, 25, 465, 153, 157, 2029, 2033, "with" +421, 17, 26, 466, 158, 162, 2034, 2038, "TTFC" +421, 17, 27, 467, 163, 164, 2039, 2040, "." +421, 18, 1, 468, 0, 3, 2041, 2044, "DOI" +421, 18, 2, 469, 4, 5, 2045, 2046, ":" +421, 18, 3, 470, 6, 8, 2047, 2049, "10" +421, 18, 4, 471, 9, 10, 2050, 2051, "." +421, 18, 5, 472, 11, 15, 2052, 2056, "1097" +421, 18, 6, 473, 16, 17, 2057, 2058, "/" +421, 18, 7, 474, 18, 21, 2059, 2062, "IJG" +421, 18, 8, 475, 22, 23, 2063, 2064, "." +421, 18, 9, 476, 24, 40, 2065, 2081, "0b013e3182867be3" +421, 18, 10, 477, 41, 45, 2082, 2086, "PMID" +421, 18, 11, 478, 46, 47, 2087, 2088, ":" +421, 18, 12, 479, 48, 56, 2089, 2097, "23429621" +421, 18, 13, 480, 57, 58, 2098, 2099, "[" +421, 18, 14, 481, 59, 66, 2100, 2107, "Indexed" +421, 18, 15, 482, 67, 70, 2108, 2111, "for" +421, 18, 16, 483, 71, 78, 2112, 2119, "MEDLINE" +421, 18, 17, 484, 79, 80, 2120, 2121, "]" diff --git a/data/gl 23429621_jshahinitiran.annodb b/data/gl 23429621_jshahinitiran.annodb new file mode 100644 index 0000000..201b0db --- /dev/null +++ b/data/gl 23429621_jshahinitiran.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16678, Journal, 0, 10, "J Glaucoma", "", +16679, PublicationYear, 13, 17, "2014", "", +16680, Title, 94, 240, "Bimatoprost / timolol versus travoprost / timolol fixed combinations in an Egyptian population : a hospital - based prospective randomized study .", "", +16681, Bimatoprost, 94, 105, "Bimatoprost", "", +16693, Drug, 94, 115, "Bimatoprost / timolol", "BTFC", +16682, Timolol, 108, 115, "timolol", "", +16683, Drug, 123, 133, "travoprost", "Trav", +16706, Drug, 123, 143, "travoprost / timolol", "TTFC", +16684, Timolol, 136, 143, "timolol", "", +16685, Ethnicity, 169, 177, "Egyptian", "", +16686, CTDesign, 210, 221, "prospective", "", +16687, Randomized, 222, 232, "randomized", "", +16688, Author, 241, 249, "Macky TA", "", +16689, Egypt, 433, 438, "Egypt", "", +16690, ObjectiveDescription, 451, 630, "To compare the efficacy of bimatoprost / timolol ( BTFC ) or travoprost / timolol ( TTFC ) fixed combinations on intraocular pressure ( IOP ) reduction in an Egyptian population .", "", +16681, Bimatoprost, 478, 489, "bimatoprost", "", +16693, Drug, 478, 499, "bimatoprost / timolol", "BTFC", +16682, Timolol, 492, 499, "timolol", "", +16693, Drug, 502, 506, "BTFC", "BTFC", +16683, Drug, 512, 522, "travoprost", "Trav", +16705, Drug, 512, 532, "travoprost / timolol", "TTFC", +16684, Timolol, 525, 532, "timolol", "", +16701, Drug, 535, 539, "TTFC", "TTFC", +16707, IOP, 564, 584, "intraocular pressure", "TTFC", +16708, IOP, 587, 590, "IOP", "TTFC", +16685, Ethnicity, 609, 617, "Egyptian", "", +16710, OpenAngleGlaucoma, 655, 682, "primary open angle glaucoma", "", +16687, Randomized, 688, 698, "randomized", "", +16693, Drug, 717, 721, "BTFC", "BTFC", +16701, Drug, 725, 729, "TTFC", "TTFC", +16714, IOP, 732, 736, "IOPs", "", +16748, TimePoint, 765, 772, "2 weeks", "", +16749, TimePoint, 795, 803, "6 months", "", +16715, Mean, 842, 846, "mean", "", +16716, Mean, 857, 860, "IOP", "", +16717, NumberPatientsCT, 971, 977, "Eighty", "", +16718, NumberPatientsArm, 1023, 1025, "40", "", +16719, Mean, 1056, 1060, "mean", "", +16720, IOP, 1061, 1065, "IOPs", "", +16721, BaseLineValue, 1071, 1078, "24 . 78", "", +16723, SdErrorBL, 1081, 1087, "3 . 53", "", +16722, BaseLineValue, 1092, 1099, "25 . 26", "", +16724, SdErrorBL, 1102, 1108, "3 . 51", "", +16725, mmHg, 1109, 1114, "mm Hg", "", +16693, Drug, 1119, 1123, "BTFC", "BTFC", +16701, Drug, 1128, 1132, "TTFC", "TTFC", +16728, PValueBL, 1150, 1161, "P = 0 . 344", "", +16731, Eyedrops, 1171, 1176, "drops", "", +16729, IOP, 1212, 1215, "IOP", "", +16730, PValueChangeValue, 1257, 1268, "P < 0 . 001", "", +16693, Drug, 1273, 1277, "BTFC", "BTFC", +16719, Mean, 1307, 1311, "mean", "", +16734, IOP, 1312, 1315, "IOP", "", +16701, Drug, 1346, 1350, "TTFC", "TTFC", +16736, PvalueDiff, 1367, 1378, "P < 0 . 001", "", +16737, Mean, 1383, 1387, "Mean", "", +16738, IOP, 1388, 1391, "IOP", "", +16739, Reduction, 1408, 1415, "11 . 34", "", +16740, Reduction, 1420, 1426, "6 . 42", "", +16741, mmHg, 1427, 1432, "mm Hg", "", +16742, TimePoint, 1436, 1443, "2 weeks", "", +16743, PValueChangeValue, 1446, 1457, "P = 0 . 000", "", +16744, Reduction, 1466, 1473, "11 . 17", "", +16745, Reduction, 1478, 1484, "7 . 89", "", +16746, mmHg, 1485, 1492, "mm   Hg", "", +16747, TimePoint, 1496, 1504, "6 months", "", +16750, PValueChangeValue, 1507, 1518, "P = 0 . 001", "", +16693, Drug, 1525, 1529, "BTFC", "BTFC", +16701, Drug, 1534, 1538, "TTFC", "TTFC", +16753, IOP, 1556, 1560, "IOPs", "", +16754, TimePoint, 1564, 1571, "2 weeks", "", +16755, EndPointDescription, 1577, 1587, "≤ 18 mm Hg", "", +16767, mmHg, 1582, 1587, "mm Hg", "", +16759, NumberAffected, 1591, 1593, "36", "", +16773, PercentageAffected, 1596, 1602, "90 . 8", "", +16760, NumberAffected, 1614, 1616, "22", "", +16774, PercentageAffected, 1619, 1621, "55", "", +16769, EndPointDescription, 1635, 1645, "≤ 16 mm Hg", "", +16768, mmHg, 1640, 1645, "mm Hg", "", +16761, NumberAffected, 1649, 1651, "28", "", +16775, PercentageAffected, 1654, 1656, "70", "", +16762, NumberAffected, 1668, 1670, "16", "", +16776, PercentageAffected, 1673, 1675, "40", "", +16781, PvalueDiff, 1687, 1698, "P < 0 . 001", "", +16790, TimePoint, 1710, 1718, "6 months", "", +16755, EndPointDescription, 1721, 1731, "≤ 18 mm Hg", "", +16771, mmHg, 1726, 1731, "mm Hg", "", +16763, NumberAffected, 1735, 1737, "38", "", +16777, PercentageAffected, 1740, 1742, "95", "", +16764, NumberAffected, 1754, 1756, "28", "", +16778, PercentageAffected, 1759, 1761, "70", "", +16769, EndPointDescription, 1775, 1785, "≤ 16 mm Hg", "", +16772, mmHg, 1780, 1785, "mm Hg", "", +16765, NumberAffected, 1789, 1791, "30", "", +16779, PercentageAffected, 1794, 1796, "75", "", +16766, NumberAffected, 1808, 1810, "18", "", +16780, PercentageAffected, 1813, 1815, "45", "", +16693, Drug, 1829, 1833, "BTFC", "BTFC", +16701, Drug, 1838, 1842, "TTFC", "TTFC", +16782, PvalueDiff, 1860, 1871, "P < 0 . 001", "", +16785, ConclusionComment, 1889, 2040, "Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC .", "", +16791, Eyedrops, 1894, 1899, "drops", "", +16786, IOP, 1919, 1922, "IOP", "", +16693, Drug, 2019, 2023, "BTFC", "BTFC", +16701, Drug, 2034, 2038, "TTFC", "TTFC", +16789, PMID, 2089, 2097, "23429621", "", diff --git a/data/gl 23429621_jshahinitiran.n-triples b/data/gl 23429621_jshahinitiran.n-triples new file mode 100644 index 0000000..2356c14 --- /dev/null +++ b/data/gl 23429621_jshahinitiran.n-triples @@ -0,0 +1,15 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication + . + "Medication 19174" . + . + . + . +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23429621_tstrakeljahn.annodb b/data/gl 23429621_tstrakeljahn.annodb new file mode 100644 index 0000000..691279f --- /dev/null +++ b/data/gl 23429621_tstrakeljahn.annodb @@ -0,0 +1,99 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +12260, Journal, 0, 10, "J Glaucoma", "", +12263, PublicationYear, 13, 17, "2014", "", +12367, Title, 94, 238, "Bimatoprost / timolol versus travoprost / timolol fixed combinations in an Egyptian population : a hospital - based prospective randomized study", "", +12265, Bimatoprost, 94, 105, "Bimatoprost", "", +12267, Timolol, 108, 115, "timolol", "", +12270, Medication, 123, 133, "travoprost", "travoprost", +12272, Timolol, 136, 143, "timolol", "", +12276, Randomized, 222, 232, "randomized", "", +12277, Author, 241, 249, "Macky TA", "", +12273, Egypt, 433, 438, "Egypt", "", +12278, Bimatoprost, 478, 489, "bimatoprost", "", +12279, Timolol, 492, 499, "timolol", "", +12280, Medication, 502, 506, "BTFC", "bimatoprost / timolol fixed combination", +12281, Medication, 512, 522, "travoprost", "travoprost", +12282, Timolol, 525, 532, "timolol", "", +12284, Medication, 535, 539, "TTFC", "travoprost / timolol fixed combination", +12285, IOP, 564, 584, "intraocular pressure", "", +12286, IOP, 587, 590, "IOP", "", +12287, OpenAngleGlaucoma, 663, 682, "open angle glaucoma", "", +12288, Randomized, 688, 698, "randomized", "", +12289, Medication, 717, 721, "BTFC", "bimatoprost / timolol fixed combination", +12290, Medication, 725, 729, "TTFC", "travoprost / timolol fixed combination", +12291, IOP, 732, 736, "IOPs", "", +12292, Mean, 842, 846, "mean", "", +12293, IOP, 857, 860, "IOP", "", +12294, NumberPatientsCT, 971, 986, "Eighty patients", "", +12295, NumberPatientsArm, 1023, 1025, "40", "", +12296, Mean, 1056, 1060, "mean", "", +12297, IOP, 1056, 1065, "mean IOPs", "", +12298, BaseLineValue, 1071, 1078, "24 . 78", "", +12300, SdDevBL, 1081, 1087, "3 . 53", "", +12299, BaseLineValue, 1092, 1099, "25 . 26", "", +12301, SdDevBL, 1102, 1108, "3 . 51", "", +12302, mmHg, 1109, 1114, "mm Hg", "", +12303, Medication, 1119, 1123, "BTFC", "bimatoprost / timolol fixed combination", +12304, Medication, 1128, 1132, "TTFC", "travoprost / timolol fixed combination", +12305, PvalueDiff, 1150, 1161, "P = 0 . 344", "", +12329, ObservedResult, 1166, 1270, "Both drops provided statistically significant IOP reductions from baseline at all visits ( P < 0 . 001 )", "", +12308, Eyedrops, 1171, 1176, "drops", "", +12306, IOP, 1212, 1215, "IOP", "", +12307, PvalueDiff, 1257, 1268, "P < 0 . 001", "", +12309, Medication, 1273, 1277, "BTFC", "bimatoprost / timolol fixed combination", +12328, ObservedResult, 1273, 1380, "BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit ( P < 0 . 001 )", "", +12310, Mean, 1307, 1311, "mean", "", +12311, IOP, 1312, 1315, "IOP", "", +12312, Medication, 1346, 1350, "TTFC", "travoprost / timolol fixed combination", +12313, PvalueDiff, 1367, 1378, "P < 0 . 001", "", +12314, Mean, 1383, 1387, "Mean", "", +12315, IOP, 1388, 1391, "IOP", "", +12317, Reduction, 1408, 1415, "11 . 34", "", +12316, Reduction, 1420, 1426, "6 . 42", "", +12320, mmHg, 1427, 1432, "mm Hg", "", +12322, TimePoint, 1436, 1443, "2 weeks", "", +12323, PValueChangeValue, 1446, 1457, "P = 0 . 000", "", +12318, Reduction, 1466, 1473, "11 . 17", "", +12319, Reduction, 1478, 1484, "7 . 89", "", +12321, mmHg, 1485, 1492, "mm   Hg", "", +12325, TimePoint, 1496, 1504, "6 months", "", +12324, PValueChangeValue, 1507, 1518, "P = 0 . 001", "", +12326, Medication, 1525, 1529, "BTFC", "bimatoprost / timolol fixed combination", +12327, Medication, 1534, 1538, "TTFC", "travoprost / timolol fixed combination", +12330, IOP, 1556, 1560, "IOPs", "", +12331, TimePoint, 1564, 1571, "2 weeks", "", +12333, Endpoint, 1577, 1581, "≤ 18", "", +12335, mmHg, 1582, 1587, "mm Hg", "", +12339, NumberAffected, 1591, 1593, "36", "", +12347, PercentageAffected, 1596, 1602, "90 . 8", "", +12340, NumberAffected, 1614, 1616, "22", "", +12348, PercentageAffected, 1619, 1621, "55", "", +12355, Endpoint, 1635, 1639, "≤ 16", "", +12336, mmHg, 1640, 1645, "mm Hg", "", +12341, NumberAffected, 1649, 1651, "28", "", +12349, PercentageAffected, 1654, 1656, "70", "", +12342, NumberAffected, 1668, 1670, "16", "", +12350, PercentageAffected, 1673, 1675, "40", "", +12357, PvalueDiff, 1687, 1698, "P < 0 . 001", "", +12332, TimePoint, 1710, 1718, "6 months", "", +12334, Endpoint, 1721, 1725, "≤ 18", "", +12337, mmHg, 1726, 1731, "mm Hg", "", +12343, NumberAffected, 1735, 1737, "38", "", +12351, PercentageAffected, 1740, 1742, "95", "", +12344, NumberAffected, 1754, 1756, "28", "", +12352, PercentageAffected, 1759, 1761, "70", "", +12356, Endpoint, 1775, 1779, "≤ 16", "", +12338, mmHg, 1780, 1785, "mm Hg", "", +12345, NumberAffected, 1789, 1791, "30", "", +12353, PercentageAffected, 1794, 1796, "75", "", +12346, NumberAffected, 1808, 1810, "18", "", +12354, PercentageAffected, 1813, 1815, "45", "", +12359, Medication, 1829, 1833, "BTFC", "bimatoprost / timolol fixed combination", +12360, Medication, 1838, 1842, "TTFC", "travoprost / timolol fixed combination", +12358, PvalueDiff, 1860, 1871, "P < 0 . 001", "", +12366, ConclusionComment, 1889, 2038, "Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC", "", +12361, Eyedrops, 1894, 1899, "drops", "", +12362, IOP, 1919, 1922, "IOP", "", +12363, Medication, 2019, 2023, "BTFC", "bimatoprost / timolol fixed combination", +12364, Medication, 2034, 2038, "TTFC", "travoprost / timolol fixed combination", +12365, PMID, 2089, 2097, "23429621", "", diff --git a/data/gl 23429621_tstrakeljahn.n-triples b/data/gl 23429621_tstrakeljahn.n-triples new file mode 100644 index 0000000..27cc25c --- /dev/null +++ b/data/gl 23429621_tstrakeljahn.n-triples @@ -0,0 +1,28 @@ +# RDF export of group: Publication + . + "Publication 19137" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial 19144" . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population 19160" . + . + . + . +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23550916_admin.annodb b/data/gl 23550916_admin.annodb new file mode 100644 index 0000000..aece0fc --- /dev/null +++ b/data/gl 23550916_admin.annodb @@ -0,0 +1,103 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2013", "", " \"2013\"." +2, Title, 112, 283, "Comparison of 24 - hour intraocular pressure reduction obtained with brinzolamide / timolol or brimonidine / timolol fixed - combination adjunctive to travoprost therapy .", "", " \"Comparison of 24 - hour intraocular pressure reduction obtained with brinzolamide / timolol or brimonidine / timolol fixed - combination adjunctive to travoprost therapy .\"." +3, IOP, 136, 156, "intraocular pressure", "", " . ." +4, Brinzolamide, 181, 193, "brinzolamide", "", +75, Brinz/TimFC, 181, 203, "brinzolamide / timolol", "", " ." +5, Timolol, 196, 203, "timolol", "", +6, Brimonidine, 207, 218, "brimonidine", "", +76, Brimo/TimFC, 207, 228, "brimonidine / timolol", "", " ." +7, Timolol, 221, 228, "timolol", "", +74, Travoprost, 263, 273, "travoprost", "", +9, Author, 284, 294, "Konstas AG", "", " \"Konstas AG\"." +10, Author, 303, 311, "Holl ó G", "", " \"Holl ó G\"." +11, Author, 314, 324, "Haidich AB", "", " \"Haidich AB\"." +12, Author, 327, 341, "Mikropoulos DG", "", " \"Mikropoulos DG\"." +13, Author, 344, 358, "Giannopoulos T", "", " \"Giannopoulos T\"." +14, Author, 361, 377, "Voudouragkaki IC", "", " \"Voudouragkaki IC\"." +15, Author, 380, 393, "Paschalinou E", "", " \"Paschalinou E\"." +16, Author, 396, 407, "Konidaris V", "", " \"Konidaris V\"." +17, Author, 410, 420, "Samples JR", "", " \"Samples JR\"." +18, Greece, 543, 549, "Greece", "", " ." +19, ObjectiveDescription, 591, 813, "To determine the adjunctive 24 - h efficacy obtained with brinzolamide / timolol , or brimonidine / timolol fixed combinations ( FCs ) in open - angle glaucoma patients insufficiently controlled on travoprost monotherapy .", "", " \"To determine the adjunctive 24 - h efficacy obtained with brinzolamide / timolol , or brimonidine / timolol fixed combinations ( FCs ) in open - angle glaucoma patients insufficiently controlled on travoprost monotherapy .\"." +92230, Brinz/TimFC, 649, 671, "brinzolamide / timolol", "", +4, Brinzolamide, 649, 661, "brinzolamide", "", +5, Timolol, 664, 671, "timolol", "", +92235, Brimo/TimFC, 677, 698, "brimonidine / timolol", "", +6, Brimonidine, 677, 688, "brimonidine", "", +7, Timolol, 691, 698, "timolol", "", +94, Precondition, 729, 811, "open - angle glaucoma patients insufficiently controlled on travoprost monotherapy", "", " \"open - angle glaucoma patients insufficiently controlled on travoprost monotherapy\"." +20, OpenAngleGlaucoma, 729, 750, "open - angle glaucoma", "", " ." +93, Travoprost, 789, 799, "travoprost", "", +96, Prospective, 824, 835, "Prospective", "", " ." +23, Blind, 838, 855, "observer - masked", "", " ." +24, CTDesign, 858, 875, "active controlled", "", " . ." +32, Crossover, 878, 887, "crossover", "", " ." +99, Primary_OpenAngleGlaucoma, 913, 933, "primary open - angle", "", " ." +26, IOP, 983, 1003, "intraocular pressure", "", +27, IOP, 1006, 1009, "IOP", "", +28, mmHg, 1019, 1024, "mm Hg", "", +104, TimePoint, 1028, 1035, "10 : 00", "", +105, Travoprost, 1039, 1049, "travoprost", "", +30, Randomized, 1067, 1077, "randomized", "", " ." +31, Duration, 1082, 1090, "3 months", "", " \"3 months\"." +112, Brinz/TimFC, 1101, 1123, "brinzolamide / timolol", "", +4, Brinzolamide, 1101, 1113, "brinzolamide", "", +5, Timolol, 1116, 1123, "timolol", "", +113, Brimo/TimFC, 1129, 1150, "brimonidine / timolol", "", +6, Brimonidine, 1129, 1140, "brimonidine", "", +7, Timolol, 1143, 1150, "timolol", "", +114, Travoprost, 1173, 1183, "travoprost", "", +32, Crossover, 1205, 1219, "crossed - over", "", " ." +33, Duration, 1256, 1264, "3 months", "", +92236, TimePoint, 1270, 1278, "baseline", "", +34, IOP, 1351, 1354, "IOP", "", +35, FinalNumPatientsCT, 1378, 1383, "Fifty", "", " \"Fifty\"." +36, Mean, 1419, 1423, "mean", "", " . ." +37, IOP, 1440, 1443, "IOP", "", +118, Travoprost, 1447, 1457, "travoprost", "", +38, BaseLineValue, 1474, 1480, "20 . 1", "", " \"20 . 1\". \"20 . 1\"." +39, mmHg, 1483, 1488, "mm Hg", "", " ." +40, ConfIntervalBL, 1491, 1548, "95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg", "", " \"95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg\". \"95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg\"." +41, mmHg, 1543, 1548, "mm Hg", "", +42, IOP, 1608, 1611, "IOP", "", +43, Mean, 1643, 1647, "mean", "", +44, IOP, 1655, 1658, "IOP", "", +45, PValueChangeValue, 1661, 1672, "P < 0 . 001", "", +126, Travoprost, 1689, 1699, "travoprost", "", +129, Brinz/TimFC, 1714, 1739, "Brinzolamide / timolol FC", "", +4, Brinzolamide, 1714, 1726, "Brinzolamide", "", +5, Timolol, 1729, 1736, "timolol", "", +46, Mean, 1771, 1775, "mean", "", +47, IOP, 1783, 1786, "IOP", "", +48, ResultMeasuredValue, 1789, 1795, "17 . 2", "", " \"17 . 2\"." +50, mmHg, 1798, 1803, "mm Hg", "", +55, ConfIntervalResValue, 1806, 1839, "95 % CI : 16 . 4 , 17 . 9   mm Hg", "", " \"95 % CI : 16 . 4 , 17 . 9   mm Hg\"." +51, mmHg, 1834, 1839, "mm Hg", "", +142, Brimo/TimFC, 1847, 1871, "brimonidine / timolol FC", "", +6, Brimonidine, 1847, 1858, "brimonidine", "", +7, Timolol, 1861, 1868, "timolol", "", +49, ResultMeasuredValue, 1874, 1880, "18 . 0", "", " \"18 . 0\"." +52, mmHg, 1883, 1888, "mm Hg", "", +56, ConfIntervalResValue, 1891, 1924, "95 % CI : 17 . 3 , 18 . 8   mm Hg", "", " \"95 % CI : 17 . 3 , 18 . 8   mm Hg\"." +53, mmHg, 1919, 1924, "mm Hg", "", +54, PvalueDiff, 1929, 1940, "P < 0 . 001", "", " \"P < 0 . 001\"." +146, Brinz/TimFC, 2004, 2029, "brinzolamide / timolol FC", "", +4, Brinzolamide, 2004, 2016, "brinzolamide", "", +5, Timolol, 2019, 2026, "timolol", "", +57, IOP, 2061, 2064, "IOP", "", +150, Brimo/TimFC, 2074, 2098, "brimonidine / timolol FC", "", +6, Brimonidine, 2074, 2085, "brimonidine", "", +7, Timolol, 2088, 2095, "timolol", "", +58, PvalueDiff, 2101, 2112, "P ≤ 0 . 036", "", +61, ConclusionComment, 2203, 2349, "This study demonstrated that both FCs provide statistically and clinically significant incremental 24 - h IOP lowering to travoprost monotherapy .", "", " \"This study demonstrated that both FCs provide statistically and clinically significant incremental 24 - h IOP lowering to travoprost monotherapy .\"." +63, IOP, 2309, 2312, "IOP", "", +153, Travoprost, 2325, 2335, "travoprost", "", +62, ConclusionComment, 2350, 2500, "The brinzolamide / timolol FC however achieves a better mean 24 - h IOP control owing to the greater efficacy in late afternoon and during the night .", "", " \"The brinzolamide / timolol FC however achieves a better mean 24 - h IOP control owing to the greater efficacy in late afternoon and during the night .\"." +156, Brinz/TimFC, 2354, 2379, "brinzolamide / timolol FC", "", +4, Brinzolamide, 2354, 2366, "brinzolamide", "", +5, Timolol, 2369, 2376, "timolol", "", +64, Mean, 2406, 2410, "mean", "", +65, IOP, 2418, 2421, "IOP", "", +66, PMID, 2544, 2552, "23550916", "", " \"23550916\"." diff --git a/data/gl 23550916_admin.n-triples b/data/gl 23550916_admin.n-triples new file mode 100644 index 0000000..34a0a17 --- /dev/null +++ b/data/gl 23550916_admin.n-triples @@ -0,0 +1,109 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of 24 - hour intraocular pressure reduction obtained with brinzolamide / timolol or brimonidine / timolol fixed - combination adjunctive to travoprost therapy ." . + "Konstas AG" . + "2013" . + "J Ocul Pharmacol Ther ." . + "23550916" . + . + "Holl ó G" . + "Haidich AB" . + "Mikropoulos DG" . + "Giannopoulos T" . + "Voudouragkaki IC" . + "Paschalinou E" . + "Konidaris V" . + "Samples JR" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To determine the adjunctive 24 - h efficacy obtained with brinzolamide / timolol , or brimonidine / timolol fixed combinations ( FCs ) in open - angle glaucoma patients insufficiently controlled on travoprost monotherapy ." . + "3 months" . + . + . + . + "This study demonstrated that both FCs provide statistically and clinically significant incremental 24 - h IOP lowering to travoprost monotherapy ." . + . + . + . + . + . + "Fifty" . + . + . + . + . + . + "The brinzolamide / timolol FC however achieves a better mean 24 - h IOP control owing to the greater efficacy in late afternoon and during the night ." . + . + . +# RDF export of group: Population + . + "Population" . + "open - angle glaucoma patients insufficiently controlled on travoprost monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BrinzTim" . + . + . + . + . + "Arm_BrimTim" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BrinzTim" . + . + . + . + "Intervention_BrimTim" . + . + . +# RDF export of group: Medication + . + "Medication_BrinzTim" . + . + . + . + . + "Medication_BrimTim" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BrinzTim" . + . + "20 . 1" . + "95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg" . + "17 . 2" . + "95 % CI : 16 . 4 , 17 . 9   mm Hg" . + . + "Outcome_BrimTim" . + . + "20 . 1" . + "95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg" . + "18 . 0" . + "95 % CI : 17 . 3 , 18 . 8   mm Hg" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23550916_export.csv b/data/gl 23550916_export.csv new file mode 100644 index 0000000..a19f787 --- /dev/null +++ b/data/gl 23550916_export.csv @@ -0,0 +1,527 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +420, 1, 1, 1, 0, 1, 0, 1, "J" +420, 1, 2, 2, 2, 6, 2, 6, "Ocul" +420, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +420, 1, 4, 4, 17, 21, 17, 21, "Ther" +420, 1, 5, 5, 22, 23, 22, 23, "." +420, 2, 1, 6, 0, 4, 24, 28, "2013" +420, 2, 2, 7, 5, 8, 29, 32, "Sep" +420, 2, 3, 8, 9, 10, 33, 34, ";" +420, 2, 4, 9, 11, 13, 35, 37, "29" +420, 2, 5, 10, 14, 15, 38, 39, "(" +420, 2, 6, 11, 16, 17, 40, 41, "7" +420, 2, 7, 12, 18, 19, 42, 43, ")" +420, 2, 8, 13, 20, 21, 44, 45, ":" +420, 2, 9, 14, 22, 25, 46, 49, "652" +420, 2, 10, 15, 26, 27, 50, 51, "-" +420, 2, 11, 16, 28, 29, 52, 53, "7" +420, 2, 12, 17, 30, 31, 54, 55, "." +420, 2, 13, 18, 32, 35, 56, 59, "doi" +420, 2, 14, 19, 36, 37, 60, 61, ":" +420, 2, 15, 20, 38, 40, 62, 64, "10" +420, 2, 16, 21, 41, 42, 65, 66, "." +420, 2, 17, 22, 43, 47, 67, 71, "1089" +420, 2, 18, 23, 48, 49, 72, 73, "/" +420, 2, 19, 24, 50, 53, 74, 77, "jop" +420, 2, 20, 25, 54, 55, 78, 79, "." +420, 2, 21, 26, 56, 60, 80, 84, "2012" +420, 2, 22, 27, 61, 62, 85, 86, "." +420, 2, 23, 28, 63, 67, 87, 91, "0195" +420, 2, 24, 29, 68, 69, 92, 93, "." +420, 3, 1, 30, 0, 4, 94, 98, "Epub" +420, 3, 2, 31, 5, 9, 99, 103, "2013" +420, 3, 3, 32, 10, 13, 104, 107, "Apr" +420, 3, 4, 33, 14, 15, 108, 109, "3" +420, 3, 5, 34, 16, 17, 110, 111, "." +420, 4, 1, 35, 0, 10, 112, 122, "Comparison" +420, 4, 2, 36, 11, 13, 123, 125, "of" +420, 4, 3, 37, 14, 16, 126, 128, "24" +420, 4, 4, 38, 17, 18, 129, 130, "-" +420, 4, 5, 39, 19, 23, 131, 135, "hour" +420, 4, 6, 40, 24, 35, 136, 147, "intraocular" +420, 4, 7, 41, 36, 44, 148, 156, "pressure" +420, 4, 8, 42, 45, 54, 157, 166, "reduction" +420, 4, 9, 43, 55, 63, 167, 175, "obtained" +420, 4, 10, 44, 64, 68, 176, 180, "with" +420, 4, 11, 45, 69, 81, 181, 193, "brinzolamide" +420, 4, 12, 46, 82, 83, 194, 195, "/" +420, 4, 13, 47, 84, 91, 196, 203, "timolol" +420, 4, 14, 48, 92, 94, 204, 206, "or" +420, 4, 15, 49, 95, 106, 207, 218, "brimonidine" +420, 4, 16, 50, 107, 108, 219, 220, "/" +420, 4, 17, 51, 109, 116, 221, 228, "timolol" +420, 4, 18, 52, 117, 122, 229, 234, "fixed" +420, 4, 19, 53, 123, 124, 235, 236, "-" +420, 4, 20, 54, 125, 136, 237, 248, "combination" +420, 4, 21, 55, 137, 147, 249, 259, "adjunctive" +420, 4, 22, 56, 148, 150, 260, 262, "to" +420, 4, 23, 57, 151, 161, 263, 273, "travoprost" +420, 4, 24, 58, 162, 169, 274, 281, "therapy" +420, 4, 25, 59, 170, 171, 282, 283, "." +420, 5, 1, 60, 0, 7, 284, 291, "Konstas" +420, 5, 2, 61, 8, 10, 292, 294, "AG" +420, 5, 3, 62, 11, 12, 295, 296, "(" +420, 5, 4, 63, 13, 14, 297, 298, "1" +420, 5, 5, 64, 15, 16, 299, 300, ")" +420, 5, 6, 65, 17, 18, 301, 302, "," +420, 5, 7, 66, 19, 23, 303, 307, "Holl" +420, 5, 8, 67, 24, 25, 308, 309, "ó" +420, 5, 9, 68, 26, 27, 310, 311, "G" +420, 5, 10, 69, 28, 29, 312, 313, "," +420, 5, 11, 70, 30, 37, 314, 321, "Haidich" +420, 5, 12, 71, 38, 40, 322, 324, "AB" +420, 5, 13, 72, 41, 42, 325, 326, "," +420, 5, 14, 73, 43, 54, 327, 338, "Mikropoulos" +420, 5, 15, 74, 55, 57, 339, 341, "DG" +420, 5, 16, 75, 58, 59, 342, 343, "," +420, 5, 17, 76, 60, 72, 344, 356, "Giannopoulos" +420, 5, 18, 77, 73, 74, 357, 358, "T" +420, 5, 19, 78, 75, 76, 359, 360, "," +420, 5, 20, 79, 77, 90, 361, 374, "Voudouragkaki" +420, 5, 21, 80, 91, 93, 375, 377, "IC" +420, 5, 22, 81, 94, 95, 378, 379, "," +420, 5, 23, 82, 96, 107, 380, 391, "Paschalinou" +420, 5, 24, 83, 108, 109, 392, 393, "E" +420, 5, 25, 84, 110, 111, 394, 395, "," +420, 5, 26, 85, 112, 121, 396, 405, "Konidaris" +420, 5, 27, 86, 122, 123, 406, 407, "V" +420, 5, 28, 87, 124, 125, 408, 409, "," +420, 5, 29, 88, 126, 133, 410, 417, "Samples" +420, 5, 30, 89, 134, 136, 418, 420, "JR" +420, 5, 31, 90, 137, 138, 421, 422, "." +420, 6, 1, 91, 0, 6, 423, 429, "Author" +420, 6, 2, 92, 7, 18, 430, 441, "information" +420, 6, 3, 93, 19, 20, 442, 443, ":" +420, 6, 4, 94, 21, 22, 444, 445, "(" +420, 6, 5, 95, 23, 24, 446, 447, "1" +420, 6, 6, 96, 25, 26, 448, 449, ")" +420, 6, 7, 97, 27, 35, 450, 458, "Glaucoma" +420, 6, 8, 98, 36, 40, 459, 463, "Unit" +420, 6, 9, 99, 41, 42, 464, 465, "," +420, 6, 10, 100, 43, 46, 466, 469, "1st" +420, 6, 11, 101, 47, 57, 470, 480, "University" +420, 6, 12, 102, 58, 68, 481, 491, "Department" +420, 6, 13, 103, 69, 71, 492, 494, "of" +420, 6, 14, 104, 72, 85, 495, 508, "Ophthalmology" +420, 6, 15, 105, 86, 87, 509, 510, "," +420, 6, 16, 106, 88, 93, 511, 516, "AHEPA" +420, 6, 17, 107, 94, 102, 517, 525, "Hospital" +420, 6, 18, 108, 103, 104, 526, 527, "," +420, 6, 19, 109, 105, 117, 528, 540, "Thessaloniki" +420, 6, 20, 110, 118, 119, 541, 542, "," +420, 6, 21, 111, 120, 126, 543, 549, "Greece" +420, 6, 22, 112, 127, 128, 550, 551, "." +420, 7, 1, 113, 0, 7, 552, 559, "konstas" +420, 7, 2, 114, 8, 9, 560, 561, "@" +420, 7, 3, 115, 10, 13, 562, 565, "med" +420, 7, 4, 116, 14, 15, 566, 567, "." +420, 7, 5, 117, 16, 20, 568, 572, "auth" +420, 7, 6, 118, 21, 22, 573, 574, "." +420, 7, 7, 119, 23, 25, 575, 577, "gr" +420, 7, 8, 120, 26, 36, 578, 588, "BACKGROUND" +420, 7, 9, 121, 37, 38, 589, 590, ":" +420, 7, 10, 122, 39, 41, 591, 593, "To" +420, 7, 11, 123, 42, 51, 594, 603, "determine" +420, 7, 12, 124, 52, 55, 604, 607, "the" +420, 7, 13, 125, 56, 66, 608, 618, "adjunctive" +420, 7, 14, 126, 67, 69, 619, 621, "24" +420, 7, 15, 127, 70, 71, 622, 623, "-" +420, 7, 16, 128, 72, 73, 624, 625, "h" +420, 7, 17, 129, 74, 82, 626, 634, "efficacy" +420, 7, 18, 130, 83, 91, 635, 643, "obtained" +420, 7, 19, 131, 92, 96, 644, 648, "with" +420, 7, 20, 132, 97, 109, 649, 661, "brinzolamide" +420, 7, 21, 133, 110, 111, 662, 663, "/" +420, 7, 22, 134, 112, 119, 664, 671, "timolol" +420, 7, 23, 135, 120, 121, 672, 673, "," +420, 7, 24, 136, 122, 124, 674, 676, "or" +420, 7, 25, 137, 125, 136, 677, 688, "brimonidine" +420, 7, 26, 138, 137, 138, 689, 690, "/" +420, 7, 27, 139, 139, 146, 691, 698, "timolol" +420, 7, 28, 140, 147, 152, 699, 704, "fixed" +420, 7, 29, 141, 153, 165, 705, 717, "combinations" +420, 7, 30, 142, 166, 167, 718, 719, "(" +420, 7, 31, 143, 168, 171, 720, 723, "FCs" +420, 7, 32, 144, 172, 173, 724, 725, ")" +420, 7, 33, 145, 174, 176, 726, 728, "in" +420, 7, 34, 146, 177, 181, 729, 733, "open" +420, 7, 35, 147, 182, 183, 734, 735, "-" +420, 7, 36, 148, 184, 189, 736, 741, "angle" +420, 7, 37, 149, 190, 198, 742, 750, "glaucoma" +420, 7, 38, 150, 199, 207, 751, 759, "patients" +420, 7, 39, 151, 208, 222, 760, 774, "insufficiently" +420, 7, 40, 152, 223, 233, 775, 785, "controlled" +420, 7, 41, 153, 234, 236, 786, 788, "on" +420, 7, 42, 154, 237, 247, 789, 799, "travoprost" +420, 7, 43, 155, 248, 259, 800, 811, "monotherapy" +420, 7, 44, 156, 260, 261, 812, 813, "." +420, 8, 1, 157, 0, 7, 814, 821, "METHODS" +420, 8, 2, 158, 8, 9, 822, 823, ":" +420, 8, 3, 159, 10, 21, 824, 835, "Prospective" +420, 8, 4, 160, 22, 23, 836, 837, "," +420, 8, 5, 161, 24, 32, 838, 846, "observer" +420, 8, 6, 162, 33, 34, 847, 848, "-" +420, 8, 7, 163, 35, 41, 849, 855, "masked" +420, 8, 8, 164, 42, 43, 856, 857, "," +420, 8, 9, 165, 44, 50, 858, 864, "active" +420, 8, 10, 166, 51, 61, 865, 875, "controlled" +420, 8, 11, 167, 62, 63, 876, 877, "," +420, 8, 12, 168, 64, 73, 878, 887, "crossover" +420, 8, 13, 169, 74, 75, 888, 889, "," +420, 8, 14, 170, 76, 86, 890, 900, "comparison" +420, 8, 15, 171, 87, 88, 901, 902, "." +420, 9, 1, 172, 0, 9, 903, 912, "Qualified" +420, 9, 2, 173, 10, 17, 913, 920, "primary" +420, 9, 3, 174, 18, 22, 921, 925, "open" +420, 9, 4, 175, 23, 24, 926, 927, "-" +420, 9, 5, 176, 25, 30, 928, 933, "angle" +420, 9, 6, 177, 31, 33, 934, 936, "or" +420, 9, 7, 178, 34, 45, 937, 948, "exfoliative" +420, 9, 8, 179, 46, 54, 949, 957, "glaucoma" +420, 9, 9, 180, 55, 63, 958, 966, "patients" +420, 9, 10, 181, 64, 68, 967, 971, "with" +420, 9, 11, 182, 69, 70, 972, 973, "a" +420, 9, 12, 183, 71, 79, 974, 982, "baseline" +420, 9, 13, 184, 80, 91, 983, 994, "intraocular" +420, 9, 14, 185, 92, 100, 995, 1003, "pressure" +420, 9, 15, 186, 101, 102, 1004, 1005, "(" +420, 9, 16, 187, 103, 106, 1006, 1009, "IOP" +420, 9, 17, 188, 107, 108, 1010, 1011, ")" +420, 9, 18, 189, 109, 110, 1012, 1013, ">" +420, 9, 19, 190, 111, 113, 1014, 1016, "18" +420, 9, 20, 191, 114, 115, 1017, 1018, " " +420, 9, 21, 192, 116, 118, 1019, 1021, "mm" +420, 9, 22, 193, 119, 121, 1022, 1024, "Hg" +420, 9, 23, 194, 122, 124, 1025, 1027, "at" +420, 9, 24, 195, 125, 127, 1028, 1030, "10" +420, 9, 25, 196, 128, 129, 1031, 1032, ":" +420, 9, 26, 197, 130, 132, 1033, 1035, "00" +420, 9, 27, 198, 133, 135, 1036, 1038, "on" +420, 9, 28, 199, 136, 146, 1039, 1049, "travoprost" +420, 9, 29, 200, 147, 158, 1050, 1061, "monotherapy" +420, 9, 30, 201, 159, 163, 1062, 1066, "were" +420, 9, 31, 202, 164, 174, 1067, 1077, "randomized" +420, 9, 32, 203, 175, 178, 1078, 1081, "for" +420, 9, 33, 204, 179, 180, 1082, 1083, "3" +420, 9, 34, 205, 181, 187, 1084, 1090, "months" +420, 9, 35, 206, 188, 190, 1091, 1093, "to" +420, 9, 36, 207, 191, 197, 1094, 1100, "either" +420, 9, 37, 208, 198, 210, 1101, 1113, "brinzolamide" +420, 9, 38, 209, 211, 212, 1114, 1115, "/" +420, 9, 39, 210, 213, 220, 1116, 1123, "timolol" +420, 9, 40, 211, 221, 222, 1124, 1125, "," +420, 9, 41, 212, 223, 225, 1126, 1128, "or" +420, 9, 42, 213, 226, 237, 1129, 1140, "brimonidine" +420, 9, 43, 214, 238, 239, 1141, 1142, "/" +420, 9, 44, 215, 240, 247, 1143, 1150, "timolol" +420, 9, 45, 216, 248, 250, 1151, 1153, "FC" +420, 9, 46, 217, 251, 258, 1154, 1161, "therapy" +420, 9, 47, 218, 259, 266, 1162, 1169, "adjunct" +420, 9, 48, 219, 267, 269, 1170, 1172, "to" +420, 9, 49, 220, 270, 280, 1173, 1183, "travoprost" +420, 9, 50, 221, 281, 282, 1184, 1185, "." +420, 10, 1, 222, 0, 8, 1186, 1194, "Patients" +420, 10, 2, 223, 9, 13, 1195, 1199, "were" +420, 10, 3, 224, 14, 18, 1200, 1204, "then" +420, 10, 4, 225, 19, 26, 1205, 1212, "crossed" +420, 10, 5, 226, 27, 28, 1213, 1214, "-" +420, 10, 6, 227, 29, 33, 1215, 1219, "over" +420, 10, 7, 228, 34, 36, 1220, 1222, "to" +420, 10, 8, 229, 37, 40, 1223, 1226, "the" +420, 10, 9, 230, 41, 49, 1227, 1235, "opposite" +420, 10, 10, 231, 50, 57, 1236, 1243, "therapy" +420, 10, 11, 232, 58, 61, 1244, 1247, "for" +420, 10, 12, 233, 62, 69, 1248, 1255, "another" +420, 10, 13, 234, 70, 71, 1256, 1257, "3" +420, 10, 14, 235, 72, 78, 1258, 1264, "months" +420, 10, 15, 236, 79, 80, 1265, 1266, "." +420, 11, 1, 237, 0, 2, 1267, 1269, "At" +420, 11, 2, 238, 3, 11, 1270, 1278, "baseline" +420, 11, 3, 239, 12, 15, 1279, 1282, "and" +420, 11, 4, 240, 16, 18, 1283, 1285, "at" +420, 11, 5, 241, 19, 22, 1286, 1289, "the" +420, 11, 6, 242, 23, 26, 1290, 1293, "end" +420, 11, 7, 243, 27, 29, 1294, 1296, "of" +420, 11, 8, 244, 30, 34, 1297, 1301, "each" +420, 11, 9, 245, 35, 44, 1302, 1311, "treatment" +420, 11, 10, 246, 45, 51, 1312, 1318, "period" +420, 11, 11, 247, 52, 53, 1319, 1320, "," +420, 11, 12, 248, 54, 57, 1321, 1324, "the" +420, 11, 13, 249, 58, 66, 1325, 1333, "patients" +420, 11, 14, 250, 67, 76, 1334, 1343, "underwent" +420, 11, 15, 251, 77, 79, 1344, 1346, "24" +420, 11, 16, 252, 80, 81, 1347, 1348, "-" +420, 11, 17, 253, 82, 83, 1349, 1350, "h" +420, 11, 18, 254, 84, 87, 1351, 1354, "IOP" +420, 11, 19, 255, 88, 98, 1355, 1365, "monitoring" +420, 11, 20, 256, 99, 100, 1366, 1367, "." +420, 12, 1, 257, 0, 7, 1368, 1375, "RESULTS" +420, 12, 2, 258, 8, 9, 1376, 1377, ":" +420, 12, 3, 259, 10, 15, 1378, 1383, "Fifty" +420, 12, 4, 260, 16, 24, 1384, 1392, "patients" +420, 12, 5, 261, 25, 34, 1393, 1402, "completed" +420, 12, 6, 262, 35, 38, 1403, 1406, "the" +420, 12, 7, 263, 39, 44, 1407, 1412, "study" +420, 12, 8, 264, 45, 46, 1413, 1414, "." +420, 13, 1, 265, 0, 3, 1415, 1418, "The" +420, 13, 2, 266, 4, 8, 1419, 1423, "mean" +420, 13, 3, 267, 9, 11, 1424, 1426, "24" +420, 13, 4, 268, 12, 13, 1427, 1428, "-" +420, 13, 5, 269, 14, 15, 1429, 1430, "h" +420, 13, 6, 270, 16, 24, 1431, 1439, "baseline" +420, 13, 7, 271, 25, 28, 1440, 1443, "IOP" +420, 13, 8, 272, 29, 31, 1444, 1446, "on" +420, 13, 9, 273, 32, 42, 1447, 1457, "travoprost" +420, 13, 10, 274, 43, 54, 1458, 1469, "monotherapy" +420, 13, 11, 275, 55, 58, 1470, 1473, "was" +420, 13, 12, 276, 59, 61, 1474, 1476, "20" +420, 13, 13, 277, 62, 63, 1477, 1478, "." +420, 13, 14, 278, 64, 65, 1479, 1480, "1" +420, 13, 15, 279, 66, 67, 1481, 1482, " " +420, 13, 16, 280, 68, 70, 1483, 1485, "mm" +420, 13, 17, 281, 71, 73, 1486, 1488, "Hg" +420, 13, 18, 282, 74, 75, 1489, 1490, "[" +420, 13, 19, 283, 76, 78, 1491, 1493, "95" +420, 13, 20, 284, 79, 80, 1494, 1495, "%" +420, 13, 21, 285, 81, 91, 1496, 1506, "confidence" +420, 13, 22, 286, 92, 100, 1507, 1515, "interval" +420, 13, 23, 287, 101, 102, 1516, 1517, "(" +420, 13, 24, 288, 103, 105, 1518, 1520, "CI" +420, 13, 25, 289, 106, 107, 1521, 1522, ")" +420, 13, 26, 290, 108, 109, 1523, 1524, ":" +420, 13, 27, 291, 110, 112, 1525, 1527, "19" +420, 13, 28, 292, 113, 114, 1528, 1529, "." +420, 13, 29, 293, 115, 116, 1530, 1531, "6" +420, 13, 30, 294, 117, 118, 1532, 1533, "," +420, 13, 31, 295, 119, 121, 1534, 1536, "20" +420, 13, 32, 296, 122, 123, 1537, 1538, "." +420, 13, 33, 297, 124, 125, 1539, 1540, "7" +420, 13, 34, 298, 126, 127, 1541, 1542, " " +420, 13, 35, 299, 128, 130, 1543, 1545, "mm" +420, 13, 36, 300, 131, 133, 1546, 1548, "Hg" +420, 13, 37, 301, 134, 135, 1549, 1550, "]" +420, 13, 38, 302, 136, 137, 1551, 1552, "." +420, 14, 1, 303, 0, 4, 1553, 1557, "Both" +420, 14, 2, 304, 5, 15, 1558, 1568, "adjunctive" +420, 14, 3, 305, 16, 18, 1569, 1571, "FC" +420, 14, 4, 306, 19, 28, 1572, 1581, "therapies" +420, 14, 5, 307, 29, 42, 1582, 1595, "significantly" +420, 14, 6, 308, 43, 50, 1596, 1603, "reduced" +420, 14, 7, 309, 51, 54, 1604, 1607, "the" +420, 14, 8, 310, 55, 58, 1608, 1611, "IOP" +420, 14, 9, 311, 59, 61, 1612, 1614, "at" +420, 14, 10, 312, 62, 66, 1615, 1619, "each" +420, 14, 11, 313, 67, 71, 1620, 1624, "time" +420, 14, 12, 314, 72, 77, 1625, 1630, "point" +420, 14, 13, 315, 78, 81, 1631, 1634, "and" +420, 14, 14, 316, 82, 85, 1635, 1638, "for" +420, 14, 15, 317, 86, 89, 1639, 1642, "the" +420, 14, 16, 318, 90, 94, 1643, 1647, "mean" +420, 14, 17, 319, 95, 97, 1648, 1650, "24" +420, 14, 18, 320, 98, 99, 1651, 1652, "-" +420, 14, 19, 321, 100, 101, 1653, 1654, "h" +420, 14, 20, 322, 102, 105, 1655, 1658, "IOP" +420, 14, 21, 323, 106, 107, 1659, 1660, "(" +420, 14, 22, 324, 108, 109, 1661, 1662, "P" +420, 14, 23, 325, 110, 111, 1663, 1664, "<" +420, 14, 24, 326, 112, 113, 1665, 1666, "0" +420, 14, 25, 327, 114, 115, 1667, 1668, "." +420, 14, 26, 328, 116, 119, 1669, 1672, "001" +420, 14, 27, 329, 120, 121, 1673, 1674, ")" +420, 14, 28, 330, 122, 130, 1675, 1683, "compared" +420, 14, 29, 331, 131, 135, 1684, 1688, "with" +420, 14, 30, 332, 136, 146, 1689, 1699, "travoprost" +420, 14, 31, 333, 147, 158, 1700, 1711, "monotherapy" +420, 14, 32, 334, 159, 160, 1712, 1713, "." +420, 15, 1, 335, 0, 12, 1714, 1726, "Brinzolamide" +420, 15, 2, 336, 13, 14, 1727, 1728, "/" +420, 15, 3, 337, 15, 22, 1729, 1736, "timolol" +420, 15, 4, 338, 23, 25, 1737, 1739, "FC" +420, 15, 5, 339, 26, 34, 1740, 1748, "provided" +420, 15, 6, 340, 35, 36, 1749, 1750, "a" +420, 15, 7, 341, 37, 50, 1751, 1764, "significantly" +420, 15, 8, 342, 51, 56, 1765, 1770, "lower" +420, 15, 9, 343, 57, 61, 1771, 1775, "mean" +420, 15, 10, 344, 62, 64, 1776, 1778, "24" +420, 15, 11, 345, 65, 66, 1779, 1780, "-" +420, 15, 12, 346, 67, 68, 1781, 1782, "h" +420, 15, 13, 347, 69, 72, 1783, 1786, "IOP" +420, 15, 14, 348, 73, 74, 1787, 1788, "(" +420, 15, 15, 349, 75, 77, 1789, 1791, "17" +420, 15, 16, 350, 78, 79, 1792, 1793, "." +420, 15, 17, 351, 80, 81, 1794, 1795, "2" +420, 15, 18, 352, 82, 83, 1796, 1797, " " +420, 15, 19, 353, 84, 86, 1798, 1800, "mm" +420, 15, 20, 354, 87, 89, 1801, 1803, "Hg" +420, 15, 21, 355, 90, 91, 1804, 1805, "," +420, 15, 22, 356, 92, 94, 1806, 1808, "95" +420, 15, 23, 357, 95, 96, 1809, 1810, "%" +420, 15, 24, 358, 97, 99, 1811, 1813, "CI" +420, 15, 25, 359, 100, 101, 1814, 1815, ":" +420, 15, 26, 360, 102, 104, 1816, 1818, "16" +420, 15, 27, 361, 105, 106, 1819, 1820, "." +420, 15, 28, 362, 107, 108, 1821, 1822, "4" +420, 15, 29, 363, 109, 110, 1823, 1824, "," +420, 15, 30, 364, 111, 113, 1825, 1827, "17" +420, 15, 31, 365, 114, 115, 1828, 1829, "." +420, 15, 32, 366, 116, 117, 1830, 1831, "9" +420, 15, 33, 367, 118, 119, 1832, 1833, " " +420, 15, 34, 368, 120, 122, 1834, 1836, "mm" +420, 15, 35, 369, 123, 125, 1837, 1839, "Hg" +420, 15, 36, 370, 126, 127, 1840, 1841, ")" +420, 15, 37, 371, 128, 132, 1842, 1846, "than" +420, 15, 38, 372, 133, 144, 1847, 1858, "brimonidine" +420, 15, 39, 373, 145, 146, 1859, 1860, "/" +420, 15, 40, 374, 147, 154, 1861, 1868, "timolol" +420, 15, 41, 375, 155, 157, 1869, 1871, "FC" +420, 15, 42, 376, 158, 159, 1872, 1873, "(" +420, 15, 43, 377, 160, 162, 1874, 1876, "18" +420, 15, 44, 378, 163, 164, 1877, 1878, "." +420, 15, 45, 379, 165, 166, 1879, 1880, "0" +420, 15, 46, 380, 167, 168, 1881, 1882, " " +420, 15, 47, 381, 169, 171, 1883, 1885, "mm" +420, 15, 48, 382, 172, 174, 1886, 1888, "Hg" +420, 15, 49, 383, 175, 176, 1889, 1890, "," +420, 15, 50, 384, 177, 179, 1891, 1893, "95" +420, 15, 51, 385, 180, 181, 1894, 1895, "%" +420, 15, 52, 386, 182, 184, 1896, 1898, "CI" +420, 15, 53, 387, 185, 186, 1899, 1900, ":" +420, 15, 54, 388, 187, 189, 1901, 1903, "17" +420, 15, 55, 389, 190, 191, 1904, 1905, "." +420, 15, 56, 390, 192, 193, 1906, 1907, "3" +420, 15, 57, 391, 194, 195, 1908, 1909, "," +420, 15, 58, 392, 196, 198, 1910, 1912, "18" +420, 15, 59, 393, 199, 200, 1913, 1914, "." +420, 15, 60, 394, 201, 202, 1915, 1916, "8" +420, 15, 61, 395, 203, 204, 1917, 1918, " " +420, 15, 62, 396, 205, 207, 1919, 1921, "mm" +420, 15, 63, 397, 208, 210, 1922, 1924, "Hg" +420, 15, 64, 398, 211, 212, 1925, 1926, ")" +420, 15, 65, 399, 213, 214, 1927, 1928, "(" +420, 15, 66, 400, 215, 216, 1929, 1930, "P" +420, 15, 67, 401, 217, 218, 1931, 1932, "<" +420, 15, 68, 402, 219, 220, 1933, 1934, "0" +420, 15, 69, 403, 221, 222, 1935, 1936, "." +420, 15, 70, 404, 223, 226, 1937, 1940, "001" +420, 15, 71, 405, 227, 228, 1941, 1942, ")" +420, 15, 72, 406, 229, 230, 1943, 1944, "." +420, 16, 1, 407, 0, 3, 1945, 1948, "For" +420, 16, 2, 408, 4, 7, 1949, 1952, "all" +420, 16, 3, 409, 8, 11, 1953, 1956, "the" +420, 16, 4, 410, 12, 13, 1957, 1958, "3" +420, 16, 5, 411, 14, 24, 1959, 1969, "timepoints" +420, 16, 6, 412, 25, 32, 1970, 1977, "between" +420, 16, 7, 413, 33, 35, 1978, 1980, "18" +420, 16, 8, 414, 36, 37, 1981, 1982, ":" +420, 16, 9, 415, 38, 40, 1983, 1985, "00" +420, 16, 10, 416, 41, 44, 1986, 1989, "and" +420, 16, 11, 417, 45, 47, 1990, 1992, "02" +420, 16, 12, 418, 48, 49, 1993, 1994, ":" +420, 16, 13, 419, 50, 52, 1995, 1997, "00" +420, 16, 14, 420, 53, 54, 1998, 1999, "," +420, 16, 15, 421, 55, 58, 2000, 2003, "the" +420, 16, 16, 422, 59, 71, 2004, 2016, "brinzolamide" +420, 16, 17, 423, 72, 73, 2017, 2018, "/" +420, 16, 18, 424, 74, 81, 2019, 2026, "timolol" +420, 16, 19, 425, 82, 84, 2027, 2029, "FC" +420, 16, 20, 426, 85, 93, 2030, 2038, "provided" +420, 16, 21, 427, 94, 95, 2039, 2040, "a" +420, 16, 22, 428, 96, 109, 2041, 2054, "significantly" +420, 16, 23, 429, 110, 115, 2055, 2060, "lower" +420, 16, 24, 430, 116, 119, 2061, 2064, "IOP" +420, 16, 25, 431, 120, 124, 2065, 2069, "than" +420, 16, 26, 432, 125, 128, 2070, 2073, "the" +420, 16, 27, 433, 129, 140, 2074, 2085, "brimonidine" +420, 16, 28, 434, 141, 142, 2086, 2087, "/" +420, 16, 29, 435, 143, 150, 2088, 2095, "timolol" +420, 16, 30, 436, 151, 153, 2096, 2098, "FC" +420, 16, 31, 437, 154, 155, 2099, 2100, "(" +420, 16, 32, 438, 156, 157, 2101, 2102, "P" +420, 16, 33, 439, 158, 159, 2103, 2104, "≤" +420, 16, 34, 440, 160, 161, 2105, 2106, "0" +420, 16, 35, 441, 162, 163, 2107, 2108, "." +420, 16, 36, 442, 164, 167, 2109, 2112, "036" +420, 16, 37, 443, 168, 169, 2113, 2114, ")" +420, 16, 38, 444, 170, 171, 2115, 2116, "." +420, 17, 1, 445, 0, 3, 2117, 2120, "For" +420, 17, 2, 446, 4, 7, 2121, 2124, "the" +420, 17, 3, 447, 8, 13, 2125, 2130, "other" +420, 17, 4, 448, 14, 15, 2131, 2132, "3" +420, 17, 5, 449, 16, 26, 2133, 2143, "timepoints" +420, 17, 6, 450, 27, 28, 2144, 2145, "," +420, 17, 7, 451, 29, 31, 2146, 2148, "no" +420, 17, 8, 452, 32, 43, 2149, 2160, "significant" +420, 17, 9, 453, 44, 55, 2161, 2172, "differences" +420, 17, 10, 454, 56, 60, 2173, 2177, "were" +420, 17, 11, 455, 61, 69, 2178, 2186, "detected" +420, 17, 12, 456, 70, 71, 2187, 2188, "." +420, 18, 1, 457, 0, 11, 2189, 2200, "CONCLUSIONS" +420, 18, 2, 458, 12, 13, 2201, 2202, ":" +420, 18, 3, 459, 14, 18, 2203, 2207, "This" +420, 18, 4, 460, 19, 24, 2208, 2213, "study" +420, 18, 5, 461, 25, 37, 2214, 2226, "demonstrated" +420, 18, 6, 462, 38, 42, 2227, 2231, "that" +420, 18, 7, 463, 43, 47, 2232, 2236, "both" +420, 18, 8, 464, 48, 51, 2237, 2240, "FCs" +420, 18, 9, 465, 52, 59, 2241, 2248, "provide" +420, 18, 10, 466, 60, 73, 2249, 2262, "statistically" +420, 18, 11, 467, 74, 77, 2263, 2266, "and" +420, 18, 12, 468, 78, 88, 2267, 2277, "clinically" +420, 18, 13, 469, 89, 100, 2278, 2289, "significant" +420, 18, 14, 470, 101, 112, 2290, 2301, "incremental" +420, 18, 15, 471, 113, 115, 2302, 2304, "24" +420, 18, 16, 472, 116, 117, 2305, 2306, "-" +420, 18, 17, 473, 118, 119, 2307, 2308, "h" +420, 18, 18, 474, 120, 123, 2309, 2312, "IOP" +420, 18, 19, 475, 124, 132, 2313, 2321, "lowering" +420, 18, 20, 476, 133, 135, 2322, 2324, "to" +420, 18, 21, 477, 136, 146, 2325, 2335, "travoprost" +420, 18, 22, 478, 147, 158, 2336, 2347, "monotherapy" +420, 18, 23, 479, 159, 160, 2348, 2349, "." +420, 19, 1, 480, 0, 3, 2350, 2353, "The" +420, 19, 2, 481, 4, 16, 2354, 2366, "brinzolamide" +420, 19, 3, 482, 17, 18, 2367, 2368, "/" +420, 19, 4, 483, 19, 26, 2369, 2376, "timolol" +420, 19, 5, 484, 27, 29, 2377, 2379, "FC" +420, 19, 6, 485, 30, 37, 2380, 2387, "however" +420, 19, 7, 486, 38, 46, 2388, 2396, "achieves" +420, 19, 8, 487, 47, 48, 2397, 2398, "a" +420, 19, 9, 488, 49, 55, 2399, 2405, "better" +420, 19, 10, 489, 56, 60, 2406, 2410, "mean" +420, 19, 11, 490, 61, 63, 2411, 2413, "24" +420, 19, 12, 491, 64, 65, 2414, 2415, "-" +420, 19, 13, 492, 66, 67, 2416, 2417, "h" +420, 19, 14, 493, 68, 71, 2418, 2421, "IOP" +420, 19, 15, 494, 72, 79, 2422, 2429, "control" +420, 19, 16, 495, 80, 85, 2430, 2435, "owing" +420, 19, 17, 496, 86, 88, 2436, 2438, "to" +420, 19, 18, 497, 89, 92, 2439, 2442, "the" +420, 19, 19, 498, 93, 100, 2443, 2450, "greater" +420, 19, 20, 499, 101, 109, 2451, 2459, "efficacy" +420, 19, 21, 500, 110, 112, 2460, 2462, "in" +420, 19, 22, 501, 113, 117, 2463, 2467, "late" +420, 19, 23, 502, 118, 127, 2468, 2477, "afternoon" +420, 19, 24, 503, 128, 131, 2478, 2481, "and" +420, 19, 25, 504, 132, 138, 2482, 2488, "during" +420, 19, 26, 505, 139, 142, 2489, 2492, "the" +420, 19, 27, 506, 143, 148, 2493, 2498, "night" +420, 19, 28, 507, 149, 150, 2499, 2500, "." +420, 20, 1, 508, 0, 3, 2501, 2504, "DOI" +420, 20, 2, 509, 4, 5, 2505, 2506, ":" +420, 20, 3, 510, 6, 8, 2507, 2509, "10" +420, 20, 4, 511, 9, 10, 2510, 2511, "." +420, 20, 5, 512, 11, 15, 2512, 2516, "1089" +420, 20, 6, 513, 16, 17, 2517, 2518, "/" +420, 20, 7, 514, 18, 21, 2519, 2522, "jop" +420, 20, 8, 515, 22, 23, 2523, 2524, "." +420, 20, 9, 516, 24, 28, 2525, 2529, "2012" +420, 20, 10, 517, 29, 30, 2530, 2531, "." +420, 20, 11, 518, 31, 35, 2532, 2536, "0195" +420, 20, 12, 519, 36, 40, 2537, 2541, "PMID" +420, 20, 13, 520, 41, 42, 2542, 2543, ":" +420, 20, 14, 521, 43, 51, 2544, 2552, "23550916" +420, 20, 15, 522, 52, 53, 2553, 2554, "[" +420, 20, 16, 523, 54, 61, 2555, 2562, "Indexed" +420, 20, 17, 524, 62, 65, 2563, 2566, "for" +420, 20, 18, 525, 66, 73, 2567, 2574, "MEDLINE" +420, 20, 19, 526, 74, 75, 2575, 2576, "]" diff --git a/data/gl 23550916_jshahinitiran.annodb b/data/gl 23550916_jshahinitiran.annodb new file mode 100644 index 0000000..b1c184b --- /dev/null +++ b/data/gl 23550916_jshahinitiran.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16792, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +16793, PublicationYear, 24, 28, "2013", "", +16794, Title, 112, 283, "Comparison of 24 - hour intraocular pressure reduction obtained with brinzolamide / timolol or brimonidine / timolol fixed - combination adjunctive to travoprost therapy .", "", +16795, IOP, 136, 156, "intraocular pressure", "", +16796, Brinzolamide, 181, 193, "brinzolamide", "", +16797, Timolol, 196, 203, "timolol", "", +16798, Brimonidine, 207, 218, "brimonidine", "", +16799, Timolol, 221, 228, "timolol", "", +16800, Drug, 263, 273, "travoprost", "Travoprost", +16801, Author, 284, 294, "Konstas AG", "", +16802, Author, 303, 311, "Holl ó G", "", +16803, Author, 314, 324, "Haidich AB", "", +16804, Author, 327, 341, "Mikropoulos DG", "", +16805, Author, 344, 358, "Giannopoulos T", "", +16806, Author, 361, 377, "Voudouragkaki IC", "", +16807, Author, 380, 393, "Paschalinou E", "", +16808, Author, 396, 407, "Konidaris V", "", +16809, Author, 410, 420, "Samples JR", "", +16810, Greece, 543, 549, "Greece", "", +16811, ObjectiveDescription, 591, 813, "To determine the adjunctive 24 - h efficacy obtained with brinzolamide / timolol , or brimonidine / timolol fixed combinations ( FCs ) in open - angle glaucoma patients insufficiently controlled on travoprost monotherapy .", "", +16796, Brinzolamide, 649, 661, "brinzolamide", "", +16797, Timolol, 664, 671, "timolol", "", +16798, Brimonidine, 677, 688, "brimonidine", "", +16799, Timolol, 691, 698, "timolol", "", +16816, OpenAngleGlaucoma, 729, 750, "open - angle glaucoma", "", +16818, Precondition, 760, 813, "insufficiently controlled on travoprost monotherapy .", "", +16800, Drug, 789, 799, "travoprost", "Travoprost", +16819, CTDesign, 824, 835, "Prospective", "", +16820, Blind, 838, 855, "observer - masked", "", +16821, CTDesign, 858, 875, "active controlled", "", +16837, Crossover, 878, 887, "crossover", "", +16823, OpenAngleGlaucoma, 913, 957, "primary open - angle or exfoliative glaucoma", "", +16828, Precondition, 967, 1061, "with a baseline intraocular pressure ( IOP ) > 18   mm Hg at 10 : 00 on travoprost monotherapy", "", +16824, IOP, 983, 1003, "intraocular pressure", "", +16825, IOP, 1006, 1009, "IOP", "", +16826, mmHg, 1019, 1024, "mm Hg", "", +16800, Drug, 1039, 1049, "travoprost", "Travoprost", +16830, Randomized, 1067, 1077, "randomized", "", +16831, Duration, 1082, 1090, "3 months", "", +16796, Brinzolamide, 1101, 1113, "brinzolamide", "", +16797, Timolol, 1116, 1123, "timolol", "", +16798, Brimonidine, 1129, 1140, "brimonidine", "", +16799, Timolol, 1143, 1150, "timolol", "", +16800, Drug, 1173, 1183, "travoprost", "Travoprost", +16837, Crossover, 1205, 1219, "crossed - over", "", +16840, Duration, 1256, 1264, "3 months", "", +16841, IOP, 1351, 1354, "IOP", "", +16842, FinalNumPatientsCT, 1378, 1383, "Fifty", "", +16843, Mean, 1419, 1423, "mean", "", +16844, IOP, 1440, 1443, "IOP", "", +16800, Drug, 1447, 1457, "travoprost", "Travoprost", +16846, BaseLineValue, 1474, 1480, "20 . 1", "", +16847, mmHg, 1483, 1488, "mm Hg", "", +16848, ConfIntervalBL, 1491, 1548, "95 % confidence interval ( CI ) : 19 . 6 , 20 . 7   mm Hg", "", +16849, mmHg, 1543, 1548, "mm Hg", "", +16850, IOP, 1608, 1611, "IOP", "", +16851, Mean, 1643, 1647, "mean", "", +16852, IOP, 1655, 1658, "IOP", "", +16853, PValueChangeValue, 1661, 1672, "P < 0 . 001", "", +16800, Drug, 1689, 1699, "travoprost", "Travoprost", +16796, Brinzolamide, 1714, 1726, "Brinzolamide", "", +16797, Timolol, 1729, 1736, "timolol", "", +16857, Mean, 1771, 1775, "mean", "", +16858, IOP, 1783, 1786, "IOP", "", +16859, ResultMeasuredValue, 1789, 1795, "17 . 2", "", +16861, mmHg, 1798, 1803, "mm Hg", "", +16868, ConfIntervalResValue, 1806, 1839, "95 % CI : 16 . 4 , 17 . 9   mm Hg", "", +16862, mmHg, 1834, 1839, "mm Hg", "", +16798, Brimonidine, 1847, 1858, "brimonidine", "", +16799, Timolol, 1861, 1868, "timolol", "", +16860, ResultMeasuredValue, 1874, 1880, "18 . 0", "", +16865, mmHg, 1883, 1888, "mm Hg", "", +16869, ConfIntervalResValue, 1891, 1924, "95 % CI : 17 . 3 , 18 . 8   mm Hg", "", +16866, mmHg, 1919, 1924, "mm Hg", "", +16867, PvalueDiff, 1929, 1940, "P < 0 . 001", "", +16876, ObservedResult, 1945, 2116, "For all the 3 timepoints between 18 : 00 and 02 : 00 , the brinzolamide / timolol FC provided a significantly lower IOP than the brimonidine / timolol FC ( P ≤ 0 . 036 ) .", "", +16796, Brinzolamide, 2004, 2016, "brinzolamide", "", +16797, Timolol, 2019, 2026, "timolol", "", +16872, IOP, 2061, 2064, "IOP", "", +16798, Brimonidine, 2074, 2085, "brimonidine", "", +16799, Timolol, 2088, 2095, "timolol", "", +16875, PvalueDiff, 2101, 2112, "P ≤ 0 . 036", "", +16877, ObservedResult, 2117, 2188, "For the other 3 timepoints , no significant differences were detected .", "", +16878, ConclusionComment, 2203, 2349, "This study demonstrated that both FCs provide statistically and clinically significant incremental 24 - h IOP lowering to travoprost monotherapy .", "", +16880, IOP, 2309, 2312, "IOP", "", +16800, Drug, 2325, 2335, "travoprost", "Travoprost", +16879, ConclusionComment, 2350, 2500, "The brinzolamide / timolol FC however achieves a better mean 24 - h IOP control owing to the greater efficacy in late afternoon and during the night .", "", +16796, Brinzolamide, 2354, 2366, "brinzolamide", "", +16797, Timolol, 2369, 2376, "timolol", "", +16884, Mean, 2406, 2410, "mean", "", +16885, IOP, 2418, 2421, "IOP", "", +16886, PMID, 2544, 2552, "23550916", "", diff --git a/data/gl 23550916_jshahinitiran.n-triples b/data/gl 23550916_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23550916_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23550916_tstrakeljahn.annodb b/data/gl 23550916_tstrakeljahn.annodb new file mode 100644 index 0000000..733f90e --- /dev/null +++ b/data/gl 23550916_tstrakeljahn.annodb @@ -0,0 +1,95 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +74365, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +74366, PublicationYear, 24, 28, "2013", "", +74386, Title, 112, 283, "Comparison of 24 - hour intraocular pressure reduction obtained with brinzolamide / timolol or brimonidine / timolol fixed - combination adjunctive to travoprost therapy .", "", +74367, IOP, 136, 156, "intraocular pressure", "", +74368, Brinzolamide, 181, 193, "brinzolamide", "", +74373, Brinz/TimFC, 181, 203, "brinzolamide / timolol", "", +74369, Timolol, 196, 203, "timolol", "", +74370, Brimonidine, 207, 218, "brimonidine", "", +74374, Brimo/TimFC, 207, 228, "brimonidine / timolol", "", +74371, Timolol, 221, 228, "timolol", "", +74372, Travoprost, 263, 273, "travoprost", "", +74375, Author, 284, 294, "Konstas AG", "", +74376, Author, 303, 311, "Holl ó G", "", +74378, Author, 314, 324, "Haidich AB", "", +74379, Author, 327, 341, "Mikropoulos DG", "", +74380, Author, 344, 358, "Giannopoulos T", "", +74381, Author, 361, 377, "Voudouragkaki IC", "", +74382, Author, 380, 393, "Paschalinou E", "", +74383, Author, 396, 407, "Konidaris V", "", +74384, Author, 410, 420, "Samples JR", "", +74385, Greece, 543, 549, "Greece", "", +74394, ObjectiveDescription, 591, 813, "To determine the adjunctive 24 - h efficacy obtained with brinzolamide / timolol , or brimonidine / timolol fixed combinations ( FCs ) in open - angle glaucoma patients insufficiently controlled on travoprost monotherapy .", "", +74387, Brinzolamide, 649, 661, "brinzolamide", "", +74388, Timolol, 664, 671, "timolol", "", +74389, Brimonidine, 677, 688, "brimonidine", "", +74390, Timolol, 691, 698, "timolol", "", +74391, OpenAngleGlaucoma, 729, 750, "open - angle glaucoma", "", +74393, Precondition, 760, 811, "insufficiently controlled on travoprost monotherapy", "", +74392, Travoprost, 789, 799, "travoprost", "", +74395, Prospective, 824, 835, "Prospective", "", +74396, Blind, 838, 855, "observer - masked", "", +74397, Crossover, 878, 887, "crossover", "", +74398, Primary_OpenAngleGlaucoma, 913, 933, "primary open - angle", "", +74399, Glaucoma, 949, 957, "glaucoma", "", +74400, IOP, 983, 1003, "intraocular pressure", "", +74401, IOP, 1006, 1009, "IOP", "", +74402, mmHg, 1019, 1024, "mm Hg", "", +74403, TimePoint, 1028, 1035, "10 : 00", "", +74404, Travoprost, 1039, 1049, "travoprost", "", +74405, Randomized, 1067, 1077, "randomized", "", +74406, Duration, 1082, 1090, "3 months", "", +74407, Brinzolamide, 1101, 1113, "brinzolamide", "", +74411, Brinz/TimFC, 1101, 1123, "brinzolamide / timolol", "", +74408, Timolol, 1116, 1123, "timolol", "", +74409, Brimonidine, 1129, 1140, "brimonidine", "", +74412, Brimo/TimFC, 1129, 1150, "brimonidine / timolol", "", +74410, Timolol, 1143, 1150, "timolol", "", +74414, Travoprost, 1173, 1183, "travoprost", "", +74415, IOP, 1351, 1354, "IOP", "", +74416, FinalNumPatientsCT, 1378, 1383, "Fifty", "", +74417, IOP, 1440, 1443, "IOP", "", +74418, Travoprost, 1447, 1457, "travoprost", "", +74419, BaseLineValue, 1474, 1480, "20 . 1", "", +74420, mmHg, 1483, 1488, "mm Hg", "", +74422, ConfIntervalBL, 1525, 1540, "19 . 6 , 20 . 7", "", +74421, mmHg, 1543, 1548, "mm Hg", "", +74423, IOP, 1608, 1611, "IOP", "", +74424, IOP, 1655, 1658, "IOP", "", +74425, PValueResValue, 1663, 1672, "< 0 . 001", "", +74426, Travoprost, 1689, 1699, "travoprost", "", +74427, Brinzolamide, 1714, 1726, "Brinzolamide", "", +74429, Brinz/TimFC, 1714, 1739, "Brinzolamide / timolol FC", "", +74428, Timolol, 1729, 1736, "timolol", "", +74430, Mean, 1771, 1775, "mean", "", +74431, IOP, 1783, 1786, "IOP", "", +74432, ResultMeasuredValue, 1789, 1795, "17 . 2", "", +74434, mmHg, 1798, 1803, "mm Hg", "", +74435, ConfIntervalResValue, 1816, 1831, "16 . 4 , 17 . 9", "", +74437, mmHg, 1834, 1839, "mm Hg", "", +74440, Brimonidine, 1847, 1858, "brimonidine", "", +74442, Brimo/TimFC, 1847, 1871, "brimonidine / timolol FC", "", +74441, Timolol, 1861, 1868, "timolol", "", +74433, ResultMeasuredValue, 1874, 1880, "18 . 0", "", +74443, mmHg, 1883, 1888, "mm Hg", "", +74436, ConfIntervalResValue, 1901, 1916, "17 . 3 , 18 . 8", "", +74438, mmHg, 1919, 1924, "mm Hg", "", +74439, PvalueDiff, 1931, 1940, "< 0 . 001", "", +74444, Brinzolamide, 2004, 2016, "brinzolamide", "", +74446, Brinz/TimFC, 2004, 2029, "brinzolamide / timolol FC", "", +74445, Timolol, 2019, 2026, "timolol", "", +74447, IOP, 2061, 2064, "IOP", "", +74448, Brimonidine, 2074, 2085, "brimonidine", "", +74450, Brimo/TimFC, 2074, 2098, "brimonidine / timolol FC", "", +74449, Timolol, 2088, 2095, "timolol", "", +74451, PvalueDiff, 2103, 2112, "≤ 0 . 036", "", +74458, ConclusionComment, 2203, 2349, "This study demonstrated that both FCs provide statistically and clinically significant incremental 24 - h IOP lowering to travoprost monotherapy .", "", +74452, IOP, 2309, 2312, "IOP", "", +74453, Travoprost, 2325, 2335, "travoprost", "", +74459, ConclusionComment, 2350, 2500, "The brinzolamide / timolol FC however achieves a better mean 24 - h IOP control owing to the greater efficacy in late afternoon and during the night .", "", +74454, Brinzolamide, 2354, 2366, "brinzolamide", "", +74456, Brinz/TimFC, 2354, 2379, "brinzolamide / timolol FC", "", +74455, Timolol, 2369, 2376, "timolol", "", +74457, IOP, 2418, 2421, "IOP", "", +74460, PMID, 2544, 2552, "23550916", "", diff --git a/data/gl 23550916_tstrakeljahn.n-triples b/data/gl 23550916_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23550916_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23686322_admin.annodb b/data/gl 23686322_admin.annodb new file mode 100644 index 0000000..86ca34e --- /dev/null +++ b/data/gl 23686322_admin.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "2013", "", " \"2013\"." +2, Title, 119, 296, "24 - hour efficacy of the bimatoprost - timolol fixed combination versus latanoprost as first choice therapy in subjects with high - pressure exfoliation syndrome and glaucoma .", "", " \"24 - hour efficacy of the bimatoprost - timolol fixed combination versus latanoprost as first choice therapy in subjects with high - pressure exfoliation syndrome and glaucoma .\"." +12, Bimatoprost, 145, 156, "bimatoprost", "", +14, Bima/TimFC, 145, 184, "bimatoprost - timolol fixed combination", "", +13, Timolol, 159, 166, "timolol", "", +15, Latanoprost, 192, 203, "latanoprost", "", +87, Precondition, 231, 294, "subjects with high - pressure exfoliation syndrome and glaucoma", "", " \"subjects with high - pressure exfoliation syndrome and glaucoma\"." +17, DisorderOrSyndrome, 245, 281, "high - pressure exfoliation syndrome", "", " . ." +16, Glaucoma, 286, 294, "glaucoma", "", " . ." +3, Author, 297, 307, "Konstas AG", "", " \"Konstas AG\"." +4, Author, 316, 324, "Holl ó G", "", " \"Holl ó G\"." +5, Author, 327, 341, "Mikropoulos DG", "", " \"Mikropoulos DG\"." +6, Author, 344, 354, "Haidich AB", "", " \"Haidich AB\"." +7, Author, 357, 370, "Dimopoulos AT", "", " \"Dimopoulos AT\"." +8, Author, 373, 385, "Empeslidis T", "", " \"Empeslidis T\"." +9, Author, 388, 395, "Teus MA", "", " \"Teus MA\"." +10, Author, 398, 405, "Ritch R", "", " \"Ritch R\"." +11, Greece, 528, 534, "Greece", "", " ." +18, ObjectiveDescription, 543, 687, "To compare the 24 - h intraocular pressure ( IOP ) control obtained with the bimatoprost - timolol fixed combination ( BTFC ) versus latanoprost", "", " \"To compare the 24 - h intraocular pressure ( IOP ) control obtained with the bimatoprost - timolol fixed combination ( BTFC ) versus latanoprost\"." +139, Diurnal_IOP, 558, 585, "24 - h intraocular pressure", "", +20, IOP, 565, 585, "intraocular pressure", "", +21, IOP, 588, 591, "IOP", "", +22, Bimatoprost, 620, 631, "bimatoprost", "", +24, Bima/TimFC, 620, 659, "bimatoprost - timolol fixed combination", "", " ." +23, Timolol, 634, 641, "timolol", "", +25, Bima/TimFC, 662, 666, "BTFC", "", +26, Latanoprost, 676, 687, "latanoprost", "", " . ." +19, ObjectiveDescription, 688, 849, "in newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG ) patients with baseline morning IOP greater than 29 mm Hg .", "", " \"in newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG ) patients with baseline morning IOP greater than 29 mm Hg .\"." +108, Precondition, 691, 790, "newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG )", "", " \"newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG )\"." +28, DisorderOrSyndrome, 730, 750, "exfoliation syndrome", "", +29, DisorderOrSyndrome, 753, 756, "XFS", "", " . ." +30, Glaucoma, 762, 782, "exfoliative glaucoma", "", +31, Glaucoma, 785, 788, "XFG", "", " . ." +119, ObjectiveDescription, 791, 849, "patients with baseline morning IOP greater than 29 mm Hg .", "", " \"patients with baseline morning IOP greater than 29 mm Hg .\"." +105, Morning, 814, 821, "morning", "", +32, IOP, 822, 825, "IOP", "", +34, mmHg, 842, 847, "mm Hg", "", +35, NumberPatientsCT, 871, 873, "41", "", " \"41\"." +36, DisorderOrSyndrome, 874, 877, "XFS", "", +37, Glaucoma, 880, 883, "XFG", "", +38, Prospective, 941, 952, "prospective", "", " ." +39, Blind, 955, 972, "observer - masked", "", " ." +40, Crossover, 975, 984, "crossover", "", " ." +41, Randomized, 1071, 1081, "randomised", "", " ." +42, Evening, 1092, 1099, "evening", "", " . ." +43, Bima/TimFC, 1113, 1117, "BTFC", "", +44, Latanoprost, 1121, 1132, "latanoprost", "", +45, Duration, 1137, 1145, "3 months", "", " \"3 months\"." +140, Diurnal_IOP, 1257, 1267, "24 - h IOP", "", +47, FinalNumPatientsCT, 1291, 1293, "37", "", " \"37\"." +92453, TimePoint, 1328, 1336, "baseline", "", +48, Mean, 1339, 1343, "mean", "", +141, Diurnal_IOP, 1354, 1364, "24 - h IOP", "", " ." +50, BaseLineValue, 1369, 1375, "31 . 1", "", " \"31 . 1\". \"31 . 1\"." +123, mmHg, 1376, 1381, "mm Hg", "", " ." +52, Mean, 1384, 1388, "Mean", "", " . ." +142, Diurnal_IOP, 1389, 1399, "24 - h IOP", "", +54, Bima/TimFC, 1405, 1409, "BTFC", "", +55, Latanoprost, 1444, 1455, "latanoprost", "", +56, ResultMeasuredValue, 1458, 1464, "18 . 9", "", " \"18 . 9\"." +57, ResultMeasuredValue, 1468, 1474, "21 . 2", "", " \"21 . 2\"." +129, mmHg, 1475, 1480, "mm Hg", "", +130, PvalueDiff, 1485, 1494, "< 0 . 001", "", " \"< 0 . 001\"." +60, Bima/TimFC, 1513, 1517, "BTFC", "", +61, IOP, 1526, 1529, "IOP", "", +62, Latanoprost, 1554, 1565, "latanoprost", "", +63, Mean, 1596, 1600, "mean", "", +64, Peak_IOP, 1601, 1605, "peak", "", +65, Trough_IOP, 1610, 1616, "trough", "", +143, Diurnal_IOP, 1617, 1627, "24 - h IOP", "", +137, PvalueDiff, 1632, 1641, "< 0 . 001", "", +68, Mean, 1685, 1689, "mean", "", +144, Diurnal_IOP, 1690, 1700, "24 - h IOP", "", +92457, EndPointDescription, 1690, 1712, "24 - h IOP fluctuation", "", +70, Bima/TimFC, 1754, 1758, "BTFC", "", +71, Latanoprost, 1773, 1784, "latanoprost", "", +72, PvalueDiff, 1787, 1798, "p = 0 . 161", "", +74, ConclusionComment, 1944, 2105, "As first choice therapy in high - pressure , at - risk exfoliation patients , BTFC controlled mean 24 - h IOP significantly better than latanoprost monotherapy .", "", " \"As first choice therapy in high - pressure , at - risk exfoliation patients , BTFC controlled mean 24 - h IOP significantly better than latanoprost monotherapy .\"." +75, Bima/TimFC, 2022, 2026, "BTFC", "", +76, Mean, 2038, 2042, "mean", "", +151, Diurnal_IOP, 2043, 2053, "24 - h IOP", "", +78, Latanoprost, 2080, 2091, "latanoprost", "", +79, PMID, 2160, 2168, "23686322", "", " \"23686322\"." diff --git a/data/gl 23686322_admin.n-triples b/data/gl 23686322_admin.n-triples new file mode 100644 index 0000000..28d48ad --- /dev/null +++ b/data/gl 23686322_admin.n-triples @@ -0,0 +1,111 @@ +# RDF export of group: Publication + . + "Publication" . + "24 - hour efficacy of the bimatoprost - timolol fixed combination versus latanoprost as first choice therapy in subjects with high - pressure exfoliation syndrome and glaucoma ." . + "Konstas AG" . + "2013" . + "Br J Ophthalmol ." . + "23686322" . + . + "Holl ó G" . + "Mikropoulos DG" . + "Haidich AB" . + "Dimopoulos AT" . + "Empeslidis T" . + "Teus MA" . + "Ritch R" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the 24 - h intraocular pressure ( IOP ) control obtained with the bimatoprost - timolol fixed combination ( BTFC ) versus latanoprost" . + "41" . + "3 months" . + . + . + . + . + . + . + . + . + . + "37" . + "in newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG ) patients with baseline morning IOP greater than 29 mm Hg ." . + "patients with baseline morning IOP greater than 29 mm Hg ." . + . + . + . + "As first choice therapy in high - pressure , at - risk exfoliation patients , BTFC controlled mean 24 - h IOP significantly better than latanoprost monotherapy ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "subjects with high - pressure exfoliation syndrome and glaucoma" . + . + . + . + "newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG )" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + . + . + . + . + "Arm_lat" . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + . + . + "Intervention_lat" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_lat" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC" . + . + "31 . 1" . + "18 . 9" . + . + "Outcome_lat" . + . + "31 . 1" . + "21 . 2" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups" . + "< 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23686322_export.csv b/data/gl 23686322_export.csv new file mode 100644 index 0000000..5d2d6a9 --- /dev/null +++ b/data/gl 23686322_export.csv @@ -0,0 +1,438 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +506, 1, 1, 1, 0, 2, 0, 2, "Br" +506, 1, 2, 2, 3, 4, 3, 4, "J" +506, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +506, 1, 4, 4, 16, 17, 16, 17, "." +506, 2, 1, 5, 0, 4, 18, 22, "2013" +506, 2, 2, 6, 5, 8, 23, 26, "Jul" +506, 2, 3, 7, 9, 10, 27, 28, ";" +506, 2, 4, 8, 11, 13, 29, 31, "97" +506, 2, 5, 9, 14, 15, 32, 33, "(" +506, 2, 6, 10, 16, 17, 34, 35, "7" +506, 2, 7, 11, 18, 19, 36, 37, ")" +506, 2, 8, 12, 20, 21, 38, 39, ":" +506, 2, 9, 13, 22, 25, 40, 43, "857" +506, 2, 10, 14, 26, 27, 44, 45, "-" +506, 2, 11, 15, 28, 30, 46, 48, "61" +506, 2, 12, 16, 31, 32, 49, 50, "." +506, 2, 13, 17, 33, 36, 51, 54, "doi" +506, 2, 14, 18, 37, 38, 55, 56, ":" +506, 2, 15, 19, 39, 41, 57, 59, "10" +506, 2, 16, 20, 42, 43, 60, 61, "." +506, 2, 17, 21, 44, 48, 62, 66, "1136" +506, 2, 18, 22, 49, 50, 67, 68, "/" +506, 2, 19, 23, 51, 63, 69, 81, "bjophthalmol" +506, 2, 20, 24, 64, 65, 82, 83, "-" +506, 2, 21, 25, 66, 70, 84, 88, "2012" +506, 2, 22, 26, 71, 72, 89, 90, "-" +506, 2, 23, 27, 73, 79, 91, 97, "302843" +506, 2, 24, 28, 80, 81, 98, 99, "." +506, 3, 1, 29, 0, 4, 100, 104, "Epub" +506, 3, 2, 30, 5, 9, 105, 109, "2013" +506, 3, 3, 31, 10, 13, 110, 113, "May" +506, 3, 4, 32, 14, 16, 114, 116, "18" +506, 3, 5, 33, 17, 18, 117, 118, "." +506, 4, 1, 34, 0, 2, 119, 121, "24" +506, 4, 2, 35, 3, 4, 122, 123, "-" +506, 4, 3, 36, 5, 9, 124, 128, "hour" +506, 4, 4, 37, 10, 18, 129, 137, "efficacy" +506, 4, 5, 38, 19, 21, 138, 140, "of" +506, 4, 6, 39, 22, 25, 141, 144, "the" +506, 4, 7, 40, 26, 37, 145, 156, "bimatoprost" +506, 4, 8, 41, 38, 39, 157, 158, "-" +506, 4, 9, 42, 40, 47, 159, 166, "timolol" +506, 4, 10, 43, 48, 53, 167, 172, "fixed" +506, 4, 11, 44, 54, 65, 173, 184, "combination" +506, 4, 12, 45, 66, 72, 185, 191, "versus" +506, 4, 13, 46, 73, 84, 192, 203, "latanoprost" +506, 4, 14, 47, 85, 87, 204, 206, "as" +506, 4, 15, 48, 88, 93, 207, 212, "first" +506, 4, 16, 49, 94, 100, 213, 219, "choice" +506, 4, 17, 50, 101, 108, 220, 227, "therapy" +506, 4, 18, 51, 109, 111, 228, 230, "in" +506, 4, 19, 52, 112, 120, 231, 239, "subjects" +506, 4, 20, 53, 121, 125, 240, 244, "with" +506, 4, 21, 54, 126, 130, 245, 249, "high" +506, 4, 22, 55, 131, 132, 250, 251, "-" +506, 4, 23, 56, 133, 141, 252, 260, "pressure" +506, 4, 24, 57, 142, 153, 261, 272, "exfoliation" +506, 4, 25, 58, 154, 162, 273, 281, "syndrome" +506, 4, 26, 59, 163, 166, 282, 285, "and" +506, 4, 27, 60, 167, 175, 286, 294, "glaucoma" +506, 4, 28, 61, 176, 177, 295, 296, "." +506, 5, 1, 62, 0, 7, 297, 304, "Konstas" +506, 5, 2, 63, 8, 10, 305, 307, "AG" +506, 5, 3, 64, 11, 12, 308, 309, "(" +506, 5, 4, 65, 13, 14, 310, 311, "1" +506, 5, 5, 66, 15, 16, 312, 313, ")" +506, 5, 6, 67, 17, 18, 314, 315, "," +506, 5, 7, 68, 19, 23, 316, 320, "Holl" +506, 5, 8, 69, 24, 25, 321, 322, "ó" +506, 5, 9, 70, 26, 27, 323, 324, "G" +506, 5, 10, 71, 28, 29, 325, 326, "," +506, 5, 11, 72, 30, 41, 327, 338, "Mikropoulos" +506, 5, 12, 73, 42, 44, 339, 341, "DG" +506, 5, 13, 74, 45, 46, 342, 343, "," +506, 5, 14, 75, 47, 54, 344, 351, "Haidich" +506, 5, 15, 76, 55, 57, 352, 354, "AB" +506, 5, 16, 77, 58, 59, 355, 356, "," +506, 5, 17, 78, 60, 70, 357, 367, "Dimopoulos" +506, 5, 18, 79, 71, 73, 368, 370, "AT" +506, 5, 19, 80, 74, 75, 371, 372, "," +506, 5, 20, 81, 76, 86, 373, 383, "Empeslidis" +506, 5, 21, 82, 87, 88, 384, 385, "T" +506, 5, 22, 83, 89, 90, 386, 387, "," +506, 5, 23, 84, 91, 95, 388, 392, "Teus" +506, 5, 24, 85, 96, 98, 393, 395, "MA" +506, 5, 25, 86, 99, 100, 396, 397, "," +506, 5, 26, 87, 101, 106, 398, 403, "Ritch" +506, 5, 27, 88, 107, 108, 404, 405, "R" +506, 5, 28, 89, 109, 110, 406, 407, "." +506, 5, 29, 90, 111, 117, 408, 414, "Author" +506, 5, 30, 91, 118, 129, 415, 426, "information" +506, 5, 31, 92, 130, 131, 427, 428, ":" +506, 5, 32, 93, 132, 133, 429, 430, "(" +506, 5, 33, 94, 134, 135, 431, 432, "1" +506, 5, 34, 95, 136, 137, 433, 434, ")" +506, 5, 35, 96, 138, 146, 435, 443, "Glaucoma" +506, 5, 36, 97, 147, 151, 444, 448, "Unit" +506, 5, 37, 98, 152, 153, 449, 450, "," +506, 5, 38, 99, 154, 157, 451, 454, "1st" +506, 5, 39, 100, 158, 168, 455, 465, "University" +506, 5, 40, 101, 169, 179, 466, 476, "Department" +506, 5, 41, 102, 180, 182, 477, 479, "of" +506, 5, 42, 103, 183, 196, 480, 493, "Ophthalmology" +506, 5, 43, 104, 197, 198, 494, 495, "," +506, 5, 44, 105, 199, 204, 496, 501, "AHEPA" +506, 5, 45, 106, 205, 213, 502, 510, "Hospital" +506, 5, 46, 107, 214, 215, 511, 512, "," +506, 5, 47, 108, 216, 228, 513, 525, "Thessaloniki" +506, 5, 48, 109, 229, 230, 526, 527, "," +506, 5, 49, 110, 231, 237, 528, 534, "Greece" +506, 5, 50, 111, 238, 239, 535, 536, "." +506, 6, 1, 112, 0, 3, 537, 540, "AIM" +506, 6, 2, 113, 4, 5, 541, 542, ":" +506, 6, 3, 114, 6, 8, 543, 545, "To" +506, 6, 4, 115, 9, 16, 546, 553, "compare" +506, 6, 5, 116, 17, 20, 554, 557, "the" +506, 6, 6, 117, 21, 23, 558, 560, "24" +506, 6, 7, 118, 24, 25, 561, 562, "-" +506, 6, 8, 119, 26, 27, 563, 564, "h" +506, 6, 9, 120, 28, 39, 565, 576, "intraocular" +506, 6, 10, 121, 40, 48, 577, 585, "pressure" +506, 6, 11, 122, 49, 50, 586, 587, "(" +506, 6, 12, 123, 51, 54, 588, 591, "IOP" +506, 6, 13, 124, 55, 56, 592, 593, ")" +506, 6, 14, 125, 57, 64, 594, 601, "control" +506, 6, 15, 126, 65, 73, 602, 610, "obtained" +506, 6, 16, 127, 74, 78, 611, 615, "with" +506, 6, 17, 128, 79, 82, 616, 619, "the" +506, 6, 18, 129, 83, 94, 620, 631, "bimatoprost" +506, 6, 19, 130, 95, 96, 632, 633, "-" +506, 6, 20, 131, 97, 104, 634, 641, "timolol" +506, 6, 21, 132, 105, 110, 642, 647, "fixed" +506, 6, 22, 133, 111, 122, 648, 659, "combination" +506, 6, 23, 134, 123, 124, 660, 661, "(" +506, 6, 24, 135, 125, 129, 662, 666, "BTFC" +506, 6, 25, 136, 130, 131, 667, 668, ")" +506, 6, 26, 137, 132, 138, 669, 675, "versus" +506, 6, 27, 138, 139, 150, 676, 687, "latanoprost" +506, 6, 28, 139, 151, 153, 688, 690, "in" +506, 6, 29, 140, 154, 159, 691, 696, "newly" +506, 6, 30, 141, 160, 169, 697, 706, "diagnosed" +506, 6, 31, 142, 170, 171, 707, 708, "," +506, 6, 32, 143, 172, 182, 709, 719, "previously" +506, 6, 33, 144, 183, 192, 720, 729, "untreated" +506, 6, 34, 145, 193, 204, 730, 741, "exfoliation" +506, 6, 35, 146, 205, 213, 742, 750, "syndrome" +506, 6, 36, 147, 214, 215, 751, 752, "(" +506, 6, 37, 148, 216, 219, 753, 756, "XFS" +506, 6, 38, 149, 220, 221, 757, 758, ")" +506, 6, 39, 150, 222, 224, 759, 761, "or" +506, 6, 40, 151, 225, 236, 762, 773, "exfoliative" +506, 6, 41, 152, 237, 245, 774, 782, "glaucoma" +506, 6, 42, 153, 246, 247, 783, 784, "(" +506, 6, 43, 154, 248, 251, 785, 788, "XFG" +506, 6, 44, 155, 252, 253, 789, 790, ")" +506, 6, 45, 156, 254, 262, 791, 799, "patients" +506, 6, 46, 157, 263, 267, 800, 804, "with" +506, 6, 47, 158, 268, 276, 805, 813, "baseline" +506, 6, 48, 159, 277, 284, 814, 821, "morning" +506, 6, 49, 160, 285, 288, 822, 825, "IOP" +506, 6, 50, 161, 289, 296, 826, 833, "greater" +506, 6, 51, 162, 297, 301, 834, 838, "than" +506, 6, 52, 163, 302, 304, 839, 841, "29" +506, 6, 53, 164, 305, 307, 842, 844, "mm" +506, 6, 54, 165, 308, 310, 845, 847, "Hg" +506, 6, 55, 166, 311, 312, 848, 849, "." +506, 7, 1, 167, 0, 7, 850, 857, "METHODS" +506, 7, 2, 168, 8, 9, 858, 859, ":" +506, 7, 3, 169, 10, 13, 860, 863, "One" +506, 7, 4, 170, 14, 17, 864, 867, "eye" +506, 7, 5, 171, 18, 20, 868, 870, "of" +506, 7, 6, 172, 21, 23, 871, 873, "41" +506, 7, 7, 173, 24, 27, 874, 877, "XFS" +506, 7, 8, 174, 28, 29, 878, 879, "/" +506, 7, 9, 175, 30, 33, 880, 883, "XFG" +506, 7, 10, 176, 34, 42, 884, 892, "patients" +506, 7, 11, 177, 43, 46, 893, 896, "who" +506, 7, 12, 178, 47, 50, 897, 900, "met" +506, 7, 13, 179, 51, 60, 901, 910, "inclusion" +506, 7, 14, 180, 61, 69, 911, 919, "criteria" +506, 7, 15, 181, 70, 73, 920, 923, "was" +506, 7, 16, 182, 74, 82, 924, 932, "included" +506, 7, 17, 183, 83, 85, 933, 935, "in" +506, 7, 18, 184, 86, 90, 936, 940, "this" +506, 7, 19, 185, 91, 102, 941, 952, "prospective" +506, 7, 20, 186, 103, 104, 953, 954, "," +506, 7, 21, 187, 105, 113, 955, 963, "observer" +506, 7, 22, 188, 114, 115, 964, 965, "-" +506, 7, 23, 189, 116, 122, 966, 972, "masked" +506, 7, 24, 190, 123, 124, 973, 974, "," +506, 7, 25, 191, 125, 134, 975, 984, "crossover" +506, 7, 26, 192, 135, 136, 985, 986, "," +506, 7, 27, 193, 137, 147, 987, 997, "comparison" +506, 7, 28, 194, 148, 156, 998, 1006, "protocol" +506, 7, 29, 195, 157, 158, 1007, 1008, "." +506, 8, 1, 196, 0, 3, 1009, 1012, "All" +506, 8, 2, 197, 4, 12, 1013, 1021, "subjects" +506, 8, 3, 198, 13, 22, 1022, 1031, "underwent" +506, 8, 4, 199, 23, 24, 1032, 1033, "a" +506, 8, 5, 200, 25, 27, 1034, 1036, "24" +506, 8, 6, 201, 28, 29, 1037, 1038, "-" +506, 8, 7, 202, 30, 31, 1039, 1040, "h" +506, 8, 8, 203, 32, 41, 1041, 1050, "untreated" +506, 8, 9, 204, 42, 47, 1051, 1056, "curve" +506, 8, 10, 205, 48, 51, 1057, 1060, "and" +506, 8, 11, 206, 52, 56, 1061, 1065, "were" +506, 8, 12, 207, 57, 61, 1066, 1070, "then" +506, 8, 13, 208, 62, 72, 1071, 1081, "randomised" +506, 8, 14, 209, 73, 75, 1082, 1084, "to" +506, 8, 15, 210, 76, 82, 1085, 1091, "either" +506, 8, 16, 211, 83, 90, 1092, 1099, "evening" +506, 8, 17, 212, 91, 103, 1100, 1112, "administered" +506, 8, 18, 213, 104, 108, 1113, 1117, "BTFC" +506, 8, 19, 214, 109, 111, 1118, 1120, "or" +506, 8, 20, 215, 112, 123, 1121, 1132, "latanoprost" +506, 8, 21, 216, 124, 127, 1133, 1136, "for" +506, 8, 22, 217, 128, 129, 1137, 1138, "3" +506, 8, 23, 218, 130, 136, 1139, 1145, "months" +506, 8, 24, 219, 137, 140, 1146, 1149, "and" +506, 8, 25, 220, 141, 145, 1150, 1154, "then" +506, 8, 26, 221, 146, 154, 1155, 1163, "switched" +506, 8, 27, 222, 155, 157, 1164, 1166, "to" +506, 8, 28, 223, 158, 161, 1167, 1170, "the" +506, 8, 29, 224, 162, 170, 1171, 1179, "opposite" +506, 8, 30, 225, 171, 178, 1180, 1187, "therapy" +506, 8, 31, 226, 179, 180, 1188, 1189, "." +506, 9, 1, 227, 0, 2, 1190, 1192, "At" +506, 9, 2, 228, 3, 6, 1193, 1196, "the" +506, 9, 3, 229, 7, 10, 1197, 1200, "end" +506, 9, 4, 230, 11, 13, 1201, 1203, "of" +506, 9, 5, 231, 14, 18, 1204, 1208, "each" +506, 9, 6, 232, 19, 28, 1209, 1218, "treatment" +506, 9, 7, 233, 29, 35, 1219, 1225, "period" +506, 9, 8, 234, 36, 37, 1226, 1227, "," +506, 9, 9, 235, 38, 46, 1228, 1236, "patients" +506, 9, 10, 236, 47, 56, 1237, 1246, "underwent" +506, 9, 11, 237, 57, 58, 1247, 1248, "a" +506, 9, 12, 238, 59, 66, 1249, 1256, "treated" +506, 9, 13, 239, 67, 69, 1257, 1259, "24" +506, 9, 14, 240, 70, 71, 1260, 1261, "-" +506, 9, 15, 241, 72, 73, 1262, 1263, "h" +506, 9, 16, 242, 74, 77, 1264, 1267, "IOP" +506, 9, 17, 243, 78, 88, 1268, 1278, "assessment" +506, 9, 18, 244, 89, 90, 1279, 1280, "." +506, 10, 1, 245, 0, 7, 1281, 1288, "RESULTS" +506, 10, 2, 246, 8, 9, 1289, 1290, ":" +506, 10, 3, 247, 10, 12, 1291, 1293, "37" +506, 10, 4, 248, 13, 21, 1294, 1302, "patients" +506, 10, 5, 249, 22, 31, 1303, 1312, "completed" +506, 10, 6, 250, 32, 35, 1313, 1316, "the" +506, 10, 7, 251, 36, 41, 1317, 1322, "trial" +506, 10, 8, 252, 42, 43, 1323, 1324, "." +506, 11, 1, 253, 0, 2, 1325, 1327, "At" +506, 11, 2, 254, 3, 11, 1328, 1336, "baseline" +506, 11, 3, 255, 12, 13, 1337, 1338, "," +506, 11, 4, 256, 14, 18, 1339, 1343, "mean" +506, 11, 5, 257, 19, 28, 1344, 1353, "untreated" +506, 11, 6, 258, 29, 31, 1354, 1356, "24" +506, 11, 7, 259, 32, 33, 1357, 1358, "-" +506, 11, 8, 260, 34, 35, 1359, 1360, "h" +506, 11, 9, 261, 36, 39, 1361, 1364, "IOP" +506, 11, 10, 262, 40, 43, 1365, 1368, "was" +506, 11, 11, 263, 44, 46, 1369, 1371, "31" +506, 11, 12, 264, 47, 48, 1372, 1373, "." +506, 11, 13, 265, 49, 50, 1374, 1375, "1" +506, 11, 14, 266, 51, 53, 1376, 1378, "mm" +506, 11, 15, 267, 54, 56, 1379, 1381, "Hg" +506, 11, 16, 268, 57, 58, 1382, 1383, "." +506, 12, 1, 269, 0, 4, 1384, 1388, "Mean" +506, 12, 2, 270, 5, 7, 1389, 1391, "24" +506, 12, 3, 271, 8, 9, 1392, 1393, "-" +506, 12, 4, 272, 10, 11, 1394, 1395, "h" +506, 12, 5, 273, 12, 15, 1396, 1399, "IOP" +506, 12, 6, 274, 16, 20, 1400, 1404, "with" +506, 12, 7, 275, 21, 25, 1405, 1409, "BTFC" +506, 12, 8, 276, 26, 29, 1410, 1413, "was" +506, 12, 9, 277, 30, 43, 1414, 1427, "significantly" +506, 12, 10, 278, 44, 49, 1428, 1433, "lower" +506, 12, 11, 279, 50, 54, 1434, 1438, "than" +506, 12, 12, 280, 55, 59, 1439, 1443, "with" +506, 12, 13, 281, 60, 71, 1444, 1455, "latanoprost" +506, 12, 14, 282, 72, 73, 1456, 1457, "(" +506, 12, 15, 283, 74, 76, 1458, 1460, "18" +506, 12, 16, 284, 77, 78, 1461, 1462, "." +506, 12, 17, 285, 79, 80, 1463, 1464, "9" +506, 12, 18, 286, 81, 83, 1465, 1467, "vs" +506, 12, 19, 287, 84, 86, 1468, 1470, "21" +506, 12, 20, 288, 87, 88, 1471, 1472, "." +506, 12, 21, 289, 89, 90, 1473, 1474, "2" +506, 12, 22, 290, 91, 93, 1475, 1477, "mm" +506, 12, 23, 291, 94, 96, 1478, 1480, "Hg" +506, 12, 24, 292, 97, 98, 1481, 1482, ";" +506, 12, 25, 293, 99, 100, 1483, 1484, "p" +506, 12, 26, 294, 101, 102, 1485, 1486, "<" +506, 12, 27, 295, 103, 104, 1487, 1488, "0" +506, 12, 28, 296, 105, 106, 1489, 1490, "." +506, 12, 29, 297, 107, 110, 1491, 1494, "001" +506, 12, 30, 298, 111, 112, 1495, 1496, ")" +506, 12, 31, 299, 113, 114, 1497, 1498, "." +506, 13, 1, 300, 0, 11, 1499, 1510, "Furthermore" +506, 13, 2, 301, 12, 13, 1511, 1512, "," +506, 13, 3, 302, 14, 18, 1513, 1517, "BTFC" +506, 13, 4, 303, 19, 26, 1518, 1525, "reduced" +506, 13, 5, 304, 27, 30, 1526, 1529, "IOP" +506, 13, 6, 305, 31, 44, 1530, 1543, "significantly" +506, 13, 7, 306, 45, 49, 1544, 1548, "more" +506, 13, 8, 307, 50, 54, 1549, 1553, "than" +506, 13, 9, 308, 55, 66, 1554, 1565, "latanoprost" +506, 13, 10, 309, 67, 69, 1566, 1568, "at" +506, 13, 11, 310, 70, 75, 1569, 1574, "every" +506, 13, 12, 311, 76, 80, 1575, 1579, "time" +506, 13, 13, 312, 81, 86, 1580, 1585, "point" +506, 13, 14, 313, 87, 88, 1586, 1587, "," +506, 13, 15, 314, 89, 92, 1588, 1591, "for" +506, 13, 16, 315, 93, 96, 1592, 1595, "the" +506, 13, 17, 316, 97, 101, 1596, 1600, "mean" +506, 13, 18, 317, 102, 106, 1601, 1605, "peak" +506, 13, 19, 318, 107, 110, 1606, 1609, "and" +506, 13, 20, 319, 111, 117, 1610, 1616, "trough" +506, 13, 21, 320, 118, 120, 1617, 1619, "24" +506, 13, 22, 321, 121, 122, 1620, 1621, "-" +506, 13, 23, 322, 123, 124, 1622, 1623, "h" +506, 13, 24, 323, 125, 128, 1624, 1627, "IOP" +506, 13, 25, 324, 129, 130, 1628, 1629, "(" +506, 13, 26, 325, 131, 132, 1630, 1631, "p" +506, 13, 27, 326, 133, 134, 1632, 1633, "<" +506, 13, 28, 327, 135, 136, 1634, 1635, "0" +506, 13, 29, 328, 137, 138, 1636, 1637, "." +506, 13, 30, 329, 139, 142, 1638, 1641, "001" +506, 13, 31, 330, 143, 144, 1642, 1643, ")" +506, 13, 32, 331, 145, 146, 1644, 1645, "." +506, 14, 1, 332, 0, 5, 1646, 1651, "There" +506, 14, 2, 333, 6, 9, 1652, 1655, "was" +506, 14, 3, 334, 10, 12, 1656, 1658, "no" +506, 14, 4, 335, 13, 23, 1659, 1669, "difference" +506, 14, 5, 336, 24, 25, 1670, 1671, "," +506, 14, 6, 337, 26, 33, 1672, 1679, "however" +506, 14, 7, 338, 34, 35, 1680, 1681, "," +506, 14, 8, 339, 36, 38, 1682, 1684, "in" +506, 14, 9, 340, 39, 43, 1685, 1689, "mean" +506, 14, 10, 341, 44, 46, 1690, 1692, "24" +506, 14, 11, 342, 47, 48, 1693, 1694, "-" +506, 14, 12, 343, 49, 50, 1695, 1696, "h" +506, 14, 13, 344, 51, 54, 1697, 1700, "IOP" +506, 14, 14, 345, 55, 66, 1701, 1712, "fluctuation" +506, 14, 15, 346, 67, 74, 1713, 1720, "between" +506, 14, 16, 347, 75, 78, 1721, 1724, "the" +506, 14, 17, 348, 79, 82, 1725, 1728, "two" +506, 14, 18, 349, 83, 94, 1729, 1740, "medications" +506, 14, 19, 350, 95, 96, 1741, 1742, "(" +506, 14, 20, 351, 97, 98, 1743, 1744, "3" +506, 14, 21, 352, 99, 100, 1745, 1746, "." +506, 14, 22, 353, 101, 102, 1747, 1748, "8" +506, 14, 23, 354, 103, 107, 1749, 1753, "with" +506, 14, 24, 355, 108, 112, 1754, 1758, "BTFC" +506, 14, 25, 356, 113, 115, 1759, 1761, "vs" +506, 14, 26, 357, 116, 117, 1762, 1763, "4" +506, 14, 27, 358, 118, 119, 1764, 1765, "." +506, 14, 28, 359, 120, 121, 1766, 1767, "2" +506, 14, 29, 360, 122, 126, 1768, 1772, "with" +506, 14, 30, 361, 127, 138, 1773, 1784, "latanoprost" +506, 14, 31, 362, 139, 140, 1785, 1786, ";" +506, 14, 32, 363, 141, 142, 1787, 1788, "p" +506, 14, 33, 364, 143, 144, 1789, 1790, "=" +506, 14, 34, 365, 145, 146, 1791, 1792, "0" +506, 14, 35, 366, 147, 148, 1793, 1794, "." +506, 14, 36, 367, 149, 152, 1795, 1798, "161" +506, 14, 37, 368, 153, 154, 1799, 1800, ")" +506, 14, 38, 369, 155, 156, 1801, 1802, "." +506, 15, 1, 370, 0, 4, 1803, 1807, "Both" +506, 15, 2, 371, 5, 15, 1808, 1818, "treatments" +506, 15, 3, 372, 16, 20, 1819, 1823, "were" +506, 15, 4, 373, 21, 25, 1824, 1828, "well" +506, 15, 5, 374, 26, 35, 1829, 1838, "tolerated" +506, 15, 6, 375, 36, 39, 1839, 1842, "and" +506, 15, 7, 376, 40, 45, 1843, 1848, "there" +506, 15, 8, 377, 46, 49, 1849, 1852, "was" +506, 15, 9, 378, 50, 52, 1853, 1855, "no" +506, 15, 10, 379, 53, 66, 1856, 1869, "statistically" +506, 15, 11, 380, 67, 78, 1870, 1881, "significant" +506, 15, 12, 381, 79, 89, 1882, 1892, "difference" +506, 15, 13, 382, 90, 93, 1893, 1896, "for" +506, 15, 14, 383, 94, 97, 1897, 1900, "any" +506, 15, 15, 384, 98, 105, 1901, 1908, "adverse" +506, 15, 16, 385, 106, 111, 1909, 1914, "event" +506, 15, 17, 386, 112, 119, 1915, 1922, "between" +506, 15, 18, 387, 120, 124, 1923, 1927, "them" +506, 15, 19, 388, 125, 126, 1928, 1929, "." +506, 16, 1, 389, 0, 11, 1930, 1941, "CONCLUSIONS" +506, 16, 2, 390, 12, 13, 1942, 1943, ":" +506, 16, 3, 391, 14, 16, 1944, 1946, "As" +506, 16, 4, 392, 17, 22, 1947, 1952, "first" +506, 16, 5, 393, 23, 29, 1953, 1959, "choice" +506, 16, 6, 394, 30, 37, 1960, 1967, "therapy" +506, 16, 7, 395, 38, 40, 1968, 1970, "in" +506, 16, 8, 396, 41, 45, 1971, 1975, "high" +506, 16, 9, 397, 46, 47, 1976, 1977, "-" +506, 16, 10, 398, 48, 56, 1978, 1986, "pressure" +506, 16, 11, 399, 57, 58, 1987, 1988, "," +506, 16, 12, 400, 59, 61, 1989, 1991, "at" +506, 16, 13, 401, 62, 63, 1992, 1993, "-" +506, 16, 14, 402, 64, 68, 1994, 1998, "risk" +506, 16, 15, 403, 69, 80, 1999, 2010, "exfoliation" +506, 16, 16, 404, 81, 89, 2011, 2019, "patients" +506, 16, 17, 405, 90, 91, 2020, 2021, "," +506, 16, 18, 406, 92, 96, 2022, 2026, "BTFC" +506, 16, 19, 407, 97, 107, 2027, 2037, "controlled" +506, 16, 20, 408, 108, 112, 2038, 2042, "mean" +506, 16, 21, 409, 113, 115, 2043, 2045, "24" +506, 16, 22, 410, 116, 117, 2046, 2047, "-" +506, 16, 23, 411, 118, 119, 2048, 2049, "h" +506, 16, 24, 412, 120, 123, 2050, 2053, "IOP" +506, 16, 25, 413, 124, 137, 2054, 2067, "significantly" +506, 16, 26, 414, 138, 144, 2068, 2074, "better" +506, 16, 27, 415, 145, 149, 2075, 2079, "than" +506, 16, 28, 416, 150, 161, 2080, 2091, "latanoprost" +506, 16, 29, 417, 162, 173, 2092, 2103, "monotherapy" +506, 16, 30, 418, 174, 175, 2104, 2105, "." +506, 17, 1, 419, 0, 3, 2106, 2109, "DOI" +506, 17, 2, 420, 4, 5, 2110, 2111, ":" +506, 17, 3, 421, 6, 8, 2112, 2114, "10" +506, 17, 4, 422, 9, 10, 2115, 2116, "." +506, 17, 5, 423, 11, 15, 2117, 2121, "1136" +506, 17, 6, 424, 16, 17, 2122, 2123, "/" +506, 17, 7, 425, 18, 30, 2124, 2136, "bjophthalmol" +506, 17, 8, 426, 31, 32, 2137, 2138, "-" +506, 17, 9, 427, 33, 37, 2139, 2143, "2012" +506, 17, 10, 428, 38, 39, 2144, 2145, "-" +506, 17, 11, 429, 40, 46, 2146, 2152, "302843" +506, 17, 12, 430, 47, 51, 2153, 2157, "PMID" +506, 17, 13, 431, 52, 53, 2158, 2159, ":" +506, 17, 14, 432, 54, 62, 2160, 2168, "23686322" +506, 17, 15, 433, 63, 64, 2169, 2170, "[" +506, 17, 16, 434, 65, 72, 2171, 2178, "Indexed" +506, 17, 17, 435, 73, 76, 2179, 2182, "for" +506, 17, 18, 436, 77, 84, 2183, 2190, "MEDLINE" +506, 17, 19, 437, 85, 86, 2191, 2192, "]" diff --git a/data/gl 23686322_jshahinitiran.annodb b/data/gl 23686322_jshahinitiran.annodb new file mode 100644 index 0000000..e8a3e57 --- /dev/null +++ b/data/gl 23686322_jshahinitiran.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +72668, Journal, 0, 17, "Br J Ophthalmol .", "", +72669, PublicationYear, 18, 22, "2013", "", +72670, Title, 119, 296, "24 - hour efficacy of the bimatoprost - timolol fixed combination versus latanoprost as first choice therapy in subjects with high - pressure exfoliation syndrome and glaucoma .", "", +72680, Bimatoprost, 145, 156, "bimatoprost", "", +72682, Bima/TimFC, 145, 184, "bimatoprost - timolol fixed combination", "", +72681, Timolol, 159, 166, "timolol", "", +72683, Latanoprost, 192, 203, "latanoprost", "", +72685, DisorderOrSyndrome, 245, 281, "high - pressure exfoliation syndrome", "", +72684, Glaucoma, 286, 294, "glaucoma", "", +72671, Author, 297, 307, "Konstas AG", "", +72672, Author, 316, 324, "Holl ó G", "", +72673, Author, 327, 341, "Mikropoulos DG", "", +72674, Author, 344, 354, "Haidich AB", "", +72675, Author, 357, 370, "Dimopoulos AT", "", +72676, Author, 373, 385, "Empeslidis T", "", +72677, Author, 388, 395, "Teus MA", "", +72678, Author, 398, 405, "Ritch R", "", +72679, Greece, 528, 534, "Greece", "", +72686, ObjectiveDescription, 543, 687, "To compare the 24 - h intraocular pressure ( IOP ) control obtained with the bimatoprost - timolol fixed combination ( BTFC ) versus latanoprost", "", +72688, IOP, 565, 585, "intraocular pressure", "", +72689, IOP, 588, 591, "IOP", "", +72690, Bimatoprost, 620, 631, "bimatoprost", "", +72692, Bima/TimFC, 620, 659, "bimatoprost - timolol fixed combination", "", +72691, Timolol, 634, 641, "timolol", "", +72693, Bima/TimFC, 662, 666, "BTFC", "", +72694, Latanoprost, 676, 687, "latanoprost", "", +72687, ObjectiveDescription, 688, 849, "in newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG ) patients with baseline morning IOP greater than 29 mm Hg .", "", +72695, Precondition, 691, 729, "newly diagnosed , previously untreated", "", +72696, DisorderOrSyndrome, 730, 750, "exfoliation syndrome", "", +72697, DisorderOrSyndrome, 753, 756, "XFS", "", +72698, Glaucoma, 762, 782, "exfoliative glaucoma", "", +72699, Glaucoma, 785, 788, "XFG", "", +72701, Precondition, 805, 849, "baseline morning IOP greater than 29 mm Hg .", "", +72700, IOP, 822, 825, "IOP", "", +72702, mmHg, 842, 847, "mm Hg", "", +72703, NumberPatientsCT, 871, 873, "41", "", +72704, DisorderOrSyndrome, 874, 877, "XFS", "", +72705, Glaucoma, 880, 883, "XFG", "", +72706, Prospective, 941, 952, "prospective", "", +72707, Blind, 955, 972, "observer - masked", "", +72708, Crossover, 975, 984, "crossover", "", +72709, Randomized, 1071, 1081, "randomised", "", +72710, Evening, 1092, 1099, "evening", "", +72711, Bima/TimFC, 1113, 1117, "BTFC", "", +72712, Latanoprost, 1121, 1132, "latanoprost", "", +72713, Duration, 1137, 1145, "3 months", "", +72714, IOP, 1264, 1267, "IOP", "", +72715, FinalNumPatientsCT, 1291, 1293, "37", "", +72716, Mean, 1339, 1343, "mean", "", +72717, IOP, 1361, 1364, "IOP", "", +72718, BaseLineValue, 1369, 1375, "31 . 1", "", +72719, BaseLineValue, 1376, 1381, "mm Hg", "", +72720, Mean, 1384, 1388, "Mean", "", +72721, IOP, 1396, 1399, "IOP", "", +72722, Bima/TimFC, 1405, 1409, "BTFC", "", +72723, Latanoprost, 1444, 1455, "latanoprost", "", +72724, ResultMeasuredValue, 1458, 1464, "18 . 9", "", +72725, ResultMeasuredValue, 1468, 1474, "21 . 2", "", +72726, ResultMeasuredValue, 1475, 1480, "mm Hg", "", +72727, PValueResValue, 1483, 1494, "p < 0 . 001", "", +72728, Bima/TimFC, 1513, 1517, "BTFC", "", +72729, IOP, 1526, 1529, "IOP", "", +72730, Latanoprost, 1554, 1565, "latanoprost", "", +72731, Mean, 1596, 1600, "mean", "", +72732, Peak_IOP, 1601, 1605, "peak", "", +72733, Trough_IOP, 1610, 1616, "trough", "", +72734, IOP, 1624, 1627, "IOP", "", +72735, PValueChangeValue, 1630, 1641, "p < 0 . 001", "", +72736, Mean, 1685, 1689, "mean", "", +72737, IOP, 1697, 1700, "IOP", "", +72738, Bima/TimFC, 1754, 1758, "BTFC", "", +72740, Latanoprost, 1773, 1784, "latanoprost", "", +72741, PvalueDiff, 1787, 1798, "p = 0 . 161", "", +72742, ObservedResult, 1803, 1929, "Both treatments were well tolerated and there was no statistically significant difference for any adverse event between them .", "", +72743, ConclusionComment, 1944, 2105, "As first choice therapy in high - pressure , at - risk exfoliation patients , BTFC controlled mean 24 - h IOP significantly better than latanoprost monotherapy .", "", +72744, Bima/TimFC, 2022, 2026, "BTFC", "", +72745, Mean, 2038, 2042, "mean", "", +72746, IOP, 2050, 2053, "IOP", "", +72747, Latanoprost, 2080, 2091, "latanoprost", "", +72748, PMID, 2160, 2168, "23686322", "", diff --git a/data/gl 23686322_jshahinitiran.n-triples b/data/gl 23686322_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23686322_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23686322_tstrakeljahn.annodb b/data/gl 23686322_tstrakeljahn.annodb new file mode 100644 index 0000000..19c3c0c --- /dev/null +++ b/data/gl 23686322_tstrakeljahn.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84097, Journal, 0, 15, "Br J Ophthalmol", "", +84098, PublicationYear, 18, 22, "2013", "", +84105, Title, 119, 296, "24 - hour efficacy of the bimatoprost - timolol fixed combination versus latanoprost as first choice therapy in subjects with high - pressure exfoliation syndrome and glaucoma .", "", +84099, Bimatoprost, 145, 156, "bimatoprost", "", +84101, Bima/TimFC, 145, 166, "bimatoprost - timolol", "", +84100, Timolol, 159, 166, "timolol", "", +84102, Latanoprost, 192, 203, "latanoprost", "", +84104, Precondition, 231, 294, "subjects with high - pressure exfoliation syndrome and glaucoma", "", +84103, Glaucoma, 286, 294, "glaucoma", "", +84106, Author, 297, 307, "Konstas AG", "", +84107, Author, 316, 324, "Holl ó G", "", +84108, Author, 327, 341, "Mikropoulos DG", "", +84109, Author, 344, 354, "Haidich AB", "", +84110, Author, 357, 370, "Dimopoulos AT", "", +84111, Author, 373, 385, "Empeslidis T", "", +84112, Author, 388, 395, "Teus MA", "", +84113, Author, 398, 405, "Ritch R", "", +84114, Greece, 528, 534, "Greece", "", +84137, ObjectiveDescription, 543, 790, "To compare the 24 - h intraocular pressure ( IOP ) control obtained with the bimatoprost - timolol fixed combination ( BTFC ) versus latanoprost in newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG )", "", +84161, Diurnal_IOP, 558, 585, "24 - h intraocular pressure", "", +84116, IOP, 588, 591, "IOP", "", +84117, Bimatoprost, 620, 631, "bimatoprost", "", +84119, Brimo/TimFC, 620, 641, "bimatoprost - timolol", "", +84118, Timolol, 634, 641, "timolol", "", +84120, Brimo/TimFC, 662, 666, "BTFC", "", +84121, Latanoprost, 676, 687, "latanoprost", "", +84126, Precondition, 691, 847, "newly diagnosed , previously untreated exfoliation syndrome ( XFS ) or exfoliative glaucoma ( XFG ) patients with baseline morning IOP greater than 29 mm Hg", "", +84122, Glaucoma, 774, 782, "glaucoma", "", +84138, ObjectiveDescription, 791, 849, "patients with baseline morning IOP greater than 29 mm Hg .", "", +84123, Morning, 814, 821, "morning", "", +84124, IOP, 822, 825, "IOP", "", +84125, mmHg, 842, 847, "mm Hg", "", +84127, NumberPatientsCT, 871, 873, "41", "", +84128, Prospective, 941, 952, "prospective", "", +84129, Blind, 955, 972, "observer - masked", "", +84130, Crossover, 975, 984, "crossover", "", +84131, Randomized, 1071, 1081, "randomised", "", +84132, Evening, 1092, 1099, "evening", "", +84133, Brimo/TimFC, 1113, 1117, "BTFC", "", +84134, Latanoprost, 1121, 1132, "latanoprost", "", +84135, Duration, 1137, 1145, "3 months", "", +84162, Diurnal_IOP, 1257, 1267, "24 - h IOP", "", +84139, FinalNumPatientsCT, 1291, 1293, "37", "", +84140, Mean, 1339, 1343, "mean", "", +84163, Diurnal_IOP, 1354, 1364, "24 - h IOP", "", +84142, BaseLineValue, 1369, 1375, "31 . 1", "", +84143, mmHg, 1376, 1381, "mm Hg", "", +84144, Mean, 1384, 1388, "Mean", "", +84164, Diurnal_IOP, 1389, 1399, "24 - h IOP", "", +84146, Brimo/TimFC, 1405, 1409, "BTFC", "", +84147, Latanoprost, 1444, 1455, "latanoprost", "", +84148, ResultMeasuredValue, 1458, 1464, "18 . 9", "", +84149, ResultMeasuredValue, 1468, 1474, "21 . 2", "", +84150, mmHg, 1475, 1480, "mm Hg", "", +84151, PvalueDiff, 1485, 1494, "< 0 . 001", "", +84152, Brimo/TimFC, 1513, 1517, "BTFC", "", +84153, IOP, 1526, 1529, "IOP", "", +84154, Latanoprost, 1554, 1565, "latanoprost", "", +84155, Mean, 1596, 1600, "mean", "", +84157, Peak_IOP, 1601, 1627, "peak and trough 24 - h IOP", "", +84156, Trough_IOP, 1610, 1627, "trough 24 - h IOP", "", +84165, Diurnal_IOP, 1617, 1627, "24 - h IOP", "", +84158, PvalueDiff, 1632, 1641, "< 0 . 001", "", +84159, Mean, 1685, 1689, "mean", "", +84166, Diurnal_IOP, 1690, 1700, "24 - h IOP", "", +84169, Brimo/TimFC, 1754, 1758, "BTFC", "", +84168, Latanoprost, 1773, 1784, "latanoprost", "", +84167, PvalueDiff, 1789, 1798, "= 0 . 161", "", +84170, ObservedResult, 1803, 1929, "Both treatments were well tolerated and there was no statistically significant difference for any adverse event between them .", "", +84175, ConclusionComment, 1944, 2105, "As first choice therapy in high - pressure , at - risk exfoliation patients , BTFC controlled mean 24 - h IOP significantly better than latanoprost monotherapy .", "", +84171, Brimo/TimFC, 2022, 2026, "BTFC", "", +84172, Mean, 2038, 2042, "mean", "", +84173, Diurnal_IOP, 2043, 2053, "24 - h IOP", "", +84174, Latanoprost, 2080, 2091, "latanoprost", "", +84176, PMID, 2160, 2168, "23686322", "", diff --git a/data/gl 23686322_tstrakeljahn.n-triples b/data/gl 23686322_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23686322_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23807349_admin.annodb b/data/gl 23807349_admin.annodb new file mode 100644 index 0000000..4a12c52 --- /dev/null +++ b/data/gl 23807349_admin.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2015", "", " \"2015\"." +197, Title, 88, 239, "Comparison of dorzolamide / timolol versus brimonidine / timolol fixed combination therapy in the management of steroid - induced ocular hypertension .", "", " \"Comparison of dorzolamide / timolol versus brimonidine / timolol fixed combination therapy in the management of steroid - induced ocular hypertension .\"." +38443, Dorz/TimFC, 102, 123, "dorzolamide / timolol", "", +2, Dorzolamide, 102, 113, "dorzolamide", "", +4, Timolol, 116, 123, "timolol", "", +38454, Brimo/TimFC, 131, 152, "brimonidine / timolol", "", +10, Brimonidine, 131, 142, "brimonidine", "", +5, Timolol, 145, 152, "timolol", "", +11, OcularHypertension, 218, 237, "ocular hypertension", "", " ." +13, Author, 240, 254, "Seymeno ğ lu G", "", " \"Seymeno ğ lu G\"." +14, Author, 263, 271, "Baser EF", "", " \"Baser EF\"." +15, Author, 274, 285, "Ö zt ü rk B", "", " \"Ö zt ü rk B\"." +16, Author, 288, 298, "G ü lhan C", "", " \"G ü lhan C\"." +12, Turkey, 532, 538, "Turkey", "", +118, ObjectiveDescription, 551, 787, "To compare the efficacy of fixed combinations of dorzolamide - timolol ( FCDT ) and brimonidine - timolol ( FCBT ) in patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections .", "", " \"To compare the efficacy of fixed combinations of dorzolamide - timolol ( FCDT ) and brimonidine - timolol ( FCBT ) in patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections .\"." +38444, Dorz/TimFC, 600, 621, "dorzolamide - timolol", "", +3, Dorzolamide, 600, 611, "dorzolamide", "", +6, Timolol, 614, 621, "timolol", "", +38445, Dorz/TimFC, 624, 628, "FCDT", "", +9, Brimonidine, 635, 646, "brimonidine", "", +7, Timolol, 649, 656, "timolol", "", +38455, Brimo/TimFC, 659, 663, "FCBT", "", +20, Precondition, 669, 785, "patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections", "", " \"patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections\"." +18, IOP, 683, 703, "intraocular pressure", "", +19, IOP, 706, 709, "IOP", "", +128, CTDesign, 823, 834, "prospective", "", " . ." +22, Randomized, 837, 847, "randomized", "", " ." +130, OpenLabel, 850, 862, "open - label", "", " ." +133, Precondition, 871, 946, "Patients who received IVTA injections due to diffuse diabetic macular edema", "", " \"Patients who received IVTA injections due to diffuse diabetic macular edema\"." +134, Precondition, 951, 1008, "who had an IOP of 24 mm Hg or higher after IVTA treatment", "", " \"who had an IOP of 24 mm Hg or higher after IVTA treatment\"." +25, IOP, 962, 965, "IOP", "", +132, mmHg, 972, 977, "mm Hg", "", +27, Randomized, 1035, 1045, "randomized", "", +38456, Brimo/TimFC, 1064, 1068, "FCBT", "", " ." +38446, Dorz/TimFC, 1072, 1076, "FCDT", "", " ." +30, Frequency, 1077, 1088, "twice daily", "", " \"twice daily\". \"twice daily\"." +25806, TimePoint, 1128, 1134, "week 4", "", +25808, TimePoint, 1139, 1147, "12 weeks", "", +31, IOP, 1214, 1217, "IOP", "", +25773, MeasurementDevice, 1236, 1266, "Goldmann applanation tonometry", "", +32, Mean, 1301, 1305, "mean", "", +33, IOP, 1306, 1309, "IOP", "", +35, Mean, 1351, 1355, "mean", "", +34, IOP, 1356, 1359, "IOP", "", +25807, TimePoint, 1363, 1377, "4 and 12 weeks", "", +37026, TimePoint, 1369, 1377, "12 weeks", "", +68, NumberPatientsCT, 1425, 1430, "Sixty", "", " \"Sixty\"." +67, Randomized, 1445, 1455, "randomized", "", +66, AllocationRatio, 1459, 1464, "1 : 1", "", " . ." +38457, Brimo/TimFC, 1477, 1481, "FCBT", "", +38465, Dorz/TimFC, 1486, 1490, "FCDT", "", +39, IOP, 1552, 1555, "IOP", "", +25776, PValueBL, 1558, 1568, "P > 0 . 05", "", +147, Mean, 1581, 1585, "Mean", "", " . ." +46, IOP, 1600, 1603, "IOP", "", " . ." +69, BaseLineValue, 1608, 1615, "31 . 95", "", " \"31 . 95\". \"31 . 95\"." +71, SdDevBL, 1618, 1624, "7 . 39", "", " \"7 . 39\". \"7 . 39\"." +70, BaseLineValue, 1629, 1636, "29 . 83", "", " \"29 . 83\". \"29 . 83\"." +72, SdDevBL, 1639, 1645, "5 . 17", "", " \"5 . 17\". \"5 . 17\"." +73, mmHg, 1646, 1651, "mm Hg", "", " ." +38458, Brimo/TimFC, 1655, 1659, "FCBT", "", +38447, Dorz/TimFC, 1664, 1668, "FCDT", "", +154, PValueBL, 1693, 1704, "P = 0 . 239", "", " \"P = 0 . 239\". \"P = 0 . 239\". \"P = 0 . 239\". \"P = 0 . 239\"." +74, TimePoint, 1715, 1722, "4 weeks", "", " \"4 weeks\". \"4 weeks\"." +156, Mean, 1725, 1729, "mean", "", +47, IOP, 1730, 1733, "IOP", "", +76, ResultMeasuredValue, 1738, 1745, "17 . 05", "", " \"17 . 05\"." +80, SdDevResValue, 1748, 1754, "3 . 61", "", " \"3 . 61\"." +101, mmHg, 1755, 1760, "mm Hg", "", +38459, Brimo/TimFC, 1764, 1768, "FCBT", "", +77, ResultMeasuredValue, 1773, 1780, "18 . 93", "", " \"18 . 93\"." +81, SdDevResValue, 1783, 1789, "3 . 30", "", " \"3 . 30\"." +102, mmHg, 1790, 1795, "mm Hg", "", +38448, Dorz/TimFC, 1799, 1803, "FCDT", "", +41, PvalueDiff, 1813, 1824, "P = 0 . 063", "", +75, TimePoint, 1835, 1843, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +166, Mean, 1846, 1850, "mean", "", +48, IOP, 1851, 1854, "IOP", "", +38460, Brimo/TimFC, 1862, 1866, "FCBT", "", +38449, Dorz/TimFC, 1871, 1875, "FCDT", "", +78, ResultMeasuredValue, 1893, 1900, "16 . 35", "", " \"16 . 35\"." +82, SdDevResValue, 1903, 1909, "2 . 70", "", " \"2 . 70\"." +79, ResultMeasuredValue, 1914, 1921, "18 . 43", "", " \"18 . 43\"." +83, SdDevResValue, 1924, 1930, "2 . 82", "", " \"2 . 82\"." +100, mmHg, 1931, 1936, "mm Hg", "", +42, PvalueDiff, 1954, 1965, "P = 0 . 012", "", +53, IOP, 2016, 2019, "IOP", "", +43, PvalueDiff, 2066, 2076, "P < 0 . 05", "", +87, Mean, 2081, 2085, "Mean", "", +49, IOP, 2099, 2102, "IOP", "", +84, TimePoint, 2109, 2116, "4 weeks", "", +86, Reduction, 2122, 2129, "14 . 90", "", " \"14 . 90\"." +88, SdDevChangeValue, 2132, 2138, "7 . 28", "", " \"7 . 28\"." +97, mmHg, 2139, 2144, "mm Hg", "", +38461, Brimo/TimFC, 2148, 2152, "FCBT", "", +96, Reduction, 2157, 2164, "10 . 90", "", " \"10 . 90\"." +89, SdDevChangeValue, 2167, 2173, "4 . 83", "", " \"4 . 83\"." +98, mmHg, 2174, 2179, "mm Hg", "", +38450, Dorz/TimFC, 2183, 2187, "FCDT", "", +44, PvalueDiff, 2197, 2208, "P = 0 . 024", "", " \"P = 0 . 024\"." +85, TimePoint, 2219, 2227, "12 weeks", "", +94, Reduction, 2248, 2255, "15 . 60", "", " \"15 . 60\"." +90, SdDevChangeValue, 2258, 2264, "7 . 77", "", " \"7 . 77\"." +95, Reduction, 2269, 2276, "11 . 40", "", " \"11 . 40\"." +91, SdDevChangeValue, 2279, 2285, "5 . 89", "", " \"5 . 89\"." +99, mmHg, 2286, 2291, "mm Hg", "", +38462, Brimo/TimFC, 2295, 2299, "FCBT", "", +38451, Dorz/TimFC, 2304, 2308, "FCDT", "", +45, PvalueDiff, 2333, 2344, "P = 0 . 035", "", " \"P = 0 . 035\"." +191, ConclusionComment, 2363, 2449, "Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections .", "", " \"Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections .\"." +38463, Brimo/TimFC, 2368, 2372, "FCBT", "", +38452, Dorz/TimFC, 2377, 2381, "FCDT", "", +51, IOP, 2411, 2414, "IOP", "", +192, ConclusionComment, 2450, 2585, "The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections .", "", " \"The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections .\"." +38464, Brimo/TimFC, 2489, 2493, "FCBT", "", +38453, Dorz/TimFC, 2509, 2513, "FCDT", "", +50, IOP, 2526, 2529, "IOP", "", +52, IOP, 2550, 2553, "IOP", "", +103, PMID, 2634, 2642, "23807349", "", " \"23807349\"." diff --git a/data/gl 23807349_admin.n-triples b/data/gl 23807349_admin.n-triples new file mode 100644 index 0000000..6b6969c --- /dev/null +++ b/data/gl 23807349_admin.n-triples @@ -0,0 +1,143 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of dorzolamide / timolol versus brimonidine / timolol fixed combination therapy in the management of steroid - induced ocular hypertension ." . + "Seymeno ğ lu G" . + "2015" . + "J Glaucoma" . + "23807349" . + . + "Baser EF" . + "Ö zt ü rk B" . + "G ü lhan C" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy of fixed combinations of dorzolamide - timolol ( FCDT ) and brimonidine - timolol ( FCBT ) in patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections ." . + "Sixty" . + . + . + . + . + . + "Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections ." . + . + . + . + . + . + . + . + "The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections ." . + . + . +# RDF export of group: Population + . + "Population" . + "patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections" . + . + . + . + "Patients who received IVTA injections due to diffuse diabetic macular edema" . + "who had an IOP of 24 mm Hg or higher after IVTA treatment" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_FCBT" . + . + . + . + . + . + "Arm_FCDT" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_FCBT" . + . + "twice daily" . + . + . + "Intervention_FCDT" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_FCBT" . + . + . + . + . + "Medication_FCDT" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_FCBT_4" . + . + "31 . 95" . + "P = 0 . 239" . + "7 . 39" . + "17 . 05" . + "3 . 61" . + "14 . 90" . + "7 . 28" . + "4 weeks" . + . + "Outcome_FCBT_12" . + . + "31 . 95" . + "P = 0 . 239" . + "7 . 39" . + "16 . 35" . + "2 . 70" . + "15 . 60" . + "7 . 77" . + "12 weeks" . + . + "Outcome_FCDT_4" . + . + "29 . 83" . + "P = 0 . 239" . + "5 . 17" . + "18 . 93" . + "3 . 30" . + "10 . 90" . + "4 . 83" . + "4 weeks" . + . + "Outcome_FCDT_12" . + . + "29 . 83" . + "P = 0 . 239" . + "5 . 17" . + "18 . 43" . + "2 . 82" . + "11 . 40" . + "5 . 89" . + "12 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_4" . + "P = 0 . 024" . + . + . + . + "DiffBetweenGroups_12" . + "P = 0 . 035" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23807349_export.csv b/data/gl 23807349_export.csv new file mode 100644 index 0000000..9a78622 --- /dev/null +++ b/data/gl 23807349_export.csv @@ -0,0 +1,577 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +418, 1, 1, 1, 0, 1, 0, 1, "J" +418, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +418, 1, 3, 3, 11, 12, 11, 12, "." +418, 2, 1, 4, 0, 4, 13, 17, "2015" +418, 2, 2, 5, 5, 8, 18, 21, "Feb" +418, 2, 3, 6, 9, 10, 22, 23, ";" +418, 2, 4, 7, 11, 13, 24, 26, "24" +418, 2, 5, 8, 14, 15, 27, 28, "(" +418, 2, 6, 9, 16, 17, 29, 30, "2" +418, 2, 7, 10, 18, 19, 31, 32, ")" +418, 2, 8, 11, 20, 21, 33, 34, ":" +418, 2, 9, 12, 22, 25, 35, 38, "111" +418, 2, 10, 13, 26, 27, 39, 40, "-" +418, 2, 11, 14, 28, 29, 41, 42, "6" +418, 2, 12, 15, 30, 31, 43, 44, "." +418, 2, 13, 16, 32, 35, 45, 48, "doi" +418, 2, 14, 17, 36, 37, 49, 50, ":" +418, 2, 15, 18, 38, 40, 51, 53, "10" +418, 2, 16, 19, 41, 42, 54, 55, "." +418, 2, 17, 20, 43, 47, 56, 60, "1097" +418, 2, 18, 21, 48, 49, 61, 62, "/" +418, 2, 19, 22, 50, 53, 63, 66, "IJG" +418, 2, 20, 23, 54, 55, 67, 68, "." +418, 2, 21, 24, 56, 72, 69, 85, "0b013e31829d9b5c" +418, 2, 22, 25, 73, 74, 86, 87, "." +418, 3, 1, 26, 0, 10, 88, 98, "Comparison" +418, 3, 2, 27, 11, 13, 99, 101, "of" +418, 3, 3, 28, 14, 25, 102, 113, "dorzolamide" +418, 3, 4, 29, 26, 27, 114, 115, "/" +418, 3, 5, 30, 28, 35, 116, 123, "timolol" +418, 3, 6, 31, 36, 42, 124, 130, "versus" +418, 3, 7, 32, 43, 54, 131, 142, "brimonidine" +418, 3, 8, 33, 55, 56, 143, 144, "/" +418, 3, 9, 34, 57, 64, 145, 152, "timolol" +418, 3, 10, 35, 65, 70, 153, 158, "fixed" +418, 3, 11, 36, 71, 82, 159, 170, "combination" +418, 3, 12, 37, 83, 90, 171, 178, "therapy" +418, 3, 13, 38, 91, 93, 179, 181, "in" +418, 3, 14, 39, 94, 97, 182, 185, "the" +418, 3, 15, 40, 98, 108, 186, 196, "management" +418, 3, 16, 41, 109, 111, 197, 199, "of" +418, 3, 17, 42, 112, 119, 200, 207, "steroid" +418, 3, 18, 43, 120, 121, 208, 209, "-" +418, 3, 19, 44, 122, 129, 210, 217, "induced" +418, 3, 20, 45, 130, 136, 218, 224, "ocular" +418, 3, 21, 46, 137, 149, 225, 237, "hypertension" +418, 3, 22, 47, 150, 151, 238, 239, "." +418, 4, 1, 48, 0, 7, 240, 247, "Seymeno" +418, 4, 2, 49, 8, 9, 248, 249, "ğ" +418, 4, 3, 50, 10, 12, 250, 252, "lu" +418, 4, 4, 51, 13, 14, 253, 254, "G" +418, 4, 5, 52, 15, 16, 255, 256, "(" +418, 4, 6, 53, 17, 18, 257, 258, "1" +418, 4, 7, 54, 19, 20, 259, 260, ")" +418, 4, 8, 55, 21, 22, 261, 262, "," +418, 4, 9, 56, 23, 28, 263, 268, "Baser" +418, 4, 10, 57, 29, 31, 269, 271, "EF" +418, 4, 11, 58, 32, 33, 272, 273, "," +418, 4, 12, 59, 34, 35, 274, 275, "Ö" +418, 4, 13, 60, 36, 38, 276, 278, "zt" +418, 4, 14, 61, 39, 40, 279, 280, "ü" +418, 4, 15, 62, 41, 43, 281, 283, "rk" +418, 4, 16, 63, 44, 45, 284, 285, "B" +418, 4, 17, 64, 46, 47, 286, 287, "," +418, 4, 18, 65, 48, 49, 288, 289, "G" +418, 4, 19, 66, 50, 51, 290, 291, "ü" +418, 4, 20, 67, 52, 56, 292, 296, "lhan" +418, 4, 21, 68, 57, 58, 297, 298, "C" +418, 4, 22, 69, 59, 60, 299, 300, "." +418, 4, 23, 70, 61, 67, 301, 307, "Author" +418, 4, 24, 71, 68, 79, 308, 319, "information" +418, 4, 25, 72, 80, 81, 320, 321, ":" +418, 4, 26, 73, 82, 83, 322, 323, "(" +418, 4, 27, 74, 84, 85, 324, 325, "1" +418, 4, 28, 75, 86, 87, 326, 327, ")" +418, 4, 29, 76, 88, 89, 328, 329, "*" +418, 4, 30, 77, 90, 100, 330, 340, "Department" +418, 4, 31, 78, 101, 103, 341, 343, "of" +418, 4, 32, 79, 104, 117, 344, 357, "Ophthalmology" +418, 4, 33, 80, 118, 119, 358, 359, "," +418, 4, 34, 81, 120, 127, 360, 367, "Medical" +418, 4, 35, 82, 128, 135, 368, 375, "Faculty" +418, 4, 36, 83, 136, 137, 376, 377, "," +418, 4, 37, 84, 138, 143, 378, 383, "Celal" +418, 4, 38, 85, 144, 149, 384, 389, "Bayar" +418, 4, 39, 86, 150, 160, 390, 400, "University" +418, 4, 40, 87, 161, 162, 401, 402, "†" +418, 4, 41, 88, 163, 170, 403, 410, "Akhisar" +418, 4, 42, 89, 171, 176, 411, 416, "State" +418, 4, 43, 90, 177, 185, 417, 425, "Hospital" +418, 4, 44, 91, 186, 187, 426, 427, "," +418, 4, 45, 92, 188, 198, 428, 438, "Department" +418, 4, 46, 93, 199, 201, 439, 441, "of" +418, 4, 47, 94, 202, 215, 442, 455, "Ophthalmology" +418, 4, 48, 95, 216, 217, 456, 457, "," +418, 4, 49, 96, 218, 224, 458, 464, "Manisa" +418, 4, 50, 97, 225, 226, 465, 466, "‡" +418, 4, 51, 98, 227, 234, 467, 474, "Horasan" +418, 4, 52, 99, 235, 240, 475, 480, "State" +418, 4, 53, 100, 241, 249, 481, 489, "Hospital" +418, 4, 54, 101, 250, 251, 490, 491, "," +418, 4, 55, 102, 252, 262, 492, 502, "Department" +418, 4, 56, 103, 263, 265, 503, 505, "of" +418, 4, 57, 104, 266, 279, 506, 519, "Ophthalmology" +418, 4, 58, 105, 280, 281, 520, 521, "," +418, 4, 59, 106, 282, 289, 522, 529, "Erzurum" +418, 4, 60, 107, 290, 291, 530, 531, "," +418, 4, 61, 108, 292, 298, 532, 538, "Turkey" +418, 4, 62, 109, 299, 300, 539, 540, "." +418, 5, 1, 110, 0, 7, 541, 548, "PURPOSE" +418, 5, 2, 111, 8, 9, 549, 550, ":" +418, 5, 3, 112, 10, 12, 551, 553, "To" +418, 5, 4, 113, 13, 20, 554, 561, "compare" +418, 5, 5, 114, 21, 24, 562, 565, "the" +418, 5, 6, 115, 25, 33, 566, 574, "efficacy" +418, 5, 7, 116, 34, 36, 575, 577, "of" +418, 5, 8, 117, 37, 42, 578, 583, "fixed" +418, 5, 9, 118, 43, 55, 584, 596, "combinations" +418, 5, 10, 119, 56, 58, 597, 599, "of" +418, 5, 11, 120, 59, 70, 600, 611, "dorzolamide" +418, 5, 12, 121, 71, 72, 612, 613, "-" +418, 5, 13, 122, 73, 80, 614, 621, "timolol" +418, 5, 14, 123, 81, 82, 622, 623, "(" +418, 5, 15, 124, 83, 87, 624, 628, "FCDT" +418, 5, 16, 125, 88, 89, 629, 630, ")" +418, 5, 17, 126, 90, 93, 631, 634, "and" +418, 5, 18, 127, 94, 105, 635, 646, "brimonidine" +418, 5, 19, 128, 106, 107, 647, 648, "-" +418, 5, 20, 129, 108, 115, 649, 656, "timolol" +418, 5, 21, 130, 116, 117, 657, 658, "(" +418, 5, 22, 131, 118, 122, 659, 663, "FCBT" +418, 5, 23, 132, 123, 124, 664, 665, ")" +418, 5, 24, 133, 125, 127, 666, 668, "in" +418, 5, 25, 134, 128, 136, 669, 677, "patients" +418, 5, 26, 135, 137, 141, 678, 682, "with" +418, 5, 27, 136, 142, 153, 683, 694, "intraocular" +418, 5, 28, 137, 154, 162, 695, 703, "pressure" +418, 5, 29, 138, 163, 164, 704, 705, "(" +418, 5, 30, 139, 165, 168, 706, 709, "IOP" +418, 5, 31, 140, 169, 170, 710, 711, ")" +418, 5, 32, 141, 171, 181, 712, 722, "elevations" +418, 5, 33, 142, 182, 187, 723, 728, "after" +418, 5, 34, 143, 188, 200, 729, 741, "intravitreal" +418, 5, 35, 144, 201, 214, 742, 755, "triamcinolone" +418, 5, 36, 145, 215, 224, 756, 765, "acetonide" +418, 5, 37, 146, 225, 226, 766, 767, "(" +418, 5, 38, 147, 227, 231, 768, 772, "IVTA" +418, 5, 39, 148, 232, 233, 773, 774, ")" +418, 5, 40, 149, 234, 244, 775, 785, "injections" +418, 5, 41, 150, 245, 246, 786, 787, "." +418, 6, 1, 151, 0, 9, 788, 797, "MATERIALS" +418, 6, 2, 152, 10, 13, 798, 801, "AND" +418, 6, 3, 153, 14, 21, 802, 809, "METHODS" +418, 6, 4, 154, 22, 23, 810, 811, ":" +418, 6, 5, 155, 24, 28, 812, 816, "This" +418, 6, 6, 156, 29, 32, 817, 820, "was" +418, 6, 7, 157, 33, 34, 821, 822, "a" +418, 6, 8, 158, 35, 46, 823, 834, "prospective" +418, 6, 9, 159, 47, 48, 835, 836, "," +418, 6, 10, 160, 49, 59, 837, 847, "randomized" +418, 6, 11, 161, 60, 61, 848, 849, "," +418, 6, 12, 162, 62, 66, 850, 854, "open" +418, 6, 13, 163, 67, 68, 855, 856, "-" +418, 6, 14, 164, 69, 74, 857, 862, "label" +418, 6, 15, 165, 75, 80, 863, 868, "study" +418, 6, 16, 166, 81, 82, 869, 870, "." +418, 7, 1, 167, 0, 8, 871, 879, "Patients" +418, 7, 2, 168, 9, 12, 880, 883, "who" +418, 7, 3, 169, 13, 21, 884, 892, "received" +418, 7, 4, 170, 22, 26, 893, 897, "IVTA" +418, 7, 5, 171, 27, 37, 898, 908, "injections" +418, 7, 6, 172, 38, 41, 909, 912, "due" +418, 7, 7, 173, 42, 44, 913, 915, "to" +418, 7, 8, 174, 45, 52, 916, 923, "diffuse" +418, 7, 9, 175, 53, 61, 924, 932, "diabetic" +418, 7, 10, 176, 62, 69, 933, 940, "macular" +418, 7, 11, 177, 70, 75, 941, 946, "edema" +418, 7, 12, 178, 76, 79, 947, 950, "and" +418, 7, 13, 179, 80, 83, 951, 954, "who" +418, 7, 14, 180, 84, 87, 955, 958, "had" +418, 7, 15, 181, 88, 90, 959, 961, "an" +418, 7, 16, 182, 91, 94, 962, 965, "IOP" +418, 7, 17, 183, 95, 97, 966, 968, "of" +418, 7, 18, 184, 98, 100, 969, 971, "24" +418, 7, 19, 185, 101, 103, 972, 974, "mm" +418, 7, 20, 186, 104, 106, 975, 977, "Hg" +418, 7, 21, 187, 107, 109, 978, 980, "or" +418, 7, 22, 188, 110, 116, 981, 987, "higher" +418, 7, 23, 189, 117, 122, 988, 993, "after" +418, 7, 24, 190, 123, 127, 994, 998, "IVTA" +418, 7, 25, 191, 128, 137, 999, 1008, "treatment" +418, 7, 26, 192, 138, 142, 1009, 1013, "were" +418, 7, 27, 193, 143, 151, 1014, 1022, "included" +418, 7, 28, 194, 152, 153, 1023, 1024, "." +418, 8, 1, 195, 0, 4, 1025, 1029, "They" +418, 8, 2, 196, 5, 9, 1030, 1034, "were" +418, 8, 3, 197, 10, 20, 1035, 1045, "randomized" +418, 8, 4, 198, 21, 23, 1046, 1048, "to" +418, 8, 5, 199, 24, 31, 1049, 1056, "receive" +418, 8, 6, 200, 32, 38, 1057, 1063, "either" +418, 8, 7, 201, 39, 43, 1064, 1068, "FCBT" +418, 8, 8, 202, 44, 46, 1069, 1071, "or" +418, 8, 9, 203, 47, 51, 1072, 1076, "FCDT" +418, 8, 10, 204, 52, 57, 1077, 1082, "twice" +418, 8, 11, 205, 58, 63, 1083, 1088, "daily" +418, 8, 12, 206, 64, 65, 1089, 1090, "." +418, 9, 1, 207, 0, 6, 1091, 1097, "Follow" +418, 9, 2, 208, 7, 8, 1098, 1099, "-" +418, 9, 3, 209, 9, 11, 1100, 1102, "up" +418, 9, 4, 210, 12, 18, 1103, 1109, "visits" +418, 9, 5, 211, 19, 23, 1110, 1114, "were" +418, 9, 6, 212, 24, 33, 1115, 1124, "scheduled" +418, 9, 7, 213, 34, 36, 1125, 1127, "on" +418, 9, 8, 214, 37, 41, 1128, 1132, "week" +418, 9, 9, 215, 42, 43, 1133, 1134, "4" +418, 9, 10, 216, 44, 47, 1135, 1138, "and" +418, 9, 11, 217, 48, 50, 1139, 1141, "12" +418, 9, 12, 218, 51, 56, 1142, 1147, "weeks" +418, 9, 13, 219, 57, 62, 1148, 1153, "after" +418, 9, 14, 220, 63, 71, 1154, 1162, "starting" +418, 9, 15, 221, 72, 75, 1163, 1166, "the" +418, 9, 16, 222, 76, 81, 1167, 1172, "study" +418, 9, 17, 223, 82, 92, 1173, 1183, "medication" +418, 9, 18, 224, 93, 94, 1184, 1185, "." +418, 10, 1, 225, 0, 2, 1186, 1188, "At" +418, 10, 2, 226, 3, 6, 1189, 1192, "all" +418, 10, 3, 227, 7, 13, 1193, 1199, "follow" +418, 10, 4, 228, 14, 15, 1200, 1201, "-" +418, 10, 5, 229, 16, 18, 1202, 1204, "up" +418, 10, 6, 230, 19, 25, 1205, 1211, "visits" +418, 10, 7, 231, 26, 27, 1212, 1213, "," +418, 10, 8, 232, 28, 31, 1214, 1217, "IOP" +418, 10, 9, 233, 32, 35, 1218, 1221, "was" +418, 10, 10, 234, 36, 44, 1222, 1230, "measured" +418, 10, 11, 235, 45, 49, 1231, 1235, "with" +418, 10, 12, 236, 50, 58, 1236, 1244, "Goldmann" +418, 10, 13, 237, 59, 70, 1245, 1256, "applanation" +418, 10, 14, 238, 71, 80, 1257, 1266, "tonometry" +418, 10, 15, 239, 81, 82, 1267, 1268, "." +418, 11, 1, 240, 0, 3, 1269, 1272, "The" +418, 11, 2, 241, 4, 11, 1273, 1280, "primary" +418, 11, 3, 242, 12, 19, 1281, 1288, "outcome" +418, 11, 4, 243, 20, 27, 1289, 1296, "measure" +418, 11, 5, 244, 28, 31, 1297, 1300, "was" +418, 11, 6, 245, 32, 36, 1301, 1305, "mean" +418, 11, 7, 246, 37, 40, 1306, 1309, "IOP" +418, 11, 8, 247, 41, 42, 1310, 1311, "," +418, 11, 9, 248, 43, 46, 1312, 1315, "the" +418, 11, 10, 249, 47, 56, 1316, 1325, "secondary" +418, 11, 11, 250, 57, 64, 1326, 1333, "outcome" +418, 11, 12, 251, 65, 68, 1334, 1337, "was" +418, 11, 13, 252, 69, 78, 1338, 1347, "reduction" +418, 11, 14, 253, 79, 81, 1348, 1350, "in" +418, 11, 15, 254, 82, 86, 1351, 1355, "mean" +418, 11, 16, 255, 87, 90, 1356, 1359, "IOP" +418, 11, 17, 256, 91, 93, 1360, 1362, "at" +418, 11, 18, 257, 94, 95, 1363, 1364, "4" +418, 11, 19, 258, 96, 99, 1365, 1368, "and" +418, 11, 20, 259, 100, 102, 1369, 1371, "12" +418, 11, 21, 260, 103, 108, 1372, 1377, "weeks" +418, 11, 22, 261, 109, 117, 1378, 1386, "compared" +418, 11, 23, 262, 118, 122, 1387, 1391, "with" +418, 11, 24, 263, 123, 136, 1392, 1405, "postinjection" +418, 11, 25, 264, 137, 143, 1406, 1412, "values" +418, 11, 26, 265, 144, 145, 1413, 1414, "." +418, 12, 1, 266, 0, 7, 1415, 1422, "RESULTS" +418, 12, 2, 267, 8, 9, 1423, 1424, ":" +418, 12, 3, 268, 10, 15, 1425, 1430, "Sixty" +418, 12, 4, 269, 16, 24, 1431, 1439, "patients" +418, 12, 5, 270, 25, 29, 1440, 1444, "were" +418, 12, 6, 271, 30, 40, 1445, 1455, "randomized" +418, 12, 7, 272, 41, 43, 1456, 1458, "in" +418, 12, 8, 273, 44, 45, 1459, 1460, "1" +418, 12, 9, 274, 46, 47, 1461, 1462, ":" +418, 12, 10, 275, 48, 49, 1463, 1464, "1" +418, 12, 11, 276, 50, 55, 1465, 1470, "ratio" +418, 12, 12, 277, 56, 57, 1471, 1472, "." +418, 13, 1, 278, 0, 3, 1473, 1476, "The" +418, 13, 2, 279, 4, 8, 1477, 1481, "FCBT" +418, 13, 3, 280, 9, 12, 1482, 1485, "and" +418, 13, 4, 281, 13, 17, 1486, 1490, "FCDT" +418, 13, 5, 282, 18, 24, 1491, 1497, "groups" +418, 13, 6, 283, 25, 29, 1498, 1502, "were" +418, 13, 7, 284, 30, 37, 1503, 1510, "similar" +418, 13, 8, 285, 38, 40, 1511, 1513, "in" +418, 13, 9, 286, 41, 46, 1514, 1519, "terms" +418, 13, 10, 287, 47, 49, 1520, 1522, "of" +418, 13, 11, 288, 50, 53, 1523, 1526, "age" +418, 13, 12, 289, 54, 55, 1527, 1528, "," +418, 13, 13, 290, 56, 59, 1529, 1532, "sex" +418, 13, 14, 291, 60, 61, 1533, 1534, "," +418, 13, 15, 292, 62, 65, 1535, 1538, "and" +418, 13, 16, 293, 66, 78, 1539, 1551, "preinjection" +418, 13, 17, 294, 79, 82, 1552, 1555, "IOP" +418, 13, 18, 295, 83, 84, 1556, 1557, "(" +418, 13, 19, 296, 85, 86, 1558, 1559, "P" +418, 13, 20, 297, 87, 88, 1560, 1561, ">" +418, 13, 21, 298, 89, 90, 1562, 1563, "0" +418, 13, 22, 299, 91, 92, 1564, 1565, "." +418, 13, 23, 300, 93, 95, 1566, 1568, "05" +418, 13, 24, 301, 96, 99, 1569, 1572, "for" +418, 13, 25, 302, 100, 103, 1573, 1576, "all" +418, 13, 26, 303, 104, 105, 1577, 1578, ")" +418, 13, 27, 304, 106, 107, 1579, 1580, "." +418, 14, 1, 305, 0, 4, 1581, 1585, "Mean" +418, 14, 2, 306, 5, 18, 1586, 1599, "postinjection" +418, 14, 3, 307, 19, 22, 1600, 1603, "IOP" +418, 14, 4, 308, 23, 26, 1604, 1607, "was" +418, 14, 5, 309, 27, 29, 1608, 1610, "31" +418, 14, 6, 310, 30, 31, 1611, 1612, "." +418, 14, 7, 311, 32, 34, 1613, 1615, "95" +418, 14, 8, 312, 35, 36, 1616, 1617, "±" +418, 14, 9, 313, 37, 38, 1618, 1619, "7" +418, 14, 10, 314, 39, 40, 1620, 1621, "." +418, 14, 11, 315, 41, 43, 1622, 1624, "39" +418, 14, 12, 316, 44, 47, 1625, 1628, "and" +418, 14, 13, 317, 48, 50, 1629, 1631, "29" +418, 14, 14, 318, 51, 52, 1632, 1633, "." +418, 14, 15, 319, 53, 55, 1634, 1636, "83" +418, 14, 16, 320, 56, 57, 1637, 1638, "±" +418, 14, 17, 321, 58, 59, 1639, 1640, "5" +418, 14, 18, 322, 60, 61, 1641, 1642, "." +418, 14, 19, 323, 62, 64, 1643, 1645, "17" +418, 14, 20, 324, 65, 67, 1646, 1648, "mm" +418, 14, 21, 325, 68, 70, 1649, 1651, "Hg" +418, 14, 22, 326, 71, 73, 1652, 1654, "in" +418, 14, 23, 327, 74, 78, 1655, 1659, "FCBT" +418, 14, 24, 328, 79, 82, 1660, 1663, "and" +418, 14, 25, 329, 83, 87, 1664, 1668, "FCDT" +418, 14, 26, 330, 88, 94, 1669, 1675, "groups" +418, 14, 27, 331, 95, 96, 1676, 1677, "," +418, 14, 28, 332, 97, 109, 1678, 1690, "respectively" +418, 14, 29, 333, 110, 111, 1691, 1692, "(" +418, 14, 30, 334, 112, 113, 1693, 1694, "P" +418, 14, 31, 335, 114, 115, 1695, 1696, "=" +418, 14, 32, 336, 116, 117, 1697, 1698, "0" +418, 14, 33, 337, 118, 119, 1699, 1700, "." +418, 14, 34, 338, 120, 123, 1701, 1704, "239" +418, 14, 35, 339, 124, 125, 1705, 1706, ")" +418, 14, 36, 340, 126, 127, 1707, 1708, "." +418, 15, 1, 341, 0, 5, 1709, 1714, "After" +418, 15, 2, 342, 6, 7, 1715, 1716, "4" +418, 15, 3, 343, 8, 13, 1717, 1722, "weeks" +418, 15, 4, 344, 14, 15, 1723, 1724, "," +418, 15, 5, 345, 16, 20, 1725, 1729, "mean" +418, 15, 6, 346, 21, 24, 1730, 1733, "IOP" +418, 15, 7, 347, 25, 28, 1734, 1737, "was" +418, 15, 8, 348, 29, 31, 1738, 1740, "17" +418, 15, 9, 349, 32, 33, 1741, 1742, "." +418, 15, 10, 350, 34, 36, 1743, 1745, "05" +418, 15, 11, 351, 37, 38, 1746, 1747, "±" +418, 15, 12, 352, 39, 40, 1748, 1749, "3" +418, 15, 13, 353, 41, 42, 1750, 1751, "." +418, 15, 14, 354, 43, 45, 1752, 1754, "61" +418, 15, 15, 355, 46, 48, 1755, 1757, "mm" +418, 15, 16, 356, 49, 51, 1758, 1760, "Hg" +418, 15, 17, 357, 52, 54, 1761, 1763, "in" +418, 15, 18, 358, 55, 59, 1764, 1768, "FCBT" +418, 15, 19, 359, 60, 63, 1769, 1772, "and" +418, 15, 20, 360, 64, 66, 1773, 1775, "18" +418, 15, 21, 361, 67, 68, 1776, 1777, "." +418, 15, 22, 362, 69, 71, 1778, 1780, "93" +418, 15, 23, 363, 72, 73, 1781, 1782, "±" +418, 15, 24, 364, 74, 75, 1783, 1784, "3" +418, 15, 25, 365, 76, 77, 1785, 1786, "." +418, 15, 26, 366, 78, 80, 1787, 1789, "30" +418, 15, 27, 367, 81, 83, 1790, 1792, "mm" +418, 15, 28, 368, 84, 86, 1793, 1795, "Hg" +418, 15, 29, 369, 87, 89, 1796, 1798, "in" +418, 15, 30, 370, 90, 94, 1799, 1803, "FCDT" +418, 15, 31, 371, 95, 101, 1804, 1810, "groups" +418, 15, 32, 372, 102, 103, 1811, 1812, "(" +418, 15, 33, 373, 104, 105, 1813, 1814, "P" +418, 15, 34, 374, 106, 107, 1815, 1816, "=" +418, 15, 35, 375, 108, 109, 1817, 1818, "0" +418, 15, 36, 376, 110, 111, 1819, 1820, "." +418, 15, 37, 377, 112, 115, 1821, 1824, "063" +418, 15, 38, 378, 116, 117, 1825, 1826, ")" +418, 15, 39, 379, 118, 119, 1827, 1828, "." +418, 16, 1, 380, 0, 5, 1829, 1834, "After" +418, 16, 2, 381, 6, 8, 1835, 1837, "12" +418, 16, 3, 382, 9, 14, 1838, 1843, "weeks" +418, 16, 4, 383, 15, 16, 1844, 1845, "," +418, 16, 5, 384, 17, 21, 1846, 1850, "mean" +418, 16, 6, 385, 22, 25, 1851, 1854, "IOP" +418, 16, 7, 386, 26, 28, 1855, 1857, "in" +418, 16, 8, 387, 29, 32, 1858, 1861, "the" +418, 16, 9, 388, 33, 37, 1862, 1866, "FCBT" +418, 16, 10, 389, 38, 41, 1867, 1870, "and" +418, 16, 11, 390, 42, 46, 1871, 1875, "FCDT" +418, 16, 12, 391, 47, 52, 1876, 1881, "study" +418, 16, 13, 392, 53, 59, 1882, 1888, "groups" +418, 16, 14, 393, 60, 63, 1889, 1892, "was" +418, 16, 15, 394, 64, 66, 1893, 1895, "16" +418, 16, 16, 395, 67, 68, 1896, 1897, "." +418, 16, 17, 396, 69, 71, 1898, 1900, "35" +418, 16, 18, 397, 72, 73, 1901, 1902, "±" +418, 16, 19, 398, 74, 75, 1903, 1904, "2" +418, 16, 20, 399, 76, 77, 1905, 1906, "." +418, 16, 21, 400, 78, 80, 1907, 1909, "70" +418, 16, 22, 401, 81, 84, 1910, 1913, "and" +418, 16, 23, 402, 85, 87, 1914, 1916, "18" +418, 16, 24, 403, 88, 89, 1917, 1918, "." +418, 16, 25, 404, 90, 92, 1919, 1921, "43" +418, 16, 26, 405, 93, 94, 1922, 1923, "±" +418, 16, 27, 406, 95, 96, 1924, 1925, "2" +418, 16, 28, 407, 97, 98, 1926, 1927, "." +418, 16, 29, 408, 99, 101, 1928, 1930, "82" +418, 16, 30, 409, 102, 104, 1931, 1933, "mm" +418, 16, 31, 410, 105, 107, 1934, 1936, "Hg" +418, 16, 32, 411, 108, 109, 1937, 1938, "," +418, 16, 33, 412, 110, 122, 1939, 1951, "respectively" +418, 16, 34, 413, 123, 124, 1952, 1953, "(" +418, 16, 35, 414, 125, 126, 1954, 1955, "P" +418, 16, 36, 415, 127, 128, 1956, 1957, "=" +418, 16, 37, 416, 129, 130, 1958, 1959, "0" +418, 16, 38, 417, 131, 132, 1960, 1961, "." +418, 16, 39, 418, 133, 136, 1962, 1965, "012" +418, 16, 40, 419, 137, 138, 1966, 1967, ")" +418, 16, 41, 420, 139, 140, 1968, 1969, "." +418, 17, 1, 421, 0, 4, 1970, 1974, "Both" +418, 17, 2, 422, 5, 10, 1975, 1980, "fixed" +418, 17, 3, 423, 11, 23, 1981, 1993, "combinations" +418, 17, 4, 424, 24, 37, 1994, 2007, "significantly" +418, 17, 5, 425, 38, 45, 2008, 2015, "reduced" +418, 17, 6, 426, 46, 49, 2016, 2019, "IOP" +418, 17, 7, 427, 50, 52, 2020, 2022, "in" +418, 17, 8, 428, 53, 63, 2023, 2033, "comparison" +418, 17, 9, 429, 64, 68, 2034, 2038, "with" +418, 17, 10, 430, 69, 72, 2039, 2042, "the" +418, 17, 11, 431, 73, 86, 2043, 2056, "postinjection" +418, 17, 12, 432, 87, 93, 2057, 2063, "values" +418, 17, 13, 433, 94, 95, 2064, 2065, "(" +418, 17, 14, 434, 96, 97, 2066, 2067, "P" +418, 17, 15, 435, 98, 99, 2068, 2069, "<" +418, 17, 16, 436, 100, 101, 2070, 2071, "0" +418, 17, 17, 437, 102, 103, 2072, 2073, "." +418, 17, 18, 438, 104, 106, 2074, 2076, "05" +418, 17, 19, 439, 107, 108, 2077, 2078, ")" +418, 17, 20, 440, 109, 110, 2079, 2080, "." +418, 18, 1, 441, 0, 4, 2081, 2085, "Mean" +418, 18, 2, 442, 5, 14, 2086, 2095, "reduction" +418, 18, 3, 443, 15, 17, 2096, 2098, "in" +418, 18, 4, 444, 18, 21, 2099, 2102, "IOP" +418, 18, 5, 445, 22, 27, 2103, 2108, "after" +418, 18, 6, 446, 28, 29, 2109, 2110, "4" +418, 18, 7, 447, 30, 35, 2111, 2116, "weeks" +418, 18, 8, 448, 36, 40, 2117, 2121, "were" +418, 18, 9, 449, 41, 43, 2122, 2124, "14" +418, 18, 10, 450, 44, 45, 2125, 2126, "." +418, 18, 11, 451, 46, 48, 2127, 2129, "90" +418, 18, 12, 452, 49, 50, 2130, 2131, "±" +418, 18, 13, 453, 51, 52, 2132, 2133, "7" +418, 18, 14, 454, 53, 54, 2134, 2135, "." +418, 18, 15, 455, 55, 57, 2136, 2138, "28" +418, 18, 16, 456, 58, 60, 2139, 2141, "mm" +418, 18, 17, 457, 61, 63, 2142, 2144, "Hg" +418, 18, 18, 458, 64, 66, 2145, 2147, "in" +418, 18, 19, 459, 67, 71, 2148, 2152, "FCBT" +418, 18, 20, 460, 72, 75, 2153, 2156, "and" +418, 18, 21, 461, 76, 78, 2157, 2159, "10" +418, 18, 22, 462, 79, 80, 2160, 2161, "." +418, 18, 23, 463, 81, 83, 2162, 2164, "90" +418, 18, 24, 464, 84, 85, 2165, 2166, "±" +418, 18, 25, 465, 86, 87, 2167, 2168, "4" +418, 18, 26, 466, 88, 89, 2169, 2170, "." +418, 18, 27, 467, 90, 92, 2171, 2173, "83" +418, 18, 28, 468, 93, 95, 2174, 2176, "mm" +418, 18, 29, 469, 96, 98, 2177, 2179, "Hg" +418, 18, 30, 470, 99, 101, 2180, 2182, "in" +418, 18, 31, 471, 102, 106, 2183, 2187, "FCDT" +418, 18, 32, 472, 107, 113, 2188, 2194, "groups" +418, 18, 33, 473, 114, 115, 2195, 2196, "(" +418, 18, 34, 474, 116, 117, 2197, 2198, "P" +418, 18, 35, 475, 118, 119, 2199, 2200, "=" +418, 18, 36, 476, 120, 121, 2201, 2202, "0" +418, 18, 37, 477, 122, 123, 2203, 2204, "." +418, 18, 38, 478, 124, 127, 2205, 2208, "024" +418, 18, 39, 479, 128, 129, 2209, 2210, ")" +418, 18, 40, 480, 130, 131, 2211, 2212, ";" +418, 18, 41, 481, 132, 137, 2213, 2218, "after" +418, 18, 42, 482, 138, 140, 2219, 2221, "12" +418, 18, 43, 483, 141, 146, 2222, 2227, "weeks" +418, 18, 44, 484, 147, 148, 2228, 2229, "," +418, 18, 45, 485, 149, 154, 2230, 2235, "these" +418, 18, 46, 486, 155, 161, 2236, 2242, "values" +418, 18, 47, 487, 162, 166, 2243, 2247, "were" +418, 18, 48, 488, 167, 169, 2248, 2250, "15" +418, 18, 49, 489, 170, 171, 2251, 2252, "." +418, 18, 50, 490, 172, 174, 2253, 2255, "60" +418, 18, 51, 491, 175, 176, 2256, 2257, "±" +418, 18, 52, 492, 177, 178, 2258, 2259, "7" +418, 18, 53, 493, 179, 180, 2260, 2261, "." +418, 18, 54, 494, 181, 183, 2262, 2264, "77" +418, 18, 55, 495, 184, 187, 2265, 2268, "and" +418, 18, 56, 496, 188, 190, 2269, 2271, "11" +418, 18, 57, 497, 191, 192, 2272, 2273, "." +418, 18, 58, 498, 193, 195, 2274, 2276, "40" +418, 18, 59, 499, 196, 197, 2277, 2278, "±" +418, 18, 60, 500, 198, 199, 2279, 2280, "5" +418, 18, 61, 501, 200, 201, 2281, 2282, "." +418, 18, 62, 502, 202, 204, 2283, 2285, "89" +418, 18, 63, 503, 205, 207, 2286, 2288, "mm" +418, 18, 64, 504, 208, 210, 2289, 2291, "Hg" +418, 18, 65, 505, 211, 213, 2292, 2294, "in" +418, 18, 66, 506, 214, 218, 2295, 2299, "FCBT" +418, 18, 67, 507, 219, 222, 2300, 2303, "and" +418, 18, 68, 508, 223, 227, 2304, 2308, "FCDT" +418, 18, 69, 509, 228, 234, 2309, 2315, "groups" +418, 18, 70, 510, 235, 236, 2316, 2317, "," +418, 18, 71, 511, 237, 249, 2318, 2330, "respectively" +418, 18, 72, 512, 250, 251, 2331, 2332, "(" +418, 18, 73, 513, 252, 253, 2333, 2334, "P" +418, 18, 74, 514, 254, 255, 2335, 2336, "=" +418, 18, 75, 515, 256, 257, 2337, 2338, "0" +418, 18, 76, 516, 258, 259, 2339, 2340, "." +418, 18, 77, 517, 260, 263, 2341, 2344, "035" +418, 18, 78, 518, 264, 265, 2345, 2346, ")" +418, 18, 79, 519, 266, 267, 2347, 2348, "." +418, 19, 1, 520, 0, 11, 2349, 2360, "CONCLUSIONS" +418, 19, 2, 521, 12, 13, 2361, 2362, ":" +418, 19, 3, 522, 14, 18, 2363, 2367, "Both" +418, 19, 4, 523, 19, 23, 2368, 2372, "FCBT" +418, 19, 5, 524, 24, 27, 2373, 2376, "and" +418, 19, 6, 525, 28, 32, 2377, 2381, "FCDT" +418, 19, 7, 526, 33, 36, 2382, 2385, "are" +418, 19, 8, 527, 37, 46, 2386, 2395, "effective" +418, 19, 9, 528, 47, 49, 2396, 2398, "in" +418, 19, 10, 529, 50, 61, 2399, 2410, "controlling" +418, 19, 11, 530, 62, 65, 2411, 2414, "IOP" +418, 19, 12, 531, 66, 76, 2415, 2425, "elevations" +418, 19, 13, 532, 77, 82, 2426, 2431, "after" +418, 19, 14, 533, 83, 87, 2432, 2436, "IVTA" +418, 19, 15, 534, 88, 98, 2437, 2447, "injections" +418, 19, 16, 535, 99, 100, 2448, 2449, "." +418, 20, 1, 536, 0, 3, 2450, 2453, "The" +418, 20, 2, 537, 4, 11, 2454, 2461, "results" +418, 20, 3, 538, 12, 14, 2462, 2464, "of" +418, 20, 4, 539, 15, 19, 2465, 2469, "this" +418, 20, 5, 540, 20, 25, 2470, 2475, "study" +418, 20, 6, 541, 26, 33, 2476, 2483, "suggest" +418, 20, 7, 542, 34, 38, 2484, 2488, "that" +418, 20, 8, 543, 39, 43, 2489, 2493, "FCBT" +418, 20, 9, 544, 44, 46, 2494, 2496, "is" +418, 20, 10, 545, 47, 55, 2497, 2505, "superior" +418, 20, 11, 546, 56, 58, 2506, 2508, "to" +418, 20, 12, 547, 59, 63, 2509, 2513, "FCDT" +418, 20, 13, 548, 64, 66, 2514, 2516, "in" +418, 20, 14, 549, 67, 75, 2517, 2525, "reducing" +418, 20, 15, 550, 76, 79, 2526, 2529, "IOP" +418, 20, 16, 551, 80, 83, 2530, 2533, "and" +418, 20, 17, 552, 84, 92, 2534, 2542, "provides" +418, 20, 18, 553, 93, 99, 2543, 2549, "better" +418, 20, 19, 554, 100, 103, 2550, 2553, "IOP" +418, 20, 20, 555, 104, 111, 2554, 2561, "control" +418, 20, 21, 556, 112, 117, 2562, 2567, "after" +418, 20, 22, 557, 118, 122, 2568, 2572, "IVTA" +418, 20, 23, 558, 123, 133, 2573, 2583, "injections" +418, 20, 24, 559, 134, 135, 2584, 2585, "." +418, 21, 1, 560, 0, 3, 2586, 2589, "DOI" +418, 21, 2, 561, 4, 5, 2590, 2591, ":" +418, 21, 3, 562, 6, 8, 2592, 2594, "10" +418, 21, 4, 563, 9, 10, 2595, 2596, "." +418, 21, 5, 564, 11, 15, 2597, 2601, "1097" +418, 21, 6, 565, 16, 17, 2602, 2603, "/" +418, 21, 7, 566, 18, 21, 2604, 2607, "IJG" +418, 21, 8, 567, 22, 23, 2608, 2609, "." +418, 21, 9, 568, 24, 40, 2610, 2626, "0b013e31829d9b5c" +418, 21, 10, 569, 41, 45, 2627, 2631, "PMID" +418, 21, 11, 570, 46, 47, 2632, 2633, ":" +418, 21, 12, 571, 48, 56, 2634, 2642, "23807349" +418, 21, 13, 572, 57, 58, 2643, 2644, "[" +418, 21, 14, 573, 59, 66, 2645, 2652, "Indexed" +418, 21, 15, 574, 67, 70, 2653, 2656, "for" +418, 21, 16, 575, 71, 78, 2657, 2664, "MEDLINE" +418, 21, 17, 576, 79, 80, 2665, 2666, "]" diff --git a/data/gl 23807349_jshahinitiran.annodb b/data/gl 23807349_jshahinitiran.annodb new file mode 100644 index 0000000..232a115 --- /dev/null +++ b/data/gl 23807349_jshahinitiran.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +16887, Journal, 0, 10, "J Glaucoma", "", +16888, PublicationYear, 13, 17, "2015", "", +17005, Title, 88, 239, "Comparison of dorzolamide / timolol versus brimonidine / timolol fixed combination therapy in the management of steroid - induced ocular hypertension .", "", +16902, Drug, 102, 123, "dorzolamide / timolol", "FCDT", +16889, Dorzolamide, 102, 113, "dorzolamide", "", +16890, Timolol, 116, 123, "timolol", "", +16906, Drug, 131, 152, "brimonidine / timolol", "FCBT", +16891, Brimonidine, 131, 142, "brimonidine", "", +16892, Timolol, 145, 152, "timolol", "", +16893, OcularHypertension, 218, 237, "ocular hypertension", "", +16894, Author, 240, 254, "Seymeno ğ lu G", "", +16895, Author, 263, 271, "Baser EF", "", +16896, Author, 274, 285, "Ö zt ü rk B", "", +16897, Author, 288, 298, "G ü lhan C", "", +16898, Turkey, 532, 538, "Turkey", "", +16899, ObjectiveDescription, 551, 787, "To compare the efficacy of fixed combinations of dorzolamide - timolol ( FCDT ) and brimonidine - timolol ( FCBT ) in patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections .", "", +16900, Dorzolamide, 600, 611, "dorzolamide", "", +16902, Drug, 600, 621, "dorzolamide - timolol", "FCDT", +16901, Timolol, 614, 621, "timolol", "", +16902, Drug, 624, 628, "FCDT", "FCDT", +16904, Brimonidine, 635, 646, "brimonidine", "", +16906, Drug, 635, 656, "brimonidine - timolol", "FCBT", +16905, Timolol, 649, 656, "timolol", "", +16906, Drug, 659, 663, "FCBT", "FCBT", +16912, Precondition, 669, 787, "patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections .", "", +16910, IOP, 683, 703, "intraocular pressure", "", +16911, IOP, 706, 709, "IOP", "", +16913, CTDesign, 823, 834, "prospective", "", +16914, Randomized, 837, 847, "randomized", "", +16915, OpenLabel, 850, 862, "open - label", "", +16918, Precondition, 871, 946, "Patients who received IVTA injections due to diffuse diabetic macular edema", "", +16919, Precondition, 951, 1008, "who had an IOP of 24 mm Hg or higher after IVTA treatment", "", +16916, IOP, 962, 965, "IOP", "", +16917, mmHg, 972, 977, "mm Hg", "", +16914, Randomized, 1035, 1045, "randomized", "", +16906, Drug, 1064, 1068, "FCBT", "FCBT", +16902, Drug, 1072, 1076, "FCDT", "FCDT", +16923, Frequency, 1077, 1088, "twice daily", "", +16924, TimePoint, 1128, 1134, "week 4", "", +16925, TimePoint, 1139, 1147, "12 weeks", "", +16926, IOP, 1214, 1217, "IOP", "", +16927, Mean, 1301, 1305, "mean", "", +16929, IOP, 1306, 1309, "IOP", "", +16930, Mean, 1351, 1355, "mean", "", +16931, IOP, 1356, 1359, "IOP", "", +16924, TimePoint, 1363, 1364, "4", "", +16925, TimePoint, 1369, 1377, "12 weeks", "", +16934, NumberPatientsCT, 1425, 1430, "Sixty", "", +16935, Randomized, 1445, 1455, "randomized", "", +16936, AllocationRatio, 1459, 1464, "1 : 1", "", +16906, Drug, 1477, 1481, "FCBT", "FCBT", +16902, Drug, 1486, 1490, "FCDT", "FCDT", +16939, IOP, 1552, 1555, "IOP", "", +16940, Mean, 1581, 1585, "Mean", "", +16941, IOP, 1600, 1603, "IOP", "", +16942, BaseLineValue, 1608, 1615, "31 . 95", "", +16944, SdErrorBL, 1618, 1624, "7 . 39", "", +16943, BaseLineValue, 1629, 1636, "29 . 83", "", +16945, SdErrorBL, 1639, 1645, "5 . 17", "", +16946, mmHg, 1646, 1651, "mm Hg", "", +16906, Drug, 1655, 1659, "FCBT", "FCBT", +16902, Drug, 1664, 1668, "FCDT", "FCDT", +16949, PValueBL, 1693, 1704, "P = 0 . 239", "", +16950, TimePoint, 1715, 1722, "4 weeks", "", +16951, Mean, 1725, 1729, "mean", "", +16952, IOP, 1730, 1733, "IOP", "", +16953, ResultMeasuredValue, 1738, 1745, "17 . 05", "", +16955, SdErrorResValue, 1748, 1754, "3 . 61", "", +16959, mmHg, 1755, 1760, "mm Hg", "", +16906, Drug, 1764, 1768, "FCBT", "FCBT", +16954, ResultMeasuredValue, 1773, 1780, "18 . 93", "", +16956, SdErrorResValue, 1783, 1789, "3 . 30", "", +16960, mmHg, 1790, 1795, "mm Hg", "", +16902, Drug, 1799, 1803, "FCDT", "FCDT", +16961, PValueResValue, 1813, 1824, "P = 0 . 063", "", +16962, TimePoint, 1835, 1843, "12 weeks", "", +16963, Mean, 1846, 1850, "mean", "", +16964, IOP, 1851, 1854, "IOP", "", +16906, Drug, 1862, 1866, "FCBT", "FCBT", +16902, Drug, 1871, 1875, "FCDT", "FCDT", +16967, ResultMeasuredValue, 1893, 1900, "16 . 35", "", +16969, SdErrorResValue, 1903, 1909, "2 . 70", "", +16968, ResultMeasuredValue, 1914, 1921, "18 . 43", "", +16970, SdErrorResValue, 1924, 1930, "2 . 82", "", +16971, mmHg, 1931, 1936, "mm Hg", "", +16972, PValueResValue, 1954, 1965, "P = 0 . 012", "", +16973, IOP, 2016, 2019, "IOP", "", +16994, PvalueDiff, 2066, 2076, "P < 0 . 05", "", +16975, Mean, 2081, 2085, "Mean", "", +16976, IOP, 2099, 2102, "IOP", "", +16977, TimePoint, 2109, 2116, "4 weeks", "", +16978, Reduction, 2122, 2129, "14 . 90", "", +16982, SdErrorChangeValue, 2132, 2138, "7 . 28", "", +16986, mmHg, 2139, 2144, "mm Hg", "", +16906, Drug, 2148, 2152, "FCBT", "FCBT", +16979, Reduction, 2157, 2164, "10 . 90", "", +16983, SdErrorChangeValue, 2167, 2173, "4 . 83", "", +16987, mmHg, 2174, 2179, "mm Hg", "", +16902, Drug, 2183, 2187, "FCDT", "FCDT", +17007, PValueChangeValue, 2197, 2208, "P = 0 . 024", "", +17006, TimePoint, 2219, 2227, "12 weeks", "", +16980, Reduction, 2248, 2255, "15 . 60", "", +16984, SdErrorChangeValue, 2258, 2264, "7 . 77", "", +16981, Reduction, 2269, 2276, "11 . 40", "", +16985, SdErrorChangeValue, 2279, 2285, "5 . 89", "", +16988, mmHg, 2286, 2291, "mm Hg", "", +16906, Drug, 2295, 2299, "FCBT", "FCBT", +16902, Drug, 2304, 2308, "FCDT", "FCDT", +16993, PValueChangeValue, 2333, 2344, "P = 0 . 035", "", +16995, ConclusionComment, 2363, 2449, "Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections .", "", +16906, Drug, 2368, 2372, "FCBT", "FCBT", +16902, Drug, 2377, 2381, "FCDT", "FCDT", +16999, IOP, 2411, 2414, "IOP", "", +16996, ConclusionComment, 2450, 2585, "The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections .", "", +16906, Drug, 2489, 2493, "FCBT", "FCBT", +16902, Drug, 2509, 2513, "FCDT", "FCDT", +17002, IOP, 2526, 2529, "IOP", "", +17003, IOP, 2550, 2553, "IOP", "", +17004, PMID, 2634, 2642, "23807349", "", diff --git a/data/gl 23807349_jshahinitiran.n-triples b/data/gl 23807349_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23807349_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23807349_tstrakeljahn.annodb b/data/gl 23807349_tstrakeljahn.annodb new file mode 100644 index 0000000..48b936d --- /dev/null +++ b/data/gl 23807349_tstrakeljahn.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11518, Journal, 0, 10, "J Glaucoma", "", +11519, PublicationYear, 13, 17, "2015", "", +11542, Title, 88, 237, "Comparison of dorzolamide / timolol versus brimonidine / timolol fixed combination therapy in the management of steroid - induced ocular hypertension", "", +11520, Dorzolamide, 102, 113, "dorzolamide", "", +11522, Timolol, 116, 123, "timolol", "", +11528, Brimonidine, 131, 142, "brimonidine", "", +11523, Timolol, 145, 152, "timolol", "", +11529, OcularHypertension, 218, 237, "ocular hypertension", "", +11531, Author, 240, 254, "Seymeno ğ lu G", "", +11532, Author, 263, 271, "Baser EF", "", +11533, Author, 274, 285, "Ö zt ü rk B", "", +11534, Author, 288, 298, "G ü lhan C", "", +11530, Turkey, 532, 538, "Turkey", "", +11539, ObjectiveDescription, 551, 785, "To compare the efficacy of fixed combinations of dorzolamide - timolol ( FCDT ) and brimonidine - timolol ( FCBT ) in patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections", "", +11521, Dorzolamide, 600, 611, "dorzolamide", "", +11524, Timolol, 614, 621, "timolol", "", +11526, Medication, 624, 628, "FCDT", "fixed combination dorzolamide / timolol", +11527, Brimonidine, 635, 646, "brimonidine", "", +11525, Timolol, 649, 656, "timolol", "", +11535, Medication, 659, 663, "FCBT", "fixed combination brimonidine / timolol", +11538, Precondition, 669, 785, "patients with intraocular pressure ( IOP ) elevations after intravitreal triamcinolone acetonide ( IVTA ) injections", "", +11536, IOP, 683, 703, "intraocular pressure", "", +11537, IOP, 706, 709, "IOP", "", +11540, Randomized, 837, 847, "randomized", "", +11541, OpenLabel, 850, 868, "open - label study", "", +11544, Precondition, 871, 1022, "Patients who received IVTA injections due to diffuse diabetic macular edema and who had an IOP of 24 mm Hg or higher after IVTA treatment were included", "", +11543, IOP, 962, 965, "IOP", "", +11545, Randomized, 1035, 1045, "randomized", "", +11546, Medication, 1064, 1068, "FCBT", "fixed combination brimonidine / timolol", +11547, Medication, 1072, 1076, "FCDT", "fixed combination dorzolamide / timolol", +11548, Frequency, 1077, 1088, "twice daily", "", +11549, IOP, 1214, 1217, "IOP", "", +11550, Mean, 1301, 1305, "mean", "", +11551, IOP, 1306, 1309, "IOP", "", +11553, Mean, 1351, 1355, "mean", "", +11552, IOP, 1356, 1359, "IOP", "", +11586, NumberPatientsCT, 1425, 1430, "Sixty", "", +11585, Randomized, 1445, 1455, "randomized", "", +11584, AllocationRatio, 1459, 1464, "1 : 1", "", +11554, Medication, 1477, 1481, "FCBT", "fixed combination brimonidine / timolol", +11555, Medication, 1486, 1490, "FCDT", "fixed combination dorzolamide / timolol", +11557, IOP, 1552, 1555, "IOP", "", +11556, PvalueDiff, 1558, 1568, "P > 0 . 05", "", +11564, IOP, 1600, 1603, "IOP", "", +11587, BaseLineValue, 1608, 1615, "31 . 95", "", +11589, SdDevBL, 1618, 1624, "7 . 39", "", +11588, BaseLineValue, 1629, 1636, "29 . 83", "", +11590, SdDevBL, 1639, 1645, "5 . 17", "", +11591, mmHg, 1646, 1651, "mm Hg", "", +11572, Medication, 1655, 1659, "FCBT", "fixed combination brimonidine / timolol", +11580, Medication, 1664, 1668, "FCDT", "fixed combination dorzolamide / timolol", +11558, PvalueDiff, 1693, 1704, "P = 0 . 239", "", +11592, TimePoint, 1715, 1722, "4 weeks", "", +11565, IOP, 1730, 1733, "IOP", "", +11594, ResultMeasuredValue, 1738, 1745, "17 . 05", "", +11598, SdDevResValue, 1748, 1754, "3 . 61", "", +11621, mmHg, 1755, 1760, "mm Hg", "", +11573, Medication, 1764, 1768, "FCBT", "fixed combination brimonidine / timolol", +11595, ResultMeasuredValue, 1773, 1780, "18 . 93", "", +11601, SdDevResValue, 1783, 1789, "3 . 30", "", +11622, mmHg, 1790, 1795, "mm Hg", "", +11579, Medication, 1799, 1803, "FCDT", "fixed combination dorzolamide / timolol", +11559, PvalueDiff, 1813, 1824, "P = 0 . 063", "", +11593, TimePoint, 1835, 1843, "12 weeks", "", +11566, IOP, 1851, 1854, "IOP", "", +11574, Medication, 1862, 1866, "FCBT", "fixed combination brimonidine / timolol", +11578, Medication, 1871, 1875, "FCDT", "fixed combination dorzolamide / timolol", +11596, ResultMeasuredValue, 1893, 1900, "16 . 35", "", +11602, SdDevResValue, 1903, 1909, "2 . 70", "", +11597, ResultMeasuredValue, 1914, 1921, "18 . 43", "", +11603, SdDevResValue, 1924, 1930, "2 . 82", "", +11620, mmHg, 1931, 1936, "mm Hg", "", +11560, PvalueDiff, 1954, 1965, "P = 0 . 012", "", +11571, IOP, 2016, 2019, "IOP", "", +11561, PvalueDiff, 2066, 2076, "P < 0 . 05", "", +11607, Mean, 2081, 2085, "Mean", "", +11567, IOP, 2099, 2102, "IOP", "", +11604, TimePoint, 2109, 2116, "4 weeks", "", +11606, Reduction, 2122, 2129, "14 . 90", "", +11608, SdDevChangeValue, 2132, 2138, "7 . 28", "", +11617, mmHg, 2139, 2144, "mm Hg", "", +11575, Medication, 2148, 2152, "FCBT", "fixed combination brimonidine / timolol", +11616, Reduction, 2157, 2164, "10 . 90", "", +11609, SdDevChangeValue, 2167, 2173, "4 . 83", "", +11618, mmHg, 2174, 2179, "mm Hg", "", +11581, Medication, 2183, 2187, "FCDT", "fixed combination dorzolamide / timolol", +11562, PvalueDiff, 2197, 2208, "P = 0 . 024", "", +11605, TimePoint, 2219, 2227, "12 weeks", "", +11614, Reduction, 2248, 2255, "15 . 60", "", +11610, SdDevChangeValue, 2258, 2264, "7 . 77", "", +11615, Reduction, 2269, 2276, "11 . 40", "", +11611, SdDevChangeValue, 2279, 2285, "5 . 89", "", +11619, mmHg, 2286, 2291, "mm Hg", "", +11612, Medication, 2295, 2299, "FCBT", "fixed combination brimonidine / timolol", +11613, Medication, 2304, 2308, "FCDT", "fixed combinationdorzolamide / timolol", +11563, PvalueDiff, 2333, 2344, "P = 0 . 035", "", +11624, ConclusionComment, 2363, 2447, "Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections", "", +11577, Medication, 2368, 2372, "FCBT", "fixed combination brimonidine / timolol", +11582, Medication, 2377, 2381, "FCDT", "fixed combination dorzolamide / timolol", +11569, IOP, 2411, 2414, "IOP", "", +11625, ConclusionComment, 2450, 2583, "The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections", "", +11576, Medication, 2489, 2493, "FCBT", "fixed combination brimonidine / timolol", +11583, Medication, 2509, 2513, "FCDT", "fixed combination dorzolamide / timolol", +11568, IOP, 2526, 2529, "IOP", "", +11570, IOP, 2550, 2553, "IOP", "", +11623, PMID, 2634, 2642, "23807349", "", diff --git a/data/gl 23807349_tstrakeljahn.n-triples b/data/gl 23807349_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23807349_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23950156_admin.annodb b/data/gl 23950156_admin.annodb new file mode 100644 index 0000000..1a18d6d --- /dev/null +++ b/data/gl 23950156_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 27, "Invest Ophthalmol Vis Sci .", "", " \"Invest Ophthalmol Vis Sci .\"." +1, PublicationYear, 28, 32, "2013", "", " \"2013\"." +85, Title, 102, 266, "Hypotensive effect of latanoprost / timolol versus travoprost / timolol fixed combinations in NTG patients : a randomized , multicenter , crossover clinical trial .", "", " \"Hypotensive effect of latanoprost / timolol versus travoprost / timolol fixed combinations in NTG patients : a randomized , multicenter , crossover clinical trial .\"." +3, Latanoprost, 124, 135, "latanoprost", "", " . ." +73, Lat/TimFC, 124, 145, "latanoprost / timolol", "", +4, Timolol, 138, 145, "timolol", "", +58, Travoprost, 153, 163, "travoprost", "", +74, Trav/TimFC, 153, 173, "travoprost / timolol", "", +6, Timolol, 166, 173, "timolol", "", " ." +60, NormalTensionGlaucoma, 196, 199, "NTG", "", +106344, Randomized, 213, 223, "randomized", "", +106340, Multicenter, 226, 237, "multicenter", "", " ." +106341, Crossover, 240, 249, "crossover", "", +11, Author, 267, 274, "Shoji T", "", " \"Shoji T\"." +12, Author, 283, 289, "Sato H", "", " \"Sato H\"." +13, Author, 292, 302, "Mizukawa A", "", " \"Mizukawa A\"." +14, Author, 305, 313, "Hirota N", "", " \"Hirota N\"." +15, Author, 316, 323, "Enoki T", "", " \"Enoki T\"." +16, Author, 326, 334, "Kojima T", "", " \"Kojima T\"." +17, Author, 337, 344, "Kanda T", "", " \"Kanda T\"." +18, Author, 347, 357, "Takeuchi M", "", " \"Takeuchi M\"." +53, Japan, 464, 469, "Japan", "", " ." +19, ObjectiveDescription, 482, 668, "To compare the ocular hypotensive effect of travoprost plus timolol ( TTFC ) and latanoprost plus timolol fixed combinations ( LTFC ) in patients with normal - tension glaucoma ( NTG ) .", "", " \"To compare the ocular hypotensive effect of travoprost plus timolol ( TTFC ) and latanoprost plus timolol fixed combinations ( LTFC ) in patients with normal - tension glaucoma ( NTG ) .\"." +76, Travoprost, 526, 536, "travoprost", "", " ." +78, Trav/TimFC, 526, 549, "travoprost plus timolol", "", +6, Timolol, 542, 549, "timolol", "", " ." +75, Trav/TimFC, 552, 556, "TTFC", "", +3, Latanoprost, 563, 574, "latanoprost", "", " . ." +81, Lat/TimFC, 563, 587, "latanoprost plus timolol", "", +4, Timolol, 580, 587, "timolol", "", +82, Lat/TimFC, 609, 613, "LTFC", "", +83, NormalTensionGlaucoma, 633, 658, "normal - tension glaucoma", "", " ." +84, NormalTensionGlaucoma, 661, 664, "NTG", "", +22, CTDesign, 681, 695, "two - sequence", "", " . ." +94196, Duration, 696, 705, "12 - week", "", " \"12 - week\"." +106339, Multicenter, 708, 719, "multicenter", "", +87, Prospective, 722, 733, "prospective", "", " ." +106345, Randomized, 736, 746, "randomized", "", " ." +24, Blind, 749, 765, "single - blinded", "", " ." +106342, Crossover, 768, 777, "crossover", "", " ." +25, NumberPatientsCT, 802, 804, "59", "", " \"59\"." +92, NormalTensionGlaucoma, 805, 808, "NTG", "", +97, Precondition, 918, 999, "After a 12 - week run - in period with dorzolamide plus timolol fixed combination", "", " \"After a 12 - week run - in period with dorzolamide plus timolol fixed combination\"." +94201, TimePoint, 926, 935, "12 - week", "", +27, Dorzolamide, 957, 968, "dorzolamide", "", +95, Dorz/TimFC, 957, 999, "dorzolamide plus timolol fixed combination", "", +28, Timolol, 974, 981, "timolol", "", +96, Dorz/TimFC, 1002, 1006, "DTFC", "", +106346, Randomized, 1025, 1035, "randomized", "", +106343, Crossover, 1056, 1065, "crossover", "", +94198, Duration, 1093, 1101, "12 weeks", "", +100, Trav/TimFC, 1107, 1111, "TTFC", "", +101, Lat/TimFC, 1115, 1119, "LTFC", "", +94199, Duration, 1198, 1206, "12 weeks", "", +30, IOP, 1247, 1250, "IOP", "", +94200, TimePoint, 1257, 1265, "12 weeks", "", +31, IOP, 1322, 1325, "IOP", "", +32, Mean, 1382, 1386, "mean", "", " . ." +33, IOP, 1396, 1399, "IOP", "", " . ." +34, BaseLineValue, 1404, 1410, "14 . 8", "", +108, SdDevBL, 1413, 1418, "3 . 3", "", +36, mmHg, 1419, 1424, "mm Hg", "", " ." +37, ConfIntervalBL, 1427, 1482, "95 % confidence interval [ CI ] , 14 . 1 - 15 . 3 mm Hg", "", +38, mmHg, 1477, 1482, "mm Hg", "", +112, Dorz/TimFC, 1504, 1508, "DTFC", "", +113, Trav/TimFC, 1515, 1519, "TTFC", "", +39, Mean, 1563, 1567, "mean", "", +40, IOP, 1568, 1571, "IOP", "", +116, Lat/TimFC, 1586, 1590, "LTFC", "", +41, Mean, 1641, 1645, "Mean", "", +42, IOP, 1659, 1662, "IOP", "", +123, TimePoint, 1666, 1674, "12 weeks", "", +124, Trav/TimFC, 1708, 1712, "TTFC", "", +125, Lat/TimFC, 1731, 1735, "LTFC", "", +43, Reduction, 1746, 1751, "2 . 4", "", " \"2 . 4\"." +128, SdDevChangeValue, 1754, 1759, "2 . 3", "", " \"2 . 3\"." +45, mmHg, 1760, 1765, "mm Hg", "", +46, Reduction, 1773, 1778, "1 . 1", "", " \"1 . 1\"." +129, SdDevChangeValue, 1781, 1786, "2 . 3", "", " \"2 . 3\"." +48, mmHg, 1787, 1792, "mm Hg", "", +132, PvalueDiff, 1799, 1806, "0 . 021", "", " \"0 . 021\"." +50, ConclusionComment, 2049, 2166, "The additional reduction in IOP was greater with TTFC than with LTFC , and their tolerability profiles were similar .", "", " \"The additional reduction in IOP was greater with TTFC than with LTFC , and their tolerability profiles were similar .\"." +52, IOP, 2077, 2080, "IOP", "", +119912, Trav/TimFC, 2098, 2102, "TTFC", "", +119, Lat/TimFC, 2113, 2117, "LTFC", "", +51, PMID, 2282, 2290, "23950156", "", " \"23950156\"." diff --git a/data/gl 23950156_admin.n-triples b/data/gl 23950156_admin.n-triples new file mode 100644 index 0000000..782ec08 --- /dev/null +++ b/data/gl 23950156_admin.n-triples @@ -0,0 +1,111 @@ +# RDF export of group: Publication + . + "Publication " . + "Hypotensive effect of latanoprost / timolol versus travoprost / timolol fixed combinations in NTG patients : a randomized , multicenter , crossover clinical trial ." . + "Shoji T" . + "2013" . + "Invest Ophthalmol Vis Sci ." . + "23950156" . + . + "Sato H" . + "Mizukawa A" . + "Hirota N" . + "Enoki T" . + "Kojima T" . + "Kanda T" . + "Takeuchi M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the ocular hypotensive effect of travoprost plus timolol ( TTFC ) and latanoprost plus timolol fixed combinations ( LTFC ) in patients with normal - tension glaucoma ( NTG ) ." . + "59" . + "12 - week" . + . + . + "The additional reduction in IOP was greater with TTFC than with LTFC , and their tolerability profiles were similar ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "After a 12 - week run - in period with dorzolamide plus timolol fixed combination" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm trav/tim" . + . + . + . + . + "Arm lat/tim" . + . + . + . +# RDF export of group: Intervention + . + "Intervention trav/tim" . + . + . + . + . + "Intervention lat/tim" . + . + . + . +# RDF export of group: Medication + . + "Medication trav" . + . + . + . + . + "Medication tim" . + . + . + . + . + "Medication lat" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP trav/tim" . + . + "2 . 4" . + "2 . 3" . + . + "Outcome IOP lat/tim" . + . + "1 . 1" . + "2 . 3" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP " . + "0 . 021" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23950156_export.csv b/data/gl 23950156_export.csv new file mode 100644 index 0000000..16c4220 --- /dev/null +++ b/data/gl 23950156_export.csv @@ -0,0 +1,475 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +417, 1, 1, 1, 0, 6, 0, 6, "Invest" +417, 1, 2, 2, 7, 17, 7, 17, "Ophthalmol" +417, 1, 3, 3, 18, 21, 18, 21, "Vis" +417, 1, 4, 4, 22, 25, 22, 25, "Sci" +417, 1, 5, 5, 26, 27, 26, 27, "." +417, 2, 1, 6, 0, 4, 28, 32, "2013" +417, 2, 2, 7, 5, 8, 33, 36, "Sep" +417, 2, 3, 8, 9, 11, 37, 39, "17" +417, 2, 4, 9, 12, 13, 40, 41, ";" +417, 2, 5, 10, 14, 16, 42, 44, "54" +417, 2, 6, 11, 17, 18, 45, 46, "(" +417, 2, 7, 12, 19, 20, 47, 48, "9" +417, 2, 8, 13, 21, 22, 49, 50, ")" +417, 2, 9, 14, 23, 24, 51, 52, ":" +417, 2, 10, 15, 25, 29, 53, 57, "6242" +417, 2, 11, 16, 30, 31, 58, 59, "-" +417, 2, 12, 17, 32, 33, 60, 61, "7" +417, 2, 13, 18, 34, 35, 62, 63, "." +417, 2, 14, 19, 36, 39, 64, 67, "doi" +417, 2, 15, 20, 40, 41, 68, 69, ":" +417, 2, 16, 21, 42, 44, 70, 72, "10" +417, 2, 17, 22, 45, 46, 73, 74, "." +417, 2, 18, 23, 47, 51, 75, 79, "1167" +417, 2, 19, 24, 52, 53, 80, 81, "/" +417, 2, 20, 25, 54, 58, 82, 86, "iovs" +417, 2, 21, 26, 59, 60, 87, 88, "." +417, 2, 22, 27, 61, 63, 89, 91, "13" +417, 2, 23, 28, 64, 65, 92, 93, "-" +417, 2, 24, 29, 66, 71, 94, 99, "11942" +417, 2, 25, 30, 72, 73, 100, 101, "." +417, 3, 1, 31, 0, 11, 102, 113, "Hypotensive" +417, 3, 2, 32, 12, 18, 114, 120, "effect" +417, 3, 3, 33, 19, 21, 121, 123, "of" +417, 3, 4, 34, 22, 33, 124, 135, "latanoprost" +417, 3, 5, 35, 34, 35, 136, 137, "/" +417, 3, 6, 36, 36, 43, 138, 145, "timolol" +417, 3, 7, 37, 44, 50, 146, 152, "versus" +417, 3, 8, 38, 51, 61, 153, 163, "travoprost" +417, 3, 9, 39, 62, 63, 164, 165, "/" +417, 3, 10, 40, 64, 71, 166, 173, "timolol" +417, 3, 11, 41, 72, 77, 174, 179, "fixed" +417, 3, 12, 42, 78, 90, 180, 192, "combinations" +417, 3, 13, 43, 91, 93, 193, 195, "in" +417, 3, 14, 44, 94, 97, 196, 199, "NTG" +417, 3, 15, 45, 98, 106, 200, 208, "patients" +417, 3, 16, 46, 107, 108, 209, 210, ":" +417, 3, 17, 47, 109, 110, 211, 212, "a" +417, 3, 18, 48, 111, 121, 213, 223, "randomized" +417, 3, 19, 49, 122, 123, 224, 225, "," +417, 3, 20, 50, 124, 135, 226, 237, "multicenter" +417, 3, 21, 51, 136, 137, 238, 239, "," +417, 3, 22, 52, 138, 147, 240, 249, "crossover" +417, 3, 23, 53, 148, 156, 250, 258, "clinical" +417, 3, 24, 54, 157, 162, 259, 264, "trial" +417, 3, 25, 55, 163, 164, 265, 266, "." +417, 4, 1, 56, 0, 5, 267, 272, "Shoji" +417, 4, 2, 57, 6, 7, 273, 274, "T" +417, 4, 3, 58, 8, 9, 275, 276, "(" +417, 4, 4, 59, 10, 11, 277, 278, "1" +417, 4, 5, 60, 12, 13, 279, 280, ")" +417, 4, 6, 61, 14, 15, 281, 282, "," +417, 4, 7, 62, 16, 20, 283, 287, "Sato" +417, 4, 8, 63, 21, 22, 288, 289, "H" +417, 4, 9, 64, 23, 24, 290, 291, "," +417, 4, 10, 65, 25, 33, 292, 300, "Mizukawa" +417, 4, 11, 66, 34, 35, 301, 302, "A" +417, 4, 12, 67, 36, 37, 303, 304, "," +417, 4, 13, 68, 38, 44, 305, 311, "Hirota" +417, 4, 14, 69, 45, 46, 312, 313, "N" +417, 4, 15, 70, 47, 48, 314, 315, "," +417, 4, 16, 71, 49, 54, 316, 321, "Enoki" +417, 4, 17, 72, 55, 56, 322, 323, "T" +417, 4, 18, 73, 57, 58, 324, 325, "," +417, 4, 19, 74, 59, 65, 326, 332, "Kojima" +417, 4, 20, 75, 66, 67, 333, 334, "T" +417, 4, 21, 76, 68, 69, 335, 336, "," +417, 4, 22, 77, 70, 75, 337, 342, "Kanda" +417, 4, 23, 78, 76, 77, 343, 344, "T" +417, 4, 24, 79, 78, 79, 345, 346, "," +417, 4, 25, 80, 80, 88, 347, 355, "Takeuchi" +417, 4, 26, 81, 89, 90, 356, 357, "M" +417, 4, 27, 82, 91, 92, 358, 359, "." +417, 4, 28, 83, 93, 99, 360, 366, "Author" +417, 4, 29, 84, 100, 111, 367, 378, "information" +417, 4, 30, 85, 112, 113, 379, 380, ":" +417, 4, 31, 86, 114, 115, 381, 382, "(" +417, 4, 32, 87, 116, 117, 383, 384, "1" +417, 4, 33, 88, 118, 119, 385, 386, ")" +417, 4, 34, 89, 120, 130, 387, 397, "Department" +417, 4, 35, 90, 131, 133, 398, 400, "of" +417, 4, 36, 91, 134, 147, 401, 414, "Ophthalmology" +417, 4, 37, 92, 148, 149, 415, 416, "," +417, 4, 38, 93, 150, 157, 417, 424, "Saitama" +417, 4, 39, 94, 158, 165, 425, 432, "Medical" +417, 4, 40, 95, 166, 176, 433, 443, "University" +417, 4, 41, 96, 177, 178, 444, 445, "," +417, 4, 42, 97, 179, 184, 446, 451, "Iruma" +417, 4, 43, 98, 185, 186, 452, 453, "," +417, 4, 44, 99, 187, 194, 454, 461, "Saitama" +417, 4, 45, 100, 195, 196, 462, 463, "," +417, 4, 46, 101, 197, 202, 464, 469, "Japan" +417, 4, 47, 102, 203, 204, 470, 471, "." +417, 5, 1, 103, 0, 7, 472, 479, "PURPOSE" +417, 5, 2, 104, 8, 9, 480, 481, ":" +417, 5, 3, 105, 10, 12, 482, 484, "To" +417, 5, 4, 106, 13, 20, 485, 492, "compare" +417, 5, 5, 107, 21, 24, 493, 496, "the" +417, 5, 6, 108, 25, 31, 497, 503, "ocular" +417, 5, 7, 109, 32, 43, 504, 515, "hypotensive" +417, 5, 8, 110, 44, 50, 516, 522, "effect" +417, 5, 9, 111, 51, 53, 523, 525, "of" +417, 5, 10, 112, 54, 64, 526, 536, "travoprost" +417, 5, 11, 113, 65, 69, 537, 541, "plus" +417, 5, 12, 114, 70, 77, 542, 549, "timolol" +417, 5, 13, 115, 78, 79, 550, 551, "(" +417, 5, 14, 116, 80, 84, 552, 556, "TTFC" +417, 5, 15, 117, 85, 86, 557, 558, ")" +417, 5, 16, 118, 87, 90, 559, 562, "and" +417, 5, 17, 119, 91, 102, 563, 574, "latanoprost" +417, 5, 18, 120, 103, 107, 575, 579, "plus" +417, 5, 19, 121, 108, 115, 580, 587, "timolol" +417, 5, 20, 122, 116, 121, 588, 593, "fixed" +417, 5, 21, 123, 122, 134, 594, 606, "combinations" +417, 5, 22, 124, 135, 136, 607, 608, "(" +417, 5, 23, 125, 137, 141, 609, 613, "LTFC" +417, 5, 24, 126, 142, 143, 614, 615, ")" +417, 5, 25, 127, 144, 146, 616, 618, "in" +417, 5, 26, 128, 147, 155, 619, 627, "patients" +417, 5, 27, 129, 156, 160, 628, 632, "with" +417, 5, 28, 130, 161, 167, 633, 639, "normal" +417, 5, 29, 131, 168, 169, 640, 641, "-" +417, 5, 30, 132, 170, 177, 642, 649, "tension" +417, 5, 31, 133, 178, 186, 650, 658, "glaucoma" +417, 5, 32, 134, 187, 188, 659, 660, "(" +417, 5, 33, 135, 189, 192, 661, 664, "NTG" +417, 5, 34, 136, 193, 194, 665, 666, ")" +417, 5, 35, 137, 195, 196, 667, 668, "." +417, 6, 1, 138, 0, 7, 669, 676, "METHODS" +417, 6, 2, 139, 8, 9, 677, 678, ":" +417, 6, 3, 140, 10, 11, 679, 680, "A" +417, 6, 4, 141, 12, 15, 681, 684, "two" +417, 6, 5, 142, 16, 17, 685, 686, "-" +417, 6, 6, 143, 18, 26, 687, 695, "sequence" +417, 6, 7, 144, 27, 29, 696, 698, "12" +417, 6, 8, 145, 30, 31, 699, 700, "-" +417, 6, 9, 146, 32, 36, 701, 705, "week" +417, 6, 10, 147, 37, 38, 706, 707, "," +417, 6, 11, 148, 39, 50, 708, 719, "multicenter" +417, 6, 12, 149, 51, 52, 720, 721, "," +417, 6, 13, 150, 53, 64, 722, 733, "prospective" +417, 6, 14, 151, 65, 66, 734, 735, "," +417, 6, 15, 152, 67, 77, 736, 746, "randomized" +417, 6, 16, 153, 78, 79, 747, 748, "," +417, 6, 17, 154, 80, 86, 749, 755, "single" +417, 6, 18, 155, 87, 88, 756, 757, "-" +417, 6, 19, 156, 89, 96, 758, 765, "blinded" +417, 6, 20, 157, 97, 98, 766, 767, "," +417, 6, 21, 158, 99, 108, 768, 777, "crossover" +417, 6, 22, 159, 109, 117, 778, 786, "clinical" +417, 6, 23, 160, 118, 123, 787, 792, "trial" +417, 6, 24, 161, 124, 132, 793, 801, "examined" +417, 6, 25, 162, 133, 135, 802, 804, "59" +417, 6, 26, 163, 136, 139, 805, 808, "NTG" +417, 6, 27, 164, 140, 148, 809, 817, "patients" +417, 6, 28, 165, 149, 150, 818, 819, "." +417, 7, 1, 166, 0, 2, 820, 822, "If" +417, 7, 2, 167, 3, 7, 823, 827, "both" +417, 7, 3, 168, 8, 12, 828, 832, "eyes" +417, 7, 4, 169, 13, 17, 833, 837, "were" +417, 7, 5, 170, 18, 26, 838, 846, "eligible" +417, 7, 6, 171, 27, 28, 847, 848, "," +417, 7, 7, 172, 29, 33, 849, 853, "only" +417, 7, 8, 173, 34, 37, 854, 857, "one" +417, 7, 9, 174, 38, 41, 858, 861, "eye" +417, 7, 10, 175, 42, 43, 862, 863, "(" +417, 7, 11, 176, 44, 50, 864, 870, "chosen" +417, 7, 12, 177, 51, 53, 871, 873, "at" +417, 7, 13, 178, 54, 60, 874, 880, "random" +417, 7, 14, 179, 61, 62, 881, 882, ")" +417, 7, 15, 180, 63, 66, 883, 886, "was" +417, 7, 16, 181, 67, 71, 887, 891, "used" +417, 7, 17, 182, 72, 75, 892, 895, "for" +417, 7, 18, 183, 76, 86, 896, 906, "analytical" +417, 7, 19, 184, 87, 95, 907, 915, "purposes" +417, 7, 20, 185, 96, 97, 916, 917, "." +417, 8, 1, 186, 0, 5, 918, 923, "After" +417, 8, 2, 187, 6, 7, 924, 925, "a" +417, 8, 3, 188, 8, 10, 926, 928, "12" +417, 8, 4, 189, 11, 12, 929, 930, "-" +417, 8, 5, 190, 13, 17, 931, 935, "week" +417, 8, 6, 191, 18, 21, 936, 939, "run" +417, 8, 7, 192, 22, 23, 940, 941, "-" +417, 8, 8, 193, 24, 26, 942, 944, "in" +417, 8, 9, 194, 27, 33, 945, 951, "period" +417, 8, 10, 195, 34, 38, 952, 956, "with" +417, 8, 11, 196, 39, 50, 957, 968, "dorzolamide" +417, 8, 12, 197, 51, 55, 969, 973, "plus" +417, 8, 13, 198, 56, 63, 974, 981, "timolol" +417, 8, 14, 199, 64, 69, 982, 987, "fixed" +417, 8, 15, 200, 70, 81, 988, 999, "combination" +417, 8, 16, 201, 82, 83, 1000, 1001, "(" +417, 8, 17, 202, 84, 88, 1002, 1006, "DTFC" +417, 8, 18, 203, 89, 90, 1007, 1008, ")" +417, 8, 19, 204, 91, 92, 1009, 1010, "," +417, 8, 20, 205, 93, 101, 1011, 1019, "patients" +417, 8, 21, 206, 102, 106, 1020, 1024, "were" +417, 8, 22, 207, 107, 117, 1025, 1035, "randomized" +417, 8, 23, 208, 118, 122, 1036, 1040, "into" +417, 8, 24, 209, 123, 126, 1041, 1044, "one" +417, 8, 25, 210, 127, 129, 1045, 1047, "of" +417, 8, 26, 211, 130, 133, 1048, 1051, "the" +417, 8, 27, 212, 134, 137, 1052, 1055, "two" +417, 8, 28, 213, 138, 147, 1056, 1065, "crossover" +417, 8, 29, 214, 148, 157, 1066, 1075, "sequences" +417, 8, 30, 215, 158, 160, 1076, 1078, "of" +417, 8, 31, 216, 161, 170, 1079, 1088, "treatment" +417, 8, 32, 217, 171, 174, 1089, 1092, "for" +417, 8, 33, 218, 175, 177, 1093, 1095, "12" +417, 8, 34, 219, 178, 183, 1096, 1101, "weeks" +417, 8, 35, 220, 184, 188, 1102, 1106, "with" +417, 8, 36, 221, 189, 193, 1107, 1111, "TTFC" +417, 8, 37, 222, 194, 196, 1112, 1114, "or" +417, 8, 38, 223, 197, 201, 1115, 1119, "LTFC" +417, 8, 39, 224, 202, 205, 1120, 1123, "and" +417, 8, 40, 225, 206, 210, 1124, 1128, "were" +417, 8, 41, 226, 211, 223, 1129, 1141, "subsequently" +417, 8, 42, 227, 224, 231, 1142, 1149, "crossed" +417, 8, 43, 228, 232, 236, 1150, 1154, "over" +417, 8, 44, 229, 237, 239, 1155, 1157, "to" +417, 8, 45, 230, 240, 243, 1158, 1161, "the" +417, 8, 46, 231, 244, 255, 1162, 1173, "alternative" +417, 8, 47, 232, 256, 265, 1174, 1183, "treatment" +417, 8, 48, 233, 266, 269, 1184, 1187, "for" +417, 8, 49, 234, 270, 271, 1188, 1189, "a" +417, 8, 50, 235, 272, 279, 1190, 1197, "further" +417, 8, 51, 236, 280, 282, 1198, 1200, "12" +417, 8, 52, 237, 283, 288, 1201, 1206, "weeks" +417, 8, 53, 238, 289, 290, 1207, 1208, "." +417, 9, 1, 239, 0, 3, 1209, 1212, "The" +417, 9, 2, 240, 4, 11, 1213, 1220, "primary" +417, 9, 3, 241, 12, 20, 1221, 1229, "endpoint" +417, 9, 4, 242, 21, 24, 1230, 1233, "was" +417, 9, 5, 243, 25, 34, 1234, 1243, "reduction" +417, 9, 6, 244, 35, 37, 1244, 1246, "in" +417, 9, 7, 245, 38, 41, 1247, 1250, "IOP" +417, 9, 8, 246, 42, 47, 1251, 1256, "after" +417, 9, 9, 247, 48, 50, 1257, 1259, "12" +417, 9, 10, 248, 51, 56, 1260, 1265, "weeks" +417, 9, 11, 249, 57, 59, 1266, 1268, "of" +417, 9, 12, 250, 60, 64, 1269, 1273, "each" +417, 9, 13, 251, 65, 74, 1274, 1283, "treatment" +417, 9, 14, 252, 75, 83, 1284, 1292, "sequence" +417, 9, 15, 253, 84, 85, 1293, 1294, "." +417, 10, 1, 254, 0, 3, 1295, 1298, "The" +417, 10, 2, 255, 4, 10, 1299, 1305, "effect" +417, 10, 3, 256, 11, 13, 1306, 1308, "of" +417, 10, 4, 257, 14, 23, 1309, 1318, "treatment" +417, 10, 5, 258, 24, 26, 1319, 1321, "on" +417, 10, 6, 259, 27, 30, 1322, 1325, "IOP" +417, 10, 7, 260, 31, 34, 1326, 1329, "was" +417, 10, 8, 261, 35, 43, 1330, 1338, "assessed" +417, 10, 9, 262, 44, 49, 1339, 1344, "using" +417, 10, 10, 263, 50, 51, 1345, 1346, "a" +417, 10, 11, 264, 52, 58, 1347, 1353, "linear" +417, 10, 12, 265, 59, 64, 1354, 1359, "mixed" +417, 10, 13, 266, 65, 70, 1360, 1365, "model" +417, 10, 14, 267, 71, 72, 1366, 1367, "." +417, 11, 1, 268, 0, 7, 1368, 1375, "RESULTS" +417, 11, 2, 269, 8, 9, 1376, 1377, ":" +417, 11, 3, 270, 10, 13, 1378, 1381, "The" +417, 11, 4, 271, 14, 18, 1382, 1386, "mean" +417, 11, 5, 272, 19, 27, 1387, 1395, "baseline" +417, 11, 6, 273, 28, 31, 1396, 1399, "IOP" +417, 11, 7, 274, 32, 35, 1400, 1403, "was" +417, 11, 8, 275, 36, 38, 1404, 1406, "14" +417, 11, 9, 276, 39, 40, 1407, 1408, "." +417, 11, 10, 277, 41, 42, 1409, 1410, "8" +417, 11, 11, 278, 43, 44, 1411, 1412, "±" +417, 11, 12, 279, 45, 46, 1413, 1414, "3" +417, 11, 13, 280, 47, 48, 1415, 1416, "." +417, 11, 14, 281, 49, 50, 1417, 1418, "3" +417, 11, 15, 282, 51, 53, 1419, 1421, "mm" +417, 11, 16, 283, 54, 56, 1422, 1424, "Hg" +417, 11, 17, 284, 57, 58, 1425, 1426, "(" +417, 11, 18, 285, 59, 61, 1427, 1429, "95" +417, 11, 19, 286, 62, 63, 1430, 1431, "%" +417, 11, 20, 287, 64, 74, 1432, 1442, "confidence" +417, 11, 21, 288, 75, 83, 1443, 1451, "interval" +417, 11, 22, 289, 84, 85, 1452, 1453, "[" +417, 11, 23, 290, 86, 88, 1454, 1456, "CI" +417, 11, 24, 291, 89, 90, 1457, 1458, "]" +417, 11, 25, 292, 91, 92, 1459, 1460, "," +417, 11, 26, 293, 93, 95, 1461, 1463, "14" +417, 11, 27, 294, 96, 97, 1464, 1465, "." +417, 11, 28, 295, 98, 99, 1466, 1467, "1" +417, 11, 29, 296, 100, 101, 1468, 1469, "-" +417, 11, 30, 297, 102, 104, 1470, 1472, "15" +417, 11, 31, 298, 105, 106, 1473, 1474, "." +417, 11, 32, 299, 107, 108, 1475, 1476, "3" +417, 11, 33, 300, 109, 111, 1477, 1479, "mm" +417, 11, 34, 301, 112, 114, 1480, 1482, "Hg" +417, 11, 35, 302, 115, 116, 1483, 1484, ")" +417, 11, 36, 303, 117, 120, 1485, 1488, "for" +417, 11, 37, 304, 121, 130, 1489, 1498, "treatment" +417, 11, 38, 305, 131, 135, 1499, 1503, "with" +417, 11, 39, 306, 136, 140, 1504, 1508, "DTFC" +417, 11, 40, 307, 141, 142, 1509, 1510, "." +417, 12, 1, 308, 0, 3, 1511, 1514, "The" +417, 12, 2, 309, 4, 8, 1515, 1519, "TTFC" +417, 12, 3, 310, 9, 18, 1520, 1529, "treatment" +417, 12, 4, 311, 19, 25, 1530, 1536, "period" +417, 12, 5, 312, 26, 32, 1537, 1543, "showed" +417, 12, 6, 313, 33, 45, 1544, 1556, "consistently" +417, 12, 7, 314, 46, 51, 1557, 1562, "lower" +417, 12, 8, 315, 52, 56, 1563, 1567, "mean" +417, 12, 9, 316, 57, 60, 1568, 1571, "IOP" +417, 12, 10, 317, 61, 69, 1572, 1580, "compared" +417, 12, 11, 318, 70, 74, 1581, 1585, "with" +417, 12, 12, 319, 75, 79, 1586, 1590, "LTFC" +417, 12, 13, 320, 80, 89, 1591, 1600, "treatment" +417, 12, 14, 321, 90, 96, 1601, 1607, "period" +417, 12, 15, 322, 97, 99, 1608, 1610, "at" +417, 12, 16, 323, 100, 103, 1611, 1614, "all" +417, 12, 17, 324, 104, 115, 1615, 1626, "measurement" +417, 12, 18, 325, 116, 120, 1627, 1631, "time" +417, 12, 19, 326, 121, 127, 1632, 1638, "points" +417, 12, 20, 327, 128, 129, 1639, 1640, "." +417, 13, 1, 328, 0, 4, 1641, 1645, "Mean" +417, 13, 2, 329, 5, 14, 1646, 1655, "reduction" +417, 13, 3, 330, 15, 17, 1656, 1658, "in" +417, 13, 4, 331, 18, 21, 1659, 1662, "IOP" +417, 13, 5, 332, 22, 24, 1663, 1665, "at" +417, 13, 6, 333, 25, 27, 1666, 1668, "12" +417, 13, 7, 334, 28, 33, 1669, 1674, "weeks" +417, 13, 8, 335, 34, 37, 1675, 1678, "was" +417, 13, 9, 336, 38, 51, 1679, 1692, "significantly" +417, 13, 10, 337, 52, 59, 1693, 1700, "greater" +417, 13, 11, 338, 60, 62, 1701, 1703, "in" +417, 13, 12, 339, 63, 66, 1704, 1707, "the" +417, 13, 13, 340, 67, 71, 1708, 1712, "TTFC" +417, 13, 14, 341, 72, 77, 1713, 1718, "group" +417, 13, 15, 342, 78, 82, 1719, 1723, "than" +417, 13, 16, 343, 83, 85, 1724, 1726, "in" +417, 13, 17, 344, 86, 89, 1727, 1730, "the" +417, 13, 18, 345, 90, 94, 1731, 1735, "LTFC" +417, 13, 19, 346, 95, 100, 1736, 1741, "group" +417, 13, 20, 347, 101, 102, 1742, 1743, "(" +417, 13, 21, 348, 103, 104, 1744, 1745, "-" +417, 13, 22, 349, 105, 106, 1746, 1747, "2" +417, 13, 23, 350, 107, 108, 1748, 1749, "." +417, 13, 24, 351, 109, 110, 1750, 1751, "4" +417, 13, 25, 352, 111, 112, 1752, 1753, "±" +417, 13, 26, 353, 113, 114, 1754, 1755, "2" +417, 13, 27, 354, 115, 116, 1756, 1757, "." +417, 13, 28, 355, 117, 118, 1758, 1759, "3" +417, 13, 29, 356, 119, 121, 1760, 1762, "mm" +417, 13, 30, 357, 122, 124, 1763, 1765, "Hg" +417, 13, 31, 358, 125, 127, 1766, 1768, "vs" +417, 13, 32, 359, 128, 129, 1769, 1770, "." +417, 13, 33, 360, 130, 131, 1771, 1772, "-" +417, 13, 34, 361, 132, 133, 1773, 1774, "1" +417, 13, 35, 362, 134, 135, 1775, 1776, "." +417, 13, 36, 363, 136, 137, 1777, 1778, "1" +417, 13, 37, 364, 138, 139, 1779, 1780, "±" +417, 13, 38, 365, 140, 141, 1781, 1782, "2" +417, 13, 39, 366, 142, 143, 1783, 1784, "." +417, 13, 40, 367, 144, 145, 1785, 1786, "3" +417, 13, 41, 368, 146, 148, 1787, 1789, "mm" +417, 13, 42, 369, 149, 151, 1790, 1792, "Hg" +417, 13, 43, 370, 152, 153, 1793, 1794, ";" +417, 13, 44, 371, 154, 155, 1795, 1796, "P" +417, 13, 45, 372, 156, 157, 1797, 1798, "=" +417, 13, 46, 373, 158, 159, 1799, 1800, "0" +417, 13, 47, 374, 160, 161, 1801, 1802, "." +417, 13, 48, 375, 162, 165, 1803, 1806, "021" +417, 13, 49, 376, 166, 167, 1807, 1808, ")" +417, 13, 50, 377, 168, 169, 1809, 1810, "." +417, 14, 1, 378, 0, 2, 1811, 1813, "No" +417, 14, 2, 379, 3, 14, 1814, 1825, "interaction" +417, 14, 3, 380, 15, 22, 1826, 1833, "between" +417, 14, 4, 381, 23, 26, 1834, 1837, "the" +417, 14, 5, 382, 27, 31, 1838, 1842, "drug" +417, 14, 6, 383, 32, 35, 1843, 1846, "and" +417, 14, 7, 384, 36, 45, 1847, 1856, "treatment" +417, 14, 8, 385, 46, 54, 1857, 1865, "sequence" +417, 14, 9, 386, 55, 58, 1866, 1869, "was" +417, 14, 10, 387, 59, 67, 1870, 1878, "detected" +417, 14, 11, 388, 68, 69, 1879, 1880, "." +417, 15, 1, 389, 0, 3, 1881, 1884, "The" +417, 15, 2, 390, 4, 11, 1885, 1892, "effects" +417, 15, 3, 391, 12, 14, 1893, 1895, "of" +417, 15, 4, 392, 15, 26, 1896, 1907, "intraocular" +417, 15, 5, 393, 27, 31, 1908, 1912, "lens" +417, 15, 6, 394, 32, 44, 1913, 1925, "implantation" +417, 15, 7, 395, 45, 48, 1926, 1929, "and" +417, 15, 8, 396, 49, 60, 1930, 1941, "measurement" +417, 15, 9, 397, 61, 65, 1942, 1946, "time" +417, 15, 10, 398, 66, 70, 1947, 1951, "were" +417, 15, 11, 399, 71, 75, 1952, 1956, "also" +417, 15, 12, 400, 76, 79, 1957, 1960, "not" +417, 15, 13, 401, 80, 91, 1961, 1972, "significant" +417, 15, 14, 402, 92, 93, 1973, 1974, "." +417, 16, 1, 403, 0, 3, 1975, 1978, "The" +417, 16, 2, 404, 4, 16, 1979, 1991, "tolerability" +417, 16, 3, 405, 17, 25, 1992, 2000, "profiles" +417, 16, 4, 406, 26, 28, 2001, 2003, "of" +417, 16, 5, 407, 29, 33, 2004, 2008, "both" +417, 16, 6, 408, 34, 44, 2009, 2019, "treatments" +417, 16, 7, 409, 45, 49, 2020, 2024, "were" +417, 16, 8, 410, 50, 57, 2025, 2032, "similar" +417, 16, 9, 411, 58, 59, 2033, 2034, "." +417, 17, 1, 412, 0, 11, 2035, 2046, "CONCLUSIONS" +417, 17, 2, 413, 12, 13, 2047, 2048, ":" +417, 17, 3, 414, 14, 17, 2049, 2052, "The" +417, 17, 4, 415, 18, 28, 2053, 2063, "additional" +417, 17, 5, 416, 29, 38, 2064, 2073, "reduction" +417, 17, 6, 417, 39, 41, 2074, 2076, "in" +417, 17, 7, 418, 42, 45, 2077, 2080, "IOP" +417, 17, 8, 419, 46, 49, 2081, 2084, "was" +417, 17, 9, 420, 50, 57, 2085, 2092, "greater" +417, 17, 10, 421, 58, 62, 2093, 2097, "with" +417, 17, 11, 422, 63, 67, 2098, 2102, "TTFC" +417, 17, 12, 423, 68, 72, 2103, 2107, "than" +417, 17, 13, 424, 73, 77, 2108, 2112, "with" +417, 17, 14, 425, 78, 82, 2113, 2117, "LTFC" +417, 17, 15, 426, 83, 84, 2118, 2119, "," +417, 17, 16, 427, 85, 88, 2120, 2123, "and" +417, 17, 17, 428, 89, 94, 2124, 2129, "their" +417, 17, 18, 429, 95, 107, 2130, 2142, "tolerability" +417, 17, 19, 430, 108, 116, 2143, 2151, "profiles" +417, 17, 20, 431, 117, 121, 2152, 2156, "were" +417, 17, 21, 432, 122, 129, 2157, 2164, "similar" +417, 17, 22, 433, 130, 131, 2165, 2166, "." +417, 18, 1, 434, 0, 1, 2167, 2168, "(" +417, 18, 2, 435, 2, 6, 2169, 2173, "http" +417, 18, 3, 436, 7, 8, 2174, 2175, ":" +417, 18, 4, 437, 9, 10, 2176, 2177, "/" +417, 18, 5, 438, 11, 12, 2178, 2179, "/" +417, 18, 6, 439, 13, 16, 2180, 2183, "www" +417, 18, 7, 440, 17, 18, 2184, 2185, "." +417, 18, 8, 441, 19, 23, 2186, 2190, "umin" +417, 18, 9, 442, 24, 25, 2191, 2192, "." +417, 18, 10, 443, 26, 28, 2193, 2195, "ac" +417, 18, 11, 444, 29, 30, 2196, 2197, "." +417, 18, 12, 445, 31, 33, 2198, 2200, "jp" +417, 18, 13, 446, 34, 35, 2201, 2202, "/" +417, 18, 14, 447, 36, 39, 2203, 2206, "ctr" +417, 18, 15, 448, 40, 41, 2207, 2208, "/" +417, 18, 16, 449, 42, 48, 2209, 2215, "number" +417, 18, 17, 450, 49, 50, 2216, 2217, "," +417, 18, 18, 451, 51, 55, 2218, 2222, "UMIN" +417, 18, 19, 452, 56, 65, 2223, 2232, "000005974" +417, 18, 20, 453, 66, 67, 2233, 2234, "." +417, 18, 21, 454, 68, 69, 2235, 2236, ")" +417, 18, 22, 455, 70, 71, 2237, 2238, "." +417, 19, 1, 456, 0, 3, 2239, 2242, "DOI" +417, 19, 2, 457, 4, 5, 2243, 2244, ":" +417, 19, 3, 458, 6, 8, 2245, 2247, "10" +417, 19, 4, 459, 9, 10, 2248, 2249, "." +417, 19, 5, 460, 11, 15, 2250, 2254, "1167" +417, 19, 6, 461, 16, 17, 2255, 2256, "/" +417, 19, 7, 462, 18, 22, 2257, 2261, "iovs" +417, 19, 8, 463, 23, 24, 2262, 2263, "." +417, 19, 9, 464, 25, 27, 2264, 2266, "13" +417, 19, 10, 465, 28, 29, 2267, 2268, "-" +417, 19, 11, 466, 30, 35, 2269, 2274, "11942" +417, 19, 12, 467, 36, 40, 2275, 2279, "PMID" +417, 19, 13, 468, 41, 42, 2280, 2281, ":" +417, 19, 14, 469, 43, 51, 2282, 2290, "23950156" +417, 19, 15, 470, 52, 53, 2291, 2292, "[" +417, 19, 16, 471, 54, 61, 2293, 2300, "Indexed" +417, 19, 17, 472, 62, 65, 2301, 2304, "for" +417, 19, 18, 473, 66, 73, 2305, 2312, "MEDLINE" +417, 19, 19, 474, 74, 75, 2313, 2314, "]" diff --git a/data/gl 23950156_jshahinitiran.annodb b/data/gl 23950156_jshahinitiran.annodb new file mode 100644 index 0000000..d5dcca4 --- /dev/null +++ b/data/gl 23950156_jshahinitiran.annodb @@ -0,0 +1,83 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +17008, Journal, 0, 25, "Invest Ophthalmol Vis Sci", "", +17009, PublicationYear, 28, 32, "2013", "", +17010, Title, 102, 264, "Hypotensive effect of latanoprost / timolol versus travoprost / timolol fixed combinations in NTG patients : a randomized , multicenter , crossover clinical trial", "", +17011, Latanoprost, 124, 135, "latanoprost", "", +17036, Drug, 124, 145, "latanoprost / timolol", "LTFC", +17012, Timolol, 138, 145, "timolol", "", +17013, Drug, 153, 163, "travoprost", "Travoprost", +17032, Drug, 153, 173, "travoprost / timolol", "TTFC", +17014, Timolol, 166, 173, "timolol", "Travoprost", +17015, Glaucoma, 196, 199, "NTG", "Normal Tension Glaucoma", +17017, Randomized, 213, 223, "randomized", "", +17019, Multicenter, 226, 237, "multicenter", "", +17020, Crossover, 240, 249, "crossover", "", +17021, Author, 267, 274, "Shoji T", "", +17022, Author, 283, 289, "Sato H", "", +17023, Author, 292, 302, "Mizukawa A", "", +17024, Author, 305, 313, "Hirota N", "", +17025, Author, 316, 323, "Enoki T", "", +17026, Author, 326, 334, "Kojima T", "", +17027, Author, 337, 344, "Kanda T", "", +17028, Author, 347, 357, "Takeuchi M", "", +17127, Japan, 464, 469, "Japan", "", +17029, ObjectiveDescription, 482, 668, "To compare the ocular hypotensive effect of travoprost plus timolol ( TTFC ) and latanoprost plus timolol fixed combinations ( LTFC ) in patients with normal - tension glaucoma ( NTG ) .", "", +17013, Drug, 526, 536, "travoprost", "Travoprost", +17014, Timolol, 542, 549, "timolol", "Travoprost", +17032, Drug, 552, 556, "TTFC", "TTFC", +17011, Latanoprost, 563, 574, "latanoprost", "", +17012, Timolol, 580, 587, "timolol", "", +17036, Drug, 609, 613, "LTFC", "LTFC", +17015, Glaucoma, 633, 658, "normal - tension glaucoma", "Normal Tension Glaucoma", +17015, Glaucoma, 661, 664, "NTG", "Normal Tension Glaucoma", +17040, CTDesign, 681, 695, "two - sequence", "", +17049, Duration, 696, 705, "12 - week", "", +17019, Multicenter, 708, 719, "multicenter", "", +17043, CTDesign, 722, 733, "prospective", "", +17017, Randomized, 736, 746, "randomized", "", +17045, Blind, 749, 765, "single - blinded", "", +17020, Crossover, 768, 777, "crossover", "", +17047, NumberPatientsCT, 802, 804, "59", "", +17015, Glaucoma, 805, 808, "NTG", "Normal Tension Glaucoma", +17051, Dorzolamide, 957, 968, "dorzolamide", "", +17052, Timolol, 974, 981, "timolol", "", +17053, Drug, 1002, 1006, "DTFC", "DTFC", +17017, Randomized, 1025, 1035, "randomized", "", +17020, Crossover, 1056, 1065, "crossover", "", +17049, Duration, 1093, 1101, "12 weeks", "", +17032, Drug, 1107, 1111, "TTFC", "TTFC", +17036, Drug, 1115, 1119, "LTFC", "LTFC", +17020, Crossover, 1142, 1154, "crossed over", "", +17049, Duration, 1198, 1206, "12 weeks", "", +17061, IOP, 1247, 1250, "IOP", "", +17049, Duration, 1257, 1265, "12 weeks", "", +17063, IOP, 1322, 1325, "IOP", "", +17064, Mean, 1382, 1386, "mean", "", +17065, IOP, 1396, 1399, "IOP", "", +17066, BaseLineValue, 1404, 1410, "14 . 8", "", +17067, SdErrorBL, 1413, 1418, "3 . 3", "", +17068, mmHg, 1419, 1424, "mm Hg", "", +17069, ConfIntervalBL, 1427, 1482, "95 % confidence interval [ CI ] , 14 . 1 - 15 . 3 mm Hg", "", +17070, mmHg, 1477, 1482, "mm Hg", "", +17053, Drug, 1504, 1508, "DTFC", "DTFC", +17032, Drug, 1515, 1519, "TTFC", "TTFC", +17073, Mean, 1563, 1567, "mean", "", +17074, IOP, 1568, 1571, "IOP", "", +17036, Drug, 1586, 1590, "LTFC", "LTFC", +17076, Mean, 1641, 1645, "Mean", "", +17077, IOP, 1659, 1662, "IOP", "", +17049, Duration, 1666, 1674, "12 weeks", "", +17032, Drug, 1708, 1712, "TTFC", "TTFC", +17036, Drug, 1731, 1735, "LTFC", "LTFC", +17081, Reduction, 1746, 1751, "2 . 4", "", +17082, SdErrorChangeValue, 1754, 1759, "2 . 3", "", +17083, mmHg, 1760, 1765, "mm Hg", "", +17084, Reduction, 1773, 1778, "1 . 1", "", +17085, SdErrorChangeValue, 1781, 1786, "2 . 3", "", +17086, mmHg, 1787, 1792, "mm Hg", "", +17087, PValueChangeValue, 1795, 1806, "P = 0 . 021", "", +17088, ConclusionComment, 2049, 2166, "The additional reduction in IOP was greater with TTFC than with LTFC , and their tolerability profiles were similar .", "", +17090, IOP, 2077, 2080, "IOP", "", +17032, Drug, 2098, 2102, "TTFC", "TTFC", +17036, Drug, 2113, 2117, "LTFC", "LTFC", +17089, PMID, 2282, 2290, "23950156", "", diff --git a/data/gl 23950156_jshahinitiran.n-triples b/data/gl 23950156_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23950156_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 23950156_tstrakeljahn.annodb b/data/gl 23950156_tstrakeljahn.annodb new file mode 100644 index 0000000..ada0eb4 --- /dev/null +++ b/data/gl 23950156_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +74280, Journal, 0, 25, "Invest Ophthalmol Vis Sci", "", +74281, PublicationYear, 28, 32, "2013", "", +74314, Title, 102, 266, "Hypotensive effect of latanoprost / timolol versus travoprost / timolol fixed combinations in NTG patients : a randomized , multicenter , crossover clinical trial .", "", +74282, Latanoprost, 124, 135, "latanoprost", "", +74302, Lat/TimFC, 124, 145, "latanoprost / timolol", "", +74283, Timolol, 138, 145, "timolol", "", +74284, Travoprost, 153, 163, "travoprost", "", +74303, Trav/TimFC, 153, 173, "travoprost / timolol", "", +74285, Timolol, 166, 173, "timolol", "", +74286, NormalTensionGlaucoma, 196, 199, "NTG", "", +74287, Randomized, 213, 223, "randomized", "", +74288, Multicenter, 226, 237, "multicenter", "", +74289, Crossover, 240, 249, "crossover", "", +74290, Author, 267, 274, "Shoji T", "", +74294, Author, 283, 289, "Sato H", "", +74295, Author, 292, 302, "Mizukawa A", "", +74296, Author, 305, 313, "Hirota N", "", +74297, Author, 316, 323, "Enoki T", "", +74298, Author, 326, 334, "Kojima T", "", +74299, Author, 337, 344, "Kanda T", "", +74300, Author, 347, 357, "Takeuchi M", "", +74301, Japan, 464, 469, "Japan", "", +74305, Travoprost, 526, 536, "travoprost", "", +74307, Trav/TimFC, 526, 549, "travoprost plus timolol", "", +74306, Timolol, 542, 549, "timolol", "", +74304, Trav/TimFC, 552, 556, "TTFC", "", +74308, Latanoprost, 563, 574, "latanoprost", "", +74310, Lat/TimFC, 563, 587, "latanoprost plus timolol", "", +74309, Timolol, 580, 587, "timolol", "", +74311, Lat/TimFC, 609, 613, "LTFC", "", +74312, NormalTensionGlaucoma, 633, 658, "normal - tension glaucoma", "", +74313, NormalTensionGlaucoma, 661, 664, "NTG", "", +74332, Duration, 696, 705, "12 - week", "", +74316, Multicenter, 708, 719, "multicenter", "", +74317, Prospective, 722, 733, "prospective", "", +74318, Randomized, 736, 746, "randomized", "", +74319, Blind, 749, 765, "single - blinded", "", +74320, Crossover, 768, 777, "crossover", "", +74321, NumberPatientsCT, 802, 804, "59", "", +74322, NormalTensionGlaucoma, 805, 808, "NTG", "", +74327, Precondition, 918, 999, "After a 12 - week run - in period with dorzolamide plus timolol fixed combination", "", +74323, Dorzolamide, 957, 968, "dorzolamide", "", +74325, Dorz/TimFC, 957, 999, "dorzolamide plus timolol fixed combination", "", +74324, Timolol, 974, 981, "timolol", "", +74326, Dorz/TimFC, 1002, 1006, "DTFC", "", +74328, Randomized, 1025, 1035, "randomized", "", +74329, Crossover, 1056, 1065, "crossover", "", +74330, Trav/TimFC, 1107, 1111, "TTFC", "", +74331, Lat/TimFC, 1115, 1119, "LTFC", "", +74333, IOP, 1247, 1250, "IOP", "", +74334, IOP, 1322, 1325, "IOP", "", +74335, Mean, 1382, 1386, "mean", "", +74336, IOP, 1396, 1399, "IOP", "", +74337, BaseLineValue, 1404, 1410, "14 . 8", "", +74338, SdDevBL, 1413, 1418, "3 . 3", "", +74339, mmHg, 1419, 1424, "mm Hg", "", +74340, ConfIntervalBL, 1461, 1476, "14 . 1 - 15 . 3", "", +74342, mmHg, 1477, 1482, "mm Hg", "", +74343, Dorz/TimFC, 1504, 1508, "DTFC", "", +74344, Trav/TimFC, 1515, 1519, "TTFC", "", +74346, Mean, 1563, 1567, "mean", "", +74347, IOP, 1568, 1571, "IOP", "", +74348, Lat/TimFC, 1586, 1590, "LTFC", "", +74353, Mean, 1641, 1645, "Mean", "", +74354, IOP, 1659, 1662, "IOP", "", +74355, TimePoint, 1666, 1674, "12 weeks", "", +74356, Trav/TimFC, 1708, 1712, "TTFC", "", +74357, Lat/TimFC, 1731, 1735, "LTFC", "", +74358, Reduction, 1746, 1751, "2 . 4", "", +74360, SdDevChangeValue, 1754, 1759, "2 . 3", "", +74362, mmHg, 1760, 1765, "mm Hg", "", +74359, Reduction, 1773, 1778, "1 . 1", "", +74361, SdDevChangeValue, 1781, 1786, "2 . 3", "", +74363, mmHg, 1787, 1792, "mm Hg", "", +74364, PvalueDiff, 1799, 1806, "0 . 021", "", +74377, ConclusionComment, 2049, 2166, "The additional reduction in IOP was greater with TTFC than with LTFC , and their tolerability profiles were similar .", "", +74349, IOP, 2077, 2080, "IOP", "", +74350, Travoprost, 2098, 2102, "TTFC", "", +74351, Lat/TimFC, 2113, 2117, "LTFC", "", +74352, PMID, 2282, 2290, "23950156", "", diff --git a/data/gl 23950156_tstrakeljahn.n-triples b/data/gl 23950156_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 23950156_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24073548_admin.annodb b/data/gl 24073548_admin.annodb new file mode 100644 index 0000000..cd25808 --- /dev/null +++ b/data/gl 24073548_admin.annodb @@ -0,0 +1,127 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 19, "Srp Arh Celok Lek .", "", " \"Srp Arh Celok Lek .\"." +1, PublicationYear, 20, 24, "2013", "", " \"2013\"." +2, Title, 63, 241, "Comparison of the efficacy and safety of fixed combination travoprost / timolol and dorzolamide / timolol in patients with primary open - angle glaucoma and ocular hypertension .", "", " \"Comparison of the efficacy and safety of fixed combination travoprost / timolol and dorzolamide / timolol in patients with primary open - angle glaucoma and ocular hypertension .\"." +111, Trav/TimFC, 122, 142, "travoprost / timolol", "", +3, Travoprost, 122, 132, "travoprost", "", +4, Timolol, 135, 142, "timolol", "", +50, Dorz/TimFC, 147, 168, "dorzolamide / timolol", "", +5, Dorzolamide, 147, 158, "dorzolamide", "", +6, Timolol, 161, 168, "timolol", "", +119, Precondition, 172, 239, "patients with primary open - angle glaucoma and ocular hypertension", "", " \"patients with primary open - angle glaucoma and ocular hypertension\"." +7, Primary_OpenAngleGlaucoma, 186, 215, "primary open - angle glaucoma", "", " ." +8, OcularHypertension, 220, 239, "ocular hypertension", "", " ." +10, Author, 242, 250, "Babi ć N", "", " \"Babi ć N\"." +11, Author, 259, 269, "Andrei ć V", "", " \"Andrei ć V\"." +12, Author, 272, 284, "Miljkovi ć A", "", " \"Miljkovi ć A\"." +13, Author, 287, 297, "Grkovi ć D", "", " \"Grkovi ć D\"." +14, Author, 300, 312, "Jovanovi ć P", "", " \"Jovanovi ć P\"." +18, Country, 397, 403, "Serbia", "", " . ." +15, Eyedrops, 547, 552, "drops", "", +16, ObjectiveDescription, 627, 761, "To compare the efficacy of reduced intraocular pressure ( IOP ) and safety of fixed combination travoprost 0 . 004 % / timolol 0 . 5 %", "", " \"To compare the efficacy of reduced intraocular pressure ( IOP ) and safety of fixed combination travoprost 0 . 004 % / timolol 0 . 5 %\"." +19, IOP, 662, 682, "intraocular pressure", "", +20, IOP, 685, 688, "IOP", "", +141, Trav/TimFC, 705, 761, "fixed combination travoprost 0 . 004 % / timolol 0 . 5 %", "", +21, Travoprost, 723, 733, "travoprost", "", " ." +24, DoseValue, 734, 741, "0 . 004", "", " \"0 . 004\"." +140, Percentage, 742, 743, "%", "", " ." +22, Timolol, 746, 753, "timolol", "", " ." +25, DoseValue, 754, 759, "0 . 5", "", " \"0 . 5\"." +139, Percentage, 760, 761, "%", "", " ." +17, ObjectiveDescription, 762, 890, "vs . fixed combination dorzolamide 2 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .", "", " \"vs . fixed combination dorzolamide 2 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .\"." +30, Dorz/TimFC, 767, 821, "fixed combination dorzolamide 2 % / timolol 0 . 5 % in", "", +26, Dorzolamide, 785, 796, "dorzolamide", "", " ." +28, DoseValue, 797, 798, "2", "", " \"2\"." +138, Percentage, 799, 800, "%", "", " ." +27, Timolol, 803, 810, "timolol", "", " ." +29, DoseValue, 811, 816, "0 . 5", "", " \"0 . 5\"." +137, Percentage, 817, 818, "%", "", " ." +145, Precondition, 822, 888, "patients with primary open - angle glaucoma or ocular hypertension", "", +31, Primary_OpenAngleGlaucoma, 836, 865, "primary open - angle glaucoma", "", +32, OcularHypertension, 869, 888, "ocular hypertension", "", +33, Prospective, 901, 912, "Prospective", "", " ." +34, Randomized, 913, 923, "randomized", "", " ." +35, NumberPatientsCT, 948, 950, "60", "", " \"60\"." +36, TimePoint, 1008, 1014, "day 14", "", +37, TimePoint, 1008, 1021, "day 14 and 45", "", +38, TimePoint, 1026, 1033, "month 3", "", +39, IOP, 1036, 1039, "IOP", "", +156, TimePoint, 1099, 1103, "8 am", "", +157, TimePoint, 1106, 1111, "10 am", "", +158, TimePoint, 1116, 1120, "4 pm", "", +40, IOP, 1165, 1168, "IOP", "", +41, PValueChangeValue, 1232, 1248, "p & lt ; 0 . 001", "", +42, Mean, 1253, 1257, "Mean", "", +43, IOP, 1265, 1268, "IOP", "", +44, Travoprost, 1325, 1335, "travoprost", "", +48, Trav/TimFC, 1325, 1345, "travoprost / timolol", "", +45, Timolol, 1338, 1345, "timolol", "", +47, Dorzolamide, 1370, 1381, "dorzolamide", "", +49, Dorz/TimFC, 1370, 1391, "dorzolamide / timolol", "", +46, Timolol, 1384, 1391, "timolol", "", +51, ResultMeasuredValue, 1400, 1407, "16 . 13", "", +53, mmHg, 1408, 1412, "mmHg", "", +52, ResultMeasuredValue, 1418, 1425, "16 . 15", "", +54, mmHg, 1426, 1430, "mmHg", "", +59, Mean, 1435, 1439, "Mean", "", " . ." +60, IOP, 1440, 1443, "IOP", "", " . ." +176, Reduction, 1482, 1488, "7 . 46", "", +55, mmHg, 1489, 1493, "mmHg", "", " ." +177, Reduction, 1499, 1505, "9 . 92", "", +56, mmHg, 1506, 1510, "mmHg", "", +61, Travoprost, 1518, 1528, "travoprost", "", +65, Trav/TimFC, 1518, 1538, "travoprost / timolol", "", +63, Timolol, 1531, 1538, "timolol", "", +178, Reduction, 1556, 1562, "6 . 93", "", +57, mmHg, 1563, 1567, "mmHg", "", +179, Reduction, 1573, 1579, "8 . 93", "", +58, mmHg, 1580, 1584, "mmHg", "", +62, Dorzolamide, 1593, 1604, "dorzolamide", "", +66, Dorz/TimFC, 1593, 1614, "dorzolamide / timolol", "", +64, Timolol, 1607, 1614, "timolol", "", +67, Mean, 1623, 1627, "Mean", "", " . ." +234, Mean, 1658, 1662, "mean", "", +68, Diurnal_IOP, 1678, 1689, "diurnal LOP", "", " ." +69, TimePoint, 1695, 1703, "baseline", "", +70, TimePoint, 1707, 1716, "3rd month", "", " \"3rd month\". \"3rd month\"." +71, Reduction, 1721, 1727, "8 . 96", "", " \"8 . 96\"." +73, SdErrorChangeValue, 1734, 1740, "2 . 79", "", " \"2 . 79\"." +75, Travoprost, 1748, 1758, "travoprost", "", +80, Trav/TimFC, 1748, 1768, "travoprost / timolol", "", +76, Timolol, 1761, 1768, "timolol", "", +72, Reduction, 1782, 1788, "8 . 07", "", " \"8 . 07\"." +74, SdErrorChangeValue, 1795, 1801, "2 . 91", "", " \"2 . 91\"." +78, Dorzolamide, 1824, 1835, "dorzolamide", "", +79, Dorz/TimFC, 1824, 1863, "dorzolamide / timolol fixed combination", "", +77, Timolol, 1838, 1845, "timolol", "", +235, PvalueDiff, 1868, 1877, "= 0 . 196", "", " \"= 0 . 196\"." +212, ObservedResult, 1882, 2074, "The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group .", "", " \"The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group .\". \"The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group .\". \"The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group .\"." +82, ConjunctivalHyperemia, 1940, 1962, "conjunctival hyperemia", "", " ." +83, Travoprost, 1970, 1980, "travoprost", "", +88, Trav/TimFC, 1970, 1990, "travoprost / timolol", "", +84, Timolol, 1983, 1990, "timolol", "", +94438, EndPointDescription, 2003, 2010, "dry eye", "", " . ." +94439, EndPointDescription, 2015, 2037, "foreign body sensation", "", " . ." +86, Dorzolamide, 2045, 2056, "dorzolamide", "", +87, Dorz/TimFC, 2045, 2066, "dorzolamide / timolol", "", +85, Timolol, 2059, 2066, "timolol", "", +91, Travoprost, 2088, 2098, "Travoprost", "", +95, Trav/TimFC, 2088, 2126, "Travoprost / timolol fixed combination", "", +221, ConclusionComment, 2088, 2230, "Travoprost / timolol fixed combination was slightly more effective than dorzolamide / timolol fixed combination in reducing mean diurnal IOP .", "", " \"Travoprost / timolol fixed combination was slightly more effective than dorzolamide / timolol fixed combination in reducing mean diurnal IOP .\"." +92, Timolol, 2101, 2108, "timolol", "", +94, Dorzolamide, 2160, 2171, "dorzolamide", "", +96, Dorz/TimFC, 2160, 2199, "dorzolamide / timolol fixed combination", "", +93, Timolol, 2174, 2181, "timolol", "", +97, Mean, 2212, 2216, "mean", "", +98, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +99, Travoprost, 2231, 2241, "Travoprost", "", +104, Trav/TimFC, 2231, 2251, "Travoprost / timolol", "", +231, ConclusionComment, 2231, 2350, "Travoprost / timolol group resulted in an IOP reduction for up to 1 . 07 mmHg higher than dorzolamide / timolol group .", "", " \"Travoprost / timolol group resulted in an IOP reduction for up to 1 . 07 mmHg higher than dorzolamide / timolol group .\"." +100, Timolol, 2244, 2251, "timolol", "", +101, IOP, 2273, 2276, "IOP", "", +102, mmHg, 2304, 2308, "mmHg", "", +105, Dorzolamide, 2321, 2332, "dorzolamide", "", +107, Dorz/TimFC, 2321, 2342, "dorzolamide / timolol", "", +106, Timolol, 2335, 2342, "timolol", "", +232, ConclusionComment, 2351, 2405, "Both fixed combinations were well tolerated and safe .", "", " \"Both fixed combinations were well tolerated and safe .\"." +108, PMID, 2444, 2452, "24073548", "", " \"24073548\"." diff --git a/data/gl 24073548_admin.n-triples b/data/gl 24073548_admin.n-triples new file mode 100644 index 0000000..24374d3 --- /dev/null +++ b/data/gl 24073548_admin.n-triples @@ -0,0 +1,157 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of the efficacy and safety of fixed combination travoprost / timolol and dorzolamide / timolol in patients with primary open - angle glaucoma and ocular hypertension ." . + "Babi ć N" . + "2013" . + "Srp Arh Celok Lek ." . + "24073548" . + . + "Andrei ć V" . + "Miljkovi ć A" . + "Grkovi ć D" . + "Jovanovi ć P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficacy of reduced intraocular pressure ( IOP ) and safety of fixed combination travoprost 0 . 004 % / timolol 0 . 5 %" . + "60" . + . + . + . + "Travoprost / timolol fixed combination was slightly more effective than dorzolamide / timolol fixed combination in reducing mean diurnal IOP ." . + . + . + . + . + . + "vs . fixed combination dorzolamide 2 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension ." . + . + "Travoprost / timolol group resulted in an IOP reduction for up to 1 . 07 mmHg higher than dorzolamide / timolol group ." . + "Both fixed combinations were well tolerated and safe ." . + . + . +# RDF export of group: Population + . + "Population " . + "patients with primary open - angle glaucoma and ocular hypertension" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint d IOP " . + . + . + . + . + . + . + "Endpoint CH" . + . + . + . + . + . + "Endpoint dry eye" . + . + . + . + . + . + . + "Endpoint fbs" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm trav/tim" . + . + . + . + . + "Arm dorz/tim" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention trav/tim" . + . + . + . + . + "Intervention dorz/tim" . + . + . + . +# RDF export of group: Medication + . + "Medication trav" . + . + "0 . 004" . + . + . + . + "Medication tim" . + . + "0 . 5" . + . + . + . + "Medication d" . + . + "2" . + . + . + . + "Medication tim2" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome IOP dt" . + . + "8 . 07" . + "2 . 91" . + "3rd month" . + . + . + "Outcome CH tt" . + . + "The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group ." . + . + "Outcome de dt " . + . + "The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group ." . + . + "Outcome fbs dt " . + . + "The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group ." . + . + "Outcome IOP tt" . + . + "8 . 96" . + "2 . 79" . + "3rd month" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups d IOP " . + "= 0 . 196" . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24073548_export.csv b/data/gl 24073548_export.csv new file mode 100644 index 0000000..c915b0b --- /dev/null +++ b/data/gl 24073548_export.csv @@ -0,0 +1,502 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +544, 1, 1, 1, 0, 3, 0, 3, "Srp" +544, 1, 2, 2, 4, 7, 4, 7, "Arh" +544, 1, 3, 3, 8, 13, 8, 13, "Celok" +544, 1, 4, 4, 14, 17, 14, 17, "Lek" +544, 1, 5, 5, 18, 19, 18, 19, "." +544, 2, 1, 6, 0, 4, 20, 24, "2013" +544, 2, 2, 7, 5, 8, 25, 28, "Jul" +544, 2, 3, 8, 9, 10, 29, 30, "-" +544, 2, 4, 9, 11, 14, 31, 34, "Aug" +544, 2, 5, 10, 15, 16, 35, 36, ";" +544, 2, 6, 11, 17, 20, 37, 40, "141" +544, 2, 7, 12, 21, 22, 41, 42, "(" +544, 2, 8, 13, 23, 24, 43, 44, "7" +544, 2, 9, 14, 25, 26, 45, 46, "-" +544, 2, 10, 15, 27, 28, 47, 48, "8" +544, 2, 11, 16, 29, 30, 49, 50, ")" +544, 2, 12, 17, 31, 32, 51, 52, ":" +544, 2, 13, 18, 33, 36, 53, 56, "441" +544, 2, 14, 19, 37, 38, 57, 58, "-" +544, 2, 15, 20, 39, 40, 59, 60, "6" +544, 2, 16, 21, 41, 42, 61, 62, "." +544, 3, 1, 22, 0, 10, 63, 73, "Comparison" +544, 3, 2, 23, 11, 13, 74, 76, "of" +544, 3, 3, 24, 14, 17, 77, 80, "the" +544, 3, 4, 25, 18, 26, 81, 89, "efficacy" +544, 3, 5, 26, 27, 30, 90, 93, "and" +544, 3, 6, 27, 31, 37, 94, 100, "safety" +544, 3, 7, 28, 38, 40, 101, 103, "of" +544, 3, 8, 29, 41, 46, 104, 109, "fixed" +544, 3, 9, 30, 47, 58, 110, 121, "combination" +544, 3, 10, 31, 59, 69, 122, 132, "travoprost" +544, 3, 11, 32, 70, 71, 133, 134, "/" +544, 3, 12, 33, 72, 79, 135, 142, "timolol" +544, 3, 13, 34, 80, 83, 143, 146, "and" +544, 3, 14, 35, 84, 95, 147, 158, "dorzolamide" +544, 3, 15, 36, 96, 97, 159, 160, "/" +544, 3, 16, 37, 98, 105, 161, 168, "timolol" +544, 3, 17, 38, 106, 108, 169, 171, "in" +544, 3, 18, 39, 109, 117, 172, 180, "patients" +544, 3, 19, 40, 118, 122, 181, 185, "with" +544, 3, 20, 41, 123, 130, 186, 193, "primary" +544, 3, 21, 42, 131, 135, 194, 198, "open" +544, 3, 22, 43, 136, 137, 199, 200, "-" +544, 3, 23, 44, 138, 143, 201, 206, "angle" +544, 3, 24, 45, 144, 152, 207, 215, "glaucoma" +544, 3, 25, 46, 153, 156, 216, 219, "and" +544, 3, 26, 47, 157, 163, 220, 226, "ocular" +544, 3, 27, 48, 164, 176, 227, 239, "hypertension" +544, 3, 28, 49, 177, 178, 240, 241, "." +544, 4, 1, 50, 0, 4, 242, 246, "Babi" +544, 4, 2, 51, 5, 6, 247, 248, "ć" +544, 4, 3, 52, 7, 8, 249, 250, "N" +544, 4, 4, 53, 9, 10, 251, 252, "(" +544, 4, 5, 54, 11, 12, 253, 254, "1" +544, 4, 6, 55, 13, 14, 255, 256, ")" +544, 4, 7, 56, 15, 16, 257, 258, "," +544, 4, 8, 57, 17, 23, 259, 265, "Andrei" +544, 4, 9, 58, 24, 25, 266, 267, "ć" +544, 4, 10, 59, 26, 27, 268, 269, "V" +544, 4, 11, 60, 28, 29, 270, 271, "," +544, 4, 12, 61, 30, 38, 272, 280, "Miljkovi" +544, 4, 13, 62, 39, 40, 281, 282, "ć" +544, 4, 14, 63, 41, 42, 283, 284, "A" +544, 4, 15, 64, 43, 44, 285, 286, "," +544, 4, 16, 65, 45, 51, 287, 293, "Grkovi" +544, 4, 17, 66, 52, 53, 294, 295, "ć" +544, 4, 18, 67, 54, 55, 296, 297, "D" +544, 4, 19, 68, 56, 57, 298, 299, "," +544, 4, 20, 69, 58, 66, 300, 308, "Jovanovi" +544, 4, 21, 70, 67, 68, 309, 310, "ć" +544, 4, 22, 71, 69, 70, 311, 312, "P" +544, 4, 23, 72, 71, 72, 313, 314, "." +544, 4, 24, 73, 73, 79, 315, 321, "Author" +544, 4, 25, 74, 80, 91, 322, 333, "information" +544, 4, 26, 75, 92, 93, 334, 335, ":" +544, 4, 27, 76, 94, 95, 336, 337, "(" +544, 4, 28, 77, 96, 97, 338, 339, "1" +544, 4, 29, 78, 98, 99, 340, 341, ")" +544, 4, 30, 79, 100, 103, 342, 345, "Eye" +544, 4, 31, 80, 104, 110, 346, 352, "Clinic" +544, 4, 32, 81, 111, 112, 353, 354, "," +544, 4, 33, 82, 113, 121, 355, 363, "Clinical" +544, 4, 34, 83, 122, 128, 364, 370, "Center" +544, 4, 35, 84, 129, 131, 371, 373, "of" +544, 4, 36, 85, 132, 141, 374, 383, "Vojvodina" +544, 4, 37, 86, 142, 143, 384, 385, "," +544, 4, 38, 87, 144, 148, 386, 390, "Novi" +544, 4, 39, 88, 149, 152, 391, 394, "Sad" +544, 4, 40, 89, 153, 154, 395, 396, "," +544, 4, 41, 90, 155, 161, 397, 403, "Serbia" +544, 4, 42, 91, 162, 163, 404, 405, "." +544, 5, 1, 92, 0, 7, 406, 413, "nikobab" +544, 5, 2, 93, 8, 9, 414, 415, "@" +544, 5, 3, 94, 10, 13, 416, 419, "sbb" +544, 5, 4, 95, 14, 15, 420, 421, "." +544, 5, 5, 96, 16, 18, 422, 424, "rs" +544, 5, 6, 97, 19, 31, 425, 437, "INTRODUCTION" +544, 5, 7, 98, 32, 33, 438, 439, ":" +544, 5, 8, 99, 34, 43, 440, 449, "Combining" +544, 5, 9, 100, 44, 47, 450, 453, "two" +544, 5, 10, 101, 48, 59, 454, 465, "medications" +544, 5, 11, 102, 60, 62, 466, 468, "in" +544, 5, 12, 103, 63, 66, 469, 472, "one" +544, 5, 13, 104, 67, 73, 473, 479, "bottle" +544, 5, 14, 105, 74, 77, 480, 483, "may" +544, 5, 15, 106, 78, 85, 484, 491, "improve" +544, 5, 16, 107, 86, 96, 492, 502, "compliance" +544, 5, 17, 108, 97, 99, 503, 505, "by" +544, 5, 18, 109, 100, 108, 506, 514, "reducing" +544, 5, 19, 110, 109, 112, 515, 518, "the" +544, 5, 20, 111, 113, 117, 519, 523, "time" +544, 5, 21, 112, 118, 126, 524, 532, "required" +544, 5, 22, 113, 127, 129, 533, 535, "to" +544, 5, 23, 114, 130, 140, 536, 546, "administer" +544, 5, 24, 115, 141, 146, 547, 552, "drops" +544, 5, 25, 116, 147, 150, 553, 556, "and" +544, 5, 26, 117, 151, 154, 557, 560, "the" +544, 5, 27, 118, 155, 164, 561, 570, "frequency" +544, 5, 28, 119, 165, 167, 571, 573, "of" +544, 5, 29, 120, 168, 171, 574, 577, "the" +544, 5, 30, 121, 172, 177, 578, 583, "total" +544, 5, 31, 122, 178, 184, 584, 590, "number" +544, 5, 32, 123, 185, 187, 591, 593, "of" +544, 5, 33, 124, 188, 198, 594, 604, "medication" +544, 5, 34, 125, 199, 206, 605, 612, "bottles" +544, 5, 35, 126, 207, 208, 613, 614, "." +544, 6, 1, 127, 0, 9, 615, 624, "OBJECTIVE" +544, 6, 2, 128, 10, 11, 625, 626, ":" +544, 6, 3, 129, 12, 14, 627, 629, "To" +544, 6, 4, 130, 15, 22, 630, 637, "compare" +544, 6, 5, 131, 23, 26, 638, 641, "the" +544, 6, 6, 132, 27, 35, 642, 650, "efficacy" +544, 6, 7, 133, 36, 38, 651, 653, "of" +544, 6, 8, 134, 39, 46, 654, 661, "reduced" +544, 6, 9, 135, 47, 58, 662, 673, "intraocular" +544, 6, 10, 136, 59, 67, 674, 682, "pressure" +544, 6, 11, 137, 68, 69, 683, 684, "(" +544, 6, 12, 138, 70, 73, 685, 688, "IOP" +544, 6, 13, 139, 74, 75, 689, 690, ")" +544, 6, 14, 140, 76, 79, 691, 694, "and" +544, 6, 15, 141, 80, 86, 695, 701, "safety" +544, 6, 16, 142, 87, 89, 702, 704, "of" +544, 6, 17, 143, 90, 95, 705, 710, "fixed" +544, 6, 18, 144, 96, 107, 711, 722, "combination" +544, 6, 19, 145, 108, 118, 723, 733, "travoprost" +544, 6, 20, 146, 119, 120, 734, 735, "0" +544, 6, 21, 147, 121, 122, 736, 737, "." +544, 6, 22, 148, 123, 126, 738, 741, "004" +544, 6, 23, 149, 127, 128, 742, 743, "%" +544, 6, 24, 150, 129, 130, 744, 745, "/" +544, 6, 25, 151, 131, 138, 746, 753, "timolol" +544, 6, 26, 152, 139, 140, 754, 755, "0" +544, 6, 27, 153, 141, 142, 756, 757, "." +544, 6, 28, 154, 143, 144, 758, 759, "5" +544, 6, 29, 155, 145, 146, 760, 761, "%" +544, 6, 30, 156, 147, 149, 762, 764, "vs" +544, 6, 31, 157, 150, 151, 765, 766, "." +544, 6, 32, 158, 152, 157, 767, 772, "fixed" +544, 6, 33, 159, 158, 169, 773, 784, "combination" +544, 6, 34, 160, 170, 181, 785, 796, "dorzolamide" +544, 6, 35, 161, 182, 183, 797, 798, "2" +544, 6, 36, 162, 184, 185, 799, 800, "%" +544, 6, 37, 163, 186, 187, 801, 802, "/" +544, 6, 38, 164, 188, 195, 803, 810, "timolol" +544, 6, 39, 165, 196, 197, 811, 812, "0" +544, 6, 40, 166, 198, 199, 813, 814, "." +544, 6, 41, 167, 200, 201, 815, 816, "5" +544, 6, 42, 168, 202, 203, 817, 818, "%" +544, 6, 43, 169, 204, 206, 819, 821, "in" +544, 6, 44, 170, 207, 215, 822, 830, "patients" +544, 6, 45, 171, 216, 220, 831, 835, "with" +544, 6, 46, 172, 221, 228, 836, 843, "primary" +544, 6, 47, 173, 229, 233, 844, 848, "open" +544, 6, 48, 174, 234, 235, 849, 850, "-" +544, 6, 49, 175, 236, 241, 851, 856, "angle" +544, 6, 50, 176, 242, 250, 857, 865, "glaucoma" +544, 6, 51, 177, 251, 253, 866, 868, "or" +544, 6, 52, 178, 254, 260, 869, 875, "ocular" +544, 6, 53, 179, 261, 273, 876, 888, "hypertension" +544, 6, 54, 180, 274, 275, 889, 890, "." +544, 7, 1, 181, 0, 7, 891, 898, "METHODS" +544, 7, 2, 182, 8, 9, 899, 900, ":" +544, 7, 3, 183, 10, 21, 901, 912, "Prospective" +544, 7, 4, 184, 22, 32, 913, 923, "randomized" +544, 7, 5, 185, 33, 41, 924, 932, "clinical" +544, 7, 6, 186, 42, 47, 933, 938, "study" +544, 7, 7, 187, 48, 56, 939, 947, "included" +544, 7, 8, 188, 57, 59, 948, 950, "60" +544, 7, 9, 189, 60, 68, 951, 959, "patients" +544, 7, 10, 190, 69, 76, 960, 967, "divided" +544, 7, 11, 191, 77, 81, 968, 972, "into" +544, 7, 12, 192, 82, 83, 973, 974, "2" +544, 7, 13, 193, 84, 90, 975, 981, "groups" +544, 7, 14, 194, 91, 92, 982, 983, "." +544, 8, 1, 195, 0, 6, 984, 990, "Follow" +544, 8, 2, 196, 7, 8, 991, 992, "-" +544, 8, 3, 197, 9, 11, 993, 995, "up" +544, 8, 4, 198, 12, 15, 996, 999, "was" +544, 8, 5, 199, 16, 20, 1000, 1004, "done" +544, 8, 6, 200, 21, 23, 1005, 1007, "at" +544, 8, 7, 201, 24, 27, 1008, 1011, "day" +544, 8, 8, 202, 28, 30, 1012, 1014, "14" +544, 8, 9, 203, 31, 34, 1015, 1018, "and" +544, 8, 10, 204, 35, 37, 1019, 1021, "45" +544, 8, 11, 205, 38, 41, 1022, 1025, "and" +544, 8, 12, 206, 42, 47, 1026, 1031, "month" +544, 8, 13, 207, 48, 49, 1032, 1033, "3" +544, 8, 14, 208, 50, 51, 1034, 1035, "." +544, 9, 1, 209, 0, 3, 1036, 1039, "IOP" +544, 9, 2, 210, 4, 16, 1040, 1052, "measurements" +544, 9, 3, 211, 17, 21, 1053, 1057, "were" +544, 9, 4, 212, 22, 27, 1058, 1063, "taken" +544, 9, 5, 213, 28, 30, 1064, 1066, "at" +544, 9, 6, 214, 31, 35, 1067, 1071, "each" +544, 9, 7, 215, 36, 42, 1072, 1078, "follow" +544, 9, 8, 216, 43, 44, 1079, 1080, "-" +544, 9, 9, 217, 45, 47, 1081, 1083, "up" +544, 9, 10, 218, 48, 59, 1084, 1095, "examination" +544, 9, 11, 219, 60, 62, 1096, 1098, "at" +544, 9, 12, 220, 63, 64, 1099, 1100, "8" +544, 9, 13, 221, 65, 67, 1101, 1103, "am" +544, 9, 14, 222, 68, 69, 1104, 1105, "," +544, 9, 15, 223, 70, 72, 1106, 1108, "10" +544, 9, 16, 224, 73, 75, 1109, 1111, "am" +544, 9, 17, 225, 76, 79, 1112, 1115, "and" +544, 9, 18, 226, 80, 81, 1116, 1117, "4" +544, 9, 19, 227, 82, 84, 1118, 1120, "pm" +544, 9, 20, 228, 85, 86, 1121, 1122, "." +544, 10, 1, 229, 0, 7, 1123, 1130, "RESULTS" +544, 10, 2, 230, 8, 9, 1131, 1132, ":" +544, 10, 3, 231, 10, 14, 1133, 1137, "Both" +544, 10, 4, 232, 15, 20, 1138, 1143, "fixed" +544, 10, 5, 233, 21, 33, 1144, 1156, "combinations" +544, 10, 6, 234, 34, 41, 1157, 1164, "reduced" +544, 10, 7, 235, 42, 45, 1165, 1168, "IOP" +544, 10, 8, 236, 46, 59, 1169, 1182, "significantly" +544, 10, 9, 237, 60, 68, 1183, 1191, "compared" +544, 10, 10, 238, 69, 71, 1192, 1194, "to" +544, 10, 11, 239, 72, 79, 1195, 1202, "initial" +544, 10, 12, 240, 80, 86, 1203, 1209, "values" +544, 10, 13, 241, 87, 89, 1210, 1212, "at" +544, 10, 14, 242, 90, 93, 1213, 1216, "all" +544, 10, 15, 243, 94, 100, 1217, 1223, "follow" +544, 10, 16, 244, 101, 102, 1224, 1225, "-" +544, 10, 17, 245, 103, 106, 1226, 1229, "ups" +544, 10, 18, 246, 107, 108, 1230, 1231, "(" +544, 10, 19, 247, 109, 110, 1232, 1233, "p" +544, 10, 20, 248, 111, 112, 1234, 1235, "&" +544, 10, 21, 249, 113, 115, 1236, 1238, "lt" +544, 10, 22, 250, 116, 117, 1239, 1240, ";" +544, 10, 23, 251, 118, 119, 1241, 1242, "0" +544, 10, 24, 252, 120, 121, 1243, 1244, "." +544, 10, 25, 253, 122, 125, 1245, 1248, "001" +544, 10, 26, 254, 126, 127, 1249, 1250, ")" +544, 10, 27, 255, 128, 129, 1251, 1252, "." +544, 11, 1, 256, 0, 4, 1253, 1257, "Mean" +544, 11, 2, 257, 5, 11, 1258, 1264, "pooled" +544, 11, 3, 258, 12, 15, 1265, 1268, "IOP" +544, 11, 4, 259, 16, 18, 1269, 1271, "at" +544, 11, 5, 260, 19, 22, 1272, 1275, "all" +544, 11, 6, 261, 23, 29, 1276, 1282, "visits" +544, 11, 7, 262, 30, 33, 1283, 1286, "and" +544, 11, 8, 263, 34, 38, 1287, 1291, "time" +544, 11, 9, 264, 39, 45, 1292, 1298, "points" +544, 11, 10, 265, 46, 49, 1299, 1302, "was" +544, 11, 11, 266, 50, 58, 1303, 1311, "slightly" +544, 11, 12, 267, 59, 64, 1312, 1317, "lower" +544, 11, 13, 268, 65, 67, 1318, 1320, "in" +544, 11, 14, 269, 68, 71, 1321, 1324, "the" +544, 11, 15, 270, 72, 82, 1325, 1335, "travoprost" +544, 11, 16, 271, 83, 84, 1336, 1337, "/" +544, 11, 17, 272, 85, 92, 1338, 1345, "timolol" +544, 11, 18, 273, 93, 98, 1346, 1351, "group" +544, 11, 19, 274, 99, 107, 1352, 1360, "compared" +544, 11, 20, 275, 108, 112, 1361, 1365, "with" +544, 11, 21, 276, 113, 116, 1366, 1369, "the" +544, 11, 22, 277, 117, 128, 1370, 1381, "dorzolamide" +544, 11, 23, 278, 129, 130, 1382, 1383, "/" +544, 11, 24, 279, 131, 138, 1384, 1391, "timolol" +544, 11, 25, 280, 139, 144, 1392, 1397, "group" +544, 11, 26, 281, 145, 146, 1398, 1399, "(" +544, 11, 27, 282, 147, 149, 1400, 1402, "16" +544, 11, 28, 283, 150, 151, 1403, 1404, "." +544, 11, 29, 284, 152, 154, 1405, 1407, "13" +544, 11, 30, 285, 155, 159, 1408, 1412, "mmHg" +544, 11, 31, 286, 160, 162, 1413, 1415, "vs" +544, 11, 32, 287, 163, 164, 1416, 1417, "." +544, 11, 33, 288, 165, 167, 1418, 1420, "16" +544, 11, 34, 289, 168, 169, 1421, 1422, "." +544, 11, 35, 290, 170, 172, 1423, 1425, "15" +544, 11, 36, 291, 173, 177, 1426, 1430, "mmHg" +544, 11, 37, 292, 178, 179, 1431, 1432, ")" +544, 11, 38, 293, 180, 181, 1433, 1434, "." +544, 12, 1, 294, 0, 4, 1435, 1439, "Mean" +544, 12, 2, 295, 5, 8, 1440, 1443, "IOP" +544, 12, 3, 296, 9, 18, 1444, 1453, "reduction" +544, 12, 4, 297, 19, 23, 1454, 1458, "from" +544, 12, 5, 298, 24, 32, 1459, 1467, "baseline" +544, 12, 6, 299, 33, 39, 1468, 1474, "ranged" +544, 12, 7, 300, 40, 44, 1475, 1479, "from" +544, 12, 8, 301, 45, 46, 1480, 1481, "-" +544, 12, 9, 302, 47, 48, 1482, 1483, "7" +544, 12, 10, 303, 49, 50, 1484, 1485, "." +544, 12, 11, 304, 51, 53, 1486, 1488, "46" +544, 12, 12, 305, 54, 58, 1489, 1493, "mmHg" +544, 12, 13, 306, 59, 61, 1494, 1496, "to" +544, 12, 14, 307, 62, 63, 1497, 1498, "-" +544, 12, 15, 308, 64, 65, 1499, 1500, "9" +544, 12, 16, 309, 66, 67, 1501, 1502, "." +544, 12, 17, 310, 68, 70, 1503, 1505, "92" +544, 12, 18, 311, 71, 75, 1506, 1510, "mmHg" +544, 12, 19, 312, 76, 78, 1511, 1513, "in" +544, 12, 20, 313, 79, 82, 1514, 1517, "the" +544, 12, 21, 314, 83, 93, 1518, 1528, "travoprost" +544, 12, 22, 315, 94, 95, 1529, 1530, "/" +544, 12, 23, 316, 96, 103, 1531, 1538, "timolol" +544, 12, 24, 317, 104, 109, 1539, 1544, "group" +544, 12, 25, 318, 110, 113, 1545, 1548, "and" +544, 12, 26, 319, 114, 118, 1549, 1553, "from" +544, 12, 27, 320, 119, 120, 1554, 1555, "-" +544, 12, 28, 321, 121, 122, 1556, 1557, "6" +544, 12, 29, 322, 123, 124, 1558, 1559, "." +544, 12, 30, 323, 125, 127, 1560, 1562, "93" +544, 12, 31, 324, 128, 132, 1563, 1567, "mmHg" +544, 12, 32, 325, 133, 135, 1568, 1570, "to" +544, 12, 33, 326, 136, 137, 1571, 1572, "-" +544, 12, 34, 327, 138, 139, 1573, 1574, "8" +544, 12, 35, 328, 140, 141, 1575, 1576, "." +544, 12, 36, 329, 142, 144, 1577, 1579, "93" +544, 12, 37, 330, 145, 149, 1580, 1584, "mmHg" +544, 12, 38, 331, 150, 153, 1585, 1588, "for" +544, 12, 39, 332, 154, 157, 1589, 1592, "the" +544, 12, 40, 333, 158, 169, 1593, 1604, "dorzolamide" +544, 12, 41, 334, 170, 171, 1605, 1606, "/" +544, 12, 42, 335, 172, 179, 1607, 1614, "timolol" +544, 12, 43, 336, 180, 185, 1615, 1620, "group" +544, 12, 44, 337, 186, 187, 1621, 1622, "." +544, 13, 1, 338, 0, 4, 1623, 1627, "Mean" +544, 13, 2, 339, 5, 6, 1628, 1629, "(" +544, 13, 3, 340, 7, 8, 1630, 1631, "+" +544, 13, 4, 341, 9, 10, 1632, 1633, "/" +544, 13, 5, 342, 11, 12, 1634, 1635, "-" +544, 13, 6, 343, 13, 21, 1636, 1644, "standard" +544, 13, 7, 344, 22, 27, 1645, 1650, "error" +544, 13, 8, 345, 28, 30, 1651, 1653, "of" +544, 13, 9, 346, 31, 34, 1654, 1657, "the" +544, 13, 10, 347, 35, 39, 1658, 1662, "mean" +544, 13, 11, 348, 40, 41, 1663, 1664, ")" +544, 13, 12, 349, 42, 51, 1665, 1674, "reduction" +544, 13, 13, 350, 52, 54, 1675, 1677, "in" +544, 13, 14, 351, 55, 62, 1678, 1685, "diurnal" +544, 13, 15, 352, 63, 66, 1686, 1689, "LOP" +544, 13, 16, 353, 67, 71, 1690, 1694, "from" +544, 13, 17, 354, 72, 80, 1695, 1703, "baseline" +544, 13, 18, 355, 81, 83, 1704, 1706, "to" +544, 13, 19, 356, 84, 87, 1707, 1710, "3rd" +544, 13, 20, 357, 88, 93, 1711, 1716, "month" +544, 13, 21, 358, 94, 97, 1717, 1720, "was" +544, 13, 22, 359, 98, 99, 1721, 1722, "8" +544, 13, 23, 360, 100, 101, 1723, 1724, "." +544, 13, 24, 361, 102, 104, 1725, 1727, "96" +544, 13, 25, 362, 105, 106, 1728, 1729, "+" +544, 13, 26, 363, 107, 108, 1730, 1731, "/" +544, 13, 27, 364, 109, 110, 1732, 1733, "-" +544, 13, 28, 365, 111, 112, 1734, 1735, "2" +544, 13, 29, 366, 113, 114, 1736, 1737, "." +544, 13, 30, 367, 115, 117, 1738, 1740, "79" +544, 13, 31, 368, 118, 120, 1741, 1743, "in" +544, 13, 32, 369, 121, 124, 1744, 1747, "the" +544, 13, 33, 370, 125, 135, 1748, 1758, "travoprost" +544, 13, 34, 371, 136, 137, 1759, 1760, "/" +544, 13, 35, 372, 138, 145, 1761, 1768, "timolol" +544, 13, 36, 373, 146, 151, 1769, 1774, "group" +544, 13, 37, 374, 152, 158, 1775, 1781, "versus" +544, 13, 38, 375, 159, 160, 1782, 1783, "8" +544, 13, 39, 376, 161, 162, 1784, 1785, "." +544, 13, 40, 377, 163, 165, 1786, 1788, "07" +544, 13, 41, 378, 166, 167, 1789, 1790, "+" +544, 13, 42, 379, 168, 169, 1791, 1792, "/" +544, 13, 43, 380, 170, 171, 1793, 1794, "-" +544, 13, 44, 381, 172, 173, 1795, 1796, "2" +544, 13, 45, 382, 174, 175, 1797, 1798, "." +544, 13, 46, 383, 176, 178, 1799, 1801, "91" +544, 13, 47, 384, 179, 181, 1802, 1804, "in" +544, 13, 48, 385, 182, 190, 1805, 1813, "patients" +544, 13, 49, 386, 191, 200, 1814, 1823, "receiving" +544, 13, 50, 387, 201, 212, 1824, 1835, "dorzolamide" +544, 13, 51, 388, 213, 214, 1836, 1837, "/" +544, 13, 52, 389, 215, 222, 1838, 1845, "timolol" +544, 13, 53, 390, 223, 228, 1846, 1851, "fixed" +544, 13, 54, 391, 229, 240, 1852, 1863, "combination" +544, 13, 55, 392, 241, 242, 1864, 1865, "(" +544, 13, 56, 393, 243, 244, 1866, 1867, "p" +544, 13, 57, 394, 245, 246, 1868, 1869, "=" +544, 13, 58, 395, 247, 248, 1870, 1871, "0" +544, 13, 59, 396, 249, 250, 1872, 1873, "." +544, 13, 60, 397, 251, 254, 1874, 1877, "196" +544, 13, 61, 398, 255, 256, 1878, 1879, ")" +544, 13, 62, 399, 257, 258, 1880, 1881, "." +544, 14, 1, 400, 0, 3, 1882, 1885, "The" +544, 14, 2, 401, 4, 8, 1886, 1890, "most" +544, 14, 3, 402, 9, 17, 1891, 1899, "frequent" +544, 14, 4, 403, 18, 27, 1900, 1909, "treatment" +544, 14, 5, 404, 28, 29, 1910, 1911, "-" +544, 14, 6, 405, 30, 37, 1912, 1919, "related" +544, 14, 7, 406, 38, 45, 1920, 1927, "adverse" +544, 14, 8, 407, 46, 52, 1928, 1934, "events" +544, 14, 9, 408, 53, 57, 1935, 1939, "were" +544, 14, 10, 409, 58, 70, 1940, 1952, "conjunctival" +544, 14, 11, 410, 71, 80, 1953, 1962, "hyperemia" +544, 14, 12, 411, 81, 83, 1963, 1965, "in" +544, 14, 13, 412, 84, 87, 1966, 1969, "the" +544, 14, 14, 413, 88, 98, 1970, 1980, "travoprost" +544, 14, 15, 414, 99, 100, 1981, 1982, "/" +544, 14, 16, 415, 101, 108, 1983, 1990, "timolol" +544, 14, 17, 416, 109, 114, 1991, 1996, "group" +544, 14, 18, 417, 115, 116, 1997, 1998, "," +544, 14, 19, 418, 117, 120, 1999, 2002, "and" +544, 14, 20, 419, 121, 124, 2003, 2006, "dry" +544, 14, 21, 420, 125, 128, 2007, 2010, "eye" +544, 14, 22, 421, 129, 132, 2011, 2014, "and" +544, 14, 23, 422, 133, 140, 2015, 2022, "foreign" +544, 14, 24, 423, 141, 145, 2023, 2027, "body" +544, 14, 25, 424, 146, 155, 2028, 2037, "sensation" +544, 14, 26, 425, 156, 158, 2038, 2040, "in" +544, 14, 27, 426, 159, 162, 2041, 2044, "the" +544, 14, 28, 427, 163, 174, 2045, 2056, "dorzolamide" +544, 14, 29, 428, 175, 176, 2057, 2058, "/" +544, 14, 30, 429, 177, 184, 2059, 2066, "timolol" +544, 14, 31, 430, 185, 190, 2067, 2072, "group" +544, 14, 32, 431, 191, 192, 2073, 2074, "." +544, 15, 1, 432, 0, 10, 2075, 2085, "CONCLUSION" +544, 15, 2, 433, 11, 12, 2086, 2087, ":" +544, 15, 3, 434, 13, 23, 2088, 2098, "Travoprost" +544, 15, 4, 435, 24, 25, 2099, 2100, "/" +544, 15, 5, 436, 26, 33, 2101, 2108, "timolol" +544, 15, 6, 437, 34, 39, 2109, 2114, "fixed" +544, 15, 7, 438, 40, 51, 2115, 2126, "combination" +544, 15, 8, 439, 52, 55, 2127, 2130, "was" +544, 15, 9, 440, 56, 64, 2131, 2139, "slightly" +544, 15, 10, 441, 65, 69, 2140, 2144, "more" +544, 15, 11, 442, 70, 79, 2145, 2154, "effective" +544, 15, 12, 443, 80, 84, 2155, 2159, "than" +544, 15, 13, 444, 85, 96, 2160, 2171, "dorzolamide" +544, 15, 14, 445, 97, 98, 2172, 2173, "/" +544, 15, 15, 446, 99, 106, 2174, 2181, "timolol" +544, 15, 16, 447, 107, 112, 2182, 2187, "fixed" +544, 15, 17, 448, 113, 124, 2188, 2199, "combination" +544, 15, 18, 449, 125, 127, 2200, 2202, "in" +544, 15, 19, 450, 128, 136, 2203, 2211, "reducing" +544, 15, 20, 451, 137, 141, 2212, 2216, "mean" +544, 15, 21, 452, 142, 149, 2217, 2224, "diurnal" +544, 15, 22, 453, 150, 153, 2225, 2228, "IOP" +544, 15, 23, 454, 154, 155, 2229, 2230, "." +544, 16, 1, 455, 0, 10, 2231, 2241, "Travoprost" +544, 16, 2, 456, 11, 12, 2242, 2243, "/" +544, 16, 3, 457, 13, 20, 2244, 2251, "timolol" +544, 16, 4, 458, 21, 26, 2252, 2257, "group" +544, 16, 5, 459, 27, 35, 2258, 2266, "resulted" +544, 16, 6, 460, 36, 38, 2267, 2269, "in" +544, 16, 7, 461, 39, 41, 2270, 2272, "an" +544, 16, 8, 462, 42, 45, 2273, 2276, "IOP" +544, 16, 9, 463, 46, 55, 2277, 2286, "reduction" +544, 16, 10, 464, 56, 59, 2287, 2290, "for" +544, 16, 11, 465, 60, 62, 2291, 2293, "up" +544, 16, 12, 466, 63, 65, 2294, 2296, "to" +544, 16, 13, 467, 66, 67, 2297, 2298, "1" +544, 16, 14, 468, 68, 69, 2299, 2300, "." +544, 16, 15, 469, 70, 72, 2301, 2303, "07" +544, 16, 16, 470, 73, 77, 2304, 2308, "mmHg" +544, 16, 17, 471, 78, 84, 2309, 2315, "higher" +544, 16, 18, 472, 85, 89, 2316, 2320, "than" +544, 16, 19, 473, 90, 101, 2321, 2332, "dorzolamide" +544, 16, 20, 474, 102, 103, 2333, 2334, "/" +544, 16, 21, 475, 104, 111, 2335, 2342, "timolol" +544, 16, 22, 476, 112, 117, 2343, 2348, "group" +544, 16, 23, 477, 118, 119, 2349, 2350, "." +544, 17, 1, 478, 0, 4, 2351, 2355, "Both" +544, 17, 2, 479, 5, 10, 2356, 2361, "fixed" +544, 17, 3, 480, 11, 23, 2362, 2374, "combinations" +544, 17, 4, 481, 24, 28, 2375, 2379, "were" +544, 17, 5, 482, 29, 33, 2380, 2384, "well" +544, 17, 6, 483, 34, 43, 2385, 2394, "tolerated" +544, 17, 7, 484, 44, 47, 2395, 2398, "and" +544, 17, 8, 485, 48, 52, 2399, 2403, "safe" +544, 17, 9, 486, 53, 54, 2404, 2405, "." +544, 18, 1, 487, 0, 3, 2406, 2409, "DOI" +544, 18, 2, 488, 4, 5, 2410, 2411, ":" +544, 18, 3, 489, 6, 8, 2412, 2414, "10" +544, 18, 4, 490, 9, 10, 2415, 2416, "." +544, 18, 5, 491, 11, 15, 2417, 2421, "2298" +544, 18, 6, 492, 16, 17, 2422, 2423, "/" +544, 18, 7, 493, 18, 30, 2424, 2436, "sarh1308441b" +544, 18, 8, 494, 31, 35, 2437, 2441, "PMID" +544, 18, 9, 495, 36, 37, 2442, 2443, ":" +544, 18, 10, 496, 38, 46, 2444, 2452, "24073548" +544, 18, 11, 497, 47, 48, 2453, 2454, "[" +544, 18, 12, 498, 49, 56, 2455, 2462, "Indexed" +544, 18, 13, 499, 57, 60, 2463, 2466, "for" +544, 18, 14, 500, 61, 68, 2467, 2474, "MEDLINE" +544, 18, 15, 501, 69, 70, 2475, 2476, "]" diff --git a/data/gl 24073548_jshahinitiran.annodb b/data/gl 24073548_jshahinitiran.annodb new file mode 100644 index 0000000..309e71f --- /dev/null +++ b/data/gl 24073548_jshahinitiran.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +87438, Journal, 0, 17, "Srp Arh Celok Lek", "", +87439, PublicationYear, 20, 24, "2013", "", +87440, Title, 63, 241, "Comparison of the efficacy and safety of fixed combination travoprost / timolol and dorzolamide / timolol in patients with primary open - angle glaucoma and ocular hypertension .", "", +87447, Trav/TimFC, 104, 142, "fixed combination travoprost / timolol", "", +87441, Travoprost, 122, 132, "travoprost", "", +87442, Timolol, 135, 142, "timolol", "", +87443, Dorzolamide, 147, 158, "dorzolamide", "", +87488, Dorz/TimFC, 147, 168, "dorzolamide / timolol", "", +87444, Timolol, 161, 168, "timolol", "", +87445, Primary_OpenAngleGlaucoma, 186, 215, "primary open - angle glaucoma", "", +87446, OcularHypertension, 220, 239, "ocular hypertension", "", +87448, Author, 242, 250, "Babi ć N", "", +87449, Author, 259, 269, "Andrei ć V", "", +87450, Author, 272, 284, "Miljkovi ć A", "", +87451, Author, 287, 297, "Grkovi ć D", "", +87452, Author, 300, 312, "Jovanovi ć P", "", +87456, Country, 397, 403, "Serbia", "", +87453, Eyedrops, 547, 552, "drops", "", +87454, ObjectiveDescription, 627, 761, "To compare the efficacy of reduced intraocular pressure ( IOP ) and safety of fixed combination travoprost 0 . 004 % / timolol 0 . 5 %", "", +87457, IOP, 662, 682, "intraocular pressure", "", +87458, IOP, 685, 688, "IOP", "", +87461, Trav/TimFC, 705, 761, "fixed combination travoprost 0 . 004 % / timolol 0 . 5 %", "", +87459, Travoprost, 723, 733, "travoprost", "", +87462, DoseValue, 734, 741, "0 . 004", "", +87460, Timolol, 746, 753, "timolol", "", +87463, DoseValue, 754, 759, "0 . 5", "", +87455, ObjectiveDescription, 762, 890, "vs . fixed combination dorzolamide 2 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular hypertension .", "", +87468, Dorz/TimFC, 767, 821, "fixed combination dorzolamide 2 % / timolol 0 . 5 % in", "", +87464, Dorzolamide, 785, 796, "dorzolamide", "", +87466, DoseValue, 797, 798, "2", "", +87465, Timolol, 803, 810, "timolol", "", +87467, DoseValue, 811, 816, "0 . 5", "", +87469, Primary_OpenAngleGlaucoma, 836, 865, "primary open - angle glaucoma", "", +87470, OcularHypertension, 869, 888, "ocular hypertension", "", +87471, Prospective, 901, 912, "Prospective", "", +87472, Randomized, 913, 923, "randomized", "", +87473, NumberPatientsCT, 948, 950, "60", "", +87474, TimePoint, 1008, 1014, "day 14", "", +87475, TimePoint, 1008, 1021, "day 14 and 45", "", +87476, TimePoint, 1026, 1033, "month 3", "", +87477, IOP, 1036, 1039, "IOP", "", +87478, IOP, 1165, 1168, "IOP", "", +87479, PValueChangeValue, 1232, 1248, "p & lt ; 0 . 001", "", +87480, Mean, 1253, 1257, "Mean", "", +87481, IOP, 1265, 1268, "IOP", "", +87482, Travoprost, 1325, 1335, "travoprost", "", +87486, Trav/TimFC, 1325, 1345, "travoprost / timolol", "", +87483, Timolol, 1338, 1345, "timolol", "", +87485, Dorzolamide, 1370, 1381, "dorzolamide", "", +87487, Dorz/TimFC, 1370, 1391, "dorzolamide / timolol", "", +87484, Timolol, 1384, 1391, "timolol", "", +87489, ResultMeasuredValue, 1400, 1407, "16 . 13", "", +87491, mmHg, 1408, 1412, "mmHg", "", +87490, ResultMeasuredValue, 1418, 1425, "16 . 15", "", +87492, mmHg, 1426, 1430, "mmHg", "", +87497, Mean, 1435, 1439, "Mean", "", +87498, IOP, 1440, 1443, "IOP", "", +87493, mmHg, 1489, 1493, "mmHg", "", +87494, mmHg, 1506, 1510, "mmHg", "", +87499, Travoprost, 1518, 1528, "travoprost", "", +87503, Trav/TimFC, 1518, 1538, "travoprost / timolol", "", +87501, Timolol, 1531, 1538, "timolol", "", +87495, mmHg, 1563, 1567, "mmHg", "", +87496, mmHg, 1580, 1584, "mmHg", "", +87500, Dorzolamide, 1593, 1604, "dorzolamide", "", +87504, Dorz/TimFC, 1593, 1614, "dorzolamide / timolol", "", +87502, Timolol, 1607, 1614, "timolol", "", +87505, Mean, 1623, 1627, "Mean", "", +87506, Diurnal_IOP, 1678, 1689, "diurnal LOP", "", +87507, TimePoint, 1695, 1703, "baseline", "", +87508, TimePoint, 1707, 1716, "3rd month", "", +87509, Reduction, 1721, 1727, "8 . 96", "", +87511, SdErrorChangeValue, 1734, 1740, "2 . 79", "", +87513, Travoprost, 1748, 1758, "travoprost", "", +87518, Trav/TimFC, 1748, 1768, "travoprost / timolol", "", +87514, Timolol, 1761, 1768, "timolol", "", +87510, Reduction, 1782, 1788, "8 . 07", "", +87512, SdErrorChangeValue, 1795, 1801, "2 . 91", "", +87516, Dorzolamide, 1824, 1835, "dorzolamide", "", +87517, Dorz/TimFC, 1824, 1863, "dorzolamide / timolol fixed combination", "", +87515, Timolol, 1838, 1845, "timolol", "", +87519, PValueChangeValue, 1866, 1877, "p = 0 . 196", "", +87520, ConjunctivalHyperemia, 1940, 1962, "conjunctival hyperemia", "", +87521, Travoprost, 1970, 1980, "travoprost", "", +87526, Trav/TimFC, 1970, 1990, "travoprost / timolol", "", +87522, Timolol, 1983, 1990, "timolol", "", +87524, Dorzolamide, 2045, 2056, "dorzolamide", "", +87525, Dorz/TimFC, 2045, 2066, "dorzolamide / timolol", "", +87523, Timolol, 2059, 2066, "timolol", "", +87529, Travoprost, 2088, 2098, "Travoprost", "", +87533, Trav/TimFC, 2088, 2126, "Travoprost / timolol fixed combination", "", +87530, Timolol, 2101, 2108, "timolol", "", +87532, Dorzolamide, 2160, 2171, "dorzolamide", "", +87534, Dorz/TimFC, 2160, 2199, "dorzolamide / timolol fixed combination", "", +87531, Timolol, 2174, 2181, "timolol", "", +87535, Mean, 2212, 2216, "mean", "", +87536, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +87537, Travoprost, 2231, 2241, "Travoprost", "", +87542, Trav/TimFC, 2231, 2251, "Travoprost / timolol", "", +87538, Timolol, 2244, 2251, "timolol", "", +87539, IOP, 2273, 2276, "IOP", "", +87541, DiffGroupAbsValue, 2297, 2303, "1 . 07", "", +87540, mmHg, 2304, 2308, "mmHg", "", +87543, Dorzolamide, 2321, 2332, "dorzolamide", "", +87545, Dorz/TimFC, 2321, 2342, "dorzolamide / timolol", "", +87544, Timolol, 2335, 2342, "timolol", "", +87546, PMID, 2444, 2452, "24073548", "", diff --git a/data/gl 24073548_jshahinitiran.n-triples b/data/gl 24073548_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24073548_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24073548_tstrakeljahn.annodb b/data/gl 24073548_tstrakeljahn.annodb new file mode 100644 index 0000000..598a407 --- /dev/null +++ b/data/gl 24073548_tstrakeljahn.annodb @@ -0,0 +1,126 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89757, Journal, 0, 17, "Srp Arh Celok Lek", "", +89758, PublicationYear, 20, 24, "2013", "", +89768, Title, 63, 241, "Comparison of the efficacy and safety of fixed combination travoprost / timolol and dorzolamide / timolol in patients with primary open - angle glaucoma and ocular hypertension .", "", +89759, Trav/TimFC, 122, 142, "travoprost / timolol", "", +89760, Travoprost, 122, 132, "travoprost", "", +89761, Timolol, 135, 142, "timolol", "", +89763, Dorzolamide, 147, 158, "dorzolamide", "", +89764, Dorz/TimFC, 147, 168, "dorzolamide / timolol", "", +89762, Timolol, 161, 168, "timolol", "", +89767, Precondition, 172, 239, "patients with primary open - angle glaucoma and ocular hypertension", "", +89765, Primary_OpenAngleGlaucoma, 186, 215, "primary open - angle glaucoma", "", +89766, OcularHypertension, 220, 239, "ocular hypertension", "", +89769, Author, 242, 250, "Babi ć N", "", +89770, Author, 259, 269, "Andrei ć V", "", +89771, Author, 272, 284, "Miljkovi ć A", "", +89772, Author, 287, 297, "Grkovi ć D", "", +89773, Author, 300, 312, "Jovanovi ć P", "", +89774, Country, 397, 403, "Serbia", "Serbia", +89798, ObjectiveDescription, 627, 875, "To compare the efficacy of reduced intraocular pressure ( IOP ) and safety of fixed combination travoprost 0 . 004 % / timolol 0 . 5 % vs . fixed combination dorzolamide 2 % / timolol 0 . 5 % in patients with primary open - angle glaucoma or ocular", "", +89775, IOP, 662, 682, "intraocular pressure", "", +89776, IOP, 685, 688, "IOP", "", +89777, Travoprost, 723, 733, "travoprost", "", +89789, Trav/TimFC, 723, 761, "travoprost 0 . 004 % / timolol 0 . 5 %", "", +89781, DoseValue, 734, 741, "0 . 004", "", +89788, Percentage, 742, 743, "%", "", +89778, Timolol, 746, 753, "timolol", "", +89782, DoseValue, 754, 759, "0 . 5", "", +89787, Percentage, 760, 761, "%", "", +89780, Dorzolamide, 785, 796, "dorzolamide", "", +89790, Dorz/TimFC, 785, 818, "dorzolamide 2 % / timolol 0 . 5 %", "", +89783, DoseValue, 797, 798, "2", "", +89786, Percentage, 799, 800, "%", "", +89779, Timolol, 803, 810, "timolol", "", +89784, DoseValue, 811, 816, "0 . 5", "", +89785, Percentage, 817, 818, "%", "", +89793, Precondition, 822, 888, "patients with primary open - angle glaucoma or ocular hypertension", "", +89791, Primary_OpenAngleGlaucoma, 836, 865, "primary open - angle glaucoma", "", +89792, OcularHypertension, 869, 888, "ocular hypertension", "", +89799, ObjectiveDescription, 876, 890, "hypertension .", "", +89794, Prospective, 901, 912, "Prospective", "", +89795, Randomized, 913, 923, "randomized", "", +89796, ClinicalTrial, 924, 938, "clinical study", "", +89797, NumberPatientsCT, 948, 950, "60", "", +89800, TimePoint, 1008, 1014, "day 14", "", +89801, TimePoint, 1008, 1021, "day 14 and 45", "", +89802, TimePoint, 1026, 1033, "month 3", "", +89803, IOP, 1036, 1039, "IOP", "", +89804, TimePoint, 1099, 1103, "8 am", "", +89805, TimePoint, 1106, 1111, "10 am", "", +89806, TimePoint, 1116, 1120, "4 pm", "", +89807, IOP, 1165, 1168, "IOP", "", +89808, PValueResValue, 1234, 1248, "& lt ; 0 . 001", "", +89809, Mean, 1253, 1257, "Mean", "", +89823, ObservedResult, 1253, 1434, "Mean pooled IOP at all visits and time points was slightly lower in the travoprost / timolol group compared with the dorzolamide / timolol group ( 16 . 13 mmHg vs . 16 . 15 mmHg ) .", "", +89810, IOP, 1265, 1268, "IOP", "", +89811, Travoprost, 1325, 1335, "travoprost", "", +89816, Trav/TimFC, 1325, 1345, "travoprost / timolol", "", +89812, Timolol, 1338, 1345, "timolol", "", +89814, Dorzolamide, 1370, 1381, "dorzolamide", "", +89815, Dorz/TimFC, 1370, 1391, "dorzolamide / timolol", "", +89813, Timolol, 1384, 1391, "timolol", "", +89817, ResultMeasuredValue, 1400, 1407, "16 . 13", "", +89819, mmHg, 1408, 1412, "mmHg", "", +89818, ResultMeasuredValue, 1418, 1425, "16 . 15", "", +89820, mmHg, 1426, 1430, "mmHg", "", +89821, Mean, 1435, 1439, "Mean", "", +89822, IOP, 1440, 1443, "IOP", "", +89824, Reduction, 1482, 1488, "7 . 46", "", +89828, mmHg, 1489, 1493, "mmHg", "", +89825, Reduction, 1499, 1505, "9 . 92", "", +89829, mmHg, 1506, 1510, "mmHg", "", +89832, Travoprost, 1518, 1528, "travoprost", "", +89837, Trav/TimFC, 1518, 1538, "travoprost / timolol", "", +89833, Timolol, 1531, 1538, "timolol", "", +89826, Reduction, 1556, 1562, "6 . 93", "", +89830, mmHg, 1563, 1567, "mmHg", "", +89827, Reduction, 1573, 1579, "8 . 93", "", +89831, mmHg, 1580, 1584, "mmHg", "", +89835, Dorzolamide, 1593, 1604, "dorzolamide", "", +89836, Dorz/TimFC, 1593, 1614, "dorzolamide / timolol", "", +89834, Timolol, 1607, 1614, "timolol", "", +89882, Mean, 1658, 1662, "mean", "", +89838, Diurnal_IOP, 1678, 1689, "diurnal LOP", "", +89839, TimePoint, 1695, 1703, "baseline", "", +89840, TimePoint, 1707, 1716, "3rd month", "", +89841, Reduction, 1721, 1727, "8 . 96", "", +89843, SdErrorChangeValue, 1734, 1740, "2 . 79", "", +89845, Travoprost, 1748, 1758, "travoprost", "", +89847, Trav/TimFC, 1748, 1768, "travoprost / timolol", "", +89846, Timolol, 1761, 1768, "timolol", "", +89842, Reduction, 1782, 1788, "8 . 07", "", +89844, SdErrorChangeValue, 1795, 1801, "2 . 91", "", +89848, Dorzolamide, 1824, 1835, "dorzolamide", "", +89850, Dorz/TimFC, 1824, 1845, "dorzolamide / timolol", "", +89849, Timolol, 1838, 1845, "timolol", "", +89889, PvalueDiff, 1868, 1877, "= 0 . 196", "", +89860, ObservedResult, 1882, 2074, "The most frequent treatment - related adverse events were conjunctival hyperemia in the travoprost / timolol group , and dry eye and foreign body sensation in the dorzolamide / timolol group .", "", +89851, ConjunctivalHyperemia, 1940, 1962, "conjunctival hyperemia", "", +89852, Travoprost, 1970, 1980, "travoprost", "", +89854, Trav/TimFC, 1970, 1990, "travoprost / timolol", "", +89853, Timolol, 1983, 1990, "timolol", "", +89857, Dorzolamide, 2045, 2056, "dorzolamide", "", +89859, Dorz/TimFC, 2045, 2066, "dorzolamide / timolol", "", +89858, Timolol, 2059, 2066, "timolol", "", +89861, Travoprost, 2088, 2098, "Travoprost", "", +89863, Trav/TimFC, 2088, 2108, "Travoprost / timolol", "", +89869, ConclusionComment, 2088, 2230, "Travoprost / timolol fixed combination was slightly more effective than dorzolamide / timolol fixed combination in reducing mean diurnal IOP .", "", +89862, Timolol, 2101, 2108, "timolol", "", +89864, Dorzolamide, 2160, 2171, "dorzolamide", "", +89866, Dorz/TimFC, 2160, 2181, "dorzolamide / timolol", "", +89865, Timolol, 2174, 2181, "timolol", "", +89867, Mean, 2212, 2216, "mean", "", +89868, Diurnal_IOP, 2217, 2228, "diurnal IOP", "", +89870, Travoprost, 2231, 2241, "Travoprost", "", +89875, Trav/TimFC, 2231, 2251, "Travoprost / timolol", "", +89879, ConclusionComment, 2231, 2350, "Travoprost / timolol group resulted in an IOP reduction for up to 1 . 07 mmHg higher than dorzolamide / timolol group .", "", +89871, Timolol, 2244, 2251, "timolol", "", +89876, IOP, 2273, 2276, "IOP", "", +89877, DiffGroupAbsValue, 2297, 2303, "1 . 07", "", +89878, mmHg, 2304, 2308, "mmHg", "", +89872, Dorzolamide, 2321, 2332, "dorzolamide", "", +89874, Dorz/TimFC, 2321, 2342, "dorzolamide / timolol", "", +89873, Timolol, 2335, 2342, "timolol", "", +89880, ConclusionComment, 2351, 2405, "Both fixed combinations were well tolerated and safe .", "", +89881, PMID, 2444, 2452, "24073548", "", diff --git a/data/gl 24073548_tstrakeljahn.n-triples b/data/gl 24073548_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24073548_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24672097_admin.annodb b/data/gl 24672097_admin.annodb new file mode 100644 index 0000000..1b492cf --- /dev/null +++ b/data/gl 24672097_admin.annodb @@ -0,0 +1,126 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 24, "Curr Ther Res Clin Exp .", "", " \"Curr Ther Res Clin Exp .\"." +1, PublicationYear, 25, 29, "2004", "", " \"2004\"." +92, Title, 110, 348, "Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open - angle glaucoma : A prospective , open - label , randomized , two - arm , parallel - group study .", "", " \"Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open - angle glaucoma : A prospective , open - label , randomized , two - arm , parallel - group study .\"." +2, Bimatoprost, 139, 150, "bimatoprost", "", +3, Timolol, 155, 162, "timolol", "", +4, IOP, 166, 186, "intraocular pressure", "", +92869, PulsatileOcularFlow, 191, 218, "pulsatile ocular blood flow", "", +26991, Primary_OpenAngleGlaucoma, 236, 265, "primary open - angle glaucoma", "", " ." +37027, Prospective, 270, 281, "prospective", "", +6, OpenLabel, 284, 296, "open - label", "", +7, Randomized, 299, 309, "randomized", "", +8, Parallel, 324, 332, "parallel", "", +9, Author, 349, 359, "Vetrugno M", "", " \"Vetrugno M\"." +10, Author, 368, 379, "Cardascia N", "", " \"Cardascia N\"." +11, Author, 388, 399, "Cantatore F", "", " \"Cantatore F\"." +12, Author, 408, 417, "Sborgia C", "", " \"Sborgia C\"." +13, Italy, 536, 541, "Italy", "", " ." +14, Italy, 638, 643, "Italy", "", +16, IOP, 733, 753, "intraocular pressure", "", +17, IOP, 756, 759, "IOP", "", +31420, EndPointDescription, 1011, 1031, "choroidal blood flow", "AdverseEffect", +18, Bimatoprost, 1034, 1045, "Bimatoprost", "", +19, IOP, 1108, 1111, "IOP", "", +20, Timolol, 1196, 1211, "timolol maleate", "", +111, ObjectiveDescription, 1297, 1521, "The aim of this study was to compare the effects of bimatoprost and timolol on IOP and choroidal blood flow ( as measured using pulsatile ocular blood flow [ pOBF ] ) in patients with primary open - angle glaucoma ( POAG ) .", "", " \"The aim of this study was to compare the effects of bimatoprost and timolol on IOP and choroidal blood flow ( as measured using pulsatile ocular blood flow [ pOBF ] ) in patients with primary open - angle glaucoma ( POAG ) .\"." +22, Bimatoprost, 1349, 1360, "bimatoprost", "", +23, Timolol, 1365, 1372, "timolol", "", +24, IOP, 1376, 1379, "IOP", "", +31421, EndPointDescription, 1384, 1404, "choroidal blood flow", "AdverseEffect", +92870, PulsatileOcularFlow, 1425, 1452, "pulsatile ocular blood flow", "", +92871, PulsatileOcularFlow, 1455, 1459, "pOBF", "", +26995, Primary_OpenAngleGlaucoma, 1481, 1510, "primary open - angle glaucoma", "", +26996, Primary_OpenAngleGlaucoma, 1513, 1517, "POAG", "", +37028, Prospective, 1537, 1548, "prospective", "", " ." +26, OpenLabel, 1551, 1563, "open - label", "", " ." +27, Randomized, 1566, 1576, "randomized", "", " ." +28, Parallel, 1589, 1597, "parallel", "", " ." +117, Glaucoma, 1633, 1641, "Glaucoma", "", +29, Italy, 1727, 1732, "Italy", "", +121, Precondition, 1735, 1970, "Patients with POAG having well - controlled IOP ( < 16 mm Hg ) on monotherapy with timolol 0 . 5 % ophthalmic solution ( 2 drops per affected eye BID ) for ≥ 12 months but with a progressive decrease in pOBF during the same time period", "", " \"Patients with POAG having well - controlled IOP ( < 16 mm Hg ) on monotherapy with timolol 0 . 5 % ophthalmic solution ( 2 drops per affected eye BID ) for ≥ 12 months but with a progressive decrease in pOBF during the same time period\"." +26997, Primary_OpenAngleGlaucoma, 1749, 1753, "POAG", "", +34, IOP, 1779, 1782, "IOP", "", +120, mmHg, 1790, 1795, "mm Hg", "", +31, Timolol, 1818, 1825, "timolol", "", +32, DoseValue, 1826, 1831, "0 . 5", "", +33, Percentage, 1832, 1833, "%", "", +68, DoseValue, 1856, 1857, "2", "", +69, Eyedrops, 1858, 1863, "drops", "", +126, Frequency, 1881, 1884, "BID", "", +92872, PulsatileOcularFlow, 1938, 1942, "pOBF", "", +106348, Randomized, 1976, 1984, "randomly", "", +35, Timolol, 2061, 2068, "timolol", "", " ." +66, DoseValue, 2071, 2072, "2", "", " \"2\"." +65, Eyedrops, 2073, 2078, "drops", "", " ." +129, Frequency, 2096, 2099, "BID", "", " \"BID\"." +36, Bimatoprost, 2154, 2165, "bimatoprost", "", " ." +37, DoseValue, 2166, 2171, "0 . 3", "", " \"0 . 3\"." +132, Percentage, 2172, 2173, "%", "", " ." +31423, DeliveryMethod, 2174, 2193, "ophthalmic solution", "", " . ." +67, DoseValue, 2196, 2197, "2", "", +38, Eyedrops, 2198, 2203, "drops", "", +134, Frequency, 2221, 2223, "QD", "", " \"QD\"." +106347, Evening, 2226, 2230, "9 pm", "", +135, Duration, 2261, 2269, "180 days", "", " \"180 days\"." +40, IOP, 2272, 2275, "IOP", "", +92877, PulsatileOcularFlow, 2280, 2284, "pOBF", "", +42, Timolol, 2331, 2338, "timolol", "", +31418, TimePoint, 2343, 2351, "baseline", "", +31419, TimePoint, 2354, 2359, "day 0", "", +26999, TimePoint, 2378, 2410, "days 15 , 30 , 60 , 90 , and 180", "", +138, ConjunctivalHyperemia, 2452, 2474, "conjunctival hyperemia", "", +37031, EndPointDescription, 2477, 2498, "conjunctival papillae", "AdverseEffect", +37032, Stinging, 2501, 2509, "stinging", "AdverseEffect", +37033, EndPointDescription, 2512, 2519, "burning", "AdverseEffect", +37034, EndPointDescription, 2522, 2544, "foreign body sensation", "AdverseEffect", +37035, EndPointDescription, 2551, 2583, "pigmentation of periorbital skin", "AdverseEffect", +139, NumberPatientsCT, 2634, 2648, "Thirty - eight", "", " \"Thirty - eight\"." +140, Male, 2677, 2680, "men", "", " ." +141, Female, 2686, 2691, "women", "", " ." +142, Mean, 2694, 2698, "mean", "", +46, AvgAge, 2712, 2718, "51 . 7", "", " \"51 . 7\"." +45, NumberPatientsArm, 2737, 2739, "19", "", " \"19\". \"19\"." +51, ObservedResult, 2792, 2902, "At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline", "", " \"At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline\". \"At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline\"." +27000, TimePoint, 2795, 2804, "180 - day", "", " \"180 - day\". \"180 - day\"." +48, Timolol, 2824, 2831, "timolol", "", +49, IOP, 2844, 2847, "IOP", "", " . ." +92875, PulsatileOcularFlow, 2856, 2860, "pOBF", "", " ." +146, Bimatoprost, 2912, 2923, "bimatoprost", "", +147, IOP, 2934, 2937, "IOP", "", +106349, ObservedResult, 2938, 2956, "remained unchanged", "", " \"remained unchanged\"." +92876, PulsatileOcularFlow, 2965, 2969, "pOBF", "", +53, RelativeReduction, 2987, 2993, "38 . 9", "", " \"38 . 9\"." +54, PValueChangeValue, 3021, 3031, "P < 0 . 01", "", " \"P < 0 . 01\"." +58, ConjunctivalHyperemia, 3079, 3101, "conjunctival hyperemia", "", +105204, Ocular_Itching, 3106, 3120, "ocular itching", "", +55, NumberAffected, 3123, 3124, "5", "", +151, PercentageAffected, 3136, 3142, "26 . 3", "", +59, Bimatoprost, 3154, 3165, "bimatoprost", "", +60, IrisPigmentation, 3178, 3210, "pigmentation of periorbital skin", "", +61, NumberAffected, 3213, 3214, "2", "", +154, PercentageAffected, 3226, 3232, "40 . 0", "", +62, Bimatoprost, 3244, 3255, "bimatoprost", "", +64, ObservedResult, 3266, 3352, "The incidence of each AE was higher in the bimatoprost group than in the timolol group", "", +63, PvalueDiff, 3355, 3366, "P = 0 . 008", "", +169, ConclusionComment, 3385, 3586, "In this population of patients with POAG , bimatoprost was associated with increased pOBF , and the reduction in pOBF associated with timolol was corrected after patients were switched to bimatoprost .", "", " \"In this population of patients with POAG , bimatoprost was associated with increased pOBF , and the reduction in pOBF associated with timolol was corrected after patients were switched to bimatoprost .\"." +27002, Primary_OpenAngleGlaucoma, 3421, 3425, "POAG", "", +72, Bimatoprost, 3428, 3439, "bimatoprost", "", +92873, PulsatileOcularFlow, 3470, 3474, "pOBF", "", +92874, PulsatileOcularFlow, 3498, 3502, "pOBF", "", +73, Timolol, 3519, 3526, "timolol", "", +74, Bimatoprost, 3573, 3584, "bimatoprost", "", +170, ConclusionComment, 3587, 3705, "Bimatoprost was associated with increased choroidal blood flow , beyond the levels recorded before timolol treatment .", "", " \"Bimatoprost was associated with increased choroidal blood flow , beyond the levels recorded before timolol treatment .\"." +78, Bimatoprost, 3587, 3598, "Bimatoprost", "", +31417, EndPointDescription, 3619, 3649, "increased choroidal blood flow", "AdverseEffect", +79, Timolol, 3686, 3693, "timolol", "", +171, ConclusionComment, 3706, 3806, "The decreased IOP level achieved in the timolol group seemed to be improved further by bimatoprost .", "", " \"The decreased IOP level achieved in the timolol group seemed to be improved further by bimatoprost .\"." +85, IOP, 3720, 3723, "IOP", "", +86, Timolol, 3746, 3753, "timolol", "", +87, Bimatoprost, 3793, 3804, "bimatoprost", "", +172, ConclusionComment, 3807, 3972, "Considering the potential efficacy of bimatoprost on IOP and pOBF , we suggest that this new drug may represent a clinical advance in the medical treatment of POAG .", "", " \"Considering the potential efficacy of bimatoprost on IOP and pOBF , we suggest that this new drug may represent a clinical advance in the medical treatment of POAG .\"." +83, Bimatoprost, 3845, 3856, "bimatoprost", "", +81, IOP, 3860, 3863, "IOP", "", +92878, PulsatileOcularFlow, 3868, 3872, "pOBF", "", +27004, Primary_OpenAngleGlaucoma, 3966, 3970, "POAG", "", +80, PMID, 4049, 4057, "24672097", "", " \"24672097\"." diff --git a/data/gl 24672097_admin.n-triples b/data/gl 24672097_admin.n-triples new file mode 100644 index 0000000..dc9a0b2 --- /dev/null +++ b/data/gl 24672097_admin.n-triples @@ -0,0 +1,118 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open - angle glaucoma : A prospective , open - label , randomized , two - arm , parallel - group study ." . + "Vetrugno M" . + "2004" . + "Curr Ther Res Clin Exp ." . + "24672097" . + . + "Cardascia N" . + "Cantatore F" . + "Sborgia C" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The aim of this study was to compare the effects of bimatoprost and timolol on IOP and choroidal blood flow ( as measured using pulsatile ocular blood flow [ pOBF ] ) in patients with primary open - angle glaucoma ( POAG ) ." . + "Thirty - eight" . + "180 days" . + . + . + . + "In this population of patients with POAG , bimatoprost was associated with increased pOBF , and the reduction in pOBF associated with timolol was corrected after patients were switched to bimatoprost ." . + . + . + . + . + . + . + . + . + "Bimatoprost was associated with increased choroidal blood flow , beyond the levels recorded before timolol treatment ." . + "The decreased IOP level achieved in the timolol group seemed to be improved further by bimatoprost ." . + "Considering the potential efficacy of bimatoprost on IOP and pOBF , we suggest that this new drug may represent a clinical advance in the medical treatment of POAG ." . + . +# RDF export of group: Population + . + "Population " . + "Patients with POAG having well - controlled IOP ( < 16 mm Hg ) on monotherapy with timolol 0 . 5 % ophthalmic solution ( 2 drops per affected eye BID ) for ≥ 12 months but with a progressive decrease in pOBF during the same time period" . + . + . + "51 . 7" . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP " . + . + . + . + . + . + . + "Endpoint pOBF" . + . + . + . + . +# RDF export of group: Arm + . + "Arm tim" . + "19" . + . + . + . + . + . + "Arm bim" . + "19" . + . + . + . +# RDF export of group: Intervention + . + "Intervention tim" . + . + "BID" . + . + . + "Intervention bim" . + . + "QD" . + . +# RDF export of group: Medication + . + "Medication tim" . + . + "2" . + . + . + . + "Medication bim" . + . + "0 . 3" . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP tim" . + . + "At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline" . + "180 - day" . + . + "Outcome pOBF tim" . + . + "At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline" . + "180 - day" . + . + "Outcome IOP bim" . + . + "remained unchanged" . + . + "Outcome pOBF bim" . + . + "38 . 9" . + "P < 0 . 01" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24672097_export.csv b/data/gl 24672097_export.csv new file mode 100644 index 0000000..9ef53c6 --- /dev/null +++ b/data/gl 24672097_export.csv @@ -0,0 +1,796 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +415, 1, 1, 1, 0, 4, 0, 4, "Curr" +415, 1, 2, 2, 5, 9, 5, 9, "Ther" +415, 1, 3, 3, 10, 13, 10, 13, "Res" +415, 1, 4, 4, 14, 18, 14, 18, "Clin" +415, 1, 5, 5, 19, 22, 19, 22, "Exp" +415, 1, 6, 6, 23, 24, 23, 24, "." +415, 2, 1, 7, 0, 4, 25, 29, "2004" +415, 2, 2, 8, 5, 8, 30, 33, "Nov" +415, 2, 3, 9, 9, 10, 34, 35, ";" +415, 2, 4, 10, 11, 13, 36, 38, "65" +415, 2, 5, 11, 14, 15, 39, 40, "(" +415, 2, 6, 12, 16, 17, 41, 42, "6" +415, 2, 7, 13, 18, 19, 43, 44, ")" +415, 2, 8, 14, 20, 21, 45, 46, ":" +415, 2, 9, 15, 22, 25, 47, 50, "444" +415, 2, 10, 16, 26, 27, 51, 52, "-" +415, 2, 11, 17, 28, 30, 53, 55, "54" +415, 2, 12, 18, 31, 32, 56, 57, "." +415, 2, 13, 19, 33, 36, 58, 61, "doi" +415, 2, 14, 20, 37, 38, 62, 63, ":" +415, 2, 15, 21, 39, 41, 64, 66, "10" +415, 2, 16, 22, 42, 43, 67, 68, "." +415, 2, 17, 23, 44, 48, 69, 73, "1016" +415, 2, 18, 24, 49, 50, 74, 75, "/" +415, 2, 19, 25, 51, 52, 76, 77, "j" +415, 2, 20, 26, 53, 54, 78, 79, "." +415, 2, 21, 27, 55, 64, 80, 89, "curtheres" +415, 2, 22, 28, 65, 66, 90, 91, "." +415, 2, 23, 29, 67, 71, 92, 96, "2005" +415, 2, 24, 30, 72, 73, 97, 98, "." +415, 2, 25, 31, 74, 76, 99, 101, "01" +415, 2, 26, 32, 77, 78, 102, 103, "." +415, 2, 27, 33, 79, 82, 104, 107, "004" +415, 2, 28, 34, 83, 84, 108, 109, "." +415, 3, 1, 35, 0, 10, 110, 120, "Comparison" +415, 3, 2, 36, 11, 13, 121, 123, "of" +415, 3, 3, 37, 14, 17, 124, 127, "the" +415, 3, 4, 38, 18, 25, 128, 135, "effects" +415, 3, 5, 39, 26, 28, 136, 138, "of" +415, 3, 6, 40, 29, 40, 139, 150, "bimatoprost" +415, 3, 7, 41, 41, 44, 151, 154, "and" +415, 3, 8, 42, 45, 52, 155, 162, "timolol" +415, 3, 9, 43, 53, 55, 163, 165, "on" +415, 3, 10, 44, 56, 67, 166, 177, "intraocular" +415, 3, 11, 45, 68, 76, 178, 186, "pressure" +415, 3, 12, 46, 77, 80, 187, 190, "and" +415, 3, 13, 47, 81, 90, 191, 200, "pulsatile" +415, 3, 14, 48, 91, 97, 201, 207, "ocular" +415, 3, 15, 49, 98, 103, 208, 213, "blood" +415, 3, 16, 50, 104, 108, 214, 218, "flow" +415, 3, 17, 51, 109, 111, 219, 221, "in" +415, 3, 18, 52, 112, 120, 222, 230, "patients" +415, 3, 19, 53, 121, 125, 231, 235, "with" +415, 3, 20, 54, 126, 133, 236, 243, "primary" +415, 3, 21, 55, 134, 138, 244, 248, "open" +415, 3, 22, 56, 139, 140, 249, 250, "-" +415, 3, 23, 57, 141, 146, 251, 256, "angle" +415, 3, 24, 58, 147, 155, 257, 265, "glaucoma" +415, 3, 25, 59, 156, 157, 266, 267, ":" +415, 3, 26, 60, 158, 159, 268, 269, "A" +415, 3, 27, 61, 160, 171, 270, 281, "prospective" +415, 3, 28, 62, 172, 173, 282, 283, "," +415, 3, 29, 63, 174, 178, 284, 288, "open" +415, 3, 30, 64, 179, 180, 289, 290, "-" +415, 3, 31, 65, 181, 186, 291, 296, "label" +415, 3, 32, 66, 187, 188, 297, 298, "," +415, 3, 33, 67, 189, 199, 299, 309, "randomized" +415, 3, 34, 68, 200, 201, 310, 311, "," +415, 3, 35, 69, 202, 205, 312, 315, "two" +415, 3, 36, 70, 206, 207, 316, 317, "-" +415, 3, 37, 71, 208, 211, 318, 321, "arm" +415, 3, 38, 72, 212, 213, 322, 323, "," +415, 3, 39, 73, 214, 222, 324, 332, "parallel" +415, 3, 40, 74, 223, 224, 333, 334, "-" +415, 3, 41, 75, 225, 230, 335, 340, "group" +415, 3, 42, 76, 231, 236, 341, 346, "study" +415, 3, 43, 77, 237, 238, 347, 348, "." +415, 4, 1, 78, 0, 8, 349, 357, "Vetrugno" +415, 4, 2, 79, 9, 10, 358, 359, "M" +415, 4, 3, 80, 11, 12, 360, 361, "(" +415, 4, 4, 81, 13, 14, 362, 363, "1" +415, 4, 5, 82, 15, 16, 364, 365, ")" +415, 4, 6, 83, 17, 18, 366, 367, "," +415, 4, 7, 84, 19, 28, 368, 377, "Cardascia" +415, 4, 8, 85, 29, 30, 378, 379, "N" +415, 4, 9, 86, 31, 32, 380, 381, "(" +415, 4, 10, 87, 33, 34, 382, 383, "1" +415, 4, 11, 88, 35, 36, 384, 385, ")" +415, 4, 12, 89, 37, 38, 386, 387, "," +415, 4, 13, 90, 39, 48, 388, 397, "Cantatore" +415, 4, 14, 91, 49, 50, 398, 399, "F" +415, 4, 15, 92, 51, 52, 400, 401, "(" +415, 4, 16, 93, 53, 54, 402, 403, "1" +415, 4, 17, 94, 55, 56, 404, 405, ")" +415, 4, 18, 95, 57, 58, 406, 407, "," +415, 4, 19, 96, 59, 66, 408, 415, "Sborgia" +415, 4, 20, 97, 67, 68, 416, 417, "C" +415, 4, 21, 98, 69, 70, 418, 419, "(" +415, 4, 22, 99, 71, 72, 420, 421, "1" +415, 4, 23, 100, 73, 74, 422, 423, ")" +415, 4, 24, 101, 75, 76, 424, 425, "." +415, 5, 1, 102, 0, 6, 426, 432, "Author" +415, 5, 2, 103, 7, 18, 433, 444, "information" +415, 5, 3, 104, 19, 20, 445, 446, ":" +415, 5, 4, 105, 21, 22, 447, 448, "(" +415, 5, 5, 106, 23, 24, 449, 450, "1" +415, 5, 6, 107, 25, 26, 451, 452, ")" +415, 5, 7, 108, 27, 38, 453, 464, "Departments" +415, 5, 8, 109, 39, 41, 465, 467, "of" +415, 5, 9, 110, 42, 55, 468, 481, "Ophthalmology" +415, 5, 10, 111, 56, 59, 482, 485, "and" +415, 5, 11, 112, 60, 79, 486, 505, "Otorhinolaryngology" +415, 5, 12, 113, 80, 81, 506, 507, "," +415, 5, 13, 114, 82, 92, 508, 518, "University" +415, 5, 14, 115, 93, 95, 519, 521, "of" +415, 5, 15, 116, 96, 100, 522, 526, "Bari" +415, 5, 16, 117, 101, 102, 527, 528, "," +415, 5, 17, 118, 103, 107, 529, 533, "Bari" +415, 5, 18, 119, 108, 109, 534, 535, "," +415, 5, 19, 120, 110, 115, 536, 541, "Italy" +415, 5, 20, 121, 116, 117, 542, 543, ";" +415, 5, 21, 122, 118, 126, 544, 552, "Glaucoma" +415, 5, 22, 123, 127, 135, 553, 561, "Research" +415, 5, 23, 124, 136, 142, 562, 568, "Centre" +415, 5, 24, 125, 143, 144, 569, 570, "," +415, 5, 25, 126, 145, 155, 571, 581, "Department" +415, 5, 26, 127, 156, 158, 582, 584, "of" +415, 5, 27, 128, 159, 172, 585, 598, "Ophthalmology" +415, 5, 28, 129, 173, 174, 599, 600, "," +415, 5, 29, 130, 175, 185, 601, 611, "University" +415, 5, 30, 131, 186, 194, 612, 620, "Hospital" +415, 5, 31, 132, 195, 197, 621, 623, "of" +415, 5, 32, 133, 198, 202, 624, 628, "Bari" +415, 5, 33, 134, 203, 204, 629, 630, "," +415, 5, 34, 135, 205, 209, 631, 635, "Bari" +415, 5, 35, 136, 210, 211, 636, 637, "," +415, 5, 36, 137, 212, 217, 638, 643, "Italy" +415, 5, 37, 138, 218, 219, 644, 645, "." +415, 6, 1, 139, 0, 8, 646, 654, "Abstract" +415, 6, 2, 140, 9, 10, 655, 656, "." +415, 6, 3, 141, 11, 21, 657, 667, "BACKGROUND" +415, 6, 4, 142, 22, 23, 668, 669, ":" +415, 6, 5, 143, 24, 27, 670, 673, "The" +415, 6, 6, 144, 28, 35, 674, 681, "current" +415, 6, 7, 145, 36, 45, 682, 691, "objective" +415, 6, 8, 146, 46, 48, 692, 694, "of" +415, 6, 9, 147, 49, 65, 695, 711, "antiglaucomatous" +415, 6, 10, 148, 66, 73, 712, 719, "therapy" +415, 6, 11, 149, 74, 76, 720, 722, "is" +415, 6, 12, 150, 77, 79, 723, 725, "to" +415, 6, 13, 151, 80, 86, 726, 732, "reduce" +415, 6, 14, 152, 87, 98, 733, 744, "intraocular" +415, 6, 15, 153, 99, 107, 745, 753, "pressure" +415, 6, 16, 154, 108, 109, 754, 755, "(" +415, 6, 17, 155, 110, 113, 756, 759, "IOP" +415, 6, 18, 156, 114, 115, 760, 761, ")" +415, 6, 19, 157, 116, 117, 762, 763, "," +415, 6, 20, 158, 118, 121, 764, 767, "and" +415, 6, 21, 159, 122, 126, 768, 772, "thus" +415, 6, 22, 160, 127, 129, 773, 775, "to" +415, 6, 23, 161, 130, 138, 776, 784, "preserve" +415, 6, 24, 162, 139, 145, 785, 791, "visual" +415, 6, 25, 163, 146, 154, 792, 800, "function" +415, 6, 26, 164, 155, 156, 801, 802, "." +415, 7, 1, 165, 0, 4, 803, 807, "Many" +415, 7, 2, 166, 5, 21, 808, 824, "ophthalmologists" +415, 7, 3, 167, 22, 29, 825, 832, "believe" +415, 7, 4, 168, 30, 34, 833, 837, "this" +415, 7, 5, 169, 35, 44, 838, 847, "objective" +415, 7, 6, 170, 45, 47, 848, 850, "is" +415, 7, 7, 171, 48, 52, 851, 855, "best" +415, 7, 8, 172, 53, 61, 856, 864, "achieved" +415, 7, 9, 173, 62, 64, 865, 867, "by" +415, 7, 10, 174, 65, 72, 868, 875, "methods" +415, 7, 11, 175, 73, 77, 876, 880, "that" +415, 7, 12, 176, 78, 85, 881, 888, "improve" +415, 7, 13, 177, 86, 92, 889, 895, "ocular" +415, 7, 14, 178, 93, 98, 896, 901, "blood" +415, 7, 15, 179, 99, 103, 902, 906, "flow" +415, 7, 16, 180, 104, 106, 907, 909, "to" +415, 7, 17, 181, 107, 110, 910, 913, "the" +415, 7, 18, 182, 111, 116, 914, 919, "optic" +415, 7, 19, 183, 117, 122, 920, 925, "nerve" +415, 7, 20, 184, 123, 127, 926, 930, "head" +415, 7, 21, 185, 128, 129, 931, 932, "." +415, 8, 1, 186, 0, 4, 933, 937, "Beta" +415, 8, 2, 187, 5, 6, 938, 939, "-" +415, 8, 3, 188, 7, 15, 940, 948, "blockers" +415, 8, 4, 189, 16, 19, 949, 952, "are" +415, 8, 5, 190, 20, 29, 953, 962, "effective" +415, 8, 6, 191, 30, 36, 963, 969, "ocular" +415, 8, 7, 192, 37, 48, 970, 981, "hypotensive" +415, 8, 8, 193, 49, 55, 982, 988, "agents" +415, 8, 9, 194, 56, 57, 989, 990, "," +415, 8, 10, 195, 58, 61, 991, 994, "but" +415, 8, 11, 196, 62, 66, 995, 999, "they" +415, 8, 12, 197, 67, 70, 1000, 1003, "can" +415, 8, 13, 198, 71, 77, 1004, 1010, "reduce" +415, 8, 14, 199, 78, 87, 1011, 1020, "choroidal" +415, 8, 15, 200, 88, 93, 1021, 1026, "blood" +415, 8, 16, 201, 94, 98, 1027, 1031, "flow" +415, 8, 17, 202, 99, 100, 1032, 1033, "." +415, 9, 1, 203, 0, 11, 1034, 1045, "Bimatoprost" +415, 9, 2, 204, 12, 13, 1046, 1047, "," +415, 9, 3, 205, 14, 15, 1048, 1049, "a" +415, 9, 4, 206, 16, 19, 1050, 1053, "new" +415, 9, 5, 207, 20, 30, 1054, 1064, "prostamide" +415, 9, 6, 208, 31, 39, 1065, 1073, "analogue" +415, 9, 7, 209, 40, 41, 1074, 1075, "," +415, 9, 8, 210, 42, 45, 1076, 1079, "has" +415, 9, 9, 211, 46, 50, 1080, 1084, "been" +415, 9, 10, 212, 51, 56, 1085, 1090, "shown" +415, 9, 11, 213, 57, 59, 1091, 1093, "to" +415, 9, 12, 214, 60, 64, 1094, 1098, "have" +415, 9, 13, 215, 65, 66, 1099, 1100, "a" +415, 9, 14, 216, 67, 73, 1101, 1107, "better" +415, 9, 15, 217, 74, 77, 1108, 1111, "IOP" +415, 9, 16, 218, 78, 79, 1112, 1113, "-" +415, 9, 17, 219, 80, 88, 1114, 1122, "lowering" +415, 9, 18, 220, 89, 95, 1123, 1129, "effect" +415, 9, 19, 221, 96, 104, 1130, 1138, "compared" +415, 9, 20, 222, 105, 109, 1139, 1143, "with" +415, 9, 21, 223, 110, 113, 1144, 1147, "the" +415, 9, 22, 224, 114, 126, 1148, 1160, "nonselective" +415, 9, 23, 225, 127, 131, 1161, 1165, "beta" +415, 9, 24, 226, 132, 133, 1166, 1167, "-" +415, 9, 25, 227, 134, 144, 1168, 1178, "adrenergic" +415, 9, 26, 228, 145, 153, 1179, 1187, "receptor" +415, 9, 27, 229, 154, 161, 1188, 1195, "blocker" +415, 9, 28, 230, 162, 169, 1196, 1203, "timolol" +415, 9, 29, 231, 170, 177, 1204, 1211, "maleate" +415, 9, 30, 232, 178, 179, 1212, 1213, "," +415, 9, 31, 233, 180, 183, 1214, 1217, "but" +415, 9, 32, 234, 184, 190, 1218, 1224, "little" +415, 9, 33, 235, 191, 193, 1225, 1227, "is" +415, 9, 34, 236, 194, 199, 1228, 1233, "known" +415, 9, 35, 237, 200, 205, 1234, 1239, "about" +415, 9, 36, 238, 206, 209, 1240, 1243, "its" +415, 9, 37, 239, 210, 217, 1244, 1251, "effects" +415, 9, 38, 240, 218, 220, 1252, 1254, "on" +415, 9, 39, 241, 221, 224, 1255, 1258, "the" +415, 9, 40, 242, 225, 233, 1259, 1267, "vascular" +415, 9, 41, 243, 234, 237, 1268, 1271, "bed" +415, 9, 42, 244, 238, 240, 1272, 1274, "of" +415, 9, 43, 245, 241, 244, 1275, 1278, "the" +415, 9, 44, 246, 245, 248, 1279, 1282, "eye" +415, 9, 45, 247, 249, 250, 1283, 1284, "." +415, 10, 1, 248, 0, 9, 1285, 1294, "OBJECTIVE" +415, 10, 2, 249, 10, 11, 1295, 1296, ":" +415, 10, 3, 250, 12, 15, 1297, 1300, "The" +415, 10, 4, 251, 16, 19, 1301, 1304, "aim" +415, 10, 5, 252, 20, 22, 1305, 1307, "of" +415, 10, 6, 253, 23, 27, 1308, 1312, "this" +415, 10, 7, 254, 28, 33, 1313, 1318, "study" +415, 10, 8, 255, 34, 37, 1319, 1322, "was" +415, 10, 9, 256, 38, 40, 1323, 1325, "to" +415, 10, 10, 257, 41, 48, 1326, 1333, "compare" +415, 10, 11, 258, 49, 52, 1334, 1337, "the" +415, 10, 12, 259, 53, 60, 1338, 1345, "effects" +415, 10, 13, 260, 61, 63, 1346, 1348, "of" +415, 10, 14, 261, 64, 75, 1349, 1360, "bimatoprost" +415, 10, 15, 262, 76, 79, 1361, 1364, "and" +415, 10, 16, 263, 80, 87, 1365, 1372, "timolol" +415, 10, 17, 264, 88, 90, 1373, 1375, "on" +415, 10, 18, 265, 91, 94, 1376, 1379, "IOP" +415, 10, 19, 266, 95, 98, 1380, 1383, "and" +415, 10, 20, 267, 99, 108, 1384, 1393, "choroidal" +415, 10, 21, 268, 109, 114, 1394, 1399, "blood" +415, 10, 22, 269, 115, 119, 1400, 1404, "flow" +415, 10, 23, 270, 120, 121, 1405, 1406, "(" +415, 10, 24, 271, 122, 124, 1407, 1409, "as" +415, 10, 25, 272, 125, 133, 1410, 1418, "measured" +415, 10, 26, 273, 134, 139, 1419, 1424, "using" +415, 10, 27, 274, 140, 149, 1425, 1434, "pulsatile" +415, 10, 28, 275, 150, 156, 1435, 1441, "ocular" +415, 10, 29, 276, 157, 162, 1442, 1447, "blood" +415, 10, 30, 277, 163, 167, 1448, 1452, "flow" +415, 10, 31, 278, 168, 169, 1453, 1454, "[" +415, 10, 32, 279, 170, 174, 1455, 1459, "pOBF" +415, 10, 33, 280, 175, 176, 1460, 1461, "]" +415, 10, 34, 281, 177, 178, 1462, 1463, ")" +415, 10, 35, 282, 179, 181, 1464, 1466, "in" +415, 10, 36, 283, 182, 190, 1467, 1475, "patients" +415, 10, 37, 284, 191, 195, 1476, 1480, "with" +415, 10, 38, 285, 196, 203, 1481, 1488, "primary" +415, 10, 39, 286, 204, 208, 1489, 1493, "open" +415, 10, 40, 287, 209, 210, 1494, 1495, "-" +415, 10, 41, 288, 211, 216, 1496, 1501, "angle" +415, 10, 42, 289, 217, 225, 1502, 1510, "glaucoma" +415, 10, 43, 290, 226, 227, 1511, 1512, "(" +415, 10, 44, 291, 228, 232, 1513, 1517, "POAG" +415, 10, 45, 292, 233, 234, 1518, 1519, ")" +415, 10, 46, 293, 235, 236, 1520, 1521, "." +415, 11, 1, 294, 0, 7, 1522, 1529, "METHODS" +415, 11, 2, 295, 8, 9, 1530, 1531, ":" +415, 11, 3, 296, 10, 14, 1532, 1536, "This" +415, 11, 4, 297, 15, 26, 1537, 1548, "prospective" +415, 11, 5, 298, 27, 28, 1549, 1550, "," +415, 11, 6, 299, 29, 33, 1551, 1555, "open" +415, 11, 7, 300, 34, 35, 1556, 1557, "-" +415, 11, 8, 301, 36, 41, 1558, 1563, "label" +415, 11, 9, 302, 42, 43, 1564, 1565, "," +415, 11, 10, 303, 44, 54, 1566, 1576, "randomized" +415, 11, 11, 304, 55, 56, 1577, 1578, "," +415, 11, 12, 305, 57, 58, 1579, 1580, "2" +415, 11, 13, 306, 59, 60, 1581, 1582, "-" +415, 11, 14, 307, 61, 64, 1583, 1586, "arm" +415, 11, 15, 308, 65, 66, 1587, 1588, "," +415, 11, 16, 309, 67, 75, 1589, 1597, "parallel" +415, 11, 17, 310, 76, 77, 1598, 1599, "-" +415, 11, 18, 311, 78, 83, 1600, 1605, "group" +415, 11, 19, 312, 84, 89, 1606, 1611, "study" +415, 11, 20, 313, 90, 93, 1612, 1615, "was" +415, 11, 21, 314, 94, 103, 1616, 1625, "conducted" +415, 11, 22, 315, 104, 106, 1626, 1628, "at" +415, 11, 23, 316, 107, 110, 1629, 1632, "the" +415, 11, 24, 317, 111, 119, 1633, 1641, "Glaucoma" +415, 11, 25, 318, 120, 128, 1642, 1650, "Research" +415, 11, 26, 319, 129, 135, 1651, 1657, "Centre" +415, 11, 27, 320, 136, 137, 1658, 1659, "," +415, 11, 28, 321, 138, 148, 1660, 1670, "Department" +415, 11, 29, 322, 149, 151, 1671, 1673, "of" +415, 11, 30, 323, 152, 165, 1674, 1687, "Ophthalmology" +415, 11, 31, 324, 166, 167, 1688, 1689, "," +415, 11, 32, 325, 168, 178, 1690, 1700, "University" +415, 11, 33, 326, 179, 187, 1701, 1709, "Hospital" +415, 11, 34, 327, 188, 190, 1710, 1712, "of" +415, 11, 35, 328, 191, 195, 1713, 1717, "Bari" +415, 11, 36, 329, 196, 197, 1718, 1719, "," +415, 11, 37, 330, 198, 202, 1720, 1724, "Bari" +415, 11, 38, 331, 203, 204, 1725, 1726, "," +415, 11, 39, 332, 205, 210, 1727, 1732, "Italy" +415, 11, 40, 333, 211, 212, 1733, 1734, "." +415, 12, 1, 334, 0, 8, 1735, 1743, "Patients" +415, 12, 2, 335, 9, 13, 1744, 1748, "with" +415, 12, 3, 336, 14, 18, 1749, 1753, "POAG" +415, 12, 4, 337, 19, 25, 1754, 1760, "having" +415, 12, 5, 338, 26, 30, 1761, 1765, "well" +415, 12, 6, 339, 31, 32, 1766, 1767, "-" +415, 12, 7, 340, 33, 43, 1768, 1778, "controlled" +415, 12, 8, 341, 44, 47, 1779, 1782, "IOP" +415, 12, 9, 342, 48, 49, 1783, 1784, "(" +415, 12, 10, 343, 50, 51, 1785, 1786, "<" +415, 12, 11, 344, 52, 54, 1787, 1789, "16" +415, 12, 12, 345, 55, 57, 1790, 1792, "mm" +415, 12, 13, 346, 58, 60, 1793, 1795, "Hg" +415, 12, 14, 347, 61, 62, 1796, 1797, ")" +415, 12, 15, 348, 63, 65, 1798, 1800, "on" +415, 12, 16, 349, 66, 77, 1801, 1812, "monotherapy" +415, 12, 17, 350, 78, 82, 1813, 1817, "with" +415, 12, 18, 351, 83, 90, 1818, 1825, "timolol" +415, 12, 19, 352, 91, 92, 1826, 1827, "0" +415, 12, 20, 353, 93, 94, 1828, 1829, "." +415, 12, 21, 354, 95, 96, 1830, 1831, "5" +415, 12, 22, 355, 97, 98, 1832, 1833, "%" +415, 12, 23, 356, 99, 109, 1834, 1844, "ophthalmic" +415, 12, 24, 357, 110, 118, 1845, 1853, "solution" +415, 12, 25, 358, 119, 120, 1854, 1855, "(" +415, 12, 26, 359, 121, 122, 1856, 1857, "2" +415, 12, 27, 360, 123, 128, 1858, 1863, "drops" +415, 12, 28, 361, 129, 132, 1864, 1867, "per" +415, 12, 29, 362, 133, 141, 1868, 1876, "affected" +415, 12, 30, 363, 142, 145, 1877, 1880, "eye" +415, 12, 31, 364, 146, 149, 1881, 1884, "BID" +415, 12, 32, 365, 150, 151, 1885, 1886, ")" +415, 12, 33, 366, 152, 155, 1887, 1890, "for" +415, 12, 34, 367, 156, 157, 1891, 1892, "≥" +415, 12, 35, 368, 158, 160, 1893, 1895, "12" +415, 12, 36, 369, 161, 167, 1896, 1902, "months" +415, 12, 37, 370, 168, 171, 1903, 1906, "but" +415, 12, 38, 371, 172, 176, 1907, 1911, "with" +415, 12, 39, 372, 177, 178, 1912, 1913, "a" +415, 12, 40, 373, 179, 190, 1914, 1925, "progressive" +415, 12, 41, 374, 191, 199, 1926, 1934, "decrease" +415, 12, 42, 375, 200, 202, 1935, 1937, "in" +415, 12, 43, 376, 203, 207, 1938, 1942, "pOBF" +415, 12, 44, 377, 208, 214, 1943, 1949, "during" +415, 12, 45, 378, 215, 218, 1950, 1953, "the" +415, 12, 46, 379, 219, 223, 1954, 1958, "same" +415, 12, 47, 380, 224, 228, 1959, 1963, "time" +415, 12, 48, 381, 229, 235, 1964, 1970, "period" +415, 12, 49, 382, 236, 240, 1971, 1975, "were" +415, 12, 50, 383, 241, 249, 1976, 1984, "randomly" +415, 12, 51, 384, 250, 259, 1985, 1994, "allocated" +415, 12, 52, 385, 260, 262, 1995, 1997, "to" +415, 12, 53, 386, 263, 264, 1998, 1999, "1" +415, 12, 54, 387, 265, 267, 2000, 2002, "of" +415, 12, 55, 388, 268, 269, 2003, 2004, "2" +415, 12, 56, 389, 270, 279, 2005, 2014, "treatment" +415, 12, 57, 390, 280, 286, 2015, 2021, "groups" +415, 12, 58, 391, 287, 288, 2022, 2023, "." +415, 13, 1, 392, 0, 3, 2024, 2027, "One" +415, 13, 2, 393, 4, 9, 2028, 2033, "group" +415, 13, 3, 394, 10, 19, 2034, 2043, "continued" +415, 13, 4, 395, 20, 31, 2044, 2055, "monotherapy" +415, 13, 5, 396, 32, 36, 2056, 2060, "with" +415, 13, 6, 397, 37, 44, 2061, 2068, "timolol" +415, 13, 7, 398, 45, 46, 2069, 2070, "," +415, 13, 8, 399, 47, 48, 2071, 2072, "2" +415, 13, 9, 400, 49, 54, 2073, 2078, "drops" +415, 13, 10, 401, 55, 58, 2079, 2082, "per" +415, 13, 11, 402, 59, 67, 2083, 2091, "affected" +415, 13, 12, 403, 68, 71, 2092, 2095, "eye" +415, 13, 13, 404, 72, 75, 2096, 2099, "BID" +415, 13, 14, 405, 76, 77, 2100, 2101, "." +415, 14, 1, 406, 0, 3, 2102, 2105, "The" +415, 14, 2, 407, 4, 9, 2106, 2111, "other" +415, 14, 3, 408, 10, 15, 2112, 2117, "group" +415, 14, 4, 409, 16, 19, 2118, 2121, "was" +415, 14, 5, 410, 20, 28, 2122, 2130, "switched" +415, 14, 6, 411, 29, 30, 2131, 2132, "(" +415, 14, 7, 412, 31, 38, 2133, 2140, "without" +415, 14, 8, 413, 39, 46, 2141, 2148, "washout" +415, 14, 9, 414, 47, 48, 2149, 2150, ")" +415, 14, 10, 415, 49, 51, 2151, 2153, "to" +415, 14, 11, 416, 52, 63, 2154, 2165, "bimatoprost" +415, 14, 12, 417, 64, 65, 2166, 2167, "0" +415, 14, 13, 418, 66, 67, 2168, 2169, "." +415, 14, 14, 419, 68, 69, 2170, 2171, "3" +415, 14, 15, 420, 70, 71, 2172, 2173, "%" +415, 14, 16, 421, 72, 82, 2174, 2184, "ophthalmic" +415, 14, 17, 422, 83, 91, 2185, 2193, "solution" +415, 14, 18, 423, 92, 93, 2194, 2195, "(" +415, 14, 19, 424, 94, 95, 2196, 2197, "2" +415, 14, 20, 425, 96, 101, 2198, 2203, "drops" +415, 14, 21, 426, 102, 105, 2204, 2207, "per" +415, 14, 22, 427, 106, 114, 2208, 2216, "affected" +415, 14, 23, 428, 115, 118, 2217, 2220, "eye" +415, 14, 24, 429, 119, 121, 2221, 2223, "QD" +415, 14, 25, 430, 122, 123, 2224, 2225, "[" +415, 14, 26, 431, 124, 125, 2226, 2227, "9" +415, 14, 27, 432, 126, 128, 2228, 2230, "pm" +415, 14, 28, 433, 129, 130, 2231, 2232, "]" +415, 14, 29, 434, 131, 132, 2233, 2234, ")" +415, 14, 30, 435, 133, 134, 2235, 2236, "." +415, 15, 1, 436, 0, 9, 2237, 2246, "Treatment" +415, 15, 2, 437, 10, 13, 2247, 2250, "was" +415, 15, 3, 438, 14, 19, 2251, 2256, "given" +415, 15, 4, 439, 20, 23, 2257, 2260, "for" +415, 15, 5, 440, 24, 27, 2261, 2264, "180" +415, 15, 6, 441, 28, 32, 2265, 2269, "days" +415, 15, 7, 442, 33, 34, 2270, 2271, "." +415, 16, 1, 443, 0, 3, 2272, 2275, "IOP" +415, 16, 2, 444, 4, 7, 2276, 2279, "and" +415, 16, 3, 445, 8, 12, 2280, 2284, "pOBF" +415, 16, 4, 446, 13, 17, 2285, 2289, "were" +415, 16, 5, 447, 18, 26, 2290, 2298, "assessed" +415, 16, 6, 448, 27, 29, 2299, 2301, "at" +415, 16, 7, 449, 30, 33, 2302, 2305, "the" +415, 16, 8, 450, 34, 44, 2306, 2316, "diagnostic" +415, 16, 9, 451, 45, 50, 2317, 2322, "visit" +415, 16, 10, 452, 51, 52, 2323, 2324, "(" +415, 16, 11, 453, 53, 56, 2325, 2328, "pre" +415, 16, 12, 454, 57, 58, 2329, 2330, "-" +415, 16, 13, 455, 59, 66, 2331, 2338, "timolol" +415, 16, 14, 456, 67, 68, 2339, 2340, ")" +415, 16, 15, 457, 69, 70, 2341, 2342, "," +415, 16, 16, 458, 71, 79, 2343, 2351, "baseline" +415, 16, 17, 459, 80, 81, 2352, 2353, "(" +415, 16, 18, 460, 82, 85, 2354, 2357, "day" +415, 16, 19, 461, 86, 87, 2358, 2359, "0" +415, 16, 20, 462, 88, 89, 2360, 2361, ")" +415, 16, 21, 463, 90, 91, 2362, 2363, "," +415, 16, 22, 464, 92, 95, 2364, 2367, "and" +415, 16, 23, 465, 96, 105, 2368, 2377, "treatment" +415, 16, 24, 466, 106, 110, 2378, 2382, "days" +415, 16, 25, 467, 111, 113, 2383, 2385, "15" +415, 16, 26, 468, 114, 115, 2386, 2387, "," +415, 16, 27, 469, 116, 118, 2388, 2390, "30" +415, 16, 28, 470, 119, 120, 2391, 2392, "," +415, 16, 29, 471, 121, 123, 2393, 2395, "60" +415, 16, 30, 472, 124, 125, 2396, 2397, "," +415, 16, 31, 473, 126, 128, 2398, 2400, "90" +415, 16, 32, 474, 129, 130, 2401, 2402, "," +415, 16, 33, 475, 131, 134, 2403, 2406, "and" +415, 16, 34, 476, 135, 138, 2407, 2410, "180" +415, 16, 35, 477, 139, 140, 2411, 2412, "." +415, 17, 1, 478, 0, 7, 2413, 2420, "Primary" +415, 17, 2, 479, 8, 15, 2421, 2428, "adverse" +415, 17, 3, 480, 16, 23, 2429, 2436, "effects" +415, 17, 4, 481, 24, 25, 2437, 2438, "(" +415, 17, 5, 482, 26, 29, 2439, 2442, "AEs" +415, 17, 6, 483, 30, 31, 2443, 2444, ")" +415, 17, 7, 484, 32, 33, 2445, 2446, "(" +415, 17, 8, 485, 34, 36, 2447, 2449, "ie" +415, 17, 9, 486, 37, 38, 2450, 2451, "," +415, 17, 10, 487, 39, 51, 2452, 2464, "conjunctival" +415, 17, 11, 488, 52, 61, 2465, 2474, "hyperemia" +415, 17, 12, 489, 62, 63, 2475, 2476, "," +415, 17, 13, 490, 64, 76, 2477, 2489, "conjunctival" +415, 17, 14, 491, 77, 85, 2490, 2498, "papillae" +415, 17, 15, 492, 86, 87, 2499, 2500, "," +415, 17, 16, 493, 88, 96, 2501, 2509, "stinging" +415, 17, 17, 494, 97, 98, 2510, 2511, "," +415, 17, 18, 495, 99, 106, 2512, 2519, "burning" +415, 17, 19, 496, 107, 108, 2520, 2521, "," +415, 17, 20, 497, 109, 116, 2522, 2529, "foreign" +415, 17, 21, 498, 117, 121, 2530, 2534, "body" +415, 17, 22, 499, 122, 131, 2535, 2544, "sensation" +415, 17, 23, 500, 132, 133, 2545, 2546, "," +415, 17, 24, 501, 134, 137, 2547, 2550, "and" +415, 17, 25, 502, 138, 150, 2551, 2563, "pigmentation" +415, 17, 26, 503, 151, 153, 2564, 2566, "of" +415, 17, 27, 504, 154, 165, 2567, 2578, "periorbital" +415, 17, 28, 505, 166, 170, 2579, 2583, "skin" +415, 17, 29, 506, 171, 172, 2584, 2585, ")" +415, 17, 30, 507, 173, 177, 2586, 2590, "were" +415, 17, 31, 508, 178, 187, 2591, 2600, "monitored" +415, 17, 32, 509, 188, 198, 2601, 2611, "throughout" +415, 17, 33, 510, 199, 202, 2612, 2615, "the" +415, 17, 34, 511, 203, 208, 2616, 2621, "study" +415, 17, 35, 512, 209, 210, 2622, 2623, "." +415, 18, 1, 513, 0, 7, 2624, 2631, "RESULTS" +415, 18, 2, 514, 8, 9, 2632, 2633, ":" +415, 18, 3, 515, 10, 16, 2634, 2640, "Thirty" +415, 18, 4, 516, 17, 18, 2641, 2642, "-" +415, 18, 5, 517, 19, 24, 2643, 2648, "eight" +415, 18, 6, 518, 25, 33, 2649, 2657, "patients" +415, 18, 7, 519, 34, 38, 2658, 2662, "were" +415, 18, 8, 520, 39, 47, 2663, 2671, "enrolled" +415, 18, 9, 521, 48, 49, 2672, 2673, "(" +415, 18, 10, 522, 50, 52, 2674, 2676, "22" +415, 18, 11, 523, 53, 56, 2677, 2680, "men" +415, 18, 12, 524, 57, 58, 2681, 2682, "," +415, 18, 13, 525, 59, 61, 2683, 2685, "16" +415, 18, 14, 526, 62, 67, 2686, 2691, "women" +415, 18, 15, 527, 68, 69, 2692, 2693, ";" +415, 18, 16, 528, 70, 74, 2694, 2698, "mean" +415, 18, 17, 529, 75, 76, 2699, 2700, "[" +415, 18, 18, 530, 77, 79, 2701, 2703, "SD" +415, 18, 19, 531, 80, 81, 2704, 2705, "]" +415, 18, 20, 532, 82, 85, 2706, 2709, "age" +415, 18, 21, 533, 86, 87, 2710, 2711, "," +415, 18, 22, 534, 88, 90, 2712, 2714, "51" +415, 18, 23, 535, 91, 92, 2715, 2716, "." +415, 18, 24, 536, 93, 94, 2717, 2718, "7" +415, 18, 25, 537, 95, 96, 2719, 2720, "[" +415, 18, 26, 538, 97, 98, 2721, 2722, "4" +415, 18, 27, 539, 99, 100, 2723, 2724, "." +415, 18, 28, 540, 101, 102, 2725, 2726, "8" +415, 18, 29, 541, 103, 104, 2727, 2728, "]" +415, 18, 30, 542, 105, 110, 2729, 2734, "years" +415, 18, 31, 543, 111, 112, 2735, 2736, ";" +415, 18, 32, 544, 113, 115, 2737, 2739, "19" +415, 18, 33, 545, 116, 124, 2740, 2748, "patients" +415, 18, 34, 546, 125, 128, 2749, 2752, "per" +415, 18, 35, 547, 129, 138, 2753, 2762, "treatment" +415, 18, 36, 548, 139, 144, 2763, 2768, "group" +415, 18, 37, 549, 145, 146, 2769, 2770, ";" +415, 18, 38, 550, 147, 149, 2771, 2773, "38" +415, 18, 39, 551, 150, 158, 2774, 2782, "eligible" +415, 18, 40, 552, 159, 163, 2783, 2787, "eyes" +415, 18, 41, 553, 164, 165, 2788, 2789, ")" +415, 18, 42, 554, 166, 167, 2790, 2791, "." +415, 19, 1, 555, 0, 2, 2792, 2794, "At" +415, 19, 2, 556, 3, 6, 2795, 2798, "180" +415, 19, 3, 557, 7, 8, 2799, 2800, "-" +415, 19, 4, 558, 9, 12, 2801, 2804, "day" +415, 19, 5, 559, 13, 19, 2805, 2811, "follow" +415, 19, 6, 560, 20, 21, 2812, 2813, "-" +415, 19, 7, 561, 22, 24, 2814, 2816, "up" +415, 19, 8, 562, 25, 27, 2817, 2819, "in" +415, 19, 9, 563, 28, 31, 2820, 2823, "the" +415, 19, 10, 564, 32, 39, 2824, 2831, "timolol" +415, 19, 11, 565, 40, 45, 2832, 2837, "group" +415, 19, 12, 566, 46, 47, 2838, 2839, "," +415, 19, 13, 567, 48, 51, 2840, 2843, "the" +415, 19, 14, 568, 52, 55, 2844, 2847, "IOP" +415, 19, 15, 569, 56, 59, 2848, 2851, "and" +415, 19, 16, 570, 60, 63, 2852, 2855, "the" +415, 19, 17, 571, 64, 68, 2856, 2860, "pOBF" +415, 19, 18, 572, 69, 77, 2861, 2869, "remained" +415, 19, 19, 573, 78, 87, 2870, 2879, "unchanged" +415, 19, 20, 574, 88, 96, 2880, 2888, "compared" +415, 19, 21, 575, 97, 101, 2889, 2893, "with" +415, 19, 22, 576, 102, 110, 2894, 2902, "baseline" +415, 19, 23, 577, 111, 112, 2903, 2904, "." +415, 20, 1, 578, 0, 2, 2905, 2907, "In" +415, 20, 2, 579, 3, 6, 2908, 2911, "the" +415, 20, 3, 580, 7, 18, 2912, 2923, "bimatoprost" +415, 20, 4, 581, 19, 24, 2924, 2929, "group" +415, 20, 5, 582, 25, 28, 2930, 2933, "the" +415, 20, 6, 583, 29, 32, 2934, 2937, "IOP" +415, 20, 7, 584, 33, 41, 2938, 2946, "remained" +415, 20, 8, 585, 42, 51, 2947, 2956, "unchanged" +415, 20, 9, 586, 52, 55, 2957, 2960, "and" +415, 20, 10, 587, 56, 59, 2961, 2964, "the" +415, 20, 11, 588, 60, 64, 2965, 2969, "pOBF" +415, 20, 12, 589, 65, 68, 2970, 2973, "was" +415, 20, 13, 590, 69, 78, 2974, 2983, "decreased" +415, 20, 14, 591, 79, 81, 2984, 2986, "by" +415, 20, 15, 592, 82, 84, 2987, 2989, "38" +415, 20, 16, 593, 85, 86, 2990, 2991, "." +415, 20, 17, 594, 87, 88, 2992, 2993, "9" +415, 20, 18, 595, 89, 90, 2994, 2995, "%" +415, 20, 19, 596, 91, 99, 2996, 3004, "compared" +415, 20, 20, 597, 100, 104, 3005, 3009, "with" +415, 20, 21, 598, 105, 113, 3010, 3018, "baseline" +415, 20, 22, 599, 114, 115, 3019, 3020, "(" +415, 20, 23, 600, 116, 117, 3021, 3022, "P" +415, 20, 24, 601, 118, 119, 3023, 3024, "<" +415, 20, 25, 602, 120, 121, 3025, 3026, "0" +415, 20, 26, 603, 122, 123, 3027, 3028, "." +415, 20, 27, 604, 124, 126, 3029, 3031, "01" +415, 20, 28, 605, 127, 128, 3032, 3033, ")" +415, 20, 29, 606, 129, 130, 3034, 3035, "." +415, 21, 1, 607, 0, 3, 3036, 3039, "All" +415, 21, 2, 608, 4, 7, 3040, 3043, "AEs" +415, 21, 3, 609, 8, 12, 3044, 3048, "were" +415, 21, 4, 610, 13, 17, 3049, 3053, "mild" +415, 21, 5, 611, 18, 20, 3054, 3056, "to" +415, 21, 6, 612, 21, 29, 3057, 3065, "moderate" +415, 21, 7, 613, 30, 33, 3066, 3069, "and" +415, 21, 8, 614, 34, 42, 3070, 3078, "included" +415, 21, 9, 615, 43, 55, 3079, 3091, "conjunctival" +415, 21, 10, 616, 56, 65, 3092, 3101, "hyperemia" +415, 21, 11, 617, 66, 69, 3102, 3105, "and" +415, 21, 12, 618, 70, 76, 3106, 3112, "ocular" +415, 21, 13, 619, 77, 84, 3113, 3120, "itching" +415, 21, 14, 620, 85, 86, 3121, 3122, "(" +415, 21, 15, 621, 87, 88, 3123, 3124, "5" +415, 21, 16, 622, 89, 97, 3125, 3133, "patients" +415, 21, 17, 623, 98, 99, 3134, 3135, "[" +415, 21, 18, 624, 100, 102, 3136, 3138, "26" +415, 21, 19, 625, 103, 104, 3139, 3140, "." +415, 21, 20, 626, 105, 106, 3141, 3142, "3" +415, 21, 21, 627, 107, 108, 3143, 3144, "%" +415, 21, 22, 628, 109, 110, 3145, 3146, "]" +415, 21, 23, 629, 111, 113, 3147, 3149, "in" +415, 21, 24, 630, 114, 117, 3150, 3153, "the" +415, 21, 25, 631, 118, 129, 3154, 3165, "bimatoprost" +415, 21, 26, 632, 130, 135, 3166, 3171, "group" +415, 21, 27, 633, 136, 137, 3172, 3173, ")" +415, 21, 28, 634, 138, 141, 3174, 3177, "and" +415, 21, 29, 635, 142, 154, 3178, 3190, "pigmentation" +415, 21, 30, 636, 155, 157, 3191, 3193, "of" +415, 21, 31, 637, 158, 169, 3194, 3205, "periorbital" +415, 21, 32, 638, 170, 174, 3206, 3210, "skin" +415, 21, 33, 639, 175, 176, 3211, 3212, "(" +415, 21, 34, 640, 177, 178, 3213, 3214, "2" +415, 21, 35, 641, 179, 187, 3215, 3223, "patients" +415, 21, 36, 642, 188, 189, 3224, 3225, "[" +415, 21, 37, 643, 190, 192, 3226, 3228, "40" +415, 21, 38, 644, 193, 194, 3229, 3230, "." +415, 21, 39, 645, 195, 196, 3231, 3232, "0" +415, 21, 40, 646, 197, 198, 3233, 3234, "%" +415, 21, 41, 647, 199, 200, 3235, 3236, "]" +415, 21, 42, 648, 201, 203, 3237, 3239, "in" +415, 21, 43, 649, 204, 207, 3240, 3243, "the" +415, 21, 44, 650, 208, 219, 3244, 3255, "bimatoprost" +415, 21, 45, 651, 220, 225, 3256, 3261, "group" +415, 21, 46, 652, 226, 227, 3262, 3263, ")" +415, 21, 47, 653, 228, 229, 3264, 3265, "." +415, 22, 1, 654, 0, 3, 3266, 3269, "The" +415, 22, 2, 655, 4, 13, 3270, 3279, "incidence" +415, 22, 3, 656, 14, 16, 3280, 3282, "of" +415, 22, 4, 657, 17, 21, 3283, 3287, "each" +415, 22, 5, 658, 22, 24, 3288, 3290, "AE" +415, 22, 6, 659, 25, 28, 3291, 3294, "was" +415, 22, 7, 660, 29, 35, 3295, 3301, "higher" +415, 22, 8, 661, 36, 38, 3302, 3304, "in" +415, 22, 9, 662, 39, 42, 3305, 3308, "the" +415, 22, 10, 663, 43, 54, 3309, 3320, "bimatoprost" +415, 22, 11, 664, 55, 60, 3321, 3326, "group" +415, 22, 12, 665, 61, 65, 3327, 3331, "than" +415, 22, 13, 666, 66, 68, 3332, 3334, "in" +415, 22, 14, 667, 69, 72, 3335, 3338, "the" +415, 22, 15, 668, 73, 80, 3339, 3346, "timolol" +415, 22, 16, 669, 81, 86, 3347, 3352, "group" +415, 22, 17, 670, 87, 88, 3353, 3354, "(" +415, 22, 18, 671, 89, 90, 3355, 3356, "P" +415, 22, 19, 672, 91, 92, 3357, 3358, "=" +415, 22, 20, 673, 93, 94, 3359, 3360, "0" +415, 22, 21, 674, 95, 96, 3361, 3362, "." +415, 22, 22, 675, 97, 100, 3363, 3366, "008" +415, 22, 23, 676, 101, 102, 3367, 3368, ")" +415, 22, 24, 677, 103, 104, 3369, 3370, "." +415, 23, 1, 678, 0, 11, 3371, 3382, "CONCLUSIONS" +415, 23, 2, 679, 12, 13, 3383, 3384, ":" +415, 23, 3, 680, 14, 16, 3385, 3387, "In" +415, 23, 4, 681, 17, 21, 3388, 3392, "this" +415, 23, 5, 682, 22, 32, 3393, 3403, "population" +415, 23, 6, 683, 33, 35, 3404, 3406, "of" +415, 23, 7, 684, 36, 44, 3407, 3415, "patients" +415, 23, 8, 685, 45, 49, 3416, 3420, "with" +415, 23, 9, 686, 50, 54, 3421, 3425, "POAG" +415, 23, 10, 687, 55, 56, 3426, 3427, "," +415, 23, 11, 688, 57, 68, 3428, 3439, "bimatoprost" +415, 23, 12, 689, 69, 72, 3440, 3443, "was" +415, 23, 13, 690, 73, 83, 3444, 3454, "associated" +415, 23, 14, 691, 84, 88, 3455, 3459, "with" +415, 23, 15, 692, 89, 98, 3460, 3469, "increased" +415, 23, 16, 693, 99, 103, 3470, 3474, "pOBF" +415, 23, 17, 694, 104, 105, 3475, 3476, "," +415, 23, 18, 695, 106, 109, 3477, 3480, "and" +415, 23, 19, 696, 110, 113, 3481, 3484, "the" +415, 23, 20, 697, 114, 123, 3485, 3494, "reduction" +415, 23, 21, 698, 124, 126, 3495, 3497, "in" +415, 23, 22, 699, 127, 131, 3498, 3502, "pOBF" +415, 23, 23, 700, 132, 142, 3503, 3513, "associated" +415, 23, 24, 701, 143, 147, 3514, 3518, "with" +415, 23, 25, 702, 148, 155, 3519, 3526, "timolol" +415, 23, 26, 703, 156, 159, 3527, 3530, "was" +415, 23, 27, 704, 160, 169, 3531, 3540, "corrected" +415, 23, 28, 705, 170, 175, 3541, 3546, "after" +415, 23, 29, 706, 176, 184, 3547, 3555, "patients" +415, 23, 30, 707, 185, 189, 3556, 3560, "were" +415, 23, 31, 708, 190, 198, 3561, 3569, "switched" +415, 23, 32, 709, 199, 201, 3570, 3572, "to" +415, 23, 33, 710, 202, 213, 3573, 3584, "bimatoprost" +415, 23, 34, 711, 214, 215, 3585, 3586, "." +415, 24, 1, 712, 0, 11, 3587, 3598, "Bimatoprost" +415, 24, 2, 713, 12, 15, 3599, 3602, "was" +415, 24, 3, 714, 16, 26, 3603, 3613, "associated" +415, 24, 4, 715, 27, 31, 3614, 3618, "with" +415, 24, 5, 716, 32, 41, 3619, 3628, "increased" +415, 24, 6, 717, 42, 51, 3629, 3638, "choroidal" +415, 24, 7, 718, 52, 57, 3639, 3644, "blood" +415, 24, 8, 719, 58, 62, 3645, 3649, "flow" +415, 24, 9, 720, 63, 64, 3650, 3651, "," +415, 24, 10, 721, 65, 71, 3652, 3658, "beyond" +415, 24, 11, 722, 72, 75, 3659, 3662, "the" +415, 24, 12, 723, 76, 82, 3663, 3669, "levels" +415, 24, 13, 724, 83, 91, 3670, 3678, "recorded" +415, 24, 14, 725, 92, 98, 3679, 3685, "before" +415, 24, 15, 726, 99, 106, 3686, 3693, "timolol" +415, 24, 16, 727, 107, 116, 3694, 3703, "treatment" +415, 24, 17, 728, 117, 118, 3704, 3705, "." +415, 25, 1, 729, 0, 3, 3706, 3709, "The" +415, 25, 2, 730, 4, 13, 3710, 3719, "decreased" +415, 25, 3, 731, 14, 17, 3720, 3723, "IOP" +415, 25, 4, 732, 18, 23, 3724, 3729, "level" +415, 25, 5, 733, 24, 32, 3730, 3738, "achieved" +415, 25, 6, 734, 33, 35, 3739, 3741, "in" +415, 25, 7, 735, 36, 39, 3742, 3745, "the" +415, 25, 8, 736, 40, 47, 3746, 3753, "timolol" +415, 25, 9, 737, 48, 53, 3754, 3759, "group" +415, 25, 10, 738, 54, 60, 3760, 3766, "seemed" +415, 25, 11, 739, 61, 63, 3767, 3769, "to" +415, 25, 12, 740, 64, 66, 3770, 3772, "be" +415, 25, 13, 741, 67, 75, 3773, 3781, "improved" +415, 25, 14, 742, 76, 83, 3782, 3789, "further" +415, 25, 15, 743, 84, 86, 3790, 3792, "by" +415, 25, 16, 744, 87, 98, 3793, 3804, "bimatoprost" +415, 25, 17, 745, 99, 100, 3805, 3806, "." +415, 26, 1, 746, 0, 11, 3807, 3818, "Considering" +415, 26, 2, 747, 12, 15, 3819, 3822, "the" +415, 26, 3, 748, 16, 25, 3823, 3832, "potential" +415, 26, 4, 749, 26, 34, 3833, 3841, "efficacy" +415, 26, 5, 750, 35, 37, 3842, 3844, "of" +415, 26, 6, 751, 38, 49, 3845, 3856, "bimatoprost" +415, 26, 7, 752, 50, 52, 3857, 3859, "on" +415, 26, 8, 753, 53, 56, 3860, 3863, "IOP" +415, 26, 9, 754, 57, 60, 3864, 3867, "and" +415, 26, 10, 755, 61, 65, 3868, 3872, "pOBF" +415, 26, 11, 756, 66, 67, 3873, 3874, "," +415, 26, 12, 757, 68, 70, 3875, 3877, "we" +415, 26, 13, 758, 71, 78, 3878, 3885, "suggest" +415, 26, 14, 759, 79, 83, 3886, 3890, "that" +415, 26, 15, 760, 84, 88, 3891, 3895, "this" +415, 26, 16, 761, 89, 92, 3896, 3899, "new" +415, 26, 17, 762, 93, 97, 3900, 3904, "drug" +415, 26, 18, 763, 98, 101, 3905, 3908, "may" +415, 26, 19, 764, 102, 111, 3909, 3918, "represent" +415, 26, 20, 765, 112, 113, 3919, 3920, "a" +415, 26, 21, 766, 114, 122, 3921, 3929, "clinical" +415, 26, 22, 767, 123, 130, 3930, 3937, "advance" +415, 26, 23, 768, 131, 133, 3938, 3940, "in" +415, 26, 24, 769, 134, 137, 3941, 3944, "the" +415, 26, 25, 770, 138, 145, 3945, 3952, "medical" +415, 26, 26, 771, 146, 155, 3953, 3962, "treatment" +415, 26, 27, 772, 156, 158, 3963, 3965, "of" +415, 26, 28, 773, 159, 163, 3966, 3970, "POAG" +415, 26, 29, 774, 164, 165, 3971, 3972, "." +415, 27, 1, 775, 0, 3, 3973, 3976, "DOI" +415, 27, 2, 776, 4, 5, 3977, 3978, ":" +415, 27, 3, 777, 6, 8, 3979, 3981, "10" +415, 27, 4, 778, 9, 10, 3982, 3983, "." +415, 27, 5, 779, 11, 15, 3984, 3988, "1016" +415, 27, 6, 780, 16, 17, 3989, 3990, "/" +415, 27, 7, 781, 18, 19, 3991, 3992, "j" +415, 27, 8, 782, 20, 21, 3993, 3994, "." +415, 27, 9, 783, 22, 31, 3995, 4004, "curtheres" +415, 27, 10, 784, 32, 33, 4005, 4006, "." +415, 27, 11, 785, 34, 38, 4007, 4011, "2005" +415, 27, 12, 786, 39, 40, 4012, 4013, "." +415, 27, 13, 787, 41, 43, 4014, 4016, "01" +415, 27, 14, 788, 44, 45, 4017, 4018, "." +415, 27, 15, 789, 46, 49, 4019, 4022, "004" +415, 27, 16, 790, 50, 55, 4023, 4028, "PMCID" +415, 27, 17, 791, 56, 57, 4029, 4030, ":" +415, 27, 18, 792, 58, 68, 4031, 4041, "PMC3964529" +415, 27, 19, 793, 69, 73, 4042, 4046, "PMID" +415, 27, 20, 794, 74, 75, 4047, 4048, ":" +415, 27, 21, 795, 76, 84, 4049, 4057, "24672097" diff --git a/data/gl 24672097_jshahinitiran.annodb b/data/gl 24672097_jshahinitiran.annodb new file mode 100644 index 0000000..1a7b492 --- /dev/null +++ b/data/gl 24672097_jshahinitiran.annodb @@ -0,0 +1,106 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +17093, Journal, 0, 22, "Curr Ther Res Clin Exp", "", +17094, PublicationYear, 25, 29, "2004", "", +17095, Title, 110, 348, "Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open - angle glaucoma : A prospective , open - label , randomized , two - arm , parallel - group study .", "", +17096, Bimatoprost, 139, 150, "bimatoprost", "", +17097, Timolol, 155, 162, "timolol", "", +17098, IOP, 166, 186, "intraocular pressure", "", +17148, EndPointDescription, 191, 218, "pulsatile ocular blood flow", "", +17099, OpenAngleGlaucoma, 236, 265, "primary open - angle glaucoma", "", +17100, CTDesign, 270, 281, "prospective", "", +17101, OpenLabel, 284, 296, "open - label", "", +17102, Randomized, 299, 309, "randomized", "", +17103, CTDesign, 312, 321, "two - arm", "", +17104, Parallel, 324, 340, "parallel - group", "", +17105, Author, 349, 359, "Vetrugno M", "", +17106, Author, 368, 379, "Cardascia N", "", +17107, Author, 388, 399, "Cantatore F", "", +17108, Author, 408, 417, "Sborgia C", "", +17207, Italy, 536, 541, "Italy", "", +17206, Italy, 638, 643, "Italy", "", +17109, IOP, 733, 753, "intraocular pressure", "", +17110, IOP, 756, 759, "IOP", "", +17111, Bimatoprost, 1034, 1045, "Bimatoprost", "", +17112, IOP, 1108, 1111, "IOP", "", +17113, Timolol, 1196, 1211, "timolol maleate", "", +17114, ObjectiveDescription, 1297, 1521, "The aim of this study was to compare the effects of bimatoprost and timolol on IOP and choroidal blood flow ( as measured using pulsatile ocular blood flow [ pOBF ] ) in patients with primary open - angle glaucoma ( POAG ) .", "", +17115, Bimatoprost, 1349, 1360, "bimatoprost", "", +17116, Timolol, 1365, 1372, "timolol", "", +17117, IOP, 1376, 1379, "IOP", "", +17148, EndPointDescription, 1455, 1459, "pOBF", "", +17118, OpenAngleGlaucoma, 1481, 1510, "primary open - angle glaucoma", "", +17119, OpenAngleGlaucoma, 1513, 1517, "POAG", "", +17100, CTDesign, 1537, 1548, "prospective", "", +17101, OpenLabel, 1551, 1563, "open - label", "", +17102, Randomized, 1566, 1576, "randomized", "", +17103, CTDesign, 1579, 1586, "2 - arm", "", +17104, Parallel, 1589, 1605, "parallel - group", "", +17125, Glaucoma, 1633, 1641, "Glaucoma", "", +17126, Italy, 1727, 1732, "Italy", "", +17131, Precondition, 1735, 1970, "Patients with POAG having well - controlled IOP ( < 16 mm Hg ) on monotherapy with timolol 0 . 5 % ophthalmic solution ( 2 drops per affected eye BID ) for ≥ 12 months but with a progressive decrease in pOBF during the same time period", "", +17118, OpenAngleGlaucoma, 1749, 1753, "POAG", "", +17129, IOP, 1779, 1782, "IOP", "", +17130, mmHg, 1790, 1795, "mm Hg", "", +17132, Timolol, 1818, 1825, "timolol", "", +17133, DoseValue, 1826, 1831, "0 . 5", "", +17134, Percentage, 1832, 1833, "%", "", +17135, Eyedrops, 1858, 1863, "drops", "", +17136, Frequency, 1881, 1884, "BID", "", +17148, EndPointDescription, 1938, 1942, "pOBF", "", +17102, Randomized, 1976, 1984, "randomly", "", +17138, Timolol, 2061, 2068, "timolol", "", +17139, Eyedrops, 2073, 2078, "drops", "", +17140, Frequency, 2096, 2099, "BID", "", +17141, Bimatoprost, 2154, 2165, "bimatoprost", "", +17142, DoseValue, 2166, 2171, "0 . 3", "", +17143, Percentage, 2172, 2173, "%", "", +17144, Eyedrops, 2198, 2203, "drops", "", +17145, Frequency, 2221, 2223, "QD", "", +17146, Duration, 2261, 2269, "180 days", "", +17147, IOP, 2272, 2275, "IOP", "", +17148, EndPointDescription, 2280, 2284, "pOBF", "", +17208, TimePoint, 2407, 2410, "180", "", +17152, ConjunctivalHyperemia, 2452, 2474, "conjunctival hyperemia", "", +17158, NumberPatientsCT, 2634, 2648, "Thirty - eight", "", +17159, Male, 2677, 2680, "men", "", +17160, Female, 2686, 2691, "women", "", +17161, Mean, 2694, 2698, "mean", "", +17162, AvgAge, 2712, 2718, "51 . 7", "", +17163, NumberPatientsArm, 2737, 2739, "19", "", +17208, TimePoint, 2795, 2804, "180 - day", "", +17164, IOP, 2844, 2847, "IOP", "", +17148, EndPointDescription, 2856, 2860, "pOBF", "", +17166, Bimatoprost, 2912, 2923, "bimatoprost", "", +17167, IOP, 2934, 2937, "IOP", "", +17148, EndPointDescription, 2965, 2969, "pOBF", "", +17169, RelativeReduction, 2987, 2993, "38 . 9", "", +17170, PValueChangeValue, 3021, 3031, "P < 0 . 01", "", +17152, ConjunctivalHyperemia, 3079, 3101, "conjunctival hyperemia", "", +17173, NumberAffected, 3123, 3124, "5", "", +17174, PercentageAffected, 3136, 3142, "26 . 3", "", +17175, Bimatoprost, 3154, 3165, "bimatoprost", "", +17177, NumberAffected, 3213, 3214, "2", "", +17178, PercentageAffected, 3226, 3232, "40 . 0", "", +17180, Bimatoprost, 3244, 3255, "bimatoprost", "", +17182, ObservedResult, 3266, 3370, "The incidence of each AE was higher in the bimatoprost group than in the timolol group ( P = 0 . 008 ) .", "", +17181, PValueNumAffected, 3355, 3366, "P = 0 . 008", "", +17202, ConclusionComment, 3385, 3586, "In this population of patients with POAG , bimatoprost was associated with increased pOBF , and the reduction in pOBF associated with timolol was corrected after patients were switched to bimatoprost .", "", +17099, OpenAngleGlaucoma, 3421, 3425, "POAG", "", +17184, Bimatoprost, 3428, 3439, "bimatoprost", "", +17148, EndPointDescription, 3470, 3474, "pOBF", "", +17148, EndPointDescription, 3498, 3502, "pOBF", "", +17187, Timolol, 3519, 3526, "timolol", "", +17191, Bimatoprost, 3573, 3584, "bimatoprost", "", +17192, Bimatoprost, 3587, 3598, "Bimatoprost", "", +17203, ConclusionComment, 3587, 3705, "Bimatoprost was associated with increased choroidal blood flow , beyond the levels recorded before timolol treatment .", "", +17193, Timolol, 3686, 3693, "timolol", "", +17204, ConclusionComment, 3706, 3806, "The decreased IOP level achieved in the timolol group seemed to be improved further by bimatoprost .", "", +17194, IOP, 3720, 3723, "IOP", "", +17195, Timolol, 3746, 3753, "timolol", "", +17196, Bimatoprost, 3793, 3804, "bimatoprost", "", +17205, ConclusionComment, 3807, 3972, "Considering the potential efficacy of bimatoprost on IOP and pOBF , we suggest that this new drug may represent a clinical advance in the medical treatment of POAG .", "", +17197, Bimatoprost, 3845, 3856, "bimatoprost", "", +17198, IOP, 3860, 3863, "IOP", "", +17148, EndPointDescription, 3868, 3872, "pOBF", "", +17099, OpenAngleGlaucoma, 3966, 3970, "POAG", "", +17201, PMID, 4049, 4057, "24672097", "", diff --git a/data/gl 24672097_jshahinitiran.n-triples b/data/gl 24672097_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24672097_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24672097_tstrakeljahn.annodb b/data/gl 24672097_tstrakeljahn.annodb new file mode 100644 index 0000000..8a09298 --- /dev/null +++ b/data/gl 24672097_tstrakeljahn.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11281, Journal, 0, 22, "Curr Ther Res Clin Exp", "", +11282, PublicationYear, 25, 29, "2004", "", +11296, Title, 110, 346, "Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open - angle glaucoma : A prospective , open - label , randomized , two - arm , parallel - group study", "", +11283, Bimatoprost, 139, 150, "bimatoprost", "", +11284, Timolol, 155, 162, "timolol", "", +11285, IOP, 166, 186, "intraocular pressure", "", +11286, OpenAngleGlaucoma, 244, 265, "open - angle glaucoma", "", +11287, OpenLabel, 284, 296, "open - label", "", +11288, Randomized, 299, 309, "randomized", "", +11289, Parallel, 324, 332, "parallel", "", +11290, Author, 349, 359, "Vetrugno M", "", +11291, Author, 368, 379, "Cardascia N", "", +11292, Author, 388, 399, "Cantatore F", "", +11293, Author, 408, 417, "Sborgia C", "", +11294, Italy, 536, 541, "Italy", "", +11295, Italy, 638, 643, "Italy", "", +11297, IOP, 733, 753, "intraocular pressure", "", +11298, IOP, 756, 759, "IOP", "", +11299, Bimatoprost, 1034, 1045, "Bimatoprost", "", +11300, IOP, 1108, 1111, "IOP", "", +11301, Timolol, 1196, 1211, "timolol maleate", "", +11311, ObjectiveDescription, 1297, 1521, "The aim of this study was to compare the effects of bimatoprost and timolol on IOP and choroidal blood flow ( as measured using pulsatile ocular blood flow [ pOBF ] ) in patients with primary open - angle glaucoma ( POAG ) .", "", +11303, Bimatoprost, 1349, 1360, "bimatoprost", "", +11304, Timolol, 1365, 1372, "timolol", "", +11305, IOP, 1376, 1379, "IOP", "", +11306, Endpoint, 1384, 1404, "choroidal blood flow", "", +11302, OpenAngleGlaucoma, 1489, 1510, "open - angle glaucoma", "", +11307, OpenLabel, 1551, 1563, "open - label", "", +11308, Randomized, 1566, 1576, "randomized", "", +11309, Parallel, 1589, 1597, "parallel", "", +11310, Italy, 1727, 1732, "Italy", "", +11460, IOP, 1779, 1782, "IOP", "", +11313, Timolol, 1818, 1825, "timolol", "", +11314, DoseValue, 1826, 1831, "0 . 5", "", +11315, Percentage, 1832, 1833, "%", "", +11495, DoseValue, 1856, 1857, "2", "", +11496, Eyedrops, 1858, 1863, "drops", "", +11497, Endpoint, 1938, 1942, "pOBF", "", +11498, Randomized, 1976, 1984, "randomly", "", +11461, Timolol, 2061, 2068, "timolol", "", +11493, DoseValue, 2071, 2072, "2", "", +11492, Eyedrops, 2073, 2078, "drops", "", +11462, Bimatoprost, 2154, 2165, "bimatoprost", "", +11463, DoseValue, 2166, 2171, "0 . 3", "", +11494, DoseValue, 2196, 2197, "2", "", +11464, Eyedrops, 2198, 2203, "drops", "", +11465, Duration, 2261, 2264, "180", "", +11466, IOP, 2272, 2275, "IOP", "", +11467, Endpoint, 2280, 2284, "pOBF", "", +11468, Timolol, 2331, 2338, "timolol", "", +11469, ObservedResult, 2413, 2621, "Primary adverse effects ( AEs ) ( ie , conjunctival hyperemia , conjunctival papillae , stinging , burning , foreign body sensation , and pigmentation of periorbital skin ) were monitored throughout the study", "", +11470, NumberPatientsCT, 2634, 2657, "Thirty - eight patients", "", +11472, AvgAge, 2712, 2718, "51 . 7", "", +11471, NumberPatientsArm, 2737, 2739, "19", "", +11477, ObservedResult, 2792, 2904, "At 180 - day follow - up in the timolol group , the IOP and the pOBF remained unchanged compared with baseline .", "", +11473, TimePoint, 2795, 2816, "180 - day follow - up", "", +11474, Timolol, 2824, 2831, "timolol", "", +11475, IOP, 2844, 2847, "IOP", "", +11476, Endpoint, 2856, 2860, "pOBF", "", +11478, Endpoint, 2965, 2969, "pOBF", "", +11479, RelativeReduction, 2987, 2993, "38 . 9", "", +11480, PValueChangeValue, 3021, 3031, "P < 0 . 01", "", +11484, ConjunctivalHyperemia, 3079, 3101, "conjunctival hyperemia", "", +11481, NumberAffected, 3123, 3124, "5", "", +11482, RelNumPatientsLeftCT, 3136, 3142, "26 . 3", "", +11486, Bimatoprost, 3154, 3165, "bimatoprost", "", +11487, IrisPigmentation, 3178, 3210, "pigmentation of periorbital skin", "", +11488, NumberAffected, 3213, 3214, "2", "", +11483, RelNumPatientsLeftCT, 3226, 3232, "40 . 0", "", +11489, Bimatoprost, 3244, 3255, "bimatoprost", "", +11491, ObservedResult, 3266, 3352, "The incidence of each AE was higher in the bimatoprost group than in the timolol group", "", +11490, PvalueDiff, 3355, 3366, "P = 0 . 008", "", +11504, ConclusionComment, 3385, 3586, "In this population of patients with POAG , bimatoprost was associated with increased pOBF , and the reduction in pOBF associated with timolol was corrected after patients were switched to bimatoprost .", "", +11499, Bimatoprost, 3428, 3439, "bimatoprost", "", +11502, Endpoint, 3470, 3474, "pOBF", "", +11503, Endpoint, 3498, 3502, "pOBF", "", +11500, Timolol, 3519, 3526, "timolol", "", +11501, Bimatoprost, 3573, 3584, "bimatoprost", "", +11505, Bimatoprost, 3587, 3598, "Bimatoprost", "", +11516, ConclusionComment, 3587, 3703, "Bimatoprost was associated with increased choroidal blood flow , beyond the levels recorded before timolol treatment", "", +11506, Timolol, 3686, 3693, "timolol", "", +11515, ConclusionComment, 3706, 3804, "The decreased IOP level achieved in the timolol group seemed to be improved further by bimatoprost", "", +11512, IOP, 3720, 3723, "IOP", "", +11513, Timolol, 3746, 3753, "timolol", "", +11514, Bimatoprost, 3793, 3804, "bimatoprost", "", +11511, ConclusionComment, 3807, 3972, "Considering the potential efficacy of bimatoprost on IOP and pOBF , we suggest that this new drug may represent a clinical advance in the medical treatment of POAG .", "", +11510, Bimatoprost, 3845, 3856, "bimatoprost", "", +11508, IOP, 3860, 3863, "IOP", "", +11509, Endpoint, 3868, 3872, "pOBF", "", +11507, PMID, 4049, 4057, "24672097", "", diff --git a/data/gl 24672097_tstrakeljahn.n-triples b/data/gl 24672097_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24672097_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24919410_admin.annodb b/data/gl 24919410_admin.annodb new file mode 100644 index 0000000..2f77a6e --- /dev/null +++ b/data/gl 24919410_admin.annodb @@ -0,0 +1,132 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "Adv Ther .", "", " \"Adv Ther .\"." +1, PublicationYear, 11, 15, "2014", "", " \"2014\"." +2, Title, 108, 266, "24 - hour efficacy of travoprost / timolol BAK - free versus latanoprost / timolol fixed combinations in patients insufficiently controlled with latanoprost .", "", " \"24 - hour efficacy of travoprost / timolol BAK - free versus latanoprost / timolol fixed combinations in patients insufficiently controlled with latanoprost .\"." +104340, FixedCombDrug, 130, 161, "travoprost / timolol BAK - free", "", +15, Travoprost, 130, 140, "travoprost", "", +16, Timolol, 143, 161, "timolol BAK - free", "", +18, Latanoprost, 169, 180, "latanoprost", "", +20, Lat/TimFC, 169, 209, "latanoprost / timolol fixed combinations", "", +17, Timolol, 183, 190, "timolol", "", +22, Precondition, 213, 264, "patients insufficiently controlled with latanoprost", "", +21, Latanoprost, 253, 264, "latanoprost", "", +3, Author, 267, 277, "Konstas AG", "", " \"Konstas AG\"." +4, Author, 286, 302, "Voudouragkaki IC", "", " \"Voudouragkaki IC\"." +5, Author, 305, 317, "Boboridis KG", "", " \"Boboridis KG\"." +6, Author, 320, 330, "Haidich AB", "", " \"Haidich AB\"." +7, Author, 333, 346, "Paschalinou E", "", " \"Paschalinou E\"." +8, Author, 349, 363, "Giannopoulos T", "", " \"Giannopoulos T\"." +9, Author, 366, 378, "Dragoumis ND", "", " \"Dragoumis ND\"." +10, Author, 381, 392, "Makridis AK", "", " \"Makridis AK\"." +11, Author, 395, 404, "Kahook MY", "", " \"Kahook MY\"." +12, Greece, 563, 569, "Greece", "", " ." +154, ObjectiveDescription, 615, 867, "To compare the 24 - h intraocular pressure ( IOP ) control and tolerability of travoprost / timolol benzalkonium chloride ( BAK ) - free ( TTFC ) vs . latanoprost / timolol fixed combination preserved with BAK ( LTFC ) in open - angle glaucoma patients", "", " \"To compare the 24 - h intraocular pressure ( IOP ) control and tolerability of travoprost / timolol benzalkonium chloride ( BAK ) - free ( TTFC ) vs . latanoprost / timolol fixed combination preserved with BAK ( LTFC ) in open - angle glaucoma patients\"." +23, IOP, 630, 657, "24 - h intraocular pressure", "", " . ." +24, IOP, 660, 663, "IOP", "", +104343, FixedCombDrug, 694, 751, "travoprost / timolol benzalkonium chloride ( BAK ) - free", "", +25, Travoprost, 694, 704, "travoprost", "", " ." +26, Timolol, 707, 751, "timolol benzalkonium chloride ( BAK ) - free", "", " ." +104352, FixedCombDrug, 754, 758, "TTFC", "", +29, Latanoprost, 766, 777, "latanoprost", "", " . ." +31, Lat/TimFC, 766, 824, "latanoprost / timolol fixed combination preserved with BAK", "", +30, Timolol, 780, 787, "timolol", "", +32, Lat/TimFC, 827, 831, "LTFC", "", +33, OpenAngleGlaucoma, 837, 858, "open - angle glaucoma", "", " ." +34, Precondition, 859, 932, "patients insufficiently controlled with latanoprost 0 . 005 % monotherapy", "", " \"patients insufficiently controlled with latanoprost 0 . 005 % monotherapy\"." +155, ObjectiveDescription, 868, 960, "insufficiently controlled with latanoprost 0 . 005 % monotherapy given once in the evening .", "", " \"insufficiently controlled with latanoprost 0 . 005 % monotherapy given once in the evening .\"." +35, Latanoprost, 899, 910, "latanoprost", "", +36, DoseValue, 911, 918, "0 . 005", "", +151, Percentage, 919, 920, "%", "", +153, Frequency, 939, 958, "once in the evening", "", +38, Evening, 951, 958, "evening", "", +39, Prospective, 1000, 1011, "prospective", "", " ." +40, Blind, 1014, 1031, "observer - masked", "", " ." +41, CTDesign, 1034, 1053, "active - controlled", "", " . ." +42, Crossover, 1056, 1068, "cross - over", "", " ." +43, OpenAngleGlaucoma, 1100, 1121, "open - angle glaucoma", "", +44, Latanoprost, 1150, 1161, "latanoprost", "", +162, Morning, 1172, 1179, "morning", "", +45, IOP, 1180, 1183, "IOP", "", +164, TimePoint, 1186, 1199, "10 : 00 ± 1 h", "", +46, mmHg, 1218, 1222, "mmHg", "", +48, Randomized, 1251, 1261, "randomized", "", " ." +49, Duration, 1266, 1274, "3 months", "", +104344, FixedCombDrug, 1293, 1297, "TTFC", "", +51, Lat/TimFC, 1301, 1305, "LTFC", "", +52, Crossover, 1327, 1339, "crossed over", "", +53, Duration, 1378, 1386, "3 months", "", +54, Latanoprost, 1407, 1418, "latanoprost", "", +55, TimePoint, 1443, 1452, "3 - month", "", +56, IOP, 1487, 1497, "24 - h IOP", "", +57, MeasurementDevice, 1540, 1570, "Goldmann applanation tonometry", "", " . ." +104346, RelativeTime, 1595, 1609, "during the day", "", +175, TimePoint, 1612, 1619, "10 : 00", "", +176, TimePoint, 1622, 1629, "14 : 00", "", +177, TimePoint, 1632, 1639, "18 : 00", "", +178, TimePoint, 1644, 1651, "22 : 00", "", +58, MeasurementDevice, 1658, 1675, "Perkins tonometry", "", " . ." +104345, RelativeTime, 1699, 1707, "at night", "", +179, TimePoint, 1710, 1717, "02 : 00", "", +180, TimePoint, 1722, 1729, "06 : 00", "", +59, FinalNumPatientsCT, 1822, 1833, "Forty - two", "", " \"Forty - two\"." +60, OpenAngleGlaucoma, 1834, 1855, "open - angle glaucoma", "", +61, Mean, 1891, 1895, "mean", "", +69, IOP, 1912, 1915, "IOP", "", +62, Latanoprost, 1919, 1930, "latanoprost", "", +63, BaseLineValue, 1935, 1941, "21 . 5", "", " \"21 . 5\". \"21 . 5\"." +186, SdDevBL, 1944, 1949, "1 . 6", "", " \"1 . 6\". \"1 . 6\"." +65, mmHg, 1950, 1954, "mmHg", "", " ." +66, IOP, 2007, 2010, "IOP", "", +67, Mean, 2040, 2044, "mean", "", " . ." +190, Peak_IOP, 2047, 2051, "peak", "", +68, IOP, 2071, 2081, "24 - h IOP", "", +70, Latanoprost, 2096, 2107, "latanoprost", "", +104347, PvalueDiff, 2122, 2132, "P < 0 . 01", "", +104348, FixedCombDrug, 2194, 2198, "TTFC", "", +73, Mean, 2228, 2232, "mean", "", +74, IOP, 2233, 2243, "24 - h IOP", "", +75, ResultMeasuredValue, 2246, 2252, "18 . 9", "", " \"18 . 9\"." +208, SdDevResValue, 2255, 2260, "2 . 2", "", " \"2 . 2\"." +80, mmHg, 2261, 2265, "mmHg", "", +79, Lat/TimFC, 2273, 2277, "LTFC", "", +76, ResultMeasuredValue, 2280, 2286, "19 . 3", "", " \"19 . 3\"." +209, SdDevResValue, 2289, 2294, "2 . 3", "", " \"2 . 3\"." +81, mmHg, 2295, 2299, "mmHg", "", +212, PvalueDiff, 2304, 2315, "P = 0 . 004", "", " \"P = 0 . 004\"." +83, IOP, 2342, 2345, "IOP", "", +213, TimePoint, 2349, 2356, "18 : 00", "", " \"18 : 00\". \"18 : 00\"." +84, ResultMeasuredValue, 2359, 2365, "18 . 6", "", " \"18 . 6\"." +210, SdDevResValue, 2368, 2373, "2 . 5", "", " \"2 . 5\"." +85, ResultMeasuredValue, 2379, 2385, "19 . 5", "", " \"19 . 5\"." +211, SdDevResValue, 2388, 2393, "2 . 7", "", " \"2 . 7\"." +88, mmHg, 2394, 2398, "mmHg", "", +89, Lat/TimFC, 2403, 2407, "LTFC", "", +202, PvalueDiff, 2412, 2423, "P < 0 . 001", "", " \"P < 0 . 001\"." +104349, FixedCombDrug, 2438, 2442, "TTFC", "", +92, EndPointDescription, 2477, 2502, "tear film break - up time", "", " . ." +93, ResultMeasuredValue, 2505, 2511, "5 . 15", "", " \"5 . 15\"." +94, ResultMeasuredValue, 2517, 2523, "4 . 65", "", " \"4 . 65\"." +95, Second, 2524, 2525, "s", "", " ." +96, EndPointDescription, 2530, 2543, "corneal stain", "", " . ." +97, ResultMeasuredValue, 2546, 2551, "1 . 5", "", " \"1 . 5\"." +98, ResultMeasuredValue, 2557, 2562, "1 . 8", "", " \"1 . 8\"." +101, EndPointDescription, 2569, 2584, "Schirmer I test", "", " . ." +99, ResultMeasuredValue, 2587, 2592, "9 . 9", "", " \"9 . 9\"." +100, ResultMeasuredValue, 2598, 2603, "9 . 2", "", " \"9 . 2\"." +102, BioAndMedicalUnit, 2604, 2606, "mm", "", " . ." +103, Lat/TimFC, 2623, 2627, "LTFC", "", +223, TimePoint, 2628, 2642, "after 3 months", "", " \"after 3 months\". \"after 3 months\". \"after 3 months\". \"after 3 months\". \"after 3 months\". \"after 3 months\"." +104, Duration, 2634, 2642, "3 months", "", +105, PvalueDiff, 2656, 2666, "P < 0 . 01", "", " \"P < 0 . 01\". \"P < 0 . 01\". \"P < 0 . 01\"." +112, ConclusionComment, 2704, 2861, "The mean 24 - h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy .", "", " \"The mean 24 - h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy .\"." +106, Mean, 2708, 2712, "mean", "", +107, IOP, 2713, 2723, "24 - h IOP", "", +104350, FixedCombDrug, 2736, 2740, "TTFC", "", +109, Lat/TimFC, 2788, 2792, "LTFC", "", +110, Latanoprost, 2836, 2847, "latanoprost", "", +113, ConclusionComment, 2862, 2966, "Measurement of ocular surface health and tear film status favored the BAK - free TTFC compared to LTFC .", "", " \"Measurement of ocular surface health and tear film status favored the BAK - free TTFC compared to LTFC .\"." +114, EndPointDescription, 2877, 2898, "ocular surface health", "", +115, EndPointDescription, 2903, 2919, "tear film status", "", +104351, FixedCombDrug, 2932, 2947, "BAK - free TTFC", "", +117, Lat/TimFC, 2960, 2964, "LTFC", "", +118, PMID, 3016, 3024, "24919410", "", " \"24919410\"." diff --git a/data/gl 24919410_admin.n-triples b/data/gl 24919410_admin.n-triples new file mode 100644 index 0000000..d671a8e --- /dev/null +++ b/data/gl 24919410_admin.n-triples @@ -0,0 +1,215 @@ +# RDF export of group: Publication + . + "Publication " . + "24 - hour efficacy of travoprost / timolol BAK - free versus latanoprost / timolol fixed combinations in patients insufficiently controlled with latanoprost ." . + "Konstas AG" . + "2014" . + "Adv Ther ." . + "24919410" . + . + "Voudouragkaki IC" . + "Boboridis KG" . + "Haidich AB" . + "Paschalinou E" . + "Giannopoulos T" . + "Dragoumis ND" . + "Makridis AK" . + "Kahook MY" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the 24 - h intraocular pressure ( IOP ) control and tolerability of travoprost / timolol benzalkonium chloride ( BAK ) - free ( TTFC ) vs . latanoprost / timolol fixed combination preserved with BAK ( LTFC ) in open - angle glaucoma patients" . + . + . + . + "The mean 24 - h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy ." . + . + . + . + . + . + "Forty - two" . + "insufficiently controlled with latanoprost 0 . 005 % monotherapy given once in the evening ." . + . + . + . + . + . + "Measurement of ocular surface health and tear film status favored the BAK - free TTFC compared to LTFC ." . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients insufficiently controlled with latanoprost 0 . 005 % monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + . + . + . + "Endpoint tfbt" . + . + . + . + . + . + . + "Endpoint cs" . + . + . + . + . + . + . + "Endpoint s1t" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm trav/tim" . + . + . + . + . + . + . + . + . + "Arm lat/tim" . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention trav/tim" . + . + . + . + . + "Intervention lat/tim" . + . + . + . +# RDF export of group: Medication + . + "Medication trav" . + . + . + . + . + "Medication tim" . + . + . + . + . + "Medication lat" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP tt" . + . + "21 . 5" . + "1 . 6" . + "18 . 9" . + "2 . 2" . + . + "Outcome IOP lt" . + . + "21 . 5" . + "1 . 6" . + "19 . 3" . + "2 . 3" . + . + "Outcome IOP timepoint tt " . + . + "18 . 6" . + "2 . 5" . + "18 : 00" . + . + "Outcome IOP timepoint lt" . + . + "19 . 5" . + "2 . 7" . + "18 : 00" . + . + "Outcome tfbt tt" . + . + "5 . 15" . + "after 3 months" . + . + "Outcome tfbt lt" . + . + "4 . 65" . + "after 3 months" . + . + "Outcome cs tt " . + . + "1 . 5" . + "after 3 months" . + . + "Outcome cs lt" . + . + "1 . 8" . + "after 3 months" . + . + "Outcome s1t tt" . + . + "9 . 9" . + "after 3 months" . + . + "Outcome s1t lt" . + . + "9 . 2" . + "after 3 months" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP" . + "P = 0 . 004" . + . + . + . + "DiffBetweenGroups IOP timepoint" . + "P < 0 . 001" . + . + . + . + "DiffBetweenGroups tfbt" . + "P < 0 . 01" . + . + . + . + "DiffBetweenGroups cs" . + "P < 0 . 01" . + . + . + . + "DiffBetweenGroups s1t" . + "P < 0 . 01" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24919410_export.csv b/data/gl 24919410_export.csv new file mode 100644 index 0000000..4fc6ccc --- /dev/null +++ b/data/gl 24919410_export.csv @@ -0,0 +1,645 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +536, 1, 1, 1, 0, 3, 0, 3, "Adv" +536, 1, 2, 2, 4, 8, 4, 8, "Ther" +536, 1, 3, 3, 9, 10, 9, 10, "." +536, 2, 1, 4, 0, 4, 11, 15, "2014" +536, 2, 2, 5, 5, 8, 16, 19, "Jun" +536, 2, 3, 6, 9, 10, 20, 21, ";" +536, 2, 4, 7, 11, 13, 22, 24, "31" +536, 2, 5, 8, 14, 15, 25, 26, "(" +536, 2, 6, 9, 16, 17, 27, 28, "6" +536, 2, 7, 10, 18, 19, 29, 30, ")" +536, 2, 8, 11, 20, 21, 31, 32, ":" +536, 2, 9, 12, 22, 25, 33, 36, "592" +536, 2, 10, 13, 26, 27, 37, 38, "-" +536, 2, 11, 14, 28, 31, 39, 42, "603" +536, 2, 12, 15, 32, 33, 43, 44, "." +536, 2, 13, 16, 34, 37, 45, 48, "doi" +536, 2, 14, 17, 38, 39, 49, 50, ":" +536, 2, 15, 18, 40, 42, 51, 53, "10" +536, 2, 16, 19, 43, 44, 54, 55, "." +536, 2, 17, 20, 45, 49, 56, 60, "1007" +536, 2, 18, 21, 50, 51, 61, 62, "/" +536, 2, 19, 22, 52, 58, 63, 69, "s12325" +536, 2, 20, 23, 59, 60, 70, 71, "-" +536, 2, 21, 24, 61, 64, 72, 75, "014" +536, 2, 22, 25, 65, 66, 76, 77, "-" +536, 2, 23, 26, 67, 71, 78, 82, "0125" +536, 2, 24, 27, 72, 73, 83, 84, "-" +536, 2, 25, 28, 74, 75, 85, 86, "9" +536, 2, 26, 29, 76, 77, 87, 88, "." +536, 3, 1, 30, 0, 4, 89, 93, "Epub" +536, 3, 2, 31, 5, 9, 94, 98, "2014" +536, 3, 3, 32, 10, 13, 99, 102, "Jun" +536, 3, 4, 33, 14, 16, 103, 105, "12" +536, 3, 5, 34, 17, 18, 106, 107, "." +536, 4, 1, 35, 0, 2, 108, 110, "24" +536, 4, 2, 36, 3, 4, 111, 112, "-" +536, 4, 3, 37, 5, 9, 113, 117, "hour" +536, 4, 4, 38, 10, 18, 118, 126, "efficacy" +536, 4, 5, 39, 19, 21, 127, 129, "of" +536, 4, 6, 40, 22, 32, 130, 140, "travoprost" +536, 4, 7, 41, 33, 34, 141, 142, "/" +536, 4, 8, 42, 35, 42, 143, 150, "timolol" +536, 4, 9, 43, 43, 46, 151, 154, "BAK" +536, 4, 10, 44, 47, 48, 155, 156, "-" +536, 4, 11, 45, 49, 53, 157, 161, "free" +536, 4, 12, 46, 54, 60, 162, 168, "versus" +536, 4, 13, 47, 61, 72, 169, 180, "latanoprost" +536, 4, 14, 48, 73, 74, 181, 182, "/" +536, 4, 15, 49, 75, 82, 183, 190, "timolol" +536, 4, 16, 50, 83, 88, 191, 196, "fixed" +536, 4, 17, 51, 89, 101, 197, 209, "combinations" +536, 4, 18, 52, 102, 104, 210, 212, "in" +536, 4, 19, 53, 105, 113, 213, 221, "patients" +536, 4, 20, 54, 114, 128, 222, 236, "insufficiently" +536, 4, 21, 55, 129, 139, 237, 247, "controlled" +536, 4, 22, 56, 140, 144, 248, 252, "with" +536, 4, 23, 57, 145, 156, 253, 264, "latanoprost" +536, 4, 24, 58, 157, 158, 265, 266, "." +536, 5, 1, 59, 0, 7, 267, 274, "Konstas" +536, 5, 2, 60, 8, 10, 275, 277, "AG" +536, 5, 3, 61, 11, 12, 278, 279, "(" +536, 5, 4, 62, 13, 14, 280, 281, "1" +536, 5, 5, 63, 15, 16, 282, 283, ")" +536, 5, 6, 64, 17, 18, 284, 285, "," +536, 5, 7, 65, 19, 32, 286, 299, "Voudouragkaki" +536, 5, 8, 66, 33, 35, 300, 302, "IC" +536, 5, 9, 67, 36, 37, 303, 304, "," +536, 5, 10, 68, 38, 47, 305, 314, "Boboridis" +536, 5, 11, 69, 48, 50, 315, 317, "KG" +536, 5, 12, 70, 51, 52, 318, 319, "," +536, 5, 13, 71, 53, 60, 320, 327, "Haidich" +536, 5, 14, 72, 61, 63, 328, 330, "AB" +536, 5, 15, 73, 64, 65, 331, 332, "," +536, 5, 16, 74, 66, 77, 333, 344, "Paschalinou" +536, 5, 17, 75, 78, 79, 345, 346, "E" +536, 5, 18, 76, 80, 81, 347, 348, "," +536, 5, 19, 77, 82, 94, 349, 361, "Giannopoulos" +536, 5, 20, 78, 95, 96, 362, 363, "T" +536, 5, 21, 79, 97, 98, 364, 365, "," +536, 5, 22, 80, 99, 108, 366, 375, "Dragoumis" +536, 5, 23, 81, 109, 111, 376, 378, "ND" +536, 5, 24, 82, 112, 113, 379, 380, "," +536, 5, 25, 83, 114, 122, 381, 389, "Makridis" +536, 5, 26, 84, 123, 125, 390, 392, "AK" +536, 5, 27, 85, 126, 127, 393, 394, "," +536, 5, 28, 86, 128, 134, 395, 401, "Kahook" +536, 5, 29, 87, 135, 137, 402, 404, "MY" +536, 5, 30, 88, 138, 139, 405, 406, "." +536, 6, 1, 89, 0, 6, 407, 413, "Author" +536, 6, 2, 90, 7, 18, 414, 425, "information" +536, 6, 3, 91, 19, 20, 426, 427, ":" +536, 6, 4, 92, 21, 22, 428, 429, "(" +536, 6, 5, 93, 23, 24, 430, 431, "1" +536, 6, 6, 94, 25, 26, 432, 433, ")" +536, 6, 7, 95, 27, 30, 434, 437, "1st" +536, 6, 8, 96, 31, 41, 438, 448, "University" +536, 6, 9, 97, 42, 52, 449, 459, "Department" +536, 6, 10, 98, 53, 55, 460, 462, "of" +536, 6, 11, 99, 56, 69, 463, 476, "Ophthalmology" +536, 6, 12, 100, 70, 71, 477, 478, "," +536, 6, 13, 101, 72, 81, 479, 488, "Aristotle" +536, 6, 14, 102, 82, 92, 489, 499, "University" +536, 6, 15, 103, 93, 95, 500, 502, "of" +536, 6, 16, 104, 96, 108, 503, 515, "Thessaloniki" +536, 6, 17, 105, 109, 110, 516, 517, "," +536, 6, 18, 106, 111, 112, 518, 519, "1" +536, 6, 19, 107, 113, 122, 520, 529, "Kyriakidi" +536, 6, 20, 108, 123, 129, 530, 536, "Street" +536, 6, 21, 109, 130, 131, 537, 538, "," +536, 6, 22, 110, 132, 135, 539, 542, "546" +536, 6, 23, 111, 136, 138, 543, 545, "36" +536, 6, 24, 112, 139, 140, 546, 547, "," +536, 6, 25, 113, 141, 153, 548, 560, "Thessaloniki" +536, 6, 26, 114, 154, 155, 561, 562, "," +536, 6, 27, 115, 156, 162, 563, 569, "Greece" +536, 6, 28, 116, 163, 164, 570, 571, "," +536, 6, 29, 117, 165, 172, 572, 579, "konstas" +536, 6, 30, 118, 173, 174, 580, 581, "@" +536, 6, 31, 119, 175, 178, 582, 585, "med" +536, 6, 32, 120, 179, 180, 586, 587, "." +536, 6, 33, 121, 181, 185, 588, 592, "auth" +536, 6, 34, 122, 186, 187, 593, 594, "." +536, 6, 35, 123, 188, 190, 595, 597, "gr" +536, 6, 36, 124, 191, 192, 598, 599, "." +536, 7, 1, 125, 0, 12, 600, 612, "INTRODUCTION" +536, 7, 2, 126, 13, 14, 613, 614, ":" +536, 7, 3, 127, 15, 17, 615, 617, "To" +536, 7, 4, 128, 18, 25, 618, 625, "compare" +536, 7, 5, 129, 26, 29, 626, 629, "the" +536, 7, 6, 130, 30, 32, 630, 632, "24" +536, 7, 7, 131, 33, 34, 633, 634, "-" +536, 7, 8, 132, 35, 36, 635, 636, "h" +536, 7, 9, 133, 37, 48, 637, 648, "intraocular" +536, 7, 10, 134, 49, 57, 649, 657, "pressure" +536, 7, 11, 135, 58, 59, 658, 659, "(" +536, 7, 12, 136, 60, 63, 660, 663, "IOP" +536, 7, 13, 137, 64, 65, 664, 665, ")" +536, 7, 14, 138, 66, 73, 666, 673, "control" +536, 7, 15, 139, 74, 77, 674, 677, "and" +536, 7, 16, 140, 78, 90, 678, 690, "tolerability" +536, 7, 17, 141, 91, 93, 691, 693, "of" +536, 7, 18, 142, 94, 104, 694, 704, "travoprost" +536, 7, 19, 143, 105, 106, 705, 706, "/" +536, 7, 20, 144, 107, 114, 707, 714, "timolol" +536, 7, 21, 145, 115, 127, 715, 727, "benzalkonium" +536, 7, 22, 146, 128, 136, 728, 736, "chloride" +536, 7, 23, 147, 137, 138, 737, 738, "(" +536, 7, 24, 148, 139, 142, 739, 742, "BAK" +536, 7, 25, 149, 143, 144, 743, 744, ")" +536, 7, 26, 150, 145, 146, 745, 746, "-" +536, 7, 27, 151, 147, 151, 747, 751, "free" +536, 7, 28, 152, 152, 153, 752, 753, "(" +536, 7, 29, 153, 154, 158, 754, 758, "TTFC" +536, 7, 30, 154, 159, 160, 759, 760, ")" +536, 7, 31, 155, 161, 163, 761, 763, "vs" +536, 7, 32, 156, 164, 165, 764, 765, "." +536, 7, 33, 157, 166, 177, 766, 777, "latanoprost" +536, 7, 34, 158, 178, 179, 778, 779, "/" +536, 7, 35, 159, 180, 187, 780, 787, "timolol" +536, 7, 36, 160, 188, 193, 788, 793, "fixed" +536, 7, 37, 161, 194, 205, 794, 805, "combination" +536, 7, 38, 162, 206, 215, 806, 815, "preserved" +536, 7, 39, 163, 216, 220, 816, 820, "with" +536, 7, 40, 164, 221, 224, 821, 824, "BAK" +536, 7, 41, 165, 225, 226, 825, 826, "(" +536, 7, 42, 166, 227, 231, 827, 831, "LTFC" +536, 7, 43, 167, 232, 233, 832, 833, ")" +536, 7, 44, 168, 234, 236, 834, 836, "in" +536, 7, 45, 169, 237, 241, 837, 841, "open" +536, 7, 46, 170, 242, 243, 842, 843, "-" +536, 7, 47, 171, 244, 249, 844, 849, "angle" +536, 7, 48, 172, 250, 258, 850, 858, "glaucoma" +536, 7, 49, 173, 259, 267, 859, 867, "patients" +536, 7, 50, 174, 268, 282, 868, 882, "insufficiently" +536, 7, 51, 175, 283, 293, 883, 893, "controlled" +536, 7, 52, 176, 294, 298, 894, 898, "with" +536, 7, 53, 177, 299, 310, 899, 910, "latanoprost" +536, 7, 54, 178, 311, 312, 911, 912, "0" +536, 7, 55, 179, 313, 314, 913, 914, "." +536, 7, 56, 180, 315, 318, 915, 918, "005" +536, 7, 57, 181, 319, 320, 919, 920, "%" +536, 7, 58, 182, 321, 332, 921, 932, "monotherapy" +536, 7, 59, 183, 333, 338, 933, 938, "given" +536, 7, 60, 184, 339, 343, 939, 943, "once" +536, 7, 61, 185, 344, 346, 944, 946, "in" +536, 7, 62, 186, 347, 350, 947, 950, "the" +536, 7, 63, 187, 351, 358, 951, 958, "evening" +536, 7, 64, 188, 359, 360, 959, 960, "." +536, 8, 1, 189, 0, 7, 961, 968, "METHODS" +536, 8, 2, 190, 8, 9, 969, 970, ":" +536, 8, 3, 191, 10, 13, 971, 974, "The" +536, 8, 4, 192, 14, 21, 975, 982, "authors" +536, 8, 5, 193, 22, 26, 983, 987, "have" +536, 8, 6, 194, 27, 36, 988, 997, "conducted" +536, 8, 7, 195, 37, 38, 998, 999, "a" +536, 8, 8, 196, 39, 50, 1000, 1011, "prospective" +536, 8, 9, 197, 51, 52, 1012, 1013, "," +536, 8, 10, 198, 53, 61, 1014, 1022, "observer" +536, 8, 11, 199, 62, 63, 1023, 1024, "-" +536, 8, 12, 200, 64, 70, 1025, 1031, "masked" +536, 8, 13, 201, 71, 72, 1032, 1033, "," +536, 8, 14, 202, 73, 79, 1034, 1040, "active" +536, 8, 15, 203, 80, 81, 1041, 1042, "-" +536, 8, 16, 204, 82, 92, 1043, 1053, "controlled" +536, 8, 17, 205, 93, 94, 1054, 1055, "," +536, 8, 18, 206, 95, 100, 1056, 1061, "cross" +536, 8, 19, 207, 101, 102, 1062, 1063, "-" +536, 8, 20, 208, 103, 107, 1064, 1068, "over" +536, 8, 21, 209, 108, 109, 1069, 1070, "," +536, 8, 22, 210, 110, 120, 1071, 1081, "comparison" +536, 8, 23, 211, 121, 126, 1082, 1087, "study" +536, 8, 24, 212, 127, 128, 1088, 1089, "." +536, 9, 1, 213, 0, 9, 1090, 1099, "Qualified" +536, 9, 2, 214, 10, 14, 1100, 1104, "open" +536, 9, 3, 215, 15, 16, 1105, 1106, "-" +536, 9, 4, 216, 17, 22, 1107, 1112, "angle" +536, 9, 5, 217, 23, 31, 1113, 1121, "glaucoma" +536, 9, 6, 218, 32, 40, 1122, 1130, "patients" +536, 9, 7, 219, 41, 44, 1131, 1134, "who" +536, 9, 8, 220, 45, 57, 1135, 1147, "demonstrated" +536, 9, 9, 221, 58, 59, 1148, 1149, "a" +536, 9, 10, 222, 60, 71, 1150, 1161, "latanoprost" +536, 9, 11, 223, 72, 73, 1162, 1163, "-" +536, 9, 12, 224, 74, 81, 1164, 1171, "treated" +536, 9, 13, 225, 82, 89, 1172, 1179, "morning" +536, 9, 14, 226, 90, 93, 1180, 1183, "IOP" +536, 9, 15, 227, 94, 95, 1184, 1185, "(" +536, 9, 16, 228, 96, 98, 1186, 1188, "10" +536, 9, 17, 229, 99, 100, 1189, 1190, ":" +536, 9, 18, 230, 101, 103, 1191, 1193, "00" +536, 9, 19, 231, 104, 105, 1194, 1195, "±" +536, 9, 20, 232, 106, 107, 1196, 1197, "1" +536, 9, 21, 233, 108, 109, 1198, 1199, "h" +536, 9, 22, 234, 110, 111, 1200, 1201, ")" +536, 9, 23, 235, 112, 119, 1202, 1209, "greater" +536, 9, 24, 236, 120, 124, 1210, 1214, "than" +536, 9, 25, 237, 125, 127, 1215, 1217, "20" +536, 9, 26, 238, 128, 132, 1218, 1222, "mmHg" +536, 9, 27, 239, 133, 135, 1223, 1225, "on" +536, 9, 28, 240, 136, 139, 1226, 1229, "two" +536, 9, 29, 241, 140, 148, 1230, 1238, "separate" +536, 9, 30, 242, 149, 155, 1239, 1245, "visits" +536, 9, 31, 243, 156, 160, 1246, 1250, "were" +536, 9, 32, 244, 161, 171, 1251, 1261, "randomized" +536, 9, 33, 245, 172, 175, 1262, 1265, "for" +536, 9, 34, 246, 176, 177, 1266, 1267, "3" +536, 9, 35, 247, 178, 184, 1268, 1274, "months" +536, 9, 36, 248, 185, 187, 1275, 1277, "to" +536, 9, 37, 249, 188, 195, 1278, 1285, "receive" +536, 9, 38, 250, 196, 202, 1286, 1292, "either" +536, 9, 39, 251, 203, 207, 1293, 1297, "TTFC" +536, 9, 40, 252, 208, 210, 1298, 1300, "or" +536, 9, 41, 253, 211, 215, 1301, 1305, "LTFC" +536, 9, 42, 254, 216, 217, 1306, 1307, "." +536, 10, 1, 255, 0, 8, 1308, 1316, "Patients" +536, 10, 2, 256, 9, 13, 1317, 1321, "were" +536, 10, 3, 257, 14, 18, 1322, 1326, "then" +536, 10, 4, 258, 19, 26, 1327, 1334, "crossed" +536, 10, 5, 259, 27, 31, 1335, 1339, "over" +536, 10, 6, 260, 32, 34, 1340, 1342, "to" +536, 10, 7, 261, 35, 38, 1343, 1346, "the" +536, 10, 8, 262, 39, 47, 1347, 1355, "opposite" +536, 10, 9, 263, 48, 57, 1356, 1365, "treatment" +536, 10, 10, 264, 58, 61, 1366, 1369, "for" +536, 10, 11, 265, 62, 69, 1370, 1377, "another" +536, 10, 12, 266, 70, 71, 1378, 1379, "3" +536, 10, 13, 267, 72, 78, 1380, 1386, "months" +536, 10, 14, 268, 79, 80, 1387, 1388, "." +536, 11, 1, 269, 0, 2, 1389, 1391, "At" +536, 11, 2, 270, 3, 6, 1392, 1395, "the" +536, 11, 3, 271, 7, 10, 1396, 1399, "end" +536, 11, 4, 272, 11, 13, 1400, 1402, "of" +536, 11, 5, 273, 14, 17, 1403, 1406, "the" +536, 11, 6, 274, 18, 29, 1407, 1418, "latanoprost" +536, 11, 7, 275, 30, 33, 1419, 1422, "run" +536, 11, 8, 276, 34, 35, 1423, 1424, "-" +536, 11, 9, 277, 36, 38, 1425, 1427, "in" +536, 11, 10, 278, 39, 42, 1428, 1431, "and" +536, 11, 11, 279, 43, 48, 1432, 1437, "after" +536, 11, 12, 280, 49, 53, 1438, 1442, "each" +536, 11, 13, 281, 54, 55, 1443, 1444, "3" +536, 11, 14, 282, 56, 57, 1445, 1446, "-" +536, 11, 15, 283, 58, 63, 1447, 1452, "month" +536, 11, 16, 284, 64, 71, 1453, 1460, "therapy" +536, 11, 17, 285, 72, 78, 1461, 1467, "period" +536, 11, 18, 286, 79, 87, 1468, 1476, "patients" +536, 11, 19, 287, 88, 97, 1477, 1486, "underwent" +536, 11, 20, 288, 98, 100, 1487, 1489, "24" +536, 11, 21, 289, 101, 102, 1490, 1491, "-" +536, 11, 22, 290, 103, 104, 1492, 1493, "h" +536, 11, 23, 291, 105, 108, 1494, 1497, "IOP" +536, 11, 24, 292, 109, 119, 1498, 1508, "monitoring" +536, 11, 25, 293, 120, 122, 1509, 1511, "in" +536, 11, 26, 294, 123, 126, 1512, 1515, "the" +536, 11, 27, 295, 127, 135, 1516, 1524, "habitual" +536, 11, 28, 296, 136, 144, 1525, 1533, "position" +536, 11, 29, 297, 145, 150, 1534, 1539, "using" +536, 11, 30, 298, 151, 159, 1540, 1548, "Goldmann" +536, 11, 31, 299, 160, 171, 1549, 1560, "applanation" +536, 11, 32, 300, 172, 181, 1561, 1570, "tonometry" +536, 11, 33, 301, 182, 184, 1571, 1573, "in" +536, 11, 34, 302, 185, 188, 1574, 1577, "the" +536, 11, 35, 303, 189, 196, 1578, 1585, "sitting" +536, 11, 36, 304, 197, 205, 1586, 1594, "position" +536, 11, 37, 305, 206, 212, 1595, 1601, "during" +536, 11, 38, 306, 213, 216, 1602, 1605, "the" +536, 11, 39, 307, 217, 220, 1606, 1609, "day" +536, 11, 40, 308, 221, 222, 1610, 1611, "(" +536, 11, 41, 309, 223, 225, 1612, 1614, "10" +536, 11, 42, 310, 226, 227, 1615, 1616, ":" +536, 11, 43, 311, 228, 230, 1617, 1619, "00" +536, 11, 44, 312, 231, 232, 1620, 1621, "," +536, 11, 45, 313, 233, 235, 1622, 1624, "14" +536, 11, 46, 314, 236, 237, 1625, 1626, ":" +536, 11, 47, 315, 238, 240, 1627, 1629, "00" +536, 11, 48, 316, 241, 242, 1630, 1631, "," +536, 11, 49, 317, 243, 245, 1632, 1634, "18" +536, 11, 50, 318, 246, 247, 1635, 1636, ":" +536, 11, 51, 319, 248, 250, 1637, 1639, "00" +536, 11, 52, 320, 251, 254, 1640, 1643, "and" +536, 11, 53, 321, 255, 257, 1644, 1646, "22" +536, 11, 54, 322, 258, 259, 1647, 1648, ":" +536, 11, 55, 323, 260, 262, 1649, 1651, "00" +536, 11, 56, 324, 263, 264, 1652, 1653, ")" +536, 11, 57, 325, 265, 268, 1654, 1657, "and" +536, 11, 58, 326, 269, 276, 1658, 1665, "Perkins" +536, 11, 59, 327, 277, 286, 1666, 1675, "tonometry" +536, 11, 60, 328, 287, 289, 1676, 1678, "in" +536, 11, 61, 329, 290, 293, 1679, 1682, "the" +536, 11, 62, 330, 294, 300, 1683, 1689, "supine" +536, 11, 63, 331, 301, 309, 1690, 1698, "position" +536, 11, 64, 332, 310, 312, 1699, 1701, "at" +536, 11, 65, 333, 313, 318, 1702, 1707, "night" +536, 11, 66, 334, 319, 320, 1708, 1709, "(" +536, 11, 67, 335, 321, 323, 1710, 1712, "02" +536, 11, 68, 336, 324, 325, 1713, 1714, ":" +536, 11, 69, 337, 326, 328, 1715, 1717, "00" +536, 11, 70, 338, 329, 332, 1718, 1721, "and" +536, 11, 71, 339, 333, 335, 1722, 1724, "06" +536, 11, 72, 340, 336, 337, 1725, 1726, ":" +536, 11, 73, 341, 338, 340, 1727, 1729, "00" +536, 11, 74, 342, 341, 342, 1730, 1731, ")" +536, 11, 75, 343, 343, 344, 1732, 1733, "." +536, 12, 1, 344, 0, 8, 1734, 1742, "Selected" +536, 12, 2, 345, 9, 15, 1743, 1749, "ocular" +536, 12, 3, 346, 16, 23, 1750, 1757, "surface" +536, 12, 4, 347, 24, 34, 1758, 1768, "parameters" +536, 12, 5, 348, 35, 39, 1769, 1773, "were" +536, 12, 6, 349, 40, 49, 1774, 1783, "evaluated" +536, 12, 7, 350, 50, 55, 1784, 1789, "after" +536, 12, 8, 351, 56, 60, 1790, 1794, "each" +536, 12, 9, 352, 61, 68, 1795, 1802, "therapy" +536, 12, 10, 353, 69, 75, 1803, 1809, "period" +536, 12, 11, 354, 76, 77, 1810, 1811, "." +536, 13, 1, 355, 0, 7, 1812, 1819, "RESULTS" +536, 13, 2, 356, 8, 9, 1820, 1821, ":" +536, 13, 3, 357, 10, 15, 1822, 1827, "Forty" +536, 13, 4, 358, 16, 17, 1828, 1829, "-" +536, 13, 5, 359, 18, 21, 1830, 1833, "two" +536, 13, 6, 360, 22, 26, 1834, 1838, "open" +536, 13, 7, 361, 27, 28, 1839, 1840, "-" +536, 13, 8, 362, 29, 34, 1841, 1846, "angle" +536, 13, 9, 363, 35, 43, 1847, 1855, "glaucoma" +536, 13, 10, 364, 44, 52, 1856, 1864, "patients" +536, 13, 11, 365, 53, 62, 1865, 1874, "completed" +536, 13, 12, 366, 63, 66, 1875, 1878, "the" +536, 13, 13, 367, 67, 72, 1879, 1884, "study" +536, 13, 14, 368, 73, 74, 1885, 1886, "." +536, 14, 1, 369, 0, 3, 1887, 1890, "The" +536, 14, 2, 370, 4, 8, 1891, 1895, "mean" +536, 14, 3, 371, 9, 11, 1896, 1898, "24" +536, 14, 4, 372, 12, 13, 1899, 1900, "-" +536, 14, 5, 373, 14, 15, 1901, 1902, "h" +536, 14, 6, 374, 16, 24, 1903, 1911, "baseline" +536, 14, 7, 375, 25, 28, 1912, 1915, "IOP" +536, 14, 8, 376, 29, 31, 1916, 1918, "on" +536, 14, 9, 377, 32, 43, 1919, 1930, "latanoprost" +536, 14, 10, 378, 44, 47, 1931, 1934, "was" +536, 14, 11, 379, 48, 50, 1935, 1937, "21" +536, 14, 12, 380, 51, 52, 1938, 1939, "." +536, 14, 13, 381, 53, 54, 1940, 1941, "5" +536, 14, 14, 382, 55, 56, 1942, 1943, "±" +536, 14, 15, 383, 57, 58, 1944, 1945, "1" +536, 14, 16, 384, 59, 60, 1946, 1947, "." +536, 14, 17, 385, 61, 62, 1948, 1949, "6" +536, 14, 18, 386, 63, 67, 1950, 1954, "mmHg" +536, 14, 19, 387, 68, 69, 1955, 1956, "." +536, 15, 1, 388, 0, 4, 1957, 1961, "Both" +536, 15, 2, 389, 5, 10, 1962, 1967, "fixed" +536, 15, 3, 390, 11, 23, 1968, 1980, "combinations" +536, 15, 4, 391, 24, 37, 1981, 1994, "significantly" +536, 15, 5, 392, 38, 45, 1995, 2002, "reduced" +536, 15, 6, 393, 46, 49, 2003, 2006, "the" +536, 15, 7, 394, 50, 53, 2007, 2010, "IOP" +536, 15, 8, 395, 54, 56, 2011, 2013, "at" +536, 15, 9, 396, 57, 61, 2014, 2018, "each" +536, 15, 10, 397, 62, 66, 2019, 2023, "time" +536, 15, 11, 398, 67, 72, 2024, 2029, "point" +536, 15, 12, 399, 73, 74, 2030, 2031, "," +536, 15, 13, 400, 75, 78, 2032, 2035, "for" +536, 15, 14, 401, 79, 82, 2036, 2039, "the" +536, 15, 15, 402, 83, 87, 2040, 2044, "mean" +536, 15, 16, 403, 88, 89, 2045, 2046, "," +536, 15, 17, 404, 90, 94, 2047, 2051, "peak" +536, 15, 18, 405, 95, 98, 2052, 2055, "and" +536, 15, 19, 406, 99, 110, 2056, 2067, "fluctuation" +536, 15, 20, 407, 111, 113, 2068, 2070, "of" +536, 15, 21, 408, 114, 116, 2071, 2073, "24" +536, 15, 22, 409, 117, 118, 2074, 2075, "-" +536, 15, 23, 410, 119, 120, 2076, 2077, "h" +536, 15, 24, 411, 121, 124, 2078, 2081, "IOP" +536, 15, 25, 412, 125, 133, 2082, 2090, "compared" +536, 15, 26, 413, 134, 138, 2091, 2095, "with" +536, 15, 27, 414, 139, 150, 2096, 2107, "latanoprost" +536, 15, 28, 415, 151, 162, 2108, 2119, "monotherapy" +536, 15, 29, 416, 163, 164, 2120, 2121, "(" +536, 15, 30, 417, 165, 166, 2122, 2123, "P" +536, 15, 31, 418, 167, 168, 2124, 2125, "<" +536, 15, 32, 419, 169, 170, 2126, 2127, "0" +536, 15, 33, 420, 171, 172, 2128, 2129, "." +536, 15, 34, 421, 173, 175, 2130, 2132, "01" +536, 15, 35, 422, 176, 177, 2133, 2134, ")" +536, 15, 36, 423, 178, 179, 2135, 2136, "." +536, 16, 1, 424, 0, 4, 2137, 2141, "When" +536, 16, 2, 425, 5, 8, 2142, 2145, "the" +536, 16, 3, 426, 9, 12, 2146, 2149, "two" +536, 16, 4, 427, 13, 18, 2150, 2155, "fixed" +536, 16, 5, 428, 19, 31, 2156, 2168, "combinations" +536, 16, 6, 429, 32, 36, 2169, 2173, "were" +536, 16, 7, 430, 37, 45, 2174, 2182, "compared" +536, 16, 8, 431, 46, 54, 2183, 2191, "directly" +536, 16, 9, 432, 55, 56, 2192, 2193, "," +536, 16, 10, 433, 57, 61, 2194, 2198, "TTFC" +536, 16, 11, 434, 62, 70, 2199, 2207, "provided" +536, 16, 12, 435, 71, 84, 2208, 2221, "significantly" +536, 16, 13, 436, 85, 90, 2222, 2227, "lower" +536, 16, 14, 437, 91, 95, 2228, 2232, "mean" +536, 16, 15, 438, 96, 98, 2233, 2235, "24" +536, 16, 16, 439, 99, 100, 2236, 2237, "-" +536, 16, 17, 440, 101, 102, 2238, 2239, "h" +536, 16, 18, 441, 103, 106, 2240, 2243, "IOP" +536, 16, 19, 442, 107, 108, 2244, 2245, "(" +536, 16, 20, 443, 109, 111, 2246, 2248, "18" +536, 16, 21, 444, 112, 113, 2249, 2250, "." +536, 16, 22, 445, 114, 115, 2251, 2252, "9" +536, 16, 23, 446, 116, 117, 2253, 2254, "±" +536, 16, 24, 447, 118, 119, 2255, 2256, "2" +536, 16, 25, 448, 120, 121, 2257, 2258, "." +536, 16, 26, 449, 122, 123, 2259, 2260, "2" +536, 16, 27, 450, 124, 128, 2261, 2265, "mmHg" +536, 16, 28, 451, 129, 130, 2266, 2267, ")" +536, 16, 29, 452, 131, 133, 2268, 2270, "vs" +536, 16, 30, 453, 134, 135, 2271, 2272, "." +536, 16, 31, 454, 136, 140, 2273, 2277, "LTFC" +536, 16, 32, 455, 141, 142, 2278, 2279, "(" +536, 16, 33, 456, 143, 145, 2280, 2282, "19" +536, 16, 34, 457, 146, 147, 2283, 2284, "." +536, 16, 35, 458, 148, 149, 2285, 2286, "3" +536, 16, 36, 459, 150, 151, 2287, 2288, "±" +536, 16, 37, 460, 152, 153, 2289, 2290, "2" +536, 16, 38, 461, 154, 155, 2291, 2292, "." +536, 16, 39, 462, 156, 157, 2293, 2294, "3" +536, 16, 40, 463, 158, 162, 2295, 2299, "mmHg" +536, 16, 41, 464, 163, 164, 2300, 2301, ")" +536, 16, 42, 465, 165, 166, 2302, 2303, "(" +536, 16, 43, 466, 167, 168, 2304, 2305, "P" +536, 16, 44, 467, 169, 170, 2306, 2307, "=" +536, 16, 45, 468, 171, 172, 2308, 2309, "0" +536, 16, 46, 469, 173, 174, 2310, 2311, "." +536, 16, 47, 470, 175, 178, 2312, 2315, "004" +536, 16, 48, 471, 179, 180, 2316, 2317, ")" +536, 16, 49, 472, 181, 184, 2318, 2321, "and" +536, 16, 50, 473, 185, 198, 2322, 2335, "significantly" +536, 16, 51, 474, 199, 204, 2336, 2341, "lower" +536, 16, 52, 475, 205, 208, 2342, 2345, "IOP" +536, 16, 53, 476, 209, 211, 2346, 2348, "at" +536, 16, 54, 477, 212, 214, 2349, 2351, "18" +536, 16, 55, 478, 215, 216, 2352, 2353, ":" +536, 16, 56, 479, 217, 219, 2354, 2356, "00" +536, 16, 57, 480, 220, 221, 2357, 2358, "(" +536, 16, 58, 481, 222, 224, 2359, 2361, "18" +536, 16, 59, 482, 225, 226, 2362, 2363, "." +536, 16, 60, 483, 227, 228, 2364, 2365, "6" +536, 16, 61, 484, 229, 230, 2366, 2367, "±" +536, 16, 62, 485, 231, 232, 2368, 2369, "2" +536, 16, 63, 486, 233, 234, 2370, 2371, "." +536, 16, 64, 487, 235, 236, 2372, 2373, "5" +536, 16, 65, 488, 237, 239, 2374, 2376, "vs" +536, 16, 66, 489, 240, 241, 2377, 2378, "." +536, 16, 67, 490, 242, 244, 2379, 2381, "19" +536, 16, 68, 491, 245, 246, 2382, 2383, "." +536, 16, 69, 492, 247, 248, 2384, 2385, "5" +536, 16, 70, 493, 249, 250, 2386, 2387, "±" +536, 16, 71, 494, 251, 252, 2388, 2389, "2" +536, 16, 72, 495, 253, 254, 2390, 2391, "." +536, 16, 73, 496, 255, 256, 2392, 2393, "7" +536, 16, 74, 497, 257, 261, 2394, 2398, "mmHg" +536, 16, 75, 498, 262, 265, 2399, 2402, "for" +536, 16, 76, 499, 266, 270, 2403, 2407, "LTFC" +536, 16, 77, 500, 271, 272, 2408, 2409, ")" +536, 16, 78, 501, 273, 274, 2410, 2411, "(" +536, 16, 79, 502, 275, 276, 2412, 2413, "P" +536, 16, 80, 503, 277, 278, 2414, 2415, "<" +536, 16, 81, 504, 279, 280, 2416, 2417, "0" +536, 16, 82, 505, 281, 282, 2418, 2419, "." +536, 16, 83, 506, 283, 286, 2420, 2423, "001" +536, 16, 84, 507, 287, 288, 2424, 2425, ")" +536, 16, 85, 508, 289, 290, 2426, 2427, "." +536, 17, 1, 509, 0, 7, 2428, 2435, "Further" +536, 17, 2, 510, 8, 9, 2436, 2437, "," +536, 17, 3, 511, 10, 14, 2438, 2442, "TTFC" +536, 17, 4, 512, 15, 27, 2443, 2455, "demonstrated" +536, 17, 5, 513, 28, 41, 2456, 2469, "significantly" +536, 17, 6, 514, 42, 48, 2470, 2476, "better" +536, 17, 7, 515, 49, 53, 2477, 2481, "tear" +536, 17, 8, 516, 54, 58, 2482, 2486, "film" +536, 17, 9, 517, 59, 64, 2487, 2492, "break" +536, 17, 10, 518, 65, 66, 2493, 2494, "-" +536, 17, 11, 519, 67, 69, 2495, 2497, "up" +536, 17, 12, 520, 70, 74, 2498, 2502, "time" +536, 17, 13, 521, 75, 76, 2503, 2504, "(" +536, 17, 14, 522, 77, 78, 2505, 2506, "5" +536, 17, 15, 523, 79, 80, 2507, 2508, "." +536, 17, 16, 524, 81, 83, 2509, 2511, "15" +536, 17, 17, 525, 84, 86, 2512, 2514, "vs" +536, 17, 18, 526, 87, 88, 2515, 2516, "." +536, 17, 19, 527, 89, 90, 2517, 2518, "4" +536, 17, 20, 528, 91, 92, 2519, 2520, "." +536, 17, 21, 529, 93, 95, 2521, 2523, "65" +536, 17, 22, 530, 96, 97, 2524, 2525, "s" +536, 17, 23, 531, 98, 99, 2526, 2527, ")" +536, 17, 24, 532, 100, 101, 2528, 2529, "," +536, 17, 25, 533, 102, 109, 2530, 2537, "corneal" +536, 17, 26, 534, 110, 115, 2538, 2543, "stain" +536, 17, 27, 535, 116, 117, 2544, 2545, "(" +536, 17, 28, 536, 118, 119, 2546, 2547, "1" +536, 17, 29, 537, 120, 121, 2548, 2549, "." +536, 17, 30, 538, 122, 123, 2550, 2551, "5" +536, 17, 31, 539, 124, 126, 2552, 2554, "vs" +536, 17, 32, 540, 127, 128, 2555, 2556, "." +536, 17, 33, 541, 129, 130, 2557, 2558, "1" +536, 17, 34, 542, 131, 132, 2559, 2560, "." +536, 17, 35, 543, 133, 134, 2561, 2562, "8" +536, 17, 36, 544, 135, 136, 2563, 2564, ")" +536, 17, 37, 545, 137, 140, 2565, 2568, "and" +536, 17, 38, 546, 141, 149, 2569, 2577, "Schirmer" +536, 17, 39, 547, 150, 151, 2578, 2579, "I" +536, 17, 40, 548, 152, 156, 2580, 2584, "test" +536, 17, 41, 549, 157, 158, 2585, 2586, "(" +536, 17, 42, 550, 159, 160, 2587, 2588, "9" +536, 17, 43, 551, 161, 162, 2589, 2590, "." +536, 17, 44, 552, 163, 164, 2591, 2592, "9" +536, 17, 45, 553, 165, 167, 2593, 2595, "vs" +536, 17, 46, 554, 168, 169, 2596, 2597, "." +536, 17, 47, 555, 170, 171, 2598, 2599, "9" +536, 17, 48, 556, 172, 173, 2600, 2601, "." +536, 17, 49, 557, 174, 175, 2602, 2603, "2" +536, 17, 50, 558, 176, 178, 2604, 2606, "mm" +536, 17, 51, 559, 179, 180, 2607, 2608, ")" +536, 17, 52, 560, 181, 189, 2609, 2617, "compared" +536, 17, 53, 561, 190, 194, 2618, 2622, "with" +536, 17, 54, 562, 195, 199, 2623, 2627, "LTFC" +536, 17, 55, 563, 200, 205, 2628, 2633, "after" +536, 17, 56, 564, 206, 207, 2634, 2635, "3" +536, 17, 57, 565, 208, 214, 2636, 2642, "months" +536, 17, 58, 566, 215, 217, 2643, 2645, "of" +536, 17, 59, 567, 218, 225, 2646, 2653, "therapy" +536, 17, 60, 568, 226, 227, 2654, 2655, "(" +536, 17, 61, 569, 228, 229, 2656, 2657, "P" +536, 17, 62, 570, 230, 231, 2658, 2659, "<" +536, 17, 63, 571, 232, 233, 2660, 2661, "0" +536, 17, 64, 572, 234, 235, 2662, 2663, "." +536, 17, 65, 573, 236, 238, 2664, 2666, "01" +536, 17, 66, 574, 239, 242, 2667, 2670, "for" +536, 17, 67, 575, 243, 246, 2671, 2674, "all" +536, 17, 68, 576, 247, 258, 2675, 2686, "comparisons" +536, 17, 69, 577, 259, 260, 2687, 2688, ")" +536, 17, 70, 578, 261, 262, 2689, 2690, "." +536, 18, 1, 579, 0, 10, 2691, 2701, "CONCLUSION" +536, 18, 2, 580, 11, 12, 2702, 2703, ":" +536, 18, 3, 581, 13, 16, 2704, 2707, "The" +536, 18, 4, 582, 17, 21, 2708, 2712, "mean" +536, 18, 5, 583, 22, 24, 2713, 2715, "24" +536, 18, 6, 584, 25, 26, 2716, 2717, "-" +536, 18, 7, 585, 27, 28, 2718, 2719, "h" +536, 18, 8, 586, 29, 32, 2720, 2723, "IOP" +536, 18, 9, 587, 33, 41, 2724, 2732, "lowering" +536, 18, 10, 588, 42, 44, 2733, 2735, "of" +536, 18, 11, 589, 45, 49, 2736, 2740, "TTFC" +536, 18, 12, 590, 50, 53, 2741, 2744, "was" +536, 18, 13, 591, 54, 67, 2745, 2758, "statistically" +536, 18, 14, 592, 68, 72, 2759, 2763, "more" +536, 18, 15, 593, 73, 84, 2764, 2775, "significant" +536, 18, 16, 594, 85, 93, 2776, 2784, "compared" +536, 18, 17, 595, 94, 96, 2785, 2787, "to" +536, 18, 18, 596, 97, 101, 2788, 2792, "LTFC" +536, 18, 19, 597, 102, 104, 2793, 2795, "in" +536, 18, 20, 598, 105, 113, 2796, 2804, "patients" +536, 18, 21, 599, 114, 128, 2805, 2819, "insufficiently" +536, 18, 22, 600, 129, 139, 2820, 2830, "controlled" +536, 18, 23, 601, 140, 144, 2831, 2835, "with" +536, 18, 24, 602, 145, 156, 2836, 2847, "latanoprost" +536, 18, 25, 603, 157, 168, 2848, 2859, "monotherapy" +536, 18, 26, 604, 169, 170, 2860, 2861, "." +536, 19, 1, 605, 0, 11, 2862, 2873, "Measurement" +536, 19, 2, 606, 12, 14, 2874, 2876, "of" +536, 19, 3, 607, 15, 21, 2877, 2883, "ocular" +536, 19, 4, 608, 22, 29, 2884, 2891, "surface" +536, 19, 5, 609, 30, 36, 2892, 2898, "health" +536, 19, 6, 610, 37, 40, 2899, 2902, "and" +536, 19, 7, 611, 41, 45, 2903, 2907, "tear" +536, 19, 8, 612, 46, 50, 2908, 2912, "film" +536, 19, 9, 613, 51, 57, 2913, 2919, "status" +536, 19, 10, 614, 58, 65, 2920, 2927, "favored" +536, 19, 11, 615, 66, 69, 2928, 2931, "the" +536, 19, 12, 616, 70, 73, 2932, 2935, "BAK" +536, 19, 13, 617, 74, 75, 2936, 2937, "-" +536, 19, 14, 618, 76, 80, 2938, 2942, "free" +536, 19, 15, 619, 81, 85, 2943, 2947, "TTFC" +536, 19, 16, 620, 86, 94, 2948, 2956, "compared" +536, 19, 17, 621, 95, 97, 2957, 2959, "to" +536, 19, 18, 622, 98, 102, 2960, 2964, "LTFC" +536, 19, 19, 623, 103, 104, 2965, 2966, "." +536, 20, 1, 624, 0, 3, 2967, 2970, "DOI" +536, 20, 2, 625, 4, 5, 2971, 2972, ":" +536, 20, 3, 626, 6, 8, 2973, 2975, "10" +536, 20, 4, 627, 9, 10, 2976, 2977, "." +536, 20, 5, 628, 11, 15, 2978, 2982, "1007" +536, 20, 6, 629, 16, 17, 2983, 2984, "/" +536, 20, 7, 630, 18, 24, 2985, 2991, "s12325" +536, 20, 8, 631, 25, 26, 2992, 2993, "-" +536, 20, 9, 632, 27, 30, 2994, 2997, "014" +536, 20, 10, 633, 31, 32, 2998, 2999, "-" +536, 20, 11, 634, 33, 37, 3000, 3004, "0125" +536, 20, 12, 635, 38, 39, 3005, 3006, "-" +536, 20, 13, 636, 40, 41, 3007, 3008, "9" +536, 20, 14, 637, 42, 46, 3009, 3013, "PMID" +536, 20, 15, 638, 47, 48, 3014, 3015, ":" +536, 20, 16, 639, 49, 57, 3016, 3024, "24919410" +536, 20, 17, 640, 58, 59, 3025, 3026, "[" +536, 20, 18, 641, 60, 67, 3027, 3034, "Indexed" +536, 20, 19, 642, 68, 71, 3035, 3038, "for" +536, 20, 20, 643, 72, 79, 3039, 3046, "MEDLINE" +536, 20, 21, 644, 80, 81, 3047, 3048, "]" diff --git a/data/gl 24919410_jshahinitiran.annodb b/data/gl 24919410_jshahinitiran.annodb new file mode 100644 index 0000000..64153ec --- /dev/null +++ b/data/gl 24919410_jshahinitiran.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88235, Journal, 0, 8, "Adv Ther", "", +88237, PublicationYear, 11, 15, "2014", "", +88238, Title, 108, 266, "24 - hour efficacy of travoprost / timolol BAK - free versus latanoprost / timolol fixed combinations in patients insufficiently controlled with latanoprost .", "", +88252, Travoprost, 130, 140, "travoprost", "", +88256, Trav/TimFC, 130, 161, "travoprost / timolol BAK - free", "", +88253, Timolol, 143, 161, "timolol BAK - free", "", +88255, Latanoprost, 169, 180, "latanoprost", "", +88257, Lat/TimFC, 169, 209, "latanoprost / timolol fixed combinations", "", +88254, Timolol, 183, 190, "timolol", "", +88259, Precondition, 222, 264, "insufficiently controlled with latanoprost", "", +88258, Latanoprost, 253, 264, "latanoprost", "", +88239, Author, 267, 277, "Konstas AG", "", +88240, Author, 286, 302, "Voudouragkaki IC", "", +88242, Author, 305, 317, "Boboridis KG", "", +88243, Author, 320, 330, "Haidich AB", "", +88244, Author, 333, 346, "Paschalinou E", "", +88245, Author, 349, 363, "Giannopoulos T", "", +88246, Author, 366, 378, "Dragoumis ND", "", +88247, Author, 381, 392, "Makridis AK", "", +88248, Author, 395, 404, "Kahook MY", "", +88249, Greece, 563, 569, "Greece", "", +88250, ObjectiveDescription, 615, 760, "To compare the 24 - h intraocular pressure ( IOP ) control and tolerability of travoprost / timolol benzalkonium chloride ( BAK ) - free ( TTFC )", "", +88260, IOP, 637, 657, "intraocular pressure", "", +88261, IOP, 660, 663, "IOP", "", +88262, Travoprost, 694, 704, "travoprost", "", +88266, Trav/TimFC, 694, 751, "travoprost / timolol benzalkonium chloride ( BAK ) - free", "", +88263, Timolol, 707, 751, "timolol benzalkonium chloride ( BAK ) - free", "", +88267, Trav/TimFC, 754, 758, "TTFC", "", +88251, ObjectiveDescription, 761, 960, "vs . latanoprost / timolol fixed combination preserved with BAK ( LTFC ) in open - angle glaucoma patients insufficiently controlled with latanoprost 0 . 005 % monotherapy given once in the evening .", "", +88268, Latanoprost, 766, 777, "latanoprost", "", +88270, Lat/TimFC, 766, 824, "latanoprost / timolol fixed combination preserved with BAK", "", +88269, Timolol, 780, 787, "timolol", "", +88271, Lat/TimFC, 827, 831, "LTFC", "", +88272, OpenAngleGlaucoma, 837, 858, "open - angle glaucoma", "", +88273, Precondition, 868, 932, "insufficiently controlled with latanoprost 0 . 005 % monotherapy", "", +88274, Latanoprost, 899, 910, "latanoprost", "", +88275, DoseValue, 911, 918, "0 . 005", "", +88276, Frequency, 939, 943, "once", "", +88277, Evening, 951, 958, "evening", "", +88278, Prospective, 1000, 1011, "prospective", "", +88279, Blind, 1014, 1031, "observer - masked", "", +88280, CTDesign, 1034, 1053, "active - controlled", "", +88281, Crossover, 1056, 1068, "cross - over", "", +88282, OpenAngleGlaucoma, 1100, 1121, "open - angle glaucoma", "", +88286, Precondition, 1131, 1245, "who demonstrated a latanoprost - treated morning IOP ( 10 : 00 ± 1 h ) greater than 20 mmHg on two separate visits", "", +88283, Latanoprost, 1150, 1161, "latanoprost", "", +88284, IOP, 1180, 1183, "IOP", "", +88285, mmHg, 1218, 1222, "mmHg", "", +88287, Randomized, 1251, 1261, "randomized", "", +88288, Duration, 1266, 1274, "3 months", "", +88289, Trav/TimFC, 1293, 1297, "TTFC", "", +88290, Lat/TimFC, 1301, 1305, "LTFC", "", +88291, Crossover, 1327, 1339, "crossed over", "", +88292, Duration, 1378, 1386, "3 months", "", +88293, Latanoprost, 1407, 1418, "latanoprost", "", +88294, TimePoint, 1443, 1452, "3 - month", "", +88295, IOP, 1494, 1497, "IOP", "", +88296, MeasurementDevice, 1540, 1570, "Goldmann applanation tonometry", "", +88297, MeasurementDevice, 1658, 1675, "Perkins tonometry", "", +88298, FinalNumPatientsCT, 1822, 1833, "Forty - two", "", +88299, OpenAngleGlaucoma, 1834, 1855, "open - angle glaucoma", "", +88300, Mean, 1891, 1895, "mean", "", +88310, IOP, 1912, 1915, "IOP", "", +88302, Latanoprost, 1919, 1930, "latanoprost", "", +88303, BaseLineValue, 1935, 1941, "21 . 5", "", +88304, SdErrorBL, 1944, 1949, "1 . 6", "", +88305, mmHg, 1950, 1954, "mmHg", "", +88307, IOP, 2007, 2010, "IOP", "", +88308, Mean, 2040, 2044, "mean", "", +88309, IOP, 2078, 2081, "IOP", "", +88311, Latanoprost, 2096, 2107, "latanoprost", "", +88312, PValueChangeValue, 2122, 2132, "P < 0 . 01", "", +88313, Trav/TimFC, 2194, 2198, "TTFC", "", +88314, Mean, 2228, 2232, "mean", "", +88315, IOP, 2240, 2243, "IOP", "", +88316, ResultMeasuredValue, 2246, 2252, "18 . 9", "", +88318, SdErrorResValue, 2255, 2260, "2 . 2", "", +88321, mmHg, 2261, 2265, "mmHg", "", +88320, Lat/TimFC, 2273, 2277, "LTFC", "", +88317, ResultMeasuredValue, 2280, 2286, "19 . 3", "", +88319, SdErrorResValue, 2289, 2294, "2 . 3", "", +88322, mmHg, 2295, 2299, "mmHg", "", +88323, PValueResValue, 2302, 2315, "( P = 0 . 004", "", +88324, IOP, 2342, 2345, "IOP", "", +88325, ResultMeasuredValue, 2359, 2365, "18 . 6", "", +88327, SdErrorResValue, 2368, 2373, "2 . 5", "", +88326, ResultMeasuredValue, 2379, 2385, "19 . 5", "", +88328, SdErrorResValue, 2388, 2393, "2 . 7", "", +88329, mmHg, 2394, 2398, "mmHg", "", +88330, Lat/TimFC, 2403, 2407, "LTFC", "", +88331, PValueResValue, 2412, 2423, "P < 0 . 001", "", +88332, Trav/TimFC, 2438, 2442, "TTFC", "", +88333, EndPointDescription, 2477, 2502, "tear film break - up time", "", +88334, ResultMeasuredValue, 2505, 2511, "5 . 15", "", +88335, ResultMeasuredValue, 2517, 2523, "4 . 65", "", +88336, Second, 2524, 2525, "s", "", +88337, EndPointDescription, 2530, 2543, "corneal stain", "", +88338, ResultMeasuredValue, 2546, 2551, "1 . 5", "", +88339, ResultMeasuredValue, 2557, 2562, "1 . 8", "", +88342, EndPointDescription, 2569, 2584, "Schirmer I test", "", +88340, ResultMeasuredValue, 2587, 2592, "9 . 9", "", +88341, ResultMeasuredValue, 2598, 2603, "9 . 2", "", +88343, BioAndMedicalUnit, 2604, 2606, "mm", "", +88344, Lat/TimFC, 2623, 2627, "LTFC", "", +88345, Duration, 2634, 2642, "3 months", "", +88346, PvalueDiff, 2656, 2666, "P < 0 . 01", "", +88353, ConclusionComment, 2704, 2861, "The mean 24 - h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy .", "", +88347, Mean, 2708, 2712, "mean", "", +88348, IOP, 2720, 2723, "IOP", "", +88349, Trav/TimFC, 2736, 2740, "TTFC", "", +88350, Lat/TimFC, 2788, 2792, "LTFC", "", +88352, Precondition, 2805, 2859, "insufficiently controlled with latanoprost monotherapy", "", +88351, Latanoprost, 2836, 2847, "latanoprost", "", +88354, ConclusionComment, 2862, 2966, "Measurement of ocular surface health and tear film status favored the BAK - free TTFC compared to LTFC .", "", +88355, EndPointDescription, 2877, 2898, "ocular surface health", "", +88356, EndPointDescription, 2903, 2919, "tear film status", "", +88357, Trav/TimFC, 2932, 2947, "BAK - free TTFC", "", +88358, Lat/TimFC, 2960, 2964, "LTFC", "", +88359, PMID, 3016, 3024, "24919410", "", diff --git a/data/gl 24919410_jshahinitiran.n-triples b/data/gl 24919410_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24919410_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 24919410_tstrakeljahn.annodb b/data/gl 24919410_tstrakeljahn.annodb new file mode 100644 index 0000000..ec690c5 --- /dev/null +++ b/data/gl 24919410_tstrakeljahn.annodb @@ -0,0 +1,118 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89635, Journal, 0, 8, "Adv Ther", "", +89636, PublicationYear, 11, 15, "2014", "", +89637, Travoprost, 130, 140, "travoprost", "", +89642, Trav/TimFC, 130, 150, "travoprost / timolol", "", +89645, Drug, 130, 161, "travoprost / timolol BAK - free", "BAK-free Trav/TimFC", +89638, Timolol, 143, 150, "timolol", "", +89640, Latanoprost, 169, 180, "latanoprost", "", +89639, Timolol, 183, 190, "timolol", "", +89647, Latanoprost, 253, 264, "latanoprost", "", +89649, Author, 267, 277, "Konstas AG", "", +89650, Author, 286, 302, "Voudouragkaki IC", "", +89651, Author, 305, 317, "Boboridis KG", "", +89652, Author, 320, 330, "Haidich AB", "", +89653, Author, 333, 346, "Paschalinou E", "", +89654, Author, 349, 363, "Giannopoulos T", "", +89655, Author, 366, 378, "Dragoumis ND", "", +89656, Author, 381, 392, "Makridis AK", "", +89657, Author, 395, 404, "Kahook MY", "", +89677, Greece, 563, 569, "Greece", "", +89675, ObjectiveDescription, 615, 867, "To compare the 24 - h intraocular pressure ( IOP ) control and tolerability of travoprost / timolol benzalkonium chloride ( BAK ) - free ( TTFC ) vs . latanoprost / timolol fixed combination preserved with BAK ( LTFC ) in open - angle glaucoma patients", "", +89658, IOP, 637, 657, "intraocular pressure", "", +89659, IOP, 660, 663, "IOP", "", +89660, Travoprost, 694, 704, "travoprost", "", +89662, Trav/TimFC, 694, 714, "travoprost / timolol", "", +89664, Drug, 694, 751, "travoprost / timolol benzalkonium chloride ( BAK ) - free", "BAK-free Trav/TimFC", +89661, Timolol, 707, 714, "timolol", "", +89663, Trav/TimFC, 754, 758, "TTFC", "", +89665, Latanoprost, 766, 777, "latanoprost", "", +89667, Lat/TimFC, 766, 787, "latanoprost / timolol", "", +89666, Timolol, 780, 787, "timolol", "", +89668, Lat/TimFC, 827, 831, "LTFC", "", +89669, OpenAngleGlaucoma, 837, 858, "open - angle glaucoma", "", +89676, ObjectiveDescription, 883, 960, "controlled with latanoprost 0 . 005 % monotherapy given once in the evening .", "", +89670, Latanoprost, 899, 910, "latanoprost", "", +89671, DoseValue, 911, 918, "0 . 005", "", +89672, Percentage, 919, 920, "%", "", +89674, Frequency, 939, 958, "once in the evening", "", +89673, Evening, 951, 958, "evening", "", +89678, Prospective, 1000, 1011, "prospective", "", +89679, Blind, 1014, 1031, "observer - masked", "", +89680, Crossover, 1056, 1068, "cross - over", "", +89681, OpenAngleGlaucoma, 1100, 1121, "open - angle glaucoma", "", +89682, Latanoprost, 1150, 1161, "latanoprost", "", +89687, Precondition, 1150, 1245, "latanoprost - treated morning IOP ( 10 : 00 ± 1 h ) greater than 20 mmHg on two separate visits", "", +89683, Morning, 1172, 1179, "morning", "", +89684, IOP, 1180, 1183, "IOP", "", +89685, TimePoint, 1186, 1199, "10 : 00 ± 1 h", "", +89686, mmHg, 1218, 1222, "mmHg", "", +89688, Randomized, 1251, 1261, "randomized", "", +89689, Duration, 1266, 1274, "3 months", "", +89690, Trav/TimFC, 1293, 1297, "TTFC", "", +89691, Lat/TimFC, 1301, 1305, "LTFC", "", +89692, Duration, 1378, 1386, "3 months", "", +89693, Latanoprost, 1407, 1418, "latanoprost", "", +89694, Duration, 1443, 1452, "3 - month", "", +89695, IOP, 1494, 1497, "IOP", "", +89696, TimePoint, 1612, 1619, "10 : 00", "", +89697, TimePoint, 1622, 1629, "14 : 00", "", +89698, TimePoint, 1632, 1639, "18 : 00", "", +89699, TimePoint, 1644, 1651, "22 : 00", "", +89700, TimePoint, 1710, 1717, "02 : 00", "", +89701, TimePoint, 1722, 1729, "06 : 00", "", +89702, FinalNumPatientsCT, 1822, 1833, "Forty - two", "", +89703, Mean, 1891, 1895, "mean", "", +89704, IOP, 1912, 1915, "IOP", "", +89705, Latanoprost, 1919, 1930, "latanoprost", "", +89706, BaseLineValue, 1935, 1941, "21 . 5", "", +89707, SdDevBL, 1944, 1949, "1 . 6", "", +89708, mmHg, 1950, 1954, "mmHg", "", +89724, ObservedResult, 1957, 2136, "Both fixed combinations significantly reduced the IOP at each time point , for the mean , peak and fluctuation of 24 - h IOP compared with latanoprost monotherapy ( P < 0 . 01 ) .", "", +89709, IOP, 2007, 2010, "IOP", "", +89710, Mean, 2040, 2044, "mean", "", +89711, Peak_IOP, 2047, 2051, "peak", "", +89712, IOP, 2078, 2081, "IOP", "", +89713, Latanoprost, 2096, 2107, "latanoprost", "", +89714, PValueResValue, 2124, 2132, "< 0 . 01", "", +89715, Trav/TimFC, 2194, 2198, "TTFC", "", +89716, IOP, 2240, 2243, "IOP", "", +89725, ResultMeasuredValue, 2246, 2252, "18 . 9", "", +89729, SdDevResValue, 2255, 2260, "2 . 2", "", +89718, mmHg, 2261, 2265, "mmHg", "", +89717, Lat/TimFC, 2273, 2277, "LTFC", "", +89726, ResultMeasuredValue, 2280, 2286, "19 . 3", "", +89730, SdDevResValue, 2289, 2294, "2 . 3", "", +89719, mmHg, 2295, 2299, "mmHg", "", +89733, PvalueDiff, 2306, 2315, "= 0 . 004", "", +89720, IOP, 2342, 2345, "IOP", "", +89734, TimePoint, 2349, 2356, "18 : 00", "", +89727, ResultMeasuredValue, 2359, 2365, "18 . 6", "", +89731, SdDevResValue, 2368, 2373, "2 . 5", "", +89728, ResultMeasuredValue, 2379, 2385, "19 . 5", "", +89732, SdDevResValue, 2388, 2393, "2 . 7", "", +89721, mmHg, 2394, 2398, "mmHg", "", +89722, Lat/TimFC, 2403, 2407, "LTFC", "", +89723, PvalueDiff, 2414, 2423, "< 0 . 001", "", +89735, Trav/TimFC, 2438, 2442, "TTFC", "", +89737, ResultMeasuredValue, 2505, 2511, "5 . 15", "", +89738, ResultMeasuredValue, 2517, 2523, "4 . 65", "", +89736, Second, 2524, 2525, "s", "", +89739, ResultMeasuredValue, 2546, 2551, "1 . 5", "", +89740, ResultMeasuredValue, 2557, 2562, "1 . 8", "", +89741, ResultMeasuredValue, 2587, 2592, "9 . 9", "", +89742, ResultMeasuredValue, 2598, 2603, "9 . 2", "", +89743, Lat/TimFC, 2623, 2627, "LTFC", "", +89744, TimePoint, 2628, 2642, "after 3 months", "", +89745, PvalueDiff, 2658, 2666, "< 0 . 01", "", +89751, ConclusionComment, 2704, 2861, "The mean 24 - h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy .", "", +89750, Mean, 2708, 2712, "mean", "", +89746, IOP, 2720, 2723, "IOP", "", +89747, Trav/TimFC, 2736, 2740, "TTFC", "", +89748, Lat/TimFC, 2788, 2792, "LTFC", "", +89749, Latanoprost, 2836, 2847, "latanoprost", "", +89755, ConclusionComment, 2862, 2966, "Measurement of ocular surface health and tear film status favored the BAK - free TTFC compared to LTFC .", "", +89754, Drug, 2932, 2947, "BAK - free TTFC", "BAK-free Trav/TimFC", +89752, Trav/TimFC, 2943, 2947, "TTFC", "", +89753, Lat/TimFC, 2960, 2964, "LTFC", "", +89756, PMID, 3016, 3024, "24919410", "", diff --git a/data/gl 24919410_tstrakeljahn.n-triples b/data/gl 24919410_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 24919410_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25264990_admin.annodb b/data/gl 25264990_admin.annodb new file mode 100644 index 0000000..f41d4ec --- /dev/null +++ b/data/gl 25264990_admin.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "J Glaucoma", "", " \"J Glaucoma\"." +1, PublicationYear, 13, 17, "2016", "", " \"2016\"." +2, Title, 88, 253, "The Efficacy of a Latanoprost / Timolol Fixed Combination Versus Latanoprost and Timolol Gel - forming Solution Unfixed Combination on Daytime Intraocular Pressure .", "", " \"The Efficacy of a Latanoprost / Timolol Fixed Combination Versus Latanoprost and Timolol Gel - forming Solution Unfixed Combination on Daytime Intraocular Pressure .\"." +3, Latanoprost, 106, 117, "Latanoprost", "", +7, Lat/TimFC, 106, 145, "Latanoprost / Timolol Fixed Combination", "", +4, Timolol, 120, 127, "Timolol", "", +6, Latanoprost, 153, 164, "Latanoprost", "", +5, Timolol, 169, 199, "Timolol Gel - forming Solution", "", +104514, Diurnal_IOP, 223, 251, "Daytime Intraocular Pressure", "", +9, Author, 254, 262, "Ö zyol E", "", " \"Ö zyol E\"." +10, Author, 271, 279, "Ö zyol P", "", " \"Ö zyol P\"." +11, Turkey, 369, 375, "Turkey", "", " ." +12, ObjectiveDescription, 388, 616, "To evaluate the effect of a latanoprost / timolol fixed combination ( LTFC ) versus a latanoprost and timolol gel - forming solution unfixed combination ( LTuFC ) on daytime intraocular pressure ( IOP ) levels and fluctuations .", "", " \"To evaluate the effect of a latanoprost / timolol fixed combination ( LTFC ) versus a latanoprost and timolol gel - forming solution unfixed combination ( LTuFC ) on daytime intraocular pressure ( IOP ) levels and fluctuations .\"." +13, Latanoprost, 416, 427, "latanoprost", "", +15, Lat/TimFC, 416, 455, "latanoprost / timolol fixed combination", "", +14, Timolol, 430, 437, "timolol", "", +16, Lat/TimFC, 458, 462, "LTFC", "", +17, Latanoprost, 474, 485, "latanoprost", "", +18, Timolol, 490, 520, "timolol gel - forming solution", "", +104518, Diurnal_IOP, 554, 582, "daytime intraocular pressure", "", +20, IOP, 585, 588, "IOP", "", +21, Duration, 639, 647, "8 - week", "", " \"8 - week\"." +22, Randomized, 650, 660, "randomized", "", " ." +23, Parallel, 663, 679, "parallel - group", "", " ." +24, NumberPatientsCT, 703, 705, "90", "", " \"90\"." +104519, Precondition, 706, 847, "patients diagnosed with primary open - angle glaucoma or ocular hypertension that were insufficiently controlled with latanoprost monotherapy", "", " \"patients diagnosed with primary open - angle glaucoma or ocular hypertension that were insufficiently controlled with latanoprost monotherapy\"." +25, Primary_OpenAngleGlaucoma, 730, 759, "primary open - angle glaucoma", "", " ." +26, OcularHypertension, 763, 782, "ocular hypertension", "", " ." +100, Latanoprost, 824, 835, "latanoprost", "", +28, Randomized, 864, 874, "Randomized", "", +104520, DoseDescription, 902, 921, "single evening dose", "", " \"single evening dose\"." +29, Evening, 909, 916, "evening", "", " ." +30, Lat/TimFC, 925, 929, "LTFC", "", " ." +31, Latanoprost, 956, 967, "latanoprost", "", " . ." +32, Frequency, 981, 991, "once daily", "", " \"once daily\"." +33, Evening, 999, 1006, "evening", "", " ." +34, Timolol, 1011, 1041, "timolol gel - forming solution", "", " ." +35, Frequency, 1055, 1065, "once daily", "", " \"once daily\"." +36, Morning, 1073, 1080, "morning", "", " ." +37, IOP, 1108, 1111, "IOP", "", +111, TimePoint, 1139, 1143, "8 AM", "", +112, TimePoint, 1146, 1151, "11 AM", "", +113, TimePoint, 1154, 1158, "2 PM", "", +114, TimePoint, 1165, 1169, "5 PM", "", +38, Mean, 1176, 1180, "mean", "", +39, IOP, 1181, 1184, "IOP", "", +104522, Diurnal_IOP, 1187, 1198, "daytime IOP", "", +40, IOP, 1233, 1236, "IOP", "", +41, TimePoint, 1254, 1267, "weeks 4 and 8", "", +42, TimePoint, 1254, 1261, "weeks 4", "", +43, Mean, 1284, 1288, "mean", "", +44, IOP, 1289, 1292, "IOP", "", +45, PValueChangeValue, 1364, 1374, "P < 0 . 01", "", " \"P < 0 . 01\". \"P < 0 . 01\"." +47, Mean, 1421, 1425, "mean", "", " . ." +48, IOP, 1426, 1429, "IOP", "", " . ." +49, TimePoint, 1448, 1454, "week 4", "", " \"week 4\". \"week 4\"." +50, PvalueDiff, 1457, 1469, "P = 0 . 0021", "", " \"P = 0 . 0021\"." +51, TimePoint, 1477, 1483, "week 8", "", " \"week 8\"." +52, Mean, 1490, 1494, "mean", "", +53, IOP, 1495, 1498, "IOP", "", +54, Reduction, 1513, 1518, "3 . 2", "", " \"3 . 2\"." +133, SdDevChangeValue, 1521, 1526, "2 . 1", "", " \"2 . 1\"." +55, Reduction, 1531, 1536, "5 . 7", "", " \"5 . 7\"." +134, SdDevChangeValue, 1539, 1544, "3 . 2", "", " \"3 . 2\"." +58, mmHg, 1545, 1550, "mm Hg", "", " ." +59, Lat/TimFC, 1554, 1558, "LTFC", "", +137, PvalueDiff, 1630, 1641, "P = 0 . 001", "", " \"P = 0 . 001\"." +104524, Diurnal_IOP, 1664, 1675, "daytime IOP", "", +63, TimePoint, 1784, 1790, "week 8", "", +64, Mean, 1797, 1801, "mean", "", +65, IOP, 1802, 1805, "IOP", "", +145, TimePoint, 1822, 1826, "8 AM", "", +146, TimePoint, 1829, 1834, "11 AM", "", +147, TimePoint, 1837, 1841, "2 PM", "", +148, TimePoint, 1848, 1852, "5 PM", "", +66, Lat/TimFC, 1905, 1909, "LTFC", "", +67, PvalueDiff, 1918, 1929, "P = 0 . 024", "", +151, PvalueDiff, 1932, 1940, "0 . 0001", "", +152, PvalueDiff, 1943, 1951, "0 . 0008", "", +153, PvalueDiff, 1958, 1966, "0 . 0011", "", +159, ConclusionComment, 2000, 2182, "The concomitant use of latanoprost and timolol gel - forming solution leads to a larger additional IOP reduction and lower daytime IOP levels as compared with the fixed combination .", "", " \"The concomitant use of latanoprost and timolol gel - forming solution leads to a larger additional IOP reduction and lower daytime IOP levels as compared with the fixed combination .\"." +70, Latanoprost, 2023, 2034, "latanoprost", "", +71, Timolol, 2039, 2069, "timolol gel - forming solution", "", +72, IOP, 2099, 2102, "IOP", "", +104523, Diurnal_IOP, 2123, 2134, "daytime IOP", "", +74, PMID, 2231, 2239, "25264990", "", " \"25264990\"." diff --git a/data/gl 25264990_admin.n-triples b/data/gl 25264990_admin.n-triples new file mode 100644 index 0000000..1d20900 --- /dev/null +++ b/data/gl 25264990_admin.n-triples @@ -0,0 +1,134 @@ +# RDF export of group: Publication + . + "Publication " . + "The Efficacy of a Latanoprost / Timolol Fixed Combination Versus Latanoprost and Timolol Gel - forming Solution Unfixed Combination on Daytime Intraocular Pressure ." . + "Ö zyol E" . + "2016" . + "J Glaucoma" . + "25264990" . + . + "Ö zyol P" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the effect of a latanoprost / timolol fixed combination ( LTFC ) versus a latanoprost and timolol gel - forming solution unfixed combination ( LTuFC ) on daytime intraocular pressure ( IOP ) levels and fluctuations ." . + "90" . + "8 - week" . + . + . + . + "The concomitant use of latanoprost and timolol gel - forming solution leads to a larger additional IOP reduction and lower daytime IOP levels as compared with the fixed combination ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "patients diagnosed with primary open - angle glaucoma or ocular hypertension that were insufficiently controlled with latanoprost monotherapy" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm lat/tim" . + . + . + . + . + . + . + . + "Arm fixed lat/tim" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention lat" . + . + "once daily" . + . + . + "Intervention tim" . + . + "once daily" . + . + . + "Intervention fixed lat/tim " . + . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + . + . + "Medication tim" . + . + . + . + . + "Medication fixed lat/tim " . + . + . + . + "single evening dose" . +# RDF export of group: Outcome + . + "Outcome IOP lat/tim" . + . + "P < 0 . 01" . + . + "Outcome IOP fixed lat/tim" . + . + "P < 0 . 01" . + . + "Outcome IOP lat/tim week 4" . + . + "week 4" . + . + "Outcome IOP fixed lat/tim week 4" . + . + "week 4" . + . + "Outcome IOP lat/tim week 8 " . + . + "3 . 2" . + "2 . 1" . + "week 8" . + . + "Outcome IOP fixed lat/tim week 8 " . + . + "5 . 7" . + "3 . 2" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP week 4" . + "P = 0 . 0021" . + . + . + . + "DiffBetweenGroups IOP week 8 " . + "P = 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25264990_export.csv b/data/gl 25264990_export.csv new file mode 100644 index 0000000..4bd4bc5 --- /dev/null +++ b/data/gl 25264990_export.csv @@ -0,0 +1,460 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +504, 1, 1, 1, 0, 1, 0, 1, "J" +504, 1, 2, 2, 2, 10, 2, 10, "Glaucoma" +504, 1, 3, 3, 11, 12, 11, 12, "." +504, 2, 1, 4, 0, 4, 13, 17, "2016" +504, 2, 2, 5, 5, 8, 18, 21, "Feb" +504, 2, 3, 6, 9, 10, 22, 23, ";" +504, 2, 4, 7, 11, 13, 24, 26, "25" +504, 2, 5, 8, 14, 15, 27, 28, "(" +504, 2, 6, 9, 16, 17, 29, 30, "2" +504, 2, 7, 10, 18, 19, 31, 32, ")" +504, 2, 8, 11, 20, 21, 33, 34, ":" +504, 2, 9, 12, 22, 25, 35, 38, "135" +504, 2, 10, 13, 26, 27, 39, 40, "-" +504, 2, 11, 14, 28, 29, 41, 42, "9" +504, 2, 12, 15, 30, 31, 43, 44, "." +504, 2, 13, 16, 32, 35, 45, 48, "doi" +504, 2, 14, 17, 36, 37, 49, 50, ":" +504, 2, 15, 18, 38, 40, 51, 53, "10" +504, 2, 16, 19, 41, 42, 54, 55, "." +504, 2, 17, 20, 43, 47, 56, 60, "1097" +504, 2, 18, 21, 48, 49, 61, 62, "/" +504, 2, 19, 22, 50, 53, 63, 66, "IJG" +504, 2, 20, 23, 54, 55, 67, 68, "." +504, 2, 21, 24, 56, 72, 69, 85, "0000000000000170" +504, 2, 22, 25, 73, 74, 86, 87, "." +504, 3, 1, 26, 0, 3, 88, 91, "The" +504, 3, 2, 27, 4, 12, 92, 100, "Efficacy" +504, 3, 3, 28, 13, 15, 101, 103, "of" +504, 3, 4, 29, 16, 17, 104, 105, "a" +504, 3, 5, 30, 18, 29, 106, 117, "Latanoprost" +504, 3, 6, 31, 30, 31, 118, 119, "/" +504, 3, 7, 32, 32, 39, 120, 127, "Timolol" +504, 3, 8, 33, 40, 45, 128, 133, "Fixed" +504, 3, 9, 34, 46, 57, 134, 145, "Combination" +504, 3, 10, 35, 58, 64, 146, 152, "Versus" +504, 3, 11, 36, 65, 76, 153, 164, "Latanoprost" +504, 3, 12, 37, 77, 80, 165, 168, "and" +504, 3, 13, 38, 81, 88, 169, 176, "Timolol" +504, 3, 14, 39, 89, 92, 177, 180, "Gel" +504, 3, 15, 40, 93, 94, 181, 182, "-" +504, 3, 16, 41, 95, 102, 183, 190, "forming" +504, 3, 17, 42, 103, 111, 191, 199, "Solution" +504, 3, 18, 43, 112, 119, 200, 207, "Unfixed" +504, 3, 19, 44, 120, 131, 208, 219, "Combination" +504, 3, 20, 45, 132, 134, 220, 222, "on" +504, 3, 21, 46, 135, 142, 223, 230, "Daytime" +504, 3, 22, 47, 143, 154, 231, 242, "Intraocular" +504, 3, 23, 48, 155, 163, 243, 251, "Pressure" +504, 3, 24, 49, 164, 165, 252, 253, "." +504, 4, 1, 50, 0, 1, 254, 255, "Ö" +504, 4, 2, 51, 2, 6, 256, 260, "zyol" +504, 4, 3, 52, 7, 8, 261, 262, "E" +504, 4, 4, 53, 9, 10, 263, 264, "(" +504, 4, 5, 54, 11, 12, 265, 266, "1" +504, 4, 6, 55, 13, 14, 267, 268, ")" +504, 4, 7, 56, 15, 16, 269, 270, "," +504, 4, 8, 57, 17, 18, 271, 272, "Ö" +504, 4, 9, 58, 19, 23, 273, 277, "zyol" +504, 4, 10, 59, 24, 25, 278, 279, "P" +504, 4, 11, 60, 26, 27, 280, 281, "." +504, 4, 12, 61, 28, 34, 282, 288, "Author" +504, 4, 13, 62, 35, 46, 289, 300, "information" +504, 4, 14, 63, 47, 48, 301, 302, ":" +504, 4, 15, 64, 49, 50, 303, 304, "(" +504, 4, 16, 65, 51, 52, 305, 306, "1" +504, 4, 17, 66, 53, 54, 307, 308, ")" +504, 4, 18, 67, 55, 65, 309, 319, "Department" +504, 4, 19, 68, 66, 68, 320, 322, "of" +504, 4, 20, 69, 69, 82, 323, 336, "Ophthalmology" +504, 4, 21, 70, 83, 84, 337, 338, "," +504, 4, 22, 71, 85, 86, 339, 340, "Ü" +504, 4, 23, 72, 87, 90, 341, 344, "nye" +504, 4, 24, 73, 91, 96, 345, 350, "State" +504, 4, 25, 74, 97, 105, 351, 359, "Hospital" +504, 4, 26, 75, 106, 107, 360, 361, "," +504, 4, 27, 76, 108, 112, 362, 366, "Ordu" +504, 4, 28, 77, 113, 114, 367, 368, "," +504, 4, 29, 78, 115, 121, 369, 375, "Turkey" +504, 4, 30, 79, 122, 123, 376, 377, "." +504, 5, 1, 80, 0, 7, 378, 385, "PURPOSE" +504, 5, 2, 81, 8, 9, 386, 387, ":" +504, 5, 3, 82, 10, 12, 388, 390, "To" +504, 5, 4, 83, 13, 21, 391, 399, "evaluate" +504, 5, 5, 84, 22, 25, 400, 403, "the" +504, 5, 6, 85, 26, 32, 404, 410, "effect" +504, 5, 7, 86, 33, 35, 411, 413, "of" +504, 5, 8, 87, 36, 37, 414, 415, "a" +504, 5, 9, 88, 38, 49, 416, 427, "latanoprost" +504, 5, 10, 89, 50, 51, 428, 429, "/" +504, 5, 11, 90, 52, 59, 430, 437, "timolol" +504, 5, 12, 91, 60, 65, 438, 443, "fixed" +504, 5, 13, 92, 66, 77, 444, 455, "combination" +504, 5, 14, 93, 78, 79, 456, 457, "(" +504, 5, 15, 94, 80, 84, 458, 462, "LTFC" +504, 5, 16, 95, 85, 86, 463, 464, ")" +504, 5, 17, 96, 87, 93, 465, 471, "versus" +504, 5, 18, 97, 94, 95, 472, 473, "a" +504, 5, 19, 98, 96, 107, 474, 485, "latanoprost" +504, 5, 20, 99, 108, 111, 486, 489, "and" +504, 5, 21, 100, 112, 119, 490, 497, "timolol" +504, 5, 22, 101, 120, 123, 498, 501, "gel" +504, 5, 23, 102, 124, 125, 502, 503, "-" +504, 5, 24, 103, 126, 133, 504, 511, "forming" +504, 5, 25, 104, 134, 142, 512, 520, "solution" +504, 5, 26, 105, 143, 150, 521, 528, "unfixed" +504, 5, 27, 106, 151, 162, 529, 540, "combination" +504, 5, 28, 107, 163, 164, 541, 542, "(" +504, 5, 29, 108, 165, 170, 543, 548, "LTuFC" +504, 5, 30, 109, 171, 172, 549, 550, ")" +504, 5, 31, 110, 173, 175, 551, 553, "on" +504, 5, 32, 111, 176, 183, 554, 561, "daytime" +504, 5, 33, 112, 184, 195, 562, 573, "intraocular" +504, 5, 34, 113, 196, 204, 574, 582, "pressure" +504, 5, 35, 114, 205, 206, 583, 584, "(" +504, 5, 36, 115, 207, 210, 585, 588, "IOP" +504, 5, 37, 116, 211, 212, 589, 590, ")" +504, 5, 38, 117, 213, 219, 591, 597, "levels" +504, 5, 39, 118, 220, 223, 598, 601, "and" +504, 5, 40, 119, 224, 236, 602, 614, "fluctuations" +504, 5, 41, 120, 237, 238, 615, 616, "." +504, 6, 1, 121, 0, 7, 617, 624, "METHODS" +504, 6, 2, 122, 8, 9, 625, 626, ":" +504, 6, 3, 123, 10, 14, 627, 631, "This" +504, 6, 4, 124, 15, 18, 632, 635, "was" +504, 6, 5, 125, 19, 21, 636, 638, "an" +504, 6, 6, 126, 22, 23, 639, 640, "8" +504, 6, 7, 127, 24, 25, 641, 642, "-" +504, 6, 8, 128, 26, 30, 643, 647, "week" +504, 6, 9, 129, 31, 32, 648, 649, "," +504, 6, 10, 130, 33, 43, 650, 660, "randomized" +504, 6, 11, 131, 44, 45, 661, 662, "," +504, 6, 12, 132, 46, 54, 663, 671, "parallel" +504, 6, 13, 133, 55, 56, 672, 673, "-" +504, 6, 14, 134, 57, 62, 674, 679, "group" +504, 6, 15, 135, 63, 68, 680, 685, "study" +504, 6, 16, 136, 69, 70, 686, 687, "." +504, 7, 1, 137, 0, 6, 688, 694, "Ninety" +504, 7, 2, 138, 7, 11, 695, 699, "eyes" +504, 7, 3, 139, 12, 14, 700, 702, "of" +504, 7, 4, 140, 15, 17, 703, 705, "90" +504, 7, 5, 141, 18, 26, 706, 714, "patients" +504, 7, 6, 142, 27, 36, 715, 724, "diagnosed" +504, 7, 7, 143, 37, 41, 725, 729, "with" +504, 7, 8, 144, 42, 49, 730, 737, "primary" +504, 7, 9, 145, 50, 54, 738, 742, "open" +504, 7, 10, 146, 55, 56, 743, 744, "-" +504, 7, 11, 147, 57, 62, 745, 750, "angle" +504, 7, 12, 148, 63, 71, 751, 759, "glaucoma" +504, 7, 13, 149, 72, 74, 760, 762, "or" +504, 7, 14, 150, 75, 81, 763, 769, "ocular" +504, 7, 15, 151, 82, 94, 770, 782, "hypertension" +504, 7, 16, 152, 95, 99, 783, 787, "that" +504, 7, 17, 153, 100, 104, 788, 792, "were" +504, 7, 18, 154, 105, 119, 793, 807, "insufficiently" +504, 7, 19, 155, 120, 130, 808, 818, "controlled" +504, 7, 20, 156, 131, 135, 819, 823, "with" +504, 7, 21, 157, 136, 147, 824, 835, "latanoprost" +504, 7, 22, 158, 148, 159, 836, 847, "monotherapy" +504, 7, 23, 159, 160, 164, 848, 852, "were" +504, 7, 24, 160, 165, 173, 853, 861, "enrolled" +504, 7, 25, 161, 174, 175, 862, 863, "." +504, 8, 1, 162, 0, 10, 864, 874, "Randomized" +504, 8, 2, 163, 11, 19, 875, 883, "patients" +504, 8, 3, 164, 20, 28, 884, 892, "received" +504, 8, 4, 165, 29, 35, 893, 899, "either" +504, 8, 5, 166, 36, 37, 900, 901, "a" +504, 8, 6, 167, 38, 44, 902, 908, "single" +504, 8, 7, 168, 45, 52, 909, 916, "evening" +504, 8, 8, 169, 53, 57, 917, 921, "dose" +504, 8, 9, 170, 58, 60, 922, 924, "of" +504, 8, 10, 171, 61, 65, 925, 929, "LTFC" +504, 8, 11, 172, 66, 68, 930, 932, "or" +504, 8, 12, 173, 69, 76, 933, 940, "unfixed" +504, 8, 13, 174, 77, 88, 941, 952, "combination" +504, 8, 14, 175, 89, 91, 953, 955, "of" +504, 8, 15, 176, 92, 103, 956, 967, "latanoprost" +504, 8, 16, 177, 104, 116, 968, 980, "administered" +504, 8, 17, 178, 117, 121, 981, 985, "once" +504, 8, 18, 179, 122, 127, 986, 991, "daily" +504, 8, 19, 180, 128, 130, 992, 994, "in" +504, 8, 20, 181, 131, 134, 995, 998, "the" +504, 8, 21, 182, 135, 142, 999, 1006, "evening" +504, 8, 22, 183, 143, 146, 1007, 1010, "and" +504, 8, 23, 184, 147, 154, 1011, 1018, "timolol" +504, 8, 24, 185, 155, 158, 1019, 1022, "gel" +504, 8, 25, 186, 159, 160, 1023, 1024, "-" +504, 8, 26, 187, 161, 168, 1025, 1032, "forming" +504, 8, 27, 188, 169, 177, 1033, 1041, "solution" +504, 8, 28, 189, 178, 190, 1042, 1054, "administered" +504, 8, 29, 190, 191, 195, 1055, 1059, "once" +504, 8, 30, 191, 196, 201, 1060, 1065, "daily" +504, 8, 31, 192, 202, 204, 1066, 1068, "in" +504, 8, 32, 193, 205, 208, 1069, 1072, "the" +504, 8, 33, 194, 209, 216, 1073, 1080, "morning" +504, 8, 34, 195, 217, 224, 1081, 1088, "without" +504, 8, 35, 196, 225, 226, 1089, 1090, "a" +504, 8, 36, 197, 227, 234, 1091, 1098, "washout" +504, 8, 37, 198, 235, 241, 1099, 1105, "period" +504, 8, 38, 199, 242, 243, 1106, 1107, "." +504, 9, 1, 200, 0, 3, 1108, 1111, "IOP" +504, 9, 2, 201, 4, 16, 1112, 1124, "measurements" +504, 9, 3, 202, 17, 21, 1125, 1129, "were" +504, 9, 4, 203, 22, 27, 1130, 1135, "taken" +504, 9, 5, 204, 28, 30, 1136, 1138, "at" +504, 9, 6, 205, 31, 32, 1139, 1140, "8" +504, 9, 7, 206, 33, 35, 1141, 1143, "AM" +504, 9, 8, 207, 36, 37, 1144, 1145, "," +504, 9, 9, 208, 38, 40, 1146, 1148, "11" +504, 9, 10, 209, 41, 43, 1149, 1151, "AM" +504, 9, 11, 210, 44, 45, 1152, 1153, "," +504, 9, 12, 211, 46, 47, 1154, 1155, "2" +504, 9, 13, 212, 48, 50, 1156, 1158, "PM" +504, 9, 14, 213, 51, 52, 1159, 1160, "," +504, 9, 15, 214, 53, 56, 1161, 1164, "and" +504, 9, 16, 215, 57, 58, 1165, 1166, "5" +504, 9, 17, 216, 59, 61, 1167, 1169, "PM" +504, 9, 18, 217, 62, 63, 1170, 1171, "." +504, 10, 1, 218, 0, 3, 1172, 1175, "The" +504, 10, 2, 219, 4, 8, 1176, 1180, "mean" +504, 10, 3, 220, 9, 12, 1181, 1184, "IOP" +504, 10, 4, 221, 13, 14, 1185, 1186, "," +504, 10, 5, 222, 15, 22, 1187, 1194, "daytime" +504, 10, 6, 223, 23, 26, 1195, 1198, "IOP" +504, 10, 7, 224, 27, 39, 1199, 1211, "measurements" +504, 10, 8, 225, 40, 41, 1212, 1213, "," +504, 10, 9, 226, 42, 45, 1214, 1217, "and" +504, 10, 10, 227, 46, 57, 1218, 1229, "fluctuation" +504, 10, 11, 228, 58, 60, 1230, 1232, "in" +504, 10, 12, 229, 61, 64, 1233, 1236, "IOP" +504, 10, 13, 230, 65, 69, 1237, 1241, "were" +504, 10, 14, 231, 70, 78, 1242, 1250, "assessed" +504, 10, 15, 232, 79, 81, 1251, 1253, "at" +504, 10, 16, 233, 82, 87, 1254, 1259, "weeks" +504, 10, 17, 234, 88, 89, 1260, 1261, "4" +504, 10, 18, 235, 90, 93, 1262, 1265, "and" +504, 10, 19, 236, 94, 95, 1266, 1267, "8" +504, 10, 20, 237, 96, 97, 1268, 1269, "." +504, 11, 1, 238, 0, 7, 1270, 1277, "RESULTS" +504, 11, 2, 239, 8, 9, 1278, 1279, ":" +504, 11, 3, 240, 10, 13, 1280, 1283, "The" +504, 11, 4, 241, 14, 18, 1284, 1288, "mean" +504, 11, 5, 242, 19, 22, 1289, 1292, "IOP" +504, 11, 6, 243, 23, 32, 1293, 1302, "reduction" +504, 11, 7, 244, 33, 37, 1303, 1307, "from" +504, 11, 8, 245, 38, 46, 1308, 1316, "baseline" +504, 11, 9, 246, 47, 49, 1317, 1319, "to" +504, 11, 10, 247, 50, 54, 1320, 1324, "each" +504, 11, 11, 248, 55, 60, 1325, 1330, "visit" +504, 11, 12, 249, 61, 64, 1331, 1334, "was" +504, 11, 13, 250, 65, 76, 1335, 1346, "significant" +504, 11, 14, 251, 77, 79, 1347, 1349, "in" +504, 11, 15, 252, 80, 84, 1350, 1354, "both" +504, 11, 16, 253, 85, 91, 1355, 1361, "groups" +504, 11, 17, 254, 92, 93, 1362, 1363, "(" +504, 11, 18, 255, 94, 95, 1364, 1365, "P" +504, 11, 19, 256, 96, 97, 1366, 1367, "<" +504, 11, 20, 257, 98, 99, 1368, 1369, "0" +504, 11, 21, 258, 100, 101, 1370, 1371, "." +504, 11, 22, 259, 102, 104, 1372, 1374, "01" +504, 11, 23, 260, 105, 106, 1375, 1376, ")" +504, 11, 24, 261, 107, 108, 1377, 1378, "." +504, 12, 1, 262, 0, 5, 1379, 1384, "There" +504, 12, 2, 263, 6, 9, 1385, 1388, "was" +504, 12, 3, 264, 10, 11, 1389, 1390, "a" +504, 12, 4, 265, 12, 23, 1391, 1402, "significant" +504, 12, 5, 266, 24, 34, 1403, 1413, "difference" +504, 12, 6, 267, 35, 37, 1414, 1416, "in" +504, 12, 7, 268, 38, 41, 1417, 1420, "the" +504, 12, 8, 269, 42, 46, 1421, 1425, "mean" +504, 12, 9, 270, 47, 50, 1426, 1429, "IOP" +504, 12, 10, 271, 51, 58, 1430, 1437, "between" +504, 12, 11, 272, 59, 65, 1438, 1444, "groups" +504, 12, 12, 273, 66, 68, 1445, 1447, "at" +504, 12, 13, 274, 69, 73, 1448, 1452, "week" +504, 12, 14, 275, 74, 75, 1453, 1454, "4" +504, 12, 15, 276, 76, 77, 1455, 1456, "(" +504, 12, 16, 277, 78, 79, 1457, 1458, "P" +504, 12, 17, 278, 80, 81, 1459, 1460, "=" +504, 12, 18, 279, 82, 83, 1461, 1462, "0" +504, 12, 19, 280, 84, 85, 1463, 1464, "." +504, 12, 20, 281, 86, 90, 1465, 1469, "0021" +504, 12, 21, 282, 91, 92, 1470, 1471, ")" +504, 12, 22, 283, 93, 94, 1472, 1473, "." +504, 13, 1, 284, 0, 2, 1474, 1476, "At" +504, 13, 2, 285, 3, 7, 1477, 1481, "week" +504, 13, 3, 286, 8, 9, 1482, 1483, "8" +504, 13, 4, 287, 10, 11, 1484, 1485, "," +504, 13, 5, 288, 12, 15, 1486, 1489, "the" +504, 13, 6, 289, 16, 20, 1490, 1494, "mean" +504, 13, 7, 290, 21, 24, 1495, 1498, "IOP" +504, 13, 8, 291, 25, 34, 1499, 1508, "reduction" +504, 13, 9, 292, 35, 38, 1509, 1512, "was" +504, 13, 10, 293, 39, 40, 1513, 1514, "3" +504, 13, 11, 294, 41, 42, 1515, 1516, "." +504, 13, 12, 295, 43, 44, 1517, 1518, "2" +504, 13, 13, 296, 45, 46, 1519, 1520, "±" +504, 13, 14, 297, 47, 48, 1521, 1522, "2" +504, 13, 15, 298, 49, 50, 1523, 1524, "." +504, 13, 16, 299, 51, 52, 1525, 1526, "1" +504, 13, 17, 300, 53, 56, 1527, 1530, "and" +504, 13, 18, 301, 57, 58, 1531, 1532, "5" +504, 13, 19, 302, 59, 60, 1533, 1534, "." +504, 13, 20, 303, 61, 62, 1535, 1536, "7" +504, 13, 21, 304, 63, 64, 1537, 1538, "±" +504, 13, 22, 305, 65, 66, 1539, 1540, "3" +504, 13, 23, 306, 67, 68, 1541, 1542, "." +504, 13, 24, 307, 69, 70, 1543, 1544, "2" +504, 13, 25, 308, 71, 73, 1545, 1547, "mm" +504, 13, 26, 309, 74, 76, 1548, 1550, "Hg" +504, 13, 27, 310, 77, 79, 1551, 1553, "in" +504, 13, 28, 311, 80, 84, 1554, 1558, "LTFC" +504, 13, 29, 312, 85, 88, 1559, 1562, "and" +504, 13, 30, 313, 89, 94, 1563, 1568, "LTuFC" +504, 13, 31, 314, 95, 101, 1569, 1575, "groups" +504, 13, 32, 315, 102, 103, 1576, 1577, "," +504, 13, 33, 316, 104, 116, 1578, 1590, "respectively" +504, 13, 34, 317, 117, 118, 1591, 1592, "," +504, 13, 35, 318, 119, 122, 1593, 1596, "and" +504, 13, 36, 319, 123, 126, 1597, 1600, "the" +504, 13, 37, 320, 127, 137, 1601, 1611, "difference" +504, 13, 38, 321, 138, 141, 1612, 1615, "was" +504, 13, 39, 322, 142, 153, 1616, 1627, "significant" +504, 13, 40, 323, 154, 155, 1628, 1629, "(" +504, 13, 41, 324, 156, 157, 1630, 1631, "P" +504, 13, 42, 325, 158, 159, 1632, 1633, "=" +504, 13, 43, 326, 160, 161, 1634, 1635, "0" +504, 13, 44, 327, 162, 163, 1636, 1637, "." +504, 13, 45, 328, 164, 167, 1638, 1641, "001" +504, 13, 46, 329, 168, 169, 1642, 1643, ")" +504, 13, 47, 330, 170, 171, 1644, 1645, "." +504, 14, 1, 331, 0, 1, 1646, 1647, "A" +504, 14, 2, 332, 2, 10, 1648, 1656, "decrease" +504, 14, 3, 333, 11, 13, 1657, 1659, "in" +504, 14, 4, 334, 14, 17, 1660, 1663, "the" +504, 14, 5, 335, 18, 25, 1664, 1671, "daytime" +504, 14, 6, 336, 26, 29, 1672, 1675, "IOP" +504, 14, 7, 337, 30, 41, 1676, 1687, "fluctuation" +504, 14, 8, 338, 42, 45, 1688, 1691, "was" +504, 14, 9, 339, 46, 54, 1692, 1700, "observed" +504, 14, 10, 340, 55, 57, 1701, 1703, "in" +504, 14, 11, 341, 58, 62, 1704, 1708, "both" +504, 14, 12, 342, 63, 69, 1709, 1715, "groups" +504, 14, 13, 343, 70, 74, 1716, 1720, "over" +504, 14, 14, 344, 75, 79, 1721, 1725, "time" +504, 14, 15, 345, 80, 81, 1726, 1727, "," +504, 14, 16, 346, 82, 85, 1728, 1731, "but" +504, 14, 17, 347, 86, 89, 1732, 1735, "the" +504, 14, 18, 348, 90, 98, 1736, 1744, "decrease" +504, 14, 19, 349, 99, 101, 1745, 1747, "in" +504, 14, 20, 350, 102, 106, 1748, 1752, "each" +504, 14, 21, 351, 107, 112, 1753, 1758, "group" +504, 14, 22, 352, 113, 116, 1759, 1762, "was" +504, 14, 23, 353, 117, 120, 1763, 1766, "not" +504, 14, 24, 354, 121, 132, 1767, 1778, "significant" +504, 14, 25, 355, 133, 134, 1779, 1780, "." +504, 15, 1, 356, 0, 2, 1781, 1783, "At" +504, 15, 2, 357, 3, 7, 1784, 1788, "week" +504, 15, 3, 358, 8, 9, 1789, 1790, "8" +504, 15, 4, 359, 10, 11, 1791, 1792, "," +504, 15, 5, 360, 12, 15, 1793, 1796, "the" +504, 15, 6, 361, 16, 20, 1797, 1801, "mean" +504, 15, 7, 362, 21, 24, 1802, 1805, "IOP" +504, 15, 8, 363, 25, 37, 1806, 1818, "measurements" +504, 15, 9, 364, 38, 40, 1819, 1821, "at" +504, 15, 10, 365, 41, 42, 1822, 1823, "8" +504, 15, 11, 366, 43, 45, 1824, 1826, "AM" +504, 15, 12, 367, 46, 47, 1827, 1828, "," +504, 15, 13, 368, 48, 50, 1829, 1831, "11" +504, 15, 14, 369, 51, 53, 1832, 1834, "AM" +504, 15, 15, 370, 54, 55, 1835, 1836, "," +504, 15, 16, 371, 56, 57, 1837, 1838, "2" +504, 15, 17, 372, 58, 60, 1839, 1841, "PM" +504, 15, 18, 373, 61, 62, 1842, 1843, "," +504, 15, 19, 374, 63, 66, 1844, 1847, "and" +504, 15, 20, 375, 67, 68, 1848, 1849, "5" +504, 15, 21, 376, 69, 71, 1850, 1852, "PM" +504, 15, 22, 377, 72, 74, 1853, 1855, "in" +504, 15, 23, 378, 75, 80, 1856, 1861, "LTuFC" +504, 15, 24, 379, 81, 86, 1862, 1867, "group" +504, 15, 25, 380, 87, 91, 1868, 1872, "were" +504, 15, 26, 381, 92, 105, 1873, 1886, "significantly" +504, 15, 27, 382, 106, 111, 1887, 1892, "lower" +504, 15, 28, 383, 112, 116, 1893, 1897, "than" +504, 15, 29, 384, 117, 119, 1898, 1900, "in" +504, 15, 30, 385, 120, 123, 1901, 1904, "the" +504, 15, 31, 386, 124, 128, 1905, 1909, "LTFC" +504, 15, 32, 387, 129, 134, 1910, 1915, "group" +504, 15, 33, 388, 135, 136, 1916, 1917, "(" +504, 15, 34, 389, 137, 138, 1918, 1919, "P" +504, 15, 35, 390, 139, 140, 1920, 1921, "=" +504, 15, 36, 391, 141, 142, 1922, 1923, "0" +504, 15, 37, 392, 143, 144, 1924, 1925, "." +504, 15, 38, 393, 145, 148, 1926, 1929, "024" +504, 15, 39, 394, 149, 150, 1930, 1931, "," +504, 15, 40, 395, 151, 152, 1932, 1933, "0" +504, 15, 41, 396, 153, 154, 1934, 1935, "." +504, 15, 42, 397, 155, 159, 1936, 1940, "0001" +504, 15, 43, 398, 160, 161, 1941, 1942, "," +504, 15, 44, 399, 162, 163, 1943, 1944, "0" +504, 15, 45, 400, 164, 165, 1945, 1946, "." +504, 15, 46, 401, 166, 170, 1947, 1951, "0008" +504, 15, 47, 402, 171, 172, 1952, 1953, "," +504, 15, 48, 403, 173, 176, 1954, 1957, "and" +504, 15, 49, 404, 177, 178, 1958, 1959, "0" +504, 15, 50, 405, 179, 180, 1960, 1961, "." +504, 15, 51, 406, 181, 185, 1962, 1966, "0011" +504, 15, 52, 407, 186, 187, 1967, 1968, "," +504, 15, 53, 408, 188, 200, 1969, 1981, "respectively" +504, 15, 54, 409, 201, 202, 1982, 1983, ")" +504, 15, 55, 410, 203, 204, 1984, 1985, "." +504, 16, 1, 411, 0, 11, 1986, 1997, "CONCLUSIONS" +504, 16, 2, 412, 12, 13, 1998, 1999, ":" +504, 16, 3, 413, 14, 17, 2000, 2003, "The" +504, 16, 4, 414, 18, 29, 2004, 2015, "concomitant" +504, 16, 5, 415, 30, 33, 2016, 2019, "use" +504, 16, 6, 416, 34, 36, 2020, 2022, "of" +504, 16, 7, 417, 37, 48, 2023, 2034, "latanoprost" +504, 16, 8, 418, 49, 52, 2035, 2038, "and" +504, 16, 9, 419, 53, 60, 2039, 2046, "timolol" +504, 16, 10, 420, 61, 64, 2047, 2050, "gel" +504, 16, 11, 421, 65, 66, 2051, 2052, "-" +504, 16, 12, 422, 67, 74, 2053, 2060, "forming" +504, 16, 13, 423, 75, 83, 2061, 2069, "solution" +504, 16, 14, 424, 84, 89, 2070, 2075, "leads" +504, 16, 15, 425, 90, 92, 2076, 2078, "to" +504, 16, 16, 426, 93, 94, 2079, 2080, "a" +504, 16, 17, 427, 95, 101, 2081, 2087, "larger" +504, 16, 18, 428, 102, 112, 2088, 2098, "additional" +504, 16, 19, 429, 113, 116, 2099, 2102, "IOP" +504, 16, 20, 430, 117, 126, 2103, 2112, "reduction" +504, 16, 21, 431, 127, 130, 2113, 2116, "and" +504, 16, 22, 432, 131, 136, 2117, 2122, "lower" +504, 16, 23, 433, 137, 144, 2123, 2130, "daytime" +504, 16, 24, 434, 145, 148, 2131, 2134, "IOP" +504, 16, 25, 435, 149, 155, 2135, 2141, "levels" +504, 16, 26, 436, 156, 158, 2142, 2144, "as" +504, 16, 27, 437, 159, 167, 2145, 2153, "compared" +504, 16, 28, 438, 168, 172, 2154, 2158, "with" +504, 16, 29, 439, 173, 176, 2159, 2162, "the" +504, 16, 30, 440, 177, 182, 2163, 2168, "fixed" +504, 16, 31, 441, 183, 194, 2169, 2180, "combination" +504, 16, 32, 442, 195, 196, 2181, 2182, "." +504, 17, 1, 443, 0, 3, 2183, 2186, "DOI" +504, 17, 2, 444, 4, 5, 2187, 2188, ":" +504, 17, 3, 445, 6, 8, 2189, 2191, "10" +504, 17, 4, 446, 9, 10, 2192, 2193, "." +504, 17, 5, 447, 11, 15, 2194, 2198, "1097" +504, 17, 6, 448, 16, 17, 2199, 2200, "/" +504, 17, 7, 449, 18, 21, 2201, 2204, "IJG" +504, 17, 8, 450, 22, 23, 2205, 2206, "." +504, 17, 9, 451, 24, 40, 2207, 2223, "0000000000000170" +504, 17, 10, 452, 41, 45, 2224, 2228, "PMID" +504, 17, 11, 453, 46, 47, 2229, 2230, ":" +504, 17, 12, 454, 48, 56, 2231, 2239, "25264990" +504, 17, 13, 455, 57, 58, 2240, 2241, "[" +504, 17, 14, 456, 59, 66, 2242, 2249, "Indexed" +504, 17, 15, 457, 67, 70, 2250, 2253, "for" +504, 17, 16, 458, 71, 78, 2254, 2261, "MEDLINE" +504, 17, 17, 459, 79, 80, 2262, 2263, "]" diff --git a/data/gl 25264990_jshahinitiran.annodb b/data/gl 25264990_jshahinitiran.annodb new file mode 100644 index 0000000..e5dbd25 --- /dev/null +++ b/data/gl 25264990_jshahinitiran.annodb @@ -0,0 +1,76 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +75214, Journal, 0, 10, "J Glaucoma", "", +75215, PublicationYear, 13, 17, "2016", "", +75216, Title, 88, 253, "The Efficacy of a Latanoprost / Timolol Fixed Combination Versus Latanoprost and Timolol Gel - forming Solution Unfixed Combination on Daytime Intraocular Pressure .", "", +75217, Latanoprost, 106, 117, "Latanoprost", "", +75221, Lat/TimFC, 106, 145, "Latanoprost / Timolol Fixed Combination", "", +75218, Timolol, 120, 127, "Timolol", "", +75220, Latanoprost, 153, 164, "Latanoprost", "", +75219, Timolol, 169, 199, "Timolol Gel - forming Solution", "", +75222, IOP, 231, 251, "Intraocular Pressure", "", +75223, Author, 254, 262, "Ö zyol E", "", +75224, Author, 271, 279, "Ö zyol P", "", +75225, Turkey, 369, 375, "Turkey", "", +75226, ObjectiveDescription, 388, 616, "To evaluate the effect of a latanoprost / timolol fixed combination ( LTFC ) versus a latanoprost and timolol gel - forming solution unfixed combination ( LTuFC ) on daytime intraocular pressure ( IOP ) levels and fluctuations .", "", +75227, Latanoprost, 416, 427, "latanoprost", "", +75229, Lat/TimFC, 416, 455, "latanoprost / timolol fixed combination", "", +75228, Timolol, 430, 437, "timolol", "", +75230, Lat/TimFC, 458, 462, "LTFC", "", +75231, Latanoprost, 474, 485, "latanoprost", "", +75232, Timolol, 490, 520, "timolol gel - forming solution", "", +75233, IOP, 562, 582, "intraocular pressure", "", +75234, IOP, 585, 588, "IOP", "", +75235, Duration, 639, 647, "8 - week", "", +75236, Randomized, 650, 660, "randomized", "", +75237, Parallel, 663, 679, "parallel - group", "", +75238, NumberPatientsCT, 703, 705, "90", "", +75239, Primary_OpenAngleGlaucoma, 730, 759, "primary open - angle glaucoma", "", +75241, OcularHypertension, 763, 782, "ocular hypertension", "", +75244, Precondition, 793, 847, "insufficiently controlled with latanoprost monotherapy", "", +75245, Randomized, 864, 874, "Randomized", "", +75246, Evening, 909, 916, "evening", "", +75247, Lat/TimFC, 925, 929, "LTFC", "", +75248, Latanoprost, 956, 967, "latanoprost", "", +75249, Frequency, 981, 991, "once daily", "", +75250, Evening, 999, 1006, "evening", "", +75251, Timolol, 1011, 1041, "timolol gel - forming solution", "", +75252, Frequency, 1055, 1065, "once daily", "", +75253, Morning, 1073, 1080, "morning", "", +75254, IOP, 1108, 1111, "IOP", "", +75255, Mean, 1176, 1180, "mean", "", +75256, IOP, 1181, 1184, "IOP", "", +75257, IOP, 1233, 1236, "IOP", "", +75258, TimePoint, 1254, 1267, "weeks 4 and 8", "", +75259, TimePoint, 1254, 1261, "weeks 4", "", +75263, ObservedResult, 1280, 1378, "The mean IOP reduction from baseline to each visit was significant in both groups ( P < 0 . 01 ) .", "", +75260, Mean, 1284, 1288, "mean", "", +75261, IOP, 1289, 1292, "IOP", "", +75262, PValueChangeValue, 1364, 1374, "P < 0 . 01", "", +75264, Mean, 1421, 1425, "mean", "", +75265, IOP, 1426, 1429, "IOP", "", +75266, TimePoint, 1448, 1454, "week 4", "", +75267, PvalueDiff, 1457, 1469, "P = 0 . 0021", "", +75268, TimePoint, 1477, 1483, "week 8", "", +75269, Mean, 1490, 1494, "mean", "", +75270, IOP, 1495, 1498, "IOP", "", +75271, Reduction, 1513, 1518, "3 . 2", "", +75274, SdErrorChangeValue, 1521, 1526, "2 . 1", "", +75273, Reduction, 1531, 1536, "5 . 7", "", +75275, SdErrorChangeValue, 1539, 1544, "3 . 2", "", +75276, mmHg, 1545, 1550, "mm Hg", "", +75277, Lat/TimFC, 1554, 1558, "LTFC", "", +75279, PValueChangeValue, 1630, 1641, "P = 0 . 001", "", +75286, ObservedResult, 1646, 1780, "A decrease in the daytime IOP fluctuation was observed in both groups over time , but the decrease in each group was not significant .", "", +75282, IOP, 1672, 1675, "IOP", "", +75288, TimePoint, 1784, 1790, "week 8", "", +75290, Mean, 1797, 1801, "mean", "", +75291, IOP, 1802, 1805, "IOP", "", +75293, Lat/TimFC, 1905, 1909, "LTFC", "", +75294, PvalueDiff, 1918, 1929, "P = 0 . 024", "", +75295, ConclusionComment, 2000, 2141, "The concomitant use of latanoprost and timolol gel - forming solution leads to a larger additional IOP reduction and lower daytime IOP levels", "", +75297, Latanoprost, 2023, 2034, "latanoprost", "", +75301, Timolol, 2039, 2069, "timolol gel - forming solution", "", +75302, IOP, 2099, 2102, "IOP", "", +75304, IOP, 2131, 2134, "IOP", "", +75296, ConclusionComment, 2142, 2182, "as compared with the fixed combination .", "", +75305, PMID, 2231, 2239, "25264990", "", diff --git a/data/gl 25264990_jshahinitiran.n-triples b/data/gl 25264990_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25264990_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25264990_tstrakeljahn.annodb b/data/gl 25264990_tstrakeljahn.annodb new file mode 100644 index 0000000..b01c913 --- /dev/null +++ b/data/gl 25264990_tstrakeljahn.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84435, Journal, 0, 10, "J Glaucoma", "", +84436, PublicationYear, 13, 17, "2016", "", +84357, Title, 88, 253, "The Efficacy of a Latanoprost / Timolol Fixed Combination Versus Latanoprost and Timolol Gel - forming Solution Unfixed Combination on Daytime Intraocular Pressure .", "", +84349, Latanoprost, 106, 117, "Latanoprost", "", +84351, Lat/TimFC, 106, 127, "Latanoprost / Timolol", "", +84350, Timolol, 120, 127, "Timolol", "", +84353, Latanoprost, 153, 164, "Latanoprost", "", +84347, Drug, 169, 199, "Timolol Gel - forming Solution", "Timolol Gel-forming solution", +84352, IOP, 231, 251, "Intraocular Pressure", "", +84354, Author, 254, 262, "Ö zyol E", "", +84355, Author, 271, 279, "Ö zyol P", "", +84356, Turkey, 369, 375, "Turkey", "", +84366, ObjectiveDescription, 388, 616, "To evaluate the effect of a latanoprost / timolol fixed combination ( LTFC ) versus a latanoprost and timolol gel - forming solution unfixed combination ( LTuFC ) on daytime intraocular pressure ( IOP ) levels and fluctuations .", "", +84358, Latanoprost, 416, 427, "latanoprost", "", +84360, Lat/TimFC, 416, 437, "latanoprost / timolol", "", +84359, Timolol, 430, 437, "timolol", "", +84361, Lat/TimFC, 458, 462, "LTFC", "", +84362, Latanoprost, 474, 485, "latanoprost", "", +84363, Drug, 490, 501, "timolol gel", "Timolol Gel-forming solution", +84364, IOP, 562, 582, "intraocular pressure", "", +84365, IOP, 585, 588, "IOP", "", +84367, Duration, 639, 647, "8 - week", "", +84368, Randomized, 650, 660, "randomized", "", +84369, Parallel, 663, 671, "parallel", "", +84370, NumberPatientsCT, 703, 705, "90", "", +84371, Primary_OpenAngleGlaucoma, 730, 759, "primary open - angle glaucoma", "", +84372, OcularHypertension, 763, 782, "ocular hypertension", "", +84373, Latanoprost, 824, 835, "latanoprost", "", +84374, Randomized, 864, 874, "Randomized", "", +84379, Frequency, 902, 921, "single evening dose", "", +84375, Evening, 909, 916, "evening", "", +84376, Lat/TimFC, 925, 929, "LTFC", "", +84377, Latanoprost, 956, 967, "latanoprost", "", +84378, Frequency, 981, 991, "once daily", "", +84380, Drug, 1011, 1041, "timolol gel - forming solution", "Timolol Gel-forming solution", +84382, Frequency, 1055, 1065, "once daily", "", +84383, Morning, 1073, 1080, "morning", "", +84384, IOP, 1108, 1111, "IOP", "", +84385, TimePoint, 1139, 1143, "8 AM", "", +84386, TimePoint, 1146, 1151, "11 AM", "", +84387, TimePoint, 1154, 1158, "2 PM", "", +84388, TimePoint, 1165, 1169, "5 PM", "", +84389, Mean, 1176, 1180, "mean", "", +84390, IOP, 1181, 1184, "IOP", "", +84391, IOP, 1195, 1198, "IOP", "", +84392, IOP, 1233, 1236, "IOP", "", +84393, TimePoint, 1254, 1261, "weeks 4", "", +84394, TimePoint, 1254, 1267, "weeks 4 and 8", "", +84413, ObservedResult, 1280, 1378, "The mean IOP reduction from baseline to each visit was significant in both groups ( P < 0 . 01 ) .", "", +84395, Mean, 1284, 1288, "mean", "", +84396, IOP, 1289, 1292, "IOP", "", +84397, PValueChangeValue, 1366, 1374, "< 0 . 01", "", +84412, ObservedResult, 1379, 1473, "There was a significant difference in the mean IOP between groups at week 4 ( P = 0 . 0021 ) .", "", +84398, Mean, 1421, 1425, "mean", "", +84399, IOP, 1426, 1429, "IOP", "", +84400, TimePoint, 1448, 1454, "week 4", "", +84401, PvalueDiff, 1459, 1469, "= 0 . 0021", "", +84402, TimePoint, 1477, 1483, "week 8", "", +84403, Mean, 1490, 1494, "mean", "", +84404, IOP, 1495, 1498, "IOP", "", +84405, Reduction, 1513, 1518, "3 . 2", "", +84407, SdDevChangeValue, 1521, 1526, "2 . 1", "", +84406, Reduction, 1531, 1536, "5 . 7", "", +84408, SdDevChangeValue, 1539, 1544, "3 . 2", "", +84409, mmHg, 1545, 1550, "mm Hg", "", +84410, Lat/TimFC, 1554, 1558, "LTFC", "", +84411, PvalueDiff, 1632, 1641, "= 0 . 001", "", +84415, ObservedResult, 1646, 1780, "A decrease in the daytime IOP fluctuation was observed in both groups over time , but the decrease in each group was not significant .", "", +84414, IOP, 1672, 1675, "IOP", "", +84428, ObservedResult, 1781, 1985, "At week 8 , the mean IOP measurements at 8 AM , 11 AM , 2 PM , and 5 PM in LTuFC group were significantly lower than in the LTFC group ( P = 0 . 024 , 0 . 0001 , 0 . 0008 , and 0 . 0011 , respectively ) .", "", +84416, TimePoint, 1784, 1790, "week 8", "", +84417, Mean, 1797, 1801, "mean", "", +84418, IOP, 1802, 1805, "IOP", "", +84419, TimePoint, 1822, 1826, "8 AM", "", +84420, TimePoint, 1829, 1834, "11 AM", "", +84421, TimePoint, 1837, 1841, "2 PM", "", +84422, TimePoint, 1848, 1852, "5 PM", "", +84423, Lat/TimFC, 1905, 1909, "LTFC", "", +84424, PvalueDiff, 1920, 1929, "= 0 . 024", "", +84425, PvalueDiff, 1932, 1940, "0 . 0001", "", +84426, PvalueDiff, 1943, 1951, "0 . 0008", "", +84427, PvalueDiff, 1958, 1966, "0 . 0011", "", +84433, ConclusionComment, 2000, 2182, "The concomitant use of latanoprost and timolol gel - forming solution leads to a larger additional IOP reduction and lower daytime IOP levels as compared with the fixed combination .", "", +84429, Latanoprost, 2023, 2034, "latanoprost", "", +84430, Drug, 2039, 2069, "timolol gel - forming solution", "Timolol Gel-forming solution", +84431, IOP, 2099, 2102, "IOP", "", +84432, IOP, 2131, 2134, "IOP", "", +84434, PMID, 2231, 2239, "25264990", "", diff --git a/data/gl 25264990_tstrakeljahn.n-triples b/data/gl 25264990_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25264990_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25430900_admin.annodb b/data/gl 25430900_admin.annodb new file mode 100644 index 0000000..50210bb --- /dev/null +++ b/data/gl 25430900_admin.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 10, "Adv Ther .", "", " \"Adv Ther .\"." +1, PublicationYear, 11, 15, "2014", "", " \"2014\"." +2, Randomized, 109, 119, "Randomized", "", " ." +54, Title, 109, 243, "Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open - angle glaucoma or ocular hypertension .", "", " \"Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open - angle glaucoma or ocular hypertension .\"." +38466, Brinz/BrimoFC, 129, 155, "brinzolamide / brimonidine", "", +3, Brinzolamide, 129, 141, "brinzolamide", "", +4, Brimonidine, 144, 155, "brimonidine", "", +5, Brinzolamide, 163, 175, "brinzolamide", "", +6, Brimonidine, 181, 192, "brimonidine", "", +7, OpenAngleGlaucoma, 197, 218, "open - angle glaucoma", "", " ." +8, OcularHypertension, 222, 241, "ocular hypertension", "", " ." +9, Author, 244, 255, "Gandolfi SA", "", " \"Gandolfi SA\"." +10, Author, 264, 269, "Lim J", "", " \"Lim J\"." +11, Author, 272, 282, "Sanseau AC", "", " \"Sanseau AC\"." +12, Author, 285, 302, "Parra Restrepo JC", "", " \"Parra Restrepo JC\"." +13, Author, 305, 315, "Hamacher T", "", " \"Hamacher T\"." +14, Italy, 471, 476, "Italy", "", " ." +18, ObjectiveDescription, 528, 713, "Fixed - combination intraocular pressure ( IOP ) - lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP .", "", " \"Fixed - combination intraocular pressure ( IOP ) - lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP .\"." +15, IOP, 548, 568, "intraocular pressure", "", +16, IOP, 571, 574, "IOP", "", +17, IOP, 708, 711, "IOP", "", +92, ObjectiveDescription, 714, 900, "The aim of this study was to evaluate the safety and efficacy of fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) versus concomitant administration of brinzolamide 1 %", "", " \"The aim of this study was to evaluate the safety and efficacy of fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) versus concomitant administration of brinzolamide 1 %\"." +94, Brinzolamide, 799, 811, "brinzolamide", "", " ." +38467, Brinz/BrimoFC, 799, 837, "brinzolamide 1 % / brimonidine 0 . 2 %", "", +96, DoseValue, 812, 813, "1", "", " \"1\"." +33381, Percentage, 814, 815, "%", "", " ." +95, Brimonidine, 818, 829, "brimonidine", "", " ." +97, DoseValue, 830, 835, "0 . 2", "", " \"0 . 2\"." +33382, Percentage, 836, 837, "%", "", " ." +38468, Brinz/BrimoFC, 840, 844, "BBFC", "", +101, Brinzolamide, 884, 896, "brinzolamide", "", " ." +99, DoseValue, 897, 898, "1", "", " \"1\"." +33383, Percentage, 899, 900, "%", "", " ." +93, ObjectiveDescription, 901, 1008, "plus brimonidine 0 . 2 % ( BRINZ  +  BRIM ) in patients with open - angle glaucoma or ocular hypertension .", "", " \"plus brimonidine 0 . 2 % ( BRINZ  +  BRIM ) in patients with open - angle glaucoma or ocular hypertension .\"." +102, Brimonidine, 906, 917, "brimonidine", "", " ." +98, DoseValue, 918, 923, "0 . 2", "", " \"0 . 2\"." +33384, Percentage, 924, 925, "%", "", " ." +103, OpenAngleGlaucoma, 962, 983, "open - angle glaucoma", "", +104, OcularHypertension, 987, 1006, "ocular hypertension", "", +60185, Prospective, 1030, 1041, "prospective", "", " ." +21, Multicenter, 1054, 1065, "multicenter", "", " ." +22, DoubleBlind, 1068, 1083, "double - masked", "", " ." +23, Duration, 1086, 1095, "6 - month", "", " \"6 - month\"." +33387, Precondition, 1104, 1215, "Patients who had insufficient IOP control with monotherapy or who were receiving   2 IOP - lowering medications", "", " \"Patients who had insufficient IOP control with monotherapy or who were receiving   2 IOP - lowering medications\"." +24, IOP, 1134, 1137, "IOP", "", +25, IOP, 1189, 1192, "IOP", "", +26, Randomized, 1221, 1231, "randomized", "", +115, AllocationRatio, 1232, 1237, "1 : 1", "", " . ." +116, Frequency, 1249, 1262, "twice - daily", "", " \"twice - daily\". \"twice - daily\"." +38469, Brinz/BrimoFC, 1263, 1267, "BBFC", "", +38475, Brinzolamide, 1271, 1276, "BRINZ", "", +38476, Brimonidine, 1281, 1285, "BRIM", "", +29, IOP, 1288, 1291, "IOP", "", +119, TimePoint, 1340, 1346, "week 2", "", +120, TimePoint, 1349, 1355, "week 6", "", +121, TimePoint, 1358, 1365, "month 3", "", +122, TimePoint, 1372, 1379, "month 6", "", +31, Mean, 1423, 1427, "mean", "", +30, Diurnal_IOP, 1428, 1439, "diurnal IOP", "", +121, TimePoint, 1464, 1471, "month 3", "", +33, Mean, 1623, 1627, "mean", "", +34, IOP, 1628, 1631, "IOP", "", +35, IOP, 1634, 1637, "IOP", "", +33394, EndPointDescription, 1665, 1709, "percentage of patients with IOP  < 18   mmHg", "", +129, IOP, 1693, 1696, "IOP", "", +130, mmHg, 1705, 1709, "mmHg", "", +37, Mean, 1757, 1761, "mean", "", " . ." +38, Diurnal_IOP, 1762, 1773, "diurnal IOP", "", " ." +38474, Brinz/BrimoFC, 1800, 1804, "BBFC", "", +133, LeastSquaresMean, 1807, 1825, "least squares mean", "", +42, Reduction, 1847, 1852, "8 . 5", "", " \"8 . 5\"." +135, SdErrorChangeValue, 1857, 1863, "0 . 16", "", " \"0 . 16\"." +46, mmHg, 1866, 1870, "mmHg", "", " ." +38472, Brinzolamide, 1902, 1907, "BRINZ", "", +38473, Brimonidine, 1912, 1916, "BRIM", "", +44, Reduction, 1921, 1926, "8 . 3", "", " \"8 . 3\"." +138, SdErrorChangeValue, 1931, 1937, "0 . 16", "", " \"0 . 16\"." +47, mmHg, 1940, 1944, "mmHg", "", +48, Mean, 1947, 1951, "mean", "", +33398, DiffGroupAbsValue, 1963, 1970, "- 0 . 1", "", " \"- 0 . 1\"." +50, mmHg, 1973, 1977, "mmHg", "", +143, ConfIntervalDiff, 1980, 2004, "95 % CI - 0 . 5 to 0 . 2", "", " \"95 % CI - 0 . 5 to 0 . 2\"." +52, mmHg, 2007, 2011, "mmHg", "", +39, ObservedResult, 2016, 2088, "The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points", "", " \"The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points\". \"The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points\"." +145, mmHg, 2065, 2069, "mmHg", "", +38477, TimePoint, 2106, 2114, "baseline", "", +58, mmHg, 2122, 2126, "mmHg", "", +33399, LeastSquaresMean, 2145, 2163, "least squares mean", "", +56, Diurnal_IOP, 2164, 2175, "diurnal IOP", "", +57, TimePoint, 2203, 2209, "week 2", "", +167, TimePoint, 2227, 2247, "the end of the study", "", +61, ObservedResult, 2344, 2540, "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .", "", " \"The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .\". \"The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .\". \"The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .\". \"The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .\"." +59, ConjunctivalHyperemia, 2395, 2404, "hyperemia", "", " ." +60, ConjunctivalHyperemia, 2440, 2462, "conjunctival hyperemia", "", +33403, EndPointDescription, 2467, 2486, "visual disturbances", "AdverseEffect", " . ." +33401, EndPointDescription, 2489, 2514, "ocular allergic reactions", "AdverseEffect", " . ." +33402, EndPointDescription, 2521, 2538, "ocular discomfort", "AdverseEffect", " . ." +62, ObservedResult, 2541, 2642, "Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness .", "", " \"Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness .\". \"Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness .\". \"Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness .\"." +33404, EndPointDescription, 2589, 2598, "dysgeusia", "AdverseEffect", " . ." +92879, OralDryness, 2601, 2613, "oral dryness", "", " ." +33406, EndPointDescription, 2620, 2640, "fatigue / drowsiness", "AdverseEffect", " . ." +69, ConclusionComment, 2656, 2793, "Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination was as well tolerated and effective as concomitant therapy with its components .", "", " \"Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination was as well tolerated and effective as concomitant therapy with its components .\"." +38470, Brinz/BrimoFC, 2656, 2694, "Brinzolamide 1 % / brimonidine 0 . 2 %", "", +63, Brinzolamide, 2656, 2668, "Brinzolamide", "", +65, DoseValue, 2669, 2670, "1", "", +67, Percentage, 2671, 2672, "%", "", +64, Brimonidine, 2675, 2686, "brimonidine", "", +66, DoseValue, 2687, 2692, "0 . 2", "", +68, Percentage, 2693, 2694, "%", "", +160, ConclusionComment, 2794, 2885, "BBFC reduces treatment burden in patients who require multiple IOP - lowering medications .", "", " \"BBFC reduces treatment burden in patients who require multiple IOP - lowering medications .\"." +38471, Brinz/BrimoFC, 2794, 2798, "BBFC", "", +70, IOP, 2857, 2860, "IOP", "", +72, PMID, 2954, 2962, "25430900", "", " \"25430900\"." diff --git a/data/gl 25430900_admin.n-triples b/data/gl 25430900_admin.n-triples new file mode 100644 index 0000000..b7866ae --- /dev/null +++ b/data/gl 25430900_admin.n-triples @@ -0,0 +1,208 @@ +# RDF export of group: Publication + . + "Publication" . + "Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open - angle glaucoma or ocular hypertension ." . + "Gandolfi SA" . + "2014" . + "Adv Ther ." . + "25430900" . + . + "Lim J" . + "Sanseau AC" . + "Parra Restrepo JC" . + "Hamacher T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "Fixed - combination intraocular pressure ( IOP ) - lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP ." . + "6 - month" . + . + . + . + . + "Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination was as well tolerated and effective as concomitant therapy with its components ." . + . + . + . + . + . + "The aim of this study was to evaluate the safety and efficacy of fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) versus concomitant administration of brinzolamide 1 %" . + "plus brimonidine 0 . 2 % ( BRINZ  +  BRIM ) in patients with open - angle glaucoma or ocular hypertension ." . + . + . + . + "BBFC reduces treatment burden in patients who require multiple IOP - lowering medications ." . + . + . +# RDF export of group: Population + . + "Population" . + "Patients who had insufficient IOP control with monotherapy or who were receiving   2 IOP - lowering medications" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint d IOP " . + . + . + . + . + . + . + "Endpoint CH" . + . + . + . + . + . + "Endpoint VD" . + . + . + . + . + . + . + "Endpoint OAR" . + . + . + . + . + . + . + "Endpoint OD" . + . + . + . + . + . + . + "Endpoint D" . + . + . + . + . + . + . + "Endpoint oral dryness" . + . + . + . + . + . + "Endpoint f/d" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Brinz/BrimoFC" . + . + . + . + . + . + . + . + . + . + . + "Arm BRINZ + BRIM" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention Brinz/BrimoFC" . + . + "twice - daily" . + . + . + . + "Intervention BRINZ + BRIM" . + . + "twice - daily" . + . + . +# RDF export of group: Medication + . + "Medication brin1" . + . + "1" . + . + . + . + "Medication brim1" . + . + "0 . 2" . + . + . + . + "Medication brin2" . + . + "1" . + . + . + . + "Medication brim2" . + . + "0 . 2" . + . + . +# RDF export of group: Outcome + . + "Outcome d IOP bb1" . + . + "8 . 5" . + "0 . 16" . + "The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points" . + . + "Outcome d IOP bb2" . + . + "8 . 3" . + "0 . 16" . + "The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points" . + . + "Outcome CH both treatments " . + . + "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort ." . + . + "Outcome VD both treatments" . + . + "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort ." . + . + "Outcome OAD both treatments" . + . + "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort ." . + . + "Outcome OD both treatments" . + . + "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort ." . + . + "Outcome D both treatments" . + . + "Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness ." . + . + "Outcome oral dryness" . + . + "Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness ." . + . + "Outcome f/d" . + . + "Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups d IOP " . + "- 0 . 1" . + "95 % CI - 0 . 5 to 0 . 2" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25430900_export.csv b/data/gl 25430900_export.csv new file mode 100644 index 0000000..d2e958e --- /dev/null +++ b/data/gl 25430900_export.csv @@ -0,0 +1,601 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +414, 1, 1, 1, 0, 3, 0, 3, "Adv" +414, 1, 2, 2, 4, 8, 4, 8, "Ther" +414, 1, 3, 3, 9, 10, 9, 10, "." +414, 2, 1, 4, 0, 4, 11, 15, "2014" +414, 2, 2, 5, 5, 8, 16, 19, "Dec" +414, 2, 3, 6, 9, 10, 20, 21, ";" +414, 2, 4, 7, 11, 13, 22, 24, "31" +414, 2, 5, 8, 14, 15, 25, 26, "(" +414, 2, 6, 9, 16, 18, 27, 29, "12" +414, 2, 7, 10, 19, 20, 30, 31, ")" +414, 2, 8, 11, 21, 22, 32, 33, ":" +414, 2, 9, 12, 23, 27, 34, 38, "1213" +414, 2, 10, 13, 28, 29, 39, 40, "-" +414, 2, 11, 14, 30, 32, 41, 43, "27" +414, 2, 12, 15, 33, 34, 44, 45, "." +414, 2, 13, 16, 35, 38, 46, 49, "doi" +414, 2, 14, 17, 39, 40, 50, 51, ":" +414, 2, 15, 18, 41, 43, 52, 54, "10" +414, 2, 16, 19, 44, 45, 55, 56, "." +414, 2, 17, 20, 46, 50, 57, 61, "1007" +414, 2, 18, 21, 51, 52, 62, 63, "/" +414, 2, 19, 22, 53, 59, 64, 70, "s12325" +414, 2, 20, 23, 60, 61, 71, 72, "-" +414, 2, 21, 24, 62, 65, 73, 76, "014" +414, 2, 22, 25, 66, 67, 77, 78, "-" +414, 2, 23, 26, 68, 72, 79, 83, "0168" +414, 2, 24, 27, 73, 74, 84, 85, "-" +414, 2, 25, 28, 75, 76, 86, 87, "y" +414, 2, 26, 29, 77, 78, 88, 89, "." +414, 3, 1, 30, 0, 4, 90, 94, "Epub" +414, 3, 2, 31, 5, 9, 95, 99, "2014" +414, 3, 3, 32, 10, 13, 100, 103, "Nov" +414, 3, 4, 33, 14, 16, 104, 106, "28" +414, 3, 5, 34, 17, 18, 107, 108, "." +414, 4, 1, 35, 0, 10, 109, 119, "Randomized" +414, 4, 2, 36, 11, 16, 120, 125, "trial" +414, 4, 3, 37, 17, 19, 126, 128, "of" +414, 4, 4, 38, 20, 32, 129, 141, "brinzolamide" +414, 4, 5, 39, 33, 34, 142, 143, "/" +414, 4, 6, 40, 35, 46, 144, 155, "brimonidine" +414, 4, 7, 41, 47, 53, 156, 162, "versus" +414, 4, 8, 42, 54, 66, 163, 175, "brinzolamide" +414, 4, 9, 43, 67, 71, 176, 180, "plus" +414, 4, 10, 44, 72, 83, 181, 192, "brimonidine" +414, 4, 11, 45, 84, 87, 193, 196, "for" +414, 4, 12, 46, 88, 92, 197, 201, "open" +414, 4, 13, 47, 93, 94, 202, 203, "-" +414, 4, 14, 48, 95, 100, 204, 209, "angle" +414, 4, 15, 49, 101, 109, 210, 218, "glaucoma" +414, 4, 16, 50, 110, 112, 219, 221, "or" +414, 4, 17, 51, 113, 119, 222, 228, "ocular" +414, 4, 18, 52, 120, 132, 229, 241, "hypertension" +414, 4, 19, 53, 133, 134, 242, 243, "." +414, 5, 1, 54, 0, 8, 244, 252, "Gandolfi" +414, 5, 2, 55, 9, 11, 253, 255, "SA" +414, 5, 3, 56, 12, 13, 256, 257, "(" +414, 5, 4, 57, 14, 15, 258, 259, "1" +414, 5, 5, 58, 16, 17, 260, 261, ")" +414, 5, 6, 59, 18, 19, 262, 263, "," +414, 5, 7, 60, 20, 23, 264, 267, "Lim" +414, 5, 8, 61, 24, 25, 268, 269, "J" +414, 5, 9, 62, 26, 27, 270, 271, "," +414, 5, 10, 63, 28, 35, 272, 279, "Sanseau" +414, 5, 11, 64, 36, 38, 280, 282, "AC" +414, 5, 12, 65, 39, 40, 283, 284, "," +414, 5, 13, 66, 41, 46, 285, 290, "Parra" +414, 5, 14, 67, 47, 55, 291, 299, "Restrepo" +414, 5, 15, 68, 56, 58, 300, 302, "JC" +414, 5, 16, 69, 59, 60, 303, 304, "," +414, 5, 17, 70, 61, 69, 305, 313, "Hamacher" +414, 5, 18, 71, 70, 71, 314, 315, "T" +414, 5, 19, 72, 72, 73, 316, 317, "." +414, 5, 20, 73, 74, 80, 318, 324, "Author" +414, 5, 21, 74, 81, 92, 325, 336, "information" +414, 5, 22, 75, 93, 94, 337, 338, ":" +414, 5, 23, 76, 95, 96, 339, 340, "(" +414, 5, 24, 77, 97, 98, 341, 342, "1" +414, 5, 25, 78, 99, 100, 343, 344, ")" +414, 5, 26, 79, 101, 105, 345, 349, "Unit" +414, 5, 27, 80, 106, 107, 350, 351, "à" +414, 5, 28, 81, 108, 110, 352, 354, "di" +414, 5, 29, 82, 111, 123, 355, 367, "Oftalmologia" +414, 5, 30, 83, 124, 125, 368, 369, "," +414, 5, 31, 84, 126, 129, 370, 373, "Dip" +414, 5, 32, 85, 130, 131, 374, 375, "." +414, 6, 1, 86, 0, 7, 376, 383, "Scienze" +414, 6, 2, 87, 8, 18, 384, 394, "Biomediche" +414, 6, 3, 88, 19, 34, 395, 410, "Biotecnologiche" +414, 6, 4, 89, 35, 36, 411, 412, "e" +414, 6, 5, 90, 37, 50, 413, 426, "Traslazionali" +414, 6, 6, 91, 51, 52, 427, 428, "," +414, 6, 7, 92, 53, 63, 429, 439, "Universita" +414, 6, 8, 93, 64, 69, 440, 445, "degli" +414, 6, 9, 94, 70, 75, 446, 451, "Studi" +414, 6, 10, 95, 76, 78, 452, 454, "di" +414, 6, 11, 96, 79, 84, 455, 460, "Parma" +414, 6, 12, 97, 85, 86, 461, 462, "," +414, 6, 13, 98, 87, 92, 463, 468, "Parma" +414, 6, 14, 99, 93, 94, 469, 470, "," +414, 6, 15, 100, 95, 100, 471, 476, "Italy" +414, 6, 16, 101, 101, 102, 477, 478, "," +414, 6, 17, 102, 103, 110, 479, 486, "stefano" +414, 6, 18, 103, 111, 112, 487, 488, "." +414, 6, 19, 104, 113, 121, 489, 497, "gandolfi" +414, 6, 20, 105, 122, 123, 498, 499, "@" +414, 6, 21, 106, 124, 129, 500, 505, "unipr" +414, 6, 22, 107, 130, 131, 506, 507, "." +414, 6, 23, 108, 132, 134, 508, 510, "it" +414, 6, 24, 109, 135, 136, 511, 512, "." +414, 7, 1, 110, 0, 12, 513, 525, "INTRODUCTION" +414, 7, 2, 111, 13, 14, 526, 527, ":" +414, 7, 3, 112, 15, 20, 528, 533, "Fixed" +414, 7, 4, 113, 21, 22, 534, 535, "-" +414, 7, 5, 114, 23, 34, 536, 547, "combination" +414, 7, 6, 115, 35, 46, 548, 559, "intraocular" +414, 7, 7, 116, 47, 55, 560, 568, "pressure" +414, 7, 8, 117, 56, 57, 569, 570, "(" +414, 7, 9, 118, 58, 61, 571, 574, "IOP" +414, 7, 10, 119, 62, 63, 575, 576, ")" +414, 7, 11, 120, 64, 65, 577, 578, "-" +414, 7, 12, 121, 66, 74, 579, 587, "lowering" +414, 7, 13, 122, 75, 86, 588, 599, "medications" +414, 7, 14, 123, 87, 95, 600, 608, "simplify" +414, 7, 15, 124, 96, 105, 609, 618, "treatment" +414, 7, 16, 125, 106, 114, 619, 627, "regimens" +414, 7, 17, 126, 115, 118, 628, 631, "for" +414, 7, 18, 127, 119, 127, 632, 640, "patients" +414, 7, 19, 128, 128, 137, 641, 650, "requiring" +414, 7, 20, 129, 138, 139, 651, 652, "2" +414, 7, 21, 130, 140, 146, 653, 659, "ocular" +414, 7, 22, 131, 147, 158, 660, 671, "hypotensive" +414, 7, 23, 132, 159, 165, 672, 678, "agents" +414, 7, 24, 133, 166, 168, 679, 681, "to" +414, 7, 25, 134, 169, 177, 682, 690, "maintain" +414, 7, 26, 135, 178, 190, 691, 703, "sufficiently" +414, 7, 27, 136, 191, 194, 704, 707, "low" +414, 7, 28, 137, 195, 198, 708, 711, "IOP" +414, 7, 29, 138, 199, 200, 712, 713, "." +414, 8, 1, 139, 0, 3, 714, 717, "The" +414, 8, 2, 140, 4, 7, 718, 721, "aim" +414, 8, 3, 141, 8, 10, 722, 724, "of" +414, 8, 4, 142, 11, 15, 725, 729, "this" +414, 8, 5, 143, 16, 21, 730, 735, "study" +414, 8, 6, 144, 22, 25, 736, 739, "was" +414, 8, 7, 145, 26, 28, 740, 742, "to" +414, 8, 8, 146, 29, 37, 743, 751, "evaluate" +414, 8, 9, 147, 38, 41, 752, 755, "the" +414, 8, 10, 148, 42, 48, 756, 762, "safety" +414, 8, 11, 149, 49, 52, 763, 766, "and" +414, 8, 12, 150, 53, 61, 767, 775, "efficacy" +414, 8, 13, 151, 62, 64, 776, 778, "of" +414, 8, 14, 152, 65, 70, 779, 784, "fixed" +414, 8, 15, 153, 71, 72, 785, 786, "-" +414, 8, 16, 154, 73, 84, 787, 798, "combination" +414, 8, 17, 155, 85, 97, 799, 811, "brinzolamide" +414, 8, 18, 156, 98, 99, 812, 813, "1" +414, 8, 19, 157, 100, 101, 814, 815, "%" +414, 8, 20, 158, 102, 103, 816, 817, "/" +414, 8, 21, 159, 104, 115, 818, 829, "brimonidine" +414, 8, 22, 160, 116, 117, 830, 831, "0" +414, 8, 23, 161, 118, 119, 832, 833, "." +414, 8, 24, 162, 120, 121, 834, 835, "2" +414, 8, 25, 163, 122, 123, 836, 837, "%" +414, 8, 26, 164, 124, 125, 838, 839, "(" +414, 8, 27, 165, 126, 130, 840, 844, "BBFC" +414, 8, 28, 166, 131, 132, 845, 846, ")" +414, 8, 29, 167, 133, 139, 847, 853, "versus" +414, 8, 30, 168, 140, 151, 854, 865, "concomitant" +414, 8, 31, 169, 152, 166, 866, 880, "administration" +414, 8, 32, 170, 167, 169, 881, 883, "of" +414, 8, 33, 171, 170, 182, 884, 896, "brinzolamide" +414, 8, 34, 172, 183, 184, 897, 898, "1" +414, 8, 35, 173, 185, 186, 899, 900, "%" +414, 8, 36, 174, 187, 191, 901, 905, "plus" +414, 8, 37, 175, 192, 203, 906, 917, "brimonidine" +414, 8, 38, 176, 204, 205, 918, 919, "0" +414, 8, 39, 177, 206, 207, 920, 921, "." +414, 8, 40, 178, 208, 209, 922, 923, "2" +414, 8, 41, 179, 210, 211, 924, 925, "%" +414, 8, 42, 180, 212, 213, 926, 927, "(" +414, 8, 43, 181, 214, 219, 928, 933, "BRINZ" +414, 8, 44, 182, 220, 223, 934, 937, " + " +414, 8, 45, 183, 224, 228, 938, 942, "BRIM" +414, 8, 46, 184, 229, 230, 943, 944, ")" +414, 8, 47, 185, 231, 233, 945, 947, "in" +414, 8, 48, 186, 234, 242, 948, 956, "patients" +414, 8, 49, 187, 243, 247, 957, 961, "with" +414, 8, 50, 188, 248, 252, 962, 966, "open" +414, 8, 51, 189, 253, 254, 967, 968, "-" +414, 8, 52, 190, 255, 260, 969, 974, "angle" +414, 8, 53, 191, 261, 269, 975, 983, "glaucoma" +414, 8, 54, 192, 270, 272, 984, 986, "or" +414, 8, 55, 193, 273, 279, 987, 993, "ocular" +414, 8, 56, 194, 280, 292, 994, 1006, "hypertension" +414, 8, 57, 195, 293, 294, 1007, 1008, "." +414, 9, 1, 196, 0, 7, 1009, 1016, "METHODS" +414, 9, 2, 197, 8, 9, 1017, 1018, ":" +414, 9, 3, 198, 10, 14, 1019, 1023, "This" +414, 9, 4, 199, 15, 18, 1024, 1027, "was" +414, 9, 5, 200, 19, 20, 1028, 1029, "a" +414, 9, 6, 201, 21, 32, 1030, 1041, "prospective" +414, 9, 7, 202, 33, 34, 1042, 1043, "," +414, 9, 8, 203, 35, 40, 1044, 1049, "phase" +414, 9, 9, 204, 41, 42, 1050, 1051, "3" +414, 9, 10, 205, 43, 44, 1052, 1053, "," +414, 9, 11, 206, 45, 56, 1054, 1065, "multicenter" +414, 9, 12, 207, 57, 58, 1066, 1067, "," +414, 9, 13, 208, 59, 65, 1068, 1074, "double" +414, 9, 14, 209, 66, 67, 1075, 1076, "-" +414, 9, 15, 210, 68, 74, 1077, 1083, "masked" +414, 9, 16, 211, 75, 76, 1084, 1085, "," +414, 9, 17, 212, 77, 78, 1086, 1087, "6" +414, 9, 18, 213, 79, 80, 1088, 1089, "-" +414, 9, 19, 214, 81, 86, 1090, 1095, "month" +414, 9, 20, 215, 87, 92, 1096, 1101, "trial" +414, 9, 21, 216, 93, 94, 1102, 1103, "." +414, 10, 1, 217, 0, 8, 1104, 1112, "Patients" +414, 10, 2, 218, 9, 12, 1113, 1116, "who" +414, 10, 3, 219, 13, 16, 1117, 1120, "had" +414, 10, 4, 220, 17, 29, 1121, 1133, "insufficient" +414, 10, 5, 221, 30, 33, 1134, 1137, "IOP" +414, 10, 6, 222, 34, 41, 1138, 1145, "control" +414, 10, 7, 223, 42, 46, 1146, 1150, "with" +414, 10, 8, 224, 47, 58, 1151, 1162, "monotherapy" +414, 10, 9, 225, 59, 61, 1163, 1165, "or" +414, 10, 10, 226, 62, 65, 1166, 1169, "who" +414, 10, 11, 227, 66, 70, 1170, 1174, "were" +414, 10, 12, 228, 71, 80, 1175, 1184, "receiving" +414, 10, 13, 229, 81, 82, 1185, 1186, " " +414, 10, 14, 230, 83, 84, 1187, 1188, "2" +414, 10, 15, 231, 85, 88, 1189, 1192, "IOP" +414, 10, 16, 232, 89, 90, 1193, 1194, "-" +414, 10, 17, 233, 91, 99, 1195, 1203, "lowering" +414, 10, 18, 234, 100, 111, 1204, 1215, "medications" +414, 10, 19, 235, 112, 116, 1216, 1220, "were" +414, 10, 20, 236, 117, 127, 1221, 1231, "randomized" +414, 10, 21, 237, 128, 129, 1232, 1233, "1" +414, 10, 22, 238, 130, 131, 1234, 1235, ":" +414, 10, 23, 239, 132, 133, 1236, 1237, "1" +414, 10, 24, 240, 134, 136, 1238, 1240, "to" +414, 10, 25, 241, 137, 144, 1241, 1248, "receive" +414, 10, 26, 242, 145, 150, 1249, 1254, "twice" +414, 10, 27, 243, 151, 152, 1255, 1256, "-" +414, 10, 28, 244, 153, 158, 1257, 1262, "daily" +414, 10, 29, 245, 159, 163, 1263, 1267, "BBFC" +414, 10, 30, 246, 164, 166, 1268, 1270, "or" +414, 10, 31, 247, 167, 172, 1271, 1276, "BRINZ" +414, 10, 32, 248, 173, 176, 1277, 1280, " + " +414, 10, 33, 249, 177, 181, 1281, 1285, "BRIM" +414, 10, 34, 250, 182, 183, 1286, 1287, "." +414, 11, 1, 251, 0, 3, 1288, 1291, "IOP" +414, 11, 2, 252, 4, 7, 1292, 1295, "was" +414, 11, 3, 253, 8, 16, 1296, 1304, "assessed" +414, 11, 4, 254, 17, 19, 1305, 1307, "at" +414, 11, 5, 255, 20, 21, 1308, 1309, "9" +414, 11, 6, 256, 22, 23, 1310, 1311, "a" +414, 11, 7, 257, 24, 25, 1312, 1313, "." +414, 11, 8, 258, 26, 27, 1314, 1315, "m" +414, 11, 9, 259, 28, 29, 1316, 1317, "." +414, 11, 10, 260, 30, 33, 1318, 1321, "and" +414, 11, 11, 261, 34, 36, 1322, 1324, "11" +414, 11, 12, 262, 37, 38, 1325, 1326, "a" +414, 11, 13, 263, 39, 40, 1327, 1328, "." +414, 11, 14, 264, 41, 42, 1329, 1330, "m" +414, 11, 15, 265, 43, 44, 1331, 1332, "." +414, 11, 16, 266, 45, 51, 1333, 1339, "during" +414, 11, 17, 267, 52, 56, 1340, 1344, "week" +414, 11, 18, 268, 57, 58, 1345, 1346, "2" +414, 11, 19, 269, 59, 60, 1347, 1348, "," +414, 11, 20, 270, 61, 65, 1349, 1353, "week" +414, 11, 21, 271, 66, 67, 1354, 1355, "6" +414, 11, 22, 272, 68, 69, 1356, 1357, "," +414, 11, 23, 273, 70, 75, 1358, 1363, "month" +414, 11, 24, 274, 76, 77, 1364, 1365, "3" +414, 11, 25, 275, 78, 79, 1366, 1367, "," +414, 11, 26, 276, 80, 83, 1368, 1371, "and" +414, 11, 27, 277, 84, 89, 1372, 1377, "month" +414, 11, 28, 278, 90, 91, 1378, 1379, "6" +414, 11, 29, 279, 92, 98, 1380, 1386, "visits" +414, 11, 30, 280, 99, 100, 1387, 1388, "." +414, 12, 1, 281, 0, 3, 1389, 1392, "The" +414, 12, 2, 282, 4, 11, 1393, 1400, "primary" +414, 12, 3, 283, 12, 20, 1401, 1409, "efficacy" +414, 12, 4, 284, 21, 29, 1410, 1418, "endpoint" +414, 12, 5, 285, 30, 33, 1419, 1422, "was" +414, 12, 6, 286, 34, 38, 1423, 1427, "mean" +414, 12, 7, 287, 39, 46, 1428, 1435, "diurnal" +414, 12, 8, 288, 47, 50, 1436, 1439, "IOP" +414, 12, 9, 289, 51, 57, 1440, 1446, "change" +414, 12, 10, 290, 58, 62, 1447, 1451, "from" +414, 12, 11, 291, 63, 71, 1452, 1460, "baseline" +414, 12, 12, 292, 72, 74, 1461, 1463, "to" +414, 12, 13, 293, 75, 80, 1464, 1469, "month" +414, 12, 14, 294, 81, 82, 1470, 1471, "3" +414, 12, 15, 295, 83, 84, 1472, 1473, ";" +414, 12, 16, 296, 85, 99, 1474, 1488, "noninferiority" +414, 12, 17, 297, 100, 103, 1489, 1492, "was" +414, 12, 18, 298, 104, 113, 1493, 1502, "concluded" +414, 12, 19, 299, 114, 116, 1503, 1505, "if" +414, 12, 20, 300, 117, 120, 1506, 1509, "the" +414, 12, 21, 301, 121, 126, 1510, 1515, "upper" +414, 12, 22, 302, 127, 132, 1516, 1521, "limit" +414, 12, 23, 303, 133, 135, 1522, 1524, "of" +414, 12, 24, 304, 136, 139, 1525, 1528, "the" +414, 12, 25, 305, 140, 142, 1529, 1531, "95" +414, 12, 26, 306, 143, 144, 1532, 1533, "%" +414, 12, 27, 307, 145, 147, 1534, 1536, "CI" +414, 12, 28, 308, 148, 150, 1537, 1539, "of" +414, 12, 29, 309, 151, 154, 1540, 1543, "the" +414, 12, 30, 310, 155, 162, 1544, 1551, "between" +414, 12, 31, 311, 163, 164, 1552, 1553, "-" +414, 12, 32, 312, 165, 170, 1554, 1559, "group" +414, 12, 33, 313, 171, 181, 1560, 1570, "difference" +414, 12, 34, 314, 182, 185, 1571, 1574, "was" +414, 12, 35, 315, 186, 188, 1575, 1577, " <" +414, 12, 36, 316, 189, 190, 1578, 1579, "1" +414, 12, 37, 317, 191, 192, 1580, 1581, "." +414, 12, 38, 318, 193, 194, 1582, 1583, "5" +414, 12, 39, 319, 195, 196, 1584, 1585, " " +414, 12, 40, 320, 197, 201, 1586, 1590, "mmHg" +414, 12, 41, 321, 202, 203, 1591, 1592, "." +414, 13, 1, 322, 0, 10, 1593, 1603, "Supportive" +414, 13, 2, 323, 11, 20, 1604, 1613, "endpoints" +414, 13, 3, 324, 21, 29, 1614, 1622, "included" +414, 13, 4, 325, 30, 34, 1623, 1627, "mean" +414, 13, 5, 326, 35, 38, 1628, 1631, "IOP" +414, 13, 6, 327, 39, 40, 1632, 1633, "," +414, 13, 7, 328, 41, 44, 1634, 1637, "IOP" +414, 13, 8, 329, 45, 51, 1638, 1644, "change" +414, 13, 9, 330, 52, 56, 1645, 1649, "from" +414, 13, 10, 331, 57, 65, 1650, 1658, "baseline" +414, 13, 11, 332, 66, 67, 1659, 1660, "," +414, 13, 12, 333, 68, 71, 1661, 1664, "and" +414, 13, 13, 334, 72, 82, 1665, 1675, "percentage" +414, 13, 14, 335, 83, 85, 1676, 1678, "of" +414, 13, 15, 336, 86, 94, 1679, 1687, "patients" +414, 13, 16, 337, 95, 99, 1688, 1692, "with" +414, 13, 17, 338, 100, 103, 1693, 1696, "IOP" +414, 13, 18, 339, 104, 106, 1697, 1699, " <" +414, 13, 19, 340, 107, 109, 1700, 1702, "18" +414, 13, 20, 341, 110, 111, 1703, 1704, " " +414, 13, 21, 342, 112, 116, 1705, 1709, "mmHg" +414, 13, 22, 343, 117, 118, 1710, 1711, "." +414, 14, 1, 344, 0, 7, 1712, 1719, "Adverse" +414, 14, 2, 345, 8, 14, 1720, 1726, "events" +414, 14, 3, 346, 15, 19, 1727, 1731, "were" +414, 14, 4, 347, 20, 28, 1732, 1740, "recorded" +414, 14, 5, 348, 29, 30, 1741, 1742, "." +414, 15, 1, 349, 0, 7, 1743, 1750, "RESULTS" +414, 15, 2, 350, 8, 9, 1751, 1752, ":" +414, 15, 3, 351, 10, 13, 1753, 1756, "The" +414, 15, 4, 352, 14, 18, 1757, 1761, "mean" +414, 15, 5, 353, 19, 26, 1762, 1769, "diurnal" +414, 15, 6, 354, 27, 30, 1770, 1773, "IOP" +414, 15, 7, 355, 31, 37, 1774, 1780, "change" +414, 15, 8, 356, 38, 42, 1781, 1785, "from" +414, 15, 9, 357, 43, 51, 1786, 1794, "baseline" +414, 15, 10, 358, 52, 56, 1795, 1799, "with" +414, 15, 11, 359, 57, 61, 1800, 1804, "BBFC" +414, 15, 12, 360, 62, 63, 1805, 1806, "(" +414, 15, 13, 361, 64, 69, 1807, 1812, "least" +414, 15, 14, 362, 70, 77, 1813, 1820, "squares" +414, 15, 15, 363, 78, 82, 1821, 1825, "mean" +414, 15, 16, 364, 83, 86, 1826, 1829, " ± " +414, 15, 17, 365, 87, 95, 1830, 1838, "standard" +414, 15, 18, 366, 96, 101, 1839, 1844, "error" +414, 15, 19, 367, 102, 103, 1845, 1846, "-" +414, 15, 20, 368, 104, 105, 1847, 1848, "8" +414, 15, 21, 369, 106, 107, 1849, 1850, "." +414, 15, 22, 370, 108, 109, 1851, 1852, "5" +414, 15, 23, 371, 110, 113, 1853, 1856, " ± " +414, 15, 24, 372, 114, 115, 1857, 1858, "0" +414, 15, 25, 373, 116, 117, 1859, 1860, "." +414, 15, 26, 374, 118, 120, 1861, 1863, "16" +414, 15, 27, 375, 121, 122, 1864, 1865, " " +414, 15, 28, 376, 123, 127, 1866, 1870, "mmHg" +414, 15, 29, 377, 128, 129, 1871, 1872, ")" +414, 15, 30, 378, 130, 133, 1873, 1876, "was" +414, 15, 31, 379, 134, 145, 1877, 1888, "noninferior" +414, 15, 32, 380, 146, 148, 1889, 1891, "to" +414, 15, 33, 381, 149, 153, 1892, 1896, "that" +414, 15, 34, 382, 154, 158, 1897, 1901, "with" +414, 15, 35, 383, 159, 164, 1902, 1907, "BRINZ" +414, 15, 36, 384, 165, 168, 1908, 1911, " + " +414, 15, 37, 385, 169, 173, 1912, 1916, "BRIM" +414, 15, 38, 386, 174, 175, 1917, 1918, "(" +414, 15, 39, 387, 176, 177, 1919, 1920, "-" +414, 15, 40, 388, 178, 179, 1921, 1922, "8" +414, 15, 41, 389, 180, 181, 1923, 1924, "." +414, 15, 42, 390, 182, 183, 1925, 1926, "3" +414, 15, 43, 391, 184, 187, 1927, 1930, " ± " +414, 15, 44, 392, 188, 189, 1931, 1932, "0" +414, 15, 45, 393, 190, 191, 1933, 1934, "." +414, 15, 46, 394, 192, 194, 1935, 1937, "16" +414, 15, 47, 395, 195, 196, 1938, 1939, " " +414, 15, 48, 396, 197, 201, 1940, 1944, "mmHg" +414, 15, 49, 397, 202, 203, 1945, 1946, ";" +414, 15, 50, 398, 204, 208, 1947, 1951, "mean" +414, 15, 51, 399, 209, 219, 1952, 1962, "difference" +414, 15, 52, 400, 220, 221, 1963, 1964, "-" +414, 15, 53, 401, 222, 223, 1965, 1966, "0" +414, 15, 54, 402, 224, 225, 1967, 1968, "." +414, 15, 55, 403, 226, 227, 1969, 1970, "1" +414, 15, 56, 404, 228, 229, 1971, 1972, " " +414, 15, 57, 405, 230, 234, 1973, 1977, "mmHg" +414, 15, 58, 406, 235, 236, 1978, 1979, ";" +414, 15, 59, 407, 237, 239, 1980, 1982, "95" +414, 15, 60, 408, 240, 241, 1983, 1984, "%" +414, 15, 61, 409, 242, 244, 1985, 1987, "CI" +414, 15, 62, 410, 245, 246, 1988, 1989, "-" +414, 15, 63, 411, 247, 248, 1990, 1991, "0" +414, 15, 64, 412, 249, 250, 1992, 1993, "." +414, 15, 65, 413, 251, 252, 1994, 1995, "5" +414, 15, 66, 414, 253, 255, 1996, 1998, "to" +414, 15, 67, 415, 256, 257, 1999, 2000, "0" +414, 15, 68, 416, 258, 259, 2001, 2002, "." +414, 15, 69, 417, 260, 261, 2003, 2004, "2" +414, 15, 70, 418, 262, 263, 2005, 2006, " " +414, 15, 71, 419, 264, 268, 2007, 2011, "mmHg" +414, 15, 72, 420, 269, 270, 2012, 2013, ")" +414, 15, 73, 421, 271, 272, 2014, 2015, "." +414, 16, 1, 422, 0, 3, 2016, 2019, "The" +414, 16, 2, 423, 4, 9, 2020, 2025, "upper" +414, 16, 3, 424, 10, 16, 2026, 2032, "limits" +414, 16, 4, 425, 17, 19, 2033, 2035, "of" +414, 16, 5, 426, 20, 23, 2036, 2039, "the" +414, 16, 6, 427, 24, 26, 2040, 2042, "95" +414, 16, 7, 428, 27, 28, 2043, 2044, "%" +414, 16, 8, 429, 29, 32, 2045, 2048, "CIs" +414, 16, 9, 430, 33, 37, 2049, 2053, "were" +414, 16, 10, 431, 38, 40, 2054, 2056, " <" +414, 16, 11, 432, 41, 42, 2057, 2058, "1" +414, 16, 12, 433, 43, 44, 2059, 2060, "." +414, 16, 13, 434, 45, 46, 2061, 2062, "5" +414, 16, 14, 435, 47, 48, 2063, 2064, " " +414, 16, 15, 436, 49, 53, 2065, 2069, "mmHg" +414, 16, 16, 437, 54, 56, 2070, 2072, "at" +414, 16, 17, 438, 57, 60, 2073, 2076, "all" +414, 16, 18, 439, 61, 65, 2077, 2081, "time" +414, 16, 19, 440, 66, 72, 2082, 2088, "points" +414, 16, 20, 441, 73, 74, 2089, 2090, "." +414, 17, 1, 442, 0, 9, 2091, 2100, "Decreases" +414, 17, 2, 443, 10, 14, 2101, 2105, "from" +414, 17, 3, 444, 15, 23, 2106, 2114, "baseline" +414, 17, 4, 445, 24, 26, 2115, 2117, " >" +414, 17, 5, 446, 27, 28, 2118, 2119, "8" +414, 17, 6, 447, 29, 30, 2120, 2121, " " +414, 17, 7, 448, 31, 35, 2122, 2126, "mmHg" +414, 17, 8, 449, 36, 40, 2127, 2131, "were" +414, 17, 9, 450, 41, 49, 2132, 2140, "observed" +414, 17, 10, 451, 50, 53, 2141, 2144, "for" +414, 17, 11, 452, 54, 59, 2145, 2150, "least" +414, 17, 12, 453, 60, 67, 2151, 2158, "squares" +414, 17, 13, 454, 68, 72, 2159, 2163, "mean" +414, 17, 14, 455, 73, 80, 2164, 2171, "diurnal" +414, 17, 15, 456, 81, 84, 2172, 2175, "IOP" +414, 17, 16, 457, 85, 87, 2176, 2178, "in" +414, 17, 17, 458, 88, 92, 2179, 2183, "both" +414, 17, 18, 459, 93, 99, 2184, 2190, "groups" +414, 17, 19, 460, 100, 102, 2191, 2193, "as" +414, 17, 20, 461, 103, 108, 2194, 2199, "early" +414, 17, 21, 462, 109, 111, 2200, 2202, "as" +414, 17, 22, 463, 112, 116, 2203, 2207, "week" +414, 17, 23, 464, 117, 118, 2208, 2209, "2" +414, 17, 24, 465, 119, 122, 2210, 2213, "and" +414, 17, 25, 466, 123, 132, 2214, 2223, "continued" +414, 17, 26, 467, 133, 135, 2224, 2226, "to" +414, 17, 27, 468, 136, 139, 2227, 2230, "the" +414, 17, 28, 469, 140, 143, 2231, 2234, "end" +414, 17, 29, 470, 144, 146, 2235, 2237, "of" +414, 17, 30, 471, 147, 150, 2238, 2241, "the" +414, 17, 31, 472, 151, 156, 2242, 2247, "study" +414, 17, 32, 473, 157, 158, 2248, 2249, "." +414, 18, 1, 474, 0, 3, 2250, 2253, "The" +414, 18, 2, 475, 4, 11, 2254, 2261, "results" +414, 18, 3, 476, 12, 14, 2262, 2264, "of" +414, 18, 4, 477, 15, 18, 2265, 2268, "all" +414, 18, 5, 478, 19, 24, 2269, 2274, "other" +414, 18, 6, 479, 25, 35, 2275, 2285, "supportive" +414, 18, 7, 480, 36, 45, 2286, 2295, "endpoints" +414, 18, 8, 481, 46, 50, 2296, 2300, "were" +414, 18, 9, 482, 51, 58, 2301, 2308, "similar" +414, 18, 10, 483, 59, 61, 2309, 2311, "to" +414, 18, 11, 484, 62, 65, 2312, 2315, "the" +414, 18, 12, 485, 66, 73, 2316, 2323, "primary" +414, 18, 13, 486, 74, 82, 2324, 2332, "efficacy" +414, 18, 14, 487, 83, 91, 2333, 2341, "endpoint" +414, 18, 15, 488, 92, 93, 2342, 2343, "." +414, 19, 1, 489, 0, 3, 2344, 2347, "The" +414, 19, 2, 490, 4, 8, 2348, 2352, "most" +414, 19, 3, 491, 9, 15, 2353, 2359, "common" +414, 19, 4, 492, 16, 22, 2360, 2366, "ocular" +414, 19, 5, 493, 23, 30, 2367, 2374, "adverse" +414, 19, 6, 494, 31, 35, 2375, 2379, "drug" +414, 19, 7, 495, 36, 45, 2380, 2389, "reactions" +414, 19, 8, 496, 46, 50, 2390, 2394, "were" +414, 19, 9, 497, 51, 60, 2395, 2404, "hyperemia" +414, 19, 10, 498, 61, 63, 2405, 2407, "of" +414, 19, 11, 499, 64, 67, 2408, 2411, "the" +414, 19, 12, 500, 68, 71, 2412, 2415, "eye" +414, 19, 13, 501, 72, 73, 2416, 2417, "(" +414, 19, 14, 502, 74, 82, 2418, 2426, "reported" +414, 19, 15, 503, 83, 85, 2427, 2429, "as" +414, 19, 16, 504, 86, 92, 2430, 2436, "ocular" +414, 19, 17, 505, 93, 95, 2437, 2439, "or" +414, 19, 18, 506, 96, 108, 2440, 2452, "conjunctival" +414, 19, 19, 507, 109, 118, 2453, 2462, "hyperemia" +414, 19, 20, 508, 119, 120, 2463, 2464, ")" +414, 19, 21, 509, 121, 122, 2465, 2466, "," +414, 19, 22, 510, 123, 129, 2467, 2473, "visual" +414, 19, 23, 511, 130, 142, 2474, 2486, "disturbances" +414, 19, 24, 512, 143, 144, 2487, 2488, "," +414, 19, 25, 513, 145, 151, 2489, 2495, "ocular" +414, 19, 26, 514, 152, 160, 2496, 2504, "allergic" +414, 19, 27, 515, 161, 170, 2505, 2514, "reactions" +414, 19, 28, 516, 171, 172, 2515, 2516, "," +414, 19, 29, 517, 173, 176, 2517, 2520, "and" +414, 19, 30, 518, 177, 183, 2521, 2527, "ocular" +414, 19, 31, 519, 184, 194, 2528, 2538, "discomfort" +414, 19, 32, 520, 195, 196, 2539, 2540, "." +414, 20, 1, 521, 0, 6, 2541, 2547, "Common" +414, 20, 2, 522, 7, 15, 2548, 2556, "systemic" +414, 20, 3, 523, 16, 23, 2557, 2564, "adverse" +414, 20, 4, 524, 24, 28, 2565, 2569, "drug" +414, 20, 5, 525, 29, 38, 2570, 2579, "reactions" +414, 20, 6, 526, 39, 47, 2580, 2588, "included" +414, 20, 7, 527, 48, 57, 2589, 2598, "dysgeusia" +414, 20, 8, 528, 58, 59, 2599, 2600, "," +414, 20, 9, 529, 60, 64, 2601, 2605, "oral" +414, 20, 10, 530, 65, 72, 2606, 2613, "dryness" +414, 20, 11, 531, 73, 74, 2614, 2615, "," +414, 20, 12, 532, 75, 78, 2616, 2619, "and" +414, 20, 13, 533, 79, 86, 2620, 2627, "fatigue" +414, 20, 14, 534, 87, 88, 2628, 2629, "/" +414, 20, 15, 535, 89, 99, 2630, 2640, "drowsiness" +414, 20, 16, 536, 100, 101, 2641, 2642, "." +414, 21, 1, 537, 0, 10, 2643, 2653, "CONCLUSION" +414, 21, 2, 538, 11, 12, 2654, 2655, ":" +414, 21, 3, 539, 13, 25, 2656, 2668, "Brinzolamide" +414, 21, 4, 540, 26, 27, 2669, 2670, "1" +414, 21, 5, 541, 28, 29, 2671, 2672, "%" +414, 21, 6, 542, 30, 31, 2673, 2674, "/" +414, 21, 7, 543, 32, 43, 2675, 2686, "brimonidine" +414, 21, 8, 544, 44, 45, 2687, 2688, "0" +414, 21, 9, 545, 46, 47, 2689, 2690, "." +414, 21, 10, 546, 48, 49, 2691, 2692, "2" +414, 21, 11, 547, 50, 51, 2693, 2694, "%" +414, 21, 12, 548, 52, 57, 2695, 2700, "fixed" +414, 21, 13, 549, 58, 69, 2701, 2712, "combination" +414, 21, 14, 550, 70, 73, 2713, 2716, "was" +414, 21, 15, 551, 74, 76, 2717, 2719, "as" +414, 21, 16, 552, 77, 81, 2720, 2724, "well" +414, 21, 17, 553, 82, 91, 2725, 2734, "tolerated" +414, 21, 18, 554, 92, 95, 2735, 2738, "and" +414, 21, 19, 555, 96, 105, 2739, 2748, "effective" +414, 21, 20, 556, 106, 108, 2749, 2751, "as" +414, 21, 21, 557, 109, 120, 2752, 2763, "concomitant" +414, 21, 22, 558, 121, 128, 2764, 2771, "therapy" +414, 21, 23, 559, 129, 133, 2772, 2776, "with" +414, 21, 24, 560, 134, 137, 2777, 2780, "its" +414, 21, 25, 561, 138, 148, 2781, 2791, "components" +414, 21, 26, 562, 149, 150, 2792, 2793, "." +414, 22, 1, 563, 0, 4, 2794, 2798, "BBFC" +414, 22, 2, 564, 5, 12, 2799, 2806, "reduces" +414, 22, 3, 565, 13, 22, 2807, 2816, "treatment" +414, 22, 4, 566, 23, 29, 2817, 2823, "burden" +414, 22, 5, 567, 30, 32, 2824, 2826, "in" +414, 22, 6, 568, 33, 41, 2827, 2835, "patients" +414, 22, 7, 569, 42, 45, 2836, 2839, "who" +414, 22, 8, 570, 46, 53, 2840, 2847, "require" +414, 22, 9, 571, 54, 62, 2848, 2856, "multiple" +414, 22, 10, 572, 63, 66, 2857, 2860, "IOP" +414, 22, 11, 573, 67, 68, 2861, 2862, "-" +414, 22, 12, 574, 69, 77, 2863, 2871, "lowering" +414, 22, 13, 575, 78, 89, 2872, 2883, "medications" +414, 22, 14, 576, 90, 91, 2884, 2885, "." +414, 23, 1, 577, 0, 3, 2886, 2889, "DOI" +414, 23, 2, 578, 4, 5, 2890, 2891, ":" +414, 23, 3, 579, 6, 8, 2892, 2894, "10" +414, 23, 4, 580, 9, 10, 2895, 2896, "." +414, 23, 5, 581, 11, 15, 2897, 2901, "1007" +414, 23, 6, 582, 16, 17, 2902, 2903, "/" +414, 23, 7, 583, 18, 24, 2904, 2910, "s12325" +414, 23, 8, 584, 25, 26, 2911, 2912, "-" +414, 23, 9, 585, 27, 30, 2913, 2916, "014" +414, 23, 10, 586, 31, 32, 2917, 2918, "-" +414, 23, 11, 587, 33, 37, 2919, 2923, "0168" +414, 23, 12, 588, 38, 39, 2924, 2925, "-" +414, 23, 13, 589, 40, 41, 2926, 2927, "y" +414, 23, 14, 590, 42, 47, 2928, 2933, "PMCID" +414, 23, 15, 591, 48, 49, 2934, 2935, ":" +414, 23, 16, 592, 50, 60, 2936, 2946, "PMC4271137" +414, 23, 17, 593, 61, 65, 2947, 2951, "PMID" +414, 23, 18, 594, 66, 67, 2952, 2953, ":" +414, 23, 19, 595, 68, 76, 2954, 2962, "25430900" +414, 23, 20, 596, 77, 78, 2963, 2964, "[" +414, 23, 21, 597, 79, 86, 2965, 2972, "Indexed" +414, 23, 22, 598, 87, 90, 2973, 2976, "for" +414, 23, 23, 599, 91, 98, 2977, 2984, "MEDLINE" +414, 23, 24, 600, 99, 100, 2985, 2986, "]" diff --git a/data/gl 25430900_jshahinitiran.annodb b/data/gl 25430900_jshahinitiran.annodb new file mode 100644 index 0000000..1f5e00f --- /dev/null +++ b/data/gl 25430900_jshahinitiran.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +17210, Journal, 0, 8, "Adv Ther", "", +17211, PublicationYear, 11, 15, "2014", "", +17212, Title, 109, 243, "Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open - angle glaucoma or ocular hypertension .", "", +17213, Randomized, 109, 119, "Randomized", "", +17214, Brinzolamide, 129, 141, "brinzolamide", "", +17215, Brimonidine, 144, 155, "brimonidine", "", +17216, Brinzolamide, 163, 175, "brinzolamide", "", +17217, Brimonidine, 181, 192, "brimonidine", "", +17218, OpenAngleGlaucoma, 197, 218, "open - angle glaucoma", "", +17219, OcularHypertension, 222, 241, "ocular hypertension", "", +17220, Author, 244, 255, "Gandolfi SA", "", +17221, Author, 264, 269, "Lim J", "", +17222, Author, 272, 282, "Sanseau AC", "", +17223, Author, 285, 302, "Parra Restrepo JC", "", +17224, Author, 305, 315, "Hamacher T", "", +17225, Italy, 471, 476, "Italy", "", +17226, IOP, 548, 568, "intraocular pressure", "", +17227, IOP, 571, 574, "IOP", "", +17228, IOP, 708, 711, "IOP", "", +17229, ObjectiveDescription, 714, 900, "The aim of this study was to evaluate the safety and efficacy of fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) versus concomitant administration of brinzolamide 1 %", "", +17237, Drug, 779, 837, "fixed - combination brinzolamide 1 % / brimonidine 0 . 2 %", "BBFC", +17231, Brinzolamide, 799, 811, "brinzolamide", "", +17233, DoseValue, 812, 813, "1", "", +17232, Brimonidine, 818, 829, "brimonidine", "", +17234, DoseValue, 830, 835, "0 . 2", "", +17237, Drug, 840, 844, "BBFC", "BBFC", +17239, Brinzolamide, 884, 896, "brinzolamide", "", +17236, DoseValue, 897, 898, "1", "", +17230, ObjectiveDescription, 901, 1008, "plus brimonidine 0 . 2 % ( BRINZ  +  BRIM ) in patients with open - angle glaucoma or ocular hypertension .", "", +17240, Brimonidine, 906, 917, "brimonidine", "", +17235, DoseValue, 918, 923, "0 . 2", "", +17256, Drug, 928, 942, "BRINZ  +  BRIM", "", +17241, OpenAngleGlaucoma, 962, 983, "open - angle glaucoma", "", +17242, OcularHypertension, 987, 1006, "ocular hypertension", "", +17243, CTDesign, 1030, 1041, "prospective", "", +17244, CTDesign, 1044, 1051, "phase 3", "", +17245, Multicenter, 1054, 1065, "multicenter", "", +17246, DoubleBlind, 1068, 1083, "double - masked", "", +17247, Duration, 1086, 1095, "6 - month", "", +17249, Precondition, 1104, 1162, "Patients who had insufficient IOP control with monotherapy", "", +17248, IOP, 1134, 1137, "IOP", "", +17250, Precondition, 1166, 1215, "who were receiving   2 IOP - lowering medications", "", +17251, IOP, 1189, 1192, "IOP", "", +17252, Randomized, 1221, 1231, "randomized", "", +17254, AllocationRatio, 1232, 1237, "1 : 1", "", +17255, Frequency, 1249, 1262, "twice - daily", "", +17237, Drug, 1263, 1267, "BBFC", "BBFC", +17256, Drug, 1271, 1285, "BRINZ  +  BRIM", "", +17259, IOP, 1288, 1291, "IOP", "", +17260, TimePoint, 1340, 1346, "week 2", "", +17261, TimePoint, 1349, 1355, "week 6", "", +17262, TimePoint, 1358, 1365, "month 3", "", +17263, TimePoint, 1372, 1379, "month 6", "", +17264, Mean, 1423, 1427, "mean", "", +17265, Diurnal_IOP, 1428, 1439, "diurnal IOP", "", +17262, TimePoint, 1464, 1471, "month 3", "", +17267, Mean, 1623, 1627, "mean", "", +17268, IOP, 1628, 1631, "IOP", "", +17269, IOP, 1634, 1637, "IOP", "", +17270, EndPointDescription, 1665, 1709, "percentage of patients with IOP  < 18   mmHg", "", +17271, IOP, 1693, 1696, "IOP", "", +17272, mmHg, 1705, 1709, "mmHg", "", +17273, Mean, 1757, 1761, "mean", "", +17274, Diurnal_IOP, 1762, 1773, "diurnal IOP", "", +17237, Drug, 1800, 1804, "BBFC", "BBFC", +17276, LeastSquaresMean, 1807, 1825, "least squares mean", "", +17277, Reduction, 1847, 1852, "8 . 5", "", +17278, SdErrorChangeValue, 1857, 1863, "0 . 16", "", +17279, mmHg, 1866, 1870, "mmHg", "", +17256, Drug, 1902, 1916, "BRINZ  +  BRIM", "", +17281, Reduction, 1921, 1926, "8 . 3", "", +17282, SdErrorChangeValue, 1931, 1937, "0 . 16", "", +17283, mmHg, 1940, 1944, "mmHg", "", +17284, Mean, 1947, 1951, "mean", "", +17285, DiffGroupAbsValue, 1965, 1970, "0 . 1", "", +17286, mmHg, 1973, 1977, "mmHg", "", +17287, ConfIntervalDiff, 1980, 2011, "95 % CI - 0 . 5 to 0 . 2   mmHg", "", +17288, mmHg, 2007, 2011, "mmHg", "", +17289, mmHg, 2065, 2069, "mmHg", "", +35865, EndPointDescription, 2091, 2126, "Decreases from baseline  > 8   mmHg", "", +35867, ObservedResult, 2091, 2247, "Decreases from baseline  > 8   mmHg were observed for least squares mean diurnal IOP in both groups as early as week 2 and continued to the end of the study", "", +35866, mmHg, 2122, 2126, "mmHg", "", +35862, LeastSquaresMean, 2145, 2163, "least squares mean", "", +35861, Diurnal_IOP, 2164, 2175, "diurnal IOP", "", +35863, TimePoint, 2203, 2209, "week 2", "", +35864, TimePoint, 2227, 2247, "the end of the study", "", +35868, ObservedResult, 2250, 2341, "The results of all other supportive endpoints were similar to the primary efficacy endpoint", "", +17290, ConjunctivalHyperemia, 2395, 2415, "hyperemia of the eye", "", +17291, ConjunctivalHyperemia, 2440, 2462, "conjunctival hyperemia", "", +35856, ConclusionComment, 2656, 2791, "Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination was as well tolerated and effective as concomitant therapy with its components", "", +17299, Brinzolamide, 2656, 2668, "Brinzolamide", "", +17237, Drug, 2656, 2712, "Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination", "BBFC", +17302, DoseValue, 2669, 2670, "1", "", +17304, Percentage, 2671, 2672, "%", "", +17300, Brimonidine, 2675, 2686, "brimonidine", "", +17303, DoseValue, 2687, 2692, "0 . 2", "", +17305, Percentage, 2693, 2694, "%", "", +35857, ConclusionComment, 2794, 2885, "BBFC reduces treatment burden in patients who require multiple IOP - lowering medications .", "", +17237, Drug, 2794, 2798, "BBFC", "BBFC", +17307, IOP, 2857, 2860, "IOP", "", +17308, PMID, 2954, 2962, "25430900", "", diff --git a/data/gl 25430900_jshahinitiran.n-triples b/data/gl 25430900_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25430900_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25430900_tstrakeljahn.annodb b/data/gl 25430900_tstrakeljahn.annodb new file mode 100644 index 0000000..1253ac0 --- /dev/null +++ b/data/gl 25430900_tstrakeljahn.annodb @@ -0,0 +1,77 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11204, Journal, 0, 8, "Adv Ther", "", +11205, PublicationYear, 11, 15, "2014", "", +11206, Randomized, 109, 119, "Randomized", "", +11260, Title, 109, 243, "Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open - angle glaucoma or ocular hypertension .", "", +11207, Brinzolamide, 129, 141, "brinzolamide", "", +11208, Brimonidine, 144, 155, "brimonidine", "", +11209, Brinzolamide, 163, 175, "brinzolamide", "", +11210, Brimonidine, 181, 192, "brimonidine", "", +11211, OpenAngleGlaucoma, 197, 218, "open - angle glaucoma", "", +11212, OcularHypertension, 222, 241, "ocular hypertension", "", +11213, Author, 244, 255, "Gandolfi SA", "", +11214, Author, 264, 269, "Lim J", "", +11215, Author, 272, 282, "Sanseau AC", "", +11216, Author, 285, 302, "Parra Restrepo JC", "", +11217, Author, 305, 315, "Hamacher T", "", +11218, Italy, 471, 476, "Italy", "", +11222, ObjectiveDescription, 528, 713, "Fixed - combination intraocular pressure ( IOP ) - lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP .", "", +11219, IOP, 548, 568, "intraocular pressure", "", +11220, IOP, 571, 574, "IOP", "", +11221, IOP, 708, 711, "IOP", "", +11223, ObjectiveDescription, 714, 968, "The aim of this study was to evaluate the safety and efficacy of fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) versus concomitant administration of brinzolamide 1 % plus brimonidine 0 . 2 % ( BRINZ  +  BRIM ) in patients with open -", "", +11224, ObjectiveDescription, 967, 1008, "- angle glaucoma or ocular hypertension .", "", +11225, Multicenter, 1054, 1065, "multicenter", "", +11226, DoubleBlind, 1068, 1083, "double - masked", "", +11227, Duration, 1086, 1095, "6 - month", "", +11228, IOP, 1134, 1137, "IOP", "", +11229, IOP, 1189, 1192, "IOP", "", +11230, Randomized, 1221, 1231, "randomized", "", +29878, Drug, 1263, 1267, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +11232, Brinzolamide, 1271, 1276, "BRINZ", "", +11233, Brimonidine, 1281, 1285, "BRIM", "", +11234, IOP, 1288, 1291, "IOP", "", +11237, EndPointDescription, 1389, 1471, "The primary efficacy endpoint was mean diurnal IOP change from baseline to month 3", "", +11236, Mean, 1423, 1427, "mean", "", +11235, Diurnal_IOP, 1428, 1439, "diurnal IOP", "", +11238, Mean, 1623, 1627, "mean", "", +11239, IOP, 1628, 1631, "IOP", "", +11240, IOP, 1634, 1637, "IOP", "", +11241, Endpoint, 1665, 1709, "percentage of patients with IOP  < 18   mmHg", "", +11242, Mean, 1757, 1761, "mean", "", +11243, Diurnal_IOP, 1762, 1773, "diurnal IOP", "", +29879, Drug, 1800, 1804, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +11248, Reduction, 1847, 1852, "8 . 5", "", +11249, SdErrorChangeValue, 1853, 1863, " ±  0 . 16", "", +11252, mmHg, 1866, 1870, "mmHg", "", +11246, Brinzolamide, 1902, 1907, "BRINZ", "", +11247, Brimonidine, 1912, 1916, "BRIM", "", +11250, Reduction, 1921, 1926, "8 . 3", "", +11251, SdErrorChangeValue, 1927, 1937, " ±  0 . 16", "", +11253, mmHg, 1940, 1944, "mmHg", "", +11254, Mean, 1947, 1951, "mean", "", +11255, DiffGroupAbsValue, 1965, 1970, "0 . 1", "", +11256, mmHg, 1973, 1977, "mmHg", "", +11257, ConfIntervalDiff, 1980, 2004, "95 % CI - 0 . 5 to 0 . 2", "", +11258, mmHg, 2007, 2011, "mmHg", "", +11245, ObservedResult, 2016, 2088, "The upper limits of the 95 % CIs were  < 1 . 5   mmHg at all time points", "", +11259, Endpoint, 2091, 2126, "Decreases from baseline  > 8   mmHg", "", +11264, mmHg, 2122, 2126, "mmHg", "", +11261, Mean, 2159, 2163, "mean", "", +11262, Diurnal_IOP, 2164, 2175, "diurnal IOP", "", +11263, TimePoint, 2203, 2209, "week 2", "", +11267, ObservedResult, 2344, 2540, "The most common ocular adverse drug reactions were hyperemia of the eye ( reported as ocular or conjunctival hyperemia ) , visual disturbances , ocular allergic reactions , and ocular discomfort .", "", +11265, ConjunctivalHyperemia, 2395, 2404, "hyperemia", "", +11266, ConjunctivalHyperemia, 2440, 2462, "conjunctival hyperemia", "", +11268, ObservedResult, 2541, 2642, "Common systemic adverse drug reactions included dysgeusia , oral dryness , and fatigue / drowsiness .", "", +11269, Brinzolamide, 2656, 2668, "Brinzolamide", "", +11275, ConclusionComment, 2656, 2793, "Brinzolamide 1 % / brimonidine 0 . 2 % fixed combination was as well tolerated and effective as concomitant therapy with its components .", "", +11271, DoseValue, 2669, 2670, "1", "", +11273, Percentage, 2671, 2672, "%", "", +11270, Brimonidine, 2675, 2686, "brimonidine", "", +11272, DoseValue, 2687, 2692, "0 . 2", "", +11274, Percentage, 2693, 2694, "%", "", +11278, ConclusionComment, 2794, 2883, "BBFC reduces treatment burden in patients who require multiple IOP - lowering medications", "", +29880, Drug, 2794, 2798, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +11277, IOP, 2857, 2860, "IOP", "", +11279, PMID, 2954, 2962, "25430900", "", diff --git a/data/gl 25430900_tstrakeljahn.n-triples b/data/gl 25430900_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25430900_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25432143_admin.annodb b/data/gl 25432143_admin.annodb new file mode 100644 index 0000000..817148c --- /dev/null +++ b/data/gl 25432143_admin.annodb @@ -0,0 +1,121 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "BMC Ophthalmol .", "", " \"BMC Ophthalmol .\"." +1, PublicationYear, 17, 21, "2014", "", " \"2014\"." +2, Title, 85, 290, "Late - day intraocular pressure - lowering efficacy and tolerability of travoprost 0 . 004 % versus bimatoprost 0 . 01 % in patients with open - angle glaucoma or ocular hypertension : a randomized trial .", "", " \"Late - day intraocular pressure - lowering efficacy and tolerability of travoprost 0 . 004 % versus bimatoprost 0 . 01 % in patients with open - angle glaucoma or ocular hypertension : a randomized trial .\"." +3, IOP, 96, 116, "intraocular pressure", "", +4, Travoprost, 157, 167, "travoprost", "", +6, DoseValue, 168, 175, "0 . 004", "", +110, Percentage, 176, 177, "%", "", +5, Bimatoprost, 185, 196, "bimatoprost", "", +7, DoseValue, 197, 203, "0 . 01", "", +111, Percentage, 204, 205, "%", "", +8, OpenAngleGlaucoma, 223, 244, "open - angle glaucoma", "", " ." +9, OcularHypertension, 248, 267, "ocular hypertension", "", " ." +10, Randomized, 272, 282, "randomized", "", +11, Author, 291, 301, "DuBiner HB", "", " \"DuBiner HB\"." +12, Author, 310, 321, "Hubatsch DA", "", " \"Hubatsch DA\"." +114, USA, 434, 437, "USA", "", " ." +13, IOP, 508, 528, "intraocular pressure", "", +14, IOP, 531, 534, "IOP", "", +104734, ProstaglandinAnalogs, 698, 711, "prostaglandin", "", +23, ObjectiveDescription, 751, 997, "The present study compared the efficacy and safety of BAK - free travoprost 0 . 004 % ( TRAV ) and BAK 0 . 02 % - preserved bimatoprost 0 . 01 % ( BIM ) during late - day time points in patients with open - angle glaucoma or ocular hypertension .", "", " \"The present study compared the efficacy and safety of BAK - free travoprost 0 . 004 % ( TRAV ) and BAK 0 . 02 % - preserved bimatoprost 0 . 01 % ( BIM ) during late - day time points in patients with open - angle glaucoma or ocular hypertension .\"." +15, Travoprost, 805, 826, "BAK - free travoprost", "", " ." +17, DoseValue, 827, 834, "0 . 004", "", " \"0 . 004\"." +130, Percentage, 835, 836, "%", "", " ." +19, Travoprost, 839, 843, "TRAV", "", +104738, Bimatoprost, 850, 853, "BAK", "", +126, DoseValue, 854, 860, "0 . 02", "", +128, Percentage, 861, 862, "%", "", +104738, Bimatoprost, 863, 886, "- preserved bimatoprost", "", " ." +18, DoseValue, 887, 893, "0 . 01", "", " \"0 . 01\"." +129, Percentage, 894, 895, "%", "", " ." +20, Bimatoprost, 898, 901, "BIM", "", +104743, Precondition, 937, 995, "patients with open - angle glaucoma or ocular hypertension", "", " \"patients with open - angle glaucoma or ocular hypertension\"." +21, OpenAngleGlaucoma, 951, 972, "open - angle glaucoma", "", +22, OcularHypertension, 976, 995, "ocular hypertension", "", +24, Duration, 1019, 1028, "12 - week", "", " \"12 - week\"." +25, CTDesign, 1031, 1038, "phase 4", "", " . ." +26, Randomized, 1041, 1051, "randomized", "", " ." +27, Blind, 1054, 1075, "investigator - masked", "", " ." +28, Crossover, 1078, 1087, "crossover", "", " ." +29, NumberPatientsCT, 1096, 1098, "84", "", " \"84\"." +32, Precondition, 1099, 1135, "patients with IOP ≥ 24 and < 36 mmHg", "", " \"patients with IOP ≥ 24 and < 36 mmHg\"." +30, IOP, 1113, 1116, "IOP", "", +31, mmHg, 1131, 1135, "mmHg", "", +33, Randomized, 1141, 1151, "randomized", "", +34, AllocationRatio, 1152, 1157, "1 : 1", "", " . ." +35, Frequency, 1169, 1181, "once - daily", "", " \"once - daily\". \"once - daily\"." +36, Travoprost, 1182, 1186, "TRAV", "", +37, Bimatoprost, 1190, 1193, "BIM", "", +38, Duration, 1198, 1205, "6 weeks", "", +39, Duration, 1232, 1240, "6 - week", "", +40, Crossover, 1241, 1250, "crossover", "", +41, IOP, 1260, 1263, "IOP", "", +148, TimePoint, 1316, 1332, "4 , 6 , and 8 pm", "", +147, TimePoint, 1320, 1332, "6 , and 8 pm", "", +146, TimePoint, 1328, 1332, "8 pm", "", +42, Travoprost, 1335, 1339, "TRAV", "", +43, Bimatoprost, 1370, 1373, "BIM", "", +44, Mean, 1445, 1449, "mean", "", +45, IOP, 1450, 1453, "IOP", "", +46, mmHg, 1466, 1470, "mmHg", "", +155, NumPatientsLeftCT, 1535, 1538, "One", "", " \"One\"." +104745, EndPointDescription, 1567, 1590, "allergic conjunctivitis", "", +156, NumPatientsLeftCT, 1597, 1598, "2", "", +47, FinalNumPatientsCT, 1642, 1644, "81", "", " \"81\"." +48, PerProtocol, 1675, 1689, "per - protocol", "", " ." +49, Mean, 1703, 1707, "mean", "", +50, AvgAge, 1719, 1725, "58 . 3", "", " \"58 . 3\"." +51, Travoprost, 1743, 1747, "TRAV", "", +52, Bimatoprost, 1750, 1753, "BIM", "", +161, FinalNumPatientsArm, 1760, 1762, "41", "", " \"41\"." +166, Bimatoprost, 1765, 1768, "BIM", "", +164, Travoprost, 1771, 1775, "TRAV", "", +162, FinalNumPatientsArm, 1782, 1784, "40", "", " \"40\"." +106372, TimePoint, 1795, 1802, "6 weeks", "", " \"6 weeks\". \"6 weeks\"." +56, Mean, 1805, 1809, "mean", "", " . ." +57, IOP, 1810, 1813, "IOP", "", " . ." +58, Travoprost, 1819, 1823, "TRAV", "", +59, ResultMeasuredValue, 1826, 1832, "17 . 4", "", " \"17 . 4\"." +61, SdDevResValue, 1835, 1840, "2 . 7", "", " \"2 . 7\"." +63, mmHg, 1841, 1845, "mmHg", "", " ." +65, Reduction, 1873, 1878, "6 . 0", "", " \"6 . 0\"." +67, mmHg, 1879, 1883, "mmHg", "", +68, Bimatoprost, 1901, 1904, "BIM", "", +60, ResultMeasuredValue, 1907, 1913, "17 . 2", "", " \"17 . 2\"." +62, SdDevResValue, 1916, 1921, "2 . 6", "", " \"2 . 6\"." +69, mmHg, 1922, 1926, "mmHg", "", +66, Reduction, 1954, 1959, "6 . 3", "", " \"6 . 3\"." +64, mmHg, 1960, 1964, "mmHg", "", +70, DiffGroupAbsValue, 2004, 2010, "0 . 22", "", " \"0 . 22\"." +71, mmHg, 2011, 2015, "mmHg", "", +72, ConfIntervalDiff, 2018, 2046, "95 % CI , - 0 . 22 to 0 . 67", "", " \"95 % CI , - 0 . 22 to 0 . 67\"." +73, Travoprost, 2076, 2080, "TRAV", "", +74, Bimatoprost, 2088, 2091, "BIM", "", +75, Mean, 2111, 2115, "Mean", "", +76, IOP, 2116, 2119, "IOP", "", +77, Mean, 2143, 2147, "mean", "", +78, IOP, 2163, 2166, "IOP", "", +104747, EndPointDescription, 2324, 2345, "mild ocular hyperemia", "", " . ." +199, ConjunctivalHyperemia, 2329, 2345, "ocular hyperemia", "", +82, Travoprost, 2351, 2355, "TRAV", "", +83, Bimatoprost, 2360, 2363, "BIM", "", +84, PercentageAffected, 2369, 2371, "31", "", " \"31\"." +85, PercentageAffected, 2378, 2380, "39", "", " \"39\"." +104749, EndPointDescription, 2400, 2418, "moderate hyperemia", "", " . ." +200, ConjunctivalHyperemia, 2409, 2418, "hyperemia", "", +86, PercentageAffected, 2435, 2436, "2", "", " \"2\"." +88, Bimatoprost, 2461, 2464, "BIM", "", +97, ConclusionComment, 2480, 2627, "Late - day IOP - lowering efficacy of BAK - free TRAV was noninferior to that of BAK 0 . 02 % - preserved BIM ; both reduced baseline IOP by 25 % .", "", " \"Late - day IOP - lowering efficacy of BAK - free TRAV was noninferior to that of BAK 0 . 02 % - preserved BIM ; both reduced baseline IOP by 25 % .\"." +90, IOP, 2491, 2494, "IOP", "", +91, Travoprost, 2518, 2533, "BAK - free TRAV", "", +204, Bimatoprost, 2561, 2564, "BAK", "", +203, DoseValue, 2565, 2571, "0 . 02", "", +204, Bimatoprost, 2574, 2589, "- preserved BIM", "", +93, IOP, 2614, 2617, "IOP", "", +94, RelativeReduction, 2621, 2623, "25", "", +98, ConclusionComment, 2628, 2746, "Both treatments were well tolerated , although a higher incidence of moderate ocular hyperemia was observed with BIM .", "", " \"Both treatments were well tolerated , although a higher incidence of moderate ocular hyperemia was observed with BIM .\"." +104750, EndPointDescription, 2697, 2722, "moderate ocular hyperemia", "", +208, ConjunctivalHyperemia, 2706, 2722, "ocular hyperemia", "", +95, Bimatoprost, 2741, 2744, "BIM", "", +99, PMID, 2914, 2922, "25432143", "", " \"25432143\"." diff --git a/data/gl 25432143_admin.n-triples b/data/gl 25432143_admin.n-triples new file mode 100644 index 0000000..d347dae --- /dev/null +++ b/data/gl 25432143_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication " . + "Late - day intraocular pressure - lowering efficacy and tolerability of travoprost 0 . 004 % versus bimatoprost 0 . 01 % in patients with open - angle glaucoma or ocular hypertension : a randomized trial ." . + "DuBiner HB" . + "2014" . + "BMC Ophthalmol ." . + "25432143" . + . + "Hubatsch DA" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The present study compared the efficacy and safety of BAK - free travoprost 0 . 004 % ( TRAV ) and BAK 0 . 02 % - preserved bimatoprost 0 . 01 % ( BIM ) during late - day time points in patients with open - angle glaucoma or ocular hypertension ." . + "84" . + "12 - week" . + . + . + . + . + . + "Late - day IOP - lowering efficacy of BAK - free TRAV was noninferior to that of BAK 0 . 02 % - preserved BIM ; both reduced baseline IOP by 25 % ." . + . + . + . + . + . + "81" . + "One" . + . + . + . + "Both treatments were well tolerated , although a higher incidence of moderate ocular hyperemia was observed with BIM ." . + . + . +# RDF export of group: Population + . + "Population " . + "patients with open - angle glaucoma or ocular hypertension" . + . + . + "58 . 3" . + . + "patients with IOP ≥ 24 and < 36 mmHg" . +# RDF export of group: Endpoint + . + "Endpoint IOP " . + . + . + . + . + . + . + . + "Endpoint mild oh" . + . + . + . + . + . + . + "Endpoint moderate oh" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm trav" . + "41" . + . + . + . + . + "Arm bim" . + "40" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention trav" . + . + "once - daily" . + . + . + "Intervention bim" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication trav" . + . + "0 . 004" . + . + . + . + "Medication bim" . + . + "0 . 01" . + . + . +# RDF export of group: Outcome + . + "Outcome IOP trav 6 weeks " . + . + "17 . 4" . + "2 . 7" . + "6 . 0" . + "6 weeks" . + . + "Outcome IOP bim 6 weeks " . + . + "17 . 2" . + "2 . 6" . + "6 . 3" . + "6 weeks" . + . + "Outcome mild oh trav" . + . + "31" . + . + "Outcome mild oh bim " . + . + "39" . + . + "Outcome moderate oh bim " . + . + "2" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP 6 weeks" . + "0 . 22" . + "95 % CI , - 0 . 22 to 0 . 67" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25432143_export.csv b/data/gl 25432143_export.csv new file mode 100644 index 0000000..51a9264 --- /dev/null +++ b/data/gl 25432143_export.csv @@ -0,0 +1,623 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +503, 1, 1, 1, 0, 3, 0, 3, "BMC" +503, 1, 2, 2, 4, 14, 4, 14, "Ophthalmol" +503, 1, 3, 3, 15, 16, 15, 16, "." +503, 2, 1, 4, 0, 4, 17, 21, "2014" +503, 2, 2, 5, 5, 8, 22, 25, "Nov" +503, 2, 3, 6, 9, 11, 26, 28, "28" +503, 2, 4, 7, 12, 13, 29, 30, ";" +503, 2, 5, 8, 14, 16, 31, 33, "14" +503, 2, 6, 9, 17, 18, 34, 35, ":" +503, 2, 7, 10, 19, 22, 36, 39, "151" +503, 2, 8, 11, 23, 24, 40, 41, "." +503, 2, 9, 12, 25, 28, 42, 45, "doi" +503, 2, 10, 13, 29, 30, 46, 47, ":" +503, 2, 11, 14, 31, 33, 48, 50, "10" +503, 2, 12, 15, 34, 35, 51, 52, "." +503, 2, 13, 16, 36, 40, 53, 57, "1186" +503, 2, 14, 17, 41, 42, 58, 59, "/" +503, 2, 15, 18, 43, 47, 60, 64, "1471" +503, 2, 16, 19, 48, 49, 65, 66, "-" +503, 2, 17, 20, 50, 54, 67, 71, "2415" +503, 2, 18, 21, 55, 56, 72, 73, "-" +503, 2, 19, 22, 57, 59, 74, 76, "14" +503, 2, 20, 23, 60, 61, 77, 78, "-" +503, 2, 21, 24, 62, 65, 79, 82, "151" +503, 2, 22, 25, 66, 67, 83, 84, "." +503, 3, 1, 26, 0, 4, 85, 89, "Late" +503, 3, 2, 27, 5, 6, 90, 91, "-" +503, 3, 3, 28, 7, 10, 92, 95, "day" +503, 3, 4, 29, 11, 22, 96, 107, "intraocular" +503, 3, 5, 30, 23, 31, 108, 116, "pressure" +503, 3, 6, 31, 32, 33, 117, 118, "-" +503, 3, 7, 32, 34, 42, 119, 127, "lowering" +503, 3, 8, 33, 43, 51, 128, 136, "efficacy" +503, 3, 9, 34, 52, 55, 137, 140, "and" +503, 3, 10, 35, 56, 68, 141, 153, "tolerability" +503, 3, 11, 36, 69, 71, 154, 156, "of" +503, 3, 12, 37, 72, 82, 157, 167, "travoprost" +503, 3, 13, 38, 83, 84, 168, 169, "0" +503, 3, 14, 39, 85, 86, 170, 171, "." +503, 3, 15, 40, 87, 90, 172, 175, "004" +503, 3, 16, 41, 91, 92, 176, 177, "%" +503, 3, 17, 42, 93, 99, 178, 184, "versus" +503, 3, 18, 43, 100, 111, 185, 196, "bimatoprost" +503, 3, 19, 44, 112, 113, 197, 198, "0" +503, 3, 20, 45, 114, 115, 199, 200, "." +503, 3, 21, 46, 116, 118, 201, 203, "01" +503, 3, 22, 47, 119, 120, 204, 205, "%" +503, 3, 23, 48, 121, 123, 206, 208, "in" +503, 3, 24, 49, 124, 132, 209, 217, "patients" +503, 3, 25, 50, 133, 137, 218, 222, "with" +503, 3, 26, 51, 138, 142, 223, 227, "open" +503, 3, 27, 52, 143, 144, 228, 229, "-" +503, 3, 28, 53, 145, 150, 230, 235, "angle" +503, 3, 29, 54, 151, 159, 236, 244, "glaucoma" +503, 3, 30, 55, 160, 162, 245, 247, "or" +503, 3, 31, 56, 163, 169, 248, 254, "ocular" +503, 3, 32, 57, 170, 182, 255, 267, "hypertension" +503, 3, 33, 58, 183, 184, 268, 269, ":" +503, 3, 34, 59, 185, 186, 270, 271, "a" +503, 3, 35, 60, 187, 197, 272, 282, "randomized" +503, 3, 36, 61, 198, 203, 283, 288, "trial" +503, 3, 37, 62, 204, 205, 289, 290, "." +503, 4, 1, 63, 0, 7, 291, 298, "DuBiner" +503, 4, 2, 64, 8, 10, 299, 301, "HB" +503, 4, 3, 65, 11, 12, 302, 303, "(" +503, 4, 4, 66, 13, 14, 304, 305, "1" +503, 4, 5, 67, 15, 16, 306, 307, ")" +503, 4, 6, 68, 17, 18, 308, 309, "," +503, 4, 7, 69, 19, 27, 310, 318, "Hubatsch" +503, 4, 8, 70, 28, 30, 319, 321, "DA" +503, 4, 9, 71, 31, 32, 322, 323, "." +503, 5, 1, 72, 0, 6, 324, 330, "Author" +503, 5, 2, 73, 7, 18, 331, 342, "information" +503, 5, 3, 74, 19, 20, 343, 344, ":" +503, 5, 4, 75, 21, 22, 345, 346, "(" +503, 5, 5, 76, 23, 24, 347, 348, "1" +503, 5, 6, 77, 25, 26, 349, 350, ")" +503, 5, 7, 78, 27, 34, 351, 358, "Clayton" +503, 5, 8, 79, 35, 38, 359, 362, "Eye" +503, 5, 9, 80, 39, 45, 363, 369, "Center" +503, 5, 10, 81, 46, 47, 370, 371, "," +503, 5, 11, 82, 48, 52, 372, 376, "1000" +503, 5, 12, 83, 53, 62, 377, 386, "Corporate" +503, 5, 13, 84, 63, 69, 387, 393, "Center" +503, 5, 14, 85, 70, 75, 394, 399, "Drive" +503, 5, 15, 86, 76, 77, 400, 401, "," +503, 5, 16, 87, 78, 83, 402, 407, "Suite" +503, 5, 17, 88, 84, 87, 408, 411, "102" +503, 5, 18, 89, 88, 89, 412, 413, "," +503, 5, 19, 90, 90, 96, 414, 420, "Morrow" +503, 5, 20, 91, 97, 98, 421, 422, "," +503, 5, 21, 92, 99, 101, 423, 425, "GA" +503, 5, 22, 93, 102, 107, 426, 431, "30260" +503, 5, 23, 94, 108, 109, 432, 433, "," +503, 5, 24, 95, 110, 113, 434, 437, "USA" +503, 5, 25, 96, 114, 115, 438, 439, "." +503, 6, 1, 97, 0, 11, 440, 451, "glaucdocatl" +503, 6, 2, 98, 12, 13, 452, 453, "@" +503, 6, 3, 99, 14, 23, 454, 463, "mindsping" +503, 6, 4, 100, 24, 25, 464, 465, "." +503, 6, 5, 101, 26, 29, 466, 469, "com" +503, 6, 6, 102, 30, 31, 470, 471, "." +503, 7, 1, 103, 0, 10, 472, 482, "BACKGROUND" +503, 7, 2, 104, 11, 12, 483, 484, ":" +503, 7, 3, 105, 13, 24, 485, 496, "Medications" +503, 7, 4, 106, 25, 27, 497, 499, "to" +503, 7, 5, 107, 28, 35, 500, 507, "control" +503, 7, 6, 108, 36, 47, 508, 519, "intraocular" +503, 7, 7, 109, 48, 56, 520, 528, "pressure" +503, 7, 8, 110, 57, 58, 529, 530, "(" +503, 7, 9, 111, 59, 62, 531, 534, "IOP" +503, 7, 10, 112, 63, 64, 535, 536, ")" +503, 7, 11, 113, 65, 68, 537, 540, "are" +503, 7, 12, 114, 69, 79, 541, 551, "frequently" +503, 7, 13, 115, 80, 89, 552, 561, "preserved" +503, 7, 14, 116, 90, 95, 562, 567, "using" +503, 7, 15, 117, 96, 108, 568, 580, "benzalkonium" +503, 7, 16, 118, 109, 117, 581, 589, "chloride" +503, 7, 17, 119, 118, 119, 590, 591, "(" +503, 7, 18, 120, 120, 123, 592, 595, "BAK" +503, 7, 19, 121, 124, 125, 596, 597, ")" +503, 7, 20, 122, 126, 127, 598, 599, "," +503, 7, 21, 123, 128, 133, 600, 605, "which" +503, 7, 22, 124, 134, 137, 606, 609, "can" +503, 7, 23, 125, 138, 148, 610, 620, "negatively" +503, 7, 24, 126, 149, 155, 621, 627, "affect" +503, 7, 25, 127, 156, 159, 628, 631, "the" +503, 7, 26, 128, 160, 166, 632, 638, "ocular" +503, 7, 27, 129, 167, 174, 639, 646, "surface" +503, 7, 28, 130, 175, 176, 647, 648, "." +503, 8, 1, 131, 0, 4, 649, 653, "Data" +503, 8, 2, 132, 5, 8, 654, 657, "are" +503, 8, 3, 133, 9, 15, 658, 664, "needed" +503, 8, 4, 134, 16, 18, 665, 667, "to" +503, 8, 5, 135, 19, 25, 668, 674, "assess" +503, 8, 6, 136, 26, 34, 675, 683, "efficacy" +503, 8, 7, 137, 35, 38, 684, 687, "and" +503, 8, 8, 138, 39, 45, 688, 694, "safety" +503, 8, 9, 139, 46, 48, 695, 697, "of" +503, 8, 10, 140, 49, 62, 698, 711, "prostaglandin" +503, 8, 11, 141, 63, 68, 712, 717, "drugs" +503, 8, 12, 142, 69, 78, 718, 727, "preserved" +503, 8, 13, 143, 79, 83, 728, 732, "with" +503, 8, 14, 144, 84, 87, 733, 736, "and" +503, 8, 15, 145, 88, 95, 737, 744, "without" +503, 8, 16, 146, 96, 99, 745, 748, "BAK" +503, 8, 17, 147, 100, 101, 749, 750, "." +503, 9, 1, 148, 0, 3, 751, 754, "The" +503, 9, 2, 149, 4, 11, 755, 762, "present" +503, 9, 3, 150, 12, 17, 763, 768, "study" +503, 9, 4, 151, 18, 26, 769, 777, "compared" +503, 9, 5, 152, 27, 30, 778, 781, "the" +503, 9, 6, 153, 31, 39, 782, 790, "efficacy" +503, 9, 7, 154, 40, 43, 791, 794, "and" +503, 9, 8, 155, 44, 50, 795, 801, "safety" +503, 9, 9, 156, 51, 53, 802, 804, "of" +503, 9, 10, 157, 54, 57, 805, 808, "BAK" +503, 9, 11, 158, 58, 59, 809, 810, "-" +503, 9, 12, 159, 60, 64, 811, 815, "free" +503, 9, 13, 160, 65, 75, 816, 826, "travoprost" +503, 9, 14, 161, 76, 77, 827, 828, "0" +503, 9, 15, 162, 78, 79, 829, 830, "." +503, 9, 16, 163, 80, 83, 831, 834, "004" +503, 9, 17, 164, 84, 85, 835, 836, "%" +503, 9, 18, 165, 86, 87, 837, 838, "(" +503, 9, 19, 166, 88, 92, 839, 843, "TRAV" +503, 9, 20, 167, 93, 94, 844, 845, ")" +503, 9, 21, 168, 95, 98, 846, 849, "and" +503, 9, 22, 169, 99, 102, 850, 853, "BAK" +503, 9, 23, 170, 103, 104, 854, 855, "0" +503, 9, 24, 171, 105, 106, 856, 857, "." +503, 9, 25, 172, 107, 109, 858, 860, "02" +503, 9, 26, 173, 110, 111, 861, 862, "%" +503, 9, 27, 174, 112, 113, 863, 864, "-" +503, 9, 28, 175, 114, 123, 865, 874, "preserved" +503, 9, 29, 176, 124, 135, 875, 886, "bimatoprost" +503, 9, 30, 177, 136, 137, 887, 888, "0" +503, 9, 31, 178, 138, 139, 889, 890, "." +503, 9, 32, 179, 140, 142, 891, 893, "01" +503, 9, 33, 180, 143, 144, 894, 895, "%" +503, 9, 34, 181, 145, 146, 896, 897, "(" +503, 9, 35, 182, 147, 150, 898, 901, "BIM" +503, 9, 36, 183, 151, 152, 902, 903, ")" +503, 9, 37, 184, 153, 159, 904, 910, "during" +503, 9, 38, 185, 160, 164, 911, 915, "late" +503, 9, 39, 186, 165, 166, 916, 917, "-" +503, 9, 40, 187, 167, 170, 918, 921, "day" +503, 9, 41, 188, 171, 175, 922, 926, "time" +503, 9, 42, 189, 176, 182, 927, 933, "points" +503, 9, 43, 190, 183, 185, 934, 936, "in" +503, 9, 44, 191, 186, 194, 937, 945, "patients" +503, 9, 45, 192, 195, 199, 946, 950, "with" +503, 9, 46, 193, 200, 204, 951, 955, "open" +503, 9, 47, 194, 205, 206, 956, 957, "-" +503, 9, 48, 195, 207, 212, 958, 963, "angle" +503, 9, 49, 196, 213, 221, 964, 972, "glaucoma" +503, 9, 50, 197, 222, 224, 973, 975, "or" +503, 9, 51, 198, 225, 231, 976, 982, "ocular" +503, 9, 52, 199, 232, 244, 983, 995, "hypertension" +503, 9, 53, 200, 245, 246, 996, 997, "." +503, 10, 1, 201, 0, 7, 998, 1005, "METHODS" +503, 10, 2, 202, 8, 9, 1006, 1007, ":" +503, 10, 3, 203, 10, 14, 1008, 1012, "This" +503, 10, 4, 204, 15, 18, 1013, 1016, "was" +503, 10, 5, 205, 19, 20, 1017, 1018, "a" +503, 10, 6, 206, 21, 23, 1019, 1021, "12" +503, 10, 7, 207, 24, 25, 1022, 1023, "-" +503, 10, 8, 208, 26, 30, 1024, 1028, "week" +503, 10, 9, 209, 31, 32, 1029, 1030, "," +503, 10, 10, 210, 33, 38, 1031, 1036, "phase" +503, 10, 11, 211, 39, 40, 1037, 1038, "4" +503, 10, 12, 212, 41, 42, 1039, 1040, "," +503, 10, 13, 213, 43, 53, 1041, 1051, "randomized" +503, 10, 14, 214, 54, 55, 1052, 1053, "," +503, 10, 15, 215, 56, 68, 1054, 1066, "investigator" +503, 10, 16, 216, 69, 70, 1067, 1068, "-" +503, 10, 17, 217, 71, 77, 1069, 1075, "masked" +503, 10, 18, 218, 78, 79, 1076, 1077, "," +503, 10, 19, 219, 80, 89, 1078, 1087, "crossover" +503, 10, 20, 220, 90, 95, 1088, 1093, "study" +503, 10, 21, 221, 96, 97, 1094, 1095, "." +503, 11, 1, 222, 0, 2, 1096, 1098, "84" +503, 11, 2, 223, 3, 11, 1099, 1107, "patients" +503, 11, 3, 224, 12, 16, 1108, 1112, "with" +503, 11, 4, 225, 17, 20, 1113, 1116, "IOP" +503, 11, 5, 226, 21, 22, 1117, 1118, "≥" +503, 11, 6, 227, 23, 25, 1119, 1121, "24" +503, 11, 7, 228, 26, 29, 1122, 1125, "and" +503, 11, 8, 229, 30, 31, 1126, 1127, "<" +503, 11, 9, 230, 32, 34, 1128, 1130, "36" +503, 11, 10, 231, 35, 39, 1131, 1135, "mmHg" +503, 11, 11, 232, 40, 44, 1136, 1140, "were" +503, 11, 12, 233, 45, 55, 1141, 1151, "randomized" +503, 11, 13, 234, 56, 57, 1152, 1153, "1" +503, 11, 14, 235, 58, 59, 1154, 1155, ":" +503, 11, 15, 236, 60, 61, 1156, 1157, "1" +503, 11, 16, 237, 62, 64, 1158, 1160, "to" +503, 11, 17, 238, 65, 72, 1161, 1168, "receive" +503, 11, 18, 239, 73, 77, 1169, 1173, "once" +503, 11, 19, 240, 78, 79, 1174, 1175, "-" +503, 11, 20, 241, 80, 85, 1176, 1181, "daily" +503, 11, 21, 242, 86, 90, 1182, 1186, "TRAV" +503, 11, 22, 243, 91, 93, 1187, 1189, "or" +503, 11, 23, 244, 94, 97, 1190, 1193, "BIM" +503, 11, 24, 245, 98, 101, 1194, 1197, "for" +503, 11, 25, 246, 102, 103, 1198, 1199, "6" +503, 11, 26, 247, 104, 109, 1200, 1205, "weeks" +503, 11, 27, 248, 110, 118, 1206, 1214, "followed" +503, 11, 28, 249, 119, 121, 1215, 1217, "by" +503, 11, 29, 250, 122, 124, 1218, 1220, "an" +503, 11, 30, 251, 125, 135, 1221, 1231, "additional" +503, 11, 31, 252, 136, 137, 1232, 1233, "6" +503, 11, 32, 253, 138, 139, 1234, 1235, "-" +503, 11, 33, 254, 140, 144, 1236, 1240, "week" +503, 11, 34, 255, 145, 154, 1241, 1250, "crossover" +503, 11, 35, 256, 155, 161, 1251, 1257, "period" +503, 11, 36, 257, 162, 163, 1258, 1259, "." +503, 12, 1, 258, 0, 3, 1260, 1263, "IOP" +503, 12, 2, 259, 4, 7, 1264, 1267, "was" +503, 12, 3, 260, 8, 16, 1268, 1276, "measured" +503, 12, 4, 261, 17, 19, 1277, 1279, "at" +503, 12, 5, 262, 20, 23, 1280, 1283, "the" +503, 12, 6, 263, 24, 27, 1284, 1287, "end" +503, 12, 7, 264, 28, 30, 1288, 1290, "of" +503, 12, 8, 265, 31, 35, 1291, 1295, "each" +503, 12, 9, 266, 36, 45, 1296, 1305, "treatment" +503, 12, 10, 267, 46, 52, 1306, 1312, "period" +503, 12, 11, 268, 53, 55, 1313, 1315, "at" +503, 12, 12, 269, 56, 57, 1316, 1317, "4" +503, 12, 13, 270, 58, 59, 1318, 1319, "," +503, 12, 14, 271, 60, 61, 1320, 1321, "6" +503, 12, 15, 272, 62, 63, 1322, 1323, "," +503, 12, 16, 273, 64, 67, 1324, 1327, "and" +503, 12, 17, 274, 68, 69, 1328, 1329, "8" +503, 12, 18, 275, 70, 72, 1330, 1332, "pm" +503, 12, 19, 276, 73, 74, 1333, 1334, "." +503, 13, 1, 277, 0, 4, 1335, 1339, "TRAV" +503, 13, 2, 278, 5, 8, 1340, 1343, "was" +503, 13, 3, 279, 9, 19, 1344, 1354, "considered" +503, 13, 4, 280, 20, 31, 1355, 1366, "noninferior" +503, 13, 5, 281, 32, 34, 1367, 1369, "to" +503, 13, 6, 282, 35, 38, 1370, 1373, "BIM" +503, 13, 7, 283, 39, 41, 1374, 1376, "if" +503, 13, 8, 284, 42, 45, 1377, 1380, "the" +503, 13, 9, 285, 46, 51, 1381, 1386, "upper" +503, 13, 10, 286, 52, 57, 1387, 1392, "limit" +503, 13, 11, 287, 58, 60, 1393, 1395, "of" +503, 13, 12, 288, 61, 64, 1396, 1399, "the" +503, 13, 13, 289, 65, 67, 1400, 1402, "95" +503, 13, 14, 290, 68, 69, 1403, 1404, "%" +503, 13, 15, 291, 70, 72, 1405, 1407, "CI" +503, 13, 16, 292, 73, 75, 1408, 1410, "of" +503, 13, 17, 293, 76, 79, 1411, 1414, "the" +503, 13, 18, 294, 80, 87, 1415, 1422, "between" +503, 13, 19, 295, 88, 89, 1423, 1424, "-" +503, 13, 20, 296, 90, 95, 1425, 1430, "group" +503, 13, 21, 297, 96, 106, 1431, 1441, "difference" +503, 13, 22, 298, 107, 109, 1442, 1444, "in" +503, 13, 23, 299, 110, 114, 1445, 1449, "mean" +503, 13, 24, 300, 115, 118, 1450, 1453, "IOP" +503, 13, 25, 301, 119, 122, 1454, 1457, "was" +503, 13, 26, 302, 123, 124, 1458, 1459, "≤" +503, 13, 27, 303, 125, 126, 1460, 1461, "1" +503, 13, 28, 304, 127, 128, 1462, 1463, "." +503, 13, 29, 305, 129, 130, 1464, 1465, "5" +503, 13, 30, 306, 131, 135, 1466, 1470, "mmHg" +503, 13, 31, 307, 136, 137, 1471, 1472, "." +503, 14, 1, 308, 0, 7, 1473, 1480, "Adverse" +503, 14, 2, 309, 8, 14, 1481, 1487, "events" +503, 14, 3, 310, 15, 19, 1488, 1492, "were" +503, 14, 4, 311, 20, 28, 1493, 1501, "assessed" +503, 14, 5, 312, 29, 39, 1502, 1512, "throughout" +503, 14, 6, 313, 40, 43, 1513, 1516, "the" +503, 14, 7, 314, 44, 49, 1517, 1522, "study" +503, 14, 8, 315, 50, 51, 1523, 1524, "." +503, 15, 1, 316, 0, 7, 1525, 1532, "RESULTS" +503, 15, 2, 317, 8, 9, 1533, 1534, ":" +503, 15, 3, 318, 10, 13, 1535, 1538, "One" +503, 15, 4, 319, 14, 21, 1539, 1546, "patient" +503, 15, 5, 320, 22, 34, 1547, 1559, "discontinued" +503, 15, 6, 321, 35, 38, 1560, 1563, "due" +503, 15, 7, 322, 39, 41, 1564, 1566, "to" +503, 15, 8, 323, 42, 50, 1567, 1575, "allergic" +503, 15, 9, 324, 51, 65, 1576, 1590, "conjunctivitis" +503, 15, 10, 325, 66, 67, 1591, 1592, "," +503, 15, 11, 326, 68, 71, 1593, 1596, "and" +503, 15, 12, 327, 72, 73, 1597, 1598, "2" +503, 15, 13, 328, 74, 82, 1599, 1607, "patients" +503, 15, 14, 329, 83, 87, 1608, 1612, "with" +503, 15, 15, 330, 88, 95, 1613, 1620, "missing" +503, 15, 16, 331, 96, 100, 1621, 1625, "data" +503, 15, 17, 332, 101, 105, 1626, 1630, "were" +503, 15, 18, 333, 106, 114, 1631, 1639, "excluded" +503, 15, 19, 334, 115, 116, 1640, 1641, ";" +503, 15, 20, 335, 117, 119, 1642, 1644, "81" +503, 15, 21, 336, 120, 128, 1645, 1653, "patients" +503, 15, 22, 337, 129, 133, 1654, 1658, "were" +503, 15, 23, 338, 134, 142, 1659, 1667, "included" +503, 15, 24, 339, 143, 145, 1668, 1670, "in" +503, 15, 25, 340, 146, 149, 1671, 1674, "the" +503, 15, 26, 341, 150, 153, 1675, 1678, "per" +503, 15, 27, 342, 154, 155, 1679, 1680, "-" +503, 15, 28, 343, 156, 164, 1681, 1689, "protocol" +503, 15, 29, 344, 165, 175, 1690, 1700, "population" +503, 15, 30, 345, 176, 177, 1701, 1702, "(" +503, 15, 31, 346, 178, 182, 1703, 1707, "mean" +503, 15, 32, 347, 183, 184, 1708, 1709, "±" +503, 15, 33, 348, 185, 187, 1710, 1712, "SD" +503, 15, 34, 349, 188, 191, 1713, 1716, "age" +503, 15, 35, 350, 192, 193, 1717, 1718, "," +503, 15, 36, 351, 194, 196, 1719, 1721, "58" +503, 15, 37, 352, 197, 198, 1722, 1723, "." +503, 15, 38, 353, 199, 200, 1724, 1725, "3" +503, 15, 39, 354, 201, 202, 1726, 1727, "±" +503, 15, 40, 355, 203, 205, 1728, 1730, "11" +503, 15, 41, 356, 206, 207, 1731, 1732, "." +503, 15, 42, 357, 208, 209, 1733, 1734, "4" +503, 15, 43, 358, 210, 215, 1735, 1740, "years" +503, 15, 44, 359, 216, 217, 1741, 1742, ";" +503, 15, 45, 360, 218, 222, 1743, 1747, "TRAV" +503, 15, 46, 361, 223, 224, 1748, 1749, "/" +503, 15, 47, 362, 225, 228, 1750, 1753, "BIM" +503, 15, 48, 363, 229, 230, 1754, 1755, "," +503, 15, 49, 364, 231, 232, 1756, 1757, "n" +503, 15, 50, 365, 233, 234, 1758, 1759, "=" +503, 15, 51, 366, 235, 237, 1760, 1762, "41" +503, 15, 52, 367, 238, 239, 1763, 1764, ";" +503, 15, 53, 368, 240, 243, 1765, 1768, "BIM" +503, 15, 54, 369, 244, 245, 1769, 1770, "/" +503, 15, 55, 370, 246, 250, 1771, 1775, "TRAV" +503, 15, 56, 371, 251, 252, 1776, 1777, "," +503, 15, 57, 372, 253, 254, 1778, 1779, "n" +503, 15, 58, 373, 255, 256, 1780, 1781, "=" +503, 15, 59, 374, 257, 259, 1782, 1784, "40" +503, 15, 60, 375, 260, 261, 1785, 1786, ")" +503, 15, 61, 376, 262, 263, 1787, 1788, "." +503, 16, 1, 377, 0, 5, 1789, 1794, "After" +503, 16, 2, 378, 6, 7, 1795, 1796, "6" +503, 16, 3, 379, 8, 13, 1797, 1802, "weeks" +503, 16, 4, 380, 14, 15, 1803, 1804, "," +503, 16, 5, 381, 16, 20, 1805, 1809, "mean" +503, 16, 6, 382, 21, 24, 1810, 1813, "IOP" +503, 16, 7, 383, 25, 29, 1814, 1818, "with" +503, 16, 8, 384, 30, 34, 1819, 1823, "TRAV" +503, 16, 9, 385, 35, 36, 1824, 1825, "(" +503, 16, 10, 386, 37, 39, 1826, 1828, "17" +503, 16, 11, 387, 40, 41, 1829, 1830, "." +503, 16, 12, 388, 42, 43, 1831, 1832, "4" +503, 16, 13, 389, 44, 45, 1833, 1834, "±" +503, 16, 14, 390, 46, 47, 1835, 1836, "2" +503, 16, 15, 391, 48, 49, 1837, 1838, "." +503, 16, 16, 392, 50, 51, 1839, 1840, "7" +503, 16, 17, 393, 52, 56, 1841, 1845, "mmHg" +503, 16, 18, 394, 57, 58, 1846, 1847, ";" +503, 16, 19, 395, 59, 65, 1848, 1854, "change" +503, 16, 20, 396, 66, 70, 1855, 1859, "from" +503, 16, 21, 397, 71, 79, 1860, 1868, "baseline" +503, 16, 22, 398, 80, 81, 1869, 1870, "," +503, 16, 23, 399, 82, 83, 1871, 1872, "-" +503, 16, 24, 400, 84, 85, 1873, 1874, "6" +503, 16, 25, 401, 86, 87, 1875, 1876, "." +503, 16, 26, 402, 88, 89, 1877, 1878, "0" +503, 16, 27, 403, 90, 94, 1879, 1883, "mmHg" +503, 16, 28, 404, 95, 96, 1884, 1885, ")" +503, 16, 29, 405, 97, 100, 1886, 1889, "was" +503, 16, 30, 406, 101, 108, 1890, 1897, "similar" +503, 16, 31, 407, 109, 111, 1898, 1900, "to" +503, 16, 32, 408, 112, 115, 1901, 1904, "BIM" +503, 16, 33, 409, 116, 117, 1905, 1906, "(" +503, 16, 34, 410, 118, 120, 1907, 1909, "17" +503, 16, 35, 411, 121, 122, 1910, 1911, "." +503, 16, 36, 412, 123, 124, 1912, 1913, "2" +503, 16, 37, 413, 125, 126, 1914, 1915, "±" +503, 16, 38, 414, 127, 128, 1916, 1917, "2" +503, 16, 39, 415, 129, 130, 1918, 1919, "." +503, 16, 40, 416, 131, 132, 1920, 1921, "6" +503, 16, 41, 417, 133, 137, 1922, 1926, "mmHg" +503, 16, 42, 418, 138, 139, 1927, 1928, ";" +503, 16, 43, 419, 140, 146, 1929, 1935, "change" +503, 16, 44, 420, 147, 151, 1936, 1940, "from" +503, 16, 45, 421, 152, 160, 1941, 1949, "baseline" +503, 16, 46, 422, 161, 162, 1950, 1951, "," +503, 16, 47, 423, 163, 164, 1952, 1953, "-" +503, 16, 48, 424, 165, 166, 1954, 1955, "6" +503, 16, 49, 425, 167, 168, 1956, 1957, "." +503, 16, 50, 426, 169, 170, 1958, 1959, "3" +503, 16, 51, 427, 171, 175, 1960, 1964, "mmHg" +503, 16, 52, 428, 176, 177, 1965, 1966, ")" +503, 16, 53, 429, 178, 179, 1967, 1968, ";" +503, 16, 54, 430, 180, 183, 1969, 1972, "the" +503, 16, 55, 431, 184, 191, 1973, 1980, "between" +503, 16, 56, 432, 192, 193, 1981, 1982, "-" +503, 16, 57, 433, 194, 199, 1983, 1988, "group" +503, 16, 58, 434, 200, 210, 1989, 1999, "difference" +503, 16, 59, 435, 211, 214, 2000, 2003, "was" +503, 16, 60, 436, 215, 216, 2004, 2005, "0" +503, 16, 61, 437, 217, 218, 2006, 2007, "." +503, 16, 62, 438, 219, 221, 2008, 2010, "22" +503, 16, 63, 439, 222, 226, 2011, 2015, "mmHg" +503, 16, 64, 440, 227, 228, 2016, 2017, "(" +503, 16, 65, 441, 229, 231, 2018, 2020, "95" +503, 16, 66, 442, 232, 233, 2021, 2022, "%" +503, 16, 67, 443, 234, 236, 2023, 2025, "CI" +503, 16, 68, 444, 237, 238, 2026, 2027, "," +503, 16, 69, 445, 239, 240, 2028, 2029, "-" +503, 16, 70, 446, 241, 242, 2030, 2031, "0" +503, 16, 71, 447, 243, 244, 2032, 2033, "." +503, 16, 72, 448, 245, 247, 2034, 2036, "22" +503, 16, 73, 449, 248, 250, 2037, 2039, "to" +503, 16, 74, 450, 251, 252, 2040, 2041, "0" +503, 16, 75, 451, 253, 254, 2042, 2043, "." +503, 16, 76, 452, 255, 257, 2044, 2046, "67" +503, 16, 77, 453, 258, 259, 2047, 2048, ")" +503, 16, 78, 454, 260, 261, 2049, 2050, "." +503, 17, 1, 455, 0, 4, 2051, 2055, "Thus" +503, 17, 2, 456, 5, 6, 2056, 2057, "," +503, 17, 3, 457, 7, 21, 2058, 2072, "noninferiority" +503, 17, 4, 458, 22, 24, 2073, 2075, "of" +503, 17, 5, 459, 25, 29, 2076, 2080, "TRAV" +503, 17, 6, 460, 30, 36, 2081, 2087, "versus" +503, 17, 7, 461, 37, 40, 2088, 2091, "BIM" +503, 17, 8, 462, 41, 44, 2092, 2095, "was" +503, 17, 9, 463, 45, 57, 2096, 2108, "demonstrated" +503, 17, 10, 464, 58, 59, 2109, 2110, "." +503, 18, 1, 465, 0, 4, 2111, 2115, "Mean" +503, 18, 2, 466, 5, 8, 2116, 2119, "IOP" +503, 18, 3, 467, 9, 11, 2120, 2122, "at" +503, 18, 4, 468, 12, 16, 2123, 2127, "each" +503, 18, 5, 469, 17, 21, 2128, 2132, "time" +503, 18, 6, 470, 22, 27, 2133, 2138, "point" +503, 18, 7, 471, 28, 31, 2139, 2142, "and" +503, 18, 8, 472, 32, 36, 2143, 2147, "mean" +503, 18, 9, 473, 37, 40, 2148, 2151, "and" +503, 18, 10, 474, 41, 51, 2152, 2162, "percentage" +503, 18, 11, 475, 52, 55, 2163, 2166, "IOP" +503, 18, 12, 476, 56, 62, 2167, 2173, "change" +503, 18, 13, 477, 63, 67, 2174, 2178, "from" +503, 18, 14, 478, 68, 76, 2179, 2187, "baseline" +503, 18, 15, 479, 77, 81, 2188, 2192, "were" +503, 18, 16, 480, 82, 85, 2193, 2196, "not" +503, 18, 17, 481, 86, 99, 2197, 2210, "significantly" +503, 18, 18, 482, 100, 109, 2211, 2220, "different" +503, 18, 19, 483, 110, 117, 2221, 2228, "between" +503, 18, 20, 484, 118, 128, 2229, 2239, "treatments" +503, 18, 21, 485, 129, 130, 2240, 2241, "." +503, 19, 1, 486, 0, 3, 2242, 2245, "All" +503, 19, 2, 487, 4, 13, 2246, 2255, "treatment" +503, 19, 3, 488, 14, 15, 2256, 2257, "-" +503, 19, 4, 489, 16, 24, 2258, 2266, "emergent" +503, 19, 5, 490, 25, 32, 2267, 2274, "adverse" +503, 19, 6, 491, 33, 39, 2275, 2281, "events" +503, 19, 7, 492, 40, 44, 2282, 2286, "were" +503, 19, 8, 493, 45, 49, 2287, 2291, "mild" +503, 19, 9, 494, 50, 52, 2292, 2294, "to" +503, 19, 10, 495, 53, 61, 2295, 2303, "moderate" +503, 19, 11, 496, 62, 63, 2304, 2305, "." +503, 20, 1, 497, 0, 3, 2306, 2309, "The" +503, 20, 2, 498, 4, 14, 2310, 2320, "incidences" +503, 20, 3, 499, 15, 17, 2321, 2323, "of" +503, 20, 4, 500, 18, 22, 2324, 2328, "mild" +503, 20, 5, 501, 23, 29, 2329, 2335, "ocular" +503, 20, 6, 502, 30, 39, 2336, 2345, "hyperemia" +503, 20, 7, 503, 40, 44, 2346, 2350, "with" +503, 20, 8, 504, 45, 49, 2351, 2355, "TRAV" +503, 20, 9, 505, 50, 53, 2356, 2359, "and" +503, 20, 10, 506, 54, 57, 2360, 2363, "BIM" +503, 20, 11, 507, 58, 62, 2364, 2368, "were" +503, 20, 12, 508, 63, 65, 2369, 2371, "31" +503, 20, 13, 509, 66, 67, 2372, 2373, "%" +503, 20, 14, 510, 68, 71, 2374, 2377, "and" +503, 20, 15, 511, 72, 74, 2378, 2380, "39" +503, 20, 16, 512, 75, 76, 2381, 2382, "%" +503, 20, 17, 513, 77, 78, 2383, 2384, "," +503, 20, 18, 514, 79, 91, 2385, 2397, "respectively" +503, 20, 19, 515, 92, 93, 2398, 2399, ";" +503, 20, 20, 516, 94, 102, 2400, 2408, "moderate" +503, 20, 21, 517, 103, 112, 2409, 2418, "hyperemia" +503, 20, 22, 518, 113, 116, 2419, 2422, "was" +503, 20, 23, 519, 117, 125, 2423, 2431, "observed" +503, 20, 24, 520, 126, 128, 2432, 2434, "in" +503, 20, 25, 521, 129, 130, 2435, 2436, "2" +503, 20, 26, 522, 131, 132, 2437, 2438, "%" +503, 20, 27, 523, 133, 135, 2439, 2441, "of" +503, 20, 28, 524, 136, 144, 2442, 2450, "patients" +503, 20, 29, 525, 145, 154, 2451, 2460, "receiving" +503, 20, 30, 526, 155, 158, 2461, 2464, "BIM" +503, 20, 31, 527, 159, 160, 2465, 2466, "." +503, 21, 1, 528, 0, 10, 2467, 2477, "CONCLUSION" +503, 21, 2, 529, 11, 12, 2478, 2479, ":" +503, 21, 3, 530, 13, 17, 2480, 2484, "Late" +503, 21, 4, 531, 18, 19, 2485, 2486, "-" +503, 21, 5, 532, 20, 23, 2487, 2490, "day" +503, 21, 6, 533, 24, 27, 2491, 2494, "IOP" +503, 21, 7, 534, 28, 29, 2495, 2496, "-" +503, 21, 8, 535, 30, 38, 2497, 2505, "lowering" +503, 21, 9, 536, 39, 47, 2506, 2514, "efficacy" +503, 21, 10, 537, 48, 50, 2515, 2517, "of" +503, 21, 11, 538, 51, 54, 2518, 2521, "BAK" +503, 21, 12, 539, 55, 56, 2522, 2523, "-" +503, 21, 13, 540, 57, 61, 2524, 2528, "free" +503, 21, 14, 541, 62, 66, 2529, 2533, "TRAV" +503, 21, 15, 542, 67, 70, 2534, 2537, "was" +503, 21, 16, 543, 71, 82, 2538, 2549, "noninferior" +503, 21, 17, 544, 83, 85, 2550, 2552, "to" +503, 21, 18, 545, 86, 90, 2553, 2557, "that" +503, 21, 19, 546, 91, 93, 2558, 2560, "of" +503, 21, 20, 547, 94, 97, 2561, 2564, "BAK" +503, 21, 21, 548, 98, 99, 2565, 2566, "0" +503, 21, 22, 549, 100, 101, 2567, 2568, "." +503, 21, 23, 550, 102, 104, 2569, 2571, "02" +503, 21, 24, 551, 105, 106, 2572, 2573, "%" +503, 21, 25, 552, 107, 108, 2574, 2575, "-" +503, 21, 26, 553, 109, 118, 2576, 2585, "preserved" +503, 21, 27, 554, 119, 122, 2586, 2589, "BIM" +503, 21, 28, 555, 123, 124, 2590, 2591, ";" +503, 21, 29, 556, 125, 129, 2592, 2596, "both" +503, 21, 30, 557, 130, 137, 2597, 2604, "reduced" +503, 21, 31, 558, 138, 146, 2605, 2613, "baseline" +503, 21, 32, 559, 147, 150, 2614, 2617, "IOP" +503, 21, 33, 560, 151, 153, 2618, 2620, "by" +503, 21, 34, 561, 154, 156, 2621, 2623, "25" +503, 21, 35, 562, 157, 158, 2624, 2625, "%" +503, 21, 36, 563, 159, 160, 2626, 2627, "." +503, 22, 1, 564, 0, 4, 2628, 2632, "Both" +503, 22, 2, 565, 5, 15, 2633, 2643, "treatments" +503, 22, 3, 566, 16, 20, 2644, 2648, "were" +503, 22, 4, 567, 21, 25, 2649, 2653, "well" +503, 22, 5, 568, 26, 35, 2654, 2663, "tolerated" +503, 22, 6, 569, 36, 37, 2664, 2665, "," +503, 22, 7, 570, 38, 46, 2666, 2674, "although" +503, 22, 8, 571, 47, 48, 2675, 2676, "a" +503, 22, 9, 572, 49, 55, 2677, 2683, "higher" +503, 22, 10, 573, 56, 65, 2684, 2693, "incidence" +503, 22, 11, 574, 66, 68, 2694, 2696, "of" +503, 22, 12, 575, 69, 77, 2697, 2705, "moderate" +503, 22, 13, 576, 78, 84, 2706, 2712, "ocular" +503, 22, 14, 577, 85, 94, 2713, 2722, "hyperemia" +503, 22, 15, 578, 95, 98, 2723, 2726, "was" +503, 22, 16, 579, 99, 107, 2727, 2735, "observed" +503, 22, 17, 580, 108, 112, 2736, 2740, "with" +503, 22, 18, 581, 113, 116, 2741, 2744, "BIM" +503, 22, 19, 582, 117, 118, 2745, 2746, "." +503, 23, 1, 583, 0, 5, 2747, 2752, "TRIAL" +503, 23, 2, 584, 6, 18, 2753, 2765, "REGISTRATION" +503, 23, 3, 585, 19, 20, 2766, 2767, ":" +503, 23, 4, 586, 21, 35, 2768, 2782, "ClinicalTrials" +503, 23, 5, 587, 36, 37, 2783, 2784, "." +503, 23, 6, 588, 38, 41, 2785, 2788, "gov" +503, 23, 7, 589, 42, 52, 2789, 2799, "identifier" +503, 23, 8, 590, 53, 54, 2800, 2801, "," +503, 23, 9, 591, 55, 66, 2802, 2813, "NCT01464424" +503, 23, 10, 592, 67, 68, 2814, 2815, ";" +503, 23, 11, 593, 69, 79, 2816, 2826, "registered" +503, 23, 12, 594, 80, 88, 2827, 2835, "November" +503, 23, 13, 595, 89, 90, 2836, 2837, "1" +503, 23, 14, 596, 91, 92, 2838, 2839, "," +503, 23, 15, 597, 93, 97, 2840, 2844, "2011" +503, 23, 16, 598, 98, 99, 2845, 2846, "." +503, 24, 1, 599, 0, 3, 2847, 2850, "DOI" +503, 24, 2, 600, 4, 5, 2851, 2852, ":" +503, 24, 3, 601, 6, 8, 2853, 2855, "10" +503, 24, 4, 602, 9, 10, 2856, 2857, "." +503, 24, 5, 603, 11, 15, 2858, 2862, "1186" +503, 24, 6, 604, 16, 17, 2863, 2864, "/" +503, 24, 7, 605, 18, 22, 2865, 2869, "1471" +503, 24, 8, 606, 23, 24, 2870, 2871, "-" +503, 24, 9, 607, 25, 29, 2872, 2876, "2415" +503, 24, 10, 608, 30, 31, 2877, 2878, "-" +503, 24, 11, 609, 32, 34, 2879, 2881, "14" +503, 24, 12, 610, 35, 36, 2882, 2883, "-" +503, 24, 13, 611, 37, 40, 2884, 2887, "151" +503, 24, 14, 612, 41, 46, 2888, 2893, "PMCID" +503, 24, 15, 613, 47, 48, 2894, 2895, ":" +503, 24, 16, 614, 49, 59, 2896, 2906, "PMC4298043" +503, 24, 17, 615, 60, 64, 2907, 2911, "PMID" +503, 24, 18, 616, 65, 66, 2912, 2913, ":" +503, 24, 19, 617, 67, 75, 2914, 2922, "25432143" +503, 24, 20, 618, 76, 77, 2923, 2924, "[" +503, 24, 21, 619, 78, 85, 2925, 2932, "Indexed" +503, 24, 22, 620, 86, 89, 2933, 2936, "for" +503, 24, 23, 621, 90, 97, 2937, 2944, "MEDLINE" +503, 24, 24, 622, 98, 99, 2945, 2946, "]" diff --git a/data/gl 25432143_jshahinitiran.annodb b/data/gl 25432143_jshahinitiran.annodb new file mode 100644 index 0000000..dfa74c6 --- /dev/null +++ b/data/gl 25432143_jshahinitiran.annodb @@ -0,0 +1,101 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +75511, Journal, 0, 16, "BMC Ophthalmol .", "", +75512, PublicationYear, 17, 21, "2014", "", +75513, Title, 85, 290, "Late - day intraocular pressure - lowering efficacy and tolerability of travoprost 0 . 004 % versus bimatoprost 0 . 01 % in patients with open - angle glaucoma or ocular hypertension : a randomized trial .", "", +75514, IOP, 96, 116, "intraocular pressure", "", +75515, Travoprost, 157, 167, "travoprost", "", +75517, DoseValue, 168, 175, "0 . 004", "", +75516, Bimatoprost, 185, 196, "bimatoprost", "", +75518, DoseValue, 197, 203, "0 . 01", "", +75519, OpenAngleGlaucoma, 223, 244, "open - angle glaucoma", "", +75520, OcularHypertension, 248, 267, "ocular hypertension", "", +75521, Randomized, 272, 282, "randomized", "", +75522, Author, 291, 301, "DuBiner HB", "", +75523, Author, 310, 321, "Hubatsch DA", "", +75524, IOP, 508, 528, "intraocular pressure", "", +75525, IOP, 531, 534, "IOP", "", +75535, ObjectiveDescription, 751, 997, "The present study compared the efficacy and safety of BAK - free travoprost 0 . 004 % ( TRAV ) and BAK 0 . 02 % - preserved bimatoprost 0 . 01 % ( BIM ) during late - day time points in patients with open - angle glaucoma or ocular hypertension .", "", +75526, Travoprost, 805, 826, "BAK - free travoprost", "", +75528, DoseValue, 827, 834, "0 . 004", "", +75530, Travoprost, 839, 843, "TRAV", "", +75527, Bimatoprost, 850, 886, "BAK 0 . 02 % - preserved bimatoprost", "", +75529, DoseValue, 887, 893, "0 . 01", "", +75531, Bimatoprost, 898, 901, "BIM", "", +75532, OpenAngleGlaucoma, 951, 972, "open - angle glaucoma", "", +75533, OcularHypertension, 976, 995, "ocular hypertension", "", +75537, Duration, 1019, 1028, "12 - week", "", +75538, CTDesign, 1031, 1038, "phase 4", "", +75539, Randomized, 1041, 1051, "randomized", "", +75540, Blind, 1054, 1075, "investigator - masked", "", +75541, Crossover, 1078, 1087, "crossover", "", +75543, NumberPatientsCT, 1096, 1098, "84", "", +75548, Precondition, 1108, 1135, "with IOP ≥ 24 and < 36 mmHg", "", +75545, IOP, 1113, 1116, "IOP", "", +75547, mmHg, 1131, 1135, "mmHg", "", +75549, Randomized, 1141, 1151, "randomized", "", +75550, AllocationRatio, 1152, 1157, "1 : 1", "", +75551, Frequency, 1169, 1181, "once - daily", "", +75552, Travoprost, 1182, 1186, "TRAV", "", +75553, Bimatoprost, 1190, 1193, "BIM", "", +75554, Duration, 1198, 1205, "6 weeks", "", +75555, Duration, 1232, 1240, "6 - week", "", +75556, Crossover, 1241, 1250, "crossover", "", +75557, IOP, 1260, 1263, "IOP", "", +75558, Travoprost, 1335, 1339, "TRAV", "", +75559, Bimatoprost, 1370, 1373, "BIM", "", +75560, Mean, 1445, 1449, "mean", "", +75561, IOP, 1450, 1453, "IOP", "", +75562, mmHg, 1466, 1470, "mmHg", "", +75563, FinalNumPatientsCT, 1642, 1644, "81", "", +75565, PerProtocol, 1675, 1689, "per - protocol", "", +75566, Mean, 1703, 1707, "mean", "", +75567, AvgAge, 1719, 1725, "58 . 3", "", +75568, Travoprost, 1743, 1747, "TRAV", "", +75569, Bimatoprost, 1750, 1753, "BIM", "", +75570, NumberPatientsArm, 1760, 1762, "41", "", +75571, NumberPatientsArm, 1782, 1784, "40", "", +75572, Duration, 1795, 1802, "6 weeks", "", +75573, Mean, 1805, 1809, "mean", "", +75574, IOP, 1810, 1813, "IOP", "", +75575, Travoprost, 1819, 1823, "TRAV", "", +75576, ResultMeasuredValue, 1826, 1832, "17 . 4", "", +75578, SdDevResValue, 1835, 1840, "2 . 7", "", +75580, mmHg, 1841, 1845, "mmHg", "", +75582, Reduction, 1873, 1878, "6 . 0", "", +75584, mmHg, 1879, 1883, "mmHg", "", +75585, Bimatoprost, 1901, 1904, "BIM", "", +75577, ResultMeasuredValue, 1907, 1913, "17 . 2", "", +75579, SdDevResValue, 1916, 1921, "2 . 6", "", +75586, mmHg, 1922, 1926, "mmHg", "", +75583, Reduction, 1954, 1959, "6 . 3", "", +75581, mmHg, 1960, 1964, "mmHg", "", +75587, DiffGroupAbsValue, 2004, 2010, "0 . 22", "", +75588, mmHg, 2011, 2015, "mmHg", "", +75589, ConfIntervalDiff, 2018, 2046, "95 % CI , - 0 . 22 to 0 . 67", "", +75590, Travoprost, 2076, 2080, "TRAV", "", +75591, Bimatoprost, 2088, 2091, "BIM", "", +75592, Mean, 2111, 2115, "Mean", "", +75596, ObservedResult, 2111, 2241, "Mean IOP at each time point and mean and percentage IOP change from baseline were not significantly different between treatments .", "", +75593, IOP, 2116, 2119, "IOP", "", +75594, Mean, 2143, 2147, "mean", "", +75595, IOP, 2163, 2166, "IOP", "", +75597, ObservedResult, 2242, 2305, "All treatment - emergent adverse events were mild to moderate .", "", +75606, ObservedResult, 2306, 2466, "The incidences of mild ocular hyperemia with TRAV and BIM were 31 % and 39 % , respectively ; moderate hyperemia was observed in 2 % of patients receiving BIM .", "", +75598, ConjunctivalHyperemia, 2329, 2345, "ocular hyperemia", "", +75599, Travoprost, 2351, 2355, "TRAV", "", +75600, Bimatoprost, 2360, 2363, "BIM", "", +75601, PercentageAffected, 2369, 2371, "31", "", +75602, PercentageAffected, 2378, 2380, "39", "", +75604, ConjunctivalHyperemia, 2409, 2418, "hyperemia", "", +75603, PercentageAffected, 2435, 2436, "2", "", +75605, Bimatoprost, 2461, 2464, "BIM", "", +75614, ConclusionComment, 2480, 2627, "Late - day IOP - lowering efficacy of BAK - free TRAV was noninferior to that of BAK 0 . 02 % - preserved BIM ; both reduced baseline IOP by 25 % .", "", +75607, IOP, 2491, 2494, "IOP", "", +75608, Travoprost, 2518, 2533, "BAK - free TRAV", "", +75609, Bimatoprost, 2561, 2589, "BAK 0 . 02 % - preserved BIM", "", +75610, IOP, 2614, 2617, "IOP", "", +75611, RelativeReduction, 2621, 2623, "25", "", +75615, ConclusionComment, 2628, 2746, "Both treatments were well tolerated , although a higher incidence of moderate ocular hyperemia was observed with BIM .", "", +75613, ConjunctivalHyperemia, 2706, 2722, "ocular hyperemia", "", +75612, Bimatoprost, 2741, 2744, "BIM", "", +75616, PMID, 2914, 2922, "25432143", "", diff --git a/data/gl 25432143_jshahinitiran.n-triples b/data/gl 25432143_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25432143_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25432143_tstrakeljahn.annodb b/data/gl 25432143_tstrakeljahn.annodb new file mode 100644 index 0000000..e667a10 --- /dev/null +++ b/data/gl 25432143_tstrakeljahn.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +84789, Journal, 0, 14, "BMC Ophthalmol", "", +84790, PublicationYear, 17, 21, "2014", "", +84804, Title, 85, 290, "Late - day intraocular pressure - lowering efficacy and tolerability of travoprost 0 . 004 % versus bimatoprost 0 . 01 % in patients with open - angle glaucoma or ocular hypertension : a randomized trial .", "", +84791, IOP, 96, 116, "intraocular pressure", "", +84792, Travoprost, 157, 167, "travoprost", "", +84797, DoseValue, 168, 175, "0 . 004", "", +84799, Percentage, 176, 177, "%", "", +84793, Bimatoprost, 185, 196, "bimatoprost", "", +84798, DoseValue, 197, 203, "0 . 01", "", +84800, Percentage, 204, 205, "%", "", +84794, OpenAngleGlaucoma, 223, 244, "open - angle glaucoma", "", +84795, OcularHypertension, 248, 267, "ocular hypertension", "", +84796, Randomized, 272, 282, "randomized", "", +84801, Author, 291, 301, "DuBiner HB", "", +84802, Author, 310, 321, "Hubatsch DA", "", +84803, USA, 434, 437, "USA", "", +84805, IOP, 508, 528, "intraocular pressure", "", +84806, IOP, 531, 534, "IOP", "", +84807, Drug, 698, 717, "prostaglandin drugs", "prostaglandin analogue", +84808, Travoprost, 816, 826, "travoprost", "", +84814, DoseValue, 827, 834, "0 . 004", "", +84819, Percentage, 835, 836, "%", "", +84811, Travoprost, 839, 843, "TRAV", "", +84820, Drug, 850, 895, "BAK 0 . 02 % - preserved bimatoprost 0 . 01 %", "BAK preserved bimatoprost", +84815, DoseValue, 854, 860, "0 . 02", "", +84817, Percentage, 861, 862, "%", "", +84809, Bimatoprost, 875, 886, "bimatoprost", "", +84816, DoseValue, 887, 893, "0 . 01", "", +84818, Percentage, 894, 895, "%", "", +84810, Bimatoprost, 898, 901, "BIM", "", +84812, OpenAngleGlaucoma, 951, 972, "open - angle glaucoma", "", +84813, OcularHypertension, 976, 995, "ocular hypertension", "", +84821, Duration, 1019, 1028, "12 - week", "", +84822, Randomized, 1041, 1051, "randomized", "", +84823, Blind, 1054, 1075, "investigator - masked", "", +84824, Crossover, 1078, 1087, "crossover", "", +84825, NumberPatientsCT, 1096, 1098, "84", "", +84826, IOP, 1113, 1116, "IOP", "", +84841, Precondition, 1113, 1135, "IOP ≥ 24 and < 36 mmHg", "", +84827, mmHg, 1131, 1135, "mmHg", "", +84828, Randomized, 1141, 1151, "randomized", "", +84829, AllocationRatio, 1152, 1157, "1 : 1", "", +84830, Frequency, 1169, 1181, "once - daily", "", +84831, Travoprost, 1182, 1186, "TRAV", "", +84832, Bimatoprost, 1190, 1193, "BIM", "", +84833, Crossover, 1241, 1250, "crossover", "", +84834, IOP, 1260, 1263, "IOP", "", +84837, TimePoint, 1316, 1332, "4 , 6 , and 8 pm", "", +84836, TimePoint, 1320, 1332, "6 , and 8 pm", "", +84835, TimePoint, 1328, 1332, "8 pm", "", +84839, Travoprost, 1335, 1339, "TRAV", "", +84840, Bimatoprost, 1370, 1373, "BIM", "", +84842, Mean, 1445, 1449, "mean", "", +84843, IOP, 1450, 1453, "IOP", "", +84844, mmHg, 1466, 1470, "mmHg", "", +84845, NumPatientsLeftCT, 1535, 1538, "One", "", +84846, NumPatientsLeftCT, 1597, 1598, "2", "", +84847, FinalNumPatientsCT, 1642, 1644, "81", "", +84848, PerProtocol, 1675, 1689, "per - protocol", "", +84849, Mean, 1703, 1707, "mean", "", +84850, AvgAge, 1719, 1725, "58 . 3", "mean age", +84854, Travoprost, 1743, 1747, "TRAV", "", +84856, Bimatoprost, 1750, 1753, "BIM", "", +84851, FinalNumPatientsArm, 1760, 1762, "41", "", +84857, Bimatoprost, 1765, 1768, "BIM", "", +84855, Travoprost, 1771, 1775, "TRAV", "", +84853, FinalNumPatientsArm, 1782, 1784, "40", "", +84877, TimePoint, 1789, 1802, "After 6 weeks", "", +84858, Mean, 1805, 1809, "mean", "", +84859, IOP, 1810, 1813, "IOP", "", +84860, Travoprost, 1819, 1823, "TRAV", "", +84864, ResultMeasuredValue, 1826, 1832, "17 . 4", "", +84866, SdDevResValue, 1835, 1840, "2 . 7", "", +84868, mmHg, 1841, 1845, "mmHg", "", +84871, Reduction, 1873, 1878, "6 . 0", "", +84870, mmHg, 1879, 1883, "mmHg", "", +84861, Bimatoprost, 1901, 1904, "BIM", "", +84865, ResultMeasuredValue, 1907, 1913, "17 . 2", "", +84867, SdDevResValue, 1916, 1921, "2 . 6", "", +84869, mmHg, 1922, 1926, "mmHg", "", +84872, Reduction, 1954, 1959, "6 . 3", "", +84873, mmHg, 1960, 1964, "mmHg", "", +84875, DiffBetweenGroups, 2004, 2010, "0 . 22", "", +84874, mmHg, 2011, 2015, "mmHg", "", +84876, ConfIntervalDiff, 2028, 2046, "- 0 . 22 to 0 . 67", "", +84863, Travoprost, 2076, 2080, "TRAV", "", +84862, Bimatoprost, 2088, 2091, "BIM", "", +84878, Mean, 2111, 2115, "Mean", "", +84882, ObservedResult, 2111, 2241, "Mean IOP at each time point and mean and percentage IOP change from baseline were not significantly different between treatments .", "", +84879, IOP, 2116, 2119, "IOP", "", +84880, Mean, 2143, 2147, "mean", "", +84881, IOP, 2163, 2166, "IOP", "", +84883, ObservedResult, 2242, 2305, "All treatment - emergent adverse events were mild to moderate .", "", +84892, ConjunctivalHyperemia, 2324, 2345, "mild ocular hyperemia", "mild", +84886, Travoprost, 2351, 2355, "TRAV", "", +84887, Bimatoprost, 2360, 2363, "BIM", "", +84889, PercentageAffected, 2369, 2371, "31", "", +84890, PercentageAffected, 2378, 2380, "39", "", +84893, ConjunctivalHyperemia, 2400, 2418, "moderate hyperemia", "moderate", +84891, PercentageAffected, 2435, 2436, "2", "", +84888, Bimatoprost, 2461, 2464, "BIM", "", +84900, ConclusionComment, 2480, 2627, "Late - day IOP - lowering efficacy of BAK - free TRAV was noninferior to that of BAK 0 . 02 % - preserved BIM ; both reduced baseline IOP by 25 % .", "", +84894, IOP, 2491, 2494, "IOP", "", +84895, Travoprost, 2529, 2533, "TRAV", "", +84898, Drug, 2561, 2589, "BAK 0 . 02 % - preserved BIM", "BAK preserved bimatoprost", +84896, DoseValue, 2565, 2571, "0 . 02", "", +84897, Bimatoprost, 2586, 2589, "BIM", "", +84899, RelativeReduction, 2621, 2623, "25", "", +84903, ConclusionComment, 2628, 2746, "Both treatments were well tolerated , although a higher incidence of moderate ocular hyperemia was observed with BIM .", "", +84901, ConjunctivalHyperemia, 2697, 2722, "moderate ocular hyperemia", "moderate", +84902, Bimatoprost, 2741, 2744, "BIM", "", +84904, PMID, 2914, 2922, "25432143", "", diff --git a/data/gl 25432143_tstrakeljahn.n-triples b/data/gl 25432143_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25432143_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25533656_admin.annodb b/data/gl 25533656_admin.annodb new file mode 100644 index 0000000..6e4c707 --- /dev/null +++ b/data/gl 25533656_admin.annodb @@ -0,0 +1,125 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 6, "Lancet", "", " \"Lancet\"." +1, PublicationYear, 9, 13, "2015", "", " \"2015\"." +2, Title, 119, 226, "Latanoprost for open - angle glaucoma ( UKGTS ) : a randomised , multicentre , placebo - controlled trial .", "", " \"Latanoprost for open - angle glaucoma ( UKGTS ) : a randomised , multicentre , placebo - controlled trial .\"." +3, Latanoprost, 119, 130, "Latanoprost", "", +4, OpenAngleGlaucoma, 135, 156, "open - angle glaucoma", "", " ." +5, Randomized, 171, 181, "randomised", "", +6, Multicenter, 184, 195, "multicentre", "", +104982, CTDesign, 198, 218, "placebo - controlled", "", " . ." +8, Author, 227, 244, "Garway - Heath DF", "", " \"Garway - Heath DF\"." +9, Author, 253, 261, "Crabb DP", "", " \"Crabb DP\"." +10, Author, 270, 277, "Bunce C", "", " \"Bunce C\"." +11, Author, 286, 298, "Lascaratos G", "", " \"Lascaratos G\"." +12, Author, 307, 319, "Amalfitano F", "", " \"Amalfitano F\"." +13, Author, 328, 335, "Anand N", "", " \"Anand N\"." +14, Author, 344, 361, "Azuara - Blanco A", "", " \"Azuara - Blanco A\"." +15, Author, 370, 379, "Bourne RR", "", " \"Bourne RR\"." +16, Author, 388, 399, "Broadway DC", "", " \"Broadway DC\"." +17, Author, 406, 419, ", Cunliffe IA", "", " \", Cunliffe IA\"." +136, Author, 408, 419, "Cunliffe IA", "", " \"Cunliffe IA\"." +18, Author, 428, 438, "Diamond JP", "", " \"Diamond JP\"." +19, Author, 447, 456, "Fraser SG", "", " \"Fraser SG\"." +20, Author, 466, 471, "Ho TA", "", " \"Ho TA\"." +21, Author, 480, 489, "Martin KR", "", " \"Martin KR\"." +22, Author, 499, 510, "McNaught AI", "", " \"McNaught AI\"." +23, Author, 520, 526, "Negi A", "", " \"Negi A\"." +24, Author, 535, 542, "Patel K", "", " \"Patel K\"." +25, Author, 551, 561, "Russell RA", "", " \"Russell RA\"." +26, Author, 571, 577, "Shah A", "", " \"Shah A\"." +27, Author, 586, 593, "Spry PG", "", " \"Spry PG\"." +28, Author, 602, 610, "Suzuki K", "", " \"Suzuki K\"." +29, Author, 619, 627, "White ET", "", " \"White ET\"." +30, Author, 636, 646, "Wormald RP", "", " \"Wormald RP\"." +31, Author, 655, 661, "Xing W", "", " \"Xing W\"." +32, Author, 670, 678, "Zeyen TG", "", " \"Zeyen TG\"." +33, UK, 875, 877, "UK", "", " ." +34, UK, 945, 947, "uk", "", +35, UK, 1028, 1030, "UK", "", +36, UK, 1199, 1201, "UK", "", +37, UK, 1256, 1258, "UK", "", +38, UK, 1305, 1307, "UK", "", +39, UK, 1355, 1357, "UK", "", +40, UK, 1418, 1420, "UK", "", +41, UK, 1479, 1481, "UK", "", +42, UK, 1523, 1525, "UK", "", +43, UK, 1575, 1577, "UK", "", +44, UK, 1626, 1628, "UK", "", +45, UK, 1681, 1683, "UK", "", +165, UK, 1853, 1855, "UK", "", +46, UK, 1930, 1932, "UK", "", +47, Country, 1981, 1988, "Belgium", "", " . ." +49, OpenAngleGlaucoma, 2276, 2297, "open - angle glaucoma", "", +50, IOP, 2345, 2365, "intraocular pressure", "", +104984, CTDesign, 2392, 2412, "placebo - controlled", "", +48, ObjectiveDescription, 2564, 2661, "We assessed vision preservation in patients given latanoprost compared with those given placebo .", "", " \"We assessed vision preservation in patients given latanoprost compared with those given placebo .\"." +171, Latanoprost, 2614, 2625, "latanoprost", "", +172, Placebo, 2652, 2659, "placebo", "", +52, Randomized, 2680, 2690, "randomised", "", " ." +106373, CTDesign, 2693, 2708, "triple - masked", "", +55, CTDesign, 2711, 2731, "placebo - controlled", "", +178, Precondition, 2752, 2803, "patients with newly diagnosed open - angle glaucoma", "", " \"patients with newly diagnosed open - angle glaucoma\"." +56, OpenAngleGlaucoma, 2782, 2803, "open - angle glaucoma", "", +58, Multicenter, 2807, 2821, "ten UK centres", "", " ." +57, UK, 2811, 2813, "UK", "", +59, Randomized, 2931, 2939, "randomly", "", +60, AllocationRatio, 2952, 2957, "1 : 1", "", " . ." +61, Randomized, 2987, 3000, "randomisation", "", +62, Latanoprost, 3086, 3097, "latanoprost", "", " . ." +63, DoseValue, 3098, 3105, "0 · 005", "", " \"0 · 005\"." +184, Percentage, 3106, 3107, "%", "", " ." +64, Placebo, 3134, 3141, "placebo", "", " ." +65, Eyedrops, 3160, 3169, "eye drops", "", " . ." +104985, DoseDescription, 3172, 3246, "Drops were administered from identical bottles , once a day , to both eyes", "", " \"Drops were administered from identical bottles , once a day , to both eyes\". \"Drops were administered from identical bottles , once a day , to both eyes\"." +66, Eyedrops, 3172, 3177, "Drops", "", +67, Frequency, 3221, 3231, "once a day", "", " \"once a day\". \"once a day\"." +70, EndPointDescription, 3273, 3307, "time to visual field deterioration", "", +68, Duration, 3315, 3324, "24 months", "", " \"24 months\"." +104986, TimePoint, 3473, 3485, "Jan 6 , 2011", "", +71, EndPointDescription, 3684, 3718, "time to visual field deterioration", "", +69, Duration, 3726, 3735, "24 months", "", +72, NumberPatientsCT, 3812, 3815, "516", "", " \"516\"." +192, TimePoint, 3836, 3848, "Dec 1 , 2006", "", +193, TimePoint, 3855, 3870, "March 16 , 2010", "", +77, Mean, 3882, 3886, "mean", "", " . ." +78, IOP, 3887, 3907, "intraocular pressure", "", " . ." +79, BaseLineValue, 3912, 3918, "19 · 6", "", " \"19 · 6\"." +81, mmHg, 3919, 3924, "mm Hg", "", " ." +83, SdDevBL, 3930, 3935, "4 · 6", "", " \"4 · 6\"." +85, NumberPatientsArm, 3941, 3944, "258", "", " \"258\"." +87, Latanoprost, 3961, 3972, "latanoprost", "", +80, BaseLineValue, 3983, 3989, "20 · 1", "", " \"20 · 1\"." +82, mmHg, 3990, 3995, "mm Hg", "", +84, SdDevBL, 3998, 4003, "4 · 8", "", " \"4 · 8\"." +86, NumberPatientsArm, 4009, 4012, "258", "", " \"258\"." +88, Placebo, 4013, 4021, "controls", "", +205, TimePoint, 4027, 4036, "24 months", "", " \"24 months\". \"24 months\"." +90, Mean, 4039, 4043, "mean", "", +91, IOP, 4057, 4077, "intraocular pressure", "", +92, Reduction, 4082, 4087, "3 · 8", "", " \"3 · 8\"." +94, mmHg, 4088, 4093, "mm Hg", "", +96, SdDevChangeValue, 4096, 4101, "4 · 0", "", " \"4 · 0\"." +98, FinalNumPatientsArm, 4107, 4110, "231", "", " \"231\"." +101, Latanoprost, 4136, 4147, "latanoprost", "", +93, Reduction, 4158, 4163, "0 · 9", "", " \"0 · 9\"." +95, mmHg, 4164, 4169, "mm Hg", "", +97, SdDevChangeValue, 4172, 4177, "3 · 8", "", " \"3 · 8\"." +99, FinalNumPatientsArm, 4183, 4186, "230", "", " \"230\"." +100, Placebo, 4212, 4219, "placebo", "", +102, EndPointDescription, 4228, 4253, "Visual field preservation", "", " . ." +106376, ObservedResult, 4254, 4329, "was significantly longer in the latanoprost group than in the placebo group", "", " \"was significantly longer in the latanoprost group than in the placebo group\"." +103, Latanoprost, 4286, 4297, "latanoprost", "", +104, Placebo, 4316, 4323, "placebo", "", +106375, DiffGroupAbsValue, 4361, 4367, "0 · 44", "", " \"0 · 44\"." +104987, ConfIntervalDiff, 4370, 4393, "95 % CI 0 · 28 - 0 · 69", "", " \"95 % CI 0 · 28 - 0 · 69\"." +106, PvalueDiff, 4396, 4408, "p = 0 · 0003", "", " \"p = 0 · 0003\"." +220, NumberAffected, 4422, 4424, "18", "", +117, ConclusionComment, 4505, 4689, "This is the first randomised placebo - controlled trial to show preservation of the visual field with an intraocular - pressure - lowering drug in patients with open - angle glaucoma .", "", " \"This is the first randomised placebo - controlled trial to show preservation of the visual field with an intraocular - pressure - lowering drug in patients with open - angle glaucoma .\"." +110, Randomized, 4523, 4533, "randomised", "", +112, CTDesign, 4534, 4554, "placebo - controlled", "", +113, IOP, 4610, 4632, "intraocular - pressure", "", +114, OpenAngleGlaucoma, 4666, 4687, "open - angle glaucoma", "", +118, ConclusionComment, 4690, 4806, "The study design enabled significant differences in vision to be assessed in a relatively short observation period .", "", " \"The study design enabled significant differences in vision to be assessed in a relatively short observation period .\"." +115, ConflictInterest, 4817, 4896, "Pfizer , UK National Institute for Health Research Biomedical Research Centre .", "", +230, UK, 4826, 4828, "UK", "", +116, PMID, 5101, 5109, "25533656", "", " \"25533656\"." diff --git a/data/gl 25533656_admin.n-triples b/data/gl 25533656_admin.n-triples new file mode 100644 index 0000000..e916827 --- /dev/null +++ b/data/gl 25533656_admin.n-triples @@ -0,0 +1,151 @@ +# RDF export of group: Publication + . + "Publication " . + "Latanoprost for open - angle glaucoma ( UKGTS ) : a randomised , multicentre , placebo - controlled trial ." . + "Garway - Heath DF" . + "2015" . + "Lancet" . + "25533656" . + . + "Crabb DP" . + "Bunce C" . + "Lascaratos G" . + "Amalfitano F" . + "Anand N" . + "Azuara - Blanco A" . + "Bourne RR" . + "Broadway DC" . + ", Cunliffe IA" . + "Cunliffe IA" . + "Diamond JP" . + "Fraser SG" . + "Ho TA" . + "Martin KR" . + "McNaught AI" . + "Negi A" . + "Patel K" . + "Russell RA" . + "Shah A" . + "Spry PG" . + "Suzuki K" . + "White ET" . + "Wormald RP" . + "Xing W" . + "Zeyen TG" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "We assessed vision preservation in patients given latanoprost compared with those given placebo ." . + "516" . + "24 months" . + . + . + . + . + "This is the first randomised placebo - controlled trial to show preservation of the visual field with an intraocular - pressure - lowering drug in patients with open - angle glaucoma ." . + . + . + . + . + . + . + . + . + "The study design enabled significant differences in vision to be assessed in a relatively short observation period ." . + . +# RDF export of group: Population + . + "Population " . + "patients with newly diagnosed open - angle glaucoma" . + . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint vfp" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm lat" . + "258" . + "231" . + . + . + . + . + "Arm p" . + "258" . + "230" . + . + . + . +# RDF export of group: Intervention + . + "Intervention lat" . + . + "once a day" . + . + . + "Intervention p" . + . + "once a day" . + . +# RDF export of group: Medication + . + "Medication lat" . + . + . + "0 · 005" . + . + . + "Drops were administered from identical bottles , once a day , to both eyes" . + . + "Medication p" . + . + . + . + "Drops were administered from identical bottles , once a day , to both eyes" . +# RDF export of group: Outcome + . + "Outcome IOP lat" . + . + "19 · 6" . + "4 · 6" . + "3 · 8" . + "4 · 0" . + "24 months" . + . + "Outcome IOP p " . + . + "20 · 1" . + "4 · 8" . + "0 · 9" . + "3 · 8" . + "24 months" . + . + "Outcome vfp both drugs " . + . + "was significantly longer in the latanoprost group than in the placebo group" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_vfp" . + "0 · 44" . + "p = 0 · 0003" . + "95 % CI 0 · 28 - 0 · 69" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25533656_export.csv b/data/gl 25533656_export.csv new file mode 100644 index 0000000..d7c95ad --- /dev/null +++ b/data/gl 25533656_export.csv @@ -0,0 +1,1079 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +543, 1, 1, 1, 0, 6, 0, 6, "Lancet" +543, 1, 2, 2, 7, 8, 7, 8, "." +543, 2, 1, 3, 0, 4, 9, 13, "2015" +543, 2, 2, 4, 5, 8, 14, 17, "Apr" +543, 2, 3, 5, 9, 10, 18, 19, "4" +543, 2, 4, 6, 11, 12, 20, 21, ";" +543, 2, 5, 7, 13, 16, 22, 25, "385" +543, 2, 6, 8, 17, 18, 26, 27, "(" +543, 2, 7, 9, 19, 23, 28, 32, "9975" +543, 2, 8, 10, 24, 25, 33, 34, ")" +543, 2, 9, 11, 26, 27, 35, 36, ":" +543, 2, 10, 12, 28, 32, 37, 41, "1295" +543, 2, 11, 13, 33, 34, 42, 43, "-" +543, 2, 12, 14, 35, 38, 44, 47, "304" +543, 2, 13, 15, 39, 40, 48, 49, "." +543, 2, 14, 16, 41, 44, 50, 53, "doi" +543, 2, 15, 17, 45, 46, 54, 55, ":" +543, 2, 16, 18, 47, 49, 56, 58, "10" +543, 2, 17, 19, 50, 51, 59, 60, "." +543, 2, 18, 20, 52, 56, 61, 65, "1016" +543, 2, 19, 21, 57, 58, 66, 67, "/" +543, 2, 20, 22, 59, 64, 68, 73, "S0140" +543, 2, 21, 23, 65, 66, 74, 75, "-" +543, 2, 22, 24, 67, 71, 76, 80, "6736" +543, 2, 23, 25, 72, 73, 81, 82, "(" +543, 2, 24, 26, 74, 76, 83, 85, "14" +543, 2, 25, 27, 77, 78, 86, 87, ")" +543, 2, 26, 28, 79, 84, 88, 93, "62111" +543, 2, 27, 29, 85, 86, 94, 95, "-" +543, 2, 28, 30, 87, 88, 96, 97, "5" +543, 2, 29, 31, 89, 90, 98, 99, "." +543, 3, 1, 32, 0, 4, 100, 104, "Epub" +543, 3, 2, 33, 5, 9, 105, 109, "2014" +543, 3, 3, 34, 10, 13, 110, 113, "Dec" +543, 3, 4, 35, 14, 16, 114, 116, "19" +543, 3, 5, 36, 17, 18, 117, 118, "." +543, 4, 1, 37, 0, 11, 119, 130, "Latanoprost" +543, 4, 2, 38, 12, 15, 131, 134, "for" +543, 4, 3, 39, 16, 20, 135, 139, "open" +543, 4, 4, 40, 21, 22, 140, 141, "-" +543, 4, 5, 41, 23, 28, 142, 147, "angle" +543, 4, 6, 42, 29, 37, 148, 156, "glaucoma" +543, 4, 7, 43, 38, 39, 157, 158, "(" +543, 4, 8, 44, 40, 45, 159, 164, "UKGTS" +543, 4, 9, 45, 46, 47, 165, 166, ")" +543, 4, 10, 46, 48, 49, 167, 168, ":" +543, 4, 11, 47, 50, 51, 169, 170, "a" +543, 4, 12, 48, 52, 62, 171, 181, "randomised" +543, 4, 13, 49, 63, 64, 182, 183, "," +543, 4, 14, 50, 65, 76, 184, 195, "multicentre" +543, 4, 15, 51, 77, 78, 196, 197, "," +543, 4, 16, 52, 79, 86, 198, 205, "placebo" +543, 4, 17, 53, 87, 88, 206, 207, "-" +543, 4, 18, 54, 89, 99, 208, 218, "controlled" +543, 4, 19, 55, 100, 105, 219, 224, "trial" +543, 4, 20, 56, 106, 107, 225, 226, "." +543, 5, 1, 57, 0, 6, 227, 233, "Garway" +543, 5, 2, 58, 7, 8, 234, 235, "-" +543, 5, 3, 59, 9, 14, 236, 241, "Heath" +543, 5, 4, 60, 15, 17, 242, 244, "DF" +543, 5, 5, 61, 18, 19, 245, 246, "(" +543, 5, 6, 62, 20, 21, 247, 248, "1" +543, 5, 7, 63, 22, 23, 249, 250, ")" +543, 5, 8, 64, 24, 25, 251, 252, "," +543, 5, 9, 65, 26, 31, 253, 258, "Crabb" +543, 5, 10, 66, 32, 34, 259, 261, "DP" +543, 5, 11, 67, 35, 36, 262, 263, "(" +543, 5, 12, 68, 37, 38, 264, 265, "2" +543, 5, 13, 69, 39, 40, 266, 267, ")" +543, 5, 14, 70, 41, 42, 268, 269, "," +543, 5, 15, 71, 43, 48, 270, 275, "Bunce" +543, 5, 16, 72, 49, 50, 276, 277, "C" +543, 5, 17, 73, 51, 52, 278, 279, "(" +543, 5, 18, 74, 53, 54, 280, 281, "3" +543, 5, 19, 75, 55, 56, 282, 283, ")" +543, 5, 20, 76, 57, 58, 284, 285, "," +543, 5, 21, 77, 59, 69, 286, 296, "Lascaratos" +543, 5, 22, 78, 70, 71, 297, 298, "G" +543, 5, 23, 79, 72, 73, 299, 300, "(" +543, 5, 24, 80, 74, 75, 301, 302, "3" +543, 5, 25, 81, 76, 77, 303, 304, ")" +543, 5, 26, 82, 78, 79, 305, 306, "," +543, 5, 27, 83, 80, 90, 307, 317, "Amalfitano" +543, 5, 28, 84, 91, 92, 318, 319, "F" +543, 5, 29, 85, 93, 94, 320, 321, "(" +543, 5, 30, 86, 95, 96, 322, 323, "3" +543, 5, 31, 87, 97, 98, 324, 325, ")" +543, 5, 32, 88, 99, 100, 326, 327, "," +543, 5, 33, 89, 101, 106, 328, 333, "Anand" +543, 5, 34, 90, 107, 108, 334, 335, "N" +543, 5, 35, 91, 109, 110, 336, 337, "(" +543, 5, 36, 92, 111, 112, 338, 339, "4" +543, 5, 37, 93, 113, 114, 340, 341, ")" +543, 5, 38, 94, 115, 116, 342, 343, "," +543, 5, 39, 95, 117, 123, 344, 350, "Azuara" +543, 5, 40, 96, 124, 125, 351, 352, "-" +543, 5, 41, 97, 126, 132, 353, 359, "Blanco" +543, 5, 42, 98, 133, 134, 360, 361, "A" +543, 5, 43, 99, 135, 136, 362, 363, "(" +543, 5, 44, 100, 137, 138, 364, 365, "5" +543, 5, 45, 101, 139, 140, 366, 367, ")" +543, 5, 46, 102, 141, 142, 368, 369, "," +543, 5, 47, 103, 143, 149, 370, 376, "Bourne" +543, 5, 48, 104, 150, 152, 377, 379, "RR" +543, 5, 49, 105, 153, 154, 380, 381, "(" +543, 5, 50, 106, 155, 156, 382, 383, "6" +543, 5, 51, 107, 157, 158, 384, 385, ")" +543, 5, 52, 108, 159, 160, 386, 387, "," +543, 5, 53, 109, 161, 169, 388, 396, "Broadway" +543, 5, 54, 110, 170, 172, 397, 399, "DC" +543, 5, 55, 111, 173, 174, 400, 401, "(" +543, 5, 56, 112, 175, 176, 402, 403, "7" +543, 5, 57, 113, 177, 178, 404, 405, ")" +543, 5, 58, 114, 179, 180, 406, 407, "," +543, 5, 59, 115, 181, 189, 408, 416, "Cunliffe" +543, 5, 60, 116, 190, 192, 417, 419, "IA" +543, 5, 61, 117, 193, 194, 420, 421, "(" +543, 5, 62, 118, 195, 196, 422, 423, "8" +543, 5, 63, 119, 197, 198, 424, 425, ")" +543, 5, 64, 120, 199, 200, 426, 427, "," +543, 5, 65, 121, 201, 208, 428, 435, "Diamond" +543, 5, 66, 122, 209, 211, 436, 438, "JP" +543, 5, 67, 123, 212, 213, 439, 440, "(" +543, 5, 68, 124, 214, 215, 441, 442, "9" +543, 5, 69, 125, 216, 217, 443, 444, ")" +543, 5, 70, 126, 218, 219, 445, 446, "," +543, 5, 71, 127, 220, 226, 447, 453, "Fraser" +543, 5, 72, 128, 227, 229, 454, 456, "SG" +543, 5, 73, 129, 230, 231, 457, 458, "(" +543, 5, 74, 130, 232, 234, 459, 461, "10" +543, 5, 75, 131, 235, 236, 462, 463, ")" +543, 5, 76, 132, 237, 238, 464, 465, "," +543, 5, 77, 133, 239, 241, 466, 468, "Ho" +543, 5, 78, 134, 242, 244, 469, 471, "TA" +543, 5, 79, 135, 245, 246, 472, 473, "(" +543, 5, 80, 136, 247, 248, 474, 475, "3" +543, 5, 81, 137, 249, 250, 476, 477, ")" +543, 5, 82, 138, 251, 252, 478, 479, "," +543, 5, 83, 139, 253, 259, 480, 486, "Martin" +543, 5, 84, 140, 260, 262, 487, 489, "KR" +543, 5, 85, 141, 263, 264, 490, 491, "(" +543, 5, 86, 142, 265, 267, 492, 494, "11" +543, 5, 87, 143, 268, 269, 495, 496, ")" +543, 5, 88, 144, 270, 271, 497, 498, "," +543, 5, 89, 145, 272, 280, 499, 507, "McNaught" +543, 5, 90, 146, 281, 283, 508, 510, "AI" +543, 5, 91, 147, 284, 285, 511, 512, "(" +543, 5, 92, 148, 286, 288, 513, 515, "12" +543, 5, 93, 149, 289, 290, 516, 517, ")" +543, 5, 94, 150, 291, 292, 518, 519, "," +543, 5, 95, 151, 293, 297, 520, 524, "Negi" +543, 5, 96, 152, 298, 299, 525, 526, "A" +543, 5, 97, 153, 300, 301, 527, 528, "(" +543, 5, 98, 154, 302, 303, 529, 530, "8" +543, 5, 99, 155, 304, 305, 531, 532, ")" +543, 5, 100, 156, 306, 307, 533, 534, "," +543, 5, 101, 157, 308, 313, 535, 540, "Patel" +543, 5, 102, 158, 314, 315, 541, 542, "K" +543, 5, 103, 159, 316, 317, 543, 544, "(" +543, 5, 104, 160, 318, 319, 545, 546, "3" +543, 5, 105, 161, 320, 321, 547, 548, ")" +543, 5, 106, 162, 322, 323, 549, 550, "," +543, 5, 107, 163, 324, 331, 551, 558, "Russell" +543, 5, 108, 164, 332, 334, 559, 561, "RA" +543, 5, 109, 165, 335, 336, 562, 563, "(" +543, 5, 110, 166, 337, 339, 564, 566, "13" +543, 5, 111, 167, 340, 341, 567, 568, ")" +543, 5, 112, 168, 342, 343, 569, 570, "," +543, 5, 113, 169, 344, 348, 571, 575, "Shah" +543, 5, 114, 170, 349, 350, 576, 577, "A" +543, 5, 115, 171, 351, 352, 578, 579, "(" +543, 5, 116, 172, 353, 354, 580, 581, "3" +543, 5, 117, 173, 355, 356, 582, 583, ")" +543, 5, 118, 174, 357, 358, 584, 585, "," +543, 5, 119, 175, 359, 363, 586, 590, "Spry" +543, 5, 120, 176, 364, 366, 591, 593, "PG" +543, 5, 121, 177, 367, 368, 594, 595, "(" +543, 5, 122, 178, 369, 370, 596, 597, "9" +543, 5, 123, 179, 371, 372, 598, 599, ")" +543, 5, 124, 180, 373, 374, 600, 601, "," +543, 5, 125, 181, 375, 381, 602, 608, "Suzuki" +543, 5, 126, 182, 382, 383, 609, 610, "K" +543, 5, 127, 183, 384, 385, 611, 612, "(" +543, 5, 128, 184, 386, 387, 613, 614, "3" +543, 5, 129, 185, 388, 389, 615, 616, ")" +543, 5, 130, 186, 390, 391, 617, 618, "," +543, 5, 131, 187, 392, 397, 619, 624, "White" +543, 5, 132, 188, 398, 400, 625, 627, "ET" +543, 5, 133, 189, 401, 402, 628, 629, "(" +543, 5, 134, 190, 403, 404, 630, 631, "3" +543, 5, 135, 191, 405, 406, 632, 633, ")" +543, 5, 136, 192, 407, 408, 634, 635, "," +543, 5, 137, 193, 409, 416, 636, 643, "Wormald" +543, 5, 138, 194, 417, 419, 644, 646, "RP" +543, 5, 139, 195, 420, 421, 647, 648, "(" +543, 5, 140, 196, 422, 423, 649, 650, "3" +543, 5, 141, 197, 424, 425, 651, 652, ")" +543, 5, 142, 198, 426, 427, 653, 654, "," +543, 5, 143, 199, 428, 432, 655, 659, "Xing" +543, 5, 144, 200, 433, 434, 660, 661, "W" +543, 5, 145, 201, 435, 436, 662, 663, "(" +543, 5, 146, 202, 437, 438, 664, 665, "3" +543, 5, 147, 203, 439, 440, 666, 667, ")" +543, 5, 148, 204, 441, 442, 668, 669, "," +543, 5, 149, 205, 443, 448, 670, 675, "Zeyen" +543, 5, 150, 206, 449, 451, 676, 678, "TG" +543, 5, 151, 207, 452, 453, 679, 680, "(" +543, 5, 152, 208, 454, 456, 681, 683, "14" +543, 5, 153, 209, 457, 458, 684, 685, ")" +543, 5, 154, 210, 459, 460, 686, 687, "." +543, 6, 1, 211, 0, 6, 688, 694, "Author" +543, 6, 2, 212, 7, 18, 695, 706, "information" +543, 6, 3, 213, 19, 20, 707, 708, ":" +543, 6, 4, 214, 21, 22, 709, 710, "(" +543, 6, 5, 215, 23, 24, 711, 712, "1" +543, 6, 6, 216, 25, 26, 713, 714, ")" +543, 6, 7, 217, 27, 35, 715, 723, "National" +543, 6, 8, 218, 36, 45, 724, 733, "Institute" +543, 6, 9, 219, 46, 49, 734, 737, "for" +543, 6, 10, 220, 50, 56, 738, 744, "Health" +543, 6, 11, 221, 57, 65, 745, 753, "Research" +543, 6, 12, 222, 66, 76, 754, 764, "Biomedical" +543, 6, 13, 223, 77, 85, 765, 773, "Research" +543, 6, 14, 224, 86, 92, 774, 780, "Centre" +543, 6, 15, 225, 93, 95, 781, 783, "at" +543, 6, 16, 226, 96, 106, 784, 794, "Moorfields" +543, 6, 17, 227, 107, 110, 795, 798, "Eye" +543, 6, 18, 228, 111, 119, 799, 807, "Hospital" +543, 6, 19, 229, 120, 123, 808, 811, "NHS" +543, 6, 20, 230, 124, 134, 812, 822, "Foundation" +543, 6, 21, 231, 135, 140, 823, 828, "Trust" +543, 6, 22, 232, 141, 144, 829, 832, "and" +543, 6, 23, 233, 145, 148, 833, 836, "UCL" +543, 6, 24, 234, 149, 158, 837, 846, "Institute" +543, 6, 25, 235, 159, 161, 847, 849, "of" +543, 6, 26, 236, 162, 175, 850, 863, "Ophthalmology" +543, 6, 27, 237, 176, 177, 864, 865, "," +543, 6, 28, 238, 178, 184, 866, 872, "London" +543, 6, 29, 239, 185, 186, 873, 874, "," +543, 6, 30, 240, 187, 189, 875, 877, "UK" +543, 6, 31, 241, 190, 191, 878, 879, "." +543, 7, 1, 242, 0, 10, 880, 890, "Electronic" +543, 7, 2, 243, 11, 18, 891, 898, "address" +543, 7, 3, 244, 19, 20, 899, 900, ":" +543, 7, 4, 245, 21, 26, 901, 906, "david" +543, 7, 5, 246, 27, 28, 907, 908, "." +543, 7, 6, 247, 29, 35, 909, 915, "garway" +543, 7, 7, 248, 36, 37, 916, 917, "-" +543, 7, 8, 249, 38, 43, 918, 923, "heath" +543, 7, 9, 250, 44, 45, 924, 925, "@" +543, 7, 10, 251, 46, 56, 926, 936, "moorfields" +543, 7, 11, 252, 57, 58, 937, 938, "." +543, 7, 12, 253, 59, 62, 939, 942, "nhs" +543, 7, 13, 254, 63, 64, 943, 944, "." +543, 7, 14, 255, 65, 67, 945, 947, "uk" +543, 7, 15, 256, 68, 69, 948, 949, "." +543, 8, 1, 257, 0, 1, 950, 951, "(" +543, 8, 2, 258, 2, 3, 952, 953, "2" +543, 8, 3, 259, 4, 5, 954, 955, ")" +543, 8, 4, 260, 6, 16, 956, 966, "Department" +543, 8, 5, 261, 17, 19, 967, 969, "of" +543, 8, 6, 262, 20, 29, 970, 979, "Optometry" +543, 8, 7, 263, 30, 33, 980, 983, "and" +543, 8, 8, 264, 34, 40, 984, 990, "Visual" +543, 8, 9, 265, 41, 48, 991, 998, "Science" +543, 8, 10, 266, 49, 50, 999, 1000, "," +543, 8, 11, 267, 51, 55, 1001, 1005, "City" +543, 8, 12, 268, 56, 66, 1006, 1016, "University" +543, 8, 13, 269, 67, 68, 1017, 1018, "," +543, 8, 14, 270, 69, 75, 1019, 1025, "London" +543, 8, 15, 271, 76, 77, 1026, 1027, "," +543, 8, 16, 272, 78, 80, 1028, 1030, "UK" +543, 8, 17, 273, 81, 82, 1031, 1032, "." +543, 9, 1, 274, 0, 1, 1033, 1034, "(" +543, 9, 2, 275, 2, 3, 1035, 1036, "3" +543, 9, 3, 276, 4, 5, 1037, 1038, ")" +543, 9, 4, 277, 6, 14, 1039, 1047, "National" +543, 9, 5, 278, 15, 24, 1048, 1057, "Institute" +543, 9, 6, 279, 25, 28, 1058, 1061, "for" +543, 9, 7, 280, 29, 35, 1062, 1068, "Health" +543, 9, 8, 281, 36, 44, 1069, 1077, "Research" +543, 9, 9, 282, 45, 55, 1078, 1088, "Biomedical" +543, 9, 10, 283, 56, 64, 1089, 1097, "Research" +543, 9, 11, 284, 65, 71, 1098, 1104, "Centre" +543, 9, 12, 285, 72, 74, 1105, 1107, "at" +543, 9, 13, 286, 75, 85, 1108, 1118, "Moorfields" +543, 9, 14, 287, 86, 89, 1119, 1122, "Eye" +543, 9, 15, 288, 90, 98, 1123, 1131, "Hospital" +543, 9, 16, 289, 99, 102, 1132, 1135, "NHS" +543, 9, 17, 290, 103, 113, 1136, 1146, "Foundation" +543, 9, 18, 291, 114, 119, 1147, 1152, "Trust" +543, 9, 19, 292, 120, 123, 1153, 1156, "and" +543, 9, 20, 293, 124, 127, 1157, 1160, "UCL" +543, 9, 21, 294, 128, 137, 1161, 1170, "Institute" +543, 9, 22, 295, 138, 140, 1171, 1173, "of" +543, 9, 23, 296, 141, 154, 1174, 1187, "Ophthalmology" +543, 9, 24, 297, 155, 156, 1188, 1189, "," +543, 9, 25, 298, 157, 163, 1190, 1196, "London" +543, 9, 26, 299, 164, 165, 1197, 1198, "," +543, 9, 27, 300, 166, 168, 1199, 1201, "UK" +543, 9, 28, 301, 169, 170, 1202, 1203, "." +543, 10, 1, 302, 0, 1, 1204, 1205, "(" +543, 10, 2, 303, 2, 3, 1206, 1207, "4" +543, 10, 3, 304, 4, 5, 1208, 1209, ")" +543, 10, 4, 305, 6, 18, 1210, 1222, "Huddersfield" +543, 10, 5, 306, 19, 24, 1223, 1228, "Royal" +543, 10, 6, 307, 25, 34, 1229, 1238, "Infirmary" +543, 10, 7, 308, 35, 36, 1239, 1240, "," +543, 10, 8, 309, 37, 49, 1241, 1253, "Huddersfield" +543, 10, 9, 310, 50, 51, 1254, 1255, "," +543, 10, 10, 311, 52, 54, 1256, 1258, "UK" +543, 10, 11, 312, 55, 56, 1259, 1260, "." +543, 11, 1, 313, 0, 1, 1261, 1262, "(" +543, 11, 2, 314, 2, 3, 1263, 1264, "5" +543, 11, 3, 315, 4, 5, 1265, 1266, ")" +543, 11, 4, 316, 6, 14, 1267, 1275, "Aberdeen" +543, 11, 5, 317, 15, 20, 1276, 1281, "Royal" +543, 11, 6, 318, 21, 30, 1282, 1291, "Infirmary" +543, 11, 7, 319, 31, 32, 1292, 1293, "," +543, 11, 8, 320, 33, 41, 1294, 1302, "Aberdeen" +543, 11, 9, 321, 42, 43, 1303, 1304, "," +543, 11, 10, 322, 44, 46, 1305, 1307, "UK" +543, 11, 11, 323, 47, 48, 1308, 1309, "." +543, 12, 1, 324, 0, 1, 1310, 1311, "(" +543, 12, 2, 325, 2, 3, 1312, 1313, "6" +543, 12, 3, 326, 4, 5, 1314, 1315, ")" +543, 12, 4, 327, 6, 20, 1316, 1330, "Hinchingbrooke" +543, 12, 5, 328, 21, 29, 1331, 1339, "Hospital" +543, 12, 6, 329, 30, 31, 1340, 1341, "," +543, 12, 7, 330, 32, 42, 1342, 1352, "Huntingdon" +543, 12, 8, 331, 43, 44, 1353, 1354, "," +543, 12, 9, 332, 45, 47, 1355, 1357, "UK" +543, 12, 10, 333, 48, 49, 1358, 1359, "." +543, 13, 1, 334, 0, 1, 1360, 1361, "(" +543, 13, 2, 335, 2, 3, 1362, 1363, "7" +543, 13, 3, 336, 4, 5, 1364, 1365, ")" +543, 13, 4, 337, 6, 13, 1366, 1373, "Norfolk" +543, 13, 5, 338, 14, 17, 1374, 1377, "and" +543, 13, 6, 339, 18, 25, 1378, 1385, "Norwich" +543, 13, 7, 340, 26, 36, 1386, 1396, "University" +543, 13, 8, 341, 37, 45, 1397, 1405, "Hospital" +543, 13, 9, 342, 46, 47, 1406, 1407, "," +543, 13, 10, 343, 48, 55, 1408, 1415, "Norfolk" +543, 13, 11, 344, 56, 57, 1416, 1417, "," +543, 13, 12, 345, 58, 60, 1418, 1420, "UK" +543, 13, 13, 346, 61, 62, 1421, 1422, "." +543, 14, 1, 347, 0, 1, 1423, 1424, "(" +543, 14, 2, 348, 2, 3, 1425, 1426, "8" +543, 14, 3, 349, 4, 5, 1427, 1428, ")" +543, 14, 4, 350, 6, 16, 1429, 1439, "Birmingham" +543, 14, 5, 351, 17, 27, 1440, 1450, "Heartlands" +543, 14, 6, 352, 28, 31, 1451, 1454, "and" +543, 14, 7, 353, 32, 40, 1455, 1463, "Solihull" +543, 14, 8, 354, 41, 42, 1464, 1465, "," +543, 14, 9, 355, 43, 53, 1466, 1476, "Birmingham" +543, 14, 10, 356, 54, 55, 1477, 1478, "," +543, 14, 11, 357, 56, 58, 1479, 1481, "UK" +543, 14, 12, 358, 59, 60, 1482, 1483, "." +543, 15, 1, 359, 0, 1, 1484, 1485, "(" +543, 15, 2, 360, 2, 3, 1486, 1487, "9" +543, 15, 3, 361, 4, 5, 1488, 1489, ")" +543, 15, 4, 362, 6, 13, 1490, 1497, "Bristol" +543, 15, 5, 363, 14, 17, 1498, 1501, "Eye" +543, 15, 6, 364, 18, 26, 1502, 1510, "Hospital" +543, 15, 7, 365, 27, 28, 1511, 1512, "," +543, 15, 8, 366, 29, 36, 1513, 1520, "Bristol" +543, 15, 9, 367, 37, 38, 1521, 1522, "," +543, 15, 10, 368, 39, 41, 1523, 1525, "UK" +543, 15, 11, 369, 42, 43, 1526, 1527, "." +543, 16, 1, 370, 0, 1, 1528, 1529, "(" +543, 16, 2, 371, 2, 4, 1530, 1532, "10" +543, 16, 3, 372, 5, 6, 1533, 1534, ")" +543, 16, 4, 373, 7, 17, 1535, 1545, "Sunderland" +543, 16, 5, 374, 18, 21, 1546, 1549, "Eye" +543, 16, 6, 375, 22, 31, 1550, 1559, "Infirmary" +543, 16, 7, 376, 32, 33, 1560, 1561, "," +543, 16, 8, 377, 34, 44, 1562, 1572, "Sunderland" +543, 16, 9, 378, 45, 46, 1573, 1574, "," +543, 16, 10, 379, 47, 49, 1575, 1577, "UK" +543, 16, 11, 380, 50, 51, 1578, 1579, "." +543, 17, 1, 381, 0, 1, 1580, 1581, "(" +543, 17, 2, 382, 2, 4, 1582, 1584, "11" +543, 17, 3, 383, 5, 6, 1585, 1586, ")" +543, 17, 4, 384, 7, 18, 1587, 1598, "Addenbrooke" +543, 17, 5, 385, 19, 20, 1599, 1600, "'" +543, 17, 6, 386, 21, 22, 1601, 1602, "s" +543, 17, 7, 387, 23, 31, 1603, 1611, "Hospital" +543, 17, 8, 388, 32, 33, 1612, 1613, "," +543, 17, 9, 389, 34, 43, 1614, 1623, "Cambridge" +543, 17, 10, 390, 44, 45, 1624, 1625, "," +543, 17, 11, 391, 46, 48, 1626, 1628, "UK" +543, 17, 12, 392, 49, 50, 1629, 1630, "." +543, 18, 1, 393, 0, 1, 1631, 1632, "(" +543, 18, 2, 394, 2, 4, 1633, 1635, "12" +543, 18, 3, 395, 5, 6, 1636, 1637, ")" +543, 18, 4, 396, 7, 17, 1638, 1648, "Cheltenham" +543, 18, 5, 397, 18, 25, 1649, 1656, "General" +543, 18, 6, 398, 26, 34, 1657, 1665, "Hospital" +543, 18, 7, 399, 35, 36, 1666, 1667, "," +543, 18, 8, 400, 37, 47, 1668, 1678, "Cheltenham" +543, 18, 9, 401, 48, 49, 1679, 1680, "," +543, 18, 10, 402, 50, 52, 1681, 1683, "UK" +543, 18, 11, 403, 53, 54, 1684, 1685, "." +543, 19, 1, 404, 0, 1, 1686, 1687, "(" +543, 19, 2, 405, 2, 4, 1688, 1690, "13" +543, 19, 3, 406, 5, 6, 1691, 1692, ")" +543, 19, 4, 407, 7, 15, 1693, 1701, "National" +543, 19, 5, 408, 16, 25, 1702, 1711, "Institute" +543, 19, 6, 409, 26, 29, 1712, 1715, "for" +543, 19, 7, 410, 30, 36, 1716, 1722, "Health" +543, 19, 8, 411, 37, 45, 1723, 1731, "Research" +543, 19, 9, 412, 46, 56, 1732, 1742, "Biomedical" +543, 19, 10, 413, 57, 65, 1743, 1751, "Research" +543, 19, 11, 414, 66, 72, 1752, 1758, "Centre" +543, 19, 12, 415, 73, 75, 1759, 1761, "at" +543, 19, 13, 416, 76, 86, 1762, 1772, "Moorfields" +543, 19, 14, 417, 87, 90, 1773, 1776, "Eye" +543, 19, 15, 418, 91, 99, 1777, 1785, "Hospital" +543, 19, 16, 419, 100, 103, 1786, 1789, "NHS" +543, 19, 17, 420, 104, 114, 1790, 1800, "Foundation" +543, 19, 18, 421, 115, 120, 1801, 1806, "Trust" +543, 19, 19, 422, 121, 124, 1807, 1810, "and" +543, 19, 20, 423, 125, 128, 1811, 1814, "UCL" +543, 19, 21, 424, 129, 138, 1815, 1824, "Institute" +543, 19, 22, 425, 139, 141, 1825, 1827, "of" +543, 19, 23, 426, 142, 155, 1828, 1841, "Ophthalmology" +543, 19, 24, 427, 156, 157, 1842, 1843, "," +543, 19, 25, 428, 158, 164, 1844, 1850, "London" +543, 19, 26, 429, 165, 166, 1851, 1852, "," +543, 19, 27, 430, 167, 169, 1853, 1855, "UK" +543, 19, 28, 431, 170, 171, 1856, 1857, ";" +543, 19, 29, 432, 172, 182, 1858, 1868, "Department" +543, 19, 30, 433, 183, 185, 1869, 1871, "of" +543, 19, 31, 434, 186, 195, 1872, 1881, "Optometry" +543, 19, 32, 435, 196, 199, 1882, 1885, "and" +543, 19, 33, 436, 200, 206, 1886, 1892, "Visual" +543, 19, 34, 437, 207, 214, 1893, 1900, "Science" +543, 19, 35, 438, 215, 216, 1901, 1902, "," +543, 19, 36, 439, 217, 221, 1903, 1907, "City" +543, 19, 37, 440, 222, 232, 1908, 1918, "University" +543, 19, 38, 441, 233, 234, 1919, 1920, "," +543, 19, 39, 442, 235, 241, 1921, 1927, "London" +543, 19, 40, 443, 242, 243, 1928, 1929, "," +543, 19, 41, 444, 244, 246, 1930, 1932, "UK" +543, 19, 42, 445, 247, 248, 1933, 1934, "." +543, 20, 1, 446, 0, 1, 1935, 1936, "(" +543, 20, 2, 447, 2, 4, 1937, 1939, "14" +543, 20, 3, 448, 5, 6, 1940, 1941, ")" +543, 20, 4, 449, 7, 17, 1942, 1952, "University" +543, 20, 5, 450, 18, 27, 1953, 1962, "Hospitals" +543, 20, 6, 451, 28, 34, 1963, 1969, "Leuven" +543, 20, 7, 452, 35, 36, 1970, 1971, "," +543, 20, 8, 453, 37, 43, 1972, 1978, "Leuven" +543, 20, 9, 454, 44, 45, 1979, 1980, "," +543, 20, 10, 455, 46, 53, 1981, 1988, "Belgium" +543, 20, 11, 456, 54, 55, 1989, 1990, "." +543, 21, 1, 457, 0, 7, 1991, 1998, "Erratum" +543, 21, 2, 458, 8, 10, 1999, 2001, "in" +543, 21, 3, 459, 11, 17, 2002, 2008, "Lancet" +543, 21, 4, 460, 18, 19, 2009, 2010, "." +543, 22, 1, 461, 0, 4, 2011, 2015, "2015" +543, 22, 2, 462, 5, 8, 2016, 2019, "Jul" +543, 22, 3, 463, 9, 11, 2020, 2022, "11" +543, 22, 4, 464, 12, 13, 2023, 2024, ";" +543, 22, 5, 465, 14, 17, 2025, 2028, "386" +543, 22, 6, 466, 18, 19, 2029, 2030, "(" +543, 22, 7, 467, 20, 24, 2031, 2035, "9989" +543, 22, 8, 468, 25, 26, 2036, 2037, ")" +543, 22, 9, 469, 27, 28, 2038, 2039, ":" +543, 22, 10, 470, 29, 32, 2040, 2043, "136" +543, 22, 11, 471, 33, 34, 2044, 2045, "." +543, 23, 1, 472, 0, 7, 2046, 2053, "Comment" +543, 23, 2, 473, 8, 10, 2054, 2056, "in" +543, 23, 3, 474, 11, 17, 2057, 2063, "Lancet" +543, 23, 4, 475, 18, 19, 2064, 2065, "." +543, 24, 1, 476, 0, 4, 2066, 2070, "2015" +543, 24, 2, 477, 5, 8, 2071, 2074, "Apr" +543, 24, 3, 478, 9, 10, 2075, 2076, "4" +543, 24, 4, 479, 11, 12, 2077, 2078, ";" +543, 24, 5, 480, 13, 16, 2079, 2082, "385" +543, 24, 6, 481, 17, 18, 2083, 2084, "(" +543, 24, 7, 482, 19, 23, 2085, 2089, "9975" +543, 24, 8, 483, 24, 25, 2090, 2091, ")" +543, 24, 9, 484, 26, 27, 2092, 2093, ":" +543, 24, 10, 485, 28, 32, 2094, 2098, "1264" +543, 24, 11, 486, 33, 34, 2099, 2100, "-" +543, 24, 12, 487, 35, 36, 2101, 2102, "6" +543, 24, 13, 488, 37, 38, 2103, 2104, "." +543, 25, 1, 489, 0, 3, 2105, 2108, "Ann" +543, 25, 2, 490, 4, 10, 2109, 2115, "Intern" +543, 25, 3, 491, 11, 14, 2116, 2119, "Med" +543, 25, 4, 492, 15, 16, 2120, 2121, "." +543, 26, 1, 493, 0, 4, 2122, 2126, "2015" +543, 26, 2, 494, 5, 8, 2127, 2130, "Jun" +543, 26, 3, 495, 9, 11, 2131, 2133, "16" +543, 26, 4, 496, 12, 13, 2134, 2135, ";" +543, 26, 5, 497, 14, 17, 2136, 2139, "162" +543, 26, 6, 498, 18, 19, 2140, 2141, "(" +543, 26, 7, 499, 20, 22, 2142, 2144, "12" +543, 26, 8, 500, 23, 24, 2145, 2146, ")" +543, 26, 9, 501, 25, 26, 2147, 2148, ":" +543, 26, 10, 502, 27, 31, 2149, 2153, "JC10" +543, 26, 11, 503, 32, 33, 2154, 2155, "." +543, 27, 1, 504, 0, 6, 2156, 2162, "Lancet" +543, 27, 2, 505, 7, 8, 2163, 2164, "." +543, 28, 1, 506, 0, 4, 2165, 2169, "2015" +543, 28, 2, 507, 5, 8, 2170, 2173, "Aug" +543, 28, 3, 508, 9, 11, 2174, 2176, "15" +543, 28, 4, 509, 12, 13, 2177, 2178, ";" +543, 28, 5, 510, 14, 17, 2179, 2182, "386" +543, 28, 6, 511, 18, 19, 2183, 2184, "(" +543, 28, 7, 512, 20, 24, 2185, 2189, "9994" +543, 28, 8, 513, 25, 26, 2190, 2191, ")" +543, 28, 9, 514, 27, 28, 2192, 2193, ":" +543, 28, 10, 515, 29, 32, 2194, 2197, "651" +543, 28, 11, 516, 33, 34, 2198, 2199, "-" +543, 28, 12, 517, 35, 36, 2200, 2201, "2" +543, 28, 13, 518, 37, 38, 2202, 2203, "." +543, 29, 1, 519, 0, 6, 2204, 2210, "Lancet" +543, 29, 2, 520, 7, 8, 2211, 2212, "." +543, 30, 1, 521, 0, 4, 2213, 2217, "2015" +543, 30, 2, 522, 5, 8, 2218, 2221, "Aug" +543, 30, 3, 523, 9, 11, 2222, 2224, "15" +543, 30, 4, 524, 12, 13, 2225, 2226, ";" +543, 30, 5, 525, 14, 17, 2227, 2230, "386" +543, 30, 6, 526, 18, 19, 2231, 2232, "(" +543, 30, 7, 527, 20, 24, 2233, 2237, "9994" +543, 30, 8, 528, 25, 26, 2238, 2239, ")" +543, 30, 9, 529, 27, 28, 2240, 2241, ":" +543, 30, 10, 530, 29, 32, 2242, 2245, "652" +543, 30, 11, 531, 33, 34, 2246, 2247, "." +543, 31, 1, 532, 0, 10, 2248, 2258, "BACKGROUND" +543, 31, 2, 533, 11, 12, 2259, 2260, ":" +543, 31, 3, 534, 13, 23, 2261, 2271, "Treatments" +543, 31, 4, 535, 24, 27, 2272, 2275, "for" +543, 31, 5, 536, 28, 32, 2276, 2280, "open" +543, 31, 6, 537, 33, 34, 2281, 2282, "-" +543, 31, 7, 538, 35, 40, 2283, 2288, "angle" +543, 31, 8, 539, 41, 49, 2289, 2297, "glaucoma" +543, 31, 9, 540, 50, 53, 2298, 2301, "aim" +543, 31, 10, 541, 54, 56, 2302, 2304, "to" +543, 31, 11, 542, 57, 64, 2305, 2312, "prevent" +543, 31, 12, 543, 65, 71, 2313, 2319, "vision" +543, 31, 13, 544, 72, 76, 2320, 2324, "loss" +543, 31, 14, 545, 77, 84, 2325, 2332, "through" +543, 31, 15, 546, 85, 93, 2333, 2341, "lowering" +543, 31, 16, 547, 94, 96, 2342, 2344, "of" +543, 31, 17, 548, 97, 108, 2345, 2356, "intraocular" +543, 31, 18, 549, 109, 117, 2357, 2365, "pressure" +543, 31, 19, 550, 118, 119, 2366, 2367, "," +543, 31, 20, 551, 120, 123, 2368, 2371, "but" +543, 31, 21, 552, 124, 126, 2372, 2374, "to" +543, 31, 22, 553, 127, 130, 2375, 2378, "our" +543, 31, 23, 554, 131, 140, 2379, 2388, "knowledge" +543, 31, 24, 555, 141, 143, 2389, 2391, "no" +543, 31, 25, 556, 144, 151, 2392, 2399, "placebo" +543, 31, 26, 557, 152, 153, 2400, 2401, "-" +543, 31, 27, 558, 154, 164, 2402, 2412, "controlled" +543, 31, 28, 559, 165, 171, 2413, 2419, "trials" +543, 31, 29, 560, 172, 176, 2420, 2424, "have" +543, 31, 30, 561, 177, 185, 2425, 2433, "assessed" +543, 31, 31, 562, 186, 192, 2434, 2440, "visual" +543, 31, 32, 563, 193, 201, 2441, 2449, "function" +543, 31, 33, 564, 202, 214, 2450, 2462, "preservation" +543, 31, 34, 565, 215, 216, 2463, 2464, "," +543, 31, 35, 566, 217, 220, 2465, 2468, "and" +543, 31, 36, 567, 221, 224, 2469, 2472, "the" +543, 31, 37, 568, 225, 236, 2473, 2484, "observation" +543, 31, 38, 569, 237, 244, 2485, 2492, "periods" +543, 31, 39, 570, 245, 247, 2493, 2495, "of" +543, 31, 40, 571, 248, 256, 2496, 2504, "previous" +543, 31, 41, 572, 257, 258, 2505, 2506, "(" +543, 31, 42, 573, 259, 267, 2507, 2515, "unmasked" +543, 31, 43, 574, 268, 269, 2516, 2517, ")" +543, 31, 44, 575, 270, 276, 2518, 2524, "trials" +543, 31, 45, 576, 277, 281, 2525, 2529, "have" +543, 31, 46, 577, 282, 291, 2530, 2539, "typically" +543, 31, 47, 578, 292, 296, 2540, 2544, "been" +543, 31, 48, 579, 297, 299, 2545, 2547, "at" +543, 31, 49, 580, 300, 305, 2548, 2553, "least" +543, 31, 50, 581, 306, 307, 2554, 2555, "5" +543, 31, 51, 582, 308, 313, 2556, 2561, "years" +543, 31, 52, 583, 314, 315, 2562, 2563, "." +543, 32, 1, 584, 0, 2, 2564, 2566, "We" +543, 32, 2, 585, 3, 11, 2567, 2575, "assessed" +543, 32, 3, 586, 12, 18, 2576, 2582, "vision" +543, 32, 4, 587, 19, 31, 2583, 2595, "preservation" +543, 32, 5, 588, 32, 34, 2596, 2598, "in" +543, 32, 6, 589, 35, 43, 2599, 2607, "patients" +543, 32, 7, 590, 44, 49, 2608, 2613, "given" +543, 32, 8, 591, 50, 61, 2614, 2625, "latanoprost" +543, 32, 9, 592, 62, 70, 2626, 2634, "compared" +543, 32, 10, 593, 71, 75, 2635, 2639, "with" +543, 32, 11, 594, 76, 81, 2640, 2645, "those" +543, 32, 12, 595, 82, 87, 2646, 2651, "given" +543, 32, 13, 596, 88, 95, 2652, 2659, "placebo" +543, 32, 14, 597, 96, 97, 2660, 2661, "." +543, 33, 1, 598, 0, 7, 2662, 2669, "METHODS" +543, 33, 2, 599, 8, 9, 2670, 2671, ":" +543, 33, 3, 600, 10, 12, 2672, 2674, "In" +543, 33, 4, 601, 13, 17, 2675, 2679, "this" +543, 33, 5, 602, 18, 28, 2680, 2690, "randomised" +543, 33, 6, 603, 29, 30, 2691, 2692, "," +543, 33, 7, 604, 31, 37, 2693, 2699, "triple" +543, 33, 8, 605, 38, 39, 2700, 2701, "-" +543, 33, 9, 606, 40, 46, 2702, 2708, "masked" +543, 33, 10, 607, 47, 48, 2709, 2710, "," +543, 33, 11, 608, 49, 56, 2711, 2718, "placebo" +543, 33, 12, 609, 57, 58, 2719, 2720, "-" +543, 33, 13, 610, 59, 69, 2721, 2731, "controlled" +543, 33, 14, 611, 70, 75, 2732, 2737, "trial" +543, 33, 15, 612, 76, 77, 2738, 2739, "," +543, 33, 16, 613, 78, 80, 2740, 2742, "we" +543, 33, 17, 614, 81, 89, 2743, 2751, "enrolled" +543, 33, 18, 615, 90, 98, 2752, 2760, "patients" +543, 33, 19, 616, 99, 103, 2761, 2765, "with" +543, 33, 20, 617, 104, 109, 2766, 2771, "newly" +543, 33, 21, 618, 110, 119, 2772, 2781, "diagnosed" +543, 33, 22, 619, 120, 124, 2782, 2786, "open" +543, 33, 23, 620, 125, 126, 2787, 2788, "-" +543, 33, 24, 621, 127, 132, 2789, 2794, "angle" +543, 33, 25, 622, 133, 141, 2795, 2803, "glaucoma" +543, 33, 26, 623, 142, 144, 2804, 2806, "at" +543, 33, 27, 624, 145, 148, 2807, 2810, "ten" +543, 33, 28, 625, 149, 151, 2811, 2813, "UK" +543, 33, 29, 626, 152, 159, 2814, 2821, "centres" +543, 33, 30, 627, 160, 161, 2822, 2823, "(" +543, 33, 31, 628, 162, 170, 2824, 2832, "tertiary" +543, 33, 32, 629, 171, 179, 2833, 2841, "referral" +543, 33, 33, 630, 180, 187, 2842, 2849, "centres" +543, 33, 34, 631, 188, 189, 2850, 2851, "," +543, 33, 35, 632, 190, 198, 2852, 2860, "teaching" +543, 33, 36, 633, 199, 208, 2861, 2870, "hospitals" +543, 33, 37, 634, 209, 210, 2871, 2872, "," +543, 33, 38, 635, 211, 214, 2873, 2876, "and" +543, 33, 39, 636, 215, 223, 2877, 2885, "district" +543, 33, 40, 637, 224, 231, 2886, 2893, "general" +543, 33, 41, 638, 232, 241, 2894, 2903, "hospitals" +543, 33, 42, 639, 242, 243, 2904, 2905, ")" +543, 33, 43, 640, 244, 245, 2906, 2907, "." +543, 34, 1, 641, 0, 8, 2908, 2916, "Eligible" +543, 34, 2, 642, 9, 17, 2917, 2925, "patients" +543, 34, 3, 643, 18, 22, 2926, 2930, "were" +543, 34, 4, 644, 23, 31, 2931, 2939, "randomly" +543, 34, 5, 645, 32, 41, 2940, 2949, "allocated" +543, 34, 6, 646, 42, 43, 2950, 2951, "(" +543, 34, 7, 647, 44, 45, 2952, 2953, "1" +543, 34, 8, 648, 46, 47, 2954, 2955, ":" +543, 34, 9, 649, 48, 49, 2956, 2957, "1" +543, 34, 10, 650, 50, 51, 2958, 2959, ")" +543, 34, 11, 651, 52, 56, 2960, 2964, "with" +543, 34, 12, 652, 57, 58, 2965, 2966, "a" +543, 34, 13, 653, 59, 66, 2967, 2974, "website" +543, 34, 14, 654, 67, 68, 2975, 2976, "-" +543, 34, 15, 655, 69, 78, 2977, 2986, "generated" +543, 34, 16, 656, 79, 92, 2987, 3000, "randomisation" +543, 34, 17, 657, 93, 101, 3001, 3009, "schedule" +543, 34, 18, 658, 102, 103, 3010, 3011, "," +543, 34, 19, 659, 104, 114, 3012, 3022, "stratified" +543, 34, 20, 660, 115, 117, 3023, 3025, "by" +543, 34, 21, 661, 118, 124, 3026, 3032, "centre" +543, 34, 22, 662, 125, 128, 3033, 3036, "and" +543, 34, 23, 663, 129, 133, 3037, 3041, "with" +543, 34, 24, 664, 134, 135, 3042, 3043, "a" +543, 34, 25, 665, 136, 144, 3044, 3052, "permuted" +543, 34, 26, 666, 145, 150, 3053, 3058, "block" +543, 34, 27, 667, 151, 157, 3059, 3065, "design" +543, 34, 28, 668, 158, 159, 3066, 3067, "," +543, 34, 29, 669, 160, 162, 3068, 3070, "to" +543, 34, 30, 670, 163, 170, 3071, 3078, "receive" +543, 34, 31, 671, 171, 177, 3079, 3085, "either" +543, 34, 32, 672, 178, 189, 3086, 3097, "latanoprost" +543, 34, 33, 673, 190, 191, 3098, 3099, "0" +543, 34, 34, 674, 192, 193, 3100, 3101, "·" +543, 34, 35, 675, 194, 197, 3102, 3105, "005" +543, 34, 36, 676, 198, 199, 3106, 3107, "%" +543, 34, 37, 677, 200, 201, 3108, 3109, "(" +543, 34, 38, 678, 202, 214, 3110, 3122, "intervention" +543, 34, 39, 679, 215, 220, 3123, 3128, "group" +543, 34, 40, 680, 221, 222, 3129, 3130, ")" +543, 34, 41, 681, 223, 225, 3131, 3133, "or" +543, 34, 42, 682, 226, 233, 3134, 3141, "placebo" +543, 34, 43, 683, 234, 235, 3142, 3143, "(" +543, 34, 44, 684, 236, 243, 3144, 3151, "control" +543, 34, 45, 685, 244, 249, 3152, 3157, "group" +543, 34, 46, 686, 250, 251, 3158, 3159, ")" +543, 34, 47, 687, 252, 255, 3160, 3163, "eye" +543, 34, 48, 688, 256, 261, 3164, 3169, "drops" +543, 34, 49, 689, 262, 263, 3170, 3171, "." +543, 35, 1, 690, 0, 5, 3172, 3177, "Drops" +543, 35, 2, 691, 6, 10, 3178, 3182, "were" +543, 35, 3, 692, 11, 23, 3183, 3195, "administered" +543, 35, 4, 693, 24, 28, 3196, 3200, "from" +543, 35, 5, 694, 29, 38, 3201, 3210, "identical" +543, 35, 6, 695, 39, 46, 3211, 3218, "bottles" +543, 35, 7, 696, 47, 48, 3219, 3220, "," +543, 35, 8, 697, 49, 53, 3221, 3225, "once" +543, 35, 9, 698, 54, 55, 3226, 3227, "a" +543, 35, 10, 699, 56, 59, 3228, 3231, "day" +543, 35, 11, 700, 60, 61, 3232, 3233, "," +543, 35, 12, 701, 62, 64, 3234, 3236, "to" +543, 35, 13, 702, 65, 69, 3237, 3241, "both" +543, 35, 14, 703, 70, 74, 3242, 3246, "eyes" +543, 35, 15, 704, 75, 76, 3247, 3248, "." +543, 36, 1, 705, 0, 3, 3249, 3252, "The" +543, 36, 2, 706, 4, 11, 3253, 3260, "primary" +543, 36, 3, 707, 12, 19, 3261, 3268, "outcome" +543, 36, 4, 708, 20, 23, 3269, 3272, "was" +543, 36, 5, 709, 24, 28, 3273, 3277, "time" +543, 36, 6, 710, 29, 31, 3278, 3280, "to" +543, 36, 7, 711, 32, 38, 3281, 3287, "visual" +543, 36, 8, 712, 39, 44, 3288, 3293, "field" +543, 36, 9, 713, 45, 58, 3294, 3307, "deterioration" +543, 36, 10, 714, 59, 65, 3308, 3314, "within" +543, 36, 11, 715, 66, 68, 3315, 3317, "24" +543, 36, 12, 716, 69, 75, 3318, 3324, "months" +543, 36, 13, 717, 76, 77, 3325, 3326, "." +543, 37, 1, 718, 0, 8, 3327, 3335, "Analyses" +543, 37, 2, 719, 9, 13, 3336, 3340, "were" +543, 37, 3, 720, 14, 18, 3341, 3345, "done" +543, 37, 4, 721, 19, 21, 3346, 3348, "in" +543, 37, 5, 722, 22, 25, 3349, 3352, "all" +543, 37, 6, 723, 26, 37, 3353, 3364, "individuals" +543, 37, 7, 724, 38, 42, 3365, 3369, "with" +543, 37, 8, 725, 43, 49, 3370, 3376, "follow" +543, 37, 9, 726, 50, 51, 3377, 3378, "-" +543, 37, 10, 727, 52, 54, 3379, 3381, "up" +543, 37, 11, 728, 55, 59, 3382, 3386, "data" +543, 37, 12, 729, 60, 61, 3387, 3388, "." +543, 38, 1, 730, 0, 3, 3389, 3392, "The" +543, 38, 2, 731, 4, 8, 3393, 3397, "Data" +543, 38, 3, 732, 9, 12, 3398, 3401, "and" +543, 38, 4, 733, 13, 19, 3402, 3408, "Safety" +543, 38, 5, 734, 20, 30, 3409, 3419, "Monitoring" +543, 38, 6, 735, 31, 40, 3420, 3429, "Committee" +543, 38, 7, 736, 41, 42, 3430, 3431, "(" +543, 38, 8, 737, 43, 47, 3432, 3436, "DSMC" +543, 38, 9, 738, 48, 49, 3437, 3438, ")" +543, 38, 10, 739, 50, 61, 3439, 3450, "recommended" +543, 38, 11, 740, 62, 70, 3451, 3459, "stopping" +543, 38, 12, 741, 71, 74, 3460, 3463, "the" +543, 38, 13, 742, 75, 80, 3464, 3469, "trial" +543, 38, 14, 743, 81, 83, 3470, 3472, "on" +543, 38, 15, 744, 84, 87, 3473, 3476, "Jan" +543, 38, 16, 745, 88, 89, 3477, 3478, "6" +543, 38, 17, 746, 90, 91, 3479, 3480, "," +543, 38, 18, 747, 92, 96, 3481, 3485, "2011" +543, 38, 19, 748, 97, 98, 3486, 3487, "(" +543, 38, 20, 749, 99, 103, 3488, 3492, "last" +543, 38, 21, 750, 104, 111, 3493, 3500, "patient" +543, 38, 22, 751, 112, 117, 3501, 3506, "visit" +543, 38, 23, 752, 118, 122, 3507, 3511, "July" +543, 38, 24, 753, 123, 124, 3512, 3513, "," +543, 38, 25, 754, 125, 129, 3514, 3518, "2011" +543, 38, 26, 755, 130, 131, 3519, 3520, ")" +543, 38, 27, 756, 132, 133, 3521, 3522, "," +543, 38, 28, 757, 134, 139, 3523, 3528, "after" +543, 38, 29, 758, 140, 142, 3529, 3531, "an" +543, 38, 30, 759, 143, 150, 3532, 3539, "interim" +543, 38, 31, 760, 151, 159, 3540, 3548, "analysis" +543, 38, 32, 761, 160, 161, 3549, 3550, "," +543, 38, 33, 762, 162, 165, 3551, 3554, "and" +543, 38, 34, 763, 166, 175, 3555, 3564, "suggested" +543, 38, 35, 764, 176, 177, 3565, 3566, "a" +543, 38, 36, 765, 178, 184, 3567, 3573, "change" +543, 38, 37, 766, 185, 187, 3574, 3576, "in" +543, 38, 38, 767, 188, 195, 3577, 3584, "primary" +543, 38, 39, 768, 196, 203, 3585, 3592, "outcome" +543, 38, 40, 769, 204, 208, 3593, 3597, "from" +543, 38, 41, 770, 209, 212, 3598, 3601, "the" +543, 38, 42, 771, 213, 223, 3602, 3612, "difference" +543, 38, 43, 772, 224, 226, 3613, 3615, "in" +543, 38, 44, 773, 227, 238, 3616, 3627, "proportions" +543, 38, 45, 774, 239, 241, 3628, 3630, "of" +543, 38, 46, 775, 242, 250, 3631, 3639, "patients" +543, 38, 47, 776, 251, 255, 3640, 3644, "with" +543, 38, 48, 777, 256, 264, 3645, 3653, "incident" +543, 38, 49, 778, 265, 276, 3654, 3665, "progression" +543, 38, 50, 779, 277, 284, 3666, 3673, "between" +543, 38, 51, 780, 285, 291, 3674, 3680, "groups" +543, 38, 52, 781, 292, 294, 3681, 3683, "to" +543, 38, 53, 782, 295, 299, 3684, 3688, "time" +543, 38, 54, 783, 300, 302, 3689, 3691, "to" +543, 38, 55, 784, 303, 309, 3692, 3698, "visual" +543, 38, 56, 785, 310, 315, 3699, 3704, "field" +543, 38, 57, 786, 316, 329, 3705, 3718, "deterioration" +543, 38, 58, 787, 330, 336, 3719, 3725, "within" +543, 38, 59, 788, 337, 339, 3726, 3728, "24" +543, 38, 60, 789, 340, 346, 3729, 3735, "months" +543, 38, 61, 790, 347, 348, 3736, 3737, "." +543, 39, 1, 791, 0, 4, 3738, 3742, "This" +543, 39, 2, 792, 5, 10, 3743, 3748, "trial" +543, 39, 3, 793, 11, 13, 3749, 3751, "is" +543, 39, 4, 794, 14, 24, 3752, 3762, "registered" +543, 39, 5, 795, 25, 26, 3763, 3764, "," +543, 39, 6, 796, 27, 33, 3765, 3771, "number" +543, 39, 7, 797, 34, 48, 3772, 3786, "ISRCTN96423140" +543, 39, 8, 798, 49, 50, 3787, 3788, "." +543, 40, 1, 799, 0, 8, 3789, 3797, "FINDINGS" +543, 40, 2, 800, 9, 10, 3798, 3799, ":" +543, 40, 3, 801, 11, 13, 3800, 3802, "We" +543, 40, 4, 802, 14, 22, 3803, 3811, "enrolled" +543, 40, 5, 803, 23, 26, 3812, 3815, "516" +543, 40, 6, 804, 27, 38, 3816, 3827, "individuals" +543, 40, 7, 805, 39, 46, 3828, 3835, "between" +543, 40, 8, 806, 47, 50, 3836, 3839, "Dec" +543, 40, 9, 807, 51, 52, 3840, 3841, "1" +543, 40, 10, 808, 53, 54, 3842, 3843, "," +543, 40, 11, 809, 55, 59, 3844, 3848, "2006" +543, 40, 12, 810, 60, 61, 3849, 3850, "," +543, 40, 13, 811, 62, 65, 3851, 3854, "and" +543, 40, 14, 812, 66, 71, 3855, 3860, "March" +543, 40, 15, 813, 72, 74, 3861, 3863, "16" +543, 40, 16, 814, 75, 76, 3864, 3865, "," +543, 40, 17, 815, 77, 81, 3866, 3870, "2010" +543, 40, 18, 816, 82, 83, 3871, 3872, "." +543, 41, 1, 817, 0, 8, 3873, 3881, "Baseline" +543, 41, 2, 818, 9, 13, 3882, 3886, "mean" +543, 41, 3, 819, 14, 25, 3887, 3898, "intraocular" +543, 41, 4, 820, 26, 34, 3899, 3907, "pressure" +543, 41, 5, 821, 35, 38, 3908, 3911, "was" +543, 41, 6, 822, 39, 41, 3912, 3914, "19" +543, 41, 7, 823, 42, 43, 3915, 3916, "·" +543, 41, 8, 824, 44, 45, 3917, 3918, "6" +543, 41, 9, 825, 46, 48, 3919, 3921, "mm" +543, 41, 10, 826, 49, 51, 3922, 3924, "Hg" +543, 41, 11, 827, 52, 53, 3925, 3926, "(" +543, 41, 12, 828, 54, 56, 3927, 3929, "SD" +543, 41, 13, 829, 57, 58, 3930, 3931, "4" +543, 41, 14, 830, 59, 60, 3932, 3933, "·" +543, 41, 15, 831, 61, 62, 3934, 3935, "6" +543, 41, 16, 832, 63, 64, 3936, 3937, ")" +543, 41, 17, 833, 65, 67, 3938, 3940, "in" +543, 41, 18, 834, 68, 71, 3941, 3944, "258" +543, 41, 19, 835, 72, 80, 3945, 3953, "patients" +543, 41, 20, 836, 81, 83, 3954, 3956, "in" +543, 41, 21, 837, 84, 87, 3957, 3960, "the" +543, 41, 22, 838, 88, 99, 3961, 3972, "latanoprost" +543, 41, 23, 839, 100, 105, 3973, 3978, "group" +543, 41, 24, 840, 106, 109, 3979, 3982, "and" +543, 41, 25, 841, 110, 112, 3983, 3985, "20" +543, 41, 26, 842, 113, 114, 3986, 3987, "·" +543, 41, 27, 843, 115, 116, 3988, 3989, "1" +543, 41, 28, 844, 117, 119, 3990, 3992, "mm" +543, 41, 29, 845, 120, 122, 3993, 3995, "Hg" +543, 41, 30, 846, 123, 124, 3996, 3997, "(" +543, 41, 31, 847, 125, 126, 3998, 3999, "4" +543, 41, 32, 848, 127, 128, 4000, 4001, "·" +543, 41, 33, 849, 129, 130, 4002, 4003, "8" +543, 41, 34, 850, 131, 132, 4004, 4005, ")" +543, 41, 35, 851, 133, 135, 4006, 4008, "in" +543, 41, 36, 852, 136, 139, 4009, 4012, "258" +543, 41, 37, 853, 140, 148, 4013, 4021, "controls" +543, 41, 38, 854, 149, 150, 4022, 4023, "." +543, 42, 1, 855, 0, 2, 4024, 4026, "At" +543, 42, 2, 856, 3, 5, 4027, 4029, "24" +543, 42, 3, 857, 6, 12, 4030, 4036, "months" +543, 42, 4, 858, 13, 14, 4037, 4038, "," +543, 42, 5, 859, 15, 19, 4039, 4043, "mean" +543, 42, 6, 860, 20, 29, 4044, 4053, "reduction" +543, 42, 7, 861, 30, 32, 4054, 4056, "in" +543, 42, 8, 862, 33, 44, 4057, 4068, "intraocular" +543, 42, 9, 863, 45, 53, 4069, 4077, "pressure" +543, 42, 10, 864, 54, 57, 4078, 4081, "was" +543, 42, 11, 865, 58, 59, 4082, 4083, "3" +543, 42, 12, 866, 60, 61, 4084, 4085, "·" +543, 42, 13, 867, 62, 63, 4086, 4087, "8" +543, 42, 14, 868, 64, 66, 4088, 4090, "mm" +543, 42, 15, 869, 67, 69, 4091, 4093, "Hg" +543, 42, 16, 870, 70, 71, 4094, 4095, "(" +543, 42, 17, 871, 72, 73, 4096, 4097, "4" +543, 42, 18, 872, 74, 75, 4098, 4099, "·" +543, 42, 19, 873, 76, 77, 4100, 4101, "0" +543, 42, 20, 874, 78, 79, 4102, 4103, ")" +543, 42, 21, 875, 80, 82, 4104, 4106, "in" +543, 42, 22, 876, 83, 86, 4107, 4110, "231" +543, 42, 23, 877, 87, 95, 4111, 4119, "patients" +543, 42, 24, 878, 96, 104, 4120, 4128, "assessed" +543, 42, 25, 879, 105, 107, 4129, 4131, "in" +543, 42, 26, 880, 108, 111, 4132, 4135, "the" +543, 42, 27, 881, 112, 123, 4136, 4147, "latanoprost" +543, 42, 28, 882, 124, 129, 4148, 4153, "group" +543, 42, 29, 883, 130, 133, 4154, 4157, "and" +543, 42, 30, 884, 134, 135, 4158, 4159, "0" +543, 42, 31, 885, 136, 137, 4160, 4161, "·" +543, 42, 32, 886, 138, 139, 4162, 4163, "9" +543, 42, 33, 887, 140, 142, 4164, 4166, "mm" +543, 42, 34, 888, 143, 145, 4167, 4169, "Hg" +543, 42, 35, 889, 146, 147, 4170, 4171, "(" +543, 42, 36, 890, 148, 149, 4172, 4173, "3" +543, 42, 37, 891, 150, 151, 4174, 4175, "·" +543, 42, 38, 892, 152, 153, 4176, 4177, "8" +543, 42, 39, 893, 154, 155, 4178, 4179, ")" +543, 42, 40, 894, 156, 158, 4180, 4182, "in" +543, 42, 41, 895, 159, 162, 4183, 4186, "230" +543, 42, 42, 896, 163, 171, 4187, 4195, "patients" +543, 42, 43, 897, 172, 180, 4196, 4204, "assessed" +543, 42, 44, 898, 181, 183, 4205, 4207, "in" +543, 42, 45, 899, 184, 187, 4208, 4211, "the" +543, 42, 46, 900, 188, 195, 4212, 4219, "placebo" +543, 42, 47, 901, 196, 201, 4220, 4225, "group" +543, 42, 48, 902, 202, 203, 4226, 4227, "." +543, 43, 1, 903, 0, 6, 4228, 4234, "Visual" +543, 43, 2, 904, 7, 12, 4235, 4240, "field" +543, 43, 3, 905, 13, 25, 4241, 4253, "preservation" +543, 43, 4, 906, 26, 29, 4254, 4257, "was" +543, 43, 5, 907, 30, 43, 4258, 4271, "significantly" +543, 43, 6, 908, 44, 50, 4272, 4278, "longer" +543, 43, 7, 909, 51, 53, 4279, 4281, "in" +543, 43, 8, 910, 54, 57, 4282, 4285, "the" +543, 43, 9, 911, 58, 69, 4286, 4297, "latanoprost" +543, 43, 10, 912, 70, 75, 4298, 4303, "group" +543, 43, 11, 913, 76, 80, 4304, 4308, "than" +543, 43, 12, 914, 81, 83, 4309, 4311, "in" +543, 43, 13, 915, 84, 87, 4312, 4315, "the" +543, 43, 14, 916, 88, 95, 4316, 4323, "placebo" +543, 43, 15, 917, 96, 101, 4324, 4329, "group" +543, 43, 16, 918, 102, 103, 4330, 4331, ":" +543, 43, 17, 919, 104, 112, 4332, 4340, "adjusted" +543, 43, 18, 920, 113, 119, 4341, 4347, "hazard" +543, 43, 19, 921, 120, 125, 4348, 4353, "ratio" +543, 43, 20, 922, 126, 127, 4354, 4355, "(" +543, 43, 21, 923, 128, 130, 4356, 4358, "HR" +543, 43, 22, 924, 131, 132, 4359, 4360, ")" +543, 43, 23, 925, 133, 134, 4361, 4362, "0" +543, 43, 24, 926, 135, 136, 4363, 4364, "·" +543, 43, 25, 927, 137, 139, 4365, 4367, "44" +543, 43, 26, 928, 140, 141, 4368, 4369, "(" +543, 43, 27, 929, 142, 144, 4370, 4372, "95" +543, 43, 28, 930, 145, 146, 4373, 4374, "%" +543, 43, 29, 931, 147, 149, 4375, 4377, "CI" +543, 43, 30, 932, 150, 151, 4378, 4379, "0" +543, 43, 31, 933, 152, 153, 4380, 4381, "·" +543, 43, 32, 934, 154, 156, 4382, 4384, "28" +543, 43, 33, 935, 157, 158, 4385, 4386, "-" +543, 43, 34, 936, 159, 160, 4387, 4388, "0" +543, 43, 35, 937, 161, 162, 4389, 4390, "·" +543, 43, 36, 938, 163, 165, 4391, 4393, "69" +543, 43, 37, 939, 166, 167, 4394, 4395, ";" +543, 43, 38, 940, 168, 169, 4396, 4397, "p" +543, 43, 39, 941, 170, 171, 4398, 4399, "=" +543, 43, 40, 942, 172, 173, 4400, 4401, "0" +543, 43, 41, 943, 174, 175, 4402, 4403, "·" +543, 43, 42, 944, 176, 180, 4404, 4408, "0003" +543, 43, 43, 945, 181, 182, 4409, 4410, ")" +543, 43, 44, 946, 183, 184, 4411, 4412, "." +543, 44, 1, 947, 0, 2, 4413, 4415, "We" +543, 44, 2, 948, 3, 8, 4416, 4421, "noted" +543, 44, 3, 949, 9, 11, 4422, 4424, "18" +543, 44, 4, 950, 12, 19, 4425, 4432, "serious" +543, 44, 5, 951, 20, 27, 4433, 4440, "adverse" +543, 44, 6, 952, 28, 34, 4441, 4447, "events" +543, 44, 7, 953, 35, 36, 4448, 4449, "," +543, 44, 8, 954, 37, 41, 4450, 4454, "none" +543, 44, 9, 955, 42, 54, 4455, 4467, "attributable" +543, 44, 10, 956, 55, 57, 4468, 4470, "to" +543, 44, 11, 957, 58, 61, 4471, 4474, "the" +543, 44, 12, 958, 62, 67, 4475, 4480, "study" +543, 44, 13, 959, 68, 72, 4481, 4485, "drug" +543, 44, 14, 960, 73, 74, 4486, 4487, "." +543, 45, 1, 961, 0, 14, 4488, 4502, "INTERPRETATION" +543, 45, 2, 962, 15, 16, 4503, 4504, ":" +543, 45, 3, 963, 17, 21, 4505, 4509, "This" +543, 45, 4, 964, 22, 24, 4510, 4512, "is" +543, 45, 5, 965, 25, 28, 4513, 4516, "the" +543, 45, 6, 966, 29, 34, 4517, 4522, "first" +543, 45, 7, 967, 35, 45, 4523, 4533, "randomised" +543, 45, 8, 968, 46, 53, 4534, 4541, "placebo" +543, 45, 9, 969, 54, 55, 4542, 4543, "-" +543, 45, 10, 970, 56, 66, 4544, 4554, "controlled" +543, 45, 11, 971, 67, 72, 4555, 4560, "trial" +543, 45, 12, 972, 73, 75, 4561, 4563, "to" +543, 45, 13, 973, 76, 80, 4564, 4568, "show" +543, 45, 14, 974, 81, 93, 4569, 4581, "preservation" +543, 45, 15, 975, 94, 96, 4582, 4584, "of" +543, 45, 16, 976, 97, 100, 4585, 4588, "the" +543, 45, 17, 977, 101, 107, 4589, 4595, "visual" +543, 45, 18, 978, 108, 113, 4596, 4601, "field" +543, 45, 19, 979, 114, 118, 4602, 4606, "with" +543, 45, 20, 980, 119, 121, 4607, 4609, "an" +543, 45, 21, 981, 122, 133, 4610, 4621, "intraocular" +543, 45, 22, 982, 134, 135, 4622, 4623, "-" +543, 45, 23, 983, 136, 144, 4624, 4632, "pressure" +543, 45, 24, 984, 145, 146, 4633, 4634, "-" +543, 45, 25, 985, 147, 155, 4635, 4643, "lowering" +543, 45, 26, 986, 156, 160, 4644, 4648, "drug" +543, 45, 27, 987, 161, 163, 4649, 4651, "in" +543, 45, 28, 988, 164, 172, 4652, 4660, "patients" +543, 45, 29, 989, 173, 177, 4661, 4665, "with" +543, 45, 30, 990, 178, 182, 4666, 4670, "open" +543, 45, 31, 991, 183, 184, 4671, 4672, "-" +543, 45, 32, 992, 185, 190, 4673, 4678, "angle" +543, 45, 33, 993, 191, 199, 4679, 4687, "glaucoma" +543, 45, 34, 994, 200, 201, 4688, 4689, "." +543, 46, 1, 995, 0, 3, 4690, 4693, "The" +543, 46, 2, 996, 4, 9, 4694, 4699, "study" +543, 46, 3, 997, 10, 16, 4700, 4706, "design" +543, 46, 4, 998, 17, 24, 4707, 4714, "enabled" +543, 46, 5, 999, 25, 36, 4715, 4726, "significant" +543, 46, 6, 1000, 37, 48, 4727, 4738, "differences" +543, 46, 7, 1001, 49, 51, 4739, 4741, "in" +543, 46, 8, 1002, 52, 58, 4742, 4748, "vision" +543, 46, 9, 1003, 59, 61, 4749, 4751, "to" +543, 46, 10, 1004, 62, 64, 4752, 4754, "be" +543, 46, 11, 1005, 65, 73, 4755, 4763, "assessed" +543, 46, 12, 1006, 74, 76, 4764, 4766, "in" +543, 46, 13, 1007, 77, 78, 4767, 4768, "a" +543, 46, 14, 1008, 79, 89, 4769, 4779, "relatively" +543, 46, 15, 1009, 90, 95, 4780, 4785, "short" +543, 46, 16, 1010, 96, 107, 4786, 4797, "observation" +543, 46, 17, 1011, 108, 114, 4798, 4804, "period" +543, 46, 18, 1012, 115, 116, 4805, 4806, "." +543, 47, 1, 1013, 0, 7, 4807, 4814, "FUNDING" +543, 47, 2, 1014, 8, 9, 4815, 4816, ":" +543, 47, 3, 1015, 10, 16, 4817, 4823, "Pfizer" +543, 47, 4, 1016, 17, 18, 4824, 4825, "," +543, 47, 5, 1017, 19, 21, 4826, 4828, "UK" +543, 47, 6, 1018, 22, 30, 4829, 4837, "National" +543, 47, 7, 1019, 31, 40, 4838, 4847, "Institute" +543, 47, 8, 1020, 41, 44, 4848, 4851, "for" +543, 47, 9, 1021, 45, 51, 4852, 4858, "Health" +543, 47, 10, 1022, 52, 60, 4859, 4867, "Research" +543, 47, 11, 1023, 61, 71, 4868, 4878, "Biomedical" +543, 47, 12, 1024, 72, 80, 4879, 4887, "Research" +543, 47, 13, 1025, 81, 87, 4888, 4894, "Centre" +543, 47, 14, 1026, 88, 89, 4895, 4896, "." +543, 48, 1, 1027, 0, 9, 4897, 4906, "Copyright" +543, 48, 2, 1028, 10, 11, 4907, 4908, "©" +543, 48, 3, 1029, 12, 16, 4909, 4913, "2015" +543, 48, 4, 1030, 17, 23, 4914, 4920, "Garway" +543, 48, 5, 1031, 24, 25, 4921, 4922, "-" +543, 48, 6, 1032, 26, 31, 4923, 4928, "Heath" +543, 48, 7, 1033, 32, 34, 4929, 4931, "et" +543, 48, 8, 1034, 35, 37, 4932, 4934, "al" +543, 48, 9, 1035, 38, 39, 4935, 4936, "." +543, 49, 1, 1036, 0, 4, 4937, 4941, "Open" +543, 49, 2, 1037, 5, 11, 4942, 4948, "Access" +543, 49, 3, 1038, 12, 19, 4949, 4956, "article" +543, 49, 4, 1039, 20, 31, 4957, 4968, "distributed" +543, 49, 5, 1040, 32, 37, 4969, 4974, "under" +543, 49, 6, 1041, 38, 41, 4975, 4978, "the" +543, 49, 7, 1042, 42, 47, 4979, 4984, "terms" +543, 49, 8, 1043, 48, 50, 4985, 4987, "of" +543, 49, 9, 1044, 51, 53, 4988, 4990, "CC" +543, 49, 10, 1045, 54, 56, 4991, 4993, "BY" +543, 49, 11, 1046, 57, 58, 4994, 4995, "." +543, 50, 1, 1047, 0, 9, 4996, 5005, "Published" +543, 50, 2, 1048, 10, 12, 5006, 5008, "by" +543, 50, 3, 1049, 13, 21, 5009, 5017, "Elsevier" +543, 50, 4, 1050, 22, 25, 5018, 5021, "Ltd" +543, 50, 5, 1051, 26, 27, 5022, 5023, "." +543, 50, 6, 1052, 28, 31, 5024, 5027, "All" +543, 50, 7, 1053, 32, 38, 5028, 5034, "rights" +543, 50, 8, 1054, 39, 47, 5035, 5043, "reserved" +543, 50, 9, 1055, 48, 49, 5044, 5045, "." +543, 51, 1, 1056, 0, 3, 5046, 5049, "DOI" +543, 51, 2, 1057, 4, 5, 5050, 5051, ":" +543, 51, 3, 1058, 6, 8, 5052, 5054, "10" +543, 51, 4, 1059, 9, 10, 5055, 5056, "." +543, 51, 5, 1060, 11, 15, 5057, 5061, "1016" +543, 51, 6, 1061, 16, 17, 5062, 5063, "/" +543, 51, 7, 1062, 18, 23, 5064, 5069, "S0140" +543, 51, 8, 1063, 24, 25, 5070, 5071, "-" +543, 51, 9, 1064, 26, 30, 5072, 5076, "6736" +543, 51, 10, 1065, 31, 32, 5077, 5078, "(" +543, 51, 11, 1066, 33, 35, 5079, 5081, "14" +543, 51, 12, 1067, 36, 37, 5082, 5083, ")" +543, 51, 13, 1068, 38, 43, 5084, 5089, "62111" +543, 51, 14, 1069, 44, 45, 5090, 5091, "-" +543, 51, 15, 1070, 46, 47, 5092, 5093, "5" +543, 51, 16, 1071, 48, 52, 5094, 5098, "PMID" +543, 51, 17, 1072, 53, 54, 5099, 5100, ":" +543, 51, 18, 1073, 55, 63, 5101, 5109, "25533656" +543, 51, 19, 1074, 64, 65, 5110, 5111, "[" +543, 51, 20, 1075, 66, 73, 5112, 5119, "Indexed" +543, 51, 21, 1076, 74, 77, 5120, 5123, "for" +543, 51, 22, 1077, 78, 85, 5124, 5131, "MEDLINE" +543, 51, 23, 1078, 86, 87, 5132, 5133, "]" diff --git a/data/gl 25533656_jshahinitiran.annodb b/data/gl 25533656_jshahinitiran.annodb new file mode 100644 index 0000000..9035627 --- /dev/null +++ b/data/gl 25533656_jshahinitiran.annodb @@ -0,0 +1,120 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88622, Journal, 0, 6, "Lancet", "", +88664, PublicationYear, 9, 13, "2015", "", +88666, Title, 119, 226, "Latanoprost for open - angle glaucoma ( UKGTS ) : a randomised , multicentre , placebo - controlled trial .", "", +88671, Latanoprost, 119, 130, "Latanoprost", "", +88673, OpenAngleGlaucoma, 135, 156, "open - angle glaucoma", "", +88674, Randomized, 171, 181, "randomised", "", +88676, Multicenter, 184, 195, "multicentre", "", +88678, Placebo, 198, 205, "placebo", "", +88679, Author, 227, 244, "Garway - Heath DF", "", +88681, Author, 253, 261, "Crabb DP", "", +88686, Author, 270, 277, "Bunce C", "", +88688, Author, 286, 298, "Lascaratos G", "", +88689, Author, 307, 319, "Amalfitano F", "", +88690, Author, 328, 335, "Anand N", "", +88692, Author, 344, 361, "Azuara - Blanco A", "", +88693, Author, 370, 379, "Bourne RR", "", +88694, Author, 388, 399, "Broadway DC", "", +88696, Author, 406, 419, ", Cunliffe IA", "", +88697, Author, 428, 438, "Diamond JP", "", +88699, Author, 447, 456, "Fraser SG", "", +88700, Author, 466, 471, "Ho TA", "", +88701, Author, 480, 489, "Martin KR", "", +88702, Author, 499, 510, "McNaught AI", "", +88703, Author, 520, 526, "Negi A", "", +88704, Author, 535, 542, "Patel K", "", +88705, Author, 551, 561, "Russell RA", "", +88706, Author, 571, 577, "Shah A", "", +88707, Author, 586, 593, "Spry PG", "", +88709, Author, 602, 610, "Suzuki K", "", +88710, Author, 619, 627, "White ET", "", +88712, Author, 636, 646, "Wormald RP", "", +88713, Author, 655, 661, "Xing W", "", +88715, Author, 670, 678, "Zeyen TG", "", +88717, UK, 875, 877, "UK", "", +88718, UK, 945, 947, "uk", "", +88719, UK, 1028, 1030, "UK", "", +88721, UK, 1199, 1201, "UK", "", +88722, UK, 1256, 1258, "UK", "", +88723, UK, 1305, 1307, "UK", "", +88725, UK, 1355, 1357, "UK", "", +88726, UK, 1418, 1420, "UK", "", +88727, UK, 1479, 1481, "UK", "", +88729, UK, 1523, 1525, "UK", "", +88730, UK, 1575, 1577, "UK", "", +88732, UK, 1626, 1628, "UK", "", +88733, UK, 1681, 1683, "UK", "", +88734, UK, 1930, 1932, "UK", "", +88736, Country, 1981, 1988, "Belgium", "", +88749, OpenAngleGlaucoma, 2276, 2297, "open - angle glaucoma", "", +88750, IOP, 2345, 2365, "intraocular pressure", "", +88751, Placebo, 2392, 2399, "placebo", "", +88742, ObjectiveDescription, 2564, 2661, "We assessed vision preservation in patients given latanoprost compared with those given placebo .", "", +88754, Randomized, 2680, 2690, "randomised", "", +88756, DoubleBlind, 2693, 2708, "triple - masked", "", +88758, Placebo, 2711, 2718, "placebo", "", +88759, CTDesign, 2711, 2731, "placebo - controlled", "", +88761, OpenAngleGlaucoma, 2782, 2803, "open - angle glaucoma", "", +88763, Multicenter, 2807, 2821, "ten UK centres", "", +88762, UK, 2811, 2813, "UK", "", +88764, Randomized, 2931, 2939, "randomly", "", +88765, AllocationRatio, 2952, 2957, "1 : 1", "", +88767, Randomized, 2987, 3000, "randomisation", "", +88768, Latanoprost, 3086, 3097, "latanoprost", "", +88770, DoseValue, 3098, 3105, "0 · 005", "", +88772, Placebo, 3134, 3141, "placebo", "", +88774, Eyedrops, 3160, 3169, "eye drops", "", +88776, Eyedrops, 3172, 3177, "Drops", "", +88777, Frequency, 3221, 3231, "once a day", "", +88786, EndPointDescription, 3273, 3307, "time to visual field deterioration", "", +88783, Duration, 3315, 3324, "24 months", "", +88794, Year, 3481, 3485, "2011", "", +88795, Year, 3514, 3518, "2011", "", +88788, EndPointDescription, 3684, 3718, "time to visual field deterioration", "", +88785, Duration, 3726, 3735, "24 months", "", +88790, NumberPatientsCT, 3812, 3815, "516", "", +88792, Year, 3844, 3848, "2006", "", +88793, Year, 3866, 3870, "2010", "", +88796, Mean, 3882, 3886, "mean", "", +88798, IOP, 3887, 3907, "intraocular pressure", "", +88799, BaseLineValue, 3912, 3918, "19 · 6", "", +88802, mmHg, 3919, 3924, "mm Hg", "", +88804, SdDevBL, 3930, 3935, "4 · 6", "", +88806, NumberPatientsArm, 3941, 3944, "258", "", +88808, Latanoprost, 3961, 3972, "latanoprost", "", +88800, BaseLineValue, 3983, 3989, "20 · 1", "", +88803, mmHg, 3990, 3995, "mm Hg", "", +88805, SdDevBL, 3998, 4003, "4 · 8", "", +88807, NumberPatientsArm, 4009, 4012, "258", "", +88809, Placebo, 4013, 4021, "controls", "", +88810, Duration, 4027, 4036, "24 months", "", +88811, Mean, 4039, 4043, "mean", "", +88814, IOP, 4057, 4077, "intraocular pressure", "", +88815, Reduction, 4082, 4087, "3 · 8", "", +88817, mmHg, 4088, 4093, "mm Hg", "", +88822, SdDevChangeValue, 4096, 4101, "4 · 0", "", +88829, FinalNumPatientsArm, 4107, 4110, "231", "", +88833, Latanoprost, 4136, 4147, "latanoprost", "", +88816, Reduction, 4158, 4163, "0 · 9", "", +88819, mmHg, 4164, 4169, "mm Hg", "", +88824, SdDevChangeValue, 4172, 4177, "3 · 8", "", +88830, FinalNumPatientsArm, 4183, 4186, "230", "", +88832, Placebo, 4212, 4219, "placebo", "", +88838, EndPointDescription, 4228, 4253, "Visual field preservation", "", +88840, Latanoprost, 4286, 4297, "latanoprost", "", +88841, Placebo, 4316, 4323, "placebo", "", +88849, EndPointDescription, 4332, 4353, "adjusted hazard ratio", "", +88850, EndPointDescription, 4356, 4358, "HR", "", +88853, ResultMeasuredValue, 4361, 4367, "0 · 44", "", +88843, ConfIntervalDiff, 4370, 4393, "95 % CI 0 · 28 - 0 · 69", "", +88844, PvalueDiff, 4396, 4408, "p = 0 · 0003", "", +88861, ConclusionComment, 4505, 4689, "This is the first randomised placebo - controlled trial to show preservation of the visual field with an intraocular - pressure - lowering drug in patients with open - angle glaucoma .", "", +88854, Randomized, 4523, 4533, "randomised", "", +88855, Placebo, 4534, 4541, "placebo", "", +88856, CTDesign, 4534, 4554, "placebo - controlled", "", +88857, IOP, 4610, 4632, "intraocular - pressure", "", +88858, OpenAngleGlaucoma, 4666, 4687, "open - angle glaucoma", "", +88862, ConclusionComment, 4690, 4806, "The study design enabled significant differences in vision to be assessed in a relatively short observation period .", "", +88859, ConflictInterest, 4817, 4896, "Pfizer , UK National Institute for Health Research Biomedical Research Centre .", "", +88860, PMID, 5101, 5109, "25533656", "", diff --git a/data/gl 25533656_jshahinitiran.n-triples b/data/gl 25533656_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25533656_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 25533656_tstrakeljahn.annodb b/data/gl 25533656_tstrakeljahn.annodb new file mode 100644 index 0000000..8a7be64 --- /dev/null +++ b/data/gl 25533656_tstrakeljahn.annodb @@ -0,0 +1,114 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89169, Journal, 0, 6, "Lancet", "", +89170, PublicationYear, 9, 13, "2015", "", +89171, Latanoprost, 119, 130, "Latanoprost", "", +89176, Title, 119, 226, "Latanoprost for open - angle glaucoma ( UKGTS ) : a randomised , multicentre , placebo - controlled trial .", "", +89172, OpenAngleGlaucoma, 135, 156, "open - angle glaucoma", "", +89173, Randomized, 171, 181, "randomised", "", +89174, Multicenter, 184, 195, "multicentre", "", +89175, Placebo, 198, 205, "placebo", "", +89177, Author, 227, 244, "Garway - Heath DF", "", +89178, Author, 253, 261, "Crabb DP", "", +89179, Author, 270, 277, "Bunce C", "", +89180, Author, 286, 298, "Lascaratos G", "", +89181, Author, 307, 319, "Amalfitano F", "", +89182, Author, 328, 335, "Anand N", "", +89183, Author, 344, 361, "Azuara - Blanco A", "", +89184, Author, 370, 379, "Bourne RR", "", +89185, Author, 388, 399, "Broadway DC", "", +89186, Author, 408, 419, "Cunliffe IA", "", +89187, Author, 428, 438, "Diamond JP", "", +89188, Author, 447, 456, "Fraser SG", "", +89189, Author, 466, 471, "Ho TA", "", +89190, Author, 480, 489, "Martin KR", "", +89191, Author, 499, 510, "McNaught AI", "", +89192, Author, 520, 526, "Negi A", "", +89193, Author, 535, 542, "Patel K", "", +89194, Author, 551, 561, "Russell RA", "", +89195, Author, 571, 577, "Shah A", "", +89196, Author, 586, 593, "Spry PG", "", +89197, Author, 602, 610, "Suzuki K", "", +89198, Author, 619, 627, "White ET", "", +89199, Author, 636, 646, "Wormald RP", "", +89200, Author, 655, 661, "Xing W", "", +89201, Author, 670, 678, "Zeyen TG", "", +89202, UK, 875, 877, "UK", "", +89203, UK, 945, 947, "uk", "", +89204, UK, 1028, 1030, "UK", "", +89205, UK, 1199, 1201, "UK", "", +89206, UK, 1256, 1258, "UK", "", +89207, UK, 1305, 1307, "UK", "", +89208, UK, 1355, 1357, "UK", "", +89209, UK, 1418, 1420, "UK", "", +89210, UK, 1479, 1481, "UK", "", +89211, UK, 1523, 1525, "UK", "", +89212, UK, 1575, 1577, "UK", "", +89213, UK, 1626, 1628, "UK", "", +89214, UK, 1681, 1683, "UK", "", +89215, UK, 1853, 1855, "UK", "", +89216, UK, 1930, 1932, "UK", "", +89217, Country, 1981, 1988, "Belgium", "Belgium", +89218, OpenAngleGlaucoma, 2276, 2297, "open - angle glaucoma", "", +89219, IOP, 2345, 2365, "intraocular pressure", "", +89220, Placebo, 2392, 2399, "placebo", "", +89223, ObjectiveDescription, 2564, 2661, "We assessed vision preservation in patients given latanoprost compared with those given placebo .", "", +89221, Latanoprost, 2614, 2625, "latanoprost", "", +89222, Placebo, 2652, 2659, "placebo", "", +89224, Randomized, 2680, 2690, "randomised", "", +89225, DoubleBlind, 2693, 2708, "triple - masked", "", +89226, Placebo, 2711, 2718, "placebo", "", +89228, Precondition, 2766, 2803, "newly diagnosed open - angle glaucoma", "", +89227, OpenAngleGlaucoma, 2782, 2803, "open - angle glaucoma", "", +89230, Multicenter, 2807, 2821, "ten UK centres", "", +89229, UK, 2811, 2813, "UK", "", +89231, AllocationRatio, 2952, 2957, "1 : 1", "", +89232, Latanoprost, 3086, 3097, "latanoprost", "", +89233, DoseValue, 3098, 3105, "0 · 005", "", +89234, Percentage, 3106, 3107, "%", "", +89235, Placebo, 3134, 3141, "placebo", "", +89236, Eyedrops, 3160, 3169, "eye drops", "", +89237, Eyedrops, 3172, 3177, "Drops", "", +89238, Frequency, 3221, 3231, "once a day", "", +89443, Endpoint, 3273, 3324, "time to visual field deterioration within 24 months", "", +89436, Duration, 3315, 3324, "24 months", "", +89444, NumberPatientsCT, 3812, 3815, "516", "", +89445, TimePoint, 3836, 3848, "Dec 1 , 2006", "", +89446, TimePoint, 3855, 3870, "March 16 , 2010", "", +89447, Mean, 3882, 3886, "mean", "", +89448, IOP, 3887, 3907, "intraocular pressure", "", +89449, BaseLineValue, 3912, 3918, "19 · 6", "", +89450, mmHg, 3919, 3924, "mm Hg", "", +89453, SdDevBL, 3930, 3935, "4 · 6", "", +89455, NumberPatientsArm, 3941, 3944, "258", "", +89457, Latanoprost, 3961, 3972, "latanoprost", "", +89452, BaseLineValue, 3983, 3989, "20 · 1", "", +89451, mmHg, 3990, 3995, "mm Hg", "", +89454, SdDevBL, 3998, 4003, "4 · 8", "", +89456, NumberPatientsArm, 4009, 4012, "258", "", +89458, TimePoint, 4024, 4036, "At 24 months", "", +89459, Mean, 4039, 4043, "mean", "", +89460, IOP, 4057, 4077, "intraocular pressure", "", +89461, Reduction, 4082, 4087, "3 · 8", "", +89464, mmHg, 4088, 4093, "mm Hg", "", +89466, SdDevChangeValue, 4096, 4101, "4 · 0", "", +89472, FinalNumPatientsArm, 4107, 4110, "231", "", +89469, Latanoprost, 4136, 4147, "latanoprost", "", +89462, Reduction, 4158, 4163, "0 · 9", "", +89465, mmHg, 4164, 4169, "mm Hg", "", +89467, SdDevChangeValue, 4172, 4177, "3 · 8", "", +89473, FinalNumPatientsArm, 4183, 4186, "230", "", +89470, Placebo, 4212, 4219, "placebo", "", +89474, Latanoprost, 4286, 4297, "latanoprost", "", +89475, Placebo, 4316, 4323, "placebo", "", +89477, ResultMeasuredValue, 4361, 4367, "0 · 44", "", +89478, ConfIntervalResValue, 4378, 4393, "0 · 28 - 0 · 69", "", +89479, PValueResValue, 4398, 4408, "= 0 · 0003", "", +89476, NumberAffected, 4422, 4424, "18", "", +89485, ConclusionComment, 4505, 4689, "This is the first randomised placebo - controlled trial to show preservation of the visual field with an intraocular - pressure - lowering drug in patients with open - angle glaucoma .", "", +89480, Randomized, 4523, 4533, "randomised", "", +89481, Placebo, 4534, 4541, "placebo", "", +89482, IOP, 4610, 4632, "intraocular - pressure", "", +89483, OpenAngleGlaucoma, 4666, 4687, "open - angle glaucoma", "", +89484, ConclusionComment, 4690, 4806, "The study design enabled significant differences in vision to be assessed in a relatively short observation period .", "", +89486, UK, 4826, 4828, "UK", "", +89487, PMID, 5101, 5109, "25533656", "", diff --git a/data/gl 25533656_tstrakeljahn.n-triples b/data/gl 25533656_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 25533656_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26578422_admin.annodb b/data/gl 26578422_admin.annodb new file mode 100644 index 0000000..e4ea214 --- /dev/null +++ b/data/gl 26578422_admin.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 16, "Jpn J Ophthalmol", "", " \"Jpn J Ophthalmol\"." +1, PublicationYear, 19, 23, "2016", "", " \"2016\"." +14, Title, 113, 283, "Comparison of the intraocular pressure - lowering effect and safety of brimonidine / timolol fixed combination and 0 . 5 % timolol in normal - tension glaucoma patients .", "", " \"Comparison of the intraocular pressure - lowering effect and safety of brimonidine / timolol fixed combination and 0 . 5 % timolol in normal - tension glaucoma patients .\"." +2, IOP, 131, 151, "intraocular pressure", "", +3, Brimonidine, 184, 195, "brimonidine", "", +4, Timolol, 198, 205, "timolol", "", +12, DoseValue, 228, 233, "0 . 5", "", +13, Percentage, 234, 235, "%", "", +5, Timolol, 236, 243, "timolol", "", +33599, NormalTensionGlaucoma, 247, 272, "normal - tension glaucoma", "", " ." +7, Author, 284, 290, "Kim JM", "", " \"Kim JM\"." +8, Author, 299, 305, "Kim TW", "", " \"Kim TW\"." +9, Author, 314, 320, "Kim CY", "", " \"Kim CY\"." +10, Author, 329, 335, "Kim HK", "", " \"Kim HK\"." +11, Author, 344, 351, "Park KH", "", " \"Park KH\"." +33600, SouthKorea, 497, 514, "Republic of Korea", "", " ." +33601, SouthKorea, 657, 674, "Republic of Korea", "", +33602, SouthKorea, 761, 778, "Republic of Korea", "", +33603, SouthKorea, 926, 943, "Republic of Korea", "", +33604, SouthKorea, 1075, 1092, "Republic of Korea", "", +29, ObjectiveDescription, 1132, 1320, "To compare the therapeutic efficacy and safety of brimonidine / timolol fixed - combination ( BTFC ) and 0 . 5 % timolol ophthalmic solution in normal - tension glaucoma ( NTG ) patients .", "", " \"To compare the therapeutic efficacy and safety of brimonidine / timolol fixed - combination ( BTFC ) and 0 . 5 % timolol ophthalmic solution in normal - tension glaucoma ( NTG ) patients .\"." +54368, Brimo/TimFC, 1182, 1223, "brimonidine / timolol fixed - combination", "", " ." +54367, Brimo/TimFC, 1226, 1230, "BTFC", "", +22, DoseValue, 1237, 1242, "0 . 5", "", +23, Percentage, 1243, 1244, "%", "", +21, Timolol, 1245, 1252, "timolol", "", +33605, NormalTensionGlaucoma, 1276, 1301, "normal - tension glaucoma", "", +54369, Precondition, 1276, 1318, "normal - tension glaucoma ( NTG ) patients", "", " \"normal - tension glaucoma ( NTG ) patients\"." +33606, NormalTensionGlaucoma, 1304, 1307, "NTG", "", " ." +25, Multicenter, 1342, 1361, "multi - institution", "", " ." +26, Randomized, 1364, 1374, "randomized", "", " ." +96, CTDesign, 1377, 1396, "active - controlled", "", " . ." +27, OpenLabel, 1399, 1411, "open - label", "", " ." +28, Parallel, 1414, 1422, "parallel", "", " ." +36, Glaucoma, 1467, 1475, "glaucoma", "", " . ." +30, NumberPatientsCT, 1501, 1504, "110", "", " \"110\"." +33612, NormalTensionGlaucoma, 1505, 1508, "NTG", "", +34, NumberPatientsArm, 1522, 1524, "55", "", " \"55\"." +54371, Brimo/TimFC, 1549, 1553, "BTFC", "", +35, NumberPatientsArm, 1558, 1560, "55", "", " \"55\"." +38, DoseValue, 1561, 1566, "0 . 5", "", +37, Percentage, 1567, 1568, "%", "", +39, Timolol, 1576, 1583, "timolol", "", +31, FinalNumPatientsCT, 1841, 1843, "95", "", " \"95\"." +32, FinalNumPatientsArm, 1857, 1859, "48", "", " \"48\"." +54370, Brimo/TimFC, 1867, 1871, "BTFC", "", +33, FinalNumPatientsArm, 1882, 1884, "47", "", " \"47\"." +42, DoseValue, 1892, 1897, "0 . 5", "", +41, Percentage, 1898, 1899, "%", "", +40, Timolol, 1900, 1907, "timolol", "", +37037, TimePoint, 1971, 1979, "baseline", "", +37038, TimePoint, 1987, 2001, "4 and 12 weeks", "", +113, TimePoint, 1993, 2001, "12 weeks", "", +43, Diurnal_IOP, 2004, 2015, "Diurnal IOP", "", +37036, TimePoint, 2082, 2090, "baseline", "", +115, TimePoint, 2114, 2122, "12 weeks", "", +116, Eyedrops, 2129, 2139, "eye - drop", "", " . ." +117, Mean, 2316, 2323, "average", "", " . ." +45, IOP, 2338, 2341, "IOP", "", " . ." +119, TimePoint, 2372, 2380, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +120, DiffGroupAbsValue, 2429, 2435, "2 . 10", "", " \"2 . 10\"." +33598, SdDevDiff, 2438, 2444, "2 . 59", "", " \"2 . 59\"." +48, mmHg, 2445, 2449, "mmHg", "", " ." +123, IOP, 2480, 2483, "IOP", "", +124, DoseValue, 2534, 2539, "0 . 5", "", " \"0 . 5\"." +125, Percentage, 2540, 2541, "%", "", " ." +126, Timolol, 2542, 2549, "timolol", "", " ." +127, Mean, 2586, 2593, "average", "", " . ." +129, EndPointDescription, 2586, 2621, "average IOP had decreased by > 20 %", "", " . ." +49, IOP, 2594, 2597, "IOP", "", +106362, TimePoint, 2628, 2642, "4 and 12 weeks", "", " \"4 and 12 weeks\". \"4 and 12 weeks\"." +52, TimePoint, 2634, 2642, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +53, PercentageAffected, 2647, 2649, "50", "", " \"12 weeks\". \"12 weeks\"." +54, PercentageAffected, 2654, 2656, "56", "", " \"56\"." +54372, Brimo/TimFC, 2666, 2670, "BTFC", "", +55, PercentageAffected, 2709, 2716, "29 . 41", "", " \"29 . 41\"." +56, PercentageAffected, 2721, 2728, "23 . 53", "", " \"23 . 53\"." +58, DoseValue, 2738, 2743, "0 . 5", "", +59, Percentage, 2744, 2745, "%", "", +57, Timolol, 2746, 2753, "timolol", "", +60, PvalueDiff, 2777, 2788, "p = 0 . 034", "", " \"p = 0 . 034\"." +140, ConclusionComment, 2819, 2899, "BTFC has a superior IOP - lowering effect than 0 . 5 % timolol in NTG patients .", "", " \"BTFC has a superior IOP - lowering effect than 0 . 5 % timolol in NTG patients .\"." +54373, Brimo/TimFC, 2819, 2823, "BTFC", "", +62, IOP, 2839, 2842, "IOP", "", +65, DoseValue, 2866, 2871, "0 . 5", "", +63, Percentage, 2872, 2873, "%", "", +64, Timolol, 2874, 2881, "timolol", "", +33613, NormalTensionGlaucoma, 2885, 2888, "NTG", "", +61, PMID, 2949, 2957, "26578422", "", " \"26578422\"." diff --git a/data/gl 26578422_admin.n-triples b/data/gl 26578422_admin.n-triples new file mode 100644 index 0000000..65a4c93 --- /dev/null +++ b/data/gl 26578422_admin.n-triples @@ -0,0 +1,143 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the intraocular pressure - lowering effect and safety of brimonidine / timolol fixed combination and 0 . 5 % timolol in normal - tension glaucoma patients ." . + "Kim JM" . + "2016" . + "Jpn J Ophthalmol" . + "26578422" . + . + "Kim TW" . + "Kim CY" . + "Kim HK" . + "Park KH" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the therapeutic efficacy and safety of brimonidine / timolol fixed - combination ( BTFC ) and 0 . 5 % timolol ophthalmic solution in normal - tension glaucoma ( NTG ) patients ." . + "110" . + . + . + . + "BTFC has a superior IOP - lowering effect than 0 . 5 % timolol in NTG patients ." . + . + . + . + . + . + "95" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "normal - tension glaucoma ( NTG ) patients" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop_20" . + . + . + . + . + . + . + . + "Endpoint_iop" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + "55" . + "48" . + . + . + . + . + . + . + "Arm_Tim" . + "55" . + "47" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + . + . + "Intervention_Tim" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_Tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC_4" . + . + "50" . + "4 and 12 weeks" . + . + "Outcome_BTFC_12" . + . + "56" . + "12 weeks" . + . + "Outcome_Tim_4" . + . + "29 . 41" . + "4 and 12 weeks" . + . + "Outcome_Tim_12" . + . + "23 . 53" . + "12 weeks" . + . + "Outcome_BTFC_iop_12" . + . + "12 weeks" . + . + "Outcome_Tim_iop_12" . + . + "12 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_12" . + "p = 0 . 034" . + . + . + . + "DiffBetweenGroups_iop_12" . + "2 . 10" . + "2 . 59" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26578422_export.csv b/data/gl 26578422_export.csv new file mode 100644 index 0000000..f7ac315 --- /dev/null +++ b/data/gl 26578422_export.csv @@ -0,0 +1,641 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +412, 1, 1, 1, 0, 3, 0, 3, "Jpn" +412, 1, 2, 2, 4, 5, 4, 5, "J" +412, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +412, 1, 4, 4, 17, 18, 17, 18, "." +412, 2, 1, 5, 0, 4, 19, 23, "2016" +412, 2, 2, 6, 5, 8, 24, 27, "Jan" +412, 2, 3, 7, 9, 10, 28, 29, ";" +412, 2, 4, 8, 11, 13, 30, 32, "60" +412, 2, 5, 9, 14, 15, 33, 34, "(" +412, 2, 6, 10, 16, 17, 35, 36, "1" +412, 2, 7, 11, 18, 19, 37, 38, ")" +412, 2, 8, 12, 20, 21, 39, 40, ":" +412, 2, 9, 13, 22, 24, 41, 43, "20" +412, 2, 10, 14, 25, 26, 44, 45, "-" +412, 2, 11, 15, 27, 28, 46, 47, "6" +412, 2, 12, 16, 29, 30, 48, 49, "." +412, 2, 13, 17, 31, 34, 50, 53, "doi" +412, 2, 14, 18, 35, 36, 54, 55, ":" +412, 2, 15, 19, 37, 39, 56, 58, "10" +412, 2, 16, 20, 40, 41, 59, 60, "." +412, 2, 17, 21, 42, 46, 61, 65, "1007" +412, 2, 18, 22, 47, 48, 66, 67, "/" +412, 2, 19, 23, 49, 55, 68, 74, "s10384" +412, 2, 20, 24, 56, 57, 75, 76, "-" +412, 2, 21, 25, 58, 61, 77, 80, "015" +412, 2, 22, 26, 62, 63, 81, 82, "-" +412, 2, 23, 27, 64, 68, 83, 87, "0420" +412, 2, 24, 28, 69, 70, 88, 89, "-" +412, 2, 25, 29, 71, 72, 90, 91, "2" +412, 2, 26, 30, 73, 74, 92, 93, "." +412, 3, 1, 31, 0, 4, 94, 98, "Epub" +412, 3, 2, 32, 5, 9, 99, 103, "2015" +412, 3, 3, 33, 10, 13, 104, 107, "Nov" +412, 3, 4, 34, 14, 16, 108, 110, "18" +412, 3, 5, 35, 17, 18, 111, 112, "." +412, 4, 1, 36, 0, 10, 113, 123, "Comparison" +412, 4, 2, 37, 11, 13, 124, 126, "of" +412, 4, 3, 38, 14, 17, 127, 130, "the" +412, 4, 4, 39, 18, 29, 131, 142, "intraocular" +412, 4, 5, 40, 30, 38, 143, 151, "pressure" +412, 4, 6, 41, 39, 40, 152, 153, "-" +412, 4, 7, 42, 41, 49, 154, 162, "lowering" +412, 4, 8, 43, 50, 56, 163, 169, "effect" +412, 4, 9, 44, 57, 60, 170, 173, "and" +412, 4, 10, 45, 61, 67, 174, 180, "safety" +412, 4, 11, 46, 68, 70, 181, 183, "of" +412, 4, 12, 47, 71, 82, 184, 195, "brimonidine" +412, 4, 13, 48, 83, 84, 196, 197, "/" +412, 4, 14, 49, 85, 92, 198, 205, "timolol" +412, 4, 15, 50, 93, 98, 206, 211, "fixed" +412, 4, 16, 51, 99, 110, 212, 223, "combination" +412, 4, 17, 52, 111, 114, 224, 227, "and" +412, 4, 18, 53, 115, 116, 228, 229, "0" +412, 4, 19, 54, 117, 118, 230, 231, "." +412, 4, 20, 55, 119, 120, 232, 233, "5" +412, 4, 21, 56, 121, 122, 234, 235, "%" +412, 4, 22, 57, 123, 130, 236, 243, "timolol" +412, 4, 23, 58, 131, 133, 244, 246, "in" +412, 4, 24, 59, 134, 140, 247, 253, "normal" +412, 4, 25, 60, 141, 142, 254, 255, "-" +412, 4, 26, 61, 143, 150, 256, 263, "tension" +412, 4, 27, 62, 151, 159, 264, 272, "glaucoma" +412, 4, 28, 63, 160, 168, 273, 281, "patients" +412, 4, 29, 64, 169, 170, 282, 283, "." +412, 5, 1, 65, 0, 3, 284, 287, "Kim" +412, 5, 2, 66, 4, 6, 288, 290, "JM" +412, 5, 3, 67, 7, 8, 291, 292, "(" +412, 5, 4, 68, 9, 10, 293, 294, "1" +412, 5, 5, 69, 11, 12, 295, 296, ")" +412, 5, 6, 70, 13, 14, 297, 298, "," +412, 5, 7, 71, 15, 18, 299, 302, "Kim" +412, 5, 8, 72, 19, 21, 303, 305, "TW" +412, 5, 9, 73, 22, 23, 306, 307, "(" +412, 5, 10, 74, 24, 25, 308, 309, "2" +412, 5, 11, 75, 26, 27, 310, 311, ")" +412, 5, 12, 76, 28, 29, 312, 313, "," +412, 5, 13, 77, 30, 33, 314, 317, "Kim" +412, 5, 14, 78, 34, 36, 318, 320, "CY" +412, 5, 15, 79, 37, 38, 321, 322, "(" +412, 5, 16, 80, 39, 40, 323, 324, "3" +412, 5, 17, 81, 41, 42, 325, 326, ")" +412, 5, 18, 82, 43, 44, 327, 328, "," +412, 5, 19, 83, 45, 48, 329, 332, "Kim" +412, 5, 20, 84, 49, 51, 333, 335, "HK" +412, 5, 21, 85, 52, 53, 336, 337, "(" +412, 5, 22, 86, 54, 55, 338, 339, "4" +412, 5, 23, 87, 56, 57, 340, 341, ")" +412, 5, 24, 88, 58, 59, 342, 343, "," +412, 5, 25, 89, 60, 64, 344, 348, "Park" +412, 5, 26, 90, 65, 67, 349, 351, "KH" +412, 5, 27, 91, 68, 69, 352, 353, "(" +412, 5, 28, 92, 70, 71, 354, 355, "5" +412, 5, 29, 93, 72, 73, 356, 357, ")" +412, 5, 30, 94, 74, 75, 358, 359, "." +412, 6, 1, 95, 0, 6, 360, 366, "Author" +412, 6, 2, 96, 7, 18, 367, 378, "information" +412, 6, 3, 97, 19, 20, 379, 380, ":" +412, 6, 4, 98, 21, 22, 381, 382, "(" +412, 6, 5, 99, 23, 24, 383, 384, "1" +412, 6, 6, 100, 25, 26, 385, 386, ")" +412, 6, 7, 101, 27, 37, 387, 397, "Department" +412, 6, 8, 102, 38, 40, 398, 400, "of" +412, 6, 9, 103, 41, 54, 401, 414, "Ophthalmology" +412, 6, 10, 104, 55, 56, 415, 416, "," +412, 6, 11, 105, 57, 64, 417, 424, "Kangbuk" +412, 6, 12, 106, 65, 72, 425, 432, "Samsung" +412, 6, 13, 107, 73, 81, 433, 441, "Hospital" +412, 6, 14, 108, 82, 83, 442, 443, "," +412, 6, 15, 109, 84, 96, 444, 456, "Sungkyunkwan" +412, 6, 16, 110, 97, 107, 457, 467, "University" +412, 6, 17, 111, 108, 114, 468, 474, "School" +412, 6, 18, 112, 115, 117, 475, 477, "of" +412, 6, 19, 113, 118, 126, 478, 486, "Medicine" +412, 6, 20, 114, 127, 128, 487, 488, "," +412, 6, 21, 115, 129, 134, 489, 494, "Seoul" +412, 6, 22, 116, 135, 136, 495, 496, "," +412, 6, 23, 117, 137, 145, 497, 505, "Republic" +412, 6, 24, 118, 146, 148, 506, 508, "of" +412, 6, 25, 119, 149, 154, 509, 514, "Korea" +412, 6, 26, 120, 155, 156, 515, 516, "." +412, 7, 1, 121, 0, 1, 517, 518, "(" +412, 7, 2, 122, 2, 3, 519, 520, "2" +412, 7, 3, 123, 4, 5, 521, 522, ")" +412, 7, 4, 124, 6, 16, 523, 533, "Department" +412, 7, 5, 125, 17, 19, 534, 536, "of" +412, 7, 6, 126, 20, 33, 537, 550, "Ophthalmology" +412, 7, 7, 127, 34, 35, 551, 552, "," +412, 7, 8, 128, 36, 41, 553, 558, "Seoul" +412, 7, 9, 129, 42, 50, 559, 567, "National" +412, 7, 10, 130, 51, 61, 568, 578, "University" +412, 7, 11, 131, 62, 69, 579, 586, "Bundang" +412, 7, 12, 132, 70, 78, 587, 595, "Hospital" +412, 7, 13, 133, 79, 80, 596, 597, "," +412, 7, 14, 134, 81, 86, 598, 603, "Seoul" +412, 7, 15, 135, 87, 95, 604, 612, "National" +412, 7, 16, 136, 96, 106, 613, 623, "University" +412, 7, 17, 137, 107, 114, 624, 631, "College" +412, 7, 18, 138, 115, 117, 632, 634, "of" +412, 7, 19, 139, 118, 126, 635, 643, "Medicine" +412, 7, 20, 140, 127, 128, 644, 645, "," +412, 7, 21, 141, 129, 137, 646, 654, "Seongnam" +412, 7, 22, 142, 138, 139, 655, 656, "," +412, 7, 23, 143, 140, 148, 657, 665, "Republic" +412, 7, 24, 144, 149, 151, 666, 668, "of" +412, 7, 25, 145, 152, 157, 669, 674, "Korea" +412, 7, 26, 146, 158, 159, 675, 676, "." +412, 8, 1, 147, 0, 1, 677, 678, "(" +412, 8, 2, 148, 2, 3, 679, 680, "3" +412, 8, 3, 149, 4, 5, 681, 682, ")" +412, 8, 4, 150, 6, 16, 683, 693, "Department" +412, 8, 5, 151, 17, 19, 694, 696, "of" +412, 8, 6, 152, 20, 33, 697, 710, "Ophthalmology" +412, 8, 7, 153, 34, 35, 711, 712, "," +412, 8, 8, 154, 36, 42, 713, 719, "Yonsei" +412, 8, 9, 155, 43, 53, 720, 730, "University" +412, 8, 10, 156, 54, 61, 731, 738, "College" +412, 8, 11, 157, 62, 64, 739, 741, "of" +412, 8, 12, 158, 65, 73, 742, 750, "Medicine" +412, 8, 13, 159, 74, 75, 751, 752, "," +412, 8, 14, 160, 76, 81, 753, 758, "Seoul" +412, 8, 15, 161, 82, 83, 759, 760, "," +412, 8, 16, 162, 84, 92, 761, 769, "Republic" +412, 8, 17, 163, 93, 95, 770, 772, "of" +412, 8, 18, 164, 96, 101, 773, 778, "Korea" +412, 8, 19, 165, 102, 103, 779, 780, "." +412, 9, 1, 166, 0, 1, 781, 782, "(" +412, 9, 2, 167, 2, 3, 783, 784, "4" +412, 9, 3, 168, 4, 5, 785, 786, ")" +412, 9, 4, 169, 6, 16, 787, 797, "Department" +412, 9, 5, 170, 17, 19, 798, 800, "of" +412, 9, 6, 171, 20, 33, 801, 814, "Ophthalmology" +412, 9, 7, 172, 34, 35, 815, 816, "," +412, 9, 8, 173, 36, 41, 817, 822, "Myung" +412, 9, 9, 174, 42, 43, 823, 824, "-" +412, 9, 10, 175, 44, 47, 825, 828, "Gok" +412, 9, 11, 176, 48, 51, 829, 832, "Eye" +412, 9, 12, 177, 52, 60, 833, 841, "Research" +412, 9, 13, 178, 61, 70, 842, 851, "Institute" +412, 9, 14, 179, 71, 72, 852, 853, "," +412, 9, 15, 180, 73, 76, 854, 857, "Kim" +412, 9, 16, 181, 77, 78, 858, 859, "'" +412, 9, 17, 182, 79, 80, 860, 861, "s" +412, 9, 18, 183, 81, 84, 862, 865, "Eye" +412, 9, 19, 184, 85, 93, 866, 874, "Hospital" +412, 9, 20, 185, 94, 95, 875, 876, "," +412, 9, 21, 186, 96, 103, 877, 884, "Konyang" +412, 9, 22, 187, 104, 114, 885, 895, "University" +412, 9, 23, 188, 115, 122, 896, 903, "College" +412, 9, 24, 189, 123, 125, 904, 906, "of" +412, 9, 25, 190, 126, 134, 907, 915, "Medicine" +412, 9, 26, 191, 135, 136, 916, 917, "," +412, 9, 27, 192, 137, 142, 918, 923, "Seoul" +412, 9, 28, 193, 143, 144, 924, 925, "," +412, 9, 29, 194, 145, 153, 926, 934, "Republic" +412, 9, 30, 195, 154, 156, 935, 937, "of" +412, 9, 31, 196, 157, 162, 938, 943, "Korea" +412, 9, 32, 197, 163, 164, 944, 945, "." +412, 10, 1, 198, 0, 1, 946, 947, "(" +412, 10, 2, 199, 2, 3, 948, 949, "5" +412, 10, 3, 200, 4, 5, 950, 951, ")" +412, 10, 4, 201, 6, 16, 952, 962, "Department" +412, 10, 5, 202, 17, 19, 963, 965, "of" +412, 10, 6, 203, 20, 33, 966, 979, "Ophthalmology" +412, 10, 7, 204, 34, 35, 980, 981, "," +412, 10, 8, 205, 36, 41, 982, 987, "Seoul" +412, 10, 9, 206, 42, 50, 988, 996, "National" +412, 10, 10, 207, 51, 61, 997, 1007, "University" +412, 10, 11, 208, 62, 69, 1008, 1015, "College" +412, 10, 12, 209, 70, 72, 1016, 1018, "of" +412, 10, 13, 210, 73, 81, 1019, 1027, "Medicine" +412, 10, 14, 211, 82, 83, 1028, 1029, "," +412, 10, 15, 212, 84, 89, 1030, 1035, "Seoul" +412, 10, 16, 213, 90, 98, 1036, 1044, "National" +412, 10, 17, 214, 99, 109, 1045, 1055, "University" +412, 10, 18, 215, 110, 118, 1056, 1064, "Hospital" +412, 10, 19, 216, 119, 120, 1065, 1066, "," +412, 10, 20, 217, 121, 126, 1067, 1072, "Seoul" +412, 10, 21, 218, 127, 128, 1073, 1074, "," +412, 10, 22, 219, 129, 137, 1075, 1083, "Republic" +412, 10, 23, 220, 138, 140, 1084, 1086, "of" +412, 10, 24, 221, 141, 146, 1087, 1092, "Korea" +412, 10, 25, 222, 147, 148, 1093, 1094, "." +412, 11, 1, 223, 0, 8, 1095, 1103, "kihopark" +412, 11, 2, 224, 9, 10, 1104, 1105, "@" +412, 11, 3, 225, 11, 14, 1106, 1109, "snu" +412, 11, 4, 226, 15, 16, 1110, 1111, "." +412, 11, 5, 227, 17, 19, 1112, 1114, "ac" +412, 11, 6, 228, 20, 21, 1115, 1116, "." +412, 11, 7, 229, 22, 24, 1117, 1119, "kr" +412, 11, 8, 230, 25, 26, 1120, 1121, "." +412, 12, 1, 231, 0, 7, 1122, 1129, "PURPOSE" +412, 12, 2, 232, 8, 9, 1130, 1131, ":" +412, 12, 3, 233, 10, 12, 1132, 1134, "To" +412, 12, 4, 234, 13, 20, 1135, 1142, "compare" +412, 12, 5, 235, 21, 24, 1143, 1146, "the" +412, 12, 6, 236, 25, 36, 1147, 1158, "therapeutic" +412, 12, 7, 237, 37, 45, 1159, 1167, "efficacy" +412, 12, 8, 238, 46, 49, 1168, 1171, "and" +412, 12, 9, 239, 50, 56, 1172, 1178, "safety" +412, 12, 10, 240, 57, 59, 1179, 1181, "of" +412, 12, 11, 241, 60, 71, 1182, 1193, "brimonidine" +412, 12, 12, 242, 72, 73, 1194, 1195, "/" +412, 12, 13, 243, 74, 81, 1196, 1203, "timolol" +412, 12, 14, 244, 82, 87, 1204, 1209, "fixed" +412, 12, 15, 245, 88, 89, 1210, 1211, "-" +412, 12, 16, 246, 90, 101, 1212, 1223, "combination" +412, 12, 17, 247, 102, 103, 1224, 1225, "(" +412, 12, 18, 248, 104, 108, 1226, 1230, "BTFC" +412, 12, 19, 249, 109, 110, 1231, 1232, ")" +412, 12, 20, 250, 111, 114, 1233, 1236, "and" +412, 12, 21, 251, 115, 116, 1237, 1238, "0" +412, 12, 22, 252, 117, 118, 1239, 1240, "." +412, 12, 23, 253, 119, 120, 1241, 1242, "5" +412, 12, 24, 254, 121, 122, 1243, 1244, "%" +412, 12, 25, 255, 123, 130, 1245, 1252, "timolol" +412, 12, 26, 256, 131, 141, 1253, 1263, "ophthalmic" +412, 12, 27, 257, 142, 150, 1264, 1272, "solution" +412, 12, 28, 258, 151, 153, 1273, 1275, "in" +412, 12, 29, 259, 154, 160, 1276, 1282, "normal" +412, 12, 30, 260, 161, 162, 1283, 1284, "-" +412, 12, 31, 261, 163, 170, 1285, 1292, "tension" +412, 12, 32, 262, 171, 179, 1293, 1301, "glaucoma" +412, 12, 33, 263, 180, 181, 1302, 1303, "(" +412, 12, 34, 264, 182, 185, 1304, 1307, "NTG" +412, 12, 35, 265, 186, 187, 1308, 1309, ")" +412, 12, 36, 266, 188, 196, 1310, 1318, "patients" +412, 12, 37, 267, 197, 198, 1319, 1320, "." +412, 13, 1, 268, 0, 7, 1321, 1328, "METHODS" +412, 13, 2, 269, 8, 9, 1329, 1330, ":" +412, 13, 3, 270, 10, 14, 1331, 1335, "This" +412, 13, 4, 271, 15, 18, 1336, 1339, "was" +412, 13, 5, 272, 19, 20, 1340, 1341, "a" +412, 13, 6, 273, 21, 26, 1342, 1347, "multi" +412, 13, 7, 274, 27, 28, 1348, 1349, "-" +412, 13, 8, 275, 29, 40, 1350, 1361, "institution" +412, 13, 9, 276, 41, 42, 1362, 1363, "," +412, 13, 10, 277, 43, 53, 1364, 1374, "randomized" +412, 13, 11, 278, 54, 55, 1375, 1376, "," +412, 13, 12, 279, 56, 62, 1377, 1383, "active" +412, 13, 13, 280, 63, 64, 1384, 1385, "-" +412, 13, 14, 281, 65, 75, 1386, 1396, "controlled" +412, 13, 15, 282, 76, 77, 1397, 1398, "," +412, 13, 16, 283, 78, 82, 1399, 1403, "open" +412, 13, 17, 284, 83, 84, 1404, 1405, "-" +412, 13, 18, 285, 85, 90, 1406, 1411, "label" +412, 13, 19, 286, 91, 92, 1412, 1413, "," +412, 13, 20, 287, 93, 101, 1414, 1422, "parallel" +412, 13, 21, 288, 102, 103, 1423, 1424, "-" +412, 13, 22, 289, 104, 109, 1425, 1430, "group" +412, 13, 23, 290, 110, 115, 1431, 1436, "study" +412, 13, 24, 291, 116, 117, 1437, 1438, "." +412, 14, 1, 292, 0, 5, 1439, 1444, "After" +412, 14, 2, 293, 6, 7, 1445, 1446, "a" +412, 14, 3, 294, 8, 12, 1447, 1451, "full" +412, 14, 4, 295, 13, 23, 1452, 1462, "ophthalmic" +412, 14, 5, 296, 24, 27, 1463, 1466, "and" +412, 14, 6, 297, 28, 36, 1467, 1475, "glaucoma" +412, 14, 7, 298, 37, 48, 1476, 1487, "examination" +412, 14, 8, 299, 49, 50, 1488, 1489, "," +412, 14, 9, 300, 51, 52, 1490, 1491, "a" +412, 14, 10, 301, 53, 58, 1492, 1497, "total" +412, 14, 11, 302, 59, 61, 1498, 1500, "of" +412, 14, 12, 303, 62, 65, 1501, 1504, "110" +412, 14, 13, 304, 66, 69, 1505, 1508, "NTG" +412, 14, 14, 305, 70, 78, 1509, 1517, "patients" +412, 14, 15, 306, 79, 80, 1518, 1519, "-" +412, 14, 16, 307, 81, 82, 1520, 1521, "-" +412, 14, 17, 308, 83, 85, 1522, 1524, "55" +412, 14, 18, 309, 86, 96, 1525, 1535, "undergoing" +412, 14, 19, 310, 97, 104, 1536, 1543, "therapy" +412, 14, 20, 311, 105, 109, 1544, 1548, "with" +412, 14, 21, 312, 110, 114, 1549, 1553, "BTFC" +412, 14, 22, 313, 115, 118, 1554, 1557, "and" +412, 14, 23, 314, 119, 121, 1558, 1560, "55" +412, 14, 24, 315, 122, 123, 1561, 1562, "0" +412, 14, 25, 316, 124, 125, 1563, 1564, "." +412, 14, 26, 317, 126, 127, 1565, 1566, "5" +412, 14, 27, 318, 128, 129, 1567, 1568, "%" +412, 14, 28, 319, 130, 131, 1569, 1570, "," +412, 14, 29, 320, 132, 136, 1571, 1575, "with" +412, 14, 30, 321, 137, 144, 1576, 1583, "timolol" +412, 14, 31, 322, 145, 146, 1584, 1585, "-" +412, 14, 32, 323, 147, 148, 1586, 1587, "-" +412, 14, 33, 324, 149, 161, 1588, 1600, "participated" +412, 14, 34, 325, 162, 164, 1601, 1603, "in" +412, 14, 35, 326, 165, 169, 1604, 1608, "this" +412, 14, 36, 327, 170, 175, 1609, 1614, "study" +412, 14, 37, 328, 176, 177, 1615, 1616, "." +412, 15, 1, 329, 0, 5, 1617, 1622, "Among" +412, 15, 2, 330, 6, 10, 1623, 1627, "them" +412, 15, 3, 331, 11, 12, 1628, 1629, "," +412, 15, 4, 332, 13, 14, 1630, 1631, "1" +412, 15, 5, 333, 15, 21, 1632, 1638, "failed" +412, 15, 6, 334, 22, 24, 1639, 1641, "to" +412, 15, 7, 335, 25, 29, 1642, 1646, "meet" +412, 15, 8, 336, 30, 33, 1647, 1650, "the" +412, 15, 9, 337, 34, 43, 1651, 1660, "inclusion" +412, 15, 10, 338, 44, 45, 1661, 1662, "/" +412, 15, 11, 339, 46, 55, 1663, 1672, "exclusion" +412, 15, 12, 340, 56, 64, 1673, 1681, "criteria" +412, 15, 13, 341, 65, 66, 1682, 1683, "," +412, 15, 14, 342, 67, 69, 1684, 1686, "10" +412, 15, 15, 343, 70, 77, 1687, 1694, "revoked" +412, 15, 16, 344, 78, 83, 1695, 1700, "their" +412, 15, 17, 345, 84, 91, 1701, 1708, "consent" +412, 15, 18, 346, 92, 94, 1709, 1711, "to" +412, 15, 19, 347, 95, 106, 1712, 1723, "participate" +412, 15, 20, 348, 107, 109, 1724, 1726, "in" +412, 15, 21, 349, 110, 113, 1727, 1730, "the" +412, 15, 22, 350, 114, 119, 1731, 1736, "study" +412, 15, 23, 351, 120, 121, 1737, 1738, "," +412, 15, 24, 352, 122, 123, 1739, 1740, "3" +412, 15, 25, 353, 124, 127, 1741, 1744, "had" +412, 15, 26, 354, 128, 135, 1745, 1752, "adverse" +412, 15, 27, 355, 136, 145, 1753, 1762, "reactions" +412, 15, 28, 356, 146, 147, 1763, 1764, "," +412, 15, 29, 357, 148, 151, 1765, 1768, "and" +412, 15, 30, 358, 152, 153, 1769, 1770, "1" +412, 15, 31, 359, 154, 157, 1771, 1774, "had" +412, 15, 32, 360, 158, 159, 1775, 1776, "a" +412, 15, 33, 361, 160, 164, 1777, 1781, "drug" +412, 15, 34, 362, 165, 174, 1782, 1791, "adherence" +412, 15, 35, 363, 175, 179, 1792, 1796, "rate" +412, 15, 36, 364, 180, 182, 1797, 1799, "of" +412, 15, 37, 365, 183, 187, 1800, 1804, "less" +412, 15, 38, 366, 188, 192, 1805, 1809, "than" +412, 15, 39, 367, 193, 195, 1810, 1812, "70" +412, 15, 40, 368, 196, 197, 1813, 1814, "%" +412, 15, 41, 369, 198, 199, 1815, 1816, "." +412, 16, 1, 370, 0, 10, 1817, 1827, "Ultimately" +412, 16, 2, 371, 11, 12, 1828, 1829, "," +412, 16, 3, 372, 13, 14, 1830, 1831, "a" +412, 16, 4, 373, 15, 20, 1832, 1837, "total" +412, 16, 5, 374, 21, 23, 1838, 1840, "of" +412, 16, 6, 375, 24, 26, 1841, 1843, "95" +412, 16, 7, 376, 27, 35, 1844, 1852, "patients" +412, 16, 8, 377, 36, 37, 1853, 1854, "-" +412, 16, 9, 378, 38, 39, 1855, 1856, "-" +412, 16, 10, 379, 40, 42, 1857, 1859, "48" +412, 16, 11, 380, 43, 45, 1860, 1862, "in" +412, 16, 12, 381, 46, 49, 1863, 1866, "the" +412, 16, 13, 382, 50, 54, 1867, 1871, "BTFC" +412, 16, 14, 383, 55, 60, 1872, 1877, "group" +412, 16, 15, 384, 61, 64, 1878, 1881, "and" +412, 16, 16, 385, 65, 67, 1882, 1884, "47" +412, 16, 17, 386, 68, 70, 1885, 1887, "in" +412, 16, 18, 387, 71, 74, 1888, 1891, "the" +412, 16, 19, 388, 75, 76, 1892, 1893, "0" +412, 16, 20, 389, 77, 78, 1894, 1895, "." +412, 16, 21, 390, 79, 80, 1896, 1897, "5" +412, 16, 22, 391, 81, 82, 1898, 1899, "%" +412, 16, 23, 392, 83, 90, 1900, 1907, "timolol" +412, 16, 24, 393, 91, 96, 1908, 1913, "group" +412, 16, 25, 394, 97, 98, 1914, 1915, "-" +412, 16, 26, 395, 99, 100, 1916, 1917, "-" +412, 16, 27, 396, 101, 110, 1918, 1927, "completed" +412, 16, 28, 397, 111, 114, 1928, 1931, "the" +412, 16, 29, 398, 115, 120, 1932, 1937, "study" +412, 16, 30, 399, 121, 122, 1938, 1939, "." +412, 17, 1, 400, 0, 3, 1940, 1943, "The" +412, 17, 2, 401, 4, 9, 1944, 1949, "study" +412, 17, 3, 402, 10, 16, 1950, 1956, "visits" +412, 17, 4, 403, 17, 21, 1957, 1961, "took" +412, 17, 5, 404, 22, 27, 1962, 1967, "place" +412, 17, 6, 405, 28, 30, 1968, 1970, "at" +412, 17, 7, 406, 31, 39, 1971, 1979, "baseline" +412, 17, 8, 407, 40, 43, 1980, 1983, "and" +412, 17, 9, 408, 44, 46, 1984, 1986, "at" +412, 17, 10, 409, 47, 48, 1987, 1988, "4" +412, 17, 11, 410, 49, 52, 1989, 1992, "and" +412, 17, 12, 411, 53, 55, 1993, 1995, "12" +412, 17, 13, 412, 56, 61, 1996, 2001, "weeks" +412, 17, 14, 413, 62, 63, 2002, 2003, "." +412, 18, 1, 414, 0, 7, 2004, 2011, "Diurnal" +412, 18, 2, 415, 8, 11, 2012, 2015, "IOP" +412, 18, 3, 416, 12, 15, 2016, 2019, "was" +412, 18, 4, 417, 16, 24, 2020, 2028, "measured" +412, 18, 5, 418, 25, 27, 2029, 2031, "at" +412, 18, 6, 419, 28, 29, 2032, 2033, "9" +412, 18, 7, 420, 30, 31, 2034, 2035, "a" +412, 18, 8, 421, 32, 33, 2036, 2037, "." +412, 18, 9, 422, 34, 35, 2038, 2039, "m" +412, 18, 10, 423, 36, 37, 2040, 2041, "." +412, 18, 11, 424, 38, 39, 2042, 2043, "," +412, 18, 12, 425, 40, 42, 2044, 2046, "11" +412, 18, 13, 426, 43, 44, 2047, 2048, "a" +412, 18, 14, 427, 45, 46, 2049, 2050, "." +412, 18, 15, 428, 47, 48, 2051, 2052, "m" +412, 18, 16, 429, 49, 50, 2053, 2054, "." +412, 18, 17, 430, 51, 52, 2055, 2056, "," +412, 18, 18, 431, 53, 56, 2057, 2060, "and" +412, 18, 19, 432, 57, 58, 2061, 2062, "5" +412, 18, 20, 433, 59, 60, 2063, 2064, "p" +412, 18, 21, 434, 61, 62, 2065, 2066, "." +412, 18, 22, 435, 63, 64, 2067, 2068, "m" +412, 18, 23, 436, 65, 66, 2069, 2070, "." +412, 18, 24, 437, 67, 73, 2071, 2077, "during" +412, 18, 25, 438, 74, 77, 2078, 2081, "the" +412, 18, 26, 439, 78, 86, 2082, 2090, "baseline" +412, 18, 27, 440, 87, 92, 2091, 2096, "visit" +412, 18, 28, 441, 93, 96, 2097, 2100, "and" +412, 18, 29, 442, 97, 100, 2101, 2104, "the" +412, 18, 30, 443, 101, 106, 2105, 2110, "visit" +412, 18, 31, 444, 107, 109, 2111, 2113, "at" +412, 18, 32, 445, 110, 112, 2114, 2116, "12" +412, 18, 33, 446, 113, 118, 2117, 2122, "weeks" +412, 18, 34, 447, 119, 124, 2123, 2128, "after" +412, 18, 35, 448, 125, 128, 2129, 2132, "eye" +412, 18, 36, 449, 129, 130, 2133, 2134, "-" +412, 18, 37, 450, 131, 135, 2135, 2139, "drop" +412, 18, 38, 451, 136, 148, 2140, 2152, "instillation" +412, 18, 39, 452, 149, 150, 2153, 2154, "." +412, 19, 1, 453, 0, 2, 2155, 2157, "At" +412, 19, 2, 454, 3, 7, 2158, 2162, "each" +412, 19, 3, 455, 8, 14, 2163, 2169, "follow" +412, 19, 4, 456, 15, 16, 2170, 2171, "-" +412, 19, 5, 457, 17, 19, 2172, 2174, "up" +412, 19, 6, 458, 20, 25, 2175, 2180, "visit" +412, 19, 7, 459, 26, 27, 2181, 2182, "," +412, 19, 8, 460, 28, 38, 2183, 2193, "compliance" +412, 19, 9, 461, 39, 42, 2194, 2197, "was" +412, 19, 10, 462, 43, 51, 2198, 2206, "assessed" +412, 19, 11, 463, 52, 53, 2207, 2208, "." +412, 20, 1, 464, 0, 10, 2209, 2219, "Throughout" +412, 20, 2, 465, 11, 14, 2220, 2223, "the" +412, 20, 3, 466, 15, 20, 2224, 2229, "study" +412, 20, 4, 467, 21, 22, 2230, 2231, "," +412, 20, 5, 468, 23, 26, 2232, 2235, "all" +412, 20, 6, 469, 27, 34, 2236, 2243, "adverse" +412, 20, 7, 470, 35, 41, 2244, 2250, "events" +412, 20, 8, 471, 42, 46, 2251, 2255, "were" +412, 20, 9, 472, 47, 55, 2256, 2264, "recorded" +412, 20, 10, 473, 56, 59, 2265, 2268, "and" +412, 20, 11, 474, 60, 69, 2269, 2278, "monitored" +412, 20, 12, 475, 70, 72, 2279, 2281, "by" +412, 20, 13, 476, 73, 76, 2282, 2285, "the" +412, 20, 14, 477, 77, 90, 2286, 2299, "investigators" +412, 20, 15, 478, 91, 92, 2300, 2301, "." +412, 21, 1, 479, 0, 7, 2302, 2309, "RESULTS" +412, 21, 2, 480, 8, 9, 2310, 2311, ":" +412, 21, 3, 481, 10, 13, 2312, 2315, "The" +412, 21, 4, 482, 14, 21, 2316, 2323, "average" +412, 21, 5, 483, 22, 32, 2324, 2334, "difference" +412, 21, 6, 484, 33, 35, 2335, 2337, "in" +412, 21, 7, 485, 36, 39, 2338, 2341, "IOP" +412, 21, 8, 486, 40, 46, 2342, 2348, "change" +412, 21, 9, 487, 47, 55, 2349, 2357, "measured" +412, 21, 10, 488, 56, 58, 2358, 2360, "at" +412, 21, 11, 489, 59, 61, 2361, 2363, "11" +412, 21, 12, 490, 62, 63, 2364, 2365, "a" +412, 21, 13, 491, 64, 65, 2366, 2367, "." +412, 21, 14, 492, 66, 67, 2368, 2369, "m" +412, 21, 15, 493, 68, 69, 2370, 2371, "." +412, 21, 16, 494, 70, 72, 2372, 2374, "12" +412, 21, 17, 495, 73, 78, 2375, 2380, "weeks" +412, 21, 18, 496, 79, 84, 2381, 2386, "after" +412, 21, 19, 497, 85, 99, 2387, 2401, "administration" +412, 21, 20, 498, 100, 107, 2402, 2409, "between" +412, 21, 21, 499, 108, 111, 2410, 2413, "the" +412, 21, 22, 500, 112, 115, 2414, 2417, "two" +412, 21, 23, 501, 116, 122, 2418, 2424, "groups" +412, 21, 24, 502, 123, 126, 2425, 2428, "was" +412, 21, 25, 503, 127, 128, 2429, 2430, "2" +412, 21, 26, 504, 129, 130, 2431, 2432, "." +412, 21, 27, 505, 131, 133, 2433, 2435, "10" +412, 21, 28, 506, 134, 135, 2436, 2437, "±" +412, 21, 29, 507, 136, 137, 2438, 2439, "2" +412, 21, 30, 508, 138, 139, 2440, 2441, "." +412, 21, 31, 509, 140, 142, 2442, 2444, "59" +412, 21, 32, 510, 143, 147, 2445, 2449, "mmHg" +412, 21, 33, 511, 148, 149, 2450, 2451, "." +412, 22, 1, 512, 0, 3, 2452, 2455, "The" +412, 22, 2, 513, 4, 8, 2456, 2460, "BTFC" +412, 22, 3, 514, 9, 14, 2461, 2466, "group" +412, 22, 4, 515, 15, 18, 2467, 2470, "had" +412, 22, 5, 516, 19, 20, 2471, 2472, "a" +412, 22, 6, 517, 21, 27, 2473, 2479, "better" +412, 22, 7, 518, 28, 31, 2480, 2483, "IOP" +412, 22, 8, 519, 32, 33, 2484, 2485, "-" +412, 22, 9, 520, 34, 42, 2486, 2494, "lowering" +412, 22, 10, 521, 43, 49, 2495, 2501, "effect" +412, 22, 11, 522, 50, 52, 2502, 2504, "at" +412, 22, 12, 523, 53, 56, 2505, 2508, "all" +412, 22, 13, 524, 57, 61, 2509, 2513, "time" +412, 22, 14, 525, 62, 68, 2514, 2520, "points" +412, 22, 15, 526, 69, 73, 2521, 2525, "than" +412, 22, 16, 527, 74, 77, 2526, 2529, "did" +412, 22, 17, 528, 78, 81, 2530, 2533, "the" +412, 22, 18, 529, 82, 83, 2534, 2535, "0" +412, 22, 19, 530, 84, 85, 2536, 2537, "." +412, 22, 20, 531, 86, 87, 2538, 2539, "5" +412, 22, 21, 532, 88, 89, 2540, 2541, "%" +412, 22, 22, 533, 90, 97, 2542, 2549, "timolol" +412, 22, 23, 534, 98, 103, 2550, 2555, "group" +412, 22, 24, 535, 104, 105, 2556, 2557, "." +412, 23, 1, 536, 0, 3, 2558, 2561, "The" +412, 23, 2, 537, 4, 9, 2562, 2567, "ratio" +412, 23, 3, 538, 10, 12, 2568, 2570, "of" +412, 23, 4, 539, 13, 21, 2571, 2579, "patients" +412, 23, 5, 540, 22, 27, 2580, 2585, "whose" +412, 23, 6, 541, 28, 35, 2586, 2593, "average" +412, 23, 7, 542, 36, 39, 2594, 2597, "IOP" +412, 23, 8, 543, 40, 43, 2598, 2601, "had" +412, 23, 9, 544, 44, 53, 2602, 2611, "decreased" +412, 23, 10, 545, 54, 56, 2612, 2614, "by" +412, 23, 11, 546, 57, 58, 2615, 2616, ">" +412, 23, 12, 547, 59, 61, 2617, 2619, "20" +412, 23, 13, 548, 62, 63, 2620, 2621, "%" +412, 23, 14, 549, 64, 69, 2622, 2627, "after" +412, 23, 15, 550, 70, 71, 2628, 2629, "4" +412, 23, 16, 551, 72, 75, 2630, 2633, "and" +412, 23, 17, 552, 76, 78, 2634, 2636, "12" +412, 23, 18, 553, 79, 84, 2637, 2642, "weeks" +412, 23, 19, 554, 85, 88, 2643, 2646, "was" +412, 23, 20, 555, 89, 91, 2647, 2649, "50" +412, 23, 21, 556, 92, 95, 2650, 2653, "and" +412, 23, 22, 557, 96, 98, 2654, 2656, "56" +412, 23, 23, 558, 99, 100, 2657, 2658, "%" +412, 23, 24, 559, 101, 103, 2659, 2661, "in" +412, 23, 25, 560, 104, 107, 2662, 2665, "the" +412, 23, 26, 561, 108, 112, 2666, 2670, "BTFC" +412, 23, 27, 562, 113, 118, 2671, 2676, "group" +412, 23, 28, 563, 119, 120, 2677, 2678, "," +412, 23, 29, 564, 121, 133, 2679, 2691, "respectively" +412, 23, 30, 565, 134, 135, 2692, 2693, "," +412, 23, 31, 566, 136, 143, 2694, 2701, "whereas" +412, 23, 32, 567, 144, 146, 2702, 2704, "it" +412, 23, 33, 568, 147, 150, 2705, 2708, "was" +412, 23, 34, 569, 151, 153, 2709, 2711, "29" +412, 23, 35, 570, 154, 155, 2712, 2713, "." +412, 23, 36, 571, 156, 158, 2714, 2716, "41" +412, 23, 37, 572, 159, 162, 2717, 2720, "and" +412, 23, 38, 573, 163, 165, 2721, 2723, "23" +412, 23, 39, 574, 166, 167, 2724, 2725, "." +412, 23, 40, 575, 168, 170, 2726, 2728, "53" +412, 23, 41, 576, 171, 172, 2729, 2730, "%" +412, 23, 42, 577, 173, 175, 2731, 2733, "in" +412, 23, 43, 578, 176, 179, 2734, 2737, "the" +412, 23, 44, 579, 180, 181, 2738, 2739, "0" +412, 23, 45, 580, 182, 183, 2740, 2741, "." +412, 23, 46, 581, 184, 185, 2742, 2743, "5" +412, 23, 47, 582, 186, 187, 2744, 2745, "%" +412, 23, 48, 583, 188, 195, 2746, 2753, "timolol" +412, 23, 49, 584, 196, 201, 2754, 2759, "group" +412, 23, 50, 585, 202, 203, 2760, 2761, "," +412, 23, 51, 586, 204, 216, 2762, 2774, "respectively" +412, 23, 52, 587, 217, 218, 2775, 2776, "(" +412, 23, 53, 588, 219, 220, 2777, 2778, "p" +412, 23, 54, 589, 221, 222, 2779, 2780, "=" +412, 23, 55, 590, 223, 224, 2781, 2782, "0" +412, 23, 56, 591, 225, 226, 2783, 2784, "." +412, 23, 57, 592, 227, 230, 2785, 2788, "034" +412, 23, 58, 593, 231, 232, 2789, 2790, "," +412, 23, 59, 594, 233, 234, 2791, 2792, "<" +412, 23, 60, 595, 235, 236, 2793, 2794, "0" +412, 23, 61, 596, 237, 238, 2795, 2796, "." +412, 23, 62, 597, 239, 242, 2797, 2800, "001" +412, 23, 63, 598, 243, 244, 2801, 2802, ")" +412, 23, 64, 599, 245, 246, 2803, 2804, "." +412, 24, 1, 600, 0, 11, 2805, 2816, "CONCLUSIONS" +412, 24, 2, 601, 12, 13, 2817, 2818, ":" +412, 24, 3, 602, 14, 18, 2819, 2823, "BTFC" +412, 24, 4, 603, 19, 22, 2824, 2827, "has" +412, 24, 5, 604, 23, 24, 2828, 2829, "a" +412, 24, 6, 605, 25, 33, 2830, 2838, "superior" +412, 24, 7, 606, 34, 37, 2839, 2842, "IOP" +412, 24, 8, 607, 38, 39, 2843, 2844, "-" +412, 24, 9, 608, 40, 48, 2845, 2853, "lowering" +412, 24, 10, 609, 49, 55, 2854, 2860, "effect" +412, 24, 11, 610, 56, 60, 2861, 2865, "than" +412, 24, 12, 611, 61, 62, 2866, 2867, "0" +412, 24, 13, 612, 63, 64, 2868, 2869, "." +412, 24, 14, 613, 65, 66, 2870, 2871, "5" +412, 24, 15, 614, 67, 68, 2872, 2873, "%" +412, 24, 16, 615, 69, 76, 2874, 2881, "timolol" +412, 24, 17, 616, 77, 79, 2882, 2884, "in" +412, 24, 18, 617, 80, 83, 2885, 2888, "NTG" +412, 24, 19, 618, 84, 92, 2889, 2897, "patients" +412, 24, 20, 619, 93, 94, 2898, 2899, "." +412, 25, 1, 620, 0, 3, 2900, 2903, "DOI" +412, 25, 2, 621, 4, 5, 2904, 2905, ":" +412, 25, 3, 622, 6, 8, 2906, 2908, "10" +412, 25, 4, 623, 9, 10, 2909, 2910, "." +412, 25, 5, 624, 11, 15, 2911, 2915, "1007" +412, 25, 6, 625, 16, 17, 2916, 2917, "/" +412, 25, 7, 626, 18, 24, 2918, 2924, "s10384" +412, 25, 8, 627, 25, 26, 2925, 2926, "-" +412, 25, 9, 628, 27, 30, 2927, 2930, "015" +412, 25, 10, 629, 31, 32, 2931, 2932, "-" +412, 25, 11, 630, 33, 37, 2933, 2937, "0420" +412, 25, 12, 631, 38, 39, 2938, 2939, "-" +412, 25, 13, 632, 40, 41, 2940, 2941, "2" +412, 25, 14, 633, 42, 46, 2942, 2946, "PMID" +412, 25, 15, 634, 47, 48, 2947, 2948, ":" +412, 25, 16, 635, 49, 57, 2949, 2957, "26578422" +412, 25, 17, 636, 58, 59, 2958, 2959, "[" +412, 25, 18, 637, 60, 67, 2960, 2967, "Indexed" +412, 25, 19, 638, 68, 71, 2968, 2971, "for" +412, 25, 20, 639, 72, 79, 2972, 2979, "MEDLINE" +412, 25, 21, 640, 80, 81, 2980, 2981, "]" diff --git a/data/gl 26578422_jshahinitiran.annodb b/data/gl 26578422_jshahinitiran.annodb new file mode 100644 index 0000000..7f9e375 --- /dev/null +++ b/data/gl 26578422_jshahinitiran.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +17309, Journal, 0, 16, "Jpn J Ophthalmol", "", +17310, PublicationYear, 19, 23, "2016", "", +17312, Title, 113, 283, "Comparison of the intraocular pressure - lowering effect and safety of brimonidine / timolol fixed combination and 0 . 5 % timolol in normal - tension glaucoma patients .", "", +17313, IOP, 131, 151, "intraocular pressure", "", +17314, Brimonidine, 184, 195, "brimonidine", "", +17316, Drug, 184, 223, "brimonidine / timolol fixed combination", "BTFC", +17315, Timolol, 198, 205, "timolol", "", +17317, DoseValue, 228, 233, "0 . 5", "", +17318, Percentage, 234, 235, "%", "", +17319, Timolol, 236, 243, "timolol", "", +17320, Glaucoma, 247, 272, "normal - tension glaucoma", "Normal Tension Glaucoma", +17321, Author, 284, 290, "Kim JM", "", +17322, Author, 299, 305, "Kim TW", "", +17323, Author, 314, 320, "Kim CY", "", +17324, Author, 329, 335, "Kim HK", "", +17325, Author, 344, 351, "Park KH", "", +35873, SouthKorea, 497, 514, "Republic of Korea", "", +35874, SouthKorea, 657, 674, "Republic of Korea", "", +35875, SouthKorea, 761, 778, "Republic of Korea", "", +35876, SouthKorea, 926, 943, "Republic of Korea", "", +35877, SouthKorea, 1075, 1092, "Republic of Korea", "", +17331, ObjectiveDescription, 1132, 1320, "To compare the therapeutic efficacy and safety of brimonidine / timolol fixed - combination ( BTFC ) and 0 . 5 % timolol ophthalmic solution in normal - tension glaucoma ( NTG ) patients .", "", +17332, Brimonidine, 1182, 1193, "brimonidine", "", +17316, Drug, 1182, 1223, "brimonidine / timolol fixed - combination", "BTFC", +17333, Timolol, 1196, 1203, "timolol", "", +17316, Drug, 1226, 1230, "BTFC", "BTFC", +17336, DoseValue, 1237, 1242, "0 . 5", "", +17337, Percentage, 1243, 1244, "%", "", +17338, Timolol, 1245, 1272, "timolol ophthalmic solution", "", +17320, Glaucoma, 1276, 1301, "normal - tension glaucoma", "Normal Tension Glaucoma", +17320, Glaucoma, 1304, 1307, "NTG", "Normal Tension Glaucoma", +17341, Multicenter, 1342, 1361, "multi - institution", "", +17342, Randomized, 1364, 1374, "randomized", "", +17343, CTDesign, 1377, 1396, "active - controlled", "", +17344, OpenLabel, 1399, 1411, "open - label", "", +17345, Parallel, 1414, 1430, "parallel - group", "", +17346, Glaucoma, 1467, 1475, "glaucoma", "", +17347, NumberPatientsCT, 1501, 1504, "110", "", +17320, Glaucoma, 1505, 1508, "NTG", "Normal Tension Glaucoma", +17349, NumberPatientsArm, 1522, 1524, "55", "", +17316, Drug, 1549, 1553, "BTFC", "BTFC", +17350, NumberPatientsArm, 1558, 1560, "55", "", +17352, DoseValue, 1561, 1566, "0 . 5", "", +17353, Percentage, 1567, 1568, "%", "", +17354, Timolol, 1576, 1583, "timolol", "", +17355, FinalNumPatientsCT, 1841, 1843, "95", "", +17356, FinalNumPatientsArm, 1857, 1859, "48", "", +17316, Drug, 1867, 1871, "BTFC", "BTFC", +17357, FinalNumPatientsArm, 1882, 1884, "47", "", +17359, DoseValue, 1892, 1897, "0 . 5", "", +17360, Percentage, 1898, 1899, "%", "", +17361, Timolol, 1900, 1907, "timolol", "", +17362, TimePoint, 1987, 1988, "4", "", +17363, TimePoint, 1993, 2001, "12 weeks", "", +17364, Diurnal_IOP, 2004, 2015, "Diurnal IOP", "", +17365, TimePoint, 2114, 2122, "12 weeks", "", +17366, Eyedrops, 2129, 2139, "eye - drop", "", +17367, Mean, 2316, 2323, "average", "", +17368, IOP, 2338, 2341, "IOP", "", +17369, TimePoint, 2372, 2380, "12 weeks", "", +17370, DiffGroupAbsValue, 2429, 2435, "2 . 10", "", +17371, SdErrorDiff, 2438, 2444, "2 . 59", "", +17372, mmHg, 2445, 2449, "mmHg", "", +17316, Drug, 2456, 2460, "BTFC", "BTFC", +17374, IOP, 2480, 2483, "IOP", "", +17375, DoseValue, 2534, 2539, "0 . 5", "", +17376, Percentage, 2540, 2541, "%", "", +17377, Timolol, 2542, 2549, "timolol", "", +17378, Mean, 2586, 2593, "average", "", +17380, EndPointDescription, 2586, 2621, "average IOP had decreased by > 20 %", "", +17379, IOP, 2594, 2597, "IOP", "", +17381, TimePoint, 2628, 2629, "4", "", +17382, TimePoint, 2634, 2642, "12 weeks", "", +17383, PercentageAffected, 2647, 2649, "50", "", +17384, PercentageAffected, 2654, 2656, "56", "", +17316, Drug, 2666, 2670, "BTFC", "BTFC", +17386, PercentageAffected, 2709, 2716, "29 . 41", "", +17387, PercentageAffected, 2721, 2728, "23 . 53", "", +17388, DoseValue, 2738, 2743, "0 . 5", "", +17389, Percentage, 2744, 2745, "%", "", +17390, Timolol, 2746, 2753, "timolol", "", +17391, PValueNumAffected, 2777, 2788, "p = 0 . 034", "", +17392, ConclusionComment, 2819, 2899, "BTFC has a superior IOP - lowering effect than 0 . 5 % timolol in NTG patients .", "", +17316, Drug, 2819, 2823, "BTFC", "BTFC", +17394, IOP, 2839, 2842, "IOP", "", +17395, DoseValue, 2866, 2871, "0 . 5", "", +17396, Percentage, 2872, 2873, "%", "", +17397, Timolol, 2874, 2881, "timolol", "", +17320, Glaucoma, 2885, 2888, "NTG", "Normal Tension Glaucoma", +17399, PMID, 2949, 2957, "26578422", "", diff --git a/data/gl 26578422_jshahinitiran.n-triples b/data/gl 26578422_jshahinitiran.n-triples new file mode 100644 index 0000000..6215cfc --- /dev/null +++ b/data/gl 26578422_jshahinitiran.n-triples @@ -0,0 +1,15 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication + . + "Medication 19131" . + . + . + . +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26578422_tstrakeljahn.annodb b/data/gl 26578422_tstrakeljahn.annodb new file mode 100644 index 0000000..712d043 --- /dev/null +++ b/data/gl 26578422_tstrakeljahn.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +11111, Journal, 0, 16, "Jpn J Ophthalmol", "", +11112, PublicationYear, 19, 23, "2016", "", +11125, Title, 113, 283, "Comparison of the intraocular pressure - lowering effect and safety of brimonidine / timolol fixed combination and 0 . 5 % timolol in normal - tension glaucoma patients .", "", +11113, IOP, 131, 151, "intraocular pressure", "", +11114, Brimonidine, 184, 195, "brimonidine", "", +11115, Timolol, 198, 205, "timolol", "", +11123, DoseValue, 228, 233, "0 . 5", "", +11124, Percentage, 234, 235, "%", "", +11116, Timolol, 236, 243, "timolol", "", +11117, Glaucoma, 264, 272, "glaucoma", "", +11118, Author, 284, 290, "Kim JM", "", +11119, Author, 299, 305, "Kim TW", "", +11120, Author, 314, 320, "Kim CY", "", +11121, Author, 329, 335, "Kim HK", "", +11122, Author, 344, 351, "Park KH", "", +11126, Country, 497, 514, "Republic of Korea", "Republic of Korea", +11127, Country, 657, 674, "Republic of Korea", "Republic of Korea", +11128, Country, 926, 943, "Republic of Korea", "Republic of Korea", +11129, Country, 1075, 1092, "Republic of Korea", "Republic of Korea", +11142, ObjectiveDescription, 1132, 1320, "To compare the therapeutic efficacy and safety of brimonidine / timolol fixed - combination ( BTFC ) and 0 . 5 % timolol ophthalmic solution in normal - tension glaucoma ( NTG ) patients .", "", +11130, Brimonidine, 1182, 1193, "brimonidine", "", +11131, Timolol, 1196, 1203, "timolol", "", +29872, Drug, 1226, 1230, "BTFC", "Brimonidine Timolol Fixed Combination", +11135, DoseValue, 1237, 1242, "0 . 5", "", +11136, Percentage, 1243, 1244, "%", "", +11133, Timolol, 1245, 1252, "timolol", "", +11137, Glaucoma, 1293, 1301, "glaucoma", "", +11138, Multicenter, 1342, 1361, "multi - institution", "", +11139, Randomized, 1364, 1374, "randomized", "", +11140, OpenLabel, 1399, 1411, "open - label", "", +11141, Parallel, 1414, 1422, "parallel", "", +11150, Glaucoma, 1467, 1475, "glaucoma", "", +11143, NumberPatientsCT, 1501, 1504, "110", "", +11147, NumberPatientsArm, 1522, 1524, "55", "", +29873, Drug, 1549, 1553, "BTFC", "Brimonidine Timolol Fixed Combination", +11148, NumberPatientsArm, 1558, 1560, "55", "", +11152, DoseValue, 1561, 1566, "0 . 5", "", +11151, Percentage, 1567, 1568, "%", "", +11153, Timolol, 1576, 1583, "timolol", "", +11144, FinalNumPatientsCT, 1841, 1843, "95", "", +11145, FinalNumPatientsArm, 1857, 1859, "48", "", +29874, Drug, 1867, 1871, "BTFC", "Brimonidine Timolol Fixed Combination", +11146, FinalNumPatientsArm, 1882, 1884, "47", "", +11156, DoseValue, 1892, 1897, "0 . 5", "", +11155, Percentage, 1898, 1899, "%", "", +11154, Timolol, 1900, 1907, "timolol", "", +11157, Diurnal_IOP, 2004, 2015, "Diurnal IOP", "", +11159, IOP, 2338, 2341, "IOP", "", +11158, TimePoint, 2361, 2401, "11 a . m . 12 weeks after administration", "", +11160, DiffBetweenGroups, 2429, 2435, "2 . 10", "", +11161, SdErrorDiff, 2436, 2444, "± 2 . 59", "", +11162, mmHg, 2445, 2449, "mmHg", "", +29875, Drug, 2456, 2460, "BTFC", "Brimonidine Timolol Fixed Combination", +11167, IOP, 2594, 2597, "IOP", "", +11168, Endpoint, 2594, 2621, "IOP had decreased by > 20 %", "", +11169, TimePoint, 2628, 2629, "4", "", +11170, TimePoint, 2634, 2642, "12 weeks", "", +11169, TimePoint, 2637, 2642, "weeks", "", +11172, PercentageAffected, 2647, 2649, "50", "", +11173, PercentageAffected, 2654, 2656, "56", "", +29876, Drug, 2666, 2670, "BTFC", "Brimonidine Timolol Fixed Combination", +11174, PercentageAffected, 2709, 2716, "29 . 41", "", +11175, PercentageAffected, 2721, 2728, "23 . 53", "", +11177, DoseValue, 2738, 2743, "0 . 5", "", +11178, Percentage, 2744, 2745, "%", "", +11176, Timolol, 2746, 2753, "timolol", "", +11179, PvalueDiff, 2777, 2788, "p = 0 . 034", "", +11185, ConclusionComment, 2819, 2897, "BTFC has a superior IOP - lowering effect than 0 . 5 % timolol in NTG patients", "", +29877, Drug, 2819, 2823, "BTFC", "Brimonidine Timolol Fixed Combination", +11181, IOP, 2839, 2842, "IOP", "", +11184, DoseValue, 2866, 2871, "0 . 5", "", +11182, Percentage, 2872, 2873, "%", "", +11183, Timolol, 2874, 2881, "timolol", "", +11180, PMID, 2949, 2957, "26578422", "", diff --git a/data/gl 26578422_tstrakeljahn.n-triples b/data/gl 26578422_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 26578422_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26940161_admin.annodb b/data/gl 26940161_admin.annodb new file mode 100644 index 0000000..552f878 --- /dev/null +++ b/data/gl 26940161_admin.annodb @@ -0,0 +1,115 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Am J Ophthalmol", "", " \"Am J Ophthalmol\"." +1, PublicationYear, 18, 22, "2016", "", " \"2016\"." +35, Title, 110, 241, "A Randomized Trial of Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 % as Adjunctive Therapy to Travoprost 0 . 004 .", "", " \"A Randomized Trial of Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 % as Adjunctive Therapy to Travoprost 0 . 004 .\"." +2, Randomized, 112, 122, "Randomized", "", " ." +38417, Brinz/BrimoFC, 157, 195, "Brinzolamide 1 % / Brimonidine 0 . 2 %", "", +3, Brinzolamide, 157, 169, "Brinzolamide", "", +5, DoseValue, 170, 171, "1", "", +8, Percentage, 172, 173, "%", "", +4, Brimonidine, 176, 187, "Brimonidine", "", +6, DoseValue, 188, 193, "0 . 2", "", +9, Percentage, 194, 195, "%", "", +112, Travoprost, 221, 231, "Travoprost", "", +7, DoseValue, 232, 239, "0 . 004", "", +10, Author, 242, 252, "Feldman RM", "", " \"Feldman RM\"." +11, Author, 261, 267, "Katz G", "", " \"Katz G\"." +12, Author, 276, 286, "McMenemy M", "", " \"McMenemy M\"." +13, Author, 295, 306, "Hubatsch DA", "", " \"Hubatsch DA\"." +14, Author, 315, 324, "Realini T", "", " \"Realini T\"." +15, USA, 539, 544, "Texas", "", +16, USA, 692, 700, "Michigan", "", +17, USA, 748, 753, "Texas", "", +18, USA, 802, 807, "Texas", "", +19, USA, 886, 899, "West Virginia", "", +97, ObjectiveDescription, 912, 1144, "To evaluate the safety and efficacy of adding fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) as adjunctive therapy to travoprost 0 . 004 % ( TRAV ) in patients with open - angle glaucoma or ocular hypertension .", "", " \"To evaluate the safety and efficacy of adding fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) as adjunctive therapy to travoprost 0 . 004 % ( TRAV ) in patients with open - angle glaucoma or ocular hypertension .\"." +38416, Brinz/BrimoFC, 978, 1016, "brinzolamide 1 % / brimonidine 0 . 2 %", "", +20, Brinzolamide, 978, 990, "brinzolamide", "", +22, DoseValue, 991, 992, "1", "", +25, Percentage, 993, 994, "%", "", +21, Brimonidine, 997, 1008, "brimonidine", "", +23, DoseValue, 1009, 1014, "0 . 2", "", +26, Percentage, 1015, 1016, "%", "", +37039, Brinz/BrimoFC, 1019, 1023, "BBFC", "", +133, Travoprost, 1051, 1061, "travoprost", "", +24, DoseValue, 1062, 1069, "0 . 004", "", +27, Percentage, 1070, 1071, "%", "", +162, Travoprost, 1074, 1078, "TRAV", "", +54366, Precondition, 1084, 1142, "patients with open - angle glaucoma or ocular hypertension", "", " \"patients with open - angle glaucoma or ocular hypertension\"." +28, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", " ." +29, OcularHypertension, 1123, 1142, "ocular hypertension", "", " ." +30, Multicenter, 1154, 1165, "Multicenter", "", " ." +31, Randomized, 1168, 1178, "randomized", "", +32, DoubleBlind, 1181, 1196, "double - masked", "", " ." +33, Parallel, 1199, 1207, "parallel", "", " ." +36, Multicenter, 1261, 1272, "Multicenter", "", +37, USA, 1291, 1304, "United States", "", " ." +38, NumberPatientsCT, 1337, 1340, "233", "", " \"233\"." +39, OpenAngleGlaucoma, 1355, 1376, "open - angle glaucoma", "", +46, Precondition, 1355, 1518, "open - angle glaucoma or ocular hypertension and with mean intraocular pressure ( IOP ) ≥ 21   mm Hg and < 32   mm Hg while receiving once - daily TRAV monotherapy", "", " \"open - angle glaucoma or ocular hypertension and with mean intraocular pressure ( IOP ) ≥ 21   mm Hg and < 32   mm Hg while receiving once - daily TRAV monotherapy\"." +40, OcularHypertension, 1380, 1399, "ocular hypertension", "", +41, Mean, 1409, 1413, "mean", "", +42, IOP, 1414, 1434, "intraocular pressure", "", +43, IOP, 1437, 1440, "IOP", "", +44, mmHg, 1450, 1455, "mm Hg", "", +45, mmHg, 1467, 1472, "mm Hg", "", +35841, Frequency, 1489, 1501, "once - daily", "", " \"once - daily\"." +35768, Travoprost, 1502, 1506, "TRAV", "", +37040, Brinz/BrimoFC, 1543, 1547, "BBFC", "", " ." +92844, Vehicle, 1551, 1558, "vehicle", "", " ." +48, Frequency, 1561, 1574, "3 times daily", "", " \"3 times daily\". \"3 times daily\"." +165, Travoprost, 1591, 1595, "TRAV", "", " ." +49, Duration, 1600, 1609, "6   weeks", "", " \"6   weeks\"." +50, Mean, 1635, 1639, "Mean", "", +51, Diurnal_IOP, 1640, 1651, "diurnal IOP", "", +168, TimePoint, 1712, 1718, "week 6", "", +37046, Brinz/BrimoFC, 1736, 1740, "BBFC", "", +169, Travoprost, 1743, 1747, "TRAV", "", +92845, Vehicle, 1753, 1760, "vehicle", "", +171, Travoprost, 1763, 1767, "TRAV", "", +37041, Brinz/BrimoFC, 1841, 1845, "BBFC", "", +172, Travoprost, 1848, 1852, "TRAV", "", +52, Mean, 1865, 1869, "Mean", "", +53, Diurnal_IOP, 1870, 1881, "diurnal IOP", "", " ." +54, TimePoint, 1885, 1891, "week 6", "", " \"week 6\". \"week 6\"." +35842, LeastSquaresMean, 1894, 1912, "least squares mean", "", " ." +55, ResultMeasuredValue, 1936, 1942, "17 . 6", "", " \"17 . 6\"." +178, SdErrorResValue, 1945, 1950, "0 . 4", "", " \"0 . 4\"." +58, mmHg, 1953, 1958, "mm Hg", "", " ." +56, ResultMeasuredValue, 1963, 1969, "20 . 7", "", " \"20 . 7\"." +179, SdErrorResValue, 1972, 1977, "0 . 4", "", " \"0 . 4\"." +59, mmHg, 1980, 1985, "mm Hg", "", +37044, Brinz/BrimoFC, 1993, 1997, "BBFC", "", +37043, Travoprost, 2000, 2004, "TRAV", "", +92850, Vehicle, 2009, 2016, "vehicle", "", +37042, Travoprost, 2019, 2023, "TRAV", "", +35843, DiffGroupAbsValue, 2075, 2084, ", - 3 . 2", "", " \", - 3 . 2\"." +36226, SdErrorDiff, 2087, 2092, "0 . 5", "", " \"0 . 5\"." +64, mmHg, 2095, 2100, "mm Hg", "", +65, PvalueDiff, 2103, 2113, "P < . 0001", "", " \"P < . 0001\"." +37045, Brinz/BrimoFC, 2133, 2137, "BBFC", "", +182, Travoprost, 2140, 2144, "TRAV", "", +92847, Vehicle, 2150, 2157, "vehicle", "", +183, Travoprost, 2160, 2164, "TRAV", "", +67, Mean, 2183, 2187, "Mean", "", +68, Diurnal_IOP, 2200, 2211, "diurnal IOP", "", +37047, Brinz/BrimoFC, 2265, 2269, "BBFC", "", +187, Travoprost, 2272, 2276, "TRAV", "", +92846, Vehicle, 2291, 2298, "vehicle", "", +188, Travoprost, 2301, 2305, "TRAV", "", +69, PValueChangeValue, 2308, 2318, "P < . 0001", "", " \"P < . 0001\". \"P < . 0001\"." +70, ConjunctivalHyperemia, 2332, 2354, "Conjunctival hyperemia", "", " ." +37048, Brinz/BrimoFC, 2427, 2431, "BBFC", "", +192, Travoprost, 2434, 2438, "TRAV", "", +71, PercentageAffected, 2441, 2447, "12 . 8", "", " \"12 . 8\"." +92848, Vehicle, 2452, 2459, "vehicle", "", +195, Travoprost, 2462, 2466, "TRAV", "", +72, PercentageAffected, 2469, 2474, "6 . 0", "", " \"6 . 0\"." +78, ConclusionComment, 2495, 2709, "Adjunctive treatment with BBFC added to TRAV resulted in lower mean diurnal IOP after 6   weeks of treatment compared with vehicle added to TRAV ; this difference was both statistically and clinically significant .", "", " \"Adjunctive treatment with BBFC added to TRAV resulted in lower mean diurnal IOP after 6   weeks of treatment compared with vehicle added to TRAV ; this difference was both statistically and clinically significant .\"." +197, Travoprost, 2535, 2539, "TRAV", "", +74, Mean, 2558, 2562, "mean", "", +75, Diurnal_IOP, 2563, 2574, "diurnal IOP", "", +76, Duration, 2581, 2590, "6   weeks", "", +92849, Vehicle, 2618, 2625, "vehicle", "", +203, Travoprost, 2635, 2639, "TRAV", "", +79, PMID, 2842, 2850, "26940161", "", " \"26940161\"." diff --git a/data/gl 26940161_admin.n-triples b/data/gl 26940161_admin.n-triples new file mode 100644 index 0000000..62b8a4b --- /dev/null +++ b/data/gl 26940161_admin.n-triples @@ -0,0 +1,131 @@ +# RDF export of group: Publication + . + "Publication" . + "A Randomized Trial of Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 % as Adjunctive Therapy to Travoprost 0 . 004 ." . + "Feldman RM" . + "2016" . + "Am J Ophthalmol" . + "26940161" . + . + "Katz G" . + "McMenemy M" . + "Hubatsch DA" . + "Realini T" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To evaluate the safety and efficacy of adding fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) as adjunctive therapy to travoprost 0 . 004 % ( TRAV ) in patients with open - angle glaucoma or ocular hypertension ." . + "233" . + "6   weeks" . + . + . + . + "Adjunctive treatment with BBFC added to TRAV resulted in lower mean diurnal IOP after 6   weeks of treatment compared with vehicle added to TRAV ; this difference was both statistically and clinically significant ." . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with open - angle glaucoma or ocular hypertension" . + . + . + . + "open - angle glaucoma or ocular hypertension and with mean intraocular pressure ( IOP ) ≥ 21   mm Hg and < 32   mm Hg while receiving once - daily TRAV monotherapy" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + "Endpoint_CH" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BBFC" . + . + . + . + . + . + "Arm_Pla" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BBFC" . + . + "3 times daily" . + . + . + "Intervention_Pla" . + . + "3 times daily" . + . + . + "Intervention_trav" . + . + "once - daily" . + . +# RDF export of group: Medication + . + "Medication_BBFC" . + . + . + . + . + "Medication_Pla" . + . + . + . + . + "Medication_trav" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BBFC" . + . + "17 . 6" . + "0 . 4" . + "P < . 0001" . + "week 6" . + . + "Outcome_Pla" . + . + "20 . 7" . + "0 . 4" . + "P < . 0001" . + "week 6" . + . + "Outcome_CH_BBFC" . + . + "12 . 8" . + . + "Outcome_CH_Pla" . + . + "6 . 0" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + ", - 3 . 2" . + "P < . 0001" . + "0 . 5" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26940161_export.csv b/data/gl 26940161_export.csv new file mode 100644 index 0000000..8031480 --- /dev/null +++ b/data/gl 26940161_export.csv @@ -0,0 +1,620 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +409, 1, 1, 1, 0, 2, 0, 2, "Am" +409, 1, 2, 2, 3, 4, 3, 4, "J" +409, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +409, 1, 4, 4, 16, 17, 16, 17, "." +409, 2, 1, 5, 0, 4, 18, 22, "2016" +409, 2, 2, 6, 5, 8, 23, 26, "May" +409, 2, 3, 7, 9, 10, 27, 28, ";" +409, 2, 4, 8, 11, 14, 29, 32, "165" +409, 2, 5, 9, 15, 16, 33, 34, ":" +409, 2, 6, 10, 17, 20, 35, 38, "188" +409, 2, 7, 11, 21, 22, 39, 40, "-" +409, 2, 8, 12, 23, 25, 41, 43, "97" +409, 2, 9, 13, 26, 27, 44, 45, "." +409, 2, 10, 14, 28, 31, 46, 49, "doi" +409, 2, 11, 15, 32, 33, 50, 51, ":" +409, 2, 12, 16, 34, 36, 52, 54, "10" +409, 2, 13, 17, 37, 38, 55, 56, "." +409, 2, 14, 18, 39, 43, 57, 61, "1016" +409, 2, 15, 19, 44, 45, 62, 63, "/" +409, 2, 16, 20, 46, 47, 64, 65, "j" +409, 2, 17, 21, 48, 49, 66, 67, "." +409, 2, 18, 22, 50, 53, 68, 71, "ajo" +409, 2, 19, 23, 54, 55, 72, 73, "." +409, 2, 20, 24, 56, 60, 74, 78, "2016" +409, 2, 21, 25, 61, 62, 79, 80, "." +409, 2, 22, 26, 63, 65, 81, 83, "02" +409, 2, 23, 27, 66, 67, 84, 85, "." +409, 2, 24, 28, 68, 71, 86, 89, "026" +409, 2, 25, 29, 72, 73, 90, 91, "." +409, 3, 1, 30, 0, 4, 92, 96, "Epub" +409, 3, 2, 31, 5, 9, 97, 101, "2016" +409, 3, 3, 32, 10, 13, 102, 105, "Mar" +409, 3, 4, 33, 14, 15, 106, 107, "3" +409, 3, 5, 34, 16, 17, 108, 109, "." +409, 4, 1, 35, 0, 1, 110, 111, "A" +409, 4, 2, 36, 2, 12, 112, 122, "Randomized" +409, 4, 3, 37, 13, 18, 123, 128, "Trial" +409, 4, 4, 38, 19, 21, 129, 131, "of" +409, 4, 5, 39, 22, 27, 132, 137, "Fixed" +409, 4, 6, 40, 28, 29, 138, 139, "-" +409, 4, 7, 41, 30, 34, 140, 144, "Dose" +409, 4, 8, 42, 35, 46, 145, 156, "Combination" +409, 4, 9, 43, 47, 59, 157, 169, "Brinzolamide" +409, 4, 10, 44, 60, 61, 170, 171, "1" +409, 4, 11, 45, 62, 63, 172, 173, "%" +409, 4, 12, 46, 64, 65, 174, 175, "/" +409, 4, 13, 47, 66, 77, 176, 187, "Brimonidine" +409, 4, 14, 48, 78, 79, 188, 189, "0" +409, 4, 15, 49, 80, 81, 190, 191, "." +409, 4, 16, 50, 82, 83, 192, 193, "2" +409, 4, 17, 51, 84, 85, 194, 195, "%" +409, 4, 18, 52, 86, 88, 196, 198, "as" +409, 4, 19, 53, 89, 99, 199, 209, "Adjunctive" +409, 4, 20, 54, 100, 107, 210, 217, "Therapy" +409, 4, 21, 55, 108, 110, 218, 220, "to" +409, 4, 22, 56, 111, 121, 221, 231, "Travoprost" +409, 4, 23, 57, 122, 123, 232, 233, "0" +409, 4, 24, 58, 124, 125, 234, 235, "." +409, 4, 25, 59, 126, 129, 236, 239, "004" +409, 4, 26, 60, 130, 131, 240, 241, "." +409, 5, 1, 61, 0, 7, 242, 249, "Feldman" +409, 5, 2, 62, 8, 10, 250, 252, "RM" +409, 5, 3, 63, 11, 12, 253, 254, "(" +409, 5, 4, 64, 13, 14, 255, 256, "1" +409, 5, 5, 65, 15, 16, 257, 258, ")" +409, 5, 6, 66, 17, 18, 259, 260, "," +409, 5, 7, 67, 19, 23, 261, 265, "Katz" +409, 5, 8, 68, 24, 25, 266, 267, "G" +409, 5, 9, 69, 26, 27, 268, 269, "(" +409, 5, 10, 70, 28, 29, 270, 271, "2" +409, 5, 11, 71, 30, 31, 272, 273, ")" +409, 5, 12, 72, 32, 33, 274, 275, "," +409, 5, 13, 73, 34, 42, 276, 284, "McMenemy" +409, 5, 14, 74, 43, 44, 285, 286, "M" +409, 5, 15, 75, 45, 46, 287, 288, "(" +409, 5, 16, 76, 47, 48, 289, 290, "3" +409, 5, 17, 77, 49, 50, 291, 292, ")" +409, 5, 18, 78, 51, 52, 293, 294, "," +409, 5, 19, 79, 53, 61, 295, 303, "Hubatsch" +409, 5, 20, 80, 62, 64, 304, 306, "DA" +409, 5, 21, 81, 65, 66, 307, 308, "(" +409, 5, 22, 82, 67, 68, 309, 310, "4" +409, 5, 23, 83, 69, 70, 311, 312, ")" +409, 5, 24, 84, 71, 72, 313, 314, "," +409, 5, 25, 85, 73, 80, 315, 322, "Realini" +409, 5, 26, 86, 81, 82, 323, 324, "T" +409, 5, 27, 87, 83, 84, 325, 326, "(" +409, 5, 28, 88, 85, 86, 327, 328, "5" +409, 5, 29, 89, 87, 88, 329, 330, ")" +409, 5, 30, 90, 89, 90, 331, 332, "." +409, 6, 1, 91, 0, 6, 333, 339, "Author" +409, 6, 2, 92, 7, 18, 340, 351, "information" +409, 6, 3, 93, 19, 20, 352, 353, ":" +409, 6, 4, 94, 21, 22, 354, 355, "(" +409, 6, 5, 95, 23, 24, 356, 357, "1" +409, 6, 6, 96, 25, 26, 358, 359, ")" +409, 6, 7, 97, 27, 33, 360, 366, "Robert" +409, 6, 8, 98, 34, 39, 367, 372, "Cizik" +409, 6, 9, 99, 40, 43, 373, 376, "Eye" +409, 6, 10, 100, 44, 50, 377, 383, "Clinic" +409, 6, 11, 101, 51, 52, 384, 385, "," +409, 6, 12, 102, 53, 57, 386, 390, "Ruiz" +409, 6, 13, 103, 58, 68, 391, 401, "Department" +409, 6, 14, 104, 69, 71, 402, 404, "of" +409, 6, 15, 105, 72, 85, 405, 418, "Ophthalmology" +409, 6, 16, 106, 86, 89, 419, 422, "and" +409, 6, 17, 107, 90, 96, 423, 429, "Visual" +409, 6, 18, 108, 97, 105, 430, 438, "Sciences" +409, 6, 19, 109, 106, 107, 439, 440, "," +409, 6, 20, 110, 108, 116, 441, 449, "McGovern" +409, 6, 21, 111, 117, 124, 450, 457, "Medical" +409, 6, 22, 112, 125, 131, 458, 464, "School" +409, 6, 23, 113, 132, 134, 465, 467, "at" +409, 6, 24, 114, 135, 138, 468, 471, "The" +409, 6, 25, 115, 139, 149, 472, 482, "University" +409, 6, 26, 116, 150, 152, 483, 485, "of" +409, 6, 27, 117, 153, 158, 486, 491, "Texas" +409, 6, 28, 118, 159, 165, 492, 498, "Health" +409, 6, 29, 119, 166, 173, 499, 506, "Science" +409, 6, 30, 120, 174, 180, 507, 513, "Center" +409, 6, 31, 121, 181, 182, 514, 515, "(" +409, 6, 32, 122, 183, 191, 516, 524, "UTHealth" +409, 6, 33, 123, 192, 193, 525, 526, ")" +409, 6, 34, 124, 194, 195, 527, 528, "," +409, 6, 35, 125, 196, 203, 529, 536, "Houston" +409, 6, 36, 126, 204, 205, 537, 538, "," +409, 6, 37, 127, 206, 211, 539, 544, "Texas" +409, 6, 38, 128, 212, 213, 545, 546, "." +409, 7, 1, 129, 0, 10, 547, 557, "Electronic" +409, 7, 2, 130, 11, 18, 558, 565, "address" +409, 7, 3, 131, 19, 20, 566, 567, ":" +409, 7, 4, 132, 21, 27, 568, 574, "robert" +409, 7, 5, 133, 28, 29, 575, 576, "." +409, 7, 6, 134, 30, 31, 577, 578, "m" +409, 7, 7, 135, 32, 33, 579, 580, "." +409, 7, 8, 136, 34, 41, 581, 588, "feldman" +409, 7, 9, 137, 42, 43, 589, 590, "@" +409, 7, 10, 138, 44, 47, 591, 594, "uth" +409, 7, 11, 139, 48, 49, 595, 596, "." +409, 7, 12, 140, 50, 53, 597, 600, "tmc" +409, 7, 13, 141, 54, 55, 601, 602, "." +409, 7, 14, 142, 56, 59, 603, 606, "edu" +409, 7, 15, 143, 60, 61, 607, 608, "." +409, 8, 1, 144, 0, 1, 609, 610, "(" +409, 8, 2, 145, 2, 3, 611, 612, "2" +409, 8, 3, 146, 4, 5, 613, 614, ")" +409, 8, 4, 147, 6, 16, 615, 625, "Department" +409, 8, 5, 148, 17, 19, 626, 628, "of" +409, 8, 6, 149, 20, 33, 629, 642, "Ophthalmology" +409, 8, 7, 150, 34, 35, 643, 644, "," +409, 8, 8, 151, 36, 38, 645, 647, "St" +409, 8, 9, 152, 39, 40, 648, 649, "." +409, 8, 10, 153, 41, 47, 650, 656, "Joseph" +409, 8, 11, 154, 48, 53, 657, 662, "Mercy" +409, 8, 12, 155, 54, 61, 663, 670, "Medical" +409, 8, 13, 156, 62, 68, 671, 677, "Center" +409, 8, 14, 157, 69, 70, 678, 679, "," +409, 8, 15, 158, 71, 74, 680, 683, "Ann" +409, 8, 16, 159, 75, 80, 684, 689, "Arbor" +409, 8, 17, 160, 81, 82, 690, 691, "," +409, 8, 18, 161, 83, 91, 692, 700, "Michigan" +409, 8, 19, 162, 92, 93, 701, 702, "." +409, 9, 1, 163, 0, 1, 703, 704, "(" +409, 9, 2, 164, 2, 3, 705, 706, "3" +409, 9, 3, 165, 4, 5, 707, 708, ")" +409, 9, 4, 166, 6, 10, 709, 713, "Lone" +409, 9, 5, 167, 11, 15, 714, 718, "Star" +409, 9, 6, 168, 16, 19, 719, 722, "Eye" +409, 9, 7, 169, 20, 24, 723, 727, "Care" +409, 9, 8, 170, 25, 26, 728, 729, "," +409, 9, 9, 171, 27, 29, 730, 732, "PA" +409, 9, 10, 172, 30, 31, 733, 734, "," +409, 9, 11, 173, 32, 37, 735, 740, "Sugar" +409, 9, 12, 174, 38, 42, 741, 745, "Land" +409, 9, 13, 175, 43, 44, 746, 747, "," +409, 9, 14, 176, 45, 50, 748, 753, "Texas" +409, 9, 15, 177, 51, 52, 754, 755, "." +409, 10, 1, 178, 0, 1, 756, 757, "(" +409, 10, 2, 179, 2, 3, 758, 759, "4" +409, 10, 3, 180, 4, 5, 760, 761, ")" +409, 10, 4, 181, 6, 11, 762, 767, "Alcon" +409, 10, 5, 182, 12, 24, 768, 780, "Laboratories" +409, 10, 6, 183, 25, 26, 781, 782, "," +409, 10, 7, 184, 27, 30, 783, 786, "Inc" +409, 10, 8, 185, 31, 32, 787, 788, "," +409, 10, 9, 186, 33, 37, 789, 793, "Fort" +409, 10, 10, 187, 38, 43, 794, 799, "Worth" +409, 10, 11, 188, 44, 45, 800, 801, "," +409, 10, 12, 189, 46, 51, 802, 807, "Texas" +409, 10, 13, 190, 52, 53, 808, 809, "." +409, 11, 1, 191, 0, 1, 810, 811, "(" +409, 11, 2, 192, 2, 3, 812, 813, "5" +409, 11, 3, 193, 4, 5, 814, 815, ")" +409, 11, 4, 194, 6, 16, 816, 826, "Department" +409, 11, 5, 195, 17, 19, 827, 829, "of" +409, 11, 6, 196, 20, 33, 830, 843, "Ophthalmology" +409, 11, 7, 197, 34, 35, 844, 845, "," +409, 11, 8, 198, 36, 40, 846, 850, "West" +409, 11, 9, 199, 41, 49, 851, 859, "Virginia" +409, 11, 10, 200, 50, 60, 860, 870, "University" +409, 11, 11, 201, 61, 62, 871, 872, "," +409, 11, 12, 202, 63, 73, 873, 883, "Morgantown" +409, 11, 13, 203, 74, 75, 884, 885, "," +409, 11, 14, 204, 76, 80, 886, 890, "West" +409, 11, 15, 205, 81, 89, 891, 899, "Virginia" +409, 11, 16, 206, 90, 91, 900, 901, "." +409, 12, 1, 207, 0, 7, 902, 909, "PURPOSE" +409, 12, 2, 208, 8, 9, 910, 911, ":" +409, 12, 3, 209, 10, 12, 912, 914, "To" +409, 12, 4, 210, 13, 21, 915, 923, "evaluate" +409, 12, 5, 211, 22, 25, 924, 927, "the" +409, 12, 6, 212, 26, 32, 928, 934, "safety" +409, 12, 7, 213, 33, 36, 935, 938, "and" +409, 12, 8, 214, 37, 45, 939, 947, "efficacy" +409, 12, 9, 215, 46, 48, 948, 950, "of" +409, 12, 10, 216, 49, 55, 951, 957, "adding" +409, 12, 11, 217, 56, 61, 958, 963, "fixed" +409, 12, 12, 218, 62, 63, 964, 965, "-" +409, 12, 13, 219, 64, 75, 966, 977, "combination" +409, 12, 14, 220, 76, 88, 978, 990, "brinzolamide" +409, 12, 15, 221, 89, 90, 991, 992, "1" +409, 12, 16, 222, 91, 92, 993, 994, "%" +409, 12, 17, 223, 93, 94, 995, 996, "/" +409, 12, 18, 224, 95, 106, 997, 1008, "brimonidine" +409, 12, 19, 225, 107, 108, 1009, 1010, "0" +409, 12, 20, 226, 109, 110, 1011, 1012, "." +409, 12, 21, 227, 111, 112, 1013, 1014, "2" +409, 12, 22, 228, 113, 114, 1015, 1016, "%" +409, 12, 23, 229, 115, 116, 1017, 1018, "(" +409, 12, 24, 230, 117, 121, 1019, 1023, "BBFC" +409, 12, 25, 231, 122, 123, 1024, 1025, ")" +409, 12, 26, 232, 124, 126, 1026, 1028, "as" +409, 12, 27, 233, 127, 137, 1029, 1039, "adjunctive" +409, 12, 28, 234, 138, 145, 1040, 1047, "therapy" +409, 12, 29, 235, 146, 148, 1048, 1050, "to" +409, 12, 30, 236, 149, 159, 1051, 1061, "travoprost" +409, 12, 31, 237, 160, 161, 1062, 1063, "0" +409, 12, 32, 238, 162, 163, 1064, 1065, "." +409, 12, 33, 239, 164, 167, 1066, 1069, "004" +409, 12, 34, 240, 168, 169, 1070, 1071, "%" +409, 12, 35, 241, 170, 171, 1072, 1073, "(" +409, 12, 36, 242, 172, 176, 1074, 1078, "TRAV" +409, 12, 37, 243, 177, 178, 1079, 1080, ")" +409, 12, 38, 244, 179, 181, 1081, 1083, "in" +409, 12, 39, 245, 182, 190, 1084, 1092, "patients" +409, 12, 40, 246, 191, 195, 1093, 1097, "with" +409, 12, 41, 247, 196, 200, 1098, 1102, "open" +409, 12, 42, 248, 201, 202, 1103, 1104, "-" +409, 12, 43, 249, 203, 208, 1105, 1110, "angle" +409, 12, 44, 250, 209, 217, 1111, 1119, "glaucoma" +409, 12, 45, 251, 218, 220, 1120, 1122, "or" +409, 12, 46, 252, 221, 227, 1123, 1129, "ocular" +409, 12, 47, 253, 228, 240, 1130, 1142, "hypertension" +409, 12, 48, 254, 241, 242, 1143, 1144, "." +409, 13, 1, 255, 0, 6, 1145, 1151, "DESIGN" +409, 13, 2, 256, 7, 8, 1152, 1153, ":" +409, 13, 3, 257, 9, 20, 1154, 1165, "Multicenter" +409, 13, 4, 258, 21, 22, 1166, 1167, "," +409, 13, 5, 259, 23, 33, 1168, 1178, "randomized" +409, 13, 6, 260, 34, 35, 1179, 1180, "," +409, 13, 7, 261, 36, 42, 1181, 1187, "double" +409, 13, 8, 262, 43, 44, 1188, 1189, "-" +409, 13, 9, 263, 45, 51, 1190, 1196, "masked" +409, 13, 10, 264, 52, 53, 1197, 1198, "," +409, 13, 11, 265, 54, 62, 1199, 1207, "parallel" +409, 13, 12, 266, 63, 64, 1208, 1209, "-" +409, 13, 13, 267, 65, 70, 1210, 1215, "group" +409, 13, 14, 268, 71, 76, 1216, 1221, "phase" +409, 13, 15, 269, 77, 78, 1222, 1223, "4" +409, 13, 16, 270, 79, 87, 1224, 1232, "clinical" +409, 13, 17, 271, 88, 93, 1233, 1238, "trial" +409, 13, 18, 272, 94, 95, 1239, 1240, "." +409, 14, 1, 273, 0, 7, 1241, 1248, "METHODS" +409, 14, 2, 274, 8, 9, 1249, 1250, ":" +409, 14, 3, 275, 10, 17, 1251, 1258, "setting" +409, 14, 4, 276, 18, 19, 1259, 1260, ":" +409, 14, 5, 277, 20, 31, 1261, 1272, "Multicenter" +409, 14, 6, 278, 32, 33, 1273, 1274, ";" +409, 14, 7, 279, 34, 36, 1275, 1277, "32" +409, 14, 8, 280, 37, 42, 1278, 1283, "sites" +409, 14, 9, 281, 43, 45, 1284, 1286, "in" +409, 14, 10, 282, 46, 49, 1287, 1290, "the" +409, 14, 11, 283, 50, 56, 1291, 1297, "United" +409, 14, 12, 284, 57, 63, 1298, 1304, "States" +409, 14, 13, 285, 64, 65, 1305, 1306, "." +409, 15, 1, 286, 0, 7, 1307, 1314, "PATIENT" +409, 15, 2, 287, 8, 18, 1315, 1325, "POPULATION" +409, 15, 3, 288, 19, 20, 1326, 1327, ":" +409, 15, 4, 289, 21, 26, 1328, 1333, "Total" +409, 15, 5, 290, 27, 29, 1334, 1336, "of" +409, 15, 6, 291, 30, 33, 1337, 1340, "233" +409, 15, 7, 292, 34, 42, 1341, 1349, "patients" +409, 15, 8, 293, 43, 47, 1350, 1354, "with" +409, 15, 9, 294, 48, 52, 1355, 1359, "open" +409, 15, 10, 295, 53, 54, 1360, 1361, "-" +409, 15, 11, 296, 55, 60, 1362, 1367, "angle" +409, 15, 12, 297, 61, 69, 1368, 1376, "glaucoma" +409, 15, 13, 298, 70, 72, 1377, 1379, "or" +409, 15, 14, 299, 73, 79, 1380, 1386, "ocular" +409, 15, 15, 300, 80, 92, 1387, 1399, "hypertension" +409, 15, 16, 301, 93, 96, 1400, 1403, "and" +409, 15, 17, 302, 97, 101, 1404, 1408, "with" +409, 15, 18, 303, 102, 106, 1409, 1413, "mean" +409, 15, 19, 304, 107, 118, 1414, 1425, "intraocular" +409, 15, 20, 305, 119, 127, 1426, 1434, "pressure" +409, 15, 21, 306, 128, 129, 1435, 1436, "(" +409, 15, 22, 307, 130, 133, 1437, 1440, "IOP" +409, 15, 23, 308, 134, 135, 1441, 1442, ")" +409, 15, 24, 309, 136, 137, 1443, 1444, "≥" +409, 15, 25, 310, 138, 140, 1445, 1447, "21" +409, 15, 26, 311, 141, 142, 1448, 1449, " " +409, 15, 27, 312, 143, 145, 1450, 1452, "mm" +409, 15, 28, 313, 146, 148, 1453, 1455, "Hg" +409, 15, 29, 314, 149, 152, 1456, 1459, "and" +409, 15, 30, 315, 153, 154, 1460, 1461, "<" +409, 15, 31, 316, 155, 157, 1462, 1464, "32" +409, 15, 32, 317, 158, 159, 1465, 1466, " " +409, 15, 33, 318, 160, 162, 1467, 1469, "mm" +409, 15, 34, 319, 163, 165, 1470, 1472, "Hg" +409, 15, 35, 320, 166, 171, 1473, 1478, "while" +409, 15, 36, 321, 172, 181, 1479, 1488, "receiving" +409, 15, 37, 322, 182, 186, 1489, 1493, "once" +409, 15, 38, 323, 187, 188, 1494, 1495, "-" +409, 15, 39, 324, 189, 194, 1496, 1501, "daily" +409, 15, 40, 325, 195, 199, 1502, 1506, "TRAV" +409, 15, 41, 326, 200, 211, 1507, 1518, "monotherapy" +409, 15, 42, 327, 212, 213, 1519, 1520, "." +409, 16, 1, 328, 0, 12, 1521, 1533, "INTERVENTION" +409, 16, 2, 329, 13, 14, 1534, 1535, ":" +409, 16, 3, 330, 15, 21, 1536, 1542, "Masked" +409, 16, 4, 331, 22, 26, 1543, 1547, "BBFC" +409, 16, 5, 332, 27, 29, 1548, 1550, "or" +409, 16, 6, 333, 30, 37, 1551, 1558, "vehicle" +409, 16, 7, 334, 38, 39, 1559, 1560, "(" +409, 16, 8, 335, 40, 41, 1561, 1562, "3" +409, 16, 9, 336, 42, 47, 1563, 1568, "times" +409, 16, 10, 337, 48, 53, 1569, 1574, "daily" +409, 16, 11, 338, 54, 55, 1575, 1576, ")" +409, 16, 12, 339, 56, 66, 1577, 1587, "adjunctive" +409, 16, 13, 340, 67, 69, 1588, 1590, "to" +409, 16, 14, 341, 70, 74, 1591, 1595, "TRAV" +409, 16, 15, 342, 75, 78, 1596, 1599, "for" +409, 16, 16, 343, 79, 80, 1600, 1601, "6" +409, 16, 17, 344, 81, 82, 1602, 1603, " " +409, 16, 18, 345, 83, 88, 1604, 1609, "weeks" +409, 16, 19, 346, 89, 90, 1610, 1611, "." +409, 17, 1, 347, 0, 4, 1612, 1616, "MAIN" +409, 17, 2, 348, 5, 12, 1617, 1624, "OUTCOME" +409, 17, 3, 349, 13, 20, 1625, 1632, "MEASURE" +409, 17, 4, 350, 21, 22, 1633, 1634, ":" +409, 17, 5, 351, 23, 27, 1635, 1639, "Mean" +409, 17, 6, 352, 28, 35, 1640, 1647, "diurnal" +409, 17, 7, 353, 36, 39, 1648, 1651, "IOP" +409, 17, 8, 354, 40, 48, 1652, 1660, "averaged" +409, 17, 9, 355, 49, 53, 1661, 1665, "over" +409, 17, 10, 356, 54, 55, 1666, 1667, "8" +409, 17, 11, 357, 56, 58, 1668, 1670, "AM" +409, 17, 12, 358, 59, 60, 1671, 1672, "," +409, 17, 13, 359, 61, 63, 1673, 1675, "10" +409, 17, 14, 360, 64, 66, 1676, 1678, "AM" +409, 17, 15, 361, 67, 68, 1679, 1680, "," +409, 17, 16, 362, 69, 70, 1681, 1682, "3" +409, 17, 17, 363, 71, 73, 1683, 1685, "PM" +409, 17, 18, 364, 74, 75, 1686, 1687, "," +409, 17, 19, 365, 76, 79, 1688, 1691, "and" +409, 17, 20, 366, 80, 81, 1692, 1693, "5" +409, 17, 21, 367, 82, 84, 1694, 1696, "PM" +409, 17, 22, 368, 85, 89, 1697, 1701, "time" +409, 17, 23, 369, 90, 96, 1702, 1708, "points" +409, 17, 24, 370, 97, 99, 1709, 1711, "at" +409, 17, 25, 371, 100, 104, 1712, 1716, "week" +409, 17, 26, 372, 105, 106, 1717, 1718, "6" +409, 17, 27, 373, 107, 108, 1719, 1720, "." +409, 18, 1, 374, 0, 11, 1721, 1732, "Superiority" +409, 18, 2, 375, 12, 14, 1733, 1735, "of" +409, 18, 3, 376, 15, 19, 1736, 1740, "BBFC" +409, 18, 4, 377, 20, 21, 1741, 1742, "+" +409, 18, 5, 378, 22, 26, 1743, 1747, "TRAV" +409, 18, 6, 379, 27, 31, 1748, 1752, "over" +409, 18, 7, 380, 32, 39, 1753, 1760, "vehicle" +409, 18, 8, 381, 40, 41, 1761, 1762, "+" +409, 18, 9, 382, 42, 46, 1763, 1767, "TRAV" +409, 18, 10, 383, 47, 50, 1768, 1771, "was" +409, 18, 11, 384, 51, 56, 1772, 1777, "based" +409, 18, 12, 385, 57, 59, 1778, 1780, "on" +409, 18, 13, 386, 60, 71, 1781, 1792, "statistical" +409, 18, 14, 387, 72, 84, 1793, 1805, "significance" +409, 18, 15, 388, 85, 87, 1806, 1808, "of" +409, 18, 16, 389, 88, 89, 1809, 1810, "a" +409, 18, 17, 390, 90, 99, 1811, 1820, "treatment" +409, 18, 18, 391, 100, 110, 1821, 1831, "difference" +409, 18, 19, 392, 111, 119, 1832, 1840, "favoring" +409, 18, 20, 393, 120, 124, 1841, 1845, "BBFC" +409, 18, 21, 394, 125, 126, 1846, 1847, "+" +409, 18, 22, 395, 127, 131, 1848, 1852, "TRAV" +409, 18, 23, 396, 132, 133, 1853, 1854, "." +409, 19, 1, 397, 0, 7, 1855, 1862, "RESULTS" +409, 19, 2, 398, 8, 9, 1863, 1864, ":" +409, 19, 3, 399, 10, 14, 1865, 1869, "Mean" +409, 19, 4, 400, 15, 22, 1870, 1877, "diurnal" +409, 19, 5, 401, 23, 26, 1878, 1881, "IOP" +409, 19, 6, 402, 27, 29, 1882, 1884, "at" +409, 19, 7, 403, 30, 34, 1885, 1889, "week" +409, 19, 8, 404, 35, 36, 1890, 1891, "6" +409, 19, 9, 405, 37, 38, 1892, 1893, "(" +409, 19, 10, 406, 39, 44, 1894, 1899, "least" +409, 19, 11, 407, 45, 52, 1900, 1907, "squares" +409, 19, 12, 408, 53, 57, 1908, 1912, "mean" +409, 19, 13, 409, 58, 59, 1913, 1914, "±" +409, 19, 14, 410, 60, 68, 1915, 1923, "standard" +409, 19, 15, 411, 69, 74, 1924, 1929, "error" +409, 19, 16, 412, 75, 76, 1930, 1931, ")" +409, 19, 17, 413, 77, 80, 1932, 1935, "was" +409, 19, 18, 414, 81, 83, 1936, 1938, "17" +409, 19, 19, 415, 84, 85, 1939, 1940, "." +409, 19, 20, 416, 86, 87, 1941, 1942, "6" +409, 19, 21, 417, 88, 89, 1943, 1944, "±" +409, 19, 22, 418, 90, 91, 1945, 1946, "0" +409, 19, 23, 419, 92, 93, 1947, 1948, "." +409, 19, 24, 420, 94, 95, 1949, 1950, "4" +409, 19, 25, 421, 96, 97, 1951, 1952, " " +409, 19, 26, 422, 98, 100, 1953, 1955, "mm" +409, 19, 27, 423, 101, 103, 1956, 1958, "Hg" +409, 19, 28, 424, 104, 107, 1959, 1962, "and" +409, 19, 29, 425, 108, 110, 1963, 1965, "20" +409, 19, 30, 426, 111, 112, 1966, 1967, "." +409, 19, 31, 427, 113, 114, 1968, 1969, "7" +409, 19, 32, 428, 115, 116, 1970, 1971, "±" +409, 19, 33, 429, 117, 118, 1972, 1973, "0" +409, 19, 34, 430, 119, 120, 1974, 1975, "." +409, 19, 35, 431, 121, 122, 1976, 1977, "4" +409, 19, 36, 432, 123, 124, 1978, 1979, " " +409, 19, 37, 433, 125, 127, 1980, 1982, "mm" +409, 19, 38, 434, 128, 130, 1983, 1985, "Hg" +409, 19, 39, 435, 131, 133, 1986, 1988, "in" +409, 19, 40, 436, 134, 137, 1989, 1992, "the" +409, 19, 41, 437, 138, 142, 1993, 1997, "BBFC" +409, 19, 42, 438, 143, 144, 1998, 1999, "+" +409, 19, 43, 439, 145, 149, 2000, 2004, "TRAV" +409, 19, 44, 440, 150, 153, 2005, 2008, "and" +409, 19, 45, 441, 154, 161, 2009, 2016, "vehicle" +409, 19, 46, 442, 162, 163, 2017, 2018, "+" +409, 19, 47, 443, 164, 168, 2019, 2023, "TRAV" +409, 19, 48, 444, 169, 175, 2024, 2030, "groups" +409, 19, 49, 445, 176, 177, 2031, 2032, "," +409, 19, 50, 446, 178, 190, 2033, 2045, "respectively" +409, 19, 51, 447, 191, 192, 2046, 2047, "(" +409, 19, 52, 448, 193, 200, 2048, 2055, "between" +409, 19, 53, 449, 201, 202, 2056, 2057, "-" +409, 19, 54, 450, 203, 208, 2058, 2063, "group" +409, 19, 55, 451, 209, 219, 2064, 2074, "difference" +409, 19, 56, 452, 220, 223, 2075, 2078, ", -" +409, 19, 57, 453, 224, 225, 2079, 2080, "3" +409, 19, 58, 454, 226, 227, 2081, 2082, "." +409, 19, 59, 455, 228, 229, 2083, 2084, "2" +409, 19, 60, 456, 230, 231, 2085, 2086, "±" +409, 19, 61, 457, 232, 233, 2087, 2088, "0" +409, 19, 62, 458, 234, 235, 2089, 2090, "." +409, 19, 63, 459, 236, 237, 2091, 2092, "5" +409, 19, 64, 460, 238, 239, 2093, 2094, " " +409, 19, 65, 461, 240, 242, 2095, 2097, "mm" +409, 19, 66, 462, 243, 245, 2098, 2100, "Hg" +409, 19, 67, 463, 246, 247, 2101, 2102, ";" +409, 19, 68, 464, 248, 249, 2103, 2104, "P" +409, 19, 69, 465, 250, 251, 2105, 2106, "<" +409, 19, 70, 466, 252, 253, 2107, 2108, "." +409, 19, 71, 467, 254, 258, 2109, 2113, "0001" +409, 19, 72, 468, 259, 260, 2114, 2115, ")" +409, 19, 73, 469, 261, 262, 2116, 2117, "." +409, 20, 1, 470, 0, 11, 2118, 2129, "Superiority" +409, 20, 2, 471, 12, 14, 2130, 2132, "of" +409, 20, 3, 472, 15, 19, 2133, 2137, "BBFC" +409, 20, 4, 473, 20, 21, 2138, 2139, "+" +409, 20, 5, 474, 22, 26, 2140, 2144, "TRAV" +409, 20, 6, 475, 27, 31, 2145, 2149, "over" +409, 20, 7, 476, 32, 39, 2150, 2157, "vehicle" +409, 20, 8, 477, 40, 41, 2158, 2159, "+" +409, 20, 9, 478, 42, 46, 2160, 2164, "TRAV" +409, 20, 10, 479, 47, 50, 2165, 2168, "was" +409, 20, 11, 480, 51, 62, 2169, 2180, "established" +409, 20, 12, 481, 63, 64, 2181, 2182, "." +409, 21, 1, 482, 0, 4, 2183, 2187, "Mean" +409, 21, 2, 483, 5, 8, 2188, 2191, "and" +409, 21, 3, 484, 9, 16, 2192, 2199, "percent" +409, 21, 4, 485, 17, 24, 2200, 2207, "diurnal" +409, 21, 5, 486, 25, 28, 2208, 2211, "IOP" +409, 21, 6, 487, 29, 35, 2212, 2218, "change" +409, 21, 7, 488, 36, 40, 2219, 2223, "from" +409, 21, 8, 489, 41, 49, 2224, 2232, "baseline" +409, 21, 9, 490, 50, 54, 2233, 2237, "were" +409, 21, 10, 491, 55, 68, 2238, 2251, "significantly" +409, 21, 11, 492, 69, 76, 2252, 2259, "greater" +409, 21, 12, 493, 77, 81, 2260, 2264, "with" +409, 21, 13, 494, 82, 86, 2265, 2269, "BBFC" +409, 21, 14, 495, 87, 88, 2270, 2271, "+" +409, 21, 15, 496, 89, 93, 2272, 2276, "TRAV" +409, 21, 16, 497, 94, 102, 2277, 2285, "compared" +409, 21, 17, 498, 103, 107, 2286, 2290, "with" +409, 21, 18, 499, 108, 115, 2291, 2298, "vehicle" +409, 21, 19, 500, 116, 117, 2299, 2300, "+" +409, 21, 20, 501, 118, 122, 2301, 2305, "TRAV" +409, 21, 21, 502, 123, 124, 2306, 2307, "(" +409, 21, 22, 503, 125, 126, 2308, 2309, "P" +409, 21, 23, 504, 127, 128, 2310, 2311, "<" +409, 21, 24, 505, 129, 130, 2312, 2313, "." +409, 21, 25, 506, 131, 135, 2314, 2318, "0001" +409, 21, 26, 507, 136, 139, 2319, 2322, "for" +409, 21, 27, 508, 140, 144, 2323, 2327, "both" +409, 21, 28, 509, 145, 146, 2328, 2329, ")" +409, 21, 29, 510, 147, 148, 2330, 2331, "." +409, 22, 1, 511, 0, 12, 2332, 2344, "Conjunctival" +409, 22, 2, 512, 13, 22, 2345, 2354, "hyperemia" +409, 22, 3, 513, 23, 26, 2355, 2358, "was" +409, 22, 4, 514, 27, 30, 2359, 2362, "the" +409, 22, 5, 515, 31, 35, 2363, 2367, "most" +409, 22, 6, 516, 36, 42, 2368, 2374, "common" +409, 22, 7, 517, 43, 52, 2375, 2384, "treatment" +409, 22, 8, 518, 53, 54, 2385, 2386, "-" +409, 22, 9, 519, 55, 62, 2387, 2394, "related" +409, 22, 10, 520, 63, 70, 2395, 2402, "adverse" +409, 22, 11, 521, 71, 76, 2403, 2408, "event" +409, 22, 12, 522, 77, 79, 2409, 2411, "in" +409, 22, 13, 523, 80, 86, 2412, 2418, "either" +409, 22, 14, 524, 87, 92, 2419, 2424, "group" +409, 22, 15, 525, 93, 94, 2425, 2426, "(" +409, 22, 16, 526, 95, 99, 2427, 2431, "BBFC" +409, 22, 17, 527, 100, 101, 2432, 2433, "+" +409, 22, 18, 528, 102, 106, 2434, 2438, "TRAV" +409, 22, 19, 529, 107, 108, 2439, 2440, "," +409, 22, 20, 530, 109, 111, 2441, 2443, "12" +409, 22, 21, 531, 112, 113, 2444, 2445, "." +409, 22, 22, 532, 114, 115, 2446, 2447, "8" +409, 22, 23, 533, 116, 117, 2448, 2449, "%" +409, 22, 24, 534, 118, 119, 2450, 2451, ";" +409, 22, 25, 535, 120, 127, 2452, 2459, "vehicle" +409, 22, 26, 536, 128, 129, 2460, 2461, "+" +409, 22, 27, 537, 130, 134, 2462, 2466, "TRAV" +409, 22, 28, 538, 135, 136, 2467, 2468, "," +409, 22, 29, 539, 137, 138, 2469, 2470, "6" +409, 22, 30, 540, 139, 140, 2471, 2472, "." +409, 22, 31, 541, 141, 142, 2473, 2474, "0" +409, 22, 32, 542, 143, 144, 2475, 2476, "%" +409, 22, 33, 543, 145, 146, 2477, 2478, ")" +409, 22, 34, 544, 147, 148, 2479, 2480, "." +409, 23, 1, 545, 0, 11, 2481, 2492, "CONCLUSIONS" +409, 23, 2, 546, 12, 13, 2493, 2494, ":" +409, 23, 3, 547, 14, 24, 2495, 2505, "Adjunctive" +409, 23, 4, 548, 25, 34, 2506, 2515, "treatment" +409, 23, 5, 549, 35, 39, 2516, 2520, "with" +409, 23, 6, 550, 40, 44, 2521, 2525, "BBFC" +409, 23, 7, 551, 45, 50, 2526, 2531, "added" +409, 23, 8, 552, 51, 53, 2532, 2534, "to" +409, 23, 9, 553, 54, 58, 2535, 2539, "TRAV" +409, 23, 10, 554, 59, 67, 2540, 2548, "resulted" +409, 23, 11, 555, 68, 70, 2549, 2551, "in" +409, 23, 12, 556, 71, 76, 2552, 2557, "lower" +409, 23, 13, 557, 77, 81, 2558, 2562, "mean" +409, 23, 14, 558, 82, 89, 2563, 2570, "diurnal" +409, 23, 15, 559, 90, 93, 2571, 2574, "IOP" +409, 23, 16, 560, 94, 99, 2575, 2580, "after" +409, 23, 17, 561, 100, 101, 2581, 2582, "6" +409, 23, 18, 562, 102, 103, 2583, 2584, " " +409, 23, 19, 563, 104, 109, 2585, 2590, "weeks" +409, 23, 20, 564, 110, 112, 2591, 2593, "of" +409, 23, 21, 565, 113, 122, 2594, 2603, "treatment" +409, 23, 22, 566, 123, 131, 2604, 2612, "compared" +409, 23, 23, 567, 132, 136, 2613, 2617, "with" +409, 23, 24, 568, 137, 144, 2618, 2625, "vehicle" +409, 23, 25, 569, 145, 150, 2626, 2631, "added" +409, 23, 26, 570, 151, 153, 2632, 2634, "to" +409, 23, 27, 571, 154, 158, 2635, 2639, "TRAV" +409, 23, 28, 572, 159, 160, 2640, 2641, ";" +409, 23, 29, 573, 161, 165, 2642, 2646, "this" +409, 23, 30, 574, 166, 176, 2647, 2657, "difference" +409, 23, 31, 575, 177, 180, 2658, 2661, "was" +409, 23, 32, 576, 181, 185, 2662, 2666, "both" +409, 23, 33, 577, 186, 199, 2667, 2680, "statistically" +409, 23, 34, 578, 200, 203, 2681, 2684, "and" +409, 23, 35, 579, 204, 214, 2685, 2695, "clinically" +409, 23, 36, 580, 215, 226, 2696, 2707, "significant" +409, 23, 37, 581, 227, 228, 2708, 2709, "." +409, 24, 1, 582, 0, 9, 2710, 2719, "Copyright" +409, 24, 2, 583, 10, 11, 2720, 2721, "©" +409, 24, 3, 584, 12, 16, 2722, 2726, "2016" +409, 24, 4, 585, 17, 20, 2727, 2730, "The" +409, 24, 5, 586, 21, 28, 2731, 2738, "Authors" +409, 24, 6, 587, 29, 30, 2739, 2740, "." +409, 25, 1, 588, 0, 9, 2741, 2750, "Published" +409, 25, 2, 589, 10, 12, 2751, 2753, "by" +409, 25, 3, 590, 13, 21, 2754, 2762, "Elsevier" +409, 25, 4, 591, 22, 25, 2763, 2766, "Inc" +409, 25, 5, 592, 26, 27, 2767, 2768, "." +409, 25, 6, 593, 28, 31, 2769, 2772, "All" +409, 25, 7, 594, 32, 38, 2773, 2779, "rights" +409, 25, 8, 595, 39, 47, 2780, 2788, "reserved" +409, 25, 9, 596, 48, 49, 2789, 2790, "." +409, 26, 1, 597, 0, 3, 2791, 2794, "DOI" +409, 26, 2, 598, 4, 5, 2795, 2796, ":" +409, 26, 3, 599, 6, 8, 2797, 2799, "10" +409, 26, 4, 600, 9, 10, 2800, 2801, "." +409, 26, 5, 601, 11, 15, 2802, 2806, "1016" +409, 26, 6, 602, 16, 17, 2807, 2808, "/" +409, 26, 7, 603, 18, 19, 2809, 2810, "j" +409, 26, 8, 604, 20, 21, 2811, 2812, "." +409, 26, 9, 605, 22, 25, 2813, 2816, "ajo" +409, 26, 10, 606, 26, 27, 2817, 2818, "." +409, 26, 11, 607, 28, 32, 2819, 2823, "2016" +409, 26, 12, 608, 33, 34, 2824, 2825, "." +409, 26, 13, 609, 35, 37, 2826, 2828, "02" +409, 26, 14, 610, 38, 39, 2829, 2830, "." +409, 26, 15, 611, 40, 43, 2831, 2834, "026" +409, 26, 16, 612, 44, 48, 2835, 2839, "PMID" +409, 26, 17, 613, 49, 50, 2840, 2841, ":" +409, 26, 18, 614, 51, 59, 2842, 2850, "26940161" +409, 26, 19, 615, 60, 61, 2851, 2852, "[" +409, 26, 20, 616, 62, 69, 2853, 2860, "Indexed" +409, 26, 21, 617, 70, 73, 2861, 2864, "for" +409, 26, 22, 618, 74, 81, 2865, 2872, "MEDLINE" +409, 26, 23, 619, 82, 83, 2873, 2874, "]" diff --git a/data/gl 26940161_jshahinitiran.annodb b/data/gl 26940161_jshahinitiran.annodb new file mode 100644 index 0000000..9f206fb --- /dev/null +++ b/data/gl 26940161_jshahinitiran.annodb @@ -0,0 +1,102 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32338, Journal, 0, 15, "Am J Ophthalmol", "", +32581, PublicationYear, 18, 22, "2016", "", +32339, Title, 110, 241, "A Randomized Trial of Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 % as Adjunctive Therapy to Travoprost 0 . 004 .", "", +32340, Randomized, 112, 122, "Randomized", "", +39012, Brinz/BrimoFC, 132, 195, "Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 %", "", +32357, Drug, 132, 195, "Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 %", "BBFC", +32341, Brinzolamide, 157, 169, "Brinzolamide", "", +32344, DoseValue, 170, 171, "1", "", +32346, Percentage, 172, 173, "%", "", +32342, Brimonidine, 176, 187, "Brimonidine", "", +32345, DoseValue, 188, 193, "0 . 2", "", +32347, Percentage, 194, 195, "%", "", +32343, Travoprost, 221, 231, "Travoprost", "", +32348, DoseValue, 232, 239, "0 . 004", "", +32349, Author, 242, 252, "Feldman RM", "", +32350, Author, 261, 267, "Katz G", "", +32351, Author, 276, 286, "McMenemy M", "", +32352, Author, 295, 306, "Hubatsch DA", "", +32353, Author, 315, 324, "Realini T", "", +32354, ObjectiveDescription, 912, 1142, "To evaluate the safety and efficacy of adding fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) as adjunctive therapy to travoprost 0 . 004 % ( TRAV ) in patients with open - angle glaucoma or ocular hypertension", "", +32359, Drug, 958, 1016, "fixed - combination brinzolamide 1 % / brimonidine 0 . 2 %", "BBFC", +32355, Brinzolamide, 978, 990, "brinzolamide", "", +32360, DoseValue, 991, 992, "1", "", +32363, Percentage, 993, 994, "%", "", +32356, Brimonidine, 997, 1008, "brimonidine", "", +32362, DoseValue, 1009, 1014, "0 . 2", "", +32364, Percentage, 1015, 1016, "%", "", +32358, Drug, 1019, 1023, "BBFC", "BBFC", +32365, Travoprost, 1051, 1061, "travoprost", "", +32366, DoseValue, 1062, 1069, "0 . 004", "", +32367, Percentage, 1070, 1071, "%", "", +32394, Travoprost, 1074, 1078, "TRAV", "", +32368, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", +32369, OcularHypertension, 1123, 1142, "ocular hypertension", "", +32370, Multicenter, 1154, 1165, "Multicenter", "", +32371, Randomized, 1168, 1178, "randomized", "", +32372, DoubleBlind, 1181, 1196, "double - masked", "", +32373, Parallel, 1199, 1215, "parallel - group", "", +32374, CTDesign, 1216, 1223, "phase 4", "", +32375, Multicenter, 1261, 1272, "Multicenter", "", +32376, USA, 1291, 1304, "United States", "", +32377, NumberPatientsCT, 1337, 1340, "233", "", +32378, OpenAngleGlaucoma, 1355, 1376, "open - angle glaucoma", "", +32379, OcularHypertension, 1380, 1399, "ocular hypertension", "", +32380, Mean, 1409, 1413, "mean", "", +32385, Precondition, 1409, 1518, "mean intraocular pressure ( IOP ) ≥ 21   mm Hg and < 32   mm Hg while receiving once - daily TRAV monotherapy", "", +32381, IOP, 1414, 1434, "intraocular pressure", "", +32382, IOP, 1437, 1440, "IOP", "", +32383, mmHg, 1450, 1455, "mm Hg", "", +32384, mmHg, 1467, 1472, "mm Hg", "", +32386, Drug, 1543, 1547, "BBFC", "BBFC", +32395, Placebo, 1551, 1558, "vehicle", "", +32396, Frequency, 1561, 1574, "3 times daily", "", +32397, Travoprost, 1591, 1595, "TRAV", "", +32398, Duration, 1600, 1609, "6   weeks", "", +32434, LeastSquaresMean, 1635, 1639, "Mean", "", +32400, Diurnal_IOP, 1640, 1651, "diurnal IOP", "", +32401, TimePoint, 1712, 1718, "week 6", "", +32387, Drug, 1736, 1740, "BBFC", "BBFC", +32402, Travoprost, 1743, 1747, "TRAV", "", +32403, Placebo, 1753, 1760, "vehicle", "", +32404, Travoprost, 1763, 1767, "TRAV", "", +32388, Drug, 1841, 1845, "BBFC", "BBFC", +32405, Travoprost, 1848, 1852, "TRAV", "", +32409, LeastSquaresMean, 1865, 1869, "Mean", "", +32407, Diurnal_IOP, 1870, 1881, "diurnal IOP", "", +32408, TimePoint, 1885, 1891, "week 6", "", +32410, ResultMeasuredValue, 1936, 1942, "17 . 6", "", +32412, SdErrorResValue, 1945, 1950, "0 . 4", "", +32414, mmHg, 1953, 1958, "mm Hg", "", +32411, ResultMeasuredValue, 1963, 1969, "20 . 7", "", +32413, SdErrorResValue, 1972, 1977, "0 . 4", "", +32415, mmHg, 1980, 1985, "mm Hg", "", +32389, Drug, 1993, 1997, "BBFC", "BBFC", +32390, Drug, 2133, 2137, "BBFC", "BBFC", +32416, Travoprost, 2140, 2144, "TRAV", "", +32418, Placebo, 2150, 2157, "vehicle", "", +32417, Travoprost, 2160, 2164, "TRAV", "", +32419, LeastSquaresMean, 2183, 2187, "Mean", "", +32420, Diurnal_IOP, 2200, 2211, "diurnal IOP", "", +32391, Drug, 2265, 2269, "BBFC", "BBFC", +32421, Travoprost, 2272, 2276, "TRAV", "", +32423, Placebo, 2291, 2298, "vehicle", "", +32422, Travoprost, 2301, 2305, "TRAV", "", +32424, PValueChangeValue, 2308, 2318, "P < . 0001", "", +32425, ConjunctivalHyperemia, 2332, 2354, "Conjunctival hyperemia", "", +32392, Drug, 2427, 2431, "BBFC", "BBFC", +32426, Travoprost, 2434, 2438, "TRAV", "", +32427, PercentageAffected, 2441, 2447, "12 . 8", "", +32428, Placebo, 2452, 2459, "vehicle", "", +32429, Travoprost, 2462, 2466, "TRAV", "", +32430, PercentageAffected, 2469, 2474, "6 . 0", "", +32440, ConclusionComment, 2495, 2707, "Adjunctive treatment with BBFC added to TRAV resulted in lower mean diurnal IOP after 6   weeks of treatment compared with vehicle added to TRAV ; this difference was both statistically and clinically significant", "", +32393, Drug, 2521, 2525, "BBFC", "BBFC", +32432, Travoprost, 2535, 2539, "TRAV", "", +32433, LeastSquaresMean, 2558, 2562, "mean", "", +32435, Diurnal_IOP, 2563, 2574, "diurnal IOP", "", +32436, Duration, 2581, 2590, "6   weeks", "", +32437, Placebo, 2618, 2625, "vehicle", "", +32438, Travoprost, 2635, 2639, "TRAV", "", +32439, PMID, 2842, 2850, "26940161", "", diff --git a/data/gl 26940161_jshahinitiran.n-triples b/data/gl 26940161_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 26940161_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 26940161_tstrakeljahn.annodb b/data/gl 26940161_tstrakeljahn.annodb new file mode 100644 index 0000000..b677895 --- /dev/null +++ b/data/gl 26940161_tstrakeljahn.annodb @@ -0,0 +1,108 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8358, Journal, 0, 15, "Am J Ophthalmol", "", +8359, PublicationYear, 18, 22, "2016", "", +8397, Title, 110, 241, "A Randomized Trial of Fixed - Dose Combination Brinzolamide 1 % / Brimonidine 0 . 2 % as Adjunctive Therapy to Travoprost 0 . 004 .", "", +8360, Randomized, 112, 122, "Randomized", "", +8361, Brinzolamide, 157, 169, "Brinzolamide", "", +8363, DoseValue, 170, 171, "1", "", +8366, Percentage, 172, 173, "%", "", +8362, Brimonidine, 176, 187, "Brimonidine", "", +8364, DoseValue, 188, 193, "0 . 2", "", +8367, Percentage, 194, 195, "%", "", +29844, Drug, 221, 231, "Travoprost", "Travoprost", +8365, DoseValue, 232, 239, "0 . 004", "", +8369, Author, 242, 252, "Feldman RM", "", +8370, Author, 261, 267, "Katz G", "", +8371, Author, 276, 286, "McMenemy M", "", +8372, Author, 295, 306, "Hubatsch DA", "", +8373, Author, 315, 324, "Realini T", "", +8374, USA, 539, 544, "Texas", "", +8375, USA, 692, 700, "Michigan", "", +8376, USA, 748, 753, "Texas", "", +8377, USA, 802, 807, "Texas", "", +8378, USA, 886, 899, "West Virginia", "", +29862, ObjectiveDescription, 912, 1144, "To evaluate the safety and efficacy of adding fixed - combination brinzolamide 1 % / brimonidine 0 . 2 % ( BBFC ) as adjunctive therapy to travoprost 0 . 004 % ( TRAV ) in patients with open - angle glaucoma or ocular hypertension .", "", +8379, Brinzolamide, 978, 990, "brinzolamide", "", +8384, DoseValue, 991, 992, "1", "", +8387, Percentage, 993, 994, "%", "", +8380, Brimonidine, 997, 1008, "brimonidine", "", +8385, DoseValue, 1009, 1014, "0 . 2", "", +8388, Percentage, 1015, 1016, "%", "", +29863, Drug, 1019, 1023, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29846, Drug, 1051, 1061, "travoprost", "Travoprost", +8386, DoseValue, 1062, 1069, "0 . 004", "", +8389, Percentage, 1070, 1071, "%", "", +29847, Drug, 1074, 1078, "TRAV", "Travoprost", +8390, OpenAngleGlaucoma, 1098, 1119, "open - angle glaucoma", "", +8391, OcularHypertension, 1123, 1142, "ocular hypertension", "", +8392, Multicenter, 1154, 1165, "Multicenter", "", +8393, Randomized, 1168, 1178, "randomized", "", +8394, DoubleBlind, 1181, 1196, "double - masked", "", +8395, Parallel, 1199, 1207, "parallel", "", +8396, ClinicalTrial, 1224, 1238, "clinical trial", "", +8398, Multicenter, 1261, 1272, "Multicenter", "", +8399, USA, 1291, 1304, "United States", "", +8400, NumberPatientsCT, 1337, 1340, "233", "", +8401, OpenAngleGlaucoma, 1355, 1376, "open - angle glaucoma", "", +8402, OcularHypertension, 1380, 1399, "ocular hypertension", "", +8403, Mean, 1409, 1413, "mean", "", +8408, Precondition, 1409, 1518, "mean intraocular pressure ( IOP ) ≥ 21   mm Hg and < 32   mm Hg while receiving once - daily TRAV monotherapy", "", +8404, IOP, 1414, 1434, "intraocular pressure", "", +8405, IOP, 1437, 1440, "IOP", "", +8406, mmHg, 1450, 1455, "mm Hg", "", +8407, mmHg, 1467, 1472, "mm Hg", "", +29864, Drug, 1543, 1547, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8417, Placebo, 1551, 1558, "vehicle", "", +8418, Frequency, 1561, 1574, "3 times daily", "", +29848, Drug, 1591, 1595, "TRAV", "Travoprost", +8420, Duration, 1600, 1609, "6   weeks", "", +8421, Mean, 1635, 1639, "Mean", "", +8422, Diurnal_IOP, 1640, 1651, "diurnal IOP", "", +29865, Drug, 1736, 1740, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29849, Drug, 1743, 1747, "TRAV", "Travoprost", +29850, Drug, 1763, 1767, "TRAV", "Travoprost", +29866, Drug, 1841, 1845, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29851, Drug, 1848, 1852, "TRAV", "Travoprost", +8432, Mean, 1865, 1869, "Mean", "", +8433, Diurnal_IOP, 1870, 1881, "diurnal IOP", "", +8434, TimePoint, 1885, 1891, "week 6", "", +8435, ResultMeasuredValue, 1936, 1942, "17 . 6", "", +8437, SdDevChangeValue, 1943, 1950, "± 0 . 4", "", +8438, mmHg, 1953, 1958, "mm Hg", "", +8436, ResultMeasuredValue, 1963, 1969, "20 . 7", "", +8440, SdDevChangeValue, 1970, 1977, "± 0 . 4", "", +8439, mmHg, 1980, 1985, "mm Hg", "", +29867, Drug, 1993, 1997, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29852, Drug, 2000, 2004, "TRAV", "Travoprost", +8441, Placebo, 2009, 2016, "vehicle", "", +29853, Drug, 2019, 2023, "TRAV", "Travoprost", +8442, DiffGroupAbsValue, 2079, 2084, "3 . 2", "", +8443, SdDevDiff, 2085, 2092, "± 0 . 5", "", +8444, mmHg, 2095, 2100, "mm Hg", "", +8445, PvalueDiff, 2103, 2113, "P < . 0001", "", +29868, Drug, 2133, 2137, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29854, Drug, 2140, 2144, "TRAV", "Travoprost", +8446, Placebo, 2150, 2157, "vehicle", "", +29855, Drug, 2160, 2164, "TRAV", "Travoprost", +8447, Mean, 2183, 2187, "Mean", "", +8448, Diurnal_IOP, 2200, 2211, "diurnal IOP", "", +29869, Drug, 2265, 2269, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29856, Drug, 2272, 2276, "TRAV", "Travoprost", +29857, Drug, 2301, 2305, "TRAV", "Travoprost", +8449, PValueChangeValue, 2308, 2318, "P < . 0001", "", +8450, ConjunctivalHyperemia, 2332, 2354, "Conjunctival hyperemia", "", +29870, Drug, 2427, 2431, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29858, Drug, 2434, 2438, "TRAV", "Travoprost", +8451, PercentageAffected, 2441, 2447, "12 . 8", "", +8457, Placebo, 2452, 2459, "vehicle", "", +29859, Drug, 2462, 2466, "TRAV", "Travoprost", +8452, PercentageAffected, 2469, 2474, "6 . 0", "", +8463, ConclusionComment, 2495, 2707, "Adjunctive treatment with BBFC added to TRAV resulted in lower mean diurnal IOP after 6   weeks of treatment compared with vehicle added to TRAV ; this difference was both statistically and clinically significant", "", +29871, Drug, 2521, 2525, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +29860, Drug, 2535, 2539, "TRAV", "Travoprost", +8459, Mean, 2558, 2562, "mean", "", +8460, Diurnal_IOP, 2563, 2574, "diurnal IOP", "", +8461, Duration, 2581, 2590, "6   weeks", "", +8462, Placebo, 2618, 2625, "vehicle", "", +29861, Drug, 2635, 2639, "TRAV", "Travoprost", +8464, PMID, 2842, 2850, "26940161", "", diff --git a/data/gl 26940161_tstrakeljahn.n-triples b/data/gl 26940161_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 26940161_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27050347_admin.annodb b/data/gl 27050347_admin.annodb new file mode 100644 index 0000000..0cca6c5 --- /dev/null +++ b/data/gl 27050347_admin.annodb @@ -0,0 +1,91 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 21, "Indian J Ophthalmol .", "", " \"Indian J Ophthalmol .\"." +1, PublicationYear, 22, 26, "2016", "", " \"2016\"." +56, Title, 96, 222, "Brinzolamide / timolol versus dorzolamide / timolol fixed combinations : A hospital - based , prospective , randomized study .", "", " \"Brinzolamide / timolol versus dorzolamide / timolol fixed combinations : A hospital - based , prospective , randomized study .\"." +53665, Brinz/TimFC, 96, 118, "Brinzolamide / timolol", "", " ." +53681, Dorz/TimFC, 126, 147, "dorzolamide / timolol", "", " ." +53700, SingleCenter, 171, 187, "hospital - based", "", " ." +53680, Prospective, 190, 201, "prospective", "", " ." +7, Randomized, 204, 214, "randomized", "", " ." +8, Author, 223, 232, "Galose MS", "", " \"Galose MS\"." +9, Author, 235, 245, "Elsaied HM", "", " \"Elsaied HM\"." +10, Author, 248, 256, "Macky TA", "", " \"Macky TA\"." +11, Author, 265, 273, "Fouad PH", "", " \"Fouad PH\"." +12, Egypt, 422, 427, "Egypt", "", " ." +19, ObjectiveDescription, 440, 609, "To compare the efficacy and tolerability of brinzolamide / timolol ( BT ) and dorzolamide / timolol ( DT ) fixed combinations on intraocular pressure ( IOP ) reduction .", "", " \"To compare the efficacy and tolerability of brinzolamide / timolol ( BT ) and dorzolamide / timolol ( DT ) fixed combinations on intraocular pressure ( IOP ) reduction .\"." +53670, Brinz/TimFC, 484, 506, "brinzolamide / timolol", "", +53671, Brinz/TimFC, 509, 511, "BT", "", +53683, Dorz/TimFC, 518, 539, "dorzolamide / timolol", "", +53682, Dorz/TimFC, 542, 544, "DT", "", +17, IOP, 569, 589, "intraocular pressure", "", +18, IOP, 592, 595, "IOP", "", +54365, Precondition, 620, 688, "Patients with primary open angle glaucoma or normal tension glaucoma", "", " \"Patients with primary open angle glaucoma or normal tension glaucoma\"." +114, Primary_OpenAngleGlaucoma, 634, 661, "primary open angle glaucoma", "", " ." +115, Glaucoma, 665, 688, "normal tension glaucoma", "", " . ." +21, Glaucoma, 680, 688, "glaucoma", "", " . ." +22, Randomized, 694, 704, "randomized", "", +53669, Brinz/TimFC, 723, 725, "BT", "", +53684, Dorz/TimFC, 729, 731, "DT", "", +117, IOP, 734, 738, "IOPs", "", +118, TimePoint, 756, 764, "baseline", "", +119, TimePoint, 767, 774, "2 weeks", "", +120, TimePoint, 781, 801, "1 , 2 , and 3 months", "", +53695, TimePoint, 785, 801, "2 , and 3 months", "", +53696, TimePoint, 793, 801, "3 months", "", +23, Mean, 842, 846, "mean", "", " . ." +24, IOP, 857, 860, "IOP", "", " . ." +123, NumberPatientsCT, 982, 997, "Seventy - three", "", " \"Seventy - three\"." +124, NumberPatientsArm, 1035, 1037, "37", "", " \"37\"." +53672, Brinz/TimFC, 1046, 1048, "BT", "", +125, NumberPatientsArm, 1059, 1061, "36", "", " \"36\"." +53685, Dorz/TimFC, 1070, 1072, "DT", "", +126, Mean, 1090, 1094, "mean", "", +26, IOP, 1095, 1098, "IOP", "", +27, BaseLineValue, 1104, 1111, "24 . 14", "", " \"24 . 14\". \"24 . 14\"." +28, SdDevBL, 1112, 1119, "± 4 . 5", "", " \"± 4 . 5\". \"± 4 . 5\"." +29, BaseLineValue, 1124, 1131, "29 . 53", "", " \"29 . 53\". \"29 . 53\"." +30, SdDevBL, 1132, 1135, "± 6", "", " \"± 6\". \"± 6\"." +31, mmHg, 1136, 1140, "mmHg", "", " ." +53673, Brinz/TimFC, 1145, 1147, "BT", "", +53686, Dorz/TimFC, 1152, 1154, "DT", "", +53697, PvalueDiff, 1172, 1183, "P < 0 . 001", "", +53674, Brinz/TimFC, 1193, 1195, "BT", "", +53687, Dorz/TimFC, 1200, 1202, "DT", "", +131, Mean, 1238, 1242, "mean", "", +34, IOP, 1243, 1246, "IOP", "", +53698, TimePoint, 1263, 1271, "baseline", "", +33, PValueChangeValue, 1319, 1330, "P < 0 . 001", "", +53688, Dorz/TimFC, 1335, 1337, "DT", "", +35, Mean, 1355, 1359, "mean", "", +36, IOP, 1360, 1363, "IOP", "", +53675, Brinz/TimFC, 1394, 1396, "BT", "", +37, TimePoint, 1450, 1457, "2 weeks", "", +38, PvalueDiff, 1460, 1471, "P = 0 . 037", "", +139, Mean, 1476, 1480, "Mean", "", +39, IOP, 1495, 1498, "IOP", "", +40, RelativeReduction, 1513, 1520, "24 . 35", "", " \"24 . 35\"." +41, RelativeReduction, 1527, 1534, "46 . 33", "", " \"46 . 33\"." +42, TimePoint, 1540, 1547, "2 weeks", "", " \"2 weeks\". \"2 weeks\"." +43, PValueChangeValue, 1550, 1561, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\"." +45, RelativeReduction, 1570, 1577, "24 . 65", "", " \"24 . 65\"." +46, RelativeReduction, 1584, 1586, "47", "", " \"47\"." +47, TimePoint, 1592, 1600, "3 months", "", " \"3 months\". \"3 months\"." +44, PValueChangeValue, 1603, 1614, "P < 0 . 001", "", " \"P < 0 . 001\". \"P < 0 . 001\"." +53679, Brinz/TimFC, 1621, 1623, "BT", "", +53699, Dorz/TimFC, 1624, 1630, "and DT", "", +53689, Dorz/TimFC, 1698, 1700, "DT", "", +53676, Brinz/TimFC, 1710, 1712, "BT", "", +53692, EndPointDescription, 1718, 1741, "complete ocular comfort", "", " . ." +53693, ObservedResult, 1742, 1776, "without any ocular adverse effects", "", " \"without any ocular adverse effects\". \"without any ocular adverse effects\"." +48, NumberAffected, 1780, 1782, "31", "", " \"31\"." +49, PercentageAffected, 1794, 1800, "81 . 1", "", " \"81 . 1\"." +53690, Dorz/TimFC, 1808, 1810, "DT", "", +50, NumberAffected, 1821, 1823, "11", "", " \"11\"." +51, PercentageAffected, 1835, 1841, "29 . 7", "", " \"29 . 7\"." +53678, Brinz/TimFC, 1849, 1851, "BT", "", +53694, PvalueDiff, 1860, 1871, "P < 0 . 001", "", " \"P < 0 . 001\"." +150, ConclusionComment, 1889, 2038, "Both drops provide effective IOP reduction which was greater , and patients were more likely to achieve lower target pressures with DT than with BT .", "", " \"Both drops provide effective IOP reduction which was greater , and patients were more likely to achieve lower target pressures with DT than with BT .\"." +53, IOP, 1918, 1921, "IOP", "", +53691, Dorz/TimFC, 2021, 2023, "DT", "", +53677, Brinz/TimFC, 2034, 2036, "BT", "", +55, PMID, 2104, 2112, "27050347", "", " \"27050347\"." diff --git a/data/gl 27050347_admin.n-triples b/data/gl 27050347_admin.n-triples new file mode 100644 index 0000000..c719ad8 --- /dev/null +++ b/data/gl 27050347_admin.n-triples @@ -0,0 +1,145 @@ +# RDF export of group: Publication + . + "Publication" . + "Brinzolamide / timolol versus dorzolamide / timolol fixed combinations : A hospital - based , prospective , randomized study ." . + "Galose MS" . + "2016" . + "Indian J Ophthalmol ." . + "27050347" . + . + "Elsaied HM" . + "Macky TA" . + "Fouad PH" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the efficacy and tolerability of brinzolamide / timolol ( BT ) and dorzolamide / timolol ( DT ) fixed combinations on intraocular pressure ( IOP ) reduction ." . + "Seventy - three" . + . + . + . + "Both drops provide effective IOP reduction which was greater , and patients were more likely to achieve lower target pressures with DT than with BT ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "Patients with primary open angle glaucoma or normal tension glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_comf" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_BTFC" . + "37" . + . + . + . + . + . + . + "Arm_DTFC" . + "36" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BTFC" . + . + . + . + "Intervention_DTFC" . + . + . +# RDF export of group: Medication + . + "Medication_BTFC" . + . + . + . + . + "Medication_DTFC" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_BTFC_2weeks" . + . + "24 . 14" . + "± 4 . 5" . + "24 . 35" . + "P < 0 . 001" . + "2 weeks" . + . + "Outcome_BTFC_3months" . + . + "24 . 14" . + "± 4 . 5" . + "24 . 65" . + "P < 0 . 001" . + "3 months" . + . + "Outcome_DTFC_2weeks" . + . + "29 . 53" . + "± 6" . + "46 . 33" . + "P < 0 . 001" . + "2 weeks" . + . + "Outcome_DTFC_3months" . + . + "29 . 53" . + "± 6" . + "47" . + "P < 0 . 001" . + "3 months" . + . + "Outcome_BTFC_comf" . + . + "11" . + "29 . 7" . + "without any ocular adverse effects" . + . + "Outcome_DTFC_comf" . + . + "31" . + "81 . 1" . + "without any ocular adverse effects" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_comf" . + "P < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27050347_export.csv b/data/gl 27050347_export.csv new file mode 100644 index 0000000..3c08682 --- /dev/null +++ b/data/gl 27050347_export.csv @@ -0,0 +1,459 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +408, 1, 1, 1, 0, 6, 0, 6, "Indian" +408, 1, 2, 2, 7, 8, 7, 8, "J" +408, 1, 3, 3, 9, 19, 9, 19, "Ophthalmol" +408, 1, 4, 4, 20, 21, 20, 21, "." +408, 2, 1, 5, 0, 4, 22, 26, "2016" +408, 2, 2, 6, 5, 8, 27, 30, "Feb" +408, 2, 3, 7, 9, 10, 31, 32, ";" +408, 2, 4, 8, 11, 13, 33, 35, "64" +408, 2, 5, 9, 14, 15, 36, 37, "(" +408, 2, 6, 10, 16, 17, 38, 39, "2" +408, 2, 7, 11, 18, 19, 40, 41, ")" +408, 2, 8, 12, 20, 21, 42, 43, ":" +408, 2, 9, 13, 22, 25, 44, 47, "127" +408, 2, 10, 14, 26, 27, 48, 49, "-" +408, 2, 11, 15, 28, 30, 50, 52, "31" +408, 2, 12, 16, 31, 32, 53, 54, "." +408, 2, 13, 17, 33, 36, 55, 58, "doi" +408, 2, 14, 18, 37, 38, 59, 60, ":" +408, 2, 15, 19, 39, 41, 61, 63, "10" +408, 2, 16, 20, 42, 43, 64, 65, "." +408, 2, 17, 21, 44, 48, 66, 70, "4103" +408, 2, 18, 22, 49, 50, 71, 72, "/" +408, 2, 19, 23, 51, 55, 73, 77, "0301" +408, 2, 20, 24, 56, 57, 78, 79, "-" +408, 2, 21, 25, 58, 62, 80, 84, "4738" +408, 2, 22, 26, 63, 64, 85, 86, "." +408, 2, 23, 27, 65, 71, 87, 93, "179718" +408, 2, 24, 28, 72, 73, 94, 95, "." +408, 3, 1, 29, 0, 12, 96, 108, "Brinzolamide" +408, 3, 2, 30, 13, 14, 109, 110, "/" +408, 3, 3, 31, 15, 22, 111, 118, "timolol" +408, 3, 4, 32, 23, 29, 119, 125, "versus" +408, 3, 5, 33, 30, 41, 126, 137, "dorzolamide" +408, 3, 6, 34, 42, 43, 138, 139, "/" +408, 3, 7, 35, 44, 51, 140, 147, "timolol" +408, 3, 8, 36, 52, 57, 148, 153, "fixed" +408, 3, 9, 37, 58, 70, 154, 166, "combinations" +408, 3, 10, 38, 71, 72, 167, 168, ":" +408, 3, 11, 39, 73, 74, 169, 170, "A" +408, 3, 12, 40, 75, 83, 171, 179, "hospital" +408, 3, 13, 41, 84, 85, 180, 181, "-" +408, 3, 14, 42, 86, 91, 182, 187, "based" +408, 3, 15, 43, 92, 93, 188, 189, "," +408, 3, 16, 44, 94, 105, 190, 201, "prospective" +408, 3, 17, 45, 106, 107, 202, 203, "," +408, 3, 18, 46, 108, 118, 204, 214, "randomized" +408, 3, 19, 47, 119, 124, 215, 220, "study" +408, 3, 20, 48, 125, 126, 221, 222, "." +408, 4, 1, 49, 0, 6, 223, 229, "Galose" +408, 4, 2, 50, 7, 9, 230, 232, "MS" +408, 4, 3, 51, 10, 11, 233, 234, "," +408, 4, 4, 52, 12, 19, 235, 242, "Elsaied" +408, 4, 5, 53, 20, 22, 243, 245, "HM" +408, 4, 6, 54, 23, 24, 246, 247, "," +408, 4, 7, 55, 25, 30, 248, 253, "Macky" +408, 4, 8, 56, 31, 33, 254, 256, "TA" +408, 4, 9, 57, 34, 35, 257, 258, "(" +408, 4, 10, 58, 36, 37, 259, 260, "1" +408, 4, 11, 59, 38, 39, 261, 262, ")" +408, 4, 12, 60, 40, 41, 263, 264, "," +408, 4, 13, 61, 42, 47, 265, 270, "Fouad" +408, 4, 14, 62, 48, 50, 271, 273, "PH" +408, 4, 15, 63, 51, 52, 274, 275, "." +408, 5, 1, 64, 0, 6, 276, 282, "Author" +408, 5, 2, 65, 7, 18, 283, 294, "information" +408, 5, 3, 66, 19, 20, 295, 296, ":" +408, 5, 4, 67, 21, 22, 297, 298, "(" +408, 5, 5, 68, 23, 24, 299, 300, "1" +408, 5, 6, 69, 25, 26, 301, 302, ")" +408, 5, 7, 70, 27, 37, 303, 313, "Department" +408, 5, 8, 71, 38, 40, 314, 316, "of" +408, 5, 9, 72, 41, 54, 317, 330, "Ophthalmology" +408, 5, 10, 73, 55, 56, 331, 332, "," +408, 5, 11, 74, 57, 67, 333, 343, "Diagnostic" +408, 5, 12, 75, 68, 73, 344, 349, "Laser" +408, 5, 13, 76, 74, 78, 350, 354, "Unit" +408, 5, 14, 77, 79, 80, 355, 356, "," +408, 5, 15, 78, 81, 85, 357, 361, "Kasr" +408, 5, 16, 79, 86, 88, 362, 364, "El" +408, 5, 17, 80, 89, 93, 365, 369, "Aini" +408, 5, 18, 81, 94, 102, 370, 378, "Hospital" +408, 5, 19, 82, 103, 104, 379, 380, "," +408, 5, 20, 83, 105, 110, 381, 386, "Cairo" +408, 5, 21, 84, 111, 121, 387, 397, "University" +408, 5, 22, 85, 122, 123, 398, 399, "," +408, 5, 23, 86, 124, 126, 400, 402, "El" +408, 5, 24, 87, 127, 128, 403, 404, "-" +408, 5, 25, 88, 129, 135, 405, 411, "Manial" +408, 5, 26, 89, 136, 137, 412, 413, "," +408, 5, 27, 90, 138, 143, 414, 419, "Cairo" +408, 5, 28, 91, 144, 145, 420, 421, "," +408, 5, 29, 92, 146, 151, 422, 427, "Egypt" +408, 5, 30, 93, 152, 153, 428, 429, "." +408, 6, 1, 94, 0, 7, 430, 437, "PURPOSE" +408, 6, 2, 95, 8, 9, 438, 439, ":" +408, 6, 3, 96, 10, 12, 440, 442, "To" +408, 6, 4, 97, 13, 20, 443, 450, "compare" +408, 6, 5, 98, 21, 24, 451, 454, "the" +408, 6, 6, 99, 25, 33, 455, 463, "efficacy" +408, 6, 7, 100, 34, 37, 464, 467, "and" +408, 6, 8, 101, 38, 50, 468, 480, "tolerability" +408, 6, 9, 102, 51, 53, 481, 483, "of" +408, 6, 10, 103, 54, 66, 484, 496, "brinzolamide" +408, 6, 11, 104, 67, 68, 497, 498, "/" +408, 6, 12, 105, 69, 76, 499, 506, "timolol" +408, 6, 13, 106, 77, 78, 507, 508, "(" +408, 6, 14, 107, 79, 81, 509, 511, "BT" +408, 6, 15, 108, 82, 83, 512, 513, ")" +408, 6, 16, 109, 84, 87, 514, 517, "and" +408, 6, 17, 110, 88, 99, 518, 529, "dorzolamide" +408, 6, 18, 111, 100, 101, 530, 531, "/" +408, 6, 19, 112, 102, 109, 532, 539, "timolol" +408, 6, 20, 113, 110, 111, 540, 541, "(" +408, 6, 21, 114, 112, 114, 542, 544, "DT" +408, 6, 22, 115, 115, 116, 545, 546, ")" +408, 6, 23, 116, 117, 122, 547, 552, "fixed" +408, 6, 24, 117, 123, 135, 553, 565, "combinations" +408, 6, 25, 118, 136, 138, 566, 568, "on" +408, 6, 26, 119, 139, 150, 569, 580, "intraocular" +408, 6, 27, 120, 151, 159, 581, 589, "pressure" +408, 6, 28, 121, 160, 161, 590, 591, "(" +408, 6, 29, 122, 162, 165, 592, 595, "IOP" +408, 6, 30, 123, 166, 167, 596, 597, ")" +408, 6, 31, 124, 168, 177, 598, 607, "reduction" +408, 6, 32, 125, 178, 179, 608, 609, "." +408, 7, 1, 126, 0, 7, 610, 617, "METHODS" +408, 7, 2, 127, 8, 9, 618, 619, ":" +408, 7, 3, 128, 10, 18, 620, 628, "Patients" +408, 7, 4, 129, 19, 23, 629, 633, "with" +408, 7, 5, 130, 24, 31, 634, 641, "primary" +408, 7, 6, 131, 32, 36, 642, 646, "open" +408, 7, 7, 132, 37, 42, 647, 652, "angle" +408, 7, 8, 133, 43, 51, 653, 661, "glaucoma" +408, 7, 9, 134, 52, 54, 662, 664, "or" +408, 7, 10, 135, 55, 61, 665, 671, "normal" +408, 7, 11, 136, 62, 69, 672, 679, "tension" +408, 7, 12, 137, 70, 78, 680, 688, "glaucoma" +408, 7, 13, 138, 79, 83, 689, 693, "were" +408, 7, 14, 139, 84, 94, 694, 704, "randomized" +408, 7, 15, 140, 95, 97, 705, 707, "to" +408, 7, 16, 141, 98, 105, 708, 715, "receive" +408, 7, 17, 142, 106, 112, 716, 722, "either" +408, 7, 18, 143, 113, 115, 723, 725, "BT" +408, 7, 19, 144, 116, 118, 726, 728, "or" +408, 7, 20, 145, 119, 121, 729, 731, "DT" +408, 7, 21, 146, 122, 123, 732, 733, "." +408, 8, 1, 147, 0, 4, 734, 738, "IOPs" +408, 8, 2, 148, 5, 9, 739, 743, "were" +408, 8, 3, 149, 10, 18, 744, 752, "measured" +408, 8, 4, 150, 19, 21, 753, 755, "at" +408, 8, 5, 151, 22, 30, 756, 764, "baseline" +408, 8, 6, 152, 31, 32, 765, 766, "," +408, 8, 7, 153, 33, 34, 767, 768, "2" +408, 8, 8, 154, 35, 40, 769, 774, "weeks" +408, 8, 9, 155, 41, 42, 775, 776, "," +408, 8, 10, 156, 43, 46, 777, 780, "and" +408, 8, 11, 157, 47, 48, 781, 782, "1" +408, 8, 12, 158, 49, 50, 783, 784, "," +408, 8, 13, 159, 51, 52, 785, 786, "2" +408, 8, 14, 160, 53, 54, 787, 788, "," +408, 8, 15, 161, 55, 58, 789, 792, "and" +408, 8, 16, 162, 59, 60, 793, 794, "3" +408, 8, 17, 163, 61, 67, 795, 801, "months" +408, 8, 18, 164, 68, 69, 802, 803, "." +408, 9, 1, 165, 0, 3, 804, 807, "The" +408, 9, 2, 166, 4, 11, 808, 815, "primary" +408, 9, 3, 167, 12, 19, 816, 823, "outcome" +408, 9, 4, 168, 20, 28, 824, 832, "measures" +408, 9, 5, 169, 29, 33, 833, 837, "were" +408, 9, 6, 170, 34, 37, 838, 841, "the" +408, 9, 7, 171, 38, 42, 842, 846, "mean" +408, 9, 8, 172, 43, 49, 847, 853, "change" +408, 9, 9, 173, 50, 52, 854, 856, "in" +408, 9, 10, 174, 53, 56, 857, 860, "IOP" +408, 9, 11, 175, 57, 61, 861, 865, "from" +408, 9, 12, 176, 62, 70, 866, 874, "baseline" +408, 9, 13, 177, 71, 73, 875, 877, "at" +408, 9, 14, 178, 74, 78, 878, 882, "each" +408, 9, 15, 179, 79, 84, 883, 888, "visit" +408, 9, 16, 180, 85, 86, 889, 890, "." +408, 10, 1, 181, 0, 9, 891, 900, "Secondary" +408, 10, 2, 182, 10, 17, 901, 908, "outcome" +408, 10, 3, 183, 18, 26, 909, 917, "measures" +408, 10, 4, 184, 27, 35, 918, 926, "included" +408, 10, 5, 185, 36, 39, 927, 930, "the" +408, 10, 6, 186, 40, 52, 931, 943, "tolerability" +408, 10, 7, 187, 53, 55, 944, 946, "of" +408, 10, 8, 188, 56, 60, 947, 951, "each" +408, 10, 9, 189, 61, 66, 952, 957, "fixed" +408, 10, 10, 190, 67, 78, 958, 969, "combination" +408, 10, 11, 191, 79, 80, 970, 971, "." +408, 11, 1, 192, 0, 7, 972, 979, "RESULTS" +408, 11, 2, 193, 8, 9, 980, 981, ":" +408, 11, 3, 194, 10, 17, 982, 989, "Seventy" +408, 11, 4, 195, 18, 19, 990, 991, "-" +408, 11, 5, 196, 20, 25, 992, 997, "three" +408, 11, 6, 197, 26, 34, 998, 1006, "patients" +408, 11, 7, 198, 35, 36, 1007, 1008, "(" +408, 11, 8, 199, 37, 39, 1009, 1011, "73" +408, 11, 9, 200, 40, 44, 1012, 1016, "eyes" +408, 11, 10, 201, 45, 46, 1017, 1018, ")" +408, 11, 11, 202, 47, 51, 1019, 1023, "were" +408, 11, 12, 203, 52, 60, 1024, 1032, "included" +408, 11, 13, 204, 61, 62, 1033, 1034, ";" +408, 11, 14, 205, 63, 65, 1035, 1037, "37" +408, 11, 15, 206, 66, 70, 1038, 1042, "eyes" +408, 11, 16, 207, 71, 73, 1043, 1045, "in" +408, 11, 17, 208, 74, 76, 1046, 1048, "BT" +408, 11, 18, 209, 77, 82, 1049, 1054, "group" +408, 11, 19, 210, 83, 86, 1055, 1058, "and" +408, 11, 20, 211, 87, 89, 1059, 1061, "36" +408, 11, 21, 212, 90, 94, 1062, 1066, "eyes" +408, 11, 22, 213, 95, 97, 1067, 1069, "in" +408, 11, 23, 214, 98, 100, 1070, 1072, "DT" +408, 11, 24, 215, 101, 106, 1073, 1078, "group" +408, 11, 25, 216, 107, 108, 1079, 1080, "." +408, 12, 1, 217, 0, 8, 1081, 1089, "Baseline" +408, 12, 2, 218, 9, 13, 1090, 1094, "mean" +408, 12, 3, 219, 14, 17, 1095, 1098, "IOP" +408, 12, 4, 220, 18, 22, 1099, 1103, "were" +408, 12, 5, 221, 23, 25, 1104, 1106, "24" +408, 12, 6, 222, 26, 27, 1107, 1108, "." +408, 12, 7, 223, 28, 30, 1109, 1111, "14" +408, 12, 8, 224, 31, 32, 1112, 1113, "±" +408, 12, 9, 225, 33, 34, 1114, 1115, "4" +408, 12, 10, 226, 35, 36, 1116, 1117, "." +408, 12, 11, 227, 37, 38, 1118, 1119, "5" +408, 12, 12, 228, 39, 42, 1120, 1123, "and" +408, 12, 13, 229, 43, 45, 1124, 1126, "29" +408, 12, 14, 230, 46, 47, 1127, 1128, "." +408, 12, 15, 231, 48, 50, 1129, 1131, "53" +408, 12, 16, 232, 51, 52, 1132, 1133, "±" +408, 12, 17, 233, 53, 54, 1134, 1135, "6" +408, 12, 18, 234, 55, 59, 1136, 1140, "mmHg" +408, 12, 19, 235, 60, 63, 1141, 1144, "for" +408, 12, 20, 236, 64, 66, 1145, 1147, "BT" +408, 12, 21, 237, 67, 70, 1148, 1151, "and" +408, 12, 22, 238, 71, 73, 1152, 1154, "DT" +408, 12, 23, 239, 74, 75, 1155, 1156, "," +408, 12, 24, 240, 76, 88, 1157, 1169, "respectively" +408, 12, 25, 241, 89, 90, 1170, 1171, "(" +408, 12, 26, 242, 91, 92, 1172, 1173, "P" +408, 12, 27, 243, 93, 94, 1174, 1175, "<" +408, 12, 28, 244, 95, 96, 1176, 1177, "0" +408, 12, 29, 245, 97, 98, 1178, 1179, "." +408, 12, 30, 246, 99, 102, 1180, 1183, "001" +408, 12, 31, 247, 103, 104, 1184, 1185, ")" +408, 12, 32, 248, 105, 106, 1186, 1187, "." +408, 13, 1, 249, 0, 4, 1188, 1192, "Both" +408, 13, 2, 250, 5, 7, 1193, 1195, "BT" +408, 13, 3, 251, 8, 11, 1196, 1199, "and" +408, 13, 4, 252, 12, 14, 1200, 1202, "DT" +408, 13, 5, 253, 15, 23, 1203, 1211, "provided" +408, 13, 6, 254, 24, 37, 1212, 1225, "statistically" +408, 13, 7, 255, 38, 49, 1226, 1237, "significant" +408, 13, 8, 256, 50, 54, 1238, 1242, "mean" +408, 13, 9, 257, 55, 58, 1243, 1246, "IOP" +408, 13, 10, 258, 59, 69, 1247, 1257, "reductions" +408, 13, 11, 259, 70, 74, 1258, 1262, "from" +408, 13, 12, 260, 75, 83, 1263, 1271, "baseline" +408, 13, 13, 261, 84, 90, 1272, 1278, "values" +408, 13, 14, 262, 91, 97, 1279, 1285, "within" +408, 13, 15, 263, 98, 102, 1286, 1290, "each" +408, 13, 16, 264, 103, 108, 1291, 1296, "group" +408, 13, 17, 265, 109, 111, 1297, 1299, "at" +408, 13, 18, 266, 112, 115, 1300, 1303, "all" +408, 13, 19, 267, 116, 121, 1304, 1309, "study" +408, 13, 20, 268, 122, 128, 1310, 1316, "visits" +408, 13, 21, 269, 129, 130, 1317, 1318, "(" +408, 13, 22, 270, 131, 132, 1319, 1320, "P" +408, 13, 23, 271, 133, 134, 1321, 1322, "<" +408, 13, 24, 272, 135, 136, 1323, 1324, "0" +408, 13, 25, 273, 137, 138, 1325, 1326, "." +408, 13, 26, 274, 139, 142, 1327, 1330, "001" +408, 13, 27, 275, 143, 144, 1331, 1332, ")" +408, 13, 28, 276, 145, 146, 1333, 1334, "." +408, 14, 1, 277, 0, 2, 1335, 1337, "DT" +408, 14, 2, 278, 3, 11, 1338, 1346, "provided" +408, 14, 3, 279, 12, 19, 1347, 1354, "greater" +408, 14, 4, 280, 20, 24, 1355, 1359, "mean" +408, 14, 5, 281, 25, 28, 1360, 1363, "IOP" +408, 14, 6, 282, 29, 39, 1364, 1374, "reductions" +408, 14, 7, 283, 40, 44, 1375, 1379, "from" +408, 14, 8, 284, 45, 53, 1380, 1388, "baseline" +408, 14, 9, 285, 54, 58, 1389, 1393, "than" +408, 14, 10, 286, 59, 61, 1394, 1396, "BT" +408, 14, 11, 287, 62, 64, 1397, 1399, "at" +408, 14, 12, 288, 65, 69, 1400, 1404, "each" +408, 14, 13, 289, 70, 75, 1405, 1410, "visit" +408, 14, 14, 290, 76, 81, 1411, 1416, "which" +408, 14, 15, 291, 82, 85, 1417, 1420, "was" +408, 14, 16, 292, 86, 99, 1421, 1434, "statistically" +408, 14, 17, 293, 100, 111, 1435, 1446, "significant" +408, 14, 18, 294, 112, 114, 1447, 1449, "at" +408, 14, 19, 295, 115, 116, 1450, 1451, "2" +408, 14, 20, 296, 117, 122, 1452, 1457, "weeks" +408, 14, 21, 297, 123, 124, 1458, 1459, "(" +408, 14, 22, 298, 125, 126, 1460, 1461, "P" +408, 14, 23, 299, 127, 128, 1462, 1463, "=" +408, 14, 24, 300, 129, 130, 1464, 1465, "0" +408, 14, 25, 301, 131, 132, 1466, 1467, "." +408, 14, 26, 302, 133, 136, 1468, 1471, "037" +408, 14, 27, 303, 137, 138, 1472, 1473, ")" +408, 14, 28, 304, 139, 140, 1474, 1475, "." +408, 15, 1, 305, 0, 4, 1476, 1480, "Mean" +408, 15, 2, 306, 5, 15, 1481, 1491, "percentage" +408, 15, 3, 307, 16, 18, 1492, 1494, "of" +408, 15, 4, 308, 19, 22, 1495, 1498, "IOP" +408, 15, 5, 309, 23, 32, 1499, 1508, "reduction" +408, 15, 6, 310, 33, 36, 1509, 1512, "was" +408, 15, 7, 311, 37, 39, 1513, 1515, "24" +408, 15, 8, 312, 40, 41, 1516, 1517, "." +408, 15, 9, 313, 42, 44, 1518, 1520, "35" +408, 15, 10, 314, 45, 46, 1521, 1522, "%" +408, 15, 11, 315, 47, 50, 1523, 1526, "and" +408, 15, 12, 316, 51, 53, 1527, 1529, "46" +408, 15, 13, 317, 54, 55, 1530, 1531, "." +408, 15, 14, 318, 56, 58, 1532, 1534, "33" +408, 15, 15, 319, 59, 60, 1535, 1536, "%" +408, 15, 16, 320, 61, 63, 1537, 1539, "at" +408, 15, 17, 321, 64, 65, 1540, 1541, "2" +408, 15, 18, 322, 66, 71, 1542, 1547, "weeks" +408, 15, 19, 323, 72, 73, 1548, 1549, "(" +408, 15, 20, 324, 74, 75, 1550, 1551, "P" +408, 15, 21, 325, 76, 77, 1552, 1553, "<" +408, 15, 22, 326, 78, 79, 1554, 1555, "0" +408, 15, 23, 327, 80, 81, 1556, 1557, "." +408, 15, 24, 328, 82, 85, 1558, 1561, "001" +408, 15, 25, 329, 86, 87, 1562, 1563, ")" +408, 15, 26, 330, 88, 89, 1564, 1565, "," +408, 15, 27, 331, 90, 93, 1566, 1569, "and" +408, 15, 28, 332, 94, 96, 1570, 1572, "24" +408, 15, 29, 333, 97, 98, 1573, 1574, "." +408, 15, 30, 334, 99, 101, 1575, 1577, "65" +408, 15, 31, 335, 102, 103, 1578, 1579, "%" +408, 15, 32, 336, 104, 107, 1580, 1583, "and" +408, 15, 33, 337, 108, 110, 1584, 1586, "47" +408, 15, 34, 338, 111, 112, 1587, 1588, "%" +408, 15, 35, 339, 113, 115, 1589, 1591, "at" +408, 15, 36, 340, 116, 117, 1592, 1593, "3" +408, 15, 37, 341, 118, 124, 1594, 1600, "months" +408, 15, 38, 342, 125, 126, 1601, 1602, "(" +408, 15, 39, 343, 127, 128, 1603, 1604, "P" +408, 15, 40, 344, 129, 130, 1605, 1606, "<" +408, 15, 41, 345, 131, 132, 1607, 1608, "0" +408, 15, 42, 346, 133, 134, 1609, 1610, "." +408, 15, 43, 347, 135, 138, 1611, 1614, "001" +408, 15, 44, 348, 139, 140, 1615, 1616, ")" +408, 15, 45, 349, 141, 144, 1617, 1620, "for" +408, 15, 46, 350, 145, 147, 1621, 1623, "BT" +408, 15, 47, 351, 148, 151, 1624, 1627, "and" +408, 15, 48, 352, 152, 154, 1628, 1630, "DT" +408, 15, 49, 353, 155, 156, 1631, 1632, "," +408, 15, 50, 354, 157, 169, 1633, 1645, "respectively" +408, 15, 51, 355, 170, 171, 1646, 1647, "." +408, 16, 1, 356, 0, 8, 1648, 1656, "Patients" +408, 16, 2, 357, 9, 10, 1657, 1658, "'" +408, 16, 3, 358, 11, 23, 1659, 1671, "tolerability" +408, 16, 4, 359, 24, 32, 1672, 1680, "appeared" +408, 16, 5, 360, 33, 35, 1681, 1683, "to" +408, 16, 6, 361, 36, 38, 1684, 1686, "be" +408, 16, 7, 362, 39, 45, 1687, 1693, "better" +408, 16, 8, 363, 46, 49, 1694, 1697, "for" +408, 16, 9, 364, 50, 52, 1698, 1700, "DT" +408, 16, 10, 365, 53, 57, 1701, 1705, "than" +408, 16, 11, 366, 58, 61, 1706, 1709, "for" +408, 16, 12, 367, 62, 64, 1710, 1712, "BT" +408, 16, 13, 368, 65, 69, 1713, 1717, "with" +408, 16, 14, 369, 70, 78, 1718, 1726, "complete" +408, 16, 15, 370, 79, 85, 1727, 1733, "ocular" +408, 16, 16, 371, 86, 93, 1734, 1741, "comfort" +408, 16, 17, 372, 94, 101, 1742, 1749, "without" +408, 16, 18, 373, 102, 105, 1750, 1753, "any" +408, 16, 19, 374, 106, 112, 1754, 1760, "ocular" +408, 16, 20, 375, 113, 120, 1761, 1768, "adverse" +408, 16, 21, 376, 121, 128, 1769, 1776, "effects" +408, 16, 22, 377, 129, 131, 1777, 1779, "in" +408, 16, 23, 378, 132, 134, 1780, 1782, "31" +408, 16, 24, 379, 135, 143, 1783, 1791, "patients" +408, 16, 25, 380, 144, 145, 1792, 1793, "(" +408, 16, 26, 381, 146, 148, 1794, 1796, "81" +408, 16, 27, 382, 149, 150, 1797, 1798, "." +408, 16, 28, 383, 151, 152, 1799, 1800, "1" +408, 16, 29, 384, 153, 154, 1801, 1802, "%" +408, 16, 30, 385, 155, 156, 1803, 1804, ")" +408, 16, 31, 386, 157, 159, 1805, 1807, "in" +408, 16, 32, 387, 160, 162, 1808, 1810, "DT" +408, 16, 33, 388, 163, 168, 1811, 1816, "group" +408, 16, 34, 389, 169, 172, 1817, 1820, "and" +408, 16, 35, 390, 173, 175, 1821, 1823, "11" +408, 16, 36, 391, 176, 184, 1824, 1832, "patients" +408, 16, 37, 392, 185, 186, 1833, 1834, "(" +408, 16, 38, 393, 187, 189, 1835, 1837, "29" +408, 16, 39, 394, 190, 191, 1838, 1839, "." +408, 16, 40, 395, 192, 193, 1840, 1841, "7" +408, 16, 41, 396, 194, 195, 1842, 1843, "%" +408, 16, 42, 397, 196, 197, 1844, 1845, ")" +408, 16, 43, 398, 198, 200, 1846, 1848, "in" +408, 16, 44, 399, 201, 203, 1849, 1851, "BT" +408, 16, 45, 400, 204, 209, 1852, 1857, "group" +408, 16, 46, 401, 210, 211, 1858, 1859, "(" +408, 16, 47, 402, 212, 213, 1860, 1861, "P" +408, 16, 48, 403, 214, 215, 1862, 1863, "<" +408, 16, 49, 404, 216, 217, 1864, 1865, "0" +408, 16, 50, 405, 218, 219, 1866, 1867, "." +408, 16, 51, 406, 220, 223, 1868, 1871, "001" +408, 16, 52, 407, 224, 225, 1872, 1873, ")" +408, 16, 53, 408, 226, 227, 1874, 1875, "." +408, 17, 1, 409, 0, 10, 1876, 1886, "CONCLUSION" +408, 17, 2, 410, 11, 12, 1887, 1888, ":" +408, 17, 3, 411, 13, 17, 1889, 1893, "Both" +408, 17, 4, 412, 18, 23, 1894, 1899, "drops" +408, 17, 5, 413, 24, 31, 1900, 1907, "provide" +408, 17, 6, 414, 32, 41, 1908, 1917, "effective" +408, 17, 7, 415, 42, 45, 1918, 1921, "IOP" +408, 17, 8, 416, 46, 55, 1922, 1931, "reduction" +408, 17, 9, 417, 56, 61, 1932, 1937, "which" +408, 17, 10, 418, 62, 65, 1938, 1941, "was" +408, 17, 11, 419, 66, 73, 1942, 1949, "greater" +408, 17, 12, 420, 74, 75, 1950, 1951, "," +408, 17, 13, 421, 76, 79, 1952, 1955, "and" +408, 17, 14, 422, 80, 88, 1956, 1964, "patients" +408, 17, 15, 423, 89, 93, 1965, 1969, "were" +408, 17, 16, 424, 94, 98, 1970, 1974, "more" +408, 17, 17, 425, 99, 105, 1975, 1981, "likely" +408, 17, 18, 426, 106, 108, 1982, 1984, "to" +408, 17, 19, 427, 109, 116, 1985, 1992, "achieve" +408, 17, 20, 428, 117, 122, 1993, 1998, "lower" +408, 17, 21, 429, 123, 129, 1999, 2005, "target" +408, 17, 22, 430, 130, 139, 2006, 2015, "pressures" +408, 17, 23, 431, 140, 144, 2016, 2020, "with" +408, 17, 24, 432, 145, 147, 2021, 2023, "DT" +408, 17, 25, 433, 148, 152, 2024, 2028, "than" +408, 17, 26, 434, 153, 157, 2029, 2033, "with" +408, 17, 27, 435, 158, 160, 2034, 2036, "BT" +408, 17, 28, 436, 161, 162, 2037, 2038, "." +408, 18, 1, 437, 0, 3, 2039, 2042, "DOI" +408, 18, 2, 438, 4, 5, 2043, 2044, ":" +408, 18, 3, 439, 6, 8, 2045, 2047, "10" +408, 18, 4, 440, 9, 10, 2048, 2049, "." +408, 18, 5, 441, 11, 15, 2050, 2054, "4103" +408, 18, 6, 442, 16, 17, 2055, 2056, "/" +408, 18, 7, 443, 18, 22, 2057, 2061, "0301" +408, 18, 8, 444, 23, 24, 2062, 2063, "-" +408, 18, 9, 445, 25, 29, 2064, 2068, "4738" +408, 18, 10, 446, 30, 31, 2069, 2070, "." +408, 18, 11, 447, 32, 38, 2071, 2077, "179718" +408, 18, 12, 448, 39, 44, 2078, 2083, "PMCID" +408, 18, 13, 449, 45, 46, 2084, 2085, ":" +408, 18, 14, 450, 47, 57, 2086, 2096, "PMC4850807" +408, 18, 15, 451, 58, 62, 2097, 2101, "PMID" +408, 18, 16, 452, 63, 64, 2102, 2103, ":" +408, 18, 17, 453, 65, 73, 2104, 2112, "27050347" +408, 18, 18, 454, 74, 75, 2113, 2114, "[" +408, 18, 19, 455, 76, 83, 2115, 2122, "Indexed" +408, 18, 20, 456, 84, 87, 2123, 2126, "for" +408, 18, 21, 457, 88, 95, 2127, 2134, "MEDLINE" +408, 18, 22, 458, 96, 97, 2135, 2136, "]" diff --git a/data/gl 27050347_jshahinitiran.annodb b/data/gl 27050347_jshahinitiran.annodb new file mode 100644 index 0000000..fc7ca36 --- /dev/null +++ b/data/gl 27050347_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32441, Journal, 0, 19, "Indian J Ophthalmol", "", +32580, PublicationYear, 22, 26, "2016", "", +32442, Title, 96, 220, "Brinzolamide / timolol versus dorzolamide / timolol fixed combinations : A hospital - based , prospective , randomized study", "", +32443, Brinzolamide, 96, 108, "Brinzolamide", "", +32444, Timolol, 111, 118, "timolol", "", +32445, Dorzolamide, 126, 137, "dorzolamide", "", +32446, Timolol, 140, 147, "timolol", "", +32447, CTDesign, 171, 187, "hospital - based", "", +32448, CTDesign, 190, 201, "prospective", "", +32449, Randomized, 204, 214, "randomized", "", +32450, Author, 223, 232, "Galose MS", "", +32451, Author, 235, 245, "Elsaied HM", "", +32452, Author, 248, 256, "Macky TA", "", +32453, Author, 265, 273, "Fouad PH", "", +32454, Egypt, 422, 427, "Egypt", "", +32456, ObjectiveDescription, 440, 609, "To compare the efficacy and tolerability of brinzolamide / timolol ( BT ) and dorzolamide / timolol ( DT ) fixed combinations on intraocular pressure ( IOP ) reduction .", "", +32457, Brinzolamide, 484, 496, "brinzolamide", "", +32458, Timolol, 499, 506, "timolol", "", +32461, Drug, 509, 511, "BT", "BT", +32459, Dorzolamide, 518, 529, "dorzolamide", "", +32460, Timolol, 532, 539, "timolol", "", +32471, Drug, 542, 544, "DT", "DT", +32481, IOP, 569, 589, "intraocular pressure", "", +32482, IOP, 592, 595, "IOP", "", +32483, Primary_OpenAngleGlaucoma, 634, 661, "primary open angle glaucoma", "", +32484, Glaucoma, 665, 688, "normal tension glaucoma", "", +32485, Randomized, 694, 704, "randomized", "", +32462, Drug, 723, 725, "BT", "BT", +32472, Drug, 729, 731, "DT", "DT", +32486, IOP, 734, 738, "IOPs", "", +32487, TimePoint, 756, 764, "baseline", "", +32488, TimePoint, 767, 774, "2 weeks", "", +32489, TimePoint, 781, 801, "1 , 2 , and 3 months", "", +32490, Mean, 842, 846, "mean", "", +32491, IOP, 857, 860, "IOP", "", +32492, NumberPatientsCT, 982, 997, "Seventy - three", "", +32493, NumberPatientsArm, 1035, 1037, "37", "", +32463, Drug, 1046, 1048, "BT", "BT", +32494, NumberPatientsArm, 1059, 1061, "36", "", +32473, Drug, 1070, 1072, "DT", "DT", +32495, Mean, 1090, 1094, "mean", "", +32496, IOP, 1095, 1098, "IOP", "", +32497, ResultMeasuredValue, 1104, 1111, "24 . 14", "", +32499, SdErrorResValue, 1114, 1119, "4 . 5", "", +32498, ResultMeasuredValue, 1124, 1131, "29 . 53", "", +32464, Drug, 1145, 1147, "BT", "BT", +32474, Drug, 1152, 1154, "DT", "DT", +32465, Drug, 1193, 1195, "BT", "BT", +32475, Drug, 1200, 1202, "DT", "DT", +32500, Mean, 1238, 1242, "mean", "", +32501, IOP, 1243, 1246, "IOP", "", +32502, PValueChangeValue, 1319, 1330, "P < 0 . 001", "", +32476, Drug, 1335, 1337, "DT", "DT", +32507, ObservedResult, 1335, 1475, "DT provided greater mean IOP reductions from baseline than BT at each visit which was statistically significant at 2 weeks ( P = 0 . 037 ) .", "", +32503, Mean, 1355, 1359, "mean", "", +32504, IOP, 1360, 1363, "IOP", "", +32466, Drug, 1394, 1396, "BT", "BT", +32505, TimePoint, 1450, 1457, "2 weeks", "", +32506, PValueChangeValue, 1460, 1471, "P = 0 . 037", "", +32508, Mean, 1476, 1480, "Mean", "", +32509, IOP, 1495, 1498, "IOP", "", +32510, RelativeReduction, 1513, 1520, "24 . 35", "", +32511, RelativeReduction, 1527, 1534, "46 . 33", "", +32512, TimePoint, 1540, 1547, "2 weeks", "", +32513, PValueChangeValue, 1550, 1561, "P < 0 . 001", "", +32514, RelativeReduction, 1570, 1577, "24 . 65", "", +32515, RelativeReduction, 1584, 1586, "47", "", +32516, TimePoint, 1592, 1600, "3 months", "", +32517, PValueChangeValue, 1603, 1614, "P < 0 . 001", "", +32467, Drug, 1621, 1623, "BT", "BT", +32477, Drug, 1628, 1630, "DT", "DT", +32518, ObservedResult, 1648, 1875, "Patients ' tolerability appeared to be better for DT than for BT with complete ocular comfort without any ocular adverse effects in 31 patients ( 81 . 1 % ) in DT group and 11 patients ( 29 . 7 % ) in BT group ( P < 0 . 001 ) .", "", +32478, Drug, 1698, 1700, "DT", "DT", +32468, Drug, 1710, 1712, "BT", "BT", +32479, Drug, 1808, 1810, "DT", "DT", +32469, Drug, 1849, 1851, "BT", "BT", +32519, ConclusionComment, 1889, 2038, "Both drops provide effective IOP reduction which was greater , and patients were more likely to achieve lower target pressures with DT than with BT .", "", +32520, IOP, 1918, 1921, "IOP", "", +32480, Drug, 2021, 2023, "DT", "DT", +32470, Drug, 2034, 2036, "BT", "BT", +32521, PMID, 2104, 2112, "27050347", "", diff --git a/data/gl 27050347_jshahinitiran.n-triples b/data/gl 27050347_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27050347_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27050347_tstrakeljahn.annodb b/data/gl 27050347_tstrakeljahn.annodb new file mode 100644 index 0000000..70f9b81 --- /dev/null +++ b/data/gl 27050347_tstrakeljahn.annodb @@ -0,0 +1,74 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8282, Journal, 0, 19, "Indian J Ophthalmol", "", +8283, PublicationYear, 22, 26, "2016", "", +8284, Brinzolamide, 96, 108, "Brinzolamide", "", +29827, Title, 96, 222, "Brinzolamide / timolol versus dorzolamide / timolol fixed combinations : A hospital - based , prospective , randomized study .", "", +8285, Timolol, 111, 118, "timolol", "", +8286, Dorzolamide, 126, 137, "dorzolamide", "", +8287, Timolol, 140, 147, "timolol", "", +8288, ClinicalTrial, 169, 187, "A hospital - based", "", +8289, Randomized, 204, 214, "randomized", "", +8290, Author, 223, 232, "Galose MS", "", +8291, Author, 235, 245, "Elsaied HM", "", +8292, Author, 248, 256, "Macky TA", "", +8293, Author, 265, 273, "Fouad PH", "", +8294, Egypt, 422, 427, "Egypt", "", +8301, ObjectiveDescription, 440, 609, "To compare the efficacy and tolerability of brinzolamide / timolol ( BT ) and dorzolamide / timolol ( DT ) fixed combinations on intraocular pressure ( IOP ) reduction .", "", +8295, Brinzolamide, 484, 496, "brinzolamide", "", +8296, Timolol, 499, 506, "timolol", "", +8298, Timolol, 518, 529, "dorzolamide", "", +8297, Timolol, 532, 539, "timolol", "", +8299, IOP, 569, 589, "intraocular pressure", "", +8300, IOP, 592, 595, "IOP", "", +8302, OpenAngleGlaucoma, 642, 661, "open angle glaucoma", "", +8303, Glaucoma, 680, 688, "glaucoma", "", +8304, Randomized, 694, 704, "randomized", "", +29828, Drug, 723, 725, "BT", "Brinzolamide / Timolol", +29836, Drug, 729, 731, "DT", "Dorzolamide / Timolol", +8307, Mean, 842, 846, "mean", "", +8311, IOP, 857, 860, "IOP", "", +8312, FinalNumPatientsCT, 982, 1006, "Seventy - three patients", "", +8313, IOP, 1095, 1098, "IOP", "", +8314, BaseLineValue, 1104, 1111, "24 . 14", "", +8315, SdDevBL, 1112, 1119, "± 4 . 5", "", +8316, BaseLineValue, 1124, 1131, "29 . 53", "", +8317, SdDevBL, 1132, 1135, "± 6", "", +8318, mmHg, 1136, 1140, "mmHg", "", +29829, Drug, 1145, 1147, "BT", "Brinzolamide / Timolol", +29837, Drug, 1152, 1154, "DT", "Dorzolamide / Timolol", +8322, PValueChangeValue, 1172, 1183, "P < 0 . 001", "", +29830, Drug, 1193, 1195, "BT", "Brinzolamide / Timolol", +29838, Drug, 1200, 1202, "DT", "Dorzolamide / Timolol", +8336, IOP, 1243, 1246, "IOP", "", +8323, PValueChangeValue, 1319, 1330, "P < 0 . 001", "", +29839, Drug, 1335, 1337, "DT", "Dorzolamide / Timolol", +8337, Mean, 1355, 1359, "mean", "", +8338, IOP, 1360, 1363, "IOP", "", +29831, Drug, 1394, 1396, "BT", "Brinzolamide / Timolol", +8339, TimePoint, 1450, 1457, "2 weeks", "", +8340, PvalueDiff, 1460, 1471, "P = 0 . 037", "", +8341, IOP, 1495, 1498, "IOP", "", +8342, RelativeReduction, 1513, 1520, "24 . 35", "", +8343, RelativeReduction, 1527, 1534, "46 . 33", "", +8344, TimePoint, 1540, 1547, "2 weeks", "", +8345, PValueChangeValue, 1550, 1561, "P < 0 . 001", "", +8347, RelativeReduction, 1570, 1577, "24 . 65", "", +8348, RelativeReduction, 1584, 1586, "47", "", +8349, TimePoint, 1592, 1600, "3 months", "", +8346, PValueChangeValue, 1603, 1614, "P < 0 . 001", "", +29832, Drug, 1621, 1623, "BT", "Brinzolamide / Timolol", +29840, Drug, 1628, 1630, "DT", "Dorzolamide / Timolol", +29841, Drug, 1698, 1700, "DT", "Dorzolamide / Timolol", +29833, Drug, 1710, 1712, "BT", "Brinzolamide / Timolol", +8350, NumberAffected, 1780, 1782, "31", "", +8351, PercentageAffected, 1794, 1800, "81 . 1", "", +29842, Drug, 1808, 1810, "DT", "Dorzolamide / Timolol", +8352, NumberAffected, 1821, 1823, "11", "", +8353, PercentageAffected, 1835, 1841, "29 . 7", "", +29834, Drug, 1849, 1851, "BT", "Brinzolamide / Timolol", +8354, PValueChangeValue, 1860, 1871, "P < 0 . 001", "", +8356, ConclusionComment, 1889, 2036, "Both drops provide effective IOP reduction which was greater , and patients were more likely to achieve lower target pressures with DT than with BT", "", +8355, IOP, 1918, 1921, "IOP", "", +29843, Drug, 2021, 2023, "DT", "Dorzolamide / Timolol", +29835, Drug, 2034, 2036, "BT", "Brinzolamide / Timolol", +8357, PMID, 2104, 2112, "27050347", "", diff --git a/data/gl 27050347_tstrakeljahn.n-triples b/data/gl 27050347_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27050347_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27367743_admin.annodb b/data/gl 27367743_admin.annodb new file mode 100644 index 0000000..336e246 --- /dev/null +++ b/data/gl 27367743_admin.annodb @@ -0,0 +1,116 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 14, "Eye ( Lond ) .", "", " \"Eye ( Lond ) .\"." +1, PublicationYear, 15, 19, "2016", "", " \"2016\"." +2, Title, 107, 251, "Ocular hypotensive effect of fixed - combination brinzolamide / brimonidine adjunctive to a prostaglandin analog : a randomized clinical trial .", "", " \"Ocular hypotensive effect of fixed - combination brinzolamide / brimonidine adjunctive to a prostaglandin analog : a randomized clinical trial .\"." +6, Brinz/BrimoFC, 136, 182, "fixed - combination brinzolamide / brimonidine", "", +3, Brinzolamide, 156, 168, "brinzolamide", "", +4, Brimonidine, 171, 182, "brimonidine", "", +92828, ProstaglandinAnalogs, 199, 219, "prostaglandin analog", "", +5, Randomized, 224, 234, "randomized", "", +7, Author, 252, 263, "Fechtner RD", "", " \"Fechtner RD\"." +8, Author, 272, 280, "Myers JS", "", " \"Myers JS\"." +9, Author, 289, 300, "Hubatsch DA", "", " \"Hubatsch DA\"." +10, Author, 309, 318, "Budenz DL", "", " \"Budenz DL\"." +11, Author, 327, 337, "DuBiner HB", "", " \"DuBiner HB\"." +12, USA, 453, 456, "USA", "", " ." +13, USA, 506, 509, "USA", "", +14, USA, 565, 568, "USA", "", +15, USA, 657, 660, "USA", "", +16, USA, 704, 707, "USA", "", +92796, ObjectiveDescription, 710, 936, "PurposeTo determine whether intraocular pressure ( IOP ) lowering with fixed - combination brinzolamide / brimonidine ( BBFC ) adjunctive to a prostaglandin analog ( PGA ) was superior to that of vehicle + PGA in patients with", "", " \"PurposeTo determine whether intraocular pressure ( IOP ) lowering with fixed - combination brinzolamide / brimonidine ( BBFC ) adjunctive to a prostaglandin analog ( PGA ) was superior to that of vehicle + PGA in patients with\"." +123, IOP, 738, 758, "intraocular pressure", "", +124, IOP, 761, 764, "IOP", "", +125, Brinzolamide, 801, 813, "brinzolamide", "", " ." +127, Brinz/BrimoFC, 801, 827, "brinzolamide / brimonidine", "", +126, Brimonidine, 816, 827, "brimonidine", "", " ." +128, Brinz/BrimoFC, 830, 834, "BBFC", "", +92829, ProstaglandinAnalogs, 853, 873, "prostaglandin analog", "", " ." +92830, ProstaglandinAnalogs, 876, 879, "PGA", "", +92824, Vehicle, 906, 913, "vehicle", "", " ." +92831, ProstaglandinAnalogs, 916, 919, "PGA", "", +130, OpenAngleGlaucoma, 937, 958, "open - angle glaucoma", "", " ." +92818, ObjectiveDescription, 937, 1046, "open - angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis", "", " \"open - angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis\"." +150, OcularHypertension, 962, 981, "ocular hypertension", "", " ." +131, Precondition, 991, 1023, "inadequately controlled with PGA", "", " \"inadequately controlled with PGA\"." +92832, ProstaglandinAnalogs, 1020, 1023, "PGA", "", +20, Duration, 1047, 1055, "6 - week", "", " \"6 - week\"." +21, Multicenter, 1058, 1069, "multicenter", "", " ." +22, Randomized, 1072, 1082, "randomized", "", " ." +23, DoubleBlind, 1085, 1100, "double - masked", "", " ." +24, Parallel, 1103, 1119, "parallel - group", "", " ." +25, Multicenter, 1143, 1160, "30 clinical sites", "", +26, USA, 1168, 1181, "United States", "", +92819, Precondition, 1241, 1379, "adults with open - angle glaucoma or ocular hypertension and with mean IOP ≥ 21 and < 32   mm   Hg , whereas receiving an open - label PGA", "", " \"adults with open - angle glaucoma or ocular hypertension and with mean IOP ≥ 21 and < 32   mm   Hg , whereas receiving an open - label PGA\"." +28, OpenAngleGlaucoma, 1253, 1274, "open - angle glaucoma", "", +29, OcularHypertension, 1278, 1297, "ocular hypertension", "", +30, Mean, 1307, 1311, "mean", "", +31, IOP, 1312, 1315, "IOP", "", +32, mmHg, 1332, 1339, "mm   Hg", "", +144, OpenLabel, 1363, 1375, "open - label", "", " ." +92840, ProstaglandinAnalogs, 1376, 1379, "PGA", "", +34, Latanoprost, 1382, 1393, "latanoprost", "", +35, Bimatoprost, 1396, 1407, "bimatoprost", "", +36, Travoprost, 1413, 1423, "travoprost", "", +92820, DeliveryMethod, 1437, 1446, "instilled", "", " . . . . . . . ." +92841, ProstaglandinAnalogs, 1449, 1452, "PGA", "", +37, Frequency, 1453, 1465, "once - daily", "", " \"once - daily\"." +38, Randomized, 1493, 1506, "randomization", "", +92823, Blind, 1510, 1516, "masked", "", " ." +39, Brinz/BrimoFC, 1517, 1521, "BBFC", "", +92825, Vehicle, 1525, 1532, "vehicle", "", +92821, Blind, 1556, 1562, "Masked", "", +92822, DeliveryMethod, 1579, 1588, "instilled", "", +41, Frequency, 1589, 1602, "3 times daily", "", " \"3 times daily\". \"3 times daily\"." +42, Duration, 1607, 1614, "6 weeks", "", +43, Frequency, 1640, 1652, "once - daily", "", +92833, ProstaglandinAnalogs, 1666, 1669, "PGA", "", +44, Mean, 1741, 1745, "mean", "", +45, Diurnal_IOP, 1746, 1757, "diurnal IOP", "", +161, TimePoint, 1771, 1775, "0800", "", +162, TimePoint, 1778, 1782, "1000", "", +163, TimePoint, 1785, 1789, "1500", "", +164, TimePoint, 1796, 1800, "1700", "", +165, TimePoint, 1824, 1830, "week 6", "", +47, TimePoint, 1843, 1849, "week 6", "", " \"week 6\". \"week 6\"." +48, Mean, 1852, 1856, "mean", "", " . ." +49, Diurnal_IOP, 1857, 1868, "diurnal IOP", "", " ." +50, Brinz/BrimoFC, 1874, 1878, "BBFC", "", +92834, ProstaglandinAnalogs, 1881, 1884, "PGA", "", +92826, Vehicle, 1905, 1912, "vehicle", "", +92835, ProstaglandinAnalogs, 1915, 1918, "PGA", "", +55, ResultMeasuredValue, 1921, 1927, "17 . 1", "", " \"17 . 1\"." +57, SdErrorResValue, 1930, 1935, "0 . 4", "", " \"0 . 4\"." +58, mmHg, 1938, 1945, "mm   Hg", "", " ." +56, ResultMeasuredValue, 1949, 1955, "20 . 5", "", " \"20 . 5\"." +59, SdErrorResValue, 1958, 1963, "0 . 4", "", " \"0 . 4\"." +60, mmHg, 1966, 1973, "mm   Hg", "", +176, DiffGroupAbsValue, 2005, 2012, "- 3 . 4", "", " \"- 3 . 4\"." +62, SdErrorDiff, 2015, 2020, "0 . 5", "", " \"0 . 5\"." +63, mmHg, 2023, 2030, "mm   Hg", "", +64, PvalueDiff, 2033, 2045, "P < 0 . 0001", "", " \"P < 0 . 0001\"." +65, ConfIntervalDiff, 2048, 2103, "95 % confidence interval , - 4 . 5 to - 2 . 4   mm   Hg", "", " \"95 % confidence interval , - 4 . 5 to - 2 . 4   mm   Hg\"." +66, mmHg, 2096, 2103, "mm   Hg", "", +67, Brinz/BrimoFC, 2108, 2112, "BBFC", "", +92836, ProstaglandinAnalogs, 2115, 2118, "PGA", "", +69, Mean, 2127, 2131, "mean", "", +70, Diurnal_IOP, 2132, 2143, "diurnal IOP", "", +71, Reduction, 2147, 2152, "5 . 7", "", " \"5 . 7\"." +72, mmHg, 2155, 2162, "mm   Hg", "", +73, RelativeReduction, 2165, 2167, "25", "", " \"25\"." +74, IOP, 2190, 2193, "IOP", "", +92837, ProstaglandinAnalogs, 2208, 2211, "PGA", "", +76, ConclusionComment, 2226, 2356, "ConclusionsTherapy with BBFC produced an additive IOP - lowering effect compared with a PGA alone or in conjunction with vehicle .", "", " \"ConclusionsTherapy with BBFC produced an additive IOP - lowering effect compared with a PGA alone or in conjunction with vehicle .\"." +77, Brinz/BrimoFC, 2250, 2254, "BBFC", "", +78, IOP, 2276, 2279, "IOP", "", +92838, ProstaglandinAnalogs, 2314, 2317, "PGA", "", +92827, Vehicle, 2347, 2354, "vehicle", "", +81, ConclusionComment, 2357, 2481, "BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction .", "", " \"BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction .\"." +82, Brinz/BrimoFC, 2357, 2361, "BBFC", "", +92839, ProstaglandinAnalogs, 2427, 2430, "PGA", "", +84, IOP, 2466, 2469, "IOP", "", +85, PMID, 2543, 2551, "27367743", "", " \"27367743\"." +86, ConflictInterest, 2609, 2719, "RDF has received consultant fees from Alcon and Bausch & Lomb , and research support from Alcon and Allergan .", "", +87, ConflictInterest, 2720, 2934, "JSM has received research funding from Alcon , Allergan , Glaukos , Inotek , and Merck ; consultant fees from Aerie , Alcon , Allergan , Inotek , and Sucampo ; and lecture fees from Alcon , Allergan , and Sucampo .", "", " \"JSM has received research funding from Alcon , Allergan , Glaukos , Inotek , and Merck ; consultant fees from Aerie , Alcon , Allergan , Inotek , and Sucampo ; and lecture fees from Alcon , Allergan , and Sucampo .\"." +88, ConflictInterest, 2935, 2961, "DAH is an Alcon employee .", "", " \"DAH is an Alcon employee .\"." +90, ConflictInterest, 2962, 2965, "DLB", "", " \"DLB\"." +89, ConflictInterest, 2966, 3218, "has received consultant fees from Alcon and Ivantis , and research support from the National Eye Institute , Glaucoma Research Foundation , Research to Prevent Blindness , and New World Medical , Inc . HBD has received speakers bureau fees from Alcon .", "", " \"has received consultant fees from Alcon and Ivantis , and research support from the National Eye Institute , Glaucoma Research Foundation , Research to Prevent Blindness , and New World Medical , Inc . HBD has received speakers bureau fees from Alcon .\"." diff --git a/data/gl 27367743_admin.n-triples b/data/gl 27367743_admin.n-triples new file mode 100644 index 0000000..45cdf61 --- /dev/null +++ b/data/gl 27367743_admin.n-triples @@ -0,0 +1,142 @@ +# RDF export of group: Publication + . + "Publication " . + "Ocular hypotensive effect of fixed - combination brinzolamide / brimonidine adjunctive to a prostaglandin analog : a randomized clinical trial ." . + "Fechtner RD" . + "2016" . + "Eye ( Lond ) ." . + "27367743" . + . + "Myers JS" . + "Hubatsch DA" . + "Budenz DL" . + "DuBiner HB" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "PurposeTo determine whether intraocular pressure ( IOP ) lowering with fixed - combination brinzolamide / brimonidine ( BBFC ) adjunctive to a prostaglandin analog ( PGA ) was superior to that of vehicle + PGA in patients with" . + "6 - week" . + . + . + . + "ConclusionsTherapy with BBFC produced an additive IOP - lowering effect compared with a PGA alone or in conjunction with vehicle ." . + . + . + . + . + . + "open - angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis" . + . + . + . + . + . + "BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction ." . + . + . +# RDF export of group: Population + . + "Population " . + "inadequately controlled with PGA" . + . + . + . + "adults with open - angle glaucoma or ocular hypertension and with mean IOP ≥ 21 and < 32   mm   Hg , whereas receiving an open - label PGA" . +# RDF export of group: Endpoint + . + "Endpoint d IOP " . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Brinz/BrimoFC" . + . + . + . + . + . + . + "Arm v+PGA" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention Brinz/BrimoFC" . + . + "3 times daily" . + . + . + . + "Intervention pa" . + . + "once - daily" . + . + . + "Intervention v" . + . + "3 times daily" . + . +# RDF export of group: Medication + . + "Medication brin " . + . + . + . + . + . + "Medication brim" . + . + . + . + . + . + "Medication pa" . + . + . + . + . + . + "Medication vehicle " . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome d IOP bb week 6" . + . + "17 . 1" . + "0 . 4" . + "week 6" . + . + "Outcome d IOP v week 6" . + . + "20 . 5" . + "0 . 4" . + "week 6" . + . + "Outcome d IOP bb " . + . + "5 . 7" . + "25" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups d IOP week 6" . + "- 3 . 4" . + "P < 0 . 0001" . + "95 % confidence interval , - 4 . 5 to - 2 . 4   mm   Hg" . + "0 . 5" . + . + . +# RDF export of group: EvidenceQuality + . + "EvidenceQuality " . + "JSM has received research funding from Alcon , Allergan , Glaukos , Inotek , and Merck ; consultant fees from Aerie , Alcon , Allergan , Inotek , and Sucampo ; and lecture fees from Alcon , Allergan , and Sucampo ." . + "DAH is an Alcon employee ." . + "DLB" . + "has received consultant fees from Alcon and Ivantis , and research support from the National Eye Institute , Glaucoma Research Foundation , Research to Prevent Blindness , and New World Medical , Inc . HBD has received speakers bureau fees from Alcon ." . \ No newline at end of file diff --git a/data/gl 27367743_export.csv b/data/gl 27367743_export.csv new file mode 100644 index 0000000..3b3f9d2 --- /dev/null +++ b/data/gl 27367743_export.csv @@ -0,0 +1,667 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +500, 1, 1, 1, 0, 3, 0, 3, "Eye" +500, 1, 2, 2, 4, 5, 4, 5, "(" +500, 1, 3, 3, 6, 10, 6, 10, "Lond" +500, 1, 4, 4, 11, 12, 11, 12, ")" +500, 1, 5, 5, 13, 14, 13, 14, "." +500, 2, 1, 6, 0, 4, 15, 19, "2016" +500, 2, 2, 7, 5, 8, 20, 23, "Oct" +500, 2, 3, 8, 9, 10, 24, 25, ";" +500, 2, 4, 9, 11, 13, 26, 28, "30" +500, 2, 5, 10, 14, 15, 29, 30, "(" +500, 2, 6, 11, 16, 18, 31, 33, "10" +500, 2, 7, 12, 19, 20, 34, 35, ")" +500, 2, 8, 13, 21, 22, 36, 37, ":" +500, 2, 9, 14, 23, 27, 38, 42, "1343" +500, 2, 10, 15, 28, 29, 43, 44, "-" +500, 2, 11, 16, 30, 34, 45, 49, "1350" +500, 2, 12, 17, 35, 36, 50, 51, "." +500, 2, 13, 18, 37, 40, 52, 55, "doi" +500, 2, 14, 19, 41, 42, 56, 57, ":" +500, 2, 15, 20, 43, 45, 58, 60, "10" +500, 2, 16, 21, 46, 47, 61, 62, "." +500, 2, 17, 22, 48, 52, 63, 67, "1038" +500, 2, 18, 23, 53, 54, 68, 69, "/" +500, 2, 19, 24, 55, 58, 70, 73, "eye" +500, 2, 20, 25, 59, 60, 74, 75, "." +500, 2, 21, 26, 61, 65, 76, 80, "2016" +500, 2, 22, 27, 66, 67, 81, 82, "." +500, 2, 23, 28, 68, 71, 83, 86, "126" +500, 2, 24, 29, 72, 73, 87, 88, "." +500, 3, 1, 30, 0, 4, 89, 93, "Epub" +500, 3, 2, 31, 5, 9, 94, 98, "2016" +500, 3, 3, 32, 10, 13, 99, 102, "Jul" +500, 3, 4, 33, 14, 15, 103, 104, "1" +500, 3, 5, 34, 16, 17, 105, 106, "." +500, 4, 1, 35, 0, 6, 107, 113, "Ocular" +500, 4, 2, 36, 7, 18, 114, 125, "hypotensive" +500, 4, 3, 37, 19, 25, 126, 132, "effect" +500, 4, 4, 38, 26, 28, 133, 135, "of" +500, 4, 5, 39, 29, 34, 136, 141, "fixed" +500, 4, 6, 40, 35, 36, 142, 143, "-" +500, 4, 7, 41, 37, 48, 144, 155, "combination" +500, 4, 8, 42, 49, 61, 156, 168, "brinzolamide" +500, 4, 9, 43, 62, 63, 169, 170, "/" +500, 4, 10, 44, 64, 75, 171, 182, "brimonidine" +500, 4, 11, 45, 76, 86, 183, 193, "adjunctive" +500, 4, 12, 46, 87, 89, 194, 196, "to" +500, 4, 13, 47, 90, 91, 197, 198, "a" +500, 4, 14, 48, 92, 105, 199, 212, "prostaglandin" +500, 4, 15, 49, 106, 112, 213, 219, "analog" +500, 4, 16, 50, 113, 114, 220, 221, ":" +500, 4, 17, 51, 115, 116, 222, 223, "a" +500, 4, 18, 52, 117, 127, 224, 234, "randomized" +500, 4, 19, 53, 128, 136, 235, 243, "clinical" +500, 4, 20, 54, 137, 142, 244, 249, "trial" +500, 4, 21, 55, 143, 144, 250, 251, "." +500, 5, 1, 56, 0, 8, 252, 260, "Fechtner" +500, 5, 2, 57, 9, 11, 261, 263, "RD" +500, 5, 3, 58, 12, 13, 264, 265, "(" +500, 5, 4, 59, 14, 15, 266, 267, "1" +500, 5, 5, 60, 16, 17, 268, 269, ")" +500, 5, 6, 61, 18, 19, 270, 271, "," +500, 5, 7, 62, 20, 25, 272, 277, "Myers" +500, 5, 8, 63, 26, 28, 278, 280, "JS" +500, 5, 9, 64, 29, 30, 281, 282, "(" +500, 5, 10, 65, 31, 32, 283, 284, "2" +500, 5, 11, 66, 33, 34, 285, 286, ")" +500, 5, 12, 67, 35, 36, 287, 288, "," +500, 5, 13, 68, 37, 45, 289, 297, "Hubatsch" +500, 5, 14, 69, 46, 48, 298, 300, "DA" +500, 5, 15, 70, 49, 50, 301, 302, "(" +500, 5, 16, 71, 51, 52, 303, 304, "3" +500, 5, 17, 72, 53, 54, 305, 306, ")" +500, 5, 18, 73, 55, 56, 307, 308, "," +500, 5, 19, 74, 57, 63, 309, 315, "Budenz" +500, 5, 20, 75, 64, 66, 316, 318, "DL" +500, 5, 21, 76, 67, 68, 319, 320, "(" +500, 5, 22, 77, 69, 70, 321, 322, "4" +500, 5, 23, 78, 71, 72, 323, 324, ")" +500, 5, 24, 79, 73, 74, 325, 326, "," +500, 5, 25, 80, 75, 82, 327, 334, "DuBiner" +500, 5, 26, 81, 83, 85, 335, 337, "HB" +500, 5, 27, 82, 86, 87, 338, 339, "(" +500, 5, 28, 83, 88, 89, 340, 341, "5" +500, 5, 29, 84, 90, 91, 342, 343, ")" +500, 5, 30, 85, 92, 93, 344, 345, "." +500, 6, 1, 86, 0, 6, 346, 352, "Author" +500, 6, 2, 87, 7, 18, 353, 364, "information" +500, 6, 3, 88, 19, 20, 365, 366, ":" +500, 6, 4, 89, 21, 22, 367, 368, "(" +500, 6, 5, 90, 23, 24, 369, 370, "1" +500, 6, 6, 91, 25, 26, 371, 372, ")" +500, 6, 7, 92, 27, 37, 373, 383, "Department" +500, 6, 8, 93, 38, 40, 384, 386, "of" +500, 6, 9, 94, 41, 54, 387, 400, "Ophthalmology" +500, 6, 10, 95, 55, 56, 401, 402, "," +500, 6, 11, 96, 57, 61, 403, 407, "SUNY" +500, 6, 12, 97, 62, 69, 408, 415, "Upstate" +500, 6, 13, 98, 70, 77, 416, 423, "Medical" +500, 6, 14, 99, 78, 88, 424, 434, "University" +500, 6, 15, 100, 89, 90, 435, 436, "," +500, 6, 16, 101, 91, 99, 437, 445, "Syracuse" +500, 6, 17, 102, 100, 101, 446, 447, "," +500, 6, 18, 103, 102, 104, 448, 450, "NY" +500, 6, 19, 104, 105, 106, 451, 452, "," +500, 6, 20, 105, 107, 110, 453, 456, "USA" +500, 6, 21, 106, 111, 112, 457, 458, "." +500, 7, 1, 107, 0, 1, 459, 460, "(" +500, 7, 2, 108, 2, 3, 461, 462, "2" +500, 7, 3, 109, 4, 5, 463, 464, ")" +500, 7, 4, 110, 6, 11, 465, 470, "Wills" +500, 7, 5, 111, 12, 15, 471, 474, "Eye" +500, 7, 6, 112, 16, 24, 475, 483, "Hospital" +500, 7, 7, 113, 25, 26, 484, 485, "," +500, 7, 8, 114, 27, 39, 486, 498, "Philadelphia" +500, 7, 9, 115, 40, 41, 499, 500, "," +500, 7, 10, 116, 42, 44, 501, 503, "PA" +500, 7, 11, 117, 45, 46, 504, 505, "," +500, 7, 12, 118, 47, 50, 506, 509, "USA" +500, 7, 13, 119, 51, 52, 510, 511, "." +500, 8, 1, 120, 0, 1, 512, 513, "(" +500, 8, 2, 121, 2, 3, 514, 515, "3" +500, 8, 3, 122, 4, 5, 516, 517, ")" +500, 8, 4, 123, 6, 11, 518, 523, "Alcon" +500, 8, 5, 124, 12, 24, 524, 536, "Laboratories" +500, 8, 6, 125, 25, 26, 537, 538, "," +500, 8, 7, 126, 27, 30, 539, 542, "Inc" +500, 8, 8, 127, 31, 32, 543, 544, "." +500, 8, 9, 128, 33, 34, 545, 546, "," +500, 8, 10, 129, 35, 39, 547, 551, "Fort" +500, 8, 11, 130, 40, 45, 552, 557, "Worth" +500, 8, 12, 131, 46, 47, 558, 559, "," +500, 8, 13, 132, 48, 50, 560, 562, "TX" +500, 8, 14, 133, 51, 52, 563, 564, "," +500, 8, 15, 134, 53, 56, 565, 568, "USA" +500, 8, 16, 135, 57, 58, 569, 570, "." +500, 9, 1, 136, 0, 1, 571, 572, "(" +500, 9, 2, 137, 2, 3, 573, 574, "4" +500, 9, 3, 138, 4, 5, 575, 576, ")" +500, 9, 4, 139, 6, 16, 577, 587, "Department" +500, 9, 5, 140, 17, 19, 588, 590, "of" +500, 9, 6, 141, 20, 33, 591, 604, "Ophthalmology" +500, 9, 7, 142, 34, 35, 605, 606, "," +500, 9, 8, 143, 36, 46, 607, 617, "University" +500, 9, 9, 144, 47, 49, 618, 620, "of" +500, 9, 10, 145, 50, 55, 621, 626, "North" +500, 9, 11, 146, 56, 64, 627, 635, "Carolina" +500, 9, 12, 147, 65, 66, 636, 637, "," +500, 9, 13, 148, 67, 73, 638, 644, "Chapel" +500, 9, 14, 149, 74, 78, 645, 649, "Hill" +500, 9, 15, 150, 79, 80, 650, 651, "," +500, 9, 16, 151, 81, 83, 652, 654, "NC" +500, 9, 17, 152, 84, 85, 655, 656, "," +500, 9, 18, 153, 86, 89, 657, 660, "USA" +500, 9, 19, 154, 90, 91, 661, 662, "." +500, 10, 1, 155, 0, 1, 663, 664, "(" +500, 10, 2, 156, 2, 3, 665, 666, "5" +500, 10, 3, 157, 4, 5, 667, 668, ")" +500, 10, 4, 158, 6, 13, 669, 676, "Clayton" +500, 10, 5, 159, 14, 17, 677, 680, "Eye" +500, 10, 6, 160, 18, 24, 681, 687, "Center" +500, 10, 7, 161, 25, 26, 688, 689, "," +500, 10, 8, 162, 27, 33, 690, 696, "Morrow" +500, 10, 9, 163, 34, 35, 697, 698, "," +500, 10, 10, 164, 36, 38, 699, 701, "GA" +500, 10, 11, 165, 39, 40, 702, 703, "," +500, 10, 12, 166, 41, 44, 704, 707, "USA" +500, 10, 13, 167, 45, 46, 708, 709, "." +500, 11, 1, 168, 0, 9, 710, 719, "PurposeTo" +500, 11, 2, 169, 10, 19, 720, 729, "determine" +500, 11, 3, 170, 20, 27, 730, 737, "whether" +500, 11, 4, 171, 28, 39, 738, 749, "intraocular" +500, 11, 5, 172, 40, 48, 750, 758, "pressure" +500, 11, 6, 173, 49, 50, 759, 760, "(" +500, 11, 7, 174, 51, 54, 761, 764, "IOP" +500, 11, 8, 175, 55, 56, 765, 766, ")" +500, 11, 9, 176, 57, 65, 767, 775, "lowering" +500, 11, 10, 177, 66, 70, 776, 780, "with" +500, 11, 11, 178, 71, 76, 781, 786, "fixed" +500, 11, 12, 179, 77, 78, 787, 788, "-" +500, 11, 13, 180, 79, 90, 789, 800, "combination" +500, 11, 14, 181, 91, 103, 801, 813, "brinzolamide" +500, 11, 15, 182, 104, 105, 814, 815, "/" +500, 11, 16, 183, 106, 117, 816, 827, "brimonidine" +500, 11, 17, 184, 118, 119, 828, 829, "(" +500, 11, 18, 185, 120, 124, 830, 834, "BBFC" +500, 11, 19, 186, 125, 126, 835, 836, ")" +500, 11, 20, 187, 127, 137, 837, 847, "adjunctive" +500, 11, 21, 188, 138, 140, 848, 850, "to" +500, 11, 22, 189, 141, 142, 851, 852, "a" +500, 11, 23, 190, 143, 156, 853, 866, "prostaglandin" +500, 11, 24, 191, 157, 163, 867, 873, "analog" +500, 11, 25, 192, 164, 165, 874, 875, "(" +500, 11, 26, 193, 166, 169, 876, 879, "PGA" +500, 11, 27, 194, 170, 171, 880, 881, ")" +500, 11, 28, 195, 172, 175, 882, 885, "was" +500, 11, 29, 196, 176, 184, 886, 894, "superior" +500, 11, 30, 197, 185, 187, 895, 897, "to" +500, 11, 31, 198, 188, 192, 898, 902, "that" +500, 11, 32, 199, 193, 195, 903, 905, "of" +500, 11, 33, 200, 196, 203, 906, 913, "vehicle" +500, 11, 34, 201, 204, 205, 914, 915, "+" +500, 11, 35, 202, 206, 209, 916, 919, "PGA" +500, 11, 36, 203, 210, 212, 920, 922, "in" +500, 11, 37, 204, 213, 221, 923, 931, "patients" +500, 11, 38, 205, 222, 226, 932, 936, "with" +500, 11, 39, 206, 227, 231, 937, 941, "open" +500, 11, 40, 207, 232, 233, 942, 943, "-" +500, 11, 41, 208, 234, 239, 944, 949, "angle" +500, 11, 42, 209, 240, 248, 950, 958, "glaucoma" +500, 11, 43, 210, 249, 251, 959, 961, "or" +500, 11, 44, 211, 252, 258, 962, 968, "ocular" +500, 11, 45, 212, 259, 271, 969, 981, "hypertension" +500, 11, 46, 213, 272, 275, 982, 985, "who" +500, 11, 47, 214, 276, 280, 986, 990, "were" +500, 11, 48, 215, 281, 293, 991, 1003, "inadequately" +500, 11, 49, 216, 294, 304, 1004, 1014, "controlled" +500, 11, 50, 217, 305, 309, 1015, 1019, "with" +500, 11, 51, 218, 310, 313, 1020, 1023, "PGA" +500, 11, 52, 219, 314, 336, 1024, 1046, "monotherapyMethodsThis" +500, 11, 53, 220, 337, 338, 1047, 1048, "6" +500, 11, 54, 221, 339, 340, 1049, 1050, "-" +500, 11, 55, 222, 341, 345, 1051, 1055, "week" +500, 11, 56, 223, 346, 347, 1056, 1057, "," +500, 11, 57, 224, 348, 359, 1058, 1069, "multicenter" +500, 11, 58, 225, 360, 361, 1070, 1071, "," +500, 11, 59, 226, 362, 372, 1072, 1082, "randomized" +500, 11, 60, 227, 373, 374, 1083, 1084, "," +500, 11, 61, 228, 375, 381, 1085, 1091, "double" +500, 11, 62, 229, 382, 383, 1092, 1093, "-" +500, 11, 63, 230, 384, 390, 1094, 1100, "masked" +500, 11, 64, 231, 391, 392, 1101, 1102, "," +500, 11, 65, 232, 393, 401, 1103, 1111, "parallel" +500, 11, 66, 233, 402, 403, 1112, 1113, "-" +500, 11, 67, 234, 404, 409, 1114, 1119, "group" +500, 11, 68, 235, 410, 415, 1120, 1125, "trial" +500, 11, 69, 236, 416, 419, 1126, 1129, "was" +500, 11, 70, 237, 420, 429, 1130, 1139, "conducted" +500, 11, 71, 238, 430, 432, 1140, 1142, "at" +500, 11, 72, 239, 433, 435, 1143, 1145, "30" +500, 11, 73, 240, 436, 444, 1146, 1154, "clinical" +500, 11, 74, 241, 445, 450, 1155, 1160, "sites" +500, 11, 75, 242, 451, 453, 1161, 1163, "in" +500, 11, 76, 243, 454, 457, 1164, 1167, "the" +500, 11, 77, 244, 458, 464, 1168, 1174, "United" +500, 11, 78, 245, 465, 471, 1175, 1181, "States" +500, 11, 79, 246, 472, 479, 1182, 1189, "between" +500, 11, 80, 247, 480, 487, 1190, 1197, "October" +500, 11, 81, 248, 488, 492, 1198, 1202, "2013" +500, 11, 82, 249, 493, 496, 1203, 1206, "and" +500, 11, 83, 250, 497, 500, 1207, 1210, "May" +500, 11, 84, 251, 501, 505, 1211, 1215, "2014" +500, 11, 85, 252, 506, 507, 1216, 1217, "." +500, 12, 1, 253, 0, 8, 1218, 1226, "Eligible" +500, 12, 2, 254, 9, 17, 1227, 1235, "patients" +500, 12, 3, 255, 18, 22, 1236, 1240, "were" +500, 12, 4, 256, 23, 29, 1241, 1247, "adults" +500, 12, 5, 257, 30, 34, 1248, 1252, "with" +500, 12, 6, 258, 35, 39, 1253, 1257, "open" +500, 12, 7, 259, 40, 41, 1258, 1259, "-" +500, 12, 8, 260, 42, 47, 1260, 1265, "angle" +500, 12, 9, 261, 48, 56, 1266, 1274, "glaucoma" +500, 12, 10, 262, 57, 59, 1275, 1277, "or" +500, 12, 11, 263, 60, 66, 1278, 1284, "ocular" +500, 12, 12, 264, 67, 79, 1285, 1297, "hypertension" +500, 12, 13, 265, 80, 83, 1298, 1301, "and" +500, 12, 14, 266, 84, 88, 1302, 1306, "with" +500, 12, 15, 267, 89, 93, 1307, 1311, "mean" +500, 12, 16, 268, 94, 97, 1312, 1315, "IOP" +500, 12, 17, 269, 98, 99, 1316, 1317, "≥" +500, 12, 18, 270, 100, 102, 1318, 1320, "21" +500, 12, 19, 271, 103, 106, 1321, 1324, "and" +500, 12, 20, 272, 107, 108, 1325, 1326, "<" +500, 12, 21, 273, 109, 111, 1327, 1329, "32" +500, 12, 22, 274, 112, 113, 1330, 1331, " " +500, 12, 23, 275, 114, 116, 1332, 1334, "mm" +500, 12, 24, 276, 117, 118, 1335, 1336, " " +500, 12, 25, 277, 119, 121, 1337, 1339, "Hg" +500, 12, 26, 278, 122, 123, 1340, 1341, "," +500, 12, 27, 279, 124, 131, 1342, 1349, "whereas" +500, 12, 28, 280, 132, 141, 1350, 1359, "receiving" +500, 12, 29, 281, 142, 144, 1360, 1362, "an" +500, 12, 30, 282, 145, 149, 1363, 1367, "open" +500, 12, 31, 283, 150, 151, 1368, 1369, "-" +500, 12, 32, 284, 152, 157, 1370, 1375, "label" +500, 12, 33, 285, 158, 161, 1376, 1379, "PGA" +500, 12, 34, 286, 162, 163, 1380, 1381, "(" +500, 12, 35, 287, 164, 175, 1382, 1393, "latanoprost" +500, 12, 36, 288, 176, 177, 1394, 1395, "," +500, 12, 37, 289, 178, 189, 1396, 1407, "bimatoprost" +500, 12, 38, 290, 190, 191, 1408, 1409, "," +500, 12, 39, 291, 192, 194, 1410, 1412, "or" +500, 12, 40, 292, 195, 205, 1413, 1423, "travoprost" +500, 12, 41, 293, 206, 207, 1424, 1425, ")" +500, 12, 42, 294, 208, 209, 1426, 1427, "." +500, 13, 1, 295, 0, 8, 1428, 1436, "Patients" +500, 13, 2, 296, 9, 18, 1437, 1446, "instilled" +500, 13, 3, 297, 19, 20, 1447, 1448, "a" +500, 13, 4, 298, 21, 24, 1449, 1452, "PGA" +500, 13, 5, 299, 25, 29, 1453, 1457, "once" +500, 13, 6, 300, 30, 31, 1458, 1459, "-" +500, 13, 7, 301, 32, 37, 1460, 1465, "daily" +500, 13, 8, 302, 38, 40, 1466, 1468, "in" +500, 13, 9, 303, 41, 42, 1469, 1470, "a" +500, 13, 10, 304, 43, 46, 1471, 1474, "run" +500, 13, 11, 305, 47, 48, 1475, 1476, "-" +500, 13, 12, 306, 49, 51, 1477, 1479, "in" +500, 13, 13, 307, 52, 57, 1480, 1485, "phase" +500, 13, 14, 308, 58, 64, 1486, 1492, "before" +500, 13, 15, 309, 65, 78, 1493, 1506, "randomization" +500, 13, 16, 310, 79, 81, 1507, 1509, "to" +500, 13, 17, 311, 82, 88, 1510, 1516, "masked" +500, 13, 18, 312, 89, 93, 1517, 1521, "BBFC" +500, 13, 19, 313, 94, 96, 1522, 1524, "or" +500, 13, 20, 314, 97, 104, 1525, 1532, "vehicle" +500, 13, 21, 315, 105, 115, 1533, 1543, "adjunctive" +500, 13, 22, 316, 116, 125, 1544, 1553, "treatment" +500, 13, 23, 317, 126, 127, 1554, 1555, "." +500, 14, 1, 318, 0, 6, 1556, 1562, "Masked" +500, 14, 2, 319, 7, 17, 1563, 1573, "treatments" +500, 14, 3, 320, 18, 22, 1574, 1578, "were" +500, 14, 4, 321, 23, 32, 1579, 1588, "instilled" +500, 14, 5, 322, 33, 34, 1589, 1590, "3" +500, 14, 6, 323, 35, 40, 1591, 1596, "times" +500, 14, 7, 324, 41, 46, 1597, 1602, "daily" +500, 14, 8, 325, 47, 50, 1603, 1606, "for" +500, 14, 9, 326, 51, 52, 1607, 1608, "6" +500, 14, 10, 327, 53, 58, 1609, 1614, "weeks" +500, 14, 11, 328, 59, 60, 1615, 1616, "," +500, 14, 12, 329, 61, 64, 1617, 1620, "and" +500, 14, 13, 330, 65, 73, 1621, 1629, "patients" +500, 14, 14, 331, 74, 83, 1630, 1639, "continued" +500, 14, 15, 332, 84, 88, 1640, 1644, "once" +500, 14, 16, 333, 89, 90, 1645, 1646, "-" +500, 14, 17, 334, 91, 96, 1647, 1652, "daily" +500, 14, 18, 335, 97, 100, 1653, 1656, "use" +500, 14, 19, 336, 101, 103, 1657, 1659, "of" +500, 14, 20, 337, 104, 109, 1660, 1665, "their" +500, 14, 21, 338, 110, 113, 1666, 1669, "PGA" +500, 14, 22, 339, 114, 115, 1670, 1671, "." +500, 15, 1, 340, 0, 3, 1672, 1675, "The" +500, 15, 2, 341, 4, 11, 1676, 1683, "primary" +500, 15, 3, 342, 12, 20, 1684, 1692, "efficacy" +500, 15, 4, 343, 21, 24, 1693, 1696, "end" +500, 15, 5, 344, 25, 30, 1697, 1702, "point" +500, 15, 6, 345, 31, 34, 1703, 1706, "was" +500, 15, 7, 346, 35, 38, 1707, 1710, "the" +500, 15, 8, 347, 39, 46, 1711, 1718, "between" +500, 15, 9, 348, 47, 48, 1719, 1720, "-" +500, 15, 10, 349, 49, 54, 1721, 1726, "group" +500, 15, 11, 350, 55, 65, 1727, 1737, "difference" +500, 15, 12, 351, 66, 68, 1738, 1740, "in" +500, 15, 13, 352, 69, 73, 1741, 1745, "mean" +500, 15, 14, 353, 74, 81, 1746, 1753, "diurnal" +500, 15, 15, 354, 82, 85, 1754, 1757, "IOP" +500, 15, 16, 355, 86, 87, 1758, 1759, "(" +500, 15, 17, 356, 88, 95, 1760, 1767, "average" +500, 15, 18, 357, 96, 98, 1768, 1770, "of" +500, 15, 19, 358, 99, 103, 1771, 1775, "0800" +500, 15, 20, 359, 104, 105, 1776, 1777, "," +500, 15, 21, 360, 106, 110, 1778, 1782, "1000" +500, 15, 22, 361, 111, 112, 1783, 1784, "," +500, 15, 23, 362, 113, 117, 1785, 1789, "1500" +500, 15, 24, 363, 118, 119, 1790, 1791, "," +500, 15, 25, 364, 120, 123, 1792, 1795, "and" +500, 15, 26, 365, 124, 128, 1796, 1800, "1700" +500, 15, 27, 366, 129, 134, 1801, 1806, "hours" +500, 15, 28, 367, 135, 139, 1807, 1811, "time" +500, 15, 29, 368, 140, 146, 1812, 1818, "points" +500, 15, 30, 369, 147, 148, 1819, 1820, ")" +500, 15, 31, 370, 149, 151, 1821, 1823, "at" +500, 15, 32, 371, 152, 156, 1824, 1828, "week" +500, 15, 33, 372, 157, 158, 1829, 1830, "6" +500, 15, 34, 373, 159, 160, 1831, 1832, "." +500, 15, 35, 374, 161, 170, 1833, 1842, "ResultsAt" +500, 15, 36, 375, 171, 175, 1843, 1847, "week" +500, 15, 37, 376, 176, 177, 1848, 1849, "6" +500, 15, 38, 377, 178, 179, 1850, 1851, "," +500, 15, 39, 378, 180, 184, 1852, 1856, "mean" +500, 15, 40, 379, 185, 192, 1857, 1864, "diurnal" +500, 15, 41, 380, 193, 196, 1865, 1868, "IOP" +500, 15, 42, 381, 197, 201, 1869, 1873, "with" +500, 15, 43, 382, 202, 206, 1874, 1878, "BBFC" +500, 15, 44, 383, 207, 208, 1879, 1880, "+" +500, 15, 45, 384, 209, 212, 1881, 1884, "PGA" +500, 15, 46, 385, 213, 216, 1885, 1888, "was" +500, 15, 47, 386, 217, 222, 1889, 1894, "lower" +500, 15, 48, 387, 223, 227, 1895, 1899, "than" +500, 15, 49, 388, 228, 232, 1900, 1904, "with" +500, 15, 50, 389, 233, 240, 1905, 1912, "vehicle" +500, 15, 51, 390, 241, 242, 1913, 1914, "+" +500, 15, 52, 391, 243, 246, 1915, 1918, "PGA" +500, 15, 53, 392, 247, 248, 1919, 1920, "(" +500, 15, 54, 393, 249, 251, 1921, 1923, "17" +500, 15, 55, 394, 252, 253, 1924, 1925, "." +500, 15, 56, 395, 254, 255, 1926, 1927, "1" +500, 15, 57, 396, 256, 257, 1928, 1929, "±" +500, 15, 58, 397, 258, 259, 1930, 1931, "0" +500, 15, 59, 398, 260, 261, 1932, 1933, "." +500, 15, 60, 399, 262, 263, 1934, 1935, "4" +500, 15, 61, 400, 264, 265, 1936, 1937, " " +500, 15, 62, 401, 266, 268, 1938, 1940, "mm" +500, 15, 63, 402, 269, 270, 1941, 1942, " " +500, 15, 64, 403, 271, 273, 1943, 1945, "Hg" +500, 15, 65, 404, 274, 276, 1946, 1948, "vs" +500, 15, 66, 405, 277, 279, 1949, 1951, "20" +500, 15, 67, 406, 280, 281, 1952, 1953, "." +500, 15, 68, 407, 282, 283, 1954, 1955, "5" +500, 15, 69, 408, 284, 285, 1956, 1957, "±" +500, 15, 70, 409, 286, 287, 1958, 1959, "0" +500, 15, 71, 410, 288, 289, 1960, 1961, "." +500, 15, 72, 411, 290, 291, 1962, 1963, "4" +500, 15, 73, 412, 292, 293, 1964, 1965, " " +500, 15, 74, 413, 294, 296, 1966, 1968, "mm" +500, 15, 75, 414, 297, 298, 1969, 1970, " " +500, 15, 76, 415, 299, 301, 1971, 1973, "Hg" +500, 15, 77, 416, 302, 303, 1974, 1975, ";" +500, 15, 78, 417, 304, 311, 1976, 1983, "between" +500, 15, 79, 418, 312, 313, 1984, 1985, "-" +500, 15, 80, 419, 314, 319, 1986, 1991, "group" +500, 15, 81, 420, 320, 330, 1992, 2002, "difference" +500, 15, 82, 421, 331, 332, 2003, 2004, "," +500, 15, 83, 422, 333, 334, 2005, 2006, "-" +500, 15, 84, 423, 335, 336, 2007, 2008, "3" +500, 15, 85, 424, 337, 338, 2009, 2010, "." +500, 15, 86, 425, 339, 340, 2011, 2012, "4" +500, 15, 87, 426, 341, 342, 2013, 2014, "±" +500, 15, 88, 427, 343, 344, 2015, 2016, "0" +500, 15, 89, 428, 345, 346, 2017, 2018, "." +500, 15, 90, 429, 347, 348, 2019, 2020, "5" +500, 15, 91, 430, 349, 350, 2021, 2022, " " +500, 15, 92, 431, 351, 353, 2023, 2025, "mm" +500, 15, 93, 432, 354, 355, 2026, 2027, " " +500, 15, 94, 433, 356, 358, 2028, 2030, "Hg" +500, 15, 95, 434, 359, 360, 2031, 2032, ";" +500, 15, 96, 435, 361, 362, 2033, 2034, "P" +500, 15, 97, 436, 363, 364, 2035, 2036, "<" +500, 15, 98, 437, 365, 366, 2037, 2038, "0" +500, 15, 99, 438, 367, 368, 2039, 2040, "." +500, 15, 100, 439, 369, 373, 2041, 2045, "0001" +500, 15, 101, 440, 374, 375, 2046, 2047, ";" +500, 15, 102, 441, 376, 378, 2048, 2050, "95" +500, 15, 103, 442, 379, 380, 2051, 2052, "%" +500, 15, 104, 443, 381, 391, 2053, 2063, "confidence" +500, 15, 105, 444, 392, 400, 2064, 2072, "interval" +500, 15, 106, 445, 401, 402, 2073, 2074, "," +500, 15, 107, 446, 403, 404, 2075, 2076, "-" +500, 15, 108, 447, 405, 406, 2077, 2078, "4" +500, 15, 109, 448, 407, 408, 2079, 2080, "." +500, 15, 110, 449, 409, 410, 2081, 2082, "5" +500, 15, 111, 450, 411, 413, 2083, 2085, "to" +500, 15, 112, 451, 414, 415, 2086, 2087, "-" +500, 15, 113, 452, 416, 417, 2088, 2089, "2" +500, 15, 114, 453, 418, 419, 2090, 2091, "." +500, 15, 115, 454, 420, 421, 2092, 2093, "4" +500, 15, 116, 455, 422, 423, 2094, 2095, " " +500, 15, 117, 456, 424, 426, 2096, 2098, "mm" +500, 15, 118, 457, 427, 428, 2099, 2100, " " +500, 15, 119, 458, 429, 431, 2101, 2103, "Hg" +500, 15, 120, 459, 432, 433, 2104, 2105, ")" +500, 15, 121, 460, 434, 435, 2106, 2107, "." +500, 16, 1, 461, 0, 4, 2108, 2112, "BBFC" +500, 16, 2, 462, 5, 6, 2113, 2114, "+" +500, 16, 3, 463, 7, 10, 2115, 2118, "PGA" +500, 16, 4, 464, 11, 18, 2119, 2126, "reduced" +500, 16, 5, 465, 19, 23, 2127, 2131, "mean" +500, 16, 6, 466, 24, 31, 2132, 2139, "diurnal" +500, 16, 7, 467, 32, 35, 2140, 2143, "IOP" +500, 16, 8, 468, 36, 38, 2144, 2146, "by" +500, 16, 9, 469, 39, 40, 2147, 2148, "5" +500, 16, 10, 470, 41, 42, 2149, 2150, "." +500, 16, 11, 471, 43, 44, 2151, 2152, "7" +500, 16, 12, 472, 45, 46, 2153, 2154, " " +500, 16, 13, 473, 47, 49, 2155, 2157, "mm" +500, 16, 14, 474, 50, 51, 2158, 2159, " " +500, 16, 15, 475, 52, 54, 2160, 2162, "Hg" +500, 16, 16, 476, 55, 56, 2163, 2164, "(" +500, 16, 17, 477, 57, 59, 2165, 2167, "25" +500, 16, 18, 478, 60, 61, 2168, 2169, "%" +500, 16, 19, 479, 62, 63, 2170, 2171, ")" +500, 16, 20, 480, 64, 68, 2172, 2176, "from" +500, 16, 21, 481, 69, 72, 2177, 2180, "the" +500, 16, 22, 482, 73, 81, 2181, 2189, "baseline" +500, 16, 23, 483, 82, 85, 2190, 2193, "IOP" +500, 16, 24, 484, 86, 94, 2194, 2202, "achieved" +500, 16, 25, 485, 95, 99, 2203, 2207, "with" +500, 16, 26, 486, 100, 103, 2208, 2211, "PGA" +500, 16, 27, 487, 104, 115, 2212, 2223, "monotherapy" +500, 16, 28, 488, 116, 117, 2224, 2225, "." +500, 16, 29, 489, 118, 136, 2226, 2244, "ConclusionsTherapy" +500, 16, 30, 490, 137, 141, 2245, 2249, "with" +500, 16, 31, 491, 142, 146, 2250, 2254, "BBFC" +500, 16, 32, 492, 147, 155, 2255, 2263, "produced" +500, 16, 33, 493, 156, 158, 2264, 2266, "an" +500, 16, 34, 494, 159, 167, 2267, 2275, "additive" +500, 16, 35, 495, 168, 171, 2276, 2279, "IOP" +500, 16, 36, 496, 172, 173, 2280, 2281, "-" +500, 16, 37, 497, 174, 182, 2282, 2290, "lowering" +500, 16, 38, 498, 183, 189, 2291, 2297, "effect" +500, 16, 39, 499, 190, 198, 2298, 2306, "compared" +500, 16, 40, 500, 199, 203, 2307, 2311, "with" +500, 16, 41, 501, 204, 205, 2312, 2313, "a" +500, 16, 42, 502, 206, 209, 2314, 2317, "PGA" +500, 16, 43, 503, 210, 215, 2318, 2323, "alone" +500, 16, 44, 504, 216, 218, 2324, 2326, "or" +500, 16, 45, 505, 219, 221, 2327, 2329, "in" +500, 16, 46, 506, 222, 233, 2330, 2341, "conjunction" +500, 16, 47, 507, 234, 238, 2342, 2346, "with" +500, 16, 48, 508, 239, 246, 2347, 2354, "vehicle" +500, 16, 49, 509, 247, 248, 2355, 2356, "." +500, 17, 1, 510, 0, 4, 2357, 2361, "BBFC" +500, 17, 2, 511, 5, 8, 2362, 2365, "may" +500, 17, 3, 512, 9, 16, 2366, 2373, "provide" +500, 17, 4, 513, 17, 19, 2374, 2376, "an" +500, 17, 5, 514, 20, 29, 2377, 2386, "effective" +500, 17, 6, 515, 30, 39, 2387, 2396, "treatment" +500, 17, 7, 516, 40, 46, 2397, 2403, "option" +500, 17, 8, 517, 47, 50, 2404, 2407, "for" +500, 17, 9, 518, 51, 59, 2408, 2416, "patients" +500, 17, 10, 519, 60, 69, 2417, 2426, "receiving" +500, 17, 11, 520, 70, 73, 2427, 2430, "PGA" +500, 17, 12, 521, 74, 85, 2431, 2442, "monotherapy" +500, 17, 13, 522, 86, 89, 2443, 2446, "who" +500, 17, 14, 523, 90, 97, 2447, 2454, "require" +500, 17, 15, 524, 98, 108, 2455, 2465, "additional" +500, 17, 16, 525, 109, 112, 2466, 2469, "IOP" +500, 17, 17, 526, 113, 122, 2470, 2479, "reduction" +500, 17, 18, 527, 123, 124, 2480, 2481, "." +500, 18, 1, 528, 0, 3, 2482, 2485, "DOI" +500, 18, 2, 529, 4, 5, 2486, 2487, ":" +500, 18, 3, 530, 6, 8, 2488, 2490, "10" +500, 18, 4, 531, 9, 10, 2491, 2492, "." +500, 18, 5, 532, 11, 15, 2493, 2497, "1038" +500, 18, 6, 533, 16, 17, 2498, 2499, "/" +500, 18, 7, 534, 18, 21, 2500, 2503, "eye" +500, 18, 8, 535, 22, 23, 2504, 2505, "." +500, 18, 9, 536, 24, 28, 2506, 2510, "2016" +500, 18, 10, 537, 29, 30, 2511, 2512, "." +500, 18, 11, 538, 31, 34, 2513, 2516, "126" +500, 18, 12, 539, 35, 40, 2517, 2522, "PMCID" +500, 18, 13, 540, 41, 42, 2523, 2524, ":" +500, 18, 14, 541, 43, 53, 2525, 2535, "PMC5129854" +500, 18, 15, 542, 54, 58, 2536, 2540, "PMID" +500, 18, 16, 543, 59, 60, 2541, 2542, ":" +500, 18, 17, 544, 61, 69, 2543, 2551, "27367743" +500, 18, 18, 545, 70, 71, 2552, 2553, "[" +500, 18, 19, 546, 72, 79, 2554, 2561, "Indexed" +500, 18, 20, 547, 80, 83, 2562, 2565, "for" +500, 18, 21, 548, 84, 91, 2566, 2573, "MEDLINE" +500, 18, 22, 549, 92, 93, 2574, 2575, "]" +500, 18, 23, 550, 94, 102, 2576, 2584, "Conflict" +500, 18, 24, 551, 103, 105, 2585, 2587, "of" +500, 18, 25, 552, 106, 114, 2588, 2596, "interest" +500, 18, 26, 553, 115, 124, 2597, 2606, "statement" +500, 18, 27, 554, 125, 126, 2607, 2608, ":" +500, 18, 28, 555, 127, 130, 2609, 2612, "RDF" +500, 18, 29, 556, 131, 134, 2613, 2616, "has" +500, 18, 30, 557, 135, 143, 2617, 2625, "received" +500, 18, 31, 558, 144, 154, 2626, 2636, "consultant" +500, 18, 32, 559, 155, 159, 2637, 2641, "fees" +500, 18, 33, 560, 160, 164, 2642, 2646, "from" +500, 18, 34, 561, 165, 170, 2647, 2652, "Alcon" +500, 18, 35, 562, 171, 174, 2653, 2656, "and" +500, 18, 36, 563, 175, 181, 2657, 2663, "Bausch" +500, 18, 37, 564, 182, 183, 2664, 2665, "&" +500, 18, 38, 565, 184, 188, 2666, 2670, "Lomb" +500, 18, 39, 566, 189, 190, 2671, 2672, "," +500, 18, 40, 567, 191, 194, 2673, 2676, "and" +500, 18, 41, 568, 195, 203, 2677, 2685, "research" +500, 18, 42, 569, 204, 211, 2686, 2693, "support" +500, 18, 43, 570, 212, 216, 2694, 2698, "from" +500, 18, 44, 571, 217, 222, 2699, 2704, "Alcon" +500, 18, 45, 572, 223, 226, 2705, 2708, "and" +500, 18, 46, 573, 227, 235, 2709, 2717, "Allergan" +500, 18, 47, 574, 236, 237, 2718, 2719, "." +500, 19, 1, 575, 0, 3, 2720, 2723, "JSM" +500, 19, 2, 576, 4, 7, 2724, 2727, "has" +500, 19, 3, 577, 8, 16, 2728, 2736, "received" +500, 19, 4, 578, 17, 25, 2737, 2745, "research" +500, 19, 5, 579, 26, 33, 2746, 2753, "funding" +500, 19, 6, 580, 34, 38, 2754, 2758, "from" +500, 19, 7, 581, 39, 44, 2759, 2764, "Alcon" +500, 19, 8, 582, 45, 46, 2765, 2766, "," +500, 19, 9, 583, 47, 55, 2767, 2775, "Allergan" +500, 19, 10, 584, 56, 57, 2776, 2777, "," +500, 19, 11, 585, 58, 65, 2778, 2785, "Glaukos" +500, 19, 12, 586, 66, 67, 2786, 2787, "," +500, 19, 13, 587, 68, 74, 2788, 2794, "Inotek" +500, 19, 14, 588, 75, 76, 2795, 2796, "," +500, 19, 15, 589, 77, 80, 2797, 2800, "and" +500, 19, 16, 590, 81, 86, 2801, 2806, "Merck" +500, 19, 17, 591, 87, 88, 2807, 2808, ";" +500, 19, 18, 592, 89, 99, 2809, 2819, "consultant" +500, 19, 19, 593, 100, 104, 2820, 2824, "fees" +500, 19, 20, 594, 105, 109, 2825, 2829, "from" +500, 19, 21, 595, 110, 115, 2830, 2835, "Aerie" +500, 19, 22, 596, 116, 117, 2836, 2837, "," +500, 19, 23, 597, 118, 123, 2838, 2843, "Alcon" +500, 19, 24, 598, 124, 125, 2844, 2845, "," +500, 19, 25, 599, 126, 134, 2846, 2854, "Allergan" +500, 19, 26, 600, 135, 136, 2855, 2856, "," +500, 19, 27, 601, 137, 143, 2857, 2863, "Inotek" +500, 19, 28, 602, 144, 145, 2864, 2865, "," +500, 19, 29, 603, 146, 149, 2866, 2869, "and" +500, 19, 30, 604, 150, 157, 2870, 2877, "Sucampo" +500, 19, 31, 605, 158, 159, 2878, 2879, ";" +500, 19, 32, 606, 160, 163, 2880, 2883, "and" +500, 19, 33, 607, 164, 171, 2884, 2891, "lecture" +500, 19, 34, 608, 172, 176, 2892, 2896, "fees" +500, 19, 35, 609, 177, 181, 2897, 2901, "from" +500, 19, 36, 610, 182, 187, 2902, 2907, "Alcon" +500, 19, 37, 611, 188, 189, 2908, 2909, "," +500, 19, 38, 612, 190, 198, 2910, 2918, "Allergan" +500, 19, 39, 613, 199, 200, 2919, 2920, "," +500, 19, 40, 614, 201, 204, 2921, 2924, "and" +500, 19, 41, 615, 205, 212, 2925, 2932, "Sucampo" +500, 19, 42, 616, 213, 214, 2933, 2934, "." +500, 20, 1, 617, 0, 3, 2935, 2938, "DAH" +500, 20, 2, 618, 4, 6, 2939, 2941, "is" +500, 20, 3, 619, 7, 9, 2942, 2944, "an" +500, 20, 4, 620, 10, 15, 2945, 2950, "Alcon" +500, 20, 5, 621, 16, 24, 2951, 2959, "employee" +500, 20, 6, 622, 25, 26, 2960, 2961, "." +500, 21, 1, 623, 0, 3, 2962, 2965, "DLB" +500, 21, 2, 624, 4, 7, 2966, 2969, "has" +500, 21, 3, 625, 8, 16, 2970, 2978, "received" +500, 21, 4, 626, 17, 27, 2979, 2989, "consultant" +500, 21, 5, 627, 28, 32, 2990, 2994, "fees" +500, 21, 6, 628, 33, 37, 2995, 2999, "from" +500, 21, 7, 629, 38, 43, 3000, 3005, "Alcon" +500, 21, 8, 630, 44, 47, 3006, 3009, "and" +500, 21, 9, 631, 48, 55, 3010, 3017, "Ivantis" +500, 21, 10, 632, 56, 57, 3018, 3019, "," +500, 21, 11, 633, 58, 61, 3020, 3023, "and" +500, 21, 12, 634, 62, 70, 3024, 3032, "research" +500, 21, 13, 635, 71, 78, 3033, 3040, "support" +500, 21, 14, 636, 79, 83, 3041, 3045, "from" +500, 21, 15, 637, 84, 87, 3046, 3049, "the" +500, 21, 16, 638, 88, 96, 3050, 3058, "National" +500, 21, 17, 639, 97, 100, 3059, 3062, "Eye" +500, 21, 18, 640, 101, 110, 3063, 3072, "Institute" +500, 21, 19, 641, 111, 112, 3073, 3074, "," +500, 21, 20, 642, 113, 121, 3075, 3083, "Glaucoma" +500, 21, 21, 643, 122, 130, 3084, 3092, "Research" +500, 21, 22, 644, 131, 141, 3093, 3103, "Foundation" +500, 21, 23, 645, 142, 143, 3104, 3105, "," +500, 21, 24, 646, 144, 152, 3106, 3114, "Research" +500, 21, 25, 647, 153, 155, 3115, 3117, "to" +500, 21, 26, 648, 156, 163, 3118, 3125, "Prevent" +500, 21, 27, 649, 164, 173, 3126, 3135, "Blindness" +500, 21, 28, 650, 174, 175, 3136, 3137, "," +500, 21, 29, 651, 176, 179, 3138, 3141, "and" +500, 21, 30, 652, 180, 183, 3142, 3145, "New" +500, 21, 31, 653, 184, 189, 3146, 3151, "World" +500, 21, 32, 654, 190, 197, 3152, 3159, "Medical" +500, 21, 33, 655, 198, 199, 3160, 3161, "," +500, 21, 34, 656, 200, 203, 3162, 3165, "Inc" +500, 21, 35, 657, 204, 205, 3166, 3167, "." +500, 21, 36, 658, 206, 209, 3168, 3171, "HBD" +500, 21, 37, 659, 210, 213, 3172, 3175, "has" +500, 21, 38, 660, 214, 222, 3176, 3184, "received" +500, 21, 39, 661, 223, 231, 3185, 3193, "speakers" +500, 21, 40, 662, 232, 238, 3194, 3200, "bureau" +500, 21, 41, 663, 239, 243, 3201, 3205, "fees" +500, 21, 42, 664, 244, 248, 3206, 3210, "from" +500, 21, 43, 665, 249, 254, 3211, 3216, "Alcon" +500, 21, 44, 666, 255, 256, 3217, 3218, "." diff --git a/data/gl 27367743_jshahinitiran.annodb b/data/gl 27367743_jshahinitiran.annodb new file mode 100644 index 0000000..081e699 --- /dev/null +++ b/data/gl 27367743_jshahinitiran.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +76816, Journal, 0, 14, "Eye ( Lond ) .", "", +76817, PublicationYear, 15, 19, "2016", "", +76820, Title, 107, 251, "Ocular hypotensive effect of fixed - combination brinzolamide / brimonidine adjunctive to a prostaglandin analog : a randomized clinical trial .", "", +76826, Brinz/BrimoFC, 136, 182, "fixed - combination brinzolamide / brimonidine", "", +76822, Brinzolamide, 156, 168, "brinzolamide", "", +76824, Brimonidine, 171, 182, "brimonidine", "", +76825, Randomized, 224, 234, "randomized", "", +76828, Author, 252, 263, "Fechtner RD", "", +76829, Author, 272, 280, "Myers JS", "", +76830, Author, 289, 300, "Hubatsch DA", "", +76832, Author, 309, 318, "Budenz DL", "", +76833, Author, 327, 337, "DuBiner HB", "", +76835, USA, 453, 456, "USA", "", +76836, USA, 506, 509, "USA", "", +76838, USA, 565, 568, "USA", "", +76839, USA, 657, 660, "USA", "", +76840, USA, 704, 707, "USA", "", +76843, ObjectiveDescription, 710, 836, "PurposeTo determine whether intraocular pressure ( IOP ) lowering with fixed - combination brinzolamide / brimonidine ( BBFC )", "", +76846, ObjectiveDescription, 837, 981, "adjunctive to a prostaglandin analog ( PGA ) was superior to that of vehicle + PGA in patients with open - angle glaucoma or ocular hypertension", "", +76848, ObjectiveDescription, 969, 1046, "hypertension who were inadequately controlled with PGA monotherapyMethodsThis", "", +76850, Duration, 1047, 1055, "6 - week", "", +76851, Multicenter, 1058, 1069, "multicenter", "", +76853, Randomized, 1072, 1082, "randomized", "", +76854, DoubleBlind, 1085, 1100, "double - masked", "", +76855, Parallel, 1103, 1119, "parallel - group", "", +76856, Multicenter, 1143, 1160, "30 clinical sites", "", +76857, USA, 1168, 1181, "United States", "", +76858, Precondition, 1241, 1247, "adults", "", +76859, OpenAngleGlaucoma, 1253, 1274, "open - angle glaucoma", "", +76860, OcularHypertension, 1278, 1297, "ocular hypertension", "", +76861, Mean, 1307, 1311, "mean", "", +76866, Precondition, 1307, 1339, "mean IOP ≥ 21 and < 32   mm   Hg", "", +76862, IOP, 1312, 1315, "IOP", "", +76863, mmHg, 1332, 1339, "mm   Hg", "", +76890, Drug, 1363, 1379, "open - label PGA", "", +76867, Latanoprost, 1382, 1393, "latanoprost", "", +76869, Bimatoprost, 1396, 1407, "bimatoprost", "", +76870, Travoprost, 1413, 1423, "travoprost", "", +76871, Frequency, 1453, 1465, "once - daily", "", +76872, Randomized, 1493, 1506, "randomization", "", +76873, Brinz/BrimoFC, 1517, 1521, "BBFC", "", +76874, Placebo, 1525, 1532, "vehicle", "", +76875, Frequency, 1589, 1602, "3 times daily", "", +76876, Duration, 1607, 1614, "6 weeks", "", +76877, Frequency, 1640, 1652, "once - daily", "", +76878, Mean, 1741, 1745, "mean", "", +76879, Diurnal_IOP, 1746, 1757, "diurnal IOP", "", +76881, Duration, 1824, 1830, "week 6", "", +76883, TimePoint, 1843, 1849, "week 6", "", +76885, Mean, 1852, 1856, "mean", "", +76886, Diurnal_IOP, 1857, 1868, "diurnal IOP", "", +76888, Brinz/BrimoFC, 1874, 1878, "BBFC", "", +76891, Drug, 1881, 1884, "PGA", "", +76893, Placebo, 1905, 1912, "vehicle", "", +76894, Drug, 1915, 1918, "PGA", "", +76896, ResultMeasuredValue, 1921, 1927, "17 . 1", "", +76898, SdErrorResValue, 1930, 1935, "0 . 4", "", +76900, mmHg, 1938, 1945, "mm   Hg", "", +76897, ResultMeasuredValue, 1949, 1955, "20 . 5", "", +76901, SdErrorResValue, 1958, 1963, "0 . 4", "", +76902, mmHg, 1966, 1973, "mm   Hg", "", +76905, DiffGroupRelValue, 2007, 2012, "3 . 4", "", +76906, SdErrorDiff, 2015, 2020, "0 . 5", "", +76908, mmHg, 2023, 2030, "mm   Hg", "", +76910, PvalueDiff, 2033, 2045, "P < 0 . 0001", "", +76913, ConfIntervalDiff, 2048, 2093, "95 % confidence interval , - 4 . 5 to - 2 . 4", "", +76915, mmHg, 2096, 2103, "mm   Hg", "", +76917, Brinz/BrimoFC, 2108, 2112, "BBFC", "", +76918, Drug, 2115, 2118, "PGA", "", +76919, Mean, 2127, 2131, "mean", "", +76920, Diurnal_IOP, 2132, 2143, "diurnal IOP", "", +76922, Reduction, 2147, 2152, "5 . 7", "", +76924, mmHg, 2155, 2162, "mm   Hg", "", +76926, RelativeReduction, 2165, 2167, "25", "", +76927, IOP, 2190, 2193, "IOP", "", +76929, Drug, 2208, 2211, "PGA", "", +76933, ConclusionComment, 2226, 2356, "ConclusionsTherapy with BBFC produced an additive IOP - lowering effect compared with a PGA alone or in conjunction with vehicle .", "", +76934, Brinz/BrimoFC, 2250, 2254, "BBFC", "", +76936, IOP, 2276, 2279, "IOP", "", +76938, Drug, 2314, 2317, "PGA", "", +76940, Placebo, 2347, 2354, "vehicle", "", +76943, ConclusionComment, 2357, 2481, "BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction .", "", +76944, Brinz/BrimoFC, 2357, 2361, "BBFC", "", +76945, Drug, 2427, 2430, "PGA", "", +76946, IOP, 2466, 2469, "IOP", "", +76949, PMID, 2543, 2551, "27367743", "", diff --git a/data/gl 27367743_jshahinitiran.n-triples b/data/gl 27367743_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27367743_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27367743_tstrakeljahn.annodb b/data/gl 27367743_tstrakeljahn.annodb new file mode 100644 index 0000000..e5bf9b3 --- /dev/null +++ b/data/gl 27367743_tstrakeljahn.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +82943, Journal, 0, 10, "Eye ( Lond", "", +82944, PublicationYear, 15, 19, "2016", "", +82964, Title, 107, 251, "Ocular hypotensive effect of fixed - combination brinzolamide / brimonidine adjunctive to a prostaglandin analog : a randomized clinical trial .", "", +82945, Brinzolamide, 156, 168, "brinzolamide", "", +82947, Brinz/BrimoFC, 156, 182, "brinzolamide / brimonidine", "", +82946, Brimonidine, 171, 182, "brimonidine", "", +82948, Drug, 199, 219, "prostaglandin analog", "prostaglandin analog", +82962, Randomized, 224, 234, "randomized", "", +82963, ClinicalTrial, 235, 249, "clinical trial", "", +82965, Author, 252, 263, "Fechtner RD", "", +82966, Author, 272, 280, "Myers JS", "", +82967, Author, 289, 300, "Hubatsch DA", "", +82968, Author, 309, 318, "Budenz DL", "", +82969, Author, 327, 337, "DuBiner HB", "", +82970, USA, 453, 456, "USA", "", +82971, USA, 506, 509, "USA", "", +82972, USA, 565, 568, "USA", "", +82973, USA, 657, 660, "USA", "", +82974, USA, 704, 707, "USA", "", +83002, ObjectiveDescription, 710, 961, "PurposeTo determine whether intraocular pressure ( IOP ) lowering with fixed - combination brinzolamide / brimonidine ( BBFC ) adjunctive to a prostaglandin analog ( PGA ) was superior to that of vehicle + PGA in patients with open - angle glaucoma or", "", +82975, IOP, 738, 758, "intraocular pressure", "", +82976, IOP, 761, 764, "IOP", "", +82977, Brinzolamide, 801, 813, "brinzolamide", "", +82979, Brinz/BrimoFC, 801, 827, "brinzolamide / brimonidine", "", +82978, Brimonidine, 816, 827, "brimonidine", "", +82980, Brinz/BrimoFC, 830, 834, "BBFC", "", +82949, Drug, 853, 873, "prostaglandin analog", "prostaglandin analog", +82950, Drug, 876, 879, "PGA", "prostaglandin analog", +82981, Placebo, 906, 913, "vehicle", "", +82951, Drug, 916, 919, "PGA", "prostaglandin analog", +82982, OpenAngleGlaucoma, 937, 958, "open - angle glaucoma", "", +83004, OcularHypertension, 962, 981, "ocular hypertension", "", +83005, ObjectiveDescription, 962, 1129, "ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6 - week , multicenter , randomized , double - masked , parallel - group trial was", "", +82984, Precondition, 991, 1023, "inadequately controlled with PGA", "", +82952, Drug, 1020, 1023, "PGA", "prostaglandin analog", +82985, Duration, 1047, 1055, "6 - week", "", +82986, Multicenter, 1058, 1069, "multicenter", "", +82987, Randomized, 1072, 1082, "randomized", "", +82988, DoubleBlind, 1085, 1100, "double - masked", "", +82989, Parallel, 1103, 1111, "parallel", "", +83006, ObjectiveDescription, 1130, 1217, "conducted at 30 clinical sites in the United States between October 2013 and May 2014 .", "", +82990, Multicenter, 1143, 1160, "30 clinical sites", "", +82991, USA, 1168, 1181, "United States", "", +82992, OpenAngleGlaucoma, 1253, 1274, "open - angle glaucoma", "", +82993, OcularHypertension, 1278, 1297, "ocular hypertension", "", +83001, Precondition, 1302, 1339, "with mean IOP ≥ 21 and < 32   mm   Hg", "", +82994, Mean, 1307, 1311, "mean", "", +82995, IOP, 1312, 1315, "IOP", "", +82996, mmHg, 1332, 1339, "mm   Hg", "", +82997, OpenLabel, 1363, 1375, "open - label", "", +82953, Drug, 1376, 1379, "PGA", "prostaglandin analog", +82998, Latanoprost, 1382, 1393, "latanoprost", "", +82999, Bimatoprost, 1396, 1407, "bimatoprost", "", +83000, Travoprost, 1413, 1423, "travoprost", "", +82954, Drug, 1449, 1452, "PGA", "prostaglandin analog", +83007, Frequency, 1453, 1465, "once - daily", "", +83008, Brinz/BrimoFC, 1517, 1521, "BBFC", "", +83009, Placebo, 1525, 1532, "vehicle", "", +83010, Frequency, 1589, 1602, "3 times daily", "", +83011, Duration, 1607, 1614, "6 weeks", "", +83012, Frequency, 1640, 1652, "once - daily", "", +82955, Drug, 1666, 1669, "PGA", "prostaglandin analog", +83021, Endpoint, 1711, 1832, "between - group difference in mean diurnal IOP ( average of 0800 , 1000 , 1500 , and 1700 hours time points ) at week 6 .", "", +83013, Mean, 1741, 1745, "mean", "", +83014, Diurnal_IOP, 1746, 1757, "diurnal IOP", "", +83015, TimePoint, 1771, 1775, "0800", "", +83016, TimePoint, 1778, 1782, "1000", "", +83017, TimePoint, 1785, 1789, "1500", "", +83018, TimePoint, 1796, 1800, "1700", "", +83019, TimePoint, 1824, 1830, "week 6", "", +83020, TimePoint, 1843, 1849, "week 6", "", +83022, Mean, 1852, 1856, "mean", "", +83023, Diurnal_IOP, 1857, 1868, "diurnal IOP", "", +83024, Brinz/BrimoFC, 1874, 1878, "BBFC", "", +82956, Drug, 1881, 1884, "PGA", "prostaglandin analog", +83025, Placebo, 1905, 1912, "vehicle", "", +82957, Drug, 1915, 1918, "PGA", "prostaglandin analog", +83026, ResultMeasuredValue, 1921, 1927, "17 . 1", "", +83028, SdErrorResValue, 1930, 1935, "0 . 4", "", +83035, mmHg, 1938, 1945, "mm   Hg", "", +83027, ResultMeasuredValue, 1949, 1955, "20 . 5", "", +83029, SdErrorResValue, 1958, 1963, "0 . 4", "", +83036, mmHg, 1966, 1973, "mm   Hg", "", +83030, DiffGroupAbsValue, 2007, 2012, "3 . 4", "", +83031, SdDevChangeValue, 2015, 2020, "0 . 5", "", +83037, mmHg, 2023, 2030, "mm   Hg", "", +83032, PvalueDiff, 2035, 2045, "< 0 . 0001", "", +83033, ConfIntervalDiff, 2075, 2093, "- 4 . 5 to - 2 . 4", "", +83038, mmHg, 2096, 2103, "mm   Hg", "", +83039, Brinz/BrimoFC, 2108, 2112, "BBFC", "", +82958, Drug, 2115, 2118, "PGA", "prostaglandin analog", +83040, Mean, 2127, 2131, "mean", "", +83041, Diurnal_IOP, 2132, 2143, "diurnal IOP", "", +83042, Reduction, 2147, 2152, "5 . 7", "", +83044, mmHg, 2155, 2162, "mm   Hg", "", +83043, RelativeReduction, 2165, 2167, "25", "", +83045, IOP, 2190, 2193, "IOP", "", +82959, Drug, 2208, 2211, "PGA", "prostaglandin analog", +83049, ConclusionComment, 2226, 2356, "ConclusionsTherapy with BBFC produced an additive IOP - lowering effect compared with a PGA alone or in conjunction with vehicle .", "", +83046, Brinz/BrimoFC, 2250, 2254, "BBFC", "", +83047, IOP, 2276, 2279, "IOP", "", +82960, Drug, 2314, 2317, "PGA", "prostaglandin analog", +83048, Placebo, 2347, 2354, "vehicle", "", +83050, Brinz/BrimoFC, 2357, 2361, "BBFC", "", +82961, Drug, 2427, 2430, "PGA", "prostaglandin analog", +83051, IOP, 2466, 2469, "IOP", "", +83052, PMID, 2543, 2551, "27367743", "", +82937, ConflictInterest, 2609, 2719, "RDF has received consultant fees from Alcon and Bausch & Lomb , and research support from Alcon and Allergan .", "", +82938, ConflictInterest, 2720, 2934, "JSM has received research funding from Alcon , Allergan , Glaukos , Inotek , and Merck ; consultant fees from Aerie , Alcon , Allergan , Inotek , and Sucampo ; and lecture fees from Alcon , Allergan , and Sucampo .", "", +82939, ConflictInterest, 2935, 2961, "DAH is an Alcon employee .", "", +82942, ConflictInterest, 2962, 2965, "DLB", "", +82940, ConflictInterest, 2966, 3218, "has received consultant fees from Alcon and Ivantis , and research support from the National Eye Institute , Glaucoma Research Foundation , Research to Prevent Blindness , and New World Medical , Inc . HBD has received speakers bureau fees from Alcon .", "", diff --git a/data/gl 27367743_tstrakeljahn.n-triples b/data/gl 27367743_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27367743_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27445072_admin.annodb b/data/gl 27445072_admin.annodb new file mode 100644 index 0000000..3c88f2f --- /dev/null +++ b/data/gl 27445072_admin.annodb @@ -0,0 +1,69 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 18, "Eur J Ophthalmol .", "", " \"Eur J Ophthalmol .\"." +1, PublicationYear, 19, 23, "2017", "", " \"2017\"." +13, Title, 109, 253, "Comparison of dorzolamide / timolol vs brinzolamide / brimonidine fixed combination therapy in the management of primary open - angle glaucoma .", "", " \"Comparison of dorzolamide / timolol vs brinzolamide / brimonidine fixed combination therapy in the management of primary open - angle glaucoma .\"." +2, Dorzolamide, 123, 134, "dorzolamide", "", +105392, Dorz/TimFC, 123, 144, "dorzolamide / timolol", "", +4, Timolol, 137, 144, "timolol", "", +6, Brinzolamide, 148, 160, "brinzolamide", "", +105394, Brinz/BrimoFC, 148, 192, "brinzolamide / brimonidine fixed combination", "", +9, Brimonidine, 163, 174, "brimonidine", "", +58, Primary_OpenAngleGlaucoma, 222, 251, "primary open - angle glaucoma", "", " ." +14, Author, 254, 265, "Kozobolis V", "", " \"Kozobolis V\"." +15, Author, 286, 294, "Panos GD", "", " \"Panos GD\"." +16, Author, 303, 319, "Konstantinidis A", "", " \"Konstantinidis A\"." +17, Author, 328, 337, "Labiris G", "", " \"Labiris G\"." +18, Greece, 468, 474, "Greece", "", " ." +19, Greece, 573, 579, "Greece", "", +20, Greece, 627, 633, "Greece", "", +25, ObjectiveDescription, 646, 766, "To compare the efficiency of brinzolamide / brimonidine fixed combination vs the dorzolamide / timolol fixed combination", "", " \"To compare the efficiency of brinzolamide / brimonidine fixed combination vs the dorzolamide / timolol fixed combination\"." +21, Brinzolamide, 675, 687, "brinzolamide", "", +105395, Brinz/BrimoFC, 675, 719, "brinzolamide / brimonidine fixed combination", "", +22, Brimonidine, 690, 701, "brimonidine", "", +23, Dorzolamide, 727, 738, "dorzolamide", "", +105398, Dorz/TimFC, 727, 766, "dorzolamide / timolol fixed combination", "", +24, Timolol, 741, 748, "timolol", "", +26, NumberPatientsCT, 800, 802, "44", "", " \"44\"." +3, Dorzolamide, 857, 868, "dorzolamide", "", " ." +105399, Dorz/TimFC, 857, 878, "dorzolamide / timolol", "", +5, Timolol, 871, 878, "timolol", "", " ." +27, Frequency, 879, 890, "twice a day", "", " \"twice a day\"." +7, Brinzolamide, 911, 923, "brinzolamide", "", " ." +105397, Brinz/BrimoFC, 911, 937, "brinzolamide / brimonidine", "", +10, Brimonidine, 926, 937, "brimonidine", "", " ." +28, Frequency, 938, 949, "twice a day", "", " \"twice a day\"." +105400, TimePoint, 1087, 1111, "1 , 4 , 8 , and 12 weeks", "", +105403, TimePoint, 1091, 1111, "4 , 8 , and 12 weeks", "", +105404, TimePoint, 1095, 1111, "8 , and 12 weeks", "", +81, TimePoint, 1103, 1111, "12 weeks", "", +29, IOP, 1129, 1149, "intraocular pressure", "", +30, IOP, 1152, 1155, "IOP", "", +31, Frequency, 1171, 1182, "twice a day", "", +32, TimePoint, 1185, 1200, "morning at 9 AM", "", +33, TimePoint, 1205, 1222, "afternoon at 4 PM", "", +105405, TimePoint, 1276, 1284, "12 weeks", "", +84, Mean, 1289, 1293, "mean", "", " . ." +105408, EndPointDescription, 1294, 1305, "morning IOP", "", " . ." +105406, IOP, 1302, 1305, "IOP", "", +35, Reduction, 1320, 1325, "7 . 0", "", " \"7 . 0\"." +36, SdDevChangeValue, 1328, 1333, "2 . 8", "", " \"2 . 8\"." +37, mmHg, 1334, 1339, "mm Hg", "", " ." +38, Reduction, 1355, 1360, "8 . 4", "", " \"8 . 4\"." +39, SdDevChangeValue, 1363, 1368, "1 . 9", "", " \"1 . 9\"." +40, mmHg, 1369, 1374, "mm Hg", "", +41, PvalueDiff, 1425, 1437, "p = 0 . 0343", "", " \"p = 0 . 0343\"." +91, Mean, 1456, 1460, "mean", "", " . ." +102, EndPointDescription, 1461, 1474, "afternoon IOP", "", " . ." +42, IOP, 1471, 1474, "IOP", "", +43, Reduction, 1489, 1494, "8 . 6", "", " \"8 . 6\"." +45, SdDevChangeValue, 1495, 1502, "± 2 . 7", "", " \"± 2 . 7\"." +47, mmHg, 1503, 1508, "mm Hg", "", " ." +44, Reduction, 1524, 1529, "7 . 9", "", " \"7 . 9\"." +46, SdDevChangeValue, 1530, 1537, "± 1 . 6", "", " \"± 1 . 6\"." +48, mmHg, 1538, 1543, "mm Hg", "", +49, PvalueDiff, 1597, 1609, "p = 0 . 3413", "", " \"p = 0 . 3413\"." +8, Brinzolamide, 1691, 1703, "Brinzolamide", "", +50, ConclusionComment, 1691, 1886, "Brinzolamide / brimonidine seems to be an effective and safe alternative β- blocker free fixed combination , especially for patients with comorbidities , having its own antihypertensive profile .", "", " \"Brinzolamide / brimonidine seems to be an effective and safe alternative β- blocker free fixed combination , especially for patients with comorbidities , having its own antihypertensive profile .\"." +105396, Brinz/BrimoFC, 1691, 1717, "Brinzolamide / brimonidine", "", +11, Brimonidine, 1706, 1717, "brimonidine", "", +51, PMID, 1926, 1934, "27445072", "", " \"27445072\"." diff --git a/data/gl 27445072_admin.n-triples b/data/gl 27445072_admin.n-triples new file mode 100644 index 0000000..884e986 --- /dev/null +++ b/data/gl 27445072_admin.n-triples @@ -0,0 +1,131 @@ +# RDF export of group: Publication + . + "Publication " . + "Comparison of dorzolamide / timolol vs brinzolamide / brimonidine fixed combination therapy in the management of primary open - angle glaucoma ." . + "Kozobolis V" . + "2017" . + "Eur J Ophthalmol ." . + "27445072" . + . + "Panos GD" . + "Konstantinidis A" . + "Labiris G" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To compare the efficiency of brinzolamide / brimonidine fixed combination vs the dorzolamide / timolol fixed combination" . + "44" . + . + . + . + "Brinzolamide / brimonidine seems to be an effective and safe alternative β- blocker free fixed combination , especially for patients with comorbidities , having its own antihypertensive profile ." . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint morning IOP" . + . + . + . + . + . + . + . + "Endpoint afternoon IOP" . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm Dorz/TimFC" . + . + . + . + . + . + "Arm Brinz/BrimoFC" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention Dorz/TimFC" . + . + "twice a day" . + . + . + . + "Intervention Brinz/BrimoFC" . + . + "twice a day" . + . + . +# RDF export of group: Medication + . + "Medication dorz" . + . + . + . + . + "Medication tim " . + . + . + . + . + "Medication Brinz" . + . + . + . + . + "Medication brimo " . + . + . + . +# RDF export of group: Outcome + . + "Outcome morning IOP dt " . + . + "7 . 0" . + "2 . 8" . + . + "Outcome morning IOP bb" . + . + "8 . 4" . + "1 . 9" . + . + "Outcome afternoon IOP dt " . + . + "8 . 6" . + "± 2 . 7" . + . + "Outcome afternoon IOP bb " . + . + "7 . 9" . + "± 1 . 6" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups morning IOP " . + "p = 0 . 0343" . + . + . + . + "DiffBetweenGroups afternoon IOP " . + "p = 0 . 3413" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27445072_export.csv b/data/gl 27445072_export.csv new file mode 100644 index 0000000..ba685ce --- /dev/null +++ b/data/gl 27445072_export.csv @@ -0,0 +1,415 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +407, 1, 1, 1, 0, 3, 0, 3, "Eur" +407, 1, 2, 2, 4, 5, 4, 5, "J" +407, 1, 3, 3, 6, 16, 6, 16, "Ophthalmol" +407, 1, 4, 4, 17, 18, 17, 18, "." +407, 2, 1, 5, 0, 4, 19, 23, "2017" +407, 2, 2, 6, 5, 8, 24, 27, "Mar" +407, 2, 3, 7, 9, 11, 28, 30, "10" +407, 2, 4, 8, 12, 13, 31, 32, ";" +407, 2, 5, 9, 14, 16, 33, 35, "27" +407, 2, 6, 10, 17, 18, 36, 37, "(" +407, 2, 7, 11, 19, 20, 38, 39, "2" +407, 2, 8, 12, 21, 22, 40, 41, ")" +407, 2, 9, 13, 23, 24, 42, 43, ":" +407, 2, 10, 14, 25, 28, 44, 47, "160" +407, 2, 11, 15, 29, 30, 48, 49, "-" +407, 2, 12, 16, 31, 34, 50, 53, "163" +407, 2, 13, 17, 35, 36, 54, 55, "." +407, 2, 14, 18, 37, 40, 56, 59, "doi" +407, 2, 15, 19, 41, 42, 60, 61, ":" +407, 2, 16, 20, 43, 45, 62, 64, "10" +407, 2, 17, 21, 46, 47, 65, 66, "." +407, 2, 18, 22, 48, 52, 67, 71, "5301" +407, 2, 19, 23, 53, 54, 72, 73, "/" +407, 2, 20, 24, 55, 58, 74, 77, "ejo" +407, 2, 21, 25, 59, 60, 78, 79, "." +407, 2, 22, 26, 61, 68, 80, 87, "5000826" +407, 2, 23, 27, 69, 70, 88, 89, "." +407, 3, 1, 28, 0, 4, 90, 94, "Epub" +407, 3, 2, 29, 5, 9, 95, 99, "2016" +407, 3, 3, 30, 10, 13, 100, 103, "Jul" +407, 3, 4, 31, 14, 16, 104, 106, "16" +407, 3, 5, 32, 17, 18, 107, 108, "." +407, 4, 1, 33, 0, 10, 109, 119, "Comparison" +407, 4, 2, 34, 11, 13, 120, 122, "of" +407, 4, 3, 35, 14, 25, 123, 134, "dorzolamide" +407, 4, 4, 36, 26, 27, 135, 136, "/" +407, 4, 5, 37, 28, 35, 137, 144, "timolol" +407, 4, 6, 38, 36, 38, 145, 147, "vs" +407, 4, 7, 39, 39, 51, 148, 160, "brinzolamide" +407, 4, 8, 40, 52, 53, 161, 162, "/" +407, 4, 9, 41, 54, 65, 163, 174, "brimonidine" +407, 4, 10, 42, 66, 71, 175, 180, "fixed" +407, 4, 11, 43, 72, 83, 181, 192, "combination" +407, 4, 12, 44, 84, 91, 193, 200, "therapy" +407, 4, 13, 45, 92, 94, 201, 203, "in" +407, 4, 14, 46, 95, 98, 204, 207, "the" +407, 4, 15, 47, 99, 109, 208, 218, "management" +407, 4, 16, 48, 110, 112, 219, 221, "of" +407, 4, 17, 49, 113, 120, 222, 229, "primary" +407, 4, 18, 50, 121, 125, 230, 234, "open" +407, 4, 19, 51, 126, 127, 235, 236, "-" +407, 4, 20, 52, 128, 133, 237, 242, "angle" +407, 4, 21, 53, 134, 142, 243, 251, "glaucoma" +407, 4, 22, 54, 143, 144, 252, 253, "." +407, 5, 1, 55, 0, 9, 254, 263, "Kozobolis" +407, 5, 2, 56, 10, 11, 264, 265, "V" +407, 5, 3, 57, 12, 13, 266, 267, "(" +407, 5, 4, 58, 14, 15, 268, 269, "1" +407, 5, 5, 59, 16, 17, 270, 271, ")" +407, 5, 6, 60, 18, 19, 272, 273, "(" +407, 5, 7, 61, 20, 21, 274, 275, "2" +407, 5, 8, 62, 22, 23, 276, 277, ")" +407, 5, 9, 63, 24, 25, 278, 279, "(" +407, 5, 10, 64, 26, 27, 280, 281, "3" +407, 5, 11, 65, 28, 29, 282, 283, ")" +407, 5, 12, 66, 30, 31, 284, 285, "," +407, 5, 13, 67, 32, 37, 286, 291, "Panos" +407, 5, 14, 68, 38, 40, 292, 294, "GD" +407, 5, 15, 69, 41, 42, 295, 296, "(" +407, 5, 16, 70, 43, 44, 297, 298, "2" +407, 5, 17, 71, 45, 46, 299, 300, ")" +407, 5, 18, 72, 47, 48, 301, 302, "," +407, 5, 19, 73, 49, 63, 303, 317, "Konstantinidis" +407, 5, 20, 74, 64, 65, 318, 319, "A" +407, 5, 21, 75, 66, 67, 320, 321, "(" +407, 5, 22, 76, 68, 69, 322, 323, "1" +407, 5, 23, 77, 70, 71, 324, 325, ")" +407, 5, 24, 78, 72, 73, 326, 327, "," +407, 5, 25, 79, 74, 81, 328, 335, "Labiris" +407, 5, 26, 80, 82, 83, 336, 337, "G" +407, 5, 27, 81, 84, 85, 338, 339, "(" +407, 5, 28, 82, 86, 87, 340, 341, "1" +407, 5, 29, 83, 88, 89, 342, 343, ")" +407, 5, 30, 84, 90, 91, 344, 345, "(" +407, 5, 31, 85, 92, 93, 346, 347, "2" +407, 5, 32, 86, 94, 95, 348, 349, ")" +407, 5, 33, 87, 96, 97, 350, 351, "." +407, 6, 1, 88, 0, 6, 352, 358, "Author" +407, 6, 2, 89, 7, 18, 359, 370, "information" +407, 6, 3, 90, 19, 20, 371, 372, ":" +407, 6, 4, 91, 21, 22, 373, 374, "(" +407, 6, 5, 92, 23, 24, 375, 376, "1" +407, 6, 6, 93, 25, 26, 377, 378, ")" +407, 6, 7, 94, 27, 28, 379, 380, " " +407, 6, 8, 95, 29, 39, 381, 391, "Department" +407, 6, 9, 96, 40, 42, 392, 394, "of" +407, 6, 10, 97, 43, 56, 395, 408, "Ophthalmology" +407, 6, 11, 98, 57, 58, 409, 410, "," +407, 6, 12, 99, 59, 69, 411, 421, "University" +407, 6, 13, 100, 70, 77, 422, 429, "General" +407, 6, 14, 101, 78, 86, 430, 438, "Hospital" +407, 6, 15, 102, 87, 89, 439, 441, "of" +407, 6, 16, 103, 90, 95, 442, 447, "Evros" +407, 6, 17, 104, 96, 97, 448, 449, "," +407, 6, 18, 105, 98, 113, 450, 465, "Alexandroupolis" +407, 6, 19, 106, 114, 115, 466, 467, "-" +407, 6, 20, 107, 116, 122, 468, 474, "Greece" +407, 6, 21, 108, 123, 124, 475, 476, "." +407, 7, 1, 109, 0, 1, 477, 478, "(" +407, 7, 2, 110, 2, 3, 479, 480, "2" +407, 7, 3, 111, 4, 5, 481, 482, ")" +407, 7, 4, 112, 6, 7, 483, 484, " " +407, 7, 5, 113, 8, 11, 485, 488, "Eye" +407, 7, 6, 114, 12, 21, 489, 498, "Institute" +407, 7, 7, 115, 22, 24, 499, 501, "of" +407, 7, 8, 116, 25, 31, 502, 508, "Thrace" +407, 7, 9, 117, 32, 33, 509, 510, "," +407, 7, 10, 118, 34, 40, 511, 517, "School" +407, 7, 11, 119, 41, 43, 518, 520, "of" +407, 7, 12, 120, 44, 52, 521, 529, "Medicine" +407, 7, 13, 121, 53, 54, 530, 531, "," +407, 7, 14, 122, 55, 65, 532, 542, "University" +407, 7, 15, 123, 66, 68, 543, 545, "of" +407, 7, 16, 124, 69, 75, 546, 552, "Thrace" +407, 7, 17, 125, 76, 77, 553, 554, "," +407, 7, 18, 126, 78, 93, 555, 570, "Alexandroupolis" +407, 7, 19, 127, 94, 95, 571, 572, "-" +407, 7, 20, 128, 96, 102, 573, 579, "Greece" +407, 7, 21, 129, 103, 104, 580, 581, "." +407, 8, 1, 130, 0, 1, 582, 583, "(" +407, 8, 2, 131, 2, 3, 584, 585, "3" +407, 8, 3, 132, 4, 5, 586, 587, ")" +407, 8, 4, 133, 6, 7, 588, 589, " " +407, 8, 5, 134, 8, 16, 590, 598, "Glaucoma" +407, 8, 6, 135, 17, 22, 599, 604, "Laser" +407, 8, 7, 136, 23, 26, 605, 608, "Eye" +407, 8, 8, 137, 27, 33, 609, 615, "Center" +407, 8, 9, 138, 34, 35, 616, 617, "," +407, 8, 10, 139, 36, 42, 618, 624, "Athens" +407, 8, 11, 140, 43, 44, 625, 626, "-" +407, 8, 12, 141, 45, 51, 627, 633, "Greece" +407, 8, 13, 142, 52, 53, 634, 635, "." +407, 9, 1, 143, 0, 7, 636, 643, "PURPOSE" +407, 9, 2, 144, 8, 9, 644, 645, ":" +407, 9, 3, 145, 10, 12, 646, 648, "To" +407, 9, 4, 146, 13, 20, 649, 656, "compare" +407, 9, 5, 147, 21, 24, 657, 660, "the" +407, 9, 6, 148, 25, 35, 661, 671, "efficiency" +407, 9, 7, 149, 36, 38, 672, 674, "of" +407, 9, 8, 150, 39, 51, 675, 687, "brinzolamide" +407, 9, 9, 151, 52, 53, 688, 689, "/" +407, 9, 10, 152, 54, 65, 690, 701, "brimonidine" +407, 9, 11, 153, 66, 71, 702, 707, "fixed" +407, 9, 12, 154, 72, 83, 708, 719, "combination" +407, 9, 13, 155, 84, 86, 720, 722, "vs" +407, 9, 14, 156, 87, 90, 723, 726, "the" +407, 9, 15, 157, 91, 102, 727, 738, "dorzolamide" +407, 9, 16, 158, 103, 104, 739, 740, "/" +407, 9, 17, 159, 105, 112, 741, 748, "timolol" +407, 9, 18, 160, 113, 118, 749, 754, "fixed" +407, 9, 19, 161, 119, 130, 755, 766, "combination" +407, 9, 20, 162, 131, 132, 767, 768, "." +407, 10, 1, 163, 0, 7, 769, 776, "METHODS" +407, 10, 2, 164, 8, 9, 777, 778, ":" +407, 10, 3, 165, 10, 15, 779, 784, "Forty" +407, 10, 4, 166, 16, 17, 785, 786, "-" +407, 10, 5, 167, 18, 22, 787, 791, "four" +407, 10, 6, 168, 23, 27, 792, 796, "eyes" +407, 10, 7, 169, 28, 30, 797, 799, "of" +407, 10, 8, 170, 31, 33, 800, 802, "44" +407, 10, 9, 171, 34, 42, 803, 811, "patients" +407, 10, 10, 172, 43, 47, 812, 816, "were" +407, 10, 11, 173, 48, 55, 817, 824, "divided" +407, 10, 12, 174, 56, 58, 825, 827, "in" +407, 10, 13, 175, 59, 60, 828, 829, "2" +407, 10, 14, 176, 61, 67, 830, 836, "groups" +407, 10, 15, 177, 68, 75, 837, 844, "treated" +407, 10, 16, 178, 76, 82, 845, 851, "either" +407, 10, 17, 179, 83, 87, 852, 856, "with" +407, 10, 18, 180, 88, 99, 857, 868, "dorzolamide" +407, 10, 19, 181, 100, 101, 869, 870, "/" +407, 10, 20, 182, 102, 109, 871, 878, "timolol" +407, 10, 21, 183, 110, 115, 879, 884, "twice" +407, 10, 22, 184, 116, 117, 885, 886, "a" +407, 10, 23, 185, 118, 121, 887, 890, "day" +407, 10, 24, 186, 122, 123, 891, 892, "(" +407, 10, 25, 187, 124, 129, 893, 898, "group" +407, 10, 26, 188, 130, 131, 899, 900, "A" +407, 10, 27, 189, 132, 133, 901, 902, ")" +407, 10, 28, 190, 134, 136, 903, 905, "or" +407, 10, 29, 191, 137, 141, 906, 910, "with" +407, 10, 30, 192, 142, 154, 911, 923, "brinzolamide" +407, 10, 31, 193, 155, 156, 924, 925, "/" +407, 10, 32, 194, 157, 168, 926, 937, "brimonidine" +407, 10, 33, 195, 169, 174, 938, 943, "twice" +407, 10, 34, 196, 175, 176, 944, 945, "a" +407, 10, 35, 197, 177, 180, 946, 949, "day" +407, 10, 36, 198, 181, 182, 950, 951, "(" +407, 10, 37, 199, 183, 188, 952, 957, "group" +407, 10, 38, 200, 189, 190, 958, 959, "B" +407, 10, 39, 201, 191, 192, 960, 961, ")" +407, 10, 40, 202, 193, 194, 962, 963, "." +407, 11, 1, 203, 0, 8, 964, 972, "Complete" +407, 11, 2, 204, 9, 19, 973, 983, "ophthalmic" +407, 11, 3, 205, 20, 31, 984, 995, "examination" +407, 11, 4, 206, 32, 41, 996, 1005, "including" +407, 11, 5, 207, 42, 50, 1006, 1014, "Goldmann" +407, 11, 6, 208, 51, 62, 1015, 1026, "applanation" +407, 11, 7, 209, 63, 72, 1027, 1036, "tonometry" +407, 11, 8, 210, 73, 76, 1037, 1040, "was" +407, 11, 9, 211, 77, 86, 1041, 1050, "performed" +407, 11, 10, 212, 87, 93, 1051, 1057, "before" +407, 11, 11, 213, 94, 103, 1058, 1067, "treatment" +407, 11, 12, 214, 104, 118, 1068, 1082, "administration" +407, 11, 13, 215, 119, 122, 1083, 1086, "and" +407, 11, 14, 216, 123, 124, 1087, 1088, "1" +407, 11, 15, 217, 125, 126, 1089, 1090, "," +407, 11, 16, 218, 127, 128, 1091, 1092, "4" +407, 11, 17, 219, 129, 130, 1093, 1094, "," +407, 11, 18, 220, 131, 132, 1095, 1096, "8" +407, 11, 19, 221, 133, 134, 1097, 1098, "," +407, 11, 20, 222, 135, 138, 1099, 1102, "and" +407, 11, 21, 223, 139, 141, 1103, 1105, "12" +407, 11, 22, 224, 142, 147, 1106, 1111, "weeks" +407, 11, 23, 225, 148, 158, 1112, 1122, "afterwards" +407, 11, 24, 226, 159, 160, 1123, 1124, "." +407, 12, 1, 227, 0, 3, 1125, 1128, "The" +407, 12, 2, 228, 4, 15, 1129, 1140, "intraocular" +407, 12, 3, 229, 16, 24, 1141, 1149, "pressure" +407, 12, 4, 230, 25, 26, 1150, 1151, "(" +407, 12, 5, 231, 27, 30, 1152, 1155, "IOP" +407, 12, 6, 232, 31, 32, 1156, 1157, ")" +407, 12, 7, 233, 33, 36, 1158, 1161, "was" +407, 12, 8, 234, 37, 45, 1162, 1170, "measured" +407, 12, 9, 235, 46, 51, 1171, 1176, "twice" +407, 12, 10, 236, 52, 53, 1177, 1178, "a" +407, 12, 11, 237, 54, 57, 1179, 1182, "day" +407, 12, 12, 238, 58, 59, 1183, 1184, "(" +407, 12, 13, 239, 60, 67, 1185, 1192, "morning" +407, 12, 14, 240, 68, 70, 1193, 1195, "at" +407, 12, 15, 241, 71, 72, 1196, 1197, "9" +407, 12, 16, 242, 73, 75, 1198, 1200, "AM" +407, 12, 17, 243, 76, 79, 1201, 1204, "and" +407, 12, 18, 244, 80, 89, 1205, 1214, "afternoon" +407, 12, 19, 245, 90, 92, 1215, 1217, "at" +407, 12, 20, 246, 93, 94, 1218, 1219, "4" +407, 12, 21, 247, 95, 97, 1220, 1222, "PM" +407, 12, 22, 248, 98, 99, 1223, 1224, ")" +407, 12, 23, 249, 100, 101, 1225, 1226, "." +407, 13, 1, 250, 0, 7, 1227, 1234, "RESULTS" +407, 13, 2, 251, 8, 9, 1235, 1236, ":" +407, 13, 3, 252, 10, 12, 1237, 1239, "At" +407, 13, 4, 253, 13, 16, 1240, 1243, "the" +407, 13, 5, 254, 17, 20, 1244, 1247, "end" +407, 13, 6, 255, 21, 23, 1248, 1250, "of" +407, 13, 7, 256, 24, 27, 1251, 1254, "the" +407, 13, 8, 257, 28, 34, 1255, 1261, "follow" +407, 13, 9, 258, 35, 36, 1262, 1263, "-" +407, 13, 10, 259, 37, 39, 1264, 1266, "up" +407, 13, 11, 260, 40, 46, 1267, 1273, "period" +407, 13, 12, 261, 47, 48, 1274, 1275, "(" +407, 13, 13, 262, 49, 51, 1276, 1278, "12" +407, 13, 14, 263, 52, 57, 1279, 1284, "weeks" +407, 13, 15, 264, 58, 59, 1285, 1286, ")" +407, 13, 16, 265, 60, 61, 1287, 1288, "," +407, 13, 17, 266, 62, 66, 1289, 1293, "mean" +407, 13, 18, 267, 67, 74, 1294, 1301, "morning" +407, 13, 19, 268, 75, 78, 1302, 1305, "IOP" +407, 13, 20, 269, 79, 88, 1306, 1315, "reduction" +407, 13, 21, 270, 89, 92, 1316, 1319, "was" +407, 13, 22, 271, 93, 94, 1320, 1321, "7" +407, 13, 23, 272, 95, 96, 1322, 1323, "." +407, 13, 24, 273, 97, 98, 1324, 1325, "0" +407, 13, 25, 274, 99, 100, 1326, 1327, "±" +407, 13, 26, 275, 101, 102, 1328, 1329, "2" +407, 13, 27, 276, 103, 104, 1330, 1331, "." +407, 13, 28, 277, 105, 106, 1332, 1333, "8" +407, 13, 29, 278, 107, 109, 1334, 1336, "mm" +407, 13, 30, 279, 110, 112, 1337, 1339, "Hg" +407, 13, 31, 280, 113, 115, 1340, 1342, "in" +407, 13, 32, 281, 116, 121, 1343, 1348, "group" +407, 13, 33, 282, 122, 123, 1349, 1350, "A" +407, 13, 34, 283, 124, 127, 1351, 1354, "and" +407, 13, 35, 284, 128, 129, 1355, 1356, "8" +407, 13, 36, 285, 130, 131, 1357, 1358, "." +407, 13, 37, 286, 132, 133, 1359, 1360, "4" +407, 13, 38, 287, 134, 135, 1361, 1362, "±" +407, 13, 39, 288, 136, 137, 1363, 1364, "1" +407, 13, 40, 289, 138, 139, 1365, 1366, "." +407, 13, 41, 290, 140, 141, 1367, 1368, "9" +407, 13, 42, 291, 142, 144, 1369, 1371, "mm" +407, 13, 43, 292, 145, 147, 1372, 1374, "Hg" +407, 13, 44, 293, 148, 150, 1375, 1377, "in" +407, 13, 45, 294, 151, 156, 1378, 1383, "group" +407, 13, 46, 295, 157, 158, 1384, 1385, "B" +407, 13, 47, 296, 159, 160, 1386, 1387, "." +407, 14, 1, 297, 0, 1, 1388, 1389, "A" +407, 14, 2, 298, 2, 13, 1390, 1401, "significant" +407, 14, 3, 299, 14, 24, 1402, 1412, "difference" +407, 14, 4, 300, 25, 28, 1413, 1416, "was" +407, 14, 5, 301, 29, 34, 1417, 1422, "found" +407, 14, 6, 302, 35, 36, 1423, 1424, "(" +407, 14, 7, 303, 37, 38, 1425, 1426, "p" +407, 14, 8, 304, 39, 40, 1427, 1428, "=" +407, 14, 9, 305, 41, 42, 1429, 1430, "0" +407, 14, 10, 306, 43, 44, 1431, 1432, "." +407, 14, 11, 307, 45, 49, 1433, 1437, "0343" +407, 14, 12, 308, 50, 51, 1438, 1439, ")" +407, 14, 13, 309, 52, 53, 1440, 1441, "." +407, 15, 1, 310, 0, 2, 1442, 1444, "In" +407, 15, 2, 311, 3, 11, 1445, 1453, "contrast" +407, 15, 3, 312, 12, 13, 1454, 1455, "," +407, 15, 4, 313, 14, 18, 1456, 1460, "mean" +407, 15, 5, 314, 19, 28, 1461, 1470, "afternoon" +407, 15, 6, 315, 29, 32, 1471, 1474, "IOP" +407, 15, 7, 316, 33, 42, 1475, 1484, "reduction" +407, 15, 8, 317, 43, 46, 1485, 1488, "was" +407, 15, 9, 318, 47, 48, 1489, 1490, "8" +407, 15, 10, 319, 49, 50, 1491, 1492, "." +407, 15, 11, 320, 51, 52, 1493, 1494, "6" +407, 15, 12, 321, 53, 54, 1495, 1496, "±" +407, 15, 13, 322, 55, 56, 1497, 1498, "2" +407, 15, 14, 323, 57, 58, 1499, 1500, "." +407, 15, 15, 324, 59, 60, 1501, 1502, "7" +407, 15, 16, 325, 61, 63, 1503, 1505, "mm" +407, 15, 17, 326, 64, 66, 1506, 1508, "Hg" +407, 15, 18, 327, 67, 69, 1509, 1511, "in" +407, 15, 19, 328, 70, 75, 1512, 1517, "group" +407, 15, 20, 329, 76, 77, 1518, 1519, "A" +407, 15, 21, 330, 78, 81, 1520, 1523, "and" +407, 15, 22, 331, 82, 83, 1524, 1525, "7" +407, 15, 23, 332, 84, 85, 1526, 1527, "." +407, 15, 24, 333, 86, 87, 1528, 1529, "9" +407, 15, 25, 334, 88, 89, 1530, 1531, "±" +407, 15, 26, 335, 90, 91, 1532, 1533, "1" +407, 15, 27, 336, 92, 93, 1534, 1535, "." +407, 15, 28, 337, 94, 95, 1536, 1537, "6" +407, 15, 29, 338, 96, 98, 1538, 1540, "mm" +407, 15, 30, 339, 99, 101, 1541, 1543, "Hg" +407, 15, 31, 340, 102, 104, 1544, 1546, "in" +407, 15, 32, 341, 105, 110, 1547, 1552, "group" +407, 15, 33, 342, 111, 112, 1553, 1554, "B" +407, 15, 34, 343, 113, 116, 1555, 1558, "and" +407, 15, 35, 344, 117, 119, 1559, 1561, "no" +407, 15, 36, 345, 120, 131, 1562, 1573, "significant" +407, 15, 37, 346, 132, 142, 1574, 1584, "difference" +407, 15, 38, 347, 143, 146, 1585, 1588, "was" +407, 15, 39, 348, 147, 152, 1589, 1594, "found" +407, 15, 40, 349, 153, 154, 1595, 1596, "(" +407, 15, 41, 350, 155, 156, 1597, 1598, "p" +407, 15, 42, 351, 157, 158, 1599, 1600, "=" +407, 15, 43, 352, 159, 160, 1601, 1602, "0" +407, 15, 44, 353, 161, 162, 1603, 1604, "." +407, 15, 45, 354, 163, 167, 1605, 1609, "3413" +407, 15, 46, 355, 168, 169, 1610, 1611, ")" +407, 15, 47, 356, 170, 171, 1612, 1613, "." +407, 16, 1, 357, 0, 2, 1614, 1616, "No" +407, 16, 2, 358, 3, 14, 1617, 1628, "significant" +407, 16, 3, 359, 15, 22, 1629, 1636, "adverse" +407, 16, 4, 360, 23, 30, 1637, 1644, "effects" +407, 16, 5, 361, 31, 35, 1645, 1649, "were" +407, 16, 6, 362, 36, 44, 1650, 1658, "observed" +407, 16, 7, 363, 45, 47, 1659, 1661, "in" +407, 16, 8, 364, 48, 54, 1662, 1668, "either" +407, 16, 9, 365, 55, 60, 1669, 1674, "group" +407, 16, 10, 366, 61, 62, 1675, 1676, "." +407, 17, 1, 367, 0, 11, 1677, 1688, "CONCLUSIONS" +407, 17, 2, 368, 12, 13, 1689, 1690, ":" +407, 17, 3, 369, 14, 26, 1691, 1703, "Brinzolamide" +407, 17, 4, 370, 27, 28, 1704, 1705, "/" +407, 17, 5, 371, 29, 40, 1706, 1717, "brimonidine" +407, 17, 6, 372, 41, 46, 1718, 1723, "seems" +407, 17, 7, 373, 47, 49, 1724, 1726, "to" +407, 17, 8, 374, 50, 52, 1727, 1729, "be" +407, 17, 9, 375, 53, 55, 1730, 1732, "an" +407, 17, 10, 376, 56, 65, 1733, 1742, "effective" +407, 17, 11, 377, 66, 69, 1743, 1746, "and" +407, 17, 12, 378, 70, 74, 1747, 1751, "safe" +407, 17, 13, 379, 75, 86, 1752, 1763, "alternative" +407, 17, 14, 380, 87, 89, 1764, 1766, "β-" +407, 17, 15, 381, 90, 97, 1767, 1774, "blocker" +407, 17, 16, 382, 98, 102, 1775, 1779, "free" +407, 17, 17, 383, 103, 108, 1780, 1785, "fixed" +407, 17, 18, 384, 109, 120, 1786, 1797, "combination" +407, 17, 19, 385, 121, 122, 1798, 1799, "," +407, 17, 20, 386, 123, 133, 1800, 1810, "especially" +407, 17, 21, 387, 134, 137, 1811, 1814, "for" +407, 17, 22, 388, 138, 146, 1815, 1823, "patients" +407, 17, 23, 389, 147, 151, 1824, 1828, "with" +407, 17, 24, 390, 152, 165, 1829, 1842, "comorbidities" +407, 17, 25, 391, 166, 167, 1843, 1844, "," +407, 17, 26, 392, 168, 174, 1845, 1851, "having" +407, 17, 27, 393, 175, 178, 1852, 1855, "its" +407, 17, 28, 394, 179, 182, 1856, 1859, "own" +407, 17, 29, 395, 183, 199, 1860, 1876, "antihypertensive" +407, 17, 30, 396, 200, 207, 1877, 1884, "profile" +407, 17, 31, 397, 208, 209, 1885, 1886, "." +407, 18, 1, 398, 0, 3, 1887, 1890, "DOI" +407, 18, 2, 399, 4, 5, 1891, 1892, ":" +407, 18, 3, 400, 6, 8, 1893, 1895, "10" +407, 18, 4, 401, 9, 10, 1896, 1897, "." +407, 18, 5, 402, 11, 15, 1898, 1902, "5301" +407, 18, 6, 403, 16, 17, 1903, 1904, "/" +407, 18, 7, 404, 18, 21, 1905, 1908, "ejo" +407, 18, 8, 405, 22, 23, 1909, 1910, "." +407, 18, 9, 406, 24, 31, 1911, 1918, "5000826" +407, 18, 10, 407, 32, 36, 1919, 1923, "PMID" +407, 18, 11, 408, 37, 38, 1924, 1925, ":" +407, 18, 12, 409, 39, 47, 1926, 1934, "27445072" +407, 18, 13, 410, 48, 49, 1935, 1936, "[" +407, 18, 14, 411, 50, 57, 1937, 1944, "Indexed" +407, 18, 15, 412, 58, 61, 1945, 1948, "for" +407, 18, 16, 413, 62, 69, 1949, 1956, "MEDLINE" +407, 18, 17, 414, 70, 71, 1957, 1958, "]" diff --git a/data/gl 27445072_jshahinitiran.annodb b/data/gl 27445072_jshahinitiran.annodb new file mode 100644 index 0000000..efbf3b3 --- /dev/null +++ b/data/gl 27445072_jshahinitiran.annodb @@ -0,0 +1,57 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32522, Journal, 0, 16, "Eur J Ophthalmol", "", +32579, PublicationYear, 19, 23, "2017", "", +32523, Title, 109, 251, "Comparison of dorzolamide / timolol vs brinzolamide / brimonidine fixed combination therapy in the management of primary open - angle glaucoma", "", +32524, Dorzolamide, 123, 134, "dorzolamide", "", +32525, Timolol, 137, 144, "timolol", "", +32526, Brinzolamide, 148, 160, "brinzolamide", "", +32527, Brimonidine, 163, 174, "brimonidine", "", +32528, Primary_OpenAngleGlaucoma, 222, 251, "primary open - angle glaucoma", "", +32529, Author, 254, 265, "Kozobolis V", "", +32530, Author, 286, 294, "Panos GD", "", +32531, Author, 303, 319, "Konstantinidis A", "", +32532, Author, 328, 337, "Labiris G", "", +32533, Greece, 468, 474, "Greece", "", +32534, Greece, 573, 579, "Greece", "", +32535, Greece, 627, 633, "Greece", "", +32536, ObjectiveDescription, 646, 766, "To compare the efficiency of brinzolamide / brimonidine fixed combination vs the dorzolamide / timolol fixed combination", "", +32537, Brinzolamide, 675, 687, "brinzolamide", "", +32538, Brimonidine, 690, 701, "brimonidine", "", +32539, Dorzolamide, 727, 738, "dorzolamide", "", +32540, Timolol, 741, 748, "timolol", "", +32541, NumberPatientsCT, 800, 802, "44", "", +32542, Dorzolamide, 857, 868, "dorzolamide", "", +32543, Timolol, 871, 878, "timolol", "", +32544, Frequency, 879, 890, "twice a day", "", +32545, Brinzolamide, 911, 923, "brinzolamide", "", +32546, Brimonidine, 926, 937, "brimonidine", "", +32547, Frequency, 938, 949, "twice a day", "", +32548, TimePoint, 1087, 1088, "1", "", +32549, TimePoint, 1091, 1092, "4", "", +32550, TimePoint, 1095, 1096, "8", "", +32551, TimePoint, 1103, 1111, "12 weeks", "", +32552, IOP, 1129, 1149, "intraocular pressure", "", +32553, IOP, 1152, 1155, "IOP", "", +32554, Mean, 1289, 1293, "mean", "", +32573, EndPointDescription, 1294, 1305, "morning IOP", "", +32555, IOP, 1302, 1305, "IOP", "", +32566, Reduction, 1320, 1325, "7 . 0", "", +32558, SdErrorChangeValue, 1328, 1333, "2 . 8", "", +32560, mmHg, 1334, 1339, "mm Hg", "", +32567, Reduction, 1355, 1360, "8 . 4", "", +32559, SdErrorChangeValue, 1363, 1368, "1 . 9", "", +32561, mmHg, 1369, 1374, "mm Hg", "", +32562, PvalueDiff, 1425, 1437, "p = 0 . 0343", "", +32563, Mean, 1456, 1460, "mean", "", +32574, EndPointDescription, 1461, 1474, "afternoon IOP", "", +32564, IOP, 1471, 1474, "IOP", "", +32565, Reduction, 1489, 1494, "8 . 6", "", +32569, SdErrorChangeValue, 1497, 1502, "2 . 7", "", +32571, mmHg, 1503, 1508, "mm Hg", "", +32568, Reduction, 1524, 1529, "7 . 9", "", +32570, SdErrorChangeValue, 1532, 1537, "1 . 6", "", +32572, mmHg, 1538, 1543, "mm Hg", "", +32575, PvalueDiff, 1597, 1609, "p = 0 . 3413", "", +32576, Brinzolamide, 1691, 1703, "Brinzolamide", "", +32578, ConclusionComment, 1691, 1884, "Brinzolamide / brimonidine seems to be an effective and safe alternative β- blocker free fixed combination , especially for patients with comorbidities , having its own antihypertensive profile", "", +32577, Brimonidine, 1706, 1717, "brimonidine", "", diff --git a/data/gl 27445072_jshahinitiran.n-triples b/data/gl 27445072_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27445072_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 27445072_tstrakeljahn.annodb b/data/gl 27445072_tstrakeljahn.annodb new file mode 100644 index 0000000..8fee586 --- /dev/null +++ b/data/gl 27445072_tstrakeljahn.annodb @@ -0,0 +1,53 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8230, Journal, 0, 16, "Eur J Ophthalmol", "", +8231, PublicationYear, 19, 23, "2017", "", +8243, Title, 109, 251, "Comparison of dorzolamide / timolol vs brinzolamide / brimonidine fixed combination therapy in the management of primary open - angle glaucoma", "", +8232, Dorzolamide, 123, 134, "dorzolamide", "", +8234, Timolol, 137, 144, "timolol", "", +8236, Brinzolamide, 148, 160, "brinzolamide", "", +8239, Brimonidine, 163, 174, "brimonidine", "", +8242, OpenAngleGlaucoma, 230, 251, "open - angle glaucoma", "", +8244, Author, 254, 265, "Kozobolis V", "", +8245, Author, 286, 294, "Panos GD", "", +8246, Author, 303, 319, "Konstantinidis A", "", +8247, Author, 328, 337, "Labiris G", "", +8248, Greece, 468, 474, "Greece", "", +8249, Greece, 573, 579, "Greece", "", +8250, Greece, 627, 633, "Greece", "", +8255, ObjectiveDescription, 646, 766, "To compare the efficiency of brinzolamide / brimonidine fixed combination vs the dorzolamide / timolol fixed combination", "", +8251, Brinzolamide, 675, 687, "brinzolamide", "", +8252, Brimonidine, 690, 701, "brimonidine", "", +8253, Dorzolamide, 727, 738, "dorzolamide", "", +8254, Timolol, 741, 748, "timolol", "", +8256, NumberPatientsCT, 800, 802, "44", "", +8233, Dorzolamide, 857, 868, "dorzolamide", "", +8235, Timolol, 871, 878, "timolol", "", +8257, Frequency, 879, 890, "twice a day", "", +8237, Brinzolamide, 911, 923, "brinzolamide", "", +8240, Brimonidine, 926, 937, "brimonidine", "", +8258, Frequency, 938, 949, "twice a day", "", +8259, IOP, 1129, 1149, "intraocular pressure", "", +8260, IOP, 1152, 1155, "IOP", "", +8261, Frequency, 1171, 1182, "twice a day", "", +8262, TimePoint, 1185, 1200, "morning at 9 AM", "", +8263, TimePoint, 1205, 1222, "afternoon at 4 PM", "", +8264, IOP, 1302, 1305, "IOP", "", +8265, Reduction, 1320, 1325, "7 . 0", "", +8266, SdDevChangeValue, 1326, 1333, "± 2 . 8", "", +8267, mmHg, 1334, 1339, "mm Hg", "", +8268, Reduction, 1355, 1360, "8 . 4", "", +8269, SdDevChangeValue, 1361, 1368, "± 1 . 9", "", +8270, mmHg, 1369, 1374, "mm Hg", "", +8271, PvalueDiff, 1425, 1437, "p = 0 . 0343", "", +8272, IOP, 1471, 1474, "IOP", "", +8273, Reduction, 1489, 1494, "8 . 6", "", +8275, SdDevChangeValue, 1495, 1502, "± 2 . 7", "", +8277, mmHg, 1503, 1508, "mm Hg", "", +8274, Reduction, 1524, 1529, "7 . 9", "", +8276, SdDevChangeValue, 1530, 1537, "± 1 . 6", "", +8278, mmHg, 1538, 1543, "mm Hg", "", +8279, PvalueDiff, 1597, 1609, "p = 0 . 3413", "", +8238, Brinzolamide, 1691, 1703, "Brinzolamide", "", +8280, ConclusionComment, 1691, 1886, "Brinzolamide / brimonidine seems to be an effective and safe alternative β- blocker free fixed combination , especially for patients with comorbidities , having its own antihypertensive profile .", "", +8241, Brimonidine, 1706, 1717, "brimonidine", "", +8281, PMID, 1926, 1934, "27445072", "", diff --git a/data/gl 27445072_tstrakeljahn.n-triples b/data/gl 27445072_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 27445072_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 28129020_admin.annodb b/data/gl 28129020_admin.annodb new file mode 100644 index 0000000..18d65da --- /dev/null +++ b/data/gl 28129020_admin.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 23, "J Ocul Pharmacol Ther .", "", " \"J Ocul Pharmacol Ther .\"." +1, PublicationYear, 24, 28, "2017", "", " \"2017\"." +12, Title, 115, 252, "The 24 - Hour Effects of Brinzolamide / Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure .", "", " \"The 24 - Hour Effects of Brinzolamide / Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure .\"." +53867, Brinz/BrimoFC, 140, 166, "Brinzolamide / Brimonidine", "", " ." +4, Timolol, 189, 196, "Timolol", "", " ." +5, IOP, 200, 220, "Intraocular Pressure", "", " . ." +6, Author, 253, 263, "Seibold LK", "", " \"Seibold LK\"." +7, Author, 272, 281, "DeWitt PE", "", " \"DeWitt PE\"." +8, Author, 290, 299, "Kroehl ME", "", " \"Kroehl ME\"." +9, Author, 308, 317, "Kahook MY", "", " \"Kahook MY\"." +10, USA, 437, 445, "Colorado", "", " ." +11, USA, 546, 554, "Colorado", "", +21, ObjectiveDescription, 567, 794, "To determine the 24 - h effects of brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination ( BBFC ) on intraocular pressure ( IOP ) , ocular perfusion pressure ( OPP ) , blood pressure ( BP ) , and heart rate ( HR )", "", " \"To determine the 24 - h effects of brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination ( BBFC ) on intraocular pressure ( IOP ) , ocular perfusion pressure ( OPP ) , blood pressure ( BP ) , and heart rate ( HR )\"." +53868, Brinz/BrimoFC, 602, 669, "brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination", "", +15, DoseValue, 638, 639, "1", "", +17, Percentage, 640, 641, "%", "", +16, DoseValue, 644, 649, "0 . 2", "", +18, Percentage, 650, 651, "%", "", +53869, Brinz/BrimoFC, 672, 676, "BBFC", "", +19, IOP, 682, 702, "intraocular pressure", "", +20, IOP, 705, 708, "IOP", "", +102, EndPointDescription, 713, 738, "ocular perfusion pressure", "", " . ." +103, EndPointDescription, 741, 744, "OPP", "", +32, BloodPressure, 749, 763, "blood pressure", "", +31, BloodPressure, 766, 768, "BP", "", +29, HeartRate, 777, 787, "heart rate", "", +30, HeartRate, 790, 792, "HR", "", +22, NumberPatientsCT, 807, 812, "Sixty", "", " \"Sixty\"." +54364, Precondition, 813, 886, "subjects with open angle glaucoma ( OAG ) or ocular hypertension ( OHTN )", "", " \"subjects with open angle glaucoma ( OAG ) or ocular hypertension ( OHTN )\"." +23, OpenAngleGlaucoma, 827, 846, "open angle glaucoma", "", " ." +24, OpenAngleGlaucoma, 849, 852, "OAG", "", " ." +25, OcularHypertension, 858, 877, "ocular hypertension", "", " ." +26, OcularHypertension, 880, 884, "OHTN", "", " ." +27, IOP, 936, 939, "IOP", "", +33, BloodPressure, 942, 944, "BP", "", +28, HeartRate, 951, 953, "HR", "", +34, Randomized, 1082, 1092, "randomized", "", " ." +35, Timolol, 1117, 1132, "timolol maleate", "", +36, DoseValue, 1133, 1138, "0 . 5", "", " \"0 . 5\"." +119, Percentage, 1139, 1140, "%", "", " ." +37, Frequency, 1141, 1152, "twice daily", "", " \"twice daily\"." +53870, Brinz/BrimoFC, 1162, 1166, "BBFC", "", +38, Frequency, 1167, 1180, "3 times daily", "", " \"3 times daily\"." +39, Duration, 1189, 1196, "4 weeks", "", " \"4 weeks\"." +40, IOP, 1292, 1295, "IOP", "", +41, BloodPressure, 1298, 1300, "BP", "", +42, HeartRate, 1307, 1309, "HR", "", +131, EndPointDescription, 1363, 1366, "OPP", "", +43, BloodPressure, 1403, 1405, "BP", "", +44, BloodPressure, 1425, 1427, "BP", "", +45, BloodPressure, 1440, 1442, "BP", "", +46, IOP, 1449, 1452, "IOP", "", +53871, Brinz/BrimoFC, 1480, 1484, "BBFC", "", +53881, Diurnal_IOP, 1507, 1536, "IOP during the diurnal period", "", +48, Reduction, 1541, 1546, "2 . 7", "", " \"2 . 7\"." +49, SdDevChangeValue, 1551, 1556, "0 . 4", "", " \"0 . 4\"." +50, mmHg, 1559, 1563, "mmHg", "", " ." +51, PValueChangeValue, 1566, 1578, "P  <  0 . 01", "", " \"P  <  0 . 01\"." +53882, EndPointDescription, 1585, 1601, "nocturnal period", "", " . ." +53, Reduction, 1606, 1611, "0 . 8", "", " \"0 . 8\"." +54, SdDevChangeValue, 1616, 1621, "0 . 3", "", " \"0 . 3\"." +55, mmHg, 1624, 1628, "mmHg", "", " ." +56, PValueChangeValue, 1631, 1643, "P  <  0 . 01", "", " \"P  <  0 . 01\"." +106363, ObservedResult, 1648, 1703, "Timolol similarly reduced IOP during the diurnal period", "", " \"Timolol similarly reduced IOP during the diurnal period\"." +57, Timolol, 1648, 1655, "Timolol", "", +58, Diurnal_IOP, 1674, 1703, "IOP during the diurnal period", "", " ." +106364, ObservedResult, 1706, 1739, "but did not lower IOP overnight .", "", " \"but did not lower IOP overnight .\"." +53879, EndPointDescription, 1724, 1737, "IOP overnight", "", +106413, SubGroupDescription, 1747, 1760, "24 - h period", "", " \"24 - h period\". \"24 - h period\"." +53875, Brinz/BrimoFC, 1763, 1767, "BBFC", "", +60, IOP, 1801, 1804, "IOP", "", +61, Timolol, 1820, 1827, "timolol", "", +106410, DiffGroupAbsValue, 1830, 1837, "- 0 . 7", "", " \"- 0 . 7\"." +106411, SdDevDiff, 1842, 1847, "0 . 4", "", " \"0 . 4\"." +64, mmHg, 1850, 1854, "mmHg", "", " ." +106412, PvalueDiff, 1857, 1869, "P  =  0 . 04", "", " \"P  =  0 . 04\"." +66, ObservedResult, 1874, 1938, "BBFC failed to achieve an increase in OPP during any time period", "", " \"BBFC failed to achieve an increase in OPP during any time period\"." +53876, Brinz/BrimoFC, 1874, 1878, "BBFC", "", +150, EndPointDescription, 1912, 1915, "OPP", "", +67, Timolol, 1947, 1954, "timolol", "", +53883, ObservedResult, 1947, 1999, "timolol increased OPP during the diurnal period only", "", " \"timolol increased OPP during the diurnal period only\"." +152, EndPointDescription, 1965, 1968, "OPP", "", +106414, ObservedResult, 2002, 2071, "A significantly greater reduction in HR occurred in the timolol group", "", " \"A significantly greater reduction in HR occurred in the timolol group\"." +68, HeartRate, 2039, 2041, "HR", "", " . ." +69, Timolol, 2058, 2065, "timolol", "", +155, ConclusionComment, 2088, 2192, "BBFC significantly lowers IOP during both the diurnal and nocturnal periods , but has no effect on OPP .", "", " \"BBFC significantly lowers IOP during both the diurnal and nocturnal periods , but has no effect on OPP .\"." +53877, Brinz/BrimoFC, 2088, 2092, "BBFC", "", +70, IOP, 2114, 2117, "IOP", "", +158, EndPointDescription, 2187, 2190, "OPP", "", +71, Timolol, 2193, 2200, "Timolol", "", +156, ConclusionComment, 2193, 2244, "Timolol only lowers IOP during the diurnal period .", "", " \"Timolol only lowers IOP during the diurnal period .\"." +72, Diurnal_IOP, 2213, 2242, "IOP during the diurnal period", "", +73, PMID, 2307, 2315, "28129020", "", " \"28129020\"." diff --git a/data/gl 28129020_admin.n-triples b/data/gl 28129020_admin.n-triples new file mode 100644 index 0000000..82f82c6 --- /dev/null +++ b/data/gl 28129020_admin.n-triples @@ -0,0 +1,162 @@ +# RDF export of group: Publication + . + "Publication" . + "The 24 - Hour Effects of Brinzolamide / Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure ." . + "Seibold LK" . + "2017" . + "J Ocul Pharmacol Ther ." . + "28129020" . + . + "DeWitt PE" . + "Kroehl ME" . + "Kahook MY" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To determine the 24 - h effects of brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination ( BBFC ) on intraocular pressure ( IOP ) , ocular perfusion pressure ( OPP ) , blood pressure ( BP ) , and heart rate ( HR )" . + "Sixty" . + "4 weeks" . + . + . + . + "BBFC significantly lowers IOP during both the diurnal and nocturnal periods , but has no effect on OPP ." . + . + . + . + . + . + "Timolol only lowers IOP during the diurnal period ." . + . + . +# RDF export of group: Population + . + "Population" . + "subjects with open angle glaucoma ( OAG ) or ocular hypertension ( OHTN )" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_OPP" . + . + . + . + . + . + . + "Endpoint_DiuIOP" . + . + . + . + . + . + "Endpoint_NocIOP" . + . + . + . + . + . + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_HeartRate" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_Tim" . + . + . + . + . + . + . + . + "Arm_BBFC" . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_BBFC" . + . + "3 times daily" . + . + . + "Intervention_Tim" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_BBFC" . + . + . + . + . + "Medication_Tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_OPP_BTFC" . + . + "BBFC failed to achieve an increase in OPP during any time period" . + . + "Outcome_OPP_Tim" . + . + "timolol increased OPP during the diurnal period only" . + . + "Outcome_DiuIOP_BTFC" . + . + "2 . 7" . + "P  <  0 . 01" . + "0 . 4" . + . + "Outcome_NocIOP_BTFC" . + . + "0 . 8" . + "P  <  0 . 01" . + "0 . 3" . + . + "Outcome_NocIOP_Tim" . + . + "but did not lower IOP overnight ." . + . + "Outcome_iop_bbfc" . + . + "24 - h period" . + . + "Outcome_iop_Tim" . + . + "24 - h period" . + . + "Outcome_DiuIOP_Tim" . + . + "Timolol similarly reduced IOP during the diurnal period" . + . + "Outcome_HeartRate" . + . + "A significantly greater reduction in HR occurred in the timolol group" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_24h_iop" . + "- 0 . 7" . + "P  =  0 . 04" . + "0 . 4" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 28129020_export.csv b/data/gl 28129020_export.csv new file mode 100644 index 0000000..92980a5 --- /dev/null +++ b/data/gl 28129020_export.csv @@ -0,0 +1,510 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +406, 1, 1, 1, 0, 1, 0, 1, "J" +406, 1, 2, 2, 2, 6, 2, 6, "Ocul" +406, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +406, 1, 4, 4, 17, 21, 17, 21, "Ther" +406, 1, 5, 5, 22, 23, 22, 23, "." +406, 2, 1, 6, 0, 4, 24, 28, "2017" +406, 2, 2, 7, 5, 8, 29, 32, "Apr" +406, 2, 3, 8, 9, 10, 33, 34, ";" +406, 2, 4, 9, 11, 13, 35, 37, "33" +406, 2, 5, 10, 14, 15, 38, 39, "(" +406, 2, 6, 11, 16, 17, 40, 41, "3" +406, 2, 7, 12, 18, 19, 42, 43, ")" +406, 2, 8, 13, 20, 21, 44, 45, ":" +406, 2, 9, 14, 22, 25, 46, 49, "161" +406, 2, 10, 15, 26, 27, 50, 51, "-" +406, 2, 11, 16, 28, 31, 52, 55, "169" +406, 2, 12, 17, 32, 33, 56, 57, "." +406, 2, 13, 18, 34, 37, 58, 61, "doi" +406, 2, 14, 19, 38, 39, 62, 63, ":" +406, 2, 15, 20, 40, 42, 64, 66, "10" +406, 2, 16, 21, 43, 44, 67, 68, "." +406, 2, 17, 22, 45, 49, 69, 73, "1089" +406, 2, 18, 23, 50, 51, 74, 75, "/" +406, 2, 19, 24, 52, 55, 76, 79, "jop" +406, 2, 20, 25, 56, 57, 80, 81, "." +406, 2, 21, 26, 58, 62, 82, 86, "2016" +406, 2, 22, 27, 63, 64, 87, 88, "." +406, 2, 23, 28, 65, 69, 89, 93, "0141" +406, 2, 24, 29, 70, 71, 94, 95, "." +406, 3, 1, 30, 0, 4, 96, 100, "Epub" +406, 3, 2, 31, 5, 9, 101, 105, "2017" +406, 3, 3, 32, 10, 13, 106, 109, "Jan" +406, 3, 4, 33, 14, 16, 110, 112, "27" +406, 3, 5, 34, 17, 18, 113, 114, "." +406, 4, 1, 35, 0, 3, 115, 118, "The" +406, 4, 2, 36, 4, 6, 119, 121, "24" +406, 4, 3, 37, 7, 8, 122, 123, "-" +406, 4, 4, 38, 9, 13, 124, 128, "Hour" +406, 4, 5, 39, 14, 21, 129, 136, "Effects" +406, 4, 6, 40, 22, 24, 137, 139, "of" +406, 4, 7, 41, 25, 37, 140, 152, "Brinzolamide" +406, 4, 8, 42, 38, 39, 153, 154, "/" +406, 4, 9, 43, 40, 51, 155, 166, "Brimonidine" +406, 4, 10, 44, 52, 57, 167, 172, "Fixed" +406, 4, 11, 45, 58, 69, 173, 184, "Combination" +406, 4, 12, 46, 70, 73, 185, 188, "and" +406, 4, 13, 47, 74, 81, 189, 196, "Timolol" +406, 4, 14, 48, 82, 84, 197, 199, "on" +406, 4, 15, 49, 85, 96, 200, 211, "Intraocular" +406, 4, 16, 50, 97, 105, 212, 220, "Pressure" +406, 4, 17, 51, 106, 109, 221, 224, "and" +406, 4, 18, 52, 110, 116, 225, 231, "Ocular" +406, 4, 19, 53, 117, 126, 232, 241, "Perfusion" +406, 4, 20, 54, 127, 135, 242, 250, "Pressure" +406, 4, 21, 55, 136, 137, 251, 252, "." +406, 5, 1, 56, 0, 7, 253, 260, "Seibold" +406, 5, 2, 57, 8, 10, 261, 263, "LK" +406, 5, 3, 58, 11, 12, 264, 265, "(" +406, 5, 4, 59, 13, 14, 266, 267, "1" +406, 5, 5, 60, 15, 16, 268, 269, ")" +406, 5, 6, 61, 17, 18, 270, 271, "," +406, 5, 7, 62, 19, 25, 272, 278, "DeWitt" +406, 5, 8, 63, 26, 28, 279, 281, "PE" +406, 5, 9, 64, 29, 30, 282, 283, "(" +406, 5, 10, 65, 31, 32, 284, 285, "2" +406, 5, 11, 66, 33, 34, 286, 287, ")" +406, 5, 12, 67, 35, 36, 288, 289, "," +406, 5, 13, 68, 37, 43, 290, 296, "Kroehl" +406, 5, 14, 69, 44, 46, 297, 299, "ME" +406, 5, 15, 70, 47, 48, 300, 301, "(" +406, 5, 16, 71, 49, 50, 302, 303, "2" +406, 5, 17, 72, 51, 52, 304, 305, ")" +406, 5, 18, 73, 53, 54, 306, 307, "," +406, 5, 19, 74, 55, 61, 308, 314, "Kahook" +406, 5, 20, 75, 62, 64, 315, 317, "MY" +406, 5, 21, 76, 65, 66, 318, 319, "(" +406, 5, 22, 77, 67, 68, 320, 321, "1" +406, 5, 23, 78, 69, 70, 322, 323, ")" +406, 5, 24, 79, 71, 72, 324, 325, "." +406, 6, 1, 80, 0, 6, 326, 332, "Author" +406, 6, 2, 81, 7, 18, 333, 344, "information" +406, 6, 3, 82, 19, 20, 345, 346, ":" +406, 6, 4, 83, 21, 22, 347, 348, "(" +406, 6, 5, 84, 23, 24, 349, 350, "1" +406, 6, 6, 85, 25, 26, 351, 352, ")" +406, 6, 7, 86, 27, 28, 353, 354, "1" +406, 6, 8, 87, 29, 39, 355, 365, "Department" +406, 6, 9, 88, 40, 42, 366, 368, "of" +406, 6, 10, 89, 43, 56, 369, 382, "Ophthalmology" +406, 6, 11, 90, 57, 58, 383, 384, "," +406, 6, 12, 91, 59, 69, 385, 395, "University" +406, 6, 13, 92, 70, 72, 396, 398, "of" +406, 6, 14, 93, 73, 81, 399, 407, "Colorado" +406, 6, 15, 94, 82, 88, 408, 414, "Health" +406, 6, 16, 95, 89, 92, 415, 418, "Eye" +406, 6, 17, 96, 93, 99, 419, 425, "Center" +406, 6, 18, 97, 100, 101, 426, 427, "," +406, 6, 19, 98, 102, 108, 428, 434, "Aurora" +406, 6, 20, 99, 109, 110, 435, 436, "," +406, 6, 21, 100, 111, 119, 437, 445, "Colorado" +406, 6, 22, 101, 120, 121, 446, 447, "." +406, 7, 1, 102, 0, 1, 448, 449, "(" +406, 7, 2, 103, 2, 3, 450, 451, "2" +406, 7, 3, 104, 4, 5, 452, 453, ")" +406, 7, 4, 105, 6, 7, 454, 455, "2" +406, 7, 5, 106, 8, 18, 456, 466, "Department" +406, 7, 6, 107, 19, 21, 467, 469, "of" +406, 7, 7, 108, 22, 36, 470, 484, "Bioinformatics" +406, 7, 8, 109, 37, 40, 485, 488, "and" +406, 7, 9, 110, 41, 54, 489, 502, "Biostatistics" +406, 7, 10, 111, 55, 56, 503, 504, "," +406, 7, 11, 112, 57, 67, 505, 515, "University" +406, 7, 12, 113, 68, 70, 516, 518, "of" +406, 7, 13, 114, 71, 79, 519, 527, "Colorado" +406, 7, 14, 115, 80, 86, 528, 534, "Denver" +406, 7, 15, 116, 87, 88, 535, 536, "," +406, 7, 16, 117, 89, 95, 537, 543, "Aurora" +406, 7, 17, 118, 96, 97, 544, 545, "," +406, 7, 18, 119, 98, 106, 546, 554, "Colorado" +406, 7, 19, 120, 107, 108, 555, 556, "." +406, 8, 1, 121, 0, 7, 557, 564, "PURPOSE" +406, 8, 2, 122, 8, 9, 565, 566, ":" +406, 8, 3, 123, 10, 12, 567, 569, "To" +406, 8, 4, 124, 13, 22, 570, 579, "determine" +406, 8, 5, 125, 23, 26, 580, 583, "the" +406, 8, 6, 126, 27, 29, 584, 586, "24" +406, 8, 7, 127, 30, 31, 587, 588, "-" +406, 8, 8, 128, 32, 33, 589, 590, "h" +406, 8, 9, 129, 34, 41, 591, 598, "effects" +406, 8, 10, 130, 42, 44, 599, 601, "of" +406, 8, 11, 131, 45, 57, 602, 614, "brinzolamide" +406, 8, 12, 132, 58, 59, 615, 616, "/" +406, 8, 13, 133, 60, 71, 617, 628, "brimonidine" +406, 8, 14, 134, 72, 80, 629, 637, "tartrate" +406, 8, 15, 135, 81, 82, 638, 639, "1" +406, 8, 16, 136, 83, 84, 640, 641, "%" +406, 8, 17, 137, 85, 86, 642, 643, "/" +406, 8, 18, 138, 87, 88, 644, 645, "0" +406, 8, 19, 139, 89, 90, 646, 647, "." +406, 8, 20, 140, 91, 92, 648, 649, "2" +406, 8, 21, 141, 93, 94, 650, 651, "%" +406, 8, 22, 142, 95, 100, 652, 657, "fixed" +406, 8, 23, 143, 101, 112, 658, 669, "combination" +406, 8, 24, 144, 113, 114, 670, 671, "(" +406, 8, 25, 145, 115, 119, 672, 676, "BBFC" +406, 8, 26, 146, 120, 121, 677, 678, ")" +406, 8, 27, 147, 122, 124, 679, 681, "on" +406, 8, 28, 148, 125, 136, 682, 693, "intraocular" +406, 8, 29, 149, 137, 145, 694, 702, "pressure" +406, 8, 30, 150, 146, 147, 703, 704, "(" +406, 8, 31, 151, 148, 151, 705, 708, "IOP" +406, 8, 32, 152, 152, 153, 709, 710, ")" +406, 8, 33, 153, 154, 155, 711, 712, "," +406, 8, 34, 154, 156, 162, 713, 719, "ocular" +406, 8, 35, 155, 163, 172, 720, 729, "perfusion" +406, 8, 36, 156, 173, 181, 730, 738, "pressure" +406, 8, 37, 157, 182, 183, 739, 740, "(" +406, 8, 38, 158, 184, 187, 741, 744, "OPP" +406, 8, 39, 159, 188, 189, 745, 746, ")" +406, 8, 40, 160, 190, 191, 747, 748, "," +406, 8, 41, 161, 192, 197, 749, 754, "blood" +406, 8, 42, 162, 198, 206, 755, 763, "pressure" +406, 8, 43, 163, 207, 208, 764, 765, "(" +406, 8, 44, 164, 209, 211, 766, 768, "BP" +406, 8, 45, 165, 212, 213, 769, 770, ")" +406, 8, 46, 166, 214, 215, 771, 772, "," +406, 8, 47, 167, 216, 219, 773, 776, "and" +406, 8, 48, 168, 220, 225, 777, 782, "heart" +406, 8, 49, 169, 226, 230, 783, 787, "rate" +406, 8, 50, 170, 231, 232, 788, 789, "(" +406, 8, 51, 171, 233, 235, 790, 792, "HR" +406, 8, 52, 172, 236, 237, 793, 794, ")" +406, 8, 53, 173, 238, 239, 795, 796, "." +406, 9, 1, 174, 0, 7, 797, 804, "METHODS" +406, 9, 2, 175, 8, 9, 805, 806, ":" +406, 9, 3, 176, 10, 15, 807, 812, "Sixty" +406, 9, 4, 177, 16, 24, 813, 821, "subjects" +406, 9, 5, 178, 25, 29, 822, 826, "with" +406, 9, 6, 179, 30, 34, 827, 831, "open" +406, 9, 7, 180, 35, 40, 832, 837, "angle" +406, 9, 8, 181, 41, 49, 838, 846, "glaucoma" +406, 9, 9, 182, 50, 51, 847, 848, "(" +406, 9, 10, 183, 52, 55, 849, 852, "OAG" +406, 9, 11, 184, 56, 57, 853, 854, ")" +406, 9, 12, 185, 58, 60, 855, 857, "or" +406, 9, 13, 186, 61, 67, 858, 864, "ocular" +406, 9, 14, 187, 68, 80, 865, 877, "hypertension" +406, 9, 15, 188, 81, 82, 878, 879, "(" +406, 9, 16, 189, 83, 87, 880, 884, "OHTN" +406, 9, 17, 190, 88, 89, 885, 886, ")" +406, 9, 18, 191, 90, 94, 887, 891, "were" +406, 9, 19, 192, 95, 103, 892, 900, "admitted" +406, 9, 20, 193, 104, 113, 901, 910, "overnight" +406, 9, 21, 194, 114, 117, 911, 914, "for" +406, 9, 22, 195, 118, 120, 915, 917, "24" +406, 9, 23, 196, 121, 122, 918, 919, "-" +406, 9, 24, 197, 123, 124, 920, 921, "h" +406, 9, 25, 198, 125, 135, 922, 932, "monitoring" +406, 9, 26, 199, 136, 138, 933, 935, "of" +406, 9, 27, 200, 139, 142, 936, 939, "IOP" +406, 9, 28, 201, 143, 144, 940, 941, "," +406, 9, 29, 202, 145, 147, 942, 944, "BP" +406, 9, 30, 203, 148, 149, 945, 946, "," +406, 9, 31, 204, 150, 153, 947, 950, "and" +406, 9, 32, 205, 154, 156, 951, 953, "HR" +406, 9, 33, 206, 157, 158, 954, 955, "." +406, 10, 1, 207, 0, 3, 956, 959, "All" +406, 10, 2, 208, 4, 12, 960, 968, "subjects" +406, 10, 3, 209, 13, 22, 969, 978, "underwent" +406, 10, 4, 210, 23, 26, 979, 982, "the" +406, 10, 5, 211, 27, 32, 983, 988, "first" +406, 10, 6, 212, 33, 34, 989, 990, "," +406, 10, 7, 213, 35, 43, 991, 999, "baseline" +406, 10, 8, 214, 44, 46, 1000, 1002, "24" +406, 10, 9, 215, 47, 48, 1003, 1004, "-" +406, 10, 10, 216, 49, 50, 1005, 1006, "h" +406, 10, 11, 217, 51, 56, 1007, 1012, "study" +406, 10, 12, 218, 57, 62, 1013, 1018, "after" +406, 10, 13, 219, 63, 70, 1019, 1026, "washout" +406, 10, 14, 220, 71, 73, 1027, 1029, "of" +406, 10, 15, 221, 74, 77, 1030, 1033, "all" +406, 10, 16, 222, 78, 89, 1034, 1045, "medications" +406, 10, 17, 223, 90, 91, 1046, 1047, "," +406, 10, 18, 224, 92, 94, 1048, 1050, "if" +406, 10, 19, 225, 95, 104, 1051, 1060, "necessary" +406, 10, 20, 226, 105, 106, 1061, 1062, "." +406, 11, 1, 227, 0, 8, 1063, 1071, "Subjects" +406, 11, 2, 228, 9, 13, 1072, 1076, "were" +406, 11, 3, 229, 14, 18, 1077, 1081, "then" +406, 11, 4, 230, 19, 29, 1082, 1092, "randomized" +406, 11, 5, 231, 30, 32, 1093, 1095, "to" +406, 11, 6, 232, 33, 40, 1096, 1103, "receive" +406, 11, 7, 233, 41, 47, 1104, 1110, "either" +406, 11, 8, 234, 48, 49, 1111, 1112, "(" +406, 11, 9, 235, 50, 51, 1113, 1114, "1" +406, 11, 10, 236, 52, 53, 1115, 1116, ")" +406, 11, 11, 237, 54, 61, 1117, 1124, "timolol" +406, 11, 12, 238, 62, 69, 1125, 1132, "maleate" +406, 11, 13, 239, 70, 71, 1133, 1134, "0" +406, 11, 14, 240, 72, 73, 1135, 1136, "." +406, 11, 15, 241, 74, 75, 1137, 1138, "5" +406, 11, 16, 242, 76, 77, 1139, 1140, "%" +406, 11, 17, 243, 78, 83, 1141, 1146, "twice" +406, 11, 18, 244, 84, 89, 1147, 1152, "daily" +406, 11, 19, 245, 90, 92, 1153, 1155, "or" +406, 11, 20, 246, 93, 94, 1156, 1157, "(" +406, 11, 21, 247, 95, 96, 1158, 1159, "2" +406, 11, 22, 248, 97, 98, 1160, 1161, ")" +406, 11, 23, 249, 99, 103, 1162, 1166, "BBFC" +406, 11, 24, 250, 104, 105, 1167, 1168, "3" +406, 11, 25, 251, 106, 111, 1169, 1174, "times" +406, 11, 26, 252, 112, 117, 1175, 1180, "daily" +406, 11, 27, 253, 118, 119, 1181, 1182, "." +406, 12, 1, 254, 0, 5, 1183, 1188, "After" +406, 12, 2, 255, 6, 7, 1189, 1190, "4" +406, 12, 3, 256, 8, 13, 1191, 1196, "weeks" +406, 12, 4, 257, 14, 16, 1197, 1199, "of" +406, 12, 5, 258, 17, 26, 1200, 1209, "treatment" +406, 12, 6, 259, 27, 28, 1210, 1211, "," +406, 12, 7, 260, 29, 32, 1212, 1215, "all" +406, 12, 8, 261, 33, 41, 1216, 1224, "subjects" +406, 12, 9, 262, 42, 51, 1225, 1234, "completed" +406, 12, 10, 263, 52, 53, 1235, 1236, "a" +406, 12, 11, 264, 54, 60, 1237, 1243, "follow" +406, 12, 12, 265, 61, 62, 1244, 1245, "-" +406, 12, 13, 266, 63, 65, 1246, 1248, "up" +406, 12, 14, 267, 66, 68, 1249, 1251, "24" +406, 12, 15, 268, 69, 70, 1252, 1253, "-" +406, 12, 16, 269, 71, 72, 1254, 1255, "h" +406, 12, 17, 270, 73, 78, 1256, 1261, "study" +406, 12, 18, 271, 79, 84, 1262, 1267, "visit" +406, 12, 19, 272, 85, 86, 1268, 1269, "." +406, 13, 1, 273, 0, 2, 1270, 1272, "At" +406, 13, 2, 274, 3, 7, 1273, 1277, "each" +406, 13, 3, 275, 8, 13, 1278, 1283, "study" +406, 13, 4, 276, 14, 19, 1284, 1289, "visit" +406, 13, 5, 277, 20, 21, 1290, 1291, "," +406, 13, 6, 278, 22, 25, 1292, 1295, "IOP" +406, 13, 7, 279, 26, 27, 1296, 1297, "," +406, 13, 8, 280, 28, 30, 1298, 1300, "BP" +406, 13, 9, 281, 31, 32, 1301, 1302, "," +406, 13, 10, 282, 33, 36, 1303, 1306, "and" +406, 13, 11, 283, 37, 39, 1307, 1309, "HR" +406, 13, 12, 284, 40, 44, 1310, 1314, "were" +406, 13, 13, 285, 45, 53, 1315, 1323, "measured" +406, 13, 14, 286, 54, 59, 1324, 1329, "every" +406, 13, 15, 287, 60, 61, 1330, 1331, "2" +406, 13, 16, 288, 62, 63, 1332, 1333, " " +406, 13, 17, 289, 64, 65, 1334, 1335, "h" +406, 13, 18, 290, 66, 68, 1336, 1338, "in" +406, 13, 19, 291, 69, 72, 1339, 1342, "the" +406, 13, 20, 292, 73, 81, 1343, 1351, "habitual" +406, 13, 21, 293, 82, 90, 1352, 1360, "position" +406, 13, 22, 294, 91, 92, 1361, 1362, "." +406, 14, 1, 295, 0, 3, 1363, 1366, "OPP" +406, 14, 2, 296, 4, 7, 1367, 1370, "was" +406, 14, 3, 297, 8, 18, 1371, 1381, "calculated" +406, 14, 4, 298, 19, 21, 1382, 1384, "as" +406, 14, 5, 299, 22, 23, 1385, 1386, "2" +406, 14, 6, 300, 24, 25, 1387, 1388, "/" +406, 14, 7, 301, 26, 27, 1389, 1390, "3" +406, 14, 8, 302, 28, 29, 1391, 1392, "[" +406, 14, 9, 303, 30, 39, 1393, 1402, "diastolic" +406, 14, 10, 304, 40, 42, 1403, 1405, "BP" +406, 14, 11, 305, 43, 44, 1406, 1407, "+" +406, 14, 12, 306, 45, 46, 1408, 1409, "1" +406, 14, 13, 307, 47, 48, 1410, 1411, "/" +406, 14, 14, 308, 49, 50, 1412, 1413, "3" +406, 14, 15, 309, 51, 52, 1414, 1415, "(" +406, 14, 16, 310, 53, 61, 1416, 1424, "systolic" +406, 14, 17, 311, 62, 64, 1425, 1427, "BP" +406, 14, 18, 312, 65, 66, 1428, 1429, "-" +406, 14, 19, 313, 67, 76, 1430, 1439, "diastolic" +406, 14, 20, 314, 77, 79, 1440, 1442, "BP" +406, 14, 21, 315, 80, 81, 1443, 1444, ")" +406, 14, 22, 316, 82, 83, 1445, 1446, "]" +406, 14, 23, 317, 84, 85, 1447, 1448, "-" +406, 14, 24, 318, 86, 89, 1449, 1452, "IOP" +406, 14, 25, 319, 90, 91, 1453, 1454, "." +406, 15, 1, 320, 0, 7, 1455, 1462, "RESULTS" +406, 15, 2, 321, 8, 9, 1463, 1464, ":" +406, 15, 3, 322, 10, 19, 1465, 1474, "Treatment" +406, 15, 4, 323, 20, 24, 1475, 1479, "with" +406, 15, 5, 324, 25, 29, 1480, 1484, "BBFC" +406, 15, 6, 325, 30, 43, 1485, 1498, "significantly" +406, 15, 7, 326, 44, 51, 1499, 1506, "lowered" +406, 15, 8, 327, 52, 55, 1507, 1510, "IOP" +406, 15, 9, 328, 56, 62, 1511, 1517, "during" +406, 15, 10, 329, 63, 66, 1518, 1521, "the" +406, 15, 11, 330, 67, 74, 1522, 1529, "diurnal" +406, 15, 12, 331, 75, 81, 1530, 1536, "period" +406, 15, 13, 332, 82, 83, 1537, 1538, "(" +406, 15, 14, 333, 84, 85, 1539, 1540, "-" +406, 15, 15, 334, 86, 87, 1541, 1542, "2" +406, 15, 16, 335, 88, 89, 1543, 1544, "." +406, 15, 17, 336, 90, 91, 1545, 1546, "7" +406, 15, 18, 337, 92, 95, 1547, 1550, " ± " +406, 15, 19, 338, 96, 97, 1551, 1552, "0" +406, 15, 20, 339, 98, 99, 1553, 1554, "." +406, 15, 21, 340, 100, 101, 1555, 1556, "4" +406, 15, 22, 341, 102, 103, 1557, 1558, " " +406, 15, 23, 342, 104, 108, 1559, 1563, "mmHg" +406, 15, 24, 343, 109, 110, 1564, 1565, ";" +406, 15, 25, 344, 111, 112, 1566, 1567, "P" +406, 15, 26, 345, 113, 116, 1568, 1571, " < " +406, 15, 27, 346, 117, 118, 1572, 1573, "0" +406, 15, 28, 347, 119, 120, 1574, 1575, "." +406, 15, 29, 348, 121, 123, 1576, 1578, "01" +406, 15, 30, 349, 124, 125, 1579, 1580, ")" +406, 15, 31, 350, 126, 129, 1581, 1584, "and" +406, 15, 32, 351, 130, 139, 1585, 1594, "nocturnal" +406, 15, 33, 352, 140, 146, 1595, 1601, "period" +406, 15, 34, 353, 147, 148, 1602, 1603, "(" +406, 15, 35, 354, 149, 150, 1604, 1605, "-" +406, 15, 36, 355, 151, 152, 1606, 1607, "0" +406, 15, 37, 356, 153, 154, 1608, 1609, "." +406, 15, 38, 357, 155, 156, 1610, 1611, "8" +406, 15, 39, 358, 157, 160, 1612, 1615, " ± " +406, 15, 40, 359, 161, 162, 1616, 1617, "0" +406, 15, 41, 360, 163, 164, 1618, 1619, "." +406, 15, 42, 361, 165, 166, 1620, 1621, "3" +406, 15, 43, 362, 167, 168, 1622, 1623, " " +406, 15, 44, 363, 169, 173, 1624, 1628, "mmHg" +406, 15, 45, 364, 174, 175, 1629, 1630, ";" +406, 15, 46, 365, 176, 177, 1631, 1632, "P" +406, 15, 47, 366, 178, 181, 1633, 1636, " < " +406, 15, 48, 367, 182, 183, 1637, 1638, "0" +406, 15, 49, 368, 184, 185, 1639, 1640, "." +406, 15, 50, 369, 186, 188, 1641, 1643, "01" +406, 15, 51, 370, 189, 190, 1644, 1645, ")" +406, 15, 52, 371, 191, 192, 1646, 1647, "." +406, 16, 1, 372, 0, 7, 1648, 1655, "Timolol" +406, 16, 2, 373, 8, 17, 1656, 1665, "similarly" +406, 16, 3, 374, 18, 25, 1666, 1673, "reduced" +406, 16, 4, 375, 26, 29, 1674, 1677, "IOP" +406, 16, 5, 376, 30, 36, 1678, 1684, "during" +406, 16, 6, 377, 37, 40, 1685, 1688, "the" +406, 16, 7, 378, 41, 48, 1689, 1696, "diurnal" +406, 16, 8, 379, 49, 55, 1697, 1703, "period" +406, 16, 9, 380, 56, 57, 1704, 1705, "," +406, 16, 10, 381, 58, 61, 1706, 1709, "but" +406, 16, 11, 382, 62, 65, 1710, 1713, "did" +406, 16, 12, 383, 66, 69, 1714, 1717, "not" +406, 16, 13, 384, 70, 75, 1718, 1723, "lower" +406, 16, 14, 385, 76, 79, 1724, 1727, "IOP" +406, 16, 15, 386, 80, 89, 1728, 1737, "overnight" +406, 16, 16, 387, 90, 91, 1738, 1739, "." +406, 17, 1, 388, 0, 4, 1740, 1744, "Over" +406, 17, 2, 389, 5, 6, 1745, 1746, "a" +406, 17, 3, 390, 7, 9, 1747, 1749, "24" +406, 17, 4, 391, 10, 11, 1750, 1751, "-" +406, 17, 5, 392, 12, 13, 1752, 1753, "h" +406, 17, 6, 393, 14, 20, 1754, 1760, "period" +406, 17, 7, 394, 21, 22, 1761, 1762, "," +406, 17, 8, 395, 23, 27, 1763, 1767, "BBFC" +406, 17, 9, 396, 28, 36, 1768, 1776, "achieved" +406, 17, 10, 397, 37, 38, 1777, 1778, "a" +406, 17, 11, 398, 39, 52, 1779, 1792, "significantly" +406, 17, 12, 399, 53, 60, 1793, 1800, "greater" +406, 17, 13, 400, 61, 64, 1801, 1804, "IOP" +406, 17, 14, 401, 65, 74, 1805, 1814, "reduction" +406, 17, 15, 402, 75, 79, 1815, 1819, "than" +406, 17, 16, 403, 80, 87, 1820, 1827, "timolol" +406, 17, 17, 404, 88, 89, 1828, 1829, "(" +406, 17, 18, 405, 90, 91, 1830, 1831, "-" +406, 17, 19, 406, 92, 93, 1832, 1833, "0" +406, 17, 20, 407, 94, 95, 1834, 1835, "." +406, 17, 21, 408, 96, 97, 1836, 1837, "7" +406, 17, 22, 409, 98, 101, 1838, 1841, " ± " +406, 17, 23, 410, 102, 103, 1842, 1843, "0" +406, 17, 24, 411, 104, 105, 1844, 1845, "." +406, 17, 25, 412, 106, 107, 1846, 1847, "4" +406, 17, 26, 413, 108, 109, 1848, 1849, " " +406, 17, 27, 414, 110, 114, 1850, 1854, "mmHg" +406, 17, 28, 415, 115, 116, 1855, 1856, ";" +406, 17, 29, 416, 117, 118, 1857, 1858, "P" +406, 17, 30, 417, 119, 122, 1859, 1862, " = " +406, 17, 31, 418, 123, 124, 1863, 1864, "0" +406, 17, 32, 419, 125, 126, 1865, 1866, "." +406, 17, 33, 420, 127, 129, 1867, 1869, "04" +406, 17, 34, 421, 130, 131, 1870, 1871, ")" +406, 17, 35, 422, 132, 133, 1872, 1873, "." +406, 18, 1, 423, 0, 4, 1874, 1878, "BBFC" +406, 18, 2, 424, 5, 11, 1879, 1885, "failed" +406, 18, 3, 425, 12, 14, 1886, 1888, "to" +406, 18, 4, 426, 15, 22, 1889, 1896, "achieve" +406, 18, 5, 427, 23, 25, 1897, 1899, "an" +406, 18, 6, 428, 26, 34, 1900, 1908, "increase" +406, 18, 7, 429, 35, 37, 1909, 1911, "in" +406, 18, 8, 430, 38, 41, 1912, 1915, "OPP" +406, 18, 9, 431, 42, 48, 1916, 1922, "during" +406, 18, 10, 432, 49, 52, 1923, 1926, "any" +406, 18, 11, 433, 53, 57, 1927, 1931, "time" +406, 18, 12, 434, 58, 64, 1932, 1938, "period" +406, 18, 13, 435, 65, 66, 1939, 1940, "," +406, 18, 14, 436, 67, 72, 1941, 1946, "while" +406, 18, 15, 437, 73, 80, 1947, 1954, "timolol" +406, 18, 16, 438, 81, 90, 1955, 1964, "increased" +406, 18, 17, 439, 91, 94, 1965, 1968, "OPP" +406, 18, 18, 440, 95, 101, 1969, 1975, "during" +406, 18, 19, 441, 102, 105, 1976, 1979, "the" +406, 18, 20, 442, 106, 113, 1980, 1987, "diurnal" +406, 18, 21, 443, 114, 120, 1988, 1994, "period" +406, 18, 22, 444, 121, 125, 1995, 1999, "only" +406, 18, 23, 445, 126, 127, 2000, 2001, "." +406, 19, 1, 446, 0, 1, 2002, 2003, "A" +406, 19, 2, 447, 2, 15, 2004, 2017, "significantly" +406, 19, 3, 448, 16, 23, 2018, 2025, "greater" +406, 19, 4, 449, 24, 33, 2026, 2035, "reduction" +406, 19, 5, 450, 34, 36, 2036, 2038, "in" +406, 19, 6, 451, 37, 39, 2039, 2041, "HR" +406, 19, 7, 452, 40, 48, 2042, 2050, "occurred" +406, 19, 8, 453, 49, 51, 2051, 2053, "in" +406, 19, 9, 454, 52, 55, 2054, 2057, "the" +406, 19, 10, 455, 56, 63, 2058, 2065, "timolol" +406, 19, 11, 456, 64, 69, 2066, 2071, "group" +406, 19, 12, 457, 70, 71, 2072, 2073, "." +406, 20, 1, 458, 0, 11, 2074, 2085, "CONCLUSIONS" +406, 20, 2, 459, 12, 13, 2086, 2087, ":" +406, 20, 3, 460, 14, 18, 2088, 2092, "BBFC" +406, 20, 4, 461, 19, 32, 2093, 2106, "significantly" +406, 20, 5, 462, 33, 39, 2107, 2113, "lowers" +406, 20, 6, 463, 40, 43, 2114, 2117, "IOP" +406, 20, 7, 464, 44, 50, 2118, 2124, "during" +406, 20, 8, 465, 51, 55, 2125, 2129, "both" +406, 20, 9, 466, 56, 59, 2130, 2133, "the" +406, 20, 10, 467, 60, 67, 2134, 2141, "diurnal" +406, 20, 11, 468, 68, 71, 2142, 2145, "and" +406, 20, 12, 469, 72, 81, 2146, 2155, "nocturnal" +406, 20, 13, 470, 82, 89, 2156, 2163, "periods" +406, 20, 14, 471, 90, 91, 2164, 2165, "," +406, 20, 15, 472, 92, 95, 2166, 2169, "but" +406, 20, 16, 473, 96, 99, 2170, 2173, "has" +406, 20, 17, 474, 100, 102, 2174, 2176, "no" +406, 20, 18, 475, 103, 109, 2177, 2183, "effect" +406, 20, 19, 476, 110, 112, 2184, 2186, "on" +406, 20, 20, 477, 113, 116, 2187, 2190, "OPP" +406, 20, 21, 478, 117, 118, 2191, 2192, "." +406, 21, 1, 479, 0, 7, 2193, 2200, "Timolol" +406, 21, 2, 480, 8, 12, 2201, 2205, "only" +406, 21, 3, 481, 13, 19, 2206, 2212, "lowers" +406, 21, 4, 482, 20, 23, 2213, 2216, "IOP" +406, 21, 5, 483, 24, 30, 2217, 2223, "during" +406, 21, 6, 484, 31, 34, 2224, 2227, "the" +406, 21, 7, 485, 35, 42, 2228, 2235, "diurnal" +406, 21, 8, 486, 43, 49, 2236, 2242, "period" +406, 21, 9, 487, 50, 51, 2243, 2244, "." +406, 22, 1, 488, 0, 3, 2245, 2248, "DOI" +406, 22, 2, 489, 4, 5, 2249, 2250, ":" +406, 22, 3, 490, 6, 8, 2251, 2253, "10" +406, 22, 4, 491, 9, 10, 2254, 2255, "." +406, 22, 5, 492, 11, 15, 2256, 2260, "1089" +406, 22, 6, 493, 16, 17, 2261, 2262, "/" +406, 22, 7, 494, 18, 21, 2263, 2266, "jop" +406, 22, 8, 495, 22, 23, 2267, 2268, "." +406, 22, 9, 496, 24, 28, 2269, 2273, "2016" +406, 22, 10, 497, 29, 30, 2274, 2275, "." +406, 22, 11, 498, 31, 35, 2276, 2280, "0141" +406, 22, 12, 499, 36, 41, 2281, 2286, "PMCID" +406, 22, 13, 500, 42, 43, 2287, 2288, ":" +406, 22, 14, 501, 44, 54, 2289, 2299, "PMC5385426" +406, 22, 15, 502, 55, 59, 2300, 2304, "PMID" +406, 22, 16, 503, 60, 61, 2305, 2306, ":" +406, 22, 17, 504, 62, 70, 2307, 2315, "28129020" +406, 22, 18, 505, 71, 72, 2316, 2317, "[" +406, 22, 19, 506, 73, 80, 2318, 2325, "Indexed" +406, 22, 20, 507, 81, 84, 2326, 2329, "for" +406, 22, 21, 508, 85, 92, 2330, 2337, "MEDLINE" +406, 22, 22, 509, 93, 94, 2338, 2339, "]" diff --git a/data/gl 28129020_jshahinitiran.annodb b/data/gl 28129020_jshahinitiran.annodb new file mode 100644 index 0000000..5c880f4 --- /dev/null +++ b/data/gl 28129020_jshahinitiran.annodb @@ -0,0 +1,87 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32582, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +32583, PublicationYear, 24, 28, "2017", "", +32584, Title, 115, 250, "The 24 - Hour Effects of Brinzolamide / Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure", "", +32585, Brinzolamide, 140, 152, "Brinzolamide", "", +32586, Brimonidine, 155, 166, "Brimonidine", "", +32587, Timolol, 189, 196, "Timolol", "", +32588, IOP, 200, 220, "Intraocular Pressure", "", +32589, Author, 253, 263, "Seibold LK", "", +32590, Author, 272, 281, "DeWitt PE", "", +32591, Author, 290, 299, "Kroehl ME", "", +32592, Author, 308, 317, "Kahook MY", "", +32593, ObjectiveDescription, 567, 794, "To determine the 24 - h effects of brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination ( BBFC ) on intraocular pressure ( IOP ) , ocular perfusion pressure ( OPP ) , blood pressure ( BP ) , and heart rate ( HR )", "", +32594, Brinzolamide, 602, 614, "brinzolamide", "", +32601, Drug, 602, 669, "brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination", "BBFC", +32595, Brinzolamide, 617, 637, "brimonidine tartrate", "", +32596, DoseValue, 638, 639, "1", "", +32598, Percentage, 640, 641, "%", "", +32597, DoseValue, 644, 649, "0 . 2", "", +32599, Percentage, 650, 651, "%", "", +32600, Drug, 672, 676, "BBFC", "BBFC", +32602, IOP, 682, 702, "intraocular pressure", "", +32603, IOP, 705, 708, "IOP", "", +32604, EndPointDescription, 713, 738, "ocular perfusion pressure", "OPP", +32605, EndPointDescription, 741, 744, "OPP", "OPP", +32606, BloodPressure, 749, 763, "blood pressure", "", +32607, BloodPressure, 766, 768, "BP", "", +32608, HeartRate, 777, 787, "heart rate", "", +32610, HeartRate, 790, 792, "HR", "", +32611, NumberPatientsCT, 807, 812, "Sixty", "", +32612, OpenAngleGlaucoma, 827, 846, "open angle glaucoma", "", +32613, OpenAngleGlaucoma, 849, 852, "OAG", "", +32614, OcularHypertension, 858, 877, "ocular hypertension", "", +32615, OcularHypertension, 880, 884, "OHTN", "", +32616, IOP, 936, 939, "IOP", "", +32617, BloodPressure, 942, 944, "BP", "", +32618, HeartRate, 951, 953, "HR", "", +32619, Randomized, 1082, 1092, "randomized", "", +32620, Timolol, 1117, 1132, "timolol maleate", "", +32621, DoseValue, 1133, 1138, "0 . 5", "", +32622, Percentage, 1139, 1140, "%", "", +32623, Frequency, 1141, 1152, "twice daily", "", +32625, Drug, 1162, 1166, "BBFC", "BBFC", +32630, Frequency, 1167, 1180, "3 times daily", "", +32631, Duration, 1189, 1196, "4 weeks", "", +32632, IOP, 1292, 1295, "IOP", "", +32633, BloodPressure, 1298, 1300, "BP", "", +32634, HeartRate, 1307, 1309, "HR", "", +32635, EndPointDescription, 1363, 1366, "OPP", "", +32668, BloodPressure, 1403, 1405, "BP", "", +32666, BloodPressure, 1425, 1427, "BP", "", +32667, BloodPressure, 1440, 1442, "BP", "", +32636, IOP, 1449, 1452, "IOP", "", +32626, Drug, 1480, 1484, "BBFC", "BBFC", +32669, Diurnal_IOP, 1507, 1510, "IOP", "", +32638, Reduction, 1541, 1546, "2 . 7", "", +32639, SdErrorChangeValue, 1551, 1556, "0 . 4", "", +32640, mmHg, 1559, 1563, "mmHg", "", +32641, PValueChangeValue, 1566, 1578, "P  <  0 . 01", "", +32670, IOP, 1585, 1594, "nocturnal", "", +32642, Reduction, 1606, 1611, "0 . 8", "", +32643, SdErrorChangeValue, 1616, 1621, "0 . 3", "", +32644, mmHg, 1624, 1628, "mmHg", "", +32645, PValueChangeValue, 1631, 1643, "P  <  0 . 01", "", +32646, Timolol, 1648, 1655, "Timolol", "", +32647, IOP, 1674, 1677, "IOP", "", +32648, IOP, 1724, 1727, "IOP", "", +32627, Drug, 1763, 1767, "BBFC", "BBFC", +32649, IOP, 1801, 1804, "IOP", "", +32650, Timolol, 1820, 1827, "timolol", "", +32651, Reduction, 1832, 1837, "0 . 7", "", +32652, SdErrorChangeValue, 1842, 1847, "0 . 4", "", +32653, mmHg, 1850, 1854, "mmHg", "", +32654, PValueChangeValue, 1857, 1869, "P  =  0 . 04", "", +32628, Drug, 1874, 1878, "BBFC", "BBFC", +32655, EndPointDescription, 1912, 1915, "OPP", "OPP", +32656, Timolol, 1947, 1954, "timolol", "", +32657, EndPointDescription, 1965, 1968, "OPP", "OPP", +32658, HeartRate, 2039, 2041, "HR", "", +32659, Timolol, 2058, 2065, "timolol", "", +32629, Drug, 2088, 2092, "BBFC", "BBFC", +32660, ConclusionComment, 2088, 2192, "BBFC significantly lowers IOP during both the diurnal and nocturnal periods , but has no effect on OPP .", "", +32662, IOP, 2114, 2117, "IOP", "", +32663, EndPointDescription, 2187, 2190, "OPP", "OPP", +32661, ConclusionComment, 2193, 2244, "Timolol only lowers IOP during the diurnal period .", "", +32671, Diurnal_IOP, 2213, 2216, "IOP", "", +32665, PMID, 2307, 2315, "28129020", "", diff --git a/data/gl 28129020_jshahinitiran.n-triples b/data/gl 28129020_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 28129020_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 28129020_tstrakeljahn.annodb b/data/gl 28129020_tstrakeljahn.annodb new file mode 100644 index 0000000..06c120e --- /dev/null +++ b/data/gl 28129020_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8144, Journal, 0, 21, "J Ocul Pharmacol Ther", "", +8145, PublicationYear, 24, 28, "2017", "", +8156, Title, 115, 252, "The 24 - Hour Effects of Brinzolamide / Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure .", "", +8146, Brinzolamide, 140, 152, "Brinzolamide", "", +8147, Brimonidine, 155, 166, "Brimonidine", "", +8148, Timolol, 189, 196, "Timolol", "", +8149, IOP, 200, 220, "Intraocular Pressure", "", +8150, Author, 253, 263, "Seibold LK", "", +8151, Author, 272, 281, "DeWitt PE", "", +8152, Author, 290, 299, "Kroehl ME", "", +8153, Author, 308, 317, "Kahook MY", "", +8154, USA, 437, 445, "Colorado", "", +8155, USA, 546, 554, "Colorado", "", +8165, ObjectiveDescription, 567, 794, "To determine the 24 - h effects of brinzolamide / brimonidine tartrate 1 % / 0 . 2 % fixed combination ( BBFC ) on intraocular pressure ( IOP ) , ocular perfusion pressure ( OPP ) , blood pressure ( BP ) , and heart rate ( HR )", "", +8157, Brinzolamide, 602, 614, "brinzolamide", "", +8158, Brimonidine, 617, 637, "brimonidine tartrate", "", +8159, DoseValue, 638, 639, "1", "", +8161, Percentage, 640, 641, "%", "", +8160, DoseValue, 644, 649, "0 . 2", "", +8162, Percentage, 650, 651, "%", "", +29821, Drug, 672, 676, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8163, IOP, 682, 702, "intraocular pressure", "", +8164, IOP, 705, 708, "IOP", "", +8178, BloodPressure, 749, 763, "blood pressure", "", +8177, BloodPressure, 766, 768, "BP", "", +8175, HeartRate, 777, 787, "heart rate", "", +8176, HeartRate, 790, 792, "HR", "", +8166, NumberPatientsCT, 807, 812, "Sixty", "", +8167, OpenAngleGlaucoma, 827, 846, "open angle glaucoma", "", +8168, OpenAngleGlaucoma, 849, 852, "OAG", "", +8169, OcularHypertension, 858, 877, "ocular hypertension", "", +8170, OcularHypertension, 880, 884, "OHTN", "", +8172, IOP, 936, 939, "IOP", "", +8179, BloodPressure, 942, 944, "BP", "", +8174, HeartRate, 951, 953, "HR", "", +8185, Randomized, 1082, 1092, "randomized", "", +8186, Timolol, 1117, 1132, "timolol maleate", "", +8187, DoseValue, 1133, 1138, "0 . 5", "", +8188, Frequency, 1141, 1152, "twice daily", "", +29822, Drug, 1162, 1166, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8189, Frequency, 1167, 1180, "3 times daily", "", +8190, Duration, 1189, 1196, "4 weeks", "", +8191, IOP, 1292, 1295, "IOP", "", +8192, BloodPressure, 1298, 1300, "BP", "", +8193, HeartRate, 1307, 1309, "HR", "", +8194, BloodPressure, 1403, 1405, "BP", "", +8195, BloodPressure, 1425, 1427, "BP", "", +8196, BloodPressure, 1440, 1442, "BP", "", +8197, IOP, 1449, 1452, "IOP", "", +29823, Drug, 1480, 1484, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8198, Diurnal_IOP, 1507, 1510, "IOP", "", +8199, Reduction, 1541, 1546, "2 . 7", "", +8200, SdDevChangeValue, 1551, 1556, "0 . 4", "", +8201, mmHg, 1559, 1563, "mmHg", "", +8202, PValueChangeValue, 1566, 1578, "P  <  0 . 01", "", +8203, IOP, 1585, 1594, "nocturnal", "nocturnal iop", +8204, Reduction, 1606, 1611, "0 . 8", "nocturnal iop", +8207, SdDevChangeValue, 1616, 1621, "0 . 3", "", +8208, mmHg, 1624, 1628, "mmHg", "", +8209, PValueChangeValue, 1631, 1643, "P  <  0 . 01", "", +8210, Timolol, 1648, 1655, "Timolol", "", +8211, Diurnal_IOP, 1674, 1703, "IOP during the diurnal period", "", +8213, IOP, 1724, 1727, "IOP", "", +29824, Drug, 1763, 1767, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8214, IOP, 1801, 1804, "IOP", "", +8215, Timolol, 1820, 1827, "timolol", "", +8216, Reduction, 1832, 1837, "0 . 7", "", +8217, SdDevChangeValue, 1842, 1847, "0 . 4", "", +8218, mmHg, 1850, 1854, "mmHg", "", +8219, PValueChangeValue, 1857, 1869, "P  =  0 . 04", "", +8220, ObservedResult, 1874, 2001, "BBFC failed to achieve an increase in OPP during any time period , while timolol increased OPP during the diurnal period only .", "", +29825, Drug, 1874, 1878, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8221, Timolol, 1947, 1954, "timolol", "", +8223, HeartRate, 2039, 2041, "HR", "", +8224, Timolol, 2058, 2065, "timolol", "", +29826, Drug, 2088, 2092, "BBFC", "Brinzolamide Brimonidine Fixed Combination", +8225, IOP, 2114, 2117, "IOP", "", +8226, Timolol, 2193, 2200, "Timolol", "", +8227, Diurnal_IOP, 2213, 2242, "IOP during the diurnal period", "", +8229, PMID, 2307, 2315, "28129020", "", diff --git a/data/gl 28129020_tstrakeljahn.n-triples b/data/gl 28129020_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 28129020_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 7880782_admin.annodb b/data/gl 7880782_admin.annodb new file mode 100644 index 0000000..1c9e844 --- /dev/null +++ b/data/gl 7880782_admin.annodb @@ -0,0 +1,84 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Br J Ophthalmol .", "", " \"Br J Ophthalmol .\"." +1, PublicationYear, 18, 22, "1995", "", " \"1995\"." +2, Title, 49, 196, "Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol .", "", " \"Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol .\"." +3, Latanoprost, 49, 60, "Latanoprost", "", +4, Frequency, 74, 84, "once daily", "", +5, IOP, 118, 138, "intraocular pressure", "", +6, Glaucoma, 142, 150, "glaucoma", "", +7, Timolol, 187, 194, "timolol", "", +8, Author, 197, 202, "Alm A", "", " \"Alm A\"." +9, Author, 211, 224, "Wideng å rd I", "", " \"Wideng å rd I\"." +10, Author, 227, 238, "Kjellgren D", "", " \"Kjellgren D\"." +11, Author, 241, 257, "S ö derstr ö m M", "", " \"S ö derstr ö m M\"." +12, Author, 260, 272, "Fristr ö m B", "", " \"Fristr ö m B\"." +13, Author, 275, 282, "Heijl A", "", " \"Heijl A\"." +14, Author, 285, 299, "Stjerschantz J", "", " \"Stjerschantz J\"." +15, Sweden, 391, 397, "Sweden", "", " ." +16, PublicationYear, 429, 433, "1995", "", +17, ObjectiveDescription, 459, 657, "The long term effects of two dose regimens of latanoprost ( PhXA41 ) administered to eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone were compared .", "", " \"The long term effects of two dose regimens of latanoprost ( PhXA41 ) administered to eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone were compared .\"." +18, Latanoprost, 505, 516, "latanoprost", "", +51, Latanoprost, 519, 525, "PhXA41", "", +20, Precondition, 544, 641, "eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone", "", " \"eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone\"." +19, Timolol, 576, 583, "timolol", "", +21, Timolol, 628, 635, "timolol", "", +22, NumberPatientsCT, 669, 671, "50", "", " \"50\"." +55, NumberAffected, 683, 685, "17", "", +23, Primary_OpenAngleGlaucoma, 691, 718, "primary open angle glaucoma", "", " ." +57, NumberAffected, 723, 725, "33", "", +24, Glaucoma, 731, 748, "capsular glaucoma", "", " . ." +35, Multicenter, 771, 783, "five clinics", "", " ." +49, Precondition, 794, 935, "glaucomatous visual field defects and an intraocular pressure ( IOP ) of at least 22 mm Hg despite treatment with 0 . 5 % timolol twice daily", "", " \"glaucomatous visual field defects and an intraocular pressure ( IOP ) of at least 22 mm Hg despite treatment with 0 . 5 % timolol twice daily\"." +38, IOP, 835, 855, "intraocular pressure", "", +40, IOP, 858, 861, "IOP", "", +41, mmHg, 879, 884, "mm Hg", "", +43, DoseValue, 908, 913, "0 . 5", "", +71, Percentage, 914, 915, "%", "", +44, Timolol, 916, 923, "timolol", "", +45, Frequency, 924, 935, "twice daily", "", +59, Randomized, 952, 962, "randomised", "", " ." +61, DoseValue, 1002, 1009, "0 . 006", "", " \"0 . 006\"." +85, Percentage, 1010, 1011, "%", "", " ." +62, Latanoprost, 1012, 1023, "latanoprost", "", " . ." +65, Frequency, 1034, 1045, "twice daily", "", " \"twice daily\"." +66, Placebo, 1067, 1074, "placebo", "", " ." +106386, Morning, 1088, 1092, "8 am", "", " ." +68, Latanoprost, 1097, 1108, "latanoprost", "", " . ." +106387, Evening, 1112, 1116, "8 pm", "", " ." +69, Duration, 1121, 1129, "3 months", "", " \"3 months\"." +72, Timolol, 1149, 1156, "timolol", "", +105583, Diurnal_IOP, 1192, 1203, "daytime IOP", "", " ." +112, Mean, 1206, 1210, "mean", "", " . ." +107, TimePoint, 1223, 1231, "baseline", "", +76, Timolol, 1237, 1244, "timolol", "", +77, TimePoint, 1263, 1277, "4 and 12 weeks", "", " \"4 and 12 weeks\". \"4 and 12 weeks\"." +78, TimePoint, 1269, 1277, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +79, BaseLineValue, 1294, 1300, "24 . 8", "", " \"24 . 8\". \"24 . 8\"." +91, SdDevBL, 1303, 1308, "3 . 6", "", " \"3 . 6\". \"3 . 6\"." +105584, ResultMeasuredValue, 1313, 1319, "16 . 8", "", " \"16 . 8\"." +105586, SdDevResValue, 1322, 1327, "4 . 3", "", " \"4 . 3\"." +105585, ResultMeasuredValue, 1336, 1342, "15 . 7", "", " \"15 . 7\"." +105588, SdDevResValue, 1345, 1350, "2 . 4", "", " \"2 . 4\"." +102, mmHg, 1353, 1358, "mm Hg", "", +110, Frequency, 1377, 1387, "once daily", "", +109, Latanoprost, 1403, 1414, "latanoprost", "", +96, BaseLineValue, 1419, 1425, "24 . 9", "", " \"24 . 9\". \"24 . 9\"." +135, SdDevBL, 1428, 1433, "2 . 9", "", " \"2 . 9\". \"2 . 9\"." +86, ResultMeasuredValue, 1438, 1444, "18 . 1", "", " \"18 . 1\"." +105, SdDevResValue, 1447, 1452, "3 . 0", "", " \"3 . 0\"." +87, ResultMeasuredValue, 1461, 1467, "18 . 0", "", " \"18 . 0\"." +106, SdDevResValue, 1470, 1475, "3 . 6", "", " \"3 . 6\"." +103, mmHg, 1478, 1483, "mm Hg", "", +108, Latanoprost, 1502, 1513, "latanoprost", "", +111, Frequency, 1514, 1525, "twice daily", "", +143, ObservedResult, 1528, 1599, "No clinically significant side effects were observed during treatment .", "", " \"No clinically significant side effects were observed during treatment .\"." +105589, EndPointDescription, 1554, 1566, "side effects", "", " . ." +113, Latanoprost, 1600, 1611, "Latanoprost", "", +121, ConclusionComment, 1600, 1707, "Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol .", "", " \"Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol .\"." +115, IOP, 1642, 1645, "IOP", "", +117, Timolol, 1698, 1705, "timolol", "", +114, Latanoprost, 1708, 1719, "Latanoprost", "", +123, ConclusionComment, 1708, 1815, "Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen .", "", " \"Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen .\"." +119, Frequency, 1726, 1736, "once daily", "", +120, Frequency, 1789, 1800, "twice daily", "", +124, PMID, 1877, 1884, "7880782", "", " \"7880782\"." diff --git a/data/gl 7880782_admin.n-triples b/data/gl 7880782_admin.n-triples new file mode 100644 index 0000000..df4230f --- /dev/null +++ b/data/gl 7880782_admin.n-triples @@ -0,0 +1,144 @@ +# RDF export of group: Publication + . + "Publication " . + "Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol ." . + "Alm A" . + "1995" . + "Br J Ophthalmol ." . + "7880782" . + . + "Wideng å rd I" . + "Kjellgren D" . + "S ö derstr ö m M" . + "Fristr ö m B" . + "Heijl A" . + "Stjerschantz J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "The long term effects of two dose regimens of latanoprost ( PhXA41 ) administered to eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone were compared ." . + "50" . + "3 months" . + . + . + . + "Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol ." . + . + . + . + . + . + . + "Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen ." . + . + . + . +# RDF export of group: Population + . + "Population " . + "eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone" . + . + . + . + "glaucomatous visual field defects and an intraocular pressure ( IOP ) of at least 22 mm Hg despite treatment with 0 . 5 % timolol twice daily" . +# RDF export of group: Endpoint + . + "Endpoint d IOP" . + . + . + . + . + . + . + "Endpoint side effects " . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + . + "Arm p+l2" . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "twice daily" . + . + . + "Intervention p" . + . + . + . + "Intervention l2" . + . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + "0 . 006" . + . + . + . + "Medication p" . + . + . + . + . + "Medication l2" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome side effects both treatments " . + . + "No clinically significant side effects were observed during treatment ." . + . + "Outcome IOP once daily" . + . + "24 . 8" . + "3 . 6" . + "15 . 7" . + "2 . 4" . + "12 weeks" . + . + "Outcome IOP twice daily" . + . + "24 . 9" . + "2 . 9" . + "18 . 0" . + "3 . 6" . + "12 weeks" . + . + "Outcome IOP once daily-4w" . + . + "24 . 8" . + "3 . 6" . + "16 . 8" . + "4 . 3" . + "4 and 12 weeks" . + . + "Outcome IOP twice daily -4w" . + . + "24 . 9" . + "2 . 9" . + "18 . 1" . + "3 . 0" . + "4 and 12 weeks" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 7880782_export.csv b/data/gl 7880782_export.csv new file mode 100644 index 0000000..1e4ad8d --- /dev/null +++ b/data/gl 7880782_export.csv @@ -0,0 +1,405 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +542, 1, 1, 1, 0, 2, 0, 2, "Br" +542, 1, 2, 2, 3, 4, 3, 4, "J" +542, 1, 3, 3, 5, 15, 5, 15, "Ophthalmol" +542, 1, 4, 4, 16, 17, 16, 17, "." +542, 2, 1, 5, 0, 4, 18, 22, "1995" +542, 2, 2, 6, 5, 8, 23, 26, "Jan" +542, 2, 3, 7, 9, 10, 27, 28, ";" +542, 2, 4, 8, 11, 13, 29, 31, "79" +542, 2, 5, 9, 14, 15, 32, 33, "(" +542, 2, 6, 10, 16, 17, 34, 35, "1" +542, 2, 7, 11, 18, 19, 36, 37, ")" +542, 2, 8, 12, 20, 21, 38, 39, ":" +542, 2, 9, 13, 22, 24, 40, 42, "12" +542, 2, 10, 14, 25, 26, 43, 44, "-" +542, 2, 11, 15, 27, 28, 45, 46, "6" +542, 2, 12, 16, 29, 30, 47, 48, "." +542, 3, 1, 17, 0, 11, 49, 60, "Latanoprost" +542, 3, 2, 18, 12, 24, 61, 73, "administered" +542, 3, 3, 19, 25, 29, 74, 78, "once" +542, 3, 4, 20, 30, 35, 79, 84, "daily" +542, 3, 5, 21, 36, 42, 85, 91, "caused" +542, 3, 6, 22, 43, 44, 92, 93, "a" +542, 3, 7, 23, 45, 55, 94, 104, "maintained" +542, 3, 8, 24, 56, 65, 105, 114, "reduction" +542, 3, 9, 25, 66, 68, 115, 117, "of" +542, 3, 10, 26, 69, 80, 118, 129, "intraocular" +542, 3, 11, 27, 81, 89, 130, 138, "pressure" +542, 3, 12, 28, 90, 92, 139, 141, "in" +542, 3, 13, 29, 93, 101, 142, 150, "glaucoma" +542, 3, 14, 30, 102, 110, 151, 159, "patients" +542, 3, 15, 31, 111, 118, 160, 167, "treated" +542, 3, 16, 32, 119, 132, 168, 181, "concomitantly" +542, 3, 17, 33, 133, 137, 182, 186, "with" +542, 3, 18, 34, 138, 145, 187, 194, "timolol" +542, 3, 19, 35, 146, 147, 195, 196, "." +542, 4, 1, 36, 0, 3, 197, 200, "Alm" +542, 4, 2, 37, 4, 5, 201, 202, "A" +542, 4, 3, 38, 6, 7, 203, 204, "(" +542, 4, 4, 39, 8, 9, 205, 206, "1" +542, 4, 5, 40, 10, 11, 207, 208, ")" +542, 4, 6, 41, 12, 13, 209, 210, "," +542, 4, 7, 42, 14, 20, 211, 217, "Wideng" +542, 4, 8, 43, 21, 22, 218, 219, "å" +542, 4, 9, 44, 23, 25, 220, 222, "rd" +542, 4, 10, 45, 26, 27, 223, 224, "I" +542, 4, 11, 46, 28, 29, 225, 226, "," +542, 4, 12, 47, 30, 39, 227, 236, "Kjellgren" +542, 4, 13, 48, 40, 41, 237, 238, "D" +542, 4, 14, 49, 42, 43, 239, 240, "," +542, 4, 15, 50, 44, 45, 241, 242, "S" +542, 4, 16, 51, 46, 47, 243, 244, "ö" +542, 4, 17, 52, 48, 54, 245, 251, "derstr" +542, 4, 18, 53, 55, 56, 252, 253, "ö" +542, 4, 19, 54, 57, 58, 254, 255, "m" +542, 4, 20, 55, 59, 60, 256, 257, "M" +542, 4, 21, 56, 61, 62, 258, 259, "," +542, 4, 22, 57, 63, 69, 260, 266, "Fristr" +542, 4, 23, 58, 70, 71, 267, 268, "ö" +542, 4, 24, 59, 72, 73, 269, 270, "m" +542, 4, 25, 60, 74, 75, 271, 272, "B" +542, 4, 26, 61, 76, 77, 273, 274, "," +542, 4, 27, 62, 78, 83, 275, 280, "Heijl" +542, 4, 28, 63, 84, 85, 281, 282, "A" +542, 4, 29, 64, 86, 87, 283, 284, "," +542, 4, 30, 65, 88, 100, 285, 297, "Stjerschantz" +542, 4, 31, 66, 101, 102, 298, 299, "J" +542, 4, 32, 67, 103, 104, 300, 301, "." +542, 5, 1, 68, 0, 6, 302, 308, "Author" +542, 5, 2, 69, 7, 18, 309, 320, "information" +542, 5, 3, 70, 19, 20, 321, 322, ":" +542, 5, 4, 71, 21, 22, 323, 324, "(" +542, 5, 5, 72, 23, 24, 325, 326, "1" +542, 5, 6, 73, 25, 26, 327, 328, ")" +542, 5, 7, 74, 27, 37, 329, 339, "Department" +542, 5, 8, 75, 38, 40, 340, 342, "of" +542, 5, 9, 76, 41, 54, 343, 356, "Ophthalmology" +542, 5, 10, 77, 55, 56, 357, 358, "," +542, 5, 11, 78, 57, 67, 359, 369, "University" +542, 5, 12, 79, 68, 76, 370, 378, "Hospital" +542, 5, 13, 80, 77, 78, 379, 380, "," +542, 5, 14, 81, 79, 86, 381, 388, "Uppsala" +542, 5, 15, 82, 87, 88, 389, 390, "," +542, 5, 16, 83, 89, 95, 391, 397, "Sweden" +542, 5, 17, 84, 96, 97, 398, 399, "." +542, 6, 1, 85, 0, 7, 400, 407, "Comment" +542, 6, 2, 86, 8, 10, 408, 410, "in" +542, 6, 3, 87, 11, 13, 411, 413, "Br" +542, 6, 4, 88, 14, 15, 414, 415, "J" +542, 6, 5, 89, 16, 26, 416, 426, "Ophthalmol" +542, 6, 6, 90, 27, 28, 427, 428, "." +542, 7, 1, 91, 0, 4, 429, 433, "1995" +542, 7, 2, 92, 5, 8, 434, 437, "Jan" +542, 7, 3, 93, 9, 10, 438, 439, ";" +542, 7, 4, 94, 11, 13, 440, 442, "79" +542, 7, 5, 95, 14, 15, 443, 444, "(" +542, 7, 6, 96, 16, 17, 445, 446, "1" +542, 7, 7, 97, 18, 19, 447, 448, ")" +542, 7, 8, 98, 20, 21, 449, 450, ":" +542, 7, 9, 99, 22, 23, 451, 452, "3" +542, 7, 10, 100, 24, 25, 453, 454, "-" +542, 7, 11, 101, 26, 27, 455, 456, "4" +542, 7, 12, 102, 28, 29, 457, 458, "." +542, 8, 1, 103, 0, 3, 459, 462, "The" +542, 8, 2, 104, 4, 8, 463, 467, "long" +542, 8, 3, 105, 9, 13, 468, 472, "term" +542, 8, 4, 106, 14, 21, 473, 480, "effects" +542, 8, 5, 107, 22, 24, 481, 483, "of" +542, 8, 6, 108, 25, 28, 484, 487, "two" +542, 8, 7, 109, 29, 33, 488, 492, "dose" +542, 8, 8, 110, 34, 42, 493, 501, "regimens" +542, 8, 9, 111, 43, 45, 502, 504, "of" +542, 8, 10, 112, 46, 57, 505, 516, "latanoprost" +542, 8, 11, 113, 58, 59, 517, 518, "(" +542, 8, 12, 114, 60, 66, 519, 525, "PhXA41" +542, 8, 13, 115, 67, 68, 526, 527, ")" +542, 8, 14, 116, 69, 81, 528, 540, "administered" +542, 8, 15, 117, 82, 84, 541, 543, "to" +542, 8, 16, 118, 85, 89, 544, 548, "eyes" +542, 8, 17, 119, 90, 103, 549, 562, "concomitantly" +542, 8, 18, 120, 104, 111, 563, 570, "treated" +542, 8, 19, 121, 112, 116, 571, 575, "with" +542, 8, 20, 122, 117, 124, 576, 583, "timolol" +542, 8, 21, 123, 125, 130, 584, 589, "which" +542, 8, 22, 124, 131, 134, 590, 593, "had" +542, 8, 23, 125, 135, 138, 594, 597, "not" +542, 8, 24, 126, 139, 149, 598, 608, "adequately" +542, 8, 25, 127, 150, 154, 609, 613, "been" +542, 8, 26, 128, 155, 165, 614, 624, "controlled" +542, 8, 27, 129, 166, 168, 625, 627, "by" +542, 8, 28, 130, 169, 176, 628, 635, "timolol" +542, 8, 29, 131, 177, 182, 636, 641, "alone" +542, 8, 30, 132, 183, 187, 642, 646, "were" +542, 8, 31, 133, 188, 196, 647, 655, "compared" +542, 8, 32, 134, 197, 198, 656, 657, "." +542, 9, 1, 135, 0, 1, 658, 659, "A" +542, 9, 2, 136, 2, 7, 660, 665, "total" +542, 9, 3, 137, 8, 10, 666, 668, "of" +542, 9, 4, 138, 11, 13, 669, 671, "50" +542, 9, 5, 139, 14, 22, 672, 680, "patients" +542, 9, 6, 140, 23, 24, 681, 682, "," +542, 9, 7, 141, 25, 27, 683, 685, "17" +542, 9, 8, 142, 28, 32, 686, 690, "with" +542, 9, 9, 143, 33, 40, 691, 698, "primary" +542, 9, 10, 144, 41, 45, 699, 703, "open" +542, 9, 11, 145, 46, 51, 704, 709, "angle" +542, 9, 12, 146, 52, 60, 710, 718, "glaucoma" +542, 9, 13, 147, 61, 64, 719, 722, "and" +542, 9, 14, 148, 65, 67, 723, 725, "33" +542, 9, 15, 149, 68, 72, 726, 730, "with" +542, 9, 16, 150, 73, 81, 731, 739, "capsular" +542, 9, 17, 151, 82, 90, 740, 748, "glaucoma" +542, 9, 18, 152, 91, 92, 749, 750, "," +542, 9, 19, 153, 93, 97, 751, 755, "were" +542, 9, 20, 154, 98, 107, 756, 765, "recruited" +542, 9, 21, 155, 108, 112, 766, 770, "from" +542, 9, 22, 156, 113, 117, 771, 775, "five" +542, 9, 23, 157, 118, 125, 776, 783, "clinics" +542, 9, 24, 158, 126, 127, 784, 785, "." +542, 10, 1, 159, 0, 3, 786, 789, "All" +542, 10, 2, 160, 4, 7, 790, 793, "had" +542, 10, 3, 161, 8, 20, 794, 806, "glaucomatous" +542, 10, 4, 162, 21, 27, 807, 813, "visual" +542, 10, 5, 163, 28, 33, 814, 819, "field" +542, 10, 6, 164, 34, 41, 820, 827, "defects" +542, 10, 7, 165, 42, 45, 828, 831, "and" +542, 10, 8, 166, 46, 48, 832, 834, "an" +542, 10, 9, 167, 49, 60, 835, 846, "intraocular" +542, 10, 10, 168, 61, 69, 847, 855, "pressure" +542, 10, 11, 169, 70, 71, 856, 857, "(" +542, 10, 12, 170, 72, 75, 858, 861, "IOP" +542, 10, 13, 171, 76, 77, 862, 863, ")" +542, 10, 14, 172, 78, 80, 864, 866, "of" +542, 10, 15, 173, 81, 83, 867, 869, "at" +542, 10, 16, 174, 84, 89, 870, 875, "least" +542, 10, 17, 175, 90, 92, 876, 878, "22" +542, 10, 18, 176, 93, 95, 879, 881, "mm" +542, 10, 19, 177, 96, 98, 882, 884, "Hg" +542, 10, 20, 178, 99, 106, 885, 892, "despite" +542, 10, 21, 179, 107, 116, 893, 902, "treatment" +542, 10, 22, 180, 117, 121, 903, 907, "with" +542, 10, 23, 181, 122, 123, 908, 909, "0" +542, 10, 24, 182, 124, 125, 910, 911, "." +542, 10, 25, 183, 126, 127, 912, 913, "5" +542, 10, 26, 184, 128, 129, 914, 915, "%" +542, 10, 27, 185, 130, 137, 916, 923, "timolol" +542, 10, 28, 186, 138, 143, 924, 929, "twice" +542, 10, 29, 187, 144, 149, 930, 935, "daily" +542, 10, 30, 188, 150, 151, 936, 937, "." +542, 11, 1, 189, 0, 8, 938, 946, "Patients" +542, 11, 2, 190, 9, 13, 947, 951, "were" +542, 11, 3, 191, 14, 24, 952, 962, "randomised" +542, 11, 4, 192, 25, 27, 963, 965, "to" +542, 11, 5, 193, 28, 31, 966, 969, "two" +542, 11, 6, 194, 32, 41, 970, 979, "treatment" +542, 11, 7, 195, 42, 48, 980, 986, "groups" +542, 11, 8, 196, 49, 50, 987, 988, "." +542, 12, 1, 197, 0, 2, 989, 991, "In" +542, 12, 2, 198, 3, 6, 992, 995, "one" +542, 12, 3, 199, 7, 12, 996, 1001, "group" +542, 12, 4, 200, 13, 14, 1002, 1003, "0" +542, 12, 5, 201, 15, 16, 1004, 1005, "." +542, 12, 6, 202, 17, 20, 1006, 1009, "006" +542, 12, 7, 203, 21, 22, 1010, 1011, "%" +542, 12, 8, 204, 23, 34, 1012, 1023, "latanoprost" +542, 12, 9, 205, 35, 38, 1024, 1027, "was" +542, 12, 10, 206, 39, 44, 1028, 1033, "given" +542, 12, 11, 207, 45, 50, 1034, 1039, "twice" +542, 12, 12, 208, 51, 56, 1040, 1045, "daily" +542, 12, 13, 209, 57, 58, 1046, 1047, "," +542, 12, 14, 210, 59, 61, 1048, 1050, "in" +542, 12, 15, 211, 62, 65, 1051, 1054, "the" +542, 12, 16, 212, 66, 71, 1055, 1060, "other" +542, 12, 17, 213, 72, 77, 1061, 1066, "group" +542, 12, 18, 214, 78, 85, 1067, 1074, "placebo" +542, 12, 19, 215, 86, 89, 1075, 1078, "was" +542, 12, 20, 216, 90, 95, 1079, 1084, "given" +542, 12, 21, 217, 96, 98, 1085, 1087, "at" +542, 12, 22, 218, 99, 100, 1088, 1089, "8" +542, 12, 23, 219, 101, 103, 1090, 1092, "am" +542, 12, 24, 220, 104, 107, 1093, 1096, "and" +542, 12, 25, 221, 108, 119, 1097, 1108, "latanoprost" +542, 12, 26, 222, 120, 122, 1109, 1111, "at" +542, 12, 27, 223, 123, 124, 1112, 1113, "8" +542, 12, 28, 224, 125, 127, 1114, 1116, "pm" +542, 12, 29, 225, 128, 131, 1117, 1120, "for" +542, 12, 30, 226, 132, 133, 1121, 1122, "3" +542, 12, 31, 227, 134, 140, 1123, 1129, "months" +542, 12, 32, 228, 141, 142, 1130, 1131, "," +542, 12, 33, 229, 143, 147, 1132, 1136, "with" +542, 12, 34, 230, 148, 159, 1137, 1148, "concomitant" +542, 12, 35, 231, 160, 167, 1149, 1156, "timolol" +542, 12, 36, 232, 168, 177, 1157, 1166, "treatment" +542, 12, 37, 233, 178, 180, 1167, 1169, "in" +542, 12, 38, 234, 181, 185, 1170, 1174, "both" +542, 12, 39, 235, 186, 192, 1175, 1181, "groups" +542, 12, 40, 236, 193, 194, 1182, 1183, "." +542, 13, 1, 237, 0, 7, 1184, 1191, "Average" +542, 13, 2, 238, 8, 15, 1192, 1199, "daytime" +542, 13, 3, 239, 16, 19, 1200, 1203, "IOP" +542, 13, 4, 240, 20, 21, 1204, 1205, "(" +542, 13, 5, 241, 22, 26, 1206, 1210, "mean" +542, 13, 6, 242, 27, 28, 1211, 1212, "(" +542, 13, 7, 243, 29, 31, 1213, 1215, "SD" +542, 13, 8, 244, 32, 33, 1216, 1217, ")" +542, 13, 9, 245, 34, 35, 1218, 1219, ")" +542, 13, 10, 246, 36, 38, 1220, 1222, "at" +542, 13, 11, 247, 39, 47, 1223, 1231, "baseline" +542, 13, 12, 248, 48, 49, 1232, 1233, "(" +542, 13, 13, 249, 50, 52, 1234, 1236, "on" +542, 13, 14, 250, 53, 60, 1237, 1244, "timolol" +542, 13, 15, 251, 61, 66, 1245, 1250, "alone" +542, 13, 16, 252, 67, 68, 1251, 1252, ")" +542, 13, 17, 253, 69, 72, 1253, 1256, "and" +542, 13, 18, 254, 73, 78, 1257, 1262, "after" +542, 13, 19, 255, 79, 80, 1263, 1264, "4" +542, 13, 20, 256, 81, 84, 1265, 1268, "and" +542, 13, 21, 257, 85, 87, 1269, 1271, "12" +542, 13, 22, 258, 88, 93, 1272, 1277, "weeks" +542, 13, 23, 259, 94, 95, 1278, 1279, "'" +542, 13, 24, 260, 96, 105, 1280, 1289, "treatment" +542, 13, 25, 261, 106, 109, 1290, 1293, "was" +542, 13, 26, 262, 110, 112, 1294, 1296, "24" +542, 13, 27, 263, 113, 114, 1297, 1298, "." +542, 13, 28, 264, 115, 116, 1299, 1300, "8" +542, 13, 29, 265, 117, 118, 1301, 1302, "(" +542, 13, 30, 266, 119, 120, 1303, 1304, "3" +542, 13, 31, 267, 121, 122, 1305, 1306, "." +542, 13, 32, 268, 123, 124, 1307, 1308, "6" +542, 13, 33, 269, 125, 126, 1309, 1310, ")" +542, 13, 34, 270, 127, 128, 1311, 1312, "," +542, 13, 35, 271, 129, 131, 1313, 1315, "16" +542, 13, 36, 272, 132, 133, 1316, 1317, "." +542, 13, 37, 273, 134, 135, 1318, 1319, "8" +542, 13, 38, 274, 136, 137, 1320, 1321, "(" +542, 13, 39, 275, 138, 139, 1322, 1323, "4" +542, 13, 40, 276, 140, 141, 1324, 1325, "." +542, 13, 41, 277, 142, 143, 1326, 1327, "3" +542, 13, 42, 278, 144, 145, 1328, 1329, ")" +542, 13, 43, 279, 146, 147, 1330, 1331, "," +542, 13, 44, 280, 148, 151, 1332, 1335, "and" +542, 13, 45, 281, 152, 154, 1336, 1338, "15" +542, 13, 46, 282, 155, 156, 1339, 1340, "." +542, 13, 47, 283, 157, 158, 1341, 1342, "7" +542, 13, 48, 284, 159, 160, 1343, 1344, "(" +542, 13, 49, 285, 161, 162, 1345, 1346, "2" +542, 13, 50, 286, 163, 164, 1347, 1348, "." +542, 13, 51, 287, 165, 166, 1349, 1350, "4" +542, 13, 52, 288, 167, 168, 1351, 1352, ")" +542, 13, 53, 289, 169, 171, 1353, 1355, "mm" +542, 13, 54, 290, 172, 174, 1356, 1358, "Hg" +542, 13, 55, 291, 175, 187, 1359, 1371, "respectively" +542, 13, 56, 292, 188, 192, 1372, 1376, "with" +542, 13, 57, 293, 193, 197, 1377, 1381, "once" +542, 13, 58, 294, 198, 203, 1382, 1387, "daily" +542, 13, 59, 295, 204, 215, 1388, 1399, "application" +542, 13, 60, 296, 216, 218, 1400, 1402, "of" +542, 13, 61, 297, 219, 230, 1403, 1414, "latanoprost" +542, 13, 62, 298, 231, 234, 1415, 1418, "and" +542, 13, 63, 299, 235, 237, 1419, 1421, "24" +542, 13, 64, 300, 238, 239, 1422, 1423, "." +542, 13, 65, 301, 240, 241, 1424, 1425, "9" +542, 13, 66, 302, 242, 243, 1426, 1427, "(" +542, 13, 67, 303, 244, 245, 1428, 1429, "2" +542, 13, 68, 304, 246, 247, 1430, 1431, "." +542, 13, 69, 305, 248, 249, 1432, 1433, "9" +542, 13, 70, 306, 250, 251, 1434, 1435, ")" +542, 13, 71, 307, 252, 253, 1436, 1437, "," +542, 13, 72, 308, 254, 256, 1438, 1440, "18" +542, 13, 73, 309, 257, 258, 1441, 1442, "." +542, 13, 74, 310, 259, 260, 1443, 1444, "1" +542, 13, 75, 311, 261, 262, 1445, 1446, "(" +542, 13, 76, 312, 263, 264, 1447, 1448, "3" +542, 13, 77, 313, 265, 266, 1449, 1450, "." +542, 13, 78, 314, 267, 268, 1451, 1452, "0" +542, 13, 79, 315, 269, 270, 1453, 1454, ")" +542, 13, 80, 316, 271, 272, 1455, 1456, "," +542, 13, 81, 317, 273, 276, 1457, 1460, "and" +542, 13, 82, 318, 277, 279, 1461, 1463, "18" +542, 13, 83, 319, 280, 281, 1464, 1465, "." +542, 13, 84, 320, 282, 283, 1466, 1467, "0" +542, 13, 85, 321, 284, 285, 1468, 1469, "(" +542, 13, 86, 322, 286, 287, 1470, 1471, "3" +542, 13, 87, 323, 288, 289, 1472, 1473, "." +542, 13, 88, 324, 290, 291, 1474, 1475, "6" +542, 13, 89, 325, 292, 293, 1476, 1477, ")" +542, 13, 90, 326, 294, 296, 1478, 1480, "mm" +542, 13, 91, 327, 297, 299, 1481, 1483, "Hg" +542, 13, 92, 328, 300, 312, 1484, 1496, "respectively" +542, 13, 93, 329, 313, 317, 1497, 1501, "with" +542, 13, 94, 330, 318, 329, 1502, 1513, "latanoprost" +542, 13, 95, 331, 330, 335, 1514, 1519, "twice" +542, 13, 96, 332, 336, 341, 1520, 1525, "daily" +542, 13, 97, 333, 342, 343, 1526, 1527, "." +542, 14, 1, 334, 0, 2, 1528, 1530, "No" +542, 14, 2, 335, 3, 13, 1531, 1541, "clinically" +542, 14, 3, 336, 14, 25, 1542, 1553, "significant" +542, 14, 4, 337, 26, 30, 1554, 1558, "side" +542, 14, 5, 338, 31, 38, 1559, 1566, "effects" +542, 14, 6, 339, 39, 43, 1567, 1571, "were" +542, 14, 7, 340, 44, 52, 1572, 1580, "observed" +542, 14, 8, 341, 53, 59, 1581, 1587, "during" +542, 14, 9, 342, 60, 69, 1588, 1597, "treatment" +542, 14, 10, 343, 70, 71, 1598, 1599, "." +542, 15, 1, 344, 0, 11, 1600, 1611, "Latanoprost" +542, 15, 2, 345, 12, 18, 1612, 1618, "causes" +542, 15, 3, 346, 19, 20, 1619, 1620, "a" +542, 15, 4, 347, 21, 27, 1621, 1627, "marked" +542, 15, 5, 348, 28, 31, 1628, 1631, "and" +542, 15, 6, 349, 32, 41, 1632, 1641, "sustained" +542, 15, 7, 350, 42, 45, 1642, 1645, "IOP" +542, 15, 8, 351, 46, 55, 1646, 1655, "reduction" +542, 15, 9, 352, 56, 58, 1656, 1658, "in" +542, 15, 10, 353, 59, 63, 1659, 1663, "eyes" +542, 15, 11, 354, 64, 69, 1664, 1669, "which" +542, 15, 12, 355, 70, 73, 1670, 1673, "are" +542, 15, 13, 356, 74, 78, 1674, 1678, "also" +542, 15, 14, 357, 79, 84, 1679, 1684, "being" +542, 15, 15, 358, 85, 92, 1685, 1692, "treated" +542, 15, 16, 359, 93, 97, 1693, 1697, "with" +542, 15, 17, 360, 98, 105, 1698, 1705, "timolol" +542, 15, 18, 361, 106, 107, 1706, 1707, "." +542, 16, 1, 362, 0, 11, 1708, 1719, "Latanoprost" +542, 16, 2, 363, 12, 17, 1720, 1725, "given" +542, 16, 3, 364, 18, 22, 1726, 1730, "once" +542, 16, 4, 365, 23, 28, 1731, 1736, "daily" +542, 16, 5, 366, 29, 31, 1737, 1739, "is" +542, 16, 6, 367, 32, 34, 1740, 1742, "at" +542, 16, 7, 368, 35, 40, 1743, 1748, "least" +542, 16, 8, 369, 41, 43, 1749, 1751, "as" +542, 16, 9, 370, 44, 53, 1752, 1761, "effective" +542, 16, 10, 371, 54, 57, 1762, 1765, "and" +542, 16, 11, 372, 58, 66, 1766, 1774, "probably" +542, 16, 12, 373, 67, 75, 1775, 1783, "superior" +542, 16, 13, 374, 76, 78, 1784, 1786, "to" +542, 16, 14, 375, 79, 80, 1787, 1788, "a" +542, 16, 15, 376, 81, 86, 1789, 1794, "twice" +542, 16, 16, 377, 87, 92, 1795, 1800, "daily" +542, 16, 17, 378, 93, 97, 1801, 1805, "dose" +542, 16, 18, 379, 98, 105, 1806, 1813, "regimen" +542, 16, 19, 380, 106, 107, 1814, 1815, "." +542, 17, 1, 381, 0, 3, 1816, 1819, "DOI" +542, 17, 2, 382, 4, 5, 1820, 1821, ":" +542, 17, 3, 383, 6, 8, 1822, 1824, "10" +542, 17, 4, 384, 9, 10, 1825, 1826, "." +542, 17, 5, 385, 11, 15, 1827, 1831, "1136" +542, 17, 6, 386, 16, 17, 1832, 1833, "/" +542, 17, 7, 387, 18, 21, 1834, 1837, "bjo" +542, 17, 8, 388, 22, 23, 1838, 1839, "." +542, 17, 9, 389, 24, 26, 1840, 1842, "79" +542, 17, 10, 390, 27, 28, 1843, 1844, "." +542, 17, 11, 391, 29, 30, 1845, 1846, "1" +542, 17, 12, 392, 31, 32, 1847, 1848, "." +542, 17, 13, 393, 33, 35, 1849, 1851, "12" +542, 17, 14, 394, 36, 41, 1852, 1857, "PMCID" +542, 17, 15, 395, 42, 43, 1858, 1859, ":" +542, 17, 16, 396, 44, 53, 1860, 1869, "PMC505011" +542, 17, 17, 397, 54, 58, 1870, 1874, "PMID" +542, 17, 18, 398, 59, 60, 1875, 1876, ":" +542, 17, 19, 399, 61, 68, 1877, 1884, "7880782" +542, 17, 20, 400, 69, 70, 1885, 1886, "[" +542, 17, 21, 401, 71, 78, 1887, 1894, "Indexed" +542, 17, 22, 402, 79, 82, 1895, 1898, "for" +542, 17, 23, 403, 83, 90, 1899, 1906, "MEDLINE" +542, 17, 24, 404, 91, 92, 1907, 1908, "]" diff --git a/data/gl 7880782_jshahinitiran.annodb b/data/gl 7880782_jshahinitiran.annodb new file mode 100644 index 0000000..a903357 --- /dev/null +++ b/data/gl 7880782_jshahinitiran.annodb @@ -0,0 +1,75 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88868, Journal, 0, 15, "Br J Ophthalmol", "", +88869, PublicationYear, 18, 22, "1995", "", +88871, Title, 49, 196, "Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol .", "", +88873, Latanoprost, 49, 60, "Latanoprost", "", +88874, Frequency, 74, 84, "once daily", "", +88876, IOP, 118, 138, "intraocular pressure", "", +88877, Glaucoma, 142, 150, "glaucoma", "", +88879, Timolol, 187, 194, "timolol", "", +88881, Author, 197, 202, "Alm A", "", +88883, Author, 211, 224, "Wideng å rd I", "", +88884, Author, 227, 238, "Kjellgren D", "", +88885, Author, 241, 257, "S ö derstr ö m M", "", +88887, Author, 260, 272, "Fristr ö m B", "", +88888, Author, 275, 282, "Heijl A", "", +88890, Author, 285, 299, "Stjerschantz J", "", +88891, Sweden, 391, 397, "Sweden", "", +88893, PublicationYear, 429, 433, "1995", "", +88896, ObjectiveDescription, 459, 657, "The long term effects of two dose regimens of latanoprost ( PhXA41 ) administered to eyes concomitantly treated with timolol which had not adequately been controlled by timolol alone were compared .", "", +88898, Latanoprost, 505, 516, "latanoprost", "", +88902, Timolol, 576, 583, "timolol", "", +88904, Precondition, 584, 641, "which had not adequately been controlled by timolol alone", "", +88906, Timolol, 628, 635, "timolol", "", +88909, NumberPatientsCT, 669, 671, "50", "", +88910, Primary_OpenAngleGlaucoma, 691, 718, "primary open angle glaucoma", "", +88912, Glaucoma, 731, 748, "capsular glaucoma", "capsular", +88934, Multicenter, 771, 783, "five clinics", "", +88935, Precondition, 794, 827, "glaucomatous visual field defects", "", +88937, IOP, 835, 855, "intraocular pressure", "", +88948, Precondition, 835, 935, "intraocular pressure ( IOP ) of at least 22 mm Hg despite treatment with 0 . 5 % timolol twice daily", "", +88939, IOP, 858, 861, "IOP", "", +88940, mmHg, 879, 884, "mm Hg", "", +88942, DoseValue, 908, 913, "0 . 5", "", +88943, Timolol, 916, 923, "timolol", "", +88944, Frequency, 924, 935, "twice daily", "", +88958, Randomized, 952, 962, "randomised", "", +88960, DoseValue, 1002, 1009, "0 . 006", "", +88961, Latanoprost, 1012, 1023, "latanoprost", "", +88964, Frequency, 1034, 1045, "twice daily", "", +88965, Placebo, 1067, 1074, "placebo", "", +88967, Latanoprost, 1097, 1108, "latanoprost", "", +88968, Duration, 1121, 1129, "3 months", "", +88971, Timolol, 1149, 1156, "timolol", "", +88974, IOP, 1200, 1203, "IOP", "", +89012, Mean, 1206, 1210, "mean", "", +88975, Timolol, 1237, 1244, "timolol", "", +88976, TimePoint, 1263, 1277, "4 and 12 weeks", "", +88977, TimePoint, 1269, 1277, "12 weeks", "", +88978, BaseLineValue, 1294, 1300, "24 . 8", "", +88990, SdDevBL, 1303, 1308, "3 . 6", "", +88980, ResultMeasuredValue, 1313, 1319, "16 . 8", "", +88997, SdDevResValue, 1322, 1327, "4 . 3", "", +88982, ResultMeasuredValue, 1336, 1342, "15 . 7", "", +88999, SdDevResValue, 1345, 1350, "2 . 4", "", +89001, mmHg, 1353, 1358, "mm Hg", "", +89010, Frequency, 1377, 1387, "once daily", "", +89009, Latanoprost, 1403, 1414, "latanoprost", "", +88995, BaseLineValue, 1419, 1425, "24 . 9", "", +88991, BaseLineValue, 1428, 1433, "2 . 9", "", +88985, ResultMeasuredValue, 1438, 1444, "18 . 1", "", +89004, SdDevResValue, 1447, 1452, "3 . 0", "", +88986, ResultMeasuredValue, 1461, 1467, "18 . 0", "", +89005, SdDevResValue, 1470, 1475, "3 . 6", "", +89002, mmHg, 1478, 1483, "mm Hg", "", +89008, Latanoprost, 1502, 1513, "latanoprost", "", +89011, Frequency, 1514, 1525, "twice daily", "", +89013, Latanoprost, 1600, 1611, "Latanoprost", "", +89021, ConclusionComment, 1600, 1707, "Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol .", "", +89015, IOP, 1642, 1645, "IOP", "", +89017, Timolol, 1698, 1705, "timolol", "", +89014, Latanoprost, 1708, 1719, "Latanoprost", "", +89023, ConclusionComment, 1708, 1815, "Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen .", "", +89019, Frequency, 1726, 1736, "once daily", "", +89020, Frequency, 1789, 1800, "twice daily", "", +89024, PMID, 1877, 1884, "7880782", "", diff --git a/data/gl 7880782_jshahinitiran.n-triples b/data/gl 7880782_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 7880782_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 7880782_tstrakeljahn.annodb b/data/gl 7880782_tstrakeljahn.annodb new file mode 100644 index 0000000..21f3ea8 --- /dev/null +++ b/data/gl 7880782_tstrakeljahn.annodb @@ -0,0 +1,80 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88920, Journal, 0, 15, "Br J Ophthalmol", "", +88921, PublicationYear, 18, 22, "1995", "", +88923, Latanoprost, 49, 60, "Latanoprost", "", +88931, Title, 49, 196, "Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol .", "", +88925, Frequency, 74, 84, "once daily", "", +88928, IOP, 118, 138, "intraocular pressure", "", +88929, Glaucoma, 142, 150, "glaucoma", "", +88930, Timolol, 187, 194, "timolol", "", +88932, Author, 197, 202, "Alm A", "", +88933, Author, 211, 224, "Wideng å rd I", "", +88936, Author, 227, 238, "Kjellgren D", "", +88938, Author, 241, 257, "S ö derstr ö m M", "", +88941, Author, 260, 272, "Fristr ö m B", "", +88945, Author, 275, 282, "Heijl A", "", +88946, Author, 285, 299, "Stjerschantz J", "", +88947, Sweden, 391, 397, "Sweden", "", +88949, Latanoprost, 505, 516, "latanoprost", "", +88950, Latanoprost, 519, 525, "PhXA41", "", +88951, Timolol, 576, 583, "timolol", "", +88952, Timolol, 628, 635, "timolol", "", +88953, NumberPatientsCT, 669, 671, "50", "", +88954, NumberAffected, 683, 685, "17", "", +88955, Primary_OpenAngleGlaucoma, 691, 718, "primary open angle glaucoma", "", +88956, NumberAffected, 723, 725, "33", "", +88957, Glaucoma, 731, 748, "capsular glaucoma", "", +88959, Multicenter, 771, 783, "five clinics", "", +88979, Precondition, 786, 937, "All had glaucomatous visual field defects and an intraocular pressure ( IOP ) of at least 22 mm Hg despite treatment with 0 . 5 % timolol twice daily .", "", +88962, IOP, 835, 855, "intraocular pressure", "", +88963, IOP, 858, 861, "IOP", "", +88966, mmHg, 879, 884, "mm Hg", "", +88969, DoseValue, 908, 913, "0 . 5", "", +88970, Percentage, 914, 915, "%", "", +88972, Timolol, 916, 923, "timolol", "", +88973, Frequency, 924, 935, "twice daily", "", +88981, Randomized, 952, 962, "randomised", "", +88983, DoseValue, 1002, 1009, "0 . 006", "", +88984, Percentage, 1010, 1011, "%", "", +88987, Latanoprost, 1012, 1023, "latanoprost", "", +88988, Frequency, 1034, 1045, "twice daily", "", +88989, Placebo, 1067, 1074, "placebo", "", +88992, TimePoint, 1088, 1092, "8 am", "", +88996, Latanoprost, 1097, 1108, "latanoprost", "", +88993, TimePoint, 1112, 1116, "8 pm", "", +88994, Duration, 1121, 1129, "3 months", "", +88998, Timolol, 1149, 1156, "timolol", "", +89000, IOP, 1200, 1203, "IOP", "", +89032, Mean, 1206, 1210, "mean", "", +89007, TimePoint, 1220, 1231, "at baseline", "", +89003, Timolol, 1237, 1244, "timolol", "", +89018, TimePoint, 1257, 1277, "after 4 and 12 weeks", "", +89016, TimePoint, 1269, 1277, "12 weeks", "", +89022, BaseLineValue, 1294, 1300, "24 . 8", "", +89027, SdDevBL, 1303, 1308, "3 . 6", "", +89025, ResultMeasuredValue, 1313, 1319, "16 . 8", "", +89028, SdDevResValue, 1322, 1327, "4 . 3", "", +89026, ResultMeasuredValue, 1336, 1342, "15 . 7", "", +89030, SdDevResValue, 1345, 1350, "2 . 4", "", +89031, mmHg, 1353, 1358, "mm Hg", "", +89033, Frequency, 1377, 1387, "once daily", "", +89034, Latanoprost, 1403, 1414, "latanoprost", "", +89035, BaseLineValue, 1419, 1425, "24 . 9", "", +89036, SdDevBL, 1428, 1433, "2 . 9", "", +89037, ResultMeasuredValue, 1438, 1444, "18 . 1", "", +89039, SdDevResValue, 1447, 1452, "3 . 0", "", +89038, ResultMeasuredValue, 1461, 1467, "18 . 0", "", +89040, SdDevResValue, 1470, 1475, "3 . 6", "", +89041, mmHg, 1478, 1483, "mm Hg", "", +89042, Latanoprost, 1502, 1513, "latanoprost", "", +89043, Frequency, 1514, 1525, "twice daily", "", +89044, ObservedResult, 1528, 1599, "No clinically significant side effects were observed during treatment .", "", +89045, Latanoprost, 1600, 1611, "Latanoprost", "", +89049, ConclusionComment, 1600, 1707, "Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol .", "", +89046, IOP, 1642, 1645, "IOP", "", +89047, Timolol, 1698, 1705, "timolol", "", +89050, Latanoprost, 1708, 1719, "Latanoprost", "", +89054, ConclusionComment, 1708, 1815, "Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen .", "", +89051, Frequency, 1726, 1736, "once daily", "", +89052, Frequency, 1789, 1800, "twice daily", "", +89055, PMID, 1877, 1884, "7880782", "", diff --git a/data/gl 7880782_tstrakeljahn.n-triples b/data/gl 7880782_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 7880782_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8123096_admin.annodb b/data/gl 8123096_admin.annodb new file mode 100644 index 0000000..c508206 --- /dev/null +++ b/data/gl 8123096_admin.annodb @@ -0,0 +1,60 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 18, "J Ocul Pharmacol .", "", " \"J Ocul Pharmacol .\"." +1, PublicationYear, 19, 23, "1993", "", " \"1993\"." +2, Levobunolol, 52, 63, "Levobunolol", "", +7, Title, 52, 142, "Levobunolol compared to dipivefrin in African American patients with open angle glaucoma .", "", " \"Levobunolol compared to dipivefrin in African American patients with open angle glaucoma .\"." +3, Drug, 76, 86, "dipivefrin", "", +5, Ethnicity, 90, 106, "African American", "", " . ." +4, OpenAngleGlaucoma, 121, 140, "open angle glaucoma", "", " ." +8, Author, 143, 151, "Drake MV", "", " \"Drake MV\"." +9, Author, 160, 169, "Wilson MR", "", " \"Wilson MR\"." +10, Author, 172, 180, "Harris D", "", " \"Harris D\"." +11, Author, 183, 192, "Goodwin L", "", " \"Goodwin L\"." +105681, USA, 279, 292, "San Francisco", "", " ." +65, PublicationYear, 323, 327, "1993", "", +12, OpenAngleGlaucoma, 371, 390, "open angle glaucoma", "", +6, Ethnicity, 425, 441, "African American", "", +13, Glaucoma, 501, 509, "glaucoma", "", +14, Ethnicity, 540, 556, "African American", "", +77, ObjectiveDescription, 581, 705, "We treated both eyes of 38 African American patients who have stable open angle glaucoma with either levobunolol b . i . d .", "", " \"We treated both eyes of 38 African American patients who have stable open angle glaucoma with either levobunolol b . i . d .\"." +15, NumberPatientsCT, 605, 607, "38", "", " \"38\"." +16, Ethnicity, 608, 624, "African American", "", +18, OpenAngleGlaucoma, 650, 669, "open angle glaucoma", "", +19, Levobunolol, 682, 693, "levobunolol", "", " ." +22, Frequency, 694, 703, "b . i . d", "", " \"b . i . d\"." +77, ObjectiveDescription, 706, 731, "or dipivefrin b . i . d .", "", " \"or dipivefrin b . i . d .\"." +20, Drug, 709, 719, "dipivefrin", "", " . ." +21, Frequency, 720, 729, "b . i . d", "", " \"b . i . d\"." +77, ObjectiveDescription, 732, 809, "to evaluate the effectiveness of each drug in lowering intraocular pressure .", "", " \"to evaluate the effectiveness of each drug in lowering intraocular pressure .\"." +23, IOP, 787, 807, "intraocular pressure", "", +24, Duration, 836, 845, "six weeks", "", " \"six weeks\"." +25, Precondition, 846, 881, "following a two week washout period", "", " \"following a two week washout period\"." +26, IOP, 896, 916, "intraocular pressure", "", +82, TimePoint, 930, 957, "one , three , and six weeks", "", +83, TimePoint, 936, 957, "three , and six weeks", "", +84, TimePoint, 948, 957, "six weeks", "", +30, IOP, 1025, 1045, "intraocular pressure", "", " . ." +31, TimePoint, 1049, 1057, "week one", "", +33, Mean, 1064, 1068, "mean", "", +105706, IOP, 1085, 1093, "pressure", "", +34, BaseLineValue, 1097, 1103, "24 . 4", "", " \"24 . 4\"." +35, mmHg, 1104, 1108, "mmHg", "", " ." +38, Levobunolol, 1116, 1127, "levobunolol", "", +39, ResultMeasuredValue, 1143, 1149, "17 . 0", "", " \"17 . 0\"." +36, mmHg, 1150, 1154, "mmHg", "", +37, TimePoint, 1158, 1166, "week six", "", " \"week six\"." +40, Mean, 1173, 1177, "mean", "", +90, IOP, 1194, 1202, "pressure", "", +41, BaseLineValue, 1206, 1212, "25 . 4", "", " \"25 . 4\"." +42, mmHg, 1213, 1217, "mmHg", "", +43, Drug, 1225, 1235, "dipivefrin", "", +44, ResultMeasuredValue, 1265, 1271, "18 . 2", "", " \"18 . 2\"." +45, mmHg, 1272, 1276, "mmHg", "", +46, TimePoint, 1280, 1288, "week six", "", " \"week six\"." +53, ConclusionComment, 1414, 1570, "Both levobunolol and dipivefrin produce a statistically significant decrease in intraocular pressure in African American patients with open angle glaucoma .", "", " \"Both levobunolol and dipivefrin produce a statistically significant decrease in intraocular pressure in African American patients with open angle glaucoma .\"." +47, Levobunolol, 1419, 1430, "levobunolol", "", +48, Drug, 1435, 1445, "dipivefrin", "", +49, IOP, 1494, 1514, "intraocular pressure", "", +17, Ethnicity, 1518, 1534, "African American", "", +50, OpenAngleGlaucoma, 1549, 1568, "open angle glaucoma", "", +51, PMID, 1616, 1623, "8123096", "", " \"8123096\"." diff --git a/data/gl 8123096_admin.n-triples b/data/gl 8123096_admin.n-triples new file mode 100644 index 0000000..8706996 --- /dev/null +++ b/data/gl 8123096_admin.n-triples @@ -0,0 +1,95 @@ +# RDF export of group: Publication + . + "Publication " . + "Levobunolol compared to dipivefrin in African American patients with open angle glaucoma ." . + "Drake MV" . + "1993" . + "J Ocul Pharmacol ." . + "8123096" . + . + "Wilson MR" . + "Harris D" . + "Goodwin L" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "We treated both eyes of 38 African American patients who have stable open angle glaucoma with either levobunolol b . i . d ." . + "or dipivefrin b . i . d ." . + "to evaluate the effectiveness of each drug in lowering intraocular pressure ." . + "38" . + "six weeks" . + . + . + . + "Both levobunolol and dipivefrin produce a statistically significant decrease in intraocular pressure in African American patients with open angle glaucoma ." . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + "following a two week washout period" . + . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP " . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + "Arm d" . + . + . + . +# RDF export of group: Intervention + . + "Intervention l " . + . + "b . i . d" . + . + . + "Intervention d" . + . + "b . i . d" . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + . + . + "Medication d" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome IOP l" . + . + "24 . 4" . + "17 . 0" . + "week six" . + . + "Outcome IOP d" . + . + "25 . 4" . + "18 . 2" . + "week six" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8123096_export.csv b/data/gl 8123096_export.csv new file mode 100644 index 0000000..b3313a6 --- /dev/null +++ b/data/gl 8123096_export.csv @@ -0,0 +1,310 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +529, 1, 1, 1, 0, 1, 0, 1, "J" +529, 1, 2, 2, 2, 6, 2, 6, "Ocul" +529, 1, 3, 3, 7, 16, 7, 16, "Pharmacol" +529, 1, 4, 4, 17, 18, 17, 18, "." +529, 2, 1, 5, 0, 4, 19, 23, "1993" +529, 2, 2, 6, 5, 11, 24, 30, "Summer" +529, 2, 3, 7, 12, 13, 31, 32, ";" +529, 2, 4, 8, 14, 15, 33, 34, "9" +529, 2, 5, 9, 16, 17, 35, 36, "(" +529, 2, 6, 10, 18, 19, 37, 38, "2" +529, 2, 7, 11, 20, 21, 39, 40, ")" +529, 2, 8, 12, 22, 23, 41, 42, ":" +529, 2, 9, 13, 24, 26, 43, 45, "91" +529, 2, 10, 14, 27, 28, 46, 47, "-" +529, 2, 11, 15, 29, 30, 48, 49, "5" +529, 2, 12, 16, 31, 32, 50, 51, "." +529, 3, 1, 17, 0, 11, 52, 63, "Levobunolol" +529, 3, 2, 18, 12, 20, 64, 72, "compared" +529, 3, 3, 19, 21, 23, 73, 75, "to" +529, 3, 4, 20, 24, 34, 76, 86, "dipivefrin" +529, 3, 5, 21, 35, 37, 87, 89, "in" +529, 3, 6, 22, 38, 45, 90, 97, "African" +529, 3, 7, 23, 46, 54, 98, 106, "American" +529, 3, 8, 24, 55, 63, 107, 115, "patients" +529, 3, 9, 25, 64, 68, 116, 120, "with" +529, 3, 10, 26, 69, 73, 121, 125, "open" +529, 3, 11, 27, 74, 79, 126, 131, "angle" +529, 3, 12, 28, 80, 88, 132, 140, "glaucoma" +529, 3, 13, 29, 89, 90, 141, 142, "." +529, 4, 1, 30, 0, 5, 143, 148, "Drake" +529, 4, 2, 31, 6, 8, 149, 151, "MV" +529, 4, 3, 32, 9, 10, 152, 153, "(" +529, 4, 4, 33, 11, 12, 154, 155, "1" +529, 4, 5, 34, 13, 14, 156, 157, ")" +529, 4, 6, 35, 15, 16, 158, 159, "," +529, 4, 7, 36, 17, 23, 160, 166, "Wilson" +529, 4, 8, 37, 24, 26, 167, 169, "MR" +529, 4, 9, 38, 27, 28, 170, 171, "," +529, 4, 10, 39, 29, 35, 172, 178, "Harris" +529, 4, 11, 40, 36, 37, 179, 180, "D" +529, 4, 12, 41, 38, 39, 181, 182, "," +529, 4, 13, 42, 40, 47, 183, 190, "Goodwin" +529, 4, 14, 43, 48, 49, 191, 192, "L" +529, 4, 15, 44, 50, 51, 193, 194, "." +529, 4, 16, 45, 52, 58, 195, 201, "Author" +529, 4, 17, 46, 59, 70, 202, 213, "information" +529, 4, 18, 47, 71, 72, 214, 215, ":" +529, 4, 19, 48, 73, 74, 216, 217, "(" +529, 4, 20, 49, 75, 76, 218, 219, "1" +529, 4, 21, 50, 77, 78, 220, 221, ")" +529, 4, 22, 51, 79, 89, 222, 232, "Department" +529, 4, 23, 52, 90, 92, 233, 235, "of" +529, 4, 24, 53, 93, 106, 236, 249, "Ophthalmology" +529, 4, 25, 54, 107, 108, 250, 251, "," +529, 4, 26, 55, 109, 119, 252, 262, "University" +529, 4, 27, 56, 120, 122, 263, 265, "of" +529, 4, 28, 57, 123, 133, 266, 276, "California" +529, 4, 29, 58, 134, 135, 277, 278, "," +529, 4, 30, 59, 136, 139, 279, 282, "San" +529, 4, 31, 60, 140, 149, 283, 292, "Francisco" +529, 4, 32, 61, 150, 151, 293, 294, "." +529, 5, 1, 62, 0, 7, 295, 302, "Erratum" +529, 5, 2, 63, 8, 10, 303, 305, "in" +529, 5, 3, 64, 11, 12, 306, 307, "J" +529, 5, 4, 65, 13, 17, 308, 312, "Ocul" +529, 5, 5, 66, 18, 27, 313, 322, "Pharmacol" +529, 5, 6, 67, 28, 32, 323, 327, "1993" +529, 5, 7, 68, 33, 39, 328, 334, "Winter" +529, 5, 8, 69, 40, 41, 335, 336, ";" +529, 5, 9, 70, 42, 43, 337, 338, "9" +529, 5, 10, 71, 44, 45, 339, 340, "(" +529, 5, 11, 72, 46, 47, 341, 342, "4" +529, 5, 12, 73, 48, 49, 343, 344, ")" +529, 5, 13, 74, 50, 51, 345, 346, ":" +529, 5, 14, 75, 52, 55, 347, 350, "385" +529, 5, 15, 76, 56, 57, 351, 352, "." +529, 6, 1, 77, 0, 3, 353, 356, "The" +529, 6, 2, 78, 4, 14, 357, 367, "prevalence" +529, 6, 3, 79, 15, 17, 368, 370, "of" +529, 6, 4, 80, 18, 22, 371, 375, "open" +529, 6, 5, 81, 23, 28, 376, 381, "angle" +529, 6, 6, 82, 29, 37, 382, 390, "glaucoma" +529, 6, 7, 83, 38, 40, 391, 393, "is" +529, 6, 8, 84, 41, 59, 394, 412, "disproportionately" +529, 6, 9, 85, 60, 64, 413, 417, "high" +529, 6, 10, 86, 65, 67, 418, 420, "in" +529, 6, 11, 87, 68, 71, 421, 424, "the" +529, 6, 12, 88, 72, 79, 425, 432, "African" +529, 6, 13, 89, 80, 88, 433, 441, "American" +529, 6, 14, 90, 89, 99, 442, 452, "population" +529, 6, 15, 91, 100, 101, 453, 454, "." +529, 7, 1, 92, 0, 11, 455, 466, "Information" +529, 7, 2, 93, 12, 17, 467, 472, "about" +529, 7, 3, 94, 18, 21, 473, 476, "the" +529, 7, 4, 95, 22, 35, 477, 490, "effectiveness" +529, 7, 5, 96, 36, 38, 491, 493, "of" +529, 7, 6, 97, 39, 43, 494, 498, "anti" +529, 7, 7, 98, 44, 45, 499, 500, "-" +529, 7, 8, 99, 46, 54, 501, 509, "glaucoma" +529, 7, 9, 100, 55, 66, 510, 521, "medications" +529, 7, 10, 101, 67, 69, 522, 524, "in" +529, 7, 11, 102, 70, 72, 525, 527, "an" +529, 7, 12, 103, 73, 84, 528, 539, "exclusively" +529, 7, 13, 104, 85, 92, 540, 547, "African" +529, 7, 14, 105, 93, 101, 548, 556, "American" +529, 7, 15, 106, 102, 112, 557, 567, "population" +529, 7, 16, 107, 113, 115, 568, 570, "is" +529, 7, 17, 108, 116, 123, 571, 578, "lacking" +529, 7, 18, 109, 124, 125, 579, 580, "." +529, 8, 1, 110, 0, 2, 581, 583, "We" +529, 8, 2, 111, 3, 10, 584, 591, "treated" +529, 8, 3, 112, 11, 15, 592, 596, "both" +529, 8, 4, 113, 16, 20, 597, 601, "eyes" +529, 8, 5, 114, 21, 23, 602, 604, "of" +529, 8, 6, 115, 24, 26, 605, 607, "38" +529, 8, 7, 116, 27, 34, 608, 615, "African" +529, 8, 8, 117, 35, 43, 616, 624, "American" +529, 8, 9, 118, 44, 52, 625, 633, "patients" +529, 8, 10, 119, 53, 56, 634, 637, "who" +529, 8, 11, 120, 57, 61, 638, 642, "have" +529, 8, 12, 121, 62, 68, 643, 649, "stable" +529, 8, 13, 122, 69, 73, 650, 654, "open" +529, 8, 14, 123, 74, 79, 655, 660, "angle" +529, 8, 15, 124, 80, 88, 661, 669, "glaucoma" +529, 8, 16, 125, 89, 93, 670, 674, "with" +529, 8, 17, 126, 94, 100, 675, 681, "either" +529, 8, 18, 127, 101, 112, 682, 693, "levobunolol" +529, 8, 19, 128, 113, 114, 694, 695, "b" +529, 8, 20, 129, 115, 116, 696, 697, "." +529, 8, 21, 130, 117, 118, 698, 699, "i" +529, 8, 22, 131, 119, 120, 700, 701, "." +529, 8, 23, 132, 121, 122, 702, 703, "d" +529, 8, 24, 133, 123, 124, 704, 705, "." +529, 9, 1, 134, 0, 2, 706, 708, "or" +529, 9, 2, 135, 3, 13, 709, 719, "dipivefrin" +529, 9, 3, 136, 14, 15, 720, 721, "b" +529, 9, 4, 137, 16, 17, 722, 723, "." +529, 9, 5, 138, 18, 19, 724, 725, "i" +529, 9, 6, 139, 20, 21, 726, 727, "." +529, 9, 7, 140, 22, 23, 728, 729, "d" +529, 9, 8, 141, 24, 25, 730, 731, "." +529, 10, 1, 142, 0, 2, 732, 734, "to" +529, 10, 2, 143, 3, 11, 735, 743, "evaluate" +529, 10, 3, 144, 12, 15, 744, 747, "the" +529, 10, 4, 145, 16, 29, 748, 761, "effectiveness" +529, 10, 5, 146, 30, 32, 762, 764, "of" +529, 10, 6, 147, 33, 37, 765, 769, "each" +529, 10, 7, 148, 38, 42, 770, 774, "drug" +529, 10, 8, 149, 43, 45, 775, 777, "in" +529, 10, 9, 150, 46, 54, 778, 786, "lowering" +529, 10, 10, 151, 55, 66, 787, 798, "intraocular" +529, 10, 11, 152, 67, 75, 799, 807, "pressure" +529, 10, 12, 153, 76, 77, 808, 809, "." +529, 11, 1, 154, 0, 8, 810, 818, "Patients" +529, 11, 2, 155, 9, 13, 819, 823, "were" +529, 11, 3, 156, 14, 21, 824, 831, "treated" +529, 11, 4, 157, 22, 25, 832, 835, "for" +529, 11, 5, 158, 26, 29, 836, 839, "six" +529, 11, 6, 159, 30, 35, 840, 845, "weeks" +529, 11, 7, 160, 36, 45, 846, 855, "following" +529, 11, 8, 161, 46, 47, 856, 857, "a" +529, 11, 9, 162, 48, 51, 858, 861, "two" +529, 11, 10, 163, 52, 56, 862, 866, "week" +529, 11, 11, 164, 57, 64, 867, 874, "washout" +529, 11, 12, 165, 65, 71, 875, 881, "period" +529, 11, 13, 166, 72, 73, 882, 883, "." +529, 12, 1, 167, 0, 2, 884, 886, "We" +529, 12, 2, 168, 3, 11, 887, 895, "measured" +529, 12, 3, 169, 12, 23, 896, 907, "intraocular" +529, 12, 4, 170, 24, 32, 908, 916, "pressure" +529, 12, 5, 171, 33, 39, 917, 923, "levels" +529, 12, 6, 172, 40, 45, 924, 929, "after" +529, 12, 7, 173, 46, 49, 930, 933, "one" +529, 12, 8, 174, 50, 51, 934, 935, "," +529, 12, 9, 175, 52, 57, 936, 941, "three" +529, 12, 10, 176, 58, 59, 942, 943, "," +529, 12, 11, 177, 60, 63, 944, 947, "and" +529, 12, 12, 178, 64, 67, 948, 951, "six" +529, 12, 13, 179, 68, 73, 952, 957, "weeks" +529, 12, 14, 180, 74, 75, 958, 959, "." +529, 13, 1, 181, 0, 4, 960, 964, "Each" +529, 13, 2, 182, 5, 15, 965, 975, "medication" +529, 13, 3, 183, 16, 24, 976, 984, "produced" +529, 13, 4, 184, 25, 26, 985, 986, "a" +529, 13, 5, 185, 27, 40, 987, 1000, "statistically" +529, 13, 6, 186, 41, 52, 1001, 1012, "significant" +529, 13, 7, 187, 53, 61, 1013, 1021, "decrease" +529, 13, 8, 188, 62, 64, 1022, 1024, "in" +529, 13, 9, 189, 65, 76, 1025, 1036, "intraocular" +529, 13, 10, 190, 77, 85, 1037, 1045, "pressure" +529, 13, 11, 191, 86, 88, 1046, 1048, "by" +529, 13, 12, 192, 89, 93, 1049, 1053, "week" +529, 13, 13, 193, 94, 97, 1054, 1057, "one" +529, 13, 14, 194, 98, 99, 1058, 1059, "." +529, 14, 1, 195, 0, 3, 1060, 1063, "The" +529, 14, 2, 196, 4, 8, 1064, 1068, "mean" +529, 14, 3, 197, 9, 12, 1069, 1072, "pre" +529, 14, 4, 198, 13, 14, 1073, 1074, "-" +529, 14, 5, 199, 15, 24, 1075, 1084, "treatment" +529, 14, 6, 200, 25, 33, 1085, 1093, "pressure" +529, 14, 7, 201, 34, 36, 1094, 1096, "of" +529, 14, 8, 202, 37, 39, 1097, 1099, "24" +529, 14, 9, 203, 40, 41, 1100, 1101, "." +529, 14, 10, 204, 42, 43, 1102, 1103, "4" +529, 14, 11, 205, 44, 48, 1104, 1108, "mmHg" +529, 14, 12, 206, 49, 51, 1109, 1111, "in" +529, 14, 13, 207, 52, 55, 1112, 1115, "the" +529, 14, 14, 208, 56, 67, 1116, 1127, "levobunolol" +529, 14, 15, 209, 68, 71, 1128, 1131, "was" +529, 14, 16, 210, 72, 79, 1132, 1139, "reduced" +529, 14, 17, 211, 80, 82, 1140, 1142, "to" +529, 14, 18, 212, 83, 85, 1143, 1145, "17" +529, 14, 19, 213, 86, 87, 1146, 1147, "." +529, 14, 20, 214, 88, 89, 1148, 1149, "0" +529, 14, 21, 215, 90, 94, 1150, 1154, "mmHg" +529, 14, 22, 216, 95, 97, 1155, 1157, "by" +529, 14, 23, 217, 98, 102, 1158, 1162, "week" +529, 14, 24, 218, 103, 106, 1163, 1166, "six" +529, 14, 25, 219, 107, 108, 1167, 1168, "." +529, 15, 1, 220, 0, 3, 1169, 1172, "The" +529, 15, 2, 221, 4, 8, 1173, 1177, "mean" +529, 15, 3, 222, 9, 12, 1178, 1181, "pre" +529, 15, 4, 223, 13, 14, 1182, 1183, "-" +529, 15, 5, 224, 15, 24, 1184, 1193, "treatment" +529, 15, 6, 225, 25, 33, 1194, 1202, "pressure" +529, 15, 7, 226, 34, 36, 1203, 1205, "of" +529, 15, 8, 227, 37, 39, 1206, 1208, "25" +529, 15, 9, 228, 40, 41, 1209, 1210, "." +529, 15, 10, 229, 42, 43, 1211, 1212, "4" +529, 15, 11, 230, 44, 48, 1213, 1217, "mmHg" +529, 15, 12, 231, 49, 51, 1218, 1220, "in" +529, 15, 13, 232, 52, 55, 1221, 1224, "the" +529, 15, 14, 233, 56, 66, 1225, 1235, "dipivefrin" +529, 15, 15, 234, 67, 74, 1236, 1243, "treated" +529, 15, 16, 235, 75, 80, 1244, 1249, "group" +529, 15, 17, 236, 81, 84, 1250, 1253, "was" +529, 15, 18, 237, 85, 92, 1254, 1261, "reduced" +529, 15, 19, 238, 93, 95, 1262, 1264, "to" +529, 15, 20, 239, 96, 98, 1265, 1267, "18" +529, 15, 21, 240, 99, 100, 1268, 1269, "." +529, 15, 22, 241, 101, 102, 1270, 1271, "2" +529, 15, 23, 242, 103, 107, 1272, 1276, "mmHg" +529, 15, 24, 243, 108, 110, 1277, 1279, "by" +529, 15, 25, 244, 111, 115, 1280, 1284, "week" +529, 15, 26, 245, 116, 119, 1285, 1288, "six" +529, 15, 27, 246, 120, 121, 1289, 1290, "." +529, 16, 1, 247, 0, 5, 1291, 1296, "There" +529, 16, 2, 248, 6, 9, 1297, 1300, "was" +529, 16, 3, 249, 10, 13, 1301, 1304, "not" +529, 16, 4, 250, 14, 15, 1305, 1306, "a" +529, 16, 5, 251, 16, 29, 1307, 1320, "statistically" +529, 16, 6, 252, 30, 41, 1321, 1332, "significant" +529, 16, 7, 253, 42, 52, 1333, 1343, "difference" +529, 16, 8, 254, 53, 55, 1344, 1346, "in" +529, 16, 9, 255, 56, 59, 1347, 1350, "the" +529, 16, 10, 256, 60, 63, 1351, 1354, "pre" +529, 16, 11, 257, 64, 65, 1355, 1356, "-" +529, 16, 12, 258, 66, 75, 1357, 1366, "treatment" +529, 16, 13, 259, 76, 78, 1367, 1369, "or" +529, 16, 14, 260, 79, 82, 1370, 1373, "the" +529, 16, 15, 261, 83, 88, 1374, 1379, "final" +529, 16, 16, 262, 89, 97, 1380, 1388, "pressure" +529, 16, 17, 263, 98, 105, 1389, 1396, "between" +529, 16, 18, 264, 106, 109, 1397, 1400, "the" +529, 16, 19, 265, 110, 113, 1401, 1404, "two" +529, 16, 20, 266, 114, 120, 1405, 1411, "groups" +529, 16, 21, 267, 121, 122, 1412, 1413, "." +529, 17, 1, 268, 0, 4, 1414, 1418, "Both" +529, 17, 2, 269, 5, 16, 1419, 1430, "levobunolol" +529, 17, 3, 270, 17, 20, 1431, 1434, "and" +529, 17, 4, 271, 21, 31, 1435, 1445, "dipivefrin" +529, 17, 5, 272, 32, 39, 1446, 1453, "produce" +529, 17, 6, 273, 40, 41, 1454, 1455, "a" +529, 17, 7, 274, 42, 55, 1456, 1469, "statistically" +529, 17, 8, 275, 56, 67, 1470, 1481, "significant" +529, 17, 9, 276, 68, 76, 1482, 1490, "decrease" +529, 17, 10, 277, 77, 79, 1491, 1493, "in" +529, 17, 11, 278, 80, 91, 1494, 1505, "intraocular" +529, 17, 12, 279, 92, 100, 1506, 1514, "pressure" +529, 17, 13, 280, 101, 103, 1515, 1517, "in" +529, 17, 14, 281, 104, 111, 1518, 1525, "African" +529, 17, 15, 282, 112, 120, 1526, 1534, "American" +529, 17, 16, 283, 121, 129, 1535, 1543, "patients" +529, 17, 17, 284, 130, 134, 1544, 1548, "with" +529, 17, 18, 285, 135, 139, 1549, 1553, "open" +529, 17, 19, 286, 140, 145, 1554, 1559, "angle" +529, 17, 20, 287, 146, 154, 1560, 1568, "glaucoma" +529, 17, 21, 288, 155, 156, 1569, 1570, "." +529, 18, 1, 289, 0, 3, 1571, 1574, "DOI" +529, 18, 2, 290, 4, 5, 1575, 1576, ":" +529, 18, 3, 291, 6, 8, 1577, 1579, "10" +529, 18, 4, 292, 9, 10, 1580, 1581, "." +529, 18, 5, 293, 11, 15, 1582, 1586, "1089" +529, 18, 6, 294, 16, 17, 1587, 1588, "/" +529, 18, 7, 295, 18, 21, 1589, 1592, "jop" +529, 18, 8, 296, 22, 23, 1593, 1594, "." +529, 18, 9, 297, 24, 28, 1595, 1599, "1993" +529, 18, 10, 298, 29, 30, 1600, 1601, "." +529, 18, 11, 299, 31, 32, 1602, 1603, "9" +529, 18, 12, 300, 33, 34, 1604, 1605, "." +529, 18, 13, 301, 35, 37, 1606, 1608, "91" +529, 18, 14, 302, 38, 42, 1609, 1613, "PMID" +529, 18, 15, 303, 43, 44, 1614, 1615, ":" +529, 18, 16, 304, 45, 52, 1616, 1623, "8123096" +529, 18, 17, 305, 53, 54, 1624, 1625, "[" +529, 18, 18, 306, 55, 62, 1626, 1633, "Indexed" +529, 18, 19, 307, 63, 66, 1634, 1637, "for" +529, 18, 20, 308, 67, 74, 1638, 1645, "MEDLINE" +529, 18, 21, 309, 75, 76, 1646, 1647, "]" diff --git a/data/gl 8123096_jshahinitiran.annodb b/data/gl 8123096_jshahinitiran.annodb new file mode 100644 index 0000000..7f1d16f --- /dev/null +++ b/data/gl 8123096_jshahinitiran.annodb @@ -0,0 +1,59 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89048, Journal, 2, 16, "Ocul Pharmacol", "", +89053, PublicationYear, 19, 23, "1993", "", +89056, Title, 52, 142, "Levobunolol compared to dipivefrin in African American patients with open angle glaucoma .", "", +89057, Levobunolol, 52, 63, "Levobunolol", "", +89060, Drug, 76, 86, "dipivefrin", "", +89058, Ethnicity, 90, 106, "African American", "", +89059, OpenAngleGlaucoma, 121, 140, "open angle glaucoma", "", +89061, Author, 143, 151, "Drake MV", "", +89062, Author, 160, 169, "Wilson MR", "", +89063, Author, 172, 180, "Harris D", "", +89064, Author, 183, 192, "Goodwin L", "", +89065, PublicationYear, 323, 327, "1993", "", +89066, OpenAngleGlaucoma, 371, 390, "open angle glaucoma", "", +89067, Ethnicity, 425, 441, "African American", "", +89069, Glaucoma, 501, 509, "glaucoma", "", +89068, Ethnicity, 540, 556, "African American", "", +89078, ObjectiveDescription, 581, 705, "We treated both eyes of 38 African American patients who have stable open angle glaucoma with either levobunolol b . i . d .", "", +89070, NumberPatientsCT, 605, 607, "38", "", +89071, OpenAngleGlaucoma, 650, 669, "open angle glaucoma", "", +89072, Levobunolol, 682, 693, "levobunolol", "", +89073, Frequency, 694, 703, "b . i . d", "", +89079, ObjectiveDescription, 706, 731, "or dipivefrin b . i . d .", "", +89075, Drug, 709, 719, "dipivefrin", "", +89076, Frequency, 720, 729, "b . i . d", "", +89080, ObjectiveDescription, 732, 809, "to evaluate the effectiveness of each drug in lowering intraocular pressure .", "", +89077, IOP, 787, 807, "intraocular pressure", "", +89081, Duration, 836, 845, "six weeks", "", +89082, IOP, 896, 916, "intraocular pressure", "", +89083, TimePoint, 930, 957, "one , three , and six weeks", "", +89084, TimePoint, 936, 957, "three , and six weeks", "", +89085, TimePoint, 948, 957, "six weeks", "", +89105, ObservedResult, 960, 1059, "Each medication produced a statistically significant decrease in intraocular pressure by week one .", "", +89086, IOP, 1025, 1045, "intraocular pressure", "", +89087, TimePoint, 1049, 1057, "week one", "", +89088, Mean, 1064, 1068, "mean", "", +89090, IOP, 1085, 1093, "pressure", "", +89092, BaseLineValue, 1097, 1103, "24 . 4", "", +89094, mmHg, 1104, 1108, "mmHg", "", +89096, Levobunolol, 1116, 1127, "levobunolol", "", +89098, ResultMeasuredValue, 1143, 1149, "17 . 0", "", +89100, mmHg, 1150, 1154, "mmHg", "", +89102, TimePoint, 1158, 1166, "week six", "", +89089, Mean, 1173, 1177, "mean", "", +89091, IOP, 1194, 1202, "pressure", "", +89093, BaseLineValue, 1206, 1212, "25 . 4", "", +89095, mmHg, 1213, 1217, "mmHg", "", +89097, Drug, 1225, 1235, "dipivefrin", "", +89099, ResultMeasuredValue, 1265, 1271, "18 . 2", "", +89101, mmHg, 1272, 1276, "mmHg", "", +89103, TimePoint, 1280, 1288, "week six", "", +89104, ObservedResult, 1291, 1413, "There was not a statistically significant difference in the pre - treatment or the final pressure between the two groups .", "", +89106, ConclusionComment, 1414, 1570, "Both levobunolol and dipivefrin produce a statistically significant decrease in intraocular pressure in African American patients with open angle glaucoma .", "", +89107, Levobunolol, 1419, 1430, "levobunolol", "", +89108, Drug, 1435, 1445, "dipivefrin", "", +89109, IOP, 1494, 1514, "intraocular pressure", "", +89110, Ethnicity, 1518, 1534, "African American", "", +89111, OpenAngleGlaucoma, 1549, 1568, "open angle glaucoma", "", +89112, PMID, 1616, 1623, "8123096", "", diff --git a/data/gl 8123096_jshahinitiran.n-triples b/data/gl 8123096_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8123096_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8123096_tstrakeljahn.annodb b/data/gl 8123096_tstrakeljahn.annodb new file mode 100644 index 0000000..a6acc49 --- /dev/null +++ b/data/gl 8123096_tstrakeljahn.annodb @@ -0,0 +1,55 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88787, Journal, 0, 16, "J Ocul Pharmacol", "", +88789, PublicationYear, 19, 23, "1993", "", +88791, Levobunolol, 52, 63, "Levobunolol", "", +88818, Title, 52, 142, "Levobunolol compared to dipivefrin in African American patients with open angle glaucoma .", "", +88797, Drug, 76, 86, "dipivefrin", "Dipivefrin", +88812, Ethnicity, 90, 106, "African American", "", +88801, OpenAngleGlaucoma, 121, 140, "open angle glaucoma", "", +88820, Author, 143, 151, "Drake MV", "", +88821, Author, 160, 169, "Wilson MR", "", +88823, Author, 172, 180, "Harris D", "", +88825, Author, 183, 192, "Goodwin L", "", +88826, OpenAngleGlaucoma, 371, 390, "open angle glaucoma", "", +88813, Ethnicity, 425, 441, "African American", "", +88827, Glaucoma, 501, 509, "glaucoma", "", +88831, Ethnicity, 540, 556, "African American", "", +88834, NumberPatientsCT, 605, 607, "38", "", +88835, Ethnicity, 608, 624, "African American", "", +88837, OpenAngleGlaucoma, 650, 669, "open angle glaucoma", "", +88839, Levobunolol, 682, 693, "levobunolol", "", +88846, Frequency, 694, 703, "b . i . d", "", +88842, Drug, 709, 719, "dipivefrin", "Dipivefrin", +88845, Frequency, 720, 729, "b . i . d", "", +88847, IOP, 787, 807, "intraocular pressure", "", +88848, Duration, 836, 845, "six weeks", "", +88851, Precondition, 846, 881, "following a two week washout period", "", +88852, IOP, 896, 916, "intraocular pressure", "", +88863, TimePoint, 924, 933, "after one", "", +88864, TimePoint, 924, 941, "after one , three", "", +88865, TimePoint, 924, 957, "after one , three , and six weeks", "", +88870, ObservedResult, 960, 1059, "Each medication produced a statistically significant decrease in intraocular pressure by week one .", "", +88866, IOP, 1025, 1045, "intraocular pressure", "", +88867, TimePoint, 1049, 1057, "week one", "", +88872, Mean, 1064, 1068, "mean", "", +88875, BaseLineValue, 1097, 1103, "24 . 4", "", +88878, mmHg, 1104, 1108, "mmHg", "", +88886, Levobunolol, 1116, 1127, "levobunolol", "", +88889, ResultMeasuredValue, 1143, 1149, "17 . 0", "", +88880, mmHg, 1150, 1154, "mmHg", "", +88882, TimePoint, 1158, 1166, "week six", "", +88892, Mean, 1173, 1177, "mean", "", +88894, BaseLineValue, 1206, 1212, "25 . 4", "", +88895, mmHg, 1213, 1217, "mmHg", "", +88897, Drug, 1225, 1235, "dipivefrin", "Dipivefrin", +88899, ResultMeasuredValue, 1265, 1271, "18 . 2", "", +88900, mmHg, 1272, 1276, "mmHg", "", +88901, TimePoint, 1280, 1288, "week six", "", +88913, ObservedResult, 1291, 1413, "There was not a statistically significant difference in the pre - treatment or the final pressure between the two groups .", "", +88915, ConclusionComment, 1414, 1570, "Both levobunolol and dipivefrin produce a statistically significant decrease in intraocular pressure in African American patients with open angle glaucoma .", "", +88903, Levobunolol, 1419, 1430, "levobunolol", "", +88905, Drug, 1435, 1445, "dipivefrin", "Dipivefrin", +88907, IOP, 1494, 1514, "intraocular pressure", "", +88836, Ethnicity, 1518, 1534, "African American", "", +88908, OpenAngleGlaucoma, 1549, 1568, "open angle glaucoma", "", +88911, PMID, 1616, 1623, "8123096", "", diff --git a/data/gl 8123096_tstrakeljahn.n-triples b/data/gl 8123096_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8123096_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8145982_admin.annodb b/data/gl 8145982_admin.annodb new file mode 100644 index 0000000..eec6f71 --- /dev/null +++ b/data/gl 8145982_admin.annodb @@ -0,0 +1,63 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 15, "Ophthalmologica", "", " \"Ophthalmologica\"." +1, PublicationYear, 18, 22, "1994", "", " \"1994\"." +8, Title, 46, 156, "A comparison of the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol .", "", " \"A comparison of the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol .\"." +2, DoseValue, 117, 122, "0 . 5", "", +4, Percentage, 123, 124, "%", "", +6, Levobunolol, 125, 136, "levobunolol", "", +3, DoseValue, 141, 142, "2", "", +5, Percentage, 143, 144, "%", "", +7, Carteolol, 145, 154, "carteolol", "", +10, Author, 157, 176, "Behrens - Baumann W", "", " \"Behrens - Baumann W\"." +11, Author, 185, 194, "Kimmich F", "", " \"Kimmich F\"." +12, Author, 197, 204, "Walt JG", "", " \"Walt JG\"." +13, Author, 207, 212, "Lue J", "", " \"Lue J\"." +9, Germany, 298, 301, "FRG", "", " ." +85, ObjectiveDescription, 304, 540, "In a 3 - month , double - masked , randomized clinical trial , the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol were compared in 59 patients with open - angle glaucoma or ocular hypertension .", "", " \"In a 3 - month , double - masked , randomized clinical trial , the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol were compared in 59 patients with open - angle glaucoma or ocular hypertension .\"." +14, Duration, 309, 318, "3 - month", "", " \"3 - month\"." +15, DoubleBlind, 321, 336, "double - masked", "", " ." +16, Randomized, 339, 349, "randomized", "", " ." +18, DoseValue, 422, 427, "0 . 5", "", " \"0 . 5\"." +20, Percentage, 428, 429, "%", "", " ." +23, Levobunolol, 430, 441, "levobunolol", "", " ." +19, DoseValue, 446, 447, "2", "", " \"2\"." +21, Percentage, 448, 449, "%", "", " ." +22, Carteolol, 450, 459, "carteolol", "", " ." +24, NumberPatientsCT, 477, 479, "59", "", " \"59\"." +25, OpenAngleGlaucoma, 494, 515, "open - angle glaucoma", "", " ." +26, OcularHypertension, 519, 538, "ocular hypertension", "", " ." +27, Mean, 553, 557, "mean", "", " . ." +28, IOP, 570, 590, "intraocular pressure", "", " . ." +29, Reduction, 595, 600, "7 . 3", "", " \"7 . 3\"." +33, mmHg, 601, 606, "mm Hg", "", " ." +31, RelativeReduction, 609, 615, "27 . 4", "", " \"27 . 4\"." +35, DoseValue, 627, 632, "0 . 5", "", +36, Percentage, 633, 634, "%", "", +37, Levobunolol, 635, 646, "levobunolol", "", +30, Reduction, 657, 662, "4 . 1", "", " \"4 . 1\"." +34, mmHg, 663, 668, "mm Hg", "", +32, RelativeReduction, 671, 677, "14 . 8", "", " \"14 . 8\"." +38, Carteolol, 689, 698, "carteolol", "", +96, PvalueDiff, 755, 767, "p = 0 . 0004", "", " \"p = 0 . 0004\"." +41, Mean, 871, 875, "mean", "", +42, HeartRate, 876, 886, "heart rate", "", +44, Mean, 929, 933, "mean", "", " . ." +45, HeartRate, 946, 956, "heart rate", "", " . ." +46, Carteolol, 964, 973, "carteolol", "", +49, Reduction, 996, 1001, "8 . 4", "", " \"8 . 4\"." +105, BioAndMedicalUnit, 1002, 1013, "beats / min", "", " . ." +108, Levobunolol, 1028, 1039, "levobunolol", "", +50, Reduction, 1050, 1055, "3 . 1", "", " \"3 . 1\"." +106, BioAndMedicalUnit, 1056, 1067, "beats / min", "", +109, PvalueDiff, 1128, 1139, "p = 0 . 059", "", " \"p = 0 . 059\"." +61, ConclusionComment, 1144, 1307, "We conclude that 0 . 5 % levobunolol and 2 % carteolol administered twice daily differ in lowering intraocular pressure as well as in their effects on heart rate .", "", " \"We conclude that 0 . 5 % levobunolol and 2 % carteolol administered twice daily differ in lowering intraocular pressure as well as in their effects on heart rate .\"." +52, DoseValue, 1161, 1166, "0 . 5", "", +59, Percentage, 1167, 1168, "%", "", +56, Levobunolol, 1169, 1180, "levobunolol", "", +53, DoseValue, 1185, 1186, "2", "", +60, Percentage, 1187, 1188, "%", "", +54, Carteolol, 1189, 1198, "carteolol", "", +55, Frequency, 1212, 1223, "twice daily", "", " \"twice daily\". \"twice daily\"." +57, IOP, 1243, 1263, "intraocular pressure", "", +58, HeartRate, 1295, 1305, "heart rate", "", +62, PMID, 1343, 1350, "8145982", "", " \"8145982\"." diff --git a/data/gl 8145982_admin.n-triples b/data/gl 8145982_admin.n-triples new file mode 100644 index 0000000..6f80656 --- /dev/null +++ b/data/gl 8145982_admin.n-triples @@ -0,0 +1,123 @@ +# RDF export of group: Publication + . + "Publication " . + "A comparison of the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol ." . + "Behrens - Baumann W" . + "1994" . + "Ophthalmologica" . + "8145982" . + . + "Kimmich F" . + "Walt JG" . + "Lue J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "In a 3 - month , double - masked , randomized clinical trial , the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol were compared in 59 patients with open - angle glaucoma or ocular hypertension ." . + "59" . + "3 - month" . + . + . + . + "We conclude that 0 . 5 % levobunolol and 2 % carteolol administered twice daily differ in lowering intraocular pressure as well as in their effects on heart rate ." . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population " . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint hr" . + . + . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + . + "Arm c" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "twice daily" . + . + . + "Intervention c" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication l" . + . + "0 . 5" . + . + . + . + "Medication c" . + . + "2" . + . + . +# RDF export of group: Outcome + . + "Outcome IOP l " . + . + "4 . 1" . + "14 . 8" . + . + "Outcome IOP c" . + . + "7 . 3" . + "27 . 4" . + . + "Outcome hr l " . + . + "3 . 1" . + . + "Outcome hr c" . + . + "8 . 4" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups IOP " . + "p = 0 . 0004" . + . + . + . + "DiffBetweenGroups hr" . + "p = 0 . 059" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8145982_export.csv b/data/gl 8145982_export.csv new file mode 100644 index 0000000..c0a578f --- /dev/null +++ b/data/gl 8145982_export.csv @@ -0,0 +1,294 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +530, 1, 1, 1, 0, 15, 0, 15, "Ophthalmologica" +530, 1, 2, 2, 16, 17, 16, 17, "." +530, 2, 1, 3, 0, 4, 18, 22, "1994" +530, 2, 2, 4, 5, 6, 23, 24, ";" +530, 2, 3, 5, 7, 10, 25, 28, "208" +530, 2, 4, 6, 11, 12, 29, 30, "(" +530, 2, 5, 7, 13, 14, 31, 32, "1" +530, 2, 6, 8, 15, 16, 33, 34, ")" +530, 2, 7, 9, 17, 18, 35, 36, ":" +530, 2, 8, 10, 19, 21, 37, 39, "32" +530, 2, 9, 11, 22, 23, 40, 41, "-" +530, 2, 10, 12, 24, 25, 42, 43, "6" +530, 2, 11, 13, 26, 27, 44, 45, "." +530, 3, 1, 14, 0, 1, 46, 47, "A" +530, 3, 2, 15, 2, 12, 48, 58, "comparison" +530, 3, 3, 16, 13, 15, 59, 61, "of" +530, 3, 4, 17, 16, 19, 62, 65, "the" +530, 3, 5, 18, 20, 26, 66, 72, "ocular" +530, 3, 6, 19, 27, 38, 73, 84, "hypotensive" +530, 3, 7, 20, 39, 47, 85, 93, "efficacy" +530, 3, 8, 21, 48, 51, 94, 97, "and" +530, 3, 9, 22, 52, 60, 98, 106, "systemic" +530, 3, 10, 23, 61, 67, 107, 113, "safety" +530, 3, 11, 24, 68, 70, 114, 116, "of" +530, 3, 12, 25, 71, 72, 117, 118, "0" +530, 3, 13, 26, 73, 74, 119, 120, "." +530, 3, 14, 27, 75, 76, 121, 122, "5" +530, 3, 15, 28, 77, 78, 123, 124, "%" +530, 3, 16, 29, 79, 90, 125, 136, "levobunolol" +530, 3, 17, 30, 91, 94, 137, 140, "and" +530, 3, 18, 31, 95, 96, 141, 142, "2" +530, 3, 19, 32, 97, 98, 143, 144, "%" +530, 3, 20, 33, 99, 108, 145, 154, "carteolol" +530, 3, 21, 34, 109, 110, 155, 156, "." +530, 4, 1, 35, 0, 7, 157, 164, "Behrens" +530, 4, 2, 36, 8, 9, 165, 166, "-" +530, 4, 3, 37, 10, 17, 167, 174, "Baumann" +530, 4, 4, 38, 18, 19, 175, 176, "W" +530, 4, 5, 39, 20, 21, 177, 178, "(" +530, 4, 6, 40, 22, 23, 179, 180, "1" +530, 4, 7, 41, 24, 25, 181, 182, ")" +530, 4, 8, 42, 26, 27, 183, 184, "," +530, 4, 9, 43, 28, 35, 185, 192, "Kimmich" +530, 4, 10, 44, 36, 37, 193, 194, "F" +530, 4, 11, 45, 38, 39, 195, 196, "," +530, 4, 12, 46, 40, 44, 197, 201, "Walt" +530, 4, 13, 47, 45, 47, 202, 204, "JG" +530, 4, 14, 48, 48, 49, 205, 206, "," +530, 4, 15, 49, 50, 53, 207, 210, "Lue" +530, 4, 16, 50, 54, 55, 211, 212, "J" +530, 4, 17, 51, 56, 57, 213, 214, "." +530, 5, 1, 52, 0, 6, 215, 221, "Author" +530, 5, 2, 53, 7, 18, 222, 233, "information" +530, 5, 3, 54, 19, 20, 234, 235, ":" +530, 5, 4, 55, 21, 22, 236, 237, "(" +530, 5, 5, 56, 23, 24, 238, 239, "1" +530, 5, 6, 57, 25, 26, 240, 241, ")" +530, 5, 7, 58, 27, 37, 242, 252, "Department" +530, 5, 8, 59, 38, 40, 253, 255, "of" +530, 5, 9, 60, 41, 54, 256, 269, "Ophthalmology" +530, 5, 10, 61, 55, 56, 270, 271, "," +530, 5, 11, 62, 57, 67, 272, 282, "University" +530, 5, 12, 63, 68, 70, 283, 285, "of" +530, 5, 13, 64, 71, 80, 286, 295, "Magdeburg" +530, 5, 14, 65, 81, 82, 296, 297, "," +530, 5, 15, 66, 83, 86, 298, 301, "FRG" +530, 5, 16, 67, 87, 88, 302, 303, "." +530, 6, 1, 68, 0, 2, 304, 306, "In" +530, 6, 2, 69, 3, 4, 307, 308, "a" +530, 6, 3, 70, 5, 6, 309, 310, "3" +530, 6, 4, 71, 7, 8, 311, 312, "-" +530, 6, 5, 72, 9, 14, 313, 318, "month" +530, 6, 6, 73, 15, 16, 319, 320, "," +530, 6, 7, 74, 17, 23, 321, 327, "double" +530, 6, 8, 75, 24, 25, 328, 329, "-" +530, 6, 9, 76, 26, 32, 330, 336, "masked" +530, 6, 10, 77, 33, 34, 337, 338, "," +530, 6, 11, 78, 35, 45, 339, 349, "randomized" +530, 6, 12, 79, 46, 54, 350, 358, "clinical" +530, 6, 13, 80, 55, 60, 359, 364, "trial" +530, 6, 14, 81, 61, 62, 365, 366, "," +530, 6, 15, 82, 63, 66, 367, 370, "the" +530, 6, 16, 83, 67, 73, 371, 377, "ocular" +530, 6, 17, 84, 74, 85, 378, 389, "hypotensive" +530, 6, 18, 85, 86, 94, 390, 398, "efficacy" +530, 6, 19, 86, 95, 98, 399, 402, "and" +530, 6, 20, 87, 99, 107, 403, 411, "systemic" +530, 6, 21, 88, 108, 114, 412, 418, "safety" +530, 6, 22, 89, 115, 117, 419, 421, "of" +530, 6, 23, 90, 118, 119, 422, 423, "0" +530, 6, 24, 91, 120, 121, 424, 425, "." +530, 6, 25, 92, 122, 123, 426, 427, "5" +530, 6, 26, 93, 124, 125, 428, 429, "%" +530, 6, 27, 94, 126, 137, 430, 441, "levobunolol" +530, 6, 28, 95, 138, 141, 442, 445, "and" +530, 6, 29, 96, 142, 143, 446, 447, "2" +530, 6, 30, 97, 144, 145, 448, 449, "%" +530, 6, 31, 98, 146, 155, 450, 459, "carteolol" +530, 6, 32, 99, 156, 160, 460, 464, "were" +530, 6, 33, 100, 161, 169, 465, 473, "compared" +530, 6, 34, 101, 170, 172, 474, 476, "in" +530, 6, 35, 102, 173, 175, 477, 479, "59" +530, 6, 36, 103, 176, 184, 480, 488, "patients" +530, 6, 37, 104, 185, 189, 489, 493, "with" +530, 6, 38, 105, 190, 194, 494, 498, "open" +530, 6, 39, 106, 195, 196, 499, 500, "-" +530, 6, 40, 107, 197, 202, 501, 506, "angle" +530, 6, 41, 108, 203, 211, 507, 515, "glaucoma" +530, 6, 42, 109, 212, 214, 516, 518, "or" +530, 6, 43, 110, 215, 221, 519, 525, "ocular" +530, 6, 44, 111, 222, 234, 526, 538, "hypertension" +530, 6, 45, 112, 235, 236, 539, 540, "." +530, 7, 1, 113, 0, 3, 541, 544, "The" +530, 7, 2, 114, 4, 11, 545, 552, "overall" +530, 7, 3, 115, 12, 16, 553, 557, "mean" +530, 7, 4, 116, 17, 25, 558, 566, "decrease" +530, 7, 5, 117, 26, 28, 567, 569, "in" +530, 7, 6, 118, 29, 40, 570, 581, "intraocular" +530, 7, 7, 119, 41, 49, 582, 590, "pressure" +530, 7, 8, 120, 50, 53, 591, 594, "was" +530, 7, 9, 121, 54, 55, 595, 596, "7" +530, 7, 10, 122, 56, 57, 597, 598, "." +530, 7, 11, 123, 58, 59, 599, 600, "3" +530, 7, 12, 124, 60, 62, 601, 603, "mm" +530, 7, 13, 125, 63, 65, 604, 606, "Hg" +530, 7, 14, 126, 66, 67, 607, 608, "(" +530, 7, 15, 127, 68, 70, 609, 611, "27" +530, 7, 16, 128, 71, 72, 612, 613, "." +530, 7, 17, 129, 73, 74, 614, 615, "4" +530, 7, 18, 130, 75, 76, 616, 617, "%" +530, 7, 19, 131, 77, 78, 618, 619, ")" +530, 7, 20, 132, 79, 81, 620, 622, "in" +530, 7, 21, 133, 82, 85, 623, 626, "the" +530, 7, 22, 134, 86, 87, 627, 628, "0" +530, 7, 23, 135, 88, 89, 629, 630, "." +530, 7, 24, 136, 90, 91, 631, 632, "5" +530, 7, 25, 137, 92, 93, 633, 634, "%" +530, 7, 26, 138, 94, 105, 635, 646, "levobunolol" +530, 7, 27, 139, 106, 111, 647, 652, "group" +530, 7, 28, 140, 112, 115, 653, 656, "and" +530, 7, 29, 141, 116, 117, 657, 658, "4" +530, 7, 30, 142, 118, 119, 659, 660, "." +530, 7, 31, 143, 120, 121, 661, 662, "1" +530, 7, 32, 144, 122, 124, 663, 665, "mm" +530, 7, 33, 145, 125, 127, 666, 668, "Hg" +530, 7, 34, 146, 128, 129, 669, 670, "(" +530, 7, 35, 147, 130, 132, 671, 673, "14" +530, 7, 36, 148, 133, 134, 674, 675, "." +530, 7, 37, 149, 135, 136, 676, 677, "8" +530, 7, 38, 150, 137, 138, 678, 679, "%" +530, 7, 39, 151, 139, 140, 680, 681, ")" +530, 7, 40, 152, 141, 143, 682, 684, "in" +530, 7, 41, 153, 144, 147, 685, 688, "the" +530, 7, 42, 154, 148, 157, 689, 698, "carteolol" +530, 7, 43, 155, 158, 163, 699, 704, "group" +530, 7, 44, 156, 164, 165, 705, 706, "." +530, 8, 1, 157, 0, 4, 707, 711, "This" +530, 8, 2, 158, 5, 15, 712, 722, "difference" +530, 8, 3, 159, 16, 19, 723, 726, "was" +530, 8, 4, 160, 20, 33, 727, 740, "statistically" +530, 8, 5, 161, 34, 45, 741, 752, "significant" +530, 8, 6, 162, 46, 47, 753, 754, "(" +530, 8, 7, 163, 48, 49, 755, 756, "p" +530, 8, 8, 164, 50, 51, 757, 758, "=" +530, 8, 9, 165, 52, 53, 759, 760, "0" +530, 8, 10, 166, 54, 55, 761, 762, "." +530, 8, 11, 167, 56, 60, 763, 767, "0004" +530, 8, 12, 168, 61, 62, 768, 769, ")" +530, 8, 13, 169, 63, 64, 770, 771, "." +530, 9, 1, 170, 0, 7, 772, 779, "Changes" +530, 9, 2, 171, 8, 10, 780, 782, "in" +530, 9, 3, 172, 11, 17, 783, 789, "visual" +530, 9, 4, 173, 18, 23, 790, 795, "field" +530, 9, 5, 174, 24, 27, 796, 799, "and" +530, 9, 6, 175, 28, 31, 800, 803, "cup" +530, 9, 7, 176, 32, 33, 804, 805, "-" +530, 9, 8, 177, 34, 38, 806, 810, "disk" +530, 9, 9, 178, 39, 45, 811, 817, "ratios" +530, 9, 10, 179, 46, 50, 818, 822, "were" +530, 9, 11, 180, 51, 54, 823, 826, "few" +530, 9, 12, 181, 55, 58, 827, 830, "and" +530, 9, 13, 182, 59, 66, 831, 838, "similar" +530, 9, 14, 183, 67, 74, 839, 846, "between" +530, 9, 15, 184, 75, 78, 847, 850, "the" +530, 9, 16, 185, 79, 85, 851, 857, "groups" +530, 9, 17, 186, 86, 87, 858, 859, "." +530, 10, 1, 187, 0, 7, 860, 867, "Effects" +530, 10, 2, 188, 8, 10, 868, 870, "on" +530, 10, 3, 189, 11, 15, 871, 875, "mean" +530, 10, 4, 190, 16, 21, 876, 881, "heart" +530, 10, 5, 191, 22, 26, 882, 886, "rate" +530, 10, 6, 192, 27, 31, 887, 891, "were" +530, 10, 7, 193, 32, 37, 892, 897, "noted" +530, 10, 8, 194, 38, 40, 898, 900, "in" +530, 10, 9, 195, 41, 45, 901, 905, "both" +530, 10, 10, 196, 46, 55, 906, 915, "treatment" +530, 10, 11, 197, 56, 62, 916, 922, "groups" +530, 10, 12, 198, 63, 64, 923, 924, "." +530, 11, 1, 199, 0, 3, 925, 928, "The" +530, 11, 2, 200, 4, 8, 929, 933, "mean" +530, 11, 3, 201, 9, 17, 934, 942, "decrease" +530, 11, 4, 202, 18, 20, 943, 945, "in" +530, 11, 5, 203, 21, 26, 946, 951, "heart" +530, 11, 6, 204, 27, 31, 952, 956, "rate" +530, 11, 7, 205, 32, 34, 957, 959, "in" +530, 11, 8, 206, 35, 38, 960, 963, "the" +530, 11, 9, 207, 39, 48, 964, 973, "carteolol" +530, 11, 10, 208, 49, 54, 974, 979, "group" +530, 11, 11, 209, 55, 58, 980, 983, "was" +530, 11, 12, 210, 59, 66, 984, 991, "greater" +530, 11, 13, 211, 67, 68, 992, 993, "(" +530, 11, 14, 212, 69, 70, 994, 995, "-" +530, 11, 15, 213, 71, 72, 996, 997, "8" +530, 11, 16, 214, 73, 74, 998, 999, "." +530, 11, 17, 215, 75, 76, 1000, 1001, "4" +530, 11, 18, 216, 77, 82, 1002, 1007, "beats" +530, 11, 19, 217, 83, 84, 1008, 1009, "/" +530, 11, 20, 218, 85, 88, 1010, 1013, "min" +530, 11, 21, 219, 89, 90, 1014, 1015, ")" +530, 11, 22, 220, 91, 95, 1016, 1020, "than" +530, 11, 23, 221, 96, 98, 1021, 1023, "in" +530, 11, 24, 222, 99, 102, 1024, 1027, "the" +530, 11, 25, 223, 103, 114, 1028, 1039, "levobunolol" +530, 11, 26, 224, 115, 120, 1040, 1045, "group" +530, 11, 27, 225, 121, 122, 1046, 1047, "(" +530, 11, 28, 226, 123, 124, 1048, 1049, "-" +530, 11, 29, 227, 125, 126, 1050, 1051, "3" +530, 11, 30, 228, 127, 128, 1052, 1053, "." +530, 11, 31, 229, 129, 130, 1054, 1055, "1" +530, 11, 32, 230, 131, 136, 1056, 1061, "beats" +530, 11, 33, 231, 137, 138, 1062, 1063, "/" +530, 11, 34, 232, 139, 142, 1064, 1067, "min" +530, 11, 35, 233, 143, 144, 1068, 1069, ")" +530, 11, 36, 234, 145, 146, 1070, 1071, "." +530, 12, 1, 235, 0, 4, 1072, 1076, "This" +530, 12, 2, 236, 5, 15, 1077, 1087, "difference" +530, 12, 3, 237, 16, 19, 1088, 1091, "had" +530, 12, 4, 238, 20, 28, 1092, 1100, "marginal" +530, 12, 5, 239, 29, 40, 1101, 1112, "statistical" +530, 12, 6, 240, 41, 53, 1113, 1125, "significance" +530, 12, 7, 241, 54, 55, 1126, 1127, "(" +530, 12, 8, 242, 56, 57, 1128, 1129, "p" +530, 12, 9, 243, 58, 59, 1130, 1131, "=" +530, 12, 10, 244, 60, 61, 1132, 1133, "0" +530, 12, 11, 245, 62, 63, 1134, 1135, "." +530, 12, 12, 246, 64, 67, 1136, 1139, "059" +530, 12, 13, 247, 68, 69, 1140, 1141, ")" +530, 12, 14, 248, 70, 71, 1142, 1143, "." +530, 13, 1, 249, 0, 2, 1144, 1146, "We" +530, 13, 2, 250, 3, 11, 1147, 1155, "conclude" +530, 13, 3, 251, 12, 16, 1156, 1160, "that" +530, 13, 4, 252, 17, 18, 1161, 1162, "0" +530, 13, 5, 253, 19, 20, 1163, 1164, "." +530, 13, 6, 254, 21, 22, 1165, 1166, "5" +530, 13, 7, 255, 23, 24, 1167, 1168, "%" +530, 13, 8, 256, 25, 36, 1169, 1180, "levobunolol" +530, 13, 9, 257, 37, 40, 1181, 1184, "and" +530, 13, 10, 258, 41, 42, 1185, 1186, "2" +530, 13, 11, 259, 43, 44, 1187, 1188, "%" +530, 13, 12, 260, 45, 54, 1189, 1198, "carteolol" +530, 13, 13, 261, 55, 67, 1199, 1211, "administered" +530, 13, 14, 262, 68, 73, 1212, 1217, "twice" +530, 13, 15, 263, 74, 79, 1218, 1223, "daily" +530, 13, 16, 264, 80, 86, 1224, 1230, "differ" +530, 13, 17, 265, 87, 89, 1231, 1233, "in" +530, 13, 18, 266, 90, 98, 1234, 1242, "lowering" +530, 13, 19, 267, 99, 110, 1243, 1254, "intraocular" +530, 13, 20, 268, 111, 119, 1255, 1263, "pressure" +530, 13, 21, 269, 120, 122, 1264, 1266, "as" +530, 13, 22, 270, 123, 127, 1267, 1271, "well" +530, 13, 23, 271, 128, 130, 1272, 1274, "as" +530, 13, 24, 272, 131, 133, 1275, 1277, "in" +530, 13, 25, 273, 134, 139, 1278, 1283, "their" +530, 13, 26, 274, 140, 147, 1284, 1291, "effects" +530, 13, 27, 275, 148, 150, 1292, 1294, "on" +530, 13, 28, 276, 151, 156, 1295, 1300, "heart" +530, 13, 29, 277, 157, 161, 1301, 1305, "rate" +530, 13, 30, 278, 162, 163, 1306, 1307, "." +530, 14, 1, 279, 0, 3, 1308, 1311, "DOI" +530, 14, 2, 280, 4, 5, 1312, 1313, ":" +530, 14, 3, 281, 6, 8, 1314, 1316, "10" +530, 14, 4, 282, 9, 10, 1317, 1318, "." +530, 14, 5, 283, 11, 15, 1319, 1323, "1159" +530, 14, 6, 284, 16, 17, 1324, 1325, "/" +530, 14, 7, 285, 18, 27, 1326, 1335, "000310446" +530, 14, 8, 286, 28, 32, 1336, 1340, "PMID" +530, 14, 9, 287, 33, 34, 1341, 1342, ":" +530, 14, 10, 288, 35, 42, 1343, 1350, "8145982" +530, 14, 11, 289, 43, 44, 1351, 1352, "[" +530, 14, 12, 290, 45, 52, 1353, 1360, "Indexed" +530, 14, 13, 291, 53, 56, 1361, 1364, "for" +530, 14, 14, 292, 57, 64, 1365, 1372, "MEDLINE" +530, 14, 15, 293, 65, 66, 1373, 1374, "]" diff --git a/data/gl 8145982_jshahinitiran.annodb b/data/gl 8145982_jshahinitiran.annodb new file mode 100644 index 0000000..41c84f4 --- /dev/null +++ b/data/gl 8145982_jshahinitiran.annodb @@ -0,0 +1,57 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +89113, Journal, 0, 15, "Ophthalmologica", "", +89114, PublicationYear, 18, 22, "1994", "", +89115, Title, 46, 156, "A comparison of the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol .", "", +89116, DoseValue, 117, 122, "0 . 5", "", +89118, Levobunolol, 125, 136, "levobunolol", "", +89117, DoseValue, 141, 142, "2", "", +89119, Carteolol, 145, 154, "carteolol", "", +89120, Author, 157, 176, "Behrens - Baumann W", "", +89121, Author, 185, 194, "Kimmich F", "", +89122, Author, 197, 204, "Walt JG", "", +89123, Author, 207, 210, "Lue", "", +89135, ObjectiveDescription, 304, 540, "In a 3 - month , double - masked , randomized clinical trial , the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol were compared in 59 patients with open - angle glaucoma or ocular hypertension .", "", +89124, Duration, 309, 318, "3 - month", "", +89125, DoubleBlind, 321, 336, "double - masked", "", +89126, Randomized, 339, 349, "randomized", "", +89128, DoseValue, 422, 427, "0 . 5", "", +89127, Levobunolol, 430, 441, "levobunolol", "", +89129, DoseValue, 446, 447, "2", "", +89130, Carteolol, 450, 459, "carteolol", "", +89131, NumberPatientsCT, 477, 479, "59", "", +89132, OpenAngleGlaucoma, 494, 515, "open - angle glaucoma", "", +89133, OcularHypertension, 519, 538, "ocular hypertension", "", +89134, Mean, 553, 557, "mean", "", +89136, IOP, 570, 590, "intraocular pressure", "", +89137, Reduction, 595, 600, "7 . 3", "", +89139, mmHg, 601, 606, "mm Hg", "", +89141, RelativeReduction, 609, 615, "27 . 4", "", +89143, DoseValue, 627, 632, "0 . 5", "", +89144, Levobunolol, 635, 646, "levobunolol", "", +89138, Reduction, 657, 662, "4 . 1", "", +89140, mmHg, 663, 668, "mm Hg", "", +89142, RelativeReduction, 671, 677, "14 . 8", "", +89145, Carteolol, 689, 698, "carteolol", "", +89146, PvalueDiff, 755, 767, "p = 0 . 0004", "", +89147, ObservedResult, 772, 859, "Changes in visual field and cup - disk ratios were few and similar between the groups .", "", +89150, ObservedResult, 860, 924, "Effects on mean heart rate were noted in both treatment groups .", "", +89148, Mean, 871, 875, "mean", "", +89149, HeartRate, 876, 886, "heart rate", "", +89151, Mean, 929, 933, "mean", "", +89152, HeartRate, 946, 956, "heart rate", "", +89153, Carteolol, 964, 973, "carteolol", "", +89154, Reduction, 996, 1001, "8 . 4", "", +89155, BioAndMedicalUnit, 1002, 1013, "beats / min", "", +89158, Levobunolol, 1028, 1039, "levobunolol", "", +89157, Reduction, 1050, 1055, "3 . 1", "", +89156, BioAndMedicalUnit, 1056, 1067, "beats / min", "", +89159, PvalueDiff, 1128, 1139, "p = 0 . 059", "", +89160, ConclusionComment, 1144, 1307, "We conclude that 0 . 5 % levobunolol and 2 % carteolol administered twice daily differ in lowering intraocular pressure as well as in their effects on heart rate .", "", +89161, DoseValue, 1161, 1166, "0 . 5", "", +89162, Levobunolol, 1169, 1180, "levobunolol", "", +89163, DoseValue, 1185, 1186, "2", "", +89164, Carteolol, 1189, 1198, "carteolol", "", +89165, Frequency, 1212, 1223, "twice daily", "", +89166, IOP, 1243, 1263, "intraocular pressure", "", +89167, HeartRate, 1295, 1305, "heart rate", "", +89168, PMID, 1343, 1350, "8145982", "", diff --git a/data/gl 8145982_jshahinitiran.n-triples b/data/gl 8145982_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8145982_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8145982_tstrakeljahn.annodb b/data/gl 8145982_tstrakeljahn.annodb new file mode 100644 index 0000000..845aab1 --- /dev/null +++ b/data/gl 8145982_tstrakeljahn.annodb @@ -0,0 +1,64 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88653, Journal, 0, 15, "Ophthalmologica", "", +88654, PublicationYear, 18, 22, "1994", "", +88661, Title, 46, 156, "A comparison of the ocular hypotensive efficacy and systemic safety of 0 . 5 % levobunolol and 2 % carteolol .", "", +88655, DoseValue, 117, 122, "0 . 5", "", +88657, Percentage, 123, 124, "%", "", +88659, Levobunolol, 125, 136, "levobunolol", "", +88656, DoseValue, 141, 142, "2", "", +88658, Percentage, 143, 144, "%", "", +88660, Carteolol, 145, 154, "carteolol", "", +88665, Author, 157, 176, "Behrens - Baumann W", "", +88667, Author, 185, 194, "Kimmich F", "", +88668, Author, 197, 204, "Walt JG", "", +88669, Author, 207, 212, "Lue J", "", +88662, Germany, 298, 301, "FRG", "Federal Republic of Germany", +88670, Duration, 309, 318, "3 - month", "", +88672, DoubleBlind, 321, 336, "double - masked", "", +88675, Randomized, 339, 349, "randomized", "", +88677, ClinicalTrial, 350, 364, "clinical trial", "", +88680, DoseValue, 422, 427, "0 . 5", "", +88683, Percentage, 428, 429, "%", "", +88687, Levobunolol, 430, 441, "levobunolol", "", +88682, DoseValue, 446, 447, "2", "", +88684, Percentage, 448, 449, "%", "", +88685, Carteolol, 450, 459, "carteolol", "", +88691, NumberPatientsCT, 477, 479, "59", "", +88695, OpenAngleGlaucoma, 494, 515, "open - angle glaucoma", "", +88698, OcularHypertension, 519, 538, "ocular hypertension", "", +88708, Mean, 553, 557, "mean", "", +88711, IOP, 570, 590, "intraocular pressure", "", +88714, Reduction, 595, 600, "7 . 3", "", +88728, mmHg, 601, 606, "mm Hg", "", +88720, RelativeReduction, 609, 615, "27 . 4", "", +88735, DoseValue, 627, 632, "0 . 5", "", +88737, Percentage, 633, 634, "%", "", +88738, Levobunolol, 635, 646, "levobunolol", "", +88716, Reduction, 657, 662, "4 . 1", "", +88731, mmHg, 663, 668, "mm Hg", "", +88724, RelativeReduction, 671, 677, "14 . 8", "", +88739, Carteolol, 689, 698, "carteolol", "", +88740, PvalueDiff, 757, 767, "= 0 . 0004", "", +88741, ObservedResult, 772, 859, "Changes in visual field and cup - disk ratios were few and similar between the groups .", "", +88745, ObservedResult, 860, 924, "Effects on mean heart rate were noted in both treatment groups .", "", +88743, Mean, 871, 875, "mean", "", +88744, HeartRate, 876, 886, "heart rate", "", +88746, Mean, 929, 933, "mean", "", +88747, HeartRate, 946, 956, "heart rate", "", +88748, Carteolol, 964, 973, "carteolol", "", +88755, Reduction, 996, 1001, "8 . 4", "", +88752, Minute, 1010, 1013, "min", "", +88757, Reduction, 1050, 1055, "3 . 1", "", +88753, Minute, 1064, 1067, "min", "", +88760, PvalueDiff, 1130, 1139, "= 0 . 059", "", +88782, ConclusionComment, 1144, 1307, "We conclude that 0 . 5 % levobunolol and 2 % carteolol administered twice daily differ in lowering intraocular pressure as well as in their effects on heart rate .", "", +88766, DoseValue, 1161, 1166, "0 . 5", "", +88780, Percentage, 1167, 1168, "%", "", +88775, Levobunolol, 1169, 1180, "levobunolol", "", +88769, DoseValue, 1185, 1186, "2", "", +88781, Percentage, 1187, 1188, "%", "", +88771, Carteolol, 1189, 1198, "carteolol", "", +88773, Frequency, 1212, 1223, "twice daily", "", +88778, IOP, 1243, 1263, "intraocular pressure", "", +88779, HeartRate, 1295, 1305, "heart rate", "", +88784, PMID, 1343, 1350, "8145982", "", diff --git a/data/gl 8145982_tstrakeljahn.n-triples b/data/gl 8145982_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8145982_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628543_admin.annodb b/data/gl 8628543_admin.annodb new file mode 100644 index 0000000..4e230b4 --- /dev/null +++ b/data/gl 8628543_admin.annodb @@ -0,0 +1,90 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "1996", "", " \"1996\"." +24, Title, 50, 186, "A six - month , randomized , double - masked study comparing latanoprost with timolol in open - angle glaucoma and ocular hypertension .", "", " \"A six - month , randomized , double - masked study comparing latanoprost with timolol in open - angle glaucoma and ocular hypertension .\"." +106379, Duration, 52, 63, "six - month", "", " \"six - month\"." +3, Randomized, 66, 76, "randomized", "", " ." +4, DoubleBlind, 79, 94, "double - masked", "", " ." +5, Latanoprost, 111, 122, "latanoprost", "", +6, Timolol, 128, 135, "timolol", "", +7, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", " ." +8, OcularHypertension, 165, 184, "ocular hypertension", "", " ." +79, Latanoprost, 191, 202, "Latanoprost", "", +106377, Author, 217, 225, "Watson P", "", " \"Watson P\"." +10, Author, 234, 249, "Stjernschantz J", "", " \"Stjernschantz J\"." +106378, UK, 318, 325, "England", "", " ." +25, ObjectiveDescription, 338, 575, "To compare the intraocular pressure ( IOP ) - reducing effect and side effects of 0 . 005 % latanoprost administered once daily with 0 . 5 % timolol administered twice daily in patients with open - angle glaucoma or ocular hypertension .", "", " \"To compare the intraocular pressure ( IOP ) - reducing effect and side effects of 0 . 005 % latanoprost administered once daily with 0 . 5 % timolol administered twice daily in patients with open - angle glaucoma or ocular hypertension .\"." +12, IOP, 353, 373, "intraocular pressure", "", +13, IOP, 376, 379, "IOP", "", +14, DoseValue, 420, 427, "0 . 005", "", +20, Percentage, 428, 429, "%", "", +22, Latanoprost, 430, 441, "latanoprost", "", " . ." +23, Frequency, 455, 465, "once daily", "", +15, DoseValue, 471, 476, "0 . 5", "", +21, Percentage, 477, 478, "%", "", +16, Timolol, 479, 486, "timolol", "", +17, Frequency, 500, 511, "twice daily", "", +54362, Precondition, 515, 573, "patients with open - angle glaucoma or ocular hypertension", "", " \"patients with open - angle glaucoma or ocular hypertension\"." +18, OpenAngleGlaucoma, 529, 550, "open - angle glaucoma", "", +19, OcularHypertension, 554, 573, "ocular hypertension", "", +26, Randomized, 597, 607, "randomized", "", +27, DoubleBlind, 610, 625, "double - masked", "", +28, Parallel, 641, 649, "parallel", "", " ." +29, Duration, 683, 691, "6 months", "", +34, ObjectiveDescription, 694, 852, "The primary objective of the study is to compare the IOP - reducing effect of lantanoprost with that of timolol at the end of the 6 - month treatment period .", "", " \"The primary objective of the study is to compare the IOP - reducing effect of lantanoprost with that of timolol at the end of the 6 - month treatment period .\"." +30, IOP, 747, 750, "IOP", "", +31, Latanoprost, 772, 784, "lantanoprost", "", +32, Timolol, 798, 805, "timolol", "", +33, Duration, 824, 833, "6 - month", "", +35, NumberPatientsCT, 864, 867, "294", "", " \"294\"." +36, NumberPatientsArm, 893, 896, "149", "", " \"149\"." +38, Latanoprost, 909, 920, "latanoprost", "", +37, NumberPatientsArm, 931, 934, "145", "", " \"145\"." +39, Timolol, 943, 950, "timolol", "", +40, Latanoprost, 959, 970, "Latanoprost", "", +54045, Evening, 995, 1002, "evening", "", +41, Diurnal_IOP, 1015, 1026, "Diurnal IOP", "", " ." +42, TimePoint, 1029, 1038, "9 : 00 am", "", +43, TimePoint, 1041, 1050, "1 : 00 pm", "", +44, TimePoint, 1053, 1062, "5 : 00 pm", "", +45, BaseLineValue, 1082, 1088, "25 . 2", "", " \"25 . 2\"." +46, ResultMeasuredValue, 1092, 1098, "16 . 7", "", " \"16 . 7\"." +47, mmHg, 1099, 1103, "mmHg", "", " ." +48, RelativeReduction, 1106, 1112, "33 . 7", "", " \"33 . 7\"." +49, Latanoprost, 1122, 1134, "lantanoprost", "", +50, BaseLineValue, 1144, 1150, "25 . 4", "", " \"25 . 4\"." +51, ResultMeasuredValue, 1154, 1160, "17 . 1", "", " \"17 . 1\"." +52, mmHg, 1161, 1165, "mmHg", "", +53, RelativeReduction, 1168, 1174, "32 . 7", "", " \"32 . 7\"." +54, Timolol, 1184, 1191, "timolol", "", +55, Duration, 1224, 1233, "6 - month", "", +57, ObservedResult, 1253, 1331, "No upward drift in IOP occurred with either drug during the treatment period .", "", +56, IOP, 1272, 1275, "IOP", "", +58, Latanoprost, 1332, 1343, "Latanoprost", "", +60, ObservedResult, 1332, 1451, "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions .", "", " \"Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions .\". \"Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions .\"." +136, ConjunctivalHyperemia, 1367, 1389, "conjunctival hyperemia", "", " ." +59, Timolol, 1395, 1402, "timolol", "", +106371, Corneal_PPE, 1412, 1449, "corneal punctuate epithelial erosions", "", " ." +61, ObservedResult, 1462, 1504, "both drugs were generally well tolerated .", "", +62, Latanoprost, 1541, 1552, "latanoprost", "", +140, IrisPigmentation, 1567, 1591, "pigmentation of the iris", "", " . ." +63, NumberAffected, 1614, 1616, "15", "", " \"15\"." +64, PercentageAffected, 1628, 1634, "10 . 1", "", " \"10 . 1\"." +65, Timolol, 1641, 1648, "Timolol", "", +66, Latanoprost, 1688, 1699, "latanoprost", "", +145, ConclusionComment, 1716, 1851, "Latanoprost 0 . 005 % administered once daily in the evening reduced IOP at least as well as timolol 0 . 5 % administered twice daily .", "", " \"Latanoprost 0 . 005 % administered once daily in the evening reduced IOP at least as well as timolol 0 . 5 % administered twice daily .\"." +67, Latanoprost, 1716, 1727, "Latanoprost", "", +68, DoseValue, 1728, 1735, "0 . 005", "", " \"0 . 005\"." +70, Percentage, 1736, 1737, "%", "", " ." +72, Frequency, 1751, 1761, "once daily", "", " \"once daily\"." +54048, Evening, 1769, 1776, "evening", "", " ." +154, IOP, 1785, 1788, "IOP", "", +75, Timolol, 1809, 1816, "timolol", "", " ." +69, DoseValue, 1817, 1822, "0 . 5", "", " \"0 . 5\"." +71, Percentage, 1823, 1824, "%", "", " ." +73, Frequency, 1838, 1849, "twice daily", "", " \"twice daily\"." +146, ConclusionComment, 1852, 1922, "Latanoprost was generally well tolerated systemically and in the eye .", "", " \"Latanoprost was generally well tolerated systemically and in the eye .\"." +76, Latanoprost, 1852, 1863, "Latanoprost", "", +147, ConclusionComment, 1923, 2083, "However , the drug has an unusual side effect of increasing the pigmentation of the iris , particularly in individuals with green - brown or blue - brown eyes .", "", " \"However , the drug has an unusual side effect of increasing the pigmentation of the iris , particularly in individuals with green - brown or blue - brown eyes .\"." +160, IrisPigmentation, 1987, 2011, "pigmentation of the iris", "", +80, PMID, 2091, 2098, "8628543", "", " \"8628543\"." diff --git a/data/gl 8628543_admin.n-triples b/data/gl 8628543_admin.n-triples new file mode 100644 index 0000000..e476cae --- /dev/null +++ b/data/gl 8628543_admin.n-triples @@ -0,0 +1,134 @@ +# RDF export of group: Publication + . + "Publication" . + "A six - month , randomized , double - masked study comparing latanoprost with timolol in open - angle glaucoma and ocular hypertension ." . + "Watson P" . + "1996" . + "Ophthalmology" . + "8628543" . + . + "Stjernschantz J" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "To compare the intraocular pressure ( IOP ) - reducing effect and side effects of 0 . 005 % latanoprost administered once daily with 0 . 5 % timolol administered twice daily in patients with open - angle glaucoma or ocular hypertension ." . + "294" . + "six - month" . + . + . + . + "Latanoprost 0 . 005 % administered once daily in the evening reduced IOP at least as well as timolol 0 . 5 % administered twice daily ." . + . + . + . + . + . + "The primary objective of the study is to compare the IOP - reducing effect of lantanoprost with that of timolol at the end of the 6 - month treatment period ." . + . + . + "Latanoprost was generally well tolerated systemically and in the eye ." . + "However , the drug has an unusual side effect of increasing the pigmentation of the iris , particularly in individuals with green - brown or blue - brown eyes ." . + . + . +# RDF export of group: Population + . + "Population" . + "patients with open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + "AE_CH" . + . + . + . + . + . + "AE_P" . + . + . + . + . + . + . + "corneal_ppe" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_Lat" . + "149" . + . + . + . + . + . + . + "Arm_Tim" . + "145" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_Lat" . + . + "once daily" . + . + . + "Intervention_Tim" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_Lat" . + "0 . 005" . + . + . + . + . + . + "Medication_Tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_IOP_Lat" . + . + "25 . 2" . + "16 . 7" . + "33 . 7" . + . + "Outcome_IOP_Tim" . + . + "25 . 4" . + "17 . 1" . + "32 . 7" . + . + "Outcome_CH" . + . + "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions ." . + . + "Outcome_P_Lat" . + . + "15" . + "10 . 1" . + . + "Outcome_Corneal_ppe" . + . + "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions ." . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628543_export.csv b/data/gl 8628543_export.csv new file mode 100644 index 0000000..16505e1 --- /dev/null +++ b/data/gl 8628543_export.csv @@ -0,0 +1,417 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +405, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +405, 1, 2, 2, 14, 15, 14, 15, "." +405, 2, 1, 3, 0, 4, 16, 20, "1996" +405, 2, 2, 4, 5, 8, 21, 24, "Jan" +405, 2, 3, 5, 9, 10, 25, 26, ";" +405, 2, 4, 6, 11, 14, 27, 30, "103" +405, 2, 5, 7, 15, 16, 31, 32, "(" +405, 2, 6, 8, 17, 18, 33, 34, "1" +405, 2, 7, 9, 19, 20, 35, 36, ")" +405, 2, 8, 10, 21, 22, 37, 38, ":" +405, 2, 9, 11, 23, 26, 39, 42, "126" +405, 2, 10, 12, 27, 28, 43, 44, "-" +405, 2, 11, 13, 29, 31, 45, 47, "37" +405, 2, 12, 14, 32, 33, 48, 49, "." +405, 3, 1, 15, 0, 1, 50, 51, "A" +405, 3, 2, 16, 2, 5, 52, 55, "six" +405, 3, 3, 17, 6, 7, 56, 57, "-" +405, 3, 4, 18, 8, 13, 58, 63, "month" +405, 3, 5, 19, 14, 15, 64, 65, "," +405, 3, 6, 20, 16, 26, 66, 76, "randomized" +405, 3, 7, 21, 27, 28, 77, 78, "," +405, 3, 8, 22, 29, 35, 79, 85, "double" +405, 3, 9, 23, 36, 37, 86, 87, "-" +405, 3, 10, 24, 38, 44, 88, 94, "masked" +405, 3, 11, 25, 45, 50, 95, 100, "study" +405, 3, 12, 26, 51, 60, 101, 110, "comparing" +405, 3, 13, 27, 61, 72, 111, 122, "latanoprost" +405, 3, 14, 28, 73, 77, 123, 127, "with" +405, 3, 15, 29, 78, 85, 128, 135, "timolol" +405, 3, 16, 30, 86, 88, 136, 138, "in" +405, 3, 17, 31, 89, 93, 139, 143, "open" +405, 3, 18, 32, 94, 95, 144, 145, "-" +405, 3, 19, 33, 96, 101, 146, 151, "angle" +405, 3, 20, 34, 102, 110, 152, 160, "glaucoma" +405, 3, 21, 35, 111, 114, 161, 164, "and" +405, 3, 22, 36, 115, 121, 165, 171, "ocular" +405, 3, 23, 37, 122, 134, 172, 184, "hypertension" +405, 3, 24, 38, 135, 136, 185, 186, "." +405, 4, 1, 39, 0, 3, 187, 190, "The" +405, 4, 2, 40, 4, 15, 191, 202, "Latanoprost" +405, 4, 3, 41, 16, 21, 203, 208, "Study" +405, 4, 4, 42, 22, 27, 209, 214, "Group" +405, 4, 5, 43, 28, 29, 215, 216, "." +405, 5, 1, 44, 0, 6, 217, 223, "Watson" +405, 5, 2, 45, 7, 8, 224, 225, "P" +405, 5, 3, 46, 9, 10, 226, 227, "(" +405, 5, 4, 47, 11, 12, 228, 229, "1" +405, 5, 5, 48, 13, 14, 230, 231, ")" +405, 5, 6, 49, 15, 16, 232, 233, "," +405, 5, 7, 50, 17, 30, 234, 247, "Stjernschantz" +405, 5, 8, 51, 31, 32, 248, 249, "J" +405, 5, 9, 52, 33, 34, 250, 251, "." +405, 6, 1, 53, 0, 6, 252, 258, "Author" +405, 6, 2, 54, 7, 18, 259, 270, "information" +405, 6, 3, 55, 19, 20, 271, 272, ":" +405, 6, 4, 56, 21, 22, 273, 274, "(" +405, 6, 5, 57, 23, 24, 275, 276, "1" +405, 6, 6, 58, 25, 26, 277, 278, ")" +405, 6, 7, 59, 27, 38, 279, 290, "Addenbrooke" +405, 6, 8, 60, 39, 40, 291, 292, "'" +405, 6, 9, 61, 41, 42, 293, 294, "s" +405, 6, 10, 62, 43, 51, 295, 303, "Hospital" +405, 6, 11, 63, 52, 53, 304, 305, "," +405, 6, 12, 64, 54, 63, 306, 315, "Cambridge" +405, 6, 13, 65, 64, 65, 316, 317, "," +405, 6, 14, 66, 66, 73, 318, 325, "England" +405, 6, 15, 67, 74, 75, 326, 327, "." +405, 7, 1, 68, 0, 7, 328, 335, "PURPOSE" +405, 7, 2, 69, 8, 9, 336, 337, ":" +405, 7, 3, 70, 10, 12, 338, 340, "To" +405, 7, 4, 71, 13, 20, 341, 348, "compare" +405, 7, 5, 72, 21, 24, 349, 352, "the" +405, 7, 6, 73, 25, 36, 353, 364, "intraocular" +405, 7, 7, 74, 37, 45, 365, 373, "pressure" +405, 7, 8, 75, 46, 47, 374, 375, "(" +405, 7, 9, 76, 48, 51, 376, 379, "IOP" +405, 7, 10, 77, 52, 53, 380, 381, ")" +405, 7, 11, 78, 54, 55, 382, 383, "-" +405, 7, 12, 79, 56, 64, 384, 392, "reducing" +405, 7, 13, 80, 65, 71, 393, 399, "effect" +405, 7, 14, 81, 72, 75, 400, 403, "and" +405, 7, 15, 82, 76, 80, 404, 408, "side" +405, 7, 16, 83, 81, 88, 409, 416, "effects" +405, 7, 17, 84, 89, 91, 417, 419, "of" +405, 7, 18, 85, 92, 93, 420, 421, "0" +405, 7, 19, 86, 94, 95, 422, 423, "." +405, 7, 20, 87, 96, 99, 424, 427, "005" +405, 7, 21, 88, 100, 101, 428, 429, "%" +405, 7, 22, 89, 102, 113, 430, 441, "latanoprost" +405, 7, 23, 90, 114, 126, 442, 454, "administered" +405, 7, 24, 91, 127, 131, 455, 459, "once" +405, 7, 25, 92, 132, 137, 460, 465, "daily" +405, 7, 26, 93, 138, 142, 466, 470, "with" +405, 7, 27, 94, 143, 144, 471, 472, "0" +405, 7, 28, 95, 145, 146, 473, 474, "." +405, 7, 29, 96, 147, 148, 475, 476, "5" +405, 7, 30, 97, 149, 150, 477, 478, "%" +405, 7, 31, 98, 151, 158, 479, 486, "timolol" +405, 7, 32, 99, 159, 171, 487, 499, "administered" +405, 7, 33, 100, 172, 177, 500, 505, "twice" +405, 7, 34, 101, 178, 183, 506, 511, "daily" +405, 7, 35, 102, 184, 186, 512, 514, "in" +405, 7, 36, 103, 187, 195, 515, 523, "patients" +405, 7, 37, 104, 196, 200, 524, 528, "with" +405, 7, 38, 105, 201, 205, 529, 533, "open" +405, 7, 39, 106, 206, 207, 534, 535, "-" +405, 7, 40, 107, 208, 213, 536, 541, "angle" +405, 7, 41, 108, 214, 222, 542, 550, "glaucoma" +405, 7, 42, 109, 223, 225, 551, 553, "or" +405, 7, 43, 110, 226, 232, 554, 560, "ocular" +405, 7, 44, 111, 233, 245, 561, 573, "hypertension" +405, 7, 45, 112, 246, 247, 574, 575, "." +405, 8, 1, 113, 0, 7, 576, 583, "METHODS" +405, 8, 2, 114, 8, 9, 584, 585, ":" +405, 8, 3, 115, 10, 14, 586, 590, "This" +405, 8, 4, 116, 15, 18, 591, 594, "was" +405, 8, 5, 117, 19, 20, 595, 596, "a" +405, 8, 6, 118, 21, 31, 597, 607, "randomized" +405, 8, 7, 119, 32, 33, 608, 609, "," +405, 8, 8, 120, 34, 40, 610, 616, "double" +405, 8, 9, 121, 41, 42, 617, 618, "-" +405, 8, 10, 122, 43, 49, 619, 625, "masked" +405, 8, 11, 123, 50, 55, 626, 631, "study" +405, 8, 12, 124, 56, 60, 632, 636, "with" +405, 8, 13, 125, 61, 64, 637, 640, "two" +405, 8, 14, 126, 65, 73, 641, 649, "parallel" +405, 8, 15, 127, 74, 80, 650, 656, "groups" +405, 8, 16, 128, 81, 84, 657, 660, "and" +405, 8, 17, 129, 85, 86, 661, 662, "a" +405, 8, 18, 130, 87, 96, 663, 672, "treatment" +405, 8, 19, 131, 97, 103, 673, 679, "period" +405, 8, 20, 132, 104, 106, 680, 682, "of" +405, 8, 21, 133, 107, 108, 683, 684, "6" +405, 8, 22, 134, 109, 115, 685, 691, "months" +405, 8, 23, 135, 116, 117, 692, 693, "." +405, 9, 1, 136, 0, 3, 694, 697, "The" +405, 9, 2, 137, 4, 11, 698, 705, "primary" +405, 9, 3, 138, 12, 21, 706, 715, "objective" +405, 9, 4, 139, 22, 24, 716, 718, "of" +405, 9, 5, 140, 25, 28, 719, 722, "the" +405, 9, 6, 141, 29, 34, 723, 728, "study" +405, 9, 7, 142, 35, 37, 729, 731, "is" +405, 9, 8, 143, 38, 40, 732, 734, "to" +405, 9, 9, 144, 41, 48, 735, 742, "compare" +405, 9, 10, 145, 49, 52, 743, 746, "the" +405, 9, 11, 146, 53, 56, 747, 750, "IOP" +405, 9, 12, 147, 57, 58, 751, 752, "-" +405, 9, 13, 148, 59, 67, 753, 761, "reducing" +405, 9, 14, 149, 68, 74, 762, 768, "effect" +405, 9, 15, 150, 75, 77, 769, 771, "of" +405, 9, 16, 151, 78, 90, 772, 784, "lantanoprost" +405, 9, 17, 152, 91, 95, 785, 789, "with" +405, 9, 18, 153, 96, 100, 790, 794, "that" +405, 9, 19, 154, 101, 103, 795, 797, "of" +405, 9, 20, 155, 104, 111, 798, 805, "timolol" +405, 9, 21, 156, 112, 114, 806, 808, "at" +405, 9, 22, 157, 115, 118, 809, 812, "the" +405, 9, 23, 158, 119, 122, 813, 816, "end" +405, 9, 24, 159, 123, 125, 817, 819, "of" +405, 9, 25, 160, 126, 129, 820, 823, "the" +405, 9, 26, 161, 130, 131, 824, 825, "6" +405, 9, 27, 162, 132, 133, 826, 827, "-" +405, 9, 28, 163, 134, 139, 828, 833, "month" +405, 9, 29, 164, 140, 149, 834, 843, "treatment" +405, 9, 30, 165, 150, 156, 844, 850, "period" +405, 9, 31, 166, 157, 158, 851, 852, "." +405, 10, 1, 167, 0, 1, 853, 854, "A" +405, 10, 2, 168, 2, 7, 855, 860, "total" +405, 10, 3, 169, 8, 10, 861, 863, "of" +405, 10, 4, 170, 11, 14, 864, 867, "294" +405, 10, 5, 171, 15, 23, 868, 876, "patients" +405, 10, 6, 172, 24, 28, 877, 881, "were" +405, 10, 7, 173, 29, 37, 882, 890, "included" +405, 10, 8, 174, 38, 39, 891, 892, ":" +405, 10, 9, 175, 40, 43, 893, 896, "149" +405, 10, 10, 176, 44, 48, 897, 901, "were" +405, 10, 11, 177, 49, 51, 902, 904, "in" +405, 10, 12, 178, 52, 55, 905, 908, "the" +405, 10, 13, 179, 56, 67, 909, 920, "latanoprost" +405, 10, 14, 180, 68, 73, 921, 926, "group" +405, 10, 15, 181, 74, 77, 927, 930, "and" +405, 10, 16, 182, 78, 81, 931, 934, "145" +405, 10, 17, 183, 82, 86, 935, 939, "were" +405, 10, 18, 184, 87, 89, 940, 942, "in" +405, 10, 19, 185, 90, 97, 943, 950, "timolol" +405, 10, 20, 186, 98, 103, 951, 956, "group" +405, 10, 21, 187, 104, 105, 957, 958, "." +405, 11, 1, 188, 0, 11, 959, 970, "Latanoprost" +405, 11, 2, 189, 12, 15, 971, 974, "was" +405, 11, 3, 190, 16, 28, 975, 987, "administered" +405, 11, 4, 191, 29, 31, 988, 990, "in" +405, 11, 5, 192, 32, 35, 991, 994, "the" +405, 11, 6, 193, 36, 43, 995, 1002, "evening" +405, 11, 7, 194, 44, 45, 1003, 1004, "." +405, 12, 1, 195, 0, 7, 1005, 1012, "RESULTS" +405, 12, 2, 196, 8, 9, 1013, 1014, ":" +405, 12, 3, 197, 10, 17, 1015, 1022, "Diurnal" +405, 12, 4, 198, 18, 21, 1023, 1026, "IOP" +405, 12, 5, 199, 22, 23, 1027, 1028, "(" +405, 12, 6, 200, 24, 25, 1029, 1030, "9" +405, 12, 7, 201, 26, 27, 1031, 1032, ":" +405, 12, 8, 202, 28, 30, 1033, 1035, "00" +405, 12, 9, 203, 31, 33, 1036, 1038, "am" +405, 12, 10, 204, 34, 35, 1039, 1040, "," +405, 12, 11, 205, 36, 37, 1041, 1042, "1" +405, 12, 12, 206, 38, 39, 1043, 1044, ":" +405, 12, 13, 207, 40, 42, 1045, 1047, "00" +405, 12, 14, 208, 43, 45, 1048, 1050, "pm" +405, 12, 15, 209, 46, 47, 1051, 1052, "," +405, 12, 16, 210, 48, 49, 1053, 1054, "5" +405, 12, 17, 211, 50, 51, 1055, 1056, ":" +405, 12, 18, 212, 52, 54, 1057, 1059, "00" +405, 12, 19, 213, 55, 57, 1060, 1062, "pm" +405, 12, 20, 214, 58, 59, 1063, 1064, ")" +405, 12, 21, 215, 60, 63, 1065, 1068, "was" +405, 12, 22, 216, 64, 71, 1069, 1076, "reduced" +405, 12, 23, 217, 72, 76, 1077, 1081, "from" +405, 12, 24, 218, 77, 79, 1082, 1084, "25" +405, 12, 25, 219, 80, 81, 1085, 1086, "." +405, 12, 26, 220, 82, 83, 1087, 1088, "2" +405, 12, 27, 221, 84, 86, 1089, 1091, "to" +405, 12, 28, 222, 87, 89, 1092, 1094, "16" +405, 12, 29, 223, 90, 91, 1095, 1096, "." +405, 12, 30, 224, 92, 93, 1097, 1098, "7" +405, 12, 31, 225, 94, 98, 1099, 1103, "mmHg" +405, 12, 32, 226, 99, 100, 1104, 1105, "(" +405, 12, 33, 227, 101, 103, 1106, 1108, "33" +405, 12, 34, 228, 104, 105, 1109, 1110, "." +405, 12, 35, 229, 106, 107, 1111, 1112, "7" +405, 12, 36, 230, 108, 109, 1113, 1114, "%" +405, 12, 37, 231, 110, 111, 1115, 1116, ")" +405, 12, 38, 232, 112, 116, 1117, 1121, "with" +405, 12, 39, 233, 117, 129, 1122, 1134, "lantanoprost" +405, 12, 40, 234, 130, 133, 1135, 1138, "and" +405, 12, 41, 235, 134, 138, 1139, 1143, "from" +405, 12, 42, 236, 139, 141, 1144, 1146, "25" +405, 12, 43, 237, 142, 143, 1147, 1148, "." +405, 12, 44, 238, 144, 145, 1149, 1150, "4" +405, 12, 45, 239, 146, 148, 1151, 1153, "to" +405, 12, 46, 240, 149, 151, 1154, 1156, "17" +405, 12, 47, 241, 152, 153, 1157, 1158, "." +405, 12, 48, 242, 154, 155, 1159, 1160, "1" +405, 12, 49, 243, 156, 160, 1161, 1165, "mmHg" +405, 12, 50, 244, 161, 162, 1166, 1167, "(" +405, 12, 51, 245, 163, 165, 1168, 1170, "32" +405, 12, 52, 246, 166, 167, 1171, 1172, "." +405, 12, 53, 247, 168, 169, 1173, 1174, "7" +405, 12, 54, 248, 170, 171, 1175, 1176, "%" +405, 12, 55, 249, 172, 173, 1177, 1178, ")" +405, 12, 56, 250, 174, 178, 1179, 1183, "with" +405, 12, 57, 251, 179, 186, 1184, 1191, "timolol" +405, 12, 58, 252, 187, 189, 1192, 1194, "as" +405, 12, 59, 253, 190, 200, 1195, 1205, "determined" +405, 12, 60, 254, 201, 203, 1206, 1208, "at" +405, 12, 61, 255, 204, 207, 1209, 1212, "the" +405, 12, 62, 256, 208, 211, 1213, 1216, "end" +405, 12, 63, 257, 212, 214, 1217, 1219, "of" +405, 12, 64, 258, 215, 218, 1220, 1223, "the" +405, 12, 65, 259, 219, 220, 1224, 1225, "6" +405, 12, 66, 260, 221, 222, 1226, 1227, "-" +405, 12, 67, 261, 223, 228, 1228, 1233, "month" +405, 12, 68, 262, 229, 238, 1234, 1243, "treatment" +405, 12, 69, 263, 239, 245, 1244, 1250, "period" +405, 12, 70, 264, 246, 247, 1251, 1252, "." +405, 13, 1, 265, 0, 2, 1253, 1255, "No" +405, 13, 2, 266, 3, 9, 1256, 1262, "upward" +405, 13, 3, 267, 10, 15, 1263, 1268, "drift" +405, 13, 4, 268, 16, 18, 1269, 1271, "in" +405, 13, 5, 269, 19, 22, 1272, 1275, "IOP" +405, 13, 6, 270, 23, 31, 1276, 1284, "occurred" +405, 13, 7, 271, 32, 36, 1285, 1289, "with" +405, 13, 8, 272, 37, 43, 1290, 1296, "either" +405, 13, 9, 273, 44, 48, 1297, 1301, "drug" +405, 13, 10, 274, 49, 55, 1302, 1308, "during" +405, 13, 11, 275, 56, 59, 1309, 1312, "the" +405, 13, 12, 276, 60, 69, 1313, 1322, "treatment" +405, 13, 13, 277, 70, 76, 1323, 1329, "period" +405, 13, 14, 278, 77, 78, 1330, 1331, "." +405, 14, 1, 279, 0, 11, 1332, 1343, "Latanoprost" +405, 14, 2, 280, 12, 18, 1344, 1350, "caused" +405, 14, 3, 281, 19, 20, 1351, 1352, "a" +405, 14, 4, 282, 21, 29, 1353, 1361, "somewhat" +405, 14, 5, 283, 30, 34, 1362, 1366, "more" +405, 14, 6, 284, 35, 47, 1367, 1379, "conjunctival" +405, 14, 7, 285, 48, 57, 1380, 1389, "hyperemia" +405, 14, 8, 286, 58, 62, 1390, 1394, "than" +405, 14, 9, 287, 63, 70, 1395, 1402, "timolol" +405, 14, 10, 288, 71, 74, 1403, 1406, "and" +405, 14, 11, 289, 75, 79, 1407, 1411, "more" +405, 14, 12, 290, 80, 87, 1412, 1419, "corneal" +405, 14, 13, 291, 88, 97, 1420, 1429, "punctuate" +405, 14, 14, 292, 98, 108, 1430, 1440, "epithelial" +405, 14, 15, 293, 109, 117, 1441, 1449, "erosions" +405, 14, 16, 294, 118, 119, 1450, 1451, "." +405, 15, 1, 295, 0, 7, 1452, 1459, "However" +405, 15, 2, 296, 8, 9, 1460, 1461, "," +405, 15, 3, 297, 10, 14, 1462, 1466, "both" +405, 15, 4, 298, 15, 20, 1467, 1472, "drugs" +405, 15, 5, 299, 21, 25, 1473, 1477, "were" +405, 15, 6, 300, 26, 35, 1478, 1487, "generally" +405, 15, 7, 301, 36, 40, 1488, 1492, "well" +405, 15, 8, 302, 41, 50, 1493, 1502, "tolerated" +405, 15, 9, 303, 51, 52, 1503, 1504, "." +405, 16, 1, 304, 0, 3, 1505, 1508, "The" +405, 16, 2, 305, 4, 8, 1509, 1513, "most" +405, 16, 3, 306, 9, 20, 1514, 1525, "significant" +405, 16, 4, 307, 21, 25, 1526, 1530, "side" +405, 16, 5, 308, 26, 32, 1531, 1537, "effect" +405, 16, 6, 309, 33, 35, 1538, 1540, "of" +405, 16, 7, 310, 36, 47, 1541, 1552, "latanoprost" +405, 16, 8, 311, 48, 51, 1553, 1556, "was" +405, 16, 9, 312, 52, 61, 1557, 1566, "increased" +405, 16, 10, 313, 62, 74, 1567, 1579, "pigmentation" +405, 16, 11, 314, 75, 77, 1580, 1582, "of" +405, 16, 12, 315, 78, 81, 1583, 1586, "the" +405, 16, 13, 316, 82, 86, 1587, 1591, "iris" +405, 16, 14, 317, 87, 92, 1592, 1597, "which" +405, 16, 15, 318, 93, 96, 1598, 1601, "was" +405, 16, 16, 319, 97, 105, 1602, 1610, "observed" +405, 16, 17, 320, 106, 108, 1611, 1613, "in" +405, 16, 18, 321, 109, 111, 1614, 1616, "15" +405, 16, 19, 322, 112, 120, 1617, 1625, "patients" +405, 16, 20, 323, 121, 122, 1626, 1627, "(" +405, 16, 21, 324, 123, 125, 1628, 1630, "10" +405, 16, 22, 325, 126, 127, 1631, 1632, "." +405, 16, 23, 326, 128, 129, 1633, 1634, "1" +405, 16, 24, 327, 130, 131, 1635, 1636, "%" +405, 16, 25, 328, 132, 133, 1637, 1638, ")" +405, 16, 26, 329, 134, 135, 1639, 1640, "." +405, 17, 1, 330, 0, 7, 1641, 1648, "Timolol" +405, 17, 2, 331, 8, 14, 1649, 1655, "caused" +405, 17, 3, 332, 15, 19, 1656, 1660, "more" +405, 17, 4, 333, 20, 28, 1661, 1669, "systemic" +405, 17, 5, 334, 29, 33, 1670, 1674, "side" +405, 17, 6, 335, 34, 41, 1675, 1682, "effects" +405, 17, 7, 336, 42, 46, 1683, 1687, "than" +405, 17, 8, 337, 47, 58, 1688, 1699, "latanoprost" +405, 17, 9, 338, 59, 60, 1700, 1701, "." +405, 18, 1, 339, 0, 11, 1702, 1713, "CONCLUSIONS" +405, 18, 2, 340, 12, 13, 1714, 1715, ":" +405, 18, 3, 341, 14, 25, 1716, 1727, "Latanoprost" +405, 18, 4, 342, 26, 27, 1728, 1729, "0" +405, 18, 5, 343, 28, 29, 1730, 1731, "." +405, 18, 6, 344, 30, 33, 1732, 1735, "005" +405, 18, 7, 345, 34, 35, 1736, 1737, "%" +405, 18, 8, 346, 36, 48, 1738, 1750, "administered" +405, 18, 9, 347, 49, 53, 1751, 1755, "once" +405, 18, 10, 348, 54, 59, 1756, 1761, "daily" +405, 18, 11, 349, 60, 62, 1762, 1764, "in" +405, 18, 12, 350, 63, 66, 1765, 1768, "the" +405, 18, 13, 351, 67, 74, 1769, 1776, "evening" +405, 18, 14, 352, 75, 82, 1777, 1784, "reduced" +405, 18, 15, 353, 83, 86, 1785, 1788, "IOP" +405, 18, 16, 354, 87, 89, 1789, 1791, "at" +405, 18, 17, 355, 90, 95, 1792, 1797, "least" +405, 18, 18, 356, 96, 98, 1798, 1800, "as" +405, 18, 19, 357, 99, 103, 1801, 1805, "well" +405, 18, 20, 358, 104, 106, 1806, 1808, "as" +405, 18, 21, 359, 107, 114, 1809, 1816, "timolol" +405, 18, 22, 360, 115, 116, 1817, 1818, "0" +405, 18, 23, 361, 117, 118, 1819, 1820, "." +405, 18, 24, 362, 119, 120, 1821, 1822, "5" +405, 18, 25, 363, 121, 122, 1823, 1824, "%" +405, 18, 26, 364, 123, 135, 1825, 1837, "administered" +405, 18, 27, 365, 136, 141, 1838, 1843, "twice" +405, 18, 28, 366, 142, 147, 1844, 1849, "daily" +405, 18, 29, 367, 148, 149, 1850, 1851, "." +405, 19, 1, 368, 0, 11, 1852, 1863, "Latanoprost" +405, 19, 2, 369, 12, 15, 1864, 1867, "was" +405, 19, 3, 370, 16, 25, 1868, 1877, "generally" +405, 19, 4, 371, 26, 30, 1878, 1882, "well" +405, 19, 5, 372, 31, 40, 1883, 1892, "tolerated" +405, 19, 6, 373, 41, 53, 1893, 1905, "systemically" +405, 19, 7, 374, 54, 57, 1906, 1909, "and" +405, 19, 8, 375, 58, 60, 1910, 1912, "in" +405, 19, 9, 376, 61, 64, 1913, 1916, "the" +405, 19, 10, 377, 65, 68, 1917, 1920, "eye" +405, 19, 11, 378, 69, 70, 1921, 1922, "." +405, 20, 1, 379, 0, 7, 1923, 1930, "However" +405, 20, 2, 380, 8, 9, 1931, 1932, "," +405, 20, 3, 381, 10, 13, 1933, 1936, "the" +405, 20, 4, 382, 14, 18, 1937, 1941, "drug" +405, 20, 5, 383, 19, 22, 1942, 1945, "has" +405, 20, 6, 384, 23, 25, 1946, 1948, "an" +405, 20, 7, 385, 26, 33, 1949, 1956, "unusual" +405, 20, 8, 386, 34, 38, 1957, 1961, "side" +405, 20, 9, 387, 39, 45, 1962, 1968, "effect" +405, 20, 10, 388, 46, 48, 1969, 1971, "of" +405, 20, 11, 389, 49, 59, 1972, 1982, "increasing" +405, 20, 12, 390, 60, 63, 1983, 1986, "the" +405, 20, 13, 391, 64, 76, 1987, 1999, "pigmentation" +405, 20, 14, 392, 77, 79, 2000, 2002, "of" +405, 20, 15, 393, 80, 83, 2003, 2006, "the" +405, 20, 16, 394, 84, 88, 2007, 2011, "iris" +405, 20, 17, 395, 89, 90, 2012, 2013, "," +405, 20, 18, 396, 91, 103, 2014, 2026, "particularly" +405, 20, 19, 397, 104, 106, 2027, 2029, "in" +405, 20, 20, 398, 107, 118, 2030, 2041, "individuals" +405, 20, 21, 399, 119, 123, 2042, 2046, "with" +405, 20, 22, 400, 124, 129, 2047, 2052, "green" +405, 20, 23, 401, 130, 131, 2053, 2054, "-" +405, 20, 24, 402, 132, 137, 2055, 2060, "brown" +405, 20, 25, 403, 138, 140, 2061, 2063, "or" +405, 20, 26, 404, 141, 145, 2064, 2068, "blue" +405, 20, 27, 405, 146, 147, 2069, 2070, "-" +405, 20, 28, 406, 148, 153, 2071, 2076, "brown" +405, 20, 29, 407, 154, 158, 2077, 2081, "eyes" +405, 20, 30, 408, 159, 160, 2082, 2083, "." +405, 21, 1, 409, 0, 4, 2084, 2088, "PMID" +405, 21, 2, 410, 5, 6, 2089, 2090, ":" +405, 21, 3, 411, 7, 14, 2091, 2098, "8628543" +405, 21, 4, 412, 15, 16, 2099, 2100, "[" +405, 21, 5, 413, 17, 24, 2101, 2108, "Indexed" +405, 21, 6, 414, 25, 28, 2109, 2112, "for" +405, 21, 7, 415, 29, 36, 2113, 2120, "MEDLINE" +405, 21, 8, 416, 37, 38, 2121, 2122, "]" diff --git a/data/gl 8628543_jshahinitiran.annodb b/data/gl 8628543_jshahinitiran.annodb new file mode 100644 index 0000000..15e4417 --- /dev/null +++ b/data/gl 8628543_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32672, Journal, 0, 13, "Ophthalmology", "", +32673, PublicationYear, 16, 20, "1996", "", +32674, Title, 50, 184, "A six - month , randomized , double - masked study comparing latanoprost with timolol in open - angle glaucoma and ocular hypertension", "", +32676, Duration, 52, 63, "six - month", "", +32677, Randomized, 66, 76, "randomized", "", +32678, DoubleBlind, 79, 94, "double - masked", "", +32679, Latanoprost, 111, 122, "latanoprost", "", +32680, Timolol, 128, 135, "timolol", "", +32681, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", +32682, OcularHypertension, 165, 184, "ocular hypertension", "", +32675, Latanoprost, 191, 202, "Latanoprost", "", +32683, Author, 217, 225, "Watson P", "", +32684, Author, 234, 249, "Stjernschantz J", "", +32685, UK, 318, 325, "England", "", +32686, ObjectiveDescription, 338, 573, "To compare the intraocular pressure ( IOP ) - reducing effect and side effects of 0 . 005 % latanoprost administered once daily with 0 . 5 % timolol administered twice daily in patients with open - angle glaucoma or ocular hypertension", "", +32687, IOP, 353, 373, "intraocular pressure", "", +32688, IOP, 376, 379, "IOP", "", +32691, DoseValue, 420, 427, "0 . 005", "", +32693, Percentage, 428, 429, "%", "", +32689, Latanoprost, 430, 441, "latanoprost", "", +32695, Frequency, 455, 465, "once daily", "", +32692, DoseValue, 471, 476, "0 . 5", "", +32694, Percentage, 477, 478, "%", "", +32690, Timolol, 479, 486, "timolol", "", +32696, Frequency, 500, 511, "twice daily", "", +32697, OpenAngleGlaucoma, 529, 550, "open - angle glaucoma", "", +32698, OcularHypertension, 554, 573, "ocular hypertension", "", +32699, Randomized, 597, 607, "randomized", "", +32700, DoubleBlind, 610, 625, "double - masked", "", +32701, Parallel, 641, 649, "parallel", "", +32702, Duration, 683, 691, "6 months", "", +32753, ObjectiveDescription, 694, 850, "The primary objective of the study is to compare the IOP - reducing effect of lantanoprost with that of timolol at the end of the 6 - month treatment period", "", +32703, IOP, 747, 750, "IOP", "", +32704, Latanoprost, 772, 784, "lantanoprost", "", +32705, Timolol, 798, 805, "timolol", "", +32706, Duration, 824, 833, "6 - month", "", +32707, NumberPatientsCT, 864, 867, "294", "", +32708, NumberPatientsArm, 893, 896, "149", "", +32710, Latanoprost, 909, 920, "latanoprost", "", +32709, NumberPatientsArm, 931, 934, "145", "", +32711, Timolol, 943, 950, "timolol", "", +32712, Latanoprost, 959, 970, "Latanoprost", "", +32752, Bedtime, 995, 1002, "evening", "", +32713, Diurnal_IOP, 1015, 1026, "Diurnal IOP", "", +32714, BaseLineValue, 1082, 1088, "25 . 2", "", +32715, ResultMeasuredValue, 1092, 1098, "16 . 7", "", +32716, mmHg, 1099, 1103, "mmHg", "", +32717, RelativeReduction, 1106, 1112, "33 . 7", "", +32718, Latanoprost, 1122, 1134, "lantanoprost", "", +32719, BaseLineValue, 1144, 1150, "25 . 4", "", +32720, ResultMeasuredValue, 1154, 1160, "17 . 1", "", +32721, mmHg, 1161, 1165, "mmHg", "", +32722, RelativeReduction, 1168, 1174, "32 . 7", "", +32723, Timolol, 1184, 1191, "timolol", "", +32724, TimePoint, 1224, 1233, "6 - month", "", +32725, IOP, 1272, 1275, "IOP", "", +32726, Latanoprost, 1332, 1343, "Latanoprost", "", +32727, ConjunctivalHyperemia, 1367, 1389, "conjunctival hyperemia", "", +32728, Timolol, 1395, 1402, "timolol", "", +32730, Latanoprost, 1541, 1552, "latanoprost", "", +32731, IrisPigmentation, 1567, 1591, "pigmentation of the iris", "", +32732, NumberAffected, 1614, 1616, "15", "", +32733, PercentageAffected, 1628, 1634, "10 . 1", "", +32734, Timolol, 1641, 1648, "Timolol", "", +32735, Latanoprost, 1688, 1699, "latanoprost", "", +32736, ConclusionComment, 1716, 1851, "Latanoprost 0 . 005 % administered once daily in the evening reduced IOP at least as well as timolol 0 . 5 % administered twice daily .", "", +32740, Latanoprost, 1716, 1727, "Latanoprost", "", +32741, DoseValue, 1728, 1735, "0 . 005", "", +32742, Percentage, 1736, 1737, "%", "", +32743, Frequency, 1751, 1761, "once daily", "", +32744, Bedtime, 1769, 1776, "evening", "", +32745, IOP, 1785, 1788, "IOP", "", +32746, Timolol, 1809, 1816, "timolol", "", +32747, DoseValue, 1817, 1822, "0 . 5", "", +32748, Percentage, 1823, 1824, "%", "", +32749, Frequency, 1838, 1849, "twice daily", "", +32737, ConclusionComment, 1852, 1922, "Latanoprost was generally well tolerated systemically and in the eye .", "", +32750, Latanoprost, 1852, 1863, "Latanoprost", "", +32738, ConclusionComment, 1923, 2083, "However , the drug has an unusual side effect of increasing the pigmentation of the iris , particularly in individuals with green - brown or blue - brown eyes .", "", +32751, IrisPigmentation, 1987, 2011, "pigmentation of the iris", "", +32739, PMID, 2091, 2098, "8628543", "", diff --git a/data/gl 8628543_jshahinitiran.n-triples b/data/gl 8628543_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8628543_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628543_tstrakeljahn.annodb b/data/gl 8628543_tstrakeljahn.annodb new file mode 100644 index 0000000..9cc007b --- /dev/null +++ b/data/gl 8628543_tstrakeljahn.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +8062, Journal, 0, 13, "Ophthalmology", "", +8063, PublicationYear, 16, 20, "1996", "", +8086, Title, 50, 186, "A six - month , randomized , double - masked study comparing latanoprost with timolol in open - angle glaucoma and ocular hypertension .", "", +8064, Duration, 52, 63, "six - month", "", +8065, Randomized, 66, 76, "randomized", "", +8066, DoubleBlind, 79, 94, "double - masked", "", +8067, Latanoprost, 111, 122, "latanoprost", "", +8068, Timolol, 128, 135, "timolol", "", +8069, OpenAngleGlaucoma, 139, 160, "open - angle glaucoma", "", +8070, OcularHypertension, 165, 184, "ocular hypertension", "", +29819, Latanoprost, 191, 202, "Latanoprost", "", +8071, Author, 217, 225, "Watson P", "", +8072, Author, 234, 249, "Stjernschantz J", "", +8073, UK, 318, 325, "England", "", +8087, ObjectiveDescription, 338, 575, "To compare the intraocular pressure ( IOP ) - reducing effect and side effects of 0 . 005 % latanoprost administered once daily with 0 . 5 % timolol administered twice daily in patients with open - angle glaucoma or ocular hypertension .", "", +8074, IOP, 353, 373, "intraocular pressure", "", +8075, IOP, 376, 379, "IOP", "", +8076, DoseValue, 420, 427, "0 . 005", "", +8082, Percentage, 428, 429, "%", "", +8084, Latanoprost, 430, 441, "latanoprost", "", +8085, Frequency, 455, 465, "once daily", "", +8077, DoseValue, 471, 476, "0 . 5", "", +8083, Percentage, 477, 478, "%", "", +8078, Timolol, 479, 486, "timolol", "", +8079, Frequency, 500, 511, "twice daily", "", +8080, OpenAngleGlaucoma, 529, 550, "open - angle glaucoma", "", +8081, OcularHypertension, 554, 573, "ocular hypertension", "", +8088, Randomized, 597, 607, "randomized", "", +8089, DoubleBlind, 610, 625, "double - masked", "", +8090, Parallel, 641, 649, "parallel", "", +8091, Duration, 683, 691, "6 months", "", +8096, ObjectiveDescription, 694, 852, "The primary objective of the study is to compare the IOP - reducing effect of lantanoprost with that of timolol at the end of the 6 - month treatment period .", "", +8092, IOP, 747, 750, "IOP", "", +8093, Latanoprost, 772, 784, "lantanoprost", "", +8094, Timolol, 798, 805, "timolol", "", +8095, Duration, 824, 833, "6 - month", "", +8097, NumberPatientsCT, 864, 867, "294", "", +8098, NumberPatientsArm, 893, 896, "149", "", +8100, Latanoprost, 909, 920, "latanoprost", "", +8099, NumberPatientsArm, 931, 934, "145", "", +8101, Timolol, 943, 950, "timolol", "", +8102, Latanoprost, 959, 970, "Latanoprost", "", +8103, Diurnal_IOP, 1015, 1026, "Diurnal IOP", "", +8104, TimePoint, 1029, 1038, "9 : 00 am", "", +8105, TimePoint, 1041, 1050, "1 : 00 pm", "", +8106, TimePoint, 1053, 1062, "5 : 00 pm", "", +8107, BaseLineValue, 1082, 1088, "25 . 2", "", +8108, ResultMeasuredValue, 1092, 1098, "16 . 7", "", +8109, mmHg, 1099, 1103, "mmHg", "", +8110, RelativeReduction, 1106, 1112, "33 . 7", "", +8111, Latanoprost, 1122, 1134, "lantanoprost", "", +8112, BaseLineValue, 1144, 1150, "25 . 4", "", +8113, ResultMeasuredValue, 1154, 1160, "17 . 1", "", +8114, mmHg, 1161, 1165, "mmHg", "", +8115, RelativeReduction, 1168, 1174, "32 . 7", "", +8116, Timolol, 1184, 1191, "timolol", "", +8117, Duration, 1224, 1233, "6 - month", "", +8119, ObservedResult, 1253, 1331, "No upward drift in IOP occurred with either drug during the treatment period .", "", +8118, IOP, 1272, 1275, "IOP", "", +8120, Latanoprost, 1332, 1343, "Latanoprost", "", +8124, ObservedResult, 1332, 1451, "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions .", "", +8121, Timolol, 1395, 1402, "timolol", "", +8125, ObservedResult, 1462, 1504, "both drugs were generally well tolerated .", "", +8126, Latanoprost, 1541, 1552, "latanoprost", "", +8128, NumberAffected, 1614, 1616, "15", "", +8129, PercentageAffected, 1628, 1634, "10 . 1", "", +8130, Timolol, 1641, 1648, "Timolol", "", +8131, Latanoprost, 1688, 1699, "latanoprost", "", +8132, Latanoprost, 1716, 1727, "Latanoprost", "", +8133, DoseValue, 1728, 1735, "0 . 005", "", +8135, Percentage, 1736, 1737, "%", "", +8137, Frequency, 1751, 1761, "once daily", "", +8139, Frequency, 1785, 1788, "IOP", "", +8140, Timolol, 1809, 1816, "timolol", "", +8134, DoseValue, 1817, 1822, "0 . 5", "", +8136, Percentage, 1823, 1824, "%", "", +8138, Frequency, 1838, 1849, "twice daily", "", +8141, Latanoprost, 1852, 1863, "Latanoprost", "", +8142, ObservedResult, 1852, 1922, "Latanoprost was generally well tolerated systemically and in the eye .", "", +8143, ObservedResult, 1923, 2083, "However , the drug has an unusual side effect of increasing the pigmentation of the iris , particularly in individuals with green - brown or blue - brown eyes .", "", +29820, PMID, 2091, 2098, "8628543", "", diff --git a/data/gl 8628543_tstrakeljahn.n-triples b/data/gl 8628543_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8628543_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628544_admin.annodb b/data/gl 8628544_admin.annodb new file mode 100644 index 0000000..3c4d1e2 --- /dev/null +++ b/data/gl 8628544_admin.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +70, PublicationYear, 16, 20, "1996", "", " \"1996\"." +15, Title, 50, 203, "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six - month masked , multicenter trial in the United States .", "", " \"Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six - month masked , multicenter trial in the United States .\"." +2, Latanoprost, 64, 75, "latanoprost", "", +3, Timolol, 80, 87, "timolol", "", +4, OcularHypertension, 105, 124, "ocular hypertension", "", " ." +5, Glaucoma, 129, 137, "glaucoma", "", " . ." +6, Duration, 142, 153, "six - month", "", " \"six - month\"." +7, Blind, 154, 160, "masked", "", " ." +8, Multicenter, 163, 174, "multicenter", "", " ." +9, USA, 188, 201, "United States", "", " ." +79, USA, 208, 221, "United States", "", +67, Latanoprost, 222, 233, "Latanoprost", "", +10, Author, 248, 257, "Camras CB", "", " \"Camras CB\"." +11, USA, 357, 360, "USA", "", " ." +12, Latanoprost, 373, 384, "Latanoprost", "", +14, ObjectiveDescription, 373, 494, "Latanoprost , a new prostaglandin analogue , was compared with timolol for ocular hypotensive efficacy and side effects .", "", " \"Latanoprost , a new prostaglandin analogue , was compared with timolol for ocular hypotensive efficacy and side effects .\"." +92862, ProstaglandinAnalogs, 393, 415, "prostaglandin analogue", "", +13, Timolol, 436, 443, "timolol", "", +16, Multicenter, 510, 521, "multicenter", "", +17, Randomized, 524, 534, "randomized", "", " ." +18, DoubleBlind, 537, 552, "double - masked", "", " ." +19, Parallel, 555, 563, "parallel", "", " ." +20, NumberPatientsCT, 578, 581, "268", "", " \"268\"." +54363, Precondition, 582, 654, "patients with ocular hypertension or early primary open - angle glaucoma", "", " \"patients with ocular hypertension or early primary open - angle glaucoma\"." +21, OcularHypertension, 596, 615, "ocular hypertension", "", +93, Primary_OpenAngleGlaucoma, 625, 654, "primary open - angle glaucoma", "", " ." +23, DoseValue, 671, 678, "0 . 005", "", " \"0 . 005\"." +98, Percentage, 679, 680, "%", "", " ." +25, Latanoprost, 681, 692, "latanoprost", "", " . ." +26, Frequency, 693, 703, "once daily", "", " \"once daily\"." +24, DoseValue, 707, 712, "0 . 5", "", " \"0 . 5\"." +99, Percentage, 713, 714, "%", "", " ." +27, Timolol, 715, 722, "timolol", "", " ." +28, Frequency, 723, 734, "twice daily", "", " \"twice daily\"." +29, Duration, 739, 747, "6 months", "", +30, NumPatientsLeftArm, 761, 764, "ten", "", " \"ten\". \"ten\"." +31, IOP, 835, 855, "Intraocular pressure", "", +32, IOP, 858, 861, "IOP", "", +33, PValueChangeValue, 884, 895, "P < 0 . 001", "", +34, Duration, 986, 994, "6 months", "", +108, TimePoint, 1007, 1016, "6 - month", "", " \"6 - month\". \"6 - month\"." +54185, TimePoint, 1022, 1030, "baseline", "", +36, Diurnal_IOP, 1031, 1042, "diurnal IOP", "", " ." +37, IOP, 1056, 1059, "IOP", "", +114, Mean, 1072, 1076, "mean", "", " . ." +46, Latanoprost, 1118, 1129, "latanoprost", "", +39, Reduction, 1134, 1139, "6 . 7", "", " \"6 . 7\"." +115, SdDevChangeValue, 1146, 1151, "3 . 4", "", " \"3 . 4\"." +43, mmHg, 1152, 1156, "mmHg", "", " ." +44, PValueChangeValue, 1179, 1190, "P < 0 . 001", "", " \"P < 0 . 001\"." +45, Timolol, 1225, 1232, "timolol", "", +40, Reduction, 1235, 1240, "4 . 9", "", " \"4 . 9\"." +116, SdDevChangeValue, 1247, 1252, "2 . 9", "", " \"2 . 9\"." +42, mmHg, 1253, 1257, "mmHg", "", +47, NumPatientsLeftArm, 1262, 1266, "Four", "", +48, Timolol, 1289, 1296, "timolol", "", +49, Latanoprost, 1319, 1330, "latanoprost", "", +50, IOP, 1383, 1386, "IOP", "", +53, ObservedResult, 1397, 1475, "Pulse rate was significantly reduced with timolol , but not with latanoprost .", "", " \"Pulse rate was significantly reduced with timolol , but not with latanoprost .\"." +54190, PulseRate, 1397, 1407, "Pulse rate", "", " . ." +51, Timolol, 1439, 1446, "timolol", "", +52, Latanoprost, 1462, 1473, "latanoprost", "", +56, ObservedResult, 1476, 1585, "Slightly more conjunctival hyperemia appeared in latanoprost - treated compared with timolol - treated eyes .", "", " \"Slightly more conjunctival hyperemia appeared in latanoprost - treated compared with timolol - treated eyes .\"." +127, ConjunctivalHyperemia, 1490, 1512, "conjunctival hyperemia", "", " ." +54, Latanoprost, 1525, 1536, "latanoprost", "", +55, Timolol, 1561, 1568, "timolol", "", +58, ObservedResult, 1586, 1656, "Fewer subjective side effects occurred in latanoprost - treated eyes .", "", " \"Fewer subjective side effects occurred in latanoprost - treated eyes .\"." +54191, EndPointDescription, 1592, 1615, "subjective side effects", "", " . ." +57, Latanoprost, 1628, 1639, "latanoprost", "", +60, ObservedResult, 1657, 1907, "Both eyes of a patient with a characteristic , concentric iris heterochromia ( darker centrally ) at baseline showed a definite , photographically documented increase in pigmentation during latanoprost treatment , making the irides uniformly darker .", "", " \"Both eyes of a patient with a characteristic , concentric iris heterochromia ( darker centrally ) at baseline showed a definite , photographically documented increase in pigmentation during latanoprost treatment , making the irides uniformly darker .\"." +54192, TimePoint, 1758, 1766, "baseline", "", +131, IrisPigmentation, 1827, 1839, "pigmentation", "", +59, Latanoprost, 1847, 1858, "latanoprost", "", +61, ObservedResult, 1908, 1996, "Three additional patients treated with latanoprost were suspects for this color change .", "", " \"Three additional patients treated with latanoprost were suspects for this color change .\"." +62, Latanoprost, 1947, 1958, "latanoprost", "", +54193, IrisPigmentation, 1982, 1994, "color change", "", " . ." +63, ObservedResult, 1997, 2151, "Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values .", "", " \"Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values .\". \"Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values .\"." +54194, EndPointDescription, 2069, 2082, "visual acuity", "", " . ." +135, BloodPressure, 2111, 2125, "blood pressure", "", " . ." +64, Latanoprost, 2165, 2176, "Latanoprost", "", +66, ConclusionComment, 2165, 2251, "Latanoprost has the potential for becoming a new first - line treatment for glaucoma .", "", " \"Latanoprost has the potential for becoming a new first - line treatment for glaucoma .\"." +65, Glaucoma, 2241, 2249, "glaucoma", "", +68, PMID, 2259, 2266, "8628544", "", " \"8628544\"." diff --git a/data/gl 8628544_admin.n-triples b/data/gl 8628544_admin.n-triples new file mode 100644 index 0000000..69a9c6e --- /dev/null +++ b/data/gl 8628544_admin.n-triples @@ -0,0 +1,179 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six - month masked , multicenter trial in the United States ." . + "Camras CB" . + "1996" . + "Ophthalmology" . + "8628544" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "Latanoprost , a new prostaglandin analogue , was compared with timolol for ocular hypotensive efficacy and side effects ." . + "268" . + "six - month" . + . + . + . + "Latanoprost has the potential for becoming a new first - line treatment for glaucoma ." . + . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with ocular hypertension or early primary open - angle glaucoma" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_CH" . + . + . + . + . + . + "Endpoint_SE" . + . + . + . + . + . + . + "Endpoint_IP" . + . + . + . + . + . + . + "Endpoint_VA" . + . + . + . + . + . + . + "Endpoint_BP" . + . + . + . + . + . + . + "Endpoint_PR" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_lat" . + . + . + . + "ten" . + . + . + . + . + . + . + "Arm_tim" . + . + . + . + "ten" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat" . + . + "once daily" . + . + . + "Intervention_tim" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_lat" . + . + . + "0 . 005" . + . + . + . + "Medication_tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_iop_lat" . + . + "6 . 7" . + "P < 0 . 001" . + "3 . 4" . + "6 - month" . + . + "Outcome_iop_tim" . + . + "4 . 9" . + "2 . 9" . + "6 - month" . + . + "Outcome_PR" . + . + "Pulse rate was significantly reduced with timolol , but not with latanoprost ." . + . + "Outcome_CH" . + . + "Slightly more conjunctival hyperemia appeared in latanoprost - treated compared with timolol - treated eyes ." . + . + "Outcome_SE_lat" . + . + "Fewer subjective side effects occurred in latanoprost - treated eyes ." . + . + "Outcome_IP_lat" . + . + "Both eyes of a patient with a characteristic , concentric iris heterochromia ( darker centrally ) at baseline showed a definite , photographically documented increase in pigmentation during latanoprost treatment , making the irides uniformly darker ." . + . + "Outcome_IP_tim" . + . + "Three additional patients treated with latanoprost were suspects for this color change ." . + . + "Outcome_VA" . + . + "Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values ." . + . + "Outcome_BP" . + . + "Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values ." . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628544_export.csv b/data/gl 8628544_export.csv new file mode 100644 index 0000000..a3342e4 --- /dev/null +++ b/data/gl 8628544_export.csv @@ -0,0 +1,413 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +404, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +404, 1, 2, 2, 14, 15, 14, 15, "." +404, 2, 1, 3, 0, 4, 16, 20, "1996" +404, 2, 2, 4, 5, 8, 21, 24, "Jan" +404, 2, 3, 5, 9, 10, 25, 26, ";" +404, 2, 4, 6, 11, 14, 27, 30, "103" +404, 2, 5, 7, 15, 16, 31, 32, "(" +404, 2, 6, 8, 17, 18, 33, 34, "1" +404, 2, 7, 9, 19, 20, 35, 36, ")" +404, 2, 8, 10, 21, 22, 37, 38, ":" +404, 2, 9, 11, 23, 26, 39, 42, "138" +404, 2, 10, 12, 27, 28, 43, 44, "-" +404, 2, 11, 13, 29, 31, 45, 47, "47" +404, 2, 12, 14, 32, 33, 48, 49, "." +404, 3, 1, 15, 0, 10, 50, 60, "Comparison" +404, 3, 2, 16, 11, 13, 61, 63, "of" +404, 3, 3, 17, 14, 25, 64, 75, "latanoprost" +404, 3, 4, 18, 26, 29, 76, 79, "and" +404, 3, 5, 19, 30, 37, 80, 87, "timolol" +404, 3, 6, 20, 38, 40, 88, 90, "in" +404, 3, 7, 21, 41, 49, 91, 99, "patients" +404, 3, 8, 22, 50, 54, 100, 104, "with" +404, 3, 9, 23, 55, 61, 105, 111, "ocular" +404, 3, 10, 24, 62, 74, 112, 124, "hypertension" +404, 3, 11, 25, 75, 78, 125, 128, "and" +404, 3, 12, 26, 79, 87, 129, 137, "glaucoma" +404, 3, 13, 27, 88, 89, 138, 139, ":" +404, 3, 14, 28, 90, 91, 140, 141, "a" +404, 3, 15, 29, 92, 95, 142, 145, "six" +404, 3, 16, 30, 96, 97, 146, 147, "-" +404, 3, 17, 31, 98, 103, 148, 153, "month" +404, 3, 18, 32, 104, 110, 154, 160, "masked" +404, 3, 19, 33, 111, 112, 161, 162, "," +404, 3, 20, 34, 113, 124, 163, 174, "multicenter" +404, 3, 21, 35, 125, 130, 175, 180, "trial" +404, 3, 22, 36, 131, 133, 181, 183, "in" +404, 3, 23, 37, 134, 137, 184, 187, "the" +404, 3, 24, 38, 138, 144, 188, 194, "United" +404, 3, 25, 39, 145, 151, 195, 201, "States" +404, 3, 26, 40, 152, 153, 202, 203, "." +404, 4, 1, 41, 0, 3, 204, 207, "The" +404, 4, 2, 42, 4, 10, 208, 214, "United" +404, 4, 3, 43, 11, 17, 215, 221, "States" +404, 4, 4, 44, 18, 29, 222, 233, "Latanoprost" +404, 4, 5, 45, 30, 35, 234, 239, "Study" +404, 4, 6, 46, 36, 41, 240, 245, "Group" +404, 4, 7, 47, 42, 43, 246, 247, "." +404, 5, 1, 48, 0, 6, 248, 254, "Camras" +404, 5, 2, 49, 7, 9, 255, 257, "CB" +404, 5, 3, 50, 10, 11, 258, 259, "(" +404, 5, 4, 51, 12, 13, 260, 261, "1" +404, 5, 5, 52, 14, 15, 262, 263, ")" +404, 5, 6, 53, 16, 17, 264, 265, "." +404, 6, 1, 54, 0, 6, 266, 272, "Author" +404, 6, 2, 55, 7, 18, 273, 284, "information" +404, 6, 3, 56, 19, 20, 285, 286, ":" +404, 6, 4, 57, 21, 22, 287, 288, "(" +404, 6, 5, 58, 23, 24, 289, 290, "1" +404, 6, 6, 59, 25, 26, 291, 292, ")" +404, 6, 7, 60, 27, 40, 293, 306, "Ophthalmology" +404, 6, 8, 61, 41, 42, 307, 308, "," +404, 6, 9, 62, 43, 53, 309, 319, "University" +404, 6, 10, 63, 54, 56, 320, 322, "of" +404, 6, 11, 64, 57, 65, 323, 331, "Nebraska" +404, 6, 12, 65, 66, 73, 332, 339, "Medical" +404, 6, 13, 66, 74, 80, 340, 346, "Center" +404, 6, 14, 67, 81, 82, 347, 348, "," +404, 6, 15, 68, 83, 88, 349, 354, "Omaha" +404, 6, 16, 69, 89, 90, 355, 356, "," +404, 6, 17, 70, 91, 94, 357, 360, "USA" +404, 6, 18, 71, 95, 96, 361, 362, "." +404, 7, 1, 72, 0, 7, 363, 370, "PURPOSE" +404, 7, 2, 73, 8, 9, 371, 372, ":" +404, 7, 3, 74, 10, 21, 373, 384, "Latanoprost" +404, 7, 4, 75, 22, 23, 385, 386, "," +404, 7, 5, 76, 24, 25, 387, 388, "a" +404, 7, 6, 77, 26, 29, 389, 392, "new" +404, 7, 7, 78, 30, 43, 393, 406, "prostaglandin" +404, 7, 8, 79, 44, 52, 407, 415, "analogue" +404, 7, 9, 80, 53, 54, 416, 417, "," +404, 7, 10, 81, 55, 58, 418, 421, "was" +404, 7, 11, 82, 59, 67, 422, 430, "compared" +404, 7, 12, 83, 68, 72, 431, 435, "with" +404, 7, 13, 84, 73, 80, 436, 443, "timolol" +404, 7, 14, 85, 81, 84, 444, 447, "for" +404, 7, 15, 86, 85, 91, 448, 454, "ocular" +404, 7, 16, 87, 92, 103, 455, 466, "hypotensive" +404, 7, 17, 88, 104, 112, 467, 475, "efficacy" +404, 7, 18, 89, 113, 116, 476, 479, "and" +404, 7, 19, 90, 117, 121, 480, 484, "side" +404, 7, 20, 91, 122, 129, 485, 492, "effects" +404, 7, 21, 92, 130, 131, 493, 494, "." +404, 8, 1, 93, 0, 7, 495, 502, "METHODS" +404, 8, 2, 94, 8, 9, 503, 504, ":" +404, 8, 3, 95, 10, 12, 505, 507, "In" +404, 8, 4, 96, 13, 14, 508, 509, "a" +404, 8, 5, 97, 15, 26, 510, 521, "multicenter" +404, 8, 6, 98, 27, 28, 522, 523, "," +404, 8, 7, 99, 29, 39, 524, 534, "randomized" +404, 8, 8, 100, 40, 41, 535, 536, "," +404, 8, 9, 101, 42, 48, 537, 543, "double" +404, 8, 10, 102, 49, 50, 544, 545, "-" +404, 8, 11, 103, 51, 57, 546, 552, "masked" +404, 8, 12, 104, 58, 59, 553, 554, "," +404, 8, 13, 105, 60, 68, 555, 563, "parallel" +404, 8, 14, 106, 69, 74, 564, 569, "group" +404, 8, 15, 107, 75, 80, 570, 575, "study" +404, 8, 16, 108, 81, 82, 576, 577, "," +404, 8, 17, 109, 83, 86, 578, 581, "268" +404, 8, 18, 110, 87, 95, 582, 590, "patients" +404, 8, 19, 111, 96, 100, 591, 595, "with" +404, 8, 20, 112, 101, 107, 596, 602, "ocular" +404, 8, 21, 113, 108, 120, 603, 615, "hypertension" +404, 8, 22, 114, 121, 123, 616, 618, "or" +404, 8, 23, 115, 124, 129, 619, 624, "early" +404, 8, 24, 116, 130, 137, 625, 632, "primary" +404, 8, 25, 117, 138, 142, 633, 637, "open" +404, 8, 26, 118, 143, 144, 638, 639, "-" +404, 8, 27, 119, 145, 150, 640, 645, "angle" +404, 8, 28, 120, 151, 159, 646, 654, "glaucoma" +404, 8, 29, 121, 160, 168, 655, 663, "received" +404, 8, 30, 122, 169, 175, 664, 670, "either" +404, 8, 31, 123, 176, 177, 671, 672, "0" +404, 8, 32, 124, 178, 179, 673, 674, "." +404, 8, 33, 125, 180, 183, 675, 678, "005" +404, 8, 34, 126, 184, 185, 679, 680, "%" +404, 8, 35, 127, 186, 197, 681, 692, "latanoprost" +404, 8, 36, 128, 198, 202, 693, 697, "once" +404, 8, 37, 129, 203, 208, 698, 703, "daily" +404, 8, 38, 130, 209, 211, 704, 706, "or" +404, 8, 39, 131, 212, 213, 707, 708, "0" +404, 8, 40, 132, 214, 215, 709, 710, "." +404, 8, 41, 133, 216, 217, 711, 712, "5" +404, 8, 42, 134, 218, 219, 713, 714, "%" +404, 8, 43, 135, 220, 227, 715, 722, "timolol" +404, 8, 44, 136, 228, 233, 723, 728, "twice" +404, 8, 45, 137, 234, 239, 729, 734, "daily" +404, 8, 46, 138, 240, 243, 735, 738, "for" +404, 8, 47, 139, 244, 245, 739, 740, "6" +404, 8, 48, 140, 246, 252, 741, 747, "months" +404, 8, 49, 141, 253, 254, 748, 749, "." +404, 9, 1, 142, 0, 3, 750, 753, "All" +404, 9, 2, 143, 4, 10, 754, 760, "except" +404, 9, 3, 144, 11, 14, 761, 764, "ten" +404, 9, 4, 145, 15, 23, 765, 773, "patients" +404, 9, 5, 146, 24, 28, 774, 778, "from" +404, 9, 6, 147, 29, 33, 779, 783, "each" +404, 9, 7, 148, 34, 39, 784, 789, "group" +404, 9, 8, 149, 40, 52, 790, 802, "successfully" +404, 9, 9, 150, 53, 62, 803, 812, "completed" +404, 9, 10, 151, 63, 66, 813, 816, "the" +404, 9, 11, 152, 67, 72, 817, 822, "study" +404, 9, 12, 153, 73, 74, 823, 824, "." +404, 10, 1, 154, 0, 7, 825, 832, "RESULTS" +404, 10, 2, 155, 8, 9, 833, 834, ":" +404, 10, 3, 156, 10, 21, 835, 846, "Intraocular" +404, 10, 4, 157, 22, 30, 847, 855, "pressure" +404, 10, 5, 158, 31, 32, 856, 857, "(" +404, 10, 6, 159, 33, 36, 858, 861, "IOP" +404, 10, 7, 160, 37, 38, 862, 863, ")" +404, 10, 8, 161, 39, 42, 864, 867, "was" +404, 10, 9, 162, 43, 56, 868, 881, "significantly" +404, 10, 10, 163, 57, 58, 882, 883, "(" +404, 10, 11, 164, 59, 60, 884, 885, "P" +404, 10, 12, 165, 61, 62, 886, 887, "<" +404, 10, 13, 166, 63, 64, 888, 889, "0" +404, 10, 14, 167, 65, 66, 890, 891, "." +404, 10, 15, 168, 67, 70, 892, 895, "001" +404, 10, 16, 169, 71, 72, 896, 897, ")" +404, 10, 17, 170, 73, 80, 898, 905, "reduced" +404, 10, 18, 171, 81, 84, 906, 909, "and" +404, 10, 19, 172, 85, 95, 910, 920, "maintained" +404, 10, 20, 173, 96, 98, 921, 923, "by" +404, 10, 21, 174, 99, 103, 924, 928, "both" +404, 10, 22, 175, 104, 115, 929, 940, "medications" +404, 10, 23, 176, 116, 123, 941, 948, "without" +404, 10, 24, 177, 124, 132, 949, 957, "evidence" +404, 10, 25, 178, 133, 135, 958, 960, "of" +404, 10, 26, 179, 136, 137, 961, 962, "a" +404, 10, 27, 180, 138, 142, 963, 967, "long" +404, 10, 28, 181, 143, 144, 968, 969, "-" +404, 10, 29, 182, 145, 149, 970, 974, "term" +404, 10, 30, 183, 150, 155, 975, 980, "drift" +404, 10, 31, 184, 156, 160, 981, 985, "over" +404, 10, 32, 185, 161, 162, 986, 987, "6" +404, 10, 33, 186, 163, 169, 988, 994, "months" +404, 10, 34, 187, 170, 171, 995, 996, "." +404, 11, 1, 188, 0, 9, 997, 1006, "Comparing" +404, 11, 2, 189, 10, 11, 1007, 1008, "6" +404, 11, 3, 190, 12, 13, 1009, 1010, "-" +404, 11, 4, 191, 14, 19, 1011, 1016, "month" +404, 11, 5, 192, 20, 24, 1017, 1021, "with" +404, 11, 6, 193, 25, 33, 1022, 1030, "baseline" +404, 11, 7, 194, 34, 41, 1031, 1038, "diurnal" +404, 11, 8, 195, 42, 45, 1039, 1042, "IOP" +404, 11, 9, 196, 46, 52, 1043, 1049, "values" +404, 11, 10, 197, 53, 54, 1050, 1051, "," +404, 11, 11, 198, 55, 58, 1052, 1055, "the" +404, 11, 12, 199, 59, 62, 1056, 1059, "IOP" +404, 11, 13, 200, 63, 72, 1060, 1069, "reduction" +404, 11, 14, 201, 73, 74, 1070, 1071, "(" +404, 11, 15, 202, 75, 79, 1072, 1076, "mean" +404, 11, 16, 203, 80, 81, 1077, 1078, "+" +404, 11, 17, 204, 82, 83, 1079, 1080, "/" +404, 11, 18, 205, 84, 85, 1081, 1082, "-" +404, 11, 19, 206, 86, 94, 1083, 1091, "standard" +404, 11, 20, 207, 95, 104, 1092, 1101, "deviation" +404, 11, 21, 208, 105, 106, 1102, 1103, ")" +404, 11, 22, 209, 107, 115, 1104, 1112, "achieved" +404, 11, 23, 210, 116, 120, 1113, 1117, "with" +404, 11, 24, 211, 121, 132, 1118, 1129, "latanoprost" +404, 11, 25, 212, 133, 134, 1130, 1131, "(" +404, 11, 26, 213, 135, 136, 1132, 1133, "-" +404, 11, 27, 214, 137, 138, 1134, 1135, "6" +404, 11, 28, 215, 139, 140, 1136, 1137, "." +404, 11, 29, 216, 141, 142, 1138, 1139, "7" +404, 11, 30, 217, 143, 144, 1140, 1141, "+" +404, 11, 31, 218, 145, 146, 1142, 1143, "/" +404, 11, 32, 219, 147, 148, 1144, 1145, "-" +404, 11, 33, 220, 149, 150, 1146, 1147, "3" +404, 11, 34, 221, 151, 152, 1148, 1149, "." +404, 11, 35, 222, 153, 154, 1150, 1151, "4" +404, 11, 36, 223, 155, 159, 1152, 1156, "mmHg" +404, 11, 37, 224, 160, 161, 1157, 1158, ")" +404, 11, 38, 225, 162, 165, 1159, 1162, "was" +404, 11, 39, 226, 166, 179, 1163, 1176, "significantly" +404, 11, 40, 227, 180, 181, 1177, 1178, "(" +404, 11, 41, 228, 182, 183, 1179, 1180, "P" +404, 11, 42, 229, 184, 185, 1181, 1182, "<" +404, 11, 43, 230, 186, 187, 1183, 1184, "0" +404, 11, 44, 231, 188, 189, 1185, 1186, "." +404, 11, 45, 232, 190, 193, 1187, 1190, "001" +404, 11, 46, 233, 194, 195, 1191, 1192, ")" +404, 11, 47, 234, 196, 203, 1193, 1200, "greater" +404, 11, 48, 235, 204, 208, 1201, 1205, "than" +404, 11, 49, 236, 209, 213, 1206, 1210, "that" +404, 11, 50, 237, 214, 222, 1211, 1219, "produced" +404, 11, 51, 238, 223, 227, 1220, 1224, "with" +404, 11, 52, 239, 228, 235, 1225, 1232, "timolol" +404, 11, 53, 240, 236, 237, 1233, 1234, "(" +404, 11, 54, 241, 238, 239, 1235, 1236, "4" +404, 11, 55, 242, 240, 241, 1237, 1238, "." +404, 11, 56, 243, 242, 243, 1239, 1240, "9" +404, 11, 57, 244, 244, 245, 1241, 1242, "+" +404, 11, 58, 245, 246, 247, 1243, 1244, "/" +404, 11, 59, 246, 248, 249, 1245, 1246, "-" +404, 11, 60, 247, 250, 251, 1247, 1248, "2" +404, 11, 61, 248, 252, 253, 1249, 1250, "." +404, 11, 62, 249, 254, 255, 1251, 1252, "9" +404, 11, 63, 250, 256, 260, 1253, 1257, "mmHg" +404, 11, 64, 251, 261, 262, 1258, 1259, ")" +404, 11, 65, 252, 263, 264, 1260, 1261, "." +404, 12, 1, 253, 0, 4, 1262, 1266, "Four" +404, 12, 2, 254, 5, 13, 1267, 1275, "patients" +404, 12, 3, 255, 14, 21, 1276, 1283, "treated" +404, 12, 4, 256, 22, 26, 1284, 1288, "with" +404, 12, 5, 257, 27, 34, 1289, 1296, "timolol" +404, 12, 6, 258, 35, 38, 1297, 1300, "and" +404, 12, 7, 259, 39, 43, 1301, 1305, "none" +404, 12, 8, 260, 44, 51, 1306, 1313, "treated" +404, 12, 9, 261, 52, 56, 1314, 1318, "with" +404, 12, 10, 262, 57, 68, 1319, 1330, "latanoprost" +404, 12, 11, 263, 69, 73, 1331, 1335, "were" +404, 12, 12, 264, 74, 83, 1336, 1345, "withdrawn" +404, 12, 13, 265, 84, 88, 1346, 1350, "from" +404, 12, 14, 266, 89, 92, 1351, 1354, "the" +404, 12, 15, 267, 93, 98, 1355, 1360, "study" +404, 12, 16, 268, 99, 106, 1361, 1368, "because" +404, 12, 17, 269, 107, 109, 1369, 1371, "of" +404, 12, 18, 270, 110, 120, 1372, 1382, "inadequate" +404, 12, 19, 271, 121, 124, 1383, 1386, "IOP" +404, 12, 20, 272, 125, 132, 1387, 1394, "control" +404, 12, 21, 273, 133, 134, 1395, 1396, "." +404, 13, 1, 274, 0, 5, 1397, 1402, "Pulse" +404, 13, 2, 275, 6, 10, 1403, 1407, "rate" +404, 13, 3, 276, 11, 14, 1408, 1411, "was" +404, 13, 4, 277, 15, 28, 1412, 1425, "significantly" +404, 13, 5, 278, 29, 36, 1426, 1433, "reduced" +404, 13, 6, 279, 37, 41, 1434, 1438, "with" +404, 13, 7, 280, 42, 49, 1439, 1446, "timolol" +404, 13, 8, 281, 50, 51, 1447, 1448, "," +404, 13, 9, 282, 52, 55, 1449, 1452, "but" +404, 13, 10, 283, 56, 59, 1453, 1456, "not" +404, 13, 11, 284, 60, 64, 1457, 1461, "with" +404, 13, 12, 285, 65, 76, 1462, 1473, "latanoprost" +404, 13, 13, 286, 77, 78, 1474, 1475, "." +404, 14, 1, 287, 0, 8, 1476, 1484, "Slightly" +404, 14, 2, 288, 9, 13, 1485, 1489, "more" +404, 14, 3, 289, 14, 26, 1490, 1502, "conjunctival" +404, 14, 4, 290, 27, 36, 1503, 1512, "hyperemia" +404, 14, 5, 291, 37, 45, 1513, 1521, "appeared" +404, 14, 6, 292, 46, 48, 1522, 1524, "in" +404, 14, 7, 293, 49, 60, 1525, 1536, "latanoprost" +404, 14, 8, 294, 61, 62, 1537, 1538, "-" +404, 14, 9, 295, 63, 70, 1539, 1546, "treated" +404, 14, 10, 296, 71, 79, 1547, 1555, "compared" +404, 14, 11, 297, 80, 84, 1556, 1560, "with" +404, 14, 12, 298, 85, 92, 1561, 1568, "timolol" +404, 14, 13, 299, 93, 94, 1569, 1570, "-" +404, 14, 14, 300, 95, 102, 1571, 1578, "treated" +404, 14, 15, 301, 103, 107, 1579, 1583, "eyes" +404, 14, 16, 302, 108, 109, 1584, 1585, "." +404, 15, 1, 303, 0, 5, 1586, 1591, "Fewer" +404, 15, 2, 304, 6, 16, 1592, 1602, "subjective" +404, 15, 3, 305, 17, 21, 1603, 1607, "side" +404, 15, 4, 306, 22, 29, 1608, 1615, "effects" +404, 15, 5, 307, 30, 38, 1616, 1624, "occurred" +404, 15, 6, 308, 39, 41, 1625, 1627, "in" +404, 15, 7, 309, 42, 53, 1628, 1639, "latanoprost" +404, 15, 8, 310, 54, 55, 1640, 1641, "-" +404, 15, 9, 311, 56, 63, 1642, 1649, "treated" +404, 15, 10, 312, 64, 68, 1650, 1654, "eyes" +404, 15, 11, 313, 69, 70, 1655, 1656, "." +404, 16, 1, 314, 0, 4, 1657, 1661, "Both" +404, 16, 2, 315, 5, 9, 1662, 1666, "eyes" +404, 16, 3, 316, 10, 12, 1667, 1669, "of" +404, 16, 4, 317, 13, 14, 1670, 1671, "a" +404, 16, 5, 318, 15, 22, 1672, 1679, "patient" +404, 16, 6, 319, 23, 27, 1680, 1684, "with" +404, 16, 7, 320, 28, 29, 1685, 1686, "a" +404, 16, 8, 321, 30, 44, 1687, 1701, "characteristic" +404, 16, 9, 322, 45, 46, 1702, 1703, "," +404, 16, 10, 323, 47, 57, 1704, 1714, "concentric" +404, 16, 11, 324, 58, 62, 1715, 1719, "iris" +404, 16, 12, 325, 63, 76, 1720, 1733, "heterochromia" +404, 16, 13, 326, 77, 78, 1734, 1735, "(" +404, 16, 14, 327, 79, 85, 1736, 1742, "darker" +404, 16, 15, 328, 86, 95, 1743, 1752, "centrally" +404, 16, 16, 329, 96, 97, 1753, 1754, ")" +404, 16, 17, 330, 98, 100, 1755, 1757, "at" +404, 16, 18, 331, 101, 109, 1758, 1766, "baseline" +404, 16, 19, 332, 110, 116, 1767, 1773, "showed" +404, 16, 20, 333, 117, 118, 1774, 1775, "a" +404, 16, 21, 334, 119, 127, 1776, 1784, "definite" +404, 16, 22, 335, 128, 129, 1785, 1786, "," +404, 16, 23, 336, 130, 146, 1787, 1803, "photographically" +404, 16, 24, 337, 147, 157, 1804, 1814, "documented" +404, 16, 25, 338, 158, 166, 1815, 1823, "increase" +404, 16, 26, 339, 167, 169, 1824, 1826, "in" +404, 16, 27, 340, 170, 182, 1827, 1839, "pigmentation" +404, 16, 28, 341, 183, 189, 1840, 1846, "during" +404, 16, 29, 342, 190, 201, 1847, 1858, "latanoprost" +404, 16, 30, 343, 202, 211, 1859, 1868, "treatment" +404, 16, 31, 344, 212, 213, 1869, 1870, "," +404, 16, 32, 345, 214, 220, 1871, 1877, "making" +404, 16, 33, 346, 221, 224, 1878, 1881, "the" +404, 16, 34, 347, 225, 231, 1882, 1888, "irides" +404, 16, 35, 348, 232, 241, 1889, 1898, "uniformly" +404, 16, 36, 349, 242, 248, 1899, 1905, "darker" +404, 16, 37, 350, 249, 250, 1906, 1907, "." +404, 17, 1, 351, 0, 5, 1908, 1913, "Three" +404, 17, 2, 352, 6, 16, 1914, 1924, "additional" +404, 17, 3, 353, 17, 25, 1925, 1933, "patients" +404, 17, 4, 354, 26, 33, 1934, 1941, "treated" +404, 17, 5, 355, 34, 38, 1942, 1946, "with" +404, 17, 6, 356, 39, 50, 1947, 1958, "latanoprost" +404, 17, 7, 357, 51, 55, 1959, 1963, "were" +404, 17, 8, 358, 56, 64, 1964, 1972, "suspects" +404, 17, 9, 359, 65, 68, 1973, 1976, "for" +404, 17, 10, 360, 69, 73, 1977, 1981, "this" +404, 17, 11, 361, 74, 79, 1982, 1987, "color" +404, 17, 12, 362, 80, 86, 1988, 1994, "change" +404, 17, 13, 363, 87, 88, 1995, 1996, "." +404, 18, 1, 364, 0, 9, 1997, 2006, "Otherwise" +404, 18, 2, 365, 10, 11, 2007, 2008, "," +404, 18, 3, 366, 12, 14, 2009, 2011, "no" +404, 18, 4, 367, 15, 26, 2012, 2023, "significant" +404, 18, 5, 368, 27, 37, 2024, 2034, "difference" +404, 18, 6, 369, 38, 45, 2035, 2042, "between" +404, 18, 7, 370, 46, 55, 2043, 2052, "treatment" +404, 18, 8, 371, 56, 62, 2053, 2059, "groups" +404, 18, 9, 372, 63, 71, 2060, 2068, "occurred" +404, 18, 10, 373, 72, 78, 2069, 2075, "visual" +404, 18, 11, 374, 79, 85, 2076, 2082, "acuity" +404, 18, 12, 375, 86, 87, 2083, 2084, "," +404, 18, 13, 376, 88, 92, 2085, 2089, "slit" +404, 18, 14, 377, 93, 94, 2090, 2091, "-" +404, 18, 15, 378, 95, 99, 2092, 2096, "lamp" +404, 18, 16, 379, 100, 111, 2097, 2108, "examination" +404, 18, 17, 380, 112, 113, 2109, 2110, "," +404, 18, 18, 381, 114, 119, 2111, 2116, "blood" +404, 18, 19, 382, 120, 128, 2117, 2125, "pressure" +404, 18, 20, 383, 129, 130, 2126, 2127, "," +404, 18, 21, 384, 131, 134, 2128, 2131, "and" +404, 18, 22, 385, 135, 145, 2132, 2142, "laboratory" +404, 18, 23, 386, 146, 152, 2143, 2149, "values" +404, 18, 24, 387, 153, 154, 2150, 2151, "." +404, 19, 1, 388, 0, 10, 2152, 2162, "CONCLUSION" +404, 19, 2, 389, 11, 12, 2163, 2164, ":" +404, 19, 3, 390, 13, 24, 2165, 2176, "Latanoprost" +404, 19, 4, 391, 25, 28, 2177, 2180, "has" +404, 19, 5, 392, 29, 32, 2181, 2184, "the" +404, 19, 6, 393, 33, 42, 2185, 2194, "potential" +404, 19, 7, 394, 43, 46, 2195, 2198, "for" +404, 19, 8, 395, 47, 55, 2199, 2207, "becoming" +404, 19, 9, 396, 56, 57, 2208, 2209, "a" +404, 19, 10, 397, 58, 61, 2210, 2213, "new" +404, 19, 11, 398, 62, 67, 2214, 2219, "first" +404, 19, 12, 399, 68, 69, 2220, 2221, "-" +404, 19, 13, 400, 70, 74, 2222, 2226, "line" +404, 19, 14, 401, 75, 84, 2227, 2236, "treatment" +404, 19, 15, 402, 85, 88, 2237, 2240, "for" +404, 19, 16, 403, 89, 97, 2241, 2249, "glaucoma" +404, 19, 17, 404, 98, 99, 2250, 2251, "." +404, 20, 1, 405, 0, 4, 2252, 2256, "PMID" +404, 20, 2, 406, 5, 6, 2257, 2258, ":" +404, 20, 3, 407, 7, 14, 2259, 2266, "8628544" +404, 20, 4, 408, 15, 16, 2267, 2268, "[" +404, 20, 5, 409, 17, 24, 2269, 2276, "Indexed" +404, 20, 6, 410, 25, 28, 2277, 2280, "for" +404, 20, 7, 411, 29, 36, 2281, 2288, "MEDLINE" +404, 20, 8, 412, 37, 38, 2289, 2290, "]" diff --git a/data/gl 8628544_jshahinitiran.annodb b/data/gl 8628544_jshahinitiran.annodb new file mode 100644 index 0000000..11a2c60 --- /dev/null +++ b/data/gl 8628544_jshahinitiran.annodb @@ -0,0 +1,71 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32754, Journal, 0, 13, "Ophthalmology", "", +32755, PublicationYear, 16, 20, "1996", "", +32756, Title, 50, 201, "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six - month masked , multicenter trial in the United States", "", +32757, Latanoprost, 64, 75, "latanoprost", "", +32758, Timolol, 80, 87, "timolol", "", +32759, OcularHypertension, 105, 124, "ocular hypertension", "", +32761, Glaucoma, 129, 137, "glaucoma", "", +32762, Duration, 142, 153, "six - month", "", +32776, DoubleBlind, 154, 160, "masked", "", +32764, Multicenter, 163, 174, "multicenter", "", +32765, USA, 188, 201, "United States", "", +32766, USA, 208, 221, "United States", "", +32767, Latanoprost, 222, 233, "Latanoprost", "", +32768, Author, 248, 257, "Camras CB", "", +32769, USA, 357, 360, "USA", "", +32770, ObjectiveDescription, 373, 494, "Latanoprost , a new prostaglandin analogue , was compared with timolol for ocular hypotensive efficacy and side effects .", "", +32771, Latanoprost, 373, 384, "Latanoprost", "", +32772, Timolol, 436, 443, "timolol", "", +32773, Multicenter, 510, 521, "multicenter", "", +32774, Randomized, 524, 534, "randomized", "", +32775, DoubleBlind, 537, 552, "double - masked", "", +32777, Parallel, 555, 563, "parallel", "", +32778, NumberPatientsCT, 578, 581, "268", "", +32779, OcularHypertension, 596, 615, "ocular hypertension", "", +32780, Primary_OpenAngleGlaucoma, 625, 654, "primary open - angle glaucoma", "", +32783, DoseValue, 671, 678, "0 . 005", "", +32785, Percentage, 679, 680, "%", "", +32781, Latanoprost, 681, 692, "latanoprost", "", +32787, Frequency, 693, 703, "once daily", "", +32784, DoseValue, 707, 712, "0 . 5", "", +32786, Percentage, 713, 714, "%", "", +32782, Timolol, 715, 722, "timolol", "", +32788, Frequency, 723, 734, "twice daily", "", +32789, Duration, 739, 747, "6 months", "", +32790, NumPatientsLeftArm, 761, 764, "ten", "", +32791, IOP, 835, 855, "Intraocular pressure", "", +32792, IOP, 858, 861, "IOP", "", +32793, PValueChangeValue, 884, 895, "P < 0 . 001", "", +32794, Duration, 986, 994, "6 months", "", +32795, TimePoint, 1007, 1016, "6 - month", "", +32796, Diurnal_IOP, 1031, 1042, "diurnal IOP", "", +32797, IOP, 1056, 1059, "IOP", "", +32801, Mean, 1072, 1076, "mean", "", +32798, Latanoprost, 1118, 1129, "latanoprost", "", +32799, Reduction, 1134, 1139, "6 . 7", "", +32802, SdDevChangeValue, 1146, 1151, "3 . 4", "", +32804, mmHg, 1152, 1156, "mmHg", "", +32806, PValueChangeValue, 1179, 1190, "P < 0 . 001", "", +32807, Timolol, 1225, 1232, "timolol", "", +32800, Reduction, 1235, 1240, "4 . 9", "", +32803, SdDevChangeValue, 1247, 1252, "2 . 9", "", +32805, mmHg, 1253, 1257, "mmHg", "", +32808, Timolol, 1289, 1296, "timolol", "", +32809, Latanoprost, 1319, 1330, "latanoprost", "", +32810, IOP, 1383, 1386, "IOP", "", +32811, HeartRate, 1397, 1407, "Pulse rate", "", +32812, Timolol, 1439, 1446, "timolol", "", +32813, Latanoprost, 1462, 1473, "latanoprost", "", +32814, ConjunctivalHyperemia, 1490, 1512, "conjunctival hyperemia", "", +32815, Latanoprost, 1525, 1536, "latanoprost", "", +32816, Timolol, 1561, 1568, "timolol", "", +32817, Latanoprost, 1628, 1639, "latanoprost", "", +32818, IrisPigmentation, 1827, 1839, "pigmentation", "", +32819, Latanoprost, 1847, 1858, "latanoprost", "", +32820, Latanoprost, 1947, 1958, "latanoprost", "", +32822, BloodPressure, 2111, 2125, "blood pressure", "", +32823, ConclusionComment, 2165, 2251, "Latanoprost has the potential for becoming a new first - line treatment for glaucoma .", "", +32824, Latanoprost, 2165, 2176, "Latanoprost", "", +32825, Glaucoma, 2241, 2249, "glaucoma", "", +32826, PMID, 2259, 2266, "8628544", "", diff --git a/data/gl 8628544_jshahinitiran.n-triples b/data/gl 8628544_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8628544_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8628544_tstrakeljahn.annodb b/data/gl 8628544_tstrakeljahn.annodb new file mode 100644 index 0000000..fc16b15 --- /dev/null +++ b/data/gl 8628544_tstrakeljahn.annodb @@ -0,0 +1,70 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7989, Journal, 0, 13, "Ophthalmology", "", +7990, Year, 16, 20, "1996", "", +8004, Title, 50, 203, "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six - month masked , multicenter trial in the United States .", "", +7991, Latanoprost, 64, 75, "latanoprost", "", +7992, Timolol, 80, 87, "timolol", "", +7993, OcularHypertension, 105, 124, "ocular hypertension", "", +7994, Glaucoma, 129, 137, "glaucoma", "", +7995, Duration, 142, 153, "six - month", "", +7996, Blind, 154, 160, "masked", "", +7997, Multicenter, 163, 174, "multicenter", "", +7998, USA, 188, 201, "United States", "", +29817, Latanoprost, 222, 233, "Latanoprost", "", +7999, Author, 248, 257, "Camras CB", "", +8000, USA, 357, 360, "USA", "", +8001, Latanoprost, 373, 384, "Latanoprost", "", +8003, ObjectiveDescription, 373, 494, "Latanoprost , a new prostaglandin analogue , was compared with timolol for ocular hypotensive efficacy and side effects .", "", +8002, Timolol, 436, 443, "timolol", "", +8005, Multicenter, 510, 521, "multicenter", "", +8006, Randomized, 524, 534, "randomized", "", +8007, DoubleBlind, 537, 552, "double - masked", "", +8008, Parallel, 555, 563, "parallel", "", +8009, NumberPatientsCT, 578, 581, "268", "", +8010, OcularHypertension, 596, 615, "ocular hypertension", "", +8011, OpenAngleGlaucoma, 633, 654, "open - angle glaucoma", "", +8012, DoseValue, 671, 678, "0 . 005", "", +8014, Latanoprost, 681, 692, "latanoprost", "", +8015, Frequency, 693, 703, "once daily", "", +8013, DoseValue, 707, 712, "0 . 5", "", +8016, Timolol, 715, 722, "timolol", "", +8017, Frequency, 723, 734, "twice daily", "", +8018, Duration, 739, 747, "6 months", "", +8019, NumPatientsLeftArm, 761, 764, "ten", "", +8020, IOP, 835, 855, "Intraocular pressure", "", +8021, IOP, 858, 861, "IOP", "", +8022, PValueChangeValue, 884, 895, "P < 0 . 001", "", +8023, Duration, 986, 994, "6 months", "", +8024, Duration, 1007, 1016, "6 - month", "", +8025, Diurnal_IOP, 1031, 1042, "diurnal IOP", "", +8026, IOP, 1056, 1059, "IOP", "", +8035, Latanoprost, 1118, 1129, "latanoprost", "", +8028, Reduction, 1134, 1139, "6 . 7", "", +8027, SdDevResValue, 1140, 1151, "+ / - 3 . 4", "", +8032, mmHg, 1152, 1156, "mmHg", "", +8033, PValueChangeValue, 1179, 1190, "P < 0 . 001", "", +8034, Timolol, 1225, 1232, "timolol", "", +8029, Reduction, 1235, 1240, "4 . 9", "", +8030, SdDevChangeValue, 1241, 1252, "+ / - 2 . 9", "", +8031, mmHg, 1253, 1257, "mmHg", "", +8036, NumPatientsLeftArm, 1262, 1266, "Four", "", +8037, Timolol, 1289, 1296, "timolol", "", +8038, Latanoprost, 1319, 1330, "latanoprost", "", +8039, IOP, 1383, 1386, "IOP", "", +8042, ObservedResult, 1397, 1475, "Pulse rate was significantly reduced with timolol , but not with latanoprost .", "", +8040, Timolol, 1439, 1446, "timolol", "", +8041, Latanoprost, 1462, 1473, "latanoprost", "", +8046, ObservedResult, 1476, 1585, "Slightly more conjunctival hyperemia appeared in latanoprost - treated compared with timolol - treated eyes .", "", +8044, Latanoprost, 1525, 1536, "latanoprost", "", +8045, Timolol, 1561, 1568, "timolol", "", +8048, ObservedResult, 1586, 1656, "Fewer subjective side effects occurred in latanoprost - treated eyes .", "", +8047, Latanoprost, 1628, 1639, "latanoprost", "", +8051, ObservedResult, 1657, 1907, "Both eyes of a patient with a characteristic , concentric iris heterochromia ( darker centrally ) at baseline showed a definite , photographically documented increase in pigmentation during latanoprost treatment , making the irides uniformly darker .", "", +8050, Latanoprost, 1847, 1858, "latanoprost", "", +8052, ObservedResult, 1908, 1996, "Three additional patients treated with latanoprost were suspects for this color change .", "", +8053, Latanoprost, 1947, 1958, "latanoprost", "", +8054, ObservedResult, 1997, 2151, "Otherwise , no significant difference between treatment groups occurred visual acuity , slit - lamp examination , blood pressure , and laboratory values .", "", +8055, Latanoprost, 2165, 2176, "Latanoprost", "", +8057, ConclusionComment, 2165, 2251, "Latanoprost has the potential for becoming a new first - line treatment for glaucoma .", "", +8056, Glaucoma, 2241, 2249, "glaucoma", "", +29818, PMID, 2259, 2266, "8628544", "", diff --git a/data/gl 8628544_tstrakeljahn.n-triples b/data/gl 8628544_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8628544_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8694726_admin.annodb b/data/gl 8694726_admin.annodb new file mode 100644 index 0000000..0802f45 --- /dev/null +++ b/data/gl 8694726_admin.annodb @@ -0,0 +1,85 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Arch Ophthalmol .", "", " \"Arch Ophthalmol .\"." +1, PublicationYear, 18, 22, "1996", "", " \"1996\"." +6, Title, 52, 150, "A comparison of latanoprost and timolol in primary open - angle glaucoma and ocular hypertension .", "", " \"A comparison of latanoprost and timolol in primary open - angle glaucoma and ocular hypertension .\"." +2, Latanoprost, 68, 79, "latanoprost", "", +3, Timolol, 84, 91, "timolol", "", +4, Primary_OpenAngleGlaucoma, 95, 124, "primary open - angle glaucoma", "", " ." +5, OcularHypertension, 129, 148, "ocular hypertension", "", " ." +6, Title, 151, 170, "A 12 - week study .", "", " \"A 12 - week study .\"." +7, Duration, 153, 162, "12 - week", "", " \"12 - week\"." +8, Author, 171, 181, "Mishima HK", "", " \"Mishima HK\"." +9, Author, 190, 198, "Masuda K", "", " \"Masuda K\"." +10, Author, 201, 211, "Kitazawa Y", "", " \"Kitazawa Y\"." +11, Author, 214, 221, "Azuma I", "", " \"Azuma I\"." +12, Author, 224, 231, "Araie M", "", " \"Araie M\"." +13, Japan, 314, 319, "Japan", "", " ." +91, PublicationYear, 351, 355, "1996", "", +21, ObjectiveDescription, 396, 647, "To evaluate the intraocular pressure ( IOP ) - reducing effect and the side effects of latanoprost ( PhXA41 ) , a new phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue , in patients with elevated IOP , using timolol maleate as the", "", " \"To evaluate the intraocular pressure ( IOP ) - reducing effect and the side effects of latanoprost ( PhXA41 ) , a new phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue , in patients with elevated IOP , using timolol maleate as the\"." +14, IOP, 412, 432, "intraocular pressure", "", +15, IOP, 435, 438, "IOP", "", +16, Latanoprost, 483, 494, "latanoprost", "", +17, Latanoprost, 497, 503, "PhXA41", "", +105982, ProstaglandinAnalogs, 535, 584, "prostaglandin F2 alpha - isopropyl ester analogue", "", +97, Precondition, 590, 616, "patients with elevated IOP", "", " \"patients with elevated IOP\"." +19, IOP, 613, 616, "IOP", "", +20, Timolol, 625, 640, "timolol maleate", "", +22, ObjectiveDescription, 648, 664, "reference drug .", "", " \"reference drug .\"." +23, NumberPatientsCT, 686, 689, "184", "", " \"184\"." +24, Primary_OpenAngleGlaucoma, 704, 733, "primary open - angle glaucoma", "", +25, OcularHypertension, 737, 756, "ocular hypertension", "", +26, Multicenter, 760, 778, "35 medical centers", "", " ." +27, Randomized, 800, 810, "randomized", "", " ." +28, DoubleBlind, 811, 826, "double - masked", "", " ." +29, Randomized, 853, 863, "randomized", "", +30, DoseValue, 882, 889, "0 . 005", "", " \"0 . 005\"." +32, Percentage, 890, 891, "%", "", " ." +34, Latanoprost, 892, 903, "latanoprost", "", " . ." +36, Frequency, 904, 914, "once daily", "", " \"once daily\"." +31, DoseValue, 918, 923, "0 . 5", "", " \"0 . 5\"." +33, Percentage, 924, 925, "%", "", " ." +35, Timolol, 926, 941, "timolol maleate", "", " ." +37, Frequency, 942, 953, "twice daily", "", " \"twice daily\"." +38, Duration, 972, 980, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +39, IOP, 983, 1003, "Intraocular pressure", "", " . ." +40, Timolol, 1054, 1061, "timolol", "", +44, TimePoint, 1067, 1091, "2 , 4 , 8 , and 12 weeks", "", +43, TimePoint, 1071, 1091, "4 , 8 , and 12 weeks", "", +42, TimePoint, 1075, 1091, "8 , and 12 weeks", "", +41, TimePoint, 1083, 1091, "12 weeks", "", +45, Latanoprost, 1117, 1128, "Latanoprost", "", +46, IOP, 1137, 1140, "IOP", "", +121, TimePoint, 1155, 1163, "12 weeks", "", " \"12 weeks\". \"12 weeks\"." +48, Reduction, 1167, 1172, "6 . 2", "", " \"6 . 2\"." +50, SdDevChangeValue, 1179, 1184, "2 . 7", "", " \"2 . 7\"." +52, mmHg, 1185, 1190, "mm Hg", "", " ." +125, Mean, 1193, 1197, "mean", "", " . ." +56, RelativeReduction, 1211, 1217, "26 . 8", "", " \"26 . 8\"." +54, Timolol, 1230, 1237, "timolol", "", +55, IOP, 1246, 1249, "IOP", "", +49, Reduction, 1253, 1258, "4 . 4", "", " \"4 . 4\"." +51, SdDevChangeValue, 1265, 1270, "2 . 3", "", " \"2 . 3\"." +53, mmHg, 1271, 1276, "mm Hg", "", " ." +57, RelativeReduction, 1279, 1285, "19 . 9", "", " \"19 . 9\"." +58, Latanoprost, 1306, 1317, "latanoprost", "", +59, IOP, 1326, 1329, "IOP", "", +60, Timolol, 1354, 1361, "timolol", "", +105986, ObservedResult, 1368, 1420, "The main ocular side effects observed in both groups", "", " \"The main ocular side effects observed in both groups\". \"The main ocular side effects observed in both groups\"." +62, ConjunctivalHyperemia, 1426, 1448, "conjunctival hyperemia", "", " ." +63, Smarting, 1453, 1461, "smarting", "", " ." +105985, ObservedResult, 1464, 1493, "The main systemic side effect", "", " \"The main systemic side effect\"." +105984, EndPointDescription, 1500, 1518, "reduced pulse rate", "", " . ." +65, PulseRate, 1508, 1518, "pulse rate", "", +66, Timolol, 1561, 1568, "timolol", "", +77, ConclusionComment, 1585, 1761, "The results of this study demonstrated that 0 . 005 % latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .", "", " \"The results of this study demonstrated that 0 . 005 % latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .\"." +68, DoseValue, 1629, 1636, "0 . 005", "", +70, Latanoprost, 1639, 1650, "latanoprost", "", +72, Frequency, 1657, 1667, "once daily", "", +74, IOP, 1717, 1720, "IOP", "", +69, DoseValue, 1726, 1731, "0 . 5", "", +71, Timolol, 1734, 1741, "timolol", "", +73, Frequency, 1748, 1759, "twice daily", "", +78, ConclusionComment, 1762, 1851, "Thus , latanoprost may become an important choice for the medical treatment of glaucoma .", "", " \"Thus , latanoprost may become an important choice for the medical treatment of glaucoma .\"." +75, Latanoprost, 1769, 1780, "latanoprost", "", +76, Glaucoma, 1841, 1849, "glaucoma", "", +79, PMID, 1910, 1917, "8694726", "", " \"8694726\"." diff --git a/data/gl 8694726_admin.n-triples b/data/gl 8694726_admin.n-triples new file mode 100644 index 0000000..ce87920 --- /dev/null +++ b/data/gl 8694726_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication " . + "A comparison of latanoprost and timolol in primary open - angle glaucoma and ocular hypertension ." . + "A 12 - week study ." . + "Mishima HK" . + "1996" . + "Arch Ophthalmol ." . + "8694726" . + . + "Masuda K" . + "Kitazawa Y" . + "Azuma I" . + "Araie M" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial " . + "To evaluate the intraocular pressure ( IOP ) - reducing effect and the side effects of latanoprost ( PhXA41 ) , a new phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue , in patients with elevated IOP , using timolol maleate as the" . + "184" . + "12 - week" . + . + . + . + "The results of this study demonstrated that 0 . 005 % latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily ." . + . + . + . + . + . + "reference drug ." . + . + . + "Thus , latanoprost may become an important choice for the medical treatment of glaucoma ." . + . + . +# RDF export of group: Population + . + "Population " . + "patients with elevated IOP" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint IOP" . + . + . + . + . + . + . + . + "Endpoint ch " . + . + . + . + . + . + "Endpoint s" . + . + . + . + . + . + "Endpoint pr " . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm l" . + . + . + . + . + . + "Arm tim " . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention l" . + . + "once daily" . + "12 weeks" . + . + . + "Intervention tim" . + . + "twice daily" . + "12 weeks" . + . +# RDF export of group: Medication + . + "Medication l" . + . + . + "0 . 005" . + . + . + . + "Medication tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome IOP l " . + . + "6 . 2" . + "26 . 8" . + "2 . 7" . + "12 weeks" . + . + "Outcome IOP tim " . + . + "4 . 4" . + "19 . 9" . + "2 . 3" . + "12 weeks" . + . + "Outcome ch both drugs " . + . + "The main ocular side effects observed in both groups" . + . + "Outcome s both drugs" . + . + "The main ocular side effects observed in both groups" . + . + "Outcome pr tim " . + . + "The main systemic side effect" . +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8694726_export.csv b/data/gl 8694726_export.csv new file mode 100644 index 0000000..369845b --- /dev/null +++ b/data/gl 8694726_export.csv @@ -0,0 +1,399 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +541, 1, 1, 1, 0, 4, 0, 4, "Arch" +541, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +541, 1, 3, 3, 16, 17, 16, 17, "." +541, 2, 1, 4, 0, 4, 18, 22, "1996" +541, 2, 2, 5, 5, 8, 23, 26, "Aug" +541, 2, 3, 6, 9, 10, 27, 28, ";" +541, 2, 4, 7, 11, 14, 29, 32, "114" +541, 2, 5, 8, 15, 16, 33, 34, "(" +541, 2, 6, 9, 17, 18, 35, 36, "8" +541, 2, 7, 10, 19, 20, 37, 38, ")" +541, 2, 8, 11, 21, 22, 39, 40, ":" +541, 2, 9, 12, 23, 26, 41, 44, "929" +541, 2, 10, 13, 27, 28, 45, 46, "-" +541, 2, 11, 14, 29, 31, 47, 49, "32" +541, 2, 12, 15, 32, 33, 50, 51, "." +541, 3, 1, 16, 0, 1, 52, 53, "A" +541, 3, 2, 17, 2, 12, 54, 64, "comparison" +541, 3, 3, 18, 13, 15, 65, 67, "of" +541, 3, 4, 19, 16, 27, 68, 79, "latanoprost" +541, 3, 5, 20, 28, 31, 80, 83, "and" +541, 3, 6, 21, 32, 39, 84, 91, "timolol" +541, 3, 7, 22, 40, 42, 92, 94, "in" +541, 3, 8, 23, 43, 50, 95, 102, "primary" +541, 3, 9, 24, 51, 55, 103, 107, "open" +541, 3, 10, 25, 56, 57, 108, 109, "-" +541, 3, 11, 26, 58, 63, 110, 115, "angle" +541, 3, 12, 27, 64, 72, 116, 124, "glaucoma" +541, 3, 13, 28, 73, 76, 125, 128, "and" +541, 3, 14, 29, 77, 83, 129, 135, "ocular" +541, 3, 15, 30, 84, 96, 136, 148, "hypertension" +541, 3, 16, 31, 97, 98, 149, 150, "." +541, 4, 1, 32, 0, 1, 151, 152, "A" +541, 4, 2, 33, 2, 4, 153, 155, "12" +541, 4, 3, 34, 5, 6, 156, 157, "-" +541, 4, 4, 35, 7, 11, 158, 162, "week" +541, 4, 5, 36, 12, 17, 163, 168, "study" +541, 4, 6, 37, 18, 19, 169, 170, "." +541, 5, 1, 38, 0, 7, 171, 178, "Mishima" +541, 5, 2, 39, 8, 10, 179, 181, "HK" +541, 5, 3, 40, 11, 12, 182, 183, "(" +541, 5, 4, 41, 13, 14, 184, 185, "1" +541, 5, 5, 42, 15, 16, 186, 187, ")" +541, 5, 6, 43, 17, 18, 188, 189, "," +541, 5, 7, 44, 19, 25, 190, 196, "Masuda" +541, 5, 8, 45, 26, 27, 197, 198, "K" +541, 5, 9, 46, 28, 29, 199, 200, "," +541, 5, 10, 47, 30, 38, 201, 209, "Kitazawa" +541, 5, 11, 48, 39, 40, 210, 211, "Y" +541, 5, 12, 49, 41, 42, 212, 213, "," +541, 5, 13, 50, 43, 48, 214, 219, "Azuma" +541, 5, 14, 51, 49, 50, 220, 221, "I" +541, 5, 15, 52, 51, 52, 222, 223, "," +541, 5, 16, 53, 53, 58, 224, 229, "Araie" +541, 5, 17, 54, 59, 60, 230, 231, "M" +541, 5, 18, 55, 61, 62, 232, 233, "." +541, 5, 19, 56, 63, 69, 234, 240, "Author" +541, 5, 20, 57, 70, 81, 241, 252, "information" +541, 5, 21, 58, 82, 83, 253, 254, ":" +541, 5, 22, 59, 84, 85, 255, 256, "(" +541, 5, 23, 60, 86, 87, 257, 258, "1" +541, 5, 24, 61, 88, 89, 259, 260, ")" +541, 5, 25, 62, 90, 100, 261, 271, "Department" +541, 5, 26, 63, 101, 103, 272, 274, "of" +541, 5, 27, 64, 104, 117, 275, 288, "Ophthalmology" +541, 5, 28, 65, 118, 119, 289, 290, "," +541, 5, 29, 66, 120, 129, 291, 300, "Hiroshima" +541, 5, 30, 67, 130, 140, 301, 311, "University" +541, 5, 31, 68, 141, 142, 312, 313, "," +541, 5, 32, 69, 143, 148, 314, 319, "Japan" +541, 5, 33, 70, 149, 150, 320, 321, "." +541, 6, 1, 71, 0, 7, 322, 329, "Comment" +541, 6, 2, 72, 8, 10, 330, 332, "in" +541, 6, 3, 73, 11, 15, 333, 337, "Arch" +541, 6, 4, 74, 16, 26, 338, 348, "Ophthalmol" +541, 6, 5, 75, 27, 28, 349, 350, "." +541, 7, 1, 76, 0, 4, 351, 355, "1996" +541, 7, 2, 77, 5, 8, 356, 359, "Aug" +541, 7, 3, 78, 9, 10, 360, 361, ";" +541, 7, 4, 79, 11, 14, 362, 365, "114" +541, 7, 5, 80, 15, 16, 366, 367, "(" +541, 7, 6, 81, 17, 18, 368, 369, "8" +541, 7, 7, 82, 19, 20, 370, 371, ")" +541, 7, 8, 83, 21, 22, 372, 373, ":" +541, 7, 9, 84, 23, 26, 374, 377, "998" +541, 7, 10, 85, 27, 28, 378, 379, "-" +541, 7, 11, 86, 29, 30, 380, 381, "9" +541, 7, 12, 87, 31, 32, 382, 383, "." +541, 8, 1, 88, 0, 9, 384, 393, "OBJECTIVE" +541, 8, 2, 89, 10, 11, 394, 395, ":" +541, 8, 3, 90, 12, 14, 396, 398, "To" +541, 8, 4, 91, 15, 23, 399, 407, "evaluate" +541, 8, 5, 92, 24, 27, 408, 411, "the" +541, 8, 6, 93, 28, 39, 412, 423, "intraocular" +541, 8, 7, 94, 40, 48, 424, 432, "pressure" +541, 8, 8, 95, 49, 50, 433, 434, "(" +541, 8, 9, 96, 51, 54, 435, 438, "IOP" +541, 8, 10, 97, 55, 56, 439, 440, ")" +541, 8, 11, 98, 57, 58, 441, 442, "-" +541, 8, 12, 99, 59, 67, 443, 451, "reducing" +541, 8, 13, 100, 68, 74, 452, 458, "effect" +541, 8, 14, 101, 75, 78, 459, 462, "and" +541, 8, 15, 102, 79, 82, 463, 466, "the" +541, 8, 16, 103, 83, 87, 467, 471, "side" +541, 8, 17, 104, 88, 95, 472, 479, "effects" +541, 8, 18, 105, 96, 98, 480, 482, "of" +541, 8, 19, 106, 99, 110, 483, 494, "latanoprost" +541, 8, 20, 107, 111, 112, 495, 496, "(" +541, 8, 21, 108, 113, 119, 497, 503, "PhXA41" +541, 8, 22, 109, 120, 121, 504, 505, ")" +541, 8, 23, 110, 122, 123, 506, 507, "," +541, 8, 24, 111, 124, 125, 508, 509, "a" +541, 8, 25, 112, 126, 129, 510, 513, "new" +541, 8, 26, 113, 130, 136, 514, 520, "phenyl" +541, 8, 27, 114, 137, 138, 521, 522, "-" +541, 8, 28, 115, 139, 150, 523, 534, "substituted" +541, 8, 29, 116, 151, 164, 535, 548, "prostaglandin" +541, 8, 30, 117, 165, 167, 549, 551, "F2" +541, 8, 31, 118, 168, 173, 552, 557, "alpha" +541, 8, 32, 119, 174, 175, 558, 559, "-" +541, 8, 33, 120, 176, 185, 560, 569, "isopropyl" +541, 8, 34, 121, 186, 191, 570, 575, "ester" +541, 8, 35, 122, 192, 200, 576, 584, "analogue" +541, 8, 36, 123, 201, 202, 585, 586, "," +541, 8, 37, 124, 203, 205, 587, 589, "in" +541, 8, 38, 125, 206, 214, 590, 598, "patients" +541, 8, 39, 126, 215, 219, 599, 603, "with" +541, 8, 40, 127, 220, 228, 604, 612, "elevated" +541, 8, 41, 128, 229, 232, 613, 616, "IOP" +541, 8, 42, 129, 233, 234, 617, 618, "," +541, 8, 43, 130, 235, 240, 619, 624, "using" +541, 8, 44, 131, 241, 248, 625, 632, "timolol" +541, 8, 45, 132, 249, 256, 633, 640, "maleate" +541, 8, 46, 133, 257, 259, 641, 643, "as" +541, 8, 47, 134, 260, 263, 644, 647, "the" +541, 8, 48, 135, 264, 273, 648, 657, "reference" +541, 8, 49, 136, 274, 278, 658, 662, "drug" +541, 8, 50, 137, 279, 280, 663, 664, "." +541, 9, 1, 138, 0, 7, 665, 672, "METHODS" +541, 9, 2, 139, 8, 9, 673, 674, ":" +541, 9, 3, 140, 10, 11, 675, 676, "A" +541, 9, 4, 141, 12, 17, 677, 682, "total" +541, 9, 5, 142, 18, 20, 683, 685, "of" +541, 9, 6, 143, 21, 24, 686, 689, "184" +541, 9, 7, 144, 25, 33, 690, 698, "patients" +541, 9, 8, 145, 34, 38, 699, 703, "with" +541, 9, 9, 146, 39, 46, 704, 711, "primary" +541, 9, 10, 147, 47, 51, 712, 716, "open" +541, 9, 11, 148, 52, 53, 717, 718, "-" +541, 9, 12, 149, 54, 59, 719, 724, "angle" +541, 9, 13, 150, 60, 68, 725, 733, "glaucoma" +541, 9, 14, 151, 69, 71, 734, 736, "or" +541, 9, 15, 152, 72, 78, 737, 743, "ocular" +541, 9, 16, 153, 79, 91, 744, 756, "hypertension" +541, 9, 17, 154, 92, 94, 757, 759, "at" +541, 9, 18, 155, 95, 97, 760, 762, "35" +541, 9, 19, 156, 98, 105, 763, 770, "medical" +541, 9, 20, 157, 106, 113, 771, 778, "centers" +541, 9, 21, 158, 114, 126, 779, 791, "participated" +541, 9, 22, 159, 127, 129, 792, 794, "in" +541, 9, 23, 160, 130, 134, 795, 799, "this" +541, 9, 24, 161, 135, 145, 800, 810, "randomized" +541, 9, 25, 162, 146, 152, 811, 817, "double" +541, 9, 26, 163, 153, 154, 818, 819, "-" +541, 9, 27, 164, 155, 161, 820, 826, "masked" +541, 9, 28, 165, 162, 167, 827, 832, "study" +541, 9, 29, 166, 168, 169, 833, 834, "." +541, 10, 1, 167, 0, 3, 835, 838, "The" +541, 10, 2, 168, 4, 12, 839, 847, "patients" +541, 10, 3, 169, 13, 17, 848, 852, "were" +541, 10, 4, 170, 18, 28, 853, 863, "randomized" +541, 10, 5, 171, 29, 31, 864, 866, "to" +541, 10, 6, 172, 32, 39, 867, 874, "receive" +541, 10, 7, 173, 40, 46, 875, 881, "either" +541, 10, 8, 174, 47, 48, 882, 883, "0" +541, 10, 9, 175, 49, 50, 884, 885, "." +541, 10, 10, 176, 51, 54, 886, 889, "005" +541, 10, 11, 177, 55, 56, 890, 891, "%" +541, 10, 12, 178, 57, 68, 892, 903, "latanoprost" +541, 10, 13, 179, 69, 73, 904, 908, "once" +541, 10, 14, 180, 74, 79, 909, 914, "daily" +541, 10, 15, 181, 80, 82, 915, 917, "or" +541, 10, 16, 182, 83, 84, 918, 919, "0" +541, 10, 17, 183, 85, 86, 920, 921, "." +541, 10, 18, 184, 87, 88, 922, 923, "5" +541, 10, 19, 185, 89, 90, 924, 925, "%" +541, 10, 20, 186, 91, 98, 926, 933, "timolol" +541, 10, 21, 187, 99, 106, 934, 941, "maleate" +541, 10, 22, 188, 107, 112, 942, 947, "twice" +541, 10, 23, 189, 113, 118, 948, 953, "daily" +541, 10, 24, 190, 119, 120, 954, 955, "," +541, 10, 25, 191, 121, 124, 956, 959, "for" +541, 10, 26, 192, 125, 126, 960, 961, "a" +541, 10, 27, 193, 127, 133, 962, 968, "period" +541, 10, 28, 194, 134, 136, 969, 971, "of" +541, 10, 29, 195, 137, 139, 972, 974, "12" +541, 10, 30, 196, 140, 145, 975, 980, "weeks" +541, 10, 31, 197, 146, 147, 981, 982, "." +541, 11, 1, 198, 0, 11, 983, 994, "Intraocular" +541, 11, 2, 199, 12, 20, 995, 1003, "pressure" +541, 11, 3, 200, 21, 24, 1004, 1007, "was" +541, 11, 4, 201, 25, 33, 1008, 1016, "measured" +541, 11, 5, 202, 34, 36, 1017, 1019, "24" +541, 11, 6, 203, 37, 42, 1020, 1025, "hours" +541, 11, 7, 204, 43, 48, 1026, 1031, "after" +541, 11, 8, 205, 49, 52, 1032, 1035, "the" +541, 11, 9, 206, 53, 67, 1036, 1050, "administration" +541, 11, 10, 207, 68, 70, 1051, 1053, "of" +541, 11, 11, 208, 71, 78, 1054, 1061, "timolol" +541, 11, 12, 209, 79, 80, 1062, 1063, "," +541, 11, 13, 210, 81, 83, 1064, 1066, "at" +541, 11, 14, 211, 84, 85, 1067, 1068, "2" +541, 11, 15, 212, 86, 87, 1069, 1070, "," +541, 11, 16, 213, 88, 89, 1071, 1072, "4" +541, 11, 17, 214, 90, 91, 1073, 1074, "," +541, 11, 18, 215, 92, 93, 1075, 1076, "8" +541, 11, 19, 216, 94, 95, 1077, 1078, "," +541, 11, 20, 217, 96, 99, 1079, 1082, "and" +541, 11, 21, 218, 100, 102, 1083, 1085, "12" +541, 11, 22, 219, 103, 108, 1086, 1091, "weeks" +541, 11, 23, 220, 109, 111, 1092, 1094, "of" +541, 11, 24, 221, 112, 121, 1095, 1104, "treatment" +541, 11, 25, 222, 122, 123, 1105, 1106, "." +541, 12, 1, 223, 0, 7, 1107, 1114, "RESULTS" +541, 12, 2, 224, 8, 9, 1115, 1116, ":" +541, 12, 3, 225, 10, 21, 1117, 1128, "Latanoprost" +541, 12, 4, 226, 22, 29, 1129, 1136, "reduced" +541, 12, 5, 227, 30, 33, 1137, 1140, "IOP" +541, 12, 6, 228, 34, 36, 1141, 1143, "at" +541, 12, 7, 229, 37, 40, 1144, 1147, "the" +541, 12, 8, 230, 41, 44, 1148, 1151, "end" +541, 12, 9, 231, 45, 47, 1152, 1154, "of" +541, 12, 10, 232, 48, 50, 1155, 1157, "12" +541, 12, 11, 233, 51, 56, 1158, 1163, "weeks" +541, 12, 12, 234, 57, 59, 1164, 1166, "by" +541, 12, 13, 235, 60, 61, 1167, 1168, "6" +541, 12, 14, 236, 62, 63, 1169, 1170, "." +541, 12, 15, 237, 64, 65, 1171, 1172, "2" +541, 12, 16, 238, 66, 67, 1173, 1174, "+" +541, 12, 17, 239, 68, 69, 1175, 1176, "/" +541, 12, 18, 240, 70, 71, 1177, 1178, "-" +541, 12, 19, 241, 72, 73, 1179, 1180, "2" +541, 12, 20, 242, 74, 75, 1181, 1182, "." +541, 12, 21, 243, 76, 77, 1183, 1184, "7" +541, 12, 22, 244, 78, 80, 1185, 1187, "mm" +541, 12, 23, 245, 81, 83, 1188, 1190, "Hg" +541, 12, 24, 246, 84, 85, 1191, 1192, "(" +541, 12, 25, 247, 86, 90, 1193, 1197, "mean" +541, 12, 26, 248, 91, 92, 1198, 1199, "+" +541, 12, 27, 249, 93, 94, 1200, 1201, "/" +541, 12, 28, 250, 95, 96, 1202, 1203, "-" +541, 12, 29, 251, 97, 99, 1204, 1206, "SD" +541, 12, 30, 252, 100, 101, 1207, 1208, ")" +541, 12, 31, 253, 102, 103, 1209, 1210, "(" +541, 12, 32, 254, 104, 106, 1211, 1213, "26" +541, 12, 33, 255, 107, 108, 1214, 1215, "." +541, 12, 34, 256, 109, 110, 1216, 1217, "8" +541, 12, 35, 257, 111, 112, 1218, 1219, "%" +541, 12, 36, 258, 113, 114, 1220, 1221, ")" +541, 12, 37, 259, 115, 116, 1222, 1223, "," +541, 12, 38, 260, 117, 122, 1224, 1229, "while" +541, 12, 39, 261, 123, 130, 1230, 1237, "timolol" +541, 12, 40, 262, 131, 138, 1238, 1245, "reduced" +541, 12, 41, 263, 139, 142, 1246, 1249, "IOP" +541, 12, 42, 264, 143, 145, 1250, 1252, "by" +541, 12, 43, 265, 146, 147, 1253, 1254, "4" +541, 12, 44, 266, 148, 149, 1255, 1256, "." +541, 12, 45, 267, 150, 151, 1257, 1258, "4" +541, 12, 46, 268, 152, 153, 1259, 1260, "+" +541, 12, 47, 269, 154, 155, 1261, 1262, "/" +541, 12, 48, 270, 156, 157, 1263, 1264, "-" +541, 12, 49, 271, 158, 159, 1265, 1266, "2" +541, 12, 50, 272, 160, 161, 1267, 1268, "." +541, 12, 51, 273, 162, 163, 1269, 1270, "3" +541, 12, 52, 274, 164, 166, 1271, 1273, "mm" +541, 12, 53, 275, 167, 169, 1274, 1276, "Hg" +541, 12, 54, 276, 170, 171, 1277, 1278, "(" +541, 12, 55, 277, 172, 174, 1279, 1281, "19" +541, 12, 56, 278, 175, 176, 1282, 1283, "." +541, 12, 57, 279, 177, 178, 1284, 1285, "9" +541, 12, 58, 280, 179, 180, 1286, 1287, "%" +541, 12, 59, 281, 181, 182, 1288, 1289, ")" +541, 12, 60, 282, 183, 184, 1290, 1291, "." +541, 13, 1, 283, 0, 2, 1292, 1294, "At" +541, 13, 2, 284, 3, 6, 1295, 1298, "all" +541, 13, 3, 285, 7, 13, 1299, 1305, "visits" +541, 13, 4, 286, 14, 25, 1306, 1317, "latanoprost" +541, 13, 5, 287, 26, 33, 1318, 1325, "reduced" +541, 13, 6, 288, 34, 37, 1326, 1329, "IOP" +541, 13, 7, 289, 38, 51, 1330, 1343, "significantly" +541, 13, 8, 290, 52, 56, 1344, 1348, "more" +541, 13, 9, 291, 57, 61, 1349, 1353, "than" +541, 13, 10, 292, 62, 69, 1354, 1361, "timolol" +541, 13, 11, 293, 70, 73, 1362, 1365, "did" +541, 13, 12, 294, 74, 75, 1366, 1367, "." +541, 14, 1, 295, 0, 3, 1368, 1371, "The" +541, 14, 2, 296, 4, 8, 1372, 1376, "main" +541, 14, 3, 297, 9, 15, 1377, 1383, "ocular" +541, 14, 4, 298, 16, 20, 1384, 1388, "side" +541, 14, 5, 299, 21, 28, 1389, 1396, "effects" +541, 14, 6, 300, 29, 37, 1397, 1405, "observed" +541, 14, 7, 301, 38, 40, 1406, 1408, "in" +541, 14, 8, 302, 41, 45, 1409, 1413, "both" +541, 14, 9, 303, 46, 52, 1414, 1420, "groups" +541, 14, 10, 304, 53, 57, 1421, 1425, "were" +541, 14, 11, 305, 58, 70, 1426, 1438, "conjunctival" +541, 14, 12, 306, 71, 80, 1439, 1448, "hyperemia" +541, 14, 13, 307, 81, 84, 1449, 1452, "and" +541, 14, 14, 308, 85, 93, 1453, 1461, "smarting" +541, 14, 15, 309, 94, 95, 1462, 1463, "." +541, 15, 1, 310, 0, 3, 1464, 1467, "The" +541, 15, 2, 311, 4, 8, 1468, 1472, "main" +541, 15, 3, 312, 9, 17, 1473, 1481, "systemic" +541, 15, 4, 313, 18, 22, 1482, 1486, "side" +541, 15, 5, 314, 23, 29, 1487, 1493, "effect" +541, 15, 6, 315, 30, 33, 1494, 1497, "was" +541, 15, 7, 316, 34, 35, 1498, 1499, "a" +541, 15, 8, 317, 36, 43, 1500, 1507, "reduced" +541, 15, 9, 318, 44, 49, 1508, 1513, "pulse" +541, 15, 10, 319, 50, 54, 1514, 1518, "rate" +541, 15, 11, 320, 55, 56, 1519, 1520, "," +541, 15, 12, 321, 57, 62, 1521, 1526, "which" +541, 15, 13, 322, 63, 71, 1527, 1535, "occurred" +541, 15, 14, 323, 72, 74, 1536, 1538, "in" +541, 15, 15, 324, 75, 83, 1539, 1547, "patients" +541, 15, 16, 325, 84, 91, 1548, 1555, "treated" +541, 15, 17, 326, 92, 96, 1556, 1560, "with" +541, 15, 18, 327, 97, 104, 1561, 1568, "timolol" +541, 15, 19, 328, 105, 106, 1569, 1570, "." +541, 16, 1, 329, 0, 11, 1571, 1582, "CONCLUSIONS" +541, 16, 2, 330, 12, 13, 1583, 1584, ":" +541, 16, 3, 331, 14, 17, 1585, 1588, "The" +541, 16, 4, 332, 18, 25, 1589, 1596, "results" +541, 16, 5, 333, 26, 28, 1597, 1599, "of" +541, 16, 6, 334, 29, 33, 1600, 1604, "this" +541, 16, 7, 335, 34, 39, 1605, 1610, "study" +541, 16, 8, 336, 40, 52, 1611, 1623, "demonstrated" +541, 16, 9, 337, 53, 57, 1624, 1628, "that" +541, 16, 10, 338, 58, 59, 1629, 1630, "0" +541, 16, 11, 339, 60, 61, 1631, 1632, "." +541, 16, 12, 340, 62, 65, 1633, 1636, "005" +541, 16, 13, 341, 66, 67, 1637, 1638, "%" +541, 16, 14, 342, 68, 79, 1639, 1650, "latanoprost" +541, 16, 15, 343, 80, 85, 1651, 1656, "taken" +541, 16, 16, 344, 86, 90, 1657, 1661, "once" +541, 16, 17, 345, 91, 96, 1662, 1667, "daily" +541, 16, 18, 346, 97, 99, 1668, 1670, "is" +541, 16, 19, 347, 100, 104, 1671, 1675, "well" +541, 16, 20, 348, 105, 114, 1676, 1685, "tolerated" +541, 16, 21, 349, 115, 118, 1686, 1689, "and" +541, 16, 22, 350, 119, 123, 1690, 1694, "more" +541, 16, 23, 351, 124, 133, 1695, 1704, "effective" +541, 16, 24, 352, 134, 136, 1705, 1707, "in" +541, 16, 25, 353, 137, 145, 1708, 1716, "reducing" +541, 16, 26, 354, 146, 149, 1717, 1720, "IOP" +541, 16, 27, 355, 150, 154, 1721, 1725, "than" +541, 16, 28, 356, 155, 156, 1726, 1727, "0" +541, 16, 29, 357, 157, 158, 1728, 1729, "." +541, 16, 30, 358, 159, 160, 1730, 1731, "5" +541, 16, 31, 359, 161, 162, 1732, 1733, "%" +541, 16, 32, 360, 163, 170, 1734, 1741, "timolol" +541, 16, 33, 361, 171, 176, 1742, 1747, "taken" +541, 16, 34, 362, 177, 182, 1748, 1753, "twice" +541, 16, 35, 363, 183, 188, 1754, 1759, "daily" +541, 16, 36, 364, 189, 190, 1760, 1761, "." +541, 17, 1, 365, 0, 4, 1762, 1766, "Thus" +541, 17, 2, 366, 5, 6, 1767, 1768, "," +541, 17, 3, 367, 7, 18, 1769, 1780, "latanoprost" +541, 17, 4, 368, 19, 22, 1781, 1784, "may" +541, 17, 5, 369, 23, 29, 1785, 1791, "become" +541, 17, 6, 370, 30, 32, 1792, 1794, "an" +541, 17, 7, 371, 33, 42, 1795, 1804, "important" +541, 17, 8, 372, 43, 49, 1805, 1811, "choice" +541, 17, 9, 373, 50, 53, 1812, 1815, "for" +541, 17, 10, 374, 54, 57, 1816, 1819, "the" +541, 17, 11, 375, 58, 65, 1820, 1827, "medical" +541, 17, 12, 376, 66, 75, 1828, 1837, "treatment" +541, 17, 13, 377, 76, 78, 1838, 1840, "of" +541, 17, 14, 378, 79, 87, 1841, 1849, "glaucoma" +541, 17, 15, 379, 88, 89, 1850, 1851, "." +541, 18, 1, 380, 0, 3, 1852, 1855, "DOI" +541, 18, 2, 381, 4, 5, 1856, 1857, ":" +541, 18, 3, 382, 6, 8, 1858, 1860, "10" +541, 18, 4, 383, 9, 10, 1861, 1862, "." +541, 18, 5, 384, 11, 15, 1863, 1867, "1001" +541, 18, 6, 385, 16, 17, 1868, 1869, "/" +541, 18, 7, 386, 18, 26, 1870, 1878, "archopht" +541, 18, 8, 387, 27, 28, 1879, 1880, "." +541, 18, 9, 388, 29, 33, 1881, 1885, "1996" +541, 18, 10, 389, 34, 35, 1886, 1887, "." +541, 18, 11, 390, 36, 50, 1888, 1902, "01100140137004" +541, 18, 12, 391, 51, 55, 1903, 1907, "PMID" +541, 18, 13, 392, 56, 57, 1908, 1909, ":" +541, 18, 14, 393, 58, 65, 1910, 1917, "8694726" +541, 18, 15, 394, 66, 67, 1918, 1919, "[" +541, 18, 16, 395, 68, 75, 1920, 1927, "Indexed" +541, 18, 17, 396, 76, 79, 1928, 1931, "for" +541, 18, 18, 397, 80, 87, 1932, 1939, "MEDLINE" +541, 18, 19, 398, 88, 89, 1940, 1941, "]" diff --git a/data/gl 8694726_jshahinitiran.annodb b/data/gl 8694726_jshahinitiran.annodb new file mode 100644 index 0000000..9cc62d9 --- /dev/null +++ b/data/gl 8694726_jshahinitiran.annodb @@ -0,0 +1,72 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +91323, Journal, 0, 15, "Arch Ophthalmol", "", +91324, PublicationYear, 18, 22, "1996", "", +91325, Title, 52, 150, "A comparison of latanoprost and timolol in primary open - angle glaucoma and ocular hypertension .", "", +91327, Title, 151, 168, "A 12 - week study", "", +91326, Duration, 153, 162, "12 - week", "", +91328, Author, 171, 181, "Mishima HK", "", +91329, Author, 190, 198, "Masuda K", "", +91330, Author, 201, 211, "Kitazawa Y", "", +91331, Author, 214, 221, "Azuma I", "", +91332, Author, 224, 231, "Araie M", "", +91333, Japan, 314, 319, "Japan", "", +91334, PublicationYear, 351, 355, "1996", "", +91335, ObjectiveDescription, 396, 618, "To evaluate the intraocular pressure ( IOP ) - reducing effect and the side effects of latanoprost ( PhXA41 ) , a new phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue , in patients with elevated IOP ,", "", +91337, IOP, 412, 432, "intraocular pressure", "", +91338, IOP, 435, 438, "IOP", "", +91339, Latanoprost, 483, 494, "latanoprost", "", +91340, Precondition, 604, 616, "elevated IOP", "", +91336, ObjectiveDescription, 619, 664, "using timolol maleate as the reference drug .", "", +91341, Timolol, 625, 640, "timolol maleate", "", +91342, NumberPatientsCT, 686, 689, "184", "", +91343, Primary_OpenAngleGlaucoma, 704, 733, "primary open - angle glaucoma", "", +91344, OcularHypertension, 737, 756, "ocular hypertension", "", +91345, Multicenter, 760, 778, "35 medical centers", "", +91346, Randomized, 800, 810, "randomized", "", +91347, DoubleBlind, 811, 826, "double - masked", "", +91348, Randomized, 853, 863, "randomized", "", +91349, DoseValue, 882, 889, "0 . 005", "", +91351, Latanoprost, 892, 903, "latanoprost", "", +91353, Frequency, 904, 914, "once daily", "", +91350, DoseValue, 918, 923, "0 . 5", "", +91352, Timolol, 926, 941, "timolol maleate", "", +91354, Frequency, 942, 953, "twice daily", "", +91355, Duration, 972, 980, "12 weeks", "", +91356, IOP, 983, 1003, "Intraocular pressure", "", +91357, Timolol, 1054, 1061, "timolol", "", +91358, TimePoint, 1067, 1091, "2 , 4 , 8 , and 12 weeks", "", +91359, TimePoint, 1071, 1091, "4 , 8 , and 12 weeks", "", +91360, TimePoint, 1075, 1091, "8 , and 12 weeks", "", +91361, TimePoint, 1083, 1091, "12 weeks", "", +91362, Latanoprost, 1117, 1128, "Latanoprost", "", +91363, IOP, 1137, 1140, "IOP", "", +91364, TimePoint, 1155, 1163, "12 weeks", "", +91365, Reduction, 1167, 1172, "6 . 2", "", +91366, SdDevChangeValue, 1179, 1184, "2 . 7", "", +91367, mmHg, 1185, 1190, "mm Hg", "", +91368, Mean, 1193, 1197, "mean", "", +91369, RelativeReduction, 1211, 1217, "26 . 8", "", +91371, Timolol, 1230, 1237, "timolol", "", +91372, IOP, 1246, 1249, "IOP", "", +91373, Reduction, 1253, 1258, "4 . 4", "", +91374, SdDevChangeValue, 1265, 1270, "2 . 3", "", +91375, mmHg, 1271, 1276, "mm Hg", "", +91376, RelativeReduction, 1279, 1285, "19 . 9", "", +91377, Latanoprost, 1306, 1317, "latanoprost", "", +91378, IOP, 1326, 1329, "IOP", "", +91379, Timolol, 1354, 1361, "timolol", "", +91380, ConjunctivalHyperemia, 1426, 1448, "conjunctival hyperemia", "", +91382, PulseRate, 1508, 1518, "pulse rate", "", +91384, Timolol, 1561, 1568, "timolol", "", +91385, ConclusionComment, 1585, 1761, "The results of this study demonstrated that 0 . 005 % latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .", "", +91386, DoseValue, 1629, 1636, "0 . 005", "", +91389, Latanoprost, 1639, 1650, "latanoprost", "", +91391, Frequency, 1657, 1667, "once daily", "", +91393, IOP, 1717, 1720, "IOP", "", +91388, DoseValue, 1726, 1731, "0 . 5", "", +91390, Timolol, 1734, 1741, "timolol", "", +91392, Frequency, 1748, 1759, "twice daily", "", +91394, ConclusionComment, 1762, 1851, "Thus , latanoprost may become an important choice for the medical treatment of glaucoma .", "", +91395, Latanoprost, 1769, 1780, "latanoprost", "", +91396, Glaucoma, 1841, 1849, "glaucoma", "", +91397, PMID, 1910, 1917, "8694726", "", diff --git a/data/gl 8694726_jshahinitiran.n-triples b/data/gl 8694726_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8694726_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8694726_tstrakeljahn.annodb b/data/gl 8694726_tstrakeljahn.annodb new file mode 100644 index 0000000..7532306 --- /dev/null +++ b/data/gl 8694726_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88572, Journal, 0, 15, "Arch Ophthalmol", "", +88573, PublicationYear, 18, 22, "1996", "", +88578, Title, 52, 150, "A comparison of latanoprost and timolol in primary open - angle glaucoma and ocular hypertension .", "", +88574, Latanoprost, 68, 79, "latanoprost", "", +88575, Timolol, 84, 91, "timolol", "", +88576, Primary_OpenAngleGlaucoma, 95, 124, "primary open - angle glaucoma", "", +88577, OcularHypertension, 129, 148, "ocular hypertension", "", +88579, Duration, 153, 162, "12 - week", "", +88580, Author, 171, 181, "Mishima HK", "", +88581, Author, 190, 198, "Masuda K", "", +88582, Author, 201, 211, "Kitazawa Y", "", +88583, Author, 214, 221, "Azuma I", "", +88584, Author, 224, 231, "Araie M", "", +88585, Japan, 314, 319, "Japan", "", +88593, ObjectiveDescription, 396, 647, "To evaluate the intraocular pressure ( IOP ) - reducing effect and the side effects of latanoprost ( PhXA41 ) , a new phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue , in patients with elevated IOP , using timolol maleate as the", "", +88586, IOP, 412, 432, "intraocular pressure", "", +88587, IOP, 435, 438, "IOP", "", +88588, Latanoprost, 483, 494, "latanoprost", "", +88589, Latanoprost, 497, 503, "PhXA41", "", +88590, Drug, 514, 584, "phenyl - substituted prostaglandin F2 alpha - isopropyl ester analogue", "prostaglandin analogue", +88591, IOP, 613, 616, "IOP", "", +88592, Timolol, 625, 640, "timolol maleate", "", +88594, ObjectiveDescription, 648, 664, "reference drug .", "", +88595, NumberPatientsCT, 686, 689, "184", "", +88596, Primary_OpenAngleGlaucoma, 704, 733, "primary open - angle glaucoma", "", +88597, OcularHypertension, 737, 756, "ocular hypertension", "", +88598, Multicenter, 760, 778, "35 medical centers", "", +88599, Randomized, 800, 810, "randomized", "", +88600, DoubleBlind, 811, 826, "double - masked", "", +88601, Randomized, 853, 863, "randomized", "", +88602, DoseValue, 882, 889, "0 . 005", "", +88604, Percentage, 890, 891, "%", "", +88606, Latanoprost, 892, 903, "latanoprost", "", +88608, Frequency, 904, 914, "once daily", "", +88603, DoseValue, 918, 923, "0 . 5", "", +88605, Percentage, 924, 925, "%", "", +88607, Timolol, 926, 941, "timolol maleate", "", +88609, Frequency, 942, 953, "twice daily", "", +88610, Duration, 972, 980, "12 weeks", "", +88611, IOP, 983, 1003, "Intraocular pressure", "", +88612, Timolol, 1054, 1061, "timolol", "", +88616, TimePoint, 1067, 1091, "2 , 4 , 8 , and 12 weeks", "", +88615, TimePoint, 1071, 1091, "4 , 8 , and 12 weeks", "", +88614, TimePoint, 1075, 1091, "8 , and 12 weeks", "", +88613, TimePoint, 1083, 1091, "12 weeks", "", +88617, Latanoprost, 1117, 1128, "Latanoprost", "", +88618, IOP, 1137, 1140, "IOP", "", +88619, TimePoint, 1141, 1163, "at the end of 12 weeks", "", +88620, Reduction, 1167, 1172, "6 . 2", "", +88623, SdDevChangeValue, 1179, 1184, "2 . 7", "", +88625, mmHg, 1185, 1190, "mm Hg", "", +88629, RelativeReduction, 1211, 1217, "26 . 8", "", +88627, Timolol, 1230, 1237, "timolol", "", +88628, IOP, 1246, 1249, "IOP", "", +88621, Reduction, 1253, 1258, "4 . 4", "", +88624, SdDevChangeValue, 1265, 1270, "2 . 3", "", +88626, mmHg, 1271, 1276, "mm Hg", "", +88630, RelativeReduction, 1279, 1285, "19 . 9", "", +88634, ObservedResult, 1292, 1367, "At all visits latanoprost reduced IOP significantly more than timolol did .", "", +88631, Latanoprost, 1306, 1317, "latanoprost", "", +88632, IOP, 1326, 1329, "IOP", "", +88633, Timolol, 1354, 1361, "timolol", "", +88637, ObservedResult, 1368, 1463, "The main ocular side effects observed in both groups were conjunctival hyperemia and smarting .", "", +88635, ConjunctivalHyperemia, 1426, 1448, "conjunctival hyperemia", "", +88636, Smarting, 1453, 1461, "smarting", "", +88640, ObservedResult, 1464, 1570, "The main systemic side effect was a reduced pulse rate , which occurred in patients treated with timolol .", "", +88638, PulseRate, 1508, 1518, "pulse rate", "", +88639, Timolol, 1561, 1568, "timolol", "", +88650, ConclusionComment, 1585, 1761, "The results of this study demonstrated that 0 . 005 % latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0 . 5 % timolol taken twice daily .", "", +88641, DoseValue, 1629, 1636, "0 . 005", "", +88643, Latanoprost, 1639, 1650, "latanoprost", "", +88645, Frequency, 1657, 1667, "once daily", "", +88647, IOP, 1717, 1720, "IOP", "", +88642, DoseValue, 1726, 1731, "0 . 5", "", +88644, Timolol, 1734, 1741, "timolol", "", +88646, Frequency, 1748, 1759, "twice daily", "", +88651, ConclusionComment, 1762, 1851, "Thus , latanoprost may become an important choice for the medical treatment of glaucoma .", "", +88648, Latanoprost, 1769, 1780, "latanoprost", "", +88649, Glaucoma, 1841, 1849, "glaucoma", "", +88652, PMID, 1910, 1917, "8694726", "", diff --git a/data/gl 8694726_tstrakeljahn.n-triples b/data/gl 8694726_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8694726_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8970248_admin.annodb b/data/gl 8970248_admin.annodb new file mode 100644 index 0000000..77272ec --- /dev/null +++ b/data/gl 8970248_admin.annodb @@ -0,0 +1,89 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Surv Ophthalmol .", "", " \"Surv Ophthalmol .\"." +81, PublicationYear, 18, 22, "1996", "", " \"1996\"." +11, Title, 53, 202, "A comparison of the safety and efficacy of twice daily brimonidine 0 . 2 % versus betaxolol 0 . 25 % in subjects with elevated intraocular pressure .", "", " \"A comparison of the safety and efficacy of twice daily brimonidine 0 . 2 % versus betaxolol 0 . 25 % in subjects with elevated intraocular pressure .\"." +2, Frequency, 96, 107, "twice daily", "", " \"twice daily\". \"twice daily\"." +3, Brimonidine, 108, 119, "brimonidine", "", " ." +4, DoseValue, 120, 125, "0 . 2", "", " \"0 . 2\"." +7, Percentage, 126, 127, "%", "", " ." +6, Betaxolol, 135, 144, "betaxolol", "", " ." +5, DoseValue, 145, 151, "0 . 25", "", " \"0 . 25\"." +8, Percentage, 152, 153, "%", "", " ." +87, Precondition, 157, 200, "subjects with elevated intraocular pressure", "", " \"subjects with elevated intraocular pressure\". \"subjects with open - angle glaucoma or ocular hypertension\"." +86, IOP, 180, 200, "intraocular pressure", "", +77, Brimonidine, 207, 218, "Brimonidine", "", +12, Author, 237, 245, "Serle JB", "", " \"Serle JB\"." +10, USA, 362, 365, "USA", "", " ." +74, ObjectiveDescription, 368, 585, "The safety and ocular hypotensive efficacy of twice - daily administration of brimonidine 0 . 2 % solution or betaxolol 0 . 25 % suspension were compared in subjects with open - angle glaucoma or ocular hypertension .", "", " \"The safety and ocular hypotensive efficacy of twice - daily administration of brimonidine 0 . 2 % solution or betaxolol 0 . 25 % suspension were compared in subjects with open - angle glaucoma or ocular hypertension .\"." +13, Frequency, 414, 427, "twice - daily", "", +14, Brimonidine, 446, 457, "brimonidine", "", +16, DoseValue, 458, 463, "0 . 2", "", +18, Percentage, 464, 465, "%", "", +15, Betaxolol, 478, 487, "betaxolol", "", +17, DoseValue, 488, 494, "0 . 25", "", +19, Percentage, 495, 496, "%", "", +87, Precondition, 525, 583, "subjects with open - angle glaucoma or ocular hypertension", "", " \"subjects with open - angle glaucoma or ocular hypertension\"." +20, OpenAngleGlaucoma, 539, 560, "open - angle glaucoma", "", " ." +21, OcularHypertension, 564, 583, "ocular hypertension", "", " ." +22, NumberPatientsCT, 597, 600, "206", "", " \"206\"." +54357, Prospective, 635, 646, "prospective", "", " ." +23, Duration, 649, 658, "3 - month", "", " \"3 - month\"." +24, Multicenter, 661, 674, "multicentered", "", " ." +25, Randomized, 677, 687, "randomized", "", " ." +26, DoubleBlind, 690, 705, "double - masked", "", " ." +27, Parallel, 708, 716, "parallel", "", " ." +111, PValueChangeValue, 760, 771, "p < 0 . 001", "", " \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\". \"p < 0 . 001\"." +112, Peak_IOP, 782, 786, "peak", "", " ." +113, Trough_IOP, 791, 818, "trough intraocular pressure", "", " ." +30, IOP, 821, 824, "IOP", "", +31, Duration, 873, 882, "3 - month", "", +117, Peak_IOP, 891, 898, "At peak", "", +33, Mean, 913, 917, "mean", "", " . ." +54358, TimePoint, 932, 940, "baseline", "", +117, Peak_IOP, 941, 944, "IOP", "", +118, PvalueDiff, 959, 970, "p = 0 . 004", "", " \"p = 0 . 004\"." +35, Brimonidine, 980, 991, "brimonidine", "", +36, Reduction, 1010, 1015, "5 . 8", "", " \"5 . 8\"." +37, mmHg, 1016, 1021, "mm Hg", "", " ." +38, Betaxolol, 1036, 1045, "betaxolol", "", +39, Reduction, 1064, 1069, "3 . 8", "", " \"3 . 8\"." +40, mmHg, 1070, 1075, "mm Hg", "", +54360, Trough_IOP, 1080, 1089, "At trough", "", +41, Mean, 1104, 1108, "mean", "", " . ." +126, PvalueDiff, 1134, 1145, "p < 0 . 001", "", " \"p < 0 . 001\"." +43, Reduction, 1152, 1157, "3 . 9", "", " \"3 . 9\"." +44, mmHg, 1158, 1163, "mm Hg", "", +45, Brimonidine, 1171, 1182, "brimonidine", "", +46, Reduction, 1203, 1208, "3 . 2", "", " \"3 . 2\"." +47, mmHg, 1209, 1214, "mm Hg", "", " ." +48, Betaxolol, 1222, 1231, "betaxolol", "", +49, IOP, 1254, 1257, "IOP", "", +50, Brimonidine, 1279, 1290, "brimonidine", "", +51, Duration, 1320, 1329, "3 - month", "", +54, RelNumPatientsLeftArm, 1406, 1411, "2 . 9", "", " \"2 . 9\"." +56, NumPatientsLeftArm, 1416, 1417, "3", "", " \"3\"." +78, NumberPatientsArm, 1420, 1423, "103", "", " \"103\"." +53, Brimonidine, 1445, 1456, "brimonidine", "", +55, RelNumPatientsLeftArm, 1467, 1472, "4 . 2", "", " \"4 . 2\"." +57, NumPatientsLeftArm, 1477, 1478, "4", "", " \"4\"." +79, NumberPatientsArm, 1481, 1483, "96", "", " \"96\"." +58, Betaxolol, 1502, 1511, "betaxolol", "", +59, PvalueDiff, 1627, 1638, "p = 0 . 027", "", +92868, BlurredVison, 1679, 1694, "ocular blurring", "", " ." +62, ObservedResult, 1679, 1809, "ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving brimonidine treatment .", "", " \"ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving brimonidine treatment .\"." +60, Betaxolol, 1741, 1750, "betaxolol", "", +61, Brimonidine, 1786, 1797, "brimonidine", "", +63, PvalueDiff, 1864, 1875, "p = 0 . 036", "", +64, Brimonidine, 1886, 1897, "brimonidine", "", +65, Betaxolol, 1922, 1931, "betaxolol", "", +75, ConclusionComment, 1953, 2199, "Overall , brimonidine 0 . 2 % solution was well - tolerated , safe and clinically and statistically more effective than betaxolol 0 . 25 % suspension in lowering intraocular pressure in patients with open - angle glaucoma or ocular hypertension .", "", " \"Overall , brimonidine 0 . 2 % solution was well - tolerated , safe and clinically and statistically more effective than betaxolol 0 . 25 % suspension in lowering intraocular pressure in patients with open - angle glaucoma or ocular hypertension .\"." +66, Brimonidine, 1963, 1974, "brimonidine", "", +68, DoseValue, 1975, 1980, "0 . 2", "", +69, Percentage, 1981, 1982, "%", "", +67, Betaxolol, 2073, 2082, "betaxolol", "", +70, DoseValue, 2083, 2089, "0 . 25", "", +71, Percentage, 2090, 2091, "%", "", +154, IOP, 2115, 2135, "intraocular pressure", "", +72, OpenAngleGlaucoma, 2153, 2174, "open - angle glaucoma", "", +73, OcularHypertension, 2178, 2197, "ocular hypertension", "", +76, PMID, 2207, 2214, "8970248", "", " \"8970248\"." diff --git a/data/gl 8970248_admin.n-triples b/data/gl 8970248_admin.n-triples new file mode 100644 index 0000000..c4a8595 --- /dev/null +++ b/data/gl 8970248_admin.n-triples @@ -0,0 +1,140 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparison of the safety and efficacy of twice daily brimonidine 0 . 2 % versus betaxolol 0 . 25 % in subjects with elevated intraocular pressure ." . + "Serle JB" . + "1996" . + "Surv Ophthalmol ." . + "8970248" . + . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The safety and ocular hypotensive efficacy of twice - daily administration of brimonidine 0 . 2 % solution or betaxolol 0 . 25 % suspension were compared in subjects with open - angle glaucoma or ocular hypertension ." . + "206" . + "3 - month" . + . + . + . + "Overall , brimonidine 0 . 2 % solution was well - tolerated , safe and clinically and statistically more effective than betaxolol 0 . 25 % suspension in lowering intraocular pressure in patients with open - angle glaucoma or ocular hypertension ." . + . + . + . + . + . + . + . + . + . + . + . + . +# RDF export of group: Population + . + "Population" . + "subjects with elevated intraocular pressure" . + "subjects with open - angle glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_piop" . + . + . + . + . + . + . + "Endpoint_tiop" . + . + . + . + . + . + . + "Endpoint_BV" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bri" . + "103" . + . + . + . + "3" . + "2 . 9" . + . + . + "Arm_bet" . + "96" . + . + . + . + "4" . + "4 . 2" . + . +# RDF export of group: Intervention + . + "Intervention_bri" . + . + "twice daily" . + . + . + "Intervention_bet" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_bri" . + . + "0 . 2" . + . + . + . + "Medication_bet" . + . + "0 . 25" . + . + . +# RDF export of group: Outcome + . + "Outcome_piop_bri" . + . + "5 . 8" . + "p < 0 . 001" . + . + "Outcome_piop_bet" . + . + "3 . 8" . + "p < 0 . 001" . + . + "Outcome_tiop_bri" . + . + "3 . 9" . + "p < 0 . 001" . + . + "Outcome_tiop_bet" . + . + "3 . 2" . + "p < 0 . 001" . + . + "Outcome_BV" . + . + "ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving brimonidine treatment ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_piop" . + "p = 0 . 004" . + . + . + . + "DiffBetweenGroups_tiop" . + "p < 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8970248_export.csv b/data/gl 8970248_export.csv new file mode 100644 index 0000000..3238719 --- /dev/null +++ b/data/gl 8970248_export.csv @@ -0,0 +1,450 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +402, 1, 1, 1, 0, 4, 0, 4, "Surv" +402, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +402, 1, 3, 3, 16, 17, 16, 17, "." +402, 2, 1, 4, 0, 4, 18, 22, "1996" +402, 2, 2, 5, 5, 8, 23, 26, "Nov" +402, 2, 3, 6, 9, 10, 27, 28, ";" +402, 2, 4, 7, 11, 13, 29, 31, "41" +402, 2, 5, 8, 14, 19, 32, 37, "Suppl" +402, 2, 6, 9, 20, 21, 38, 39, "1" +402, 2, 7, 10, 22, 23, 40, 41, ":" +402, 2, 8, 11, 24, 27, 42, 45, "S39" +402, 2, 9, 12, 28, 29, 46, 47, "-" +402, 2, 10, 13, 30, 32, 48, 50, "47" +402, 2, 11, 14, 33, 34, 51, 52, "." +402, 3, 1, 15, 0, 1, 53, 54, "A" +402, 3, 2, 16, 2, 12, 55, 65, "comparison" +402, 3, 3, 17, 13, 15, 66, 68, "of" +402, 3, 4, 18, 16, 19, 69, 72, "the" +402, 3, 5, 19, 20, 26, 73, 79, "safety" +402, 3, 6, 20, 27, 30, 80, 83, "and" +402, 3, 7, 21, 31, 39, 84, 92, "efficacy" +402, 3, 8, 22, 40, 42, 93, 95, "of" +402, 3, 9, 23, 43, 48, 96, 101, "twice" +402, 3, 10, 24, 49, 54, 102, 107, "daily" +402, 3, 11, 25, 55, 66, 108, 119, "brimonidine" +402, 3, 12, 26, 67, 68, 120, 121, "0" +402, 3, 13, 27, 69, 70, 122, 123, "." +402, 3, 14, 28, 71, 72, 124, 125, "2" +402, 3, 15, 29, 73, 74, 126, 127, "%" +402, 3, 16, 30, 75, 81, 128, 134, "versus" +402, 3, 17, 31, 82, 91, 135, 144, "betaxolol" +402, 3, 18, 32, 92, 93, 145, 146, "0" +402, 3, 19, 33, 94, 95, 147, 148, "." +402, 3, 20, 34, 96, 98, 149, 151, "25" +402, 3, 21, 35, 99, 100, 152, 153, "%" +402, 3, 22, 36, 101, 103, 154, 156, "in" +402, 3, 23, 37, 104, 112, 157, 165, "subjects" +402, 3, 24, 38, 113, 117, 166, 170, "with" +402, 3, 25, 39, 118, 126, 171, 179, "elevated" +402, 3, 26, 40, 127, 138, 180, 191, "intraocular" +402, 3, 27, 41, 139, 147, 192, 200, "pressure" +402, 3, 28, 42, 148, 149, 201, 202, "." +402, 4, 1, 43, 0, 3, 203, 206, "The" +402, 4, 2, 44, 4, 15, 207, 218, "Brimonidine" +402, 4, 3, 45, 16, 21, 219, 224, "Study" +402, 4, 4, 46, 22, 27, 225, 230, "Group" +402, 4, 5, 47, 28, 31, 231, 234, "III" +402, 4, 6, 48, 32, 33, 235, 236, "." +402, 5, 1, 49, 0, 5, 237, 242, "Serle" +402, 5, 2, 50, 6, 8, 243, 245, "JB" +402, 5, 3, 51, 9, 10, 246, 247, "(" +402, 5, 4, 52, 11, 12, 248, 249, "1" +402, 5, 5, 53, 13, 14, 250, 251, ")" +402, 5, 6, 54, 15, 16, 252, 253, "." +402, 6, 1, 55, 0, 6, 254, 260, "Author" +402, 6, 2, 56, 7, 18, 261, 272, "information" +402, 6, 3, 57, 19, 20, 273, 274, ":" +402, 6, 4, 58, 21, 22, 275, 276, "(" +402, 6, 5, 59, 23, 24, 277, 278, "1" +402, 6, 6, 60, 25, 26, 279, 280, ")" +402, 6, 7, 61, 27, 37, 281, 291, "Department" +402, 6, 8, 62, 38, 40, 292, 294, "of" +402, 6, 9, 63, 41, 54, 295, 308, "Ophthalmology" +402, 6, 10, 64, 55, 56, 309, 310, "," +402, 6, 11, 65, 57, 62, 311, 316, "Mount" +402, 6, 12, 66, 63, 68, 317, 322, "Sinai" +402, 6, 13, 67, 69, 76, 323, 330, "Medical" +402, 6, 14, 68, 77, 83, 331, 337, "Center" +402, 6, 15, 69, 84, 85, 338, 339, "," +402, 6, 16, 70, 86, 89, 340, 343, "New" +402, 6, 17, 71, 90, 94, 344, 348, "York" +402, 6, 18, 72, 95, 96, 349, 350, "," +402, 6, 19, 73, 97, 100, 351, 354, "New" +402, 6, 20, 74, 101, 105, 355, 359, "York" +402, 6, 21, 75, 106, 107, 360, 361, "," +402, 6, 22, 76, 108, 111, 362, 365, "USA" +402, 6, 23, 77, 112, 113, 366, 367, "." +402, 7, 1, 78, 0, 3, 368, 371, "The" +402, 7, 2, 79, 4, 10, 372, 378, "safety" +402, 7, 3, 80, 11, 14, 379, 382, "and" +402, 7, 4, 81, 15, 21, 383, 389, "ocular" +402, 7, 5, 82, 22, 33, 390, 401, "hypotensive" +402, 7, 6, 83, 34, 42, 402, 410, "efficacy" +402, 7, 7, 84, 43, 45, 411, 413, "of" +402, 7, 8, 85, 46, 51, 414, 419, "twice" +402, 7, 9, 86, 52, 53, 420, 421, "-" +402, 7, 10, 87, 54, 59, 422, 427, "daily" +402, 7, 11, 88, 60, 74, 428, 442, "administration" +402, 7, 12, 89, 75, 77, 443, 445, "of" +402, 7, 13, 90, 78, 89, 446, 457, "brimonidine" +402, 7, 14, 91, 90, 91, 458, 459, "0" +402, 7, 15, 92, 92, 93, 460, 461, "." +402, 7, 16, 93, 94, 95, 462, 463, "2" +402, 7, 17, 94, 96, 97, 464, 465, "%" +402, 7, 18, 95, 98, 106, 466, 474, "solution" +402, 7, 19, 96, 107, 109, 475, 477, "or" +402, 7, 20, 97, 110, 119, 478, 487, "betaxolol" +402, 7, 21, 98, 120, 121, 488, 489, "0" +402, 7, 22, 99, 122, 123, 490, 491, "." +402, 7, 23, 100, 124, 126, 492, 494, "25" +402, 7, 24, 101, 127, 128, 495, 496, "%" +402, 7, 25, 102, 129, 139, 497, 507, "suspension" +402, 7, 26, 103, 140, 144, 508, 512, "were" +402, 7, 27, 104, 145, 153, 513, 521, "compared" +402, 7, 28, 105, 154, 156, 522, 524, "in" +402, 7, 29, 106, 157, 165, 525, 533, "subjects" +402, 7, 30, 107, 166, 170, 534, 538, "with" +402, 7, 31, 108, 171, 175, 539, 543, "open" +402, 7, 32, 109, 176, 177, 544, 545, "-" +402, 7, 33, 110, 178, 183, 546, 551, "angle" +402, 7, 34, 111, 184, 192, 552, 560, "glaucoma" +402, 7, 35, 112, 193, 195, 561, 563, "or" +402, 7, 36, 113, 196, 202, 564, 570, "ocular" +402, 7, 37, 114, 203, 215, 571, 583, "hypertension" +402, 7, 38, 115, 216, 217, 584, 585, "." +402, 8, 1, 116, 0, 1, 586, 587, "A" +402, 8, 2, 117, 2, 7, 588, 593, "total" +402, 8, 3, 118, 8, 10, 594, 596, "of" +402, 8, 4, 119, 11, 14, 597, 600, "206" +402, 8, 5, 120, 15, 20, 601, 606, "adult" +402, 8, 6, 121, 21, 29, 607, 615, "patients" +402, 8, 7, 122, 30, 34, 616, 620, "were" +402, 8, 8, 123, 35, 43, 621, 629, "enrolled" +402, 8, 9, 124, 44, 46, 630, 632, "in" +402, 8, 10, 125, 47, 48, 633, 634, "a" +402, 8, 11, 126, 49, 60, 635, 646, "prospective" +402, 8, 12, 127, 61, 62, 647, 648, "," +402, 8, 13, 128, 63, 64, 649, 650, "3" +402, 8, 14, 129, 65, 66, 651, 652, "-" +402, 8, 15, 130, 67, 72, 653, 658, "month" +402, 8, 16, 131, 73, 74, 659, 660, "," +402, 8, 17, 132, 75, 88, 661, 674, "multicentered" +402, 8, 18, 133, 89, 90, 675, 676, "," +402, 8, 19, 134, 91, 101, 677, 687, "randomized" +402, 8, 20, 135, 102, 103, 688, 689, "," +402, 8, 21, 136, 104, 110, 690, 696, "double" +402, 8, 22, 137, 111, 112, 697, 698, "-" +402, 8, 23, 138, 113, 119, 699, 705, "masked" +402, 8, 24, 139, 120, 121, 706, 707, "," +402, 8, 25, 140, 122, 130, 708, 716, "parallel" +402, 8, 26, 141, 131, 132, 717, 718, "-" +402, 8, 27, 142, 133, 138, 719, 724, "group" +402, 8, 28, 143, 139, 144, 725, 730, "study" +402, 8, 29, 144, 145, 146, 731, 732, "." +402, 9, 1, 145, 0, 4, 733, 737, "Both" +402, 9, 2, 146, 5, 10, 738, 743, "drugs" +402, 9, 3, 147, 11, 24, 744, 757, "significantly" +402, 9, 4, 148, 25, 26, 758, 759, "(" +402, 9, 5, 149, 27, 28, 760, 761, "p" +402, 9, 6, 150, 29, 30, 762, 763, "<" +402, 9, 7, 151, 31, 32, 764, 765, "0" +402, 9, 8, 152, 33, 34, 766, 767, "." +402, 9, 9, 153, 35, 38, 768, 771, "001" +402, 9, 10, 154, 39, 40, 772, 773, ")" +402, 9, 11, 155, 41, 48, 774, 781, "reduced" +402, 9, 12, 156, 49, 53, 782, 786, "peak" +402, 9, 13, 157, 54, 57, 787, 790, "and" +402, 9, 14, 158, 58, 64, 791, 797, "trough" +402, 9, 15, 159, 65, 76, 798, 809, "intraocular" +402, 9, 16, 160, 77, 85, 810, 818, "pressure" +402, 9, 17, 161, 86, 87, 819, 820, "(" +402, 9, 18, 162, 88, 91, 821, 824, "IOP" +402, 9, 19, 163, 92, 93, 825, 826, ")" +402, 9, 20, 164, 94, 96, 827, 829, "at" +402, 9, 21, 165, 97, 102, 830, 835, "every" +402, 9, 22, 166, 103, 112, 836, 845, "scheduled" +402, 9, 23, 167, 113, 119, 846, 852, "follow" +402, 9, 24, 168, 120, 121, 853, 854, "-" +402, 9, 25, 169, 122, 124, 855, 857, "up" +402, 9, 26, 170, 125, 130, 858, 863, "visit" +402, 9, 27, 171, 131, 135, 864, 868, "over" +402, 9, 28, 172, 136, 139, 869, 872, "the" +402, 9, 29, 173, 140, 141, 873, 874, "3" +402, 9, 30, 174, 142, 143, 875, 876, "-" +402, 9, 31, 175, 144, 149, 877, 882, "month" +402, 9, 32, 176, 150, 155, 883, 888, "study" +402, 9, 33, 177, 156, 157, 889, 890, "." +402, 10, 1, 178, 0, 2, 891, 893, "At" +402, 10, 2, 179, 3, 7, 894, 898, "peak" +402, 10, 3, 180, 8, 9, 899, 900, "," +402, 10, 4, 181, 10, 13, 901, 904, "the" +402, 10, 5, 182, 14, 21, 905, 912, "overall" +402, 10, 6, 183, 22, 26, 913, 917, "mean" +402, 10, 7, 184, 27, 35, 918, 926, "decrease" +402, 10, 8, 185, 36, 40, 927, 931, "from" +402, 10, 9, 186, 41, 49, 932, 940, "baseline" +402, 10, 10, 187, 50, 53, 941, 944, "IOP" +402, 10, 11, 188, 54, 57, 945, 948, "was" +402, 10, 12, 189, 58, 65, 949, 956, "greater" +402, 10, 13, 190, 66, 67, 957, 958, "(" +402, 10, 14, 191, 68, 69, 959, 960, "p" +402, 10, 15, 192, 70, 71, 961, 962, "=" +402, 10, 16, 193, 72, 73, 963, 964, "0" +402, 10, 17, 194, 74, 75, 965, 966, "." +402, 10, 18, 195, 76, 79, 967, 970, "004" +402, 10, 19, 196, 80, 81, 971, 972, ")" +402, 10, 20, 197, 82, 84, 973, 975, "in" +402, 10, 21, 198, 85, 88, 976, 979, "the" +402, 10, 22, 199, 89, 100, 980, 991, "brimonidine" +402, 10, 23, 200, 101, 102, 992, 993, "-" +402, 10, 24, 201, 103, 110, 994, 1001, "treated" +402, 10, 25, 202, 111, 116, 1002, 1007, "group" +402, 10, 26, 203, 117, 118, 1008, 1009, "(" +402, 10, 27, 204, 119, 120, 1010, 1011, "5" +402, 10, 28, 205, 121, 122, 1012, 1013, "." +402, 10, 29, 206, 123, 124, 1014, 1015, "8" +402, 10, 30, 207, 125, 127, 1016, 1018, "mm" +402, 10, 31, 208, 128, 130, 1019, 1021, "Hg" +402, 10, 32, 209, 131, 132, 1022, 1023, ")" +402, 10, 33, 210, 133, 137, 1024, 1028, "than" +402, 10, 34, 211, 138, 140, 1029, 1031, "in" +402, 10, 35, 212, 141, 144, 1032, 1035, "the" +402, 10, 36, 213, 145, 154, 1036, 1045, "betaxolol" +402, 10, 37, 214, 155, 156, 1046, 1047, "-" +402, 10, 38, 215, 157, 164, 1048, 1055, "treated" +402, 10, 39, 216, 165, 170, 1056, 1061, "group" +402, 10, 40, 217, 171, 172, 1062, 1063, "(" +402, 10, 41, 218, 173, 174, 1064, 1065, "3" +402, 10, 42, 219, 175, 176, 1066, 1067, "." +402, 10, 43, 220, 177, 178, 1068, 1069, "8" +402, 10, 44, 221, 179, 181, 1070, 1072, "mm" +402, 10, 45, 222, 182, 184, 1073, 1075, "Hg" +402, 10, 46, 223, 185, 186, 1076, 1077, ")" +402, 10, 47, 224, 187, 188, 1078, 1079, "." +402, 11, 1, 225, 0, 2, 1080, 1082, "At" +402, 11, 2, 226, 3, 9, 1083, 1089, "trough" +402, 11, 3, 227, 10, 11, 1090, 1091, "," +402, 11, 4, 228, 12, 15, 1092, 1095, "the" +402, 11, 5, 229, 16, 23, 1096, 1103, "overall" +402, 11, 6, 230, 24, 28, 1104, 1108, "mean" +402, 11, 7, 231, 29, 37, 1109, 1117, "decrease" +402, 11, 8, 232, 38, 42, 1118, 1122, "from" +402, 11, 9, 233, 43, 51, 1123, 1131, "baseline" +402, 11, 10, 234, 52, 53, 1132, 1133, "(" +402, 11, 11, 235, 54, 55, 1134, 1135, "p" +402, 11, 12, 236, 56, 57, 1136, 1137, "<" +402, 11, 13, 237, 58, 59, 1138, 1139, "0" +402, 11, 14, 238, 60, 61, 1140, 1141, "." +402, 11, 15, 239, 62, 65, 1142, 1145, "001" +402, 11, 16, 240, 66, 67, 1146, 1147, ")" +402, 11, 17, 241, 68, 71, 1148, 1151, "was" +402, 11, 18, 242, 72, 73, 1152, 1153, "3" +402, 11, 19, 243, 74, 75, 1154, 1155, "." +402, 11, 20, 244, 76, 77, 1156, 1157, "9" +402, 11, 21, 245, 78, 80, 1158, 1160, "mm" +402, 11, 22, 246, 81, 83, 1161, 1163, "Hg" +402, 11, 23, 247, 84, 86, 1164, 1166, "in" +402, 11, 24, 248, 87, 90, 1167, 1170, "the" +402, 11, 25, 249, 91, 102, 1171, 1182, "brimonidine" +402, 11, 26, 250, 103, 104, 1183, 1184, "-" +402, 11, 27, 251, 105, 112, 1185, 1192, "treated" +402, 11, 28, 252, 113, 118, 1193, 1198, "group" +402, 11, 29, 253, 119, 122, 1199, 1202, "and" +402, 11, 30, 254, 123, 124, 1203, 1204, "3" +402, 11, 31, 255, 125, 126, 1205, 1206, "." +402, 11, 32, 256, 127, 128, 1207, 1208, "2" +402, 11, 33, 257, 129, 131, 1209, 1211, "mm" +402, 11, 34, 258, 132, 134, 1212, 1214, "Hg" +402, 11, 35, 259, 135, 137, 1215, 1217, "in" +402, 11, 36, 260, 138, 141, 1218, 1221, "the" +402, 11, 37, 261, 142, 151, 1222, 1231, "betaxolol" +402, 11, 38, 262, 152, 153, 1232, 1233, "-" +402, 11, 39, 263, 154, 161, 1234, 1241, "treated" +402, 11, 40, 264, 162, 167, 1242, 1247, "group" +402, 11, 41, 265, 168, 169, 1248, 1249, "." +402, 12, 1, 266, 0, 3, 1250, 1253, "The" +402, 12, 2, 267, 4, 7, 1254, 1257, "IOP" +402, 12, 3, 268, 8, 9, 1258, 1259, "-" +402, 12, 4, 269, 10, 18, 1260, 1268, "lowering" +402, 12, 5, 270, 19, 25, 1269, 1275, "effect" +402, 12, 6, 271, 26, 28, 1276, 1278, "of" +402, 12, 7, 272, 29, 40, 1279, 1290, "brimonidine" +402, 12, 8, 273, 41, 44, 1291, 1294, "was" +402, 12, 9, 274, 45, 54, 1295, 1304, "sustained" +402, 12, 10, 275, 55, 65, 1305, 1315, "throughout" +402, 12, 11, 276, 66, 69, 1316, 1319, "the" +402, 12, 12, 277, 70, 71, 1320, 1321, "3" +402, 12, 13, 278, 72, 73, 1322, 1323, "-" +402, 12, 14, 279, 74, 79, 1324, 1329, "month" +402, 12, 15, 280, 80, 85, 1330, 1335, "study" +402, 12, 16, 281, 86, 92, 1336, 1342, "period" +402, 12, 17, 282, 93, 94, 1343, 1344, "." +402, 13, 1, 283, 0, 12, 1345, 1357, "Terminations" +402, 13, 2, 284, 13, 17, 1358, 1362, "from" +402, 13, 3, 285, 18, 21, 1363, 1366, "the" +402, 13, 4, 286, 22, 27, 1367, 1372, "study" +402, 13, 5, 287, 28, 31, 1373, 1376, "due" +402, 13, 6, 288, 32, 34, 1377, 1379, "to" +402, 13, 7, 289, 35, 39, 1380, 1384, "lack" +402, 13, 8, 290, 40, 42, 1385, 1387, "of" +402, 13, 9, 291, 43, 51, 1388, 1396, "efficacy" +402, 13, 10, 292, 52, 60, 1397, 1405, "included" +402, 13, 11, 293, 61, 62, 1406, 1407, "2" +402, 13, 12, 294, 63, 64, 1408, 1409, "." +402, 13, 13, 295, 65, 66, 1410, 1411, "9" +402, 13, 14, 296, 67, 68, 1412, 1413, "%" +402, 13, 15, 297, 69, 70, 1414, 1415, "(" +402, 13, 16, 298, 71, 72, 1416, 1417, "3" +402, 13, 17, 299, 73, 74, 1418, 1419, "/" +402, 13, 18, 300, 75, 78, 1420, 1423, "103" +402, 13, 19, 301, 79, 80, 1424, 1425, ")" +402, 13, 20, 302, 81, 83, 1426, 1428, "of" +402, 13, 21, 303, 84, 92, 1429, 1437, "patients" +402, 13, 22, 304, 93, 95, 1438, 1440, "in" +402, 13, 23, 305, 96, 99, 1441, 1444, "the" +402, 13, 24, 306, 100, 111, 1445, 1456, "brimonidine" +402, 13, 25, 307, 112, 117, 1457, 1462, "group" +402, 13, 26, 308, 118, 121, 1463, 1466, "and" +402, 13, 27, 309, 122, 123, 1467, 1468, "4" +402, 13, 28, 310, 124, 125, 1469, 1470, "." +402, 13, 29, 311, 126, 127, 1471, 1472, "2" +402, 13, 30, 312, 128, 129, 1473, 1474, "%" +402, 13, 31, 313, 130, 131, 1475, 1476, "(" +402, 13, 32, 314, 132, 133, 1477, 1478, "4" +402, 13, 33, 315, 134, 135, 1479, 1480, "/" +402, 13, 34, 316, 136, 138, 1481, 1483, "96" +402, 13, 35, 317, 139, 140, 1484, 1485, ")" +402, 13, 36, 318, 141, 143, 1486, 1488, "of" +402, 13, 37, 319, 144, 149, 1489, 1494, "those" +402, 13, 38, 320, 150, 152, 1495, 1497, "in" +402, 13, 39, 321, 153, 156, 1498, 1501, "the" +402, 13, 40, 322, 157, 166, 1502, 1511, "betaxolol" +402, 13, 41, 323, 167, 172, 1512, 1517, "group" +402, 13, 42, 324, 173, 174, 1518, 1519, "." +402, 14, 1, 325, 0, 3, 1520, 1523, "The" +402, 14, 2, 326, 4, 11, 1524, 1531, "overall" +402, 14, 3, 327, 12, 21, 1532, 1541, "incidence" +402, 14, 4, 328, 22, 24, 1542, 1544, "of" +402, 14, 5, 329, 25, 32, 1545, 1552, "adverse" +402, 14, 6, 330, 33, 39, 1553, 1559, "events" +402, 14, 7, 331, 40, 43, 1560, 1563, "was" +402, 14, 8, 332, 44, 51, 1564, 1571, "similar" +402, 14, 9, 333, 52, 54, 1572, 1574, "in" +402, 14, 10, 334, 55, 59, 1575, 1579, "both" +402, 14, 11, 335, 60, 69, 1580, 1589, "treatment" +402, 14, 12, 336, 70, 76, 1590, 1596, "groups" +402, 14, 13, 337, 77, 78, 1597, 1598, "," +402, 14, 14, 338, 79, 83, 1599, 1603, "with" +402, 14, 15, 339, 84, 87, 1604, 1607, "the" +402, 14, 16, 340, 88, 92, 1608, 1612, "only" +402, 14, 17, 341, 93, 104, 1613, 1624, "significant" +402, 14, 18, 342, 105, 106, 1625, 1626, "(" +402, 14, 19, 343, 107, 108, 1627, 1628, "p" +402, 14, 20, 344, 109, 110, 1629, 1630, "=" +402, 14, 21, 345, 111, 112, 1631, 1632, "0" +402, 14, 22, 346, 113, 114, 1633, 1634, "." +402, 14, 23, 347, 115, 118, 1635, 1638, "027" +402, 14, 24, 348, 119, 120, 1639, 1640, ")" +402, 14, 25, 349, 121, 128, 1641, 1648, "between" +402, 14, 26, 350, 129, 130, 1649, 1650, "-" +402, 14, 27, 351, 131, 136, 1651, 1656, "group" +402, 14, 28, 352, 137, 147, 1657, 1667, "difference" +402, 14, 29, 353, 148, 153, 1668, 1673, "being" +402, 14, 30, 354, 154, 158, 1674, 1678, "that" +402, 14, 31, 355, 159, 165, 1679, 1685, "ocular" +402, 14, 32, 356, 166, 174, 1686, 1694, "blurring" +402, 14, 33, 357, 175, 178, 1695, 1698, "was" +402, 14, 34, 358, 179, 187, 1699, 1707, "reported" +402, 14, 35, 359, 188, 192, 1708, 1712, "more" +402, 14, 36, 360, 193, 198, 1713, 1718, "often" +402, 14, 37, 361, 199, 201, 1719, 1721, "by" +402, 14, 38, 362, 202, 210, 1722, 1730, "patients" +402, 14, 39, 363, 211, 220, 1731, 1740, "receiving" +402, 14, 40, 364, 221, 230, 1741, 1750, "betaxolol" +402, 14, 41, 365, 231, 241, 1751, 1761, "suspension" +402, 14, 42, 366, 242, 246, 1762, 1766, "than" +402, 14, 43, 367, 247, 249, 1767, 1769, "by" +402, 14, 44, 368, 250, 255, 1770, 1775, "those" +402, 14, 45, 369, 256, 265, 1776, 1785, "receiving" +402, 14, 46, 370, 266, 277, 1786, 1797, "brimonidine" +402, 14, 47, 371, 278, 287, 1798, 1807, "treatment" +402, 14, 48, 372, 288, 289, 1808, 1809, "." +402, 15, 1, 373, 0, 12, 1810, 1822, "Instillation" +402, 15, 2, 374, 13, 15, 1823, 1825, "of" +402, 15, 3, 375, 16, 20, 1826, 1830, "drug" +402, 15, 4, 376, 21, 24, 1831, 1834, "was" +402, 15, 5, 377, 25, 33, 1835, 1843, "reported" +402, 15, 6, 378, 34, 36, 1844, 1846, "to" +402, 15, 7, 379, 37, 39, 1847, 1849, "be" +402, 15, 8, 380, 40, 51, 1850, 1861, "comfortable" +402, 15, 9, 381, 52, 53, 1862, 1863, "(" +402, 15, 10, 382, 54, 55, 1864, 1865, "p" +402, 15, 11, 383, 56, 57, 1866, 1867, "=" +402, 15, 12, 384, 58, 59, 1868, 1869, "0" +402, 15, 13, 385, 60, 61, 1870, 1871, "." +402, 15, 14, 386, 62, 65, 1872, 1875, "036" +402, 15, 15, 387, 66, 67, 1876, 1877, ")" +402, 15, 16, 388, 68, 70, 1878, 1880, "by" +402, 15, 17, 389, 71, 75, 1881, 1885, "more" +402, 15, 18, 390, 76, 87, 1886, 1897, "brimonidine" +402, 15, 19, 391, 88, 89, 1898, 1899, "-" +402, 15, 20, 392, 90, 97, 1900, 1907, "treated" +402, 15, 21, 393, 98, 106, 1908, 1916, "patients" +402, 15, 22, 394, 107, 111, 1917, 1921, "than" +402, 15, 23, 395, 112, 121, 1922, 1931, "betaxolol" +402, 15, 24, 396, 122, 123, 1932, 1933, "-" +402, 15, 25, 397, 124, 131, 1934, 1941, "treated" +402, 15, 26, 398, 132, 140, 1942, 1950, "patients" +402, 15, 27, 399, 141, 142, 1951, 1952, "." +402, 16, 1, 400, 0, 7, 1953, 1960, "Overall" +402, 16, 2, 401, 8, 9, 1961, 1962, "," +402, 16, 3, 402, 10, 21, 1963, 1974, "brimonidine" +402, 16, 4, 403, 22, 23, 1975, 1976, "0" +402, 16, 5, 404, 24, 25, 1977, 1978, "." +402, 16, 6, 405, 26, 27, 1979, 1980, "2" +402, 16, 7, 406, 28, 29, 1981, 1982, "%" +402, 16, 8, 407, 30, 38, 1983, 1991, "solution" +402, 16, 9, 408, 39, 42, 1992, 1995, "was" +402, 16, 10, 409, 43, 47, 1996, 2000, "well" +402, 16, 11, 410, 48, 49, 2001, 2002, "-" +402, 16, 12, 411, 50, 59, 2003, 2012, "tolerated" +402, 16, 13, 412, 60, 61, 2013, 2014, "," +402, 16, 14, 413, 62, 66, 2015, 2019, "safe" +402, 16, 15, 414, 67, 70, 2020, 2023, "and" +402, 16, 16, 415, 71, 81, 2024, 2034, "clinically" +402, 16, 17, 416, 82, 85, 2035, 2038, "and" +402, 16, 18, 417, 86, 99, 2039, 2052, "statistically" +402, 16, 19, 418, 100, 104, 2053, 2057, "more" +402, 16, 20, 419, 105, 114, 2058, 2067, "effective" +402, 16, 21, 420, 115, 119, 2068, 2072, "than" +402, 16, 22, 421, 120, 129, 2073, 2082, "betaxolol" +402, 16, 23, 422, 130, 131, 2083, 2084, "0" +402, 16, 24, 423, 132, 133, 2085, 2086, "." +402, 16, 25, 424, 134, 136, 2087, 2089, "25" +402, 16, 26, 425, 137, 138, 2090, 2091, "%" +402, 16, 27, 426, 139, 149, 2092, 2102, "suspension" +402, 16, 28, 427, 150, 152, 2103, 2105, "in" +402, 16, 29, 428, 153, 161, 2106, 2114, "lowering" +402, 16, 30, 429, 162, 173, 2115, 2126, "intraocular" +402, 16, 31, 430, 174, 182, 2127, 2135, "pressure" +402, 16, 32, 431, 183, 185, 2136, 2138, "in" +402, 16, 33, 432, 186, 194, 2139, 2147, "patients" +402, 16, 34, 433, 195, 199, 2148, 2152, "with" +402, 16, 35, 434, 200, 204, 2153, 2157, "open" +402, 16, 36, 435, 205, 206, 2158, 2159, "-" +402, 16, 37, 436, 207, 212, 2160, 2165, "angle" +402, 16, 38, 437, 213, 221, 2166, 2174, "glaucoma" +402, 16, 39, 438, 222, 224, 2175, 2177, "or" +402, 16, 40, 439, 225, 231, 2178, 2184, "ocular" +402, 16, 41, 440, 232, 244, 2185, 2197, "hypertension" +402, 16, 42, 441, 245, 246, 2198, 2199, "." +402, 17, 1, 442, 0, 4, 2200, 2204, "PMID" +402, 17, 2, 443, 5, 6, 2205, 2206, ":" +402, 17, 3, 444, 7, 14, 2207, 2214, "8970248" +402, 17, 4, 445, 15, 16, 2215, 2216, "[" +402, 17, 5, 446, 17, 24, 2217, 2224, "Indexed" +402, 17, 6, 447, 25, 28, 2225, 2228, "for" +402, 17, 7, 448, 29, 36, 2229, 2236, "MEDLINE" +402, 17, 8, 449, 37, 38, 2237, 2238, "]" diff --git a/data/gl 8970248_jshahinitiran.annodb b/data/gl 8970248_jshahinitiran.annodb new file mode 100644 index 0000000..09b4477 --- /dev/null +++ b/data/gl 8970248_jshahinitiran.annodb @@ -0,0 +1,82 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32874, Journal, 0, 15, "Surv Ophthalmol", "", +32875, PublicationYear, 18, 22, "1996", "", +32876, Title, 53, 200, "A comparison of the safety and efficacy of twice daily brimonidine 0 . 2 % versus betaxolol 0 . 25 % in subjects with elevated intraocular pressure", "", +32877, Frequency, 96, 107, "twice daily", "", +32878, Brimonidine, 108, 119, "brimonidine", "", +32882, DoseValue, 120, 125, "0 . 2", "", +32884, Percentage, 126, 127, "%", "", +32879, Betaxolol, 135, 144, "betaxolol", "", +32883, DoseValue, 145, 151, "0 . 25", "", +32885, Percentage, 152, 153, "%", "", +32881, Precondition, 171, 200, "elevated intraocular pressure", "", +32880, IOP, 180, 200, "intraocular pressure", "", +32886, Brimonidine, 207, 218, "Brimonidine", "", +32887, Author, 237, 245, "Serle JB", "", +32888, USA, 362, 365, "USA", "", +32889, Frequency, 414, 427, "twice - daily", "", +32890, Brimonidine, 446, 457, "brimonidine", "", +32894, DoseValue, 458, 463, "0 . 2", "", +32896, Percentage, 464, 465, "%", "", +32891, Betaxolol, 478, 487, "betaxolol", "", +32895, DoseValue, 488, 494, "0 . 25", "", +32897, Percentage, 495, 496, "%", "", +32892, OpenAngleGlaucoma, 539, 560, "open - angle glaucoma", "", +32893, OcularHypertension, 564, 583, "ocular hypertension", "", +32898, NumberPatientsCT, 597, 600, "206", "", +32899, CTDesign, 635, 646, "prospective", "", +32900, Duration, 649, 658, "3 - month", "", +32901, Multicenter, 661, 674, "multicentered", "", +32902, Randomized, 677, 687, "randomized", "", +32903, DoubleBlind, 690, 705, "double - masked", "", +32904, Parallel, 708, 716, "parallel", "", +32905, PValueChangeValue, 760, 771, "p < 0 . 001", "", +32906, Peak_IOP, 782, 786, "peak", "", +32907, Trough_IOP, 791, 818, "trough intraocular pressure", "", +32908, IOP, 821, 824, "IOP", "", +32909, Duration, 873, 882, "3 - month", "", +32910, Mean, 913, 917, "mean", "", +32911, Peak_IOP, 941, 944, "IOP", "", +32912, PvalueDiff, 959, 970, "p = 0 . 004", "", +32913, Brimonidine, 980, 991, "brimonidine", "", +32914, Reduction, 1010, 1015, "5 . 8", "", +32915, mmHg, 1016, 1021, "mm Hg", "", +32916, Betaxolol, 1036, 1045, "betaxolol", "", +32917, Reduction, 1064, 1069, "3 . 8", "", +32918, mmHg, 1070, 1075, "mm Hg", "", +32919, Mean, 1104, 1108, "mean", "", +32920, PvalueDiff, 1134, 1145, "p < 0 . 001", "", +32921, Reduction, 1152, 1157, "3 . 9", "", +32923, mmHg, 1158, 1163, "mm Hg", "", +32925, Brimonidine, 1171, 1182, "brimonidine", "", +32922, Reduction, 1203, 1208, "3 . 2", "", +32924, mmHg, 1209, 1214, "mm Hg", "", +32926, Betaxolol, 1222, 1231, "betaxolol", "", +32927, IOP, 1254, 1257, "IOP", "", +32928, Brimonidine, 1279, 1290, "brimonidine", "", +32929, Duration, 1320, 1329, "3 - month", "", +32953, RelNumPatientsLeftArm, 1406, 1411, "2 . 9", "", +32930, NumPatientsLeftArm, 1416, 1417, "3", "", +32931, NumberPatientsArm, 1420, 1423, "103", "", +32935, Brimonidine, 1445, 1456, "brimonidine", "", +32952, RelNumPatientsLeftArm, 1467, 1472, "4 . 2", "", +32933, NumPatientsLeftArm, 1477, 1478, "4", "", +32932, NumberPatientsArm, 1481, 1483, "96", "", +32934, Betaxolol, 1502, 1511, "betaxolol", "", +32936, PvalueDiff, 1627, 1638, "p = 0 . 027", "", +32937, Betaxolol, 1741, 1750, "betaxolol", "", +32938, Brimonidine, 1786, 1797, "brimonidine", "", +32939, PValueNumAffected, 1864, 1875, "p = 0 . 036", "", +32940, Brimonidine, 1886, 1897, "brimonidine", "", +32941, Betaxolol, 1922, 1931, "betaxolol", "", +32954, ConclusionComment, 1953, 2197, "Overall , brimonidine 0 . 2 % solution was well - tolerated , safe and clinically and statistically more effective than betaxolol 0 . 25 % suspension in lowering intraocular pressure in patients with open - angle glaucoma or ocular hypertension", "", +32942, Brimonidine, 1963, 1974, "brimonidine", "", +32944, DoseValue, 1975, 1980, "0 . 2", "", +32946, Percentage, 1981, 1982, "%", "", +32943, Betaxolol, 2073, 2082, "betaxolol", "", +32945, DoseValue, 2083, 2089, "0 . 25", "", +32947, Percentage, 2090, 2091, "%", "", +32948, IOP, 2115, 2135, "intraocular pressure", "", +32949, OpenAngleGlaucoma, 2153, 2174, "open - angle glaucoma", "", +32950, OcularHypertension, 2178, 2197, "ocular hypertension", "", +32951, PMID, 2207, 2214, "8970248", "", diff --git a/data/gl 8970248_jshahinitiran.n-triples b/data/gl 8970248_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8970248_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 8970248_tstrakeljahn.annodb b/data/gl 8970248_tstrakeljahn.annodb new file mode 100644 index 0000000..3809e15 --- /dev/null +++ b/data/gl 8970248_tstrakeljahn.annodb @@ -0,0 +1,81 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7713, Journal, 0, 15, "Surv Ophthalmol", "", +7714, Year, 18, 22, "1996", "", +7725, Title, 53, 202, "A comparison of the safety and efficacy of twice daily brimonidine 0 . 2 % versus betaxolol 0 . 25 % in subjects with elevated intraocular pressure .", "", +7715, Frequency, 96, 107, "twice daily", "", +7716, Brimonidine, 108, 119, "brimonidine", "", +7718, DoseValue, 120, 125, "0 . 2", "", +7721, Percentage, 126, 127, "%", "", +7720, Betaxolol, 135, 144, "betaxolol", "", +7719, DoseValue, 145, 151, "0 . 25", "", +7722, Percentage, 152, 153, "%", "", +7723, OcularHypertension, 171, 200, "elevated intraocular pressure", "", +29811, Brimonidine, 207, 218, "Brimonidine", "", +7726, Author, 237, 245, "Serle JB", "", +7724, USA, 362, 365, "USA", "", +7792, ObjectiveDescription, 368, 585, "The safety and ocular hypotensive efficacy of twice - daily administration of brimonidine 0 . 2 % solution or betaxolol 0 . 25 % suspension were compared in subjects with open - angle glaucoma or ocular hypertension .", "", +7727, Frequency, 414, 427, "twice - daily", "", +7728, Brimonidine, 446, 457, "brimonidine", "", +7730, DoseValue, 458, 463, "0 . 2", "", +7732, Percentage, 464, 465, "%", "", +7729, Betaxolol, 478, 487, "betaxolol", "", +7731, DoseValue, 488, 494, "0 . 25", "", +7733, Percentage, 495, 496, "%", "", +7734, OpenAngleGlaucoma, 539, 560, "open - angle glaucoma", "", +7735, OcularHypertension, 564, 583, "ocular hypertension", "", +7736, NumberPatientsCT, 597, 600, "206", "", +7737, Duration, 649, 658, "3 - month", "", +7738, Multicenter, 661, 674, "multicentered", "", +7739, Randomized, 677, 687, "randomized", "", +7740, DoubleBlind, 690, 705, "double - masked", "", +7741, Parallel, 708, 716, "parallel", "", +7742, PvalueDiff, 760, 771, "p < 0 . 001", "", +7743, IOP, 798, 818, "intraocular pressure", "", +7744, IOP, 821, 824, "IOP", "", +7745, Duration, 873, 882, "3 - month", "", +7747, Mean, 913, 917, "mean", "", +7746, IOP, 941, 944, "IOP", "", +7748, PValueChangeValue, 959, 970, "p = 0 . 004", "", +7749, Brimonidine, 980, 991, "brimonidine", "", +7750, Reduction, 1010, 1015, "5 . 8", "", +7751, mmHg, 1016, 1021, "mm Hg", "", +7752, Betaxolol, 1036, 1045, "betaxolol", "", +7753, Reduction, 1064, 1069, "3 . 8", "", +7754, mmHg, 1070, 1075, "mm Hg", "", +7755, Mean, 1104, 1108, "mean", "", +7756, PValueChangeValue, 1134, 1145, "p < 0 . 001", "", +7757, Reduction, 1152, 1157, "3 . 9", "", +7758, mmHg, 1158, 1163, "mm Hg", "", +7759, Brimonidine, 1171, 1182, "brimonidine", "", +7760, Reduction, 1203, 1208, "3 . 2", "", +7761, mmHg, 1209, 1214, "mm Hg", "", +7762, Betaxolol, 1222, 1231, "betaxolol", "", +7766, ObservedResult, 1250, 1344, "The IOP - lowering effect of brimonidine was sustained throughout the 3 - month study period .", "", +7763, IOP, 1254, 1257, "IOP", "", +7764, Brimonidine, 1279, 1290, "brimonidine", "", +7765, Duration, 1320, 1329, "3 - month", "", +7770, RelNumPatientsLeftArm, 1406, 1411, "2 . 9", "", +7772, NumPatientsLeftArm, 1416, 1417, "3", "", +29812, NumberPatientsArm, 1420, 1423, "103", "", +7769, Brimonidine, 1445, 1456, "brimonidine", "", +7771, RelNumPatientsLeftArm, 1467, 1472, "4 . 2", "", +7773, NumPatientsLeftArm, 1477, 1478, "4", "", +29813, NumberPatientsArm, 1481, 1483, "96", "", +7774, Betaxolol, 1502, 1511, "betaxolol", "", +7775, PvalueDiff, 1627, 1638, "p = 0 . 027", "", +7779, ObservedResult, 1679, 1809, "ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving brimonidine treatment .", "", +7777, Betaxolol, 1741, 1750, "betaxolol", "", +7778, Brimonidine, 1786, 1797, "brimonidine", "", +7780, PvalueDiff, 1864, 1875, "p = 0 . 036", "", +7781, Brimonidine, 1886, 1897, "brimonidine", "", +7782, Betaxolol, 1922, 1931, "betaxolol", "", +7793, ConclusionComment, 1953, 2199, "Overall , brimonidine 0 . 2 % solution was well - tolerated , safe and clinically and statistically more effective than betaxolol 0 . 25 % suspension in lowering intraocular pressure in patients with open - angle glaucoma or ocular hypertension .", "", +7783, Brimonidine, 1963, 1974, "brimonidine", "", +7785, DoseValue, 1975, 1980, "0 . 2", "", +7786, Percentage, 1981, 1982, "%", "", +7784, Betaxolol, 2073, 2082, "betaxolol", "", +7787, DoseValue, 2083, 2089, "0 . 25", "", +7788, Percentage, 2090, 2091, "%", "", +7789, OpenAngleGlaucoma, 2153, 2174, "open - angle glaucoma", "", +7790, OcularHypertension, 2178, 2197, "ocular hypertension", "", +7794, PMID, 2207, 2214, "8970248", "", diff --git a/data/gl 8970248_tstrakeljahn.n-triples b/data/gl 8970248_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 8970248_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9230823_admin.annodb b/data/gl 9230823_admin.annodb new file mode 100644 index 0000000..8a940e0 --- /dev/null +++ b/data/gl 9230823_admin.annodb @@ -0,0 +1,113 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 17, "Arch Ophthalmol .", "", " \"Arch Ophthalmol .\"." +1, PublicationYear, 18, 22, "1997", "", " \"1997\"." +16, Title, 52, 133, "A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension .", "", " \"A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension .\"." +88, Duration, 54, 62, "1 - year", "", " \"1 - year\"." +2, Brimonidine, 72, 83, "brimonidine", "", +3, Frequency, 84, 95, "twice daily", "", +4, Glaucoma, 99, 107, "glaucoma", "", " . ." +5, OcularHypertension, 112, 131, "ocular hypertension", "", " ." +24, Title, 134, 190, "A controlled , randomized , multicenter clinical trial .", "", +93, CTDesign, 136, 146, "controlled", "", " . ." +6, Randomized, 149, 159, "randomized", "", " ." +7, Multicenter, 162, 173, "multicenter", "", " ." +84, Brimonidine, 199, 210, "Brimonidine", "", +9, Author, 225, 235, "Schuman JS", "", " \"Schuman JS\"." +10, Author, 244, 253, "Horwitz B", "", " \"Horwitz B\"." +11, Author, 256, 266, "Choplin NT", "", " \"Choplin NT\"." +12, Author, 269, 276, "David R", "", " \"David R\"." +13, Author, 279, 289, "Albracht D", "", " \"Albracht D\"." +14, Author, 292, 298, "Chen K", "", " \"Chen K\"." +15, USA, 409, 412, "USA", "", " ." +17, Brimonidine, 510, 529, "Brimonidin tartrate", "", +18, ObjectiveDescription, 572, 729, "This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension .", "", " \"This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension .\"." +19, DoseValue, 623, 628, "0 . 2", "", +25, Percentage, 629, 630, "%", "", +26, Brimonidine, 631, 642, "brimonidine", "", +20, Frequency, 656, 667, "twice daily", "", +21, Duration, 672, 678, "1 year", "", +54561, Precondition, 682, 727, "patients with glaucoma or ocular hypertension", "", " \"patients with glaucoma or ocular hypertension\"." +22, Glaucoma, 696, 704, "glaucoma", "", +23, OcularHypertension, 708, 727, "ocular hypertension", "", +27, Multicenter, 763, 774, "multicenter", "", +28, DoubleBlind, 777, 792, "double - masked", "", " ." +29, Randomized, 795, 805, "randomized", "", +30, Parallel, 808, 816, "parallel", "", " ." +117, CTDesign, 827, 846, "active - controlled", "", " . ." +32, DoseValue, 894, 899, "0 . 2", "", " \"0 . 2\"." +120, Percentage, 900, 901, "%", "", " ." +34, Brimonidine, 902, 913, "brimonidine", "", " ." +33, DoseValue, 917, 922, "0 . 5", "", " \"0 . 5\"." +36, Percentage, 923, 924, "%", "", " ." +35, Timolol, 925, 940, "timolol maleate", "", " ." +37, Frequency, 941, 952, "twice daily", "", " \"twice daily\". \"twice daily\"." +38, Duration, 957, 966, "12 months", "", +126, TimePoint, 995, 1003, "baseline", "", +127, TimePoint, 1006, 1012, "week 1", "", +54563, TimePoint, 1019, 1035, "months 1 , 2 , 3", "", +128, TimePoint, 1019, 1027, "months 1", "", +130, TimePoint, 1019, 1031, "months 1 , 2", "", +131, TimePoint, 1019, 1039, "months 1 , 2 , 3 , 6", "", +132, TimePoint, 1019, 1043, "months 1 , 2 , 3 , 6 , 9", "", +133, TimePoint, 1019, 1052, "months 1 , 2 , 3 , 6 , 9 , and 12", "", +134, TimePoint, 1092, 1098, "week 2", "", +39, NumberPatientsCT, 1114, 1117, "443", "", " \"443\"." +40, FinalNumPatientsCT, 1152, 1155, "374", "", " \"374\"." +54564, FinalNumPatientsArm, 1181, 1184, "186", "", " \"186\"." +43, Brimonidine, 1194, 1205, "brimonidine", "", +42, FinalNumPatientsArm, 1210, 1213, "188", "", " \"188\"." +44, Timolol, 1223, 1230, "timolol", "", +45, Brimonidine, 1233, 1244, "Brimonidine", "", +46, Mean, 1282, 1286, "mean", "", " . ." +142, Peak_IOP, 1287, 1291, "peak", "", " ." +47, IOP, 1305, 1325, "intraocular pressure", "", +142, Peak_IOP, 1305, 1325, "intraocular pressure", "", " ." +48, IOP, 1328, 1331, "IOP", "", +49, Reduction, 1337, 1342, "6 . 5", "", " \"6 . 5\"." +50, mmHg, 1343, 1348, "mm Hg", "", " ." +51, Timolol, 1351, 1358, "timolol", "", +52, Mean, 1384, 1388, "mean", "", +148, Peak_IOP, 1389, 1393, "peak", "", +148, Peak_IOP, 1407, 1410, "IOP", "", +53, IOP, 1407, 1410, "IOP", "", +54, Reduction, 1414, 1419, "6 . 1", "", " \"6 . 1\"." +55, mmHg, 1420, 1425, "mm Hg", "", +106391, ObservedResult, 1428, 1528, "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )", "", " \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\"." +56, Brimonidine, 1428, 1439, "Brimonidine", "", +58, Mean, 1448, 1452, "mean", "", +57, Peak_IOP, 1453, 1461, "peak IOP", "", +59, Timolol, 1486, 1493, "timolol", "", +60, TimePoint, 1497, 1503, "week 2", "", " \"week 2\". \"week 2\"." +61, TimePoint, 1508, 1515, "month 3", "", " \"month 3\". \"month 3\"." +62, PvalueDiff, 1518, 1526, "P < . 03", "", " \"P < . 03\". \"P < . 03\"." +158, Duration, 1638, 1646, "1 - year", "", +66, ObservedResult, 1725, 1787, "Allergy was seen in 9 % of subjects treated with brimonidine .", "", " \"Allergy was seen in 9 % of subjects treated with brimonidine .\"." +105208, Ocular_Allergy, 1725, 1732, "Allergy", "", " ." +64, PercentageAffected, 1745, 1746, "9", "", " \"9\"." +65, Brimonidine, 1774, 1785, "brimonidine", "", +54568, EndPointDescription, 1788, 1797, "Dry mouth", "", " . ." +71, ObservedResult, 1788, 1909, "Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )", "", " \"Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )\". \"Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )\"." +67, Brimonidine, 1821, 1832, "brimonidine", "", +68, Timolol, 1861, 1868, "timolol", "", +69, PercentageAffected, 1887, 1893, "33 . 0", "", " \"33 . 0\"." +70, PercentageAffected, 1899, 1905, "19 . 4", "", " \"19 . 4\"." +54576, EndPointDescription, 1916, 1950, "complaints of burning and stinging", "", " . ." +76, ObservedResult, 1916, 2067, "complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )", "", " \"complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )\". \"complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )\"." +54569, EndPointDescription, 1930, 1937, "burning", "", +54573, Stinging, 1942, 1950, "stinging", "", +73, Timolol, 1975, 1982, "timolol", "", +72, PercentageAffected, 2001, 2007, "41 . 9", "", +75, Brimonidine, 2024, 2035, "brimonidine", "", +74, PercentageAffected, 2057, 2063, "28 . 1", "", +172, Headache, 2070, 2078, "Headache", "", " ." +77, ObservedResult, 2070, 2136, "Headache , fatigue , and drowsiness were similar in the 2 groups .", "", " \"Headache , fatigue , and drowsiness were similar in the 2 groups .\". \"Headache , fatigue , and drowsiness were similar in the 2 groups .\". \"Headache , fatigue , and drowsiness were similar in the 2 groups .\"." +54577, EndPointDescription, 2081, 2088, "fatigue", "", " . ." +54578, EndPointDescription, 2095, 2105, "drowsiness", "", " . ." +78, ObservedResult, 2137, 2194, "In general , the tolerance to medication was acceptable .", "", " \"In general , the tolerance to medication was acceptable .\". \"In general , the tolerance to medication was acceptable .\"." +79, Brimonidine, 2209, 2220, "Brimonidine", "", +81, ConclusionComment, 2209, 2281, "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .", "", " \"Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .\"." +80, IOP, 2255, 2258, "IOP", "", +178, Glaucoma, 2262, 2274, "glaucomatous", "", +180, Brimonidine, 2282, 2293, "Brimonidine", "", +82, ConclusionComment, 2282, 2416, "Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .", "", " \"Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .\"." +83, PMID, 2475, 2482, "9230823", "", " \"9230823\"." diff --git a/data/gl 9230823_admin.n-triples b/data/gl 9230823_admin.n-triples new file mode 100644 index 0000000..f5b8d12 --- /dev/null +++ b/data/gl 9230823_admin.n-triples @@ -0,0 +1,225 @@ +# RDF export of group: Publication + . + "Publication" . + "A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension ." . + "Schuman JS" . + "1997" . + "Arch Ophthalmol ." . + "9230823" . + . + "Horwitz B" . + "Choplin NT" . + "David R" . + "Albracht D" . + "Chen K" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension ." . + "443" . + "1 - year" . + . + . + . + . + "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes ." . + . + . + . + . + . + . + "374" . + . + . + . + . + . + . + "Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with glaucoma or ocular hypertension" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_piop" . + . + . + . + . + . + . + "Endpoint_OA" . + . + . + . + . + . + "Endpoint_DM" . + . + . + . + . + . + . + "Endpoint_BS" . + . + . + . + . + . + . + "Endpoint_HA" . + . + . + . + . + . + "Endpoint_F" . + . + . + . + . + . + . + "Endpoint_D" . + . + . + . + . + . +# RDF export of group: Arm + . + "Arm_bri" . + "186" . + . + . + . + . + . + . + . + . + . + . + . + "Arm_tim" . + "188" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_bri" . + . + . + "twice daily" . + . + "Intervention_tim" . + . + "twice daily" . + . +# RDF export of group: Medication + . + "Medication_bri" . + . + "0 . 2" . + . + . + . + "Medication_tim" . + . + "0 . 5" . + . + . +# RDF export of group: Outcome + . + "Outcome_piop_bri" . + . + "6 . 5" . + "In general , the tolerance to medication was acceptable ." . + . + "Outcome_piop_tim" . + . + "6 . 1" . + "In general , the tolerance to medication was acceptable ." . + . + "Outcome_piop_2w_bri" . + . + "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )" . + "week 2" . + . + "Outcome_piop_2w_tim" . + . + "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )" . + "week 2" . + . + "Outcome_piop_3m_bri" . + . + "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )" . + "month 3" . + . + "Outcome_piop_3m_tim" . + . + "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )" . + "month 3" . + . + "Outcome_OA_bri" . + . + "9" . + "Allergy was seen in 9 % of subjects treated with brimonidine ." . + . + "Outcome_DM_bri" . + . + "33 . 0" . + "Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )" . + . + "Outcome_DM_tim" . + . + "19 . 4" . + "Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )" . + . + "Outcome_BS_bri" . + . + "complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )" . + . + "Outcome_BS_tim" . + . + "complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )" . + . + "Outcome_HA" . + . + "Headache , fatigue , and drowsiness were similar in the 2 groups ." . + . + "Outcome_F" . + . + "Headache , fatigue , and drowsiness were similar in the 2 groups ." . + . + "Outcome_D" . + . + "Headache , fatigue , and drowsiness were similar in the 2 groups ." . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_piop_2w" . + "P < . 03" . + . + . + . + "DiffBetweenGroups_piop_3m" . + "P < . 03" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9230823_export.csv b/data/gl 9230823_export.csv new file mode 100644 index 0000000..5280c59 --- /dev/null +++ b/data/gl 9230823_export.csv @@ -0,0 +1,510 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +401, 1, 1, 1, 0, 4, 0, 4, "Arch" +401, 1, 2, 2, 5, 15, 5, 15, "Ophthalmol" +401, 1, 3, 3, 16, 17, 16, 17, "." +401, 2, 1, 4, 0, 4, 18, 22, "1997" +401, 2, 2, 5, 5, 8, 23, 26, "Jul" +401, 2, 3, 6, 9, 10, 27, 28, ";" +401, 2, 4, 7, 11, 14, 29, 32, "115" +401, 2, 5, 8, 15, 16, 33, 34, "(" +401, 2, 6, 9, 17, 18, 35, 36, "7" +401, 2, 7, 10, 19, 20, 37, 38, ")" +401, 2, 8, 11, 21, 22, 39, 40, ":" +401, 2, 9, 12, 23, 26, 41, 44, "847" +401, 2, 10, 13, 27, 28, 45, 46, "-" +401, 2, 11, 14, 29, 31, 47, 49, "52" +401, 2, 12, 15, 32, 33, 50, 51, "." +401, 3, 1, 16, 0, 1, 52, 53, "A" +401, 3, 2, 17, 2, 3, 54, 55, "1" +401, 3, 3, 18, 4, 5, 56, 57, "-" +401, 3, 4, 19, 6, 10, 58, 62, "year" +401, 3, 5, 20, 11, 16, 63, 68, "study" +401, 3, 6, 21, 17, 19, 69, 71, "of" +401, 3, 7, 22, 20, 31, 72, 83, "brimonidine" +401, 3, 8, 23, 32, 37, 84, 89, "twice" +401, 3, 9, 24, 38, 43, 90, 95, "daily" +401, 3, 10, 25, 44, 46, 96, 98, "in" +401, 3, 11, 26, 47, 55, 99, 107, "glaucoma" +401, 3, 12, 27, 56, 59, 108, 111, "and" +401, 3, 13, 28, 60, 66, 112, 118, "ocular" +401, 3, 14, 29, 67, 79, 119, 131, "hypertension" +401, 3, 15, 30, 80, 81, 132, 133, "." +401, 4, 1, 31, 0, 1, 134, 135, "A" +401, 4, 2, 32, 2, 12, 136, 146, "controlled" +401, 4, 3, 33, 13, 14, 147, 148, "," +401, 4, 4, 34, 15, 25, 149, 159, "randomized" +401, 4, 5, 35, 26, 27, 160, 161, "," +401, 4, 6, 36, 28, 39, 162, 173, "multicenter" +401, 4, 7, 37, 40, 48, 174, 182, "clinical" +401, 4, 8, 38, 49, 54, 183, 188, "trial" +401, 4, 9, 39, 55, 56, 189, 190, "." +401, 5, 1, 40, 0, 7, 191, 198, "Chronic" +401, 5, 2, 41, 8, 19, 199, 210, "Brimonidine" +401, 5, 3, 42, 20, 25, 211, 216, "Study" +401, 5, 4, 43, 26, 31, 217, 222, "Group" +401, 5, 5, 44, 32, 33, 223, 224, "." +401, 6, 1, 45, 0, 7, 225, 232, "Schuman" +401, 6, 2, 46, 8, 10, 233, 235, "JS" +401, 6, 3, 47, 11, 12, 236, 237, "(" +401, 6, 4, 48, 13, 14, 238, 239, "1" +401, 6, 5, 49, 15, 16, 240, 241, ")" +401, 6, 6, 50, 17, 18, 242, 243, "," +401, 6, 7, 51, 19, 26, 244, 251, "Horwitz" +401, 6, 8, 52, 27, 28, 252, 253, "B" +401, 6, 9, 53, 29, 30, 254, 255, "," +401, 6, 10, 54, 31, 38, 256, 263, "Choplin" +401, 6, 11, 55, 39, 41, 264, 266, "NT" +401, 6, 12, 56, 42, 43, 267, 268, "," +401, 6, 13, 57, 44, 49, 269, 274, "David" +401, 6, 14, 58, 50, 51, 275, 276, "R" +401, 6, 15, 59, 52, 53, 277, 278, "," +401, 6, 16, 60, 54, 62, 279, 287, "Albracht" +401, 6, 17, 61, 63, 64, 288, 289, "D" +401, 6, 18, 62, 65, 66, 290, 291, "," +401, 6, 19, 63, 67, 71, 292, 296, "Chen" +401, 6, 20, 64, 72, 73, 297, 298, "K" +401, 6, 21, 65, 74, 75, 299, 300, "." +401, 6, 22, 66, 76, 82, 301, 307, "Author" +401, 6, 23, 67, 83, 94, 308, 319, "information" +401, 6, 24, 68, 95, 96, 320, 321, ":" +401, 6, 25, 69, 97, 98, 322, 323, "(" +401, 6, 26, 70, 99, 100, 324, 325, "1" +401, 6, 27, 71, 101, 102, 326, 327, ")" +401, 6, 28, 72, 103, 106, 328, 331, "New" +401, 6, 29, 73, 107, 114, 332, 339, "England" +401, 6, 30, 74, 115, 118, 340, 343, "Eye" +401, 6, 31, 75, 119, 125, 344, 350, "Center" +401, 6, 32, 76, 126, 127, 351, 352, "," +401, 6, 33, 77, 128, 133, 353, 358, "Tufts" +401, 6, 34, 78, 134, 144, 359, 369, "University" +401, 6, 35, 79, 145, 151, 370, 376, "School" +401, 6, 36, 80, 152, 154, 377, 379, "of" +401, 6, 37, 81, 155, 163, 380, 388, "Medicine" +401, 6, 38, 82, 164, 165, 389, 390, "," +401, 6, 39, 83, 166, 172, 391, 397, "Boston" +401, 6, 40, 84, 173, 174, 398, 399, "," +401, 6, 41, 85, 175, 179, 400, 404, "Mass" +401, 6, 42, 86, 180, 181, 405, 406, "." +401, 6, 43, 87, 182, 183, 407, 408, "," +401, 6, 44, 88, 184, 187, 409, 412, "USA" +401, 6, 45, 89, 188, 189, 413, 414, "." +401, 7, 1, 90, 0, 3, 415, 418, "jss" +401, 7, 2, 91, 4, 5, 419, 420, "@" +401, 7, 3, 92, 6, 14, 421, 429, "mediaone" +401, 7, 4, 93, 15, 16, 430, 431, "." +401, 7, 5, 94, 17, 20, 432, 435, "net" +401, 7, 6, 95, 21, 28, 436, 443, "Comment" +401, 7, 7, 96, 29, 31, 444, 446, "in" +401, 7, 8, 97, 32, 36, 447, 451, "Arch" +401, 7, 9, 98, 37, 47, 452, 462, "Ophthalmol" +401, 7, 10, 99, 48, 49, 463, 464, "." +401, 8, 1, 100, 0, 4, 465, 469, "1999" +401, 8, 2, 101, 5, 8, 470, 473, "Mar" +401, 8, 3, 102, 9, 10, 474, 475, ";" +401, 8, 4, 103, 11, 14, 476, 479, "117" +401, 8, 5, 104, 15, 16, 480, 481, "(" +401, 8, 6, 105, 17, 18, 482, 483, "3" +401, 8, 7, 106, 19, 20, 484, 485, ")" +401, 8, 8, 107, 21, 22, 486, 487, ":" +401, 8, 9, 108, 23, 26, 488, 491, "417" +401, 8, 10, 109, 27, 28, 492, 493, "-" +401, 8, 11, 110, 29, 30, 494, 495, "9" +401, 8, 12, 111, 31, 32, 496, 497, "." +401, 9, 1, 112, 0, 9, 498, 507, "OBJECTIVE" +401, 9, 2, 113, 10, 11, 508, 509, ":" +401, 9, 3, 114, 12, 22, 510, 520, "Brimonidin" +401, 9, 4, 115, 23, 31, 521, 529, "tartrate" +401, 9, 5, 116, 32, 34, 530, 532, "is" +401, 9, 6, 117, 35, 36, 533, 534, "a" +401, 9, 7, 118, 37, 43, 535, 541, "highly" +401, 9, 8, 119, 44, 53, 542, 551, "selective" +401, 9, 9, 120, 54, 59, 552, 557, "alpha" +401, 9, 10, 121, 60, 61, 558, 559, "2" +401, 9, 11, 122, 62, 63, 560, 561, "-" +401, 9, 12, 123, 64, 71, 562, 569, "agonist" +401, 9, 13, 124, 72, 73, 570, 571, "." +401, 10, 1, 125, 0, 4, 572, 576, "This" +401, 10, 2, 126, 5, 10, 577, 582, "study" +401, 10, 3, 127, 11, 23, 583, 595, "investigates" +401, 10, 4, 128, 24, 27, 596, 599, "the" +401, 10, 5, 129, 28, 34, 600, 606, "safety" +401, 10, 6, 130, 35, 38, 607, 610, "and" +401, 10, 7, 131, 39, 47, 611, 619, "efficacy" +401, 10, 8, 132, 48, 50, 620, 622, "of" +401, 10, 9, 133, 51, 52, 623, 624, "0" +401, 10, 10, 134, 53, 54, 625, 626, "." +401, 10, 11, 135, 55, 56, 627, 628, "2" +401, 10, 12, 136, 57, 58, 629, 630, "%" +401, 10, 13, 137, 59, 70, 631, 642, "brimonidine" +401, 10, 14, 138, 71, 83, 643, 655, "administered" +401, 10, 15, 139, 84, 89, 656, 661, "twice" +401, 10, 16, 140, 90, 95, 662, 667, "daily" +401, 10, 17, 141, 96, 99, 668, 671, "for" +401, 10, 18, 142, 100, 101, 672, 673, "1" +401, 10, 19, 143, 102, 106, 674, 678, "year" +401, 10, 20, 144, 107, 109, 679, 681, "in" +401, 10, 21, 145, 110, 118, 682, 690, "patients" +401, 10, 22, 146, 119, 123, 691, 695, "with" +401, 10, 23, 147, 124, 132, 696, 704, "glaucoma" +401, 10, 24, 148, 133, 135, 705, 707, "or" +401, 10, 25, 149, 136, 142, 708, 714, "ocular" +401, 10, 26, 150, 143, 155, 715, 727, "hypertension" +401, 10, 27, 151, 156, 157, 728, 729, "." +401, 11, 1, 152, 0, 7, 730, 737, "METHODS" +401, 11, 2, 153, 8, 9, 738, 739, ":" +401, 11, 3, 154, 10, 13, 740, 743, "The" +401, 11, 4, 155, 14, 19, 744, 749, "study" +401, 11, 5, 156, 20, 26, 750, 756, "design" +401, 11, 6, 157, 27, 30, 757, 760, "was" +401, 11, 7, 158, 31, 32, 761, 762, "a" +401, 11, 8, 159, 33, 44, 763, 774, "multicenter" +401, 11, 9, 160, 45, 46, 775, 776, "," +401, 11, 10, 161, 47, 53, 777, 783, "double" +401, 11, 11, 162, 54, 55, 784, 785, "-" +401, 11, 12, 163, 56, 62, 786, 792, "masked" +401, 11, 13, 164, 63, 64, 793, 794, "," +401, 11, 14, 165, 65, 75, 795, 805, "randomized" +401, 11, 15, 166, 76, 77, 806, 807, "," +401, 11, 16, 167, 78, 86, 808, 816, "parallel" +401, 11, 17, 168, 87, 88, 817, 818, "-" +401, 11, 18, 169, 89, 94, 819, 824, "group" +401, 11, 19, 170, 95, 96, 825, 826, "," +401, 11, 20, 171, 97, 103, 827, 833, "active" +401, 11, 21, 172, 104, 105, 834, 835, "-" +401, 11, 22, 173, 106, 116, 836, 846, "controlled" +401, 11, 23, 174, 117, 127, 847, 857, "comparison" +401, 11, 24, 175, 128, 136, 858, 866, "clinical" +401, 11, 25, 176, 137, 142, 867, 872, "trial" +401, 11, 26, 177, 143, 144, 873, 874, "." +401, 12, 1, 178, 0, 8, 875, 883, "Subjects" +401, 12, 2, 179, 9, 18, 884, 893, "instilled" +401, 12, 3, 180, 19, 20, 894, 895, "0" +401, 12, 4, 181, 21, 22, 896, 897, "." +401, 12, 5, 182, 23, 24, 898, 899, "2" +401, 12, 6, 183, 25, 26, 900, 901, "%" +401, 12, 7, 184, 27, 38, 902, 913, "brimonidine" +401, 12, 8, 185, 39, 41, 914, 916, "or" +401, 12, 9, 186, 42, 43, 917, 918, "0" +401, 12, 10, 187, 44, 45, 919, 920, "." +401, 12, 11, 188, 46, 47, 921, 922, "5" +401, 12, 12, 189, 48, 49, 923, 924, "%" +401, 12, 13, 190, 50, 57, 925, 932, "timolol" +401, 12, 14, 191, 58, 65, 933, 940, "maleate" +401, 12, 15, 192, 66, 71, 941, 946, "twice" +401, 12, 16, 193, 72, 77, 947, 952, "daily" +401, 12, 17, 194, 78, 81, 953, 956, "for" +401, 12, 18, 195, 82, 84, 957, 959, "12" +401, 12, 19, 196, 85, 91, 960, 966, "months" +401, 12, 20, 197, 92, 93, 967, 968, "." +401, 13, 1, 198, 0, 8, 969, 977, "Subjects" +401, 13, 2, 199, 9, 13, 978, 982, "were" +401, 13, 3, 200, 14, 22, 983, 991, "examined" +401, 13, 4, 201, 23, 25, 992, 994, "at" +401, 13, 5, 202, 26, 34, 995, 1003, "baseline" +401, 13, 6, 203, 35, 36, 1004, 1005, "," +401, 13, 7, 204, 37, 41, 1006, 1010, "week" +401, 13, 8, 205, 42, 43, 1011, 1012, "1" +401, 13, 9, 206, 44, 45, 1013, 1014, "," +401, 13, 10, 207, 46, 49, 1015, 1018, "and" +401, 13, 11, 208, 50, 56, 1019, 1025, "months" +401, 13, 12, 209, 57, 58, 1026, 1027, "1" +401, 13, 13, 210, 59, 60, 1028, 1029, "," +401, 13, 14, 211, 61, 62, 1030, 1031, "2" +401, 13, 15, 212, 63, 64, 1032, 1033, "," +401, 13, 16, 213, 65, 66, 1034, 1035, "3" +401, 13, 17, 214, 67, 68, 1036, 1037, "," +401, 13, 18, 215, 69, 70, 1038, 1039, "6" +401, 13, 19, 216, 71, 72, 1040, 1041, "," +401, 13, 20, 217, 73, 74, 1042, 1043, "9" +401, 13, 21, 218, 75, 76, 1044, 1045, "," +401, 13, 22, 219, 77, 80, 1046, 1049, "and" +401, 13, 23, 220, 81, 83, 1050, 1052, "12" +401, 13, 24, 221, 84, 85, 1053, 1054, "." +401, 14, 1, 222, 0, 1, 1055, 1056, "A" +401, 14, 2, 223, 2, 8, 1057, 1063, "subset" +401, 14, 3, 224, 9, 11, 1064, 1066, "of" +401, 14, 4, 225, 12, 20, 1067, 1075, "subjects" +401, 14, 5, 226, 21, 24, 1076, 1079, "was" +401, 14, 6, 227, 25, 33, 1080, 1088, "examined" +401, 14, 7, 228, 34, 36, 1089, 1091, "at" +401, 14, 8, 229, 37, 41, 1092, 1096, "week" +401, 14, 9, 230, 42, 43, 1097, 1098, "2" +401, 14, 10, 231, 44, 45, 1099, 1100, "." +401, 15, 1, 232, 0, 7, 1101, 1108, "RESULTS" +401, 15, 2, 233, 8, 9, 1109, 1110, ":" +401, 15, 3, 234, 10, 12, 1111, 1113, "Of" +401, 15, 4, 235, 13, 16, 1114, 1117, "443" +401, 15, 5, 236, 17, 25, 1118, 1126, "subjects" +401, 15, 6, 237, 26, 34, 1127, 1135, "enrolled" +401, 15, 7, 238, 35, 37, 1136, 1138, "in" +401, 15, 8, 239, 38, 42, 1139, 1143, "this" +401, 15, 9, 240, 43, 48, 1144, 1149, "study" +401, 15, 10, 241, 49, 50, 1150, 1151, "," +401, 15, 11, 242, 51, 54, 1152, 1155, "374" +401, 15, 12, 243, 55, 58, 1156, 1159, "met" +401, 15, 13, 244, 59, 62, 1160, 1163, "the" +401, 15, 14, 245, 63, 68, 1164, 1169, "entry" +401, 15, 15, 246, 69, 77, 1170, 1178, "criteria" +401, 15, 16, 247, 78, 79, 1179, 1180, ";" +401, 15, 17, 248, 80, 83, 1181, 1184, "186" +401, 15, 18, 249, 84, 92, 1185, 1193, "received" +401, 15, 19, 250, 93, 104, 1194, 1205, "brimonidine" +401, 15, 20, 251, 105, 108, 1206, 1209, "and" +401, 15, 21, 252, 109, 112, 1210, 1213, "188" +401, 15, 22, 253, 113, 121, 1214, 1222, "received" +401, 15, 23, 254, 122, 129, 1223, 1230, "timolol" +401, 15, 24, 255, 130, 131, 1231, 1232, "." +401, 16, 1, 256, 0, 11, 1233, 1244, "Brimonidine" +401, 16, 2, 257, 12, 13, 1245, 1246, "-" +401, 16, 3, 258, 14, 21, 1247, 1254, "treated" +401, 16, 4, 259, 22, 30, 1255, 1263, "subjects" +401, 16, 5, 260, 31, 37, 1264, 1270, "showed" +401, 16, 6, 261, 38, 40, 1271, 1273, "an" +401, 16, 7, 262, 41, 48, 1274, 1281, "overall" +401, 16, 8, 263, 49, 53, 1282, 1286, "mean" +401, 16, 9, 264, 54, 58, 1287, 1291, "peak" +401, 16, 10, 265, 59, 68, 1292, 1301, "reduction" +401, 16, 11, 266, 69, 71, 1302, 1304, "in" +401, 16, 12, 267, 72, 83, 1305, 1316, "intraocular" +401, 16, 13, 268, 84, 92, 1317, 1325, "pressure" +401, 16, 14, 269, 93, 94, 1326, 1327, "(" +401, 16, 15, 270, 95, 98, 1328, 1331, "IOP" +401, 16, 16, 271, 99, 100, 1332, 1333, ")" +401, 16, 17, 272, 101, 103, 1334, 1336, "of" +401, 16, 18, 273, 104, 105, 1337, 1338, "6" +401, 16, 19, 274, 106, 107, 1339, 1340, "." +401, 16, 20, 275, 108, 109, 1341, 1342, "5" +401, 16, 21, 276, 110, 112, 1343, 1345, "mm" +401, 16, 22, 277, 113, 115, 1346, 1348, "Hg" +401, 16, 23, 278, 116, 117, 1349, 1350, ";" +401, 16, 24, 279, 118, 125, 1351, 1358, "timolol" +401, 16, 25, 280, 126, 127, 1359, 1360, "-" +401, 16, 26, 281, 128, 135, 1361, 1368, "treated" +401, 16, 27, 282, 136, 144, 1369, 1377, "subjects" +401, 16, 28, 283, 145, 148, 1378, 1381, "had" +401, 16, 29, 284, 149, 150, 1382, 1383, "a" +401, 16, 30, 285, 151, 155, 1384, 1388, "mean" +401, 16, 31, 286, 156, 160, 1389, 1393, "peak" +401, 16, 32, 287, 161, 170, 1394, 1403, "reduction" +401, 16, 33, 288, 171, 173, 1404, 1406, "in" +401, 16, 34, 289, 174, 177, 1407, 1410, "IOP" +401, 16, 35, 290, 178, 180, 1411, 1413, "of" +401, 16, 36, 291, 181, 182, 1414, 1415, "6" +401, 16, 37, 292, 183, 184, 1416, 1417, "." +401, 16, 38, 293, 185, 186, 1418, 1419, "1" +401, 16, 39, 294, 187, 189, 1420, 1422, "mm" +401, 16, 40, 295, 190, 192, 1423, 1425, "Hg" +401, 16, 41, 296, 193, 194, 1426, 1427, "." +401, 17, 1, 297, 0, 11, 1428, 1439, "Brimonidine" +401, 17, 2, 298, 12, 19, 1440, 1447, "lowered" +401, 17, 3, 299, 20, 24, 1448, 1452, "mean" +401, 17, 4, 300, 25, 29, 1453, 1457, "peak" +401, 17, 5, 301, 30, 33, 1458, 1461, "IOP" +401, 17, 6, 302, 34, 47, 1462, 1475, "significantly" +401, 17, 7, 303, 48, 52, 1476, 1480, "more" +401, 17, 8, 304, 53, 57, 1481, 1485, "than" +401, 17, 9, 305, 58, 65, 1486, 1493, "timolol" +401, 17, 10, 306, 66, 68, 1494, 1496, "at" +401, 17, 11, 307, 69, 73, 1497, 1501, "week" +401, 17, 12, 308, 74, 75, 1502, 1503, "2" +401, 17, 13, 309, 76, 79, 1504, 1507, "and" +401, 17, 14, 310, 80, 85, 1508, 1513, "month" +401, 17, 15, 311, 86, 87, 1514, 1515, "3" +401, 17, 16, 312, 88, 89, 1516, 1517, "(" +401, 17, 17, 313, 90, 91, 1518, 1519, "P" +401, 17, 18, 314, 92, 93, 1520, 1521, "<" +401, 17, 19, 315, 94, 95, 1522, 1523, "." +401, 17, 20, 316, 96, 98, 1524, 1526, "03" +401, 17, 21, 317, 99, 100, 1527, 1528, ")" +401, 17, 22, 318, 101, 102, 1529, 1530, ";" +401, 17, 23, 319, 103, 105, 1531, 1533, "no" +401, 17, 24, 320, 106, 117, 1534, 1545, "significant" +401, 17, 25, 321, 118, 128, 1546, 1556, "difference" +401, 17, 26, 322, 129, 132, 1557, 1560, "was" +401, 17, 27, 323, 133, 141, 1561, 1569, "observed" +401, 17, 28, 324, 142, 149, 1570, 1577, "between" +401, 17, 29, 325, 150, 153, 1578, 1581, "the" +401, 17, 30, 326, 154, 160, 1582, 1588, "groups" +401, 17, 31, 327, 161, 164, 1589, 1592, "for" +401, 17, 32, 328, 165, 169, 1593, 1597, "this" +401, 17, 33, 329, 170, 178, 1598, 1606, "variable" +401, 17, 34, 330, 179, 181, 1607, 1609, "at" +401, 17, 35, 331, 182, 187, 1610, 1615, "other" +401, 17, 36, 332, 188, 194, 1616, 1622, "visits" +401, 17, 37, 333, 195, 205, 1623, 1633, "throughout" +401, 17, 38, 334, 206, 209, 1634, 1637, "the" +401, 17, 39, 335, 210, 211, 1638, 1639, "1" +401, 17, 40, 336, 212, 213, 1640, 1641, "-" +401, 17, 41, 337, 214, 218, 1642, 1646, "year" +401, 17, 42, 338, 219, 225, 1647, 1653, "course" +401, 17, 43, 339, 226, 228, 1654, 1656, "of" +401, 17, 44, 340, 229, 232, 1657, 1660, "the" +401, 17, 45, 341, 233, 238, 1661, 1666, "study" +401, 17, 46, 342, 239, 240, 1667, 1668, "." +401, 18, 1, 343, 0, 2, 1669, 1671, "No" +401, 18, 2, 344, 3, 11, 1672, 1680, "evidence" +401, 18, 3, 345, 12, 14, 1681, 1683, "of" +401, 18, 4, 346, 15, 28, 1684, 1697, "tachyphylaxis" +401, 18, 5, 347, 29, 32, 1698, 1701, "was" +401, 18, 6, 348, 33, 37, 1702, 1706, "seen" +401, 18, 7, 349, 38, 40, 1707, 1709, "in" +401, 18, 8, 350, 41, 47, 1710, 1716, "either" +401, 18, 9, 351, 48, 53, 1717, 1722, "group" +401, 18, 10, 352, 54, 55, 1723, 1724, "." +401, 19, 1, 353, 0, 7, 1725, 1732, "Allergy" +401, 19, 2, 354, 8, 11, 1733, 1736, "was" +401, 19, 3, 355, 12, 16, 1737, 1741, "seen" +401, 19, 4, 356, 17, 19, 1742, 1744, "in" +401, 19, 5, 357, 20, 21, 1745, 1746, "9" +401, 19, 6, 358, 22, 23, 1747, 1748, "%" +401, 19, 7, 359, 24, 26, 1749, 1751, "of" +401, 19, 8, 360, 27, 35, 1752, 1760, "subjects" +401, 19, 9, 361, 36, 43, 1761, 1768, "treated" +401, 19, 10, 362, 44, 48, 1769, 1773, "with" +401, 19, 11, 363, 49, 60, 1774, 1785, "brimonidine" +401, 19, 12, 364, 61, 62, 1786, 1787, "." +401, 20, 1, 365, 0, 3, 1788, 1791, "Dry" +401, 20, 2, 366, 4, 9, 1792, 1797, "mouth" +401, 20, 3, 367, 10, 13, 1798, 1801, "was" +401, 20, 4, 368, 14, 18, 1802, 1806, "more" +401, 20, 5, 369, 19, 25, 1807, 1813, "common" +401, 20, 6, 370, 26, 28, 1814, 1816, "in" +401, 20, 7, 371, 29, 32, 1817, 1820, "the" +401, 20, 8, 372, 33, 44, 1821, 1832, "brimonidine" +401, 20, 9, 373, 45, 46, 1833, 1834, "-" +401, 20, 10, 374, 47, 54, 1835, 1842, "treated" +401, 20, 11, 375, 55, 60, 1843, 1848, "group" +401, 20, 12, 376, 61, 65, 1849, 1853, "than" +401, 20, 13, 377, 66, 68, 1854, 1856, "in" +401, 20, 14, 378, 69, 72, 1857, 1860, "the" +401, 20, 15, 379, 73, 80, 1861, 1868, "timolol" +401, 20, 16, 380, 81, 82, 1869, 1870, "-" +401, 20, 17, 381, 83, 90, 1871, 1878, "treated" +401, 20, 18, 382, 91, 96, 1879, 1884, "group" +401, 20, 19, 383, 97, 98, 1885, 1886, "(" +401, 20, 20, 384, 99, 101, 1887, 1889, "33" +401, 20, 21, 385, 102, 103, 1890, 1891, "." +401, 20, 22, 386, 104, 105, 1892, 1893, "0" +401, 20, 23, 387, 106, 107, 1894, 1895, "%" +401, 20, 24, 388, 108, 110, 1896, 1898, "vs" +401, 20, 25, 389, 111, 113, 1899, 1901, "19" +401, 20, 26, 390, 114, 115, 1902, 1903, "." +401, 20, 27, 391, 116, 117, 1904, 1905, "4" +401, 20, 28, 392, 118, 119, 1906, 1907, "%" +401, 20, 29, 393, 120, 121, 1908, 1909, ")" +401, 20, 30, 394, 122, 123, 1910, 1911, "," +401, 20, 31, 395, 124, 127, 1912, 1915, "but" +401, 20, 32, 396, 128, 138, 1916, 1926, "complaints" +401, 20, 33, 397, 139, 141, 1927, 1929, "of" +401, 20, 34, 398, 142, 149, 1930, 1937, "burning" +401, 20, 35, 399, 150, 153, 1938, 1941, "and" +401, 20, 36, 400, 154, 162, 1942, 1950, "stinging" +401, 20, 37, 401, 163, 167, 1951, 1955, "were" +401, 20, 38, 402, 168, 172, 1956, 1960, "more" +401, 20, 39, 403, 173, 179, 1961, 1967, "common" +401, 20, 40, 404, 180, 182, 1968, 1970, "in" +401, 20, 41, 405, 183, 186, 1971, 1974, "the" +401, 20, 42, 406, 187, 194, 1975, 1982, "timolol" +401, 20, 43, 407, 195, 196, 1983, 1984, "-" +401, 20, 44, 408, 197, 204, 1985, 1992, "treated" +401, 20, 45, 409, 205, 210, 1993, 1998, "group" +401, 20, 46, 410, 211, 212, 1999, 2000, "(" +401, 20, 47, 411, 213, 215, 2001, 2003, "41" +401, 20, 48, 412, 216, 217, 2004, 2005, "." +401, 20, 49, 413, 218, 219, 2006, 2007, "9" +401, 20, 50, 414, 220, 221, 2008, 2009, "%" +401, 20, 51, 415, 222, 223, 2010, 2011, ")" +401, 20, 52, 416, 224, 228, 2012, 2016, "than" +401, 20, 53, 417, 229, 231, 2017, 2019, "in" +401, 20, 54, 418, 232, 235, 2020, 2023, "the" +401, 20, 55, 419, 236, 247, 2024, 2035, "brimonidine" +401, 20, 56, 420, 248, 249, 2036, 2037, "-" +401, 20, 57, 421, 250, 257, 2038, 2045, "treated" +401, 20, 58, 422, 258, 266, 2046, 2054, "patients" +401, 20, 59, 423, 267, 268, 2055, 2056, "(" +401, 20, 60, 424, 269, 271, 2057, 2059, "28" +401, 20, 61, 425, 272, 273, 2060, 2061, "." +401, 20, 62, 426, 274, 275, 2062, 2063, "1" +401, 20, 63, 427, 276, 277, 2064, 2065, "%" +401, 20, 64, 428, 278, 279, 2066, 2067, ")" +401, 20, 65, 429, 280, 281, 2068, 2069, "." +401, 21, 1, 430, 0, 8, 2070, 2078, "Headache" +401, 21, 2, 431, 9, 10, 2079, 2080, "," +401, 21, 3, 432, 11, 18, 2081, 2088, "fatigue" +401, 21, 4, 433, 19, 20, 2089, 2090, "," +401, 21, 5, 434, 21, 24, 2091, 2094, "and" +401, 21, 6, 435, 25, 35, 2095, 2105, "drowsiness" +401, 21, 7, 436, 36, 40, 2106, 2110, "were" +401, 21, 8, 437, 41, 48, 2111, 2118, "similar" +401, 21, 9, 438, 49, 51, 2119, 2121, "in" +401, 21, 10, 439, 52, 55, 2122, 2125, "the" +401, 21, 11, 440, 56, 57, 2126, 2127, "2" +401, 21, 12, 441, 58, 64, 2128, 2134, "groups" +401, 21, 13, 442, 65, 66, 2135, 2136, "." +401, 22, 1, 443, 0, 2, 2137, 2139, "In" +401, 22, 2, 444, 3, 10, 2140, 2147, "general" +401, 22, 3, 445, 11, 12, 2148, 2149, "," +401, 22, 4, 446, 13, 16, 2150, 2153, "the" +401, 22, 5, 447, 17, 26, 2154, 2163, "tolerance" +401, 22, 6, 448, 27, 29, 2164, 2166, "to" +401, 22, 7, 449, 30, 40, 2167, 2177, "medication" +401, 22, 8, 450, 41, 44, 2178, 2181, "was" +401, 22, 9, 451, 45, 55, 2182, 2192, "acceptable" +401, 22, 10, 452, 56, 57, 2193, 2194, "." +401, 23, 1, 453, 0, 11, 2195, 2206, "CONCLUSIONS" +401, 23, 2, 454, 12, 13, 2207, 2208, ":" +401, 23, 3, 455, 14, 25, 2209, 2220, "Brimonidine" +401, 23, 4, 456, 26, 28, 2221, 2223, "is" +401, 23, 5, 457, 29, 33, 2224, 2228, "safe" +401, 23, 6, 458, 34, 37, 2229, 2232, "and" +401, 23, 7, 459, 38, 47, 2233, 2242, "effective" +401, 23, 8, 460, 48, 50, 2243, 2245, "in" +401, 23, 9, 461, 51, 59, 2246, 2254, "lowering" +401, 23, 10, 462, 60, 63, 2255, 2258, "IOP" +401, 23, 11, 463, 64, 66, 2259, 2261, "in" +401, 23, 12, 464, 67, 79, 2262, 2274, "glaucomatous" +401, 23, 13, 465, 80, 84, 2275, 2279, "eyes" +401, 23, 14, 466, 85, 86, 2280, 2281, "." +401, 24, 1, 467, 0, 11, 2282, 2293, "Brimonidine" +401, 24, 2, 468, 12, 20, 2294, 2302, "provides" +401, 24, 3, 469, 21, 22, 2303, 2304, "a" +401, 24, 4, 470, 23, 32, 2305, 2314, "sustained" +401, 24, 5, 471, 33, 37, 2315, 2319, "long" +401, 24, 6, 472, 38, 39, 2320, 2321, "-" +401, 24, 7, 473, 40, 44, 2322, 2326, "term" +401, 24, 8, 474, 45, 51, 2327, 2333, "ocular" +401, 24, 9, 475, 52, 63, 2334, 2345, "hypotensive" +401, 24, 10, 476, 64, 70, 2346, 2352, "effect" +401, 24, 11, 477, 71, 72, 2353, 2354, "," +401, 24, 12, 478, 73, 75, 2355, 2357, "is" +401, 24, 13, 479, 76, 80, 2358, 2362, "well" +401, 24, 14, 480, 81, 90, 2363, 2372, "tolerated" +401, 24, 15, 481, 91, 92, 2373, 2374, "," +401, 24, 16, 482, 93, 96, 2375, 2378, "and" +401, 24, 17, 483, 97, 100, 2379, 2382, "has" +401, 24, 18, 484, 101, 102, 2383, 2384, "a" +401, 24, 19, 485, 103, 106, 2385, 2388, "low" +401, 24, 20, 486, 107, 111, 2389, 2393, "rate" +401, 24, 21, 487, 112, 114, 2394, 2396, "of" +401, 24, 22, 488, 115, 123, 2397, 2405, "allergic" +401, 24, 23, 489, 124, 132, 2406, 2414, "response" +401, 24, 24, 490, 133, 134, 2415, 2416, "." +401, 25, 1, 491, 0, 3, 2417, 2420, "DOI" +401, 25, 2, 492, 4, 5, 2421, 2422, ":" +401, 25, 3, 493, 6, 8, 2423, 2425, "10" +401, 25, 4, 494, 9, 10, 2426, 2427, "." +401, 25, 5, 495, 11, 15, 2428, 2432, "1001" +401, 25, 6, 496, 16, 17, 2433, 2434, "/" +401, 25, 7, 497, 18, 26, 2435, 2443, "archopht" +401, 25, 8, 498, 27, 28, 2444, 2445, "." +401, 25, 9, 499, 29, 33, 2446, 2450, "1997" +401, 25, 10, 500, 34, 35, 2451, 2452, "." +401, 25, 11, 501, 36, 50, 2453, 2467, "01100160017002" +401, 25, 12, 502, 51, 55, 2468, 2472, "PMID" +401, 25, 13, 503, 56, 57, 2473, 2474, ":" +401, 25, 14, 504, 58, 65, 2475, 2482, "9230823" +401, 25, 15, 505, 66, 67, 2483, 2484, "[" +401, 25, 16, 506, 68, 75, 2485, 2492, "Indexed" +401, 25, 17, 507, 76, 79, 2493, 2496, "for" +401, 25, 18, 508, 80, 87, 2497, 2504, "MEDLINE" +401, 25, 19, 509, 88, 89, 2505, 2506, "]" diff --git a/data/gl 9230823_jshahinitiran.annodb b/data/gl 9230823_jshahinitiran.annodb new file mode 100644 index 0000000..cac0abe --- /dev/null +++ b/data/gl 9230823_jshahinitiran.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +32955, Journal, 0, 15, "Arch Ophthalmol", "", +32956, PublicationYear, 18, 22, "1997", "", +32957, Title, 52, 131, "A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension", "", +32958, Duration, 54, 62, "1 - year", "", +32959, Brimonidine, 72, 83, "brimonidine", "", +32960, Frequency, 84, 95, "twice daily", "", +32961, Glaucoma, 99, 107, "glaucoma", "", +32962, OcularHypertension, 112, 131, "ocular hypertension", "", +32963, CTDesign, 136, 146, "controlled", "", +32964, Randomized, 149, 159, "randomized", "", +32965, Multicenter, 162, 173, "multicenter", "", +32966, Brimonidine, 199, 210, "Brimonidine", "", +32967, Author, 225, 235, "Schuman JS", "", +32968, Author, 244, 253, "Horwitz B", "", +32969, Author, 256, 266, "Choplin NT", "", +32970, Author, 269, 276, "David R", "", +32971, Author, 279, 289, "Albracht D", "", +32972, Author, 292, 298, "Chen K", "", +32973, USA, 409, 412, "USA", "", +32975, Brimonidine, 510, 529, "Brimonidin tartrate", "", +32976, ObjectiveDescription, 572, 727, "This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension", "", +32977, DoseValue, 623, 628, "0 . 2", "", +32978, Percentage, 629, 630, "%", "", +32979, Brimonidine, 631, 642, "brimonidine", "", +32980, Frequency, 656, 667, "twice daily", "", +32981, Duration, 672, 678, "1 year", "", +32982, Glaucoma, 696, 704, "glaucoma", "", +32983, OcularHypertension, 708, 727, "ocular hypertension", "", +32984, Multicenter, 763, 774, "multicenter", "", +32985, DoubleBlind, 777, 792, "double - masked", "", +32986, Randomized, 795, 805, "randomized", "", +32987, Parallel, 808, 816, "parallel", "", +32988, CTDesign, 827, 846, "active - controlled", "", +32989, DoseValue, 894, 899, "0 . 2", "", +32991, Percentage, 900, 901, "%", "", +32993, Brimonidine, 902, 913, "brimonidine", "", +32990, DoseValue, 917, 922, "0 . 5", "", +32992, Percentage, 923, 924, "%", "", +32994, Timolol, 925, 940, "timolol maleate", "", +32995, Frequency, 941, 952, "twice daily", "", +32996, Duration, 957, 966, "12 months", "", +32997, TimePoint, 995, 1003, "baseline", "", +32998, TimePoint, 1006, 1012, "week 1", "", +32999, TimePoint, 1019, 1027, "months 1", "", +33000, TimePoint, 1030, 1031, "2", "", +33001, TimePoint, 1034, 1037, "3 ,", "", +33002, TimePoint, 1038, 1039, "6", "", +33003, TimePoint, 1042, 1043, "9", "", +33004, TimePoint, 1050, 1052, "12", "", +33005, TimePoint, 1092, 1098, "week 2", "", +33006, NumberPatientsCT, 1152, 1155, "374", "", +33008, NumberPatientsArm, 1181, 1184, "186", "", +33010, Brimonidine, 1194, 1205, "brimonidine", "", +33009, NumberPatientsArm, 1210, 1213, "188", "", +33011, Timolol, 1223, 1230, "timolol", "", +33012, Brimonidine, 1233, 1244, "Brimonidine", "", +33013, Mean, 1282, 1286, "mean", "", +33014, Peak_IOP, 1305, 1325, "intraocular pressure", "", +33015, Peak_IOP, 1328, 1331, "IOP", "", +33016, Reduction, 1337, 1342, "6 . 5", "", +33017, mmHg, 1343, 1348, "mm Hg", "", +33018, Timolol, 1351, 1358, "timolol", "", +33019, Mean, 1384, 1388, "mean", "", +33020, Peak_IOP, 1407, 1410, "IOP", "", +33021, Reduction, 1414, 1419, "6 . 1", "", +33022, mmHg, 1420, 1425, "mm Hg", "", +33023, Brimonidine, 1428, 1439, "Brimonidine", "", +33024, GeometricMean, 1448, 1452, "mean", "", +33025, Peak_IOP, 1453, 1461, "peak IOP", "", +33026, Timolol, 1486, 1493, "timolol", "", +33027, TimePoint, 1497, 1503, "week 2", "", +33028, TimePoint, 1508, 1515, "month 3", "", +33029, PvalueDiff, 1518, 1526, "P < . 03", "", +33030, Duration, 1638, 1646, "1 - year", "", +33031, PercentageAffected, 1745, 1746, "9", "", +33032, Brimonidine, 1774, 1785, "brimonidine", "", +33034, Brimonidine, 1821, 1832, "brimonidine", "", +33035, Timolol, 1861, 1868, "timolol", "", +33036, PercentageAffected, 1887, 1893, "33 . 0", "", +33037, PercentageAffected, 1899, 1905, "19 . 4", "", +33038, Timolol, 1975, 1982, "timolol", "", +33041, PercentageAffected, 2001, 2007, "41 . 9", "", +33042, Brimonidine, 2024, 2035, "brimonidine", "", +33043, PercentageAffected, 2057, 2063, "28 . 1", "", +33044, Headache, 2070, 2078, "Headache", "", +33047, ConclusionComment, 2209, 2281, "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .", "", +33048, Brimonidine, 2209, 2220, "Brimonidine", "", +33049, IOP, 2255, 2258, "IOP", "", +33050, Glaucoma, 2262, 2274, "glaucomatous", "", +33051, ConclusionComment, 2282, 2416, "Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .", "", +33052, Brimonidine, 2282, 2293, "Brimonidine", "", +33053, PMID, 2475, 2482, "9230823", "", diff --git a/data/gl 9230823_jshahinitiran.n-triples b/data/gl 9230823_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9230823_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9230823_tstrakeljahn.annodb b/data/gl 9230823_tstrakeljahn.annodb new file mode 100644 index 0000000..57da3b0 --- /dev/null +++ b/data/gl 9230823_tstrakeljahn.annodb @@ -0,0 +1,86 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +7581, Journal, 0, 15, "Arch Ophthalmol", "", +7583, PublicationYear, 18, 22, "1997", "", +7611, Title, 52, 131, "A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension", "", +7586, Brimonidine, 72, 83, "brimonidine", "", +7587, Frequency, 84, 95, "twice daily", "", +7589, Glaucoma, 99, 107, "glaucoma", "", +7590, OcularHypertension, 112, 131, "ocular hypertension", "", +7620, Title, 134, 188, "A controlled , randomized , multicenter clinical trial", "", +7593, Randomized, 149, 159, "randomized", "", +7595, Multicenter, 162, 173, "multicenter", "", +7596, ClinicalTrial, 174, 188, "clinical trial", "", +29810, Brimonidine, 199, 210, "Brimonidine", "", +7601, Author, 225, 235, "Schuman JS", "", +7603, Author, 244, 253, "Horwitz B", "", +7604, Author, 256, 266, "Choplin NT", "", +7607, Author, 269, 276, "David R", "", +7608, Author, 279, 289, "Albracht D", "", +7609, Author, 292, 298, "Chen K", "", +7610, USA, 409, 412, "USA", "", +7612, Brimonidine, 510, 529, "Brimonidin tartrate", "", +7613, ObjectiveDescription, 572, 729, "This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension .", "", +7614, DoseValue, 623, 628, "0 . 2", "", +7622, Percentage, 629, 630, "%", "", +7623, Brimonidine, 631, 642, "brimonidine", "", +7615, Frequency, 656, 667, "twice daily", "", +7616, Duration, 672, 678, "1 year", "", +7617, Glaucoma, 696, 704, "glaucoma", "", +7619, OcularHypertension, 708, 727, "ocular hypertension", "", +7650, Multicenter, 763, 774, "multicenter", "", +7652, DoubleBlind, 777, 792, "double - masked", "", +7653, Randomized, 795, 805, "randomized", "", +7654, Parallel, 808, 816, "parallel", "", +7655, ClinicalTrial, 858, 872, "clinical trial", "", +7656, DoseValue, 894, 899, "0 . 2", "", +7658, Brimonidine, 902, 913, "brimonidine", "", +7657, DoseValue, 917, 922, "0 . 5", "", +7660, Percentage, 923, 924, "%", "", +7659, Timolol, 925, 940, "timolol maleate", "", +7661, Frequency, 941, 952, "twice daily", "", +7662, Duration, 957, 966, "12 months", "", +7663, NumberPatientsCT, 1114, 1117, "443", "", +7664, FinalNumPatientsCT, 1152, 1155, "374", "", +7665, FinalNumPatientsArm, 1181, 1184, "186", "", +7667, Brimonidine, 1194, 1205, "brimonidine", "", +7666, FinalNumPatientsArm, 1210, 1213, "188", "", +7668, Timolol, 1223, 1230, "timolol", "", +7669, Brimonidine, 1233, 1244, "Brimonidine", "", +7670, Mean, 1282, 1286, "mean", "", +7671, IOP, 1305, 1325, "intraocular pressure", "", +7672, IOP, 1328, 1331, "IOP", "", +7673, Reduction, 1337, 1342, "6 . 5", "", +7674, mmHg, 1343, 1348, "mm Hg", "", +7675, Timolol, 1351, 1358, "timolol", "", +7676, Mean, 1384, 1388, "mean", "", +7677, IOP, 1407, 1410, "IOP", "", +7678, Reduction, 1414, 1419, "6 . 1", "", +7679, mmHg, 1420, 1425, "mm Hg", "", +7680, Brimonidine, 1428, 1439, "Brimonidine", "", +7682, Mean, 1448, 1452, "mean", "", +7681, Peak_IOP, 1453, 1461, "peak IOP", "", +7683, Timolol, 1486, 1493, "timolol", "", +7684, TimePoint, 1497, 1503, "week 2", "", +7685, TimePoint, 1508, 1515, "month 3", "", +7686, PvalueDiff, 1518, 1526, "P < . 03", "", +7688, ObservedResult, 1669, 1724, "No evidence of tachyphylaxis was seen in either group .", "", +7692, ObservedResult, 1725, 1787, "Allergy was seen in 9 % of subjects treated with brimonidine .", "", +7689, PercentageAffected, 1745, 1746, "9", "", +7691, Brimonidine, 1774, 1785, "brimonidine", "", +7698, ObservedResult, 1788, 1909, "Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )", "", +7693, Brimonidine, 1821, 1832, "brimonidine", "", +7694, Timolol, 1861, 1868, "timolol", "", +7695, PercentageAffected, 1887, 1893, "33 . 0", "", +7696, PercentageAffected, 1899, 1905, "19 . 4", "", +7705, ObservedResult, 1916, 2067, "complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )", "", +7700, Timolol, 1975, 1982, "timolol", "", +7699, PercentageAffected, 2001, 2007, "41 . 9", "", +7702, Brimonidine, 2024, 2035, "brimonidine", "", +7701, PercentageAffected, 2057, 2063, "28 . 1", "", +7706, ObservedResult, 2070, 2136, "Headache , fatigue , and drowsiness were similar in the 2 groups .", "", +7707, ObservedResult, 2137, 2194, "In general , the tolerance to medication was acceptable .", "", +7708, Brimonidine, 2209, 2220, "Brimonidine", "", +7710, ConclusionComment, 2209, 2281, "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .", "", +7709, IOP, 2255, 2258, "IOP", "", +7711, ConclusionComment, 2282, 2416, "Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .", "", +7712, PMID, 2475, 2482, "9230823", "", diff --git a/data/gl 9230823_tstrakeljahn.n-triples b/data/gl 9230823_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9230823_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9331215_admin.annodb b/data/gl 9331215_admin.annodb new file mode 100644 index 0000000..dec3d90 --- /dev/null +++ b/data/gl 9331215_admin.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 13, "Ophthalmology", "", " \"Ophthalmology\"." +1, PublicationYear, 16, 20, "1997", "", " \"1997\"." +4, Title, 51, 155, "A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure .", "", " \"A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure .\"." +2, Latanoprost, 95, 106, "latanoprost", "", +97, Precondition, 110, 153, "patients with elevated intraocular pressure", "", " \"patients with elevated intraocular pressure\"." +3, IOP, 133, 153, "intraocular pressure", "", +5, Author, 156, 163, "Lusky M", "", " \"Lusky M\"." +6, Author, 172, 179, "Ticho U", "", " \"Ticho U\"." +7, Author, 182, 193, "Glovinsky J", "", " \"Glovinsky J\"." +8, Author, 196, 208, "Weinberger D", "", " \"Weinberger D\"." +9, Author, 211, 219, "Nesher R", "", " \"Nesher R\"." +10, Author, 222, 230, "Yassur Y", "", " \"Yassur Y\"." +11, Author, 233, 242, "Melamed S", "", " \"Melamed S\"." +12, Israel, 358, 364, "Israel", "", " ." +107, ObjectiveDescription, 379, 555, "The purpose of the study was to determine whether latanoprost ( 13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester ) , a new prostaglandin analogue", "", " \"The purpose of the study was to determine whether latanoprost ( 13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester ) , a new prostaglandin analogue\"." +13, Latanoprost, 429, 440, "latanoprost", "", +108, ObjectiveDescription, 556, 715, "that has been found effective in reducing intraocular pressure ( IOP ) in humans , is equally effective at lower concentrations than those currently employed .", "", " \"that has been found effective in reducing intraocular pressure ( IOP ) in humans , is equally effective at lower concentrations than those currently employed .\"." +15, IOP, 598, 618, "intraocular pressure", "", +16, IOP, 621, 624, "IOP", "", +19, NumberPatientsCT, 742, 747, "Fifty", "", " \"Fifty\"." +106169, Precondition, 748, 793, "patients with glaucoma or ocular hypertension", "", " \"patients with glaucoma or ocular hypertension\"." +20, Glaucoma, 762, 770, "glaucoma", "", " . ." +21, OcularHypertension, 774, 793, "ocular hypertension", "", " ." +22, Randomized, 812, 822, "randomized", "", " ." +23, Crossover, 825, 834, "crossover", "", " ." +24, DoubleBlind, 837, 852, "double - masked", "", " ." +25, DoseValue, 866, 867, "1", "", +106170, DoseDescription, 866, 872, "1 drop", "", " \"1 drop\". \"1 drop\"." +27, Eyedrops, 868, 872, "drop", "", " . ." +28, Latanoprost, 876, 887, "latanoprost", "", " . . . ." +29, DoseValue, 890, 892, "50", "", " \"50\"." +122, BioAndMedicalUnit, 893, 904, "microg / ml", "", " . ." +32, Frequency, 905, 915, "once daily", "", " \"once daily\"." +30, DoseValue, 920, 922, "15", "", " \"15\"." +126, BioAndMedicalUnit, 923, 934, "microg / ml", "", " . ." +31, Frequency, 935, 946, "twice daily", "", " \"twice daily\"." +33, Duration, 979, 986, "3 weeks", "", " \"3 weeks\"." +38, TimePoint, 1037, 1043, "8 : 00", "", +37, TimePoint, 1046, 1053, "13 : 00", "", +36, TimePoint, 1060, 1073, "17 : 00 hours", "", +129, TimePoint, 1077, 1085, "baseline", "", +130, TimePoint, 1110, 1117, "3 weeks", "", +39, Placebo, 1142, 1149, "Placebo", "", " ." +40, Latanoprost, 1173, 1184, "latanoprost", "", +41, Eyedrops, 1185, 1193, "eye drop", "", " ." +42, Mean, 1259, 1263, "Mean", "", " . ." +43, Diurnal_IOP, 1287, 1298, "diurnal IOP", "", " ." +44, BaseLineValue, 1325, 1331, "24 . 7", "", +45, mmHg, 1332, 1336, "mmHg", "", " ." +46, IOP, 1339, 1359, "Intraocular pressure", "", +47, Reduction, 1375, 1380, "6 . 1", "", " \"6 . 1\"." +49, mmHg, 1381, 1385, "mmHg", "", +51, Latanoprost, 1391, 1402, "latanoprost", "", +62, DoseValue, 1403, 1405, "15", "", +148, BioAndMedicalUnit, 1406, 1417, "microg / ml", "", +52, Frequency, 1418, 1429, "twice daily", "", +48, Reduction, 1439, 1444, "7 . 5", "", " \"7 . 5\"." +50, mmHg, 1445, 1449, "mmHg", "", +63, DoseValue, 1455, 1457, "50", "", +149, BioAndMedicalUnit, 1458, 1469, "microg / ml", "", +53, Frequency, 1470, 1480, "once daily", "", +78, ObservedResult, 1483, 1526, "Results with both regimens were significant", "", " \"Results with both regimens were significant\". \"Results with both regimens were significant\"." +152, PValueResValue, 1529, 1545, "P & lt ; 0 . 001", "", " \"P & lt ; 0 . 001\". \"P & lt ; 0 . 001\"." +65, DoseValue, 1592, 1594, "50", "", +161, BioAndMedicalUnit, 1595, 1606, "microg / ml", "", +74, DoseValue, 1654, 1656, "15", "", +162, BioAndMedicalUnit, 1657, 1668, "microg / ml", "", +75, DiffGroupAbsValue, 1697, 1702, "1 . 4", "", " \"1 . 4\"." +76, mmHg, 1703, 1707, "mmHg", "", +167, PvalueDiff, 1710, 1726, "P & lt ; 0 . 001", "", " \"P & lt ; 0 . 001\"." +106164, EndPointDescription, 1808, 1832, "mild , ocular discomfort", "", +119892, ObservedResult, 1835, 1909, "The higher dose did not cause more hyperemia at 3 weeks than the lower one", "", " \"The higher dose did not cause more hyperemia at 3 weeks than the lower one\"." +80, ConjunctivalHyperemia, 1870, 1879, "hyperemia", "", " ." +169, TimePoint, 1883, 1890, "3 weeks", "", " \"3 weeks\"." +170, PvalueDiff, 2013, 2028, "P & lt ; 0 . 29", "", +83, Latanoprost, 2055, 2066, "Latanoprost", "", +88, ConclusionComment, 2055, 2183, "Latanoprost administered at a concentration of 50 microg / ml once daily effectively reduces IOP in patients with elevated IOP .", "", " \"Latanoprost administered at a concentration of 50 microg / ml once daily effectively reduces IOP in patients with elevated IOP .\"." +84, DoseValue, 2102, 2104, "50", "", +163, BioAndMedicalUnit, 2105, 2116, "microg / ml", "", +85, Frequency, 2117, 2127, "once daily", "", +86, IOP, 2148, 2151, "IOP", "", +87, IOP, 2178, 2181, "IOP", "", +91, ConclusionComment, 2184, 2298, "Administration of a lower concentration ( 15 microg / ml ) twice daily is less effective , but still significant .", "", " \"Administration of a lower concentration ( 15 microg / ml ) twice daily is less effective , but still significant .\"." +89, DoseValue, 2226, 2228, "15", "", +164, BioAndMedicalUnit, 2229, 2240, "microg / ml", "", +90, Frequency, 2243, 2254, "twice daily", "", +92, PMID, 2354, 2361, "9331215", "", " \"9331215\"." diff --git a/data/gl 9331215_admin.n-triples b/data/gl 9331215_admin.n-triples new file mode 100644 index 0000000..09258ab --- /dev/null +++ b/data/gl 9331215_admin.n-triples @@ -0,0 +1,136 @@ +# RDF export of group: Publication + . + "Publication" . + "A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure ." . + "Lusky M" . + "1997" . + "Ophthalmology" . + "9331215" . + . + "Ticho U" . + "Glovinsky J" . + "Nesher R" . + "Weinberger D" . + "Yassur Y" . + "Melamed S" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "The purpose of the study was to determine whether latanoprost ( 13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester ) , a new prostaglandin analogue" . + "Fifty" . + "3 weeks" . + . + . + . + "Latanoprost administered at a concentration of 50 microg / ml once daily effectively reduces IOP in patients with elevated IOP ." . + . + . + . + . + . + . + "that has been found effective in reducing intraocular pressure ( IOP ) in humans , is equally effective at lower concentrations than those currently employed ." . + . + . + "Administration of a lower concentration ( 15 microg / ml ) twice daily is less effective , but still significant ." . + . + . +# RDF export of group: Population + . + "Population" . + "patients with elevated intraocular pressure" . + . + . + . + "patients with glaucoma or ocular hypertension" . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + "Endpoint_AE_H" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_15" . + . + . + . + . + "Arm_50" . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_lat_15" . + . + "twice daily" . + . + . + "Intervention_lat_50" . + . + "once daily" . + . + . + "Intervention_pla" . + . + . +# RDF export of group: Medication + . + "Medication_lat_15" . + . + . + "15" . + . + . + . + "1 drop" . + . + "Medication_lat_50" . + . + . + "50" . + . + . + . + "1 drop" . + . + "Medication_pla" . + . + . + . +# RDF export of group: Outcome + . + "Outcome_15" . + . + "P & lt ; 0 . 001" . + "6 . 1" . + "Results with both regimens were significant" . + . + "Outcome_50" . + . + "P & lt ; 0 . 001" . + "7 . 5" . + "Results with both regimens were significant" . + . + "Outcome_AE_H" . + . + "The higher dose did not cause more hyperemia at 3 weeks than the lower one" . + "3 weeks" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop" . + "1 . 4" . + "P & lt ; 0 . 001" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9331215_export.csv b/data/gl 9331215_export.csv new file mode 100644 index 0000000..f533d79 --- /dev/null +++ b/data/gl 9331215_export.csv @@ -0,0 +1,499 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +540, 1, 1, 1, 0, 13, 0, 13, "Ophthalmology" +540, 1, 2, 2, 14, 15, 14, 15, "." +540, 2, 1, 3, 0, 4, 16, 20, "1997" +540, 2, 2, 4, 5, 8, 21, 24, "Oct" +540, 2, 3, 5, 9, 10, 25, 26, ";" +540, 2, 4, 6, 11, 14, 27, 30, "104" +540, 2, 5, 7, 15, 16, 31, 32, "(" +540, 2, 6, 8, 17, 19, 33, 35, "10" +540, 2, 7, 9, 20, 21, 36, 37, ")" +540, 2, 8, 10, 22, 23, 38, 39, ":" +540, 2, 9, 11, 24, 28, 40, 44, "1720" +540, 2, 10, 12, 29, 30, 45, 46, "-" +540, 2, 11, 13, 31, 32, 47, 48, "4" +540, 2, 12, 14, 33, 34, 49, 50, "." +540, 3, 1, 15, 0, 1, 51, 52, "A" +540, 3, 2, 16, 2, 13, 53, 64, "comparative" +540, 3, 3, 17, 14, 19, 65, 70, "study" +540, 3, 4, 18, 20, 22, 71, 73, "of" +540, 3, 5, 19, 23, 26, 74, 77, "two" +540, 3, 6, 20, 27, 31, 78, 82, "dose" +540, 3, 7, 21, 32, 40, 83, 91, "regimens" +540, 3, 8, 22, 41, 43, 92, 94, "of" +540, 3, 9, 23, 44, 55, 95, 106, "latanoprost" +540, 3, 10, 24, 56, 58, 107, 109, "in" +540, 3, 11, 25, 59, 67, 110, 118, "patients" +540, 3, 12, 26, 68, 72, 119, 123, "with" +540, 3, 13, 27, 73, 81, 124, 132, "elevated" +540, 3, 14, 28, 82, 93, 133, 144, "intraocular" +540, 3, 15, 29, 94, 102, 145, 153, "pressure" +540, 3, 16, 30, 103, 104, 154, 155, "." +540, 4, 1, 31, 0, 5, 156, 161, "Lusky" +540, 4, 2, 32, 6, 7, 162, 163, "M" +540, 4, 3, 33, 8, 9, 164, 165, "(" +540, 4, 4, 34, 10, 11, 166, 167, "1" +540, 4, 5, 35, 12, 13, 168, 169, ")" +540, 4, 6, 36, 14, 15, 170, 171, "," +540, 4, 7, 37, 16, 21, 172, 177, "Ticho" +540, 4, 8, 38, 22, 23, 178, 179, "U" +540, 4, 9, 39, 24, 25, 180, 181, "," +540, 4, 10, 40, 26, 35, 182, 191, "Glovinsky" +540, 4, 11, 41, 36, 37, 192, 193, "J" +540, 4, 12, 42, 38, 39, 194, 195, "," +540, 4, 13, 43, 40, 50, 196, 206, "Weinberger" +540, 4, 14, 44, 51, 52, 207, 208, "D" +540, 4, 15, 45, 53, 54, 209, 210, "," +540, 4, 16, 46, 55, 61, 211, 217, "Nesher" +540, 4, 17, 47, 62, 63, 218, 219, "R" +540, 4, 18, 48, 64, 65, 220, 221, "," +540, 4, 19, 49, 66, 72, 222, 228, "Yassur" +540, 4, 20, 50, 73, 74, 229, 230, "Y" +540, 4, 21, 51, 75, 76, 231, 232, "," +540, 4, 22, 52, 77, 84, 233, 240, "Melamed" +540, 4, 23, 53, 85, 86, 241, 242, "S" +540, 4, 24, 54, 87, 88, 243, 244, "." +540, 4, 25, 55, 89, 95, 245, 251, "Author" +540, 4, 26, 56, 96, 107, 252, 263, "information" +540, 4, 27, 57, 108, 109, 264, 265, ":" +540, 4, 28, 58, 110, 111, 266, 267, "(" +540, 4, 29, 59, 112, 113, 268, 269, "1" +540, 4, 30, 60, 114, 115, 270, 271, ")" +540, 4, 31, 61, 116, 126, 272, 282, "Department" +540, 4, 32, 62, 127, 129, 283, 285, "of" +540, 4, 33, 63, 130, 143, 286, 299, "Ophthalmology" +540, 4, 34, 64, 144, 145, 300, 301, "," +540, 4, 35, 65, 146, 151, 302, 307, "Rabin" +540, 4, 36, 66, 152, 159, 308, 315, "Medical" +540, 4, 37, 67, 160, 166, 316, 322, "Center" +540, 4, 38, 68, 167, 168, 323, 324, "," +540, 4, 39, 69, 169, 178, 325, 334, "Beilinson" +540, 4, 40, 70, 179, 185, 335, 341, "Campus" +540, 4, 41, 71, 186, 187, 342, 343, "," +540, 4, 42, 72, 188, 193, 344, 349, "Petah" +540, 4, 43, 73, 194, 199, 350, 355, "Tiqva" +540, 4, 44, 74, 200, 201, 356, 357, "," +540, 4, 45, 75, 202, 208, 358, 364, "Israel" +540, 4, 46, 76, 209, 210, 365, 366, "." +540, 5, 1, 77, 0, 9, 367, 376, "OBJECTIVE" +540, 5, 2, 78, 10, 11, 377, 378, ":" +540, 5, 3, 79, 12, 15, 379, 382, "The" +540, 5, 4, 80, 16, 23, 383, 390, "purpose" +540, 5, 5, 81, 24, 26, 391, 393, "of" +540, 5, 6, 82, 27, 30, 394, 397, "the" +540, 5, 7, 83, 31, 36, 398, 403, "study" +540, 5, 8, 84, 37, 40, 404, 407, "was" +540, 5, 9, 85, 41, 43, 408, 410, "to" +540, 5, 10, 86, 44, 53, 411, 420, "determine" +540, 5, 11, 87, 54, 61, 421, 428, "whether" +540, 5, 12, 88, 62, 73, 429, 440, "latanoprost" +540, 5, 13, 89, 74, 75, 441, 442, "(" +540, 5, 14, 90, 76, 78, 443, 445, "13" +540, 5, 15, 91, 79, 80, 446, 447, "," +540, 5, 16, 92, 81, 83, 448, 450, "14" +540, 5, 17, 93, 84, 85, 451, 452, "-" +540, 5, 18, 94, 86, 93, 453, 460, "dihydro" +540, 5, 19, 95, 94, 95, 461, 462, "-" +540, 5, 20, 96, 96, 98, 463, 465, "17" +540, 5, 21, 97, 99, 100, 466, 467, "-" +540, 5, 22, 98, 101, 107, 468, 474, "phenyl" +540, 5, 23, 99, 108, 109, 475, 476, "-" +540, 5, 24, 100, 110, 112, 477, 479, "18" +540, 5, 25, 101, 113, 114, 480, 481, "," +540, 5, 26, 102, 115, 117, 482, 484, "19" +540, 5, 27, 103, 118, 119, 485, 486, "," +540, 5, 28, 104, 120, 122, 487, 489, "20" +540, 5, 29, 105, 123, 124, 490, 491, "-" +540, 5, 30, 106, 125, 131, 492, 498, "trinor" +540, 5, 31, 107, 132, 137, 499, 504, "PGF2a" +540, 5, 32, 108, 138, 139, 505, 506, "-" +540, 5, 33, 109, 140, 149, 507, 516, "isopropyl" +540, 5, 34, 110, 150, 155, 517, 522, "ester" +540, 5, 35, 111, 156, 157, 523, 524, ")" +540, 5, 36, 112, 158, 159, 525, 526, "," +540, 5, 37, 113, 160, 161, 527, 528, "a" +540, 5, 38, 114, 162, 165, 529, 532, "new" +540, 5, 39, 115, 166, 179, 533, 546, "prostaglandin" +540, 5, 40, 116, 180, 188, 547, 555, "analogue" +540, 5, 41, 117, 189, 193, 556, 560, "that" +540, 5, 42, 118, 194, 197, 561, 564, "has" +540, 5, 43, 119, 198, 202, 565, 569, "been" +540, 5, 44, 120, 203, 208, 570, 575, "found" +540, 5, 45, 121, 209, 218, 576, 585, "effective" +540, 5, 46, 122, 219, 221, 586, 588, "in" +540, 5, 47, 123, 222, 230, 589, 597, "reducing" +540, 5, 48, 124, 231, 242, 598, 609, "intraocular" +540, 5, 49, 125, 243, 251, 610, 618, "pressure" +540, 5, 50, 126, 252, 253, 619, 620, "(" +540, 5, 51, 127, 254, 257, 621, 624, "IOP" +540, 5, 52, 128, 258, 259, 625, 626, ")" +540, 5, 53, 129, 260, 262, 627, 629, "in" +540, 5, 54, 130, 263, 269, 630, 636, "humans" +540, 5, 55, 131, 270, 271, 637, 638, "," +540, 5, 56, 132, 272, 274, 639, 641, "is" +540, 5, 57, 133, 275, 282, 642, 649, "equally" +540, 5, 58, 134, 283, 292, 650, 659, "effective" +540, 5, 59, 135, 293, 295, 660, 662, "at" +540, 5, 60, 136, 296, 301, 663, 668, "lower" +540, 5, 61, 137, 302, 316, 669, 683, "concentrations" +540, 5, 62, 138, 317, 321, 684, 688, "than" +540, 5, 63, 139, 322, 327, 689, 694, "those" +540, 5, 64, 140, 328, 337, 695, 704, "currently" +540, 5, 65, 141, 338, 346, 705, 713, "employed" +540, 5, 66, 142, 347, 348, 714, 715, "." +540, 6, 1, 143, 0, 6, 716, 722, "DESIGN" +540, 6, 2, 144, 7, 10, 723, 726, "AND" +540, 6, 3, 145, 11, 23, 727, 739, "PARTICIPANTS" +540, 6, 4, 146, 24, 25, 740, 741, ":" +540, 6, 5, 147, 26, 31, 742, 747, "Fifty" +540, 6, 6, 148, 32, 40, 748, 756, "patients" +540, 6, 7, 149, 41, 45, 757, 761, "with" +540, 6, 8, 150, 46, 54, 762, 770, "glaucoma" +540, 6, 9, 151, 55, 57, 771, 773, "or" +540, 6, 10, 152, 58, 64, 774, 780, "ocular" +540, 6, 11, 153, 65, 77, 781, 793, "hypertension" +540, 6, 12, 154, 78, 82, 794, 798, "were" +540, 6, 13, 155, 83, 90, 799, 806, "treated" +540, 6, 14, 156, 91, 93, 807, 809, "in" +540, 6, 15, 157, 94, 95, 810, 811, "a" +540, 6, 16, 158, 96, 106, 812, 822, "randomized" +540, 6, 17, 159, 107, 108, 823, 824, "," +540, 6, 18, 160, 109, 118, 825, 834, "crossover" +540, 6, 19, 161, 119, 120, 835, 836, "," +540, 6, 20, 162, 121, 127, 837, 843, "double" +540, 6, 21, 163, 128, 129, 844, 845, "-" +540, 6, 22, 164, 130, 136, 846, 852, "masked" +540, 6, 23, 165, 137, 144, 853, 860, "fashion" +540, 6, 24, 166, 145, 149, 861, 865, "with" +540, 6, 25, 167, 150, 151, 866, 867, "1" +540, 6, 26, 168, 152, 156, 868, 872, "drop" +540, 6, 27, 169, 157, 159, 873, 875, "of" +540, 6, 28, 170, 160, 171, 876, 887, "latanoprost" +540, 6, 29, 171, 172, 173, 888, 889, "(" +540, 6, 30, 172, 174, 176, 890, 892, "50" +540, 6, 31, 173, 177, 183, 893, 899, "microg" +540, 6, 32, 174, 184, 185, 900, 901, "/" +540, 6, 33, 175, 186, 188, 902, 904, "ml" +540, 6, 34, 176, 189, 193, 905, 909, "once" +540, 6, 35, 177, 194, 199, 910, 915, "daily" +540, 6, 36, 178, 200, 203, 916, 919, "and" +540, 6, 37, 179, 204, 206, 920, 922, "15" +540, 6, 38, 180, 207, 213, 923, 929, "microg" +540, 6, 39, 181, 214, 215, 930, 931, "/" +540, 6, 40, 182, 216, 218, 932, 934, "ml" +540, 6, 41, 183, 219, 224, 935, 940, "twice" +540, 6, 42, 184, 225, 230, 941, 946, "daily" +540, 6, 43, 185, 231, 232, 947, 948, ")" +540, 6, 44, 186, 233, 235, 949, 951, "in" +540, 6, 45, 187, 236, 239, 952, 955, "the" +540, 6, 46, 188, 240, 248, 956, 964, "affected" +540, 6, 47, 189, 249, 252, 965, 968, "eye" +540, 6, 48, 190, 253, 254, 969, 970, "(" +540, 6, 49, 191, 255, 256, 971, 972, "s" +540, 6, 50, 192, 257, 258, 973, 974, ")" +540, 6, 51, 193, 259, 262, 975, 978, "for" +540, 6, 52, 194, 263, 264, 979, 980, "3" +540, 6, 53, 195, 265, 270, 981, 986, "weeks" +540, 6, 54, 196, 271, 273, 987, 989, "on" +540, 6, 55, 197, 274, 278, 990, 994, "each" +540, 6, 56, 198, 279, 292, 995, 1008, "concentration" +540, 6, 57, 199, 293, 294, 1009, 1010, "." +540, 7, 1, 200, 0, 9, 1011, 1020, "Tonometry" +540, 7, 2, 201, 10, 13, 1021, 1024, "was" +540, 7, 3, 202, 14, 22, 1025, 1033, "obtained" +540, 7, 4, 203, 23, 25, 1034, 1036, "at" +540, 7, 5, 204, 26, 27, 1037, 1038, "8" +540, 7, 6, 205, 28, 29, 1039, 1040, ":" +540, 7, 7, 206, 30, 32, 1041, 1043, "00" +540, 7, 8, 207, 33, 34, 1044, 1045, "," +540, 7, 9, 208, 35, 37, 1046, 1048, "13" +540, 7, 10, 209, 38, 39, 1049, 1050, ":" +540, 7, 11, 210, 40, 42, 1051, 1053, "00" +540, 7, 12, 211, 43, 44, 1054, 1055, "," +540, 7, 13, 212, 45, 48, 1056, 1059, "and" +540, 7, 14, 213, 49, 51, 1060, 1062, "17" +540, 7, 15, 214, 52, 53, 1063, 1064, ":" +540, 7, 16, 215, 54, 56, 1065, 1067, "00" +540, 7, 17, 216, 57, 62, 1068, 1073, "hours" +540, 7, 18, 217, 63, 65, 1074, 1076, "at" +540, 7, 19, 218, 66, 74, 1077, 1085, "baseline" +540, 7, 20, 219, 75, 76, 1086, 1087, "(" +540, 7, 21, 220, 77, 86, 1088, 1097, "untreated" +540, 7, 22, 221, 87, 88, 1098, 1099, ")" +540, 7, 23, 222, 89, 92, 1100, 1103, "and" +540, 7, 24, 223, 93, 98, 1104, 1109, "after" +540, 7, 25, 224, 99, 100, 1110, 1111, "3" +540, 7, 26, 225, 101, 106, 1112, 1117, "weeks" +540, 7, 27, 226, 107, 109, 1118, 1120, "on" +540, 7, 28, 227, 110, 114, 1121, 1125, "each" +540, 7, 29, 228, 115, 128, 1126, 1139, "concentration" +540, 7, 30, 229, 129, 130, 1140, 1141, "." +540, 8, 1, 230, 0, 7, 1142, 1149, "Placebo" +540, 8, 2, 231, 8, 9, 1150, 1151, "(" +540, 8, 3, 232, 10, 11, 1152, 1153, "a" +540, 8, 4, 233, 12, 18, 1154, 1160, "buffer" +540, 8, 5, 234, 19, 27, 1161, 1169, "solution" +540, 8, 6, 235, 28, 30, 1170, 1172, "of" +540, 8, 7, 236, 31, 42, 1173, 1184, "latanoprost" +540, 8, 8, 237, 43, 46, 1185, 1188, "eye" +540, 8, 9, 238, 47, 51, 1189, 1193, "drop" +540, 8, 10, 239, 52, 53, 1194, 1195, ")" +540, 8, 11, 240, 54, 57, 1196, 1199, "was" +540, 8, 12, 241, 58, 70, 1200, 1212, "administered" +540, 8, 13, 242, 71, 74, 1213, 1216, "for" +540, 8, 14, 243, 75, 83, 1217, 1225, "complete" +540, 8, 15, 244, 84, 91, 1226, 1233, "masking" +540, 8, 16, 245, 92, 94, 1234, 1236, "of" +540, 8, 17, 246, 95, 98, 1237, 1240, "the" +540, 8, 18, 247, 99, 104, 1241, 1246, "study" +540, 8, 19, 248, 105, 106, 1247, 1248, "." +540, 9, 1, 249, 0, 7, 1249, 1256, "RESULTS" +540, 9, 2, 250, 8, 9, 1257, 1258, ":" +540, 9, 3, 251, 10, 14, 1259, 1263, "Mean" +540, 9, 4, 252, 15, 23, 1264, 1272, "baseline" +540, 9, 5, 253, 24, 25, 1273, 1274, "(" +540, 9, 6, 254, 26, 35, 1275, 1284, "untreated" +540, 9, 7, 255, 36, 37, 1285, 1286, ")" +540, 9, 8, 256, 38, 45, 1287, 1294, "diurnal" +540, 9, 9, 257, 46, 49, 1295, 1298, "IOP" +540, 9, 10, 258, 50, 53, 1299, 1302, "for" +540, 9, 11, 259, 54, 57, 1303, 1306, "the" +540, 9, 12, 260, 58, 64, 1307, 1313, "entire" +540, 9, 13, 261, 65, 71, 1314, 1320, "sample" +540, 9, 14, 262, 72, 75, 1321, 1324, "was" +540, 9, 15, 263, 76, 78, 1325, 1327, "24" +540, 9, 16, 264, 79, 80, 1328, 1329, "." +540, 9, 17, 265, 81, 82, 1330, 1331, "7" +540, 9, 18, 266, 83, 87, 1332, 1336, "mmHg" +540, 9, 19, 267, 88, 89, 1337, 1338, "." +540, 10, 1, 268, 0, 11, 1339, 1350, "Intraocular" +540, 10, 2, 269, 12, 20, 1351, 1359, "pressure" +540, 10, 3, 270, 21, 24, 1360, 1363, "was" +540, 10, 4, 271, 25, 32, 1364, 1371, "reduced" +540, 10, 5, 272, 33, 35, 1372, 1374, "by" +540, 10, 6, 273, 36, 37, 1375, 1376, "6" +540, 10, 7, 274, 38, 39, 1377, 1378, "." +540, 10, 8, 275, 40, 41, 1379, 1380, "1" +540, 10, 9, 276, 42, 46, 1381, 1385, "mmHg" +540, 10, 10, 277, 47, 51, 1386, 1390, "with" +540, 10, 11, 278, 52, 63, 1391, 1402, "latanoprost" +540, 10, 12, 279, 64, 66, 1403, 1405, "15" +540, 10, 13, 280, 67, 73, 1406, 1412, "microg" +540, 10, 14, 281, 74, 75, 1413, 1414, "/" +540, 10, 15, 282, 76, 78, 1415, 1417, "ml" +540, 10, 16, 283, 79, 84, 1418, 1423, "twice" +540, 10, 17, 284, 85, 90, 1424, 1429, "daily" +540, 10, 18, 285, 91, 92, 1430, 1431, "," +540, 10, 19, 286, 93, 96, 1432, 1435, "and" +540, 10, 20, 287, 97, 99, 1436, 1438, "by" +540, 10, 21, 288, 100, 101, 1439, 1440, "7" +540, 10, 22, 289, 102, 103, 1441, 1442, "." +540, 10, 23, 290, 104, 105, 1443, 1444, "5" +540, 10, 24, 291, 106, 110, 1445, 1449, "mmHg" +540, 10, 25, 292, 111, 115, 1450, 1454, "with" +540, 10, 26, 293, 116, 118, 1455, 1457, "50" +540, 10, 27, 294, 119, 125, 1458, 1464, "microg" +540, 10, 28, 295, 126, 127, 1465, 1466, "/" +540, 10, 29, 296, 128, 130, 1467, 1469, "ml" +540, 10, 30, 297, 131, 135, 1470, 1474, "once" +540, 10, 31, 298, 136, 141, 1475, 1480, "daily" +540, 10, 32, 299, 142, 143, 1481, 1482, "." +540, 11, 1, 300, 0, 7, 1483, 1490, "Results" +540, 11, 2, 301, 8, 12, 1491, 1495, "with" +540, 11, 3, 302, 13, 17, 1496, 1500, "both" +540, 11, 4, 303, 18, 26, 1501, 1509, "regimens" +540, 11, 5, 304, 27, 31, 1510, 1514, "were" +540, 11, 6, 305, 32, 43, 1515, 1526, "significant" +540, 11, 7, 306, 44, 45, 1527, 1528, "(" +540, 11, 8, 307, 46, 47, 1529, 1530, "P" +540, 11, 9, 308, 48, 49, 1531, 1532, "&" +540, 11, 10, 309, 50, 52, 1533, 1535, "lt" +540, 11, 11, 310, 53, 54, 1536, 1537, ";" +540, 11, 12, 311, 55, 56, 1538, 1539, "0" +540, 11, 13, 312, 57, 58, 1540, 1541, "." +540, 11, 14, 313, 59, 62, 1542, 1545, "001" +540, 11, 15, 314, 63, 67, 1546, 1550, "each" +540, 11, 16, 315, 68, 69, 1551, 1552, "," +540, 11, 17, 316, 70, 77, 1553, 1560, "Student" +540, 11, 18, 317, 78, 79, 1561, 1562, "'" +540, 11, 19, 318, 80, 81, 1563, 1564, "s" +540, 11, 20, 319, 82, 83, 1565, 1566, "t" +540, 11, 21, 320, 84, 85, 1567, 1568, "-" +540, 11, 22, 321, 86, 90, 1569, 1573, "test" +540, 11, 23, 322, 91, 92, 1574, 1575, ")" +540, 11, 24, 323, 93, 94, 1576, 1577, "." +540, 12, 1, 324, 0, 7, 1578, 1585, "However" +540, 12, 2, 325, 8, 9, 1586, 1587, "," +540, 12, 3, 326, 10, 13, 1588, 1591, "the" +540, 12, 4, 327, 14, 16, 1592, 1594, "50" +540, 12, 5, 328, 17, 23, 1595, 1601, "microg" +540, 12, 6, 329, 24, 25, 1602, 1603, "/" +540, 12, 7, 330, 26, 28, 1604, 1606, "ml" +540, 12, 8, 331, 29, 33, 1607, 1611, "dose" +540, 12, 9, 332, 34, 37, 1612, 1615, "was" +540, 12, 10, 333, 38, 51, 1616, 1629, "significantly" +540, 12, 11, 334, 52, 56, 1630, 1634, "more" +540, 12, 12, 335, 57, 66, 1635, 1644, "effective" +540, 12, 13, 336, 67, 71, 1645, 1649, "than" +540, 12, 14, 337, 72, 75, 1650, 1653, "the" +540, 12, 15, 338, 76, 78, 1654, 1656, "15" +540, 12, 16, 339, 79, 85, 1657, 1663, "microg" +540, 12, 17, 340, 86, 87, 1664, 1665, "/" +540, 12, 18, 341, 88, 90, 1666, 1668, "ml" +540, 12, 19, 342, 91, 95, 1669, 1673, "dose" +540, 12, 20, 343, 96, 97, 1674, 1675, "," +540, 12, 21, 344, 98, 102, 1676, 1680, "with" +540, 12, 22, 345, 103, 104, 1681, 1682, "a" +540, 12, 23, 346, 105, 115, 1683, 1693, "difference" +540, 12, 24, 347, 116, 118, 1694, 1696, "of" +540, 12, 25, 348, 119, 120, 1697, 1698, "1" +540, 12, 26, 349, 121, 122, 1699, 1700, "." +540, 12, 27, 350, 123, 124, 1701, 1702, "4" +540, 12, 28, 351, 125, 129, 1703, 1707, "mmHg" +540, 12, 29, 352, 130, 131, 1708, 1709, "(" +540, 12, 30, 353, 132, 133, 1710, 1711, "P" +540, 12, 31, 354, 134, 135, 1712, 1713, "&" +540, 12, 32, 355, 136, 138, 1714, 1716, "lt" +540, 12, 33, 356, 139, 140, 1717, 1718, ";" +540, 12, 34, 357, 141, 142, 1719, 1720, "0" +540, 12, 35, 358, 143, 144, 1721, 1722, "." +540, 12, 36, 359, 145, 148, 1723, 1726, "001" +540, 12, 37, 360, 149, 150, 1727, 1728, "," +540, 12, 38, 361, 151, 156, 1729, 1734, "ANOVA" +540, 12, 39, 362, 157, 158, 1735, 1736, ")" +540, 12, 40, 363, 159, 160, 1737, 1738, "." +540, 13, 1, 364, 0, 4, 1739, 1743, "Both" +540, 13, 2, 365, 5, 9, 1744, 1748, "dose" +540, 13, 3, 366, 10, 18, 1749, 1757, "regimens" +540, 13, 4, 367, 19, 23, 1758, 1762, "were" +540, 13, 5, 368, 24, 28, 1763, 1767, "well" +540, 13, 6, 369, 29, 38, 1768, 1777, "tolerated" +540, 13, 7, 370, 39, 40, 1778, 1779, "," +540, 13, 8, 371, 41, 45, 1780, 1784, "with" +540, 13, 9, 372, 46, 52, 1785, 1791, "little" +540, 13, 10, 373, 53, 54, 1792, 1793, "," +540, 13, 11, 374, 55, 68, 1794, 1807, "predominantly" +540, 13, 12, 375, 69, 73, 1808, 1812, "mild" +540, 13, 13, 376, 74, 75, 1813, 1814, "," +540, 13, 14, 377, 76, 82, 1815, 1821, "ocular" +540, 13, 15, 378, 83, 93, 1822, 1832, "discomfort" +540, 13, 16, 379, 94, 95, 1833, 1834, "." +540, 14, 1, 380, 0, 3, 1835, 1838, "The" +540, 14, 2, 381, 4, 10, 1839, 1845, "higher" +540, 14, 3, 382, 11, 15, 1846, 1850, "dose" +540, 14, 4, 383, 16, 19, 1851, 1854, "did" +540, 14, 5, 384, 20, 23, 1855, 1858, "not" +540, 14, 6, 385, 24, 29, 1859, 1864, "cause" +540, 14, 7, 386, 30, 34, 1865, 1869, "more" +540, 14, 8, 387, 35, 44, 1870, 1879, "hyperemia" +540, 14, 9, 388, 45, 47, 1880, 1882, "at" +540, 14, 10, 389, 48, 49, 1883, 1884, "3" +540, 14, 11, 390, 50, 55, 1885, 1890, "weeks" +540, 14, 12, 391, 56, 60, 1891, 1895, "than" +540, 14, 13, 392, 61, 64, 1896, 1899, "the" +540, 14, 14, 393, 65, 70, 1900, 1905, "lower" +540, 14, 15, 394, 71, 74, 1906, 1909, "one" +540, 14, 16, 395, 75, 76, 1910, 1911, "," +540, 14, 17, 396, 77, 78, 1912, 1913, "i" +540, 14, 18, 397, 79, 80, 1914, 1915, "." +540, 14, 19, 398, 81, 82, 1916, 1917, "e" +540, 14, 20, 399, 83, 84, 1918, 1919, "." +540, 14, 21, 400, 85, 86, 1920, 1921, "," +540, 14, 22, 401, 87, 90, 1922, 1925, "the" +540, 14, 23, 402, 91, 96, 1926, 1931, "lower" +540, 14, 24, 403, 97, 101, 1932, 1936, "dose" +540, 14, 25, 404, 102, 109, 1937, 1944, "yielded" +540, 14, 26, 405, 110, 111, 1945, 1946, "a" +540, 14, 27, 406, 112, 120, 1947, 1955, "slightly" +540, 14, 28, 407, 121, 127, 1956, 1962, "higher" +540, 14, 29, 408, 128, 133, 1963, 1968, "score" +540, 14, 30, 409, 134, 135, 1969, 1970, "(" +540, 14, 31, 410, 136, 137, 1971, 1972, "1" +540, 14, 32, 411, 138, 139, 1973, 1974, "." +540, 14, 33, 412, 140, 141, 1975, 1976, "8" +540, 14, 34, 413, 142, 144, 1977, 1979, "mm" +540, 14, 35, 414, 145, 146, 1980, 1981, ")" +540, 14, 36, 415, 147, 149, 1982, 1984, "on" +540, 14, 37, 416, 150, 153, 1985, 1988, "the" +540, 14, 38, 417, 154, 160, 1989, 1995, "visual" +540, 14, 39, 418, 161, 169, 1996, 2004, "analogue" +540, 14, 40, 419, 170, 175, 2005, 2010, "scale" +540, 14, 41, 420, 176, 177, 2011, 2012, "(" +540, 14, 42, 421, 178, 179, 2013, 2014, "P" +540, 14, 43, 422, 180, 181, 2015, 2016, "&" +540, 14, 44, 423, 182, 184, 2017, 2019, "lt" +540, 14, 45, 424, 185, 186, 2020, 2021, ";" +540, 14, 46, 425, 187, 188, 2022, 2023, "0" +540, 14, 47, 426, 189, 190, 2024, 2025, "." +540, 14, 48, 427, 191, 193, 2026, 2028, "29" +540, 14, 49, 428, 194, 195, 2029, 2030, "," +540, 14, 50, 429, 196, 201, 2031, 2036, "ANOVA" +540, 14, 51, 430, 202, 203, 2037, 2038, ")" +540, 14, 52, 431, 204, 205, 2039, 2040, "." +540, 15, 1, 432, 0, 11, 2041, 2052, "CONCLUSIONS" +540, 15, 2, 433, 12, 13, 2053, 2054, ":" +540, 15, 3, 434, 14, 25, 2055, 2066, "Latanoprost" +540, 15, 4, 435, 26, 38, 2067, 2079, "administered" +540, 15, 5, 436, 39, 41, 2080, 2082, "at" +540, 15, 6, 437, 42, 43, 2083, 2084, "a" +540, 15, 7, 438, 44, 57, 2085, 2098, "concentration" +540, 15, 8, 439, 58, 60, 2099, 2101, "of" +540, 15, 9, 440, 61, 63, 2102, 2104, "50" +540, 15, 10, 441, 64, 70, 2105, 2111, "microg" +540, 15, 11, 442, 71, 72, 2112, 2113, "/" +540, 15, 12, 443, 73, 75, 2114, 2116, "ml" +540, 15, 13, 444, 76, 80, 2117, 2121, "once" +540, 15, 14, 445, 81, 86, 2122, 2127, "daily" +540, 15, 15, 446, 87, 98, 2128, 2139, "effectively" +540, 15, 16, 447, 99, 106, 2140, 2147, "reduces" +540, 15, 17, 448, 107, 110, 2148, 2151, "IOP" +540, 15, 18, 449, 111, 113, 2152, 2154, "in" +540, 15, 19, 450, 114, 122, 2155, 2163, "patients" +540, 15, 20, 451, 123, 127, 2164, 2168, "with" +540, 15, 21, 452, 128, 136, 2169, 2177, "elevated" +540, 15, 22, 453, 137, 140, 2178, 2181, "IOP" +540, 15, 23, 454, 141, 142, 2182, 2183, "." +540, 16, 1, 455, 0, 14, 2184, 2198, "Administration" +540, 16, 2, 456, 15, 17, 2199, 2201, "of" +540, 16, 3, 457, 18, 19, 2202, 2203, "a" +540, 16, 4, 458, 20, 25, 2204, 2209, "lower" +540, 16, 5, 459, 26, 39, 2210, 2223, "concentration" +540, 16, 6, 460, 40, 41, 2224, 2225, "(" +540, 16, 7, 461, 42, 44, 2226, 2228, "15" +540, 16, 8, 462, 45, 51, 2229, 2235, "microg" +540, 16, 9, 463, 52, 53, 2236, 2237, "/" +540, 16, 10, 464, 54, 56, 2238, 2240, "ml" +540, 16, 11, 465, 57, 58, 2241, 2242, ")" +540, 16, 12, 466, 59, 64, 2243, 2248, "twice" +540, 16, 13, 467, 65, 70, 2249, 2254, "daily" +540, 16, 14, 468, 71, 73, 2255, 2257, "is" +540, 16, 15, 469, 74, 78, 2258, 2262, "less" +540, 16, 16, 470, 79, 88, 2263, 2272, "effective" +540, 16, 17, 471, 89, 90, 2273, 2274, "," +540, 16, 18, 472, 91, 94, 2275, 2278, "but" +540, 16, 19, 473, 95, 100, 2279, 2284, "still" +540, 16, 20, 474, 101, 112, 2285, 2296, "significant" +540, 16, 21, 475, 113, 114, 2297, 2298, "." +540, 17, 1, 476, 0, 3, 2299, 2302, "DOI" +540, 17, 2, 477, 4, 5, 2303, 2304, ":" +540, 17, 3, 478, 6, 8, 2305, 2307, "10" +540, 17, 4, 479, 9, 10, 2308, 2309, "." +540, 17, 5, 480, 11, 15, 2310, 2314, "1016" +540, 17, 6, 481, 16, 17, 2315, 2316, "/" +540, 17, 7, 482, 18, 23, 2317, 2322, "s0161" +540, 17, 8, 483, 24, 25, 2323, 2324, "-" +540, 17, 9, 484, 26, 30, 2325, 2329, "6420" +540, 17, 10, 485, 31, 32, 2330, 2331, "(" +540, 17, 11, 486, 33, 35, 2332, 2334, "97" +540, 17, 12, 487, 36, 37, 2335, 2336, ")" +540, 17, 13, 488, 38, 43, 2337, 2342, "30074" +540, 17, 14, 489, 44, 45, 2343, 2344, "-" +540, 17, 15, 490, 46, 47, 2345, 2346, "8" +540, 17, 16, 491, 48, 52, 2347, 2351, "PMID" +540, 17, 17, 492, 53, 54, 2352, 2353, ":" +540, 17, 18, 493, 55, 62, 2354, 2361, "9331215" +540, 17, 19, 494, 63, 64, 2362, 2363, "[" +540, 17, 20, 495, 65, 72, 2364, 2371, "Indexed" +540, 17, 21, 496, 73, 76, 2372, 2375, "for" +540, 17, 22, 497, 77, 84, 2376, 2383, "MEDLINE" +540, 17, 23, 498, 85, 86, 2384, 2385, "]" diff --git a/data/gl 9331215_jshahinitiran.annodb b/data/gl 9331215_jshahinitiran.annodb new file mode 100644 index 0000000..0709a4a --- /dev/null +++ b/data/gl 9331215_jshahinitiran.annodb @@ -0,0 +1,88 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +91398, Journal, 0, 13, "Ophthalmology", "", +91399, PublicationYear, 16, 20, "1997", "", +91400, Title, 51, 155, "A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure .", "", +91401, Latanoprost, 95, 106, "latanoprost", "", +91402, Precondition, 124, 153, "elevated intraocular pressure", "", +91403, IOP, 133, 153, "intraocular pressure", "", +91404, Author, 156, 163, "Lusky M", "", +91405, Author, 172, 179, "Ticho U", "", +91406, Author, 182, 193, "Glovinsky J", "", +91407, Author, 196, 208, "Weinberger D", "", +91408, Author, 211, 219, "Nesher R", "", +91409, Author, 222, 230, "Yassur Y", "", +91410, Author, 233, 242, "Melamed S", "", +91411, Israel, 358, 364, "Israel", "", +91412, ObjectiveDescription, 379, 555, "The purpose of the study was to determine whether latanoprost ( 13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester ) , a new prostaglandin analogue", "", +91414, Latanoprost, 429, 440, "latanoprost", "", +91413, ObjectiveDescription, 556, 715, "that has been found effective in reducing intraocular pressure ( IOP ) in humans , is equally effective at lower concentrations than those currently employed .", "", +91415, IOP, 598, 618, "intraocular pressure", "", +91416, IOP, 621, 624, "IOP", "", +91417, NumberPatientsCT, 742, 747, "Fifty", "", +91418, Glaucoma, 762, 770, "glaucoma", "", +91419, OcularHypertension, 774, 793, "ocular hypertension", "", +91420, Randomized, 812, 822, "randomized", "", +91421, Crossover, 825, 834, "crossover", "", +91422, DoubleBlind, 837, 852, "double - masked", "", +91423, Eyedrops, 868, 872, "drop", "", +91424, Latanoprost, 876, 887, "latanoprost", "", +91425, DoseValue, 890, 892, "50", "", +91426, Microgram, 893, 899, "microg", "", +91427, BioAndMedicalUnit, 893, 904, "microg / ml", "", +91428, Frequency, 905, 915, "once daily", "", +91429, DoseValue, 920, 922, "15", "", +91430, Microgram, 923, 929, "microg", "", +91431, BioAndMedicalUnit, 923, 934, "microg / ml", "", +91432, Frequency, 935, 946, "twice daily", "", +91433, Duration, 979, 986, "3 weeks", "", +91434, TimePoint, 1077, 1085, "baseline", "", +91435, TimePoint, 1110, 1117, "3 weeks", "", +91436, Placebo, 1142, 1149, "Placebo", "", +91437, Latanoprost, 1173, 1184, "latanoprost", "", +91438, Eyedrops, 1185, 1193, "eye drop", "", +91439, Mean, 1259, 1263, "Mean", "", +91440, Diurnal_IOP, 1287, 1298, "diurnal IOP", "", +91441, BaseLineValue, 1325, 1331, "24 . 7", "", +91442, mmHg, 1332, 1336, "mmHg", "", +91443, IOP, 1339, 1359, "Intraocular pressure", "", +91444, Reduction, 1375, 1380, "6 . 1", "", +91446, mmHg, 1381, 1385, "mmHg", "", +91448, Latanoprost, 1391, 1402, "latanoprost", "", +91449, DoseValue, 1403, 1405, "15", "", +91451, Microgram, 1406, 1412, "microg", "", +91453, BioAndMedicalUnit, 1406, 1417, "microg / ml", "", +91455, Frequency, 1418, 1429, "twice daily", "", +91445, Reduction, 1439, 1444, "7 . 5", "", +91447, mmHg, 1445, 1449, "mmHg", "", +91450, DoseValue, 1455, 1457, "50", "", +91452, Microgram, 1458, 1464, "microg", "", +91454, BioAndMedicalUnit, 1458, 1469, "microg / ml", "", +91456, Frequency, 1470, 1480, "once daily", "", +91457, PValueResValue, 1529, 1545, "P & lt ; 0 . 001", "", +91458, DoseValue, 1592, 1594, "50", "", +91462, Microgram, 1595, 1601, "microg", "", +91466, BioAndMedicalUnit, 1595, 1606, "microg / ml", "", +91459, DoseValue, 1654, 1656, "15", "", +91463, Microgram, 1657, 1663, "microg", "", +91467, BioAndMedicalUnit, 1657, 1668, "microg / ml", "", +91470, DiffGroupAbsValue, 1697, 1702, "1 . 4", "", +91471, mmHg, 1703, 1707, "mmHg", "", +91472, PvalueDiff, 1710, 1726, "P & lt ; 0 . 001", "", +91473, ConjunctivalHyperemia, 1870, 1879, "hyperemia", "", +91474, TimePoint, 1883, 1890, "3 weeks", "", +91475, PvalueDiff, 2013, 2028, "P & lt ; 0 . 29", "", +91476, Latanoprost, 2055, 2066, "Latanoprost", "", +91482, ConclusionComment, 2055, 2183, "Latanoprost administered at a concentration of 50 microg / ml once daily effectively reduces IOP in patients with elevated IOP .", "", +91460, DoseValue, 2102, 2104, "50", "", +91464, Microgram, 2105, 2111, "microg", "", +91468, BioAndMedicalUnit, 2105, 2116, "microg / ml", "", +91477, Frequency, 2117, 2127, "once daily", "", +91479, IOP, 2148, 2151, "IOP", "", +91481, Precondition, 2169, 2181, "elevated IOP", "", +91480, IOP, 2178, 2181, "IOP", "", +91483, ConclusionComment, 2184, 2298, "Administration of a lower concentration ( 15 microg / ml ) twice daily is less effective , but still significant .", "", +91461, DoseValue, 2226, 2228, "15", "", +91465, Microgram, 2229, 2235, "microg", "", +91469, BioAndMedicalUnit, 2229, 2240, "microg / ml", "", +91478, Frequency, 2243, 2254, "twice daily", "", +91484, PMID, 2354, 2361, "9331215", "", diff --git a/data/gl 9331215_jshahinitiran.n-triples b/data/gl 9331215_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9331215_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9331215_tstrakeljahn.annodb b/data/gl 9331215_tstrakeljahn.annodb new file mode 100644 index 0000000..12b34b8 --- /dev/null +++ b/data/gl 9331215_tstrakeljahn.annodb @@ -0,0 +1,94 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88478, Journal, 0, 13, "Ophthalmology", "", +88479, PublicationYear, 16, 20, "1997", "", +88482, Title, 51, 155, "A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure .", "", +88480, Latanoprost, 95, 106, "latanoprost", "", +88481, IOP, 133, 153, "intraocular pressure", "", +88483, Author, 156, 163, "Lusky M", "", +88484, Author, 172, 179, "Ticho U", "", +88485, Author, 182, 193, "Glovinsky J", "", +88486, Author, 196, 208, "Weinberger D", "", +88487, Author, 211, 219, "Nesher R", "", +88488, Author, 222, 230, "Yassur Y", "", +88489, Author, 233, 242, "Melamed S", "", +88490, Israel, 358, 364, "Israel", "", +88495, ObjectiveDescription, 379, 629, "The purpose of the study was to determine whether latanoprost ( 13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester ) , a new prostaglandin analogue that has been found effective in reducing intraocular pressure ( IOP ) in", "", +88491, Latanoprost, 429, 440, "latanoprost", "", +88492, Latanoprost, 443, 522, "13 , 14 - dihydro - 17 - phenyl - 18 , 19 , 20 - trinor PGF2a - isopropyl ester", "", +88493, IOP, 598, 618, "intraocular pressure", "", +88494, IOP, 621, 624, "IOP", "", +88497, ObjectiveDescription, 630, 715, "humans , is equally effective at lower concentrations than those currently employed .", "", +88498, NumberPatientsCT, 742, 747, "Fifty", "", +88499, Glaucoma, 762, 770, "glaucoma", "", +88500, OcularHypertension, 774, 793, "ocular hypertension", "", +88501, Randomized, 812, 822, "randomized", "", +88502, Crossover, 825, 834, "crossover", "", +88503, DoubleBlind, 837, 852, "double - masked", "", +88504, DoseValue, 866, 867, "1", "", +88505, BioAndMedicalUnit, 868, 872, "drop", "", +88506, Eyedrops, 868, 872, "drop", "", +88507, Latanoprost, 876, 887, "latanoprost", "", +88508, DoseValue, 890, 892, "50", "", +88533, Microgram, 893, 899, "microg", "", +88537, MicroUnits_per_milliliter, 893, 904, "microg / ml", "", +88511, Frequency, 905, 915, "once daily", "", +88509, DoseValue, 920, 922, "15", "", +88534, Microgram, 923, 929, "microg", "", +88538, MicroUnits_per_milliliter, 923, 934, "microg / ml", "", +88510, Frequency, 935, 946, "twice daily", "", +88512, Duration, 979, 986, "3 weeks", "", +88517, TimePoint, 1037, 1043, "8 : 00", "", +88516, TimePoint, 1046, 1053, "13 : 00", "", +88515, TimePoint, 1060, 1073, "17 : 00 hours", "", +88514, TimePoint, 1074, 1085, "at baseline", "", +88513, TimePoint, 1104, 1117, "after 3 weeks", "", +88518, Placebo, 1142, 1149, "Placebo", "", +88519, Latanoprost, 1173, 1184, "latanoprost", "", +88520, Eyedrops, 1185, 1193, "eye drop", "", +88521, Mean, 1259, 1263, "Mean", "", +88522, Diurnal_IOP, 1287, 1298, "diurnal IOP", "", +88523, BaseLineValue, 1325, 1331, "24 . 7", "", +88524, mmHg, 1332, 1336, "mmHg", "", +88525, IOP, 1339, 1359, "Intraocular pressure", "", +88526, Reduction, 1375, 1380, "6 . 1", "", +88528, mmHg, 1381, 1385, "mmHg", "", +88530, Latanoprost, 1391, 1402, "latanoprost", "", +88541, DoseValue, 1403, 1405, "15", "", +88535, Microgram, 1406, 1412, "microg", "", +88539, MicroUnits_per_milliliter, 1406, 1417, "microg / ml", "", +88531, Frequency, 1418, 1429, "twice daily", "", +88527, Reduction, 1439, 1444, "7 . 5", "", +88529, mmHg, 1445, 1449, "mmHg", "", +88542, DoseValue, 1455, 1457, "50", "", +88536, Microgram, 1458, 1464, "microg", "", +88540, MicroUnits_per_milliliter, 1458, 1469, "microg / ml", "", +88532, Frequency, 1470, 1480, "once daily", "", +88557, ObservedResult, 1483, 1526, "Results with both regimens were significant", "", +88543, PValueResValue, 1531, 1545, "& lt ; 0 . 001", "", +88544, DoseValue, 1592, 1594, "50", "", +88545, Microgram, 1595, 1601, "microg", "", +88552, MicroUnits_per_milliliter, 1595, 1606, "microg / ml", "", +88553, DoseValue, 1654, 1656, "15", "", +88546, Microgram, 1657, 1663, "microg", "", +88549, MicroUnits_per_milliliter, 1657, 1668, "microg / ml", "", +88554, DiffGroupAbsValue, 1697, 1702, "1 . 4", "", +88555, mmHg, 1703, 1707, "mmHg", "", +88556, PvalueDiff, 1712, 1726, "& lt ; 0 . 001", "", +88558, ObservedResult, 1739, 1834, "Both dose regimens were well tolerated , with little , predominantly mild , ocular discomfort .", "", +88559, ConjunctivalHyperemia, 1870, 1879, "hyperemia", "", +88560, TimePoint, 1880, 1890, "at 3 weeks", "", +88561, PvalueDiff, 2015, 2028, "& lt ; 0 . 29", "", +88562, Latanoprost, 2055, 2066, "Latanoprost", "", +88567, ConclusionComment, 2055, 2183, "Latanoprost administered at a concentration of 50 microg / ml once daily effectively reduces IOP in patients with elevated IOP .", "", +88563, DoseValue, 2102, 2104, "50", "", +88547, Microgram, 2105, 2111, "microg", "", +88550, MicroUnits_per_milliliter, 2105, 2116, "microg / ml", "", +88564, Frequency, 2117, 2127, "once daily", "", +88565, IOP, 2148, 2151, "IOP", "", +88566, IOP, 2178, 2181, "IOP", "", +88570, ConclusionComment, 2184, 2298, "Administration of a lower concentration ( 15 microg / ml ) twice daily is less effective , but still significant .", "", +88568, DoseValue, 2226, 2228, "15", "", +88548, Microgram, 2229, 2235, "microg", "", +88551, MicroUnits_per_milliliter, 2229, 2240, "microg / ml", "", +88569, Frequency, 2243, 2254, "twice daily", "", +88571, PMID, 2354, 2361, "9331215", "", diff --git a/data/gl 9331215_tstrakeljahn.n-triples b/data/gl 9331215_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9331215_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9663361_admin.annodb b/data/gl 9663361_admin.annodb new file mode 100644 index 0000000..376ad11 --- /dev/null +++ b/data/gl 9663361_admin.annodb @@ -0,0 +1,107 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +0, Journal, 0, 11, "Clin Ther .", "", " \"Clin Ther .\"." +1, PublicationYear, 12, 16, "1998", "", " \"1998\"." +9, Title, 51, 181, "Comparison of the efficacy and safety of 2 % dorzolamide and 0 . 5 % betaxolol in the treatment of elevated intraocular pressure .", "", " \"Comparison of the efficacy and safety of 2 % dorzolamide and 0 . 5 % betaxolol in the treatment of elevated intraocular pressure .\"." +5, DoseValue, 92, 93, "2", "", +7, Percentage, 94, 95, "%", "", +2, Dorzolamide, 96, 107, "dorzolamide", "", +6, DoseValue, 112, 117, "0 . 5", "", +8, Percentage, 118, 119, "%", "", +3, Betaxolol, 120, 129, "betaxolol", "", +4, IOP, 159, 179, "intraocular pressure", "", +10, Dorzolamide, 182, 193, "Dorzolamide", "", +11, Author, 219, 225, "Rusk C", "", " \"Rusk C\"." +12, Author, 234, 242, "Sharpe E", "", " \"Sharpe E\"." +13, Author, 245, 255, "Laurence J", "", " \"Laurence J\"." +14, Author, 258, 265, "Polis A", "", " \"Polis A\"." +15, Author, 268, 278, "Adamsons I", "", " \"Adamsons I\"." +106, USA, 365, 368, "USA", "", " ." +17, Multicenter, 373, 384, "multicenter", "", " ." +108, Parallel, 387, 404, "parallel - design", "", " ." +19, Randomized, 407, 417, "randomized", "", " ." +20, DoubleBlind, 420, 435, "double - masked", "", " ." +29, ObjectiveDescription, 459, 607, "compare the efficacy and safety of 2 % dorzolamide with those of 0 . 5 % betaxolol in the treatment of elevated intraocular pressure ( i . o . p ) .", "", " \"compare the efficacy and safety of 2 % dorzolamide with those of 0 . 5 % betaxolol in the treatment of elevated intraocular pressure ( i . o . p ) .\"." +25, DoseValue, 494, 495, "2", "", +27, Percentage, 496, 497, "%", "", +21, Dorzolamide, 498, 509, "dorzolamide", "", +26, DoseValue, 524, 529, "0 . 5", "", +28, Percentage, 530, 531, "%", "", +22, Betaxolol, 532, 541, "betaxolol", "", +23, IOP, 571, 591, "intraocular pressure", "", +24, IOP, 594, 603, "i . o . p", "", +30, NumberPatientsCT, 619, 622, "311", "", " \"311\"." +31, OcularHypertension, 635, 654, "ocular hypertension", "", " ." +32, OpenAngleGlaucoma, 658, 679, "open - angle glaucoma", "", " ." +120, Randomized, 685, 693, "randomly", "", +33, DoseValue, 722, 723, "2", "", " \"2\"." +35, Percentage, 724, 725, "%", "", " ." +37, Dorzolamide, 726, 737, "dorzolamide", "", " ." +101434, DeliveryMethod, 751, 760, "topically", "", " . ." +39, Frequency, 761, 764, "TID", "", " \"TID\"." +34, DoseValue, 768, 773, "0 . 5", "", " \"0 . 5\"." +36, Percentage, 774, 775, "%", "", " ." +38, Betaxolol, 776, 785, "betaxolol", "", " ." +101438, DeliveryMethod, 799, 808, "topically", "", " . ." +40, Frequency, 809, 812, "BID", "", " \"BID\"." +41, Placebo, 818, 825, "placebo", "", " ." +101439, DeliveryMethod, 839, 848, "topically", "", " . ." +42, Frequency, 849, 851, "QD", "", " \"QD\"." +129, Duration, 856, 864, "12 weeks", "", " \"12 weeks\"." +132, Precondition, 924, 1009, "patients with IOP > or = 23 mm Hg in at least one eye at 10 AM or 4 PM on study day 1", "", " \"patients with IOP > or = 23 mm Hg in at least one eye at 10 AM or 4 PM on study day 1\"." +43, IOP, 938, 941, "IOP", "", +44, mmHg, 952, 957, "mm Hg", "", +45, TimePoint, 981, 986, "10 AM", "", +46, TimePoint, 990, 994, "4 PM", "", +47, TimePoint, 1004, 1009, "day 1", "", +133, Randomized, 1015, 1023, "randomly", "", +49, IOP, 1098, 1101, "IOP", "", +50, Morning, 1176, 1183, "morning", "", +57, Peak_IOP, 1184, 1195, "peak effect", "", +62, TimePoint, 1198, 1204, "hour 2", "", +56, Trough_IOP, 1221, 1234, "trough effect", "", +58, TimePoint, 1237, 1243, "hour 8", "", +51, Duration, 1254, 1262, "12 weeks", "", +52, Mean, 1280, 1284, "mean", "", +53, IOP, 1295, 1298, "IOP", "", +54, Dorzolamide, 1343, 1354, "dorzolamide", "", +55, Betaxolol, 1359, 1368, "betaxolol", "", +59, TimePoint, 1389, 1395, "hour 8", "", " \"hour 8\". \"hour 8\"." +60, Reduction, 1400, 1405, "3 . 6", "", " \"3 . 6\". \"3 . 6\"." +61, mmHg, 1406, 1411, "mm Hg", "", +63, TimePoint, 1432, 1438, "hour 2", "", " \"hour 2\". \"hour 2\"." +64, Reduction, 1443, 1448, "5 . 4", "", " \"5 . 4\"." +65, Reduction, 1454, 1459, "5 . 3", "", " \"5 . 3\"." +66, mmHg, 1460, 1465, "mm Hg", "", +67, Mean, 1574, 1578, "mean", "", " . ." +68, IOP, 1579, 1582, "IOP", "", " . ." +69, DiffGroupAbsValue, 1610, 1616, "0 . 02", "", " \"0 . 02\"." +71, mmHg, 1617, 1622, "mm Hg", "", " ." +75, ConfIntervalDiff, 1625, 1645, "- 0 . 870 to 0 . 901", "", " \"- 0 . 870 to 0 . 901\"." +73, TimePoint, 1652, 1658, "hour 8", "", +70, DiffGroupAbsValue, 1663, 1671, "- 0 . 14", "", " \"- 0 . 14\"." +72, mmHg, 1672, 1677, "mm Hg", "", +76, ConfIntervalDiff, 1680, 1700, "- 0 . 959 to 0 . 685", "", " \"- 0 . 959 to 0 . 685\"." +74, TimePoint, 1707, 1713, "hour 2", "", +101444, ObservedResult, 1753, 1777, "most frequently reported", "", " \"most frequently reported\". \"most frequently reported\"." +101440, EndPointDescription, 1794, 1808, "ocular burning", "", " . ." +77, Stinging, 1818, 1826, "stinging", "", " ." +101445, ObservedResult, 1833, 1875, "the most frequently reported nonocular AEs", "", " \"the most frequently reported nonocular AEs\". \"the most frequently reported nonocular AEs\". \"the most frequently reported nonocular AEs\". \"the most frequently reported nonocular AEs\"." +101441, EndPointDescription, 1881, 1897, "taste perversion", "", " . ." +101442, EndPointDescription, 1900, 1927, "upper respiratory infection", "", " . ." +158, Headache, 1934, 1942, "headache", "", " ." +101443, EndPointDescription, 1967, 1983, "taste perversion", "", +84, PercentageAffected, 2039, 2045, "14 . 6", "", " \"14 . 6\"." +86, Dorzolamide, 2056, 2067, "dorzolamide", "", +85, PercentageAffected, 2078, 2083, "0 . 0", "", " \"0 . 0\"." +87, Betaxolol, 2094, 2103, "betaxolol", "", +88, RelNumPatientsLeftCT, 2114, 2117, "Two", "", " \"Two\"." +94, ConclusionComment, 2198, 2295, "This study confirmed the similar IOP - lowering effect of 2 % dorzolamide and 0 . 5 % betaxolol .", "", " \"This study confirmed the similar IOP - lowering effect of 2 % dorzolamide and 0 . 5 % betaxolol .\"." +89, IOP, 2231, 2234, "IOP", "", +90, DoseValue, 2256, 2257, "2", "", +92, Percentage, 2258, 2259, "%", "", +168, Dorzolamide, 2260, 2271, "dorzolamide", "", +91, DoseValue, 2276, 2281, "0 . 5", "", +93, Percentage, 2282, 2283, "%", "", +169, Betaxolol, 2284, 2293, "betaxolol", "", +95, ConclusionComment, 2296, 2384, "Both treatments were generally well tolerated , and their safety profiles were similar .", "", " \"Both treatments were generally well tolerated , and their safety profiles were similar .\"." +96, PMID, 2440, 2447, "9663361", "", " \"9663361\"." diff --git a/data/gl 9663361_admin.n-triples b/data/gl 9663361_admin.n-triples new file mode 100644 index 0000000..8f7e086 --- /dev/null +++ b/data/gl 9663361_admin.n-triples @@ -0,0 +1,205 @@ +# RDF export of group: Publication + . + "Publication" . + "Comparison of the efficacy and safety of 2 % dorzolamide and 0 . 5 % betaxolol in the treatment of elevated intraocular pressure ." . + "Rusk C" . + "1998" . + "Clin Ther ." . + "9663361" . + . + "Sharpe E" . + "Laurence J" . + "Polis A" . + "Adamsons I" . +# RDF export of group: ClinicalTrial + . + "ClinicalTrial" . + "compare the efficacy and safety of 2 % dorzolamide with those of 0 . 5 % betaxolol in the treatment of elevated intraocular pressure ( i . o . p ) ." . + "311" . + "12 weeks" . + . + . + . + "This study confirmed the similar IOP - lowering effect of 2 % dorzolamide and 0 . 5 % betaxolol ." . + . + . + . + . + . + "Two" . + . + . + . + "Both treatments were generally well tolerated , and their safety profiles were similar ." . + . + . + . +# RDF export of group: Population + . + "Population" . + "patients with IOP > or = 23 mm Hg in at least one eye at 10 AM or 4 PM on study day 1" . + . + . + . +# RDF export of group: Endpoint + . + "Endpoint_iop" . + . + . + . + . + . + . + . + "Endpoint_AE_OB" . + . + . + . + . + . + . + "Endpoint_AE_S" . + . + . + . + . + . + "Endpoint_AE_I" . + . + . + . + . + . + . + "Endpoint_AE_T" . + . + . + . + . + . + . + "Endpoint_AE_H" . + . + . + . + . +# RDF export of group: Arm + . + "Arm_dor" . + . + . + . + . + . + . + . + . + . + "Arm_bet" . + . + . + . + . + . + . + . + . + . +# RDF export of group: Intervention + . + "Intervention_dor" . + . + "TID" . + . + . + "Intervention_bet" . + . + "BID" . + . + . + "Intervention_pla" . + . + "QD" . + . +# RDF export of group: Medication + . + "Medication_dor" . + . + "2" . + . + . + . + . + "Medication_bet" . + . + "0 . 5" . + . + . + . + . + "Medication_pla" . + . + . + . + . +# RDF export of group: Outcome + . + "Outcome_dor_8" . + . + "3 . 6" . + "hour 8" . + . + "Outcome_bet_8" . + . + "3 . 6" . + "hour 8" . + . + "Outcome_dor_2" . + . + "5 . 4" . + "hour 2" . + . + "Outcome_bet_2" . + . + "5 . 3" . + "hour 2" . + . + "AE_O" . + . + "most frequently reported" . + . + "AE_S" . + . + "most frequently reported" . + . + "AE_I" . + . + "the most frequently reported nonocular AEs" . + . + "AE_T_dor" . + . + "14 . 6" . + "the most frequently reported nonocular AEs" . + . + "AE_H" . + . + "the most frequently reported nonocular AEs" . + . + "AE_T_bet" . + . + "0 . 0" . + "the most frequently reported nonocular AEs" . +# RDF export of group: DiffBetweenGroups + . + "DiffBetweenGroups_iop_8" . + "0 . 02" . + "- 0 . 870 to 0 . 901" . + . + . + . + "DiffBetweenGroups_iop_2" . + "- 0 . 14" . + "- 0 . 959 to 0 . 685" . + . + . +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9663361_export.csv b/data/gl 9663361_export.csv new file mode 100644 index 0000000..2549309 --- /dev/null +++ b/data/gl 9663361_export.csv @@ -0,0 +1,508 @@ +# DocID, SentenceNr, SenTokenPos, DocTokenPos, SenCharOnset(incl), SenCharOffset(excl), DocCharOnset(incl), DocCharOffset(excl), Text +531, 1, 1, 1, 0, 4, 0, 4, "Clin" +531, 1, 2, 2, 5, 9, 5, 9, "Ther" +531, 1, 3, 3, 10, 11, 10, 11, "." +531, 2, 1, 4, 0, 4, 12, 16, "1998" +531, 2, 2, 5, 5, 8, 17, 20, "May" +531, 2, 3, 6, 9, 10, 21, 22, "-" +531, 2, 4, 7, 11, 14, 23, 26, "Jun" +531, 2, 5, 8, 15, 16, 27, 28, ";" +531, 2, 6, 9, 17, 19, 29, 31, "20" +531, 2, 7, 10, 20, 21, 32, 33, "(" +531, 2, 8, 11, 22, 23, 34, 35, "3" +531, 2, 9, 12, 24, 25, 36, 37, ")" +531, 2, 10, 13, 26, 27, 38, 39, ":" +531, 2, 11, 14, 28, 31, 40, 43, "454" +531, 2, 12, 15, 32, 33, 44, 45, "-" +531, 2, 13, 16, 34, 36, 46, 48, "66" +531, 2, 14, 17, 37, 38, 49, 50, "." +531, 3, 1, 18, 0, 10, 51, 61, "Comparison" +531, 3, 2, 19, 11, 13, 62, 64, "of" +531, 3, 3, 20, 14, 17, 65, 68, "the" +531, 3, 4, 21, 18, 26, 69, 77, "efficacy" +531, 3, 5, 22, 27, 30, 78, 81, "and" +531, 3, 6, 23, 31, 37, 82, 88, "safety" +531, 3, 7, 24, 38, 40, 89, 91, "of" +531, 3, 8, 25, 41, 42, 92, 93, "2" +531, 3, 9, 26, 43, 44, 94, 95, "%" +531, 3, 10, 27, 45, 56, 96, 107, "dorzolamide" +531, 3, 11, 28, 57, 60, 108, 111, "and" +531, 3, 12, 29, 61, 62, 112, 113, "0" +531, 3, 13, 30, 63, 64, 114, 115, "." +531, 3, 14, 31, 65, 66, 116, 117, "5" +531, 3, 15, 32, 67, 68, 118, 119, "%" +531, 3, 16, 33, 69, 78, 120, 129, "betaxolol" +531, 3, 17, 34, 79, 81, 130, 132, "in" +531, 3, 18, 35, 82, 85, 133, 136, "the" +531, 3, 19, 36, 86, 95, 137, 146, "treatment" +531, 3, 20, 37, 96, 98, 147, 149, "of" +531, 3, 21, 38, 99, 107, 150, 158, "elevated" +531, 3, 22, 39, 108, 119, 159, 170, "intraocular" +531, 3, 23, 40, 120, 128, 171, 179, "pressure" +531, 3, 24, 41, 129, 130, 180, 181, "." +531, 4, 1, 42, 0, 11, 182, 193, "Dorzolamide" +531, 4, 2, 43, 12, 22, 194, 204, "Comparison" +531, 4, 3, 44, 23, 28, 205, 210, "Study" +531, 4, 4, 45, 29, 34, 211, 216, "Group" +531, 4, 5, 46, 35, 36, 217, 218, "." +531, 5, 1, 47, 0, 4, 219, 223, "Rusk" +531, 5, 2, 48, 5, 6, 224, 225, "C" +531, 5, 3, 49, 7, 8, 226, 227, "(" +531, 5, 4, 50, 9, 10, 228, 229, "1" +531, 5, 5, 51, 11, 12, 230, 231, ")" +531, 5, 6, 52, 13, 14, 232, 233, "," +531, 5, 7, 53, 15, 21, 234, 240, "Sharpe" +531, 5, 8, 54, 22, 23, 241, 242, "E" +531, 5, 9, 55, 24, 25, 243, 244, "," +531, 5, 10, 56, 26, 34, 245, 253, "Laurence" +531, 5, 11, 57, 35, 36, 254, 255, "J" +531, 5, 12, 58, 37, 38, 256, 257, "," +531, 5, 13, 59, 39, 44, 258, 263, "Polis" +531, 5, 14, 60, 45, 46, 264, 265, "A" +531, 5, 15, 61, 47, 48, 266, 267, "," +531, 5, 16, 62, 49, 57, 268, 276, "Adamsons" +531, 5, 17, 63, 58, 59, 277, 278, "I" +531, 5, 18, 64, 60, 61, 279, 280, "." +531, 6, 1, 65, 0, 6, 281, 287, "Author" +531, 6, 2, 66, 7, 18, 288, 299, "information" +531, 6, 3, 67, 19, 20, 300, 301, ":" +531, 6, 4, 68, 21, 22, 302, 303, "(" +531, 6, 5, 69, 23, 24, 304, 305, "1" +531, 6, 6, 70, 25, 26, 306, 307, ")" +531, 6, 7, 71, 27, 32, 308, 313, "Merck" +531, 6, 8, 72, 33, 41, 314, 322, "Research" +531, 6, 9, 73, 42, 54, 323, 335, "Laboratories" +531, 6, 10, 74, 55, 56, 336, 337, "," +531, 6, 11, 75, 57, 61, 338, 342, "Blue" +531, 6, 12, 76, 62, 66, 343, 347, "Bell" +531, 6, 13, 77, 67, 68, 348, 349, "," +531, 6, 14, 78, 69, 81, 350, 362, "Pennsylvania" +531, 6, 15, 79, 82, 83, 363, 364, "," +531, 6, 16, 80, 84, 87, 365, 368, "USA" +531, 6, 17, 81, 88, 89, 369, 370, "." +531, 7, 1, 82, 0, 1, 371, 372, "A" +531, 7, 2, 83, 2, 13, 373, 384, "multicenter" +531, 7, 3, 84, 14, 15, 385, 386, "," +531, 7, 4, 85, 16, 24, 387, 395, "parallel" +531, 7, 5, 86, 25, 26, 396, 397, "-" +531, 7, 6, 87, 27, 33, 398, 404, "design" +531, 7, 7, 88, 34, 35, 405, 406, "," +531, 7, 8, 89, 36, 46, 407, 417, "randomized" +531, 7, 9, 90, 47, 48, 418, 419, "," +531, 7, 10, 91, 49, 55, 420, 426, "double" +531, 7, 11, 92, 56, 57, 427, 428, "-" +531, 7, 12, 93, 58, 64, 429, 435, "masked" +531, 7, 13, 94, 65, 70, 436, 441, "study" +531, 7, 14, 95, 71, 74, 442, 445, "was" +531, 7, 15, 96, 75, 84, 446, 455, "conducted" +531, 7, 16, 97, 85, 87, 456, 458, "to" +531, 7, 17, 98, 88, 95, 459, 466, "compare" +531, 7, 18, 99, 96, 99, 467, 470, "the" +531, 7, 19, 100, 100, 108, 471, 479, "efficacy" +531, 7, 20, 101, 109, 112, 480, 483, "and" +531, 7, 21, 102, 113, 119, 484, 490, "safety" +531, 7, 22, 103, 120, 122, 491, 493, "of" +531, 7, 23, 104, 123, 124, 494, 495, "2" +531, 7, 24, 105, 125, 126, 496, 497, "%" +531, 7, 25, 106, 127, 138, 498, 509, "dorzolamide" +531, 7, 26, 107, 139, 143, 510, 514, "with" +531, 7, 27, 108, 144, 149, 515, 520, "those" +531, 7, 28, 109, 150, 152, 521, 523, "of" +531, 7, 29, 110, 153, 154, 524, 525, "0" +531, 7, 30, 111, 155, 156, 526, 527, "." +531, 7, 31, 112, 157, 158, 528, 529, "5" +531, 7, 32, 113, 159, 160, 530, 531, "%" +531, 7, 33, 114, 161, 170, 532, 541, "betaxolol" +531, 7, 34, 115, 171, 173, 542, 544, "in" +531, 7, 35, 116, 174, 177, 545, 548, "the" +531, 7, 36, 117, 178, 187, 549, 558, "treatment" +531, 7, 37, 118, 188, 190, 559, 561, "of" +531, 7, 38, 119, 191, 199, 562, 570, "elevated" +531, 7, 39, 120, 200, 211, 571, 582, "intraocular" +531, 7, 40, 121, 212, 220, 583, 591, "pressure" +531, 7, 41, 122, 221, 222, 592, 593, "(" +531, 7, 42, 123, 223, 224, 594, 595, "i" +531, 7, 43, 124, 225, 226, 596, 597, "." +531, 7, 44, 125, 227, 228, 598, 599, "o" +531, 7, 45, 126, 229, 230, 600, 601, "." +531, 7, 46, 127, 231, 232, 602, 603, "p" +531, 7, 47, 128, 233, 234, 604, 605, ")" +531, 7, 48, 129, 235, 236, 606, 607, "." +531, 8, 1, 130, 0, 1, 608, 609, "A" +531, 8, 2, 131, 2, 7, 610, 615, "total" +531, 8, 3, 132, 8, 10, 616, 618, "of" +531, 8, 4, 133, 11, 14, 619, 622, "311" +531, 8, 5, 134, 15, 21, 623, 629, "adults" +531, 8, 6, 135, 22, 26, 630, 634, "with" +531, 8, 7, 136, 27, 33, 635, 641, "ocular" +531, 8, 8, 137, 34, 46, 642, 654, "hypertension" +531, 8, 9, 138, 47, 49, 655, 657, "or" +531, 8, 10, 139, 50, 54, 658, 662, "open" +531, 8, 11, 140, 55, 56, 663, 664, "-" +531, 8, 12, 141, 57, 62, 665, 670, "angle" +531, 8, 13, 142, 63, 71, 671, 679, "glaucoma" +531, 8, 14, 143, 72, 76, 680, 684, "were" +531, 8, 15, 144, 77, 85, 685, 693, "randomly" +531, 8, 16, 145, 86, 95, 694, 703, "allocated" +531, 8, 17, 146, 96, 98, 704, 706, "to" +531, 8, 18, 147, 99, 106, 707, 714, "receive" +531, 8, 19, 148, 107, 113, 715, 721, "either" +531, 8, 20, 149, 114, 115, 722, 723, "2" +531, 8, 21, 150, 116, 117, 724, 725, "%" +531, 8, 22, 151, 118, 129, 726, 737, "dorzolamide" +531, 8, 23, 152, 130, 142, 738, 750, "administered" +531, 8, 24, 153, 143, 152, 751, 760, "topically" +531, 8, 25, 154, 153, 156, 761, 764, "TID" +531, 8, 26, 155, 157, 159, 765, 767, "or" +531, 8, 27, 156, 160, 161, 768, 769, "0" +531, 8, 28, 157, 162, 163, 770, 771, "." +531, 8, 29, 158, 164, 165, 772, 773, "5" +531, 8, 30, 159, 166, 167, 774, 775, "%" +531, 8, 31, 160, 168, 177, 776, 785, "betaxolol" +531, 8, 32, 161, 178, 190, 786, 798, "administered" +531, 8, 33, 162, 191, 200, 799, 808, "topically" +531, 8, 34, 163, 201, 204, 809, 812, "BID" +531, 8, 35, 164, 205, 209, 813, 817, "plus" +531, 8, 36, 165, 210, 217, 818, 825, "placebo" +531, 8, 37, 166, 218, 230, 826, 838, "administered" +531, 8, 38, 167, 231, 240, 839, 848, "topically" +531, 8, 39, 168, 241, 243, 849, 851, "QD" +531, 8, 40, 169, 244, 247, 852, 855, "for" +531, 8, 41, 170, 248, 250, 856, 858, "12" +531, 8, 42, 171, 251, 256, 859, 864, "weeks" +531, 8, 43, 172, 257, 258, 865, 866, "." +531, 9, 1, 173, 0, 5, 867, 872, "After" +531, 9, 2, 174, 6, 9, 873, 876, "the" +531, 9, 3, 175, 10, 17, 877, 884, "washout" +531, 9, 4, 176, 18, 20, 885, 887, "of" +531, 9, 5, 177, 21, 29, 888, 896, "previous" +531, 9, 6, 178, 30, 36, 897, 903, "ocular" +531, 9, 7, 179, 37, 48, 904, 915, "hypotensive" +531, 9, 8, 180, 49, 54, 916, 921, "drugs" +531, 9, 9, 181, 55, 56, 922, 923, "," +531, 9, 10, 182, 57, 65, 924, 932, "patients" +531, 9, 11, 183, 66, 70, 933, 937, "with" +531, 9, 12, 184, 71, 74, 938, 941, "IOP" +531, 9, 13, 185, 75, 76, 942, 943, ">" +531, 9, 14, 186, 77, 79, 944, 946, "or" +531, 9, 15, 187, 80, 81, 947, 948, "=" +531, 9, 16, 188, 82, 84, 949, 951, "23" +531, 9, 17, 189, 85, 87, 952, 954, "mm" +531, 9, 18, 190, 88, 90, 955, 957, "Hg" +531, 9, 19, 191, 91, 93, 958, 960, "in" +531, 9, 20, 192, 94, 96, 961, 963, "at" +531, 9, 21, 193, 97, 102, 964, 969, "least" +531, 9, 22, 194, 103, 106, 970, 973, "one" +531, 9, 23, 195, 107, 110, 974, 977, "eye" +531, 9, 24, 196, 111, 113, 978, 980, "at" +531, 9, 25, 197, 114, 116, 981, 983, "10" +531, 9, 26, 198, 117, 119, 984, 986, "AM" +531, 9, 27, 199, 120, 122, 987, 989, "or" +531, 9, 28, 200, 123, 124, 990, 991, "4" +531, 9, 29, 201, 125, 127, 992, 994, "PM" +531, 9, 30, 202, 128, 130, 995, 997, "on" +531, 9, 31, 203, 131, 136, 998, 1003, "study" +531, 9, 32, 204, 137, 140, 1004, 1007, "day" +531, 9, 33, 205, 141, 142, 1008, 1009, "1" +531, 9, 34, 206, 143, 147, 1010, 1014, "were" +531, 9, 35, 207, 148, 156, 1015, 1023, "randomly" +531, 9, 36, 208, 157, 166, 1024, 1033, "allocated" +531, 9, 37, 209, 167, 169, 1034, 1036, "to" +531, 9, 38, 210, 170, 177, 1037, 1044, "receive" +531, 9, 39, 211, 178, 181, 1045, 1048, "one" +531, 9, 40, 212, 182, 184, 1049, 1051, "of" +531, 9, 41, 213, 185, 188, 1052, 1055, "the" +531, 9, 42, 214, 189, 194, 1056, 1061, "study" +531, 9, 43, 215, 195, 205, 1062, 1072, "treatments" +531, 9, 44, 216, 206, 207, 1073, 1074, "." +531, 10, 1, 217, 0, 10, 1075, 1085, "Throughout" +531, 10, 2, 218, 11, 14, 1086, 1089, "the" +531, 10, 3, 219, 15, 20, 1090, 1095, "study" +531, 10, 4, 220, 21, 22, 1096, 1097, "," +531, 10, 5, 221, 23, 26, 1098, 1101, "IOP" +531, 10, 6, 222, 27, 30, 1102, 1105, "was" +531, 10, 7, 223, 31, 39, 1106, 1114, "measured" +531, 10, 8, 224, 40, 41, 1115, 1116, "2" +531, 10, 9, 225, 42, 45, 1117, 1120, "and" +531, 10, 10, 226, 46, 47, 1121, 1122, "8" +531, 10, 11, 227, 48, 53, 1123, 1128, "hours" +531, 10, 12, 228, 54, 59, 1129, 1134, "after" +531, 10, 13, 229, 60, 72, 1135, 1147, "instillation" +531, 10, 14, 230, 73, 75, 1148, 1150, "of" +531, 10, 15, 231, 76, 81, 1151, 1156, "study" +531, 10, 16, 232, 82, 92, 1157, 1167, "medication" +531, 10, 17, 233, 93, 96, 1168, 1171, "for" +531, 10, 18, 234, 97, 100, 1172, 1175, "the" +531, 10, 19, 235, 101, 108, 1176, 1183, "morning" +531, 10, 20, 236, 109, 113, 1184, 1188, "peak" +531, 10, 21, 237, 114, 120, 1189, 1195, "effect" +531, 10, 22, 238, 121, 122, 1196, 1197, "(" +531, 10, 23, 239, 123, 127, 1198, 1202, "hour" +531, 10, 24, 240, 128, 129, 1203, 1204, "2" +531, 10, 25, 241, 130, 131, 1205, 1206, ")" +531, 10, 26, 242, 132, 135, 1207, 1210, "and" +531, 10, 27, 243, 136, 145, 1211, 1220, "afternoon" +531, 10, 28, 244, 146, 152, 1221, 1227, "trough" +531, 10, 29, 245, 153, 159, 1228, 1234, "effect" +531, 10, 30, 246, 160, 161, 1235, 1236, "(" +531, 10, 31, 247, 162, 166, 1237, 1241, "hour" +531, 10, 32, 248, 167, 168, 1242, 1243, "8" +531, 10, 33, 249, 169, 170, 1244, 1245, ")" +531, 10, 34, 250, 171, 172, 1246, 1247, "." +531, 11, 1, 251, 0, 5, 1248, 1253, "After" +531, 11, 2, 252, 6, 8, 1254, 1256, "12" +531, 11, 3, 253, 9, 14, 1257, 1262, "weeks" +531, 11, 4, 254, 15, 17, 1263, 1265, "of" +531, 11, 5, 255, 18, 25, 1266, 1273, "therapy" +531, 11, 6, 256, 26, 27, 1274, 1275, "," +531, 11, 7, 257, 28, 31, 1276, 1279, "the" +531, 11, 8, 258, 32, 36, 1280, 1284, "mean" +531, 11, 9, 259, 37, 43, 1285, 1291, "change" +531, 11, 10, 260, 44, 46, 1292, 1294, "in" +531, 11, 11, 261, 47, 50, 1295, 1298, "IOP" +531, 11, 12, 262, 51, 54, 1299, 1302, "was" +531, 11, 13, 263, 55, 58, 1303, 1306, "not" +531, 11, 14, 264, 59, 72, 1307, 1320, "significantly" +531, 11, 15, 265, 73, 82, 1321, 1330, "different" +531, 11, 16, 266, 83, 90, 1331, 1338, "between" +531, 11, 17, 267, 91, 94, 1339, 1342, "the" +531, 11, 18, 268, 95, 106, 1343, 1354, "dorzolamide" +531, 11, 19, 269, 107, 110, 1355, 1358, "and" +531, 11, 20, 270, 111, 120, 1359, 1368, "betaxolol" +531, 11, 21, 271, 121, 130, 1369, 1378, "treatment" +531, 11, 22, 272, 131, 137, 1379, 1385, "groups" +531, 11, 23, 273, 138, 140, 1386, 1388, "at" +531, 11, 24, 274, 141, 145, 1389, 1393, "hour" +531, 11, 25, 275, 146, 147, 1394, 1395, "8" +531, 11, 26, 276, 148, 149, 1396, 1397, "(" +531, 11, 27, 277, 150, 151, 1398, 1399, "-" +531, 11, 28, 278, 152, 153, 1400, 1401, "3" +531, 11, 29, 279, 154, 155, 1402, 1403, "." +531, 11, 30, 280, 156, 157, 1404, 1405, "6" +531, 11, 31, 281, 158, 160, 1406, 1408, "mm" +531, 11, 32, 282, 161, 163, 1409, 1411, "Hg" +531, 11, 33, 283, 164, 166, 1412, 1414, "in" +531, 11, 34, 284, 167, 171, 1415, 1419, "both" +531, 11, 35, 285, 172, 178, 1420, 1426, "groups" +531, 11, 36, 286, 179, 180, 1427, 1428, ")" +531, 11, 37, 287, 181, 183, 1429, 1431, "or" +531, 11, 38, 288, 184, 188, 1432, 1436, "hour" +531, 11, 39, 289, 189, 190, 1437, 1438, "2" +531, 11, 40, 290, 191, 192, 1439, 1440, "(" +531, 11, 41, 291, 193, 194, 1441, 1442, "-" +531, 11, 42, 292, 195, 196, 1443, 1444, "5" +531, 11, 43, 293, 197, 198, 1445, 1446, "." +531, 11, 44, 294, 199, 200, 1447, 1448, "4" +531, 11, 45, 295, 201, 203, 1449, 1451, "vs" +531, 11, 46, 296, 204, 205, 1452, 1453, "-" +531, 11, 47, 297, 206, 207, 1454, 1455, "5" +531, 11, 48, 298, 208, 209, 1456, 1457, "." +531, 11, 49, 299, 210, 211, 1458, 1459, "3" +531, 11, 50, 300, 212, 214, 1460, 1462, "mm" +531, 11, 51, 301, 215, 217, 1463, 1465, "Hg" +531, 11, 52, 302, 218, 219, 1466, 1467, "," +531, 11, 53, 303, 220, 232, 1468, 1480, "respectively" +531, 11, 54, 304, 233, 234, 1481, 1482, ")" +531, 11, 55, 305, 235, 236, 1483, 1484, "." +531, 12, 1, 306, 0, 3, 1485, 1488, "The" +531, 12, 2, 307, 4, 15, 1489, 1500, "differences" +531, 12, 3, 308, 16, 23, 1501, 1508, "between" +531, 12, 4, 309, 24, 34, 1509, 1519, "treatments" +531, 12, 5, 310, 35, 36, 1520, 1521, "(" +531, 12, 6, 311, 37, 40, 1522, 1525, "and" +531, 12, 7, 312, 41, 43, 1526, 1528, "95" +531, 12, 8, 313, 44, 45, 1529, 1530, "%" +531, 12, 9, 314, 46, 49, 1531, 1534, "CIs" +531, 12, 10, 315, 50, 60, 1535, 1545, "associated" +531, 12, 11, 316, 61, 65, 1546, 1550, "with" +531, 12, 12, 317, 66, 71, 1551, 1556, "these" +531, 12, 13, 318, 72, 83, 1557, 1568, "differences" +531, 12, 14, 319, 84, 85, 1569, 1570, ")" +531, 12, 15, 320, 86, 88, 1571, 1573, "in" +531, 12, 16, 321, 89, 93, 1574, 1578, "mean" +531, 12, 17, 322, 94, 97, 1579, 1582, "IOP" +531, 12, 18, 323, 98, 105, 1583, 1590, "changes" +531, 12, 19, 324, 106, 110, 1591, 1595, "from" +531, 12, 20, 325, 111, 119, 1596, 1604, "baseline" +531, 12, 21, 326, 120, 124, 1605, 1609, "were" +531, 12, 22, 327, 125, 126, 1610, 1611, "0" +531, 12, 23, 328, 127, 128, 1612, 1613, "." +531, 12, 24, 329, 129, 131, 1614, 1616, "02" +531, 12, 25, 330, 132, 134, 1617, 1619, "mm" +531, 12, 26, 331, 135, 137, 1620, 1622, "Hg" +531, 12, 27, 332, 138, 139, 1623, 1624, "(" +531, 12, 28, 333, 140, 141, 1625, 1626, "-" +531, 12, 29, 334, 142, 143, 1627, 1628, "0" +531, 12, 30, 335, 144, 145, 1629, 1630, "." +531, 12, 31, 336, 146, 149, 1631, 1634, "870" +531, 12, 32, 337, 150, 152, 1635, 1637, "to" +531, 12, 33, 338, 153, 154, 1638, 1639, "0" +531, 12, 34, 339, 155, 156, 1640, 1641, "." +531, 12, 35, 340, 157, 160, 1642, 1645, "901" +531, 12, 36, 341, 161, 162, 1646, 1647, ")" +531, 12, 37, 342, 163, 166, 1648, 1651, "for" +531, 12, 38, 343, 167, 171, 1652, 1656, "hour" +531, 12, 39, 344, 172, 173, 1657, 1658, "8" +531, 12, 40, 345, 174, 177, 1659, 1662, "and" +531, 12, 41, 346, 178, 179, 1663, 1664, "-" +531, 12, 42, 347, 180, 181, 1665, 1666, "0" +531, 12, 43, 348, 182, 183, 1667, 1668, "." +531, 12, 44, 349, 184, 186, 1669, 1671, "14" +531, 12, 45, 350, 187, 189, 1672, 1674, "mm" +531, 12, 46, 351, 190, 192, 1675, 1677, "Hg" +531, 12, 47, 352, 193, 194, 1678, 1679, "(" +531, 12, 48, 353, 195, 196, 1680, 1681, "-" +531, 12, 49, 354, 197, 198, 1682, 1683, "0" +531, 12, 50, 355, 199, 200, 1684, 1685, "." +531, 12, 51, 356, 201, 204, 1686, 1689, "959" +531, 12, 52, 357, 205, 207, 1690, 1692, "to" +531, 12, 53, 358, 208, 209, 1693, 1694, "0" +531, 12, 54, 359, 210, 211, 1695, 1696, "." +531, 12, 55, 360, 212, 215, 1697, 1700, "685" +531, 12, 56, 361, 216, 217, 1701, 1702, ")" +531, 12, 57, 362, 218, 221, 1703, 1706, "for" +531, 12, 58, 363, 222, 226, 1707, 1711, "hour" +531, 12, 59, 364, 227, 228, 1712, 1713, "2" +531, 12, 60, 365, 229, 230, 1714, 1715, "." +531, 13, 1, 366, 0, 3, 1716, 1719, "The" +531, 13, 2, 367, 4, 10, 1720, 1726, "ocular" +531, 13, 3, 368, 11, 18, 1727, 1734, "adverse" +531, 13, 4, 369, 19, 29, 1735, 1745, "experience" +531, 13, 5, 370, 30, 31, 1746, 1747, "(" +531, 13, 6, 371, 32, 34, 1748, 1750, "AE" +531, 13, 7, 372, 35, 36, 1751, 1752, ")" +531, 13, 8, 373, 37, 41, 1753, 1757, "most" +531, 13, 9, 374, 42, 52, 1758, 1768, "frequently" +531, 13, 10, 375, 53, 61, 1769, 1777, "reported" +531, 13, 11, 376, 62, 64, 1778, 1780, "by" +531, 13, 12, 377, 65, 73, 1781, 1789, "patients" +531, 13, 13, 378, 74, 77, 1790, 1793, "was" +531, 13, 14, 379, 78, 84, 1794, 1800, "ocular" +531, 13, 15, 380, 85, 92, 1801, 1808, "burning" +531, 13, 16, 381, 93, 96, 1809, 1812, "and" +531, 13, 17, 382, 97, 98, 1813, 1814, "/" +531, 13, 18, 383, 99, 101, 1815, 1817, "or" +531, 13, 19, 384, 102, 110, 1818, 1826, "stinging" +531, 13, 20, 385, 111, 112, 1827, 1828, "," +531, 13, 21, 386, 113, 116, 1829, 1832, "and" +531, 13, 22, 387, 117, 120, 1833, 1836, "the" +531, 13, 23, 388, 121, 125, 1837, 1841, "most" +531, 13, 24, 389, 126, 136, 1842, 1852, "frequently" +531, 13, 25, 390, 137, 145, 1853, 1861, "reported" +531, 13, 26, 391, 146, 155, 1862, 1871, "nonocular" +531, 13, 27, 392, 156, 159, 1872, 1875, "AEs" +531, 13, 28, 393, 160, 164, 1876, 1880, "were" +531, 13, 29, 394, 165, 170, 1881, 1886, "taste" +531, 13, 30, 395, 171, 181, 1887, 1897, "perversion" +531, 13, 31, 396, 182, 183, 1898, 1899, "," +531, 13, 32, 397, 184, 189, 1900, 1905, "upper" +531, 13, 33, 398, 190, 201, 1906, 1917, "respiratory" +531, 13, 34, 399, 202, 211, 1918, 1927, "infection" +531, 13, 35, 400, 212, 213, 1928, 1929, "," +531, 13, 36, 401, 214, 217, 1930, 1933, "and" +531, 13, 37, 402, 218, 226, 1934, 1942, "headache" +531, 13, 38, 403, 227, 228, 1943, 1944, "." +531, 14, 1, 404, 0, 4, 1945, 1949, "Only" +531, 14, 2, 405, 5, 8, 1950, 1953, "the" +531, 14, 3, 406, 9, 18, 1954, 1963, "incidence" +531, 14, 4, 407, 19, 21, 1964, 1966, "of" +531, 14, 5, 408, 22, 27, 1967, 1972, "taste" +531, 14, 6, 409, 28, 38, 1973, 1983, "perversion" +531, 14, 7, 410, 39, 42, 1984, 1987, "was" +531, 14, 8, 411, 43, 56, 1988, 2001, "significantly" +531, 14, 9, 412, 57, 66, 2002, 2011, "different" +531, 14, 10, 413, 67, 74, 2012, 2019, "between" +531, 14, 11, 414, 75, 84, 2020, 2029, "treatment" +531, 14, 12, 415, 85, 91, 2030, 2036, "groups" +531, 14, 13, 416, 92, 93, 2037, 2038, "(" +531, 14, 14, 417, 94, 96, 2039, 2041, "14" +531, 14, 15, 418, 97, 98, 2042, 2043, "." +531, 14, 16, 419, 99, 100, 2044, 2045, "6" +531, 14, 17, 420, 101, 102, 2046, 2047, "%" +531, 14, 18, 421, 103, 106, 2048, 2051, "for" +531, 14, 19, 422, 107, 110, 2052, 2055, "the" +531, 14, 20, 423, 111, 122, 2056, 2067, "dorzolamide" +531, 14, 21, 424, 123, 128, 2068, 2073, "group" +531, 14, 22, 425, 129, 132, 2074, 2077, "and" +531, 14, 23, 426, 133, 134, 2078, 2079, "0" +531, 14, 24, 427, 135, 136, 2080, 2081, "." +531, 14, 25, 428, 137, 138, 2082, 2083, "0" +531, 14, 26, 429, 139, 140, 2084, 2085, "%" +531, 14, 27, 430, 141, 144, 2086, 2089, "for" +531, 14, 28, 431, 145, 148, 2090, 2093, "the" +531, 14, 29, 432, 149, 158, 2094, 2103, "betaxolol" +531, 14, 30, 433, 159, 164, 2104, 2109, "group" +531, 14, 31, 434, 165, 166, 2110, 2111, ")" +531, 14, 32, 435, 167, 168, 2112, 2113, "." +531, 15, 1, 436, 0, 3, 2114, 2117, "Two" +531, 15, 2, 437, 4, 11, 2118, 2125, "percent" +531, 15, 3, 438, 12, 14, 2126, 2128, "of" +531, 15, 4, 439, 15, 23, 2129, 2137, "patients" +531, 15, 5, 440, 24, 26, 2138, 2140, "in" +531, 15, 6, 441, 27, 31, 2141, 2145, "each" +531, 15, 7, 442, 32, 41, 2146, 2155, "treatment" +531, 15, 8, 443, 42, 47, 2156, 2161, "group" +531, 15, 9, 444, 48, 60, 2162, 2174, "discontinued" +531, 15, 10, 445, 61, 64, 2175, 2178, "the" +531, 15, 11, 446, 65, 70, 2179, 2184, "study" +531, 15, 12, 447, 71, 74, 2185, 2188, "due" +531, 15, 13, 448, 75, 77, 2189, 2191, "to" +531, 15, 14, 449, 78, 81, 2192, 2195, "AEs" +531, 15, 15, 450, 82, 83, 2196, 2197, "." +531, 16, 1, 451, 0, 4, 2198, 2202, "This" +531, 16, 2, 452, 5, 10, 2203, 2208, "study" +531, 16, 3, 453, 11, 20, 2209, 2218, "confirmed" +531, 16, 4, 454, 21, 24, 2219, 2222, "the" +531, 16, 5, 455, 25, 32, 2223, 2230, "similar" +531, 16, 6, 456, 33, 36, 2231, 2234, "IOP" +531, 16, 7, 457, 37, 38, 2235, 2236, "-" +531, 16, 8, 458, 39, 47, 2237, 2245, "lowering" +531, 16, 9, 459, 48, 54, 2246, 2252, "effect" +531, 16, 10, 460, 55, 57, 2253, 2255, "of" +531, 16, 11, 461, 58, 59, 2256, 2257, "2" +531, 16, 12, 462, 60, 61, 2258, 2259, "%" +531, 16, 13, 463, 62, 73, 2260, 2271, "dorzolamide" +531, 16, 14, 464, 74, 77, 2272, 2275, "and" +531, 16, 15, 465, 78, 79, 2276, 2277, "0" +531, 16, 16, 466, 80, 81, 2278, 2279, "." +531, 16, 17, 467, 82, 83, 2280, 2281, "5" +531, 16, 18, 468, 84, 85, 2282, 2283, "%" +531, 16, 19, 469, 86, 95, 2284, 2293, "betaxolol" +531, 16, 20, 470, 96, 97, 2294, 2295, "." +531, 17, 1, 471, 0, 4, 2296, 2300, "Both" +531, 17, 2, 472, 5, 15, 2301, 2311, "treatments" +531, 17, 3, 473, 16, 20, 2312, 2316, "were" +531, 17, 4, 474, 21, 30, 2317, 2326, "generally" +531, 17, 5, 475, 31, 35, 2327, 2331, "well" +531, 17, 6, 476, 36, 45, 2332, 2341, "tolerated" +531, 17, 7, 477, 46, 47, 2342, 2343, "," +531, 17, 8, 478, 48, 51, 2344, 2347, "and" +531, 17, 9, 479, 52, 57, 2348, 2353, "their" +531, 17, 10, 480, 58, 64, 2354, 2360, "safety" +531, 17, 11, 481, 65, 73, 2361, 2369, "profiles" +531, 17, 12, 482, 74, 78, 2370, 2374, "were" +531, 17, 13, 483, 79, 86, 2375, 2382, "similar" +531, 17, 14, 484, 87, 88, 2383, 2384, "." +531, 18, 1, 485, 0, 3, 2385, 2388, "DOI" +531, 18, 2, 486, 4, 5, 2389, 2390, ":" +531, 18, 3, 487, 6, 8, 2391, 2393, "10" +531, 18, 4, 488, 9, 10, 2394, 2395, "." +531, 18, 5, 489, 11, 15, 2396, 2400, "1016" +531, 18, 6, 490, 16, 17, 2401, 2402, "/" +531, 18, 7, 491, 18, 23, 2403, 2408, "s0149" +531, 18, 8, 492, 24, 25, 2409, 2410, "-" +531, 18, 9, 493, 26, 30, 2411, 2415, "2918" +531, 18, 10, 494, 31, 32, 2416, 2417, "(" +531, 18, 11, 495, 33, 35, 2418, 2420, "98" +531, 18, 12, 496, 36, 37, 2421, 2422, ")" +531, 18, 13, 497, 38, 43, 2423, 2428, "80055" +531, 18, 14, 498, 44, 45, 2429, 2430, "-" +531, 18, 15, 499, 46, 47, 2431, 2432, "6" +531, 18, 16, 500, 48, 52, 2433, 2437, "PMID" +531, 18, 17, 501, 53, 54, 2438, 2439, ":" +531, 18, 18, 502, 55, 62, 2440, 2447, "9663361" +531, 18, 19, 503, 63, 64, 2448, 2449, "[" +531, 18, 20, 504, 65, 72, 2450, 2457, "Indexed" +531, 18, 21, 505, 73, 76, 2458, 2461, "for" +531, 18, 22, 506, 77, 84, 2462, 2469, "MEDLINE" +531, 18, 23, 507, 85, 86, 2470, 2471, "]" diff --git a/data/gl 9663361_jshahinitiran.annodb b/data/gl 9663361_jshahinitiran.annodb new file mode 100644 index 0000000..32755d7 --- /dev/null +++ b/data/gl 9663361_jshahinitiran.annodb @@ -0,0 +1,73 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +91485, Journal, 0, 9, "Clin Ther", "", +91486, PublicationYear, 12, 16, "1998", "", +91487, Title, 51, 181, "Comparison of the efficacy and safety of 2 % dorzolamide and 0 . 5 % betaxolol in the treatment of elevated intraocular pressure .", "", +91488, Dorzolamide, 182, 193, "Dorzolamide", "", +91489, Author, 219, 225, "Rusk C", "", +91490, Author, 234, 242, "Sharpe E", "", +91491, Author, 245, 255, "Laurence J", "", +91492, Author, 258, 265, "Polis A", "", +91493, Author, 268, 278, "Adamsons I", "", +91494, USA, 365, 368, "USA", "", +91495, Multicenter, 373, 384, "multicenter", "", +91496, Parallel, 387, 404, "parallel - design", "", +91497, Randomized, 407, 417, "randomized", "", +91498, DoubleBlind, 420, 435, "double - masked", "", +91499, DoseValue, 494, 495, "2", "", +91501, Dorzolamide, 498, 509, "dorzolamide", "", +91500, DoseValue, 524, 529, "0 . 5", "", +91502, Betaxolol, 532, 541, "betaxolol", "", +91504, DisorderOrSyndrome, 562, 591, "elevated intraocular pressure", "", +91503, IOP, 571, 591, "intraocular pressure", "", +91505, NumberPatientsCT, 619, 622, "311", "", +91506, OcularHypertension, 635, 654, "ocular hypertension", "", +91507, OpenAngleGlaucoma, 658, 679, "open - angle glaucoma", "", +91508, Randomized, 685, 693, "randomly", "", +91509, DoseValue, 722, 723, "2", "", +91511, Dorzolamide, 726, 737, "dorzolamide", "", +91513, Frequency, 761, 764, "TID", "", +91510, DoseValue, 768, 773, "0 . 5", "", +91512, Betaxolol, 776, 785, "betaxolol", "", +91514, Frequency, 809, 812, "BID", "", +91515, Placebo, 818, 825, "placebo", "", +91516, Frequency, 849, 851, "QD", "", +91517, Duration, 856, 864, "12 weeks", "", +91518, IOP, 938, 941, "IOP", "", +91521, Precondition, 938, 1009, "IOP > or = 23 mm Hg in at least one eye at 10 AM or 4 PM on study day 1", "", +91519, mmHg, 952, 957, "mm Hg", "", +91522, Randomized, 1015, 1023, "randomly", "", +91523, IOP, 1098, 1101, "IOP", "", +91524, Peak_IOP, 1184, 1188, "peak", "", +91525, Trough_IOP, 1221, 1227, "trough", "", +91526, TimePoint, 1254, 1262, "12 weeks", "", +91527, Mean, 1280, 1284, "mean", "", +91528, IOP, 1295, 1298, "IOP", "", +91529, Dorzolamide, 1343, 1354, "dorzolamide", "", +91530, Betaxolol, 1359, 1368, "betaxolol", "", +91531, Reduction, 1400, 1405, "3 . 6", "", +91534, mmHg, 1406, 1411, "mm Hg", "", +91532, Reduction, 1443, 1448, "5 . 4", "", +91533, Reduction, 1454, 1459, "5 . 3", "", +91535, mmHg, 1460, 1465, "mm Hg", "", +91536, ConfIntervalDiff, 1526, 1534, "95 % CIs", "", +91537, Mean, 1574, 1578, "mean", "", +91538, IOP, 1579, 1582, "IOP", "", +91539, DiffGroupAbsValue, 1610, 1616, "0 . 02", "", +91541, mmHg, 1617, 1622, "mm Hg", "", +91540, DiffGroupAbsValue, 1665, 1671, "0 . 14", "", +91542, mmHg, 1672, 1677, "mm Hg", "", +91544, Stinging, 1818, 1826, "stinging", "", +91547, Headache, 1934, 1942, "headache", "", +91549, PercentageAffected, 2039, 2045, "14 . 6", "", +91551, Dorzolamide, 2056, 2067, "dorzolamide", "", +91550, PercentageAffected, 2078, 2083, "0 . 0", "", +91552, Betaxolol, 2094, 2103, "betaxolol", "", +91553, RelNumPatientsLeftCT, 2114, 2117, "Two", "", +91559, ConclusionComment, 2198, 2295, "This study confirmed the similar IOP - lowering effect of 2 % dorzolamide and 0 . 5 % betaxolol .", "", +91554, IOP, 2231, 2234, "IOP", "", +91555, DoseValue, 2256, 2257, "2", "", +91557, Dorzolamide, 2260, 2271, "dorzolamide", "", +91556, DoseValue, 2276, 2281, "0 . 5", "", +91558, Betaxolol, 2284, 2293, "betaxolol", "", +91560, ConclusionComment, 2296, 2384, "Both treatments were generally well tolerated , and their safety profiles were similar .", "", +91561, PMID, 2440, 2447, "9663361", "", diff --git a/data/gl 9663361_jshahinitiran.n-triples b/data/gl 9663361_jshahinitiran.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9663361_jshahinitiran.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/data/gl 9663361_tstrakeljahn.annodb b/data/gl 9663361_tstrakeljahn.annodb new file mode 100644 index 0000000..b4f4288 --- /dev/null +++ b/data/gl 9663361_tstrakeljahn.annodb @@ -0,0 +1,93 @@ +# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances +88377, Journal, 0, 9, "Clin Ther", "", +88382, PublicationYear, 12, 16, "1998", "", +88390, Title, 51, 181, "Comparison of the efficacy and safety of 2 % dorzolamide and 0 . 5 % betaxolol in the treatment of elevated intraocular pressure .", "", +88386, DoseValue, 92, 93, "2", "", +88388, Percentage, 94, 95, "%", "", +88383, Dorzolamide, 96, 107, "dorzolamide", "", +88387, DoseValue, 112, 117, "0 . 5", "", +88389, Percentage, 118, 119, "%", "", +88384, Betaxolol, 120, 129, "betaxolol", "", +88385, IOP, 159, 179, "intraocular pressure", "", +88391, Dorzolamide, 182, 193, "Dorzolamide", "", +88392, Author, 219, 225, "Rusk C", "", +88393, Author, 234, 242, "Sharpe E", "", +88394, Author, 245, 255, "Laurence J", "", +88395, Author, 258, 265, "Polis A", "", +88396, Author, 268, 278, "Adamsons I", "", +88397, Country, 365, 368, "USA", "", +88398, Multicenter, 373, 384, "multicenter", "", +88399, Parallel, 387, 395, "parallel", "", +88400, Randomized, 407, 417, "randomized", "", +88401, DoubleBlind, 420, 435, "double - masked", "", +88410, ObjectiveDescription, 459, 607, "compare the efficacy and safety of 2 % dorzolamide with those of 0 . 5 % betaxolol in the treatment of elevated intraocular pressure ( i . o . p ) .", "", +88406, DoseValue, 494, 495, "2", "", +88408, Percentage, 496, 497, "%", "", +88402, Dorzolamide, 498, 509, "dorzolamide", "", +88407, DoseValue, 524, 529, "0 . 5", "", +88409, Percentage, 530, 531, "%", "", +88403, Betaxolol, 532, 541, "betaxolol", "", +88404, IOP, 571, 591, "intraocular pressure", "", +88405, IOP, 594, 603, "i . o . p", "", +88411, NumberPatientsCT, 619, 622, "311", "", +88412, OcularHypertension, 635, 654, "ocular hypertension", "", +88413, OpenAngleGlaucoma, 658, 679, "open - angle glaucoma", "", +88414, DoseValue, 722, 723, "2", "", +88416, Percentage, 724, 725, "%", "", +88418, Dorzolamide, 726, 737, "dorzolamide", "", +88420, Frequency, 761, 764, "TID", "", +88415, DoseValue, 768, 773, "0 . 5", "", +88417, Percentage, 774, 775, "%", "", +88419, Betaxolol, 776, 785, "betaxolol", "", +88421, Frequency, 809, 812, "BID", "", +88422, Placebo, 818, 825, "placebo", "", +88423, Frequency, 849, 851, "QD", "quaque die - once daily", +88429, Precondition, 867, 1009, "After the washout of previous ocular hypotensive drugs , patients with IOP > or = 23 mm Hg in at least one eye at 10 AM or 4 PM on study day 1", "", +88424, IOP, 938, 941, "IOP", "", +88425, mmHg, 952, 957, "mm Hg", "", +88426, TimePoint, 981, 986, "10 AM", "", +88427, TimePoint, 990, 994, "4 PM", "", +88428, TimePoint, 1004, 1009, "day 1", "", +88430, IOP, 1098, 1101, "IOP", "", +88431, Morning, 1176, 1183, "morning", "", +88438, Peak_IOP, 1184, 1195, "peak effect", "", +88443, TimePoint, 1198, 1204, "hour 2", "", +88437, Trough_IOP, 1221, 1234, "trough effect", "", +88439, TimePoint, 1237, 1243, "hour 8", "", +88432, Duration, 1254, 1262, "12 weeks", "", +88433, Mean, 1280, 1284, "mean", "", +88434, IOP, 1295, 1298, "IOP", "", +88435, Dorzolamide, 1343, 1354, "dorzolamide", "", +88436, Betaxolol, 1359, 1368, "betaxolol", "", +88440, TimePoint, 1389, 1395, "hour 8", "", +88441, Reduction, 1400, 1405, "3 . 6", "", +88442, mmHg, 1406, 1411, "mm Hg", "", +88444, TimePoint, 1432, 1438, "hour 2", "", +88445, Reduction, 1443, 1448, "5 . 4", "", +88446, Reduction, 1454, 1459, "5 . 3", "", +88447, mmHg, 1460, 1465, "mm Hg", "", +88448, Mean, 1574, 1578, "mean", "", +88449, IOP, 1579, 1582, "IOP", "", +88450, DiffGroupAbsValue, 1610, 1616, "0 . 02", "", +88452, mmHg, 1617, 1622, "mm Hg", "", +88456, ConfIntervalDiff, 1625, 1645, "- 0 . 870 to 0 . 901", "", +88454, TimePoint, 1652, 1658, "hour 8", "", +88451, DiffGroupAbsValue, 1665, 1671, "0 . 14", "", +88453, mmHg, 1672, 1677, "mm Hg", "", +88457, ConfIntervalDiff, 1680, 1700, "- 0 . 959 to 0 . 685", "", +88455, TimePoint, 1707, 1713, "hour 2", "", +88463, ObservedResult, 1716, 1944, "The ocular adverse experience ( AE ) most frequently reported by patients was ocular burning and / or stinging , and the most frequently reported nonocular AEs were taste perversion , upper respiratory infection , and headache .", "", +88458, Stinging, 1818, 1826, "stinging", "", +88465, PercentageAffected, 2039, 2045, "14 . 6", "", +88467, Dorzolamide, 2056, 2067, "dorzolamide", "", +88466, PercentageAffected, 2078, 2083, "0 . 0", "", +88468, Betaxolol, 2094, 2103, "betaxolol", "", +88469, RelNumPatientsLeftCT, 2114, 2117, "Two", "", +88475, ConclusionComment, 2198, 2295, "This study confirmed the similar IOP - lowering effect of 2 % dorzolamide and 0 . 5 % betaxolol .", "", +88470, IOP, 2231, 2234, "IOP", "", +88471, DoseValue, 2256, 2257, "2", "", +88473, Percentage, 2258, 2259, "%", "", +88472, DoseValue, 2276, 2281, "0 . 5", "", +88474, Percentage, 2282, 2283, "%", "", +88476, ConclusionComment, 2296, 2384, "Both treatments were generally well tolerated , and their safety profiles were similar .", "", +88477, PMID, 2440, 2447, "9663361", "", diff --git a/data/gl 9663361_tstrakeljahn.n-triples b/data/gl 9663361_tstrakeljahn.n-triples new file mode 100644 index 0000000..03a0ee4 --- /dev/null +++ b/data/gl 9663361_tstrakeljahn.n-triples @@ -0,0 +1,10 @@ +# RDF export of group: Publication +# RDF export of group: ClinicalTrial +# RDF export of group: Population +# RDF export of group: Endpoint +# RDF export of group: Arm +# RDF export of group: Intervention +# RDF export of group: Medication +# RDF export of group: Outcome +# RDF export of group: DiffBetweenGroups +# RDF export of group: EvidenceQuality \ No newline at end of file diff --git a/requirements.txt b/requirements.txt new file mode 100644 index 0000000..1c1ff78 --- /dev/null +++ b/requirements.txt @@ -0,0 +1,13 @@ +numpy==1.25.2 +torch==2.0.1 +transformers==4.32.0 +jsonpickle==3.0.2 +scipy==1.11.2 +scikit-learn==1.3.1 +pytest==7.4.2 +optuna==3.3.0 +SentencePiece==0.1.99 +protobuf==4.24.4 +pandas==2.1.3 +xlsxwriter==3.1.9 + diff --git a/scripts-extractive/all_runs.txt b/scripts-extractive/all_runs.txt new file mode 100644 index 0000000..befe489 --- /dev/null +++ b/scripts-extractive/all_runs.txt @@ -0,0 +1,11 @@ +scripts-extractive/extractive-dm2.sh 'allenai/longformer-base-4096' | tee train-longformer-dm2.txt + +scripts-extractive/extractive-dm2.sh "allenai/led-base-16384" | tee train-led-dm2.txt + +scripts-extractive/extractive-dm2.sh "google/flan-t5-base" | tee train-t5-dm2.txt + +scripts-extractive/extractive-gl.sh 'allenai/longformer-base-4096' | tee train-longformer-gl.txt + +scripts-extractive/extractive-gl.sh "allenai/led-base-16384" | tee train-led-gl.txt + +scripts-extractive/extractive-gl.sh "google/flan-t5-base" | tee train-t5-gl.txt \ No newline at end of file diff --git a/scripts-extractive/eval-extr.sh b/scripts-extractive/eval-extr.sh new file mode 100644 index 0000000..556c0e6 --- /dev/null +++ b/scripts-extractive/eval-extr.sh @@ -0,0 +1,11 @@ +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +export projectbase=/path/to/clinical-trial-ie/ +if [ -n "$1" ]; then + export configdate=$1 +else + export configdate=$(date '+%Y-%m-%d') +fi +ls -d1 "$projectbase"/results_"$configdate"/extr/*/ | xargs -n 1 -P 16 nice python src/full_eval.py --extr \ No newline at end of file diff --git a/scripts-extractive/extractive-best.sh b/scripts-extractive/extractive-best.sh new file mode 100755 index 0000000..10e06e8 --- /dev/null +++ b/scripts-extractive/extractive-best.sh @@ -0,0 +1,6 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +python -u src/extractive_approach/training.py $1 diff --git a/scripts-extractive/extractive-dm2.sh b/scripts-extractive/extractive-dm2.sh new file mode 100755 index 0000000..acf55d1 --- /dev/null +++ b/scripts-extractive/extractive-dm2.sh @@ -0,0 +1,10 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +configdate=$(date '+%Y-%m-%d-%H:%M:%S') +modelname=$(echo "$1" | sed -E 's/.*?\/(.*)/\1/g') +echo 'allenai/led-base-16384' 'google/flan-t5-base' 'allenai/longformer-base-4096' +python -u src/extractive_approach/create_task_config_file.py --host local --disease-prefix dm2 --min-slot-freq 10 --filename config_extr_dm2_"$modelname"_"$configdate".json --batch-size 1 --epochs 50 --model $1 +python -u src/extractive_approach/training.py config_extr_dm2_"$modelname"_"$configdate".json diff --git a/scripts-extractive/extractive-gl.sh b/scripts-extractive/extractive-gl.sh new file mode 100755 index 0000000..7cd1c48 --- /dev/null +++ b/scripts-extractive/extractive-gl.sh @@ -0,0 +1,10 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +configdate=$(date '+%Y-%m-%d-%H:%M:%S') +modelname=$(echo "$1" | sed -E 's/.*?\/(.*)/\1/g') +echo 'allenai/led-base-16384' 'google/flan-t5-base' 'allenai/longformer-base-4096' +python -u src/extractive_approach/create_task_config_file.py --host local --disease-prefix gl --min-slot-freq 10 --filename config_extr_gl_"$modelname"_"$configdate".json --batch-size 1 --epochs 50 --model $1 +python -u src/extractive_approach/training.py config_extr_gl_"$modelname"_"$configdate".json diff --git a/scripts-generative/allRuns.txt b/scripts-generative/allRuns.txt new file mode 100644 index 0000000..40f8a7e --- /dev/null +++ b/scripts-generative/allRuns.txt @@ -0,0 +1,7 @@ +scripts-generative/generative-dm2.sh 'allenai/led-base-16384' | tee train-led-dm2-gen.txt + +scripts-generative/generative-dm2.sh 'google/flan-t5-base' | tee train-t5-dm2-gen.txt + +scripts-generative/generative-gl.sh 'allenai/led-base-16384' | tee train-led-gl-gen.txt + +scripts-generative/generative-gl.sh 'google/flan-t5-base' | tee train-t5-gl-gen.txt \ No newline at end of file diff --git a/scripts-generative/eval-gen.sh b/scripts-generative/eval-gen.sh new file mode 100644 index 0000000..fd0d588 --- /dev/null +++ b/scripts-generative/eval-gen.sh @@ -0,0 +1,11 @@ +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +export projectbase=/path/to/clinical-trial-ie/ +if [ -n "$1" ]; then + export configdate=$1 +else + export configdate=$(date '+%Y-%m-%d') +fi +ls -d1 "$projectbase"/results_"$configdate"/gen/*/ | xargs -n 1 -P 16 nice python src/full_eval.py --gen \ No newline at end of file diff --git a/scripts-generative/generative-best.sh b/scripts-generative/generative-best.sh new file mode 100755 index 0000000..84f97ff --- /dev/null +++ b/scripts-generative/generative-best.sh @@ -0,0 +1,6 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +python -u src/generative_approach/training.py $1 diff --git a/scripts-generative/generative-dm2.sh b/scripts-generative/generative-dm2.sh new file mode 100755 index 0000000..680121b --- /dev/null +++ b/scripts-generative/generative-dm2.sh @@ -0,0 +1,10 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +configdate=$(date '+%Y-%m-%d-%H:%M:%S') +modelname=$(echo "$1" | sed -E 's/.*?\/(.*)/\1/g') +echo 'allenai/led-base-16384' 'google/flan-t5-base' +python src/generative_approach/create_task_config_file.py --host local --disease-prefix dm2 --min-slot-freq 10 --filename config_gen_dm2_"$modelname"_"$configdate".json --batch-size 1 --epochs 50 --model $1 #'allenai/led-base-16384' 'google/flan-t5-base' +python src/generative_approach/training.py config_gen_dm2_"$modelname"_"$configdate".json diff --git a/scripts-generative/generative-gl.sh b/scripts-generative/generative-gl.sh new file mode 100755 index 0000000..c7e87da --- /dev/null +++ b/scripts-generative/generative-gl.sh @@ -0,0 +1,10 @@ +#!/bin/bash +cd "$(dirname "$0")" +cd .. +source venv/bin/activate +export PYTHONPATH=./src/ +configdate=$(date '+%Y-%m-%d-%H:%M:%S') +modelname=$(echo "$1" | sed -E 's/.*?\/(.*)/\1/g') +echo 'allenai/led-base-16384' 'google/flan-t5-base' +python src/generative_approach/create_task_config_file.py --host local --disease-prefix gl --min-slot-freq 10 --filename config_gen_gl_"$modelname"_"$configdate".json --batch-size 1 --epochs 50 --model $1 #'allenai/led-base-16384' 'google/flan-t5-base' +python src/generative_approach/training.py config_gen_gl_"$modelname"_"$configdate".json diff --git a/sort_results.sh b/sort_results.sh new file mode 100644 index 0000000..286274a --- /dev/null +++ b/sort_results.sh @@ -0,0 +1,25 @@ +configdate=$(date '+%Y-%m-%d') +cd /path/to/clinical-trial-ie/ +mkdir -p ./results_"$configdate"/gen/dm2-t5 +mkdir -p ./results_"$configdate"/gen/dm2-led +mkdir -p ./results_"$configdate"/gen/gl-t5 +mkdir -p ./results_"$configdate"/gen/gl-led + +mkdir -p ./results_"$configdate"/extr/dm2-t5 +mkdir -p ./results_"$configdate"/extr/dm2-led +mkdir -p ./results_"$configdate"/extr/dm2-longformer +mkdir -p ./results_"$configdate"/extr/gl-t5 +mkdir -p ./results_"$configdate"/extr/gl-led +mkdir -p ./results_"$configdate"/extr/gl-longformer + +mv ./*gen_model_dm2_flan-t5* ./config_gen_dm2_flan-t5* ./results_"$configdate"/gen/dm2-t5/ +mv ./*gen_model_dm2_led* ./config_gen_dm2_led* ./results_"$configdate"/gen/dm2-led/ +mv ./*gen_model_gl_flan-t5* ./config_gen_gl_flan-t5* ./results_"$configdate"/gen/gl-t5/ +mv ./*gen_model_gl_led* ./config_gen_gl_led* ./results_"$configdate"/gen/gl-led/ + +mv ./config_extr_dm2_flan-t5* ./extr_*_dm2_flan-t5* ./results_"$configdate"/extr/dm2-t5 +mv ./config_extr_dm2_led* ./extr_*_dm2_led* ./results_"$configdate"/extr/dm2-led +mv ./config_extr_dm2_longformer* ./extr_*_dm2_longformer* ./results_"$configdate"/extr/dm2-longformer +mv ./config_extr_gl_flan-t5* ./extr_*_gl_flan-t5* ./results_"$configdate"/extr/gl-t5 +mv ./config_extr_gl_led* ./extr_*_gl_led* ./results_"$configdate"/extr/gl-led +mv ./config_extr_gl_longformer* ./extr_*_gl_longformer* ./results_"$configdate"/extr/gl-longformer diff --git a/src/eval_summary.py b/src/eval_summary.py new file mode 100644 index 0000000..99d3ff6 --- /dev/null +++ b/src/eval_summary.py @@ -0,0 +1,556 @@ +import csv +import json +import os +import pickle +import re +from argparse import ArgumentParser +from collections import defaultdict +from pprint import pprint +from typing import Optional + +import pandas as pd +import torch + +import extractive_approach.data_handling as extr_dh +import generative_approach.data_handling as gen_dh +import extractive_approach.evaluation as extr_eval +import generative_approach.evaluation as gen_eval +from extractive_approach.modules import IntraTemplateCompModule, ITCLongformer, ITCLED, ITCFlanT5 +from extractive_approach.utils import ITCTokenizer +from generative_approach.models.flan_t5 import FlanT5 +from generative_approach.template_coding import LinearTemplateEncoder +from generative_approach.utils import import_task_config, get_model_class, TemplateGenerationTokenizer +from template_lib import evaluation_utils +from template_lib.data_classes.Template import Template +from template_lib.data_classes.TemplateCollection import TemplateCollection +from template_lib.data_handling import import_train_test_valid_data_from_task_config +from template_lib.max_cardinalities_estimator import gen_max_slot_cardinalities + + +def single_result_extr(task_config: str, model_path: str, sim_path: Optional[str] = None): + torch.cuda.empty_cache() + device_str = "cuda" if torch.cuda.is_available() else "cpu" + device = torch.device(device_str) + + # load task config + with open(task_config) as fp: + task_config_dict = json.load(fp) + + # import trained pytorch model + model: IntraTemplateCompModule + itc_tokenizer: ITCTokenizer + if 'allenai/longformer' in task_config_dict['model_name']: + model = ITCLongformer( + num_entity_classes=len(task_config_dict['slot_indices']), + model_name=task_config_dict['model_name'] + ) + elif 'allenai/led' in task_config_dict['model_name']: + model = ITCLED( + num_entity_classes=len(task_config_dict['slot_indices']), + model_name=task_config_dict['model_name'] + ) + elif 'google/t5' in task_config_dict['model_name'] or 'google/flan-t5' in task_config_dict['model_name']: + model = ITCFlanT5(num_entity_classes=len(task_config_dict['slot_indices']), + model_name=task_config_dict['model_name']) + else: + raise RuntimeError("Unknown model name!") + + model.load_state_dict(torch.load(model_path, map_location=device)) + + itc_tokenizer = model.tokenizer + + # import dataset + train_set, test_set, validation_data = import_train_test_valid_data_from_task_config(task_config_dict, + itc_tokenizer) + labels = set() + for doc, templcl in test_set: + labels.update([e.get_label() for e in templcl.get_all_entities()]) + print(labels) + # exit(0) + + datat_elements = extr_dh.extract_data_elements_from_dataset( + dataset=test_set, + tokenizer=itc_tokenizer, + task_config_dict=task_config_dict + ) + + max_slots_cardinalities = gen_max_slot_cardinalities(train_set) + + same_inst_vals, diff_inst_vals = None, None + + if sim_path is not None: + with open(sim_path, "rb") as fp: + same_inst_vals, diff_inst_vals = pickle.load(fp) + + pmid = itc_tokenizer.tokenize("27740719") + studydata = [de for de in datat_elements if pmid in sum([[e.get_tokens() for e in pub.get_slot_fillers("hasPMID")] for pub in de.template_collection.grouped_by_type["Publication"]], [])] + assert len(studydata) == 1 + + # evaluation + result, _ = extr_eval.single_run( + data_element=studydata[0], + itc_module=model, + task_config_dict=task_config_dict, + max_slots_cardinalities=max_slots_cardinalities, + device=device, + same_inst_vals=same_inst_vals, + diff_inst_vals=diff_inst_vals, + instance_counter=0 + ) + + return studydata[0].template_collection, result, itc_tokenizer + + +def single_result_gen(task_config: str, model_path: str, tokenizer_path: Optional[str] = None): + torch.cuda.empty_cache() + task_config_dict = import_task_config(task_config) + + device_str = "cuda" if torch.cuda.is_available() else "cpu" + device = torch.device(device_str) + # device = "cpu" #torch.device("cpu") + + # load pretrained led model and create instantiate tokenizers ######################### + model_name = task_config_dict['model_name'] + model_class = get_model_class(model_name) + model = model_class(model_path=model_path, model_name=model_name, device=device_str) + + # led_model = LEDForConditionalGeneration.from_pretrained(model_name).to(device) + # led_tokenizer = LEDTokenizer.from_pretrained(model_name) + # led_config = LEDConfig.from_pretrained(model_name) + + # create template generation tokenizer ################################################ + temp_generation_tokenizer: TemplateGenerationTokenizer + temp_generation_tokenizer = TemplateGenerationTokenizer( + tokenizer=model.tokenizer, + json_filename=tokenizer_path, + template_names=task_config_dict['slots_ordering_dict'].keys(), + slot_names=task_config_dict['used_slots'], + start_of_sentence_token=model.tokenizer.bos_token, + end_of_sentence_token=model.tokenizer.eos_token, + filler_sep_token='[FILLER_SEP]', + control_tokens_start_id=model.tokenizer.vocab_size + ) + # temp_generation_tokenizer.to_json(sys.argv[2]) + + # add embeddings for control tokens + model.model.resize_token_embeddings( + model.tokenizer.vocab_size + len(temp_generation_tokenizer.control_token_ids) + - (1 if model.tokenizer.bos_token is not None else 0) + - (1 if model.tokenizer.eos_token is not None else 0) + - (1 if model.tokenizer.pad_token is not None else 0)) + # print(led_model.led.shared.num_embeddings) + + # load training data ############################################### + training_dataset, test_dataset, validation_dataset = import_train_test_valid_data_from_task_config(task_config_dict, + temp_generation_tokenizer) + + max_slots_cardinalities = gen_max_slot_cardinalities(training_dataset) + + pmid = temp_generation_tokenizer.tokenize("27740719") + studydata = [(doc, tc) for doc, tc in test_dataset if pmid in sum([[e.get_tokens() for e in pub.get_slot_fillers("hasPMID")] for pub in tc.grouped_by_type["Publication"]], [])] + assert len(studydata) == 1 + + + #doc = [doc for doc, tc in test_dataset][0] #PMID = 27740719 temp_generation_tokenizer.tokenize(["27740719"]) + #tc = [tc for doc, tc in test_dataset][0] + doc = studydata[0][0] + tc = studydata[0][1] + predicted_template_collection = gen_eval.single_run( + document=doc, + model=model, + temp_generation_tokenizer=temp_generation_tokenizer, + task_config_dict=task_config_dict, + max_slots_cardinalities=max_slots_cardinalities, + device=device + ) + + return tc, predicted_template_collection, temp_generation_tokenizer + + +def escape(s: str): + return s.replace("_", "\\_").replace("&", "\\&").replace("%", "\\%").replace(">", "\\textgreater{}").replace("<", + "\\textless{}") + + +def case_study_creator(gold_collection: TemplateCollection, + extr_collection: TemplateCollection, + gen_collection: TemplateCollection, + extr_tokenizer: ITCTokenizer, + gen_tokenizer: TemplateGenerationTokenizer, + label: str = None, + caption: str = None): + case_study = [] # pd.DataFrame(columns=["Slot name", "Gold Standard", "Extractive Prediction", "Generative Prediction"]) + gold_grouped = gold_collection.grouped_by_type + extr_grouped = extr_collection.grouped_by_type + gen_grouped = gen_collection.grouped_by_type + template_types = set(gold_grouped.keys()).union(set(extr_grouped.keys())).union(set(gen_grouped.keys())) + assert "Publication" in template_types + template_types.remove("Publication") + template_types = ["Publication"] + list(template_types) + + for template_type in template_types: + slot_names = list(sorted(set().union( + *[[sn for sn in t.get_filled_slot_names() if len(t.get_slot_fillers(sn)) > 0] for t in + gold_grouped[template_type]] + ).union( + *[[sn for sn in t.get_filled_slot_names() if len(t.get_slot_fillers(sn)) > 0] for t in + extr_grouped[template_type]] + ).union( + *[[sn for sn in t.get_filled_slot_names() if len(t.get_slot_fillers(sn)) > 0] for t in + gen_grouped[template_type]] + ))) + gold_templates = gold_grouped[template_type] + extr_templates = extr_grouped[template_type] + gen_templates = gen_grouped[template_type] + + # TODO: tokens back to proper string + gold_rows = [ + escape(' | '.join([ + gen_tokenizer.tokenizer.decode( + gen_tokenizer.convert_tokens_to_ids(sf.get_tokens()) + ) + for sf in t.get_slot_fillers(slot_name) if not isinstance(sf, Template) + ]).replace("", "<")) # for some reason T5 does not tokenize < correctly... + for t in gold_templates + for slot_name in slot_names + ] + extr_rows = [ + escape(' | '.join([ + extr_tokenizer.tokenizer.decode( + extr_tokenizer.convert_tokens_to_ids(sf.get_tokens()) + ) + for sf in t.get_slot_fillers(slot_name) if not isinstance(sf, Template) + ]).replace("", "<")) + for t in extr_templates + for slot_name in slot_names + ] + gen_rows = [ + escape(' | '.join([ + gen_tokenizer.tokenizer.decode( + gen_tokenizer.convert_tokens_to_ids(sf.get_tokens()) + ) + for sf in t.get_slot_fillers(slot_name) if not isinstance(sf, Template) + ]).replace("", "<")) + for t in gen_templates + for slot_name in slot_names + ] + + max_rows = max(len(gold_rows), len(extr_rows), len(gen_rows)) + gold_rows += [""] * (max_rows - len(gold_rows)) + gold_rows = [""] + gold_rows + extr_rows += [""] * (max_rows - len(extr_rows)) + extr_rows = [""] + extr_rows + gen_rows += [""] * (max_rows - len(gen_rows)) + gen_rows = [""] + gen_rows + + labels = [ + sn.replace("has", "") if i != 0 else "\\midrule " + sn.replace("has", "") + for i, sn in enumerate(slot_names) + ] * (max_rows // len(slot_names)) + labels = [("\\midrule " if len(case_study) > 0 else "") + "\\textbf{Template " + template_type + "}"] + labels + # labels[1] = "\\midrule " + labels[1] + + data = { + "\\textbf{Slot name}": labels, + "\\textbf{Gold Standard}": gold_rows, + "\\textbf{Extractive Prediction}": extr_rows, + "\\textbf{Generative Prediction}": gen_rows + } + case_study.append(pd.DataFrame(data)) + + pass + pd_case_study = pd.concat(case_study, ignore_index=True) + latex = pd_case_study.to_latex(index=False, + multicolumn_format="c", + longtable=True, + column_format='r | p{4cm} | p{4cm} | p{4cm}', + label=label, + caption=caption) + latex = re.sub(r"\\textbf{Template (.*?)}\s+&\s+&\s+&\s+\\\\", r"\\multicolumn{4}{c}{\\textbf{Template \1}} \\\\", latex) + print("### Case Study") + print(latex) + return latex + + +if __name__ == '__main__': + argparser = ArgumentParser() + argparser.add_argument('--results', required=True) + argparser.add_argument('--casestudy', action='store_true') + #argparser.add_argument('--nosloteval', action='store_false') + #argparser.add_argument('--noinstancecount', action='store_false') + arguments = argparser.parse_args() + + results_path = arguments.results + run_case_study = arguments.casestudy + run_best_eval = True #arguments.nosloteval + #run_instance_count = arguments.noinstancecount + + names = { + "gen": ["t5", "led"], + "extr": ["t5", "led", "longformer"] + } + + name_res = { + "gen": re.compile(r"^(?P.*)/gen_model_(?P.*)_(?P.*)_(?P.*)_(?P